DDI-DrugBank.d292.s0|0-3|Care|O
DDI-DrugBank.d292.s0|5-10|should|O
DDI-DrugBank.d292.s0|12-13|be|O
DDI-DrugBank.d292.s0|15-19|given|O
DDI-DrugBank.d292.s0|21-24|when|O
DDI-DrugBank.d292.s0|26-38|administering|O
DDI-DrugBank.d292.s0|40-43|this|O
DDI-DrugBank.d292.s0|45-48|drug|O
DDI-DrugBank.d292.s0|50-51|to|O
DDI-DrugBank.d292.s0|53-60|patients|O
DDI-DrugBank.d292.s0|62-65|with|O
DDI-DrugBank.d292.s0|67-74|symptoms|O
DDI-DrugBank.d292.s0|76-77|of|O
DDI-DrugBank.d292.s0|79-88|myasthenic|O
DDI-DrugBank.d292.s0|90-97|weakness|O
DDI-DrugBank.d292.s0|99-101|who|O
DDI-DrugBank.d292.s0|103-105|are|O
DDI-DrugBank.d292.s0|107-110|also|O
DDI-DrugBank.d292.s0|112-113|on|O
DDI-DrugBank.d292.s0|115-138|anticholinesterase drugs|group
DDI-DrugBank.d292.s0|139-139|.|O
DDI-DrugBank.d292.s1|0-4|Since|O
DDI-DrugBank.d292.s1|6-13|symptoms|O
DDI-DrugBank.d292.s1|15-16|of|O
DDI-DrugBank.d292.s1|18-35|anticholinesterase|O
DDI-DrugBank.d292.s1|37-44|overdose|O
DDI-DrugBank.d292.s1|46-46|(|O
DDI-DrugBank.d292.s1|47-57|cholinergic|O
DDI-DrugBank.d292.s1|59-64|crisis|O
DDI-DrugBank.d292.s1|65-65|)|O
DDI-DrugBank.d292.s1|67-69|may|O
DDI-DrugBank.d292.s1|71-75|mimic|O
DDI-DrugBank.d292.s1|77-87|underdosage|O
DDI-DrugBank.d292.s1|89-89|(|O
DDI-DrugBank.d292.s1|90-99|myasthenic|O
DDI-DrugBank.d292.s1|101-108|weakness|O
DDI-DrugBank.d292.s1|109-109|)|O
DDI-DrugBank.d292.s1|110-110|,|O
DDI-DrugBank.d292.s1|112-116|their|O
DDI-DrugBank.d292.s1|118-126|condition|O
DDI-DrugBank.d292.s1|128-130|may|O
DDI-DrugBank.d292.s1|132-133|be|O
DDI-DrugBank.d292.s1|135-142|worsened|O
DDI-DrugBank.d292.s1|144-145|by|O
DDI-DrugBank.d292.s1|147-149|the|O
DDI-DrugBank.d292.s1|151-153|use|O
DDI-DrugBank.d292.s1|155-156|of|O
DDI-DrugBank.d292.s1|158-161|this|O
DDI-DrugBank.d292.s1|163-166|drug|O
DDI-DrugBank.d292.s1|167-167|.|O
DDI-MedLine.d208.s0|0-7|Implanon|brand
DDI-MedLine.d208.s0|11-17|failure|O
DDI-MedLine.d208.s0|19-20|in|O
DDI-MedLine.d208.s0|22-23|an|O
DDI-MedLine.d208.s0|25-36|HIV-positive|O
DDI-MedLine.d208.s0|38-42|woman|O
DDI-MedLine.d208.s0|44-45|on|O
DDI-MedLine.d208.s0|47-60|antiretroviral|group
DDI-MedLine.d208.s0|62-68|therapy|O
DDI-MedLine.d208.s0|70-78|resulting|O
DDI-MedLine.d208.s0|80-81|in|O
DDI-MedLine.d208.s0|83-85|two|O
DDI-MedLine.d208.s0|87-93|ectopic|O
DDI-MedLine.d208.s0|95-105|pregnancies|O
DDI-MedLine.d208.s0|106-106|.|O
DDI-MedLine.d208.s1|0-4|Since|O
DDI-MedLine.d208.s1|6-8|its|O
DDI-MedLine.d208.s1|10-21|introduction|O
DDI-MedLine.d208.s1|23-24|in|O
DDI-MedLine.d208.s1|26-29|1999|O
DDI-MedLine.d208.s1|30-30|,|O
DDI-MedLine.d208.s1|32-39|Implanon|brand
DDI-MedLine.d208.s1|43-49|remains|O
DDI-MedLine.d208.s1|51-53|one|O
DDI-MedLine.d208.s1|55-56|of|O
DDI-MedLine.d208.s1|58-60|the|O
DDI-MedLine.d208.s1|62-70|preferred|O
DDI-MedLine.d208.s1|72-84|contraceptive|O
DDI-MedLine.d208.s1|86-92|choices|O
DDI-MedLine.d208.s1|94-96|for|O
DDI-MedLine.d208.s1|98-101|many|O
DDI-MedLine.d208.s1|103-107|women|O
DDI-MedLine.d208.s1|109-110|as|O
DDI-MedLine.d208.s1|112-113|it|O
DDI-MedLine.d208.s1|115-120|offers|O
DDI-MedLine.d208.s1|122-122|a|O
DDI-MedLine.d208.s1|124-129|highly|O
DDI-MedLine.d208.s1|131-139|effective|O
DDI-MedLine.d208.s1|141-145|means|O
DDI-MedLine.d208.s1|147-148|of|O
DDI-MedLine.d208.s1|150-158|long-term|O
DDI-MedLine.d208.s1|160-172|contraception|O
DDI-MedLine.d208.s1|174-176|for|O
DDI-MedLine.d208.s1|178-182|three|O
DDI-MedLine.d208.s1|184-188|years|O
DDI-MedLine.d208.s1|190-193|that|O
DDI-MedLine.d208.s1|195-198|does|O
DDI-MedLine.d208.s1|200-202|not|O
DDI-MedLine.d208.s1|204-207|rely|O
DDI-MedLine.d208.s1|209-210|on|O
DDI-MedLine.d208.s1|212-220|adherence|O
DDI-MedLine.d208.s1|221-221|.|O
DDI-MedLine.d208.s2|0-3|Like|O
DDI-MedLine.d208.s2|5-7|all|O
DDI-MedLine.d208.s2|9-31|hormonal contraceptives|group
DDI-MedLine.d208.s2|32-32|,|O
DDI-MedLine.d208.s2|34-40|certain|O
DDI-MedLine.d208.s2|42-48|hepatic|O
DDI-MedLine.d208.s2|50-64|enzyme-inducing|O
DDI-MedLine.d208.s2|66-70|drugs|O
DDI-MedLine.d208.s2|72-74|may|O
DDI-MedLine.d208.s2|76-81|reduce|O
DDI-MedLine.d208.s2|83-85|its|O
DDI-MedLine.d208.s2|87-94|efficacy|O
DDI-MedLine.d208.s2|95-95|.|O
DDI-MedLine.d208.s3|0-1|We|O
DDI-MedLine.d208.s3|3-9|present|O
DDI-MedLine.d208.s3|11-12|an|O
DDI-MedLine.d208.s3|14-24|interesting|O
DDI-MedLine.d208.s3|26-29|case|O
DDI-MedLine.d208.s3|31-32|of|O
DDI-MedLine.d208.s3|34-35|an|O
DDI-MedLine.d208.s3|37-48|HIV-positive|O
DDI-MedLine.d208.s3|50-54|woman|O
DDI-MedLine.d208.s3|56-57|on|O
DDI-MedLine.d208.s3|59-72|antiretroviral|group
DDI-MedLine.d208.s3|74-80|therapy|O
DDI-MedLine.d208.s3|82-87|having|O
DDI-MedLine.d208.s3|89-93|tubal|O
DDI-MedLine.d208.s3|95-105|pregnancies|O
DDI-MedLine.d208.s3|107-108|on|O
DDI-MedLine.d208.s3|110-112|two|O
DDI-MedLine.d208.s3|114-121|separate|O
DDI-MedLine.d208.s3|123-131|occasions|O
DDI-MedLine.d208.s3|133-136|with|O
DDI-MedLine.d208.s3|138-145|Implanon|brand
DDI-MedLine.d208.s3|147-148|in|O
DDI-MedLine.d208.s3|150-154|place|O
DDI-MedLine.d208.s3|155-155|.|O
DDI-DrugBank.d522.s0|0-10|Terfenadine|drug
DDI-DrugBank.d522.s0|11-11|:|O
DDI-DrugBank.d522.s0|13-14|In|O
DDI-DrugBank.d522.s0|16-16|a|O
DDI-DrugBank.d522.s0|18-28|prospective|O
DDI-DrugBank.d522.s0|30-34|study|O
DDI-DrugBank.d522.s0|36-44|involving|O
DDI-DrugBank.d522.s0|46-61|six-healthy-male|O
DDI-DrugBank.d522.s0|63-72|volunteers|O
DDI-DrugBank.d522.s0|73-73|,|O
DDI-DrugBank.d522.s0|75-87|dirithromycin|drug
DDI-DrugBank.d522.s0|89-91|did|O
DDI-DrugBank.d522.s0|93-95|not|O
DDI-DrugBank.d522.s0|97-102|affect|O
DDI-DrugBank.d522.s0|104-106|the|O
DDI-DrugBank.d522.s0|108-117|metabolism|O
DDI-DrugBank.d522.s0|119-120|of|O
DDI-DrugBank.d522.s0|122-132|terfenadine|drug
DDI-DrugBank.d522.s0|133-133|.|O
DDI-DrugBank.d522.s1|0-4|These|O
DDI-DrugBank.d522.s1|6-8|six|O
DDI-DrugBank.d522.s1|10-19|volunteers|O
DDI-DrugBank.d522.s1|21-28|received|O
DDI-DrugBank.d522.s1|30-40|terfenadine|drug
DDI-DrugBank.d522.s1|42-46|alone|O
DDI-DrugBank.d522.s1|48-48|(|O
DDI-DrugBank.d522.s1|49-50|60|O
DDI-DrugBank.d522.s1|52-53|mg|O
DDI-DrugBank.d522.s1|55-59|twice|O
DDI-DrugBank.d522.s1|61-65|daily|O
DDI-DrugBank.d522.s1|66-66|)|O
DDI-DrugBank.d522.s1|68-70|for|O
DDI-DrugBank.d522.s1|72-72|8|O
DDI-DrugBank.d522.s1|74-77|days|O
DDI-DrugBank.d522.s1|78-78|,|O
DDI-DrugBank.d522.s1|80-87|followed|O
DDI-DrugBank.d522.s1|89-90|by|O
DDI-DrugBank.d522.s1|92-102|terfenadine|drug
DDI-DrugBank.d522.s1|104-105|in|O
DDI-DrugBank.d522.s1|107-117|combination|O
DDI-DrugBank.d522.s1|119-122|with|O
DDI-DrugBank.d522.s1|124-136|dirithromycin|drug
DDI-DrugBank.d522.s1|138-138|(|O
DDI-DrugBank.d522.s1|139-141|500|O
DDI-DrugBank.d522.s1|143-144|mg|O
DDI-DrugBank.d522.s1|146-149|once|O
DDI-DrugBank.d522.s1|151-155|daily|O
DDI-DrugBank.d522.s1|156-156|)|O
DDI-DrugBank.d522.s1|158-160|for|O
DDI-DrugBank.d522.s1|162-163|10|O
DDI-DrugBank.d522.s1|165-168|days|O
DDI-DrugBank.d522.s1|169-169|.|O
DDI-DrugBank.d522.s2|0-0|(|O
DDI-DrugBank.d522.s2|1-4|Both|O
DDI-DrugBank.d522.s2|6-10|drugs|O
DDI-DrugBank.d522.s2|12-15|were|O
DDI-DrugBank.d522.s2|17-20|thus|O
DDI-DrugBank.d522.s2|22-26|dosed|O
DDI-DrugBank.d522.s2|28-29|to|O
DDI-DrugBank.d522.s2|31-36|steady|O
DDI-DrugBank.d522.s2|38-42|state|O
DDI-DrugBank.d522.s2|43-43|.|O
DDI-DrugBank.d522.s2|44-44|)|O
DDI-DrugBank.d522.s3|0-2|The|O
DDI-DrugBank.d522.s3|4-19|pharmacokinetics|O
DDI-DrugBank.d522.s3|21-22|of|O
DDI-DrugBank.d522.s3|24-34|terfenadine|drug
DDI-DrugBank.d522.s3|36-38|and|O
DDI-DrugBank.d522.s3|40-42|its|O
DDI-DrugBank.d522.s3|44-47|acid|O
DDI-DrugBank.d522.s3|49-58|metabolite|O
DDI-DrugBank.d522.s3|60-62|and|O
DDI-DrugBank.d522.s3|64-66|the|O
DDI-DrugBank.d522.s3|68-87|electrocardiographic|O
DDI-DrugBank.d522.s3|89-90|QT|O
DDI-DrugBank.d522.s3|92-92|c|O
DDI-DrugBank.d522.s3|94-101|interval|O
DDI-DrugBank.d522.s3|103-106|were|O
DDI-DrugBank.d522.s3|108-115|measured|O
DDI-DrugBank.d522.s3|117-122|during|O
DDI-DrugBank.d522.s3|124-127|both|O
DDI-DrugBank.d522.s3|129-135|periods|O
DDI-DrugBank.d522.s3|136-136|:|O
DDI-DrugBank.d522.s3|138-141|with|O
DDI-DrugBank.d522.s3|143-153|terfenadine|drug
DDI-DrugBank.d522.s3|155-159|alone|O
DDI-DrugBank.d522.s3|160-160|,|O
DDI-DrugBank.d522.s3|162-164|and|O
DDI-DrugBank.d522.s3|166-169|with|O
DDI-DrugBank.d522.s3|171-181|terfenadine|drug
DDI-DrugBank.d522.s3|183-186|plus|O
DDI-DrugBank.d522.s3|188-200|dirithromycin|drug
DDI-DrugBank.d522.s3|201-201|.|O
DDI-DrugBank.d522.s4|0-1|In|O
DDI-DrugBank.d522.s4|3-6|five|O
DDI-DrugBank.d522.s4|8-10|men|O
DDI-DrugBank.d522.s4|11-11|,|O
DDI-DrugBank.d522.s4|13-23|terfenadine|drug
DDI-DrugBank.d522.s4|25-30|levels|O
DDI-DrugBank.d522.s4|32-35|were|O
DDI-DrugBank.d522.s4|37-48|undetectable|O
DDI-DrugBank.d522.s4|50-50|(|O
DDI-DrugBank.d522.s4|52-52|5|O
DDI-DrugBank.d522.s4|54-58|ng/mL|O
DDI-DrugBank.d522.s4|59-59|)|O
DDI-DrugBank.d522.s4|61-70|throughout|O
DDI-DrugBank.d522.s4|72-74|the|O
DDI-DrugBank.d522.s4|76-80|study|O
DDI-DrugBank.d522.s4|81-81|;|O
DDI-DrugBank.d522.s5|0-1|in|O
DDI-DrugBank.d522.s5|3-5|one|O
DDI-DrugBank.d522.s5|7-9|man|O
DDI-DrugBank.d522.s5|10-10|,|O
DDI-DrugBank.d522.s5|12-14|the|O
DDI-DrugBank.d522.s5|16-16|C|O
DDI-DrugBank.d522.s5|18-20|max|O
DDI-DrugBank.d522.s5|22-23|of|O
DDI-DrugBank.d522.s5|25-35|terfenadine|drug
DDI-DrugBank.d522.s5|37-39|was|O
DDI-DrugBank.d522.s5|41-43|8.1|O
DDI-DrugBank.d522.s5|45-49|ng/mL|O
DDI-DrugBank.d522.s5|51-54|with|O
DDI-DrugBank.d522.s5|56-66|terfenadine|drug
DDI-DrugBank.d522.s5|68-72|alone|O
DDI-DrugBank.d522.s5|74-76|and|O
DDI-DrugBank.d522.s5|78-80|7.2|O
DDI-DrugBank.d522.s5|82-86|ng/mL|O
DDI-DrugBank.d522.s5|88-91|with|O
DDI-DrugBank.d522.s5|93-103|terfenadine|drug
DDI-DrugBank.d522.s5|105-108|plus|O
DDI-DrugBank.d522.s5|110-122|dirithromycin|drug
DDI-DrugBank.d522.s5|123-123|.|O
DDI-DrugBank.d522.s6|0-2|The|O
DDI-DrugBank.d522.s6|4-7|mean|O
DDI-DrugBank.d522.s6|9-9|C|O
DDI-DrugBank.d522.s6|11-13|max|O
DDI-DrugBank.d522.s6|15-15|,|O
DDI-DrugBank.d522.s6|17-17|T|O
DDI-DrugBank.d522.s6|19-21|max|O
DDI-DrugBank.d522.s6|23-23|,|O
DDI-DrugBank.d522.s6|25-27|and|O
DDI-DrugBank.d522.s6|29-31|AUC|O
DDI-DrugBank.d522.s6|33-34|of|O
DDI-DrugBank.d522.s6|36-38|the|O
DDI-DrugBank.d522.s6|40-43|acid|O
DDI-DrugBank.d522.s6|45-54|metabolite|O
DDI-DrugBank.d522.s6|56-57|of|O
DDI-DrugBank.d522.s6|59-69|terfenadine|drug
DDI-DrugBank.d522.s6|71-74|were|O
DDI-DrugBank.d522.s6|76-78|not|O
DDI-DrugBank.d522.s6|80-92|significantly|O
DDI-DrugBank.d522.s6|94-100|changed|O
DDI-DrugBank.d522.s6|101-101|.|O
DDI-DrugBank.d522.s7|0-2|The|O
DDI-DrugBank.d522.s7|4-7|mean|O
DDI-DrugBank.d522.s7|9-10|QT|O
DDI-DrugBank.d522.s7|12-12|c|O
DDI-DrugBank.d522.s7|14-21|interval|O
DDI-DrugBank.d522.s7|23-23|(|O
DDI-DrugBank.d522.s7|24-27|msec|O
DDI-DrugBank.d522.s7|28-28|)|O
DDI-DrugBank.d522.s7|30-32|was|O
DDI-DrugBank.d522.s7|34-36|369|O
DDI-DrugBank.d522.s7|38-41|with|O
DDI-DrugBank.d522.s7|43-53|terfenadine|drug
DDI-DrugBank.d522.s7|55-59|alone|O
DDI-DrugBank.d522.s7|61-63|and|O
DDI-DrugBank.d522.s7|65-67|367|O
DDI-DrugBank.d522.s7|69-72|with|O
DDI-DrugBank.d522.s7|74-84|terfenadine|drug
DDI-DrugBank.d522.s7|86-89|plus|O
DDI-DrugBank.d522.s7|91-103|dirithromycin|drug
DDI-DrugBank.d522.s7|104-104|.|O
DDI-DrugBank.d522.s8|0-3|Also|O
DDI-DrugBank.d522.s8|4-4|,|O
DDI-DrugBank.d522.s8|6-7|in|O
DDI-DrugBank.d522.s8|9-13|vitro|O
DDI-DrugBank.d522.s8|15-25|experiments|O
DDI-DrugBank.d522.s8|27-38|demonstrated|O
DDI-DrugBank.d522.s8|40-40|a|O
DDI-DrugBank.d522.s8|42-45|lack|O
DDI-DrugBank.d522.s8|47-48|of|O
DDI-DrugBank.d522.s8|50-60|interaction|O
DDI-DrugBank.d522.s8|62-68|between|O
DDI-DrugBank.d522.s8|70-82|dirithromycin|drug
DDI-DrugBank.d522.s8|84-86|and|O
DDI-DrugBank.d522.s8|88-98|terfenadine|drug
DDI-DrugBank.d522.s8|99-99|.|O
DDI-DrugBank.d522.s9|0-3|Thus|O
DDI-DrugBank.d522.s9|4-4|,|O
DDI-DrugBank.d522.s9|6-8|the|O
DDI-DrugBank.d522.s9|10-20|interaction|O
DDI-DrugBank.d522.s9|22-29|observed|O
DDI-DrugBank.d522.s9|31-37|between|O
DDI-DrugBank.d522.s9|39-50|erythromycin|drug
DDI-DrugBank.d522.s9|52-54|and|O
DDI-DrugBank.d522.s9|56-66|terfenadine|drug
DDI-DrugBank.d522.s9|68-69|is|O
DDI-DrugBank.d522.s9|71-73|not|O
DDI-DrugBank.d522.s9|75-82|expected|O
DDI-DrugBank.d522.s9|84-86|for|O
DDI-DrugBank.d522.s9|88-100|dirithromycin|drug
DDI-DrugBank.d522.s9|101-101|.|O
DDI-DrugBank.d522.s10|0-6|Serious|O
DDI-DrugBank.d522.s10|8-14|cardiac|O
DDI-DrugBank.d522.s10|16-27|dysrhythmias|O
DDI-DrugBank.d522.s10|28-28|,|O
DDI-DrugBank.d522.s10|30-33|some|O
DDI-DrugBank.d522.s10|35-43|resulting|O
DDI-DrugBank.d522.s10|45-46|in|O
DDI-DrugBank.d522.s10|48-52|death|O
DDI-DrugBank.d522.s10|53-53|,|O
DDI-DrugBank.d522.s10|55-58|have|O
DDI-DrugBank.d522.s10|60-67|occurred|O
DDI-DrugBank.d522.s10|69-70|in|O
DDI-DrugBank.d522.s10|72-79|patients|O
DDI-DrugBank.d522.s10|81-89|receiving|O
DDI-DrugBank.d522.s10|91-101|terfenadine|drug
DDI-DrugBank.d522.s10|103-115|concomitantly|O
DDI-DrugBank.d522.s10|117-120|with|O
DDI-DrugBank.d522.s10|122-126|other|O
DDI-DrugBank.d522.s10|128-148|macrolide antibiotics|group
DDI-DrugBank.d522.s10|149-149|.|O
DDI-DrugBank.d522.s11|0-1|In|O
DDI-DrugBank.d522.s11|3-10|addition|O
DDI-DrugBank.d522.s11|11-11|,|O
DDI-DrugBank.d522.s11|13-16|most|O
DDI-DrugBank.d522.s11|18-27|macrolides|group
DDI-DrugBank.d522.s11|29-31|are|O
DDI-DrugBank.d522.s11|33-47|contraindicated|O
DDI-DrugBank.d522.s11|49-50|in|O
DDI-DrugBank.d522.s11|52-59|patients|O
DDI-DrugBank.d522.s11|61-69|receiving|O
DDI-DrugBank.d522.s11|71-81|terfenadine|drug
DDI-DrugBank.d522.s11|83-89|therapy|O
DDI-DrugBank.d522.s11|91-93|who|O
DDI-DrugBank.d522.s11|95-98|have|O
DDI-DrugBank.d522.s11|100-111|pre-existing|O
DDI-DrugBank.d522.s11|113-119|cardiac|O
DDI-DrugBank.d522.s11|121-133|abnormalities|O
DDI-DrugBank.d522.s11|135-135|(|O
DDI-DrugBank.d522.s11|136-145|arrhythmia|O
DDI-DrugBank.d522.s11|146-146|,|O
DDI-DrugBank.d522.s11|148-158|bradycardia|O
DDI-DrugBank.d522.s11|159-159|,|O
DDI-DrugBank.d522.s11|161-162|QT|O
DDI-DrugBank.d522.s11|164-164|c|O
DDI-DrugBank.d522.s11|166-173|interval|O
DDI-DrugBank.d522.s11|175-186|prolongation|O
DDI-DrugBank.d522.s11|187-187|,|O
DDI-DrugBank.d522.s11|189-196|ischemic|O
DDI-DrugBank.d522.s11|198-202|heart|O
DDI-DrugBank.d522.s11|204-210|disease|O
DDI-DrugBank.d522.s11|211-211|,|O
DDI-DrugBank.d522.s11|213-222|congestive|O
DDI-DrugBank.d522.s11|224-228|heart|O
DDI-DrugBank.d522.s11|230-236|failure|O
DDI-DrugBank.d522.s11|237-237|,|O
DDI-DrugBank.d522.s11|239-242|etc.|O
DDI-DrugBank.d522.s11|243-243|)|O
DDI-DrugBank.d522.s11|245-246|or|O
DDI-DrugBank.d522.s11|248-258|electrolyte|O
DDI-DrugBank.d522.s11|260-271|disturbances|O
DDI-DrugBank.d522.s11|272-272|.|O
DDI-DrugBank.d522.s12|0-11|Theophylline|drug
DDI-DrugBank.d522.s12|12-12|:|O
DDI-DrugBank.d522.s12|14-22|Following|O
DDI-DrugBank.d522.s12|24-40|co-administration|O
DDI-DrugBank.d522.s12|42-43|of|O
DDI-DrugBank.d522.s12|45-47|two|O
DDI-DrugBank.d522.s12|49-54|250-mg|O
DDI-DrugBank.d522.s12|56-68|dirithromycin|drug
DDI-DrugBank.d522.s12|70-76|tablets|O
DDI-DrugBank.d522.s12|78-89|administered|O
DDI-DrugBank.d522.s12|91-94|once|O
DDI-DrugBank.d522.s12|96-100|daily|O
DDI-DrugBank.d522.s12|102-105|with|O
DDI-DrugBank.d522.s12|107-112|200-mg|O
DDI-DrugBank.d522.s12|114-125|theophylline|drug
DDI-DrugBank.d522.s12|127-133|tablets|O
DDI-DrugBank.d522.s12|135-146|administered|O
DDI-DrugBank.d522.s12|148-152|twice|O
DDI-DrugBank.d522.s12|154-158|daily|O
DDI-DrugBank.d522.s12|160-162|for|O
DDI-DrugBank.d522.s12|164-165|10|O
DDI-DrugBank.d522.s12|167-170|days|O
DDI-DrugBank.d522.s12|172-173|to|O
DDI-DrugBank.d522.s12|175-176|14|O
DDI-DrugBank.d522.s12|178-184|healthy|O
DDI-DrugBank.d522.s12|186-193|subjects|O
DDI-DrugBank.d522.s12|194-194|,|O
DDI-DrugBank.d522.s12|196-198|the|O
DDI-DrugBank.d522.s12|200-211|steady-state|O
DDI-DrugBank.d522.s12|213-218|plasma|O
DDI-DrugBank.d522.s12|220-232|concentration|O
DDI-DrugBank.d522.s12|234-235|of|O
DDI-DrugBank.d522.s12|237-248|theophylline|drug
DDI-DrugBank.d522.s12|250-252|was|O
DDI-DrugBank.d522.s12|254-256|not|O
DDI-DrugBank.d522.s12|258-270|significantly|O
DDI-DrugBank.d522.s12|272-278|altered|O
DDI-DrugBank.d522.s12|279-279|.|O
DDI-DrugBank.d522.s13|0-1|In|O
DDI-DrugBank.d522.s13|3-9|general|O
DDI-DrugBank.d522.s13|10-10|,|O
DDI-DrugBank.d522.s13|12-15|most|O
DDI-DrugBank.d522.s13|17-24|patients|O
DDI-DrugBank.d522.s13|26-32|treated|O
DDI-DrugBank.d522.s13|34-37|with|O
DDI-DrugBank.d522.s13|39-51|dirithromycin|drug
DDI-DrugBank.d522.s13|53-55|who|O
DDI-DrugBank.d522.s13|57-59|are|O
DDI-DrugBank.d522.s13|61-69|receiving|O
DDI-DrugBank.d522.s13|71-81|concomitant|O
DDI-DrugBank.d522.s13|83-94|theophylline|drug
DDI-DrugBank.d522.s13|96-102|therapy|O
DDI-DrugBank.d522.s13|104-106|may|O
DDI-DrugBank.d522.s13|108-110|not|O
DDI-DrugBank.d522.s13|112-118|require|O
DDI-DrugBank.d522.s13|120-126|empiric|O
DDI-DrugBank.d522.s13|128-137|adjustment|O
DDI-DrugBank.d522.s13|139-140|of|O
DDI-DrugBank.d522.s13|142-153|theophylline|drug
DDI-DrugBank.d522.s13|155-160|dosage|O
DDI-DrugBank.d522.s13|162-163|or|O
DDI-DrugBank.d522.s13|165-174|monitoring|O
DDI-DrugBank.d522.s13|176-177|of|O
DDI-DrugBank.d522.s13|179-190|theophylline|drug
DDI-DrugBank.d522.s13|192-197|plasma|O
DDI-DrugBank.d522.s13|199-212|concentrations|O
DDI-DrugBank.d522.s13|213-213|.|O
DDI-DrugBank.d522.s14|0-6|However|O
DDI-DrugBank.d522.s14|7-7|,|O
DDI-DrugBank.d522.s14|9-20|theophylline|drug
DDI-DrugBank.d522.s14|22-27|plasma|O
DDI-DrugBank.d522.s14|29-42|concentrations|O
DDI-DrugBank.d522.s14|44-49|should|O
DDI-DrugBank.d522.s14|51-52|be|O
DDI-DrugBank.d522.s14|54-62|monitored|O
DDI-DrugBank.d522.s14|63-63|,|O
DDI-DrugBank.d522.s14|65-68|with|O
DDI-DrugBank.d522.s14|70-75|dosage|O
DDI-DrugBank.d522.s14|77-86|adjustment|O
DDI-DrugBank.d522.s14|88-89|as|O
DDI-DrugBank.d522.s14|91-101|appropriate|O
DDI-DrugBank.d522.s14|102-102|,|O
DDI-DrugBank.d522.s14|104-105|in|O
DDI-DrugBank.d522.s14|107-114|patients|O
DDI-DrugBank.d522.s14|116-120|whose|O
DDI-DrugBank.d522.s14|122-130|pulmonary|O
DDI-DrugBank.d522.s14|132-138|disease|O
DDI-DrugBank.d522.s14|140-147|requires|O
DDI-DrugBank.d522.s14|149-159|maintaining|O
DDI-DrugBank.d522.s14|161-161|a|O
DDI-DrugBank.d522.s14|163-167|given|O
DDI-DrugBank.d522.s14|169-180|theophylline|drug
DDI-DrugBank.d522.s14|182-187|plasma|O
DDI-DrugBank.d522.s14|189-201|concentration|O
DDI-DrugBank.d522.s14|203-205|for|O
DDI-DrugBank.d522.s14|207-213|optimal|O
DDI-DrugBank.d522.s14|215-223|pulmonary|O
DDI-DrugBank.d522.s14|225-232|function|O
DDI-DrugBank.d522.s14|234-235|or|O
DDI-DrugBank.d522.s14|237-238|in|O
DDI-DrugBank.d522.s14|240-247|patients|O
DDI-DrugBank.d522.s14|249-252|with|O
DDI-DrugBank.d522.s14|254-265|theophylline|drug
DDI-DrugBank.d522.s14|267-280|concentrations|O
DDI-DrugBank.d522.s14|282-283|at|O
DDI-DrugBank.d522.s14|285-287|the|O
DDI-DrugBank.d522.s14|289-294|higher|O
DDI-DrugBank.d522.s14|296-298|end|O
DDI-DrugBank.d522.s14|300-301|of|O
DDI-DrugBank.d522.s14|303-305|the|O
DDI-DrugBank.d522.s14|307-317|therapeutic|O
DDI-DrugBank.d522.s14|319-323|range|O
DDI-DrugBank.d522.s14|324-324|.|O
DDI-DrugBank.d522.s15|0-7|Antacids|group
DDI-DrugBank.d522.s15|9-10|or|O
DDI-DrugBank.d522.s15|12-35|H 2 receptor antagonists|group
DDI-DrugBank.d522.s15|36-36|:|O
DDI-DrugBank.d522.s15|38-41|When|O
DDI-DrugBank.d522.s15|43-55|dirithromycin|drug
DDI-DrugBank.d522.s15|57-58|is|O
DDI-DrugBank.d522.s15|60-71|administered|O
DDI-DrugBank.d522.s15|73-83|immediately|O
DDI-DrugBank.d522.s15|85-93|following|O
DDI-DrugBank.d522.s15|95-102|antacids|group
DDI-DrugBank.d522.s15|104-105|or|O
DDI-DrugBank.d522.s15|107-131|H 2 -receptor antagonists|group
DDI-DrugBank.d522.s15|132-132|,|O
DDI-DrugBank.d522.s15|134-136|the|O
DDI-DrugBank.d522.s15|138-147|absorption|O
DDI-DrugBank.d522.s15|149-150|of|O
DDI-DrugBank.d522.s15|152-164|dirithromycin|drug
DDI-DrugBank.d522.s15|166-167|is|O
DDI-DrugBank.d522.s15|169-176|slightly|O
DDI-DrugBank.d522.s15|178-185|enhanced|O
DDI-DrugBank.d522.s15|186-186|.|O
DDI-DrugBank.d522.s16|0-2|The|O
DDI-DrugBank.d522.s16|4-12|following|O
DDI-DrugBank.d522.s16|14-17|drug|O
DDI-DrugBank.d522.s16|19-30|interactions|O
DDI-DrugBank.d522.s16|32-35|have|O
DDI-DrugBank.d522.s16|37-40|been|O
DDI-DrugBank.d522.s16|42-49|reported|O
DDI-DrugBank.d522.s16|51-54|with|O
DDI-DrugBank.d522.s16|56-67|erythromycin|drug
DDI-DrugBank.d522.s16|69-76|products|O
DDI-DrugBank.d522.s16|77-77|.|O
DDI-DrugBank.d522.s17|0-1|It|O
DDI-DrugBank.d522.s17|3-4|is|O
DDI-DrugBank.d522.s17|6-14|presently|O
DDI-DrugBank.d522.s17|16-18|not|O
DDI-DrugBank.d522.s17|20-24|known|O
DDI-DrugBank.d522.s17|26-32|whether|O
DDI-DrugBank.d522.s17|34-38|these|O
DDI-DrugBank.d522.s17|40-43|same|O
DDI-DrugBank.d522.s17|45-48|drug|O
DDI-DrugBank.d522.s17|50-61|interactions|O
DDI-DrugBank.d522.s17|63-67|occur|O
DDI-DrugBank.d522.s17|69-72|with|O
DDI-DrugBank.d522.s17|74-86|dirithromycin|drug
DDI-DrugBank.d522.s17|87-87|.|O
DDI-DrugBank.d522.s18|0-4|Until|O
DDI-DrugBank.d522.s18|6-12|further|O
DDI-DrugBank.d522.s18|14-17|data|O
DDI-DrugBank.d522.s18|19-21|are|O
DDI-DrugBank.d522.s18|23-31|available|O
DDI-DrugBank.d522.s18|33-41|regarding|O
DDI-DrugBank.d522.s18|43-45|the|O
DDI-DrugBank.d522.s18|47-55|potential|O
DDI-DrugBank.d522.s18|57-67|interaction|O
DDI-DrugBank.d522.s18|69-70|of|O
DDI-DrugBank.d522.s18|72-84|dirithromycin|drug
DDI-DrugBank.d522.s18|86-89|with|O
DDI-DrugBank.d522.s18|91-95|these|O
DDI-DrugBank.d522.s18|97-105|compounds|O
DDI-DrugBank.d522.s18|106-106|,|O
DDI-DrugBank.d522.s18|108-114|caution|O
DDI-DrugBank.d522.s18|116-121|should|O
DDI-DrugBank.d522.s18|123-124|be|O
DDI-DrugBank.d522.s18|126-129|used|O
DDI-DrugBank.d522.s18|131-136|during|O
DDI-DrugBank.d522.s18|138-153|coadministration|O
DDI-DrugBank.d522.s18|154-154|.|O
DDI-DrugBank.d522.s19|0-8|Triazolam|drug
DDI-DrugBank.d522.s19|9-9|:|O
DDI-DrugBank.d522.s19|11-22|Erythromycin|drug
DDI-DrugBank.d522.s19|24-26|has|O
DDI-DrugBank.d522.s19|28-31|been|O
DDI-DrugBank.d522.s19|33-40|reported|O
DDI-DrugBank.d522.s19|42-43|to|O
DDI-DrugBank.d522.s19|45-52|decrease|O
DDI-DrugBank.d522.s19|54-56|the|O
DDI-DrugBank.d522.s19|58-66|clearance|O
DDI-DrugBank.d522.s19|68-69|of|O
DDI-DrugBank.d522.s19|71-79|triazolam|drug
DDI-DrugBank.d522.s19|81-83|and|O
DDI-DrugBank.d522.s19|84-84|,|O
DDI-DrugBank.d522.s19|86-89|thus|O
DDI-DrugBank.d522.s19|90-90|,|O
DDI-DrugBank.d522.s19|92-94|may|O
DDI-DrugBank.d522.s19|96-103|increase|O
DDI-DrugBank.d522.s19|105-107|the|O
DDI-DrugBank.d522.s19|109-121|pharmacologic|O
DDI-DrugBank.d522.s19|123-128|effect|O
DDI-DrugBank.d522.s19|130-131|of|O
DDI-DrugBank.d522.s19|133-141|triazolam|drug
DDI-DrugBank.d522.s19|142-142|.|O
DDI-DrugBank.d522.s20|0-6|Digoxin|drug
DDI-DrugBank.d522.s20|7-7|:|O
DDI-DrugBank.d522.s20|9-19|Concomitant|O
DDI-DrugBank.d522.s20|21-34|administration|O
DDI-DrugBank.d522.s20|36-37|of|O
DDI-DrugBank.d522.s20|39-50|erythromycin|drug
DDI-DrugBank.d522.s20|52-54|and|O
DDI-DrugBank.d522.s20|56-62|digoxin|drug
DDI-DrugBank.d522.s20|64-66|has|O
DDI-DrugBank.d522.s20|68-71|been|O
DDI-DrugBank.d522.s20|73-80|reported|O
DDI-DrugBank.d522.s20|82-83|to|O
DDI-DrugBank.d522.s20|85-90|result|O
DDI-DrugBank.d522.s20|92-93|in|O
DDI-DrugBank.d522.s20|95-102|elevated|O
DDI-DrugBank.d522.s20|104-110|digoxin|drug
DDI-DrugBank.d522.s20|112-116|serum|O
DDI-DrugBank.d522.s20|118-123|levels|O
DDI-DrugBank.d522.s20|124-124|.|O
DDI-DrugBank.d522.s21|0-13|Anticoagulants|group
DDI-DrugBank.d522.s21|14-14|:|O
DDI-DrugBank.d522.s21|16-20|There|O
DDI-DrugBank.d522.s21|22-25|have|O
DDI-DrugBank.d522.s21|27-30|been|O
DDI-DrugBank.d522.s21|32-38|reports|O
DDI-DrugBank.d522.s21|40-41|of|O
DDI-DrugBank.d522.s21|43-51|increased|O
DDI-DrugBank.d522.s21|53-65|anticoagulant|O
DDI-DrugBank.d522.s21|67-73|effects|O
DDI-DrugBank.d522.s21|75-78|when|O
DDI-DrugBank.d522.s21|80-91|erythromycin|drug
DDI-DrugBank.d522.s21|93-95|and|O
DDI-DrugBank.d522.s21|97-100|oral|O
DDI-DrugBank.d522.s21|102-115|anticoagulants|group
DDI-DrugBank.d522.s21|117-120|were|O
DDI-DrugBank.d522.s21|122-125|used|O
DDI-DrugBank.d522.s21|127-139|concomitantly|O
DDI-DrugBank.d522.s21|140-140|.|O
DDI-DrugBank.d522.s22|0-8|Increased|O
DDI-DrugBank.d522.s22|10-24|anticoagulation|O
DDI-DrugBank.d522.s22|26-32|effects|O
DDI-DrugBank.d522.s22|34-36|due|O
DDI-DrugBank.d522.s22|38-39|to|O
DDI-DrugBank.d522.s22|41-41|a|O
DDI-DrugBank.d522.s22|43-46|drug|O
DDI-DrugBank.d522.s22|48-58|interaction|O
DDI-DrugBank.d522.s22|60-63|with|O
DDI-DrugBank.d522.s22|65-76|erythromycin|drug
DDI-DrugBank.d522.s22|78-80|may|O
DDI-DrugBank.d522.s22|82-83|be|O
DDI-DrugBank.d522.s22|85-88|more|O
DDI-DrugBank.d522.s22|90-99|pronounced|O
DDI-DrugBank.d522.s22|101-102|in|O
DDI-DrugBank.d522.s22|104-106|the|O
DDI-DrugBank.d522.s22|108-114|elderly|O
DDI-DrugBank.d522.s22|115-115|.|O
DDI-DrugBank.d522.s23|0-9|Ergotamine|drug
DDI-DrugBank.d522.s23|10-10|:|O
DDI-DrugBank.d522.s23|12-21|Concurrent|O
DDI-DrugBank.d522.s23|23-25|use|O
DDI-DrugBank.d522.s23|27-28|of|O
DDI-DrugBank.d522.s23|30-41|erythromycin|drug
DDI-DrugBank.d522.s23|43-45|and|O
DDI-DrugBank.d522.s23|47-56|ergotamine|drug
DDI-DrugBank.d522.s23|58-59|or|O
DDI-DrugBank.d522.s23|61-77|dihydroergotamine|drug
DDI-DrugBank.d522.s23|79-81|has|O
DDI-DrugBank.d522.s23|83-86|been|O
DDI-DrugBank.d522.s23|88-97|associated|O
DDI-DrugBank.d522.s23|99-100|in|O
DDI-DrugBank.d522.s23|102-105|some|O
DDI-DrugBank.d522.s23|107-114|patients|O
DDI-DrugBank.d522.s23|116-119|with|O
DDI-DrugBank.d522.s23|121-125|acute|O
DDI-DrugBank.d522.s23|127-131|ergot|O
DDI-DrugBank.d522.s23|133-140|toxicity|O
DDI-DrugBank.d522.s23|142-154|characterized|O
DDI-DrugBank.d522.s23|156-157|by|O
DDI-DrugBank.d522.s23|159-164|severe|O
DDI-DrugBank.d522.s23|166-175|peripheral|O
DDI-DrugBank.d522.s23|177-185|vasospasm|O
DDI-DrugBank.d522.s23|187-189|and|O
DDI-DrugBank.d522.s23|191-201|dysesthesia|O
DDI-DrugBank.d522.s23|202-202|.|O
DDI-DrugBank.d522.s24|0-4|Other|O
DDI-DrugBank.d522.s24|6-10|drugs|O
DDI-DrugBank.d522.s24|12-15|Drug|O
DDI-DrugBank.d522.s24|17-28|interactions|O
DDI-DrugBank.d522.s24|30-33|have|O
DDI-DrugBank.d522.s24|35-38|been|O
DDI-DrugBank.d522.s24|40-47|reported|O
DDI-DrugBank.d522.s24|49-52|with|O
DDI-DrugBank.d522.s24|54-64|concomitant|O
DDI-DrugBank.d522.s24|66-79|administration|O
DDI-DrugBank.d522.s24|81-82|of|O
DDI-DrugBank.d522.s24|84-95|erythromycin|drug
DDI-DrugBank.d522.s24|97-99|and|O
DDI-DrugBank.d522.s24|101-105|other|O
DDI-DrugBank.d522.s24|107-117|medications|O
DDI-DrugBank.d522.s24|118-118|,|O
DDI-DrugBank.d522.s24|120-128|including|O
DDI-DrugBank.d522.s24|130-141|cyclosporine|drug
DDI-DrugBank.d522.s24|142-142|,|O
DDI-DrugBank.d522.s24|144-155|hexobarbital|drug
DDI-DrugBank.d522.s24|156-156|,|O
DDI-DrugBank.d522.s24|158-170|carbamazepine|drug
DDI-DrugBank.d522.s24|171-171|,|O
DDI-DrugBank.d522.s24|173-182|alfentanil|drug
DDI-DrugBank.d522.s24|183-183|,|O
DDI-DrugBank.d522.s24|185-196|disopyramide|drug
DDI-DrugBank.d522.s24|197-197|,|O
DDI-DrugBank.d522.s24|199-207|phenytoin|drug
DDI-DrugBank.d522.s24|208-208|,|O
DDI-DrugBank.d522.s24|210-222|bromocriptine|drug
DDI-DrugBank.d522.s24|223-223|,|O
DDI-DrugBank.d522.s24|225-233|valproate|drug
DDI-DrugBank.d522.s24|234-234|,|O
DDI-DrugBank.d522.s24|236-245|astemizole|drug
DDI-DrugBank.d522.s24|246-246|,|O
DDI-DrugBank.d522.s24|248-250|and|O
DDI-DrugBank.d522.s24|252-261|lovastatin|drug
DDI-DrugBank.d522.s24|262-262|.|O
DDI-DrugBank.d259.s0|0-1|No|O
DDI-DrugBank.d259.s0|3-6|drug|O
DDI-DrugBank.d259.s0|8-19|interactions|O
DDI-DrugBank.d259.s0|21-24|have|O
DDI-DrugBank.d259.s0|26-29|been|O
DDI-DrugBank.d259.s0|31-38|reported|O
DDI-DrugBank.d259.s0|39-39|.|O
DDI-MedLine.d231.s0|0-10|Interaction|O
DDI-MedLine.d231.s0|12-16|study|O
DDI-MedLine.d231.s0|18-19|of|O
DDI-MedLine.d231.s0|21-32|moxifloxacin|drug
DDI-MedLine.d231.s0|34-36|and|O
DDI-MedLine.d231.s0|38-49|lomefloxacin|drug
DDI-MedLine.d231.s0|51-54|with|O
DDI-MedLine.d231.s0|56-70|co-administered|O
DDI-MedLine.d231.s0|72-76|drugs|O
DDI-MedLine.d231.s0|77-77|.|O
DDI-MedLine.d231.s1|0-11|Moxifloxacin|drug
DDI-MedLine.d231.s1|13-15|and|O
DDI-MedLine.d231.s1|17-28|lomefloxacin|drug
DDI-MedLine.d231.s1|30-32|are|O
DDI-MedLine.d231.s1|34-60|fluoroquinolone antibiotics|group
DDI-MedLine.d231.s1|62-65|used|O
DDI-MedLine.d231.s1|67-68|in|O
DDI-MedLine.d231.s1|70-77|treating|O
DDI-MedLine.d231.s1|79-85|urinary|O
DDI-MedLine.d231.s1|87-89|and|O
DDI-MedLine.d231.s1|91-101|respiratory|O
DDI-MedLine.d231.s1|103-107|tract|O
DDI-MedLine.d231.s1|109-118|infections|O
DDI-MedLine.d231.s1|119-119|.|O
DDI-MedLine.d231.s2|0-15|Fluoroquinolones|group
DDI-MedLine.d231.s2|17-19|are|O
DDI-MedLine.d231.s2|21-25|known|O
DDI-MedLine.d231.s2|27-28|to|O
DDI-MedLine.d231.s2|30-33|have|O
DDI-MedLine.d231.s2|35-46|interactions|O
DDI-MedLine.d231.s2|48-51|with|O
DDI-MedLine.d231.s2|53-57|drugs|O
DDI-MedLine.d231.s2|59-62|that|O
DDI-MedLine.d231.s2|64-66|are|O
DDI-MedLine.d231.s2|68-73|active|O
DDI-MedLine.d231.s2|75-76|in|O
DDI-MedLine.d231.s2|78-83|gastro|O
DDI-MedLine.d231.s2|85-94|intestinal|O
DDI-MedLine.d231.s2|96-100|tract|O
DDI-MedLine.d231.s2|101-101|.|O
DDI-MedLine.d231.s3|0-4|Being|O
DDI-MedLine.d231.s3|6-17|moxifloxacin|drug
DDI-MedLine.d231.s3|19-21|and|O
DDI-MedLine.d231.s3|23-34|lomefloxacin|O
DDI-MedLine.d231.s3|36-51|fluoroquinolones|group
DDI-MedLine.d231.s3|53-55|the|O
DDI-MedLine.d231.s3|57-67|interaction|O
DDI-MedLine.d231.s3|69-73|study|O
DDI-MedLine.d231.s3|75-76|of|O
DDI-MedLine.d231.s3|78-80|was|O
DDI-MedLine.d231.s3|82-88|carried|O
DDI-MedLine.d231.s3|90-92|out|O
DDI-MedLine.d231.s3|94-97|with|O
DDI-MedLine.d231.s3|99-108|sucralfate|drug
DDI-MedLine.d231.s3|109-109|,|O
DDI-MedLine.d231.s3|111-117|gelusil|brand
DDI-MedLine.d231.s3|118-118|,|O
DDI-MedLine.d231.s3|120-131|erythromycin|drug
DDI-MedLine.d231.s3|133-135|and|O
DDI-MedLine.d231.s3|137-150|multi minerals|group
DDI-MedLine.d231.s3|151-151|.|O
DDI-MedLine.d231.s4|0-2|The|O
DDI-MedLine.d231.s4|4-14|interaction|O
DDI-MedLine.d231.s4|16-18|was|O
DDI-MedLine.d231.s4|20-26|studied|O
DDI-MedLine.d231.s4|28-29|at|O
DDI-MedLine.d231.s4|31-37|neutral|O
DDI-MedLine.d231.s4|38-38|,|O
DDI-MedLine.d231.s4|40-45|acidic|O
DDI-MedLine.d231.s4|47-49|and|O
DDI-MedLine.d231.s4|51-55|basic|O
DDI-MedLine.d231.s4|57-66|conditions|O
DDI-MedLine.d231.s4|68-71|both|O
DDI-MedLine.d231.s4|73-74|at|O
DDI-MedLine.d231.s4|76-79|room|O
DDI-MedLine.d231.s4|81-91|temperature|O
DDI-MedLine.d231.s4|93-95|and|O
DDI-MedLine.d231.s4|97-98|37|O
DDI-MedLine.d231.s4|101-101|C|O
DDI-MedLine.d231.s4|102-102|.|O
DDI-MedLine.d231.s5|0-2|The|O
DDI-MedLine.d231.s5|4-9|effect|O
DDI-MedLine.d231.s5|11-12|of|O
DDI-MedLine.d231.s5|14-24|dissolution|O
DDI-MedLine.d231.s5|26-31|medium|O
DDI-MedLine.d231.s5|33-42|simulating|O
DDI-MedLine.d231.s5|44-50|various|O
DDI-MedLine.d231.s5|52-55|body|O
DDI-MedLine.d231.s5|57-68|environments|O
DDI-MedLine.d231.s5|70-73|with|O
DDI-MedLine.d231.s5|75-82|response|O
DDI-MedLine.d231.s5|84-85|to|O
DDI-MedLine.d231.s5|87-88|pH|O
DDI-MedLine.d231.s5|90-92|has|O
DDI-MedLine.d231.s5|94-97|been|O
DDI-MedLine.d231.s5|99-106|examined|O
DDI-MedLine.d231.s5|108-109|in|O
DDI-MedLine.d231.s5|111-115|order|O
DDI-MedLine.d231.s5|117-118|to|O
DDI-MedLine.d231.s5|120-128|elucidate|O
DDI-MedLine.d231.s5|130-132|the|O
DDI-MedLine.d231.s5|134-145|interactions|O
DDI-MedLine.d231.s5|146-146|.|O
DDI-MedLine.d231.s6|0-2|The|O
DDI-MedLine.d231.s6|4-11|response|O
DDI-MedLine.d231.s6|13-14|of|O
DDI-MedLine.d231.s6|16-27|moxifloxacin|drug
DDI-MedLine.d231.s6|29-31|and|O
DDI-MedLine.d231.s6|33-44|lomefloxacin|drug
DDI-MedLine.d231.s6|46-50|after|O
DDI-MedLine.d231.s6|52-62|interaction|O
DDI-MedLine.d231.s6|64-67|with|O
DDI-MedLine.d231.s6|69-83|co-administered|O
DDI-MedLine.d231.s6|85-89|drugs|O
DDI-MedLine.d231.s6|91-92|at|O
DDI-MedLine.d231.s6|94-102|different|O
DDI-MedLine.d231.s6|104-113|conditions|O
DDI-MedLine.d231.s6|115-117|and|O
DDI-MedLine.d231.s6|119-129|temperature|O
DDI-MedLine.d231.s6|131-134|were|O
DDI-MedLine.d231.s6|136-140|noted|O
DDI-MedLine.d231.s6|142-146|using|O
DDI-MedLine.d231.s6|148-148|a|O
DDI-MedLine.d231.s6|150-157|Shimadzu|O
DDI-MedLine.d231.s6|159-162|HPLC|O
DDI-MedLine.d231.s6|164-169|system|O
DDI-MedLine.d231.s6|171-174|with|O
DDI-MedLine.d231.s6|176-178|PDA|O
DDI-MedLine.d231.s6|180-187|detector|O
DDI-MedLine.d231.s6|188-188|.|O
DDI-MedLine.d231.s7|0-1|It|O
DDI-MedLine.d231.s7|3-5|was|O
DDI-MedLine.d231.s7|7-10|seen|O
DDI-MedLine.d231.s7|12-15|that|O
DDI-MedLine.d231.s7|17-27|interaction|O
DDI-MedLine.d231.s7|29-30|of|O
DDI-MedLine.d231.s7|32-36|these|O
DDI-MedLine.d231.s7|38-53|fluoroquinolones|group
DDI-MedLine.d231.s7|55-57|was|O
DDI-MedLine.d231.s7|59-62|more|O
DDI-MedLine.d231.s7|64-65|at|O
DDI-MedLine.d231.s7|67-68|37|O
DDI-MedLine.d231.s7|71-71|C|O
DDI-MedLine.d231.s7|73-76|than|O
DDI-MedLine.d231.s7|78-79|at|O
DDI-MedLine.d231.s7|81-84|room|O
DDI-MedLine.d231.s7|86-96|temperature|O
DDI-MedLine.d231.s7|97-97|.|O
DDI-MedLine.d231.s8|0-11|Moxifloxacin|drug
DDI-MedLine.d231.s8|13-15|and|O
DDI-MedLine.d231.s8|17-28|Lomefloxacin|drug
DDI-MedLine.d231.s8|30-35|reacts|O
DDI-MedLine.d231.s8|37-42|faster|O
DDI-MedLine.d231.s8|44-47|with|O
DDI-MedLine.d231.s8|49-58|sucralfate|drug
DDI-MedLine.d231.s8|60-62|and|O
DDI-MedLine.d231.s8|64-70|gelusil|brand
DDI-MedLine.d231.s8|72-73|in|O
DDI-MedLine.d231.s8|75-80|acidic|O
DDI-MedLine.d231.s8|82-86|media|O
DDI-MedLine.d231.s8|88-94|whereas|O
DDI-MedLine.d231.s8|96-99|with|O
DDI-MedLine.d231.s8|101-112|erythromycin|drug
DDI-MedLine.d231.s8|114-115|in|O
DDI-MedLine.d231.s8|117-121|basic|O
DDI-MedLine.d231.s8|123-127|media|O
DDI-MedLine.d231.s8|129-131|and|O
DDI-MedLine.d231.s8|133-146|multi-minerals|group
DDI-MedLine.d231.s8|148-149|in|O
DDI-MedLine.d231.s8|151-157|neutral|O
DDI-MedLine.d231.s8|159-163|media|O
DDI-MedLine.d231.s8|164-164|.|O
DDI-MedLine.d231.s9|0-2|The|O
DDI-MedLine.d231.s9|4-8|study|O
DDI-MedLine.d231.s9|10-16|ensures|O
DDI-MedLine.d231.s9|18-20|the|O
DDI-MedLine.d231.s9|22-32|interaction|O
DDI-MedLine.d231.s9|34-35|of|O
DDI-MedLine.d231.s9|37-52|fluoroquinolones|group
DDI-MedLine.d231.s9|54-57|with|O
DDI-MedLine.d231.s9|59-66|selected|O
DDI-MedLine.d231.s9|68-72|class|O
DDI-MedLine.d231.s9|74-75|of|O
DDI-MedLine.d231.s9|77-81|drugs|O
DDI-MedLine.d231.s9|82-82|.|O
DDI-MedLine.d231.s10|0-1|In|O
DDI-MedLine.d231.s10|3-7|order|O
DDI-MedLine.d231.s10|9-10|to|O
DDI-MedLine.d231.s10|12-18|achieve|O
DDI-MedLine.d231.s10|20-22|the|O
DDI-MedLine.d231.s10|24-32|effective|O
DDI-MedLine.d231.s10|34-44|therapeutic|O
DDI-MedLine.d231.s10|46-51|effect|O
DDI-MedLine.d231.s10|53-63|appropriate|O
DDI-MedLine.d231.s10|65-68|time|O
DDI-MedLine.d231.s10|70-78|intervals|O
DDI-MedLine.d231.s10|80-86|between|O
DDI-MedLine.d231.s10|88-102|administrations|O
DDI-MedLine.d231.s10|104-105|of|O
DDI-MedLine.d231.s10|107-111|drugs|O
DDI-MedLine.d231.s10|113-114|is|O
DDI-MedLine.d231.s10|116-124|essential|O
DDI-MedLine.d231.s10|125-125|.|O
DDI-MedLine.d112.s0|0-5|Effect|O
DDI-MedLine.d112.s0|7-8|of|O
DDI-MedLine.d112.s0|10-20|dofetillide|drug
DDI-MedLine.d112.s0|22-23|on|O
DDI-MedLine.d112.s0|25-27|the|O
DDI-MedLine.d112.s0|29-44|pharmacokinetics|O
DDI-MedLine.d112.s0|46-47|of|O
DDI-MedLine.d112.s0|49-55|digoxin|drug
DDI-MedLine.d112.s0|56-56|.|O
DDI-MedLine.d112.s1|0-2|The|O
DDI-MedLine.d112.s1|4-9|effect|O
DDI-MedLine.d112.s1|11-12|of|O
DDI-MedLine.d112.s1|14-23|dofetilide|drug
DDI-MedLine.d112.s1|25-26|on|O
DDI-MedLine.d112.s1|28-30|the|O
DDI-MedLine.d112.s1|32-43|steady-state|O
DDI-MedLine.d112.s1|45-60|pharmacokinetics|O
DDI-MedLine.d112.s1|62-63|of|O
DDI-MedLine.d112.s1|65-71|digoxin|drug
DDI-MedLine.d112.s1|73-75|was|O
DDI-MedLine.d112.s1|77-85|evaluated|O
DDI-MedLine.d112.s1|87-88|in|O
DDI-MedLine.d112.s1|90-90|a|O
DDI-MedLine.d112.s1|92-101|randomized|O
DDI-MedLine.d112.s1|102-102|,|O
DDI-MedLine.d112.s1|104-115|double-blind|O
DDI-MedLine.d112.s1|117-121|study|O
DDI-MedLine.d112.s1|122-122|.|O
DDI-MedLine.d112.s2|0-3|Five|O
DDI-MedLine.d112.s2|5-8|days|O
DDI-MedLine.d112.s2|10-11|of|O
DDI-MedLine.d112.s2|13-22|dofetilide|drug
DDI-MedLine.d112.s2|24-32|treatment|O
DDI-MedLine.d112.s2|34-36|did|O
DDI-MedLine.d112.s2|38-40|not|O
DDI-MedLine.d112.s2|42-54|significantly|O
DDI-MedLine.d112.s2|56-61|affect|O
DDI-MedLine.d112.s2|63-74|steady-state|O
DDI-MedLine.d112.s2|76-90|pharmacokinetic|O
DDI-MedLine.d112.s2|92-100|variables|O
DDI-MedLine.d112.s2|102-103|of|O
DDI-MedLine.d112.s2|105-111|digoxin|drug
DDI-MedLine.d112.s2|113-120|compared|O
DDI-MedLine.d112.s2|122-125|with|O
DDI-MedLine.d112.s2|127-133|placebo|O
DDI-MedLine.d112.s2|134-134|;|O
DDI-MedLine.d112.s3|0-8|therefore|O
DDI-MedLine.d112.s3|9-9|,|O
DDI-MedLine.d112.s3|11-13|the|O
DDI-MedLine.d112.s3|15-17|use|O
DDI-MedLine.d112.s3|19-20|of|O
DDI-MedLine.d112.s3|22-31|dofetilide|drug
DDI-MedLine.d112.s3|33-36|does|O
DDI-MedLine.d112.s3|38-40|not|O
DDI-MedLine.d112.s3|42-52|necessitate|O
DDI-MedLine.d112.s3|54-55|an|O
DDI-MedLine.d112.s3|57-66|adjustment|O
DDI-MedLine.d112.s3|68-69|in|O
DDI-MedLine.d112.s3|71-77|digoxin|drug
DDI-MedLine.d112.s3|79-82|dose|O
DDI-MedLine.d112.s3|84-85|to|O
DDI-MedLine.d112.s3|87-94|maintain|O
DDI-MedLine.d112.s3|96-106|therapeutic|O
DDI-MedLine.d112.s3|108-114|digoxin|O
DDI-MedLine.d112.s3|116-121|levels|O
DDI-MedLine.d112.s3|122-122|.|O
DDI-DrugBank.d178.s0|0-2|The|O
DDI-DrugBank.d178.s0|4-15|hypoglycemic|O
DDI-DrugBank.d178.s0|17-22|action|O
DDI-DrugBank.d178.s0|24-25|of|O
DDI-DrugBank.d178.s0|27-39|sulfonylureas|group
DDI-DrugBank.d178.s0|41-43|may|O
DDI-DrugBank.d178.s0|45-46|be|O
DDI-DrugBank.d178.s0|48-58|potentiated|O
DDI-DrugBank.d178.s0|60-61|by|O
DDI-DrugBank.d178.s0|63-69|certain|O
DDI-DrugBank.d178.s0|71-75|drugs|O
DDI-DrugBank.d178.s0|77-85|including|O
DDI-DrugBank.d178.s0|87-123|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d178.s0|125-127|and|O
DDI-DrugBank.d178.s0|129-133|other|O
DDI-DrugBank.d178.s0|135-139|drugs|O
DDI-DrugBank.d178.s0|141-144|that|O
DDI-DrugBank.d178.s0|146-148|are|O
DDI-DrugBank.d178.s0|150-155|highly|O
DDI-DrugBank.d178.s0|157-163|protein|O
DDI-DrugBank.d178.s0|165-169|bound|O
DDI-DrugBank.d178.s0|170-170|,|O
DDI-DrugBank.d178.s0|172-182|salicylates|group
DDI-DrugBank.d178.s0|183-183|,|O
DDI-DrugBank.d178.s0|185-196|sulfonamides|group
DDI-DrugBank.d178.s0|197-197|,|O
DDI-DrugBank.d178.s0|199-213|chloramphenicol|drug
DDI-DrugBank.d178.s0|214-214|,|O
DDI-DrugBank.d178.s0|216-225|probenecid|drug
DDI-DrugBank.d178.s0|226-226|,|O
DDI-DrugBank.d178.s0|228-236|coumarins|group
DDI-DrugBank.d178.s0|237-237|,|O
DDI-DrugBank.d178.s0|239-266|monoamine oxidase inhibitors|group
DDI-DrugBank.d178.s0|267-267|,|O
DDI-DrugBank.d178.s0|269-271|and|O
DDI-DrugBank.d178.s0|273-303|beta adrenergic blocking agents|group
DDI-DrugBank.d178.s0|304-304|.|O
DDI-DrugBank.d178.s1|0-3|When|O
DDI-DrugBank.d178.s1|5-8|such|O
DDI-DrugBank.d178.s1|10-14|drugs|O
DDI-DrugBank.d178.s1|16-18|are|O
DDI-DrugBank.d178.s1|20-31|administered|O
DDI-DrugBank.d178.s1|33-34|to|O
DDI-DrugBank.d178.s1|36-36|a|O
DDI-DrugBank.d178.s1|38-44|patient|O
DDI-DrugBank.d178.s1|46-54|receiving|O
DDI-DrugBank.d178.s1|56-64|MICRONASE|brand
DDI-DrugBank.d178.s1|65-65|,|O
DDI-DrugBank.d178.s1|67-69|the|O
DDI-DrugBank.d178.s1|71-77|patient|O
DDI-DrugBank.d178.s1|79-84|should|O
DDI-DrugBank.d178.s1|86-87|be|O
DDI-DrugBank.d178.s1|89-96|observed|O
DDI-DrugBank.d178.s1|98-104|closely|O
DDI-DrugBank.d178.s1|106-108|for|O
DDI-DrugBank.d178.s1|110-121|hypoglycemia|O
DDI-DrugBank.d178.s1|122-122|.|O
DDI-DrugBank.d178.s2|0-3|When|O
DDI-DrugBank.d178.s2|5-8|such|O
DDI-DrugBank.d178.s2|10-14|drugs|O
DDI-DrugBank.d178.s2|16-18|are|O
DDI-DrugBank.d178.s2|20-28|withdrawn|O
DDI-DrugBank.d178.s2|30-33|from|O
DDI-DrugBank.d178.s2|35-35|a|O
DDI-DrugBank.d178.s2|37-43|patient|O
DDI-DrugBank.d178.s2|45-53|receiving|O
DDI-DrugBank.d178.s2|55-63|MICRONASE|brand
DDI-DrugBank.d178.s2|64-64|,|O
DDI-DrugBank.d178.s2|66-68|the|O
DDI-DrugBank.d178.s2|70-76|patient|O
DDI-DrugBank.d178.s2|78-83|should|O
DDI-DrugBank.d178.s2|85-86|be|O
DDI-DrugBank.d178.s2|88-95|observed|O
DDI-DrugBank.d178.s2|97-103|closely|O
DDI-DrugBank.d178.s2|105-107|for|O
DDI-DrugBank.d178.s2|109-112|loss|O
DDI-DrugBank.d178.s2|114-115|of|O
DDI-DrugBank.d178.s2|117-123|control|O
DDI-DrugBank.d178.s2|124-124|.|O
DDI-DrugBank.d178.s3|0-6|Certain|O
DDI-DrugBank.d178.s3|8-12|drugs|O
DDI-DrugBank.d178.s3|14-17|tend|O
DDI-DrugBank.d178.s3|19-20|to|O
DDI-DrugBank.d178.s3|22-28|produce|O
DDI-DrugBank.d178.s3|30-42|hyperglycemia|O
DDI-DrugBank.d178.s3|44-46|and|O
DDI-DrugBank.d178.s3|48-50|may|O
DDI-DrugBank.d178.s3|52-55|lead|O
DDI-DrugBank.d178.s3|57-58|to|O
DDI-DrugBank.d178.s3|60-63|loss|O
DDI-DrugBank.d178.s3|65-66|of|O
DDI-DrugBank.d178.s3|68-74|control|O
DDI-DrugBank.d178.s3|75-75|.|O
DDI-DrugBank.d178.s4|0-4|These|O
DDI-DrugBank.d178.s4|6-10|drugs|O
DDI-DrugBank.d178.s4|12-18|include|O
DDI-DrugBank.d178.s4|20-22|the|O
DDI-DrugBank.d178.s4|24-32|thiazides|group
DDI-DrugBank.d178.s4|34-36|and|O
DDI-DrugBank.d178.s4|38-42|other|O
DDI-DrugBank.d178.s4|44-52|diuretics|group
DDI-DrugBank.d178.s4|53-53|,|O
DDI-DrugBank.d178.s4|55-69|corticosteroids|group
DDI-DrugBank.d178.s4|70-70|,|O
DDI-DrugBank.d178.s4|72-86|phe-nothiazines|O
DDI-DrugBank.d178.s4|87-87|,|O
DDI-DrugBank.d178.s4|89-104|thyroid products|group
DDI-DrugBank.d178.s4|105-105|,|O
DDI-DrugBank.d178.s4|107-115|estrogens|group
DDI-DrugBank.d178.s4|116-116|,|O
DDI-DrugBank.d178.s4|118-121|oral|O
DDI-DrugBank.d178.s4|123-136|contraceptives|group
DDI-DrugBank.d178.s4|137-137|,|O
DDI-DrugBank.d178.s4|139-147|phenytoin|drug
DDI-DrugBank.d178.s4|148-148|,|O
DDI-DrugBank.d178.s4|150-163|nicotinic acid|drug
DDI-DrugBank.d178.s4|164-164|,|O
DDI-DrugBank.d178.s4|166-182|sympathomimet-ics|O
DDI-DrugBank.d178.s4|183-183|,|O
DDI-DrugBank.d178.s4|185-214|calcium channel blocking drugs|group
DDI-DrugBank.d178.s4|215-215|,|O
DDI-DrugBank.d178.s4|217-219|and|O
DDI-DrugBank.d178.s4|221-229|isoniazid|drug
DDI-DrugBank.d178.s4|230-230|.|O
DDI-DrugBank.d178.s5|0-3|When|O
DDI-DrugBank.d178.s5|5-8|such|O
DDI-DrugBank.d178.s5|10-14|drugs|O
DDI-DrugBank.d178.s5|16-18|are|O
DDI-DrugBank.d178.s5|20-31|administered|O
DDI-DrugBank.d178.s5|33-34|to|O
DDI-DrugBank.d178.s5|36-36|a|O
DDI-DrugBank.d178.s5|38-44|patient|O
DDI-DrugBank.d178.s5|46-54|receiving|O
DDI-DrugBank.d178.s5|56-64|MICRONASE|brand
DDI-DrugBank.d178.s5|65-65|,|O
DDI-DrugBank.d178.s5|67-69|the|O
DDI-DrugBank.d178.s5|71-77|patient|O
DDI-DrugBank.d178.s5|79-84|should|O
DDI-DrugBank.d178.s5|86-87|be|O
DDI-DrugBank.d178.s5|89-95|closely|O
DDI-DrugBank.d178.s5|97-104|observed|O
DDI-DrugBank.d178.s5|106-108|for|O
DDI-DrugBank.d178.s5|110-113|loss|O
DDI-DrugBank.d178.s5|115-116|of|O
DDI-DrugBank.d178.s5|118-124|control|O
DDI-DrugBank.d178.s5|125-125|.|O
DDI-DrugBank.d178.s6|0-3|When|O
DDI-DrugBank.d178.s6|5-8|such|O
DDI-DrugBank.d178.s6|10-14|drugs|O
DDI-DrugBank.d178.s6|16-18|are|O
DDI-DrugBank.d178.s6|20-28|withdrawn|O
DDI-DrugBank.d178.s6|30-33|from|O
DDI-DrugBank.d178.s6|35-35|a|O
DDI-DrugBank.d178.s6|37-43|patient|O
DDI-DrugBank.d178.s6|45-53|receiving|O
DDI-DrugBank.d178.s6|55-63|MICRONASE|brand
DDI-DrugBank.d178.s6|64-64|,|O
DDI-DrugBank.d178.s6|66-68|the|O
DDI-DrugBank.d178.s6|70-76|patient|O
DDI-DrugBank.d178.s6|78-83|should|O
DDI-DrugBank.d178.s6|85-86|be|O
DDI-DrugBank.d178.s6|88-95|observed|O
DDI-DrugBank.d178.s6|97-103|closely|O
DDI-DrugBank.d178.s6|105-107|for|O
DDI-DrugBank.d178.s6|109-120|hypoglycemia|O
DDI-DrugBank.d178.s6|121-121|.|O
DDI-DrugBank.d178.s7|0-0|A|O
DDI-DrugBank.d178.s7|2-9|possible|O
DDI-DrugBank.d178.s7|11-21|interaction|O
DDI-DrugBank.d178.s7|23-29|between|O
DDI-DrugBank.d178.s7|31-39|glyburide|drug
DDI-DrugBank.d178.s7|41-43|and|O
DDI-DrugBank.d178.s7|45-57|ciprofloxacin|drug
DDI-DrugBank.d178.s7|58-58|,|O
DDI-DrugBank.d178.s7|60-60|a|O
DDI-DrugBank.d178.s7|62-87|fluoroquinolone antibiotic|group
DDI-DrugBank.d178.s7|88-88|,|O
DDI-DrugBank.d178.s7|90-92|has|O
DDI-DrugBank.d178.s7|94-97|been|O
DDI-DrugBank.d178.s7|99-106|reported|O
DDI-DrugBank.d178.s7|107-107|,|O
DDI-DrugBank.d178.s7|109-117|resulting|O
DDI-DrugBank.d178.s7|119-120|in|O
DDI-DrugBank.d178.s7|122-122|a|O
DDI-DrugBank.d178.s7|124-135|potentiation|O
DDI-DrugBank.d178.s7|137-138|of|O
DDI-DrugBank.d178.s7|140-142|the|O
DDI-DrugBank.d178.s7|144-155|hypoglycemic|O
DDI-DrugBank.d178.s7|157-162|action|O
DDI-DrugBank.d178.s7|164-165|of|O
DDI-DrugBank.d178.s7|167-175|glyburide|drug
DDI-DrugBank.d178.s7|176-176|.|O
DDI-DrugBank.d178.s8|0-2|The|O
DDI-DrugBank.d178.s8|4-12|mechanism|O
DDI-DrugBank.d178.s8|14-16|for|O
DDI-DrugBank.d178.s8|18-21|this|O
DDI-DrugBank.d178.s8|23-33|interaction|O
DDI-DrugBank.d178.s8|35-36|is|O
DDI-DrugBank.d178.s8|38-40|not|O
DDI-DrugBank.d178.s8|42-46|known|O
DDI-DrugBank.d178.s8|47-47|.|O
DDI-DrugBank.d178.s9|0-0|A|O
DDI-DrugBank.d178.s9|2-10|potential|O
DDI-DrugBank.d178.s9|12-22|interaction|O
DDI-DrugBank.d178.s9|24-30|between|O
DDI-DrugBank.d178.s9|32-35|oral|O
DDI-DrugBank.d178.s9|37-46|miconazole|drug
DDI-DrugBank.d178.s9|48-50|and|O
DDI-DrugBank.d178.s9|52-55|oral|O
DDI-DrugBank.d178.s9|57-75|hypoglycemic agents|group
DDI-DrugBank.d178.s9|77-83|leading|O
DDI-DrugBank.d178.s9|85-86|to|O
DDI-DrugBank.d178.s9|88-93|severe|O
DDI-DrugBank.d178.s9|95-106|hypoglycemia|O
DDI-DrugBank.d178.s9|108-110|has|O
DDI-DrugBank.d178.s9|112-115|been|O
DDI-DrugBank.d178.s9|117-124|reported|O
DDI-DrugBank.d178.s9|125-125|.|O
DDI-DrugBank.d178.s10|0-6|Whether|O
DDI-DrugBank.d178.s10|8-11|this|O
DDI-DrugBank.d178.s10|13-23|interaction|O
DDI-DrugBank.d178.s10|25-28|also|O
DDI-DrugBank.d178.s10|30-35|occurs|O
DDI-DrugBank.d178.s10|37-40|with|O
DDI-DrugBank.d178.s10|42-44|the|O
DDI-DrugBank.d178.s10|46-56|intravenous|O
DDI-DrugBank.d178.s10|57-57|,|O
DDI-DrugBank.d178.s10|59-65|topical|O
DDI-DrugBank.d178.s10|67-68|or|O
DDI-DrugBank.d178.s10|70-76|vaginal|O
DDI-DrugBank.d178.s10|78-89|preparations|O
DDI-DrugBank.d178.s10|91-92|of|O
DDI-DrugBank.d178.s10|94-103|miconazole|drug
DDI-DrugBank.d178.s10|105-106|is|O
DDI-DrugBank.d178.s10|108-110|not|O
DDI-DrugBank.d178.s10|112-116|known|O
DDI-DrugBank.d178.s10|117-117|.|O
DDI-DrugBank.d178.s11|0-8|Metformin|drug
DDI-DrugBank.d178.s11|9-9|:|O
DDI-DrugBank.d178.s11|11-12|In|O
DDI-DrugBank.d178.s11|14-14|a|O
DDI-DrugBank.d178.s11|16-26|single-dose|O
DDI-DrugBank.d178.s11|28-38|interaction|O
DDI-DrugBank.d178.s11|40-44|study|O
DDI-DrugBank.d178.s11|46-47|in|O
DDI-DrugBank.d178.s11|49-53|NIDDM|O
DDI-DrugBank.d178.s11|55-62|subjects|O
DDI-DrugBank.d178.s11|63-63|,|O
DDI-DrugBank.d178.s11|65-73|decreases|O
DDI-DrugBank.d178.s11|75-76|in|O
DDI-DrugBank.d178.s11|78-86|glyburide|drug
DDI-DrugBank.d178.s11|88-90|AUC|O
DDI-DrugBank.d178.s11|92-94|and|O
DDI-DrugBank.d178.s11|96-99|Cmax|O
DDI-DrugBank.d178.s11|101-104|were|O
DDI-DrugBank.d178.s11|106-113|observed|O
DDI-DrugBank.d178.s11|114-114|,|O
DDI-DrugBank.d178.s11|116-118|but|O
DDI-DrugBank.d178.s11|120-123|were|O
DDI-DrugBank.d178.s11|125-130|highly|O
DDI-DrugBank.d178.s11|132-139|variable|O
DDI-DrugBank.d178.s11|140-140|.|O
DDI-DrugBank.d178.s12|0-2|The|O
DDI-DrugBank.d178.s12|4-14|single-dose|O
DDI-DrugBank.d178.s12|16-21|nature|O
DDI-DrugBank.d178.s12|23-24|of|O
DDI-DrugBank.d178.s12|26-29|this|O
DDI-DrugBank.d178.s12|31-35|study|O
DDI-DrugBank.d178.s12|37-39|and|O
DDI-DrugBank.d178.s12|41-43|the|O
DDI-DrugBank.d178.s12|45-48|lack|O
DDI-DrugBank.d178.s12|50-51|of|O
DDI-DrugBank.d178.s12|53-63|correlation|O
DDI-DrugBank.d178.s12|65-71|between|O
DDI-DrugBank.d178.s12|73-81|glyburide|drug
DDI-DrugBank.d178.s12|83-87|blood|O
DDI-DrugBank.d178.s12|89-94|levels|O
DDI-DrugBank.d178.s12|96-98|and|O
DDI-DrugBank.d178.s12|100-115|pharmaco-dynamic|O
DDI-DrugBank.d178.s12|117-123|effects|O
DDI-DrugBank.d178.s12|124-124|,|O
DDI-DrugBank.d178.s12|126-130|makes|O
DDI-DrugBank.d178.s12|132-134|the|O
DDI-DrugBank.d178.s12|136-143|clinical|O
DDI-DrugBank.d178.s12|145-156|significance|O
DDI-DrugBank.d178.s12|158-159|of|O
DDI-DrugBank.d178.s12|161-164|this|O
DDI-DrugBank.d178.s12|166-176|interaction|O
DDI-DrugBank.d178.s12|178-186|uncertain|O
DDI-DrugBank.d178.s12|187-187|.|O
DDI-DrugBank.d178.s13|0-15|Coadministration|O
DDI-DrugBank.d178.s13|17-18|of|O
DDI-DrugBank.d178.s13|20-29|gly-buride|O
DDI-DrugBank.d178.s13|31-33|and|O
DDI-DrugBank.d178.s13|35-43|metformin|drug
DDI-DrugBank.d178.s13|45-47|did|O
DDI-DrugBank.d178.s13|49-51|not|O
DDI-DrugBank.d178.s13|53-58|result|O
DDI-DrugBank.d178.s13|60-61|in|O
DDI-DrugBank.d178.s13|63-65|any|O
DDI-DrugBank.d178.s13|67-73|changes|O
DDI-DrugBank.d178.s13|75-76|in|O
DDI-DrugBank.d178.s13|78-83|either|O
DDI-DrugBank.d178.s13|85-93|metformin|drug
DDI-DrugBank.d178.s13|95-110|pharmacokinetics|O
DDI-DrugBank.d178.s13|112-113|or|O
DDI-DrugBank.d178.s13|115-131|pharmaco-dynamics|O
DDI-DrugBank.d178.s13|132-132|.|O
DDI-DrugBank.d388.s0|0-28|Catecholamine-depleting drugs|group
DDI-DrugBank.d388.s0|29-29|,|O
DDI-DrugBank.d388.s0|31-34|such|O
DDI-DrugBank.d388.s0|36-37|as|O
DDI-DrugBank.d388.s0|39-47|reserpine|drug
DDI-DrugBank.d388.s0|48-48|,|O
DDI-DrugBank.d388.s0|50-52|may|O
DDI-DrugBank.d388.s0|54-57|have|O
DDI-DrugBank.d388.s0|59-60|an|O
DDI-DrugBank.d388.s0|62-69|additive|O
DDI-DrugBank.d388.s0|71-76|effect|O
DDI-DrugBank.d388.s0|78-81|when|O
DDI-DrugBank.d388.s0|83-87|given|O
DDI-DrugBank.d388.s0|89-92|with|O
DDI-DrugBank.d388.s0|94-113|beta-blocking agents|group
DDI-DrugBank.d388.s0|114-114|.|O
DDI-DrugBank.d388.s1|0-7|Patients|O
DDI-DrugBank.d388.s1|9-15|treated|O
DDI-DrugBank.d388.s1|17-20|with|O
DDI-DrugBank.d388.s1|22-31|acebutolol|drug
DDI-DrugBank.d388.s1|33-36|plus|O
DDI-DrugBank.d388.s1|38-60|catecholamine depletors|group
DDI-DrugBank.d388.s1|62-67|should|O
DDI-DrugBank.d388.s1|68-68|,|O
DDI-DrugBank.d388.s1|70-78|therefore|O
DDI-DrugBank.d388.s1|79-79|,|O
DDI-DrugBank.d388.s1|81-82|be|O
DDI-DrugBank.d388.s1|84-91|observed|O
DDI-DrugBank.d388.s1|93-99|closely|O
DDI-DrugBank.d388.s1|101-103|for|O
DDI-DrugBank.d388.s1|105-112|evidence|O
DDI-DrugBank.d388.s1|114-115|of|O
DDI-DrugBank.d388.s1|117-122|marked|O
DDI-DrugBank.d388.s1|124-134|bradycardia|O
DDI-DrugBank.d388.s1|136-137|or|O
DDI-DrugBank.d388.s1|139-149|hypotension|O
DDI-DrugBank.d388.s1|151-155|which|O
DDI-DrugBank.d388.s1|157-159|may|O
DDI-DrugBank.d388.s1|161-167|present|O
DDI-DrugBank.d388.s1|169-170|as|O
DDI-DrugBank.d388.s1|172-178|vertigo|O
DDI-DrugBank.d388.s1|179-179|,|O
DDI-DrugBank.d388.s1|181-198|syncope/presyncope|O
DDI-DrugBank.d388.s1|199-199|,|O
DDI-DrugBank.d388.s1|201-202|or|O
DDI-DrugBank.d388.s1|204-214|orthostatic|O
DDI-DrugBank.d388.s1|216-222|changes|O
DDI-DrugBank.d388.s1|224-225|in|O
DDI-DrugBank.d388.s1|227-231|blood|O
DDI-DrugBank.d388.s1|233-240|pressure|O
DDI-DrugBank.d388.s1|242-248|without|O
DDI-DrugBank.d388.s1|250-261|compensatory|O
DDI-DrugBank.d388.s1|263-273|tachycardia|O
DDI-DrugBank.d388.s1|274-274|.|O
DDI-DrugBank.d388.s2|0-10|Exaggerated|O
DDI-DrugBank.d388.s2|12-23|hypertensive|O
DDI-DrugBank.d388.s2|25-33|responses|O
DDI-DrugBank.d388.s2|35-38|have|O
DDI-DrugBank.d388.s2|40-43|been|O
DDI-DrugBank.d388.s2|45-52|reported|O
DDI-DrugBank.d388.s2|54-57|from|O
DDI-DrugBank.d388.s2|59-61|the|O
DDI-DrugBank.d388.s2|63-70|combined|O
DDI-DrugBank.d388.s2|72-74|use|O
DDI-DrugBank.d388.s2|76-77|of|O
DDI-DrugBank.d388.s2|79-105|beta-adrenergic antagonists|group
DDI-DrugBank.d388.s2|107-109|and|O
DDI-DrugBank.d388.s2|111-137|alpha-adrenergic stimulants|group
DDI-DrugBank.d388.s2|138-138|,|O
DDI-DrugBank.d388.s2|140-148|including|O
DDI-DrugBank.d388.s2|150-154|those|O
DDI-DrugBank.d388.s2|156-164|contained|O
DDI-DrugBank.d388.s2|166-167|in|O
DDI-DrugBank.d388.s2|169-179|proprietary|O
DDI-DrugBank.d388.s2|181-184|cold|O
DDI-DrugBank.d388.s2|186-193|remedies|O
DDI-DrugBank.d388.s2|195-197|and|O
DDI-DrugBank.d388.s2|199-214|vasoconstrictive|O
DDI-DrugBank.d388.s2|216-220|nasal|O
DDI-DrugBank.d388.s2|222-226|drops|O
DDI-DrugBank.d388.s2|227-227|.|O
DDI-DrugBank.d388.s3|0-7|Patients|O
DDI-DrugBank.d388.s3|9-17|receiving|O
DDI-DrugBank.d388.s3|19-31|beta-blockers|group
DDI-DrugBank.d388.s3|33-38|should|O
DDI-DrugBank.d388.s3|40-41|be|O
DDI-DrugBank.d388.s3|43-48|warned|O
DDI-DrugBank.d388.s3|50-51|of|O
DDI-DrugBank.d388.s3|53-56|this|O
DDI-DrugBank.d388.s3|58-66|potential|O
DDI-DrugBank.d388.s3|68-73|hazard|O
DDI-DrugBank.d388.s3|74-74|.|O
DDI-DrugBank.d388.s4|0-7|Blunting|O
DDI-DrugBank.d388.s4|9-10|of|O
DDI-DrugBank.d388.s4|12-14|the|O
DDI-DrugBank.d388.s4|16-31|antihypertensive|O
DDI-DrugBank.d388.s4|33-38|effect|O
DDI-DrugBank.d388.s4|40-41|of|O
DDI-DrugBank.d388.s4|43-75|beta-adrenoceptor blocking agents|group
DDI-DrugBank.d388.s4|77-78|by|O
DDI-DrugBank.d388.s4|80-115|nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d388.s4|117-119|has|O
DDI-DrugBank.d388.s4|121-124|been|O
DDI-DrugBank.d388.s4|126-133|reported|O
DDI-DrugBank.d388.s4|134-134|.|O
DDI-DrugBank.d388.s5|0-1|No|O
DDI-DrugBank.d388.s5|3-13|significant|O
DDI-DrugBank.d388.s5|15-26|interactions|O
DDI-DrugBank.d388.s5|28-31|with|O
DDI-DrugBank.d388.s5|33-39|digoxin|drug
DDI-DrugBank.d388.s5|40-40|,|O
DDI-DrugBank.d388.s5|42-60|hydrochlorothiazide|drug
DDI-DrugBank.d388.s5|61-61|,|O
DDI-DrugBank.d388.s5|63-73|hydralazine|drug
DDI-DrugBank.d388.s5|74-74|,|O
DDI-DrugBank.d388.s5|76-89|sulfinpyrazone|drug
DDI-DrugBank.d388.s5|90-90|,|O
DDI-DrugBank.d388.s5|92-95|oral|O
DDI-DrugBank.d388.s5|97-110|contraceptives|group
DDI-DrugBank.d388.s5|111-111|,|O
DDI-DrugBank.d388.s5|113-123|tolbutamide|drug
DDI-DrugBank.d388.s5|124-124|,|O
DDI-DrugBank.d388.s5|126-127|or|O
DDI-DrugBank.d388.s5|129-136|warfarin|drug
DDI-DrugBank.d388.s5|138-141|have|O
DDI-DrugBank.d388.s5|143-146|been|O
DDI-DrugBank.d388.s5|148-155|observed|O
DDI-DrugBank.d388.s5|156-156|.|O
DDI-MedLine.d25.s0|0-13|Rhabdomyolysis|O
DDI-MedLine.d25.s0|15-23|secondary|O
DDI-MedLine.d25.s0|25-26|to|O
DDI-MedLine.d25.s0|28-28|a|O
DDI-MedLine.d25.s0|30-33|drug|O
DDI-MedLine.d25.s0|35-45|interaction|O
DDI-MedLine.d25.s0|47-53|between|O
DDI-MedLine.d25.s0|55-65|simvastatin|drug
DDI-MedLine.d25.s0|67-69|and|O
DDI-MedLine.d25.s0|71-84|clarithromycin|drug
DDI-MedLine.d25.s0|85-85|.|O
DDI-MedLine.d25.s1|0-8|OBJECTIVE|O
DDI-MedLine.d25.s1|9-9|:|O
DDI-MedLine.d25.s1|11-12|To|O
DDI-MedLine.d25.s1|14-19|report|O
DDI-MedLine.d25.s1|21-21|a|O
DDI-MedLine.d25.s1|23-26|case|O
DDI-MedLine.d25.s1|28-29|of|O
DDI-MedLine.d25.s1|31-44|rhabdomyolysis|O
DDI-MedLine.d25.s1|46-54|resulting|O
DDI-MedLine.d25.s1|56-59|from|O
DDI-MedLine.d25.s1|61-71|concomitant|O
DDI-MedLine.d25.s1|73-75|use|O
DDI-MedLine.d25.s1|77-78|of|O
DDI-MedLine.d25.s1|80-93|clarithromycin|drug
DDI-MedLine.d25.s1|95-97|and|O
DDI-MedLine.d25.s1|99-109|simvastatin|drug
DDI-MedLine.d25.s1|110-110|.|O
DDI-MedLine.d25.s2|0-3|CASE|O
DDI-MedLine.d25.s2|5-11|SUMMARY|O
DDI-MedLine.d25.s2|12-12|:|O
DDI-MedLine.d25.s2|14-14|A|O
DDI-MedLine.d25.s2|16-26|64-year-old|O
DDI-MedLine.d25.s2|28-43|African-American|O
DDI-MedLine.d25.s2|45-47|man|O
DDI-MedLine.d25.s2|49-51|was|O
DDI-MedLine.d25.s2|53-60|admitted|O
DDI-MedLine.d25.s2|62-63|to|O
DDI-MedLine.d25.s2|65-67|the|O
DDI-MedLine.d25.s2|69-76|hospital|O
DDI-MedLine.d25.s2|78-80|for|O
DDI-MedLine.d25.s2|82-90|worsening|O
DDI-MedLine.d25.s2|92-96|renal|O
DDI-MedLine.d25.s2|98-104|failure|O
DDI-MedLine.d25.s2|105-105|,|O
DDI-MedLine.d25.s2|107-114|elevated|O
DDI-MedLine.d25.s2|116-123|creatine|O
DDI-MedLine.d25.s2|125-137|phosphokinase|O
DDI-MedLine.d25.s2|138-138|,|O
DDI-MedLine.d25.s2|140-146|diffuse|O
DDI-MedLine.d25.s2|148-153|muscle|O
DDI-MedLine.d25.s2|155-158|pain|O
DDI-MedLine.d25.s2|159-159|,|O
DDI-MedLine.d25.s2|161-163|and|O
DDI-MedLine.d25.s2|165-170|severe|O
DDI-MedLine.d25.s2|172-177|muscle|O
DDI-MedLine.d25.s2|179-186|weakness|O
DDI-MedLine.d25.s2|187-187|.|O
DDI-MedLine.d25.s3|0-4|About|O
DDI-MedLine.d25.s3|6-10|three|O
DDI-MedLine.d25.s3|12-16|weeks|O
DDI-MedLine.d25.s3|18-22|prior|O
DDI-MedLine.d25.s3|24-25|to|O
DDI-MedLine.d25.s3|27-35|admission|O
DDI-MedLine.d25.s3|36-36|,|O
DDI-MedLine.d25.s3|38-40|the|O
DDI-MedLine.d25.s3|42-48|patient|O
DDI-MedLine.d25.s3|50-52|was|O
DDI-MedLine.d25.s3|54-60|started|O
DDI-MedLine.d25.s3|62-63|on|O
DDI-MedLine.d25.s3|65-78|clarithromycin|drug
DDI-MedLine.d25.s3|80-82|for|O
DDI-MedLine.d25.s3|84-92|sinusitis|O
DDI-MedLine.d25.s3|93-93|.|O
DDI-MedLine.d25.s4|0-2|The|O
DDI-MedLine.d25.s4|4-10|patient|O
DDI-MedLine.d25.s4|12-14|had|O
DDI-MedLine.d25.s4|16-19|been|O
DDI-MedLine.d25.s4|21-29|receiving|O
DDI-MedLine.d25.s4|31-41|simvastatin|drug
DDI-MedLine.d25.s4|43-45|for|O
DDI-MedLine.d25.s4|47-59|approximately|O
DDI-MedLine.d25.s4|61-63|six|O
DDI-MedLine.d25.s4|65-70|months|O
DDI-MedLine.d25.s4|71-71|.|O
DDI-MedLine.d25.s5|0-1|He|O
DDI-MedLine.d25.s5|3-5|was|O
DDI-MedLine.d25.s5|7-13|treated|O
DDI-MedLine.d25.s5|15-26|aggressively|O
DDI-MedLine.d25.s5|28-31|with|O
DDI-MedLine.d25.s5|33-43|intravenous|O
DDI-MedLine.d25.s5|45-53|hydration|O
DDI-MedLine.d25.s5|54-54|,|O
DDI-MedLine.d25.s5|56-73|sodium bicarbonate|drug
DDI-MedLine.d25.s5|74-74|,|O
DDI-MedLine.d25.s5|76-78|and|O
DDI-MedLine.d25.s5|80-91|hemodialysis|O
DDI-MedLine.d25.s5|92-92|.|O
DDI-MedLine.d25.s6|0-0|A|O
DDI-MedLine.d25.s6|2-7|muscle|O
DDI-MedLine.d25.s6|9-14|biopsy|O
DDI-MedLine.d25.s6|16-23|revealed|O
DDI-MedLine.d25.s6|25-35|necrotizing|O
DDI-MedLine.d25.s6|37-44|myopathy|O
DDI-MedLine.d25.s6|46-54|secondary|O
DDI-MedLine.d25.s6|56-57|to|O
DDI-MedLine.d25.s6|59-59|a|O
DDI-MedLine.d25.s6|61-65|toxin|O
DDI-MedLine.d25.s6|66-66|.|O
DDI-MedLine.d25.s7|0-2|The|O
DDI-MedLine.d25.s7|4-10|patient|O
DDI-MedLine.d25.s7|12-20|continued|O
DDI-MedLine.d25.s7|22-23|to|O
DDI-MedLine.d25.s7|25-31|receive|O
DDI-MedLine.d25.s7|33-44|intermittent|O
DDI-MedLine.d25.s7|46-57|hemodialysis|O
DDI-MedLine.d25.s7|59-63|until|O
DDI-MedLine.d25.s7|65-67|his|O
DDI-MedLine.d25.s7|69-73|death|O
DDI-MedLine.d25.s7|75-78|from|O
DDI-MedLine.d25.s7|80-89|infectious|O
DDI-MedLine.d25.s7|91-103|complications|O
DDI-MedLine.d25.s7|105-108|that|O
DDI-MedLine.d25.s7|110-117|occurred|O
DDI-MedLine.d25.s7|119-123|three|O
DDI-MedLine.d25.s7|125-130|months|O
DDI-MedLine.d25.s7|132-136|after|O
DDI-MedLine.d25.s7|138-146|admission|O
DDI-MedLine.d25.s7|147-147|.|O
DDI-MedLine.d25.s8|0-4|There|O
DDI-MedLine.d25.s8|6-9|were|O
DDI-MedLine.d25.s8|11-17|several|O
DDI-MedLine.d25.s8|19-25|factors|O
DDI-MedLine.d25.s8|27-30|that|O
DDI-MedLine.d25.s8|32-36|could|O
DDI-MedLine.d25.s8|38-41|have|O
DDI-MedLine.d25.s8|43-51|increased|O
DDI-MedLine.d25.s8|53-55|his|O
DDI-MedLine.d25.s8|57-60|risk|O
DDI-MedLine.d25.s8|62-64|for|O
DDI-MedLine.d25.s8|66-75|developing|O
DDI-MedLine.d25.s8|77-90|rhabdomyolysis|O
DDI-MedLine.d25.s8|91-91|,|O
DDI-MedLine.d25.s8|93-101|including|O
DDI-MedLine.d25.s8|103-109|chronic|O
DDI-MedLine.d25.s8|111-115|renal|O
DDI-MedLine.d25.s8|117-123|failure|O
DDI-MedLine.d25.s8|124-124|.|O
DDI-MedLine.d25.s9|0-9|DISCUSSION|O
DDI-MedLine.d25.s9|10-10|:|O
DDI-MedLine.d25.s9|12-25|Clarithromycin|drug
DDI-MedLine.d25.s9|27-28|is|O
DDI-MedLine.d25.s9|30-30|a|O
DDI-MedLine.d25.s9|32-37|potent|O
DDI-MedLine.d25.s9|39-47|inhibitor|O
DDI-MedLine.d25.s9|49-50|of|O
DDI-MedLine.d25.s9|52-57|CYP3A4|O
DDI-MedLine.d25.s9|58-58|,|O
DDI-MedLine.d25.s9|60-62|the|O
DDI-MedLine.d25.s9|64-68|major|O
DDI-MedLine.d25.s9|70-75|enzyme|O
DDI-MedLine.d25.s9|77-87|responsible|O
DDI-MedLine.d25.s9|89-91|for|O
DDI-MedLine.d25.s9|93-103|simvastatin|drug
DDI-MedLine.d25.s9|105-114|metabolism|O
DDI-MedLine.d25.s9|115-115|.|O
DDI-MedLine.d25.s10|0-2|The|O
DDI-MedLine.d25.s10|4-14|concomitant|O
DDI-MedLine.d25.s10|16-29|administration|O
DDI-MedLine.d25.s10|31-32|of|O
DDI-MedLine.d25.s10|34-54|macrolide antibiotics|group
DDI-MedLine.d25.s10|56-58|and|O
DDI-MedLine.d25.s10|60-64|other|O
DDI-MedLine.d25.s10|66-128|hydroxymethylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitors|group
DDI-MedLine.d25.s10|130-133|have|O
DDI-MedLine.d25.s10|135-142|resulted|O
DDI-MedLine.d25.s10|144-145|in|O
DDI-MedLine.d25.s10|147-154|previous|O
DDI-MedLine.d25.s10|156-162|reports|O
DDI-MedLine.d25.s10|164-165|of|O
DDI-MedLine.d25.s10|167-180|rhabdomyolysis|O
DDI-MedLine.d25.s10|181-181|.|O
DDI-MedLine.d25.s11|0-4|Other|O
DDI-MedLine.d25.s11|6-12|factors|O
DDI-MedLine.d25.s11|14-16|may|O
DDI-MedLine.d25.s11|18-25|increase|O
DDI-MedLine.d25.s11|27-29|the|O
DDI-MedLine.d25.s11|31-34|risk|O
DDI-MedLine.d25.s11|36-37|of|O
DDI-MedLine.d25.s11|39-42|this|O
DDI-MedLine.d25.s11|44-47|drug|O
DDI-MedLine.d25.s11|49-59|interaction|O
DDI-MedLine.d25.s11|60-60|,|O
DDI-MedLine.d25.s11|62-70|including|O
DDI-MedLine.d25.s11|72-74|the|O
DDI-MedLine.d25.s11|76-89|administration|O
DDI-MedLine.d25.s11|91-92|of|O
DDI-MedLine.d25.s11|94-98|other|O
DDI-MedLine.d25.s11|100-110|medications|O
DDI-MedLine.d25.s11|112-115|that|O
DDI-MedLine.d25.s11|117-119|are|O
DDI-MedLine.d25.s11|121-130|associated|O
DDI-MedLine.d25.s11|132-135|with|O
DDI-MedLine.d25.s11|137-144|myopathy|O
DDI-MedLine.d25.s11|145-145|,|O
DDI-MedLine.d25.s11|147-156|underlying|O
DDI-MedLine.d25.s11|158-162|renal|O
DDI-MedLine.d25.s11|164-176|insufficiency|O
DDI-MedLine.d25.s11|177-177|,|O
DDI-MedLine.d25.s11|179-181|and|O
DDI-MedLine.d25.s11|183-196|administration|O
DDI-MedLine.d25.s11|198-199|of|O
DDI-MedLine.d25.s11|201-204|high|O
DDI-MedLine.d25.s11|206-210|doses|O
DDI-MedLine.d25.s11|212-213|of|O
DDI-MedLine.d25.s11|215-242|HMG-CoA reductase inhibitors|group
DDI-MedLine.d25.s11|243-243|.|O
DDI-MedLine.d25.s12|0-10|CONCLUSIONS|O
DDI-MedLine.d25.s12|11-11|:|O
DDI-MedLine.d25.s12|13-33|Macrolide antibiotics|group
DDI-MedLine.d25.s12|35-41|inhibit|O
DDI-MedLine.d25.s12|43-45|the|O
DDI-MedLine.d25.s12|47-56|metabolism|O
DDI-MedLine.d25.s12|58-59|of|O
DDI-MedLine.d25.s12|61-88|HMG-CoA reductase inhibitors|group
DDI-MedLine.d25.s12|90-93|that|O
DDI-MedLine.d25.s12|95-97|are|O
DDI-MedLine.d25.s12|99-109|metabolized|O
DDI-MedLine.d25.s12|111-112|by|O
DDI-MedLine.d25.s12|114-119|CYP3A4|O
DDI-MedLine.d25.s12|121-121|(|O
DDI-MedLine.d25.s12|122-125|i.e.|O
DDI-MedLine.d25.s12|126-126|,|O
DDI-MedLine.d25.s12|128-139|atorvastatin|drug
DDI-MedLine.d25.s12|140-140|,|O
DDI-MedLine.d25.s12|142-153|cerivastatin|drug
DDI-MedLine.d25.s12|154-154|,|O
DDI-MedLine.d25.s12|156-165|lovastatin|drug
DDI-MedLine.d25.s12|166-166|,|O
DDI-MedLine.d25.s12|168-178|simvastatin|drug
DDI-MedLine.d25.s12|179-179|)|O
DDI-MedLine.d25.s12|180-180|.|O
DDI-MedLine.d25.s13|0-3|This|O
DDI-MedLine.d25.s13|5-15|interaction|O
DDI-MedLine.d25.s13|17-19|may|O
DDI-MedLine.d25.s13|21-26|result|O
DDI-MedLine.d25.s13|28-29|in|O
DDI-MedLine.d25.s13|31-38|myopathy|O
DDI-MedLine.d25.s13|40-42|and|O
DDI-MedLine.d25.s13|44-57|rhabdomyolysis|O
DDI-MedLine.d25.s13|58-58|,|O
DDI-MedLine.d25.s13|60-71|particularly|O
DDI-MedLine.d25.s13|73-74|in|O
DDI-MedLine.d25.s13|76-83|patients|O
DDI-MedLine.d25.s13|85-88|with|O
DDI-MedLine.d25.s13|90-94|renal|O
DDI-MedLine.d25.s13|96-108|insufficiency|O
DDI-MedLine.d25.s13|110-111|or|O
DDI-MedLine.d25.s13|113-117|those|O
DDI-MedLine.d25.s13|119-121|who|O
DDI-MedLine.d25.s13|123-125|are|O
DDI-MedLine.d25.s13|127-138|concurrently|O
DDI-MedLine.d25.s13|140-145|taking|O
DDI-MedLine.d25.s13|147-157|medications|O
DDI-MedLine.d25.s13|159-168|associated|O
DDI-MedLine.d25.s13|170-173|with|O
DDI-MedLine.d25.s13|175-182|myopathy|O
DDI-MedLine.d25.s13|183-183|.|O
DDI-MedLine.d204.s0|0-7|Distinct|O
DDI-MedLine.d204.s0|9-19|synergistic|O
DDI-MedLine.d204.s0|21-26|action|O
DDI-MedLine.d204.s0|28-29|of|O
DDI-MedLine.d204.s0|31-42|piperacillin|drug
DDI-MedLine.d204.s0|44-46|and|O
DDI-MedLine.d204.s0|62-68|against|O
DDI-MedLine.d204.s0|70-80|Pseudomonas|O
DDI-MedLine.d204.s0|82-91|aeruginosa|O
DDI-MedLine.d204.s0|92-92|.|O
DDI-MedLine.d204.s1|0-2|The|O
DDI-MedLine.d204.s1|4-13|dicarbonyl|O
DDI-MedLine.d204.s1|15-22|compound|O
DDI-MedLine.d204.s1|38-39|is|O
DDI-MedLine.d204.s1|41-41|a|O
DDI-MedLine.d204.s1|43-49|natural|O
DDI-MedLine.d204.s1|51-61|constituent|O
DDI-MedLine.d204.s1|63-64|of|O
DDI-MedLine.d204.s1|66-71|Manuka|O
DDI-MedLine.d204.s1|73-77|honey|O
DDI-MedLine.d204.s1|79-86|produced|O
DDI-MedLine.d204.s1|88-91|from|O
DDI-MedLine.d204.s1|93-98|Manuka|O
DDI-MedLine.d204.s1|100-106|flowers|O
DDI-MedLine.d204.s1|108-109|in|O
DDI-MedLine.d204.s1|111-113|New|O
DDI-MedLine.d204.s1|115-121|Zealand|O
DDI-MedLine.d204.s1|122-122|.|O
DDI-MedLine.d204.s2|0-1|It|O
DDI-MedLine.d204.s2|3-4|is|O
DDI-MedLine.d204.s2|6-10|known|O
DDI-MedLine.d204.s2|12-13|to|O
DDI-MedLine.d204.s2|15-21|possess|O
DDI-MedLine.d204.s2|23-26|both|O
DDI-MedLine.d204.s2|28-37|anticancer|O
DDI-MedLine.d204.s2|39-41|and|O
DDI-MedLine.d204.s2|43-55|antibacterial|O
DDI-MedLine.d204.s2|57-64|activity|O
DDI-MedLine.d204.s2|65-65|.|O
DDI-MedLine.d204.s3|0-3|Such|O
DDI-MedLine.d204.s3|5-16|observations|O
DDI-MedLine.d204.s3|18-25|prompted|O
DDI-MedLine.d204.s3|27-28|to|O
DDI-MedLine.d204.s3|30-40|investigate|O
DDI-MedLine.d204.s3|42-44|the|O
DDI-MedLine.d204.s3|46-52|ability|O
DDI-MedLine.d204.s3|54-55|of|O
DDI-MedLine.d204.s3|71-72|as|O
DDI-MedLine.d204.s3|74-74|a|O
DDI-MedLine.d204.s3|76-81|potent|O
DDI-MedLine.d204.s3|83-86|drug|O
DDI-MedLine.d204.s3|88-94|against|O
DDI-MedLine.d204.s3|96-104|multidrug|O
DDI-MedLine.d204.s3|106-114|resistant|O
DDI-MedLine.d204.s3|116-126|Pseudomonas|O
DDI-MedLine.d204.s3|128-137|aeruginosa|O
DDI-MedLine.d204.s3|138-138|.|O
DDI-MedLine.d204.s4|0-0|A|O
DDI-MedLine.d204.s4|2-6|total|O
DDI-MedLine.d204.s4|8-9|of|O
DDI-MedLine.d204.s4|11-12|12|O
DDI-MedLine.d204.s4|14-17|test|O
DDI-MedLine.d204.s4|19-19|P|O
DDI-MedLine.d204.s4|20-20|.|O
DDI-MedLine.d204.s5|0-9|aeruginosa|O
DDI-MedLine.d204.s5|11-17|strains|O
DDI-MedLine.d204.s5|19-26|isolated|O
DDI-MedLine.d204.s5|28-31|from|O
DDI-MedLine.d204.s5|33-39|various|O
DDI-MedLine.d204.s5|41-49|hospitals|O
DDI-MedLine.d204.s5|51-54|were|O
DDI-MedLine.d204.s5|56-61|tested|O
DDI-MedLine.d204.s5|63-65|for|O
DDI-MedLine.d204.s5|67-71|their|O
DDI-MedLine.d204.s5|73-83|resistances|O
DDI-MedLine.d204.s5|85-91|against|O
DDI-MedLine.d204.s5|93-96|many|O
DDI-MedLine.d204.s5|98-108|antibiotics|group
DDI-MedLine.d204.s5|109-109|,|O
DDI-MedLine.d204.s5|111-114|most|O
DDI-MedLine.d204.s5|116-117|of|O
DDI-MedLine.d204.s5|119-123|which|O
DDI-MedLine.d204.s5|125-127|are|O
DDI-MedLine.d204.s5|129-135|applied|O
DDI-MedLine.d204.s5|137-138|in|O
DDI-MedLine.d204.s5|140-142|the|O
DDI-MedLine.d204.s5|144-152|treatment|O
DDI-MedLine.d204.s5|154-155|of|O
DDI-MedLine.d204.s5|157-157|P|O
DDI-MedLine.d204.s5|158-158|.|O
DDI-MedLine.d204.s6|0-9|aeruginosa|O
DDI-MedLine.d204.s6|11-20|infections|O
DDI-MedLine.d204.s6|21-21|.|O
DDI-MedLine.d204.s7|0-6|Results|O
DDI-MedLine.d204.s7|8-15|revealed|O
DDI-MedLine.d204.s7|17-20|that|O
DDI-MedLine.d204.s7|22-24|the|O
DDI-MedLine.d204.s7|26-32|strains|O
DDI-MedLine.d204.s7|34-37|were|O
DDI-MedLine.d204.s7|39-47|resistant|O
DDI-MedLine.d204.s7|49-50|to|O
DDI-MedLine.d204.s7|52-55|many|O
DDI-MedLine.d204.s7|57-61|drugs|O
DDI-MedLine.d204.s7|63-64|at|O
DDI-MedLine.d204.s7|66-69|high|O
DDI-MedLine.d204.s7|71-76|levels|O
DDI-MedLine.d204.s7|77-77|,|O
DDI-MedLine.d204.s7|79-82|only|O
DDI-MedLine.d204.s7|84-95|piperacillin|drug
DDI-MedLine.d204.s7|96-96|,|O
DDI-MedLine.d204.s7|98-110|carbenicillin|drug
DDI-MedLine.d204.s7|111-111|,|O
DDI-MedLine.d204.s7|113-120|amikacin|drug
DDI-MedLine.d204.s7|122-124|and|O
DDI-MedLine.d204.s7|126-138|ciprofloxacin|drug
DDI-MedLine.d204.s7|140-145|showed|O
DDI-MedLine.d204.s7|147-157|resistances|O
DDI-MedLine.d204.s7|159-160|at|O
DDI-MedLine.d204.s7|162-174|comparatively|O
DDI-MedLine.d204.s7|176-180|lower|O
DDI-MedLine.d204.s7|182-187|levels|O
DDI-MedLine.d204.s7|188-188|.|O
DDI-MedLine.d204.s8|0-8|Following|O
DDI-MedLine.d204.s8|10-17|multiple|O
DDI-MedLine.d204.s8|19-34|experimentations|O
DDI-MedLine.d204.s8|36-37|it|O
DDI-MedLine.d204.s8|39-41|was|O
DDI-MedLine.d204.s8|43-50|observed|O
DDI-MedLine.d204.s8|52-55|that|O
DDI-MedLine.d204.s8|71-73|was|O
DDI-MedLine.d204.s8|75-78|also|O
DDI-MedLine.d204.s8|80-91|antimicrobic|O
DDI-MedLine.d204.s8|93-99|against|O
DDI-MedLine.d204.s8|101-103|all|O
DDI-MedLine.d204.s8|105-107|the|O
DDI-MedLine.d204.s8|109-115|strains|O
DDI-MedLine.d204.s8|117-118|at|O
DDI-MedLine.d204.s8|120-129|comparable|O
DDI-MedLine.d204.s8|131-136|levels|O
DDI-MedLine.d204.s8|137-137|.|O
DDI-MedLine.d204.s9|0-7|Distinct|O
DDI-MedLine.d204.s9|9-11|and|O
DDI-MedLine.d204.s9|13-25|statistically|O
DDI-MedLine.d204.s9|27-37|significant|O
DDI-MedLine.d204.s9|39-47|synergism|O
DDI-MedLine.d204.s9|49-51|was|O
DDI-MedLine.d204.s9|53-60|observed|O
DDI-MedLine.d204.s9|62-68|between|O
DDI-MedLine.d204.s9|84-86|and|O
DDI-MedLine.d204.s9|88-99|piperacillin|drug
DDI-MedLine.d204.s9|101-102|by|O
DDI-MedLine.d204.s9|104-107|disc|O
DDI-MedLine.d204.s9|109-117|diffusion|O
DDI-MedLine.d204.s9|119-123|tests|O
DDI-MedLine.d204.s9|125-128|when|O
DDI-MedLine.d204.s9|130-137|compared|O
DDI-MedLine.d204.s9|139-142|with|O
DDI-MedLine.d204.s9|144-148|their|O
DDI-MedLine.d204.s9|150-159|individual|O
DDI-MedLine.d204.s9|161-167|effects|O
DDI-MedLine.d204.s9|168-168|.|O
DDI-MedLine.d204.s10|0-2|The|O
DDI-MedLine.d204.s10|4-13|fractional|O
DDI-MedLine.d204.s10|15-24|inhibitory|O
DDI-MedLine.d204.s10|26-38|concentration|O
DDI-MedLine.d204.s10|40-44|index|O
DDI-MedLine.d204.s10|46-47|of|O
DDI-MedLine.d204.s10|49-52|this|O
DDI-MedLine.d204.s10|54-64|combination|O
DDI-MedLine.d204.s10|66-74|evaluated|O
DDI-MedLine.d204.s10|76-77|by|O
DDI-MedLine.d204.s10|79-90|checkerboard|O
DDI-MedLine.d204.s10|92-99|analysis|O
DDI-MedLine.d204.s10|100-100|,|O
DDI-MedLine.d204.s10|102-104|was|O
DDI-MedLine.d204.s10|106-108|0.5|O
DDI-MedLine.d204.s10|109-109|,|O
DDI-MedLine.d204.s10|111-115|which|O
DDI-MedLine.d204.s10|117-125|confirmed|O
DDI-MedLine.d204.s10|127-135|synergism|O
DDI-MedLine.d204.s10|137-143|between|O
DDI-MedLine.d204.s10|145-147|the|O
DDI-MedLine.d204.s10|149-152|pair|O
DDI-MedLine.d204.s10|153-153|.|O
DDI-MedLine.d204.s11|0-8|Synergism|O
DDI-MedLine.d204.s11|10-12|was|O
DDI-MedLine.d204.s11|14-17|also|O
DDI-MedLine.d204.s11|19-23|noted|O
DDI-MedLine.d204.s11|25-28|when|O
DDI-MedLine.d204.s11|44-46|was|O
DDI-MedLine.d204.s11|48-55|combined|O
DDI-MedLine.d204.s11|57-60|with|O
DDI-MedLine.d204.s11|62-74|carbenicillin|drug
DDI-MedLine.d204.s11|76-78|and|O
DDI-MedLine.d204.s11|80-87|amikacin|drug
DDI-MedLine.d204.s11|88-88|.|O
DDI-MedLine.d92.s0|0-7|Systemic|O
DDI-MedLine.d92.s0|9-25|antibiotic agents|group
DDI-MedLine.d92.s0|26-26|.|O
DDI-MedLine.d92.s1|0-12|Understanding|O
DDI-MedLine.d92.s1|14-16|the|O
DDI-MedLine.d92.s1|18-24|breadth|O
DDI-MedLine.d92.s1|26-27|of|O
DDI-MedLine.d92.s1|29-36|systemic|O
DDI-MedLine.d92.s1|38-57|antimicrobial agents|group
DDI-MedLine.d92.s1|59-67|available|O
DDI-MedLine.d92.s1|69-71|for|O
DDI-MedLine.d92.s1|73-75|use|O
DDI-MedLine.d92.s1|77-78|by|O
DDI-MedLine.d92.s1|80-82|the|O
DDI-MedLine.d92.s1|84-96|dermatologist|O
DDI-MedLine.d92.s1|98-100|and|O
DDI-MedLine.d92.s1|102-106|their|O
DDI-MedLine.d92.s1|108-117|associated|O
DDI-MedLine.d92.s1|119-129|side-effect|O
DDI-MedLine.d92.s1|131-138|profiles|O
DDI-MedLine.d92.s1|140-142|and|O
DDI-MedLine.d92.s1|144-147|drug|O
DDI-MedLine.d92.s1|149-160|interactions|O
DDI-MedLine.d92.s1|162-167|allows|O
DDI-MedLine.d92.s1|169-171|the|O
DDI-MedLine.d92.s1|173-181|clinician|O
DDI-MedLine.d92.s1|183-184|to|O
DDI-MedLine.d92.s1|186-190|offer|O
DDI-MedLine.d92.s1|192-199|patients|O
DDI-MedLine.d92.s1|201-207|optimal|O
DDI-MedLine.d92.s1|209-212|care|O
DDI-MedLine.d92.s1|214-215|in|O
DDI-MedLine.d92.s1|217-219|the|O
DDI-MedLine.d92.s1|221-230|management|O
DDI-MedLine.d92.s1|232-233|of|O
DDI-MedLine.d92.s1|235-243|cutaneous|O
DDI-MedLine.d92.s1|245-254|infectious|O
DDI-MedLine.d92.s1|256-262|disease|O
DDI-MedLine.d92.s1|263-263|.|O
DDI-DrugBank.d226.s0|0-10|Intravenous|O
DDI-DrugBank.d226.s0|12-20|Adenocard|brand
DDI-DrugBank.d226.s0|22-22|(|O
DDI-DrugBank.d226.s0|23-31|adenosine|drug
DDI-DrugBank.d226.s0|32-32|)|O
DDI-DrugBank.d226.s0|34-36|has|O
DDI-DrugBank.d226.s0|38-41|been|O
DDI-DrugBank.d226.s0|43-53|effectively|O
DDI-DrugBank.d226.s0|55-66|administered|O
DDI-DrugBank.d226.s0|68-69|in|O
DDI-DrugBank.d226.s0|71-73|the|O
DDI-DrugBank.d226.s0|75-82|presence|O
DDI-DrugBank.d226.s0|84-85|of|O
DDI-DrugBank.d226.s0|87-91|other|O
DDI-DrugBank.d226.s0|93-104|cardioactive|O
DDI-DrugBank.d226.s0|106-110|drugs|O
DDI-DrugBank.d226.s0|111-111|,|O
DDI-DrugBank.d226.s0|113-116|such|O
DDI-DrugBank.d226.s0|118-119|as|O
DDI-DrugBank.d226.s0|121-129|quinidine|drug
DDI-DrugBank.d226.s0|130-130|,|O
DDI-DrugBank.d226.s0|132-162|beta-adrenergic blocking agents|group
DDI-DrugBank.d226.s0|163-163|,|O
DDI-DrugBank.d226.s0|165-195|calcium channel blocking agents|group
DDI-DrugBank.d226.s0|196-196|,|O
DDI-DrugBank.d226.s0|198-200|and|O
DDI-DrugBank.d226.s0|202-241|angiotensin converting enzyme inhibitors|group
DDI-DrugBank.d226.s0|242-242|,|O
DDI-DrugBank.d226.s0|244-250|without|O
DDI-DrugBank.d226.s0|252-254|any|O
DDI-DrugBank.d226.s0|256-261|change|O
DDI-DrugBank.d226.s0|263-264|in|O
DDI-DrugBank.d226.s0|266-268|the|O
DDI-DrugBank.d226.s0|270-276|adverse|O
DDI-DrugBank.d226.s0|278-285|reaction|O
DDI-DrugBank.d226.s0|287-293|profile|O
DDI-DrugBank.d226.s0|294-294|.|O
DDI-DrugBank.d226.s1|0-6|Digoxin|drug
DDI-DrugBank.d226.s1|8-10|and|O
DDI-DrugBank.d226.s1|12-20|verapamil|drug
DDI-DrugBank.d226.s1|22-24|use|O
DDI-DrugBank.d226.s1|26-28|may|O
DDI-DrugBank.d226.s1|30-31|be|O
DDI-DrugBank.d226.s1|33-38|rarely|O
DDI-DrugBank.d226.s1|40-49|associated|O
DDI-DrugBank.d226.s1|51-54|with|O
DDI-DrugBank.d226.s1|56-66|ventricular|O
DDI-DrugBank.d226.s1|68-79|fibrillation|O
DDI-DrugBank.d226.s1|81-84|when|O
DDI-DrugBank.d226.s1|86-93|combined|O
DDI-DrugBank.d226.s1|95-98|with|O
DDI-DrugBank.d226.s1|100-108|Adenocard|brand
DDI-DrugBank.d226.s1|109-109|.|O
DDI-DrugBank.d226.s2|0-6|Because|O
DDI-DrugBank.d226.s2|8-9|of|O
DDI-DrugBank.d226.s2|11-13|the|O
DDI-DrugBank.d226.s2|15-23|potential|O
DDI-DrugBank.d226.s2|25-27|for|O
DDI-DrugBank.d226.s2|29-36|additive|O
DDI-DrugBank.d226.s2|38-39|or|O
DDI-DrugBank.d226.s2|41-51|synergistic|O
DDI-DrugBank.d226.s2|53-62|depressant|O
DDI-DrugBank.d226.s2|64-70|effects|O
DDI-DrugBank.d226.s2|72-73|on|O
DDI-DrugBank.d226.s2|75-77|the|O
DDI-DrugBank.d226.s2|79-80|SA|O
DDI-DrugBank.d226.s2|82-84|and|O
DDI-DrugBank.d226.s2|86-87|AV|O
DDI-DrugBank.d226.s2|89-93|nodes|O
DDI-DrugBank.d226.s2|94-94|,|O
DDI-DrugBank.d226.s2|96-102|however|O
DDI-DrugBank.d226.s2|103-103|,|O
DDI-DrugBank.d226.s2|105-113|Adenocard|brand
DDI-DrugBank.d226.s2|115-120|should|O
DDI-DrugBank.d226.s2|122-123|be|O
DDI-DrugBank.d226.s2|125-128|used|O
DDI-DrugBank.d226.s2|130-133|with|O
DDI-DrugBank.d226.s2|135-141|caution|O
DDI-DrugBank.d226.s2|143-144|in|O
DDI-DrugBank.d226.s2|146-148|the|O
DDI-DrugBank.d226.s2|150-157|presence|O
DDI-DrugBank.d226.s2|159-160|of|O
DDI-DrugBank.d226.s2|162-166|these|O
DDI-DrugBank.d226.s2|168-173|agents|O
DDI-DrugBank.d226.s2|174-174|.|O
DDI-DrugBank.d226.s3|0-2|The|O
DDI-DrugBank.d226.s3|4-6|use|O
DDI-DrugBank.d226.s3|8-9|of|O
DDI-DrugBank.d226.s3|11-19|Adenocard|brand
DDI-DrugBank.d226.s3|21-22|in|O
DDI-DrugBank.d226.s3|24-31|patients|O
DDI-DrugBank.d226.s3|33-41|receiving|O
DDI-DrugBank.d226.s3|43-51|digitalis|group
DDI-DrugBank.d226.s3|53-55|may|O
DDI-DrugBank.d226.s3|57-58|be|O
DDI-DrugBank.d226.s3|60-65|rarely|O
DDI-DrugBank.d226.s3|67-76|associated|O
DDI-DrugBank.d226.s3|78-81|with|O
DDI-DrugBank.d226.s3|83-93|ventricular|O
DDI-DrugBank.d226.s3|95-106|fibrillation|O
DDI-DrugBank.d226.s3|107-107|.|O
DDI-DrugBank.d226.s4|0-2|The|O
DDI-DrugBank.d226.s4|4-10|effects|O
DDI-DrugBank.d226.s4|12-13|of|O
DDI-DrugBank.d226.s4|15-23|adenosine|drug
DDI-DrugBank.d226.s4|25-27|are|O
DDI-DrugBank.d226.s4|29-39|antagonized|O
DDI-DrugBank.d226.s4|41-42|by|O
DDI-DrugBank.d226.s4|44-58|methylxanthines|group
DDI-DrugBank.d226.s4|60-63|such|O
DDI-DrugBank.d226.s4|65-66|as|O
DDI-DrugBank.d226.s4|68-75|caffeine|drug
DDI-DrugBank.d226.s4|77-79|and|O
DDI-DrugBank.d226.s4|81-92|theophylline|drug
DDI-DrugBank.d226.s4|93-93|.|O
DDI-DrugBank.d226.s5|0-1|In|O
DDI-DrugBank.d226.s5|3-5|the|O
DDI-DrugBank.d226.s5|7-14|presence|O
DDI-DrugBank.d226.s5|16-17|of|O
DDI-DrugBank.d226.s5|19-23|these|O
DDI-DrugBank.d226.s5|25-39|methylxanthines|group
DDI-DrugBank.d226.s5|40-40|,|O
DDI-DrugBank.d226.s5|42-47|larger|O
DDI-DrugBank.d226.s5|49-53|doses|O
DDI-DrugBank.d226.s5|55-56|of|O
DDI-DrugBank.d226.s5|58-66|adenosine|drug
DDI-DrugBank.d226.s5|68-70|may|O
DDI-DrugBank.d226.s5|72-73|be|O
DDI-DrugBank.d226.s5|75-82|required|O
DDI-DrugBank.d226.s5|84-85|or|O
DDI-DrugBank.d226.s5|87-95|adenosine|drug
DDI-DrugBank.d226.s5|97-99|may|O
DDI-DrugBank.d226.s5|101-103|not|O
DDI-DrugBank.d226.s5|105-106|be|O
DDI-DrugBank.d226.s5|108-116|effective|O
DDI-DrugBank.d226.s5|117-117|.|O
DDI-DrugBank.d226.s6|0-8|Adenosine|drug
DDI-DrugBank.d226.s6|10-16|effects|O
DDI-DrugBank.d226.s6|18-20|are|O
DDI-DrugBank.d226.s6|22-32|potentiated|O
DDI-DrugBank.d226.s6|34-35|by|O
DDI-DrugBank.d226.s6|37-48|dipyridamole|drug
DDI-DrugBank.d226.s6|49-49|.|O
DDI-DrugBank.d226.s7|0-3|Thus|O
DDI-DrugBank.d226.s7|4-4|,|O
DDI-DrugBank.d226.s7|6-12|smaller|O
DDI-DrugBank.d226.s7|14-18|doses|O
DDI-DrugBank.d226.s7|20-21|of|O
DDI-DrugBank.d226.s7|23-31|adenosine|drug
DDI-DrugBank.d226.s7|33-35|may|O
DDI-DrugBank.d226.s7|37-38|be|O
DDI-DrugBank.d226.s7|40-48|effective|O
DDI-DrugBank.d226.s7|50-51|in|O
DDI-DrugBank.d226.s7|53-55|the|O
DDI-DrugBank.d226.s7|57-64|presence|O
DDI-DrugBank.d226.s7|66-67|of|O
DDI-DrugBank.d226.s7|69-80|dipyridamole|drug
DDI-DrugBank.d226.s7|81-81|.|O
DDI-DrugBank.d226.s8|0-12|Carbamazepine|drug
DDI-DrugBank.d226.s8|14-16|has|O
DDI-DrugBank.d226.s8|18-21|been|O
DDI-DrugBank.d226.s8|23-30|reported|O
DDI-DrugBank.d226.s8|32-33|to|O
DDI-DrugBank.d226.s8|35-42|increase|O
DDI-DrugBank.d226.s8|44-46|the|O
DDI-DrugBank.d226.s8|48-53|degree|O
DDI-DrugBank.d226.s8|55-56|of|O
DDI-DrugBank.d226.s8|58-62|heart|O
DDI-DrugBank.d226.s8|64-68|block|O
DDI-DrugBank.d226.s8|70-77|produced|O
DDI-DrugBank.d226.s8|79-80|by|O
DDI-DrugBank.d226.s8|82-86|other|O
DDI-DrugBank.d226.s8|88-93|agents|O
DDI-DrugBank.d226.s8|94-94|.|O
DDI-DrugBank.d226.s9|0-1|As|O
DDI-DrugBank.d226.s9|3-5|the|O
DDI-DrugBank.d226.s9|7-13|primary|O
DDI-DrugBank.d226.s9|15-20|effect|O
DDI-DrugBank.d226.s9|22-23|of|O
DDI-DrugBank.d226.s9|25-33|adenosine|drug
DDI-DrugBank.d226.s9|35-36|is|O
DDI-DrugBank.d226.s9|38-39|to|O
DDI-DrugBank.d226.s9|41-48|decrease|O
DDI-DrugBank.d226.s9|50-59|conduction|O
DDI-DrugBank.d226.s9|61-67|through|O
DDI-DrugBank.d226.s9|69-71|the|O
DDI-DrugBank.d226.s9|73-75|A-V|O
DDI-DrugBank.d226.s9|77-80|node|O
DDI-DrugBank.d226.s9|81-81|,|O
DDI-DrugBank.d226.s9|83-88|higher|O
DDI-DrugBank.d226.s9|90-96|degrees|O
DDI-DrugBank.d226.s9|98-99|of|O
DDI-DrugBank.d226.s9|101-105|heart|O
DDI-DrugBank.d226.s9|107-111|block|O
DDI-DrugBank.d226.s9|113-115|may|O
DDI-DrugBank.d226.s9|117-118|be|O
DDI-DrugBank.d226.s9|120-127|produced|O
DDI-DrugBank.d226.s9|129-130|in|O
DDI-DrugBank.d226.s9|132-134|the|O
DDI-DrugBank.d226.s9|136-143|presence|O
DDI-DrugBank.d226.s9|145-146|of|O
DDI-DrugBank.d226.s9|148-160|carbamazepine|drug
DDI-DrugBank.d226.s9|161-161|.|O
DDI-DrugBank.d203.s0|0-1|No|O
DDI-DrugBank.d203.s0|3-6|drug|O
DDI-DrugBank.d203.s0|8-19|interactions|O
DDI-DrugBank.d203.s0|21-24|have|O
DDI-DrugBank.d203.s0|26-29|been|O
DDI-DrugBank.d203.s0|31-40|identified|O
DDI-DrugBank.d203.s0|41-41|.|O
DDI-DrugBank.d203.s1|0-6|Studies|O
DDI-DrugBank.d203.s1|8-11|with|O
DDI-DrugBank.d203.s1|13-22|famotidine|drug
DDI-DrugBank.d203.s1|24-25|in|O
DDI-DrugBank.d203.s1|27-29|man|O
DDI-DrugBank.d203.s1|30-30|,|O
DDI-DrugBank.d203.s1|32-33|in|O
DDI-DrugBank.d203.s1|35-40|animal|O
DDI-DrugBank.d203.s1|42-47|models|O
DDI-DrugBank.d203.s1|48-48|,|O
DDI-DrugBank.d203.s1|50-52|and|O
DDI-DrugBank.d203.s1|54-55|in|O
DDI-DrugBank.d203.s1|57-61|vitro|O
DDI-DrugBank.d203.s1|63-66|have|O
DDI-DrugBank.d203.s1|68-72|shown|O
DDI-DrugBank.d203.s1|74-75|no|O
DDI-DrugBank.d203.s1|77-87|significant|O
DDI-DrugBank.d203.s1|89-100|interference|O
DDI-DrugBank.d203.s1|102-105|with|O
DDI-DrugBank.d203.s1|107-109|the|O
DDI-DrugBank.d203.s1|111-121|disposition|O
DDI-DrugBank.d203.s1|123-124|of|O
DDI-DrugBank.d203.s1|126-134|compounds|O
DDI-DrugBank.d203.s1|136-146|metabolized|O
DDI-DrugBank.d203.s1|148-149|by|O
DDI-DrugBank.d203.s1|151-153|the|O
DDI-DrugBank.d203.s1|155-161|hepatic|O
DDI-DrugBank.d203.s1|163-172|microsomal|O
DDI-DrugBank.d203.s1|174-180|enzymes|O
DDI-DrugBank.d203.s1|181-181|,|O
DDI-DrugBank.d203.s1|183-186|e.g.|O
DDI-DrugBank.d203.s1|187-187|,|O
DDI-DrugBank.d203.s1|189-198|cytochrome|O
DDI-DrugBank.d203.s1|200-203|P450|O
DDI-DrugBank.d203.s1|205-210|system|O
DDI-DrugBank.d203.s1|211-211|.|O
DDI-DrugBank.d203.s2|0-8|Compounds|O
DDI-DrugBank.d203.s2|10-15|tested|O
DDI-DrugBank.d203.s2|17-18|in|O
DDI-DrugBank.d203.s2|20-22|man|O
DDI-DrugBank.d203.s2|24-30|include|O
DDI-DrugBank.d203.s2|32-39|warfarin|drug
DDI-DrugBank.d203.s2|40-40|,|O
DDI-DrugBank.d203.s2|42-53|theophylline|drug
DDI-DrugBank.d203.s2|54-54|,|O
DDI-DrugBank.d203.s2|56-64|phenytoin|drug
DDI-DrugBank.d203.s2|65-65|,|O
DDI-DrugBank.d203.s2|67-74|diazepam|drug
DDI-DrugBank.d203.s2|75-75|,|O
DDI-DrugBank.d203.s2|77-87|aminopyrine|drug
DDI-DrugBank.d203.s2|89-91|and|O
DDI-DrugBank.d203.s2|93-102|antipyrine|drug
DDI-DrugBank.d203.s2|103-103|.|O
DDI-DrugBank.d203.s3|18-19|as|O
DDI-DrugBank.d203.s3|21-22|an|O
DDI-DrugBank.d203.s3|24-28|index|O
DDI-DrugBank.d203.s3|30-31|of|O
DDI-DrugBank.d203.s3|33-39|hepatic|O
DDI-DrugBank.d203.s3|41-44|drug|O
DDI-DrugBank.d203.s3|46-55|extraction|O
DDI-DrugBank.d203.s3|57-59|has|O
DDI-DrugBank.d203.s3|61-64|been|O
DDI-DrugBank.d203.s3|66-71|tested|O
DDI-DrugBank.d203.s3|73-75|and|O
DDI-DrugBank.d203.s3|77-78|no|O
DDI-DrugBank.d203.s3|80-90|significant|O
DDI-DrugBank.d203.s3|92-98|effects|O
DDI-DrugBank.d203.s3|100-103|have|O
DDI-DrugBank.d203.s3|105-108|been|O
DDI-DrugBank.d203.s3|110-114|found|O
DDI-DrugBank.d203.s3|115-115|.|O
DDI-DrugBank.d350.s0|0-6|Studies|O
DDI-DrugBank.d350.s0|8-9|in|O
DDI-DrugBank.d350.s0|11-15|vitro|O
DDI-DrugBank.d350.s0|17-20|show|O
DDI-DrugBank.d350.s0|22-25|that|O
DDI-DrugBank.d350.s0|27-45|caspofungin acetate|drug
DDI-DrugBank.d350.s0|47-48|is|O
DDI-DrugBank.d350.s0|50-52|not|O
DDI-DrugBank.d350.s0|54-55|an|O
DDI-DrugBank.d350.s0|57-65|inhibitor|O
DDI-DrugBank.d350.s0|67-68|of|O
DDI-DrugBank.d350.s0|70-72|any|O
DDI-DrugBank.d350.s0|74-79|enzyme|O
DDI-DrugBank.d350.s0|81-82|in|O
DDI-DrugBank.d350.s0|84-86|the|O
DDI-DrugBank.d350.s0|88-97|cytochrome|O
DDI-DrugBank.d350.s0|99-102|P450|O
DDI-DrugBank.d350.s0|104-104|(|O
DDI-DrugBank.d350.s0|105-107|CYP|O
DDI-DrugBank.d350.s0|108-108|)|O
DDI-DrugBank.d350.s0|110-115|system|O
DDI-DrugBank.d350.s0|116-116|.|O
DDI-DrugBank.d350.s1|0-1|In|O
DDI-DrugBank.d350.s1|3-10|clinical|O
DDI-DrugBank.d350.s1|12-18|studies|O
DDI-DrugBank.d350.s1|19-19|,|O
DDI-DrugBank.d350.s1|21-31|caspofungin|drug
DDI-DrugBank.d350.s1|33-35|did|O
DDI-DrugBank.d350.s1|37-39|not|O
DDI-DrugBank.d350.s1|41-46|induce|O
DDI-DrugBank.d350.s1|48-50|the|O
DDI-DrugBank.d350.s1|52-57|CYP3A4|O
DDI-DrugBank.d350.s1|59-68|metabolism|O
DDI-DrugBank.d350.s1|70-71|of|O
DDI-DrugBank.d350.s1|73-77|other|O
DDI-DrugBank.d350.s1|79-83|drugs|O
DDI-DrugBank.d350.s1|84-84|.|O
DDI-DrugBank.d350.s2|0-10|Caspofungin|drug
DDI-DrugBank.d350.s2|12-13|is|O
DDI-DrugBank.d350.s2|15-17|not|O
DDI-DrugBank.d350.s2|19-19|a|O
DDI-DrugBank.d350.s2|21-29|substrate|O
DDI-DrugBank.d350.s2|31-33|for|O
DDI-DrugBank.d350.s2|35-48|P-glycoprotein|O
DDI-DrugBank.d350.s2|50-52|and|O
DDI-DrugBank.d350.s2|54-55|is|O
DDI-DrugBank.d350.s2|57-57|a|O
DDI-DrugBank.d350.s2|59-62|poor|O
DDI-DrugBank.d350.s2|64-72|substrate|O
DDI-DrugBank.d350.s2|74-76|for|O
DDI-DrugBank.d350.s2|78-87|cytochrome|O
DDI-DrugBank.d350.s2|89-92|P450|O
DDI-DrugBank.d350.s2|94-100|enzymes|O
DDI-DrugBank.d350.s2|101-101|.|O
DDI-DrugBank.d350.s3|0-7|Clinical|O
DDI-DrugBank.d350.s3|9-15|studies|O
DDI-DrugBank.d350.s3|17-18|in|O
DDI-DrugBank.d350.s3|20-26|healthy|O
DDI-DrugBank.d350.s3|28-37|volunteers|O
DDI-DrugBank.d350.s3|39-42|show|O
DDI-DrugBank.d350.s3|44-47|that|O
DDI-DrugBank.d350.s3|49-51|the|O
DDI-DrugBank.d350.s3|53-68|pharmacokinetics|O
DDI-DrugBank.d350.s3|70-71|of|O
DDI-DrugBank.d350.s3|73-80|CANCIDAS|brand
DDI-DrugBank.d350.s3|82-84|are|O
DDI-DrugBank.d350.s3|86-88|not|O
DDI-DrugBank.d350.s3|90-96|altered|O
DDI-DrugBank.d350.s3|98-99|by|O
DDI-DrugBank.d350.s3|101-112|itraconazole|drug
DDI-DrugBank.d350.s3|113-113|,|O
DDI-DrugBank.d350.s3|115-128|amphotericin B|drug
DDI-DrugBank.d350.s3|129-129|,|O
DDI-DrugBank.d350.s3|131-143|mycophenolate|drug
DDI-DrugBank.d350.s3|144-144|,|O
DDI-DrugBank.d350.s3|146-155|nelfinavir|drug
DDI-DrugBank.d350.s3|156-156|,|O
DDI-DrugBank.d350.s3|158-159|or|O
DDI-DrugBank.d350.s3|161-170|tacrolimus|drug
DDI-DrugBank.d350.s3|171-171|.|O
DDI-DrugBank.d350.s4|0-7|CANCIDAS|brand
DDI-DrugBank.d350.s4|9-11|has|O
DDI-DrugBank.d350.s4|13-14|no|O
DDI-DrugBank.d350.s4|16-21|effect|O
DDI-DrugBank.d350.s4|23-24|on|O
DDI-DrugBank.d350.s4|26-28|the|O
DDI-DrugBank.d350.s4|30-45|pharmacokinetics|O
DDI-DrugBank.d350.s4|47-48|of|O
DDI-DrugBank.d350.s4|50-61|itraconazole|drug
DDI-DrugBank.d350.s4|62-62|,|O
DDI-DrugBank.d350.s4|64-77|amphotericin B|drug
DDI-DrugBank.d350.s4|78-78|,|O
DDI-DrugBank.d350.s4|80-81|or|O
DDI-DrugBank.d350.s4|83-85|the|O
DDI-DrugBank.d350.s4|87-92|active|O
DDI-DrugBank.d350.s4|94-103|metabolite|O
DDI-DrugBank.d350.s4|105-106|of|O
DDI-DrugBank.d350.s4|108-120|mycophenolate|O
DDI-DrugBank.d350.s4|121-121|.|O
DDI-DrugBank.d350.s5|0-7|CANCIDAS|brand
DDI-DrugBank.d350.s5|9-15|reduced|O
DDI-DrugBank.d350.s5|17-19|the|O
DDI-DrugBank.d350.s5|21-25|blood|O
DDI-DrugBank.d350.s5|27-33|AUC0-12|O
DDI-DrugBank.d350.s5|35-36|of|O
DDI-DrugBank.d350.s5|38-47|tacrolimus|drug
DDI-DrugBank.d350.s5|49-50|by|O
DDI-DrugBank.d350.s5|52-64|approximately|O
DDI-DrugBank.d350.s5|66-67|20|O
DDI-DrugBank.d350.s5|68-68|%|O
DDI-DrugBank.d350.s5|69-69|,|O
DDI-DrugBank.d350.s5|71-74|peak|O
DDI-DrugBank.d350.s5|76-80|blood|O
DDI-DrugBank.d350.s5|82-94|concentration|O
DDI-DrugBank.d350.s5|96-96|(|O
DDI-DrugBank.d350.s5|97-100|Cmax|O
DDI-DrugBank.d350.s5|101-101|)|O
DDI-DrugBank.d350.s5|103-104|by|O
DDI-DrugBank.d350.s5|106-107|16|O
DDI-DrugBank.d350.s5|108-108|%|O
DDI-DrugBank.d350.s5|109-109|,|O
DDI-DrugBank.d350.s5|111-113|and|O
DDI-DrugBank.d350.s5|115-121|12-hour|O
DDI-DrugBank.d350.s5|123-127|blood|O
DDI-DrugBank.d350.s5|129-141|concentration|O
DDI-DrugBank.d350.s5|143-143|(|O
DDI-DrugBank.d350.s5|144-148|C12hr|O
DDI-DrugBank.d350.s5|149-149|)|O
DDI-DrugBank.d350.s5|151-152|by|O
DDI-DrugBank.d350.s5|154-155|26|O
DDI-DrugBank.d350.s5|156-156|%|O
DDI-DrugBank.d350.s5|158-159|in|O
DDI-DrugBank.d350.s5|161-167|healthy|O
DDI-DrugBank.d350.s5|169-176|subjects|O
DDI-DrugBank.d350.s5|178-181|when|O
DDI-DrugBank.d350.s5|183-192|tacrolimus|drug
DDI-DrugBank.d350.s5|194-194|(|O
DDI-DrugBank.d350.s5|195-195|2|O
DDI-DrugBank.d350.s5|197-201|doses|O
DDI-DrugBank.d350.s5|203-204|of|O
DDI-DrugBank.d350.s5|206-208|0.1|O
DDI-DrugBank.d350.s5|210-214|mg/kg|O
DDI-DrugBank.d350.s5|216-217|12|O
DDI-DrugBank.d350.s5|219-223|hours|O
DDI-DrugBank.d350.s5|225-229|apart|O
DDI-DrugBank.d350.s5|230-230|)|O
DDI-DrugBank.d350.s5|232-234|was|O
DDI-DrugBank.d350.s5|236-247|administered|O
DDI-DrugBank.d350.s5|249-250|on|O
DDI-DrugBank.d350.s5|252-254|the|O
DDI-DrugBank.d350.s5|256-259|10th|O
DDI-DrugBank.d350.s5|261-263|day|O
DDI-DrugBank.d350.s5|265-266|of|O
DDI-DrugBank.d350.s5|268-275|CANCIDAS|brand
DDI-DrugBank.d350.s5|277-278|70|O
DDI-DrugBank.d350.s5|280-281|mg|O
DDI-DrugBank.d350.s5|283-287|daily|O
DDI-DrugBank.d350.s5|288-288|,|O
DDI-DrugBank.d350.s5|290-291|as|O
DDI-DrugBank.d350.s5|293-300|compared|O
DDI-DrugBank.d350.s5|302-303|to|O
DDI-DrugBank.d350.s5|305-311|results|O
DDI-DrugBank.d350.s5|313-316|from|O
DDI-DrugBank.d350.s5|318-318|a|O
DDI-DrugBank.d350.s5|320-326|control|O
DDI-DrugBank.d350.s5|328-333|period|O
DDI-DrugBank.d350.s5|335-336|in|O
DDI-DrugBank.d350.s5|338-342|which|O
DDI-DrugBank.d350.s5|344-353|tacrolimus|drug
DDI-DrugBank.d350.s5|355-357|was|O
DDI-DrugBank.d350.s5|359-370|administered|O
DDI-DrugBank.d350.s5|372-376|alone|O
DDI-DrugBank.d350.s5|377-377|.|O
DDI-DrugBank.d350.s6|0-2|For|O
DDI-DrugBank.d350.s6|4-11|patients|O
DDI-DrugBank.d350.s6|13-21|receiving|O
DDI-DrugBank.d350.s6|23-26|both|O
DDI-DrugBank.d350.s6|28-36|therapies|O
DDI-DrugBank.d350.s6|37-37|,|O
DDI-DrugBank.d350.s6|39-46|standard|O
DDI-DrugBank.d350.s6|48-57|monitoring|O
DDI-DrugBank.d350.s6|59-60|of|O
DDI-DrugBank.d350.s6|62-71|tacrolimus|drug
DDI-DrugBank.d350.s6|73-77|blood|O
DDI-DrugBank.d350.s6|79-92|concentrations|O
DDI-DrugBank.d350.s6|94-96|and|O
DDI-DrugBank.d350.s6|98-108|appropriate|O
DDI-DrugBank.d350.s6|110-119|tacrolimus|drug
DDI-DrugBank.d350.s6|121-126|dosage|O
DDI-DrugBank.d350.s6|128-138|adjustments|O
DDI-DrugBank.d350.s6|140-142|are|O
DDI-DrugBank.d350.s6|144-154|recommended|O
DDI-DrugBank.d350.s6|155-155|.|O
DDI-DrugBank.d350.s7|0-1|In|O
DDI-DrugBank.d350.s7|3-5|two|O
DDI-DrugBank.d350.s7|7-14|clinical|O
DDI-DrugBank.d350.s7|16-22|studies|O
DDI-DrugBank.d350.s7|23-23|,|O
DDI-DrugBank.d350.s7|25-36|cyclosporine|drug
DDI-DrugBank.d350.s7|38-38|(|O
DDI-DrugBank.d350.s7|39-41|one|O
DDI-DrugBank.d350.s7|43-43|4|O
DDI-DrugBank.d350.s7|45-49|mg/kg|O
DDI-DrugBank.d350.s7|51-54|dose|O
DDI-DrugBank.d350.s7|56-57|or|O
DDI-DrugBank.d350.s7|59-61|two|O
DDI-DrugBank.d350.s7|63-63|3|O
DDI-DrugBank.d350.s7|65-69|mg/kg|O
DDI-DrugBank.d350.s7|71-75|doses|O
DDI-DrugBank.d350.s7|76-76|)|O
DDI-DrugBank.d350.s7|78-86|increased|O
DDI-DrugBank.d350.s7|88-90|the|O
DDI-DrugBank.d350.s7|92-94|AUC|O
DDI-DrugBank.d350.s7|96-97|of|O
DDI-DrugBank.d350.s7|99-109|caspofungin|drug
DDI-DrugBank.d350.s7|111-112|by|O
DDI-DrugBank.d350.s7|114-126|approximately|O
DDI-DrugBank.d350.s7|128-129|35|O
DDI-DrugBank.d350.s7|130-130|%|O
DDI-DrugBank.d350.s7|131-131|.|O
DDI-DrugBank.d350.s8|0-7|CANCIDAS|brand
DDI-DrugBank.d350.s8|9-11|did|O
DDI-DrugBank.d350.s8|13-15|not|O
DDI-DrugBank.d350.s8|17-24|increase|O
DDI-DrugBank.d350.s8|26-28|the|O
DDI-DrugBank.d350.s8|30-35|plasma|O
DDI-DrugBank.d350.s8|37-42|levels|O
DDI-DrugBank.d350.s8|44-45|of|O
DDI-DrugBank.d350.s8|47-58|cyclosporine|drug
DDI-DrugBank.d350.s8|59-59|.|O
DDI-DrugBank.d350.s9|0-4|There|O
DDI-DrugBank.d350.s9|6-9|were|O
DDI-DrugBank.d350.s9|11-19|transient|O
DDI-DrugBank.d350.s9|21-29|increases|O
DDI-DrugBank.d350.s9|31-32|in|O
DDI-DrugBank.d350.s9|34-38|liver|O
DDI-DrugBank.d350.s9|40-42|ALT|O
DDI-DrugBank.d350.s9|44-46|and|O
DDI-DrugBank.d350.s9|48-50|AST|O
DDI-DrugBank.d350.s9|52-55|when|O
DDI-DrugBank.d350.s9|57-64|CANCIDAS|brand
DDI-DrugBank.d350.s9|66-68|and|O
DDI-DrugBank.d350.s9|70-81|cyclosporine|drug
DDI-DrugBank.d350.s9|83-86|were|O
DDI-DrugBank.d350.s9|88-102|co-administered|O
DDI-DrugBank.d350.s9|103-103|.|O
DDI-DrugBank.d350.s10|0-0|A|O
DDI-DrugBank.d350.s10|2-10|drug-drug|O
DDI-DrugBank.d350.s10|12-22|interaction|O
DDI-DrugBank.d350.s10|24-28|study|O
DDI-DrugBank.d350.s10|30-33|with|O
DDI-DrugBank.d350.s10|35-42|rifampin|drug
DDI-DrugBank.d350.s10|44-45|in|O
DDI-DrugBank.d350.s10|47-53|healthy|O
DDI-DrugBank.d350.s10|55-64|volunteers|O
DDI-DrugBank.d350.s10|66-68|has|O
DDI-DrugBank.d350.s10|70-74|shown|O
DDI-DrugBank.d350.s10|76-76|a|O
DDI-DrugBank.d350.s10|78-79|30|O
DDI-DrugBank.d350.s10|80-80|%|O
DDI-DrugBank.d350.s10|82-89|decrease|O
DDI-DrugBank.d350.s10|91-92|in|O
DDI-DrugBank.d350.s10|94-104|caspofungin|drug
DDI-DrugBank.d350.s10|106-111|trough|O
DDI-DrugBank.d350.s10|113-126|concentrations|O
DDI-DrugBank.d350.s10|127-127|.|O
DDI-DrugBank.d350.s11|0-7|Patients|O
DDI-DrugBank.d350.s11|9-10|on|O
DDI-DrugBank.d350.s11|12-19|rifampin|drug
DDI-DrugBank.d350.s11|21-26|should|O
DDI-DrugBank.d350.s11|28-34|receive|O
DDI-DrugBank.d350.s11|36-37|70|O
DDI-DrugBank.d350.s11|39-40|mg|O
DDI-DrugBank.d350.s11|42-43|of|O
DDI-DrugBank.d350.s11|45-52|CANCIDAS|brand
DDI-DrugBank.d350.s11|54-58|daily|O
DDI-DrugBank.d350.s11|59-59|.|O
DDI-DrugBank.d350.s12|0-1|In|O
DDI-DrugBank.d350.s12|3-10|addition|O
DDI-DrugBank.d350.s12|11-11|,|O
DDI-DrugBank.d350.s12|13-19|results|O
DDI-DrugBank.d350.s12|21-24|from|O
DDI-DrugBank.d350.s12|26-35|regression|O
DDI-DrugBank.d350.s12|37-44|analyses|O
DDI-DrugBank.d350.s12|46-47|of|O
DDI-DrugBank.d350.s12|49-55|patient|O
DDI-DrugBank.d350.s12|57-71|pharmacokinetic|O
DDI-DrugBank.d350.s12|73-76|data|O
DDI-DrugBank.d350.s12|78-84|suggest|O
DDI-DrugBank.d350.s12|86-89|that|O
DDI-DrugBank.d350.s12|91-107|co-administration|O
DDI-DrugBank.d350.s12|109-110|of|O
DDI-DrugBank.d350.s12|112-116|other|O
DDI-DrugBank.d350.s12|118-125|inducers|O
DDI-DrugBank.d350.s12|127-128|of|O
DDI-DrugBank.d350.s12|130-133|drug|O
DDI-DrugBank.d350.s12|135-143|clearance|O
DDI-DrugBank.d350.s12|145-145|(|O
DDI-DrugBank.d350.s12|146-154|efavirenz|drug
DDI-DrugBank.d350.s12|155-155|,|O
DDI-DrugBank.d350.s12|157-166|nevirapine|drug
DDI-DrugBank.d350.s12|167-167|,|O
DDI-DrugBank.d350.s12|169-177|phenytoin|drug
DDI-DrugBank.d350.s12|178-178|,|O
DDI-DrugBank.d350.s12|180-192|dexamethasone|drug
DDI-DrugBank.d350.s12|193-193|,|O
DDI-DrugBank.d350.s12|195-196|or|O
DDI-DrugBank.d350.s12|198-210|carbamazepine|drug
DDI-DrugBank.d350.s12|211-211|)|O
DDI-DrugBank.d350.s12|213-216|with|O
DDI-DrugBank.d350.s12|218-225|CANCIDAS|brand
DDI-DrugBank.d350.s12|227-229|may|O
DDI-DrugBank.d350.s12|231-236|result|O
DDI-DrugBank.d350.s12|238-239|in|O
DDI-DrugBank.d350.s12|241-250|clinically|O
DDI-DrugBank.d350.s12|252-261|meaningful|O
DDI-DrugBank.d350.s12|263-272|reductions|O
DDI-DrugBank.d350.s12|274-275|in|O
DDI-DrugBank.d350.s12|277-287|caspofungin|drug
DDI-DrugBank.d350.s12|289-302|concentrations|O
DDI-DrugBank.d350.s12|303-303|.|O
DDI-DrugBank.d350.s13|0-1|It|O
DDI-DrugBank.d350.s13|3-4|is|O
DDI-DrugBank.d350.s13|6-8|not|O
DDI-DrugBank.d350.s13|10-14|known|O
DDI-DrugBank.d350.s13|16-20|which|O
DDI-DrugBank.d350.s13|22-25|drug|O
DDI-DrugBank.d350.s13|27-35|clearance|O
DDI-DrugBank.d350.s13|37-45|mechanism|O
DDI-DrugBank.d350.s13|47-54|involved|O
DDI-DrugBank.d350.s13|56-57|in|O
DDI-DrugBank.d350.s13|59-69|caspofungin|drug
DDI-DrugBank.d350.s13|71-81|disposition|O
DDI-DrugBank.d350.s13|83-85|may|O
DDI-DrugBank.d350.s13|87-88|be|O
DDI-DrugBank.d350.s13|90-98|inducible|O
DDI-DrugBank.d350.s13|99-99|.|O
DDI-DrugBank.d350.s14|0-3|When|O
DDI-DrugBank.d350.s14|5-12|CANCIDAS|brand
DDI-DrugBank.d350.s14|14-15|is|O
DDI-DrugBank.d350.s14|17-31|co-administered|O
DDI-DrugBank.d350.s14|33-36|with|O
DDI-DrugBank.d350.s14|38-45|inducers|O
DDI-DrugBank.d350.s14|47-48|of|O
DDI-DrugBank.d350.s14|50-53|drug|O
DDI-DrugBank.d350.s14|55-63|clearance|O
DDI-DrugBank.d350.s14|64-64|,|O
DDI-DrugBank.d350.s14|66-69|such|O
DDI-DrugBank.d350.s14|71-72|as|O
DDI-DrugBank.d350.s14|74-82|efavirenz|drug
DDI-DrugBank.d350.s14|83-83|,|O
DDI-DrugBank.d350.s14|85-94|nevirapine|drug
DDI-DrugBank.d350.s14|95-95|,|O
DDI-DrugBank.d350.s14|97-105|phenytoin|drug
DDI-DrugBank.d350.s14|106-106|,|O
DDI-DrugBank.d350.s14|108-120|dexamethasone|drug
DDI-DrugBank.d350.s14|121-121|,|O
DDI-DrugBank.d350.s14|123-124|or|O
DDI-DrugBank.d350.s14|126-138|carbamazepine|drug
DDI-DrugBank.d350.s14|139-139|,|O
DDI-DrugBank.d350.s14|141-143|use|O
DDI-DrugBank.d350.s14|145-146|of|O
DDI-DrugBank.d350.s14|148-148|a|O
DDI-DrugBank.d350.s14|150-154|daily|O
DDI-DrugBank.d350.s14|156-159|dose|O
DDI-DrugBank.d350.s14|161-162|of|O
DDI-DrugBank.d350.s14|164-165|70|O
DDI-DrugBank.d350.s14|167-168|mg|O
DDI-DrugBank.d350.s14|170-171|of|O
DDI-DrugBank.d350.s14|173-180|CANCIDAS|brand
DDI-DrugBank.d350.s14|182-187|should|O
DDI-DrugBank.d350.s14|189-190|be|O
DDI-DrugBank.d350.s14|192-201|considered|O
DDI-DrugBank.d350.s15|0-0|.|O
DDI-MedLine.d101.s0|0-11|Pharmacology|O
DDI-MedLine.d101.s0|13-15|and|O
DDI-MedLine.d101.s0|17-31|pharmacotherapy|O
DDI-MedLine.d101.s0|33-34|of|O
DDI-MedLine.d101.s0|36-49|cardiovascular|O
DDI-MedLine.d101.s0|51-55|drugs|O
DDI-MedLine.d101.s0|57-58|in|O
DDI-MedLine.d101.s0|60-67|patients|O
DDI-MedLine.d101.s0|69-72|with|O
DDI-MedLine.d101.s0|74-80|chronic|O
DDI-MedLine.d101.s0|82-86|renal|O
DDI-MedLine.d101.s0|88-94|disease|O
DDI-MedLine.d101.s0|95-95|.|O
DDI-MedLine.d101.s1|0-13|Cardiovascular|O
DDI-MedLine.d101.s1|15-21|disease|O
DDI-MedLine.d101.s1|23-24|is|O
DDI-MedLine.d101.s1|26-26|a|O
DDI-MedLine.d101.s1|28-33|common|O
DDI-MedLine.d101.s1|35-45|comorbidity|O
DDI-MedLine.d101.s1|47-49|and|O
DDI-MedLine.d101.s1|51-51|a|O
DDI-MedLine.d101.s1|53-57|major|O
DDI-MedLine.d101.s1|59-63|cause|O
DDI-MedLine.d101.s1|65-66|of|O
DDI-MedLine.d101.s1|68-76|mortality|O
DDI-MedLine.d101.s1|78-79|in|O
DDI-MedLine.d101.s1|81-88|patients|O
DDI-MedLine.d101.s1|90-93|with|O
DDI-MedLine.d101.s1|95-101|chronic|O
DDI-MedLine.d101.s1|103-107|renal|O
DDI-MedLine.d101.s1|109-115|disease|O
DDI-MedLine.d101.s1|116-116|.|O
DDI-MedLine.d101.s2|0-3|Drug|O
DDI-MedLine.d101.s2|5-12|regimens|O
DDI-MedLine.d101.s2|14-15|in|O
DDI-MedLine.d101.s2|17-24|patients|O
DDI-MedLine.d101.s2|26-29|with|O
DDI-MedLine.d101.s2|31-44|cardiovascular|O
DDI-MedLine.d101.s2|46-52|disease|O
DDI-MedLine.d101.s2|54-56|are|O
DDI-MedLine.d101.s2|58-67|frequently|O
DDI-MedLine.d101.s2|69-75|complex|O
DDI-MedLine.d101.s2|77-79|and|O
DDI-MedLine.d101.s2|81-83|can|O
DDI-MedLine.d101.s2|85-86|be|O
DDI-MedLine.d101.s2|88-100|significantly|O
DDI-MedLine.d101.s2|102-109|affected|O
DDI-MedLine.d101.s2|111-112|by|O
DDI-MedLine.d101.s2|114-124|alterations|O
DDI-MedLine.d101.s2|126-127|in|O
DDI-MedLine.d101.s2|129-133|renal|O
DDI-MedLine.d101.s2|135-142|function|O
DDI-MedLine.d101.s2|143-143|.|O
DDI-MedLine.d101.s3|0-1|In|O
DDI-MedLine.d101.s3|3-10|addition|O
DDI-MedLine.d101.s3|11-11|,|O
DDI-MedLine.d101.s3|13-19|several|O
DDI-MedLine.d101.s3|21-34|cardiovascular|O
DDI-MedLine.d101.s3|36-40|drugs|O
DDI-MedLine.d101.s3|42-49|directly|O
DDI-MedLine.d101.s3|51-56|affect|O
DDI-MedLine.d101.s3|58-62|renal|O
DDI-MedLine.d101.s3|64-71|function|O
DDI-MedLine.d101.s3|73-75|and|O
DDI-MedLine.d101.s3|77-79|the|O
DDI-MedLine.d101.s3|81-90|management|O
DDI-MedLine.d101.s3|92-93|of|O
DDI-MedLine.d101.s3|95-102|patients|O
DDI-MedLine.d101.s3|104-107|with|O
DDI-MedLine.d101.s3|109-113|renal|O
DDI-MedLine.d101.s3|115-121|disease|O
DDI-MedLine.d101.s3|122-122|.|O
DDI-MedLine.d101.s4|0-3|This|O
DDI-MedLine.d101.s4|5-11|article|O
DDI-MedLine.d101.s4|13-19|reviews|O
DDI-MedLine.d101.s4|21-23|the|O
DDI-MedLine.d101.s4|25-30|impact|O
DDI-MedLine.d101.s4|32-33|of|O
DDI-MedLine.d101.s4|35-39|renal|O
DDI-MedLine.d101.s4|41-47|disease|O
DDI-MedLine.d101.s4|49-50|on|O
DDI-MedLine.d101.s4|52-54|the|O
DDI-MedLine.d101.s4|56-71|pharmacokinetics|O
DDI-MedLine.d101.s4|73-74|of|O
DDI-MedLine.d101.s4|76-89|cardiovascular|O
DDI-MedLine.d101.s4|91-95|drugs|O
DDI-MedLine.d101.s4|97-99|and|O
DDI-MedLine.d101.s4|101-110|identifies|O
DDI-MedLine.d101.s4|112-121|clinically|O
DDI-MedLine.d101.s4|123-131|important|O
DDI-MedLine.d101.s4|133-144|interactions|O
DDI-MedLine.d101.s4|146-152|between|O
DDI-MedLine.d101.s4|154-158|these|O
DDI-MedLine.d101.s4|160-162|and|O
DDI-MedLine.d101.s4|164-168|other|O
DDI-MedLine.d101.s4|170-174|drugs|O
DDI-MedLine.d101.s4|176-183|commonly|O
DDI-MedLine.d101.s4|185-188|used|O
DDI-MedLine.d101.s4|190-191|in|O
DDI-MedLine.d101.s4|193-195|the|O
DDI-MedLine.d101.s4|197-206|management|O
DDI-MedLine.d101.s4|208-209|of|O
DDI-MedLine.d101.s4|211-217|chronic|O
DDI-MedLine.d101.s4|219-223|renal|O
DDI-MedLine.d101.s4|225-231|disease|O
DDI-MedLine.d101.s4|232-232|.|O
DDI-MedLine.d101.s5|0-6|Several|O
DDI-MedLine.d101.s5|8-14|classes|O
DDI-MedLine.d101.s5|16-17|of|O
DDI-MedLine.d101.s5|19-32|cardiovascular|O
DDI-MedLine.d101.s5|34-38|drugs|O
DDI-MedLine.d101.s5|40-42|are|O
DDI-MedLine.d101.s5|44-47|also|O
DDI-MedLine.d101.s5|49-57|discussed|O
DDI-MedLine.d101.s5|59-60|in|O
DDI-MedLine.d101.s5|62-73|relationship|O
DDI-MedLine.d101.s5|75-76|to|O
DDI-MedLine.d101.s5|78-82|their|O
DDI-MedLine.d101.s5|84-95|differential|O
DDI-MedLine.d101.s5|97-103|effects|O
DDI-MedLine.d101.s5|105-106|on|O
DDI-MedLine.d101.s5|108-110|the|O
DDI-MedLine.d101.s5|112-121|management|O
DDI-MedLine.d101.s5|123-125|and|O
DDI-MedLine.d101.s5|127-137|progression|O
DDI-MedLine.d101.s5|139-140|of|O
DDI-MedLine.d101.s5|142-146|renal|O
DDI-MedLine.d101.s5|148-154|disease|O
DDI-MedLine.d101.s5|155-155|.|O
DDI-DrugBank.d581.s0|0-1|No|O
DDI-DrugBank.d581.s0|3-8|formal|O
DDI-DrugBank.d581.s0|10-13|drug|O
DDI-DrugBank.d581.s0|15-25|interaction|O
DDI-DrugBank.d581.s0|27-33|studies|O
DDI-DrugBank.d581.s0|35-41|between|O
DDI-DrugBank.d581.s0|43-50|Neulasta|brand
DDI-DrugBank.d581.s0|52-54|and|O
DDI-DrugBank.d581.s0|56-60|other|O
DDI-DrugBank.d581.s0|62-66|drugs|O
DDI-DrugBank.d581.s0|68-71|have|O
DDI-DrugBank.d581.s0|73-76|been|O
DDI-DrugBank.d581.s0|78-86|performed|O
DDI-DrugBank.d581.s0|87-87|.|O
DDI-DrugBank.d581.s1|0-4|Drugs|O
DDI-DrugBank.d581.s1|6-9|such|O
DDI-DrugBank.d581.s1|11-12|as|O
DDI-DrugBank.d581.s1|14-20|lithium|drug
DDI-DrugBank.d581.s1|22-24|may|O
DDI-DrugBank.d581.s1|26-35|potentiate|O
DDI-DrugBank.d581.s1|37-39|the|O
DDI-DrugBank.d581.s1|41-47|release|O
DDI-DrugBank.d581.s1|49-50|of|O
DDI-DrugBank.d581.s1|52-62|neutrophils|O
DDI-DrugBank.d581.s1|63-63|;|O
DDI-DrugBank.d581.s2|0-7|patients|O
DDI-DrugBank.d581.s2|9-17|receiving|O
DDI-DrugBank.d581.s2|19-25|lithium|drug
DDI-DrugBank.d581.s2|27-29|and|O
DDI-DrugBank.d581.s2|31-38|Neulasta|brand
DDI-DrugBank.d581.s2|40-45|should|O
DDI-DrugBank.d581.s2|47-50|have|O
DDI-DrugBank.d581.s2|52-55|more|O
DDI-DrugBank.d581.s2|57-64|frequent|O
DDI-DrugBank.d581.s2|66-75|monitoring|O
DDI-DrugBank.d581.s2|77-78|of|O
DDI-DrugBank.d581.s2|80-89|neutrophil|O
DDI-DrugBank.d581.s2|91-96|counts|O
DDI-DrugBank.d581.s2|97-97|.|O
DDI-DrugBank.d165.s0|0-3|Both|O
DDI-DrugBank.d165.s0|5-16|itraconazole|drug
DDI-DrugBank.d165.s0|18-20|and|O
DDI-DrugBank.d165.s0|22-24|its|O
DDI-DrugBank.d165.s0|26-30|major|O
DDI-DrugBank.d165.s0|32-41|metabolite|O
DDI-DrugBank.d165.s0|42-42|,|O
DDI-DrugBank.d165.s0|63-63|,|O
DDI-DrugBank.d165.s0|65-67|are|O
DDI-DrugBank.d165.s0|69-78|inhibitors|O
DDI-DrugBank.d165.s0|80-81|of|O
DDI-DrugBank.d165.s0|83-85|the|O
DDI-DrugBank.d165.s0|87-96|cytochrome|O
DDI-DrugBank.d165.s0|98-101|P450|O
DDI-DrugBank.d165.s0|103-105|3A4|O
DDI-DrugBank.d165.s0|107-112|enzyme|O
DDI-DrugBank.d165.s0|114-119|system|O
DDI-DrugBank.d165.s0|120-120|.|O
DDI-DrugBank.d165.s1|0-15|Coadministration|O
DDI-DrugBank.d165.s1|17-18|of|O
DDI-DrugBank.d165.s1|20-31|Itraconazole|drug
DDI-DrugBank.d165.s1|33-35|and|O
DDI-DrugBank.d165.s1|37-41|drugs|O
DDI-DrugBank.d165.s1|43-51|primarily|O
DDI-DrugBank.d165.s1|53-63|metabolized|O
DDI-DrugBank.d165.s1|65-66|by|O
DDI-DrugBank.d165.s1|68-70|the|O
DDI-DrugBank.d165.s1|72-81|cytochrome|O
DDI-DrugBank.d165.s1|83-86|P450|O
DDI-DrugBank.d165.s1|88-90|3A4|O
DDI-DrugBank.d165.s1|92-97|enzyme|O
DDI-DrugBank.d165.s1|99-104|system|O
DDI-DrugBank.d165.s1|106-108|may|O
DDI-DrugBank.d165.s1|110-115|result|O
DDI-DrugBank.d165.s1|117-118|in|O
DDI-DrugBank.d165.s1|120-128|increased|O
DDI-DrugBank.d165.s1|130-135|plasma|O
DDI-DrugBank.d165.s1|137-150|concentrations|O
DDI-DrugBank.d165.s1|152-153|of|O
DDI-DrugBank.d165.s1|155-157|the|O
DDI-DrugBank.d165.s1|159-163|drugs|O
DDI-DrugBank.d165.s1|165-168|that|O
DDI-DrugBank.d165.s1|170-174|could|O
DDI-DrugBank.d165.s1|176-183|increase|O
DDI-DrugBank.d165.s1|185-186|or|O
DDI-DrugBank.d165.s1|188-194|prolong|O
DDI-DrugBank.d165.s1|196-199|both|O
DDI-DrugBank.d165.s1|201-211|therapeutic|O
DDI-DrugBank.d165.s1|213-215|and|O
DDI-DrugBank.d165.s1|217-223|adverse|O
DDI-DrugBank.d165.s1|225-231|effects|O
DDI-DrugBank.d165.s1|232-232|.|O
DDI-DrugBank.d165.s2|0-8|Therefore|O
DDI-DrugBank.d165.s2|9-9|,|O
DDI-DrugBank.d165.s2|11-16|unless|O
DDI-DrugBank.d165.s2|18-26|otherwise|O
DDI-DrugBank.d165.s2|28-36|specified|O
DDI-DrugBank.d165.s2|37-37|,|O
DDI-DrugBank.d165.s2|39-49|appropriate|O
DDI-DrugBank.d165.s2|51-56|dosage|O
DDI-DrugBank.d165.s2|58-68|adjustments|O
DDI-DrugBank.d165.s2|70-72|may|O
DDI-DrugBank.d165.s2|74-75|be|O
DDI-DrugBank.d165.s2|77-85|necessary|O
DDI-DrugBank.d165.s2|86-86|.|O
DDI-DrugBank.d165.s3|0-15|Coadministration|O
DDI-DrugBank.d165.s3|17-18|of|O
DDI-DrugBank.d165.s3|20-30|terfenadine|drug
DDI-DrugBank.d165.s3|32-35|with|O
DDI-DrugBank.d165.s3|37-48|Itraconazole|drug
DDI-DrugBank.d165.s3|50-52|has|O
DDI-DrugBank.d165.s3|54-56|led|O
DDI-DrugBank.d165.s3|58-59|to|O
DDI-DrugBank.d165.s3|61-68|elevated|O
DDI-DrugBank.d165.s3|70-75|plasma|O
DDI-DrugBank.d165.s3|77-90|concentrations|O
DDI-DrugBank.d165.s3|92-93|of|O
DDI-DrugBank.d165.s3|95-105|terfenadine|drug
DDI-DrugBank.d165.s3|106-106|,|O
DDI-DrugBank.d165.s3|108-116|resulting|O
DDI-DrugBank.d165.s3|118-119|in|O
DDI-DrugBank.d165.s3|121-124|rare|O
DDI-DrugBank.d165.s3|126-134|instances|O
DDI-DrugBank.d165.s3|136-137|of|O
DDI-DrugBank.d165.s3|139-143|life-|O
DDI-DrugBank.d165.s3|145-155|threatening|O
DDI-DrugBank.d165.s3|157-163|cardiac|O
DDI-DrugBank.d165.s3|165-176|dysrhythmias|O
DDI-DrugBank.d165.s3|178-180|and|O
DDI-DrugBank.d165.s3|182-184|one|O
DDI-DrugBank.d165.s3|186-190|death|O
DDI-DrugBank.d165.s3|191-191|.|O
DDI-DrugBank.d165.s4|0-6|Another|O
DDI-DrugBank.d165.s4|8-11|oral|O
DDI-DrugBank.d165.s4|13-28|azole antifungal|group
DDI-DrugBank.d165.s4|29-29|,|O
DDI-DrugBank.d165.s4|31-42|ketoconazole|drug
DDI-DrugBank.d165.s4|43-43|,|O
DDI-DrugBank.d165.s4|45-52|inhibits|O
DDI-DrugBank.d165.s4|54-56|the|O
DDI-DrugBank.d165.s4|58-67|metabolism|O
DDI-DrugBank.d165.s4|69-70|of|O
DDI-DrugBank.d165.s4|72-81|astemizole|drug
DDI-DrugBank.d165.s4|82-82|,|O
DDI-DrugBank.d165.s4|84-92|resulting|O
DDI-DrugBank.d165.s4|94-95|in|O
DDI-DrugBank.d165.s4|97-104|elevated|O
DDI-DrugBank.d165.s4|106-111|plasma|O
DDI-DrugBank.d165.s4|113-126|concentrations|O
DDI-DrugBank.d165.s4|128-129|of|O
DDI-DrugBank.d165.s4|131-140|astemizole|drug
DDI-DrugBank.d165.s4|142-144|and|O
DDI-DrugBank.d165.s4|146-148|its|O
DDI-DrugBank.d165.s4|150-155|active|O
DDI-DrugBank.d165.s4|157-166|metabolite|O
DDI-DrugBank.d165.s4|189-193|which|O
DDI-DrugBank.d165.s4|195-197|may|O
DDI-DrugBank.d165.s4|199-205|prolong|O
DDI-DrugBank.d165.s4|207-208|QT|O
DDI-DrugBank.d165.s4|210-218|intervals|O
DDI-DrugBank.d165.s4|219-219|.|O
DDI-DrugBank.d165.s5|0-1|In|O
DDI-DrugBank.d165.s5|3-7|vitro|O
DDI-DrugBank.d165.s5|9-12|data|O
DDI-DrugBank.d165.s5|14-20|suggest|O
DDI-DrugBank.d165.s5|22-25|that|O
DDI-DrugBank.d165.s5|27-38|itraconazole|drug
DDI-DrugBank.d165.s5|39-39|,|O
DDI-DrugBank.d165.s5|41-44|when|O
DDI-DrugBank.d165.s5|46-53|compared|O
DDI-DrugBank.d165.s5|55-56|to|O
DDI-DrugBank.d165.s5|58-69|ketoconazole|drug
DDI-DrugBank.d165.s5|70-70|,|O
DDI-DrugBank.d165.s5|72-74|has|O
DDI-DrugBank.d165.s5|76-76|a|O
DDI-DrugBank.d165.s5|78-81|less|O
DDI-DrugBank.d165.s5|83-92|pronounced|O
DDI-DrugBank.d165.s5|94-99|effect|O
DDI-DrugBank.d165.s5|101-102|on|O
DDI-DrugBank.d165.s5|104-106|the|O
DDI-DrugBank.d165.s5|108-124|biotransformation|O
DDI-DrugBank.d165.s5|126-131|system|O
DDI-DrugBank.d165.s5|133-143|responsible|O
DDI-DrugBank.d165.s5|145-147|for|O
DDI-DrugBank.d165.s5|149-151|the|O
DDI-DrugBank.d165.s5|153-162|metabolism|O
DDI-DrugBank.d165.s5|164-165|of|O
DDI-DrugBank.d165.s5|167-176|astemizole|drug
DDI-DrugBank.d165.s5|177-177|.|O
DDI-DrugBank.d165.s6|0-4|Based|O
DDI-DrugBank.d165.s6|6-7|on|O
DDI-DrugBank.d165.s6|9-11|the|O
DDI-DrugBank.d165.s6|13-20|chemical|O
DDI-DrugBank.d165.s6|22-32|resemblance|O
DDI-DrugBank.d165.s6|34-35|of|O
DDI-DrugBank.d165.s6|37-48|itraconazole|drug
DDI-DrugBank.d165.s6|50-52|and|O
DDI-DrugBank.d165.s6|54-65|ketoconazole|drug
DDI-DrugBank.d165.s6|66-66|,|O
DDI-DrugBank.d165.s6|68-83|coadministration|O
DDI-DrugBank.d165.s6|85-86|of|O
DDI-DrugBank.d165.s6|88-97|astemizole|drug
DDI-DrugBank.d165.s6|99-102|with|O
DDI-DrugBank.d165.s6|104-115|itraconazole|drug
DDI-DrugBank.d165.s6|117-118|is|O
DDI-DrugBank.d165.s6|120-134|contraindicated|O
DDI-DrugBank.d165.s6|135-135|.|O
DDI-DrugBank.d165.s7|0-4|Human|O
DDI-DrugBank.d165.s7|6-21|pharmacokinetics|O
DDI-DrugBank.d165.s7|23-26|data|O
DDI-DrugBank.d165.s7|28-35|indicate|O
DDI-DrugBank.d165.s7|37-40|that|O
DDI-DrugBank.d165.s7|42-45|oral|O
DDI-DrugBank.d165.s7|47-58|ketoconazole|drug
DDI-DrugBank.d165.s7|60-67|potently|O
DDI-DrugBank.d165.s7|69-76|inhibits|O
DDI-DrugBank.d165.s7|78-80|the|O
DDI-DrugBank.d165.s7|82-91|metabolism|O
DDI-DrugBank.d165.s7|93-94|of|O
DDI-DrugBank.d165.s7|96-104|cisapride|drug
DDI-DrugBank.d165.s7|106-114|resulting|O
DDI-DrugBank.d165.s7|116-117|in|O
DDI-DrugBank.d165.s7|119-120|an|O
DDI-DrugBank.d165.s7|122-131|eight-fold|O
DDI-DrugBank.d165.s7|133-140|increase|O
DDI-DrugBank.d165.s7|142-143|in|O
DDI-DrugBank.d165.s7|145-147|the|O
DDI-DrugBank.d165.s7|149-152|mean|O
DDI-DrugBank.d165.s7|154-156|AUC|O
DDI-DrugBank.d165.s7|158-159|of|O
DDI-DrugBank.d165.s7|161-169|cisapride|drug
DDI-DrugBank.d165.s7|170-170|.|O
DDI-DrugBank.d165.s8|0-3|Data|O
DDI-DrugBank.d165.s8|5-11|suggest|O
DDI-DrugBank.d165.s8|13-16|that|O
DDI-DrugBank.d165.s8|18-33|coadministration|O
DDI-DrugBank.d165.s8|35-36|of|O
DDI-DrugBank.d165.s8|38-41|oral|O
DDI-DrugBank.d165.s8|43-54|ketoconazole|drug
DDI-DrugBank.d165.s8|56-58|and|O
DDI-DrugBank.d165.s8|60-68|cisapride|drug
DDI-DrugBank.d165.s8|70-72|can|O
DDI-DrugBank.d165.s8|74-79|result|O
DDI-DrugBank.d165.s8|81-82|in|O
DDI-DrugBank.d165.s8|84-95|prolongation|O
DDI-DrugBank.d165.s8|97-98|of|O
DDI-DrugBank.d165.s8|100-102|the|O
DDI-DrugBank.d165.s8|104-105|QT|O
DDI-DrugBank.d165.s8|107-114|interval|O
DDI-DrugBank.d165.s8|116-117|on|O
DDI-DrugBank.d165.s8|119-121|the|O
DDI-DrugBank.d165.s8|123-125|ECG|O
DDI-DrugBank.d165.s8|126-126|.|O
DDI-DrugBank.d165.s9|0-1|In|O
DDI-DrugBank.d165.s9|3-7|vitro|O
DDI-DrugBank.d165.s9|9-12|data|O
DDI-DrugBank.d165.s9|14-20|suggest|O
DDI-DrugBank.d165.s9|22-25|that|O
DDI-DrugBank.d165.s9|27-38|itraconazole|drug
DDI-DrugBank.d165.s9|40-43|also|O
DDI-DrugBank.d165.s9|45-52|markedly|O
DDI-DrugBank.d165.s9|54-61|inhibits|O
DDI-DrugBank.d165.s9|63-65|the|O
DDI-DrugBank.d165.s9|67-83|biotransformation|O
DDI-DrugBank.d165.s9|85-90|system|O
DDI-DrugBank.d165.s9|92-97|mainly|O
DDI-DrugBank.d165.s9|99-109|responsible|O
DDI-DrugBank.d165.s9|111-113|for|O
DDI-DrugBank.d165.s9|115-117|the|O
DDI-DrugBank.d165.s9|119-128|metabolism|O
DDI-DrugBank.d165.s9|130-131|of|O
DDI-DrugBank.d165.s9|133-141|cisapride|drug
DDI-DrugBank.d165.s9|142-142|;|O
DDI-DrugBank.d165.s10|0-8|therefore|O
DDI-DrugBank.d165.s10|10-20|concomitant|O
DDI-DrugBank.d165.s10|22-35|administration|O
DDI-DrugBank.d165.s10|37-38|of|O
DDI-DrugBank.d165.s10|40-51|Itraconazole|drug
DDI-DrugBank.d165.s10|53-56|with|O
DDI-DrugBank.d165.s10|58-66|cisapride|drug
DDI-DrugBank.d165.s10|68-69|is|O
DDI-DrugBank.d165.s10|71-85|contraindicated|O
DDI-DrugBank.d165.s10|86-86|.|O
DDI-DrugBank.d165.s11|0-15|Coadministration|O
DDI-DrugBank.d165.s11|17-18|of|O
DDI-DrugBank.d165.s11|20-31|Itraconazole|drug
DDI-DrugBank.d165.s11|33-36|with|O
DDI-DrugBank.d165.s11|38-41|oral|O
DDI-DrugBank.d165.s11|43-51|midazolam|drug
DDI-DrugBank.d165.s11|53-54|or|O
DDI-DrugBank.d165.s11|56-64|triazolam|drug
DDI-DrugBank.d165.s11|66-68|has|O
DDI-DrugBank.d165.s11|70-77|resulted|O
DDI-DrugBank.d165.s11|79-80|in|O
DDI-DrugBank.d165.s11|82-89|elevated|O
DDI-DrugBank.d165.s11|91-96|plasma|O
DDI-DrugBank.d165.s11|98-111|concentrations|O
DDI-DrugBank.d165.s11|113-114|of|O
DDI-DrugBank.d165.s11|116-118|the|O
DDI-DrugBank.d165.s11|120-125|latter|O
DDI-DrugBank.d165.s11|127-129|two|O
DDI-DrugBank.d165.s11|131-135|drugs|O
DDI-DrugBank.d165.s11|136-136|.|O
DDI-DrugBank.d165.s12|0-3|This|O
DDI-DrugBank.d165.s12|5-7|may|O
DDI-DrugBank.d165.s12|9-18|potentiate|O
DDI-DrugBank.d165.s12|20-22|and|O
DDI-DrugBank.d165.s12|24-30|prolong|O
DDI-DrugBank.d165.s12|32-39|hypnotic|O
DDI-DrugBank.d165.s12|41-43|and|O
DDI-DrugBank.d165.s12|45-52|sedative|O
DDI-DrugBank.d165.s12|54-60|effects|O
DDI-DrugBank.d165.s12|61-61|.|O
DDI-DrugBank.d165.s13|0-4|These|O
DDI-DrugBank.d165.s13|6-11|agents|O
DDI-DrugBank.d165.s13|13-18|should|O
DDI-DrugBank.d165.s13|20-22|not|O
DDI-DrugBank.d165.s13|24-25|be|O
DDI-DrugBank.d165.s13|27-30|used|O
DDI-DrugBank.d165.s13|32-33|in|O
DDI-DrugBank.d165.s13|35-42|patients|O
DDI-DrugBank.d165.s13|44-50|treated|O
DDI-DrugBank.d165.s13|52-55|with|O
DDI-DrugBank.d165.s13|57-68|Itraconazole|drug
DDI-DrugBank.d165.s13|69-69|.|O
DDI-DrugBank.d165.s14|0-1|If|O
DDI-DrugBank.d165.s14|3-11|midazolam|drug
DDI-DrugBank.d165.s14|13-14|is|O
DDI-DrugBank.d165.s14|16-27|administered|O
DDI-DrugBank.d165.s14|29-40|parenterally|O
DDI-DrugBank.d165.s14|41-41|,|O
DDI-DrugBank.d165.s14|43-49|special|O
DDI-DrugBank.d165.s14|51-60|precaution|O
DDI-DrugBank.d165.s14|62-63|is|O
DDI-DrugBank.d165.s14|65-72|required|O
DDI-DrugBank.d165.s14|74-78|since|O
DDI-DrugBank.d165.s14|80-82|the|O
DDI-DrugBank.d165.s14|84-91|sedative|O
DDI-DrugBank.d165.s14|93-98|effect|O
DDI-DrugBank.d165.s14|100-102|may|O
DDI-DrugBank.d165.s14|104-105|be|O
DDI-DrugBank.d165.s14|107-115|prolonged|O
DDI-DrugBank.d165.s14|116-116|.|O
DDI-DrugBank.d165.s15|0-15|Coadministration|O
DDI-DrugBank.d165.s15|17-18|of|O
DDI-DrugBank.d165.s15|20-31|Itraconazole|drug
DDI-DrugBank.d165.s15|33-35|and|O
DDI-DrugBank.d165.s15|37-48|cyclosporine|drug
DDI-DrugBank.d165.s15|49-49|,|O
DDI-DrugBank.d165.s15|51-60|tacrolimus|drug
DDI-DrugBank.d165.s15|62-63|or|O
DDI-DrugBank.d165.s15|65-71|digoxin|drug
DDI-DrugBank.d165.s15|73-75|has|O
DDI-DrugBank.d165.s15|77-79|led|O
DDI-DrugBank.d165.s15|81-82|to|O
DDI-DrugBank.d165.s15|84-92|increased|O
DDI-DrugBank.d165.s15|94-99|plasma|O
DDI-DrugBank.d165.s15|101-114|concentrations|O
DDI-DrugBank.d165.s15|116-117|of|O
DDI-DrugBank.d165.s15|119-121|the|O
DDI-DrugBank.d165.s15|123-128|latter|O
DDI-DrugBank.d165.s15|130-134|three|O
DDI-DrugBank.d165.s15|136-140|drugs|O
DDI-DrugBank.d165.s15|141-141|.|O
DDI-DrugBank.d165.s16|0-11|Cyclosporine|drug
DDI-DrugBank.d165.s16|12-12|,|O
DDI-DrugBank.d165.s16|14-23|tacrolimus|drug
DDI-DrugBank.d165.s16|25-27|and|O
DDI-DrugBank.d165.s16|29-35|digoxin|drug
DDI-DrugBank.d165.s16|37-50|concentrations|O
DDI-DrugBank.d165.s16|52-57|should|O
DDI-DrugBank.d165.s16|59-60|be|O
DDI-DrugBank.d165.s16|62-70|monitored|O
DDI-DrugBank.d165.s16|72-73|at|O
DDI-DrugBank.d165.s16|75-77|the|O
DDI-DrugBank.d165.s16|79-88|initiation|O
DDI-DrugBank.d165.s16|90-91|of|O
DDI-DrugBank.d165.s16|93-104|Itraconazole|drug
DDI-DrugBank.d165.s16|106-112|therapy|O
DDI-DrugBank.d165.s16|114-116|and|O
DDI-DrugBank.d165.s16|118-127|frequently|O
DDI-DrugBank.d165.s16|129-138|thereafter|O
DDI-DrugBank.d165.s16|139-139|,|O
DDI-DrugBank.d165.s16|141-143|and|O
DDI-DrugBank.d165.s16|145-147|the|O
DDI-DrugBank.d165.s16|149-152|dose|O
DDI-DrugBank.d165.s16|154-155|of|O
DDI-DrugBank.d165.s16|157-161|these|O
DDI-DrugBank.d165.s16|163-167|three|O
DDI-DrugBank.d165.s16|169-172|drug|O
DDI-DrugBank.d165.s16|174-181|products|O
DDI-DrugBank.d165.s16|183-190|adjusted|O
DDI-DrugBank.d165.s16|192-204|appropriately|O
DDI-DrugBank.d165.s16|205-205|.|O
DDI-DrugBank.d165.s17|0-13|Rhabdomyolysis|O
DDI-DrugBank.d165.s17|15-17|has|O
DDI-DrugBank.d165.s17|19-22|been|O
DDI-DrugBank.d165.s17|24-31|observed|O
DDI-DrugBank.d165.s17|33-34|in|O
DDI-DrugBank.d165.s17|36-43|patients|O
DDI-DrugBank.d165.s17|45-53|receiving|O
DDI-DrugBank.d165.s17|55-82|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d165.s17|84-95|administered|O
DDI-DrugBank.d165.s17|97-101|alone|O
DDI-DrugBank.d165.s17|103-103|(|O
DDI-DrugBank.d165.s17|104-105|at|O
DDI-DrugBank.d165.s17|107-117|recommended|O
DDI-DrugBank.d165.s17|119-125|dosages|O
DDI-DrugBank.d165.s17|126-126|)|O
DDI-DrugBank.d165.s17|128-129|or|O
DDI-DrugBank.d165.s17|131-143|concomitantly|O
DDI-DrugBank.d165.s17|145-148|with|O
DDI-DrugBank.d165.s17|150-172|immunosuppressive drugs|group
DDI-DrugBank.d165.s17|174-182|including|O
DDI-DrugBank.d165.s17|184-195|cyclosporine|drug
DDI-DrugBank.d165.s17|196-196|.|O
DDI-DrugBank.d165.s18|0-3|When|O
DDI-DrugBank.d165.s18|5-16|Itraconazole|drug
DDI-DrugBank.d165.s18|18-20|was|O
DDI-DrugBank.d165.s18|22-35|coadministered|O
DDI-DrugBank.d165.s18|37-40|with|O
DDI-DrugBank.d165.s18|42-50|phenytoin|drug
DDI-DrugBank.d165.s18|51-51|,|O
DDI-DrugBank.d165.s18|53-60|rifampin|drug
DDI-DrugBank.d165.s18|61-61|,|O
DDI-DrugBank.d165.s18|63-64|or|O
DDI-DrugBank.d165.s18|66-78|H2antagonists|O
DDI-DrugBank.d165.s18|79-79|,|O
DDI-DrugBank.d165.s18|81-87|reduced|O
DDI-DrugBank.d165.s18|89-94|plasma|O
DDI-DrugBank.d165.s18|96-109|concentrations|O
DDI-DrugBank.d165.s18|111-112|of|O
DDI-DrugBank.d165.s18|114-125|itraconazole|drug
DDI-DrugBank.d165.s18|127-130|were|O
DDI-DrugBank.d165.s18|132-139|reported|O
DDI-DrugBank.d165.s18|140-140|.|O
DDI-DrugBank.d165.s19|0-2|The|O
DDI-DrugBank.d165.s19|4-12|physician|O
DDI-DrugBank.d165.s19|14-15|is|O
DDI-DrugBank.d165.s19|17-23|advised|O
DDI-DrugBank.d165.s19|25-26|to|O
DDI-DrugBank.d165.s19|28-34|monitor|O
DDI-DrugBank.d165.s19|36-38|the|O
DDI-DrugBank.d165.s19|40-45|plasma|O
DDI-DrugBank.d165.s19|47-60|concentrations|O
DDI-DrugBank.d165.s19|62-63|of|O
DDI-DrugBank.d165.s19|65-76|itraconazole|drug
DDI-DrugBank.d165.s19|78-81|when|O
DDI-DrugBank.d165.s19|83-85|any|O
DDI-DrugBank.d165.s19|87-88|of|O
DDI-DrugBank.d165.s19|90-94|these|O
DDI-DrugBank.d165.s19|96-100|drugs|O
DDI-DrugBank.d165.s19|102-103|is|O
DDI-DrugBank.d165.s19|105-109|taken|O
DDI-DrugBank.d165.s19|111-122|concurrently|O
DDI-DrugBank.d165.s19|123-123|,|O
DDI-DrugBank.d165.s19|125-127|and|O
DDI-DrugBank.d165.s19|129-130|to|O
DDI-DrugBank.d165.s19|132-139|increase|O
DDI-DrugBank.d165.s19|141-143|the|O
DDI-DrugBank.d165.s19|145-148|dose|O
DDI-DrugBank.d165.s19|150-151|of|O
DDI-DrugBank.d165.s19|153-164|Itraconazole|drug
DDI-DrugBank.d165.s19|166-167|if|O
DDI-DrugBank.d165.s19|169-177|necessary|O
DDI-DrugBank.d165.s19|178-178|.|O
DDI-DrugBank.d165.s20|0-7|Although|O
DDI-DrugBank.d165.s20|9-10|no|O
DDI-DrugBank.d165.s20|12-18|studies|O
DDI-DrugBank.d165.s20|20-23|have|O
DDI-DrugBank.d165.s20|25-28|been|O
DDI-DrugBank.d165.s20|30-38|conducted|O
DDI-DrugBank.d165.s20|39-39|,|O
DDI-DrugBank.d165.s20|41-51|concomitant|O
DDI-DrugBank.d165.s20|53-66|administration|O
DDI-DrugBank.d165.s20|68-69|of|O
DDI-DrugBank.d165.s20|71-82|Itraconazole|drug
DDI-DrugBank.d165.s20|84-86|and|O
DDI-DrugBank.d165.s20|88-96|phenytoin|drug
DDI-DrugBank.d165.s20|98-100|may|O
DDI-DrugBank.d165.s20|102-106|alter|O
DDI-DrugBank.d165.s20|108-110|the|O
DDI-DrugBank.d165.s20|112-121|metabolism|O
DDI-DrugBank.d165.s20|123-124|of|O
DDI-DrugBank.d165.s20|126-134|phenytoin|drug
DDI-DrugBank.d165.s20|135-135|;|O
DDI-DrugBank.d165.s21|0-8|therefore|O
DDI-DrugBank.d165.s21|9-9|,|O
DDI-DrugBank.d165.s21|11-16|plasma|O
DDI-DrugBank.d165.s21|18-31|concentrations|O
DDI-DrugBank.d165.s21|33-34|of|O
DDI-DrugBank.d165.s21|36-44|phenytoin|drug
DDI-DrugBank.d165.s21|46-51|should|O
DDI-DrugBank.d165.s21|53-56|also|O
DDI-DrugBank.d165.s21|58-59|be|O
DDI-DrugBank.d165.s21|61-69|monitored|O
DDI-DrugBank.d165.s21|71-74|when|O
DDI-DrugBank.d165.s21|76-77|it|O
DDI-DrugBank.d165.s21|79-80|is|O
DDI-DrugBank.d165.s21|82-86|given|O
DDI-DrugBank.d165.s21|88-99|concurrently|O
DDI-DrugBank.d165.s21|101-104|with|O
DDI-DrugBank.d165.s21|106-117|Itraconazole|drug
DDI-DrugBank.d165.s21|118-118|.|O
DDI-DrugBank.d165.s22|0-1|It|O
DDI-DrugBank.d165.s22|3-5|has|O
DDI-DrugBank.d165.s22|7-10|been|O
DDI-DrugBank.d165.s22|12-19|reported|O
DDI-DrugBank.d165.s22|21-24|that|O
DDI-DrugBank.d165.s22|26-37|Itraconazole|drug
DDI-DrugBank.d165.s22|39-46|enhances|O
DDI-DrugBank.d165.s22|48-50|the|O
DDI-DrugBank.d165.s22|52-64|anticoagulant|O
DDI-DrugBank.d165.s22|66-71|effect|O
DDI-DrugBank.d165.s22|73-74|of|O
DDI-DrugBank.d165.s22|76-88|coumarin-like|group
DDI-DrugBank.d165.s22|90-94|drugs|O
DDI-DrugBank.d165.s22|95-95|.|O
DDI-DrugBank.d165.s23|0-8|Therefore|O
DDI-DrugBank.d165.s23|9-9|,|O
DDI-DrugBank.d165.s23|11-21|prothrombin|O
DDI-DrugBank.d165.s23|23-26|time|O
DDI-DrugBank.d165.s23|28-33|should|O
DDI-DrugBank.d165.s23|35-36|be|O
DDI-DrugBank.d165.s23|38-46|carefully|O
DDI-DrugBank.d165.s23|48-56|monitored|O
DDI-DrugBank.d165.s23|58-59|in|O
DDI-DrugBank.d165.s23|61-68|patients|O
DDI-DrugBank.d165.s23|70-78|receiving|O
DDI-DrugBank.d165.s23|80-91|Itraconazole|drug
DDI-DrugBank.d165.s23|93-95|and|O
DDI-DrugBank.d165.s23|97-109|coumarin-like|group
DDI-DrugBank.d165.s23|111-115|drugs|O
DDI-DrugBank.d165.s23|117-130|simultaneously|O
DDI-DrugBank.d165.s23|131-131|.|O
DDI-DrugBank.d165.s24|0-5|Plasma|O
DDI-DrugBank.d165.s24|7-20|concentrations|O
DDI-DrugBank.d165.s24|22-23|of|O
DDI-DrugBank.d165.s24|25-47|azole antifungal agents|group
DDI-DrugBank.d165.s24|49-51|are|O
DDI-DrugBank.d165.s24|53-59|reduced|O
DDI-DrugBank.d165.s24|61-64|when|O
DDI-DrugBank.d165.s24|66-70|given|O
DDI-DrugBank.d165.s24|72-83|concurrently|O
DDI-DrugBank.d165.s24|85-88|with|O
DDI-DrugBank.d165.s24|90-98|isoniazid|drug
DDI-DrugBank.d165.s24|99-99|.|O
DDI-DrugBank.d165.s25|0-11|Itraconazole|drug
DDI-DrugBank.d165.s25|13-18|plasma|O
DDI-DrugBank.d165.s25|20-33|concentrations|O
DDI-DrugBank.d165.s25|35-40|should|O
DDI-DrugBank.d165.s25|42-43|be|O
DDI-DrugBank.d165.s25|45-53|monitored|O
DDI-DrugBank.d165.s25|55-58|when|O
DDI-DrugBank.d165.s25|60-71|Itraconazole|drug
DDI-DrugBank.d165.s25|73-75|and|O
DDI-DrugBank.d165.s25|77-85|isoniazid|drug
DDI-DrugBank.d165.s25|87-89|are|O
DDI-DrugBank.d165.s25|91-104|coadministered|O
DDI-DrugBank.d165.s25|105-105|.|O
DDI-DrugBank.d165.s26|0-5|Severe|O
DDI-DrugBank.d165.s26|7-18|hypoglycemia|O
DDI-DrugBank.d165.s26|20-22|has|O
DDI-DrugBank.d165.s26|24-27|been|O
DDI-DrugBank.d165.s26|29-36|reported|O
DDI-DrugBank.d165.s26|38-39|in|O
DDI-DrugBank.d165.s26|41-48|patients|O
DDI-DrugBank.d165.s26|50-62|concomitantly|O
DDI-DrugBank.d165.s26|64-72|receiving|O
DDI-DrugBank.d165.s26|74-96|azole antifungal agents|group
DDI-DrugBank.d165.s26|98-100|and|O
DDI-DrugBank.d165.s26|102-105|oral|O
DDI-DrugBank.d165.s26|107-125|hypoglycemic agents|group
DDI-DrugBank.d165.s26|126-126|.|O
DDI-DrugBank.d165.s27|0-4|Blood|O
DDI-DrugBank.d165.s27|6-12|glucose|O
DDI-DrugBank.d165.s27|14-27|concentrations|O
DDI-DrugBank.d165.s27|29-34|should|O
DDI-DrugBank.d165.s27|36-37|be|O
DDI-DrugBank.d165.s27|39-47|carefully|O
DDI-DrugBank.d165.s27|49-57|monitored|O
DDI-DrugBank.d165.s27|59-62|when|O
DDI-DrugBank.d165.s27|64-75|Itraconazole|drug
DDI-DrugBank.d165.s27|77-79|and|O
DDI-DrugBank.d165.s27|81-84|oral|O
DDI-DrugBank.d165.s27|86-104|hypoglycemic agents|group
DDI-DrugBank.d165.s27|106-108|are|O
DDI-DrugBank.d165.s27|110-123|coadministered|O
DDI-DrugBank.d165.s27|124-124|.|O
DDI-DrugBank.d165.s28|0-7|Tinnitus|O
DDI-DrugBank.d165.s28|9-11|and|O
DDI-DrugBank.d165.s28|13-21|decreased|O
DDI-DrugBank.d165.s28|23-29|hearing|O
DDI-DrugBank.d165.s28|31-34|have|O
DDI-DrugBank.d165.s28|36-39|been|O
DDI-DrugBank.d165.s28|41-48|reported|O
DDI-DrugBank.d165.s28|50-51|in|O
DDI-DrugBank.d165.s28|53-60|patients|O
DDI-DrugBank.d165.s28|62-74|concomitantly|O
DDI-DrugBank.d165.s28|76-84|receiving|O
DDI-DrugBank.d165.s28|86-97|Itraconazole|drug
DDI-DrugBank.d165.s28|99-101|and|O
DDI-DrugBank.d165.s28|103-111|quinidine|drug
DDI-DrugBank.d165.s28|112-112|.|O
DDI-DrugBank.d165.s29|0-4|Edema|O
DDI-DrugBank.d165.s29|6-8|has|O
DDI-DrugBank.d165.s29|10-13|been|O
DDI-DrugBank.d165.s29|15-22|reported|O
DDI-DrugBank.d165.s29|24-25|in|O
DDI-DrugBank.d165.s29|27-34|patients|O
DDI-DrugBank.d165.s29|36-48|concomitantly|O
DDI-DrugBank.d165.s29|50-58|receiving|O
DDI-DrugBank.d165.s29|60-71|Itraconazole|drug
DDI-DrugBank.d165.s29|73-75|and|O
DDI-DrugBank.d165.s29|77-116|dihydropyridine calcium channel blockers|group
DDI-DrugBank.d165.s29|117-117|.|O
DDI-DrugBank.d165.s30|0-10|Appropriate|O
DDI-DrugBank.d165.s30|12-17|dosage|O
DDI-DrugBank.d165.s30|19-29|adjustments|O
DDI-DrugBank.d165.s30|31-33|may|O
DDI-DrugBank.d165.s30|35-36|be|O
DDI-DrugBank.d165.s30|38-46|necessary|O
DDI-DrugBank.d165.s30|47-47|.|O
DDI-DrugBank.d165.s31|0-2|The|O
DDI-DrugBank.d165.s31|4-10|results|O
DDI-DrugBank.d165.s31|12-15|from|O
DDI-DrugBank.d165.s31|17-17|a|O
DDI-DrugBank.d165.s31|19-23|study|O
DDI-DrugBank.d165.s31|25-26|in|O
DDI-DrugBank.d165.s31|28-32|which|O
DDI-DrugBank.d165.s31|34-38|eight|O
DDI-DrugBank.d165.s31|40-51|HIV-infected|O
DDI-DrugBank.d165.s31|53-63|individuals|O
DDI-DrugBank.d165.s31|65-68|were|O
DDI-DrugBank.d165.s31|70-76|treated|O
DDI-DrugBank.d165.s31|78-81|with|O
DDI-DrugBank.d165.s31|83-92|zidovudine|drug
DDI-DrugBank.d165.s31|93-93|,|O
DDI-DrugBank.d165.s31|95-95|8|O
DDI-DrugBank.d165.s31|97-99|+/-|O
DDI-DrugBank.d165.s31|101-103|0.4|O
DDI-DrugBank.d165.s31|105-113|mg/kg/day|O
DDI-DrugBank.d165.s31|114-114|,|O
DDI-DrugBank.d165.s31|116-121|showed|O
DDI-DrugBank.d165.s31|123-126|that|O
DDI-DrugBank.d165.s31|128-130|the|O
DDI-DrugBank.d165.s31|132-147|pharmacokinetics|O
DDI-DrugBank.d165.s31|149-150|of|O
DDI-DrugBank.d165.s31|152-161|zidovudine|drug
DDI-DrugBank.d165.s31|163-166|were|O
DDI-DrugBank.d165.s31|168-170|not|O
DDI-DrugBank.d165.s31|172-179|affected|O
DDI-DrugBank.d165.s31|181-186|during|O
DDI-DrugBank.d165.s31|188-198|concomitant|O
DDI-DrugBank.d165.s31|200-213|administration|O
DDI-DrugBank.d165.s31|215-216|of|O
DDI-DrugBank.d165.s31|218-229|Itraconazole|drug
DDI-DrugBank.d165.s31|230-230|,|O
DDI-DrugBank.d165.s31|232-234|100|O
DDI-DrugBank.d165.s31|236-237|mg|O
DDI-DrugBank.d165.s31|239-243|b.i.d|O
DDI-DrugBank.d165.s31|244-244|.|O
DDI-MedLine.d26.s0|0-6|Optimal|O
DDI-MedLine.d26.s0|8-14|designs|O
DDI-MedLine.d26.s0|16-18|for|O
DDI-MedLine.d26.s0|20-22|the|O
DDI-MedLine.d26.s0|24-33|individual|O
DDI-MedLine.d26.s0|35-37|and|O
DDI-MedLine.d26.s0|39-43|joint|O
DDI-MedLine.d26.s0|45-52|exposure|O
DDI-MedLine.d26.s0|54-60|general|O
DDI-MedLine.d26.s0|62-69|logistic|O
DDI-MedLine.d26.s0|71-80|regression|O
DDI-MedLine.d26.s0|82-87|models|O
DDI-MedLine.d26.s0|88-88|.|O
DDI-MedLine.d26.s1|0-7|Interest|O
DDI-MedLine.d26.s1|9-10|in|O
DDI-MedLine.d26.s1|12-24|administering|O
DDI-MedLine.d26.s1|26-34|compounds|O
DDI-MedLine.d26.s1|36-37|in|O
DDI-MedLine.d26.s1|39-49|combination|O
DDI-MedLine.d26.s1|51-54|lies|O
DDI-MedLine.d26.s1|56-59|both|O
DDI-MedLine.d26.s1|61-62|in|O
DDI-MedLine.d26.s1|64-72|enhancing|O
DDI-MedLine.d26.s1|74-84|efficacious|O
DDI-MedLine.d26.s1|86-92|effects|O
DDI-MedLine.d26.s1|94-96|and|O
DDI-MedLine.d26.s1|98-99|in|O
DDI-MedLine.d26.s1|101-108|limiting|O
DDI-MedLine.d26.s1|110-116|adverse|O
DDI-MedLine.d26.s1|118-124|effects|O
DDI-MedLine.d26.s1|125-125|.|O
DDI-MedLine.d26.s2|0-7|Although|O
DDI-MedLine.d26.s2|9-12|much|O
DDI-MedLine.d26.s2|14-24|statistical|O
DDI-MedLine.d26.s2|26-29|work|O
DDI-MedLine.d26.s2|31-33|has|O
DDI-MedLine.d26.s2|35-41|focused|O
DDI-MedLine.d26.s2|43-44|on|O
DDI-MedLine.d26.s2|46-55|developing|O
DDI-MedLine.d26.s2|57-68|mathematical|O
DDI-MedLine.d26.s2|70-78|functions|O
DDI-MedLine.d26.s2|80-81|to|O
DDI-MedLine.d26.s2|83-87|model|O
DDI-MedLine.d26.s2|89-91|the|O
DDI-MedLine.d26.s2|93-97|joint|O
DDI-MedLine.d26.s2|99-111|dose-response|O
DDI-MedLine.d26.s2|113-118|curves|O
DDI-MedLine.d26.s2|119-119|,|O
DDI-MedLine.d26.s2|121-130|relatively|O
DDI-MedLine.d26.s2|132-137|little|O
DDI-MedLine.d26.s2|139-142|work|O
DDI-MedLine.d26.s2|144-149|exists|O
DDI-MedLine.d26.s2|151-152|in|O
DDI-MedLine.d26.s2|154-159|regard|O
DDI-MedLine.d26.s2|161-162|to|O
DDI-MedLine.d26.s2|164-172|designing|O
DDI-MedLine.d26.s2|174-184|experiments|O
DDI-MedLine.d26.s2|186-188|for|O
DDI-MedLine.d26.s2|190-198|assessing|O
DDI-MedLine.d26.s2|200-204|joint|O
DDI-MedLine.d26.s2|206-211|action|O
DDI-MedLine.d26.s2|212-212|.|O
DDI-MedLine.d26.s3|0-0|A|O
DDI-MedLine.d26.s3|2-8|variety|O
DDI-MedLine.d26.s3|10-11|of|O
DDI-MedLine.d26.s3|13-22|parametric|O
DDI-MedLine.d26.s3|24-36|dose-response|O
DDI-MedLine.d26.s3|38-43|models|O
DDI-MedLine.d26.s3|45-49|based|O
DDI-MedLine.d26.s3|51-52|on|O
DDI-MedLine.d26.s3|54-59|either|O
DDI-MedLine.d26.s3|61-63|the|O
DDI-MedLine.d26.s3|65-70|normal|O
DDI-MedLine.d26.s3|72-73|or|O
DDI-MedLine.d26.s3|75-82|logistic|O
DDI-MedLine.d26.s3|84-94|probability|O
DDI-MedLine.d26.s3|96-107|distribution|O
DDI-MedLine.d26.s3|109-112|have|O
DDI-MedLine.d26.s3|114-117|been|O
DDI-MedLine.d26.s3|119-126|proposed|O
DDI-MedLine.d26.s3|128-129|in|O
DDI-MedLine.d26.s3|131-133|the|O
DDI-MedLine.d26.s3|135-144|literature|O
DDI-MedLine.d26.s3|145-145|.|O
DDI-MedLine.d26.s4|0-4|These|O
DDI-MedLine.d26.s4|6-11|models|O
DDI-MedLine.d26.s4|13-15|are|O
DDI-MedLine.d26.s4|17-25|typically|O
DDI-MedLine.d26.s4|27-35|nonlinear|O
DDI-MedLine.d26.s4|37-38|in|O
DDI-MedLine.d26.s4|40-42|the|O
DDI-MedLine.d26.s4|44-53|parameters|O
DDI-MedLine.d26.s4|54-54|,|O
DDI-MedLine.d26.s4|56-58|and|O
DDI-MedLine.d26.s4|60-61|as|O
DDI-MedLine.d26.s4|63-66|such|O
DDI-MedLine.d26.s4|67-67|,|O
DDI-MedLine.d26.s4|69-69|a|O
DDI-MedLine.d26.s4|71-79|nonlinear|O
DDI-MedLine.d26.s4|81-88|weighted|O
DDI-MedLine.d26.s4|90-94|least|O
DDI-MedLine.d26.s4|96-102|squares|O
DDI-MedLine.d26.s4|104-111|approach|O
DDI-MedLine.d26.s4|113-115|can|O
DDI-MedLine.d26.s4|117-118|be|O
DDI-MedLine.d26.s4|120-127|employed|O
DDI-MedLine.d26.s4|129-131|for|O
DDI-MedLine.d26.s4|133-135|the|O
DDI-MedLine.d26.s4|137-143|purpose|O
DDI-MedLine.d26.s4|145-146|of|O
DDI-MedLine.d26.s4|148-156|designing|O
DDI-MedLine.d26.s4|158-168|experiments|O
DDI-MedLine.d26.s4|169-169|.|O
DDI-MedLine.d26.s5|0-2|The|O
DDI-MedLine.d26.s5|4-11|approach|O
DDI-MedLine.d26.s5|13-14|is|O
DDI-MedLine.d26.s5|16-25|applicable|O
DDI-MedLine.d26.s5|27-32|across|O
DDI-MedLine.d26.s5|34-34|a|O
DDI-MedLine.d26.s5|36-39|wide|O
DDI-MedLine.d26.s5|41-47|variety|O
DDI-MedLine.d26.s5|49-50|of|O
DDI-MedLine.d26.s5|52-59|settings|O
DDI-MedLine.d26.s5|61-68|commonly|O
DDI-MedLine.d26.s5|70-79|associated|O
DDI-MedLine.d26.s5|81-84|with|O
DDI-MedLine.d26.s5|86-90|joint|O
DDI-MedLine.d26.s5|92-97|action|O
DDI-MedLine.d26.s5|99-102|data|O
DDI-MedLine.d26.s5|103-103|,|O
DDI-MedLine.d26.s5|105-113|including|O
DDI-MedLine.d26.s5|115-124|continuous|O
DDI-MedLine.d26.s5|126-128|and|O
DDI-MedLine.d26.s5|130-137|discrete|O
DDI-MedLine.d26.s5|139-147|responses|O
DDI-MedLine.d26.s5|148-148|,|O
DDI-MedLine.d26.s5|150-160|alternative|O
DDI-MedLine.d26.s5|162-166|error|O
DDI-MedLine.d26.s5|168-177|structures|O
DDI-MedLine.d26.s5|178-178|,|O
DDI-MedLine.d26.s5|180-182|and|O
DDI-MedLine.d26.s5|184-190|nonzero|O
DDI-MedLine.d26.s5|192-201|background|O
DDI-MedLine.d26.s5|203-210|response|O
DDI-MedLine.d26.s5|211-211|.|O
DDI-MedLine.d26.s6|0-6|Further|O
DDI-MedLine.d26.s6|7-7|,|O
DDI-MedLine.d26.s6|9-15|designs|O
DDI-MedLine.d26.s6|17-19|can|O
DDI-MedLine.d26.s6|21-22|be|O
DDI-MedLine.d26.s6|24-32|expressed|O
DDI-MedLine.d26.s6|34-35|in|O
DDI-MedLine.d26.s6|37-41|terms|O
DDI-MedLine.d26.s6|43-44|of|O
DDI-MedLine.d26.s6|46-58|proportionate|O
DDI-MedLine.d26.s6|60-68|responses|O
DDI-MedLine.d26.s6|70-79|associated|O
DDI-MedLine.d26.s6|81-84|with|O
DDI-MedLine.d26.s6|86-88|the|O
DDI-MedLine.d26.s6|90-99|individual|O
DDI-MedLine.d26.s6|101-109|compounds|O
DDI-MedLine.d26.s6|111-116|rather|O
DDI-MedLine.d26.s6|118-121|than|O
DDI-MedLine.d26.s6|123-126|dose|O
DDI-MedLine.d26.s6|128-133|levels|O
DDI-MedLine.d26.s6|134-134|,|O
DDI-MedLine.d26.s6|136-142|thereby|O
DDI-MedLine.d26.s6|144-152|providing|O
DDI-MedLine.d26.s6|154-156|for|O
DDI-MedLine.d26.s6|158-164|results|O
DDI-MedLine.d26.s6|166-169|that|O
DDI-MedLine.d26.s6|171-173|are|O
DDI-MedLine.d26.s6|175-184|applicable|O
DDI-MedLine.d26.s6|186-191|across|O
DDI-MedLine.d26.s6|193-201|compounds|O
DDI-MedLine.d26.s6|202-202|.|O
DDI-MedLine.d26.s7|0-1|As|O
DDI-MedLine.d26.s7|3-3|a|O
DDI-MedLine.d26.s7|5-13|precursor|O
DDI-MedLine.d26.s7|15-16|to|O
DDI-MedLine.d26.s7|18-21|this|O
DDI-MedLine.d26.s7|23-28|effort|O
DDI-MedLine.d26.s7|29-29|,|O
DDI-MedLine.d26.s7|31-37|optimal|O
DDI-MedLine.d26.s7|39-41|and|O
DDI-MedLine.d26.s7|43-49|minimal|O
DDI-MedLine.d26.s7|51-62|experimental|O
DDI-MedLine.d26.s7|64-70|designs|O
DDI-MedLine.d26.s7|72-74|for|O
DDI-MedLine.d26.s7|76-78|the|O
DDI-MedLine.d26.s7|80-83|case|O
DDI-MedLine.d26.s7|85-86|in|O
DDI-MedLine.d26.s7|88-92|which|O
DDI-MedLine.d26.s7|94-94|a|O
DDI-MedLine.d26.s7|96-101|single|O
DDI-MedLine.d26.s7|103-110|compound|O
DDI-MedLine.d26.s7|112-113|is|O
DDI-MedLine.d26.s7|115-126|administered|O
DDI-MedLine.d26.s7|128-131|have|O
DDI-MedLine.d26.s7|133-136|also|O
DDI-MedLine.d26.s7|138-141|been|O
DDI-MedLine.d26.s7|143-151|developed|O
DDI-MedLine.d26.s7|152-152|.|O
DDI-MedLine.d26.s8|0-7|Although|O
DDI-MedLine.d26.s8|9-11|the|O
DDI-MedLine.d26.s8|13-20|proposed|O
DDI-MedLine.d26.s8|22-32|methodology|O
DDI-MedLine.d26.s8|34-36|for|O
DDI-MedLine.d26.s8|38-45|deriving|O
DDI-MedLine.d26.s8|47-58|experimental|O
DDI-MedLine.d26.s8|60-66|designs|O
DDI-MedLine.d26.s8|68-70|can|O
DDI-MedLine.d26.s8|72-73|be|O
DDI-MedLine.d26.s8|75-81|applied|O
DDI-MedLine.d26.s8|83-84|to|O
DDI-MedLine.d26.s8|86-88|any|O
DDI-MedLine.d26.s8|90-98|nonlinear|O
DDI-MedLine.d26.s8|100-109|regression|O
DDI-MedLine.d26.s8|111-115|model|O
DDI-MedLine.d26.s8|116-116|,|O
DDI-MedLine.d26.s8|118-124|primary|O
DDI-MedLine.d26.s8|126-130|focus|O
DDI-MedLine.d26.s8|132-133|is|O
DDI-MedLine.d26.s8|135-139|given|O
DDI-MedLine.d26.s8|141-142|to|O
DDI-MedLine.d26.s8|144-146|the|O
DDI-MedLine.d26.s8|148-155|additive|O
DDI-MedLine.d26.s8|157-159|and|O
DDI-MedLine.d26.s8|161-171|nonadditive|O
DDI-MedLine.d26.s8|173-183|independent|O
DDI-MedLine.d26.s8|185-189|joint|O
DDI-MedLine.d26.s8|191-196|action|O
DDI-MedLine.d26.s8|198-198|(|O
DDI-MedLine.d26.s8|199-201|IJA|O
DDI-MedLine.d26.s8|202-202|)|O
DDI-MedLine.d26.s8|204-209|models|O
DDI-MedLine.d26.s8|211-213|for|O
DDI-MedLine.d26.s8|215-224|individual|O
DDI-MedLine.d26.s8|226-228|and|O
DDI-MedLine.d26.s8|230-237|combined|O
DDI-MedLine.d26.s8|239-247|exposures|O
DDI-MedLine.d26.s8|249-256|proposed|O
DDI-MedLine.d26.s8|258-259|by|O
DDI-MedLine.d26.s8|261-266|Barton|O
DDI-MedLine.d26.s8|267-267|,|O
DDI-MedLine.d26.s8|269-277|Braunberg|O
DDI-MedLine.d26.s8|278-278|,|O
DDI-MedLine.d26.s8|280-282|and|O
DDI-MedLine.d26.s8|284-291|Friedman|O
DDI-MedLine.d26.s8|293-293|(|O
DDI-MedLine.d26.s8|294-294|1|O
DDI-MedLine.d26.s8|295-295|)|O
DDI-MedLine.d26.s8|296-296|.|O
DDI-DrugBank.d125.s0|0-4|There|O
DDI-DrugBank.d125.s0|6-8|was|O
DDI-DrugBank.d125.s0|10-11|no|O
DDI-DrugBank.d125.s0|13-20|evidence|O
DDI-DrugBank.d125.s0|22-23|in|O
DDI-DrugBank.d125.s0|25-32|clinical|O
DDI-DrugBank.d125.s0|34-39|trials|O
DDI-DrugBank.d125.s0|41-42|of|O
DDI-DrugBank.d125.s0|44-47|drug|O
DDI-DrugBank.d125.s0|49-60|interactions|O
DDI-DrugBank.d125.s0|62-65|with|O
DDI-DrugBank.d125.s0|67-76|concurrent|O
DDI-DrugBank.d125.s0|78-88|medications|O
DDI-DrugBank.d125.s0|89-89|.|O
DDI-DrugBank.d528.s0|0-12|Acetaminophen|drug
DDI-DrugBank.d528.s0|14-16|and|O
DDI-DrugBank.d528.s0|18-29|methotrexate|drug
DDI-DrugBank.d528.s0|31-31|-|O
DDI-DrugBank.d528.s0|33-44|L-methionine|drug
DDI-DrugBank.d528.s0|46-48|may|O
DDI-DrugBank.d528.s0|50-57|decrease|O
DDI-DrugBank.d528.s0|59-65|hepatic|O
DDI-DrugBank.d528.s0|67-74|toxicity|O
DDI-DrugBank.d528.s0|76-77|in|O
DDI-DrugBank.d528.s0|79-83|those|O
DDI-DrugBank.d528.s0|85-88|with|O
DDI-DrugBank.d528.s0|90-102|acetaminophen|drug
DDI-DrugBank.d528.s0|104-113|overdosage|O
DDI-DrugBank.d528.s0|115-116|or|O
DDI-DrugBank.d528.s0|118-119|in|O
DDI-DrugBank.d528.s0|121-125|those|O
DDI-DrugBank.d528.s0|127-132|taking|O
DDI-DrugBank.d528.s0|134-145|methotrexate|drug
DDI-DrugBank.d528.s0|146-146|.|O
DDI-DrugBank.d528.s1|0-12|Theoretically|O
DDI-DrugBank.d528.s1|13-13|,|O
DDI-DrugBank.d528.s1|15-16|it|O
DDI-DrugBank.d528.s1|18-20|may|O
DDI-DrugBank.d528.s1|22-29|decrease|O
DDI-DrugBank.d528.s1|31-37|hepatic|O
DDI-DrugBank.d528.s1|39-46|toxicity|O
DDI-DrugBank.d528.s1|48-49|in|O
DDI-DrugBank.d528.s1|51-53|the|O
DDI-DrugBank.d528.s1|55-58|case|O
DDI-DrugBank.d528.s1|60-61|of|O
DDI-DrugBank.d528.s1|63-67|other|O
DDI-DrugBank.d528.s1|69-77|potential|O
DDI-DrugBank.d528.s1|79-89|hepatotoxic|O
DDI-DrugBank.d528.s1|91-95|drugs|O
DDI-DrugBank.d528.s1|96-96|,|O
DDI-DrugBank.d528.s1|98-99|as|O
DDI-DrugBank.d528.s1|101-104|well|O
DDI-DrugBank.d528.s1|105-105|.|O
DDI-DrugBank.d528.s2|0-9|Gentamicin|drug
DDI-DrugBank.d528.s2|11-11|-|O
DDI-DrugBank.d528.s2|13-22|Methionine|drug
DDI-DrugBank.d528.s2|24-26|may|O
DDI-DrugBank.d528.s2|28-34|protect|O
DDI-DrugBank.d528.s2|36-42|against|O
DDI-DrugBank.d528.s2|44-46|the|O
DDI-DrugBank.d528.s2|48-55|ototoxic|O
DDI-DrugBank.d528.s2|57-63|effects|O
DDI-DrugBank.d528.s2|65-66|of|O
DDI-DrugBank.d528.s2|68-77|gentamicin|drug
DDI-DrugBank.d528.s2|78-78|.|O
DDI-DrugBank.d128.s0|0-2|May|O
DDI-DrugBank.d128.s0|4-11|interact|O
DDI-DrugBank.d128.s0|13-16|with|O
DDI-DrugBank.d128.s0|18-28|wthionamide|O
DDI-DrugBank.d128.s0|30-30|(|O
DDI-DrugBank.d128.s0|31-41|Trecator-SC|brand
DDI-DrugBank.d128.s0|42-42|)|O
DDI-DrugBank.d128.s0|44-46|and|O
DDI-DrugBank.d128.s0|48-56|isoniazid|drug
DDI-DrugBank.d128.s0|58-58|(|O
DDI-DrugBank.d128.s0|59-66|Nydrazid|brand
DDI-DrugBank.d128.s0|67-67|)|O
DDI-DrugBank.d128.s0|68-68|.|O
DDI-DrugBank.d466.s0|0-3|Drug|O
DDI-DrugBank.d466.s0|5-15|Interaction|O
DDI-DrugBank.d466.s0|17-20|with|O
DDI-DrugBank.d466.s0|22-33|Erythromycin|drug
DDI-DrugBank.d466.s0|35-37|and|O
DDI-DrugBank.d466.s0|39-50|Ketoconazole|drug
DDI-DrugBank.d466.s0|39-50|Ketoconazole|drug
DDI-DrugBank.d466.s0|65-67|has|O
DDI-DrugBank.d466.s0|69-72|been|O
DDI-DrugBank.d466.s0|74-78|shown|O
DDI-DrugBank.d466.s0|80-81|to|O
DDI-DrugBank.d466.s0|83-89|exhibit|O
DDI-DrugBank.d466.s0|91-97|minimal|O
DDI-DrugBank.d466.s0|99-99|(|O
DDI-DrugBank.d466.s0|100-102|ca.|O
DDI-DrugBank.d466.s0|104-104|5|O
DDI-DrugBank.d466.s0|105-105|%|O
DDI-DrugBank.d466.s0|106-106|)|O
DDI-DrugBank.d466.s0|108-117|metabolism|O
DDI-DrugBank.d466.s0|118-118|.|O
DDI-DrugBank.d466.s1|0-6|However|O
DDI-DrugBank.d466.s1|7-7|,|O
DDI-DrugBank.d466.s1|9-10|co|O
DDI-DrugBank.d466.s1|13-26|administration|O
DDI-DrugBank.d466.s1|28-29|of|O
DDI-DrugBank.d466.s1|31-56|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s1|58-61|with|O
DDI-DrugBank.d466.s1|63-68|either|O
DDI-DrugBank.d466.s1|70-81|ketoconazole|drug
DDI-DrugBank.d466.s1|83-84|or|O
DDI-DrugBank.d466.s1|86-97|erythromycin|drug
DDI-DrugBank.d466.s1|99-101|led|O
DDI-DrugBank.d466.s1|103-104|to|O
DDI-DrugBank.d466.s1|106-114|increased|O
DDI-DrugBank.d466.s1|116-121|plasma|O
DDI-DrugBank.d466.s1|123-136|concentrations|O
DDI-DrugBank.d466.s1|138-139|of|O
DDI-DrugBank.d466.s1|141-152|fexofenadine|drug
DDI-DrugBank.d466.s1|153-153|.|O
DDI-DrugBank.d466.s2|0-11|Fexofenadine|drug
DDI-DrugBank.d466.s2|13-15|had|O
DDI-DrugBank.d466.s2|17-18|no|O
DDI-DrugBank.d466.s2|20-25|effect|O
DDI-DrugBank.d466.s2|27-28|on|O
DDI-DrugBank.d466.s2|30-32|the|O
DDI-DrugBank.d466.s2|34-49|pharmacokinetics|O
DDI-DrugBank.d466.s2|51-52|of|O
DDI-DrugBank.d466.s2|54-59|either|O
DDI-DrugBank.d466.s2|61-72|erythromycin|drug
DDI-DrugBank.d466.s2|74-75|or|O
DDI-DrugBank.d466.s2|77-88|ketoconazole|drug
DDI-DrugBank.d466.s2|89-89|.|O
DDI-DrugBank.d466.s3|0-1|In|O
DDI-DrugBank.d466.s3|3-3|2|O
DDI-DrugBank.d466.s3|5-12|separate|O
DDI-DrugBank.d466.s3|14-20|studies|O
DDI-DrugBank.d466.s3|21-21|,|O
DDI-DrugBank.d466.s3|23-48|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s3|50-52|120|O
DDI-DrugBank.d466.s3|54-55|mg|O
DDI-DrugBank.d466.s3|57-61|twice|O
DDI-DrugBank.d466.s3|63-67|daily|O
DDI-DrugBank.d466.s3|69-69|(|O
DDI-DrugBank.d466.s3|70-72|240|O
DDI-DrugBank.d466.s3|74-75|mg|O
DDI-DrugBank.d466.s3|77-81|total|O
DDI-DrugBank.d466.s3|83-87|daily|O
DDI-DrugBank.d466.s3|89-92|dose|O
DDI-DrugBank.d466.s3|93-93|)|O
DDI-DrugBank.d466.s3|95-97|was|O
DDI-DrugBank.d466.s3|99-113|co-administered|O
DDI-DrugBank.d466.s3|115-118|with|O
DDI-DrugBank.d466.s3|120-125|either|O
DDI-DrugBank.d466.s3|127-138|erythromycin|drug
DDI-DrugBank.d466.s3|140-142|500|O
DDI-DrugBank.d466.s3|144-145|mg|O
DDI-DrugBank.d466.s3|147-151|every|O
DDI-DrugBank.d466.s3|153-153|8|O
DDI-DrugBank.d466.s3|155-159|hours|O
DDI-DrugBank.d466.s3|161-162|or|O
DDI-DrugBank.d466.s3|164-175|ketoconazole|drug
DDI-DrugBank.d466.s3|177-179|400|O
DDI-DrugBank.d466.s3|181-182|mg|O
DDI-DrugBank.d466.s3|184-187|once|O
DDI-DrugBank.d466.s3|189-193|daily|O
DDI-DrugBank.d466.s3|195-199|under|O
DDI-DrugBank.d466.s3|201-212|steady-state|O
DDI-DrugBank.d466.s3|214-223|conditions|O
DDI-DrugBank.d466.s3|225-226|to|O
DDI-DrugBank.d466.s3|228-234|healthy|O
DDI-DrugBank.d466.s3|236-245|volunteers|O
DDI-DrugBank.d466.s3|247-247|(|O
DDI-DrugBank.d466.s3|248-251|n=24|O
DDI-DrugBank.d466.s3|252-252|,|O
DDI-DrugBank.d466.s3|254-257|each|O
DDI-DrugBank.d466.s3|259-263|study|O
DDI-DrugBank.d466.s3|264-264|)|O
DDI-DrugBank.d466.s3|265-265|.|O
DDI-DrugBank.d466.s4|0-1|No|O
DDI-DrugBank.d466.s4|3-13|differences|O
DDI-DrugBank.d466.s4|15-16|in|O
DDI-DrugBank.d466.s4|18-24|adverse|O
DDI-DrugBank.d466.s4|26-31|events|O
DDI-DrugBank.d466.s4|33-34|or|O
DDI-DrugBank.d466.s4|36-38|QTc|O
DDI-DrugBank.d466.s4|40-47|interval|O
DDI-DrugBank.d466.s4|49-52|were|O
DDI-DrugBank.d466.s4|54-61|observed|O
DDI-DrugBank.d466.s4|63-66|when|O
DDI-DrugBank.d466.s4|68-75|subjects|O
DDI-DrugBank.d466.s4|77-80|were|O
DDI-DrugBank.d466.s4|82-93|administered|O
DDI-DrugBank.d466.s4|95-120|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s4|122-126|alone|O
DDI-DrugBank.d466.s4|128-129|or|O
DDI-DrugBank.d466.s4|131-132|in|O
DDI-DrugBank.d466.s4|134-144|combination|O
DDI-DrugBank.d466.s4|146-149|with|O
DDI-DrugBank.d466.s4|151-156|either|O
DDI-DrugBank.d466.s4|158-169|erythromycin|drug
DDI-DrugBank.d466.s4|171-172|or|O
DDI-DrugBank.d466.s4|174-185|ketoconazole|drug
DDI-DrugBank.d466.s4|186-186|.|O
DDI-DrugBank.d466.s5|0-2|The|O
DDI-DrugBank.d466.s5|4-11|findings|O
DDI-DrugBank.d466.s5|13-14|of|O
DDI-DrugBank.d466.s5|16-20|these|O
DDI-DrugBank.d466.s5|22-28|studies|O
DDI-DrugBank.d466.s5|30-32|are|O
DDI-DrugBank.d466.s5|34-43|summarized|O
DDI-DrugBank.d466.s5|45-46|in|O
DDI-DrugBank.d466.s5|48-50|the|O
DDI-DrugBank.d466.s5|52-60|following|O
DDI-DrugBank.d466.s5|62-66|table|O
DDI-DrugBank.d466.s5|67-67|:|O
DDI-DrugBank.d466.s5|69-75|Effects|O
DDI-DrugBank.d466.s5|77-78|on|O
DDI-DrugBank.d466.s5|80-91|steady-state|O
DDI-DrugBank.d466.s5|93-104|fexofenadine|drug
DDI-DrugBank.d466.s5|106-121|pharmacokinetics|O
DDI-DrugBank.d466.s5|123-127|after|O
DDI-DrugBank.d466.s5|129-129|7|O
DDI-DrugBank.d466.s5|131-134|days|O
DDI-DrugBank.d466.s5|136-137|of|O
DDI-DrugBank.d466.s5|139-155|co-administration|O
DDI-DrugBank.d466.s5|157-160|with|O
DDI-DrugBank.d466.s5|162-187|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s5|189-191|120|O
DDI-DrugBank.d466.s5|193-194|mg|O
DDI-DrugBank.d466.s5|196-200|every|O
DDI-DrugBank.d466.s5|202-203|12|O
DDI-DrugBank.d466.s5|205-209|hours|O
DDI-DrugBank.d466.s5|211-211|(|O
DDI-DrugBank.d466.s5|212-214|two|O
DDI-DrugBank.d466.s5|216-220|times|O
DDI-DrugBank.d466.s5|222-224|the|O
DDI-DrugBank.d466.s5|226-236|recommended|O
DDI-DrugBank.d466.s5|238-242|twice|O
DDI-DrugBank.d466.s5|244-248|daily|O
DDI-DrugBank.d466.s5|250-253|dose|O
DDI-DrugBank.d466.s5|254-254|)|O
DDI-DrugBank.d466.s5|256-257|in|O
DDI-DrugBank.d466.s5|259-265|healthy|O
DDI-DrugBank.d466.s5|267-276|volunteers|O
DDI-DrugBank.d466.s5|278-278|(|O
DDI-DrugBank.d466.s5|279-282|n=24|O
DDI-DrugBank.d466.s5|283-283|)|O
DDI-DrugBank.d466.s6|0-10|Concomitant|O
DDI-DrugBank.d466.s6|12-15|Drug|O
DDI-DrugBank.d466.s7|0-5|cmaxSS|O
DDI-DrugBank.d466.s7|7-7|(|O
DDI-DrugBank.d466.s7|8-11|Peak|O
DDI-DrugBank.d466.s7|13-18|plasma|O
DDI-DrugBank.d466.s7|20-32|concentration|O
DDI-DrugBank.d466.s7|33-33|)|O
DDI-DrugBank.d466.s8|0-4|AUCss|O
DDI-DrugBank.d466.s8|5-5|(|O
DDI-DrugBank.d466.s8|6-10|0-12h|O
DDI-DrugBank.d466.s8|11-11|)|O
DDI-DrugBank.d466.s8|13-13|(|O
DDI-DrugBank.d466.s8|14-19|Extent|O
DDI-DrugBank.d466.s8|21-22|of|O
DDI-DrugBank.d466.s8|24-31|systemic|O
DDI-DrugBank.d466.s8|33-40|exposure|O
DDI-DrugBank.d466.s8|41-41|)|O
DDI-DrugBank.d466.s9|0-11|Erythromycin|drug
DDI-DrugBank.d466.s9|13-13|(|O
DDI-DrugBank.d466.s9|14-16|500|O
DDI-DrugBank.d466.s9|18-19|mg|O
DDI-DrugBank.d466.s9|21-25|every|O
DDI-DrugBank.d466.s9|27-27|8|O
DDI-DrugBank.d466.s9|29-31|hrs|O
DDI-DrugBank.d466.s9|32-32|)|O
DDI-DrugBank.d466.s10|0-2|+82|O
DDI-DrugBank.d466.s10|3-3|%|O
DDI-DrugBank.d466.s11|0-3|+109|O
DDI-DrugBank.d466.s11|4-4|%|O
DDI-DrugBank.d466.s12|0-11|Ketoconazole|drug
DDI-DrugBank.d466.s12|13-13|(|O
DDI-DrugBank.d466.s12|14-16|400|O
DDI-DrugBank.d466.s12|18-19|mg|O
DDI-DrugBank.d466.s12|21-24|once|O
DDI-DrugBank.d466.s12|26-30|daily|O
DDI-DrugBank.d466.s12|31-31|)|O
DDI-DrugBank.d466.s13|0-3|+135|O
DDI-DrugBank.d466.s13|4-4|%|O
DDI-DrugBank.d466.s14|0-3|+164|O
DDI-DrugBank.d466.s14|4-4|%|O
DDI-DrugBank.d466.s15|0-2|The|O
DDI-DrugBank.d466.s15|4-10|changes|O
DDI-DrugBank.d466.s15|12-13|in|O
DDI-DrugBank.d466.s15|15-20|plasma|O
DDI-DrugBank.d466.s15|22-27|levels|O
DDI-DrugBank.d466.s15|29-32|were|O
DDI-DrugBank.d466.s15|34-39|within|O
DDI-DrugBank.d466.s15|41-43|the|O
DDI-DrugBank.d466.s15|45-49|range|O
DDI-DrugBank.d466.s15|51-52|of|O
DDI-DrugBank.d466.s15|54-59|plasma|O
DDI-DrugBank.d466.s15|61-66|levels|O
DDI-DrugBank.d466.s15|68-75|achieved|O
DDI-DrugBank.d466.s15|77-78|in|O
DDI-DrugBank.d466.s15|80-87|adequate|O
DDI-DrugBank.d466.s15|89-91|and|O
DDI-DrugBank.d466.s15|93-107|well-controlled|O
DDI-DrugBank.d466.s15|109-116|clinical|O
DDI-DrugBank.d466.s15|118-123|trials|O
DDI-DrugBank.d466.s15|124-124|.|O
DDI-DrugBank.d466.s16|0-2|The|O
DDI-DrugBank.d466.s16|4-12|mechanism|O
DDI-DrugBank.d466.s16|14-15|of|O
DDI-DrugBank.d466.s16|17-21|these|O
DDI-DrugBank.d466.s16|23-34|interactions|O
DDI-DrugBank.d466.s16|36-38|has|O
DDI-DrugBank.d466.s16|40-43|been|O
DDI-DrugBank.d466.s16|45-53|evaluated|O
DDI-DrugBank.d466.s16|55-56|in|O
DDI-DrugBank.d466.s16|58-59|in|O
DDI-DrugBank.d466.s16|61-65|vitro|O
DDI-DrugBank.d466.s16|66-66|,|O
DDI-DrugBank.d466.s16|68-69|in|O
DDI-DrugBank.d466.s16|71-74|situ|O
DDI-DrugBank.d466.s16|75-75|,|O
DDI-DrugBank.d466.s16|77-79|and|O
DDI-DrugBank.d466.s16|81-82|in|O
DDI-DrugBank.d466.s16|84-87|vivo|O
DDI-DrugBank.d466.s16|89-94|animal|O
DDI-DrugBank.d466.s16|96-101|models|O
DDI-DrugBank.d466.s16|102-102|.|O
DDI-DrugBank.d466.s17|0-4|These|O
DDI-DrugBank.d466.s17|6-12|studies|O
DDI-DrugBank.d466.s17|14-21|indicate|O
DDI-DrugBank.d466.s17|23-26|that|O
DDI-DrugBank.d466.s17|28-39|ketoconazole|drug
DDI-DrugBank.d466.s17|41-42|or|O
DDI-DrugBank.d466.s17|44-55|erythromycin|drug
DDI-DrugBank.d466.s17|57-73|co-administration|O
DDI-DrugBank.d466.s17|75-82|enhances|O
DDI-DrugBank.d466.s17|84-95|fexofenadine|drug
DDI-DrugBank.d466.s17|97-112|gastrointestinal|O
DDI-DrugBank.d466.s17|114-123|absorption|O
DDI-DrugBank.d466.s17|124-124|.|O
DDI-DrugBank.d466.s18|0-3|This|O
DDI-DrugBank.d466.s18|5-12|observed|O
DDI-DrugBank.d466.s18|14-21|increase|O
DDI-DrugBank.d466.s18|23-24|in|O
DDI-DrugBank.d466.s18|26-28|the|O
DDI-DrugBank.d466.s18|30-44|bioavailability|O
DDI-DrugBank.d466.s18|46-47|of|O
DDI-DrugBank.d466.s18|49-60|fexofenadine|drug
DDI-DrugBank.d466.s18|62-64|may|O
DDI-DrugBank.d466.s18|66-67|be|O
DDI-DrugBank.d466.s18|69-71|due|O
DDI-DrugBank.d466.s18|73-74|to|O
DDI-DrugBank.d466.s18|76-92|transport-related|O
DDI-DrugBank.d466.s18|94-100|effects|O
DDI-DrugBank.d466.s18|101-101|,|O
DDI-DrugBank.d466.s18|103-106|such|O
DDI-DrugBank.d466.s18|108-109|as|O
DDI-DrugBank.d466.s18|111-125|p-glycoprotein.|O
DDI-DrugBank.d466.s18|127-128|in|O
DDI-DrugBank.d466.s18|130-133|vivo|O
DDI-DrugBank.d466.s18|135-140|animal|O
DDI-DrugBank.d466.s18|142-148|studies|O
DDI-DrugBank.d466.s18|150-153|also|O
DDI-DrugBank.d466.s18|155-161|suggest|O
DDI-DrugBank.d466.s18|163-166|that|O
DDI-DrugBank.d466.s18|168-169|in|O
DDI-DrugBank.d466.s18|171-178|addition|O
DDI-DrugBank.d466.s18|180-181|to|O
DDI-DrugBank.d466.s18|183-191|enhancing|O
DDI-DrugBank.d466.s18|193-202|absorption|O
DDI-DrugBank.d466.s18|203-203|,|O
DDI-DrugBank.d466.s18|205-216|ketoconazole|drug
DDI-DrugBank.d466.s18|218-226|decreases|O
DDI-DrugBank.d466.s18|228-239|fexofenadine|drug
DDI-DrugBank.d466.s18|241-256|gastrointestinal|O
DDI-DrugBank.d466.s18|258-266|secretion|O
DDI-DrugBank.d466.s18|267-267|,|O
DDI-DrugBank.d466.s18|269-273|while|O
DDI-DrugBank.d466.s18|275-286|erythromycin|drug
DDI-DrugBank.d466.s18|288-290|may|O
DDI-DrugBank.d466.s18|292-295|also|O
DDI-DrugBank.d466.s18|297-304|decrease|O
DDI-DrugBank.d466.s18|306-312|biliary|O
DDI-DrugBank.d466.s18|314-322|excretion|O
DDI-DrugBank.d466.s18|323-323|.|O
DDI-DrugBank.d466.s19|0-3|Drug|O
DDI-DrugBank.d466.s19|5-16|Interactions|O
DDI-DrugBank.d466.s19|18-21|with|O
DDI-DrugBank.d466.s19|23-30|Antacids|group
DDI-DrugBank.d466.s19|32-45|Administration|O
DDI-DrugBank.d466.s19|47-48|of|O
DDI-DrugBank.d466.s19|50-52|120|O
DDI-DrugBank.d466.s19|54-55|mg|O
DDI-DrugBank.d466.s19|57-58|of|O
DDI-DrugBank.d466.s19|60-85|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s19|87-87|(|O
DDI-DrugBank.d466.s19|88-88|2|O
DDI-DrugBank.d466.s19|90-90|x|O
DDI-DrugBank.d466.s19|92-93|60|O
DDI-DrugBank.d466.s19|95-96|mg|O
DDI-DrugBank.d466.s19|98-104|capsule|O
DDI-DrugBank.d466.s19|105-105|)|O
DDI-DrugBank.d466.s19|107-112|within|O
DDI-DrugBank.d466.s19|114-115|15|O
DDI-DrugBank.d466.s19|117-123|minutes|O
DDI-DrugBank.d466.s19|125-126|of|O
DDI-DrugBank.d466.s19|128-129|an|O
DDI-DrugBank.d466.s19|131-138|aluminum|drug
DDI-DrugBank.d466.s19|140-142|and|O
DDI-DrugBank.d466.s19|144-152|magnesium|drug
DDI-DrugBank.d466.s19|154-163|containing|O
DDI-DrugBank.d466.s19|165-171|antacid|group
DDI-DrugBank.d466.s19|173-173|(|O
DDI-DrugBank.d466.s19|174-179|Maalox|brand
DDI-DrugBank.d466.s19|181-181|)|O
DDI-DrugBank.d466.s19|183-191|decreased|O
DDI-DrugBank.d466.s19|193-204|fexofenadine|drug
DDI-DrugBank.d466.s19|206-208|AUC|O
DDI-DrugBank.d466.s19|210-211|by|O
DDI-DrugBank.d466.s19|213-214|41|O
DDI-DrugBank.d466.s19|215-215|%|O
DDI-DrugBank.d466.s19|217-219|and|O
DDI-DrugBank.d466.s19|221-224|cmax|O
DDI-DrugBank.d466.s19|226-227|by|O
DDI-DrugBank.d466.s19|229-230|43|O
DDI-DrugBank.d466.s19|231-231|%|O
DDI-DrugBank.d466.s19|232-232|.|O
DDI-DrugBank.d466.s20|0-6|ALLEGRA|brand
DDI-DrugBank.d466.s20|8-13|should|O
DDI-DrugBank.d466.s20|15-17|not|O
DDI-DrugBank.d466.s20|19-20|be|O
DDI-DrugBank.d466.s20|22-26|taken|O
DDI-DrugBank.d466.s20|28-34|closely|O
DDI-DrugBank.d466.s20|36-37|in|O
DDI-DrugBank.d466.s20|39-42|time|O
DDI-DrugBank.d466.s20|44-47|with|O
DDI-DrugBank.d466.s20|49-56|aluminum|drug
DDI-DrugBank.d466.s20|58-60|and|O
DDI-DrugBank.d466.s20|62-70|magnesium|drug
DDI-DrugBank.d466.s20|72-81|containing|O
DDI-DrugBank.d466.s20|83-90|antacids|group
DDI-DrugBank.d466.s20|91-91|.|O
DDI-DrugBank.d466.s21|0-11|Interactions|O
DDI-DrugBank.d466.s21|13-16|with|O
DDI-DrugBank.d466.s21|18-22|Fruit|O
DDI-DrugBank.d466.s21|24-29|Juices|O
DDI-DrugBank.d466.s21|31-35|Fruit|O
DDI-DrugBank.d466.s21|37-42|juices|O
DDI-DrugBank.d466.s21|44-47|such|O
DDI-DrugBank.d466.s21|49-50|as|O
DDI-DrugBank.d466.s21|52-61|grapefruit|O
DDI-DrugBank.d466.s21|62-62|,|O
DDI-DrugBank.d466.s21|64-69|orange|O
DDI-DrugBank.d466.s21|71-73|and|O
DDI-DrugBank.d466.s21|75-79|apple|O
DDI-DrugBank.d466.s21|81-83|may|O
DDI-DrugBank.d466.s21|85-90|reduce|O
DDI-DrugBank.d466.s21|92-94|the|O
DDI-DrugBank.d466.s21|96-110|bioavailability|O
DDI-DrugBank.d466.s21|112-114|and|O
DDI-DrugBank.d466.s21|116-123|exposure|O
DDI-DrugBank.d466.s21|125-126|of|O
DDI-DrugBank.d466.s21|128-139|fexofenadine|drug
DDI-DrugBank.d466.s21|140-140|.|O
DDI-DrugBank.d466.s22|0-3|This|O
DDI-DrugBank.d466.s22|5-6|is|O
DDI-DrugBank.d466.s22|8-12|based|O
DDI-DrugBank.d466.s22|14-15|on|O
DDI-DrugBank.d466.s22|17-19|the|O
DDI-DrugBank.d466.s22|21-27|results|O
DDI-DrugBank.d466.s22|29-32|from|O
DDI-DrugBank.d466.s22|34-34|3|O
DDI-DrugBank.d466.s22|36-43|clinical|O
DDI-DrugBank.d466.s22|45-51|studies|O
DDI-DrugBank.d466.s22|53-57|using|O
DDI-DrugBank.d466.s22|59-67|histamine|drug
DDI-DrugBank.d466.s22|69-75|induced|O
DDI-DrugBank.d466.s22|77-80|skin|O
DDI-DrugBank.d466.s22|82-87|wheals|O
DDI-DrugBank.d466.s22|89-91|and|O
DDI-DrugBank.d466.s22|93-98|flares|O
DDI-DrugBank.d466.s22|100-106|coupled|O
DDI-DrugBank.d466.s22|108-111|with|O
DDI-DrugBank.d466.s22|113-122|population|O
DDI-DrugBank.d466.s22|124-138|pharmacokinetic|O
DDI-DrugBank.d466.s22|140-147|analysis|O
DDI-DrugBank.d466.s22|148-148|.|O
DDI-DrugBank.d466.s23|0-2|The|O
DDI-DrugBank.d466.s23|4-7|size|O
DDI-DrugBank.d466.s23|9-10|of|O
DDI-DrugBank.d466.s23|12-16|wheal|O
DDI-DrugBank.d466.s23|18-20|and|O
DDI-DrugBank.d466.s23|22-26|flare|O
DDI-DrugBank.d466.s23|28-31|were|O
DDI-DrugBank.d466.s23|33-45|significantly|O
DDI-DrugBank.d466.s23|47-52|larger|O
DDI-DrugBank.d466.s23|54-57|when|O
DDI-DrugBank.d466.s23|59-84|fexofenadine hydrochloride|drug
DDI-DrugBank.d466.s23|86-88|was|O
DDI-DrugBank.d466.s23|90-101|administered|O
DDI-DrugBank.d466.s23|103-106|with|O
DDI-DrugBank.d466.s23|108-113|either|O
DDI-DrugBank.d466.s23|115-124|grapefruit|O
DDI-DrugBank.d466.s23|126-127|or|O
DDI-DrugBank.d466.s23|129-134|orange|O
DDI-DrugBank.d466.s23|136-141|juices|O
DDI-DrugBank.d466.s23|143-150|compared|O
DDI-DrugBank.d466.s23|152-153|to|O
DDI-DrugBank.d466.s23|155-159|water|O
DDI-DrugBank.d466.s23|160-160|.|O
DDI-DrugBank.d466.s24|0-4|Based|O
DDI-DrugBank.d466.s24|6-7|on|O
DDI-DrugBank.d466.s24|9-11|the|O
DDI-DrugBank.d466.s24|13-22|literature|O
DDI-DrugBank.d466.s24|24-30|reports|O
DDI-DrugBank.d466.s24|31-31|,|O
DDI-DrugBank.d466.s24|33-35|the|O
DDI-DrugBank.d466.s24|37-40|same|O
DDI-DrugBank.d466.s24|42-48|effects|O
DDI-DrugBank.d466.s24|50-52|may|O
DDI-DrugBank.d466.s24|54-55|be|O
DDI-DrugBank.d466.s24|57-68|extrapolated|O
DDI-DrugBank.d466.s24|70-71|to|O
DDI-DrugBank.d466.s24|73-77|other|O
DDI-DrugBank.d466.s24|79-83|fruit|O
DDI-DrugBank.d466.s24|85-90|juices|O
DDI-DrugBank.d466.s24|92-95|such|O
DDI-DrugBank.d466.s24|97-98|as|O
DDI-DrugBank.d466.s24|100-104|apple|O
DDI-DrugBank.d466.s24|106-110|juice|O
DDI-DrugBank.d466.s24|111-111|.|O
DDI-DrugBank.d466.s25|0-2|The|O
DDI-DrugBank.d466.s25|4-11|clinical|O
DDI-DrugBank.d466.s25|13-24|significance|O
DDI-DrugBank.d466.s25|26-27|of|O
DDI-DrugBank.d466.s25|29-33|these|O
DDI-DrugBank.d466.s25|35-46|observations|O
DDI-DrugBank.d466.s25|48-49|is|O
DDI-DrugBank.d466.s25|51-57|unknown|O
DDI-DrugBank.d466.s25|58-58|.|O
DDI-DrugBank.d466.s26|0-1|In|O
DDI-DrugBank.d466.s26|3-10|addition|O
DDI-DrugBank.d466.s26|11-11|,|O
DDI-DrugBank.d466.s26|13-17|based|O
DDI-DrugBank.d466.s26|19-20|on|O
DDI-DrugBank.d466.s26|22-24|the|O
DDI-DrugBank.d466.s26|26-35|population|O
DDI-DrugBank.d466.s26|37-52|pharmacokinetics|O
DDI-DrugBank.d466.s26|54-61|analysis|O
DDI-DrugBank.d466.s26|63-64|of|O
DDI-DrugBank.d466.s26|66-68|the|O
DDI-DrugBank.d466.s26|70-77|combined|O
DDI-DrugBank.d466.s26|79-82|data|O
DDI-DrugBank.d466.s26|84-87|from|O
DDI-DrugBank.d466.s26|89-98|grapefruit|O
DDI-DrugBank.d466.s26|100-102|and|O
DDI-DrugBank.d466.s26|104-109|orange|O
DDI-DrugBank.d466.s26|111-116|juices|O
DDI-DrugBank.d466.s26|118-124|studies|O
DDI-DrugBank.d466.s26|126-129|with|O
DDI-DrugBank.d466.s26|131-133|the|O
DDI-DrugBank.d466.s26|135-138|data|O
DDI-DrugBank.d466.s26|140-143|from|O
DDI-DrugBank.d466.s26|145-145|a|O
DDI-DrugBank.d466.s26|147-160|bioequivalence|O
DDI-DrugBank.d466.s26|162-166|study|O
DDI-DrugBank.d466.s26|167-167|,|O
DDI-DrugBank.d466.s26|169-171|the|O
DDI-DrugBank.d466.s26|173-187|bioavailability|O
DDI-DrugBank.d466.s26|189-190|of|O
DDI-DrugBank.d466.s26|192-203|fexofenadine|drug
DDI-DrugBank.d466.s26|205-207|was|O
DDI-DrugBank.d466.s26|209-215|reduced|O
DDI-DrugBank.d466.s26|217-218|by|O
DDI-DrugBank.d466.s26|220-221|36|O
DDI-DrugBank.d466.s26|222-222|%|O
DDI-DrugBank.d466.s26|223-223|.|O
DDI-DrugBank.d466.s27|0-8|Therefore|O
DDI-DrugBank.d466.s27|9-9|,|O
DDI-DrugBank.d466.s27|11-12|to|O
DDI-DrugBank.d466.s27|14-21|maximize|O
DDI-DrugBank.d466.s27|23-25|the|O
DDI-DrugBank.d466.s27|27-33|effects|O
DDI-DrugBank.d466.s27|35-36|of|O
DDI-DrugBank.d466.s27|38-49|fexofenadine|drug
DDI-DrugBank.d466.s27|50-50|,|O
DDI-DrugBank.d466.s27|52-53|it|O
DDI-DrugBank.d466.s27|55-56|is|O
DDI-DrugBank.d466.s27|58-68|recommended|O
DDI-DrugBank.d466.s27|70-73|that|O
DDI-DrugBank.d466.s27|75-81|ALLEGRA|brand
DDI-DrugBank.d466.s27|83-88|should|O
DDI-DrugBank.d466.s27|90-91|be|O
DDI-DrugBank.d466.s27|93-97|taken|O
DDI-DrugBank.d466.s27|99-102|with|O
DDI-DrugBank.d466.s27|104-108|water|O
DDI-DrugBank.d466.s28|0-0|.|O
DDI-DrugBank.d521.s0|0-3|Many|O
DDI-DrugBank.d521.s0|5-9|other|O
DDI-DrugBank.d521.s0|11-19|medicines|O
DDI-DrugBank.d521.s0|21-23|may|O
DDI-DrugBank.d521.s0|25-32|increase|O
DDI-DrugBank.d521.s0|34-35|or|O
DDI-DrugBank.d521.s0|37-44|decrease|O
DDI-DrugBank.d521.s0|46-48|the|O
DDI-DrugBank.d521.s0|50-56|effects|O
DDI-DrugBank.d521.s0|58-59|of|O
DDI-DrugBank.d521.s0|61-71|glimepiride|drug
DDI-DrugBank.d521.s0|73-74|or|O
DDI-DrugBank.d521.s0|76-81|affect|O
DDI-DrugBank.d521.s0|83-86|your|O
DDI-DrugBank.d521.s0|88-96|condition|O
DDI-DrugBank.d521.s0|97-97|.|O
DDI-DrugBank.d521.s1|0-5|Before|O
DDI-DrugBank.d521.s1|7-12|taking|O
DDI-DrugBank.d521.s1|14-24|glimepiride|drug
DDI-DrugBank.d521.s1|25-25|,|O
DDI-DrugBank.d521.s1|27-30|tell|O
DDI-DrugBank.d521.s1|32-35|your|O
DDI-DrugBank.d521.s1|37-42|doctor|O
DDI-DrugBank.d521.s1|44-45|if|O
DDI-DrugBank.d521.s1|47-49|you|O
DDI-DrugBank.d521.s1|51-53|are|O
DDI-DrugBank.d521.s1|55-60|taking|O
DDI-DrugBank.d521.s1|62-64|any|O
DDI-DrugBank.d521.s1|66-67|of|O
DDI-DrugBank.d521.s1|69-71|the|O
DDI-DrugBank.d521.s1|73-81|following|O
DDI-DrugBank.d521.s1|83-91|medicines|O
DDI-DrugBank.d521.s1|92-92|:|O
DDI-DrugBank.d521.s1|94-94|-|O
DDI-DrugBank.d521.s1|96-102|aspirin|brand
DDI-DrugBank.d521.s1|104-105|or|O
DDI-DrugBank.d521.s1|107-113|another|O
DDI-DrugBank.d521.s1|115-124|salicylate|group
DDI-DrugBank.d521.s1|126-129|such|O
DDI-DrugBank.d521.s1|131-132|as|O
DDI-DrugBank.d521.s1|134-161|magnesium/choline salicylate|drug
DDI-DrugBank.d521.s1|163-163|(|O
DDI-DrugBank.d521.s1|164-172|Trilisate|brand
DDI-DrugBank.d521.s1|173-173|)|O
DDI-DrugBank.d521.s1|174-174|,|O
DDI-DrugBank.d521.s1|176-184|salsalate|drug
DDI-DrugBank.d521.s1|186-186|(|O
DDI-DrugBank.d521.s1|187-194|Disalcid|brand
DDI-DrugBank.d521.s1|195-195|,|O
DDI-DrugBank.d521.s1|197-202|others|O
DDI-DrugBank.d521.s1|203-203|)|O
DDI-DrugBank.d521.s1|204-204|,|O
DDI-DrugBank.d521.s1|206-223|choline salicylate|drug
DDI-DrugBank.d521.s1|225-225|(|O
DDI-DrugBank.d521.s1|226-234|Arthropan|drug
DDI-DrugBank.d521.s1|235-235|)|O
DDI-DrugBank.d521.s1|236-236|,|O
DDI-DrugBank.d521.s1|238-257|magnesium salicylate|drug
DDI-DrugBank.d521.s1|259-259|(|O
DDI-DrugBank.d521.s1|260-264|Magan|brand
DDI-DrugBank.d521.s1|265-265|)|O
DDI-DrugBank.d521.s1|266-266|,|O
DDI-DrugBank.d521.s1|268-269|or|O
DDI-DrugBank.d521.s1|271-291|bismuth subsalicylate|drug
DDI-DrugBank.d521.s1|293-293|(|O
DDI-DrugBank.d521.s1|294-305|Pepto-Bismol|brand
DDI-DrugBank.d521.s1|306-306|)|O
DDI-DrugBank.d521.s1|307-307|;|O
DDI-DrugBank.d521.s2|0-0|-|O
DDI-DrugBank.d521.s2|2-2|a|O
DDI-DrugBank.d521.s2|4-38|nonsteroidal anti-inflammatory drug|group
DDI-DrugBank.d521.s2|40-40|(|O
DDI-DrugBank.d521.s2|41-45|NSAID|group
DDI-DrugBank.d521.s2|46-46|)|O
DDI-DrugBank.d521.s2|48-51|such|O
DDI-DrugBank.d521.s2|53-54|as|O
DDI-DrugBank.d521.s2|56-64|ibuprofen|drug
DDI-DrugBank.d521.s2|66-66|(|O
DDI-DrugBank.d521.s2|67-72|Motrin|brand
DDI-DrugBank.d521.s2|73-73|,|O
DDI-DrugBank.d521.s2|75-79|Advil|brand
DDI-DrugBank.d521.s2|80-80|,|O
DDI-DrugBank.d521.s2|82-87|Nuprin|brand
DDI-DrugBank.d521.s2|88-88|,|O
DDI-DrugBank.d521.s2|90-95|others|O
DDI-DrugBank.d521.s2|96-96|)|O
DDI-DrugBank.d521.s2|97-97|,|O
DDI-DrugBank.d521.s2|99-108|ketoprofen|drug
DDI-DrugBank.d521.s2|110-110|(|O
DDI-DrugBank.d521.s2|111-116|Orudis|brand
DDI-DrugBank.d521.s2|117-117|,|O
DDI-DrugBank.d521.s2|119-127|Orudis KT|brand
DDI-DrugBank.d521.s2|128-128|,|O
DDI-DrugBank.d521.s2|130-136|Oruvail|brand
DDI-DrugBank.d521.s2|137-137|)|O
DDI-DrugBank.d521.s2|138-138|,|O
DDI-DrugBank.d521.s2|140-149|diclofenac|drug
DDI-DrugBank.d521.s2|151-151|(|O
DDI-DrugBank.d521.s2|152-159|Voltaren|brand
DDI-DrugBank.d521.s2|160-160|,|O
DDI-DrugBank.d521.s2|162-169|Cataflam|brand
DDI-DrugBank.d521.s2|170-170|)|O
DDI-DrugBank.d521.s2|171-171|,|O
DDI-DrugBank.d521.s2|173-180|etodolac|drug
DDI-DrugBank.d521.s2|182-182|(|O
DDI-DrugBank.d521.s2|183-188|Lodine|brand
DDI-DrugBank.d521.s2|189-189|)|O
DDI-DrugBank.d521.s2|190-190|,|O
DDI-DrugBank.d521.s2|192-203|indomethacin|drug
DDI-DrugBank.d521.s2|205-205|(|O
DDI-DrugBank.d521.s2|206-212|Indocin|brand
DDI-DrugBank.d521.s2|213-213|)|O
DDI-DrugBank.d521.s2|214-214|,|O
DDI-DrugBank.d521.s2|216-225|nabumetone|drug
DDI-DrugBank.d521.s2|227-227|(|O
DDI-DrugBank.d521.s2|228-234|Relafen|brand
DDI-DrugBank.d521.s2|235-235|)|O
DDI-DrugBank.d521.s2|236-236|,|O
DDI-DrugBank.d521.s2|238-246|oxaprozin|drug
DDI-DrugBank.d521.s2|248-248|(|O
DDI-DrugBank.d521.s2|249-254|Daypro|brand
DDI-DrugBank.d521.s2|255-255|)|O
DDI-DrugBank.d521.s2|256-256|,|O
DDI-DrugBank.d521.s2|258-260|and|O
DDI-DrugBank.d521.s2|262-269|naproxen|drug
DDI-DrugBank.d521.s2|271-271|(|O
DDI-DrugBank.d521.s2|272-278|Anaprox|brand
DDI-DrugBank.d521.s2|279-279|,|O
DDI-DrugBank.d521.s2|281-288|Naprosyn|brand
DDI-DrugBank.d521.s2|289-289|,|O
DDI-DrugBank.d521.s2|291-295|Aleve|brand
DDI-DrugBank.d521.s2|296-296|)|O
DDI-DrugBank.d521.s2|297-297|;|O
DDI-DrugBank.d521.s3|0-0|-|O
DDI-DrugBank.d521.s3|2-2|a|O
DDI-DrugBank.d521.s3|4-14|sulfa-based|O
DDI-DrugBank.d521.s3|16-19|drug|O
DDI-DrugBank.d521.s3|21-24|such|O
DDI-DrugBank.d521.s3|26-27|as|O
DDI-DrugBank.d521.s3|29-57|sulfamethoxazole-trimethoprim|drug
DDI-DrugBank.d521.s3|59-59|(|O
DDI-DrugBank.d521.s3|60-66|Bactrim|brand
DDI-DrugBank.d521.s3|67-67|,|O
DDI-DrugBank.d521.s3|69-74|Septra|brand
DDI-DrugBank.d521.s3|75-75|)|O
DDI-DrugBank.d521.s3|76-76|,|O
DDI-DrugBank.d521.s3|78-90|sulfisoxazole|drug
DDI-DrugBank.d521.s3|92-92|(|O
DDI-DrugBank.d521.s3|93-101|Gantrisin|brand
DDI-DrugBank.d521.s3|102-102|)|O
DDI-DrugBank.d521.s3|103-103|,|O
DDI-DrugBank.d521.s3|105-106|or|O
DDI-DrugBank.d521.s3|108-120|sulfasalazine|drug
DDI-DrugBank.d521.s3|122-122|(|O
DDI-DrugBank.d521.s3|123-132|Azulfidine|brand
DDI-DrugBank.d521.s3|133-133|)|O
DDI-DrugBank.d521.s3|134-134|;|O
DDI-DrugBank.d521.s4|0-0|-|O
DDI-DrugBank.d521.s4|2-2|a|O
DDI-DrugBank.d521.s4|4-30|monoamine oxidase inhibitor|group
DDI-DrugBank.d521.s4|32-32|(|O
DDI-DrugBank.d521.s4|33-36|MAOI|group
DDI-DrugBank.d521.s4|37-37|)|O
DDI-DrugBank.d521.s4|39-42|such|O
DDI-DrugBank.d521.s4|44-45|as|O
DDI-DrugBank.d521.s4|47-59|isocarboxazid|drug
DDI-DrugBank.d521.s4|61-61|(|O
DDI-DrugBank.d521.s4|62-68|Marplan|brand
DDI-DrugBank.d521.s4|69-69|)|O
DDI-DrugBank.d521.s4|70-70|,|O
DDI-DrugBank.d521.s4|72-86|tranylcypromine|drug
DDI-DrugBank.d521.s4|88-88|(|O
DDI-DrugBank.d521.s4|89-95|Parnate|brand
DDI-DrugBank.d521.s4|96-96|)|O
DDI-DrugBank.d521.s4|97-97|,|O
DDI-DrugBank.d521.s4|99-100|or|O
DDI-DrugBank.d521.s4|102-111|phenelzine|drug
DDI-DrugBank.d521.s4|113-113|(|O
DDI-DrugBank.d521.s4|114-119|Nardil|brand
DDI-DrugBank.d521.s4|120-120|)|O
DDI-DrugBank.d521.s4|121-121|;|O
DDI-DrugBank.d521.s5|0-0|-|O
DDI-DrugBank.d521.s5|2-2|a|O
DDI-DrugBank.d521.s5|4-15|beta-blocker|group
DDI-DrugBank.d521.s5|17-20|such|O
DDI-DrugBank.d521.s5|22-23|as|O
DDI-DrugBank.d521.s5|25-35|propranolol|drug
DDI-DrugBank.d521.s5|37-37|(|O
DDI-DrugBank.d521.s5|38-44|Inderal|brand
DDI-DrugBank.d521.s5|45-45|)|O
DDI-DrugBank.d521.s5|46-46|,|O
DDI-DrugBank.d521.s5|48-55|atenolol|drug
DDI-DrugBank.d521.s5|57-57|(|O
DDI-DrugBank.d521.s5|58-65|Tenormin|brand
DDI-DrugBank.d521.s5|66-66|)|O
DDI-DrugBank.d521.s5|67-67|,|O
DDI-DrugBank.d521.s5|69-78|acebutolol|drug
DDI-DrugBank.d521.s5|80-80|(|O
DDI-DrugBank.d521.s5|81-87|Sectral|brand
DDI-DrugBank.d521.s5|88-88|)|O
DDI-DrugBank.d521.s5|89-89|,|O
DDI-DrugBank.d521.s5|91-100|metoprolol|drug
DDI-DrugBank.d521.s5|102-102|(|O
DDI-DrugBank.d521.s5|103-111|Lopressor|brand
DDI-DrugBank.d521.s5|112-112|)|O
DDI-DrugBank.d521.s5|113-113|,|O
DDI-DrugBank.d521.s5|115-117|and|O
DDI-DrugBank.d521.s5|119-124|others|O
DDI-DrugBank.d521.s5|125-125|;|O
DDI-DrugBank.d521.s6|0-0|-|O
DDI-DrugBank.d521.s6|2-2|a|O
DDI-DrugBank.d521.s6|4-11|diuretic|group
DDI-DrugBank.d521.s6|13-13|(|O
DDI-DrugBank.d521.s6|14-18|water|O
DDI-DrugBank.d521.s6|20-23|pill|O
DDI-DrugBank.d521.s6|24-24|)|O
DDI-DrugBank.d521.s6|26-29|such|O
DDI-DrugBank.d521.s6|31-32|as|O
DDI-DrugBank.d521.s6|34-52|hydrochlorothiazide|drug
DDI-DrugBank.d521.s6|54-54|(|O
DDI-DrugBank.d521.s6|55-58|HCTZ|drug
DDI-DrugBank.d521.s6|59-59|,|O
DDI-DrugBank.d521.s6|61-71|Hydrodiuril|brand
DDI-DrugBank.d521.s6|72-72|)|O
DDI-DrugBank.d521.s6|73-73|,|O
DDI-DrugBank.d521.s6|75-88|chlorothiazide|drug
DDI-DrugBank.d521.s6|90-90|(|O
DDI-DrugBank.d521.s6|91-96|Diuril|brand
DDI-DrugBank.d521.s6|97-97|)|O
DDI-DrugBank.d521.s6|98-98|,|O
DDI-DrugBank.d521.s6|100-102|and|O
DDI-DrugBank.d521.s6|104-109|others|O
DDI-DrugBank.d521.s6|110-110|;|O
DDI-DrugBank.d521.s7|0-0|-|O
DDI-DrugBank.d521.s7|2-2|a|O
DDI-DrugBank.d521.s7|4-19|steroid medicine|group
DDI-DrugBank.d521.s7|21-24|such|O
DDI-DrugBank.d521.s7|26-27|as|O
DDI-DrugBank.d521.s7|29-38|prednisone|drug
DDI-DrugBank.d521.s7|40-40|(|O
DDI-DrugBank.d521.s7|41-49|Deltasone|brand
DDI-DrugBank.d521.s7|50-50|,|O
DDI-DrugBank.d521.s7|52-58|Orasone|brand
DDI-DrugBank.d521.s7|59-59|,|O
DDI-DrugBank.d521.s7|61-66|others|O
DDI-DrugBank.d521.s7|67-67|)|O
DDI-DrugBank.d521.s7|68-68|,|O
DDI-DrugBank.d521.s7|70-87|methylprednisolone|drug
DDI-DrugBank.d521.s7|89-89|(|O
DDI-DrugBank.d521.s7|90-95|Medrol|brand
DDI-DrugBank.d521.s7|96-96|,|O
DDI-DrugBank.d521.s7|98-103|others|O
DDI-DrugBank.d521.s7|104-104|)|O
DDI-DrugBank.d521.s7|105-105|,|O
DDI-DrugBank.d521.s7|107-118|prednisolone|drug
DDI-DrugBank.d521.s7|120-120|(|O
DDI-DrugBank.d521.s7|121-127|Prelone|brand
DDI-DrugBank.d521.s7|128-128|,|O
DDI-DrugBank.d521.s7|130-138|Pediapred|brand
DDI-DrugBank.d521.s7|139-139|,|O
DDI-DrugBank.d521.s7|141-146|others|O
DDI-DrugBank.d521.s7|147-147|)|O
DDI-DrugBank.d521.s7|148-148|,|O
DDI-DrugBank.d521.s7|150-152|and|O
DDI-DrugBank.d521.s7|154-159|others|O
DDI-DrugBank.d521.s7|160-160|;|O
DDI-DrugBank.d521.s8|0-0|-|O
DDI-DrugBank.d521.s8|2-2|a|O
DDI-DrugBank.d521.s8|4-16|phenothiazine|group
DDI-DrugBank.d521.s8|18-21|such|O
DDI-DrugBank.d521.s8|23-24|as|O
DDI-DrugBank.d521.s8|26-39|chlorpromazine|drug
DDI-DrugBank.d521.s8|41-41|(|O
DDI-DrugBank.d521.s8|42-50|Thorazine|brand
DDI-DrugBank.d521.s8|51-51|)|O
DDI-DrugBank.d521.s8|52-52|,|O
DDI-DrugBank.d521.s8|54-65|fluphenazine|drug
DDI-DrugBank.d521.s8|67-67|(|O
DDI-DrugBank.d521.s8|68-75|Prolixin|brand
DDI-DrugBank.d521.s8|76-76|,|O
DDI-DrugBank.d521.s8|78-85|Permitil|brand
DDI-DrugBank.d521.s8|86-86|)|O
DDI-DrugBank.d521.s8|87-87|,|O
DDI-DrugBank.d521.s8|89-104|prochlorperazine|drug
DDI-DrugBank.d521.s8|106-106|(|O
DDI-DrugBank.d521.s8|107-115|Compazine|brand
DDI-DrugBank.d521.s8|116-116|)|O
DDI-DrugBank.d521.s8|117-117|,|O
DDI-DrugBank.d521.s8|119-130|promethazine|drug
DDI-DrugBank.d521.s8|132-132|(|O
DDI-DrugBank.d521.s8|133-141|Phenergan|brand
DDI-DrugBank.d521.s8|142-142|)|O
DDI-DrugBank.d521.s8|143-143|,|O
DDI-DrugBank.d521.s8|145-147|and|O
DDI-DrugBank.d521.s8|149-154|others|O
DDI-DrugBank.d521.s8|155-155|;|O
DDI-DrugBank.d521.s9|0-0|-|O
DDI-DrugBank.d521.s9|2-10|phenytoin|drug
DDI-DrugBank.d521.s9|12-12|(|O
DDI-DrugBank.d521.s9|13-20|Dilantin|brand
DDI-DrugBank.d521.s9|21-21|)|O
DDI-DrugBank.d521.s9|22-22|;|O
DDI-DrugBank.d521.s10|0-0|-|O
DDI-DrugBank.d521.s10|2-10|isoniazid|drug
DDI-DrugBank.d521.s10|12-12|(|O
DDI-DrugBank.d521.s10|13-20|Nydrazid|brand
DDI-DrugBank.d521.s10|21-21|)|O
DDI-DrugBank.d521.s10|22-22|;|O
DDI-DrugBank.d521.s11|0-0|-|O
DDI-DrugBank.d521.s11|2-9|rifampin|drug
DDI-DrugBank.d521.s11|11-11|(|O
DDI-DrugBank.d521.s11|12-18|Rifadin|brand
DDI-DrugBank.d521.s11|19-19|,|O
DDI-DrugBank.d521.s11|21-28|Rifamate|brand
DDI-DrugBank.d521.s11|29-29|)|O
DDI-DrugBank.d521.s11|30-30|;|O
DDI-DrugBank.d521.s12|0-1|or|O
DDI-DrugBank.d521.s12|3-3|-|O
DDI-DrugBank.d521.s12|5-20|over-the-counter|O
DDI-DrugBank.d521.s12|22-26|cough|O
DDI-DrugBank.d521.s12|27-27|,|O
DDI-DrugBank.d521.s12|29-32|cold|O
DDI-DrugBank.d521.s12|33-33|,|O
DDI-DrugBank.d521.s12|35-41|allergy|O
DDI-DrugBank.d521.s12|42-42|,|O
DDI-DrugBank.d521.s12|44-45|or|O
DDI-DrugBank.d521.s12|47-52|weight|O
DDI-DrugBank.d521.s12|54-57|loss|O
DDI-DrugBank.d521.s12|59-69|medications|O
DDI-DrugBank.d521.s12|70-70|.|O
DDI-DrugBank.d521.s13|0-2|You|O
DDI-DrugBank.d521.s13|4-6|may|O
DDI-DrugBank.d521.s13|8-14|require|O
DDI-DrugBank.d521.s13|16-16|a|O
DDI-DrugBank.d521.s13|18-23|dosage|O
DDI-DrugBank.d521.s13|25-34|adjustment|O
DDI-DrugBank.d521.s13|36-37|or|O
DDI-DrugBank.d521.s13|39-45|special|O
DDI-DrugBank.d521.s13|47-56|monitoring|O
DDI-DrugBank.d521.s13|58-59|if|O
DDI-DrugBank.d521.s13|61-63|you|O
DDI-DrugBank.d521.s13|65-67|are|O
DDI-DrugBank.d521.s13|69-74|taking|O
DDI-DrugBank.d521.s13|76-78|any|O
DDI-DrugBank.d521.s13|80-81|of|O
DDI-DrugBank.d521.s13|83-85|the|O
DDI-DrugBank.d521.s13|87-95|medicines|O
DDI-DrugBank.d521.s13|97-102|listed|O
DDI-DrugBank.d521.s13|104-108|above|O
DDI-DrugBank.d521.s13|109-109|.|O
DDI-DrugBank.d521.s14|0-4|Drugs|O
DDI-DrugBank.d521.s14|6-10|other|O
DDI-DrugBank.d521.s14|12-15|than|O
DDI-DrugBank.d521.s14|17-21|those|O
DDI-DrugBank.d521.s14|23-28|listed|O
DDI-DrugBank.d521.s14|30-33|here|O
DDI-DrugBank.d521.s14|35-37|may|O
DDI-DrugBank.d521.s14|39-42|also|O
DDI-DrugBank.d521.s14|44-51|interact|O
DDI-DrugBank.d521.s14|53-56|with|O
DDI-DrugBank.d521.s14|58-68|glimepiride|drug
DDI-DrugBank.d521.s14|70-71|or|O
DDI-DrugBank.d521.s14|73-78|affect|O
DDI-DrugBank.d521.s14|80-83|your|O
DDI-DrugBank.d521.s14|85-93|condition|O
DDI-DrugBank.d521.s14|94-94|.|O
DDI-DrugBank.d521.s15|0-3|Talk|O
DDI-DrugBank.d521.s15|5-6|to|O
DDI-DrugBank.d521.s15|8-11|your|O
DDI-DrugBank.d521.s15|13-18|doctor|O
DDI-DrugBank.d521.s15|20-22|and|O
DDI-DrugBank.d521.s15|24-33|pharmacist|O
DDI-DrugBank.d521.s15|35-40|before|O
DDI-DrugBank.d521.s15|42-47|taking|O
DDI-DrugBank.d521.s15|49-51|any|O
DDI-DrugBank.d521.s15|53-64|prescription|O
DDI-DrugBank.d521.s15|66-67|or|O
DDI-DrugBank.d521.s15|69-84|over-the-counter|O
DDI-DrugBank.d521.s15|86-94|medicines|O
DDI-DrugBank.d521.s15|95-95|,|O
DDI-DrugBank.d521.s15|97-105|including|O
DDI-DrugBank.d521.s15|107-112|herbal|O
DDI-DrugBank.d521.s15|114-121|products|O
DDI-DrugBank.d521.s15|122-122|.|O
DDI-MedLine.d133.s0|0-10|Suppression|O
DDI-MedLine.d133.s0|12-13|by|O
DDI-MedLine.d133.s0|15-23|verapamil|drug
DDI-MedLine.d133.s0|25-26|of|O
DDI-MedLine.d133.s0|46-55|peritoneal|O
DDI-MedLine.d133.s0|57-66|metastasis|O
DDI-MedLine.d133.s0|68-69|of|O
DDI-MedLine.d133.s0|71-80|intestinal|O
DDI-MedLine.d133.s0|82-96|adenocarcinomas|O
DDI-MedLine.d133.s0|98-104|induced|O
DDI-MedLine.d133.s0|106-107|by|O
DDI-MedLine.d133.s0|122-123|in|O
DDI-MedLine.d133.s0|125-130|wistar|O
DDI-MedLine.d133.s0|132-135|rats|O
DDI-MedLine.d133.s0|136-136|.|O
DDI-MedLine.d133.s1|0-9|BACKGROUND|O
DDI-MedLine.d133.s1|10-10|:|O
DDI-MedLine.d133.s1|12-14|The|O
DDI-MedLine.d133.s1|16-22|effects|O
DDI-MedLine.d133.s1|24-25|of|O
DDI-MedLine.d133.s1|27-34|combined|O
DDI-MedLine.d133.s1|36-49|administration|O
DDI-MedLine.d133.s1|51-52|of|O
DDI-MedLine.d133.s1|63-65|and|O
DDI-MedLine.d133.s1|67-89|verapamil hydrochloride|drug
DDI-MedLine.d133.s1|91-91|(|O
DDI-MedLine.d133.s1|92-100|verapamil|drug
DDI-MedLine.d133.s1|101-101|)|O
DDI-MedLine.d133.s1|102-102|,|O
DDI-MedLine.d133.s1|104-104|a|O
DDI-MedLine.d133.s1|106-128|calcium channel blocker|group
DDI-MedLine.d133.s1|129-129|,|O
DDI-MedLine.d133.s1|131-132|on|O
DDI-MedLine.d133.s1|134-136|the|O
DDI-MedLine.d133.s1|138-146|incidence|O
DDI-MedLine.d133.s1|148-149|of|O
DDI-MedLine.d133.s1|151-160|peritoneal|O
DDI-MedLine.d133.s1|162-171|metastasis|O
DDI-MedLine.d133.s1|173-174|of|O
DDI-MedLine.d133.s1|176-185|intestinal|O
DDI-MedLine.d133.s1|187-201|adenocarcinomas|O
DDI-MedLine.d133.s1|203-209|induced|O
DDI-MedLine.d133.s1|211-212|by|O
DDI-MedLine.d133.s1|227-227|(|O
DDI-MedLine.d133.s1|231-231|)|O
DDI-MedLine.d133.s1|233-235|and|O
DDI-MedLine.d133.s1|237-239|the|O
DDI-MedLine.d133.s1|241-248|labeling|O
DDI-MedLine.d133.s1|250-254|index|O
DDI-MedLine.d133.s1|256-257|of|O
DDI-MedLine.d133.s1|259-268|intestinal|O
DDI-MedLine.d133.s1|270-276|cancers|O
DDI-MedLine.d133.s1|278-281|were|O
DDI-MedLine.d133.s1|283-294|investigated|O
DDI-MedLine.d133.s1|296-297|in|O
DDI-MedLine.d133.s1|299-302|male|O
DDI-MedLine.d133.s1|304-309|Wistar|O
DDI-MedLine.d133.s1|311-314|rats|O
DDI-MedLine.d133.s1|315-315|.|O
DDI-MedLine.d133.s2|0-6|METHODS|O
DDI-MedLine.d133.s2|7-7|:|O
DDI-MedLine.d133.s2|9-12|From|O
DDI-MedLine.d133.s2|14-16|the|O
DDI-MedLine.d133.s2|18-26|beginning|O
DDI-MedLine.d133.s2|28-29|of|O
DDI-MedLine.d133.s2|31-33|the|O
DDI-MedLine.d133.s2|35-44|experiment|O
DDI-MedLine.d133.s2|45-45|,|O
DDI-MedLine.d133.s2|47-50|rats|O
DDI-MedLine.d133.s2|52-55|were|O
DDI-MedLine.d133.s2|57-61|given|O
DDI-MedLine.d133.s2|63-64|10|O
DDI-MedLine.d133.s2|66-71|weekly|O
DDI-MedLine.d133.s2|73-84|subcutaneous|O
DDI-MedLine.d133.s2|86-95|injections|O
DDI-MedLine.d133.s2|97-98|of|O
DDI-MedLine.d133.s2|104-104|(|O
DDI-MedLine.d133.s2|105-107|7.4|O
DDI-MedLine.d133.s2|109-113|mg/kg|O
DDI-MedLine.d133.s2|115-118|body|O
DDI-MedLine.d133.s2|120-125|weight|O
DDI-MedLine.d133.s2|126-126|)|O
DDI-MedLine.d133.s2|128-130|and|O
DDI-MedLine.d133.s2|132-143|subcutaneous|O
DDI-MedLine.d133.s2|145-154|injections|O
DDI-MedLine.d133.s2|156-157|of|O
DDI-MedLine.d133.s2|168-168|(|O
DDI-MedLine.d133.s2|169-170|40|O
DDI-MedLine.d133.s2|172-180|microg/kg|O
DDI-MedLine.d133.s2|182-185|body|O
DDI-MedLine.d133.s2|187-192|weight|O
DDI-MedLine.d133.s2|193-193|)|O
DDI-MedLine.d133.s2|195-199|every|O
DDI-MedLine.d133.s2|201-205|other|O
DDI-MedLine.d133.s2|207-209|day|O
DDI-MedLine.d133.s2|210-210|,|O
DDI-MedLine.d133.s2|212-214|and|O
DDI-MedLine.d133.s2|216-219|from|O
DDI-MedLine.d133.s2|221-224|week|O
DDI-MedLine.d133.s2|226-227|16|O
DDI-MedLine.d133.s2|228-228|,|O
DDI-MedLine.d133.s2|230-244|intraperitoneal|O
DDI-MedLine.d133.s2|246-255|injections|O
DDI-MedLine.d133.s2|257-258|of|O
DDI-MedLine.d133.s2|260-268|verapamil|drug
DDI-MedLine.d133.s2|270-270|(|O
DDI-MedLine.d133.s2|271-272|10|O
DDI-MedLine.d133.s2|274-275|or|O
DDI-MedLine.d133.s2|277-278|20|O
DDI-MedLine.d133.s2|280-284|mg/kg|O
DDI-MedLine.d133.s2|286-289|body|O
DDI-MedLine.d133.s2|291-296|weight|O
DDI-MedLine.d133.s2|297-297|)|O
DDI-MedLine.d133.s2|299-303|every|O
DDI-MedLine.d133.s2|305-309|other|O
DDI-MedLine.d133.s2|311-313|day|O
DDI-MedLine.d133.s2|315-319|until|O
DDI-MedLine.d133.s2|321-323|the|O
DDI-MedLine.d133.s2|325-327|end|O
DDI-MedLine.d133.s2|329-330|fo|O
DDI-MedLine.d133.s2|332-334|the|O
DDI-MedLine.d133.s2|336-345|experiment|O
DDI-MedLine.d133.s2|347-348|in|O
DDI-MedLine.d133.s2|350-353|week|O
DDI-MedLine.d133.s2|355-356|45|O
DDI-MedLine.d133.s2|357-357|.|O
DDI-MedLine.d133.s3|0-6|RESULTS|O
DDI-MedLine.d133.s3|7-7|:|O
DDI-MedLine.d133.s3|18-30|significantly|O
DDI-MedLine.d133.s3|32-40|increased|O
DDI-MedLine.d133.s3|42-44|the|O
DDI-MedLine.d133.s3|46-54|incidence|O
DDI-MedLine.d133.s3|56-57|of|O
DDI-MedLine.d133.s3|59-68|intestinal|O
DDI-MedLine.d133.s3|70-75|tumors|O
DDI-MedLine.d133.s3|77-79|and|O
DDI-MedLine.d133.s3|81-86|cancer|O
DDI-MedLine.d133.s3|88-97|metastasis|O
DDI-MedLine.d133.s3|99-100|to|O
DDI-MedLine.d133.s3|102-104|the|O
DDI-MedLine.d133.s3|106-115|peritoneum|O
DDI-MedLine.d133.s3|116-116|.|O
DDI-MedLine.d133.s4|0-7|Although|O
DDI-MedLine.d133.s4|9-17|verapamil|drug
DDI-MedLine.d133.s4|19-30|administered|O
DDI-MedLine.d133.s4|32-33|at|O
DDI-MedLine.d133.s4|35-40|either|O
DDI-MedLine.d133.s4|42-45|dose|O
DDI-MedLine.d133.s4|47-49|had|O
DDI-MedLine.d133.s4|51-56|little|O
DDI-MedLine.d133.s4|58-59|or|O
DDI-MedLine.d133.s4|61-62|no|O
DDI-MedLine.d133.s4|64-69|effect|O
DDI-MedLine.d133.s4|71-72|on|O
DDI-MedLine.d133.s4|74-76|the|O
DDI-MedLine.d133.s4|78-88|enhancement|O
DDI-MedLine.d133.s4|90-91|of|O
DDI-MedLine.d133.s4|93-102|intestinal|O
DDI-MedLine.d133.s4|104-117|carcinogenesis|O
DDI-MedLine.d133.s4|119-120|by|O
DDI-MedLine.d133.s4|131-132|or|O
DDI-MedLine.d133.s4|134-135|on|O
DDI-MedLine.d133.s4|137-139|the|O
DDI-MedLine.d133.s4|141-148|location|O
DDI-MedLine.d133.s4|149-149|,|O
DDI-MedLine.d133.s4|151-160|histologic|O
DDI-MedLine.d133.s4|162-165|type|O
DDI-MedLine.d133.s4|166-166|,|O
DDI-MedLine.d133.s4|168-172|depth|O
DDI-MedLine.d133.s4|174-175|of|O
DDI-MedLine.d133.s4|177-187|involvement|O
DDI-MedLine.d133.s4|188-188|,|O
DDI-MedLine.d133.s4|190-197|labeling|O
DDI-MedLine.d133.s4|199-203|index|O
DDI-MedLine.d133.s4|204-204|,|O
DDI-MedLine.d133.s4|206-214|apoptotic|O
DDI-MedLine.d133.s4|216-220|index|O
DDI-MedLine.d133.s4|222-223|or|O
DDI-MedLine.d133.s4|225-229|tumor|O
DDI-MedLine.d133.s4|231-241|vascularity|O
DDI-MedLine.d133.s4|243-244|of|O
DDI-MedLine.d133.s4|246-255|intestinal|O
DDI-MedLine.d133.s4|257-263|cancers|O
DDI-MedLine.d133.s4|264-264|,|O
DDI-MedLine.d133.s4|266-267|it|O
DDI-MedLine.d133.s4|269-281|significantly|O
DDI-MedLine.d133.s4|283-291|decreased|O
DDI-MedLine.d133.s4|293-295|the|O
DDI-MedLine.d133.s4|297-305|incidence|O
DDI-MedLine.d133.s4|307-308|of|O
DDI-MedLine.d133.s4|310-315|cancer|O
DDI-MedLine.d133.s4|317-326|metastasis|O
DDI-MedLine.d133.s4|327-327|.|O
DDI-MedLine.d133.s5|0-8|Verapamil|drug
DDI-MedLine.d133.s5|10-13|also|O
DDI-MedLine.d133.s5|15-27|significantly|O
DDI-MedLine.d133.s5|29-37|decreased|O
DDI-MedLine.d133.s5|39-41|the|O
DDI-MedLine.d133.s5|43-51|incidence|O
DDI-MedLine.d133.s5|53-54|of|O
DDI-MedLine.d133.s5|56-64|lymphatic|O
DDI-MedLine.d133.s5|66-73|invasion|O
DDI-MedLine.d133.s5|75-76|of|O
DDI-MedLine.d133.s5|78-92|adenocarcinomas|O
DDI-MedLine.d133.s5|93-93|,|O
DDI-MedLine.d133.s5|95-99|which|O
DDI-MedLine.d133.s5|101-103|was|O
DDI-MedLine.d133.s5|105-112|enhanced|O
DDI-MedLine.d133.s5|114-115|by|O
DDI-MedLine.d133.s5|125-125|.|O
DDI-MedLine.d133.s6|0-9|CONCLUSION|O
DDI-MedLine.d133.s6|10-10|:|O
DDI-MedLine.d133.s6|12-16|These|O
DDI-MedLine.d133.s6|18-25|findings|O
DDI-MedLine.d133.s6|27-34|indicate|O
DDI-MedLine.d133.s6|36-39|that|O
DDI-MedLine.d133.s6|41-49|verapamil|drug
DDI-MedLine.d133.s6|51-58|inhibits|O
DDI-MedLine.d133.s6|60-65|cancer|O
DDI-MedLine.d133.s6|67-76|metastasis|O
DDI-MedLine.d133.s6|78-84|through|O
DDI-MedLine.d133.s6|86-92|actions|O
DDI-MedLine.d133.s6|94-97|that|O
DDI-MedLine.d133.s6|99-100|do|O
DDI-MedLine.d133.s6|102-104|not|O
DDI-MedLine.d133.s6|106-111|affect|O
DDI-MedLine.d133.s6|113-115|the|O
DDI-MedLine.d133.s6|117-122|growth|O
DDI-MedLine.d133.s6|124-125|of|O
DDI-MedLine.d133.s6|127-136|intestinal|O
DDI-MedLine.d133.s6|138-144|cancers|O
DDI-MedLine.d133.s6|145-145|.|O
DDI-DrugBank.d331.s0|0-0|-|O
DDI-DrugBank.d331.s0|2-6|Drugs|O
DDI-DrugBank.d331.s0|8-11|with|O
DDI-DrugBank.d331.s0|13-20|ototoxic|O
DDI-DrugBank.d331.s0|22-30|potential|O
DDI-DrugBank.d331.s0|31-31|:|O
DDI-DrugBank.d331.s0|33-42|Especially|O
DDI-DrugBank.d331.s0|44-45|in|O
DDI-DrugBank.d331.s0|47-49|the|O
DDI-DrugBank.d331.s0|51-58|presence|O
DDI-DrugBank.d331.s0|60-61|of|O
DDI-DrugBank.d331.s0|63-70|impaired|O
DDI-DrugBank.d331.s0|72-76|renal|O
DDI-DrugBank.d331.s0|78-85|function|O
DDI-DrugBank.d331.s0|86-86|,|O
DDI-DrugBank.d331.s0|88-90|the|O
DDI-DrugBank.d331.s0|92-94|use|O
DDI-DrugBank.d331.s0|96-97|of|O
DDI-DrugBank.d331.s0|99-110|parenterally|O
DDI-DrugBank.d331.s0|112-123|administered|O
DDI-DrugBank.d331.s0|125-134|bumetanide|drug
DDI-DrugBank.d331.s0|136-137|in|O
DDI-DrugBank.d331.s0|139-146|patients|O
DDI-DrugBank.d331.s0|148-149|to|O
DDI-DrugBank.d331.s0|151-154|whom|O
DDI-DrugBank.d331.s0|156-181|aminoglycoside antibiotics|group
DDI-DrugBank.d331.s0|183-185|are|O
DDI-DrugBank.d331.s0|187-190|also|O
DDI-DrugBank.d331.s0|192-196|being|O
DDI-DrugBank.d331.s0|198-202|given|O
DDI-DrugBank.d331.s0|204-209|should|O
DDI-DrugBank.d331.s0|211-212|be|O
DDI-DrugBank.d331.s0|214-220|avoided|O
DDI-DrugBank.d331.s0|221-221|,|O
DDI-DrugBank.d331.s0|223-228|except|O
DDI-DrugBank.d331.s0|230-231|in|O
DDI-DrugBank.d331.s0|233-248|life-threatening|O
DDI-DrugBank.d331.s0|250-259|conditions|O
DDI-DrugBank.d331.s0|260-260|.|O
DDI-DrugBank.d331.s1|0-0|-|O
DDI-DrugBank.d331.s1|2-6|Drugs|O
DDI-DrugBank.d331.s1|8-11|with|O
DDI-DrugBank.d331.s1|13-23|nephrotoxic|O
DDI-DrugBank.d331.s1|25-33|potential|O
DDI-DrugBank.d331.s1|34-34|:|O
DDI-DrugBank.d331.s1|36-40|There|O
DDI-DrugBank.d331.s1|42-44|has|O
DDI-DrugBank.d331.s1|46-49|been|O
DDI-DrugBank.d331.s1|51-52|no|O
DDI-DrugBank.d331.s1|54-63|experience|O
DDI-DrugBank.d331.s1|65-66|on|O
DDI-DrugBank.d331.s1|68-70|the|O
DDI-DrugBank.d331.s1|72-81|concurrent|O
DDI-DrugBank.d331.s1|83-85|use|O
DDI-DrugBank.d331.s1|87-88|of|O
DDI-DrugBank.d331.s1|90-99|bumetanide|drug
DDI-DrugBank.d331.s1|101-104|with|O
DDI-DrugBank.d331.s1|106-110|drugs|O
DDI-DrugBank.d331.s1|112-116|known|O
DDI-DrugBank.d331.s1|118-119|to|O
DDI-DrugBank.d331.s1|121-124|have|O
DDI-DrugBank.d331.s1|126-126|a|O
DDI-DrugBank.d331.s1|128-138|nephrotoxic|O
DDI-DrugBank.d331.s1|140-148|potential|O
DDI-DrugBank.d331.s1|149-149|.|O
DDI-DrugBank.d331.s2|0-8|Therefore|O
DDI-DrugBank.d331.s2|9-9|,|O
DDI-DrugBank.d331.s2|11-13|the|O
DDI-DrugBank.d331.s2|15-26|simultaneous|O
DDI-DrugBank.d331.s2|28-41|administration|O
DDI-DrugBank.d331.s2|43-44|of|O
DDI-DrugBank.d331.s2|46-50|these|O
DDI-DrugBank.d331.s2|52-56|drugs|O
DDI-DrugBank.d331.s2|58-63|should|O
DDI-DrugBank.d331.s2|65-66|be|O
DDI-DrugBank.d331.s2|68-74|avoided|O
DDI-DrugBank.d331.s2|75-75|.|O
DDI-DrugBank.d331.s3|0-0|-|O
DDI-DrugBank.d331.s3|2-8|Lithium|drug
DDI-DrugBank.d331.s3|9-9|:|O
DDI-DrugBank.d331.s3|11-17|Lithium|drug
DDI-DrugBank.d331.s3|19-24|should|O
DDI-DrugBank.d331.s3|26-34|generally|O
DDI-DrugBank.d331.s3|36-38|not|O
DDI-DrugBank.d331.s3|40-41|be|O
DDI-DrugBank.d331.s3|43-47|given|O
DDI-DrugBank.d331.s3|49-52|with|O
DDI-DrugBank.d331.s3|54-62|diuretics|group
DDI-DrugBank.d331.s3|64-64|(|O
DDI-DrugBank.d331.s3|65-68|such|O
DDI-DrugBank.d331.s3|70-71|as|O
DDI-DrugBank.d331.s3|73-82|bumetanide|drug
DDI-DrugBank.d331.s3|83-83|)|O
DDI-DrugBank.d331.s3|85-91|because|O
DDI-DrugBank.d331.s3|93-96|they|O
DDI-DrugBank.d331.s3|98-103|reduce|O
DDI-DrugBank.d331.s3|105-107|its|O
DDI-DrugBank.d331.s3|109-113|renal|O
DDI-DrugBank.d331.s3|115-123|clearance|O
DDI-DrugBank.d331.s3|125-127|and|O
DDI-DrugBank.d331.s3|129-131|add|O
DDI-DrugBank.d331.s3|133-133|a|O
DDI-DrugBank.d331.s3|135-138|high|O
DDI-DrugBank.d331.s3|140-143|risk|O
DDI-DrugBank.d331.s3|145-146|of|O
DDI-DrugBank.d331.s3|148-154|lithium|drug
DDI-DrugBank.d331.s3|156-163|toxicity|O
DDI-DrugBank.d331.s3|164-164|.|O
DDI-DrugBank.d331.s4|0-0|-|O
DDI-DrugBank.d331.s4|2-11|Probenecid|drug
DDI-DrugBank.d331.s4|12-12|:|O
DDI-DrugBank.d331.s4|14-25|Pretreatment|O
DDI-DrugBank.d331.s4|27-30|with|O
DDI-DrugBank.d331.s4|32-41|probenecid|drug
DDI-DrugBank.d331.s4|43-49|reduces|O
DDI-DrugBank.d331.s4|51-54|both|O
DDI-DrugBank.d331.s4|56-58|the|O
DDI-DrugBank.d331.s4|60-70|natriuresis|O
DDI-DrugBank.d331.s4|72-74|and|O
DDI-DrugBank.d331.s4|76-89|hyperreninemia|O
DDI-DrugBank.d331.s4|91-98|produced|O
DDI-DrugBank.d331.s4|100-101|by|O
DDI-DrugBank.d331.s4|103-112|bumetanide|drug
DDI-DrugBank.d331.s4|113-113|.|O
DDI-DrugBank.d331.s5|0-3|This|O
DDI-DrugBank.d331.s5|5-16|antagonistic|O
DDI-DrugBank.d331.s5|18-23|effect|O
DDI-DrugBank.d331.s5|25-26|of|O
DDI-DrugBank.d331.s5|28-37|probenecid|drug
DDI-DrugBank.d331.s5|39-40|on|O
DDI-DrugBank.d331.s5|42-51|bumetanide|drug
DDI-DrugBank.d331.s5|53-63|natriuresis|O
DDI-DrugBank.d331.s5|65-66|is|O
DDI-DrugBank.d331.s5|68-70|not|O
DDI-DrugBank.d331.s5|72-74|due|O
DDI-DrugBank.d331.s5|76-77|to|O
DDI-DrugBank.d331.s5|79-79|a|O
DDI-DrugBank.d331.s5|81-86|direct|O
DDI-DrugBank.d331.s5|88-93|action|O
DDI-DrugBank.d331.s5|95-96|on|O
DDI-DrugBank.d331.s5|98-103|sodium|O
DDI-DrugBank.d331.s5|105-113|excretion|O
DDI-DrugBank.d331.s5|115-117|but|O
DDI-DrugBank.d331.s5|119-120|is|O
DDI-DrugBank.d331.s5|122-129|probably|O
DDI-DrugBank.d331.s5|131-139|secondary|O
DDI-DrugBank.d331.s5|141-142|to|O
DDI-DrugBank.d331.s5|144-146|its|O
DDI-DrugBank.d331.s5|148-157|inhibitory|O
DDI-DrugBank.d331.s5|159-164|effect|O
DDI-DrugBank.d331.s5|166-167|on|O
DDI-DrugBank.d331.s5|169-173|renal|O
DDI-DrugBank.d331.s5|175-181|tubular|O
DDI-DrugBank.d331.s5|183-191|secretion|O
DDI-DrugBank.d331.s5|193-194|of|O
DDI-DrugBank.d331.s5|196-205|bumetanide|drug
DDI-DrugBank.d331.s5|206-206|.|O
DDI-DrugBank.d331.s6|0-3|Thus|O
DDI-DrugBank.d331.s6|4-4|,|O
DDI-DrugBank.d331.s6|6-15|probenecid|drug
DDI-DrugBank.d331.s6|17-22|should|O
DDI-DrugBank.d331.s6|24-26|not|O
DDI-DrugBank.d331.s6|28-29|be|O
DDI-DrugBank.d331.s6|31-42|administered|O
DDI-DrugBank.d331.s6|44-55|concurrently|O
DDI-DrugBank.d331.s6|57-60|with|O
DDI-DrugBank.d331.s6|62-71|bumetanide|drug
DDI-DrugBank.d331.s6|72-72|.|O
DDI-DrugBank.d331.s7|0-0|-|O
DDI-DrugBank.d331.s7|2-13|Indomethacin|drug
DDI-DrugBank.d331.s7|14-14|:|O
DDI-DrugBank.d331.s7|16-27|Indomethacin|drug
DDI-DrugBank.d331.s7|29-34|blunts|O
DDI-DrugBank.d331.s7|36-38|the|O
DDI-DrugBank.d331.s7|40-48|increases|O
DDI-DrugBank.d331.s7|50-51|in|O
DDI-DrugBank.d331.s7|53-57|urine|O
DDI-DrugBank.d331.s7|59-64|volume|O
DDI-DrugBank.d331.s7|66-68|and|O
DDI-DrugBank.d331.s7|70-75|sodium|O
DDI-DrugBank.d331.s7|77-85|excretion|O
DDI-DrugBank.d331.s7|87-90|seen|O
DDI-DrugBank.d331.s7|92-97|during|O
DDI-DrugBank.d331.s7|99-108|bumetanide|drug
DDI-DrugBank.d331.s7|110-118|treatment|O
DDI-DrugBank.d331.s7|120-122|and|O
DDI-DrugBank.d331.s7|124-131|inhibits|O
DDI-DrugBank.d331.s7|133-135|the|O
DDI-DrugBank.d331.s7|137-154|bumetanide-induced|drug
DDI-DrugBank.d331.s7|156-163|increase|O
DDI-DrugBank.d331.s7|165-166|in|O
DDI-DrugBank.d331.s7|168-173|plasma|O
DDI-DrugBank.d331.s7|175-179|renin|O
DDI-DrugBank.d331.s7|181-188|activity|O
DDI-DrugBank.d331.s7|189-189|.|O
DDI-DrugBank.d331.s8|0-9|Concurrent|O
DDI-DrugBank.d331.s8|11-17|therapy|O
DDI-DrugBank.d331.s8|19-22|with|O
DDI-DrugBank.d331.s8|24-33|bumetanide|drug
DDI-DrugBank.d331.s8|35-36|is|O
DDI-DrugBank.d331.s8|38-41|thus|O
DDI-DrugBank.d331.s8|43-45|not|O
DDI-DrugBank.d331.s8|47-57|recommended|O
DDI-DrugBank.d331.s8|58-58|.|O
DDI-DrugBank.d331.s9|0-0|-|O
DDI-DrugBank.d331.s9|2-18|Antihypertensives|group
DDI-DrugBank.d331.s9|19-19|:|O
DDI-DrugBank.d331.s9|21-30|Bumetanide|drug
DDI-DrugBank.d331.s9|32-34|may|O
DDI-DrugBank.d331.s9|36-45|potentiate|O
DDI-DrugBank.d331.s9|47-49|the|O
DDI-DrugBank.d331.s9|51-56|effect|O
DDI-DrugBank.d331.s9|58-59|of|O
DDI-DrugBank.d331.s9|61-67|various|O
DDI-DrugBank.d331.s9|69-90|antihypertensive drugs|group
DDI-DrugBank.d331.s9|91-91|,|O
DDI-DrugBank.d331.s9|93-105|necessitating|O
DDI-DrugBank.d331.s9|107-107|a|O
DDI-DrugBank.d331.s9|109-117|reduction|O
DDI-DrugBank.d331.s9|119-120|in|O
DDI-DrugBank.d331.s9|122-124|the|O
DDI-DrugBank.d331.s9|126-131|dosage|O
DDI-DrugBank.d331.s9|133-134|of|O
DDI-DrugBank.d331.s9|136-140|these|O
DDI-DrugBank.d331.s9|142-146|drugs|O
DDI-DrugBank.d331.s9|147-147|.|O
DDI-DrugBank.d331.s10|0-0|-|O
DDI-DrugBank.d331.s10|2-8|Digoxin|drug
DDI-DrugBank.d331.s10|9-9|:|O
DDI-DrugBank.d331.s10|11-21|Interaction|O
DDI-DrugBank.d331.s10|23-29|studies|O
DDI-DrugBank.d331.s10|31-32|in|O
DDI-DrugBank.d331.s10|34-39|humans|O
DDI-DrugBank.d331.s10|41-44|have|O
DDI-DrugBank.d331.s10|46-50|shown|O
DDI-DrugBank.d331.s10|52-53|no|O
DDI-DrugBank.d331.s10|55-60|effect|O
DDI-DrugBank.d331.s10|62-63|on|O
DDI-DrugBank.d331.s10|65-71|digoxin|drug
DDI-DrugBank.d331.s10|73-77|blood|O
DDI-DrugBank.d331.s10|79-84|levels|O
DDI-DrugBank.d331.s10|85-85|.|O
DDI-DrugBank.d331.s11|0-0|-|O
DDI-DrugBank.d331.s11|2-15|Anticoagulants|group
DDI-DrugBank.d331.s11|16-16|:|O
DDI-DrugBank.d331.s11|18-28|Interaction|O
DDI-DrugBank.d331.s11|30-36|studies|O
DDI-DrugBank.d331.s11|38-39|in|O
DDI-DrugBank.d331.s11|41-46|humans|O
DDI-DrugBank.d331.s11|48-51|have|O
DDI-DrugBank.d331.s11|53-57|shown|O
DDI-DrugBank.d331.s11|59-68|bumetanide|drug
DDI-DrugBank.d331.s11|70-71|to|O
DDI-DrugBank.d331.s11|73-76|have|O
DDI-DrugBank.d331.s11|78-79|no|O
DDI-DrugBank.d331.s11|81-86|effect|O
DDI-DrugBank.d331.s11|88-89|on|O
DDI-DrugBank.d331.s11|91-98|warfarin|drug
DDI-DrugBank.d331.s11|100-109|metabolism|O
DDI-DrugBank.d331.s11|111-112|or|O
DDI-DrugBank.d331.s11|114-115|on|O
DDI-DrugBank.d331.s11|117-122|plasma|O
DDI-DrugBank.d331.s11|124-134|prothrombin|O
DDI-DrugBank.d331.s11|136-143|activity|O
DDI-DrugBank.d331.s11|144-144|.|O
DDI-DrugBank.d224.s0|0-12|Apraclonidine|drug
DDI-DrugBank.d224.s0|14-19|should|O
DDI-DrugBank.d224.s0|21-23|not|O
DDI-DrugBank.d224.s0|25-26|be|O
DDI-DrugBank.d224.s0|28-31|used|O
DDI-DrugBank.d224.s0|33-34|in|O
DDI-DrugBank.d224.s0|36-43|patients|O
DDI-DrugBank.d224.s0|45-53|receiving|O
DDI-DrugBank.d224.s0|55-57|MAO|group
DDI-DrugBank.d224.s0|59-70|inhibitors..|O
DDI-DrugBank.d224.s1|0-7|Although|O
DDI-DrugBank.d224.s1|9-10|no|O
DDI-DrugBank.d224.s1|12-19|specific|O
DDI-DrugBank.d224.s1|21-24|drug|O
DDI-DrugBank.d224.s1|26-37|interactions|O
DDI-DrugBank.d224.s1|39-42|with|O
DDI-DrugBank.d224.s1|44-50|topical|O
DDI-DrugBank.d224.s1|52-59|glaucoma|O
DDI-DrugBank.d224.s1|61-65|drugs|O
DDI-DrugBank.d224.s1|67-68|or|O
DDI-DrugBank.d224.s1|70-77|systemic|O
DDI-DrugBank.d224.s1|79-89|medications|O
DDI-DrugBank.d224.s1|91-94|were|O
DDI-DrugBank.d224.s1|96-105|identified|O
DDI-DrugBank.d224.s1|107-108|in|O
DDI-DrugBank.d224.s1|110-117|clinical|O
DDI-DrugBank.d224.s1|119-125|studies|O
DDI-DrugBank.d224.s1|127-128|of|O
DDI-DrugBank.d224.s1|130-137|IOPIDINE|brand
DDI-DrugBank.d224.s1|139-141|0.5|O
DDI-DrugBank.d224.s1|142-142|%|O
DDI-DrugBank.d224.s1|144-153|Ophthalmic|O
DDI-DrugBank.d224.s1|155-162|Solution|O
DDI-DrugBank.d224.s1|163-163|,|O
DDI-DrugBank.d224.s1|165-167|the|O
DDI-DrugBank.d224.s1|169-179|possibility|O
DDI-DrugBank.d224.s1|181-182|of|O
DDI-DrugBank.d224.s1|184-185|an|O
DDI-DrugBank.d224.s1|187-194|additive|O
DDI-DrugBank.d224.s1|196-197|or|O
DDI-DrugBank.d224.s1|199-210|potentiating|O
DDI-DrugBank.d224.s1|212-217|effect|O
DDI-DrugBank.d224.s1|219-222|with|O
DDI-DrugBank.d224.s1|224-238|CNS depressants|group
DDI-DrugBank.d224.s1|240-240|(|O
DDI-DrugBank.d224.s1|241-247|alcohol|drug
DDI-DrugBank.d224.s1|248-248|,|O
DDI-DrugBank.d224.s1|250-261|barbiturates|group
DDI-DrugBank.d224.s1|262-262|,|O
DDI-DrugBank.d224.s1|264-270|opiates|group
DDI-DrugBank.d224.s1|271-271|,|O
DDI-DrugBank.d224.s1|273-281|sedatives|group
DDI-DrugBank.d224.s1|282-282|,|O
DDI-DrugBank.d224.s1|284-294|anesthetics|group
DDI-DrugBank.d224.s1|295-295|)|O
DDI-DrugBank.d224.s1|297-302|should|O
DDI-DrugBank.d224.s1|304-305|be|O
DDI-DrugBank.d224.s1|307-316|considered|O
DDI-DrugBank.d224.s1|317-317|.|O
DDI-DrugBank.d224.s2|0-24|Tricyclic antidepressants|group
DDI-DrugBank.d224.s2|26-29|have|O
DDI-DrugBank.d224.s2|31-34|been|O
DDI-DrugBank.d224.s2|36-43|reported|O
DDI-DrugBank.d224.s2|45-46|to|O
DDI-DrugBank.d224.s2|48-52|blunt|O
DDI-DrugBank.d224.s2|54-56|the|O
DDI-DrugBank.d224.s2|58-68|hypotensive|O
DDI-DrugBank.d224.s2|70-75|effect|O
DDI-DrugBank.d224.s2|77-78|of|O
DDI-DrugBank.d224.s2|80-87|systemic|O
DDI-DrugBank.d224.s2|89-97|clonidine|drug
DDI-DrugBank.d224.s2|98-98|.|O
DDI-DrugBank.d224.s3|0-1|It|O
DDI-DrugBank.d224.s3|3-4|is|O
DDI-DrugBank.d224.s3|6-8|not|O
DDI-DrugBank.d224.s3|10-14|known|O
DDI-DrugBank.d224.s3|16-22|whether|O
DDI-DrugBank.d224.s3|24-26|the|O
DDI-DrugBank.d224.s3|28-37|concurrent|O
DDI-DrugBank.d224.s3|39-41|use|O
DDI-DrugBank.d224.s3|43-44|of|O
DDI-DrugBank.d224.s3|46-50|these|O
DDI-DrugBank.d224.s3|52-57|agents|O
DDI-DrugBank.d224.s3|59-62|with|O
DDI-DrugBank.d224.s3|64-76|apraclonidine|drug
DDI-DrugBank.d224.s3|78-80|can|O
DDI-DrugBank.d224.s3|82-85|lead|O
DDI-DrugBank.d224.s3|87-88|to|O
DDI-DrugBank.d224.s3|90-90|a|O
DDI-DrugBank.d224.s3|92-100|reduction|O
DDI-DrugBank.d224.s3|102-103|in|O
DDI-DrugBank.d224.s3|105-107|IOP|O
DDI-DrugBank.d224.s3|109-116|lowering|O
DDI-DrugBank.d224.s3|118-123|effect|O
DDI-DrugBank.d224.s3|124-124|.|O
DDI-DrugBank.d224.s4|0-1|No|O
DDI-DrugBank.d224.s4|3-6|data|O
DDI-DrugBank.d224.s4|8-9|on|O
DDI-DrugBank.d224.s4|11-13|the|O
DDI-DrugBank.d224.s4|15-19|level|O
DDI-DrugBank.d224.s4|21-22|of|O
DDI-DrugBank.d224.s4|24-34|circulating|O
DDI-DrugBank.d224.s4|36-49|catecholamines|O
DDI-DrugBank.d224.s4|51-55|after|O
DDI-DrugBank.d224.s4|57-69|apraclonidine|drug
DDI-DrugBank.d224.s4|71-80|withdrawal|O
DDI-DrugBank.d224.s4|82-84|are|O
DDI-DrugBank.d224.s4|86-94|available|O
DDI-DrugBank.d224.s4|95-95|.|O
DDI-DrugBank.d224.s5|0-6|Caution|O
DDI-DrugBank.d224.s5|7-7|,|O
DDI-DrugBank.d224.s5|9-15|however|O
DDI-DrugBank.d224.s5|16-16|,|O
DDI-DrugBank.d224.s5|18-19|is|O
DDI-DrugBank.d224.s5|21-27|advised|O
DDI-DrugBank.d224.s5|29-30|in|O
DDI-DrugBank.d224.s5|32-39|patients|O
DDI-DrugBank.d224.s5|41-46|taking|O
DDI-DrugBank.d224.s5|48-72|tricyclic antidepressants|group
DDI-DrugBank.d224.s5|74-78|which|O
DDI-DrugBank.d224.s5|80-82|can|O
DDI-DrugBank.d224.s5|84-89|affect|O
DDI-DrugBank.d224.s5|91-93|the|O
DDI-DrugBank.d224.s5|95-104|metabolism|O
DDI-DrugBank.d224.s5|106-108|and|O
DDI-DrugBank.d224.s5|110-115|uptake|O
DDI-DrugBank.d224.s5|117-118|of|O
DDI-DrugBank.d224.s5|120-130|circulating|O
DDI-DrugBank.d224.s5|132-137|amines|O
DDI-DrugBank.d224.s5|138-138|.|O
DDI-DrugBank.d224.s6|0-1|An|O
DDI-DrugBank.d224.s6|3-10|additive|O
DDI-DrugBank.d224.s6|12-22|hypotensive|O
DDI-DrugBank.d224.s6|24-29|effect|O
DDI-DrugBank.d224.s6|31-33|has|O
DDI-DrugBank.d224.s6|35-38|been|O
DDI-DrugBank.d224.s6|40-47|reported|O
DDI-DrugBank.d224.s6|49-52|with|O
DDI-DrugBank.d224.s6|54-56|the|O
DDI-DrugBank.d224.s6|58-68|combination|O
DDI-DrugBank.d224.s6|70-71|of|O
DDI-DrugBank.d224.s6|73-80|systemic|O
DDI-DrugBank.d224.s6|82-90|clonidine|drug
DDI-DrugBank.d224.s6|92-94|and|O
DDI-DrugBank.d224.s6|96-106|neuroleptic|group
DDI-DrugBank.d224.s6|108-114|therapy|O
DDI-DrugBank.d224.s6|115-115|.|O
DDI-DrugBank.d224.s7|0-7|Systemic|O
DDI-DrugBank.d224.s7|9-17|clonidine|drug
DDI-DrugBank.d224.s7|19-21|may|O
DDI-DrugBank.d224.s7|23-29|inhibit|O
DDI-DrugBank.d224.s7|31-33|the|O
DDI-DrugBank.d224.s7|35-44|production|O
DDI-DrugBank.d224.s7|46-47|of|O
DDI-DrugBank.d224.s7|49-62|catecholamines|O
DDI-DrugBank.d224.s7|64-65|in|O
DDI-DrugBank.d224.s7|67-74|response|O
DDI-DrugBank.d224.s7|76-77|to|O
DDI-DrugBank.d224.s7|79-93|insulin-induced|O
DDI-DrugBank.d224.s7|95-106|hypoglycemia|O
DDI-DrugBank.d224.s7|108-110|and|O
DDI-DrugBank.d224.s7|112-115|mask|O
DDI-DrugBank.d224.s7|117-119|the|O
DDI-DrugBank.d224.s7|121-125|signs|O
DDI-DrugBank.d224.s7|127-129|and|O
DDI-DrugBank.d224.s7|131-138|symptoms|O
DDI-DrugBank.d224.s7|140-141|of|O
DDI-DrugBank.d224.s7|143-154|hypoglycemia|O
DDI-DrugBank.d224.s7|155-155|.|O
DDI-DrugBank.d224.s8|0-4|Since|O
DDI-DrugBank.d224.s8|6-18|apraclonidine|drug
DDI-DrugBank.d224.s8|20-22|may|O
DDI-DrugBank.d224.s8|24-29|reduce|O
DDI-DrugBank.d224.s8|31-35|pulse|O
DDI-DrugBank.d224.s8|37-39|and|O
DDI-DrugBank.d224.s8|41-45|blood|O
DDI-DrugBank.d224.s8|47-54|pressure|O
DDI-DrugBank.d224.s8|55-55|,|O
DDI-DrugBank.d224.s8|57-63|caution|O
DDI-DrugBank.d224.s8|65-66|in|O
DDI-DrugBank.d224.s8|68-72|using|O
DDI-DrugBank.d224.s8|74-78|drugs|O
DDI-DrugBank.d224.s8|80-83|such|O
DDI-DrugBank.d224.s8|85-86|as|O
DDI-DrugBank.d224.s8|88-100|beta-blockers|group
DDI-DrugBank.d224.s8|102-102|(|O
DDI-DrugBank.d224.s8|103-112|ophthalmic|O
DDI-DrugBank.d224.s8|114-116|and|O
DDI-DrugBank.d224.s8|118-125|systemic|O
DDI-DrugBank.d224.s8|126-126|)|O
DDI-DrugBank.d224.s8|127-127|,|O
DDI-DrugBank.d224.s8|129-145|antihypertensives|group
DDI-DrugBank.d224.s8|146-146|,|O
DDI-DrugBank.d224.s8|148-150|and|O
DDI-DrugBank.d224.s8|152-169|cardiac glycosides|group
DDI-DrugBank.d224.s8|171-172|is|O
DDI-DrugBank.d224.s8|174-180|advised|O
DDI-DrugBank.d224.s8|181-181|.|O
DDI-DrugBank.d224.s9|0-7|Patients|O
DDI-DrugBank.d224.s9|9-13|using|O
DDI-DrugBank.d224.s9|15-28|cardiovascular|O
DDI-DrugBank.d224.s9|30-34|drugs|O
DDI-DrugBank.d224.s9|36-47|concurrently|O
DDI-DrugBank.d224.s9|49-52|with|O
DDI-DrugBank.d224.s9|54-61|IOPIDINE|brand
DDI-DrugBank.d224.s9|63-65|0.5|O
DDI-DrugBank.d224.s9|66-66|%|O
DDI-DrugBank.d224.s9|68-77|Ophthalmic|O
DDI-DrugBank.d224.s9|79-86|Solution|O
DDI-DrugBank.d224.s9|88-93|should|O
DDI-DrugBank.d224.s9|95-98|have|O
DDI-DrugBank.d224.s9|100-104|pulse|O
DDI-DrugBank.d224.s9|106-108|and|O
DDI-DrugBank.d224.s9|110-114|blood|O
DDI-DrugBank.d224.s9|116-124|pressures|O
DDI-DrugBank.d224.s9|126-135|frequently|O
DDI-DrugBank.d224.s9|137-145|monitored|O
DDI-DrugBank.d224.s9|146-146|.|O
DDI-DrugBank.d224.s10|0-6|Caution|O
DDI-DrugBank.d224.s10|8-13|should|O
DDI-DrugBank.d224.s10|15-16|be|O
DDI-DrugBank.d224.s10|18-26|exercised|O
DDI-DrugBank.d224.s10|28-31|with|O
DDI-DrugBank.d224.s10|33-44|simultaneous|O
DDI-DrugBank.d224.s10|46-48|use|O
DDI-DrugBank.d224.s10|50-51|of|O
DDI-DrugBank.d224.s10|53-61|clonidine|drug
DDI-DrugBank.d224.s10|63-65|and|O
DDI-DrugBank.d224.s10|67-71|other|O
DDI-DrugBank.d224.s10|73-79|similar|O
DDI-DrugBank.d224.s10|81-93|pharmacologic|O
DDI-DrugBank.d224.s10|95-100|agents|O
DDI-DrugBank.d224.s11|0-0|.|O
DDI-MedLine.d32.s0|0-10|Prescribing|O
DDI-MedLine.d32.s0|11-11|.|O
DDI-MedLine.d32.s1|0-3|Keys|O
DDI-MedLine.d32.s1|5-6|to|O
DDI-MedLine.d32.s1|8-17|maximizing|O
DDI-MedLine.d32.s1|19-25|benefit|O
DDI-MedLine.d32.s1|27-31|while|O
DDI-MedLine.d32.s1|33-40|avoiding|O
DDI-MedLine.d32.s1|42-48|adverse|O
DDI-MedLine.d32.s1|50-53|drug|O
DDI-MedLine.d32.s1|55-61|effects|O
DDI-MedLine.d32.s1|62-62|.|O
DDI-MedLine.d32.s2|0-3|When|O
DDI-MedLine.d32.s2|5-15|prescribing|O
DDI-MedLine.d32.s2|17-19|for|O
DDI-MedLine.d32.s2|21-25|older|O
DDI-MedLine.d32.s2|27-34|patients|O
DDI-MedLine.d32.s2|35-35|,|O
DDI-MedLine.d32.s2|37-40|some|O
DDI-MedLine.d32.s2|42-51|physicians|O
DDI-MedLine.d32.s2|53-55|are|O
DDI-MedLine.d32.s2|57-62|overly|O
DDI-MedLine.d32.s2|64-71|cautious|O
DDI-MedLine.d32.s2|72-72|,|O
DDI-MedLine.d32.s2|74-76|and|O
DDI-MedLine.d32.s2|78-81|this|O
DDI-MedLine.d32.s2|83-90|strategy|O
DDI-MedLine.d32.s2|92-94|can|O
DDI-MedLine.d32.s2|96-101|result|O
DDI-MedLine.d32.s2|103-104|in|O
DDI-MedLine.d32.s2|106-106|a|O
DDI-MedLine.d32.s2|108-111|less|O
DDI-MedLine.d32.s2|113-116|than|O
DDI-MedLine.d32.s2|118-124|optimal|O
DDI-MedLine.d32.s2|126-134|treatment|O
DDI-MedLine.d32.s2|136-142|outcome|O
DDI-MedLine.d32.s2|143-143|.|O
DDI-MedLine.d32.s3|0-2|The|O
DDI-MedLine.d32.s3|4-13|reluctance|O
DDI-MedLine.d32.s3|15-16|to|O
DDI-MedLine.d32.s3|18-22|treat|O
DDI-MedLine.d32.s3|24-35|aggressively|O
DDI-MedLine.d32.s3|37-38|is|O
DDI-MedLine.d32.s3|40-53|understandable|O
DDI-MedLine.d32.s3|55-61|because|O
DDI-MedLine.d32.s3|63-65|the|O
DDI-MedLine.d32.s3|67-75|geriatric|O
DDI-MedLine.d32.s3|77-86|population|O
DDI-MedLine.d32.s3|88-89|is|O
DDI-MedLine.d32.s3|91-101|susceptible|O
DDI-MedLine.d32.s3|103-104|to|O
DDI-MedLine.d32.s3|106-112|adverse|O
DDI-MedLine.d32.s3|114-117|drug|O
DDI-MedLine.d32.s3|119-127|reactions|O
DDI-MedLine.d32.s3|128-128|.|O
DDI-MedLine.d32.s4|0-2|The|O
DDI-MedLine.d32.s4|4-6|key|O
DDI-MedLine.d32.s4|8-9|to|O
DDI-MedLine.d32.s4|11-20|maximizing|O
DDI-MedLine.d32.s4|22-28|therapy|O
DDI-MedLine.d32.s4|30-33|lies|O
DDI-MedLine.d32.s4|35-36|in|O
DDI-MedLine.d32.s4|38-52|individualizing|O
DDI-MedLine.d32.s4|54-55|it|O
DDI-MedLine.d32.s4|57-58|as|O
DDI-MedLine.d32.s4|60-63|much|O
DDI-MedLine.d32.s4|65-66|as|O
DDI-MedLine.d32.s4|68-75|possible|O
DDI-MedLine.d32.s4|76-76|.|O
DDI-MedLine.d32.s5|0-4|There|O
DDI-MedLine.d32.s5|6-8|are|O
DDI-MedLine.d32.s5|10-10|a|O
DDI-MedLine.d32.s5|12-17|number|O
DDI-MedLine.d32.s5|19-20|of|O
DDI-MedLine.d32.s5|22-26|steps|O
DDI-MedLine.d32.s5|28-37|physicians|O
DDI-MedLine.d32.s5|39-41|can|O
DDI-MedLine.d32.s5|43-46|take|O
DDI-MedLine.d32.s5|48-49|to|O
DDI-MedLine.d32.s5|51-56|ensure|O
DDI-MedLine.d32.s5|58-61|that|O
DDI-MedLine.d32.s5|63-67|their|O
DDI-MedLine.d32.s5|69-76|patients|O
DDI-MedLine.d32.s5|78-80|are|O
DDI-MedLine.d32.s5|82-84|not|O
DDI-MedLine.d32.s5|86-90|being|O
DDI-MedLine.d32.s5|92-103|undertreated|O
DDI-MedLine.d32.s5|104-104|.|O
DDI-MedLine.d32.s6|0-4|These|O
DDI-MedLine.d32.s6|6-10|steps|O
DDI-MedLine.d32.s6|12-18|include|O
DDI-MedLine.d32.s6|20-26|regular|O
DDI-MedLine.d32.s6|28-40|reevaluations|O
DDI-MedLine.d32.s6|42-43|of|O
DDI-MedLine.d32.s6|45-51|dosages|O
DDI-MedLine.d32.s6|53-55|and|O
DDI-MedLine.d32.s6|57-62|plasma|O
DDI-MedLine.d32.s6|64-67|drug|O
DDI-MedLine.d32.s6|69-82|concentrations|O
DDI-MedLine.d32.s6|83-83|,|O
DDI-MedLine.d32.s6|85-95|recognition|O
DDI-MedLine.d32.s6|97-99|and|O
DDI-MedLine.d32.s6|101-113|understanding|O
DDI-MedLine.d32.s6|115-116|of|O
DDI-MedLine.d32.s6|118-121|drug|O
DDI-MedLine.d32.s6|123-126|side|O
DDI-MedLine.d32.s6|128-134|effects|O
DDI-MedLine.d32.s6|135-135|,|O
DDI-MedLine.d32.s6|137-139|and|O
DDI-MedLine.d32.s6|141-149|avoidance|O
DDI-MedLine.d32.s6|151-152|of|O
DDI-MedLine.d32.s6|154-160|certain|O
DDI-MedLine.d32.s6|162-167|agents|O
DDI-MedLine.d32.s6|168-168|.|O
DDI-MedLine.d32.s7|0-4|Close|O
DDI-MedLine.d32.s7|6-15|monitoring|O
DDI-MedLine.d32.s7|17-22|allows|O
DDI-MedLine.d32.s7|24-33|physicians|O
DDI-MedLine.d32.s7|35-36|to|O
DDI-MedLine.d32.s7|38-45|minimize|O
DDI-MedLine.d32.s7|47-51|risks|O
DDI-MedLine.d32.s7|52-52|,|O
DDI-MedLine.d32.s7|54-61|maximize|O
DDI-MedLine.d32.s7|63-70|benefits|O
DDI-MedLine.d32.s7|71-71|,|O
DDI-MedLine.d32.s7|73-75|and|O
DDI-MedLine.d32.s7|77-79|get|O
DDI-MedLine.d32.s7|81-83|the|O
DDI-MedLine.d32.s7|85-88|most|O
DDI-MedLine.d32.s7|90-92|out|O
DDI-MedLine.d32.s7|94-95|of|O
DDI-MedLine.d32.s7|97-100|what|O
DDI-MedLine.d32.s7|102-107|modern|O
DDI-MedLine.d32.s7|109-119|medications|O
DDI-MedLine.d32.s7|121-123|can|O
DDI-MedLine.d32.s7|125-126|do|O
DDI-MedLine.d32.s7|128-129|to|O
DDI-MedLine.d32.s7|131-134|help|O
DDI-MedLine.d32.s7|136-140|older|O
DDI-MedLine.d32.s7|142-149|patients|O
DDI-MedLine.d32.s7|150-150|.|O
DDI-DrugBank.d712.s0|0-4|There|O
DDI-DrugBank.d712.s0|6-9|have|O
DDI-DrugBank.d712.s0|11-14|been|O
DDI-DrugBank.d712.s0|16-17|no|O
DDI-DrugBank.d712.s0|19-24|formal|O
DDI-DrugBank.d712.s0|26-29|drug|O
DDI-DrugBank.d712.s0|31-41|interaction|O
DDI-DrugBank.d712.s0|43-49|studies|O
DDI-DrugBank.d712.s0|51-59|performed|O
DDI-DrugBank.d712.s0|61-64|with|O
DDI-DrugBank.d712.s0|66-74|HERCEPTIN|brand
DDI-DrugBank.d712.s0|76-77|in|O
DDI-DrugBank.d712.s0|79-84|humans|O
DDI-DrugBank.d712.s0|85-85|.|O
DDI-DrugBank.d712.s1|0-13|Administration|O
DDI-DrugBank.d712.s1|15-16|of|O
DDI-DrugBank.d712.s1|18-27|paclitaxel|drug
DDI-DrugBank.d712.s1|29-30|in|O
DDI-DrugBank.d712.s1|32-42|combination|O
DDI-DrugBank.d712.s1|44-47|with|O
DDI-DrugBank.d712.s1|49-57|HERCEPTIN|brand
DDI-DrugBank.d712.s1|59-66|resulted|O
DDI-DrugBank.d712.s1|68-69|in|O
DDI-DrugBank.d712.s1|71-71|a|O
DDI-DrugBank.d712.s1|73-80|two-fold|O
DDI-DrugBank.d712.s1|82-89|decrease|O
DDI-DrugBank.d712.s1|91-92|in|O
DDI-DrugBank.d712.s1|94-102|HERCEPTIN|brand
DDI-DrugBank.d712.s1|104-112|clearance|O
DDI-DrugBank.d712.s1|114-115|in|O
DDI-DrugBank.d712.s1|117-117|a|O
DDI-DrugBank.d712.s1|119-127|non-human|O
DDI-DrugBank.d712.s1|129-135|primate|O
DDI-DrugBank.d712.s1|137-141|study|O
DDI-DrugBank.d712.s1|143-145|and|O
DDI-DrugBank.d712.s1|147-148|in|O
DDI-DrugBank.d712.s1|150-150|a|O
DDI-DrugBank.d712.s1|152-159|1.5-fold|O
DDI-DrugBank.d712.s1|161-168|increase|O
DDI-DrugBank.d712.s1|170-171|in|O
DDI-DrugBank.d712.s1|173-181|HERCEPTIN|brand
DDI-DrugBank.d712.s1|183-187|serum|O
DDI-DrugBank.d712.s1|189-194|levels|O
DDI-DrugBank.d712.s1|196-197|in|O
DDI-DrugBank.d712.s1|199-206|clinical|O
DDI-DrugBank.d712.s1|208-214|studies|O
DDI-DrugBank.d712.s1|215-215|.|O
DDI-MedLine.d199.s0|0-9|Prevention|O
DDI-MedLine.d199.s0|11-12|of|O
DDI-MedLine.d199.s0|14-22|emergence|O
DDI-MedLine.d199.s0|24-32|agitation|O
DDI-MedLine.d199.s0|34-35|in|O
DDI-MedLine.d199.s0|37-41|seven|O
DDI-MedLine.d199.s0|43-50|children|O
DDI-MedLine.d199.s0|52-60|receiving|O
DDI-MedLine.d199.s0|62-69|low-dose|O
DDI-MedLine.d199.s0|71-78|ketamine|drug
DDI-MedLine.d199.s0|80-82|and|O
DDI-MedLine.d199.s0|84-91|propofol|drug
DDI-MedLine.d199.s0|93-97|total|O
DDI-MedLine.d199.s0|99-109|intravenous|O
DDI-MedLine.d199.s0|111-120|anesthesia|O
DDI-MedLine.d199.s0|121-121|.|O
DDI-MedLine.d199.s1|0-8|Emergence|O
DDI-MedLine.d199.s1|10-18|agitation|O
DDI-MedLine.d199.s1|20-20|(|O
DDI-MedLine.d199.s1|21-22|EA|O
DDI-MedLine.d199.s1|23-23|)|O
DDI-MedLine.d199.s1|25-27|can|O
DDI-MedLine.d199.s1|29-30|be|O
DDI-MedLine.d199.s1|32-32|a|O
DDI-MedLine.d199.s1|34-44|distressing|O
DDI-MedLine.d199.s1|46-49|side|O
DDI-MedLine.d199.s1|51-56|effect|O
DDI-MedLine.d199.s1|58-59|of|O
DDI-MedLine.d199.s1|61-69|pediatric|O
DDI-MedLine.d199.s1|71-80|anesthesia|O
DDI-MedLine.d199.s1|81-81|.|O
DDI-MedLine.d199.s2|0-1|We|O
DDI-MedLine.d199.s2|3-17|retrospectively|O
DDI-MedLine.d199.s2|19-26|reviewed|O
DDI-MedLine.d199.s2|28-30|the|O
DDI-MedLine.d199.s2|32-38|records|O
DDI-MedLine.d199.s2|40-41|of|O
DDI-MedLine.d199.s2|43-43|7|O
DDI-MedLine.d199.s2|45-53|pediatric|O
DDI-MedLine.d199.s2|55-62|oncology|O
DDI-MedLine.d199.s2|64-71|patients|O
DDI-MedLine.d199.s2|73-75|who|O
DDI-MedLine.d199.s2|77-84|received|O
DDI-MedLine.d199.s2|86-93|low-dose|O
DDI-MedLine.d199.s2|95-102|ketamine|drug
DDI-MedLine.d199.s2|104-105|in|O
DDI-MedLine.d199.s2|107-117|conjunction|O
DDI-MedLine.d199.s2|119-122|with|O
DDI-MedLine.d199.s2|124-131|propofol|drug
DDI-MedLine.d199.s2|133-135|for|O
DDI-MedLine.d199.s2|137-141|total|O
DDI-MedLine.d199.s2|143-153|intravenous|O
DDI-MedLine.d199.s2|155-164|anesthesia|O
DDI-MedLine.d199.s2|166-166|(|O
DDI-MedLine.d199.s2|167-170|TIVA|O
DDI-MedLine.d199.s2|171-171|)|O
DDI-MedLine.d199.s2|173-182|repeatedly|O
DDI-MedLine.d199.s2|184-186|for|O
DDI-MedLine.d199.s2|188-196|radiation|O
DDI-MedLine.d199.s2|198-204|therapy|O
DDI-MedLine.d199.s2|205-205|.|O
DDI-MedLine.d199.s3|0-1|EA|O
DDI-MedLine.d199.s3|3-7|signs|O
DDI-MedLine.d199.s3|9-12|were|O
DDI-MedLine.d199.s3|14-21|observed|O
DDI-MedLine.d199.s3|23-24|in|O
DDI-MedLine.d199.s3|26-28|all|O
DDI-MedLine.d199.s3|30-30|7|O
DDI-MedLine.d199.s3|32-39|patients|O
DDI-MedLine.d199.s3|41-42|in|O
DDI-MedLine.d199.s3|44-54|association|O
DDI-MedLine.d199.s3|56-59|with|O
DDI-MedLine.d199.s3|61-68|propofol|drug
DDI-MedLine.d199.s3|70-73|TIVA|O
DDI-MedLine.d199.s3|75-77|but|O
DDI-MedLine.d199.s3|79-81|did|O
DDI-MedLine.d199.s3|83-85|not|O
DDI-MedLine.d199.s3|87-91|recur|O
DDI-MedLine.d199.s3|93-94|in|O
DDI-MedLine.d199.s3|96-98|any|O
DDI-MedLine.d199.s3|100-101|of|O
DDI-MedLine.d199.s3|103-105|123|O
DDI-MedLine.d199.s3|107-116|subsequent|O
DDI-MedLine.d199.s3|118-128|anesthetics|O
DDI-MedLine.d199.s3|130-137|sessions|O
DDI-MedLine.d199.s3|139-144|during|O
DDI-MedLine.d199.s3|146-150|which|O
DDI-MedLine.d199.s3|152-159|low-dose|O
DDI-MedLine.d199.s3|161-168|ketamine|drug
DDI-MedLine.d199.s3|170-172|was|O
DDI-MedLine.d199.s3|174-178|added|O
DDI-MedLine.d199.s3|180-181|to|O
DDI-MedLine.d199.s3|183-190|propofol|drug
DDI-MedLine.d199.s3|191-191|.|O
DDI-MedLine.d199.s4|0-4|Based|O
DDI-MedLine.d199.s4|6-7|on|O
DDI-MedLine.d199.s4|9-12|this|O
DDI-MedLine.d199.s4|14-23|experience|O
DDI-MedLine.d199.s4|24-24|,|O
DDI-MedLine.d199.s4|26-27|we|O
DDI-MedLine.d199.s4|29-35|suggest|O
DDI-MedLine.d199.s4|37-40|that|O
DDI-MedLine.d199.s4|42-49|low-dose|O
DDI-MedLine.d199.s4|51-58|ketamine|drug
DDI-MedLine.d199.s4|60-64|added|O
DDI-MedLine.d199.s4|66-67|to|O
DDI-MedLine.d199.s4|69-76|propofol|drug
DDI-MedLine.d199.s4|78-80|may|O
DDI-MedLine.d199.s4|82-83|be|O
DDI-MedLine.d199.s4|85-94|associated|O
DDI-MedLine.d199.s4|96-99|with|O
DDI-MedLine.d199.s4|101-110|prevention|O
DDI-MedLine.d199.s4|112-113|of|O
DDI-MedLine.d199.s4|115-116|EA|O
DDI-MedLine.d199.s4|118-119|in|O
DDI-MedLine.d199.s4|121-128|children|O
DDI-MedLine.d199.s4|130-133|with|O
DDI-MedLine.d199.s4|135-135|a|O
DDI-MedLine.d199.s4|137-143|history|O
DDI-MedLine.d199.s4|145-146|of|O
DDI-MedLine.d199.s4|148-149|EA|O
DDI-MedLine.d199.s4|151-154|with|O
DDI-MedLine.d199.s4|156-163|propofol|drug
DDI-MedLine.d199.s4|165-168|TIVA|O
DDI-MedLine.d199.s4|169-169|.|O
DDI-MedLine.d15.s0|0-0|[|O
DDI-MedLine.d15.s0|1-11|Stimulation|O
DDI-MedLine.d15.s0|13-14|by|O
DDI-MedLine.d15.s0|24-25|--|O
DDI-MedLine.d15.s0|26-27|an|O
DDI-MedLine.d15.s0|29-34|analog|O
DDI-MedLine.d15.s0|36-37|of|O
DDI-MedLine.d15.s0|39-41|the|O
DDI-MedLine.d15.s0|43-53|octapeptide|O
DDI-MedLine.d15.s0|55-69|cholecystokinin|O
DDI-MedLine.d15.s0|70-71|--|O
DDI-MedLine.d15.s0|72-73|of|O
DDI-MedLine.d15.s0|91-97|binding|O
DDI-MedLine.d15.s0|99-103|after|O
DDI-MedLine.d15.s0|105-107|the|O
DDI-MedLine.d15.s0|109-117|long-term|O
DDI-MedLine.d15.s0|119-132|administration|O
DDI-MedLine.d15.s0|134-135|of|O
DDI-MedLine.d15.s0|137-148|neuroleptics|group
DDI-MedLine.d15.s0|149-149|]|O
DDI-MedLine.d15.s0|152-153|It|O
DDI-MedLine.d15.s0|155-157|has|O
DDI-MedLine.d15.s0|159-162|been|O
DDI-MedLine.d15.s0|164-174|established|O
DDI-MedLine.d15.s0|176-177|in|O
DDI-MedLine.d15.s0|179-189|experiments|O
DDI-MedLine.d15.s0|191-192|on|O
DDI-MedLine.d15.s0|194-198|white|O
DDI-MedLine.d15.s0|200-203|male|O
DDI-MedLine.d15.s0|205-208|rats|O
DDI-MedLine.d15.s0|210-213|that|O
DDI-MedLine.d15.s0|215-223|prolonged|O
DDI-MedLine.d15.s0|225-238|administration|O
DDI-MedLine.d15.s0|240-240|(|O
DDI-MedLine.d15.s0|241-245|twice|O
DDI-MedLine.d15.s0|247-247|a|O
DDI-MedLine.d15.s0|249-251|day|O
DDI-MedLine.d15.s0|253-255|for|O
DDI-MedLine.d15.s0|257-258|14|O
DDI-MedLine.d15.s0|260-263|days|O
DDI-MedLine.d15.s0|264-264|)|O
DDI-MedLine.d15.s0|266-267|of|O
DDI-MedLine.d15.s0|269-279|haloperidol|drug
DDI-MedLine.d15.s0|281-281|(|O
DDI-MedLine.d15.s0|282-285|0.25|O
DDI-MedLine.d15.s0|287-291|mg/kg|O
DDI-MedLine.d15.s0|292-292|)|O
DDI-MedLine.d15.s0|294-296|and|O
DDI-MedLine.d15.s0|311-311|(|O
DDI-MedLine.d15.s0|312-315|0.25|O
DDI-MedLine.d15.s0|317-321|mg/kg|O
DDI-MedLine.d15.s0|322-322|)|O
DDI-MedLine.d15.s0|324-331|resulted|O
DDI-MedLine.d15.s0|333-334|in|O
DDI-MedLine.d15.s0|336-338|the|O
DDI-MedLine.d15.s0|340-346|reduced|O
DDI-MedLine.d15.s0|348-358|interaction|O
DDI-MedLine.d15.s0|360-366|between|O
DDI-MedLine.d15.s0|384-386|and|O
DDI-MedLine.d15.s0|388-390|low|O
DDI-MedLine.d15.s0|392-399|affinity|O
DDI-MedLine.d15.s0|401-407|binding|O
DDI-MedLine.d15.s0|409-413|sites|O
DDI-MedLine.d15.s0|415-417|for|O
DDI-MedLine.d15.s0|419-429|apomorphine|drug
DDI-MedLine.d15.s0|431-432|in|O
DDI-MedLine.d15.s0|434-444|subcortical|O
DDI-MedLine.d15.s0|446-455|structures|O
DDI-MedLine.d15.s0|456-456|,|O
DDI-MedLine.d15.s0|458-464|whereas|O
DDI-MedLine.d15.s0|482-488|binding|O
DDI-MedLine.d15.s0|490-493|with|O
DDI-MedLine.d15.s0|495-498|high|O
DDI-MedLine.d15.s0|500-507|affinity|O
DDI-MedLine.d15.s0|509-515|binding|O
DDI-MedLine.d15.s0|517-521|sites|O
DDI-MedLine.d15.s0|523-525|for|O
DDI-MedLine.d15.s0|527-537|apomorphine|drug
DDI-MedLine.d15.s0|539-547|increased|O
DDI-MedLine.d15.s0|549-552|both|O
DDI-MedLine.d15.s0|554-555|in|O
DDI-MedLine.d15.s0|557-559|the|O
DDI-MedLine.d15.s0|561-567|frontal|O
DDI-MedLine.d15.s0|569-574|cortex|O
DDI-MedLine.d15.s0|576-578|and|O
DDI-MedLine.d15.s0|580-590|subcortical|O
DDI-MedLine.d15.s0|592-601|structures|O
DDI-MedLine.d15.s0|603-604|of|O
DDI-MedLine.d15.s0|606-608|the|O
DDI-MedLine.d15.s0|610-618|forebrain|O
DDI-MedLine.d15.s0|619-619|.|O
DDI-MedLine.d15.s1|0-4|After|O
DDI-MedLine.d15.s1|6-14|prolonged|O
DDI-MedLine.d15.s1|16-29|administration|O
DDI-MedLine.d15.s1|31-32|of|O
DDI-MedLine.d15.s1|34-45|neuroleptics|group
DDI-MedLine.d15.s1|47-49|the|O
DDI-MedLine.d15.s1|51-60|displacing|O
DDI-MedLine.d15.s1|62-67|effect|O
DDI-MedLine.d15.s1|69-70|of|O
DDI-MedLine.d15.s1|80-80|,|O
DDI-MedLine.d15.s1|82-83|an|O
DDI-MedLine.d15.s1|85-90|analog|O
DDI-MedLine.d15.s1|92-93|of|O
DDI-MedLine.d15.s1|95-109|cholecystokinin|O
DDI-MedLine.d15.s1|111-121|octapeptide|O
DDI-MedLine.d15.s1|122-122|,|O
DDI-MedLine.d15.s1|124-126|was|O
DDI-MedLine.d15.s1|128-135|replaced|O
DDI-MedLine.d15.s1|137-138|by|O
DDI-MedLine.d15.s1|140-142|the|O
DDI-MedLine.d15.s1|144-152|stimulant|O
DDI-MedLine.d15.s1|154-159|action|O
DDI-MedLine.d15.s1|161-162|on|O
DDI-MedLine.d15.s1|180-186|binding|O
DDI-MedLine.d15.s1|187-187|.|O
DDI-MedLine.d15.s2|0-1|It|O
DDI-MedLine.d15.s2|3-4|is|O
DDI-MedLine.d15.s2|6-12|assumed|O
DDI-MedLine.d15.s2|14-17|that|O
DDI-MedLine.d15.s2|19-27|increased|O
DDI-MedLine.d15.s2|29-39|interaction|O
DDI-MedLine.d15.s2|41-47|between|O
DDI-MedLine.d15.s2|65-67|and|O
DDI-MedLine.d15.s2|69-72|high|O
DDI-MedLine.d15.s2|74-81|affinity|O
DDI-MedLine.d15.s2|83-89|binding|O
DDI-MedLine.d15.s2|91-95|sites|O
DDI-MedLine.d15.s2|97-99|for|O
DDI-MedLine.d15.s2|101-111|apomorphine|drug
DDI-MedLine.d15.s2|113-114|on|O
DDI-MedLine.d15.s2|116-125|dopamine2-|O
DDI-MedLine.d15.s2|127-129|and|O
DDI-MedLine.d15.s2|131-150|serotonin2-receptors|O
DDI-MedLine.d15.s2|152-160|underlies|O
DDI-MedLine.d15.s2|162-164|the|O
DDI-MedLine.d15.s2|166-178|antipsychotic|O
DDI-MedLine.d15.s2|180-185|action|O
DDI-MedLine.d15.s2|187-188|of|O
DDI-MedLine.d15.s2|190-201|neuroleptics|group
DDI-MedLine.d15.s2|203-207|after|O
DDI-MedLine.d15.s2|209-213|their|O
DDI-MedLine.d15.s2|215-223|prolonged|O
DDI-MedLine.d15.s2|225-238|administration|O
DDI-MedLine.d15.s2|239-239|.|O
DDI-MedLine.d15.s3|0-14|Cholecystokinin|O
DDI-MedLine.d15.s3|16-26|octapeptide|O
DDI-MedLine.d15.s3|28-29|is|O
DDI-MedLine.d15.s3|31-31|a|O
DDI-MedLine.d15.s3|33-41|necessary|O
DDI-MedLine.d15.s3|43-48|factor|O
DDI-MedLine.d15.s3|50-52|for|O
DDI-MedLine.d15.s3|54-64|realization|O
DDI-MedLine.d15.s3|66-67|of|O
DDI-MedLine.d15.s3|69-72|this|O
DDI-MedLine.d15.s3|74-79|action|O
DDI-MedLine.d15.s3|81-82|of|O
DDI-MedLine.d15.s3|84-95|neuroleptics|group
DDI-MedLine.d15.s3|96-96|.|O
DDI-DrugBank.d717.s0|0-7|Mitotane|drug
DDI-DrugBank.d717.s0|9-11|has|O
DDI-DrugBank.d717.s0|13-16|been|O
DDI-DrugBank.d717.s0|18-25|reported|O
DDI-DrugBank.d717.s0|27-28|to|O
DDI-DrugBank.d717.s0|30-39|accelerate|O
DDI-DrugBank.d717.s0|41-43|the|O
DDI-DrugBank.d717.s0|45-54|metabolism|O
DDI-DrugBank.d717.s0|56-57|of|O
DDI-DrugBank.d717.s0|59-66|warfarin|drug
DDI-DrugBank.d717.s0|68-69|by|O
DDI-DrugBank.d717.s0|71-73|the|O
DDI-DrugBank.d717.s0|75-83|mechanism|O
DDI-DrugBank.d717.s0|85-86|of|O
DDI-DrugBank.d717.s0|88-94|hepatic|O
DDI-DrugBank.d717.s0|96-105|microsomal|O
DDI-DrugBank.d717.s0|107-112|enzyme|O
DDI-DrugBank.d717.s0|114-122|induction|O
DDI-DrugBank.d717.s0|123-123|,|O
DDI-DrugBank.d717.s0|125-131|leading|O
DDI-DrugBank.d717.s0|133-134|to|O
DDI-DrugBank.d717.s0|136-137|an|O
DDI-DrugBank.d717.s0|139-146|increase|O
DDI-DrugBank.d717.s0|148-149|in|O
DDI-DrugBank.d717.s0|151-156|dosage|O
DDI-DrugBank.d717.s0|158-169|requirements|O
DDI-DrugBank.d717.s0|171-173|for|O
DDI-DrugBank.d717.s0|175-182|warfarin|drug
DDI-DrugBank.d717.s0|183-183|.|O
DDI-DrugBank.d717.s1|0-8|Therefore|O
DDI-DrugBank.d717.s1|9-9|,|O
DDI-DrugBank.d717.s1|11-20|physicians|O
DDI-DrugBank.d717.s1|22-27|should|O
DDI-DrugBank.d717.s1|29-35|closely|O
DDI-DrugBank.d717.s1|37-43|monitor|O
DDI-DrugBank.d717.s1|45-52|patients|O
DDI-DrugBank.d717.s1|54-56|for|O
DDI-DrugBank.d717.s1|58-58|a|O
DDI-DrugBank.d717.s1|60-65|change|O
DDI-DrugBank.d717.s1|67-68|in|O
DDI-DrugBank.d717.s1|70-82|anticoagulant|group
DDI-DrugBank.d717.s1|84-89|dosage|O
DDI-DrugBank.d717.s1|91-102|requirements|O
DDI-DrugBank.d717.s1|104-107|when|O
DDI-DrugBank.d717.s1|109-121|administering|O
DDI-DrugBank.d717.s1|123-130|Mitotane|drug
DDI-DrugBank.d717.s1|132-133|to|O
DDI-DrugBank.d717.s1|135-142|patients|O
DDI-DrugBank.d717.s1|144-145|on|O
DDI-DrugBank.d717.s1|147-174|coumarin-type anticoagulants|group
DDI-DrugBank.d717.s1|175-175|.|O
DDI-DrugBank.d717.s2|0-1|In|O
DDI-DrugBank.d717.s2|3-10|addition|O
DDI-DrugBank.d717.s2|11-11|,|O
DDI-DrugBank.d717.s2|13-20|Mitotane|drug
DDI-DrugBank.d717.s2|22-27|should|O
DDI-DrugBank.d717.s2|29-30|be|O
DDI-DrugBank.d717.s2|32-36|given|O
DDI-DrugBank.d717.s2|38-41|with|O
DDI-DrugBank.d717.s2|43-49|caution|O
DDI-DrugBank.d717.s2|51-52|to|O
DDI-DrugBank.d717.s2|54-61|patients|O
DDI-DrugBank.d717.s2|63-71|receiving|O
DDI-DrugBank.d717.s2|73-77|other|O
DDI-DrugBank.d717.s2|79-83|drugs|O
DDI-DrugBank.d717.s2|85-95|susceptible|O
DDI-DrugBank.d717.s2|97-98|to|O
DDI-DrugBank.d717.s2|100-102|the|O
DDI-DrugBank.d717.s2|104-112|influence|O
DDI-DrugBank.d717.s2|114-115|of|O
DDI-DrugBank.d717.s2|117-123|hepatic|O
DDI-DrugBank.d717.s2|125-130|enzyme|O
DDI-DrugBank.d717.s2|132-140|induction|O
DDI-DrugBank.d717.s2|141-141|.|O
DDI-DrugBank.d310.s0|0-1|It|O
DDI-DrugBank.d310.s0|3-4|is|O
DDI-DrugBank.d310.s0|6-13|possible|O
DDI-DrugBank.d310.s0|15-18|that|O
DDI-DrugBank.d310.s0|20-22|the|O
DDI-DrugBank.d310.s0|24-37|cardiovascular|O
DDI-DrugBank.d310.s0|39-44|action|O
DDI-DrugBank.d310.s0|46-47|of|O
DDI-DrugBank.d310.s0|49-53|other|O
DDI-DrugBank.d310.s0|55-78|calcium channel blockers|group
DDI-DrugBank.d310.s0|80-84|could|O
DDI-DrugBank.d310.s0|86-87|be|O
DDI-DrugBank.d310.s0|89-96|enhanced|O
DDI-DrugBank.d310.s0|98-99|by|O
DDI-DrugBank.d310.s0|101-103|the|O
DDI-DrugBank.d310.s0|105-112|addition|O
DDI-DrugBank.d310.s0|114-115|of|O
DDI-DrugBank.d310.s0|117-123|Nimotop|brand
DDI-DrugBank.d310.s0|125-125|.|O
DDI-DrugBank.d310.s1|0-1|In|O
DDI-DrugBank.d310.s1|3-8|Europe|O
DDI-DrugBank.d310.s1|9-9|,|O
DDI-DrugBank.d310.s1|11-17|Nimotop|brand
DDI-DrugBank.d310.s1|20-22|was|O
DDI-DrugBank.d310.s1|24-31|observed|O
DDI-DrugBank.d310.s1|33-34|to|O
DDI-DrugBank.d310.s1|36-47|occasionally|O
DDI-DrugBank.d310.s1|49-57|intensify|O
DDI-DrugBank.d310.s1|59-61|the|O
DDI-DrugBank.d310.s1|63-68|effect|O
DDI-DrugBank.d310.s1|70-71|of|O
DDI-DrugBank.d310.s1|73-98|antihypertensive compounds|group
DDI-DrugBank.d310.s1|100-104|taken|O
DDI-DrugBank.d310.s1|106-118|concomitantly|O
DDI-DrugBank.d310.s1|120-121|by|O
DDI-DrugBank.d310.s1|123-130|patients|O
DDI-DrugBank.d310.s1|132-140|suffering|O
DDI-DrugBank.d310.s1|142-145|from|O
DDI-DrugBank.d310.s1|147-158|hypertension|O
DDI-DrugBank.d310.s1|159-159|;|O
DDI-DrugBank.d310.s2|0-3|this|O
DDI-DrugBank.d310.s2|5-14|phenomenon|O
DDI-DrugBank.d310.s2|16-18|was|O
DDI-DrugBank.d310.s2|20-22|not|O
DDI-DrugBank.d310.s2|24-31|observed|O
DDI-DrugBank.d310.s2|33-34|in|O
DDI-DrugBank.d310.s2|36-40|North|O
DDI-DrugBank.d310.s2|42-49|American|O
DDI-DrugBank.d310.s2|51-58|clinical|O
DDI-DrugBank.d310.s2|60-65|trials|O
DDI-DrugBank.d310.s2|66-66|.|O
DDI-DrugBank.d310.s3|0-0|A|O
DDI-DrugBank.d310.s3|2-6|study|O
DDI-DrugBank.d310.s3|8-9|in|O
DDI-DrugBank.d310.s3|11-15|eight|O
DDI-DrugBank.d310.s3|17-23|healthy|O
DDI-DrugBank.d310.s3|25-34|volunteers|O
DDI-DrugBank.d310.s3|36-38|has|O
DDI-DrugBank.d310.s3|40-44|shown|O
DDI-DrugBank.d310.s3|46-46|a|O
DDI-DrugBank.d310.s3|48-49|50|O
DDI-DrugBank.d310.s3|50-50|%|O
DDI-DrugBank.d310.s3|52-59|increase|O
DDI-DrugBank.d310.s3|61-62|in|O
DDI-DrugBank.d310.s3|64-67|mean|O
DDI-DrugBank.d310.s3|69-72|peak|O
DDI-DrugBank.d310.s3|74-83|nimodipine|drug
DDI-DrugBank.d310.s3|85-90|plasma|O
DDI-DrugBank.d310.s3|92-105|concentrations|O
DDI-DrugBank.d310.s3|107-109|and|O
DDI-DrugBank.d310.s3|111-111|a|O
DDI-DrugBank.d310.s3|113-114|90|O
DDI-DrugBank.d310.s3|115-115|%|O
DDI-DrugBank.d310.s3|117-124|increase|O
DDI-DrugBank.d310.s3|126-127|in|O
DDI-DrugBank.d310.s3|129-132|mean|O
DDI-DrugBank.d310.s3|134-137|area|O
DDI-DrugBank.d310.s3|139-143|under|O
DDI-DrugBank.d310.s3|145-147|the|O
DDI-DrugBank.d310.s3|149-153|curve|O
DDI-DrugBank.d310.s3|154-154|,|O
DDI-DrugBank.d310.s3|156-160|after|O
DDI-DrugBank.d310.s3|162-162|a|O
DDI-DrugBank.d310.s3|164-166|one|O
DDI-DrugBank.d310.s3|168-171|week|O
DDI-DrugBank.d310.s3|173-178|course|O
DDI-DrugBank.d310.s3|180-181|of|O
DDI-DrugBank.d310.s3|183-192|cimetidine|drug
DDI-DrugBank.d310.s3|194-195|at|O
DDI-DrugBank.d310.s3|197-201|1,000|O
DDI-DrugBank.d310.s3|203-208|mg/day|O
DDI-DrugBank.d310.s3|210-212|and|O
DDI-DrugBank.d310.s3|214-223|nimodipine|drug
DDI-DrugBank.d310.s3|225-226|at|O
DDI-DrugBank.d310.s3|228-229|90|O
DDI-DrugBank.d310.s3|231-236|mg/day|O
DDI-DrugBank.d310.s3|237-237|.|O
DDI-DrugBank.d310.s4|0-3|This|O
DDI-DrugBank.d310.s4|5-10|effect|O
DDI-DrugBank.d310.s4|12-14|may|O
DDI-DrugBank.d310.s4|16-17|be|O
DDI-DrugBank.d310.s4|19-26|mediated|O
DDI-DrugBank.d310.s4|28-29|by|O
DDI-DrugBank.d310.s4|31-33|the|O
DDI-DrugBank.d310.s4|35-39|known|O
DDI-DrugBank.d310.s4|41-50|inhibition|O
DDI-DrugBank.d310.s4|52-53|of|O
DDI-DrugBank.d310.s4|55-61|hepatic|O
DDI-DrugBank.d310.s4|63-72|cytochrome|O
DDI-DrugBank.d310.s4|74-75|P-|O
DDI-DrugBank.d310.s4|77-79|450|O
DDI-DrugBank.d310.s4|81-82|by|O
DDI-DrugBank.d310.s4|84-93|cimetidine|drug
DDI-DrugBank.d310.s4|94-94|,|O
DDI-DrugBank.d310.s4|96-100|which|O
DDI-DrugBank.d310.s4|102-106|could|O
DDI-DrugBank.d310.s4|108-115|decrease|O
DDI-DrugBank.d310.s4|117-121|first|O
DDI-DrugBank.d310.s4|123-126|pass|O
DDI-DrugBank.d310.s4|128-137|metabolism|O
DDI-DrugBank.d310.s4|139-140|of|O
DDI-DrugBank.d310.s4|142-151|nimodipine|drug
DDI-DrugBank.d310.s4|152-152|.|O
DDI-DrugBank.d598.s0|0-11|Trimethoprim|drug
DDI-DrugBank.d598.s0|13-15|may|O
DDI-DrugBank.d598.s0|17-23|inhibit|O
DDI-DrugBank.d598.s0|25-27|the|O
DDI-DrugBank.d598.s0|29-35|hepatic|O
DDI-DrugBank.d598.s0|37-46|metabolism|O
DDI-DrugBank.d598.s0|48-49|of|O
DDI-DrugBank.d598.s0|51-59|phenytoin|drug
DDI-DrugBank.d598.s0|60-60|.|O
DDI-DrugBank.d598.s1|0-11|Trimethoprim|drug
DDI-DrugBank.d598.s1|12-12|,|O
DDI-DrugBank.d598.s1|14-18|given|O
DDI-DrugBank.d598.s1|20-21|at|O
DDI-DrugBank.d598.s1|23-23|a|O
DDI-DrugBank.d598.s1|25-30|common|O
DDI-DrugBank.d598.s1|32-39|clinical|O
DDI-DrugBank.d598.s1|41-46|dosage|O
DDI-DrugBank.d598.s1|47-47|,|O
DDI-DrugBank.d598.s1|49-57|increased|O
DDI-DrugBank.d598.s1|59-61|the|O
DDI-DrugBank.d598.s1|63-71|phenytoin|drug
DDI-DrugBank.d598.s1|73-81|half-life|O
DDI-DrugBank.d598.s1|83-84|by|O
DDI-DrugBank.d598.s1|86-87|51|O
DDI-DrugBank.d598.s1|88-88|%|O
DDI-DrugBank.d598.s1|90-92|and|O
DDI-DrugBank.d598.s1|94-102|decreased|O
DDI-DrugBank.d598.s1|104-106|the|O
DDI-DrugBank.d598.s1|108-116|phenytoin|drug
DDI-DrugBank.d598.s1|118-126|metabolic|O
DDI-DrugBank.d598.s1|128-136|clearance|O
DDI-DrugBank.d598.s1|138-141|rate|O
DDI-DrugBank.d598.s1|143-144|by|O
DDI-DrugBank.d598.s1|146-147|30|O
DDI-DrugBank.d598.s1|148-148|%|O
DDI-DrugBank.d598.s1|149-149|.|O
DDI-DrugBank.d598.s2|0-3|When|O
DDI-DrugBank.d598.s2|5-17|administering|O
DDI-DrugBank.d598.s2|19-23|these|O
DDI-DrugBank.d598.s2|25-29|drugs|O
DDI-DrugBank.d598.s2|31-42|concurrently|O
DDI-DrugBank.d598.s2|43-43|,|O
DDI-DrugBank.d598.s2|45-47|one|O
DDI-DrugBank.d598.s2|49-54|should|O
DDI-DrugBank.d598.s2|56-57|be|O
DDI-DrugBank.d598.s2|59-63|alert|O
DDI-DrugBank.d598.s2|65-67|for|O
DDI-DrugBank.d598.s2|69-76|possible|O
DDI-DrugBank.d598.s2|78-86|excessive|O
DDI-DrugBank.d598.s2|88-96|phenytoin|drug
DDI-DrugBank.d598.s2|98-103|effect|O
DDI-DrugBank.d598.s2|104-104|.|O
DDI-DrugBank.d91.s0|0-4|Other|O
DDI-DrugBank.d91.s0|6-14|medicines|O
DDI-DrugBank.d91.s0|16-16|-|O
DDI-DrugBank.d91.s0|18-25|Although|O
DDI-DrugBank.d91.s0|27-33|certain|O
DDI-DrugBank.d91.s0|35-43|medicines|O
DDI-DrugBank.d91.s0|45-50|should|O
DDI-DrugBank.d91.s0|52-54|not|O
DDI-DrugBank.d91.s0|56-57|be|O
DDI-DrugBank.d91.s0|59-62|used|O
DDI-DrugBank.d91.s0|64-71|together|O
DDI-DrugBank.d91.s0|73-74|at|O
DDI-DrugBank.d91.s0|76-78|all|O
DDI-DrugBank.d91.s0|79-79|,|O
DDI-DrugBank.d91.s0|81-82|in|O
DDI-DrugBank.d91.s0|84-88|other|O
DDI-DrugBank.d91.s0|90-94|cases|O
DDI-DrugBank.d91.s0|96-98|two|O
DDI-DrugBank.d91.s0|100-108|different|O
DDI-DrugBank.d91.s0|110-118|medicines|O
DDI-DrugBank.d91.s0|120-122|may|O
DDI-DrugBank.d91.s0|124-125|be|O
DDI-DrugBank.d91.s0|127-130|used|O
DDI-DrugBank.d91.s0|132-139|together|O
DDI-DrugBank.d91.s0|141-144|even|O
DDI-DrugBank.d91.s0|146-147|if|O
DDI-DrugBank.d91.s0|149-150|an|O
DDI-DrugBank.d91.s0|152-162|interaction|O
DDI-DrugBank.d91.s0|164-168|might|O
DDI-DrugBank.d91.s0|170-174|occur|O
DDI-DrugBank.d91.s0|175-175|.|O
DDI-DrugBank.d91.s1|0-1|In|O
DDI-DrugBank.d91.s1|3-7|these|O
DDI-DrugBank.d91.s1|9-13|cases|O
DDI-DrugBank.d91.s1|14-14|,|O
DDI-DrugBank.d91.s1|16-19|your|O
DDI-DrugBank.d91.s1|21-26|doctor|O
DDI-DrugBank.d91.s1|28-30|may|O
DDI-DrugBank.d91.s1|32-35|want|O
DDI-DrugBank.d91.s1|37-38|to|O
DDI-DrugBank.d91.s1|40-45|change|O
DDI-DrugBank.d91.s1|47-49|the|O
DDI-DrugBank.d91.s1|51-54|dose|O
DDI-DrugBank.d91.s1|55-55|,|O
DDI-DrugBank.d91.s1|57-58|or|O
DDI-DrugBank.d91.s1|60-64|other|O
DDI-DrugBank.d91.s1|66-76|precautions|O
DDI-DrugBank.d91.s1|78-80|may|O
DDI-DrugBank.d91.s1|82-83|be|O
DDI-DrugBank.d91.s1|85-93|necessary|O
DDI-DrugBank.d91.s1|94-94|.|O
DDI-DrugBank.d91.s2|0-3|When|O
DDI-DrugBank.d91.s2|5-7|you|O
DDI-DrugBank.d91.s2|9-11|are|O
DDI-DrugBank.d91.s2|13-17|using|O
DDI-DrugBank.d91.s2|19-29|idoxuridine|drug
DDI-DrugBank.d91.s2|30-30|,|O
DDI-DrugBank.d91.s2|32-33|it|O
DDI-DrugBank.d91.s2|35-36|is|O
DDI-DrugBank.d91.s2|38-47|especially|O
DDI-DrugBank.d91.s2|49-57|important|O
DDI-DrugBank.d91.s2|59-62|that|O
DDI-DrugBank.d91.s2|64-67|your|O
DDI-DrugBank.d91.s2|69-74|health|O
DDI-DrugBank.d91.s2|76-79|care|O
DDI-DrugBank.d91.s2|81-92|professional|O
DDI-DrugBank.d91.s2|94-97|know|O
DDI-DrugBank.d91.s2|99-100|if|O
DDI-DrugBank.d91.s2|102-104|you|O
DDI-DrugBank.d91.s2|106-108|are|O
DDI-DrugBank.d91.s2|110-114|using|O
DDI-DrugBank.d91.s2|116-118|the|O
DDI-DrugBank.d91.s2|120-128|following|O
DDI-DrugBank.d91.s2|129-129|:|O
DDI-DrugBank.d91.s2|131-133|Eye|O
DDI-DrugBank.d91.s2|135-141|product|O
DDI-DrugBank.d91.s2|143-152|containing|O
DDI-DrugBank.d91.s2|154-163|boric acid|drug
DDI-DrugBank.d91.s2|164-164|.|O
DDI-DrugBank.d91.s3|0-9|Boric acid|drug
DDI-DrugBank.d91.s3|11-13|may|O
DDI-DrugBank.d91.s3|15-22|interact|O
DDI-DrugBank.d91.s3|24-27|with|O
DDI-DrugBank.d91.s3|29-31|the|O
DDI-DrugBank.d91.s3|33-43|idoxuridine|drug
DDI-DrugBank.d91.s3|45-55|preparation|O
DDI-DrugBank.d91.s3|57-63|causing|O
DDI-DrugBank.d91.s3|65-65|a|O
DDI-DrugBank.d91.s3|67-72|gritty|O
DDI-DrugBank.d91.s3|74-82|substance|O
DDI-DrugBank.d91.s3|84-85|to|O
DDI-DrugBank.d91.s3|87-90|form|O
DDI-DrugBank.d91.s3|92-93|or|O
DDI-DrugBank.d91.s3|95-97|may|O
DDI-DrugBank.d91.s3|99-106|interact|O
DDI-DrugBank.d91.s3|108-111|with|O
DDI-DrugBank.d91.s3|113-115|the|O
DDI-DrugBank.d91.s3|117-128|preservative|O
DDI-DrugBank.d91.s3|130-131|in|O
DDI-DrugBank.d91.s3|133-135|the|O
DDI-DrugBank.d91.s3|137-147|idoxuridine|drug
DDI-DrugBank.d91.s3|149-159|preparation|O
DDI-DrugBank.d91.s3|161-167|causing|O
DDI-DrugBank.d91.s3|169-169|a|O
DDI-DrugBank.d91.s3|171-175|toxic|O
DDI-DrugBank.d91.s3|177-182|effect|O
DDI-DrugBank.d91.s3|184-185|in|O
DDI-DrugBank.d91.s3|187-189|the|O
DDI-DrugBank.d91.s3|191-193|eye|O
DDI-DrugBank.d91.s3|194-194|.|O
DDI-DrugBank.d484.s0|0-11|Etonogestrel|drug
DDI-DrugBank.d484.s0|13-15|may|O
DDI-DrugBank.d484.s0|17-24|interact|O
DDI-DrugBank.d484.s0|26-29|with|O
DDI-DrugBank.d484.s0|31-33|the|O
DDI-DrugBank.d484.s0|35-43|following|O
DDI-DrugBank.d484.s0|45-55|medications|O
DDI-DrugBank.d484.s0|56-56|:|O
DDI-DrugBank.d484.s0|58-70|acetaminophen|drug
DDI-DrugBank.d484.s0|72-72|(|O
DDI-DrugBank.d484.s0|73-79|Tylenol|brand
DDI-DrugBank.d484.s0|80-80|)|O
DDI-DrugBank.d484.s0|81-81|,|O
DDI-DrugBank.d484.s0|83-93|antibiotics|group
DDI-DrugBank.d484.s0|95-98|such|O
DDI-DrugBank.d484.s0|100-101|as|O
DDI-DrugBank.d484.s0|103-112|ampicillin|drug
DDI-DrugBank.d484.s0|114-116|and|O
DDI-DrugBank.d484.s0|118-129|tetracycline|drug
DDI-DrugBank.d484.s0|130-130|,|O
DDI-DrugBank.d484.s0|132-146|anticonvulsants|group
DDI-DrugBank.d484.s0|148-148|(|O
DDI-DrugBank.d484.s0|149-156|Dilantin|brand
DDI-DrugBank.d484.s0|157-157|,|O
DDI-DrugBank.d484.s0|159-171|Phenobarbital|drug
DDI-DrugBank.d484.s0|172-172|,|O
DDI-DrugBank.d484.s0|174-181|Tegretol|brand
DDI-DrugBank.d484.s0|182-182|,|O
DDI-DrugBank.d484.s0|184-192|Trileptal|brand
DDI-DrugBank.d484.s0|193-193|,|O
DDI-DrugBank.d484.s0|195-201|Topamax|brand
DDI-DrugBank.d484.s0|202-202|,|O
DDI-DrugBank.d484.s0|204-211|Felbatol|brand
DDI-DrugBank.d484.s0|212-212|)|O
DDI-DrugBank.d484.s0|213-213|,|O
DDI-DrugBank.d484.s0|215-225|antifungals|group
DDI-DrugBank.d484.s0|227-227|(|O
DDI-DrugBank.d484.s0|228-235|Gris-PEG|brand
DDI-DrugBank.d484.s0|236-236|,|O
DDI-DrugBank.d484.s0|238-244|Nizoral|brand
DDI-DrugBank.d484.s0|245-245|,|O
DDI-DrugBank.d484.s0|247-254|Sporanox|brand
DDI-DrugBank.d484.s0|255-255|)|O
DDI-DrugBank.d484.s0|256-256|,|O
DDI-DrugBank.d484.s0|258-269|atorvastatin|drug
DDI-DrugBank.d484.s0|271-271|(|O
DDI-DrugBank.d484.s0|272-278|Lipitor|brand
DDI-DrugBank.d484.s0|279-279|)|O
DDI-DrugBank.d484.s0|280-280|,|O
DDI-DrugBank.d484.s0|282-291|clofibrate|drug
DDI-DrugBank.d484.s0|293-293|(|O
DDI-DrugBank.d484.s0|294-302|Atromid-S|brand
DDI-DrugBank.d484.s0|303-303|)|O
DDI-DrugBank.d484.s0|304-304|,|O
DDI-DrugBank.d484.s0|306-317|cyclosporine|drug
DDI-DrugBank.d484.s0|319-319|(|O
DDI-DrugBank.d484.s0|320-325|Neoral|brand
DDI-DrugBank.d484.s0|326-326|,|O
DDI-DrugBank.d484.s0|328-337|Sandimmune|brand
DDI-DrugBank.d484.s0|338-338|)|O
DDI-DrugBank.d484.s0|339-339|,|O
DDI-DrugBank.d484.s0|341-343|HIV|O
DDI-DrugBank.d484.s0|345-349|drugs|O
DDI-DrugBank.d484.s0|351-360|classified|O
DDI-DrugBank.d484.s0|362-363|as|O
DDI-DrugBank.d484.s0|365-383|protease inhibitors|group
DDI-DrugBank.d484.s0|385-385|(|O
DDI-DrugBank.d484.s0|386-394|Agenerase|brand
DDI-DrugBank.d484.s0|395-395|,|O
DDI-DrugBank.d484.s0|397-404|Crixivan|brand
DDI-DrugBank.d484.s0|405-405|,|O
DDI-DrugBank.d484.s0|407-415|Fortovase|brand
DDI-DrugBank.d484.s0|416-416|,|O
DDI-DrugBank.d484.s0|418-425|Invirase|brand
DDI-DrugBank.d484.s0|426-426|,|O
DDI-DrugBank.d484.s0|428-434|Kaletra|brand
DDI-DrugBank.d484.s0|435-435|,|O
DDI-DrugBank.d484.s0|437-442|Norvir|brand
DDI-DrugBank.d484.s0|443-443|,|O
DDI-DrugBank.d484.s0|445-452|Viracept|brand
DDI-DrugBank.d484.s0|453-453|)|O
DDI-DrugBank.d484.s0|454-454|,|O
DDI-DrugBank.d484.s0|456-463|morphine|drug
DDI-DrugBank.d484.s0|465-465|(|O
DDI-DrugBank.d484.s0|466-475|Astramorph|brand
DDI-DrugBank.d484.s0|476-476|,|O
DDI-DrugBank.d484.s0|478-483|Kadian|brand
DDI-DrugBank.d484.s0|484-484|,|O
DDI-DrugBank.d484.s0|486-494|MS Contin|brand
DDI-DrugBank.d484.s0|495-495|)|O
DDI-DrugBank.d484.s0|496-496|,|O
DDI-DrugBank.d484.s0|498-511|phenylbutazone|drug
DDI-DrugBank.d484.s0|512-512|,|O
DDI-DrugBank.d484.s0|514-525|prednisolone|drug
DDI-DrugBank.d484.s0|527-527|(|O
DDI-DrugBank.d484.s0|528-534|Prelone|brand
DDI-DrugBank.d484.s0|535-535|)|O
DDI-DrugBank.d484.s0|536-536|,|O
DDI-DrugBank.d484.s0|538-544|rifadin|brand
DDI-DrugBank.d484.s0|546-546|(|O
DDI-DrugBank.d484.s0|547-554|rifampin|drug
DDI-DrugBank.d484.s0|555-555|)|O
DDI-DrugBank.d484.s0|556-556|,|O
DDI-DrugBank.d484.s0|558-560|St.|O
DDI-DrugBank.d484.s0|562-566|Johns|O
DDI-DrugBank.d484.s0|568-571|wort|O
DDI-DrugBank.d484.s0|572-572|,|O
DDI-DrugBank.d484.s0|574-582|temazepam|drug
DDI-DrugBank.d484.s0|583-583|,|O
DDI-DrugBank.d484.s0|585-596|theophylline|drug
DDI-DrugBank.d484.s0|598-598|(|O
DDI-DrugBank.d484.s0|599-606|Theo-Dur|brand
DDI-DrugBank.d484.s0|607-607|)|O
DDI-DrugBank.d484.s0|608-608|,|O
DDI-DrugBank.d484.s0|610-612|and|O
DDI-DrugBank.d484.s0|614-622|vitamin C|drug
DDI-DrugBank.d484.s0|623-623|.|O
DDI-DrugBank.d445.s0|0-1|No|O
DDI-DrugBank.d445.s0|3-12|clinically|O
DDI-DrugBank.d445.s0|14-21|relevant|O
DDI-DrugBank.d445.s0|23-31|drug-drug|O
DDI-DrugBank.d445.s0|33-44|interactions|O
DDI-DrugBank.d445.s0|46-49|have|O
DDI-DrugBank.d445.s0|51-54|been|O
DDI-DrugBank.d445.s0|56-63|observed|O
DDI-DrugBank.d445.s0|65-68|with|O
DDI-DrugBank.d445.s0|70-74|drugs|O
DDI-DrugBank.d445.s0|76-81|likely|O
DDI-DrugBank.d445.s0|83-84|to|O
DDI-DrugBank.d445.s0|86-87|be|O
DDI-DrugBank.d445.s0|89-103|co-administered|O
DDI-DrugBank.d445.s0|105-108|with|O
DDI-DrugBank.d445.s0|110-122|anidulafungin|drug
DDI-DrugBank.d445.s0|123-123|.|O
DDI-DrugBank.d472.s0|0-32|Central nervous system depressant|group
DDI-DrugBank.d472.s0|34-34|(|O
DDI-DrugBank.d472.s0|35-37|CNS|O
DDI-DrugBank.d472.s0|38-38|)|O
DDI-DrugBank.d472.s0|40-44|drugs|O
DDI-DrugBank.d472.s0|46-54|including|O
DDI-DrugBank.d472.s0|56-62|alcohol|drug
DDI-DrugBank.d472.s0|63-63|,|O
DDI-DrugBank.d472.s0|65-79|antidepressants|group
DDI-DrugBank.d472.s0|80-80|,|O
DDI-DrugBank.d472.s0|82-95|antihistamines|group
DDI-DrugBank.d472.s0|96-96|,|O
DDI-DrugBank.d472.s0|98-111|antipsychotics|group
DDI-DrugBank.d472.s0|112-112|,|O
DDI-DrugBank.d472.s0|114-118|blood|O
DDI-DrugBank.d472.s0|120-127|pressure|O
DDI-DrugBank.d472.s0|129-139|medications|O
DDI-DrugBank.d472.s0|141-141|(|O
DDI-DrugBank.d472.s0|142-150|reserpine|drug
DDI-DrugBank.d472.s0|151-151|,|O
DDI-DrugBank.d472.s0|153-162|methyldopa|drug
DDI-DrugBank.d472.s0|163-163|,|O
DDI-DrugBank.d472.s0|165-177|beta-blockers|group
DDI-DrugBank.d472.s0|178-178|)|O
DDI-DrugBank.d472.s0|179-179|,|O
DDI-DrugBank.d472.s0|181-186|motion|O
DDI-DrugBank.d472.s0|188-195|sickness|O
DDI-DrugBank.d472.s0|197-207|medications|O
DDI-DrugBank.d472.s0|208-208|,|O
DDI-DrugBank.d472.s0|210-225|muscle relaxants|group
DDI-DrugBank.d472.s0|226-226|,|O
DDI-DrugBank.d472.s0|228-236|narcotics|group
DDI-DrugBank.d472.s0|237-237|,|O
DDI-DrugBank.d472.s0|239-247|sedatives|group
DDI-DrugBank.d472.s0|248-248|,|O
DDI-DrugBank.d472.s0|250-257|sleeping|O
DDI-DrugBank.d472.s0|259-263|pills|O
DDI-DrugBank.d472.s0|265-267|and|O
DDI-DrugBank.d370.s0|0-1|As|O
DDI-DrugBank.d370.s0|3-10|DIFFERIN|brand
DDI-DrugBank.d370.s0|12-14|Gel|O
DDI-DrugBank.d370.s0|16-18|has|O
DDI-DrugBank.d370.s0|20-22|the|O
DDI-DrugBank.d370.s0|24-32|potential|O
DDI-DrugBank.d370.s0|34-35|to|O
DDI-DrugBank.d370.s0|37-43|produce|O
DDI-DrugBank.d370.s0|45-49|local|O
DDI-DrugBank.d370.s0|51-60|irritation|O
DDI-DrugBank.d370.s0|62-63|in|O
DDI-DrugBank.d370.s0|65-68|some|O
DDI-DrugBank.d370.s0|70-77|patients|O
DDI-DrugBank.d370.s0|78-78|,|O
DDI-DrugBank.d370.s0|80-90|concomitant|O
DDI-DrugBank.d370.s0|92-94|use|O
DDI-DrugBank.d370.s0|96-97|of|O
DDI-DrugBank.d370.s0|99-103|other|O
DDI-DrugBank.d370.s0|105-115|potentially|O
DDI-DrugBank.d370.s0|117-126|irritating|O
DDI-DrugBank.d370.s0|128-134|topical|O
DDI-DrugBank.d370.s0|136-143|products|O
DDI-DrugBank.d370.s0|145-145|(|O
DDI-DrugBank.d370.s0|146-154|medicated|O
DDI-DrugBank.d370.s0|156-157|or|O
DDI-DrugBank.d370.s0|159-166|abrasive|O
DDI-DrugBank.d370.s0|168-172|soaps|O
DDI-DrugBank.d370.s0|174-176|and|O
DDI-DrugBank.d370.s0|178-186|cleansers|O
DDI-DrugBank.d370.s0|187-187|,|O
DDI-DrugBank.d370.s0|189-193|soaps|O
DDI-DrugBank.d370.s0|195-197|and|O
DDI-DrugBank.d370.s0|199-207|cosmetics|O
DDI-DrugBank.d370.s0|209-212|that|O
DDI-DrugBank.d370.s0|214-217|have|O
DDI-DrugBank.d370.s0|219-219|a|O
DDI-DrugBank.d370.s0|221-226|strong|O
DDI-DrugBank.d370.s0|228-233|drying|O
DDI-DrugBank.d370.s0|235-240|effect|O
DDI-DrugBank.d370.s0|241-241|,|O
DDI-DrugBank.d370.s0|243-245|and|O
DDI-DrugBank.d370.s0|247-254|products|O
DDI-DrugBank.d370.s0|256-259|with|O
DDI-DrugBank.d370.s0|261-264|high|O
DDI-DrugBank.d370.s0|266-279|concentrations|O
DDI-DrugBank.d370.s0|281-282|of|O
DDI-DrugBank.d370.s0|284-290|alcohol|O
DDI-DrugBank.d370.s0|291-291|,|O
DDI-DrugBank.d370.s0|293-303|astringents|O
DDI-DrugBank.d370.s0|304-304|,|O
DDI-DrugBank.d370.s0|306-311|spices|O
DDI-DrugBank.d370.s0|313-314|or|O
DDI-DrugBank.d370.s0|316-319|lime|O
DDI-DrugBank.d370.s0|320-320|)|O
DDI-DrugBank.d370.s0|322-327|should|O
DDI-DrugBank.d370.s0|329-330|be|O
DDI-DrugBank.d370.s0|332-341|approached|O
DDI-DrugBank.d370.s0|343-346|with|O
DDI-DrugBank.d370.s0|348-354|caution|O
DDI-DrugBank.d370.s0|355-355|.|O
DDI-DrugBank.d370.s1|0-9|Particular|O
DDI-DrugBank.d370.s1|11-17|caution|O
DDI-DrugBank.d370.s1|19-24|should|O
DDI-DrugBank.d370.s1|26-27|be|O
DDI-DrugBank.d370.s1|29-37|exercised|O
DDI-DrugBank.d370.s1|39-40|in|O
DDI-DrugBank.d370.s1|42-46|using|O
DDI-DrugBank.d370.s1|48-59|preparations|O
DDI-DrugBank.d370.s1|61-70|containing|O
DDI-DrugBank.d370.s1|72-77|sulfur|drug
DDI-DrugBank.d370.s1|78-78|,|O
DDI-DrugBank.d370.s1|80-89|resorcinol|drug
DDI-DrugBank.d370.s1|90-90|,|O
DDI-DrugBank.d370.s1|92-93|or|O
DDI-DrugBank.d370.s1|95-108|salicylic acid|drug
DDI-DrugBank.d370.s1|110-111|in|O
DDI-DrugBank.d370.s1|113-123|combination|O
DDI-DrugBank.d370.s1|125-128|with|O
DDI-DrugBank.d370.s1|130-137|DIFFERIN|brand
DDI-DrugBank.d370.s1|139-141|Gel|O
DDI-DrugBank.d370.s1|142-142|.|O
DDI-DrugBank.d370.s2|0-1|If|O
DDI-DrugBank.d370.s2|3-7|these|O
DDI-DrugBank.d370.s2|9-20|preparations|O
DDI-DrugBank.d370.s2|22-25|have|O
DDI-DrugBank.d370.s2|27-30|been|O
DDI-DrugBank.d370.s2|32-35|used|O
DDI-DrugBank.d370.s2|37-38|it|O
DDI-DrugBank.d370.s2|40-41|is|O
DDI-DrugBank.d370.s2|43-51|advisable|O
DDI-DrugBank.d370.s2|53-55|not|O
DDI-DrugBank.d370.s2|57-58|to|O
DDI-DrugBank.d370.s2|60-64|start|O
DDI-DrugBank.d370.s2|66-72|therapy|O
DDI-DrugBank.d370.s2|74-77|with|O
DDI-DrugBank.d370.s2|79-86|DIFFERIN|brand
DDI-DrugBank.d370.s2|88-90|Gel|O
DDI-DrugBank.d370.s2|92-96|until|O
DDI-DrugBank.d370.s2|98-100|the|O
DDI-DrugBank.d370.s2|102-108|effects|O
DDI-DrugBank.d370.s2|110-111|of|O
DDI-DrugBank.d370.s2|113-116|such|O
DDI-DrugBank.d370.s2|118-129|preparations|O
DDI-DrugBank.d370.s2|131-132|in|O
DDI-DrugBank.d370.s2|134-136|the|O
DDI-DrugBank.d370.s2|138-141|skin|O
DDI-DrugBank.d370.s2|143-146|have|O
DDI-DrugBank.d370.s2|148-155|subsided|O
DDI-DrugBank.d370.s2|156-156|.|O
DDI-DrugBank.d329.s0|0-3|When|O
DDI-DrugBank.d329.s0|5-13|ertapenem|drug
DDI-DrugBank.d329.s0|15-16|is|O
DDI-DrugBank.d329.s0|18-32|co-administered|O
DDI-DrugBank.d329.s0|34-37|with|O
DDI-DrugBank.d329.s0|39-48|probenecid|drug
DDI-DrugBank.d329.s0|50-50|(|O
DDI-DrugBank.d329.s0|51-53|500|O
DDI-DrugBank.d329.s0|55-56|mg|O
DDI-DrugBank.d329.s0|58-61|p.o.|O
DDI-DrugBank.d329.s0|63-67|every|O
DDI-DrugBank.d329.s0|69-69|6|O
DDI-DrugBank.d329.s0|71-75|hours|O
DDI-DrugBank.d329.s0|76-76|)|O
DDI-DrugBank.d329.s0|77-77|,|O
DDI-DrugBank.d329.s0|79-88|probenecid|drug
DDI-DrugBank.d329.s0|90-97|competes|O
DDI-DrugBank.d329.s0|99-101|for|O
DDI-DrugBank.d329.s0|103-108|active|O
DDI-DrugBank.d329.s0|110-116|tubular|O
DDI-DrugBank.d329.s0|118-126|secretion|O
DDI-DrugBank.d329.s0|128-130|and|O
DDI-DrugBank.d329.s0|132-138|reduces|O
DDI-DrugBank.d329.s0|140-142|the|O
DDI-DrugBank.d329.s0|144-148|renal|O
DDI-DrugBank.d329.s0|150-158|clearance|O
DDI-DrugBank.d329.s0|160-161|of|O
DDI-DrugBank.d329.s0|163-171|ertapenem|drug
DDI-DrugBank.d329.s0|172-172|.|O
DDI-DrugBank.d329.s1|0-4|Based|O
DDI-DrugBank.d329.s1|6-7|on|O
DDI-DrugBank.d329.s1|9-13|total|O
DDI-DrugBank.d329.s1|15-23|ertapenem|drug
DDI-DrugBank.d329.s1|25-38|concentrations|O
DDI-DrugBank.d329.s1|39-39|,|O
DDI-DrugBank.d329.s1|41-50|probenecid|drug
DDI-DrugBank.d329.s1|52-60|increased|O
DDI-DrugBank.d329.s1|62-64|the|O
DDI-DrugBank.d329.s1|66-68|AUC|O
DDI-DrugBank.d329.s1|70-71|by|O
DDI-DrugBank.d329.s1|73-74|25|O
DDI-DrugBank.d329.s1|75-75|%|O
DDI-DrugBank.d329.s1|77-79|and|O
DDI-DrugBank.d329.s1|81-87|reduced|O
DDI-DrugBank.d329.s1|89-91|the|O
DDI-DrugBank.d329.s1|93-98|plasma|O
DDI-DrugBank.d329.s1|100-102|and|O
DDI-DrugBank.d329.s1|104-108|renal|O
DDI-DrugBank.d329.s1|110-119|clearances|O
DDI-DrugBank.d329.s1|121-122|by|O
DDI-DrugBank.d329.s1|124-125|20|O
DDI-DrugBank.d329.s1|126-126|%|O
DDI-DrugBank.d329.s1|128-130|and|O
DDI-DrugBank.d329.s1|132-133|35|O
DDI-DrugBank.d329.s1|134-134|%|O
DDI-DrugBank.d329.s1|135-135|,|O
DDI-DrugBank.d329.s1|137-148|respectively|O
DDI-DrugBank.d329.s1|149-149|.|O
DDI-DrugBank.d329.s2|0-2|The|O
DDI-DrugBank.d329.s2|4-12|half-life|O
DDI-DrugBank.d329.s2|14-22|increased|O
DDI-DrugBank.d329.s2|24-27|from|O
DDI-DrugBank.d329.s2|29-31|4.0|O
DDI-DrugBank.d329.s2|33-34|to|O
DDI-DrugBank.d329.s2|36-38|4.8|O
DDI-DrugBank.d329.s2|40-44|hours|O
DDI-DrugBank.d329.s2|45-45|.|O
DDI-DrugBank.d329.s3|0-6|Because|O
DDI-DrugBank.d329.s3|8-9|of|O
DDI-DrugBank.d329.s3|11-13|the|O
DDI-DrugBank.d329.s3|15-19|small|O
DDI-DrugBank.d329.s3|21-26|effect|O
DDI-DrugBank.d329.s3|28-29|on|O
DDI-DrugBank.d329.s3|31-39|half-life|O
DDI-DrugBank.d329.s3|40-40|,|O
DDI-DrugBank.d329.s3|42-44|the|O
DDI-DrugBank.d329.s3|46-61|coadministration|O
DDI-DrugBank.d329.s3|63-66|with|O
DDI-DrugBank.d329.s3|68-77|probenecid|drug
DDI-DrugBank.d329.s3|79-80|to|O
DDI-DrugBank.d329.s3|82-87|extend|O
DDI-DrugBank.d329.s3|89-91|the|O
DDI-DrugBank.d329.s3|93-101|half-life|O
DDI-DrugBank.d329.s3|103-104|of|O
DDI-DrugBank.d329.s3|106-114|ertapenem|drug
DDI-DrugBank.d329.s3|116-117|is|O
DDI-DrugBank.d329.s3|119-121|not|O
DDI-DrugBank.d329.s3|123-133|recommended|O
DDI-DrugBank.d329.s3|134-134|.|O
DDI-DrugBank.d329.s4|0-1|In|O
DDI-DrugBank.d329.s4|3-7|vitro|O
DDI-DrugBank.d329.s4|9-15|studies|O
DDI-DrugBank.d329.s4|17-24|indicate|O
DDI-DrugBank.d329.s4|26-29|that|O
DDI-DrugBank.d329.s4|31-39|ertapenem|drug
DDI-DrugBank.d329.s4|41-44|does|O
DDI-DrugBank.d329.s4|46-48|not|O
DDI-DrugBank.d329.s4|50-56|inhibit|O
DDI-DrugBank.d329.s4|58-80|P-glycoprotein-mediated|O
DDI-DrugBank.d329.s4|82-90|transport|O
DDI-DrugBank.d329.s4|92-93|of|O
DDI-DrugBank.d329.s4|95-101|digoxin|drug
DDI-DrugBank.d329.s4|103-104|or|O
DDI-DrugBank.d329.s4|106-116|vinblastine|drug
DDI-DrugBank.d329.s4|118-120|and|O
DDI-DrugBank.d329.s4|122-125|that|O
DDI-DrugBank.d329.s4|127-135|ertapenem|drug
DDI-DrugBank.d329.s4|137-138|is|O
DDI-DrugBank.d329.s4|140-142|not|O
DDI-DrugBank.d329.s4|144-144|a|O
DDI-DrugBank.d329.s4|146-154|substrate|O
DDI-DrugBank.d329.s4|156-158|for|O
DDI-DrugBank.d329.s4|160-182|P-glycoprotein-mediated|O
DDI-DrugBank.d329.s4|184-192|transport|O
DDI-DrugBank.d329.s4|193-193|.|O
DDI-DrugBank.d329.s5|0-1|In|O
DDI-DrugBank.d329.s5|3-7|vitro|O
DDI-DrugBank.d329.s5|9-15|studies|O
DDI-DrugBank.d329.s5|17-18|in|O
DDI-DrugBank.d329.s5|20-24|human|O
DDI-DrugBank.d329.s5|26-30|liver|O
DDI-DrugBank.d329.s5|32-41|microsomes|O
DDI-DrugBank.d329.s5|43-50|indicate|O
DDI-DrugBank.d329.s5|52-55|that|O
DDI-DrugBank.d329.s5|57-65|ertapenem|drug
DDI-DrugBank.d329.s5|67-70|does|O
DDI-DrugBank.d329.s5|72-74|not|O
DDI-DrugBank.d329.s5|76-82|inhibit|O
DDI-DrugBank.d329.s5|84-93|metabolism|O
DDI-DrugBank.d329.s5|95-102|mediated|O
DDI-DrugBank.d329.s5|104-105|by|O
DDI-DrugBank.d329.s5|107-109|any|O
DDI-DrugBank.d329.s5|111-112|of|O
DDI-DrugBank.d329.s5|114-116|the|O
DDI-DrugBank.d329.s5|118-126|following|O
DDI-DrugBank.d329.s5|128-130|six|O
DDI-DrugBank.d329.s5|132-141|cytochrome|O
DDI-DrugBank.d329.s5|143-146|p450|O
DDI-DrugBank.d329.s5|148-148|(|O
DDI-DrugBank.d329.s5|149-151|CYP|O
DDI-DrugBank.d329.s5|152-152|)|O
DDI-DrugBank.d329.s5|154-161|isoforms|O
DDI-DrugBank.d329.s5|162-162|:|O
DDI-DrugBank.d329.s5|164-166|1A2|O
DDI-DrugBank.d329.s5|167-167|,|O
DDI-DrugBank.d329.s5|169-171|2C9|O
DDI-DrugBank.d329.s5|172-172|,|O
DDI-DrugBank.d329.s5|174-177|2C19|O
DDI-DrugBank.d329.s5|178-178|,|O
DDI-DrugBank.d329.s5|180-182|2D6|O
DDI-DrugBank.d329.s5|183-183|,|O
DDI-DrugBank.d329.s5|185-187|2E1|O
DDI-DrugBank.d329.s5|189-191|and|O
DDI-DrugBank.d329.s5|193-195|3A4|O
DDI-DrugBank.d329.s5|196-196|.|O
DDI-DrugBank.d329.s6|0-3|Drug|O
DDI-DrugBank.d329.s6|5-16|interactions|O
DDI-DrugBank.d329.s6|18-23|caused|O
DDI-DrugBank.d329.s6|25-26|by|O
DDI-DrugBank.d329.s6|28-37|inhibition|O
DDI-DrugBank.d329.s6|39-40|of|O
DDI-DrugBank.d329.s6|42-64|P-glycoprotein-mediated|O
DDI-DrugBank.d329.s6|66-69|drug|O
DDI-DrugBank.d329.s6|71-79|clearance|O
DDI-DrugBank.d329.s6|81-82|or|O
DDI-DrugBank.d329.s6|84-95|CYP-mediated|O
DDI-DrugBank.d329.s6|97-100|drug|O
DDI-DrugBank.d329.s6|102-110|clearance|O
DDI-DrugBank.d329.s6|112-115|with|O
DDI-DrugBank.d329.s6|117-119|the|O
DDI-DrugBank.d329.s6|121-126|listed|O
DDI-DrugBank.d329.s6|128-135|isoforms|O
DDI-DrugBank.d329.s6|137-139|are|O
DDI-DrugBank.d329.s6|141-148|unlikely|O
DDI-DrugBank.d329.s6|149-149|.|O
DDI-DrugBank.d329.s7|0-4|Other|O
DDI-DrugBank.d329.s7|6-9|than|O
DDI-DrugBank.d329.s7|11-14|with|O
DDI-DrugBank.d329.s7|16-25|probenecid|drug
DDI-DrugBank.d329.s7|26-26|,|O
DDI-DrugBank.d329.s7|28-29|no|O
DDI-DrugBank.d329.s7|31-38|specific|O
DDI-DrugBank.d329.s7|40-47|clinical|O
DDI-DrugBank.d329.s7|49-52|drug|O
DDI-DrugBank.d329.s7|54-64|interaction|O
DDI-DrugBank.d329.s7|66-72|studies|O
DDI-DrugBank.d329.s7|74-77|have|O
DDI-DrugBank.d329.s7|79-82|been|O
DDI-DrugBank.d329.s7|84-92|conducted|O
DDI-DrugBank.d329.s8|0-0|.|O
DDI-DrugBank.d3.s0|0-8|Ketorolac|drug
DDI-DrugBank.d3.s0|10-11|is|O
DDI-DrugBank.d3.s0|13-18|highly|O
DDI-DrugBank.d3.s0|20-24|bound|O
DDI-DrugBank.d3.s0|26-27|to|O
DDI-DrugBank.d3.s0|29-33|human|O
DDI-DrugBank.d3.s0|35-40|plasma|O
DDI-DrugBank.d3.s0|42-48|protein|O
DDI-DrugBank.d3.s0|50-50|(|O
DDI-DrugBank.d3.s0|51-54|mean|O
DDI-DrugBank.d3.s0|56-59|99.2|O
DDI-DrugBank.d3.s0|60-60|%|O
DDI-DrugBank.d3.s0|61-61|)|O
DDI-DrugBank.d3.s0|62-62|.|O
DDI-DrugBank.d3.s1|0-7|Warfarin|drug
DDI-DrugBank.d3.s1|8-8|,|O
DDI-DrugBank.d3.s1|10-16|Digoxin|drug
DDI-DrugBank.d3.s1|17-17|,|O
DDI-DrugBank.d3.s1|19-28|Salicylate|group
DDI-DrugBank.d3.s1|29-29|,|O
DDI-DrugBank.d3.s1|31-33|and|O
DDI-DrugBank.d3.s1|35-41|Heparin|drug
DDI-DrugBank.d3.s1|43-45|The|O
DDI-DrugBank.d3.s1|47-48|in|O
DDI-DrugBank.d3.s1|50-54|vitro|O
DDI-DrugBank.d3.s1|56-62|binding|O
DDI-DrugBank.d3.s1|64-65|of|O
DDI-DrugBank.d3.s1|67-74|warfarin|drug
DDI-DrugBank.d3.s1|76-77|to|O
DDI-DrugBank.d3.s1|79-84|plasma|O
DDI-DrugBank.d3.s1|86-93|proteins|O
DDI-DrugBank.d3.s1|95-96|is|O
DDI-DrugBank.d3.s1|98-101|only|O
DDI-DrugBank.d3.s1|103-110|slightly|O
DDI-DrugBank.d3.s1|112-118|reduced|O
DDI-DrugBank.d3.s1|120-121|by|O
DDI-DrugBank.d3.s1|123-144|ketorolac tromethamine|drug
DDI-DrugBank.d3.s1|146-146|(|O
DDI-DrugBank.d3.s1|147-150|99.5|O
DDI-DrugBank.d3.s1|151-151|%|O
DDI-DrugBank.d3.s1|153-159|control|O
DDI-DrugBank.d3.s1|161-162|vs|O
DDI-DrugBank.d3.s1|164-167|99.3|O
DDI-DrugBank.d3.s1|168-168|%|O
DDI-DrugBank.d3.s1|169-169|)|O
DDI-DrugBank.d3.s1|171-174|when|O
DDI-DrugBank.d3.s1|176-184|ketorolac|drug
DDI-DrugBank.d3.s1|186-191|plasma|O
DDI-DrugBank.d3.s1|193-206|concentrations|O
DDI-DrugBank.d3.s1|208-212|reach|O
DDI-DrugBank.d3.s1|214-214|5|O
DDI-DrugBank.d3.s1|216-219|to10|O
DDI-DrugBank.d3.s1|221-221|m|O
DDI-DrugBank.d3.s1|223-226|g/mL|O
DDI-DrugBank.d3.s1|227-227|.|O
DDI-DrugBank.d3.s2|0-8|Ketorolac|drug
DDI-DrugBank.d3.s2|10-13|does|O
DDI-DrugBank.d3.s2|15-17|not|O
DDI-DrugBank.d3.s2|19-23|alter|O
DDI-DrugBank.d3.s2|25-31|digoxin|drug
DDI-DrugBank.d3.s2|33-39|protein|O
DDI-DrugBank.d3.s2|41-47|binding|O
DDI-DrugBank.d3.s2|48-48|.|O
DDI-DrugBank.d3.s3|0-1|In|O
DDI-DrugBank.d3.s3|3-7|vitro|O
DDI-DrugBank.d3.s3|9-15|studies|O
DDI-DrugBank.d3.s3|17-24|indicate|O
DDI-DrugBank.d3.s3|26-29|that|O
DDI-DrugBank.d3.s3|30-30|,|O
DDI-DrugBank.d3.s3|32-33|at|O
DDI-DrugBank.d3.s3|35-45|therapeutic|O
DDI-DrugBank.d3.s3|47-60|concentrations|O
DDI-DrugBank.d3.s3|62-63|of|O
DDI-DrugBank.d3.s3|65-74|salicylate|group
DDI-DrugBank.d3.s3|76-76|(|O
DDI-DrugBank.d3.s3|77-79|300|O
DDI-DrugBank.d3.s3|81-81|m|O
DDI-DrugBank.d3.s3|83-86|g/mL|O
DDI-DrugBank.d3.s3|87-87|)|O
DDI-DrugBank.d3.s3|88-88|,|O
DDI-DrugBank.d3.s3|90-92|the|O
DDI-DrugBank.d3.s3|94-100|binding|O
DDI-DrugBank.d3.s3|102-103|of|O
DDI-DrugBank.d3.s3|105-113|ketorolac|drug
DDI-DrugBank.d3.s3|115-117|was|O
DDI-DrugBank.d3.s3|119-125|reduced|O
DDI-DrugBank.d3.s3|127-130|from|O
DDI-DrugBank.d3.s3|132-144|approximately|O
DDI-DrugBank.d3.s3|146-149|99.2|O
DDI-DrugBank.d3.s3|150-150|%|O
DDI-DrugBank.d3.s3|152-153|to|O
DDI-DrugBank.d3.s3|155-158|97.5|O
DDI-DrugBank.d3.s3|159-159|%|O
DDI-DrugBank.d3.s3|160-160|,|O
DDI-DrugBank.d3.s3|162-173|representing|O
DDI-DrugBank.d3.s3|175-175|a|O
DDI-DrugBank.d3.s3|177-185|potential|O
DDI-DrugBank.d3.s3|187-193|twofold|O
DDI-DrugBank.d3.s3|195-202|increase|O
DDI-DrugBank.d3.s3|204-205|in|O
DDI-DrugBank.d3.s3|207-213|unbound|O
DDI-DrugBank.d3.s3|215-223|ketorolac|drug
DDI-DrugBank.d3.s3|225-230|plasma|O
DDI-DrugBank.d3.s3|232-237|levels|O
DDI-DrugBank.d3.s3|238-238|.|O
DDI-DrugBank.d3.s4|0-10|Therapeutic|O
DDI-DrugBank.d3.s4|12-25|concentrations|O
DDI-DrugBank.d3.s4|27-28|of|O
DDI-DrugBank.d3.s4|30-36|digoxin|drug
DDI-DrugBank.d3.s4|37-37|,|O
DDI-DrugBank.d3.s4|39-46|warfarin|drug
DDI-DrugBank.d3.s4|47-47|,|O
DDI-DrugBank.d3.s4|49-57|ibuprofen|drug
DDI-DrugBank.d3.s4|58-58|,|O
DDI-DrugBank.d3.s4|60-67|naproxen|drug
DDI-DrugBank.d3.s4|68-68|,|O
DDI-DrugBank.d3.s4|70-78|piroxicam|drug
DDI-DrugBank.d3.s4|79-79|,|O
DDI-DrugBank.d3.s4|81-93|acetaminophen|drug
DDI-DrugBank.d3.s4|94-94|,|O
DDI-DrugBank.d3.s4|96-104|phenytoin|drug
DDI-DrugBank.d3.s4|106-119|andtolbutamide|O
DDI-DrugBank.d3.s4|121-123|did|O
DDI-DrugBank.d3.s4|125-127|not|O
DDI-DrugBank.d3.s4|129-133|alter|O
DDI-DrugBank.d3.s4|135-156|ketorolac tromethamine|drug
DDI-DrugBank.d3.s4|158-164|protein|O
DDI-DrugBank.d3.s4|166-172|binding|O
DDI-DrugBank.d3.s4|173-173|.|O
DDI-DrugBank.d3.s5|0-1|In|O
DDI-DrugBank.d3.s5|3-3|a|O
DDI-DrugBank.d3.s5|5-9|study|O
DDI-DrugBank.d3.s5|11-19|involving|O
DDI-DrugBank.d3.s5|21-22|12|O
DDI-DrugBank.d3.s5|24-28|adult|O
DDI-DrugBank.d3.s5|30-39|volunteers|O
DDI-DrugBank.d3.s5|40-40|,|O
DDI-DrugBank.d3.s5|42-52|TORADOLORAL|O
DDI-DrugBank.d3.s5|54-56|was|O
DDI-DrugBank.d3.s5|58-71|coadministered|O
DDI-DrugBank.d3.s5|73-76|with|O
DDI-DrugBank.d3.s5|78-78|a|O
DDI-DrugBank.d3.s5|80-85|single|O
DDI-DrugBank.d3.s5|87-90|dose|O
DDI-DrugBank.d3.s5|92-93|of|O
DDI-DrugBank.d3.s5|95-96|25|O
DDI-DrugBank.d3.s5|98-99|mg|O
DDI-DrugBank.d3.s5|101-108|warfarin|drug
DDI-DrugBank.d3.s5|109-109|,|O
DDI-DrugBank.d3.s5|111-117|causing|O
DDI-DrugBank.d3.s5|119-120|no|O
DDI-DrugBank.d3.s5|122-132|significant|O
DDI-DrugBank.d3.s5|134-140|changes|O
DDI-DrugBank.d3.s5|142-143|in|O
DDI-DrugBank.d3.s5|145-160|pharmacokinetics|O
DDI-DrugBank.d3.s5|162-163|or|O
DDI-DrugBank.d3.s5|165-180|pharmacodynamics|O
DDI-DrugBank.d3.s5|182-183|of|O
DDI-DrugBank.d3.s5|185-192|warfarin|drug
DDI-DrugBank.d3.s5|193-193|.|O
DDI-DrugBank.d3.s6|0-1|In|O
DDI-DrugBank.d3.s6|3-9|another|O
DDI-DrugBank.d3.s6|11-15|study|O
DDI-DrugBank.d3.s6|16-16|,|O
DDI-DrugBank.d3.s6|18-29|TORADOLIV/IM|O
DDI-DrugBank.d3.s6|31-33|was|O
DDI-DrugBank.d3.s6|35-39|given|O
DDI-DrugBank.d3.s6|41-44|with|O
DDI-DrugBank.d3.s6|46-48|two|O
DDI-DrugBank.d3.s6|50-54|doses|O
DDI-DrugBank.d3.s6|56-57|of|O
DDI-DrugBank.d3.s6|59-62|5000|O
DDI-DrugBank.d3.s6|64-64|U|O
DDI-DrugBank.d3.s6|66-67|of|O
DDI-DrugBank.d3.s6|69-75|heparin|drug
DDI-DrugBank.d3.s6|77-78|to|O
DDI-DrugBank.d3.s6|80-81|11|O
DDI-DrugBank.d3.s6|83-89|healthy|O
DDI-DrugBank.d3.s6|91-100|volunteers|O
DDI-DrugBank.d3.s6|101-101|,|O
DDI-DrugBank.d3.s6|103-111|resulting|O
DDI-DrugBank.d3.s6|113-114|in|O
DDI-DrugBank.d3.s6|116-116|a|O
DDI-DrugBank.d3.s6|118-121|mean|O
DDI-DrugBank.d3.s6|123-130|template|O
DDI-DrugBank.d3.s6|132-139|bleeding|O
DDI-DrugBank.d3.s6|141-144|time|O
DDI-DrugBank.d3.s6|146-147|of|O
DDI-DrugBank.d3.s6|149-151|6.4|O
DDI-DrugBank.d3.s6|153-159|minutes|O
DDI-DrugBank.d3.s6|161-161|(|O
DDI-DrugBank.d3.s6|162-164|3.2|O
DDI-DrugBank.d3.s6|166-167|to|O
DDI-DrugBank.d3.s6|169-172|11.4|O
DDI-DrugBank.d3.s6|174-176|min|O
DDI-DrugBank.d3.s6|177-177|)|O
DDI-DrugBank.d3.s6|179-186|compared|O
DDI-DrugBank.d3.s6|188-189|to|O
DDI-DrugBank.d3.s6|191-191|a|O
DDI-DrugBank.d3.s6|193-196|mean|O
DDI-DrugBank.d3.s6|198-199|of|O
DDI-DrugBank.d3.s6|201-203|6.0|O
DDI-DrugBank.d3.s6|205-211|minutes|O
DDI-DrugBank.d3.s6|213-213|(|O
DDI-DrugBank.d3.s6|214-216|3.4|O
DDI-DrugBank.d3.s6|218-219|to|O
DDI-DrugBank.d3.s6|221-223|7.5|O
DDI-DrugBank.d3.s6|225-227|min|O
DDI-DrugBank.d3.s6|228-228|)|O
DDI-DrugBank.d3.s6|230-232|for|O
DDI-DrugBank.d3.s6|234-240|heparin|drug
DDI-DrugBank.d3.s6|242-246|alone|O
DDI-DrugBank.d3.s6|248-250|and|O
DDI-DrugBank.d3.s6|252-254|5.1|O
DDI-DrugBank.d3.s6|256-262|minutes|O
DDI-DrugBank.d3.s6|264-264|(|O
DDI-DrugBank.d3.s6|265-267|3.5|O
DDI-DrugBank.d3.s6|269-270|to|O
DDI-DrugBank.d3.s6|272-274|8.5|O
DDI-DrugBank.d3.s6|276-278|min|O
DDI-DrugBank.d3.s6|279-279|)|O
DDI-DrugBank.d3.s6|281-283|for|O
DDI-DrugBank.d3.s6|285-291|placebo|O
DDI-DrugBank.d3.s6|292-292|.|O
DDI-DrugBank.d3.s7|0-7|Although|O
DDI-DrugBank.d3.s7|9-13|these|O
DDI-DrugBank.d3.s7|15-21|results|O
DDI-DrugBank.d3.s7|23-24|do|O
DDI-DrugBank.d3.s7|26-28|not|O
DDI-DrugBank.d3.s7|30-37|indicate|O
DDI-DrugBank.d3.s7|39-39|a|O
DDI-DrugBank.d3.s7|41-51|significant|O
DDI-DrugBank.d3.s7|53-63|interaction|O
DDI-DrugBank.d3.s7|65-71|between|O
DDI-DrugBank.d3.s7|73-79|TORADOL|brand
DDI-DrugBank.d3.s7|81-83|and|O
DDI-DrugBank.d3.s7|85-92|warfarin|drug
DDI-DrugBank.d3.s7|94-95|or|O
DDI-DrugBank.d3.s7|97-103|heparin|drug
DDI-DrugBank.d3.s7|104-104|,|O
DDI-DrugBank.d3.s7|106-108|the|O
DDI-DrugBank.d3.s7|110-123|administration|O
DDI-DrugBank.d3.s7|125-126|of|O
DDI-DrugBank.d3.s7|128-134|TORADOL|brand
DDI-DrugBank.d3.s7|136-137|to|O
DDI-DrugBank.d3.s7|139-146|patients|O
DDI-DrugBank.d3.s7|148-153|taking|O
DDI-DrugBank.d3.s7|155-168|anticoagulants|group
DDI-DrugBank.d3.s7|170-175|should|O
DDI-DrugBank.d3.s7|177-178|be|O
DDI-DrugBank.d3.s7|180-183|done|O
DDI-DrugBank.d3.s7|185-193|extremely|O
DDI-DrugBank.d3.s7|195-204|cautiously|O
DDI-DrugBank.d3.s7|205-205|,|O
DDI-DrugBank.d3.s7|207-209|and|O
DDI-DrugBank.d3.s7|211-218|patients|O
DDI-DrugBank.d3.s7|220-225|should|O
DDI-DrugBank.d3.s7|227-228|be|O
DDI-DrugBank.d3.s7|230-236|closely|O
DDI-DrugBank.d3.s7|238-246|monitored|O
DDI-DrugBank.d3.s7|247-247|.|O
DDI-DrugBank.d3.s8|0-9|Furosemide|drug
DDI-DrugBank.d3.s8|10-10|:|O
DDI-DrugBank.d3.s8|12-18|TORADOL|brand
DDI-DrugBank.d3.s8|20-24|IV/IM|O
DDI-DrugBank.d3.s8|26-32|reduced|O
DDI-DrugBank.d3.s8|34-36|the|O
DDI-DrugBank.d3.s8|38-45|diuretic|group
DDI-DrugBank.d3.s8|47-54|response|O
DDI-DrugBank.d3.s8|56-57|to|O
DDI-DrugBank.d3.s8|59-68|furosemide|drug
DDI-DrugBank.d3.s8|70-71|in|O
DDI-DrugBank.d3.s8|73-84|normovolemic|O
DDI-DrugBank.d3.s8|86-92|healthy|O
DDI-DrugBank.d3.s8|94-101|subjects|O
DDI-DrugBank.d3.s8|103-104|by|O
DDI-DrugBank.d3.s8|106-118|approximately|O
DDI-DrugBank.d3.s8|120-121|20|O
DDI-DrugBank.d3.s8|122-122|%|O
DDI-DrugBank.d3.s8|124-124|(|O
DDI-DrugBank.d3.s8|125-128|mean|O
DDI-DrugBank.d3.s8|130-135|sodium|O
DDI-DrugBank.d3.s8|137-139|and|O
DDI-DrugBank.d3.s8|141-147|urinary|O
DDI-DrugBank.d3.s8|149-154|output|O
DDI-DrugBank.d3.s8|156-164|decreased|O
DDI-DrugBank.d3.s8|166-167|17|O
DDI-DrugBank.d3.s8|168-168|%|O
DDI-DrugBank.d3.s8|169-169|)|O
DDI-DrugBank.d3.s8|170-170|.|O
DDI-DrugBank.d3.s9|0-9|Probenecid|drug
DDI-DrugBank.d3.s9|10-10|:|O
DDI-DrugBank.d3.s9|12-22|Concomitant|O
DDI-DrugBank.d3.s9|24-37|administration|O
DDI-DrugBank.d3.s9|39-40|of|O
DDI-DrugBank.d3.s9|42-48|TORADOL|brand
DDI-DrugBank.d3.s9|50-53|ORAL|O
DDI-DrugBank.d3.s9|55-57|and|O
DDI-DrugBank.d3.s9|59-68|probenecid|drug
DDI-DrugBank.d3.s9|70-77|resulted|O
DDI-DrugBank.d3.s9|79-80|in|O
DDI-DrugBank.d3.s9|82-90|decreased|O
DDI-DrugBank.d3.s9|92-100|clearance|O
DDI-DrugBank.d3.s9|102-103|of|O
DDI-DrugBank.d3.s9|105-113|ketorolac|drug
DDI-DrugBank.d3.s9|115-117|and|O
DDI-DrugBank.d3.s9|119-129|significant|O
DDI-DrugBank.d3.s9|131-139|increases|O
DDI-DrugBank.d3.s9|141-142|in|O
DDI-DrugBank.d3.s9|144-152|ketorolac|drug
DDI-DrugBank.d3.s9|154-159|plasma|O
DDI-DrugBank.d3.s9|161-166|levels|O
DDI-DrugBank.d3.s9|168-168|(|O
DDI-DrugBank.d3.s9|169-173|total|O
DDI-DrugBank.d3.s9|175-177|AUC|O
DDI-DrugBank.d3.s9|179-187|increased|O
DDI-DrugBank.d3.s9|189-201|approximately|O
DDI-DrugBank.d3.s9|203-211|threefold|O
DDI-DrugBank.d3.s9|213-216|from|O
DDI-DrugBank.d3.s9|218-220|5.4|O
DDI-DrugBank.d3.s9|222-223|to|O
DDI-DrugBank.d3.s9|225-228|17.8|O
DDI-DrugBank.d3.s9|230-230|m|O
DDI-DrugBank.d3.s9|232-237|g/h/mL|O
DDI-DrugBank.d3.s9|238-238|)|O
DDI-DrugBank.d3.s9|240-242|and|O
DDI-DrugBank.d3.s9|244-251|terminal|O
DDI-DrugBank.d3.s9|253-261|half-life|O
DDI-DrugBank.d3.s9|263-271|increased|O
DDI-DrugBank.d3.s9|273-285|approximately|O
DDI-DrugBank.d3.s9|287-293|twofold|O
DDI-DrugBank.d3.s9|295-298|from|O
DDI-DrugBank.d3.s9|300-302|6.6|O
DDI-DrugBank.d3.s9|304-305|to|O
DDI-DrugBank.d3.s9|307-310|15.1|O
DDI-DrugBank.d3.s9|312-316|hours|O
DDI-DrugBank.d3.s9|317-317|.|O
DDI-DrugBank.d3.s10|0-8|Therefore|O
DDI-DrugBank.d3.s10|9-9|,|O
DDI-DrugBank.d3.s10|11-21|concomitant|O
DDI-DrugBank.d3.s10|23-25|use|O
DDI-DrugBank.d3.s10|27-28|of|O
DDI-DrugBank.d3.s10|30-36|TORADOL|brand
DDI-DrugBank.d3.s10|38-40|and|O
DDI-DrugBank.d3.s10|42-51|probenecid|drug
DDI-DrugBank.d3.s10|53-54|is|O
DDI-DrugBank.d3.s10|56-70|contraindicated|O
DDI-DrugBank.d3.s10|71-71|.|O
DDI-DrugBank.d3.s11|0-6|Lithium|drug
DDI-DrugBank.d3.s11|7-7|:|O
DDI-DrugBank.d3.s11|9-18|Inhibition|O
DDI-DrugBank.d3.s11|20-21|of|O
DDI-DrugBank.d3.s11|23-27|renal|O
DDI-DrugBank.d3.s11|29-35|lithium|drug
DDI-DrugBank.d3.s11|37-45|clearance|O
DDI-DrugBank.d3.s11|46-46|,|O
DDI-DrugBank.d3.s11|48-54|leading|O
DDI-DrugBank.d3.s11|56-57|to|O
DDI-DrugBank.d3.s11|59-60|an|O
DDI-DrugBank.d3.s11|62-69|increase|O
DDI-DrugBank.d3.s11|71-72|in|O
DDI-DrugBank.d3.s11|74-79|plasma|O
DDI-DrugBank.d3.s11|81-87|lithium|drug
DDI-DrugBank.d3.s11|89-101|concentration|O
DDI-DrugBank.d3.s11|102-102|,|O
DDI-DrugBank.d3.s11|104-106|has|O
DDI-DrugBank.d3.s11|108-111|been|O
DDI-DrugBank.d3.s11|113-120|reported|O
DDI-DrugBank.d3.s11|122-125|with|O
DDI-DrugBank.d3.s11|127-130|some|O
DDI-DrugBank.d3.s11|132-144|prostaglandin|O
DDI-DrugBank.d3.s11|146-165|synthesis-inhibiting|O
DDI-DrugBank.d3.s11|167-171|drugs|O
DDI-DrugBank.d3.s11|172-172|.|O
DDI-DrugBank.d3.s12|0-2|The|O
DDI-DrugBank.d3.s12|4-9|effect|O
DDI-DrugBank.d3.s12|11-12|of|O
DDI-DrugBank.d3.s12|14-20|TORADOL|brand
DDI-DrugBank.d3.s12|22-23|on|O
DDI-DrugBank.d3.s12|25-30|plasma|O
DDI-DrugBank.d3.s12|32-38|lithium|drug
DDI-DrugBank.d3.s12|40-42|has|O
DDI-DrugBank.d3.s12|44-46|not|O
DDI-DrugBank.d3.s12|48-51|been|O
DDI-DrugBank.d3.s12|53-59|studied|O
DDI-DrugBank.d3.s12|60-60|,|O
DDI-DrugBank.d3.s12|62-64|but|O
DDI-DrugBank.d3.s12|66-70|cases|O
DDI-DrugBank.d3.s12|72-73|of|O
DDI-DrugBank.d3.s12|75-83|increased|O
DDI-DrugBank.d3.s12|85-91|lithium|drug
DDI-DrugBank.d3.s12|93-98|plasma|O
DDI-DrugBank.d3.s12|100-105|levels|O
DDI-DrugBank.d3.s12|107-112|during|O
DDI-DrugBank.d3.s12|114-120|TORADOL|brand
DDI-DrugBank.d3.s12|122-128|therapy|O
DDI-DrugBank.d3.s12|130-133|have|O
DDI-DrugBank.d3.s12|135-138|been|O
DDI-DrugBank.d3.s12|140-147|reported|O
DDI-DrugBank.d3.s12|148-148|.|O
DDI-DrugBank.d3.s13|0-11|Methotrexate|drug
DDI-DrugBank.d3.s13|12-12|:|O
DDI-DrugBank.d3.s13|14-24|Concomitant|O
DDI-DrugBank.d3.s13|26-39|administration|O
DDI-DrugBank.d3.s13|41-42|of|O
DDI-DrugBank.d3.s13|44-55|methotrexate|drug
DDI-DrugBank.d3.s13|57-59|and|O
DDI-DrugBank.d3.s13|61-64|some|O
DDI-DrugBank.d3.s13|66-71|NSAIDs|group
DDI-DrugBank.d3.s13|73-75|has|O
DDI-DrugBank.d3.s13|77-80|been|O
DDI-DrugBank.d3.s13|82-89|reported|O
DDI-DrugBank.d3.s13|91-92|to|O
DDI-DrugBank.d3.s13|94-99|reduce|O
DDI-DrugBank.d3.s13|101-103|the|O
DDI-DrugBank.d3.s13|105-113|clearance|O
DDI-DrugBank.d3.s13|115-116|of|O
DDI-DrugBank.d3.s13|118-129|methotrexate|drug
DDI-DrugBank.d3.s13|130-130|,|O
DDI-DrugBank.d3.s13|132-140|enhancing|O
DDI-DrugBank.d3.s13|142-144|the|O
DDI-DrugBank.d3.s13|146-153|toxicity|O
DDI-DrugBank.d3.s13|155-156|of|O
DDI-DrugBank.d3.s13|158-169|methotrexate|drug
DDI-DrugBank.d3.s13|170-170|.|O
DDI-DrugBank.d3.s14|0-2|The|O
DDI-DrugBank.d3.s14|4-9|effect|O
DDI-DrugBank.d3.s14|11-12|of|O
DDI-DrugBank.d3.s14|14-20|TORADOL|brand
DDI-DrugBank.d3.s14|22-23|on|O
DDI-DrugBank.d3.s14|25-36|methotrexate|drug
DDI-DrugBank.d3.s14|38-46|clearance|O
DDI-DrugBank.d3.s14|48-50|has|O
DDI-DrugBank.d3.s14|52-54|not|O
DDI-DrugBank.d3.s14|56-59|been|O
DDI-DrugBank.d3.s14|61-67|studied|O
DDI-DrugBank.d3.s14|68-68|.|O
DDI-DrugBank.d3.s15|0-31|Nondepolarizing Muscle Relaxants|group
DDI-DrugBank.d3.s15|32-32|:|O
DDI-DrugBank.d3.s15|34-35|In|O
DDI-DrugBank.d3.s15|37-49|postmarketing|O
DDI-DrugBank.d3.s15|51-60|experience|O
DDI-DrugBank.d3.s15|62-66|there|O
DDI-DrugBank.d3.s15|68-71|have|O
DDI-DrugBank.d3.s15|73-76|been|O
DDI-DrugBank.d3.s15|78-84|reports|O
DDI-DrugBank.d3.s15|86-87|of|O
DDI-DrugBank.d3.s15|89-89|a|O
DDI-DrugBank.d3.s15|91-98|possible|O
DDI-DrugBank.d3.s15|100-110|interaction|O
DDI-DrugBank.d3.s15|112-118|between|O
DDI-DrugBank.d3.s15|120-131|TORADOLIV/IM|O
DDI-DrugBank.d3.s15|133-135|and|O
DDI-DrugBank.d3.s15|137-168|nondepolarizing muscle relaxants|group
DDI-DrugBank.d3.s15|170-173|that|O
DDI-DrugBank.d3.s15|175-182|resulted|O
DDI-DrugBank.d3.s15|184-185|in|O
DDI-DrugBank.d3.s15|187-191|apnea|O
DDI-DrugBank.d3.s15|192-192|.|O
DDI-DrugBank.d3.s16|0-2|The|O
DDI-DrugBank.d3.s16|4-13|concurrent|O
DDI-DrugBank.d3.s16|15-17|use|O
DDI-DrugBank.d3.s16|19-20|of|O
DDI-DrugBank.d3.s16|22-28|TORADOL|brand
DDI-DrugBank.d3.s16|30-33|with|O
DDI-DrugBank.d3.s16|35-50|muscle relaxants|group
DDI-DrugBank.d3.s16|52-54|has|O
DDI-DrugBank.d3.s16|56-58|not|O
DDI-DrugBank.d3.s16|60-63|been|O
DDI-DrugBank.d3.s16|65-72|formally|O
DDI-DrugBank.d3.s16|74-80|studied|O
DDI-DrugBank.d3.s16|81-81|.|O
DDI-DrugBank.d3.s17|0-13|ACE Inhibitors|group
DDI-DrugBank.d3.s17|14-14|:|O
DDI-DrugBank.d3.s17|16-26|Concomitant|O
DDI-DrugBank.d3.s17|28-30|use|O
DDI-DrugBank.d3.s17|32-33|of|O
DDI-DrugBank.d3.s17|35-48|ACE inhibitors|group
DDI-DrugBank.d3.s17|50-52|may|O
DDI-DrugBank.d3.s17|54-61|increase|O
DDI-DrugBank.d3.s17|63-65|the|O
DDI-DrugBank.d3.s17|67-70|risk|O
DDI-DrugBank.d3.s17|72-73|of|O
DDI-DrugBank.d3.s17|75-79|renal|O
DDI-DrugBank.d3.s17|81-90|impairment|O
DDI-DrugBank.d3.s17|91-91|,|O
DDI-DrugBank.d3.s17|93-104|particularly|O
DDI-DrugBank.d3.s17|106-107|in|O
DDI-DrugBank.d3.s17|109-123|volume-depleted|O
DDI-DrugBank.d3.s17|125-132|patients|O
DDI-DrugBank.d3.s17|133-133|.|O
DDI-DrugBank.d3.s18|0-18|Antiepileptic Drugs|group
DDI-DrugBank.d3.s18|19-19|:|O
DDI-DrugBank.d3.s18|21-28|Sporadic|O
DDI-DrugBank.d3.s18|30-34|cases|O
DDI-DrugBank.d3.s18|36-37|of|O
DDI-DrugBank.d3.s18|39-46|seizures|O
DDI-DrugBank.d3.s18|48-51|have|O
DDI-DrugBank.d3.s18|53-56|been|O
DDI-DrugBank.d3.s18|58-65|reported|O
DDI-DrugBank.d3.s18|67-72|during|O
DDI-DrugBank.d3.s18|74-84|concomitant|O
DDI-DrugBank.d3.s18|86-88|use|O
DDI-DrugBank.d3.s18|90-91|of|O
DDI-DrugBank.d3.s18|93-99|TORADOL|brand
DDI-DrugBank.d3.s18|101-103|and|O
DDI-DrugBank.d3.s18|105-123|antiepileptic drugs|group
DDI-DrugBank.d3.s18|125-125|(|O
DDI-DrugBank.d3.s18|126-134|phenytoin|drug
DDI-DrugBank.d3.s18|135-135|,|O
DDI-DrugBank.d3.s18|137-149|carbamazepine|drug
DDI-DrugBank.d3.s18|150-150|)|O
DDI-DrugBank.d3.s18|151-151|.|O
DDI-DrugBank.d3.s19|0-17|Psychoactive Drugs|group
DDI-DrugBank.d3.s19|18-18|:|O
DDI-DrugBank.d3.s19|20-33|Hallucinations|O
DDI-DrugBank.d3.s19|35-38|have|O
DDI-DrugBank.d3.s19|40-43|been|O
DDI-DrugBank.d3.s19|45-52|reported|O
DDI-DrugBank.d3.s19|54-57|when|O
DDI-DrugBank.d3.s19|59-65|TORADOL|brand
DDI-DrugBank.d3.s19|67-69|was|O
DDI-DrugBank.d3.s19|71-74|used|O
DDI-DrugBank.d3.s19|76-77|in|O
DDI-DrugBank.d3.s19|79-86|patients|O
DDI-DrugBank.d3.s19|88-93|taking|O
DDI-DrugBank.d3.s19|95-112|psychoactive drugs|group
DDI-DrugBank.d3.s19|114-114|(|O
DDI-DrugBank.d3.s19|115-124|fluoxetine|drug
DDI-DrugBank.d3.s19|125-125|,|O
DDI-DrugBank.d3.s19|127-137|thiothixene|drug
DDI-DrugBank.d3.s19|138-138|,|O
DDI-DrugBank.d3.s19|140-149|alprazolam|drug
DDI-DrugBank.d3.s19|150-150|)|O
DDI-DrugBank.d3.s19|151-151|.|O
DDI-DrugBank.d3.s20|0-7|Morphine|drug
DDI-DrugBank.d3.s20|8-8|:|O
DDI-DrugBank.d3.s20|10-21|TORADOLIV/IM|O
DDI-DrugBank.d3.s20|23-25|has|O
DDI-DrugBank.d3.s20|27-30|been|O
DDI-DrugBank.d3.s20|32-43|administered|O
DDI-DrugBank.d3.s20|45-56|concurrently|O
DDI-DrugBank.d3.s20|58-61|with|O
DDI-DrugBank.d3.s20|63-70|morphine|drug
DDI-DrugBank.d3.s20|72-73|in|O
DDI-DrugBank.d3.s20|75-81|several|O
DDI-DrugBank.d3.s20|83-90|clinical|O
DDI-DrugBank.d3.s20|92-97|trials|O
DDI-DrugBank.d3.s20|99-100|of|O
DDI-DrugBank.d3.s20|102-114|postoperative|O
DDI-DrugBank.d3.s20|116-119|pain|O
DDI-DrugBank.d3.s20|121-127|without|O
DDI-DrugBank.d3.s20|129-136|evidence|O
DDI-DrugBank.d3.s20|138-139|of|O
DDI-DrugBank.d3.s20|141-147|adverse|O
DDI-DrugBank.d3.s20|149-160|interactions|O
DDI-DrugBank.d3.s20|161-161|.|O
DDI-DrugBank.d3.s21|0-1|Do|O
DDI-DrugBank.d3.s21|3-5|not|O
DDI-DrugBank.d3.s21|7-9|mix|O
DDI-DrugBank.d3.s21|11-17|TORADOL|brand
DDI-DrugBank.d3.s21|19-21|and|O
DDI-DrugBank.d3.s21|23-30|morphine|drug
DDI-DrugBank.d3.s21|32-33|in|O
DDI-DrugBank.d3.s21|35-37|the|O
DDI-DrugBank.d3.s21|39-42|same|O
DDI-DrugBank.d3.s21|44-50|syringe|O
DDI-DrugBank.d3.s21|51-51|.|O
DDI-DrugBank.d3.s22|0-4|There|O
DDI-DrugBank.d3.s22|6-7|is|O
DDI-DrugBank.d3.s22|9-10|no|O
DDI-DrugBank.d3.s22|12-19|evidence|O
DDI-DrugBank.d3.s22|21-22|in|O
DDI-DrugBank.d3.s22|24-29|animal|O
DDI-DrugBank.d3.s22|31-32|or|O
DDI-DrugBank.d3.s22|34-38|human|O
DDI-DrugBank.d3.s22|40-46|studies|O
DDI-DrugBank.d3.s22|48-51|that|O
DDI-DrugBank.d3.s22|53-59|TORADOL|brand
DDI-DrugBank.d3.s22|61-67|induces|O
DDI-DrugBank.d3.s22|69-70|or|O
DDI-DrugBank.d3.s22|72-79|inhibits|O
DDI-DrugBank.d3.s22|81-87|hepatic|O
DDI-DrugBank.d3.s22|89-95|enzymes|O
DDI-DrugBank.d3.s22|97-103|capable|O
DDI-DrugBank.d3.s22|105-106|of|O
DDI-DrugBank.d3.s22|108-119|metabolizing|O
DDI-DrugBank.d3.s22|121-126|itself|O
DDI-DrugBank.d3.s22|128-129|or|O
DDI-DrugBank.d3.s22|131-135|other|O
DDI-DrugBank.d3.s22|137-141|drugs|O
DDI-DrugBank.d3.s23|0-0|.|O
DDI-DrugBank.d669.s0|0-10|Concomitant|O
DDI-DrugBank.d669.s0|12-25|administration|O
DDI-DrugBank.d669.s0|27-28|of|O
DDI-DrugBank.d669.s0|30-39|vancomycin|drug
DDI-DrugBank.d669.s0|41-43|and|O
DDI-DrugBank.d669.s0|45-61|anesthetic agents|group
DDI-DrugBank.d669.s0|63-65|has|O
DDI-DrugBank.d669.s0|67-70|been|O
DDI-DrugBank.d669.s0|72-81|associated|O
DDI-DrugBank.d669.s0|83-86|with|O
DDI-DrugBank.d669.s0|88-95|erythema|O
DDI-DrugBank.d669.s0|97-99|and|O
DDI-DrugBank.d669.s0|101-114|histamine-like|O
DDI-DrugBank.d669.s0|116-123|flushing|O
DDI-DrugBank.d669.s0|125-127|and|O
DDI-DrugBank.d669.s0|129-141|anaphylactoid|O
DDI-DrugBank.d669.s0|143-151|reactions|O
DDI-DrugBank.d669.s0|152-152|.|O
DDI-DrugBank.d669.s1|0-9|Concurrent|O
DDI-DrugBank.d669.s1|11-16|and/or|O
DDI-DrugBank.d669.s1|18-27|sequential|O
DDI-DrugBank.d669.s1|29-36|systemic|O
DDI-DrugBank.d669.s1|38-39|or|O
DDI-DrugBank.d669.s1|41-47|topical|O
DDI-DrugBank.d669.s1|49-51|use|O
DDI-DrugBank.d669.s1|53-54|of|O
DDI-DrugBank.d669.s1|56-60|other|O
DDI-DrugBank.d669.s1|62-72|potentially|O
DDI-DrugBank.d669.s1|74-83|neurotoxic|O
DDI-DrugBank.d669.s1|85-90|and/or|O
DDI-DrugBank.d669.s1|92-102|nephrotoxic|O
DDI-DrugBank.d669.s1|104-108|drugs|O
DDI-DrugBank.d669.s1|109-109|,|O
DDI-DrugBank.d669.s1|111-114|such|O
DDI-DrugBank.d669.s1|116-117|as|O
DDI-DrugBank.d669.s1|119-132|amphotericin B|drug
DDI-DrugBank.d669.s1|133-133|,|O
DDI-DrugBank.d669.s1|135-149|aminoglycosides|group
DDI-DrugBank.d669.s1|150-150|,|O
DDI-DrugBank.d669.s1|152-161|bacitracin|drug
DDI-DrugBank.d669.s1|162-162|,|O
DDI-DrugBank.d669.s1|164-174|polymyxin B|drug
DDI-DrugBank.d669.s1|175-175|,|O
DDI-DrugBank.d669.s1|177-184|colistin|drug
DDI-DrugBank.d669.s1|185-185|,|O
DDI-DrugBank.d669.s1|187-194|viomycin|drug
DDI-DrugBank.d669.s1|195-195|,|O
DDI-DrugBank.d669.s1|197-198|or|O
DDI-DrugBank.d669.s1|200-208|cisplatin|drug
DDI-DrugBank.d669.s1|209-209|,|O
DDI-DrugBank.d669.s1|211-214|when|O
DDI-DrugBank.d669.s1|216-224|indicated|O
DDI-DrugBank.d669.s1|225-225|,|O
DDI-DrugBank.d669.s1|227-234|requires|O
DDI-DrugBank.d669.s1|236-242|careful|O
DDI-DrugBank.d669.s1|244-253|monitoring|O
DDI-DrugBank.d669.s1|254-254|.|O
DDI-DrugBank.d496.s0|0-1|No|O
DDI-DrugBank.d496.s0|3-10|evidence|O
DDI-DrugBank.d496.s0|12-13|of|O
DDI-DrugBank.d496.s0|15-25|interaction|O
DDI-DrugBank.d496.s0|27-28|of|O
DDI-DrugBank.d496.s0|30-36|PROCRIT|brand
DDI-DrugBank.d496.s0|38-41|with|O
DDI-DrugBank.d496.s0|43-47|other|O
DDI-DrugBank.d496.s0|49-53|drugs|O
DDI-DrugBank.d496.s0|55-57|was|O
DDI-DrugBank.d496.s0|59-66|observed|O
DDI-DrugBank.d496.s0|68-69|in|O
DDI-DrugBank.d496.s0|71-73|the|O
DDI-DrugBank.d496.s0|75-80|course|O
DDI-DrugBank.d496.s0|82-83|of|O
DDI-DrugBank.d496.s0|85-92|clinical|O
DDI-DrugBank.d496.s0|94-99|trials|O
DDI-DrugBank.d496.s0|100-100|.|O
DDI-DrugBank.d432.s0|0-11|APRD00513_IN|O
DDI-DrugBank.d432.s0|12-12|,|O
DDI-DrugBank.d432.s0|13-15|txt|O
DDI-DrugBank.d47.s0|0-6|Caution|O
DDI-DrugBank.d47.s0|8-13|should|O
DDI-DrugBank.d47.s0|15-16|be|O
DDI-DrugBank.d47.s0|18-26|exercised|O
DDI-DrugBank.d47.s0|28-31|when|O
DDI-DrugBank.d47.s0|33-35|the|O
DDI-DrugBank.d47.s0|37-45|following|O
DDI-DrugBank.d47.s0|47-51|drugs|O
DDI-DrugBank.d47.s0|53-55|are|O
DDI-DrugBank.d47.s0|57-68|administered|O
DDI-DrugBank.d47.s0|70-82|concomitantly|O
DDI-DrugBank.d47.s0|84-87|with|O
DDI-DrugBank.d47.s0|89-95|LODOSYN|brand
DDI-DrugBank.d47.s0|97-97|(|O
DDI-DrugBank.d47.s0|98-106|Carbidopa|drug
DDI-DrugBank.d47.s0|107-107|)|O
DDI-DrugBank.d47.s0|109-113|given|O
DDI-DrugBank.d47.s0|115-118|with|O
DDI-DrugBank.d47.s0|120-127|levodopa|drug
DDI-DrugBank.d47.s0|129-130|or|O
DDI-DrugBank.d47.s0|132-149|carbidopa-levodopa|drug
DDI-DrugBank.d47.s0|151-161|combination|O
DDI-DrugBank.d47.s0|163-170|products|O
DDI-DrugBank.d47.s0|171-171|.|O
DDI-DrugBank.d47.s1|0-2|For|O
DDI-DrugBank.d47.s1|4-11|patients|O
DDI-DrugBank.d47.s1|13-21|receiving|O
DDI-DrugBank.d47.s1|23-50|monoamine oxidase inhibitors|group
DDI-DrugBank.d47.s1|51-51|,|O
DDI-DrugBank.d47.s1|53-55|see|O
DDI-DrugBank.d47.s1|57-73|CONTRAINDICATIONS|O
DDI-DrugBank.d47.s1|74-74|.|O
DDI-DrugBank.d47.s2|0-31|Dopamine D2 receptor antagonists|group
DDI-DrugBank.d47.s2|33-33|(|O
DDI-DrugBank.d47.s2|34-37|e.g.|O
DDI-DrugBank.d47.s2|38-38|,|O
DDI-DrugBank.d47.s2|40-53|phenothiazines|group
DDI-DrugBank.d47.s2|54-54|,|O
DDI-DrugBank.d47.s2|56-69|butyrophenones|group
DDI-DrugBank.d47.s2|70-70|,|O
DDI-DrugBank.d47.s2|72-82|risperidone|drug
DDI-DrugBank.d47.s2|83-83|)|O
DDI-DrugBank.d47.s2|85-87|and|O
DDI-DrugBank.d47.s2|89-97|isoniazid|drug
DDI-DrugBank.d47.s2|99-101|may|O
DDI-DrugBank.d47.s2|103-108|reduce|O
DDI-DrugBank.d47.s2|110-112|the|O
DDI-DrugBank.d47.s2|114-124|therapeutic|O
DDI-DrugBank.d47.s2|126-132|effects|O
DDI-DrugBank.d47.s2|134-135|of|O
DDI-DrugBank.d47.s2|137-144|levodopa|drug
DDI-DrugBank.d47.s2|145-145|.|O
DDI-DrugBank.d47.s3|0-1|In|O
DDI-DrugBank.d47.s3|3-10|addition|O
DDI-DrugBank.d47.s3|11-11|,|O
DDI-DrugBank.d47.s3|13-15|the|O
DDI-DrugBank.d47.s3|17-26|beneficial|O
DDI-DrugBank.d47.s3|28-34|effects|O
DDI-DrugBank.d47.s3|36-37|of|O
DDI-DrugBank.d47.s3|39-46|levodopa|drug
DDI-DrugBank.d47.s3|48-49|in|O
DDI-DrugBank.d47.s3|51-60|Parkinsons|O
DDI-DrugBank.d47.s3|62-68|disease|O
DDI-DrugBank.d47.s3|70-73|have|O
DDI-DrugBank.d47.s3|75-78|been|O
DDI-DrugBank.d47.s3|80-87|reported|O
DDI-DrugBank.d47.s3|89-90|to|O
DDI-DrugBank.d47.s3|92-93|be|O
DDI-DrugBank.d47.s3|95-102|reversed|O
DDI-DrugBank.d47.s3|104-105|by|O
DDI-DrugBank.d47.s3|107-115|phenytoin|drug
DDI-DrugBank.d47.s3|117-119|and|O
DDI-DrugBank.d47.s3|121-130|papaverine|drug
DDI-DrugBank.d47.s3|131-131|.|O
DDI-DrugBank.d47.s4|0-7|Patients|O
DDI-DrugBank.d47.s4|9-14|taking|O
DDI-DrugBank.d47.s4|16-20|these|O
DDI-DrugBank.d47.s4|22-26|drugs|O
DDI-DrugBank.d47.s4|28-31|with|O
DDI-DrugBank.d47.s4|33-39|LODOSYN|brand
DDI-DrugBank.d47.s4|41-43|and|O
DDI-DrugBank.d47.s4|45-52|levodopa|drug
DDI-DrugBank.d47.s4|54-55|or|O
DDI-DrugBank.d47.s4|57-74|carbidopa-levodopa|drug
DDI-DrugBank.d47.s4|76-86|combination|O
DDI-DrugBank.d47.s4|88-95|products|O
DDI-DrugBank.d47.s4|97-102|should|O
DDI-DrugBank.d47.s4|104-105|be|O
DDI-DrugBank.d47.s4|107-115|carefully|O
DDI-DrugBank.d47.s4|117-124|observed|O
DDI-DrugBank.d47.s4|126-128|for|O
DDI-DrugBank.d47.s4|130-133|loss|O
DDI-DrugBank.d47.s4|135-136|of|O
DDI-DrugBank.d47.s4|138-148|therapeutic|O
DDI-DrugBank.d47.s4|150-157|response|O
DDI-DrugBank.d47.s4|158-158|.|O
DDI-DrugBank.d47.s5|0-3|Iron|drug
DDI-DrugBank.d47.s5|5-9|salts|O
DDI-DrugBank.d47.s5|11-13|may|O
DDI-DrugBank.d47.s5|15-20|reduce|O
DDI-DrugBank.d47.s5|22-24|the|O
DDI-DrugBank.d47.s5|26-40|bioavailability|O
DDI-DrugBank.d47.s5|42-43|of|O
DDI-DrugBank.d47.s5|45-53|carbidopa|drug
DDI-DrugBank.d47.s5|55-57|and|O
DDI-DrugBank.d47.s5|59-66|levodopa|drug
DDI-DrugBank.d47.s5|67-67|.|O
DDI-DrugBank.d47.s6|0-2|The|O
DDI-DrugBank.d47.s6|4-11|clinical|O
DDI-DrugBank.d47.s6|13-21|relevance|O
DDI-DrugBank.d47.s6|23-24|is|O
DDI-DrugBank.d47.s6|26-32|unclear|O
DDI-DrugBank.d47.s6|33-33|.|O
DDI-DrugBank.d47.s7|0-7|Although|O
DDI-DrugBank.d47.s7|9-22|metoclopramide|drug
DDI-DrugBank.d47.s7|24-26|may|O
DDI-DrugBank.d47.s7|28-35|increase|O
DDI-DrugBank.d47.s7|37-39|the|O
DDI-DrugBank.d47.s7|41-55|bioavailability|O
DDI-DrugBank.d47.s7|57-58|of|O
DDI-DrugBank.d47.s7|60-67|levodopa|drug
DDI-DrugBank.d47.s7|69-70|by|O
DDI-DrugBank.d47.s7|72-81|increasing|O
DDI-DrugBank.d47.s7|83-89|gastric|O
DDI-DrugBank.d47.s7|91-98|emptying|O
DDI-DrugBank.d47.s7|99-99|,|O
DDI-DrugBank.d47.s7|101-114|metoclopramide|drug
DDI-DrugBank.d47.s7|116-118|may|O
DDI-DrugBank.d47.s7|120-123|also|O
DDI-DrugBank.d47.s7|125-133|adversely|O
DDI-DrugBank.d47.s7|135-140|affect|O
DDI-DrugBank.d47.s7|142-148|disease|O
DDI-DrugBank.d47.s7|150-156|control|O
DDI-DrugBank.d47.s7|158-159|by|O
DDI-DrugBank.d47.s7|161-163|its|O
DDI-DrugBank.d47.s7|165-172|dopamine|O
DDI-DrugBank.d47.s7|174-181|receptor|O
DDI-DrugBank.d47.s7|183-194|antagonistic|O
DDI-DrugBank.d47.s7|196-205|properties|O
DDI-DrugBank.d47.s7|206-206|.|O
DDI-DrugBank.d440.s0|0-6|Calcium|drug
DDI-DrugBank.d440.s1|0-7|Products|O
DDI-DrugBank.d440.s1|9-18|containing|O
DDI-DrugBank.d440.s1|20-26|calcium|drug
DDI-DrugBank.d440.s1|28-30|and|O
DDI-DrugBank.d440.s1|32-36|other|O
DDI-DrugBank.d440.s1|38-48|multivalent|O
DDI-DrugBank.d440.s1|50-56|cations|O
DDI-DrugBank.d440.s1|58-58|(|O
DDI-DrugBank.d440.s1|59-62|such|O
DDI-DrugBank.d440.s1|64-65|as|O
DDI-DrugBank.d440.s1|67-74|aluminum|drug
DDI-DrugBank.d440.s1|75-75|,|O
DDI-DrugBank.d440.s1|77-85|magnesium|drug
DDI-DrugBank.d440.s1|86-86|,|O
DDI-DrugBank.d440.s1|88-91|iron|drug
DDI-DrugBank.d440.s1|92-92|)|O
DDI-DrugBank.d440.s1|94-96|are|O
DDI-DrugBank.d440.s1|98-103|likely|O
DDI-DrugBank.d440.s1|105-106|to|O
DDI-DrugBank.d440.s1|108-116|interfere|O
DDI-DrugBank.d440.s1|118-121|with|O
DDI-DrugBank.d440.s1|123-132|absorption|O
DDI-DrugBank.d440.s1|134-135|of|O
DDI-DrugBank.d440.s1|137-147|Ibandronate|drug
DDI-DrugBank.d440.s1|148-148|.|O
DDI-DrugBank.d440.s2|0-10|Ibandronate|drug
DDI-DrugBank.d440.s2|12-17|should|O
DDI-DrugBank.d440.s2|19-20|be|O
DDI-DrugBank.d440.s2|22-26|taken|O
DDI-DrugBank.d440.s2|28-29|at|O
DDI-DrugBank.d440.s2|31-35|least|O
DDI-DrugBank.d440.s2|37-38|60|O
DDI-DrugBank.d440.s2|40-46|minutes|O
DDI-DrugBank.d440.s2|48-53|before|O
DDI-DrugBank.d440.s2|55-57|any|O
DDI-DrugBank.d440.s2|59-62|oral|O
DDI-DrugBank.d440.s2|64-74|medications|O
DDI-DrugBank.d440.s2|76-85|containing|O
DDI-DrugBank.d440.s2|87-97|multivalent|O
DDI-DrugBank.d440.s2|99-105|cations|O
DDI-DrugBank.d440.s2|107-107|(|O
DDI-DrugBank.d440.s2|108-116|including|O
DDI-DrugBank.d440.s2|118-125|antacids|group
DDI-DrugBank.d440.s2|126-126|,|O
DDI-DrugBank.d440.s2|128-138|supplements|O
DDI-DrugBank.d440.s2|140-141|or|O
DDI-DrugBank.d440.s2|143-150|vitamins|group
DDI-DrugBank.d440.s2|151-151|)|O
DDI-DrugBank.d440.s2|152-152|.|O
DDI-DrugBank.d440.s3|0-10|H2 Blockers|group
DDI-DrugBank.d440.s3|12-14|and|O
DDI-DrugBank.d440.s3|16-37|Proton Pump Inhibitors|group
DDI-DrugBank.d440.s3|39-39|(|O
DDI-DrugBank.d440.s3|40-43|PPIs|group
DDI-DrugBank.d440.s3|44-44|)|O
DDI-DrugBank.d440.s4|0-1|Of|O
DDI-DrugBank.d440.s4|3-6|over|O
DDI-DrugBank.d440.s4|8-11|3500|O
DDI-DrugBank.d440.s4|13-20|patients|O
DDI-DrugBank.d440.s4|22-29|enrolled|O
DDI-DrugBank.d440.s4|31-32|in|O
DDI-DrugBank.d440.s4|34-36|the|O
DDI-DrugBank.d440.s4|38-48|Ibandronate|drug
DDI-DrugBank.d440.s4|50-61|osteoporosis|O
DDI-DrugBank.d440.s4|63-71|Treatment|O
DDI-DrugBank.d440.s4|73-75|and|O
DDI-DrugBank.d440.s4|77-86|Prevention|O
DDI-DrugBank.d440.s4|88-94|Studies|O
DDI-DrugBank.d440.s4|95-95|,|O
DDI-DrugBank.d440.s4|97-98|15|O
DDI-DrugBank.d440.s4|99-99|%|O
DDI-DrugBank.d440.s4|101-104|used|O
DDI-DrugBank.d440.s4|106-116|anti-peptic|O
DDI-DrugBank.d440.s4|118-123|agents|O
DDI-DrugBank.d440.s4|125-125|(|O
DDI-DrugBank.d440.s4|126-134|primarily|O
DDI-DrugBank.d440.s4|136-146|H2 blockers|group
DDI-DrugBank.d440.s4|148-150|and|O
DDI-DrugBank.d440.s4|152-155|PPIs|group
DDI-DrugBank.d440.s4|156-156|)|O
DDI-DrugBank.d440.s4|157-157|.|O
DDI-DrugBank.d440.s5|0-4|Among|O
DDI-DrugBank.d440.s5|6-10|these|O
DDI-DrugBank.d440.s5|12-19|patients|O
DDI-DrugBank.d440.s5|20-20|,|O
DDI-DrugBank.d440.s5|22-24|the|O
DDI-DrugBank.d440.s5|26-34|incidence|O
DDI-DrugBank.d440.s5|36-37|of|O
DDI-DrugBank.d440.s5|39-43|upper|O
DDI-DrugBank.d440.s5|45-60|gastrointestinal|O
DDI-DrugBank.d440.s5|62-68|adverse|O
DDI-DrugBank.d440.s5|70-80|experiences|O
DDI-DrugBank.d440.s5|82-83|in|O
DDI-DrugBank.d440.s5|85-87|the|O
DDI-DrugBank.d440.s5|89-96|patients|O
DDI-DrugBank.d440.s5|98-104|treated|O
DDI-DrugBank.d440.s5|106-109|with|O
DDI-DrugBank.d440.s5|111-121|Ibandronate|drug
DDI-DrugBank.d440.s5|123-125|was|O
DDI-DrugBank.d440.s5|127-133|similar|O
DDI-DrugBank.d440.s5|135-136|to|O
DDI-DrugBank.d440.s5|138-141|that|O
DDI-DrugBank.d440.s5|143-144|in|O
DDI-DrugBank.d440.s5|146-160|placebo-treated|O
DDI-DrugBank.d440.s5|162-169|patients|O
DDI-DrugBank.d440.s5|170-170|.|O
DDI-DrugBank.d440.s6|0-8|Similarly|O
DDI-DrugBank.d440.s6|9-9|,|O
DDI-DrugBank.d440.s6|11-12|of|O
DDI-DrugBank.d440.s6|14-17|over|O
DDI-DrugBank.d440.s6|19-22|1600|O
DDI-DrugBank.d440.s6|24-31|patients|O
DDI-DrugBank.d440.s6|33-40|enrolled|O
DDI-DrugBank.d440.s6|42-43|in|O
DDI-DrugBank.d440.s6|45-45|a|O
DDI-DrugBank.d440.s6|47-51|study|O
DDI-DrugBank.d440.s6|53-61|comparing|O
DDI-DrugBank.d440.s6|63-74|once-monthly|O
DDI-DrugBank.d440.s6|76-79|with|O
DDI-DrugBank.d440.s6|81-85|daily|O
DDI-DrugBank.d440.s6|87-92|dosing|O
DDI-DrugBank.d440.s6|94-101|regimens|O
DDI-DrugBank.d440.s6|103-104|of|O
DDI-DrugBank.d440.s6|106-116|ibandronate|drug
DDI-DrugBank.d440.s6|117-117|,|O
DDI-DrugBank.d440.s6|119-120|14|O
DDI-DrugBank.d440.s6|121-121|%|O
DDI-DrugBank.d440.s6|123-124|of|O
DDI-DrugBank.d440.s6|126-133|patients|O
DDI-DrugBank.d440.s6|135-138|used|O
DDI-DrugBank.d440.s6|140-150|anti-peptic|O
DDI-DrugBank.d440.s6|152-157|agents|O
DDI-DrugBank.d440.s6|158-158|.|O
DDI-DrugBank.d440.s7|0-4|Among|O
DDI-DrugBank.d440.s7|6-10|these|O
DDI-DrugBank.d440.s7|12-19|patients|O
DDI-DrugBank.d440.s7|20-20|,|O
DDI-DrugBank.d440.s7|22-24|the|O
DDI-DrugBank.d440.s7|26-34|incidence|O
DDI-DrugBank.d440.s7|36-37|of|O
DDI-DrugBank.d440.s7|39-43|upper|O
DDI-DrugBank.d440.s7|45-60|gastrointestinal|O
DDI-DrugBank.d440.s7|62-68|adverse|O
DDI-DrugBank.d440.s7|70-80|experiences|O
DDI-DrugBank.d440.s7|82-83|in|O
DDI-DrugBank.d440.s7|85-87|the|O
DDI-DrugBank.d440.s7|89-96|patients|O
DDI-DrugBank.d440.s7|98-104|treated|O
DDI-DrugBank.d440.s7|106-109|with|O
DDI-DrugBank.d440.s7|111-121|Ibandronate|drug
DDI-DrugBank.d440.s7|123-125|150|O
DDI-DrugBank.d440.s7|127-128|mg|O
DDI-DrugBank.d440.s7|130-133|once|O
DDI-DrugBank.d440.s7|135-141|monthly|O
DDI-DrugBank.d440.s7|143-145|was|O
DDI-DrugBank.d440.s7|147-153|similar|O
DDI-DrugBank.d440.s7|155-156|to|O
DDI-DrugBank.d440.s7|158-161|that|O
DDI-DrugBank.d440.s7|163-164|in|O
DDI-DrugBank.d440.s7|166-173|patients|O
DDI-DrugBank.d440.s7|175-181|treated|O
DDI-DrugBank.d440.s7|183-186|with|O
DDI-DrugBank.d440.s7|188-198|Ibandronate|drug
DDI-DrugBank.d440.s7|200-202|2.5|O
DDI-DrugBank.d440.s7|204-205|mg|O
DDI-DrugBank.d440.s7|207-210|once|O
DDI-DrugBank.d440.s7|212-216|daily|O
DDI-DrugBank.d440.s7|217-217|.|O
DDI-DrugBank.d440.s8|0-19|Aspirin/Nonsteroidal|brand
DDI-DrugBank.d440.s8|21-36|Antiinflammatory|group
DDI-DrugBank.d440.s8|38-42|Drugs|O
DDI-DrugBank.d440.s8|44-44|(|O
DDI-DrugBank.d440.s8|45-50|NSAIDs|group
DDI-DrugBank.d440.s8|51-51|)|O
DDI-DrugBank.d440.s9|0-1|In|O
DDI-DrugBank.d440.s9|3-5|the|O
DDI-DrugBank.d440.s9|7-11|large|O
DDI-DrugBank.d440.s9|12-12|,|O
DDI-DrugBank.d440.s9|14-31|placebo-controlled|O
DDI-DrugBank.d440.s9|33-44|osteoporosis|O
DDI-DrugBank.d440.s9|46-54|Treatment|O
DDI-DrugBank.d440.s9|56-60|Study|O
DDI-DrugBank.d440.s9|61-61|,|O
DDI-DrugBank.d440.s9|63-69|aspirin|brand
DDI-DrugBank.d440.s9|71-73|and|O
DDI-DrugBank.d440.s9|75-110|nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d440.s9|112-115|were|O
DDI-DrugBank.d440.s9|117-121|taken|O
DDI-DrugBank.d440.s9|123-124|by|O
DDI-DrugBank.d440.s9|126-127|62|O
DDI-DrugBank.d440.s9|128-128|%|O
DDI-DrugBank.d440.s9|130-131|of|O
DDI-DrugBank.d440.s9|133-135|the|O
DDI-DrugBank.d440.s9|137-140|2946|O
DDI-DrugBank.d440.s9|142-149|patients|O
DDI-DrugBank.d440.s9|150-150|.|O
DDI-DrugBank.d440.s10|0-4|Among|O
DDI-DrugBank.d440.s10|6-12|aspirin|brand
DDI-DrugBank.d440.s10|14-15|or|O
DDI-DrugBank.d440.s10|17-21|NSAID|group
DDI-DrugBank.d440.s10|23-27|users|O
DDI-DrugBank.d440.s10|28-28|,|O
DDI-DrugBank.d440.s10|30-32|the|O
DDI-DrugBank.d440.s10|34-42|incidence|O
DDI-DrugBank.d440.s10|44-45|of|O
DDI-DrugBank.d440.s10|47-51|upper|O
DDI-DrugBank.d440.s10|53-68|gastrointestinal|O
DDI-DrugBank.d440.s10|70-76|adverse|O
DDI-DrugBank.d440.s10|78-83|events|O
DDI-DrugBank.d440.s10|85-86|in|O
DDI-DrugBank.d440.s10|88-95|patients|O
DDI-DrugBank.d440.s10|97-103|treated|O
DDI-DrugBank.d440.s10|105-108|with|O
DDI-DrugBank.d440.s10|110-120|ibandronate|drug
DDI-DrugBank.d440.s10|122-124|2.5|O
DDI-DrugBank.d440.s10|126-127|mg|O
DDI-DrugBank.d440.s10|129-133|daily|O
DDI-DrugBank.d440.s10|135-135|(|O
DDI-DrugBank.d440.s10|136-139|28.9|O
DDI-DrugBank.d440.s10|140-140|%|O
DDI-DrugBank.d440.s10|141-141|)|O
DDI-DrugBank.d440.s10|143-145|was|O
DDI-DrugBank.d440.s10|147-153|similar|O
DDI-DrugBank.d440.s10|155-156|to|O
DDI-DrugBank.d440.s10|158-161|that|O
DDI-DrugBank.d440.s10|163-164|in|O
DDI-DrugBank.d440.s10|166-180|placebo-treated|O
DDI-DrugBank.d440.s10|182-189|patients|O
DDI-DrugBank.d440.s10|191-191|(|O
DDI-DrugBank.d440.s10|192-195|30.7|O
DDI-DrugBank.d440.s10|196-196|%|O
DDI-DrugBank.d440.s10|197-197|)|O
DDI-DrugBank.d440.s10|198-198|.|O
DDI-DrugBank.d440.s11|0-8|Similarly|O
DDI-DrugBank.d440.s11|9-9|,|O
DDI-DrugBank.d440.s11|11-12|in|O
DDI-DrugBank.d440.s11|14-16|the|O
DDI-DrugBank.d440.s11|18-23|1-year|O
DDI-DrugBank.d440.s11|25-31|monthly|O
DDI-DrugBank.d440.s11|33-42|comparison|O
DDI-DrugBank.d440.s11|44-48|study|O
DDI-DrugBank.d440.s11|49-49|,|O
DDI-DrugBank.d440.s11|51-57|aspirin|brand
DDI-DrugBank.d440.s11|59-61|and|O
DDI-DrugBank.d440.s11|63-98|nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d440.s11|100-103|were|O
DDI-DrugBank.d440.s11|105-109|taken|O
DDI-DrugBank.d440.s11|111-112|by|O
DDI-DrugBank.d440.s11|114-115|39|O
DDI-DrugBank.d440.s11|116-116|%|O
DDI-DrugBank.d440.s11|118-119|of|O
DDI-DrugBank.d440.s11|121-123|the|O
DDI-DrugBank.d440.s11|125-128|1602|O
DDI-DrugBank.d440.s11|130-137|patients|O
DDI-DrugBank.d440.s11|138-138|.|O
DDI-DrugBank.d440.s12|0-2|The|O
DDI-DrugBank.d440.s12|4-12|incidence|O
DDI-DrugBank.d440.s12|14-15|of|O
DDI-DrugBank.d440.s12|17-21|upper|O
DDI-DrugBank.d440.s12|23-38|gastrointestinal|O
DDI-DrugBank.d440.s12|40-45|events|O
DDI-DrugBank.d440.s12|47-48|in|O
DDI-DrugBank.d440.s12|50-57|patients|O
DDI-DrugBank.d440.s12|59-71|concomitantly|O
DDI-DrugBank.d440.s12|73-78|taking|O
DDI-DrugBank.d440.s12|80-86|aspirin|brand
DDI-DrugBank.d440.s12|88-89|or|O
DDI-DrugBank.d440.s12|91-96|NSAIDs|group
DDI-DrugBank.d440.s12|98-100|was|O
DDI-DrugBank.d440.s12|102-108|similar|O
DDI-DrugBank.d440.s12|110-111|in|O
DDI-DrugBank.d440.s12|113-120|patients|O
DDI-DrugBank.d440.s12|122-127|taking|O
DDI-DrugBank.d440.s12|129-139|ibandronate|drug
DDI-DrugBank.d440.s12|141-143|2.5|O
DDI-DrugBank.d440.s12|145-146|mg|O
DDI-DrugBank.d440.s12|148-152|daily|O
DDI-DrugBank.d440.s12|154-154|(|O
DDI-DrugBank.d440.s12|155-158|21.7|O
DDI-DrugBank.d440.s12|159-159|%|O
DDI-DrugBank.d440.s12|160-160|)|O
DDI-DrugBank.d440.s12|162-164|and|O
DDI-DrugBank.d440.s12|166-168|150|O
DDI-DrugBank.d440.s12|170-171|mg|O
DDI-DrugBank.d440.s12|173-176|once|O
DDI-DrugBank.d440.s12|178-184|monthly|O
DDI-DrugBank.d440.s12|186-186|(|O
DDI-DrugBank.d440.s12|187-190|22.0|O
DDI-DrugBank.d440.s12|191-191|%|O
DDI-DrugBank.d440.s12|192-192|)|O
DDI-DrugBank.d440.s12|193-193|.|O
DDI-DrugBank.d440.s13|0-6|However|O
DDI-DrugBank.d440.s13|7-7|,|O
DDI-DrugBank.d440.s13|9-13|since|O
DDI-DrugBank.d440.s13|15-21|aspirin|brand
DDI-DrugBank.d440.s13|22-22|,|O
DDI-DrugBank.d440.s13|24-29|NSAIDs|group
DDI-DrugBank.d440.s13|30-30|,|O
DDI-DrugBank.d440.s13|32-34|and|O
DDI-DrugBank.d440.s13|36-50|bisphosphonates|group
DDI-DrugBank.d440.s13|52-54|are|O
DDI-DrugBank.d440.s13|56-58|all|O
DDI-DrugBank.d440.s13|60-69|associated|O
DDI-DrugBank.d440.s13|71-74|with|O
DDI-DrugBank.d440.s13|76-91|gastrointestinal|O
DDI-DrugBank.d440.s13|93-102|irritation|O
DDI-DrugBank.d440.s13|103-103|,|O
DDI-DrugBank.d440.s13|105-111|caution|O
DDI-DrugBank.d440.s13|113-118|should|O
DDI-DrugBank.d440.s13|120-121|be|O
DDI-DrugBank.d440.s13|123-131|exercised|O
DDI-DrugBank.d440.s13|133-134|in|O
DDI-DrugBank.d440.s13|136-138|the|O
DDI-DrugBank.d440.s13|140-150|concomitant|O
DDI-DrugBank.d440.s13|152-154|use|O
DDI-DrugBank.d440.s13|156-157|of|O
DDI-DrugBank.d440.s13|159-165|aspirin|brand
DDI-DrugBank.d440.s13|167-168|or|O
DDI-DrugBank.d440.s13|170-175|NSAIDs|group
DDI-DrugBank.d440.s13|177-180|with|O
DDI-DrugBank.d440.s13|182-192|Ibandronate|drug
DDI-DrugBank.d440.s13|193-193|.|O
DDI-DrugBank.d440.s14|0-14|Drug/Laboratory|O
DDI-DrugBank.d440.s14|16-19|Test|O
DDI-DrugBank.d440.s14|21-32|Interactions|O
DDI-DrugBank.d440.s15|0-14|Bisphosphonates|group
DDI-DrugBank.d440.s15|16-18|are|O
DDI-DrugBank.d440.s15|20-24|known|O
DDI-DrugBank.d440.s15|26-27|to|O
DDI-DrugBank.d440.s15|29-37|interfere|O
DDI-DrugBank.d440.s15|39-42|with|O
DDI-DrugBank.d440.s15|44-46|the|O
DDI-DrugBank.d440.s15|48-50|use|O
DDI-DrugBank.d440.s15|52-53|of|O
DDI-DrugBank.d440.s15|55-66|bone-imaging|O
DDI-DrugBank.d440.s15|68-73|agents|O
DDI-DrugBank.d440.s15|74-74|.|O
DDI-DrugBank.d440.s16|0-7|Specific|O
DDI-DrugBank.d440.s16|9-15|studies|O
DDI-DrugBank.d440.s16|17-20|with|O
DDI-DrugBank.d440.s16|22-32|ibandronate|drug
DDI-DrugBank.d440.s16|34-37|have|O
DDI-DrugBank.d440.s16|39-41|not|O
DDI-DrugBank.d440.s16|43-46|been|O
DDI-DrugBank.d440.s16|48-56|performed|O
DDI-DrugBank.d440.s16|57-57|.|O
DDI-DrugBank.d551.s0|0-6|WelChol|brand
DDI-DrugBank.d551.s0|9-11|has|O
DDI-DrugBank.d551.s0|13-16|been|O
DDI-DrugBank.d551.s0|18-24|studied|O
DDI-DrugBank.d551.s0|26-27|in|O
DDI-DrugBank.d551.s0|29-35|several|O
DDI-DrugBank.d551.s0|37-41|human|O
DDI-DrugBank.d551.s0|43-46|drug|O
DDI-DrugBank.d551.s0|48-58|interaction|O
DDI-DrugBank.d551.s0|60-66|studies|O
DDI-DrugBank.d551.s0|68-69|in|O
DDI-DrugBank.d551.s0|71-75|which|O
DDI-DrugBank.d551.s0|77-78|it|O
DDI-DrugBank.d551.s0|80-82|was|O
DDI-DrugBank.d551.s0|84-95|administered|O
DDI-DrugBank.d551.s0|97-100|with|O
DDI-DrugBank.d551.s0|102-102|a|O
DDI-DrugBank.d551.s0|104-107|meal|O
DDI-DrugBank.d551.s0|109-111|and|O
DDI-DrugBank.d551.s0|113-115|the|O
DDI-DrugBank.d551.s0|117-120|test|O
DDI-DrugBank.d551.s0|122-125|drug|O
DDI-DrugBank.d551.s0|126-126|.|O
DDI-DrugBank.d551.s1|0-6|WelChol|brand
DDI-DrugBank.d551.s1|9-11|was|O
DDI-DrugBank.d551.s1|13-17|found|O
DDI-DrugBank.d551.s1|19-20|to|O
DDI-DrugBank.d551.s1|22-25|have|O
DDI-DrugBank.d551.s1|27-28|no|O
DDI-DrugBank.d551.s1|30-40|significant|O
DDI-DrugBank.d551.s1|42-47|effect|O
DDI-DrugBank.d551.s1|49-50|on|O
DDI-DrugBank.d551.s1|52-54|the|O
DDI-DrugBank.d551.s1|56-70|bioavailability|O
DDI-DrugBank.d551.s1|72-73|of|O
DDI-DrugBank.d551.s1|75-81|digoxin|drug
DDI-DrugBank.d551.s1|82-82|,|O
DDI-DrugBank.d551.s1|84-93|lovastatin|drug
DDI-DrugBank.d551.s1|94-94|,|O
DDI-DrugBank.d551.s1|96-105|metoprolol|drug
DDI-DrugBank.d551.s1|106-106|,|O
DDI-DrugBank.d551.s1|108-116|quinidine|drug
DDI-DrugBank.d551.s1|117-117|,|O
DDI-DrugBank.d551.s1|119-131|valproic acid|drug
DDI-DrugBank.d551.s1|132-132|,|O
DDI-DrugBank.d551.s1|134-136|and|O
DDI-DrugBank.d551.s1|138-145|warfarin|drug
DDI-DrugBank.d551.s1|146-146|.|O
DDI-DrugBank.d551.s2|0-6|WelChol|brand
DDI-DrugBank.d551.s2|9-17|decreased|O
DDI-DrugBank.d551.s2|19-21|the|O
DDI-DrugBank.d551.s2|23-26|Cmax|O
DDI-DrugBank.d551.s2|28-30|and|O
DDI-DrugBank.d551.s2|32-34|AUC|O
DDI-DrugBank.d551.s2|36-37|of|O
DDI-DrugBank.d551.s2|39-55|sustained-release|O
DDI-DrugBank.d551.s2|57-65|verapamil|drug
DDI-DrugBank.d551.s2|67-67|(|O
DDI-DrugBank.d551.s2|68-75|Calan SR|brand
DDI-DrugBank.d551.s2|77-77|)|O
DDI-DrugBank.d551.s2|79-80|by|O
DDI-DrugBank.d551.s2|82-94|approximately|O
DDI-DrugBank.d551.s2|96-97|31|O
DDI-DrugBank.d551.s2|98-98|%|O
DDI-DrugBank.d551.s2|100-102|and|O
DDI-DrugBank.d551.s2|104-105|11|O
DDI-DrugBank.d551.s2|106-106|%|O
DDI-DrugBank.d551.s2|107-107|,|O
DDI-DrugBank.d551.s2|109-120|respectively|O
DDI-DrugBank.d551.s2|121-121|.|O
DDI-DrugBank.d551.s3|0-4|Since|O
DDI-DrugBank.d551.s3|6-10|there|O
DDI-DrugBank.d551.s3|12-13|is|O
DDI-DrugBank.d551.s3|15-15|a|O
DDI-DrugBank.d551.s3|17-20|high|O
DDI-DrugBank.d551.s3|22-27|degree|O
DDI-DrugBank.d551.s3|29-30|of|O
DDI-DrugBank.d551.s3|32-42|variability|O
DDI-DrugBank.d551.s3|44-45|in|O
DDI-DrugBank.d551.s3|47-49|the|O
DDI-DrugBank.d551.s3|51-65|bioavailability|O
DDI-DrugBank.d551.s3|67-68|of|O
DDI-DrugBank.d551.s3|70-78|verapamil|drug
DDI-DrugBank.d551.s3|79-79|,|O
DDI-DrugBank.d551.s3|81-83|the|O
DDI-DrugBank.d551.s3|85-92|clinical|O
DDI-DrugBank.d551.s3|94-105|significance|O
DDI-DrugBank.d551.s3|107-108|of|O
DDI-DrugBank.d551.s3|110-113|this|O
DDI-DrugBank.d551.s3|115-121|finding|O
DDI-DrugBank.d551.s3|123-124|is|O
DDI-DrugBank.d551.s3|126-132|unclear|O
DDI-DrugBank.d551.s3|133-133|.|O
DDI-DrugBank.d551.s4|0-1|In|O
DDI-DrugBank.d551.s4|3-10|clinical|O
DDI-DrugBank.d551.s4|12-18|studies|O
DDI-DrugBank.d551.s4|19-19|,|O
DDI-DrugBank.d551.s4|21-36|coadministration|O
DDI-DrugBank.d551.s4|38-39|of|O
DDI-DrugBank.d551.s4|41-47|WelChol|brand
DDI-DrugBank.d551.s4|50-53|with|O
DDI-DrugBank.d551.s4|55-66|atorvastatin|drug
DDI-DrugBank.d551.s4|67-67|,|O
DDI-DrugBank.d551.s4|69-78|lovastatin|drug
DDI-DrugBank.d551.s4|79-79|,|O
DDI-DrugBank.d551.s4|81-82|or|O
DDI-DrugBank.d551.s4|84-94|simvastatin|drug
DDI-DrugBank.d551.s4|96-98|did|O
DDI-DrugBank.d551.s4|100-102|not|O
DDI-DrugBank.d551.s4|104-112|interfere|O
DDI-DrugBank.d551.s4|114-117|with|O
DDI-DrugBank.d551.s4|119-121|the|O
DDI-DrugBank.d551.s4|123-136|lipid-lowering|O
DDI-DrugBank.d551.s4|138-145|activity|O
DDI-DrugBank.d551.s4|147-148|of|O
DDI-DrugBank.d551.s4|150-152|the|O
DDI-DrugBank.d551.s4|154-180|HMG-CoA reductase inhibitor|group
DDI-DrugBank.d551.s4|181-181|.|O
DDI-DrugBank.d551.s5|0-4|Other|O
DDI-DrugBank.d551.s5|6-10|drugs|O
DDI-DrugBank.d551.s5|12-15|have|O
DDI-DrugBank.d551.s5|17-19|not|O
DDI-DrugBank.d551.s5|21-24|been|O
DDI-DrugBank.d551.s5|26-32|studied|O
DDI-DrugBank.d551.s5|33-33|.|O
DDI-DrugBank.d551.s6|0-3|When|O
DDI-DrugBank.d551.s6|5-17|administering|O
DDI-DrugBank.d551.s6|19-23|other|O
DDI-DrugBank.d551.s6|25-29|drugs|O
DDI-DrugBank.d551.s6|31-33|for|O
DDI-DrugBank.d551.s6|35-39|which|O
DDI-DrugBank.d551.s6|41-51|alterations|O
DDI-DrugBank.d551.s6|53-54|in|O
DDI-DrugBank.d551.s6|56-60|blood|O
DDI-DrugBank.d551.s6|62-67|levels|O
DDI-DrugBank.d551.s6|69-73|could|O
DDI-DrugBank.d551.s6|75-78|have|O
DDI-DrugBank.d551.s6|80-80|a|O
DDI-DrugBank.d551.s6|82-91|clinically|O
DDI-DrugBank.d551.s6|93-103|significant|O
DDI-DrugBank.d551.s6|105-110|effect|O
DDI-DrugBank.d551.s6|112-113|on|O
DDI-DrugBank.d551.s6|115-120|safety|O
DDI-DrugBank.d551.s6|122-123|or|O
DDI-DrugBank.d551.s6|125-132|efficacy|O
DDI-DrugBank.d551.s6|133-133|,|O
DDI-DrugBank.d551.s6|135-144|physicians|O
DDI-DrugBank.d551.s6|146-151|should|O
DDI-DrugBank.d551.s6|153-160|consider|O
DDI-DrugBank.d551.s6|162-171|monitoring|O
DDI-DrugBank.d551.s6|173-176|drug|O
DDI-DrugBank.d551.s6|178-183|levels|O
DDI-DrugBank.d551.s6|185-186|or|O
DDI-DrugBank.d551.s6|188-194|effects|O
DDI-DrugBank.d551.s6|195-195|.|O
DDI-MedLine.d5.s0|0-7|Repeated|O
DDI-MedLine.d5.s0|9-12|oral|O
DDI-MedLine.d5.s0|14-27|administration|O
DDI-MedLine.d5.s0|29-30|of|O
DDI-MedLine.d5.s0|42-43|in|O
DDI-MedLine.d5.s0|45-49|sheep|O
DDI-MedLine.d5.s0|50-50|:|O
DDI-MedLine.d5.s0|52-63|interactions|O
DDI-MedLine.d5.s0|65-66|of|O
DDI-MedLine.d5.s0|78-81|with|O
DDI-MedLine.d5.s0|83-100|bishydroxycoumarin|drug
DDI-MedLine.d5.s0|101-101|,|O
DDI-MedLine.d5.s0|114-114|,|O
DDI-MedLine.d5.s0|116-118|and|O
DDI-MedLine.d5.s0|120-139|phenobarbital sodium|drug
DDI-MedLine.d5.s0|140-140|.|O
DDI-MedLine.d5.s1|0-11|Interactions|O
DDI-MedLine.d5.s1|13-19|between|O
DDI-MedLine.d5.s1|21-30|treatments|O
DDI-MedLine.d5.s1|32-35|with|O
DDI-MedLine.d5.s1|46-46|,|O
DDI-MedLine.d5.s1|48-65|bishydroxycoumarin|drug
DDI-MedLine.d5.s1|67-67|(|O
DDI-MedLine.d5.s1|68-69|an|O
DDI-MedLine.d5.s1|71-83|anticoagulant|group
DDI-MedLine.d5.s1|84-84|)|O
DDI-MedLine.d5.s1|85-85|,|O
DDI-MedLine.d5.s1|99-99|(|O
DDI-MedLine.d5.s1|100-101|an|O
DDI-MedLine.d5.s1|103-128|organophosphorous compound|group
DDI-MedLine.d5.s1|129-129|)|O
DDI-MedLine.d5.s1|130-130|,|O
DDI-MedLine.d5.s1|132-134|and|O
DDI-MedLine.d5.s1|136-155|phenobarbital sodium|drug
DDI-MedLine.d5.s1|157-157|(|O
DDI-MedLine.d5.s1|158-159|an|O
DDI-MedLine.d5.s1|161-167|inducer|O
DDI-MedLine.d5.s1|169-170|of|O
DDI-MedLine.d5.s1|172-181|microsomal|O
DDI-MedLine.d5.s1|183-189|enzymes|O
DDI-MedLine.d5.s1|190-190|)|O
DDI-MedLine.d5.s1|192-195|were|O
DDI-MedLine.d5.s1|197-208|investigated|O
DDI-MedLine.d5.s1|210-211|in|O
DDI-MedLine.d5.s1|213-217|sheep|O
DDI-MedLine.d5.s1|218-218|.|O
DDI-MedLine.d5.s2|0-0|A|O
DDI-MedLine.d5.s2|2-6|daily|O
DDI-MedLine.d5.s2|8-11|dose|O
DDI-MedLine.d5.s2|13-14|of|O
DDI-MedLine.d5.s2|16-16|2|O
DDI-MedLine.d5.s2|18-19|mg|O
DDI-MedLine.d5.s2|21-22|of|O
DDI-MedLine.d5.s2|37-38|of|O
DDI-MedLine.d5.s2|40-43|body|O
DDI-MedLine.d5.s2|45-50|weight|O
DDI-MedLine.d5.s2|52-54|for|O
DDI-MedLine.d5.s2|56-56|6|O
DDI-MedLine.d5.s2|58-61|days|O
DDI-MedLine.d5.s2|63-65|did|O
DDI-MedLine.d5.s2|67-69|not|O
DDI-MedLine.d5.s2|71-76|affect|O
DDI-MedLine.d5.s2|78-80|the|O
DDI-MedLine.d5.s2|82-87|plasma|O
DDI-MedLine.d5.s2|89-95|enzymes|O
DDI-MedLine.d5.s2|97-98|or|O
DDI-MedLine.d5.s2|100-102|the|O
DDI-MedLine.d5.s2|104-122|antiprothrombinemic|O
DDI-MedLine.d5.s2|124-129|effect|O
DDI-MedLine.d5.s2|131-132|of|O
DDI-MedLine.d5.s2|134-152|bishydroxy-coumarin|drug
DDI-MedLine.d5.s2|154-155|in|O
DDI-MedLine.d5.s2|157-163|wethers|O
DDI-MedLine.d5.s2|164-164|.|O
DDI-MedLine.d5.s3|0-2|The|O
DDI-MedLine.d5.s3|4-12|treatment|O
DDI-MedLine.d5.s3|14-15|of|O
DDI-MedLine.d5.s3|17-20|ewes|O
DDI-MedLine.d5.s3|22-25|with|O
DDI-MedLine.d5.s3|27-28|an|O
DDI-MedLine.d5.s3|30-40|intravenous|O
DDI-MedLine.d5.s3|42-42|(|O
DDI-MedLine.d5.s3|43-44|IV|O
DDI-MedLine.d5.s3|45-45|)|O
DDI-MedLine.d5.s3|47-55|injection|O
DDI-MedLine.d5.s3|57-58|of|O
DDI-MedLine.d5.s3|71-71|,|O
DDI-MedLine.d5.s3|73-84|insufficient|O
DDI-MedLine.d5.s3|86-87|to|O
DDI-MedLine.d5.s3|89-95|produce|O
DDI-MedLine.d5.s3|97-107|significant|O
DDI-MedLine.d5.s3|109-118|inhibition|O
DDI-MedLine.d5.s3|120-121|of|O
DDI-MedLine.d5.s3|123-133|erythrocyte|O
DDI-MedLine.d5.s3|135-154|acetylcholinesterase|O
DDI-MedLine.d5.s3|156-156|(|O
DDI-MedLine.d5.s3|157-160|AChE|O
DDI-MedLine.d5.s3|161-161|)|O
DDI-MedLine.d5.s3|163-170|activity|O
DDI-MedLine.d5.s3|171-171|,|O
DDI-MedLine.d5.s3|173-180|appeared|O
DDI-MedLine.d5.s3|182-183|to|O
DDI-MedLine.d5.s3|185-191|produce|O
DDI-MedLine.d5.s3|193-200|additive|O
DDI-MedLine.d5.s3|202-208|effects|O
DDI-MedLine.d5.s3|210-213|with|O
DDI-MedLine.d5.s3|215-219|those|O
DDI-MedLine.d5.s3|221-228|produced|O
DDI-MedLine.d5.s3|230-231|by|O
DDI-MedLine.d5.s3|233-242|subsequent|O
DDI-MedLine.d5.s3|244-252|treatment|O
DDI-MedLine.d5.s3|254-257|with|O
DDI-MedLine.d5.s3|259-259|4|O
DDI-MedLine.d5.s3|261-262|mg|O
DDI-MedLine.d5.s3|264-265|of|O
DDI-MedLine.d5.s3|283-283|.|O
DDI-MedLine.d5.s4|0-1|In|O
DDI-MedLine.d5.s4|3-6|ewes|O
DDI-MedLine.d5.s4|8-12|given|O
DDI-MedLine.d5.s4|14-15|40|O
DDI-MedLine.d5.s4|17-18|mg|O
DDI-MedLine.d5.s4|20-21|of|O
DDI-MedLine.d5.s4|23-35|phenobarbital|drug
DDI-MedLine.d5.s4|37-45|sodium/kg|O
DDI-MedLine.d5.s4|47-49|for|O
DDI-MedLine.d5.s4|51-51|5|O
DDI-MedLine.d5.s4|53-56|days|O
DDI-MedLine.d5.s4|58-74|intraperitoneally|O
DDI-MedLine.d5.s4|76-76|(|O
DDI-MedLine.d5.s4|77-78|IP|O
DDI-MedLine.d5.s4|79-79|)|O
DDI-MedLine.d5.s4|80-80|,|O
DDI-MedLine.d5.s4|82-84|the|O
DDI-MedLine.d5.s4|86-103|anticholinesterase|O
DDI-MedLine.d5.s4|105-110|effect|O
DDI-MedLine.d5.s4|112-113|of|O
DDI-MedLine.d5.s4|115-115|4|O
DDI-MedLine.d5.s4|117-118|mg|O
DDI-MedLine.d5.s4|120-121|of|O
DDI-MedLine.d5.s4|136-138|was|O
DDI-MedLine.d5.s4|140-152|significantly|O
DDI-MedLine.d5.s4|154-160|reduced|O
DDI-MedLine.d5.s4|162-164|and|O
DDI-MedLine.d5.s4|166-170|signs|O
DDI-MedLine.d5.s4|172-173|of|O
DDI-MedLine.d5.s4|175-182|toxicity|O
DDI-MedLine.d5.s4|184-187|were|O
DDI-MedLine.d5.s4|189-191|not|O
DDI-MedLine.d5.s4|193-199|present|O
DDI-MedLine.d5.s4|200-200|.|O
DDI-MedLine.d5.s5|0-8|Treatment|O
DDI-MedLine.d5.s5|10-13|with|O
DDI-MedLine.d5.s5|15-19|daily|O
DDI-MedLine.d5.s5|21-25|doses|O
DDI-MedLine.d5.s5|27-28|of|O
DDI-MedLine.d5.s5|30-30|2|O
DDI-MedLine.d5.s5|32-33|mg|O
DDI-MedLine.d5.s5|35-36|of|O
DDI-MedLine.d5.s5|51-53|for|O
DDI-MedLine.d5.s5|55-55|6|O
DDI-MedLine.d5.s5|57-60|days|O
DDI-MedLine.d5.s5|62-64|did|O
DDI-MedLine.d5.s5|66-68|not|O
DDI-MedLine.d5.s5|70-75|modify|O
DDI-MedLine.d5.s5|77-79|the|O
DDI-MedLine.d5.s5|81-98|anticholinesterase|O
DDI-MedLine.d5.s5|100-105|effect|O
DDI-MedLine.d5.s5|107-108|of|O
DDI-MedLine.d5.s5|110-110|a|O
DDI-MedLine.d5.s5|112-114|2nd|O
DDI-MedLine.d5.s5|116-121|series|O
DDI-MedLine.d5.s5|123-124|of|O
DDI-MedLine.d5.s5|126-135|treatments|O
DDI-MedLine.d5.s5|137-141|given|O
DDI-MedLine.d5.s5|143-143|6|O
DDI-MedLine.d5.s5|145-149|weeks|O
DDI-MedLine.d5.s5|151-155|later|O
DDI-MedLine.d5.s5|156-156|.|O
DDI-MedLine.d134.s0|0-0|[|O
DDI-MedLine.d134.s0|1-9|Dose-time|O
DDI-MedLine.d134.s0|11-17|effects|O
DDI-MedLine.d134.s0|19-20|of|O
DDI-MedLine.d134.s0|22-32|competitive|O
DDI-MedLine.d134.s0|34-45|displacement|O
DDI-MedLine.d134.s0|47-48|of|O
DDI-MedLine.d134.s0|50-67|radiopertechnetate|drug
DDI-MedLine.d134.s0|69-70|by|O
DDI-MedLine.d134.s0|91-99|following|O
DDI-MedLine.d134.s0|101-104|oral|O
DDI-MedLine.d134.s0|106-108|and|O
DDI-MedLine.d134.s0|110-120|intravenous|O
DDI-MedLine.d134.s0|122-135|administration|O
DDI-MedLine.d134.s0|136-136|]|O
DDI-MedLine.d134.s0|139-141|The|O
DDI-MedLine.d134.s0|143-148|effect|O
DDI-MedLine.d134.s0|150-151|of|O
DDI-MedLine.d134.s0|153-159|various|O
DDI-MedLine.d134.s0|161-165|doses|O
DDI-MedLine.d134.s0|167-168|of|O
DDI-MedLine.d134.s0|189-190|in|O
DDI-MedLine.d134.s0|192-198|several|O
DDI-MedLine.d134.s0|200-203|dose|O
DDI-MedLine.d134.s0|205-213|fractions|O
DDI-MedLine.d134.s0|215-216|on|O
DDI-MedLine.d134.s0|218-220|the|O
DDI-MedLine.d134.s0|222-227|extent|O
DDI-MedLine.d134.s0|229-231|and|O
DDI-MedLine.d134.s0|233-235|the|O
DDI-MedLine.d134.s0|237-240|time|O
DDI-MedLine.d134.s0|242-246|scale|O
DDI-MedLine.d134.s0|248-249|of|O
DDI-MedLine.d134.s0|251-262|displacement|O
DDI-MedLine.d134.s0|264-265|of|O
DDI-MedLine.d134.s0|267-284|radiopertechnetate|drug
DDI-MedLine.d134.s0|285-285|,|O
DDI-MedLine.d134.s0|287-288|in|O
DDI-MedLine.d134.s0|290-299|dependence|O
DDI-MedLine.d134.s0|301-302|on|O
DDI-MedLine.d134.s0|304-314|application|O
DDI-MedLine.d134.s0|316-319|mode|O
DDI-MedLine.d134.s0|320-320|,|O
DDI-MedLine.d134.s0|322-324|was|O
DDI-MedLine.d134.s0|326-332|studied|O
DDI-MedLine.d134.s0|333-333|.|O
DDI-MedLine.d134.s1|0-1|An|O
DDI-MedLine.d134.s1|3-13|intravenous|O
DDI-MedLine.d134.s1|15-18|dose|O
DDI-MedLine.d134.s1|20-21|of|O
DDI-MedLine.d134.s1|23-24|50|O
DDI-MedLine.d134.s1|26-27|mg|O
DDI-MedLine.d134.s1|41-43|was|O
DDI-MedLine.d134.s1|45-46|in|O
DDI-MedLine.d134.s1|48-54|respect|O
DDI-MedLine.d134.s1|56-57|of|O
DDI-MedLine.d134.s1|59-69|competitive|O
DDI-MedLine.d134.s1|71-81|suppression|O
DDI-MedLine.d134.s1|83-84|of|O
DDI-MedLine.d134.s1|86-91|organs|O
DDI-MedLine.d134.s1|93-100|actively|O
DDI-MedLine.d134.s1|102-114|concentrating|O
DDI-MedLine.d134.s1|116-128|pertechnetate|drug
DDI-MedLine.d134.s1|130-131|as|O
DDI-MedLine.d134.s1|133-141|effective|O
DDI-MedLine.d134.s1|143-144|as|O
DDI-MedLine.d134.s1|146-156|intravenous|O
DDI-MedLine.d134.s1|158-161|1000|O
DDI-MedLine.d134.s1|163-164|mg|O
DDI-MedLine.d134.s1|166-171|ClO-4-|O
DDI-MedLine.d134.s1|173-186|simultaneously|O
DDI-MedLine.d134.s1|188-189|or|O
DDI-MedLine.d134.s1|191-194|1000|O
DDI-MedLine.d134.s1|196-197|mg|O
DDI-MedLine.d134.s1|199-204|orally|O
DDI-MedLine.d134.s1|206-207|30|O
DDI-MedLine.d134.s1|209-211|min|O
DDI-MedLine.d134.s1|213-218|before|O
DDI-MedLine.d134.s1|220-222|the|O
DDI-MedLine.d134.s1|224-232|injection|O
DDI-MedLine.d134.s1|234-235|of|O
DDI-MedLine.d134.s1|237-254|radiopertechnetate|drug
DDI-MedLine.d134.s1|255-255|.|O
DDI-MedLine.d134.s2|0-1|An|O
DDI-MedLine.d134.s2|3-13|intravenous|O
DDI-MedLine.d134.s2|15-23|injection|O
DDI-MedLine.d134.s2|25-26|of|O
DDI-MedLine.d134.s2|40-44|given|O
DDI-MedLine.d134.s2|46-50|later|O
DDI-MedLine.d134.s2|52-55|also|O
DDI-MedLine.d134.s2|57-64|produces|O
DDI-MedLine.d134.s2|66-66|a|O
DDI-MedLine.d134.s2|68-75|complete|O
DDI-MedLine.d134.s2|77-79|and|O
DDI-MedLine.d134.s2|81-91|immediately|O
DDI-MedLine.d134.s2|93-101|beginning|O
DDI-MedLine.d134.s2|103-111|depletion|O
DDI-MedLine.d134.s2|113-114|of|O
DDI-MedLine.d134.s2|116-128|pertechnetate|drug
DDI-MedLine.d134.s2|130-136|already|O
DDI-MedLine.d134.s2|138-148|accumulated|O
DDI-MedLine.d134.s2|150-151|in|O
DDI-MedLine.d134.s2|153-155|the|O
DDI-MedLine.d134.s2|157-163|thyroid|O
DDI-MedLine.d134.s2|164-164|,|O
DDI-MedLine.d134.s2|166-171|within|O
DDI-MedLine.d134.s2|173-173|a|O
DDI-MedLine.d134.s2|175-180|period|O
DDI-MedLine.d134.s2|182-183|of|O
DDI-MedLine.d134.s2|185-187|195|O
DDI-MedLine.d134.s2|189-191|min|O
DDI-MedLine.d134.s2|193-197|after|O
DDI-MedLine.d134.s2|199-217|99m-TcO-4-injection|O
DDI-MedLine.d134.s2|219-222|with|O
DDI-MedLine.d134.s2|224-224|a|O
DDI-MedLine.d134.s2|226-238|corresponding|O
DDI-MedLine.d134.s2|240-247|increase|O
DDI-MedLine.d134.s2|249-250|in|O
DDI-MedLine.d134.s2|252-256|blood|O
DDI-MedLine.d134.s2|258-263|levels|O
DDI-MedLine.d134.s2|264-264|.|O
DDI-MedLine.d134.s3|0-1|20|O
DDI-MedLine.d134.s3|3-4|mg|O
DDI-MedLine.d134.s3|6-11|result|O
DDI-MedLine.d134.s3|13-14|in|O
DDI-MedLine.d134.s3|16-25|incomplete|O
DDI-MedLine.d134.s3|27-35|depletion|O
DDI-MedLine.d134.s3|37-41|which|O
DDI-MedLine.d134.s3|43-49|becomes|O
DDI-MedLine.d134.s3|51-58|complete|O
DDI-MedLine.d134.s3|60-64|after|O
DDI-MedLine.d134.s3|66-66|a|O
DDI-MedLine.d134.s3|68-73|second|O
DDI-MedLine.d134.s3|75-84|additional|O
DDI-MedLine.d134.s3|86-89|dose|O
DDI-MedLine.d134.s3|90-90|.|O
DDI-MedLine.d134.s4|0-2|The|O
DDI-MedLine.d134.s4|4-14|intravenous|O
DDI-MedLine.d134.s4|16-26|application|O
DDI-MedLine.d134.s4|28-29|of|O
DDI-MedLine.d134.s4|43-48|offers|O
DDI-MedLine.d134.s4|50-59|advantages|O
DDI-MedLine.d134.s4|61-62|in|O
DDI-MedLine.d134.s4|64-71|clinical|O
DDI-MedLine.d134.s4|73-75|use|O
DDI-MedLine.d134.s4|76-76|.|O
DDI-DrugBank.d550.s0|0-3|Oral|O
DDI-DrugBank.d550.s0|5-18|Contraceptives|group
DDI-DrugBank.d550.s0|20-27|Multiple|O
DDI-DrugBank.d550.s0|29-33|doses|O
DDI-DrugBank.d550.s0|35-36|of|O
DDI-DrugBank.d550.s0|38-55|cefditoren pivoxil|drug
DDI-DrugBank.d550.s0|57-59|had|O
DDI-DrugBank.d550.s0|61-62|no|O
DDI-DrugBank.d550.s0|64-69|effect|O
DDI-DrugBank.d550.s0|71-72|on|O
DDI-DrugBank.d550.s0|74-76|the|O
DDI-DrugBank.d550.s0|78-93|pharmacokinetics|O
DDI-DrugBank.d550.s0|95-96|of|O
DDI-DrugBank.d550.s0|98-114|ethinyl estradiol|drug
DDI-DrugBank.d550.s0|115-115|,|O
DDI-DrugBank.d550.s0|117-119|the|O
DDI-DrugBank.d550.s0|121-130|estrogenic|O
DDI-DrugBank.d550.s0|132-140|component|O
DDI-DrugBank.d550.s0|142-143|in|O
DDI-DrugBank.d550.s0|145-148|most|O
DDI-DrugBank.d550.s0|150-153|oral|O
DDI-DrugBank.d550.s0|155-168|contraceptives|group
DDI-DrugBank.d550.s0|169-169|.|O
DDI-DrugBank.d550.s1|0-7|Although|O
DDI-DrugBank.d550.s1|9-11|the|O
DDI-DrugBank.d550.s1|13-20|clinical|O
DDI-DrugBank.d550.s1|22-33|significance|O
DDI-DrugBank.d550.s1|35-36|is|O
DDI-DrugBank.d550.s1|38-40|not|O
DDI-DrugBank.d550.s1|42-46|known|O
DDI-DrugBank.d550.s1|47-47|,|O
DDI-DrugBank.d550.s1|49-50|it|O
DDI-DrugBank.d550.s1|52-53|is|O
DDI-DrugBank.d550.s1|55-57|not|O
DDI-DrugBank.d550.s1|59-69|recommended|O
DDI-DrugBank.d550.s1|71-74|that|O
DDI-DrugBank.d550.s1|76-93|cefditoren pivoxil|drug
DDI-DrugBank.d550.s1|95-96|be|O
DDI-DrugBank.d550.s1|98-102|taken|O
DDI-DrugBank.d550.s1|104-116|concomitantly|O
DDI-DrugBank.d550.s1|118-121|with|O
DDI-DrugBank.d550.s1|123-130|antacids|group
DDI-DrugBank.d550.s1|131-131|.|O
DDI-DrugBank.d550.s2|0-22|H2-Receptor Antagonists|group
DDI-DrugBank.d550.s2|23-23|:|O
DDI-DrugBank.d550.s2|25-41|Co-administration|O
DDI-DrugBank.d550.s2|43-44|of|O
DDI-DrugBank.d550.s2|46-46|a|O
DDI-DrugBank.d550.s2|48-53|single|O
DDI-DrugBank.d550.s2|55-58|dose|O
DDI-DrugBank.d550.s2|60-61|of|O
DDI-DrugBank.d550.s2|63-75|intravenously|O
DDI-DrugBank.d550.s2|77-88|administered|O
DDI-DrugBank.d550.s2|90-99|famotidine|drug
DDI-DrugBank.d550.s2|101-101|(|O
DDI-DrugBank.d550.s2|102-103|20|O
DDI-DrugBank.d550.s2|105-106|mg|O
DDI-DrugBank.d550.s2|107-107|)|O
DDI-DrugBank.d550.s2|109-115|reduced|O
DDI-DrugBank.d550.s2|117-119|the|O
DDI-DrugBank.d550.s2|121-124|oral|O
DDI-DrugBank.d550.s2|126-135|absorption|O
DDI-DrugBank.d550.s2|137-138|of|O
DDI-DrugBank.d550.s2|140-140|a|O
DDI-DrugBank.d550.s2|142-147|single|O
DDI-DrugBank.d550.s2|149-151|400|O
DDI-DrugBank.d550.s2|153-154|mg|O
DDI-DrugBank.d550.s2|156-159|dose|O
DDI-DrugBank.d550.s2|161-162|of|O
DDI-DrugBank.d550.s2|164-181|cefditoren pivoxil|drug
DDI-DrugBank.d550.s2|183-194|administered|O
DDI-DrugBank.d550.s2|196-204|following|O
DDI-DrugBank.d550.s2|206-206|a|O
DDI-DrugBank.d550.s2|208-211|meal|O
DDI-DrugBank.d550.s2|212-212|,|O
DDI-DrugBank.d550.s2|214-215|as|O
DDI-DrugBank.d550.s2|217-225|evidenced|O
DDI-DrugBank.d550.s2|227-228|by|O
DDI-DrugBank.d550.s2|230-230|a|O
DDI-DrugBank.d550.s2|232-233|27|O
DDI-DrugBank.d550.s2|234-234|%|O
DDI-DrugBank.d550.s2|236-243|decrease|O
DDI-DrugBank.d550.s2|245-246|in|O
DDI-DrugBank.d550.s2|248-251|mean|O
DDI-DrugBank.d550.s2|253-256|Cmax|O
DDI-DrugBank.d550.s2|258-260|and|O
DDI-DrugBank.d550.s2|262-262|a|O
DDI-DrugBank.d550.s2|264-265|22|O
DDI-DrugBank.d550.s2|266-266|%|O
DDI-DrugBank.d550.s2|268-275|decrease|O
DDI-DrugBank.d550.s2|277-278|in|O
DDI-DrugBank.d550.s2|280-283|mean|O
DDI-DrugBank.d550.s2|285-287|AUC|O
DDI-DrugBank.d550.s2|288-288|.|O
DDI-DrugBank.d550.s3|0-7|Although|O
DDI-DrugBank.d550.s3|9-11|the|O
DDI-DrugBank.d550.s3|13-20|clinical|O
DDI-DrugBank.d550.s3|22-33|significance|O
DDI-DrugBank.d550.s3|35-36|is|O
DDI-DrugBank.d550.s3|38-40|not|O
DDI-DrugBank.d550.s3|42-46|known|O
DDI-DrugBank.d550.s3|47-47|,|O
DDI-DrugBank.d550.s3|49-50|it|O
DDI-DrugBank.d550.s3|52-53|is|O
DDI-DrugBank.d550.s3|55-57|not|O
DDI-DrugBank.d550.s3|59-69|recommended|O
DDI-DrugBank.d550.s3|71-74|that|O
DDI-DrugBank.d550.s3|76-93|cefditoren pivoxil|drug
DDI-DrugBank.d550.s3|95-96|be|O
DDI-DrugBank.d550.s3|98-102|taken|O
DDI-DrugBank.d550.s3|104-116|concomitantly|O
DDI-DrugBank.d550.s3|118-121|with|O
DDI-DrugBank.d550.s3|123-145|H2 receptor antagonists|group
DDI-DrugBank.d550.s3|146-146|.|O
DDI-DrugBank.d550.s4|0-9|Probenecid|drug
DDI-DrugBank.d550.s4|10-10|:|O
DDI-DrugBank.d550.s4|12-13|As|O
DDI-DrugBank.d550.s4|15-18|with|O
DDI-DrugBank.d550.s4|20-24|other|O
DDI-DrugBank.d550.s4|26-45|b-lactam antibiotics|group
DDI-DrugBank.d550.s4|46-46|,|O
DDI-DrugBank.d550.s4|48-64|co-administration|O
DDI-DrugBank.d550.s4|66-67|of|O
DDI-DrugBank.d550.s4|69-78|probenecid|drug
DDI-DrugBank.d550.s4|80-83|with|O
DDI-DrugBank.d550.s4|85-102|cefditoren pivoxil|drug
DDI-DrugBank.d550.s4|104-111|resulted|O
DDI-DrugBank.d550.s4|113-114|in|O
DDI-DrugBank.d550.s4|116-117|an|O
DDI-DrugBank.d550.s4|119-126|increase|O
DDI-DrugBank.d550.s4|128-129|in|O
DDI-DrugBank.d550.s4|131-133|the|O
DDI-DrugBank.d550.s4|135-140|plasma|O
DDI-DrugBank.d550.s4|142-149|exposure|O
DDI-DrugBank.d550.s4|151-152|of|O
DDI-DrugBank.d550.s4|154-163|cefditoren|drug
DDI-DrugBank.d550.s4|164-164|,|O
DDI-DrugBank.d550.s4|166-169|with|O
DDI-DrugBank.d550.s4|171-171|a|O
DDI-DrugBank.d550.s4|173-174|49|O
DDI-DrugBank.d550.s4|175-175|%|O
DDI-DrugBank.d550.s4|177-184|increase|O
DDI-DrugBank.d550.s4|186-187|in|O
DDI-DrugBank.d550.s4|189-192|mean|O
DDI-DrugBank.d550.s4|194-197|Cmax|O
DDI-DrugBank.d550.s4|198-198|,|O
DDI-DrugBank.d550.s4|200-200|a|O
DDI-DrugBank.d550.s4|202-204|122|O
DDI-DrugBank.d550.s4|205-205|%|O
DDI-DrugBank.d550.s4|207-214|increase|O
DDI-DrugBank.d550.s4|216-217|in|O
DDI-DrugBank.d550.s4|219-222|mean|O
DDI-DrugBank.d550.s4|224-226|AUC|O
DDI-DrugBank.d550.s4|227-227|,|O
DDI-DrugBank.d550.s4|229-231|and|O
DDI-DrugBank.d550.s4|233-233|a|O
DDI-DrugBank.d550.s4|235-236|53|O
DDI-DrugBank.d550.s4|237-237|%|O
DDI-DrugBank.d550.s4|239-246|increase|O
DDI-DrugBank.d550.s4|248-249|in|O
DDI-DrugBank.d550.s4|251-259|half-life|O
DDI-DrugBank.d550.s4|260-260|.|O
DDI-DrugBank.d550.s5|0-14|Drug/Laboratory|O
DDI-DrugBank.d550.s5|16-19|Test|O
DDI-DrugBank.d550.s5|21-32|Interactions|O
DDI-DrugBank.d550.s5|34-47|Cephalosporins|group
DDI-DrugBank.d550.s5|49-51|are|O
DDI-DrugBank.d550.s5|53-57|known|O
DDI-DrugBank.d550.s5|59-60|to|O
DDI-DrugBank.d550.s5|62-73|occasionally|O
DDI-DrugBank.d550.s5|75-80|induce|O
DDI-DrugBank.d550.s5|82-82|a|O
DDI-DrugBank.d550.s5|84-91|positive|O
DDI-DrugBank.d550.s5|93-98|direct|O
DDI-DrugBank.d550.s5|100-105|Coombs|O
DDI-DrugBank.d550.s5|107-110|test|O
DDI-DrugBank.d550.s5|111-111|.|O
DDI-DrugBank.d550.s6|0-0|A|O
DDI-DrugBank.d550.s6|2-15|false-positive|O
DDI-DrugBank.d550.s6|17-24|reaction|O
DDI-DrugBank.d550.s6|26-28|for|O
DDI-DrugBank.d550.s6|30-36|glucose|O
DDI-DrugBank.d550.s6|38-39|in|O
DDI-DrugBank.d550.s6|41-43|the|O
DDI-DrugBank.d550.s6|45-49|urine|O
DDI-DrugBank.d550.s6|51-53|may|O
DDI-DrugBank.d550.s6|55-59|occur|O
DDI-DrugBank.d550.s6|61-64|with|O
DDI-DrugBank.d550.s6|66-71|copper|O
DDI-DrugBank.d550.s6|73-81|reduction|O
DDI-DrugBank.d550.s6|83-87|tests|O
DDI-DrugBank.d550.s6|89-89|(|O
DDI-DrugBank.d550.s6|90-98|Benedicts|O
DDI-DrugBank.d550.s6|100-101|or|O
DDI-DrugBank.d550.s6|103-110|Fehlings|O
DDI-DrugBank.d550.s6|112-119|solution|O
DDI-DrugBank.d550.s6|121-122|or|O
DDI-DrugBank.d550.s6|124-127|with|O
DDI-DrugBank.d550.s6|129-137|CLINITEST|O
DDI-DrugBank.d550.s6|139-145|tablets|O
DDI-DrugBank.d550.s6|146-146|)|O
DDI-DrugBank.d550.s6|147-147|,|O
DDI-DrugBank.d550.s6|149-151|but|O
DDI-DrugBank.d550.s6|153-155|not|O
DDI-DrugBank.d550.s6|157-160|with|O
DDI-DrugBank.d550.s6|162-173|enzyme-based|O
DDI-DrugBank.d550.s6|175-179|tests|O
DDI-DrugBank.d550.s6|181-183|for|O
DDI-DrugBank.d550.s6|185-194|glycosuria|O
DDI-DrugBank.d550.s6|196-196|(|O
DDI-DrugBank.d550.s6|197-200|e.g.|O
DDI-DrugBank.d550.s6|201-201|,|O
DDI-DrugBank.d550.s6|203-211|CLINISTIX|O
DDI-DrugBank.d550.s6|212-212|,|O
DDI-DrugBank.d550.s6|214-221|TES-TAPE|O
DDI-DrugBank.d550.s6|222-222|)|O
DDI-DrugBank.d550.s6|223-223|.|O
DDI-DrugBank.d550.s7|0-1|As|O
DDI-DrugBank.d550.s7|3-3|a|O
DDI-DrugBank.d550.s7|5-18|false-negative|O
DDI-DrugBank.d550.s7|20-25|result|O
DDI-DrugBank.d550.s7|27-29|may|O
DDI-DrugBank.d550.s7|31-35|occur|O
DDI-DrugBank.d550.s7|37-38|in|O
DDI-DrugBank.d550.s7|40-42|the|O
DDI-DrugBank.d550.s7|44-55|ferricyanide|O
DDI-DrugBank.d550.s7|57-60|test|O
DDI-DrugBank.d550.s7|61-61|,|O
DDI-DrugBank.d550.s7|63-64|it|O
DDI-DrugBank.d550.s7|66-67|is|O
DDI-DrugBank.d550.s7|69-79|recommended|O
DDI-DrugBank.d550.s7|81-84|that|O
DDI-DrugBank.d550.s7|86-91|either|O
DDI-DrugBank.d550.s7|93-95|the|O
DDI-DrugBank.d550.s7|97-103|glucose|O
DDI-DrugBank.d550.s7|105-111|oxidase|O
DDI-DrugBank.d550.s7|113-114|or|O
DDI-DrugBank.d550.s7|116-125|hexokinase|O
DDI-DrugBank.d550.s7|127-132|method|O
DDI-DrugBank.d550.s7|134-135|be|O
DDI-DrugBank.d550.s7|137-140|used|O
DDI-DrugBank.d550.s7|142-143|to|O
DDI-DrugBank.d550.s7|145-153|determine|O
DDI-DrugBank.d550.s7|155-166|blood/plasma|O
DDI-DrugBank.d550.s7|168-174|glucose|O
DDI-DrugBank.d550.s7|176-181|levels|O
DDI-DrugBank.d550.s7|183-184|in|O
DDI-DrugBank.d550.s7|186-193|patients|O
DDI-DrugBank.d550.s7|195-203|receiving|O
DDI-DrugBank.d550.s7|205-222|cefditoren pivoxil|drug
DDI-DrugBank.d550.s7|223-223|.|O
DDI-DrugBank.d9.s0|0-9|Azlocillin|drug
DDI-DrugBank.d9.s0|11-16|should|O
DDI-DrugBank.d9.s0|18-20|not|O
DDI-DrugBank.d9.s0|22-23|be|O
DDI-DrugBank.d9.s0|25-36|administered|O
DDI-DrugBank.d9.s0|38-50|concomitantly|O
DDI-DrugBank.d9.s0|52-55|with|O
DDI-DrugBank.d9.s0|57-64|amikacin|drug
DDI-DrugBank.d9.s0|65-65|,|O
DDI-DrugBank.d9.s0|67-79|ciprofloxacin|drug
DDI-DrugBank.d9.s0|80-80|,|O
DDI-DrugBank.d9.s0|82-91|gentamicin|drug
DDI-DrugBank.d9.s0|92-92|,|O
DDI-DrugBank.d9.s0|94-103|netilmicin|drug
DDI-DrugBank.d9.s0|104-104|,|O
DDI-DrugBank.d9.s0|106-107|or|O
DDI-DrugBank.d9.s0|109-118|tobramycin|drug
DDI-DrugBank.d9.s0|119-119|.|O
DDI-DrugBank.d133.s0|0-16|Co-administration|O
DDI-DrugBank.d133.s0|18-19|of|O
DDI-DrugBank.d133.s0|21-25|BOTOX|brand
DDI-DrugBank.d133.s0|27-29|and|O
DDI-DrugBank.d133.s0|31-45|aminoglycosides|group
DDI-DrugBank.d133.s0|47-48|or|O
DDI-DrugBank.d133.s0|50-54|other|O
DDI-DrugBank.d133.s0|56-61|agents|O
DDI-DrugBank.d133.s0|63-73|interfering|O
DDI-DrugBank.d133.s0|75-78|with|O
DDI-DrugBank.d133.s0|80-92|neuromuscular|O
DDI-DrugBank.d133.s0|94-105|transmission|O
DDI-DrugBank.d133.s0|107-107|(|O
DDI-DrugBank.d133.s0|108-111|e.g.|O
DDI-DrugBank.d133.s0|112-112|,|O
DDI-DrugBank.d133.s0|114-134|curare-like compounds|group
DDI-DrugBank.d133.s0|135-135|)|O
DDI-DrugBank.d133.s0|137-142|should|O
DDI-DrugBank.d133.s0|144-147|only|O
DDI-DrugBank.d133.s0|149-150|be|O
DDI-DrugBank.d133.s0|152-160|performed|O
DDI-DrugBank.d133.s0|162-165|with|O
DDI-DrugBank.d133.s0|167-173|caution|O
DDI-DrugBank.d133.s0|175-176|as|O
DDI-DrugBank.d133.s0|178-180|the|O
DDI-DrugBank.d133.s0|182-187|effect|O
DDI-DrugBank.d133.s0|189-190|of|O
DDI-DrugBank.d133.s0|192-194|the|O
DDI-DrugBank.d133.s0|196-200|toxin|drug
DDI-DrugBank.d133.s0|202-204|may|O
DDI-DrugBank.d133.s0|206-207|be|O
DDI-DrugBank.d133.s0|209-219|potentiated|O
DDI-DrugBank.d133.s0|220-220|.|O
DDI-DrugBank.d133.s1|0-2|The|O
DDI-DrugBank.d133.s1|4-9|effect|O
DDI-DrugBank.d133.s1|11-12|of|O
DDI-DrugBank.d133.s1|14-26|administering|O
DDI-DrugBank.d133.s1|28-36|different|O
DDI-DrugBank.d133.s1|38-57|botulinum neurotoxin|group
DDI-DrugBank.d133.s1|59-67|serotypes|O
DDI-DrugBank.d133.s1|69-70|at|O
DDI-DrugBank.d133.s1|72-74|the|O
DDI-DrugBank.d133.s1|76-79|same|O
DDI-DrugBank.d133.s1|81-84|time|O
DDI-DrugBank.d133.s1|86-87|or|O
DDI-DrugBank.d133.s1|89-94|within|O
DDI-DrugBank.d133.s1|96-102|several|O
DDI-DrugBank.d133.s1|104-109|months|O
DDI-DrugBank.d133.s1|111-112|of|O
DDI-DrugBank.d133.s1|114-117|each|O
DDI-DrugBank.d133.s1|119-123|other|O
DDI-DrugBank.d133.s1|125-126|is|O
DDI-DrugBank.d133.s1|128-134|unknown|O
DDI-DrugBank.d133.s1|135-135|.|O
DDI-DrugBank.d133.s2|0-8|Excessive|O
DDI-DrugBank.d133.s2|10-22|neuromuscular|O
DDI-DrugBank.d133.s2|24-31|weakness|O
DDI-DrugBank.d133.s2|33-35|may|O
DDI-DrugBank.d133.s2|37-38|be|O
DDI-DrugBank.d133.s2|40-50|exacerbated|O
DDI-DrugBank.d133.s2|52-53|by|O
DDI-DrugBank.d133.s2|55-68|administration|O
DDI-DrugBank.d133.s2|70-71|of|O
DDI-DrugBank.d133.s2|73-79|another|O
DDI-DrugBank.d133.s2|81-95|botulinum toxin|group
DDI-DrugBank.d133.s2|97-101|prior|O
DDI-DrugBank.d133.s2|103-104|to|O
DDI-DrugBank.d133.s2|106-108|the|O
DDI-DrugBank.d133.s2|110-119|resolution|O
DDI-DrugBank.d133.s2|121-122|of|O
DDI-DrugBank.d133.s2|124-126|the|O
DDI-DrugBank.d133.s2|128-134|effects|O
DDI-DrugBank.d133.s2|136-137|of|O
DDI-DrugBank.d133.s2|139-139|a|O
DDI-DrugBank.d133.s2|141-150|previously|O
DDI-DrugBank.d133.s2|152-163|administered|O
DDI-DrugBank.d133.s2|165-179|botulinum toxin|group
DDI-DrugBank.d133.s2|180-180|.|O
DDI-DrugBank.d569.s0|0-7|Angiomax|brand
DDI-DrugBank.d569.s0|9-12|does|O
DDI-DrugBank.d569.s0|14-16|not|O
DDI-DrugBank.d569.s0|18-24|exhibit|O
DDI-DrugBank.d569.s0|26-32|binding|O
DDI-DrugBank.d569.s0|34-35|to|O
DDI-DrugBank.d569.s0|37-42|plasma|O
DDI-DrugBank.d569.s0|44-51|proteins|O
DDI-DrugBank.d569.s0|53-53|(|O
DDI-DrugBank.d569.s0|54-58|other|O
DDI-DrugBank.d569.s0|60-63|than|O
DDI-DrugBank.d569.s0|65-72|thrombin|O
DDI-DrugBank.d569.s0|73-73|)|O
DDI-DrugBank.d569.s0|75-76|or|O
DDI-DrugBank.d569.s0|78-80|red|O
DDI-DrugBank.d569.s0|82-86|blood|O
DDI-DrugBank.d569.s0|88-92|cells|O
DDI-DrugBank.d569.s0|93-93|.|O
DDI-DrugBank.d569.s1|0-1|In|O
DDI-DrugBank.d569.s1|3-10|clinical|O
DDI-DrugBank.d569.s1|12-17|trials|O
DDI-DrugBank.d569.s1|19-20|in|O
DDI-DrugBank.d569.s1|22-29|patients|O
DDI-DrugBank.d569.s1|31-40|undergoing|O
DDI-DrugBank.d569.s1|42-49|PTCA/PCI|O
DDI-DrugBank.d569.s1|50-50|,|O
DDI-DrugBank.d569.s1|52-68|co-administration|O
DDI-DrugBank.d569.s1|70-71|of|O
DDI-DrugBank.d569.s1|73-80|Angiomax|brand
DDI-DrugBank.d569.s1|82-85|with|O
DDI-DrugBank.d569.s1|87-93|heparin|drug
DDI-DrugBank.d569.s1|94-94|,|O
DDI-DrugBank.d569.s1|96-103|warfarin|drug
DDI-DrugBank.d569.s1|104-104|,|O
DDI-DrugBank.d569.s1|106-118|thrombolytics|group
DDI-DrugBank.d569.s1|120-121|or|O
DDI-DrugBank.d569.s1|123-134|glycoprotein|O
DDI-DrugBank.d569.s1|136-143|IIb/IIIa|O
DDI-DrugBank.d569.s1|145-154|inhibitors|O
DDI-DrugBank.d569.s1|156-158|was|O
DDI-DrugBank.d569.s1|160-169|associated|O
DDI-DrugBank.d569.s1|171-174|with|O
DDI-DrugBank.d569.s1|176-184|increased|O
DDI-DrugBank.d569.s1|186-190|risks|O
DDI-DrugBank.d569.s1|192-193|of|O
DDI-DrugBank.d569.s1|195-199|major|O
DDI-DrugBank.d569.s1|201-208|bleeding|O
DDI-DrugBank.d569.s1|210-215|events|O
DDI-DrugBank.d569.s1|217-224|compared|O
DDI-DrugBank.d569.s1|226-227|to|O
DDI-DrugBank.d569.s1|229-236|patients|O
DDI-DrugBank.d569.s1|238-240|not|O
DDI-DrugBank.d569.s1|242-250|receiving|O
DDI-DrugBank.d569.s1|252-256|these|O
DDI-DrugBank.d569.s1|258-268|concomitant|O
DDI-DrugBank.d569.s1|270-280|medications|O
DDI-DrugBank.d569.s1|281-281|.|O
DDI-DrugBank.d569.s2|0-4|There|O
DDI-DrugBank.d569.s2|6-7|is|O
DDI-DrugBank.d569.s2|9-10|no|O
DDI-DrugBank.d569.s2|12-21|experience|O
DDI-DrugBank.d569.s2|23-26|with|O
DDI-DrugBank.d569.s2|28-44|co-administration|O
DDI-DrugBank.d569.s2|46-47|of|O
DDI-DrugBank.d569.s2|49-56|Angiomax|brand
DDI-DrugBank.d569.s2|58-60|and|O
DDI-DrugBank.d569.s2|62-67|plasma|O
DDI-DrugBank.d569.s2|69-77|expanders|O
DDI-DrugBank.d569.s2|79-82|such|O
DDI-DrugBank.d569.s2|84-85|as|O
DDI-DrugBank.d569.s2|87-93|dextran|drug
DDI-DrugBank.d569.s2|94-94|.|O
DDI-DrugBank.d569.s3|0-7|Angiomax|brand
DDI-DrugBank.d569.s3|9-14|should|O
DDI-DrugBank.d569.s3|16-17|be|O
DDI-DrugBank.d569.s3|19-22|used|O
DDI-DrugBank.d569.s3|24-27|with|O
DDI-DrugBank.d569.s3|29-35|caution|O
DDI-DrugBank.d569.s3|37-38|in|O
DDI-DrugBank.d569.s3|40-47|patients|O
DDI-DrugBank.d569.s3|49-52|with|O
DDI-DrugBank.d569.s3|54-60|disease|O
DDI-DrugBank.d569.s3|62-67|states|O
DDI-DrugBank.d569.s3|69-78|associated|O
DDI-DrugBank.d569.s3|80-83|with|O
DDI-DrugBank.d569.s3|85-86|an|O
DDI-DrugBank.d569.s3|88-96|increased|O
DDI-DrugBank.d569.s3|98-101|risk|O
DDI-DrugBank.d569.s3|103-104|of|O
DDI-DrugBank.d569.s3|106-113|bleeding|O
DDI-DrugBank.d569.s3|114-114|.|O
DDI-DrugBank.d569.s4|0-25|Immunogenicity/Re-exposure|O
DDI-DrugBank.d569.s4|26-26|:|O
DDI-DrugBank.d569.s4|28-29|In|O
DDI-DrugBank.d569.s4|31-32|in|O
DDI-DrugBank.d569.s4|34-38|vitro|O
DDI-DrugBank.d569.s4|40-46|studies|O
DDI-DrugBank.d569.s4|47-47|,|O
DDI-DrugBank.d569.s4|49-56|Angiomax|brand
DDI-DrugBank.d569.s4|58-66|exhibited|O
DDI-DrugBank.d569.s4|68-69|no|O
DDI-DrugBank.d569.s4|71-78|platelet|O
DDI-DrugBank.d569.s4|80-90|aggregation|O
DDI-DrugBank.d569.s4|92-99|response|O
DDI-DrugBank.d569.s4|101-107|against|O
DDI-DrugBank.d569.s4|109-112|sera|O
DDI-DrugBank.d569.s4|114-117|from|O
DDI-DrugBank.d569.s4|119-126|patients|O
DDI-DrugBank.d569.s4|128-131|with|O
DDI-DrugBank.d569.s4|133-133|a|O
DDI-DrugBank.d569.s4|135-141|history|O
DDI-DrugBank.d569.s4|143-144|of|O
DDI-DrugBank.d569.s4|146-154|HIT/HITTS|O
DDI-DrugBank.d569.s4|155-155|.|O
DDI-DrugBank.d569.s5|0-4|Among|O
DDI-DrugBank.d569.s5|6-8|494|O
DDI-DrugBank.d569.s5|10-17|subjects|O
DDI-DrugBank.d569.s5|19-21|who|O
DDI-DrugBank.d569.s5|23-30|received|O
DDI-DrugBank.d569.s5|32-39|Angiomax|brand
DDI-DrugBank.d569.s5|41-42|in|O
DDI-DrugBank.d569.s5|44-51|clinical|O
DDI-DrugBank.d569.s5|53-58|trials|O
DDI-DrugBank.d569.s5|60-62|and|O
DDI-DrugBank.d569.s5|64-67|were|O
DDI-DrugBank.d569.s5|69-74|tested|O
DDI-DrugBank.d569.s5|76-78|for|O
DDI-DrugBank.d569.s5|80-89|antibodies|O
DDI-DrugBank.d569.s5|90-90|,|O
DDI-DrugBank.d569.s5|92-92|2|O
DDI-DrugBank.d569.s5|94-101|subjects|O
DDI-DrugBank.d569.s5|103-105|had|O
DDI-DrugBank.d569.s5|107-124|treatment-emergent|O
DDI-DrugBank.d569.s5|126-133|positive|O
DDI-DrugBank.d569.s5|135-145|bivalirudin|drug
DDI-DrugBank.d569.s5|147-154|antibody|O
DDI-DrugBank.d569.s5|156-160|tests|O
DDI-DrugBank.d569.s5|161-161|.|O
DDI-DrugBank.d569.s6|0-6|Neither|O
DDI-DrugBank.d569.s6|8-14|subject|O
DDI-DrugBank.d569.s6|16-27|demonstrated|O
DDI-DrugBank.d569.s6|29-36|clinical|O
DDI-DrugBank.d569.s6|38-45|evidence|O
DDI-DrugBank.d569.s6|47-48|of|O
DDI-DrugBank.d569.s6|50-57|allergic|O
DDI-DrugBank.d569.s6|59-60|or|O
DDI-DrugBank.d569.s6|62-73|anaphylactic|O
DDI-DrugBank.d569.s6|75-83|reactions|O
DDI-DrugBank.d569.s6|85-87|and|O
DDI-DrugBank.d569.s6|89-94|repeat|O
DDI-DrugBank.d569.s6|96-102|testing|O
DDI-DrugBank.d569.s6|104-106|was|O
DDI-DrugBank.d569.s6|108-110|not|O
DDI-DrugBank.d569.s6|112-120|performed|O
DDI-DrugBank.d569.s6|121-121|.|O
DDI-DrugBank.d569.s7|0-3|Nine|O
DDI-DrugBank.d569.s7|5-14|additional|O
DDI-DrugBank.d569.s7|16-23|patients|O
DDI-DrugBank.d569.s7|25-27|who|O
DDI-DrugBank.d569.s7|29-31|had|O
DDI-DrugBank.d569.s7|33-39|initial|O
DDI-DrugBank.d569.s7|41-48|positive|O
DDI-DrugBank.d569.s7|50-54|tests|O
DDI-DrugBank.d569.s7|56-59|were|O
DDI-DrugBank.d569.s7|61-68|negative|O
DDI-DrugBank.d569.s7|70-71|on|O
DDI-DrugBank.d569.s7|73-78|repeat|O
DDI-DrugBank.d569.s7|80-86|testing|O
DDI-DrugBank.d569.s7|87-87|.|O
DDI-DrugBank.d588.s0|0-8|Diuretics|group
DDI-DrugBank.d588.s0|9-9|:|O
DDI-DrugBank.d588.s0|11-20|Furosemide|drug
DDI-DrugBank.d588.s0|22-24|and|O
DDI-DrugBank.d588.s0|26-33|probably|O
DDI-DrugBank.d588.s0|35-39|other|O
DDI-DrugBank.d588.s0|41-54|loop diuretics|group
DDI-DrugBank.d588.s0|56-60|given|O
DDI-DrugBank.d588.s0|62-74|concomitantly|O
DDI-DrugBank.d588.s0|76-79|with|O
DDI-DrugBank.d588.s0|81-90|metolazone|drug
DDI-DrugBank.d588.s0|92-94|can|O
DDI-DrugBank.d588.s0|96-100|cause|O
DDI-DrugBank.d588.s0|102-110|unusually|O
DDI-DrugBank.d588.s0|112-116|large|O
DDI-DrugBank.d588.s0|118-119|or|O
DDI-DrugBank.d588.s0|121-129|prolonged|O
DDI-DrugBank.d588.s0|131-136|losses|O
DDI-DrugBank.d588.s0|138-139|of|O
DDI-DrugBank.d588.s0|141-145|fluid|O
DDI-DrugBank.d588.s0|147-149|and|O
DDI-DrugBank.d588.s0|151-162|electrolytes|O
DDI-DrugBank.d588.s0|163-163|.|O
DDI-DrugBank.d588.s1|0-4|Other|O
DDI-DrugBank.d588.s1|6-22|Antihypertensives|group
DDI-DrugBank.d588.s1|23-23|:|O
DDI-DrugBank.d588.s1|25-28|When|O
DDI-DrugBank.d588.s1|30-35|MYKROX|brand
DDI-DrugBank.d588.s1|37-43|Tablets|O
DDI-DrugBank.d588.s1|45-47|are|O
DDI-DrugBank.d588.s1|49-52|used|O
DDI-DrugBank.d588.s1|54-57|with|O
DDI-DrugBank.d588.s1|59-63|other|O
DDI-DrugBank.d588.s1|65-86|antihypertensive drugs|group
DDI-DrugBank.d588.s1|87-87|,|O
DDI-DrugBank.d588.s1|89-92|care|O
DDI-DrugBank.d588.s1|94-97|must|O
DDI-DrugBank.d588.s1|99-100|be|O
DDI-DrugBank.d588.s1|102-106|taken|O
DDI-DrugBank.d588.s1|107-107|,|O
DDI-DrugBank.d588.s1|109-118|especially|O
DDI-DrugBank.d588.s1|120-125|during|O
DDI-DrugBank.d588.s1|127-133|initial|O
DDI-DrugBank.d588.s1|135-141|therapy|O
DDI-DrugBank.d588.s1|142-142|.|O
DDI-DrugBank.d588.s2|0-5|Dosage|O
DDI-DrugBank.d588.s2|7-17|adjustments|O
DDI-DrugBank.d588.s2|19-20|of|O
DDI-DrugBank.d588.s2|22-26|other|O
DDI-DrugBank.d588.s2|28-44|antihypertensives|group
DDI-DrugBank.d588.s2|46-48|may|O
DDI-DrugBank.d588.s2|50-51|be|O
DDI-DrugBank.d588.s2|53-61|necessary|O
DDI-DrugBank.d588.s2|62-62|.|O
DDI-DrugBank.d588.s3|0-6|Alcohol|drug
DDI-DrugBank.d588.s3|7-7|,|O
DDI-DrugBank.d588.s3|9-20|Barbiturates|group
DDI-DrugBank.d588.s3|21-21|,|O
DDI-DrugBank.d588.s3|23-25|and|O
DDI-DrugBank.d588.s3|27-35|Narcotics|group
DDI-DrugBank.d588.s3|36-36|:|O
DDI-DrugBank.d588.s3|38-40|The|O
DDI-DrugBank.d588.s3|42-52|hypotensive|O
DDI-DrugBank.d588.s3|54-60|effects|O
DDI-DrugBank.d588.s3|62-63|of|O
DDI-DrugBank.d588.s3|65-69|these|O
DDI-DrugBank.d588.s3|71-75|drugs|O
DDI-DrugBank.d588.s3|77-79|may|O
DDI-DrugBank.d588.s3|81-82|be|O
DDI-DrugBank.d588.s3|84-94|potentiated|O
DDI-DrugBank.d588.s3|96-97|by|O
DDI-DrugBank.d588.s3|99-101|the|O
DDI-DrugBank.d588.s3|103-108|volume|O
DDI-DrugBank.d588.s3|110-120|contraction|O
DDI-DrugBank.d588.s3|122-125|that|O
DDI-DrugBank.d588.s3|127-129|may|O
DDI-DrugBank.d588.s3|131-132|be|O
DDI-DrugBank.d588.s3|134-143|associated|O
DDI-DrugBank.d588.s3|145-148|with|O
DDI-DrugBank.d588.s3|150-159|metolazone|drug
DDI-DrugBank.d588.s3|161-167|therapy|O
DDI-DrugBank.d588.s3|168-168|.|O
DDI-DrugBank.d588.s4|0-19|Digitalis Glycosides|group
DDI-DrugBank.d588.s4|20-20|:|O
DDI-DrugBank.d588.s4|22-37|Diuretic-induced|group
DDI-DrugBank.d588.s4|39-49|hypokalemia|O
DDI-DrugBank.d588.s4|51-53|can|O
DDI-DrugBank.d588.s4|55-62|increase|O
DDI-DrugBank.d588.s4|64-66|the|O
DDI-DrugBank.d588.s4|68-78|sensitivity|O
DDI-DrugBank.d588.s4|80-81|of|O
DDI-DrugBank.d588.s4|83-85|the|O
DDI-DrugBank.d588.s4|87-96|myocardium|O
DDI-DrugBank.d588.s4|98-99|to|O
DDI-DrugBank.d588.s4|101-109|digitalis|group
DDI-DrugBank.d588.s4|110-110|.|O
DDI-DrugBank.d588.s5|0-6|Serious|O
DDI-DrugBank.d588.s5|8-18|arrhythmias|O
DDI-DrugBank.d588.s5|20-22|can|O
DDI-DrugBank.d588.s5|24-29|result|O
DDI-DrugBank.d588.s5|30-30|.|O
DDI-DrugBank.d588.s6|0-14|Corticosteroids|group
DDI-DrugBank.d588.s6|16-17|or|O
DDI-DrugBank.d588.s6|19-22|ACTH|drug
DDI-DrugBank.d588.s6|23-23|:|O
DDI-DrugBank.d588.s6|25-27|May|O
DDI-DrugBank.d588.s6|29-36|increase|O
DDI-DrugBank.d588.s6|38-40|the|O
DDI-DrugBank.d588.s6|42-45|risk|O
DDI-DrugBank.d588.s6|47-48|of|O
DDI-DrugBank.d588.s6|50-60|hypokalemia|O
DDI-DrugBank.d588.s6|62-64|and|O
DDI-DrugBank.d588.s6|66-73|increase|O
DDI-DrugBank.d588.s6|75-78|salt|O
DDI-DrugBank.d588.s6|80-82|and|O
DDI-DrugBank.d588.s6|84-88|water|O
DDI-DrugBank.d588.s6|90-98|retention|O
DDI-DrugBank.d588.s6|99-99|.|O
DDI-DrugBank.d588.s7|0-6|Lithium|drug
DDI-DrugBank.d588.s7|7-7|:|O
DDI-DrugBank.d588.s7|9-13|Serum|O
DDI-DrugBank.d588.s7|15-21|lithium|drug
DDI-DrugBank.d588.s7|23-28|levels|O
DDI-DrugBank.d588.s7|30-32|may|O
DDI-DrugBank.d588.s7|34-41|increase|O
DDI-DrugBank.d588.s7|42-42|.|O
DDI-DrugBank.d588.s8|0-15|Curariform Drugs|group
DDI-DrugBank.d588.s8|16-16|:|O
DDI-DrugBank.d588.s8|18-33|Diuretic-induced|group
DDI-DrugBank.d588.s8|35-45|hypokalemia|O
DDI-DrugBank.d588.s8|47-49|may|O
DDI-DrugBank.d588.s8|51-57|enhance|O
DDI-DrugBank.d588.s8|59-71|neuromuscular|O
DDI-DrugBank.d588.s8|73-80|blocking|O
DDI-DrugBank.d588.s8|82-88|effects|O
DDI-DrugBank.d588.s8|90-91|of|O
DDI-DrugBank.d588.s8|93-108|curariform drugs|group
DDI-DrugBank.d588.s8|110-110|(|O
DDI-DrugBank.d588.s8|111-114|such|O
DDI-DrugBank.d588.s8|116-117|as|O
DDI-DrugBank.d588.s8|119-130|tubocurarine|drug
DDI-DrugBank.d588.s8|131-131|)|O
DDI-DrugBank.d588.s8|133-135|the|O
DDI-DrugBank.d588.s8|137-140|most|O
DDI-DrugBank.d588.s8|142-148|serious|O
DDI-DrugBank.d588.s8|150-155|effect|O
DDI-DrugBank.d588.s8|157-161|would|O
DDI-DrugBank.d588.s8|163-164|be|O
DDI-DrugBank.d588.s8|166-176|respiratory|O
DDI-DrugBank.d588.s8|178-187|depression|O
DDI-DrugBank.d588.s8|189-193|which|O
DDI-DrugBank.d588.s8|195-199|could|O
DDI-DrugBank.d588.s8|201-207|proceed|O
DDI-DrugBank.d588.s8|209-210|to|O
DDI-DrugBank.d588.s8|212-216|apnea|O
DDI-DrugBank.d588.s8|217-217|.|O
DDI-DrugBank.d588.s9|0-10|Accordingly|O
DDI-DrugBank.d588.s9|11-11|,|O
DDI-DrugBank.d588.s9|13-14|it|O
DDI-DrugBank.d588.s9|16-18|may|O
DDI-DrugBank.d588.s9|20-21|be|O
DDI-DrugBank.d588.s9|23-31|advisable|O
DDI-DrugBank.d588.s9|33-34|to|O
DDI-DrugBank.d588.s9|36-46|discontinue|O
DDI-DrugBank.d588.s9|48-53|MYKROX|brand
DDI-DrugBank.d588.s9|55-61|Tablets|O
DDI-DrugBank.d588.s9|63-67|three|O
DDI-DrugBank.d588.s9|69-72|days|O
DDI-DrugBank.d588.s9|74-79|before|O
DDI-DrugBank.d588.s9|81-88|elective|O
DDI-DrugBank.d588.s9|90-96|surgery|O
DDI-DrugBank.d588.s9|97-97|.|O
DDI-DrugBank.d588.s10|0-10|Salicylates|group
DDI-DrugBank.d588.s10|12-14|and|O
DDI-DrugBank.d588.s10|16-20|Other|O
DDI-DrugBank.d588.s10|22-58|Non-Steroidal Anti-Inflammatory Drugs|group
DDI-DrugBank.d588.s10|59-59|:|O
DDI-DrugBank.d588.s10|61-63|May|O
DDI-DrugBank.d588.s10|65-72|decrease|O
DDI-DrugBank.d588.s10|74-76|the|O
DDI-DrugBank.d588.s10|78-93|antihypertensive|O
DDI-DrugBank.d588.s10|95-101|effects|O
DDI-DrugBank.d588.s10|103-104|of|O
DDI-DrugBank.d588.s10|106-111|MYKROX|brand
DDI-DrugBank.d588.s10|113-119|Tablets|O
DDI-DrugBank.d588.s10|120-120|.|O
DDI-DrugBank.d588.s11|0-15|Sympathomimetics|group
DDI-DrugBank.d588.s11|16-16|:|O
DDI-DrugBank.d588.s11|18-27|Metolazone|drug
DDI-DrugBank.d588.s11|29-31|may|O
DDI-DrugBank.d588.s11|33-40|decrease|O
DDI-DrugBank.d588.s11|42-49|arterial|O
DDI-DrugBank.d588.s11|51-64|responsiveness|O
DDI-DrugBank.d588.s11|66-67|to|O
DDI-DrugBank.d588.s11|69-82|norepinephrine|drug
DDI-DrugBank.d588.s11|83-83|,|O
DDI-DrugBank.d588.s11|85-87|but|O
DDI-DrugBank.d588.s11|89-92|this|O
DDI-DrugBank.d588.s11|94-103|diminution|O
DDI-DrugBank.d588.s11|105-106|is|O
DDI-DrugBank.d588.s11|108-110|not|O
DDI-DrugBank.d588.s11|112-121|sufficient|O
DDI-DrugBank.d588.s11|123-124|to|O
DDI-DrugBank.d588.s11|126-133|preclude|O
DDI-DrugBank.d588.s11|135-147|effectiveness|O
DDI-DrugBank.d588.s11|149-150|of|O
DDI-DrugBank.d588.s11|152-154|the|O
DDI-DrugBank.d588.s11|156-162|pressor|O
DDI-DrugBank.d588.s11|164-168|agent|O
DDI-DrugBank.d588.s11|170-172|for|O
DDI-DrugBank.d588.s11|174-184|therapeutic|O
DDI-DrugBank.d588.s11|186-188|use|O
DDI-DrugBank.d588.s11|189-189|.|O
DDI-DrugBank.d588.s12|0-10|Methenamine|drug
DDI-DrugBank.d588.s12|11-11|:|O
DDI-DrugBank.d588.s12|13-20|Efficacy|O
DDI-DrugBank.d588.s12|22-24|may|O
DDI-DrugBank.d588.s12|26-27|be|O
DDI-DrugBank.d588.s12|29-37|decreased|O
DDI-DrugBank.d588.s12|39-41|due|O
DDI-DrugBank.d588.s12|43-44|to|O
DDI-DrugBank.d588.s12|46-52|urinary|O
DDI-DrugBank.d588.s12|54-63|alkalizing|O
DDI-DrugBank.d588.s12|65-70|effect|O
DDI-DrugBank.d588.s12|72-73|of|O
DDI-DrugBank.d588.s12|75-84|metolazone|drug
DDI-DrugBank.d588.s12|85-85|.|O
DDI-DrugBank.d588.s13|0-13|Anticoagulants|group
DDI-DrugBank.d588.s13|14-14|:|O
DDI-DrugBank.d588.s13|16-25|Metolazone|drug
DDI-DrugBank.d588.s13|26-26|,|O
DDI-DrugBank.d588.s13|28-29|as|O
DDI-DrugBank.d588.s13|31-34|well|O
DDI-DrugBank.d588.s13|36-37|as|O
DDI-DrugBank.d588.s13|39-43|other|O
DDI-DrugBank.d588.s13|45-67|thiazide-like diuretics|group
DDI-DrugBank.d588.s13|68-68|,|O
DDI-DrugBank.d588.s13|70-72|may|O
DDI-DrugBank.d588.s13|74-79|affect|O
DDI-DrugBank.d588.s13|81-83|the|O
DDI-DrugBank.d588.s13|85-103|hypoprothrombinemic|O
DDI-DrugBank.d588.s13|105-112|response|O
DDI-DrugBank.d588.s13|114-115|to|O
DDI-DrugBank.d588.s13|117-130|anticoagulants|group
DDI-DrugBank.d588.s13|131-131|;|O
DDI-DrugBank.d588.s14|0-5|dosage|O
DDI-DrugBank.d588.s14|7-17|adjustments|O
DDI-DrugBank.d588.s14|19-21|may|O
DDI-DrugBank.d588.s14|23-24|be|O
DDI-DrugBank.d588.s14|26-34|necessary|O
DDI-DrugBank.d588.s14|35-35|.|O
DDI-DrugBank.d391.s0|0-1|No|O
DDI-DrugBank.d391.s0|3-10|separate|O
DDI-DrugBank.d391.s0|12-22|information|O
DDI-DrugBank.d391.s0|24-32|available|O
DDI-DrugBank.d80.s0|0-8|Potential|O
DDI-DrugBank.d80.s0|10-13|drug|O
DDI-DrugBank.d80.s0|15-26|interactions|O
DDI-DrugBank.d80.s0|28-34|between|O
DDI-DrugBank.d80.s0|36-41|Mentax|brand
DDI-DrugBank.d80.s0|43-43|(|O
DDI-DrugBank.d80.s0|44-57|butenafine HCl|drug
DDI-DrugBank.d80.s0|59-63|cream|O
DDI-DrugBank.d80.s0|64-64|)|O
DDI-DrugBank.d80.s0|66-70|Cream|O
DDI-DrugBank.d80.s0|71-71|,|O
DDI-DrugBank.d80.s0|73-73|1|O
DDI-DrugBank.d80.s0|74-74|%|O
DDI-DrugBank.d80.s0|75-75|,|O
DDI-DrugBank.d80.s0|77-79|and|O
DDI-DrugBank.d80.s0|81-85|other|O
DDI-DrugBank.d80.s0|87-91|drugs|O
DDI-DrugBank.d80.s0|93-96|have|O
DDI-DrugBank.d80.s0|98-100|not|O
DDI-DrugBank.d80.s0|102-105|been|O
DDI-DrugBank.d80.s0|107-120|systematically|O
DDI-DrugBank.d80.s0|122-130|evaluated|O
DDI-DrugBank.d80.s0|131-131|.|O
DDI-DrugBank.d682.s0|0-8|Sulfoxone|drug
DDI-DrugBank.d682.s0|10-12|may|O
DDI-DrugBank.d682.s0|14-21|increase|O
DDI-DrugBank.d682.s0|23-25|the|O
DDI-DrugBank.d682.s0|27-33|effects|O
DDI-DrugBank.d682.s0|35-36|of|O
DDI-DrugBank.d682.s0|38-49|barbiturates|group
DDI-DrugBank.d682.s0|50-50|,|O
DDI-DrugBank.d682.s0|52-62|tolbutamide|drug
DDI-DrugBank.d682.s0|63-63|,|O
DDI-DrugBank.d682.s0|65-67|and|O
DDI-DrugBank.d682.s0|69-79|uricosurics|group
DDI-DrugBank.d682.s0|80-80|.|O
DDI-DrugBank.d682.s1|0-1|It|O
DDI-DrugBank.d682.s1|3-5|may|O
DDI-DrugBank.d682.s1|7-10|also|O
DDI-DrugBank.d682.s1|12-19|interact|O
DDI-DrugBank.d682.s1|21-24|with|O
DDI-DrugBank.d682.s1|26-34|thiazides|group
DDI-DrugBank.d682.s1|36-36|(|O
DDI-DrugBank.d682.s1|37-45|increased|O
DDI-DrugBank.d682.s1|47-62|thrombocytopenia|O
DDI-DrugBank.d682.s1|63-63|)|O
DDI-DrugBank.d682.s1|64-64|,|O
DDI-DrugBank.d682.s1|66-77|cyclosporine|drug
DDI-DrugBank.d682.s1|79-79|(|O
DDI-DrugBank.d682.s1|80-88|increased|O
DDI-DrugBank.d682.s1|90-103|nephrotoxicity|O
DDI-DrugBank.d682.s1|104-104|)|O
DDI-DrugBank.d682.s1|105-105|,|O
DDI-DrugBank.d682.s1|107-125|sulfonylurea agents|group
DDI-DrugBank.d682.s1|127-127|(|O
DDI-DrugBank.d682.s1|128-136|increased|O
DDI-DrugBank.d682.s1|138-149|hypoglycemic|O
DDI-DrugBank.d682.s1|151-158|response|O
DDI-DrugBank.d682.s1|159-159|)|O
DDI-DrugBank.d682.s1|160-160|,|O
DDI-DrugBank.d682.s1|162-169|warfarin|drug
DDI-DrugBank.d682.s1|171-171|(|O
DDI-DrugBank.d682.s1|172-180|increased|O
DDI-DrugBank.d682.s1|182-194|anticoagulant|O
DDI-DrugBank.d682.s1|196-201|effect|O
DDI-DrugBank.d682.s1|202-202|)|O
DDI-DrugBank.d682.s1|203-203|,|O
DDI-DrugBank.d682.s1|205-216|methotrexate|drug
DDI-DrugBank.d682.s1|218-218|(|O
DDI-DrugBank.d682.s1|219-227|decreased|O
DDI-DrugBank.d682.s1|229-233|renal|O
DDI-DrugBank.d682.s1|235-243|excretion|O
DDI-DrugBank.d682.s1|245-246|of|O
DDI-DrugBank.d682.s1|248-259|methotrexate|drug
DDI-DrugBank.d682.s1|260-260|)|O
DDI-DrugBank.d682.s1|261-261|,|O
DDI-DrugBank.d682.s1|263-271|phenytoin|drug
DDI-DrugBank.d682.s1|273-273|(|O
DDI-DrugBank.d682.s1|274-282|decreased|O
DDI-DrugBank.d682.s1|284-290|hepatic|O
DDI-DrugBank.d682.s1|292-300|clearance|O
DDI-DrugBank.d682.s1|302-303|of|O
DDI-DrugBank.d682.s1|305-313|phenytoin|drug
DDI-DrugBank.d682.s1|314-314|)|O
DDI-DrugBank.d682.s1|315-315|.|O
DDI-DrugBank.d358.s0|0-4|Since|O
DDI-DrugBank.d358.s0|6-11|PLETAL|brand
DDI-DrugBank.d358.s0|13-14|is|O
DDI-DrugBank.d358.s0|16-26|extensively|O
DDI-DrugBank.d358.s0|28-38|metabolized|O
DDI-DrugBank.d358.s0|40-41|by|O
DDI-DrugBank.d358.s0|43-52|cytochrome|O
DDI-DrugBank.d358.s0|54-58|P-450|O
DDI-DrugBank.d358.s0|60-69|isoenzymes|O
DDI-DrugBank.d358.s0|70-70|,|O
DDI-DrugBank.d358.s0|72-78|caution|O
DDI-DrugBank.d358.s0|80-85|should|O
DDI-DrugBank.d358.s0|87-88|be|O
DDI-DrugBank.d358.s0|90-98|exercised|O
DDI-DrugBank.d358.s0|100-103|when|O
DDI-DrugBank.d358.s0|105-110|PLETAL|brand
DDI-DrugBank.d358.s0|112-113|is|O
DDI-DrugBank.d358.s0|115-128|coadministered|O
DDI-DrugBank.d358.s0|130-133|with|O
DDI-DrugBank.d358.s0|135-144|inhibitors|O
DDI-DrugBank.d358.s0|146-147|of|O
DDI-DrugBank.d358.s0|149-154|C.P.A.|O
DDI-DrugBank.d358.s0|156-159|such|O
DDI-DrugBank.d358.s0|161-162|as|O
DDI-DrugBank.d358.s0|164-175|ketoconazole|drug
DDI-DrugBank.d358.s0|177-179|and|O
DDI-DrugBank.d358.s0|181-192|erythromycin|drug
DDI-DrugBank.d358.s0|194-195|or|O
DDI-DrugBank.d358.s0|197-206|inhibitors|O
DDI-DrugBank.d358.s0|208-209|of|O
DDI-DrugBank.d358.s0|211-217|CYP2C19|O
DDI-DrugBank.d358.s0|219-222|such|O
DDI-DrugBank.d358.s0|224-225|as|O
DDI-DrugBank.d358.s0|227-236|omeprazole|drug
DDI-DrugBank.d358.s0|237-237|.|O
DDI-DrugBank.d358.s1|0-14|Pharmacokinetic|O
DDI-DrugBank.d358.s1|16-22|studies|O
DDI-DrugBank.d358.s1|24-27|have|O
DDI-DrugBank.d358.s1|29-40|demonstrated|O
DDI-DrugBank.d358.s1|42-45|that|O
DDI-DrugBank.d358.s1|47-56|omeprazole|drug
DDI-DrugBank.d358.s1|58-60|and|O
DDI-DrugBank.d358.s1|62-73|erythromycin|drug
DDI-DrugBank.d358.s1|75-87|significantly|O
DDI-DrugBank.d358.s1|89-97|increased|O
DDI-DrugBank.d358.s1|99-101|the|O
DDI-DrugBank.d358.s1|103-110|systemic|O
DDI-DrugBank.d358.s1|112-119|exposure|O
DDI-DrugBank.d358.s1|121-122|of|O
DDI-DrugBank.d358.s1|124-133|cilostazol|drug
DDI-DrugBank.d358.s1|135-140|and/or|O
DDI-DrugBank.d358.s1|142-144|its|O
DDI-DrugBank.d358.s1|146-150|major|O
DDI-DrugBank.d358.s1|152-162|metabolites|O
DDI-DrugBank.d358.s1|163-163|.|O
DDI-DrugBank.d358.s2|0-9|Population|O
DDI-DrugBank.d358.s2|11-25|pharmacokinetic|O
DDI-DrugBank.d358.s2|27-33|studies|O
DDI-DrugBank.d358.s2|35-40|showed|O
DDI-DrugBank.d358.s2|42-47|higher|O
DDI-DrugBank.d358.s2|49-62|concentrations|O
DDI-DrugBank.d358.s2|64-65|of|O
DDI-DrugBank.d358.s2|67-76|cilostazol|drug
DDI-DrugBank.d358.s2|78-82|among|O
DDI-DrugBank.d358.s2|84-91|patients|O
DDI-DrugBank.d358.s2|93-104|concurrently|O
DDI-DrugBank.d358.s2|106-112|treated|O
DDI-DrugBank.d358.s2|114-117|with|O
DDI-DrugBank.d358.s2|119-127|diltiazem|drug
DDI-DrugBank.d358.s2|128-128|,|O
DDI-DrugBank.d358.s2|130-131|an|O
DDI-DrugBank.d358.s2|133-141|inhibitor|O
DDI-DrugBank.d358.s2|143-144|of|O
DDI-DrugBank.d358.s2|146-152|C.P.A..|O
DDI-DrugBank.d358.s3|0-5|Pletal|brand
DDI-DrugBank.d358.s3|7-10|does|O
DDI-DrugBank.d358.s3|12-14|not|O
DDI-DrugBank.d358.s3|15-15|,|O
DDI-DrugBank.d358.s3|17-23|however|O
DDI-DrugBank.d358.s3|24-24|,|O
DDI-DrugBank.d358.s3|26-31|appear|O
DDI-DrugBank.d358.s3|33-34|to|O
DDI-DrugBank.d358.s3|36-40|cause|O
DDI-DrugBank.d358.s3|42-50|increased|O
DDI-DrugBank.d358.s3|52-56|blood|O
DDI-DrugBank.d358.s3|58-63|levels|O
DDI-DrugBank.d358.s3|65-66|of|O
DDI-DrugBank.d358.s3|68-72|drugs|O
DDI-DrugBank.d358.s3|74-84|metabolized|O
DDI-DrugBank.d358.s3|86-87|by|O
DDI-DrugBank.d358.s3|89-94|CYP3A4|O
DDI-DrugBank.d358.s3|95-95|,|O
DDI-DrugBank.d358.s3|97-98|as|O
DDI-DrugBank.d358.s3|100-101|it|O
DDI-DrugBank.d358.s3|103-105|had|O
DDI-DrugBank.d358.s3|107-108|no|O
DDI-DrugBank.d358.s3|110-115|effect|O
DDI-DrugBank.d358.s3|117-118|on|O
DDI-DrugBank.d358.s3|120-129|lovastatin|drug
DDI-DrugBank.d358.s3|130-130|,|O
DDI-DrugBank.d358.s3|132-132|a|O
DDI-DrugBank.d358.s3|134-137|drug|O
DDI-DrugBank.d358.s3|139-142|with|O
DDI-DrugBank.d358.s3|144-153|metabolism|O
DDI-DrugBank.d358.s3|155-158|very|O
DDI-DrugBank.d358.s3|160-168|sensitive|O
DDI-DrugBank.d358.s3|170-171|to|O
DDI-DrugBank.d358.s3|173-178|C.P.A.|O
DDI-DrugBank.d358.s3|180-189|inhibition|O
DDI-DrugBank.d358.s3|190-190|.|O
DDI-DrugBank.d725.s0|0-11|Vasopressors|group
DDI-DrugBank.d725.s0|12-12|,|O
DDI-DrugBank.d725.s0|14-25|particularly|O
DDI-DrugBank.d725.s0|27-37|metaraminol|drug
DDI-DrugBank.d725.s0|38-38|,|O
DDI-DrugBank.d725.s0|40-42|may|O
DDI-DrugBank.d725.s0|44-48|cause|O
DDI-DrugBank.d725.s0|50-56|serious|O
DDI-DrugBank.d725.s0|58-64|cardiac|O
DDI-DrugBank.d725.s0|66-76|arrhythmias|O
DDI-DrugBank.d725.s0|78-83|during|O
DDI-DrugBank.d725.s0|85-93|halothane|drug
DDI-DrugBank.d725.s0|95-104|anesthesia|O
DDI-DrugBank.d725.s0|106-108|and|O
DDI-DrugBank.d725.s0|110-118|therefore|O
DDI-DrugBank.d725.s0|120-125|should|O
DDI-DrugBank.d725.s0|127-128|be|O
DDI-DrugBank.d725.s0|130-133|used|O
DDI-DrugBank.d725.s0|135-138|only|O
DDI-DrugBank.d725.s0|140-143|with|O
DDI-DrugBank.d725.s0|145-149|great|O
DDI-DrugBank.d725.s0|151-157|caution|O
DDI-DrugBank.d725.s0|159-160|or|O
DDI-DrugBank.d725.s0|162-164|not|O
DDI-DrugBank.d725.s0|166-167|at|O
DDI-DrugBank.d725.s0|169-171|all|O
DDI-DrugBank.d725.s0|172-172|.|O
DDI-DrugBank.d725.s1|0-13|MAO Inhibitors|group
DDI-DrugBank.d725.s1|14-14|:|O
DDI-DrugBank.d725.s1|16-18|The|O
DDI-DrugBank.d725.s1|20-26|pressor|O
DDI-DrugBank.d725.s1|28-33|effect|O
DDI-DrugBank.d725.s1|35-36|of|O
DDI-DrugBank.d725.s1|38-67|sympathomimetic pressor amines|group
DDI-DrugBank.d725.s1|69-70|is|O
DDI-DrugBank.d725.s1|72-79|markedly|O
DDI-DrugBank.d725.s1|81-91|potentiated|O
DDI-DrugBank.d725.s1|93-94|in|O
DDI-DrugBank.d725.s1|96-103|patients|O
DDI-DrugBank.d725.s1|105-113|receiving|O
DDI-DrugBank.d725.s1|115-142|monoamine oxidase inhibitors|group
DDI-DrugBank.d725.s1|144-144|(|O
DDI-DrugBank.d725.s1|145-148|MAOI|group
DDI-DrugBank.d725.s1|149-149|)|O
DDI-DrugBank.d725.s1|150-150|.|O
DDI-DrugBank.d725.s2|0-8|Therefore|O
DDI-DrugBank.d725.s2|9-9|,|O
DDI-DrugBank.d725.s2|11-14|when|O
DDI-DrugBank.d725.s2|16-25|initiating|O
DDI-DrugBank.d725.s2|27-33|pressor|O
DDI-DrugBank.d725.s2|35-41|therapy|O
DDI-DrugBank.d725.s2|43-44|in|O
DDI-DrugBank.d725.s2|46-50|these|O
DDI-DrugBank.d725.s2|52-59|patients|O
DDI-DrugBank.d725.s2|60-60|,|O
DDI-DrugBank.d725.s2|62-64|the|O
DDI-DrugBank.d725.s2|66-72|initial|O
DDI-DrugBank.d725.s2|74-77|dose|O
DDI-DrugBank.d725.s2|79-84|should|O
DDI-DrugBank.d725.s2|86-87|be|O
DDI-DrugBank.d725.s2|89-93|small|O
DDI-DrugBank.d725.s2|95-97|and|O
DDI-DrugBank.d725.s2|99-102|used|O
DDI-DrugBank.d725.s2|104-107|with|O
DDI-DrugBank.d725.s2|109-111|due|O
DDI-DrugBank.d725.s2|113-119|caution|O
DDI-DrugBank.d725.s2|120-120|.|O
DDI-DrugBank.d725.s3|0-2|The|O
DDI-DrugBank.d725.s3|4-10|pressor|O
DDI-DrugBank.d725.s3|12-19|response|O
DDI-DrugBank.d725.s3|21-22|of|O
DDI-DrugBank.d725.s3|24-40|adrenergic agents|group
DDI-DrugBank.d725.s3|42-44|may|O
DDI-DrugBank.d725.s3|46-49|also|O
DDI-DrugBank.d725.s3|51-52|be|O
DDI-DrugBank.d725.s3|54-64|potentiated|O
DDI-DrugBank.d725.s3|66-67|by|O
DDI-DrugBank.d725.s3|69-93|tricyclic antidepressants|group
DDI-DrugBank.d725.s3|94-94|.|O
DDI-DrugBank.d347.s0|0-13|Administration|O
DDI-DrugBank.d347.s0|15-16|of|O
DDI-DrugBank.d347.s0|18-23|repeat|O
DDI-DrugBank.d347.s0|25-29|doses|O
DDI-DrugBank.d347.s0|31-32|of|O
DDI-DrugBank.d347.s0|34-40|FACTIVE|brand
DDI-DrugBank.d347.s0|42-44|had|O
DDI-DrugBank.d347.s0|46-47|no|O
DDI-DrugBank.d347.s0|49-54|effect|O
DDI-DrugBank.d347.s0|56-57|on|O
DDI-DrugBank.d347.s0|59-61|the|O
DDI-DrugBank.d347.s0|63-68|repeat|O
DDI-DrugBank.d347.s0|70-73|dose|O
DDI-DrugBank.d347.s0|75-90|pharmacokinetics|O
DDI-DrugBank.d347.s0|92-93|of|O
DDI-DrugBank.d347.s0|95-106|theophylline|drug
DDI-DrugBank.d347.s0|107-107|,|O
DDI-DrugBank.d347.s0|109-115|digoxin|drug
DDI-DrugBank.d347.s0|117-118|or|O
DDI-DrugBank.d347.s0|120-121|an|O
DDI-DrugBank.d347.s0|123-153|ethinylestradiol/levonorgestrol|drug
DDI-DrugBank.d347.s0|155-158|oral|O
DDI-DrugBank.d347.s0|160-180|contraceptive product|group
DDI-DrugBank.d347.s0|182-183|in|O
DDI-DrugBank.d347.s0|185-191|healthy|O
DDI-DrugBank.d347.s0|193-200|subjects|O
DDI-DrugBank.d347.s0|201-201|.|O
DDI-DrugBank.d347.s1|0-10|Concomitant|O
DDI-DrugBank.d347.s1|12-25|administration|O
DDI-DrugBank.d347.s1|27-28|of|O
DDI-DrugBank.d347.s1|30-36|FACTIVE|brand
DDI-DrugBank.d347.s1|38-40|and|O
DDI-DrugBank.d347.s1|42-58|calcium carbonate|drug
DDI-DrugBank.d347.s1|59-59|,|O
DDI-DrugBank.d347.s1|61-70|cimetidine|drug
DDI-DrugBank.d347.s1|71-71|,|O
DDI-DrugBank.d347.s1|73-82|omeprazole|drug
DDI-DrugBank.d347.s1|83-83|,|O
DDI-DrugBank.d347.s1|85-86|or|O
DDI-DrugBank.d347.s1|88-89|an|O
DDI-DrugBank.d347.s1|91-111|estrogen/progesterone|group
DDI-DrugBank.d347.s1|113-116|oral|O
DDI-DrugBank.d347.s1|118-130|contraceptive|group
DDI-DrugBank.d347.s1|132-139|produced|O
DDI-DrugBank.d347.s1|141-145|minor|O
DDI-DrugBank.d347.s1|147-153|changes|O
DDI-DrugBank.d347.s1|155-156|in|O
DDI-DrugBank.d347.s1|158-160|the|O
DDI-DrugBank.d347.s1|162-177|pharmacokinetics|O
DDI-DrugBank.d347.s1|179-180|of|O
DDI-DrugBank.d347.s1|182-193|gemifloxacin|drug
DDI-DrugBank.d347.s1|194-194|,|O
DDI-DrugBank.d347.s1|196-200|which|O
DDI-DrugBank.d347.s1|202-205|were|O
DDI-DrugBank.d347.s1|207-216|considered|O
DDI-DrugBank.d347.s1|218-219|to|O
DDI-DrugBank.d347.s1|221-222|be|O
DDI-DrugBank.d347.s1|224-230|without|O
DDI-DrugBank.d347.s1|232-239|clinical|O
DDI-DrugBank.d347.s1|241-252|significance|O
DDI-DrugBank.d347.s1|253-253|.|O
DDI-DrugBank.d347.s2|0-10|Concomitant|O
DDI-DrugBank.d347.s2|12-25|administration|O
DDI-DrugBank.d347.s2|27-28|of|O
DDI-DrugBank.d347.s2|30-36|FACTIVE|brand
DDI-DrugBank.d347.s2|38-41|with|O
DDI-DrugBank.d347.s2|43-52|probenecid|drug
DDI-DrugBank.d347.s2|54-61|resulted|O
DDI-DrugBank.d347.s2|63-64|in|O
DDI-DrugBank.d347.s2|66-66|a|O
DDI-DrugBank.d347.s2|68-69|45|O
DDI-DrugBank.d347.s2|70-70|%|O
DDI-DrugBank.d347.s2|72-79|increase|O
DDI-DrugBank.d347.s2|81-82|in|O
DDI-DrugBank.d347.s2|84-91|systemic|O
DDI-DrugBank.d347.s2|93-100|exposure|O
DDI-DrugBank.d347.s2|102-103|to|O
DDI-DrugBank.d347.s2|105-116|gemifloxacin|drug
DDI-DrugBank.d347.s2|117-117|.|O
DDI-DrugBank.d347.s3|0-6|FACTIVE|brand
DDI-DrugBank.d347.s3|8-10|had|O
DDI-DrugBank.d347.s3|12-13|no|O
DDI-DrugBank.d347.s3|15-25|significant|O
DDI-DrugBank.d347.s3|27-32|effect|O
DDI-DrugBank.d347.s3|34-35|on|O
DDI-DrugBank.d347.s3|37-39|the|O
DDI-DrugBank.d347.s3|41-53|anticoagulant|O
DDI-DrugBank.d347.s3|55-60|effect|O
DDI-DrugBank.d347.s3|62-63|of|O
DDI-DrugBank.d347.s3|65-72|warfarin|drug
DDI-DrugBank.d347.s3|74-75|in|O
DDI-DrugBank.d347.s3|77-83|healthy|O
DDI-DrugBank.d347.s3|85-92|subjects|O
DDI-DrugBank.d347.s3|94-95|on|O
DDI-DrugBank.d347.s3|97-102|stable|O
DDI-DrugBank.d347.s3|104-111|warfarin|drug
DDI-DrugBank.d347.s3|113-119|therapy|O
DDI-DrugBank.d347.s3|120-120|.|O
DDI-DrugBank.d347.s4|0-6|However|O
DDI-DrugBank.d347.s4|7-7|,|O
DDI-DrugBank.d347.s4|9-15|because|O
DDI-DrugBank.d347.s4|17-20|some|O
DDI-DrugBank.d347.s4|22-31|quinolones|group
DDI-DrugBank.d347.s4|33-36|have|O
DDI-DrugBank.d347.s4|38-41|been|O
DDI-DrugBank.d347.s4|43-50|reported|O
DDI-DrugBank.d347.s4|52-53|to|O
DDI-DrugBank.d347.s4|55-61|enhance|O
DDI-DrugBank.d347.s4|63-65|the|O
DDI-DrugBank.d347.s4|67-79|anticoagulant|O
DDI-DrugBank.d347.s4|81-87|effects|O
DDI-DrugBank.d347.s4|89-90|of|O
DDI-DrugBank.d347.s4|92-99|warfarin|drug
DDI-DrugBank.d347.s4|101-102|or|O
DDI-DrugBank.d347.s4|104-106|its|O
DDI-DrugBank.d347.s4|108-118|derivatives|O
DDI-DrugBank.d347.s4|120-121|in|O
DDI-DrugBank.d347.s4|123-130|patients|O
DDI-DrugBank.d347.s4|131-131|,|O
DDI-DrugBank.d347.s4|133-135|the|O
DDI-DrugBank.d347.s4|137-147|prothrombin|O
DDI-DrugBank.d347.s4|149-152|time|O
DDI-DrugBank.d347.s4|154-155|or|O
DDI-DrugBank.d347.s4|157-161|other|O
DDI-DrugBank.d347.s4|163-170|suitable|O
DDI-DrugBank.d347.s4|172-182|coagulation|O
DDI-DrugBank.d347.s4|184-187|test|O
DDI-DrugBank.d347.s4|189-194|should|O
DDI-DrugBank.d347.s4|196-197|be|O
DDI-DrugBank.d347.s4|199-205|closely|O
DDI-DrugBank.d347.s4|207-215|monitored|O
DDI-DrugBank.d347.s4|217-218|if|O
DDI-DrugBank.d347.s4|220-220|a|O
DDI-DrugBank.d347.s4|222-244|quinolone antimicrobial|group
DDI-DrugBank.d347.s4|246-247|is|O
DDI-DrugBank.d347.s4|249-260|administered|O
DDI-DrugBank.d347.s4|262-274|concomitantly|O
DDI-DrugBank.d347.s4|276-279|with|O
DDI-DrugBank.d347.s4|281-288|warfarin|drug
DDI-DrugBank.d347.s4|290-291|or|O
DDI-DrugBank.d347.s4|293-295|its|O
DDI-DrugBank.d347.s4|297-307|derivatives|O
DDI-DrugBank.d347.s4|308-308|.|O
DDI-DrugBank.d347.s5|0-9|Quinolones|group
DDI-DrugBank.d347.s5|11-14|form|O
DDI-DrugBank.d347.s5|16-23|chelates|O
DDI-DrugBank.d347.s5|25-28|with|O
DDI-DrugBank.d347.s5|30-37|alkaline|O
DDI-DrugBank.d347.s5|39-43|earth|O
DDI-DrugBank.d347.s5|45-47|and|O
DDI-DrugBank.d347.s5|49-58|transition|O
DDI-DrugBank.d347.s5|60-65|metals|O
DDI-DrugBank.d347.s5|66-66|.|O
DDI-DrugBank.d347.s6|0-2|The|O
DDI-DrugBank.d347.s6|4-13|absorption|O
DDI-DrugBank.d347.s6|15-16|of|O
DDI-DrugBank.d347.s6|18-21|oral|O
DDI-DrugBank.d347.s6|23-34|gemifloxacin|drug
DDI-DrugBank.d347.s6|36-37|is|O
DDI-DrugBank.d347.s6|39-51|significantly|O
DDI-DrugBank.d347.s6|53-59|reduced|O
DDI-DrugBank.d347.s6|61-62|by|O
DDI-DrugBank.d347.s6|64-66|the|O
DDI-DrugBank.d347.s6|68-78|concomitant|O
DDI-DrugBank.d347.s6|80-93|administration|O
DDI-DrugBank.d347.s6|95-96|of|O
DDI-DrugBank.d347.s6|98-99|an|O
DDI-DrugBank.d347.s6|101-107|antacid|group
DDI-DrugBank.d347.s6|109-118|containing|O
DDI-DrugBank.d347.s6|120-127|aluminum|drug
DDI-DrugBank.d347.s6|129-131|and|O
DDI-DrugBank.d347.s6|133-141|magnesium|drug
DDI-DrugBank.d347.s6|142-142|.|O
DDI-DrugBank.d347.s7|0-9|Magnesium-|drug
DDI-DrugBank.d347.s7|11-16|and/or|O
DDI-DrugBank.d347.s7|18-36|aluminum-containing|drug
DDI-DrugBank.d347.s7|18-36|aluminum-containing|drug
DDI-DrugBank.d347.s7|46-46|,|O
DDI-DrugBank.d347.s7|48-55|products|O
DDI-DrugBank.d347.s7|57-66|containing|O
DDI-DrugBank.d347.s7|68-82|ferrous sulfate|drug
DDI-DrugBank.d347.s7|84-84|(|O
DDI-DrugBank.d347.s7|85-88|iron|drug
DDI-DrugBank.d347.s7|89-89|)|O
DDI-DrugBank.d347.s7|90-90|,|O
DDI-DrugBank.d347.s7|92-116|multivitamin preparations|group
DDI-DrugBank.d347.s7|118-127|containing|O
DDI-DrugBank.d347.s7|129-132|zinc|drug
DDI-DrugBank.d347.s7|134-135|or|O
DDI-DrugBank.d347.s7|137-141|other|O
DDI-DrugBank.d347.s7|143-147|metal|O
DDI-DrugBank.d347.s7|149-155|cations|O
DDI-DrugBank.d347.s7|156-156|,|O
DDI-DrugBank.d347.s7|158-159|or|O
DDI-DrugBank.d347.s7|161-165|Videx|brand
DDI-DrugBank.d347.s7|167-167|(|O
DDI-DrugBank.d347.s7|168-177|didanosine|drug
DDI-DrugBank.d347.s7|178-178|)|O
DDI-DrugBank.d347.s7|180-196|chewable/buffered|O
DDI-DrugBank.d347.s7|198-204|tablets|O
DDI-DrugBank.d347.s7|206-207|or|O
DDI-DrugBank.d347.s7|209-211|the|O
DDI-DrugBank.d347.s7|213-221|pediatric|O
DDI-DrugBank.d347.s7|223-228|powder|O
DDI-DrugBank.d347.s7|230-232|for|O
DDI-DrugBank.d347.s7|234-237|oral|O
DDI-DrugBank.d347.s7|239-246|solution|O
DDI-DrugBank.d347.s7|248-253|should|O
DDI-DrugBank.d347.s7|255-257|not|O
DDI-DrugBank.d347.s7|259-260|be|O
DDI-DrugBank.d347.s7|262-266|taken|O
DDI-DrugBank.d347.s7|268-273|within|O
DDI-DrugBank.d347.s7|275-275|3|O
DDI-DrugBank.d347.s7|277-281|hours|O
DDI-DrugBank.d347.s7|283-288|before|O
DDI-DrugBank.d347.s7|290-291|or|O
DDI-DrugBank.d347.s7|293-293|2|O
DDI-DrugBank.d347.s7|295-299|hours|O
DDI-DrugBank.d347.s7|301-305|after|O
DDI-DrugBank.d347.s7|307-313|FACTIVE|brand
DDI-DrugBank.d347.s7|314-314|.|O
DDI-DrugBank.d347.s8|0-9|Sucralfate|drug
DDI-DrugBank.d347.s8|11-16|should|O
DDI-DrugBank.d347.s8|18-20|not|O
DDI-DrugBank.d347.s8|22-23|be|O
DDI-DrugBank.d347.s8|25-29|taken|O
DDI-DrugBank.d347.s8|31-36|within|O
DDI-DrugBank.d347.s8|38-38|2|O
DDI-DrugBank.d347.s8|40-44|hours|O
DDI-DrugBank.d347.s8|46-47|of|O
DDI-DrugBank.d347.s8|49-55|FACTIVE|brand
DDI-DrugBank.d347.s8|56-56|.|O
DDI-DrugBank.d333.s0|0-5|Effect|O
DDI-DrugBank.d333.s0|7-8|of|O
DDI-DrugBank.d333.s0|10-19|Clonazepam|drug
DDI-DrugBank.d333.s0|21-22|on|O
DDI-DrugBank.d333.s0|24-26|the|O
DDI-DrugBank.d333.s0|28-43|Pharmacokinetics|O
DDI-DrugBank.d333.s0|45-46|of|O
DDI-DrugBank.d333.s0|48-52|Other|O
DDI-DrugBank.d333.s0|54-58|Drugs|O
DDI-DrugBank.d333.s0|59-59|:|O
DDI-DrugBank.d333.s0|61-70|Clonazepam|drug
DDI-DrugBank.d333.s0|72-75|does|O
DDI-DrugBank.d333.s0|77-79|not|O
DDI-DrugBank.d333.s0|81-86|appear|O
DDI-DrugBank.d333.s0|88-89|to|O
DDI-DrugBank.d333.s0|91-95|alter|O
DDI-DrugBank.d333.s0|97-99|the|O
DDI-DrugBank.d333.s0|101-116|pharmacokinetics|O
DDI-DrugBank.d333.s0|118-119|of|O
DDI-DrugBank.d333.s0|121-129|phenytoin|drug
DDI-DrugBank.d333.s0|130-130|,|O
DDI-DrugBank.d333.s0|132-144|carbamazepine|drug
DDI-DrugBank.d333.s0|145-145|,|O
DDI-DrugBank.d333.s0|147-148|or|O
DDI-DrugBank.d333.s0|150-162|phenobarbital|drug
DDI-DrugBank.d333.s0|163-163|.|O
DDI-DrugBank.d333.s1|0-2|The|O
DDI-DrugBank.d333.s1|4-9|effect|O
DDI-DrugBank.d333.s1|11-12|of|O
DDI-DrugBank.d333.s1|14-23|clonazepam|drug
DDI-DrugBank.d333.s1|25-26|on|O
DDI-DrugBank.d333.s1|28-30|the|O
DDI-DrugBank.d333.s1|32-41|metabolism|O
DDI-DrugBank.d333.s1|43-44|of|O
DDI-DrugBank.d333.s1|46-50|other|O
DDI-DrugBank.d333.s1|52-56|drugs|O
DDI-DrugBank.d333.s1|58-60|has|O
DDI-DrugBank.d333.s1|62-64|not|O
DDI-DrugBank.d333.s1|66-69|been|O
DDI-DrugBank.d333.s1|71-82|investigated|O
DDI-DrugBank.d333.s1|83-83|.|O
DDI-DrugBank.d333.s2|0-5|Effect|O
DDI-DrugBank.d333.s2|7-8|of|O
DDI-DrugBank.d333.s2|10-14|Other|O
DDI-DrugBank.d333.s2|16-20|Drugs|O
DDI-DrugBank.d333.s2|22-23|on|O
DDI-DrugBank.d333.s2|25-27|the|O
DDI-DrugBank.d333.s2|29-44|Pharmacokinetics|O
DDI-DrugBank.d333.s2|46-47|of|O
DDI-DrugBank.d333.s2|49-58|Clonazepam|drug
DDI-DrugBank.d333.s2|59-59|:|O
DDI-DrugBank.d333.s2|61-70|Literature|O
DDI-DrugBank.d333.s2|72-78|reports|O
DDI-DrugBank.d333.s2|80-86|suggest|O
DDI-DrugBank.d333.s2|88-91|that|O
DDI-DrugBank.d333.s2|93-102|ranitidine|drug
DDI-DrugBank.d333.s2|103-103|,|O
DDI-DrugBank.d333.s2|105-106|an|O
DDI-DrugBank.d333.s2|108-112|agent|O
DDI-DrugBank.d333.s2|114-117|that|O
DDI-DrugBank.d333.s2|119-127|decreases|O
DDI-DrugBank.d333.s2|129-135|stomach|O
DDI-DrugBank.d333.s2|137-143|acidity|O
DDI-DrugBank.d333.s2|144-144|,|O
DDI-DrugBank.d333.s2|146-149|does|O
DDI-DrugBank.d333.s2|151-153|not|O
DDI-DrugBank.d333.s2|155-161|greatly|O
DDI-DrugBank.d333.s2|163-167|alter|O
DDI-DrugBank.d333.s2|169-178|clonazepam|drug
DDI-DrugBank.d333.s2|180-195|pharmacokinetics|O
DDI-DrugBank.d333.s2|196-196|.|O
DDI-DrugBank.d333.s3|0-1|In|O
DDI-DrugBank.d333.s3|3-3|a|O
DDI-DrugBank.d333.s3|5-9|study|O
DDI-DrugBank.d333.s3|11-12|in|O
DDI-DrugBank.d333.s3|14-18|which|O
DDI-DrugBank.d333.s3|20-22|the|O
DDI-DrugBank.d333.s3|24-24|2|O
DDI-DrugBank.d333.s3|26-27|mg|O
DDI-DrugBank.d333.s3|29-38|clonazepam|drug
DDI-DrugBank.d333.s3|40-45|orally|O
DDI-DrugBank.d333.s3|47-60|disintegrating|O
DDI-DrugBank.d333.s3|62-67|tablet|O
DDI-DrugBank.d333.s3|69-71|was|O
DDI-DrugBank.d333.s3|73-84|administered|O
DDI-DrugBank.d333.s3|86-89|with|O
DDI-DrugBank.d333.s3|91-93|and|O
DDI-DrugBank.d333.s3|95-101|without|O
DDI-DrugBank.d333.s3|103-115|propantheline|drug
DDI-DrugBank.d333.s3|117-117|(|O
DDI-DrugBank.d333.s3|118-119|an|O
DDI-DrugBank.d333.s3|121-141|anticholinergic agent|group
DDI-DrugBank.d333.s3|143-146|with|O
DDI-DrugBank.d333.s3|148-155|multiple|O
DDI-DrugBank.d333.s3|157-163|effects|O
DDI-DrugBank.d333.s3|165-166|on|O
DDI-DrugBank.d333.s3|168-170|the|O
DDI-DrugBank.d333.s3|172-173|GI|O
DDI-DrugBank.d333.s3|175-179|tract|O
DDI-DrugBank.d333.s3|180-180|)|O
DDI-DrugBank.d333.s3|182-183|to|O
DDI-DrugBank.d333.s3|185-191|healthy|O
DDI-DrugBank.d333.s3|193-202|volunteers|O
DDI-DrugBank.d333.s3|203-203|,|O
DDI-DrugBank.d333.s3|205-207|the|O
DDI-DrugBank.d333.s3|209-211|AUC|O
DDI-DrugBank.d333.s3|213-214|of|O
DDI-DrugBank.d333.s3|216-225|clonazepam|drug
DDI-DrugBank.d333.s3|227-229|was|O
DDI-DrugBank.d333.s3|231-232|10|O
DDI-DrugBank.d333.s3|233-233|%|O
DDI-DrugBank.d333.s3|235-239|lower|O
DDI-DrugBank.d333.s3|241-243|and|O
DDI-DrugBank.d333.s3|245-247|the|O
DDI-DrugBank.d333.s3|249-252|Cmax|O
DDI-DrugBank.d333.s3|254-255|of|O
DDI-DrugBank.d333.s3|257-266|clonazepam|drug
DDI-DrugBank.d333.s3|268-270|was|O
DDI-DrugBank.d333.s3|272-273|20|O
DDI-DrugBank.d333.s3|274-274|%|O
DDI-DrugBank.d333.s3|276-280|lower|O
DDI-DrugBank.d333.s3|282-285|when|O
DDI-DrugBank.d333.s3|287-289|the|O
DDI-DrugBank.d333.s3|291-296|orally|O
DDI-DrugBank.d333.s3|298-311|disintegrating|O
DDI-DrugBank.d333.s3|313-318|tablet|O
DDI-DrugBank.d333.s3|320-322|was|O
DDI-DrugBank.d333.s3|324-328|given|O
DDI-DrugBank.d333.s3|330-333|with|O
DDI-DrugBank.d333.s3|335-347|propantheline|drug
DDI-DrugBank.d333.s3|349-356|compared|O
DDI-DrugBank.d333.s3|358-359|to|O
DDI-DrugBank.d333.s3|361-364|when|O
DDI-DrugBank.d333.s3|366-367|it|O
DDI-DrugBank.d333.s3|369-371|was|O
DDI-DrugBank.d333.s3|373-377|given|O
DDI-DrugBank.d333.s3|379-383|alone|O
DDI-DrugBank.d333.s3|384-384|.|O
DDI-DrugBank.d333.s4|0-9|Fluoxetine|drug
DDI-DrugBank.d333.s4|11-14|does|O
DDI-DrugBank.d333.s4|16-18|not|O
DDI-DrugBank.d333.s4|20-25|affect|O
DDI-DrugBank.d333.s4|27-29|the|O
DDI-DrugBank.d333.s4|31-46|pharmacokinetics|O
DDI-DrugBank.d333.s4|48-49|of|O
DDI-DrugBank.d333.s4|51-60|clonazepam|drug
DDI-DrugBank.d333.s4|61-61|.|O
DDI-DrugBank.d333.s5|0-9|Cytochrome|O
DDI-DrugBank.d333.s5|11-15|P-450|O
DDI-DrugBank.d333.s5|17-24|inducers|O
DDI-DrugBank.d333.s5|25-25|,|O
DDI-DrugBank.d333.s5|27-30|such|O
DDI-DrugBank.d333.s5|32-33|as|O
DDI-DrugBank.d333.s5|35-43|phenytoin|drug
DDI-DrugBank.d333.s5|44-44|,|O
DDI-DrugBank.d333.s5|46-58|carbamazepine|drug
DDI-DrugBank.d333.s5|60-62|and|O
DDI-DrugBank.d333.s5|64-76|phenobarbital|drug
DDI-DrugBank.d333.s5|77-77|,|O
DDI-DrugBank.d333.s5|79-84|induce|O
DDI-DrugBank.d333.s5|86-95|clonazepam|drug
DDI-DrugBank.d333.s5|97-106|metabolism|O
DDI-DrugBank.d333.s5|107-107|,|O
DDI-DrugBank.d333.s5|109-115|causing|O
DDI-DrugBank.d333.s5|117-118|an|O
DDI-DrugBank.d333.s5|120-132|approximately|O
DDI-DrugBank.d333.s5|134-135|30|O
DDI-DrugBank.d333.s5|136-136|%|O
DDI-DrugBank.d333.s5|138-145|decrease|O
DDI-DrugBank.d333.s5|147-148|in|O
DDI-DrugBank.d333.s5|150-155|plasma|O
DDI-DrugBank.d333.s5|157-166|clonazepam|drug
DDI-DrugBank.d333.s5|168-173|levels|O
DDI-DrugBank.d333.s5|174-174|.|O
DDI-DrugBank.d333.s6|0-7|Although|O
DDI-DrugBank.d333.s6|9-16|clinical|O
DDI-DrugBank.d333.s6|18-24|studies|O
DDI-DrugBank.d333.s6|26-29|have|O
DDI-DrugBank.d333.s6|31-33|not|O
DDI-DrugBank.d333.s6|35-38|been|O
DDI-DrugBank.d333.s6|40-48|performed|O
DDI-DrugBank.d333.s6|49-49|,|O
DDI-DrugBank.d333.s6|51-55|based|O
DDI-DrugBank.d333.s6|57-58|on|O
DDI-DrugBank.d333.s6|60-62|the|O
DDI-DrugBank.d333.s6|64-74|involvement|O
DDI-DrugBank.d333.s6|76-77|of|O
DDI-DrugBank.d333.s6|79-81|the|O
DDI-DrugBank.d333.s6|83-92|cytochrome|O
DDI-DrugBank.d333.s6|94-98|P-450|O
DDI-DrugBank.d333.s6|100-101|3A|O
DDI-DrugBank.d333.s6|103-108|family|O
DDI-DrugBank.d333.s6|110-111|in|O
DDI-DrugBank.d333.s6|113-122|clonazepam|drug
DDI-DrugBank.d333.s6|124-133|metabolism|O
DDI-DrugBank.d333.s6|134-134|,|O
DDI-DrugBank.d333.s6|136-145|inhibitors|O
DDI-DrugBank.d333.s6|147-148|of|O
DDI-DrugBank.d333.s6|150-153|this|O
DDI-DrugBank.d333.s6|155-160|enzyme|O
DDI-DrugBank.d333.s6|162-167|system|O
DDI-DrugBank.d333.s6|168-168|,|O
DDI-DrugBank.d333.s6|170-176|notably|O
DDI-DrugBank.d333.s6|178-181|oral|O
DDI-DrugBank.d333.s6|183-199|antifungal agents|group
DDI-DrugBank.d333.s6|200-200|,|O
DDI-DrugBank.d333.s6|202-207|should|O
DDI-DrugBank.d333.s6|209-210|be|O
DDI-DrugBank.d333.s6|212-215|used|O
DDI-DrugBank.d333.s6|217-226|cautiously|O
DDI-DrugBank.d333.s6|228-229|in|O
DDI-DrugBank.d333.s6|231-238|patients|O
DDI-DrugBank.d333.s6|240-248|receiving|O
DDI-DrugBank.d333.s6|250-259|clonazepam|drug
DDI-DrugBank.d333.s6|260-260|.|O
DDI-DrugBank.d333.s7|0-14|Pharmacodynamic|O
DDI-DrugBank.d333.s7|16-27|Interactions|O
DDI-DrugBank.d333.s7|28-28|:|O
DDI-DrugBank.d333.s7|30-32|The|O
DDI-DrugBank.d333.s7|34-47|CNS-depressant|O
DDI-DrugBank.d333.s7|49-54|action|O
DDI-DrugBank.d333.s7|56-57|of|O
DDI-DrugBank.d333.s7|59-61|the|O
DDI-DrugBank.d333.s7|63-82|benzodiazepine class|group
DDI-DrugBank.d333.s7|84-85|of|O
DDI-DrugBank.d333.s7|87-91|drugs|O
DDI-DrugBank.d333.s7|93-95|may|O
DDI-DrugBank.d333.s7|97-98|be|O
DDI-DrugBank.d333.s7|100-110|potentiated|O
DDI-DrugBank.d333.s7|112-113|by|O
DDI-DrugBank.d333.s7|115-121|alcohol|drug
DDI-DrugBank.d333.s7|122-122|,|O
DDI-DrugBank.d333.s7|124-132|narcotics|group
DDI-DrugBank.d333.s7|133-133|,|O
DDI-DrugBank.d333.s7|135-146|barbiturates|group
DDI-DrugBank.d333.s7|147-147|,|O
DDI-DrugBank.d333.s7|149-172|nonbarbiturate hypnotics|group
DDI-DrugBank.d333.s7|173-173|,|O
DDI-DrugBank.d333.s7|175-192|antianxiety agents|group
DDI-DrugBank.d333.s7|193-193|,|O
DDI-DrugBank.d333.s7|195-197|the|O
DDI-DrugBank.d333.s7|199-212|phenothiazines|group
DDI-DrugBank.d333.s7|213-213|,|O
DDI-DrugBank.d333.s7|215-226|thioxanthene|group
DDI-DrugBank.d333.s7|228-230|and|O
DDI-DrugBank.d333.s7|232-276|butyrophenone classes of antipsychotic agents|group
DDI-DrugBank.d333.s7|277-277|,|O
DDI-DrugBank.d333.s7|279-306|monoamine oxidase inhibitors|group
DDI-DrugBank.d333.s7|308-310|and|O
DDI-DrugBank.d333.s7|312-314|the|O
DDI-DrugBank.d333.s7|316-340|tricyclic antidepressants|group
DDI-DrugBank.d333.s7|341-341|,|O
DDI-DrugBank.d333.s7|343-345|and|O
DDI-DrugBank.d333.s7|347-348|by|O
DDI-DrugBank.d333.s7|350-354|other|O
DDI-DrugBank.d333.s7|356-375|anticonvulsant drugs|group
DDI-DrugBank.d333.s7|376-376|.|O
DDI-DrugBank.d649.s0|0-13|Sulfamethizole|drug
DDI-DrugBank.d649.s0|15-17|may|O
DDI-DrugBank.d649.s0|19-26|increase|O
DDI-DrugBank.d649.s0|28-30|the|O
DDI-DrugBank.d649.s0|32-38|effects|O
DDI-DrugBank.d649.s0|40-41|of|O
DDI-DrugBank.d649.s0|43-54|barbiturates|group
DDI-DrugBank.d649.s0|55-55|,|O
DDI-DrugBank.d649.s0|57-67|tolbutamide|drug
DDI-DrugBank.d649.s0|68-68|,|O
DDI-DrugBank.d649.s0|70-72|and|O
DDI-DrugBank.d649.s0|74-84|uricosurics|group
DDI-DrugBank.d649.s0|85-85|.|O
DDI-DrugBank.d649.s1|0-1|It|O
DDI-DrugBank.d649.s1|3-5|may|O
DDI-DrugBank.d649.s1|7-10|also|O
DDI-DrugBank.d649.s1|12-19|interact|O
DDI-DrugBank.d649.s1|21-24|with|O
DDI-DrugBank.d649.s1|26-34|thiazides|group
DDI-DrugBank.d649.s1|36-36|(|O
DDI-DrugBank.d649.s1|37-45|increased|O
DDI-DrugBank.d649.s1|47-62|thrombocytopenia|O
DDI-DrugBank.d649.s1|63-63|)|O
DDI-DrugBank.d649.s1|64-64|,|O
DDI-DrugBank.d649.s1|66-77|cyclosporine|drug
DDI-DrugBank.d649.s1|79-79|(|O
DDI-DrugBank.d649.s1|80-88|increased|O
DDI-DrugBank.d649.s1|90-103|nephrotoxicity|O
DDI-DrugBank.d649.s1|104-104|)|O
DDI-DrugBank.d649.s1|105-105|,|O
DDI-DrugBank.d649.s1|107-125|sulfonylurea agents|group
DDI-DrugBank.d649.s1|127-127|(|O
DDI-DrugBank.d649.s1|128-136|increased|O
DDI-DrugBank.d649.s1|138-149|hypoglycemic|O
DDI-DrugBank.d649.s1|151-158|response|O
DDI-DrugBank.d649.s1|159-159|)|O
DDI-DrugBank.d649.s1|160-160|,|O
DDI-DrugBank.d649.s1|162-169|warfarin|drug
DDI-DrugBank.d649.s1|171-171|(|O
DDI-DrugBank.d649.s1|172-180|increased|O
DDI-DrugBank.d649.s1|182-194|anticoagulant|O
DDI-DrugBank.d649.s1|196-201|effect|O
DDI-DrugBank.d649.s1|202-202|)|O
DDI-DrugBank.d649.s1|203-203|,|O
DDI-DrugBank.d649.s1|205-216|methotrexate|drug
DDI-DrugBank.d649.s1|218-218|(|O
DDI-DrugBank.d649.s1|219-227|decreased|O
DDI-DrugBank.d649.s1|229-233|renal|O
DDI-DrugBank.d649.s1|235-243|excretion|O
DDI-DrugBank.d649.s1|245-246|of|O
DDI-DrugBank.d649.s1|248-259|methotrexate|drug
DDI-DrugBank.d649.s1|260-260|)|O
DDI-DrugBank.d649.s1|261-261|,|O
DDI-DrugBank.d649.s1|263-271|phenytoin|drug
DDI-DrugBank.d649.s1|273-273|(|O
DDI-DrugBank.d649.s1|274-282|decreased|O
DDI-DrugBank.d649.s1|284-290|hepatic|O
DDI-DrugBank.d649.s1|292-300|clearance|O
DDI-DrugBank.d649.s1|302-303|of|O
DDI-DrugBank.d649.s1|305-313|phenytoin|drug
DDI-DrugBank.d649.s1|314-314|)|O
DDI-DrugBank.d649.s1|315-315|.|O
DDI-DrugBank.d401.s0|0-3|Drug|O
DDI-DrugBank.d401.s0|5-16|Interactions|O
DDI-DrugBank.d401.s0|17-17|:|O
DDI-DrugBank.d401.s0|19-21|The|O
DDI-DrugBank.d401.s0|23-29|central|O
DDI-DrugBank.d401.s0|31-45|anticholinergic|group
DDI-DrugBank.d401.s0|47-54|syndrome|O
DDI-DrugBank.d401.s0|56-58|can|O
DDI-DrugBank.d401.s0|60-64|occur|O
DDI-DrugBank.d401.s0|66-69|when|O
DDI-DrugBank.d401.s0|71-85|anticholinergic|O
DDI-DrugBank.d401.s0|87-92|agents|O
DDI-DrugBank.d401.s0|94-97|such|O
DDI-DrugBank.d401.s0|99-100|as|O
DDI-DrugBank.d401.s0|102-109|AKINETON|brand
DDI-DrugBank.d401.s0|111-113|are|O
DDI-DrugBank.d401.s0|115-126|administered|O
DDI-DrugBank.d401.s0|128-140|concomitantly|O
DDI-DrugBank.d401.s0|142-145|with|O
DDI-DrugBank.d401.s0|147-151|drugs|O
DDI-DrugBank.d401.s0|153-156|that|O
DDI-DrugBank.d401.s0|158-161|have|O
DDI-DrugBank.d401.s0|163-171|secondary|O
DDI-DrugBank.d401.s0|173-187|anticholinergic|O
DDI-DrugBank.d401.s0|189-195|actions|O
DDI-DrugBank.d401.s0|196-196|,|O
DDI-DrugBank.d401.s0|198-201|e.g.|O
DDI-DrugBank.d401.s0|202-202|,|O
DDI-DrugBank.d401.s0|204-210|certain|O
DDI-DrugBank.d401.s0|212-230|narcotic analgesics|group
DDI-DrugBank.d401.s0|232-235|such|O
DDI-DrugBank.d401.s0|237-238|as|O
DDI-DrugBank.d401.s0|240-249|meperidine|drug
DDI-DrugBank.d401.s0|250-250|,|O
DDI-DrugBank.d401.s0|252-254|the|O
DDI-DrugBank.d401.s0|256-269|phenothiazines|group
DDI-DrugBank.d401.s0|271-273|and|O
DDI-DrugBank.d401.s0|275-279|other|O
DDI-DrugBank.d401.s0|281-294|antipsychotics|group
DDI-DrugBank.d401.s0|295-295|,|O
DDI-DrugBank.d401.s0|297-321|tricyclic antidepressants|group
DDI-DrugBank.d401.s0|322-322|,|O
DDI-DrugBank.d401.s0|324-330|certain|O
DDI-DrugBank.d401.s0|332-346|antiarrhythmics|group
DDI-DrugBank.d401.s0|348-351|such|O
DDI-DrugBank.d401.s0|353-354|as|O
DDI-DrugBank.d401.s0|356-358|the|O
DDI-DrugBank.d401.s0|360-368|quinidine|drug
DDI-DrugBank.d401.s0|370-374|salts|O
DDI-DrugBank.d401.s0|375-375|,|O
DDI-DrugBank.d401.s0|377-379|and|O
DDI-DrugBank.d401.s0|381-394|antihistamines|group
DDI-DrugBank.d401.s0|395-395|.|O
DDI-DrugBank.d348.s0|0-7|Although|O
DDI-DrugBank.d348.s0|9-11|the|O
DDI-DrugBank.d348.s0|13-19|pressor|O
DDI-DrugBank.d348.s0|21-28|activity|O
DDI-DrugBank.d348.s0|30-31|of|O
DDI-DrugBank.d348.s0|33-44|Desmopressin|drug
DDI-DrugBank.d348.s0|46-47|is|O
DDI-DrugBank.d348.s0|49-52|very|O
DDI-DrugBank.d348.s0|54-56|low|O
DDI-DrugBank.d348.s0|58-65|compared|O
DDI-DrugBank.d348.s0|67-68|to|O
DDI-DrugBank.d348.s0|70-72|its|O
DDI-DrugBank.d348.s0|74-85|antidiuretic|O
DDI-DrugBank.d348.s0|87-94|activity|O
DDI-DrugBank.d348.s0|95-95|,|O
DDI-DrugBank.d348.s0|97-101|large|O
DDI-DrugBank.d348.s0|103-107|doses|O
DDI-DrugBank.d348.s0|109-110|of|O
DDI-DrugBank.d348.s0|112-123|Desmopressin|drug
DDI-DrugBank.d348.s0|125-131|Tablets|O
DDI-DrugBank.d348.s0|133-138|should|O
DDI-DrugBank.d348.s0|140-141|be|O
DDI-DrugBank.d348.s0|143-146|used|O
DDI-DrugBank.d348.s0|148-151|with|O
DDI-DrugBank.d348.s0|153-157|other|O
DDI-DrugBank.d348.s0|159-165|pressor|O
DDI-DrugBank.d348.s0|167-172|agents|O
DDI-DrugBank.d348.s0|174-177|only|O
DDI-DrugBank.d348.s0|179-182|with|O
DDI-DrugBank.d348.s0|184-190|careful|O
DDI-DrugBank.d348.s0|192-198|patient|O
DDI-DrugBank.d348.s0|200-209|monitoring|O
DDI-DrugBank.d348.s0|210-210|.|O
DDI-DrugBank.d311.s0|0-5|Taking|O
DDI-DrugBank.d311.s0|7-7|a|O
DDI-DrugBank.d311.s0|9-26|rauwolfia alkaloid|group
DDI-DrugBank.d311.s0|28-32|while|O
DDI-DrugBank.d311.s0|34-36|you|O
DDI-DrugBank.d311.s0|38-40|are|O
DDI-DrugBank.d311.s0|42-47|taking|O
DDI-DrugBank.d311.s0|49-50|or|O
DDI-DrugBank.d311.s0|52-57|within|O
DDI-DrugBank.d311.s0|59-59|2|O
DDI-DrugBank.d311.s0|61-65|weeks|O
DDI-DrugBank.d311.s0|67-68|of|O
DDI-DrugBank.d311.s0|70-75|taking|O
DDI-DrugBank.d311.s0|77-90|MAO inhibitors|group
DDI-DrugBank.d311.s0|92-94|may|O
DDI-DrugBank.d311.s0|96-103|increase|O
DDI-DrugBank.d311.s0|105-107|the|O
DDI-DrugBank.d311.s0|109-112|risk|O
DDI-DrugBank.d311.s0|114-115|of|O
DDI-DrugBank.d311.s0|117-123|central|O
DDI-DrugBank.d311.s0|125-131|nervous|O
DDI-DrugBank.d311.s0|133-138|system|O
DDI-DrugBank.d311.s0|140-149|depression|O
DDI-DrugBank.d311.s0|151-152|or|O
DDI-DrugBank.d311.s0|154-156|may|O
DDI-DrugBank.d311.s0|158-162|cause|O
DDI-DrugBank.d311.s0|164-164|a|O
DDI-DrugBank.d311.s0|166-171|severe|O
DDI-DrugBank.d311.s0|173-176|high|O
DDI-DrugBank.d311.s0|178-182|blood|O
DDI-DrugBank.d311.s0|184-191|pressure|O
DDI-DrugBank.d311.s0|193-200|reaction|O
DDI-DrugBank.d311.s0|201-201|.|O
DDI-DrugBank.d560.s0|0-2|Use|O
DDI-DrugBank.d560.s0|4-5|of|O
DDI-DrugBank.d560.s0|7-20|MAO inhibitors|group
DDI-DrugBank.d560.s0|22-24|may|O
DDI-DrugBank.d560.s0|26-30|cause|O
DDI-DrugBank.d560.s0|32-33|an|O
DDI-DrugBank.d560.s0|35-43|excessive|O
DDI-DrugBank.d560.s0|45-52|increase|O
DDI-DrugBank.d560.s0|54-55|in|O
DDI-DrugBank.d560.s0|57-61|blood|O
DDI-DrugBank.d560.s0|63-70|pressure|O
DDI-DrugBank.d560.s0|72-74|and|O
DDI-DrugBank.d560.s0|76-80|heart|O
DDI-DrugBank.d560.s0|82-92|stimulation|O
DDI-DrugBank.d560.s0|93-93|.|O
DDI-DrugBank.d560.s1|0-1|If|O
DDI-DrugBank.d560.s1|3-5|you|O
DDI-DrugBank.d560.s1|7-9|are|O
DDI-DrugBank.d560.s1|11-14|also|O
DDI-DrugBank.d560.s1|16-20|using|O
DDI-DrugBank.d560.s1|22-22|a|O
DDI-DrugBank.d560.s1|24-30|steroid|group
DDI-DrugBank.d560.s1|32-38|inhaler|O
DDI-DrugBank.d560.s1|39-39|,|O
DDI-DrugBank.d560.s1|41-44|take|O
DDI-DrugBank.d560.s1|46-55|bitolterol|drug
DDI-DrugBank.d560.s1|57-61|first|O
DDI-DrugBank.d560.s1|63-65|and|O
DDI-DrugBank.d560.s1|67-70|then|O
DDI-DrugBank.d560.s1|72-75|wait|O
DDI-DrugBank.d560.s1|77-81|about|O
DDI-DrugBank.d560.s1|83-84|15|O
DDI-DrugBank.d560.s1|86-92|minutes|O
DDI-DrugBank.d560.s1|94-99|before|O
DDI-DrugBank.d560.s1|101-105|using|O
DDI-DrugBank.d560.s1|107-109|the|O
DDI-DrugBank.d560.s1|111-117|steroid|group
DDI-DrugBank.d560.s1|119-125|inhaler|O
DDI-DrugBank.d560.s1|126-126|.|O
DDI-DrugBank.d560.s2|0-3|This|O
DDI-DrugBank.d560.s2|5-10|allows|O
DDI-DrugBank.d560.s2|12-21|bitolterol|drug
DDI-DrugBank.d560.s2|23-24|to|O
DDI-DrugBank.d560.s2|26-29|open|O
DDI-DrugBank.d560.s2|31-33|air|O
DDI-DrugBank.d560.s2|35-42|passages|O
DDI-DrugBank.d560.s2|43-43|,|O
DDI-DrugBank.d560.s2|45-54|increasing|O
DDI-DrugBank.d560.s2|56-58|the|O
DDI-DrugBank.d560.s2|60-72|effectiveness|O
DDI-DrugBank.d560.s2|74-75|of|O
DDI-DrugBank.d560.s2|77-79|the|O
DDI-DrugBank.d560.s2|81-87|steroid|group
DDI-DrugBank.d560.s2|88-88|.|O
DDI-DrugBank.d314.s0|0-16|Aminoglutethimide|drug
DDI-DrugBank.d314.s0|17-17|:|O
DDI-DrugBank.d314.s0|19-35|Aminoglutethimide|drug
DDI-DrugBank.d314.s0|37-39|may|O
DDI-DrugBank.d314.s0|41-48|diminish|O
DDI-DrugBank.d314.s0|50-56|adrenal|O
DDI-DrugBank.d314.s0|58-68|suppression|O
DDI-DrugBank.d314.s0|70-71|by|O
DDI-DrugBank.d314.s0|73-87|corticosteroids|group
DDI-DrugBank.d314.s0|88-88|.|O
DDI-DrugBank.d314.s1|0-13|Amphotericin B|drug
DDI-DrugBank.d314.s1|15-23|injection|O
DDI-DrugBank.d314.s1|25-27|and|O
DDI-DrugBank.d314.s1|29-47|potassium-depleting|O
DDI-DrugBank.d314.s1|49-54|agents|O
DDI-DrugBank.d314.s1|55-55|:|O
DDI-DrugBank.d314.s1|57-60|When|O
DDI-DrugBank.d314.s1|62-76|corticosteroids|group
DDI-DrugBank.d314.s1|78-80|are|O
DDI-DrugBank.d314.s1|82-93|administered|O
DDI-DrugBank.d314.s1|95-107|concomitantly|O
DDI-DrugBank.d314.s1|109-112|with|O
DDI-DrugBank.d314.s1|114-132|potassium-depleting|O
DDI-DrugBank.d314.s1|134-139|agents|O
DDI-DrugBank.d314.s1|141-141|(|O
DDI-DrugBank.d314.s1|142-145|e.g.|O
DDI-DrugBank.d314.s1|146-146|,|O
DDI-DrugBank.d314.s1|148-161|amphotericin B|drug
DDI-DrugBank.d314.s1|162-162|,|O
DDI-DrugBank.d314.s1|164-172|diuretics|group
DDI-DrugBank.d314.s1|173-173|)|O
DDI-DrugBank.d314.s1|174-174|,|O
DDI-DrugBank.d314.s1|176-183|patients|O
DDI-DrugBank.d314.s1|185-190|should|O
DDI-DrugBank.d314.s1|192-193|be|O
DDI-DrugBank.d314.s1|195-202|observed|O
DDI-DrugBank.d314.s1|204-210|closely|O
DDI-DrugBank.d314.s1|212-214|for|O
DDI-DrugBank.d314.s1|216-226|development|O
DDI-DrugBank.d314.s1|228-229|of|O
DDI-DrugBank.d314.s1|231-241|hypokalemia|O
DDI-DrugBank.d314.s1|242-242|.|O
DDI-DrugBank.d314.s2|0-1|In|O
DDI-DrugBank.d314.s2|3-10|addition|O
DDI-DrugBank.d314.s2|11-11|,|O
DDI-DrugBank.d314.s2|13-17|there|O
DDI-DrugBank.d314.s2|19-22|have|O
DDI-DrugBank.d314.s2|24-27|been|O
DDI-DrugBank.d314.s2|29-33|cases|O
DDI-DrugBank.d314.s2|35-42|reported|O
DDI-DrugBank.d314.s2|44-45|in|O
DDI-DrugBank.d314.s2|47-51|which|O
DDI-DrugBank.d314.s2|53-63|concomitant|O
DDI-DrugBank.d314.s2|65-67|use|O
DDI-DrugBank.d314.s2|69-70|of|O
DDI-DrugBank.d314.s2|72-85|amphotericin B|drug
DDI-DrugBank.d314.s2|87-89|and|O
DDI-DrugBank.d314.s2|91-104|hydrocortisone|drug
DDI-DrugBank.d314.s2|106-108|was|O
DDI-DrugBank.d314.s2|110-117|followed|O
DDI-DrugBank.d314.s2|119-120|by|O
DDI-DrugBank.d314.s2|122-128|cardiac|O
DDI-DrugBank.d314.s2|130-140|enlargement|O
DDI-DrugBank.d314.s2|142-144|and|O
DDI-DrugBank.d314.s2|146-155|congestive|O
DDI-DrugBank.d314.s2|157-161|heart|O
DDI-DrugBank.d314.s2|163-169|failure|O
DDI-DrugBank.d314.s2|170-170|.|O
DDI-DrugBank.d314.s3|0-10|Antibiotics|group
DDI-DrugBank.d314.s3|11-11|:|O
DDI-DrugBank.d314.s3|13-33|Macrolide antibiotics|group
DDI-DrugBank.d314.s3|35-38|have|O
DDI-DrugBank.d314.s3|40-43|been|O
DDI-DrugBank.d314.s3|45-52|reported|O
DDI-DrugBank.d314.s3|54-55|to|O
DDI-DrugBank.d314.s3|57-61|cause|O
DDI-DrugBank.d314.s3|63-63|a|O
DDI-DrugBank.d314.s3|65-75|significant|O
DDI-DrugBank.d314.s3|77-84|decrease|O
DDI-DrugBank.d314.s3|86-87|in|O
DDI-DrugBank.d314.s3|89-102|corticosteroid|group
DDI-DrugBank.d314.s3|104-112|clearance|O
DDI-DrugBank.d314.s3|113-113|.|O
DDI-DrugBank.d314.s4|0-18|Anticholinesterases|group
DDI-DrugBank.d314.s4|19-19|:|O
DDI-DrugBank.d314.s4|21-31|Concomitant|O
DDI-DrugBank.d314.s4|33-35|use|O
DDI-DrugBank.d314.s4|37-38|of|O
DDI-DrugBank.d314.s4|40-64|anticholinesterase agents|group
DDI-DrugBank.d314.s4|66-68|and|O
DDI-DrugBank.d314.s4|70-84|corticosteroids|group
DDI-DrugBank.d314.s4|86-88|may|O
DDI-DrugBank.d314.s4|90-96|produce|O
DDI-DrugBank.d314.s4|98-103|severe|O
DDI-DrugBank.d314.s4|105-112|weakness|O
DDI-DrugBank.d314.s4|114-115|in|O
DDI-DrugBank.d314.s4|117-124|patients|O
DDI-DrugBank.d314.s4|126-129|with|O
DDI-DrugBank.d314.s4|131-140|myasthenia|O
DDI-DrugBank.d314.s4|142-147|gravis|O
DDI-DrugBank.d314.s4|148-148|.|O
DDI-DrugBank.d314.s5|0-1|If|O
DDI-DrugBank.d314.s5|3-10|possible|O
DDI-DrugBank.d314.s5|11-11|,|O
DDI-DrugBank.d314.s5|13-37|anticholinesterase agents|group
DDI-DrugBank.d314.s5|39-44|should|O
DDI-DrugBank.d314.s5|46-47|be|O
DDI-DrugBank.d314.s5|49-57|withdrawn|O
DDI-DrugBank.d314.s5|59-60|at|O
DDI-DrugBank.d314.s5|62-66|least|O
DDI-DrugBank.d314.s5|68-69|24|O
DDI-DrugBank.d314.s5|71-75|hours|O
DDI-DrugBank.d314.s5|77-82|before|O
DDI-DrugBank.d314.s5|84-93|initiating|O
DDI-DrugBank.d314.s5|95-108|corticosteroid|group
DDI-DrugBank.d314.s5|110-116|therapy|O
DDI-DrugBank.d314.s5|117-117|.|O
DDI-DrugBank.d314.s6|0-13|Anticoagulants|group
DDI-DrugBank.d314.s6|14-14|,|O
DDI-DrugBank.d314.s6|16-19|oral|O
DDI-DrugBank.d314.s6|20-20|:|O
DDI-DrugBank.d314.s6|22-38|Co-administration|O
DDI-DrugBank.d314.s6|40-41|of|O
DDI-DrugBank.d314.s6|43-57|corticosteroids|group
DDI-DrugBank.d314.s6|59-61|and|O
DDI-DrugBank.d314.s6|63-70|warfarin|drug
DDI-DrugBank.d314.s6|72-78|usually|O
DDI-DrugBank.d314.s6|80-86|results|O
DDI-DrugBank.d314.s6|88-89|in|O
DDI-DrugBank.d314.s6|91-100|inhibition|O
DDI-DrugBank.d314.s6|102-103|of|O
DDI-DrugBank.d314.s6|105-112|response|O
DDI-DrugBank.d314.s6|114-115|to|O
DDI-DrugBank.d314.s6|117-124|warfarin|drug
DDI-DrugBank.d314.s6|125-125|,|O
DDI-DrugBank.d314.s6|127-134|although|O
DDI-DrugBank.d314.s6|136-140|there|O
DDI-DrugBank.d314.s6|142-145|have|O
DDI-DrugBank.d314.s6|147-150|been|O
DDI-DrugBank.d314.s6|152-155|some|O
DDI-DrugBank.d314.s6|157-167|conflicting|O
DDI-DrugBank.d314.s6|169-175|reports|O
DDI-DrugBank.d314.s6|176-176|.|O
DDI-DrugBank.d314.s7|0-8|Therefore|O
DDI-DrugBank.d314.s7|9-9|,|O
DDI-DrugBank.d314.s7|11-21|coagulation|O
DDI-DrugBank.d314.s7|23-29|indices|O
DDI-DrugBank.d314.s7|31-36|should|O
DDI-DrugBank.d314.s7|38-39|be|O
DDI-DrugBank.d314.s7|41-49|monitored|O
DDI-DrugBank.d314.s7|51-60|frequently|O
DDI-DrugBank.d314.s7|62-63|to|O
DDI-DrugBank.d314.s7|65-72|maintain|O
DDI-DrugBank.d314.s7|74-76|the|O
DDI-DrugBank.d314.s7|78-84|desired|O
DDI-DrugBank.d314.s7|86-98|anticoagulant|O
DDI-DrugBank.d314.s7|100-105|effect|O
DDI-DrugBank.d314.s7|106-106|.|O
DDI-DrugBank.d314.s8|0-12|Antidiabetics|group
DDI-DrugBank.d314.s8|13-13|:|O
DDI-DrugBank.d314.s8|15-21|Because|O
DDI-DrugBank.d314.s8|23-37|corticosteroids|group
DDI-DrugBank.d314.s8|39-41|may|O
DDI-DrugBank.d314.s8|43-50|increase|O
DDI-DrugBank.d314.s8|52-56|blood|O
DDI-DrugBank.d314.s8|58-64|glucose|O
DDI-DrugBank.d314.s8|66-79|concentrations|O
DDI-DrugBank.d314.s8|80-80|,|O
DDI-DrugBank.d314.s8|82-87|dosage|O
DDI-DrugBank.d314.s8|89-99|adjustments|O
DDI-DrugBank.d314.s8|101-102|of|O
DDI-DrugBank.d314.s8|104-122|antidiabetic agents|group
DDI-DrugBank.d314.s8|124-126|may|O
DDI-DrugBank.d314.s8|128-129|be|O
DDI-DrugBank.d314.s8|131-138|required|O
DDI-DrugBank.d314.s8|139-139|.|O
DDI-DrugBank.d314.s9|0-13|Antitubercular|O
DDI-DrugBank.d314.s9|15-19|drugs|O
DDI-DrugBank.d314.s9|20-20|:|O
DDI-DrugBank.d314.s9|22-26|Serum|O
DDI-DrugBank.d314.s9|28-41|concentrations|O
DDI-DrugBank.d314.s9|43-44|of|O
DDI-DrugBank.d314.s9|46-54|isoniazid|drug
DDI-DrugBank.d314.s9|56-58|may|O
DDI-DrugBank.d314.s9|60-61|be|O
DDI-DrugBank.d314.s9|63-71|decreased|O
DDI-DrugBank.d314.s9|72-72|.|O
DDI-DrugBank.d314.s10|0-13|Cholestyramine|drug
DDI-DrugBank.d314.s10|14-14|:|O
DDI-DrugBank.d314.s10|16-29|Cholestyramine|drug
DDI-DrugBank.d314.s10|31-33|may|O
DDI-DrugBank.d314.s10|35-42|increase|O
DDI-DrugBank.d314.s10|44-46|the|O
DDI-DrugBank.d314.s10|48-56|clearance|O
DDI-DrugBank.d314.s10|58-59|of|O
DDI-DrugBank.d314.s10|61-75|corticosteroids|group
DDI-DrugBank.d314.s10|76-76|.|O
DDI-DrugBank.d314.s11|0-11|Cyclosporine|drug
DDI-DrugBank.d314.s11|12-12|:|O
DDI-DrugBank.d314.s11|14-22|Increased|O
DDI-DrugBank.d314.s11|24-31|activity|O
DDI-DrugBank.d314.s11|33-34|of|O
DDI-DrugBank.d314.s11|36-39|both|O
DDI-DrugBank.d314.s11|41-52|cyclosporine|drug
DDI-DrugBank.d314.s11|54-56|and|O
DDI-DrugBank.d314.s11|58-72|corticosteroids|group
DDI-DrugBank.d314.s11|74-76|may|O
DDI-DrugBank.d314.s11|78-82|occur|O
DDI-DrugBank.d314.s11|84-87|when|O
DDI-DrugBank.d314.s11|89-91|the|O
DDI-DrugBank.d314.s11|93-95|two|O
DDI-DrugBank.d314.s11|97-99|are|O
DDI-DrugBank.d314.s11|101-104|used|O
DDI-DrugBank.d314.s11|106-117|concurrently|O
DDI-DrugBank.d314.s11|118-118|.|O
DDI-DrugBank.d314.s12|0-10|Convulsions|O
DDI-DrugBank.d314.s12|12-15|have|O
DDI-DrugBank.d314.s12|17-20|been|O
DDI-DrugBank.d314.s12|22-29|reported|O
DDI-DrugBank.d314.s12|31-34|with|O
DDI-DrugBank.d314.s12|36-39|this|O
DDI-DrugBank.d314.s12|41-50|concurrent|O
DDI-DrugBank.d314.s12|52-54|use|O
DDI-DrugBank.d314.s12|55-55|.|O
DDI-DrugBank.d314.s13|0-12|Dexamethasone|O
DDI-DrugBank.d314.s13|14-24|suppression|O
DDI-DrugBank.d314.s13|26-29|test|O
DDI-DrugBank.d314.s13|31-31|(|O
DDI-DrugBank.d314.s13|32-34|DST|O
DDI-DrugBank.d314.s13|35-35|)|O
DDI-DrugBank.d314.s13|36-36|:|O
DDI-DrugBank.d314.s13|38-51|False-negative|O
DDI-DrugBank.d314.s13|53-59|results|O
DDI-DrugBank.d314.s13|61-62|in|O
DDI-DrugBank.d314.s13|64-66|the|O
DDI-DrugBank.d314.s13|68-80|dexamethasone|O
DDI-DrugBank.d314.s13|82-92|suppression|O
DDI-DrugBank.d314.s13|94-97|test|O
DDI-DrugBank.d314.s13|99-99|(|O
DDI-DrugBank.d314.s13|100-102|DST|O
DDI-DrugBank.d314.s13|103-103|)|O
DDI-DrugBank.d314.s13|105-106|in|O
DDI-DrugBank.d314.s13|108-115|patients|O
DDI-DrugBank.d314.s13|117-121|being|O
DDI-DrugBank.d314.s13|123-129|treated|O
DDI-DrugBank.d314.s13|131-134|with|O
DDI-DrugBank.d314.s13|136-147|indomethacin|drug
DDI-DrugBank.d314.s13|149-152|have|O
DDI-DrugBank.d314.s13|154-157|been|O
DDI-DrugBank.d314.s13|159-166|reported|O
DDI-DrugBank.d314.s13|167-167|.|O
DDI-DrugBank.d314.s14|0-3|Thus|O
DDI-DrugBank.d314.s14|4-4|,|O
DDI-DrugBank.d314.s14|6-12|results|O
DDI-DrugBank.d314.s14|14-15|of|O
DDI-DrugBank.d314.s14|17-19|the|O
DDI-DrugBank.d314.s14|21-23|DST|O
DDI-DrugBank.d314.s14|25-30|should|O
DDI-DrugBank.d314.s14|32-33|be|O
DDI-DrugBank.d314.s14|35-45|interpreted|O
DDI-DrugBank.d314.s14|47-50|with|O
DDI-DrugBank.d314.s14|52-58|caution|O
DDI-DrugBank.d314.s14|60-61|in|O
DDI-DrugBank.d314.s14|63-67|these|O
DDI-DrugBank.d314.s14|69-76|patients|O
DDI-DrugBank.d314.s14|77-77|.|O
DDI-DrugBank.d314.s15|0-19|Digitalis glycosides|group
DDI-DrugBank.d314.s15|20-20|:|O
DDI-DrugBank.d314.s15|22-29|Patients|O
DDI-DrugBank.d314.s15|31-32|on|O
DDI-DrugBank.d314.s15|34-53|digitalis glycosides|group
DDI-DrugBank.d314.s15|55-57|may|O
DDI-DrugBank.d314.s15|59-60|be|O
DDI-DrugBank.d314.s15|62-63|at|O
DDI-DrugBank.d314.s15|65-73|increased|O
DDI-DrugBank.d314.s15|75-78|risk|O
DDI-DrugBank.d314.s15|80-81|of|O
DDI-DrugBank.d314.s15|83-93|arrhythmias|O
DDI-DrugBank.d314.s15|95-97|due|O
DDI-DrugBank.d314.s15|99-100|to|O
DDI-DrugBank.d314.s15|102-112|hypokalemia|O
DDI-DrugBank.d314.s15|113-113|.|O
DDI-DrugBank.d314.s16|0-8|Ephedrine|drug
DDI-DrugBank.d314.s16|9-9|:|O
DDI-DrugBank.d314.s16|11-19|Ephedrine|drug
DDI-DrugBank.d314.s16|21-23|may|O
DDI-DrugBank.d314.s16|25-31|enhance|O
DDI-DrugBank.d314.s16|33-35|the|O
DDI-DrugBank.d314.s16|37-45|metabolic|O
DDI-DrugBank.d314.s16|47-55|clearance|O
DDI-DrugBank.d314.s16|57-58|of|O
DDI-DrugBank.d314.s16|60-74|corticosteroids|group
DDI-DrugBank.d314.s16|75-75|,|O
DDI-DrugBank.d314.s16|77-85|resulting|O
DDI-DrugBank.d314.s16|87-88|in|O
DDI-DrugBank.d314.s16|90-98|decreased|O
DDI-DrugBank.d314.s16|100-104|blood|O
DDI-DrugBank.d314.s16|106-111|levels|O
DDI-DrugBank.d314.s16|113-115|and|O
DDI-DrugBank.d314.s16|117-124|lessened|O
DDI-DrugBank.d314.s16|126-136|physiologic|O
DDI-DrugBank.d314.s16|138-145|activity|O
DDI-DrugBank.d314.s16|146-146|,|O
DDI-DrugBank.d314.s16|148-151|thus|O
DDI-DrugBank.d314.s16|153-161|requiring|O
DDI-DrugBank.d314.s16|163-164|an|O
DDI-DrugBank.d314.s16|166-173|increase|O
DDI-DrugBank.d314.s16|175-176|in|O
DDI-DrugBank.d314.s16|178-191|corticosteroid|group
DDI-DrugBank.d314.s16|193-198|dosage|O
DDI-DrugBank.d314.s16|199-199|.|O
DDI-DrugBank.d314.s17|0-8|Estrogens|group
DDI-DrugBank.d314.s17|9-9|,|O
DDI-DrugBank.d314.s17|11-19|including|O
DDI-DrugBank.d314.s17|21-24|oral|O
DDI-DrugBank.d314.s17|26-39|contraceptives|group
DDI-DrugBank.d314.s17|40-40|:|O
DDI-DrugBank.d314.s17|42-50|Estrogens|group
DDI-DrugBank.d314.s17|52-54|may|O
DDI-DrugBank.d314.s17|56-63|decrease|O
DDI-DrugBank.d314.s17|65-67|the|O
DDI-DrugBank.d314.s17|69-75|hepatic|O
DDI-DrugBank.d314.s17|77-86|metabolism|O
DDI-DrugBank.d314.s17|88-89|of|O
DDI-DrugBank.d314.s17|91-97|certain|O
DDI-DrugBank.d314.s17|99-113|corticosteroids|group
DDI-DrugBank.d314.s17|114-114|,|O
DDI-DrugBank.d314.s17|116-122|thereby|O
DDI-DrugBank.d314.s17|124-133|increasing|O
DDI-DrugBank.d314.s17|135-139|their|O
DDI-DrugBank.d314.s17|141-146|effect|O
DDI-DrugBank.d314.s17|147-147|.|O
DDI-DrugBank.d314.s18|0-6|Hepatic|O
DDI-DrugBank.d314.s18|8-13|Enzyme|O
DDI-DrugBank.d314.s18|15-22|Inducers|O
DDI-DrugBank.d314.s18|23-23|,|O
DDI-DrugBank.d314.s18|25-34|Inhibitors|O
DDI-DrugBank.d314.s18|36-38|and|O
DDI-DrugBank.d314.s18|40-49|Substrates|O
DDI-DrugBank.d314.s18|50-50|:|O
DDI-DrugBank.d314.s18|52-56|Drugs|O
DDI-DrugBank.d314.s18|58-62|which|O
DDI-DrugBank.d314.s18|64-69|induce|O
DDI-DrugBank.d314.s18|71-80|cytochrome|O
DDI-DrugBank.d314.s18|82-85|P450|O
DDI-DrugBank.d314.s18|87-89|3A4|O
DDI-DrugBank.d314.s18|91-91|(|O
DDI-DrugBank.d314.s18|92-94|CYP|O
DDI-DrugBank.d314.s18|96-98|3A4|O
DDI-DrugBank.d314.s18|99-99|)|O
DDI-DrugBank.d314.s18|101-106|enzyme|O
DDI-DrugBank.d314.s18|108-115|activity|O
DDI-DrugBank.d314.s18|117-117|(|O
DDI-DrugBank.d314.s18|118-121|e.g.|O
DDI-DrugBank.d314.s18|122-122|,|O
DDI-DrugBank.d314.s18|124-135|barbiturates|group
DDI-DrugBank.d314.s18|136-136|,|O
DDI-DrugBank.d314.s18|138-146|phenytoin|drug
DDI-DrugBank.d314.s18|147-147|,|O
DDI-DrugBank.d314.s18|149-161|carbamazepine|drug
DDI-DrugBank.d314.s18|162-162|,|O
DDI-DrugBank.d314.s18|164-171|rifampin|drug
DDI-DrugBank.d314.s18|172-172|)|O
DDI-DrugBank.d314.s18|174-176|may|O
DDI-DrugBank.d314.s18|178-184|enhance|O
DDI-DrugBank.d314.s18|186-188|the|O
DDI-DrugBank.d314.s18|190-199|metabolism|O
DDI-DrugBank.d314.s18|201-202|of|O
DDI-DrugBank.d314.s18|204-218|corticosteroids|group
DDI-DrugBank.d314.s18|220-222|and|O
DDI-DrugBank.d314.s18|224-230|require|O
DDI-DrugBank.d314.s18|232-235|that|O
DDI-DrugBank.d314.s18|237-239|the|O
DDI-DrugBank.d314.s18|241-246|dosage|O
DDI-DrugBank.d314.s18|248-249|of|O
DDI-DrugBank.d314.s18|251-253|the|O
DDI-DrugBank.d314.s18|255-268|corticosteroid|group
DDI-DrugBank.d314.s18|270-271|be|O
DDI-DrugBank.d314.s18|273-281|increased|O
DDI-DrugBank.d314.s18|282-282|.|O
DDI-DrugBank.d314.s19|0-4|Drugs|O
DDI-DrugBank.d314.s19|6-10|which|O
DDI-DrugBank.d314.s19|12-18|inhibit|O
DDI-DrugBank.d314.s19|20-22|CYP|O
DDI-DrugBank.d314.s19|24-26|3A4|O
DDI-DrugBank.d314.s19|28-28|(|O
DDI-DrugBank.d314.s19|29-32|e.g.|O
DDI-DrugBank.d314.s19|33-33|,|O
DDI-DrugBank.d314.s19|35-46|ketoconazole|drug
DDI-DrugBank.d314.s19|47-47|,|O
DDI-DrugBank.d314.s19|49-69|macrolide antibiotics|group
DDI-DrugBank.d314.s19|71-74|such|O
DDI-DrugBank.d314.s19|76-77|as|O
DDI-DrugBank.d314.s19|79-90|erythromycin|drug
DDI-DrugBank.d314.s19|91-91|)|O
DDI-DrugBank.d314.s19|93-96|have|O
DDI-DrugBank.d314.s19|98-100|the|O
DDI-DrugBank.d314.s19|102-110|potential|O
DDI-DrugBank.d314.s19|112-113|to|O
DDI-DrugBank.d314.s19|115-120|result|O
DDI-DrugBank.d314.s19|122-123|in|O
DDI-DrugBank.d314.s19|125-133|increased|O
DDI-DrugBank.d314.s19|135-140|plasma|O
DDI-DrugBank.d314.s19|142-155|concentrations|O
DDI-DrugBank.d314.s19|157-158|of|O
DDI-DrugBank.d314.s19|160-174|corticosteroids|group
DDI-DrugBank.d314.s19|175-175|.|O
DDI-DrugBank.d314.s20|0-12|Dexamethasone|drug
DDI-DrugBank.d314.s20|14-15|is|O
DDI-DrugBank.d314.s20|17-17|a|O
DDI-DrugBank.d314.s20|19-26|moderate|O
DDI-DrugBank.d314.s20|28-34|inducer|O
DDI-DrugBank.d314.s20|36-37|of|O
DDI-DrugBank.d314.s20|39-41|CYP|O
DDI-DrugBank.d314.s20|43-45|3A4|O
DDI-DrugBank.d314.s20|46-46|.|O
DDI-DrugBank.d314.s21|0-16|Co-administration|O
DDI-DrugBank.d314.s21|18-21|with|O
DDI-DrugBank.d314.s21|23-27|other|O
DDI-DrugBank.d314.s21|29-33|drugs|O
DDI-DrugBank.d314.s21|35-38|that|O
DDI-DrugBank.d314.s21|40-42|are|O
DDI-DrugBank.d314.s21|44-54|metabolized|O
DDI-DrugBank.d314.s21|56-57|by|O
DDI-DrugBank.d314.s21|59-61|CYP|O
DDI-DrugBank.d314.s21|63-65|3A4|O
DDI-DrugBank.d314.s21|67-67|(|O
DDI-DrugBank.d314.s21|68-71|e.g.|O
DDI-DrugBank.d314.s21|72-72|,|O
DDI-DrugBank.d314.s21|74-82|indinavir|drug
DDI-DrugBank.d314.s21|83-83|,|O
DDI-DrugBank.d314.s21|85-96|erythromycin|drug
DDI-DrugBank.d314.s21|97-97|)|O
DDI-DrugBank.d314.s21|99-101|may|O
DDI-DrugBank.d314.s21|103-110|increase|O
DDI-DrugBank.d314.s21|112-116|their|O
DDI-DrugBank.d314.s21|118-126|clearance|O
DDI-DrugBank.d314.s21|127-127|,|O
DDI-DrugBank.d314.s21|129-137|resulting|O
DDI-DrugBank.d314.s21|139-140|in|O
DDI-DrugBank.d314.s21|142-150|decreased|O
DDI-DrugBank.d314.s21|152-157|plasma|O
DDI-DrugBank.d314.s21|159-171|concentration|O
DDI-DrugBank.d314.s21|172-172|.|O
DDI-DrugBank.d314.s22|0-11|Ketoconazole|drug
DDI-DrugBank.d314.s22|12-12|:|O
DDI-DrugBank.d314.s22|14-25|Ketoconazole|drug
DDI-DrugBank.d314.s22|27-29|has|O
DDI-DrugBank.d314.s22|31-34|been|O
DDI-DrugBank.d314.s22|36-43|reported|O
DDI-DrugBank.d314.s22|45-46|to|O
DDI-DrugBank.d314.s22|48-55|decrease|O
DDI-DrugBank.d314.s22|57-59|the|O
DDI-DrugBank.d314.s22|61-70|metabolism|O
DDI-DrugBank.d314.s22|72-73|of|O
DDI-DrugBank.d314.s22|75-81|certain|O
DDI-DrugBank.d314.s22|83-97|corticosteroids|group
DDI-DrugBank.d314.s22|99-100|by|O
DDI-DrugBank.d314.s22|102-103|up|O
DDI-DrugBank.d314.s22|105-106|to|O
DDI-DrugBank.d314.s22|108-109|60|O
DDI-DrugBank.d314.s22|110-110|%|O
DDI-DrugBank.d314.s22|111-111|,|O
DDI-DrugBank.d314.s22|113-119|leading|O
DDI-DrugBank.d314.s22|121-122|to|O
DDI-DrugBank.d314.s22|124-132|increased|O
DDI-DrugBank.d314.s22|134-137|risk|O
DDI-DrugBank.d314.s22|139-140|of|O
DDI-DrugBank.d314.s22|142-155|corticosteroid|group
DDI-DrugBank.d314.s22|157-160|side|O
DDI-DrugBank.d314.s22|162-168|effects|O
DDI-DrugBank.d314.s22|169-169|.|O
DDI-DrugBank.d314.s23|0-1|In|O
DDI-DrugBank.d314.s23|3-10|addition|O
DDI-DrugBank.d314.s23|11-11|,|O
DDI-DrugBank.d314.s23|13-24|ketoconazole|drug
DDI-DrugBank.d314.s23|26-30|alone|O
DDI-DrugBank.d314.s23|32-34|can|O
DDI-DrugBank.d314.s23|36-42|inhibit|O
DDI-DrugBank.d314.s23|44-50|adrenal|O
DDI-DrugBank.d314.s23|52-65|corticosteroid|drug
DDI-DrugBank.d314.s23|67-75|synthesis|O
DDI-DrugBank.d314.s23|77-79|and|O
DDI-DrugBank.d314.s23|81-83|may|O
DDI-DrugBank.d314.s23|85-89|cause|O
DDI-DrugBank.d314.s23|91-97|adrenal|O
DDI-DrugBank.d314.s23|99-111|insufficiency|O
DDI-DrugBank.d314.s23|113-118|during|O
DDI-DrugBank.d314.s23|120-133|corticosteroid|O
DDI-DrugBank.d314.s23|135-144|withdrawal|O
DDI-DrugBank.d314.s23|145-145|.|O
DDI-DrugBank.d314.s24|0-36|Nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d314.s24|38-38|(|O
DDI-DrugBank.d314.s24|39-44|NSAIDS|group
DDI-DrugBank.d314.s24|45-45|)|O
DDI-DrugBank.d314.s24|46-46|:|O
DDI-DrugBank.d314.s24|48-58|Concomitant|O
DDI-DrugBank.d314.s24|60-62|use|O
DDI-DrugBank.d314.s24|64-65|of|O
DDI-DrugBank.d314.s24|67-73|aspirin|brand
DDI-DrugBank.d314.s24|75-75|(|O
DDI-DrugBank.d314.s24|76-77|or|O
DDI-DrugBank.d314.s24|79-83|other|O
DDI-DrugBank.d314.s24|85-120|nonsteroidal antiinflammatory agents|group
DDI-DrugBank.d314.s24|121-121|)|O
DDI-DrugBank.d314.s24|123-125|and|O
DDI-DrugBank.d314.s24|127-141|corticosteroids|group
DDI-DrugBank.d314.s24|143-151|increases|O
DDI-DrugBank.d314.s24|153-155|the|O
DDI-DrugBank.d314.s24|157-160|risk|O
DDI-DrugBank.d314.s24|162-163|of|O
DDI-DrugBank.d314.s24|165-180|gastrointestinal|O
DDI-DrugBank.d314.s24|182-185|side|O
DDI-DrugBank.d314.s24|187-193|effects|O
DDI-DrugBank.d314.s24|194-194|.|O
DDI-DrugBank.d314.s25|0-6|Aspirin|brand
DDI-DrugBank.d314.s25|8-13|should|O
DDI-DrugBank.d314.s25|15-16|be|O
DDI-DrugBank.d314.s25|18-21|used|O
DDI-DrugBank.d314.s25|23-32|cautiously|O
DDI-DrugBank.d314.s25|34-35|in|O
DDI-DrugBank.d314.s25|37-47|conjunction|O
DDI-DrugBank.d314.s25|49-52|with|O
DDI-DrugBank.d314.s25|54-68|corticosteroids|group
DDI-DrugBank.d314.s25|70-71|in|O
DDI-DrugBank.d314.s25|73-91|hypoprothrombinemia|O
DDI-DrugBank.d314.s25|92-92|.|O
DDI-DrugBank.d314.s26|0-2|The|O
DDI-DrugBank.d314.s26|4-12|clearance|O
DDI-DrugBank.d314.s26|14-15|of|O
DDI-DrugBank.d314.s26|17-27|salicylates|group
DDI-DrugBank.d314.s26|29-31|may|O
DDI-DrugBank.d314.s26|33-34|be|O
DDI-DrugBank.d314.s26|36-44|increased|O
DDI-DrugBank.d314.s26|46-49|with|O
DDI-DrugBank.d314.s26|51-60|concurrent|O
DDI-DrugBank.d314.s26|62-64|use|O
DDI-DrugBank.d314.s26|66-67|of|O
DDI-DrugBank.d314.s26|69-83|corticosteroids|group
DDI-DrugBank.d314.s26|84-84|.|O
DDI-DrugBank.d314.s27|0-8|Phenytoin|drug
DDI-DrugBank.d314.s27|9-9|:|O
DDI-DrugBank.d314.s27|11-12|In|O
DDI-DrugBank.d314.s27|14-27|post-marketing|O
DDI-DrugBank.d314.s27|29-38|experience|O
DDI-DrugBank.d314.s27|39-39|,|O
DDI-DrugBank.d314.s27|41-45|there|O
DDI-DrugBank.d314.s27|47-50|have|O
DDI-DrugBank.d314.s27|52-55|been|O
DDI-DrugBank.d314.s27|57-63|reports|O
DDI-DrugBank.d314.s27|65-66|of|O
DDI-DrugBank.d314.s27|68-71|both|O
DDI-DrugBank.d314.s27|73-81|increases|O
DDI-DrugBank.d314.s27|83-85|and|O
DDI-DrugBank.d314.s27|87-95|decreases|O
DDI-DrugBank.d314.s27|97-98|in|O
DDI-DrugBank.d314.s27|100-108|phenytoin|drug
DDI-DrugBank.d314.s27|110-115|levels|O
DDI-DrugBank.d314.s27|117-120|with|O
DDI-DrugBank.d314.s27|122-134|dexamethasone|drug
DDI-DrugBank.d314.s27|136-152|co-administration|O
DDI-DrugBank.d314.s27|153-153|,|O
DDI-DrugBank.d314.s27|155-161|leading|O
DDI-DrugBank.d314.s27|163-164|to|O
DDI-DrugBank.d314.s27|166-176|alterations|O
DDI-DrugBank.d314.s27|178-179|in|O
DDI-DrugBank.d314.s27|181-187|seizure|O
DDI-DrugBank.d314.s27|189-195|control|O
DDI-DrugBank.d314.s27|196-196|.|O
DDI-DrugBank.d314.s28|0-3|Skin|O
DDI-DrugBank.d314.s28|5-9|tests|O
DDI-DrugBank.d314.s28|10-10|:|O
DDI-DrugBank.d314.s28|12-26|Corticosteroids|group
DDI-DrugBank.d314.s28|28-30|may|O
DDI-DrugBank.d314.s28|32-39|suppress|O
DDI-DrugBank.d314.s28|41-49|reactions|O
DDI-DrugBank.d314.s28|51-52|to|O
DDI-DrugBank.d314.s28|54-57|skin|O
DDI-DrugBank.d314.s28|59-63|tests|O
DDI-DrugBank.d314.s28|64-64|.|O
DDI-DrugBank.d314.s29|0-10|Thalidomide|drug
DDI-DrugBank.d314.s29|11-11|:|O
DDI-DrugBank.d314.s29|13-29|Co-administration|O
DDI-DrugBank.d314.s29|31-34|with|O
DDI-DrugBank.d314.s29|36-46|thalidomide|drug
DDI-DrugBank.d314.s29|48-53|should|O
DDI-DrugBank.d314.s29|55-56|be|O
DDI-DrugBank.d314.s29|58-65|employed|O
DDI-DrugBank.d314.s29|67-76|cautiously|O
DDI-DrugBank.d314.s29|77-77|,|O
DDI-DrugBank.d314.s29|79-80|as|O
DDI-DrugBank.d314.s29|82-86|toxic|O
DDI-DrugBank.d314.s29|88-96|epidermal|O
DDI-DrugBank.d314.s29|98-107|necrolysis|O
DDI-DrugBank.d314.s29|109-111|has|O
DDI-DrugBank.d314.s29|113-116|been|O
DDI-DrugBank.d314.s29|118-125|reported|O
DDI-DrugBank.d314.s29|127-130|with|O
DDI-DrugBank.d314.s29|132-142|concomitant|O
DDI-DrugBank.d314.s29|144-146|use|O
DDI-DrugBank.d314.s29|147-147|.|O
DDI-DrugBank.d314.s30|0-7|Vaccines|group
DDI-DrugBank.d314.s30|8-8|:|O
DDI-DrugBank.d314.s30|10-17|Patients|O
DDI-DrugBank.d314.s30|19-20|on|O
DDI-DrugBank.d314.s30|22-35|corticosteroid|group
DDI-DrugBank.d314.s30|37-43|therapy|O
DDI-DrugBank.d314.s30|45-47|may|O
DDI-DrugBank.d314.s30|49-55|exhibit|O
DDI-DrugBank.d314.s30|57-57|a|O
DDI-DrugBank.d314.s30|59-68|diminished|O
DDI-DrugBank.d314.s30|70-77|response|O
DDI-DrugBank.d314.s30|79-80|to|O
DDI-DrugBank.d314.s30|82-88|toxoids|O
DDI-DrugBank.d314.s30|90-92|and|O
DDI-DrugBank.d314.s30|94-97|live|group
DDI-DrugBank.d314.s30|99-100|or|O
DDI-DrugBank.d314.s30|102-121|inactivated vaccines|group
DDI-DrugBank.d314.s30|123-125|due|O
DDI-DrugBank.d314.s30|127-128|to|O
DDI-DrugBank.d314.s30|130-139|inhibition|O
DDI-DrugBank.d314.s30|141-142|of|O
DDI-DrugBank.d314.s30|144-151|antibody|O
DDI-DrugBank.d314.s30|153-160|response|O
DDI-DrugBank.d314.s30|161-161|.|O
DDI-DrugBank.d314.s31|0-14|Corticosteroids|group
DDI-DrugBank.d314.s31|16-18|may|O
DDI-DrugBank.d314.s31|20-23|also|O
DDI-DrugBank.d314.s31|25-34|potentiate|O
DDI-DrugBank.d314.s31|36-38|the|O
DDI-DrugBank.d314.s31|40-50|replication|O
DDI-DrugBank.d314.s31|52-53|of|O
DDI-DrugBank.d314.s31|55-58|some|O
DDI-DrugBank.d314.s31|60-68|organisms|O
DDI-DrugBank.d314.s31|70-78|contained|O
DDI-DrugBank.d314.s31|80-81|in|O
DDI-DrugBank.d314.s31|83-106|live attenuated vaccines|group
DDI-DrugBank.d314.s31|107-107|.|O
DDI-DrugBank.d314.s32|0-6|Routine|O
DDI-DrugBank.d314.s32|8-21|administration|O
DDI-DrugBank.d314.s32|23-24|of|O
DDI-DrugBank.d314.s32|26-33|vaccines|group
DDI-DrugBank.d314.s32|35-36|or|O
DDI-DrugBank.d314.s32|38-44|toxoids|O
DDI-DrugBank.d314.s32|46-51|should|O
DDI-DrugBank.d314.s32|53-54|be|O
DDI-DrugBank.d314.s32|56-63|deferred|O
DDI-DrugBank.d314.s32|65-69|until|O
DDI-DrugBank.d314.s32|71-84|corticosteroid|group
DDI-DrugBank.d314.s32|86-92|therapy|O
DDI-DrugBank.d314.s32|94-95|is|O
DDI-DrugBank.d314.s32|97-108|discontinued|O
DDI-DrugBank.d314.s32|110-111|if|O
DDI-DrugBank.d314.s32|113-120|possible|O
DDI-DrugBank.d314.s32|121-121|.|O
DDI-DrugBank.d232.s0|0-4|After|O
DDI-DrugBank.d232.s0|6-13|multiple|O
DDI-DrugBank.d232.s0|15-20|dosing|O
DDI-DrugBank.d232.s0|21-21|,|O
DDI-DrugBank.d232.s0|23-40|interferon beta-1a|drug
DDI-DrugBank.d232.s0|42-42|(|O
DDI-DrugBank.d232.s0|43-48|AVONEX|brand
DDI-DrugBank.d232.s0|51-52|30|O
DDI-DrugBank.d232.s0|54-56|mcg|O
DDI-DrugBank.d232.s0|58-59|IM|O
DDI-DrugBank.d232.s0|61-64|once|O
DDI-DrugBank.d232.s0|66-71|weekly|O
DDI-DrugBank.d232.s0|72-72|)|O
DDI-DrugBank.d232.s0|74-80|reduced|O
DDI-DrugBank.d232.s0|82-88|TYSABRI|brand
DDI-DrugBank.d232.s0|91-99|clearance|O
DDI-DrugBank.d232.s0|101-102|by|O
DDI-DrugBank.d232.s0|104-116|approximately|O
DDI-DrugBank.d232.s0|118-119|30|O
DDI-DrugBank.d232.s0|120-120|%|O
DDI-DrugBank.d232.s0|121-121|.|O
DDI-DrugBank.d232.s1|0-2|The|O
DDI-DrugBank.d232.s1|4-13|similarity|O
DDI-DrugBank.d232.s1|15-16|of|O
DDI-DrugBank.d232.s1|18-20|the|O
DDI-DrugBank.d232.s1|22-28|TYSABRI|brand
DDI-DrugBank.d232.s1|30-40|-associated|O
DDI-DrugBank.d232.s1|42-48|adverse|O
DDI-DrugBank.d232.s1|50-54|event|O
DDI-DrugBank.d232.s1|56-62|profile|O
DDI-DrugBank.d232.s1|64-70|between|O
DDI-DrugBank.d232.s1|72-76|Study|O
DDI-DrugBank.d232.s1|78-78|1|O
DDI-DrugBank.d232.s1|80-80|(|O
DDI-DrugBank.d232.s1|81-87|without|O
DDI-DrugBank.d232.s1|89-103|co-administered|O
DDI-DrugBank.d232.s1|105-110|AVONEX|brand
DDI-DrugBank.d232.s1|112-112|)|O
DDI-DrugBank.d232.s1|114-116|and|O
DDI-DrugBank.d232.s1|118-122|Study|O
DDI-DrugBank.d232.s1|124-124|2|O
DDI-DrugBank.d232.s1|126-126|(|O
DDI-DrugBank.d232.s1|127-130|with|O
DDI-DrugBank.d232.s1|132-146|co-administered|O
DDI-DrugBank.d232.s1|148-153|AVONEX|brand
DDI-DrugBank.d232.s1|155-155|)|O
DDI-DrugBank.d232.s1|157-165|indicates|O
DDI-DrugBank.d232.s1|167-170|that|O
DDI-DrugBank.d232.s1|172-175|this|O
DDI-DrugBank.d232.s1|177-186|alteration|O
DDI-DrugBank.d232.s1|188-189|in|O
DDI-DrugBank.d232.s1|191-199|clearance|O
DDI-DrugBank.d232.s1|201-204|does|O
DDI-DrugBank.d232.s1|206-208|not|O
DDI-DrugBank.d232.s1|210-220|necessitate|O
DDI-DrugBank.d232.s1|222-230|reduction|O
DDI-DrugBank.d232.s1|232-233|of|O
DDI-DrugBank.d232.s1|235-237|the|O
DDI-DrugBank.d232.s1|239-245|TYSABRI|brand
DDI-DrugBank.d232.s1|248-251|dose|O
DDI-DrugBank.d232.s1|253-254|to|O
DDI-DrugBank.d232.s1|256-263|maintain|O
DDI-DrugBank.d232.s1|265-270|safety|O
DDI-DrugBank.d232.s1|271-271|,|O
DDI-DrugBank.d232.s1|273-279|General|O
DDI-DrugBank.d232.s1|280-280|)|O
DDI-DrugBank.d232.s1|281-281|.|O
DDI-DrugBank.d232.s2|0-6|Results|O
DDI-DrugBank.d232.s2|8-9|of|O
DDI-DrugBank.d232.s2|11-17|studies|O
DDI-DrugBank.d232.s2|19-20|in|O
DDI-DrugBank.d232.s2|22-29|multiple|O
DDI-DrugBank.d232.s2|31-39|sclerosis|O
DDI-DrugBank.d232.s2|41-48|patients|O
DDI-DrugBank.d232.s2|50-55|taking|O
DDI-DrugBank.d232.s2|57-63|TYSABRI|brand
DDI-DrugBank.d232.s2|66-68|and|O
DDI-DrugBank.d232.s2|70-80|concomitant|O
DDI-DrugBank.d232.s2|82-99|interferon beta-1a|drug
DDI-DrugBank.d232.s2|101-101|(|O
DDI-DrugBank.d232.s2|102-107|AVONEX|brand
DDI-DrugBank.d232.s2|110-111|30|O
DDI-DrugBank.d232.s2|113-115|mcg|O
DDI-DrugBank.d232.s2|117-118|IM|O
DDI-DrugBank.d232.s2|120-123|once|O
DDI-DrugBank.d232.s2|125-130|weekly|O
DDI-DrugBank.d232.s2|131-131|)|O
DDI-DrugBank.d232.s2|133-134|or|O
DDI-DrugBank.d232.s2|136-153|glatiramer acetate|drug
DDI-DrugBank.d232.s2|155-158|were|O
DDI-DrugBank.d232.s2|160-171|inconclusive|O
DDI-DrugBank.d232.s2|173-176|with|O
DDI-DrugBank.d232.s2|178-183|regard|O
DDI-DrugBank.d232.s2|185-186|to|O
DDI-DrugBank.d232.s2|188-190|the|O
DDI-DrugBank.d232.s2|192-195|need|O
DDI-DrugBank.d232.s2|197-199|for|O
DDI-DrugBank.d232.s2|201-204|dose|O
DDI-DrugBank.d232.s2|206-215|adjustment|O
DDI-DrugBank.d232.s2|217-218|of|O
DDI-DrugBank.d232.s2|220-222|the|O
DDI-DrugBank.d232.s2|224-238|beta-interferon|drug
DDI-DrugBank.d232.s2|240-241|or|O
DDI-DrugBank.d232.s2|243-260|glatiramer acetate|drug
DDI-DrugBank.d232.s2|261-261|.|O
DDI-DrugBank.d306.s0|0-2|The|O
DDI-DrugBank.d306.s0|4-16|effectiveness|O
DDI-DrugBank.d306.s0|18-19|of|O
DDI-DrugBank.d306.s0|21-34|progestin-only|group
DDI-DrugBank.d306.s0|36-40|pills|O
DDI-DrugBank.d306.s0|42-43|is|O
DDI-DrugBank.d306.s0|45-51|reduced|O
DDI-DrugBank.d306.s0|53-54|by|O
DDI-DrugBank.d306.s0|56-62|hepatic|O
DDI-DrugBank.d306.s0|64-78|enzyme-inducing|O
DDI-DrugBank.d306.s0|80-84|drugs|O
DDI-DrugBank.d306.s0|86-89|such|O
DDI-DrugBank.d306.s0|91-92|as|O
DDI-DrugBank.d306.s0|94-96|the|O
DDI-DrugBank.d306.s0|98-112|anticonvulsants|group
DDI-DrugBank.d306.s0|98-112|anticonvulsants|group
DDI-DrugBank.d306.s0|123-123|,|O
DDI-DrugBank.d306.s0|125-137|carbamazepine|drug
DDI-DrugBank.d306.s0|138-138|,|O
DDI-DrugBank.d306.s0|140-142|and|O
DDI-DrugBank.d306.s0|144-155|barbiturates|group
DDI-DrugBank.d306.s0|156-156|,|O
DDI-DrugBank.d306.s0|158-160|and|O
DDI-DrugBank.d306.s0|162-164|the|O
DDI-DrugBank.d306.s0|166-186|antituberculosis drug|group
DDI-DrugBank.d306.s0|166-186|antituberculosis drug|group
DDI-DrugBank.d306.s0|196-196|.|O
DDI-DrugBank.d306.s1|0-1|No|O
DDI-DrugBank.d306.s1|3-13|significant|O
DDI-DrugBank.d306.s1|15-25|interaction|O
DDI-DrugBank.d306.s1|27-29|has|O
DDI-DrugBank.d306.s1|31-34|been|O
DDI-DrugBank.d306.s1|36-40|found|O
DDI-DrugBank.d306.s1|42-45|with|O
DDI-DrugBank.d306.s1|47-60|broad-spectrum|O
DDI-DrugBank.d306.s1|62-72|antibiotics|group
DDI-DrugBank.d306.s1|73-73|.|O
DDI-DrugBank.d636.s0|0-3|Some|O
DDI-DrugBank.d636.s0|5-19|anticonvulsants|group
DDI-DrugBank.d636.s0|21-23|may|O
DDI-DrugBank.d636.s0|25-32|interact|O
DDI-DrugBank.d636.s0|34-37|with|O
DDI-DrugBank.d636.s0|39-49|Mephenytoin|drug
DDI-DrugBank.d636.s0|50-50|.|O
DDI-DrugBank.d636.s1|0-3|They|O
DDI-DrugBank.d636.s1|5-7|can|O
DDI-DrugBank.d636.s1|9-14|either|O
DDI-DrugBank.d636.s1|16-23|increase|O
DDI-DrugBank.d636.s1|25-26|or|O
DDI-DrugBank.d636.s1|28-35|decrease|O
DDI-DrugBank.d636.s1|37-39|the|O
DDI-DrugBank.d636.s1|41-46|effect|O
DDI-DrugBank.d636.s1|48-49|of|O
DDI-DrugBank.d636.s1|51-61|Mephenytoin|drug
DDI-DrugBank.d636.s1|62-62|.|O
DDI-DrugBank.d636.s2|0-4|Those|O
DDI-DrugBank.d636.s2|6-20|anticonvulsants|group
DDI-DrugBank.d636.s2|22-28|include|O
DDI-DrugBank.d636.s2|30-46|divalproex sodium|drug
DDI-DrugBank.d636.s2|47-47|,|O
DDI-DrugBank.d636.s2|49-61|valproic acid|drug
DDI-DrugBank.d636.s2|62-62|,|O
DDI-DrugBank.d636.s2|64-66|and|O
DDI-DrugBank.d636.s2|68-80|phenobarbital|drug
DDI-DrugBank.d636.s2|81-81|.|O
DDI-DrugBank.d636.s3|0-10|Mephenytoin|drug
DDI-DrugBank.d636.s3|12-14|may|O
DDI-DrugBank.d636.s3|16-19|also|O
DDI-DrugBank.d636.s3|21-26|affect|O
DDI-DrugBank.d636.s3|28-30|the|O
DDI-DrugBank.d636.s3|32-38|effects|O
DDI-DrugBank.d636.s3|40-41|of|O
DDI-DrugBank.d636.s3|43-47|other|O
DDI-DrugBank.d636.s3|49-53|drugs|O
DDI-DrugBank.d636.s3|54-54|,|O
DDI-DrugBank.d636.s3|56-60|which|O
DDI-DrugBank.d636.s3|62-68|include|O
DDI-DrugBank.d636.s3|70-73|some|O
DDI-DrugBank.d636.s3|75-93|steroid medications|group
DDI-DrugBank.d636.s3|94-94|,|O
DDI-DrugBank.d636.s3|96-103|warfarin|drug
DDI-DrugBank.d636.s3|104-104|,|O
DDI-DrugBank.d636.s3|106-112|certain|O
DDI-DrugBank.d636.s3|114-118|heart|O
DDI-DrugBank.d636.s3|120-128|medicines|O
DDI-DrugBank.d636.s3|129-129|,|O
DDI-DrugBank.d636.s3|131-135|birth|O
DDI-DrugBank.d636.s3|137-143|control|O
DDI-DrugBank.d636.s3|145-149|pills|O
DDI-DrugBank.d636.s3|150-150|,|O
DDI-DrugBank.d636.s3|152-175|anti-infective medicines|group
DDI-DrugBank.d636.s3|176-176|,|O
DDI-DrugBank.d636.s3|178-187|furosemide|drug
DDI-DrugBank.d636.s3|189-191|and|O
DDI-DrugBank.d636.s3|193-204|theophylline|drug
DDI-DrugBank.d636.s3|206-211|Please|O
DDI-DrugBank.d636.s3|213-216|note|O
DDI-DrugBank.d636.s3|218-221|that|O
DDI-DrugBank.d636.s3|223-233|Mephenytoin|drug
DDI-DrugBank.d636.s3|235-237|may|O
DDI-DrugBank.d636.s3|239-246|interact|O
DDI-DrugBank.d636.s3|248-251|with|O
DDI-DrugBank.d636.s3|253-257|other|O
DDI-DrugBank.d636.s3|259-263|drugs|O
DDI-DrugBank.d636.s3|265-268|that|O
DDI-DrugBank.d636.s3|270-272|are|O
DDI-DrugBank.d636.s3|274-276|not|O
DDI-DrugBank.d636.s3|278-283|listed|O
DDI-DrugBank.d636.s3|285-288|here|O
DDI-DrugBank.d636.s3|289-289|.|O
DDI-DrugBank.d579.s0|0-7|Patients|O
DDI-DrugBank.d579.s0|9-17|receiving|O
DDI-DrugBank.d579.s0|19-29|antibiotics|group
DDI-DrugBank.d579.s0|31-33|and|O
DDI-DrugBank.d579.s0|35-46|sulfonamides|group
DDI-DrugBank.d579.s0|48-56|generally|O
DDI-DrugBank.d579.s0|58-63|should|O
DDI-DrugBank.d579.s0|65-67|not|O
DDI-DrugBank.d579.s0|69-70|be|O
DDI-DrugBank.d579.s0|72-78|treated|O
DDI-DrugBank.d579.s0|80-83|with|O
DDI-DrugBank.d579.s0|85-101|ganglion blockers|group
DDI-DrugBank.d579.s0|102-102|.|O
DDI-DrugBank.d579.s1|0-2|The|O
DDI-DrugBank.d579.s1|4-9|action|O
DDI-DrugBank.d579.s1|11-12|of|O
DDI-DrugBank.d579.s1|14-25|Mecamylamine|drug
DDI-DrugBank.d579.s1|27-29|may|O
DDI-DrugBank.d579.s1|31-32|be|O
DDI-DrugBank.d579.s1|34-44|potentiated|O
DDI-DrugBank.d579.s1|46-47|by|O
DDI-DrugBank.d579.s1|49-58|anesthesia|O
DDI-DrugBank.d579.s1|59-59|,|O
DDI-DrugBank.d579.s1|61-65|other|O
DDI-DrugBank.d579.s1|67-88|antihypertensive drugs|group
DDI-DrugBank.d579.s1|90-92|and|O
DDI-DrugBank.d579.s1|94-100|alcohol|drug
DDI-DrugBank.d579.s1|101-101|.|O
DDI-DrugBank.d600.s0|0-10|Methyprylon|drug
DDI-DrugBank.d600.s0|12-14|may|O
DDI-DrugBank.d600.s0|16-23|interact|O
DDI-DrugBank.d600.s0|25-28|with|O
DDI-DrugBank.d600.s0|30-34|other|O
DDI-DrugBank.d600.s0|36-44|addictive|O
DDI-DrugBank.d600.s0|46-56|medications|O
DDI-DrugBank.d600.s0|57-57|,|O
DDI-DrugBank.d600.s0|59-60|in|O
DDI-DrugBank.d600.s0|62-65|that|O
DDI-DrugBank.d600.s0|67-68|it|O
DDI-DrugBank.d600.s0|70-72|may|O
DDI-DrugBank.d600.s0|74-81|increase|O
DDI-DrugBank.d600.s0|83-85|the|O
DDI-DrugBank.d600.s0|87-96|likelyhood|O
DDI-DrugBank.d600.s0|98-99|of|O
DDI-DrugBank.d600.s0|101-109|addiction|O
DDI-DrugBank.d600.s0|111-113|and|O
DDI-DrugBank.d600.s0|115-119|abuse|O
DDI-DrugBank.d600.s0|120-120|.|O
DDI-DrugBank.d600.s1|0-9|Concurrent|O
DDI-DrugBank.d600.s1|11-13|use|O
DDI-DrugBank.d600.s1|15-16|of|O
DDI-DrugBank.d600.s1|18-24|alcohol|drug
DDI-DrugBank.d600.s1|26-28|and|O
DDI-DrugBank.d600.s1|30-34|other|O
DDI-DrugBank.d600.s1|36-65|CNS depression-producing drugs|group
DDI-DrugBank.d600.s1|67-69|may|O
DDI-DrugBank.d600.s1|71-78|increase|O
DDI-DrugBank.d600.s1|80-82|the|O
DDI-DrugBank.d600.s1|84-86|CNS|O
DDI-DrugBank.d600.s1|88-97|depressant|O
DDI-DrugBank.d600.s1|99-105|effects|O
DDI-DrugBank.d600.s1|107-108|of|O
DDI-DrugBank.d600.s1|110-120|methyprylon|drug
DDI-DrugBank.d600.s1|122-123|or|O
DDI-DrugBank.d600.s1|125-129|these|O
DDI-DrugBank.d600.s1|131-135|other|O
DDI-DrugBank.d600.s1|137-147|medications|O
DDI-DrugBank.d600.s1|148-148|.|O
DDI-DrugBank.d336.s0|0-7|Although|O
DDI-DrugBank.d336.s0|9-16|clinical|O
DDI-DrugBank.d336.s0|18-24|studies|O
DDI-DrugBank.d336.s0|26-29|have|O
DDI-DrugBank.d336.s0|31-33|not|O
DDI-DrugBank.d336.s0|35-45|established|O
DDI-DrugBank.d336.s0|47-47|a|O
DDI-DrugBank.d336.s0|49-53|cause|O
DDI-DrugBank.d336.s0|55-57|and|O
DDI-DrugBank.d336.s0|59-64|effect|O
DDI-DrugBank.d336.s0|66-77|relationship|O
DDI-DrugBank.d336.s0|78-78|,|O
DDI-DrugBank.d336.s0|80-89|physicians|O
DDI-DrugBank.d336.s0|91-96|should|O
DDI-DrugBank.d336.s0|98-99|be|O
DDI-DrugBank.d336.s0|101-105|aware|O
DDI-DrugBank.d336.s0|107-110|that|O
DDI-DrugBank.d336.s0|112-119|variable|O
DDI-DrugBank.d336.s0|121-127|effects|O
DDI-DrugBank.d336.s0|129-130|an|O
DDI-DrugBank.d336.s0|132-136|blood|O
DDI-DrugBank.d336.s0|138-148|coagulation|O
DDI-DrugBank.d336.s0|150-153|have|O
DDI-DrugBank.d336.s0|155-158|been|O
DDI-DrugBank.d336.s0|160-167|reported|O
DDI-DrugBank.d336.s0|169-172|very|O
DDI-DrugBank.d336.s0|174-179|rarely|O
DDI-DrugBank.d336.s0|181-182|in|O
DDI-DrugBank.d336.s0|184-191|patients|O
DDI-DrugBank.d336.s0|193-201|receiving|O
DDI-DrugBank.d336.s0|203-206|oral|O
DDI-DrugBank.d336.s0|208-221|anticoagulants|group
DDI-DrugBank.d336.s0|223-225|and|O
DDI-DrugBank.d336.s0|227-242|chlordiazepoxide|drug
DDI-DrugBank.d336.s0|243-243|.|O
DDI-DrugBank.d336.s1|0-2|The|O
DDI-DrugBank.d336.s1|4-14|concomitant|O
DDI-DrugBank.d336.s1|16-18|use|O
DDI-DrugBank.d336.s1|20-21|of|O
DDI-DrugBank.d336.s1|23-29|alcohol|drug
DDI-DrugBank.d336.s1|31-32|or|O
DDI-DrugBank.d336.s1|34-38|other|O
DDI-DrugBank.d336.s1|40-73|central nervous system depressants|group
DDI-DrugBank.d336.s1|75-77|may|O
DDI-DrugBank.d336.s1|79-82|have|O
DDI-DrugBank.d336.s1|84-85|an|O
DDI-DrugBank.d336.s1|87-94|additive|O
DDI-DrugBank.d336.s1|96-101|effect|O
DDI-DrugBank.d336.s1|102-102|.|O
DDI-DrugBank.d262.s0|0-2|The|O
DDI-DrugBank.d262.s0|4-14|concomitant|O
DDI-DrugBank.d262.s0|16-18|use|O
DDI-DrugBank.d262.s0|20-21|of|O
DDI-DrugBank.d262.s0|23-29|alcohol|drug
DDI-DrugBank.d262.s0|31-32|or|O
DDI-DrugBank.d262.s0|34-38|other|O
DDI-DrugBank.d262.s0|40-73|central nervous system depressants|group
DDI-DrugBank.d262.s0|75-77|may|O
DDI-DrugBank.d262.s0|79-82|have|O
DDI-DrugBank.d262.s0|84-85|an|O
DDI-DrugBank.d262.s0|87-94|additive|O
DDI-DrugBank.d262.s0|96-101|effect|O
DDI-DrugBank.d262.s0|102-102|.|O
DDI-MedLine.d28.s0|0-2|New|O
DDI-MedLine.d28.s0|4-7|oral|O
DDI-MedLine.d28.s0|9-17|therapies|O
DDI-MedLine.d28.s0|19-21|for|O
DDI-MedLine.d28.s0|23-26|type|O
DDI-MedLine.d28.s0|28-28|2|O
DDI-MedLine.d28.s0|30-37|diabetes|O
DDI-MedLine.d28.s0|39-46|mellitus|O
DDI-MedLine.d28.s0|47-47|:|O
DDI-MedLine.d28.s0|49-51|The|O
DDI-MedLine.d28.s0|53-62|glitazones|group
DDI-MedLine.d28.s0|64-65|or|O
DDI-MedLine.d28.s0|67-73|insulin|O
DDI-MedLine.d28.s0|75-85|sensitizers|O
DDI-MedLine.d28.s0|86-86|.|O
DDI-MedLine.d28.s1|0-3|Type|O
DDI-MedLine.d28.s1|5-5|2|O
DDI-MedLine.d28.s1|7-14|diabetes|O
DDI-MedLine.d28.s1|16-23|mellitus|O
DDI-MedLine.d28.s1|25-26|is|O
DDI-MedLine.d28.s1|28-28|a|O
DDI-MedLine.d28.s1|30-36|growing|O
DDI-MedLine.d28.s1|38-44|problem|O
DDI-MedLine.d28.s1|46-48|not|O
DDI-MedLine.d28.s1|50-53|only|O
DDI-MedLine.d28.s1|55-56|in|O
DDI-MedLine.d28.s1|58-60|the|O
DDI-MedLine.d28.s1|62-67|United|O
DDI-MedLine.d28.s1|69-74|States|O
DDI-MedLine.d28.s1|76-78|but|O
DDI-MedLine.d28.s1|80-83|also|O
DDI-MedLine.d28.s1|85-90|across|O
DDI-MedLine.d28.s1|92-94|the|O
DDI-MedLine.d28.s1|96-100|world|O
DDI-MedLine.d28.s1|101-101|.|O
DDI-MedLine.d28.s2|0-4|There|O
DDI-MedLine.d28.s2|6-7|is|O
DDI-MedLine.d28.s2|9-11|now|O
DDI-MedLine.d28.s2|13-18|strong|O
DDI-MedLine.d28.s2|20-27|evidence|O
DDI-MedLine.d28.s2|29-32|that|O
DDI-MedLine.d28.s2|34-42|intensive|O
DDI-MedLine.d28.s2|44-50|control|O
DDI-MedLine.d28.s2|52-53|of|O
DDI-MedLine.d28.s2|55-59|blood|O
DDI-MedLine.d28.s2|61-67|glucose|O
DDI-MedLine.d28.s2|69-71|can|O
DDI-MedLine.d28.s2|73-85|significantly|O
DDI-MedLine.d28.s2|87-92|reduce|O
DDI-MedLine.d28.s2|94-96|and|O
DDI-MedLine.d28.s2|98-103|retard|O
DDI-MedLine.d28.s2|105-107|the|O
DDI-MedLine.d28.s2|109-121|microvascular|O
DDI-MedLine.d28.s2|123-135|complications|O
DDI-MedLine.d28.s2|137-138|of|O
DDI-MedLine.d28.s2|140-150|retinopathy|O
DDI-MedLine.d28.s2|151-151|,|O
DDI-MedLine.d28.s2|153-163|nephropathy|O
DDI-MedLine.d28.s2|164-164|,|O
DDI-MedLine.d28.s2|166-168|and|O
DDI-MedLine.d28.s2|170-179|neuropathy|O
DDI-MedLine.d28.s2|180-180|.|O
DDI-MedLine.d28.s3|0-9|Ultimately|O
DDI-MedLine.d28.s3|11-17|however|O
DDI-MedLine.d28.s3|18-18|,|O
DDI-MedLine.d28.s3|20-21|up|O
DDI-MedLine.d28.s3|23-24|to|O
DDI-MedLine.d28.s3|26-27|80|O
DDI-MedLine.d28.s3|28-28|%|O
DDI-MedLine.d28.s3|30-31|of|O
DDI-MedLine.d28.s3|33-36|type|O
DDI-MedLine.d28.s3|38-38|2|O
DDI-MedLine.d28.s3|40-48|diabetics|O
DDI-MedLine.d28.s3|50-52|die|O
DDI-MedLine.d28.s3|54-57|from|O
DDI-MedLine.d28.s3|59-71|macrovascular|O
DDI-MedLine.d28.s3|73-86|cardiovascular|O
DDI-MedLine.d28.s3|88-94|disease|O
DDI-MedLine.d28.s3|95-95|.|O
DDI-MedLine.d28.s4|0-3|This|O
DDI-MedLine.d28.s4|5-13|increased|O
DDI-MedLine.d28.s4|15-23|incidence|O
DDI-MedLine.d28.s4|25-26|of|O
DDI-MedLine.d28.s4|28-42|atherosclerotic|O
DDI-MedLine.d28.s4|44-50|disease|O
DDI-MedLine.d28.s4|52-53|is|O
DDI-MedLine.d28.s4|55-65|intricately|O
DDI-MedLine.d28.s4|67-76|associated|O
DDI-MedLine.d28.s4|78-81|with|O
DDI-MedLine.d28.s4|83-89|insulin|O
DDI-MedLine.d28.s4|91-100|resistance|O
DDI-MedLine.d28.s4|101-101|,|O
DDI-MedLine.d28.s4|103-107|which|O
DDI-MedLine.d28.s4|109-110|is|O
DDI-MedLine.d28.s4|112-112|a|O
DDI-MedLine.d28.s4|114-118|major|O
DDI-MedLine.d28.s4|120-135|pathophysiologic|O
DDI-MedLine.d28.s4|137-147|abnormality|O
DDI-MedLine.d28.s4|149-150|in|O
DDI-MedLine.d28.s4|152-155|type|O
DDI-MedLine.d28.s4|157-157|2|O
DDI-MedLine.d28.s4|159-166|diabetes|O
DDI-MedLine.d28.s4|167-167|.|O
DDI-MedLine.d28.s5|0-4|There|O
DDI-MedLine.d28.s5|6-7|is|O
DDI-MedLine.d28.s5|9-14|strong|O
DDI-MedLine.d28.s5|16-23|evidence|O
DDI-MedLine.d28.s5|25-28|that|O
DDI-MedLine.d28.s5|30-36|insulin|O
DDI-MedLine.d28.s5|38-47|resistance|O
DDI-MedLine.d28.s5|49-50|is|O
DDI-MedLine.d28.s5|52-59|involved|O
DDI-MedLine.d28.s5|61-62|in|O
DDI-MedLine.d28.s5|64-66|the|O
DDI-MedLine.d28.s5|68-78|development|O
DDI-MedLine.d28.s5|80-81|of|O
DDI-MedLine.d28.s5|83-85|not|O
DDI-MedLine.d28.s5|87-90|only|O
DDI-MedLine.d28.s5|92-104|hyperglycemia|O
DDI-MedLine.d28.s5|105-105|,|O
DDI-MedLine.d28.s5|107-109|but|O
DDI-MedLine.d28.s5|111-114|also|O
DDI-MedLine.d28.s5|116-127|dyslipidemia|O
DDI-MedLine.d28.s5|128-128|,|O
DDI-MedLine.d28.s5|130-141|hypertension|O
DDI-MedLine.d28.s5|142-142|,|O
DDI-MedLine.d28.s5|144-159|hypercoagulation|O
DDI-MedLine.d28.s5|160-160|,|O
DDI-MedLine.d28.s5|162-173|vasculopathy|O
DDI-MedLine.d28.s5|174-174|,|O
DDI-MedLine.d28.s5|176-178|and|O
DDI-MedLine.d28.s5|180-189|ultimately|O
DDI-MedLine.d28.s5|191-205|atherosclerotic|O
DDI-MedLine.d28.s5|207-220|cardiovascular|O
DDI-MedLine.d28.s5|222-228|disease|O
DDI-MedLine.d28.s5|229-229|.|O
DDI-MedLine.d28.s6|0-3|This|O
DDI-MedLine.d28.s6|5-11|cluster|O
DDI-MedLine.d28.s6|13-14|of|O
DDI-MedLine.d28.s6|16-24|metabolic|O
DDI-MedLine.d28.s6|26-38|abnormalities|O
DDI-MedLine.d28.s6|40-42|has|O
DDI-MedLine.d28.s6|44-47|been|O
DDI-MedLine.d28.s6|49-54|termed|O
DDI-MedLine.d28.s6|56-58|the|O
DDI-MedLine.d28.s6|60-66|insulin|O
DDI-MedLine.d28.s6|68-77|resistance|O
DDI-MedLine.d28.s6|79-80|or|O
DDI-MedLine.d28.s6|82-95|cardiovascular|O
DDI-MedLine.d28.s6|97-108|dysmetabolic|O
DDI-MedLine.d28.s6|110-117|syndrome|O
DDI-MedLine.d28.s6|118-118|.|O
DDI-MedLine.d28.s7|0-2|The|O
DDI-MedLine.d28.s7|4-21|thiazolidinediones|group
DDI-MedLine.d28.s7|23-23|(|O
DDI-MedLine.d28.s7|24-36|rosiglitazone|drug
DDI-MedLine.d28.s7|38-40|and|O
DDI-MedLine.d28.s7|42-53|pioglitazone|drug
DDI-MedLine.d28.s7|54-54|)|O
DDI-MedLine.d28.s7|55-55|,|O
DDI-MedLine.d28.s7|57-57|a|O
DDI-MedLine.d28.s7|59-61|new|O
DDI-MedLine.d28.s7|63-67|class|O
DDI-MedLine.d28.s7|69-70|of|O
DDI-MedLine.d28.s7|72-75|oral|O
DDI-MedLine.d28.s7|77-95|antidiabetic agents|group
DDI-MedLine.d28.s7|96-96|,|O
DDI-MedLine.d28.s7|98-100|are|O
DDI-MedLine.d28.s7|102-102|"|O
DDI-MedLine.d28.s7|103-109|insulin|O
DDI-MedLine.d28.s7|111-121|sensitizers|O
DDI-MedLine.d28.s7|122-122|"|O
DDI-MedLine.d28.s8|0-2|and|O
DDI-MedLine.d28.s8|4-8|exert|O
DDI-MedLine.d28.s8|10-15|direct|O
DDI-MedLine.d28.s8|17-23|effects|O
DDI-MedLine.d28.s8|25-26|on|O
DDI-MedLine.d28.s8|28-30|the|O
DDI-MedLine.d28.s8|32-41|mechanisms|O
DDI-MedLine.d28.s8|43-44|of|O
DDI-MedLine.d28.s8|46-52|insulin|O
DDI-MedLine.d28.s8|54-63|resistance|O
DDI-MedLine.d28.s8|64-64|.|O
DDI-MedLine.d28.s9|0-4|These|O
DDI-MedLine.d28.s9|6-12|effects|O
DDI-MedLine.d28.s9|14-16|not|O
DDI-MedLine.d28.s9|18-21|only|O
DDI-MedLine.d28.s9|23-29|improve|O
DDI-MedLine.d28.s9|31-37|insulin|O
DDI-MedLine.d28.s9|39-49|sensitivity|O
DDI-MedLine.d28.s9|51-53|and|O
DDI-MedLine.d28.s9|55-62|glycemic|O
DDI-MedLine.d28.s9|64-70|control|O
DDI-MedLine.d28.s9|72-75|with|O
DDI-MedLine.d28.s9|77-83|reduced|O
DDI-MedLine.d28.s9|85-91|insulin|O
DDI-MedLine.d28.s9|93-104|requirements|O
DDI-MedLine.d28.s9|105-105|,|O
DDI-MedLine.d28.s9|107-109|but|O
DDI-MedLine.d28.s9|111-114|also|O
DDI-MedLine.d28.s9|116-119|have|O
DDI-MedLine.d28.s9|121-131|potentially|O
DDI-MedLine.d28.s9|133-141|favorable|O
DDI-MedLine.d28.s9|143-149|effects|O
DDI-MedLine.d28.s9|151-152|on|O
DDI-MedLine.d28.s9|154-158|other|O
DDI-MedLine.d28.s9|160-169|components|O
DDI-MedLine.d28.s9|171-172|of|O
DDI-MedLine.d28.s9|174-176|the|O
DDI-MedLine.d28.s9|178-191|cardiovascular|O
DDI-MedLine.d28.s9|193-204|dysmetabolic|O
DDI-MedLine.d28.s9|206-213|syndrome|O
DDI-MedLine.d28.s9|214-214|.|O
DDI-MedLine.d28.s10|0-8|Long-term|O
DDI-MedLine.d28.s10|10-16|studies|O
DDI-MedLine.d28.s10|18-20|are|O
DDI-MedLine.d28.s10|22-27|needed|O
DDI-MedLine.d28.s10|29-30|to|O
DDI-MedLine.d28.s10|32-40|determine|O
DDI-MedLine.d28.s10|42-48|whether|O
DDI-MedLine.d28.s10|50-52|the|O
DDI-MedLine.d28.s10|54-72|insulin-sensitizing|O
DDI-MedLine.d28.s10|74-80|effects|O
DDI-MedLine.d28.s10|82-83|of|O
DDI-MedLine.d28.s10|85-87|the|O
DDI-MedLine.d28.s10|89-98|glitazones|group
DDI-MedLine.d28.s10|100-102|can|O
DDI-MedLine.d28.s10|104-110|prevent|O
DDI-MedLine.d28.s10|112-113|or|O
DDI-MedLine.d28.s10|115-119|delay|O
DDI-MedLine.d28.s10|121-129|premature|O
DDI-MedLine.d28.s10|131-145|atherosclerotic|O
DDI-MedLine.d28.s10|147-160|cardiovascular|O
DDI-MedLine.d28.s10|162-168|disease|O
DDI-MedLine.d28.s10|169-169|,|O
DDI-MedLine.d28.s10|171-179|morbidity|O
DDI-MedLine.d28.s10|180-180|,|O
DDI-MedLine.d28.s10|182-184|and|O
DDI-MedLine.d28.s10|186-190|death|O
DDI-MedLine.d28.s10|191-191|.|O
DDI-DrugBank.d297.s0|0-5|Formal|O
DDI-DrugBank.d297.s0|7-10|drug|O
DDI-DrugBank.d297.s0|12-22|interaction|O
DDI-DrugBank.d297.s0|24-30|studies|O
DDI-DrugBank.d297.s0|32-35|have|O
DDI-DrugBank.d297.s0|37-39|not|O
DDI-DrugBank.d297.s0|41-44|been|O
DDI-DrugBank.d297.s0|46-54|conducted|O
DDI-DrugBank.d297.s0|56-59|with|O
DDI-DrugBank.d297.s0|61-67|ORENCIA|brand
DDI-DrugBank.d297.s0|68-68|.|O
DDI-DrugBank.d297.s1|0-9|Population|O
DDI-DrugBank.d297.s1|11-25|pharmacokinetic|O
DDI-DrugBank.d297.s1|27-34|analyses|O
DDI-DrugBank.d297.s1|36-43|revealed|O
DDI-DrugBank.d297.s1|45-48|that|O
DDI-DrugBank.d297.s1|50-52|MTX|drug
DDI-DrugBank.d297.s1|53-53|,|O
DDI-DrugBank.d297.s1|55-60|NSAIDs|group
DDI-DrugBank.d297.s1|61-61|,|O
DDI-DrugBank.d297.s1|63-77|corticosteroids|group
DDI-DrugBank.d297.s1|78-78|,|O
DDI-DrugBank.d297.s1|80-82|and|O
DDI-DrugBank.d297.s1|84-102|TNF blocking agents|group
DDI-DrugBank.d297.s1|104-106|did|O
DDI-DrugBank.d297.s1|108-110|not|O
DDI-DrugBank.d297.s1|112-120|influence|O
DDI-DrugBank.d297.s1|122-130|abatacept|drug
DDI-DrugBank.d297.s1|132-140|clearance|O
DDI-DrugBank.d297.s1|141-141|.|O
DDI-DrugBank.d297.s2|0-2|The|O
DDI-DrugBank.d297.s2|4-11|majority|O
DDI-DrugBank.d297.s2|13-14|of|O
DDI-DrugBank.d297.s2|16-23|patients|O
DDI-DrugBank.d297.s2|25-26|in|O
DDI-DrugBank.d297.s2|28-29|RA|O
DDI-DrugBank.d297.s2|31-38|clinical|O
DDI-DrugBank.d297.s2|40-46|studies|O
DDI-DrugBank.d297.s2|48-55|received|O
DDI-DrugBank.d297.s2|57-59|one|O
DDI-DrugBank.d297.s2|61-62|or|O
DDI-DrugBank.d297.s2|64-67|more|O
DDI-DrugBank.d297.s2|69-70|of|O
DDI-DrugBank.d297.s2|72-74|the|O
DDI-DrugBank.d297.s2|76-84|following|O
DDI-DrugBank.d297.s2|86-96|concomitant|O
DDI-DrugBank.d297.s2|98-108|medications|O
DDI-DrugBank.d297.s2|110-113|with|O
DDI-DrugBank.d297.s2|115-121|ORENCIA|brand
DDI-DrugBank.d297.s2|122-122|:|O
DDI-DrugBank.d297.s2|124-126|MTX|drug
DDI-DrugBank.d297.s2|127-127|,|O
DDI-DrugBank.d297.s2|129-134|NSAIDs|group
DDI-DrugBank.d297.s2|135-135|,|O
DDI-DrugBank.d297.s2|137-151|corticosteroids|group
DDI-DrugBank.d297.s2|152-152|,|O
DDI-DrugBank.d297.s2|154-172|TNF blocking agents|group
DDI-DrugBank.d297.s2|173-173|,|O
DDI-DrugBank.d297.s2|175-186|azathioprine|drug
DDI-DrugBank.d297.s2|187-187|,|O
DDI-DrugBank.d297.s2|189-199|chloroquine|drug
DDI-DrugBank.d297.s2|200-200|,|O
DDI-DrugBank.d297.s2|202-205|gold|drug
DDI-DrugBank.d297.s2|206-206|,|O
DDI-DrugBank.d297.s2|208-225|hydroxychloroquine|drug
DDI-DrugBank.d297.s2|226-226|,|O
DDI-DrugBank.d297.s2|228-238|leflunomide|drug
DDI-DrugBank.d297.s2|239-239|,|O
DDI-DrugBank.d297.s2|241-253|sulfasalazine|drug
DDI-DrugBank.d297.s2|254-254|,|O
DDI-DrugBank.d297.s2|256-258|and|O
DDI-DrugBank.d297.s2|260-267|anakinra|drug
DDI-DrugBank.d297.s2|268-268|.|O
DDI-DrugBank.d297.s3|0-9|Concurrent|O
DDI-DrugBank.d297.s3|11-24|administration|O
DDI-DrugBank.d297.s3|26-27|of|O
DDI-DrugBank.d297.s3|29-29|a|O
DDI-DrugBank.d297.s3|31-44|TNF antagonist|group
DDI-DrugBank.d297.s3|46-49|with|O
DDI-DrugBank.d297.s3|51-57|ORENCIA|brand
DDI-DrugBank.d297.s3|59-61|has|O
DDI-DrugBank.d297.s3|63-66|been|O
DDI-DrugBank.d297.s3|68-77|associated|O
DDI-DrugBank.d297.s3|79-82|with|O
DDI-DrugBank.d297.s3|84-85|an|O
DDI-DrugBank.d297.s3|87-95|increased|O
DDI-DrugBank.d297.s3|97-100|risk|O
DDI-DrugBank.d297.s3|102-103|of|O
DDI-DrugBank.d297.s3|105-111|serious|O
DDI-DrugBank.d297.s3|113-122|infections|O
DDI-DrugBank.d297.s3|124-126|and|O
DDI-DrugBank.d297.s3|128-129|no|O
DDI-DrugBank.d297.s3|131-141|significant|O
DDI-DrugBank.d297.s3|143-152|additional|O
DDI-DrugBank.d297.s3|154-161|efficacy|O
DDI-DrugBank.d297.s3|163-166|over|O
DDI-DrugBank.d297.s3|168-170|use|O
DDI-DrugBank.d297.s3|172-173|of|O
DDI-DrugBank.d297.s3|175-177|the|O
DDI-DrugBank.d297.s3|179-193|TNF antagonists|group
DDI-DrugBank.d297.s3|195-199|alone|O
DDI-DrugBank.d297.s3|200-200|.|O
DDI-DrugBank.d297.s4|0-9|Concurrent|O
DDI-DrugBank.d297.s4|11-17|therapy|O
DDI-DrugBank.d297.s4|19-22|with|O
DDI-DrugBank.d297.s4|24-30|ORENCIA|brand
DDI-DrugBank.d297.s4|32-34|and|O
DDI-DrugBank.d297.s4|36-50|TNF antagonists|group
DDI-DrugBank.d297.s4|52-53|is|O
DDI-DrugBank.d297.s4|55-57|not|O
DDI-DrugBank.d297.s4|59-69|recommended|O
DDI-DrugBank.d297.s4|70-70|.|O
DDI-DrugBank.d297.s5|0-4|There|O
DDI-DrugBank.d297.s5|6-7|is|O
DDI-DrugBank.d297.s5|9-20|insufficient|O
DDI-DrugBank.d297.s5|22-31|experience|O
DDI-DrugBank.d297.s5|33-34|to|O
DDI-DrugBank.d297.s5|36-41|assess|O
DDI-DrugBank.d297.s5|43-45|the|O
DDI-DrugBank.d297.s5|47-52|safety|O
DDI-DrugBank.d297.s5|54-56|and|O
DDI-DrugBank.d297.s5|58-65|efficacy|O
DDI-DrugBank.d297.s5|67-68|of|O
DDI-DrugBank.d297.s5|70-76|ORENCIA|brand
DDI-DrugBank.d297.s5|78-89|administered|O
DDI-DrugBank.d297.s5|91-102|concurrently|O
DDI-DrugBank.d297.s5|104-107|with|O
DDI-DrugBank.d297.s5|109-116|anakinra|drug
DDI-DrugBank.d297.s5|117-117|,|O
DDI-DrugBank.d297.s5|119-121|and|O
DDI-DrugBank.d297.s5|123-131|therefore|O
DDI-DrugBank.d297.s5|133-136|such|O
DDI-DrugBank.d297.s5|138-140|use|O
DDI-DrugBank.d297.s5|142-143|is|O
DDI-DrugBank.d297.s5|145-147|not|O
DDI-DrugBank.d297.s5|149-159|recommended|O
DDI-DrugBank.d297.s5|160-160|.|O
DDI-DrugBank.d619.s0|0-2|The|O
DDI-DrugBank.d619.s0|4-13|occurrence|O
DDI-DrugBank.d619.s0|15-16|of|O
DDI-DrugBank.d619.s0|18-23|stupor|O
DDI-DrugBank.d619.s0|24-24|,|O
DDI-DrugBank.d619.s0|26-33|muscular|O
DDI-DrugBank.d619.s0|35-42|rigidity|O
DDI-DrugBank.d619.s0|43-43|,|O
DDI-DrugBank.d619.s0|45-50|severe|O
DDI-DrugBank.d619.s0|52-60|agitation|O
DDI-DrugBank.d619.s0|61-61|,|O
DDI-DrugBank.d619.s0|63-65|and|O
DDI-DrugBank.d619.s0|67-74|elevated|O
DDI-DrugBank.d619.s0|76-86|temperature|O
DDI-DrugBank.d619.s0|88-90|has|O
DDI-DrugBank.d619.s0|92-95|been|O
DDI-DrugBank.d619.s0|97-104|reported|O
DDI-DrugBank.d619.s0|106-107|in|O
DDI-DrugBank.d619.s0|109-112|some|O
DDI-DrugBank.d619.s0|114-121|patients|O
DDI-DrugBank.d619.s0|123-131|receiving|O
DDI-DrugBank.d619.s0|133-135|the|O
DDI-DrugBank.d619.s0|137-147|combination|O
DDI-DrugBank.d619.s0|149-150|of|O
DDI-DrugBank.d619.s0|152-161|selegiline|drug
DDI-DrugBank.d619.s0|163-165|and|O
DDI-DrugBank.d619.s0|167-176|meperidine|drug
DDI-DrugBank.d619.s0|177-177|.|O
DDI-DrugBank.d619.s1|0-7|Symptoms|O
DDI-DrugBank.d619.s1|9-15|usually|O
DDI-DrugBank.d619.s1|17-23|resolve|O
DDI-DrugBank.d619.s1|25-28|over|O
DDI-DrugBank.d619.s1|30-33|days|O
DDI-DrugBank.d619.s1|35-38|when|O
DDI-DrugBank.d619.s1|40-42|the|O
DDI-DrugBank.d619.s1|44-54|combination|O
DDI-DrugBank.d619.s1|56-57|is|O
DDI-DrugBank.d619.s1|59-70|discontinued|O
DDI-DrugBank.d619.s1|71-71|.|O
DDI-DrugBank.d619.s2|0-3|This|O
DDI-DrugBank.d619.s2|5-6|is|O
DDI-DrugBank.d619.s2|8-14|typical|O
DDI-DrugBank.d619.s2|16-17|of|O
DDI-DrugBank.d619.s2|19-21|the|O
DDI-DrugBank.d619.s2|23-33|interaction|O
DDI-DrugBank.d619.s2|35-36|of|O
DDI-DrugBank.d619.s2|38-47|meperidine|drug
DDI-DrugBank.d619.s2|49-51|and|O
DDI-DrugBank.d619.s2|53-57|MAOIs|group
DDI-DrugBank.d619.s2|58-58|.|O
DDI-DrugBank.d619.s3|0-4|Other|O
DDI-DrugBank.d619.s3|6-12|serious|O
DDI-DrugBank.d619.s3|14-22|reactions|O
DDI-DrugBank.d619.s3|24-24|(|O
DDI-DrugBank.d619.s3|25-33|including|O
DDI-DrugBank.d619.s3|35-40|severe|O
DDI-DrugBank.d619.s3|42-50|agitation|O
DDI-DrugBank.d619.s3|51-51|,|O
DDI-DrugBank.d619.s3|53-66|hallucinations|O
DDI-DrugBank.d619.s3|67-67|,|O
DDI-DrugBank.d619.s3|69-71|and|O
DDI-DrugBank.d619.s3|73-77|death|O
DDI-DrugBank.d619.s3|78-78|)|O
DDI-DrugBank.d619.s3|80-83|have|O
DDI-DrugBank.d619.s3|85-88|been|O
DDI-DrugBank.d619.s3|90-97|reported|O
DDI-DrugBank.d619.s3|99-100|in|O
DDI-DrugBank.d619.s3|102-109|patients|O
DDI-DrugBank.d619.s3|111-119|receiving|O
DDI-DrugBank.d619.s3|121-124|this|O
DDI-DrugBank.d619.s3|126-136|combination|O
DDI-DrugBank.d619.s3|137-137|.|O
DDI-DrugBank.d619.s4|0-5|Severe|O
DDI-DrugBank.d619.s4|7-14|toxicity|O
DDI-DrugBank.d619.s4|16-18|has|O
DDI-DrugBank.d619.s4|20-23|also|O
DDI-DrugBank.d619.s4|25-28|been|O
DDI-DrugBank.d619.s4|30-37|reported|O
DDI-DrugBank.d619.s4|39-40|in|O
DDI-DrugBank.d619.s4|42-49|patients|O
DDI-DrugBank.d619.s4|51-59|receiving|O
DDI-DrugBank.d619.s4|61-63|the|O
DDI-DrugBank.d619.s4|65-75|combination|O
DDI-DrugBank.d619.s4|77-78|of|O
DDI-DrugBank.d619.s4|80-104|tricyclic antidepressants|group
DDI-DrugBank.d619.s4|106-108|and|O
DDI-DrugBank.d619.s4|110-117|ELDEPRYL|brand
DDI-DrugBank.d619.s4|119-121|and|O
DDI-DrugBank.d619.s4|123-161|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d619.s4|163-165|and|O
DDI-DrugBank.d619.s4|167-174|ELDEPRYL|brand
DDI-DrugBank.d619.s4|175-175|.|O
DDI-DrugBank.d619.s5|0-2|One|O
DDI-DrugBank.d619.s5|4-7|case|O
DDI-DrugBank.d619.s5|9-10|of|O
DDI-DrugBank.d619.s5|12-23|hypertensive|O
DDI-DrugBank.d619.s5|25-30|crisis|O
DDI-DrugBank.d619.s5|32-34|has|O
DDI-DrugBank.d619.s5|36-39|been|O
DDI-DrugBank.d619.s5|41-48|reported|O
DDI-DrugBank.d619.s5|50-51|in|O
DDI-DrugBank.d619.s5|53-53|a|O
DDI-DrugBank.d619.s5|55-61|patient|O
DDI-DrugBank.d619.s5|63-68|taking|O
DDI-DrugBank.d619.s5|70-72|the|O
DDI-DrugBank.d619.s5|74-84|recommended|O
DDI-DrugBank.d619.s5|86-90|doses|O
DDI-DrugBank.d619.s5|92-93|of|O
DDI-DrugBank.d619.s5|95-104|selegiline|drug
DDI-DrugBank.d619.s5|106-108|and|O
DDI-DrugBank.d619.s5|110-110|a|O
DDI-DrugBank.d619.s5|112-137|sympathomimetic medication|group
DDI-DrugBank.d619.s5|139-139|(|O
DDI-DrugBank.d619.s5|140-148|ephedrine|drug
DDI-DrugBank.d619.s5|149-149|)|O
DDI-DrugBank.d619.s5|150-150|.|O
DDI-DrugBank.d688.s0|0-14|Pharmacokinetic|O
DDI-DrugBank.d688.s0|16-22|studies|O
DDI-DrugBank.d688.s0|24-27|show|O
DDI-DrugBank.d688.s0|29-32|that|O
DDI-DrugBank.d688.s0|34-38|there|O
DDI-DrugBank.d688.s0|40-42|are|O
DDI-DrugBank.d688.s0|44-45|no|O
DDI-DrugBank.d688.s0|47-57|significant|O
DDI-DrugBank.d688.s0|59-69|alterations|O
DDI-DrugBank.d688.s0|71-72|in|O
DDI-DrugBank.d688.s0|74-88|pharmacokinetic|O
DDI-DrugBank.d688.s0|90-99|parameters|O
DDI-DrugBank.d688.s0|101-102|of|O
DDI-DrugBank.d688.s0|104-113|zidovudine|drug
DDI-DrugBank.d688.s0|115-116|or|O
DDI-DrugBank.d688.s0|118-126|rifabutin|drug
DDI-DrugBank.d688.s0|128-129|to|O
DDI-DrugBank.d688.s0|131-137|warrant|O
DDI-DrugBank.d688.s0|139-144|dosage|O
DDI-DrugBank.d688.s0|146-155|adjustment|O
DDI-DrugBank.d688.s0|157-160|when|O
DDI-DrugBank.d688.s0|162-178|megestrol acetate|drug
DDI-DrugBank.d688.s0|180-181|is|O
DDI-DrugBank.d688.s0|183-194|administered|O
DDI-DrugBank.d688.s0|196-199|with|O
DDI-DrugBank.d688.s0|201-205|these|O
DDI-DrugBank.d688.s0|207-211|drugs|O
DDI-DrugBank.d688.s0|212-212|.|O
DDI-DrugBank.d688.s1|0-0|A|O
DDI-DrugBank.d688.s1|2-16|pharmacokinetic|O
DDI-DrugBank.d688.s1|18-22|study|O
DDI-DrugBank.d688.s1|24-35|demonstrated|O
DDI-DrugBank.d688.s1|37-40|that|O
DDI-DrugBank.d688.s1|42-57|coadministration|O
DDI-DrugBank.d688.s1|59-60|of|O
DDI-DrugBank.d688.s1|62-78|megestrol acetate|drug
DDI-DrugBank.d688.s1|80-82|and|O
DDI-DrugBank.d688.s1|84-92|indinavir|drug
DDI-DrugBank.d688.s1|94-100|results|O
DDI-DrugBank.d688.s1|102-103|in|O
DDI-DrugBank.d688.s1|105-105|a|O
DDI-DrugBank.d688.s1|107-117|significant|O
DDI-DrugBank.d688.s1|119-126|decrease|O
DDI-DrugBank.d688.s1|128-129|in|O
DDI-DrugBank.d688.s1|131-133|the|O
DDI-DrugBank.d688.s1|135-149|pharmacokinetic|O
DDI-DrugBank.d688.s1|151-160|parameters|O
DDI-DrugBank.d688.s1|162-162|(|O
DDI-DrugBank.d688.s1|163-165|~36|O
DDI-DrugBank.d688.s1|166-166|%|O
DDI-DrugBank.d688.s1|168-170|for|O
DDI-DrugBank.d688.s1|172-175|Cmax|O
DDI-DrugBank.d688.s1|177-179|and|O
DDI-DrugBank.d688.s1|181-183|~28|O
DDI-DrugBank.d688.s1|184-184|%|O
DDI-DrugBank.d688.s1|186-188|for|O
DDI-DrugBank.d688.s1|190-192|AUC|O
DDI-DrugBank.d688.s1|193-193|)|O
DDI-DrugBank.d688.s1|195-196|of|O
DDI-DrugBank.d688.s1|198-206|indinavir|drug
DDI-DrugBank.d688.s1|207-207|.|O
DDI-DrugBank.d688.s2|0-13|Administration|O
DDI-DrugBank.d688.s2|15-16|of|O
DDI-DrugBank.d688.s2|18-18|a|O
DDI-DrugBank.d688.s2|20-25|higher|O
DDI-DrugBank.d688.s2|27-30|dose|O
DDI-DrugBank.d688.s2|32-33|of|O
DDI-DrugBank.d688.s2|35-43|indinavir|drug
DDI-DrugBank.d688.s2|45-50|should|O
DDI-DrugBank.d688.s2|52-53|be|O
DDI-DrugBank.d688.s2|55-64|considered|O
DDI-DrugBank.d688.s2|66-69|when|O
DDI-DrugBank.d688.s2|71-85|coadministering|O
DDI-DrugBank.d688.s2|87-90|with|O
DDI-DrugBank.d688.s2|92-108|megestrol acetate|drug
DDI-DrugBank.d688.s2|109-109|.|O
DDI-DrugBank.d688.s3|0-2|The|O
DDI-DrugBank.d688.s3|4-10|effects|O
DDI-DrugBank.d688.s3|12-13|of|O
DDI-DrugBank.d688.s3|15-23|indinavir|drug
DDI-DrugBank.d688.s3|24-24|,|O
DDI-DrugBank.d688.s3|26-35|zidovudine|drug
DDI-DrugBank.d688.s3|37-38|or|O
DDI-DrugBank.d688.s3|40-48|rifabutin|drug
DDI-DrugBank.d688.s3|50-51|on|O
DDI-DrugBank.d688.s3|53-55|the|O
DDI-DrugBank.d688.s3|57-72|pharmacokinetics|O
DDI-DrugBank.d688.s3|74-75|of|O
DDI-DrugBank.d688.s3|77-93|megestrol acetate|drug
DDI-DrugBank.d688.s3|95-98|were|O
DDI-DrugBank.d688.s3|100-102|not|O
DDI-DrugBank.d688.s3|104-110|studied|O
DDI-DrugBank.d688.s3|111-111|.|O
DDI-MedLine.d37.s0|0-13|Anticoagulants|group
DDI-MedLine.d37.s0|14-14|.|O
DDI-MedLine.d37.s1|0-8|Treatment|O
DDI-MedLine.d37.s1|10-14|plans|O
DDI-MedLine.d37.s1|16-18|for|O
DDI-MedLine.d37.s1|20-27|patients|O
DDI-MedLine.d37.s1|29-34|taking|O
DDI-MedLine.d37.s1|36-49|anticoagulants|group
DDI-MedLine.d37.s1|51-53|can|O
DDI-MedLine.d37.s1|55-60|become|O
DDI-MedLine.d37.s1|62-72|complicated|O
DDI-MedLine.d37.s1|73-73|.|O
DDI-MedLine.d37.s2|0-13|Anticoagulants|group
DDI-MedLine.d37.s2|15-24|predispose|O
DDI-MedLine.d37.s2|26-26|a|O
DDI-MedLine.d37.s2|28-34|patient|O
DDI-MedLine.d37.s2|36-37|to|O
DDI-MedLine.d37.s2|39-46|bleeding|O
DDI-MedLine.d37.s2|48-55|problems|O
DDI-MedLine.d37.s2|56-56|.|O
DDI-MedLine.d37.s3|0-3|Many|O
DDI-MedLine.d37.s3|5-9|drugs|O
DDI-MedLine.d37.s3|11-14|used|O
DDI-MedLine.d37.s3|16-17|in|O
DDI-MedLine.d37.s3|19-27|dentistry|O
DDI-MedLine.d37.s3|29-31|can|O
DDI-MedLine.d37.s3|32-34|not|O
DDI-MedLine.d37.s3|36-37|be|O
DDI-MedLine.d37.s3|39-43|taken|O
DDI-MedLine.d37.s3|45-57|concomitantly|O
DDI-MedLine.d37.s3|59-62|with|O
DDI-MedLine.d37.s3|64-68|these|O
DDI-MedLine.d37.s3|70-80|medications|O
DDI-MedLine.d37.s3|81-81|.|O
DDI-DrugBank.d37.s0|0-1|No|O
DDI-DrugBank.d37.s0|3-10|specific|O
DDI-DrugBank.d37.s0|12-22|information|O
DDI-DrugBank.d37.s0|24-32|available|O
DDI-DrugBank.d37.s1|0-0|.|O
DDI-MedLine.d154.s0|0-10|Enhancement|O
DDI-MedLine.d154.s0|12-13|of|O
DDI-MedLine.d154.s0|15-21|humoral|O
DDI-MedLine.d154.s0|23-28|immune|O
DDI-MedLine.d154.s0|30-38|responses|O
DDI-MedLine.d154.s0|40-41|to|O
DDI-MedLine.d154.s0|43-53|inactivated|O
DDI-MedLine.d154.s0|55-63|Newcastle|O
DDI-MedLine.d154.s0|65-71|disease|O
DDI-MedLine.d154.s0|73-75|and|O
DDI-MedLine.d154.s0|77-100|avian influenza vaccines|group
DDI-MedLine.d154.s0|102-103|by|O
DDI-MedLine.d154.s0|105-108|oral|O
DDI-MedLine.d154.s0|110-123|administration|O
DDI-MedLine.d154.s0|125-126|of|O
DDI-MedLine.d154.s0|159-160|in|O
DDI-MedLine.d154.s0|162-169|chickens|O
DDI-MedLine.d154.s0|170-170|.|O
DDI-MedLine.d154.s1|0-8|Newcastle|O
DDI-MedLine.d154.s1|10-16|disease|O
DDI-MedLine.d154.s1|18-18|(|O
DDI-MedLine.d154.s1|19-20|ND|O
DDI-MedLine.d154.s1|21-21|)|O
DDI-MedLine.d154.s1|23-25|and|O
DDI-MedLine.d154.s1|27-31|avian|O
DDI-MedLine.d154.s1|33-41|influenza|O
DDI-MedLine.d154.s1|43-43|(|O
DDI-MedLine.d154.s1|44-45|AI|O
DDI-MedLine.d154.s1|46-46|)|O
DDI-MedLine.d154.s1|48-50|are|O
DDI-MedLine.d154.s1|52-57|common|O
DDI-MedLine.d154.s1|59-60|in|O
DDI-MedLine.d154.s1|62-64|the|O
DDI-MedLine.d154.s1|66-72|poultry|O
DDI-MedLine.d154.s1|74-81|industry|O
DDI-MedLine.d154.s1|82-82|.|O
DDI-MedLine.d154.s2|0-2|The|O
DDI-MedLine.d154.s2|4-12|objective|O
DDI-MedLine.d154.s2|14-15|of|O
DDI-MedLine.d154.s2|17-20|this|O
DDI-MedLine.d154.s2|22-26|study|O
DDI-MedLine.d154.s2|28-30|was|O
DDI-MedLine.d154.s2|32-33|to|O
DDI-MedLine.d154.s2|35-42|evaluate|O
DDI-MedLine.d154.s2|44-46|the|O
DDI-MedLine.d154.s2|48-53|effect|O
DDI-MedLine.d154.s2|55-56|of|O
DDI-MedLine.d154.s2|58-61|oral|O
DDI-MedLine.d154.s2|63-76|administration|O
DDI-MedLine.d154.s2|78-79|of|O
DDI-MedLine.d154.s2|112-112|(|O
DDI-MedLine.d154.s2|117-117|)|O
DDI-MedLine.d154.s2|119-120|on|O
DDI-MedLine.d154.s2|122-124|the|O
DDI-MedLine.d154.s2|126-132|humoral|O
DDI-MedLine.d154.s2|134-139|immune|O
DDI-MedLine.d154.s2|141-149|responses|O
DDI-MedLine.d154.s2|151-152|of|O
DDI-MedLine.d154.s2|154-161|chickens|O
DDI-MedLine.d154.s2|163-164|to|O
DDI-MedLine.d154.s2|166-179|inactivated ND|drug
DDI-MedLine.d154.s2|181-183|and|O
DDI-MedLine.d154.s2|185-186|AI|O
DDI-MedLine.d154.s2|188-195|vaccines|O
DDI-MedLine.d154.s2|196-196|.|O
DDI-MedLine.d154.s3|0-1|In|O
DDI-MedLine.d154.s3|3-12|experiment|O
DDI-MedLine.d154.s3|14-14|1|O
DDI-MedLine.d154.s3|15-15|,|O
DDI-MedLine.d154.s3|17-20|oral|O
DDI-MedLine.d154.s3|22-35|administration|O
DDI-MedLine.d154.s3|37-38|of|O
DDI-MedLine.d154.s3|45-46|at|O
DDI-MedLine.d154.s3|48-48|a|O
DDI-MedLine.d154.s3|50-53|dose|O
DDI-MedLine.d154.s3|55-56|of|O
DDI-MedLine.d154.s3|58-58|5|O
DDI-MedLine.d154.s3|60-64|mg/kg|O
DDI-MedLine.d154.s3|66-67|of|O
DDI-MedLine.d154.s3|69-70|BW|O
DDI-MedLine.d154.s3|72-74|for|O
DDI-MedLine.d154.s3|76-76|7|O
DDI-MedLine.d154.s3|78-78|d|O
DDI-MedLine.d154.s3|80-81|on|O
DDI-MedLine.d154.s3|83-85|the|O
DDI-MedLine.d154.s3|87-92|immune|O
DDI-MedLine.d154.s3|94-101|response|O
DDI-MedLine.d154.s3|103-104|in|O
DDI-MedLine.d154.s3|106-113|chickens|O
DDI-MedLine.d154.s3|115-129|intramuscularly|O
DDI-MedLine.d154.s3|131-138|injected|O
DDI-MedLine.d154.s3|140-143|with|O
DDI-MedLine.d154.s3|145-166|inactivated ND vaccine|drug
DDI-MedLine.d154.s3|168-170|was|O
DDI-MedLine.d154.s3|172-180|evaluated|O
DDI-MedLine.d154.s3|181-181|.|O
DDI-MedLine.d154.s4|0-6|Results|O
DDI-MedLine.d154.s4|8-13|showed|O
DDI-MedLine.d154.s4|15-18|that|O
DDI-MedLine.d154.s4|25-37|significantly|O
DDI-MedLine.d154.s4|39-47|increased|O
DDI-MedLine.d154.s4|49-51|the|O
DDI-MedLine.d154.s4|53-60|antibody|O
DDI-MedLine.d154.s4|62-66|level|O
DDI-MedLine.d154.s4|68-74|against|O
DDI-MedLine.d154.s4|76-77|ND|O
DDI-MedLine.d154.s4|79-80|in|O
DDI-MedLine.d154.s4|82-84|the|O
DDI-MedLine.d154.s4|86-90|serum|O
DDI-MedLine.d154.s4|92-93|of|O
DDI-MedLine.d154.s4|95-102|chickens|O
DDI-MedLine.d154.s4|103-103|.|O
DDI-MedLine.d154.s5|0-1|In|O
DDI-MedLine.d154.s5|3-12|experiment|O
DDI-MedLine.d154.s5|14-14|2|O
DDI-MedLine.d154.s5|15-15|,|O
DDI-MedLine.d154.s5|17-19|the|O
DDI-MedLine.d154.s5|21-24|same|O
DDI-MedLine.d154.s5|26-32|regimen|O
DDI-MedLine.d154.s5|34-35|of|O
DDI-MedLine.d154.s5|42-44|was|O
DDI-MedLine.d154.s5|46-57|administered|O
DDI-MedLine.d154.s5|59-60|to|O
DDI-MedLine.d154.s5|62-69|chickens|O
DDI-MedLine.d154.s5|71-80|inoculated|O
DDI-MedLine.d154.s5|82-85|with|O
DDI-MedLine.d154.s5|87-109|inactivated AI vaccines|drug
DDI-MedLine.d154.s5|110-110|,|O
DDI-MedLine.d154.s5|112-114|and|O
DDI-MedLine.d154.s5|116-117|an|O
DDI-MedLine.d154.s5|119-126|enhanced|O
DDI-MedLine.d154.s5|128-132|serum|O
DDI-MedLine.d154.s5|134-141|antibody|O
DDI-MedLine.d154.s5|143-150|response|O
DDI-MedLine.d154.s5|152-153|to|O
DDI-MedLine.d154.s5|155-156|AI|O
DDI-MedLine.d154.s5|158-168|vaccination|O
DDI-MedLine.d154.s5|170-172|was|O
DDI-MedLine.d154.s5|174-177|also|O
DDI-MedLine.d154.s5|179-186|observed|O
DDI-MedLine.d154.s5|187-187|.|O
DDI-MedLine.d154.s6|0-10|Considering|O
DDI-MedLine.d154.s6|12-14|the|O
DDI-MedLine.d154.s6|16-21|safety|O
DDI-MedLine.d154.s6|23-24|of|O
DDI-MedLine.d154.s6|30-30|,|O
DDI-MedLine.d154.s6|32-38|because|O
DDI-MedLine.d154.s6|40-41|no|O
DDI-MedLine.d154.s6|43-49|adverse|O
DDI-MedLine.d154.s6|51-56|effect|O
DDI-MedLine.d154.s6|58-60|was|O
DDI-MedLine.d154.s6|62-66|found|O
DDI-MedLine.d154.s6|68-77|throughout|O
DDI-MedLine.d154.s6|79-81|the|O
DDI-MedLine.d154.s6|83-93|experiments|O
DDI-MedLine.d154.s6|94-94|,|O
DDI-MedLine.d154.s6|101-103|may|O
DDI-MedLine.d154.s6|105-106|be|O
DDI-MedLine.d154.s6|108-108|a|O
DDI-MedLine.d154.s6|110-118|promising|O
DDI-MedLine.d154.s6|120-123|oral|O
DDI-MedLine.d154.s6|125-132|adjuvant|O
DDI-MedLine.d154.s6|134-135|to|O
DDI-MedLine.d154.s6|137-143|improve|O
DDI-MedLine.d154.s6|145-156|immunization|O
DDI-MedLine.d154.s6|158-159|in|O
DDI-MedLine.d154.s6|161-167|poultry|O
DDI-MedLine.d154.s6|168-168|.|O
DDI-DrugBank.d242.s0|0-7|Specific|O
DDI-DrugBank.d242.s0|9-12|drug|O
DDI-DrugBank.d242.s0|14-24|interaction|O
DDI-DrugBank.d242.s0|26-32|studies|O
DDI-DrugBank.d242.s0|34-37|have|O
DDI-DrugBank.d242.s0|39-41|not|O
DDI-DrugBank.d242.s0|43-46|been|O
DDI-DrugBank.d242.s0|48-56|conducted|O
DDI-DrugBank.d242.s0|58-61|with|O
DDI-DrugBank.d242.s0|63-74|Levofloxacin|drug
DDI-DrugBank.d242.s0|75-75|.|O
DDI-DrugBank.d242.s1|0-6|However|O
DDI-DrugBank.d242.s1|7-7|,|O
DDI-DrugBank.d242.s1|9-11|the|O
DDI-DrugBank.d242.s1|13-20|systemic|O
DDI-DrugBank.d242.s1|22-35|administration|O
DDI-DrugBank.d242.s1|37-38|of|O
DDI-DrugBank.d242.s1|40-43|some|O
DDI-DrugBank.d242.s1|45-54|quinolones|group
DDI-DrugBank.d242.s1|56-58|has|O
DDI-DrugBank.d242.s1|60-63|been|O
DDI-DrugBank.d242.s1|65-69|shown|O
DDI-DrugBank.d242.s1|71-72|to|O
DDI-DrugBank.d242.s1|74-80|elevate|O
DDI-DrugBank.d242.s1|82-87|plasma|O
DDI-DrugBank.d242.s1|89-102|concentrations|O
DDI-DrugBank.d242.s1|104-105|of|O
DDI-DrugBank.d242.s1|107-118|theophylline|drug
DDI-DrugBank.d242.s1|119-119|,|O
DDI-DrugBank.d242.s1|121-129|interfere|O
DDI-DrugBank.d242.s1|131-134|with|O
DDI-DrugBank.d242.s1|136-138|the|O
DDI-DrugBank.d242.s1|140-149|metabolism|O
DDI-DrugBank.d242.s1|151-152|of|O
DDI-DrugBank.d242.s1|154-161|caffeine|drug
DDI-DrugBank.d242.s1|162-162|,|O
DDI-DrugBank.d242.s1|164-166|and|O
DDI-DrugBank.d242.s1|168-174|enhance|O
DDI-DrugBank.d242.s1|176-178|the|O
DDI-DrugBank.d242.s1|180-186|effects|O
DDI-DrugBank.d242.s1|188-189|of|O
DDI-DrugBank.d242.s1|191-193|the|O
DDI-DrugBank.d242.s1|195-198|oral|O
DDI-DrugBank.d242.s1|200-212|anticoagulant|group
DDI-DrugBank.d242.s1|200-212|anticoagulant|group
DDI-DrugBank.d242.s1|223-225|and|O
DDI-DrugBank.d242.s1|227-229|its|O
DDI-DrugBank.d242.s1|231-241|derivatives|O
DDI-DrugBank.d242.s1|242-242|,|O
DDI-DrugBank.d242.s1|244-246|and|O
DDI-DrugBank.d242.s1|248-250|has|O
DDI-DrugBank.d242.s1|252-255|been|O
DDI-DrugBank.d242.s1|257-266|associated|O
DDI-DrugBank.d242.s1|268-271|with|O
DDI-DrugBank.d242.s1|273-281|transient|O
DDI-DrugBank.d242.s1|283-292|elevations|O
DDI-DrugBank.d242.s1|294-295|in|O
DDI-DrugBank.d242.s1|297-301|serum|O
DDI-DrugBank.d242.s1|303-312|creatinine|O
DDI-DrugBank.d242.s1|314-315|in|O
DDI-DrugBank.d242.s1|317-324|patients|O
DDI-DrugBank.d242.s1|326-334|receiving|O
DDI-DrugBank.d242.s1|336-343|systemic|O
DDI-DrugBank.d242.s1|345-356|cyclosporine|drug
DDI-DrugBank.d242.s1|358-370|concomitantly|O
DDI-DrugBank.d242.s1|371-371|.|O
DDI-DrugBank.d627.s0|0-10|Pilocarpine|drug
DDI-DrugBank.d627.s0|12-17|should|O
DDI-DrugBank.d627.s0|19-20|be|O
DDI-DrugBank.d627.s0|22-33|administered|O
DDI-DrugBank.d627.s0|35-38|with|O
DDI-DrugBank.d627.s0|40-46|caution|O
DDI-DrugBank.d627.s0|48-49|to|O
DDI-DrugBank.d627.s0|51-58|patients|O
DDI-DrugBank.d627.s0|60-65|taking|O
DDI-DrugBank.d627.s0|67-93|beta adrenergic antagonists|group
DDI-DrugBank.d627.s0|95-101|because|O
DDI-DrugBank.d627.s0|103-104|of|O
DDI-DrugBank.d627.s0|106-108|the|O
DDI-DrugBank.d627.s0|110-120|possibility|O
DDI-DrugBank.d627.s0|122-123|of|O
DDI-DrugBank.d627.s0|125-134|conduction|O
DDI-DrugBank.d627.s0|136-147|disturbances|O
DDI-DrugBank.d627.s0|148-148|.|O
DDI-DrugBank.d627.s1|0-4|Drugs|O
DDI-DrugBank.d627.s1|6-9|with|O
DDI-DrugBank.d627.s1|11-29|parasympathomimetic|O
DDI-DrugBank.d627.s1|31-37|effects|O
DDI-DrugBank.d627.s1|39-50|administered|O
DDI-DrugBank.d627.s1|52-63|concurrently|O
DDI-DrugBank.d627.s1|65-68|with|O
DDI-DrugBank.d627.s1|70-80|pilocarpine|drug
DDI-DrugBank.d627.s1|82-86|would|O
DDI-DrugBank.d627.s1|88-89|be|O
DDI-DrugBank.d627.s1|91-98|expected|O
DDI-DrugBank.d627.s1|100-101|to|O
DDI-DrugBank.d627.s1|103-108|result|O
DDI-DrugBank.d627.s1|110-111|in|O
DDI-DrugBank.d627.s1|113-120|additive|O
DDI-DrugBank.d627.s1|122-134|pharmacologic|O
DDI-DrugBank.d627.s1|136-142|effects|O
DDI-DrugBank.d627.s1|143-143|.|O
DDI-DrugBank.d627.s2|0-10|Pilocarpine|drug
DDI-DrugBank.d627.s2|12-16|might|O
DDI-DrugBank.d627.s2|18-27|antagonize|O
DDI-DrugBank.d627.s2|29-31|the|O
DDI-DrugBank.d627.s2|33-47|anticholinergic|O
DDI-DrugBank.d627.s2|49-55|effects|O
DDI-DrugBank.d627.s2|57-58|of|O
DDI-DrugBank.d627.s2|60-64|drugs|O
DDI-DrugBank.d627.s2|66-69|used|O
DDI-DrugBank.d627.s2|71-83|concomitantly|O
DDI-DrugBank.d627.s2|84-84|.|O
DDI-DrugBank.d627.s3|0-4|These|O
DDI-DrugBank.d627.s3|6-12|effects|O
DDI-DrugBank.d627.s3|14-19|should|O
DDI-DrugBank.d627.s3|21-22|be|O
DDI-DrugBank.d627.s3|24-33|considered|O
DDI-DrugBank.d627.s3|35-38|when|O
DDI-DrugBank.d627.s3|40-54|anticholinergic|O
DDI-DrugBank.d627.s3|56-65|properties|O
DDI-DrugBank.d627.s3|67-69|may|O
DDI-DrugBank.d627.s3|71-72|be|O
DDI-DrugBank.d627.s3|74-85|contributing|O
DDI-DrugBank.d627.s3|87-88|to|O
DDI-DrugBank.d627.s3|90-92|the|O
DDI-DrugBank.d627.s3|94-104|therapeutic|O
DDI-DrugBank.d627.s3|106-111|effect|O
DDI-DrugBank.d627.s3|113-114|of|O
DDI-DrugBank.d627.s3|116-126|concomitant|O
DDI-DrugBank.d627.s3|128-137|medication|O
DDI-DrugBank.d627.s3|139-139|(|O
DDI-DrugBank.d627.s3|140-143|e.g.|O
DDI-DrugBank.d627.s3|144-144|,|O
DDI-DrugBank.d627.s3|146-153|atropine|drug
DDI-DrugBank.d627.s3|154-154|,|O
DDI-DrugBank.d627.s3|156-162|inhaled|O
DDI-DrugBank.d627.s3|164-174|ipratropium|drug
DDI-DrugBank.d627.s3|175-175|)|O
DDI-DrugBank.d627.s3|176-176|.|O
DDI-DrugBank.d627.s4|0-4|While|O
DDI-DrugBank.d627.s4|6-7|no|O
DDI-DrugBank.d627.s4|9-14|formal|O
DDI-DrugBank.d627.s4|16-19|drug|O
DDI-DrugBank.d627.s4|21-31|interaction|O
DDI-DrugBank.d627.s4|33-39|studies|O
DDI-DrugBank.d627.s4|41-44|have|O
DDI-DrugBank.d627.s4|46-49|been|O
DDI-DrugBank.d627.s4|51-59|performed|O
DDI-DrugBank.d627.s4|60-60|,|O
DDI-DrugBank.d627.s4|62-64|the|O
DDI-DrugBank.d627.s4|66-74|following|O
DDI-DrugBank.d627.s4|76-86|concomitant|O
DDI-DrugBank.d627.s4|88-92|drugs|O
DDI-DrugBank.d627.s4|94-97|were|O
DDI-DrugBank.d627.s4|99-102|used|O
DDI-DrugBank.d627.s4|104-105|in|O
DDI-DrugBank.d627.s4|107-108|at|O
DDI-DrugBank.d627.s4|110-114|least|O
DDI-DrugBank.d627.s4|116-117|10|O
DDI-DrugBank.d627.s4|118-118|%|O
DDI-DrugBank.d627.s4|120-121|of|O
DDI-DrugBank.d627.s4|123-130|patients|O
DDI-DrugBank.d627.s4|132-133|in|O
DDI-DrugBank.d627.s4|135-140|either|O
DDI-DrugBank.d627.s4|142-143|or|O
DDI-DrugBank.d627.s4|145-148|both|O
DDI-DrugBank.d627.s4|150-151|Sj|O
DDI-DrugBank.d627.s4|155-159|grens|O
DDI-DrugBank.d627.s4|161-168|efficacy|O
DDI-DrugBank.d627.s4|170-176|studies|O
DDI-DrugBank.d627.s4|177-177|:|O
DDI-DrugBank.d627.s4|179-198|acetylsalicylic acid|drug
DDI-DrugBank.d627.s4|199-199|,|O
DDI-DrugBank.d627.s4|201-210|artificial|O
DDI-DrugBank.d627.s4|212-216|tears|O
DDI-DrugBank.d627.s4|217-217|,|O
DDI-DrugBank.d627.s4|219-225|calcium|drug
DDI-DrugBank.d627.s4|226-226|,|O
DDI-DrugBank.d627.s4|228-247|conjugated estrogens|drug
DDI-DrugBank.d627.s4|248-248|,|O
DDI-DrugBank.d627.s4|250-275|hydroxychloroquine sulfate|drug
DDI-DrugBank.d627.s4|276-276|,|O
DDI-DrugBank.d627.s4|278-286|ibuprofen|drug
DDI-DrugBank.d627.s4|287-287|,|O
DDI-DrugBank.d627.s4|289-308|levothyroxine sodium|drug
DDI-DrugBank.d627.s4|309-309|,|O
DDI-DrugBank.d627.s4|311-337|medroxyprogesterone acetate|drug
DDI-DrugBank.d627.s4|338-338|,|O
DDI-DrugBank.d627.s4|340-351|methotrexate|drug
DDI-DrugBank.d627.s4|352-352|,|O
DDI-DrugBank.d627.s4|354-366|multivitamins|group
DDI-DrugBank.d627.s4|367-367|,|O
DDI-DrugBank.d627.s4|369-376|naproxen|drug
DDI-DrugBank.d627.s4|377-377|,|O
DDI-DrugBank.d627.s4|379-388|omeprazole|drug
DDI-DrugBank.d627.s4|389-389|,|O
DDI-DrugBank.d627.s4|391-401|paracetamol|drug
DDI-DrugBank.d627.s4|402-402|,|O
DDI-DrugBank.d627.s4|404-406|and|O
DDI-DrugBank.d627.s4|408-417|prednisone|drug
DDI-DrugBank.d627.s4|418-418|.|O
DDI-DrugBank.d382.s0|0-9|Aprepitant|drug
DDI-DrugBank.d382.s0|11-12|is|O
DDI-DrugBank.d382.s0|14-14|a|O
DDI-DrugBank.d382.s0|16-24|substrate|O
DDI-DrugBank.d382.s0|25-25|,|O
DDI-DrugBank.d382.s0|27-27|a|O
DDI-DrugBank.d382.s0|29-36|moderate|O
DDI-DrugBank.d382.s0|38-46|inhibitor|O
DDI-DrugBank.d382.s0|47-47|,|O
DDI-DrugBank.d382.s0|49-51|and|O
DDI-DrugBank.d382.s0|53-54|an|O
DDI-DrugBank.d382.s0|56-62|inducer|O
DDI-DrugBank.d382.s0|64-65|of|O
DDI-DrugBank.d382.s0|67-72|CYP3A4|O
DDI-DrugBank.d382.s0|73-73|.|O
DDI-DrugBank.d382.s1|0-9|Aprepitant|drug
DDI-DrugBank.d382.s1|11-12|is|O
DDI-DrugBank.d382.s1|14-17|also|O
DDI-DrugBank.d382.s1|19-20|an|O
DDI-DrugBank.d382.s1|22-28|inducer|O
DDI-DrugBank.d382.s1|30-31|of|O
DDI-DrugBank.d382.s1|33-38|CYP2C9|O
DDI-DrugBank.d382.s1|39-39|.|O
DDI-DrugBank.d382.s2|0-5|Effect|O
DDI-DrugBank.d382.s2|7-8|of|O
DDI-DrugBank.d382.s2|10-19|aprepitant|drug
DDI-DrugBank.d382.s2|21-22|on|O
DDI-DrugBank.d382.s2|24-26|the|O
DDI-DrugBank.d382.s2|28-43|pharmacokinetics|O
DDI-DrugBank.d382.s2|45-46|of|O
DDI-DrugBank.d382.s2|48-52|other|O
DDI-DrugBank.d382.s2|54-59|agents|O
DDI-DrugBank.d382.s3|0-1|As|O
DDI-DrugBank.d382.s3|3-3|a|O
DDI-DrugBank.d382.s3|5-12|moderate|O
DDI-DrugBank.d382.s3|14-22|inhibitor|O
DDI-DrugBank.d382.s3|24-25|of|O
DDI-DrugBank.d382.s3|27-32|CYP3A4|O
DDI-DrugBank.d382.s3|33-33|,|O
DDI-DrugBank.d382.s3|35-44|aprepitant|drug
DDI-DrugBank.d382.s3|46-48|can|O
DDI-DrugBank.d382.s3|50-57|increase|O
DDI-DrugBank.d382.s3|59-64|plasma|O
DDI-DrugBank.d382.s3|66-79|concentrations|O
DDI-DrugBank.d382.s3|81-82|of|O
DDI-DrugBank.d382.s3|84-97|coadministered|O
DDI-DrugBank.d382.s3|99-107|medicinal|O
DDI-DrugBank.d382.s3|109-116|products|O
DDI-DrugBank.d382.s3|118-121|that|O
DDI-DrugBank.d382.s3|123-125|are|O
DDI-DrugBank.d382.s3|127-137|metabolized|O
DDI-DrugBank.d382.s3|139-145|through|O
DDI-DrugBank.d382.s3|147-152|CYP3A4|O
DDI-DrugBank.d382.s3|153-153|.|O
DDI-DrugBank.d382.s4|0-9|Aprepitant|drug
DDI-DrugBank.d382.s4|11-13|has|O
DDI-DrugBank.d382.s4|15-18|been|O
DDI-DrugBank.d382.s4|20-24|shown|O
DDI-DrugBank.d382.s4|26-27|to|O
DDI-DrugBank.d382.s4|29-34|induce|O
DDI-DrugBank.d382.s4|36-38|the|O
DDI-DrugBank.d382.s4|40-49|metabolism|O
DDI-DrugBank.d382.s4|51-52|of|O
DDI-DrugBank.d382.s4|54-66|S ( - ) warfarin|drug
DDI-DrugBank.d382.s4|68-70|and|O
DDI-DrugBank.d382.s4|72-82|tolbutamide|drug
DDI-DrugBank.d382.s4|83-83|,|O
DDI-DrugBank.d382.s4|85-89|which|O
DDI-DrugBank.d382.s4|91-93|are|O
DDI-DrugBank.d382.s4|95-105|metabolized|O
DDI-DrugBank.d382.s4|107-113|through|O
DDI-DrugBank.d382.s4|115-120|CYP2C9|O
DDI-DrugBank.d382.s4|121-121|.|O
DDI-DrugBank.d382.s5|0-15|Coadministration|O
DDI-DrugBank.d382.s5|17-18|of|O
DDI-DrugBank.d382.s5|20-29|Aprepitant|drug
DDI-DrugBank.d382.s5|31-34|with|O
DDI-DrugBank.d382.s5|36-40|these|O
DDI-DrugBank.d382.s5|42-46|drugs|O
DDI-DrugBank.d382.s5|48-49|or|O
DDI-DrugBank.d382.s5|51-55|other|O
DDI-DrugBank.d382.s5|57-61|drugs|O
DDI-DrugBank.d382.s5|63-66|that|O
DDI-DrugBank.d382.s5|68-70|are|O
DDI-DrugBank.d382.s5|72-76|known|O
DDI-DrugBank.d382.s5|78-79|to|O
DDI-DrugBank.d382.s5|81-82|be|O
DDI-DrugBank.d382.s5|84-94|metabolized|O
DDI-DrugBank.d382.s5|96-97|by|O
DDI-DrugBank.d382.s5|99-104|CYP2C9|O
DDI-DrugBank.d382.s5|105-105|,|O
DDI-DrugBank.d382.s5|107-110|such|O
DDI-DrugBank.d382.s5|112-113|as|O
DDI-DrugBank.d382.s5|115-123|phenytoin|drug
DDI-DrugBank.d382.s5|124-124|,|O
DDI-DrugBank.d382.s5|126-128|may|O
DDI-DrugBank.d382.s5|130-135|result|O
DDI-DrugBank.d382.s5|137-138|in|O
DDI-DrugBank.d382.s5|140-144|lower|O
DDI-DrugBank.d382.s5|146-151|plasma|O
DDI-DrugBank.d382.s5|153-166|concentrations|O
DDI-DrugBank.d382.s5|168-169|of|O
DDI-DrugBank.d382.s5|171-175|these|O
DDI-DrugBank.d382.s5|177-181|drugs|O
DDI-DrugBank.d382.s5|182-182|.|O
DDI-DrugBank.d382.s6|0-9|Aprepitant|drug
DDI-DrugBank.d382.s6|11-12|is|O
DDI-DrugBank.d382.s6|14-21|unlikely|O
DDI-DrugBank.d382.s6|23-24|to|O
DDI-DrugBank.d382.s6|26-33|interact|O
DDI-DrugBank.d382.s6|35-38|with|O
DDI-DrugBank.d382.s6|40-44|drugs|O
DDI-DrugBank.d382.s6|46-49|that|O
DDI-DrugBank.d382.s6|51-53|are|O
DDI-DrugBank.d382.s6|55-64|substrates|O
DDI-DrugBank.d382.s6|66-68|for|O
DDI-DrugBank.d382.s6|70-72|the|O
DDI-DrugBank.d382.s6|74-87|P-glycoprotein|O
DDI-DrugBank.d382.s6|89-99|transporter|O
DDI-DrugBank.d382.s6|100-100|,|O
DDI-DrugBank.d382.s6|102-103|as|O
DDI-DrugBank.d382.s6|105-116|demonstrated|O
DDI-DrugBank.d382.s6|118-119|by|O
DDI-DrugBank.d382.s6|121-123|the|O
DDI-DrugBank.d382.s6|125-128|lack|O
DDI-DrugBank.d382.s6|130-131|of|O
DDI-DrugBank.d382.s6|133-143|interaction|O
DDI-DrugBank.d382.s6|145-146|of|O
DDI-DrugBank.d382.s6|148-157|Aprepitant|drug
DDI-DrugBank.d382.s6|159-162|with|O
DDI-DrugBank.d382.s6|164-170|digoxin|drug
DDI-DrugBank.d382.s6|172-173|in|O
DDI-DrugBank.d382.s6|175-175|a|O
DDI-DrugBank.d382.s6|177-184|clinical|O
DDI-DrugBank.d382.s6|186-189|drug|O
DDI-DrugBank.d382.s6|191-201|interaction|O
DDI-DrugBank.d382.s6|203-207|study|O
DDI-DrugBank.d382.s6|208-208|.|O
DDI-DrugBank.d382.s7|0-16|5-HT3 antagonists|group
DDI-DrugBank.d382.s7|17-17|:|O
DDI-DrugBank.d382.s7|19-20|In|O
DDI-DrugBank.d382.s7|22-29|clinical|O
DDI-DrugBank.d382.s7|31-34|drug|O
DDI-DrugBank.d382.s7|36-46|interaction|O
DDI-DrugBank.d382.s7|48-54|studies|O
DDI-DrugBank.d382.s7|55-55|,|O
DDI-DrugBank.d382.s7|57-66|aprepitant|drug
DDI-DrugBank.d382.s7|68-70|did|O
DDI-DrugBank.d382.s7|72-74|not|O
DDI-DrugBank.d382.s7|76-79|have|O
DDI-DrugBank.d382.s7|81-90|clinically|O
DDI-DrugBank.d382.s7|92-100|important|O
DDI-DrugBank.d382.s7|102-108|effects|O
DDI-DrugBank.d382.s7|110-111|on|O
DDI-DrugBank.d382.s7|113-115|the|O
DDI-DrugBank.d382.s7|117-132|pharmacokinetics|O
DDI-DrugBank.d382.s7|134-135|of|O
DDI-DrugBank.d382.s7|137-147|ondansetron|drug
DDI-DrugBank.d382.s7|149-150|or|O
DDI-DrugBank.d382.s7|152-162|granisetron|drug
DDI-DrugBank.d382.s7|163-163|.|O
DDI-DrugBank.d382.s8|0-1|No|O
DDI-DrugBank.d382.s8|3-10|clinical|O
DDI-DrugBank.d382.s8|12-13|or|O
DDI-DrugBank.d382.s8|15-18|drug|O
DDI-DrugBank.d382.s8|20-30|interaction|O
DDI-DrugBank.d382.s8|32-36|study|O
DDI-DrugBank.d382.s8|38-40|was|O
DDI-DrugBank.d382.s8|42-50|conducted|O
DDI-DrugBank.d382.s8|52-55|with|O
DDI-DrugBank.d382.s8|57-66|dolasetron|drug
DDI-DrugBank.d382.s8|67-67|.|O
DDI-DrugBank.d382.s9|0-14|Corticosteroids|group
DDI-DrugBank.d382.s9|15-15|:|O
DDI-DrugBank.d382.s9|17-29|Dexamethasone|drug
DDI-DrugBank.d382.s9|30-30|:|O
DDI-DrugBank.d382.s9|32-41|Aprepitant|drug
DDI-DrugBank.d382.s9|42-42|,|O
DDI-DrugBank.d382.s9|44-47|when|O
DDI-DrugBank.d382.s9|49-53|given|O
DDI-DrugBank.d382.s9|55-56|as|O
DDI-DrugBank.d382.s9|58-58|a|O
DDI-DrugBank.d382.s9|60-66|regimen|O
DDI-DrugBank.d382.s9|68-69|of|O
DDI-DrugBank.d382.s9|71-75|125mg|O
DDI-DrugBank.d382.s9|77-80|with|O
DDI-DrugBank.d382.s9|82-94|dexamethasone|drug
DDI-DrugBank.d382.s9|96-109|coadministered|O
DDI-DrugBank.d382.s9|111-116|orally|O
DDI-DrugBank.d382.s9|118-119|as|O
DDI-DrugBank.d382.s9|121-122|20|O
DDI-DrugBank.d382.s9|124-125|mg|O
DDI-DrugBank.d382.s9|127-128|on|O
DDI-DrugBank.d382.s9|130-132|Day|O
DDI-DrugBank.d382.s9|134-134|1|O
DDI-DrugBank.d382.s9|135-135|,|O
DDI-DrugBank.d382.s9|137-139|and|O
DDI-DrugBank.d382.s9|141-150|Aprepitant|drug
DDI-DrugBank.d382.s9|152-155|when|O
DDI-DrugBank.d382.s9|157-161|given|O
DDI-DrugBank.d382.s9|163-164|as|O
DDI-DrugBank.d382.s9|166-167|80|O
DDI-DrugBank.d382.s9|169-174|mg/day|O
DDI-DrugBank.d382.s9|176-179|with|O
DDI-DrugBank.d382.s9|181-193|dexamethasone|drug
DDI-DrugBank.d382.s9|195-208|coadministered|O
DDI-DrugBank.d382.s9|210-215|orally|O
DDI-DrugBank.d382.s9|217-218|as|O
DDI-DrugBank.d382.s9|220-220|8|O
DDI-DrugBank.d382.s9|222-223|mg|O
DDI-DrugBank.d382.s9|225-226|on|O
DDI-DrugBank.d382.s9|228-231|Days|O
DDI-DrugBank.d382.s9|233-233|2|O
DDI-DrugBank.d382.s9|235-241|through|O
DDI-DrugBank.d382.s9|243-243|5|O
DDI-DrugBank.d382.s9|244-244|,|O
DDI-DrugBank.d382.s9|246-254|increased|O
DDI-DrugBank.d382.s9|256-258|the|O
DDI-DrugBank.d382.s9|260-262|AUC|O
DDI-DrugBank.d382.s9|264-265|of|O
DDI-DrugBank.d382.s9|267-279|dexamethasone|drug
DDI-DrugBank.d382.s9|280-280|,|O
DDI-DrugBank.d382.s9|282-282|a|O
DDI-DrugBank.d382.s9|284-289|CYP3A4|O
DDI-DrugBank.d382.s9|291-299|substrate|O
DDI-DrugBank.d382.s9|301-302|by|O
DDI-DrugBank.d382.s9|304-311|2.2-fold|O
DDI-DrugBank.d382.s9|312-312|,|O
DDI-DrugBank.d382.s9|314-315|on|O
DDI-DrugBank.d382.s9|317-320|Days|O
DDI-DrugBank.d382.s9|322-322|1|O
DDI-DrugBank.d382.s9|324-326|and|O
DDI-DrugBank.d382.s9|328-328|5|O
DDI-DrugBank.d382.s9|329-329|.|O
DDI-DrugBank.d382.s10|0-2|The|O
DDI-DrugBank.d382.s10|4-7|oral|O
DDI-DrugBank.d382.s10|9-21|dexamethasone|drug
DDI-DrugBank.d382.s10|23-27|doses|O
DDI-DrugBank.d382.s10|29-34|should|O
DDI-DrugBank.d382.s10|36-37|be|O
DDI-DrugBank.d382.s10|39-45|reduced|O
DDI-DrugBank.d382.s10|47-48|by|O
DDI-DrugBank.d382.s10|50-62|approximately|O
DDI-DrugBank.d382.s10|64-65|50|O
DDI-DrugBank.d382.s10|66-66|%|O
DDI-DrugBank.d382.s10|68-71|when|O
DDI-DrugBank.d382.s10|73-86|coadministered|O
DDI-DrugBank.d382.s10|88-91|with|O
DDI-DrugBank.d382.s10|93-102|Aprepitant|drug
DDI-DrugBank.d382.s10|103-103|,|O
DDI-DrugBank.d382.s10|105-106|to|O
DDI-DrugBank.d382.s10|108-114|achieve|O
DDI-DrugBank.d382.s10|116-124|exposures|O
DDI-DrugBank.d382.s10|126-127|of|O
DDI-DrugBank.d382.s10|129-141|dexamethasone|drug
DDI-DrugBank.d382.s10|143-149|similar|O
DDI-DrugBank.d382.s10|151-152|to|O
DDI-DrugBank.d382.s10|154-158|those|O
DDI-DrugBank.d382.s10|160-167|obtained|O
DDI-DrugBank.d382.s10|169-172|when|O
DDI-DrugBank.d382.s10|174-175|it|O
DDI-DrugBank.d382.s10|177-178|is|O
DDI-DrugBank.d382.s10|180-184|given|O
DDI-DrugBank.d382.s10|186-192|without|O
DDI-DrugBank.d382.s10|194-203|Aprepitant|drug
DDI-DrugBank.d382.s10|204-204|.|O
DDI-DrugBank.d382.s11|0-2|The|O
DDI-DrugBank.d382.s11|4-8|daily|O
DDI-DrugBank.d382.s11|10-13|dose|O
DDI-DrugBank.d382.s11|15-16|of|O
DDI-DrugBank.d382.s11|18-30|dexamethasone|drug
DDI-DrugBank.d382.s11|32-43|administered|O
DDI-DrugBank.d382.s11|45-46|in|O
DDI-DrugBank.d382.s11|48-55|clinical|O
DDI-DrugBank.d382.s11|57-63|studies|O
DDI-DrugBank.d382.s11|65-68|with|O
DDI-DrugBank.d382.s11|70-79|Aprepitant|drug
DDI-DrugBank.d382.s11|81-88|reflects|O
DDI-DrugBank.d382.s11|90-91|an|O
DDI-DrugBank.d382.s11|93-103|approximate|O
DDI-DrugBank.d382.s11|105-106|50|O
DDI-DrugBank.d382.s11|107-107|%|O
DDI-DrugBank.d382.s11|109-117|reduction|O
DDI-DrugBank.d382.s11|119-120|of|O
DDI-DrugBank.d382.s11|122-124|the|O
DDI-DrugBank.d382.s11|126-129|dose|O
DDI-DrugBank.d382.s11|131-132|of|O
DDI-DrugBank.d382.s11|134-146|dexamethasone|drug
DDI-DrugBank.d382.s11|147-147|.|O
DDI-DrugBank.d382.s13|0-9|Aprepitant|drug
DDI-DrugBank.d382.s13|10-10|,|O
DDI-DrugBank.d382.s13|12-15|when|O
DDI-DrugBank.d382.s13|17-21|given|O
DDI-DrugBank.d382.s13|23-24|as|O
DDI-DrugBank.d382.s13|26-26|a|O
DDI-DrugBank.d382.s13|28-34|regimen|O
DDI-DrugBank.d382.s13|36-37|of|O
DDI-DrugBank.d382.s13|39-41|125|O
DDI-DrugBank.d382.s13|43-44|mg|O
DDI-DrugBank.d382.s13|46-47|on|O
DDI-DrugBank.d382.s13|49-51|Day|O
DDI-DrugBank.d382.s13|53-53|1|O
DDI-DrugBank.d382.s13|55-57|and|O
DDI-DrugBank.d382.s13|59-60|80|O
DDI-DrugBank.d382.s13|62-67|mg/day|O
DDI-DrugBank.d382.s13|69-70|on|O
DDI-DrugBank.d382.s13|72-75|Days|O
DDI-DrugBank.d382.s13|77-77|2|O
DDI-DrugBank.d382.s13|79-81|and|O
DDI-DrugBank.d382.s13|83-83|3|O
DDI-DrugBank.d382.s13|84-84|,|O
DDI-DrugBank.d382.s13|86-94|increased|O
DDI-DrugBank.d382.s13|96-98|the|O
DDI-DrugBank.d382.s13|100-102|AUC|O
DDI-DrugBank.d382.s13|104-105|of|O
DDI-DrugBank.d382.s13|107-124|methylprednisolone|drug
DDI-DrugBank.d382.s13|125-125|,|O
DDI-DrugBank.d382.s13|127-127|a|O
DDI-DrugBank.d382.s13|129-134|CYP3A4|O
DDI-DrugBank.d382.s13|136-144|substrate|O
DDI-DrugBank.d382.s13|145-145|,|O
DDI-DrugBank.d382.s13|147-148|by|O
DDI-DrugBank.d382.s13|150-158|1.34-fold|O
DDI-DrugBank.d382.s13|160-161|on|O
DDI-DrugBank.d382.s13|163-165|Day|O
DDI-DrugBank.d382.s13|167-167|1|O
DDI-DrugBank.d382.s13|169-171|and|O
DDI-DrugBank.d382.s13|173-174|by|O
DDI-DrugBank.d382.s13|176-183|2.5-fold|O
DDI-DrugBank.d382.s13|185-186|on|O
DDI-DrugBank.d382.s13|188-190|Day|O
DDI-DrugBank.d382.s13|192-192|3|O
DDI-DrugBank.d382.s13|193-193|,|O
DDI-DrugBank.d382.s13|195-198|when|O
DDI-DrugBank.d382.s13|200-217|methylprednisolone|drug
DDI-DrugBank.d382.s13|219-221|was|O
DDI-DrugBank.d382.s13|223-236|coadministered|O
DDI-DrugBank.d382.s13|238-250|intravenously|O
DDI-DrugBank.d382.s13|252-253|as|O
DDI-DrugBank.d382.s13|255-257|125|O
DDI-DrugBank.d382.s13|259-260|mg|O
DDI-DrugBank.d382.s13|262-263|on|O
DDI-DrugBank.d382.s13|265-267|Day|O
DDI-DrugBank.d382.s13|269-269|1|O
DDI-DrugBank.d382.s13|271-273|and|O
DDI-DrugBank.d382.s13|275-280|orally|O
DDI-DrugBank.d382.s13|282-283|as|O
DDI-DrugBank.d382.s13|285-286|40|O
DDI-DrugBank.d382.s13|288-289|mg|O
DDI-DrugBank.d382.s13|291-292|on|O
DDI-DrugBank.d382.s13|294-297|Days|O
DDI-DrugBank.d382.s13|299-299|2|O
DDI-DrugBank.d382.s13|301-303|and|O
DDI-DrugBank.d382.s13|305-305|3|O
DDI-DrugBank.d382.s13|306-306|.|O
DDI-DrugBank.d382.s14|0-2|The|O
DDI-DrugBank.d382.s14|4-5|IV|O
DDI-DrugBank.d382.s14|7-24|methylprednisolone|drug
DDI-DrugBank.d382.s14|26-29|dose|O
DDI-DrugBank.d382.s14|31-36|should|O
DDI-DrugBank.d382.s14|38-39|be|O
DDI-DrugBank.d382.s14|41-47|reduced|O
DDI-DrugBank.d382.s14|49-50|by|O
DDI-DrugBank.d382.s14|52-64|approximately|O
DDI-DrugBank.d382.s14|66-67|25|O
DDI-DrugBank.d382.s14|68-68|%|O
DDI-DrugBank.d382.s14|69-69|,|O
DDI-DrugBank.d382.s14|71-73|and|O
DDI-DrugBank.d382.s14|75-77|the|O
DDI-DrugBank.d382.s14|79-82|oral|O
DDI-DrugBank.d382.s14|84-101|methylprednisolone|drug
DDI-DrugBank.d382.s14|103-106|dose|O
DDI-DrugBank.d382.s14|108-113|should|O
DDI-DrugBank.d382.s14|115-116|be|O
DDI-DrugBank.d382.s14|118-124|reduced|O
DDI-DrugBank.d382.s14|126-127|by|O
DDI-DrugBank.d382.s14|129-141|approximately|O
DDI-DrugBank.d382.s14|143-144|50|O
DDI-DrugBank.d382.s14|145-145|%|O
DDI-DrugBank.d382.s14|147-150|when|O
DDI-DrugBank.d382.s14|152-165|coadministered|O
DDI-DrugBank.d382.s14|167-170|with|O
DDI-DrugBank.d382.s14|172-181|Aprepitant|drug
DDI-DrugBank.d382.s14|183-184|to|O
DDI-DrugBank.d382.s14|186-192|achieve|O
DDI-DrugBank.d382.s14|194-202|exposures|O
DDI-DrugBank.d382.s14|204-205|of|O
DDI-DrugBank.d382.s14|207-224|methylprednisolone|drug
DDI-DrugBank.d382.s14|226-232|similar|O
DDI-DrugBank.d382.s14|234-235|to|O
DDI-DrugBank.d382.s14|237-241|those|O
DDI-DrugBank.d382.s14|243-250|obtained|O
DDI-DrugBank.d382.s14|252-255|when|O
DDI-DrugBank.d382.s14|257-258|it|O
DDI-DrugBank.d382.s14|260-261|is|O
DDI-DrugBank.d382.s14|263-267|given|O
DDI-DrugBank.d382.s14|269-275|without|O
DDI-DrugBank.d382.s14|277-286|Aprepitant|drug
DDI-DrugBank.d382.s14|287-287|.|O
DDI-DrugBank.d382.s15|0-7|Warfarin|drug
DDI-DrugBank.d382.s15|8-8|:|O
DDI-DrugBank.d382.s15|10-10|A|O
DDI-DrugBank.d382.s15|12-17|single|O
DDI-DrugBank.d382.s15|19-24|125-mg|O
DDI-DrugBank.d382.s15|26-29|dose|O
DDI-DrugBank.d382.s15|31-32|of|O
DDI-DrugBank.d382.s15|34-43|Aprepitant|drug
DDI-DrugBank.d382.s15|45-47|was|O
DDI-DrugBank.d382.s15|49-60|administered|O
DDI-DrugBank.d382.s15|62-63|on|O
DDI-DrugBank.d382.s15|65-67|Day|O
DDI-DrugBank.d382.s15|69-69|1|O
DDI-DrugBank.d382.s15|71-73|and|O
DDI-DrugBank.d382.s15|75-76|80|O
DDI-DrugBank.d382.s15|78-83|mg/day|O
DDI-DrugBank.d382.s15|85-86|on|O
DDI-DrugBank.d382.s15|88-91|Days|O
DDI-DrugBank.d382.s15|93-93|2|O
DDI-DrugBank.d382.s15|95-97|and|O
DDI-DrugBank.d382.s15|99-99|3|O
DDI-DrugBank.d382.s15|101-102|to|O
DDI-DrugBank.d382.s15|104-110|healthy|O
DDI-DrugBank.d382.s15|112-119|subjects|O
DDI-DrugBank.d382.s15|121-123|who|O
DDI-DrugBank.d382.s15|125-128|were|O
DDI-DrugBank.d382.s15|130-139|stabilized|O
DDI-DrugBank.d382.s15|141-142|on|O
DDI-DrugBank.d382.s15|144-150|chronic|O
DDI-DrugBank.d382.s15|152-159|warfarin|drug
DDI-DrugBank.d382.s15|161-167|therapy|O
DDI-DrugBank.d382.s15|168-168|.|O
DDI-DrugBank.d382.s16|0-7|Although|O
DDI-DrugBank.d382.s16|9-13|there|O
DDI-DrugBank.d382.s16|15-17|was|O
DDI-DrugBank.d382.s16|19-20|no|O
DDI-DrugBank.d382.s16|22-27|effect|O
DDI-DrugBank.d382.s16|29-30|of|O
DDI-DrugBank.d382.s16|32-41|Aprepitant|drug
DDI-DrugBank.d382.s16|43-44|on|O
DDI-DrugBank.d382.s16|46-48|the|O
DDI-DrugBank.d382.s16|50-55|plasma|O
DDI-DrugBank.d382.s16|57-59|AUC|O
DDI-DrugBank.d382.s16|61-62|of|O
DDI-DrugBank.d382.s16|64-67|R ( + )|drug
DDI-DrugBank.d382.s16|69-70|or|O
DDI-DrugBank.d382.s16|72-84|S ( - ) warfarin|drug
DDI-DrugBank.d382.s16|86-95|determined|O
DDI-DrugBank.d382.s16|97-98|on|O
DDI-DrugBank.d382.s16|100-102|Day|O
DDI-DrugBank.d382.s16|104-104|3|O
DDI-DrugBank.d382.s16|105-105|,|O
DDI-DrugBank.d382.s16|107-111|there|O
DDI-DrugBank.d382.s16|113-115|was|O
DDI-DrugBank.d382.s16|117-117|a|O
DDI-DrugBank.d382.s16|119-120|34|O
DDI-DrugBank.d382.s16|121-121|%|O
DDI-DrugBank.d382.s16|123-130|decrease|O
DDI-DrugBank.d382.s16|132-133|in|O
DDI-DrugBank.d382.s16|135-146|S ( - ) warfarin|drug
DDI-DrugBank.d382.s16|148-148|(|O
DDI-DrugBank.d382.s16|149-149|a|O
DDI-DrugBank.d382.s16|151-156|CYP2C9|O
DDI-DrugBank.d382.s16|158-166|substrate|O
DDI-DrugBank.d382.s16|167-167|)|O
DDI-DrugBank.d382.s16|169-174|trough|O
DDI-DrugBank.d382.s16|176-188|concentration|O
DDI-DrugBank.d382.s16|190-200|accompanied|O
DDI-DrugBank.d382.s16|202-203|by|O
DDI-DrugBank.d382.s16|205-205|a|O
DDI-DrugBank.d382.s16|207-208|14|O
DDI-DrugBank.d382.s16|209-209|%|O
DDI-DrugBank.d382.s16|211-218|decrease|O
DDI-DrugBank.d382.s16|220-221|in|O
DDI-DrugBank.d382.s16|223-225|the|O
DDI-DrugBank.d382.s16|227-237|prothrombin|O
DDI-DrugBank.d382.s16|239-242|time|O
DDI-DrugBank.d382.s16|244-244|(|O
DDI-DrugBank.d382.s16|245-252|reported|O
DDI-DrugBank.d382.s16|254-255|as|O
DDI-DrugBank.d382.s16|257-269|International|O
DDI-DrugBank.d382.s16|271-280|Normalized|O
DDI-DrugBank.d382.s16|282-286|Ratio|O
DDI-DrugBank.d382.s16|288-289|or|O
DDI-DrugBank.d382.s16|291-293|INR|O
DDI-DrugBank.d382.s16|294-294|)|O
DDI-DrugBank.d382.s16|296-296|5|O
DDI-DrugBank.d382.s16|298-301|days|O
DDI-DrugBank.d382.s16|303-307|after|O
DDI-DrugBank.d382.s16|309-318|completion|O
DDI-DrugBank.d382.s16|320-321|of|O
DDI-DrugBank.d382.s16|323-328|dosing|O
DDI-DrugBank.d382.s16|330-333|with|O
DDI-DrugBank.d382.s16|335-344|Aprepitant|drug
DDI-DrugBank.d382.s16|345-345|.|O
DDI-DrugBank.d382.s17|0-1|In|O
DDI-DrugBank.d382.s17|3-10|patients|O
DDI-DrugBank.d382.s17|12-13|on|O
DDI-DrugBank.d382.s17|15-21|chronic|O
DDI-DrugBank.d382.s17|23-30|warfarin|drug
DDI-DrugBank.d382.s17|32-38|therapy|O
DDI-DrugBank.d382.s17|39-39|,|O
DDI-DrugBank.d382.s17|41-43|the|O
DDI-DrugBank.d382.s17|45-55|prothrombin|O
DDI-DrugBank.d382.s17|57-60|time|O
DDI-DrugBank.d382.s17|62-62|(|O
DDI-DrugBank.d382.s17|63-65|INR|O
DDI-DrugBank.d382.s17|66-66|)|O
DDI-DrugBank.d382.s17|68-73|should|O
DDI-DrugBank.d382.s17|75-76|be|O
DDI-DrugBank.d382.s17|78-84|closely|O
DDI-DrugBank.d382.s17|86-94|monitored|O
DDI-DrugBank.d382.s17|96-97|in|O
DDI-DrugBank.d382.s17|99-101|the|O
DDI-DrugBank.d382.s17|103-108|2-week|O
DDI-DrugBank.d382.s17|110-115|period|O
DDI-DrugBank.d382.s17|116-116|,|O
DDI-DrugBank.d382.s17|118-129|particularly|O
DDI-DrugBank.d382.s17|131-132|at|O
DDI-DrugBank.d382.s17|134-134|7|O
DDI-DrugBank.d382.s17|136-137|to|O
DDI-DrugBank.d382.s17|139-140|10|O
DDI-DrugBank.d382.s17|142-145|days|O
DDI-DrugBank.d382.s17|146-146|,|O
DDI-DrugBank.d382.s17|148-156|following|O
DDI-DrugBank.d382.s17|158-167|initiation|O
DDI-DrugBank.d382.s17|169-170|of|O
DDI-DrugBank.d382.s17|172-174|the|O
DDI-DrugBank.d382.s17|176-180|3-day|O
DDI-DrugBank.d382.s17|182-188|regimen|O
DDI-DrugBank.d382.s17|190-191|of|O
DDI-DrugBank.d382.s17|193-202|Aprepitant|drug
DDI-DrugBank.d382.s17|204-207|with|O
DDI-DrugBank.d382.s17|209-212|each|O
DDI-DrugBank.d382.s17|214-225|chemotherapy|O
DDI-DrugBank.d382.s17|227-231|cycle|O
DDI-DrugBank.d382.s17|232-232|.|O
DDI-DrugBank.d382.s18|0-10|Tolbutamide|drug
DDI-DrugBank.d382.s18|11-11|:|O
DDI-DrugBank.d382.s18|13-22|Aprepitant|drug
DDI-DrugBank.d382.s18|23-23|,|O
DDI-DrugBank.d382.s18|25-28|when|O
DDI-DrugBank.d382.s18|30-34|given|O
DDI-DrugBank.d382.s18|36-37|as|O
DDI-DrugBank.d382.s18|39-41|125|O
DDI-DrugBank.d382.s18|43-44|mg|O
DDI-DrugBank.d382.s18|46-47|on|O
DDI-DrugBank.d382.s18|49-51|Day|O
DDI-DrugBank.d382.s18|53-53|1|O
DDI-DrugBank.d382.s18|55-57|and|O
DDI-DrugBank.d382.s18|59-60|80|O
DDI-DrugBank.d382.s18|62-67|mg/day|O
DDI-DrugBank.d382.s18|69-70|on|O
DDI-DrugBank.d382.s18|72-75|Days|O
DDI-DrugBank.d382.s18|77-77|2|O
DDI-DrugBank.d382.s18|79-81|and|O
DDI-DrugBank.d382.s18|83-83|3|O
DDI-DrugBank.d382.s18|84-84|,|O
DDI-DrugBank.d382.s18|86-94|decreased|O
DDI-DrugBank.d382.s18|96-98|the|O
DDI-DrugBank.d382.s18|100-102|AUC|O
DDI-DrugBank.d382.s18|104-105|of|O
DDI-DrugBank.d382.s18|107-117|tolbutamide|drug
DDI-DrugBank.d382.s18|119-119|(|O
DDI-DrugBank.d382.s18|120-120|a|O
DDI-DrugBank.d382.s18|122-127|CYP2C9|O
DDI-DrugBank.d382.s18|129-137|substrate|O
DDI-DrugBank.d382.s18|138-138|)|O
DDI-DrugBank.d382.s18|140-141|by|O
DDI-DrugBank.d382.s18|143-144|23|O
DDI-DrugBank.d382.s18|145-145|%|O
DDI-DrugBank.d382.s18|147-148|on|O
DDI-DrugBank.d382.s18|150-152|Day|O
DDI-DrugBank.d382.s18|154-154|4|O
DDI-DrugBank.d382.s18|155-155|,|O
DDI-DrugBank.d382.s18|157-158|28|O
DDI-DrugBank.d382.s18|159-159|%|O
DDI-DrugBank.d382.s18|161-162|on|O
DDI-DrugBank.d382.s18|164-166|Day|O
DDI-DrugBank.d382.s18|168-168|8|O
DDI-DrugBank.d382.s18|169-169|,|O
DDI-DrugBank.d382.s18|171-173|and|O
DDI-DrugBank.d382.s18|175-176|15|O
DDI-DrugBank.d382.s18|177-177|%|O
DDI-DrugBank.d382.s18|179-180|on|O
DDI-DrugBank.d382.s18|182-184|Day|O
DDI-DrugBank.d382.s18|186-187|15|O
DDI-DrugBank.d382.s18|188-188|,|O
DDI-DrugBank.d382.s18|190-193|when|O
DDI-DrugBank.d382.s18|195-195|a|O
DDI-DrugBank.d382.s18|197-202|single|O
DDI-DrugBank.d382.s18|204-207|dose|O
DDI-DrugBank.d382.s18|209-210|of|O
DDI-DrugBank.d382.s18|212-222|tolbutamide|drug
DDI-DrugBank.d382.s18|224-226|500|O
DDI-DrugBank.d382.s18|228-229|mg|O
DDI-DrugBank.d382.s18|231-233|was|O
DDI-DrugBank.d382.s18|235-240|admini|O
DDI-DrugBank.d382.s18|241-241|,|O
DDI-DrugBank.d382.s18|242-247|stered|O
DDI-DrugBank.d382.s18|249-254|orally|O
DDI-DrugBank.d382.s18|256-260|prior|O
DDI-DrugBank.d382.s18|262-263|to|O
DDI-DrugBank.d382.s18|265-267|the|O
DDI-DrugBank.d382.s18|269-282|administration|O
DDI-DrugBank.d382.s18|284-285|of|O
DDI-DrugBank.d382.s18|287-289|the|O
DDI-DrugBank.d382.s18|291-295|3-day|O
DDI-DrugBank.d382.s18|297-303|regimen|O
DDI-DrugBank.d382.s18|305-306|of|O
DDI-DrugBank.d382.s18|308-317|Aprepitant|drug
DDI-DrugBank.d382.s18|319-321|and|O
DDI-DrugBank.d382.s18|323-324|on|O
DDI-DrugBank.d382.s18|326-329|Days|O
DDI-DrugBank.d382.s18|331-333|4,8|O
DDI-DrugBank.d382.s18|334-334|,|O
DDI-DrugBank.d382.s18|336-338|and|O
DDI-DrugBank.d382.s18|340-341|15|O
DDI-DrugBank.d382.s18|342-342|.|O
DDI-DrugBank.d382.s19|0-3|Oral|O
DDI-DrugBank.d382.s19|5-18|contraceptives|group
DDI-DrugBank.d382.s19|19-19|:|O
DDI-DrugBank.d382.s19|21-30|Aprepitant|drug
DDI-DrugBank.d382.s19|31-31|,|O
DDI-DrugBank.d382.s19|33-36|when|O
DDI-DrugBank.d382.s19|38-42|given|O
DDI-DrugBank.d382.s19|44-47|once|O
DDI-DrugBank.d382.s19|49-53|daily|O
DDI-DrugBank.d382.s19|55-57|for|O
DDI-DrugBank.d382.s19|59-60|14|O
DDI-DrugBank.d382.s19|62-65|days|O
DDI-DrugBank.d382.s19|67-68|as|O
DDI-DrugBank.d382.s19|70-70|a|O
DDI-DrugBank.d382.s19|72-77|100-mg|O
DDI-DrugBank.d382.s19|79-85|capsule|O
DDI-DrugBank.d382.s19|87-90|with|O
DDI-DrugBank.d382.s19|92-93|an|O
DDI-DrugBank.d382.s19|95-98|oral|O
DDI-DrugBank.d382.s19|100-112|contraceptive|group
DDI-DrugBank.d382.s19|114-123|containing|O
DDI-DrugBank.d382.s19|125-126|35|O
DDI-DrugBank.d382.s19|128-130|mcg|O
DDI-DrugBank.d382.s19|132-133|of|O
DDI-DrugBank.d382.s19|135-151|ethinyl estradiol|drug
DDI-DrugBank.d382.s19|153-155|and|O
DDI-DrugBank.d382.s19|157-157|1|O
DDI-DrugBank.d382.s19|159-160|mg|O
DDI-DrugBank.d382.s19|162-163|of|O
DDI-DrugBank.d382.s19|165-177|norethindrone|drug
DDI-DrugBank.d382.s19|178-178|,|O
DDI-DrugBank.d382.s19|180-188|decreased|O
DDI-DrugBank.d382.s19|190-192|the|O
DDI-DrugBank.d382.s19|194-196|AUC|O
DDI-DrugBank.d382.s19|198-199|of|O
DDI-DrugBank.d382.s19|201-217|ethinyl estradiol|drug
DDI-DrugBank.d382.s19|219-220|by|O
DDI-DrugBank.d382.s19|222-223|43|O
DDI-DrugBank.d382.s19|224-224|%|O
DDI-DrugBank.d382.s19|225-225|,|O
DDI-DrugBank.d382.s19|227-229|and|O
DDI-DrugBank.d382.s19|231-239|decreased|O
DDI-DrugBank.d382.s19|241-243|the|O
DDI-DrugBank.d382.s19|245-247|AUC|O
DDI-DrugBank.d382.s19|249-250|of|O
DDI-DrugBank.d382.s19|252-264|norethindrone|drug
DDI-DrugBank.d382.s19|266-267|by|O
DDI-DrugBank.d382.s19|269-269|8|O
DDI-DrugBank.d382.s19|270-270|%|O
DDI-DrugBank.d382.s19|271-271|;|O
DDI-DrugBank.d382.s20|0-8|therefore|O
DDI-DrugBank.d382.s20|9-9|,|O
DDI-DrugBank.d382.s20|11-13|the|O
DDI-DrugBank.d382.s20|15-22|efficacy|O
DDI-DrugBank.d382.s20|24-25|of|O
DDI-DrugBank.d382.s20|27-30|oral|O
DDI-DrugBank.d382.s20|32-45|contraceptives|group
DDI-DrugBank.d382.s20|47-52|during|O
DDI-DrugBank.d382.s20|54-67|administration|O
DDI-DrugBank.d382.s20|69-70|of|O
DDI-DrugBank.d382.s20|72-81|Aprepitant|drug
DDI-DrugBank.d382.s20|83-85|may|O
DDI-DrugBank.d382.s20|87-88|be|O
DDI-DrugBank.d382.s20|90-96|reduced|O
DDI-DrugBank.d382.s20|97-97|.|O
DDI-DrugBank.d382.s21|0-7|Although|O
DDI-DrugBank.d382.s21|9-9|a|O
DDI-DrugBank.d382.s21|11-15|3-day|O
DDI-DrugBank.d382.s21|17-23|regimen|O
DDI-DrugBank.d382.s21|25-26|of|O
DDI-DrugBank.d382.s21|28-37|Aprepitant|drug
DDI-DrugBank.d382.s21|39-43|given|O
DDI-DrugBank.d382.s21|45-57|concomitantly|O
DDI-DrugBank.d382.s21|59-62|with|O
DDI-DrugBank.d382.s21|64-67|oral|O
DDI-DrugBank.d382.s21|69-82|contraceptives|group
DDI-DrugBank.d382.s21|84-86|has|O
DDI-DrugBank.d382.s21|88-90|not|O
DDI-DrugBank.d382.s21|92-95|been|O
DDI-DrugBank.d382.s21|97-103|studied|O
DDI-DrugBank.d382.s21|104-104|,|O
DDI-DrugBank.d382.s21|106-116|alternative|O
DDI-DrugBank.d382.s21|118-119|or|O
DDI-DrugBank.d382.s21|121-127|back-up|O
DDI-DrugBank.d382.s21|129-135|methods|O
DDI-DrugBank.d382.s21|137-138|of|O
DDI-DrugBank.d382.s21|140-152|contraception|O
DDI-DrugBank.d382.s21|154-159|should|O
DDI-DrugBank.d382.s21|161-162|be|O
DDI-DrugBank.d382.s21|164-167|used|O
DDI-DrugBank.d382.s21|168-168|.|O
DDI-DrugBank.d382.s22|0-8|Midazolam|drug
DDI-DrugBank.d382.s22|9-9|:|O
DDI-DrugBank.d382.s22|11-20|Aprepitant|drug
DDI-DrugBank.d382.s22|22-30|increased|O
DDI-DrugBank.d382.s22|32-34|the|O
DDI-DrugBank.d382.s22|36-38|AUC|O
DDI-DrugBank.d382.s22|40-41|of|O
DDI-DrugBank.d382.s22|43-51|midazolam|drug
DDI-DrugBank.d382.s22|52-52|,|O
DDI-DrugBank.d382.s22|54-54|a|O
DDI-DrugBank.d382.s22|56-64|sensitive|O
DDI-DrugBank.d382.s22|66-71|CYP3A4|O
DDI-DrugBank.d382.s22|73-81|substrate|O
DDI-DrugBank.d382.s22|82-82|,|O
DDI-DrugBank.d382.s22|84-85|by|O
DDI-DrugBank.d382.s22|87-94|2.3-fold|O
DDI-DrugBank.d382.s22|96-97|on|O
DDI-DrugBank.d382.s22|99-101|Day|O
DDI-DrugBank.d382.s22|103-103|1|O
DDI-DrugBank.d382.s22|105-107|and|O
DDI-DrugBank.d382.s22|109-116|3.3-fold|O
DDI-DrugBank.d382.s22|118-119|on|O
DDI-DrugBank.d382.s22|121-123|Day|O
DDI-DrugBank.d382.s22|125-125|5|O
DDI-DrugBank.d382.s22|126-126|,|O
DDI-DrugBank.d382.s22|128-131|when|O
DDI-DrugBank.d382.s22|133-133|a|O
DDI-DrugBank.d382.s22|135-140|single|O
DDI-DrugBank.d382.s22|142-145|oral|O
DDI-DrugBank.d382.s22|147-150|dose|O
DDI-DrugBank.d382.s22|152-153|of|O
DDI-DrugBank.d382.s22|155-163|midazolam|drug
DDI-DrugBank.d382.s22|165-165|2|O
DDI-DrugBank.d382.s22|167-168|mg|O
DDI-DrugBank.d382.s22|170-172|was|O
DDI-DrugBank.d382.s22|174-187|coadministered|O
DDI-DrugBank.d382.s22|189-190|on|O
DDI-DrugBank.d382.s22|192-194|Day|O
DDI-DrugBank.d382.s22|196-196|1|O
DDI-DrugBank.d382.s22|198-200|and|O
DDI-DrugBank.d382.s22|202-204|Day|O
DDI-DrugBank.d382.s22|206-206|5|O
DDI-DrugBank.d382.s22|208-209|of|O
DDI-DrugBank.d382.s22|211-211|a|O
DDI-DrugBank.d382.s22|213-219|regimen|O
DDI-DrugBank.d382.s22|221-222|of|O
DDI-DrugBank.d382.s22|224-233|Aprepitant|drug
DDI-DrugBank.d382.s22|235-237|125|O
DDI-DrugBank.d382.s22|239-240|mg|O
DDI-DrugBank.d382.s22|242-243|on|O
DDI-DrugBank.d382.s22|245-247|Day|O
DDI-DrugBank.d382.s22|249-249|1|O
DDI-DrugBank.d382.s22|251-253|and|O
DDI-DrugBank.d382.s22|255-256|80|O
DDI-DrugBank.d382.s22|258-263|mg/day|O
DDI-DrugBank.d382.s22|265-266|on|O
DDI-DrugBank.d382.s22|268-271|Days|O
DDI-DrugBank.d382.s22|273-273|2|O
DDI-DrugBank.d382.s22|275-281|through|O
DDI-DrugBank.d382.s22|283-283|5|O
DDI-DrugBank.d382.s22|284-284|.|O
DDI-DrugBank.d382.s23|0-2|The|O
DDI-DrugBank.d382.s23|4-12|potential|O
DDI-DrugBank.d382.s23|14-20|effects|O
DDI-DrugBank.d382.s23|22-23|of|O
DDI-DrugBank.d382.s23|25-33|increased|O
DDI-DrugBank.d382.s23|35-40|plasma|O
DDI-DrugBank.d382.s23|42-55|concentrations|O
DDI-DrugBank.d382.s23|57-58|of|O
DDI-DrugBank.d382.s23|60-68|midazolam|drug
DDI-DrugBank.d382.s23|70-71|or|O
DDI-DrugBank.d382.s23|73-77|other|O
DDI-DrugBank.d382.s23|79-93|benzodiazepines|group
DDI-DrugBank.d382.s23|95-105|metabolized|O
DDI-DrugBank.d382.s23|107-109|via|O
DDI-DrugBank.d382.s23|111-116|CYP3A4|O
DDI-DrugBank.d382.s23|118-118|(|O
DDI-DrugBank.d382.s23|119-128|alprazolam|drug
DDI-DrugBank.d382.s23|129-129|,|O
DDI-DrugBank.d382.s23|131-139|triazolam|drug
DDI-DrugBank.d382.s23|140-140|)|O
DDI-DrugBank.d382.s23|142-147|should|O
DDI-DrugBank.d382.s23|149-150|be|O
DDI-DrugBank.d382.s23|152-161|considered|O
DDI-DrugBank.d382.s23|163-166|when|O
DDI-DrugBank.d382.s23|168-182|coadministering|O
DDI-DrugBank.d382.s23|184-188|these|O
DDI-DrugBank.d382.s23|190-195|agents|O
DDI-DrugBank.d382.s23|197-200|with|O
DDI-DrugBank.d382.s23|202-211|Aprepitant|drug
DDI-DrugBank.d382.s23|212-212|.|O
DDI-DrugBank.d382.s24|0-1|In|O
DDI-DrugBank.d382.s24|3-9|another|O
DDI-DrugBank.d382.s24|11-15|study|O
DDI-DrugBank.d382.s24|17-20|with|O
DDI-DrugBank.d382.s24|22-32|intravenous|O
DDI-DrugBank.d382.s24|34-47|administration|O
DDI-DrugBank.d382.s24|49-50|of|O
DDI-DrugBank.d382.s24|52-60|midazolam|drug
DDI-DrugBank.d382.s24|61-61|,|O
DDI-DrugBank.d382.s24|63-72|Aprepitant|drug
DDI-DrugBank.d382.s24|74-76|was|O
DDI-DrugBank.d382.s24|78-82|given|O
DDI-DrugBank.d382.s24|84-85|as|O
DDI-DrugBank.d382.s24|87-89|125|O
DDI-DrugBank.d382.s24|91-92|mg|O
DDI-DrugBank.d382.s24|94-95|on|O
DDI-DrugBank.d382.s24|97-99|Day|O
DDI-DrugBank.d382.s24|101-101|1|O
DDI-DrugBank.d382.s24|103-105|and|O
DDI-DrugBank.d382.s24|107-108|80|O
DDI-DrugBank.d382.s24|110-115|mg/day|O
DDI-DrugBank.d382.s24|117-118|on|O
DDI-DrugBank.d382.s24|120-123|Days|O
DDI-DrugBank.d382.s24|125-125|2|O
DDI-DrugBank.d382.s24|127-129|and|O
DDI-DrugBank.d382.s24|131-131|3|O
DDI-DrugBank.d382.s24|132-132|,|O
DDI-DrugBank.d382.s24|134-136|and|O
DDI-DrugBank.d382.s24|138-146|midazolam|drug
DDI-DrugBank.d382.s24|148-148|2|O
DDI-DrugBank.d382.s24|150-151|mg|O
DDI-DrugBank.d382.s24|153-154|IV|O
DDI-DrugBank.d382.s24|156-158|was|O
DDI-DrugBank.d382.s24|160-164|given|O
DDI-DrugBank.d382.s24|166-170|prior|O
DDI-DrugBank.d382.s24|172-173|to|O
DDI-DrugBank.d382.s24|175-177|the|O
DDI-DrugBank.d382.s24|179-192|administration|O
DDI-DrugBank.d382.s24|194-195|of|O
DDI-DrugBank.d382.s24|197-199|the|O
DDI-DrugBank.d382.s24|201-205|3-day|O
DDI-DrugBank.d382.s24|207-213|regimen|O
DDI-DrugBank.d382.s24|215-216|of|O
DDI-DrugBank.d382.s24|218-227|Aprepitant|drug
DDI-DrugBank.d382.s24|229-231|and|O
DDI-DrugBank.d382.s24|233-234|on|O
DDI-DrugBank.d382.s24|236-239|Days|O
DDI-DrugBank.d382.s24|241-241|4|O
DDI-DrugBank.d382.s24|242-242|,|O
DDI-DrugBank.d382.s24|244-244|8|O
DDI-DrugBank.d382.s24|245-245|,|O
DDI-DrugBank.d382.s24|247-249|and|O
DDI-DrugBank.d382.s24|251-252|15|O
DDI-DrugBank.d382.s24|253-253|.|O
DDI-DrugBank.d382.s25|0-9|Aprepitant|drug
DDI-DrugBank.d382.s25|11-19|increased|O
DDI-DrugBank.d382.s25|21-23|the|O
DDI-DrugBank.d382.s25|25-27|AUC|O
DDI-DrugBank.d382.s25|29-30|of|O
DDI-DrugBank.d382.s25|32-40|midazolam|drug
DDI-DrugBank.d382.s25|42-43|by|O
DDI-DrugBank.d382.s25|45-46|25|O
DDI-DrugBank.d382.s25|47-47|%|O
DDI-DrugBank.d382.s25|49-50|on|O
DDI-DrugBank.d382.s25|52-54|Day|O
DDI-DrugBank.d382.s25|56-56|4|O
DDI-DrugBank.d382.s25|58-60|and|O
DDI-DrugBank.d382.s25|62-70|decreased|O
DDI-DrugBank.d382.s25|72-74|the|O
DDI-DrugBank.d382.s25|76-78|AUC|O
DDI-DrugBank.d382.s25|80-81|of|O
DDI-DrugBank.d382.s25|83-91|midazolam|drug
DDI-DrugBank.d382.s25|93-94|by|O
DDI-DrugBank.d382.s25|96-97|19|O
DDI-DrugBank.d382.s25|98-98|%|O
DDI-DrugBank.d382.s25|100-101|on|O
DDI-DrugBank.d382.s25|103-105|Day|O
DDI-DrugBank.d382.s25|107-107|8|O
DDI-DrugBank.d382.s25|109-116|relative|O
DDI-DrugBank.d382.s25|118-119|to|O
DDI-DrugBank.d382.s25|121-123|the|O
DDI-DrugBank.d382.s25|125-130|dosing|O
DDI-DrugBank.d382.s25|132-133|of|O
DDI-DrugBank.d382.s25|135-144|Aprepitant|drug
DDI-DrugBank.d382.s25|146-147|on|O
DDI-DrugBank.d382.s25|149-152|Days|O
DDI-DrugBank.d382.s25|154-154|1|O
DDI-DrugBank.d382.s25|156-162|through|O
DDI-DrugBank.d382.s25|164-164|3|O
DDI-DrugBank.d382.s25|165-165|.|O
DDI-DrugBank.d382.s26|0-4|These|O
DDI-DrugBank.d382.s26|6-12|effects|O
DDI-DrugBank.d382.s26|14-17|were|O
DDI-DrugBank.d382.s26|19-21|not|O
DDI-DrugBank.d382.s26|23-32|considered|O
DDI-DrugBank.d382.s26|34-43|clinically|O
DDI-DrugBank.d382.s26|45-53|important|O
DDI-DrugBank.d382.s26|54-54|.|O
DDI-DrugBank.d382.s27|0-2|The|O
DDI-DrugBank.d382.s27|4-6|AUC|O
DDI-DrugBank.d382.s27|8-9|of|O
DDI-DrugBank.d382.s27|11-19|midazolam|drug
DDI-DrugBank.d382.s27|21-22|on|O
DDI-DrugBank.d382.s27|24-26|Day|O
DDI-DrugBank.d382.s27|28-29|15|O
DDI-DrugBank.d382.s27|31-33|was|O
DDI-DrugBank.d382.s27|35-41|similar|O
DDI-DrugBank.d382.s27|43-44|to|O
DDI-DrugBank.d382.s27|46-49|that|O
DDI-DrugBank.d382.s27|51-58|observed|O
DDI-DrugBank.d382.s27|60-61|at|O
DDI-DrugBank.d382.s27|63-70|baseline|O
DDI-DrugBank.d382.s27|71-71|.|O
DDI-DrugBank.d382.s28|0-5|Effect|O
DDI-DrugBank.d382.s28|7-8|of|O
DDI-DrugBank.d382.s28|10-14|other|O
DDI-DrugBank.d382.s28|16-21|agents|O
DDI-DrugBank.d382.s28|23-24|on|O
DDI-DrugBank.d382.s28|26-28|the|O
DDI-DrugBank.d382.s28|30-45|pharmacokinefics|O
DDI-DrugBank.d382.s28|47-48|of|O
DDI-DrugBank.d382.s29|0-9|Aprepitant|drug
DDI-DrugBank.d382.s29|11-12|is|O
DDI-DrugBank.d382.s29|14-14|a|O
DDI-DrugBank.d382.s29|16-24|substrate|O
DDI-DrugBank.d382.s29|26-28|for|O
DDI-DrugBank.d382.s29|30-35|CYP3A4|O
DDI-DrugBank.d382.s29|36-36|;|O
DDI-DrugBank.d382.s30|0-8|therefore|O
DDI-DrugBank.d382.s30|9-9|,|O
DDI-DrugBank.d382.s30|11-26|coadministration|O
DDI-DrugBank.d382.s30|28-29|of|O
DDI-DrugBank.d382.s30|31-40|Aprepitant|drug
DDI-DrugBank.d382.s30|42-45|with|O
DDI-DrugBank.d382.s30|47-51|drugs|O
DDI-DrugBank.d382.s30|53-56|that|O
DDI-DrugBank.d382.s30|58-64|inhibit|O
DDI-DrugBank.d382.s30|66-71|CYP3A4|O
DDI-DrugBank.d382.s30|73-80|activity|O
DDI-DrugBank.d382.s30|82-84|may|O
DDI-DrugBank.d382.s30|86-91|result|O
DDI-DrugBank.d382.s30|93-94|in|O
DDI-DrugBank.d382.s30|96-104|increased|O
DDI-DrugBank.d382.s30|106-111|plasma|O
DDI-DrugBank.d382.s30|113-126|concentrations|O
DDI-DrugBank.d382.s30|128-129|of|O
DDI-DrugBank.d382.s30|131-140|aprepitant|drug
DDI-DrugBank.d382.s30|141-141|.|O
DDI-DrugBank.d382.s31|0-11|Consequently|O
DDI-DrugBank.d382.s31|12-12|,|O
DDI-DrugBank.d382.s31|14-24|concomitant|O
DDI-DrugBank.d382.s31|26-39|administration|O
DDI-DrugBank.d382.s31|41-42|of|O
DDI-DrugBank.d382.s31|44-53|Aprepitant|drug
DDI-DrugBank.d382.s31|55-58|with|O
DDI-DrugBank.d382.s31|60-65|strong|O
DDI-DrugBank.d382.s31|67-72|CYP3A4|O
DDI-DrugBank.d382.s31|74-83|inhibitors|O
DDI-DrugBank.d382.s31|85-85|(|O
DDI-DrugBank.d382.s31|86-89|e.g.|O
DDI-DrugBank.d382.s31|90-90|,|O
DDI-DrugBank.d382.s31|92-103|ketoconazole|drug
DDI-DrugBank.d382.s31|104-104|,|O
DDI-DrugBank.d382.s31|106-117|itraconazole|drug
DDI-DrugBank.d382.s31|118-118|,|O
DDI-DrugBank.d382.s31|120-129|nefazodone|drug
DDI-DrugBank.d382.s31|130-130|,|O
DDI-DrugBank.d382.s31|132-145|troleandomycin|drug
DDI-DrugBank.d382.s31|146-146|,|O
DDI-DrugBank.d382.s31|148-161|clarithromycin|drug
DDI-DrugBank.d382.s31|162-162|,|O
DDI-DrugBank.d382.s31|164-172|ritonavir|drug
DDI-DrugBank.d382.s31|173-173|,|O
DDI-DrugBank.d382.s31|175-184|nelfinavir|drug
DDI-DrugBank.d382.s31|185-185|)|O
DDI-DrugBank.d382.s31|187-192|should|O
DDI-DrugBank.d382.s31|194-195|be|O
DDI-DrugBank.d382.s31|197-206|approached|O
DDI-DrugBank.d382.s31|208-211|with|O
DDI-DrugBank.d382.s31|213-219|caution|O
DDI-DrugBank.d382.s31|220-220|.|O
DDI-DrugBank.d382.s32|0-6|Because|O
DDI-DrugBank.d382.s32|8-15|moderate|O
DDI-DrugBank.d382.s32|17-22|CYP3A4|O
DDI-DrugBank.d382.s32|24-33|inhibitors|O
DDI-DrugBank.d382.s32|35-35|(|O
DDI-DrugBank.d382.s32|36-39|e.g.|O
DDI-DrugBank.d382.s32|40-40|,|O
DDI-DrugBank.d382.s32|42-50|diltiazem|drug
DDI-DrugBank.d382.s32|51-51|)|O
DDI-DrugBank.d382.s32|53-58|result|O
DDI-DrugBank.d382.s32|60-61|in|O
DDI-DrugBank.d382.s32|63-68|2-fold|O
DDI-DrugBank.d382.s32|70-77|increase|O
DDI-DrugBank.d382.s32|79-80|in|O
DDI-DrugBank.d382.s32|82-87|plasma|O
DDI-DrugBank.d382.s32|89-102|concentrations|O
DDI-DrugBank.d382.s32|104-105|of|O
DDI-DrugBank.d382.s32|107-116|aprepitant|drug
DDI-DrugBank.d382.s32|117-117|,|O
DDI-DrugBank.d382.s32|119-129|concomitant|O
DDI-DrugBank.d382.s32|131-144|administration|O
DDI-DrugBank.d382.s32|146-151|should|O
DDI-DrugBank.d382.s32|153-156|also|O
DDI-DrugBank.d382.s32|158-159|be|O
DDI-DrugBank.d382.s32|161-170|approached|O
DDI-DrugBank.d382.s32|172-175|with|O
DDI-DrugBank.d382.s32|177-183|caution|O
DDI-DrugBank.d382.s32|184-184|.|O
DDI-DrugBank.d382.s33|0-9|Aprepitant|drug
DDI-DrugBank.d382.s33|11-12|is|O
DDI-DrugBank.d382.s33|14-14|a|O
DDI-DrugBank.d382.s33|16-24|substrate|O
DDI-DrugBank.d382.s33|26-28|for|O
DDI-DrugBank.d382.s33|30-35|CYP3A4|O
DDI-DrugBank.d382.s33|36-36|;|O
DDI-DrugBank.d382.s34|0-8|therefore|O
DDI-DrugBank.d382.s34|9-9|,|O
DDI-DrugBank.d382.s34|11-26|coadministration|O
DDI-DrugBank.d382.s34|28-29|of|O
DDI-DrugBank.d382.s34|31-40|Aprepitant|drug
DDI-DrugBank.d382.s34|42-45|with|O
DDI-DrugBank.d382.s34|47-51|drugs|O
DDI-DrugBank.d382.s34|53-56|that|O
DDI-DrugBank.d382.s34|58-65|strongly|O
DDI-DrugBank.d382.s34|67-72|induce|O
DDI-DrugBank.d382.s34|74-79|CYP3A4|O
DDI-DrugBank.d382.s34|81-88|activity|O
DDI-DrugBank.d382.s34|90-90|(|O
DDI-DrugBank.d382.s34|91-94|e.g.|O
DDI-DrugBank.d382.s34|95-95|,|O
DDI-DrugBank.d382.s34|97-104|rifampin|drug
DDI-DrugBank.d382.s34|105-105|,|O
DDI-DrugBank.d382.s34|107-119|carbamazepine|drug
DDI-DrugBank.d382.s34|120-120|,|O
DDI-DrugBank.d382.s34|122-130|phenytoin|drug
DDI-DrugBank.d382.s34|131-131|)|O
DDI-DrugBank.d382.s34|133-135|may|O
DDI-DrugBank.d382.s34|137-142|result|O
DDI-DrugBank.d382.s34|144-145|in|O
DDI-DrugBank.d382.s34|147-153|reduced|O
DDI-DrugBank.d382.s34|155-160|plasma|O
DDI-DrugBank.d382.s34|162-175|concentrations|O
DDI-DrugBank.d382.s34|177-178|of|O
DDI-DrugBank.d382.s34|180-189|aprepitant|drug
DDI-DrugBank.d382.s34|191-194|that|O
DDI-DrugBank.d382.s34|196-198|may|O
DDI-DrugBank.d382.s34|200-205|result|O
DDI-DrugBank.d382.s34|207-208|in|O
DDI-DrugBank.d382.s34|210-218|decreased|O
DDI-DrugBank.d382.s34|220-227|efficacy|O
DDI-DrugBank.d382.s34|229-230|of|O
DDI-DrugBank.d382.s34|232-241|Aprepitant|drug
DDI-DrugBank.d382.s34|242-242|.|O
DDI-DrugBank.d382.s35|0-11|Ketoconazole|drug
DDI-DrugBank.d382.s35|12-12|:|O
DDI-DrugBank.d382.s35|14-17|When|O
DDI-DrugBank.d382.s35|19-19|a|O
DDI-DrugBank.d382.s35|21-26|single|O
DDI-DrugBank.d382.s35|28-33|125-mg|O
DDI-DrugBank.d382.s35|35-38|dose|O
DDI-DrugBank.d382.s35|40-41|of|O
DDI-DrugBank.d382.s35|43-52|Aprepitant|drug
DDI-DrugBank.d382.s35|54-56|was|O
DDI-DrugBank.d382.s35|58-69|administered|O
DDI-DrugBank.d382.s35|71-72|on|O
DDI-DrugBank.d382.s35|74-77|Day5|O
DDI-DrugBank.d382.s35|79-80|of|O
DDI-DrugBank.d382.s35|82-82|a|O
DDI-DrugBank.d382.s36|0-11|Ketoconazole|drug
DDI-DrugBank.d382.s36|12-12|:|O
DDI-DrugBank.d382.s36|14-17|When|O
DDI-DrugBank.d382.s36|19-19|a|O
DDI-DrugBank.d382.s36|21-26|single|O
DDI-DrugBank.d382.s36|28-33|125-mg|O
DDI-DrugBank.d382.s36|35-38|dose|O
DDI-DrugBank.d382.s36|40-41|of|O
DDI-DrugBank.d382.s36|43-52|Aprepitant|drug
DDI-DrugBank.d382.s36|54-56|was|O
DDI-DrugBank.d382.s36|58-69|administered|O
DDI-DrugBank.d382.s36|71-72|on|O
DDI-DrugBank.d382.s36|74-77|Day5|O
DDI-DrugBank.d382.s36|79-80|of|O
DDI-DrugBank.d382.s36|82-82|a|O
DDI-DrugBank.d382.s36|84-89|10-day|O
DDI-DrugBank.d382.s36|91-97|regimen|O
DDI-DrugBank.d382.s36|99-100|of|O
DDI-DrugBank.d382.s36|102-104|400|O
DDI-DrugBank.d382.s36|106-111|mg/day|O
DDI-DrugBank.d382.s36|113-114|of|O
DDI-DrugBank.d382.s36|116-127|ketoconazole|drug
DDI-DrugBank.d382.s36|128-128|,|O
DDI-DrugBank.d382.s36|130-130|a|O
DDI-DrugBank.d382.s36|132-137|strong|O
DDI-DrugBank.d382.s36|139-144|CYP3A4|O
DDI-DrugBank.d382.s36|146-154|inhibitor|O
DDI-DrugBank.d382.s36|155-155|,|O
DDI-DrugBank.d382.s36|157-159|the|O
DDI-DrugBank.d382.s36|161-163|AUC|O
DDI-DrugBank.d382.s36|165-166|of|O
DDI-DrugBank.d382.s36|168-177|aprepitant|drug
DDI-DrugBank.d382.s36|179-187|increased|O
DDI-DrugBank.d382.s36|189-201|approximately|O
DDI-DrugBank.d382.s36|203-208|5-fold|O
DDI-DrugBank.d382.s36|210-212|and|O
DDI-DrugBank.d382.s36|214-216|the|O
DDI-DrugBank.d382.s36|218-221|mean|O
DDI-DrugBank.d382.s36|223-230|terminal|O
DDI-DrugBank.d382.s36|232-240|half-life|O
DDI-DrugBank.d382.s36|242-243|of|O
DDI-DrugBank.d382.s36|245-254|aprepitant|drug
DDI-DrugBank.d382.s36|256-264|increased|O
DDI-DrugBank.d382.s36|266-278|approximately|O
DDI-DrugBank.d382.s36|280-285|3-fold|O
DDI-DrugBank.d382.s36|286-286|.|O
DDI-DrugBank.d382.s37|0-10|Concomitant|O
DDI-DrugBank.d382.s37|12-25|administration|O
DDI-DrugBank.d382.s37|27-28|of|O
DDI-DrugBank.d382.s37|30-39|Aprepitant|drug
DDI-DrugBank.d382.s37|41-44|with|O
DDI-DrugBank.d382.s37|46-51|strong|O
DDI-DrugBank.d382.s37|53-58|CYP3A4|O
DDI-DrugBank.d382.s37|60-69|inhibitors|O
DDI-DrugBank.d382.s37|71-76|should|O
DDI-DrugBank.d382.s37|78-79|be|O
DDI-DrugBank.d382.s37|81-90|approached|O
DDI-DrugBank.d382.s37|92-101|cautiously|O
DDI-DrugBank.d382.s37|102-102|.|O
DDI-DrugBank.d382.s38|0-7|Rifampin|drug
DDI-DrugBank.d382.s38|8-8|:|O
DDI-DrugBank.d382.s38|10-13|When|O
DDI-DrugBank.d382.s38|15-15|a|O
DDI-DrugBank.d382.s38|17-22|single|O
DDI-DrugBank.d382.s38|24-29|375-mg|O
DDI-DrugBank.d382.s38|31-34|dose|O
DDI-DrugBank.d382.s38|36-37|of|O
DDI-DrugBank.d382.s38|39-48|Aprepitant|drug
DDI-DrugBank.d382.s38|50-52|was|O
DDI-DrugBank.d382.s38|54-65|administered|O
DDI-DrugBank.d382.s38|67-68|on|O
DDI-DrugBank.d382.s38|70-73|Day9|O
DDI-DrugBank.d382.s38|75-76|of|O
DDI-DrugBank.d382.s38|78-78|a|O
DDI-DrugBank.d382.s38|80-85|14-day|O
DDI-DrugBank.d382.s38|87-93|regimen|O
DDI-DrugBank.d382.s38|95-96|of|O
DDI-DrugBank.d382.s38|98-100|600|O
DDI-DrugBank.d382.s38|102-107|mg/day|O
DDI-DrugBank.d382.s38|109-110|of|O
DDI-DrugBank.d382.s38|112-119|rifampin|drug
DDI-DrugBank.d382.s38|120-120|,|O
DDI-DrugBank.d382.s38|122-122|a|O
DDI-DrugBank.d382.s38|124-129|strong|O
DDI-DrugBank.d382.s38|131-136|CYP3A4|O
DDI-DrugBank.d382.s38|138-144|inducer|O
DDI-DrugBank.d382.s38|145-145|,|O
DDI-DrugBank.d382.s38|147-149|the|O
DDI-DrugBank.d382.s38|151-153|AUC|O
DDI-DrugBank.d382.s38|155-156|of|O
DDI-DrugBank.d382.s38|158-167|aprepitant|drug
DDI-DrugBank.d382.s38|169-177|decreased|O
DDI-DrugBank.d382.s38|179-191|approximately|O
DDI-DrugBank.d382.s38|193-199|11-fold|O
DDI-DrugBank.d382.s38|201-203|and|O
DDI-DrugBank.d382.s38|205-207|the|O
DDI-DrugBank.d382.s38|209-212|mean|O
DDI-DrugBank.d382.s38|214-221|terminal|O
DDI-DrugBank.d382.s38|223-231|half-life|O
DDI-DrugBank.d382.s38|233-241|decreased|O
DDI-DrugBank.d382.s38|243-255|approximately|O
DDI-DrugBank.d382.s38|257-262|3-fold|O
DDI-DrugBank.d382.s38|263-263|.|O
DDI-DrugBank.d382.s39|0-15|Coadministration|O
DDI-DrugBank.d382.s39|17-18|of|O
DDI-DrugBank.d382.s39|20-29|Aprepitant|drug
DDI-DrugBank.d382.s39|31-34|with|O
DDI-DrugBank.d382.s39|36-40|drugs|O
DDI-DrugBank.d382.s39|42-45|that|O
DDI-DrugBank.d382.s39|47-52|induce|O
DDI-DrugBank.d382.s39|54-59|CYP3A4|O
DDI-DrugBank.d382.s39|61-68|activity|O
DDI-DrugBank.d382.s39|70-72|may|O
DDI-DrugBank.d382.s39|74-79|result|O
DDI-DrugBank.d382.s39|81-82|in|O
DDI-DrugBank.d382.s39|84-90|reduced|O
DDI-DrugBank.d382.s39|92-97|plasma|O
DDI-DrugBank.d382.s39|99-112|concentrations|O
DDI-DrugBank.d382.s39|114-116|and|O
DDI-DrugBank.d382.s39|118-126|decreased|O
DDI-DrugBank.d382.s39|128-135|efficacy|O
DDI-DrugBank.d382.s39|137-138|of|O
DDI-DrugBank.d382.s39|140-149|Aprepitant|drug
DDI-DrugBank.d382.s39|150-150|.|O
DDI-DrugBank.d382.s40|0-9|Additional|O
DDI-DrugBank.d382.s40|11-22|interactions|O
DDI-DrugBank.d382.s41|0-8|Diltiazem|drug
DDI-DrugBank.d382.s41|9-9|:|O
DDI-DrugBank.d382.s41|11-12|In|O
DDI-DrugBank.d382.s41|14-21|patients|O
DDI-DrugBank.d382.s41|23-26|with|O
DDI-DrugBank.d382.s41|28-31|mild|O
DDI-DrugBank.d382.s41|33-34|to|O
DDI-DrugBank.d382.s41|36-43|moderate|O
DDI-DrugBank.d382.s41|45-56|hypertension|O
DDI-DrugBank.d382.s41|57-57|,|O
DDI-DrugBank.d382.s41|59-72|administration|O
DDI-DrugBank.d382.s41|74-75|of|O
DDI-DrugBank.d382.s41|77-86|aprepitant|drug
DDI-DrugBank.d382.s41|88-91|once|O
DDI-DrugBank.d382.s41|93-97|daily|O
DDI-DrugBank.d382.s41|98-98|,|O
DDI-DrugBank.d382.s41|100-101|as|O
DDI-DrugBank.d382.s41|103-103|a|O
DDI-DrugBank.d382.s41|105-110|tablet|O
DDI-DrugBank.d382.s41|112-122|formulation|O
DDI-DrugBank.d382.s41|124-133|comparable|O
DDI-DrugBank.d382.s41|135-136|to|O
DDI-DrugBank.d382.s41|138-140|230|O
DDI-DrugBank.d382.s41|142-143|mg|O
DDI-DrugBank.d382.s41|145-146|of|O
DDI-DrugBank.d382.s41|148-150|the|O
DDI-DrugBank.d382.s41|152-158|capsule|O
DDI-DrugBank.d382.s41|160-170|formulation|O
DDI-DrugBank.d382.s41|171-171|,|O
DDI-DrugBank.d382.s41|173-176|with|O
DDI-DrugBank.d382.s41|178-186|diltiazem|drug
DDI-DrugBank.d382.s41|188-190|120|O
DDI-DrugBank.d382.s41|192-193|mg|O
DDI-DrugBank.d382.s41|195-195|3|O
DDI-DrugBank.d382.s41|197-201|times|O
DDI-DrugBank.d382.s41|203-207|daily|O
DDI-DrugBank.d382.s41|209-211|for|O
DDI-DrugBank.d382.s41|213-213|5|O
DDI-DrugBank.d382.s41|215-218|days|O
DDI-DrugBank.d382.s41|219-219|,|O
DDI-DrugBank.d382.s41|221-228|resulted|O
DDI-DrugBank.d382.s41|230-231|in|O
DDI-DrugBank.d382.s41|233-233|a|O
DDI-DrugBank.d382.s41|235-240|2-fold|O
DDI-DrugBank.d382.s41|242-249|increase|O
DDI-DrugBank.d382.s41|251-252|of|O
DDI-DrugBank.d382.s41|254-263|aprepitant|drug
DDI-DrugBank.d382.s41|265-267|AUC|O
DDI-DrugBank.d382.s41|269-271|and|O
DDI-DrugBank.d382.s41|273-273|a|O
DDI-DrugBank.d382.s41|275-286|simultaneous|O
DDI-DrugBank.d382.s41|288-295|1.7-fold|O
DDI-DrugBank.d382.s41|297-304|increase|O
DDI-DrugBank.d382.s41|306-307|of|O
DDI-DrugBank.d382.s41|309-317|diltiazem|drug
DDI-DrugBank.d382.s41|319-321|AUC|O
DDI-DrugBank.d382.s41|322-322|.|O
DDI-DrugBank.d382.s42|0-4|These|O
DDI-DrugBank.d382.s42|6-20|pharmacokinetic|O
DDI-DrugBank.d382.s42|22-28|effects|O
DDI-DrugBank.d382.s42|30-32|did|O
DDI-DrugBank.d382.s42|34-36|not|O
DDI-DrugBank.d382.s42|38-43|result|O
DDI-DrugBank.d382.s42|45-46|in|O
DDI-DrugBank.d382.s42|48-57|clinically|O
DDI-DrugBank.d382.s42|59-68|meaningful|O
DDI-DrugBank.d382.s42|70-76|changes|O
DDI-DrugBank.d382.s42|78-79|in|O
DDI-DrugBank.d382.s42|81-83|ECG|O
DDI-DrugBank.d382.s42|84-84|,|O
DDI-DrugBank.d382.s42|86-90|heart|O
DDI-DrugBank.d382.s42|92-95|rate|O
DDI-DrugBank.d382.s42|97-98|or|O
DDI-DrugBank.d382.s42|100-104|blood|O
DDI-DrugBank.d382.s42|106-113|pressure|O
DDI-DrugBank.d382.s42|115-120|beyond|O
DDI-DrugBank.d382.s42|122-126|those|O
DDI-DrugBank.d382.s42|128-134|changes|O
DDI-DrugBank.d382.s42|136-142|induced|O
DDI-DrugBank.d382.s42|144-145|by|O
DDI-DrugBank.d382.s42|147-155|diltiazem|drug
DDI-DrugBank.d382.s42|157-161|alone|O
DDI-DrugBank.d382.s42|162-162|.|O
DDI-DrugBank.d382.s43|0-9|Paroxetine|drug
DDI-DrugBank.d382.s43|10-10|:|O
DDI-DrugBank.d382.s43|12-27|Coadministration|O
DDI-DrugBank.d382.s43|29-30|of|O
DDI-DrugBank.d382.s43|32-35|once|O
DDI-DrugBank.d382.s43|37-41|daily|O
DDI-DrugBank.d382.s43|43-47|doses|O
DDI-DrugBank.d382.s43|49-50|of|O
DDI-DrugBank.d382.s43|52-61|aprepitant|drug
DDI-DrugBank.d382.s43|62-62|,|O
DDI-DrugBank.d382.s43|64-65|as|O
DDI-DrugBank.d382.s43|67-67|a|O
DDI-DrugBank.d382.s43|69-74|tablet|O
DDI-DrugBank.d382.s43|76-86|formulation|O
DDI-DrugBank.d382.s43|88-97|comparable|O
DDI-DrugBank.d382.s43|99-100|to|O
DDI-DrugBank.d382.s43|102-103|85|O
DDI-DrugBank.d382.s43|105-106|mg|O
DDI-DrugBank.d382.s43|108-109|or|O
DDI-DrugBank.d382.s43|111-113|170|O
DDI-DrugBank.d382.s43|115-116|mg|O
DDI-DrugBank.d382.s43|118-119|of|O
DDI-DrugBank.d382.s43|121-123|the|O
DDI-DrugBank.d382.s43|125-131|capsule|O
DDI-DrugBank.d382.s43|133-143|formulation|O
DDI-DrugBank.d382.s43|144-144|,|O
DDI-DrugBank.d382.s43|146-149|with|O
DDI-DrugBank.d382.s43|151-160|paroxetine|drug
DDI-DrugBank.d382.s43|162-163|20|O
DDI-DrugBank.d382.s43|165-166|mg|O
DDI-DrugBank.d382.s43|168-171|once|O
DDI-DrugBank.d382.s43|173-177|daily|O
DDI-DrugBank.d382.s43|178-178|,|O
DDI-DrugBank.d382.s43|180-187|resulted|O
DDI-DrugBank.d382.s43|189-190|in|O
DDI-DrugBank.d382.s43|192-192|a|O
DDI-DrugBank.d382.s43|194-201|decrease|O
DDI-DrugBank.d382.s43|203-204|in|O
DDI-DrugBank.d382.s43|206-208|AUC|O
DDI-DrugBank.d382.s43|210-211|by|O
DDI-DrugBank.d382.s43|213-225|approximately|O
DDI-DrugBank.d382.s43|227-228|25|O
DDI-DrugBank.d382.s43|229-229|%|O
DDI-DrugBank.d382.s43|231-233|and|O
DDI-DrugBank.d382.s43|235-238|Cmax|O
DDI-DrugBank.d382.s43|239-239|,|O
DDI-DrugBank.d382.s43|241-242|by|O
DDI-DrugBank.d382.s43|244-256|approximately|O
DDI-DrugBank.d382.s43|258-259|20|O
DDI-DrugBank.d382.s43|260-260|%|O
DDI-DrugBank.d382.s43|262-263|of|O
DDI-DrugBank.d382.s43|265-268|both|O
DDI-DrugBank.d382.s43|270-279|aprepitant|drug
DDI-DrugBank.d382.s43|281-283|and|O
DDI-DrugBank.d382.s43|285-294|paroxetine|drug
DDI-DrugBank.d382.s43|295-295|.|O
DDI-DrugBank.d616.s0|0-11|Interactions|O
DDI-DrugBank.d616.s0|13-19|between|O
DDI-DrugBank.d616.s0|21-27|ZADAXIN|brand
DDI-DrugBank.d616.s0|29-31|and|O
DDI-DrugBank.d616.s0|33-37|other|O
DDI-DrugBank.d616.s0|39-43|drugs|O
DDI-DrugBank.d616.s0|45-48|have|O
DDI-DrugBank.d616.s0|50-52|not|O
DDI-DrugBank.d616.s0|54-57|been|O
DDI-DrugBank.d616.s0|59-63|fully|O
DDI-DrugBank.d616.s0|65-73|evaluated|O
DDI-DrugBank.d616.s0|74-74|.|O
DDI-DrugBank.d616.s1|0-6|Caution|O
DDI-DrugBank.d616.s1|8-13|should|O
DDI-DrugBank.d616.s1|15-16|be|O
DDI-DrugBank.d616.s1|18-26|exercised|O
DDI-DrugBank.d616.s1|28-31|when|O
DDI-DrugBank.d616.s1|33-45|administering|O
DDI-DrugBank.d616.s1|47-53|ZADAXIN|brand
DDI-DrugBank.d616.s1|55-61|therapy|O
DDI-DrugBank.d616.s1|63-64|in|O
DDI-DrugBank.d616.s1|66-76|combination|O
DDI-DrugBank.d616.s1|78-81|with|O
DDI-DrugBank.d616.s1|83-87|other|O
DDI-DrugBank.d616.s1|89-110|immunomodulating drugs|group
DDI-DrugBank.d616.s1|111-111|.|O
DDI-DrugBank.d616.s2|0-6|ZADAXIN|brand
DDI-DrugBank.d616.s2|8-13|should|O
DDI-DrugBank.d616.s2|15-17|not|O
DDI-DrugBank.d616.s2|19-20|be|O
DDI-DrugBank.d616.s2|22-26|mixed|O
DDI-DrugBank.d616.s2|28-31|with|O
DDI-DrugBank.d616.s2|33-35|any|O
DDI-DrugBank.d616.s2|37-41|other|O
DDI-DrugBank.d616.s2|43-46|drug|O
DDI-DrugBank.d616.s2|47-47|.|O
DDI-DrugBank.d202.s0|0-11|Steady-state|O
DDI-DrugBank.d202.s0|13-17|serum|O
DDI-DrugBank.d202.s0|19-32|concentrations|O
DDI-DrugBank.d202.s0|34-35|of|O
DDI-DrugBank.d202.s0|37-61|tricyclic antidepressants|group
DDI-DrugBank.d202.s0|63-65|are|O
DDI-DrugBank.d202.s0|67-74|reported|O
DDI-DrugBank.d202.s0|76-77|to|O
DDI-DrugBank.d202.s0|79-87|fluctuate|O
DDI-DrugBank.d202.s0|89-101|significantly|O
DDI-DrugBank.d202.s0|103-106|when|O
DDI-DrugBank.d202.s0|108-117|cimetidine|drug
DDI-DrugBank.d202.s0|119-120|is|O
DDI-DrugBank.d202.s0|122-127|either|O
DDI-DrugBank.d202.s0|129-133|added|O
DDI-DrugBank.d202.s0|135-136|or|O
DDI-DrugBank.d202.s0|138-144|deleted|O
DDI-DrugBank.d202.s0|146-149|from|O
DDI-DrugBank.d202.s0|151-153|the|O
DDI-DrugBank.d202.s0|155-158|drug|O
DDI-DrugBank.d202.s0|160-166|regimen|O
DDI-DrugBank.d202.s0|167-167|.|O
DDI-DrugBank.d202.s1|0-6|Serious|O
DDI-DrugBank.d202.s1|8-22|anticholinergic|O
DDI-DrugBank.d202.s1|24-31|symptoms|O
DDI-DrugBank.d202.s1|33-33|(|O
DDI-DrugBank.d202.s1|34-39|severe|O
DDI-DrugBank.d202.s1|41-43|dry|O
DDI-DrugBank.d202.s1|45-49|mouth|O
DDI-DrugBank.d202.s1|50-50|,|O
DDI-DrugBank.d202.s1|52-58|urinary|O
DDI-DrugBank.d202.s1|60-68|retention|O
DDI-DrugBank.d202.s1|69-69|,|O
DDI-DrugBank.d202.s1|71-77|blurred|O
DDI-DrugBank.d202.s1|79-84|vision|O
DDI-DrugBank.d202.s1|85-85|)|O
DDI-DrugBank.d202.s1|87-90|have|O
DDI-DrugBank.d202.s1|92-95|been|O
DDI-DrugBank.d202.s1|97-106|associated|O
DDI-DrugBank.d202.s1|108-111|with|O
DDI-DrugBank.d202.s1|113-122|elevations|O
DDI-DrugBank.d202.s1|124-125|in|O
DDI-DrugBank.d202.s1|127-129|the|O
DDI-DrugBank.d202.s1|131-135|serum|O
DDI-DrugBank.d202.s1|137-142|levels|O
DDI-DrugBank.d202.s1|144-145|of|O
DDI-DrugBank.d202.s1|147-171|tricyclic antidepressants|group
DDI-DrugBank.d202.s1|173-176|when|O
DDI-DrugBank.d202.s1|178-187|cimetidine|drug
DDI-DrugBank.d202.s1|189-190|is|O
DDI-DrugBank.d202.s1|192-196|added|O
DDI-DrugBank.d202.s1|198-199|to|O
DDI-DrugBank.d202.s1|201-203|the|O
DDI-DrugBank.d202.s1|205-208|drug|O
DDI-DrugBank.d202.s1|210-216|regimen|O
DDI-DrugBank.d202.s1|217-217|.|O
DDI-DrugBank.d202.s2|0-1|In|O
DDI-DrugBank.d202.s2|3-10|addition|O
DDI-DrugBank.d202.s2|11-11|,|O
DDI-DrugBank.d202.s2|13-23|higher-than|O
DDI-DrugBank.d202.s2|25-32|expected|O
DDI-DrugBank.d202.s2|34-45|steady-state|O
DDI-DrugBank.d202.s2|47-51|serum|O
DDI-DrugBank.d202.s2|53-66|concentrations|O
DDI-DrugBank.d202.s2|68-69|of|O
DDI-DrugBank.d202.s2|71-95|tricyclic antidepressants|group
DDI-DrugBank.d202.s2|97-100|have|O
DDI-DrugBank.d202.s2|102-105|been|O
DDI-DrugBank.d202.s2|107-114|observed|O
DDI-DrugBank.d202.s2|116-119|when|O
DDI-DrugBank.d202.s2|121-127|therapy|O
DDI-DrugBank.d202.s2|129-130|is|O
DDI-DrugBank.d202.s2|132-140|initiated|O
DDI-DrugBank.d202.s2|142-143|in|O
DDI-DrugBank.d202.s2|145-152|patients|O
DDI-DrugBank.d202.s2|154-160|already|O
DDI-DrugBank.d202.s2|162-167|taking|O
DDI-DrugBank.d202.s2|169-178|cimetidine|drug
DDI-DrugBank.d202.s2|179-179|.|O
DDI-DrugBank.d202.s3|0-1|In|O
DDI-DrugBank.d202.s3|3-17|well-controlled|O
DDI-DrugBank.d202.s3|19-26|patients|O
DDI-DrugBank.d202.s3|28-37|undergoing|O
DDI-DrugBank.d202.s3|39-48|concurrent|O
DDI-DrugBank.d202.s3|50-56|therapy|O
DDI-DrugBank.d202.s3|58-61|with|O
DDI-DrugBank.d202.s3|63-72|cimetidine|drug
DDI-DrugBank.d202.s3|73-73|,|O
DDI-DrugBank.d202.s3|75-75|a|O
DDI-DrugBank.d202.s3|77-84|decrease|O
DDI-DrugBank.d202.s3|86-87|in|O
DDI-DrugBank.d202.s3|89-91|the|O
DDI-DrugBank.d202.s3|93-104|steady-state|O
DDI-DrugBank.d202.s3|106-110|serum|O
DDI-DrugBank.d202.s3|112-125|concentrations|O
DDI-DrugBank.d202.s3|127-128|of|O
DDI-DrugBank.d202.s3|130-154|tricyclic antidepressants|group
DDI-DrugBank.d202.s3|156-158|may|O
DDI-DrugBank.d202.s3|160-164|occur|O
DDI-DrugBank.d202.s3|166-169|when|O
DDI-DrugBank.d202.s3|171-181|cime-tidine|O
DDI-DrugBank.d202.s3|183-189|therapy|O
DDI-DrugBank.d202.s3|191-192|is|O
DDI-DrugBank.d202.s3|194-205|discontinued|O
DDI-DrugBank.d202.s3|206-206|.|O
DDI-DrugBank.d202.s4|0-2|The|O
DDI-DrugBank.d202.s4|4-14|therapeutic|O
DDI-DrugBank.d202.s4|16-23|efficacy|O
DDI-DrugBank.d202.s4|25-26|of|O
DDI-DrugBank.d202.s4|28-52|tricyclic antidepressants|group
DDI-DrugBank.d202.s4|54-56|may|O
DDI-DrugBank.d202.s4|58-59|be|O
DDI-DrugBank.d202.s4|61-71|compromised|O
DDI-DrugBank.d202.s4|73-74|in|O
DDI-DrugBank.d202.s4|76-80|these|O
DDI-DrugBank.d202.s4|82-89|patients|O
DDI-DrugBank.d202.s4|91-94|when|O
DDI-DrugBank.d202.s4|96-105|cimetidine|drug
DDI-DrugBank.d202.s4|107-108|is|O
DDI-DrugBank.d202.s4|110-121|discontinued|O
DDI-DrugBank.d202.s4|122-122|.|O
DDI-DrugBank.d202.s5|0-6|Several|O
DDI-DrugBank.d202.s5|8-9|of|O
DDI-DrugBank.d202.s5|11-13|the|O
DDI-DrugBank.d202.s5|15-39|tricyclic antidepressants|group
DDI-DrugBank.d202.s5|41-44|have|O
DDI-DrugBank.d202.s5|46-49|been|O
DDI-DrugBank.d202.s5|51-55|cited|O
DDI-DrugBank.d202.s5|57-58|in|O
DDI-DrugBank.d202.s5|60-64|these|O
DDI-DrugBank.d202.s5|66-72|reports|O
DDI-DrugBank.d202.s5|73-73|.|O
DDI-DrugBank.d202.s6|0-4|There|O
DDI-DrugBank.d202.s6|6-9|have|O
DDI-DrugBank.d202.s6|11-14|been|O
DDI-DrugBank.d202.s6|16-22|greater|O
DDI-DrugBank.d202.s6|24-27|than|O
DDI-DrugBank.d202.s6|29-34|2-fold|O
DDI-DrugBank.d202.s6|36-44|increases|O
DDI-DrugBank.d202.s6|46-47|in|O
DDI-DrugBank.d202.s6|49-58|previously|O
DDI-DrugBank.d202.s6|60-65|stable|O
DDI-DrugBank.d202.s6|67-72|plasma|O
DDI-DrugBank.d202.s6|74-79|levels|O
DDI-DrugBank.d202.s6|81-82|of|O
DDI-DrugBank.d202.s6|84-88|other|O
DDI-DrugBank.d202.s6|90-104|antidepressants|group
DDI-DrugBank.d202.s6|105-105|,|O
DDI-DrugBank.d202.s6|107-115|including|O
DDI-DrugBank.d202.s6|117-129|nortriptyline|drug
DDI-DrugBank.d202.s6|130-130|,|O
DDI-DrugBank.d202.s6|132-135|when|O
DDI-DrugBank.d202.s6|137-160|fluoxetine hydrochloride|drug
DDI-DrugBank.d202.s6|162-164|has|O
DDI-DrugBank.d202.s6|166-169|been|O
DDI-DrugBank.d202.s6|171-182|administered|O
DDI-DrugBank.d202.s6|184-185|in|O
DDI-DrugBank.d202.s6|187-197|combination|O
DDI-DrugBank.d202.s6|199-202|with|O
DDI-DrugBank.d202.s6|204-208|these|O
DDI-DrugBank.d202.s6|210-215|agents|O
DDI-DrugBank.d202.s6|216-216|.|O
DDI-DrugBank.d202.s7|0-9|Fluoxetine|drug
DDI-DrugBank.d202.s7|11-13|and|O
DDI-DrugBank.d202.s7|15-17|its|O
DDI-DrugBank.d202.s7|19-24|active|O
DDI-DrugBank.d202.s7|26-35|metabolite|O
DDI-DrugBank.d202.s7|36-36|,|O
DDI-DrugBank.d202.s7|38-51|norfluoxe-tine|O
DDI-DrugBank.d202.s7|52-52|,|O
DDI-DrugBank.d202.s7|54-57|have|O
DDI-DrugBank.d202.s7|59-62|long|O
DDI-DrugBank.d202.s7|64-73|half-lives|O
DDI-DrugBank.d202.s7|75-75|(|O
DDI-DrugBank.d202.s7|76-76|4|O
DDI-DrugBank.d202.s7|78-79|to|O
DDI-DrugBank.d202.s7|81-82|16|O
DDI-DrugBank.d202.s7|84-87|days|O
DDI-DrugBank.d202.s7|89-91|for|O
DDI-DrugBank.d202.s7|106-106|)|O
DDI-DrugBank.d202.s7|107-107|,|O
DDI-DrugBank.d202.s7|109-112|that|O
DDI-DrugBank.d202.s7|114-116|may|O
DDI-DrugBank.d202.s7|118-123|affect|O
DDI-DrugBank.d202.s7|125-134|strategies|O
DDI-DrugBank.d202.s7|136-141|during|O
DDI-DrugBank.d202.s7|143-152|conversion|O
DDI-DrugBank.d202.s7|154-157|from|O
DDI-DrugBank.d202.s7|159-161|one|O
DDI-DrugBank.d202.s7|163-166|drug|O
DDI-DrugBank.d202.s7|168-169|to|O
DDI-DrugBank.d202.s7|171-173|the|O
DDI-DrugBank.d202.s7|175-179|other|O
DDI-DrugBank.d202.s7|180-180|.|O
DDI-DrugBank.d202.s8|0-13|Administration|O
DDI-DrugBank.d202.s8|15-16|of|O
DDI-DrugBank.d202.s8|18-26|reserpine|drug
DDI-DrugBank.d202.s8|28-33|during|O
DDI-DrugBank.d202.s8|35-41|therapy|O
DDI-DrugBank.d202.s8|43-46|with|O
DDI-DrugBank.d202.s8|48-48|a|O
DDI-DrugBank.d202.s8|50-73|tricyclic antidepressant|group
DDI-DrugBank.d202.s8|75-77|has|O
DDI-DrugBank.d202.s8|79-82|been|O
DDI-DrugBank.d202.s8|84-88|shown|O
DDI-DrugBank.d202.s8|90-91|to|O
DDI-DrugBank.d202.s8|93-99|produce|O
DDI-DrugBank.d202.s8|101-101|a|O
DDI-DrugBank.d202.s8|104-114|stimulating|O
DDI-DrugBank.d202.s8|117-122|effect|O
DDI-DrugBank.d202.s8|124-125|in|O
DDI-DrugBank.d202.s8|127-130|some|O
DDI-DrugBank.d202.s8|132-140|depressed|O
DDI-DrugBank.d202.s8|142-149|patients|O
DDI-DrugBank.d202.s8|150-150|.|O
DDI-DrugBank.d202.s9|0-4|Close|O
DDI-DrugBank.d202.s9|6-16|supervision|O
DDI-DrugBank.d202.s9|18-20|and|O
DDI-DrugBank.d202.s9|22-28|careful|O
DDI-DrugBank.d202.s9|30-39|adjustment|O
DDI-DrugBank.d202.s9|41-42|of|O
DDI-DrugBank.d202.s9|44-46|the|O
DDI-DrugBank.d202.s9|48-53|dosage|O
DDI-DrugBank.d202.s9|55-57|are|O
DDI-DrugBank.d202.s9|59-66|required|O
DDI-DrugBank.d202.s9|68-71|when|O
DDI-DrugBank.d202.s9|73-99|nortriptyline hydrochloride|drug
DDI-DrugBank.d202.s9|101-102|is|O
DDI-DrugBank.d202.s9|104-107|used|O
DDI-DrugBank.d202.s9|109-112|with|O
DDI-DrugBank.d202.s9|114-118|other|O
DDI-DrugBank.d202.s9|120-140|anticholinergic drugs|group
DDI-DrugBank.d202.s9|142-143|or|O
DDI-DrugBank.d202.s9|145-165|sympathomimetic drugs|group
DDI-DrugBank.d202.s9|166-166|.|O
DDI-DrugBank.d202.s10|0-2|The|O
DDI-DrugBank.d202.s10|4-10|patient|O
DDI-DrugBank.d202.s10|12-17|should|O
DDI-DrugBank.d202.s10|19-20|be|O
DDI-DrugBank.d202.s10|22-29|informed|O
DDI-DrugBank.d202.s10|31-34|that|O
DDI-DrugBank.d202.s10|36-38|the|O
DDI-DrugBank.d202.s10|40-47|response|O
DDI-DrugBank.d202.s10|49-50|to|O
DDI-DrugBank.d202.s10|52-58|alcohol|drug
DDI-DrugBank.d202.s10|60-62|may|O
DDI-DrugBank.d202.s10|64-65|be|O
DDI-DrugBank.d202.s10|67-77|exaggerated|O
DDI-DrugBank.d202.s10|78-78|.|O
DDI-DrugBank.d202.s11|0-4|Drugs|O
DDI-DrugBank.d202.s11|6-16|Metabolized|O
DDI-DrugBank.d202.s11|18-19|by|O
DDI-DrugBank.d202.s11|21-28|P450IID6|O
DDI-DrugBank.d202.s11|31-31|A|O
DDI-DrugBank.d202.s11|33-38|subset|O
DDI-DrugBank.d202.s11|40-40|(|O
DDI-DrugBank.d202.s11|41-41|3|O
DDI-DrugBank.d202.s11|42-42|%|O
DDI-DrugBank.d202.s11|44-45|to|O
DDI-DrugBank.d202.s11|47-48|10|O
DDI-DrugBank.d202.s11|49-49|%|O
DDI-DrugBank.d202.s11|50-50|)|O
DDI-DrugBank.d202.s11|52-53|of|O
DDI-DrugBank.d202.s11|55-57|the|O
DDI-DrugBank.d202.s11|59-68|population|O
DDI-DrugBank.d202.s11|70-72|has|O
DDI-DrugBank.d202.s11|74-80|reduced|O
DDI-DrugBank.d202.s11|82-89|activity|O
DDI-DrugBank.d202.s11|91-92|of|O
DDI-DrugBank.d202.s11|94-100|certain|O
DDI-DrugBank.d202.s11|102-105|drug|O
DDI-DrugBank.d202.s11|107-118|metabolizing|O
DDI-DrugBank.d202.s11|120-126|enzymes|O
DDI-DrugBank.d202.s11|128-131|such|O
DDI-DrugBank.d202.s11|133-134|as|O
DDI-DrugBank.d202.s11|136-138|the|O
DDI-DrugBank.d202.s11|140-149|cytochrome|O
DDI-DrugBank.d202.s11|151-154|P450|O
DDI-DrugBank.d202.s11|156-164|isoenzyme|O
DDI-DrugBank.d202.s11|166-173|P450IID6|O
DDI-DrugBank.d202.s11|174-174|.|O
DDI-DrugBank.d202.s12|0-3|Such|O
DDI-DrugBank.d202.s12|5-15|individuals|O
DDI-DrugBank.d202.s12|17-19|are|O
DDI-DrugBank.d202.s12|21-28|referred|O
DDI-DrugBank.d202.s12|30-31|to|O
DDI-DrugBank.d202.s12|33-34|as|O
DDI-DrugBank.d202.s12|37-40|poor|O
DDI-DrugBank.d202.s12|42-53|metabolizers|O
DDI-DrugBank.d202.s12|56-57|of|O
DDI-DrugBank.d202.s12|59-63|drugs|O
DDI-DrugBank.d202.s12|65-68|such|O
DDI-DrugBank.d202.s12|70-71|as|O
DDI-DrugBank.d202.s12|73-83|debrisoquin|drug
DDI-DrugBank.d202.s12|84-84|,|O
DDI-DrugBank.d202.s12|86-101|dextromethorphan|drug
DDI-DrugBank.d202.s12|102-102|,|O
DDI-DrugBank.d202.s12|104-106|and|O
DDI-DrugBank.d202.s12|108-110|the|O
DDI-DrugBank.d202.s12|112-136|tricyclic antidepressants|group
DDI-DrugBank.d202.s12|137-137|.|O
DDI-DrugBank.d202.s13|0-4|These|O
DDI-DrugBank.d202.s13|6-16|individuals|O
DDI-DrugBank.d202.s13|18-20|may|O
DDI-DrugBank.d202.s13|22-25|have|O
DDI-DrugBank.d202.s13|27-32|higher|O
DDI-DrugBank.d202.s13|34-37|than|O
DDI-DrugBank.d202.s13|39-46|expected|O
DDI-DrugBank.d202.s13|48-53|plasma|O
DDI-DrugBank.d202.s13|55-68|concentrations|O
DDI-DrugBank.d202.s13|70-71|of|O
DDI-DrugBank.d202.s13|73-97|tricyclic antidepressants|group
DDI-DrugBank.d202.s13|99-102|when|O
DDI-DrugBank.d202.s13|104-108|given|O
DDI-DrugBank.d202.s13|110-114|usual|O
DDI-DrugBank.d202.s13|116-120|doses|O
DDI-DrugBank.d202.s13|121-121|.|O
DDI-DrugBank.d202.s14|0-1|In|O
DDI-DrugBank.d202.s14|3-10|addition|O
DDI-DrugBank.d202.s14|11-11|,|O
DDI-DrugBank.d202.s14|13-19|certain|O
DDI-DrugBank.d202.s14|21-25|drugs|O
DDI-DrugBank.d202.s14|27-30|that|O
DDI-DrugBank.d202.s14|32-34|are|O
DDI-DrugBank.d202.s14|36-46|metabolized|O
DDI-DrugBank.d202.s14|48-49|by|O
DDI-DrugBank.d202.s14|51-54|this|O
DDI-DrugBank.d202.s14|56-64|isoenzyme|O
DDI-DrugBank.d202.s14|65-65|,|O
DDI-DrugBank.d202.s14|67-75|including|O
DDI-DrugBank.d202.s14|77-80|many|O
DDI-DrugBank.d202.s14|82-96|antidepressants|group
DDI-DrugBank.d202.s14|98-98|(|O
DDI-DrugBank.d202.s14|99-123|tricyclic antidepressants|group
DDI-DrugBank.d202.s14|124-124|,|O
DDI-DrugBank.d202.s14|126-164|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d202.s14|165-165|,|O
DDI-DrugBank.d202.s14|167-169|and|O
DDI-DrugBank.d202.s14|171-176|others|O
DDI-DrugBank.d202.s14|177-177|)|O
DDI-DrugBank.d202.s14|178-178|,|O
DDI-DrugBank.d202.s14|180-182|may|O
DDI-DrugBank.d202.s14|184-190|inhibit|O
DDI-DrugBank.d202.s14|192-194|the|O
DDI-DrugBank.d202.s14|196-203|activity|O
DDI-DrugBank.d202.s14|205-206|of|O
DDI-DrugBank.d202.s14|208-211|this|O
DDI-DrugBank.d202.s14|213-221|isoenzyme|O
DDI-DrugBank.d202.s14|222-222|,|O
DDI-DrugBank.d202.s14|224-226|and|O
DDI-DrugBank.d202.s14|228-231|thus|O
DDI-DrugBank.d202.s14|233-235|may|O
DDI-DrugBank.d202.s14|237-240|make|O
DDI-DrugBank.d202.s14|242-247|normal|O
DDI-DrugBank.d202.s14|249-261|metab-olizers|O
DDI-DrugBank.d202.s14|263-270|resemble|O
DDI-DrugBank.d202.s14|272-275|poor|O
DDI-DrugBank.d202.s14|277-288|metabolizers|O
DDI-DrugBank.d202.s14|290-293|with|O
DDI-DrugBank.d202.s14|295-300|regard|O
DDI-DrugBank.d202.s14|302-303|to|O
DDI-DrugBank.d202.s14|305-315|concomitant|O
DDI-DrugBank.d202.s14|317-323|therapy|O
DDI-DrugBank.d202.s14|325-328|with|O
DDI-DrugBank.d202.s14|330-334|other|O
DDI-DrugBank.d202.s14|336-340|drugs|O
DDI-DrugBank.d202.s14|342-352|metabolized|O
DDI-DrugBank.d202.s14|354-355|by|O
DDI-DrugBank.d202.s14|357-360|this|O
DDI-DrugBank.d202.s14|362-367|enzyme|O
DDI-DrugBank.d202.s14|369-374|system|O
DDI-DrugBank.d202.s14|375-375|,|O
DDI-DrugBank.d202.s14|377-383|leading|O
DDI-DrugBank.d202.s14|385-386|to|O
DDI-DrugBank.d202.s14|388-391|drug|O
DDI-DrugBank.d202.s14|393-404|interactions|O
DDI-DrugBank.d202.s14|405-405|.|O
DDI-DrugBank.d202.s15|0-10|Concomitant|O
DDI-DrugBank.d202.s15|12-14|use|O
DDI-DrugBank.d202.s15|16-17|of|O
DDI-DrugBank.d202.s15|19-43|tricyclic antidepressants|group
DDI-DrugBank.d202.s15|45-48|with|O
DDI-DrugBank.d202.s15|50-54|other|O
DDI-DrugBank.d202.s15|56-60|drugs|O
DDI-DrugBank.d202.s15|62-72|metabolized|O
DDI-DrugBank.d202.s15|74-75|by|O
DDI-DrugBank.d202.s15|77-86|cytochrome|O
DDI-DrugBank.d202.s15|88-95|P450IID6|O
DDI-DrugBank.d202.s15|97-99|may|O
DDI-DrugBank.d202.s15|101-107|require|O
DDI-DrugBank.d202.s15|109-113|lower|O
DDI-DrugBank.d202.s15|115-119|doses|O
DDI-DrugBank.d202.s15|121-124|than|O
DDI-DrugBank.d202.s15|126-132|usually|O
DDI-DrugBank.d202.s15|134-143|prescribed|O
DDI-DrugBank.d202.s15|145-147|for|O
DDI-DrugBank.d202.s15|149-154|either|O
DDI-DrugBank.d202.s15|156-158|the|O
DDI-DrugBank.d202.s15|160-183|tricyclic antidepressant|group
DDI-DrugBank.d202.s15|185-186|or|O
DDI-DrugBank.d202.s15|188-190|the|O
DDI-DrugBank.d202.s15|192-196|other|O
DDI-DrugBank.d202.s15|198-201|drug|O
DDI-DrugBank.d202.s15|202-202|.|O
DDI-DrugBank.d202.s16|0-8|Therefore|O
DDI-DrugBank.d202.s16|9-9|,|O
DDI-DrugBank.d202.s16|11-27|co-administration|O
DDI-DrugBank.d202.s16|29-30|of|O
DDI-DrugBank.d202.s16|32-56|tricyclic antidepressants|group
DDI-DrugBank.d202.s16|58-61|with|O
DDI-DrugBank.d202.s16|63-67|other|O
DDI-DrugBank.d202.s16|69-73|drugs|O
DDI-DrugBank.d202.s16|75-78|that|O
DDI-DrugBank.d202.s16|80-82|are|O
DDI-DrugBank.d202.s16|84-94|metabolized|O
DDI-DrugBank.d202.s16|96-97|by|O
DDI-DrugBank.d202.s16|99-102|this|O
DDI-DrugBank.d202.s16|104-112|isoenzyme|O
DDI-DrugBank.d202.s16|113-113|,|O
DDI-DrugBank.d202.s16|115-123|including|O
DDI-DrugBank.d202.s16|125-129|other|O
DDI-DrugBank.d202.s16|131-145|antidepressants|group
DDI-DrugBank.d202.s16|146-146|,|O
DDI-DrugBank.d202.s16|148-161|phenothiazines|group
DDI-DrugBank.d202.s16|162-162|,|O
DDI-DrugBank.d202.s16|164-176|carbamazepine|drug
DDI-DrugBank.d202.s16|177-177|,|O
DDI-DrugBank.d202.s16|179-181|and|O
DDI-DrugBank.d202.s16|183-205|Type 1C antiarrhythmics|group
DDI-DrugBank.d202.s16|207-207|(|O
DDI-DrugBank.d202.s16|208-209|eg|O
DDI-DrugBank.d202.s16|210-210|,|O
DDI-DrugBank.d202.s16|212-222|propafenone|drug
DDI-DrugBank.d202.s16|223-223|,|O
DDI-DrugBank.d202.s16|225-234|flecainide|drug
DDI-DrugBank.d202.s16|235-235|,|O
DDI-DrugBank.d202.s16|237-239|and|O
DDI-DrugBank.d202.s16|241-249|encainide|drug
DDI-DrugBank.d202.s16|250-250|)|O
DDI-DrugBank.d202.s16|251-251|,|O
DDI-DrugBank.d202.s16|253-254|or|O
DDI-DrugBank.d202.s16|256-259|that|O
DDI-DrugBank.d202.s16|261-267|inhibit|O
DDI-DrugBank.d202.s16|269-272|this|O
DDI-DrugBank.d202.s16|274-279|enzyme|O
DDI-DrugBank.d202.s16|281-281|(|O
DDI-DrugBank.d202.s16|282-283|eg|O
DDI-DrugBank.d202.s16|284-284|,|O
DDI-DrugBank.d202.s16|286-294|quinidine|drug
DDI-DrugBank.d202.s16|295-295|)|O
DDI-DrugBank.d202.s16|296-296|,|O
DDI-DrugBank.d202.s16|298-303|should|O
DDI-DrugBank.d202.s16|305-306|be|O
DDI-DrugBank.d202.s16|308-317|approached|O
DDI-DrugBank.d202.s16|319-322|with|O
DDI-DrugBank.d202.s16|324-330|caution|O
DDI-DrugBank.d202.s16|331-331|.|O
DDI-DrugBank.d601.s0|0-11|Barbiturates|group
DDI-DrugBank.d601.s0|13-15|may|O
DDI-DrugBank.d601.s0|17-24|decrease|O
DDI-DrugBank.d601.s0|26-28|the|O
DDI-DrugBank.d601.s0|30-42|effectiveness|O
DDI-DrugBank.d601.s0|44-45|of|O
DDI-DrugBank.d601.s0|47-50|oral|O
DDI-DrugBank.d601.s0|52-65|contraceptives|group
DDI-DrugBank.d601.s0|66-66|,|O
DDI-DrugBank.d601.s0|68-74|certain|O
DDI-DrugBank.d601.s0|76-86|antibiotics|group
DDI-DrugBank.d601.s0|87-87|,|O
DDI-DrugBank.d601.s0|89-97|quinidine|group
DDI-DrugBank.d601.s0|98-98|,|O
DDI-DrugBank.d601.s0|100-111|theophylline|drug
DDI-DrugBank.d601.s0|112-112|,|O
DDI-DrugBank.d601.s0|114-128|corticosteroids|group
DDI-DrugBank.d601.s0|129-129|,|O
DDI-DrugBank.d601.s0|131-144|anticoagulants|group
DDI-DrugBank.d601.s0|145-145|,|O
DDI-DrugBank.d601.s0|147-149|and|O
DDI-DrugBank.d601.s0|151-163|beta blockers|group
DDI-DrugBank.d601.s0|164-164|.|O
DDI-DrugBank.d687.s0|0-13|Administration|O
DDI-DrugBank.d687.s0|15-16|of|O
DDI-DrugBank.d687.s0|18-30|valproic acid|drug
DDI-DrugBank.d687.s0|32-40|decreases|O
DDI-DrugBank.d687.s0|42-45|oral|O
DDI-DrugBank.d687.s0|47-55|clearance|O
DDI-DrugBank.d687.s0|57-58|of|O
DDI-DrugBank.d687.s0|60-71|temozolomide|drug
DDI-DrugBank.d687.s0|73-74|by|O
DDI-DrugBank.d687.s0|76-80|about|O
DDI-DrugBank.d687.s0|82-82|5|O
DDI-DrugBank.d687.s0|83-83|%|O
DDI-DrugBank.d687.s0|84-84|.|O
DDI-DrugBank.d687.s1|0-2|The|O
DDI-DrugBank.d687.s1|4-11|clinical|O
DDI-DrugBank.d687.s1|13-23|implication|O
DDI-DrugBank.d687.s1|25-26|of|O
DDI-DrugBank.d687.s1|28-31|this|O
DDI-DrugBank.d687.s1|33-38|effect|O
DDI-DrugBank.d687.s1|40-41|is|O
DDI-DrugBank.d687.s1|43-45|not|O
DDI-DrugBank.d687.s1|47-51|known|O
DDI-DrugBank.d687.s1|52-52|.|O
DDI-DrugBank.d687.s2|0-7|Patients|O
DDI-DrugBank.d687.s2|9-12|with|O
DDI-DrugBank.d687.s2|14-19|Severe|O
DDI-DrugBank.d687.s2|21-27|Hepatic|O
DDI-DrugBank.d687.s2|29-30|or|O
DDI-DrugBank.d687.s2|32-36|Renal|O
DDI-DrugBank.d687.s2|38-47|Impairment|O
DDI-DrugBank.d687.s2|49-55|Caution|O
DDI-DrugBank.d687.s2|57-62|should|O
DDI-DrugBank.d687.s2|64-65|be|O
DDI-DrugBank.d687.s2|67-75|exercised|O
DDI-DrugBank.d687.s2|77-80|when|O
DDI-DrugBank.d687.s2|82-88|TEMODAR|brand
DDI-DrugBank.d687.s2|90-97|Capsules|O
DDI-DrugBank.d687.s2|99-101|are|O
DDI-DrugBank.d687.s2|103-114|administered|O
DDI-DrugBank.d687.s2|116-117|to|O
DDI-DrugBank.d687.s2|119-126|patients|O
DDI-DrugBank.d687.s2|128-131|with|O
DDI-DrugBank.d687.s2|133-138|severe|O
DDI-DrugBank.d687.s2|140-146|hepatic|O
DDI-DrugBank.d687.s2|148-149|or|O
DDI-DrugBank.d687.s2|151-155|renal|O
DDI-DrugBank.d687.s2|157-166|impairment|O
DDI-DrugBank.d687.s2|167-167|.|O
DDI-DrugBank.d437.s0|0-9|Amprenavir|drug
DDI-DrugBank.d437.s0|11-12|is|O
DDI-DrugBank.d437.s0|14-24|metabolized|O
DDI-DrugBank.d437.s0|26-27|in|O
DDI-DrugBank.d437.s0|29-31|the|O
DDI-DrugBank.d437.s0|33-37|liver|O
DDI-DrugBank.d437.s0|39-40|by|O
DDI-DrugBank.d437.s0|42-44|the|O
DDI-DrugBank.d437.s0|46-55|cytochrome|O
DDI-DrugBank.d437.s0|57-60|P450|O
DDI-DrugBank.d437.s0|62-67|enzyme|O
DDI-DrugBank.d437.s0|69-74|system|O
DDI-DrugBank.d437.s0|75-75|.|O
DDI-DrugBank.d437.s1|0-9|Amprenavir|drug
DDI-DrugBank.d437.s1|11-18|inhibits|O
DDI-DrugBank.d437.s1|20-25|CYP3A4|O
DDI-DrugBank.d437.s1|26-26|.|O
DDI-DrugBank.d437.s2|0-6|Caution|O
DDI-DrugBank.d437.s2|8-13|should|O
DDI-DrugBank.d437.s2|15-16|be|O
DDI-DrugBank.d437.s2|18-21|used|O
DDI-DrugBank.d437.s2|23-26|when|O
DDI-DrugBank.d437.s2|28-42|coadministering|O
DDI-DrugBank.d437.s2|44-54|medications|O
DDI-DrugBank.d437.s2|56-59|that|O
DDI-DrugBank.d437.s2|61-63|are|O
DDI-DrugBank.d437.s2|65-74|substrates|O
DDI-DrugBank.d437.s2|75-75|,|O
DDI-DrugBank.d437.s2|77-86|inhibitors|O
DDI-DrugBank.d437.s2|87-87|,|O
DDI-DrugBank.d437.s2|89-90|or|O
DDI-DrugBank.d437.s2|92-99|inducers|O
DDI-DrugBank.d437.s2|101-102|of|O
DDI-DrugBank.d437.s2|104-109|CYP3A4|O
DDI-DrugBank.d437.s2|110-110|,|O
DDI-DrugBank.d437.s2|112-113|or|O
DDI-DrugBank.d437.s2|115-125|potentially|O
DDI-DrugBank.d437.s2|127-131|toxic|O
DDI-DrugBank.d437.s2|133-143|medications|O
DDI-DrugBank.d437.s2|145-148|that|O
DDI-DrugBank.d437.s2|150-152|are|O
DDI-DrugBank.d437.s2|154-164|metabolized|O
DDI-DrugBank.d437.s2|166-167|by|O
DDI-DrugBank.d437.s2|169-174|CYP3A4|O
DDI-DrugBank.d437.s2|175-175|.|O
DDI-DrugBank.d437.s3|0-9|Amprenavir|drug
DDI-DrugBank.d437.s3|11-14|does|O
DDI-DrugBank.d437.s3|16-18|not|O
DDI-DrugBank.d437.s3|20-26|inhibit|O
DDI-DrugBank.d437.s3|28-33|CYP2D6|O
DDI-DrugBank.d437.s3|34-34|,|O
DDI-DrugBank.d437.s3|36-41|CYP1A2|O
DDI-DrugBank.d437.s3|42-42|,|O
DDI-DrugBank.d437.s3|44-49|CYP2C9|O
DDI-DrugBank.d437.s3|50-50|,|O
DDI-DrugBank.d437.s3|52-58|CYP2C19|O
DDI-DrugBank.d437.s3|59-59|,|O
DDI-DrugBank.d437.s3|61-66|CYP2E1|O
DDI-DrugBank.d437.s3|67-67|,|O
DDI-DrugBank.d437.s3|69-70|or|O
DDI-DrugBank.d437.s3|72-78|uridine|O
DDI-DrugBank.d437.s3|80-102|glucuronosyltransferase|O
DDI-DrugBank.d437.s3|104-104|(|O
DDI-DrugBank.d437.s3|105-109|UDPGT|O
DDI-DrugBank.d437.s3|110-110|)|O
DDI-DrugBank.d437.s3|111-111|.|O
DDI-DrugBank.d437.s4|0-22|HIV Protease Inhibitors|group
DDI-DrugBank.d437.s4|23-23|:|O
DDI-DrugBank.d437.s4|25-27|The|O
DDI-DrugBank.d437.s4|29-34|effect|O
DDI-DrugBank.d437.s4|36-37|of|O
DDI-DrugBank.d437.s4|39-48|amprenavir|drug
DDI-DrugBank.d437.s4|50-51|on|O
DDI-DrugBank.d437.s4|53-57|total|O
DDI-DrugBank.d437.s4|59-62|drug|O
DDI-DrugBank.d437.s4|64-77|concentrations|O
DDI-DrugBank.d437.s4|79-80|of|O
DDI-DrugBank.d437.s4|82-86|other|O
DDI-DrugBank.d437.s4|88-110|HIV protease inhibitors|group
DDI-DrugBank.d437.s4|112-113|in|O
DDI-DrugBank.d437.s4|115-122|subjects|O
DDI-DrugBank.d437.s4|124-132|receiving|O
DDI-DrugBank.d437.s4|134-137|both|O
DDI-DrugBank.d437.s4|139-144|agents|O
DDI-DrugBank.d437.s4|146-148|was|O
DDI-DrugBank.d437.s4|150-158|evaluated|O
DDI-DrugBank.d437.s4|160-164|using|O
DDI-DrugBank.d437.s4|166-176|comparisons|O
DDI-DrugBank.d437.s4|178-179|to|O
DDI-DrugBank.d437.s4|181-190|historical|O
DDI-DrugBank.d437.s4|192-195|data|O
DDI-DrugBank.d437.s4|196-196|.|O
DDI-DrugBank.d437.s5|0-8|Indinavir|drug
DDI-DrugBank.d437.s5|10-21|steady-state|O
DDI-DrugBank.d437.s5|23-26|Cmax|O
DDI-DrugBank.d437.s5|27-27|,|O
DDI-DrugBank.d437.s5|29-32|A.C.|O
DDI-DrugBank.d437.s5|34-36|and|O
DDI-DrugBank.d437.s5|38-41|Cmin|O
DDI-DrugBank.d437.s5|43-46|were|O
DDI-DrugBank.d437.s5|48-56|decreased|O
DDI-DrugBank.d437.s5|58-59|by|O
DDI-DrugBank.d437.s5|61-62|22|O
DDI-DrugBank.d437.s5|63-63|%|O
DDI-DrugBank.d437.s5|64-64|,|O
DDI-DrugBank.d437.s5|66-67|38|O
DDI-DrugBank.d437.s5|68-68|%|O
DDI-DrugBank.d437.s5|69-69|,|O
DDI-DrugBank.d437.s5|71-73|and|O
DDI-DrugBank.d437.s5|75-76|27|O
DDI-DrugBank.d437.s5|77-77|%|O
DDI-DrugBank.d437.s5|78-78|,|O
DDI-DrugBank.d437.s5|80-91|respectively|O
DDI-DrugBank.d437.s5|92-92|,|O
DDI-DrugBank.d437.s5|94-95|by|O
DDI-DrugBank.d437.s5|97-107|concomitant|O
DDI-DrugBank.d437.s5|109-118|amprenavir|drug
DDI-DrugBank.d437.s5|119-119|.|O
DDI-DrugBank.d437.s6|0-6|Similar|O
DDI-DrugBank.d437.s6|8-16|decreases|O
DDI-DrugBank.d437.s6|18-19|in|O
DDI-DrugBank.d437.s6|21-24|Cmax|O
DDI-DrugBank.d437.s6|26-28|and|O
DDI-DrugBank.d437.s6|30-32|AUC|O
DDI-DrugBank.d437.s6|34-37|were|O
DDI-DrugBank.d437.s6|39-42|seen|O
DDI-DrugBank.d437.s6|44-48|after|O
DDI-DrugBank.d437.s6|50-52|the|O
DDI-DrugBank.d437.s6|54-58|first|O
DDI-DrugBank.d437.s6|60-63|dose|O
DDI-DrugBank.d437.s6|64-64|.|O
DDI-DrugBank.d437.s7|0-9|Saquinavir|drug
DDI-DrugBank.d437.s7|11-22|steady-state|O
DDI-DrugBank.d437.s7|24-27|Cmax|O
DDI-DrugBank.d437.s7|28-28|,|O
DDI-DrugBank.d437.s7|30-33|A.C.|O
DDI-DrugBank.d437.s7|35-37|and|O
DDI-DrugBank.d437.s7|39-42|Cmin|O
DDI-DrugBank.d437.s7|44-47|were|O
DDI-DrugBank.d437.s7|49-57|increased|O
DDI-DrugBank.d437.s7|59-60|21|O
DDI-DrugBank.d437.s7|61-61|%|O
DDI-DrugBank.d437.s7|62-62|,|O
DDI-DrugBank.d437.s7|64-72|decreased|O
DDI-DrugBank.d437.s7|74-75|19|O
DDI-DrugBank.d437.s7|76-76|%|O
DDI-DrugBank.d437.s7|77-77|,|O
DDI-DrugBank.d437.s7|79-81|and|O
DDI-DrugBank.d437.s7|83-91|decreased|O
DDI-DrugBank.d437.s7|93-94|48|O
DDI-DrugBank.d437.s7|95-95|%|O
DDI-DrugBank.d437.s7|96-96|,|O
DDI-DrugBank.d437.s7|98-109|respectively|O
DDI-DrugBank.d437.s7|110-110|,|O
DDI-DrugBank.d437.s7|112-113|by|O
DDI-DrugBank.d437.s7|115-125|concomitant|O
DDI-DrugBank.d437.s7|127-136|amprenavir|drug
DDI-DrugBank.d437.s7|137-137|.|O
DDI-DrugBank.d437.s8|0-9|Nelfinavir|drug
DDI-DrugBank.d437.s8|11-22|steady-state|O
DDI-DrugBank.d437.s8|24-27|Cmax|O
DDI-DrugBank.d437.s8|28-28|,|O
DDI-DrugBank.d437.s8|30-33|A.C.|O
DDI-DrugBank.d437.s8|35-37|and|O
DDI-DrugBank.d437.s8|39-42|Cmin|O
DDI-DrugBank.d437.s8|44-47|were|O
DDI-DrugBank.d437.s8|49-57|increased|O
DDI-DrugBank.d437.s8|59-60|by|O
DDI-DrugBank.d437.s8|62-63|12|O
DDI-DrugBank.d437.s8|64-64|%|O
DDI-DrugBank.d437.s8|65-65|,|O
DDI-DrugBank.d437.s8|67-68|15|O
DDI-DrugBank.d437.s8|69-69|%|O
DDI-DrugBank.d437.s8|70-70|,|O
DDI-DrugBank.d437.s8|72-74|and|O
DDI-DrugBank.d437.s8|76-77|14|O
DDI-DrugBank.d437.s8|78-78|%|O
DDI-DrugBank.d437.s8|79-79|,|O
DDI-DrugBank.d437.s8|81-92|respectively|O
DDI-DrugBank.d437.s8|93-93|,|O
DDI-DrugBank.d437.s8|95-96|by|O
DDI-DrugBank.d437.s8|98-108|concomitant|O
DDI-DrugBank.d437.s8|110-119|amprenavir|drug
DDI-DrugBank.d437.s8|120-120|.|O
DDI-DrugBank.d437.s9|0-8|Methadone|drug
DDI-DrugBank.d437.s9|9-9|:|O
DDI-DrugBank.d437.s9|11-26|Coadministration|O
DDI-DrugBank.d437.s9|28-29|of|O
DDI-DrugBank.d437.s9|31-40|amprenavir|drug
DDI-DrugBank.d437.s9|42-44|and|O
DDI-DrugBank.d437.s9|46-54|methadone|drug
DDI-DrugBank.d437.s9|56-58|can|O
DDI-DrugBank.d437.s9|60-67|decrease|O
DDI-DrugBank.d437.s9|69-74|plasma|O
DDI-DrugBank.d437.s9|76-81|levels|O
DDI-DrugBank.d437.s9|83-84|of|O
DDI-DrugBank.d437.s9|86-94|methadone|drug
DDI-DrugBank.d437.s9|95-95|.|O
DDI-DrugBank.d437.s10|0-15|Coadministration|O
DDI-DrugBank.d437.s10|17-18|of|O
DDI-DrugBank.d437.s10|20-29|amprenavir|drug
DDI-DrugBank.d437.s10|31-33|and|O
DDI-DrugBank.d437.s10|35-43|methadone|drug
DDI-DrugBank.d437.s10|45-46|as|O
DDI-DrugBank.d437.s10|48-55|compared|O
DDI-DrugBank.d437.s10|57-58|to|O
DDI-DrugBank.d437.s10|60-60|a|O
DDI-DrugBank.d437.s10|62-72|non-matched|O
DDI-DrugBank.d437.s10|74-90|historicalcontrol|O
DDI-DrugBank.d437.s10|92-96|group|O
DDI-DrugBank.d437.s10|98-105|resulted|O
DDI-DrugBank.d437.s10|107-108|in|O
DDI-DrugBank.d437.s10|110-110|a|O
DDI-DrugBank.d437.s10|112-113|30|O
DDI-DrugBank.d437.s10|114-114|%|O
DDI-DrugBank.d437.s10|115-115|,|O
DDI-DrugBank.d437.s10|117-118|27|O
DDI-DrugBank.d437.s10|119-119|%|O
DDI-DrugBank.d437.s10|120-120|,|O
DDI-DrugBank.d437.s10|122-124|and|O
DDI-DrugBank.d437.s10|126-127|25|O
DDI-DrugBank.d437.s10|128-128|%|O
DDI-DrugBank.d437.s10|130-137|decrease|O
DDI-DrugBank.d437.s10|139-140|in|O
DDI-DrugBank.d437.s10|142-146|serum|O
DDI-DrugBank.d437.s10|148-157|amprenavir|drug
DDI-DrugBank.d437.s10|159-161|AUC|O
DDI-DrugBank.d437.s10|162-162|,|O
DDI-DrugBank.d437.s10|164-167|Cmax|O
DDI-DrugBank.d437.s10|168-168|,|O
DDI-DrugBank.d437.s10|170-176|andCmin|O
DDI-DrugBank.d437.s10|177-177|,|O
DDI-DrugBank.d437.s10|179-190|respectively|O
DDI-DrugBank.d437.s10|191-191|.|O
DDI-DrugBank.d437.s11|0-9|Amprenavir|drug
DDI-DrugBank.d437.s11|11-12|is|O
DDI-DrugBank.d437.s11|14-15|an|O
DDI-DrugBank.d437.s11|17-25|inhibitor|O
DDI-DrugBank.d437.s11|27-28|of|O
DDI-DrugBank.d437.s11|30-39|cytochrome|O
DDI-DrugBank.d437.s11|41-44|P450|O
DDI-DrugBank.d437.s11|46-51|C.P.A.|O
DDI-DrugBank.d437.s11|53-62|metabolism|O
DDI-DrugBank.d437.s11|64-66|and|O
DDI-DrugBank.d437.s11|68-76|therefore|O
DDI-DrugBank.d437.s11|78-83|should|O
DDI-DrugBank.d437.s11|85-87|not|O
DDI-DrugBank.d437.s11|89-90|be|O
DDI-DrugBank.d437.s11|92-103|administered|O
DDI-DrugBank.d437.s11|105-116|concurrently|O
DDI-DrugBank.d437.s11|118-121|with|O
DDI-DrugBank.d437.s11|123-133|medications|O
DDI-DrugBank.d437.s11|135-138|with|O
DDI-DrugBank.d437.s11|140-145|narrow|O
DDI-DrugBank.d437.s11|147-157|therapeutic|O
DDI-DrugBank.d437.s11|159-165|windows|O
DDI-DrugBank.d437.s11|167-170|that|O
DDI-DrugBank.d437.s11|172-174|are|O
DDI-DrugBank.d437.s11|176-185|substrates|O
DDI-DrugBank.d437.s11|187-188|of|O
DDI-DrugBank.d437.s11|190-195|CYP3A4|O
DDI-DrugBank.d437.s11|196-196|.|O
DDI-DrugBank.d437.s12|0-4|There|O
DDI-DrugBank.d437.s12|6-8|are|O
DDI-DrugBank.d437.s12|10-14|other|O
DDI-DrugBank.d437.s12|16-21|agents|O
DDI-DrugBank.d437.s12|23-26|that|O
DDI-DrugBank.d437.s12|28-30|may|O
DDI-DrugBank.d437.s12|32-37|result|O
DDI-DrugBank.d437.s12|39-40|in|O
DDI-DrugBank.d437.s12|42-48|serious|O
DDI-DrugBank.d437.s12|50-55|and/or|O
DDI-DrugBank.d437.s12|57-72|life-threatening|O
DDI-DrugBank.d437.s12|74-77|drug|O
DDI-DrugBank.d437.s12|79-90|interactions|O
DDI-DrugBank.d437.s12|91-91|.|O
DDI-DrugBank.d437.s13|0-9|Laboratory|O
DDI-DrugBank.d437.s13|11-15|Tests|O
DDI-DrugBank.d437.s13|16-16|:|O
DDI-DrugBank.d437.s13|18-20|The|O
DDI-DrugBank.d437.s13|22-32|combination|O
DDI-DrugBank.d437.s13|34-35|of|O
DDI-DrugBank.d437.s13|37-46|Amprenavir|drug
DDI-DrugBank.d437.s13|48-50|and|O
DDI-DrugBank.d437.s13|52-59|low-dose|O
DDI-DrugBank.d437.s13|61-69|ritonavir|drug
DDI-DrugBank.d437.s13|71-73|has|O
DDI-DrugBank.d437.s13|75-78|been|O
DDI-DrugBank.d437.s13|80-89|associated|O
DDI-DrugBank.d437.s13|91-94|with|O
DDI-DrugBank.d437.s13|96-105|elevations|O
DDI-DrugBank.d437.s13|107-108|of|O
DDI-DrugBank.d437.s13|110-120|cholesterol|O
DDI-DrugBank.d437.s13|122-124|and|O
DDI-DrugBank.d437.s13|126-138|triglycerides|O
DDI-DrugBank.d437.s13|139-139|,|O
DDI-DrugBank.d437.s13|141-144|SGOT|O
DDI-DrugBank.d437.s13|146-146|(|O
DDI-DrugBank.d437.s13|147-149|AST|O
DDI-DrugBank.d437.s13|150-150|)|O
DDI-DrugBank.d437.s13|151-151|,|O
DDI-DrugBank.d437.s13|153-155|and|O
DDI-DrugBank.d437.s13|157-160|SGPT|O
DDI-DrugBank.d437.s13|162-162|(|O
DDI-DrugBank.d437.s13|163-165|ALT|O
DDI-DrugBank.d437.s13|166-166|)|O
DDI-DrugBank.d437.s13|168-169|in|O
DDI-DrugBank.d437.s13|171-174|some|O
DDI-DrugBank.d437.s13|176-183|patients|O
DDI-DrugBank.d437.s13|184-184|.|O
DDI-DrugBank.d437.s14|0-10|Appropriate|O
DDI-DrugBank.d437.s14|12-21|laboratory|O
DDI-DrugBank.d437.s14|23-29|testing|O
DDI-DrugBank.d437.s14|31-36|should|O
DDI-DrugBank.d437.s14|38-39|be|O
DDI-DrugBank.d437.s14|41-50|considered|O
DDI-DrugBank.d437.s14|52-56|prior|O
DDI-DrugBank.d437.s14|58-59|to|O
DDI-DrugBank.d437.s14|61-70|initiating|O
DDI-DrugBank.d437.s14|72-82|combination|O
DDI-DrugBank.d437.s14|84-90|therapy|O
DDI-DrugBank.d437.s14|92-95|with|O
DDI-DrugBank.d437.s14|97-106|Amprenavir|drug
DDI-DrugBank.d437.s14|108-110|and|O
DDI-DrugBank.d437.s14|112-120|ritonavir|drug
DDI-DrugBank.d437.s14|122-124|and|O
DDI-DrugBank.d437.s14|126-127|at|O
DDI-DrugBank.d437.s14|129-136|periodic|O
DDI-DrugBank.d437.s14|138-146|intervals|O
DDI-DrugBank.d437.s14|148-149|or|O
DDI-DrugBank.d437.s14|151-152|if|O
DDI-DrugBank.d437.s14|154-156|any|O
DDI-DrugBank.d437.s14|158-165|clinical|O
DDI-DrugBank.d437.s14|167-171|signs|O
DDI-DrugBank.d437.s14|173-174|or|O
DDI-DrugBank.d437.s14|176-183|symptoms|O
DDI-DrugBank.d437.s14|185-186|of|O
DDI-DrugBank.d437.s14|188-201|hyperlipidemia|O
DDI-DrugBank.d437.s14|203-204|or|O
DDI-DrugBank.d437.s14|206-213|elevated|O
DDI-DrugBank.d437.s14|215-219|liver|O
DDI-DrugBank.d437.s14|221-228|function|O
DDI-DrugBank.d437.s14|230-234|tests|O
DDI-DrugBank.d437.s14|236-240|occur|O
DDI-DrugBank.d437.s14|242-247|during|O
DDI-DrugBank.d437.s14|249-255|therapy|O
DDI-DrugBank.d437.s14|256-256|.|O
DDI-DrugBank.d437.s15|0-2|For|O
DDI-DrugBank.d437.s15|4-16|comprehensive|O
DDI-DrugBank.d437.s15|18-28|information|O
DDI-DrugBank.d437.s15|30-39|concerning|O
DDI-DrugBank.d437.s15|41-50|laboratory|O
DDI-DrugBank.d437.s15|52-55|test|O
DDI-DrugBank.d437.s15|57-67|alterations|O
DDI-DrugBank.d437.s15|69-78|associated|O
DDI-DrugBank.d437.s15|80-83|with|O
DDI-DrugBank.d437.s15|85-93|ritonavir|drug
DDI-DrugBank.d437.s15|94-94|,|O
DDI-DrugBank.d437.s15|96-105|physicians|O
DDI-DrugBank.d437.s15|107-112|should|O
DDI-DrugBank.d437.s15|114-118|refer|O
DDI-DrugBank.d437.s15|120-121|to|O
DDI-DrugBank.d437.s15|123-125|the|O
DDI-DrugBank.d437.s15|127-134|complete|O
DDI-DrugBank.d437.s15|136-146|prescribing|O
DDI-DrugBank.d437.s15|148-158|information|O
DDI-DrugBank.d437.s15|160-162|for|O
DDI-DrugBank.d437.s15|164-169|NORVIR|brand
DDI-DrugBank.d437.s15|171-171|(|O
DDI-DrugBank.d437.s15|172-180|ritonavir|drug
DDI-DrugBank.d437.s15|181-181|)|O
DDI-DrugBank.d437.s15|182-182|.|O
DDI-DrugBank.d316.s0|0-5|CYP3A4|drug
DDI-DrugBank.d316.s0|7-16|Inhibitors|O
DDI-DrugBank.d316.s0|18-27|Felodipine|O
DDI-DrugBank.d316.s0|29-30|is|O
DDI-DrugBank.d316.s0|32-42|metabolized|O
DDI-DrugBank.d316.s0|44-45|by|O
DDI-DrugBank.d316.s0|47-52|CYP3A4|drug
DDI-DrugBank.d316.s0|53-53|.|O
DDI-DrugBank.d316.s1|0-16|Co-administration|O
DDI-DrugBank.d316.s1|18-19|of|O
DDI-DrugBank.d316.s1|21-26|CYP3A4|O
DDI-DrugBank.d316.s1|28-37|inhibitors|O
DDI-DrugBank.d316.s1|39-39|(|O
DDI-DrugBank.d316.s1|40-41|eg|O
DDI-DrugBank.d316.s1|42-42|,|O
DDI-DrugBank.d316.s1|44-55|ketoconazole|drug
DDI-DrugBank.d316.s1|56-56|,|O
DDI-DrugBank.d316.s1|58-69|itraconazole|drug
DDI-DrugBank.d316.s1|70-70|,|O
DDI-DrugBank.d316.s1|72-83|erythromycin|drug
DDI-DrugBank.d316.s1|84-84|,|O
DDI-DrugBank.d316.s1|86-95|grapefruit|O
DDI-DrugBank.d316.s1|97-101|juice|O
DDI-DrugBank.d316.s1|102-102|,|O
DDI-DrugBank.d316.s1|104-113|cimetidine|drug
DDI-DrugBank.d316.s1|114-114|)|O
DDI-DrugBank.d316.s1|116-119|with|O
DDI-DrugBank.d316.s1|121-130|felodipine|drug
DDI-DrugBank.d316.s1|132-134|may|O
DDI-DrugBank.d316.s1|136-139|lead|O
DDI-DrugBank.d316.s1|141-142|to|O
DDI-DrugBank.d316.s1|144-151|several-|O
DDI-DrugBank.d316.s1|153-156|fold|O
DDI-DrugBank.d316.s1|158-166|increases|O
DDI-DrugBank.d316.s1|168-169|in|O
DDI-DrugBank.d316.s1|171-173|the|O
DDI-DrugBank.d316.s1|175-180|plasma|O
DDI-DrugBank.d316.s1|182-187|levels|O
DDI-DrugBank.d316.s1|189-190|of|O
DDI-DrugBank.d316.s1|192-201|felodipine|drug
DDI-DrugBank.d316.s1|202-202|,|O
DDI-DrugBank.d316.s1|204-209|either|O
DDI-DrugBank.d316.s1|211-213|due|O
DDI-DrugBank.d316.s1|215-216|to|O
DDI-DrugBank.d316.s1|218-219|an|O
DDI-DrugBank.d316.s1|221-228|increase|O
DDI-DrugBank.d316.s1|230-231|in|O
DDI-DrugBank.d316.s1|233-247|bioavailability|O
DDI-DrugBank.d316.s1|249-250|or|O
DDI-DrugBank.d316.s1|252-254|due|O
DDI-DrugBank.d316.s1|256-257|to|O
DDI-DrugBank.d316.s1|259-259|a|O
DDI-DrugBank.d316.s1|261-268|decrease|O
DDI-DrugBank.d316.s1|270-271|in|O
DDI-DrugBank.d316.s1|273-282|metabolism|O
DDI-DrugBank.d316.s1|283-283|.|O
DDI-DrugBank.d316.s2|0-4|These|O
DDI-DrugBank.d316.s2|6-14|increases|O
DDI-DrugBank.d316.s2|16-17|in|O
DDI-DrugBank.d316.s2|19-31|concentration|O
DDI-DrugBank.d316.s2|33-35|may|O
DDI-DrugBank.d316.s2|37-40|lead|O
DDI-DrugBank.d316.s2|42-43|to|O
DDI-DrugBank.d316.s2|45-53|increased|O
DDI-DrugBank.d316.s2|55-61|effects|O
DDI-DrugBank.d316.s2|62-62|,|O
DDI-DrugBank.d316.s2|64-64|(|O
DDI-DrugBank.d316.s2|65-69|lower|O
DDI-DrugBank.d316.s2|71-75|blood|O
DDI-DrugBank.d316.s2|77-84|pressure|O
DDI-DrugBank.d316.s2|86-88|and|O
DDI-DrugBank.d316.s2|90-98|increased|O
DDI-DrugBank.d316.s2|100-104|heart|O
DDI-DrugBank.d316.s2|106-109|rate|O
DDI-DrugBank.d316.s2|110-110|)|O
DDI-DrugBank.d316.s2|111-111|.|O
DDI-DrugBank.d316.s3|0-4|These|O
DDI-DrugBank.d316.s3|6-12|effects|O
DDI-DrugBank.d316.s3|14-17|have|O
DDI-DrugBank.d316.s3|19-22|been|O
DDI-DrugBank.d316.s3|24-31|observed|O
DDI-DrugBank.d316.s3|33-36|with|O
DDI-DrugBank.d316.s3|38-54|co-administration|O
DDI-DrugBank.d316.s3|56-57|of|O
DDI-DrugBank.d316.s3|59-70|itraconazole|drug
DDI-DrugBank.d316.s3|72-72|(|O
DDI-DrugBank.d316.s3|73-73|a|O
DDI-DrugBank.d316.s3|75-80|potent|O
DDI-DrugBank.d316.s3|82-87|CYP3A4|drug
DDI-DrugBank.d316.s3|89-97|inhibitor|O
DDI-DrugBank.d316.s3|98-98|)|O
DDI-DrugBank.d316.s3|99-99|.|O
DDI-DrugBank.d316.s4|0-6|Caution|O
DDI-DrugBank.d316.s4|8-13|should|O
DDI-DrugBank.d316.s4|15-16|be|O
DDI-DrugBank.d316.s4|18-21|used|O
DDI-DrugBank.d316.s4|23-26|when|O
DDI-DrugBank.d316.s4|28-33|CYP3A4|drug
DDI-DrugBank.d316.s4|35-44|inhibitors|O
DDI-DrugBank.d316.s4|46-48|are|O
DDI-DrugBank.d316.s4|50-64|co-administered|O
DDI-DrugBank.d316.s4|66-69|with|O
DDI-DrugBank.d316.s4|71-80|felodipine|drug
DDI-DrugBank.d316.s4|81-81|.|O
DDI-DrugBank.d316.s5|0-0|A|O
DDI-DrugBank.d316.s5|2-13|conservative|O
DDI-DrugBank.d316.s5|15-22|approach|O
DDI-DrugBank.d316.s5|24-25|to|O
DDI-DrugBank.d316.s5|27-32|dosing|O
DDI-DrugBank.d316.s5|34-43|felodipine|drug
DDI-DrugBank.d316.s5|45-50|should|O
DDI-DrugBank.d316.s5|52-53|be|O
DDI-DrugBank.d316.s5|55-59|taken|O
DDI-DrugBank.d316.s5|60-60|.|O
DDI-DrugBank.d316.s6|0-2|The|O
DDI-DrugBank.d316.s6|4-12|following|O
DDI-DrugBank.d316.s6|14-21|specific|O
DDI-DrugBank.d316.s6|23-34|interactions|O
DDI-DrugBank.d316.s6|36-39|have|O
DDI-DrugBank.d316.s6|41-44|been|O
DDI-DrugBank.d316.s6|46-53|reported|O
DDI-DrugBank.d316.s6|54-54|:|O
DDI-DrugBank.d316.s6|56-67|Itraconazole|O
DDI-DrugBank.d316.s6|69-85|Co-administration|O
DDI-DrugBank.d316.s6|87-88|of|O
DDI-DrugBank.d316.s6|90-96|another|O
DDI-DrugBank.d316.s6|98-105|extended|O
DDI-DrugBank.d316.s6|107-113|release|O
DDI-DrugBank.d316.s6|115-125|formulation|O
DDI-DrugBank.d316.s6|127-128|of|O
DDI-DrugBank.d316.s6|130-139|felodipine|drug
DDI-DrugBank.d316.s6|141-144|with|O
DDI-DrugBank.d316.s6|146-157|itraconazole|drug
DDI-DrugBank.d316.s6|159-166|resulted|O
DDI-DrugBank.d316.s6|168-169|in|O
DDI-DrugBank.d316.s6|171-183|approximately|O
DDI-DrugBank.d316.s6|185-190|8-fold|O
DDI-DrugBank.d316.s6|192-199|increase|O
DDI-DrugBank.d316.s6|201-202|in|O
DDI-DrugBank.d316.s6|204-206|the|O
DDI-DrugBank.d316.s6|208-210|AUC|O
DDI-DrugBank.d316.s6|211-211|,|O
DDI-DrugBank.d316.s6|213-216|more|O
DDI-DrugBank.d316.s6|218-221|than|O
DDI-DrugBank.d316.s6|223-224|6-|O
DDI-DrugBank.d316.s6|226-229|fold|O
DDI-DrugBank.d316.s6|231-238|increase|O
DDI-DrugBank.d316.s6|240-241|in|O
DDI-DrugBank.d316.s6|243-245|the|O
DDI-DrugBank.d316.s6|247-250|Cmax|O
DDI-DrugBank.d316.s6|251-251|,|O
DDI-DrugBank.d316.s6|253-255|and|O
DDI-DrugBank.d316.s6|257-262|2-fold|O
DDI-DrugBank.d316.s6|264-275|prolongation|O
DDI-DrugBank.d316.s6|277-278|in|O
DDI-DrugBank.d316.s6|280-282|the|O
DDI-DrugBank.d316.s6|284-288|half-|O
DDI-DrugBank.d316.s6|290-293|life|O
DDI-DrugBank.d316.s6|295-296|of|O
DDI-DrugBank.d316.s6|298-307|felodipine|drug
DDI-DrugBank.d316.s6|308-308|.|O
DDI-DrugBank.d316.s7|0-11|Erythromycin|O
DDI-DrugBank.d316.s7|13-29|Co-administration|O
DDI-DrugBank.d316.s7|31-32|of|O
DDI-DrugBank.d316.s7|34-43|felodipine|drug
DDI-DrugBank.d316.s7|45-45|(|O
DDI-DrugBank.d316.s7|46-52|PLENDIL|drug
DDI-DrugBank.d316.s7|53-53|)|O
DDI-DrugBank.d316.s7|55-58|with|O
DDI-DrugBank.d316.s7|60-71|erythromycin|drug
DDI-DrugBank.d316.s7|73-80|resulted|O
DDI-DrugBank.d316.s7|82-83|in|O
DDI-DrugBank.d316.s7|85-97|approximately|O
DDI-DrugBank.d316.s7|99-102|2.5-|O
DDI-DrugBank.d316.s7|104-107|fold|O
DDI-DrugBank.d316.s7|109-116|increase|O
DDI-DrugBank.d316.s7|118-119|in|O
DDI-DrugBank.d316.s7|121-123|the|O
DDI-DrugBank.d316.s7|125-127|AUC|O
DDI-DrugBank.d316.s7|129-131|and|O
DDI-DrugBank.d316.s7|133-136|Cmax|O
DDI-DrugBank.d316.s7|137-137|,|O
DDI-DrugBank.d316.s7|139-141|and|O
DDI-DrugBank.d316.s7|143-147|about|O
DDI-DrugBank.d316.s7|149-150|2-|O
DDI-DrugBank.d316.s7|152-155|fold|O
DDI-DrugBank.d316.s7|157-168|prolongation|O
DDI-DrugBank.d316.s7|170-171|in|O
DDI-DrugBank.d316.s7|173-175|the|O
DDI-DrugBank.d316.s7|177-181|half-|O
DDI-DrugBank.d316.s7|183-186|life|O
DDI-DrugBank.d316.s7|188-189|of|O
DDI-DrugBank.d316.s7|191-200|felodipine|drug
DDI-DrugBank.d316.s7|201-201|.|O
DDI-DrugBank.d316.s8|0-9|Grapefruit|O
DDI-DrugBank.d316.s8|11-15|juice|O
DDI-DrugBank.d316.s8|17-33|Co-administration|O
DDI-DrugBank.d316.s8|35-36|of|O
DDI-DrugBank.d316.s8|38-47|felodipine|drug
DDI-DrugBank.d316.s8|49-52|with|O
DDI-DrugBank.d316.s8|54-63|grapefruit|O
DDI-DrugBank.d316.s8|65-69|juice|O
DDI-DrugBank.d316.s8|71-78|resulted|O
DDI-DrugBank.d316.s8|80-81|in|O
DDI-DrugBank.d316.s8|83-86|more|O
DDI-DrugBank.d316.s8|88-91|than|O
DDI-DrugBank.d316.s8|93-98|2-fold|O
DDI-DrugBank.d316.s8|100-107|increase|O
DDI-DrugBank.d316.s8|109-110|in|O
DDI-DrugBank.d316.s8|112-114|the|O
DDI-DrugBank.d316.s8|116-118|AUC|O
DDI-DrugBank.d316.s8|120-122|and|O
DDI-DrugBank.d316.s8|124-127|Cmax|O
DDI-DrugBank.d316.s8|128-128|,|O
DDI-DrugBank.d316.s8|130-132|but|O
DDI-DrugBank.d316.s8|134-135|no|O
DDI-DrugBank.d316.s8|137-148|prolongation|O
DDI-DrugBank.d316.s8|150-151|in|O
DDI-DrugBank.d316.s8|153-155|the|O
DDI-DrugBank.d316.s8|157-161|half-|O
DDI-DrugBank.d316.s8|163-166|life|O
DDI-DrugBank.d316.s8|168-169|of|O
DDI-DrugBank.d316.s8|171-180|felodipine|drug
DDI-DrugBank.d316.s8|181-181|.|O
DDI-DrugBank.d316.s9|0-9|Cimetidine|O
DDI-DrugBank.d316.s9|11-27|Co-administration|O
DDI-DrugBank.d316.s9|29-30|of|O
DDI-DrugBank.d316.s9|32-41|felodipine|drug
DDI-DrugBank.d316.s9|43-46|with|O
DDI-DrugBank.d316.s9|48-57|cimetidine|drug
DDI-DrugBank.d316.s9|59-59|(|O
DDI-DrugBank.d316.s9|60-60|a|O
DDI-DrugBank.d316.s9|62-73|non-specific|O
DDI-DrugBank.d316.s9|75-81|CYP-450|O
DDI-DrugBank.d316.s9|83-91|inhibitor|O
DDI-DrugBank.d316.s9|92-92|)|O
DDI-DrugBank.d316.s9|94-101|resulted|O
DDI-DrugBank.d316.s9|103-104|in|O
DDI-DrugBank.d316.s9|106-107|an|O
DDI-DrugBank.d316.s9|109-116|increase|O
DDI-DrugBank.d316.s9|118-119|of|O
DDI-DrugBank.d316.s9|121-133|approximately|O
DDI-DrugBank.d316.s9|135-136|50|O
DDI-DrugBank.d316.s9|137-137|%|O
DDI-DrugBank.d316.s9|139-140|in|O
DDI-DrugBank.d316.s9|142-144|the|O
DDI-DrugBank.d316.s9|146-148|AUC|O
DDI-DrugBank.d316.s9|150-152|and|O
DDI-DrugBank.d316.s9|154-156|the|O
DDI-DrugBank.d316.s9|158-161|Cmax|O
DDI-DrugBank.d316.s9|162-162|,|O
DDI-DrugBank.d316.s9|164-165|of|O
DDI-DrugBank.d316.s9|167-176|felodipine|drug
DDI-DrugBank.d316.s9|177-177|.|O
DDI-DrugBank.d316.s10|0-12|Beta-Blocking|O
DDI-DrugBank.d316.s10|14-19|Agents|O
DDI-DrugBank.d316.s10|22-22|A|O
DDI-DrugBank.d316.s10|24-38|pharmacokinetic|O
DDI-DrugBank.d316.s10|40-44|study|O
DDI-DrugBank.d316.s10|46-47|of|O
DDI-DrugBank.d316.s10|49-58|felodipine|drug
DDI-DrugBank.d316.s10|60-61|in|O
DDI-DrugBank.d316.s10|63-73|conjunction|O
DDI-DrugBank.d316.s10|75-78|with|O
DDI-DrugBank.d316.s10|80-89|metoprolol|drug
DDI-DrugBank.d316.s10|91-102|demonstrated|O
DDI-DrugBank.d316.s10|104-105|no|O
DDI-DrugBank.d316.s10|107-117|significant|O
DDI-DrugBank.d316.s10|119-125|effects|O
DDI-DrugBank.d316.s10|127-128|on|O
DDI-DrugBank.d316.s10|130-132|the|O
DDI-DrugBank.d316.s10|134-149|pharmacokinetics|O
DDI-DrugBank.d316.s10|151-152|of|O
DDI-DrugBank.d316.s10|154-163|felodipine|drug
DDI-DrugBank.d316.s10|164-164|.|O
DDI-DrugBank.d316.s11|0-2|The|O
DDI-DrugBank.d316.s11|4-6|AUC|O
DDI-DrugBank.d316.s11|8-10|and|O
DDI-DrugBank.d316.s11|12-15|Cmax|O
DDI-DrugBank.d316.s11|17-18|of|O
DDI-DrugBank.d316.s11|20-29|metoprolol|drug
DDI-DrugBank.d316.s11|30-30|,|O
DDI-DrugBank.d316.s11|32-38|however|O
DDI-DrugBank.d316.s11|39-39|,|O
DDI-DrugBank.d316.s11|41-44|were|O
DDI-DrugBank.d316.s11|46-54|increased|O
DDI-DrugBank.d316.s11|56-68|approximately|O
DDI-DrugBank.d316.s11|70-71|31|O
DDI-DrugBank.d316.s11|73-75|and|O
DDI-DrugBank.d316.s11|77-78|38|O
DDI-DrugBank.d316.s11|79-79|%|O
DDI-DrugBank.d316.s11|80-80|,|O
DDI-DrugBank.d316.s11|82-93|respectively|O
DDI-DrugBank.d316.s11|94-94|.|O
DDI-DrugBank.d316.s12|0-1|In|O
DDI-DrugBank.d316.s12|3-12|controlled|O
DDI-DrugBank.d316.s12|14-21|clinical|O
DDI-DrugBank.d316.s12|23-28|trials|O
DDI-DrugBank.d316.s12|29-29|,|O
DDI-DrugBank.d316.s12|31-37|however|O
DDI-DrugBank.d316.s12|38-38|,|O
DDI-DrugBank.d316.s12|40-52|beta blockers|drug
DDI-DrugBank.d316.s12|54-62|including|O
DDI-DrugBank.d316.s12|64-73|metoprolol|drug
DDI-DrugBank.d316.s12|75-78|were|O
DDI-DrugBank.d316.s12|80-91|concurrently|O
DDI-DrugBank.d316.s12|93-104|administered|O
DDI-DrugBank.d316.s12|106-109|with|O
DDI-DrugBank.d316.s12|111-120|felodipine|drug
DDI-DrugBank.d316.s12|122-124|and|O
DDI-DrugBank.d316.s12|126-129|were|O
DDI-DrugBank.d316.s12|131-134|well|O
DDI-DrugBank.d316.s12|136-144|tolerated|O
DDI-DrugBank.d316.s12|145-145|.|O
DDI-DrugBank.d316.s13|0-6|Digoxin|O
DDI-DrugBank.d316.s13|9-12|When|O
DDI-DrugBank.d316.s13|14-18|given|O
DDI-DrugBank.d316.s13|20-32|concomitantly|O
DDI-DrugBank.d316.s13|34-37|with|O
DDI-DrugBank.d316.s13|39-45|PLENDIL|drug
DDI-DrugBank.d316.s13|47-49|the|O
DDI-DrugBank.d316.s13|51-66|pharmacokinetics|O
DDI-DrugBank.d316.s13|68-69|of|O
DDI-DrugBank.d316.s13|71-77|digoxin|drug
DDI-DrugBank.d316.s13|79-80|in|O
DDI-DrugBank.d316.s13|82-89|patients|O
DDI-DrugBank.d316.s13|91-94|with|O
DDI-DrugBank.d316.s13|96-100|heart|O
DDI-DrugBank.d316.s13|102-108|failure|O
DDI-DrugBank.d316.s13|110-113|were|O
DDI-DrugBank.d316.s13|115-117|not|O
DDI-DrugBank.d316.s13|119-131|significantly|O
DDI-DrugBank.d316.s13|133-139|altered|O
DDI-DrugBank.d316.s13|140-140|.|O
DDI-DrugBank.d316.s14|0-14|Anticonvulsants|group
DDI-DrugBank.d316.s14|15-15|:|O
DDI-DrugBank.d316.s14|17-18|In|O
DDI-DrugBank.d316.s14|20-20|a|O
DDI-DrugBank.d316.s14|22-36|pharmacokinetic|O
DDI-DrugBank.d316.s14|38-42|study|O
DDI-DrugBank.d316.s14|43-43|,|O
DDI-DrugBank.d316.s14|45-51|maximum|O
DDI-DrugBank.d316.s14|53-58|plasma|O
DDI-DrugBank.d316.s14|60-73|concentrations|O
DDI-DrugBank.d316.s14|75-76|of|O
DDI-DrugBank.d316.s14|78-87|felodipine|drug
DDI-DrugBank.d316.s14|89-92|were|O
DDI-DrugBank.d316.s14|94-105|considerably|O
DDI-DrugBank.d316.s14|107-111|lower|O
DDI-DrugBank.d316.s14|113-114|in|O
DDI-DrugBank.d316.s14|116-124|epileptic|O
DDI-DrugBank.d316.s14|126-133|patients|O
DDI-DrugBank.d316.s14|135-136|on|O
DDI-DrugBank.d316.s14|138-146|long-term|O
DDI-DrugBank.d316.s14|148-161|anticonvulsant|group
DDI-DrugBank.d316.s14|163-169|therapy|O
DDI-DrugBank.d316.s14|171-171|(|O
DDI-DrugBank.d316.s14|172-173|eg|O
DDI-DrugBank.d316.s14|174-174|,|O
DDI-DrugBank.d316.s14|176-184|phenytoin|drug
DDI-DrugBank.d316.s14|185-185|,|O
DDI-DrugBank.d316.s14|187-199|carbamazepine|drug
DDI-DrugBank.d316.s14|200-200|,|O
DDI-DrugBank.d316.s14|202-203|or|O
DDI-DrugBank.d316.s14|205-217|phenobarbital|drug
DDI-DrugBank.d316.s14|218-218|)|O
DDI-DrugBank.d316.s14|220-223|than|O
DDI-DrugBank.d316.s14|225-226|in|O
DDI-DrugBank.d316.s14|228-234|healthy|O
DDI-DrugBank.d316.s14|236-245|volunteers|O
DDI-DrugBank.d316.s14|246-246|.|O
DDI-DrugBank.d316.s15|0-1|In|O
DDI-DrugBank.d316.s15|3-6|such|O
DDI-DrugBank.d316.s15|8-15|patients|O
DDI-DrugBank.d316.s15|16-16|,|O
DDI-DrugBank.d316.s15|18-20|the|O
DDI-DrugBank.d316.s15|22-25|mean|O
DDI-DrugBank.d316.s15|27-30|area|O
DDI-DrugBank.d316.s15|32-36|under|O
DDI-DrugBank.d316.s15|38-40|the|O
DDI-DrugBank.d316.s15|42-51|felodipine|drug
DDI-DrugBank.d316.s15|53-58|plasma|O
DDI-DrugBank.d316.s15|60-77|concentration-time|O
DDI-DrugBank.d316.s15|79-83|curve|O
DDI-DrugBank.d316.s15|85-87|was|O
DDI-DrugBank.d316.s15|89-92|also|O
DDI-DrugBank.d316.s15|94-100|reduced|O
DDI-DrugBank.d316.s15|102-103|to|O
DDI-DrugBank.d316.s15|105-117|approximately|O
DDI-DrugBank.d316.s15|119-119|6|O
DDI-DrugBank.d316.s15|120-120|%|O
DDI-DrugBank.d316.s15|122-123|of|O
DDI-DrugBank.d316.s15|125-128|that|O
DDI-DrugBank.d316.s15|130-137|observed|O
DDI-DrugBank.d316.s15|139-140|in|O
DDI-DrugBank.d316.s15|142-148|healthy|O
DDI-DrugBank.d316.s15|150-159|volunteers|O
DDI-DrugBank.d316.s15|160-160|.|O
DDI-DrugBank.d316.s16|0-4|Since|O
DDI-DrugBank.d316.s16|6-6|a|O
DDI-DrugBank.d316.s16|8-17|clinically|O
DDI-DrugBank.d316.s16|19-29|significant|O
DDI-DrugBank.d316.s16|31-41|interaction|O
DDI-DrugBank.d316.s16|43-45|may|O
DDI-DrugBank.d316.s16|47-48|be|O
DDI-DrugBank.d316.s16|50-60|anticipated|O
DDI-DrugBank.d316.s16|61-61|,|O
DDI-DrugBank.d316.s16|63-73|alternative|O
DDI-DrugBank.d316.s16|75-90|antihypertensive|drug
DDI-DrugBank.d316.s16|92-98|therapy|O
DDI-DrugBank.d316.s16|100-105|should|O
DDI-DrugBank.d316.s16|107-108|be|O
DDI-DrugBank.d316.s16|110-119|considered|O
DDI-DrugBank.d316.s16|121-122|in|O
DDI-DrugBank.d316.s16|124-128|these|O
DDI-DrugBank.d316.s16|130-137|patients|O
DDI-DrugBank.d316.s16|138-138|.|O
DDI-DrugBank.d316.s17|0-9|Tacrolimus|O
DDI-DrugBank.d316.s17|12-21|Felodipine|drug
DDI-DrugBank.d316.s17|23-25|may|O
DDI-DrugBank.d316.s17|27-34|increase|O
DDI-DrugBank.d316.s17|36-38|the|O
DDI-DrugBank.d316.s17|40-44|blood|O
DDI-DrugBank.d316.s17|46-58|concentration|O
DDI-DrugBank.d316.s17|60-61|of|O
DDI-DrugBank.d316.s17|63-72|tacrolimus|drug
DDI-DrugBank.d316.s17|73-73|.|O
DDI-DrugBank.d316.s18|0-3|When|O
DDI-DrugBank.d316.s18|5-9|given|O
DDI-DrugBank.d316.s18|11-23|concomitantly|O
DDI-DrugBank.d316.s18|25-28|with|O
DDI-DrugBank.d316.s18|30-39|felodipine|drug
DDI-DrugBank.d316.s18|40-40|,|O
DDI-DrugBank.d316.s18|42-44|the|O
DDI-DrugBank.d316.s18|46-55|tacrolimus|drug
DDI-DrugBank.d316.s18|57-61|blood|O
DDI-DrugBank.d316.s18|63-75|concentration|O
DDI-DrugBank.d316.s18|77-82|should|O
DDI-DrugBank.d316.s18|84-85|be|O
DDI-DrugBank.d316.s18|87-94|followed|O
DDI-DrugBank.d316.s18|96-98|and|O
DDI-DrugBank.d316.s18|100-102|the|O
DDI-DrugBank.d316.s18|104-113|tacrolimus|O
DDI-DrugBank.d316.s18|115-118|dose|O
DDI-DrugBank.d316.s18|120-122|may|O
DDI-DrugBank.d316.s18|124-127|need|O
DDI-DrugBank.d316.s18|129-130|to|O
DDI-DrugBank.d316.s18|132-133|be|O
DDI-DrugBank.d316.s18|135-142|adjusted|O
DDI-DrugBank.d316.s18|143-143|.|O
DDI-DrugBank.d316.s19|0-4|Other|O
DDI-DrugBank.d316.s19|6-16|Concomitant|O
DDI-DrugBank.d316.s19|18-24|Therapy|O
DDI-DrugBank.d316.s19|27-28|In|O
DDI-DrugBank.d316.s19|30-36|healthy|O
DDI-DrugBank.d316.s19|38-45|subjects|O
DDI-DrugBank.d316.s19|47-51|there|O
DDI-DrugBank.d316.s19|53-56|were|O
DDI-DrugBank.d316.s19|58-59|no|O
DDI-DrugBank.d316.s19|61-70|clinically|O
DDI-DrugBank.d316.s19|72-82|significant|O
DDI-DrugBank.d316.s19|84-95|interactions|O
DDI-DrugBank.d316.s19|97-100|when|O
DDI-DrugBank.d316.s19|102-111|felodipine|drug
DDI-DrugBank.d316.s19|113-115|was|O
DDI-DrugBank.d316.s19|117-121|given|O
DDI-DrugBank.d316.s19|123-135|concomitantly|O
DDI-DrugBank.d316.s19|137-140|with|O
DDI-DrugBank.d316.s19|142-153|indomethacin|drug
DDI-DrugBank.d316.s19|155-156|or|O
DDI-DrugBank.d316.s19|158-171|spironolactone|drug
DDI-DrugBank.d316.s19|172-172|.|O
DDI-DrugBank.d316.s20|0-10|Interaction|O
DDI-DrugBank.d316.s20|12-15|with|O
DDI-DrugBank.d316.s20|17-20|Food|O
DDI-DrugBank.d316.s20|23-25|See|O
DDI-DrugBank.d316.s20|27-34|CLINICAL|O
DDI-DrugBank.d316.s20|36-47|PHARMACOLOGY|O
DDI-DrugBank.d316.s20|48-48|,|O
DDI-DrugBank.d316.s20|50-65|Pharmacokinetics|O
DDI-DrugBank.d316.s20|67-69|and|O
DDI-DrugBank.d316.s20|71-80|Metabolism|O
DDI-DrugBank.d316.s20|81-81|.|O
DDI-DrugBank.d381.s0|0-8|ERGAMISOL|brand
DDI-DrugBank.d381.s0|11-11|(|O
DDI-DrugBank.d381.s0|12-35|levamisole hydrochloride|drug
DDI-DrugBank.d381.s0|36-36|)|O
DDI-DrugBank.d381.s0|38-40|has|O
DDI-DrugBank.d381.s0|42-45|been|O
DDI-DrugBank.d381.s0|47-54|reported|O
DDI-DrugBank.d381.s0|56-57|to|O
DDI-DrugBank.d381.s0|59-65|produce|O
DDI-DrugBank.d381.s0|67-79|ANTABUSE-like|O
DDI-DrugBank.d381.s0|81-84|side|O
DDI-DrugBank.d381.s0|86-92|effects|O
DDI-DrugBank.d381.s0|94-97|when|O
DDI-DrugBank.d381.s0|99-103|given|O
DDI-DrugBank.d381.s0|105-117|concomitantly|O
DDI-DrugBank.d381.s0|119-122|with|O
DDI-DrugBank.d381.s0|124-130|alcohol|drug
DDI-DrugBank.d381.s0|131-131|.|O
DDI-DrugBank.d381.s1|0-2|The|O
DDI-DrugBank.d381.s1|4-12|physician|O
DDI-DrugBank.d381.s1|14-15|is|O
DDI-DrugBank.d381.s1|17-23|advised|O
DDI-DrugBank.d381.s1|25-26|to|O
DDI-DrugBank.d381.s1|28-34|monitor|O
DDI-DrugBank.d381.s1|36-41|plasma|O
DDI-DrugBank.d381.s1|43-48|levels|O
DDI-DrugBank.d381.s1|50-51|of|O
DDI-DrugBank.d381.s1|53-61|phenytoin|drug
DDI-DrugBank.d381.s1|63-65|and|O
DDI-DrugBank.d381.s1|67-68|to|O
DDI-DrugBank.d381.s1|70-77|decrease|O
DDI-DrugBank.d381.s1|79-81|the|O
DDI-DrugBank.d381.s1|83-86|dose|O
DDI-DrugBank.d381.s1|88-89|if|O
DDI-DrugBank.d381.s1|91-99|necessary|O
DDI-DrugBank.d381.s1|100-100|.|O
DDI-DrugBank.d381.s2|0-6|Because|O
DDI-DrugBank.d381.s2|8-9|of|O
DDI-DrugBank.d381.s2|11-17|reports|O
DDI-DrugBank.d381.s2|19-20|of|O
DDI-DrugBank.d381.s2|22-33|prolongation|O
DDI-DrugBank.d381.s2|35-36|of|O
DDI-DrugBank.d381.s2|38-40|the|O
DDI-DrugBank.d381.s2|42-52|prothrombin|O
DDI-DrugBank.d381.s2|54-57|time|O
DDI-DrugBank.d381.s2|59-64|beyond|O
DDI-DrugBank.d381.s2|66-68|the|O
DDI-DrugBank.d381.s2|70-80|therapeutic|O
DDI-DrugBank.d381.s2|82-86|range|O
DDI-DrugBank.d381.s2|88-89|in|O
DDI-DrugBank.d381.s2|91-98|patients|O
DDI-DrugBank.d381.s2|100-105|taking|O
DDI-DrugBank.d381.s2|107-116|concurrent|O
DDI-DrugBank.d381.s2|118-127|levamisole|drug
DDI-DrugBank.d381.s2|129-131|and|O
DDI-DrugBank.d381.s2|133-147|warfarin sodium|drug
DDI-DrugBank.d381.s2|148-148|,|O
DDI-DrugBank.d381.s2|150-151|it|O
DDI-DrugBank.d381.s2|153-154|is|O
DDI-DrugBank.d381.s2|156-164|suggested|O
DDI-DrugBank.d381.s2|166-169|that|O
DDI-DrugBank.d381.s2|171-173|the|O
DDI-DrugBank.d381.s2|175-185|prothrombin|O
DDI-DrugBank.d381.s2|187-190|time|O
DDI-DrugBank.d381.s2|192-193|be|O
DDI-DrugBank.d381.s2|195-203|monitored|O
DDI-DrugBank.d381.s2|205-213|carefully|O
DDI-DrugBank.d381.s2|214-214|,|O
DDI-DrugBank.d381.s2|216-218|and|O
DDI-DrugBank.d381.s2|220-222|the|O
DDI-DrugBank.d381.s2|224-227|dose|O
DDI-DrugBank.d381.s2|229-230|of|O
DDI-DrugBank.d381.s2|232-246|warfarin sodium|drug
DDI-DrugBank.d381.s2|248-249|or|O
DDI-DrugBank.d381.s2|251-255|other|O
DDI-DrugBank.d381.s2|257-269|coumarin-like|group
DDI-DrugBank.d381.s2|271-275|drugs|O
DDI-DrugBank.d381.s2|277-282|should|O
DDI-DrugBank.d381.s2|284-285|be|O
DDI-DrugBank.d381.s2|287-294|adjusted|O
DDI-DrugBank.d381.s2|296-306|accordingly|O
DDI-DrugBank.d381.s2|307-307|,|O
DDI-DrugBank.d381.s2|309-310|in|O
DDI-DrugBank.d381.s2|312-319|patients|O
DDI-DrugBank.d381.s2|321-326|taking|O
DDI-DrugBank.d381.s2|328-331|both|O
DDI-DrugBank.d381.s2|333-337|drugs|O
DDI-DrugBank.d381.s2|338-338|.|O
DDI-DrugBank.d291.s0|0-3|When|O
DDI-DrugBank.d291.s0|5-11|Bezalip|brand
DDI-DrugBank.d291.s0|13-14|or|O
DDI-DrugBank.d291.s0|16-29|Bezalip retard|brand
DDI-DrugBank.d291.s0|31-32|is|O
DDI-DrugBank.d291.s0|34-37|used|O
DDI-DrugBank.d291.s0|39-40|at|O
DDI-DrugBank.d291.s0|42-44|the|O
DDI-DrugBank.d291.s0|46-49|same|O
DDI-DrugBank.d291.s0|51-54|time|O
DDI-DrugBank.d291.s0|56-57|as|O
DDI-DrugBank.d291.s0|59-63|other|O
DDI-DrugBank.d291.s0|65-73|medicines|O
DDI-DrugBank.d291.s0|75-76|or|O
DDI-DrugBank.d291.s0|78-87|substances|O
DDI-DrugBank.d291.s0|89-91|the|O
DDI-DrugBank.d291.s0|93-101|following|O
DDI-DrugBank.d291.s0|103-114|interactions|O
DDI-DrugBank.d291.s0|116-119|must|O
DDI-DrugBank.d291.s0|121-122|be|O
DDI-DrugBank.d291.s0|124-128|taken|O
DDI-DrugBank.d291.s0|130-133|into|O
DDI-DrugBank.d291.s0|135-141|account|O
DDI-DrugBank.d291.s0|142-142|:|O
DDI-DrugBank.d291.s0|144-144|-|O
DDI-DrugBank.d291.s0|146-152|Bezalip|brand
DDI-DrugBank.d291.s0|154-156|and|O
DDI-DrugBank.d291.s0|158-171|Bezalip retard|brand
DDI-DrugBank.d291.s0|173-175|may|O
DDI-DrugBank.d291.s0|177-183|enhance|O
DDI-DrugBank.d291.s0|185-187|the|O
DDI-DrugBank.d291.s0|189-194|action|O
DDI-DrugBank.d291.s0|196-197|of|O
DDI-DrugBank.d291.s0|199-233|anticoagulants of the coumarin type|group
DDI-DrugBank.d291.s0|234-234|.|O
DDI-DrugBank.d291.s1|0-2|For|O
DDI-DrugBank.d291.s1|4-7|this|O
DDI-DrugBank.d291.s1|9-14|reason|O
DDI-DrugBank.d291.s1|15-15|,|O
DDI-DrugBank.d291.s1|17-19|the|O
DDI-DrugBank.d291.s1|21-24|dose|O
DDI-DrugBank.d291.s1|26-27|of|O
DDI-DrugBank.d291.s1|29-31|the|O
DDI-DrugBank.d291.s1|33-45|anticoagulant|drug
DDI-DrugBank.d291.s1|47-52|should|O
DDI-DrugBank.d291.s1|54-55|be|O
DDI-DrugBank.d291.s1|57-63|reduced|O
DDI-DrugBank.d291.s1|65-66|by|O
DDI-DrugBank.d291.s1|68-69|30|O
DDI-DrugBank.d291.s1|71-71|-|O
DDI-DrugBank.d291.s1|73-74|50|O
DDI-DrugBank.d291.s1|75-75|%|O
DDI-DrugBank.d291.s1|77-78|at|O
DDI-DrugBank.d291.s1|80-82|the|O
DDI-DrugBank.d291.s1|84-88|start|O
DDI-DrugBank.d291.s1|90-91|of|O
DDI-DrugBank.d291.s1|93-101|treatment|O
DDI-DrugBank.d291.s1|103-106|with|O
DDI-DrugBank.d291.s1|108-114|Bezalip|brand
DDI-DrugBank.d291.s1|116-117|or|O
DDI-DrugBank.d291.s1|119-125|Bezalip|brand
DDI-DrugBank.d291.s1|127-132|retard|O
DDI-DrugBank.d291.s1|134-136|and|O
DDI-DrugBank.d291.s1|138-141|then|O
DDI-DrugBank.d291.s1|143-150|titrated|O
DDI-DrugBank.d291.s1|152-160|according|O
DDI-DrugBank.d291.s1|162-163|to|O
DDI-DrugBank.d291.s1|165-167|the|O
DDI-DrugBank.d291.s1|169-173|blood|O
DDI-DrugBank.d291.s1|175-182|clotting|O
DDI-DrugBank.d291.s1|184-193|parameters|O
DDI-DrugBank.d291.s2|0-0|.|O
DDI-DrugBank.d291.s3|0-0|-|O
DDI-DrugBank.d291.s3|2-4|The|O
DDI-DrugBank.d291.s3|6-11|action|O
DDI-DrugBank.d291.s3|13-14|of|O
DDI-DrugBank.d291.s3|16-29|sulphonylureas|group
DDI-DrugBank.d291.s3|31-33|and|O
DDI-DrugBank.d291.s3|35-41|insulin|drug
DDI-DrugBank.d291.s3|43-45|may|O
DDI-DrugBank.d291.s3|47-48|be|O
DDI-DrugBank.d291.s3|50-57|enhanced|O
DDI-DrugBank.d291.s3|59-60|by|O
DDI-DrugBank.d291.s3|62-68|Bezalip|brand
DDI-DrugBank.d291.s3|70-71|or|O
DDI-DrugBank.d291.s3|73-86|Bezalip retard|brand
DDI-DrugBank.d291.s3|87-87|.|O
DDI-DrugBank.d291.s4|0-3|This|O
DDI-DrugBank.d291.s4|5-7|may|O
DDI-DrugBank.d291.s4|9-10|be|O
DDI-DrugBank.d291.s4|12-14|due|O
DDI-DrugBank.d291.s4|16-17|to|O
DDI-DrugBank.d291.s4|19-20|an|O
DDI-DrugBank.d291.s4|22-29|improved|O
DDI-DrugBank.d291.s4|31-37|glucose|O
DDI-DrugBank.d291.s4|39-49|utilization|O
DDI-DrugBank.d291.s4|51-54|with|O
DDI-DrugBank.d291.s4|56-67|simultaneous|O
DDI-DrugBank.d291.s4|69-77|reduction|O
DDI-DrugBank.d291.s4|79-80|in|O
DDI-DrugBank.d291.s4|82-88|insulin|drug
DDI-DrugBank.d291.s4|90-100|requirement|O
DDI-DrugBank.d291.s5|0-0|.|O
DDI-DrugBank.d291.s6|0-0|-|O
DDI-DrugBank.d291.s6|2-3|In|O
DDI-DrugBank.d291.s6|5-12|isolated|O
DDI-DrugBank.d291.s6|14-18|cases|O
DDI-DrugBank.d291.s6|19-19|,|O
DDI-DrugBank.d291.s6|21-21|a|O
DDI-DrugBank.d291.s6|23-32|pronounced|O
DDI-DrugBank.d291.s6|34-39|though|O
DDI-DrugBank.d291.s6|41-50|reversible|O
DDI-DrugBank.d291.s6|51-51|,|O
DDI-DrugBank.d291.s6|53-62|impairment|O
DDI-DrugBank.d291.s6|64-65|of|O
DDI-DrugBank.d291.s6|67-71|renal|O
DDI-DrugBank.d291.s6|73-80|function|O
DDI-DrugBank.d291.s6|82-82|(|O
DDI-DrugBank.d291.s6|83-93|accompanied|O
DDI-DrugBank.d291.s6|95-96|by|O
DDI-DrugBank.d291.s6|98-98|a|O
DDI-DrugBank.d291.s6|100-112|corresponding|O
DDI-DrugBank.d291.s6|114-121|increase|O
DDI-DrugBank.d291.s6|123-124|in|O
DDI-DrugBank.d291.s6|126-128|the|O
DDI-DrugBank.d291.s6|130-134|serum|O
DDI-DrugBank.d291.s6|136-145|creatinine|O
DDI-DrugBank.d291.s6|147-151|level|O
DDI-DrugBank.d291.s6|152-152|)|O
DDI-DrugBank.d291.s6|154-156|has|O
DDI-DrugBank.d291.s6|158-161|been|O
DDI-DrugBank.d291.s6|163-170|reported|O
DDI-DrugBank.d291.s6|172-173|in|O
DDI-DrugBank.d291.s6|175-179|organ|O
DDI-DrugBank.d291.s6|181-190|transplant|O
DDI-DrugBank.d291.s6|192-199|patients|O
DDI-DrugBank.d291.s6|201-209|receiving|O
DDI-DrugBank.d291.s6|211-228|immuno-suppressant|group
DDI-DrugBank.d291.s6|230-236|therapy|O
DDI-DrugBank.d291.s6|238-240|and|O
DDI-DrugBank.d291.s6|242-252|concomitant|O
DDI-DrugBank.d291.s6|254-264|bezafibrate|drug
DDI-DrugBank.d291.s6|265-265|.|O
DDI-DrugBank.d291.s7|0-10|Accordingly|O
DDI-DrugBank.d291.s7|11-11|,|O
DDI-DrugBank.d291.s7|13-17|renal|O
DDI-DrugBank.d291.s7|19-26|function|O
DDI-DrugBank.d291.s7|28-33|should|O
DDI-DrugBank.d291.s7|35-36|be|O
DDI-DrugBank.d291.s7|38-44|closely|O
DDI-DrugBank.d291.s7|46-54|monitored|O
DDI-DrugBank.d291.s7|56-57|in|O
DDI-DrugBank.d291.s7|59-63|these|O
DDI-DrugBank.d291.s7|65-72|patients|O
DDI-DrugBank.d291.s7|74-76|and|O
DDI-DrugBank.d291.s7|77-77|,|O
DDI-DrugBank.d291.s7|79-80|in|O
DDI-DrugBank.d291.s7|82-84|the|O
DDI-DrugBank.d291.s7|86-90|event|O
DDI-DrugBank.d291.s7|92-93|of|O
DDI-DrugBank.d291.s7|95-102|relevant|O
DDI-DrugBank.d291.s7|104-114|significant|O
DDI-DrugBank.d291.s7|116-122|changes|O
DDI-DrugBank.d291.s7|124-125|in|O
DDI-DrugBank.d291.s7|127-136|laboratory|O
DDI-DrugBank.d291.s7|138-147|parameters|O
DDI-DrugBank.d291.s7|148-148|,|O
DDI-DrugBank.d291.s7|150-160|bezafibrate|drug
DDI-DrugBank.d291.s7|162-167|should|O
DDI-DrugBank.d291.s7|168-168|,|O
DDI-DrugBank.d291.s7|170-171|if|O
DDI-DrugBank.d291.s7|173-181|necessary|O
DDI-DrugBank.d291.s7|182-182|,|O
DDI-DrugBank.d291.s7|184-185|be|O
DDI-DrugBank.d291.s7|187-198|discontinued|O
DDI-DrugBank.d291.s8|0-0|.|O
DDI-DrugBank.d291.s9|0-0|-|O
DDI-DrugBank.d291.s9|2-5|When|O
DDI-DrugBank.d291.s9|7-13|Bezalip|brand
DDI-DrugBank.d291.s9|15-16|or|O
DDI-DrugBank.d291.s9|18-31|Bezalip retard|brand
DDI-DrugBank.d291.s9|33-34|is|O
DDI-DrugBank.d291.s9|36-39|used|O
DDI-DrugBank.d291.s9|41-52|concurrently|O
DDI-DrugBank.d291.s9|54-57|with|O
DDI-DrugBank.d291.s9|59-79|anion-exchange resins|group
DDI-DrugBank.d291.s9|81-81|(|O
DDI-DrugBank.d291.s9|82-85|e.g.|O
DDI-DrugBank.d291.s9|87-101|cholestryramine|drug
DDI-DrugBank.d291.s9|102-102|)|O
DDI-DrugBank.d291.s9|103-103|,|O
DDI-DrugBank.d291.s9|105-106|an|O
DDI-DrugBank.d291.s9|108-115|interval|O
DDI-DrugBank.d291.s9|117-118|of|O
DDI-DrugBank.d291.s9|120-121|at|O
DDI-DrugBank.d291.s9|123-127|least|O
DDI-DrugBank.d291.s9|129-129|2|O
DDI-DrugBank.d291.s9|131-135|hours|O
DDI-DrugBank.d291.s9|137-142|should|O
DDI-DrugBank.d291.s9|144-145|be|O
DDI-DrugBank.d291.s9|147-156|maintained|O
DDI-DrugBank.d291.s9|158-164|between|O
DDI-DrugBank.d291.s9|166-168|the|O
DDI-DrugBank.d291.s9|170-172|two|O
DDI-DrugBank.d291.s9|174-182|medicines|O
DDI-DrugBank.d291.s9|183-183|,|O
DDI-DrugBank.d291.s9|185-189|since|O
DDI-DrugBank.d291.s9|191-193|the|O
DDI-DrugBank.d291.s9|195-204|absorption|O
DDI-DrugBank.d291.s9|206-207|of|O
DDI-DrugBank.d291.s9|209-215|Bezalip|brand
DDI-DrugBank.d291.s9|217-218|or|O
DDI-DrugBank.d291.s9|220-233|Bezalip retard|brand
DDI-DrugBank.d291.s9|235-236|is|O
DDI-DrugBank.d291.s9|238-245|impaired|O
DDI-DrugBank.d291.s10|0-0|.|O
DDI-DrugBank.d291.s11|0-0|-|O
DDI-DrugBank.d291.s11|2-29|Perhexiline hydrogen maleate|drug
DDI-DrugBank.d291.s11|31-32|or|O
DDI-DrugBank.d291.s11|34-47|MAO-inhibitors|group
DDI-DrugBank.d291.s11|49-49|(|O
DDI-DrugBank.d291.s11|50-53|with|O
DDI-DrugBank.d291.s11|55-65|hepatotoxic|O
DDI-DrugBank.d291.s11|67-75|potential|O
DDI-DrugBank.d291.s11|76-76|)|O
DDI-DrugBank.d291.s11|78-81|must|O
DDI-DrugBank.d291.s11|83-85|not|O
DDI-DrugBank.d291.s11|87-88|be|O
DDI-DrugBank.d291.s11|90-101|administered|O
DDI-DrugBank.d291.s11|103-110|together|O
DDI-DrugBank.d291.s11|112-115|with|O
DDI-DrugBank.d291.s11|117-123|Bezalip|brand
DDI-DrugBank.d291.s11|125-126|or|O
DDI-DrugBank.d291.s11|128-141|Bezalip retard|brand
DDI-DrugBank.d291.s11|142-142|.|O
DDI-MedLine.d87.s0|0-9|ADL 8-2698|drug
DDI-MedLine.d87.s0|10-10|,|O
DDI-MedLine.d87.s0|12-12|a|O
DDI-MedLine.d87.s0|14-34|trans-3,4-dimethyl-4-|O
DDI-MedLine.d87.s0|35-35|(|O
DDI-MedLine.d87.s0|36-50|3-hydroxyphenyl|O
DDI-MedLine.d87.s0|51-51|)|O
DDI-MedLine.d87.s0|53-62|piperidine|O
DDI-MedLine.d87.s0|63-63|,|O
DDI-MedLine.d87.s0|65-72|prevents|O
DDI-MedLine.d87.s0|74-89|gastrointestinal|O
DDI-MedLine.d87.s0|91-97|effects|O
DDI-MedLine.d87.s0|99-100|of|O
DDI-MedLine.d87.s0|102-112|intravenous|O
DDI-MedLine.d87.s0|114-121|morphine|drug
DDI-MedLine.d87.s0|123-129|without|O
DDI-MedLine.d87.s0|131-139|affecting|O
DDI-MedLine.d87.s0|141-149|analgesia|O
DDI-MedLine.d87.s0|150-150|.|O
DDI-MedLine.d87.s1|0-9|ADL-8-2698|drug
DDI-MedLine.d87.s1|11-12|is|O
DDI-MedLine.d87.s1|14-14|a|O
DDI-MedLine.d87.s1|16-20|novel|O
DDI-MedLine.d87.s1|22-62|peripherally restricted opioid antagonist|group
DDI-MedLine.d87.s1|64-67|that|O
DDI-MedLine.d87.s1|69-71|may|O
DDI-MedLine.d87.s1|73-83|selectively|O
DDI-MedLine.d87.s1|85-91|prevent|O
DDI-MedLine.d87.s1|93-106|opioid-induced|group
DDI-MedLine.d87.s1|108-123|gastrointestinal|O
DDI-MedLine.d87.s1|125-131|effects|O
DDI-MedLine.d87.s1|133-139|without|O
DDI-MedLine.d87.s1|141-149|reversing|O
DDI-MedLine.d87.s1|151-159|analgesia|O
DDI-MedLine.d87.s1|160-160|.|O
DDI-MedLine.d87.s2|0-15|Gastrointestinal|O
DDI-MedLine.d87.s2|17-23|transit|O
DDI-MedLine.d87.s2|25-28|time|O
DDI-MedLine.d87.s2|30-30|(|O
DDI-MedLine.d87.s2|31-39|lactulose|O
DDI-MedLine.d87.s2|41-48|hydrogen|O
DDI-MedLine.d87.s2|50-55|breath|O
DDI-MedLine.d87.s2|57-60|test|O
DDI-MedLine.d87.s2|61-61|)|O
DDI-MedLine.d87.s2|63-65|was|O
DDI-MedLine.d87.s2|67-74|measured|O
DDI-MedLine.d87.s2|76-77|in|O
DDI-MedLine.d87.s2|79-80|14|O
DDI-MedLine.d87.s2|82-91|volunteers|O
DDI-MedLine.d87.s2|93-96|with|O
DDI-MedLine.d87.s2|98-101|oral|O
DDI-MedLine.d87.s2|103-105|and|O
DDI-MedLine.d87.s2|107-117|intravenous|O
DDI-MedLine.d87.s2|119-125|placebo|O
DDI-MedLine.d87.s2|126-126|,|O
DDI-MedLine.d87.s2|128-131|oral|O
DDI-MedLine.d87.s2|133-139|placebo|O
DDI-MedLine.d87.s2|141-143|and|O
DDI-MedLine.d87.s2|145-155|intravenous|O
DDI-MedLine.d87.s2|157-164|morphine|drug
DDI-MedLine.d87.s2|166-166|(|O
DDI-MedLine.d87.s2|167-170|0.05|O
DDI-MedLine.d87.s2|172-173|mg|O
DDI-MedLine.d87.s2|175-175|x|O
DDI-MedLine.d87.s2|177-178|kg|O
DDI-MedLine.d87.s2|179-179|(|O
DDI-MedLine.d87.s2|180-181|-1|O
DDI-MedLine.d87.s2|182-182|)|O
DDI-MedLine.d87.s2|183-183|)|O
DDI-MedLine.d87.s2|184-184|,|O
DDI-MedLine.d87.s2|186-188|and|O
DDI-MedLine.d87.s2|190-193|oral|O
DDI-MedLine.d87.s2|195-204|ADL 8-2698|drug
DDI-MedLine.d87.s2|206-206|(|O
DDI-MedLine.d87.s2|207-207|4|O
DDI-MedLine.d87.s2|209-210|mg|O
DDI-MedLine.d87.s2|211-211|)|O
DDI-MedLine.d87.s2|213-215|and|O
DDI-MedLine.d87.s2|217-227|intravenous|O
DDI-MedLine.d87.s2|229-236|morphine|drug
DDI-MedLine.d87.s2|238-238|(|O
DDI-MedLine.d87.s2|239-242|0.05|O
DDI-MedLine.d87.s2|244-245|mg|O
DDI-MedLine.d87.s2|247-247|x|O
DDI-MedLine.d87.s2|249-250|kg|O
DDI-MedLine.d87.s2|251-251|(|O
DDI-MedLine.d87.s2|252-253|-1|O
DDI-MedLine.d87.s2|254-254|)|O
DDI-MedLine.d87.s2|255-255|)|O
DDI-MedLine.d87.s2|257-258|in|O
DDI-MedLine.d87.s2|260-260|a|O
DDI-MedLine.d87.s2|262-267|double|O
DDI-MedLine.d87.s2|269-273|blind|O
DDI-MedLine.d87.s2|274-274|,|O
DDI-MedLine.d87.s2|276-285|cross-over|O
DDI-MedLine.d87.s2|287-291|study|O
DDI-MedLine.d87.s2|292-292|.|O
DDI-MedLine.d87.s3|0-7|Morphine|drug
DDI-MedLine.d87.s3|9-17|prolonged|O
DDI-MedLine.d87.s3|19-34|gastrointestinal|O
DDI-MedLine.d87.s3|36-42|transit|O
DDI-MedLine.d87.s3|44-47|time|O
DDI-MedLine.d87.s3|49-52|from|O
DDI-MedLine.d87.s3|54-55|69|O
DDI-MedLine.d87.s3|57-58|to|O
DDI-MedLine.d87.s3|60-62|103|O
DDI-MedLine.d87.s3|64-70|minutes|O
DDI-MedLine.d87.s3|72-72|(|O
DDI-MedLine.d87.s3|73-73|P|O
DDI-MedLine.d87.s3|75-75|=|O
DDI-MedLine.d87.s3|77-80|.005|O
DDI-MedLine.d87.s3|81-81|)|O
DDI-MedLine.d87.s3|82-82|;|O
DDI-MedLine.d87.s4|0-7|Morphine|drug
DDI-MedLine.d87.s4|9-17|prolonged|O
DDI-MedLine.d87.s4|19-34|gastrointestinal|O
DDI-MedLine.d87.s4|36-42|transit|O
DDI-MedLine.d87.s4|44-47|time|O
DDI-MedLine.d87.s4|49-52|from|O
DDI-MedLine.d87.s4|54-55|69|O
DDI-MedLine.d87.s4|57-58|to|O
DDI-MedLine.d87.s4|60-62|103|O
DDI-MedLine.d87.s4|64-70|minutes|O
DDI-MedLine.d87.s4|72-72|(|O
DDI-MedLine.d87.s4|73-73|P|O
DDI-MedLine.d87.s4|75-75|=|O
DDI-MedLine.d87.s4|77-80|.005|O
DDI-MedLine.d87.s4|81-81|)|O
DDI-MedLine.d87.s4|82-82|;|O
DDI-MedLine.d87.s4|84-87|this|O
DDI-MedLine.d87.s4|89-91|was|O
DDI-MedLine.d87.s4|93-101|prevented|O
DDI-MedLine.d87.s4|103-104|by|O
DDI-MedLine.d87.s4|106-115|ADL 8-2698|drug
DDI-MedLine.d87.s4|117-117|(|O
DDI-MedLine.d87.s4|118-118|P|O
DDI-MedLine.d87.s4|120-120|=|O
DDI-MedLine.d87.s4|122-125|.004|O
DDI-MedLine.d87.s4|126-126|)|O
DDI-MedLine.d87.s4|127-127|.|O
DDI-MedLine.d87.s5|0-14|Postoperatively|O
DDI-MedLine.d87.s5|15-15|,|O
DDI-MedLine.d87.s5|17-18|45|O
DDI-MedLine.d87.s5|20-27|patients|O
DDI-MedLine.d87.s5|29-32|were|O
DDI-MedLine.d87.s5|34-41|randomly|O
DDI-MedLine.d87.s5|43-50|assigned|O
DDI-MedLine.d87.s5|52-53|in|O
DDI-MedLine.d87.s5|55-55|a|O
DDI-MedLine.d87.s5|57-68|double-blind|O
DDI-MedLine.d87.s5|70-76|fashion|O
DDI-MedLine.d87.s5|78-79|to|O
DDI-MedLine.d87.s5|81-87|receive|O
DDI-MedLine.d87.s5|89-98|ADL 8-2698|drug
DDI-MedLine.d87.s5|100-100|(|O
DDI-MedLine.d87.s5|101-101|4|O
DDI-MedLine.d87.s5|103-104|mg|O
DDI-MedLine.d87.s5|105-105|)|O
DDI-MedLine.d87.s5|107-108|or|O
DDI-MedLine.d87.s5|110-116|placebo|O
DDI-MedLine.d87.s5|118-120|and|O
DDI-MedLine.d87.s5|122-132|intravenous|O
DDI-MedLine.d87.s5|134-141|morphine|drug
DDI-MedLine.d87.s5|143-143|(|O
DDI-MedLine.d87.s5|144-147|0.15|O
DDI-MedLine.d87.s5|149-153|mg/kg|O
DDI-MedLine.d87.s5|154-154|)|O
DDI-MedLine.d87.s5|156-157|or|O
DDI-MedLine.d87.s5|159-160|to|O
DDI-MedLine.d87.s5|162-168|receive|O
DDI-MedLine.d87.s5|170-173|oral|O
DDI-MedLine.d87.s5|175-177|and|O
DDI-MedLine.d87.s5|179-189|intravenous|O
DDI-MedLine.d87.s5|191-197|placebo|O
DDI-MedLine.d87.s5|198-198|.|O
DDI-MedLine.d87.s6|0-8|Analgesia|O
DDI-MedLine.d87.s6|10-12|and|O
DDI-MedLine.d87.s6|14-18|pupil|O
DDI-MedLine.d87.s6|20-31|constriction|O
DDI-MedLine.d87.s6|33-36|were|O
DDI-MedLine.d87.s6|38-45|measured|O
DDI-MedLine.d87.s6|46-46|.|O
DDI-MedLine.d87.s7|0-7|Morphine|drug
DDI-MedLine.d87.s7|9-17|analgesia|O
DDI-MedLine.d87.s7|19-21|and|O
DDI-MedLine.d87.s7|23-27|pupil|O
DDI-MedLine.d87.s7|29-40|constriction|O
DDI-MedLine.d87.s7|42-45|were|O
DDI-MedLine.d87.s7|47-56|unaffected|O
DDI-MedLine.d87.s7|58-59|by|O
DDI-MedLine.d87.s7|61-70|ADL 8-2698|drug
DDI-MedLine.d87.s7|72-74|and|O
DDI-MedLine.d87.s7|76-83|differed|O
DDI-MedLine.d87.s7|85-88|from|O
DDI-MedLine.d87.s7|90-96|placebo|O
DDI-MedLine.d87.s7|98-98|(|O
DDI-MedLine.d87.s7|99-99|P|O
DDI-MedLine.d87.s7|101-101|<|O
DDI-MedLine.d87.s7|103-106|.002|O
DDI-MedLine.d87.s7|107-107|)|O
DDI-MedLine.d87.s7|108-108|.|O
DDI-MedLine.d87.s8|0-1|We|O
DDI-MedLine.d87.s8|3-10|conclude|O
DDI-MedLine.d87.s8|12-15|that|O
DDI-MedLine.d87.s8|17-26|ADL 8-2698|drug
DDI-MedLine.d87.s8|28-35|prevents|O
DDI-MedLine.d87.s8|37-52|morphine-induced|drug
DDI-MedLine.d87.s8|54-62|increases|O
DDI-MedLine.d87.s8|64-65|in|O
DDI-MedLine.d87.s8|67-82|gastrointestinal|O
DDI-MedLine.d87.s8|84-90|transit|O
DDI-MedLine.d87.s8|92-95|time|O
DDI-MedLine.d87.s8|97-98|by|O
DDI-MedLine.d87.s8|100-104|means|O
DDI-MedLine.d87.s8|106-107|of|O
DDI-MedLine.d87.s8|109-117|selective|O
DDI-MedLine.d87.s8|119-128|peripheral|O
DDI-MedLine.d87.s8|130-135|opioid|O
DDI-MedLine.d87.s8|137-147|anitagonism|O
DDI-MedLine.d87.s8|149-155|without|O
DDI-MedLine.d87.s8|157-165|affecting|O
DDI-MedLine.d87.s8|167-173|central|O
DDI-MedLine.d87.s8|175-180|opioid|O
DDI-MedLine.d87.s8|182-190|analgesia|O
DDI-MedLine.d87.s8|191-191|.|O
DDI-DrugBank.d162.s0|0-3|When|O
DDI-DrugBank.d162.s0|5-9|given|O
DDI-DrugBank.d162.s0|11-22|concurrently|O
DDI-DrugBank.d162.s0|24-26|the|O
DDI-DrugBank.d162.s0|28-36|following|O
DDI-DrugBank.d162.s0|38-42|drugs|O
DDI-DrugBank.d162.s0|44-46|may|O
DDI-DrugBank.d162.s0|48-55|interact|O
DDI-DrugBank.d162.s0|57-60|with|O
DDI-DrugBank.d162.s0|62-79|thiazide diuretics|group
DDI-DrugBank.d162.s0|80-80|.|O
DDI-DrugBank.d162.s1|0-6|Alcohol|drug
DDI-DrugBank.d162.s1|7-7|,|O
DDI-DrugBank.d162.s1|9-20|barbiturates|group
DDI-DrugBank.d162.s1|21-21|,|O
DDI-DrugBank.d162.s1|23-24|or|O
DDI-DrugBank.d162.s1|26-34|narcotics|group
DDI-DrugBank.d162.s1|35-35|:|O
DDI-DrugBank.d162.s1|37-48|potentiation|O
DDI-DrugBank.d162.s1|50-51|of|O
DDI-DrugBank.d162.s1|53-63|orthostatic|O
DDI-DrugBank.d162.s1|65-75|hypotension|O
DDI-DrugBank.d162.s1|77-79|may|O
DDI-DrugBank.d162.s1|81-85|occur|O
DDI-DrugBank.d162.s1|86-86|.|O
DDI-DrugBank.d162.s2|0-17|Antidiabetic drugs|group
DDI-DrugBank.d162.s2|18-18|:|O
DDI-DrugBank.d162.s2|20-20|(|O
DDI-DrugBank.d162.s2|21-24|oral|O
DDI-DrugBank.d162.s2|26-31|agents|O
DDI-DrugBank.d162.s2|33-35|and|O
DDI-DrugBank.d162.s2|37-43|insulin|drug
DDI-DrugBank.d162.s2|44-44|)|O
DDI-DrugBank.d162.s2|46-46|-|O
DDI-DrugBank.d162.s2|48-53|dosage|O
DDI-DrugBank.d162.s2|55-64|adjustment|O
DDI-DrugBank.d162.s2|66-67|of|O
DDI-DrugBank.d162.s2|69-71|the|O
DDI-DrugBank.d162.s2|73-89|antidiabetic drug|group
DDI-DrugBank.d162.s2|91-93|may|O
DDI-DrugBank.d162.s2|95-96|be|O
DDI-DrugBank.d162.s2|98-105|required|O
DDI-DrugBank.d162.s2|106-106|.|O
DDI-DrugBank.d162.s3|0-4|Other|O
DDI-DrugBank.d162.s3|6-27|antihypertensive drugs|group
DDI-DrugBank.d162.s3|28-28|:|O
DDI-DrugBank.d162.s3|30-37|additive|O
DDI-DrugBank.d162.s3|39-44|effect|O
DDI-DrugBank.d162.s3|46-47|or|O
DDI-DrugBank.d162.s3|49-60|potentiation|O
DDI-DrugBank.d162.s3|61-61|.|O
DDI-DrugBank.d162.s4|0-13|Cholestyramine|drug
DDI-DrugBank.d162.s4|15-17|and|O
DDI-DrugBank.d162.s4|19-28|colestipol|drug
DDI-DrugBank.d162.s4|19-28|colestipol|drug
DDI-DrugBank.d162.s4|36-36|:|O
DDI-DrugBank.d162.s4|38-47|Absorption|O
DDI-DrugBank.d162.s4|49-50|of|O
DDI-DrugBank.d162.s4|52-70|hydrochlorothiazide|drug
DDI-DrugBank.d162.s4|72-73|is|O
DDI-DrugBank.d162.s4|75-82|impaired|O
DDI-DrugBank.d162.s4|84-85|in|O
DDI-DrugBank.d162.s4|87-89|the|O
DDI-DrugBank.d162.s4|91-98|presence|O
DDI-DrugBank.d162.s4|100-101|of|O
DDI-DrugBank.d162.s4|103-125|anionic exchange resins|group
DDI-DrugBank.d162.s4|126-126|.|O
DDI-DrugBank.d162.s5|0-5|Single|O
DDI-DrugBank.d162.s5|7-11|doses|O
DDI-DrugBank.d162.s5|13-14|of|O
DDI-DrugBank.d162.s5|16-21|either|O
DDI-DrugBank.d162.s5|23-36|cholestyramine|drug
DDI-DrugBank.d162.s5|38-39|or|O
DDI-DrugBank.d162.s5|41-50|colestipol|drug
DDI-DrugBank.d162.s5|41-50|colestipol|drug
DDI-DrugBank.d162.s5|59-62|bind|O
DDI-DrugBank.d162.s5|64-66|the|O
DDI-DrugBank.d162.s5|68-86|hydrochlorothiazide|drug
DDI-DrugBank.d162.s5|88-90|and|O
DDI-DrugBank.d162.s5|92-97|reduce|O
DDI-DrugBank.d162.s5|99-101|its|O
DDI-DrugBank.d162.s5|103-112|absorption|O
DDI-DrugBank.d162.s5|114-117|from|O
DDI-DrugBank.d162.s5|119-121|the|O
DDI-DrugBank.d162.s5|123-138|gastrointestinal|O
DDI-DrugBank.d162.s5|140-144|tract|O
DDI-DrugBank.d162.s5|146-147|by|O
DDI-DrugBank.d162.s5|149-150|up|O
DDI-DrugBank.d162.s5|152-153|to|O
DDI-DrugBank.d162.s5|155-156|85|O
DDI-DrugBank.d162.s5|158-160|and|O
DDI-DrugBank.d162.s5|162-163|43|O
DDI-DrugBank.d162.s5|165-171|percent|O
DDI-DrugBank.d162.s5|172-172|,|O
DDI-DrugBank.d162.s5|174-185|respectively|O
DDI-DrugBank.d162.s5|186-186|.|O
DDI-DrugBank.d162.s6|0-14|Corticosteroids|group
DDI-DrugBank.d162.s6|15-15|,|O
DDI-DrugBank.d162.s6|17-20|ACTH|drug
DDI-DrugBank.d162.s6|21-21|:|O
DDI-DrugBank.d162.s6|23-33|intensified|O
DDI-DrugBank.d162.s6|35-45|electrolyte|O
DDI-DrugBank.d162.s6|47-55|depletion|O
DDI-DrugBank.d162.s6|56-56|,|O
DDI-DrugBank.d162.s6|58-69|particularly|O
DDI-DrugBank.d162.s6|71-81|hypokalemia|O
DDI-DrugBank.d162.s6|82-82|.|O
DDI-DrugBank.d162.s7|0-6|Pressor|O
DDI-DrugBank.d162.s7|8-13|amines|O
DDI-DrugBank.d162.s7|15-15|(|O
DDI-DrugBank.d162.s7|16-19|e.g.|O
DDI-DrugBank.d162.s7|20-20|,|O
DDI-DrugBank.d162.s7|22-35|norepinephrine|drug
DDI-DrugBank.d162.s7|36-36|)|O
DDI-DrugBank.d162.s7|37-37|:|O
DDI-DrugBank.d162.s7|39-46|possible|O
DDI-DrugBank.d162.s7|48-56|decreased|O
DDI-DrugBank.d162.s7|58-65|response|O
DDI-DrugBank.d162.s7|67-68|to|O
DDI-DrugBank.d162.s7|70-76|pressor|O
DDI-DrugBank.d162.s7|78-83|amines|O
DDI-DrugBank.d162.s7|85-87|but|O
DDI-DrugBank.d162.s7|89-91|not|O
DDI-DrugBank.d162.s7|93-102|sufficient|O
DDI-DrugBank.d162.s7|104-105|to|O
DDI-DrugBank.d162.s7|107-114|preclude|O
DDI-DrugBank.d162.s7|116-120|their|O
DDI-DrugBank.d162.s7|122-124|use|O
DDI-DrugBank.d162.s7|125-125|.|O
DDI-DrugBank.d162.s8|0-24|Skeletal muscle relaxants|group
DDI-DrugBank.d162.s8|25-25|,|O
DDI-DrugBank.d162.s8|27-41|nondepolarizing|O
DDI-DrugBank.d162.s8|43-43|(|O
DDI-DrugBank.d162.s8|44-47|e.g.|O
DDI-DrugBank.d162.s8|48-48|,|O
DDI-DrugBank.d162.s8|50-61|tubocurarine|drug
DDI-DrugBank.d162.s8|62-62|)|O
DDI-DrugBank.d162.s8|63-63|:|O
DDI-DrugBank.d162.s8|65-72|possible|O
DDI-DrugBank.d162.s8|74-82|increased|O
DDI-DrugBank.d162.s8|84-97|responsiveness|O
DDI-DrugBank.d162.s8|99-100|to|O
DDI-DrugBank.d162.s8|102-104|the|O
DDI-DrugBank.d162.s8|106-120|muscle relaxant|group
DDI-DrugBank.d162.s8|121-121|.|O
DDI-DrugBank.d162.s9|0-6|Lithium|drug
DDI-DrugBank.d162.s9|7-7|:|O
DDI-DrugBank.d162.s9|9-17|generally|O
DDI-DrugBank.d162.s9|19-24|should|O
DDI-DrugBank.d162.s9|26-28|not|O
DDI-DrugBank.d162.s9|30-31|be|O
DDI-DrugBank.d162.s9|33-37|given|O
DDI-DrugBank.d162.s9|39-42|with|O
DDI-DrugBank.d162.s9|44-52|diuretics|group
DDI-DrugBank.d162.s9|53-53|.|O
DDI-DrugBank.d162.s10|0-14|Diuretic agents|group
DDI-DrugBank.d162.s10|16-21|reduce|O
DDI-DrugBank.d162.s10|23-25|the|O
DDI-DrugBank.d162.s10|27-31|renal|O
DDI-DrugBank.d162.s10|33-41|clearance|O
DDI-DrugBank.d162.s10|43-44|of|O
DDI-DrugBank.d162.s10|46-52|lithium|drug
DDI-DrugBank.d162.s10|54-56|and|O
DDI-DrugBank.d162.s10|58-60|add|O
DDI-DrugBank.d162.s10|62-62|a|O
DDI-DrugBank.d162.s10|64-67|high|O
DDI-DrugBank.d162.s10|69-72|risk|O
DDI-DrugBank.d162.s10|74-75|of|O
DDI-DrugBank.d162.s10|77-83|lithium|drug
DDI-DrugBank.d162.s10|85-92|toxicity|O
DDI-DrugBank.d162.s10|93-93|.|O
DDI-DrugBank.d162.s11|0-4|Refer|O
DDI-DrugBank.d162.s11|6-7|to|O
DDI-DrugBank.d162.s11|9-11|the|O
DDI-DrugBank.d162.s11|13-19|package|O
DDI-DrugBank.d162.s11|21-26|insert|O
DDI-DrugBank.d162.s11|28-30|for|O
DDI-DrugBank.d162.s11|32-38|lithium|drug
DDI-DrugBank.d162.s11|40-51|preparations|O
DDI-DrugBank.d162.s11|53-58|before|O
DDI-DrugBank.d162.s11|60-62|use|O
DDI-DrugBank.d162.s11|64-65|of|O
DDI-DrugBank.d162.s11|67-70|such|O
DDI-DrugBank.d162.s11|72-83|preparations|O
DDI-DrugBank.d162.s11|85-88|with|O
DDI-DrugBank.d162.s11|90-108|Hydrochlorothiazide|drug
DDI-DrugBank.d162.s11|109-109|.|O
DDI-DrugBank.d162.s12|0-36|Non-steroidal Anti-inflammatory Drugs|group
DDI-DrugBank.d162.s12|37-37|:|O
DDI-DrugBank.d162.s12|39-40|In|O
DDI-DrugBank.d162.s12|42-45|some|O
DDI-DrugBank.d162.s12|47-54|patients|O
DDI-DrugBank.d162.s12|55-55|,|O
DDI-DrugBank.d162.s12|57-59|the|O
DDI-DrugBank.d162.s12|61-74|administration|O
DDI-DrugBank.d162.s12|76-77|of|O
DDI-DrugBank.d162.s12|79-79|a|O
DDI-DrugBank.d162.s12|81-117|non-steroidal anti-inflammatory agent|group
DDI-DrugBank.d162.s12|119-121|can|O
DDI-DrugBank.d162.s12|123-128|reduce|O
DDI-DrugBank.d162.s12|130-132|the|O
DDI-DrugBank.d162.s12|134-141|diuretic|O
DDI-DrugBank.d162.s12|142-142|,|O
DDI-DrugBank.d162.s12|144-154|natriuretic|O
DDI-DrugBank.d162.s12|155-155|,|O
DDI-DrugBank.d162.s12|157-159|and|O
DDI-DrugBank.d162.s12|161-176|antihypertensive|O
DDI-DrugBank.d162.s12|178-184|effects|O
DDI-DrugBank.d162.s12|186-187|of|O
DDI-DrugBank.d162.s12|189-192|loop|group
DDI-DrugBank.d162.s12|193-193|,|O
DDI-DrugBank.d162.s12|195-211|potassium-sparing|group
DDI-DrugBank.d162.s12|213-215|and|O
DDI-DrugBank.d162.s12|217-234|thiazide diuretics|group
DDI-DrugBank.d162.s12|235-235|.|O
DDI-DrugBank.d162.s13|0-8|Therefore|O
DDI-DrugBank.d162.s13|9-9|,|O
DDI-DrugBank.d162.s13|11-14|when|O
DDI-DrugBank.d162.s13|16-34|Hydrochlorothiazide|drug
DDI-DrugBank.d162.s13|36-38|and|O
DDI-DrugBank.d162.s13|40-77|non-steroidal anti-inflammatory agents|group
DDI-DrugBank.d162.s13|79-81|are|O
DDI-DrugBank.d162.s13|83-86|used|O
DDI-DrugBank.d162.s13|88-100|concomitantly|O
DDI-DrugBank.d162.s13|101-101|,|O
DDI-DrugBank.d162.s13|103-105|the|O
DDI-DrugBank.d162.s13|107-113|patient|O
DDI-DrugBank.d162.s13|115-120|should|O
DDI-DrugBank.d162.s13|122-123|be|O
DDI-DrugBank.d162.s13|125-132|observed|O
DDI-DrugBank.d162.s13|134-140|closely|O
DDI-DrugBank.d162.s13|142-143|to|O
DDI-DrugBank.d162.s13|145-153|determine|O
DDI-DrugBank.d162.s13|155-156|if|O
DDI-DrugBank.d162.s13|158-160|the|O
DDI-DrugBank.d162.s13|162-168|desired|O
DDI-DrugBank.d162.s13|170-175|effect|O
DDI-DrugBank.d162.s13|177-178|of|O
DDI-DrugBank.d162.s13|180-182|the|O
DDI-DrugBank.d162.s13|184-191|diuretic|group
DDI-DrugBank.d162.s13|193-194|is|O
DDI-DrugBank.d162.s13|196-203|obtained|O
DDI-DrugBank.d162.s13|204-204|.|O
DDI-MedLine.d71.s0|0-7|Drug-lab|O
DDI-MedLine.d71.s0|9-20|interactions|O
DDI-MedLine.d71.s0|21-21|:|O
DDI-MedLine.d71.s0|23-34|implications|O
DDI-MedLine.d71.s0|36-38|for|O
DDI-MedLine.d71.s0|40-48|nutrition|O
DDI-MedLine.d71.s0|50-56|support|O
DDI-MedLine.d71.s0|57-57|.|O
DDI-MedLine.d71.s1|0-13|Acetylcysteine|drug
DDI-MedLine.d71.s1|15-26|interference|O
DDI-MedLine.d71.s1|28-31|with|O
DDI-MedLine.d71.s1|33-37|urine|O
DDI-MedLine.d71.s1|39-44|ketone|O
DDI-MedLine.d71.s1|46-49|test|O
DDI-MedLine.d71.s1|50-50|.|O
DDI-MedLine.d71.s2|0-1|It|O
DDI-MedLine.d71.s2|3-4|is|O
DDI-MedLine.d71.s2|6-14|important|O
DDI-MedLine.d71.s2|16-19|that|O
DDI-MedLine.d71.s2|21-26|health|O
DDI-MedLine.d71.s2|28-31|care|O
DDI-MedLine.d71.s2|33-45|professionals|O
DDI-MedLine.d71.s2|47-48|be|O
DDI-MedLine.d71.s2|50-54|aware|O
DDI-MedLine.d71.s2|56-57|of|O
DDI-MedLine.d71.s2|59-61|the|O
DDI-MedLine.d71.s2|63-71|potential|O
DDI-MedLine.d71.s2|73-75|for|O
DDI-MedLine.d71.s2|77-87|medications|O
DDI-MedLine.d71.s2|89-90|to|O
DDI-MedLine.d71.s2|92-100|interfere|O
DDI-MedLine.d71.s2|102-105|with|O
DDI-MedLine.d71.s2|107-114|clinical|O
DDI-MedLine.d71.s2|116-125|laboratory|O
DDI-MedLine.d71.s2|127-131|tests|O
DDI-MedLine.d71.s2|132-132|.|O
DDI-MedLine.d71.s3|0-10|Medications|O
DDI-MedLine.d71.s3|12-14|can|O
DDI-MedLine.d71.s3|16-20|cause|O
DDI-MedLine.d71.s3|22-23|in|O
DDI-MedLine.d71.s3|25-28|vivo|O
DDI-MedLine.d71.s3|30-36|effects|O
DDI-MedLine.d71.s3|38-41|when|O
DDI-MedLine.d71.s3|43-45|the|O
DDI-MedLine.d71.s3|47-59|concentration|O
DDI-MedLine.d71.s3|61-62|or|O
DDI-MedLine.d71.s3|64-71|activity|O
DDI-MedLine.d71.s3|73-74|of|O
DDI-MedLine.d71.s3|76-78|the|O
DDI-MedLine.d71.s3|80-86|analyte|O
DDI-MedLine.d71.s3|88-89|is|O
DDI-MedLine.d71.s3|91-97|altered|O
DDI-MedLine.d71.s3|99-104|before|O
DDI-MedLine.d71.s3|106-108|the|O
DDI-MedLine.d71.s3|110-117|analysis|O
DDI-MedLine.d71.s3|119-121|and|O
DDI-MedLine.d71.s3|123-131|therefore|O
DDI-MedLine.d71.s3|133-135|the|O
DDI-MedLine.d71.s3|137-141|assay|O
DDI-MedLine.d71.s3|143-148|result|O
DDI-MedLine.d71.s3|150-151|is|O
DDI-MedLine.d71.s3|153-156|true|O
DDI-MedLine.d71.s3|158-160|and|O
DDI-MedLine.d71.s3|162-169|accurate|O
DDI-MedLine.d71.s3|170-170|.|O
DDI-MedLine.d71.s4|0-1|An|O
DDI-MedLine.d71.s4|3-4|in|O
DDI-MedLine.d71.s4|6-10|vitro|O
DDI-MedLine.d71.s4|12-17|effect|O
DDI-MedLine.d71.s4|19-24|occurs|O
DDI-MedLine.d71.s4|26-29|when|O
DDI-MedLine.d71.s4|31-33|the|O
DDI-MedLine.d71.s4|35-44|medication|O
DDI-MedLine.d71.s4|46-55|interferes|O
DDI-MedLine.d71.s4|57-60|with|O
DDI-MedLine.d71.s4|62-64|the|O
DDI-MedLine.d71.s4|66-70|assay|O
DDI-MedLine.d71.s4|71-71|,|O
DDI-MedLine.d71.s4|73-75|and|O
DDI-MedLine.d71.s4|77-79|the|O
DDI-MedLine.d71.s4|81-86|result|O
DDI-MedLine.d71.s4|88-89|is|O
DDI-MedLine.d71.s4|91-99|erroneous|O
DDI-MedLine.d71.s4|101-103|and|O
DDI-MedLine.d71.s4|105-107|can|O
DDI-MedLine.d71.s4|108-110|not|O
DDI-MedLine.d71.s4|112-113|be|O
DDI-MedLine.d71.s4|115-125|interpreted|O
DDI-MedLine.d71.s4|126-126|.|O
DDI-MedLine.d71.s5|0-3|This|O
DDI-MedLine.d71.s5|5-10|report|O
DDI-MedLine.d71.s5|12-20|describes|O
DDI-MedLine.d71.s5|22-22|a|O
DDI-MedLine.d71.s5|24-31|recently|O
DDI-MedLine.d71.s5|33-42|identified|O
DDI-MedLine.d71.s5|44-47|case|O
DDI-MedLine.d71.s5|49-50|of|O
DDI-MedLine.d71.s5|52-63|interference|O
DDI-MedLine.d71.s5|65-66|of|O
DDI-MedLine.d71.s5|68-81|acetylcysteine|drug
DDI-MedLine.d71.s5|83-86|with|O
DDI-MedLine.d71.s5|88-90|the|O
DDI-MedLine.d71.s5|92-96|urine|O
DDI-MedLine.d71.s5|98-101|test|O
DDI-MedLine.d71.s5|103-105|for|O
DDI-MedLine.d71.s5|107-113|ketones|O
DDI-MedLine.d71.s5|115-117|and|O
DDI-MedLine.d71.s5|119-130|demonstrates|O
DDI-MedLine.d71.s5|132-134|the|O
DDI-MedLine.d71.s5|136-145|importance|O
DDI-MedLine.d71.s5|147-148|of|O
DDI-MedLine.d71.s5|150-150|a|O
DDI-MedLine.d71.s5|152-159|thorough|O
DDI-MedLine.d71.s5|161-170|medication|O
DDI-MedLine.d71.s5|172-177|review|O
DDI-MedLine.d71.s5|179-180|in|O
DDI-MedLine.d71.s5|182-191|evaluating|O
DDI-MedLine.d71.s5|193-200|abnormal|O
DDI-MedLine.d71.s5|202-211|laboratory|O
DDI-MedLine.d71.s5|213-217|tests|O
DDI-MedLine.d71.s5|218-218|.|O
DDI-DrugBank.d587.s0|0-4|Since|O
DDI-DrugBank.d587.s0|6-13|Celontin|brand
DDI-DrugBank.d587.s0|15-15|(|O
DDI-DrugBank.d587.s0|16-27|methsuximide|drug
DDI-DrugBank.d587.s0|28-28|)|O
DDI-DrugBank.d587.s0|30-32|may|O
DDI-DrugBank.d587.s0|34-41|interact|O
DDI-DrugBank.d587.s0|43-46|with|O
DDI-DrugBank.d587.s0|48-59|concurrently|O
DDI-DrugBank.d587.s0|61-72|administered|O
DDI-DrugBank.d587.s0|74-92|antiepileptic drugs|group
DDI-DrugBank.d587.s0|93-93|,|O
DDI-DrugBank.d587.s0|95-102|periodic|O
DDI-DrugBank.d587.s0|104-108|serum|O
DDI-DrugBank.d587.s0|110-114|level|O
DDI-DrugBank.d587.s0|116-129|determinations|O
DDI-DrugBank.d587.s0|131-132|of|O
DDI-DrugBank.d587.s0|134-138|these|O
DDI-DrugBank.d587.s0|140-144|drugs|O
DDI-DrugBank.d587.s0|146-148|may|O
DDI-DrugBank.d587.s0|150-151|be|O
DDI-DrugBank.d587.s0|153-161|necessary|O
DDI-DrugBank.d587.s0|163-163|(|O
DDI-DrugBank.d587.s0|164-165|eg|O
DDI-DrugBank.d587.s0|167-178|methsuximide|drug
DDI-DrugBank.d587.s0|180-182|may|O
DDI-DrugBank.d587.s0|184-191|increase|O
DDI-DrugBank.d587.s0|193-195|the|O
DDI-DrugBank.d587.s0|197-202|plasma|O
DDI-DrugBank.d587.s0|204-217|concentrations|O
DDI-DrugBank.d587.s0|219-220|of|O
DDI-DrugBank.d587.s0|222-230|phenytoin|drug
DDI-DrugBank.d587.s0|232-234|and|O
DDI-DrugBank.d587.s0|236-248|phenobarbital|drug
DDI-DrugBank.d587.s0|249-249|)|O
DDI-DrugBank.d587.s0|250-250|.|O
DDI-DrugBank.d538.s0|0-4|Known|O
DDI-DrugBank.d538.s0|6-9|drug|O
DDI-DrugBank.d538.s0|11-22|interactions|O
DDI-DrugBank.d538.s0|24-30|include|O
DDI-DrugBank.d538.s0|32-43|barbiturates|group
DDI-DrugBank.d538.s0|44-44|,|O
DDI-DrugBank.d538.s0|46-58|tranquilizers|group
DDI-DrugBank.d538.s0|59-59|,|O
DDI-DrugBank.d538.s0|61-63|and|O
DDI-DrugBank.d538.s0|65-71|alcohol|drug
DDI-DrugBank.d538.s0|72-72|.|O
DDI-DrugBank.d538.s1|0-16|Diphenoxylate HCl|drug
DDI-DrugBank.d538.s1|18-20|and|O
DDI-DrugBank.d538.s1|22-37|atropine sulfate|drug
DDI-DrugBank.d538.s1|39-41|may|O
DDI-DrugBank.d538.s1|43-50|interact|O
DDI-DrugBank.d538.s1|52-55|with|O
DDI-DrugBank.d538.s1|57-70|MAO inhibitors|group
DDI-DrugBank.d538.s1|72-73|In|O
DDI-DrugBank.d538.s1|75-81|studies|O
DDI-DrugBank.d538.s1|83-86|with|O
DDI-DrugBank.d538.s1|88-91|male|O
DDI-DrugBank.d538.s1|93-96|rats|O
DDI-DrugBank.d538.s1|97-97|,|O
DDI-DrugBank.d538.s1|99-125|diphenoxylate hydrochloride|drug
DDI-DrugBank.d538.s1|127-129|was|O
DDI-DrugBank.d538.s1|131-135|found|O
DDI-DrugBank.d538.s1|137-138|to|O
DDI-DrugBank.d538.s1|140-146|inhibit|O
DDI-DrugBank.d538.s1|148-150|the|O
DDI-DrugBank.d538.s1|152-158|hepatic|O
DDI-DrugBank.d538.s1|160-169|microsomal|O
DDI-DrugBank.d538.s1|171-176|enzyme|O
DDI-DrugBank.d538.s1|178-183|system|O
DDI-DrugBank.d538.s1|185-186|at|O
DDI-DrugBank.d538.s1|188-188|a|O
DDI-DrugBank.d538.s1|190-193|dose|O
DDI-DrugBank.d538.s1|195-196|of|O
DDI-DrugBank.d538.s1|198-198|2|O
DDI-DrugBank.d538.s1|200-208|mg/kg/day|O
DDI-DrugBank.d538.s1|209-209|.|O
DDI-DrugBank.d538.s2|0-8|Therefore|O
DDI-DrugBank.d538.s2|9-9|,|O
DDI-DrugBank.d538.s2|11-23|diphenoxylate|drug
DDI-DrugBank.d538.s2|25-27|has|O
DDI-DrugBank.d538.s2|29-31|the|O
DDI-DrugBank.d538.s2|33-41|potential|O
DDI-DrugBank.d538.s2|43-44|to|O
DDI-DrugBank.d538.s2|46-52|prolong|O
DDI-DrugBank.d538.s2|54-56|the|O
DDI-DrugBank.d538.s2|58-67|biological|O
DDI-DrugBank.d538.s2|69-78|half-lives|O
DDI-DrugBank.d538.s2|80-81|of|O
DDI-DrugBank.d538.s2|83-87|drugs|O
DDI-DrugBank.d538.s2|89-91|for|O
DDI-DrugBank.d538.s2|93-97|which|O
DDI-DrugBank.d538.s2|99-101|the|O
DDI-DrugBank.d538.s2|103-106|rate|O
DDI-DrugBank.d538.s2|108-109|of|O
DDI-DrugBank.d538.s2|111-121|elimination|O
DDI-DrugBank.d538.s2|123-124|is|O
DDI-DrugBank.d538.s2|126-134|dependent|O
DDI-DrugBank.d538.s2|136-137|on|O
DDI-DrugBank.d538.s2|139-141|the|O
DDI-DrugBank.d538.s2|143-152|microsomal|O
DDI-DrugBank.d538.s2|154-157|drug|O
DDI-DrugBank.d538.s2|159-170|metabolizing|O
DDI-DrugBank.d538.s2|172-177|enzyme|O
DDI-DrugBank.d538.s2|179-184|system|O
DDI-DrugBank.d538.s2|185-185|.|O
DDI-DrugBank.d476.s0|0-5|ZEBETA|brand
DDI-DrugBank.d476.s0|7-12|should|O
DDI-DrugBank.d476.s0|14-16|not|O
DDI-DrugBank.d476.s0|18-19|be|O
DDI-DrugBank.d476.s0|21-28|combined|O
DDI-DrugBank.d476.s0|30-33|with|O
DDI-DrugBank.d476.s0|35-39|other|O
DDI-DrugBank.d476.s0|41-60|beta-blocking agents|group
DDI-DrugBank.d476.s0|61-61|.|O
DDI-DrugBank.d476.s1|0-7|Patients|O
DDI-DrugBank.d476.s1|9-17|receiving|O
DDI-DrugBank.d476.s1|19-41|catecholamine-depleting|O
DDI-DrugBank.d476.s1|43-47|drugs|O
DDI-DrugBank.d476.s1|48-48|,|O
DDI-DrugBank.d476.s1|50-53|such|O
DDI-DrugBank.d476.s1|55-56|as|O
DDI-DrugBank.d476.s1|58-66|reserpine|drug
DDI-DrugBank.d476.s1|68-69|or|O
DDI-DrugBank.d476.s1|71-82|guanethidine|drug
DDI-DrugBank.d476.s1|83-83|,|O
DDI-DrugBank.d476.s1|85-90|should|O
DDI-DrugBank.d476.s1|92-93|be|O
DDI-DrugBank.d476.s1|95-101|closely|O
DDI-DrugBank.d476.s1|103-111|monitored|O
DDI-DrugBank.d476.s1|112-112|,|O
DDI-DrugBank.d476.s1|114-120|because|O
DDI-DrugBank.d476.s1|122-124|the|O
DDI-DrugBank.d476.s1|126-130|added|O
DDI-DrugBank.d476.s1|132-146|beta-adrenergic|O
DDI-DrugBank.d476.s1|148-155|blocking|O
DDI-DrugBank.d476.s1|157-162|action|O
DDI-DrugBank.d476.s1|164-165|of|O
DDI-DrugBank.d476.s1|167-172|ZEBETA|brand
DDI-DrugBank.d476.s1|174-176|may|O
DDI-DrugBank.d476.s1|178-184|produce|O
DDI-DrugBank.d476.s1|186-194|excessive|O
DDI-DrugBank.d476.s1|196-204|reduction|O
DDI-DrugBank.d476.s1|206-207|of|O
DDI-DrugBank.d476.s1|209-219|sympathetic|O
DDI-DrugBank.d476.s1|221-228|activity|O
DDI-DrugBank.d476.s1|229-229|.|O
DDI-DrugBank.d476.s2|0-1|In|O
DDI-DrugBank.d476.s2|3-10|patients|O
DDI-DrugBank.d476.s2|12-20|receiving|O
DDI-DrugBank.d476.s2|22-31|concurrent|O
DDI-DrugBank.d476.s2|33-39|therapy|O
DDI-DrugBank.d476.s2|41-44|with|O
DDI-DrugBank.d476.s2|46-54|clonidine|drug
DDI-DrugBank.d476.s2|55-55|,|O
DDI-DrugBank.d476.s2|57-58|if|O
DDI-DrugBank.d476.s2|60-66|therapy|O
DDI-DrugBank.d476.s2|68-69|is|O
DDI-DrugBank.d476.s2|71-72|to|O
DDI-DrugBank.d476.s2|74-75|be|O
DDI-DrugBank.d476.s2|77-88|discontinued|O
DDI-DrugBank.d476.s2|89-89|,|O
DDI-DrugBank.d476.s2|91-92|it|O
DDI-DrugBank.d476.s2|94-95|is|O
DDI-DrugBank.d476.s2|97-105|suggested|O
DDI-DrugBank.d476.s2|107-110|that|O
DDI-DrugBank.d476.s2|112-117|ZEBETA|brand
DDI-DrugBank.d476.s2|119-120|be|O
DDI-DrugBank.d476.s2|122-133|discontinued|O
DDI-DrugBank.d476.s2|135-137|for|O
DDI-DrugBank.d476.s2|139-145|several|O
DDI-DrugBank.d476.s2|147-150|days|O
DDI-DrugBank.d476.s2|152-157|before|O
DDI-DrugBank.d476.s2|159-161|the|O
DDI-DrugBank.d476.s2|163-172|withdrawal|O
DDI-DrugBank.d476.s2|174-175|of|O
DDI-DrugBank.d476.s2|177-185|clonidine|drug
DDI-DrugBank.d476.s2|186-186|.|O
DDI-DrugBank.d476.s3|0-5|ZEBETA|brand
DDI-DrugBank.d476.s3|7-12|should|O
DDI-DrugBank.d476.s3|14-15|be|O
DDI-DrugBank.d476.s3|17-20|used|O
DDI-DrugBank.d476.s3|22-25|with|O
DDI-DrugBank.d476.s3|27-30|care|O
DDI-DrugBank.d476.s3|32-35|when|O
DDI-DrugBank.d476.s3|37-58|myocardial depressants|group
DDI-DrugBank.d476.s3|60-61|or|O
DDI-DrugBank.d476.s3|63-72|inhibitors|O
DDI-DrugBank.d476.s3|74-75|of|O
DDI-DrugBank.d476.s3|77-78|AV|O
DDI-DrugBank.d476.s3|80-89|conduction|O
DDI-DrugBank.d476.s3|90-90|,|O
DDI-DrugBank.d476.s3|92-95|such|O
DDI-DrugBank.d476.s3|97-98|as|O
DDI-DrugBank.d476.s3|100-106|certain|O
DDI-DrugBank.d476.s3|108-126|calcium antagonists|group
DDI-DrugBank.d476.s3|128-128|(|O
DDI-DrugBank.d476.s3|129-140|particularly|O
DDI-DrugBank.d476.s3|142-143|of|O
DDI-DrugBank.d476.s3|145-147|the|O
DDI-DrugBank.d476.s3|149-164|phenylalkylamine|group
DDI-DrugBank.d476.s3|166-166|[|O
DDI-DrugBank.d476.s3|167-175|verapamil|drug
DDI-DrugBank.d476.s3|176-176|]|O
DDI-DrugBank.d476.s3|178-180|and|O
DDI-DrugBank.d476.s3|182-196|benzothiazepine|group
DDI-DrugBank.d476.s3|198-198|[|O
DDI-DrugBank.d476.s3|199-207|diltiazem|drug
DDI-DrugBank.d476.s3|208-208|]|O
DDI-DrugBank.d476.s3|210-216|classes|O
DDI-DrugBank.d476.s3|217-217|)|O
DDI-DrugBank.d476.s3|218-218|,|O
DDI-DrugBank.d476.s3|220-221|or|O
DDI-DrugBank.d476.s3|223-243|antiarrhythmic agents|group
DDI-DrugBank.d476.s3|244-244|,|O
DDI-DrugBank.d476.s3|246-249|such|O
DDI-DrugBank.d476.s3|251-252|as|O
DDI-DrugBank.d476.s3|254-265|disopyramide|drug
DDI-DrugBank.d476.s3|266-266|,|O
DDI-DrugBank.d476.s3|268-270|are|O
DDI-DrugBank.d476.s3|272-275|used|O
DDI-DrugBank.d476.s3|277-288|concurrently|O
DDI-DrugBank.d476.s3|289-289|.|O
DDI-DrugBank.d476.s4|0-9|Concurrent|O
DDI-DrugBank.d476.s4|11-13|use|O
DDI-DrugBank.d476.s4|15-16|of|O
DDI-DrugBank.d476.s4|18-25|rifampin|drug
DDI-DrugBank.d476.s4|27-35|increases|O
DDI-DrugBank.d476.s4|37-39|the|O
DDI-DrugBank.d476.s4|41-49|metabolic|O
DDI-DrugBank.d476.s4|51-59|clearance|O
DDI-DrugBank.d476.s4|61-62|of|O
DDI-DrugBank.d476.s4|64-69|ZEBETA|brand
DDI-DrugBank.d476.s4|70-70|,|O
DDI-DrugBank.d476.s4|72-80|resulting|O
DDI-DrugBank.d476.s4|82-83|in|O
DDI-DrugBank.d476.s4|85-85|a|O
DDI-DrugBank.d476.s4|87-95|shortened|O
DDI-DrugBank.d476.s4|97-107|elimination|O
DDI-DrugBank.d476.s4|109-117|half-life|O
DDI-DrugBank.d476.s4|119-120|of|O
DDI-DrugBank.d476.s4|122-127|ZEBETA|brand
DDI-DrugBank.d476.s4|128-128|.|O
DDI-DrugBank.d476.s5|0-6|However|O
DDI-DrugBank.d476.s5|7-7|,|O
DDI-DrugBank.d476.s5|9-15|initial|O
DDI-DrugBank.d476.s5|17-20|dose|O
DDI-DrugBank.d476.s5|22-33|modification|O
DDI-DrugBank.d476.s5|35-36|is|O
DDI-DrugBank.d476.s5|38-46|generally|O
DDI-DrugBank.d476.s5|48-50|not|O
DDI-DrugBank.d476.s5|52-60|necessary|O
DDI-DrugBank.d476.s5|61-61|.|O
DDI-DrugBank.d476.s6|0-14|Pharmacokinetic|O
DDI-DrugBank.d476.s6|16-22|studies|O
DDI-DrugBank.d476.s6|24-31|document|O
DDI-DrugBank.d476.s6|33-34|no|O
DDI-DrugBank.d476.s6|36-45|clinically|O
DDI-DrugBank.d476.s6|47-54|relevant|O
DDI-DrugBank.d476.s6|56-67|interactions|O
DDI-DrugBank.d476.s6|69-72|with|O
DDI-DrugBank.d476.s6|74-78|other|O
DDI-DrugBank.d476.s6|80-85|agents|O
DDI-DrugBank.d476.s6|87-91|given|O
DDI-DrugBank.d476.s6|93-105|concomitantly|O
DDI-DrugBank.d476.s6|106-106|,|O
DDI-DrugBank.d476.s6|108-116|including|O
DDI-DrugBank.d476.s6|118-135|thiazide diuretics|group
DDI-DrugBank.d476.s6|136-136|,|O
DDI-DrugBank.d476.s6|138-144|digoxin|drug
DDI-DrugBank.d476.s6|145-145|,|O
DDI-DrugBank.d476.s6|147-149|and|O
DDI-DrugBank.d476.s6|151-160|cimetidine|drug
DDI-DrugBank.d476.s6|161-161|.|O
DDI-DrugBank.d476.s7|0-4|There|O
DDI-DrugBank.d476.s7|6-8|was|O
DDI-DrugBank.d476.s7|10-11|no|O
DDI-DrugBank.d476.s7|13-18|effect|O
DDI-DrugBank.d476.s7|20-21|of|O
DDI-DrugBank.d476.s7|23-28|ZEBETA|brand
DDI-DrugBank.d476.s7|30-31|on|O
DDI-DrugBank.d476.s7|33-43|prothrombin|O
DDI-DrugBank.d476.s7|45-48|time|O
DDI-DrugBank.d476.s7|50-51|in|O
DDI-DrugBank.d476.s7|53-60|patients|O
DDI-DrugBank.d476.s7|62-63|on|O
DDI-DrugBank.d476.s7|65-70|stable|O
DDI-DrugBank.d476.s7|72-76|doses|O
DDI-DrugBank.d476.s7|78-79|of|O
DDI-DrugBank.d476.s7|81-88|warfarin|drug
DDI-DrugBank.d476.s7|89-89|.|O
DDI-DrugBank.d476.s8|0-3|Risk|O
DDI-DrugBank.d476.s8|5-6|of|O
DDI-DrugBank.d476.s8|8-19|Anaphylactic|O
DDI-DrugBank.d476.s8|21-28|Reaction|O
DDI-DrugBank.d476.s8|29-29|:|O
DDI-DrugBank.d476.s8|31-35|While|O
DDI-DrugBank.d476.s8|37-42|taking|O
DDI-DrugBank.d476.s8|44-56|beta-blockers|group
DDI-DrugBank.d476.s8|57-57|,|O
DDI-DrugBank.d476.s8|59-66|patients|O
DDI-DrugBank.d476.s8|68-71|with|O
DDI-DrugBank.d476.s8|73-73|a|O
DDI-DrugBank.d476.s8|75-81|history|O
DDI-DrugBank.d476.s8|83-84|of|O
DDI-DrugBank.d476.s8|86-91|severe|O
DDI-DrugBank.d476.s8|93-104|anaphylactic|O
DDI-DrugBank.d476.s8|106-113|reaction|O
DDI-DrugBank.d476.s8|115-116|to|O
DDI-DrugBank.d476.s8|118-118|a|O
DDI-DrugBank.d476.s8|120-126|variety|O
DDI-DrugBank.d476.s8|128-129|of|O
DDI-DrugBank.d476.s8|131-139|allergens|O
DDI-DrugBank.d476.s8|141-143|may|O
DDI-DrugBank.d476.s8|145-146|be|O
DDI-DrugBank.d476.s8|148-151|more|O
DDI-DrugBank.d476.s8|153-160|reactive|O
DDI-DrugBank.d476.s8|162-163|to|O
DDI-DrugBank.d476.s8|165-172|repeated|O
DDI-DrugBank.d476.s8|174-182|challenge|O
DDI-DrugBank.d476.s8|183-183|,|O
DDI-DrugBank.d476.s8|185-190|either|O
DDI-DrugBank.d476.s8|192-201|accidental|O
DDI-DrugBank.d476.s8|202-202|,|O
DDI-DrugBank.d476.s8|204-213|diagnostic|O
DDI-DrugBank.d476.s8|214-214|,|O
DDI-DrugBank.d476.s8|216-217|or|O
DDI-DrugBank.d476.s8|219-229|therapeutic|O
DDI-DrugBank.d476.s8|230-230|.|O
DDI-DrugBank.d476.s9|0-3|Such|O
DDI-DrugBank.d476.s9|5-12|patients|O
DDI-DrugBank.d476.s9|14-16|may|O
DDI-DrugBank.d476.s9|18-19|be|O
DDI-DrugBank.d476.s9|21-32|unresponsive|O
DDI-DrugBank.d476.s9|34-35|to|O
DDI-DrugBank.d476.s9|37-39|the|O
DDI-DrugBank.d476.s9|41-45|usual|O
DDI-DrugBank.d476.s9|47-51|doses|O
DDI-DrugBank.d476.s9|53-54|of|O
DDI-DrugBank.d476.s9|56-66|epinephrine|drug
DDI-DrugBank.d476.s9|68-71|used|O
DDI-DrugBank.d476.s9|73-74|to|O
DDI-DrugBank.d476.s9|76-80|treat|O
DDI-DrugBank.d476.s9|82-89|allergic|O
DDI-DrugBank.d476.s9|91-99|reactions|O
DDI-DrugBank.d476.s9|100-100|.|O
DDI-DrugBank.d129.s0|0-8|Androgens|group
DDI-DrugBank.d129.s0|10-12|may|O
DDI-DrugBank.d129.s0|14-21|increase|O
DDI-DrugBank.d129.s0|23-33|sensitivity|O
DDI-DrugBank.d129.s0|35-36|to|O
DDI-DrugBank.d129.s0|38-41|oral|O
DDI-DrugBank.d129.s0|43-56|anticoagulahts|O
DDI-DrugBank.d129.s0|57-57|.|O
DDI-DrugBank.d129.s1|0-5|Dosage|O
DDI-DrugBank.d129.s1|7-8|of|O
DDI-DrugBank.d129.s1|10-12|the|O
DDI-DrugBank.d129.s1|14-26|anticoagulant|group
DDI-DrugBank.d129.s1|28-30|may|O
DDI-DrugBank.d129.s1|32-38|require|O
DDI-DrugBank.d129.s1|40-48|reduction|O
DDI-DrugBank.d129.s1|50-51|in|O
DDI-DrugBank.d129.s1|53-57|order|O
DDI-DrugBank.d129.s1|59-60|to|O
DDI-DrugBank.d129.s1|62-69|maintain|O
DDI-DrugBank.d129.s1|71-82|satisfactory|O
DDI-DrugBank.d129.s1|84-94|therapeutic|O
DDI-DrugBank.d129.s1|96-114|hypoprothrombinemia|O
DDI-DrugBank.d129.s1|115-115|.|O
DDI-DrugBank.d129.s2|0-9|Concurrent|O
DDI-DrugBank.d129.s2|11-24|administration|O
DDI-DrugBank.d129.s2|26-27|of|O
DDI-DrugBank.d129.s2|29-43|oxyphenbutazone|drug
DDI-DrugBank.d129.s2|45-47|and|O
DDI-DrugBank.d129.s2|49-57|androgens|group
DDI-DrugBank.d129.s2|59-61|may|O
DDI-DrugBank.d129.s2|63-68|result|O
DDI-DrugBank.d129.s2|70-71|in|O
DDI-DrugBank.d129.s2|73-80|elevated|O
DDI-DrugBank.d129.s2|82-86|serum|O
DDI-DrugBank.d129.s2|88-93|levels|O
DDI-DrugBank.d129.s2|95-96|of|O
DDI-DrugBank.d129.s2|98-112|oxyphenbutazone|drug
DDI-DrugBank.d129.s2|113-113|.|O
DDI-DrugBank.d129.s3|0-1|In|O
DDI-DrugBank.d129.s3|3-10|diabetic|O
DDI-DrugBank.d129.s3|12-19|patients|O
DDI-DrugBank.d129.s3|20-20|,|O
DDI-DrugBank.d129.s3|22-24|the|O
DDI-DrugBank.d129.s3|26-34|metabolic|O
DDI-DrugBank.d129.s3|36-42|effects|O
DDI-DrugBank.d129.s3|44-45|of|O
DDI-DrugBank.d129.s3|47-55|androgens|group
DDI-DrugBank.d129.s3|57-59|may|O
DDI-DrugBank.d129.s3|61-68|decrease|O
DDI-DrugBank.d129.s3|70-74|blood|O
DDI-DrugBank.d129.s3|76-82|glucose|O
DDI-DrugBank.d129.s3|84-86|and|O
DDI-DrugBank.d129.s3|88-96|therefore|O
DDI-DrugBank.d129.s3|97-97|,|O
DDI-DrugBank.d129.s3|99-105|insulin|drug
DDI-DrugBank.d129.s3|107-118|requirements|O
DDI-DrugBank.d129.s3|119-119|.|O
DDI-DrugBank.d13.s0|0-3|Drug|O
DDI-DrugBank.d13.s0|5-16|Interactions|O
DDI-DrugBank.d13.s0|17-17|:|O
DDI-DrugBank.d13.s0|19-30|Flupenthixol|drug
DDI-DrugBank.d13.s0|32-34|may|O
DDI-DrugBank.d13.s0|36-43|interact|O
DDI-DrugBank.d13.s0|45-48|with|O
DDI-DrugBank.d13.s0|50-53|some|O
DDI-DrugBank.d13.s0|55-59|drugs|O
DDI-DrugBank.d13.s0|60-60|,|O
DDI-DrugBank.d13.s0|62-65|like|O
DDI-DrugBank.d13.s0|67-94|Monoamine oxidase inhibitors|group
DDI-DrugBank.d13.s0|96-96|(|O
DDI-DrugBank.d13.s0|97-100|MAOI|group
DDI-DrugBank.d13.s0|101-101|)|O
DDI-DrugBank.d13.s0|102-102|:|O
DDI-DrugBank.d13.s0|104-107|MAOI|group
DDI-DrugBank.d13.s0|109-113|could|O
DDI-DrugBank.d13.s0|115-127|theoretically|O
DDI-DrugBank.d13.s0|129-134|affect|O
DDI-DrugBank.d13.s0|136-147|flupenthixol|drug
DDI-DrugBank.d13.s0|149-164|pharmacodynamics|O
DDI-DrugBank.d13.s0|166-166|-|O
DDI-DrugBank.d13.s0|178-178|-|O
DDI-DrugBank.d13.s0|180-190|Eproxindine|O
DDI-DrugBank.d13.s0|192-192|-|O
DDI-DrugBank.d13.s0|194-200|Ethanol|drug
DDI-DrugBank.d13.s0|201-201|:|O
DDI-DrugBank.d13.s0|203-214|Flupenthixol|drug
DDI-DrugBank.d13.s0|216-218|and|O
DDI-DrugBank.d13.s0|220-226|Ethanol|drug
DDI-DrugBank.d13.s0|228-232|cause|O
DDI-DrugBank.d13.s0|234-241|additive|O
DDI-DrugBank.d13.s0|243-245|CNS|O
DDI-DrugBank.d13.s0|247-256|depression|O
DDI-DrugBank.d13.s0|258-258|-|O
DDI-DrugBank.d13.s0|260-284|Tricyclic antidepressants|group
DDI-DrugBank.d13.s0|285-285|:|O
DDI-DrugBank.d13.s0|287-298|Flupenthixol|drug
DDI-DrugBank.d13.s0|300-308|increases|O
DDI-DrugBank.d13.s0|310-312|the|O
DDI-DrugBank.d13.s0|314-319|effect|O
DDI-DrugBank.d13.s0|321-322|of|O
DDI-DrugBank.d131.s0|0-2|The|O
DDI-DrugBank.d131.s0|4-18|benzodiazepines|group
DDI-DrugBank.d131.s0|19-19|,|O
DDI-DrugBank.d131.s0|21-29|including|O
DDI-DrugBank.d131.s0|31-40|alprazolam|drug
DDI-DrugBank.d131.s0|41-41|,|O
DDI-DrugBank.d131.s0|43-49|produce|O
DDI-DrugBank.d131.s0|51-58|additive|O
DDI-DrugBank.d131.s0|60-62|CNS|O
DDI-DrugBank.d131.s0|64-73|depressant|O
DDI-DrugBank.d131.s0|75-81|effects|O
DDI-DrugBank.d131.s0|83-86|when|O
DDI-DrugBank.d131.s0|88-102|co-administered|O
DDI-DrugBank.d131.s0|104-107|with|O
DDI-DrugBank.d131.s0|109-113|other|O
DDI-DrugBank.d131.s0|115-138|psychotropic medications|group
DDI-DrugBank.d131.s0|139-139|,|O
DDI-DrugBank.d131.s0|141-155|anticonvulsants|group
DDI-DrugBank.d131.s0|156-156|,|O
DDI-DrugBank.d131.s0|158-172|antihistaminics|group
DDI-DrugBank.d131.s0|173-173|,|O
DDI-DrugBank.d131.s0|175-181|ethanol|drug
DDI-DrugBank.d131.s0|182-182|,|O
DDI-DrugBank.d131.s0|184-186|and|O
DDI-DrugBank.d131.s0|188-192|other|O
DDI-DrugBank.d131.s0|194-198|drugs|O
DDI-DrugBank.d131.s0|200-204|which|O
DDI-DrugBank.d131.s0|206-215|themselves|O
DDI-DrugBank.d131.s0|217-223|produce|O
DDI-DrugBank.d131.s0|225-227|CNS|O
DDI-DrugBank.d131.s0|229-238|depression|O
DDI-DrugBank.d131.s0|239-239|.|O
DDI-DrugBank.d131.s1|0-2|The|O
DDI-DrugBank.d131.s1|4-9|steady|O
DDI-DrugBank.d131.s1|11-15|state|O
DDI-DrugBank.d131.s1|17-22|plasma|O
DDI-DrugBank.d131.s1|24-37|concentrations|O
DDI-DrugBank.d131.s1|39-40|of|O
DDI-DrugBank.d131.s1|42-51|imipramine|drug
DDI-DrugBank.d131.s1|53-55|and|O
DDI-DrugBank.d131.s1|57-67|desipramine|drug
DDI-DrugBank.d131.s1|69-72|have|O
DDI-DrugBank.d131.s1|74-77|been|O
DDI-DrugBank.d131.s1|79-86|reported|O
DDI-DrugBank.d131.s1|88-89|to|O
DDI-DrugBank.d131.s1|91-92|be|O
DDI-DrugBank.d131.s1|94-102|increased|O
DDI-DrugBank.d131.s1|104-105|an|O
DDI-DrugBank.d131.s1|107-113|average|O
DDI-DrugBank.d131.s1|115-116|of|O
DDI-DrugBank.d131.s1|118-119|31|O
DDI-DrugBank.d131.s1|120-120|%|O
DDI-DrugBank.d131.s1|122-124|and|O
DDI-DrugBank.d131.s1|126-127|20|O
DDI-DrugBank.d131.s1|128-128|%|O
DDI-DrugBank.d131.s1|129-129|,|O
DDI-DrugBank.d131.s1|131-142|respectively|O
DDI-DrugBank.d131.s1|143-143|,|O
DDI-DrugBank.d131.s1|145-146|by|O
DDI-DrugBank.d131.s1|148-150|the|O
DDI-DrugBank.d131.s1|152-162|concomitant|O
DDI-DrugBank.d131.s1|164-177|administration|O
DDI-DrugBank.d131.s1|179-180|of|O
DDI-DrugBank.d131.s1|182-191|alprazolam|drug
DDI-DrugBank.d131.s1|193-199|tablets|O
DDI-DrugBank.d131.s1|201-202|in|O
DDI-DrugBank.d131.s1|204-208|doses|O
DDI-DrugBank.d131.s1|210-211|up|O
DDI-DrugBank.d131.s1|213-214|to|O
DDI-DrugBank.d131.s1|216-216|4|O
DDI-DrugBank.d131.s1|218-223|mg/day|O
DDI-DrugBank.d131.s1|224-224|.|O
DDI-DrugBank.d131.s2|0-2|The|O
DDI-DrugBank.d131.s2|4-11|clinical|O
DDI-DrugBank.d131.s2|13-24|significance|O
DDI-DrugBank.d131.s2|26-27|of|O
DDI-DrugBank.d131.s2|29-33|these|O
DDI-DrugBank.d131.s2|35-41|changes|O
DDI-DrugBank.d131.s2|43-44|is|O
DDI-DrugBank.d131.s2|46-52|unknown|O
DDI-DrugBank.d131.s2|53-53|.|O
DDI-DrugBank.d131.s3|0-4|Drugs|O
DDI-DrugBank.d131.s3|6-9|That|O
DDI-DrugBank.d131.s3|11-17|Inhibit|O
DDI-DrugBank.d131.s3|19-28|Alprazolam|drug
DDI-DrugBank.d131.s3|30-39|Metabolism|O
DDI-DrugBank.d131.s3|41-43|Via|O
DDI-DrugBank.d131.s3|45-54|Cytochrome|O
DDI-DrugBank.d131.s3|56-59|P450|O
DDI-DrugBank.d131.s3|61-62|3A|O
DDI-DrugBank.d131.s3|63-63|:|O
DDI-DrugBank.d131.s3|65-67|The|O
DDI-DrugBank.d131.s3|69-75|initial|O
DDI-DrugBank.d131.s3|77-80|step|O
DDI-DrugBank.d131.s3|82-83|in|O
DDI-DrugBank.d131.s3|85-94|alprazolam|drug
DDI-DrugBank.d131.s3|96-105|metabolism|O
DDI-DrugBank.d131.s3|107-108|is|O
DDI-DrugBank.d131.s3|110-122|hydroxylation|O
DDI-DrugBank.d131.s3|124-132|catalyzed|O
DDI-DrugBank.d131.s3|134-135|by|O
DDI-DrugBank.d131.s3|137-146|cytochrome|O
DDI-DrugBank.d131.s3|148-151|P450|O
DDI-DrugBank.d131.s3|153-154|3A|O
DDI-DrugBank.d131.s3|156-156|(|O
DDI-DrugBank.d131.s3|157-159|CYP|O
DDI-DrugBank.d131.s3|161-162|3A|O
DDI-DrugBank.d131.s3|163-163|)|O
DDI-DrugBank.d131.s3|164-164|.|O
DDI-DrugBank.d131.s4|0-4|Drugs|O
DDI-DrugBank.d131.s4|6-10|which|O
DDI-DrugBank.d131.s4|12-18|inhibit|O
DDI-DrugBank.d131.s4|20-23|this|O
DDI-DrugBank.d131.s4|25-33|metabolic|O
DDI-DrugBank.d131.s4|35-41|pathway|O
DDI-DrugBank.d131.s4|43-45|may|O
DDI-DrugBank.d131.s4|47-50|have|O
DDI-DrugBank.d131.s4|52-52|a|O
DDI-DrugBank.d131.s4|54-61|profound|O
DDI-DrugBank.d131.s4|63-68|effect|O
DDI-DrugBank.d131.s4|70-71|on|O
DDI-DrugBank.d131.s4|73-75|the|O
DDI-DrugBank.d131.s4|77-85|clearance|O
DDI-DrugBank.d131.s4|87-88|of|O
DDI-DrugBank.d131.s4|90-99|alprazolam|drug
DDI-DrugBank.d131.s4|101-101|.|O
DDI-DrugBank.d131.s5|0-4|Drugs|O
DDI-DrugBank.d131.s5|6-17|Demonstrated|O
DDI-DrugBank.d131.s5|19-20|to|O
DDI-DrugBank.d131.s5|22-23|be|O
DDI-DrugBank.d131.s5|25-27|CYP|O
DDI-DrugBank.d131.s5|29-30|3A|O
DDI-DrugBank.d131.s5|32-41|Inhibitors|O
DDI-DrugBank.d131.s5|43-44|of|O
DDI-DrugBank.d131.s5|46-53|Possible|O
DDI-DrugBank.d131.s5|55-62|Clinical|O
DDI-DrugBank.d131.s5|64-75|Significance|O
DDI-DrugBank.d131.s5|77-78|on|O
DDI-DrugBank.d131.s5|80-82|the|O
DDI-DrugBank.d131.s5|84-88|Basis|O
DDI-DrugBank.d131.s5|90-91|of|O
DDI-DrugBank.d131.s5|93-100|Clinical|O
DDI-DrugBank.d131.s5|102-108|Studies|O
DDI-DrugBank.d131.s5|110-118|Involving|O
DDI-DrugBank.d131.s5|120-129|Alprazolam|drug
DDI-DrugBank.d131.s5|131-131|(|O
DDI-DrugBank.d131.s5|132-138|caution|O
DDI-DrugBank.d131.s5|140-141|is|O
DDI-DrugBank.d131.s5|143-153|recommended|O
DDI-DrugBank.d131.s5|155-160|during|O
DDI-DrugBank.d131.s5|162-177|coadministration|O
DDI-DrugBank.d131.s5|179-182|with|O
DDI-DrugBank.d131.s5|184-193|alprazolam|drug
DDI-DrugBank.d131.s5|194-194|)|O
DDI-DrugBank.d131.s5|195-195|:|O
DDI-DrugBank.d131.s5|197-212|Coadministration|O
DDI-DrugBank.d131.s5|214-215|of|O
DDI-DrugBank.d131.s5|217-226|fluoxetine|drug
DDI-DrugBank.d131.s5|228-231|with|O
DDI-DrugBank.d131.s5|233-242|alprazolam|drug
DDI-DrugBank.d131.s5|244-252|increased|O
DDI-DrugBank.d131.s5|254-256|the|O
DDI-DrugBank.d131.s5|258-264|maximum|O
DDI-DrugBank.d131.s5|266-271|plasma|O
DDI-DrugBank.d131.s5|273-285|concentration|O
DDI-DrugBank.d131.s5|287-288|of|O
DDI-DrugBank.d131.s5|290-299|alprazolam|drug
DDI-DrugBank.d131.s5|301-302|by|O
DDI-DrugBank.d131.s5|304-305|46|O
DDI-DrugBank.d131.s5|306-306|%|O
DDI-DrugBank.d131.s5|307-307|,|O
DDI-DrugBank.d131.s5|309-317|decreased|O
DDI-DrugBank.d131.s5|319-327|clearance|O
DDI-DrugBank.d131.s5|329-330|by|O
DDI-DrugBank.d131.s5|332-333|21|O
DDI-DrugBank.d131.s5|334-334|%|O
DDI-DrugBank.d131.s5|335-335|,|O
DDI-DrugBank.d131.s5|337-345|increased|O
DDI-DrugBank.d131.s5|347-355|half-life|O
DDI-DrugBank.d131.s5|357-358|by|O
DDI-DrugBank.d131.s5|360-361|17|O
DDI-DrugBank.d131.s5|362-362|%|O
DDI-DrugBank.d131.s5|363-363|,|O
DDI-DrugBank.d131.s5|365-367|and|O
DDI-DrugBank.d131.s5|369-377|decreased|O
DDI-DrugBank.d131.s5|379-386|measured|O
DDI-DrugBank.d131.s5|388-398|psychomotor|O
DDI-DrugBank.d131.s5|400-410|performance|O
DDI-DrugBank.d131.s5|411-411|.|O
DDI-DrugBank.d131.s6|0-15|Coadministration|O
DDI-DrugBank.d131.s6|17-18|of|O
DDI-DrugBank.d131.s6|20-31|propoxyphene|drug
DDI-DrugBank.d131.s6|33-41|decreased|O
DDI-DrugBank.d131.s6|43-45|the|O
DDI-DrugBank.d131.s6|47-53|maximum|O
DDI-DrugBank.d131.s6|55-60|plasma|O
DDI-DrugBank.d131.s6|62-74|concentration|O
DDI-DrugBank.d131.s6|76-77|of|O
DDI-DrugBank.d131.s6|79-88|alprazolam|drug
DDI-DrugBank.d131.s6|90-91|by|O
DDI-DrugBank.d131.s6|93-93|6|O
DDI-DrugBank.d131.s6|94-94|%|O
DDI-DrugBank.d131.s6|95-95|,|O
DDI-DrugBank.d131.s6|97-105|decreased|O
DDI-DrugBank.d131.s6|107-115|clearance|O
DDI-DrugBank.d131.s6|117-118|by|O
DDI-DrugBank.d131.s6|120-121|38|O
DDI-DrugBank.d131.s6|122-122|%|O
DDI-DrugBank.d131.s6|123-123|,|O
DDI-DrugBank.d131.s6|125-127|and|O
DDI-DrugBank.d131.s6|129-137|increased|O
DDI-DrugBank.d131.s6|139-147|half-life|O
DDI-DrugBank.d131.s6|149-150|by|O
DDI-DrugBank.d131.s6|152-153|58|O
DDI-DrugBank.d131.s6|154-154|%|O
DDI-DrugBank.d131.s6|155-155|.|O
DDI-DrugBank.d131.s7|0-15|Coadministration|O
DDI-DrugBank.d131.s7|17-18|of|O
DDI-DrugBank.d131.s7|20-23|oral|O
DDI-DrugBank.d131.s7|25-38|contraceptives|group
DDI-DrugBank.d131.s7|40-48|increased|O
DDI-DrugBank.d131.s7|50-52|the|O
DDI-DrugBank.d131.s7|54-60|maximum|O
DDI-DrugBank.d131.s7|62-67|plasma|O
DDI-DrugBank.d131.s7|69-81|concentration|O
DDI-DrugBank.d131.s7|83-84|of|O
DDI-DrugBank.d131.s7|86-95|alprazolam|drug
DDI-DrugBank.d131.s7|97-98|by|O
DDI-DrugBank.d131.s7|100-101|18|O
DDI-DrugBank.d131.s7|102-102|%|O
DDI-DrugBank.d131.s7|103-103|,|O
DDI-DrugBank.d131.s7|105-113|decreased|O
DDI-DrugBank.d131.s7|115-123|clearance|O
DDI-DrugBank.d131.s7|125-126|by|O
DDI-DrugBank.d131.s7|128-129|22|O
DDI-DrugBank.d131.s7|130-130|%|O
DDI-DrugBank.d131.s7|131-131|,|O
DDI-DrugBank.d131.s7|133-135|and|O
DDI-DrugBank.d131.s7|137-145|increased|O
DDI-DrugBank.d131.s7|147-155|half-life|O
DDI-DrugBank.d131.s7|157-158|by|O
DDI-DrugBank.d131.s7|160-161|29|O
DDI-DrugBank.d131.s7|162-162|%|O
DDI-DrugBank.d131.s7|163-163|.|O
DDI-DrugBank.d131.s8|0-4|Drugs|O
DDI-DrugBank.d131.s8|6-8|and|O
DDI-DrugBank.d131.s8|10-14|other|O
DDI-DrugBank.d131.s8|16-25|substances|O
DDI-DrugBank.d131.s8|27-38|demonstrated|O
DDI-DrugBank.d131.s8|40-41|to|O
DDI-DrugBank.d131.s8|43-44|be|O
DDI-DrugBank.d131.s8|46-48|CYP|O
DDI-DrugBank.d131.s8|50-51|3A|O
DDI-DrugBank.d131.s8|53-62|inhibitors|O
DDI-DrugBank.d131.s8|64-65|on|O
DDI-DrugBank.d131.s8|67-69|the|O
DDI-DrugBank.d131.s8|71-75|basis|O
DDI-DrugBank.d131.s8|77-78|of|O
DDI-DrugBank.d131.s8|80-87|clinical|O
DDI-DrugBank.d131.s8|89-95|studies|O
DDI-DrugBank.d131.s8|97-105|involving|O
DDI-DrugBank.d131.s8|107-121|benzodiazepines|group
DDI-DrugBank.d131.s8|123-133|metabolized|O
DDI-DrugBank.d131.s8|135-143|similarly|O
DDI-DrugBank.d131.s8|145-146|to|O
DDI-DrugBank.d131.s8|148-157|alprazolam|drug
DDI-DrugBank.d131.s8|159-160|or|O
DDI-DrugBank.d131.s8|162-163|on|O
DDI-DrugBank.d131.s8|165-167|the|O
DDI-DrugBank.d131.s8|169-173|basis|O
DDI-DrugBank.d131.s8|175-176|of|O
DDI-DrugBank.d131.s8|178-179|in|O
DDI-DrugBank.d131.s8|181-185|vitro|O
DDI-DrugBank.d131.s8|187-193|studies|O
DDI-DrugBank.d131.s8|195-198|with|O
DDI-DrugBank.d131.s8|200-209|alprazolam|drug
DDI-DrugBank.d131.s8|211-212|or|O
DDI-DrugBank.d131.s8|214-218|other|O
DDI-DrugBank.d131.s8|220-234|benzodiazepines|group
DDI-DrugBank.d131.s8|236-236|(|O
DDI-DrugBank.d131.s8|237-243|caution|O
DDI-DrugBank.d131.s8|245-246|is|O
DDI-DrugBank.d131.s8|248-258|recommended|O
DDI-DrugBank.d131.s8|260-265|during|O
DDI-DrugBank.d131.s8|267-282|coadministration|O
DDI-DrugBank.d131.s8|284-287|with|O
DDI-DrugBank.d131.s8|289-298|alprazolam|drug
DDI-DrugBank.d131.s8|299-299|)|O
DDI-DrugBank.d131.s8|300-300|:|O
DDI-DrugBank.d131.s8|302-310|Available|O
DDI-DrugBank.d131.s8|312-315|data|O
DDI-DrugBank.d131.s8|317-320|from|O
DDI-DrugBank.d131.s8|322-329|clinical|O
DDI-DrugBank.d131.s8|331-337|studies|O
DDI-DrugBank.d131.s8|339-340|of|O
DDI-DrugBank.d131.s8|342-356|benzodiazepines|group
DDI-DrugBank.d131.s8|358-362|other|O
DDI-DrugBank.d131.s8|364-367|than|O
DDI-DrugBank.d131.s8|369-378|alprazolam|drug
DDI-DrugBank.d131.s8|380-386|suggest|O
DDI-DrugBank.d131.s8|388-388|a|O
DDI-DrugBank.d131.s8|390-397|possible|O
DDI-DrugBank.d131.s8|399-402|drug|O
DDI-DrugBank.d131.s8|404-414|interaction|O
DDI-DrugBank.d131.s8|416-419|with|O
DDI-DrugBank.d131.s8|421-430|alprazolam|drug
DDI-DrugBank.d131.s8|432-434|for|O
DDI-DrugBank.d131.s8|436-438|the|O
DDI-DrugBank.d131.s8|440-448|following|O
DDI-DrugBank.d131.s8|449-449|:|O
DDI-DrugBank.d131.s8|451-459|diltiazem|drug
DDI-DrugBank.d131.s8|460-460|,|O
DDI-DrugBank.d131.s8|462-470|isoniazid|drug
DDI-DrugBank.d131.s8|471-471|,|O
DDI-DrugBank.d131.s8|473-493|macrolide antibiotics|group
DDI-DrugBank.d131.s8|495-498|such|O
DDI-DrugBank.d131.s8|500-501|as|O
DDI-DrugBank.d131.s8|503-514|erythromycin|drug
DDI-DrugBank.d131.s8|516-518|and|O
DDI-DrugBank.d131.s8|520-533|clarithromycin|drug
DDI-DrugBank.d131.s8|534-534|,|O
DDI-DrugBank.d131.s8|536-538|and|O
DDI-DrugBank.d131.s8|540-549|grapefruit|O
DDI-DrugBank.d131.s8|551-555|juice|O
DDI-DrugBank.d131.s8|556-556|.|O
DDI-DrugBank.d131.s9|0-3|Data|O
DDI-DrugBank.d131.s9|5-8|from|O
DDI-DrugBank.d131.s9|10-11|in|O
DDI-DrugBank.d131.s9|13-17|vitro|O
DDI-DrugBank.d131.s9|19-25|studies|O
DDI-DrugBank.d131.s9|27-28|of|O
DDI-DrugBank.d131.s9|30-39|alprazolam|drug
DDI-DrugBank.d131.s9|41-47|suggest|O
DDI-DrugBank.d131.s9|49-49|a|O
DDI-DrugBank.d131.s9|51-58|possible|O
DDI-DrugBank.d131.s9|60-63|drug|O
DDI-DrugBank.d131.s9|65-75|interaction|O
DDI-DrugBank.d131.s9|77-80|with|O
DDI-DrugBank.d131.s9|82-91|alprazolam|drug
DDI-DrugBank.d131.s9|93-95|for|O
DDI-DrugBank.d131.s9|97-99|the|O
DDI-DrugBank.d131.s9|101-109|following|O
DDI-DrugBank.d131.s9|110-110|:|O
DDI-DrugBank.d131.s9|112-121|sertraline|drug
DDI-DrugBank.d131.s9|123-125|and|O
DDI-DrugBank.d131.s9|127-136|paroxetine|drug
DDI-DrugBank.d131.s9|137-137|.|O
DDI-DrugBank.d131.s10|0-3|Data|O
DDI-DrugBank.d131.s10|5-8|from|O
DDI-DrugBank.d131.s10|10-11|in|O
DDI-DrugBank.d131.s10|13-17|vitro|O
DDI-DrugBank.d131.s10|19-25|studies|O
DDI-DrugBank.d131.s10|27-28|of|O
DDI-DrugBank.d131.s10|30-44|benzodiazepines|group
DDI-DrugBank.d131.s10|46-50|other|O
DDI-DrugBank.d131.s10|52-55|than|O
DDI-DrugBank.d131.s10|57-66|alprazolam|drug
DDI-DrugBank.d131.s10|68-74|suggest|O
DDI-DrugBank.d131.s10|76-76|a|O
DDI-DrugBank.d131.s10|78-85|possible|O
DDI-DrugBank.d131.s10|87-90|drug|O
DDI-DrugBank.d131.s10|92-102|interaction|O
DDI-DrugBank.d131.s10|104-106|for|O
DDI-DrugBank.d131.s10|108-110|the|O
DDI-DrugBank.d131.s10|112-120|following|O
DDI-DrugBank.d131.s10|121-121|:|O
DDI-DrugBank.d131.s10|123-132|ergotamine|drug
DDI-DrugBank.d131.s10|133-133|,|O
DDI-DrugBank.d131.s10|135-146|cyclosporine|drug
DDI-DrugBank.d131.s10|147-147|,|O
DDI-DrugBank.d131.s10|149-158|amiodarone|drug
DDI-DrugBank.d131.s10|159-159|,|O
DDI-DrugBank.d131.s10|161-171|nicardipine|drug
DDI-DrugBank.d131.s10|172-172|,|O
DDI-DrugBank.d131.s10|174-176|and|O
DDI-DrugBank.d131.s10|178-187|nifedipine|drug
DDI-DrugBank.d131.s10|188-188|.|O
DDI-DrugBank.d131.s11|0-6|Caution|O
DDI-DrugBank.d131.s11|8-9|is|O
DDI-DrugBank.d131.s11|11-21|recommended|O
DDI-DrugBank.d131.s11|23-28|during|O
DDI-DrugBank.d131.s11|30-32|the|O
DDI-DrugBank.d131.s11|34-49|coadministration|O
DDI-DrugBank.d131.s11|51-52|of|O
DDI-DrugBank.d131.s11|54-56|any|O
DDI-DrugBank.d131.s11|58-59|of|O
DDI-DrugBank.d131.s11|61-65|these|O
DDI-DrugBank.d131.s11|67-70|with|O
DDI-DrugBank.d131.s11|72-81|alprazolam|drug
DDI-DrugBank.d131.s11|82-82|.|O
DDI-MedLine.d2.s0|0-6|Failure|O
DDI-MedLine.d2.s0|8-9|of|O
DDI-MedLine.d2.s0|11-18|neomycin|drug
DDI-MedLine.d2.s0|20-21|to|O
DDI-MedLine.d2.s0|23-28|modify|O
DDI-MedLine.d2.s0|30-33|ACTH|group
DDI-MedLine.d2.s0|35-41|induced|O
DDI-MedLine.d2.s0|43-54|hypertension|O
DDI-MedLine.d2.s0|56-57|in|O
DDI-MedLine.d2.s0|59-63|sheep|O
DDI-MedLine.d2.s0|64-64|.|O
DDI-MedLine.d2.s1|0-6|Studies|O
DDI-MedLine.d2.s1|8-9|in|O
DDI-MedLine.d2.s1|11-14|rats|O
DDI-MedLine.d2.s1|16-19|have|O
DDI-MedLine.d2.s1|21-25|shown|O
DDI-MedLine.d2.s1|27-30|that|O
DDI-MedLine.d2.s1|32-39|neomycin|drug
DDI-MedLine.d2.s1|41-54|administration|O
DDI-MedLine.d2.s1|56-65|attenuates|O
DDI-MedLine.d2.s1|67-73|certain|O
DDI-MedLine.d2.s1|75-79|types|O
DDI-MedLine.d2.s1|81-82|of|O
DDI-MedLine.d2.s1|84-105|adrenocortical steroid|group
DDI-MedLine.d2.s1|107-115|dependent|O
DDI-MedLine.d2.s1|117-128|hypertension|O
DDI-MedLine.d2.s1|129-129|,|O
DDI-MedLine.d2.s1|131-139|including|O
DDI-MedLine.d2.s1|141-144|ACTH|drug
DDI-MedLine.d2.s1|146-157|hypertension|O
DDI-MedLine.d2.s1|158-158|.|O
DDI-MedLine.d2.s2|0-2|The|O
DDI-MedLine.d2.s2|4-10|effects|O
DDI-MedLine.d2.s2|12-13|of|O
DDI-MedLine.d2.s2|15-18|oral|O
DDI-MedLine.d2.s2|20-27|neomycin|drug
DDI-MedLine.d2.s2|29-30|on|O
DDI-MedLine.d2.s2|32-35|ACTH|group
DDI-MedLine.d2.s2|37-43|induced|O
DDI-MedLine.d2.s2|45-56|hypertension|O
DDI-MedLine.d2.s2|58-61|were|O
DDI-MedLine.d2.s2|63-70|examined|O
DDI-MedLine.d2.s2|72-73|in|O
DDI-MedLine.d2.s2|75-83|conscious|O
DDI-MedLine.d2.s2|85-89|sheep|O
DDI-MedLine.d2.s2|90-90|.|O
DDI-MedLine.d2.s3|0-7|Neomycin|drug
DDI-MedLine.d2.s3|9-11|has|O
DDI-MedLine.d2.s3|13-14|no|O
DDI-MedLine.d2.s3|16-21|effect|O
DDI-MedLine.d2.s3|23-24|on|O
DDI-MedLine.d2.s3|26-28|the|O
DDI-MedLine.d2.s3|30-34|blood|O
DDI-MedLine.d2.s3|36-43|pressure|O
DDI-MedLine.d2.s3|45-46|or|O
DDI-MedLine.d2.s3|48-56|metabolic|O
DDI-MedLine.d2.s3|58-66|responses|O
DDI-MedLine.d2.s3|68-69|to|O
DDI-MedLine.d2.s3|71-74|ACTH|group
DDI-MedLine.d2.s3|76-77|in|O
DDI-MedLine.d2.s3|79-83|sheep|O
DDI-MedLine.d2.s3|84-84|.|O
DDI-DrugBank.d144.s0|0-10|Concomitant|O
DDI-DrugBank.d144.s0|12-15|oral|O
DDI-DrugBank.d144.s0|17-30|administration|O
DDI-DrugBank.d144.s0|32-33|of|O
DDI-DrugBank.d144.s0|35-46|ketoconazole|drug
DDI-DrugBank.d144.s0|48-48|(|O
DDI-DrugBank.d144.s0|49-49|a|O
DDI-DrugBank.d144.s0|51-55|known|O
DDI-DrugBank.d144.s0|57-65|inhibitor|O
DDI-DrugBank.d144.s0|67-68|of|O
DDI-DrugBank.d144.s0|70-75|CYP3A4|O
DDI-DrugBank.d144.s0|77-84|activity|O
DDI-DrugBank.d144.s0|86-87|in|O
DDI-DrugBank.d144.s0|89-91|the|O
DDI-DrugBank.d144.s0|93-97|liver|O
DDI-DrugBank.d144.s0|99-101|and|O
DDI-DrugBank.d144.s0|103-104|in|O
DDI-DrugBank.d144.s0|106-108|the|O
DDI-DrugBank.d144.s0|110-119|intestinal|O
DDI-DrugBank.d144.s0|121-126|mucosa|O
DDI-DrugBank.d144.s0|127-127|)|O
DDI-DrugBank.d144.s0|129-134|caused|O
DDI-DrugBank.d144.s0|136-137|an|O
DDI-DrugBank.d144.s0|139-148|eight-fold|O
DDI-DrugBank.d144.s0|150-157|increase|O
DDI-DrugBank.d144.s0|159-160|of|O
DDI-DrugBank.d144.s0|162-164|the|O
DDI-DrugBank.d144.s0|166-173|systemic|O
DDI-DrugBank.d144.s0|175-182|exposure|O
DDI-DrugBank.d144.s0|184-185|to|O
DDI-DrugBank.d144.s0|187-190|oral|O
DDI-DrugBank.d144.s0|192-201|budesonide|drug
DDI-DrugBank.d144.s0|202-202|.|O
DDI-DrugBank.d144.s1|0-1|If|O
DDI-DrugBank.d144.s1|3-11|treatment|O
DDI-DrugBank.d144.s1|13-16|with|O
DDI-DrugBank.d144.s1|18-27|inhibitors|O
DDI-DrugBank.d144.s1|29-30|of|O
DDI-DrugBank.d144.s1|32-37|CYP3A4|O
DDI-DrugBank.d144.s1|39-46|activity|O
DDI-DrugBank.d144.s1|48-48|(|O
DDI-DrugBank.d144.s1|49-52|such|O
DDI-DrugBank.d144.s1|54-55|as|O
DDI-DrugBank.d144.s1|57-68|ketoconazole|drug
DDI-DrugBank.d144.s1|69-69|,|O
DDI-DrugBank.d144.s1|71-83|intraconazole|drug
DDI-DrugBank.d144.s1|84-84|,|O
DDI-DrugBank.d144.s1|86-94|ritonavir|drug
DDI-DrugBank.d144.s1|95-95|,|O
DDI-DrugBank.d144.s1|97-105|indinavir|drug
DDI-DrugBank.d144.s1|106-106|,|O
DDI-DrugBank.d144.s1|108-117|saquinavir|drug
DDI-DrugBank.d144.s1|118-118|,|O
DDI-DrugBank.d144.s1|120-131|erythromycin|drug
DDI-DrugBank.d144.s1|132-132|,|O
DDI-DrugBank.d144.s1|134-137|etc.|O
DDI-DrugBank.d144.s1|138-138|)|O
DDI-DrugBank.d144.s1|140-141|is|O
DDI-DrugBank.d144.s1|143-151|indicated|O
DDI-DrugBank.d144.s1|152-152|,|O
DDI-DrugBank.d144.s1|154-162|reduction|O
DDI-DrugBank.d144.s1|164-165|of|O
DDI-DrugBank.d144.s1|167-169|the|O
DDI-DrugBank.d144.s1|171-180|budesonide|drug
DDI-DrugBank.d144.s1|182-185|dose|O
DDI-DrugBank.d144.s1|187-192|should|O
DDI-DrugBank.d144.s1|194-195|be|O
DDI-DrugBank.d144.s1|197-206|considered|O
DDI-DrugBank.d144.s1|207-207|.|O
DDI-DrugBank.d144.s2|0-4|After|O
DDI-DrugBank.d144.s2|6-14|extensive|O
DDI-DrugBank.d144.s2|16-21|intake|O
DDI-DrugBank.d144.s2|23-24|of|O
DDI-DrugBank.d144.s2|26-35|grapefruit|O
DDI-DrugBank.d144.s2|37-41|juice|O
DDI-DrugBank.d144.s2|43-43|(|O
DDI-DrugBank.d144.s2|44-48|which|O
DDI-DrugBank.d144.s2|50-57|inhibits|O
DDI-DrugBank.d144.s2|59-64|CYP3A4|O
DDI-DrugBank.d144.s2|66-73|activity|O
DDI-DrugBank.d144.s2|75-87|predominantly|O
DDI-DrugBank.d144.s2|89-90|in|O
DDI-DrugBank.d144.s2|92-94|the|O
DDI-DrugBank.d144.s2|96-105|intestinal|O
DDI-DrugBank.d144.s2|107-112|mucosa|O
DDI-DrugBank.d144.s2|113-113|)|O
DDI-DrugBank.d144.s2|114-114|,|O
DDI-DrugBank.d144.s2|116-118|the|O
DDI-DrugBank.d144.s2|120-127|systemic|O
DDI-DrugBank.d144.s2|129-136|exposure|O
DDI-DrugBank.d144.s2|138-140|for|O
DDI-DrugBank.d144.s2|142-145|oral|O
DDI-DrugBank.d144.s2|147-156|budesonide|drug
DDI-DrugBank.d144.s2|158-166|increased|O
DDI-DrugBank.d144.s2|168-172|about|O
DDI-DrugBank.d144.s2|174-176|two|O
DDI-DrugBank.d144.s2|178-182|times|O
DDI-DrugBank.d144.s2|183-183|.|O
DDI-DrugBank.d144.s3|0-1|As|O
DDI-DrugBank.d144.s3|3-6|with|O
DDI-DrugBank.d144.s3|8-12|other|O
DDI-DrugBank.d144.s3|14-18|drugs|O
DDI-DrugBank.d144.s3|20-28|primarily|O
DDI-DrugBank.d144.s3|30-34|being|O
DDI-DrugBank.d144.s3|36-46|metabolized|O
DDI-DrugBank.d144.s3|48-54|through|O
DDI-DrugBank.d144.s3|56-61|CYP3A4|O
DDI-DrugBank.d144.s3|62-62|,|O
DDI-DrugBank.d144.s3|64-72|ingestion|O
DDI-DrugBank.d144.s3|74-75|of|O
DDI-DrugBank.d144.s3|77-86|grapefruit|O
DDI-DrugBank.d144.s3|88-89|or|O
DDI-DrugBank.d144.s3|91-100|grapefruit|O
DDI-DrugBank.d144.s3|102-106|juice|O
DDI-DrugBank.d144.s3|108-113|should|O
DDI-DrugBank.d144.s3|115-116|be|O
DDI-DrugBank.d144.s3|118-124|avoided|O
DDI-DrugBank.d144.s3|126-127|in|O
DDI-DrugBank.d144.s3|129-138|connection|O
DDI-DrugBank.d144.s3|140-143|with|O
DDI-DrugBank.d144.s3|145-154|budesonide|drug
DDI-DrugBank.d144.s3|156-169|administration|O
DDI-DrugBank.d144.s3|170-170|.|O
DDI-DrugBank.d283.s0|0-3|Oral|O
DDI-DrugBank.d283.s0|5-18|Anticoagulants|group
DDI-DrugBank.d283.s0|20-26|CAUTION|O
DDI-DrugBank.d283.s0|28-33|SHOULD|O
DDI-DrugBank.d283.s0|35-36|BE|O
DDI-DrugBank.d283.s0|38-46|EXERCISED|O
DDI-DrugBank.d283.s0|48-51|WHEN|O
DDI-DrugBank.d283.s0|53-75|COUMARIN ANTICOAGULANTS|group
DDI-DrugBank.d283.s0|77-79|ARE|O
DDI-DrugBank.d283.s0|81-85|GIVEN|O
DDI-DrugBank.d283.s0|87-88|IN|O
DDI-DrugBank.d283.s0|90-100|CONJUNCTION|O
DDI-DrugBank.d283.s0|102-105|WITH|O
DDI-DrugBank.d283.s0|107-112|TRICOR|brand
DDI-DrugBank.d283.s0|113-113|.|O
DDI-DrugBank.d283.s1|0-2|THE|O
DDI-DrugBank.d283.s1|4-9|DOSAGE|O
DDI-DrugBank.d283.s1|11-12|OF|O
DDI-DrugBank.d283.s1|14-16|THE|O
DDI-DrugBank.d283.s1|18-31|ANTICOAGULANTS|group
DDI-DrugBank.d283.s1|33-38|SHOULD|O
DDI-DrugBank.d283.s1|40-41|BE|O
DDI-DrugBank.d283.s1|43-49|REDUCED|O
DDI-DrugBank.d283.s1|51-52|TO|O
DDI-DrugBank.d283.s1|54-61|MAINTAIN|O
DDI-DrugBank.d283.s1|63-65|THE|O
DDI-DrugBank.d283.s1|67-77|PROTHROMBIN|O
DDI-DrugBank.d283.s1|79-86|TIME/INR|O
DDI-DrugBank.d283.s1|88-89|AT|O
DDI-DrugBank.d283.s1|91-93|THE|O
DDI-DrugBank.d283.s1|95-101|DESIRED|O
DDI-DrugBank.d283.s1|103-107|LEVEL|O
DDI-DrugBank.d283.s1|109-110|TO|O
DDI-DrugBank.d283.s1|112-118|PREVENT|O
DDI-DrugBank.d283.s1|120-127|BLEEDING|O
DDI-DrugBank.d283.s1|129-141|COMPLICATIONS|O
DDI-DrugBank.d283.s1|142-142|.|O
DDI-DrugBank.d283.s2|0-7|FREQUENT|O
DDI-DrugBank.d283.s2|9-19|PROTHROMBIN|O
DDI-DrugBank.d283.s2|21-28|TIME/INR|O
DDI-DrugBank.d283.s2|30-43|DETERMINATIONS|O
DDI-DrugBank.d283.s2|45-47|ARE|O
DDI-DrugBank.d283.s2|49-57|ADVISABLE|O
DDI-DrugBank.d283.s2|59-63|UNTIL|O
DDI-DrugBank.d283.s2|65-66|IT|O
DDI-DrugBank.d283.s2|68-70|HAS|O
DDI-DrugBank.d283.s2|72-75|BEEN|O
DDI-DrugBank.d283.s2|77-86|DEFINITELY|O
DDI-DrugBank.d283.s2|88-97|DETERMINED|O
DDI-DrugBank.d283.s2|99-102|THAT|O
DDI-DrugBank.d283.s2|104-106|THE|O
DDI-DrugBank.d283.s2|108-118|PROTHROMBIN|O
DDI-DrugBank.d283.s2|120-127|TIME/INR|O
DDI-DrugBank.d283.s2|129-131|HAS|O
DDI-DrugBank.d283.s2|133-142|STABILIZED|O
DDI-DrugBank.d283.s2|143-143|.|O
DDI-DrugBank.d283.s3|0-27|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d283.s3|28-28|:|O
DDI-DrugBank.d283.s3|30-32|The|O
DDI-DrugBank.d283.s3|34-41|combined|O
DDI-DrugBank.d283.s3|43-45|use|O
DDI-DrugBank.d283.s3|47-48|of|O
DDI-DrugBank.d283.s3|50-55|TRICOR|brand
DDI-DrugBank.d283.s3|57-59|and|O
DDI-DrugBank.d283.s3|61-88|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d283.s3|90-95|should|O
DDI-DrugBank.d283.s3|97-98|be|O
DDI-DrugBank.d283.s3|100-106|avoided|O
DDI-DrugBank.d283.s3|108-113|unless|O
DDI-DrugBank.d283.s3|115-117|the|O
DDI-DrugBank.d283.s3|119-125|benefit|O
DDI-DrugBank.d283.s3|127-128|of|O
DDI-DrugBank.d283.s3|130-136|further|O
DDI-DrugBank.d283.s3|138-148|alterations|O
DDI-DrugBank.d283.s3|150-151|in|O
DDI-DrugBank.d283.s3|153-157|lipid|O
DDI-DrugBank.d283.s3|159-164|levels|O
DDI-DrugBank.d283.s3|166-167|is|O
DDI-DrugBank.d283.s3|169-174|likely|O
DDI-DrugBank.d283.s3|176-177|to|O
DDI-DrugBank.d283.s3|179-186|outweigh|O
DDI-DrugBank.d283.s3|188-190|the|O
DDI-DrugBank.d283.s3|192-200|increased|O
DDI-DrugBank.d283.s3|202-205|risk|O
DDI-DrugBank.d283.s3|207-208|of|O
DDI-DrugBank.d283.s3|210-213|this|O
DDI-DrugBank.d283.s3|215-218|drug|O
DDI-DrugBank.d283.s3|220-230|combination|O
DDI-DrugBank.d283.s3|231-231|.|O
DDI-DrugBank.d283.s4|0-5|Resins|group
DDI-DrugBank.d283.s4|6-6|:|O
DDI-DrugBank.d283.s4|8-12|Since|O
DDI-DrugBank.d283.s4|14-35|bile acid sequestrants|group
DDI-DrugBank.d283.s4|37-39|may|O
DDI-DrugBank.d283.s4|41-44|bind|O
DDI-DrugBank.d283.s4|46-50|other|O
DDI-DrugBank.d283.s4|52-56|drugs|O
DDI-DrugBank.d283.s4|58-62|given|O
DDI-DrugBank.d283.s4|64-75|concurrently|O
DDI-DrugBank.d283.s4|76-76|,|O
DDI-DrugBank.d283.s4|78-85|patients|O
DDI-DrugBank.d283.s4|87-92|should|O
DDI-DrugBank.d283.s4|94-97|take|O
DDI-DrugBank.d283.s4|99-104|TRICOR|brand
DDI-DrugBank.d283.s4|106-107|at|O
DDI-DrugBank.d283.s4|109-113|least|O
DDI-DrugBank.d283.s4|115-115|1|O
DDI-DrugBank.d283.s4|117-120|hour|O
DDI-DrugBank.d283.s4|122-127|before|O
DDI-DrugBank.d283.s4|129-130|or|O
DDI-DrugBank.d283.s4|132-134|4-6|O
DDI-DrugBank.d283.s4|136-140|hours|O
DDI-DrugBank.d283.s4|142-146|after|O
DDI-DrugBank.d283.s4|148-148|a|O
DDI-DrugBank.d283.s4|150-172|bile acid binding resin|group
DDI-DrugBank.d283.s4|174-175|to|O
DDI-DrugBank.d283.s4|177-181|avoid|O
DDI-DrugBank.d283.s4|183-190|impeding|O
DDI-DrugBank.d283.s4|192-194|its|O
DDI-DrugBank.d283.s4|196-205|absorption|O
DDI-DrugBank.d283.s4|206-206|.|O
DDI-DrugBank.d283.s5|0-11|Cyclosporine|drug
DDI-DrugBank.d283.s5|12-12|:|O
DDI-DrugBank.d283.s5|14-20|Because|O
DDI-DrugBank.d283.s5|22-33|cyclosporine|drug
DDI-DrugBank.d283.s5|35-37|can|O
DDI-DrugBank.d283.s5|39-45|produce|O
DDI-DrugBank.d283.s5|47-60|nephrotoxicity|O
DDI-DrugBank.d283.s5|62-65|with|O
DDI-DrugBank.d283.s5|67-75|decreases|O
DDI-DrugBank.d283.s5|77-78|in|O
DDI-DrugBank.d283.s5|80-89|creatinine|O
DDI-DrugBank.d283.s5|91-99|clearance|O
DDI-DrugBank.d283.s5|101-103|and|O
DDI-DrugBank.d283.s5|105-109|rises|O
DDI-DrugBank.d283.s5|111-112|in|O
DDI-DrugBank.d283.s5|114-118|serum|O
DDI-DrugBank.d283.s5|120-129|creatinine|O
DDI-DrugBank.d283.s5|130-130|,|O
DDI-DrugBank.d283.s5|132-134|and|O
DDI-DrugBank.d283.s5|136-142|because|O
DDI-DrugBank.d283.s5|144-148|renal|O
DDI-DrugBank.d283.s5|150-158|excretion|O
DDI-DrugBank.d283.s5|160-161|is|O
DDI-DrugBank.d283.s5|163-165|the|O
DDI-DrugBank.d283.s5|167-173|primary|O
DDI-DrugBank.d283.s5|175-185|elimination|O
DDI-DrugBank.d283.s5|187-191|route|O
DDI-DrugBank.d283.s5|193-194|of|O
DDI-DrugBank.d283.s5|196-208|fibrate drugs|group
DDI-DrugBank.d283.s5|210-218|including|O
DDI-DrugBank.d283.s5|220-225|TRICOR|brand
DDI-DrugBank.d283.s5|226-226|,|O
DDI-DrugBank.d283.s5|228-232|there|O
DDI-DrugBank.d283.s5|234-235|is|O
DDI-DrugBank.d283.s5|237-237|a|O
DDI-DrugBank.d283.s5|239-242|risk|O
DDI-DrugBank.d283.s5|244-247|that|O
DDI-DrugBank.d283.s5|249-250|an|O
DDI-DrugBank.d283.s5|252-262|interaction|O
DDI-DrugBank.d283.s5|264-267|will|O
DDI-DrugBank.d283.s5|269-272|lead|O
DDI-DrugBank.d283.s5|274-275|to|O
DDI-DrugBank.d283.s5|277-289|deterioration|O
DDI-DrugBank.d283.s5|290-290|.|O
DDI-DrugBank.d283.s6|0-2|The|O
DDI-DrugBank.d283.s6|4-11|benefits|O
DDI-DrugBank.d283.s6|13-15|and|O
DDI-DrugBank.d283.s6|17-21|risks|O
DDI-DrugBank.d283.s6|23-24|of|O
DDI-DrugBank.d283.s6|26-30|using|O
DDI-DrugBank.d283.s6|32-37|TRICOR|brand
DDI-DrugBank.d283.s6|39-42|with|O
DDI-DrugBank.d283.s6|44-61|immunosuppressants|group
DDI-DrugBank.d283.s6|63-65|and|O
DDI-DrugBank.d283.s6|67-71|other|O
DDI-DrugBank.d283.s6|73-83|potentially|O
DDI-DrugBank.d283.s6|85-95|nephrotoxic|O
DDI-DrugBank.d283.s6|97-102|agents|O
DDI-DrugBank.d283.s6|104-109|should|O
DDI-DrugBank.d283.s6|111-112|be|O
DDI-DrugBank.d283.s6|114-122|carefully|O
DDI-DrugBank.d283.s6|124-133|considered|O
DDI-DrugBank.d283.s6|134-134|,|O
DDI-DrugBank.d283.s6|136-138|and|O
DDI-DrugBank.d283.s6|140-142|the|O
DDI-DrugBank.d283.s6|144-149|lowest|O
DDI-DrugBank.d283.s6|151-159|effective|O
DDI-DrugBank.d283.s6|161-164|dose|O
DDI-DrugBank.d283.s6|166-173|employed|O
DDI-DrugBank.d283.s7|0-0|.|O
DDI-DrugBank.d283.s8|0-8|Drug-drug|O
DDI-DrugBank.d283.s8|10-21|interactions|O
DDI-DrugBank.d283.s8|23-24|In|O
DDI-DrugBank.d283.s8|26-30|vitro|O
DDI-DrugBank.d283.s8|32-38|studies|O
DDI-DrugBank.d283.s8|40-44|using|O
DDI-DrugBank.d283.s8|46-50|human|O
DDI-DrugBank.d283.s8|52-56|liver|O
DDI-DrugBank.d283.s8|58-67|microsomes|O
DDI-DrugBank.d283.s8|69-76|indicate|O
DDI-DrugBank.d283.s8|78-81|that|O
DDI-DrugBank.d283.s8|83-93|fenofibrate|drug
DDI-DrugBank.d283.s8|95-97|and|O
DDI-DrugBank.d283.s8|115-117|are|O
DDI-DrugBank.d283.s8|119-121|not|O
DDI-DrugBank.d283.s8|123-132|inhibitors|O
DDI-DrugBank.d283.s8|134-135|of|O
DDI-DrugBank.d283.s8|137-146|cytochrome|O
DDI-DrugBank.d283.s8|148-148|(|O
DDI-DrugBank.d283.s8|149-151|CYP|O
DDI-DrugBank.d283.s8|152-152|)|O
DDI-DrugBank.d283.s8|154-157|P450|O
DDI-DrugBank.d283.s8|159-166|isoforms|O
DDI-DrugBank.d283.s8|168-173|CYP3A4|O
DDI-DrugBank.d283.s8|174-174|,|O
DDI-DrugBank.d283.s8|176-181|CYP2D6|O
DDI-DrugBank.d283.s8|182-182|,|O
DDI-DrugBank.d283.s8|184-189|CYP2E1|O
DDI-DrugBank.d283.s8|190-190|,|O
DDI-DrugBank.d283.s8|192-193|or|O
DDI-DrugBank.d283.s8|195-200|CYP1A2|O
DDI-DrugBank.d283.s8|201-201|.|O
DDI-DrugBank.d283.s9|0-3|They|O
DDI-DrugBank.d283.s9|5-7|are|O
DDI-DrugBank.d283.s9|9-12|weak|O
DDI-DrugBank.d283.s9|14-23|inhibitors|O
DDI-DrugBank.d283.s9|25-26|of|O
DDI-DrugBank.d283.s9|28-34|CYP2C19|O
DDI-DrugBank.d283.s9|36-38|and|O
DDI-DrugBank.d283.s9|40-45|CYP2A6|O
DDI-DrugBank.d283.s9|46-46|,|O
DDI-DrugBank.d283.s9|48-50|and|O
DDI-DrugBank.d283.s9|52-67|mild-to-moderate|O
DDI-DrugBank.d283.s9|69-78|inhibitors|O
DDI-DrugBank.d283.s9|80-81|of|O
DDI-DrugBank.d283.s9|83-88|CYP2C9|O
DDI-DrugBank.d283.s9|90-91|at|O
DDI-DrugBank.d283.s9|93-103|therapeutic|O
DDI-DrugBank.d283.s9|105-118|concentrations|O
DDI-DrugBank.d283.s9|119-119|.|O
DDI-DrugBank.d283.s10|0-11|Potentiation|O
DDI-DrugBank.d283.s10|13-14|of|O
DDI-DrugBank.d283.s10|16-43|coumarin-type anticoagulants|group
DDI-DrugBank.d283.s10|45-47|has|O
DDI-DrugBank.d283.s10|49-52|been|O
DDI-DrugBank.d283.s10|54-61|observed|O
DDI-DrugBank.d283.s10|63-66|with|O
DDI-DrugBank.d283.s10|68-79|prolongation|O
DDI-DrugBank.d283.s10|81-82|of|O
DDI-DrugBank.d283.s10|84-86|the|O
DDI-DrugBank.d283.s10|88-98|prothrombin|O
DDI-DrugBank.d283.s10|100-107|time/INR|O
DDI-DrugBank.d283.s10|108-108|.|O
DDI-DrugBank.d283.s11|0-21|Bile acid sequestrants|group
DDI-DrugBank.d283.s11|23-26|have|O
DDI-DrugBank.d283.s11|28-31|been|O
DDI-DrugBank.d283.s11|33-37|shown|O
DDI-DrugBank.d283.s11|39-40|to|O
DDI-DrugBank.d283.s11|42-45|bind|O
DDI-DrugBank.d283.s11|47-51|other|O
DDI-DrugBank.d283.s11|53-57|drugs|O
DDI-DrugBank.d283.s11|59-63|given|O
DDI-DrugBank.d283.s11|65-76|concurrently|O
DDI-DrugBank.d283.s11|77-77|.|O
DDI-DrugBank.d283.s12|0-8|Therefore|O
DDI-DrugBank.d283.s12|9-9|,|O
DDI-DrugBank.d283.s12|11-21|fenofibrate|drug
DDI-DrugBank.d283.s12|23-28|should|O
DDI-DrugBank.d283.s12|30-31|be|O
DDI-DrugBank.d283.s12|33-37|taken|O
DDI-DrugBank.d283.s12|39-40|at|O
DDI-DrugBank.d283.s12|42-46|least|O
DDI-DrugBank.d283.s12|48-48|1|O
DDI-DrugBank.d283.s12|50-53|hour|O
DDI-DrugBank.d283.s12|55-60|before|O
DDI-DrugBank.d283.s12|62-63|or|O
DDI-DrugBank.d283.s12|65-67|4-6|O
DDI-DrugBank.d283.s12|69-73|hours|O
DDI-DrugBank.d283.s12|75-79|after|O
DDI-DrugBank.d283.s12|81-81|a|O
DDI-DrugBank.d283.s12|83-105|bile acid binding resin|group
DDI-DrugBank.d283.s12|107-108|to|O
DDI-DrugBank.d283.s12|110-114|avoid|O
DDI-DrugBank.d283.s12|116-123|impeding|O
DDI-DrugBank.d283.s12|125-127|its|O
DDI-DrugBank.d283.s12|129-138|absorption|O
DDI-DrugBank.d283.s12|140-140|.|O
DDI-DrugBank.d283.s13|0-10|Concomitant|O
DDI-DrugBank.d283.s13|12-25|administration|O
DDI-DrugBank.d283.s13|27-28|of|O
DDI-DrugBank.d283.s13|30-40|fenofibrate|drug
DDI-DrugBank.d283.s13|42-42|(|O
DDI-DrugBank.d283.s13|43-52|equivalent|O
DDI-DrugBank.d283.s13|54-55|to|O
DDI-DrugBank.d283.s13|57-61|145mg|O
DDI-DrugBank.d283.s13|63-68|TRICOR|brand
DDI-DrugBank.d283.s13|69-69|)|O
DDI-DrugBank.d283.s13|71-74|with|O
DDI-DrugBank.d283.s13|76-86|pravastatin|drug
DDI-DrugBank.d283.s13|88-88|(|O
DDI-DrugBank.d283.s13|89-90|40|O
DDI-DrugBank.d283.s13|92-93|mg|O
DDI-DrugBank.d283.s13|94-94|)|O
DDI-DrugBank.d283.s13|96-99|once|O
DDI-DrugBank.d283.s13|101-105|daily|O
DDI-DrugBank.d283.s13|107-109|for|O
DDI-DrugBank.d283.s13|111-112|10|O
DDI-DrugBank.d283.s13|114-117|days|O
DDI-DrugBank.d283.s13|119-121|has|O
DDI-DrugBank.d283.s13|123-126|been|O
DDI-DrugBank.d283.s13|128-132|shown|O
DDI-DrugBank.d283.s13|134-135|to|O
DDI-DrugBank.d283.s13|137-144|increase|O
DDI-DrugBank.d283.s13|146-148|the|O
DDI-DrugBank.d283.s13|150-153|mean|O
DDI-DrugBank.d283.s13|155-158|Cmax|O
DDI-DrugBank.d283.s13|160-162|and|O
DDI-DrugBank.d283.s13|164-166|AUC|O
DDI-DrugBank.d283.s13|168-173|values|O
DDI-DrugBank.d283.s13|175-177|for|O
DDI-DrugBank.d283.s13|179-189|pravastatin|drug
DDI-DrugBank.d283.s13|191-192|by|O
DDI-DrugBank.d283.s13|194-195|36|O
DDI-DrugBank.d283.s13|196-196|%|O
DDI-DrugBank.d283.s13|198-198|(|O
DDI-DrugBank.d283.s13|199-203|range|O
DDI-DrugBank.d283.s13|205-208|from|O
DDI-DrugBank.d283.s13|210-211|69|O
DDI-DrugBank.d283.s13|212-212|%|O
DDI-DrugBank.d283.s13|214-221|decrease|O
DDI-DrugBank.d283.s13|223-224|to|O
DDI-DrugBank.d283.s13|226-228|321|O
DDI-DrugBank.d283.s13|229-229|%|O
DDI-DrugBank.d283.s13|231-238|increase|O
DDI-DrugBank.d283.s13|239-239|)|O
DDI-DrugBank.d283.s13|241-243|and|O
DDI-DrugBank.d283.s13|245-246|28|O
DDI-DrugBank.d283.s13|247-247|%|O
DDI-DrugBank.d283.s13|249-249|(|O
DDI-DrugBank.d283.s13|250-254|range|O
DDI-DrugBank.d283.s13|256-259|from|O
DDI-DrugBank.d283.s13|261-262|54|O
DDI-DrugBank.d283.s13|263-263|%|O
DDI-DrugBank.d283.s13|265-272|decrease|O
DDI-DrugBank.d283.s13|274-275|to|O
DDI-DrugBank.d283.s13|277-279|128|O
DDI-DrugBank.d283.s13|280-280|%|O
DDI-DrugBank.d283.s13|282-289|increase|O
DDI-DrugBank.d283.s13|290-290|)|O
DDI-DrugBank.d283.s13|291-291|,|O
DDI-DrugBank.d283.s13|293-304|respectively|O
DDI-DrugBank.d283.s13|305-305|,|O
DDI-DrugBank.d283.s13|307-309|and|O
DDI-DrugBank.d283.s13|311-313|for|O
DDI-DrugBank.d283.s13|315-315|3|O
DDI-DrugBank.d283.s13|317-340|-hydroxy-iso-pravastatin|O
DDI-DrugBank.d283.s13|342-343|by|O
DDI-DrugBank.d283.s13|345-346|55|O
DDI-DrugBank.d283.s13|347-347|%|O
DDI-DrugBank.d283.s13|349-349|(|O
DDI-DrugBank.d283.s13|350-354|range|O
DDI-DrugBank.d283.s13|356-359|from|O
DDI-DrugBank.d283.s13|361-362|32|O
DDI-DrugBank.d283.s13|363-363|%|O
DDI-DrugBank.d283.s13|365-372|decrease|O
DDI-DrugBank.d283.s13|374-375|to|O
DDI-DrugBank.d283.s13|377-379|314|O
DDI-DrugBank.d283.s13|380-380|%|O
DDI-DrugBank.d283.s13|382-389|increase|O
DDI-DrugBank.d283.s13|390-390|)|O
DDI-DrugBank.d283.s13|392-394|and|O
DDI-DrugBank.d283.s13|396-397|39|O
DDI-DrugBank.d283.s13|398-398|%|O
DDI-DrugBank.d283.s13|400-400|(|O
DDI-DrugBank.d283.s13|401-405|range|O
DDI-DrugBank.d283.s13|407-410|from|O
DDI-DrugBank.d283.s13|412-413|24|O
DDI-DrugBank.d283.s13|414-414|%|O
DDI-DrugBank.d283.s13|416-423|decrease|O
DDI-DrugBank.d283.s13|425-426|to|O
DDI-DrugBank.d283.s13|428-430|261|O
DDI-DrugBank.d283.s13|431-431|%|O
DDI-DrugBank.d283.s13|433-440|increase|O
DDI-DrugBank.d283.s13|441-441|)|O
DDI-DrugBank.d283.s13|442-442|,|O
DDI-DrugBank.d283.s13|444-455|respectively|O
DDI-DrugBank.d283.s13|457-458|in|O
DDI-DrugBank.d283.s13|460-461|23|O
DDI-DrugBank.d283.s13|463-469|healthy|O
DDI-DrugBank.d283.s13|471-476|adults|O
DDI-DrugBank.d283.s13|477-477|.|O
DDI-DrugBank.d283.s14|0-0|A|O
DDI-DrugBank.d283.s14|2-7|single|O
DDI-DrugBank.d283.s14|9-12|dose|O
DDI-DrugBank.d283.s14|14-15|of|O
DDI-DrugBank.d283.s14|17-27|pravastatin|drug
DDI-DrugBank.d283.s14|29-31|had|O
DDI-DrugBank.d283.s14|33-34|no|O
DDI-DrugBank.d283.s14|36-45|clinically|O
DDI-DrugBank.d283.s14|47-55|important|O
DDI-DrugBank.d283.s14|57-62|effect|O
DDI-DrugBank.d283.s14|64-65|on|O
DDI-DrugBank.d283.s14|67-69|the|O
DDI-DrugBank.d283.s14|71-86|pharmacokinetics|O
DDI-DrugBank.d283.s14|88-89|of|O
DDI-DrugBank.d283.s14|106-106|.|O
DDI-DrugBank.d283.s15|0-10|Concomitant|O
DDI-DrugBank.d283.s15|12-25|administration|O
DDI-DrugBank.d283.s15|27-28|of|O
DDI-DrugBank.d283.s15|30-40|fenofibrate|drug
DDI-DrugBank.d283.s15|42-42|(|O
DDI-DrugBank.d283.s15|43-52|equivalent|O
DDI-DrugBank.d283.s15|54-55|to|O
DDI-DrugBank.d283.s15|57-59|145|O
DDI-DrugBank.d283.s15|61-62|mg|O
DDI-DrugBank.d283.s15|64-69|TRICOR|brand
DDI-DrugBank.d283.s15|70-70|)|O
DDI-DrugBank.d283.s15|72-75|with|O
DDI-DrugBank.d283.s15|77-88|atorvastatin|drug
DDI-DrugBank.d283.s15|90-90|(|O
DDI-DrugBank.d283.s15|91-92|20|O
DDI-DrugBank.d283.s15|94-95|mg|O
DDI-DrugBank.d283.s15|96-96|)|O
DDI-DrugBank.d283.s15|98-101|once|O
DDI-DrugBank.d283.s15|103-107|daily|O
DDI-DrugBank.d283.s15|109-111|for|O
DDI-DrugBank.d283.s15|113-114|10|O
DDI-DrugBank.d283.s15|116-119|days|O
DDI-DrugBank.d283.s15|121-128|resulted|O
DDI-DrugBank.d283.s15|130-131|in|O
DDI-DrugBank.d283.s15|133-145|approximately|O
DDI-DrugBank.d283.s15|147-148|17|O
DDI-DrugBank.d283.s15|149-149|%|O
DDI-DrugBank.d283.s15|151-158|decrease|O
DDI-DrugBank.d283.s15|160-160|(|O
DDI-DrugBank.d283.s15|161-165|range|O
DDI-DrugBank.d283.s15|167-170|from|O
DDI-DrugBank.d283.s15|172-173|67|O
DDI-DrugBank.d283.s15|174-174|%|O
DDI-DrugBank.d283.s15|176-183|decrease|O
DDI-DrugBank.d283.s15|185-186|to|O
DDI-DrugBank.d283.s15|188-189|44|O
DDI-DrugBank.d283.s15|190-190|%|O
DDI-DrugBank.d283.s15|192-199|increase|O
DDI-DrugBank.d283.s15|200-200|)|O
DDI-DrugBank.d283.s15|202-203|in|O
DDI-DrugBank.d283.s15|205-216|atorvastatin|drug
DDI-DrugBank.d283.s15|218-220|AUC|O
DDI-DrugBank.d283.s15|222-227|values|O
DDI-DrugBank.d283.s15|229-230|in|O
DDI-DrugBank.d283.s15|232-233|22|O
DDI-DrugBank.d283.s15|235-241|healthy|O
DDI-DrugBank.d283.s15|243-247|males|O
DDI-DrugBank.d283.s15|248-248|.|O
DDI-DrugBank.d283.s16|0-2|The|O
DDI-DrugBank.d283.s16|4-15|atorvastatin|drug
DDI-DrugBank.d283.s16|17-20|Cmax|O
DDI-DrugBank.d283.s16|22-27|values|O
DDI-DrugBank.d283.s16|29-32|were|O
DDI-DrugBank.d283.s16|34-36|not|O
DDI-DrugBank.d283.s16|38-50|significantly|O
DDI-DrugBank.d283.s16|52-59|affected|O
DDI-DrugBank.d283.s16|61-62|by|O
DDI-DrugBank.d283.s16|64-74|fenofibrate|drug
DDI-DrugBank.d283.s16|75-75|.|O
DDI-DrugBank.d283.s17|0-2|The|O
DDI-DrugBank.d283.s17|4-19|pharmacokinetics|O
DDI-DrugBank.d283.s17|21-22|of|O
DDI-DrugBank.d283.s17|40-43|were|O
DDI-DrugBank.d283.s17|45-47|not|O
DDI-DrugBank.d283.s17|49-61|significantly|O
DDI-DrugBank.d283.s17|63-70|affected|O
DDI-DrugBank.d283.s17|72-73|by|O
DDI-DrugBank.d283.s18|0-0|.|O
DDI-DrugBank.d752.s0|0-3|Drug|O
DDI-DrugBank.d752.s0|5-16|Interactions|O
DDI-DrugBank.d752.s0|17-17|:|O
DDI-DrugBank.d752.s0|19-28|Inhibitors|O
DDI-DrugBank.d752.s0|30-31|of|O
DDI-DrugBank.d752.s0|33-38|CYP3A4|O
DDI-DrugBank.d752.s0|40-47|Isozymes|O
DDI-DrugBank.d752.s0|48-48|:|O
DDI-DrugBank.d752.s0|50-56|Caution|O
DDI-DrugBank.d752.s0|58-59|is|O
DDI-DrugBank.d752.s0|61-67|advised|O
DDI-DrugBank.d752.s0|69-72|when|O
DDI-DrugBank.d752.s0|74-82|midazolam|drug
DDI-DrugBank.d752.s0|84-85|is|O
DDI-DrugBank.d752.s0|87-98|administered|O
DDI-DrugBank.d752.s0|100-112|concomitantly|O
DDI-DrugBank.d752.s0|114-117|with|O
DDI-DrugBank.d752.s0|119-123|drugs|O
DDI-DrugBank.d752.s0|125-128|that|O
DDI-DrugBank.d752.s0|130-132|are|O
DDI-DrugBank.d752.s0|134-138|known|O
DDI-DrugBank.d752.s0|140-141|to|O
DDI-DrugBank.d752.s0|143-149|inhibit|O
DDI-DrugBank.d752.s0|151-153|the|O
DDI-DrugBank.d752.s0|155-164|cytochrome|O
DDI-DrugBank.d752.s0|166-169|P450|O
DDI-DrugBank.d752.s0|171-173|3A4|O
DDI-DrugBank.d752.s0|175-180|enzyme|O
DDI-DrugBank.d752.s0|182-187|system|O
DDI-DrugBank.d752.s0|189-189|(|O
DDI-DrugBank.d752.s0|190-191|ie|O
DDI-DrugBank.d752.s0|192-192|,|O
DDI-DrugBank.d752.s0|194-197|some|O
DDI-DrugBank.d752.s0|199-203|drugs|O
DDI-DrugBank.d752.s0|205-206|in|O
DDI-DrugBank.d752.s0|208-210|the|O
DDI-DrugBank.d752.s0|212-215|drug|O
DDI-DrugBank.d752.s0|217-223|classes|O
DDI-DrugBank.d752.s0|225-226|of|O
DDI-DrugBank.d752.s0|228-245|azole antimycotics|group
DDI-DrugBank.d752.s0|246-246|,|O
DDI-DrugBank.d752.s0|248-266|protease inhibitors|group
DDI-DrugBank.d752.s0|267-267|,|O
DDI-DrugBank.d752.s0|269-295|calcium channel antagonists|group
DDI-DrugBank.d752.s0|296-296|,|O
DDI-DrugBank.d752.s0|298-300|and|O
DDI-DrugBank.d752.s0|302-322|macrolide antibiotics|group
DDI-DrugBank.d752.s0|323-323|)|O
DDI-DrugBank.d752.s0|324-324|.|O
DDI-DrugBank.d752.s1|0-4|Drugs|O
DDI-DrugBank.d752.s1|6-9|such|O
DDI-DrugBank.d752.s1|11-12|as|O
DDI-DrugBank.d752.s1|14-25|erythromycin|drug
DDI-DrugBank.d752.s1|26-26|,|O
DDI-DrugBank.d752.s1|28-36|diltiazem|drug
DDI-DrugBank.d752.s1|37-37|,|O
DDI-DrugBank.d752.s1|39-47|verapamil|drug
DDI-DrugBank.d752.s1|48-48|,|O
DDI-DrugBank.d752.s1|50-61|ketoconazole|drug
DDI-DrugBank.d752.s1|62-62|,|O
DDI-DrugBank.d752.s1|64-74|fluconazole|drug
DDI-DrugBank.d752.s1|76-78|and|O
DDI-DrugBank.d752.s1|80-91|itraconazole|drug
DDI-DrugBank.d752.s1|93-96|were|O
DDI-DrugBank.d752.s1|98-102|shown|O
DDI-DrugBank.d752.s1|104-105|to|O
DDI-DrugBank.d752.s1|107-119|significantly|O
DDI-DrugBank.d752.s1|121-128|increase|O
DDI-DrugBank.d752.s1|130-132|the|O
DDI-DrugBank.d752.s1|134-134|C|O
DDI-DrugBank.d752.s1|136-138|max|O
DDI-DrugBank.d752.s1|140-142|and|O
DDI-DrugBank.d752.s1|144-146|AUC|O
DDI-DrugBank.d752.s1|148-149|of|O
DDI-DrugBank.d752.s1|151-156|orally|O
DDI-DrugBank.d752.s1|158-169|administered|O
DDI-DrugBank.d752.s1|171-179|midazolam|drug
DDI-DrugBank.d752.s1|180-180|.|O
DDI-DrugBank.d752.s2|0-4|These|O
DDI-DrugBank.d752.s2|6-9|drug|O
DDI-DrugBank.d752.s2|11-22|interactions|O
DDI-DrugBank.d752.s2|24-26|may|O
DDI-DrugBank.d752.s2|28-33|result|O
DDI-DrugBank.d752.s2|35-36|in|O
DDI-DrugBank.d752.s2|38-46|increased|O
DDI-DrugBank.d752.s2|48-50|and|O
DDI-DrugBank.d752.s2|52-60|prolonged|O
DDI-DrugBank.d752.s2|62-69|sedation|O
DDI-DrugBank.d752.s2|71-73|due|O
DDI-DrugBank.d752.s2|75-76|to|O
DDI-DrugBank.d752.s2|78-78|a|O
DDI-DrugBank.d752.s2|80-87|decrease|O
DDI-DrugBank.d752.s2|89-90|in|O
DDI-DrugBank.d752.s2|92-97|plasma|O
DDI-DrugBank.d752.s2|99-107|clearance|O
DDI-DrugBank.d752.s2|109-110|of|O
DDI-DrugBank.d752.s2|112-120|midazolam|drug
DDI-DrugBank.d752.s2|121-121|.|O
DDI-DrugBank.d752.s3|0-7|Although|O
DDI-DrugBank.d752.s3|9-11|not|O
DDI-DrugBank.d752.s3|13-19|studied|O
DDI-DrugBank.d752.s3|20-20|,|O
DDI-DrugBank.d752.s3|22-24|the|O
DDI-DrugBank.d752.s3|26-31|potent|O
DDI-DrugBank.d752.s3|33-42|cytochrome|O
DDI-DrugBank.d752.s3|44-47|P450|O
DDI-DrugBank.d752.s3|49-51|3A4|O
DDI-DrugBank.d752.s3|53-62|inhibitors|O
DDI-DrugBank.d752.s3|64-72|ritonavir|drug
DDI-DrugBank.d752.s3|74-76|and|O
DDI-DrugBank.d752.s3|78-87|nelfinavir|drug
DDI-DrugBank.d752.s3|89-91|may|O
DDI-DrugBank.d752.s3|93-97|cause|O
DDI-DrugBank.d752.s3|99-105|intense|O
DDI-DrugBank.d752.s3|107-109|and|O
DDI-DrugBank.d752.s3|111-119|prolonged|O
DDI-DrugBank.d752.s3|121-128|sedation|O
DDI-DrugBank.d752.s3|130-132|and|O
DDI-DrugBank.d752.s3|134-144|respiratory|O
DDI-DrugBank.d752.s3|146-155|depression|O
DDI-DrugBank.d752.s3|157-159|due|O
DDI-DrugBank.d752.s3|161-162|to|O
DDI-DrugBank.d752.s3|164-164|a|O
DDI-DrugBank.d752.s3|166-173|decrease|O
DDI-DrugBank.d752.s3|175-176|in|O
DDI-DrugBank.d752.s3|178-183|plasma|O
DDI-DrugBank.d752.s3|185-193|clearance|O
DDI-DrugBank.d752.s3|195-196|of|O
DDI-DrugBank.d752.s3|198-206|midazolam|drug
DDI-DrugBank.d752.s3|207-207|.|O
DDI-DrugBank.d752.s4|0-6|Caution|O
DDI-DrugBank.d752.s4|8-9|is|O
DDI-DrugBank.d752.s4|11-17|advised|O
DDI-DrugBank.d752.s4|19-22|when|O
DDI-DrugBank.d752.s4|24-35|VERSED Syrup|brand
DDI-DrugBank.d752.s4|37-38|is|O
DDI-DrugBank.d752.s4|40-43|used|O
DDI-DrugBank.d752.s4|45-57|concomitantly|O
DDI-DrugBank.d752.s4|59-62|with|O
DDI-DrugBank.d752.s4|64-68|these|O
DDI-DrugBank.d752.s4|70-74|drugs|O
DDI-DrugBank.d752.s4|75-75|.|O
DDI-DrugBank.d752.s5|0-3|Dose|O
DDI-DrugBank.d752.s5|5-15|adjustments|O
DDI-DrugBank.d752.s5|17-22|should|O
DDI-DrugBank.d752.s5|24-25|be|O
DDI-DrugBank.d752.s5|27-36|considered|O
DDI-DrugBank.d752.s5|38-40|and|O
DDI-DrugBank.d752.s5|42-49|possible|O
DDI-DrugBank.d752.s5|51-62|prolongation|O
DDI-DrugBank.d752.s5|64-66|and|O
DDI-DrugBank.d752.s5|68-76|intensity|O
DDI-DrugBank.d752.s5|78-79|of|O
DDI-DrugBank.d752.s5|81-86|effect|O
DDI-DrugBank.d752.s5|88-93|should|O
DDI-DrugBank.d752.s5|95-96|be|O
DDI-DrugBank.d752.s5|98-108|anticipated|O
DDI-DrugBank.d752.s5|109-109|.|O
DDI-DrugBank.d752.s6|0-7|Inducers|O
DDI-DrugBank.d752.s6|9-10|of|O
DDI-DrugBank.d752.s6|12-17|CYP3A4|O
DDI-DrugBank.d752.s6|19-26|Isozymes|O
DDI-DrugBank.d752.s6|27-27|:|O
DDI-DrugBank.d752.s6|29-38|Cytochrome|O
DDI-DrugBank.d752.s6|40-43|P450|O
DDI-DrugBank.d752.s6|45-52|inducers|O
DDI-DrugBank.d752.s6|53-53|,|O
DDI-DrugBank.d752.s6|55-58|such|O
DDI-DrugBank.d752.s6|60-61|as|O
DDI-DrugBank.d752.s6|63-70|rifampin|drug
DDI-DrugBank.d752.s6|71-71|,|O
DDI-DrugBank.d752.s6|73-85|carbamazepine|drug
DDI-DrugBank.d752.s6|86-86|,|O
DDI-DrugBank.d752.s6|88-90|and|O
DDI-DrugBank.d752.s6|92-100|phenytoin|drug
DDI-DrugBank.d752.s6|101-101|,|O
DDI-DrugBank.d752.s6|103-108|induce|O
DDI-DrugBank.d752.s6|110-119|metabolism|O
DDI-DrugBank.d752.s6|121-123|and|O
DDI-DrugBank.d752.s6|125-130|caused|O
DDI-DrugBank.d752.s6|132-132|a|O
DDI-DrugBank.d752.s6|134-141|markedly|O
DDI-DrugBank.d752.s6|143-151|decreased|O
DDI-DrugBank.d752.s6|153-153|C|O
DDI-DrugBank.d752.s6|155-157|max|O
DDI-DrugBank.d752.s6|159-161|and|O
DDI-DrugBank.d752.s6|163-165|AUC|O
DDI-DrugBank.d752.s6|167-168|of|O
DDI-DrugBank.d752.s6|170-173|oral|O
DDI-DrugBank.d752.s6|175-183|midazolam|drug
DDI-DrugBank.d752.s6|185-186|in|O
DDI-DrugBank.d752.s6|188-192|adult|O
DDI-DrugBank.d752.s6|194-200|studies|O
DDI-DrugBank.d752.s6|201-201|.|O
DDI-DrugBank.d752.s7|0-7|Although|O
DDI-DrugBank.d752.s7|9-16|clinical|O
DDI-DrugBank.d752.s7|18-24|studies|O
DDI-DrugBank.d752.s7|26-29|have|O
DDI-DrugBank.d752.s7|31-33|not|O
DDI-DrugBank.d752.s7|35-38|been|O
DDI-DrugBank.d752.s7|40-48|performed|O
DDI-DrugBank.d752.s7|49-49|,|O
DDI-DrugBank.d752.s7|51-63|phenobarbital|drug
DDI-DrugBank.d752.s7|65-66|is|O
DDI-DrugBank.d752.s7|68-75|expected|O
DDI-DrugBank.d752.s7|77-78|to|O
DDI-DrugBank.d752.s7|80-83|have|O
DDI-DrugBank.d752.s7|85-87|the|O
DDI-DrugBank.d752.s7|89-92|same|O
DDI-DrugBank.d752.s7|94-99|effect|O
DDI-DrugBank.d752.s7|100-100|.|O
DDI-DrugBank.d752.s8|0-6|Caution|O
DDI-DrugBank.d752.s8|8-9|is|O
DDI-DrugBank.d752.s8|11-17|advised|O
DDI-DrugBank.d752.s8|19-22|when|O
DDI-DrugBank.d752.s8|24-36|administering|O
DDI-DrugBank.d752.s8|38-49|VERSED Syrup|brand
DDI-DrugBank.d752.s8|51-52|to|O
DDI-DrugBank.d752.s8|54-61|patients|O
DDI-DrugBank.d752.s8|63-71|receiving|O
DDI-DrugBank.d752.s8|73-77|these|O
DDI-DrugBank.d752.s8|79-89|medications|O
DDI-DrugBank.d752.s8|91-93|and|O
DDI-DrugBank.d752.s8|95-96|if|O
DDI-DrugBank.d752.s8|98-106|necessary|O
DDI-DrugBank.d752.s8|108-111|dose|O
DDI-DrugBank.d752.s8|113-123|adjustments|O
DDI-DrugBank.d752.s8|125-130|should|O
DDI-DrugBank.d752.s8|132-133|be|O
DDI-DrugBank.d752.s8|135-144|considered|O
DDI-DrugBank.d752.s8|145-145|.|O
DDI-DrugBank.d752.s9|0-2|The|O
DDI-DrugBank.d752.s9|4-13|difficulty|O
DDI-DrugBank.d752.s9|15-16|in|O
DDI-DrugBank.d752.s9|18-26|achieving|O
DDI-DrugBank.d752.s9|28-35|adequate|O
DDI-DrugBank.d752.s9|37-44|sedation|O
DDI-DrugBank.d752.s9|46-48|may|O
DDI-DrugBank.d752.s9|50-53|have|O
DDI-DrugBank.d752.s9|55-58|been|O
DDI-DrugBank.d752.s9|60-62|the|O
DDI-DrugBank.d752.s9|64-69|result|O
DDI-DrugBank.d752.s9|71-72|of|O
DDI-DrugBank.d752.s9|74-82|decreased|O
DDI-DrugBank.d752.s9|84-93|absorption|O
DDI-DrugBank.d752.s9|95-96|of|O
DDI-DrugBank.d752.s9|98-100|the|O
DDI-DrugBank.d752.s9|102-110|sedatives|group
DDI-DrugBank.d752.s9|112-114|due|O
DDI-DrugBank.d752.s9|116-117|to|O
DDI-DrugBank.d752.s9|119-122|both|O
DDI-DrugBank.d752.s9|124-126|the|O
DDI-DrugBank.d752.s9|128-143|gastrointestinal|O
DDI-DrugBank.d752.s9|145-151|effects|O
DDI-DrugBank.d752.s9|153-155|and|O
DDI-DrugBank.d752.s9|157-165|stimulant|O
DDI-DrugBank.d752.s9|167-173|effects|O
DDI-DrugBank.d752.s9|175-176|of|O
DDI-DrugBank.d752.s9|178-192|methylphenidate|drug
DDI-DrugBank.d752.s9|193-193|.|O
DDI-DrugBank.d752.s10|0-2|The|O
DDI-DrugBank.d752.s10|4-11|sedative|O
DDI-DrugBank.d752.s10|13-18|effect|O
DDI-DrugBank.d752.s10|20-21|of|O
DDI-DrugBank.d752.s10|23-34|VERSED Syrup|brand
DDI-DrugBank.d752.s10|36-37|is|O
DDI-DrugBank.d752.s10|39-49|accentuated|O
DDI-DrugBank.d752.s10|51-52|by|O
DDI-DrugBank.d752.s10|54-56|any|O
DDI-DrugBank.d752.s10|58-70|concomitantly|O
DDI-DrugBank.d752.s10|72-83|administered|O
DDI-DrugBank.d752.s10|85-94|medication|O
DDI-DrugBank.d752.s10|96-100|which|O
DDI-DrugBank.d752.s10|102-110|depresses|O
DDI-DrugBank.d752.s10|112-114|the|O
DDI-DrugBank.d752.s10|116-122|central|O
DDI-DrugBank.d752.s10|124-130|nervous|O
DDI-DrugBank.d752.s10|132-137|system|O
DDI-DrugBank.d752.s10|138-138|,|O
DDI-DrugBank.d752.s10|140-151|particularly|O
DDI-DrugBank.d752.s10|153-161|narcotics|group
DDI-DrugBank.d752.s10|163-163|(|O
DDI-DrugBank.d752.s10|164-165|eg|O
DDI-DrugBank.d752.s10|166-166|,|O
DDI-DrugBank.d752.s10|168-175|morphine|drug
DDI-DrugBank.d752.s10|176-176|,|O
DDI-DrugBank.d752.s10|178-187|meperidine|drug
DDI-DrugBank.d752.s10|189-191|and|O
DDI-DrugBank.d752.s10|193-200|fentanyl|drug
DDI-DrugBank.d752.s10|201-201|)|O
DDI-DrugBank.d752.s10|202-202|,|O
DDI-DrugBank.d752.s10|204-211|propofol|drug
DDI-DrugBank.d752.s10|212-212|,|O
DDI-DrugBank.d752.s10|214-221|ketamine|drug
DDI-DrugBank.d752.s10|222-222|,|O
DDI-DrugBank.d752.s10|224-236|nitrous oxide|drug
DDI-DrugBank.d752.s10|237-237|,|O
DDI-DrugBank.d752.s10|239-250|secobarbital|drug
DDI-DrugBank.d752.s10|252-254|and|O
DDI-DrugBank.d752.s10|256-265|droperidol|drug
DDI-DrugBank.d752.s10|266-266|.|O
DDI-DrugBank.d752.s11|0-11|Consequently|O
DDI-DrugBank.d752.s11|12-12|,|O
DDI-DrugBank.d752.s11|14-16|the|O
DDI-DrugBank.d752.s11|18-21|dose|O
DDI-DrugBank.d752.s11|23-24|of|O
DDI-DrugBank.d752.s11|26-37|VERSED Syrup|brand
DDI-DrugBank.d752.s11|39-44|should|O
DDI-DrugBank.d752.s11|46-47|be|O
DDI-DrugBank.d752.s11|49-56|adjusted|O
DDI-DrugBank.d752.s11|58-66|according|O
DDI-DrugBank.d752.s11|68-69|to|O
DDI-DrugBank.d752.s11|71-73|the|O
DDI-DrugBank.d752.s11|75-78|type|O
DDI-DrugBank.d752.s11|80-82|and|O
DDI-DrugBank.d752.s11|84-89|amount|O
DDI-DrugBank.d752.s11|91-92|of|O
DDI-DrugBank.d752.s11|94-104|concomitant|O
DDI-DrugBank.d752.s11|106-116|medications|O
DDI-DrugBank.d752.s11|118-129|administered|O
DDI-DrugBank.d752.s11|131-133|and|O
DDI-DrugBank.d752.s11|135-137|the|O
DDI-DrugBank.d752.s11|139-145|desired|O
DDI-DrugBank.d752.s11|147-154|clinical|O
DDI-DrugBank.d752.s11|156-163|response|O
DDI-DrugBank.d752.s11|164-164|.|O
DDI-DrugBank.d752.s12|0-1|No|O
DDI-DrugBank.d752.s12|3-13|significant|O
DDI-DrugBank.d752.s12|15-21|adverse|O
DDI-DrugBank.d752.s12|23-34|interactions|O
DDI-DrugBank.d752.s12|36-39|with|O
DDI-DrugBank.d752.s12|41-46|common|O
DDI-DrugBank.d752.s12|48-61|premedications|O
DDI-DrugBank.d752.s12|63-63|(|O
DDI-DrugBank.d752.s12|64-67|such|O
DDI-DrugBank.d752.s12|69-70|as|O
DDI-DrugBank.d752.s12|72-79|atropine|drug
DDI-DrugBank.d752.s12|80-80|,|O
DDI-DrugBank.d752.s12|82-92|scopolamine|drug
DDI-DrugBank.d752.s12|93-93|,|O
DDI-DrugBank.d752.s12|95-108|glycopyrrolate|drug
DDI-DrugBank.d752.s12|109-109|,|O
DDI-DrugBank.d752.s12|111-118|diazepam|drug
DDI-DrugBank.d752.s12|119-119|,|O
DDI-DrugBank.d752.s12|121-131|hydroxyzine|drug
DDI-DrugBank.d752.s12|132-132|,|O
DDI-DrugBank.d752.s12|134-136|and|O
DDI-DrugBank.d752.s12|138-142|other|O
DDI-DrugBank.d752.s12|144-159|muscle relaxants|group
DDI-DrugBank.d752.s12|160-160|)|O
DDI-DrugBank.d752.s12|162-163|or|O
DDI-DrugBank.d752.s12|165-169|local|O
DDI-DrugBank.d752.s12|171-181|anesthetics|group
DDI-DrugBank.d752.s12|183-186|have|O
DDI-DrugBank.d752.s12|188-191|been|O
DDI-DrugBank.d752.s12|193-200|observed|O
DDI-DrugBank.d752.s12|201-201|.|O
DDI-MedLine.d93.s0|0-6|Altered|O
DDI-MedLine.d93.s0|8-21|responsiveness|O
DDI-MedLine.d93.s0|23-24|to|O
DDI-MedLine.d93.s0|26-32|alcohol|drug
DDI-MedLine.d93.s0|34-38|after|O
DDI-MedLine.d93.s0|40-47|exposure|O
DDI-MedLine.d93.s0|49-50|to|O
DDI-MedLine.d93.s0|52-58|organic|O
DDI-MedLine.d93.s0|60-63|lead|O
DDI-MedLine.d93.s0|64-64|.|O
DDI-MedLine.d93.s1|0-12|Ethyl alcohol|drug
DDI-MedLine.d93.s1|14-15|is|O
DDI-MedLine.d93.s1|17-21|known|O
DDI-MedLine.d93.s1|23-24|to|O
DDI-MedLine.d93.s1|26-31|effect|O
DDI-MedLine.d93.s1|33-35|the|O
DDI-MedLine.d93.s1|37-46|functional|O
DDI-MedLine.d93.s1|48-56|integrity|O
DDI-MedLine.d93.s1|58-59|of|O
DDI-MedLine.d93.s1|61-63|the|O
DDI-MedLine.d93.s1|65-70|limbic|O
DDI-MedLine.d93.s1|72-77|system|O
DDI-MedLine.d93.s1|78-78|,|O
DDI-MedLine.d93.s1|80-91|particularly|O
DDI-MedLine.d93.s1|93-95|the|O
DDI-MedLine.d93.s1|97-107|hippocampus|O
DDI-MedLine.d93.s1|108-108|,|O
DDI-MedLine.d93.s1|110-112|and|O
DDI-MedLine.d93.s1|114-115|to|O
DDI-MedLine.d93.s1|117-121|alter|O
DDI-MedLine.d93.s1|123-131|behaviors|O
DDI-MedLine.d93.s1|133-137|which|O
DDI-MedLine.d93.s1|139-141|are|O
DDI-MedLine.d93.s1|143-149|thought|O
DDI-MedLine.d93.s1|151-152|to|O
DDI-MedLine.d93.s1|154-155|be|O
DDI-MedLine.d93.s1|157-164|mediated|O
DDI-MedLine.d93.s1|166-172|through|O
DDI-MedLine.d93.s1|174-179|limbic|O
DDI-MedLine.d93.s1|181-188|function|O
DDI-MedLine.d93.s1|189-189|.|O
DDI-MedLine.d93.s2|0-11|Organometals|O
DDI-MedLine.d93.s2|13-16|also|O
DDI-MedLine.d93.s2|18-27|compromise|O
DDI-MedLine.d93.s2|29-31|the|O
DDI-MedLine.d93.s2|33-38|limbic|O
DDI-MedLine.d93.s2|40-45|system|O
DDI-MedLine.d93.s2|47-49|and|O
DDI-MedLine.d93.s2|51-56|result|O
DDI-MedLine.d93.s2|58-59|in|O
DDI-MedLine.d93.s2|61-68|deficits|O
DDI-MedLine.d93.s2|70-71|in|O
DDI-MedLine.d93.s2|73-80|learning|O
DDI-MedLine.d93.s2|82-84|and|O
DDI-MedLine.d93.s2|86-91|memory|O
DDI-MedLine.d93.s2|92-92|.|O
DDI-MedLine.d93.s3|0-4|Since|O
DDI-MedLine.d93.s3|6-9|both|O
DDI-MedLine.d93.s3|11-17|alcohol|drug
DDI-MedLine.d93.s3|19-21|and|O
DDI-MedLine.d93.s3|23-33|organoleads|O
DDI-MedLine.d93.s3|35-37|are|O
DDI-MedLine.d93.s3|39-45|present|O
DDI-MedLine.d93.s3|47-48|in|O
DDI-MedLine.d93.s3|50-52|the|O
DDI-MedLine.d93.s3|54-64|environment|O
DDI-MedLine.d93.s3|66-68|and|O
DDI-MedLine.d93.s3|70-73|seem|O
DDI-MedLine.d93.s3|75-76|to|O
DDI-MedLine.d93.s3|78-86|influence|O
DDI-MedLine.d93.s3|88-93|limbic|O
DDI-MedLine.d93.s3|95-105|integration|O
DDI-MedLine.d93.s3|106-106|,|O
DDI-MedLine.d93.s3|108-110|the|O
DDI-MedLine.d93.s3|112-122|interaction|O
DDI-MedLine.d93.s3|124-125|of|O
DDI-MedLine.d93.s3|127-131|these|O
DDI-MedLine.d93.s3|133-135|two|O
DDI-MedLine.d93.s3|137-145|compounds|O
DDI-MedLine.d93.s3|147-149|was|O
DDI-MedLine.d93.s3|151-158|assessed|O
DDI-MedLine.d93.s3|160-161|in|O
DDI-MedLine.d93.s3|163-165|the|O
DDI-MedLine.d93.s3|167-173|present|O
DDI-MedLine.d93.s3|175-184|experiment|O
DDI-MedLine.d93.s3|185-185|.|O
DDI-MedLine.d93.s4|0-5|Thirty|O
DDI-MedLine.d93.s4|7-10|male|O
DDI-MedLine.d93.s4|12-15|rats|O
DDI-MedLine.d93.s4|17-18|of|O
DDI-MedLine.d93.s4|20-22|the|O
DDI-MedLine.d93.s4|24-34|Fischer-344|O
DDI-MedLine.d93.s4|36-41|strain|O
DDI-MedLine.d93.s4|43-46|were|O
DDI-MedLine.d93.s4|48-54|divided|O
DDI-MedLine.d93.s4|56-59|into|O
DDI-MedLine.d93.s4|61-65|three|O
DDI-MedLine.d93.s4|67-71|equal|O
DDI-MedLine.d93.s4|73-78|groups|O
DDI-MedLine.d93.s4|80-82|and|O
DDI-MedLine.d93.s4|84-87|were|O
DDI-MedLine.d93.s4|89-93|given|O
DDI-MedLine.d93.s4|95-104|injections|O
DDI-MedLine.d93.s4|106-107|of|O
DDI-MedLine.d93.s4|124-124|(|O
DDI-MedLine.d93.s4|128-128|)|O
DDI-MedLine.d93.s4|130-130|(|O
DDI-MedLine.d93.s4|131-133|8.0|O
DDI-MedLine.d93.s4|135-136|or|O
DDI-MedLine.d93.s4|138-141|17.0|O
DDI-MedLine.d93.s4|143-150|mg/kg/ml|O
DDI-MedLine.d93.s4|152-153|SC|O
DDI-MedLine.d93.s4|154-154|)|O
DDI-MedLine.d93.s4|156-157|or|O
DDI-MedLine.d93.s4|159-161|the|O
DDI-MedLine.d93.s4|163-168|saline|O
DDI-MedLine.d93.s4|170-176|vehicle|O
DDI-MedLine.d93.s4|177-177|.|O
DDI-MedLine.d93.s5|0-7|Fourteen|O
DDI-MedLine.d93.s5|9-12|days|O
DDI-MedLine.d93.s5|14-18|later|O
DDI-MedLine.d93.s5|19-19|,|O
DDI-MedLine.d93.s5|21-23|all|O
DDI-MedLine.d93.s5|25-31|animals|O
DDI-MedLine.d93.s5|33-36|were|O
DDI-MedLine.d93.s5|38-47|challenged|O
DDI-MedLine.d93.s5|49-52|with|O
DDI-MedLine.d93.s5|54-54|a|O
DDI-MedLine.d93.s5|56-61|single|O
DDI-MedLine.d93.s5|63-70|hypnotic|O
DDI-MedLine.d93.s5|72-75|dose|O
DDI-MedLine.d93.s5|77-78|of|O
DDI-MedLine.d93.s5|80-86|ethanol|drug
DDI-MedLine.d93.s5|88-88|(|O
DDI-MedLine.d93.s5|89-91|3.5|O
DDI-MedLine.d93.s5|93-96|g/kg|O
DDI-MedLine.d93.s5|98-99|IP|O
DDI-MedLine.d93.s5|100-100|)|O
DDI-MedLine.d93.s5|101-101|.|O
DDI-MedLine.d93.s6|0-2|The|O
DDI-MedLine.d93.s6|4-5|20|O
DDI-MedLine.d93.s6|6-6|%|O
DDI-MedLine.d93.s6|8-10|v/v|O
DDI-MedLine.d93.s6|12-19|solution|O
DDI-MedLine.d93.s6|21-22|of|O
DDI-MedLine.d93.s6|24-30|alcohol|drug
DDI-MedLine.d93.s6|32-34|was|O
DDI-MedLine.d93.s6|36-43|prepared|O
DDI-MedLine.d93.s6|45-46|in|O
DDI-MedLine.d93.s6|48-52|water|O
DDI-MedLine.d93.s6|54-57|from|O
DDI-MedLine.d93.s6|59-59|a|O
DDI-MedLine.d93.s6|61-65|stock|O
DDI-MedLine.d93.s6|67-74|solution|O
DDI-MedLine.d93.s6|76-77|of|O
DDI-MedLine.d93.s6|79-80|95|O
DDI-MedLine.d93.s6|81-81|%|O
DDI-MedLine.d93.s6|83-89|ethanol|drug
DDI-MedLine.d93.s6|90-90|.|O
DDI-MedLine.d93.s7|0-2|The|O
DDI-MedLine.d93.s7|4-10|latency|O
DDI-MedLine.d93.s7|12-13|to|O
DDI-MedLine.d93.s7|15-18|loss|O
DDI-MedLine.d93.s7|20-21|of|O
DDI-MedLine.d93.s7|23-25|the|O
DDI-MedLine.d93.s7|27-34|righting|O
DDI-MedLine.d93.s7|36-41|reflex|O
DDI-MedLine.d93.s7|43-45|and|O
DDI-MedLine.d93.s7|47-54|duration|O
DDI-MedLine.d93.s7|56-57|of|O
DDI-MedLine.d93.s7|59-63|sleep|O
DDI-MedLine.d93.s7|65-68|time|O
DDI-MedLine.d93.s7|70-73|were|O
DDI-MedLine.d93.s7|75-82|recorded|O
DDI-MedLine.d93.s7|84-88|while|O
DDI-MedLine.d93.s7|90-92|the|O
DDI-MedLine.d93.s7|94-97|rats|O
DDI-MedLine.d93.s7|99-102|were|O
DDI-MedLine.d93.s7|104-107|kept|O
DDI-MedLine.d93.s7|109-110|in|O
DDI-MedLine.d93.s7|112-128|sound-attenuating|O
DDI-MedLine.d93.s7|130-137|chambers|O
DDI-MedLine.d93.s7|138-138|.|O
DDI-MedLine.d93.s8|0-2|The|O
DDI-MedLine.d93.s8|4-7|rats|O
DDI-MedLine.d93.s8|9-15|treated|O
DDI-MedLine.d93.s8|17-20|with|O
DDI-MedLine.d93.s8|22-24|the|O
DDI-MedLine.d93.s8|26-32|highest|O
DDI-MedLine.d93.s8|34-37|dose|O
DDI-MedLine.d93.s8|39-40|of|O
DDI-MedLine.d93.s8|46-55|manifested|O
DDI-MedLine.d93.s8|57-69|significantly|O
DDI-MedLine.d93.s8|71-76|longer|O
DDI-MedLine.d93.s8|78-86|latencies|O
DDI-MedLine.d93.s8|88-89|to|O
DDI-MedLine.d93.s8|91-94|lose|O
DDI-MedLine.d93.s8|96-98|the|O
DDI-MedLine.d93.s8|100-107|righting|O
DDI-MedLine.d93.s8|109-114|reflex|O
DDI-MedLine.d93.s8|116-118|and|O
DDI-MedLine.d93.s8|120-126|shorter|O
DDI-MedLine.d93.s8|128-136|durations|O
DDI-MedLine.d93.s8|138-139|of|O
DDI-MedLine.d93.s8|141-145|sleep|O
DDI-MedLine.d93.s8|147-150|than|O
DDI-MedLine.d93.s8|152-154|did|O
DDI-MedLine.d93.s8|156-163|controls|O
DDI-MedLine.d93.s8|164-164|.|O
DDI-MedLine.d93.s9|0-4|These|O
DDI-MedLine.d93.s9|6-12|results|O
DDI-MedLine.d93.s9|14-20|suggest|O
DDI-MedLine.d93.s9|22-25|that|O
DDI-MedLine.d93.s9|27-34|exposure|O
DDI-MedLine.d93.s9|36-37|to|O
DDI-MedLine.d93.s9|39-51|environmental|O
DDI-MedLine.d93.s9|58-60|may|O
DDI-MedLine.d93.s9|62-66|alter|O
DDI-MedLine.d93.s9|68-70|the|O
DDI-MedLine.d93.s9|72-81|biological|O
DDI-MedLine.d93.s9|83-85|and|O
DDI-MedLine.d93.s9|87-96|behavioral|O
DDI-MedLine.d93.s9|98-111|responsiveness|O
DDI-MedLine.d93.s9|113-114|of|O
DDI-MedLine.d93.s9|116-117|an|O
DDI-MedLine.d93.s9|119-124|animal|O
DDI-MedLine.d93.s9|126-127|to|O
DDI-MedLine.d93.s9|129-135|alcohol|drug
DDI-MedLine.d93.s9|136-136|.|O
DDI-DrugBank.d290.s0|0-1|No|O
DDI-DrugBank.d290.s0|3-6|drug|O
DDI-DrugBank.d290.s0|8-19|interactions|O
DDI-DrugBank.d290.s0|21-24|have|O
DDI-DrugBank.d290.s0|26-29|been|O
DDI-DrugBank.d290.s0|31-38|reported|O
DDI-DrugBank.d290.s0|40-46|between|O
DDI-DrugBank.d290.s0|48-67|Prostin VR Pediatric|brand
DDI-DrugBank.d290.s0|69-71|and|O
DDI-DrugBank.d290.s0|73-75|the|O
DDI-DrugBank.d290.s0|77-83|therapy|O
DDI-DrugBank.d290.s0|85-92|standard|O
DDI-DrugBank.d290.s0|94-95|in|O
DDI-DrugBank.d290.s0|97-104|neonates|O
DDI-DrugBank.d290.s0|106-109|with|O
DDI-DrugBank.d290.s0|111-120|restricted|O
DDI-DrugBank.d290.s0|122-130|pulmonary|O
DDI-DrugBank.d290.s0|132-133|or|O
DDI-DrugBank.d290.s0|135-142|systemic|O
DDI-DrugBank.d290.s0|144-148|blood|O
DDI-DrugBank.d290.s0|150-153|flow|O
DDI-DrugBank.d290.s0|154-154|.|O
DDI-DrugBank.d290.s1|0-7|Standard|O
DDI-DrugBank.d290.s1|9-15|therapy|O
DDI-DrugBank.d290.s1|17-24|includes|O
DDI-DrugBank.d290.s1|26-36|antibiotics|group
DDI-DrugBank.d290.s1|37-37|,|O
DDI-DrugBank.d290.s1|39-42|such|O
DDI-DrugBank.d290.s1|44-45|as|O
DDI-DrugBank.d290.s1|47-56|penicillin|drug
DDI-DrugBank.d290.s1|58-60|and|O
DDI-DrugBank.d290.s1|62-71|gentamicin|drug
DDI-DrugBank.d290.s1|72-72|;|O
DDI-DrugBank.d290.s2|0-11|vasopressors|group
DDI-DrugBank.d290.s2|12-12|,|O
DDI-DrugBank.d290.s2|14-17|such|O
DDI-DrugBank.d290.s2|19-20|as|O
DDI-DrugBank.d290.s2|22-29|dopamine|drug
DDI-DrugBank.d290.s2|31-33|and|O
DDI-DrugBank.d290.s2|35-47|isoproterenol|drug
DDI-DrugBank.d290.s2|48-48|;|O
DDI-DrugBank.d290.s3|0-17|cardiac glycosides|group
DDI-DrugBank.d290.s3|18-18|;|O
DDI-DrugBank.d290.s4|0-2|and|O
DDI-DrugBank.d290.s4|4-12|diuretics|group
DDI-DrugBank.d290.s4|13-13|,|O
DDI-DrugBank.d290.s4|15-18|such|O
DDI-DrugBank.d290.s4|20-21|as|O
DDI-DrugBank.d290.s4|23-32|furosemide|drug
DDI-DrugBank.d290.s4|33-33|.|O
DDI-DrugBank.d290.s5|0-8|Caverject|brand
DDI-DrugBank.d290.s5|9-9|:|O
DDI-DrugBank.d290.s5|11-13|The|O
DDI-DrugBank.d290.s5|15-23|potential|O
DDI-DrugBank.d290.s5|25-27|for|O
DDI-DrugBank.d290.s5|29-43|pharmacokinetic|O
DDI-DrugBank.d290.s5|45-53|drug-drug|O
DDI-DrugBank.d290.s5|55-66|interactions|O
DDI-DrugBank.d290.s5|68-74|between|O
DDI-DrugBank.d290.s5|76-86|alprostadil|drug
DDI-DrugBank.d290.s5|88-90|and|O
DDI-DrugBank.d290.s5|92-96|other|O
DDI-DrugBank.d290.s5|98-103|agents|O
DDI-DrugBank.d290.s5|105-107|has|O
DDI-DrugBank.d290.s5|109-111|not|O
DDI-DrugBank.d290.s5|113-116|been|O
DDI-DrugBank.d290.s5|118-125|formally|O
DDI-DrugBank.d290.s5|127-133|studied|O
DDI-DrugBank.d290.s5|134-134|.|O
DDI-MedLine.d22.s0|0-7|Spermine|drug
DDI-MedLine.d22.s0|9-16|promotes|O
DDI-MedLine.d22.s0|18-20|the|O
DDI-MedLine.d22.s0|22-34|translocation|O
DDI-MedLine.d22.s0|36-37|of|O
DDI-MedLine.d22.s0|39-51|phosphatidate|O
DDI-MedLine.d22.s0|53-68|phosphohydrolase|O
DDI-MedLine.d22.s0|70-73|from|O
DDI-MedLine.d22.s0|75-77|the|O
DDI-MedLine.d22.s0|79-85|cytosol|O
DDI-MedLine.d22.s0|87-88|to|O
DDI-MedLine.d22.s0|90-92|the|O
DDI-MedLine.d22.s0|94-103|microsomal|O
DDI-MedLine.d22.s0|105-112|fraction|O
DDI-MedLine.d22.s0|114-115|of|O
DDI-MedLine.d22.s0|117-119|rat|O
DDI-MedLine.d22.s0|121-125|liver|O
DDI-MedLine.d22.s0|127-129|and|O
DDI-MedLine.d22.s0|131-132|it|O
DDI-MedLine.d22.s0|134-141|enhances|O
DDI-MedLine.d22.s0|143-145|the|O
DDI-MedLine.d22.s0|147-153|effects|O
DDI-MedLine.d22.s0|155-156|of|O
DDI-MedLine.d22.s0|158-163|oleate|O
DDI-MedLine.d22.s0|165-166|in|O
DDI-MedLine.d22.s0|168-171|this|O
DDI-MedLine.d22.s0|173-179|respect|O
DDI-MedLine.d22.s0|180-180|.|O
DDI-MedLine.d22.s1|0-7|Spermine|drug
DDI-MedLine.d22.s1|9-9|(|O
DDI-MedLine.d22.s1|10-14|0.5-2|O
DDI-MedLine.d22.s1|16-17|mM|O
DDI-MedLine.d22.s1|18-18|)|O
DDI-MedLine.d22.s1|20-27|promoted|O
DDI-MedLine.d22.s1|29-31|the|O
DDI-MedLine.d22.s1|33-45|translocation|O
DDI-MedLine.d22.s1|47-48|of|O
DDI-MedLine.d22.s1|50-62|phosphatidate|O
DDI-MedLine.d22.s1|64-79|phosphohydrolase|O
DDI-MedLine.d22.s1|81-84|from|O
DDI-MedLine.d22.s1|86-88|the|O
DDI-MedLine.d22.s1|90-96|soluble|O
DDI-MedLine.d22.s1|98-99|to|O
DDI-MedLine.d22.s1|101-103|the|O
DDI-MedLine.d22.s1|105-114|microsomal|O
DDI-MedLine.d22.s1|116-123|fraction|O
DDI-MedLine.d22.s1|125-126|in|O
DDI-MedLine.d22.s1|128-128|a|O
DDI-MedLine.d22.s1|130-138|cell-free|O
DDI-MedLine.d22.s1|140-145|system|O
DDI-MedLine.d22.s1|147-153|derived|O
DDI-MedLine.d22.s1|155-158|from|O
DDI-MedLine.d22.s1|160-162|rat|O
DDI-MedLine.d22.s1|164-168|liver|O
DDI-MedLine.d22.s1|169-169|.|O
DDI-MedLine.d22.s2|0-1|By|O
DDI-MedLine.d22.s2|3-10|contrast|O
DDI-MedLine.d22.s2|11-11|,|O
DDI-MedLine.d22.s2|24-24|(|O
DDI-MedLine.d22.s2|25-25|1|O
DDI-MedLine.d22.s2|27-28|mM|O
DDI-MedLine.d22.s2|29-29|)|O
DDI-MedLine.d22.s2|31-33|and|O
DDI-MedLine.d22.s2|46-46|(|O
DDI-MedLine.d22.s2|47-47|1|O
DDI-MedLine.d22.s2|49-50|mM|O
DDI-MedLine.d22.s2|51-51|)|O
DDI-MedLine.d22.s2|53-55|had|O
DDI-MedLine.d22.s2|57-58|no|O
DDI-MedLine.d22.s2|60-70|significant|O
DDI-MedLine.d22.s2|72-77|effect|O
DDI-MedLine.d22.s2|79-80|on|O
DDI-MedLine.d22.s2|82-84|the|O
DDI-MedLine.d22.s2|86-98|translocation|O
DDI-MedLine.d22.s2|100-103|when|O
DDI-MedLine.d22.s2|105-109|added|O
DDI-MedLine.d22.s2|111-115|alone|O
DDI-MedLine.d22.s2|116-116|.|O
DDI-MedLine.d22.s3|0-7|Spermine|drug
DDI-MedLine.d22.s3|8-8|,|O
DDI-MedLine.d22.s3|10-12|and|O
DDI-MedLine.d22.s3|14-15|to|O
DDI-MedLine.d22.s3|17-17|a|O
DDI-MedLine.d22.s3|19-24|lesser|O
DDI-MedLine.d22.s3|26-31|extent|O
DDI-MedLine.d22.s3|32-32|,|O
DDI-MedLine.d22.s3|44-44|,|O
DDI-MedLine.d22.s3|46-53|enhanced|O
DDI-MedLine.d22.s3|55-57|the|O
DDI-MedLine.d22.s3|59-71|translocating|O
DDI-MedLine.d22.s3|73-78|action|O
DDI-MedLine.d22.s3|80-81|of|O
DDI-MedLine.d22.s3|83-88|oleate|O
DDI-MedLine.d22.s3|90-92|and|O
DDI-MedLine.d22.s3|94-102|increased|O
DDI-MedLine.d22.s3|104-106|its|O
DDI-MedLine.d22.s3|108-120|effectiveness|O
DDI-MedLine.d22.s3|122-123|in|O
DDI-MedLine.d22.s3|125-136|transferring|O
DDI-MedLine.d22.s3|138-140|the|O
DDI-MedLine.d22.s3|142-157|phosphohydrolase|O
DDI-MedLine.d22.s3|159-162|from|O
DDI-MedLine.d22.s3|164-166|the|O
DDI-MedLine.d22.s3|168-174|soluble|O
DDI-MedLine.d22.s3|176-177|to|O
DDI-MedLine.d22.s3|179-181|the|O
DDI-MedLine.d22.s3|183-192|microsomal|O
DDI-MedLine.d22.s3|194-201|fraction|O
DDI-MedLine.d22.s3|202-202|.|O
DDI-MedLine.d22.s4|0-1|It|O
DDI-MedLine.d22.s4|3-4|is|O
DDI-MedLine.d22.s4|6-13|proposed|O
DDI-MedLine.d22.s4|15-18|that|O
DDI-MedLine.d22.s4|20-22|the|O
DDI-MedLine.d22.s4|24-39|phosphohydrolase|O
DDI-MedLine.d22.s4|41-47|becomes|O
DDI-MedLine.d22.s4|49-61|metabolically|O
DDI-MedLine.d22.s4|63-68|active|O
DDI-MedLine.d22.s4|70-73|when|O
DDI-MedLine.d22.s4|75-76|it|O
DDI-MedLine.d22.s4|78-85|combines|O
DDI-MedLine.d22.s4|87-90|with|O
DDI-MedLine.d22.s4|92-100|membranes|O
DDI-MedLine.d22.s4|102-104|and|O
DDI-MedLine.d22.s4|106-109|that|O
DDI-MedLine.d22.s4|111-120|polyamines|O
DDI-MedLine.d22.s4|122-126|might|O
DDI-MedLine.d22.s4|128-131|help|O
DDI-MedLine.d22.s4|133-134|to|O
DDI-MedLine.d22.s4|136-143|regulate|O
DDI-MedLine.d22.s4|145-148|this|O
DDI-MedLine.d22.s4|150-160|interaction|O
DDI-MedLine.d22.s4|161-161|.|O
DDI-MedLine.d22.s5|0-3|This|O
DDI-MedLine.d22.s5|5-9|could|O
DDI-MedLine.d22.s5|11-20|facilitate|O
DDI-MedLine.d22.s5|22-24|the|O
DDI-MedLine.d22.s5|26-31|action|O
DDI-MedLine.d22.s5|33-34|of|O
DDI-MedLine.d22.s5|36-40|fatty|O
DDI-MedLine.d22.s5|42-46|acids|O
DDI-MedLine.d22.s5|48-50|and|O
DDI-MedLine.d22.s5|52-57|enable|O
DDI-MedLine.d22.s5|59-63|cells|O
DDI-MedLine.d22.s5|65-66|to|O
DDI-MedLine.d22.s5|68-75|increase|O
DDI-MedLine.d22.s5|77-81|their|O
DDI-MedLine.d22.s5|83-90|capacity|O
DDI-MedLine.d22.s5|92-94|for|O
DDI-MedLine.d22.s5|96-110|triacylglycerol|O
DDI-MedLine.d22.s5|112-120|synthesis|O
DDI-MedLine.d22.s5|122-123|to|O
DDI-MedLine.d22.s5|125-129|match|O
DDI-MedLine.d22.s5|131-132|an|O
DDI-MedLine.d22.s5|134-142|increased|O
DDI-MedLine.d22.s5|144-155|availability|O
DDI-MedLine.d22.s5|157-158|of|O
DDI-MedLine.d22.s5|160-164|fatty|O
DDI-MedLine.d22.s5|166-170|acids|O
DDI-MedLine.d22.s5|171-171|.|O
DDI-DrugBank.d425.s0|0-10|Medications|O
DDI-DrugBank.d425.s0|12-15|that|O
DDI-DrugBank.d425.s0|17-25|interfere|O
DDI-DrugBank.d425.s0|27-30|with|O
DDI-DrugBank.d425.s0|32-35|your|O
DDI-DrugBank.d425.s0|37-41|bodys|O
DDI-DrugBank.d425.s0|43-49|ability|O
DDI-DrugBank.d425.s0|51-52|to|O
DDI-DrugBank.d425.s0|54-56|use|O
DDI-DrugBank.d425.s0|58-63|folate|O
DDI-DrugBank.d425.s0|65-67|may|O
DDI-DrugBank.d425.s0|69-72|also|O
DDI-DrugBank.d425.s0|74-81|increase|O
DDI-DrugBank.d425.s0|83-85|the|O
DDI-DrugBank.d425.s0|87-90|need|O
DDI-DrugBank.d425.s0|92-94|for|O
DDI-DrugBank.d425.s0|96-99|this|O
DDI-DrugBank.d425.s0|101-107|vitamin|group
DDI-DrugBank.d425.s0|108-108|.|O
DDI-DrugBank.d425.s1|0-10|Medications|O
DDI-DrugBank.d425.s1|12-14|can|O
DDI-DrugBank.d425.s1|16-24|interfere|O
DDI-DrugBank.d425.s1|26-29|with|O
DDI-DrugBank.d425.s1|31-36|folate|O
DDI-DrugBank.d425.s1|38-48|utilization|O
DDI-DrugBank.d425.s1|49-49|,|O
DDI-DrugBank.d425.s1|51-59|including|O
DDI-DrugBank.d425.s1|60-60|:|O
DDI-DrugBank.d425.s1|62-87|anticonvulsant medications|group
DDI-DrugBank.d425.s1|89-89|(|O
DDI-DrugBank.d425.s1|90-93|such|O
DDI-DrugBank.d425.s1|95-96|as|O
DDI-DrugBank.d425.s1|98-106|phenytoin|drug
DDI-DrugBank.d425.s1|107-107|,|O
DDI-DrugBank.d425.s1|109-111|and|O
DDI-DrugBank.d425.s1|113-121|primidone|drug
DDI-DrugBank.d425.s1|122-122|)|O
DDI-DrugBank.d425.s1|124-132|metformin|drug
DDI-DrugBank.d425.s1|134-134|(|O
DDI-DrugBank.d425.s1|135-143|sometimes|O
DDI-DrugBank.d425.s1|145-154|prescribed|O
DDI-DrugBank.d425.s1|156-157|to|O
DDI-DrugBank.d425.s1|159-165|control|O
DDI-DrugBank.d425.s1|167-171|blood|O
DDI-DrugBank.d425.s1|173-177|sugar|O
DDI-DrugBank.d425.s1|179-180|in|O
DDI-DrugBank.d425.s1|182-185|type|O
DDI-DrugBank.d425.s1|187-187|2|O
DDI-DrugBank.d425.s1|189-196|diabetes|O
DDI-DrugBank.d425.s1|197-197|)|O
DDI-DrugBank.d425.s1|199-211|sulfasalazine|drug
DDI-DrugBank.d425.s1|213-213|(|O
DDI-DrugBank.d425.s1|214-217|used|O
DDI-DrugBank.d425.s1|219-220|to|O
DDI-DrugBank.d425.s1|222-228|control|O
DDI-DrugBank.d425.s1|230-241|inflammation|O
DDI-DrugBank.d425.s1|243-252|associated|O
DDI-DrugBank.d425.s1|254-257|with|O
DDI-DrugBank.d425.s1|259-264|Crohns|O
DDI-DrugBank.d425.s1|266-272|disease|O
DDI-DrugBank.d425.s1|274-276|and|O
DDI-DrugBank.d425.s1|278-287|ulcerative|O
DDI-DrugBank.d425.s1|289-295|colitis|O
DDI-DrugBank.d425.s1|296-296|)|O
DDI-DrugBank.d425.s1|298-308|triamterene|drug
DDI-DrugBank.d425.s1|310-310|(|O
DDI-DrugBank.d425.s1|311-311|a|O
DDI-DrugBank.d425.s1|313-320|diuretic|group
DDI-DrugBank.d425.s1|321-321|)|O
DDI-DrugBank.d425.s1|323-334|Methotrexate|drug
DDI-DrugBank.d425.s1|336-340|There|O
DDI-DrugBank.d425.s1|342-344|has|O
DDI-DrugBank.d425.s1|346-349|been|O
DDI-DrugBank.d425.s1|351-357|concern|O
DDI-DrugBank.d425.s1|359-363|about|O
DDI-DrugBank.d425.s1|365-367|the|O
DDI-DrugBank.d425.s1|369-379|interaction|O
DDI-DrugBank.d425.s1|381-387|between|O
DDI-DrugBank.d425.s1|389-399|vitamin B12|drug
DDI-DrugBank.d425.s1|401-403|and|O
DDI-DrugBank.d425.s1|405-414|folic acid|drug
DDI-DrugBank.d425.s1|415-415|.|O
DDI-DrugBank.d425.s2|0-9|Folic acid|drug
DDI-DrugBank.d425.s2|11-21|supplements|O
DDI-DrugBank.d425.s2|23-25|can|O
DDI-DrugBank.d425.s2|27-33|correct|O
DDI-DrugBank.d425.s2|35-37|the|O
DDI-DrugBank.d425.s2|39-44|anemia|O
DDI-DrugBank.d425.s2|46-55|associated|O
DDI-DrugBank.d425.s2|57-60|with|O
DDI-DrugBank.d425.s2|62-68|vitamin|O
DDI-DrugBank.d425.s2|70-72|B12|O
DDI-DrugBank.d425.s2|74-83|deficiency|O
DDI-DrugBank.d425.s2|84-84|.|O
DDI-DrugBank.d425.s3|0-12|Unfortunately|O
DDI-DrugBank.d425.s3|13-13|,|O
DDI-DrugBank.d425.s3|15-24|folic acid|drug
DDI-DrugBank.d425.s3|26-29|will|O
DDI-DrugBank.d425.s3|31-33|not|O
DDI-DrugBank.d425.s3|35-41|correct|O
DDI-DrugBank.d425.s3|43-49|changes|O
DDI-DrugBank.d425.s3|51-52|in|O
DDI-DrugBank.d425.s3|54-56|the|O
DDI-DrugBank.d425.s3|58-64|nervous|O
DDI-DrugBank.d425.s3|66-71|system|O
DDI-DrugBank.d425.s3|73-76|that|O
DDI-DrugBank.d425.s3|78-83|result|O
DDI-DrugBank.d425.s3|85-88|from|O
DDI-DrugBank.d425.s3|90-96|vitamin|O
DDI-DrugBank.d425.s3|98-100|B12|O
DDI-DrugBank.d425.s3|102-111|deficiency|O
DDI-DrugBank.d425.s3|112-112|.|O
DDI-DrugBank.d425.s4|0-8|Permanent|O
DDI-DrugBank.d425.s4|10-14|nerve|O
DDI-DrugBank.d425.s4|16-21|damage|O
DDI-DrugBank.d425.s4|23-27|could|O
DDI-DrugBank.d425.s4|29-41|theoretically|O
DDI-DrugBank.d425.s4|43-47|occur|O
DDI-DrugBank.d425.s4|49-50|if|O
DDI-DrugBank.d425.s4|52-58|vitamin|O
DDI-DrugBank.d425.s4|60-62|B12|O
DDI-DrugBank.d425.s4|64-73|deficiency|O
DDI-DrugBank.d425.s4|75-76|is|O
DDI-DrugBank.d425.s4|78-80|not|O
DDI-DrugBank.d425.s4|82-88|treated|O
DDI-DrugBank.d425.s4|89-89|.|O
DDI-DrugBank.d425.s5|0-8|Therefore|O
DDI-DrugBank.d425.s5|9-9|,|O
DDI-DrugBank.d425.s5|11-16|intake|O
DDI-DrugBank.d425.s5|18-19|of|O
DDI-DrugBank.d425.s5|21-32|supplemental|O
DDI-DrugBank.d425.s5|34-43|folic acid|drug
DDI-DrugBank.d425.s5|45-50|should|O
DDI-DrugBank.d425.s5|52-54|not|O
DDI-DrugBank.d425.s5|56-61|exceed|O
DDI-DrugBank.d425.s5|63-66|1000|O
DDI-DrugBank.d425.s5|68-77|micrograms|O
DDI-DrugBank.d425.s5|79-79|(|O
DDI-DrugBank.d425.s5|81-81|g|O
DDI-DrugBank.d425.s5|82-82|,|O
DDI-DrugBank.d425.s5|84-92|sometimes|O
DDI-DrugBank.d425.s5|94-96|mcg|O
DDI-DrugBank.d425.s5|97-97|)|O
DDI-DrugBank.d425.s5|99-101|per|O
DDI-DrugBank.d425.s5|103-105|day|O
DDI-DrugBank.d425.s5|107-108|to|O
DDI-DrugBank.d425.s5|110-116|prevent|O
DDI-DrugBank.d425.s5|118-127|folic acid|drug
DDI-DrugBank.d425.s5|129-132|from|O
DDI-DrugBank.d425.s5|134-140|masking|O
DDI-DrugBank.d425.s5|142-149|symptoms|O
DDI-DrugBank.d425.s5|151-152|of|O
DDI-DrugBank.d425.s5|154-160|vitamin|O
DDI-DrugBank.d425.s5|162-164|B12|O
DDI-DrugBank.d425.s5|166-175|deficiency|O
DDI-DrugBank.d425.s5|176-176|.|O
DDI-DrugBank.d425.s6|0-1|It|O
DDI-DrugBank.d425.s6|3-4|is|O
DDI-DrugBank.d425.s6|6-14|important|O
DDI-DrugBank.d425.s6|16-18|for|O
DDI-DrugBank.d425.s6|20-24|older|O
DDI-DrugBank.d425.s6|26-31|adults|O
DDI-DrugBank.d425.s6|33-34|to|O
DDI-DrugBank.d425.s6|36-37|be|O
DDI-DrugBank.d425.s6|39-43|aware|O
DDI-DrugBank.d425.s6|45-46|of|O
DDI-DrugBank.d425.s6|48-50|the|O
DDI-DrugBank.d425.s6|52-63|relationship|O
DDI-DrugBank.d425.s6|65-71|between|O
DDI-DrugBank.d425.s6|73-82|folic acid|drug
DDI-DrugBank.d425.s6|84-86|and|O
DDI-DrugBank.d425.s6|88-98|vitamin B12|drug
DDI-DrugBank.d425.s6|100-106|because|O
DDI-DrugBank.d425.s6|108-111|they|O
DDI-DrugBank.d425.s6|113-115|are|O
DDI-DrugBank.d425.s6|117-118|at|O
DDI-DrugBank.d425.s6|120-126|greater|O
DDI-DrugBank.d425.s6|128-131|risk|O
DDI-DrugBank.d425.s6|133-134|of|O
DDI-DrugBank.d425.s6|136-141|having|O
DDI-DrugBank.d425.s6|143-143|a|O
DDI-DrugBank.d425.s6|145-151|vitamin|O
DDI-DrugBank.d425.s6|153-155|B12|O
DDI-DrugBank.d425.s6|157-166|deficiency|O
DDI-DrugBank.d425.s6|167-167|.|O
DDI-DrugBank.d425.s7|0-1|If|O
DDI-DrugBank.d425.s7|3-5|you|O
DDI-DrugBank.d425.s7|7-9|are|O
DDI-DrugBank.d425.s7|11-12|50|O
DDI-DrugBank.d425.s7|14-18|years|O
DDI-DrugBank.d425.s7|20-21|of|O
DDI-DrugBank.d425.s7|23-25|age|O
DDI-DrugBank.d425.s7|27-28|or|O
DDI-DrugBank.d425.s7|30-34|older|O
DDI-DrugBank.d425.s7|35-35|,|O
DDI-DrugBank.d425.s7|37-39|ask|O
DDI-DrugBank.d425.s7|41-44|your|O
DDI-DrugBank.d425.s7|46-54|physician|O
DDI-DrugBank.d425.s7|56-57|to|O
DDI-DrugBank.d425.s7|59-63|check|O
DDI-DrugBank.d425.s7|65-68|your|O
DDI-DrugBank.d425.s7|70-72|B12|O
DDI-DrugBank.d425.s7|74-79|status|O
DDI-DrugBank.d425.s7|81-86|before|O
DDI-DrugBank.d425.s7|88-90|you|O
DDI-DrugBank.d425.s7|92-95|take|O
DDI-DrugBank.d425.s7|97-97|a|O
DDI-DrugBank.d425.s7|99-108|supplement|O
DDI-DrugBank.d425.s7|110-113|that|O
DDI-DrugBank.d425.s7|115-122|contains|O
DDI-DrugBank.d425.s7|124-133|folic acid|drug
DDI-DrugBank.d425.s7|134-134|.|O
DDI-DrugBank.d106.s0|0-0|A|O
DDI-DrugBank.d106.s0|2-3|30|O
DDI-DrugBank.d106.s0|5-6|to|O
DDI-DrugBank.d106.s0|8-9|45|O
DDI-DrugBank.d106.s0|10-10|%|O
DDI-DrugBank.d106.s0|12-19|increase|O
DDI-DrugBank.d106.s0|21-22|in|O
DDI-DrugBank.d106.s0|24-26|AUC|O
DDI-DrugBank.d106.s0|28-30|and|O
DDI-DrugBank.d106.s0|32-35|Cmax|O
DDI-DrugBank.d106.s0|37-38|of|O
DDI-DrugBank.d106.s0|40-50|nisoldipine|drug
DDI-DrugBank.d106.s0|52-54|was|O
DDI-DrugBank.d106.s0|56-63|observed|O
DDI-DrugBank.d106.s0|65-68|with|O
DDI-DrugBank.d106.s0|70-80|concomitant|O
DDI-DrugBank.d106.s0|82-95|administration|O
DDI-DrugBank.d106.s0|97-98|of|O
DDI-DrugBank.d106.s0|100-116|cimetidine 400 mg|drug
DDI-DrugBank.d106.s0|118-122|twice|O
DDI-DrugBank.d106.s0|124-128|daily|O
DDI-DrugBank.d106.s0|129-129|.|O
DDI-DrugBank.d106.s1|0-9|Ranitidine|drug
DDI-DrugBank.d106.s1|11-13|150|O
DDI-DrugBank.d106.s1|15-16|mg|O
DDI-DrugBank.d106.s1|18-22|twice|O
DDI-DrugBank.d106.s1|24-28|daily|O
DDI-DrugBank.d106.s1|30-32|did|O
DDI-DrugBank.d106.s1|34-36|not|O
DDI-DrugBank.d106.s1|38-45|interact|O
DDI-DrugBank.d106.s1|47-59|significantly|O
DDI-DrugBank.d106.s1|61-64|with|O
DDI-DrugBank.d106.s1|66-76|nisoldipine|drug
DDI-DrugBank.d106.s1|78-78|(|O
DDI-DrugBank.d106.s1|79-81|AUC|O
DDI-DrugBank.d106.s1|83-85|was|O
DDI-DrugBank.d106.s1|87-95|decreased|O
DDI-DrugBank.d106.s1|97-98|by|O
DDI-DrugBank.d106.s1|100-104|15-20|O
DDI-DrugBank.d106.s1|106-106|%|O
DDI-DrugBank.d106.s1|107-107|)|O
DDI-DrugBank.d106.s1|108-108|.|O
DDI-DrugBank.d106.s2|0-1|No|O
DDI-DrugBank.d106.s2|3-17|pharmacodynamic|O
DDI-DrugBank.d106.s2|19-25|effects|O
DDI-DrugBank.d106.s2|27-28|of|O
DDI-DrugBank.d106.s2|30-35|either|O
DDI-DrugBank.d106.s2|37-68|histamine H2 receptor antagonist|group
DDI-DrugBank.d106.s2|70-73|were|O
DDI-DrugBank.d106.s2|75-82|observed|O
DDI-DrugBank.d106.s2|83-83|.|O
DDI-DrugBank.d106.s3|0-15|Coadministration|O
DDI-DrugBank.d106.s3|17-18|of|O
DDI-DrugBank.d106.s3|20-28|phenytoin|drug
DDI-DrugBank.d106.s3|30-33|with|O
DDI-DrugBank.d106.s3|35-36|40|O
DDI-DrugBank.d106.s3|38-39|mg|O
DDI-DrugBank.d106.s3|41-45|SULAR|brand
DDI-DrugBank.d106.s3|47-53|tablets|O
DDI-DrugBank.d106.s3|55-56|in|O
DDI-DrugBank.d106.s3|58-66|epileptic|O
DDI-DrugBank.d106.s3|68-75|patients|O
DDI-DrugBank.d106.s3|77-83|lowered|O
DDI-DrugBank.d106.s3|85-87|the|O
DDI-DrugBank.d106.s3|89-99|nisoldipine|drug
DDI-DrugBank.d106.s3|101-106|plasma|O
DDI-DrugBank.d106.s3|108-121|concentrations|O
DDI-DrugBank.d106.s3|123-124|to|O
DDI-DrugBank.d106.s3|126-137|undetectable|O
DDI-DrugBank.d106.s3|139-144|levels|O
DDI-DrugBank.d106.s3|145-145|.|O
DDI-DrugBank.d106.s4|0-15|Coadministration|O
DDI-DrugBank.d106.s4|17-18|of|O
DDI-DrugBank.d106.s4|20-24|SULAR|brand
DDI-DrugBank.d106.s4|26-29|with|O
DDI-DrugBank.d106.s4|31-39|phenytoin|drug
DDI-DrugBank.d106.s4|41-42|or|O
DDI-DrugBank.d106.s4|44-46|any|O
DDI-DrugBank.d106.s4|48-52|known|O
DDI-DrugBank.d106.s4|54-59|CYP3A4|O
DDI-DrugBank.d106.s4|61-67|inducer|O
DDI-DrugBank.d106.s4|69-74|should|O
DDI-DrugBank.d106.s4|76-77|be|O
DDI-DrugBank.d106.s4|79-85|avoided|O
DDI-DrugBank.d106.s4|87-89|and|O
DDI-DrugBank.d106.s4|91-101|alternative|O
DDI-DrugBank.d106.s4|103-118|antihypertensive|group
DDI-DrugBank.d106.s4|120-126|therapy|O
DDI-DrugBank.d106.s4|128-133|should|O
DDI-DrugBank.d106.s4|135-136|be|O
DDI-DrugBank.d106.s4|138-147|considered|O
DDI-DrugBank.d106.s4|148-148|.|O
DDI-DrugBank.d106.s5|0-14|Pharmacokinetic|O
DDI-DrugBank.d106.s5|16-27|interactions|O
DDI-DrugBank.d106.s5|29-35|between|O
DDI-DrugBank.d106.s5|37-47|nisoldipine|drug
DDI-DrugBank.d106.s5|49-51|and|O
DDI-DrugBank.d106.s5|53-65|beta-blockers|group
DDI-DrugBank.d106.s5|67-67|(|O
DDI-DrugBank.d106.s5|68-75|atenolol|drug
DDI-DrugBank.d106.s5|76-76|,|O
DDI-DrugBank.d106.s5|78-88|propranolol|drug
DDI-DrugBank.d106.s5|89-89|)|O
DDI-DrugBank.d106.s5|91-94|were|O
DDI-DrugBank.d106.s5|96-103|variable|O
DDI-DrugBank.d106.s5|105-107|and|O
DDI-DrugBank.d106.s5|109-111|not|O
DDI-DrugBank.d106.s5|113-123|significant|O
DDI-DrugBank.d106.s5|124-124|.|O
DDI-DrugBank.d106.s6|0-10|Propranolol|drug
DDI-DrugBank.d106.s6|12-21|attenuated|O
DDI-DrugBank.d106.s6|23-25|the|O
DDI-DrugBank.d106.s6|27-31|heart|O
DDI-DrugBank.d106.s6|33-36|rate|O
DDI-DrugBank.d106.s6|38-45|increase|O
DDI-DrugBank.d106.s6|47-55|following|O
DDI-DrugBank.d106.s6|57-70|administration|O
DDI-DrugBank.d106.s6|72-73|of|O
DDI-DrugBank.d106.s6|75-83|immediate|O
DDI-DrugBank.d106.s6|85-91|release|O
DDI-DrugBank.d106.s6|93-103|nisoldipine|drug
DDI-DrugBank.d106.s6|104-104|.|O
DDI-DrugBank.d106.s7|0-2|The|O
DDI-DrugBank.d106.s7|4-8|blood|O
DDI-DrugBank.d106.s7|10-17|pressure|O
DDI-DrugBank.d106.s7|19-24|effect|O
DDI-DrugBank.d106.s7|26-27|of|O
DDI-DrugBank.d106.s7|29-33|SULAR|brand
DDI-DrugBank.d106.s7|35-40|tended|O
DDI-DrugBank.d106.s7|42-43|to|O
DDI-DrugBank.d106.s7|45-46|be|O
DDI-DrugBank.d106.s7|48-54|greater|O
DDI-DrugBank.d106.s7|56-57|in|O
DDI-DrugBank.d106.s7|59-66|patients|O
DDI-DrugBank.d106.s7|68-69|on|O
DDI-DrugBank.d106.s7|71-78|atenolol|drug
DDI-DrugBank.d106.s7|80-83|than|O
DDI-DrugBank.d106.s7|85-86|in|O
DDI-DrugBank.d106.s7|88-95|patients|O
DDI-DrugBank.d106.s7|97-98|on|O
DDI-DrugBank.d106.s7|100-101|no|O
DDI-DrugBank.d106.s7|103-107|other|O
DDI-DrugBank.d106.s7|109-124|antihypertensive|group
DDI-DrugBank.d106.s7|126-132|therapy|O
DDI-DrugBank.d106.s7|133-133|.|O
DDI-DrugBank.d106.s8|0-8|Quinidine|drug
DDI-DrugBank.d106.s8|10-11|at|O
DDI-DrugBank.d106.s8|13-15|648|O
DDI-DrugBank.d106.s8|17-18|mg|O
DDI-DrugBank.d106.s8|20-22|bid|O
DDI-DrugBank.d106.s8|24-32|decreased|O
DDI-DrugBank.d106.s8|34-36|the|O
DDI-DrugBank.d106.s8|38-52|bioavailability|O
DDI-DrugBank.d106.s8|54-54|(|O
DDI-DrugBank.d106.s8|55-57|AUC|O
DDI-DrugBank.d106.s8|58-58|)|O
DDI-DrugBank.d106.s8|60-61|of|O
DDI-DrugBank.d106.s8|63-73|nisoldipine|drug
DDI-DrugBank.d106.s8|75-76|by|O
DDI-DrugBank.d106.s8|78-79|26|O
DDI-DrugBank.d106.s8|80-80|%|O
DDI-DrugBank.d106.s8|81-81|,|O
DDI-DrugBank.d106.s8|83-85|but|O
DDI-DrugBank.d106.s8|87-89|not|O
DDI-DrugBank.d106.s8|91-93|the|O
DDI-DrugBank.d106.s8|95-98|peak|O
DDI-DrugBank.d106.s8|100-112|concentration|O
DDI-DrugBank.d106.s8|113-113|.|O
DDI-DrugBank.d106.s9|0-2|The|O
DDI-DrugBank.d106.s9|4-12|immediate|O
DDI-DrugBank.d106.s9|14-20|release|O
DDI-DrugBank.d106.s9|21-21|,|O
DDI-DrugBank.d106.s9|23-25|but|O
DDI-DrugBank.d106.s9|27-29|not|O
DDI-DrugBank.d106.s9|31-33|the|O
DDI-DrugBank.d106.s9|35-43|coat-core|O
DDI-DrugBank.d106.s9|45-55|formulation|O
DDI-DrugBank.d106.s9|57-58|of|O
DDI-DrugBank.d106.s9|60-70|nisoldipine|drug
DDI-DrugBank.d106.s9|72-80|increased|O
DDI-DrugBank.d106.s9|82-87|plasma|O
DDI-DrugBank.d106.s9|89-97|quinidine|drug
DDI-DrugBank.d106.s9|99-112|concentrations|O
DDI-DrugBank.d106.s9|114-115|by|O
DDI-DrugBank.d106.s9|117-121|about|O
DDI-DrugBank.d106.s9|123-124|20|O
DDI-DrugBank.d106.s9|125-125|%|O
DDI-DrugBank.d106.s9|126-126|.|O
DDI-DrugBank.d106.s10|0-3|This|O
DDI-DrugBank.d106.s10|5-15|interaction|O
DDI-DrugBank.d106.s10|17-19|was|O
DDI-DrugBank.d106.s10|21-23|not|O
DDI-DrugBank.d106.s10|25-35|accompanied|O
DDI-DrugBank.d106.s10|37-38|by|O
DDI-DrugBank.d106.s10|40-42|ECG|O
DDI-DrugBank.d106.s10|44-50|changes|O
DDI-DrugBank.d106.s10|52-54|and|O
DDI-DrugBank.d106.s10|56-58|its|O
DDI-DrugBank.d106.s10|60-67|clinical|O
DDI-DrugBank.d106.s10|69-80|significance|O
DDI-DrugBank.d106.s10|82-83|is|O
DDI-DrugBank.d106.s10|85-87|not|O
DDI-DrugBank.d106.s10|89-93|known|O
DDI-DrugBank.d106.s10|94-94|.|O
DDI-DrugBank.d106.s11|0-1|No|O
DDI-DrugBank.d106.s11|3-13|significant|O
DDI-DrugBank.d106.s11|15-26|interactions|O
DDI-DrugBank.d106.s11|28-31|were|O
DDI-DrugBank.d106.s11|33-37|found|O
DDI-DrugBank.d106.s11|39-45|between|O
DDI-DrugBank.d106.s11|47-57|nisoldipine|drug
DDI-DrugBank.d106.s11|59-61|and|O
DDI-DrugBank.d106.s11|63-70|warfarin|drug
DDI-DrugBank.d106.s11|72-73|or|O
DDI-DrugBank.d106.s11|75-81|digoxin|drug
DDI-DrugBank.d106.s11|82-82|.|O
DDI-DrugBank.d299.s0|0-21|Ergot-Containing Drugs|group
DDI-DrugBank.d299.s0|22-22|:|O
DDI-DrugBank.d299.s0|24-28|These|O
DDI-DrugBank.d299.s0|30-34|drugs|O
DDI-DrugBank.d299.s0|36-39|have|O
DDI-DrugBank.d299.s0|41-44|been|O
DDI-DrugBank.d299.s0|46-53|reported|O
DDI-DrugBank.d299.s0|55-56|to|O
DDI-DrugBank.d299.s0|58-62|cause|O
DDI-DrugBank.d299.s0|64-72|prolonged|O
DDI-DrugBank.d299.s0|74-84|vasospastic|O
DDI-DrugBank.d299.s0|86-94|reactions|O
DDI-DrugBank.d299.s0|95-95|.|O
DDI-DrugBank.d299.s1|0-6|Because|O
DDI-DrugBank.d299.s1|8-12|there|O
DDI-DrugBank.d299.s1|14-15|is|O
DDI-DrugBank.d299.s1|17-17|a|O
DDI-DrugBank.d299.s1|19-29|theoretical|O
DDI-DrugBank.d299.s1|31-35|basis|O
DDI-DrugBank.d299.s1|37-40|that|O
DDI-DrugBank.d299.s1|42-46|these|O
DDI-DrugBank.d299.s1|48-54|effects|O
DDI-DrugBank.d299.s1|56-58|may|O
DDI-DrugBank.d299.s1|60-61|be|O
DDI-DrugBank.d299.s1|63-70|additive|O
DDI-DrugBank.d299.s1|71-71|,|O
DDI-DrugBank.d299.s1|73-75|use|O
DDI-DrugBank.d299.s1|77-78|of|O
DDI-DrugBank.d299.s1|80-100|ergotamine-containing|drug
DDI-DrugBank.d299.s1|102-103|or|O
DDI-DrugBank.d299.s1|105-126|ergot-type medications|group
DDI-DrugBank.d299.s1|128-128|(|O
DDI-DrugBank.d299.s1|129-132|like|O
DDI-DrugBank.d299.s1|134-150|dihydroergotamine|drug
DDI-DrugBank.d299.s1|152-153|or|O
DDI-DrugBank.d299.s1|155-166|methysergide|drug
DDI-DrugBank.d299.s1|167-167|)|O
DDI-DrugBank.d299.s1|169-171|and|O
DDI-DrugBank.d299.s1|173-177|AXERT|brand
DDI-DrugBank.d299.s1|179-184|within|O
DDI-DrugBank.d299.s1|186-187|24|O
DDI-DrugBank.d299.s1|189-193|hours|O
DDI-DrugBank.d299.s1|195-196|of|O
DDI-DrugBank.d299.s1|198-201|each|O
DDI-DrugBank.d299.s1|203-207|other|O
DDI-DrugBank.d299.s1|209-214|should|O
DDI-DrugBank.d299.s1|216-217|be|O
DDI-DrugBank.d299.s1|219-225|avoided|O
DDI-DrugBank.d299.s1|226-226|.|O
DDI-DrugBank.d299.s2|0-27|Monoamine Oxidase Inhibitors|group
DDI-DrugBank.d299.s2|28-28|:|O
DDI-DrugBank.d299.s2|30-45|Coadministration|O
DDI-DrugBank.d299.s2|47-48|of|O
DDI-DrugBank.d299.s2|50-60|moclobemide|drug
DDI-DrugBank.d299.s2|62-69|resulted|O
DDI-DrugBank.d299.s2|71-72|in|O
DDI-DrugBank.d299.s2|74-74|a|O
DDI-DrugBank.d299.s2|76-77|27|O
DDI-DrugBank.d299.s2|78-78|%|O
DDI-DrugBank.d299.s2|80-87|decrease|O
DDI-DrugBank.d299.s2|89-90|in|O
DDI-DrugBank.d299.s2|92-102|almotriptan|drug
DDI-DrugBank.d299.s2|104-112|clearance|O
DDI-DrugBank.d299.s2|114-116|and|O
DDI-DrugBank.d299.s2|118-119|an|O
DDI-DrugBank.d299.s2|121-128|increase|O
DDI-DrugBank.d299.s2|130-131|in|O
DDI-DrugBank.d299.s2|133-136|Cmax|O
DDI-DrugBank.d299.s2|138-139|of|O
DDI-DrugBank.d299.s2|141-153|approximately|O
DDI-DrugBank.d299.s2|155-155|6|O
DDI-DrugBank.d299.s2|156-156|%|O
DDI-DrugBank.d299.s2|157-157|.|O
DDI-DrugBank.d299.s3|0-1|No|O
DDI-DrugBank.d299.s3|3-6|dose|O
DDI-DrugBank.d299.s3|8-17|adjustment|O
DDI-DrugBank.d299.s3|19-20|is|O
DDI-DrugBank.d299.s3|22-30|necessary|O
DDI-DrugBank.d299.s3|31-31|.|O
DDI-DrugBank.d299.s4|0-4|Other|O
DDI-DrugBank.d299.s4|6-23|5-HT1B/1D Agonists|group
DDI-DrugBank.d299.s4|25-35|Concomitant|O
DDI-DrugBank.d299.s4|37-39|use|O
DDI-DrugBank.d299.s4|41-42|of|O
DDI-DrugBank.d299.s4|44-48|other|O
DDI-DrugBank.d299.s4|50-67|5-HT1B/1D agonists|group
DDI-DrugBank.d299.s4|69-74|within|O
DDI-DrugBank.d299.s4|76-77|24|O
DDI-DrugBank.d299.s4|79-83|hours|O
DDI-DrugBank.d299.s4|85-86|of|O
DDI-DrugBank.d299.s4|88-96|treatment|O
DDI-DrugBank.d299.s4|98-101|with|O
DDI-DrugBank.d299.s4|103-107|AXERT|brand
DDI-DrugBank.d299.s4|109-110|is|O
DDI-DrugBank.d299.s4|112-126|contraindicated|O
DDI-DrugBank.d299.s4|127-127|.|O
DDI-DrugBank.d299.s5|0-9|Propanolol|drug
DDI-DrugBank.d299.s5|10-10|:|O
DDI-DrugBank.d299.s5|12-14|The|O
DDI-DrugBank.d299.s5|16-31|pharmacokinetics|O
DDI-DrugBank.d299.s5|33-34|of|O
DDI-DrugBank.d299.s5|36-46|almotriptan|drug
DDI-DrugBank.d299.s5|48-51|were|O
DDI-DrugBank.d299.s5|53-55|not|O
DDI-DrugBank.d299.s5|57-64|affected|O
DDI-DrugBank.d299.s5|66-67|by|O
DDI-DrugBank.d299.s5|69-84|coadministration|O
DDI-DrugBank.d299.s5|86-87|of|O
DDI-DrugBank.d299.s5|89-99|propranolol|drug
DDI-DrugBank.d299.s5|100-100|.|O
DDI-DrugBank.d299.s6|0-38|Selective Serotonin Reuptake Inhibitors|group
DDI-DrugBank.d299.s6|40-40|(|O
DDI-DrugBank.d299.s6|41-45|SSRIs|group
DDI-DrugBank.d299.s6|46-46|)|O
DDI-DrugBank.d299.s6|47-47|:|O
DDI-DrugBank.d299.s6|49-53|SSRIs|group
DDI-DrugBank.d299.s6|55-55|(|O
DDI-DrugBank.d299.s6|56-59|e.g.|O
DDI-DrugBank.d299.s6|60-60|,|O
DDI-DrugBank.d299.s6|62-71|fluoxetine|drug
DDI-DrugBank.d299.s6|72-72|,|O
DDI-DrugBank.d299.s6|74-84|fluvoxamine|drug
DDI-DrugBank.d299.s6|85-85|,|O
DDI-DrugBank.d299.s6|87-96|paroxetine|drug
DDI-DrugBank.d299.s6|97-97|,|O
DDI-DrugBank.d299.s6|99-108|sertraline|drug
DDI-DrugBank.d299.s6|109-109|)|O
DDI-DrugBank.d299.s6|111-114|have|O
DDI-DrugBank.d299.s6|116-119|been|O
DDI-DrugBank.d299.s6|121-126|rarely|O
DDI-DrugBank.d299.s6|128-135|reported|O
DDI-DrugBank.d299.s6|137-138|to|O
DDI-DrugBank.d299.s6|140-144|cause|O
DDI-DrugBank.d299.s6|146-153|weakness|O
DDI-DrugBank.d299.s6|154-154|,|O
DDI-DrugBank.d299.s6|156-168|hyperreflexia|O
DDI-DrugBank.d299.s6|169-169|,|O
DDI-DrugBank.d299.s6|171-173|and|O
DDI-DrugBank.d299.s6|175-188|incoordination|O
DDI-DrugBank.d299.s6|190-193|when|O
DDI-DrugBank.d299.s6|195-208|coadministered|O
DDI-DrugBank.d299.s6|210-213|with|O
DDI-DrugBank.d299.s6|215-228|5-HT1 agonists|group
DDI-DrugBank.d299.s6|229-229|.|O
DDI-DrugBank.d299.s7|0-1|If|O
DDI-DrugBank.d299.s7|3-13|concomitant|O
DDI-DrugBank.d299.s7|15-23|treatment|O
DDI-DrugBank.d299.s7|25-28|with|O
DDI-DrugBank.d299.s7|30-34|AXERT|brand
DDI-DrugBank.d299.s7|36-38|and|O
DDI-DrugBank.d299.s7|40-41|an|O
DDI-DrugBank.d299.s7|43-46|SSRI|group
DDI-DrugBank.d299.s7|48-49|is|O
DDI-DrugBank.d299.s7|51-60|clinically|O
DDI-DrugBank.d299.s7|62-70|warranted|O
DDI-DrugBank.d299.s7|71-71|,|O
DDI-DrugBank.d299.s7|73-83|appropriate|O
DDI-DrugBank.d299.s7|85-95|observation|O
DDI-DrugBank.d299.s7|97-98|of|O
DDI-DrugBank.d299.s7|100-102|the|O
DDI-DrugBank.d299.s7|104-110|patient|O
DDI-DrugBank.d299.s7|112-113|is|O
DDI-DrugBank.d299.s7|115-121|advised|O
DDI-DrugBank.d299.s7|122-122|.|O
DDI-DrugBank.d299.s8|0-8|Verapamil|drug
DDI-DrugBank.d299.s8|9-9|:|O
DDI-DrugBank.d299.s8|11-26|Coadministration|O
DDI-DrugBank.d299.s8|28-29|of|O
DDI-DrugBank.d299.s8|31-41|almotriptan|drug
DDI-DrugBank.d299.s8|43-45|and|O
DDI-DrugBank.d299.s8|47-55|verapamil|drug
DDI-DrugBank.d299.s8|57-64|resulted|O
DDI-DrugBank.d299.s8|66-67|in|O
DDI-DrugBank.d299.s8|69-69|a|O
DDI-DrugBank.d299.s8|71-72|24|O
DDI-DrugBank.d299.s8|73-73|%|O
DDI-DrugBank.d299.s8|75-82|increase|O
DDI-DrugBank.d299.s8|84-85|in|O
DDI-DrugBank.d299.s8|87-92|plasma|O
DDI-DrugBank.d299.s8|94-107|concentrations|O
DDI-DrugBank.d299.s8|109-110|of|O
DDI-DrugBank.d299.s8|112-122|almotriptan|drug
DDI-DrugBank.d299.s8|123-123|.|O
DDI-DrugBank.d299.s9|0-1|No|O
DDI-DrugBank.d299.s9|3-6|dose|O
DDI-DrugBank.d299.s9|8-17|adjustment|O
DDI-DrugBank.d299.s9|19-20|is|O
DDI-DrugBank.d299.s9|22-30|necessary|O
DDI-DrugBank.d299.s9|31-31|.|O
DDI-DrugBank.d299.s10|0-15|Coadministration|O
DDI-DrugBank.d299.s10|17-18|of|O
DDI-DrugBank.d299.s10|20-30|almotriptan|drug
DDI-DrugBank.d299.s10|32-34|and|O
DDI-DrugBank.d299.s10|36-38|the|O
DDI-DrugBank.d299.s10|40-45|potent|O
DDI-DrugBank.d299.s10|47-52|CYP3A4|O
DDI-DrugBank.d299.s10|54-62|inhibitor|O
DDI-DrugBank.d299.s10|64-75|ketoconazole|drug
DDI-DrugBank.d299.s10|77-77|(|O
DDI-DrugBank.d299.s10|78-80|400|O
DDI-DrugBank.d299.s10|82-83|mg|O
DDI-DrugBank.d299.s10|85-88|q.d.|O
DDI-DrugBank.d299.s10|90-92|for|O
DDI-DrugBank.d299.s10|94-94|3|O
DDI-DrugBank.d299.s10|96-99|days|O
DDI-DrugBank.d299.s10|100-100|)|O
DDI-DrugBank.d299.s10|102-109|resulted|O
DDI-DrugBank.d299.s10|111-112|in|O
DDI-DrugBank.d299.s10|114-115|an|O
DDI-DrugBank.d299.s10|117-129|approximately|O
DDI-DrugBank.d299.s10|131-132|60|O
DDI-DrugBank.d299.s10|133-133|%|O
DDI-DrugBank.d299.s10|135-142|increase|O
DDI-DrugBank.d299.s10|144-145|in|O
DDI-DrugBank.d299.s10|147-149|the|O
DDI-DrugBank.d299.s10|151-154|area|O
DDI-DrugBank.d299.s10|156-160|under|O
DDI-DrugBank.d299.s10|162-164|the|O
DDI-DrugBank.d299.s10|166-171|plasma|O
DDI-DrugBank.d299.s10|173-190|concentration-time|O
DDI-DrugBank.d299.s10|192-196|curve|O
DDI-DrugBank.d299.s10|198-200|and|O
DDI-DrugBank.d299.s10|202-208|maximal|O
DDI-DrugBank.d299.s10|210-215|plasma|O
DDI-DrugBank.d299.s10|217-230|concentrations|O
DDI-DrugBank.d299.s10|232-233|of|O
DDI-DrugBank.d299.s10|235-245|almotriptan|drug
DDI-DrugBank.d299.s10|246-246|.|O
DDI-DrugBank.d299.s11|0-7|Although|O
DDI-DrugBank.d299.s11|9-11|the|O
DDI-DrugBank.d299.s11|13-23|interaction|O
DDI-DrugBank.d299.s11|25-31|between|O
DDI-DrugBank.d299.s11|33-43|almotriptan|drug
DDI-DrugBank.d299.s11|45-47|and|O
DDI-DrugBank.d299.s11|49-53|other|O
DDI-DrugBank.d299.s11|55-60|potent|O
DDI-DrugBank.d299.s11|62-67|CYP3A4|O
DDI-DrugBank.d299.s11|69-78|inhibitors|O
DDI-DrugBank.d299.s11|80-80|(|O
DDI-DrugBank.d299.s11|81-84|e.g.|O
DDI-DrugBank.d299.s11|85-85|,|O
DDI-DrugBank.d299.s11|87-98|itraconazole|drug
DDI-DrugBank.d299.s11|99-99|,|O
DDI-DrugBank.d299.s11|101-109|ritonavir|drug
DDI-DrugBank.d299.s11|110-110|,|O
DDI-DrugBank.d299.s11|112-114|and|O
DDI-DrugBank.d299.s11|116-127|erythromycin|drug
DDI-DrugBank.d299.s11|128-128|)|O
DDI-DrugBank.d299.s11|130-132|has|O
DDI-DrugBank.d299.s11|134-136|not|O
DDI-DrugBank.d299.s11|138-141|been|O
DDI-DrugBank.d299.s11|143-149|studied|O
DDI-DrugBank.d299.s11|150-150|,|O
DDI-DrugBank.d299.s11|152-160|increased|O
DDI-DrugBank.d299.s11|162-170|exposures|O
DDI-DrugBank.d299.s11|172-173|to|O
DDI-DrugBank.d299.s11|175-185|almotriptan|drug
DDI-DrugBank.d299.s11|187-189|may|O
DDI-DrugBank.d299.s11|191-192|be|O
DDI-DrugBank.d299.s11|194-201|expected|O
DDI-DrugBank.d299.s11|203-206|when|O
DDI-DrugBank.d299.s11|208-218|almotriptan|drug
DDI-DrugBank.d299.s11|220-221|is|O
DDI-DrugBank.d299.s11|223-226|used|O
DDI-DrugBank.d299.s11|228-240|concomitantly|O
DDI-DrugBank.d299.s11|242-245|with|O
DDI-DrugBank.d299.s11|247-251|these|O
DDI-DrugBank.d299.s11|253-263|medications|O
DDI-DrugBank.d299.s11|264-264|.|O
DDI-DrugBank.d299.s12|0-4|AXERT|brand
DDI-DrugBank.d299.s12|6-7|is|O
DDI-DrugBank.d299.s12|9-11|not|O
DDI-DrugBank.d299.s12|13-17|known|O
DDI-DrugBank.d299.s12|19-20|to|O
DDI-DrugBank.d299.s12|22-30|interfere|O
DDI-DrugBank.d299.s12|32-35|with|O
DDI-DrugBank.d299.s12|37-44|commonly|O
DDI-DrugBank.d299.s12|46-53|employed|O
DDI-DrugBank.d299.s12|55-62|clinical|O
DDI-DrugBank.d299.s12|64-73|laboratory|O
DDI-DrugBank.d299.s12|75-79|tests|O
DDI-DrugBank.d299.s12|80-80|.|O
DDI-DrugBank.d200.s0|0-16|Co-administration|O
DDI-DrugBank.d200.s0|18-19|of|O
DDI-DrugBank.d200.s0|21-30|probenecid|drug
DDI-DrugBank.d200.s0|32-35|with|O
DDI-DrugBank.d200.s0|37-45|acyclovir|drug
DDI-DrugBank.d200.s0|47-49|has|O
DDI-DrugBank.d200.s0|51-54|been|O
DDI-DrugBank.d200.s0|56-60|shown|O
DDI-DrugBank.d200.s0|62-63|to|O
DDI-DrugBank.d200.s0|65-72|increase|O
DDI-DrugBank.d200.s0|74-76|the|O
DDI-DrugBank.d200.s0|78-81|mean|O
DDI-DrugBank.d200.s0|83-91|half-life|O
DDI-DrugBank.d200.s0|93-95|and|O
DDI-DrugBank.d200.s0|97-99|the|O
DDI-DrugBank.d200.s0|101-104|area|O
DDI-DrugBank.d200.s0|106-110|under|O
DDI-DrugBank.d200.s0|112-114|the|O
DDI-DrugBank.d200.s0|116-133|concentration-time|O
DDI-DrugBank.d200.s0|135-139|curve|O
DDI-DrugBank.d200.s0|140-140|.|O
DDI-DrugBank.d200.s1|0-6|Urinary|O
DDI-DrugBank.d200.s1|8-16|excretion|O
DDI-DrugBank.d200.s1|18-20|and|O
DDI-DrugBank.d200.s1|22-26|renal|O
DDI-DrugBank.d200.s1|28-36|clearance|O
DDI-DrugBank.d200.s1|38-41|were|O
DDI-DrugBank.d200.s1|43-57|correspondingly|O
DDI-DrugBank.d200.s1|59-65|reduced|O
DDI-DrugBank.d200.s1|66-66|.|O
DDI-DrugBank.d200.s2|0-2|The|O
DDI-DrugBank.d200.s2|4-11|clinical|O
DDI-DrugBank.d200.s2|13-19|effects|O
DDI-DrugBank.d200.s2|21-22|of|O
DDI-DrugBank.d200.s2|24-27|this|O
DDI-DrugBank.d200.s2|29-39|combination|O
DDI-DrugBank.d200.s2|41-44|have|O
DDI-DrugBank.d200.s2|46-48|not|O
DDI-DrugBank.d200.s2|50-53|been|O
DDI-DrugBank.d200.s2|55-61|studied|O
DDI-DrugBank.d200.s2|62-62|.|O
DDI-DrugBank.d555.s0|0-1|No|O
DDI-DrugBank.d555.s0|3-13|information|O
DDI-DrugBank.d555.s0|15-23|available|O
DDI-DrugBank.d555.s1|0-0|.|O
DDI-DrugBank.d438.s0|0-1|In|O
DDI-DrugBank.d438.s0|3-7|vitro|O
DDI-DrugBank.d438.s0|9-15|studies|O
DDI-DrugBank.d438.s0|17-20|were|O
DDI-DrugBank.d438.s0|22-30|conducted|O
DDI-DrugBank.d438.s0|32-33|to|O
DDI-DrugBank.d438.s0|35-45|investigate|O
DDI-DrugBank.d438.s0|47-49|the|O
DDI-DrugBank.d438.s0|51-59|potential|O
DDI-DrugBank.d438.s0|61-62|of|O
DDI-DrugBank.d438.s0|64-73|gabapentin|drug
DDI-DrugBank.d438.s0|75-76|to|O
DDI-DrugBank.d438.s0|78-84|inhibit|O
DDI-DrugBank.d438.s0|86-88|the|O
DDI-DrugBank.d438.s0|90-94|major|O
DDI-DrugBank.d438.s0|96-105|cytochrome|O
DDI-DrugBank.d438.s0|107-110|P450|O
DDI-DrugBank.d438.s0|112-118|enzymes|O
DDI-DrugBank.d438.s0|120-120|(|O
DDI-DrugBank.d438.s0|121-126|CYP1A2|O
DDI-DrugBank.d438.s0|127-127|,|O
DDI-DrugBank.d438.s0|129-134|CYP2A6|O
DDI-DrugBank.d438.s0|135-135|,|O
DDI-DrugBank.d438.s0|137-142|CYP2C9|O
DDI-DrugBank.d438.s0|143-143|,|O
DDI-DrugBank.d438.s0|145-151|CYP2C19|O
DDI-DrugBank.d438.s0|152-152|,|O
DDI-DrugBank.d438.s0|154-159|CYP2D6|O
DDI-DrugBank.d438.s0|160-160|,|O
DDI-DrugBank.d438.s0|162-167|CYP2E1|O
DDI-DrugBank.d438.s0|168-168|,|O
DDI-DrugBank.d438.s0|170-172|and|O
DDI-DrugBank.d438.s0|174-179|CYP3A4|O
DDI-DrugBank.d438.s0|180-180|)|O
DDI-DrugBank.d438.s0|182-185|that|O
DDI-DrugBank.d438.s0|187-193|mediate|O
DDI-DrugBank.d438.s0|195-198|drug|O
DDI-DrugBank.d438.s0|200-202|and|O
DDI-DrugBank.d438.s0|204-213|xenobiotic|O
DDI-DrugBank.d438.s0|215-224|metabolism|O
DDI-DrugBank.d438.s0|226-230|using|O
DDI-DrugBank.d438.s0|232-238|isoform|O
DDI-DrugBank.d438.s0|240-248|selective|O
DDI-DrugBank.d438.s0|250-255|marker|O
DDI-DrugBank.d438.s0|257-266|substrates|O
DDI-DrugBank.d438.s0|268-270|and|O
DDI-DrugBank.d438.s0|272-276|human|O
DDI-DrugBank.d438.s0|278-282|liver|O
DDI-DrugBank.d438.s0|284-293|microsomal|O
DDI-DrugBank.d438.s0|295-306|preparations|O
DDI-DrugBank.d438.s0|307-307|.|O
DDI-DrugBank.d438.s1|0-3|Only|O
DDI-DrugBank.d438.s1|5-6|at|O
DDI-DrugBank.d438.s1|8-10|the|O
DDI-DrugBank.d438.s1|12-18|highest|O
DDI-DrugBank.d438.s1|20-32|concentration|O
DDI-DrugBank.d438.s1|34-39|tested|O
DDI-DrugBank.d438.s1|41-41|(|O
DDI-DrugBank.d438.s1|42-44|171|O
DDI-DrugBank.d438.s2|0-3|g/mL|O
DDI-DrugBank.d438.s2|4-4|;|O
DDI-DrugBank.d438.s3|0-0|1|O
DDI-DrugBank.d438.s3|2-3|mM|O
DDI-DrugBank.d438.s3|4-4|)|O
DDI-DrugBank.d438.s3|6-8|was|O
DDI-DrugBank.d438.s3|10-10|a|O
DDI-DrugBank.d438.s3|12-17|slight|O
DDI-DrugBank.d438.s3|19-24|degree|O
DDI-DrugBank.d438.s3|26-27|of|O
DDI-DrugBank.d438.s3|29-38|inhibition|O
DDI-DrugBank.d438.s3|40-40|(|O
DDI-DrugBank.d438.s3|41-42|14|O
DDI-DrugBank.d438.s3|43-43|%|O
DDI-DrugBank.d438.s3|44-46|-30|O
DDI-DrugBank.d438.s3|47-47|%|O
DDI-DrugBank.d438.s3|48-48|)|O
DDI-DrugBank.d438.s3|50-51|of|O
DDI-DrugBank.d438.s3|53-59|isoform|O
DDI-DrugBank.d438.s3|61-66|CYP2A6|O
DDI-DrugBank.d438.s3|68-75|observed|O
DDI-DrugBank.d438.s3|76-76|.|O
DDI-DrugBank.d438.s4|0-1|No|O
DDI-DrugBank.d438.s4|3-12|inhibition|O
DDI-DrugBank.d438.s4|14-15|of|O
DDI-DrugBank.d438.s4|17-19|any|O
DDI-DrugBank.d438.s4|21-22|of|O
DDI-DrugBank.d438.s4|24-26|the|O
DDI-DrugBank.d438.s4|28-32|other|O
DDI-DrugBank.d438.s4|34-41|isoforms|O
DDI-DrugBank.d438.s4|43-48|tested|O
DDI-DrugBank.d438.s4|50-52|was|O
DDI-DrugBank.d438.s4|54-61|observed|O
DDI-DrugBank.d438.s4|63-64|at|O
DDI-DrugBank.d438.s4|66-75|gabapentin|drug
DDI-DrugBank.d438.s4|77-90|concentrations|O
DDI-DrugBank.d438.s4|92-93|up|O
DDI-DrugBank.d438.s4|95-96|to|O
DDI-DrugBank.d438.s4|98-100|171|O
DDI-DrugBank.d438.s4|102-106|mg/mL|O
DDI-DrugBank.d438.s4|108-108|(|O
DDI-DrugBank.d438.s4|109-121|approximately|O
DDI-DrugBank.d438.s4|123-124|15|O
DDI-DrugBank.d438.s4|126-130|times|O
DDI-DrugBank.d438.s4|132-134|the|O
DDI-DrugBank.d438.s4|136-139|Cmax|O
DDI-DrugBank.d438.s4|141-142|at|O
DDI-DrugBank.d438.s4|144-147|3600|O
DDI-DrugBank.d438.s4|149-154|mg/day|O
DDI-DrugBank.d438.s4|155-155|)|O
DDI-DrugBank.d438.s4|156-156|.|O
DDI-DrugBank.d438.s5|0-9|Gabapentin|drug
DDI-DrugBank.d438.s5|11-12|is|O
DDI-DrugBank.d438.s5|14-16|not|O
DDI-DrugBank.d438.s5|18-28|appreciably|O
DDI-DrugBank.d438.s5|30-40|metabolized|O
DDI-DrugBank.d438.s5|42-44|nor|O
DDI-DrugBank.d438.s5|46-49|does|O
DDI-DrugBank.d438.s5|51-52|it|O
DDI-DrugBank.d438.s5|54-62|interfere|O
DDI-DrugBank.d438.s5|64-67|with|O
DDI-DrugBank.d438.s5|69-71|the|O
DDI-DrugBank.d438.s5|73-82|metabolism|O
DDI-DrugBank.d438.s5|84-85|of|O
DDI-DrugBank.d438.s5|87-94|commonly|O
DDI-DrugBank.d438.s5|96-109|coadministered|O
DDI-DrugBank.d438.s5|111-129|antiepileptic drugs|group
DDI-DrugBank.d438.s5|130-130|.|O
DDI-DrugBank.d438.s6|0-2|The|O
DDI-DrugBank.d438.s6|4-7|drug|O
DDI-DrugBank.d438.s6|9-19|interaction|O
DDI-DrugBank.d438.s6|21-24|data|O
DDI-DrugBank.d438.s6|26-34|described|O
DDI-DrugBank.d438.s6|36-37|in|O
DDI-DrugBank.d438.s6|39-42|this|O
DDI-DrugBank.d438.s6|44-50|section|O
DDI-DrugBank.d438.s6|52-55|were|O
DDI-DrugBank.d438.s6|57-64|obtained|O
DDI-DrugBank.d438.s6|66-69|from|O
DDI-DrugBank.d438.s6|71-77|studies|O
DDI-DrugBank.d438.s6|79-87|involving|O
DDI-DrugBank.d438.s6|89-95|healthy|O
DDI-DrugBank.d438.s6|97-102|adults|O
DDI-DrugBank.d438.s6|104-106|and|O
DDI-DrugBank.d438.s6|108-112|adult|O
DDI-DrugBank.d438.s6|114-121|patients|O
DDI-DrugBank.d438.s6|123-126|with|O
DDI-DrugBank.d438.s6|128-135|epilepsy|O
DDI-DrugBank.d438.s6|136-136|.|O
DDI-DrugBank.d438.s7|0-8|Phenytoin|drug
DDI-DrugBank.d438.s7|9-9|:|O
DDI-DrugBank.d438.s7|11-12|In|O
DDI-DrugBank.d438.s7|14-14|a|O
DDI-DrugBank.d438.s7|16-21|single|O
DDI-DrugBank.d438.s7|23-23|(|O
DDI-DrugBank.d438.s7|24-26|400|O
DDI-DrugBank.d438.s7|28-29|mg|O
DDI-DrugBank.d438.s7|30-30|)|O
DDI-DrugBank.d438.s7|32-34|and|O
DDI-DrugBank.d438.s7|36-43|multiple|O
DDI-DrugBank.d438.s7|45-48|dose|O
DDI-DrugBank.d438.s7|50-50|(|O
DDI-DrugBank.d438.s7|51-53|400|O
DDI-DrugBank.d438.s7|55-56|mg|O
DDI-DrugBank.d438.s7|58-60|TID|O
DDI-DrugBank.d438.s7|61-61|)|O
DDI-DrugBank.d438.s7|63-67|study|O
DDI-DrugBank.d438.s7|69-70|of|O
DDI-DrugBank.d438.s7|72-80|Neurontin|brand
DDI-DrugBank.d438.s7|82-83|in|O
DDI-DrugBank.d438.s7|85-93|epileptic|O
DDI-DrugBank.d438.s7|95-102|patients|O
DDI-DrugBank.d438.s7|104-104|(|O
DDI-DrugBank.d438.s7|105-107|N=8|O
DDI-DrugBank.d438.s7|108-108|)|O
DDI-DrugBank.d438.s7|110-119|maintained|O
DDI-DrugBank.d438.s7|121-122|on|O
DDI-DrugBank.d438.s7|124-132|phenytoin|drug
DDI-DrugBank.d438.s7|134-144|monotherapy|O
DDI-DrugBank.d438.s7|146-148|for|O
DDI-DrugBank.d438.s7|150-151|at|O
DDI-DrugBank.d438.s7|153-157|least|O
DDI-DrugBank.d438.s7|159-159|2|O
DDI-DrugBank.d438.s7|161-166|months|O
DDI-DrugBank.d438.s7|167-167|,|O
DDI-DrugBank.d438.s7|169-178|gabapentin|drug
DDI-DrugBank.d438.s7|180-182|had|O
DDI-DrugBank.d438.s7|184-185|no|O
DDI-DrugBank.d438.s7|187-192|effect|O
DDI-DrugBank.d438.s7|194-195|on|O
DDI-DrugBank.d438.s7|197-199|the|O
DDI-DrugBank.d438.s7|201-212|steady-state|O
DDI-DrugBank.d438.s7|214-219|trough|O
DDI-DrugBank.d438.s7|221-226|plasma|O
DDI-DrugBank.d438.s7|228-241|concentrations|O
DDI-DrugBank.d438.s7|243-244|of|O
DDI-DrugBank.d438.s7|246-254|phenytoin|drug
DDI-DrugBank.d438.s7|256-258|and|O
DDI-DrugBank.d438.s7|260-268|phenytoin|drug
DDI-DrugBank.d438.s7|270-272|had|O
DDI-DrugBank.d438.s7|274-275|no|O
DDI-DrugBank.d438.s7|277-282|effect|O
DDI-DrugBank.d438.s7|284-285|on|O
DDI-DrugBank.d438.s7|287-296|gabapentin|drug
DDI-DrugBank.d438.s7|298-313|pharmacokinetics|O
DDI-DrugBank.d438.s7|314-314|.|O
DDI-DrugBank.d438.s8|0-12|Carbamazepine|drug
DDI-DrugBank.d438.s8|13-13|:|O
DDI-DrugBank.d438.s8|15-26|Steady-state|O
DDI-DrugBank.d438.s8|28-33|trough|O
DDI-DrugBank.d438.s8|35-40|plasma|O
DDI-DrugBank.d438.s8|42-54|carbamazepine|drug
DDI-DrugBank.d438.s8|56-58|and|O
DDI-DrugBank.d438.s8|89-102|concentrations|O
DDI-DrugBank.d438.s8|104-107|were|O
DDI-DrugBank.d438.s8|109-111|not|O
DDI-DrugBank.d438.s8|113-120|affected|O
DDI-DrugBank.d438.s8|122-123|by|O
DDI-DrugBank.d438.s8|125-135|concomitant|O
DDI-DrugBank.d438.s8|137-146|gabapentin|drug
DDI-DrugBank.d438.s8|148-148|(|O
DDI-DrugBank.d438.s8|149-151|400|O
DDI-DrugBank.d438.s8|153-154|mg|O
DDI-DrugBank.d438.s8|156-158|TID|O
DDI-DrugBank.d438.s8|159-159|;|O
DDI-DrugBank.d438.s9|0-3|N=12|O
DDI-DrugBank.d438.s9|4-4|)|O
DDI-DrugBank.d438.s9|6-19|administration|O
DDI-DrugBank.d438.s9|20-20|.|O
DDI-DrugBank.d438.s10|0-7|Likewise|O
DDI-DrugBank.d438.s10|8-8|,|O
DDI-DrugBank.d438.s10|10-19|gabapentin|drug
DDI-DrugBank.d438.s10|21-36|pharmacokinetics|O
DDI-DrugBank.d438.s10|38-41|were|O
DDI-DrugBank.d438.s10|43-51|unaltered|O
DDI-DrugBank.d438.s10|53-54|by|O
DDI-DrugBank.d438.s10|56-68|carbamazepine|drug
DDI-DrugBank.d438.s10|70-83|administration|O
DDI-DrugBank.d438.s10|84-84|.|O
DDI-DrugBank.d438.s11|0-12|Valproic Acid|drug
DDI-DrugBank.d438.s11|13-13|:|O
DDI-DrugBank.d438.s11|15-17|The|O
DDI-DrugBank.d438.s11|19-22|mean|O
DDI-DrugBank.d438.s11|24-35|steady-state|O
DDI-DrugBank.d438.s11|37-42|trough|O
DDI-DrugBank.d438.s11|44-48|serum|O
DDI-DrugBank.d438.s11|50-62|valproic acid|drug
DDI-DrugBank.d438.s11|64-77|concentrations|O
DDI-DrugBank.d438.s11|79-83|prior|O
DDI-DrugBank.d438.s11|85-86|to|O
DDI-DrugBank.d438.s11|88-90|and|O
DDI-DrugBank.d438.s11|92-97|during|O
DDI-DrugBank.d438.s11|99-109|concomitant|O
DDI-DrugBank.d438.s11|111-120|gabapentin|drug
DDI-DrugBank.d438.s11|122-135|administration|O
DDI-DrugBank.d438.s11|137-137|(|O
DDI-DrugBank.d438.s11|138-140|400|O
DDI-DrugBank.d438.s11|142-143|mg|O
DDI-DrugBank.d438.s11|145-147|TID|O
DDI-DrugBank.d438.s11|148-148|;|O
DDI-DrugBank.d438.s12|0-3|N=17|O
DDI-DrugBank.d438.s12|4-4|)|O
DDI-DrugBank.d438.s12|6-9|were|O
DDI-DrugBank.d438.s12|11-13|not|O
DDI-DrugBank.d438.s12|15-23|different|O
DDI-DrugBank.d438.s12|25-27|and|O
DDI-DrugBank.d438.s12|29-35|neither|O
DDI-DrugBank.d438.s12|37-40|were|O
DDI-DrugBank.d438.s12|42-51|gabapentin|drug
DDI-DrugBank.d438.s12|53-67|pharmacokinetic|O
DDI-DrugBank.d438.s12|69-78|parameters|O
DDI-DrugBank.d438.s12|80-87|affected|O
DDI-DrugBank.d438.s12|89-90|by|O
DDI-DrugBank.d438.s12|92-104|valproic acid|drug
DDI-DrugBank.d438.s12|105-105|.|O
DDI-DrugBank.d438.s13|0-12|Phenobarbital|drug
DDI-DrugBank.d438.s13|13-13|:|O
DDI-DrugBank.d438.s13|15-23|Estimates|O
DDI-DrugBank.d438.s13|25-26|of|O
DDI-DrugBank.d438.s13|28-39|steady-state|O
DDI-DrugBank.d438.s13|41-55|pharmacokinetic|O
DDI-DrugBank.d438.s13|57-66|parameters|O
DDI-DrugBank.d438.s13|68-70|for|O
DDI-DrugBank.d438.s13|72-84|phenobarbital|drug
DDI-DrugBank.d438.s13|86-87|or|O
DDI-DrugBank.d438.s13|89-98|gabapentin|drug
DDI-DrugBank.d438.s13|100-100|(|O
DDI-DrugBank.d438.s13|101-103|300|O
DDI-DrugBank.d438.s13|105-106|mg|O
DDI-DrugBank.d438.s13|108-110|TID|O
DDI-DrugBank.d438.s13|111-111|;|O
DDI-DrugBank.d438.s14|0-3|N=12|O
DDI-DrugBank.d438.s14|4-4|)|O
DDI-DrugBank.d438.s14|6-8|are|O
DDI-DrugBank.d438.s14|10-18|identical|O
DDI-DrugBank.d438.s14|20-26|whether|O
DDI-DrugBank.d438.s14|28-30|the|O
DDI-DrugBank.d438.s14|32-36|drugs|O
DDI-DrugBank.d438.s14|38-40|are|O
DDI-DrugBank.d438.s14|42-53|administered|O
DDI-DrugBank.d438.s14|55-59|alone|O
DDI-DrugBank.d438.s14|61-62|or|O
DDI-DrugBank.d438.s14|64-71|together|O
DDI-DrugBank.d438.s14|72-72|.|O
DDI-DrugBank.d438.s15|0-7|Naproxen|drug
DDI-DrugBank.d438.s15|8-8|:|O
DDI-DrugBank.d438.s15|10-25|Coadministration|O
DDI-DrugBank.d438.s15|27-27|(|O
DDI-DrugBank.d438.s15|28-31|N=18|O
DDI-DrugBank.d438.s15|32-32|)|O
DDI-DrugBank.d438.s15|34-35|of|O
DDI-DrugBank.d438.s15|37-51|naproxen sodium|drug
DDI-DrugBank.d438.s15|53-60|capsules|O
DDI-DrugBank.d438.s15|62-62|(|O
DDI-DrugBank.d438.s15|63-65|250|O
DDI-DrugBank.d438.s15|67-68|mg|O
DDI-DrugBank.d438.s15|69-69|)|O
DDI-DrugBank.d438.s15|71-74|with|O
DDI-DrugBank.d438.s15|76-84|Neurontin|brand
DDI-DrugBank.d438.s15|86-86|(|O
DDI-DrugBank.d438.s15|87-89|125|O
DDI-DrugBank.d438.s15|91-92|mg|O
DDI-DrugBank.d438.s15|93-93|)|O
DDI-DrugBank.d438.s15|95-101|appears|O
DDI-DrugBank.d438.s15|103-104|to|O
DDI-DrugBank.d438.s15|106-113|increase|O
DDI-DrugBank.d438.s15|115-117|the|O
DDI-DrugBank.d438.s15|119-124|amount|O
DDI-DrugBank.d438.s15|126-127|of|O
DDI-DrugBank.d438.s15|129-138|gabapentin|drug
DDI-DrugBank.d438.s15|140-147|absorbed|O
DDI-DrugBank.d438.s15|149-150|by|O
DDI-DrugBank.d438.s15|152-153|12|O
DDI-DrugBank.d438.s15|154-154|%|O
DDI-DrugBank.d438.s15|156-157|to|O
DDI-DrugBank.d438.s15|159-160|15|O
DDI-DrugBank.d438.s15|161-161|%|O
DDI-DrugBank.d438.s15|162-162|.|O
DDI-DrugBank.d438.s16|0-9|Gabapentin|drug
DDI-DrugBank.d438.s16|11-13|had|O
DDI-DrugBank.d438.s16|15-16|no|O
DDI-DrugBank.d438.s16|18-23|effect|O
DDI-DrugBank.d438.s16|25-26|on|O
DDI-DrugBank.d438.s16|28-35|naproxen|drug
DDI-DrugBank.d438.s16|37-51|pharmacokinetic|O
DDI-DrugBank.d438.s16|53-62|parameters|O
DDI-DrugBank.d438.s16|63-63|.|O
DDI-DrugBank.d438.s17|0-4|These|O
DDI-DrugBank.d438.s17|6-10|doses|O
DDI-DrugBank.d438.s17|12-14|are|O
DDI-DrugBank.d438.s17|16-20|lower|O
DDI-DrugBank.d438.s17|22-25|than|O
DDI-DrugBank.d438.s17|27-29|the|O
DDI-DrugBank.d438.s17|31-41|therapeutic|O
DDI-DrugBank.d438.s17|43-47|doses|O
DDI-DrugBank.d438.s17|49-51|for|O
DDI-DrugBank.d438.s17|53-56|both|O
DDI-DrugBank.d438.s17|58-62|drugs|O
DDI-DrugBank.d438.s17|63-63|.|O
DDI-DrugBank.d438.s18|0-2|The|O
DDI-DrugBank.d438.s18|4-12|magnitude|O
DDI-DrugBank.d438.s18|14-15|of|O
DDI-DrugBank.d438.s18|17-27|interaction|O
DDI-DrugBank.d438.s18|29-34|within|O
DDI-DrugBank.d438.s18|36-38|the|O
DDI-DrugBank.d438.s18|40-50|recommended|O
DDI-DrugBank.d438.s18|52-55|dose|O
DDI-DrugBank.d438.s18|57-62|ranges|O
DDI-DrugBank.d438.s18|64-65|of|O
DDI-DrugBank.d438.s18|67-72|either|O
DDI-DrugBank.d438.s18|74-77|drug|O
DDI-DrugBank.d438.s18|79-80|is|O
DDI-DrugBank.d438.s18|82-84|not|O
DDI-DrugBank.d438.s18|86-90|known|O
DDI-DrugBank.d438.s18|91-91|.|O
DDI-DrugBank.d438.s19|0-10|Hydrocodone|drug
DDI-DrugBank.d438.s19|11-11|:|O
DDI-DrugBank.d438.s19|13-28|Coadministration|O
DDI-DrugBank.d438.s19|30-31|of|O
DDI-DrugBank.d438.s19|33-41|Neurontin|brand
DDI-DrugBank.d438.s19|44-44|(|O
DDI-DrugBank.d438.s19|45-47|125|O
DDI-DrugBank.d438.s19|49-50|to|O
DDI-DrugBank.d438.s19|52-54|500|O
DDI-DrugBank.d438.s19|56-57|mg|O
DDI-DrugBank.d438.s19|58-58|;|O
DDI-DrugBank.d438.s20|0-3|N=48|O
DDI-DrugBank.d438.s20|4-4|)|O
DDI-DrugBank.d438.s20|6-14|decreases|O
DDI-DrugBank.d438.s20|16-26|hydrocodone|drug
DDI-DrugBank.d438.s20|28-28|(|O
DDI-DrugBank.d438.s20|29-30|10|O
DDI-DrugBank.d438.s20|32-33|mg|O
DDI-DrugBank.d438.s20|34-34|;|O
DDI-DrugBank.d438.s21|0-3|N=50|O
DDI-DrugBank.d438.s21|4-4|)|O
DDI-DrugBank.d438.s21|6-9|Cmax|O
DDI-DrugBank.d438.s21|11-13|and|O
DDI-DrugBank.d438.s21|15-17|AUC|O
DDI-DrugBank.d438.s21|19-24|values|O
DDI-DrugBank.d438.s21|26-27|in|O
DDI-DrugBank.d438.s21|29-29|a|O
DDI-DrugBank.d438.s21|31-44|dose-dependent|O
DDI-DrugBank.d438.s21|46-51|manner|O
DDI-DrugBank.d438.s21|53-60|relative|O
DDI-DrugBank.d438.s21|62-63|to|O
DDI-DrugBank.d438.s21|65-78|administration|O
DDI-DrugBank.d438.s21|80-81|of|O
DDI-DrugBank.d438.s21|83-93|hydrocodone|drug
DDI-DrugBank.d438.s21|95-99|alone|O
DDI-DrugBank.d438.s21|100-100|;|O
DDI-DrugBank.d438.s22|0-3|Cmax|O
DDI-DrugBank.d438.s22|5-7|and|O
DDI-DrugBank.d438.s22|9-11|AUC|O
DDI-DrugBank.d438.s22|13-18|values|O
DDI-DrugBank.d438.s22|20-22|are|O
DDI-DrugBank.d438.s22|24-24|3|O
DDI-DrugBank.d438.s22|25-25|%|O
DDI-DrugBank.d438.s22|27-28|to|O
DDI-DrugBank.d438.s22|30-30|4|O
DDI-DrugBank.d438.s22|31-31|%|O
DDI-DrugBank.d438.s22|33-37|lower|O
DDI-DrugBank.d438.s22|38-38|,|O
DDI-DrugBank.d438.s22|40-51|respectively|O
DDI-DrugBank.d438.s22|52-52|,|O
DDI-DrugBank.d438.s22|54-58|after|O
DDI-DrugBank.d438.s22|60-73|administration|O
DDI-DrugBank.d438.s22|75-76|of|O
DDI-DrugBank.d438.s22|78-80|125|O
DDI-DrugBank.d438.s22|82-83|mg|O
DDI-DrugBank.d438.s22|85-93|Neurontin|brand
DDI-DrugBank.d438.s22|96-98|and|O
DDI-DrugBank.d438.s22|100-101|21|O
DDI-DrugBank.d438.s22|102-102|%|O
DDI-DrugBank.d438.s22|104-105|to|O
DDI-DrugBank.d438.s22|107-108|22|O
DDI-DrugBank.d438.s22|109-109|%|O
DDI-DrugBank.d438.s22|111-115|lower|O
DDI-DrugBank.d438.s22|116-116|,|O
DDI-DrugBank.d438.s22|118-129|respectively|O
DDI-DrugBank.d438.s22|130-130|,|O
DDI-DrugBank.d438.s22|132-136|after|O
DDI-DrugBank.d438.s22|138-151|administration|O
DDI-DrugBank.d438.s22|153-154|of|O
DDI-DrugBank.d438.s22|156-158|500|O
DDI-DrugBank.d438.s22|160-161|mg|O
DDI-DrugBank.d438.s22|163-171|Neurontin|brand
DDI-DrugBank.d438.s22|173-173|.|O
DDI-DrugBank.d438.s23|0-2|The|O
DDI-DrugBank.d438.s23|4-12|mechanism|O
DDI-DrugBank.d438.s23|14-16|for|O
DDI-DrugBank.d438.s23|18-21|this|O
DDI-DrugBank.d438.s23|23-33|interaction|O
DDI-DrugBank.d438.s23|35-36|is|O
DDI-DrugBank.d438.s23|38-44|unknown|O
DDI-DrugBank.d438.s23|45-45|.|O
DDI-DrugBank.d438.s24|0-10|Hydrocodone|drug
DDI-DrugBank.d438.s24|12-20|increases|O
DDI-DrugBank.d438.s24|22-31|gabapentin|drug
DDI-DrugBank.d438.s24|33-35|AUC|O
DDI-DrugBank.d438.s24|37-42|values|O
DDI-DrugBank.d438.s24|44-45|by|O
DDI-DrugBank.d438.s24|47-48|14|O
DDI-DrugBank.d438.s24|49-49|%|O
DDI-DrugBank.d438.s24|50-50|.|O
DDI-DrugBank.d438.s25|0-2|The|O
DDI-DrugBank.d438.s25|4-12|magnitude|O
DDI-DrugBank.d438.s25|14-15|of|O
DDI-DrugBank.d438.s25|17-27|interaction|O
DDI-DrugBank.d438.s25|29-30|at|O
DDI-DrugBank.d438.s25|32-36|other|O
DDI-DrugBank.d438.s25|38-42|doses|O
DDI-DrugBank.d438.s25|44-45|is|O
DDI-DrugBank.d438.s25|47-49|not|O
DDI-DrugBank.d438.s25|51-55|known|O
DDI-DrugBank.d438.s25|56-56|.|O
DDI-DrugBank.d438.s26|0-7|Morphine|drug
DDI-DrugBank.d438.s26|8-8|:|O
DDI-DrugBank.d438.s26|10-10|A|O
DDI-DrugBank.d438.s26|12-21|literature|O
DDI-DrugBank.d438.s26|23-29|article|O
DDI-DrugBank.d438.s26|31-38|reported|O
DDI-DrugBank.d438.s26|40-43|that|O
DDI-DrugBank.d438.s26|45-48|when|O
DDI-DrugBank.d438.s26|50-50|a|O
DDI-DrugBank.d438.s26|52-56|60-mg|O
DDI-DrugBank.d438.s26|58-75|controlled-release|O
DDI-DrugBank.d438.s26|77-84|morphine|drug
DDI-DrugBank.d438.s26|86-92|capsule|O
DDI-DrugBank.d438.s26|94-96|was|O
DDI-DrugBank.d438.s26|98-109|administered|O
DDI-DrugBank.d438.s26|111-111|2|O
DDI-DrugBank.d438.s26|113-117|hours|O
DDI-DrugBank.d438.s26|119-123|prior|O
DDI-DrugBank.d438.s26|125-126|to|O
DDI-DrugBank.d438.s26|128-128|a|O
DDI-DrugBank.d438.s26|130-135|600-mg|O
DDI-DrugBank.d438.s26|137-145|Neurontin|brand
DDI-DrugBank.d438.s26|148-154|capsule|O
DDI-DrugBank.d438.s26|156-156|(|O
DDI-DrugBank.d438.s26|157-160|N=12|O
DDI-DrugBank.d438.s26|161-161|)|O
DDI-DrugBank.d438.s26|162-162|,|O
DDI-DrugBank.d438.s26|164-167|mean|O
DDI-DrugBank.d438.s26|169-178|gabapentin|drug
DDI-DrugBank.d438.s26|180-182|AUC|O
DDI-DrugBank.d438.s26|184-192|increased|O
DDI-DrugBank.d438.s26|194-195|by|O
DDI-DrugBank.d438.s26|197-198|44|O
DDI-DrugBank.d438.s26|199-199|%|O
DDI-DrugBank.d438.s26|201-208|compared|O
DDI-DrugBank.d438.s26|210-211|to|O
DDI-DrugBank.d438.s26|213-222|gabapentin|drug
DDI-DrugBank.d438.s26|224-235|administered|O
DDI-DrugBank.d438.s26|237-243|without|O
DDI-DrugBank.d438.s26|245-252|morphine|drug
DDI-DrugBank.d438.s26|253-253|.|O
DDI-DrugBank.d438.s27|0-7|Morphine|drug
DDI-DrugBank.d438.s27|9-23|pharmacokinetic|O
DDI-DrugBank.d438.s27|25-33|parameter|O
DDI-DrugBank.d438.s27|35-40|values|O
DDI-DrugBank.d438.s27|42-45|were|O
DDI-DrugBank.d438.s27|47-49|not|O
DDI-DrugBank.d438.s27|51-58|affected|O
DDI-DrugBank.d438.s27|60-61|by|O
DDI-DrugBank.d438.s27|63-76|administration|O
DDI-DrugBank.d438.s27|78-79|of|O
DDI-DrugBank.d438.s27|81-89|Neurontin|brand
DDI-DrugBank.d438.s27|92-92|2|O
DDI-DrugBank.d438.s27|94-98|hours|O
DDI-DrugBank.d438.s27|100-104|after|O
DDI-DrugBank.d438.s27|106-113|morphine|drug
DDI-DrugBank.d438.s27|114-114|.|O
DDI-DrugBank.d438.s28|0-2|The|O
DDI-DrugBank.d438.s28|4-12|magnitude|O
DDI-DrugBank.d438.s28|14-15|of|O
DDI-DrugBank.d438.s28|17-27|interaction|O
DDI-DrugBank.d438.s28|29-30|at|O
DDI-DrugBank.d438.s28|32-36|other|O
DDI-DrugBank.d438.s28|38-42|doses|O
DDI-DrugBank.d438.s28|44-45|is|O
DDI-DrugBank.d438.s28|47-49|not|O
DDI-DrugBank.d438.s28|51-55|known|O
DDI-DrugBank.d438.s28|56-56|.|O
DDI-DrugBank.d438.s29|0-9|Cimetidine|drug
DDI-DrugBank.d438.s29|10-10|:|O
DDI-DrugBank.d438.s29|12-13|In|O
DDI-DrugBank.d438.s29|15-17|the|O
DDI-DrugBank.d438.s29|19-26|presence|O
DDI-DrugBank.d438.s29|28-29|of|O
DDI-DrugBank.d438.s29|31-40|cimetidine|drug
DDI-DrugBank.d438.s29|42-43|at|O
DDI-DrugBank.d438.s29|45-47|300|O
DDI-DrugBank.d438.s29|49-50|mg|O
DDI-DrugBank.d438.s29|52-54|QID|O
DDI-DrugBank.d438.s29|56-56|(|O
DDI-DrugBank.d438.s29|57-60|N=12|O
DDI-DrugBank.d438.s29|61-61|)|O
DDI-DrugBank.d438.s29|63-65|the|O
DDI-DrugBank.d438.s29|67-70|mean|O
DDI-DrugBank.d438.s29|72-79|apparent|O
DDI-DrugBank.d438.s29|81-84|oral|O
DDI-DrugBank.d438.s29|86-94|clearance|O
DDI-DrugBank.d438.s29|96-97|of|O
DDI-DrugBank.d438.s29|99-108|gabapentin|drug
DDI-DrugBank.d438.s29|110-113|fell|O
DDI-DrugBank.d438.s29|115-116|by|O
DDI-DrugBank.d438.s29|118-119|14|O
DDI-DrugBank.d438.s29|120-120|%|O
DDI-DrugBank.d438.s29|122-124|and|O
DDI-DrugBank.d438.s29|126-135|creatinine|O
DDI-DrugBank.d438.s29|137-145|clearance|O
DDI-DrugBank.d438.s29|147-150|fell|O
DDI-DrugBank.d438.s29|152-153|by|O
DDI-DrugBank.d438.s29|155-156|10|O
DDI-DrugBank.d438.s29|157-157|%|O
DDI-DrugBank.d438.s29|158-158|.|O
DDI-DrugBank.d438.s30|0-3|Thus|O
DDI-DrugBank.d438.s30|5-14|cimetidine|drug
DDI-DrugBank.d438.s30|16-23|appeared|O
DDI-DrugBank.d438.s30|25-26|to|O
DDI-DrugBank.d438.s30|28-32|alter|O
DDI-DrugBank.d438.s30|34-36|the|O
DDI-DrugBank.d438.s30|38-42|renal|O
DDI-DrugBank.d438.s30|44-52|excretion|O
DDI-DrugBank.d438.s30|54-55|of|O
DDI-DrugBank.d438.s30|57-60|both|O
DDI-DrugBank.d438.s30|62-71|gabapentin|drug
DDI-DrugBank.d438.s30|73-75|and|O
DDI-DrugBank.d438.s30|77-86|creatinine|O
DDI-DrugBank.d438.s30|87-87|,|O
DDI-DrugBank.d438.s30|89-90|an|O
DDI-DrugBank.d438.s30|92-101|endogenous|O
DDI-DrugBank.d438.s30|103-108|marker|O
DDI-DrugBank.d438.s30|110-111|of|O
DDI-DrugBank.d438.s30|113-117|renal|O
DDI-DrugBank.d438.s30|119-126|function|O
DDI-DrugBank.d438.s30|127-127|.|O
DDI-DrugBank.d438.s31|0-3|This|O
DDI-DrugBank.d438.s31|5-9|small|O
DDI-DrugBank.d438.s31|11-18|decrease|O
DDI-DrugBank.d438.s31|20-21|in|O
DDI-DrugBank.d438.s31|23-31|excretion|O
DDI-DrugBank.d438.s31|33-34|of|O
DDI-DrugBank.d438.s31|36-45|gabapentin|drug
DDI-DrugBank.d438.s31|47-48|by|O
DDI-DrugBank.d438.s31|50-59|cimetidine|drug
DDI-DrugBank.d438.s31|61-62|is|O
DDI-DrugBank.d438.s31|64-66|not|O
DDI-DrugBank.d438.s31|68-75|expected|O
DDI-DrugBank.d438.s31|77-78|to|O
DDI-DrugBank.d438.s31|80-81|be|O
DDI-DrugBank.d438.s31|83-84|of|O
DDI-DrugBank.d438.s31|86-93|clinical|O
DDI-DrugBank.d438.s31|95-104|importance|O
DDI-DrugBank.d438.s31|105-105|.|O
DDI-DrugBank.d438.s32|0-2|The|O
DDI-DrugBank.d438.s32|4-9|effect|O
DDI-DrugBank.d438.s32|11-12|of|O
DDI-DrugBank.d438.s32|14-23|gabapentin|drug
DDI-DrugBank.d438.s32|25-26|on|O
DDI-DrugBank.d438.s32|28-37|cimetidine|drug
DDI-DrugBank.d438.s32|39-41|was|O
DDI-DrugBank.d438.s32|43-45|not|O
DDI-DrugBank.d438.s32|47-55|evaluated|O
DDI-DrugBank.d438.s32|56-56|.|O
DDI-DrugBank.d438.s33|0-3|Oral|O
DDI-DrugBank.d438.s33|5-17|Contraceptive|group
DDI-DrugBank.d438.s33|18-18|:|O
DDI-DrugBank.d438.s33|20-24|Based|O
DDI-DrugBank.d438.s33|26-27|on|O
DDI-DrugBank.d438.s33|29-31|AUC|O
DDI-DrugBank.d438.s33|33-35|and|O
DDI-DrugBank.d438.s33|37-45|half-life|O
DDI-DrugBank.d438.s33|46-46|,|O
DDI-DrugBank.d438.s33|48-60|multiple-dose|O
DDI-DrugBank.d438.s33|62-76|pharmacokinetic|O
DDI-DrugBank.d438.s33|78-85|profiles|O
DDI-DrugBank.d438.s33|87-88|of|O
DDI-DrugBank.d438.s33|90-102|norethindrone|drug
DDI-DrugBank.d438.s33|104-106|and|O
DDI-DrugBank.d438.s33|108-124|ethinyl estradiol|drug
DDI-DrugBank.d438.s33|126-134|following|O
DDI-DrugBank.d438.s33|136-149|administration|O
DDI-DrugBank.d438.s33|151-152|of|O
DDI-DrugBank.d438.s33|154-160|tablets|O
DDI-DrugBank.d438.s33|162-171|containing|O
DDI-DrugBank.d438.s33|173-175|2.5|O
DDI-DrugBank.d438.s33|177-178|mg|O
DDI-DrugBank.d438.s33|180-181|of|O
DDI-DrugBank.d438.s33|183-203|norethindrone acetate|drug
DDI-DrugBank.d438.s33|205-207|and|O
DDI-DrugBank.d438.s33|209-210|50|O
DDI-DrugBank.d438.s33|212-214|mcg|O
DDI-DrugBank.d438.s33|216-217|of|O
DDI-DrugBank.d438.s33|219-235|ethinyl estradiol|drug
DDI-DrugBank.d438.s33|237-240|were|O
DDI-DrugBank.d438.s33|242-248|similar|O
DDI-DrugBank.d438.s33|250-253|with|O
DDI-DrugBank.d438.s33|255-257|and|O
DDI-DrugBank.d438.s33|259-265|without|O
DDI-DrugBank.d438.s33|267-282|coadministration|O
DDI-DrugBank.d438.s33|284-285|of|O
DDI-DrugBank.d438.s33|287-296|gabapentin|drug
DDI-DrugBank.d438.s33|298-298|(|O
DDI-DrugBank.d438.s33|299-301|400|O
DDI-DrugBank.d438.s33|303-304|mg|O
DDI-DrugBank.d438.s33|306-308|TID|O
DDI-DrugBank.d438.s33|309-309|;|O
DDI-DrugBank.d438.s34|0-3|N=13|O
DDI-DrugBank.d438.s34|4-4|)|O
DDI-DrugBank.d438.s34|5-5|.|O
DDI-DrugBank.d438.s35|0-2|The|O
DDI-DrugBank.d438.s35|4-7|Cmax|O
DDI-DrugBank.d438.s35|9-10|of|O
DDI-DrugBank.d438.s35|12-24|norethindrone|drug
DDI-DrugBank.d438.s35|26-28|was|O
DDI-DrugBank.d438.s35|30-31|13|O
DDI-DrugBank.d438.s35|32-32|%|O
DDI-DrugBank.d438.s35|34-39|higher|O
DDI-DrugBank.d438.s35|41-44|when|O
DDI-DrugBank.d438.s35|46-47|it|O
DDI-DrugBank.d438.s35|49-51|was|O
DDI-DrugBank.d438.s35|53-66|coadministered|O
DDI-DrugBank.d438.s35|68-71|with|O
DDI-DrugBank.d438.s35|73-82|gabapentin|drug
DDI-DrugBank.d438.s35|83-83|;|O
DDI-DrugBank.d438.s36|0-3|this|O
DDI-DrugBank.d438.s36|5-15|interaction|O
DDI-DrugBank.d438.s36|17-18|is|O
DDI-DrugBank.d438.s36|20-22|not|O
DDI-DrugBank.d438.s36|24-31|expected|O
DDI-DrugBank.d438.s36|33-34|to|O
DDI-DrugBank.d438.s36|36-37|be|O
DDI-DrugBank.d438.s36|39-40|of|O
DDI-DrugBank.d438.s36|42-49|clinical|O
DDI-DrugBank.d438.s36|51-60|importance|O
DDI-DrugBank.d438.s36|61-61|.|O
DDI-DrugBank.d438.s37|0-6|Antacid|group
DDI-DrugBank.d438.s37|8-8|(|O
DDI-DrugBank.d438.s37|9-14|Maalox|brand
DDI-DrugBank.d438.s37|16-16|)|O
DDI-DrugBank.d438.s37|17-17|:|O
DDI-DrugBank.d438.s37|19-24|Maalox|brand
DDI-DrugBank.d438.s37|26-32|reduced|O
DDI-DrugBank.d438.s37|34-36|the|O
DDI-DrugBank.d438.s37|38-52|bioavailability|O
DDI-DrugBank.d438.s37|54-55|of|O
DDI-DrugBank.d438.s37|57-66|gabapentin|drug
DDI-DrugBank.d438.s37|68-68|(|O
DDI-DrugBank.d438.s37|69-72|N=16|O
DDI-DrugBank.d438.s37|73-73|)|O
DDI-DrugBank.d438.s37|75-76|by|O
DDI-DrugBank.d438.s37|78-82|about|O
DDI-DrugBank.d438.s37|84-85|20|O
DDI-DrugBank.d438.s37|86-86|%|O
DDI-DrugBank.d438.s37|87-87|.|O
DDI-DrugBank.d438.s38|0-3|This|O
DDI-DrugBank.d438.s38|5-12|decrease|O
DDI-DrugBank.d438.s38|14-15|in|O
DDI-DrugBank.d438.s38|17-31|bioavailability|O
DDI-DrugBank.d438.s38|33-35|was|O
DDI-DrugBank.d438.s38|37-41|about|O
DDI-DrugBank.d438.s38|43-43|5|O
DDI-DrugBank.d438.s38|44-44|%|O
DDI-DrugBank.d438.s38|46-49|when|O
DDI-DrugBank.d438.s38|51-60|gabapentin|drug
DDI-DrugBank.d438.s38|62-64|was|O
DDI-DrugBank.d438.s38|66-77|administered|O
DDI-DrugBank.d438.s38|79-79|2|O
DDI-DrugBank.d438.s38|81-85|hours|O
DDI-DrugBank.d438.s38|87-91|after|O
DDI-DrugBank.d438.s38|93-98|Maalox|brand
DDI-DrugBank.d438.s38|99-99|.|O
DDI-DrugBank.d438.s39|0-1|It|O
DDI-DrugBank.d438.s39|3-4|is|O
DDI-DrugBank.d438.s39|6-16|recommended|O
DDI-DrugBank.d438.s39|18-21|that|O
DDI-DrugBank.d438.s39|23-32|gabapentin|drug
DDI-DrugBank.d438.s39|34-35|be|O
DDI-DrugBank.d438.s39|37-41|taken|O
DDI-DrugBank.d438.s39|43-44|at|O
DDI-DrugBank.d438.s39|46-50|least|O
DDI-DrugBank.d438.s39|52-52|2|O
DDI-DrugBank.d438.s39|54-58|hours|O
DDI-DrugBank.d438.s39|60-68|following|O
DDI-DrugBank.d438.s39|70-75|Maalox|brand
DDI-DrugBank.d438.s39|77-90|administration|O
DDI-DrugBank.d438.s39|91-91|.|O
DDI-DrugBank.d438.s40|0-5|Effect|O
DDI-DrugBank.d438.s40|7-8|of|O
DDI-DrugBank.d438.s40|10-19|Probenecid|drug
DDI-DrugBank.d438.s40|20-20|:|O
DDI-DrugBank.d438.s40|22-31|Probenecid|drug
DDI-DrugBank.d438.s40|33-34|is|O
DDI-DrugBank.d438.s40|36-36|a|O
DDI-DrugBank.d438.s40|38-44|blocker|O
DDI-DrugBank.d438.s40|46-47|of|O
DDI-DrugBank.d438.s40|49-53|renal|O
DDI-DrugBank.d438.s40|55-61|tubular|O
DDI-DrugBank.d438.s40|63-71|secretion|O
DDI-DrugBank.d438.s40|72-72|.|O
DDI-DrugBank.d438.s41|0-9|Gabapentin|drug
DDI-DrugBank.d438.s41|11-25|pharmacokinetic|O
DDI-DrugBank.d438.s41|27-36|parameters|O
DDI-DrugBank.d438.s41|38-44|without|O
DDI-DrugBank.d438.s41|46-48|and|O
DDI-DrugBank.d438.s41|50-53|with|O
DDI-DrugBank.d438.s41|55-64|probenecid|drug
DDI-DrugBank.d438.s41|66-69|were|O
DDI-DrugBank.d438.s41|71-80|comparable|O
DDI-DrugBank.d438.s41|81-81|.|O
DDI-DrugBank.d438.s42|0-3|This|O
DDI-DrugBank.d438.s42|5-13|indicates|O
DDI-DrugBank.d438.s42|15-18|that|O
DDI-DrugBank.d438.s42|20-29|gabapentin|drug
DDI-DrugBank.d438.s42|31-34|does|O
DDI-DrugBank.d438.s42|36-38|not|O
DDI-DrugBank.d438.s42|40-46|undergo|O
DDI-DrugBank.d438.s42|48-52|renal|O
DDI-DrugBank.d438.s42|54-60|tubular|O
DDI-DrugBank.d438.s42|62-70|secretion|O
DDI-DrugBank.d438.s42|72-73|by|O
DDI-DrugBank.d438.s42|75-77|the|O
DDI-DrugBank.d438.s42|79-85|pathway|O
DDI-DrugBank.d438.s42|87-90|that|O
DDI-DrugBank.d438.s42|92-93|is|O
DDI-DrugBank.d438.s42|95-101|blocked|O
DDI-DrugBank.d438.s42|103-104|by|O
DDI-DrugBank.d438.s42|106-115|probenecid|drug
DDI-DrugBank.d438.s42|116-116|.|O
DDI-DrugBank.d438.s43|0-14|Drug/Laboratory|O
DDI-DrugBank.d438.s43|16-20|Tests|O
DDI-DrugBank.d438.s43|22-33|Interactions|O
DDI-DrugBank.d438.s43|35-41|Because|O
DDI-DrugBank.d438.s43|43-47|false|O
DDI-DrugBank.d438.s43|49-56|positive|O
DDI-DrugBank.d438.s43|58-65|readings|O
DDI-DrugBank.d438.s43|67-70|were|O
DDI-DrugBank.d438.s43|72-79|reported|O
DDI-DrugBank.d438.s43|81-84|with|O
DDI-DrugBank.d438.s43|86-88|the|O
DDI-DrugBank.d438.s43|90-93|Ames|O
DDI-DrugBank.d438.s43|95-105|N-Multistix|O
DDI-DrugBank.d438.s43|107-108|SG|O
DDI-DrugBank.d438.s43|110-117|dipstick|O
DDI-DrugBank.d438.s43|119-122|test|O
DDI-DrugBank.d438.s43|124-126|for|O
DDI-DrugBank.d438.s43|128-134|urinary|O
DDI-DrugBank.d438.s43|136-142|protein|O
DDI-DrugBank.d438.s43|144-147|when|O
DDI-DrugBank.d438.s43|149-158|gabapentin|drug
DDI-DrugBank.d438.s43|160-162|was|O
DDI-DrugBank.d438.s43|164-168|added|O
DDI-DrugBank.d438.s43|170-171|to|O
DDI-DrugBank.d438.s43|173-177|other|O
DDI-DrugBank.d438.s43|179-197|antiepileptic drugs|group
DDI-DrugBank.d438.s43|198-198|,|O
DDI-DrugBank.d438.s43|200-202|the|O
DDI-DrugBank.d438.s43|204-207|more|O
DDI-DrugBank.d438.s43|209-216|specific|O
DDI-DrugBank.d438.s43|218-231|sulfosalicylic|O
DDI-DrugBank.d438.s43|233-236|acid|O
DDI-DrugBank.d438.s43|238-250|precipitation|O
DDI-DrugBank.d438.s43|252-260|procedure|O
DDI-DrugBank.d438.s43|262-263|is|O
DDI-DrugBank.d438.s43|265-275|recommended|O
DDI-DrugBank.d438.s43|277-278|to|O
DDI-DrugBank.d438.s43|280-288|determine|O
DDI-DrugBank.d438.s43|290-292|the|O
DDI-DrugBank.d438.s43|294-301|presence|O
DDI-DrugBank.d438.s43|303-304|of|O
DDI-DrugBank.d438.s43|306-310|urine|O
DDI-DrugBank.d438.s43|312-318|protein|O
DDI-DrugBank.d438.s44|0-0|.|O
DDI-DrugBank.d218.s0|0-1|No|O
DDI-DrugBank.d218.s0|3-23|pharmacokinetic-based|O
DDI-DrugBank.d218.s0|25-33|drug-drug|O
DDI-DrugBank.d218.s0|35-45|interaction|O
DDI-DrugBank.d218.s0|47-53|studies|O
DDI-DrugBank.d218.s0|55-58|have|O
DDI-DrugBank.d218.s0|60-63|been|O
DDI-DrugBank.d218.s0|65-73|conducted|O
DDI-DrugBank.d218.s0|75-78|with|O
DDI-DrugBank.d218.s0|80-86|SYNAREL|brand
DDI-DrugBank.d218.s0|87-87|.|O
DDI-DrugBank.d218.s1|0-6|However|O
DDI-DrugBank.d218.s1|7-7|,|O
DDI-DrugBank.d218.s1|9-15|because|O
DDI-DrugBank.d218.s1|17-33|nafarelin acetate|drug
DDI-DrugBank.d218.s1|35-36|is|O
DDI-DrugBank.d218.s1|38-38|a|O
DDI-DrugBank.d218.s1|40-46|peptide|O
DDI-DrugBank.d218.s1|48-51|that|O
DDI-DrugBank.d218.s1|53-54|is|O
DDI-DrugBank.d218.s1|56-64|primarily|O
DDI-DrugBank.d218.s1|66-73|degraded|O
DDI-DrugBank.d218.s1|75-76|by|O
DDI-DrugBank.d218.s1|78-86|peptidase|O
DDI-DrugBank.d218.s1|88-90|and|O
DDI-DrugBank.d218.s1|92-94|not|O
DDI-DrugBank.d218.s1|96-97|by|O
DDI-DrugBank.d218.s1|99-108|cytochrome|O
DDI-DrugBank.d218.s1|110-114|P-450|O
DDI-DrugBank.d218.s1|116-122|enzymes|O
DDI-DrugBank.d218.s1|123-123|,|O
DDI-DrugBank.d218.s1|125-127|and|O
DDI-DrugBank.d218.s1|129-131|the|O
DDI-DrugBank.d218.s1|133-136|drug|O
DDI-DrugBank.d218.s1|138-139|is|O
DDI-DrugBank.d218.s1|141-144|only|O
DDI-DrugBank.d218.s1|146-150|about|O
DDI-DrugBank.d218.s1|152-153|80|O
DDI-DrugBank.d218.s1|154-154|%|O
DDI-DrugBank.d218.s1|156-160|bound|O
DDI-DrugBank.d218.s1|162-163|to|O
DDI-DrugBank.d218.s1|165-170|plasma|O
DDI-DrugBank.d218.s1|172-179|proteins|O
DDI-DrugBank.d218.s1|181-182|at|O
DDI-DrugBank.d218.s1|184-184|4|O
DDI-DrugBank.d218.s1|186-186|C|O
DDI-DrugBank.d218.s1|187-187|,|O
DDI-DrugBank.d218.s1|189-192|drug|O
DDI-DrugBank.d218.s1|194-205|interactions|O
DDI-DrugBank.d218.s1|207-211|would|O
DDI-DrugBank.d218.s1|213-215|not|O
DDI-DrugBank.d218.s1|217-218|be|O
DDI-DrugBank.d218.s1|220-227|expected|O
DDI-DrugBank.d218.s1|229-230|to|O
DDI-DrugBank.d218.s1|232-236|occur|O
DDI-DrugBank.d218.s1|237-237|.|O
DDI-MedLine.d122.s0|0-9|Behavioral|O
DDI-MedLine.d122.s0|11-20|mechanisms|O
DDI-MedLine.d122.s0|22-31|underlying|O
DDI-MedLine.d122.s0|33-35|the|O
DDI-MedLine.d122.s0|37-40|link|O
DDI-MedLine.d122.s0|42-48|between|O
DDI-MedLine.d122.s0|50-56|smoking|O
DDI-MedLine.d122.s0|58-60|and|O
DDI-MedLine.d122.s0|62-69|drinking|O
DDI-MedLine.d122.s0|70-70|.|O
DDI-MedLine.d122.s1|0-3|Many|O
DDI-MedLine.d122.s1|5-10|people|O
DDI-MedLine.d122.s1|12-14|use|O
DDI-MedLine.d122.s1|16-19|both|O
DDI-MedLine.d122.s1|21-27|alcohol|drug
DDI-MedLine.d122.s1|29-31|and|O
DDI-MedLine.d122.s1|33-40|nicotine|drug
DDI-MedLine.d122.s1|42-42|(|O
DDI-MedLine.d122.s1|43-46|i.e.|O
DDI-MedLine.d122.s1|47-47|,|O
DDI-MedLine.d122.s1|49-58|cigarettes|O
DDI-MedLine.d122.s1|60-62|and|O
DDI-MedLine.d122.s1|64-68|other|O
DDI-MedLine.d122.s1|70-76|tobacco|O
DDI-MedLine.d122.s1|78-85|products|O
DDI-MedLine.d122.s1|86-86|)|O
DDI-MedLine.d122.s1|87-87|.|O
DDI-MedLine.d122.s2|0-2|The|O
DDI-MedLine.d122.s2|4-13|behavioral|O
DDI-MedLine.d122.s2|15-21|effects|O
DDI-MedLine.d122.s2|23-24|of|O
DDI-MedLine.d122.s2|26-30|these|O
DDI-MedLine.d122.s2|32-34|two|O
DDI-MedLine.d122.s2|36-40|drugs|O
DDI-MedLine.d122.s2|42-47|differ|O
DDI-MedLine.d122.s2|48-48|,|O
DDI-MedLine.d122.s2|50-52|and|O
DDI-MedLine.d122.s2|54-57|they|O
DDI-MedLine.d122.s2|59-60|do|O
DDI-MedLine.d122.s2|62-64|not|O
DDI-MedLine.d122.s2|66-68|act|O
DDI-MedLine.d122.s2|70-71|on|O
DDI-MedLine.d122.s2|73-75|the|O
DDI-MedLine.d122.s2|77-80|same|O
DDI-MedLine.d122.s2|82-87|target|O
DDI-MedLine.d122.s2|89-93|sites|O
DDI-MedLine.d122.s2|95-96|in|O
DDI-MedLine.d122.s2|98-100|the|O
DDI-MedLine.d122.s2|102-106|brain|O
DDI-MedLine.d122.s2|107-107|,|O
DDI-MedLine.d122.s2|109-116|although|O
DDI-MedLine.d122.s2|118-121|they|O
DDI-MedLine.d122.s2|123-125|may|O
DDI-MedLine.d122.s2|127-131|share|O
DDI-MedLine.d122.s2|132-132|,|O
DDI-MedLine.d122.s2|134-135|or|O
DDI-MedLine.d122.s2|137-142|partly|O
DDI-MedLine.d122.s2|144-148|share|O
DDI-MedLine.d122.s2|149-149|,|O
DDI-MedLine.d122.s2|151-157|certain|O
DDI-MedLine.d122.s2|159-168|properties|O
DDI-MedLine.d122.s2|169-169|.|O
DDI-MedLine.d122.s3|0-2|The|O
DDI-MedLine.d122.s3|4-13|initiation|O
DDI-MedLine.d122.s3|15-16|of|O
DDI-MedLine.d122.s3|18-24|alcohol|drug
DDI-MedLine.d122.s3|26-27|or|O
DDI-MedLine.d122.s3|29-36|nicotine|drug
DDI-MedLine.d122.s3|38-40|use|O
DDI-MedLine.d122.s3|42-44|may|O
DDI-MedLine.d122.s3|46-47|be|O
DDI-MedLine.d122.s3|49-60|precipitated|O
DDI-MedLine.d122.s3|62-63|by|O
DDI-MedLine.d122.s3|65-71|similar|O
DDI-MedLine.d122.s3|73-83|personality|O
DDI-MedLine.d122.s3|85-99|characteristics|O
DDI-MedLine.d122.s3|101-102|in|O
DDI-MedLine.d122.s3|104-106|the|O
DDI-MedLine.d122.s3|108-111|user|O
DDI-MedLine.d122.s3|112-112|,|O
DDI-MedLine.d122.s3|114-117|such|O
DDI-MedLine.d122.s3|119-120|as|O
DDI-MedLine.d122.s3|122-132|impulsivity|O
DDI-MedLine.d122.s3|134-136|and|O
DDI-MedLine.d122.s3|138-146|sensation|O
DDI-MedLine.d122.s3|148-154|seeking|O
DDI-MedLine.d122.s3|155-155|.|O
DDI-MedLine.d122.s4|0-7|Moreover|O
DDI-MedLine.d122.s4|8-8|,|O
DDI-MedLine.d122.s4|10-12|the|O
DDI-MedLine.d122.s4|14-23|mechanisms|O
DDI-MedLine.d122.s4|25-34|underlying|O
DDI-MedLine.d122.s4|36-38|the|O
DDI-MedLine.d122.s4|40-50|development|O
DDI-MedLine.d122.s4|52-53|of|O
DDI-MedLine.d122.s4|55-64|dependence|O
DDI-MedLine.d122.s4|66-68|may|O
DDI-MedLine.d122.s4|70-71|be|O
DDI-MedLine.d122.s4|73-79|similar|O
DDI-MedLine.d122.s4|81-83|for|O
DDI-MedLine.d122.s4|85-91|alcohol|drug
DDI-MedLine.d122.s4|93-95|and|O
DDI-MedLine.d122.s4|97-104|nicotine|drug
DDI-MedLine.d122.s4|105-105|.|O
DDI-MedLine.d122.s5|0-3|Thus|O
DDI-MedLine.d122.s5|4-4|,|O
DDI-MedLine.d122.s5|6-12|certain|O
DDI-MedLine.d122.s5|14-20|factors|O
DDI-MedLine.d122.s5|21-21|,|O
DDI-MedLine.d122.s5|23-26|such|O
DDI-MedLine.d122.s5|28-29|as|O
DDI-MedLine.d122.s5|31-41|reinforcing|O
DDI-MedLine.d122.s5|43-46|drug|O
DDI-MedLine.d122.s5|48-54|effects|O
DDI-MedLine.d122.s5|55-55|,|O
DDI-MedLine.d122.s5|57-68|conditioning|O
DDI-MedLine.d122.s5|70-78|processes|O
DDI-MedLine.d122.s5|79-79|,|O
DDI-MedLine.d122.s5|81-89|automatic|O
DDI-MedLine.d122.s5|91-98|behavior|O
DDI-MedLine.d122.s5|99-99|,|O
DDI-MedLine.d122.s5|101-103|and|O
DDI-MedLine.d122.s5|105-110|stress|O
DDI-MedLine.d122.s5|111-111|,|O
DDI-MedLine.d122.s5|113-115|may|O
DDI-MedLine.d122.s5|117-125|influence|O
DDI-MedLine.d122.s5|127-129|the|O
DDI-MedLine.d122.s5|131-141|development|O
DDI-MedLine.d122.s5|143-144|of|O
DDI-MedLine.d122.s5|146-155|dependence|O
DDI-MedLine.d122.s5|157-158|on|O
DDI-MedLine.d122.s5|160-163|both|O
DDI-MedLine.d122.s5|165-169|drugs|O
DDI-MedLine.d122.s5|170-170|.|O
DDI-MedLine.d122.s6|0-4|Other|O
DDI-MedLine.d122.s6|6-12|factors|O
DDI-MedLine.d122.s6|13-13|,|O
DDI-MedLine.d122.s6|15-18|such|O
DDI-MedLine.d122.s6|20-21|as|O
DDI-MedLine.d122.s6|23-31|tolerance|O
DDI-MedLine.d122.s6|33-35|and|O
DDI-MedLine.d122.s6|37-49|sensitization|O
DDI-MedLine.d122.s6|51-52|to|O
DDI-MedLine.d122.s6|54-56|the|O
DDI-MedLine.d122.s6|58-62|drugs|O
DDI-MedLine.d122.s6|63-63|'|O
DDI-MedLine.d122.s6|65-71|actions|O
DDI-MedLine.d122.s6|73-75|and|O
DDI-MedLine.d122.s6|77-79|the|O
DDI-MedLine.d122.s6|81-91|development|O
DDI-MedLine.d122.s6|93-94|of|O
DDI-MedLine.d122.s6|96-105|withdrawal|O
DDI-MedLine.d122.s6|107-114|symptoms|O
DDI-MedLine.d122.s6|115-115|,|O
DDI-MedLine.d122.s6|117-119|may|O
DDI-MedLine.d122.s6|121-124|also|O
DDI-MedLine.d122.s6|126-135|contribute|O
DDI-MedLine.d122.s6|137-138|to|O
DDI-MedLine.d122.s6|140-149|dependence|O
DDI-MedLine.d122.s6|150-150|.|O
DDI-MedLine.d122.s7|0-3|This|O
DDI-MedLine.d122.s7|5-10|review|O
DDI-MedLine.d122.s7|12-20|discusses|O
DDI-MedLine.d122.s7|22-24|the|O
DDI-MedLine.d122.s7|26-32|actions|O
DDI-MedLine.d122.s7|34-35|of|O
DDI-MedLine.d122.s7|37-39|the|O
DDI-MedLine.d122.s7|41-43|two|O
DDI-MedLine.d122.s7|45-49|drugs|O
DDI-MedLine.d122.s7|51-52|on|O
DDI-MedLine.d122.s7|54-60|certain|O
DDI-MedLine.d122.s7|62-66|brain|O
DDI-MedLine.d122.s7|68-75|chemical|O
DDI-MedLine.d122.s7|77-77|(|O
DDI-MedLine.d122.s7|78-81|i.e.|O
DDI-MedLine.d122.s7|82-82|,|O
DDI-MedLine.d122.s7|84-99|neurotransmitter|O
DDI-MedLine.d122.s7|100-100|)|O
DDI-MedLine.d122.s7|102-108|systems|O
DDI-MedLine.d122.s7|110-112|and|O
DDI-MedLine.d122.s7|114-116|the|O
DDI-MedLine.d122.s7|118-123|extent|O
DDI-MedLine.d122.s7|125-126|to|O
DDI-MedLine.d122.s7|128-132|which|O
DDI-MedLine.d122.s7|134-136|the|O
DDI-MedLine.d122.s7|138-144|effects|O
DDI-MedLine.d122.s7|146-147|of|O
DDI-MedLine.d122.s7|149-151|the|O
DDI-MedLine.d122.s7|153-155|two|O
DDI-MedLine.d122.s7|157-161|drugs|O
DDI-MedLine.d122.s7|163-165|may|O
DDI-MedLine.d122.s7|167-174|interact|O
DDI-MedLine.d122.s7|175-175|.|O
DDI-DrugBank.d243.s0|0-1|No|O
DDI-DrugBank.d243.s0|3-6|drug|O
DDI-DrugBank.d243.s0|7-7|,|O
DDI-DrugBank.d243.s0|9-19|nutritional|O
DDI-DrugBank.d243.s0|21-30|supplement|O
DDI-DrugBank.d243.s0|31-31|,|O
DDI-DrugBank.d243.s0|33-36|food|O
DDI-DrugBank.d243.s0|38-39|or|O
DDI-DrugBank.d243.s0|41-44|herb|O
DDI-DrugBank.d243.s0|46-57|interactions|O
DDI-DrugBank.d243.s0|59-61|are|O
DDI-DrugBank.d243.s0|63-67|known|O
DDI-DrugBank.d243.s0|68-68|.|O
DDI-DrugBank.d272.s0|0-2|The|O
DDI-DrugBank.d272.s0|4-7|risk|O
DDI-DrugBank.d272.s0|9-10|of|O
DDI-DrugBank.d272.s0|12-16|using|O
DDI-DrugBank.d272.s0|18-39|bromocriptine mesylate|drug
DDI-DrugBank.d272.s0|41-42|in|O
DDI-DrugBank.d272.s0|44-54|combination|O
DDI-DrugBank.d272.s0|56-59|with|O
DDI-DrugBank.d272.s0|61-65|other|O
DDI-DrugBank.d272.s0|67-71|drugs|O
DDI-DrugBank.d272.s0|73-75|has|O
DDI-DrugBank.d272.s0|77-79|not|O
DDI-DrugBank.d272.s0|81-84|been|O
DDI-DrugBank.d272.s0|86-99|systematically|O
DDI-DrugBank.d272.s0|101-109|evaluated|O
DDI-DrugBank.d272.s0|110-110|,|O
DDI-DrugBank.d272.s0|112-114|but|O
DDI-DrugBank.d272.s0|116-122|alcohol|drug
DDI-DrugBank.d272.s0|124-126|may|O
DDI-DrugBank.d272.s0|128-137|potentiate|O
DDI-DrugBank.d272.s0|139-141|the|O
DDI-DrugBank.d272.s0|143-146|side|O
DDI-DrugBank.d272.s0|148-154|effects|O
DDI-DrugBank.d272.s0|156-157|of|O
DDI-DrugBank.d272.s0|159-180|bromocriptine mesylate|drug
DDI-DrugBank.d272.s0|181-181|.|O
DDI-DrugBank.d272.s1|0-21|Bromocriptine mesylate|drug
DDI-DrugBank.d272.s1|23-25|may|O
DDI-DrugBank.d272.s1|27-34|interact|O
DDI-DrugBank.d272.s1|36-39|with|O
DDI-DrugBank.d272.s1|41-60|dopamine antagonists|group
DDI-DrugBank.d272.s1|61-61|,|O
DDI-DrugBank.d272.s1|63-76|butyrophenones|group
DDI-DrugBank.d272.s1|77-77|,|O
DDI-DrugBank.d272.s1|79-81|and|O
DDI-DrugBank.d272.s1|83-89|certain|O
DDI-DrugBank.d272.s1|91-95|other|O
DDI-DrugBank.d272.s1|97-102|agents|O
DDI-DrugBank.d272.s1|103-103|.|O
DDI-DrugBank.d272.s2|0-8|Compounds|O
DDI-DrugBank.d272.s2|10-11|in|O
DDI-DrugBank.d272.s2|13-17|these|O
DDI-DrugBank.d272.s2|19-28|categories|O
DDI-DrugBank.d272.s2|30-35|result|O
DDI-DrugBank.d272.s2|37-38|in|O
DDI-DrugBank.d272.s2|40-40|a|O
DDI-DrugBank.d272.s2|42-50|decreased|O
DDI-DrugBank.d272.s2|52-59|efficacy|O
DDI-DrugBank.d272.s2|61-62|of|O
DDI-DrugBank.d272.s2|64-85|bromocriptine mesylate|drug
DDI-DrugBank.d272.s2|86-86|:|O
DDI-DrugBank.d272.s2|88-101|phenothiazines|group
DDI-DrugBank.d272.s2|102-102|,|O
DDI-DrugBank.d272.s2|104-114|haloperidol|drug
DDI-DrugBank.d272.s2|115-115|,|O
DDI-DrugBank.d272.s2|117-130|metoclopramide|drug
DDI-DrugBank.d272.s2|131-131|,|O
DDI-DrugBank.d272.s2|133-140|pimozide|drug
DDI-DrugBank.d272.s2|141-141|.|O
DDI-DrugBank.d272.s3|0-10|Concomitant|O
DDI-DrugBank.d272.s3|12-14|use|O
DDI-DrugBank.d272.s3|16-17|of|O
DDI-DrugBank.d272.s3|19-40|bromocriptine mesylate|drug
DDI-DrugBank.d272.s3|42-45|with|O
DDI-DrugBank.d272.s3|47-51|other|O
DDI-DrugBank.d272.s3|53-67|ergot alkaloids|group
DDI-DrugBank.d272.s3|69-70|is|O
DDI-DrugBank.d272.s3|72-74|not|O
DDI-DrugBank.d272.s3|76-86|recommended|O
DDI-DrugBank.d272.s3|87-87|.|O
DDI-DrugBank.d27.s0|0-1|No|O
DDI-DrugBank.d27.s0|3-13|significant|O
DDI-DrugBank.d27.s0|15-23|drug-drug|O
DDI-DrugBank.d27.s0|25-39|pharmacokinetic|O
DDI-DrugBank.d27.s0|41-41|(|O
DDI-DrugBank.d27.s0|42-43|or|O
DDI-DrugBank.d27.s0|45-59|pharmacodynamic|O
DDI-DrugBank.d27.s0|60-60|)|O
DDI-DrugBank.d27.s0|62-73|interactions|O
DDI-DrugBank.d27.s0|75-78|have|O
DDI-DrugBank.d27.s0|80-83|been|O
DDI-DrugBank.d27.s0|85-89|found|O
DDI-DrugBank.d27.s0|91-92|in|O
DDI-DrugBank.d27.s0|94-104|interaction|O
DDI-DrugBank.d27.s0|106-112|studies|O
DDI-DrugBank.d27.s0|114-117|with|O
DDI-DrugBank.d27.s0|119-137|hydrochlorothiazide|drug
DDI-DrugBank.d27.s0|138-138|,|O
DDI-DrugBank.d27.s0|140-146|digoxin|drug
DDI-DrugBank.d27.s0|147-147|,|O
DDI-DrugBank.d27.s0|149-156|warfarin|drug
DDI-DrugBank.d27.s0|157-157|,|O
DDI-DrugBank.d27.s0|159-161|and|O
DDI-DrugBank.d27.s0|163-172|nifedipine|drug
DDI-DrugBank.d27.s0|173-173|.|O
DDI-DrugBank.d27.s1|0-1|In|O
DDI-DrugBank.d27.s1|3-7|vitro|O
DDI-DrugBank.d27.s1|9-15|studies|O
DDI-DrugBank.d27.s1|17-20|show|O
DDI-DrugBank.d27.s1|22-32|significant|O
DDI-DrugBank.d27.s1|34-43|inhibition|O
DDI-DrugBank.d27.s1|45-46|of|O
DDI-DrugBank.d27.s1|48-50|the|O
DDI-DrugBank.d27.s1|52-60|formation|O
DDI-DrugBank.d27.s1|62-63|of|O
DDI-DrugBank.d27.s1|65-72|oxidized|O
DDI-DrugBank.d27.s1|74-83|irbesartan|O
DDI-DrugBank.d27.s1|85-95|metabolites|O
DDI-DrugBank.d27.s1|97-100|with|O
DDI-DrugBank.d27.s1|102-104|the|O
DDI-DrugBank.d27.s1|106-110|known|O
DDI-DrugBank.d27.s1|112-121|cytochrome|O
DDI-DrugBank.d27.s1|123-125|CYP|O
DDI-DrugBank.d27.s1|127-129|2C9|O
DDI-DrugBank.d27.s1|131-151|substrates/inhibitors|O
DDI-DrugBank.d27.s1|153-164|sulphenazole|drug
DDI-DrugBank.d27.s1|165-165|,|O
DDI-DrugBank.d27.s1|167-177|tolbutamide|drug
DDI-DrugBank.d27.s1|179-181|and|O
DDI-DrugBank.d27.s1|183-192|nifedipine|drug
DDI-DrugBank.d27.s1|193-193|.|O
DDI-DrugBank.d27.s2|0-6|However|O
DDI-DrugBank.d27.s2|7-7|,|O
DDI-DrugBank.d27.s2|9-10|in|O
DDI-DrugBank.d27.s2|12-19|clinical|O
DDI-DrugBank.d27.s2|21-27|studies|O
DDI-DrugBank.d27.s2|29-31|the|O
DDI-DrugBank.d27.s2|33-44|consequences|O
DDI-DrugBank.d27.s2|46-47|of|O
DDI-DrugBank.d27.s2|49-59|concomitant|O
DDI-DrugBank.d27.s2|61-70|irbesartan|drug
DDI-DrugBank.d27.s2|72-73|on|O
DDI-DrugBank.d27.s2|75-77|the|O
DDI-DrugBank.d27.s2|79-94|pharmacodynamics|O
DDI-DrugBank.d27.s2|96-97|of|O
DDI-DrugBank.d27.s2|99-106|warfarin|drug
DDI-DrugBank.d27.s2|108-111|were|O
DDI-DrugBank.d27.s2|113-122|negligible|O
DDI-DrugBank.d27.s2|123-123|.|O
DDI-DrugBank.d27.s3|0-4|Based|O
DDI-DrugBank.d27.s3|6-7|on|O
DDI-DrugBank.d27.s3|9-10|in|O
DDI-DrugBank.d27.s3|12-16|vitro|O
DDI-DrugBank.d27.s3|18-21|data|O
DDI-DrugBank.d27.s3|22-22|,|O
DDI-DrugBank.d27.s3|24-25|no|O
DDI-DrugBank.d27.s3|27-37|interaction|O
DDI-DrugBank.d27.s3|39-43|would|O
DDI-DrugBank.d27.s3|45-46|be|O
DDI-DrugBank.d27.s3|48-55|expected|O
DDI-DrugBank.d27.s3|57-60|with|O
DDI-DrugBank.d27.s3|62-66|drugs|O
DDI-DrugBank.d27.s3|68-72|whose|O
DDI-DrugBank.d27.s3|74-83|metabolism|O
DDI-DrugBank.d27.s3|85-86|is|O
DDI-DrugBank.d27.s3|88-96|dependent|O
DDI-DrugBank.d27.s3|98-101|upon|O
DDI-DrugBank.d27.s3|103-112|cytochrome|O
DDI-DrugBank.d27.s3|114-117|P450|O
DDI-DrugBank.d27.s3|119-126|isozymes|O
DDI-DrugBank.d27.s3|128-130|1A1|O
DDI-DrugBank.d27.s3|131-131|,|O
DDI-DrugBank.d27.s3|133-151|1A2,2A6,2B6,2D6,2E1|O
DDI-DrugBank.d27.s3|152-152|,|O
DDI-DrugBank.d27.s3|153-154|or|O
DDI-DrugBank.d27.s3|156-158|3A4|O
DDI-DrugBank.d27.s3|159-159|.|O
DDI-DrugBank.d27.s4|0-1|In|O
DDI-DrugBank.d27.s4|3-10|separate|O
DDI-DrugBank.d27.s4|12-18|studies|O
DDI-DrugBank.d27.s4|20-21|of|O
DDI-DrugBank.d27.s4|23-30|patients|O
DDI-DrugBank.d27.s4|32-40|receiving|O
DDI-DrugBank.d27.s4|42-52|maintenance|O
DDI-DrugBank.d27.s4|54-58|doses|O
DDI-DrugBank.d27.s4|60-61|of|O
DDI-DrugBank.d27.s4|63-70|warfarin|drug
DDI-DrugBank.d27.s4|71-71|,|O
DDI-DrugBank.d27.s4|73-91|hydrochlorothiazide|drug
DDI-DrugBank.d27.s4|92-92|,|O
DDI-DrugBank.d27.s4|94-95|or|O
DDI-DrugBank.d27.s4|97-103|digoxin|drug
DDI-DrugBank.d27.s4|104-104|,|O
DDI-DrugBank.d27.s4|106-115|irbesartan|drug
DDI-DrugBank.d27.s4|117-130|administration|O
DDI-DrugBank.d27.s4|132-134|for|O
DDI-DrugBank.d27.s4|136-136|7|O
DDI-DrugBank.d27.s4|138-141|days|O
DDI-DrugBank.d27.s4|143-145|had|O
DDI-DrugBank.d27.s4|147-148|no|O
DDI-DrugBank.d27.s4|150-155|effect|O
DDI-DrugBank.d27.s4|157-158|on|O
DDI-DrugBank.d27.s4|160-162|the|O
DDI-DrugBank.d27.s4|164-179|pharmacodynamics|O
DDI-DrugBank.d27.s4|181-182|of|O
DDI-DrugBank.d27.s4|184-191|warfarin|drug
DDI-DrugBank.d27.s4|193-193|(|O
DDI-DrugBank.d27.s4|194-204|prothrombin|O
DDI-DrugBank.d27.s4|206-209|time|O
DDI-DrugBank.d27.s4|210-210|)|O
DDI-DrugBank.d27.s4|212-213|or|O
DDI-DrugBank.d27.s4|215-230|pharmacokinetics|O
DDI-DrugBank.d27.s4|232-233|of|O
DDI-DrugBank.d27.s4|235-241|digoxin|drug
DDI-DrugBank.d27.s4|242-242|.|O
DDI-DrugBank.d27.s5|0-2|The|O
DDI-DrugBank.d27.s5|4-19|pharmacokinetics|O
DDI-DrugBank.d27.s5|21-22|of|O
DDI-DrugBank.d27.s5|24-33|irbesartan|drug
DDI-DrugBank.d27.s5|35-38|were|O
DDI-DrugBank.d27.s5|40-42|not|O
DDI-DrugBank.d27.s5|44-51|affected|O
DDI-DrugBank.d27.s5|53-54|by|O
DDI-DrugBank.d27.s5|56-71|coadministration|O
DDI-DrugBank.d27.s5|73-74|of|O
DDI-DrugBank.d27.s5|76-85|nifedipine|drug
DDI-DrugBank.d27.s5|87-88|or|O
DDI-DrugBank.d27.s6|0-0|.|O
DDI-DrugBank.d134.s0|0-4|There|O
DDI-DrugBank.d134.s0|6-8|are|O
DDI-DrugBank.d134.s0|10-11|no|O
DDI-DrugBank.d134.s0|13-17|known|O
DDI-DrugBank.d134.s0|19-22|drug|O
DDI-DrugBank.d134.s0|24-35|interactions|O
DDI-DrugBank.d134.s0|37-40|with|O
DDI-DrugBank.d134.s0|42-50|LEUSTATIN|brand
DDI-DrugBank.d134.s0|52-60|Injection|O
DDI-DrugBank.d134.s0|61-61|.|O
DDI-DrugBank.d134.s1|0-6|Caution|O
DDI-DrugBank.d134.s1|8-13|should|O
DDI-DrugBank.d134.s1|15-16|be|O
DDI-DrugBank.d134.s1|18-26|exercised|O
DDI-DrugBank.d134.s1|28-29|if|O
DDI-DrugBank.d134.s1|31-39|LEUSTATIN|brand
DDI-DrugBank.d134.s1|41-49|Injection|O
DDI-DrugBank.d134.s1|51-52|is|O
DDI-DrugBank.d134.s1|54-65|administered|O
DDI-DrugBank.d134.s1|67-72|before|O
DDI-DrugBank.d134.s1|73-73|,|O
DDI-DrugBank.d134.s1|75-79|after|O
DDI-DrugBank.d134.s1|80-80|,|O
DDI-DrugBank.d134.s1|82-83|or|O
DDI-DrugBank.d134.s1|85-86|in|O
DDI-DrugBank.d134.s1|88-98|conjunction|O
DDI-DrugBank.d134.s1|100-103|with|O
DDI-DrugBank.d134.s1|105-109|other|O
DDI-DrugBank.d134.s1|111-115|drugs|O
DDI-DrugBank.d134.s1|117-121|known|O
DDI-DrugBank.d134.s1|123-124|to|O
DDI-DrugBank.d134.s1|126-130|cause|O
DDI-DrugBank.d134.s1|132-148|immunosuppression|O
DDI-DrugBank.d134.s1|150-151|or|O
DDI-DrugBank.d134.s1|153-168|myelosuppression|O
DDI-DrugBank.d134.s1|169-169|.|O
DDI-DrugBank.d413.s0|0-2|The|O
DDI-DrugBank.d413.s0|4-12|following|O
DDI-DrugBank.d413.s0|14-17|drug|O
DDI-DrugBank.d413.s0|19-30|interactions|O
DDI-DrugBank.d413.s0|32-35|were|O
DDI-DrugBank.d413.s0|37-44|observed|O
DDI-DrugBank.d413.s0|46-47|in|O
DDI-DrugBank.d413.s0|49-52|some|O
DDI-DrugBank.d413.s0|54-61|patients|O
DDI-DrugBank.d413.s0|63-72|undergoing|O
DDI-DrugBank.d413.s0|74-82|treatment|O
DDI-DrugBank.d413.s0|84-87|with|O
DDI-DrugBank.d413.s0|89-92|oral|O
DDI-DrugBank.d413.s0|94-104|allopurinol|drug
DDI-DrugBank.d413.s0|105-105|.|O
DDI-DrugBank.d413.s1|0-7|Although|O
DDI-DrugBank.d413.s1|9-11|the|O
DDI-DrugBank.d413.s1|13-19|pattern|O
DDI-DrugBank.d413.s1|21-22|of|O
DDI-DrugBank.d413.s1|24-26|use|O
DDI-DrugBank.d413.s1|28-30|for|O
DDI-DrugBank.d413.s1|32-35|oral|O
DDI-DrugBank.d413.s1|37-47|allopurinol|drug
DDI-DrugBank.d413.s1|49-56|includes|O
DDI-DrugBank.d413.s1|58-63|longer|O
DDI-DrugBank.d413.s1|65-68|term|O
DDI-DrugBank.d413.s1|70-76|therapy|O
DDI-DrugBank.d413.s1|77-77|,|O
DDI-DrugBank.d413.s1|79-90|particularly|O
DDI-DrugBank.d413.s1|92-94|for|O
DDI-DrugBank.d413.s1|96-99|gout|O
DDI-DrugBank.d413.s1|101-103|and|O
DDI-DrugBank.d413.s1|105-109|renal|O
DDI-DrugBank.d413.s1|111-117|calculi|O
DDI-DrugBank.d413.s1|118-118|,|O
DDI-DrugBank.d413.s1|120-122|the|O
DDI-DrugBank.d413.s1|124-133|experience|O
DDI-DrugBank.d413.s1|135-140|gained|O
DDI-DrugBank.d413.s1|142-144|may|O
DDI-DrugBank.d413.s1|146-147|be|O
DDI-DrugBank.d413.s1|149-156|relevant|O
DDI-DrugBank.d413.s1|157-157|.|O
DDI-DrugBank.d413.s2|0-26|Mercaptopurine/Azathioprine|drug
DDI-DrugBank.d413.s2|27-27|:|O
DDI-DrugBank.d413.s2|29-39|Allopurinol|drug
DDI-DrugBank.d413.s2|41-48|inhibits|O
DDI-DrugBank.d413.s2|50-52|the|O
DDI-DrugBank.d413.s2|54-62|enzymatic|O
DDI-DrugBank.d413.s2|64-72|oxidation|O
DDI-DrugBank.d413.s2|74-75|of|O
DDI-DrugBank.d413.s2|77-90|mercaptopurine|drug
DDI-DrugBank.d413.s2|92-94|and|O
DDI-DrugBank.d413.s2|96-107|azathioprine|drug
DDI-DrugBank.d413.s2|109-110|to|O
DDI-DrugBank.d413.s2|112-126|6-thiouric acid|drug
DDI-DrugBank.d413.s2|127-127|.|O
DDI-DrugBank.d413.s3|0-3|This|O
DDI-DrugBank.d413.s3|5-13|oxidation|O
DDI-DrugBank.d413.s3|14-14|,|O
DDI-DrugBank.d413.s3|16-20|which|O
DDI-DrugBank.d413.s3|22-23|is|O
DDI-DrugBank.d413.s3|25-33|catalyzed|O
DDI-DrugBank.d413.s3|35-36|by|O
DDI-DrugBank.d413.s3|38-45|xanthine|O
DDI-DrugBank.d413.s3|47-53|oxidase|O
DDI-DrugBank.d413.s3|54-54|,|O
DDI-DrugBank.d413.s3|56-66|inactivates|O
DDI-DrugBank.d413.s3|68-81|mercaptopurine|drug
DDI-DrugBank.d413.s3|82-82|.|O
DDI-DrugBank.d413.s4|0-1|In|O
DDI-DrugBank.d413.s4|3-10|patients|O
DDI-DrugBank.d413.s4|12-20|receiving|O
DDI-DrugBank.d413.s4|22-35|mercaptopurine|drug
DDI-DrugBank.d413.s4|37-37|(|O
DDI-DrugBank.d413.s4|38-47|Purinethol|brand
DDI-DrugBank.d413.s4|48-48|)|O
DDI-DrugBank.d413.s4|50-51|or|O
DDI-DrugBank.d413.s4|53-64|azathioprine|drug
DDI-DrugBank.d413.s4|66-66|(|O
DDI-DrugBank.d413.s4|67-72|Imuran|brand
DDI-DrugBank.d413.s4|73-73|)|O
DDI-DrugBank.d413.s4|74-74|,|O
DDI-DrugBank.d413.s4|76-78|the|O
DDI-DrugBank.d413.s4|80-90|concomitant|O
DDI-DrugBank.d413.s4|92-105|administration|O
DDI-DrugBank.d413.s4|107-108|of|O
DDI-DrugBank.d413.s4|110-116|300-600|O
DDI-DrugBank.d413.s4|118-119|mg|O
DDI-DrugBank.d413.s4|121-122|of|O
DDI-DrugBank.d413.s4|124-134|allopurinol|drug
DDI-DrugBank.d413.s4|136-138|per|O
DDI-DrugBank.d413.s4|140-142|day|O
DDI-DrugBank.d413.s4|144-147|will|O
DDI-DrugBank.d413.s4|149-155|require|O
DDI-DrugBank.d413.s4|157-157|a|O
DDI-DrugBank.d413.s4|159-167|reduction|O
DDI-DrugBank.d413.s4|169-170|in|O
DDI-DrugBank.d413.s4|172-175|dose|O
DDI-DrugBank.d413.s4|177-178|to|O
DDI-DrugBank.d413.s4|180-192|approximately|O
DDI-DrugBank.d413.s4|194-202|one-third|O
DDI-DrugBank.d413.s4|204-205|to|O
DDI-DrugBank.d413.s4|207-216|one-fourth|O
DDI-DrugBank.d413.s4|218-219|of|O
DDI-DrugBank.d413.s4|221-223|the|O
DDI-DrugBank.d413.s4|225-229|usual|O
DDI-DrugBank.d413.s4|231-234|dose|O
DDI-DrugBank.d413.s4|236-237|of|O
DDI-DrugBank.d413.s4|239-252|mercaptopurine|drug
DDI-DrugBank.d413.s4|254-255|or|O
DDI-DrugBank.d413.s4|257-268|azathioprine|drug
DDI-DrugBank.d413.s4|269-269|.|O
DDI-DrugBank.d413.s5|0-9|Subsequent|O
DDI-DrugBank.d413.s5|11-20|adjustment|O
DDI-DrugBank.d413.s5|22-23|of|O
DDI-DrugBank.d413.s5|25-29|doses|O
DDI-DrugBank.d413.s5|31-32|of|O
DDI-DrugBank.d413.s5|34-47|mercaptopurine|drug
DDI-DrugBank.d413.s5|49-50|or|O
DDI-DrugBank.d413.s5|52-63|azathioprine|drug
DDI-DrugBank.d413.s5|65-70|should|O
DDI-DrugBank.d413.s5|72-73|be|O
DDI-DrugBank.d413.s5|75-78|made|O
DDI-DrugBank.d413.s5|80-81|on|O
DDI-DrugBank.d413.s5|83-85|the|O
DDI-DrugBank.d413.s5|87-91|basis|O
DDI-DrugBank.d413.s5|93-94|of|O
DDI-DrugBank.d413.s5|96-106|therapeutic|O
DDI-DrugBank.d413.s5|108-115|response|O
DDI-DrugBank.d413.s5|117-119|and|O
DDI-DrugBank.d413.s5|121-123|the|O
DDI-DrugBank.d413.s5|125-134|appearance|O
DDI-DrugBank.d413.s5|136-137|of|O
DDI-DrugBank.d413.s5|139-143|toxic|O
DDI-DrugBank.d413.s5|145-151|effects|O
DDI-DrugBank.d413.s5|152-152|.|O
DDI-DrugBank.d413.s6|0-8|Dicumarol|drug
DDI-DrugBank.d413.s6|9-9|:|O
DDI-DrugBank.d413.s6|11-12|It|O
DDI-DrugBank.d413.s6|14-16|has|O
DDI-DrugBank.d413.s6|18-21|been|O
DDI-DrugBank.d413.s6|23-30|reported|O
DDI-DrugBank.d413.s6|32-35|that|O
DDI-DrugBank.d413.s6|37-47|allopurinol|drug
DDI-DrugBank.d413.s6|49-56|prolongs|O
DDI-DrugBank.d413.s6|58-60|the|O
DDI-DrugBank.d413.s6|62-70|half-life|O
DDI-DrugBank.d413.s6|72-73|of|O
DDI-DrugBank.d413.s6|75-77|the|O
DDI-DrugBank.d413.s6|79-91|anticoagulant|group
DDI-DrugBank.d413.s6|92-92|,|O
DDI-DrugBank.d413.s6|94-102|dicumarol|drug
DDI-DrugBank.d413.s6|103-103|.|O
DDI-DrugBank.d413.s7|0-2|The|O
DDI-DrugBank.d413.s7|4-11|clinical|O
DDI-DrugBank.d413.s7|13-17|basis|O
DDI-DrugBank.d413.s7|19-20|of|O
DDI-DrugBank.d413.s7|22-25|this|O
DDI-DrugBank.d413.s7|27-30|drug|O
DDI-DrugBank.d413.s7|32-42|interaction|O
DDI-DrugBank.d413.s7|44-46|has|O
DDI-DrugBank.d413.s7|48-50|not|O
DDI-DrugBank.d413.s7|52-55|been|O
DDI-DrugBank.d413.s7|57-67|established|O
DDI-DrugBank.d413.s7|69-71|but|O
DDI-DrugBank.d413.s7|73-78|should|O
DDI-DrugBank.d413.s7|80-81|be|O
DDI-DrugBank.d413.s7|83-87|noted|O
DDI-DrugBank.d413.s7|89-92|when|O
DDI-DrugBank.d413.s7|94-104|allopurinol|drug
DDI-DrugBank.d413.s7|106-107|is|O
DDI-DrugBank.d413.s7|109-113|given|O
DDI-DrugBank.d413.s7|115-116|to|O
DDI-DrugBank.d413.s7|118-125|patients|O
DDI-DrugBank.d413.s7|127-133|already|O
DDI-DrugBank.d413.s7|135-136|on|O
DDI-DrugBank.d413.s7|138-146|dicumarol|drug
DDI-DrugBank.d413.s7|148-154|therapy|O
DDI-DrugBank.d413.s7|155-155|.|O
DDI-DrugBank.d413.s8|0-11|Consequently|O
DDI-DrugBank.d413.s8|12-12|,|O
DDI-DrugBank.d413.s8|14-24|prothrombin|O
DDI-DrugBank.d413.s8|26-29|time|O
DDI-DrugBank.d413.s8|31-36|should|O
DDI-DrugBank.d413.s8|38-39|be|O
DDI-DrugBank.d413.s8|41-50|reassessed|O
DDI-DrugBank.d413.s8|52-63|periodically|O
DDI-DrugBank.d413.s8|65-66|in|O
DDI-DrugBank.d413.s8|68-75|patients|O
DDI-DrugBank.d413.s8|77-85|receiving|O
DDI-DrugBank.d413.s8|87-90|both|O
DDI-DrugBank.d413.s8|92-96|drugs|O
DDI-DrugBank.d413.s8|97-97|.|O
DDI-DrugBank.d413.s9|0-16|Uricosuric Agents|group
DDI-DrugBank.d413.s9|17-17|:|O
DDI-DrugBank.d413.s9|19-23|Since|O
DDI-DrugBank.d413.s9|25-27|the|O
DDI-DrugBank.d413.s9|29-37|excretion|O
DDI-DrugBank.d413.s9|39-40|of|O
DDI-DrugBank.d413.s9|42-51|oxipurinol|drug
DDI-DrugBank.d413.s9|53-54|is|O
DDI-DrugBank.d413.s9|56-62|similar|O
DDI-DrugBank.d413.s9|64-65|to|O
DDI-DrugBank.d413.s9|67-70|that|O
DDI-DrugBank.d413.s9|72-73|of|O
DDI-DrugBank.d413.s9|75-79|urate|O
DDI-DrugBank.d413.s9|80-80|,|O
DDI-DrugBank.d413.s9|82-98|uricosuric agents|group
DDI-DrugBank.d413.s9|99-99|,|O
DDI-DrugBank.d413.s9|101-105|which|O
DDI-DrugBank.d413.s9|107-114|increase|O
DDI-DrugBank.d413.s9|116-118|the|O
DDI-DrugBank.d413.s9|120-128|excretion|O
DDI-DrugBank.d413.s9|130-131|of|O
DDI-DrugBank.d413.s9|133-137|urate|O
DDI-DrugBank.d413.s9|138-138|,|O
DDI-DrugBank.d413.s9|140-142|are|O
DDI-DrugBank.d413.s9|144-147|also|O
DDI-DrugBank.d413.s9|149-154|likely|O
DDI-DrugBank.d413.s9|156-157|to|O
DDI-DrugBank.d413.s9|159-166|increase|O
DDI-DrugBank.d413.s9|168-170|the|O
DDI-DrugBank.d413.s9|172-180|excretion|O
DDI-DrugBank.d413.s9|182-183|of|O
DDI-DrugBank.d413.s9|185-194|oxipurinol|drug
DDI-DrugBank.d413.s9|196-198|and|O
DDI-DrugBank.d413.s9|200-203|thus|O
DDI-DrugBank.d413.s9|205-209|lower|O
DDI-DrugBank.d413.s9|211-213|the|O
DDI-DrugBank.d413.s9|215-220|degree|O
DDI-DrugBank.d413.s9|222-223|of|O
DDI-DrugBank.d413.s9|225-234|inhibition|O
DDI-DrugBank.d413.s9|236-237|of|O
DDI-DrugBank.d413.s9|239-246|xanthine|O
DDI-DrugBank.d413.s9|248-254|oxidase|O
DDI-DrugBank.d413.s9|255-255|.|O
DDI-DrugBank.d413.s10|0-2|The|O
DDI-DrugBank.d413.s10|4-14|concomitant|O
DDI-DrugBank.d413.s10|16-29|administration|O
DDI-DrugBank.d413.s10|31-32|of|O
DDI-DrugBank.d413.s10|34-50|uricosuric agents|group
DDI-DrugBank.d413.s10|52-54|and|O
DDI-DrugBank.d413.s10|56-66|allopurinol|drug
DDI-DrugBank.d413.s10|68-70|has|O
DDI-DrugBank.d413.s10|72-75|been|O
DDI-DrugBank.d413.s10|77-86|associated|O
DDI-DrugBank.d413.s10|88-91|with|O
DDI-DrugBank.d413.s10|93-93|a|O
DDI-DrugBank.d413.s10|95-102|decrease|O
DDI-DrugBank.d413.s10|104-105|in|O
DDI-DrugBank.d413.s10|107-109|the|O
DDI-DrugBank.d413.s10|111-119|excretion|O
DDI-DrugBank.d413.s10|121-122|of|O
DDI-DrugBank.d413.s10|124-133|oxypurines|O
DDI-DrugBank.d413.s10|135-135|(|O
DDI-DrugBank.d413.s10|136-147|hypoxanthine|O
DDI-DrugBank.d413.s10|149-151|and|O
DDI-DrugBank.d413.s10|153-160|xanthine|O
DDI-DrugBank.d413.s10|161-161|)|O
DDI-DrugBank.d413.s10|163-165|and|O
DDI-DrugBank.d413.s10|167-168|an|O
DDI-DrugBank.d413.s10|170-177|increase|O
DDI-DrugBank.d413.s10|179-180|in|O
DDI-DrugBank.d413.s10|182-188|urinary|O
DDI-DrugBank.d413.s10|190-193|uric|O
DDI-DrugBank.d413.s10|195-198|acid|O
DDI-DrugBank.d413.s10|200-208|excretion|O
DDI-DrugBank.d413.s10|210-217|compared|O
DDI-DrugBank.d413.s10|219-222|with|O
DDI-DrugBank.d413.s10|224-227|that|O
DDI-DrugBank.d413.s10|229-236|observed|O
DDI-DrugBank.d413.s10|238-241|with|O
DDI-DrugBank.d413.s10|243-253|allopurinol|drug
DDI-DrugBank.d413.s10|255-259|alone|O
DDI-DrugBank.d413.s10|260-260|.|O
DDI-DrugBank.d413.s11|0-7|Although|O
DDI-DrugBank.d413.s11|9-16|clinical|O
DDI-DrugBank.d413.s11|18-25|evidence|O
DDI-DrugBank.d413.s11|27-28|to|O
DDI-DrugBank.d413.s11|30-33|date|O
DDI-DrugBank.d413.s11|35-37|has|O
DDI-DrugBank.d413.s11|39-41|not|O
DDI-DrugBank.d413.s11|43-54|demonstrated|O
DDI-DrugBank.d413.s11|56-60|renal|O
DDI-DrugBank.d413.s11|62-74|precipitation|O
DDI-DrugBank.d413.s11|76-77|of|O
DDI-DrugBank.d413.s11|79-88|oxypurines|O
DDI-DrugBank.d413.s11|90-91|in|O
DDI-DrugBank.d413.s11|93-100|patients|O
DDI-DrugBank.d413.s11|102-107|either|O
DDI-DrugBank.d413.s11|109-110|on|O
DDI-DrugBank.d413.s11|112-122|allopurinol|drug
DDI-DrugBank.d413.s11|124-128|alone|O
DDI-DrugBank.d413.s11|130-131|or|O
DDI-DrugBank.d413.s11|133-134|in|O
DDI-DrugBank.d413.s11|136-146|combination|O
DDI-DrugBank.d413.s11|148-151|with|O
DDI-DrugBank.d413.s11|153-169|uricosuric agents|group
DDI-DrugBank.d413.s11|170-170|,|O
DDI-DrugBank.d413.s11|172-174|the|O
DDI-DrugBank.d413.s11|176-186|possibility|O
DDI-DrugBank.d413.s11|188-193|should|O
DDI-DrugBank.d413.s11|195-196|be|O
DDI-DrugBank.d413.s11|198-201|kept|O
DDI-DrugBank.d413.s11|203-204|in|O
DDI-DrugBank.d413.s11|206-209|mind|O
DDI-DrugBank.d413.s11|210-210|.|O
DDI-DrugBank.d413.s12|0-17|Thiazide Diuretics|group
DDI-DrugBank.d413.s12|18-18|:|O
DDI-DrugBank.d413.s12|20-22|The|O
DDI-DrugBank.d413.s12|24-30|reports|O
DDI-DrugBank.d413.s12|32-35|that|O
DDI-DrugBank.d413.s12|37-39|the|O
DDI-DrugBank.d413.s12|41-51|concomitant|O
DDI-DrugBank.d413.s12|53-55|use|O
DDI-DrugBank.d413.s12|57-58|of|O
DDI-DrugBank.d413.s12|60-70|allopurinol|drug
DDI-DrugBank.d413.s12|72-74|and|O
DDI-DrugBank.d413.s12|76-93|thiazide diuretics|group
DDI-DrugBank.d413.s12|95-97|may|O
DDI-DrugBank.d413.s12|99-108|contribute|O
DDI-DrugBank.d413.s12|110-111|to|O
DDI-DrugBank.d413.s12|113-115|the|O
DDI-DrugBank.d413.s12|117-127|enhancement|O
DDI-DrugBank.d413.s12|129-130|of|O
DDI-DrugBank.d413.s12|132-142|allopurinol|drug
DDI-DrugBank.d413.s12|144-151|toxicity|O
DDI-DrugBank.d413.s12|153-154|in|O
DDI-DrugBank.d413.s12|156-159|some|O
DDI-DrugBank.d413.s12|161-168|patients|O
DDI-DrugBank.d413.s12|170-173|have|O
DDI-DrugBank.d413.s12|175-178|been|O
DDI-DrugBank.d413.s12|180-187|reviewed|O
DDI-DrugBank.d413.s12|189-190|in|O
DDI-DrugBank.d413.s12|192-193|an|O
DDI-DrugBank.d413.s12|195-201|attempt|O
DDI-DrugBank.d413.s12|203-204|to|O
DDI-DrugBank.d413.s12|206-214|establish|O
DDI-DrugBank.d413.s12|216-216|a|O
DDI-DrugBank.d413.s12|218-233|cause-and-effect|O
DDI-DrugBank.d413.s12|235-246|relationship|O
DDI-DrugBank.d413.s12|248-250|and|O
DDI-DrugBank.d413.s12|252-252|a|O
DDI-DrugBank.d413.s12|254-262|mechanism|O
DDI-DrugBank.d413.s12|264-265|of|O
DDI-DrugBank.d413.s12|267-275|causation|O
DDI-DrugBank.d413.s12|276-276|.|O
DDI-DrugBank.d413.s13|0-5|Review|O
DDI-DrugBank.d413.s13|7-8|of|O
DDI-DrugBank.d413.s13|10-14|these|O
DDI-DrugBank.d413.s13|16-19|case|O
DDI-DrugBank.d413.s13|21-27|reports|O
DDI-DrugBank.d413.s13|29-37|indicates|O
DDI-DrugBank.d413.s13|39-42|that|O
DDI-DrugBank.d413.s13|44-46|the|O
DDI-DrugBank.d413.s13|48-55|patients|O
DDI-DrugBank.d413.s13|57-60|were|O
DDI-DrugBank.d413.s13|62-67|mainly|O
DDI-DrugBank.d413.s13|69-77|receiving|O
DDI-DrugBank.d413.s13|79-96|thiazide diuretics|group
DDI-DrugBank.d413.s13|98-100|for|O
DDI-DrugBank.d413.s13|102-113|hypertension|O
DDI-DrugBank.d413.s13|115-117|and|O
DDI-DrugBank.d413.s13|119-122|that|O
DDI-DrugBank.d413.s13|124-128|tests|O
DDI-DrugBank.d413.s13|130-131|to|O
DDI-DrugBank.d413.s13|133-136|rule|O
DDI-DrugBank.d413.s13|138-140|out|O
DDI-DrugBank.d413.s13|142-150|decreased|O
DDI-DrugBank.d413.s13|152-156|renal|O
DDI-DrugBank.d413.s13|158-165|function|O
DDI-DrugBank.d413.s13|167-175|secondary|O
DDI-DrugBank.d413.s13|177-178|to|O
DDI-DrugBank.d413.s13|180-191|hypertensive|O
DDI-DrugBank.d413.s13|193-203|nephropathy|O
DDI-DrugBank.d413.s13|205-208|were|O
DDI-DrugBank.d413.s13|210-212|not|O
DDI-DrugBank.d413.s13|214-218|often|O
DDI-DrugBank.d413.s13|220-228|performed|O
DDI-DrugBank.d413.s13|229-229|.|O
DDI-DrugBank.d413.s14|0-1|In|O
DDI-DrugBank.d413.s14|3-7|those|O
DDI-DrugBank.d413.s14|9-16|patients|O
DDI-DrugBank.d413.s14|18-19|in|O
DDI-DrugBank.d413.s14|21-24|whom|O
DDI-DrugBank.d413.s14|26-30|renal|O
DDI-DrugBank.d413.s14|32-44|insufficiency|O
DDI-DrugBank.d413.s14|46-48|was|O
DDI-DrugBank.d413.s14|50-59|documented|O
DDI-DrugBank.d413.s14|60-60|,|O
DDI-DrugBank.d413.s14|62-68|however|O
DDI-DrugBank.d413.s14|69-69|,|O
DDI-DrugBank.d413.s14|71-73|the|O
DDI-DrugBank.d413.s14|75-88|recommendation|O
DDI-DrugBank.d413.s14|90-91|to|O
DDI-DrugBank.d413.s14|93-97|lower|O
DDI-DrugBank.d413.s14|99-101|the|O
DDI-DrugBank.d413.s14|103-106|dose|O
DDI-DrugBank.d413.s14|108-109|of|O
DDI-DrugBank.d413.s14|111-121|allopurinol|drug
DDI-DrugBank.d413.s14|123-125|was|O
DDI-DrugBank.d413.s14|127-129|not|O
DDI-DrugBank.d413.s14|131-138|followed|O
DDI-DrugBank.d413.s14|139-139|.|O
DDI-DrugBank.d413.s15|0-7|Although|O
DDI-DrugBank.d413.s15|9-9|a|O
DDI-DrugBank.d413.s15|11-16|causal|O
DDI-DrugBank.d413.s15|18-26|mechanism|O
DDI-DrugBank.d413.s15|28-30|and|O
DDI-DrugBank.d413.s15|32-32|a|O
DDI-DrugBank.d413.s15|34-49|cause-and-effect|O
DDI-DrugBank.d413.s15|51-62|relationship|O
DDI-DrugBank.d413.s15|64-67|have|O
DDI-DrugBank.d413.s15|69-71|not|O
DDI-DrugBank.d413.s15|73-76|been|O
DDI-DrugBank.d413.s15|78-88|established|O
DDI-DrugBank.d413.s15|89-89|,|O
DDI-DrugBank.d413.s15|91-97|current|O
DDI-DrugBank.d413.s15|99-106|evidence|O
DDI-DrugBank.d413.s15|108-115|suggests|O
DDI-DrugBank.d413.s15|117-120|that|O
DDI-DrugBank.d413.s15|122-126|renal|O
DDI-DrugBank.d413.s15|128-135|function|O
DDI-DrugBank.d413.s15|137-142|should|O
DDI-DrugBank.d413.s15|144-145|be|O
DDI-DrugBank.d413.s15|147-155|monitored|O
DDI-DrugBank.d413.s15|157-158|in|O
DDI-DrugBank.d413.s15|160-167|patients|O
DDI-DrugBank.d413.s15|169-170|on|O
DDI-DrugBank.d413.s15|172-189|thiazide diuretics|group
DDI-DrugBank.d413.s15|191-193|and|O
DDI-DrugBank.d413.s15|195-205|allopurinol|drug
DDI-DrugBank.d413.s15|207-210|even|O
DDI-DrugBank.d413.s15|212-213|in|O
DDI-DrugBank.d413.s15|215-217|the|O
DDI-DrugBank.d413.s15|219-225|absence|O
DDI-DrugBank.d413.s15|227-228|of|O
DDI-DrugBank.d413.s15|230-234|renal|O
DDI-DrugBank.d413.s15|236-242|failure|O
DDI-DrugBank.d413.s15|243-243|,|O
DDI-DrugBank.d413.s15|245-247|and|O
DDI-DrugBank.d413.s15|249-254|dosage|O
DDI-DrugBank.d413.s15|256-261|levels|O
DDI-DrugBank.d413.s15|263-268|should|O
DDI-DrugBank.d413.s15|270-271|be|O
DDI-DrugBank.d413.s15|273-276|even|O
DDI-DrugBank.d413.s15|278-281|more|O
DDI-DrugBank.d413.s15|283-296|conservatively|O
DDI-DrugBank.d413.s15|298-305|adjusted|O
DDI-DrugBank.d413.s15|307-308|in|O
DDI-DrugBank.d413.s15|310-314|those|O
DDI-DrugBank.d413.s15|316-323|patients|O
DDI-DrugBank.d413.s15|325-326|on|O
DDI-DrugBank.d413.s15|328-331|such|O
DDI-DrugBank.d413.s15|333-340|combined|O
DDI-DrugBank.d413.s15|342-348|therapy|O
DDI-DrugBank.d413.s15|350-351|if|O
DDI-DrugBank.d413.s15|353-362|diminished|O
DDI-DrugBank.d413.s15|364-368|renal|O
DDI-DrugBank.d413.s15|370-377|function|O
DDI-DrugBank.d413.s15|379-380|is|O
DDI-DrugBank.d413.s15|382-391|detected..|O
DDI-DrugBank.d413.s16|0-21|Ampicillin/Amoxicillin|drug
DDI-DrugBank.d413.s16|22-22|:|O
DDI-DrugBank.d413.s16|24-25|An|O
DDI-DrugBank.d413.s16|27-34|increase|O
DDI-DrugBank.d413.s16|36-37|in|O
DDI-DrugBank.d413.s16|39-41|the|O
DDI-DrugBank.d413.s16|43-51|frequency|O
DDI-DrugBank.d413.s16|53-54|of|O
DDI-DrugBank.d413.s16|56-59|skin|O
DDI-DrugBank.d413.s16|61-64|rash|O
DDI-DrugBank.d413.s16|66-68|has|O
DDI-DrugBank.d413.s16|70-73|been|O
DDI-DrugBank.d413.s16|75-82|reported|O
DDI-DrugBank.d413.s16|84-88|among|O
DDI-DrugBank.d413.s16|90-97|patients|O
DDI-DrugBank.d413.s16|99-107|receiving|O
DDI-DrugBank.d413.s16|109-118|ampicillin|drug
DDI-DrugBank.d413.s16|120-121|or|O
DDI-DrugBank.d413.s16|123-133|amoxicillin|drug
DDI-DrugBank.d413.s16|135-146|concurrently|O
DDI-DrugBank.d413.s16|148-151|with|O
DDI-DrugBank.d413.s16|153-163|allopurinol|drug
DDI-DrugBank.d413.s16|165-172|compared|O
DDI-DrugBank.d413.s16|174-175|to|O
DDI-DrugBank.d413.s16|177-184|patients|O
DDI-DrugBank.d413.s16|186-188|who|O
DDI-DrugBank.d413.s16|190-192|are|O
DDI-DrugBank.d413.s16|194-196|not|O
DDI-DrugBank.d413.s16|198-206|receiving|O
DDI-DrugBank.d413.s16|208-211|both|O
DDI-DrugBank.d413.s16|213-217|drugs|O
DDI-DrugBank.d413.s16|218-218|.|O
DDI-DrugBank.d413.s17|0-2|The|O
DDI-DrugBank.d413.s17|4-8|cause|O
DDI-DrugBank.d413.s17|10-11|of|O
DDI-DrugBank.d413.s17|13-15|the|O
DDI-DrugBank.d413.s17|17-24|reported|O
DDI-DrugBank.d413.s17|26-36|association|O
DDI-DrugBank.d413.s17|38-40|has|O
DDI-DrugBank.d413.s17|42-44|not|O
DDI-DrugBank.d413.s17|46-49|been|O
DDI-DrugBank.d413.s17|51-61|established|O
DDI-DrugBank.d413.s17|62-62|.|O
DDI-DrugBank.d413.s18|0-15|Cytotoxic Agents|group
DDI-DrugBank.d413.s18|16-16|:|O
DDI-DrugBank.d413.s18|18-25|Enhanced|O
DDI-DrugBank.d413.s18|27-30|bone|O
DDI-DrugBank.d413.s18|32-37|marrow|O
DDI-DrugBank.d413.s18|39-49|suppression|O
DDI-DrugBank.d413.s18|51-52|by|O
DDI-DrugBank.d413.s18|54-69|cyclophosphamide|drug
DDI-DrugBank.d413.s18|71-73|and|O
DDI-DrugBank.d413.s18|75-79|other|O
DDI-DrugBank.d413.s18|81-96|cytotoxic agents|group
DDI-DrugBank.d413.s18|98-100|has|O
DDI-DrugBank.d413.s18|102-105|been|O
DDI-DrugBank.d413.s18|107-114|reported|O
DDI-DrugBank.d413.s18|116-120|among|O
DDI-DrugBank.d413.s18|122-129|patients|O
DDI-DrugBank.d413.s18|131-134|with|O
DDI-DrugBank.d413.s18|136-145|neoplastic|O
DDI-DrugBank.d413.s18|147-153|disease|O
DDI-DrugBank.d413.s18|154-154|,|O
DDI-DrugBank.d413.s18|156-161|except|O
DDI-DrugBank.d413.s18|163-170|leukemia|O
DDI-DrugBank.d413.s18|171-171|,|O
DDI-DrugBank.d413.s18|173-174|in|O
DDI-DrugBank.d413.s18|176-178|the|O
DDI-DrugBank.d413.s18|180-187|presence|O
DDI-DrugBank.d413.s18|189-190|of|O
DDI-DrugBank.d413.s18|192-202|allopurinol|drug
DDI-DrugBank.d413.s18|203-203|.|O
DDI-DrugBank.d413.s19|0-6|However|O
DDI-DrugBank.d413.s19|7-7|,|O
DDI-DrugBank.d413.s19|9-10|in|O
DDI-DrugBank.d413.s19|12-12|a|O
DDI-DrugBank.d413.s19|14-28|well-controlled|O
DDI-DrugBank.d413.s19|30-34|study|O
DDI-DrugBank.d413.s19|36-37|of|O
DDI-DrugBank.d413.s19|39-46|patients|O
DDI-DrugBank.d413.s19|48-51|with|O
DDI-DrugBank.d413.s19|53-60|lymphoma|O
DDI-DrugBank.d413.s19|62-63|on|O
DDI-DrugBank.d413.s19|65-75|combination|O
DDI-DrugBank.d413.s19|77-83|therapy|O
DDI-DrugBank.d413.s19|84-84|,|O
DDI-DrugBank.d413.s19|86-96|allopurinol|drug
DDI-DrugBank.d413.s19|98-100|did|O
DDI-DrugBank.d413.s19|102-104|not|O
DDI-DrugBank.d413.s19|106-113|increase|O
DDI-DrugBank.d413.s19|115-117|the|O
DDI-DrugBank.d413.s19|119-124|marrow|O
DDI-DrugBank.d413.s19|126-133|toxicity|O
DDI-DrugBank.d413.s19|135-136|of|O
DDI-DrugBank.d413.s19|138-145|patients|O
DDI-DrugBank.d413.s19|147-153|treated|O
DDI-DrugBank.d413.s19|155-158|with|O
DDI-DrugBank.d413.s19|160-175|cyclophosphamide|drug
DDI-DrugBank.d413.s19|176-176|,|O
DDI-DrugBank.d413.s19|178-188|doxorubicin|drug
DDI-DrugBank.d413.s19|189-189|,|O
DDI-DrugBank.d413.s19|191-199|bleomycin|drug
DDI-DrugBank.d413.s19|200-200|,|O
DDI-DrugBank.d413.s19|202-213|procarbazine|drug
DDI-DrugBank.d413.s19|215-220|and/or|O
DDI-DrugBank.d413.s19|222-236|mechlorethamine|drug
DDI-DrugBank.d413.s19|237-237|.|O
DDI-DrugBank.d413.s20|0-13|Chlorpropamide|drug
DDI-DrugBank.d413.s20|14-14|:|O
DDI-DrugBank.d413.s20|16-30|Chlorpropamides|drug
DDI-DrugBank.d413.s20|32-37|plasma|O
DDI-DrugBank.d413.s20|39-47|half-life|O
DDI-DrugBank.d413.s20|49-51|may|O
DDI-DrugBank.d413.s20|53-54|be|O
DDI-DrugBank.d413.s20|56-64|prolonged|O
DDI-DrugBank.d413.s20|66-67|by|O
DDI-DrugBank.d413.s20|69-79|allopurinol|drug
DDI-DrugBank.d413.s20|80-80|,|O
DDI-DrugBank.d413.s20|82-86|since|O
DDI-DrugBank.d413.s20|88-98|allopurinol|drug
DDI-DrugBank.d413.s20|100-102|and|O
DDI-DrugBank.d413.s20|104-117|chlorpropamide|drug
DDI-DrugBank.d413.s20|119-121|may|O
DDI-DrugBank.d413.s20|123-129|compete|O
DDI-DrugBank.d413.s20|131-133|for|O
DDI-DrugBank.d413.s20|135-143|excretion|O
DDI-DrugBank.d413.s20|145-146|in|O
DDI-DrugBank.d413.s20|148-150|the|O
DDI-DrugBank.d413.s20|152-156|renal|O
DDI-DrugBank.d413.s20|158-163|tubule|O
DDI-DrugBank.d413.s20|164-164|.|O
DDI-DrugBank.d413.s21|0-2|The|O
DDI-DrugBank.d413.s21|4-7|risk|O
DDI-DrugBank.d413.s21|9-10|of|O
DDI-DrugBank.d413.s21|12-23|hypoglycemia|O
DDI-DrugBank.d413.s21|25-33|secondary|O
DDI-DrugBank.d413.s21|35-36|to|O
DDI-DrugBank.d413.s21|38-41|this|O
DDI-DrugBank.d413.s21|43-51|mechanism|O
DDI-DrugBank.d413.s21|53-55|may|O
DDI-DrugBank.d413.s21|57-58|be|O
DDI-DrugBank.d413.s21|60-68|increased|O
DDI-DrugBank.d413.s21|70-71|if|O
DDI-DrugBank.d413.s21|73-83|allopurinol|drug
DDI-DrugBank.d413.s21|85-87|and|O
DDI-DrugBank.d413.s21|89-102|chlorpropamide|drug
DDI-DrugBank.d413.s21|104-106|are|O
DDI-DrugBank.d413.s21|108-112|given|O
DDI-DrugBank.d413.s21|114-126|concomitantly|O
DDI-DrugBank.d413.s21|128-129|in|O
DDI-DrugBank.d413.s21|131-133|the|O
DDI-DrugBank.d413.s21|135-142|presence|O
DDI-DrugBank.d413.s21|144-145|of|O
DDI-DrugBank.d413.s21|147-151|renal|O
DDI-DrugBank.d413.s21|153-165|insufficiency|O
DDI-DrugBank.d413.s21|166-166|.|O
DDI-DrugBank.d413.s22|0-10|Cyclosporin|drug
DDI-DrugBank.d413.s22|11-11|:|O
DDI-DrugBank.d413.s22|13-19|Reports|O
DDI-DrugBank.d413.s22|21-28|indicate|O
DDI-DrugBank.d413.s22|30-33|that|O
DDI-DrugBank.d413.s22|35-46|cyclosporine|drug
DDI-DrugBank.d413.s22|48-53|levels|O
DDI-DrugBank.d413.s22|55-57|may|O
DDI-DrugBank.d413.s22|59-60|be|O
DDI-DrugBank.d413.s22|62-70|increased|O
DDI-DrugBank.d413.s22|72-77|during|O
DDI-DrugBank.d413.s22|79-89|concomitant|O
DDI-DrugBank.d413.s22|91-99|treatment|O
DDI-DrugBank.d413.s22|101-104|with|O
DDI-DrugBank.d413.s22|106-123|allopurinol sodium|drug
DDI-DrugBank.d413.s22|125-127|for|O
DDI-DrugBank.d413.s22|129-137|injection|O
DDI-DrugBank.d413.s22|138-138|.|O
DDI-DrugBank.d413.s23|0-9|Monitoring|O
DDI-DrugBank.d413.s23|11-12|of|O
DDI-DrugBank.d413.s23|14-25|cyclosporine|drug
DDI-DrugBank.d413.s23|27-32|levels|O
DDI-DrugBank.d413.s23|34-36|and|O
DDI-DrugBank.d413.s23|38-45|possible|O
DDI-DrugBank.d413.s23|47-56|adjustment|O
DDI-DrugBank.d413.s23|58-59|of|O
DDI-DrugBank.d413.s23|61-72|cyclosporine|drug
DDI-DrugBank.d413.s23|74-79|dosage|O
DDI-DrugBank.d413.s23|81-86|should|O
DDI-DrugBank.d413.s23|88-89|be|O
DDI-DrugBank.d413.s23|91-100|considered|O
DDI-DrugBank.d413.s23|102-105|when|O
DDI-DrugBank.d413.s23|107-111|these|O
DDI-DrugBank.d413.s23|113-117|drugs|O
DDI-DrugBank.d413.s23|119-121|are|O
DDI-DrugBank.d413.s23|123-137|co-administered|O
DDI-DrugBank.d413.s23|138-138|.|O
DDI-DrugBank.d413.s24|0-11|Tolbutamides|drug
DDI-DrugBank.d413.s24|13-22|conversion|O
DDI-DrugBank.d413.s24|24-25|to|O
DDI-DrugBank.d413.s24|27-34|inactive|O
DDI-DrugBank.d413.s24|36-46|metabolites|O
DDI-DrugBank.d413.s24|48-50|has|O
DDI-DrugBank.d413.s24|52-55|been|O
DDI-DrugBank.d413.s24|57-61|shown|O
DDI-DrugBank.d413.s24|63-64|to|O
DDI-DrugBank.d413.s24|66-67|be|O
DDI-DrugBank.d413.s24|69-77|catalyzed|O
DDI-DrugBank.d413.s24|79-80|by|O
DDI-DrugBank.d413.s24|82-89|xanthine|O
DDI-DrugBank.d413.s24|91-97|oxidase|O
DDI-DrugBank.d413.s24|99-102|from|O
DDI-DrugBank.d413.s24|104-106|rat|O
DDI-DrugBank.d413.s24|108-112|liver|O
DDI-DrugBank.d413.s24|113-113|.|O
DDI-DrugBank.d413.s25|0-2|The|O
DDI-DrugBank.d413.s25|4-11|clinical|O
DDI-DrugBank.d413.s25|13-24|significance|O
DDI-DrugBank.d413.s25|25-25|,|O
DDI-DrugBank.d413.s25|27-28|if|O
DDI-DrugBank.d413.s25|30-32|any|O
DDI-DrugBank.d413.s25|33-33|,|O
DDI-DrugBank.d413.s25|35-36|of|O
DDI-DrugBank.d413.s25|38-42|these|O
DDI-DrugBank.d413.s25|44-55|observations|O
DDI-DrugBank.d413.s25|57-58|is|O
DDI-DrugBank.d413.s25|60-66|unknown|O
DDI-DrugBank.d413.s25|67-67|.|O
DDI-MedLine.d147.s0|0-10|Interaction|O
DDI-MedLine.d147.s0|12-13|of|O
DDI-MedLine.d147.s0|15-25|dacarbazine|drug
DDI-MedLine.d147.s0|27-29|and|O
DDI-MedLine.d147.s0|37-37|,|O
DDI-MedLine.d147.s0|39-40|in|O
DDI-MedLine.d147.s0|42-46|vitro|O
DDI-MedLine.d147.s0|48-50|and|O
DDI-MedLine.d147.s0|52-53|in|O
DDI-MedLine.d147.s0|55-58|vivo|O
DDI-MedLine.d147.s0|59-59|,|O
DDI-MedLine.d147.s0|61-62|in|O
DDI-MedLine.d147.s0|64-68|human|O
DDI-MedLine.d147.s0|70-73|A375|O
DDI-MedLine.d147.s0|75-82|melanoma|O
DDI-MedLine.d147.s0|84-88|cells|O
DDI-MedLine.d147.s0|89-89|.|O
DDI-MedLine.d147.s1|0-1|We|O
DDI-MedLine.d147.s1|3-11|evaluated|O
DDI-MedLine.d147.s1|13-22|mechanisms|O
DDI-MedLine.d147.s1|24-25|of|O
DDI-MedLine.d147.s1|27-37|interaction|O
DDI-MedLine.d147.s1|39-45|between|O
DDI-MedLine.d147.s1|47-49|the|O
DDI-MedLine.d147.s1|51-59|alkyating|O
DDI-MedLine.d147.s1|61-65|agent|O
DDI-MedLine.d147.s1|67-77|dacarbazine|drug
DDI-MedLine.d147.s1|79-79|(|O
DDI-MedLine.d147.s1|80-83|DTIC|drug
DDI-MedLine.d147.s1|84-84|)|O
DDI-MedLine.d147.s1|86-88|and|O
DDI-MedLine.d147.s1|90-92|the|O
DDI-MedLine.d147.s1|94-104|pro-oxidant|O
DDI-MedLine.d147.s1|105-105|,|O
DDI-MedLine.d147.s1|107-112|imexon|drug
DDI-MedLine.d147.s1|113-113|,|O
DDI-MedLine.d147.s1|115-116|in|O
DDI-MedLine.d147.s1|118-120|the|O
DDI-MedLine.d147.s1|122-126|human|O
DDI-MedLine.d147.s1|128-131|A375|O
DDI-MedLine.d147.s1|133-140|melanoma|O
DDI-MedLine.d147.s1|142-145|cell|O
DDI-MedLine.d147.s1|147-150|line|O
DDI-MedLine.d147.s1|151-151|.|O
DDI-MedLine.d147.s2|0-2|The|O
DDI-MedLine.d147.s2|4-9|effect|O
DDI-MedLine.d147.s2|11-12|of|O
DDI-MedLine.d147.s2|14-17|DTIC|drug
DDI-MedLine.d147.s2|19-21|and|O
DDI-MedLine.d147.s2|23-28|imexon|drug
DDI-MedLine.d147.s2|29-29|,|O
DDI-MedLine.d147.s2|31-35|alone|O
DDI-MedLine.d147.s2|37-39|and|O
DDI-MedLine.d147.s2|41-42|in|O
DDI-MedLine.d147.s2|44-54|combination|O
DDI-MedLine.d147.s2|55-55|,|O
DDI-MedLine.d147.s2|57-59|was|O
DDI-MedLine.d147.s2|61-69|evaluated|O
DDI-MedLine.d147.s2|71-73|for|O
DDI-MedLine.d147.s2|75-80|growth|O
DDI-MedLine.d147.s2|82-91|inhibition|O
DDI-MedLine.d147.s2|93-93|(|O
DDI-MedLine.d147.s2|94-96|MTT|O
DDI-MedLine.d147.s2|97-97|)|O
DDI-MedLine.d147.s2|98-98|,|O
DDI-MedLine.d147.s2|100-111|radiolabeled|O
DDI-MedLine.d147.s2|113-116|drug|O
DDI-MedLine.d147.s2|118-123|uptake|O
DDI-MedLine.d147.s2|124-124|,|O
DDI-MedLine.d147.s2|126-133|cellular|O
DDI-MedLine.d147.s2|135-139|thiol|O
DDI-MedLine.d147.s2|141-147|content|O
DDI-MedLine.d147.s2|149-149|(|O
DDI-MedLine.d147.s2|150-153|HPLC|O
DDI-MedLine.d147.s2|154-154|)|O
DDI-MedLine.d147.s2|155-155|,|O
DDI-MedLine.d147.s2|157-159|and|O
DDI-MedLine.d147.s2|161-163|DNA|O
DDI-MedLine.d147.s2|165-170|strand|O
DDI-MedLine.d147.s2|172-177|breaks|O
DDI-MedLine.d147.s2|179-179|(|O
DDI-MedLine.d147.s2|180-184|Comet|O
DDI-MedLine.d147.s2|186-190|assay|O
DDI-MedLine.d147.s2|191-191|)|O
DDI-MedLine.d147.s2|192-192|.|O
DDI-MedLine.d147.s3|0-14|Pharmacokinetic|O
DDI-MedLine.d147.s3|16-18|and|O
DDI-MedLine.d147.s3|20-28|antitumor|O
DDI-MedLine.d147.s3|30-36|effects|O
DDI-MedLine.d147.s3|38-41|were|O
DDI-MedLine.d147.s3|43-51|evaluated|O
DDI-MedLine.d147.s3|53-54|in|O
DDI-MedLine.d147.s3|56-59|mice|O
DDI-MedLine.d147.s3|60-60|.|O
DDI-MedLine.d147.s4|0-5|Growth|O
DDI-MedLine.d147.s4|7-16|inhibition|O
DDI-MedLine.d147.s4|18-19|in|O
DDI-MedLine.d147.s4|21-25|vitro|O
DDI-MedLine.d147.s4|27-29|was|O
DDI-MedLine.d147.s4|31-38|additive|O
DDI-MedLine.d147.s4|40-43|with|O
DDI-MedLine.d147.s4|45-47|the|O
DDI-MedLine.d147.s4|49-51|two|O
DDI-MedLine.d147.s4|53-57|drugs|O
DDI-MedLine.d147.s4|58-58|.|O
DDI-MedLine.d147.s5|0-4|There|O
DDI-MedLine.d147.s5|6-8|was|O
DDI-MedLine.d147.s5|10-11|no|O
DDI-MedLine.d147.s5|13-18|effect|O
DDI-MedLine.d147.s5|20-21|on|O
DDI-MedLine.d147.s5|23-26|drug|O
DDI-MedLine.d147.s5|28-33|uptake|O
DDI-MedLine.d147.s5|35-36|or|O
DDI-MedLine.d147.s5|38-39|on|O
DDI-MedLine.d147.s5|41-43|the|O
DDI-MedLine.d147.s5|45-50|number|O
DDI-MedLine.d147.s5|52-53|of|O
DDI-MedLine.d147.s5|55-57|DNA|O
DDI-MedLine.d147.s5|59-64|strand|O
DDI-MedLine.d147.s5|66-71|breaks|O
DDI-MedLine.d147.s5|72-72|.|O
DDI-MedLine.d147.s6|0-4|There|O
DDI-MedLine.d147.s6|6-8|was|O
DDI-MedLine.d147.s6|10-10|a|O
DDI-MedLine.d147.s6|12-12|>|O
DDI-MedLine.d147.s6|13-14|75|O
DDI-MedLine.d147.s6|15-15|%|O
DDI-MedLine.d147.s6|17-25|reduction|O
DDI-MedLine.d147.s6|27-28|in|O
DDI-MedLine.d147.s6|30-37|cellular|O
DDI-MedLine.d147.s6|39-49|glutathione|O
DDI-MedLine.d147.s6|51-53|and|O
DDI-MedLine.d147.s6|55-62|cysteine|O
DDI-MedLine.d147.s6|64-67|with|O
DDI-MedLine.d147.s6|69-74|imexon|drug
DDI-MedLine.d147.s6|76-78|but|O
DDI-MedLine.d147.s6|80-82|not|O
DDI-MedLine.d147.s6|84-87|DTIC|drug
DDI-MedLine.d147.s6|88-88|.|O
DDI-MedLine.d147.s7|0-16|Co-administration|O
DDI-MedLine.d147.s7|18-19|of|O
DDI-MedLine.d147.s7|21-23|the|O
DDI-MedLine.d147.s7|25-27|two|O
DDI-MedLine.d147.s7|29-33|drugs|O
DDI-MedLine.d147.s7|35-36|in|O
DDI-MedLine.d147.s7|38-41|mice|O
DDI-MedLine.d147.s7|43-48|caused|O
DDI-MedLine.d147.s7|50-51|an|O
DDI-MedLine.d147.s7|53-60|increase|O
DDI-MedLine.d147.s7|62-63|in|O
DDI-MedLine.d147.s7|65-67|the|O
DDI-MedLine.d147.s7|69-72|area|O
DDI-MedLine.d147.s7|74-78|under|O
DDI-MedLine.d147.s7|80-82|the|O
DDI-MedLine.d147.s7|84-88|curve|O
DDI-MedLine.d147.s7|90-91|of|O
DDI-MedLine.d147.s7|93-96|both|O
DDI-MedLine.d147.s7|98-102|drugs|O
DDI-MedLine.d147.s7|103-103|,|O
DDI-MedLine.d147.s7|105-107|but|O
DDI-MedLine.d147.s7|109-111|the|O
DDI-MedLine.d147.s7|113-123|combination|O
DDI-MedLine.d147.s7|125-127|was|O
DDI-MedLine.d147.s7|129-131|not|O
DDI-MedLine.d147.s7|133-141|effective|O
DDI-MedLine.d147.s7|143-144|in|O
DDI-MedLine.d147.s7|146-153|reducing|O
DDI-MedLine.d147.s7|155-159|human|O
DDI-MedLine.d147.s7|161-164|A375|O
DDI-MedLine.d147.s7|166-173|melanoma|O
DDI-MedLine.d147.s7|175-180|tumors|O
DDI-MedLine.d147.s7|182-183|in|O
DDI-MedLine.d147.s7|185-188|vivo|O
DDI-MedLine.d147.s7|189-189|.|O
DDI-MedLine.d147.s8|0-5|Imexon|drug
DDI-MedLine.d147.s8|7-9|and|O
DDI-MedLine.d147.s8|11-21|dacarbazine|drug
DDI-MedLine.d147.s8|23-26|show|O
DDI-MedLine.d147.s8|28-35|additive|O
DDI-MedLine.d147.s8|37-43|effects|O
DDI-MedLine.d147.s8|45-46|in|O
DDI-MedLine.d147.s8|48-52|vitro|O
DDI-MedLine.d147.s8|54-56|but|O
DDI-MedLine.d147.s8|58-60|not|O
DDI-MedLine.d147.s8|62-63|in|O
DDI-MedLine.d147.s8|65-68|vivo|O
DDI-MedLine.d147.s8|70-71|in|O
DDI-MedLine.d147.s8|73-77|human|O
DDI-MedLine.d147.s8|79-82|A375|O
DDI-MedLine.d147.s8|84-91|melanoma|O
DDI-MedLine.d147.s8|93-97|cells|O
DDI-MedLine.d147.s8|98-98|.|O
DDI-DrugBank.d166.s0|0-7|Trecator|brand
DDI-DrugBank.d166.s0|9-11|has|O
DDI-DrugBank.d166.s0|13-16|been|O
DDI-DrugBank.d166.s0|18-22|found|O
DDI-DrugBank.d166.s0|24-25|to|O
DDI-DrugBank.d166.s0|27-37|temporarily|O
DDI-DrugBank.d166.s0|39-43|raise|O
DDI-DrugBank.d166.s0|45-49|serum|O
DDI-DrugBank.d166.s0|51-64|concentrations|O
DDI-DrugBank.d166.s0|66-67|of|O
DDI-DrugBank.d166.s0|69-77|isoniazid|drug
DDI-DrugBank.d166.s0|78-78|.|O
DDI-DrugBank.d166.s1|0-7|Trecator|brand
DDI-DrugBank.d166.s1|9-11|may|O
DDI-DrugBank.d166.s1|13-22|potentiate|O
DDI-DrugBank.d166.s1|24-26|the|O
DDI-DrugBank.d166.s1|28-34|adverse|O
DDI-DrugBank.d166.s1|36-42|effects|O
DDI-DrugBank.d166.s1|44-45|of|O
DDI-DrugBank.d166.s1|47-51|other|O
DDI-DrugBank.d166.s1|53-73|antituberculous drugs|group
DDI-DrugBank.d166.s1|75-86|administered|O
DDI-DrugBank.d166.s1|88-100|concomitantly|O
DDI-DrugBank.d166.s1|101-101|.|O
DDI-DrugBank.d166.s2|0-1|In|O
DDI-DrugBank.d166.s2|3-12|particular|O
DDI-DrugBank.d166.s2|13-13|,|O
DDI-DrugBank.d166.s2|15-25|convulsions|O
DDI-DrugBank.d166.s2|27-30|have|O
DDI-DrugBank.d166.s2|32-35|been|O
DDI-DrugBank.d166.s2|37-44|reported|O
DDI-DrugBank.d166.s2|46-49|when|O
DDI-DrugBank.d166.s2|51-61|ethionamide|drug
DDI-DrugBank.d166.s2|63-64|is|O
DDI-DrugBank.d166.s2|66-77|administered|O
DDI-DrugBank.d166.s2|79-82|with|O
DDI-DrugBank.d166.s2|84-94|cycloserine|drug
DDI-DrugBank.d166.s2|96-98|and|O
DDI-DrugBank.d166.s2|100-106|special|O
DDI-DrugBank.d166.s2|108-111|care|O
DDI-DrugBank.d166.s2|113-118|should|O
DDI-DrugBank.d166.s2|120-121|be|O
DDI-DrugBank.d166.s2|123-127|taken|O
DDI-DrugBank.d166.s2|129-132|when|O
DDI-DrugBank.d166.s2|134-136|the|O
DDI-DrugBank.d166.s2|138-146|treatment|O
DDI-DrugBank.d166.s2|148-154|regimen|O
DDI-DrugBank.d166.s2|156-163|includes|O
DDI-DrugBank.d166.s2|165-168|both|O
DDI-DrugBank.d166.s2|170-171|of|O
DDI-DrugBank.d166.s2|173-177|these|O
DDI-DrugBank.d166.s2|179-183|drugs|O
DDI-DrugBank.d166.s2|184-184|.|O
DDI-DrugBank.d166.s3|0-8|Excessive|O
DDI-DrugBank.d166.s3|10-16|ethanol|drug
DDI-DrugBank.d166.s3|18-26|ingestion|O
DDI-DrugBank.d166.s3|28-33|should|O
DDI-DrugBank.d166.s3|35-36|be|O
DDI-DrugBank.d166.s3|38-44|avoided|O
DDI-DrugBank.d166.s3|46-52|because|O
DDI-DrugBank.d166.s3|54-54|a|O
DDI-DrugBank.d166.s3|56-64|psychotic|O
DDI-DrugBank.d166.s3|66-73|reaction|O
DDI-DrugBank.d166.s3|75-77|has|O
DDI-DrugBank.d166.s3|79-82|been|O
DDI-DrugBank.d166.s3|84-91|reported|O
DDI-DrugBank.d166.s3|92-92|.|O
DDI-DrugBank.d610.s0|0-14|Pharmacokinetic|O
DDI-DrugBank.d610.s0|16-25|properties|O
DDI-DrugBank.d610.s0|27-28|of|O
DDI-DrugBank.d610.s0|30-37|abacavir|drug
DDI-DrugBank.d610.s0|39-42|were|O
DDI-DrugBank.d610.s0|44-46|not|O
DDI-DrugBank.d610.s0|48-54|altered|O
DDI-DrugBank.d610.s0|56-57|by|O
DDI-DrugBank.d610.s0|59-61|the|O
DDI-DrugBank.d610.s0|63-70|addition|O
DDI-DrugBank.d610.s0|72-73|of|O
DDI-DrugBank.d610.s0|75-80|either|O
DDI-DrugBank.d610.s0|82-91|lamivudine|drug
DDI-DrugBank.d610.s0|93-94|or|O
DDI-DrugBank.d610.s0|96-105|zidovudine|drug
DDI-DrugBank.d610.s0|107-108|or|O
DDI-DrugBank.d610.s0|110-112|the|O
DDI-DrugBank.d610.s0|114-124|combination|O
DDI-DrugBank.d610.s0|126-127|of|O
DDI-DrugBank.d610.s0|129-138|lamivudine|drug
DDI-DrugBank.d610.s0|140-142|and|O
DDI-DrugBank.d610.s0|144-153|zidovudine|drug
DDI-DrugBank.d610.s0|154-154|.|O
DDI-DrugBank.d610.s1|0-1|No|O
DDI-DrugBank.d610.s1|3-12|clinically|O
DDI-DrugBank.d610.s1|14-24|significant|O
DDI-DrugBank.d610.s1|26-32|changes|O
DDI-DrugBank.d610.s1|34-35|to|O
DDI-DrugBank.d610.s1|37-46|lamivudine|drug
DDI-DrugBank.d610.s1|48-49|or|O
DDI-DrugBank.d610.s1|51-60|zidovudine|drug
DDI-DrugBank.d610.s1|62-77|pharmacokinetics|O
DDI-DrugBank.d610.s1|79-82|were|O
DDI-DrugBank.d610.s1|84-91|observed|O
DDI-DrugBank.d610.s1|93-101|following|O
DDI-DrugBank.d610.s1|103-113|concomitant|O
DDI-DrugBank.d610.s1|115-128|administration|O
DDI-DrugBank.d610.s1|130-131|of|O
DDI-DrugBank.d610.s1|133-140|abacavir|drug
DDI-DrugBank.d610.s1|141-141|.|O
DDI-DrugBank.d610.s2|0-7|Abacavir|drug
DDI-DrugBank.d610.s2|9-11|has|O
DDI-DrugBank.d610.s2|13-14|no|O
DDI-DrugBank.d610.s2|16-21|effect|O
DDI-DrugBank.d610.s2|23-24|on|O
DDI-DrugBank.d610.s2|26-28|the|O
DDI-DrugBank.d610.s2|30-44|pharmacokinetic|O
DDI-DrugBank.d610.s2|46-55|properties|O
DDI-DrugBank.d610.s2|57-58|of|O
DDI-DrugBank.d610.s2|60-66|ethanol|drug
DDI-DrugBank.d610.s2|67-67|.|O
DDI-DrugBank.d610.s3|0-6|Ethanol|drug
DDI-DrugBank.d610.s3|8-16|decreases|O
DDI-DrugBank.d610.s3|18-20|the|O
DDI-DrugBank.d610.s3|22-32|elimination|O
DDI-DrugBank.d610.s3|34-35|of|O
DDI-DrugBank.d610.s3|37-44|abacavir|drug
DDI-DrugBank.d610.s3|46-52|causing|O
DDI-DrugBank.d610.s3|54-55|an|O
DDI-DrugBank.d610.s3|57-64|increase|O
DDI-DrugBank.d610.s3|66-67|in|O
DDI-DrugBank.d610.s3|69-75|overall|O
DDI-DrugBank.d610.s3|77-84|exposure|O
DDI-DrugBank.d610.s3|86-86|.|O
DDI-DrugBank.d610.s3|88-90|The|O
DDI-DrugBank.d610.s3|92-99|addition|O
DDI-DrugBank.d610.s3|101-102|of|O
DDI-DrugBank.d610.s3|104-112|methadone|drug
DDI-DrugBank.d610.s3|114-116|has|O
DDI-DrugBank.d610.s3|118-119|no|O
DDI-DrugBank.d610.s3|121-130|clinically|O
DDI-DrugBank.d610.s3|132-142|significant|O
DDI-DrugBank.d610.s3|144-149|effect|O
DDI-DrugBank.d610.s3|151-152|on|O
DDI-DrugBank.d610.s3|154-156|the|O
DDI-DrugBank.d610.s3|158-172|pharmacokinetic|O
DDI-DrugBank.d610.s3|174-183|properties|O
DDI-DrugBank.d610.s3|185-186|of|O
DDI-DrugBank.d610.s3|188-195|abacavir|drug
DDI-DrugBank.d610.s3|196-196|.|O
DDI-DrugBank.d610.s4|0-1|In|O
DDI-DrugBank.d610.s4|3-3|a|O
DDI-DrugBank.d610.s4|5-9|study|O
DDI-DrugBank.d610.s4|11-12|of|O
DDI-DrugBank.d610.s4|14-15|11|O
DDI-DrugBank.d610.s4|17-28|HIV-infected|O
DDI-DrugBank.d610.s4|30-37|patients|O
DDI-DrugBank.d610.s4|39-47|receiving|O
DDI-DrugBank.d610.s4|49-69|methadone-maintenance|drug
DDI-DrugBank.d610.s4|71-77|therapy|O
DDI-DrugBank.d610.s4|79-79|(|O
DDI-DrugBank.d610.s4|80-81|40|O
DDI-DrugBank.d610.s4|83-84|mg|O
DDI-DrugBank.d610.s4|86-88|and|O
DDI-DrugBank.d610.s4|90-91|90|O
DDI-DrugBank.d610.s4|93-94|mg|O
DDI-DrugBank.d610.s4|96-100|daily|O
DDI-DrugBank.d610.s4|101-101|)|O
DDI-DrugBank.d610.s4|103-106|with|O
DDI-DrugBank.d610.s4|108-110|600|O
DDI-DrugBank.d610.s4|112-113|mg|O
DDI-DrugBank.d610.s4|115-116|of|O
DDI-DrugBank.d610.s4|118-123|ZIAGEN|brand
DDI-DrugBank.d610.s4|125-129|twice|O
DDI-DrugBank.d610.s4|131-135|daily|O
DDI-DrugBank.d610.s4|137-137|(|O
DDI-DrugBank.d610.s4|138-142|twice|O
DDI-DrugBank.d610.s4|144-146|the|O
DDI-DrugBank.d610.s4|148-156|currently|O
DDI-DrugBank.d610.s4|158-168|recommended|O
DDI-DrugBank.d610.s4|170-173|dose|O
DDI-DrugBank.d610.s4|174-174|)|O
DDI-DrugBank.d610.s4|175-175|,|O
DDI-DrugBank.d610.s4|177-180|oral|O
DDI-DrugBank.d610.s4|182-190|methadone|drug
DDI-DrugBank.d610.s4|192-200|clearance|O
DDI-DrugBank.d610.s4|202-210|increased|O
DDI-DrugBank.d610.s4|212-213|22|O
DDI-DrugBank.d610.s4|214-214|%|O
DDI-DrugBank.d610.s4|216-216|(|O
DDI-DrugBank.d610.s4|217-218|90|O
DDI-DrugBank.d610.s4|219-219|%|O
DDI-DrugBank.d610.s4|221-222|CI|O
DDI-DrugBank.d610.s4|224-224|6|O
DDI-DrugBank.d610.s4|225-225|%|O
DDI-DrugBank.d610.s4|227-228|to|O
DDI-DrugBank.d610.s4|230-231|42|O
DDI-DrugBank.d610.s4|232-232|%|O
DDI-DrugBank.d610.s4|233-233|)|O
DDI-DrugBank.d610.s4|234-234|.|O
DDI-DrugBank.d610.s5|0-3|This|O
DDI-DrugBank.d610.s5|5-14|alteration|O
DDI-DrugBank.d610.s5|16-19|will|O
DDI-DrugBank.d610.s5|21-23|not|O
DDI-DrugBank.d610.s5|25-30|result|O
DDI-DrugBank.d610.s5|32-33|in|O
DDI-DrugBank.d610.s5|35-35|a|O
DDI-DrugBank.d610.s5|37-45|methadone|drug
DDI-DrugBank.d610.s5|47-50|dose|O
DDI-DrugBank.d610.s5|52-63|modification|O
DDI-DrugBank.d610.s5|65-66|in|O
DDI-DrugBank.d610.s5|68-70|the|O
DDI-DrugBank.d610.s5|72-79|majority|O
DDI-DrugBank.d610.s5|81-82|of|O
DDI-DrugBank.d610.s5|84-91|patients|O
DDI-DrugBank.d610.s5|92-92|;|O
DDI-DrugBank.d610.s6|0-6|however|O
DDI-DrugBank.d610.s6|7-7|,|O
DDI-DrugBank.d610.s6|9-10|an|O
DDI-DrugBank.d610.s6|12-20|increased|O
DDI-DrugBank.d610.s6|22-30|methadone|drug
DDI-DrugBank.d610.s6|32-35|dose|O
DDI-DrugBank.d610.s6|37-39|may|O
DDI-DrugBank.d610.s6|41-42|be|O
DDI-DrugBank.d610.s6|44-51|required|O
DDI-DrugBank.d610.s6|53-54|in|O
DDI-DrugBank.d610.s6|56-56|a|O
DDI-DrugBank.d610.s6|58-62|small|O
DDI-DrugBank.d610.s6|64-69|number|O
DDI-DrugBank.d610.s6|71-72|of|O
DDI-DrugBank.d610.s6|74-81|patients|O
DDI-DrugBank.d610.s6|82-82|.|O
DDI-MedLine.d77.s0|0-6|Effects|O
DDI-MedLine.d77.s0|8-9|of|O
DDI-MedLine.d77.s0|11-13|low|O
DDI-MedLine.d77.s0|15-26|temperatures|O
DDI-MedLine.d77.s0|28-29|on|O
DDI-MedLine.d77.s0|31-42|microtubules|O
DDI-MedLine.d77.s0|44-45|in|O
DDI-MedLine.d77.s0|47-49|the|O
DDI-MedLine.d77.s0|51-64|non-myelinated|O
DDI-MedLine.d77.s0|66-70|axons|O
DDI-MedLine.d77.s0|72-73|of|O
DDI-MedLine.d77.s0|75-89|post-ganglionic|O
DDI-MedLine.d77.s0|91-101|sympathetic|O
DDI-MedLine.d77.s0|103-108|nerves|O
DDI-MedLine.d77.s0|109-109|.|O
DDI-MedLine.d77.s1|0-2|The|O
DDI-MedLine.d77.s1|4-9|effect|O
DDI-MedLine.d77.s1|11-12|of|O
DDI-MedLine.d77.s1|14-24|temperature|O
DDI-MedLine.d77.s1|26-32|changes|O
DDI-MedLine.d77.s1|34-35|on|O
DDI-MedLine.d77.s1|37-39|the|O
DDI-MedLine.d77.s1|41-46|number|O
DDI-MedLine.d77.s1|48-49|of|O
DDI-MedLine.d77.s1|51-62|microtubules|O
DDI-MedLine.d77.s1|64-65|in|O
DDI-MedLine.d77.s1|67-80|non-myelinated|O
DDI-MedLine.d77.s1|82-86|axons|O
DDI-MedLine.d77.s1|88-90|has|O
DDI-MedLine.d77.s1|92-95|been|O
DDI-MedLine.d77.s1|97-103|studied|O
DDI-MedLine.d77.s1|105-106|in|O
DDI-MedLine.d77.s1|108-110|cat|O
DDI-MedLine.d77.s1|112-119|inferior|O
DDI-MedLine.d77.s1|121-130|mesenteric|O
DDI-MedLine.d77.s1|132-151|ganglion/hypogastric|O
DDI-MedLine.d77.s1|153-157|nerve|O
DDI-MedLine.d77.s1|159-170|preparations|O
DDI-MedLine.d77.s1|172-180|incubated|O
DDI-MedLine.d77.s1|182-183|at|O
DDI-MedLine.d77.s1|185-191|various|O
DDI-MedLine.d77.s1|193-204|temperatures|O
DDI-MedLine.d77.s1|206-207|in|O
DDI-MedLine.d77.s1|209-214|Eagles|O
DDI-MedLine.d77.s1|216-222|minimal|O
DDI-MedLine.d77.s1|224-232|essential|O
DDI-MedLine.d77.s1|234-239|tissue|O
DDI-MedLine.d77.s1|241-247|culture|O
DDI-MedLine.d77.s1|249-254|medium|O
DDI-MedLine.d77.s1|256-257|in|O
DDI-MedLine.d77.s1|259-263|vitro|O
DDI-MedLine.d77.s1|264-264|.|O
DDI-MedLine.d77.s2|0-1|At|O
DDI-MedLine.d77.s2|3-4|37|O
DDI-MedLine.d77.s2|6-12|degrees|O
DDI-MedLine.d77.s2|14-14|C|O
DDI-MedLine.d77.s2|16-18|the|O
DDI-MedLine.d77.s2|20-33|non-myelinated|O
DDI-MedLine.d77.s2|35-39|axons|O
DDI-MedLine.d77.s2|41-49|contained|O
DDI-MedLine.d77.s2|51-54|28.4|O
DDI-MedLine.d77.s2|56-59|plus|O
DDI-MedLine.d77.s2|61-62|or|O
DDI-MedLine.d77.s2|64-68|minus|O
DDI-MedLine.d77.s2|70-72|0.8|O
DDI-MedLine.d77.s2|74-78|S.E.M|O
DDI-MedLine.d77.s2|79-79|.|O
DDI-MedLine.d77.s3|0-0|(|O
DDI-MedLine.d77.s3|1-2|54|O
DDI-MedLine.d77.s3|3-3|)|O
DDI-MedLine.d77.s3|5-16|microtubules|O
DDI-MedLine.d77.s3|18-20|per|O
DDI-MedLine.d77.s3|22-25|axon|O
DDI-MedLine.d77.s3|26-26|.|O
DDI-MedLine.d77.s4|0-4|After|O
DDI-MedLine.d77.s4|6-15|incubation|O
DDI-MedLine.d77.s4|17-18|at|O
DDI-MedLine.d77.s4|20-20|0|O
DDI-MedLine.d77.s4|22-28|degrees|O
DDI-MedLine.d77.s4|30-30|C|O
DDI-MedLine.d77.s4|32-34|for|O
DDI-MedLine.d77.s4|36-36|4|O
DDI-MedLine.d77.s4|38-38|h|O
DDI-MedLine.d77.s4|40-43|this|O
DDI-MedLine.d77.s4|45-50|number|O
DDI-MedLine.d77.s4|52-55|fell|O
DDI-MedLine.d77.s4|57-58|to|O
DDI-MedLine.d77.s4|60-62|2.3|O
DDI-MedLine.d77.s4|64-67|plus|O
DDI-MedLine.d77.s4|69-70|or|O
DDI-MedLine.d77.s4|72-76|minus|O
DDI-MedLine.d77.s4|78-80|0.1|O
DDI-MedLine.d77.s4|82-86|S.E.M|O
DDI-MedLine.d77.s4|87-87|.|O
DDI-MedLine.d77.s5|0-0|(|O
DDI-MedLine.d77.s5|1-2|41|O
DDI-MedLine.d77.s5|3-3|)|O
DDI-MedLine.d77.s5|5-7|but|O
DDI-MedLine.d77.s5|9-16|returned|O
DDI-MedLine.d77.s5|18-19|to|O
DDI-MedLine.d77.s5|21-26|normal|O
DDI-MedLine.d77.s5|28-33|levels|O
DDI-MedLine.d77.s5|35-38|when|O
DDI-MedLine.d77.s5|40-42|the|O
DDI-MedLine.d77.s5|44-49|nerves|O
DDI-MedLine.d77.s5|51-54|were|O
DDI-MedLine.d77.s5|56-63|rewarmed|O
DDI-MedLine.d77.s5|64-64|.|O
DDI-MedLine.d77.s6|0-3|This|O
DDI-MedLine.d77.s6|5-8|loss|O
DDI-MedLine.d77.s6|10-11|of|O
DDI-MedLine.d77.s6|13-24|microtubules|O
DDI-MedLine.d77.s6|26-27|on|O
DDI-MedLine.d77.s6|29-35|cooling|O
DDI-MedLine.d77.s6|37-39|the|O
DDI-MedLine.d77.s6|41-46|nerves|O
DDI-MedLine.d77.s6|48-50|and|O
DDI-MedLine.d77.s6|52-56|their|O
DDI-MedLine.d77.s6|58-69|reappearance|O
DDI-MedLine.d77.s6|71-72|on|O
DDI-MedLine.d77.s6|74-82|rewarming|O
DDI-MedLine.d77.s6|84-86|was|O
DDI-MedLine.d77.s6|88-88|a|O
DDI-MedLine.d77.s6|90-94|rapid|O
DDI-MedLine.d77.s6|96-102|process|O
DDI-MedLine.d77.s6|103-103|;|O
DDI-MedLine.d77.s7|0-1|it|O
DDI-MedLine.d77.s7|3-5|was|O
DDI-MedLine.d77.s7|7-17|independent|O
DDI-MedLine.d77.s7|19-20|of|O
DDI-MedLine.d77.s7|22-24|the|O
DDI-MedLine.d77.s7|26-34|influence|O
DDI-MedLine.d77.s7|36-37|of|O
DDI-MedLine.d77.s7|39-41|the|O
DDI-MedLine.d77.s7|43-50|nueronal|O
DDI-MedLine.d77.s7|52-55|cell|O
DDI-MedLine.d77.s7|57-60|body|O
DDI-MedLine.d77.s7|62-64|and|O
DDI-MedLine.d77.s7|66-67|of|O
DDI-MedLine.d77.s7|69-75|protein|O
DDI-MedLine.d77.s7|77-85|synthesis|O
DDI-MedLine.d77.s7|87-92|within|O
DDI-MedLine.d77.s7|94-96|the|O
DDI-MedLine.d77.s7|98-101|axon|O
DDI-MedLine.d77.s7|102-102|.|O
DDI-MedLine.d77.s8|0-2|The|O
DDI-MedLine.d77.s8|4-15|preservation|O
DDI-MedLine.d77.s8|17-18|of|O
DDI-MedLine.d77.s8|20-22|the|O
DDI-MedLine.d77.s8|24-35|microtubules|O
DDI-MedLine.d77.s8|37-39|was|O
DDI-MedLine.d77.s8|41-48|improved|O
DDI-MedLine.d77.s8|50-53|when|O
DDI-MedLine.d77.s8|55-57|D2O|O
DDI-MedLine.d77.s8|59-61|was|O
DDI-MedLine.d77.s8|63-69|present|O
DDI-MedLine.d77.s8|71-72|in|O
DDI-MedLine.d77.s8|74-76|the|O
DDI-MedLine.d77.s8|78-87|incubation|O
DDI-MedLine.d77.s8|89-94|medium|O
DDI-MedLine.d77.s8|95-95|.|O
DDI-MedLine.d77.s9|0-7|Reformed|O
DDI-MedLine.d77.s9|9-20|microtubules|O
DDI-MedLine.d77.s9|22-29|appeared|O
DDI-MedLine.d77.s9|31-32|to|O
DDI-MedLine.d77.s9|34-41|function|O
DDI-MedLine.d77.s9|43-50|normally|O
DDI-MedLine.d77.s9|52-55|with|O
DDI-MedLine.d77.s9|57-63|respect|O
DDI-MedLine.d77.s9|65-66|to|O
DDI-MedLine.d77.s9|68-72|their|O
DDI-MedLine.d77.s9|74-81|possible|O
DDI-MedLine.d77.s9|83-86|role|O
DDI-MedLine.d77.s9|88-89|in|O
DDI-MedLine.d77.s9|91-93|the|O
DDI-MedLine.d77.s9|95-103|transport|O
DDI-MedLine.d77.s9|105-106|of|O
DDI-MedLine.d77.s9|108-120|noradrenaline|O
DDI-MedLine.d77.s9|122-128|storage|O
DDI-MedLine.d77.s9|130-137|vesicles|O
DDI-MedLine.d77.s9|139-143|along|O
DDI-MedLine.d77.s9|145-147|the|O
DDI-MedLine.d77.s9|149-153|axons|O
DDI-MedLine.d77.s9|154-154|.|O
DDI-DrugBank.d501.s0|0-6|General|O
DDI-DrugBank.d501.s0|8-9|No|O
DDI-DrugBank.d501.s0|11-18|clinical|O
DDI-DrugBank.d501.s0|20-23|drug|O
DDI-DrugBank.d501.s0|25-35|interaction|O
DDI-DrugBank.d501.s0|37-43|studies|O
DDI-DrugBank.d501.s0|45-48|were|O
DDI-DrugBank.d501.s0|50-58|performed|O
DDI-DrugBank.d501.s0|59-59|.|O
DDI-DrugBank.d501.s1|0-1|No|O
DDI-DrugBank.d501.s1|3-12|evaluation|O
DDI-DrugBank.d501.s1|14-15|of|O
DDI-DrugBank.d501.s1|17-26|EXTRANEALs|brand
DDI-DrugBank.d501.s1|28-34|effects|O
DDI-DrugBank.d501.s1|36-37|on|O
DDI-DrugBank.d501.s1|39-41|the|O
DDI-DrugBank.d501.s1|43-52|cytochrome|O
DDI-DrugBank.d501.s1|54-57|P450|O
DDI-DrugBank.d501.s1|59-64|system|O
DDI-DrugBank.d501.s1|66-68|was|O
DDI-DrugBank.d501.s1|70-78|conducted|O
DDI-DrugBank.d501.s1|79-79|.|O
DDI-DrugBank.d501.s2|0-1|As|O
DDI-DrugBank.d501.s2|3-6|with|O
DDI-DrugBank.d501.s2|8-12|other|O
DDI-DrugBank.d501.s2|14-31|dialysis solutions|group
DDI-DrugBank.d501.s2|32-32|,|O
DDI-DrugBank.d501.s2|34-38|blood|O
DDI-DrugBank.d501.s2|40-53|concentrations|O
DDI-DrugBank.d501.s2|55-56|of|O
DDI-DrugBank.d501.s2|58-67|dialyzable|O
DDI-DrugBank.d501.s2|69-73|drugs|O
DDI-DrugBank.d501.s2|75-77|may|O
DDI-DrugBank.d501.s2|79-80|be|O
DDI-DrugBank.d501.s2|82-88|reduced|O
DDI-DrugBank.d501.s2|90-91|by|O
DDI-DrugBank.d501.s2|93-100|dialysis|O
DDI-DrugBank.d501.s2|101-101|.|O
DDI-DrugBank.d501.s3|0-5|Dosage|O
DDI-DrugBank.d501.s3|7-16|adjustment|O
DDI-DrugBank.d501.s3|18-19|of|O
DDI-DrugBank.d501.s3|21-31|concomitant|O
DDI-DrugBank.d501.s3|33-43|medications|O
DDI-DrugBank.d501.s3|45-47|may|O
DDI-DrugBank.d501.s3|49-50|be|O
DDI-DrugBank.d501.s3|52-60|necessary|O
DDI-DrugBank.d501.s3|61-61|.|O
DDI-DrugBank.d501.s4|0-1|In|O
DDI-DrugBank.d501.s4|3-10|patients|O
DDI-DrugBank.d501.s4|12-16|using|O
DDI-DrugBank.d501.s4|18-35|cardiac glycosides|group
DDI-DrugBank.d501.s4|37-37|(|O
DDI-DrugBank.d501.s4|38-44|digoxin|drug
DDI-DrugBank.d501.s4|46-48|and|O
DDI-DrugBank.d501.s4|50-55|others|O
DDI-DrugBank.d501.s4|56-56|)|O
DDI-DrugBank.d501.s4|57-57|,|O
DDI-DrugBank.d501.s4|59-64|plasma|O
DDI-DrugBank.d501.s4|66-71|levels|O
DDI-DrugBank.d501.s4|73-74|of|O
DDI-DrugBank.d501.s4|76-82|calcium|O
DDI-DrugBank.d501.s4|83-83|,|O
DDI-DrugBank.d501.s4|85-93|potassium|O
DDI-DrugBank.d501.s4|95-97|and|O
DDI-DrugBank.d501.s4|99-107|magnesium|O
DDI-DrugBank.d501.s4|109-112|must|O
DDI-DrugBank.d501.s4|114-115|be|O
DDI-DrugBank.d501.s4|117-125|carefully|O
DDI-DrugBank.d501.s4|127-135|monitored|O
DDI-DrugBank.d501.s4|136-136|.|O
DDI-DrugBank.d501.s5|0-6|Insulin|drug
DDI-DrugBank.d501.s5|7-7|:|O
DDI-DrugBank.d501.s5|9-9|A|O
DDI-DrugBank.d501.s5|11-18|clinical|O
DDI-DrugBank.d501.s5|20-24|study|O
DDI-DrugBank.d501.s5|26-27|in|O
DDI-DrugBank.d501.s5|29-29|6|O
DDI-DrugBank.d501.s5|31-47|insulin-dependent|O
DDI-DrugBank.d501.s5|49-56|diabetic|O
DDI-DrugBank.d501.s5|58-65|patients|O
DDI-DrugBank.d501.s5|67-78|demonstrated|O
DDI-DrugBank.d501.s5|80-81|no|O
DDI-DrugBank.d501.s5|83-88|effect|O
DDI-DrugBank.d501.s5|90-91|of|O
DDI-DrugBank.d501.s5|93-101|EXTRANEAL|brand
DDI-DrugBank.d501.s5|103-104|on|O
DDI-DrugBank.d501.s5|106-112|insulin|drug
DDI-DrugBank.d501.s5|114-123|absorption|O
DDI-DrugBank.d501.s5|125-128|from|O
DDI-DrugBank.d501.s5|130-132|the|O
DDI-DrugBank.d501.s5|134-143|peritoneal|O
DDI-DrugBank.d501.s5|145-150|cavity|O
DDI-DrugBank.d501.s5|152-153|or|O
DDI-DrugBank.d501.s5|155-156|on|O
DDI-DrugBank.d501.s5|158-165|insulins|drug
DDI-DrugBank.d501.s5|167-173|ability|O
DDI-DrugBank.d501.s5|175-176|to|O
DDI-DrugBank.d501.s5|178-184|control|O
DDI-DrugBank.d501.s5|186-190|blood|O
DDI-DrugBank.d501.s5|192-198|glucose|O
DDI-DrugBank.d501.s5|200-203|when|O
DDI-DrugBank.d501.s5|205-211|insulin|drug
DDI-DrugBank.d501.s5|213-215|was|O
DDI-DrugBank.d501.s5|217-228|administered|O
DDI-DrugBank.d501.s5|230-246|intraperitoneally|O
DDI-DrugBank.d501.s5|248-251|with|O
DDI-DrugBank.d501.s5|253-261|EXTRANEAL|brand
DDI-DrugBank.d501.s5|262-262|.|O
DDI-DrugBank.d501.s6|0-6|However|O
DDI-DrugBank.d501.s6|7-7|,|O
DDI-DrugBank.d501.s6|9-19|appropriate|O
DDI-DrugBank.d501.s6|21-30|monitoring|O
DDI-DrugBank.d501.s6|32-33|of|O
DDI-DrugBank.d501.s6|35-39|blood|O
DDI-DrugBank.d501.s6|41-47|glucose|O
DDI-DrugBank.d501.s6|49-54|should|O
DDI-DrugBank.d501.s6|56-57|be|O
DDI-DrugBank.d501.s6|59-67|performed|O
DDI-DrugBank.d501.s6|69-72|when|O
DDI-DrugBank.d501.s6|74-83|initiating|O
DDI-DrugBank.d501.s6|85-93|EXTRANEAL|brand
DDI-DrugBank.d501.s6|95-96|in|O
DDI-DrugBank.d501.s6|98-105|diabetic|O
DDI-DrugBank.d501.s6|107-114|patients|O
DDI-DrugBank.d501.s6|116-118|and|O
DDI-DrugBank.d501.s6|120-126|insulin|drug
DDI-DrugBank.d501.s6|128-133|dosage|O
DDI-DrugBank.d501.s6|135-140|should|O
DDI-DrugBank.d501.s6|142-143|be|O
DDI-DrugBank.d501.s6|145-152|adjusted|O
DDI-DrugBank.d501.s6|154-155|if|O
DDI-DrugBank.d501.s6|157-162|needed|O
DDI-DrugBank.d501.s6|163-163|.|O
DDI-DrugBank.d501.s7|0-6|Heparin|drug
DDI-DrugBank.d501.s7|7-7|:|O
DDI-DrugBank.d501.s7|9-10|No|O
DDI-DrugBank.d501.s7|12-16|human|O
DDI-DrugBank.d501.s7|18-21|drug|O
DDI-DrugBank.d501.s7|23-33|interaction|O
DDI-DrugBank.d501.s7|35-41|studies|O
DDI-DrugBank.d501.s7|43-46|with|O
DDI-DrugBank.d501.s7|48-54|heparin|drug
DDI-DrugBank.d501.s7|56-59|were|O
DDI-DrugBank.d501.s7|61-69|conducted|O
DDI-DrugBank.d501.s7|70-70|.|O
DDI-DrugBank.d501.s8|0-1|In|O
DDI-DrugBank.d501.s8|3-7|vitro|O
DDI-DrugBank.d501.s8|9-15|studies|O
DDI-DrugBank.d501.s8|17-28|demonstrated|O
DDI-DrugBank.d501.s8|30-31|no|O
DDI-DrugBank.d501.s8|33-40|evidence|O
DDI-DrugBank.d501.s8|42-43|of|O
DDI-DrugBank.d501.s8|45-59|incompatibility|O
DDI-DrugBank.d501.s8|61-62|of|O
DDI-DrugBank.d501.s8|64-70|heparin|drug
DDI-DrugBank.d501.s8|72-75|with|O
DDI-DrugBank.d501.s8|77-85|EXTRANEAL|brand
DDI-DrugBank.d501.s8|86-86|.|O
DDI-DrugBank.d501.s9|0-10|Antibiotics|group
DDI-DrugBank.d501.s9|11-11|:|O
DDI-DrugBank.d501.s9|13-14|No|O
DDI-DrugBank.d501.s9|16-20|human|O
DDI-DrugBank.d501.s9|22-25|drug|O
DDI-DrugBank.d501.s9|27-37|interaction|O
DDI-DrugBank.d501.s9|39-45|studies|O
DDI-DrugBank.d501.s9|47-50|with|O
DDI-DrugBank.d501.s9|52-62|antibiotics|group
DDI-DrugBank.d501.s9|64-67|were|O
DDI-DrugBank.d501.s9|69-77|conducted|O
DDI-DrugBank.d501.s9|78-78|.|O
DDI-DrugBank.d501.s10|0-1|In|O
DDI-DrugBank.d501.s10|3-7|vitro|O
DDI-DrugBank.d501.s10|9-15|studies|O
DDI-DrugBank.d501.s10|17-26|evaluating|O
DDI-DrugBank.d501.s10|28-30|the|O
DDI-DrugBank.d501.s10|32-38|minimum|O
DDI-DrugBank.d501.s10|40-49|inhibitory|O
DDI-DrugBank.d501.s10|51-63|concentration|O
DDI-DrugBank.d501.s10|65-65|(|O
DDI-DrugBank.d501.s10|66-68|MIC|O
DDI-DrugBank.d501.s10|69-69|)|O
DDI-DrugBank.d501.s10|71-72|of|O
DDI-DrugBank.d501.s10|74-83|vancomycin|drug
DDI-DrugBank.d501.s10|84-84|,|O
DDI-DrugBank.d501.s10|86-94|cefazolin|drug
DDI-DrugBank.d501.s10|95-95|,|O
DDI-DrugBank.d501.s10|97-106|ampicillin|drug
DDI-DrugBank.d501.s10|107-107|,|O
DDI-DrugBank.d501.s10|109-132|ampicillin/flucoxacillin|drug
DDI-DrugBank.d501.s10|133-133|,|O
DDI-DrugBank.d501.s10|135-145|ceftazidime|drug
DDI-DrugBank.d501.s10|146-146|,|O
DDI-DrugBank.d501.s10|148-157|gentamicin|drug
DDI-DrugBank.d501.s10|158-158|,|O
DDI-DrugBank.d501.s10|160-162|and|O
DDI-DrugBank.d501.s10|164-175|amphotericin|drug
DDI-DrugBank.d501.s10|177-188|demonstrated|O
DDI-DrugBank.d501.s10|190-191|no|O
DDI-DrugBank.d501.s10|193-200|evidence|O
DDI-DrugBank.d501.s10|202-203|of|O
DDI-DrugBank.d501.s10|205-219|incompatibility|O
DDI-DrugBank.d501.s10|221-222|of|O
DDI-DrugBank.d501.s10|224-228|these|O
DDI-DrugBank.d501.s10|230-240|antibiotics|group
DDI-DrugBank.d501.s10|242-245|with|O
DDI-DrugBank.d501.s10|247-255|EXTRANEAL|brand
DDI-DrugBank.d501.s10|256-256|.|O
DDI-DrugBank.d501.s11|0-14|Drug/Laboratory|O
DDI-DrugBank.d501.s11|16-19|Test|O
DDI-DrugBank.d501.s11|21-32|Interactions|O
DDI-DrugBank.d501.s11|34-38|Blood|O
DDI-DrugBank.d501.s11|40-46|Glucose|O
DDI-DrugBank.d501.s11|48-52|Blood|O
DDI-DrugBank.d501.s11|54-60|glucose|O
DDI-DrugBank.d501.s11|62-72|measurement|O
DDI-DrugBank.d501.s11|74-77|must|O
DDI-DrugBank.d501.s11|79-80|be|O
DDI-DrugBank.d501.s11|82-85|done|O
DDI-DrugBank.d501.s11|87-90|with|O
DDI-DrugBank.d501.s11|92-92|a|O
DDI-DrugBank.d501.s11|94-109|glucose-specific|O
DDI-DrugBank.d501.s11|111-116|method|O
DDI-DrugBank.d501.s11|118-119|to|O
DDI-DrugBank.d501.s11|121-127|prevent|O
DDI-DrugBank.d501.s11|129-135|maltose|O
DDI-DrugBank.d501.s11|137-148|interference|O
DDI-DrugBank.d501.s11|150-153|with|O
DDI-DrugBank.d501.s11|155-158|test|O
DDI-DrugBank.d501.s11|160-166|results|O
DDI-DrugBank.d501.s11|167-167|.|O
DDI-DrugBank.d501.s12|0-4|Since|O
DDI-DrugBank.d501.s12|6-12|falsely|O
DDI-DrugBank.d501.s12|14-21|elevated|O
DDI-DrugBank.d501.s12|23-29|glucose|O
DDI-DrugBank.d501.s12|31-36|levels|O
DDI-DrugBank.d501.s12|38-41|have|O
DDI-DrugBank.d501.s12|43-46|been|O
DDI-DrugBank.d501.s12|48-55|observed|O
DDI-DrugBank.d501.s12|57-60|with|O
DDI-DrugBank.d501.s12|62-66|blood|O
DDI-DrugBank.d501.s12|68-74|glucose|O
DDI-DrugBank.d501.s12|76-85|monitoring|O
DDI-DrugBank.d501.s12|87-93|devices|O
DDI-DrugBank.d501.s12|95-97|and|O
DDI-DrugBank.d501.s12|99-102|test|O
DDI-DrugBank.d501.s12|104-109|strips|O
DDI-DrugBank.d501.s12|111-114|that|O
DDI-DrugBank.d501.s12|116-118|use|O
DDI-DrugBank.d501.s12|120-126|glucose|O
DDI-DrugBank.d501.s12|128-140|dehydrogenase|O
DDI-DrugBank.d501.s12|142-164|pyrroloquinolinequinone|O
DDI-DrugBank.d501.s12|166-166|(|O
DDI-DrugBank.d501.s12|167-169|GDH|O
DDI-DrugBank.d501.s12|171-173|PQQ|O
DDI-DrugBank.d501.s12|174-174|)|O
DDI-DrugBank.d501.s12|175-180|-based|O
DDI-DrugBank.d501.s12|182-188|methods|O
DDI-DrugBank.d501.s12|189-189|,|O
DDI-DrugBank.d501.s12|191-193|GDH|O
DDI-DrugBank.d501.s12|195-203|PQQ-based|O
DDI-DrugBank.d501.s12|205-211|methods|O
DDI-DrugBank.d501.s12|213-218|should|O
DDI-DrugBank.d501.s12|220-222|not|O
DDI-DrugBank.d501.s12|224-225|be|O
DDI-DrugBank.d501.s12|227-230|used|O
DDI-DrugBank.d501.s12|232-233|to|O
DDI-DrugBank.d501.s12|235-241|measure|O
DDI-DrugBank.d501.s12|243-249|glucose|O
DDI-DrugBank.d501.s12|251-256|levels|O
DDI-DrugBank.d501.s12|258-259|in|O
DDI-DrugBank.d501.s12|261-268|patients|O
DDI-DrugBank.d501.s12|270-281|administered|O
DDI-DrugBank.d501.s13|0-4|Serum|O
DDI-DrugBank.d501.s13|6-12|Amylase|O
DDI-DrugBank.d501.s13|14-15|An|O
DDI-DrugBank.d501.s13|17-24|apparent|O
DDI-DrugBank.d501.s13|26-33|decrease|O
DDI-DrugBank.d501.s13|35-36|in|O
DDI-DrugBank.d501.s13|38-42|serum|O
DDI-DrugBank.d501.s13|44-50|amylase|O
DDI-DrugBank.d501.s13|52-59|activity|O
DDI-DrugBank.d501.s13|61-63|has|O
DDI-DrugBank.d501.s13|65-68|been|O
DDI-DrugBank.d501.s13|70-77|observed|O
DDI-DrugBank.d501.s13|79-80|in|O
DDI-DrugBank.d501.s13|82-89|patients|O
DDI-DrugBank.d501.s13|91-102|administered|O
DDI-DrugBank.d501.s13|104-112|EXTRANEAL|brand
DDI-DrugBank.d501.s13|113-113|.|O
DDI-DrugBank.d501.s14|0-10|Preliminary|O
DDI-DrugBank.d501.s14|12-25|investigations|O
DDI-DrugBank.d501.s14|27-34|indicate|O
DDI-DrugBank.d501.s14|36-39|that|O
DDI-DrugBank.d501.s14|41-50|icodextrin|drug
DDI-DrugBank.d501.s14|52-54|and|O
DDI-DrugBank.d501.s14|56-58|its|O
DDI-DrugBank.d501.s14|60-70|metabolites|O
DDI-DrugBank.d501.s14|72-80|interfere|O
DDI-DrugBank.d501.s14|82-85|with|O
DDI-DrugBank.d501.s14|87-101|enzymatic-based|O
DDI-DrugBank.d501.s14|103-109|amylase|O
DDI-DrugBank.d501.s14|111-116|assays|O
DDI-DrugBank.d501.s14|117-117|,|O
DDI-DrugBank.d501.s14|119-127|resulting|O
DDI-DrugBank.d501.s14|129-130|in|O
DDI-DrugBank.d501.s14|132-143|inaccurately|O
DDI-DrugBank.d501.s14|145-147|low|O
DDI-DrugBank.d501.s14|149-154|values|O
DDI-DrugBank.d501.s14|155-155|.|O
DDI-DrugBank.d501.s15|0-3|This|O
DDI-DrugBank.d501.s15|5-10|should|O
DDI-DrugBank.d501.s15|12-13|be|O
DDI-DrugBank.d501.s15|15-19|taken|O
DDI-DrugBank.d501.s15|21-24|into|O
DDI-DrugBank.d501.s15|26-32|account|O
DDI-DrugBank.d501.s15|34-37|when|O
DDI-DrugBank.d501.s15|39-48|evaluating|O
DDI-DrugBank.d501.s15|50-54|serum|O
DDI-DrugBank.d501.s15|56-62|amylase|O
DDI-DrugBank.d501.s15|64-69|levels|O
DDI-DrugBank.d501.s15|71-73|for|O
DDI-DrugBank.d501.s15|75-83|diagnosis|O
DDI-DrugBank.d501.s15|85-86|or|O
DDI-DrugBank.d501.s15|88-97|monitoring|O
DDI-DrugBank.d501.s15|99-100|of|O
DDI-DrugBank.d501.s15|102-113|pancreatitis|O
DDI-DrugBank.d501.s15|115-116|in|O
DDI-DrugBank.d501.s15|118-125|patients|O
DDI-DrugBank.d501.s15|127-131|using|O
DDI-DrugBank.d501.s15|133-141|EXTRANEAL|brand
DDI-DrugBank.d501.s15|142-142|.|O
DDI-DrugBank.d298.s0|0-13|Cyclopentolate|drug
DDI-DrugBank.d298.s0|15-17|may|O
DDI-DrugBank.d298.s0|19-27|interfere|O
DDI-DrugBank.d298.s0|29-32|with|O
DDI-DrugBank.d298.s0|34-36|the|O
DDI-DrugBank.d298.s0|38-50|anti-glaucoma|O
DDI-DrugBank.d298.s0|52-57|action|O
DDI-DrugBank.d298.s0|59-60|of|O
DDI-DrugBank.d298.s0|62-70|carbachol|drug
DDI-DrugBank.d298.s0|72-73|or|O
DDI-DrugBank.d298.s0|75-85|pilocarpine|drug
DDI-DrugBank.d298.s0|86-86|;|O
DDI-DrugBank.d298.s1|0-3|also|O
DDI-DrugBank.d298.s1|4-4|,|O
DDI-DrugBank.d298.s1|6-15|concurrent|O
DDI-DrugBank.d298.s1|17-19|use|O
DDI-DrugBank.d298.s1|21-22|of|O
DDI-DrugBank.d298.s1|24-27|this|O
DDI-DrugBank.d298.s1|29-38|medication|O
DDI-DrugBank.d298.s1|40-42|may|O
DDI-DrugBank.d298.s1|44-53|antagonise|O
DDI-DrugBank.d298.s1|55-57|the|O
DDI-DrugBank.d298.s1|59-71|anti-glaucoma|O
DDI-DrugBank.d298.s1|73-75|and|O
DDI-DrugBank.d298.s1|77-82|miotic|O
DDI-DrugBank.d298.s1|84-90|actions|O
DDI-DrugBank.d298.s1|92-93|of|O
DDI-DrugBank.d298.s1|95-104|ophthalmic|O
DDI-DrugBank.d298.s1|106-130|cholinesterase inhibitors|group
DDI-DrugBank.d298.s1|131-131|.|O
DDI-DrugBank.d190.s0|0-3|Drug|O
DDI-DrugBank.d190.s0|5-15|interaction|O
DDI-DrugBank.d190.s0|17-23|studies|O
DDI-DrugBank.d190.s0|25-28|with|O
DDI-DrugBank.d190.s0|30-35|Xigris|brand
DDI-DrugBank.d190.s0|37-40|have|O
DDI-DrugBank.d190.s0|42-44|not|O
DDI-DrugBank.d190.s0|46-49|been|O
DDI-DrugBank.d190.s0|51-59|performed|O
DDI-DrugBank.d190.s0|61-62|in|O
DDI-DrugBank.d190.s0|64-71|patients|O
DDI-DrugBank.d190.s0|73-76|with|O
DDI-DrugBank.d190.s0|78-83|severe|O
DDI-DrugBank.d190.s0|85-90|sepsis|O
DDI-DrugBank.d190.s0|91-91|.|O
DDI-DrugBank.d190.s1|0-6|However|O
DDI-DrugBank.d190.s1|7-7|,|O
DDI-DrugBank.d190.s1|9-13|since|O
DDI-DrugBank.d190.s1|15-19|there|O
DDI-DrugBank.d190.s1|21-22|is|O
DDI-DrugBank.d190.s1|24-25|an|O
DDI-DrugBank.d190.s1|27-35|increased|O
DDI-DrugBank.d190.s1|37-40|risk|O
DDI-DrugBank.d190.s1|42-43|of|O
DDI-DrugBank.d190.s1|45-52|bleeding|O
DDI-DrugBank.d190.s1|54-57|with|O
DDI-DrugBank.d190.s1|59-64|Xigris|brand
DDI-DrugBank.d190.s1|65-65|,|O
DDI-DrugBank.d190.s1|67-73|caution|O
DDI-DrugBank.d190.s1|75-80|should|O
DDI-DrugBank.d190.s1|82-83|be|O
DDI-DrugBank.d190.s1|85-92|employed|O
DDI-DrugBank.d190.s1|94-97|when|O
DDI-DrugBank.d190.s1|99-104|Xigris|brand
DDI-DrugBank.d190.s1|106-107|is|O
DDI-DrugBank.d190.s1|109-112|used|O
DDI-DrugBank.d190.s1|114-117|with|O
DDI-DrugBank.d190.s1|119-123|other|O
DDI-DrugBank.d190.s1|125-129|drugs|O
DDI-DrugBank.d190.s1|131-134|that|O
DDI-DrugBank.d190.s1|136-141|affect|O
DDI-DrugBank.d190.s1|143-152|hemostasis|O
DDI-DrugBank.d190.s1|153-153|.|O
DDI-DrugBank.d190.s2|0-12|Approximately|O
DDI-DrugBank.d190.s2|14-16|2/3|O
DDI-DrugBank.d190.s2|18-19|of|O
DDI-DrugBank.d190.s2|21-23|the|O
DDI-DrugBank.d190.s2|25-32|patients|O
DDI-DrugBank.d190.s2|34-35|in|O
DDI-DrugBank.d190.s2|37-39|the|O
DDI-DrugBank.d190.s2|41-45|Phase|O
DDI-DrugBank.d190.s2|47-47|3|O
DDI-DrugBank.d190.s2|49-53|study|O
DDI-DrugBank.d190.s2|55-62|received|O
DDI-DrugBank.d190.s2|64-69|either|O
DDI-DrugBank.d190.s2|71-82|prophylactic|O
DDI-DrugBank.d190.s2|84-86|low|O
DDI-DrugBank.d190.s2|88-91|dose|O
DDI-DrugBank.d190.s2|93-99|heparin|drug
DDI-DrugBank.d190.s2|101-101|(|O
DDI-DrugBank.d190.s2|102-123|unfractionated heparin|drug
DDI-DrugBank.d190.s2|125-126|up|O
DDI-DrugBank.d190.s2|128-129|to|O
DDI-DrugBank.d190.s2|131-136|15,000|O
DDI-DrugBank.d190.s2|138-146|units/day|O
DDI-DrugBank.d190.s2|147-147|)|O
DDI-DrugBank.d190.s2|149-150|or|O
DDI-DrugBank.d190.s2|152-163|prophylactic|O
DDI-DrugBank.d190.s2|165-169|doses|O
DDI-DrugBank.d190.s2|171-172|of|O
DDI-DrugBank.d190.s2|174-202|low molecular weight heparins|group
DDI-DrugBank.d190.s2|204-205|as|O
DDI-DrugBank.d190.s2|207-215|indicated|O
DDI-DrugBank.d190.s2|217-218|in|O
DDI-DrugBank.d190.s2|220-222|the|O
DDI-DrugBank.d190.s2|224-234|prescribing|O
DDI-DrugBank.d190.s2|236-246|information|O
DDI-DrugBank.d190.s2|248-250|for|O
DDI-DrugBank.d190.s2|252-254|the|O
DDI-DrugBank.d190.s2|256-263|specific|O
DDI-DrugBank.d190.s2|265-272|products|O
DDI-DrugBank.d190.s2|273-273|.|O
DDI-DrugBank.d190.s3|0-10|Concomitant|O
DDI-DrugBank.d190.s3|12-14|use|O
DDI-DrugBank.d190.s3|16-17|of|O
DDI-DrugBank.d190.s3|19-30|prophylactic|O
DDI-DrugBank.d190.s3|32-34|low|O
DDI-DrugBank.d190.s3|36-39|dose|O
DDI-DrugBank.d190.s3|41-47|heparin|drug
DDI-DrugBank.d190.s3|49-51|did|O
DDI-DrugBank.d190.s3|53-55|not|O
DDI-DrugBank.d190.s3|57-62|appear|O
DDI-DrugBank.d190.s3|64-65|to|O
DDI-DrugBank.d190.s3|67-72|affect|O
DDI-DrugBank.d190.s3|74-79|safety|O
DDI-DrugBank.d190.s3|80-80|,|O
DDI-DrugBank.d190.s3|82-88|however|O
DDI-DrugBank.d190.s3|89-89|,|O
DDI-DrugBank.d190.s3|91-93|its|O
DDI-DrugBank.d190.s3|95-101|effects|O
DDI-DrugBank.d190.s3|103-104|on|O
DDI-DrugBank.d190.s3|106-108|the|O
DDI-DrugBank.d190.s3|110-117|efficacy|O
DDI-DrugBank.d190.s3|119-120|of|O
DDI-DrugBank.d190.s3|122-127|Xigris|brand
DDI-DrugBank.d190.s3|129-132|have|O
DDI-DrugBank.d190.s3|134-136|not|O
DDI-DrugBank.d190.s3|138-141|been|O
DDI-DrugBank.d190.s3|143-151|evaluated|O
DDI-DrugBank.d190.s3|153-154|in|O
DDI-DrugBank.d190.s3|156-157|an|O
DDI-DrugBank.d190.s3|159-166|adequate|O
DDI-DrugBank.d190.s3|168-170|and|O
DDI-DrugBank.d190.s3|172-186|well-controlled|O
DDI-DrugBank.d190.s3|188-195|clinical|O
DDI-DrugBank.d190.s3|197-201|trial|O
DDI-DrugBank.d190.s3|202-202|.|O
DDI-DrugBank.d190.s4|0-14|Drug/Laboratory|O
DDI-DrugBank.d190.s4|16-19|Test|O
DDI-DrugBank.d190.s4|21-31|Interaction|O
DDI-DrugBank.d190.s4|33-39|Because|O
DDI-DrugBank.d190.s4|41-46|Xigris|brand
DDI-DrugBank.d190.s4|48-50|may|O
DDI-DrugBank.d190.s4|52-57|affect|O
DDI-DrugBank.d190.s4|59-61|the|O
DDI-DrugBank.d190.s4|63-66|APTT|O
DDI-DrugBank.d190.s4|68-72|assay|O
DDI-DrugBank.d190.s4|73-73|,|O
DDI-DrugBank.d190.s4|75-80|Xigris|brand
DDI-DrugBank.d190.s4|82-88|present|O
DDI-DrugBank.d190.s4|90-91|in|O
DDI-DrugBank.d190.s4|93-98|plasma|O
DDI-DrugBank.d190.s4|100-106|samples|O
DDI-DrugBank.d190.s4|108-110|may|O
DDI-DrugBank.d190.s4|112-120|interfere|O
DDI-DrugBank.d190.s4|122-125|with|O
DDI-DrugBank.d190.s4|127-135|one-stage|O
DDI-DrugBank.d190.s4|137-147|coagulation|O
DDI-DrugBank.d190.s4|149-154|assays|O
DDI-DrugBank.d190.s4|156-160|based|O
DDI-DrugBank.d190.s4|162-163|on|O
DDI-DrugBank.d190.s4|165-167|the|O
DDI-DrugBank.d190.s4|169-172|APTT|O
DDI-DrugBank.d190.s4|174-174|(|O
DDI-DrugBank.d190.s4|175-178|such|O
DDI-DrugBank.d190.s4|180-181|as|O
DDI-DrugBank.d190.s4|183-188|factor|O
DDI-DrugBank.d190.s4|190-193|VIII|O
DDI-DrugBank.d190.s4|194-194|,|O
DDI-DrugBank.d190.s4|196-197|IX|O
DDI-DrugBank.d190.s4|198-198|,|O
DDI-DrugBank.d190.s4|200-202|and|O
DDI-DrugBank.d190.s4|204-205|XI|O
DDI-DrugBank.d190.s4|207-212|assays|O
DDI-DrugBank.d190.s4|213-213|)|O
DDI-DrugBank.d190.s4|214-214|.|O
DDI-DrugBank.d190.s5|0-3|This|O
DDI-DrugBank.d190.s5|5-16|interference|O
DDI-DrugBank.d190.s5|18-20|may|O
DDI-DrugBank.d190.s5|22-27|result|O
DDI-DrugBank.d190.s5|29-30|in|O
DDI-DrugBank.d190.s5|32-33|an|O
DDI-DrugBank.d190.s5|35-42|apparent|O
DDI-DrugBank.d190.s5|44-49|factor|O
DDI-DrugBank.d190.s5|51-63|concentration|O
DDI-DrugBank.d190.s5|65-68|that|O
DDI-DrugBank.d190.s5|70-71|is|O
DDI-DrugBank.d190.s5|73-77|lower|O
DDI-DrugBank.d190.s5|79-82|than|O
DDI-DrugBank.d190.s5|84-86|the|O
DDI-DrugBank.d190.s5|88-91|true|O
DDI-DrugBank.d190.s5|93-105|concentration|O
DDI-DrugBank.d190.s5|106-106|.|O
DDI-DrugBank.d190.s6|0-5|Xigris|brand
DDI-DrugBank.d190.s6|7-13|present|O
DDI-DrugBank.d190.s6|15-16|in|O
DDI-DrugBank.d190.s6|18-23|plasma|O
DDI-DrugBank.d190.s6|25-31|samples|O
DDI-DrugBank.d190.s6|33-36|does|O
DDI-DrugBank.d190.s6|38-40|not|O
DDI-DrugBank.d190.s6|42-50|interfere|O
DDI-DrugBank.d190.s6|52-55|with|O
DDI-DrugBank.d190.s6|57-65|one-stage|O
DDI-DrugBank.d190.s6|67-72|factor|O
DDI-DrugBank.d190.s6|74-79|assays|O
DDI-DrugBank.d190.s6|81-85|based|O
DDI-DrugBank.d190.s6|87-88|on|O
DDI-DrugBank.d190.s6|90-92|the|O
DDI-DrugBank.d190.s6|94-95|PT|O
DDI-DrugBank.d190.s6|97-97|(|O
DDI-DrugBank.d190.s6|98-101|such|O
DDI-DrugBank.d190.s6|103-104|as|O
DDI-DrugBank.d190.s6|106-111|factor|O
DDI-DrugBank.d190.s6|113-114|II|O
DDI-DrugBank.d190.s6|115-115|,|O
DDI-DrugBank.d190.s6|117-117|V|O
DDI-DrugBank.d190.s6|118-118|,|O
DDI-DrugBank.d190.s6|120-122|VII|O
DDI-DrugBank.d190.s6|123-123|,|O
DDI-DrugBank.d190.s6|125-127|and|O
DDI-DrugBank.d190.s6|129-129|X|O
DDI-DrugBank.d190.s6|131-136|assays|O
DDI-DrugBank.d190.s6|137-137|)|O
DDI-DrugBank.d190.s6|138-138|.|O
DDI-DrugBank.d193.s0|0-0|A|O
DDI-DrugBank.d193.s0|2-5|drug|O
DDI-DrugBank.d193.s0|7-17|interaction|O
DDI-DrugBank.d193.s0|19-23|study|O
DDI-DrugBank.d193.s0|25-27|was|O
DDI-DrugBank.d193.s0|29-37|performed|O
DDI-DrugBank.d193.s0|39-40|in|O
DDI-DrugBank.d193.s0|42-46|which|O
DDI-DrugBank.d193.s0|48-54|ERBITUX|brand
DDI-DrugBank.d193.s0|56-58|was|O
DDI-DrugBank.d193.s0|60-71|administered|O
DDI-DrugBank.d193.s0|73-74|in|O
DDI-DrugBank.d193.s0|76-86|combination|O
DDI-DrugBank.d193.s0|88-91|with|O
DDI-DrugBank.d193.s0|93-102|irinotecan|drug
DDI-DrugBank.d193.s0|103-103|.|O
DDI-DrugBank.d193.s1|0-4|There|O
DDI-DrugBank.d193.s1|6-8|was|O
DDI-DrugBank.d193.s1|10-11|no|O
DDI-DrugBank.d193.s1|13-20|evidence|O
DDI-DrugBank.d193.s1|22-23|of|O
DDI-DrugBank.d193.s1|25-27|any|O
DDI-DrugBank.d193.s1|29-43|pharmacokinetic|O
DDI-DrugBank.d193.s1|45-56|interactions|O
DDI-DrugBank.d193.s1|58-64|between|O
DDI-DrugBank.d193.s1|66-72|ERBITUX|brand
DDI-DrugBank.d193.s1|74-76|and|O
DDI-DrugBank.d193.s1|78-87|irinotecan|drug
DDI-DrugBank.d193.s1|88-88|.|O
DDI-DrugBank.d42.s0|0-2|The|O
DDI-DrugBank.d42.s0|4-12|potential|O
DDI-DrugBank.d42.s0|14-16|for|O
DDI-DrugBank.d42.s0|18-27|clinically|O
DDI-DrugBank.d42.s0|29-39|significant|O
DDI-DrugBank.d42.s0|41-49|drug-drug|O
DDI-DrugBank.d42.s0|51-62|interactions|O
DDI-DrugBank.d42.s0|64-68|posed|O
DDI-DrugBank.d42.s0|70-71|by|O
DDI-DrugBank.d42.s0|73-82|dolasetron|drug
DDI-DrugBank.d42.s0|84-86|and|O
DDI-DrugBank.d42.s0|104-110|appears|O
DDI-DrugBank.d42.s0|112-113|to|O
DDI-DrugBank.d42.s0|115-116|be|O
DDI-DrugBank.d42.s0|118-120|low|O
DDI-DrugBank.d42.s0|122-124|for|O
DDI-DrugBank.d42.s0|126-130|drugs|O
DDI-DrugBank.d42.s0|132-139|commonly|O
DDI-DrugBank.d42.s0|141-144|used|O
DDI-DrugBank.d42.s0|146-147|in|O
DDI-DrugBank.d42.s0|149-160|chemotherapy|O
DDI-DrugBank.d42.s0|162-163|or|O
DDI-DrugBank.d42.s0|165-171|surgery|O
DDI-DrugBank.d42.s0|172-172|,|O
DDI-DrugBank.d42.s0|174-180|because|O
DDI-DrugBank.d42.s0|198-199|is|O
DDI-DrugBank.d42.s0|201-210|eliminated|O
DDI-DrugBank.d42.s0|212-213|by|O
DDI-DrugBank.d42.s0|215-222|multiple|O
DDI-DrugBank.d42.s0|224-229|routes|O
DDI-DrugBank.d42.s0|230-230|.|O
DDI-DrugBank.d42.s1|0-4|Blood|O
DDI-DrugBank.d42.s1|6-11|levels|O
DDI-DrugBank.d42.s1|13-14|of|O
DDI-DrugBank.d42.s1|32-40|increased|O
DDI-DrugBank.d42.s1|42-43|24|O
DDI-DrugBank.d42.s1|44-44|%|O
DDI-DrugBank.d42.s1|46-49|when|O
DDI-DrugBank.d42.s1|51-60|dolasetron|drug
DDI-DrugBank.d42.s1|62-64|was|O
DDI-DrugBank.d42.s1|66-79|coadministered|O
DDI-DrugBank.d42.s1|81-84|with|O
DDI-DrugBank.d42.s1|86-95|cimetidine|drug
DDI-DrugBank.d42.s1|97-97|(|O
DDI-DrugBank.d42.s1|98-109|nonselective|O
DDI-DrugBank.d42.s1|111-119|inhibitor|O
DDI-DrugBank.d42.s1|121-122|of|O
DDI-DrugBank.d42.s1|124-133|cytochrome|O
DDI-DrugBank.d42.s1|135-139|P-450|O
DDI-DrugBank.d42.s1|140-140|)|O
DDI-DrugBank.d42.s1|142-144|for|O
DDI-DrugBank.d42.s1|146-146|7|O
DDI-DrugBank.d42.s1|148-151|days|O
DDI-DrugBank.d42.s1|152-152|,|O
DDI-DrugBank.d42.s1|154-156|and|O
DDI-DrugBank.d42.s1|158-166|decreased|O
DDI-DrugBank.d42.s1|168-169|28|O
DDI-DrugBank.d42.s1|170-170|%|O
DDI-DrugBank.d42.s1|172-175|with|O
DDI-DrugBank.d42.s1|177-192|coadministration|O
DDI-DrugBank.d42.s1|194-195|of|O
DDI-DrugBank.d42.s1|197-204|rifampin|drug
DDI-DrugBank.d42.s1|206-206|(|O
DDI-DrugBank.d42.s1|207-212|potent|O
DDI-DrugBank.d42.s1|214-220|inducer|O
DDI-DrugBank.d42.s1|222-223|of|O
DDI-DrugBank.d42.s1|225-234|cytochrome|O
DDI-DrugBank.d42.s1|236-240|P-450|O
DDI-DrugBank.d42.s1|241-241|)|O
DDI-DrugBank.d42.s1|243-245|for|O
DDI-DrugBank.d42.s1|247-247|7|O
DDI-DrugBank.d42.s1|249-252|days|O
DDI-DrugBank.d42.s1|253-253|.|O
DDI-DrugBank.d42.s2|0-9|Dolasetron|drug
DDI-DrugBank.d42.s2|11-13|has|O
DDI-DrugBank.d42.s2|15-18|been|O
DDI-DrugBank.d42.s2|20-25|safely|O
DDI-DrugBank.d42.s2|27-40|coadministered|O
DDI-DrugBank.d42.s2|42-45|with|O
DDI-DrugBank.d42.s2|47-51|drugs|O
DDI-DrugBank.d42.s2|53-56|used|O
DDI-DrugBank.d42.s2|58-59|in|O
DDI-DrugBank.d42.s2|61-72|chemotherapy|O
DDI-DrugBank.d42.s2|74-76|and|O
DDI-DrugBank.d42.s2|78-84|surgery|O
DDI-DrugBank.d42.s2|85-85|.|O
DDI-DrugBank.d42.s3|0-1|As|O
DDI-DrugBank.d42.s3|3-6|with|O
DDI-DrugBank.d42.s3|8-12|other|O
DDI-DrugBank.d42.s3|14-19|agents|O
DDI-DrugBank.d42.s3|21-25|which|O
DDI-DrugBank.d42.s3|27-33|prolong|O
DDI-DrugBank.d42.s3|35-37|ECG|O
DDI-DrugBank.d42.s3|39-47|intervals|O
DDI-DrugBank.d42.s3|48-48|,|O
DDI-DrugBank.d42.s3|50-56|caution|O
DDI-DrugBank.d42.s3|58-63|should|O
DDI-DrugBank.d42.s3|65-66|be|O
DDI-DrugBank.d42.s3|68-76|exercised|O
DDI-DrugBank.d42.s3|78-79|in|O
DDI-DrugBank.d42.s3|81-88|patients|O
DDI-DrugBank.d42.s3|90-95|taking|O
DDI-DrugBank.d42.s3|97-101|drugs|O
DDI-DrugBank.d42.s3|103-107|which|O
DDI-DrugBank.d42.s3|109-115|prolong|O
DDI-DrugBank.d42.s3|117-119|ECG|O
DDI-DrugBank.d42.s3|121-129|intervals|O
DDI-DrugBank.d42.s3|130-130|,|O
DDI-DrugBank.d42.s3|132-143|particularly|O
DDI-DrugBank.d42.s3|145-147|QTc|O
DDI-DrugBank.d42.s3|148-148|.|O
DDI-DrugBank.d42.s4|0-1|In|O
DDI-DrugBank.d42.s4|3-10|patients|O
DDI-DrugBank.d42.s4|12-17|taking|O
DDI-DrugBank.d42.s4|19-28|furosemide|drug
DDI-DrugBank.d42.s4|29-29|,|O
DDI-DrugBank.d42.s4|31-40|nifedipine|drug
DDI-DrugBank.d42.s4|41-41|,|O
DDI-DrugBank.d42.s4|43-51|diltiazem|drug
DDI-DrugBank.d42.s4|52-52|,|O
DDI-DrugBank.d42.s4|54-67|ACE inhibitors|group
DDI-DrugBank.d42.s4|68-68|,|O
DDI-DrugBank.d42.s4|70-78|verapamil|drug
DDI-DrugBank.d42.s4|79-79|,|O
DDI-DrugBank.d42.s4|81-89|glyburide|drug
DDI-DrugBank.d42.s4|90-90|,|O
DDI-DrugBank.d42.s4|92-102|propranolol|drug
DDI-DrugBank.d42.s4|103-103|,|O
DDI-DrugBank.d42.s4|105-107|and|O
DDI-DrugBank.d42.s4|109-115|various|O
DDI-DrugBank.d42.s4|117-128|chemotherapy|O
DDI-DrugBank.d42.s4|130-135|agents|O
DDI-DrugBank.d42.s4|136-136|,|O
DDI-DrugBank.d42.s4|138-139|no|O
DDI-DrugBank.d42.s4|141-146|effect|O
DDI-DrugBank.d42.s4|148-150|was|O
DDI-DrugBank.d42.s4|152-156|shown|O
DDI-DrugBank.d42.s4|158-159|on|O
DDI-DrugBank.d42.s4|161-163|the|O
DDI-DrugBank.d42.s4|165-173|clearance|O
DDI-DrugBank.d42.s4|175-176|of|O
DDI-DrugBank.d42.s4|193-193|.|O
DDI-DrugBank.d42.s5|0-8|Clearance|O
DDI-DrugBank.d42.s5|10-11|of|O
DDI-DrugBank.d42.s5|29-37|decreased|O
DDI-DrugBank.d42.s5|39-40|by|O
DDI-DrugBank.d42.s5|42-46|about|O
DDI-DrugBank.d42.s5|48-49|27|O
DDI-DrugBank.d42.s5|50-50|%|O
DDI-DrugBank.d42.s5|52-55|when|O
DDI-DrugBank.d42.s5|57-75|dolasetron mesylate|drug
DDI-DrugBank.d42.s5|77-79|was|O
DDI-DrugBank.d42.s5|81-92|administered|O
DDI-DrugBank.d42.s5|94-106|intravenously|O
DDI-DrugBank.d42.s5|108-120|concomitantly|O
DDI-DrugBank.d42.s5|122-125|with|O
DDI-DrugBank.d42.s5|127-134|atenolol|drug
DDI-DrugBank.d42.s5|135-135|.|O
DDI-DrugBank.d42.s6|0-9|Dolasetron|drug
DDI-DrugBank.d42.s6|11-14|does|O
DDI-DrugBank.d42.s6|16-18|not|O
DDI-DrugBank.d42.s6|20-28|influence|O
DDI-DrugBank.d42.s6|30-39|anesthesia|O
DDI-DrugBank.d42.s6|41-48|recovery|O
DDI-DrugBank.d42.s6|50-53|time|O
DDI-DrugBank.d42.s6|55-56|in|O
DDI-DrugBank.d42.s6|58-65|patients|O
DDI-DrugBank.d42.s6|66-66|.|O
DDI-DrugBank.d42.s7|0-18|Dolasetron mesylate|drug
DDI-DrugBank.d42.s7|20-22|did|O
DDI-DrugBank.d42.s7|24-26|not|O
DDI-DrugBank.d42.s7|28-34|inhibit|O
DDI-DrugBank.d42.s7|36-38|the|O
DDI-DrugBank.d42.s7|40-48|antitumor|O
DDI-DrugBank.d42.s7|50-57|activity|O
DDI-DrugBank.d42.s7|59-60|of|O
DDI-DrugBank.d42.s7|62-65|four|O
DDI-DrugBank.d42.s7|67-89|chemotherapeutic agents|group
DDI-DrugBank.d42.s7|91-91|(|O
DDI-DrugBank.d42.s7|92-100|cisplatin|drug
DDI-DrugBank.d42.s7|101-101|,|O
DDI-DrugBank.d42.s7|103-116|5-fluorouracil|drug
DDI-DrugBank.d42.s7|117-117|,|O
DDI-DrugBank.d42.s7|119-129|doxorubicin|drug
DDI-DrugBank.d42.s7|130-130|,|O
DDI-DrugBank.d42.s7|132-147|cyclophosphamide|drug
DDI-DrugBank.d42.s7|148-148|)|O
DDI-DrugBank.d42.s7|150-151|in|O
DDI-DrugBank.d42.s7|153-156|four|O
DDI-DrugBank.d42.s7|158-163|murine|O
DDI-DrugBank.d42.s7|165-170|models|O
DDI-DrugBank.d42.s7|171-171|.|O
DDI-DrugBank.d344.s0|0-10|Concomitant|O
DDI-DrugBank.d344.s0|12-14|use|O
DDI-DrugBank.d344.s0|16-17|of|O
DDI-DrugBank.d344.s0|19-25|calcium|drug
DDI-DrugBank.d344.s0|27-37|supplements|O
DDI-DrugBank.d344.s0|39-41|and|O
DDI-DrugBank.d344.s0|43-50|L-lysine|drug
DDI-DrugBank.d344.s0|52-54|may|O
DDI-DrugBank.d344.s0|56-63|increase|O
DDI-DrugBank.d344.s0|65-71|calcium|drug
DDI-DrugBank.d344.s0|73-82|absorption|O
DDI-DrugBank.d273.s0|0-8|Drug-Drug|O
DDI-DrugBank.d273.s0|10-21|Interactions|O
DDI-DrugBank.d273.s0|22-22|:|O
DDI-DrugBank.d273.s0|24-26|The|O
DDI-DrugBank.d273.s0|28-42|pharmacokinetic|O
DDI-DrugBank.d273.s0|44-46|and|O
DDI-DrugBank.d273.s0|48-62|pharmacodynamic|O
DDI-DrugBank.d273.s0|64-75|interactions|O
DDI-DrugBank.d273.s0|77-83|between|O
DDI-DrugBank.d273.s0|85-93|UROXATRAL|brand
DDI-DrugBank.d273.s0|95-97|and|O
DDI-DrugBank.d273.s0|99-103|other|O
DDI-DrugBank.d273.s0|105-118|alpha-blockers|group
DDI-DrugBank.d273.s0|120-123|have|O
DDI-DrugBank.d273.s0|125-127|not|O
DDI-DrugBank.d273.s0|129-132|been|O
DDI-DrugBank.d273.s0|134-143|determined|O
DDI-DrugBank.d273.s0|144-144|.|O
DDI-DrugBank.d273.s1|0-6|However|O
DDI-DrugBank.d273.s1|7-7|,|O
DDI-DrugBank.d273.s1|9-20|interactions|O
DDI-DrugBank.d273.s1|22-24|may|O
DDI-DrugBank.d273.s1|26-27|be|O
DDI-DrugBank.d273.s1|29-36|expected|O
DDI-DrugBank.d273.s1|37-37|,|O
DDI-DrugBank.d273.s1|39-41|and|O
DDI-DrugBank.d273.s1|43-51|UROXATRAL|brand
DDI-DrugBank.d273.s1|53-58|should|O
DDI-DrugBank.d273.s1|60-62|NOT|O
DDI-DrugBank.d273.s1|64-65|be|O
DDI-DrugBank.d273.s1|67-70|used|O
DDI-DrugBank.d273.s1|72-73|in|O
DDI-DrugBank.d273.s1|75-85|combination|O
DDI-DrugBank.d273.s1|87-90|with|O
DDI-DrugBank.d273.s1|92-96|other|O
DDI-DrugBank.d273.s1|98-111|alpha-blockers|group
DDI-DrugBank.d273.s1|112-112|.|O
DDI-DrugBank.d118.s0|0-1|In|O
DDI-DrugBank.d118.s0|3-7|vitro|O
DDI-DrugBank.d118.s0|9-15|studies|O
DDI-DrugBank.d118.s0|17-20|have|O
DDI-DrugBank.d118.s0|22-26|shown|O
DDI-DrugBank.d118.s0|28-31|that|O
DDI-DrugBank.d118.s0|33-45|precipitation|O
DDI-DrugBank.d118.s0|47-52|occurs|O
DDI-DrugBank.d118.s0|54-57|when|O
DDI-DrugBank.d118.s0|59-61|eye|O
DDI-DrugBank.d118.s0|63-67|drops|O
DDI-DrugBank.d118.s0|69-78|containing|O
DDI-DrugBank.d118.s0|91-93|are|O
DDI-DrugBank.d118.s0|95-99|mixed|O
DDI-DrugBank.d118.s0|101-104|with|O
DDI-DrugBank.d118.s0|106-116|latanoprost|drug
DDI-DrugBank.d118.s0|117-117|.|O
DDI-DrugBank.d118.s1|0-1|If|O
DDI-DrugBank.d118.s1|3-6|such|O
DDI-DrugBank.d118.s1|8-12|drugs|O
DDI-DrugBank.d118.s1|14-16|are|O
DDI-DrugBank.d118.s1|18-21|used|O
DDI-DrugBank.d118.s1|23-26|they|O
DDI-DrugBank.d118.s1|28-33|should|O
DDI-DrugBank.d118.s1|35-36|be|O
DDI-DrugBank.d118.s1|38-49|administered|O
DDI-DrugBank.d118.s1|51-54|with|O
DDI-DrugBank.d118.s1|56-57|an|O
DDI-DrugBank.d118.s1|59-66|interval|O
DDI-DrugBank.d118.s1|68-69|of|O
DDI-DrugBank.d118.s1|71-72|at|O
DDI-DrugBank.d118.s1|74-78|least|O
DDI-DrugBank.d118.s1|80-80|5|O
DDI-DrugBank.d118.s1|82-88|minutes|O
DDI-DrugBank.d118.s1|90-96|between|O
DDI-DrugBank.d118.s1|98-109|applications|O
DDI-DrugBank.d118.s1|110-110|.|O
DDI-DrugBank.d208.s0|0-11|Benzthiazide|drug
DDI-DrugBank.d208.s0|13-15|may|O
DDI-DrugBank.d208.s0|17-24|interact|O
DDI-DrugBank.d208.s0|26-29|with|O
DDI-DrugBank.d208.s0|31-37|alcohol|drug
DDI-DrugBank.d208.s0|38-38|,|O
DDI-DrugBank.d208.s0|40-44|blood|group
DDI-DrugBank.d208.s0|46-53|thinners|O
DDI-DrugBank.d208.s0|54-54|,|O
DDI-DrugBank.d208.s0|56-73|decongestant drugs|group
DDI-DrugBank.d208.s0|75-75|(|O
DDI-DrugBank.d208.s0|76-82|allergy|O
DDI-DrugBank.d208.s0|83-83|,|O
DDI-DrugBank.d208.s0|85-88|cold|O
DDI-DrugBank.d208.s0|89-89|,|O
DDI-DrugBank.d208.s0|91-93|and|O
DDI-DrugBank.d208.s0|95-99|sinus|O
DDI-DrugBank.d208.s0|101-109|medicines|O
DDI-DrugBank.d208.s0|110-110|)|O
DDI-DrugBank.d208.s0|111-111|,|O
DDI-DrugBank.d208.s0|113-120|diabetic|O
DDI-DrugBank.d208.s0|122-126|drugs|O
DDI-DrugBank.d208.s0|127-127|,|O
DDI-DrugBank.d208.s0|129-135|lithium|drug
DDI-DrugBank.d208.s0|136-136|,|O
DDI-DrugBank.d208.s0|138-151|norepinephrine|drug
DDI-DrugBank.d208.s0|152-152|,|O
DDI-DrugBank.d208.s0|154-159|NSAIDs|group
DDI-DrugBank.d208.s0|161-164|like|O
DDI-DrugBank.d208.s0|166-170|Aleve|brand
DDI-DrugBank.d208.s0|172-173|or|O
DDI-DrugBank.d208.s0|175-183|Ibuprofen|drug
DDI-DrugBank.d208.s0|184-184|,|O
DDI-DrugBank.d208.s0|186-188|and|O
DDI-DrugBank.d208.s0|190-193|high|O
DDI-DrugBank.d208.s0|195-199|blood|O
DDI-DrugBank.d208.s0|201-208|pressure|O
DDI-DrugBank.d208.s0|210-220|medications|O
DDI-DrugBank.d208.s0|221-221|.|O
DDI-MedLine.d96.s0|7-7|:|O
DDI-MedLine.d96.s0|9-10|an|O
DDI-MedLine.d96.s0|12-22|IgA-binding|O
DDI-MedLine.d96.s0|24-29|lectin|O
DDI-MedLine.d96.s0|30-30|.|O
DDI-MedLine.d96.s1|0-1|We|O
DDI-MedLine.d96.s1|3-12|previously|O
DDI-MedLine.d96.s1|14-21|reported|O
DDI-MedLine.d96.s1|23-26|that|O
DDI-MedLine.d96.s1|28-32|seeds|O
DDI-MedLine.d96.s1|34-35|of|O
DDI-MedLine.d96.s1|37-46|Artocarpus|O
DDI-MedLine.d96.s1|48-59|integrifolia|O
DDI-MedLine.d96.s1|61-61|(|O
DDI-MedLine.d96.s1|62-70|jackfruit|O
DDI-MedLine.d96.s1|71-71|)|O
DDI-MedLine.d96.s1|73-79|contain|O
DDI-MedLine.d96.s1|81-81|a|O
DDI-MedLine.d96.s1|83-88|lectin|O
DDI-MedLine.d96.s1|89-89|,|O
DDI-MedLine.d96.s1|91-95|which|O
DDI-MedLine.d96.s1|97-98|we|O
DDI-MedLine.d96.s1|100-103|call|O
DDI-MedLine.d96.s1|112-112|,|O
DDI-MedLine.d96.s1|114-117|that|O
DDI-MedLine.d96.s1|119-120|is|O
DDI-MedLine.d96.s1|122-125|both|O
DDI-MedLine.d96.s1|127-127|a|O
DDI-MedLine.d96.s1|129-134|potent|O
DDI-MedLine.d96.s1|136-136|T|O
DDI-MedLine.d96.s1|138-141|cell|O
DDI-MedLine.d96.s1|143-149|mitogen|O
DDI-MedLine.d96.s1|151-153|and|O
DDI-MedLine.d96.s1|155-156|an|O
DDI-MedLine.d96.s1|158-167|apparently|O
DDI-MedLine.d96.s1|169-169|T|O
DDI-MedLine.d96.s1|171-186|cell-independent|O
DDI-MedLine.d96.s1|188-196|activator|O
DDI-MedLine.d96.s1|198-199|of|O
DDI-MedLine.d96.s1|201-205|human|O
DDI-MedLine.d96.s1|207-207|B|O
DDI-MedLine.d96.s1|209-213|cells|O
DDI-MedLine.d96.s1|215-217|for|O
DDI-MedLine.d96.s1|219-221|the|O
DDI-MedLine.d96.s1|223-231|secretion|O
DDI-MedLine.d96.s1|233-234|of|O
DDI-MedLine.d96.s1|236-250|immunoglobulins|O
DDI-MedLine.d96.s1|251-251|.|O
DDI-MedLine.d96.s2|0-5|During|O
DDI-MedLine.d96.s2|7-9|the|O
DDI-MedLine.d96.s2|11-15|above|O
DDI-MedLine.d96.s2|17-27|experiments|O
DDI-MedLine.d96.s2|29-30|we|O
DDI-MedLine.d96.s2|32-36|noted|O
DDI-MedLine.d96.s2|38-38|a|O
DDI-MedLine.d96.s2|40-46|massive|O
DDI-MedLine.d96.s2|48-60|precipitation|O
DDI-MedLine.d96.s2|62-63|in|O
DDI-MedLine.d96.s2|65-68|cell|O
DDI-MedLine.d96.s2|70-77|cultures|O
DDI-MedLine.d96.s2|79-88|stimulated|O
DDI-MedLine.d96.s2|90-93|with|O
DDI-MedLine.d96.s2|95-101|greater|O
DDI-MedLine.d96.s2|103-106|than|O
DDI-MedLine.d96.s2|108-109|or|O
DDI-MedLine.d96.s2|111-115|equal|O
DDI-MedLine.d96.s2|117-118|to|O
DDI-MedLine.d96.s2|120-122|100|O
DDI-MedLine.d96.s2|124-133|micrograms|O
DDI-MedLine.d96.s2|135-136|of|O
DDI-MedLine.d96.s2|138-143|lectin|O
DDI-MedLine.d96.s2|144-144|.|O
DDI-MedLine.d96.s3|0-1|In|O
DDI-MedLine.d96.s3|3-6|this|O
DDI-MedLine.d96.s3|8-12|paper|O
DDI-MedLine.d96.s3|13-13|,|O
DDI-MedLine.d96.s3|15-16|we|O
DDI-MedLine.d96.s3|18-21|show|O
DDI-MedLine.d96.s3|23-26|that|O
DDI-MedLine.d96.s3|28-30|the|O
DDI-MedLine.d96.s3|32-42|precipitate|O
DDI-MedLine.d96.s3|44-45|is|O
DDI-MedLine.d96.s3|47-52|formed|O
DDI-MedLine.d96.s3|54-58|after|O
DDI-MedLine.d96.s3|60-62|the|O
DDI-MedLine.d96.s3|64-74|interaction|O
DDI-MedLine.d96.s3|76-77|of|O
DDI-MedLine.d96.s3|87-89|and|O
DDI-MedLine.d96.s3|91-93|the|O
DDI-MedLine.d96.s3|95-99|serum|O
DDI-MedLine.d96.s3|101-107|protein|O
DDI-MedLine.d96.s3|109-113|added|O
DDI-MedLine.d96.s3|115-116|to|O
DDI-MedLine.d96.s3|118-120|the|O
DDI-MedLine.d96.s3|122-128|culture|O
DDI-MedLine.d96.s3|130-135|medium|O
DDI-MedLine.d96.s3|136-136|.|O
DDI-MedLine.d96.s4|0-3|More|O
DDI-MedLine.d96.s4|5-15|importantly|O
DDI-MedLine.d96.s4|16-16|,|O
DDI-MedLine.d96.s4|18-19|we|O
DDI-MedLine.d96.s4|21-31|demonstrate|O
DDI-MedLine.d96.s4|33-36|that|O
DDI-MedLine.d96.s4|38-40|IgA|O
DDI-MedLine.d96.s4|42-43|is|O
DDI-MedLine.d96.s4|45-52|probably|O
DDI-MedLine.d96.s4|54-56|the|O
DDI-MedLine.d96.s4|58-62|major|O
DDI-MedLine.d96.s4|64-68|serum|O
DDI-MedLine.d96.s4|70-80|constituent|O
DDI-MedLine.d96.s4|82-93|precipitated|O
DDI-MedLine.d96.s4|95-96|by|O
DDI-MedLine.d96.s4|98-100|the|O
DDI-MedLine.d96.s4|102-107|lectin|O
DDI-MedLine.d96.s4|109-111|and|O
DDI-MedLine.d96.s4|113-116|that|O
DDI-MedLine.d96.s4|118-119|no|O
DDI-MedLine.d96.s4|121-123|IgG|O
DDI-MedLine.d96.s4|125-126|or|O
DDI-MedLine.d96.s4|128-130|IgM|O
DDI-MedLine.d96.s4|132-134|can|O
DDI-MedLine.d96.s4|136-137|be|O
DDI-MedLine.d96.s4|139-146|detected|O
DDI-MedLine.d96.s4|148-149|in|O
DDI-MedLine.d96.s4|151-153|the|O
DDI-MedLine.d96.s4|155-166|precipitates|O
DDI-MedLine.d96.s4|167-167|.|O
DDI-MedLine.d96.s5|0-1|In|O
DDI-MedLine.d96.s5|3-12|secretions|O
DDI-MedLine.d96.s5|14-17|such|O
DDI-MedLine.d96.s5|19-20|as|O
DDI-MedLine.d96.s5|22-30|colostrum|O
DDI-MedLine.d96.s5|31-31|,|O
DDI-MedLine.d96.s5|33-35|IgA|O
DDI-MedLine.d96.s5|37-38|is|O
DDI-MedLine.d96.s5|40-42|the|O
DDI-MedLine.d96.s5|44-47|only|O
DDI-MedLine.d96.s5|49-55|protein|O
DDI-MedLine.d96.s5|57-68|precipitated|O
DDI-MedLine.d96.s5|70-71|by|O
DDI-MedLine.d96.s5|80-80|.|O
DDI-MedLine.d96.s6|0-1|On|O
DDI-MedLine.d96.s6|3-5|the|O
DDI-MedLine.d96.s6|7-11|basis|O
DDI-MedLine.d96.s6|13-14|of|O
DDI-MedLine.d96.s6|16-19|this|O
DDI-MedLine.d96.s6|21-31|specificity|O
DDI-MedLine.d96.s6|33-34|we|O
DDI-MedLine.d96.s6|36-43|describe|O
DDI-MedLine.d96.s6|45-45|a|O
DDI-MedLine.d96.s6|47-52|simple|O
DDI-MedLine.d96.s6|54-56|and|O
DDI-MedLine.d96.s6|58-65|reliable|O
DDI-MedLine.d96.s6|67-74|affinity|O
DDI-MedLine.d96.s6|76-89|chromatography|O
DDI-MedLine.d96.s6|91-99|procedure|O
DDI-MedLine.d96.s6|101-103|for|O
DDI-MedLine.d96.s6|105-107|the|O
DDI-MedLine.d96.s6|109-120|purification|O
DDI-MedLine.d96.s6|122-123|of|O
DDI-MedLine.d96.s6|125-128|both|O
DDI-MedLine.d96.s6|130-134|human|O
DDI-MedLine.d96.s6|136-140|serum|O
DDI-MedLine.d96.s6|142-144|and|O
DDI-MedLine.d96.s6|146-154|colostrum|O
DDI-MedLine.d96.s6|156-158|IgA|O
DDI-MedLine.d96.s6|159-159|.|O
DDI-MedLine.d96.s7|8-9|is|O
DDI-MedLine.d96.s7|11-11|a|O
DDI-MedLine.d96.s7|13-17|D-Gal|O
DDI-MedLine.d96.s7|19-25|binding|O
DDI-MedLine.d96.s7|27-32|lectin|O
DDI-MedLine.d96.s7|34-36|and|O
DDI-MedLine.d96.s7|38-43|should|O
DDI-MedLine.d96.s7|45-46|be|O
DDI-MedLine.d96.s7|48-48|a|O
DDI-MedLine.d96.s7|50-55|useful|O
DDI-MedLine.d96.s7|57-60|tool|O
DDI-MedLine.d96.s7|62-64|for|O
DDI-MedLine.d96.s7|66-73|studying|O
DDI-MedLine.d96.s7|75-76|of|O
DDI-MedLine.d96.s7|78-82|serum|O
DDI-MedLine.d96.s7|84-86|and|O
DDI-MedLine.d96.s7|88-96|secretory|O
DDI-MedLine.d96.s7|98-100|IgA|O
DDI-MedLine.d96.s7|101-101|.|O
DDI-MedLine.d95.s0|0-2|The|O
DDI-MedLine.d95.s0|4-12|mechanism|O
DDI-MedLine.d95.s0|14-15|of|O
DDI-MedLine.d95.s0|37-50|vasorelaxation|O
DDI-MedLine.d95.s0|52-58|differs|O
DDI-MedLine.d95.s0|60-61|in|O
DDI-MedLine.d95.s0|63-65|the|O
DDI-MedLine.d95.s0|67-76|mesenteric|O
DDI-MedLine.d95.s0|78-87|resistance|O
DDI-MedLine.d95.s0|89-96|arteries|O
DDI-MedLine.d95.s0|98-99|of|O
DDI-MedLine.d95.s0|101-104|lean|O
DDI-MedLine.d95.s0|106-108|and|O
DDI-MedLine.d95.s0|110-114|obese|O
DDI-MedLine.d95.s0|116-119|rats|O
DDI-MedLine.d95.s0|120-120|.|O
DDI-MedLine.d95.s1|12-14|has|O
DDI-MedLine.d95.s1|16-19|been|O
DDI-MedLine.d95.s1|21-25|shown|O
DDI-MedLine.d95.s1|27-28|to|O
DDI-MedLine.d95.s1|30-35|induce|O
DDI-MedLine.d95.s1|37-50|vasorelaxation|O
DDI-MedLine.d95.s1|51-51|.|O
DDI-MedLine.d95.s2|0-1|In|O
DDI-MedLine.d95.s2|3-6|this|O
DDI-MedLine.d95.s2|8-12|study|O
DDI-MedLine.d95.s2|13-13|,|O
DDI-MedLine.d95.s2|15-16|we|O
DDI-MedLine.d95.s2|18-29|investigated|O
DDI-MedLine.d95.s2|31-33|the|O
DDI-MedLine.d95.s2|35-43|mechanism|O
DDI-MedLine.d95.s2|44-44|(|O
DDI-MedLine.d95.s2|45-45|s|O
DDI-MedLine.d95.s2|46-46|)|O
DDI-MedLine.d95.s2|48-49|of|O
DDI-MedLine.d95.s2|71-84|vasorelaxation|O
DDI-MedLine.d95.s2|86-87|in|O
DDI-MedLine.d95.s2|89-98|resistance|O
DDI-MedLine.d95.s2|100-109|mesenteric|O
DDI-MedLine.d95.s2|111-118|arteries|O
DDI-MedLine.d95.s2|120-123|from|O
DDI-MedLine.d95.s2|125-128|male|O
DDI-MedLine.d95.s2|130-133|lean|O
DDI-MedLine.d95.s2|135-137|and|O
DDI-MedLine.d95.s2|139-153|dietary-induced|O
DDI-MedLine.d95.s2|155-159|obese|O
DDI-MedLine.d95.s2|161-164|rats|O
DDI-MedLine.d95.s2|165-165|.|O
DDI-MedLine.d95.s3|0-7|Compared|O
DDI-MedLine.d95.s3|9-12|with|O
DDI-MedLine.d95.s3|14-17|lean|O
DDI-MedLine.d95.s3|19-22|rats|O
DDI-MedLine.d95.s3|23-23|,|O
DDI-MedLine.d95.s3|25-32|arteries|O
DDI-MedLine.d95.s3|34-37|from|O
DDI-MedLine.d95.s3|39-51|dietary-obese|O
DDI-MedLine.d95.s3|53-56|rats|O
DDI-MedLine.d95.s3|58-63|showed|O
DDI-MedLine.d95.s3|65-75|significant|O
DDI-MedLine.d95.s3|77-77|(|O
DDI-MedLine.d95.s3|78-78|P|O
DDI-MedLine.d95.s3|79-79|<|O
DDI-MedLine.d95.s3|80-84|0.001|O
DDI-MedLine.d95.s3|85-85|)|O
DDI-MedLine.d95.s3|87-97|endothelial|O
DDI-MedLine.d95.s3|99-109|dysfunction|O
DDI-MedLine.d95.s3|110-110|,|O
DDI-MedLine.d95.s3|112-113|as|O
DDI-MedLine.d95.s3|115-123|indicated|O
DDI-MedLine.d95.s3|125-126|by|O
DDI-MedLine.d95.s3|128-128|a|O
DDI-MedLine.d95.s3|130-137|decrease|O
DDI-MedLine.d95.s3|139-139|(|O
DDI-MedLine.d95.s3|140-140|>|O
DDI-MedLine.d95.s3|141-142|20|O
DDI-MedLine.d95.s3|143-143|%|O
DDI-MedLine.d95.s3|144-144|)|O
DDI-MedLine.d95.s3|146-147|in|O
DDI-MedLine.d95.s3|149-155|maximal|O
DDI-MedLine.d95.s3|157-177|acetylcholine-induced|O
DDI-MedLine.d95.s3|179-192|vasorelaxation|O
DDI-MedLine.d95.s3|193-193|.|O
DDI-MedLine.d95.s4|12-12|(|O
DDI-MedLine.d95.s4|13-16|5-35|O
DDI-MedLine.d95.s4|18-27|micromol/l|O
DDI-MedLine.d95.s4|28-28|)|O
DDI-MedLine.d95.s4|30-36|induced|O
DDI-MedLine.d95.s4|38-60|concentration-dependent|O
DDI-MedLine.d95.s4|62-71|relaxation|O
DDI-MedLine.d95.s4|73-74|of|O
DDI-MedLine.d95.s4|76-85|mesenteric|O
DDI-MedLine.d95.s4|87-94|arteries|O
DDI-MedLine.d95.s4|96-109|preconstricted|O
DDI-MedLine.d95.s4|111-114|with|O
DDI-MedLine.d95.s4|116-128|noradrenaline|drug
DDI-MedLine.d95.s4|130-130|(|O
DDI-MedLine.d95.s4|131-131|8|O
DDI-MedLine.d95.s4|133-142|micromol/l|O
DDI-MedLine.d95.s4|143-143|)|O
DDI-MedLine.d95.s4|145-146|or|O
DDI-MedLine.d95.s4|148-150|KCl|drug
DDI-MedLine.d95.s4|152-152|(|O
DDI-MedLine.d95.s4|153-155|125|O
DDI-MedLine.d95.s4|157-162|mmol/l|O
DDI-MedLine.d95.s4|163-163|)|O
DDI-MedLine.d95.s4|165-168|from|O
DDI-MedLine.d95.s4|170-173|both|O
DDI-MedLine.d95.s4|175-178|lean|O
DDI-MedLine.d95.s4|180-182|and|O
DDI-MedLine.d95.s4|184-196|dietary-obese|O
DDI-MedLine.d95.s4|198-201|rats|O
DDI-MedLine.d95.s4|202-202|.|O
DDI-MedLine.d95.s5|0-4|There|O
DDI-MedLine.d95.s5|6-9|were|O
DDI-MedLine.d95.s5|11-12|no|O
DDI-MedLine.d95.s5|14-24|significant|O
DDI-MedLine.d95.s5|26-36|differences|O
DDI-MedLine.d95.s5|38-44|between|O
DDI-MedLine.d95.s5|46-48|the|O
DDI-MedLine.d95.s5|50-52|two|O
DDI-MedLine.d95.s5|54-59|groups|O
DDI-MedLine.d95.s5|60-60|,|O
DDI-MedLine.d95.s5|62-70|achieving|O
DDI-MedLine.d95.s5|72-72|a|O
DDI-MedLine.d95.s5|74-80|maximum|O
DDI-MedLine.d95.s5|82-91|relaxation|O
DDI-MedLine.d95.s5|93-94|of|O
DDI-MedLine.d95.s5|96-96|>|O
DDI-MedLine.d95.s5|97-98|95|O
DDI-MedLine.d95.s5|99-99|%|O
DDI-MedLine.d95.s5|101-102|at|O
DDI-MedLine.d95.s5|104-104|a|O
DDI-MedLine.d95.s5|106-118|concentration|O
DDI-MedLine.d95.s5|120-121|of|O
DDI-MedLine.d95.s5|123-124|35|O
DDI-MedLine.d95.s5|126-135|micromol/l|O
DDI-MedLine.d95.s5|136-136|.|O
DDI-MedLine.d95.s6|0-6|However|O
DDI-MedLine.d95.s6|7-7|,|O
DDI-MedLine.d95.s6|16-16|(|O
DDI-MedLine.d95.s6|17-19|100|O
DDI-MedLine.d95.s6|21-23|and|O
DDI-MedLine.d95.s6|25-27|300|O
DDI-MedLine.d95.s6|29-38|micromol/l|O
DDI-MedLine.d95.s6|39-39|)|O
DDI-MedLine.d95.s6|41-43|did|O
DDI-MedLine.d95.s6|45-47|not|O
DDI-MedLine.d95.s6|49-53|alter|O
DDI-MedLine.d95.s6|55-57|the|O
DDI-MedLine.d95.s6|59-65|effects|O
DDI-MedLine.d95.s6|67-68|of|O
DDI-MedLine.d95.s6|83-84|on|O
DDI-MedLine.d95.s6|86-93|arteries|O
DDI-MedLine.d95.s6|95-98|from|O
DDI-MedLine.d95.s6|100-112|dietary-obese|O
DDI-MedLine.d95.s6|114-117|rats|O
DDI-MedLine.d95.s6|118-118|,|O
DDI-MedLine.d95.s6|120-125|giving|O
DDI-MedLine.d95.s6|127-138|superimposed|O
DDI-MedLine.d95.s6|140-162|concentration-responses|O
DDI-MedLine.d95.s6|164-169|curves|O
DDI-MedLine.d95.s6|170-170|.|O
DDI-MedLine.d95.s7|0-11|Indomethacin|drug
DDI-MedLine.d95.s7|13-15|was|O
DDI-MedLine.d95.s7|17-20|also|O
DDI-MedLine.d95.s7|22-32|ineffective|O
DDI-MedLine.d95.s7|34-35|in|O
DDI-MedLine.d95.s7|37-44|altering|O
DDI-MedLine.d95.s7|58-65|activity|O
DDI-MedLine.d95.s7|67-68|in|O
DDI-MedLine.d95.s7|70-77|arteries|O
DDI-MedLine.d95.s7|79-82|from|O
DDI-MedLine.d95.s7|84-87|both|O
DDI-MedLine.d95.s7|89-92|lean|O
DDI-MedLine.d95.s7|94-96|and|O
DDI-MedLine.d95.s7|98-110|dietary-obese|O
DDI-MedLine.d95.s7|112-115|rats|O
DDI-MedLine.d95.s7|116-116|.|O
DDI-MedLine.d95.s8|0-1|In|O
DDI-MedLine.d95.s8|3-29|noradrenaline-precontracted|drug
DDI-MedLine.d95.s8|31-38|arteries|O
DDI-MedLine.d95.s8|40-43|from|O
DDI-MedLine.d95.s8|45-57|dietary-obese|O
DDI-MedLine.d95.s8|59-62|rats|O
DDI-MedLine.d95.s8|63-63|,|O
DDI-MedLine.d95.s8|65-73|responses|O
DDI-MedLine.d95.s8|75-76|to|O
DDI-MedLine.d95.s8|90-93|were|O
DDI-MedLine.d95.s8|95-97|not|O
DDI-MedLine.d95.s8|99-108|attenuated|O
DDI-MedLine.d95.s8|110-111|by|O
DDI-MedLine.d95.s8|113-123|endothelial|O
DDI-MedLine.d95.s8|125-134|denudation|O
DDI-MedLine.d95.s8|135-135|,|O
DDI-MedLine.d95.s8|137-146|indicating|O
DDI-MedLine.d95.s8|148-149|an|O
DDI-MedLine.d95.s8|151-156|action|O
DDI-MedLine.d95.s8|158-168|independent|O
DDI-MedLine.d95.s8|170-171|of|O
DDI-MedLine.d95.s8|173-175|the|O
DDI-MedLine.d95.s8|177-187|endothelium|O
DDI-MedLine.d95.s8|188-188|.|O
DDI-MedLine.d95.s9|0-3|This|O
DDI-MedLine.d95.s9|5-9|study|O
DDI-MedLine.d95.s9|11-19|indicates|O
DDI-MedLine.d95.s9|21-24|that|O
DDI-MedLine.d95.s9|25-25|:|O
DDI-MedLine.d95.s9|27-27|(|O
DDI-MedLine.d95.s9|28-28|a|O
DDI-MedLine.d95.s9|29-29|)|O
DDI-MedLine.d95.s9|31-33|the|O
DDI-MedLine.d95.s9|35-41|maximal|O
DDI-MedLine.d95.s9|43-49|effects|O
DDI-MedLine.d95.s9|51-52|of|O
DDI-MedLine.d95.s9|66-67|on|O
DDI-MedLine.d95.s9|69-78|resistance|O
DDI-MedLine.d95.s9|80-87|arteries|O
DDI-MedLine.d95.s9|89-92|from|O
DDI-MedLine.d95.s9|94-97|lean|O
DDI-MedLine.d95.s9|99-101|and|O
DDI-MedLine.d95.s9|103-115|dietary-obese|O
DDI-MedLine.d95.s9|117-120|rats|O
DDI-MedLine.d95.s9|122-124|are|O
DDI-MedLine.d95.s9|126-128|not|O
DDI-MedLine.d95.s9|130-137|effected|O
DDI-MedLine.d95.s9|139-140|by|O
DDI-MedLine.d95.s9|142-152|endothelial|O
DDI-MedLine.d95.s9|154-164|dysfunction|O
DDI-MedLine.d95.s9|165-165|,|O
DDI-MedLine.d95.s9|167-169|and|O
DDI-MedLine.d95.s9|171-171|(|O
DDI-MedLine.d95.s9|172-172|b|O
DDI-MedLine.d95.s9|173-173|)|O
DDI-MedLine.d95.s9|175-177|the|O
DDI-MedLine.d95.s9|179-185|effects|O
DDI-MedLine.d95.s9|187-188|of|O
DDI-MedLine.d95.s9|202-203|in|O
DDI-MedLine.d95.s9|205-208|lean|O
DDI-MedLine.d95.s9|210-216|animals|O
DDI-MedLine.d95.s9|218-218|(|O
DDI-MedLine.d95.s9|219-223|where|O
DDI-MedLine.d95.s9|225-235|endothelial|O
DDI-MedLine.d95.s9|237-244|function|O
DDI-MedLine.d95.s9|246-247|is|O
DDI-MedLine.d95.s9|249-251|not|O
DDI-MedLine.d95.s9|253-260|impaired|O
DDI-MedLine.d95.s9|261-261|)|O
DDI-MedLine.d95.s9|262-262|,|O
DDI-MedLine.d95.s9|264-266|but|O
DDI-MedLine.d95.s9|268-270|not|O
DDI-MedLine.d95.s9|272-273|in|O
DDI-MedLine.d95.s9|275-287|dietary-obese|O
DDI-MedLine.d95.s9|289-292|rats|O
DDI-MedLine.d95.s9|293-293|,|O
DDI-MedLine.d95.s9|295-297|are|O
DDI-MedLine.d95.s9|299-306|mediated|O
DDI-MedLine.d95.s9|308-310|via|O
DDI-MedLine.d95.s9|312-313|NO|O
DDI-MedLine.d95.s9|314-314|.|O
DDI-DrugBank.d307.s0|0-12|Oxcarbazepine|drug
DDI-DrugBank.d307.s0|14-16|can|O
DDI-DrugBank.d307.s0|18-24|inhibit|O
DDI-DrugBank.d307.s0|26-32|CYP2C19|O
DDI-DrugBank.d307.s0|34-36|and|O
DDI-DrugBank.d307.s0|38-43|induce|O
DDI-DrugBank.d307.s0|45-52|CYP3A4/5|O
DDI-DrugBank.d307.s0|54-57|with|O
DDI-DrugBank.d307.s0|59-69|potentially|O
DDI-DrugBank.d307.s0|71-79|important|O
DDI-DrugBank.d307.s0|81-87|effects|O
DDI-DrugBank.d307.s0|89-90|on|O
DDI-DrugBank.d307.s0|92-97|plasma|O
DDI-DrugBank.d307.s0|99-112|concentrations|O
DDI-DrugBank.d307.s0|114-115|of|O
DDI-DrugBank.d307.s0|117-121|other|O
DDI-DrugBank.d307.s0|123-127|drugs|O
DDI-DrugBank.d307.s0|128-128|.|O
DDI-DrugBank.d307.s1|0-1|In|O
DDI-DrugBank.d307.s1|3-10|addition|O
DDI-DrugBank.d307.s1|11-11|,|O
DDI-DrugBank.d307.s1|13-19|several|O
DDI-DrugBank.d307.s1|21-23|AED|group
DDI-DrugBank.d307.s1|25-25|s|O
DDI-DrugBank.d307.s1|27-30|that|O
DDI-DrugBank.d307.s1|32-34|are|O
DDI-DrugBank.d307.s1|36-45|cytochrome|O
DDI-DrugBank.d307.s1|47-50|P450|O
DDI-DrugBank.d307.s1|52-59|inducers|O
DDI-DrugBank.d307.s1|61-63|can|O
DDI-DrugBank.d307.s1|65-72|decrease|O
DDI-DrugBank.d307.s1|74-79|plasma|O
DDI-DrugBank.d307.s1|81-94|concentrations|O
DDI-DrugBank.d307.s1|96-97|of|O
DDI-DrugBank.d307.s1|99-111|oxcarbazepine|drug
DDI-DrugBank.d307.s1|113-115|and|O
DDI-DrugBank.d307.s1|120-120|.|O
DDI-DrugBank.d307.s2|0-12|Oxcarbazepine|drug
DDI-DrugBank.d307.s2|14-16|was|O
DDI-DrugBank.d307.s2|18-26|evaluated|O
DDI-DrugBank.d307.s2|28-29|in|O
DDI-DrugBank.d307.s2|31-35|human|O
DDI-DrugBank.d307.s2|37-41|liver|O
DDI-DrugBank.d307.s2|43-52|microsomes|O
DDI-DrugBank.d307.s2|54-55|to|O
DDI-DrugBank.d307.s2|57-65|determine|O
DDI-DrugBank.d307.s2|67-69|its|O
DDI-DrugBank.d307.s2|71-78|capacity|O
DDI-DrugBank.d307.s2|80-81|to|O
DDI-DrugBank.d307.s2|83-89|inhibit|O
DDI-DrugBank.d307.s2|91-93|the|O
DDI-DrugBank.d307.s2|95-99|major|O
DDI-DrugBank.d307.s2|101-110|cytochrome|O
DDI-DrugBank.d307.s2|112-115|P450|O
DDI-DrugBank.d307.s2|117-123|enzymes|O
DDI-DrugBank.d307.s2|125-135|responsible|O
DDI-DrugBank.d307.s2|137-139|for|O
DDI-DrugBank.d307.s2|141-143|the|O
DDI-DrugBank.d307.s2|145-154|metabolism|O
DDI-DrugBank.d307.s2|156-157|of|O
DDI-DrugBank.d307.s2|159-163|other|O
DDI-DrugBank.d307.s2|165-169|drugs|O
DDI-DrugBank.d307.s2|170-170|.|O
DDI-DrugBank.d307.s3|0-6|Results|O
DDI-DrugBank.d307.s3|8-18|demonstrate|O
DDI-DrugBank.d307.s3|20-23|that|O
DDI-DrugBank.d307.s3|25-37|oxcarbazepine|drug
DDI-DrugBank.d307.s3|39-41|and|O
DDI-DrugBank.d307.s3|43-45|its|O
DDI-DrugBank.d307.s3|47-63|pharmacologically|O
DDI-DrugBank.d307.s3|65-70|active|O
DDI-DrugBank.d307.s3|72-85|10-monohydroxy|O
DDI-DrugBank.d307.s3|87-96|metabolite|O
DDI-DrugBank.d307.s3|98-98|(|O
DDI-DrugBank.d307.s3|102-102|)|O
DDI-DrugBank.d307.s3|104-107|have|O
DDI-DrugBank.d307.s3|109-114|little|O
DDI-DrugBank.d307.s3|116-117|or|O
DDI-DrugBank.d307.s3|119-120|no|O
DDI-DrugBank.d307.s3|122-129|capacity|O
DDI-DrugBank.d307.s3|131-132|to|O
DDI-DrugBank.d307.s3|134-141|function|O
DDI-DrugBank.d307.s3|143-144|as|O
DDI-DrugBank.d307.s3|146-155|inhibitors|O
DDI-DrugBank.d307.s3|157-159|for|O
DDI-DrugBank.d307.s3|161-164|most|O
DDI-DrugBank.d307.s3|166-167|of|O
DDI-DrugBank.d307.s3|169-171|the|O
DDI-DrugBank.d307.s3|173-177|human|O
DDI-DrugBank.d307.s3|179-188|cytochrome|O
DDI-DrugBank.d307.s3|190-193|P450|O
DDI-DrugBank.d307.s3|195-201|enzymes|O
DDI-DrugBank.d307.s3|203-211|evaluated|O
DDI-DrugBank.d307.s3|213-213|(|O
DDI-DrugBank.d307.s3|214-219|CYP1A2|O
DDI-DrugBank.d307.s3|220-220|,|O
DDI-DrugBank.d307.s3|222-227|CYP2A6|O
DDI-DrugBank.d307.s3|228-228|,|O
DDI-DrugBank.d307.s3|230-235|CYP2C9|O
DDI-DrugBank.d307.s3|236-236|,|O
DDI-DrugBank.d307.s3|238-243|CYP2D6|O
DDI-DrugBank.d307.s3|244-244|,|O
DDI-DrugBank.d307.s3|246-251|CYP2E1|O
DDI-DrugBank.d307.s3|252-252|,|O
DDI-DrugBank.d307.s3|254-259|CYP4A9|O
DDI-DrugBank.d307.s3|261-263|and|O
DDI-DrugBank.d307.s3|265-271|CYP4A11|O
DDI-DrugBank.d307.s3|272-272|)|O
DDI-DrugBank.d307.s3|274-277|with|O
DDI-DrugBank.d307.s3|279-281|the|O
DDI-DrugBank.d307.s3|283-291|exception|O
DDI-DrugBank.d307.s3|293-294|of|O
DDI-DrugBank.d307.s3|296-302|CYP2C19|O
DDI-DrugBank.d307.s3|304-306|and|O
DDI-DrugBank.d307.s3|308-315|CYP3A4/5|O
DDI-DrugBank.d307.s3|316-316|.|O
DDI-DrugBank.d307.s4|0-7|Although|O
DDI-DrugBank.d307.s4|9-18|inhibition|O
DDI-DrugBank.d307.s4|20-21|of|O
DDI-DrugBank.d307.s4|23-25|CYP|O
DDI-DrugBank.d307.s4|27-31|3A4/5|O
DDI-DrugBank.d307.s4|33-34|by|O
DDI-DrugBank.d307.s4|36-38|OXC|drug
DDI-DrugBank.d307.s4|40-42|and|O
DDI-DrugBank.d307.s4|48-50|did|O
DDI-DrugBank.d307.s4|52-56|occur|O
DDI-DrugBank.d307.s4|58-59|at|O
DDI-DrugBank.d307.s4|61-64|high|O
DDI-DrugBank.d307.s4|66-79|concentrations|O
DDI-DrugBank.d307.s4|80-80|,|O
DDI-DrugBank.d307.s4|82-83|it|O
DDI-DrugBank.d307.s4|85-86|is|O
DDI-DrugBank.d307.s4|88-90|not|O
DDI-DrugBank.d307.s4|92-97|likely|O
DDI-DrugBank.d307.s4|99-100|to|O
DDI-DrugBank.d307.s4|102-103|be|O
DDI-DrugBank.d307.s4|105-106|of|O
DDI-DrugBank.d307.s4|108-115|clinical|O
DDI-DrugBank.d307.s4|117-128|significance|O
DDI-DrugBank.d307.s4|129-129|.|O
DDI-DrugBank.d307.s5|0-2|The|O
DDI-DrugBank.d307.s5|4-13|inhibition|O
DDI-DrugBank.d307.s5|15-16|of|O
DDI-DrugBank.d307.s5|18-25|CYP-2C19|O
DDI-DrugBank.d307.s5|27-28|by|O
DDI-DrugBank.d307.s5|30-32|OXC|drug
DDI-DrugBank.d307.s5|34-36|and|O
DDI-DrugBank.d307.s5|41-41|,|O
DDI-DrugBank.d307.s5|43-49|however|O
DDI-DrugBank.d307.s5|50-50|,|O
DDI-DrugBank.d307.s5|52-53|is|O
DDI-DrugBank.d307.s5|55-64|clinically|O
DDI-DrugBank.d307.s5|66-73|relevant|O
DDI-DrugBank.d307.s5|74-74|.|O
DDI-DrugBank.d307.s6|0-1|In|O
DDI-DrugBank.d307.s6|3-7|vitro|O
DDI-DrugBank.d307.s6|8-8|,|O
DDI-DrugBank.d307.s6|10-12|the|O
DDI-DrugBank.d307.s6|14-27|UDP-glucuronyl|O
DDI-DrugBank.d307.s6|29-39|transferase|O
DDI-DrugBank.d307.s6|41-45|level|O
DDI-DrugBank.d307.s6|47-49|was|O
DDI-DrugBank.d307.s6|51-59|increased|O
DDI-DrugBank.d307.s6|60-60|,|O
DDI-DrugBank.d307.s6|62-71|indicating|O
DDI-DrugBank.d307.s6|73-81|induction|O
DDI-DrugBank.d307.s6|83-84|of|O
DDI-DrugBank.d307.s6|86-89|this|O
DDI-DrugBank.d307.s6|91-96|enzyme|O
DDI-DrugBank.d307.s6|97-97|.|O
DDI-DrugBank.d307.s7|0-8|Increases|O
DDI-DrugBank.d307.s7|10-11|of|O
DDI-DrugBank.d307.s7|13-14|22|O
DDI-DrugBank.d307.s7|15-15|%|O
DDI-DrugBank.d307.s7|17-20|with|O
DDI-DrugBank.d307.s7|26-28|and|O
DDI-DrugBank.d307.s7|30-31|47|O
DDI-DrugBank.d307.s7|32-32|%|O
DDI-DrugBank.d307.s7|34-37|with|O
DDI-DrugBank.d307.s7|39-51|oxcarbazepine|drug
DDI-DrugBank.d307.s7|53-56|were|O
DDI-DrugBank.d307.s7|58-65|observed|O
DDI-DrugBank.d307.s7|66-66|.|O
DDI-DrugBank.d307.s8|0-1|As|O
DDI-DrugBank.d307.s8|6-6|,|O
DDI-DrugBank.d307.s8|8-10|the|O
DDI-DrugBank.d307.s8|12-22|predominant|O
DDI-DrugBank.d307.s8|24-29|plasma|O
DDI-DrugBank.d307.s8|31-39|substrate|O
DDI-DrugBank.d307.s8|40-40|,|O
DDI-DrugBank.d307.s8|42-43|is|O
DDI-DrugBank.d307.s8|45-48|only|O
DDI-DrugBank.d307.s8|50-50|a|O
DDI-DrugBank.d307.s8|52-55|weak|O
DDI-DrugBank.d307.s8|57-63|inducer|O
DDI-DrugBank.d307.s8|65-66|of|O
DDI-DrugBank.d307.s8|68-81|UDP-glucuronyl|O
DDI-DrugBank.d307.s8|83-93|transferase|O
DDI-DrugBank.d307.s8|94-94|,|O
DDI-DrugBank.d307.s8|96-97|it|O
DDI-DrugBank.d307.s8|99-100|is|O
DDI-DrugBank.d307.s8|102-109|unlikely|O
DDI-DrugBank.d307.s8|111-112|to|O
DDI-DrugBank.d307.s8|114-117|have|O
DDI-DrugBank.d307.s8|119-120|an|O
DDI-DrugBank.d307.s8|122-127|effect|O
DDI-DrugBank.d307.s8|129-130|on|O
DDI-DrugBank.d307.s8|132-136|drugs|O
DDI-DrugBank.d307.s8|138-141|that|O
DDI-DrugBank.d307.s8|143-145|are|O
DDI-DrugBank.d307.s8|147-152|mainly|O
DDI-DrugBank.d307.s8|154-163|eliminated|O
DDI-DrugBank.d307.s8|165-166|by|O
DDI-DrugBank.d307.s8|168-178|conjugation|O
DDI-DrugBank.d307.s8|180-186|through|O
DDI-DrugBank.d307.s8|188-201|UDP-glucuronyl|O
DDI-DrugBank.d307.s8|203-213|transferase|O
DDI-DrugBank.d307.s8|215-215|(|O
DDI-DrugBank.d307.s8|216-219|e.g.|O
DDI-DrugBank.d307.s8|220-220|,|O
DDI-DrugBank.d307.s8|222-234|valproic acid|drug
DDI-DrugBank.d307.s8|235-235|,|O
DDI-DrugBank.d307.s8|237-247|lamotrigine|drug
DDI-DrugBank.d307.s8|248-248|)|O
DDI-DrugBank.d307.s8|249-249|.|O
DDI-DrugBank.d307.s9|0-1|In|O
DDI-DrugBank.d307.s9|3-10|addition|O
DDI-DrugBank.d307.s9|11-11|,|O
DDI-DrugBank.d307.s9|13-25|oxcarbazepine|drug
DDI-DrugBank.d307.s9|27-29|and|O
DDI-DrugBank.d307.s9|35-40|induce|O
DDI-DrugBank.d307.s9|42-42|a|O
DDI-DrugBank.d307.s9|44-51|subgroup|O
DDI-DrugBank.d307.s9|53-54|of|O
DDI-DrugBank.d307.s9|56-58|the|O
DDI-DrugBank.d307.s9|60-69|cytochrome|O
DDI-DrugBank.d307.s9|71-74|P450|O
DDI-DrugBank.d307.s9|76-77|3A|O
DDI-DrugBank.d307.s9|79-84|family|O
DDI-DrugBank.d307.s9|86-86|(|O
DDI-DrugBank.d307.s9|87-92|CYP3A4|O
DDI-DrugBank.d307.s9|94-96|and|O
DDI-DrugBank.d307.s9|98-103|CYP3A5|O
DDI-DrugBank.d307.s9|104-104|)|O
DDI-DrugBank.d307.s9|106-116|responsible|O
DDI-DrugBank.d307.s9|118-120|for|O
DDI-DrugBank.d307.s9|122-124|the|O
DDI-DrugBank.d307.s9|126-135|metabolism|O
DDI-DrugBank.d307.s9|137-138|of|O
DDI-DrugBank.d307.s9|140-174|dihydropyridine calcium antagonists|group
DDI-DrugBank.d307.s9|176-178|and|O
DDI-DrugBank.d307.s9|180-183|oral|O
DDI-DrugBank.d307.s9|185-198|contraceptives|group
DDI-DrugBank.d307.s9|199-199|,|O
DDI-DrugBank.d307.s9|201-209|resulting|O
DDI-DrugBank.d307.s9|211-212|in|O
DDI-DrugBank.d307.s9|214-214|a|O
DDI-DrugBank.d307.s9|216-220|lower|O
DDI-DrugBank.d307.s9|222-227|plasma|O
DDI-DrugBank.d307.s9|229-241|concentration|O
DDI-DrugBank.d307.s9|243-244|of|O
DDI-DrugBank.d307.s9|246-250|these|O
DDI-DrugBank.d307.s9|252-256|drugs|O
DDI-DrugBank.d307.s9|257-257|.|O
DDI-DrugBank.d307.s10|0-1|As|O
DDI-DrugBank.d307.s10|3-9|binding|O
DDI-DrugBank.d307.s10|11-12|of|O
DDI-DrugBank.d307.s10|18-19|to|O
DDI-DrugBank.d307.s10|21-26|plasma|O
DDI-DrugBank.d307.s10|28-35|proteins|O
DDI-DrugBank.d307.s10|37-38|is|O
DDI-DrugBank.d307.s10|40-42|low|O
DDI-DrugBank.d307.s10|44-44|(|O
DDI-DrugBank.d307.s10|45-46|40|O
DDI-DrugBank.d307.s10|47-47|%|O
DDI-DrugBank.d307.s10|48-48|)|O
DDI-DrugBank.d307.s10|49-49|,|O
DDI-DrugBank.d307.s10|51-60|clinically|O
DDI-DrugBank.d307.s10|62-72|significant|O
DDI-DrugBank.d307.s10|74-85|interactions|O
DDI-DrugBank.d307.s10|87-90|with|O
DDI-DrugBank.d307.s10|92-96|other|O
DDI-DrugBank.d307.s10|98-102|drugs|O
DDI-DrugBank.d307.s10|104-110|through|O
DDI-DrugBank.d307.s10|112-122|competition|O
DDI-DrugBank.d307.s10|124-126|for|O
DDI-DrugBank.d307.s10|128-134|protein|O
DDI-DrugBank.d307.s10|136-142|binding|O
DDI-DrugBank.d307.s10|144-148|sites|O
DDI-DrugBank.d307.s10|150-152|are|O
DDI-DrugBank.d307.s10|154-161|unlikely|O
DDI-DrugBank.d307.s10|162-162|.|O
DDI-DrugBank.d307.s11|0-18|Antiepileptic drugs|group
DDI-DrugBank.d307.s11|19-19|:|O
DDI-DrugBank.d307.s11|21-29|Potential|O
DDI-DrugBank.d307.s11|31-42|interactions|O
DDI-DrugBank.d307.s11|44-50|between|O
DDI-DrugBank.d307.s11|52-60|Trileptal|brand
DDI-DrugBank.d307.s11|62-64|and|O
DDI-DrugBank.d307.s11|66-70|other|O
DDI-DrugBank.d307.s11|72-75|AEDs|group
DDI-DrugBank.d307.s11|77-80|were|O
DDI-DrugBank.d307.s11|82-89|assessed|O
DDI-DrugBank.d307.s11|91-92|in|O
DDI-DrugBank.d307.s11|94-101|clinical|O
DDI-DrugBank.d307.s11|103-109|studies|O
DDI-DrugBank.d307.s11|110-110|.|O
DDI-DrugBank.d307.s12|0-2|The|O
DDI-DrugBank.d307.s12|4-9|effect|O
DDI-DrugBank.d307.s12|11-12|of|O
DDI-DrugBank.d307.s12|14-18|these|O
DDI-DrugBank.d307.s12|20-31|interactions|O
DDI-DrugBank.d307.s12|33-34|on|O
DDI-DrugBank.d307.s12|36-39|mean|O
DDI-DrugBank.d307.s12|41-44|AUCs|O
DDI-DrugBank.d307.s12|46-48|and|O
DDI-DrugBank.d307.s12|50-53|Cmin|O
DDI-DrugBank.d307.s12|55-57|are|O
DDI-DrugBank.d307.s12|59-68|summarized|O
DDI-DrugBank.d307.s12|70-71|in|O
DDI-DrugBank.d307.s12|73-77|Table|O
DDI-DrugBank.d307.s12|79-79|2|O
DDI-DrugBank.d307.s12|80-80|:|O
DDI-DrugBank.d307.s12|82-86|Table|O
DDI-DrugBank.d307.s12|88-88|2|O
DDI-DrugBank.d307.s12|89-89|:|O
DDI-DrugBank.d307.s12|91-97|Summary|O
DDI-DrugBank.d307.s12|99-100|of|O
DDI-DrugBank.d307.s12|102-104|AED|O
DDI-DrugBank.d307.s12|106-117|interactions|O
DDI-DrugBank.d307.s12|119-122|with|O
DDI-DrugBank.d307.s13|0-2|AED|group
DDI-DrugBank.d307.s13|4-18|Co-administered|O
DDI-DrugBank.d307.s14|0-3|Dose|O
DDI-DrugBank.d307.s14|5-6|of|O
DDI-DrugBank.d307.s14|8-10|AED|group
DDI-DrugBank.d307.s14|12-12|(|O
DDI-DrugBank.d307.s14|13-18|mg/day|O
DDI-DrugBank.d307.s14|19-19|)|O
DDI-DrugBank.d307.s15|0-8|Trileptal|brand
DDI-DrugBank.d307.s15|10-13|dose|O
DDI-DrugBank.d307.s15|15-15|(|O
DDI-DrugBank.d307.s15|16-21|mg/day|O
DDI-DrugBank.d307.s15|22-22|)|O
DDI-DrugBank.d307.s16|0-8|Influence|O
DDI-DrugBank.d307.s16|10-11|of|O
DDI-DrugBank.d307.s16|13-21|Trileptal|brand
DDI-DrugBank.d307.s16|23-24|on|O
DDI-DrugBank.d307.s16|26-28|AED|group
DDI-DrugBank.d307.s16|30-42|Concentration|O
DDI-DrugBank.d307.s16|44-44|(|O
DDI-DrugBank.d307.s16|45-48|Mean|O
DDI-DrugBank.d307.s16|50-55|change|O
DDI-DrugBank.d307.s16|56-56|,|O
DDI-DrugBank.d307.s16|58-59|90|O
DDI-DrugBank.d307.s16|60-60|%|O
DDI-DrugBank.d307.s16|62-71|Confidence|O
DDI-DrugBank.d307.s16|73-80|Interval|O
DDI-DrugBank.d307.s16|81-81|)|O
DDI-DrugBank.d307.s17|0-8|Influence|O
DDI-DrugBank.d307.s17|10-11|of|O
DDI-DrugBank.d307.s17|13-15|AED|group
DDI-DrugBank.d307.s17|17-18|On|O
DDI-DrugBank.d307.s17|24-36|Concentration|O
DDI-DrugBank.d307.s17|38-38|(|O
DDI-DrugBank.d307.s17|39-42|Mean|O
DDI-DrugBank.d307.s17|44-49|change|O
DDI-DrugBank.d307.s17|50-50|,|O
DDI-DrugBank.d307.s17|52-53|90|O
DDI-DrugBank.d307.s17|54-54|%|O
DDI-DrugBank.d307.s17|56-65|Confidence|O
DDI-DrugBank.d307.s17|67-74|Interval|O
DDI-DrugBank.d307.s17|75-75|)|O
DDI-DrugBank.d307.s19|0-7|400-2000|O
DDI-DrugBank.d307.s20|0-2|900|O
DDI-DrugBank.d307.s21|0-2|nc1|O
DDI-DrugBank.d307.s21|4-5|40|O
DDI-DrugBank.d307.s21|6-6|%|O
DDI-DrugBank.d307.s21|8-15|decrease|O
DDI-DrugBank.d307.s21|17-17|[|O
DDI-DrugBank.d307.s21|18-19|CI|O
DDI-DrugBank.d307.s21|20-20|:|O
DDI-DrugBank.d307.s21|22-23|17|O
DDI-DrugBank.d307.s21|24-24|%|O
DDI-DrugBank.d307.s21|26-33|decrease|O
DDI-DrugBank.d307.s21|34-34|,|O
DDI-DrugBank.d307.s21|36-37|57|O
DDI-DrugBank.d307.s21|38-38|%|O
DDI-DrugBank.d307.s21|40-47|decrease|O
DDI-DrugBank.d307.s21|48-48|]|O
DDI-DrugBank.d307.s23|0-6|100-150|O
DDI-DrugBank.d307.s24|0-7|600-1800|O
DDI-DrugBank.d307.s25|0-1|14|O
DDI-DrugBank.d307.s25|2-2|%|O
DDI-DrugBank.d307.s25|4-11|increase|O
DDI-DrugBank.d307.s25|13-13|[|O
DDI-DrugBank.d307.s25|14-15|CI|O
DDI-DrugBank.d307.s25|16-16|:|O
DDI-DrugBank.d307.s25|18-18|2|O
DDI-DrugBank.d307.s25|19-19|%|O
DDI-DrugBank.d307.s25|21-28|increase|O
DDI-DrugBank.d307.s25|29-29|,|O
DDI-DrugBank.d307.s25|31-32|24|O
DDI-DrugBank.d307.s25|33-33|%|O
DDI-DrugBank.d307.s25|35-42|increase|O
DDI-DrugBank.d307.s25|43-43|]|O
DDI-DrugBank.d307.s25|45-46|25|O
DDI-DrugBank.d307.s25|47-47|%|O
DDI-DrugBank.d307.s25|49-56|decrease|O
DDI-DrugBank.d307.s25|58-58|[|O
DDI-DrugBank.d307.s25|59-60|CI|O
DDI-DrugBank.d307.s25|61-61|:|O
DDI-DrugBank.d307.s25|63-64|12|O
DDI-DrugBank.d307.s25|65-65|%|O
DDI-DrugBank.d307.s25|67-74|decrease|O
DDI-DrugBank.d307.s25|75-75|,|O
DDI-DrugBank.d307.s25|77-78|51|O
DDI-DrugBank.d307.s25|79-79|%|O
DDI-DrugBank.d307.s25|81-88|decrease|O
DDI-DrugBank.d307.s25|89-89|]|O
DDI-DrugBank.d307.s27|0-6|250-500|O
DDI-DrugBank.d307.s28|0-7|600-1800|O
DDI-DrugBank.d307.s29|0-4|nc1,2|O
DDI-DrugBank.d307.s29|6-7|30|O
DDI-DrugBank.d307.s29|8-8|%|O
DDI-DrugBank.d307.s29|10-17|decrease|O
DDI-DrugBank.d307.s29|19-19|[|O
DDI-DrugBank.d307.s29|20-21|CI|O
DDI-DrugBank.d307.s29|22-22|:|O
DDI-DrugBank.d307.s29|24-24|3|O
DDI-DrugBank.d307.s29|25-25|%|O
DDI-DrugBank.d307.s29|27-34|decrease|O
DDI-DrugBank.d307.s29|35-35|,|O
DDI-DrugBank.d307.s29|37-38|48|O
DDI-DrugBank.d307.s29|40-40|%|O
DDI-DrugBank.d307.s29|42-49|decrease|O
DDI-DrugBank.d307.s29|50-50|]|O
DDI-DrugBank.d307.s30|0-8|1200-2400|O
DDI-DrugBank.d307.s30|10-11|up|O
DDI-DrugBank.d307.s30|13-14|to|O
DDI-DrugBank.d307.s30|16-17|40|O
DDI-DrugBank.d307.s30|18-18|%|O
DDI-DrugBank.d307.s30|20-28|increase3|O
DDI-DrugBank.d307.s30|30-30|[|O
DDI-DrugBank.d307.s30|31-32|CI|O
DDI-DrugBank.d307.s30|33-33|:|O
DDI-DrugBank.d307.s30|35-36|12|O
DDI-DrugBank.d307.s30|37-37|%|O
DDI-DrugBank.d307.s30|39-46|increase|O
DDI-DrugBank.d307.s30|47-47|,|O
DDI-DrugBank.d307.s30|49-50|60|O
DDI-DrugBank.d307.s30|52-52|%|O
DDI-DrugBank.d307.s30|54-61|increase|O
DDI-DrugBank.d307.s30|62-62|]|O
DDI-DrugBank.d307.s32|0-7|400-2800|O
DDI-DrugBank.d307.s33|0-7|600-1800|O
DDI-DrugBank.d307.s34|0-2|nc1|O
DDI-DrugBank.d307.s34|4-5|18|O
DDI-DrugBank.d307.s34|6-6|%|O
DDI-DrugBank.d307.s34|8-15|decrease|O
DDI-DrugBank.d307.s34|17-17|[|O
DDI-DrugBank.d307.s34|18-19|CI|O
DDI-DrugBank.d307.s34|20-20|:|O
DDI-DrugBank.d307.s34|22-23|13|O
DDI-DrugBank.d307.s34|24-24|%|O
DDI-DrugBank.d307.s34|26-33|decrease|O
DDI-DrugBank.d307.s34|34-34|,|O
DDI-DrugBank.d307.s34|36-37|40|O
DDI-DrugBank.d307.s34|39-39|%|O
DDI-DrugBank.d307.s34|41-48|decrease|O
DDI-DrugBank.d307.s34|49-49|]|O
DDI-DrugBank.d307.s35|0-1|1-|O
DDI-DrugBank.d307.s35|3-4|nc|O
DDI-DrugBank.d307.s35|6-12|denotes|O
DDI-DrugBank.d307.s35|14-14|a|O
DDI-DrugBank.d307.s35|16-19|mean|O
DDI-DrugBank.d307.s35|21-26|change|O
DDI-DrugBank.d307.s35|28-29|of|O
DDI-DrugBank.d307.s35|31-34|less|O
DDI-DrugBank.d307.s35|36-39|than|O
DDI-DrugBank.d307.s35|41-42|10|O
DDI-DrugBank.d307.s35|43-43|%|O
DDI-DrugBank.d307.s35|45-46|2-|O
DDI-DrugBank.d307.s35|48-57|Pediatrics|O
DDI-DrugBank.d307.s35|59-60|3-|O
DDI-DrugBank.d307.s35|62-65|Mean|O
DDI-DrugBank.d307.s35|67-74|increase|O
DDI-DrugBank.d307.s35|76-77|in|O
DDI-DrugBank.d307.s35|79-84|adults|O
DDI-DrugBank.d307.s35|86-87|at|O
DDI-DrugBank.d307.s35|89-92|high|O
DDI-DrugBank.d307.s35|94-102|Trileptal|brand
DDI-DrugBank.d307.s35|104-108|doses|O
DDI-DrugBank.d307.s35|110-111|In|O
DDI-DrugBank.d307.s35|113-116|vivo|O
DDI-DrugBank.d307.s35|117-117|,|O
DDI-DrugBank.d307.s35|119-121|the|O
DDI-DrugBank.d307.s35|123-128|plasma|O
DDI-DrugBank.d307.s35|130-135|levels|O
DDI-DrugBank.d307.s35|137-138|of|O
DDI-DrugBank.d307.s35|140-148|phenytoin|drug
DDI-DrugBank.d307.s35|150-158|increased|O
DDI-DrugBank.d307.s35|160-161|by|O
DDI-DrugBank.d307.s35|163-164|up|O
DDI-DrugBank.d307.s35|166-167|to|O
DDI-DrugBank.d307.s35|169-170|40|O
DDI-DrugBank.d307.s35|171-171|%|O
DDI-DrugBank.d307.s35|172-172|,|O
DDI-DrugBank.d307.s35|174-177|when|O
DDI-DrugBank.d307.s35|179-187|Trileptal|brand
DDI-DrugBank.d307.s35|189-191|was|O
DDI-DrugBank.d307.s35|193-197|given|O
DDI-DrugBank.d307.s35|199-200|at|O
DDI-DrugBank.d307.s35|202-206|doses|O
DDI-DrugBank.d307.s35|208-212|above|O
DDI-DrugBank.d307.s35|214-217|1200|O
DDI-DrugBank.d307.s35|219-224|mg/day|O
DDI-DrugBank.d307.s35|225-225|.|O
DDI-DrugBank.d307.s36|0-8|Therefore|O
DDI-DrugBank.d307.s36|9-9|,|O
DDI-DrugBank.d307.s36|11-14|when|O
DDI-DrugBank.d307.s36|16-20|using|O
DDI-DrugBank.d307.s36|22-26|doses|O
DDI-DrugBank.d307.s36|28-29|of|O
DDI-DrugBank.d307.s36|31-39|Trileptal|brand
DDI-DrugBank.d307.s36|41-47|greater|O
DDI-DrugBank.d307.s36|49-52|than|O
DDI-DrugBank.d307.s36|54-57|1200|O
DDI-DrugBank.d307.s36|59-64|mg/day|O
DDI-DrugBank.d307.s36|66-71|during|O
DDI-DrugBank.d307.s36|73-82|adjunctive|O
DDI-DrugBank.d307.s36|84-90|therapy|O
DDI-DrugBank.d307.s36|91-91|,|O
DDI-DrugBank.d307.s36|93-93|a|O
DDI-DrugBank.d307.s36|95-102|decrease|O
DDI-DrugBank.d307.s36|104-105|in|O
DDI-DrugBank.d307.s36|107-109|the|O
DDI-DrugBank.d307.s36|111-114|dose|O
DDI-DrugBank.d307.s36|116-117|of|O
DDI-DrugBank.d307.s36|119-127|phenytoin|drug
DDI-DrugBank.d307.s36|129-131|may|O
DDI-DrugBank.d307.s36|133-134|be|O
DDI-DrugBank.d307.s36|136-143|required|O
DDI-DrugBank.d307.s36|144-144|.|O
DDI-DrugBank.d307.s37|0-2|The|O
DDI-DrugBank.d307.s37|4-11|increase|O
DDI-DrugBank.d307.s37|13-14|of|O
DDI-DrugBank.d307.s37|16-28|phenobarbital|drug
DDI-DrugBank.d307.s37|30-34|level|O
DDI-DrugBank.d307.s37|35-35|,|O
DDI-DrugBank.d307.s37|37-43|however|O
DDI-DrugBank.d307.s37|44-44|,|O
DDI-DrugBank.d307.s37|46-47|is|O
DDI-DrugBank.d307.s37|49-53|small|O
DDI-DrugBank.d307.s37|55-55|(|O
DDI-DrugBank.d307.s37|56-57|15|O
DDI-DrugBank.d307.s37|58-58|%|O
DDI-DrugBank.d307.s37|59-59|)|O
DDI-DrugBank.d307.s37|61-64|when|O
DDI-DrugBank.d307.s37|66-70|given|O
DDI-DrugBank.d307.s37|72-75|with|O
DDI-DrugBank.d307.s37|77-85|Trileptal|brand
DDI-DrugBank.d307.s37|86-86|.|O
DDI-DrugBank.d307.s38|0-5|Strong|O
DDI-DrugBank.d307.s38|7-14|inducers|O
DDI-DrugBank.d307.s38|16-17|of|O
DDI-DrugBank.d307.s38|19-28|cytochrome|O
DDI-DrugBank.d307.s38|30-33|P450|O
DDI-DrugBank.d307.s38|35-41|enzymes|O
DDI-DrugBank.d307.s38|43-43|(|O
DDI-DrugBank.d307.s38|44-47|i.e.|O
DDI-DrugBank.d307.s38|49-61|carbamazepine|drug
DDI-DrugBank.d307.s38|62-62|,|O
DDI-DrugBank.d307.s38|64-72|phenytoin|drug
DDI-DrugBank.d307.s38|74-76|and|O
DDI-DrugBank.d307.s38|78-90|phenobarbital|drug
DDI-DrugBank.d307.s38|91-91|)|O
DDI-DrugBank.d307.s38|93-96|have|O
DDI-DrugBank.d307.s38|98-101|been|O
DDI-DrugBank.d307.s38|103-107|shown|O
DDI-DrugBank.d307.s38|109-110|to|O
DDI-DrugBank.d307.s38|112-119|decrease|O
DDI-DrugBank.d307.s38|121-123|the|O
DDI-DrugBank.d307.s38|125-130|plasma|O
DDI-DrugBank.d307.s38|132-137|levels|O
DDI-DrugBank.d307.s38|139-140|of|O
DDI-DrugBank.d307.s38|146-146|(|O
DDI-DrugBank.d307.s38|147-151|29-40|O
DDI-DrugBank.d307.s38|152-152|%|O
DDI-DrugBank.d307.s38|153-153|)|O
DDI-DrugBank.d307.s38|154-154|.|O
DDI-DrugBank.d307.s39|0-1|No|O
DDI-DrugBank.d307.s39|3-15|autoinduction|O
DDI-DrugBank.d307.s39|17-19|has|O
DDI-DrugBank.d307.s39|21-24|been|O
DDI-DrugBank.d307.s39|26-33|observed|O
DDI-DrugBank.d307.s39|35-38|with|O
DDI-DrugBank.d307.s39|40-48|Trileptal|brand
DDI-DrugBank.d307.s39|49-49|.|O
DDI-DrugBank.d307.s40|0-7|Hormonal|O
DDI-DrugBank.d307.s40|9-22|contraceptives|group
DDI-DrugBank.d307.s40|24-40|Co-administration|O
DDI-DrugBank.d307.s40|42-43|of|O
DDI-DrugBank.d307.s40|45-53|Trileptal|brand
DDI-DrugBank.d307.s40|55-58|with|O
DDI-DrugBank.d307.s40|60-61|an|O
DDI-DrugBank.d307.s40|63-66|oral|O
DDI-DrugBank.d307.s40|68-80|contraceptive|group
DDI-DrugBank.d307.s40|82-84|has|O
DDI-DrugBank.d307.s40|86-89|been|O
DDI-DrugBank.d307.s40|91-95|shown|O
DDI-DrugBank.d307.s40|97-98|to|O
DDI-DrugBank.d307.s40|100-108|influence|O
DDI-DrugBank.d307.s40|110-112|the|O
DDI-DrugBank.d307.s40|114-119|plasma|O
DDI-DrugBank.d307.s40|121-134|concentrations|O
DDI-DrugBank.d307.s40|136-137|of|O
DDI-DrugBank.d307.s40|139-141|the|O
DDI-DrugBank.d307.s40|143-145|two|O
DDI-DrugBank.d307.s40|147-154|hormonal|O
DDI-DrugBank.d307.s40|156-165|components|O
DDI-DrugBank.d307.s40|166-166|,|O
DDI-DrugBank.d307.s40|168-183|ethinylestradiol|drug
DDI-DrugBank.d307.s40|185-185|(|O
DDI-DrugBank.d307.s40|186-187|EE|O
DDI-DrugBank.d307.s40|188-188|)|O
DDI-DrugBank.d307.s40|190-192|and|O
DDI-DrugBank.d307.s40|194-207|levonorgestrel|drug
DDI-DrugBank.d307.s40|209-209|(|O
DDI-DrugBank.d307.s40|210-212|LNG|O
DDI-DrugBank.d307.s40|213-213|)|O
DDI-DrugBank.d307.s40|214-214|.|O
DDI-DrugBank.d307.s41|0-2|The|O
DDI-DrugBank.d307.s41|4-7|mean|O
DDI-DrugBank.d307.s41|9-11|AUC|O
DDI-DrugBank.d307.s41|13-18|values|O
DDI-DrugBank.d307.s41|20-21|of|O
DDI-DrugBank.d307.s41|23-24|EE|O
DDI-DrugBank.d307.s41|26-29|were|O
DDI-DrugBank.d307.s41|31-39|decreased|O
DDI-DrugBank.d307.s41|41-42|by|O
DDI-DrugBank.d307.s41|44-45|48|O
DDI-DrugBank.d307.s41|46-46|%|O
DDI-DrugBank.d307.s41|48-48|[|O
DDI-DrugBank.d307.s41|49-50|90|O
DDI-DrugBank.d307.s41|51-51|%|O
DDI-DrugBank.d307.s41|53-54|CI|O
DDI-DrugBank.d307.s41|55-55|:|O
DDI-DrugBank.d307.s41|57-61|22-65|O
DDI-DrugBank.d307.s41|62-62|]|O
DDI-DrugBank.d307.s41|64-65|in|O
DDI-DrugBank.d307.s41|67-69|one|O
DDI-DrugBank.d307.s41|71-75|study|O
DDI-DrugBank.d307.s41|77-79|and|O
DDI-DrugBank.d307.s41|81-82|52|O
DDI-DrugBank.d307.s41|83-83|%|O
DDI-DrugBank.d307.s41|85-85|[|O
DDI-DrugBank.d307.s41|86-87|90|O
DDI-DrugBank.d307.s41|88-88|%|O
DDI-DrugBank.d307.s41|90-91|CI|O
DDI-DrugBank.d307.s41|92-92|:|O
DDI-DrugBank.d307.s41|94-98|38-52|O
DDI-DrugBank.d307.s41|99-99|]|O
DDI-DrugBank.d307.s41|101-102|in|O
DDI-DrugBank.d307.s41|104-110|another|O
DDI-DrugBank.d307.s41|112-116|study|O
DDI-DrugBank.d307.s41|118-118|[|O
DDI-DrugBank.d307.s41|119-121|1,2|O
DDI-DrugBank.d307.s41|122-122|]|O
DDI-DrugBank.d307.s41|123-123|.|O
DDI-DrugBank.d307.s42|0-2|The|O
DDI-DrugBank.d307.s42|4-7|mean|O
DDI-DrugBank.d307.s42|9-11|AUC|O
DDI-DrugBank.d307.s42|13-18|values|O
DDI-DrugBank.d307.s42|20-21|of|O
DDI-DrugBank.d307.s42|23-25|LNG|O
DDI-DrugBank.d307.s42|27-30|were|O
DDI-DrugBank.d307.s42|32-40|decreased|O
DDI-DrugBank.d307.s42|42-43|by|O
DDI-DrugBank.d307.s42|45-46|32|O
DDI-DrugBank.d307.s42|47-47|%|O
DDI-DrugBank.d307.s42|49-49|[|O
DDI-DrugBank.d307.s42|50-51|90|O
DDI-DrugBank.d307.s42|52-52|%|O
DDI-DrugBank.d307.s42|54-55|CI|O
DDI-DrugBank.d307.s42|56-56|:|O
DDI-DrugBank.d307.s42|58-62|20-45|O
DDI-DrugBank.d307.s42|63-63|]|O
DDI-DrugBank.d307.s42|65-66|in|O
DDI-DrugBank.d307.s42|68-70|one|O
DDI-DrugBank.d307.s42|72-76|study|O
DDI-DrugBank.d307.s42|78-80|and|O
DDI-DrugBank.d307.s42|82-83|52|O
DDI-DrugBank.d307.s42|84-84|%|O
DDI-DrugBank.d307.s42|86-86|[|O
DDI-DrugBank.d307.s42|87-88|90|O
DDI-DrugBank.d307.s42|89-89|%|O
DDI-DrugBank.d307.s42|91-92|CI|O
DDI-DrugBank.d307.s42|93-93|:|O
DDI-DrugBank.d307.s42|95-99|42-52|O
DDI-DrugBank.d307.s42|100-100|]|O
DDI-DrugBank.d307.s42|102-103|in|O
DDI-DrugBank.d307.s42|105-111|another|O
DDI-DrugBank.d307.s42|113-117|study|O
DDI-DrugBank.d307.s42|118-118|.|O
DDI-DrugBank.d307.s43|0-8|Therefore|O
DDI-DrugBank.d307.s43|9-9|,|O
DDI-DrugBank.d307.s43|11-20|concurrent|O
DDI-DrugBank.d307.s43|22-24|use|O
DDI-DrugBank.d307.s43|26-27|of|O
DDI-DrugBank.d307.s43|29-37|Trileptal|brand
DDI-DrugBank.d307.s43|39-42|with|O
DDI-DrugBank.d307.s43|44-66|hormonal contraceptives|group
DDI-DrugBank.d307.s43|68-70|may|O
DDI-DrugBank.d307.s43|72-77|render|O
DDI-DrugBank.d307.s43|79-83|these|O
DDI-DrugBank.d307.s43|85-98|contraceptives|group
DDI-DrugBank.d307.s43|100-103|less|O
DDI-DrugBank.d307.s43|105-113|effective|O
DDI-DrugBank.d307.s43|114-114|.|O
DDI-DrugBank.d307.s44|0-6|Studies|O
DDI-DrugBank.d307.s44|8-11|with|O
DDI-DrugBank.d307.s44|13-17|other|O
DDI-DrugBank.d307.s44|19-22|oral|O
DDI-DrugBank.d307.s44|24-25|or|O
DDI-DrugBank.d307.s44|27-33|implant|O
DDI-DrugBank.d307.s44|35-48|contraceptives|group
DDI-DrugBank.d307.s44|50-53|have|O
DDI-DrugBank.d307.s44|55-57|not|O
DDI-DrugBank.d307.s44|59-62|been|O
DDI-DrugBank.d307.s44|64-72|conducted|O
DDI-DrugBank.d307.s44|73-73|.|O
DDI-DrugBank.d307.s45|0-6|Calcium|group
DDI-DrugBank.d307.s45|8-18|Antagonists|O
DDI-DrugBank.d307.s45|19-19|:|O
DDI-DrugBank.d307.s45|21-25|After|O
DDI-DrugBank.d307.s45|27-34|repeated|O
DDI-DrugBank.d307.s45|36-52|co-administration|O
DDI-DrugBank.d307.s45|54-55|of|O
DDI-DrugBank.d307.s45|57-65|Trileptal|brand
DDI-DrugBank.d307.s45|66-66|,|O
DDI-DrugBank.d307.s45|68-70|the|O
DDI-DrugBank.d307.s45|72-74|AUC|O
DDI-DrugBank.d307.s45|76-77|of|O
DDI-DrugBank.d307.s45|79-88|felodipine|drug
DDI-DrugBank.d307.s45|90-92|was|O
DDI-DrugBank.d307.s45|94-100|lowered|O
DDI-DrugBank.d307.s45|102-103|by|O
DDI-DrugBank.d307.s45|105-106|28|O
DDI-DrugBank.d307.s45|107-107|%|O
DDI-DrugBank.d307.s45|109-109|[|O
DDI-DrugBank.d307.s45|110-111|90|O
DDI-DrugBank.d307.s45|112-112|%|O
DDI-DrugBank.d307.s45|114-115|CI|O
DDI-DrugBank.d307.s45|116-116|:|O
DDI-DrugBank.d307.s45|118-122|20-33|O
DDI-DrugBank.d307.s45|123-123|]|O
DDI-DrugBank.d307.s45|124-124|.|O
DDI-DrugBank.d307.s46|0-8|Verapamil|drug
DDI-DrugBank.d307.s46|10-17|produced|O
DDI-DrugBank.d307.s46|19-19|a|O
DDI-DrugBank.d307.s46|21-28|decrease|O
DDI-DrugBank.d307.s46|30-31|of|O
DDI-DrugBank.d307.s46|33-34|20|O
DDI-DrugBank.d307.s46|35-35|%|O
DDI-DrugBank.d307.s46|37-37|[|O
DDI-DrugBank.d307.s46|38-39|90|O
DDI-DrugBank.d307.s46|40-40|%|O
DDI-DrugBank.d307.s46|42-43|CI|O
DDI-DrugBank.d307.s46|44-44|:|O
DDI-DrugBank.d307.s46|46-50|18-27|O
DDI-DrugBank.d307.s46|51-51|]|O
DDI-DrugBank.d307.s46|53-54|of|O
DDI-DrugBank.d307.s46|56-58|the|O
DDI-DrugBank.d307.s46|60-65|plasma|O
DDI-DrugBank.d307.s46|67-72|levels|O
DDI-DrugBank.d307.s46|74-75|of|O
DDI-DrugBank.d307.s46|80-80|.|O
DDI-DrugBank.d307.s47|0-4|Other|O
DDI-DrugBank.d307.s47|6-9|drug|O
DDI-DrugBank.d307.s47|11-22|interactions|O
DDI-DrugBank.d307.s47|24-33|Cimetidine|drug
DDI-DrugBank.d307.s47|34-34|,|O
DDI-DrugBank.d307.s47|36-47|erythromycin|drug
DDI-DrugBank.d307.s47|49-51|and|O
DDI-DrugBank.d307.s47|53-70|dextropropoxyphene|drug
DDI-DrugBank.d307.s47|72-74|had|O
DDI-DrugBank.d307.s47|76-77|no|O
DDI-DrugBank.d307.s47|79-84|effect|O
DDI-DrugBank.d307.s47|86-87|on|O
DDI-DrugBank.d307.s47|89-91|the|O
DDI-DrugBank.d307.s47|93-108|pharmacokinetics|O
DDI-DrugBank.d307.s47|110-111|of|O
DDI-DrugBank.d307.s47|116-116|.|O
DDI-DrugBank.d307.s48|0-6|Results|O
DDI-DrugBank.d307.s48|8-11|with|O
DDI-DrugBank.d307.s48|13-20|warfarin|drug
DDI-DrugBank.d307.s48|22-26|wshow|O
DDI-DrugBank.d307.s48|28-29|no|O
DDI-DrugBank.d307.s48|31-38|evidence|O
DDI-DrugBank.d307.s48|40-41|of|O
DDI-DrugBank.d307.s48|43-53|interaction|O
DDI-DrugBank.d307.s48|55-58|with|O
DDI-DrugBank.d307.s48|60-65|either|O
DDI-DrugBank.d307.s48|67-72|single|O
DDI-DrugBank.d307.s48|74-75|or|O
DDI-DrugBank.d307.s48|77-84|repeated|O
DDI-DrugBank.d307.s48|86-90|doses|O
DDI-DrugBank.d307.s48|92-93|of|O
DDI-DrugBank.d307.s48|95-103|Trileptal|brand
DDI-DrugBank.d307.s48|104-104|.|O
DDI-MedLine.d117.s0|0-8|Increased|O
DDI-MedLine.d117.s0|10-18|stability|O
DDI-MedLine.d117.s0|20-21|of|O
DDI-MedLine.d117.s0|23-39|nucleophosmin/B23|O
DDI-MedLine.d117.s0|41-42|in|O
DDI-MedLine.d117.s0|44-57|anti-apoptotic|O
DDI-MedLine.d117.s0|59-64|effect|O
DDI-MedLine.d117.s0|66-67|of|O
DDI-MedLine.d117.s0|69-71|ras|O
DDI-MedLine.d117.s0|73-78|during|O
DDI-MedLine.d117.s0|80-84|serum|O
DDI-MedLine.d117.s0|86-96|deprivation|O
DDI-MedLine.d117.s0|97-97|.|O
DDI-MedLine.d117.s1|0-1|We|O
DDI-MedLine.d117.s1|3-10|obtained|O
DDI-MedLine.d117.s1|12-19|evidence|O
DDI-MedLine.d117.s1|21-24|that|O
DDI-MedLine.d117.s1|26-34|increased|O
DDI-MedLine.d117.s1|36-44|stability|O
DDI-MedLine.d117.s1|46-47|of|O
DDI-MedLine.d117.s1|49-65|nucleophosmin/B23|O
DDI-MedLine.d117.s1|67-68|is|O
DDI-MedLine.d117.s1|70-77|involved|O
DDI-MedLine.d117.s1|79-80|in|O
DDI-MedLine.d117.s1|82-94|antiapoptotic|O
DDI-MedLine.d117.s1|96-101|effect|O
DDI-MedLine.d117.s1|103-104|of|O
DDI-MedLine.d117.s1|106-108|ras|O
DDI-MedLine.d117.s1|110-115|during|O
DDI-MedLine.d117.s1|117-121|serum|O
DDI-MedLine.d117.s1|123-133|deprivation|O
DDI-MedLine.d117.s1|134-134|.|O
DDI-MedLine.d117.s2|0-16|Nucleophosmin/B23|O
DDI-MedLine.d117.s2|18-19|in|O
DDI-MedLine.d117.s2|21-34|serum-deprived|O
DDI-MedLine.d117.s2|36-36|(|O
DDI-MedLine.d117.s2|37-37|0|O
DDI-MedLine.d117.s2|38-38|%|O
DDI-MedLine.d117.s2|40-44|serum|O
DDI-MedLine.d117.s2|45-45|)|O
DDI-MedLine.d117.s2|47-53|NIH-3T3|O
DDI-MedLine.d117.s2|55-59|cells|O
DDI-MedLine.d117.s2|61-63|was|O
DDI-MedLine.d117.s2|65-69|found|O
DDI-MedLine.d117.s2|71-72|to|O
DDI-MedLine.d117.s2|74-75|be|O
DDI-MedLine.d117.s2|77-82|highly|O
DDI-MedLine.d117.s2|84-91|unstable|O
DDI-MedLine.d117.s2|93-96|with|O
DDI-MedLine.d117.s2|98-98|a|O
DDI-MedLine.d117.s2|100-108|half-life|O
DDI-MedLine.d117.s2|110-113|less|O
DDI-MedLine.d117.s2|115-118|than|O
DDI-MedLine.d117.s2|120-120|4|O
DDI-MedLine.d117.s2|122-122|h|O
DDI-MedLine.d117.s2|123-123|.|O
DDI-MedLine.d117.s3|0-1|In|O
DDI-MedLine.d117.s3|3-10|contrast|O
DDI-MedLine.d117.s3|11-11|,|O
DDI-MedLine.d117.s3|13-29|nucleophosmin/B23|O
DDI-MedLine.d117.s3|31-32|in|O
DDI-MedLine.d117.s3|34-47|serum-deprived|O
DDI-MedLine.d117.s3|49-63|ras-transformed|O
DDI-MedLine.d117.s3|65-65|(|O
DDI-MedLine.d117.s3|66-72|RAS-3T3|O
DDI-MedLine.d117.s3|73-73|)|O
DDI-MedLine.d117.s3|75-79|cells|O
DDI-MedLine.d117.s3|81-83|was|O
DDI-MedLine.d117.s3|85-86|as|O
DDI-MedLine.d117.s3|88-93|stable|O
DDI-MedLine.d117.s3|95-96|as|O
DDI-MedLine.d117.s3|98-101|that|O
DDI-MedLine.d117.s3|103-104|in|O
DDI-MedLine.d117.s3|106-123|serum-supplemented|O
DDI-MedLine.d117.s3|125-131|NIH-3T3|O
DDI-MedLine.d117.s3|133-134|or|O
DDI-MedLine.d117.s3|136-142|RAS-3T3|O
DDI-MedLine.d117.s3|144-148|cells|O
DDI-MedLine.d117.s3|149-149|.|O
DDI-MedLine.d117.s4|0-8|Treatment|O
DDI-MedLine.d117.s4|10-11|of|O
DDI-MedLine.d117.s4|13-19|RAS-3T3|O
DDI-MedLine.d117.s4|21-25|cells|O
DDI-MedLine.d117.s4|27-30|with|O
DDI-MedLine.d117.s4|32-48|nucleophosmin/B23|O
DDI-MedLine.d117.s4|50-58|antisense|O
DDI-MedLine.d117.s4|60-67|oligomer|O
DDI-MedLine.d117.s4|69-81|significantly|O
DDI-MedLine.d117.s4|83-93|potentiated|O
DDI-MedLine.d117.s4|95-97|the|O
DDI-MedLine.d117.s4|99-107|apoptosis|O
DDI-MedLine.d117.s4|109-115|induced|O
DDI-MedLine.d117.s4|117-118|by|O
DDI-MedLine.d117.s4|120-124|serum|O
DDI-MedLine.d117.s4|126-136|deprivation|O
DDI-MedLine.d117.s4|137-137|.|O
DDI-MedLine.d117.s5|0-3|Much|O
DDI-MedLine.d117.s5|5-8|less|O
DDI-MedLine.d117.s5|10-18|caspase-3|O
DDI-MedLine.d117.s5|20-27|activity|O
DDI-MedLine.d117.s5|29-31|was|O
DDI-MedLine.d117.s5|33-37|noted|O
DDI-MedLine.d117.s5|39-40|in|O
DDI-MedLine.d117.s5|42-44|the|O
DDI-MedLine.d117.s5|46-51|lysate|O
DDI-MedLine.d117.s5|53-59|derived|O
DDI-MedLine.d117.s5|61-64|from|O
DDI-MedLine.d117.s5|66-79|serum-deprived|O
DDI-MedLine.d117.s5|81-87|RAS-3T3|O
DDI-MedLine.d117.s5|89-93|cells|O
DDI-MedLine.d117.s5|95-102|compared|O
DDI-MedLine.d117.s5|104-107|with|O
DDI-MedLine.d117.s5|109-112|that|O
DDI-MedLine.d117.s5|114-115|in|O
DDI-MedLine.d117.s5|117-119|the|O
DDI-MedLine.d117.s5|121-126|lysate|O
DDI-MedLine.d117.s5|128-129|of|O
DDI-MedLine.d117.s5|131-144|serum-deprived|O
DDI-MedLine.d117.s5|146-152|NIH-3T3|O
DDI-MedLine.d117.s5|154-158|cells|O
DDI-MedLine.d117.s5|159-159|.|O
DDI-MedLine.d117.s6|0-3|Cell|O
DDI-MedLine.d117.s6|5-13|permeable|O
DDI-MedLine.d117.s6|15-23|caspase-3|O
DDI-MedLine.d117.s6|25-33|inhibitor|O
DDI-MedLine.d117.s6|35-39|added|O
DDI-MedLine.d117.s6|41-42|in|O
DDI-MedLine.d117.s6|44-46|the|O
DDI-MedLine.d117.s6|48-53|medium|O
DDI-MedLine.d117.s6|55-61|blocked|O
DDI-MedLine.d117.s6|63-65|the|O
DDI-MedLine.d117.s6|67-74|decrease|O
DDI-MedLine.d117.s6|76-77|of|O
DDI-MedLine.d117.s6|79-95|nucleophosmin/B23|O
DDI-MedLine.d117.s6|97-99|and|O
DDI-MedLine.d117.s6|101-109|apoptosis|O
DDI-MedLine.d117.s6|111-117|induced|O
DDI-MedLine.d117.s6|119-120|by|O
DDI-MedLine.d117.s6|122-126|serum|O
DDI-MedLine.d117.s6|128-138|deprivation|O
DDI-MedLine.d117.s6|140-141|in|O
DDI-MedLine.d117.s6|143-149|NIH-3T3|O
DDI-MedLine.d117.s6|151-155|cells|O
DDI-MedLine.d117.s6|156-156|.|O
DDI-MedLine.d117.s7|0-2|The|O
DDI-MedLine.d117.s7|4-12|inhibitor|O
DDI-MedLine.d117.s7|13-13|,|O
DDI-MedLine.d117.s7|15-16|on|O
DDI-MedLine.d117.s7|18-20|the|O
DDI-MedLine.d117.s7|22-26|other|O
DDI-MedLine.d117.s7|28-31|hand|O
DDI-MedLine.d117.s7|32-32|,|O
DDI-MedLine.d117.s7|34-41|promoted|O
DDI-MedLine.d117.s7|43-53|significant|O
DDI-MedLine.d117.s7|55-62|decrease|O
DDI-MedLine.d117.s7|64-65|of|O
DDI-MedLine.d117.s7|67-79|nucleolin/C23|O
DDI-MedLine.d117.s7|81-82|in|O
DDI-MedLine.d117.s7|84-90|NIH-3T3|O
DDI-MedLine.d117.s7|92-96|cells|O
DDI-MedLine.d117.s7|98-103|during|O
DDI-MedLine.d117.s7|105-109|serum|O
DDI-MedLine.d117.s7|111-121|deprivation|O
DDI-MedLine.d117.s7|122-122|.|O
DDI-MedLine.d117.s8|0-5|Unlike|O
DDI-MedLine.d117.s8|7-19|nucleolin/C23|O
DDI-MedLine.d117.s8|20-20|,|O
DDI-MedLine.d117.s8|22-36|down-regulation|O
DDI-MedLine.d117.s8|38-39|of|O
DDI-MedLine.d117.s8|41-57|nucleophosmin/B23|O
DDI-MedLine.d117.s8|59-61|was|O
DDI-MedLine.d117.s8|63-66|thus|O
DDI-MedLine.d117.s8|68-70|not|O
DDI-MedLine.d117.s8|72-94|proliferation-dependent|O
DDI-MedLine.d117.s8|96-98|but|O
DDI-MedLine.d117.s8|100-109|caspase-3-|O
DDI-MedLine.d117.s8|111-113|and|O
DDI-MedLine.d117.s8|115-133|apoptosis-dependent|O
DDI-MedLine.d117.s8|134-134|.|O
DDI-MedLine.d117.s9|0-2|Our|O
DDI-MedLine.d117.s9|4-10|results|O
DDI-MedLine.d117.s9|12-19|indicate|O
DDI-MedLine.d117.s9|21-29|important|O
DDI-MedLine.d117.s9|31-43|relationships|O
DDI-MedLine.d117.s9|45-49|among|O
DDI-MedLine.d117.s9|51-53|ras|O
DDI-MedLine.d117.s9|54-54|,|O
DDI-MedLine.d117.s9|56-72|nucleophosmin/B23|O
DDI-MedLine.d117.s9|73-73|,|O
DDI-MedLine.d117.s9|75-84|activation|O
DDI-MedLine.d117.s9|86-87|of|O
DDI-MedLine.d117.s9|89-97|caspase-3|O
DDI-MedLine.d117.s9|98-98|,|O
DDI-MedLine.d117.s9|100-102|and|O
DDI-MedLine.d117.s9|104-112|induction|O
DDI-MedLine.d117.s9|114-115|of|O
DDI-MedLine.d117.s9|117-125|apoptosis|O
DDI-MedLine.d117.s9|126-126|.|O
DDI-MedLine.d124.s0|0-3|Lack|O
DDI-MedLine.d124.s0|5-6|of|O
DDI-MedLine.d124.s0|8-18|interaction|O
DDI-MedLine.d124.s0|20-26|between|O
DDI-MedLine.d124.s0|28-39|levofloxacin|drug
DDI-MedLine.d124.s0|41-43|and|O
DDI-MedLine.d124.s0|45-53|oxycodone|drug
DDI-MedLine.d124.s0|54-54|:|O
DDI-MedLine.d124.s0|56-71|pharmacokinetics|O
DDI-MedLine.d124.s0|73-75|and|O
DDI-MedLine.d124.s0|77-80|drug|O
DDI-MedLine.d124.s0|82-92|disposition|O
DDI-MedLine.d124.s0|93-93|.|O
DDI-MedLine.d124.s1|0-7|Previous|O
DDI-MedLine.d124.s1|9-15|studies|O
DDI-MedLine.d124.s1|17-20|have|O
DDI-MedLine.d124.s1|22-33|demonstrated|O
DDI-MedLine.d124.s1|35-35|a|O
DDI-MedLine.d124.s1|37-47|significant|O
DDI-MedLine.d124.s1|49-57|reduction|O
DDI-MedLine.d124.s1|59-60|in|O
DDI-MedLine.d124.s1|62-64|the|O
DDI-MedLine.d124.s1|66-69|oral|O
DDI-MedLine.d124.s1|71-85|bioavailability|O
DDI-MedLine.d124.s1|87-88|of|O
DDI-MedLine.d124.s1|90-102|trovafloxacin|drug
DDI-MedLine.d124.s1|104-106|and|O
DDI-MedLine.d124.s1|108-120|ciprofloxacin|drug
DDI-MedLine.d124.s1|122-125|when|O
DDI-MedLine.d124.s1|127-138|administered|O
DDI-MedLine.d124.s1|140-152|concomitantly|O
DDI-MedLine.d124.s1|154-157|with|O
DDI-MedLine.d124.s1|159-160|an|O
DDI-MedLine.d124.s1|162-172|intravenous|O
DDI-MedLine.d124.s1|174-179|opiate|group
DDI-MedLine.d124.s1|181-184|such|O
DDI-MedLine.d124.s1|186-187|as|O
DDI-MedLine.d124.s1|189-196|morphine|drug
DDI-MedLine.d124.s1|197-197|.|O
DDI-MedLine.d124.s2|0-3|This|O
DDI-MedLine.d124.s2|5-12|decrease|O
DDI-MedLine.d124.s2|14-15|in|O
DDI-MedLine.d124.s2|17-26|absorption|O
DDI-MedLine.d124.s2|28-34|results|O
DDI-MedLine.d124.s2|36-37|in|O
DDI-MedLine.d124.s2|39-39|a|O
DDI-MedLine.d124.s2|41-42|36|O
DDI-MedLine.d124.s2|43-43|%|O
DDI-MedLine.d124.s2|45-47|and|O
DDI-MedLine.d124.s2|49-50|50|O
DDI-MedLine.d124.s2|51-51|%|O
DDI-MedLine.d124.s2|53-57|lower|O
DDI-MedLine.d124.s2|59-61|AUC|O
DDI-MedLine.d124.s2|63-65|for|O
DDI-MedLine.d124.s2|67-79|trovafloxacin|drug
DDI-MedLine.d124.s2|81-83|and|O
DDI-MedLine.d124.s2|85-97|ciprofloxacin|drug
DDI-MedLine.d124.s2|98-98|,|O
DDI-MedLine.d124.s2|100-111|respectively|O
DDI-MedLine.d124.s2|112-112|,|O
DDI-MedLine.d124.s2|114-118|which|O
DDI-MedLine.d124.s2|120-124|could|O
DDI-MedLine.d124.s2|126-130|cause|O
DDI-MedLine.d124.s2|132-139|clinical|O
DDI-MedLine.d124.s2|141-148|failures|O
DDI-MedLine.d124.s2|149-149|.|O
DDI-MedLine.d124.s3|0-2|The|O
DDI-MedLine.d124.s3|4-10|authors|O
DDI-MedLine.d124.s3|12-23|investigated|O
DDI-MedLine.d124.s3|25-27|the|O
DDI-MedLine.d124.s3|29-39|possibility|O
DDI-MedLine.d124.s3|41-42|of|O
DDI-MedLine.d124.s3|44-44|a|O
DDI-MedLine.d124.s3|46-52|similar|O
DDI-MedLine.d124.s3|54-64|interaction|O
DDI-MedLine.d124.s3|66-72|between|O
DDI-MedLine.d124.s3|74-82|oxycodone|drug
DDI-MedLine.d124.s3|84-86|and|O
DDI-MedLine.d124.s3|88-99|levofloxacin|drug
DDI-MedLine.d124.s3|100-100|.|O
DDI-MedLine.d124.s4|0-4|Eight|O
DDI-MedLine.d124.s4|6-12|healthy|O
DDI-MedLine.d124.s4|14-23|volunteers|O
DDI-MedLine.d124.s4|25-28|were|O
DDI-MedLine.d124.s4|30-39|randomized|O
DDI-MedLine.d124.s4|41-42|in|O
DDI-MedLine.d124.s4|44-45|an|O
DDI-MedLine.d124.s4|47-56|open-label|O
DDI-MedLine.d124.s4|57-57|,|O
DDI-MedLine.d124.s4|59-65|two-way|O
DDI-MedLine.d124.s4|67-75|crossover|O
DDI-MedLine.d124.s4|77-81|study|O
DDI-MedLine.d124.s4|83-84|to|O
DDI-MedLine.d124.s4|86-92|receive|O
DDI-MedLine.d124.s4|94-102|oxycodone|drug
DDI-MedLine.d124.s4|103-103|,|O
DDI-MedLine.d124.s4|105-105|5|O
DDI-MedLine.d124.s4|107-108|mg|O
DDI-MedLine.d124.s4|110-112|p.o|O
DDI-MedLine.d124.s4|113-113|.|O
DDI-MedLine.d124.s5|0-2|Q4H|O
DDI-MedLine.d124.s5|3-3|,|O
DDI-MedLine.d124.s5|5-7|and|O
DDI-MedLine.d124.s5|9-20|levofloxacin|drug
DDI-MedLine.d124.s5|21-21|,|O
DDI-MedLine.d124.s5|23-25|500|O
DDI-MedLine.d124.s5|27-28|mg|O
DDI-MedLine.d124.s5|30-32|p.o|O
DDI-MedLine.d124.s5|33-33|.|O
DDI-MedLine.d124.s6|0-0|1|O
DDI-MedLine.d124.s6|2-5|hour|O
DDI-MedLine.d124.s6|7-11|after|O
DDI-MedLine.d124.s6|13-20|starting|O
DDI-MedLine.d124.s6|22-24|the|O
DDI-MedLine.d124.s6|26-34|oxycodone|drug
DDI-MedLine.d124.s6|36-37|or|O
DDI-MedLine.d124.s6|39-50|levofloxacin|drug
DDI-MedLine.d124.s6|52-54|500|O
DDI-MedLine.d124.s6|56-57|mg|O
DDI-MedLine.d124.s6|59-61|p.o|O
DDI-MedLine.d124.s6|62-62|.|O
DDI-MedLine.d124.s7|0-4|alone|O
DDI-MedLine.d124.s7|5-5|.|O
DDI-MedLine.d124.s8|0-4|Blood|O
DDI-MedLine.d124.s8|6-12|samples|O
DDI-MedLine.d124.s8|14-17|were|O
DDI-MedLine.d124.s8|19-23|drawn|O
DDI-MedLine.d124.s8|25-26|at|O
DDI-MedLine.d124.s8|28-28|0|O
DDI-MedLine.d124.s8|29-29|,|O
DDI-MedLine.d124.s8|31-33|0.5|O
DDI-MedLine.d124.s8|34-34|,|O
DDI-MedLine.d124.s8|36-36|1|O
DDI-MedLine.d124.s8|37-37|,|O
DDI-MedLine.d124.s8|39-41|1.5|O
DDI-MedLine.d124.s8|42-42|,|O
DDI-MedLine.d124.s8|44-44|2|O
DDI-MedLine.d124.s8|45-45|,|O
DDI-MedLine.d124.s8|47-47|3|O
DDI-MedLine.d124.s8|48-48|,|O
DDI-MedLine.d124.s8|50-50|4|O
DDI-MedLine.d124.s8|51-51|,|O
DDI-MedLine.d124.s8|53-53|6|O
DDI-MedLine.d124.s8|54-54|,|O
DDI-MedLine.d124.s8|56-56|8|O
DDI-MedLine.d124.s8|57-57|,|O
DDI-MedLine.d124.s8|59-60|12|O
DDI-MedLine.d124.s8|61-61|,|O
DDI-MedLine.d124.s8|63-64|18|O
DDI-MedLine.d124.s8|65-65|,|O
DDI-MedLine.d124.s8|67-69|and|O
DDI-MedLine.d124.s8|71-72|24|O
DDI-MedLine.d124.s8|74-78|hours|O
DDI-MedLine.d124.s8|80-82|for|O
DDI-MedLine.d124.s8|84-87|Cmax|O
DDI-MedLine.d124.s8|88-88|,|O
DDI-MedLine.d124.s8|90-93|tmax|O
DDI-MedLine.d124.s8|94-94|,|O
DDI-MedLine.d124.s8|96-98|and|O
DDI-MedLine.d124.s8|100-102|AUC|O
DDI-MedLine.d124.s8|104-117|determinations|O
DDI-MedLine.d124.s8|118-118|.|O
DDI-MedLine.d124.s9|0-4|There|O
DDI-MedLine.d124.s9|6-8|was|O
DDI-MedLine.d124.s9|10-12|not|O
DDI-MedLine.d124.s9|14-14|a|O
DDI-MedLine.d124.s9|16-26|significant|O
DDI-MedLine.d124.s9|28-37|difference|O
DDI-MedLine.d124.s9|39-39|(|O
DDI-MedLine.d124.s9|40-40|p|O
DDI-MedLine.d124.s9|42-42|>|O
DDI-MedLine.d124.s9|44-47|0.05|O
DDI-MedLine.d124.s9|48-48|)|O
DDI-MedLine.d124.s9|50-51|in|O
DDI-MedLine.d124.s9|53-55|AUC|O
DDI-MedLine.d124.s9|57-57|(|O
DDI-MedLine.d124.s9|58-62|48.59|O
DDI-MedLine.d124.s9|64-66|+/-|O
DDI-MedLine.d124.s9|68-71|8.52|O
DDI-MedLine.d124.s9|73-75|vs.|O
DDI-MedLine.d124.s9|77-80|49.9|O
DDI-MedLine.d124.s9|82-84|+/-|O
DDI-MedLine.d124.s9|86-89|9.93|O
DDI-MedLine.d124.s9|90-90|)|O
DDI-MedLine.d124.s9|91-91|,|O
DDI-MedLine.d124.s9|93-96|Cmax|O
DDI-MedLine.d124.s9|98-98|(|O
DDI-MedLine.d124.s9|99-102|7.73|O
DDI-MedLine.d124.s9|104-106|+/-|O
DDI-MedLine.d124.s9|108-110|2.6|O
DDI-MedLine.d124.s9|112-114|vs.|O
DDI-MedLine.d124.s9|116-118|6.6|O
DDI-MedLine.d124.s9|120-122|+/-|O
DDI-MedLine.d124.s9|124-126|2.0|O
DDI-MedLine.d124.s9|127-127|)|O
DDI-MedLine.d124.s9|128-128|,|O
DDI-MedLine.d124.s9|130-132|and|O
DDI-MedLine.d124.s9|134-137|tmax|O
DDI-MedLine.d124.s9|139-139|(|O
DDI-MedLine.d124.s9|140-142|1.1|O
DDI-MedLine.d124.s9|144-146|+/-|O
DDI-MedLine.d124.s9|148-150|0.6|O
DDI-MedLine.d124.s9|152-154|vs.|O
DDI-MedLine.d124.s9|156-158|1.6|O
DDI-MedLine.d124.s9|160-162|+/-|O
DDI-MedLine.d124.s9|164-166|1.1|O
DDI-MedLine.d124.s9|167-167|)|O
DDI-MedLine.d124.s9|169-171|for|O
DDI-MedLine.d124.s9|173-184|levofloxacin|drug
DDI-MedLine.d124.s9|186-191|versus|O
DDI-MedLine.d124.s9|193-214|levofloxacin/oxycodone|drug
DDI-MedLine.d124.s9|216-223|regimens|O
DDI-MedLine.d124.s9|224-224|.|O
DDI-MedLine.d124.s10|0-1|It|O
DDI-MedLine.d124.s10|3-5|was|O
DDI-MedLine.d124.s10|7-15|concluded|O
DDI-MedLine.d124.s10|17-20|that|O
DDI-MedLine.d124.s10|22-25|oral|O
DDI-MedLine.d124.s10|27-35|oxycodone|drug
DDI-MedLine.d124.s10|37-39|and|O
DDI-MedLine.d124.s10|41-52|levofloxacin|drug
DDI-MedLine.d124.s10|54-56|can|O
DDI-MedLine.d124.s10|58-59|be|O
DDI-MedLine.d124.s10|61-72|administered|O
DDI-MedLine.d124.s10|74-86|concomitantly|O
DDI-MedLine.d124.s10|88-94|without|O
DDI-MedLine.d124.s10|96-96|a|O
DDI-MedLine.d124.s10|98-108|significant|O
DDI-MedLine.d124.s10|110-117|decrease|O
DDI-MedLine.d124.s10|119-120|in|O
DDI-MedLine.d124.s10|122-124|AUC|O
DDI-MedLine.d124.s10|125-125|,|O
DDI-MedLine.d124.s10|127-130|Cmax|O
DDI-MedLine.d124.s10|131-131|,|O
DDI-MedLine.d124.s10|133-134|or|O
DDI-MedLine.d124.s10|136-139|tmax|O
DDI-MedLine.d124.s10|140-140|.|O
DDI-DrugBank.d777.s0|0-2|The|O
DDI-DrugBank.d777.s0|4-14|interaction|O
DDI-DrugBank.d777.s0|16-17|of|O
DDI-DrugBank.d777.s0|19-27|Streptase|brand
DDI-DrugBank.d777.s0|28-28|,|O
DDI-DrugBank.d777.s0|30-42|Streptokinase|drug
DDI-DrugBank.d777.s0|43-43|,|O
DDI-DrugBank.d777.s0|45-48|with|O
DDI-DrugBank.d777.s0|50-54|other|O
DDI-DrugBank.d777.s0|56-60|drugs|O
DDI-DrugBank.d777.s0|62-64|has|O
DDI-DrugBank.d777.s0|66-68|not|O
DDI-DrugBank.d777.s0|70-73|been|O
DDI-DrugBank.d777.s0|75-78|well|O
DDI-DrugBank.d777.s0|80-86|studied|O
DDI-DrugBank.d777.s0|87-87|.|O
DDI-DrugBank.d777.s1|0-2|Use|O
DDI-DrugBank.d777.s1|4-5|of|O
DDI-DrugBank.d777.s1|7-20|Anticoagulants|group
DDI-DrugBank.d777.s1|22-24|and|O
DDI-DrugBank.d777.s1|26-44|Antiplatelet Agents|group
DDI-DrugBank.d777.s1|46-47|--|O
DDI-DrugBank.d777.s1|49-57|Streptase|brand
DDI-DrugBank.d777.s1|58-58|,|O
DDI-DrugBank.d777.s1|60-72|Streptokinase|drug
DDI-DrugBank.d777.s1|73-73|,|O
DDI-DrugBank.d777.s1|75-79|alone|O
DDI-DrugBank.d777.s1|81-82|or|O
DDI-DrugBank.d777.s1|84-85|in|O
DDI-DrugBank.d777.s1|87-97|combination|O
DDI-DrugBank.d777.s1|99-102|with|O
DDI-DrugBank.d777.s1|104-122|antiplatelet agents|group
DDI-DrugBank.d777.s1|124-126|and|O
DDI-DrugBank.d777.s1|128-141|anticoagulants|group
DDI-DrugBank.d777.s1|142-142|,|O
DDI-DrugBank.d777.s1|144-146|may|O
DDI-DrugBank.d777.s1|148-152|cause|O
DDI-DrugBank.d777.s1|154-161|bleeding|O
DDI-DrugBank.d777.s1|163-175|complications|O
DDI-DrugBank.d777.s1|176-176|.|O
DDI-DrugBank.d777.s2|0-8|Therefore|O
DDI-DrugBank.d777.s2|9-9|,|O
DDI-DrugBank.d777.s2|11-17|careful|O
DDI-DrugBank.d777.s2|19-28|monitoring|O
DDI-DrugBank.d777.s2|30-31|is|O
DDI-DrugBank.d777.s2|33-39|advised|O
DDI-DrugBank.d777.s2|40-40|.|O
DDI-DrugBank.d777.s3|0-1|In|O
DDI-DrugBank.d777.s3|3-5|the|O
DDI-DrugBank.d777.s3|7-15|treatment|O
DDI-DrugBank.d777.s3|17-18|of|O
DDI-DrugBank.d777.s3|20-24|acute|O
DDI-DrugBank.d777.s3|26-27|MI|O
DDI-DrugBank.d777.s3|28-28|,|O
DDI-DrugBank.d777.s3|30-36|aspirin|brand
DDI-DrugBank.d777.s3|37-37|,|O
DDI-DrugBank.d777.s3|39-42|when|O
DDI-DrugBank.d777.s3|44-46|not|O
DDI-DrugBank.d777.s3|48-56|otherwise|O
DDI-DrugBank.d777.s3|58-72|contraindicated|O
DDI-DrugBank.d777.s3|73-73|,|O
DDI-DrugBank.d777.s3|75-80|should|O
DDI-DrugBank.d777.s3|82-83|be|O
DDI-DrugBank.d777.s3|85-96|administered|O
DDI-DrugBank.d777.s3|98-101|with|O
DDI-DrugBank.d777.s3|103-115|Streptokinase|drug
DDI-DrugBank.d777.s3|117-117|(|O
DDI-DrugBank.d777.s3|119-121|see|O
DDI-DrugBank.d777.s3|123-127|below|O
DDI-DrugBank.d777.s3|129-129|)|O
DDI-DrugBank.d777.s3|130-130|.|O
DDI-DrugBank.d777.s4|0-14|Anticoagulation|O
DDI-DrugBank.d777.s4|16-18|and|O
DDI-DrugBank.d777.s4|20-32|Antiplatelets|group
DDI-DrugBank.d777.s4|34-38|After|O
DDI-DrugBank.d777.s4|40-48|Treatment|O
DDI-DrugBank.d777.s4|50-52|for|O
DDI-DrugBank.d777.s4|54-63|Myocardial|O
DDI-DrugBank.d777.s4|65-74|Infarction|O
DDI-DrugBank.d777.s4|76-77|--|O
DDI-DrugBank.d777.s4|79-80|In|O
DDI-DrugBank.d777.s4|82-84|the|O
DDI-DrugBank.d777.s4|86-94|treatment|O
DDI-DrugBank.d777.s4|96-97|of|O
DDI-DrugBank.d777.s4|99-103|acute|O
DDI-DrugBank.d777.s4|105-114|myocardial|O
DDI-DrugBank.d777.s4|116-125|infarction|O
DDI-DrugBank.d777.s4|126-126|,|O
DDI-DrugBank.d777.s4|128-130|the|O
DDI-DrugBank.d777.s4|132-134|use|O
DDI-DrugBank.d777.s4|136-137|of|O
DDI-DrugBank.d777.s4|139-145|aspirin|brand
DDI-DrugBank.d777.s4|147-149|has|O
DDI-DrugBank.d777.s4|151-154|been|O
DDI-DrugBank.d777.s4|156-160|shown|O
DDI-DrugBank.d777.s4|162-163|to|O
DDI-DrugBank.d777.s4|165-170|reduce|O
DDI-DrugBank.d777.s4|172-174|the|O
DDI-DrugBank.d777.s4|176-184|incidence|O
DDI-DrugBank.d777.s4|186-187|of|O
DDI-DrugBank.d777.s4|189-200|reinfarction|O
DDI-DrugBank.d777.s4|202-204|and|O
DDI-DrugBank.d777.s4|206-211|stroke|O
DDI-DrugBank.d777.s4|212-212|.|O
DDI-DrugBank.d777.s5|0-2|The|O
DDI-DrugBank.d777.s5|4-11|addition|O
DDI-DrugBank.d777.s5|13-14|of|O
DDI-DrugBank.d777.s5|16-22|aspirin|brand
DDI-DrugBank.d777.s5|24-25|to|O
DDI-DrugBank.d777.s5|27-39|Streptokinase|drug
DDI-DrugBank.d777.s5|41-46|causes|O
DDI-DrugBank.d777.s5|48-48|a|O
DDI-DrugBank.d777.s5|50-56|minimal|O
DDI-DrugBank.d777.s5|58-65|increase|O
DDI-DrugBank.d777.s5|67-68|in|O
DDI-DrugBank.d777.s5|70-72|the|O
DDI-DrugBank.d777.s5|74-77|risk|O
DDI-DrugBank.d777.s5|79-80|of|O
DDI-DrugBank.d777.s5|82-86|minor|O
DDI-DrugBank.d777.s5|88-95|bleeding|O
DDI-DrugBank.d777.s5|97-97|(|O
DDI-DrugBank.d777.s5|98-100|3.9|O
DDI-DrugBank.d777.s5|101-101|%|O
DDI-DrugBank.d777.s5|103-105|vs.|O
DDI-DrugBank.d777.s5|107-109|3.1|O
DDI-DrugBank.d777.s5|110-110|%|O
DDI-DrugBank.d777.s5|111-111|)|O
DDI-DrugBank.d777.s5|112-112|,|O
DDI-DrugBank.d777.s5|114-116|but|O
DDI-DrugBank.d777.s5|118-121|does|O
DDI-DrugBank.d777.s5|123-125|not|O
DDI-DrugBank.d777.s5|127-132|appear|O
DDI-DrugBank.d777.s5|134-135|to|O
DDI-DrugBank.d777.s5|137-144|increase|O
DDI-DrugBank.d777.s5|146-148|the|O
DDI-DrugBank.d777.s5|150-158|incidence|O
DDI-DrugBank.d777.s5|160-161|of|O
DDI-DrugBank.d777.s5|163-167|major|O
DDI-DrugBank.d777.s5|169-176|bleeding|O
DDI-DrugBank.d777.s5|178-178|(|O
DDI-DrugBank.d777.s5|179-181|see|O
DDI-DrugBank.d461.s0|0-7|Additive|O
DDI-DrugBank.d461.s0|9-18|depressant|O
DDI-DrugBank.d461.s0|20-25|effect|O
DDI-DrugBank.d461.s0|27-30|when|O
DDI-DrugBank.d461.s0|32-35|used|O
DDI-DrugBank.d461.s0|37-40|with|O
DDI-DrugBank.d461.s0|42-48|general|O
DDI-DrugBank.d461.s0|50-60|anesthetics|group
DDI-DrugBank.d461.s0|61-61|,|O
DDI-DrugBank.d461.s0|63-71|sedatives|group
DDI-DrugBank.d461.s0|72-72|,|O
DDI-DrugBank.d461.s0|74-90|antianxiety drugs|group
DDI-DrugBank.d461.s0|91-91|,|O
DDI-DrugBank.d461.s0|93-101|hypnotics|group
DDI-DrugBank.d461.s0|102-102|,|O
DDI-DrugBank.d461.s0|104-110|alcohol|drug
DDI-DrugBank.d461.s0|111-111|,|O
DDI-DrugBank.d461.s0|113-115|and|O
DDI-DrugBank.d461.s0|117-121|other|O
DDI-DrugBank.d461.s0|123-139|opiate analgesics|group
DDI-DrugBank.d461.s0|140-140|.|O
DDI-DrugBank.d368.s0|0-5|DIAMOX|brand
DDI-DrugBank.d368.s0|7-14|modifies|O
DDI-DrugBank.d368.s0|16-24|phenytoin|drug
DDI-DrugBank.d368.s0|26-35|metabolism|O
DDI-DrugBank.d368.s0|37-40|with|O
DDI-DrugBank.d368.s0|42-50|increased|O
DDI-DrugBank.d368.s0|52-56|serum|O
DDI-DrugBank.d368.s0|58-63|levels|O
DDI-DrugBank.d368.s0|65-66|of|O
DDI-DrugBank.d368.s0|68-76|phenytoin|drug
DDI-DrugBank.d368.s0|77-77|.|O
DDI-DrugBank.d368.s1|0-3|This|O
DDI-DrugBank.d368.s1|5-7|may|O
DDI-DrugBank.d368.s1|9-16|increase|O
DDI-DrugBank.d368.s1|18-19|or|O
DDI-DrugBank.d368.s1|21-27|enhance|O
DDI-DrugBank.d368.s1|29-31|the|O
DDI-DrugBank.d368.s1|33-42|occurrence|O
DDI-DrugBank.d368.s1|44-45|of|O
DDI-DrugBank.d368.s1|47-58|osteomalacia|O
DDI-DrugBank.d368.s1|60-61|in|O
DDI-DrugBank.d368.s1|63-66|some|O
DDI-DrugBank.d368.s1|68-75|patients|O
DDI-DrugBank.d368.s1|77-85|receiving|O
DDI-DrugBank.d368.s1|87-93|chronic|O
DDI-DrugBank.d368.s1|95-103|phenytoin|drug
DDI-DrugBank.d368.s1|105-111|therapy|O
DDI-DrugBank.d368.s1|112-112|.|O
DDI-DrugBank.d368.s2|0-6|Caution|O
DDI-DrugBank.d368.s2|8-9|is|O
DDI-DrugBank.d368.s2|11-17|advised|O
DDI-DrugBank.d368.s2|19-20|in|O
DDI-DrugBank.d368.s2|22-29|patients|O
DDI-DrugBank.d368.s2|31-39|receiving|O
DDI-DrugBank.d368.s2|41-47|chronic|O
DDI-DrugBank.d368.s2|49-59|concomitant|O
DDI-DrugBank.d368.s2|61-67|therapy|O
DDI-DrugBank.d368.s2|68-68|.|O
DDI-DrugBank.d368.s3|0-1|By|O
DDI-DrugBank.d368.s3|3-12|decreasing|O
DDI-DrugBank.d368.s3|14-16|the|O
DDI-DrugBank.d368.s3|18-33|gastrointestinal|O
DDI-DrugBank.d368.s3|35-44|absorption|O
DDI-DrugBank.d368.s3|46-47|of|O
DDI-DrugBank.d368.s3|49-57|primidone|drug
DDI-DrugBank.d368.s3|58-58|,|O
DDI-DrugBank.d368.s3|60-65|DIAMOX|brand
DDI-DrugBank.d368.s3|67-69|may|O
DDI-DrugBank.d368.s3|71-78|decrease|O
DDI-DrugBank.d368.s3|80-84|serum|O
DDI-DrugBank.d368.s3|86-99|concentrations|O
DDI-DrugBank.d368.s3|101-102|of|O
DDI-DrugBank.d368.s3|104-112|primidone|drug
DDI-DrugBank.d368.s3|114-116|and|O
DDI-DrugBank.d368.s3|118-120|its|O
DDI-DrugBank.d368.s3|122-132|metabolites|O
DDI-DrugBank.d368.s3|133-133|,|O
DDI-DrugBank.d368.s3|135-138|with|O
DDI-DrugBank.d368.s3|140-140|a|O
DDI-DrugBank.d368.s3|142-151|consequent|O
DDI-DrugBank.d368.s3|153-160|possible|O
DDI-DrugBank.d368.s3|162-169|decrease|O
DDI-DrugBank.d368.s3|171-172|in|O
DDI-DrugBank.d368.s3|174-187|anticonvulsant|O
DDI-DrugBank.d368.s3|189-194|effect|O
DDI-DrugBank.d368.s3|195-195|.|O
DDI-DrugBank.d368.s4|0-6|Caution|O
DDI-DrugBank.d368.s4|8-9|is|O
DDI-DrugBank.d368.s4|11-17|advised|O
DDI-DrugBank.d368.s4|19-22|when|O
DDI-DrugBank.d368.s4|24-32|beginning|O
DDI-DrugBank.d368.s4|33-33|,|O
DDI-DrugBank.d368.s4|35-47|discontinuing|O
DDI-DrugBank.d368.s4|48-48|,|O
DDI-DrugBank.d368.s4|50-51|or|O
DDI-DrugBank.d368.s4|53-60|changing|O
DDI-DrugBank.d368.s4|62-64|the|O
DDI-DrugBank.d368.s4|66-69|dose|O
DDI-DrugBank.d368.s4|71-72|of|O
DDI-DrugBank.d368.s4|74-79|DIAMOX|brand
DDI-DrugBank.d368.s4|81-82|in|O
DDI-DrugBank.d368.s4|84-91|patients|O
DDI-DrugBank.d368.s4|93-101|receiving|O
DDI-DrugBank.d368.s4|103-111|primidone|drug
DDI-DrugBank.d368.s4|112-112|.|O
DDI-DrugBank.d368.s5|0-6|Because|O
DDI-DrugBank.d368.s5|8-9|of|O
DDI-DrugBank.d368.s5|11-18|possible|O
DDI-DrugBank.d368.s5|20-27|additive|O
DDI-DrugBank.d368.s5|29-35|effects|O
DDI-DrugBank.d368.s5|37-40|with|O
DDI-DrugBank.d368.s5|42-46|other|O
DDI-DrugBank.d368.s5|48-76|carbonic anhydrase inhibitors|group
DDI-DrugBank.d368.s5|77-77|,|O
DDI-DrugBank.d368.s5|79-89|concomitant|O
DDI-DrugBank.d368.s5|91-93|use|O
DDI-DrugBank.d368.s5|95-96|is|O
DDI-DrugBank.d368.s5|98-100|not|O
DDI-DrugBank.d368.s5|102-110|advisable|O
DDI-DrugBank.d368.s5|111-111|.|O
DDI-DrugBank.d368.s6|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s6|14-16|may|O
DDI-DrugBank.d368.s6|18-25|increase|O
DDI-DrugBank.d368.s6|27-29|the|O
DDI-DrugBank.d368.s6|31-37|effects|O
DDI-DrugBank.d368.s6|39-40|of|O
DDI-DrugBank.d368.s6|42-46|other|O
DDI-DrugBank.d368.s6|48-69|folic acid antagonists|group
DDI-DrugBank.d368.s6|70-70|.|O
DDI-DrugBank.d368.s7|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s7|14-16|may|O
DDI-DrugBank.d368.s7|18-25|increase|O
DDI-DrugBank.d368.s7|27-28|or|O
DDI-DrugBank.d368.s7|30-37|decrease|O
DDI-DrugBank.d368.s7|39-43|blood|O
DDI-DrugBank.d368.s7|45-51|glucose|O
DDI-DrugBank.d368.s7|53-58|levels|O
DDI-DrugBank.d368.s7|59-59|.|O
DDI-DrugBank.d368.s8|0-12|Consideration|O
DDI-DrugBank.d368.s8|14-19|should|O
DDI-DrugBank.d368.s8|21-22|be|O
DDI-DrugBank.d368.s8|24-28|taken|O
DDI-DrugBank.d368.s8|30-31|in|O
DDI-DrugBank.d368.s8|33-40|patients|O
DDI-DrugBank.d368.s8|42-46|being|O
DDI-DrugBank.d368.s8|48-54|treated|O
DDI-DrugBank.d368.s8|56-59|with|O
DDI-DrugBank.d368.s8|61-72|antidiabetic|drug
DDI-DrugBank.d368.s8|74-79|agents|O
DDI-DrugBank.d368.s8|80-80|.|O
DDI-DrugBank.d368.s9|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s9|14-22|decreases|O
DDI-DrugBank.d368.s9|24-30|urinary|O
DDI-DrugBank.d368.s9|32-40|excretion|O
DDI-DrugBank.d368.s9|42-43|of|O
DDI-DrugBank.d368.s9|45-55|amphetamine|drug
DDI-DrugBank.d368.s9|57-59|and|O
DDI-DrugBank.d368.s9|61-63|may|O
DDI-DrugBank.d368.s9|65-71|enhance|O
DDI-DrugBank.d368.s9|73-75|the|O
DDI-DrugBank.d368.s9|77-85|magnitude|O
DDI-DrugBank.d368.s9|87-89|and|O
DDI-DrugBank.d368.s9|91-98|duration|O
DDI-DrugBank.d368.s9|100-101|of|O
DDI-DrugBank.d368.s9|103-107|their|O
DDI-DrugBank.d368.s9|109-114|effect|O
DDI-DrugBank.d368.s9|115-115|.|O
DDI-DrugBank.d368.s10|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s10|14-20|reduces|O
DDI-DrugBank.d368.s10|22-28|urinary|O
DDI-DrugBank.d368.s10|30-38|excretion|O
DDI-DrugBank.d368.s10|40-41|of|O
DDI-DrugBank.d368.s10|43-51|quinidine|drug
DDI-DrugBank.d368.s10|53-55|and|O
DDI-DrugBank.d368.s10|57-59|may|O
DDI-DrugBank.d368.s10|61-67|enhance|O
DDI-DrugBank.d368.s10|69-71|its|O
DDI-DrugBank.d368.s10|73-78|effect|O
DDI-DrugBank.d368.s10|79-79|.|O
DDI-DrugBank.d368.s11|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s11|14-16|may|O
DDI-DrugBank.d368.s11|18-24|prevent|O
DDI-DrugBank.d368.s11|26-28|the|O
DDI-DrugBank.d368.s11|30-36|urinary|O
DDI-DrugBank.d368.s11|38-47|antiseptic|O
DDI-DrugBank.d368.s11|49-54|effect|O
DDI-DrugBank.d368.s11|56-57|of|O
DDI-DrugBank.d368.s11|59-69|methenamine|drug
DDI-DrugBank.d368.s11|70-70|.|O
DDI-DrugBank.d368.s12|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s12|14-22|increases|O
DDI-DrugBank.d368.s12|24-30|lithium|drug
DDI-DrugBank.d368.s12|32-40|excretion|O
DDI-DrugBank.d368.s12|42-44|and|O
DDI-DrugBank.d368.s12|46-48|the|O
DDI-DrugBank.d368.s12|50-56|lithium|drug
DDI-DrugBank.d368.s12|58-60|may|O
DDI-DrugBank.d368.s12|62-63|be|O
DDI-DrugBank.d368.s12|65-73|decreased|O
DDI-DrugBank.d368.s12|74-74|.|O
DDI-DrugBank.d368.s13|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s13|14-16|and|O
DDI-DrugBank.d368.s13|18-35|sodium bicarbonate|drug
DDI-DrugBank.d368.s13|37-40|used|O
DDI-DrugBank.d368.s13|42-53|concurrently|O
DDI-DrugBank.d368.s13|55-63|increases|O
DDI-DrugBank.d368.s13|65-67|the|O
DDI-DrugBank.d368.s13|69-72|risk|O
DDI-DrugBank.d368.s13|74-75|of|O
DDI-DrugBank.d368.s13|77-81|renal|O
DDI-DrugBank.d368.s13|83-90|calculus|O
DDI-DrugBank.d368.s13|92-100|formation|O
DDI-DrugBank.d368.s13|101-101|.|O
DDI-DrugBank.d368.s14|0-12|Acetazolamide|drug
DDI-DrugBank.d368.s14|14-16|may|O
DDI-DrugBank.d368.s14|18-24|elevate|O
DDI-DrugBank.d368.s14|26-37|cyclosporine|drug
DDI-DrugBank.d368.s14|39-44|levels|O
DDI-DrugBank.d368.s14|45-45|.|O
DDI-DrugBank.d334.s0|0-10|Hypotension|O
DDI-DrugBank.d334.s0|12-12|-|O
DDI-DrugBank.d334.s0|14-21|Patients|O
DDI-DrugBank.d334.s0|23-24|on|O
DDI-DrugBank.d334.s0|26-33|Diuretic|O
DDI-DrugBank.d334.s0|35-41|Therapy|O
DDI-DrugBank.d334.s0|42-42|:|O
DDI-DrugBank.d334.s0|44-51|Patients|O
DDI-DrugBank.d334.s0|53-54|on|O
DDI-DrugBank.d334.s0|56-64|diuretics|group
DDI-DrugBank.d334.s0|65-65|,|O
DDI-DrugBank.d334.s0|67-69|and|O
DDI-DrugBank.d334.s0|71-80|especially|O
DDI-DrugBank.d334.s0|82-86|those|O
DDI-DrugBank.d334.s0|88-89|in|O
DDI-DrugBank.d334.s0|91-94|whom|O
DDI-DrugBank.d334.s0|96-103|diuretic|O
DDI-DrugBank.d334.s0|105-111|therapy|O
DDI-DrugBank.d334.s0|113-115|was|O
DDI-DrugBank.d334.s0|117-124|recently|O
DDI-DrugBank.d334.s0|126-135|instituted|O
DDI-DrugBank.d334.s0|136-136|,|O
DDI-DrugBank.d334.s0|138-140|may|O
DDI-DrugBank.d334.s0|142-153|occasionally|O
DDI-DrugBank.d334.s0|155-164|experience|O
DDI-DrugBank.d334.s0|166-167|an|O
DDI-DrugBank.d334.s0|169-177|excessive|O
DDI-DrugBank.d334.s0|179-187|reduction|O
DDI-DrugBank.d334.s0|189-190|of|O
DDI-DrugBank.d334.s0|192-196|blood|O
DDI-DrugBank.d334.s0|198-205|pressure|O
DDI-DrugBank.d334.s0|207-211|after|O
DDI-DrugBank.d334.s0|213-222|initiation|O
DDI-DrugBank.d334.s0|224-225|of|O
DDI-DrugBank.d334.s0|227-233|therapy|O
DDI-DrugBank.d334.s0|235-238|with|O
DDI-DrugBank.d334.s0|240-247|PRINIVIL|brand
DDI-DrugBank.d334.s0|248-248|.|O
DDI-DrugBank.d334.s1|0-2|The|O
DDI-DrugBank.d334.s1|4-14|possibility|O
DDI-DrugBank.d334.s1|16-17|of|O
DDI-DrugBank.d334.s1|19-29|hypotensive|O
DDI-DrugBank.d334.s1|31-37|effects|O
DDI-DrugBank.d334.s1|39-42|with|O
DDI-DrugBank.d334.s1|44-51|PRINIVIL|brand
DDI-DrugBank.d334.s1|53-55|can|O
DDI-DrugBank.d334.s1|57-58|be|O
DDI-DrugBank.d334.s1|60-68|minimized|O
DDI-DrugBank.d334.s1|70-71|by|O
DDI-DrugBank.d334.s1|73-78|either|O
DDI-DrugBank.d334.s1|80-92|discontinuing|O
DDI-DrugBank.d334.s1|94-96|the|O
DDI-DrugBank.d334.s1|98-105|diuretic|group
DDI-DrugBank.d334.s1|107-108|or|O
DDI-DrugBank.d334.s1|110-119|increasing|O
DDI-DrugBank.d334.s1|121-123|the|O
DDI-DrugBank.d334.s1|125-128|salt|O
DDI-DrugBank.d334.s1|130-135|intake|O
DDI-DrugBank.d334.s1|137-141|prior|O
DDI-DrugBank.d334.s1|143-144|to|O
DDI-DrugBank.d334.s1|146-155|initiation|O
DDI-DrugBank.d334.s1|157-158|of|O
DDI-DrugBank.d334.s1|160-168|treatment|O
DDI-DrugBank.d334.s1|170-173|with|O
DDI-DrugBank.d334.s1|175-182|PRINIVIL|brand
DDI-DrugBank.d334.s1|183-183|.|O
DDI-DrugBank.d334.s2|0-1|If|O
DDI-DrugBank.d334.s2|3-4|it|O
DDI-DrugBank.d334.s2|6-7|is|O
DDI-DrugBank.d334.s2|9-17|necessary|O
DDI-DrugBank.d334.s2|19-20|to|O
DDI-DrugBank.d334.s2|22-29|continue|O
DDI-DrugBank.d334.s2|31-33|the|O
DDI-DrugBank.d334.s2|35-42|diuretic|group
DDI-DrugBank.d334.s2|43-43|,|O
DDI-DrugBank.d334.s2|45-52|initiate|O
DDI-DrugBank.d334.s2|54-60|therapy|O
DDI-DrugBank.d334.s2|62-65|with|O
DDI-DrugBank.d334.s2|67-74|PRINIVIL|brand
DDI-DrugBank.d334.s2|76-77|at|O
DDI-DrugBank.d334.s2|79-79|a|O
DDI-DrugBank.d334.s2|81-84|dose|O
DDI-DrugBank.d334.s2|86-87|of|O
DDI-DrugBank.d334.s2|89-89|5|O
DDI-DrugBank.d334.s2|91-92|mg|O
DDI-DrugBank.d334.s2|94-98|daily|O
DDI-DrugBank.d334.s2|99-99|,|O
DDI-DrugBank.d334.s2|101-103|and|O
DDI-DrugBank.d334.s2|105-111|provide|O
DDI-DrugBank.d334.s2|113-117|close|O
DDI-DrugBank.d334.s2|119-125|medical|O
DDI-DrugBank.d334.s2|127-137|supervision|O
DDI-DrugBank.d334.s2|139-143|after|O
DDI-DrugBank.d334.s2|145-147|the|O
DDI-DrugBank.d334.s2|149-155|initial|O
DDI-DrugBank.d334.s2|157-160|dose|O
DDI-DrugBank.d334.s2|162-166|until|O
DDI-DrugBank.d334.s2|168-172|blood|O
DDI-DrugBank.d334.s2|174-181|pressure|O
DDI-DrugBank.d334.s2|183-185|has|O
DDI-DrugBank.d334.s2|187-196|stabilized|O
DDI-DrugBank.d334.s2|197-197|.|O
DDI-DrugBank.d334.s3|0-3|When|O
DDI-DrugBank.d334.s3|5-5|a|O
DDI-DrugBank.d334.s3|7-14|diuretic|group
DDI-DrugBank.d334.s3|16-17|is|O
DDI-DrugBank.d334.s3|19-23|added|O
DDI-DrugBank.d334.s3|25-26|to|O
DDI-DrugBank.d334.s3|28-30|the|O
DDI-DrugBank.d334.s3|32-38|therapy|O
DDI-DrugBank.d334.s3|40-41|of|O
DDI-DrugBank.d334.s3|43-43|a|O
DDI-DrugBank.d334.s3|45-51|patient|O
DDI-DrugBank.d334.s3|53-61|receiving|O
DDI-DrugBank.d334.s3|63-70|PRINIVIL|brand
DDI-DrugBank.d334.s3|71-71|,|O
DDI-DrugBank.d334.s3|73-74|an|O
DDI-DrugBank.d334.s3|76-85|additional|O
DDI-DrugBank.d334.s3|87-102|antihypertensive|O
DDI-DrugBank.d334.s3|104-109|effect|O
DDI-DrugBank.d334.s3|111-112|is|O
DDI-DrugBank.d334.s3|114-120|usually|O
DDI-DrugBank.d334.s3|122-129|observed|O
DDI-DrugBank.d334.s3|130-130|.|O
DDI-DrugBank.d334.s4|0-6|Studies|O
DDI-DrugBank.d334.s4|8-11|with|O
DDI-DrugBank.d334.s4|13-26|ACE inhibitors|group
DDI-DrugBank.d334.s4|28-29|in|O
DDI-DrugBank.d334.s4|31-41|combination|O
DDI-DrugBank.d334.s4|43-46|with|O
DDI-DrugBank.d334.s4|48-56|diuretics|group
DDI-DrugBank.d334.s4|58-65|indicate|O
DDI-DrugBank.d334.s4|67-70|that|O
DDI-DrugBank.d334.s4|72-74|the|O
DDI-DrugBank.d334.s4|76-79|dose|O
DDI-DrugBank.d334.s4|81-82|of|O
DDI-DrugBank.d334.s4|84-86|the|O
DDI-DrugBank.d334.s4|88-100|ACE inhibitor|group
DDI-DrugBank.d334.s4|102-104|can|O
DDI-DrugBank.d334.s4|106-107|be|O
DDI-DrugBank.d334.s4|109-115|reduced|O
DDI-DrugBank.d334.s4|117-120|when|O
DDI-DrugBank.d334.s4|122-123|it|O
DDI-DrugBank.d334.s4|125-126|is|O
DDI-DrugBank.d334.s4|128-132|given|O
DDI-DrugBank.d334.s4|134-137|with|O
DDI-DrugBank.d334.s4|139-139|a|O
DDI-DrugBank.d334.s4|141-148|diuretic|group
DDI-DrugBank.d334.s4|149-149|.|O
DDI-DrugBank.d334.s5|0-37|Non-steroidal Anti-inflammatory Agents|group
DDI-DrugBank.d334.s5|38-38|:|O
DDI-DrugBank.d334.s5|40-41|In|O
DDI-DrugBank.d334.s5|43-46|some|O
DDI-DrugBank.d334.s5|48-55|patients|O
DDI-DrugBank.d334.s5|57-60|with|O
DDI-DrugBank.d334.s5|62-72|compromised|O
DDI-DrugBank.d334.s5|74-78|renal|O
DDI-DrugBank.d334.s5|80-87|function|O
DDI-DrugBank.d334.s5|89-91|who|O
DDI-DrugBank.d334.s5|93-95|are|O
DDI-DrugBank.d334.s5|97-101|being|O
DDI-DrugBank.d334.s5|103-109|treated|O
DDI-DrugBank.d334.s5|111-114|with|O
DDI-DrugBank.d334.s5|116-152|non-steroidal anti-inflammatory drugs|group
DDI-DrugBank.d334.s5|153-153|,|O
DDI-DrugBank.d334.s5|155-157|the|O
DDI-DrugBank.d334.s5|159-175|co-administration|O
DDI-DrugBank.d334.s5|177-178|of|O
DDI-DrugBank.d334.s5|180-189|lisinopril|drug
DDI-DrugBank.d334.s5|191-193|may|O
DDI-DrugBank.d334.s5|195-200|result|O
DDI-DrugBank.d334.s5|202-203|in|O
DDI-DrugBank.d334.s5|205-205|a|O
DDI-DrugBank.d334.s5|207-213|further|O
DDI-DrugBank.d334.s5|215-227|deterioration|O
DDI-DrugBank.d334.s5|229-230|of|O
DDI-DrugBank.d334.s5|232-236|renal|O
DDI-DrugBank.d334.s5|238-245|function|O
DDI-DrugBank.d334.s5|246-246|.|O
DDI-DrugBank.d334.s6|0-4|These|O
DDI-DrugBank.d334.s6|6-12|effects|O
DDI-DrugBank.d334.s6|14-16|are|O
DDI-DrugBank.d334.s6|18-24|usually|O
DDI-DrugBank.d334.s6|26-35|reversible|O
DDI-DrugBank.d334.s6|36-36|.|O
DDI-DrugBank.d334.s7|0-6|Reports|O
DDI-DrugBank.d334.s7|8-14|suggest|O
DDI-DrugBank.d334.s7|16-19|that|O
DDI-DrugBank.d334.s7|21-26|NSAIDs|group
DDI-DrugBank.d334.s7|28-30|may|O
DDI-DrugBank.d334.s7|32-39|diminish|O
DDI-DrugBank.d334.s7|41-43|the|O
DDI-DrugBank.d334.s7|45-60|antihypertensive|O
DDI-DrugBank.d334.s7|62-67|effect|O
DDI-DrugBank.d334.s7|69-70|of|O
DDI-DrugBank.d334.s7|72-85|ACE inhibitors|group
DDI-DrugBank.d334.s7|86-86|,|O
DDI-DrugBank.d334.s7|88-96|including|O
DDI-DrugBank.d334.s7|98-107|lisinopril|drug
DDI-DrugBank.d334.s7|108-108|.|O
DDI-DrugBank.d334.s8|0-3|This|O
DDI-DrugBank.d334.s8|5-15|interaction|O
DDI-DrugBank.d334.s8|17-22|should|O
DDI-DrugBank.d334.s8|24-25|be|O
DDI-DrugBank.d334.s8|27-31|given|O
DDI-DrugBank.d334.s8|33-45|consideration|O
DDI-DrugBank.d334.s8|47-48|in|O
DDI-DrugBank.d334.s8|50-57|patients|O
DDI-DrugBank.d334.s8|59-64|taking|O
DDI-DrugBank.d334.s8|66-71|NSAIDs|group
DDI-DrugBank.d334.s8|73-85|concomitantly|O
DDI-DrugBank.d334.s8|87-90|with|O
DDI-DrugBank.d334.s8|92-105|ACE inhibitors|group
DDI-DrugBank.d334.s8|106-106|.|O
DDI-DrugBank.d334.s9|0-1|In|O
DDI-DrugBank.d334.s9|3-3|a|O
DDI-DrugBank.d334.s9|5-9|study|O
DDI-DrugBank.d334.s9|11-12|in|O
DDI-DrugBank.d334.s9|14-15|36|O
DDI-DrugBank.d334.s9|17-24|patients|O
DDI-DrugBank.d334.s9|26-29|with|O
DDI-DrugBank.d334.s9|31-34|mild|O
DDI-DrugBank.d334.s9|36-37|to|O
DDI-DrugBank.d334.s9|39-46|moderate|O
DDI-DrugBank.d334.s9|48-59|hypertension|O
DDI-DrugBank.d334.s9|61-65|where|O
DDI-DrugBank.d334.s9|67-69|the|O
DDI-DrugBank.d334.s9|71-86|antihypertensive|O
DDI-DrugBank.d334.s9|88-94|effects|O
DDI-DrugBank.d334.s9|96-97|of|O
DDI-DrugBank.d334.s9|99-106|PRINIVIL|brand
DDI-DrugBank.d334.s9|108-112|alone|O
DDI-DrugBank.d334.s9|114-117|were|O
DDI-DrugBank.d334.s9|119-126|compared|O
DDI-DrugBank.d334.s9|128-129|to|O
DDI-DrugBank.d334.s9|131-138|PRINIVIL|brand
DDI-DrugBank.d334.s9|140-144|given|O
DDI-DrugBank.d334.s9|146-158|concomitantly|O
DDI-DrugBank.d334.s9|160-163|with|O
DDI-DrugBank.d334.s9|165-176|indomethacin|drug
DDI-DrugBank.d334.s9|177-177|,|O
DDI-DrugBank.d334.s9|179-181|the|O
DDI-DrugBank.d334.s9|183-185|use|O
DDI-DrugBank.d334.s9|187-188|of|O
DDI-DrugBank.d334.s9|190-201|indomethacin|drug
DDI-DrugBank.d334.s9|203-205|was|O
DDI-DrugBank.d334.s9|207-216|associated|O
DDI-DrugBank.d334.s9|218-221|with|O
DDI-DrugBank.d334.s9|223-223|a|O
DDI-DrugBank.d334.s9|225-231|reduced|O
DDI-DrugBank.d334.s9|233-248|antihypertensive|O
DDI-DrugBank.d334.s9|250-255|effect|O
DDI-DrugBank.d334.s9|256-256|,|O
DDI-DrugBank.d334.s9|258-265|although|O
DDI-DrugBank.d334.s9|267-269|the|O
DDI-DrugBank.d334.s9|271-280|difference|O
DDI-DrugBank.d334.s9|282-288|between|O
DDI-DrugBank.d334.s9|290-292|the|O
DDI-DrugBank.d334.s9|294-296|two|O
DDI-DrugBank.d334.s9|298-305|regimens|O
DDI-DrugBank.d334.s9|307-309|was|O
DDI-DrugBank.d334.s9|311-313|not|O
DDI-DrugBank.d334.s9|315-325|significant|O
DDI-DrugBank.d334.s9|326-326|.|O
DDI-DrugBank.d334.s10|0-4|Other|O
DDI-DrugBank.d334.s10|6-11|Agents|O
DDI-DrugBank.d334.s10|12-12|:|O
DDI-DrugBank.d334.s10|14-21|PRINIVIL|brand
DDI-DrugBank.d334.s10|23-25|has|O
DDI-DrugBank.d334.s10|27-30|been|O
DDI-DrugBank.d334.s10|32-35|used|O
DDI-DrugBank.d334.s10|37-49|concomitantly|O
DDI-DrugBank.d334.s10|51-54|with|O
DDI-DrugBank.d334.s10|56-63|nitrates|group
DDI-DrugBank.d334.s10|65-70|and/or|O
DDI-DrugBank.d334.s10|72-78|digoxin|drug
DDI-DrugBank.d334.s10|80-86|without|O
DDI-DrugBank.d334.s10|88-95|evidence|O
DDI-DrugBank.d334.s10|97-98|of|O
DDI-DrugBank.d334.s10|100-109|clinically|O
DDI-DrugBank.d334.s10|111-121|significant|O
DDI-DrugBank.d334.s10|123-129|adverse|O
DDI-DrugBank.d334.s10|131-142|interactions|O
DDI-DrugBank.d334.s10|143-143|.|O
DDI-DrugBank.d334.s11|0-3|This|O
DDI-DrugBank.d334.s11|5-12|included|O
DDI-DrugBank.d334.s11|14-17|post|O
DDI-DrugBank.d334.s11|19-28|myocardial|O
DDI-DrugBank.d334.s11|30-39|infarction|O
DDI-DrugBank.d334.s11|41-48|patients|O
DDI-DrugBank.d334.s11|50-52|who|O
DDI-DrugBank.d334.s11|54-57|were|O
DDI-DrugBank.d334.s11|59-67|receiving|O
DDI-DrugBank.d334.s11|69-79|intravenous|O
DDI-DrugBank.d334.s11|81-82|or|O
DDI-DrugBank.d334.s11|84-94|transdermal|O
DDI-DrugBank.d334.s11|96-108|nitroglycerin|drug
DDI-DrugBank.d334.s11|109-109|.|O
DDI-DrugBank.d334.s12|0-1|No|O
DDI-DrugBank.d334.s12|3-12|clinically|O
DDI-DrugBank.d334.s12|14-22|important|O
DDI-DrugBank.d334.s12|24-38|pharmacokinetic|O
DDI-DrugBank.d334.s12|40-51|interactions|O
DDI-DrugBank.d334.s12|53-60|occurred|O
DDI-DrugBank.d334.s12|62-65|when|O
DDI-DrugBank.d334.s12|67-74|PRINIVIL|brand
DDI-DrugBank.d334.s12|76-78|was|O
DDI-DrugBank.d334.s12|80-83|used|O
DDI-DrugBank.d334.s12|85-97|concomitantly|O
DDI-DrugBank.d334.s12|99-102|with|O
DDI-DrugBank.d334.s12|104-114|propranolol|drug
DDI-DrugBank.d334.s12|116-117|or|O
DDI-DrugBank.d334.s12|119-137|hydrochlorothiazide|drug
DDI-DrugBank.d334.s12|138-138|.|O
DDI-DrugBank.d334.s13|0-2|The|O
DDI-DrugBank.d334.s13|4-11|presence|O
DDI-DrugBank.d334.s13|13-14|of|O
DDI-DrugBank.d334.s13|16-19|food|O
DDI-DrugBank.d334.s13|21-22|in|O
DDI-DrugBank.d334.s13|24-26|the|O
DDI-DrugBank.d334.s13|28-34|stomach|O
DDI-DrugBank.d334.s13|36-39|does|O
DDI-DrugBank.d334.s13|41-43|not|O
DDI-DrugBank.d334.s13|45-49|alter|O
DDI-DrugBank.d334.s13|51-53|the|O
DDI-DrugBank.d334.s13|55-69|bioavailability|O
DDI-DrugBank.d334.s13|71-72|of|O
DDI-DrugBank.d334.s13|74-81|PRINIVIL|brand
DDI-DrugBank.d334.s13|82-82|.|O
DDI-DrugBank.d334.s14|0-5|Agents|O
DDI-DrugBank.d334.s14|7-16|Increasing|O
DDI-DrugBank.d334.s14|18-22|Serum|O
DDI-DrugBank.d334.s14|24-32|Potassium|O
DDI-DrugBank.d334.s14|33-33|:|O
DDI-DrugBank.d334.s14|35-42|PRINIVIL|brand
DDI-DrugBank.d334.s14|44-53|attenuates|O
DDI-DrugBank.d334.s14|55-63|potassium|O
DDI-DrugBank.d334.s14|65-68|loss|O
DDI-DrugBank.d334.s14|70-75|caused|O
DDI-DrugBank.d334.s14|77-78|by|O
DDI-DrugBank.d334.s14|80-102|thiazide-type diuretics|group
DDI-DrugBank.d334.s14|103-103|.|O
DDI-DrugBank.d334.s15|0-2|Use|O
DDI-DrugBank.d334.s15|4-5|of|O
DDI-DrugBank.d334.s15|7-14|PRINIVIL|brand
DDI-DrugBank.d334.s15|16-19|with|O
DDI-DrugBank.d334.s15|21-47|potassium-sparing diuretics|group
DDI-DrugBank.d334.s15|49-49|(|O
DDI-DrugBank.d334.s15|50-53|e.g.|O
DDI-DrugBank.d334.s15|54-54|,|O
DDI-DrugBank.d334.s15|56-69|spironolactone|drug
DDI-DrugBank.d334.s15|70-70|,|O
DDI-DrugBank.d334.s15|72-82|triamterene|drug
DDI-DrugBank.d334.s15|83-83|,|O
DDI-DrugBank.d334.s15|85-86|or|O
DDI-DrugBank.d334.s15|88-96|amiloride|drug
DDI-DrugBank.d334.s15|97-97|)|O
DDI-DrugBank.d334.s15|98-98|,|O
DDI-DrugBank.d334.s15|100-108|potassium|drug
DDI-DrugBank.d334.s15|110-120|supplements|O
DDI-DrugBank.d334.s15|121-121|,|O
DDI-DrugBank.d334.s15|123-124|or|O
DDI-DrugBank.d334.s15|126-145|potassium-containing|O
DDI-DrugBank.d334.s15|147-150|salt|O
DDI-DrugBank.d334.s15|152-162|substitutes|O
DDI-DrugBank.d334.s15|164-166|may|O
DDI-DrugBank.d334.s15|168-171|lead|O
DDI-DrugBank.d334.s15|173-174|to|O
DDI-DrugBank.d334.s15|176-186|significant|O
DDI-DrugBank.d334.s15|188-196|increases|O
DDI-DrugBank.d334.s15|198-199|in|O
DDI-DrugBank.d334.s15|201-205|serum|O
DDI-DrugBank.d334.s15|207-215|potassium|O
DDI-DrugBank.d334.s15|216-216|.|O
DDI-DrugBank.d334.s16|0-8|Therefore|O
DDI-DrugBank.d334.s16|9-9|,|O
DDI-DrugBank.d334.s16|11-12|if|O
DDI-DrugBank.d334.s16|14-24|concomitant|O
DDI-DrugBank.d334.s16|26-28|use|O
DDI-DrugBank.d334.s16|30-31|of|O
DDI-DrugBank.d334.s16|33-37|these|O
DDI-DrugBank.d334.s16|39-44|agents|O
DDI-DrugBank.d334.s16|46-47|is|O
DDI-DrugBank.d334.s16|49-57|indicated|O
DDI-DrugBank.d334.s16|59-65|because|O
DDI-DrugBank.d334.s16|67-68|of|O
DDI-DrugBank.d334.s16|70-81|demonstrated|O
DDI-DrugBank.d334.s16|83-93|hypokalemia|O
DDI-DrugBank.d334.s16|94-94|,|O
DDI-DrugBank.d334.s16|96-99|they|O
DDI-DrugBank.d334.s16|101-106|should|O
DDI-DrugBank.d334.s16|108-109|be|O
DDI-DrugBank.d334.s16|111-114|used|O
DDI-DrugBank.d334.s16|116-119|with|O
DDI-DrugBank.d334.s16|121-127|caution|O
DDI-DrugBank.d334.s16|129-131|and|O
DDI-DrugBank.d334.s16|133-136|with|O
DDI-DrugBank.d334.s16|138-145|frequent|O
DDI-DrugBank.d334.s16|147-156|monitoring|O
DDI-DrugBank.d334.s16|158-159|of|O
DDI-DrugBank.d334.s16|161-165|serum|O
DDI-DrugBank.d334.s16|167-175|potassium|O
DDI-DrugBank.d334.s16|176-176|.|O
DDI-DrugBank.d334.s17|0-8|Potassium|O
DDI-DrugBank.d334.s17|10-16|sparing|O
DDI-DrugBank.d334.s17|18-23|agents|O
DDI-DrugBank.d334.s17|25-30|should|O
DDI-DrugBank.d334.s17|32-40|generally|O
DDI-DrugBank.d334.s17|42-44|not|O
DDI-DrugBank.d334.s17|46-47|be|O
DDI-DrugBank.d334.s17|49-52|used|O
DDI-DrugBank.d334.s17|54-55|in|O
DDI-DrugBank.d334.s17|57-64|patients|O
DDI-DrugBank.d334.s17|66-69|with|O
DDI-DrugBank.d334.s17|71-75|heart|O
DDI-DrugBank.d334.s17|77-83|failure|O
DDI-DrugBank.d334.s17|85-87|who|O
DDI-DrugBank.d334.s17|89-91|are|O
DDI-DrugBank.d334.s17|93-101|receiving|O
DDI-DrugBank.d334.s17|103-110|PRINIVIL|brand
DDI-DrugBank.d334.s17|111-111|.|O
DDI-DrugBank.d334.s18|0-6|Lithium|drug
DDI-DrugBank.d334.s18|7-7|:|O
DDI-DrugBank.d334.s18|9-15|Lithium|drug
DDI-DrugBank.d334.s18|17-24|toxicity|O
DDI-DrugBank.d334.s18|26-28|has|O
DDI-DrugBank.d334.s18|30-33|been|O
DDI-DrugBank.d334.s18|35-42|reported|O
DDI-DrugBank.d334.s18|44-45|in|O
DDI-DrugBank.d334.s18|47-54|patients|O
DDI-DrugBank.d334.s18|56-64|receiving|O
DDI-DrugBank.d334.s18|66-72|lithium|drug
DDI-DrugBank.d334.s18|74-86|concomitantly|O
DDI-DrugBank.d334.s18|88-91|with|O
DDI-DrugBank.d334.s18|93-97|drugs|O
DDI-DrugBank.d334.s18|99-103|which|O
DDI-DrugBank.d334.s18|105-109|cause|O
DDI-DrugBank.d334.s18|111-121|elimination|O
DDI-DrugBank.d334.s18|123-124|of|O
DDI-DrugBank.d334.s18|126-131|sodium|O
DDI-DrugBank.d334.s18|132-132|,|O
DDI-DrugBank.d334.s18|134-142|including|O
DDI-DrugBank.d334.s18|144-157|ACE inhibitors|group
DDI-DrugBank.d334.s18|158-158|.|O
DDI-DrugBank.d334.s19|0-6|Lithium|drug
DDI-DrugBank.d334.s19|8-15|toxicity|O
DDI-DrugBank.d334.s19|17-19|was|O
DDI-DrugBank.d334.s19|21-27|usually|O
DDI-DrugBank.d334.s19|29-38|reversible|O
DDI-DrugBank.d334.s19|40-43|upon|O
DDI-DrugBank.d334.s19|45-59|discontinuation|O
DDI-DrugBank.d334.s19|61-62|of|O
DDI-DrugBank.d334.s19|64-70|lithium|drug
DDI-DrugBank.d334.s19|72-74|and|O
DDI-DrugBank.d334.s19|76-78|the|O
DDI-DrugBank.d334.s19|80-92|ACE inhibitor|group
DDI-DrugBank.d334.s19|93-93|.|O
DDI-DrugBank.d334.s20|0-1|It|O
DDI-DrugBank.d334.s20|3-4|is|O
DDI-DrugBank.d334.s20|6-16|recommended|O
DDI-DrugBank.d334.s20|18-21|that|O
DDI-DrugBank.d334.s20|23-27|serum|O
DDI-DrugBank.d334.s20|29-35|lithium|drug
DDI-DrugBank.d334.s20|37-42|levels|O
DDI-DrugBank.d334.s20|44-45|be|O
DDI-DrugBank.d334.s20|47-55|monitored|O
DDI-DrugBank.d334.s20|57-66|frequently|O
DDI-DrugBank.d334.s20|68-69|if|O
DDI-DrugBank.d334.s20|71-78|PRINIVIL|brand
DDI-DrugBank.d334.s20|80-81|is|O
DDI-DrugBank.d334.s20|83-94|administered|O
DDI-DrugBank.d334.s20|96-108|concomitantly|O
DDI-DrugBank.d334.s20|110-113|with|O
DDI-DrugBank.d334.s20|115-121|lithium|drug
DDI-DrugBank.d334.s20|122-122|.|O
DDI-DrugBank.d770.s0|0-4|Nasal|O
DDI-DrugBank.d770.s0|6-10|Spray|O
DDI-DrugBank.d770.s0|11-11|:|O
DDI-DrugBank.d770.s0|13-18|Formal|O
DDI-DrugBank.d770.s0|20-26|studies|O
DDI-DrugBank.d770.s0|28-35|designed|O
DDI-DrugBank.d770.s0|37-38|to|O
DDI-DrugBank.d770.s0|40-47|evaluate|O
DDI-DrugBank.d770.s0|49-52|drug|O
DDI-DrugBank.d770.s0|54-65|interactions|O
DDI-DrugBank.d770.s0|67-70|with|O
DDI-DrugBank.d770.s0|72-90|Calcitonin ( salmon )|drug
DDI-DrugBank.d770.s0|92-95|have|O
DDI-DrugBank.d770.s0|97-99|not|O
DDI-DrugBank.d770.s0|101-104|been|O
DDI-DrugBank.d770.s0|106-109|done|O
DDI-DrugBank.d770.s0|110-110|.|O
DDI-DrugBank.d770.s1|0-1|No|O
DDI-DrugBank.d770.s1|3-6|drug|O
DDI-DrugBank.d770.s1|8-18|interaction|O
DDI-DrugBank.d770.s1|20-26|studies|O
DDI-DrugBank.d770.s1|28-31|have|O
DDI-DrugBank.d770.s1|33-36|been|O
DDI-DrugBank.d770.s1|38-46|performed|O
DDI-DrugBank.d770.s1|48-51|with|O
DDI-DrugBank.d770.s1|53-71|Calcitonin ( salmon )|drug
DDI-DrugBank.d770.s1|73-77|nasal|O
DDI-DrugBank.d770.s1|79-83|spray|O
DDI-DrugBank.d770.s1|85-95|ingredients|O
DDI-DrugBank.d770.s1|96-96|.|O
DDI-DrugBank.d770.s2|0-8|Currently|O
DDI-DrugBank.d770.s2|9-9|,|O
DDI-DrugBank.d770.s2|11-12|no|O
DDI-DrugBank.d770.s2|14-17|drug|O
DDI-DrugBank.d770.s2|19-30|interactions|O
DDI-DrugBank.d770.s2|32-35|with|O
DDI-DrugBank.d770.s2|37-55|Calcitonin ( salmon )|drug
DDI-DrugBank.d770.s2|57-60|have|O
DDI-DrugBank.d770.s2|62-65|been|O
DDI-DrugBank.d770.s2|67-74|observed|O
DDI-DrugBank.d770.s2|75-75|.|O
DDI-DrugBank.d770.s3|0-2|The|O
DDI-DrugBank.d770.s3|4-10|effects|O
DDI-DrugBank.d770.s3|12-13|of|O
DDI-DrugBank.d770.s3|15-19|prior|O
DDI-DrugBank.d770.s3|21-23|use|O
DDI-DrugBank.d770.s3|25-26|of|O
DDI-DrugBank.d770.s3|28-41|diphosphonates|group
DDI-DrugBank.d770.s3|43-44|in|O
DDI-DrugBank.d770.s3|46-59|postmenopausal|O
DDI-DrugBank.d770.s3|61-72|osteoporosis|O
DDI-DrugBank.d770.s3|74-81|patients|O
DDI-DrugBank.d770.s3|83-86|have|O
DDI-DrugBank.d770.s3|88-90|not|O
DDI-DrugBank.d770.s3|92-95|been|O
DDI-DrugBank.d770.s3|97-104|assessed|O
DDI-DrugBank.d770.s3|105-105|;|O
DDI-DrugBank.d770.s4|0-6|however|O
DDI-DrugBank.d770.s4|7-7|,|O
DDI-DrugBank.d770.s4|9-10|in|O
DDI-DrugBank.d770.s4|12-19|patients|O
DDI-DrugBank.d770.s4|21-24|with|O
DDI-DrugBank.d770.s4|26-30|Paget|O
DDI-DrugBank.d770.s4|31-32|'s|O
DDI-DrugBank.d770.s4|34-40|Disease|O
DDI-DrugBank.d770.s4|42-46|prior|O
DDI-DrugBank.d770.s4|48-60|diphosphonate|group
DDI-DrugBank.d770.s4|62-64|use|O
DDI-DrugBank.d770.s4|66-72|appears|O
DDI-DrugBank.d770.s4|74-75|to|O
DDI-DrugBank.d770.s4|77-82|reduce|O
DDI-DrugBank.d770.s4|84-86|the|O
DDI-DrugBank.d770.s4|88-102|anti-resorptive|O
DDI-DrugBank.d770.s4|104-111|response|O
DDI-DrugBank.d770.s4|113-114|to|O
DDI-DrugBank.d770.s4|116-134|Calcitonin ( salmon )|drug
DDI-DrugBank.d770.s4|136-140|nasal|O
DDI-DrugBank.d770.s4|142-146|spray|O
DDI-DrugBank.d770.s4|147-147|.|O
DDI-DrugBank.d545.s0|0-8|Geocillin|brand
DDI-DrugBank.d545.s0|10-10|(|O
DDI-DrugBank.d545.s0|11-38|carbenicillin indanyl sodium|drug
DDI-DrugBank.d545.s0|39-39|)|O
DDI-DrugBank.d545.s0|41-45|blood|O
DDI-DrugBank.d545.s0|47-52|levels|O
DDI-DrugBank.d545.s0|54-56|may|O
DDI-DrugBank.d545.s0|58-59|be|O
DDI-DrugBank.d545.s0|61-69|increased|O
DDI-DrugBank.d545.s0|71-73|and|O
DDI-DrugBank.d545.s0|75-83|prolonged|O
DDI-DrugBank.d545.s0|85-86|by|O
DDI-DrugBank.d545.s0|88-97|concurrent|O
DDI-DrugBank.d545.s0|99-112|administration|O
DDI-DrugBank.d545.s0|114-115|of|O
DDI-DrugBank.d545.s0|117-126|probenecid|drug
DDI-DrugBank.d545.s0|127-127|.|O
DDI-DrugBank.d127.s0|0-1|No|O
DDI-DrugBank.d127.s0|3-8|formal|O
DDI-DrugBank.d127.s0|10-13|drug|O
DDI-DrugBank.d127.s0|15-25|interaction|O
DDI-DrugBank.d127.s0|27-33|studies|O
DDI-DrugBank.d127.s0|35-38|have|O
DDI-DrugBank.d127.s0|40-43|been|O
DDI-DrugBank.d127.s0|45-53|conducted|O
DDI-DrugBank.d127.s0|55-58|with|O
DDI-DrugBank.d127.s0|60-64|DOXIL|brand
DDI-DrugBank.d127.s0|67-67|.|O
DDI-DrugBank.d127.s1|0-4|Until|O
DDI-DrugBank.d127.s1|6-13|specific|O
DDI-DrugBank.d127.s1|15-27|compatibility|O
DDI-DrugBank.d127.s1|29-32|data|O
DDI-DrugBank.d127.s1|34-36|are|O
DDI-DrugBank.d127.s1|38-46|available|O
DDI-DrugBank.d127.s1|47-47|,|O
DDI-DrugBank.d127.s1|49-50|it|O
DDI-DrugBank.d127.s1|52-53|is|O
DDI-DrugBank.d127.s1|55-57|not|O
DDI-DrugBank.d127.s1|59-69|recommended|O
DDI-DrugBank.d127.s1|71-74|that|O
DDI-DrugBank.d127.s1|76-80|DOXIL|brand
DDI-DrugBank.d127.s1|83-84|be|O
DDI-DrugBank.d127.s1|86-90|mixed|O
DDI-DrugBank.d127.s1|92-95|with|O
DDI-DrugBank.d127.s1|97-101|other|O
DDI-DrugBank.d127.s1|103-107|drugs|O
DDI-DrugBank.d127.s1|108-108|.|O
DDI-DrugBank.d127.s2|0-4|DOXIL|brand
DDI-DrugBank.d127.s2|7-9|may|O
DDI-DrugBank.d127.s2|11-18|interact|O
DDI-DrugBank.d127.s2|20-23|with|O
DDI-DrugBank.d127.s2|25-29|drugs|O
DDI-DrugBank.d127.s2|31-35|known|O
DDI-DrugBank.d127.s2|37-38|to|O
DDI-DrugBank.d127.s2|40-47|interact|O
DDI-DrugBank.d127.s2|49-52|with|O
DDI-DrugBank.d127.s2|54-56|the|O
DDI-DrugBank.d127.s2|58-69|conventional|O
DDI-DrugBank.d127.s2|71-81|formulation|O
DDI-DrugBank.d127.s2|83-84|of|O
DDI-DrugBank.d127.s2|86-100|doxorubicin HCl|drug
DDI-DrugBank.d127.s2|101-101|.|O
DDI-MedLine.d119.s0|0-10|Development|O
DDI-MedLine.d119.s0|12-14|and|O
DDI-MedLine.d119.s0|16-27|pharmacology|O
DDI-MedLine.d119.s0|29-30|of|O
DDI-MedLine.d119.s0|32-42|fluvastatin|drug
DDI-MedLine.d119.s0|43-43|.|O
DDI-MedLine.d119.s1|0-10|Fluvastatin|drug
DDI-MedLine.d119.s1|12-13|is|O
DDI-MedLine.d119.s1|15-17|the|O
DDI-MedLine.d119.s1|19-23|first|O
DDI-MedLine.d119.s1|25-100|synthetic 3-hydroxy-3-methylglutaryl coenzyme A ( HMGCoA ) reductase inhibitor|group
DDI-MedLine.d119.s1|102-103|to|O
DDI-MedLine.d119.s1|105-106|be|O
DDI-MedLine.d119.s1|108-115|approved|O
DDI-MedLine.d119.s1|117-119|for|O
DDI-MedLine.d119.s1|121-128|clinical|O
DDI-MedLine.d119.s1|130-132|use|O
DDI-MedLine.d119.s1|133-133|,|O
DDI-MedLine.d119.s1|135-137|and|O
DDI-MedLine.d119.s1|139-141|has|O
DDI-MedLine.d119.s1|143-146|been|O
DDI-MedLine.d119.s1|148-154|studied|O
DDI-MedLine.d119.s1|156-166|extensively|O
DDI-MedLine.d119.s1|168-169|in|O
DDI-MedLine.d119.s1|171-176|humans|O
DDI-MedLine.d119.s1|178-182|since|O
DDI-MedLine.d119.s1|184-187|1986|O
DDI-MedLine.d119.s1|188-188|.|O
DDI-MedLine.d119.s2|0-1|It|O
DDI-MedLine.d119.s2|3-4|is|O
DDI-MedLine.d119.s2|6-17|structurally|O
DDI-MedLine.d119.s2|19-26|distinct|O
DDI-MedLine.d119.s2|28-31|from|O
DDI-MedLine.d119.s2|33-35|the|O
DDI-MedLine.d119.s2|37-41|other|O
DDI-MedLine.d119.s2|43-51|currently|O
DDI-MedLine.d119.s2|53-61|available|O
DDI-MedLine.d119.s2|63-89|HMGCoA reductase inhibitors|group
DDI-MedLine.d119.s2|91-91|(|O
DDI-MedLine.d119.s2|92-101|lovastatin|drug
DDI-MedLine.d119.s2|102-102|,|O
DDI-MedLine.d119.s2|104-114|simvastatin|drug
DDI-MedLine.d119.s2|115-115|,|O
DDI-MedLine.d119.s2|117-119|and|O
DDI-MedLine.d119.s2|121-131|pravastatin|drug
DDI-MedLine.d119.s2|132-132|)|O
DDI-MedLine.d119.s2|133-133|,|O
DDI-MedLine.d119.s2|135-141|leading|O
DDI-MedLine.d119.s2|143-144|to|O
DDI-MedLine.d119.s2|146-151|unique|O
DDI-MedLine.d119.s2|153-169|biopharmaceutical|O
DDI-MedLine.d119.s2|171-180|properties|O
DDI-MedLine.d119.s2|182-189|relative|O
DDI-MedLine.d119.s2|191-192|to|O
DDI-MedLine.d119.s2|194-196|the|O
DDI-MedLine.d119.s2|198-202|other|O
DDI-MedLine.d119.s2|204-209|agents|O
DDI-MedLine.d119.s2|211-212|of|O
DDI-MedLine.d119.s2|214-217|this|O
DDI-MedLine.d119.s2|219-223|class|O
DDI-MedLine.d119.s2|224-224|.|O
DDI-MedLine.d119.s3|0-9|Absorption|O
DDI-MedLine.d119.s3|11-12|of|O
DDI-MedLine.d119.s3|14-24|fluvastatin|drug
DDI-MedLine.d119.s3|26-27|is|O
DDI-MedLine.d119.s3|29-37|virtually|O
DDI-MedLine.d119.s3|39-46|complete|O
DDI-MedLine.d119.s3|48-53|across|O
DDI-MedLine.d119.s3|55-57|all|O
DDI-MedLine.d119.s3|59-65|species|O
DDI-MedLine.d119.s3|66-66|,|O
DDI-MedLine.d119.s3|68-76|including|O
DDI-MedLine.d119.s3|78-80|man|O
DDI-MedLine.d119.s3|81-81|,|O
DDI-MedLine.d119.s3|83-85|and|O
DDI-MedLine.d119.s3|87-88|is|O
DDI-MedLine.d119.s3|90-92|not|O
DDI-MedLine.d119.s3|94-101|affected|O
DDI-MedLine.d119.s3|103-104|by|O
DDI-MedLine.d119.s3|106-108|the|O
DDI-MedLine.d119.s3|110-117|presence|O
DDI-MedLine.d119.s3|119-120|of|O
DDI-MedLine.d119.s3|122-125|food|O
DDI-MedLine.d119.s3|126-126|.|O
DDI-MedLine.d119.s4|0-7|Systemic|O
DDI-MedLine.d119.s4|9-16|exposure|O
DDI-MedLine.d119.s4|18-19|is|O
DDI-MedLine.d119.s4|21-27|limited|O
DDI-MedLine.d119.s4|28-28|,|O
DDI-MedLine.d119.s4|30-31|as|O
DDI-MedLine.d119.s4|33-43|fluvastatin|drug
DDI-MedLine.d119.s4|45-46|is|O
DDI-MedLine.d119.s4|48-54|subject|O
DDI-MedLine.d119.s4|56-57|to|O
DDI-MedLine.d119.s4|59-68|first-pass|O
DDI-MedLine.d119.s4|70-79|metabolism|O
DDI-MedLine.d119.s4|80-80|,|O
DDI-MedLine.d119.s4|82-84|and|O
DDI-MedLine.d119.s4|86-88|the|O
DDI-MedLine.d119.s4|90-95|plasma|O
DDI-MedLine.d119.s4|97-105|half-life|O
DDI-MedLine.d119.s4|107-108|of|O
DDI-MedLine.d119.s4|110-112|the|O
DDI-MedLine.d119.s4|114-117|drug|O
DDI-MedLine.d119.s4|119-120|is|O
DDI-MedLine.d119.s4|122-134|approximately|O
DDI-MedLine.d119.s4|136-137|30|O
DDI-MedLine.d119.s4|139-145|minutes|O
DDI-MedLine.d119.s4|146-146|.|O
DDI-MedLine.d119.s5|0-3|Some|O
DDI-MedLine.d119.s5|5-6|95|O
DDI-MedLine.d119.s5|7-7|%|O
DDI-MedLine.d119.s5|9-10|of|O
DDI-MedLine.d119.s5|12-12|a|O
DDI-MedLine.d119.s5|14-19|single|O
DDI-MedLine.d119.s5|21-26|dosage|O
DDI-MedLine.d119.s5|28-29|of|O
DDI-MedLine.d119.s5|31-41|fluvastatin|drug
DDI-MedLine.d119.s5|43-44|is|O
DDI-MedLine.d119.s5|46-53|excreted|O
DDI-MedLine.d119.s5|55-57|via|O
DDI-MedLine.d119.s5|59-61|the|O
DDI-MedLine.d119.s5|63-69|biliary|O
DDI-MedLine.d119.s5|71-75|route|O
DDI-MedLine.d119.s5|76-76|,|O
DDI-MedLine.d119.s5|78-81|with|O
DDI-MedLine.d119.s5|83-86|less|O
DDI-MedLine.d119.s5|88-91|than|O
DDI-MedLine.d119.s5|93-93|2|O
DDI-MedLine.d119.s5|94-94|%|O
DDI-MedLine.d119.s5|96-97|of|O
DDI-MedLine.d119.s5|99-102|this|O
DDI-MedLine.d119.s5|104-108|being|O
DDI-MedLine.d119.s5|110-112|the|O
DDI-MedLine.d119.s5|114-119|parent|O
DDI-MedLine.d119.s5|121-128|compound|O
DDI-MedLine.d119.s5|129-129|.|O
DDI-MedLine.d119.s6|0-11|Additionally|O
DDI-MedLine.d119.s6|12-12|,|O
DDI-MedLine.d119.s6|14-18|there|O
DDI-MedLine.d119.s6|20-21|is|O
DDI-MedLine.d119.s6|23-24|no|O
DDI-MedLine.d119.s6|26-33|evidence|O
DDI-MedLine.d119.s6|35-36|of|O
DDI-MedLine.d119.s6|38-48|circulating|O
DDI-MedLine.d119.s6|50-55|active|O
DDI-MedLine.d119.s6|57-67|metabolites|O
DDI-MedLine.d119.s6|69-70|or|O
DDI-MedLine.d119.s6|72-83|accumulation|O
DDI-MedLine.d119.s6|85-90|during|O
DDI-MedLine.d119.s6|92-98|chronic|O
DDI-MedLine.d119.s6|100-105|dosing|O
DDI-MedLine.d119.s6|106-106|.|O
DDI-MedLine.d119.s7|0-6|Studies|O
DDI-MedLine.d119.s7|8-9|of|O
DDI-MedLine.d119.s7|11-13|the|O
DDI-MedLine.d119.s7|15-20|effect|O
DDI-MedLine.d119.s7|22-23|of|O
DDI-MedLine.d119.s7|25-28|food|O
DDI-MedLine.d119.s7|30-31|on|O
DDI-MedLine.d119.s7|33-35|the|O
DDI-MedLine.d119.s7|37-52|pharmacokinetics|O
DDI-MedLine.d119.s7|54-55|of|O
DDI-MedLine.d119.s7|57-67|fluvastatin|drug
DDI-MedLine.d119.s7|69-72|have|O
DDI-MedLine.d119.s7|74-85|demonstrated|O
DDI-MedLine.d119.s7|87-92|marked|O
DDI-MedLine.d119.s7|94-103|reductions|O
DDI-MedLine.d119.s7|105-106|in|O
DDI-MedLine.d119.s7|108-110|the|O
DDI-MedLine.d119.s7|112-115|rate|O
DDI-MedLine.d119.s7|117-118|of|O
DDI-MedLine.d119.s7|120-134|bioavailability|O
DDI-MedLine.d119.s7|135-136|--|O
DDI-MedLine.d119.s7|137-140|from|O
DDI-MedLine.d119.s7|142-143|40|O
DDI-MedLine.d119.s7|144-144|%|O
DDI-MedLine.d119.s7|146-147|to|O
DDI-MedLine.d119.s7|149-150|60|O
DDI-MedLine.d119.s7|151-151|%|O
DDI-MedLine.d119.s7|152-152|;|O
DDI-MedLine.d119.s8|0-6|however|O
DDI-MedLine.d119.s8|7-7|,|O
DDI-MedLine.d119.s8|9-9|a|O
DDI-MedLine.d119.s8|11-20|comparison|O
DDI-MedLine.d119.s8|22-23|of|O
DDI-MedLine.d119.s8|25-35|fluvastatin|drug
DDI-MedLine.d119.s8|37-50|administration|O
DDI-MedLine.d119.s8|52-55|with|O
DDI-MedLine.d119.s8|57-59|the|O
DDI-MedLine.d119.s8|61-67|evening|O
DDI-MedLine.d119.s8|69-72|meal|O
DDI-MedLine.d119.s8|74-75|or|O
DDI-MedLine.d119.s8|77-78|at|O
DDI-MedLine.d119.s8|80-86|bedtime|O
DDI-MedLine.d119.s8|88-90|has|O
DDI-MedLine.d119.s8|92-99|revealed|O
DDI-MedLine.d119.s8|101-102|no|O
DDI-MedLine.d119.s8|104-114|significant|O
DDI-MedLine.d119.s8|116-126|differences|O
DDI-MedLine.d119.s8|128-129|in|O
DDI-MedLine.d119.s8|131-133|the|O
DDI-MedLine.d119.s8|135-140|extent|O
DDI-MedLine.d119.s8|142-143|of|O
DDI-MedLine.d119.s8|145-159|bioavailability|O
DDI-MedLine.d119.s8|161-161|(|O
DDI-MedLine.d119.s8|162-165|area|O
DDI-MedLine.d119.s8|167-171|under|O
DDI-MedLine.d119.s8|173-175|the|O
DDI-MedLine.d119.s8|177-181|curve|O
DDI-MedLine.d119.s8|182-182|)|O
DDI-MedLine.d119.s8|184-185|of|O
DDI-MedLine.d119.s8|187-191|these|O
DDI-MedLine.d119.s8|193-195|two|O
DDI-MedLine.d119.s8|197-204|regimens|O
DDI-MedLine.d119.s8|205-205|.|O
DDI-MedLine.d119.s9|0-10|Furthermore|O
DDI-MedLine.d119.s9|11-11|,|O
DDI-MedLine.d119.s9|13-14|no|O
DDI-MedLine.d119.s9|16-26|significant|O
DDI-MedLine.d119.s9|28-37|difference|O
DDI-MedLine.d119.s9|39-40|in|O
DDI-MedLine.d119.s9|42-56|pharmacodynamic|O
DDI-MedLine.d119.s9|58-63|effect|O
DDI-MedLine.d119.s9|65-65|(|O
DDI-MedLine.d119.s9|66-74|reduction|O
DDI-MedLine.d119.s9|76-77|in|O
DDI-MedLine.d119.s9|79-89|low-density|O
DDI-MedLine.d119.s9|91-101|lipoprotein|O
DDI-MedLine.d119.s9|103-113|cholesterol|O
DDI-MedLine.d119.s9|115-120|levels|O
DDI-MedLine.d119.s9|121-121|)|O
DDI-MedLine.d119.s9|123-127|could|O
DDI-MedLine.d119.s9|129-130|be|O
DDI-MedLine.d119.s9|132-142|ascertained|O
DDI-MedLine.d119.s9|144-150|between|O
DDI-MedLine.d119.s9|152-159|mealtime|O
DDI-MedLine.d119.s9|161-166|dosing|O
DDI-MedLine.d119.s9|168-170|and|O
DDI-MedLine.d119.s9|172-178|bedtime|O
DDI-MedLine.d119.s9|180-185|dosing|O
DDI-MedLine.d119.s9|186-186|.|O
DDI-MedLine.d119.s10|0-2|The|O
DDI-MedLine.d119.s10|4-19|pharmacokinetics|O
DDI-MedLine.d119.s10|21-22|of|O
DDI-MedLine.d119.s10|24-34|fluvastatin|drug
DDI-MedLine.d119.s10|36-39|have|O
DDI-MedLine.d119.s10|41-44|also|O
DDI-MedLine.d119.s10|46-49|been|O
DDI-MedLine.d119.s10|51-58|assessed|O
DDI-MedLine.d119.s10|60-61|in|O
DDI-MedLine.d119.s10|63-69|various|O
DDI-MedLine.d119.s10|71-81|demographic|O
DDI-MedLine.d119.s10|83-88|groups|O
DDI-MedLine.d119.s10|89-89|.|O
DDI-MedLine.d119.s11|0-7|Relative|O
DDI-MedLine.d119.s11|9-10|to|O
DDI-MedLine.d119.s11|12-14|the|O
DDI-MedLine.d119.s11|16-22|general|O
DDI-MedLine.d119.s11|24-33|population|O
DDI-MedLine.d119.s11|34-34|,|O
DDI-MedLine.d119.s11|36-41|plasma|O
DDI-MedLine.d119.s11|43-56|concentrations|O
DDI-MedLine.d119.s11|58-59|of|O
DDI-MedLine.d119.s11|61-71|fluvastatin|drug
DDI-MedLine.d119.s11|73-74|do|O
DDI-MedLine.d119.s11|76-78|not|O
DDI-MedLine.d119.s11|80-83|vary|O
DDI-MedLine.d119.s11|85-86|as|O
DDI-MedLine.d119.s11|88-88|a|O
DDI-MedLine.d119.s11|90-97|function|O
DDI-MedLine.d119.s11|99-100|of|O
DDI-MedLine.d119.s11|102-107|either|O
DDI-MedLine.d119.s11|109-111|age|O
DDI-MedLine.d119.s11|113-114|or|O
DDI-MedLine.d119.s11|116-121|gender|O
DDI-MedLine.d119.s11|122-122|.|O
DDI-MedLine.d119.s12|0-1|In|O
DDI-MedLine.d119.s12|3-10|addition|O
DDI-MedLine.d119.s12|11-11|,|O
DDI-MedLine.d119.s12|13-26|administration|O
DDI-MedLine.d119.s12|28-29|to|O
DDI-MedLine.d119.s12|31-31|a|O
DDI-MedLine.d119.s12|33-39|patient|O
DDI-MedLine.d119.s12|41-50|population|O
DDI-MedLine.d119.s12|52-55|with|O
DDI-MedLine.d119.s12|57-63|hepatic|O
DDI-MedLine.d119.s12|65-77|insufficiency|O
DDI-MedLine.d119.s12|79-86|resulted|O
DDI-MedLine.d119.s12|88-89|in|O
DDI-MedLine.d119.s12|91-91|a|O
DDI-MedLine.d119.s12|93-100|2.5-fold|O
DDI-MedLine.d119.s12|102-109|increase|O
DDI-MedLine.d119.s12|111-112|in|O
DDI-MedLine.d119.s12|114-117|both|O
DDI-MedLine.d119.s12|119-121|the|O
DDI-MedLine.d119.s12|123-126|rate|O
DDI-MedLine.d119.s12|128-130|and|O
DDI-MedLine.d119.s12|132-137|extent|O
DDI-MedLine.d119.s12|139-140|of|O
DDI-MedLine.d119.s12|142-156|bioavailability|O
DDI-MedLine.d119.s12|158-165|relative|O
DDI-MedLine.d119.s12|167-168|to|O
DDI-MedLine.d119.s12|170-177|controls|O
DDI-MedLine.d119.s12|178-178|.|O
DDI-MedLine.d119.s13|0-3|Also|O
DDI-MedLine.d119.s13|4-4|,|O
DDI-MedLine.d119.s13|6-13|although|O
DDI-MedLine.d119.s13|15-21|minimal|O
DDI-MedLine.d119.s13|23-33|alterations|O
DDI-MedLine.d119.s13|35-36|of|O
DDI-MedLine.d119.s13|38-48|fluvastatin|drug
DDI-MedLine.d119.s13|50-58|clearance|O
DDI-MedLine.d119.s13|60-61|in|O
DDI-MedLine.d119.s13|63-70|patients|O
DDI-MedLine.d119.s13|72-75|with|O
DDI-MedLine.d119.s13|77-81|renal|O
DDI-MedLine.d119.s13|83-95|insufficiency|O
DDI-MedLine.d119.s13|97-99|are|O
DDI-MedLine.d119.s13|101-111|anticipated|O
DDI-MedLine.d119.s13|113-115|due|O
DDI-MedLine.d119.s13|117-118|to|O
DDI-MedLine.d119.s13|120-126|limited|O
DDI-MedLine.d119.s13|128-132|renal|O
DDI-MedLine.d119.s13|134-142|excretion|O
DDI-MedLine.d119.s13|144-144|(|O
DDI-MedLine.d119.s13|145-145|5|O
DDI-MedLine.d119.s13|146-146|%|O
DDI-MedLine.d119.s13|147-147|)|O
DDI-MedLine.d119.s13|148-148|,|O
DDI-MedLine.d119.s13|150-150|a|O
DDI-MedLine.d119.s13|152-156|study|O
DDI-MedLine.d119.s13|158-159|in|O
DDI-MedLine.d119.s13|161-164|this|O
DDI-MedLine.d119.s13|166-172|patient|O
DDI-MedLine.d119.s13|174-178|group|O
DDI-MedLine.d119.s13|180-181|is|O
DDI-MedLine.d119.s13|183-191|currently|O
DDI-MedLine.d119.s13|193-200|underway|O
DDI-MedLine.d119.s13|202-203|to|O
DDI-MedLine.d119.s13|205-211|examine|O
DDI-MedLine.d119.s13|213-216|this|O
DDI-MedLine.d119.s13|218-224|further|O
DDI-MedLine.d119.s13|225-225|.|O
DDI-MedLine.d119.s14|0-10|Interaction|O
DDI-MedLine.d119.s14|12-18|studies|O
DDI-MedLine.d119.s14|20-23|have|O
DDI-MedLine.d119.s14|25-28|been|O
DDI-MedLine.d119.s14|30-38|performed|O
DDI-MedLine.d119.s14|40-43|with|O
DDI-MedLine.d119.s14|45-55|fluvastatin|drug
DDI-MedLine.d119.s14|57-59|and|O
DDI-MedLine.d119.s14|61-67|several|O
DDI-MedLine.d119.s14|69-73|drugs|O
DDI-MedLine.d119.s14|75-78|with|O
DDI-MedLine.d119.s14|80-84|which|O
DDI-MedLine.d119.s14|86-87|it|O
DDI-MedLine.d119.s14|89-93|might|O
DDI-MedLine.d119.s14|95-96|be|O
DDI-MedLine.d119.s14|98-111|coadministered|O
DDI-MedLine.d119.s14|112-112|.|O
DDI-MedLine.d119.s15|0-13|Cholestyramine|drug
DDI-MedLine.d119.s15|14-14|,|O
DDI-MedLine.d119.s15|16-17|an|O
DDI-MedLine.d119.s15|19-33|anionic-binding|O
DDI-MedLine.d119.s15|35-39|resin|O
DDI-MedLine.d119.s15|40-40|,|O
DDI-MedLine.d119.s15|42-44|has|O
DDI-MedLine.d119.s15|46-46|a|O
DDI-MedLine.d119.s15|48-59|considerable|O
DDI-MedLine.d119.s15|61-66|effect|O
DDI-MedLine.d119.s15|68-69|in|O
DDI-MedLine.d119.s15|71-78|lowering|O
DDI-MedLine.d119.s15|80-82|the|O
DDI-MedLine.d119.s15|84-87|rate|O
DDI-MedLine.d119.s15|89-91|and|O
DDI-MedLine.d119.s15|93-98|extent|O
DDI-MedLine.d119.s15|100-101|of|O
DDI-MedLine.d119.s15|103-113|fluvastatin|drug
DDI-MedLine.d119.s15|115-129|bioavailability|O
DDI-MedLine.d119.s15|130-130|.|O
DDI-MedLine.d119.s16|0-7|Although|O
DDI-MedLine.d119.s16|9-12|this|O
DDI-MedLine.d119.s16|14-19|effect|O
DDI-MedLine.d119.s16|21-23|was|O
DDI-MedLine.d119.s16|25-29|noted|O
DDI-MedLine.d119.s16|31-34|even|O
DDI-MedLine.d119.s16|36-39|when|O
DDI-MedLine.d119.s16|41-54|cholestyramine|drug
DDI-MedLine.d119.s16|56-58|was|O
DDI-MedLine.d119.s16|60-64|given|O
DDI-MedLine.d119.s16|66-66|4|O
DDI-MedLine.d119.s16|68-72|hours|O
DDI-MedLine.d119.s16|74-78|prior|O
DDI-MedLine.d119.s16|80-81|to|O
DDI-MedLine.d119.s16|83-93|fluvastatin|drug
DDI-MedLine.d119.s16|94-94|,|O
DDI-MedLine.d119.s16|96-99|this|O
DDI-MedLine.d119.s16|101-107|regimen|O
DDI-MedLine.d119.s16|109-111|did|O
DDI-MedLine.d119.s16|113-115|not|O
DDI-MedLine.d119.s16|117-122|result|O
DDI-MedLine.d119.s16|124-125|in|O
DDI-MedLine.d119.s16|127-136|diminished|O
DDI-MedLine.d119.s16|138-145|efficacy|O
DDI-MedLine.d119.s16|146-146|.|O
DDI-MedLine.d119.s17|0-6|Further|O
DDI-MedLine.d119.s17|7-7|,|O
DDI-MedLine.d119.s17|9-10|no|O
DDI-MedLine.d119.s17|12-18|effects|O
DDI-MedLine.d119.s17|20-21|on|O
DDI-MedLine.d119.s17|23-28|either|O
DDI-MedLine.d119.s17|30-37|warfarin|drug
DDI-MedLine.d119.s17|39-44|levels|O
DDI-MedLine.d119.s17|46-47|or|O
DDI-MedLine.d119.s17|49-59|prothrombin|O
DDI-MedLine.d119.s17|61-65|times|O
DDI-MedLine.d119.s17|67-70|were|O
DDI-MedLine.d119.s17|72-79|observed|O
DDI-MedLine.d119.s17|81-82|in|O
DDI-MedLine.d119.s17|84-84|a|O
DDI-MedLine.d119.s17|86-90|study|O
DDI-MedLine.d119.s17|92-100|involving|O
DDI-MedLine.d119.s17|102-112|concomitant|O
DDI-MedLine.d119.s17|114-127|administration|O
DDI-MedLine.d119.s17|129-130|of|O
DDI-MedLine.d119.s17|132-139|warfarin|drug
DDI-MedLine.d119.s17|141-143|and|O
DDI-MedLine.d119.s17|145-155|fluvastatin|drug
DDI-MedLine.d119.s17|156-156|.|O
DDI-MedLine.d119.s18|0-7|Moreover|O
DDI-MedLine.d119.s18|8-8|,|O
DDI-MedLine.d119.s18|10-19|additional|O
DDI-MedLine.d119.s18|21-31|interaction|O
DDI-MedLine.d119.s18|33-39|studies|O
DDI-MedLine.d119.s18|41-44|with|O
DDI-MedLine.d119.s18|46-51|niacin|drug
DDI-MedLine.d119.s18|53-55|and|O
DDI-MedLine.d119.s18|57-67|propranolol|drug
DDI-MedLine.d119.s18|69-72|have|O
DDI-MedLine.d119.s18|74-76|not|O
DDI-MedLine.d119.s18|78-89|demonstrated|O
DDI-MedLine.d119.s18|91-93|any|O
DDI-MedLine.d119.s18|95-100|effect|O
DDI-MedLine.d119.s18|102-103|on|O
DDI-MedLine.d119.s18|105-115|fluvastatin|drug
DDI-MedLine.d119.s18|117-122|plasma|O
DDI-MedLine.d119.s18|124-129|levels|O
DDI-MedLine.d119.s18|130-130|,|O
DDI-MedLine.d119.s18|132-134|and|O
DDI-MedLine.d119.s18|136-149|administration|O
DDI-MedLine.d119.s18|151-152|to|O
DDI-MedLine.d119.s18|154-154|a|O
DDI-MedLine.d119.s18|156-162|patient|O
DDI-MedLine.d119.s18|164-173|population|O
DDI-MedLine.d119.s18|175-185|chronically|O
DDI-MedLine.d119.s18|187-195|receiving|O
DDI-MedLine.d119.s18|197-203|digoxin|drug
DDI-MedLine.d119.s18|205-212|resulted|O
DDI-MedLine.d119.s18|214-215|in|O
DDI-MedLine.d119.s18|217-218|no|O
DDI-MedLine.d119.s18|220-229|difference|O
DDI-MedLine.d119.s18|231-232|in|O
DDI-MedLine.d119.s18|234-236|the|O
DDI-MedLine.d119.s18|238-243|extent|O
DDI-MedLine.d119.s18|245-246|of|O
DDI-MedLine.d119.s18|248-262|bioavailability|O
DDI-MedLine.d119.s18|264-265|of|O
DDI-MedLine.d119.s18|267-273|digoxin|drug
DDI-MedLine.d119.s18|275-282|relative|O
DDI-MedLine.d119.s18|284-285|to|O
DDI-MedLine.d119.s18|287-293|control|O
DDI-MedLine.d119.s18|295-298|data|O
DDI-MedLine.d119.s18|299-299|.|O
DDI-MedLine.d119.s19|0-2|The|O
DDI-MedLine.d119.s19|4-10|results|O
DDI-MedLine.d119.s19|12-20|generated|O
DDI-MedLine.d119.s19|22-23|to|O
DDI-MedLine.d119.s19|25-28|date|O
DDI-MedLine.d119.s19|30-31|in|O
DDI-MedLine.d119.s19|33-40|clinical|O
DDI-MedLine.d119.s19|42-56|pharmacokinetic|O
DDI-MedLine.d119.s19|58-64|studies|O
DDI-MedLine.d119.s19|66-69|with|O
DDI-MedLine.d119.s19|71-81|fluvastatin|drug
DDI-MedLine.d119.s19|83-86|thus|O
DDI-MedLine.d119.s19|88-94|support|O
DDI-MedLine.d119.s19|96-98|its|O
DDI-MedLine.d119.s19|100-102|use|O
DDI-MedLine.d119.s19|104-105|in|O
DDI-MedLine.d119.s19|107-107|a|O
DDI-MedLine.d119.s19|109-113|broad|O
DDI-MedLine.d119.s19|115-124|population|O
DDI-MedLine.d119.s19|126-127|of|O
DDI-MedLine.d119.s19|129-149|hypercholesterolaemic|O
DDI-MedLine.d119.s19|151-158|patients|O
DDI-MedLine.d119.s19|159-159|.|O
DDI-MedLine.d166.s0|0-7|Improved|O
DDI-MedLine.d166.s0|9-19|parathyroid|O
DDI-MedLine.d166.s0|21-27|hormone|O
DDI-MedLine.d166.s0|29-35|control|O
DDI-MedLine.d166.s0|37-38|by|O
DDI-MedLine.d166.s0|40-49|cinacalcet|drug
DDI-MedLine.d166.s0|51-52|is|O
DDI-MedLine.d166.s0|54-63|associated|O
DDI-MedLine.d166.s0|65-68|with|O
DDI-MedLine.d166.s0|70-78|reduction|O
DDI-MedLine.d166.s0|80-81|in|O
DDI-MedLine.d166.s0|83-93|darbepoetin|drug
DDI-MedLine.d166.s0|95-105|requirement|O
DDI-MedLine.d166.s0|107-108|in|O
DDI-MedLine.d166.s0|110-117|patients|O
DDI-MedLine.d166.s0|119-122|with|O
DDI-MedLine.d166.s0|124-132|end-stage|O
DDI-MedLine.d166.s0|134-138|renal|O
DDI-MedLine.d166.s0|140-146|disease|O
DDI-MedLine.d166.s0|147-147|.|O
DDI-MedLine.d166.s1|0-11|Uncontrolled|O
DDI-MedLine.d166.s1|13-33|hy-per-parathyroidism|O
DDI-MedLine.d166.s1|35-40|causes|O
DDI-MedLine.d166.s1|42-45|bone|O
DDI-MedLine.d166.s1|47-52|marrow|O
DDI-MedLine.d166.s1|54-61|fibrosis|O
DDI-MedLine.d166.s1|62-62|,|O
DDI-MedLine.d166.s1|64-70|leading|O
DDI-MedLine.d166.s1|72-73|to|O
DDI-MedLine.d166.s1|75-88|erythropoietin|drug
DDI-MedLine.d166.s1|90-90|(|O
DDI-MedLine.d166.s1|91-93|EPO|drug
DDI-MedLine.d166.s1|94-94|)|O
DDI-MedLine.d166.s1|96-105|resistance|O
DDI-MedLine.d166.s1|106-106|.|O
DDI-MedLine.d166.s2|0-6|Medical|O
DDI-MedLine.d166.s2|8-16|treatment|O
DDI-MedLine.d166.s2|18-21|with|O
DDI-MedLine.d166.s2|23-32|cinacalcet|drug
DDI-MedLine.d166.s2|34-35|is|O
DDI-MedLine.d166.s2|37-45|effective|O
DDI-MedLine.d166.s2|47-48|in|O
DDI-MedLine.d166.s2|50-57|reducing|O
DDI-MedLine.d166.s2|59-64|plasma|O
DDI-MedLine.d166.s2|66-76|parathyroid|O
DDI-MedLine.d166.s2|78-84|hormone|O
DDI-MedLine.d166.s2|86-86|(|O
DDI-MedLine.d166.s2|87-89|PTH|O
DDI-MedLine.d166.s2|90-90|)|O
DDI-MedLine.d166.s2|92-97|levels|O
DDI-MedLine.d166.s2|98-98|,|O
DDI-MedLine.d166.s2|100-102|but|O
DDI-MedLine.d166.s2|104-106|its|O
DDI-MedLine.d166.s2|108-113|effect|O
DDI-MedLine.d166.s2|115-116|on|O
DDI-MedLine.d166.s2|118-128|darbepoetin|drug
DDI-MedLine.d166.s2|130-135|dosing|O
DDI-MedLine.d166.s2|137-138|is|O
DDI-MedLine.d166.s2|140-146|unknown|O
DDI-MedLine.d166.s2|147-147|.|O
DDI-MedLine.d166.s3|0-6|METHODS|O
DDI-MedLine.d166.s3|8-10|AND|O
DDI-MedLine.d166.s3|12-15|AIMS|O
DDI-MedLine.d166.s3|16-16|:|O
DDI-MedLine.d166.s3|18-19|We|O
DDI-MedLine.d166.s3|21-29|conducted|O
DDI-MedLine.d166.s3|31-31|a|O
DDI-MedLine.d166.s3|33-45|retrospective|O
DDI-MedLine.d166.s3|47-52|cohort|O
DDI-MedLine.d166.s3|54-58|study|O
DDI-MedLine.d166.s3|60-61|of|O
DDI-MedLine.d166.s3|63-64|40|O
DDI-MedLine.d166.s3|66-74|end-stage|O
DDI-MedLine.d166.s3|76-80|renal|O
DDI-MedLine.d166.s3|82-88|disease|O
DDI-MedLine.d166.s3|90-90|(|O
DDI-MedLine.d166.s3|91-94|ESRD|O
DDI-MedLine.d166.s3|95-95|)|O
DDI-MedLine.d166.s3|97-104|patients|O
DDI-MedLine.d166.s3|106-106|(|O
DDI-MedLine.d166.s3|107-109|age|O
DDI-MedLine.d166.s3|110-110|:|O
DDI-MedLine.d166.s3|112-113|55|O
DDI-MedLine.d166.s3|118-119|14|O
DDI-MedLine.d166.s3|120-120|;|O
DDI-MedLine.d166.s3|122-125|mean|O
DDI-MedLine.d166.s3|130-131|SD|O
DDI-MedLine.d166.s3|132-132|;|O
DDI-MedLine.d166.s3|134-135|21|O
DDI-MedLine.d166.s3|136-136|:|O
DDI-MedLine.d166.s3|137-140|male|O
DDI-MedLine.d166.s3|141-141|)|O
DDI-MedLine.d166.s3|143-145|who|O
DDI-MedLine.d166.s3|147-149|had|O
DDI-MedLine.d166.s3|151-152|at|O
DDI-MedLine.d166.s3|154-158|least|O
DDI-MedLine.d166.s3|160-161|12|O
DDI-MedLine.d166.s3|163-168|months|O
DDI-MedLine.d166.s3|170-171|of|O
DDI-MedLine.d166.s3|173-182|cinacalcet|drug
DDI-MedLine.d166.s3|184-190|therapy|O
DDI-MedLine.d166.s3|191-191|.|O
DDI-MedLine.d166.s4|0-2|The|O
DDI-MedLine.d166.s4|4-15|distribution|O
DDI-MedLine.d166.s4|17-18|of|O
DDI-MedLine.d166.s4|20-24|renal|O
DDI-MedLine.d166.s4|26-36|replacement|O
DDI-MedLine.d166.s4|38-46|therapies|O
DDI-MedLine.d166.s4|48-51|were|O
DDI-MedLine.d166.s4|52-52|:|O
DDI-MedLine.d166.s4|54-55|14|O
DDI-MedLine.d166.s4|57-66|peritoneal|O
DDI-MedLine.d166.s4|68-75|dialysis|O
DDI-MedLine.d166.s4|76-76|,|O
DDI-MedLine.d166.s4|78-79|18|O
DDI-MedLine.d166.s4|81-92|conventional|O
DDI-MedLine.d166.s4|94-105|hemodialysis|O
DDI-MedLine.d166.s4|107-109|and|O
DDI-MedLine.d166.s4|111-111|8|O
DDI-MedLine.d166.s4|113-121|nocturnal|O
DDI-MedLine.d166.s4|123-134|hemodialysis|O
DDI-MedLine.d166.s4|135-135|.|O
DDI-MedLine.d166.s5|0-7|Standard|O
DDI-MedLine.d166.s5|9-16|dialysis|O
DDI-MedLine.d166.s5|18-24|related|O
DDI-MedLine.d166.s5|26-36|biochemical|O
DDI-MedLine.d166.s5|38-44|indices|O
DDI-MedLine.d166.s5|46-48|and|O
DDI-MedLine.d166.s5|50-60|medications|O
DDI-MedLine.d166.s5|62-65|used|O
DDI-MedLine.d166.s5|67-70|were|O
DDI-MedLine.d166.s5|72-79|recorded|O
DDI-MedLine.d166.s5|80-80|.|O
DDI-MedLine.d166.s6|0-2|The|O
DDI-MedLine.d166.s6|4-10|primary|O
DDI-MedLine.d166.s6|12-20|objective|O
DDI-MedLine.d166.s6|22-23|of|O
DDI-MedLine.d166.s6|25-27|the|O
DDI-MedLine.d166.s6|29-33|study|O
DDI-MedLine.d166.s6|35-37|was|O
DDI-MedLine.d166.s6|39-40|to|O
DDI-MedLine.d166.s6|42-50|ascertain|O
DDI-MedLine.d166.s6|52-54|the|O
DDI-MedLine.d166.s6|56-65|difference|O
DDI-MedLine.d166.s6|67-68|in|O
DDI-MedLine.d166.s6|70-80|darbepoetin|drug
DDI-MedLine.d166.s6|82-95|responsiveness|O
DDI-MedLine.d166.s6|97-102|before|O
DDI-MedLine.d166.s6|104-106|and|O
DDI-MedLine.d166.s6|108-112|after|O
DDI-MedLine.d166.s6|114-115|12|O
DDI-MedLine.d166.s6|117-122|months|O
DDI-MedLine.d166.s6|124-125|of|O
DDI-MedLine.d166.s6|127-136|cinacalcet|drug
DDI-MedLine.d166.s6|138-144|therapy|O
DDI-MedLine.d166.s6|145-145|.|O
DDI-MedLine.d166.s7|0-2|Our|O
DDI-MedLine.d166.s7|4-12|secondary|O
DDI-MedLine.d166.s7|14-22|objective|O
DDI-MedLine.d166.s7|24-26|was|O
DDI-MedLine.d166.s7|28-29|to|O
DDI-MedLine.d166.s7|31-39|determine|O
DDI-MedLine.d166.s7|41-42|if|O
DDI-MedLine.d166.s7|44-48|there|O
DDI-MedLine.d166.s7|50-52|was|O
DDI-MedLine.d166.s7|54-54|a|O
DDI-MedLine.d166.s7|56-67|relationship|O
DDI-MedLine.d166.s7|69-75|between|O
DDI-MedLine.d166.s7|77-79|the|O
DDI-MedLine.d166.s7|81-87|changes|O
DDI-MedLine.d166.s7|89-90|in|O
DDI-MedLine.d166.s7|92-94|PTH|O
DDI-MedLine.d166.s7|96-98|and|O
DDI-MedLine.d166.s7|100-110|darbepoetin|drug
DDI-MedLine.d166.s7|112-122|requirement|O
DDI-MedLine.d166.s7|123-123|.|O
DDI-MedLine.d166.s8|0-6|Overall|O
DDI-MedLine.d166.s8|7-7|,|O
DDI-MedLine.d166.s8|9-11|PTH|O
DDI-MedLine.d166.s8|13-18|levels|O
DDI-MedLine.d166.s8|20-28|decreased|O
DDI-MedLine.d166.s8|30-33|from|O
DDI-MedLine.d166.s8|35-39|197.5|O
DDI-MedLine.d166.s8|41-41|(|O
DDI-MedLine.d166.s8|42-46|151.8|O
DDI-MedLine.d166.s8|47-47|;|O
DDI-MedLine.d166.s8|49-53|249.2|O
DDI-MedLine.d166.s8|54-54|)|O
DDI-MedLine.d166.s8|56-57|to|O
DDI-MedLine.d166.s8|59-62|66.1|O
DDI-MedLine.d166.s8|64-64|(|O
DDI-MedLine.d166.s8|65-68|41.2|O
DDI-MedLine.d166.s8|69-69|;|O
DDI-MedLine.d166.s8|71-75|136.5|O
DDI-MedLine.d166.s8|76-76|)|O
DDI-MedLine.d166.s8|78-78|(|O
DDI-MedLine.d166.s8|79-84|median|O
DDI-MedLine.d166.s8|86-86|(|O
DDI-MedLine.d166.s8|87-90|25th|O
DDI-MedLine.d166.s8|91-91|;|O
DDI-MedLine.d166.s8|92-95|75th|O
DDI-MedLine.d166.s8|97-106|percentile|O
DDI-MedLine.d166.s8|107-107|)|O
DDI-MedLine.d166.s8|108-108|)|O
DDI-MedLine.d166.s8|110-115|pmol/l|O
DDI-MedLine.d166.s8|116-116|;|O
DDI-MedLine.d166.s9|0-0|p|O
DDI-MedLine.d166.s9|2-2|&|O
DDI-MedLine.d166.s9|3-4|lt|O
DDI-MedLine.d166.s9|5-5|;|O
DDI-MedLine.d166.s10|0-4|0.001|O
DDI-MedLine.d166.s10|5-5|.|O
DDI-MedLine.d166.s11|0-9|Cinacalcet|drug
DDI-MedLine.d166.s11|11-14|dose|O
DDI-MedLine.d166.s11|16-24|increased|O
DDI-MedLine.d166.s11|26-29|from|O
DDI-MedLine.d166.s11|31-34|30.0|O
DDI-MedLine.d166.s11|38-38|6|O
DDI-MedLine.d166.s11|40-41|to|O
DDI-MedLine.d166.s11|43-44|63|O
DDI-MedLine.d166.s11|48-49|25|O
DDI-MedLine.d166.s11|51-56|mg/day|O
DDI-MedLine.d166.s11|57-57|,|O
DDI-MedLine.d166.s11|59-59|p|O
DDI-MedLine.d166.s11|61-61|<|O
DDI-MedLine.d166.s12|0-3|0.05|O
DDI-MedLine.d166.s12|4-4|.|O
DDI-MedLine.d166.s13|0-9|Hemoglobin|O
DDI-MedLine.d166.s13|11-18|remained|O
DDI-MedLine.d166.s13|20-28|unchanged|O
DDI-MedLine.d166.s13|30-30|(|O
DDI-MedLine.d166.s13|31-33|116|O
DDI-MedLine.d166.s13|37-38|13|O
DDI-MedLine.d166.s13|40-41|to|O
DDI-MedLine.d166.s13|43-45|116|O
DDI-MedLine.d166.s13|49-50|13|O
DDI-MedLine.d166.s13|52-54|g/l|O
DDI-MedLine.d166.s13|55-55|)|O
DDI-MedLine.d166.s13|56-56|,|O
DDI-MedLine.d166.s13|58-62|while|O
DDI-MedLine.d166.s13|64-74|darbepoetin|drug
DDI-MedLine.d166.s13|76-86|requirement|O
DDI-MedLine.d166.s13|88-96|decreased|O
DDI-MedLine.d166.s13|98-101|from|O
DDI-MedLine.d166.s13|103-104|40|O
DDI-MedLine.d166.s13|106-106|(|O
DDI-MedLine.d166.s13|107-108|20|O
DDI-MedLine.d166.s13|109-109|;|O
DDI-MedLine.d166.s13|111-112|60|O
DDI-MedLine.d166.s13|113-113|)|O
DDI-MedLine.d166.s13|115-116|to|O
DDI-MedLine.d166.s13|118-119|24|O
DDI-MedLine.d166.s13|121-121|(|O
DDI-MedLine.d166.s13|122-123|19|O
DDI-MedLine.d166.s13|124-124|;|O
DDI-MedLine.d166.s13|126-127|59|O
DDI-MedLine.d166.s13|128-128|)|O
DDI-MedLine.d166.s13|132-137|g/week|O
DDI-MedLine.d166.s13|138-138|,|O
DDI-MedLine.d166.s13|140-140|p|O
DDI-MedLine.d166.s13|142-142|=|O
DDI-MedLine.d166.s13|144-147|0.02|O
DDI-MedLine.d166.s13|148-148|.|O
DDI-MedLine.d166.s14|0-2|The|O
DDI-MedLine.d166.s14|4-12|remainder|O
DDI-MedLine.d166.s14|14-15|of|O
DDI-MedLine.d166.s14|17-19|the|O
DDI-MedLine.d166.s14|21-36|dialysis-related|O
DDI-MedLine.d166.s14|38-49|biochemistry|O
DDI-MedLine.d166.s14|51-51|(|O
DDI-MedLine.d166.s14|52-63|electrolytes|O
DDI-MedLine.d166.s14|64-64|,|O
DDI-MedLine.d166.s14|66-72|calcium|O
DDI-MedLine.d166.s14|73-73|,|O
DDI-MedLine.d166.s14|75-83|phosphate|O
DDI-MedLine.d166.s14|84-84|,|O
DDI-MedLine.d166.s14|86-89|iron|O
DDI-MedLine.d166.s14|91-96|status|O
DDI-MedLine.d166.s14|97-97|)|O
DDI-MedLine.d166.s14|99-101|and|O
DDI-MedLine.d166.s14|103-109|vitamin|O
DDI-MedLine.d166.s14|111-111|D|O
DDI-MedLine.d166.s14|113-115|use|O
DDI-MedLine.d166.s14|117-124|remained|O
DDI-MedLine.d166.s14|126-134|unchanged|O
DDI-MedLine.d166.s14|135-135|.|O
DDI-MedLine.d166.s15|0-0|A|O
DDI-MedLine.d166.s15|2-10|reduction|O
DDI-MedLine.d166.s15|12-13|in|O
DDI-MedLine.d166.s15|15-17|PTH|O
DDI-MedLine.d166.s15|19-23|level|O
DDI-MedLine.d166.s15|25-26|of|O
DDI-MedLine.d166.s15|28-34|greater|O
DDI-MedLine.d166.s15|36-39|than|O
DDI-MedLine.d166.s15|41-42|30|O
DDI-MedLine.d166.s15|43-43|%|O
DDI-MedLine.d166.s15|45-47|was|O
DDI-MedLine.d166.s15|49-59|experienced|O
DDI-MedLine.d166.s15|61-62|by|O
DDI-MedLine.d166.s15|64-67|82.5|O
DDI-MedLine.d166.s15|68-68|%|O
DDI-MedLine.d166.s15|70-70|(|O
DDI-MedLine.d166.s15|71-75|33/40|O
DDI-MedLine.d166.s15|76-76|)|O
DDI-MedLine.d166.s15|78-79|of|O
DDI-MedLine.d166.s15|81-83|our|O
DDI-MedLine.d166.s15|85-90|cohort|O
DDI-MedLine.d166.s15|91-91|.|O
DDI-MedLine.d166.s16|0-4|Among|O
DDI-MedLine.d166.s16|6-8|the|O
DDI-MedLine.d166.s16|10-19|responders|O
DDI-MedLine.d166.s16|20-20|,|O
DDI-MedLine.d166.s16|22-24|the|O
DDI-MedLine.d166.s16|26-29|fall|O
DDI-MedLine.d166.s16|31-32|in|O
DDI-MedLine.d166.s16|34-36|PTH|O
DDI-MedLine.d166.s16|38-40|and|O
DDI-MedLine.d166.s16|42-50|reduction|O
DDI-MedLine.d166.s16|52-62|darbepoetin|drug
DDI-MedLine.d166.s16|64-74|requirement|O
DDI-MedLine.d166.s16|76-79|were|O
DDI-MedLine.d166.s16|81-87|related|O
DDI-MedLine.d166.s16|89-89|(|O
DDI-MedLine.d166.s16|90-90|R|O
DDI-MedLine.d166.s16|92-92|=|O
DDI-MedLine.d166.s16|94-98|-0.48|O
DDI-MedLine.d166.s16|99-99|,|O
DDI-MedLine.d166.s16|101-101|p|O
DDI-MedLine.d166.s16|103-103|=|O
DDI-MedLine.d166.s16|105-109|0.004|O
DDI-MedLine.d166.s16|110-110|)|O
DDI-MedLine.d166.s16|111-111|.|O
DDI-MedLine.d166.s17|0-8|Reduction|O
DDI-MedLine.d166.s17|10-11|of|O
DDI-MedLine.d166.s17|13-15|PTH|O
DDI-MedLine.d166.s17|17-18|by|O
DDI-MedLine.d166.s17|20-29|cinacalcet|drug
DDI-MedLine.d166.s17|31-32|is|O
DDI-MedLine.d166.s17|34-43|associated|O
DDI-MedLine.d166.s17|45-48|with|O
DDI-MedLine.d166.s17|50-50|a|O
DDI-MedLine.d166.s17|52-59|decrease|O
DDI-MedLine.d166.s17|61-62|in|O
DDI-MedLine.d166.s17|64-74|darbepoetin|drug
DDI-MedLine.d166.s17|76-86|requirement|O
DDI-MedLine.d166.s17|87-87|.|O
DDI-MedLine.d166.s18|0-2|The|O
DDI-MedLine.d166.s18|4-12|interface|O
DDI-MedLine.d166.s18|14-20|between|O
DDI-MedLine.d166.s18|22-25|bone|O
DDI-MedLine.d166.s18|27-29|and|O
DDI-MedLine.d166.s18|31-34|bone|O
DDI-MedLine.d166.s18|36-41|marrow|O
DDI-MedLine.d166.s18|43-44|in|O
DDI-MedLine.d166.s18|46-51|uremia|O
DDI-MedLine.d166.s18|53-62|represents|O
DDI-MedLine.d166.s18|64-64|a|O
DDI-MedLine.d166.s18|66-73|critical|O
DDI-MedLine.d166.s18|75-78|step|O
DDI-MedLine.d166.s18|80-81|in|O
DDI-MedLine.d166.s18|83-85|red|O
DDI-MedLine.d166.s18|87-91|blood|O
DDI-MedLine.d166.s18|93-96|cell|O
DDI-MedLine.d166.s18|98-107|production|O
DDI-MedLine.d166.s18|109-113|which|O
DDI-MedLine.d166.s18|115-120|merits|O
DDI-MedLine.d166.s18|122-128|further|O
DDI-MedLine.d166.s18|130-142|investigation|O
DDI-MedLine.d166.s18|143-143|.|O
DDI-DrugBank.d282.s0|0-7|DOSTINEX|brand
DDI-DrugBank.d282.s0|9-14|should|O
DDI-DrugBank.d282.s0|16-18|not|O
DDI-DrugBank.d282.s0|20-21|be|O
DDI-DrugBank.d282.s0|23-34|administered|O
DDI-DrugBank.d282.s0|36-47|concurrently|O
DDI-DrugBank.d282.s0|49-52|with|O
DDI-DrugBank.d282.s0|54-67|D2-antagonists|O
DDI-DrugBank.d282.s0|68-68|,|O
DDI-DrugBank.d282.s0|70-73|such|O
DDI-DrugBank.d282.s0|75-76|as|O
DDI-DrugBank.d282.s0|78-91|phenothiazines|group
DDI-DrugBank.d282.s0|92-92|,|O
DDI-DrugBank.d282.s0|94-107|butyrophenones|group
DDI-DrugBank.d282.s0|108-108|,|O
DDI-DrugBank.d282.s0|110-122|thioxanthines|group
DDI-DrugBank.d282.s0|123-123|,|O
DDI-DrugBank.d282.s0|125-126|or|O
DDI-DrugBank.d282.s0|128-141|metoclopramide|drug
DDI-DrugBank.d282.s0|142-142|.|O
DDI-DrugBank.d633.s0|0-4|Since|O
DDI-DrugBank.d633.s0|6-12|MEXITIL|brand
DDI-DrugBank.d633.s0|14-15|is|O
DDI-DrugBank.d633.s0|17-17|a|O
DDI-DrugBank.d633.s0|19-27|substrate|O
DDI-DrugBank.d633.s0|29-31|for|O
DDI-DrugBank.d633.s0|33-35|the|O
DDI-DrugBank.d633.s0|37-45|metabolic|O
DDI-DrugBank.d633.s0|47-54|pathways|O
DDI-DrugBank.d633.s0|56-64|involving|O
DDI-DrugBank.d633.s0|66-71|CYP2D6|O
DDI-DrugBank.d633.s0|73-75|and|O
DDI-DrugBank.d633.s0|77-82|CYP1A2|O
DDI-DrugBank.d633.s0|84-90|enzymes|O
DDI-DrugBank.d633.s0|91-91|,|O
DDI-DrugBank.d633.s0|93-102|inhibition|O
DDI-DrugBank.d633.s0|104-105|or|O
DDI-DrugBank.d633.s0|107-115|induction|O
DDI-DrugBank.d633.s0|117-118|of|O
DDI-DrugBank.d633.s0|120-125|either|O
DDI-DrugBank.d633.s0|127-128|of|O
DDI-DrugBank.d633.s0|130-134|these|O
DDI-DrugBank.d633.s0|136-142|enzymes|O
DDI-DrugBank.d633.s0|144-148|would|O
DDI-DrugBank.d633.s0|150-151|be|O
DDI-DrugBank.d633.s0|153-160|expected|O
DDI-DrugBank.d633.s0|162-163|to|O
DDI-DrugBank.d633.s0|165-169|alter|O
DDI-DrugBank.d633.s0|171-180|mexiletine|drug
DDI-DrugBank.d633.s0|182-187|plasma|O
DDI-DrugBank.d633.s0|189-202|concentrations|O
DDI-DrugBank.d633.s0|203-203|.|O
DDI-DrugBank.d633.s1|0-1|In|O
DDI-DrugBank.d633.s1|3-3|a|O
DDI-DrugBank.d633.s1|5-10|formal|O
DDI-DrugBank.d633.s1|11-11|,|O
DDI-DrugBank.d633.s1|13-23|single-dose|O
DDI-DrugBank.d633.s1|25-35|interaction|O
DDI-DrugBank.d633.s1|37-41|study|O
DDI-DrugBank.d633.s1|43-43|(|O
DDI-DrugBank.d633.s1|44-44|n|O
DDI-DrugBank.d633.s1|46-46|=|O
DDI-DrugBank.d633.s1|48-48|6|O
DDI-DrugBank.d633.s1|50-54|males|O
DDI-DrugBank.d633.s1|55-55|)|O
DDI-DrugBank.d633.s1|57-59|the|O
DDI-DrugBank.d633.s1|61-69|clearance|O
DDI-DrugBank.d633.s1|71-72|of|O
DDI-DrugBank.d633.s1|74-83|mexiletine|drug
DDI-DrugBank.d633.s1|85-87|was|O
DDI-DrugBank.d633.s1|89-97|decreased|O
DDI-DrugBank.d633.s1|99-100|by|O
DDI-DrugBank.d633.s1|102-103|38|O
DDI-DrugBank.d633.s1|104-104|%|O
DDI-DrugBank.d633.s1|106-114|following|O
DDI-DrugBank.d633.s1|116-118|the|O
DDI-DrugBank.d633.s1|120-135|coadministration|O
DDI-DrugBank.d633.s1|137-138|of|O
DDI-DrugBank.d633.s1|140-150|fluvoxamine|drug
DDI-DrugBank.d633.s1|151-151|,|O
DDI-DrugBank.d633.s1|153-154|an|O
DDI-DrugBank.d633.s1|156-164|inhibitor|O
DDI-DrugBank.d633.s1|166-167|of|O
DDI-DrugBank.d633.s1|169-174|CYP1A2|O
DDI-DrugBank.d633.s1|175-175|.|O
DDI-DrugBank.d633.s2|0-1|In|O
DDI-DrugBank.d633.s2|3-9|another|O
DDI-DrugBank.d633.s2|11-16|formal|O
DDI-DrugBank.d633.s2|18-22|study|O
DDI-DrugBank.d633.s2|24-24|(|O
DDI-DrugBank.d633.s2|25-25|n|O
DDI-DrugBank.d633.s2|27-27|=|O
DDI-DrugBank.d633.s2|29-29|8|O
DDI-DrugBank.d633.s2|31-39|extensive|O
DDI-DrugBank.d633.s2|41-43|and|O
DDI-DrugBank.d633.s2|45-45|n|O
DDI-DrugBank.d633.s2|47-47|=|O
DDI-DrugBank.d633.s2|49-49|7|O
DDI-DrugBank.d633.s2|51-54|poor|O
DDI-DrugBank.d633.s2|56-67|metabolizers|O
DDI-DrugBank.d633.s2|69-70|of|O
DDI-DrugBank.d633.s2|72-77|CYP2D6|O
DDI-DrugBank.d633.s2|78-78|)|O
DDI-DrugBank.d633.s2|79-79|,|O
DDI-DrugBank.d633.s2|81-96|coadministration|O
DDI-DrugBank.d633.s2|98-99|of|O
DDI-DrugBank.d633.s2|101-111|propafenone|drug
DDI-DrugBank.d633.s2|113-115|did|O
DDI-DrugBank.d633.s2|117-119|not|O
DDI-DrugBank.d633.s2|121-125|alter|O
DDI-DrugBank.d633.s2|127-129|the|O
DDI-DrugBank.d633.s2|131-138|kinetics|O
DDI-DrugBank.d633.s2|140-141|of|O
DDI-DrugBank.d633.s2|143-152|mexiletine|drug
DDI-DrugBank.d633.s2|154-155|in|O
DDI-DrugBank.d633.s2|157-159|the|O
DDI-DrugBank.d633.s2|161-164|poor|O
DDI-DrugBank.d633.s2|166-171|CYP2D6|O
DDI-DrugBank.d633.s2|173-183|metabolizer|O
DDI-DrugBank.d633.s2|185-189|group|O
DDI-DrugBank.d633.s2|190-190|.|O
DDI-DrugBank.d633.s3|0-6|However|O
DDI-DrugBank.d633.s3|7-7|,|O
DDI-DrugBank.d633.s3|9-11|the|O
DDI-DrugBank.d633.s3|13-21|metabolic|O
DDI-DrugBank.d633.s3|23-31|clearance|O
DDI-DrugBank.d633.s3|33-34|of|O
DDI-DrugBank.d633.s3|36-45|mexiletine|drug
DDI-DrugBank.d633.s3|47-48|in|O
DDI-DrugBank.d633.s3|50-52|the|O
DDI-DrugBank.d633.s3|54-62|extensive|O
DDI-DrugBank.d633.s3|64-74|metabolizer|O
DDI-DrugBank.d633.s3|76-84|phenotype|O
DDI-DrugBank.d633.s3|86-94|decreased|O
DDI-DrugBank.d633.s3|96-97|by|O
DDI-DrugBank.d633.s3|99-103|about|O
DDI-DrugBank.d633.s3|105-106|70|O
DDI-DrugBank.d633.s3|107-107|%|O
DDI-DrugBank.d633.s3|109-114|making|O
DDI-DrugBank.d633.s3|116-118|the|O
DDI-DrugBank.d633.s3|120-123|poor|O
DDI-DrugBank.d633.s3|125-127|and|O
DDI-DrugBank.d633.s3|129-137|extensive|O
DDI-DrugBank.d633.s3|139-149|metabolizer|O
DDI-DrugBank.d633.s3|151-156|groups|O
DDI-DrugBank.d633.s3|158-174|indistinguishable|O
DDI-DrugBank.d633.s3|175-175|.|O
DDI-DrugBank.d633.s4|0-1|In|O
DDI-DrugBank.d633.s4|3-6|this|O
DDI-DrugBank.d633.s4|8-16|crossover|O
DDI-DrugBank.d633.s4|18-23|steady|O
DDI-DrugBank.d633.s4|25-29|state|O
DDI-DrugBank.d633.s4|31-35|study|O
DDI-DrugBank.d633.s4|36-36|,|O
DDI-DrugBank.d633.s4|38-40|the|O
DDI-DrugBank.d633.s4|42-57|pharmacokinetics|O
DDI-DrugBank.d633.s4|59-60|of|O
DDI-DrugBank.d633.s4|62-72|propafenone|drug
DDI-DrugBank.d633.s4|74-77|were|O
DDI-DrugBank.d633.s4|79-88|unaffected|O
DDI-DrugBank.d633.s4|90-91|in|O
DDI-DrugBank.d633.s4|93-98|either|O
DDI-DrugBank.d633.s4|100-108|phenotype|O
DDI-DrugBank.d633.s4|110-111|by|O
DDI-DrugBank.d633.s4|113-115|the|O
DDI-DrugBank.d633.s4|117-132|coadministration|O
DDI-DrugBank.d633.s4|134-135|of|O
DDI-DrugBank.d633.s4|137-146|mexiletine|drug
DDI-DrugBank.d633.s4|147-147|.|O
DDI-DrugBank.d633.s5|0-7|Addition|O
DDI-DrugBank.d633.s5|9-10|of|O
DDI-DrugBank.d633.s5|12-21|mexiletine|drug
DDI-DrugBank.d633.s5|23-24|to|O
DDI-DrugBank.d633.s5|26-36|propafenone|drug
DDI-DrugBank.d633.s5|38-40|did|O
DDI-DrugBank.d633.s5|42-44|not|O
DDI-DrugBank.d633.s5|46-49|lead|O
DDI-DrugBank.d633.s5|51-52|to|O
DDI-DrugBank.d633.s5|54-60|further|O
DDI-DrugBank.d633.s5|62-81|electrocardiographic|O
DDI-DrugBank.d633.s5|83-92|parameters|O
DDI-DrugBank.d633.s5|94-100|changes|O
DDI-DrugBank.d633.s5|102-103|of|O
DDI-DrugBank.d633.s5|105-107|QRS|O
DDI-DrugBank.d633.s5|108-108|,|O
DDI-DrugBank.d633.s5|110-112|QTc|O
DDI-DrugBank.d633.s5|113-113|,|O
DDI-DrugBank.d633.s5|115-116|RR|O
DDI-DrugBank.d633.s5|117-117|,|O
DDI-DrugBank.d633.s5|119-121|and|O
DDI-DrugBank.d633.s5|123-124|PR|O
DDI-DrugBank.d633.s5|126-134|intervals|O
DDI-DrugBank.d633.s5|136-139|than|O
DDI-DrugBank.d633.s5|141-151|propafenone|drug
DDI-DrugBank.d633.s5|153-157|alone|O
DDI-DrugBank.d633.s5|158-158|.|O
DDI-DrugBank.d633.s6|0-3|When|O
DDI-DrugBank.d633.s6|5-15|concomitant|O
DDI-DrugBank.d633.s6|17-30|administration|O
DDI-DrugBank.d633.s6|32-33|of|O
DDI-DrugBank.d633.s6|35-40|either|O
DDI-DrugBank.d633.s6|42-43|of|O
DDI-DrugBank.d633.s6|45-49|these|O
DDI-DrugBank.d633.s6|51-53|two|O
DDI-DrugBank.d633.s6|55-59|drugs|O
DDI-DrugBank.d633.s6|61-64|with|O
DDI-DrugBank.d633.s6|66-75|mexiletine|drug
DDI-DrugBank.d633.s6|77-78|is|O
DDI-DrugBank.d633.s6|80-88|initiated|O
DDI-DrugBank.d633.s6|89-89|,|O
DDI-DrugBank.d633.s6|91-93|the|O
DDI-DrugBank.d633.s6|95-98|dose|O
DDI-DrugBank.d633.s6|100-101|of|O
DDI-DrugBank.d633.s6|103-112|mexiletine|drug
DDI-DrugBank.d633.s6|114-119|should|O
DDI-DrugBank.d633.s6|121-122|be|O
DDI-DrugBank.d633.s6|124-129|slowly|O
DDI-DrugBank.d633.s6|131-138|titrated|O
DDI-DrugBank.d633.s6|140-141|to|O
DDI-DrugBank.d633.s6|143-149|desired|O
DDI-DrugBank.d633.s6|151-156|effect|O
DDI-DrugBank.d633.s6|157-157|.|O
DDI-DrugBank.d633.s7|0-1|In|O
DDI-DrugBank.d633.s7|3-3|a|O
DDI-DrugBank.d633.s7|5-9|large|O
DDI-DrugBank.d633.s7|11-23|compassionate|O
DDI-DrugBank.d633.s7|25-27|use|O
DDI-DrugBank.d633.s7|29-35|program|O
DDI-DrugBank.d633.s7|37-43|Mexitil|brand
DDI-DrugBank.d633.s7|48-50|has|O
DDI-DrugBank.d633.s7|52-55|been|O
DDI-DrugBank.d633.s7|57-60|used|O
DDI-DrugBank.d633.s7|62-73|concurrently|O
DDI-DrugBank.d633.s7|75-78|with|O
DDI-DrugBank.d633.s7|80-87|commonly|O
DDI-DrugBank.d633.s7|89-96|employed|O
DDI-DrugBank.d633.s7|98-108|antianginal|O
DDI-DrugBank.d633.s7|109-109|,|O
DDI-DrugBank.d633.s7|111-126|antihypertensive|group
DDI-DrugBank.d633.s7|127-127|,|O
DDI-DrugBank.d633.s7|129-131|and|O
DDI-DrugBank.d633.s7|133-151|anticoagulant drugs|group
DDI-DrugBank.d633.s7|153-159|without|O
DDI-DrugBank.d633.s7|161-168|observed|O
DDI-DrugBank.d633.s7|170-181|interactions|O
DDI-DrugBank.d633.s7|182-182|.|O
DDI-DrugBank.d633.s8|0-0|A|O
DDI-DrugBank.d633.s8|2-8|variety|O
DDI-DrugBank.d633.s8|10-11|of|O
DDI-DrugBank.d633.s8|13-27|antiarrhythmics|group
DDI-DrugBank.d633.s8|29-32|such|O
DDI-DrugBank.d633.s8|34-35|as|O
DDI-DrugBank.d633.s8|37-45|quinidine|drug
DDI-DrugBank.d633.s8|47-48|or|O
DDI-DrugBank.d633.s8|50-60|propranolol|drug
DDI-DrugBank.d633.s8|62-65|were|O
DDI-DrugBank.d633.s8|67-70|also|O
DDI-DrugBank.d633.s8|72-76|added|O
DDI-DrugBank.d633.s8|77-77|,|O
DDI-DrugBank.d633.s8|79-87|sometimes|O
DDI-DrugBank.d633.s8|89-92|with|O
DDI-DrugBank.d633.s8|94-101|improved|O
DDI-DrugBank.d633.s8|103-109|control|O
DDI-DrugBank.d633.s8|111-112|of|O
DDI-DrugBank.d633.s8|114-124|ventricular|O
DDI-DrugBank.d633.s8|126-131|ectopy|O
DDI-DrugBank.d633.s8|132-132|.|O
DDI-DrugBank.d633.s9|0-3|When|O
DDI-DrugBank.d633.s9|5-13|phenytoin|drug
DDI-DrugBank.d633.s9|15-16|or|O
DDI-DrugBank.d633.s9|18-22|other|O
DDI-DrugBank.d633.s9|24-30|hepatic|O
DDI-DrugBank.d633.s9|32-37|enzyme|O
DDI-DrugBank.d633.s9|39-46|inducers|O
DDI-DrugBank.d633.s9|48-51|such|O
DDI-DrugBank.d633.s9|53-54|as|O
DDI-DrugBank.d633.s9|56-63|rifampin|drug
DDI-DrugBank.d633.s9|65-67|and|O
DDI-DrugBank.d633.s9|69-81|phenobarbital|drug
DDI-DrugBank.d633.s9|83-86|have|O
DDI-DrugBank.d633.s9|88-91|been|O
DDI-DrugBank.d633.s9|93-97|taken|O
DDI-DrugBank.d633.s9|99-110|concurrently|O
DDI-DrugBank.d633.s9|112-115|with|O
DDI-DrugBank.d633.s9|117-123|Mexitil|brand
DDI-DrugBank.d633.s9|127-127|,|O
DDI-DrugBank.d633.s9|129-135|lowered|O
DDI-DrugBank.d633.s9|137-143|Mexitil|brand
DDI-DrugBank.d633.s9|148-153|plasma|O
DDI-DrugBank.d633.s9|155-160|levels|O
DDI-DrugBank.d633.s9|162-165|have|O
DDI-DrugBank.d633.s9|167-170|been|O
DDI-DrugBank.d633.s9|172-179|reported|O
DDI-DrugBank.d633.s9|180-180|.|O
DDI-DrugBank.d633.s10|0-9|Monitoring|O
DDI-DrugBank.d633.s10|11-12|of|O
DDI-DrugBank.d633.s10|14-20|Mexitil|brand
DDI-DrugBank.d633.s10|25-30|plasma|O
DDI-DrugBank.d633.s10|32-37|levels|O
DDI-DrugBank.d633.s10|39-40|is|O
DDI-DrugBank.d633.s10|42-52|recommended|O
DDI-DrugBank.d633.s10|54-59|during|O
DDI-DrugBank.d633.s10|61-64|such|O
DDI-DrugBank.d633.s10|66-75|concurrent|O
DDI-DrugBank.d633.s10|77-79|use|O
DDI-DrugBank.d633.s10|81-82|to|O
DDI-DrugBank.d633.s10|84-88|avoid|O
DDI-DrugBank.d633.s10|90-100|ineffective|O
DDI-DrugBank.d633.s10|102-108|therapy|O
DDI-DrugBank.d633.s10|109-109|.|O
DDI-DrugBank.d633.s11|0-1|In|O
DDI-DrugBank.d633.s11|3-3|a|O
DDI-DrugBank.d633.s11|5-10|formal|O
DDI-DrugBank.d633.s11|12-16|study|O
DDI-DrugBank.d633.s11|17-17|,|O
DDI-DrugBank.d633.s11|19-33|benzodiazepines|group
DDI-DrugBank.d633.s11|35-38|were|O
DDI-DrugBank.d633.s11|40-44|shown|O
DDI-DrugBank.d633.s11|46-48|not|O
DDI-DrugBank.d633.s11|50-51|to|O
DDI-DrugBank.d633.s11|53-58|affect|O
DDI-DrugBank.d633.s11|60-66|Mexitil|brand
DDI-DrugBank.d633.s11|71-76|plasma|O
DDI-DrugBank.d633.s11|78-91|concentrations|O
DDI-DrugBank.d633.s11|92-92|.|O
DDI-DrugBank.d633.s12|0-2|ECG|O
DDI-DrugBank.d633.s12|4-12|intervals|O
DDI-DrugBank.d633.s12|14-14|(|O
DDI-DrugBank.d633.s12|15-16|PR|O
DDI-DrugBank.d633.s12|17-17|,|O
DDI-DrugBank.d633.s12|19-21|QRS|O
DDI-DrugBank.d633.s12|22-22|,|O
DDI-DrugBank.d633.s12|24-26|and|O
DDI-DrugBank.d633.s12|28-29|QT|O
DDI-DrugBank.d633.s12|30-30|)|O
DDI-DrugBank.d633.s12|32-35|were|O
DDI-DrugBank.d633.s12|37-39|not|O
DDI-DrugBank.d633.s12|41-48|affected|O
DDI-DrugBank.d633.s12|50-51|by|O
DDI-DrugBank.d633.s12|53-62|concurrent|O
DDI-DrugBank.d633.s12|64-70|Mexitil|brand
DDI-DrugBank.d633.s12|75-77|and|O
DDI-DrugBank.d633.s12|79-85|digoxin|drug
DDI-DrugBank.d633.s12|86-86|,|O
DDI-DrugBank.d633.s12|88-96|diuretics|group
DDI-DrugBank.d633.s12|97-97|,|O
DDI-DrugBank.d633.s12|99-100|or|O
DDI-DrugBank.d633.s12|102-112|propranolol|drug
DDI-DrugBank.d633.s12|113-113|.|O
DDI-DrugBank.d633.s13|0-9|Concurrent|O
DDI-DrugBank.d633.s13|11-24|administration|O
DDI-DrugBank.d633.s13|26-27|of|O
DDI-DrugBank.d633.s13|29-38|cimetidine|drug
DDI-DrugBank.d633.s13|40-42|and|O
DDI-DrugBank.d633.s13|44-50|Mexitil|brand
DDI-DrugBank.d633.s13|55-57|has|O
DDI-DrugBank.d633.s13|59-62|been|O
DDI-DrugBank.d633.s13|64-71|reported|O
DDI-DrugBank.d633.s13|73-74|to|O
DDI-DrugBank.d633.s13|76-83|increase|O
DDI-DrugBank.d633.s13|84-84|,|O
DDI-DrugBank.d633.s13|86-93|decrease|O
DDI-DrugBank.d633.s13|94-94|,|O
DDI-DrugBank.d633.s13|96-97|or|O
DDI-DrugBank.d633.s13|99-103|leave|O
DDI-DrugBank.d633.s13|105-113|unchanged|O
DDI-DrugBank.d633.s13|115-121|Mexitil|brand
DDI-DrugBank.d633.s13|126-131|plasma|O
DDI-DrugBank.d633.s13|133-138|levels|O
DDI-DrugBank.d633.s13|139-139|;|O
DDI-DrugBank.d633.s14|0-8|therefore|O
DDI-DrugBank.d633.s14|10-17|patients|O
DDI-DrugBank.d633.s14|19-24|should|O
DDI-DrugBank.d633.s14|26-27|be|O
DDI-DrugBank.d633.s14|29-36|followed|O
DDI-DrugBank.d633.s14|38-46|carefully|O
DDI-DrugBank.d633.s14|48-53|during|O
DDI-DrugBank.d633.s14|55-64|concurrent|O
DDI-DrugBank.d633.s14|66-72|therapy|O
DDI-DrugBank.d633.s14|73-73|.|O
DDI-DrugBank.d633.s15|0-6|Mexitil|brand
DDI-DrugBank.d633.s15|11-14|does|O
DDI-DrugBank.d633.s15|16-18|not|O
DDI-DrugBank.d633.s15|20-24|alter|O
DDI-DrugBank.d633.s15|26-30|serum|O
DDI-DrugBank.d633.s15|32-38|digoxin|drug
DDI-DrugBank.d633.s15|40-45|levels|O
DDI-DrugBank.d633.s15|47-49|but|O
DDI-DrugBank.d633.s15|51-78|magnesium-aluminum hydroxide|drug
DDI-DrugBank.d633.s15|79-79|,|O
DDI-DrugBank.d633.s15|81-84|when|O
DDI-DrugBank.d633.s15|86-89|used|O
DDI-DrugBank.d633.s15|91-92|to|O
DDI-DrugBank.d633.s15|94-98|treat|O
DDI-DrugBank.d633.s15|100-115|gastrointestinal|O
DDI-DrugBank.d633.s15|117-124|symptoms|O
DDI-DrugBank.d633.s15|126-128|due|O
DDI-DrugBank.d633.s15|130-131|to|O
DDI-DrugBank.d633.s15|133-139|Mexitil|brand
DDI-DrugBank.d633.s15|143-143|,|O
DDI-DrugBank.d633.s15|145-147|has|O
DDI-DrugBank.d633.s15|149-152|been|O
DDI-DrugBank.d633.s15|154-161|reported|O
DDI-DrugBank.d633.s15|163-164|to|O
DDI-DrugBank.d633.s15|166-170|lower|O
DDI-DrugBank.d633.s15|172-176|serum|O
DDI-DrugBank.d633.s15|178-184|digoxin|drug
DDI-DrugBank.d633.s15|186-191|levels|O
DDI-DrugBank.d633.s15|192-192|.|O
DDI-DrugBank.d633.s16|0-9|Concurrent|O
DDI-DrugBank.d633.s16|11-13|use|O
DDI-DrugBank.d633.s16|15-16|of|O
DDI-DrugBank.d633.s16|18-24|Mexitil|brand
DDI-DrugBank.d633.s16|29-31|and|O
DDI-DrugBank.d633.s16|33-44|theophylline|drug
DDI-DrugBank.d633.s16|46-48|may|O
DDI-DrugBank.d633.s16|50-53|lead|O
DDI-DrugBank.d633.s16|55-56|to|O
DDI-DrugBank.d633.s16|58-66|increased|O
DDI-DrugBank.d633.s16|68-73|plasma|O
DDI-DrugBank.d633.s16|75-86|theophylline|drug
DDI-DrugBank.d633.s16|88-93|levels|O
DDI-DrugBank.d633.s16|94-94|.|O
DDI-DrugBank.d633.s17|0-2|One|O
DDI-DrugBank.d633.s17|4-13|controlled|O
DDI-DrugBank.d633.s17|15-19|study|O
DDI-DrugBank.d633.s17|21-22|in|O
DDI-DrugBank.d633.s17|24-28|eight|O
DDI-DrugBank.d633.s17|30-35|normal|O
DDI-DrugBank.d633.s17|37-44|subjects|O
DDI-DrugBank.d633.s17|46-51|showed|O
DDI-DrugBank.d633.s17|53-53|a|O
DDI-DrugBank.d633.s17|55-56|72|O
DDI-DrugBank.d633.s17|57-57|%|O
DDI-DrugBank.d633.s17|59-62|mean|O
DDI-DrugBank.d633.s17|64-71|increase|O
DDI-DrugBank.d633.s17|73-73|(|O
DDI-DrugBank.d633.s17|74-78|range|O
DDI-DrugBank.d633.s17|80-85|35-136|O
DDI-DrugBank.d633.s17|86-86|%|O
DDI-DrugBank.d633.s17|87-87|)|O
DDI-DrugBank.d633.s17|89-90|in|O
DDI-DrugBank.d633.s17|92-97|plasma|O
DDI-DrugBank.d633.s17|99-110|theophylline|drug
DDI-DrugBank.d633.s17|112-117|levels|O
DDI-DrugBank.d633.s17|118-118|.|O
DDI-DrugBank.d633.s18|0-3|This|O
DDI-DrugBank.d633.s18|5-12|increase|O
DDI-DrugBank.d633.s18|14-16|was|O
DDI-DrugBank.d633.s18|18-25|observed|O
DDI-DrugBank.d633.s18|27-28|at|O
DDI-DrugBank.d633.s18|30-32|the|O
DDI-DrugBank.d633.s18|34-38|first|O
DDI-DrugBank.d633.s18|40-43|test|O
DDI-DrugBank.d633.s18|45-49|point|O
DDI-DrugBank.d633.s18|51-55|which|O
DDI-DrugBank.d633.s18|57-59|was|O
DDI-DrugBank.d633.s18|61-63|the|O
DDI-DrugBank.d633.s18|65-70|second|O
DDI-DrugBank.d633.s18|72-74|day|O
DDI-DrugBank.d633.s18|76-80|after|O
DDI-DrugBank.d633.s18|82-89|starting|O
DDI-DrugBank.d633.s18|91-97|Mexitil|brand
DDI-DrugBank.d633.s18|101-101|.|O
DDI-DrugBank.d633.s18|103-114|Theophylline|drug
DDI-DrugBank.d633.s18|116-121|plasma|O
DDI-DrugBank.d633.s18|123-128|levels|O
DDI-DrugBank.d633.s18|130-137|returned|O
DDI-DrugBank.d633.s18|139-140|to|O
DDI-DrugBank.d633.s18|142-152|pre-Mexitil|brand
DDI-DrugBank.d633.s18|157-162|values|O
DDI-DrugBank.d633.s18|164-169|within|O
DDI-DrugBank.d633.s18|171-172|48|O
DDI-DrugBank.d633.s18|174-178|hours|O
DDI-DrugBank.d633.s18|180-184|after|O
DDI-DrugBank.d633.s18|186-198|discontinuing|O
DDI-DrugBank.d633.s18|200-206|Mexitil|brand
DDI-DrugBank.d633.s18|210-210|.|O
DDI-DrugBank.d633.s18|212-213|If|O
DDI-DrugBank.d633.s18|215-221|Mexitil|brand
DDI-DrugBank.d633.s18|223-225|and|O
DDI-DrugBank.d633.s18|227-238|theophylline|drug
DDI-DrugBank.d633.s18|240-242|are|O
DDI-DrugBank.d633.s18|244-245|to|O
DDI-DrugBank.d633.s18|247-248|be|O
DDI-DrugBank.d633.s18|250-253|used|O
DDI-DrugBank.d633.s18|255-266|concurrently|O
DDI-DrugBank.d633.s18|267-267|,|O
DDI-DrugBank.d633.s18|269-280|theophylline|drug
DDI-DrugBank.d633.s18|282-286|blood|O
DDI-DrugBank.d633.s18|288-293|levels|O
DDI-DrugBank.d633.s18|295-300|should|O
DDI-DrugBank.d633.s18|302-303|be|O
DDI-DrugBank.d633.s18|305-313|monitored|O
DDI-DrugBank.d633.s18|314-314|,|O
DDI-DrugBank.d633.s18|316-327|particularly|O
DDI-DrugBank.d633.s18|329-332|when|O
DDI-DrugBank.d633.s18|334-336|the|O
DDI-DrugBank.d633.s18|338-344|Mexitil|brand
DDI-DrugBank.d633.s18|349-352|dose|O
DDI-DrugBank.d633.s18|354-355|is|O
DDI-DrugBank.d633.s18|357-363|changed|O
DDI-DrugBank.d633.s18|364-364|.|O
DDI-DrugBank.d633.s19|0-1|An|O
DDI-DrugBank.d633.s19|3-13|appropriate|O
DDI-DrugBank.d633.s19|15-24|adjustment|O
DDI-DrugBank.d633.s19|26-27|in|O
DDI-DrugBank.d633.s19|29-40|theophylline|drug
DDI-DrugBank.d633.s19|42-45|dose|O
DDI-DrugBank.d633.s19|47-52|should|O
DDI-DrugBank.d633.s19|54-55|be|O
DDI-DrugBank.d633.s19|57-66|considered|O
DDI-DrugBank.d633.s19|67-67|.|O
DDI-DrugBank.d633.s20|0-11|Additionally|O
DDI-DrugBank.d633.s20|12-12|,|O
DDI-DrugBank.d633.s20|14-15|in|O
DDI-DrugBank.d633.s20|17-19|one|O
DDI-DrugBank.d633.s20|21-30|controlled|O
DDI-DrugBank.d633.s20|32-36|study|O
DDI-DrugBank.d633.s20|38-39|in|O
DDI-DrugBank.d633.s20|41-44|five|O
DDI-DrugBank.d633.s20|46-51|normal|O
DDI-DrugBank.d633.s20|53-60|subjects|O
DDI-DrugBank.d633.s20|62-64|and|O
DDI-DrugBank.d633.s20|66-70|seven|O
DDI-DrugBank.d633.s20|72-79|patients|O
DDI-DrugBank.d633.s20|80-80|,|O
DDI-DrugBank.d633.s20|82-84|the|O
DDI-DrugBank.d633.s20|86-94|clearance|O
DDI-DrugBank.d633.s20|96-97|of|O
DDI-DrugBank.d633.s20|99-106|caffeine|drug
DDI-DrugBank.d633.s20|108-110|was|O
DDI-DrugBank.d633.s20|112-120|decreased|O
DDI-DrugBank.d633.s20|122-123|50|O
DDI-DrugBank.d633.s20|124-124|%|O
DDI-DrugBank.d633.s20|126-134|following|O
DDI-DrugBank.d633.s20|136-138|the|O
DDI-DrugBank.d633.s20|140-153|administration|O
DDI-DrugBank.d633.s20|155-156|of|O
DDI-DrugBank.d633.s20|158-164|Mexitil|brand
DDI-DrugBank.d633.s20|168-168|.|O
DDI-DrugBank.d249.s0|0-6|Aspirin|brand
DDI-DrugBank.d249.s0|7-7|:|O
DDI-DrugBank.d249.s0|9-19|Concomitant|O
DDI-DrugBank.d249.s0|21-34|administration|O
DDI-DrugBank.d249.s0|36-37|of|O
DDI-DrugBank.d249.s0|39-48|diclofenac|drug
DDI-DrugBank.d249.s0|50-52|and|O
DDI-DrugBank.d249.s0|54-60|aspirin|brand
DDI-DrugBank.d249.s0|62-63|is|O
DDI-DrugBank.d249.s0|65-67|not|O
DDI-DrugBank.d249.s0|69-79|recommended|O
DDI-DrugBank.d249.s0|81-87|because|O
DDI-DrugBank.d249.s0|89-98|diclofenac|drug
DDI-DrugBank.d249.s0|100-101|is|O
DDI-DrugBank.d249.s0|103-111|displaced|O
DDI-DrugBank.d249.s0|113-116|from|O
DDI-DrugBank.d249.s0|118-120|its|O
DDI-DrugBank.d249.s0|122-128|binding|O
DDI-DrugBank.d249.s0|130-134|sites|O
DDI-DrugBank.d249.s0|136-141|during|O
DDI-DrugBank.d249.s0|143-145|the|O
DDI-DrugBank.d249.s0|147-157|concomitant|O
DDI-DrugBank.d249.s0|159-172|administration|O
DDI-DrugBank.d249.s0|174-175|of|O
DDI-DrugBank.d249.s0|177-183|aspirin|brand
DDI-DrugBank.d249.s0|184-184|,|O
DDI-DrugBank.d249.s0|186-194|resulting|O
DDI-DrugBank.d249.s0|196-197|in|O
DDI-DrugBank.d249.s0|199-203|lower|O
DDI-DrugBank.d249.s0|205-210|plasma|O
DDI-DrugBank.d249.s0|212-225|concentrations|O
DDI-DrugBank.d249.s0|226-226|,|O
DDI-DrugBank.d249.s0|228-231|peak|O
DDI-DrugBank.d249.s0|233-238|plasma|O
DDI-DrugBank.d249.s0|240-245|levels|O
DDI-DrugBank.d249.s0|246-246|,|O
DDI-DrugBank.d249.s0|248-250|and|O
DDI-DrugBank.d249.s0|252-254|AUC|O
DDI-DrugBank.d249.s0|256-261|values|O
DDI-DrugBank.d249.s0|262-262|.|O
DDI-DrugBank.d249.s1|0-13|Anticoagulants|group
DDI-DrugBank.d249.s1|14-14|:|O
DDI-DrugBank.d249.s1|16-20|While|O
DDI-DrugBank.d249.s1|22-28|studies|O
DDI-DrugBank.d249.s1|30-33|have|O
DDI-DrugBank.d249.s1|35-37|not|O
DDI-DrugBank.d249.s1|39-43|shown|O
DDI-DrugBank.d249.s1|45-54|diclofenac|drug
DDI-DrugBank.d249.s1|56-57|to|O
DDI-DrugBank.d249.s1|59-66|interact|O
DDI-DrugBank.d249.s1|68-71|with|O
DDI-DrugBank.d249.s1|73-107|anticoagulants of the warfarin type|group
DDI-DrugBank.d249.s1|108-108|,|O
DDI-DrugBank.d249.s1|110-116|caution|O
DDI-DrugBank.d249.s1|118-123|should|O
DDI-DrugBank.d249.s1|125-126|be|O
DDI-DrugBank.d249.s1|128-136|exercised|O
DDI-DrugBank.d249.s1|137-137|,|O
DDI-DrugBank.d249.s1|139-149|nonetheless|O
DDI-DrugBank.d249.s1|150-150|,|O
DDI-DrugBank.d249.s1|152-156|since|O
DDI-DrugBank.d249.s1|158-169|interactions|O
DDI-DrugBank.d249.s1|171-174|have|O
DDI-DrugBank.d249.s1|176-179|been|O
DDI-DrugBank.d249.s1|181-184|seen|O
DDI-DrugBank.d249.s1|186-189|with|O
DDI-DrugBank.d249.s1|191-195|other|O
DDI-DrugBank.d249.s1|197-202|NSAIDs|group
DDI-DrugBank.d249.s1|203-203|.|O
DDI-DrugBank.d249.s2|0-6|Because|O
DDI-DrugBank.d249.s2|8-21|prostaglandins|O
DDI-DrugBank.d249.s2|23-26|play|O
DDI-DrugBank.d249.s2|28-29|an|O
DDI-DrugBank.d249.s2|31-39|important|O
DDI-DrugBank.d249.s2|41-44|role|O
DDI-DrugBank.d249.s2|46-47|in|O
DDI-DrugBank.d249.s2|49-58|hemostasis|O
DDI-DrugBank.d249.s2|59-59|,|O
DDI-DrugBank.d249.s2|61-63|and|O
DDI-DrugBank.d249.s2|65-70|NSAIDs|group
DDI-DrugBank.d249.s2|72-77|affect|O
DDI-DrugBank.d249.s2|79-86|platelet|O
DDI-DrugBank.d249.s2|88-95|function|O
DDI-DrugBank.d249.s2|97-98|as|O
DDI-DrugBank.d249.s2|100-103|well|O
DDI-DrugBank.d249.s2|104-104|,|O
DDI-DrugBank.d249.s2|106-115|concurrent|O
DDI-DrugBank.d249.s2|117-123|therapy|O
DDI-DrugBank.d249.s2|125-128|with|O
DDI-DrugBank.d249.s2|130-132|all|O
DDI-DrugBank.d249.s2|134-139|NSAIDs|group
DDI-DrugBank.d249.s2|140-140|,|O
DDI-DrugBank.d249.s2|142-150|including|O
DDI-DrugBank.d249.s2|152-161|diclofenac|drug
DDI-DrugBank.d249.s2|162-162|,|O
DDI-DrugBank.d249.s2|164-166|and|O
DDI-DrugBank.d249.s2|168-175|warfarin|drug
DDI-DrugBank.d249.s2|177-184|requires|O
DDI-DrugBank.d249.s2|186-190|close|O
DDI-DrugBank.d249.s2|192-201|monitoring|O
DDI-DrugBank.d249.s2|203-204|of|O
DDI-DrugBank.d249.s2|206-213|patients|O
DDI-DrugBank.d249.s2|215-216|to|O
DDI-DrugBank.d249.s2|218-219|be|O
DDI-DrugBank.d249.s2|221-227|certain|O
DDI-DrugBank.d249.s2|229-232|that|O
DDI-DrugBank.d249.s2|234-235|no|O
DDI-DrugBank.d249.s2|237-242|change|O
DDI-DrugBank.d249.s2|244-245|in|O
DDI-DrugBank.d249.s2|247-251|their|O
DDI-DrugBank.d249.s2|253-265|anticoagulant|group
DDI-DrugBank.d249.s2|267-272|dosage|O
DDI-DrugBank.d249.s2|274-275|is|O
DDI-DrugBank.d249.s2|277-284|required|O
DDI-DrugBank.d249.s2|285-285|.|O
DDI-DrugBank.d249.s3|0-6|Digoxin|drug
DDI-DrugBank.d249.s3|7-7|,|O
DDI-DrugBank.d249.s3|9-20|Methotrexate|drug
DDI-DrugBank.d249.s3|21-21|,|O
DDI-DrugBank.d249.s3|23-34|Cyclosporine|drug
DDI-DrugBank.d249.s3|35-35|:|O
DDI-DrugBank.d249.s3|37-46|Diclofenac|drug
DDI-DrugBank.d249.s3|47-47|,|O
DDI-DrugBank.d249.s3|49-52|like|O
DDI-DrugBank.d249.s3|54-58|other|O
DDI-DrugBank.d249.s3|60-65|NSAIDs|group
DDI-DrugBank.d249.s3|66-66|,|O
DDI-DrugBank.d249.s3|68-70|may|O
DDI-DrugBank.d249.s3|72-77|affect|O
DDI-DrugBank.d249.s3|79-83|renal|O
DDI-DrugBank.d249.s3|85-98|prostaglandins|O
DDI-DrugBank.d249.s3|100-102|and|O
DDI-DrugBank.d249.s3|104-111|increase|O
DDI-DrugBank.d249.s3|113-115|the|O
DDI-DrugBank.d249.s3|117-124|toxicity|O
DDI-DrugBank.d249.s3|126-127|of|O
DDI-DrugBank.d249.s3|129-135|certain|O
DDI-DrugBank.d249.s3|137-141|drugs|O
DDI-DrugBank.d249.s3|142-142|.|O
DDI-DrugBank.d249.s4|0-8|Ingestion|O
DDI-DrugBank.d249.s4|10-11|of|O
DDI-DrugBank.d249.s4|13-22|diclofenac|drug
DDI-DrugBank.d249.s4|24-26|may|O
DDI-DrugBank.d249.s4|28-35|increase|O
DDI-DrugBank.d249.s4|37-41|serum|O
DDI-DrugBank.d249.s4|43-56|concentrations|O
DDI-DrugBank.d249.s4|58-59|of|O
DDI-DrugBank.d249.s4|61-67|digoxin|drug
DDI-DrugBank.d249.s4|69-71|and|O
DDI-DrugBank.d249.s4|73-84|methotrexate|drug
DDI-DrugBank.d249.s4|86-88|and|O
DDI-DrugBank.d249.s4|90-97|increase|O
DDI-DrugBank.d249.s4|99-110|cyclosporine|drug
DDI-DrugBank.d249.s4|112-112|s|O
DDI-DrugBank.d249.s4|114-127|nephrotoxicity|O
DDI-DrugBank.d249.s4|128-128|.|O
DDI-DrugBank.d249.s5|0-7|Patients|O
DDI-DrugBank.d249.s5|9-11|who|O
DDI-DrugBank.d249.s5|13-17|begin|O
DDI-DrugBank.d249.s5|19-24|taking|O
DDI-DrugBank.d249.s5|26-35|diclofenac|drug
DDI-DrugBank.d249.s5|37-38|or|O
DDI-DrugBank.d249.s5|40-42|who|O
DDI-DrugBank.d249.s5|44-51|increase|O
DDI-DrugBank.d249.s5|53-57|their|O
DDI-DrugBank.d249.s5|59-68|diclofenac|drug
DDI-DrugBank.d249.s5|70-73|dose|O
DDI-DrugBank.d249.s5|75-76|or|O
DDI-DrugBank.d249.s5|78-80|any|O
DDI-DrugBank.d249.s5|82-86|other|O
DDI-DrugBank.d249.s5|88-92|NSAID|group
DDI-DrugBank.d249.s5|94-98|while|O
DDI-DrugBank.d249.s5|100-105|taking|O
DDI-DrugBank.d249.s5|107-113|digoxin|drug
DDI-DrugBank.d249.s5|114-114|,|O
DDI-DrugBank.d249.s5|116-127|methotrexate|drug
DDI-DrugBank.d249.s5|128-128|,|O
DDI-DrugBank.d249.s5|130-131|or|O
DDI-DrugBank.d249.s5|133-144|cyclosporine|drug
DDI-DrugBank.d249.s5|146-148|may|O
DDI-DrugBank.d249.s5|150-156|develop|O
DDI-DrugBank.d249.s5|158-165|toxicity|O
DDI-DrugBank.d249.s5|167-181|characteristics|O
DDI-DrugBank.d249.s5|183-185|for|O
DDI-DrugBank.d249.s5|187-191|these|O
DDI-DrugBank.d249.s5|193-197|drugs|O
DDI-DrugBank.d249.s5|198-198|.|O
DDI-DrugBank.d249.s6|0-3|They|O
DDI-DrugBank.d249.s6|5-10|should|O
DDI-DrugBank.d249.s6|12-13|be|O
DDI-DrugBank.d249.s6|15-22|observed|O
DDI-DrugBank.d249.s6|24-30|closely|O
DDI-DrugBank.d249.s6|31-31|,|O
DDI-DrugBank.d249.s6|33-44|particularly|O
DDI-DrugBank.d249.s6|46-47|if|O
DDI-DrugBank.d249.s6|49-53|renal|O
DDI-DrugBank.d249.s6|55-62|function|O
DDI-DrugBank.d249.s6|64-65|is|O
DDI-DrugBank.d249.s6|67-74|impaired|O
DDI-DrugBank.d249.s6|75-75|.|O
DDI-DrugBank.d249.s7|0-1|In|O
DDI-DrugBank.d249.s7|3-5|the|O
DDI-DrugBank.d249.s7|7-10|case|O
DDI-DrugBank.d249.s7|12-13|of|O
DDI-DrugBank.d249.s7|15-21|digoxin|drug
DDI-DrugBank.d249.s7|22-22|,|O
DDI-DrugBank.d249.s7|24-28|serum|O
DDI-DrugBank.d249.s7|30-35|levels|O
DDI-DrugBank.d249.s7|37-42|should|O
DDI-DrugBank.d249.s7|44-45|be|O
DDI-DrugBank.d249.s7|47-55|monitored|O
DDI-DrugBank.d249.s7|56-56|.|O
DDI-DrugBank.d249.s8|0-6|Lithium|drug
DDI-DrugBank.d249.s8|7-7|:|O
DDI-DrugBank.d249.s8|9-18|Diclofenac|drug
DDI-DrugBank.d249.s8|20-28|decreases|O
DDI-DrugBank.d249.s8|30-36|lithium|drug
DDI-DrugBank.d249.s8|38-42|renal|O
DDI-DrugBank.d249.s8|44-52|clearance|O
DDI-DrugBank.d249.s8|54-56|and|O
DDI-DrugBank.d249.s8|58-66|increases|O
DDI-DrugBank.d249.s8|68-74|lithium|drug
DDI-DrugBank.d249.s8|76-81|plasma|O
DDI-DrugBank.d249.s8|83-88|levels|O
DDI-DrugBank.d249.s8|89-89|.|O
DDI-DrugBank.d249.s9|0-1|In|O
DDI-DrugBank.d249.s9|3-10|patients|O
DDI-DrugBank.d249.s9|12-17|taking|O
DDI-DrugBank.d249.s9|19-28|diclofenac|drug
DDI-DrugBank.d249.s9|30-32|and|O
DDI-DrugBank.d249.s9|34-40|lithium|drug
DDI-DrugBank.d249.s9|42-54|concomitantly|O
DDI-DrugBank.d249.s9|55-55|,|O
DDI-DrugBank.d249.s9|57-63|lithium|drug
DDI-DrugBank.d249.s9|65-72|toxicity|O
DDI-DrugBank.d249.s9|74-76|may|O
DDI-DrugBank.d249.s9|78-84|develop|O
DDI-DrugBank.d249.s9|85-85|.|O
DDI-DrugBank.d249.s10|0-3|Oral|O
DDI-DrugBank.d249.s10|5-17|Hypoglycemics|group
DDI-DrugBank.d249.s10|18-18|:|O
DDI-DrugBank.d249.s10|20-29|Diclofenac|drug
DDI-DrugBank.d249.s10|31-34|does|O
DDI-DrugBank.d249.s10|36-38|not|O
DDI-DrugBank.d249.s10|40-44|alter|O
DDI-DrugBank.d249.s10|46-52|glucose|O
DDI-DrugBank.d249.s10|54-63|metabolism|O
DDI-DrugBank.d249.s10|65-66|in|O
DDI-DrugBank.d249.s10|68-73|normal|O
DDI-DrugBank.d249.s10|75-82|subjects|O
DDI-DrugBank.d249.s10|84-86|nor|O
DDI-DrugBank.d249.s10|88-91|does|O
DDI-DrugBank.d249.s10|93-94|it|O
DDI-DrugBank.d249.s10|96-100|alter|O
DDI-DrugBank.d249.s10|102-104|the|O
DDI-DrugBank.d249.s10|106-112|effects|O
DDI-DrugBank.d249.s10|114-115|of|O
DDI-DrugBank.d249.s10|117-120|oral|O
DDI-DrugBank.d249.s10|122-140|hypoglycemic agents|group
DDI-DrugBank.d249.s10|141-141|.|O
DDI-DrugBank.d249.s11|0-4|There|O
DDI-DrugBank.d249.s11|6-8|are|O
DDI-DrugBank.d249.s11|10-13|rare|O
DDI-DrugBank.d249.s11|15-21|reports|O
DDI-DrugBank.d249.s11|22-22|,|O
DDI-DrugBank.d249.s11|24-30|however|O
DDI-DrugBank.d249.s11|31-31|,|O
DDI-DrugBank.d249.s11|33-36|from|O
DDI-DrugBank.d249.s11|38-46|marketing|O
DDI-DrugBank.d249.s11|48-58|experiences|O
DDI-DrugBank.d249.s11|59-59|,|O
DDI-DrugBank.d249.s11|61-62|of|O
DDI-DrugBank.d249.s11|64-70|changes|O
DDI-DrugBank.d249.s11|72-73|in|O
DDI-DrugBank.d249.s11|75-81|effects|O
DDI-DrugBank.d249.s11|83-84|of|O
DDI-DrugBank.d249.s11|86-92|insulin|drug
DDI-DrugBank.d249.s11|94-95|or|O
DDI-DrugBank.d249.s11|97-100|oral|O
DDI-DrugBank.d249.s11|102-120|hypoglycemic agents|group
DDI-DrugBank.d249.s11|122-123|in|O
DDI-DrugBank.d249.s11|125-127|the|O
DDI-DrugBank.d249.s11|129-136|presence|O
DDI-DrugBank.d249.s11|138-139|of|O
DDI-DrugBank.d249.s11|141-150|diclofenac|drug
DDI-DrugBank.d249.s11|152-155|that|O
DDI-DrugBank.d249.s11|157-168|necessitated|O
DDI-DrugBank.d249.s11|170-176|changes|O
DDI-DrugBank.d249.s11|178-179|in|O
DDI-DrugBank.d249.s11|181-183|the|O
DDI-DrugBank.d249.s11|185-189|doses|O
DDI-DrugBank.d249.s11|191-192|of|O
DDI-DrugBank.d249.s11|194-197|such|O
DDI-DrugBank.d249.s11|199-204|agents|O
DDI-DrugBank.d249.s11|205-205|.|O
DDI-DrugBank.d249.s12|0-3|Both|O
DDI-DrugBank.d249.s12|5-9|hypo-|O
DDI-DrugBank.d249.s12|11-13|and|O
DDI-DrugBank.d249.s12|15-27|hyperglycemic|O
DDI-DrugBank.d249.s12|29-35|effects|O
DDI-DrugBank.d249.s12|37-40|have|O
DDI-DrugBank.d249.s12|42-45|been|O
DDI-DrugBank.d249.s12|47-54|reported|O
DDI-DrugBank.d249.s12|55-55|.|O
DDI-DrugBank.d249.s13|0-0|A|O
DDI-DrugBank.d249.s13|2-7|direct|O
DDI-DrugBank.d249.s13|9-14|causal|O
DDI-DrugBank.d249.s13|16-27|relationship|O
DDI-DrugBank.d249.s13|29-31|has|O
DDI-DrugBank.d249.s13|33-35|not|O
DDI-DrugBank.d249.s13|37-40|been|O
DDI-DrugBank.d249.s13|42-52|established|O
DDI-DrugBank.d249.s13|53-53|,|O
DDI-DrugBank.d249.s13|55-57|but|O
DDI-DrugBank.d249.s13|59-68|physicians|O
DDI-DrugBank.d249.s13|70-75|should|O
DDI-DrugBank.d249.s13|77-84|consider|O
DDI-DrugBank.d249.s13|86-88|the|O
DDI-DrugBank.d249.s13|90-100|possibility|O
DDI-DrugBank.d249.s13|102-105|that|O
DDI-DrugBank.d249.s13|107-116|diclofenac|drug
DDI-DrugBank.d249.s13|118-120|may|O
DDI-DrugBank.d249.s13|122-126|alter|O
DDI-DrugBank.d249.s13|128-128|a|O
DDI-DrugBank.d249.s13|130-137|diabetic|O
DDI-DrugBank.d249.s13|139-145|patient|O
DDI-DrugBank.d249.s13|147-147|s|O
DDI-DrugBank.d249.s13|149-156|response|O
DDI-DrugBank.d249.s13|158-159|to|O
DDI-DrugBank.d249.s13|161-167|insulin|drug
DDI-DrugBank.d249.s13|169-170|or|O
DDI-DrugBank.d249.s13|172-175|oral|O
DDI-DrugBank.d249.s13|177-195|hypoglycemic agents|group
DDI-DrugBank.d249.s13|196-196|.|O
DDI-DrugBank.d249.s14|0-8|Diuretics|group
DDI-DrugBank.d249.s14|9-9|:|O
DDI-DrugBank.d249.s14|11-20|Diclofenac|drug
DDI-DrugBank.d249.s14|22-24|and|O
DDI-DrugBank.d249.s14|26-30|other|O
DDI-DrugBank.d249.s14|32-37|NSAIDs|group
DDI-DrugBank.d249.s14|39-41|can|O
DDI-DrugBank.d249.s14|43-49|inhibit|O
DDI-DrugBank.d249.s14|51-53|the|O
DDI-DrugBank.d249.s14|55-62|activity|O
DDI-DrugBank.d249.s14|64-65|of|O
DDI-DrugBank.d249.s14|67-75|diuretics|group
DDI-DrugBank.d249.s14|76-76|.|O
DDI-DrugBank.d249.s15|0-10|Concomitant|O
DDI-DrugBank.d249.s15|12-20|treatment|O
DDI-DrugBank.d249.s15|22-25|with|O
DDI-DrugBank.d249.s15|27-53|potassium-sparing diuretics|group
DDI-DrugBank.d249.s15|55-57|may|O
DDI-DrugBank.d249.s15|59-60|be|O
DDI-DrugBank.d249.s15|62-71|associated|O
DDI-DrugBank.d249.s15|73-76|with|O
DDI-DrugBank.d249.s15|78-86|increased|O
DDI-DrugBank.d249.s15|88-92|serum|O
DDI-DrugBank.d249.s15|94-102|potassium|O
DDI-DrugBank.d249.s15|104-109|levels|O
DDI-DrugBank.d249.s15|110-110|.|O
DDI-DrugBank.d249.s16|0-4|Other|O
DDI-DrugBank.d249.s16|6-10|Drugs|O
DDI-DrugBank.d249.s16|11-11|:|O
DDI-DrugBank.d249.s16|13-14|In|O
DDI-DrugBank.d249.s16|16-20|small|O
DDI-DrugBank.d249.s16|22-27|groups|O
DDI-DrugBank.d249.s16|29-30|of|O
DDI-DrugBank.d249.s16|32-39|patients|O
DDI-DrugBank.d249.s16|41-41|(|O
DDI-DrugBank.d249.s16|42-57|7-10/interaction|O
DDI-DrugBank.d249.s16|59-63|study|O
DDI-DrugBank.d249.s16|64-64|)|O
DDI-DrugBank.d249.s16|65-65|,|O
DDI-DrugBank.d249.s16|67-69|the|O
DDI-DrugBank.d249.s16|71-81|concomitant|O
DDI-DrugBank.d249.s16|83-96|administration|O
DDI-DrugBank.d249.s16|98-99|of|O
DDI-DrugBank.d249.s16|101-112|azathioprine|drug
DDI-DrugBank.d249.s16|113-113|,|O
DDI-DrugBank.d249.s16|115-118|gold|group
DDI-DrugBank.d249.s16|119-119|,|O
DDI-DrugBank.d249.s16|121-131|chloroquine|drug
DDI-DrugBank.d249.s16|132-132|,|O
DDI-DrugBank.d249.s16|134-148|D-penicillamine|drug
DDI-DrugBank.d249.s16|149-149|,|O
DDI-DrugBank.d249.s16|151-162|prednisolone|drug
DDI-DrugBank.d249.s16|163-163|,|O
DDI-DrugBank.d249.s16|165-175|doxycycline|drug
DDI-DrugBank.d249.s16|176-176|,|O
DDI-DrugBank.d249.s16|178-179|or|O
DDI-DrugBank.d249.s16|181-189|digitoxin|drug
DDI-DrugBank.d249.s16|191-193|did|O
DDI-DrugBank.d249.s16|195-197|not|O
DDI-DrugBank.d249.s16|199-211|significantly|O
DDI-DrugBank.d249.s16|213-218|affect|O
DDI-DrugBank.d249.s16|220-222|the|O
DDI-DrugBank.d249.s16|224-227|peak|O
DDI-DrugBank.d249.s16|229-234|levels|O
DDI-DrugBank.d249.s16|236-238|and|O
DDI-DrugBank.d249.s16|240-242|AUC|O
DDI-DrugBank.d249.s16|244-249|values|O
DDI-DrugBank.d249.s16|251-252|of|O
DDI-DrugBank.d249.s16|254-263|diclofenac|drug
DDI-DrugBank.d249.s16|264-264|.|O
DDI-DrugBank.d249.s17|0-12|Phenobarbital|drug
DDI-DrugBank.d249.s17|14-21|toxicity|O
DDI-DrugBank.d249.s17|23-25|has|O
DDI-DrugBank.d249.s17|27-30|been|O
DDI-DrugBank.d249.s17|32-39|reported|O
DDI-DrugBank.d249.s17|41-42|to|O
DDI-DrugBank.d249.s17|44-47|have|O
DDI-DrugBank.d249.s17|49-56|occurred|O
DDI-DrugBank.d249.s17|58-59|in|O
DDI-DrugBank.d249.s17|61-61|a|O
DDI-DrugBank.d249.s17|63-69|patient|O
DDI-DrugBank.d249.s17|71-72|on|O
DDI-DrugBank.d249.s17|74-80|chronic|O
DDI-DrugBank.d249.s17|82-94|phenobarbital|drug
DDI-DrugBank.d249.s17|96-104|treatment|O
DDI-DrugBank.d249.s17|106-114|following|O
DDI-DrugBank.d249.s17|116-118|the|O
DDI-DrugBank.d249.s17|120-129|initiation|O
DDI-DrugBank.d249.s17|131-132|of|O
DDI-DrugBank.d249.s17|134-143|diclofenac|drug
DDI-DrugBank.d249.s17|145-151|therapy|O
DDI-DrugBank.d249.s17|152-152|.|O
DDI-DrugBank.d249.s18|0-6|Protein|O
DDI-DrugBank.d249.s18|8-14|Binding|O
DDI-DrugBank.d249.s18|16-17|In|O
DDI-DrugBank.d249.s18|19-23|vitro|O
DDI-DrugBank.d249.s18|24-24|,|O
DDI-DrugBank.d249.s18|26-35|diclofenac|drug
DDI-DrugBank.d249.s18|37-46|interferes|O
DDI-DrugBank.d249.s18|48-56|minimally|O
DDI-DrugBank.d249.s18|58-59|or|O
DDI-DrugBank.d249.s18|61-63|not|O
DDI-DrugBank.d249.s18|65-66|at|O
DDI-DrugBank.d249.s18|68-70|all|O
DDI-DrugBank.d249.s18|72-75|with|O
DDI-DrugBank.d249.s18|77-79|the|O
DDI-DrugBank.d249.s18|81-87|protein|O
DDI-DrugBank.d249.s18|89-95|binding|O
DDI-DrugBank.d249.s18|97-98|of|O
DDI-DrugBank.d249.s18|100-113|salicylic acid|drug
DDI-DrugBank.d249.s18|115-115|(|O
DDI-DrugBank.d249.s18|116-117|20|O
DDI-DrugBank.d249.s18|118-118|%|O
DDI-DrugBank.d249.s18|120-127|decrease|O
DDI-DrugBank.d249.s18|129-130|in|O
DDI-DrugBank.d249.s18|132-138|binding|O
DDI-DrugBank.d249.s18|139-139|)|O
DDI-DrugBank.d249.s18|140-140|,|O
DDI-DrugBank.d249.s18|142-152|tolbutamide|drug
DDI-DrugBank.d249.s18|153-153|,|O
DDI-DrugBank.d249.s18|155-166|prednisolone|drug
DDI-DrugBank.d249.s18|168-168|(|O
DDI-DrugBank.d249.s18|169-170|10|O
DDI-DrugBank.d249.s18|171-171|%|O
DDI-DrugBank.d249.s18|173-180|decrease|O
DDI-DrugBank.d249.s18|182-183|in|O
DDI-DrugBank.d249.s18|185-191|binding|O
DDI-DrugBank.d249.s18|192-192|)|O
DDI-DrugBank.d249.s18|193-193|,|O
DDI-DrugBank.d249.s18|195-196|or|O
DDI-DrugBank.d249.s18|198-205|warfarin|drug
DDI-DrugBank.d249.s18|206-206|.|O
DDI-DrugBank.d249.s19|0-15|Benzylpenicillin|drug
DDI-DrugBank.d249.s19|16-16|,|O
DDI-DrugBank.d249.s19|18-27|ampicillin|drug
DDI-DrugBank.d249.s19|28-28|,|O
DDI-DrugBank.d249.s19|30-38|oxacillin|drug
DDI-DrugBank.d249.s19|39-39|,|O
DDI-DrugBank.d249.s19|41-57|chlortetracycline|drug
DDI-DrugBank.d249.s19|58-58|,|O
DDI-DrugBank.d249.s19|60-70|doxycycline|drug
DDI-DrugBank.d249.s19|71-71|,|O
DDI-DrugBank.d249.s19|73-83|cephalothin|drug
DDI-DrugBank.d249.s19|84-84|,|O
DDI-DrugBank.d249.s19|86-97|erythromycin|drug
DDI-DrugBank.d249.s19|98-98|,|O
DDI-DrugBank.d249.s19|100-102|and|O
DDI-DrugBank.d249.s19|104-119|sulfamethoxazole|drug
DDI-DrugBank.d249.s19|121-124|have|O
DDI-DrugBank.d249.s19|126-127|no|O
DDI-DrugBank.d249.s19|129-137|influence|O
DDI-DrugBank.d249.s19|139-140|in|O
DDI-DrugBank.d249.s19|142-146|vitro|O
DDI-DrugBank.d249.s19|148-149|on|O
DDI-DrugBank.d249.s19|151-153|the|O
DDI-DrugBank.d249.s19|155-161|protein|O
DDI-DrugBank.d249.s19|163-169|binding|O
DDI-DrugBank.d249.s19|171-172|of|O
DDI-DrugBank.d249.s19|174-183|diclofenac|drug
DDI-DrugBank.d249.s19|185-186|in|O
DDI-DrugBank.d249.s19|188-192|human|O
DDI-DrugBank.d249.s19|194-198|serum|O
DDI-DrugBank.d249.s19|199-199|.|O
DDI-DrugBank.d249.s20|0-14|Drug/Laboratory|O
DDI-DrugBank.d249.s20|16-19|Test|O
DDI-DrugBank.d249.s20|21-32|Interactions|O
DDI-DrugBank.d249.s20|34-39|Effect|O
DDI-DrugBank.d249.s20|41-42|on|O
DDI-DrugBank.d249.s20|44-48|Blood|O
DDI-DrugBank.d249.s20|50-60|Coagulation|O
DDI-DrugBank.d249.s20|61-61|:|O
DDI-DrugBank.d249.s20|63-72|Diclofenac|drug
DDI-DrugBank.d249.s20|74-82|increases|O
DDI-DrugBank.d249.s20|84-91|platelet|O
DDI-DrugBank.d249.s20|93-103|aggregation|O
DDI-DrugBank.d249.s20|105-108|time|O
DDI-DrugBank.d249.s20|110-112|but|O
DDI-DrugBank.d249.s20|114-117|does|O
DDI-DrugBank.d249.s20|119-121|not|O
DDI-DrugBank.d249.s20|123-128|affect|O
DDI-DrugBank.d249.s20|130-137|bleeding|O
DDI-DrugBank.d249.s20|139-142|time|O
DDI-DrugBank.d249.s20|143-143|,|O
DDI-DrugBank.d249.s20|145-150|plasma|O
DDI-DrugBank.d249.s20|152-159|thrombin|O
DDI-DrugBank.d249.s20|161-168|clotting|O
DDI-DrugBank.d249.s20|170-173|time|O
DDI-DrugBank.d249.s20|174-174|,|O
DDI-DrugBank.d249.s20|176-181|plasma|O
DDI-DrugBank.d249.s20|183-192|fibrinogen|O
DDI-DrugBank.d249.s20|193-193|,|O
DDI-DrugBank.d249.s20|195-196|or|O
DDI-DrugBank.d249.s20|198-204|factors|O
DDI-DrugBank.d249.s20|206-206|V|O
DDI-DrugBank.d249.s20|208-210|and|O
DDI-DrugBank.d249.s20|212-214|VII|O
DDI-DrugBank.d249.s20|216-217|to|O
DDI-DrugBank.d249.s20|219-221|XII|O
DDI-DrugBank.d249.s20|222-222|.|O
DDI-DrugBank.d249.s21|0-12|Statistically|O
DDI-DrugBank.d249.s21|14-24|significant|O
DDI-DrugBank.d249.s21|26-32|changes|O
DDI-DrugBank.d249.s21|34-35|in|O
DDI-DrugBank.d249.s21|37-47|prothrombin|O
DDI-DrugBank.d249.s21|49-51|and|O
DDI-DrugBank.d249.s21|53-59|partial|O
DDI-DrugBank.d249.s21|61-74|thromboplastin|O
DDI-DrugBank.d249.s21|76-80|times|O
DDI-DrugBank.d249.s21|82-85|have|O
DDI-DrugBank.d249.s21|87-90|been|O
DDI-DrugBank.d249.s21|92-99|reported|O
DDI-DrugBank.d249.s21|101-102|in|O
DDI-DrugBank.d249.s21|104-109|normal|O
DDI-DrugBank.d249.s21|111-120|volunteers|O
DDI-DrugBank.d249.s21|121-121|.|O
DDI-DrugBank.d249.s22|0-2|The|O
DDI-DrugBank.d249.s22|4-7|mean|O
DDI-DrugBank.d249.s22|9-15|changes|O
DDI-DrugBank.d249.s22|17-20|were|O
DDI-DrugBank.d249.s22|22-29|observed|O
DDI-DrugBank.d249.s22|31-32|to|O
DDI-DrugBank.d249.s22|34-35|be|O
DDI-DrugBank.d249.s22|37-40|less|O
DDI-DrugBank.d249.s22|42-45|than|O
DDI-DrugBank.d249.s22|47-47|1|O
DDI-DrugBank.d249.s22|49-54|second|O
DDI-DrugBank.d249.s22|56-57|in|O
DDI-DrugBank.d249.s22|59-62|both|O
DDI-DrugBank.d249.s22|64-72|instances|O
DDI-DrugBank.d249.s22|73-73|,|O
DDI-DrugBank.d249.s22|75-81|however|O
DDI-DrugBank.d249.s22|82-82|,|O
DDI-DrugBank.d249.s22|84-86|and|O
DDI-DrugBank.d249.s22|88-90|are|O
DDI-DrugBank.d249.s22|92-99|unlikely|O
DDI-DrugBank.d249.s22|101-102|to|O
DDI-DrugBank.d249.s22|104-105|be|O
DDI-DrugBank.d249.s22|107-116|clinically|O
DDI-DrugBank.d249.s22|118-126|important|O
DDI-DrugBank.d249.s22|127-127|.|O
DDI-DrugBank.d249.s23|0-9|Diclofenac|drug
DDI-DrugBank.d249.s23|11-12|is|O
DDI-DrugBank.d249.s23|14-14|a|O
DDI-DrugBank.d249.s23|16-28|prostaglandin|O
DDI-DrugBank.d249.s23|30-39|synthetase|O
DDI-DrugBank.d249.s23|41-49|inhibitor|O
DDI-DrugBank.d249.s23|50-50|,|O
DDI-DrugBank.d249.s23|52-58|however|O
DDI-DrugBank.d249.s23|59-59|,|O
DDI-DrugBank.d249.s23|61-63|and|O
DDI-DrugBank.d249.s23|65-67|all|O
DDI-DrugBank.d249.s23|69-73|drugs|O
DDI-DrugBank.d249.s23|75-78|that|O
DDI-DrugBank.d249.s23|80-86|inhibit|O
DDI-DrugBank.d249.s23|88-100|prostaglandin|O
DDI-DrugBank.d249.s23|102-110|synthesis|O
DDI-DrugBank.d249.s23|112-120|interfere|O
DDI-DrugBank.d249.s23|122-125|with|O
DDI-DrugBank.d249.s23|127-134|platelet|O
DDI-DrugBank.d249.s23|136-143|function|O
DDI-DrugBank.d249.s23|145-146|to|O
DDI-DrugBank.d249.s23|148-151|some|O
DDI-DrugBank.d249.s23|153-158|degree|O
DDI-DrugBank.d249.s23|159-159|;|O
DDI-DrugBank.d249.s24|0-8|therefore|O
DDI-DrugBank.d249.s24|9-9|,|O
DDI-DrugBank.d249.s24|11-18|patients|O
DDI-DrugBank.d249.s24|20-22|who|O
DDI-DrugBank.d249.s24|24-26|may|O
DDI-DrugBank.d249.s24|28-29|be|O
DDI-DrugBank.d249.s24|31-39|adversely|O
DDI-DrugBank.d249.s24|41-48|affected|O
DDI-DrugBank.d249.s24|50-51|by|O
DDI-DrugBank.d249.s24|53-56|such|O
DDI-DrugBank.d249.s24|58-59|an|O
DDI-DrugBank.d249.s24|61-66|action|O
DDI-DrugBank.d249.s24|68-73|should|O
DDI-DrugBank.d249.s24|75-76|be|O
DDI-DrugBank.d249.s24|78-86|carefully|O
DDI-DrugBank.d249.s24|88-95|observed|O
DDI-DrugBank.d249.s24|96-96|.|O
DDI-DrugBank.d470.s0|0-1|No|O
DDI-DrugBank.d470.s0|3-8|formal|O
DDI-DrugBank.d470.s0|10-20|assessments|O
DDI-DrugBank.d470.s0|22-23|of|O
DDI-DrugBank.d470.s0|25-39|pharmacokinetic|O
DDI-DrugBank.d470.s0|41-49|drug-drug|O
DDI-DrugBank.d470.s0|51-62|interactions|O
DDI-DrugBank.d470.s0|64-70|between|O
DDI-DrugBank.d470.s0|72-79|TRISENOX|brand
DDI-DrugBank.d470.s0|81-83|and|O
DDI-DrugBank.d470.s0|85-89|other|O
DDI-DrugBank.d470.s0|91-96|agents|O
DDI-DrugBank.d470.s0|98-101|have|O
DDI-DrugBank.d470.s0|103-106|been|O
DDI-DrugBank.d470.s0|108-116|conducted|O
DDI-DrugBank.d470.s0|117-117|.|O
DDI-DrugBank.d470.s1|0-6|Caution|O
DDI-DrugBank.d470.s1|8-9|is|O
DDI-DrugBank.d470.s1|11-17|advised|O
DDI-DrugBank.d470.s1|19-22|when|O
DDI-DrugBank.d470.s1|24-31|TRISENOX|brand
DDI-DrugBank.d470.s1|33-34|is|O
DDI-DrugBank.d470.s1|36-49|coadministered|O
DDI-DrugBank.d470.s1|51-54|with|O
DDI-DrugBank.d470.s1|56-60|other|O
DDI-DrugBank.d470.s1|62-72|medications|O
DDI-DrugBank.d470.s1|74-77|that|O
DDI-DrugBank.d470.s1|79-81|can|O
DDI-DrugBank.d470.s1|83-89|prolong|O
DDI-DrugBank.d470.s1|91-93|the|O
DDI-DrugBank.d470.s1|95-96|QT|O
DDI-DrugBank.d470.s1|98-105|interval|O
DDI-DrugBank.d470.s1|107-107|(|O
DDI-DrugBank.d470.s1|108-111|e.g.|O
DDI-DrugBank.d470.s1|113-119|certain|O
DDI-DrugBank.d470.s1|121-135|antiarrhythmics|group
DDI-DrugBank.d470.s1|137-138|or|O
DDI-DrugBank.d470.s1|140-151|thioridazine|drug
DDI-DrugBank.d470.s1|152-152|)|O
DDI-DrugBank.d470.s1|154-155|or|O
DDI-DrugBank.d470.s1|157-160|lead|O
DDI-DrugBank.d470.s1|162-163|to|O
DDI-DrugBank.d470.s1|165-175|electrolyte|O
DDI-DrugBank.d470.s1|177-189|abnormalities|O
DDI-DrugBank.d470.s1|191-191|(|O
DDI-DrugBank.d470.s1|192-195|such|O
DDI-DrugBank.d470.s1|197-198|as|O
DDI-DrugBank.d470.s1|200-208|diuretics|group
DDI-DrugBank.d470.s1|210-211|or|O
DDI-DrugBank.d470.s1|213-226|amphotericin B|drug
DDI-DrugBank.d470.s1|227-227|)|O
DDI-DrugBank.d470.s1|228-228|.|O
DDI-MedLine.d131.s0|0-10|Interaction|O
DDI-MedLine.d131.s0|12-13|on|O
DDI-MedLine.d131.s0|15-17|the|O
DDI-MedLine.d131.s0|19-33|antinociceptive|O
DDI-MedLine.d131.s0|35-40|effect|O
DDI-MedLine.d131.s0|42-48|between|O
DDI-MedLine.d131.s0|62-64|and|O
DDI-MedLine.d131.s0|78-79|or|O
DDI-MedLine.d131.s0|88-88|.|O
DDI-MedLine.d131.s1|0-2|The|O
DDI-MedLine.d131.s1|4-6|aim|O
DDI-MedLine.d131.s1|8-9|of|O
DDI-MedLine.d131.s1|11-14|this|O
DDI-MedLine.d131.s1|16-20|paper|O
DDI-MedLine.d131.s1|22-24|was|O
DDI-MedLine.d131.s1|26-27|to|O
DDI-MedLine.d131.s1|29-33|study|O
DDI-MedLine.d131.s1|35-37|the|O
DDI-MedLine.d131.s1|39-49|interaction|O
DDI-MedLine.d131.s1|51-57|between|O
DDI-MedLine.d131.s1|71-73|and|O
DDI-MedLine.d131.s1|75-78|both|O
DDI-MedLine.d131.s1|92-93|or|O
DDI-MedLine.d131.s1|95-97|its|O
DDI-MedLine.d131.s1|99-107|synthetic|O
DDI-MedLine.d131.s1|109-116|analogue|O
DDI-MedLine.d131.s1|143-143|,|O
DDI-MedLine.d131.s1|145-146|or|O
DDI-MedLine.d131.s1|155-155|,|O
DDI-MedLine.d131.s1|157-158|on|O
DDI-MedLine.d131.s1|160-162|the|O
DDI-MedLine.d131.s1|164-179|antinonciceptive|O
DDI-MedLine.d131.s1|181-186|effect|O
DDI-MedLine.d131.s1|188-189|of|O
DDI-MedLine.d131.s1|191-195|these|O
DDI-MedLine.d131.s1|197-204|peptides|O
DDI-MedLine.d131.s1|206-207|in|O
DDI-MedLine.d131.s1|209-212|mice|O
DDI-MedLine.d131.s1|214-218|after|O
DDI-MedLine.d131.s1|220-233|intracisternal|O
DDI-MedLine.d131.s1|235-243|injection|O
DDI-MedLine.d131.s1|244-244|.|O
DDI-MedLine.d131.s2|0-14|Antinociception|O
DDI-MedLine.d131.s2|16-18|was|O
DDI-MedLine.d131.s2|20-27|measured|O
DDI-MedLine.d131.s2|29-30|by|O
DDI-MedLine.d131.s2|32-34|the|O
DDI-MedLine.d131.s2|36-44|hot-plate|O
DDI-MedLine.d131.s2|46-51|method|O
DDI-MedLine.d131.s2|52-52|.|O
DDI-MedLine.d131.s3|0-1|It|O
DDI-MedLine.d131.s3|3-5|was|O
DDI-MedLine.d131.s3|7-11|shown|O
DDI-MedLine.d131.s3|13-16|that|O
DDI-MedLine.d131.s3|30-40|antagonized|O
DDI-MedLine.d131.s3|42-50|evidently|O
DDI-MedLine.d131.s3|52-54|the|O
DDI-MedLine.d131.s3|56-70|antinociceptive|O
DDI-MedLine.d131.s3|72-77|effect|O
DDI-MedLine.d131.s3|79-80|of|O
DDI-MedLine.d131.s3|94-96|and|O
DDI-MedLine.d131.s3|98-102|their|O
DDI-MedLine.d131.s3|104-111|analogue|O
DDI-MedLine.d131.s3|112-112|.|O
DDI-MedLine.d131.s4|0-1|On|O
DDI-MedLine.d131.s4|3-5|the|O
DDI-MedLine.d131.s4|7-14|contrary|O
DDI-MedLine.d131.s4|15-15|,|O
DDI-MedLine.d131.s4|29-31|and|O
DDI-MedLine.d131.s4|41-44|were|O
DDI-MedLine.d131.s4|46-53|agonists|O
DDI-MedLine.d131.s4|55-56|in|O
DDI-MedLine.d131.s4|58-66|induction|O
DDI-MedLine.d131.s4|68-69|of|O
DDI-MedLine.d131.s4|71-79|analgesia|O
DDI-MedLine.d131.s4|80-80|.|O
DDI-MedLine.d131.s5|0-1|It|O
DDI-MedLine.d131.s5|3-4|is|O
DDI-MedLine.d131.s5|6-14|concluded|O
DDI-MedLine.d131.s5|16-19|that|O
DDI-MedLine.d131.s5|33-41|modulates|O
DDI-MedLine.d131.s5|43-44|in|O
DDI-MedLine.d131.s5|46-47|an|O
DDI-MedLine.d131.s5|49-56|opposite|O
DDI-MedLine.d131.s5|58-60|way|O
DDI-MedLine.d131.s5|62-64|the|O
DDI-MedLine.d131.s5|66-73|function|O
DDI-MedLine.d131.s5|75-76|of|O
DDI-MedLine.d131.s5|78-80|the|O
DDI-MedLine.d131.s5|82-96|enkephalinergic|O
DDI-MedLine.d131.s5|98-104|neurons|O
DDI-MedLine.d131.s5|106-108|and|O
DDI-MedLine.d131.s5|110-112|the|O
DDI-MedLine.d131.s5|114-120|central|O
DDI-MedLine.d131.s5|122-127|action|O
DDI-MedLine.d131.s5|129-130|of|O
DDI-MedLine.d131.s5|139-139|.|O
DDI-DrugBank.d99.s0|0-4|Drugs|O
DDI-DrugBank.d99.s0|6-16|Metabolized|O
DDI-DrugBank.d99.s0|18-19|by|O
DDI-DrugBank.d99.s0|21-24|P450|O
DDI-DrugBank.d99.s0|26-28|2D6|O
DDI-DrugBank.d99.s0|30-30|-|O
DDI-DrugBank.d99.s0|32-34|The|O
DDI-DrugBank.d99.s0|36-46|biochemical|O
DDI-DrugBank.d99.s0|48-55|activity|O
DDI-DrugBank.d99.s0|57-58|of|O
DDI-DrugBank.d99.s0|60-62|the|O
DDI-DrugBank.d99.s0|64-67|drug|O
DDI-DrugBank.d99.s0|69-80|metabolizing|O
DDI-DrugBank.d99.s0|82-88|isozyme|O
DDI-DrugBank.d99.s0|90-99|cytochrome|O
DDI-DrugBank.d99.s0|101-104|P450|O
DDI-DrugBank.d99.s0|106-108|2D6|O
DDI-DrugBank.d99.s0|110-110|(|O
DDI-DrugBank.d99.s0|111-121|debrisoquin|O
DDI-DrugBank.d99.s0|123-133|hydroxylase|O
DDI-DrugBank.d99.s0|134-134|)|O
DDI-DrugBank.d99.s0|136-137|is|O
DDI-DrugBank.d99.s0|139-145|reduced|O
DDI-DrugBank.d99.s0|147-148|in|O
DDI-DrugBank.d99.s0|150-150|a|O
DDI-DrugBank.d99.s0|152-157|subset|O
DDI-DrugBank.d99.s0|159-160|of|O
DDI-DrugBank.d99.s0|162-164|the|O
DDI-DrugBank.d99.s0|166-174|caucasian|O
DDI-DrugBank.d99.s0|176-185|population|O
DDI-DrugBank.d99.s0|187-187|(|O
DDI-DrugBank.d99.s0|188-192|about|O
DDI-DrugBank.d99.s0|194-197|7-10|O
DDI-DrugBank.d99.s0|198-198|%|O
DDI-DrugBank.d99.s0|200-201|of|O
DDI-DrugBank.d99.s0|203-212|caucasians|O
DDI-DrugBank.d99.s0|214-216|are|O
DDI-DrugBank.d99.s0|218-219|so|O
DDI-DrugBank.d99.s0|221-226|called|O
DDI-DrugBank.d99.s0|228-231|poor|O
DDI-DrugBank.d99.s0|233-244|metabolizers|O
DDI-DrugBank.d99.s0|245-245|)|O
DDI-DrugBank.d99.s0|246-246|;|O
DDI-DrugBank.d99.s1|0-7|reliable|O
DDI-DrugBank.d99.s1|9-17|estimates|O
DDI-DrugBank.d99.s1|19-20|of|O
DDI-DrugBank.d99.s1|22-24|the|O
DDI-DrugBank.d99.s1|26-35|prevalence|O
DDI-DrugBank.d99.s1|37-38|of|O
DDI-DrugBank.d99.s1|40-46|reduced|O
DDI-DrugBank.d99.s1|48-51|P450|O
DDI-DrugBank.d99.s1|53-55|2D6|O
DDI-DrugBank.d99.s1|57-63|isozyme|O
DDI-DrugBank.d99.s1|65-72|activity|O
DDI-DrugBank.d99.s1|74-78|among|O
DDI-DrugBank.d99.s1|80-84|Asian|O
DDI-DrugBank.d99.s1|85-85|,|O
DDI-DrugBank.d99.s1|87-93|African|O
DDI-DrugBank.d99.s1|95-97|and|O
DDI-DrugBank.d99.s1|99-103|other|O
DDI-DrugBank.d99.s1|105-115|populations|O
DDI-DrugBank.d99.s1|117-119|are|O
DDI-DrugBank.d99.s1|121-123|not|O
DDI-DrugBank.d99.s1|125-127|yet|O
DDI-DrugBank.d99.s1|129-137|available|O
DDI-DrugBank.d99.s1|138-138|.|O
DDI-DrugBank.d99.s2|0-3|Poor|O
DDI-DrugBank.d99.s2|5-16|metabolizers|O
DDI-DrugBank.d99.s2|18-21|have|O
DDI-DrugBank.d99.s2|23-28|higher|O
DDI-DrugBank.d99.s2|30-33|than|O
DDI-DrugBank.d99.s2|35-42|expected|O
DDI-DrugBank.d99.s2|44-49|plasma|O
DDI-DrugBank.d99.s2|51-64|concentrations|O
DDI-DrugBank.d99.s2|66-67|of|O
DDI-DrugBank.d99.s2|69-93|tricyclic antidepressants|group
DDI-DrugBank.d99.s2|95-95|(|O
DDI-DrugBank.d99.s2|96-99|TCAs|group
DDI-DrugBank.d99.s2|100-100|)|O
DDI-DrugBank.d99.s2|102-105|when|O
DDI-DrugBank.d99.s2|107-111|given|O
DDI-DrugBank.d99.s2|113-117|usual|O
DDI-DrugBank.d99.s2|119-123|doses|O
DDI-DrugBank.d99.s2|124-124|.|O
DDI-DrugBank.d99.s3|0-8|Depending|O
DDI-DrugBank.d99.s3|10-11|on|O
DDI-DrugBank.d99.s3|13-15|the|O
DDI-DrugBank.d99.s3|17-24|fraction|O
DDI-DrugBank.d99.s3|26-27|of|O
DDI-DrugBank.d99.s3|29-32|drug|O
DDI-DrugBank.d99.s3|34-44|metabolized|O
DDI-DrugBank.d99.s3|46-47|by|O
DDI-DrugBank.d99.s3|49-52|P450|O
DDI-DrugBank.d99.s3|54-56|2D6|O
DDI-DrugBank.d99.s3|57-57|,|O
DDI-DrugBank.d99.s3|59-61|the|O
DDI-DrugBank.d99.s3|63-70|increase|O
DDI-DrugBank.d99.s3|72-73|in|O
DDI-DrugBank.d99.s3|75-80|plasma|O
DDI-DrugBank.d99.s3|82-94|concentration|O
DDI-DrugBank.d99.s3|96-98|may|O
DDI-DrugBank.d99.s3|100-101|be|O
DDI-DrugBank.d99.s3|103-107|small|O
DDI-DrugBank.d99.s3|108-108|,|O
DDI-DrugBank.d99.s3|110-111|or|O
DDI-DrugBank.d99.s3|113-117|quite|O
DDI-DrugBank.d99.s3|119-123|large|O
DDI-DrugBank.d99.s3|125-125|(|O
DDI-DrugBank.d99.s3|126-131|8-fold|O
DDI-DrugBank.d99.s3|133-140|increase|O
DDI-DrugBank.d99.s3|142-143|in|O
DDI-DrugBank.d99.s3|145-150|plasma|O
DDI-DrugBank.d99.s3|152-154|AUC|O
DDI-DrugBank.d99.s3|156-157|of|O
DDI-DrugBank.d99.s3|159-161|the|O
DDI-DrugBank.d99.s3|163-165|TCA|group
DDI-DrugBank.d99.s3|166-166|)|O
DDI-DrugBank.d99.s3|167-167|.|O
DDI-DrugBank.d99.s4|0-1|In|O
DDI-DrugBank.d99.s4|3-10|addition|O
DDI-DrugBank.d99.s4|11-11|,|O
DDI-DrugBank.d99.s4|13-19|certain|O
DDI-DrugBank.d99.s4|21-25|drugs|O
DDI-DrugBank.d99.s4|27-33|inhibit|O
DDI-DrugBank.d99.s4|35-37|the|O
DDI-DrugBank.d99.s4|39-46|activity|O
DDI-DrugBank.d99.s4|48-49|of|O
DDI-DrugBank.d99.s4|51-54|this|O
DDI-DrugBank.d99.s4|56-62|isozyme|O
DDI-DrugBank.d99.s4|64-66|and|O
DDI-DrugBank.d99.s4|68-71|make|O
DDI-DrugBank.d99.s4|73-78|normal|O
DDI-DrugBank.d99.s4|80-91|metabolizers|O
DDI-DrugBank.d99.s4|93-100|resemble|O
DDI-DrugBank.d99.s4|102-105|poor|O
DDI-DrugBank.d99.s4|107-118|metabolizers|O
DDI-DrugBank.d99.s4|119-119|.|O
DDI-DrugBank.d99.s5|0-1|An|O
DDI-DrugBank.d99.s5|3-12|individual|O
DDI-DrugBank.d99.s5|14-16|who|O
DDI-DrugBank.d99.s5|18-19|is|O
DDI-DrugBank.d99.s5|21-26|stable|O
DDI-DrugBank.d99.s5|28-29|on|O
DDI-DrugBank.d99.s5|31-31|a|O
DDI-DrugBank.d99.s5|33-37|given|O
DDI-DrugBank.d99.s5|39-42|dose|O
DDI-DrugBank.d99.s5|44-45|of|O
DDI-DrugBank.d99.s5|47-49|TCA|group
DDI-DrugBank.d99.s5|51-53|may|O
DDI-DrugBank.d99.s5|55-60|become|O
DDI-DrugBank.d99.s5|62-69|abruptly|O
DDI-DrugBank.d99.s5|71-75|toxic|O
DDI-DrugBank.d99.s5|77-80|when|O
DDI-DrugBank.d99.s5|82-86|given|O
DDI-DrugBank.d99.s5|88-90|one|O
DDI-DrugBank.d99.s5|92-93|of|O
DDI-DrugBank.d99.s5|95-99|these|O
DDI-DrugBank.d99.s5|101-110|inhibiting|O
DDI-DrugBank.d99.s5|112-116|drugs|O
DDI-DrugBank.d99.s5|118-119|as|O
DDI-DrugBank.d99.s5|121-131|concomitant|O
DDI-DrugBank.d99.s5|133-139|therapy|O
DDI-DrugBank.d99.s5|140-140|.|O
DDI-DrugBank.d99.s6|0-2|The|O
DDI-DrugBank.d99.s6|4-8|drugs|O
DDI-DrugBank.d99.s6|10-13|that|O
DDI-DrugBank.d99.s6|15-21|inhibit|O
DDI-DrugBank.d99.s6|23-32|cytochrome|O
DDI-DrugBank.d99.s6|34-37|P450|O
DDI-DrugBank.d99.s6|39-41|2D6|O
DDI-DrugBank.d99.s6|43-49|include|O
DDI-DrugBank.d99.s6|51-54|some|O
DDI-DrugBank.d99.s6|56-59|that|O
DDI-DrugBank.d99.s6|61-63|are|O
DDI-DrugBank.d99.s6|65-67|not|O
DDI-DrugBank.d99.s6|69-79|metabolized|O
DDI-DrugBank.d99.s6|81-82|by|O
DDI-DrugBank.d99.s6|84-86|the|O
DDI-DrugBank.d99.s6|88-93|enzyme|O
DDI-DrugBank.d99.s6|95-95|(|O
DDI-DrugBank.d99.s6|96-104|quinidine|drug
DDI-DrugBank.d99.s6|105-105|;|O
DDI-DrugBank.d99.s7|0-9|cimetidine|drug
DDI-DrugBank.d99.s7|10-10|)|O
DDI-DrugBank.d99.s7|12-14|and|O
DDI-DrugBank.d99.s7|16-19|many|O
DDI-DrugBank.d99.s7|21-24|that|O
DDI-DrugBank.d99.s7|26-28|are|O
DDI-DrugBank.d99.s7|30-39|substrates|O
DDI-DrugBank.d99.s7|41-43|for|O
DDI-DrugBank.d99.s7|45-48|P450|O
DDI-DrugBank.d99.s7|50-52|2D6|O
DDI-DrugBank.d99.s7|54-54|(|O
DDI-DrugBank.d99.s7|55-58|many|O
DDI-DrugBank.d99.s7|60-64|other|O
DDI-DrugBank.d99.s7|66-80|antidepressants|group
DDI-DrugBank.d99.s7|81-81|,|O
DDI-DrugBank.d99.s7|83-96|phenothiazines|group
DDI-DrugBank.d99.s7|97-97|,|O
DDI-DrugBank.d99.s7|99-101|and|O
DDI-DrugBank.d99.s7|103-105|the|O
DDI-DrugBank.d99.s7|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d99.s7|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d99.s7|143-145|and|O
DDI-DrugBank.d99.s7|147-156|flecainide|drug
DDI-DrugBank.d99.s7|157-157|)|O
DDI-DrugBank.d99.s7|158-158|.|O
DDI-DrugBank.d99.s8|0-4|While|O
DDI-DrugBank.d99.s8|6-8|all|O
DDI-DrugBank.d99.s8|10-12|the|O
DDI-DrugBank.d99.s8|14-22|selective|O
DDI-DrugBank.d99.s8|24-52|serotonin reuptake inhibitors|group
DDI-DrugBank.d99.s8|54-54|(|O
DDI-DrugBank.d99.s8|55-59|SSRIs|group
DDI-DrugBank.d99.s8|60-60|)|O
DDI-DrugBank.d99.s8|61-61|,|O
DDI-DrugBank.d99.s8|63-66|e.g.|O
DDI-DrugBank.d99.s8|67-67|,|O
DDI-DrugBank.d99.s8|69-78|fluoxetine|drug
DDI-DrugBank.d99.s8|79-79|,|O
DDI-DrugBank.d99.s8|81-90|sertraline|drug
DDI-DrugBank.d99.s8|91-91|,|O
DDI-DrugBank.d99.s8|93-95|and|O
DDI-DrugBank.d99.s8|97-106|paroxetine|drug
DDI-DrugBank.d99.s8|107-107|,|O
DDI-DrugBank.d99.s8|109-115|inhibit|O
DDI-DrugBank.d99.s8|117-120|P450|O
DDI-DrugBank.d99.s8|122-124|2D6|O
DDI-DrugBank.d99.s8|125-125|,|O
DDI-DrugBank.d99.s8|127-130|they|O
DDI-DrugBank.d99.s8|132-134|may|O
DDI-DrugBank.d99.s8|136-139|vary|O
DDI-DrugBank.d99.s8|141-142|in|O
DDI-DrugBank.d99.s8|144-146|the|O
DDI-DrugBank.d99.s8|148-153|extent|O
DDI-DrugBank.d99.s8|155-156|of|O
DDI-DrugBank.d99.s8|158-167|inhibition|O
DDI-DrugBank.d99.s8|168-168|.|O
DDI-DrugBank.d99.s9|0-2|The|O
DDI-DrugBank.d99.s9|4-9|extent|O
DDI-DrugBank.d99.s9|11-12|to|O
DDI-DrugBank.d99.s9|14-18|which|O
DDI-DrugBank.d99.s9|20-27|SSRI-TCA|group
DDI-DrugBank.d99.s9|29-40|interactions|O
DDI-DrugBank.d99.s9|42-44|may|O
DDI-DrugBank.d99.s9|46-49|pose|O
DDI-DrugBank.d99.s9|51-58|clinical|O
DDI-DrugBank.d99.s9|60-67|problems|O
DDI-DrugBank.d99.s9|69-72|will|O
DDI-DrugBank.d99.s9|74-79|depend|O
DDI-DrugBank.d99.s9|81-82|on|O
DDI-DrugBank.d99.s9|84-86|the|O
DDI-DrugBank.d99.s9|88-93|degree|O
DDI-DrugBank.d99.s9|95-96|of|O
DDI-DrugBank.d99.s9|98-107|inhibition|O
DDI-DrugBank.d99.s9|109-111|and|O
DDI-DrugBank.d99.s9|113-115|the|O
DDI-DrugBank.d99.s9|117-132|pharmacokinetics|O
DDI-DrugBank.d99.s9|134-135|of|O
DDI-DrugBank.d99.s9|137-139|the|O
DDI-DrugBank.d99.s9|141-144|SSRI|group
DDI-DrugBank.d99.s9|146-153|involved|O
DDI-DrugBank.d99.s9|154-154|.|O
DDI-DrugBank.d99.s10|0-11|Nevertheless|O
DDI-DrugBank.d99.s10|12-12|,|O
DDI-DrugBank.d99.s10|14-20|caution|O
DDI-DrugBank.d99.s10|22-23|is|O
DDI-DrugBank.d99.s10|25-33|indicated|O
DDI-DrugBank.d99.s10|35-36|in|O
DDI-DrugBank.d99.s10|38-40|the|O
DDI-DrugBank.d99.s10|42-57|coadministration|O
DDI-DrugBank.d99.s10|59-60|of|O
DDI-DrugBank.d99.s10|62-65|TCAs|group
DDI-DrugBank.d99.s10|67-70|with|O
DDI-DrugBank.d99.s10|72-74|any|O
DDI-DrugBank.d99.s10|76-77|of|O
DDI-DrugBank.d99.s10|79-81|the|O
DDI-DrugBank.d99.s10|83-87|SSRIs|group
DDI-DrugBank.d99.s10|89-91|and|O
DDI-DrugBank.d99.s10|93-96|also|O
DDI-DrugBank.d99.s10|98-99|in|O
DDI-DrugBank.d99.s10|101-109|switching|O
DDI-DrugBank.d99.s10|111-114|from|O
DDI-DrugBank.d99.s10|116-118|one|O
DDI-DrugBank.d99.s10|120-124|class|O
DDI-DrugBank.d99.s10|126-127|to|O
DDI-DrugBank.d99.s10|129-131|the|O
DDI-DrugBank.d99.s10|133-137|other|O
DDI-DrugBank.d99.s10|138-138|.|O
DDI-DrugBank.d99.s11|0-1|Of|O
DDI-DrugBank.d99.s11|3-12|particular|O
DDI-DrugBank.d99.s11|14-23|importance|O
DDI-DrugBank.d99.s11|24-24|,|O
DDI-DrugBank.d99.s11|26-35|sufficient|O
DDI-DrugBank.d99.s11|37-40|time|O
DDI-DrugBank.d99.s11|42-45|must|O
DDI-DrugBank.d99.s11|47-52|elapse|O
DDI-DrugBank.d99.s11|54-59|before|O
DDI-DrugBank.d99.s11|61-70|initiating|O
DDI-DrugBank.d99.s11|72-74|TCA|O
DDI-DrugBank.d99.s11|76-84|treatment|O
DDI-DrugBank.d99.s11|86-87|in|O
DDI-DrugBank.d99.s11|89-89|a|O
DDI-DrugBank.d99.s11|91-97|patient|O
DDI-DrugBank.d99.s11|99-103|being|O
DDI-DrugBank.d99.s11|105-113|withdrawn|O
DDI-DrugBank.d99.s11|115-118|from|O
DDI-DrugBank.d99.s11|120-129|fluoxetine|drug
DDI-DrugBank.d99.s11|130-130|,|O
DDI-DrugBank.d99.s11|132-136|given|O
DDI-DrugBank.d99.s11|138-140|the|O
DDI-DrugBank.d99.s11|142-145|long|O
DDI-DrugBank.d99.s11|147-155|half-life|O
DDI-DrugBank.d99.s11|157-158|of|O
DDI-DrugBank.d99.s11|160-162|the|O
DDI-DrugBank.d99.s11|164-169|parent|O
DDI-DrugBank.d99.s11|171-173|and|O
DDI-DrugBank.d99.s11|175-180|active|O
DDI-DrugBank.d99.s11|182-191|metabolite|O
DDI-DrugBank.d99.s11|193-193|(|O
DDI-DrugBank.d99.s11|194-195|at|O
DDI-DrugBank.d99.s11|197-201|least|O
DDI-DrugBank.d99.s11|203-203|5|O
DDI-DrugBank.d99.s11|205-209|weeks|O
DDI-DrugBank.d99.s11|211-213|may|O
DDI-DrugBank.d99.s11|215-216|be|O
DDI-DrugBank.d99.s11|218-226|necessary|O
DDI-DrugBank.d99.s11|227-227|)|O
DDI-DrugBank.d99.s11|228-228|.|O
DDI-DrugBank.d99.s12|0-10|Concomitant|O
DDI-DrugBank.d99.s12|12-14|use|O
DDI-DrugBank.d99.s12|16-17|of|O
DDI-DrugBank.d99.s12|19-43|tricyclic antidepressants|group
DDI-DrugBank.d99.s12|45-48|with|O
DDI-DrugBank.d99.s12|50-54|drugs|O
DDI-DrugBank.d99.s12|56-59|that|O
DDI-DrugBank.d99.s12|61-63|can|O
DDI-DrugBank.d99.s12|65-71|inhibit|O
DDI-DrugBank.d99.s12|73-82|cytochrome|O
DDI-DrugBank.d99.s12|84-87|P450|O
DDI-DrugBank.d99.s12|89-91|2D6|O
DDI-DrugBank.d99.s12|93-95|may|O
DDI-DrugBank.d99.s12|97-103|require|O
DDI-DrugBank.d99.s12|105-109|lower|O
DDI-DrugBank.d99.s12|111-115|doses|O
DDI-DrugBank.d99.s12|117-120|than|O
DDI-DrugBank.d99.s12|122-128|usually|O
DDI-DrugBank.d99.s12|130-139|prescribed|O
DDI-DrugBank.d99.s12|141-143|for|O
DDI-DrugBank.d99.s12|145-150|either|O
DDI-DrugBank.d99.s12|152-154|the|O
DDI-DrugBank.d99.s12|156-179|tricyclic antidepressant|group
DDI-DrugBank.d99.s12|181-182|or|O
DDI-DrugBank.d99.s12|184-186|the|O
DDI-DrugBank.d99.s12|188-192|other|O
DDI-DrugBank.d99.s12|194-197|drug|O
DDI-DrugBank.d99.s12|198-198|.|O
DDI-DrugBank.d99.s13|0-10|Furthermore|O
DDI-DrugBank.d99.s13|11-11|,|O
DDI-DrugBank.d99.s13|13-20|whenever|O
DDI-DrugBank.d99.s13|22-24|one|O
DDI-DrugBank.d99.s13|26-27|of|O
DDI-DrugBank.d99.s13|29-33|these|O
DDI-DrugBank.d99.s13|35-39|other|O
DDI-DrugBank.d99.s13|41-45|drugs|O
DDI-DrugBank.d99.s13|47-48|is|O
DDI-DrugBank.d99.s13|50-58|withdrawn|O
DDI-DrugBank.d99.s13|60-63|from|O
DDI-DrugBank.d99.s13|65-74|co-therapy|O
DDI-DrugBank.d99.s13|75-75|,|O
DDI-DrugBank.d99.s13|77-78|an|O
DDI-DrugBank.d99.s13|80-88|increased|O
DDI-DrugBank.d99.s13|90-93|dose|O
DDI-DrugBank.d99.s13|95-96|of|O
DDI-DrugBank.d99.s13|98-121|tricyclic antidepressant|drug
DDI-DrugBank.d99.s13|123-125|may|O
DDI-DrugBank.d99.s13|127-128|be|O
DDI-DrugBank.d99.s13|130-137|required|O
DDI-DrugBank.d99.s13|138-138|.|O
DDI-DrugBank.d99.s14|0-1|It|O
DDI-DrugBank.d99.s14|3-4|is|O
DDI-DrugBank.d99.s14|6-14|desirable|O
DDI-DrugBank.d99.s14|16-17|to|O
DDI-DrugBank.d99.s14|19-25|monitor|O
DDI-DrugBank.d99.s14|27-29|TCA|group
DDI-DrugBank.d99.s14|31-36|plasma|O
DDI-DrugBank.d99.s14|38-43|levels|O
DDI-DrugBank.d99.s14|45-52|whenever|O
DDI-DrugBank.d99.s14|54-54|a|O
DDI-DrugBank.d99.s14|56-58|TCA|group
DDI-DrugBank.d99.s14|60-61|is|O
DDI-DrugBank.d99.s14|63-67|going|O
DDI-DrugBank.d99.s14|69-70|to|O
DDI-DrugBank.d99.s14|72-73|be|O
DDI-DrugBank.d99.s14|75-88|coadministered|O
DDI-DrugBank.d99.s14|90-93|with|O
DDI-DrugBank.d99.s14|95-101|another|O
DDI-DrugBank.d99.s14|103-106|drug|O
DDI-DrugBank.d99.s14|108-112|known|O
DDI-DrugBank.d99.s14|114-115|to|O
DDI-DrugBank.d99.s14|117-118|be|O
DDI-DrugBank.d99.s14|120-121|an|O
DDI-DrugBank.d99.s14|123-131|inhibitor|O
DDI-DrugBank.d99.s14|133-134|of|O
DDI-DrugBank.d99.s14|136-139|P450|O
DDI-DrugBank.d99.s14|141-143|2D6|O
DDI-DrugBank.d99.s14|144-144|.|O
DDI-DrugBank.d99.s15|0-27|Monoamine Oxidase Inhibitors|drug
DDI-DrugBank.d99.s15|28-28|:|O
DDI-DrugBank.d99.s15|30-41|Guanethidine|drug
DDI-DrugBank.d99.s15|43-44|or|O
DDI-DrugBank.d99.s15|46-54|similarly|O
DDI-DrugBank.d99.s15|56-61|acting|O
DDI-DrugBank.d99.s15|63-71|compounds|O
DDI-DrugBank.d99.s15|72-72|;|O
DDI-DrugBank.d99.s16|0-6|thyroid|drug
DDI-DrugBank.d99.s16|8-17|medication|O
DDI-DrugBank.d99.s16|18-18|;|O
DDI-DrugBank.d99.s17|0-6|alcohol|drug
DDI-DrugBank.d99.s17|7-7|,|O
DDI-DrugBank.d99.s17|9-20|barbiturates|drug
DDI-DrugBank.d99.s17|22-24|and|O
DDI-DrugBank.d99.s17|26-30|other|O
DDI-DrugBank.d99.s17|32-46|CNS depressants|drug
DDI-DrugBank.d99.s17|47-47|;|O
DDI-DrugBank.d99.s18|0-2|and|O
DDI-DrugBank.d99.s18|4-13|disulfiram|drug
DDI-DrugBank.d99.s18|15-18|When|O
DDI-DrugBank.d99.s18|20-36|amitriptyline HCl|drug
DDI-DrugBank.d99.s18|38-39|is|O
DDI-DrugBank.d99.s18|41-45|given|O
DDI-DrugBank.d99.s18|47-50|with|O
DDI-DrugBank.d99.s18|52-66|anticholinergic|drug
DDI-DrugBank.d99.s18|68-73|agents|O
DDI-DrugBank.d99.s18|75-76|or|O
DDI-DrugBank.d99.s18|78-92|sympathomimetic|drug
DDI-DrugBank.d99.s18|94-98|drugs|O
DDI-DrugBank.d99.s18|99-99|,|O
DDI-DrugBank.d99.s18|101-109|including|O
DDI-DrugBank.d99.s18|111-121|epinephrine|drug
DDI-DrugBank.d99.s18|123-130|combined|O
DDI-DrugBank.d99.s18|132-135|with|O
DDI-DrugBank.d99.s18|137-141|local|O
DDI-DrugBank.d99.s18|143-153|anesthetics|drug
DDI-DrugBank.d99.s18|154-154|,|O
DDI-DrugBank.d99.s18|156-160|close|O
DDI-DrugBank.d99.s18|162-172|supervision|O
DDI-DrugBank.d99.s18|174-176|and|O
DDI-DrugBank.d99.s18|178-184|careful|O
DDI-DrugBank.d99.s18|186-195|adjustment|O
DDI-DrugBank.d99.s18|197-198|of|O
DDI-DrugBank.d99.s18|200-206|dosages|O
DDI-DrugBank.d99.s18|208-210|are|O
DDI-DrugBank.d99.s18|212-219|required|O
DDI-DrugBank.d99.s18|220-220|.|O
DDI-DrugBank.d99.s19|0-11|Hyperpyrexia|O
DDI-DrugBank.d99.s19|13-15|has|O
DDI-DrugBank.d99.s19|17-20|been|O
DDI-DrugBank.d99.s19|22-29|reported|O
DDI-DrugBank.d99.s19|31-34|when|O
DDI-DrugBank.d99.s19|36-52|amitriptyline HCl|drug
DDI-DrugBank.d99.s19|54-55|is|O
DDI-DrugBank.d99.s19|57-68|administered|O
DDI-DrugBank.d99.s19|70-73|with|O
DDI-DrugBank.d99.s19|75-89|anticholinergic|drug
DDI-DrugBank.d99.s19|91-96|agents|O
DDI-DrugBank.d99.s19|98-99|or|O
DDI-DrugBank.d99.s19|101-104|with|O
DDI-DrugBank.d99.s19|106-116|neuroleptic|drug
DDI-DrugBank.d99.s19|118-122|drugs|O
DDI-DrugBank.d99.s19|123-123|,|O
DDI-DrugBank.d99.s19|125-136|particularly|O
DDI-DrugBank.d99.s19|138-143|during|O
DDI-DrugBank.d99.s19|145-147|hot|O
DDI-DrugBank.d99.s19|149-155|weather|O
DDI-DrugBank.d99.s19|156-156|.|O
DDI-DrugBank.d99.s20|0-8|Paralytic|O
DDI-DrugBank.d99.s20|10-14|ileus|O
DDI-DrugBank.d99.s20|16-18|may|O
DDI-DrugBank.d99.s20|20-24|occur|O
DDI-DrugBank.d99.s20|26-27|in|O
DDI-DrugBank.d99.s20|29-36|patients|O
DDI-DrugBank.d99.s20|38-43|taking|O
DDI-DrugBank.d99.s20|45-69|tricyclic antidepressants|drug
DDI-DrugBank.d99.s20|71-72|in|O
DDI-DrugBank.d99.s20|74-84|combination|O
DDI-DrugBank.d99.s20|86-89|with|O
DDI-DrugBank.d99.s20|91-110|anticholinergic-type|drug
DDI-DrugBank.d99.s20|112-116|drugs|O
DDI-DrugBank.d99.s20|117-117|.|O
DDI-DrugBank.d99.s21|0-9|Cimetidine|drug
DDI-DrugBank.d99.s21|11-12|is|O
DDI-DrugBank.d99.s21|14-21|reported|O
DDI-DrugBank.d99.s21|23-24|to|O
DDI-DrugBank.d99.s21|26-31|reduce|O
DDI-DrugBank.d99.s21|33-39|hepatic|O
DDI-DrugBank.d99.s21|41-50|metabolism|O
DDI-DrugBank.d99.s21|52-53|of|O
DDI-DrugBank.d99.s21|55-61|certain|O
DDI-DrugBank.d99.s21|63-87|tricyclic antidepressants|drug
DDI-DrugBank.d99.s21|88-88|,|O
DDI-DrugBank.d99.s21|90-96|thereby|O
DDI-DrugBank.d99.s21|98-105|delaying|O
DDI-DrugBank.d99.s21|107-117|elimination|O
DDI-DrugBank.d99.s21|119-121|and|O
DDI-DrugBank.d99.s21|123-132|increasing|O
DDI-DrugBank.d99.s21|134-145|steady-state|O
DDI-DrugBank.d99.s21|147-160|concentrations|O
DDI-DrugBank.d99.s21|162-163|of|O
DDI-DrugBank.d99.s21|165-169|these|O
DDI-DrugBank.d99.s21|171-175|drugs|drug
DDI-DrugBank.d99.s21|176-176|.|O
DDI-DrugBank.d99.s22|0-9|Clinically|O
DDI-DrugBank.d99.s22|11-21|significant|O
DDI-DrugBank.d99.s22|23-29|effects|O
DDI-DrugBank.d99.s22|31-34|have|O
DDI-DrugBank.d99.s22|36-39|been|O
DDI-DrugBank.d99.s22|41-48|reported|O
DDI-DrugBank.d99.s22|50-53|with|O
DDI-DrugBank.d99.s22|55-57|the|O
DDI-DrugBank.d99.s22|59-83|tricyclic antidepressants|drug
DDI-DrugBank.d99.s22|85-88|when|O
DDI-DrugBank.d99.s22|90-93|used|O
DDI-DrugBank.d99.s22|95-107|concomitantly|O
DDI-DrugBank.d99.s22|109-112|with|O
DDI-DrugBank.d99.s22|114-123|cimetidine|drug
DDI-DrugBank.d99.s22|124-124|.|O
DDI-DrugBank.d99.s23|0-8|Increases|O
DDI-DrugBank.d99.s23|10-11|in|O
DDI-DrugBank.d99.s23|13-18|plasma|O
DDI-DrugBank.d99.s23|20-25|levels|O
DDI-DrugBank.d99.s23|27-28|of|O
DDI-DrugBank.d99.s23|30-54|tricyclic antidepressants|drug
DDI-DrugBank.d99.s23|55-55|,|O
DDI-DrugBank.d99.s23|57-59|and|O
DDI-DrugBank.d99.s23|61-62|in|O
DDI-DrugBank.d99.s23|64-66|the|O
DDI-DrugBank.d99.s23|68-76|frequency|O
DDI-DrugBank.d99.s23|78-80|and|O
DDI-DrugBank.d99.s23|82-89|severity|O
DDI-DrugBank.d99.s23|91-92|of|O
DDI-DrugBank.d99.s23|94-97|side|O
DDI-DrugBank.d99.s23|99-105|effects|O
DDI-DrugBank.d99.s23|106-106|,|O
DDI-DrugBank.d99.s23|108-119|particularly|O
DDI-DrugBank.d99.s23|121-135|anticholinergic|drug
DDI-DrugBank.d99.s23|136-136|,|O
DDI-DrugBank.d99.s23|138-141|have|O
DDI-DrugBank.d99.s23|143-146|been|O
DDI-DrugBank.d99.s23|148-155|reported|O
DDI-DrugBank.d99.s23|157-160|when|O
DDI-DrugBank.d99.s23|162-171|cimetidine|drug
DDI-DrugBank.d99.s23|173-175|was|O
DDI-DrugBank.d99.s23|177-181|added|O
DDI-DrugBank.d99.s23|183-184|to|O
DDI-DrugBank.d99.s23|186-188|the|O
DDI-DrugBank.d99.s23|190-193|drug|drug
DDI-DrugBank.d99.s23|195-201|regimen|O
DDI-DrugBank.d99.s23|202-202|.|O
DDI-DrugBank.d99.s24|0-14|Discontinuation|O
DDI-DrugBank.d99.s24|16-17|of|O
DDI-DrugBank.d99.s24|19-28|cimetidine|drug
DDI-DrugBank.d99.s24|30-31|in|O
DDI-DrugBank.d99.s24|33-47|well-controlled|O
DDI-DrugBank.d99.s24|49-56|patients|O
DDI-DrugBank.d99.s24|58-66|receiving|O
DDI-DrugBank.d99.s24|68-92|tricyclic antidepressants|drug
DDI-DrugBank.d99.s24|94-96|and|O
DDI-DrugBank.d99.s24|98-107|cimetidine|drug
DDI-DrugBank.d99.s24|109-111|may|O
DDI-DrugBank.d99.s24|113-120|decrease|O
DDI-DrugBank.d99.s24|122-124|the|O
DDI-DrugBank.d99.s24|126-131|plasma|O
DDI-DrugBank.d99.s24|133-138|levels|O
DDI-DrugBank.d99.s24|140-142|and|O
DDI-DrugBank.d99.s24|144-151|efficacy|O
DDI-DrugBank.d99.s24|153-154|of|O
DDI-DrugBank.d99.s24|156-158|the|O
DDI-DrugBank.d99.s24|160-174|antidepressants|drug
DDI-DrugBank.d99.s24|175-175|.|O
DDI-DrugBank.d99.s25|0-6|Caution|O
DDI-DrugBank.d99.s25|8-9|is|O
DDI-DrugBank.d99.s25|11-17|advised|O
DDI-DrugBank.d99.s25|19-20|if|O
DDI-DrugBank.d99.s25|22-29|patients|O
DDI-DrugBank.d99.s25|31-37|receive|O
DDI-DrugBank.d99.s25|39-43|large|O
DDI-DrugBank.d99.s25|45-49|doses|O
DDI-DrugBank.d99.s25|51-52|of|O
DDI-DrugBank.d99.s25|54-66|ethchlorvynol|drug
DDI-DrugBank.d99.s25|68-79|concurrently|O
DDI-DrugBank.d99.s25|80-80|.|O
DDI-DrugBank.d99.s26|0-8|Transient|O
DDI-DrugBank.d99.s26|10-17|delirium|O
DDI-DrugBank.d99.s26|19-21|has|O
DDI-DrugBank.d99.s26|23-26|been|O
DDI-DrugBank.d99.s26|28-35|reported|O
DDI-DrugBank.d99.s26|37-38|in|O
DDI-DrugBank.d99.s26|40-47|patients|O
DDI-DrugBank.d99.s26|49-51|who|O
DDI-DrugBank.d99.s26|53-56|were|O
DDI-DrugBank.d99.s26|58-64|treated|O
DDI-DrugBank.d99.s26|66-69|with|O
DDI-DrugBank.d99.s26|71-73|one|O
DDI-DrugBank.d99.s26|75-78|gram|O
DDI-DrugBank.d99.s26|80-81|of|O
DDI-DrugBank.d99.s26|83-95|ethchlorvynol|drug
DDI-DrugBank.d99.s26|97-99|and|O
DDI-DrugBank.d99.s26|101-102|75|O
DDI-DrugBank.d99.s26|104-104|-|O
DDI-DrugBank.d99.s26|106-108|150|O
DDI-DrugBank.d99.s26|110-111|mg|O
DDI-DrugBank.d99.s26|113-114|of|O
DDI-DrugBank.d99.s26|116-132|amitriptyline HCl|drug
DDI-DrugBank.d99.s26|133-133|.|O
DDI-MedLine.d21.s0|0-4|Acute|O
DDI-MedLine.d21.s0|6-11|effect|O
DDI-MedLine.d21.s0|13-14|of|O
DDI-MedLine.d21.s0|16-24|different|O
DDI-MedLine.d21.s0|26-40|antidepressants|group
DDI-MedLine.d21.s0|42-43|on|O
DDI-MedLine.d21.s0|45-52|glycemia|O
DDI-MedLine.d21.s0|54-55|in|O
DDI-MedLine.d21.s0|57-64|diabetic|O
DDI-MedLine.d21.s0|66-68|and|O
DDI-MedLine.d21.s0|70-81|non-diabetic|O
DDI-MedLine.d21.s0|83-86|rats|O
DDI-MedLine.d21.s0|87-87|.|O
DDI-MedLine.d21.s1|0-7|Diabetic|O
DDI-MedLine.d21.s1|9-16|patients|O
DDI-MedLine.d21.s1|18-21|have|O
DDI-MedLine.d21.s1|23-23|a|O
DDI-MedLine.d21.s1|25-26|20|O
DDI-MedLine.d21.s1|27-27|%|O
DDI-MedLine.d21.s1|29-34|higher|O
DDI-MedLine.d21.s1|36-39|risk|O
DDI-MedLine.d21.s1|41-42|of|O
DDI-MedLine.d21.s1|44-53|depression|O
DDI-MedLine.d21.s1|55-58|than|O
DDI-MedLine.d21.s1|60-62|the|O
DDI-MedLine.d21.s1|64-70|general|O
DDI-MedLine.d21.s1|72-81|population|O
DDI-MedLine.d21.s1|82-82|.|O
DDI-MedLine.d21.s2|0-8|Treatment|O
DDI-MedLine.d21.s2|10-13|with|O
DDI-MedLine.d21.s2|15-34|antidepressant drugs|group
DDI-MedLine.d21.s2|36-38|can|O
DDI-MedLine.d21.s2|40-47|directly|O
DDI-MedLine.d21.s2|49-57|interfere|O
DDI-MedLine.d21.s2|59-62|with|O
DDI-MedLine.d21.s2|64-68|blood|O
DDI-MedLine.d21.s2|70-76|glucose|O
DDI-MedLine.d21.s2|78-83|levels|O
DDI-MedLine.d21.s2|85-86|or|O
DDI-MedLine.d21.s2|88-90|may|O
DDI-MedLine.d21.s2|92-99|interact|O
DDI-MedLine.d21.s2|101-104|with|O
DDI-MedLine.d21.s2|106-124|hypoglycemic agents|group
DDI-MedLine.d21.s2|125-125|.|O
DDI-MedLine.d21.s3|0-2|The|O
DDI-MedLine.d21.s3|4-12|treatment|O
DDI-MedLine.d21.s3|14-15|of|O
DDI-MedLine.d21.s3|17-26|depression|O
DDI-MedLine.d21.s3|28-29|in|O
DDI-MedLine.d21.s3|31-38|diabetic|O
DDI-MedLine.d21.s3|40-47|patients|O
DDI-MedLine.d21.s3|49-52|must|O
DDI-MedLine.d21.s3|54-57|take|O
DDI-MedLine.d21.s3|59-62|into|O
DDI-MedLine.d21.s3|64-70|account|O
DDI-MedLine.d21.s3|72-81|variations|O
DDI-MedLine.d21.s3|83-84|of|O
DDI-MedLine.d21.s3|86-93|glycemic|O
DDI-MedLine.d21.s3|95-100|levels|O
DDI-MedLine.d21.s3|102-103|at|O
DDI-MedLine.d21.s3|105-113|different|O
DDI-MedLine.d21.s3|115-119|times|O
DDI-MedLine.d21.s3|121-123|and|O
DDI-MedLine.d21.s3|125-125|a|O
DDI-MedLine.d21.s3|127-136|comparison|O
DDI-MedLine.d21.s3|138-139|of|O
DDI-MedLine.d21.s3|141-143|the|O
DDI-MedLine.d21.s3|145-153|available|O
DDI-MedLine.d21.s3|155-175|antidepressant agents|group
DDI-MedLine.d21.s3|177-178|is|O
DDI-MedLine.d21.s3|180-188|important|O
DDI-MedLine.d21.s3|189-189|.|O
DDI-MedLine.d21.s4|0-1|In|O
DDI-MedLine.d21.s4|3-5|the|O
DDI-MedLine.d21.s4|7-13|present|O
DDI-MedLine.d21.s4|15-19|study|O
DDI-MedLine.d21.s4|21-22|we|O
DDI-MedLine.d21.s4|24-32|evaluated|O
DDI-MedLine.d21.s4|34-36|the|O
DDI-MedLine.d21.s4|38-49|interference|O
DDI-MedLine.d21.s4|51-52|of|O
DDI-MedLine.d21.s4|54-68|antidepressants|group
DDI-MedLine.d21.s4|70-73|with|O
DDI-MedLine.d21.s4|75-79|blood|O
DDI-MedLine.d21.s4|81-87|glucose|O
DDI-MedLine.d21.s4|89-94|levels|O
DDI-MedLine.d21.s4|96-97|of|O
DDI-MedLine.d21.s4|99-106|diabetic|O
DDI-MedLine.d21.s4|108-110|and|O
DDI-MedLine.d21.s4|112-123|non-diabetic|O
DDI-MedLine.d21.s4|125-128|rats|O
DDI-MedLine.d21.s4|129-129|.|O
DDI-MedLine.d21.s5|0-1|In|O
DDI-MedLine.d21.s5|3-3|a|O
DDI-MedLine.d21.s5|5-9|first|O
DDI-MedLine.d21.s5|11-20|experiment|O
DDI-MedLine.d21.s5|21-21|,|O
DDI-MedLine.d21.s5|23-26|male|O
DDI-MedLine.d21.s5|28-32|adult|O
DDI-MedLine.d21.s5|34-39|Wistar|O
DDI-MedLine.d21.s5|41-44|rats|O
DDI-MedLine.d21.s5|46-49|were|O
DDI-MedLine.d21.s5|51-56|fasted|O
DDI-MedLine.d21.s5|58-60|for|O
DDI-MedLine.d21.s5|62-63|12|O
DDI-MedLine.d21.s5|65-65|h|O
DDI-MedLine.d21.s5|66-66|.|O
DDI-MedLine.d21.s6|0-9|Imipramine|drug
DDI-MedLine.d21.s6|11-11|(|O
DDI-MedLine.d21.s6|12-12|5|O
DDI-MedLine.d21.s6|14-18|mg/kg|O
DDI-MedLine.d21.s6|19-19|)|O
DDI-MedLine.d21.s6|20-20|,|O
DDI-MedLine.d21.s6|22-32|moclobemide|drug
DDI-MedLine.d21.s6|34-34|(|O
DDI-MedLine.d21.s6|35-36|30|O
DDI-MedLine.d21.s6|38-42|mg/kg|O
DDI-MedLine.d21.s6|43-43|)|O
DDI-MedLine.d21.s6|44-44|,|O
DDI-MedLine.d21.s6|46-55|clonazepam|drug
DDI-MedLine.d21.s6|57-57|(|O
DDI-MedLine.d21.s6|58-61|0.25|O
DDI-MedLine.d21.s6|63-67|mg/kg|O
DDI-MedLine.d21.s6|68-68|)|O
DDI-MedLine.d21.s6|69-69|,|O
DDI-MedLine.d21.s6|71-80|fluoxetine|drug
DDI-MedLine.d21.s6|82-82|(|O
DDI-MedLine.d21.s6|83-84|20|O
DDI-MedLine.d21.s6|86-90|mg/kg|O
DDI-MedLine.d21.s6|91-91|)|O
DDI-MedLine.d21.s6|93-102|sertraline|drug
DDI-MedLine.d21.s6|104-104|(|O
DDI-MedLine.d21.s6|105-106|30|O
DDI-MedLine.d21.s6|108-112|mg/kg|O
DDI-MedLine.d21.s6|113-113|)|O
DDI-MedLine.d21.s6|115-116|or|O
DDI-MedLine.d21.s6|118-124|vehicle|O
DDI-MedLine.d21.s6|126-128|was|O
DDI-MedLine.d21.s6|130-141|administered|O
DDI-MedLine.d21.s6|142-142|.|O
DDI-MedLine.d21.s7|0-4|After|O
DDI-MedLine.d21.s7|6-7|30|O
DDI-MedLine.d21.s7|9-11|min|O
DDI-MedLine.d21.s7|12-12|,|O
DDI-MedLine.d21.s7|14-20|fasting|O
DDI-MedLine.d21.s7|22-29|glycemia|O
DDI-MedLine.d21.s7|31-33|was|O
DDI-MedLine.d21.s7|35-42|measured|O
DDI-MedLine.d21.s7|43-43|.|O
DDI-MedLine.d21.s8|0-1|An|O
DDI-MedLine.d21.s8|3-6|oral|O
DDI-MedLine.d21.s8|8-14|glucose|drug
DDI-MedLine.d21.s8|16-23|overload|O
DDI-MedLine.d21.s8|25-26|of|O
DDI-MedLine.d21.s8|28-28|1|O
DDI-MedLine.d21.s8|30-31|ml|O
DDI-MedLine.d21.s8|33-34|of|O
DDI-MedLine.d21.s8|36-36|a|O
DDI-MedLine.d21.s8|38-39|50|O
DDI-MedLine.d21.s8|40-40|%|O
DDI-MedLine.d21.s8|42-48|glucose|drug
DDI-MedLine.d21.s8|50-57|solution|O
DDI-MedLine.d21.s8|59-61|was|O
DDI-MedLine.d21.s8|63-67|given|O
DDI-MedLine.d21.s8|69-70|to|O
DDI-MedLine.d21.s8|72-75|rats|O
DDI-MedLine.d21.s8|77-79|and|O
DDI-MedLine.d21.s8|81-85|blood|O
DDI-MedLine.d21.s8|87-93|glucose|O
DDI-MedLine.d21.s8|95-97|was|O
DDI-MedLine.d21.s8|99-108|determined|O
DDI-MedLine.d21.s8|110-114|after|O
DDI-MedLine.d21.s8|116-117|30|O
DDI-MedLine.d21.s8|118-118|,|O
DDI-MedLine.d21.s8|120-121|60|O
DDI-MedLine.d21.s8|123-125|and|O
DDI-MedLine.d21.s8|127-128|90|O
DDI-MedLine.d21.s8|130-132|min|O
DDI-MedLine.d21.s8|133-133|.|O
DDI-MedLine.d21.s9|0-9|Imipramine|drug
DDI-MedLine.d21.s9|11-13|and|O
DDI-MedLine.d21.s9|15-24|clonazepam|drug
DDI-MedLine.d21.s9|26-28|did|O
DDI-MedLine.d21.s9|30-32|not|O
DDI-MedLine.d21.s9|34-39|change|O
DDI-MedLine.d21.s9|41-47|fasting|O
DDI-MedLine.d21.s9|49-50|or|O
DDI-MedLine.d21.s9|52-59|overload|O
DDI-MedLine.d21.s9|61-68|glycemia|O
DDI-MedLine.d21.s9|69-69|.|O
DDI-MedLine.d21.s10|0-9|Fluoxetine|drug
DDI-MedLine.d21.s10|11-13|and|O
DDI-MedLine.d21.s10|15-25|moclobemide|drug
DDI-MedLine.d21.s10|27-35|increased|O
DDI-MedLine.d21.s10|37-41|blood|O
DDI-MedLine.d21.s10|43-49|glucose|drug
DDI-MedLine.d21.s10|51-52|at|O
DDI-MedLine.d21.s10|54-62|different|O
DDI-MedLine.d21.s10|64-68|times|O
DDI-MedLine.d21.s10|70-74|after|O
DDI-MedLine.d21.s10|76-78|the|O
DDI-MedLine.d21.s10|80-86|glucose|O
DDI-MedLine.d21.s10|88-95|overload|O
DDI-MedLine.d21.s10|96-96|.|O
DDI-MedLine.d21.s11|0-9|Sertraline|drug
DDI-MedLine.d21.s11|11-21|neutralized|O
DDI-MedLine.d21.s11|23-25|the|O
DDI-MedLine.d21.s11|27-34|increase|O
DDI-MedLine.d21.s11|36-37|of|O
DDI-MedLine.d21.s11|39-46|glycemia|O
DDI-MedLine.d21.s11|48-54|induced|O
DDI-MedLine.d21.s11|56-57|by|O
DDI-MedLine.d21.s11|59-62|oral|O
DDI-MedLine.d21.s11|64-70|glucose|drug
DDI-MedLine.d21.s11|72-79|overload|O
DDI-MedLine.d21.s11|80-80|.|O
DDI-MedLine.d21.s12|0-1|In|O
DDI-MedLine.d21.s12|3-5|the|O
DDI-MedLine.d21.s12|7-12|second|O
DDI-MedLine.d21.s12|14-23|experiment|O
DDI-MedLine.d21.s12|24-24|,|O
DDI-MedLine.d21.s12|26-37|non-diabetic|O
DDI-MedLine.d21.s12|39-41|and|O
DDI-MedLine.d21.s12|43-64|streptozotocin-induced|O
DDI-MedLine.d21.s12|66-73|diabetic|O
DDI-MedLine.d21.s12|75-78|rats|O
DDI-MedLine.d21.s12|80-83|were|O
DDI-MedLine.d21.s12|85-90|fasted|O
DDI-MedLine.d21.s12|91-91|,|O
DDI-MedLine.d21.s12|93-95|and|O
DDI-MedLine.d21.s12|97-99|the|O
DDI-MedLine.d21.s12|101-104|same|O
DDI-MedLine.d21.s12|106-115|procedures|O
DDI-MedLine.d21.s12|117-120|were|O
DDI-MedLine.d21.s12|122-129|followed|O
DDI-MedLine.d21.s12|131-133|for|O
DDI-MedLine.d21.s12|135-144|estimation|O
DDI-MedLine.d21.s12|146-147|of|O
DDI-MedLine.d21.s12|149-155|glucose|drug
DDI-MedLine.d21.s12|157-165|tolerance|O
DDI-MedLine.d21.s12|167-168|30|O
DDI-MedLine.d21.s12|170-172|min|O
DDI-MedLine.d21.s12|174-178|after|O
DDI-MedLine.d21.s12|180-186|glucose|drug
DDI-MedLine.d21.s12|188-195|overload|O
DDI-MedLine.d21.s12|196-196|.|O
DDI-MedLine.d21.s13|0-4|Again|O
DDI-MedLine.d21.s13|5-5|,|O
DDI-MedLine.d21.s13|7-16|sertraline|drug
DDI-MedLine.d21.s13|18-28|neutralized|O
DDI-MedLine.d21.s13|30-32|the|O
DDI-MedLine.d21.s13|34-41|increase|O
DDI-MedLine.d21.s13|43-44|in|O
DDI-MedLine.d21.s13|46-53|glycemia|O
DDI-MedLine.d21.s13|55-59|after|O
DDI-MedLine.d21.s13|61-67|glucose|drug
DDI-MedLine.d21.s13|69-76|overload|O
DDI-MedLine.d21.s13|78-81|both|O
DDI-MedLine.d21.s13|83-84|in|O
DDI-MedLine.d21.s13|86-93|diabetic|O
DDI-MedLine.d21.s13|95-97|and|O
DDI-MedLine.d21.s13|99-110|non-diabetic|O
DDI-MedLine.d21.s13|112-115|rats|O
DDI-MedLine.d21.s13|116-116|.|O
DDI-MedLine.d21.s14|0-4|These|O
DDI-MedLine.d21.s14|6-9|data|O
DDI-MedLine.d21.s14|11-15|raise|O
DDI-MedLine.d21.s14|17-19|the|O
DDI-MedLine.d21.s14|21-28|question|O
DDI-MedLine.d21.s14|30-31|of|O
DDI-MedLine.d21.s14|33-39|whether|O
DDI-MedLine.d21.s14|41-50|sertraline|drug
DDI-MedLine.d21.s14|52-53|is|O
DDI-MedLine.d21.s14|55-57|the|O
DDI-MedLine.d21.s14|59-62|best|O
DDI-MedLine.d21.s14|64-69|choice|O
DDI-MedLine.d21.s14|71-73|for|O
DDI-MedLine.d21.s14|75-83|prolonged|O
DDI-MedLine.d21.s14|85-87|use|O
DDI-MedLine.d21.s14|89-91|for|O
DDI-MedLine.d21.s14|93-100|diabetic|O
DDI-MedLine.d21.s14|102-112|individuals|O
DDI-MedLine.d21.s14|113-113|,|O
DDI-MedLine.d21.s14|115-121|because|O
DDI-MedLine.d21.s14|123-124|of|O
DDI-MedLine.d21.s14|126-128|its|O
DDI-MedLine.d21.s14|130-146|antihyperglycemic|O
DDI-MedLine.d21.s14|148-154|effects|O
DDI-MedLine.d21.s14|155-155|.|O
DDI-MedLine.d21.s15|0-9|Clonazepam|drug
DDI-MedLine.d21.s15|11-15|would|O
DDI-MedLine.d21.s15|17-18|be|O
DDI-MedLine.d21.s15|20-25|useful|O
DDI-MedLine.d21.s15|27-28|in|O
DDI-MedLine.d21.s15|30-34|cases|O
DDI-MedLine.d21.s15|36-39|with|O
DDI-MedLine.d21.s15|41-49|potential|O
DDI-MedLine.d21.s15|51-54|risk|O
DDI-MedLine.d21.s15|56-57|of|O
DDI-MedLine.d21.s15|59-70|hypoglycemia|O
DDI-MedLine.d21.s15|71-71|.|O
DDI-DrugBank.d615.s0|0-11|Triprolidine|drug
DDI-DrugBank.d615.s0|13-15|may|O
DDI-DrugBank.d615.s0|17-23|enhance|O
DDI-DrugBank.d615.s0|25-27|the|O
DDI-DrugBank.d615.s0|29-36|sedative|O
DDI-DrugBank.d615.s0|38-44|effects|O
DDI-DrugBank.d615.s0|46-47|of|O
DDI-DrugBank.d615.s0|49-82|central nervous system depressants|group
DDI-DrugBank.d615.s0|84-92|including|O
DDI-DrugBank.d615.s0|94-100|alcohol|drug
DDI-DrugBank.d615.s0|101-101|,|O
DDI-DrugBank.d615.s0|103-114|barbiturates|group
DDI-DrugBank.d615.s0|115-115|,|O
DDI-DrugBank.d615.s0|117-125|hypnotics|group
DDI-DrugBank.d615.s0|126-126|,|O
DDI-DrugBank.d615.s0|128-146|narcotic analgesics|group
DDI-DrugBank.d615.s0|147-147|,|O
DDI-DrugBank.d615.s0|149-157|sedatives|group
DDI-DrugBank.d615.s0|158-158|,|O
DDI-DrugBank.d615.s0|160-162|and|O
DDI-DrugBank.d615.s0|164-177|tranquillisers|group
DDI-DrugBank.d615.s0|178-178|.|O
DDI-DrugBank.d615.s1|0-2|The|O
DDI-DrugBank.d615.s1|4-10|effects|O
DDI-DrugBank.d615.s1|12-13|of|O
DDI-DrugBank.d615.s1|15-35|anticholinergic drugs|group
DDI-DrugBank.d615.s1|36-36|,|O
DDI-DrugBank.d615.s1|38-41|such|O
DDI-DrugBank.d615.s1|43-44|as|O
DDI-DrugBank.d615.s1|46-53|atropine|drug
DDI-DrugBank.d615.s1|55-57|and|O
DDI-DrugBank.d615.s1|59-83|tricyclic antidepressants|group
DDI-DrugBank.d615.s1|85-87|may|O
DDI-DrugBank.d615.s1|89-90|be|O
DDI-DrugBank.d615.s1|92-99|enhanced|O
DDI-DrugBank.d615.s1|101-102|by|O
DDI-DrugBank.d615.s1|104-106|the|O
DDI-DrugBank.d615.s1|108-118|concomitant|O
DDI-DrugBank.d615.s1|120-133|administration|O
DDI-DrugBank.d615.s1|135-136|of|O
DDI-DrugBank.d615.s1|138-149|triprolidine|drug
DDI-DrugBank.d615.s1|150-150|.|O
DDI-DrugBank.d615.s2|0-11|Triprolidine|drug
DDI-DrugBank.d615.s2|13-15|may|O
DDI-DrugBank.d615.s2|17-22|effect|O
DDI-DrugBank.d615.s2|24-26|the|O
DDI-DrugBank.d615.s2|28-37|metabolism|O
DDI-DrugBank.d615.s2|39-40|of|O
DDI-DrugBank.d615.s2|42-46|drugs|O
DDI-DrugBank.d615.s2|48-49|in|O
DDI-DrugBank.d615.s2|51-53|the|O
DDI-DrugBank.d615.s2|55-59|liver|O
DDI-DrugBank.d615.s2|60-60|.|O
DDI-DrugBank.d220.s0|0-8|Drug-drug|O
DDI-DrugBank.d220.s0|10-21|interactions|O
DDI-DrugBank.d220.s0|23-26|with|O
DDI-DrugBank.d220.s0|28-37|Mefloquine|drug
DDI-DrugBank.d220.s0|39-42|have|O
DDI-DrugBank.d220.s0|44-46|not|O
DDI-DrugBank.d220.s0|48-51|been|O
DDI-DrugBank.d220.s0|53-60|explored|O
DDI-DrugBank.d220.s0|62-63|in|O
DDI-DrugBank.d220.s0|65-70|detail|O
DDI-DrugBank.d220.s0|71-71|.|O
DDI-DrugBank.d220.s1|0-4|There|O
DDI-DrugBank.d220.s1|6-7|is|O
DDI-DrugBank.d220.s1|9-11|one|O
DDI-DrugBank.d220.s1|13-18|report|O
DDI-DrugBank.d220.s1|20-21|of|O
DDI-DrugBank.d220.s1|23-37|cardiopulmonary|O
DDI-DrugBank.d220.s1|39-44|arrest|O
DDI-DrugBank.d220.s1|45-45|,|O
DDI-DrugBank.d220.s1|47-50|with|O
DDI-DrugBank.d220.s1|52-55|full|O
DDI-DrugBank.d220.s1|57-64|recovery|O
DDI-DrugBank.d220.s1|65-65|,|O
DDI-DrugBank.d220.s1|67-68|in|O
DDI-DrugBank.d220.s1|70-70|a|O
DDI-DrugBank.d220.s1|72-78|patient|O
DDI-DrugBank.d220.s1|80-82|who|O
DDI-DrugBank.d220.s1|84-86|was|O
DDI-DrugBank.d220.s1|88-93|taking|O
DDI-DrugBank.d220.s1|95-95|a|O
DDI-DrugBank.d220.s1|97-108|beta blocker|group
DDI-DrugBank.d220.s1|110-110|(|O
DDI-DrugBank.d220.s1|111-121|propranolol|drug
DDI-DrugBank.d220.s1|122-122|)|O
DDI-DrugBank.d220.s1|123-123|.|O
DDI-DrugBank.d220.s2|0-2|The|O
DDI-DrugBank.d220.s2|4-10|effects|O
DDI-DrugBank.d220.s2|12-13|of|O
DDI-DrugBank.d220.s2|15-28|Mefloquineuine|O
DDI-DrugBank.d220.s2|30-31|on|O
DDI-DrugBank.d220.s2|33-35|the|O
DDI-DrugBank.d220.s2|37-47|compromised|O
DDI-DrugBank.d220.s2|49-62|cardiovascular|O
DDI-DrugBank.d220.s2|64-69|system|O
DDI-DrugBank.d220.s2|71-74|have|O
DDI-DrugBank.d220.s2|76-78|not|O
DDI-DrugBank.d220.s2|80-83|been|O
DDI-DrugBank.d220.s2|85-93|evaluated|O
DDI-DrugBank.d220.s2|94-94|.|O
DDI-DrugBank.d220.s3|0-2|The|O
DDI-DrugBank.d220.s3|4-11|benefits|O
DDI-DrugBank.d220.s3|13-14|of|O
DDI-DrugBank.d220.s3|16-25|Mefloquine|drug
DDI-DrugBank.d220.s3|27-33|therapy|O
DDI-DrugBank.d220.s3|35-40|should|O
DDI-DrugBank.d220.s3|42-43|be|O
DDI-DrugBank.d220.s3|45-51|weighed|O
DDI-DrugBank.d220.s3|53-59|against|O
DDI-DrugBank.d220.s3|61-63|the|O
DDI-DrugBank.d220.s3|65-75|possibility|O
DDI-DrugBank.d220.s3|77-78|of|O
DDI-DrugBank.d220.s3|80-86|adverse|O
DDI-DrugBank.d220.s3|88-94|effects|O
DDI-DrugBank.d220.s3|96-97|in|O
DDI-DrugBank.d220.s3|99-106|patients|O
DDI-DrugBank.d220.s3|108-111|with|O
DDI-DrugBank.d220.s3|113-119|cardiac|O
DDI-DrugBank.d220.s3|121-127|disease|O
DDI-DrugBank.d220.s3|128-128|.|O
DDI-DrugBank.d220.s4|0-6|Because|O
DDI-DrugBank.d220.s4|8-9|of|O
DDI-DrugBank.d220.s4|11-13|the|O
DDI-DrugBank.d220.s4|15-20|danger|O
DDI-DrugBank.d220.s4|22-23|of|O
DDI-DrugBank.d220.s4|25-25|a|O
DDI-DrugBank.d220.s4|27-37|potentially|O
DDI-DrugBank.d220.s4|39-43|fatal|O
DDI-DrugBank.d220.s4|45-56|prolongation|O
DDI-DrugBank.d220.s4|58-59|of|O
DDI-DrugBank.d220.s4|61-63|the|O
DDI-DrugBank.d220.s4|65-67|QTc|O
DDI-DrugBank.d220.s4|69-76|interval|O
DDI-DrugBank.d220.s4|77-77|,|O
DDI-DrugBank.d220.s4|79-90|halofantrine|drug
DDI-DrugBank.d220.s4|92-95|must|O
DDI-DrugBank.d220.s4|97-99|not|O
DDI-DrugBank.d220.s4|101-102|be|O
DDI-DrugBank.d220.s4|104-108|given|O
DDI-DrugBank.d220.s4|110-123|simultaneously|O
DDI-DrugBank.d220.s4|125-128|with|O
DDI-DrugBank.d220.s4|130-131|or|O
DDI-DrugBank.d220.s4|133-142|subsequent|O
DDI-DrugBank.d220.s4|144-145|to|O
DDI-DrugBank.d220.s4|147-156|Mefloquine|drug
DDI-DrugBank.d220.s4|157-157|.|O
DDI-DrugBank.d220.s5|0-10|Concomitant|O
DDI-DrugBank.d220.s5|12-25|administration|O
DDI-DrugBank.d220.s5|27-28|of|O
DDI-DrugBank.d220.s5|30-39|Mefloquine|drug
DDI-DrugBank.d220.s5|41-43|and|O
DDI-DrugBank.d220.s5|45-49|other|O
DDI-DrugBank.d220.s5|51-57|related|O
DDI-DrugBank.d220.s5|59-67|compounds|O
DDI-DrugBank.d220.s5|69-69|(|O
DDI-DrugBank.d220.s5|70-71|eg|O
DDI-DrugBank.d220.s5|72-72|,|O
DDI-DrugBank.d220.s5|74-80|quinine|drug
DDI-DrugBank.d220.s5|81-81|,|O
DDI-DrugBank.d220.s5|83-91|quinidine|drug
DDI-DrugBank.d220.s5|93-95|and|O
DDI-DrugBank.d220.s5|97-107|chloroquine|drug
DDI-DrugBank.d220.s5|108-108|)|O
DDI-DrugBank.d220.s5|110-112|may|O
DDI-DrugBank.d220.s5|114-120|produce|O
DDI-DrugBank.d220.s5|122-141|electrocardiographic|O
DDI-DrugBank.d220.s5|143-155|abnormalities|O
DDI-DrugBank.d220.s5|157-159|and|O
DDI-DrugBank.d220.s5|161-168|increase|O
DDI-DrugBank.d220.s5|170-172|the|O
DDI-DrugBank.d220.s5|174-177|risk|O
DDI-DrugBank.d220.s5|179-180|of|O
DDI-DrugBank.d220.s5|182-192|convulsions|O
DDI-DrugBank.d220.s5|193-193|.|O
DDI-DrugBank.d220.s6|0-1|If|O
DDI-DrugBank.d220.s6|3-7|these|O
DDI-DrugBank.d220.s6|9-13|drugs|O
DDI-DrugBank.d220.s6|15-17|are|O
DDI-DrugBank.d220.s6|19-20|to|O
DDI-DrugBank.d220.s6|22-23|be|O
DDI-DrugBank.d220.s6|25-28|used|O
DDI-DrugBank.d220.s6|30-31|in|O
DDI-DrugBank.d220.s6|33-35|the|O
DDI-DrugBank.d220.s6|37-43|initial|O
DDI-DrugBank.d220.s6|45-53|treatment|O
DDI-DrugBank.d220.s6|55-56|of|O
DDI-DrugBank.d220.s6|58-63|severe|O
DDI-DrugBank.d220.s6|65-71|malaria|O
DDI-DrugBank.d220.s6|72-72|,|O
DDI-DrugBank.d220.s6|74-83|Mefloquine|drug
DDI-DrugBank.d220.s6|85-98|administration|O
DDI-DrugBank.d220.s6|100-105|should|O
DDI-DrugBank.d220.s6|107-108|be|O
DDI-DrugBank.d220.s6|110-116|delayed|O
DDI-DrugBank.d220.s6|118-119|at|O
DDI-DrugBank.d220.s6|121-125|least|O
DDI-DrugBank.d220.s6|127-128|12|O
DDI-DrugBank.d220.s6|130-134|hours|O
DDI-DrugBank.d220.s6|136-140|after|O
DDI-DrugBank.d220.s6|142-144|the|O
DDI-DrugBank.d220.s6|146-149|last|O
DDI-DrugBank.d220.s6|151-154|dose|O
DDI-DrugBank.d220.s6|155-155|.|O
DDI-DrugBank.d220.s7|0-4|There|O
DDI-DrugBank.d220.s7|6-7|is|O
DDI-DrugBank.d220.s7|9-16|evidence|O
DDI-DrugBank.d220.s7|18-21|that|O
DDI-DrugBank.d220.s7|23-25|the|O
DDI-DrugBank.d220.s7|27-29|use|O
DDI-DrugBank.d220.s7|31-32|of|O
DDI-DrugBank.d220.s7|34-45|halofantrine|drug
DDI-DrugBank.d220.s7|47-51|after|O
DDI-DrugBank.d220.s7|53-66|Mefloquineuine|O
DDI-DrugBank.d220.s7|68-73|causes|O
DDI-DrugBank.d220.s7|75-75|a|O
DDI-DrugBank.d220.s7|77-87|significant|O
DDI-DrugBank.d220.s7|89-99|lengthening|O
DDI-DrugBank.d220.s7|101-102|of|O
DDI-DrugBank.d220.s7|104-106|the|O
DDI-DrugBank.d220.s7|108-110|QTc|O
DDI-DrugBank.d220.s7|112-119|interval|O
DDI-DrugBank.d220.s7|120-120|.|O
DDI-DrugBank.d220.s8|0-9|Clinically|O
DDI-DrugBank.d220.s8|11-21|significant|O
DDI-DrugBank.d220.s8|23-25|QTc|O
DDI-DrugBank.d220.s8|27-38|prolongation|O
DDI-DrugBank.d220.s8|40-42|has|O
DDI-DrugBank.d220.s8|44-46|not|O
DDI-DrugBank.d220.s8|48-51|been|O
DDI-DrugBank.d220.s8|53-57|found|O
DDI-DrugBank.d220.s8|59-62|with|O
DDI-DrugBank.d220.s8|64-77|Mefloquineuine|O
DDI-DrugBank.d220.s8|79-83|alone|O
DDI-DrugBank.d220.s8|84-84|.|O
DDI-DrugBank.d220.s9|0-3|This|O
DDI-DrugBank.d220.s9|5-11|appears|O
DDI-DrugBank.d220.s9|13-14|to|O
DDI-DrugBank.d220.s9|16-17|be|O
DDI-DrugBank.d220.s9|19-21|the|O
DDI-DrugBank.d220.s9|23-26|only|O
DDI-DrugBank.d220.s9|28-37|clinically|O
DDI-DrugBank.d220.s9|39-46|relevant|O
DDI-DrugBank.d220.s9|48-58|interaction|O
DDI-DrugBank.d220.s9|60-61|of|O
DDI-DrugBank.d220.s9|63-66|this|O
DDI-DrugBank.d220.s9|68-71|kind|O
DDI-DrugBank.d220.s9|73-76|with|O
DDI-DrugBank.d220.s9|78-87|Mefloquine|drug
DDI-DrugBank.d220.s9|88-88|,|O
DDI-DrugBank.d220.s9|90-97|although|O
DDI-DrugBank.d220.s9|99-111|theoretically|O
DDI-DrugBank.d220.s9|112-112|,|O
DDI-DrugBank.d220.s9|114-129|coadministration|O
DDI-DrugBank.d220.s9|131-132|of|O
DDI-DrugBank.d220.s9|134-138|other|O
DDI-DrugBank.d220.s9|140-144|drugs|O
DDI-DrugBank.d220.s9|146-150|known|O
DDI-DrugBank.d220.s9|152-153|to|O
DDI-DrugBank.d220.s9|155-159|alter|O
DDI-DrugBank.d220.s9|161-167|cardiac|O
DDI-DrugBank.d220.s9|169-178|conduction|O
DDI-DrugBank.d220.s9|180-180|(|O
DDI-DrugBank.d220.s9|181-182|eg|O
DDI-DrugBank.d220.s9|183-183|,|O
DDI-DrugBank.d220.s9|185-199|anti-arrhythmic|drug
DDI-DrugBank.d220.s9|201-202|or|O
DDI-DrugBank.d220.s9|204-234|beta-adrenergic blocking agents|group
DDI-DrugBank.d220.s9|235-235|,|O
DDI-DrugBank.d220.s9|237-260|calcium channel blockers|group
DDI-DrugBank.d220.s9|261-261|,|O
DDI-DrugBank.d220.s9|263-276|antihistamines|group
DDI-DrugBank.d220.s9|278-279|or|O
DDI-DrugBank.d220.s9|281-298|H1-blocking agents|group
DDI-DrugBank.d220.s9|299-299|,|O
DDI-DrugBank.d220.s9|301-325|tricyclic antidepressants|group
DDI-DrugBank.d220.s9|327-329|and|O
DDI-DrugBank.d220.s9|331-344|phenothiazines|group
DDI-DrugBank.d220.s9|345-345|)|O
DDI-DrugBank.d220.s9|347-351|might|O
DDI-DrugBank.d220.s9|353-356|also|O
DDI-DrugBank.d220.s9|358-367|contribute|O
DDI-DrugBank.d220.s9|369-370|to|O
DDI-DrugBank.d220.s9|372-372|a|O
DDI-DrugBank.d220.s9|374-385|prolongation|O
DDI-DrugBank.d220.s9|387-388|of|O
DDI-DrugBank.d220.s9|390-392|the|O
DDI-DrugBank.d220.s9|394-396|QTc|O
DDI-DrugBank.d220.s9|398-405|interval|O
DDI-DrugBank.d220.s9|406-406|.|O
DDI-DrugBank.d220.s10|0-4|There|O
DDI-DrugBank.d220.s10|6-8|are|O
DDI-DrugBank.d220.s10|10-11|no|O
DDI-DrugBank.d220.s10|13-16|data|O
DDI-DrugBank.d220.s10|18-21|that|O
DDI-DrugBank.d220.s10|23-34|conclusively|O
DDI-DrugBank.d220.s10|36-44|establish|O
DDI-DrugBank.d220.s10|46-52|whether|O
DDI-DrugBank.d220.s10|54-56|the|O
DDI-DrugBank.d220.s10|58-68|concomitant|O
DDI-DrugBank.d220.s10|70-83|administration|O
DDI-DrugBank.d220.s10|85-86|of|O
DDI-DrugBank.d220.s10|88-101|Mefloquineuine|O
DDI-DrugBank.d220.s10|103-105|and|O
DDI-DrugBank.d220.s10|107-109|the|O
DDI-DrugBank.d220.s10|111-115|above|O
DDI-DrugBank.d220.s10|117-122|listed|O
DDI-DrugBank.d220.s10|124-129|agents|O
DDI-DrugBank.d220.s10|131-133|has|O
DDI-DrugBank.d220.s10|135-136|an|O
DDI-DrugBank.d220.s10|138-143|effect|O
DDI-DrugBank.d220.s10|145-146|on|O
DDI-DrugBank.d220.s10|148-154|cardiac|O
DDI-DrugBank.d220.s10|156-163|function|O
DDI-DrugBank.d220.s10|164-164|.|O
DDI-DrugBank.d220.s11|0-1|In|O
DDI-DrugBank.d220.s11|3-10|patients|O
DDI-DrugBank.d220.s11|12-17|taking|O
DDI-DrugBank.d220.s11|19-20|an|O
DDI-DrugBank.d220.s11|22-35|anticonvulsant|group
DDI-DrugBank.d220.s11|37-37|(|O
DDI-DrugBank.d220.s11|38-39|eg|O
DDI-DrugBank.d220.s11|40-40|,|O
DDI-DrugBank.d220.s11|42-54|valproic acid|drug
DDI-DrugBank.d220.s11|55-55|,|O
DDI-DrugBank.d220.s11|57-69|carbamazepine|drug
DDI-DrugBank.d220.s11|70-70|,|O
DDI-DrugBank.d220.s11|72-84|phenobarbital|drug
DDI-DrugBank.d220.s11|86-87|or|O
DDI-DrugBank.d220.s11|89-97|phenytoin|drug
DDI-DrugBank.d220.s11|98-98|)|O
DDI-DrugBank.d220.s11|99-99|,|O
DDI-DrugBank.d220.s11|101-103|the|O
DDI-DrugBank.d220.s11|105-115|concomitant|O
DDI-DrugBank.d220.s11|117-119|use|O
DDI-DrugBank.d220.s11|121-122|of|O
DDI-DrugBank.d220.s11|124-133|Mefloquine|drug
DDI-DrugBank.d220.s11|135-137|may|O
DDI-DrugBank.d220.s11|139-144|reduce|O
DDI-DrugBank.d220.s11|146-152|seizure|O
DDI-DrugBank.d220.s11|154-160|control|O
DDI-DrugBank.d220.s11|162-163|by|O
DDI-DrugBank.d220.s11|165-172|lowering|O
DDI-DrugBank.d220.s11|174-176|the|O
DDI-DrugBank.d220.s11|178-183|plasma|O
DDI-DrugBank.d220.s11|185-190|levels|O
DDI-DrugBank.d220.s11|192-193|of|O
DDI-DrugBank.d220.s11|195-197|the|O
DDI-DrugBank.d220.s11|199-212|anticonvulsant|group
DDI-DrugBank.d220.s11|213-213|.|O
DDI-DrugBank.d220.s12|0-8|Therefore|O
DDI-DrugBank.d220.s12|9-9|,|O
DDI-DrugBank.d220.s12|11-18|patients|O
DDI-DrugBank.d220.s12|20-31|concurrently|O
DDI-DrugBank.d220.s12|33-38|taking|O
DDI-DrugBank.d220.s12|40-50|antiseizure|O
DDI-DrugBank.d220.s12|52-61|medication|O
DDI-DrugBank.d220.s12|63-65|and|O
DDI-DrugBank.d220.s12|67-76|Mefloquine|drug
DDI-DrugBank.d220.s12|78-83|should|O
DDI-DrugBank.d220.s12|85-88|have|O
DDI-DrugBank.d220.s12|90-92|the|O
DDI-DrugBank.d220.s12|94-98|blood|O
DDI-DrugBank.d220.s12|100-104|level|O
DDI-DrugBank.d220.s12|106-107|of|O
DDI-DrugBank.d220.s12|109-113|their|O
DDI-DrugBank.d220.s12|115-125|antiseizure|O
DDI-DrugBank.d220.s12|127-136|medication|O
DDI-DrugBank.d220.s12|138-146|monitored|O
DDI-DrugBank.d220.s12|148-150|and|O
DDI-DrugBank.d220.s12|152-154|the|O
DDI-DrugBank.d220.s12|156-161|dosage|O
DDI-DrugBank.d220.s12|163-170|adjusted|O
DDI-DrugBank.d220.s12|172-184|appropriately|O
DDI-DrugBank.d220.s12|185-185|.|O
DDI-DrugBank.d220.s13|0-3|When|O
DDI-DrugBank.d220.s13|5-14|Mefloquine|drug
DDI-DrugBank.d220.s13|16-17|is|O
DDI-DrugBank.d220.s13|19-23|taken|O
DDI-DrugBank.d220.s13|25-36|concurrently|O
DDI-DrugBank.d220.s13|38-41|with|O
DDI-DrugBank.d220.s13|43-46|oral|O
DDI-DrugBank.d220.s13|48-68|live typhoid vaccines|group
DDI-DrugBank.d220.s13|69-69|,|O
DDI-DrugBank.d220.s13|71-81|attenuation|O
DDI-DrugBank.d220.s13|83-84|of|O
DDI-DrugBank.d220.s13|86-97|immunization|O
DDI-DrugBank.d220.s13|99-101|can|O
DDI-DrugBank.d220.s13|102-104|not|O
DDI-DrugBank.d220.s13|106-107|be|O
DDI-DrugBank.d220.s13|109-116|excluded|O
DDI-DrugBank.d220.s13|117-117|.|O
DDI-DrugBank.d220.s14|0-11|Vaccinations|O
DDI-DrugBank.d220.s14|13-16|with|O
DDI-DrugBank.d220.s14|18-27|attenuated|O
DDI-DrugBank.d220.s14|29-32|live|O
DDI-DrugBank.d220.s14|34-41|bacteria|O
DDI-DrugBank.d220.s14|43-48|should|O
DDI-DrugBank.d220.s14|50-58|therefore|O
DDI-DrugBank.d220.s14|60-61|be|O
DDI-DrugBank.d220.s14|63-71|completed|O
DDI-DrugBank.d220.s14|73-74|at|O
DDI-DrugBank.d220.s14|76-80|least|O
DDI-DrugBank.d220.s14|82-82|3|O
DDI-DrugBank.d220.s14|84-87|days|O
DDI-DrugBank.d220.s14|89-94|before|O
DDI-DrugBank.d220.s14|96-98|the|O
DDI-DrugBank.d220.s14|100-104|first|O
DDI-DrugBank.d220.s14|106-109|dose|O
DDI-DrugBank.d220.s14|111-112|of|O
DDI-DrugBank.d220.s14|114-123|Mefloquine|drug
DDI-DrugBank.d220.s14|124-124|.|O
DDI-DrugBank.d220.s15|0-1|No|O
DDI-DrugBank.d220.s15|3-7|other|O
DDI-DrugBank.d220.s15|9-12|drug|O
DDI-DrugBank.d220.s15|14-25|interactions|O
DDI-DrugBank.d220.s15|27-29|are|O
DDI-DrugBank.d220.s15|31-35|known|O
DDI-DrugBank.d220.s15|36-36|.|O
DDI-DrugBank.d220.s16|0-11|Nevertheless|O
DDI-DrugBank.d220.s16|12-12|,|O
DDI-DrugBank.d220.s16|14-16|the|O
DDI-DrugBank.d220.s16|18-24|effects|O
DDI-DrugBank.d220.s16|26-27|of|O
DDI-DrugBank.d220.s16|29-38|Mefloquine|drug
DDI-DrugBank.d220.s16|40-41|on|O
DDI-DrugBank.d220.s16|43-51|travelers|O
DDI-DrugBank.d220.s16|53-61|receiving|O
DDI-DrugBank.d220.s16|63-74|comedication|O
DDI-DrugBank.d220.s16|75-75|,|O
DDI-DrugBank.d220.s16|77-88|particularly|O
DDI-DrugBank.d220.s16|90-98|diabetics|O
DDI-DrugBank.d220.s16|100-101|or|O
DDI-DrugBank.d220.s16|103-110|patients|O
DDI-DrugBank.d220.s16|112-116|using|O
DDI-DrugBank.d220.s16|118-131|anticoagulants|group
DDI-DrugBank.d220.s16|132-132|,|O
DDI-DrugBank.d220.s16|134-139|should|O
DDI-DrugBank.d220.s16|141-142|be|O
DDI-DrugBank.d220.s16|144-150|checked|O
DDI-DrugBank.d220.s16|152-157|before|O
DDI-DrugBank.d220.s16|159-167|departure|O
DDI-DrugBank.d220.s16|168-168|.|O
DDI-DrugBank.d220.s17|0-1|In|O
DDI-DrugBank.d220.s17|3-10|clinical|O
DDI-DrugBank.d220.s17|12-17|trials|O
DDI-DrugBank.d220.s17|18-18|,|O
DDI-DrugBank.d220.s17|20-22|the|O
DDI-DrugBank.d220.s17|24-34|concomitant|O
DDI-DrugBank.d220.s17|36-49|administration|O
DDI-DrugBank.d220.s17|51-52|of|O
DDI-DrugBank.d220.s17|54-64|sulfadoxine|drug
DDI-DrugBank.d220.s17|66-68|and|O
DDI-DrugBank.d220.s17|70-82|pyrimethamine|drug
DDI-DrugBank.d220.s17|84-86|did|O
DDI-DrugBank.d220.s17|88-90|not|O
DDI-DrugBank.d220.s17|92-96|alter|O
DDI-DrugBank.d220.s17|98-100|the|O
DDI-DrugBank.d220.s17|102-108|adverse|O
DDI-DrugBank.d220.s17|110-117|reaction|O
DDI-DrugBank.d220.s17|119-125|profile|O
DDI-DrugBank.d220.s17|126-126|.|O
DDI-DrugBank.d713.s0|0-2|The|O
DDI-DrugBank.d713.s0|4-14|concomitant|O
DDI-DrugBank.d713.s0|16-18|use|O
DDI-DrugBank.d713.s0|20-21|of|O
DDI-DrugBank.d713.s0|23-30|Sanctura|brand
DDI-DrugBank.d713.s0|32-35|with|O
DDI-DrugBank.d713.s0|37-41|other|O
DDI-DrugBank.d713.s0|43-64|anticholinergic agents|group
DDI-DrugBank.d713.s0|66-69|that|O
DDI-DrugBank.d713.s0|71-77|produce|O
DDI-DrugBank.d713.s0|79-81|dry|O
DDI-DrugBank.d713.s0|83-87|mouth|O
DDI-DrugBank.d713.s0|88-88|,|O
DDI-DrugBank.d713.s0|90-101|constipation|O
DDI-DrugBank.d713.s0|102-102|,|O
DDI-DrugBank.d713.s0|104-106|and|O
DDI-DrugBank.d713.s0|108-112|other|O
DDI-DrugBank.d713.s0|114-128|anticholinergic|O
DDI-DrugBank.d713.s0|130-144|pharmacological|O
DDI-DrugBank.d713.s0|146-152|effects|O
DDI-DrugBank.d713.s0|154-156|may|O
DDI-DrugBank.d713.s0|158-165|increase|O
DDI-DrugBank.d713.s0|167-169|the|O
DDI-DrugBank.d713.s0|171-179|frequency|O
DDI-DrugBank.d713.s0|181-186|and/or|O
DDI-DrugBank.d713.s0|188-195|severity|O
DDI-DrugBank.d713.s0|197-198|of|O
DDI-DrugBank.d713.s0|200-203|such|O
DDI-DrugBank.d713.s0|205-211|effects|O
DDI-DrugBank.d713.s0|212-212|.|O
DDI-DrugBank.d713.s1|0-21|Anticholinergic agents|group
DDI-DrugBank.d713.s1|23-25|may|O
DDI-DrugBank.d713.s1|27-37|potentially|O
DDI-DrugBank.d713.s1|39-43|alter|O
DDI-DrugBank.d713.s1|45-47|the|O
DDI-DrugBank.d713.s1|49-58|absorption|O
DDI-DrugBank.d713.s1|60-61|of|O
DDI-DrugBank.d713.s1|63-66|some|O
DDI-DrugBank.d713.s1|68-80|concomitantly|O
DDI-DrugBank.d713.s1|82-93|administered|O
DDI-DrugBank.d713.s1|95-99|drugs|O
DDI-DrugBank.d713.s1|101-103|due|O
DDI-DrugBank.d713.s1|105-106|to|O
DDI-DrugBank.d713.s1|108-122|anticholinergic|O
DDI-DrugBank.d713.s1|124-130|effects|O
DDI-DrugBank.d713.s1|132-133|on|O
DDI-DrugBank.d713.s1|135-150|gastrointestinal|O
DDI-DrugBank.d713.s1|152-159|motility|O
DDI-DrugBank.d713.s1|160-160|.|O
DDI-DrugBank.d713.s2|0-4|Drugs|O
DDI-DrugBank.d713.s2|6-15|Eliminated|O
DDI-DrugBank.d713.s2|17-18|by|O
DDI-DrugBank.d713.s2|20-25|Active|O
DDI-DrugBank.d713.s2|27-33|Tubular|O
DDI-DrugBank.d713.s2|35-43|Secretion|O
DDI-DrugBank.d713.s2|44-44|:|O
DDI-DrugBank.d713.s2|46-53|Although|O
DDI-DrugBank.d713.s2|55-61|studies|O
DDI-DrugBank.d713.s2|63-64|to|O
DDI-DrugBank.d713.s2|66-71|assess|O
DDI-DrugBank.d713.s2|73-81|drug-drug|O
DDI-DrugBank.d713.s2|83-94|interactions|O
DDI-DrugBank.d713.s2|96-99|with|O
DDI-DrugBank.d713.s2|101-108|Sanctura|brand
DDI-DrugBank.d713.s2|110-113|have|O
DDI-DrugBank.d713.s2|115-117|not|O
DDI-DrugBank.d713.s2|119-122|been|O
DDI-DrugBank.d713.s2|124-132|conducted|O
DDI-DrugBank.d713.s2|133-133|,|O
DDI-DrugBank.d713.s2|135-142|Sanctura|brand
DDI-DrugBank.d713.s2|144-146|has|O
DDI-DrugBank.d713.s2|148-150|the|O
DDI-DrugBank.d713.s2|152-160|potential|O
DDI-DrugBank.d713.s2|162-164|for|O
DDI-DrugBank.d713.s2|166-180|pharmacokinetic|O
DDI-DrugBank.d713.s2|182-193|interactions|O
DDI-DrugBank.d713.s2|195-198|with|O
DDI-DrugBank.d713.s2|200-204|other|O
DDI-DrugBank.d713.s2|206-210|drugs|O
DDI-DrugBank.d713.s2|212-215|that|O
DDI-DrugBank.d713.s2|217-219|are|O
DDI-DrugBank.d713.s2|221-230|eliminated|O
DDI-DrugBank.d713.s2|232-233|by|O
DDI-DrugBank.d713.s2|235-240|active|O
DDI-DrugBank.d713.s2|242-248|tubular|O
DDI-DrugBank.d713.s2|250-258|secretion|O
DDI-DrugBank.d713.s2|260-260|(|O
DDI-DrugBank.d713.s2|261-264|e.g.|O
DDI-DrugBank.d713.s2|266-272|digoxin|drug
DDI-DrugBank.d713.s2|273-273|,|O
DDI-DrugBank.d713.s2|275-286|procainamide|drug
DDI-DrugBank.d713.s2|287-287|,|O
DDI-DrugBank.d713.s2|289-299|pancuronium|drug
DDI-DrugBank.d713.s2|300-300|,|O
DDI-DrugBank.d713.s2|302-309|morphine|drug
DDI-DrugBank.d713.s2|310-310|,|O
DDI-DrugBank.d713.s2|312-321|vancomycin|drug
DDI-DrugBank.d713.s2|322-322|,|O
DDI-DrugBank.d713.s2|324-332|metformin|drug
DDI-DrugBank.d713.s2|334-336|and|O
DDI-DrugBank.d713.s2|338-346|tenofovir|drug
DDI-DrugBank.d713.s2|347-347|)|O
DDI-DrugBank.d713.s2|348-348|.|O
DDI-DrugBank.d713.s3|0-15|Coadministration|O
DDI-DrugBank.d713.s3|17-18|of|O
DDI-DrugBank.d713.s3|20-27|Sanctura|brand
DDI-DrugBank.d713.s3|29-32|with|O
DDI-DrugBank.d713.s3|34-38|drugs|O
DDI-DrugBank.d713.s3|40-43|that|O
DDI-DrugBank.d713.s3|45-47|are|O
DDI-DrugBank.d713.s3|49-58|eliminated|O
DDI-DrugBank.d713.s3|60-61|by|O
DDI-DrugBank.d713.s3|63-68|active|O
DDI-DrugBank.d713.s3|70-74|renal|O
DDI-DrugBank.d713.s3|76-82|tubular|O
DDI-DrugBank.d713.s3|84-92|secretion|O
DDI-DrugBank.d713.s3|94-96|may|O
DDI-DrugBank.d713.s3|98-105|increase|O
DDI-DrugBank.d713.s3|107-109|the|O
DDI-DrugBank.d713.s3|111-115|serum|O
DDI-DrugBank.d713.s3|117-129|concentration|O
DDI-DrugBank.d713.s3|131-132|of|O
DDI-DrugBank.d713.s3|134-141|Sanctura|brand
DDI-DrugBank.d713.s3|143-148|and/or|O
DDI-DrugBank.d713.s3|150-152|the|O
DDI-DrugBank.d713.s3|154-167|coadministered|O
DDI-DrugBank.d713.s3|169-172|drug|O
DDI-DrugBank.d713.s3|174-176|due|O
DDI-DrugBank.d713.s3|178-179|to|O
DDI-DrugBank.d713.s3|181-191|competition|O
DDI-DrugBank.d713.s3|193-195|for|O
DDI-DrugBank.d713.s3|197-200|this|O
DDI-DrugBank.d713.s3|202-212|elimination|O
DDI-DrugBank.d713.s3|214-220|pathway|O
DDI-DrugBank.d713.s3|221-221|.|O
DDI-DrugBank.d713.s4|0-6|Careful|O
DDI-DrugBank.d713.s4|8-14|patient|O
DDI-DrugBank.d713.s4|16-25|monitoring|O
DDI-DrugBank.d713.s4|27-28|is|O
DDI-DrugBank.d713.s4|30-40|recommended|O
DDI-DrugBank.d713.s4|42-43|in|O
DDI-DrugBank.d713.s4|45-52|patients|O
DDI-DrugBank.d713.s4|54-62|receiving|O
DDI-DrugBank.d713.s4|64-67|such|O
DDI-DrugBank.d713.s4|69-73|drugs|O
DDI-DrugBank.d713.s4|74-74|.|O
DDI-DrugBank.d713.s5|0-19|Drug-Laboratory-Test|O
DDI-DrugBank.d713.s5|21-32|Interactions|O
DDI-DrugBank.d713.s5|34-45|Interactions|O
DDI-DrugBank.d713.s5|47-53|between|O
DDI-DrugBank.d713.s5|55-62|Sanctura|brand
DDI-DrugBank.d713.s5|64-66|and|O
DDI-DrugBank.d713.s5|68-77|laboratory|O
DDI-DrugBank.d713.s5|79-83|tests|O
DDI-DrugBank.d713.s5|85-88|have|O
DDI-DrugBank.d713.s5|90-92|not|O
DDI-DrugBank.d713.s5|94-97|been|O
DDI-DrugBank.d713.s5|99-105|studied|O
DDI-DrugBank.d713.s5|106-106|.|O
DDI-DrugBank.d765.s0|0-5|CYP3A4|O
DDI-DrugBank.d765.s0|7-16|Inhibitors|O
DDI-DrugBank.d765.s0|17-17|:|O
DDI-DrugBank.d765.s0|19-30|Ketoconazole|drug
DDI-DrugBank.d765.s0|31-31|,|O
DDI-DrugBank.d765.s0|33-34|an|O
DDI-DrugBank.d765.s0|36-44|inhibitor|O
DDI-DrugBank.d765.s0|46-47|of|O
DDI-DrugBank.d765.s0|49-51|the|O
DDI-DrugBank.d765.s0|53-56|drug|O
DDI-DrugBank.d765.s0|58-69|metabolizing|O
DDI-DrugBank.d765.s0|71-76|enzyme|O
DDI-DrugBank.d765.s0|78-83|CYP3A4|O
DDI-DrugBank.d765.s0|84-84|,|O
DDI-DrugBank.d765.s0|86-98|significantly|O
DDI-DrugBank.d765.s0|100-108|increased|O
DDI-DrugBank.d765.s0|110-115|plasma|O
DDI-DrugBank.d765.s0|117-130|concentrations|O
DDI-DrugBank.d765.s0|132-133|of|O
DDI-DrugBank.d765.s0|135-145|tolterodine|drug
DDI-DrugBank.d765.s0|147-150|when|O
DDI-DrugBank.d765.s0|152-165|coadministered|O
DDI-DrugBank.d765.s0|167-168|to|O
DDI-DrugBank.d765.s0|170-177|subjects|O
DDI-DrugBank.d765.s0|179-181|who|O
DDI-DrugBank.d765.s0|183-186|were|O
DDI-DrugBank.d765.s0|188-191|poor|O
DDI-DrugBank.d765.s0|193-204|metabolizers|O
DDI-DrugBank.d765.s0|206-206|(|O
DDI-DrugBank.d765.s0|207-209|see|O
DDI-DrugBank.d765.s0|211-218|CLINICAL|O
DDI-DrugBank.d765.s0|220-231|PHARMACOLOGY|O
DDI-DrugBank.d765.s0|232-232|,|O
DDI-DrugBank.d765.s0|234-244|Variability|O
DDI-DrugBank.d765.s0|246-247|in|O
DDI-DrugBank.d765.s0|249-258|Metabolism|O
DDI-DrugBank.d765.s0|260-262|and|O
DDI-DrugBank.d765.s0|264-272|Drug-Drug|O
DDI-DrugBank.d765.s0|274-285|Interactions|O
DDI-DrugBank.d765.s0|286-286|)|O
DDI-DrugBank.d765.s0|287-287|.|O
DDI-DrugBank.d765.s1|0-2|For|O
DDI-DrugBank.d765.s1|4-11|patients|O
DDI-DrugBank.d765.s1|13-21|receiving|O
DDI-DrugBank.d765.s1|23-34|ketoconazole|drug
DDI-DrugBank.d765.s1|36-37|or|O
DDI-DrugBank.d765.s1|39-43|other|O
DDI-DrugBank.d765.s1|45-50|potent|O
DDI-DrugBank.d765.s1|52-57|CYP3A4|O
DDI-DrugBank.d765.s1|59-68|inhibitors|O
DDI-DrugBank.d765.s1|70-73|such|O
DDI-DrugBank.d765.s1|75-76|as|O
DDI-DrugBank.d765.s1|78-82|other|O
DDI-DrugBank.d765.s1|84-100|azole antifungals|group
DDI-DrugBank.d765.s1|102-102|(|O
DDI-DrugBank.d765.s1|103-104|eg|O
DDI-DrugBank.d765.s1|105-105|,|O
DDI-DrugBank.d765.s1|107-118|itraconazole|drug
DDI-DrugBank.d765.s1|119-119|,|O
DDI-DrugBank.d765.s1|121-130|miconazole|drug
DDI-DrugBank.d765.s1|131-131|)|O
DDI-DrugBank.d765.s1|133-134|or|O
DDI-DrugBank.d765.s1|136-156|macrolide antibiotics|group
DDI-DrugBank.d765.s1|158-158|(|O
DDI-DrugBank.d765.s1|159-160|eg|O
DDI-DrugBank.d765.s1|161-161|,|O
DDI-DrugBank.d765.s1|163-174|erythromycin|drug
DDI-DrugBank.d765.s1|175-175|,|O
DDI-DrugBank.d765.s1|177-190|clarithromycin|drug
DDI-DrugBank.d765.s1|191-191|)|O
DDI-DrugBank.d765.s1|193-194|or|O
DDI-DrugBank.d765.s1|196-207|cyclosporine|drug
DDI-DrugBank.d765.s1|209-210|or|O
DDI-DrugBank.d765.s1|212-222|vinblastine|drug
DDI-DrugBank.d765.s1|223-223|,|O
DDI-DrugBank.d765.s1|225-227|the|O
DDI-DrugBank.d765.s1|229-239|recommended|O
DDI-DrugBank.d765.s1|241-244|dose|O
DDI-DrugBank.d765.s1|246-247|of|O
DDI-DrugBank.d765.s1|249-257|DETROL LA|brand
DDI-DrugBank.d765.s1|259-260|is|O
DDI-DrugBank.d765.s1|262-262|2|O
DDI-DrugBank.d765.s1|264-265|mg|O
DDI-DrugBank.d765.s1|267-271|daily|O
DDI-DrugBank.d765.s1|272-272|.|O
DDI-DrugBank.d765.s2|0-19|Drug-Laboratory-Test|O
DDI-DrugBank.d765.s2|21-32|Interactions|O
DDI-DrugBank.d765.s2|34-45|Interactions|O
DDI-DrugBank.d765.s2|47-53|between|O
DDI-DrugBank.d765.s2|55-65|tolterodine|drug
DDI-DrugBank.d765.s2|67-69|and|O
DDI-DrugBank.d765.s2|71-80|laboratory|O
DDI-DrugBank.d765.s2|82-86|tests|O
DDI-DrugBank.d765.s2|88-91|have|O
DDI-DrugBank.d765.s2|93-95|not|O
DDI-DrugBank.d765.s2|97-100|been|O
DDI-DrugBank.d765.s2|102-108|studied|O
DDI-DrugBank.d765.s2|109-109|.|O
DDI-DrugBank.d28.s0|0-11|Interactions|O
DDI-DrugBank.d28.s0|13-19|between|O
DDI-DrugBank.d28.s0|21-28|COPAXONE|brand
DDI-DrugBank.d28.s0|31-33|and|O
DDI-DrugBank.d28.s0|35-39|other|O
DDI-DrugBank.d28.s0|41-45|drugs|O
DDI-DrugBank.d28.s0|47-50|have|O
DDI-DrugBank.d28.s0|52-54|not|O
DDI-DrugBank.d28.s0|56-59|been|O
DDI-DrugBank.d28.s0|61-65|fully|O
DDI-DrugBank.d28.s0|67-75|evaluated|O
DDI-DrugBank.d28.s0|76-76|.|O
DDI-DrugBank.d28.s1|0-6|Results|O
DDI-DrugBank.d28.s1|8-11|from|O
DDI-DrugBank.d28.s1|13-20|existing|O
DDI-DrugBank.d28.s1|22-29|clinical|O
DDI-DrugBank.d28.s1|31-36|trials|O
DDI-DrugBank.d28.s1|38-44|suggest|O
DDI-DrugBank.d28.s1|46-47|no|O
DDI-DrugBank.d28.s1|49-59|significant|O
DDI-DrugBank.d28.s1|61-72|interactions|O
DDI-DrugBank.d28.s1|74-80|between|O
DDI-DrugBank.d28.s1|82-89|COPAXONE|brand
DDI-DrugBank.d28.s1|92-94|and|O
DDI-DrugBank.d28.s1|96-100|other|O
DDI-DrugBank.d28.s1|102-110|therapies|O
DDI-DrugBank.d28.s1|112-119|commonly|O
DDI-DrugBank.d28.s1|121-124|used|O
DDI-DrugBank.d28.s1|126-127|in|O
DDI-DrugBank.d28.s1|129-130|MS|O
DDI-DrugBank.d28.s1|132-139|patients|O
DDI-DrugBank.d28.s1|140-140|,|O
DDI-DrugBank.d28.s1|142-150|including|O
DDI-DrugBank.d28.s1|152-154|the|O
DDI-DrugBank.d28.s1|156-165|concurrent|O
DDI-DrugBank.d28.s1|167-169|use|O
DDI-DrugBank.d28.s1|171-172|of|O
DDI-DrugBank.d28.s1|174-188|corticosteroids|group
DDI-DrugBank.d28.s1|190-192|for|O
DDI-DrugBank.d28.s1|194-195|up|O
DDI-DrugBank.d28.s1|197-198|to|O
DDI-DrugBank.d28.s1|200-201|28|O
DDI-DrugBank.d28.s1|203-206|days|O
DDI-DrugBank.d28.s1|207-207|.|O
DDI-DrugBank.d28.s2|0-7|COPAXONE|brand
DDI-DrugBank.d28.s2|10-12|has|O
DDI-DrugBank.d28.s2|14-16|not|O
DDI-DrugBank.d28.s2|18-21|been|O
DDI-DrugBank.d28.s2|23-30|formally|O
DDI-DrugBank.d28.s2|32-40|evaluated|O
DDI-DrugBank.d28.s2|42-43|in|O
DDI-DrugBank.d28.s2|45-55|combination|O
DDI-DrugBank.d28.s2|57-60|with|O
DDI-DrugBank.d28.s2|62-76|Interferon beta|drug
DDI-DrugBank.d28.s2|77-77|.|O
DDI-DrugBank.d28.s3|0-6|However|O
DDI-DrugBank.d28.s3|7-7|,|O
DDI-DrugBank.d28.s3|9-10|10|O
DDI-DrugBank.d28.s3|12-19|patients|O
DDI-DrugBank.d28.s3|21-23|who|O
DDI-DrugBank.d28.s3|25-32|switched|O
DDI-DrugBank.d28.s3|34-37|from|O
DDI-DrugBank.d28.s3|39-45|therapy|O
DDI-DrugBank.d28.s3|47-50|with|O
DDI-DrugBank.d28.s3|52-66|Interferon beta|drug
DDI-DrugBank.d28.s3|68-69|to|O
DDI-DrugBank.d28.s3|71-78|COPAXONE|brand
DDI-DrugBank.d28.s3|81-83|did|O
DDI-DrugBank.d28.s3|85-87|not|O
DDI-DrugBank.d28.s3|89-94|report|O
DDI-DrugBank.d28.s3|96-98|any|O
DDI-DrugBank.d28.s3|100-106|serious|O
DDI-DrugBank.d28.s3|108-110|and|O
DDI-DrugBank.d28.s3|112-121|unexpected|O
DDI-DrugBank.d28.s3|123-129|adverse|O
DDI-DrugBank.d28.s3|131-139|reactions|O
DDI-DrugBank.d28.s3|141-147|thought|O
DDI-DrugBank.d28.s3|149-150|to|O
DDI-DrugBank.d28.s3|152-153|be|O
DDI-DrugBank.d28.s3|155-161|related|O
DDI-DrugBank.d28.s3|163-164|to|O
DDI-DrugBank.d28.s3|166-174|treatment|O
DDI-DrugBank.d28.s3|175-175|.|O
DDI-DrugBank.d387.s0|0-8|Potential|O
DDI-DrugBank.d387.s0|10-13|drug|O
DDI-DrugBank.d387.s0|15-26|interactions|O
DDI-DrugBank.d387.s0|28-30|for|O
DDI-DrugBank.d387.s0|32-41|doxylamine|drug
DDI-DrugBank.d387.s0|43-49|include|O
DDI-DrugBank.d387.s0|50-50|,|O
DDI-DrugBank.d387.s0|52-60|increased|O
DDI-DrugBank.d387.s0|62-69|sedation|O
DDI-DrugBank.d387.s0|71-72|if|O
DDI-DrugBank.d387.s0|74-83|doxylamine|drug
DDI-DrugBank.d387.s0|85-86|is|O
DDI-DrugBank.d387.s0|88-95|combined|O
DDI-DrugBank.d387.s0|97-100|with|O
DDI-DrugBank.d387.s0|102-106|other|O
DDI-DrugBank.d387.s0|108-127|CNS depressant drugs|group
DDI-DrugBank.d387.s0|128-128|.|O
DDI-DrugBank.d387.s1|0-13|Antihistamines|group
DDI-DrugBank.d387.s1|15-17|may|O
DDI-DrugBank.d387.s1|19-27|partially|O
DDI-DrugBank.d387.s1|29-38|counteract|O
DDI-DrugBank.d387.s1|40-42|the|O
DDI-DrugBank.d387.s1|44-58|anticoagulation|O
DDI-DrugBank.d387.s1|60-66|effects|O
DDI-DrugBank.d387.s1|68-69|of|O
DDI-DrugBank.d387.s1|71-77|heparin|drug
DDI-DrugBank.d387.s1|79-80|or|O
DDI-DrugBank.d387.s1|82-89|warfarin|drug
DDI-DrugBank.d387.s1|90-90|.|O
DDI-DrugBank.d387.s2|0-9|Doxylamine|drug
DDI-DrugBank.d387.s2|11-13|may|O
DDI-DrugBank.d387.s2|15-21|enhance|O
DDI-DrugBank.d387.s2|23-25|the|O
DDI-DrugBank.d387.s2|27-33|effects|O
DDI-DrugBank.d387.s2|35-36|of|O
DDI-DrugBank.d387.s2|38-48|epinephrine|drug
DDI-DrugBank.d387.s2|49-49|.|O
DDI-DrugBank.d342.s0|0-3|This|O
DDI-DrugBank.d342.s0|5-8|drug|O
DDI-DrugBank.d342.s0|10-12|may|O
DDI-DrugBank.d342.s0|14-21|interact|O
DDI-DrugBank.d342.s0|23-26|with|O
DDI-DrugBank.d342.s0|28-34|alcohol|drug
DDI-DrugBank.d342.s0|36-37|or|O
DDI-DrugBank.d342.s0|39-43|other|O
DDI-DrugBank.d342.s0|45-59|CNS depressants|group
DDI-DrugBank.d342.s0|61-61|(|O
DDI-DrugBank.d342.s0|62-64|may|O
DDI-DrugBank.d342.s0|66-75|potentiate|O
DDI-DrugBank.d342.s0|77-79|the|O
DDI-DrugBank.d342.s0|81-83|CNS|O
DDI-DrugBank.d342.s0|85-94|depressant|O
DDI-DrugBank.d342.s0|96-102|effects|O
DDI-DrugBank.d342.s0|104-105|of|O
DDI-DrugBank.d342.s0|107-112|either|O
DDI-DrugBank.d342.s0|114-118|these|O
DDI-DrugBank.d342.s0|120-130|medications|O
DDI-DrugBank.d342.s0|132-133|or|O
DDI-DrugBank.d342.s0|135-148|antihistamines|group
DDI-DrugBank.d342.s0|149-149|)|O
DDI-DrugBank.d342.s0|150-150|,|O
DDI-DrugBank.d342.s0|152-167|anticholinergics|group
DDI-DrugBank.d342.s0|169-170|or|O
DDI-DrugBank.d342.s0|172-176|other|O
DDI-DrugBank.d342.s0|178-188|medications|O
DDI-DrugBank.d342.s0|190-193|with|O
DDI-DrugBank.d342.s0|195-209|anticholinergic|O
DDI-DrugBank.d342.s0|211-218|activity|O
DDI-DrugBank.d342.s0|220-220|(|O
DDI-DrugBank.d342.s0|221-235|anticholinergic|O
DDI-DrugBank.d342.s0|237-243|effects|O
DDI-DrugBank.d342.s0|245-247|may|O
DDI-DrugBank.d342.s0|249-250|be|O
DDI-DrugBank.d342.s0|252-262|potentiated|O
DDI-DrugBank.d342.s0|264-267|when|O
DDI-DrugBank.d342.s0|269-273|these|O
DDI-DrugBank.d342.s0|275-285|medications|O
DDI-DrugBank.d342.s0|287-289|are|O
DDI-DrugBank.d342.s0|291-294|used|O
DDI-DrugBank.d342.s0|296-307|concurrently|O
DDI-DrugBank.d342.s0|309-312|with|O
DDI-DrugBank.d342.s0|314-327|antihistamines|group
DDI-DrugBank.d342.s0|328-328|)|O
DDI-DrugBank.d342.s0|329-329|,|O
DDI-DrugBank.d342.s0|331-333|and|O
DDI-DrugBank.d342.s0|335-368|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d342.s0|370-370|(|O
DDI-DrugBank.d342.s0|371-380|concurrent|O
DDI-DrugBank.d342.s0|382-384|use|O
DDI-DrugBank.d342.s0|386-389|with|O
DDI-DrugBank.d342.s0|391-404|antihistamines|group
DDI-DrugBank.d342.s0|406-408|may|O
DDI-DrugBank.d342.s0|410-416|prolong|O
DDI-DrugBank.d342.s0|418-420|and|O
DDI-DrugBank.d342.s0|422-430|intensify|O
DDI-DrugBank.d342.s0|432-434|the|O
DDI-DrugBank.d342.s0|436-450|anticholinergic|O
DDI-DrugBank.d342.s0|452-454|and|O
DDI-DrugBank.d342.s0|456-458|CNS|O
DDI-DrugBank.d342.s0|460-469|depressant|O
DDI-DrugBank.d342.s0|471-477|effects|O
DDI-DrugBank.d342.s0|479-480|of|O
DDI-DrugBank.d342.s0|482-495|antihistamines|group
DDI-DrugBank.d342.s0|496-496|)|O
DDI-DrugBank.d342.s0|497-497|.|O
DDI-DrugBank.d214.s0|0-1|No|O
DDI-DrugBank.d214.s0|3-13|information|O
DDI-DrugBank.d214.s0|15-23|available|O
DDI-DrugBank.d214.s0|24-24|.|O
DDI-MedLine.d56.s0|0-3|Dual|O
DDI-MedLine.d56.s0|5-10|effect|O
DDI-MedLine.d56.s0|12-13|of|O
DDI-MedLine.d56.s0|15-21|ouabain|drug
DDI-MedLine.d56.s0|23-24|on|O
DDI-MedLine.d56.s0|26-28|the|O
DDI-MedLine.d56.s0|48-58|contraction|O
DDI-MedLine.d56.s0|60-62|and|O
DDI-MedLine.d56.s0|64-77|norepinephrine|O
DDI-MedLine.d56.s0|79-85|release|O
DDI-MedLine.d56.s0|87-88|in|O
DDI-MedLine.d56.s0|90-92|the|O
DDI-MedLine.d56.s0|94-103|guinea-pig|O
DDI-MedLine.d56.s0|105-107|vas|O
DDI-MedLine.d56.s0|109-116|deferens|O
DDI-MedLine.d56.s0|117-117|.|O
DDI-MedLine.d56.s1|10-10|(|O
DDI-MedLine.d56.s1|14-14|)|O
DDI-MedLine.d56.s1|15-15|,|O
DDI-MedLine.d56.s1|17-29|C129H223N3O54|O
DDI-MedLine.d56.s1|30-30|,|O
DDI-MedLine.d56.s1|32-39|isolated|O
DDI-MedLine.d56.s1|41-44|from|O
DDI-MedLine.d56.s1|46-51|marine|O
DDI-MedLine.d56.s1|53-65|coelenterates|O
DDI-MedLine.d56.s1|67-68|of|O
DDI-MedLine.d56.s1|70-77|Palythoa|O
DDI-MedLine.d56.s1|79-89|tuberculosa|O
DDI-MedLine.d56.s1|90-90|,|O
DDI-MedLine.d56.s1|92-97|caused|O
DDI-MedLine.d56.s1|99-99|a|O
DDI-MedLine.d56.s1|101-105|first|O
DDI-MedLine.d56.s1|107-111|rapid|O
DDI-MedLine.d56.s1|113-123|contraction|O
DDI-MedLine.d56.s1|125-132|followed|O
DDI-MedLine.d56.s1|134-135|by|O
DDI-MedLine.d56.s1|137-139|the|O
DDI-MedLine.d56.s1|141-144|slow|O
DDI-MedLine.d56.s1|146-151|phasic|O
DDI-MedLine.d56.s1|153-163|contraction|O
DDI-MedLine.d56.s1|165-166|of|O
DDI-MedLine.d56.s1|168-177|guinea-pig|O
DDI-MedLine.d56.s1|179-181|vas|O
DDI-MedLine.d56.s1|183-190|deferens|O
DDI-MedLine.d56.s1|191-191|.|O
DDI-MedLine.d56.s2|0-1|In|O
DDI-MedLine.d56.s2|3-5|the|O
DDI-MedLine.d56.s2|7-14|presence|O
DDI-MedLine.d56.s2|16-17|of|O
DDI-MedLine.d56.s2|19-25|ouabain|drug
DDI-MedLine.d56.s2|27-27|(|O
DDI-MedLine.d56.s2|28-29|10|O
DDI-MedLine.d56.s2|30-30|(|O
DDI-MedLine.d56.s2|31-32|-5|O
DDI-MedLine.d56.s2|33-33|)|O
DDI-MedLine.d56.s2|35-35|M|O
DDI-MedLine.d56.s2|36-36|)|O
DDI-MedLine.d56.s2|37-37|,|O
DDI-MedLine.d56.s2|43-43|(|O
DDI-MedLine.d56.s2|44-45|10|O
DDI-MedLine.d56.s2|46-46|(|O
DDI-MedLine.d56.s2|47-48|-8|O
DDI-MedLine.d56.s2|49-49|)|O
DDI-MedLine.d56.s2|51-51|M|O
DDI-MedLine.d56.s2|52-52|)|O
DDI-MedLine.d56.s2|54-59|failed|O
DDI-MedLine.d56.s2|61-62|to|O
DDI-MedLine.d56.s2|64-68|cause|O
DDI-MedLine.d56.s2|70-72|the|O
DDI-MedLine.d56.s2|74-78|first|O
DDI-MedLine.d56.s2|80-90|contraction|O
DDI-MedLine.d56.s2|91-91|;|O
DDI-MedLine.d56.s3|0-6|however|O
DDI-MedLine.d56.s3|7-7|,|O
DDI-MedLine.d56.s3|9-11|the|O
DDI-MedLine.d56.s3|13-18|second|O
DDI-MedLine.d56.s3|20-30|contraction|O
DDI-MedLine.d56.s3|32-34|was|O
DDI-MedLine.d56.s3|36-46|potentiated|O
DDI-MedLine.d56.s3|47-47|.|O
DDI-MedLine.d56.s4|0-1|In|O
DDI-MedLine.d56.s4|3-5|the|O
DDI-MedLine.d56.s4|7-14|presence|O
DDI-MedLine.d56.s4|16-17|of|O
DDI-MedLine.d56.s4|19-30|phentolamine|drug
DDI-MedLine.d56.s4|32-32|(|O
DDI-MedLine.d56.s4|33-34|10|O
DDI-MedLine.d56.s4|35-35|(|O
DDI-MedLine.d56.s4|36-37|-6|O
DDI-MedLine.d56.s4|38-38|)|O
DDI-MedLine.d56.s4|40-40|M|O
DDI-MedLine.d56.s4|41-41|)|O
DDI-MedLine.d56.s4|42-42|,|O
DDI-MedLine.d56.s4|44-46|the|O
DDI-MedLine.d56.s4|48-53|second|O
DDI-MedLine.d56.s4|55-65|contraction|O
DDI-MedLine.d56.s4|67-69|was|O
DDI-MedLine.d56.s4|71-79|inhibited|O
DDI-MedLine.d56.s4|81-91|selectively|O
DDI-MedLine.d56.s4|92-92|.|O
DDI-MedLine.d56.s5|0-3|When|O
DDI-MedLine.d56.s5|5-11|ouabain|drug
DDI-MedLine.d56.s5|13-15|was|O
DDI-MedLine.d56.s5|17-23|applied|O
DDI-MedLine.d56.s5|25-26|to|O
DDI-MedLine.d56.s5|28-30|the|O
DDI-MedLine.d56.s5|32-37|muscle|O
DDI-MedLine.d56.s5|39-40|in|O
DDI-MedLine.d56.s5|42-44|the|O
DDI-MedLine.d56.s5|46-53|presence|O
DDI-MedLine.d56.s5|55-56|of|O
DDI-MedLine.d56.s5|58-69|phentolamine|drug
DDI-MedLine.d56.s5|70-70|,|O
DDI-MedLine.d56.s5|72-75|both|O
DDI-MedLine.d56.s5|77-81|first|O
DDI-MedLine.d56.s5|83-85|and|O
DDI-MedLine.d56.s5|87-92|second|O
DDI-MedLine.d56.s5|94-104|contractile|O
DDI-MedLine.d56.s5|106-114|responses|O
DDI-MedLine.d56.s5|116-117|to|O
DDI-MedLine.d56.s5|123-126|were|O
DDI-MedLine.d56.s5|128-136|abolished|O
DDI-MedLine.d56.s5|137-137|.|O
DDI-MedLine.d56.s6|0-3|When|O
DDI-MedLine.d56.s6|5-7|the|O
DDI-MedLine.d56.s6|9-14|muscle|O
DDI-MedLine.d56.s6|16-18|was|O
DDI-MedLine.d56.s6|20-26|exposed|O
DDI-MedLine.d56.s6|28-29|to|O
DDI-MedLine.d56.s6|31-33|the|O
DDI-MedLine.d56.s6|35-52|potassium-depleted|O
DDI-MedLine.d56.s6|54-61|solution|O
DDI-MedLine.d56.s6|62-62|,|O
DDI-MedLine.d56.s6|64-66|the|O
DDI-MedLine.d56.s6|68-72|first|O
DDI-MedLine.d56.s6|74-84|contractile|O
DDI-MedLine.d56.s6|86-93|response|O
DDI-MedLine.d56.s6|95-96|to|O
DDI-MedLine.d56.s6|102-104|was|O
DDI-MedLine.d56.s6|106-111|rather|O
DDI-MedLine.d56.s6|113-123|potentiated|O
DDI-MedLine.d56.s6|124-124|.|O
DDI-MedLine.d56.s7|4-9|caused|O
DDI-MedLine.d56.s7|11-13|the|O
DDI-MedLine.d56.s7|15-21|release|O
DDI-MedLine.d56.s7|23-24|of|O
DDI-MedLine.d56.s7|26-39|norepinephrine|O
DDI-MedLine.d56.s7|41-44|from|O
DDI-MedLine.d56.s7|46-48|the|O
DDI-MedLine.d56.s7|50-55|muscle|O
DDI-MedLine.d56.s7|56-56|.|O
DDI-MedLine.d56.s8|0-7|Exposure|O
DDI-MedLine.d56.s8|9-10|of|O
DDI-MedLine.d56.s8|12-14|the|O
DDI-MedLine.d56.s8|16-21|muscle|O
DDI-MedLine.d56.s8|23-24|to|O
DDI-MedLine.d56.s8|26-32|ouabain|drug
DDI-MedLine.d56.s8|34-34|(|O
DDI-MedLine.d56.s8|35-36|10|O
DDI-MedLine.d56.s8|37-37|(|O
DDI-MedLine.d56.s8|38-39|-5|O
DDI-MedLine.d56.s8|40-40|)|O
DDI-MedLine.d56.s8|42-42|M|O
DDI-MedLine.d56.s8|43-43|)|O
DDI-MedLine.d56.s8|45-52|markedly|O
DDI-MedLine.d56.s8|54-62|increased|O
DDI-MedLine.d56.s8|64-66|the|O
DDI-MedLine.d56.s8|80-86|release|O
DDI-MedLine.d56.s8|87-87|.|O
DDI-MedLine.d56.s9|0-1|It|O
DDI-MedLine.d56.s9|3-4|is|O
DDI-MedLine.d56.s9|6-14|indicated|O
DDI-MedLine.d56.s9|16-19|that|O
DDI-MedLine.d56.s9|21-23|the|O
DDI-MedLine.d56.s9|25-29|first|O
DDI-MedLine.d56.s9|31-33|and|O
DDI-MedLine.d56.s9|35-40|second|O
DDI-MedLine.d56.s9|42-52|contractile|O
DDI-MedLine.d56.s9|54-62|responses|O
DDI-MedLine.d56.s9|64-65|to|O
DDI-MedLine.d56.s9|71-74|have|O
DDI-MedLine.d56.s9|76-83|entirely|O
DDI-MedLine.d56.s9|85-93|different|O
DDI-MedLine.d56.s9|95-104|properties|O
DDI-MedLine.d56.s9|105-105|.|O
DDI-MedLine.d56.s10|0-2|The|O
DDI-MedLine.d56.s10|4-9|second|O
DDI-MedLine.d56.s10|11-18|response|O
DDI-MedLine.d56.s10|20-21|is|O
DDI-MedLine.d56.s10|23-25|due|O
DDI-MedLine.d56.s10|27-28|to|O
DDI-MedLine.d56.s10|30-30|a|O
DDI-MedLine.d56.s10|32-38|release|O
DDI-MedLine.d56.s10|40-41|of|O
DDI-MedLine.d56.s10|43-56|norepinephrine|O
DDI-MedLine.d56.s10|58-61|from|O
DDI-MedLine.d56.s10|63-68|nerves|O
DDI-MedLine.d56.s10|70-72|and|O
DDI-MedLine.d56.s10|74-76|was|O
DDI-MedLine.d56.s10|78-88|potentiated|O
DDI-MedLine.d56.s10|90-91|by|O
DDI-MedLine.d56.s10|93-99|ouabain|drug
DDI-MedLine.d56.s10|101-107|through|O
DDI-MedLine.d56.s10|109-111|the|O
DDI-MedLine.d56.s10|113-120|increase|O
DDI-MedLine.d56.s10|122-123|in|O
DDI-MedLine.d56.s10|125-127|the|O
DDI-MedLine.d56.s10|129-142|norepinephrine|O
DDI-MedLine.d56.s10|144-150|release|O
DDI-MedLine.d56.s10|151-151|,|O
DDI-MedLine.d56.s10|153-159|whereas|O
DDI-MedLine.d56.s10|161-163|the|O
DDI-MedLine.d56.s10|165-169|first|O
DDI-MedLine.d56.s10|171-178|response|O
DDI-MedLine.d56.s10|180-182|was|O
DDI-MedLine.d56.s10|184-186|not|O
DDI-MedLine.d56.s10|188-190|due|O
DDI-MedLine.d56.s10|192-193|to|O
DDI-MedLine.d56.s10|195-197|the|O
DDI-MedLine.d56.s10|199-212|norepinephrine|O
DDI-MedLine.d56.s10|214-220|release|O
DDI-MedLine.d56.s10|222-224|but|O
DDI-MedLine.d56.s10|226-235|presumably|O
DDI-MedLine.d56.s10|237-238|to|O
DDI-MedLine.d56.s10|240-240|a|O
DDI-MedLine.d56.s10|242-247|direct|O
DDI-MedLine.d56.s10|249-254|action|O
DDI-MedLine.d56.s10|256-257|on|O
DDI-MedLine.d56.s10|259-264|smooth|O
DDI-MedLine.d56.s10|266-271|muscle|O
DDI-MedLine.d56.s10|273-276|cell|O
DDI-MedLine.d56.s10|278-280|and|O
DDI-MedLine.d56.s10|282-284|was|O
DDI-MedLine.d56.s10|286-294|inhibited|O
DDI-MedLine.d56.s10|296-297|by|O
DDI-MedLine.d56.s10|299-305|ouabain|drug
DDI-MedLine.d56.s10|306-306|.|O
DDI-MedLine.d56.s11|0-2|The|O
DDI-MedLine.d56.s11|4-12|mechanism|O
DDI-MedLine.d56.s11|14-15|of|O
DDI-MedLine.d56.s11|17-19|the|O
DDI-MedLine.d56.s11|21-26|action|O
DDI-MedLine.d56.s11|28-29|of|O
DDI-MedLine.d56.s11|35-37|was|O
DDI-MedLine.d56.s11|39-47|discussed|O
DDI-MedLine.d56.s11|49-50|in|O
DDI-MedLine.d56.s11|52-54|the|O
DDI-MedLine.d56.s11|56-63|relation|O
DDI-MedLine.d56.s11|65-68|with|O
DDI-MedLine.d56.s11|70-71|Na|O
DDI-MedLine.d56.s11|72-72|,|O
DDI-MedLine.d56.s11|73-80|K-ATPase|O
DDI-MedLine.d56.s11|81-81|.|O
DDI-DrugBank.d698.s0|0-11|Interactions|O
DDI-DrugBank.d698.s0|13-15|for|O
DDI-DrugBank.d698.s0|17-26|Vitamin B2|drug
DDI-DrugBank.d698.s0|28-28|(|O
DDI-DrugBank.d698.s0|29-38|Riboflavin|drug
DDI-DrugBank.d698.s0|39-39|)|O
DDI-DrugBank.d698.s0|40-40|:|O
DDI-DrugBank.d698.s0|43-49|Alcohol|drug
DDI-DrugBank.d698.s0|51-51|-|O
DDI-DrugBank.d698.s0|53-59|impairs|O
DDI-DrugBank.d698.s0|61-63|the|O
DDI-DrugBank.d698.s0|65-74|intestinal|O
DDI-DrugBank.d698.s0|76-85|absorption|O
DDI-DrugBank.d698.s0|87-88|of|O
DDI-DrugBank.d698.s1|0-9|Probenecid|drug
DDI-DrugBank.d698.s1|11-11|-|O
DDI-DrugBank.d698.s1|13-22|concurrent|O
DDI-DrugBank.d698.s1|24-26|use|O
DDI-DrugBank.d698.s1|28-36|decreases|O
DDI-DrugBank.d698.s1|38-53|gastrointestinal|O
DDI-DrugBank.d698.s1|55-64|absorption|O
DDI-DrugBank.d698.s1|66-67|of|O
DDI-DrugBank.d698.s1|69-78|riboflavin|drug
DDI-DrugBank.d698.s1|79-79|;|O
DDI-DrugBank.d698.s2|0-11|requirements|O
DDI-DrugBank.d698.s2|13-15|for|O
DDI-DrugBank.d698.s2|17-26|riboflavin|drug
DDI-DrugBank.d698.s2|28-30|may|O
DDI-DrugBank.d698.s2|32-33|be|O
DDI-DrugBank.d698.s2|35-43|increased|O
DDI-DrugBank.d698.s2|45-46|in|O
DDI-DrugBank.d698.s2|48-55|patients|O
DDI-DrugBank.d698.s2|57-65|receiving|O
DDI-DrugBank.d698.s2|67-76|probenecid|drug
DDI-DrugBank.d698.s2|77-77|.|O
DDI-DrugBank.d624.s0|0-1|In|O
DDI-DrugBank.d624.s0|3-10|clinical|O
DDI-DrugBank.d624.s0|12-18|studies|O
DDI-DrugBank.d624.s0|20-21|of|O
DDI-DrugBank.d624.s0|23-26|TOBI|brand
DDI-DrugBank.d624.s0|27-27|,|O
DDI-DrugBank.d624.s0|29-36|patients|O
DDI-DrugBank.d624.s0|38-43|taking|O
DDI-DrugBank.d624.s0|45-48|TOBI|brand
DDI-DrugBank.d624.s0|50-62|concomitantly|O
DDI-DrugBank.d624.s0|64-67|with|O
DDI-DrugBank.d624.s0|69-80|dornase alfa|drug
DDI-DrugBank.d624.s0|82-82|(|O
DDI-DrugBank.d624.s0|83-91|PULMOZYME|brand
DDI-DrugBank.d624.s0|95-95|,|O
DDI-DrugBank.d624.s0|97-105|Genentech|O
DDI-DrugBank.d624.s0|106-106|)|O
DDI-DrugBank.d624.s0|107-107|,|O
DDI-DrugBank.d624.s0|109-123|( beta ) -agonists|group
DDI-DrugBank.d624.s0|124-124|,|O
DDI-DrugBank.d624.s0|126-132|inhaled|O
DDI-DrugBank.d624.s0|134-148|corticosteroids|group
DDI-DrugBank.d624.s0|149-149|,|O
DDI-DrugBank.d624.s0|151-155|other|O
DDI-DrugBank.d624.s0|157-184|anti-pseudomonal antibiotics|group
DDI-DrugBank.d624.s0|185-185|,|O
DDI-DrugBank.d624.s0|187-188|or|O
DDI-DrugBank.d624.s0|190-199|parenteral|O
DDI-DrugBank.d624.s0|201-215|aminoglycosides|group
DDI-DrugBank.d624.s0|217-228|demonstrated|O
DDI-DrugBank.d624.s0|230-236|adverse|O
DDI-DrugBank.d624.s0|238-247|experience|O
DDI-DrugBank.d624.s0|249-256|profiles|O
DDI-DrugBank.d624.s0|258-264|similar|O
DDI-DrugBank.d624.s0|266-267|to|O
DDI-DrugBank.d624.s0|269-271|the|O
DDI-DrugBank.d624.s0|273-277|study|O
DDI-DrugBank.d624.s0|279-288|population|O
DDI-DrugBank.d624.s0|290-291|as|O
DDI-DrugBank.d624.s0|293-293|a|O
DDI-DrugBank.d624.s0|295-299|whole|O
DDI-DrugBank.d624.s0|300-300|.|O
DDI-DrugBank.d624.s1|0-9|Concurrent|O
DDI-DrugBank.d624.s1|11-16|and/or|O
DDI-DrugBank.d624.s1|18-27|sequential|O
DDI-DrugBank.d624.s1|29-31|use|O
DDI-DrugBank.d624.s1|33-34|of|O
DDI-DrugBank.d624.s1|36-39|TOBI|brand
DDI-DrugBank.d624.s1|41-44|with|O
DDI-DrugBank.d624.s1|46-50|other|O
DDI-DrugBank.d624.s1|52-56|drugs|O
DDI-DrugBank.d624.s1|58-61|with|O
DDI-DrugBank.d624.s1|63-72|neurotoxic|O
DDI-DrugBank.d624.s1|74-75|or|O
DDI-DrugBank.d624.s1|77-84|ototoxic|O
DDI-DrugBank.d624.s1|86-94|potential|O
DDI-DrugBank.d624.s1|96-101|should|O
DDI-DrugBank.d624.s1|103-104|be|O
DDI-DrugBank.d624.s1|106-112|avoided|O
DDI-DrugBank.d624.s1|113-113|.|O
DDI-DrugBank.d624.s2|0-3|Some|O
DDI-DrugBank.d624.s2|5-13|diuretics|group
DDI-DrugBank.d624.s2|15-17|can|O
DDI-DrugBank.d624.s2|19-25|enhance|O
DDI-DrugBank.d624.s2|27-40|aminoglycoside|group
DDI-DrugBank.d624.s2|42-49|toxicity|O
DDI-DrugBank.d624.s2|51-52|by|O
DDI-DrugBank.d624.s2|54-61|altering|O
DDI-DrugBank.d624.s2|63-72|antibiotic|group
DDI-DrugBank.d624.s2|74-87|concentrations|O
DDI-DrugBank.d624.s2|89-90|in|O
DDI-DrugBank.d624.s2|92-96|serum|O
DDI-DrugBank.d624.s2|98-100|and|O
DDI-DrugBank.d624.s2|102-107|tissue|O
DDI-DrugBank.d624.s2|108-108|.|O
DDI-DrugBank.d624.s3|0-3|TOBI|brand
DDI-DrugBank.d624.s3|5-10|should|O
DDI-DrugBank.d624.s3|12-14|not|O
DDI-DrugBank.d624.s3|16-17|be|O
DDI-DrugBank.d624.s3|19-30|administered|O
DDI-DrugBank.d624.s3|32-44|concomitantly|O
DDI-DrugBank.d624.s3|46-49|with|O
DDI-DrugBank.d624.s3|51-65|ethacrynic acid|drug
DDI-DrugBank.d624.s3|66-66|,|O
DDI-DrugBank.d624.s3|68-77|furosemide|drug
DDI-DrugBank.d624.s3|78-78|,|O
DDI-DrugBank.d624.s3|80-83|urea|drug
DDI-DrugBank.d624.s3|84-84|,|O
DDI-DrugBank.d624.s3|86-87|or|O
DDI-DrugBank.d624.s3|89-96|mannitol|drug
DDI-DrugBank.d624.s3|97-97|.|O
DDI-DrugBank.d286.s0|0-12|Ethoxzolamide|drug
DDI-DrugBank.d286.s0|14-16|may|O
DDI-DrugBank.d286.s0|18-25|increase|O
DDI-DrugBank.d286.s0|27-29|the|O
DDI-DrugBank.d286.s0|31-36|action|O
DDI-DrugBank.d286.s0|38-39|of|O
DDI-DrugBank.d286.s0|41-50|tricyclics|group
DDI-DrugBank.d286.s0|51-51|,|O
DDI-DrugBank.d286.s0|53-64|amphetamines|group
DDI-DrugBank.d286.s0|65-65|,|O
DDI-DrugBank.d286.s0|67-78|procainamide|drug
DDI-DrugBank.d286.s0|79-79|,|O
DDI-DrugBank.d286.s0|81-83|and|O
DDI-DrugBank.d286.s0|85-93|quinidine|drug
DDI-DrugBank.d286.s0|94-94|.|O
DDI-DrugBank.d286.s1|0-1|It|O
DDI-DrugBank.d286.s1|3-5|may|O
DDI-DrugBank.d286.s1|7-14|increase|O
DDI-DrugBank.d286.s1|16-24|excretion|O
DDI-DrugBank.d286.s1|26-27|of|O
DDI-DrugBank.d286.s1|29-40|barbiturates|group
DDI-DrugBank.d286.s1|41-41|,|O
DDI-DrugBank.d286.s1|43-49|lithium|drug
DDI-DrugBank.d286.s1|50-50|,|O
DDI-DrugBank.d286.s1|52-54|and|O
DDI-DrugBank.d286.s1|56-58|ASA|drug
DDI-DrugBank.d286.s1|60-62|and|O
DDI-DrugBank.d286.s1|64-66|may|O
DDI-DrugBank.d286.s1|68-71|also|O
DDI-DrugBank.d286.s1|73-80|increase|O
DDI-DrugBank.d286.s1|82-84|the|O
DDI-DrugBank.d286.s1|86-93|toxicity|O
DDI-DrugBank.d286.s1|95-96|of|O
DDI-DrugBank.d286.s1|98-108|salicylates|group
DDI-DrugBank.d286.s1|109-109|.|O
DDI-DrugBank.d286.s2|0-15|Coadministration|O
DDI-DrugBank.d286.s2|17-18|of|O
DDI-DrugBank.d286.s2|20-32|ethoxzolamide|drug
DDI-DrugBank.d286.s2|34-37|with|O
DDI-DrugBank.d286.s2|39-43|other|O
DDI-DrugBank.d286.s2|45-53|diuretics|group
DDI-DrugBank.d286.s2|54-54|,|O
DDI-DrugBank.d286.s2|56-69|amphotericin B|drug
DDI-DrugBank.d286.s2|70-70|,|O
DDI-DrugBank.d286.s2|72-74|and|O
DDI-DrugBank.d286.s2|76-90|corticosteroids|group
DDI-DrugBank.d286.s2|92-94|may|O
DDI-DrugBank.d286.s2|96-100|cause|O
DDI-DrugBank.d286.s2|102-112|hypokalemia|O
DDI-DrugBank.d286.s2|113-113|.|O
DDI-DrugBank.d36.s0|0-6|Caution|O
DDI-DrugBank.d36.s0|8-9|is|O
DDI-DrugBank.d36.s0|11-17|advised|O
DDI-DrugBank.d36.s0|19-20|in|O
DDI-DrugBank.d36.s0|22-29|patients|O
DDI-DrugBank.d36.s0|31-39|receiving|O
DDI-DrugBank.d36.s0|41-51|concomitant|O
DDI-DrugBank.d36.s0|53-61|high-dose|O
DDI-DrugBank.d36.s0|63-69|aspirin|brand
DDI-DrugBank.d36.s0|71-73|and|O
DDI-DrugBank.d36.s0|75-103|carbonic anhydrase inhibitors|group
DDI-DrugBank.d36.s0|104-104|,|O
DDI-DrugBank.d36.s0|106-107|as|O
DDI-DrugBank.d36.s0|109-116|anorexia|O
DDI-DrugBank.d36.s0|117-117|,|O
DDI-DrugBank.d36.s0|119-127|tachypnea|O
DDI-DrugBank.d36.s0|128-128|,|O
DDI-DrugBank.d36.s0|130-137|lethargy|O
DDI-DrugBank.d36.s0|139-141|and|O
DDI-DrugBank.d36.s0|143-146|coma|O
DDI-DrugBank.d36.s0|148-151|have|O
DDI-DrugBank.d36.s0|153-156|been|O
DDI-DrugBank.d36.s0|158-163|rarely|O
DDI-DrugBank.d36.s0|165-172|reported|O
DDI-DrugBank.d36.s0|174-176|due|O
DDI-DrugBank.d36.s0|178-179|to|O
DDI-DrugBank.d36.s0|181-181|a|O
DDI-DrugBank.d36.s0|183-190|possible|O
DDI-DrugBank.d36.s0|192-195|drug|O
DDI-DrugBank.d36.s0|197-207|interaction|O
DDI-DrugBank.d36.s0|208-208|.|O
DDI-DrugBank.d676.s0|0-1|To|O
DDI-DrugBank.d676.s0|3-10|minimize|O
DDI-DrugBank.d676.s0|12-14|CNS|O
DDI-DrugBank.d676.s0|16-25|depression|O
DDI-DrugBank.d676.s0|27-29|and|O
DDI-DrugBank.d676.s0|31-38|possible|O
DDI-DrugBank.d676.s0|40-51|potentiation|O
DDI-DrugBank.d676.s0|52-52|,|O
DDI-DrugBank.d676.s0|54-65|barbiturates|group
DDI-DrugBank.d676.s0|66-66|,|O
DDI-DrugBank.d676.s0|68-81|antihistamines|group
DDI-DrugBank.d676.s0|82-82|,|O
DDI-DrugBank.d676.s0|84-92|narcotics|group
DDI-DrugBank.d676.s0|93-93|,|O
DDI-DrugBank.d676.s0|95-112|hypotensive agents|group
DDI-DrugBank.d676.s0|114-115|or|O
DDI-DrugBank.d676.s0|117-130|phenothiazines|group
DDI-DrugBank.d676.s0|132-137|should|O
DDI-DrugBank.d676.s0|139-140|be|O
DDI-DrugBank.d676.s0|142-145|used|O
DDI-DrugBank.d676.s0|147-150|with|O
DDI-DrugBank.d676.s0|152-158|caution|O
DDI-DrugBank.d676.s0|159-159|.|O
DDI-DrugBank.d676.s1|0-12|Ethyl alcohol|drug
DDI-DrugBank.d676.s1|14-19|should|O
DDI-DrugBank.d676.s1|21-23|not|O
DDI-DrugBank.d676.s1|25-26|be|O
DDI-DrugBank.d676.s1|28-31|used|O
DDI-DrugBank.d676.s1|33-37|since|O
DDI-DrugBank.d676.s1|39-43|there|O
DDI-DrugBank.d676.s1|45-47|may|O
DDI-DrugBank.d676.s1|49-50|be|O
DDI-DrugBank.d676.s1|52-53|an|O
DDI-DrugBank.d676.s1|55-62|Antabuse|O
DDI-DrugBank.d676.s1|64-64|(|O
DDI-DrugBank.d676.s1|65-74|disulfiram|O
DDI-DrugBank.d676.s1|75-75|)|O
DDI-DrugBank.d676.s1|76-80|-like|O
DDI-DrugBank.d676.s1|82-89|reaction|O
DDI-DrugBank.d676.s1|90-90|.|O
DDI-DrugBank.d676.s2|0-6|Because|O
DDI-DrugBank.d676.s2|8-15|Matulane|brand
DDI-DrugBank.d676.s2|17-24|exhibits|O
DDI-DrugBank.d676.s2|26-29|some|O
DDI-DrugBank.d676.s2|31-39|monoamine|O
DDI-DrugBank.d676.s2|41-47|oxidase|O
DDI-DrugBank.d676.s2|49-58|inhibitory|O
DDI-DrugBank.d676.s2|60-67|activity|O
DDI-DrugBank.d676.s2|68-68|,|O
DDI-DrugBank.d676.s2|70-90|sympathomimetic drugs|group
DDI-DrugBank.d676.s2|91-91|,|O
DDI-DrugBank.d676.s2|93-116|tricyclic antidepressant|group
DDI-DrugBank.d676.s2|118-122|drugs|O
DDI-DrugBank.d676.s2|124-124|(|O
DDI-DrugBank.d676.s2|125-128|e.g.|O
DDI-DrugBank.d676.s2|129-129|,|O
DDI-DrugBank.d676.s2|131-147|amitriptyline HCl|drug
DDI-DrugBank.d676.s2|148-148|,|O
DDI-DrugBank.d676.s2|150-163|imipramine HCl|drug
DDI-DrugBank.d676.s2|164-164|)|O
DDI-DrugBank.d676.s2|166-168|and|O
DDI-DrugBank.d676.s2|170-174|other|O
DDI-DrugBank.d676.s2|176-180|drugs|O
DDI-DrugBank.d676.s2|182-184|and|O
DDI-DrugBank.d676.s2|186-190|foods|O
DDI-DrugBank.d676.s2|192-195|with|O
DDI-DrugBank.d676.s2|197-201|known|O
DDI-DrugBank.d676.s2|203-206|high|O
DDI-DrugBank.d676.s2|217-223|content|O
DDI-DrugBank.d676.s2|224-224|,|O
DDI-DrugBank.d676.s2|226-229|such|O
DDI-DrugBank.d676.s2|231-232|as|O
DDI-DrugBank.d676.s2|234-237|wine|O
DDI-DrugBank.d676.s2|238-238|,|O
DDI-DrugBank.d676.s2|240-245|yogurt|O
DDI-DrugBank.d676.s2|246-246|,|O
DDI-DrugBank.d676.s2|248-251|ripe|O
DDI-DrugBank.d676.s2|253-258|cheese|O
DDI-DrugBank.d676.s2|260-262|and|O
DDI-DrugBank.d676.s2|264-270|bananas|O
DDI-DrugBank.d676.s2|271-271|,|O
DDI-DrugBank.d676.s2|273-278|should|O
DDI-DrugBank.d676.s2|280-281|be|O
DDI-DrugBank.d676.s2|283-289|avoided|O
DDI-DrugBank.d676.s2|290-290|.|O
DDI-DrugBank.d676.s3|0-0|A|O
DDI-DrugBank.d676.s3|2-8|further|O
DDI-DrugBank.d676.s3|10-19|phenomenon|O
DDI-DrugBank.d676.s3|21-22|of|O
DDI-DrugBank.d676.s3|24-31|toxicity|O
DDI-DrugBank.d676.s3|33-38|common|O
DDI-DrugBank.d676.s3|40-41|to|O
DDI-DrugBank.d676.s3|43-46|many|O
DDI-DrugBank.d676.s3|48-68|hydrazine derivatives|group
DDI-DrugBank.d676.s3|70-71|is|O
DDI-DrugBank.d676.s3|73-81|hemolysis|O
DDI-DrugBank.d676.s3|83-85|and|O
DDI-DrugBank.d676.s3|87-89|the|O
DDI-DrugBank.d676.s3|91-100|appearance|O
DDI-DrugBank.d676.s3|102-103|of|O
DDI-DrugBank.d676.s3|105-117|Heinz-Ehrlich|O
DDI-DrugBank.d676.s3|119-127|inclusion|O
DDI-DrugBank.d676.s3|129-134|bodies|O
DDI-DrugBank.d676.s3|136-137|in|O
DDI-DrugBank.d676.s3|139-150|erythrocytes|O
DDI-DrugBank.d676.s3|151-151|.|O
DDI-DrugBank.d676.s4|0-1|No|O
DDI-DrugBank.d676.s4|3-18|cross-resistance|O
DDI-DrugBank.d676.s4|20-23|with|O
DDI-DrugBank.d676.s4|25-29|other|O
DDI-DrugBank.d676.s4|31-53|chemotherapeutic agents|group
DDI-DrugBank.d676.s4|54-54|,|O
DDI-DrugBank.d676.s4|56-67|radiotherapy|O
DDI-DrugBank.d676.s4|69-70|or|O
DDI-DrugBank.d676.s4|72-79|steroids|group
DDI-DrugBank.d676.s4|81-83|has|O
DDI-DrugBank.d676.s4|85-88|been|O
DDI-DrugBank.d676.s4|90-101|demonstrated|O
DDI-DrugBank.d676.s4|102-102|.|O
DDI-DrugBank.d50.s0|0-1|No|O
DDI-DrugBank.d50.s0|3-8|formal|O
DDI-DrugBank.d50.s0|10-18|drug-drug|O
DDI-DrugBank.d50.s0|20-30|interaction|O
DDI-DrugBank.d50.s0|32-38|studies|O
DDI-DrugBank.d50.s0|40-43|have|O
DDI-DrugBank.d50.s0|45-48|been|O
DDI-DrugBank.d50.s0|50-58|performed|O
DDI-DrugBank.d50.s0|59-59|.|O
DDI-DrugBank.d50.s1|0-1|No|O
DDI-DrugBank.d50.s1|3-11|confirmed|O
DDI-DrugBank.d50.s1|13-24|interactions|O
DDI-DrugBank.d50.s1|26-29|have|O
DDI-DrugBank.d50.s1|31-34|been|O
DDI-DrugBank.d50.s1|36-43|reported|O
DDI-DrugBank.d50.s1|45-51|between|O
DDI-DrugBank.d50.s1|53-59|ZOLADEX|brand
DDI-DrugBank.d50.s1|61-63|and|O
DDI-DrugBank.d50.s1|65-69|other|O
DDI-DrugBank.d50.s1|71-75|drugs|O
DDI-DrugBank.d491.s0|0-1|No|O
DDI-DrugBank.d491.s0|3-8|formal|O
DDI-DrugBank.d491.s0|10-20|interaction|O
DDI-DrugBank.d491.s0|22-28|studies|O
DDI-DrugBank.d491.s0|30-33|have|O
DDI-DrugBank.d491.s0|35-38|been|O
DDI-DrugBank.d491.s0|40-48|performed|O
DDI-DrugBank.d491.s0|49-49|.|O
DDI-DrugBank.d491.s1|0-2|The|O
DDI-DrugBank.d491.s1|4-11|duration|O
DDI-DrugBank.d491.s1|13-14|of|O
DDI-DrugBank.d491.s1|16-18|the|O
DDI-DrugBank.d491.s1|20-25|period|O
DDI-DrugBank.d491.s1|27-35|following|O
DDI-DrugBank.d491.s1|37-45|treatment|O
DDI-DrugBank.d491.s1|47-50|with|O
DDI-DrugBank.d491.s1|52-58|AMEVIVE|brand
DDI-DrugBank.d491.s1|61-66|before|O
DDI-DrugBank.d491.s1|68-70|one|O
DDI-DrugBank.d491.s1|72-77|should|O
DDI-DrugBank.d491.s1|79-86|consider|O
DDI-DrugBank.d491.s1|88-95|starting|O
DDI-DrugBank.d491.s1|97-101|other|O
DDI-DrugBank.d491.s1|103-119|immunosuppressive|group
DDI-DrugBank.d491.s1|121-127|therapy|O
DDI-DrugBank.d491.s1|129-131|has|O
DDI-DrugBank.d491.s1|133-135|not|O
DDI-DrugBank.d491.s1|137-140|been|O
DDI-DrugBank.d491.s1|142-150|evaluated|O
DDI-DrugBank.d491.s1|151-151|.|O
DDI-DrugBank.d491.s2|0-13|Carcinogenesis|O
DDI-DrugBank.d491.s2|14-14|,|O
DDI-DrugBank.d491.s2|16-26|Mutagenesis|O
DDI-DrugBank.d491.s2|27-27|,|O
DDI-DrugBank.d491.s2|29-31|and|O
DDI-DrugBank.d491.s2|33-41|Fertility|O
DDI-DrugBank.d491.s3|0-1|In|O
DDI-DrugBank.d491.s3|3-3|a|O
DDI-DrugBank.d491.s3|5-11|chronic|O
DDI-DrugBank.d491.s3|13-20|toxicity|O
DDI-DrugBank.d491.s3|22-26|study|O
DDI-DrugBank.d491.s3|27-27|,|O
DDI-DrugBank.d491.s3|29-38|cynomolgus|O
DDI-DrugBank.d491.s3|40-46|monkeys|O
DDI-DrugBank.d491.s3|48-51|were|O
DDI-DrugBank.d491.s3|53-57|dosed|O
DDI-DrugBank.d491.s3|59-64|weekly|O
DDI-DrugBank.d491.s3|66-68|for|O
DDI-DrugBank.d491.s3|70-71|52|O
DDI-DrugBank.d491.s3|73-77|weeks|O
DDI-DrugBank.d491.s3|79-82|with|O
DDI-DrugBank.d491.s3|84-94|intravenous|O
DDI-DrugBank.d491.s3|96-104|alefacept|drug
DDI-DrugBank.d491.s3|106-107|at|O
DDI-DrugBank.d491.s3|109-109|1|O
DDI-DrugBank.d491.s3|111-120|mg/kg/dose|O
DDI-DrugBank.d491.s3|122-123|or|O
DDI-DrugBank.d491.s3|125-126|20|O
DDI-DrugBank.d491.s3|128-137|mg/kg/dose|O
DDI-DrugBank.d491.s3|138-138|.|O
DDI-DrugBank.d491.s4|0-2|One|O
DDI-DrugBank.d491.s4|4-9|animal|O
DDI-DrugBank.d491.s4|11-12|in|O
DDI-DrugBank.d491.s4|14-16|the|O
DDI-DrugBank.d491.s4|18-21|high|O
DDI-DrugBank.d491.s4|23-26|dose|O
DDI-DrugBank.d491.s4|28-32|group|O
DDI-DrugBank.d491.s4|34-42|developed|O
DDI-DrugBank.d491.s4|44-44|a|O
DDI-DrugBank.d491.s4|46-51|B-cell|O
DDI-DrugBank.d491.s4|53-60|lymphoma|O
DDI-DrugBank.d491.s4|62-65|that|O
DDI-DrugBank.d491.s4|67-69|was|O
DDI-DrugBank.d491.s4|71-78|detected|O
DDI-DrugBank.d491.s4|80-84|after|O
DDI-DrugBank.d491.s4|86-87|28|O
DDI-DrugBank.d491.s4|89-93|weeks|O
DDI-DrugBank.d491.s4|95-96|of|O
DDI-DrugBank.d491.s4|98-103|dosing|O
DDI-DrugBank.d491.s4|104-104|.|O
DDI-DrugBank.d491.s5|0-9|Additional|O
DDI-DrugBank.d491.s5|11-17|animals|O
DDI-DrugBank.d491.s5|19-20|in|O
DDI-DrugBank.d491.s5|22-25|both|O
DDI-DrugBank.d491.s5|27-30|dose|O
DDI-DrugBank.d491.s5|32-37|groups|O
DDI-DrugBank.d491.s5|39-47|developed|O
DDI-DrugBank.d491.s5|49-54|B-cell|O
DDI-DrugBank.d491.s5|56-66|hyperplasia|O
DDI-DrugBank.d491.s5|68-69|of|O
DDI-DrugBank.d491.s5|71-73|the|O
DDI-DrugBank.d491.s5|75-80|spleen|O
DDI-DrugBank.d491.s5|82-84|and|O
DDI-DrugBank.d491.s5|86-90|lymph|O
DDI-DrugBank.d491.s5|92-96|nodes|O
DDI-DrugBank.d491.s5|97-97|.|O
DDI-DrugBank.d491.s6|0-2|All|O
DDI-DrugBank.d491.s6|4-10|animals|O
DDI-DrugBank.d491.s6|12-13|in|O
DDI-DrugBank.d491.s6|15-17|the|O
DDI-DrugBank.d491.s6|19-23|study|O
DDI-DrugBank.d491.s6|25-28|were|O
DDI-DrugBank.d491.s6|30-37|positive|O
DDI-DrugBank.d491.s6|39-41|for|O
DDI-DrugBank.d491.s6|43-44|an|O
DDI-DrugBank.d491.s6|46-52|endemic|O
DDI-DrugBank.d491.s6|54-60|primate|O
DDI-DrugBank.d491.s6|62-72|gammaherpes|O
DDI-DrugBank.d491.s6|74-78|virus|O
DDI-DrugBank.d491.s6|80-83|also|O
DDI-DrugBank.d491.s6|85-89|known|O
DDI-DrugBank.d491.s6|91-92|as|O
DDI-DrugBank.d491.s6|94-110|lymphocryptovirus|O
DDI-DrugBank.d491.s6|112-112|(|O
DDI-DrugBank.d491.s6|113-115|LCV|O
DDI-DrugBank.d491.s6|116-116|)|O
DDI-DrugBank.d491.s6|117-117|.|O
DDI-DrugBank.d491.s7|0-5|Latent|O
DDI-DrugBank.d491.s7|7-9|LCV|O
DDI-DrugBank.d491.s7|11-19|infection|O
DDI-DrugBank.d491.s7|21-22|is|O
DDI-DrugBank.d491.s7|24-32|generally|O
DDI-DrugBank.d491.s7|34-45|asymptomatic|O
DDI-DrugBank.d491.s7|46-46|,|O
DDI-DrugBank.d491.s7|48-50|but|O
DDI-DrugBank.d491.s7|52-54|can|O
DDI-DrugBank.d491.s7|56-59|lead|O
DDI-DrugBank.d491.s7|61-62|to|O
DDI-DrugBank.d491.s7|64-69|B-cell|O
DDI-DrugBank.d491.s7|71-79|lymphomas|O
DDI-DrugBank.d491.s7|81-84|when|O
DDI-DrugBank.d491.s7|86-92|animals|O
DDI-DrugBank.d491.s7|94-96|are|O
DDI-DrugBank.d491.s7|98-103|immune|O
DDI-DrugBank.d491.s7|105-114|suppressed|O
DDI-DrugBank.d491.s7|115-115|.|O
DDI-DrugBank.d491.s8|0-1|In|O
DDI-DrugBank.d491.s8|3-3|a|O
DDI-DrugBank.d491.s8|5-12|separate|O
DDI-DrugBank.d491.s8|14-18|study|O
DDI-DrugBank.d491.s8|19-19|,|O
DDI-DrugBank.d491.s8|21-27|baboons|O
DDI-DrugBank.d491.s8|29-33|given|O
DDI-DrugBank.d491.s8|35-35|3|O
DDI-DrugBank.d491.s8|37-41|doses|O
DDI-DrugBank.d491.s8|43-44|of|O
DDI-DrugBank.d491.s8|46-54|alefacept|drug
DDI-DrugBank.d491.s8|56-57|at|O
DDI-DrugBank.d491.s8|59-59|1|O
DDI-DrugBank.d491.s8|61-65|mg/kg|O
DDI-DrugBank.d491.s8|67-71|every|O
DDI-DrugBank.d491.s8|73-73|8|O
DDI-DrugBank.d491.s8|75-79|weeks|O
DDI-DrugBank.d491.s8|81-84|were|O
DDI-DrugBank.d491.s8|86-90|found|O
DDI-DrugBank.d491.s8|92-93|to|O
DDI-DrugBank.d491.s8|95-98|have|O
DDI-DrugBank.d491.s8|100-110|centroblast|O
DDI-DrugBank.d491.s8|112-124|proliferation|O
DDI-DrugBank.d491.s8|126-127|in|O
DDI-DrugBank.d491.s8|129-134|B-cell|O
DDI-DrugBank.d491.s8|136-144|dependent|O
DDI-DrugBank.d491.s8|146-150|areas|O
DDI-DrugBank.d491.s8|152-153|in|O
DDI-DrugBank.d491.s8|155-157|the|O
DDI-DrugBank.d491.s8|159-166|germinal|O
DDI-DrugBank.d491.s8|168-174|centers|O
DDI-DrugBank.d491.s8|176-177|of|O
DDI-DrugBank.d491.s8|179-181|the|O
DDI-DrugBank.d491.s8|183-188|spleen|O
DDI-DrugBank.d491.s8|190-198|following|O
DDI-DrugBank.d491.s8|200-200|a|O
DDI-DrugBank.d491.s8|202-208|116-day|O
DDI-DrugBank.d491.s8|210-216|washout|O
DDI-DrugBank.d491.s8|218-223|period|O
DDI-DrugBank.d491.s8|224-224|.|O
DDI-DrugBank.d491.s9|0-2|The|O
DDI-DrugBank.d491.s9|4-7|role|O
DDI-DrugBank.d491.s9|9-10|of|O
DDI-DrugBank.d491.s9|12-18|AMEVIVE|brand
DDI-DrugBank.d491.s9|20-21|in|O
DDI-DrugBank.d491.s9|23-25|the|O
DDI-DrugBank.d491.s9|27-37|development|O
DDI-DrugBank.d491.s9|39-40|of|O
DDI-DrugBank.d491.s9|42-44|the|O
DDI-DrugBank.d491.s9|46-53|lymphoid|O
DDI-DrugBank.d491.s9|55-64|malignancy|O
DDI-DrugBank.d491.s9|66-68|and|O
DDI-DrugBank.d491.s9|70-72|the|O
DDI-DrugBank.d491.s9|74-84|hyperplasia|O
DDI-DrugBank.d491.s9|86-93|observed|O
DDI-DrugBank.d491.s9|95-96|in|O
DDI-DrugBank.d491.s9|98-106|non-human|O
DDI-DrugBank.d491.s9|108-115|primates|O
DDI-DrugBank.d491.s9|117-119|and|O
DDI-DrugBank.d491.s9|121-123|the|O
DDI-DrugBank.d491.s9|125-133|relevance|O
DDI-DrugBank.d491.s9|135-136|to|O
DDI-DrugBank.d491.s9|138-143|humans|O
DDI-DrugBank.d491.s9|145-146|is|O
DDI-DrugBank.d491.s9|148-154|unknown|O
DDI-DrugBank.d491.s9|155-155|.|O
DDI-DrugBank.d491.s10|0-26|Immunodeficiency-associated|O
DDI-DrugBank.d491.s10|28-37|lymphocyte|O
DDI-DrugBank.d491.s10|39-47|disorders|O
DDI-DrugBank.d491.s10|49-49|(|O
DDI-DrugBank.d491.s10|50-60|plasmacytic|O
DDI-DrugBank.d491.s10|62-72|hyperplasia|O
DDI-DrugBank.d491.s10|73-73|,|O
DDI-DrugBank.d491.s10|75-85|polymorphic|O
DDI-DrugBank.d491.s10|87-99|proliferation|O
DDI-DrugBank.d491.s10|100-100|,|O
DDI-DrugBank.d491.s10|102-104|and|O
DDI-DrugBank.d491.s10|106-111|B-cell|O
DDI-DrugBank.d491.s10|113-121|lymphomas|O
DDI-DrugBank.d491.s10|122-122|)|O
DDI-DrugBank.d491.s10|124-128|occur|O
DDI-DrugBank.d491.s10|130-131|in|O
DDI-DrugBank.d491.s10|133-140|patients|O
DDI-DrugBank.d491.s10|142-144|who|O
DDI-DrugBank.d491.s10|146-149|have|O
DDI-DrugBank.d491.s10|151-160|congenital|O
DDI-DrugBank.d491.s10|162-163|or|O
DDI-DrugBank.d491.s10|165-172|acquired|O
DDI-DrugBank.d491.s10|174-191|immunodeficiencies|O
DDI-DrugBank.d491.s10|193-201|including|O
DDI-DrugBank.d491.s10|203-207|those|O
DDI-DrugBank.d491.s10|209-217|resulting|O
DDI-DrugBank.d491.s10|219-222|from|O
DDI-DrugBank.d491.s10|224-240|immunosuppressive|group
DDI-DrugBank.d491.s10|242-248|therapy|O
DDI-DrugBank.d491.s10|249-249|.|O
DDI-DrugBank.d491.s11|0-1|No|O
DDI-DrugBank.d491.s11|3-17|carcinogenicity|O
DDI-DrugBank.d491.s11|19-20|or|O
DDI-DrugBank.d491.s11|22-30|fertility|O
DDI-DrugBank.d491.s11|32-38|studies|O
DDI-DrugBank.d491.s11|40-43|were|O
DDI-DrugBank.d491.s11|45-53|conducted|O
DDI-DrugBank.d491.s11|54-54|.|O
DDI-DrugBank.d491.s12|0-11|Mutagenicity|O
DDI-DrugBank.d491.s12|13-19|studies|O
DDI-DrugBank.d491.s12|21-24|were|O
DDI-DrugBank.d491.s12|26-34|conducted|O
DDI-DrugBank.d491.s12|36-37|in|O
DDI-DrugBank.d491.s12|39-43|vitro|O
DDI-DrugBank.d491.s12|45-47|and|O
DDI-DrugBank.d491.s12|49-50|in|O
DDI-DrugBank.d491.s12|52-55|vivo|O
DDI-DrugBank.d491.s12|56-56|;|O
DDI-DrugBank.d491.s13|0-1|no|O
DDI-DrugBank.d491.s13|3-10|evidence|O
DDI-DrugBank.d491.s13|12-13|of|O
DDI-DrugBank.d491.s13|15-26|mutagenicity|O
DDI-DrugBank.d491.s13|28-30|was|O
DDI-DrugBank.d491.s13|32-39|observed|O
DDI-DrugBank.d491.s13|40-40|.|O
DDI-DrugBank.d491.s14|0-8|Pregnancy|O
DDI-DrugBank.d491.s14|10-10|(|O
DDI-DrugBank.d491.s14|11-18|Category|O
DDI-DrugBank.d491.s14|20-20|B|O
DDI-DrugBank.d491.s14|21-21|)|O
DDI-DrugBank.d491.s15|0-4|Women|O
DDI-DrugBank.d491.s15|6-7|of|O
DDI-DrugBank.d491.s15|9-20|childbearing|O
DDI-DrugBank.d491.s15|22-30|potential|O
DDI-DrugBank.d491.s15|32-35|make|O
DDI-DrugBank.d491.s15|37-38|up|O
DDI-DrugBank.d491.s15|40-40|a|O
DDI-DrugBank.d491.s15|42-53|considerable|O
DDI-DrugBank.d491.s15|55-61|segment|O
DDI-DrugBank.d491.s15|63-64|of|O
DDI-DrugBank.d491.s15|66-68|the|O
DDI-DrugBank.d491.s15|70-76|patient|O
DDI-DrugBank.d491.s15|78-87|population|O
DDI-DrugBank.d491.s15|89-96|affected|O
DDI-DrugBank.d491.s15|98-99|by|O
DDI-DrugBank.d491.s15|101-109|psoriasis|O
DDI-DrugBank.d491.s15|110-110|.|O
DDI-DrugBank.d491.s16|0-4|Since|O
DDI-DrugBank.d491.s16|6-8|the|O
DDI-DrugBank.d491.s16|10-15|effect|O
DDI-DrugBank.d491.s16|17-18|of|O
DDI-DrugBank.d491.s16|20-26|AMEVIVE|brand
DDI-DrugBank.d491.s16|28-29|on|O
DDI-DrugBank.d491.s16|31-39|pregnancy|O
DDI-DrugBank.d491.s16|41-43|and|O
DDI-DrugBank.d491.s16|45-49|fetal|O
DDI-DrugBank.d491.s16|51-61|development|O
DDI-DrugBank.d491.s16|62-62|,|O
DDI-DrugBank.d491.s16|64-72|including|O
DDI-DrugBank.d491.s16|74-79|immune|O
DDI-DrugBank.d491.s16|81-86|system|O
DDI-DrugBank.d491.s16|88-98|development|O
DDI-DrugBank.d491.s16|99-99|,|O
DDI-DrugBank.d491.s16|101-102|is|O
DDI-DrugBank.d491.s16|104-106|not|O
DDI-DrugBank.d491.s16|108-112|known|O
DDI-DrugBank.d491.s16|113-113|,|O
DDI-DrugBank.d491.s16|115-120|health|O
DDI-DrugBank.d491.s16|122-125|care|O
DDI-DrugBank.d491.s16|127-135|providers|O
DDI-DrugBank.d491.s16|137-139|are|O
DDI-DrugBank.d491.s16|141-150|encouraged|O
DDI-DrugBank.d491.s16|152-153|to|O
DDI-DrugBank.d491.s16|155-160|enroll|O
DDI-DrugBank.d491.s16|162-169|patients|O
DDI-DrugBank.d491.s16|171-179|currently|O
DDI-DrugBank.d491.s16|181-186|taking|O
DDI-DrugBank.d491.s16|188-194|AMEVIVE|brand
DDI-DrugBank.d491.s16|196-198|who|O
DDI-DrugBank.d491.s16|200-205|become|O
DDI-DrugBank.d491.s16|207-214|pregnant|O
DDI-DrugBank.d491.s16|216-219|into|O
DDI-DrugBank.d491.s16|221-223|the|O
DDI-DrugBank.d491.s16|225-230|Biogen|O
DDI-DrugBank.d491.s16|232-240|Pregnancy|O
DDI-DrugBank.d491.s16|242-249|Registry|O
DDI-DrugBank.d491.s16|251-252|by|O
DDI-DrugBank.d491.s16|254-260|calling|O
DDI-DrugBank.d491.s16|262-274|1-866-AMEVIVE|brand
DDI-DrugBank.d491.s16|276-276|(|O
DDI-DrugBank.d491.s16|277-290|1-866-263-8483|O
DDI-DrugBank.d491.s16|291-291|)|O
DDI-DrugBank.d491.s16|292-292|.|O
DDI-DrugBank.d491.s17|0-11|Reproductive|O
DDI-DrugBank.d491.s17|13-22|toxicology|O
DDI-DrugBank.d491.s17|24-30|studies|O
DDI-DrugBank.d491.s17|32-35|have|O
DDI-DrugBank.d491.s17|37-40|been|O
DDI-DrugBank.d491.s17|42-50|performed|O
DDI-DrugBank.d491.s17|52-53|in|O
DDI-DrugBank.d491.s17|55-64|cynomolgus|O
DDI-DrugBank.d491.s17|66-72|monkeys|O
DDI-DrugBank.d491.s17|74-75|at|O
DDI-DrugBank.d491.s17|77-81|doses|O
DDI-DrugBank.d491.s17|83-84|up|O
DDI-DrugBank.d491.s17|86-87|to|O
DDI-DrugBank.d491.s17|89-89|5|O
DDI-DrugBank.d491.s17|91-100|mg/kg/week|O
DDI-DrugBank.d491.s17|102-102|(|O
DDI-DrugBank.d491.s17|103-107|about|O
DDI-DrugBank.d491.s17|109-110|62|O
DDI-DrugBank.d491.s17|112-116|times|O
DDI-DrugBank.d491.s17|118-120|the|O
DDI-DrugBank.d491.s17|122-126|human|O
DDI-DrugBank.d491.s17|128-131|dose|O
DDI-DrugBank.d491.s17|133-137|based|O
DDI-DrugBank.d491.s17|139-140|on|O
DDI-DrugBank.d491.s17|142-145|body|O
DDI-DrugBank.d491.s17|147-152|weight|O
DDI-DrugBank.d491.s17|153-153|)|O
DDI-DrugBank.d491.s17|155-157|and|O
DDI-DrugBank.d491.s17|159-162|have|O
DDI-DrugBank.d491.s17|164-171|revealed|O
DDI-DrugBank.d491.s17|173-174|no|O
DDI-DrugBank.d491.s17|176-183|evidence|O
DDI-DrugBank.d491.s17|185-186|of|O
DDI-DrugBank.d491.s17|188-195|impaired|O
DDI-DrugBank.d491.s17|197-205|fertility|O
DDI-DrugBank.d491.s17|207-208|or|O
DDI-DrugBank.d491.s17|210-213|harm|O
DDI-DrugBank.d491.s17|215-216|to|O
DDI-DrugBank.d491.s17|218-220|the|O
DDI-DrugBank.d491.s17|222-226|fetus|O
DDI-DrugBank.d491.s17|228-230|due|O
DDI-DrugBank.d491.s17|232-233|to|O
DDI-DrugBank.d491.s17|235-241|AMEVIVE|brand
DDI-DrugBank.d491.s17|242-242|.|O
DDI-DrugBank.d491.s18|0-1|No|O
DDI-DrugBank.d491.s18|3-15|abortifacient|O
DDI-DrugBank.d491.s18|17-18|or|O
DDI-DrugBank.d491.s18|20-30|teratogenic|O
DDI-DrugBank.d491.s18|32-38|effects|O
DDI-DrugBank.d491.s18|40-43|were|O
DDI-DrugBank.d491.s18|45-52|observed|O
DDI-DrugBank.d491.s18|54-55|in|O
DDI-DrugBank.d491.s18|57-66|cynomolgus|O
DDI-DrugBank.d491.s18|68-74|monkeys|O
DDI-DrugBank.d491.s18|76-84|following|O
DDI-DrugBank.d491.s18|86-96|intravenous|O
DDI-DrugBank.d491.s18|98-102|bolus|O
DDI-DrugBank.d491.s18|104-113|injections|O
DDI-DrugBank.d491.s18|115-116|of|O
DDI-DrugBank.d491.s18|118-124|AMEVIVE|brand
DDI-DrugBank.d491.s18|126-137|administered|O
DDI-DrugBank.d491.s18|139-144|weekly|O
DDI-DrugBank.d491.s18|146-151|during|O
DDI-DrugBank.d491.s18|153-155|the|O
DDI-DrugBank.d491.s18|157-162|period|O
DDI-DrugBank.d491.s18|164-165|of|O
DDI-DrugBank.d491.s18|167-179|organogenesis|O
DDI-DrugBank.d491.s18|181-182|to|O
DDI-DrugBank.d491.s18|184-192|gestation|O
DDI-DrugBank.d491.s18|193-193|.|O
DDI-DrugBank.d491.s19|0-6|AMEVIVE|brand
DDI-DrugBank.d491.s19|8-16|underwent|O
DDI-DrugBank.d491.s19|18-32|trans-placental|O
DDI-DrugBank.d491.s19|34-40|passage|O
DDI-DrugBank.d491.s19|42-44|and|O
DDI-DrugBank.d491.s19|46-53|produced|O
DDI-DrugBank.d491.s19|55-56|in|O
DDI-DrugBank.d491.s19|58-62|utero|O
DDI-DrugBank.d491.s19|64-71|exposure|O
DDI-DrugBank.d491.s19|73-74|in|O
DDI-DrugBank.d491.s19|76-78|the|O
DDI-DrugBank.d491.s19|80-89|developing|O
DDI-DrugBank.d491.s19|91-97|monkeys|O
DDI-DrugBank.d491.s19|98-98|.|O
DDI-DrugBank.d491.s20|0-1|In|O
DDI-DrugBank.d491.s20|3-7|utero|O
DDI-DrugBank.d491.s20|8-8|,|O
DDI-DrugBank.d491.s20|10-14|serum|O
DDI-DrugBank.d491.s20|16-21|levels|O
DDI-DrugBank.d491.s20|23-24|of|O
DDI-DrugBank.d491.s20|26-33|exposure|O
DDI-DrugBank.d491.s20|35-36|in|O
DDI-DrugBank.d491.s20|38-42|these|O
DDI-DrugBank.d491.s20|44-50|monkeys|O
DDI-DrugBank.d491.s20|52-55|were|O
DDI-DrugBank.d491.s20|57-58|23|O
DDI-DrugBank.d491.s20|59-59|%|O
DDI-DrugBank.d491.s20|61-62|of|O
DDI-DrugBank.d491.s20|64-71|maternal|O
DDI-DrugBank.d491.s20|73-77|serum|O
DDI-DrugBank.d491.s20|79-84|levels|O
DDI-DrugBank.d491.s20|85-85|.|O
DDI-DrugBank.d491.s21|0-1|No|O
DDI-DrugBank.d491.s21|3-10|evidence|O
DDI-DrugBank.d491.s21|12-13|of|O
DDI-DrugBank.d491.s21|15-19|fetal|O
DDI-DrugBank.d491.s21|21-28|toxicity|O
DDI-DrugBank.d491.s21|30-38|including|O
DDI-DrugBank.d491.s21|40-46|adverse|O
DDI-DrugBank.d491.s21|48-54|effects|O
DDI-DrugBank.d491.s21|56-57|on|O
DDI-DrugBank.d491.s21|59-64|immune|O
DDI-DrugBank.d491.s21|66-71|system|O
DDI-DrugBank.d491.s21|73-83|development|O
DDI-DrugBank.d491.s21|85-87|was|O
DDI-DrugBank.d491.s21|89-96|observed|O
DDI-DrugBank.d491.s21|98-99|in|O
DDI-DrugBank.d491.s21|101-103|any|O
DDI-DrugBank.d491.s21|105-106|of|O
DDI-DrugBank.d491.s21|108-112|these|O
DDI-DrugBank.d491.s21|114-120|animals|O
DDI-DrugBank.d491.s21|121-121|.|O
DDI-DrugBank.d491.s22|0-5|Animal|O
DDI-DrugBank.d491.s22|7-18|reproduction|O
DDI-DrugBank.d491.s22|20-26|studies|O
DDI-DrugBank.d491.s22|27-27|,|O
DDI-DrugBank.d491.s22|29-35|however|O
DDI-DrugBank.d491.s22|36-36|,|O
DDI-DrugBank.d491.s22|38-40|are|O
DDI-DrugBank.d491.s22|42-44|not|O
DDI-DrugBank.d491.s22|46-51|always|O
DDI-DrugBank.d491.s22|53-62|predictive|O
DDI-DrugBank.d491.s22|64-65|of|O
DDI-DrugBank.d491.s22|67-71|human|O
DDI-DrugBank.d491.s22|73-80|response|O
DDI-DrugBank.d491.s22|82-84|and|O
DDI-DrugBank.d491.s22|86-90|there|O
DDI-DrugBank.d491.s22|92-94|are|O
DDI-DrugBank.d491.s22|96-97|no|O
DDI-DrugBank.d491.s22|99-106|adequate|O
DDI-DrugBank.d491.s22|108-110|and|O
DDI-DrugBank.d491.s22|112-126|well-controlled|O
DDI-DrugBank.d491.s22|128-134|studies|O
DDI-DrugBank.d491.s22|136-137|in|O
DDI-DrugBank.d491.s22|139-146|pregnant|O
DDI-DrugBank.d491.s22|148-152|women|O
DDI-DrugBank.d491.s22|153-153|.|O
DDI-DrugBank.d491.s23|0-6|Because|O
DDI-DrugBank.d491.s23|8-10|the|O
DDI-DrugBank.d491.s23|12-15|risk|O
DDI-DrugBank.d491.s23|17-18|to|O
DDI-DrugBank.d491.s23|20-22|the|O
DDI-DrugBank.d491.s23|24-34|development|O
DDI-DrugBank.d491.s23|36-37|of|O
DDI-DrugBank.d491.s23|39-41|the|O
DDI-DrugBank.d491.s23|43-47|fetal|O
DDI-DrugBank.d491.s23|49-54|immune|O
DDI-DrugBank.d491.s23|56-61|system|O
DDI-DrugBank.d491.s23|63-65|and|O
DDI-DrugBank.d491.s23|67-75|postnatal|O
DDI-DrugBank.d491.s23|77-82|immune|O
DDI-DrugBank.d491.s23|84-91|function|O
DDI-DrugBank.d491.s23|93-94|in|O
DDI-DrugBank.d491.s23|96-101|humans|O
DDI-DrugBank.d491.s23|103-104|is|O
DDI-DrugBank.d491.s23|106-112|unknown|O
DDI-DrugBank.d491.s23|113-113|,|O
DDI-DrugBank.d491.s23|115-121|AMEVIVE|brand
DDI-DrugBank.d491.s23|124-129|should|O
DDI-DrugBank.d491.s23|131-132|be|O
DDI-DrugBank.d491.s23|134-137|used|O
DDI-DrugBank.d491.s23|139-144|during|O
DDI-DrugBank.d491.s23|146-154|pregnancy|O
DDI-DrugBank.d491.s23|156-159|only|O
DDI-DrugBank.d491.s23|161-162|if|O
DDI-DrugBank.d491.s23|164-170|clearly|O
DDI-DrugBank.d491.s23|172-177|needed|O
DDI-DrugBank.d491.s23|178-178|.|O
DDI-DrugBank.d491.s24|0-1|If|O
DDI-DrugBank.d491.s24|3-11|pregnancy|O
DDI-DrugBank.d491.s24|13-18|occurs|O
DDI-DrugBank.d491.s24|20-24|while|O
DDI-DrugBank.d491.s24|26-31|taking|O
DDI-DrugBank.d491.s24|33-39|AMEVIVE|brand
DDI-DrugBank.d491.s24|40-40|,|O
DDI-DrugBank.d491.s24|42-50|continued|O
DDI-DrugBank.d491.s24|52-54|use|O
DDI-DrugBank.d491.s24|56-57|of|O
DDI-DrugBank.d491.s24|59-61|the|O
DDI-DrugBank.d491.s24|63-66|drug|O
DDI-DrugBank.d491.s24|68-73|should|O
DDI-DrugBank.d491.s24|75-76|be|O
DDI-DrugBank.d491.s24|78-85|assessed|O
DDI-DrugBank.d491.s24|86-86|.|O
DDI-DrugBank.d491.s25|0-6|Nursing|O
DDI-DrugBank.d491.s25|8-14|Mothers|O
DDI-DrugBank.d491.s26|0-1|It|O
DDI-DrugBank.d491.s26|3-4|is|O
DDI-DrugBank.d491.s26|6-8|not|O
DDI-DrugBank.d491.s26|10-14|known|O
DDI-DrugBank.d491.s26|16-22|whether|O
DDI-DrugBank.d491.s26|24-30|AMEVIVE|brand
DDI-DrugBank.d491.s26|32-33|is|O
DDI-DrugBank.d491.s26|35-42|excreted|O
DDI-DrugBank.d491.s26|44-45|in|O
DDI-DrugBank.d491.s26|47-51|human|O
DDI-DrugBank.d491.s26|53-56|milk|O
DDI-DrugBank.d491.s26|57-57|.|O
DDI-DrugBank.d491.s27|0-6|Because|O
DDI-DrugBank.d491.s27|8-11|many|O
DDI-DrugBank.d491.s27|13-17|drugs|O
DDI-DrugBank.d491.s27|19-21|are|O
DDI-DrugBank.d491.s27|23-30|excreted|O
DDI-DrugBank.d491.s27|32-33|in|O
DDI-DrugBank.d491.s27|35-39|human|O
DDI-DrugBank.d491.s27|41-44|milk|O
DDI-DrugBank.d491.s27|45-45|,|O
DDI-DrugBank.d491.s27|47-49|and|O
DDI-DrugBank.d491.s27|51-57|because|O
DDI-DrugBank.d491.s27|59-63|there|O
DDI-DrugBank.d491.s27|65-70|exists|O
DDI-DrugBank.d491.s27|72-74|the|O
DDI-DrugBank.d491.s27|76-84|potential|O
DDI-DrugBank.d491.s27|86-88|for|O
DDI-DrugBank.d491.s27|90-96|serious|O
DDI-DrugBank.d491.s27|98-104|adverse|O
DDI-DrugBank.d491.s27|106-114|reactions|O
DDI-DrugBank.d491.s27|116-117|in|O
DDI-DrugBank.d491.s27|119-125|nursing|O
DDI-DrugBank.d491.s27|127-133|infants|O
DDI-DrugBank.d491.s27|135-138|from|O
DDI-DrugBank.d491.s27|140-146|AMEVIVE|brand
DDI-DrugBank.d491.s27|147-147|,|O
DDI-DrugBank.d491.s27|149-149|a|O
DDI-DrugBank.d491.s27|151-158|decision|O
DDI-DrugBank.d491.s27|160-165|should|O
DDI-DrugBank.d491.s27|167-168|be|O
DDI-DrugBank.d491.s27|170-173|made|O
DDI-DrugBank.d491.s27|175-181|whether|O
DDI-DrugBank.d491.s27|183-184|to|O
DDI-DrugBank.d491.s27|186-196|discontinue|O
DDI-DrugBank.d491.s27|198-204|nursing|O
DDI-DrugBank.d491.s27|206-210|while|O
DDI-DrugBank.d491.s27|212-217|taking|O
DDI-DrugBank.d491.s27|219-221|the|O
DDI-DrugBank.d491.s27|223-226|drug|O
DDI-DrugBank.d491.s27|228-229|or|O
DDI-DrugBank.d491.s27|231-232|to|O
DDI-DrugBank.d491.s27|234-244|discontinue|O
DDI-DrugBank.d491.s27|246-248|the|O
DDI-DrugBank.d491.s27|250-252|use|O
DDI-DrugBank.d491.s27|254-255|of|O
DDI-DrugBank.d491.s27|257-259|the|O
DDI-DrugBank.d491.s27|261-264|drug|O
DDI-DrugBank.d491.s27|265-265|,|O
DDI-DrugBank.d491.s27|267-272|taking|O
DDI-DrugBank.d491.s27|274-277|into|O
DDI-DrugBank.d491.s27|279-285|account|O
DDI-DrugBank.d491.s27|287-289|the|O
DDI-DrugBank.d491.s27|291-300|importance|O
DDI-DrugBank.d491.s27|302-303|of|O
DDI-DrugBank.d491.s27|305-307|the|O
DDI-DrugBank.d491.s27|309-312|drug|O
DDI-DrugBank.d491.s27|314-315|to|O
DDI-DrugBank.d491.s27|317-319|the|O
DDI-DrugBank.d491.s27|321-326|mother|O
DDI-DrugBank.d491.s27|327-327|.|O
DDI-DrugBank.d491.s28|0-8|Geriatric|O
DDI-DrugBank.d491.s28|10-12|Use|O
DDI-DrugBank.d491.s29|0-1|Of|O
DDI-DrugBank.d491.s29|3-5|the|O
DDI-DrugBank.d491.s29|7-10|1357|O
DDI-DrugBank.d491.s29|12-19|patients|O
DDI-DrugBank.d491.s29|21-23|who|O
DDI-DrugBank.d491.s29|25-32|received|O
DDI-DrugBank.d491.s29|34-40|AMEVIVE|brand
DDI-DrugBank.d491.s29|42-43|in|O
DDI-DrugBank.d491.s29|45-52|clinical|O
DDI-DrugBank.d491.s29|54-59|trials|O
DDI-DrugBank.d491.s29|60-60|,|O
DDI-DrugBank.d491.s29|62-62|a|O
DDI-DrugBank.d491.s29|64-68|total|O
DDI-DrugBank.d491.s29|70-71|of|O
DDI-DrugBank.d491.s29|73-75|100|O
DDI-DrugBank.d491.s29|77-84|patients|O
DDI-DrugBank.d491.s29|86-89|were|O
DDI-DrugBank.d491.s30|0-1|65|O
DDI-DrugBank.d491.s30|3-7|years|O
DDI-DrugBank.d491.s30|9-10|of|O
DDI-DrugBank.d491.s30|12-14|age|O
DDI-DrugBank.d491.s30|16-18|and|O
DDI-DrugBank.d491.s30|20-21|13|O
DDI-DrugBank.d491.s30|23-30|patients|O
DDI-DrugBank.d491.s30|32-35|were|O
DDI-DrugBank.d491.s31|0-1|75|O
DDI-DrugBank.d491.s31|3-7|years|O
DDI-DrugBank.d491.s31|9-10|of|O
DDI-DrugBank.d491.s31|12-14|age|O
DDI-DrugBank.d491.s31|15-15|.|O
DDI-DrugBank.d491.s32|0-1|No|O
DDI-DrugBank.d491.s32|3-13|differences|O
DDI-DrugBank.d491.s32|15-16|in|O
DDI-DrugBank.d491.s32|18-23|safety|O
DDI-DrugBank.d491.s32|25-26|or|O
DDI-DrugBank.d491.s32|28-35|efficacy|O
DDI-DrugBank.d491.s32|37-40|were|O
DDI-DrugBank.d491.s32|42-49|observed|O
DDI-DrugBank.d491.s32|51-57|between|O
DDI-DrugBank.d491.s32|59-63|older|O
DDI-DrugBank.d491.s32|65-67|and|O
DDI-DrugBank.d491.s32|69-75|younger|O
DDI-DrugBank.d491.s32|77-84|patients|O
DDI-DrugBank.d491.s32|85-85|,|O
DDI-DrugBank.d491.s32|87-89|but|O
DDI-DrugBank.d491.s32|91-95|there|O
DDI-DrugBank.d491.s32|97-100|were|O
DDI-DrugBank.d491.s32|102-104|not|O
DDI-DrugBank.d491.s32|106-115|sufficient|O
DDI-DrugBank.d491.s32|117-120|data|O
DDI-DrugBank.d491.s32|122-123|to|O
DDI-DrugBank.d491.s32|125-131|exclude|O
DDI-DrugBank.d491.s32|133-141|important|O
DDI-DrugBank.d491.s32|143-153|differences|O
DDI-DrugBank.d491.s32|154-154|.|O
DDI-DrugBank.d491.s33|0-6|Because|O
DDI-DrugBank.d491.s33|8-10|the|O
DDI-DrugBank.d491.s33|12-20|incidence|O
DDI-DrugBank.d491.s33|22-23|of|O
DDI-DrugBank.d491.s33|25-34|infections|O
DDI-DrugBank.d491.s33|36-38|and|O
DDI-DrugBank.d491.s33|40-46|certain|O
DDI-DrugBank.d491.s33|48-59|malignancies|O
DDI-DrugBank.d491.s33|61-62|is|O
DDI-DrugBank.d491.s33|64-69|higher|O
DDI-DrugBank.d491.s33|71-72|in|O
DDI-DrugBank.d491.s33|74-76|the|O
DDI-DrugBank.d491.s33|78-84|elderly|O
DDI-DrugBank.d491.s33|86-95|population|O
DDI-DrugBank.d491.s33|96-96|,|O
DDI-DrugBank.d491.s33|98-99|in|O
DDI-DrugBank.d491.s33|101-107|general|O
DDI-DrugBank.d491.s33|108-108|,|O
DDI-DrugBank.d491.s33|110-116|caution|O
DDI-DrugBank.d491.s33|118-123|should|O
DDI-DrugBank.d491.s33|125-126|be|O
DDI-DrugBank.d491.s33|128-131|used|O
DDI-DrugBank.d491.s33|133-134|in|O
DDI-DrugBank.d491.s33|136-143|treating|O
DDI-DrugBank.d491.s33|145-147|the|O
DDI-DrugBank.d491.s33|149-155|elderly|O
DDI-DrugBank.d491.s33|156-156|.|O
DDI-DrugBank.d491.s34|0-8|Pediatric|O
DDI-DrugBank.d491.s34|10-12|Use|O
DDI-DrugBank.d491.s35|0-2|The|O
DDI-DrugBank.d491.s35|4-9|safety|O
DDI-DrugBank.d491.s35|11-13|and|O
DDI-DrugBank.d491.s35|15-22|efficacy|O
DDI-DrugBank.d491.s35|24-25|of|O
DDI-DrugBank.d491.s35|27-33|AMEVIVE|brand
DDI-DrugBank.d491.s35|35-36|in|O
DDI-DrugBank.d491.s35|38-46|pediatric|O
DDI-DrugBank.d491.s35|48-55|patients|O
DDI-DrugBank.d491.s35|57-60|have|O
DDI-DrugBank.d491.s35|62-64|not|O
DDI-DrugBank.d491.s35|66-69|been|O
DDI-DrugBank.d491.s35|71-77|studied|O
DDI-DrugBank.d491.s35|78-78|.|O
DDI-DrugBank.d491.s36|0-6|AMEVIVE|brand
DDI-DrugBank.d491.s36|8-9|is|O
DDI-DrugBank.d491.s36|11-13|not|O
DDI-DrugBank.d491.s36|15-23|indicated|O
DDI-DrugBank.d491.s36|25-27|for|O
DDI-DrugBank.d491.s36|29-37|pediatric|O
DDI-DrugBank.d491.s36|39-46|patients|O
DDI-DrugBank.d491.s36|47-47|.|O
DDI-DrugBank.d175.s0|0-10|Hypotension|O
DDI-DrugBank.d175.s0|14-21|Patients|O
DDI-DrugBank.d175.s0|23-24|on|O
DDI-DrugBank.d175.s0|26-33|Diuretic|group
DDI-DrugBank.d175.s0|35-41|Therapy|O
DDI-DrugBank.d175.s0|42-42|:|O
DDI-DrugBank.d175.s0|44-51|Patients|O
DDI-DrugBank.d175.s0|53-54|on|O
DDI-DrugBank.d175.s0|56-64|diuretics|group
DDI-DrugBank.d175.s0|66-68|and|O
DDI-DrugBank.d175.s0|70-79|especially|O
DDI-DrugBank.d175.s0|81-85|those|O
DDI-DrugBank.d175.s0|87-88|in|O
DDI-DrugBank.d175.s0|90-93|whom|O
DDI-DrugBank.d175.s0|95-102|diuretic|group
DDI-DrugBank.d175.s0|104-110|therapy|O
DDI-DrugBank.d175.s0|112-114|was|O
DDI-DrugBank.d175.s0|116-123|recently|O
DDI-DrugBank.d175.s0|125-134|instituted|O
DDI-DrugBank.d175.s0|135-135|,|O
DDI-DrugBank.d175.s0|137-138|as|O
DDI-DrugBank.d175.s0|140-143|well|O
DDI-DrugBank.d175.s0|145-146|as|O
DDI-DrugBank.d175.s0|148-152|those|O
DDI-DrugBank.d175.s0|154-155|on|O
DDI-DrugBank.d175.s0|157-162|severe|O
DDI-DrugBank.d175.s0|164-170|dietary|O
DDI-DrugBank.d175.s0|172-175|salt|O
DDI-DrugBank.d175.s0|177-187|restriction|O
DDI-DrugBank.d175.s0|189-190|or|O
DDI-DrugBank.d175.s0|192-199|dialysis|O
DDI-DrugBank.d175.s0|200-200|,|O
DDI-DrugBank.d175.s0|202-204|may|O
DDI-DrugBank.d175.s0|206-217|occasionally|O
DDI-DrugBank.d175.s0|219-228|experience|O
DDI-DrugBank.d175.s0|230-230|a|O
DDI-DrugBank.d175.s0|232-242|precipitous|O
DDI-DrugBank.d175.s0|244-252|reduction|O
DDI-DrugBank.d175.s0|254-255|of|O
DDI-DrugBank.d175.s0|257-261|blood|O
DDI-DrugBank.d175.s0|263-270|pressure|O
DDI-DrugBank.d175.s0|272-278|usually|O
DDI-DrugBank.d175.s0|280-285|within|O
DDI-DrugBank.d175.s0|287-289|the|O
DDI-DrugBank.d175.s0|291-295|first|O
DDI-DrugBank.d175.s0|297-300|hour|O
DDI-DrugBank.d175.s0|302-306|after|O
DDI-DrugBank.d175.s0|308-316|receiving|O
DDI-DrugBank.d175.s0|318-320|the|O
DDI-DrugBank.d175.s0|322-328|initial|O
DDI-DrugBank.d175.s0|330-333|dose|O
DDI-DrugBank.d175.s0|335-336|of|O
DDI-DrugBank.d175.s0|338-346|captopril|drug
DDI-DrugBank.d175.s0|347-347|.|O
DDI-DrugBank.d175.s1|0-2|The|O
DDI-DrugBank.d175.s1|4-14|possibility|O
DDI-DrugBank.d175.s1|16-17|of|O
DDI-DrugBank.d175.s1|19-29|hypotensive|O
DDI-DrugBank.d175.s1|31-37|effects|O
DDI-DrugBank.d175.s1|39-42|with|O
DDI-DrugBank.d175.s1|44-52|captopril|drug
DDI-DrugBank.d175.s1|54-56|can|O
DDI-DrugBank.d175.s1|58-59|be|O
DDI-DrugBank.d175.s1|61-69|minimized|O
DDI-DrugBank.d175.s1|71-72|by|O
DDI-DrugBank.d175.s1|74-79|either|O
DDI-DrugBank.d175.s1|81-93|discontinuing|O
DDI-DrugBank.d175.s1|95-97|the|O
DDI-DrugBank.d175.s1|99-106|diuretic|group
DDI-DrugBank.d175.s1|108-109|or|O
DDI-DrugBank.d175.s1|111-120|increasing|O
DDI-DrugBank.d175.s1|122-124|the|O
DDI-DrugBank.d175.s1|126-129|salt|O
DDI-DrugBank.d175.s1|131-136|intake|O
DDI-DrugBank.d175.s1|138-150|approximately|O
DDI-DrugBank.d175.s1|152-154|one|O
DDI-DrugBank.d175.s1|156-159|week|O
DDI-DrugBank.d175.s1|161-165|prior|O
DDI-DrugBank.d175.s1|167-168|to|O
DDI-DrugBank.d175.s1|170-179|initiation|O
DDI-DrugBank.d175.s1|181-182|of|O
DDI-DrugBank.d175.s1|184-192|treatment|O
DDI-DrugBank.d175.s1|194-197|with|O
DDI-DrugBank.d175.s1|199-207|captopril|drug
DDI-DrugBank.d175.s1|209-209|(|O
DDI-DrugBank.d175.s1|210-218|captopril|drug
DDI-DrugBank.d175.s1|220-226|tablets|O
DDI-DrugBank.d175.s1|227-227|,|O
DDI-DrugBank.d175.s1|229-231|USP|O
DDI-DrugBank.d175.s1|232-232|)|O
DDI-DrugBank.d175.s1|234-235|or|O
DDI-DrugBank.d175.s1|237-246|initiating|O
DDI-DrugBank.d175.s1|248-254|therapy|O
DDI-DrugBank.d175.s1|256-259|with|O
DDI-DrugBank.d175.s1|261-265|small|O
DDI-DrugBank.d175.s1|267-271|doses|O
DDI-DrugBank.d175.s1|273-273|(|O
DDI-DrugBank.d175.s1|274-277|6.25|O
DDI-DrugBank.d175.s1|279-280|or|O
DDI-DrugBank.d175.s1|282-285|12.5|O
DDI-DrugBank.d175.s1|287-288|mg|O
DDI-DrugBank.d175.s1|289-289|)|O
DDI-DrugBank.d175.s1|290-290|.|O
DDI-DrugBank.d175.s2|0-12|Alternatively|O
DDI-DrugBank.d175.s2|13-13|,|O
DDI-DrugBank.d175.s2|15-21|provide|O
DDI-DrugBank.d175.s2|23-29|medical|O
DDI-DrugBank.d175.s2|31-41|supervision|O
DDI-DrugBank.d175.s2|43-45|for|O
DDI-DrugBank.d175.s2|47-48|at|O
DDI-DrugBank.d175.s2|50-54|least|O
DDI-DrugBank.d175.s2|56-58|one|O
DDI-DrugBank.d175.s2|60-63|hour|O
DDI-DrugBank.d175.s2|65-69|after|O
DDI-DrugBank.d175.s2|71-73|the|O
DDI-DrugBank.d175.s2|75-81|initial|O
DDI-DrugBank.d175.s2|83-86|dose|O
DDI-DrugBank.d175.s2|87-87|.|O
DDI-DrugBank.d175.s3|0-1|If|O
DDI-DrugBank.d175.s3|3-13|hypotension|O
DDI-DrugBank.d175.s3|15-20|occurs|O
DDI-DrugBank.d175.s3|21-21|,|O
DDI-DrugBank.d175.s3|23-25|the|O
DDI-DrugBank.d175.s3|27-33|patient|O
DDI-DrugBank.d175.s3|35-40|should|O
DDI-DrugBank.d175.s3|42-43|be|O
DDI-DrugBank.d175.s3|45-50|placed|O
DDI-DrugBank.d175.s3|52-53|in|O
DDI-DrugBank.d175.s3|55-55|a|O
DDI-DrugBank.d175.s3|57-62|supine|O
DDI-DrugBank.d175.s3|64-71|position|O
DDI-DrugBank.d175.s3|73-75|and|O
DDI-DrugBank.d175.s3|76-76|,|O
DDI-DrugBank.d175.s3|78-79|if|O
DDI-DrugBank.d175.s3|81-89|necessary|O
DDI-DrugBank.d175.s3|90-90|,|O
DDI-DrugBank.d175.s3|92-98|receive|O
DDI-DrugBank.d175.s3|100-101|an|O
DDI-DrugBank.d175.s3|103-113|intravenous|O
DDI-DrugBank.d175.s3|115-122|infusion|O
DDI-DrugBank.d175.s3|124-125|of|O
DDI-DrugBank.d175.s3|127-132|normal|O
DDI-DrugBank.d175.s3|134-139|saline|O
DDI-DrugBank.d175.s3|140-140|.|O
DDI-DrugBank.d175.s4|0-3|This|O
DDI-DrugBank.d175.s4|5-13|transient|O
DDI-DrugBank.d175.s4|15-25|hypotensive|O
DDI-DrugBank.d175.s4|27-34|response|O
DDI-DrugBank.d175.s4|36-37|is|O
DDI-DrugBank.d175.s4|39-41|not|O
DDI-DrugBank.d175.s4|43-43|a|O
DDI-DrugBank.d175.s4|45-60|contraindication|O
DDI-DrugBank.d175.s4|62-63|to|O
DDI-DrugBank.d175.s4|65-71|further|O
DDI-DrugBank.d175.s4|73-77|doses|O
DDI-DrugBank.d175.s4|79-83|which|O
DDI-DrugBank.d175.s4|85-87|can|O
DDI-DrugBank.d175.s4|89-90|be|O
DDI-DrugBank.d175.s4|92-96|given|O
DDI-DrugBank.d175.s4|98-104|without|O
DDI-DrugBank.d175.s4|106-115|difficulty|O
DDI-DrugBank.d175.s4|117-120|once|O
DDI-DrugBank.d175.s4|122-124|the|O
DDI-DrugBank.d175.s4|126-130|blood|O
DDI-DrugBank.d175.s4|132-139|pressure|O
DDI-DrugBank.d175.s4|141-143|has|O
DDI-DrugBank.d175.s4|145-153|increased|O
DDI-DrugBank.d175.s4|155-159|after|O
DDI-DrugBank.d175.s4|161-166|volume|O
DDI-DrugBank.d175.s4|168-176|expansion|O
DDI-DrugBank.d175.s4|177-177|.|O
DDI-DrugBank.d175.s5|0-5|Agents|O
DDI-DrugBank.d175.s5|7-12|Having|O
DDI-DrugBank.d175.s5|14-24|Vasodilator|O
DDI-DrugBank.d175.s5|26-33|Activity|O
DDI-DrugBank.d175.s5|34-34|:|O
DDI-DrugBank.d175.s5|36-39|Data|O
DDI-DrugBank.d175.s5|41-42|on|O
DDI-DrugBank.d175.s5|44-46|the|O
DDI-DrugBank.d175.s5|48-53|effect|O
DDI-DrugBank.d175.s5|55-56|of|O
DDI-DrugBank.d175.s5|58-68|concomitant|O
DDI-DrugBank.d175.s5|70-72|use|O
DDI-DrugBank.d175.s5|74-75|of|O
DDI-DrugBank.d175.s5|77-81|other|O
DDI-DrugBank.d175.s5|83-94|vasodilators|group
DDI-DrugBank.d175.s5|96-97|in|O
DDI-DrugBank.d175.s5|99-106|patients|O
DDI-DrugBank.d175.s5|108-116|receiving|O
DDI-DrugBank.d175.s5|118-126|captopril|drug
DDI-DrugBank.d175.s5|128-130|for|O
DDI-DrugBank.d175.s5|132-136|heart|O
DDI-DrugBank.d175.s5|138-144|failure|O
DDI-DrugBank.d175.s5|146-148|are|O
DDI-DrugBank.d175.s5|150-152|not|O
DDI-DrugBank.d175.s5|154-162|available|O
DDI-DrugBank.d175.s5|163-163|;|O
DDI-DrugBank.d175.s6|0-8|therefore|O
DDI-DrugBank.d175.s6|9-9|,|O
DDI-DrugBank.d175.s6|11-23|nitroglycerin|drug
DDI-DrugBank.d175.s6|25-26|or|O
DDI-DrugBank.d175.s6|28-32|other|O
DDI-DrugBank.d175.s6|34-41|nitrates|group
DDI-DrugBank.d175.s6|43-43|(|O
DDI-DrugBank.d175.s6|44-45|as|O
DDI-DrugBank.d175.s6|47-50|used|O
DDI-DrugBank.d175.s6|52-54|for|O
DDI-DrugBank.d175.s6|56-65|management|O
DDI-DrugBank.d175.s6|67-68|of|O
DDI-DrugBank.d175.s6|70-75|angina|O
DDI-DrugBank.d175.s6|76-76|)|O
DDI-DrugBank.d175.s6|78-79|or|O
DDI-DrugBank.d175.s6|81-85|other|O
DDI-DrugBank.d175.s6|87-91|drugs|O
DDI-DrugBank.d175.s6|93-98|having|O
DDI-DrugBank.d175.s6|100-110|vasodilator|O
DDI-DrugBank.d175.s6|112-119|activity|O
DDI-DrugBank.d175.s6|121-126|should|O
DDI-DrugBank.d175.s6|127-127|,|O
DDI-DrugBank.d175.s6|129-130|if|O
DDI-DrugBank.d175.s6|132-139|possible|O
DDI-DrugBank.d175.s6|140-140|,|O
DDI-DrugBank.d175.s6|142-143|be|O
DDI-DrugBank.d175.s6|145-156|discontinued|O
DDI-DrugBank.d175.s6|158-163|before|O
DDI-DrugBank.d175.s6|165-172|starting|O
DDI-DrugBank.d175.s6|174-182|captopril|drug
DDI-DrugBank.d175.s6|183-183|.|O
DDI-DrugBank.d175.s7|0-1|If|O
DDI-DrugBank.d175.s7|3-9|resumed|O
DDI-DrugBank.d175.s7|11-16|during|O
DDI-DrugBank.d175.s7|18-26|captopril|drug
DDI-DrugBank.d175.s7|28-34|therapy|O
DDI-DrugBank.d175.s7|35-35|,|O
DDI-DrugBank.d175.s7|37-40|such|O
DDI-DrugBank.d175.s7|42-47|agents|O
DDI-DrugBank.d175.s7|49-54|should|O
DDI-DrugBank.d175.s7|56-57|be|O
DDI-DrugBank.d175.s7|59-70|administered|O
DDI-DrugBank.d175.s7|72-81|cautiously|O
DDI-DrugBank.d175.s7|82-82|,|O
DDI-DrugBank.d175.s7|84-86|and|O
DDI-DrugBank.d175.s7|88-94|perhaps|O
DDI-DrugBank.d175.s7|96-97|at|O
DDI-DrugBank.d175.s7|99-103|lower|O
DDI-DrugBank.d175.s7|105-110|dosage|O
DDI-DrugBank.d175.s7|111-111|.|O
DDI-DrugBank.d175.s8|0-5|Agents|O
DDI-DrugBank.d175.s8|7-13|Causing|O
DDI-DrugBank.d175.s8|15-19|Renin|O
DDI-DrugBank.d175.s8|21-27|Release|O
DDI-DrugBank.d175.s8|29-37|Captopril|drug
DDI-DrugBank.d175.s8|38-39|'s|O
DDI-DrugBank.d175.s8|41-46|effect|O
DDI-DrugBank.d175.s8|48-51|will|O
DDI-DrugBank.d175.s8|53-54|be|O
DDI-DrugBank.d175.s8|56-64|augmented|O
DDI-DrugBank.d175.s8|66-67|by|O
DDI-DrugBank.d175.s8|69-91|antihypertensive agents|group
DDI-DrugBank.d175.s8|93-96|that|O
DDI-DrugBank.d175.s8|98-102|cause|O
DDI-DrugBank.d175.s8|104-108|renin|O
DDI-DrugBank.d175.s8|110-116|release|O
DDI-DrugBank.d175.s8|117-117|.|O
DDI-DrugBank.d175.s9|0-2|For|O
DDI-DrugBank.d175.s9|4-10|example|O
DDI-DrugBank.d175.s9|11-11|,|O
DDI-DrugBank.d175.s9|13-21|diuretics|group
DDI-DrugBank.d175.s9|23-23|(|O
DDI-DrugBank.d175.s9|24-27|e.g.|O
DDI-DrugBank.d175.s9|28-28|,|O
DDI-DrugBank.d175.s9|30-38|thiazides|group
DDI-DrugBank.d175.s9|39-39|)|O
DDI-DrugBank.d175.s9|41-43|may|O
DDI-DrugBank.d175.s9|45-52|activate|O
DDI-DrugBank.d175.s9|54-56|the|O
DDI-DrugBank.d175.s9|58-86|renin-angiotensin-aldosterone|O
DDI-DrugBank.d175.s9|88-93|system|O
DDI-DrugBank.d175.s9|94-94|.|O
DDI-DrugBank.d175.s10|0-5|Agents|O
DDI-DrugBank.d175.s10|7-15|Affecting|O
DDI-DrugBank.d175.s10|17-27|Sympathetic|O
DDI-DrugBank.d175.s10|29-36|Activity|O
DDI-DrugBank.d175.s10|38-40|The|O
DDI-DrugBank.d175.s10|42-52|sympathetic|O
DDI-DrugBank.d175.s10|54-60|nervous|O
DDI-DrugBank.d175.s10|62-67|system|O
DDI-DrugBank.d175.s10|69-71|may|O
DDI-DrugBank.d175.s10|73-74|be|O
DDI-DrugBank.d175.s10|76-85|especially|O
DDI-DrugBank.d175.s10|87-95|important|O
DDI-DrugBank.d175.s10|97-98|in|O
DDI-DrugBank.d175.s10|100-109|supporting|O
DDI-DrugBank.d175.s10|111-115|blood|O
DDI-DrugBank.d175.s10|117-124|pressure|O
DDI-DrugBank.d175.s10|126-127|in|O
DDI-DrugBank.d175.s10|129-136|patients|O
DDI-DrugBank.d175.s10|138-146|receiving|O
DDI-DrugBank.d175.s10|148-156|captopril|drug
DDI-DrugBank.d175.s10|158-162|alone|O
DDI-DrugBank.d175.s10|164-165|or|O
DDI-DrugBank.d175.s10|167-170|with|O
DDI-DrugBank.d175.s10|172-180|diuretics|group
DDI-DrugBank.d175.s10|181-181|.|O
DDI-DrugBank.d175.s11|0-8|Therefore|O
DDI-DrugBank.d175.s11|9-9|,|O
DDI-DrugBank.d175.s11|11-16|agents|O
DDI-DrugBank.d175.s11|18-26|affecting|O
DDI-DrugBank.d175.s11|28-38|sympathetic|O
DDI-DrugBank.d175.s11|40-47|activity|O
DDI-DrugBank.d175.s11|49-49|(|O
DDI-DrugBank.d175.s11|50-53|e.g.|O
DDI-DrugBank.d175.s11|54-54|,|O
DDI-DrugBank.d175.s11|56-81|ganglionic blocking agents|group
DDI-DrugBank.d175.s11|83-84|or|O
DDI-DrugBank.d175.s11|86-118|adrenergic neuron blocking agents|group
DDI-DrugBank.d175.s11|119-119|)|O
DDI-DrugBank.d175.s11|121-126|should|O
DDI-DrugBank.d175.s11|128-129|be|O
DDI-DrugBank.d175.s11|131-134|used|O
DDI-DrugBank.d175.s11|136-139|with|O
DDI-DrugBank.d175.s11|141-147|caution|O
DDI-DrugBank.d175.s11|148-148|.|O
DDI-DrugBank.d175.s12|0-29|Beta-adrenergic blocking drugs|group
DDI-DrugBank.d175.s12|31-33|add|O
DDI-DrugBank.d175.s12|35-38|some|O
DDI-DrugBank.d175.s12|40-46|further|O
DDI-DrugBank.d175.s12|48-63|antihypertensive|O
DDI-DrugBank.d175.s12|65-70|effect|O
DDI-DrugBank.d175.s12|72-73|to|O
DDI-DrugBank.d175.s12|75-83|captopril|drug
DDI-DrugBank.d175.s12|84-84|,|O
DDI-DrugBank.d175.s12|86-88|but|O
DDI-DrugBank.d175.s12|90-92|the|O
DDI-DrugBank.d175.s12|94-100|overall|O
DDI-DrugBank.d175.s12|102-109|response|O
DDI-DrugBank.d175.s12|111-112|is|O
DDI-DrugBank.d175.s12|114-117|less|O
DDI-DrugBank.d175.s12|119-122|than|O
DDI-DrugBank.d175.s12|124-131|additive|O
DDI-DrugBank.d175.s12|132-132|.|O
DDI-DrugBank.d175.s13|0-5|Agents|O
DDI-DrugBank.d175.s13|7-16|Increasing|O
DDI-DrugBank.d175.s13|18-22|Serum|O
DDI-DrugBank.d175.s13|24-32|Potassium|O
DDI-DrugBank.d175.s13|34-38|Since|O
DDI-DrugBank.d175.s13|40-48|captopril|drug
DDI-DrugBank.d175.s13|50-58|decreases|O
DDI-DrugBank.d175.s13|60-70|aldosterone|O
DDI-DrugBank.d175.s13|72-81|production|O
DDI-DrugBank.d175.s13|82-82|,|O
DDI-DrugBank.d175.s13|84-92|elevation|O
DDI-DrugBank.d175.s13|94-95|of|O
DDI-DrugBank.d175.s13|97-101|serum|O
DDI-DrugBank.d175.s13|103-111|potassium|O
DDI-DrugBank.d175.s13|113-115|may|O
DDI-DrugBank.d175.s13|117-121|occur|O
DDI-DrugBank.d175.s13|122-122|.|O
DDI-DrugBank.d175.s14|0-26|Potassium-sparing diuretics|group
DDI-DrugBank.d175.s14|28-31|such|O
DDI-DrugBank.d175.s14|33-34|as|O
DDI-DrugBank.d175.s14|36-49|spironolactone|drug
DDI-DrugBank.d175.s14|50-50|,|O
DDI-DrugBank.d175.s14|52-62|triamterene|drug
DDI-DrugBank.d175.s14|63-63|,|O
DDI-DrugBank.d175.s14|65-66|or|O
DDI-DrugBank.d175.s14|68-76|amiloride|drug
DDI-DrugBank.d175.s14|77-77|,|O
DDI-DrugBank.d175.s14|79-80|or|O
DDI-DrugBank.d175.s14|82-90|potassium|drug
DDI-DrugBank.d175.s14|92-102|supplements|O
DDI-DrugBank.d175.s14|104-109|should|O
DDI-DrugBank.d175.s14|111-112|be|O
DDI-DrugBank.d175.s14|114-118|given|O
DDI-DrugBank.d175.s14|120-123|only|O
DDI-DrugBank.d175.s14|125-127|for|O
DDI-DrugBank.d175.s14|129-138|documented|O
DDI-DrugBank.d175.s14|140-150|hypokalemia|O
DDI-DrugBank.d175.s14|151-151|,|O
DDI-DrugBank.d175.s14|153-155|and|O
DDI-DrugBank.d175.s14|157-160|then|O
DDI-DrugBank.d175.s14|162-165|with|O
DDI-DrugBank.d175.s14|167-173|caution|O
DDI-DrugBank.d175.s14|174-174|,|O
DDI-DrugBank.d175.s14|176-180|since|O
DDI-DrugBank.d175.s14|182-185|they|O
DDI-DrugBank.d175.s14|187-189|may|O
DDI-DrugBank.d175.s14|191-194|lead|O
DDI-DrugBank.d175.s14|196-197|to|O
DDI-DrugBank.d175.s14|199-199|a|O
DDI-DrugBank.d175.s14|201-211|significant|O
DDI-DrugBank.d175.s14|213-220|increase|O
DDI-DrugBank.d175.s14|222-223|of|O
DDI-DrugBank.d175.s14|225-229|serum|O
DDI-DrugBank.d175.s14|231-239|potassium|O
DDI-DrugBank.d175.s14|240-240|.|O
DDI-DrugBank.d175.s15|0-3|Salt|O
DDI-DrugBank.d175.s15|5-15|substitutes|O
DDI-DrugBank.d175.s15|17-26|containing|O
DDI-DrugBank.d175.s15|28-36|potassium|drug
DDI-DrugBank.d175.s15|38-43|should|O
DDI-DrugBank.d175.s15|45-48|also|O
DDI-DrugBank.d175.s15|50-51|be|O
DDI-DrugBank.d175.s15|53-56|used|O
DDI-DrugBank.d175.s15|58-61|with|O
DDI-DrugBank.d175.s15|63-69|caution|O
DDI-DrugBank.d175.s15|70-70|.|O
DDI-DrugBank.d175.s16|0-9|Inhibitors|O
DDI-DrugBank.d175.s16|11-12|Of|O
DDI-DrugBank.d175.s16|14-23|Endogenous|O
DDI-DrugBank.d175.s16|25-37|Prostaglandin|O
DDI-DrugBank.d175.s16|39-47|Synthesis|O
DDI-DrugBank.d175.s16|49-50|It|O
DDI-DrugBank.d175.s16|52-54|has|O
DDI-DrugBank.d175.s16|56-59|been|O
DDI-DrugBank.d175.s16|61-68|reported|O
DDI-DrugBank.d175.s16|70-73|that|O
DDI-DrugBank.d175.s16|75-86|indomethacin|drug
DDI-DrugBank.d175.s16|88-90|may|O
DDI-DrugBank.d175.s16|92-97|reduce|O
DDI-DrugBank.d175.s16|99-101|the|O
DDI-DrugBank.d175.s16|103-118|antihypertensive|O
DDI-DrugBank.d175.s16|120-125|effect|O
DDI-DrugBank.d175.s16|127-128|of|O
DDI-DrugBank.d175.s16|130-138|captopril|drug
DDI-DrugBank.d175.s16|139-139|,|O
DDI-DrugBank.d175.s16|141-150|especially|O
DDI-DrugBank.d175.s16|152-153|in|O
DDI-DrugBank.d175.s16|155-159|cases|O
DDI-DrugBank.d175.s16|161-162|of|O
DDI-DrugBank.d175.s16|164-166|low|O
DDI-DrugBank.d175.s16|168-172|renin|O
DDI-DrugBank.d175.s16|174-185|hypertension|O
DDI-DrugBank.d175.s16|186-186|.|O
DDI-DrugBank.d175.s17|0-4|Other|O
DDI-DrugBank.d175.s17|6-42|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d175.s17|44-44|(|O
DDI-DrugBank.d175.s17|45-48|e.g.|O
DDI-DrugBank.d175.s17|49-49|,|O
DDI-DrugBank.d175.s17|51-57|aspirin|brand
DDI-DrugBank.d175.s17|58-58|)|O
DDI-DrugBank.d175.s17|60-62|may|O
DDI-DrugBank.d175.s17|64-67|also|O
DDI-DrugBank.d175.s17|69-72|have|O
DDI-DrugBank.d175.s17|74-77|this|O
DDI-DrugBank.d175.s17|79-84|effect|O
DDI-DrugBank.d175.s17|85-85|.|O
DDI-DrugBank.d175.s18|0-6|Lithium|drug
DDI-DrugBank.d175.s18|7-7|:|O
DDI-DrugBank.d175.s18|9-17|Increased|O
DDI-DrugBank.d175.s18|19-23|serum|O
DDI-DrugBank.d175.s18|25-31|lithium|drug
DDI-DrugBank.d175.s18|33-38|levels|O
DDI-DrugBank.d175.s18|40-42|and|O
DDI-DrugBank.d175.s18|44-51|symptoms|O
DDI-DrugBank.d175.s18|53-54|of|O
DDI-DrugBank.d175.s18|56-62|lithium|drug
DDI-DrugBank.d175.s18|64-71|toxicity|O
DDI-DrugBank.d175.s18|73-76|have|O
DDI-DrugBank.d175.s18|78-81|been|O
DDI-DrugBank.d175.s18|83-90|reported|O
DDI-DrugBank.d175.s18|92-93|in|O
DDI-DrugBank.d175.s18|95-102|patients|O
DDI-DrugBank.d175.s18|104-112|receiving|O
DDI-DrugBank.d175.s18|114-124|concomitant|O
DDI-DrugBank.d175.s18|126-132|lithium|drug
DDI-DrugBank.d175.s18|134-136|and|O
DDI-DrugBank.d175.s18|138-150|ACE inhibitor|group
DDI-DrugBank.d175.s18|152-158|therapy|O
DDI-DrugBank.d175.s18|159-159|.|O
DDI-DrugBank.d175.s19|0-4|These|O
DDI-DrugBank.d175.s19|6-10|drugs|O
DDI-DrugBank.d175.s19|12-17|should|O
DDI-DrugBank.d175.s19|19-20|be|O
DDI-DrugBank.d175.s19|22-36|coad-ministered|O
DDI-DrugBank.d175.s19|38-41|with|O
DDI-DrugBank.d175.s19|43-49|caution|O
DDI-DrugBank.d175.s19|51-53|and|O
DDI-DrugBank.d175.s19|55-62|frequent|O
DDI-DrugBank.d175.s19|64-73|monitoring|O
DDI-DrugBank.d175.s19|75-76|of|O
DDI-DrugBank.d175.s19|78-82|serum|O
DDI-DrugBank.d175.s19|84-90|lithium|drug
DDI-DrugBank.d175.s19|92-97|levels|O
DDI-DrugBank.d175.s19|99-100|is|O
DDI-DrugBank.d175.s19|102-112|recommended|O
DDI-DrugBank.d175.s19|113-113|.|O
DDI-DrugBank.d175.s20|0-1|If|O
DDI-DrugBank.d175.s20|3-3|a|O
DDI-DrugBank.d175.s20|5-12|diuretic|group
DDI-DrugBank.d175.s20|14-15|is|O
DDI-DrugBank.d175.s20|17-20|also|O
DDI-DrugBank.d175.s20|22-25|used|O
DDI-DrugBank.d175.s20|26-26|,|O
DDI-DrugBank.d175.s20|28-29|it|O
DDI-DrugBank.d175.s20|31-33|may|O
DDI-DrugBank.d175.s20|35-42|increase|O
DDI-DrugBank.d175.s20|44-46|the|O
DDI-DrugBank.d175.s20|48-51|risk|O
DDI-DrugBank.d175.s20|53-54|of|O
DDI-DrugBank.d175.s20|56-62|lithium|drug
DDI-DrugBank.d175.s20|64-71|toxicity|O
DDI-DrugBank.d175.s20|72-72|.|O
DDI-DrugBank.d175.s21|0-17|Cardiac Glycosides|group
DDI-DrugBank.d175.s21|18-18|:|O
DDI-DrugBank.d175.s21|20-21|In|O
DDI-DrugBank.d175.s21|23-23|a|O
DDI-DrugBank.d175.s21|25-29|study|O
DDI-DrugBank.d175.s21|31-32|of|O
DDI-DrugBank.d175.s21|34-38|young|O
DDI-DrugBank.d175.s21|40-46|healthy|O
DDI-DrugBank.d175.s21|48-51|male|O
DDI-DrugBank.d175.s21|53-60|subjects|O
DDI-DrugBank.d175.s21|62-63|no|O
DDI-DrugBank.d175.s21|65-72|evidence|O
DDI-DrugBank.d175.s21|74-75|of|O
DDI-DrugBank.d175.s21|77-77|a|O
DDI-DrugBank.d175.s21|79-84|direct|O
DDI-DrugBank.d175.s21|86-100|pharmacokinetic|O
DDI-DrugBank.d175.s21|102-118|captopril-digoxin|drug
DDI-DrugBank.d175.s21|120-130|interaction|O
DDI-DrugBank.d175.s21|132-136|could|O
DDI-DrugBank.d175.s21|138-139|be|O
DDI-DrugBank.d175.s21|141-145|found|O
DDI-DrugBank.d175.s21|146-146|.|O
DDI-DrugBank.d175.s22|0-13|Loop Diuretics|group
DDI-DrugBank.d175.s22|14-14|:|O
DDI-DrugBank.d175.s22|16-25|Furosemide|drug
DDI-DrugBank.d175.s22|27-38|administered|O
DDI-DrugBank.d175.s22|40-51|concurrently|O
DDI-DrugBank.d175.s22|53-56|with|O
DDI-DrugBank.d175.s22|58-66|captopril|drug
DDI-DrugBank.d175.s22|68-71|does|O
DDI-DrugBank.d175.s22|73-75|not|O
DDI-DrugBank.d175.s22|77-81|alter|O
DDI-DrugBank.d175.s22|83-85|the|O
DDI-DrugBank.d175.s22|87-102|pharmacokinetics|O
DDI-DrugBank.d175.s22|104-105|of|O
DDI-DrugBank.d175.s22|107-115|captopril|drug
DDI-DrugBank.d175.s22|117-118|in|O
DDI-DrugBank.d175.s22|120-126|renally|O
DDI-DrugBank.d175.s22|128-135|impaired|O
DDI-DrugBank.d175.s22|137-148|hypertensive|O
DDI-DrugBank.d175.s22|150-157|patients|O
DDI-DrugBank.d175.s22|158-158|.|O
DDI-DrugBank.d175.s23|0-10|Allopurinol|drug
DDI-DrugBank.d175.s23|11-11|:|O
DDI-DrugBank.d175.s23|13-14|In|O
DDI-DrugBank.d175.s23|16-16|a|O
DDI-DrugBank.d175.s23|18-22|study|O
DDI-DrugBank.d175.s23|24-25|of|O
DDI-DrugBank.d175.s23|27-33|healthy|O
DDI-DrugBank.d175.s23|35-38|male|O
DDI-DrugBank.d175.s23|40-49|volunteers|O
DDI-DrugBank.d175.s23|51-52|no|O
DDI-DrugBank.d175.s23|54-64|significant|O
DDI-DrugBank.d175.s23|66-80|pharmacokinetic|O
DDI-DrugBank.d175.s23|82-92|interaction|O
DDI-DrugBank.d175.s23|94-101|occurred|O
DDI-DrugBank.d175.s23|103-106|when|O
DDI-DrugBank.d175.s23|108-116|captopril|drug
DDI-DrugBank.d175.s23|118-120|and|O
DDI-DrugBank.d175.s23|122-132|allopurinol|drug
DDI-DrugBank.d175.s23|134-137|were|O
DDI-DrugBank.d175.s23|139-150|administered|O
DDI-DrugBank.d175.s23|152-164|concomitantly|O
DDI-DrugBank.d175.s23|166-168|for|O
DDI-DrugBank.d175.s23|170-170|6|O
DDI-DrugBank.d175.s23|172-175|days|O
DDI-DrugBank.d175.s23|176-176|.|O
DDI-DrugBank.d175.s24|0-14|Drug/Laboratory|O
DDI-DrugBank.d175.s24|16-19|Test|O
DDI-DrugBank.d175.s24|21-31|Interaction|O
DDI-DrugBank.d175.s24|33-41|Captopril|drug
DDI-DrugBank.d175.s24|43-45|may|O
DDI-DrugBank.d175.s24|47-51|cause|O
DDI-DrugBank.d175.s24|53-53|a|O
DDI-DrugBank.d175.s24|55-68|false-positive|O
DDI-DrugBank.d175.s24|70-74|urine|O
DDI-DrugBank.d175.s24|76-79|test|O
DDI-DrugBank.d175.s24|81-83|for|O
DDI-DrugBank.d175.s24|85-91|acetone|O
DDI-DrugBank.d175.s24|92-92|.|O
DDI-DrugBank.d68.s0|0-1|No|O
DDI-DrugBank.d68.s0|3-10|specific|O
DDI-DrugBank.d68.s0|12-26|pharmacokinetic|O
DDI-DrugBank.d68.s0|28-29|or|O
DDI-DrugBank.d68.s0|31-35|other|O
DDI-DrugBank.d68.s0|37-42|formal|O
DDI-DrugBank.d68.s0|44-47|drug|O
DDI-DrugBank.d68.s0|49-59|interaction|O
DDI-DrugBank.d68.s0|61-67|studies|O
DDI-DrugBank.d68.s0|69-72|were|O
DDI-DrugBank.d68.s0|74-82|conducted|O
DDI-DrugBank.d68.s0|83-83|.|O
DDI-DrugBank.d68.s1|0-6|Digoxin|drug
DDI-DrugBank.d68.s1|7-7|:|O
DDI-DrugBank.d68.s1|9-24|Supraventricular|O
DDI-DrugBank.d68.s1|26-36|arrhythmias|O
DDI-DrugBank.d68.s1|38-40|may|O
DDI-DrugBank.d68.s1|42-45|mask|O
DDI-DrugBank.d68.s1|47-49|the|O
DDI-DrugBank.d68.s1|51-64|cardiotoxicity|O
DDI-DrugBank.d68.s1|66-75|associated|O
DDI-DrugBank.d68.s1|77-80|with|O
DDI-DrugBank.d68.s1|82-90|excessive|O
DDI-DrugBank.d68.s1|92-98|digoxin|drug
DDI-DrugBank.d68.s1|100-105|levels|O
DDI-DrugBank.d68.s1|106-106|.|O
DDI-DrugBank.d68.s2|0-8|Therefore|O
DDI-DrugBank.d68.s2|9-9|,|O
DDI-DrugBank.d68.s2|11-12|it|O
DDI-DrugBank.d68.s2|14-15|is|O
DDI-DrugBank.d68.s2|17-25|advisable|O
DDI-DrugBank.d68.s2|27-28|to|O
DDI-DrugBank.d68.s2|30-31|be|O
DDI-DrugBank.d68.s2|33-44|particularly|O
DDI-DrugBank.d68.s2|46-53|cautious|O
DDI-DrugBank.d68.s2|55-56|in|O
DDI-DrugBank.d68.s2|58-65|patients|O
DDI-DrugBank.d68.s2|67-71|whose|O
DDI-DrugBank.d68.s2|73-78|plasma|O
DDI-DrugBank.d68.s2|80-86|digoxin|drug
DDI-DrugBank.d68.s2|88-93|levels|O
DDI-DrugBank.d68.s2|95-97|are|O
DDI-DrugBank.d68.s2|99-103|above|O
DDI-DrugBank.d68.s2|105-106|or|O
DDI-DrugBank.d68.s2|108-116|suspected|O
DDI-DrugBank.d68.s2|118-119|to|O
DDI-DrugBank.d68.s2|121-122|be|O
DDI-DrugBank.d68.s2|124-128|above|O
DDI-DrugBank.d68.s2|130-132|the|O
DDI-DrugBank.d68.s2|134-138|usual|O
DDI-DrugBank.d68.s2|140-150|therapeutic|O
DDI-DrugBank.d68.s2|152-156|range|O
DDI-DrugBank.d68.s2|157-157|.|O
DDI-DrugBank.d68.s3|0-15|Coadministration|O
DDI-DrugBank.d68.s3|17-18|of|O
DDI-DrugBank.d68.s3|20-26|digoxin|drug
DDI-DrugBank.d68.s3|28-30|did|O
DDI-DrugBank.d68.s3|32-34|not|O
DDI-DrugBank.d68.s3|36-39|have|O
DDI-DrugBank.d68.s3|41-47|effects|O
DDI-DrugBank.d68.s3|49-50|on|O
DDI-DrugBank.d68.s3|52-57|either|O
DDI-DrugBank.d68.s3|59-61|the|O
DDI-DrugBank.d68.s3|63-68|safety|O
DDI-DrugBank.d68.s3|70-71|or|O
DDI-DrugBank.d68.s3|73-80|efficacy|O
DDI-DrugBank.d68.s3|82-83|of|O
DDI-DrugBank.d68.s3|85-93|ibutilide|drug
DDI-DrugBank.d68.s3|95-96|in|O
DDI-DrugBank.d68.s3|98-100|the|O
DDI-DrugBank.d68.s3|102-109|clinical|O
DDI-DrugBank.d68.s3|111-116|trials|O
DDI-DrugBank.d68.s3|117-117|.|O
DDI-DrugBank.d68.s4|0-30|Calcium channel blocking agents|group
DDI-DrugBank.d68.s4|31-31|:|O
DDI-DrugBank.d68.s4|33-48|Coadministration|O
DDI-DrugBank.d68.s4|50-51|of|O
DDI-DrugBank.d68.s4|53-76|calcium channel blockers|group
DDI-DrugBank.d68.s4|78-80|did|O
DDI-DrugBank.d68.s4|82-84|not|O
DDI-DrugBank.d68.s4|86-89|have|O
DDI-DrugBank.d68.s4|91-93|any|O
DDI-DrugBank.d68.s4|95-100|effect|O
DDI-DrugBank.d68.s4|102-103|on|O
DDI-DrugBank.d68.s4|105-110|either|O
DDI-DrugBank.d68.s4|112-114|the|O
DDI-DrugBank.d68.s4|116-121|safety|O
DDI-DrugBank.d68.s4|123-124|or|O
DDI-DrugBank.d68.s4|126-133|efficacy|O
DDI-DrugBank.d68.s4|135-136|of|O
DDI-DrugBank.d68.s4|138-146|ibutilide|drug
DDI-DrugBank.d68.s4|148-149|in|O
DDI-DrugBank.d68.s4|151-153|the|O
DDI-DrugBank.d68.s4|155-162|clinical|O
DDI-DrugBank.d68.s4|164-169|trials|O
DDI-DrugBank.d68.s4|170-170|.|O
DDI-DrugBank.d68.s5|0-30|Beta-adrenergic blocking agents|group
DDI-DrugBank.d68.s5|31-31|:|O
DDI-DrugBank.d68.s5|33-48|Coadministration|O
DDI-DrugBank.d68.s5|50-51|of|O
DDI-DrugBank.d68.s5|53-83|beta-adrenergic blocking agents|group
DDI-DrugBank.d68.s5|85-87|did|O
DDI-DrugBank.d68.s5|89-91|not|O
DDI-DrugBank.d68.s5|93-96|have|O
DDI-DrugBank.d68.s5|98-100|any|O
DDI-DrugBank.d68.s5|102-107|effect|O
DDI-DrugBank.d68.s5|109-110|on|O
DDI-DrugBank.d68.s5|112-117|either|O
DDI-DrugBank.d68.s5|119-121|the|O
DDI-DrugBank.d68.s5|123-128|safety|O
DDI-DrugBank.d68.s5|130-131|or|O
DDI-DrugBank.d68.s5|133-140|efficacy|O
DDI-DrugBank.d68.s5|142-143|of|O
DDI-DrugBank.d68.s5|145-153|ibutilide|drug
DDI-DrugBank.d68.s5|155-156|in|O
DDI-DrugBank.d68.s5|158-160|the|O
DDI-DrugBank.d68.s5|162-169|clinical|O
DDI-DrugBank.d68.s5|171-176|trials|O
DDI-DrugBank.d68.s5|177-177|.|O
DDI-MedLine.d0.s0|0-2|The|O
DDI-MedLine.d0.s0|4-10|effects|O
DDI-MedLine.d0.s0|12-13|of|O
DDI-MedLine.d0.s0|15-25|concomitant|O
DDI-MedLine.d0.s0|27-35|phenytoin|drug
DDI-MedLine.d0.s0|37-50|administration|O
DDI-MedLine.d0.s0|52-53|on|O
DDI-MedLine.d0.s0|55-57|the|O
DDI-MedLine.d0.s0|59-70|steady-state|O
DDI-MedLine.d0.s0|72-87|pharmacokinetics|O
DDI-MedLine.d0.s0|89-90|of|O
DDI-MedLine.d0.s0|92-101|quetiapine|drug
DDI-MedLine.d0.s0|102-102|.|O
DDI-MedLine.d0.s1|0-18|Quetiapine fumarate|drug
DDI-MedLine.d0.s1|20-20|(|O
DDI-MedLine.d0.s1|21-29|'Seroquel|brand
DDI-MedLine.d0.s1|30-30|'|O
DDI-MedLine.d0.s1|31-31|)|O
DDI-MedLine.d0.s1|33-34|is|O
DDI-MedLine.d0.s1|36-36|a|O
DDI-MedLine.d0.s1|38-42|newly|O
DDI-MedLine.d0.s1|44-53|introduced|O
DDI-MedLine.d0.s1|55-76|atypical antipsychotic|group
DDI-MedLine.d0.s1|78-81|with|O
DDI-MedLine.d0.s1|83-94|demonstrated|O
DDI-MedLine.d0.s1|96-103|efficacy|O
DDI-MedLine.d0.s1|105-106|in|O
DDI-MedLine.d0.s1|108-110|the|O
DDI-MedLine.d0.s1|112-120|treatment|O
DDI-MedLine.d0.s1|122-123|of|O
DDI-MedLine.d0.s1|125-132|positive|O
DDI-MedLine.d0.s1|134-136|and|O
DDI-MedLine.d0.s1|138-145|negative|O
DDI-MedLine.d0.s1|147-154|symptoms|O
DDI-MedLine.d0.s1|156-157|of|O
DDI-MedLine.d0.s1|159-171|schizophrenia|O
DDI-MedLine.d0.s1|172-172|.|O
DDI-MedLine.d0.s2|0-1|It|O
DDI-MedLine.d0.s2|3-4|is|O
DDI-MedLine.d0.s2|6-16|extensively|O
DDI-MedLine.d0.s2|18-28|metabolized|O
DDI-MedLine.d0.s2|29-29|,|O
DDI-MedLine.d0.s2|31-43|predominantly|O
DDI-MedLine.d0.s2|45-46|by|O
DDI-MedLine.d0.s2|48-57|cytochrome|O
DDI-MedLine.d0.s2|59-62|P450|O
DDI-MedLine.d0.s2|64-66|3A4|O
DDI-MedLine.d0.s2|67-67|.|O
DDI-MedLine.d0.s3|0-8|Therefore|O
DDI-MedLine.d0.s3|9-9|,|O
DDI-MedLine.d0.s3|11-20|concurrent|O
DDI-MedLine.d0.s3|22-35|administration|O
DDI-MedLine.d0.s3|37-38|of|O
DDI-MedLine.d0.s3|40-44|drugs|O
DDI-MedLine.d0.s3|46-49|that|O
DDI-MedLine.d0.s3|51-56|induce|O
DDI-MedLine.d0.s3|58-59|or|O
DDI-MedLine.d0.s3|61-67|inhibit|O
DDI-MedLine.d0.s3|69-72|this|O
DDI-MedLine.d0.s3|74-79|enzyme|O
DDI-MedLine.d0.s3|81-83|may|O
DDI-MedLine.d0.s3|85-90|affect|O
DDI-MedLine.d0.s3|92-101|quetiapine|drug
DDI-MedLine.d0.s3|103-118|pharmacokinetics|O
DDI-MedLine.d0.s3|119-119|.|O
DDI-MedLine.d0.s4|0-3|This|O
DDI-MedLine.d0.s4|5-9|study|O
DDI-MedLine.d0.s4|11-22|demonstrated|O
DDI-MedLine.d0.s4|24-27|that|O
DDI-MedLine.d0.s4|29-31|the|O
DDI-MedLine.d0.s4|33-38|potent|O
DDI-MedLine.d0.s4|40-49|cytochrome|O
DDI-MedLine.d0.s4|51-54|P450|O
DDI-MedLine.d0.s4|56-69|enzyme-inducer|O
DDI-MedLine.d0.s4|71-79|phenytoin|drug
DDI-MedLine.d0.s4|81-83|did|O
DDI-MedLine.d0.s4|85-90|indeed|O
DDI-MedLine.d0.s4|92-95|have|O
DDI-MedLine.d0.s4|97-97|a|O
DDI-MedLine.d0.s4|99-104|marked|O
DDI-MedLine.d0.s4|106-111|effect|O
DDI-MedLine.d0.s4|113-114|on|O
DDI-MedLine.d0.s4|116-118|the|O
DDI-MedLine.d0.s4|120-129|metabolism|O
DDI-MedLine.d0.s4|131-132|of|O
DDI-MedLine.d0.s4|134-143|quetiapine|drug
DDI-MedLine.d0.s4|144-144|,|O
DDI-MedLine.d0.s4|146-154|resulting|O
DDI-MedLine.d0.s4|156-157|in|O
DDI-MedLine.d0.s4|159-159|a|O
DDI-MedLine.d0.s4|161-166|5-fold|O
DDI-MedLine.d0.s4|168-175|increase|O
DDI-MedLine.d0.s4|177-178|in|O
DDI-MedLine.d0.s4|180-188|clearance|O
DDI-MedLine.d0.s4|190-193|when|O
DDI-MedLine.d0.s4|195-206|administered|O
DDI-MedLine.d0.s4|208-220|concomitantly|O
DDI-MedLine.d0.s4|222-223|to|O
DDI-MedLine.d0.s4|225-232|patients|O
DDI-MedLine.d0.s4|234-237|with|O
DDI-MedLine.d0.s4|239-254|DSM-IV-diagnosed|O
DDI-MedLine.d0.s4|256-268|schizophrenia|O
DDI-MedLine.d0.s4|269-269|,|O
DDI-MedLine.d0.s4|271-285|schizoaffective|O
DDI-MedLine.d0.s4|287-294|disorder|O
DDI-MedLine.d0.s4|295-295|,|O
DDI-MedLine.d0.s4|297-298|or|O
DDI-MedLine.d0.s4|300-306|bipolar|O
DDI-MedLine.d0.s4|308-315|disorder|O
DDI-MedLine.d0.s4|316-316|.|O
DDI-MedLine.d0.s5|0-4|These|O
DDI-MedLine.d0.s5|6-12|results|O
DDI-MedLine.d0.s5|14-21|indicate|O
DDI-MedLine.d0.s5|23-26|that|O
DDI-MedLine.d0.s5|28-33|dosage|O
DDI-MedLine.d0.s5|35-44|adjustment|O
DDI-MedLine.d0.s5|46-47|of|O
DDI-MedLine.d0.s5|49-58|quetiapine|drug
DDI-MedLine.d0.s5|60-62|may|O
DDI-MedLine.d0.s5|64-65|be|O
DDI-MedLine.d0.s5|67-75|necessary|O
DDI-MedLine.d0.s5|77-80|when|O
DDI-MedLine.d0.s5|82-84|the|O
DDI-MedLine.d0.s5|86-88|two|O
DDI-MedLine.d0.s5|90-94|drugs|O
DDI-MedLine.d0.s5|96-98|are|O
DDI-MedLine.d0.s5|100-104|given|O
DDI-MedLine.d0.s5|106-117|concurrently|O
DDI-MedLine.d0.s5|119-121|and|O
DDI-MedLine.d0.s5|123-126|that|O
DDI-MedLine.d0.s5|128-134|caution|O
DDI-MedLine.d0.s5|136-138|may|O
DDI-MedLine.d0.s5|140-141|be|O
DDI-MedLine.d0.s5|143-150|required|O
DDI-MedLine.d0.s5|152-155|when|O
DDI-MedLine.d0.s5|157-169|administering|O
DDI-MedLine.d0.s5|171-175|other|O
DDI-MedLine.d0.s5|177-181|drugs|O
DDI-MedLine.d0.s5|183-186|that|O
DDI-MedLine.d0.s5|188-194|inhibit|O
DDI-MedLine.d0.s5|196-197|or|O
DDI-MedLine.d0.s5|199-204|induce|O
DDI-MedLine.d0.s5|206-216|cytochromes|O
DDI-MedLine.d0.s5|217-217|,|O
DDI-MedLine.d0.s5|219-230|particularly|O
DDI-MedLine.d0.s5|232-235|P450|O
DDI-MedLine.d0.s5|237-239|3A4|O
DDI-MedLine.d0.s5|240-240|.|O
DDI-MedLine.d136.s0|0-0|[|O
DDI-MedLine.d136.s0|1-8|Multiple|O
DDI-MedLine.d136.s0|10-21|occupational|O
DDI-MedLine.d136.s0|23-30|exposure|O
DDI-MedLine.d136.s0|32-33|to|O
DDI-MedLine.d136.s0|35-42|solvents|O
DDI-MedLine.d136.s0|43-43|]|O
DDI-MedLine.d136.s0|46-49|This|O
DDI-MedLine.d136.s0|51-57|article|O
DDI-MedLine.d136.s0|59-64|review|O
DDI-MedLine.d136.s0|66-71|papers|O
DDI-MedLine.d136.s0|73-81|published|O
DDI-MedLine.d136.s0|83-86|over|O
DDI-MedLine.d136.s0|88-90|the|O
DDI-MedLine.d136.s0|92-95|last|O
DDI-MedLine.d136.s0|97-98|20|O
DDI-MedLine.d136.s0|100-104|years|O
DDI-MedLine.d136.s0|106-107|on|O
DDI-MedLine.d136.s0|109-116|multiple|O
DDI-MedLine.d136.s0|118-129|occupational|O
DDI-MedLine.d136.s0|131-138|exposure|O
DDI-MedLine.d136.s0|140-141|to|O
DDI-MedLine.d136.s0|143-150|solvents|O
DDI-MedLine.d136.s0|151-151|.|O
DDI-MedLine.d136.s1|0-1|At|O
DDI-MedLine.d136.s1|3-12|low-levels|O
DDI-MedLine.d136.s1|14-15|of|O
DDI-MedLine.d136.s1|17-24|exposure|O
DDI-MedLine.d136.s1|26-28|the|O
DDI-MedLine.d136.s1|30-42|toxicokinetic|O
DDI-MedLine.d136.s1|44-56|interferences|O
DDI-MedLine.d136.s1|58-64|between|O
DDI-MedLine.d136.s1|66-73|solvents|O
DDI-MedLine.d136.s1|75-78|have|O
DDI-MedLine.d136.s1|80-88|generally|O
DDI-MedLine.d136.s1|90-92|not|O
DDI-MedLine.d136.s1|94-97|been|O
DDI-MedLine.d136.s1|99-106|observed|O
DDI-MedLine.d136.s1|108-109|in|O
DDI-MedLine.d136.s1|111-113|man|O
DDI-MedLine.d136.s1|115-117|and|O
DDI-MedLine.d136.s1|119-128|presumably|O
DDI-MedLine.d136.s1|130-130|a|O
DDI-MedLine.d136.s1|132-140|threshold|O
DDI-MedLine.d136.s1|142-146|limit|O
DDI-MedLine.d136.s1|148-153|exists|O
DDI-MedLine.d136.s1|154-154|.|O
DDI-MedLine.d136.s2|0-9|Conversely|O
DDI-MedLine.d136.s2|10-10|,|O
DDI-MedLine.d136.s2|12-13|at|O
DDI-MedLine.d136.s2|15-22|exposure|O
DDI-MedLine.d136.s2|24-29|levels|O
DDI-MedLine.d136.s2|31-35|close|O
DDI-MedLine.d136.s2|37-38|to|O
DDI-MedLine.d136.s2|40-42|the|O
DDI-MedLine.d136.s2|44-44|"|O
DDI-MedLine.d136.s2|45-49|limit|O
DDI-MedLine.d136.s2|51-56|values|O
DDI-MedLine.d136.s2|57-57|"|O
DDI-MedLine.d136.s3|0-8|metabolic|O
DDI-MedLine.d136.s3|10-21|interference|O
DDI-MedLine.d136.s3|23-25|has|O
DDI-MedLine.d136.s3|27-35|sometimes|O
DDI-MedLine.d136.s3|37-40|been|O
DDI-MedLine.d136.s3|42-49|observed|O
DDI-MedLine.d136.s3|51-53|and|O
DDI-MedLine.d136.s3|55-57|the|O
DDI-MedLine.d136.s3|59-67|behaviour|O
DDI-MedLine.d136.s3|69-70|of|O
DDI-MedLine.d136.s3|72-74|the|O
DDI-MedLine.d136.s3|76-85|biological|O
DDI-MedLine.d136.s3|87-96|indicators|O
DDI-MedLine.d136.s3|98-104|differs|O
DDI-MedLine.d136.s3|106-109|from|O
DDI-MedLine.d136.s3|111-114|what|O
DDI-MedLine.d136.s3|116-120|would|O
DDI-MedLine.d136.s3|122-123|be|O
DDI-MedLine.d136.s3|125-132|expected|O
DDI-MedLine.d136.s3|133-133|.|O
DDI-MedLine.d136.s4|0-12|Toxicodynamic|O
DDI-MedLine.d136.s4|14-25|interference|O
DDI-MedLine.d136.s4|27-33|between|O
DDI-MedLine.d136.s4|35-42|solvents|O
DDI-MedLine.d136.s4|44-46|can|O
DDI-MedLine.d136.s4|48-51|give|O
DDI-MedLine.d136.s4|53-56|rise|O
DDI-MedLine.d136.s4|58-59|to|O
DDI-MedLine.d136.s4|61-68|additive|O
DDI-MedLine.d136.s4|69-69|,|O
DDI-MedLine.d136.s4|71-82|potentiation|O
DDI-MedLine.d136.s4|83-83|,|O
DDI-MedLine.d136.s4|85-95|synergistic|O
DDI-MedLine.d136.s4|96-96|,|O
DDI-MedLine.d136.s4|98-109|antagonistic|O
DDI-MedLine.d136.s4|111-117|effects|O
DDI-MedLine.d136.s4|118-118|.|O
DDI-MedLine.d136.s5|0-2|For|O
DDI-MedLine.d136.s5|4-6|the|O
DDI-MedLine.d136.s5|8-21|identification|O
DDI-MedLine.d136.s5|23-24|of|O
DDI-MedLine.d136.s5|26-26|"|O
DDI-MedLine.d136.s5|27-31|limit|O
DDI-MedLine.d136.s5|33-38|values|O
DDI-MedLine.d136.s5|39-39|"|O
DDI-MedLine.d136.s5|40-40|,|O
DDI-MedLine.d136.s5|42-43|it|O
DDI-MedLine.d136.s5|45-47|has|O
DDI-MedLine.d136.s5|49-57|generally|O
DDI-MedLine.d136.s5|59-62|been|O
DDI-MedLine.d136.s5|64-72|suggested|O
DDI-MedLine.d136.s5|74-75|in|O
DDI-MedLine.d136.s5|77-79|the|O
DDI-MedLine.d136.s5|81-90|literature|O
DDI-MedLine.d136.s5|92-95|that|O
DDI-MedLine.d136.s5|97-99|the|O
DDI-MedLine.d136.s5|101-108|possible|O
DDI-MedLine.d136.s5|110-116|effects|O
DDI-MedLine.d136.s5|118-125|deriving|O
DDI-MedLine.d136.s5|127-130|from|O
DDI-MedLine.d136.s5|132-139|multiple|O
DDI-MedLine.d136.s5|141-148|exposure|O
DDI-MedLine.d136.s5|150-151|be|O
DDI-MedLine.d136.s5|153-162|considered|O
DDI-MedLine.d136.s5|164-165|as|O
DDI-MedLine.d136.s5|167-174|additive|O
DDI-MedLine.d136.s5|175-175|.|O
DDI-MedLine.d136.s6|0-6|However|O
DDI-MedLine.d136.s6|7-7|,|O
DDI-MedLine.d136.s6|9-16|numerous|O
DDI-MedLine.d136.s6|18-29|potentiation|O
DDI-MedLine.d136.s6|31-37|effects|O
DDI-MedLine.d136.s6|39-42|have|O
DDI-MedLine.d136.s6|44-53|frequently|O
DDI-MedLine.d136.s6|55-58|been|O
DDI-MedLine.d136.s6|60-67|reported|O
DDI-MedLine.d136.s6|69-71|for|O
DDI-MedLine.d136.s6|73-80|combined|O
DDI-MedLine.d136.s6|82-89|exposure|O
DDI-MedLine.d136.s6|91-92|to|O
DDI-MedLine.d136.s6|94-103|substances|O
DDI-MedLine.d136.s6|105-106|of|O
DDI-MedLine.d136.s6|108-117|widespread|O
DDI-MedLine.d136.s6|119-121|use|O
DDI-MedLine.d136.s6|122-122|.|O
DDI-MedLine.d136.s7|0-1|In|O
DDI-MedLine.d136.s7|3-6|this|O
DDI-MedLine.d136.s7|8-12|paper|O
DDI-MedLine.d136.s7|14-18|lists|O
DDI-MedLine.d136.s7|20-21|of|O
DDI-MedLine.d136.s7|23-30|multiple|O
DDI-MedLine.d136.s7|32-39|exposure|O
DDI-MedLine.d136.s7|41-42|in|O
DDI-MedLine.d136.s7|44-48|which|O
DDI-MedLine.d136.s7|50-52|the|O
DDI-MedLine.d136.s7|54-58|doses|O
DDI-MedLine.d136.s7|60-61|of|O
DDI-MedLine.d136.s7|63-65|the|O
DDI-MedLine.d136.s7|67-76|substances|O
DDI-MedLine.d136.s7|77-77|,|O
DDI-MedLine.d136.s7|79-81|the|O
DDI-MedLine.d136.s7|83-87|types|O
DDI-MedLine.d136.s7|89-90|of|O
DDI-MedLine.d136.s7|92-104|interferences|O
DDI-MedLine.d136.s7|106-108|and|O
DDI-MedLine.d136.s7|110-112|the|O
DDI-MedLine.d136.s7|114-122|behaviour|O
DDI-MedLine.d136.s7|124-125|of|O
DDI-MedLine.d136.s7|127-129|the|O
DDI-MedLine.d136.s7|131-140|biological|O
DDI-MedLine.d136.s7|142-147|levels|O
DDI-MedLine.d136.s7|149-152|have|O
DDI-MedLine.d136.s7|154-157|been|O
DDI-MedLine.d136.s7|159-163|drawn|O
DDI-MedLine.d136.s7|165-166|up|O
DDI-MedLine.d136.s7|168-170|and|O
DDI-MedLine.d136.s7|172-179|proposed|O
DDI-MedLine.d136.s7|181-182|as|O
DDI-MedLine.d136.s7|184-184|a|O
DDI-MedLine.d136.s7|186-189|tool|O
DDI-MedLine.d136.s7|191-193|for|O
DDI-MedLine.d136.s7|195-198|easy|O
DDI-MedLine.d136.s7|200-211|consultation|O
DDI-MedLine.d136.s7|212-212|.|O
DDI-DrugBank.d319.s0|0-4|Drugs|O
DDI-DrugBank.d319.s0|6-9|that|O
DDI-DrugBank.d319.s0|11-17|inhibit|O
DDI-DrugBank.d319.s0|19-20|or|O
DDI-DrugBank.d319.s0|22-27|Induce|O
DDI-DrugBank.d319.s0|29-31|CYP|O
DDI-DrugBank.d319.s0|33-35|2D6|O
DDI-DrugBank.d319.s0|37-39|and|O
DDI-DrugBank.d319.s0|41-43|CYP|O
DDI-DrugBank.d319.s0|45-47|3A4|O
DDI-DrugBank.d319.s0|49-51|may|O
DDI-DrugBank.d319.s0|53-58|affect|O
DDI-DrugBank.d319.s0|60-62|the|O
DDI-DrugBank.d319.s0|64-76|concentration|O
DDI-DrugBank.d319.s0|78-79|on|O
DDI-DrugBank.d319.s0|81-87|Aricept|brand
DDI-DrugBank.d319.s0|88-88|.|O
DDI-DrugBank.d294.s0|0-18|Drug/LaboratoryTest|O
DDI-DrugBank.d294.s0|20-31|Interactions|O
DDI-DrugBank.d294.s0|33-44|Dactinomycin|drug
DDI-DrugBank.d294.s0|46-48|may|O
DDI-DrugBank.d294.s0|50-58|interfere|O
DDI-DrugBank.d294.s0|60-63|with|O
DDI-DrugBank.d294.s0|65-72|bioassay|O
DDI-DrugBank.d294.s0|74-83|procedures|O
DDI-DrugBank.d294.s0|85-87|for|O
DDI-DrugBank.d294.s0|89-91|the|O
DDI-DrugBank.d294.s0|93-105|determination|O
DDI-DrugBank.d294.s0|107-108|of|O
DDI-DrugBank.d294.s0|110-127|antibacterial drug|group
DDI-DrugBank.d294.s0|129-134|levels|O
DDI-DrugBank.d294.s0|135-135|.|O
DDI-DrugBank.d556.s0|0-8|Increased|O
DDI-DrugBank.d556.s0|10-23|nephrotoxicity|O
DDI-DrugBank.d556.s0|25-27|has|O
DDI-DrugBank.d556.s0|29-32|been|O
DDI-DrugBank.d556.s0|34-41|reported|O
DDI-DrugBank.d556.s0|43-51|following|O
DDI-DrugBank.d556.s0|53-63|concomitant|O
DDI-DrugBank.d556.s0|65-78|administration|O
DDI-DrugBank.d556.s0|80-81|of|O
DDI-DrugBank.d556.s0|83-96|cephalosporins|group
DDI-DrugBank.d556.s0|98-100|and|O
DDI-DrugBank.d556.s0|102-127|aminoglycoside antibiotics|group
DDI-DrugBank.d556.s0|128-128|.|O
DDI-DrugBank.d556.s1|0-14|Drug/Laboratory|O
DDI-DrugBank.d556.s1|16-19|Test|O
DDI-DrugBank.d556.s1|21-32|Interactions|O
DDI-DrugBank.d556.s1|34-35|As|O
DDI-DrugBank.d556.s1|37-40|with|O
DDI-DrugBank.d556.s1|42-52|cephalothin|drug
DDI-DrugBank.d556.s1|53-53|,|O
DDI-DrugBank.d556.s1|55-58|high|O
DDI-DrugBank.d556.s1|60-73|concentrations|O
DDI-DrugBank.d556.s1|75-76|of|O
DDI-DrugBank.d556.s1|78-86|cefoxitin|drug
DDI-DrugBank.d556.s1|88-88|(|O
DDI-DrugBank.d556.s1|90-92|100|O
DDI-DrugBank.d556.s1|94-106|micrograms/mL|O
DDI-DrugBank.d556.s1|107-107|)|O
DDI-DrugBank.d556.s1|109-111|may|O
DDI-DrugBank.d556.s1|113-121|interfere|O
DDI-DrugBank.d556.s1|123-126|with|O
DDI-DrugBank.d556.s1|128-138|measurement|O
DDI-DrugBank.d556.s1|140-141|of|O
DDI-DrugBank.d556.s1|143-147|serum|O
DDI-DrugBank.d556.s1|149-151|and|O
DDI-DrugBank.d556.s1|153-157|urine|O
DDI-DrugBank.d556.s1|159-168|creatinine|O
DDI-DrugBank.d556.s1|170-175|levels|O
DDI-DrugBank.d556.s1|177-178|by|O
DDI-DrugBank.d556.s1|180-182|the|O
DDI-DrugBank.d556.s1|184-187|Jaff|O
DDI-DrugBank.d556.s1|190-197|reaction|O
DDI-DrugBank.d556.s1|198-198|,|O
DDI-DrugBank.d556.s1|200-202|and|O
DDI-DrugBank.d556.s1|204-210|produce|O
DDI-DrugBank.d556.s1|212-216|false|O
DDI-DrugBank.d556.s1|218-226|increases|O
DDI-DrugBank.d556.s1|228-229|of|O
DDI-DrugBank.d556.s1|231-236|modest|O
DDI-DrugBank.d556.s1|238-243|degree|O
DDI-DrugBank.d556.s1|245-246|in|O
DDI-DrugBank.d556.s1|248-250|the|O
DDI-DrugBank.d556.s1|252-257|levels|O
DDI-DrugBank.d556.s1|259-260|of|O
DDI-DrugBank.d556.s1|262-271|creatinine|O
DDI-DrugBank.d556.s1|273-280|reported|O
DDI-DrugBank.d556.s1|281-281|.|O
DDI-DrugBank.d556.s2|0-4|Serum|O
DDI-DrugBank.d556.s2|6-12|samples|O
DDI-DrugBank.d556.s2|14-17|from|O
DDI-DrugBank.d556.s2|19-26|patients|O
DDI-DrugBank.d556.s2|28-34|treated|O
DDI-DrugBank.d556.s2|36-39|with|O
DDI-DrugBank.d556.s2|41-49|cefoxitin|drug
DDI-DrugBank.d556.s2|51-56|should|O
DDI-DrugBank.d556.s2|58-60|not|O
DDI-DrugBank.d556.s2|62-63|be|O
DDI-DrugBank.d556.s2|65-72|analyzed|O
DDI-DrugBank.d556.s2|74-76|for|O
DDI-DrugBank.d556.s2|78-87|creatinine|O
DDI-DrugBank.d556.s2|89-90|if|O
DDI-DrugBank.d556.s2|92-100|withdrawn|O
DDI-DrugBank.d556.s2|102-107|within|O
DDI-DrugBank.d556.s2|109-109|2|O
DDI-DrugBank.d556.s2|111-115|hours|O
DDI-DrugBank.d556.s2|117-118|of|O
DDI-DrugBank.d556.s2|120-123|drug|O
DDI-DrugBank.d556.s2|125-138|administration|O
DDI-DrugBank.d556.s2|139-139|.|O
DDI-DrugBank.d556.s3|0-3|High|O
DDI-DrugBank.d556.s3|5-18|concentrations|O
DDI-DrugBank.d556.s3|20-21|of|O
DDI-DrugBank.d556.s3|23-31|cefoxitin|drug
DDI-DrugBank.d556.s3|33-34|in|O
DDI-DrugBank.d556.s3|36-38|the|O
DDI-DrugBank.d556.s3|40-44|urine|O
DDI-DrugBank.d556.s3|46-48|may|O
DDI-DrugBank.d556.s3|50-58|interfere|O
DDI-DrugBank.d556.s3|60-63|with|O
DDI-DrugBank.d556.s3|65-75|measurement|O
DDI-DrugBank.d556.s3|77-78|of|O
DDI-DrugBank.d556.s3|80-86|urinary|O
DDI-DrugBank.d556.s3|88-113|17-hydroxy-corticosteroids|O
DDI-DrugBank.d556.s3|115-116|by|O
DDI-DrugBank.d556.s3|118-120|the|O
DDI-DrugBank.d556.s3|122-134|Porter-Silber|O
DDI-DrugBank.d556.s3|136-143|reaction|O
DDI-DrugBank.d556.s3|144-144|,|O
DDI-DrugBank.d556.s3|146-148|and|O
DDI-DrugBank.d556.s3|150-156|produce|O
DDI-DrugBank.d556.s3|158-162|false|O
DDI-DrugBank.d556.s3|164-172|increases|O
DDI-DrugBank.d556.s3|174-175|of|O
DDI-DrugBank.d556.s3|177-182|modest|O
DDI-DrugBank.d556.s3|184-189|degree|O
DDI-DrugBank.d556.s3|191-192|in|O
DDI-DrugBank.d556.s3|194-196|the|O
DDI-DrugBank.d556.s3|198-203|levels|O
DDI-DrugBank.d556.s3|205-212|reported|O
DDI-DrugBank.d556.s3|213-213|.|O
DDI-DrugBank.d556.s4|0-0|A|O
DDI-DrugBank.d556.s4|2-15|false-positive|O
DDI-DrugBank.d556.s4|17-24|reaction|O
DDI-DrugBank.d556.s4|26-28|for|O
DDI-DrugBank.d556.s4|30-36|glucose|O
DDI-DrugBank.d556.s4|38-39|in|O
DDI-DrugBank.d556.s4|41-43|the|O
DDI-DrugBank.d556.s4|45-49|urine|O
DDI-DrugBank.d556.s4|51-53|may|O
DDI-DrugBank.d556.s4|55-59|occur|O
DDI-DrugBank.d556.s4|60-60|.|O
DDI-DrugBank.d556.s5|0-3|This|O
DDI-DrugBank.d556.s5|5-7|has|O
DDI-DrugBank.d556.s5|9-12|been|O
DDI-DrugBank.d556.s5|14-21|observed|O
DDI-DrugBank.d556.s5|23-26|with|O
DDI-DrugBank.d556.s5|28-36|CLINITEST|O
DDI-DrugBank.d556.s5|39-45|reagent|O
DDI-DrugBank.d556.s5|47-53|tablets|O
DDI-DrugBank.d556.s6|0-0|.|O
DDI-DrugBank.d556.s7|0-9|Registered|O
DDI-DrugBank.d556.s7|11-19|trademark|O
DDI-DrugBank.d556.s7|21-22|of|O
DDI-DrugBank.d556.s7|24-27|Ames|O
DDI-DrugBank.d556.s7|29-35|Company|O
DDI-DrugBank.d556.s7|36-36|,|O
DDI-DrugBank.d556.s7|38-45|Division|O
DDI-DrugBank.d556.s7|47-48|of|O
DDI-DrugBank.d556.s7|50-54|Miles|O
DDI-DrugBank.d556.s7|56-67|Laboratories|O
DDI-DrugBank.d556.s7|68-68|,|O
DDI-DrugBank.d556.s7|70-72|Inc|O
DDI-DrugBank.d556.s7|73-73|.|O
DDI-MedLine.d66.s0|0-6|Changes|O
DDI-MedLine.d66.s0|8-9|in|O
DDI-MedLine.d66.s0|11-17|urinary|O
DDI-MedLine.d66.s0|19-30|homocysteine|O
DDI-MedLine.d66.s0|32-40|following|O
DDI-MedLine.d66.s0|42-69|synthetic steroidal estrogen|group
DDI-MedLine.d66.s0|71-73|and|O
DDI-MedLine.d66.s0|75-85|progestogen|O
DDI-MedLine.d66.s0|87-100|administration|O
DDI-MedLine.d66.s0|102-103|to|O
DDI-MedLine.d66.s0|105-108|rats|O
DDI-MedLine.d66.s0|109-109|.|O
DDI-MedLine.d66.s1|0-2|The|O
DDI-MedLine.d66.s1|4-10|present|O
DDI-MedLine.d66.s1|12-15|work|O
DDI-MedLine.d66.s1|17-24|involved|O
DDI-MedLine.d66.s1|26-28|the|O
DDI-MedLine.d66.s1|30-43|administration|O
DDI-MedLine.d66.s1|45-46|of|O
DDI-MedLine.d66.s1|48-51|both|O
DDI-MedLine.d66.s1|53-69|ethynyl estradiol|drug
DDI-MedLine.d66.s1|71-73|and|O
DDI-MedLine.d66.s1|75-88|levonorgestrel|drug
DDI-MedLine.d66.s1|90-91|to|O
DDI-MedLine.d66.s1|93-98|groups|O
DDI-MedLine.d66.s1|100-101|of|O
DDI-MedLine.d66.s1|103-106|rats|O
DDI-MedLine.d66.s1|107-107|,|O
DDI-MedLine.d66.s1|109-116|followed|O
DDI-MedLine.d66.s1|118-119|by|O
DDI-MedLine.d66.s1|121-133|determination|O
DDI-MedLine.d66.s1|135-136|of|O
DDI-MedLine.d66.s1|138-140|the|O
DDI-MedLine.d66.s1|142-153|homocysteine|O
DDI-MedLine.d66.s1|155-163|excretion|O
DDI-MedLine.d66.s1|165-168|rate|O
DDI-MedLine.d66.s1|170-171|in|O
DDI-MedLine.d66.s1|173-177|urine|O
DDI-MedLine.d66.s1|178-178|.|O
DDI-MedLine.d66.s2|0-2|The|O
DDI-MedLine.d66.s2|4-10|results|O
DDI-MedLine.d66.s2|12-19|indicate|O
DDI-MedLine.d66.s2|21-24|that|O
DDI-MedLine.d66.s2|26-26|a|O
DDI-MedLine.d66.s2|28-40|statistically|O
DDI-MedLine.d66.s2|42-52|significant|O
DDI-MedLine.d66.s2|54-63|difference|O
DDI-MedLine.d66.s2|65-70|exists|O
DDI-MedLine.d66.s2|72-78|between|O
DDI-MedLine.d66.s2|80-82|the|O
DDI-MedLine.d66.s2|84-91|excreted|O
DDI-MedLine.d66.s2|93-98|levels|O
DDI-MedLine.d66.s2|100-101|of|O
DDI-MedLine.d66.s2|103-114|homocysteine|O
DDI-MedLine.d66.s2|116-117|in|O
DDI-MedLine.d66.s2|119-121|the|O
DDI-MedLine.d66.s2|123-127|urine|O
DDI-MedLine.d66.s2|129-130|of|O
DDI-MedLine.d66.s2|132-135|both|O
DDI-MedLine.d66.s2|137-143|control|O
DDI-MedLine.d66.s2|145-147|and|O
DDI-MedLine.d66.s2|149-170|levonorgestrel-treated|drug
DDI-MedLine.d66.s2|172-175|rats|O
DDI-MedLine.d66.s2|177-179|and|O
DDI-MedLine.d66.s2|181-183|the|O
DDI-MedLine.d66.s2|185-190|levels|O
DDI-MedLine.d66.s2|192-196|shown|O
DDI-MedLine.d66.s2|198-199|by|O
DDI-MedLine.d66.s2|201-204|rats|O
DDI-MedLine.d66.s2|206-212|treated|O
DDI-MedLine.d66.s2|214-217|with|O
DDI-MedLine.d66.s2|219-235|ethynyl estradiol|drug
DDI-MedLine.d66.s2|236-236|.|O
DDI-MedLine.d66.s3|0-2|The|O
DDI-MedLine.d66.s3|4-15|implications|O
DDI-MedLine.d66.s3|17-18|of|O
DDI-MedLine.d66.s3|20-24|these|O
DDI-MedLine.d66.s3|26-32|results|O
DDI-MedLine.d66.s3|34-36|are|O
DDI-MedLine.d66.s3|38-46|discussed|O
DDI-MedLine.d66.s3|47-47|,|O
DDI-MedLine.d66.s3|49-58|especially|O
DDI-MedLine.d66.s3|60-63|with|O
DDI-MedLine.d66.s3|65-71|respect|O
DDI-MedLine.d66.s3|73-74|to|O
DDI-MedLine.d66.s3|76-87|observations|O
DDI-MedLine.d66.s3|89-93|which|O
DDI-MedLine.d66.s3|95-102|indicate|O
DDI-MedLine.d66.s3|104-107|that|O
DDI-MedLine.d66.s3|109-120|homocysteine|O
DDI-MedLine.d66.s3|122-124|may|O
DDI-MedLine.d66.s3|126-127|be|O
DDI-MedLine.d66.s3|129-129|a|O
DDI-MedLine.d66.s3|131-143|precipitating|O
DDI-MedLine.d66.s3|145-150|factor|O
DDI-MedLine.d66.s3|152-153|in|O
DDI-MedLine.d66.s3|155-157|the|O
DDI-MedLine.d66.s3|159-169|development|O
DDI-MedLine.d66.s3|171-172|of|O
DDI-MedLine.d66.s3|174-183|thrombosis|O
DDI-MedLine.d66.s3|184-184|.|O
DDI-MedLine.d66.s4|0-3|Also|O
DDI-MedLine.d66.s4|5-12|included|O
DDI-MedLine.d66.s4|14-15|in|O
DDI-MedLine.d66.s4|17-20|this|O
DDI-MedLine.d66.s4|22-26|paper|O
DDI-MedLine.d66.s4|28-29|is|O
DDI-MedLine.d66.s4|31-31|a|O
DDI-MedLine.d66.s4|33-37|study|O
DDI-MedLine.d66.s4|39-43|which|O
DDI-MedLine.d66.s4|45-52|confirms|O
DDI-MedLine.d66.s4|54-56|the|O
DDI-MedLine.d66.s4|58-65|identity|O
DDI-MedLine.d66.s4|67-68|of|O
DDI-MedLine.d66.s4|70-72|the|O
DDI-MedLine.d66.s4|74-77|HPLC|O
DDI-MedLine.d66.s4|79-82|peak|O
DDI-MedLine.d66.s4|84-85|as|O
DDI-MedLine.d66.s4|87-91|being|O
DDI-MedLine.d66.s4|93-104|homocysteine|O
DDI-MedLine.d66.s4|106-107|by|O
DDI-MedLine.d66.s4|109-115|forming|O
DDI-MedLine.d66.s4|117-117|a|O
DDI-MedLine.d66.s4|119-129|radioactive|O
DDI-MedLine.d66.s4|131-140|derivative|O
DDI-MedLine.d66.s4|142-143|of|O
DDI-MedLine.d66.s4|145-148|this|O
DDI-MedLine.d66.s4|150-159|particular|O
DDI-MedLine.d66.s4|161-181|sulphydryl-containing|O
DDI-MedLine.d66.s4|183-187|amino|O
DDI-MedLine.d66.s4|189-192|acid|O
DDI-MedLine.d66.s4|193-193|,|O
DDI-MedLine.d66.s4|195-197|and|O
DDI-MedLine.d66.s4|199-202|then|O
DDI-MedLine.d66.s4|204-212|analysing|O
DDI-MedLine.d66.s4|214-216|the|O
DDI-MedLine.d66.s4|218-226|resulting|O
DDI-MedLine.d66.s4|228-234|mixture|O
DDI-MedLine.d66.s4|236-237|by|O
DDI-MedLine.d66.s4|239-241|TLC|O
DDI-MedLine.d66.s4|242-242|.|O
DDI-DrugBank.d196.s0|0-8|Treatment|O
DDI-DrugBank.d196.s0|10-13|with|O
DDI-DrugBank.d196.s0|15-21|PEGASYS|brand
DDI-DrugBank.d196.s0|23-26|once|O
DDI-DrugBank.d196.s0|28-33|weekly|O
DDI-DrugBank.d196.s0|35-37|for|O
DDI-DrugBank.d196.s0|39-39|4|O
DDI-DrugBank.d196.s0|41-45|weeks|O
DDI-DrugBank.d196.s0|47-48|in|O
DDI-DrugBank.d196.s0|50-56|healthy|O
DDI-DrugBank.d196.s0|58-65|subjects|O
DDI-DrugBank.d196.s0|67-69|was|O
DDI-DrugBank.d196.s0|71-80|associated|O
DDI-DrugBank.d196.s0|82-85|with|O
DDI-DrugBank.d196.s0|87-88|an|O
DDI-DrugBank.d196.s0|90-99|inhibition|O
DDI-DrugBank.d196.s0|101-102|of|O
DDI-DrugBank.d196.s0|104-107|P450|O
DDI-DrugBank.d196.s0|109-111|1A2|O
DDI-DrugBank.d196.s0|113-115|and|O
DDI-DrugBank.d196.s0|117-117|a|O
DDI-DrugBank.d196.s0|119-120|25|O
DDI-DrugBank.d196.s0|121-121|%|O
DDI-DrugBank.d196.s0|123-130|increase|O
DDI-DrugBank.d196.s0|132-133|in|O
DDI-DrugBank.d196.s0|135-146|theophylline|drug
DDI-DrugBank.d196.s0|148-150|AUC|O
DDI-DrugBank.d196.s0|151-151|.|O
DDI-DrugBank.d196.s1|0-11|Theophylline|drug
DDI-DrugBank.d196.s1|13-17|serum|O
DDI-DrugBank.d196.s1|19-24|levels|O
DDI-DrugBank.d196.s1|26-31|should|O
DDI-DrugBank.d196.s1|33-34|be|O
DDI-DrugBank.d196.s1|36-44|monitored|O
DDI-DrugBank.d196.s1|46-48|and|O
DDI-DrugBank.d196.s1|50-60|appropriate|O
DDI-DrugBank.d196.s1|62-65|dose|O
DDI-DrugBank.d196.s1|67-77|adjustments|O
DDI-DrugBank.d196.s1|79-88|considered|O
DDI-DrugBank.d196.s1|90-92|for|O
DDI-DrugBank.d196.s1|94-101|patients|O
DDI-DrugBank.d196.s1|103-107|given|O
DDI-DrugBank.d196.s1|109-112|both|O
DDI-DrugBank.d196.s1|114-125|theophylline|drug
DDI-DrugBank.d196.s1|127-129|and|O
DDI-DrugBank.d196.s1|131-137|PEGASYS|brand
DDI-DrugBank.d196.s1|138-138|.|O
DDI-DrugBank.d196.s2|0-4|There|O
DDI-DrugBank.d196.s2|6-8|was|O
DDI-DrugBank.d196.s2|10-11|no|O
DDI-DrugBank.d196.s2|13-18|effect|O
DDI-DrugBank.d196.s2|20-21|on|O
DDI-DrugBank.d196.s2|23-25|the|O
DDI-DrugBank.d196.s2|27-42|pharmacokinetics|O
DDI-DrugBank.d196.s2|44-45|of|O
DDI-DrugBank.d196.s2|47-60|representative|O
DDI-DrugBank.d196.s2|62-66|drugs|O
DDI-DrugBank.d196.s2|68-78|metabolized|O
DDI-DrugBank.d196.s2|80-81|by|O
DDI-DrugBank.d196.s2|83-85|CYP|O
DDI-DrugBank.d196.s2|87-89|2C9|O
DDI-DrugBank.d196.s2|90-90|,|O
DDI-DrugBank.d196.s2|92-94|CYP|O
DDI-DrugBank.d196.s2|96-99|2C19|O
DDI-DrugBank.d196.s2|100-100|,|O
DDI-DrugBank.d196.s2|102-104|CYP|O
DDI-DrugBank.d196.s2|106-108|2D6|O
DDI-DrugBank.d196.s2|110-111|or|O
DDI-DrugBank.d196.s2|113-115|CYP|O
DDI-DrugBank.d196.s2|117-119|3A4|O
DDI-DrugBank.d196.s2|120-120|.|O
DDI-DrugBank.d196.s3|0-1|In|O
DDI-DrugBank.d196.s3|3-10|patients|O
DDI-DrugBank.d196.s3|12-15|with|O
DDI-DrugBank.d196.s3|17-23|chronic|O
DDI-DrugBank.d196.s3|25-33|hepatitis|O
DDI-DrugBank.d196.s3|35-35|C|O
DDI-DrugBank.d196.s3|37-43|treated|O
DDI-DrugBank.d196.s3|45-48|with|O
DDI-DrugBank.d196.s3|50-56|PEGASYS|brand
DDI-DrugBank.d196.s3|58-59|in|O
DDI-DrugBank.d196.s3|61-71|combination|O
DDI-DrugBank.d196.s3|73-76|with|O
DDI-DrugBank.d196.s3|78-84|COPEGUS|brand
DDI-DrugBank.d196.s3|85-85|,|O
DDI-DrugBank.d196.s3|87-93|PEGASYS|brand
DDI-DrugBank.d196.s3|95-103|treatment|O
DDI-DrugBank.d196.s3|105-107|did|O
DDI-DrugBank.d196.s3|109-111|not|O
DDI-DrugBank.d196.s3|113-118|affect|O
DDI-DrugBank.d196.s3|120-128|ribavirin|drug
DDI-DrugBank.d196.s3|130-141|distribution|O
DDI-DrugBank.d196.s3|143-144|or|O
DDI-DrugBank.d196.s3|146-154|clearance|O
DDI-DrugBank.d196.s3|155-155|.|O
DDI-DrugBank.d196.s4|0-9|Nucleoside|O
DDI-DrugBank.d196.s4|11-19|Analogues|O
DDI-DrugBank.d196.s4|21-30|Didanosine|drug
DDI-DrugBank.d196.s4|32-48|Co-administration|O
DDI-DrugBank.d196.s4|50-51|of|O
DDI-DrugBank.d196.s4|53-59|COPEGUS|brand
DDI-DrugBank.d196.s4|61-63|and|O
DDI-DrugBank.d196.s4|65-74|didanosine|drug
DDI-DrugBank.d196.s4|76-77|is|O
DDI-DrugBank.d196.s4|79-81|not|O
DDI-DrugBank.d196.s4|83-93|recommended|O
DDI-DrugBank.d196.s4|94-94|.|O
DDI-DrugBank.d196.s5|0-6|Reports|O
DDI-DrugBank.d196.s5|8-9|of|O
DDI-DrugBank.d196.s5|11-15|fatal|O
DDI-DrugBank.d196.s5|17-23|hepatic|O
DDI-DrugBank.d196.s5|25-31|failure|O
DDI-DrugBank.d196.s5|32-32|,|O
DDI-DrugBank.d196.s5|34-35|as|O
DDI-DrugBank.d196.s5|37-40|well|O
DDI-DrugBank.d196.s5|42-43|as|O
DDI-DrugBank.d196.s5|45-54|peripheral|O
DDI-DrugBank.d196.s5|56-65|neuropathy|O
DDI-DrugBank.d196.s5|66-66|,|O
DDI-DrugBank.d196.s5|68-79|pancreatitis|O
DDI-DrugBank.d196.s5|80-80|,|O
DDI-DrugBank.d196.s5|82-84|and|O
DDI-DrugBank.d196.s5|86-96|symptomatic|O
DDI-DrugBank.d196.s5|98-119|hyperlactatemia/lactic|O
DDI-DrugBank.d196.s5|121-128|acidosis|O
DDI-DrugBank.d196.s5|130-133|have|O
DDI-DrugBank.d196.s5|135-138|been|O
DDI-DrugBank.d196.s5|140-147|reported|O
DDI-DrugBank.d196.s5|149-150|in|O
DDI-DrugBank.d196.s5|152-159|clinical|O
DDI-DrugBank.d196.s5|161-166|trials|O
DDI-DrugBank.d196.s5|167-167|.|O
DDI-DrugBank.d196.s6|0-8|Stavudine|drug
DDI-DrugBank.d196.s6|10-12|and|O
DDI-DrugBank.d196.s6|14-23|Zidovudine|drug
DDI-DrugBank.d196.s6|14-23|Zidovudine|drug
DDI-DrugBank.d196.s6|35-37|can|O
DDI-DrugBank.d196.s6|39-48|antagonize|O
DDI-DrugBank.d196.s6|50-52|the|O
DDI-DrugBank.d196.s6|54-55|in|O
DDI-DrugBank.d196.s6|57-61|vitro|O
DDI-DrugBank.d196.s6|63-71|antiviral|O
DDI-DrugBank.d196.s6|73-80|activity|O
DDI-DrugBank.d196.s6|82-83|of|O
DDI-DrugBank.d196.s6|85-93|stavudine|drug
DDI-DrugBank.d196.s6|95-97|and|O
DDI-DrugBank.d196.s6|99-108|zidovudine|drug
DDI-DrugBank.d196.s6|110-116|against|O
DDI-DrugBank.d196.s6|118-120|HIV|O
DDI-DrugBank.d196.s6|121-121|.|O
DDI-DrugBank.d196.s7|0-8|Therefore|O
DDI-DrugBank.d196.s7|9-9|,|O
DDI-DrugBank.d196.s7|11-21|concomitant|O
DDI-DrugBank.d196.s7|23-25|use|O
DDI-DrugBank.d196.s7|27-28|of|O
DDI-DrugBank.d196.s7|30-38|ribavirin|drug
DDI-DrugBank.d196.s7|40-43|with|O
DDI-DrugBank.d196.s7|45-50|either|O
DDI-DrugBank.d196.s7|52-53|of|O
DDI-DrugBank.d196.s7|55-59|these|O
DDI-DrugBank.d196.s7|61-65|drugs|O
DDI-DrugBank.d196.s7|67-72|should|O
DDI-DrugBank.d196.s7|74-75|be|O
DDI-DrugBank.d196.s7|77-83|avoided|O
DDI-DrugBank.d196.s7|84-84|.|O
DDI-DrugBank.d196.s8|0-13|Carcinogenesis|O
DDI-DrugBank.d196.s8|14-14|,|O
DDI-DrugBank.d196.s8|16-26|Mutagenesis|O
DDI-DrugBank.d196.s8|27-27|,|O
DDI-DrugBank.d196.s8|29-38|Impairment|O
DDI-DrugBank.d196.s8|40-41|of|O
DDI-DrugBank.d196.s8|43-51|Fertility|O
DDI-DrugBank.d196.s8|53-66|Carcinogenesis|O
DDI-DrugBank.d196.s8|68-74|PEGASYS|brand
DDI-DrugBank.d196.s8|76-78|has|O
DDI-DrugBank.d196.s8|80-82|not|O
DDI-DrugBank.d196.s8|84-87|been|O
DDI-DrugBank.d196.s8|89-94|tested|O
DDI-DrugBank.d196.s8|96-98|for|O
DDI-DrugBank.d196.s8|100-102|its|O
DDI-DrugBank.d196.s8|104-115|carcinogenic|O
DDI-DrugBank.d196.s8|117-125|potential|O
DDI-DrugBank.d196.s8|126-126|.|O
DDI-DrugBank.d196.s9|0-10|Mutagenesis|O
DDI-DrugBank.d196.s9|12-18|PEGASYS|brand
DDI-DrugBank.d196.s9|20-22|did|O
DDI-DrugBank.d196.s9|24-26|not|O
DDI-DrugBank.d196.s9|28-32|cause|O
DDI-DrugBank.d196.s9|34-36|DNA|O
DDI-DrugBank.d196.s9|38-43|damage|O
DDI-DrugBank.d196.s9|45-48|when|O
DDI-DrugBank.d196.s9|50-55|tested|O
DDI-DrugBank.d196.s9|57-58|in|O
DDI-DrugBank.d196.s9|60-62|the|O
DDI-DrugBank.d196.s9|64-67|Ames|O
DDI-DrugBank.d196.s9|69-77|bacterial|O
DDI-DrugBank.d196.s9|79-90|mutagenicity|O
DDI-DrugBank.d196.s9|92-96|assay|O
DDI-DrugBank.d196.s9|98-100|and|O
DDI-DrugBank.d196.s9|102-103|in|O
DDI-DrugBank.d196.s9|105-107|the|O
DDI-DrugBank.d196.s9|109-110|in|O
DDI-DrugBank.d196.s9|112-116|vitro|O
DDI-DrugBank.d196.s9|118-128|chromosomal|O
DDI-DrugBank.d196.s9|130-139|aberration|O
DDI-DrugBank.d196.s9|141-145|assay|O
DDI-DrugBank.d196.s9|147-148|in|O
DDI-DrugBank.d196.s9|150-154|human|O
DDI-DrugBank.d196.s9|156-166|lymphocytes|O
DDI-DrugBank.d196.s9|167-167|,|O
DDI-DrugBank.d196.s9|169-174|either|O
DDI-DrugBank.d196.s9|176-177|in|O
DDI-DrugBank.d196.s9|179-181|the|O
DDI-DrugBank.d196.s9|183-190|presence|O
DDI-DrugBank.d196.s9|192-193|or|O
DDI-DrugBank.d196.s9|195-201|absence|O
DDI-DrugBank.d196.s9|203-204|of|O
DDI-DrugBank.d196.s9|206-214|metabolic|O
DDI-DrugBank.d196.s9|216-225|activation|O
DDI-DrugBank.d196.s9|226-226|.|O
DDI-DrugBank.d196.s10|0-2|Use|O
DDI-DrugBank.d196.s10|4-7|With|O
DDI-DrugBank.d196.s10|9-17|Ribavirin|drug
DDI-DrugBank.d196.s10|9-17|Ribavirin|drug
DDI-DrugBank.d196.s10|29-30|is|O
DDI-DrugBank.d196.s10|32-40|genotoxic|O
DDI-DrugBank.d196.s10|42-44|and|O
DDI-DrugBank.d196.s10|46-54|mutagenic|O
DDI-DrugBank.d196.s10|55-55|.|O
DDI-DrugBank.d196.s11|0-2|The|O
DDI-DrugBank.d196.s11|4-15|carcinogenic|O
DDI-DrugBank.d196.s11|17-25|potential|O
DDI-DrugBank.d196.s11|27-28|of|O
DDI-DrugBank.d196.s11|30-38|ribavirin|drug
DDI-DrugBank.d196.s11|40-42|has|O
DDI-DrugBank.d196.s11|44-46|not|O
DDI-DrugBank.d196.s11|48-51|been|O
DDI-DrugBank.d196.s11|53-57|fully|O
DDI-DrugBank.d196.s11|59-68|determined|O
DDI-DrugBank.d196.s11|69-69|.|O
DDI-DrugBank.d196.s12|0-1|In|O
DDI-DrugBank.d196.s12|3-3|a|O
DDI-DrugBank.d196.s12|5-7|p53|O
DDI-DrugBank.d196.s12|9-9|(|O
DDI-DrugBank.d196.s12|10-12|+/-|O
DDI-DrugBank.d196.s12|13-13|)|O
DDI-DrugBank.d196.s12|15-19|mouse|O
DDI-DrugBank.d196.s12|21-35|carcinogenicity|O
DDI-DrugBank.d196.s12|37-41|study|O
DDI-DrugBank.d196.s12|43-44|at|O
DDI-DrugBank.d196.s12|46-50|doses|O
DDI-DrugBank.d196.s12|52-53|up|O
DDI-DrugBank.d196.s12|55-56|to|O
DDI-DrugBank.d196.s12|58-60|the|O
DDI-DrugBank.d196.s12|62-68|maximum|O
DDI-DrugBank.d196.s12|70-78|tolerated|O
DDI-DrugBank.d196.s12|80-83|dose|O
DDI-DrugBank.d196.s12|85-86|of|O
DDI-DrugBank.d196.s12|88-90|100|O
DDI-DrugBank.d196.s12|92-100|mg/kg/day|O
DDI-DrugBank.d196.s12|102-110|ribavirin|drug
DDI-DrugBank.d196.s12|112-114|was|O
DDI-DrugBank.d196.s12|116-118|not|O
DDI-DrugBank.d196.s12|120-128|oncogenic|O
DDI-DrugBank.d196.s12|129-129|.|O
DDI-DrugBank.d196.s13|0-6|However|O
DDI-DrugBank.d196.s13|7-7|,|O
DDI-DrugBank.d196.s13|9-10|on|O
DDI-DrugBank.d196.s13|12-12|a|O
DDI-DrugBank.d196.s13|14-17|body|O
DDI-DrugBank.d196.s13|19-25|surface|O
DDI-DrugBank.d196.s13|27-30|area|O
DDI-DrugBank.d196.s13|32-36|basis|O
DDI-DrugBank.d196.s13|37-37|,|O
DDI-DrugBank.d196.s13|39-42|this|O
DDI-DrugBank.d196.s13|44-47|dose|O
DDI-DrugBank.d196.s13|49-51|was|O
DDI-DrugBank.d196.s13|53-55|0.5|O
DDI-DrugBank.d196.s13|57-61|times|O
DDI-DrugBank.d196.s13|63-69|maximum|O
DDI-DrugBank.d196.s13|71-81|recommended|O
DDI-DrugBank.d196.s13|83-87|human|O
DDI-DrugBank.d196.s13|89-95|24-hour|O
DDI-DrugBank.d196.s13|97-100|dose|O
DDI-DrugBank.d196.s13|102-103|of|O
DDI-DrugBank.d196.s13|105-113|ribavirin|drug
DDI-DrugBank.d196.s13|114-114|.|O
DDI-DrugBank.d196.s14|0-0|A|O
DDI-DrugBank.d196.s14|2-6|study|O
DDI-DrugBank.d196.s14|8-9|in|O
DDI-DrugBank.d196.s14|11-14|rats|O
DDI-DrugBank.d196.s14|16-17|to|O
DDI-DrugBank.d196.s14|19-24|assess|O
DDI-DrugBank.d196.s14|26-28|the|O
DDI-DrugBank.d196.s14|30-41|carcinogenic|O
DDI-DrugBank.d196.s14|43-51|potential|O
DDI-DrugBank.d196.s14|53-54|of|O
DDI-DrugBank.d196.s14|56-64|ribavirin|drug
DDI-DrugBank.d196.s14|66-67|is|O
DDI-DrugBank.d196.s14|69-75|ongoing|O
DDI-DrugBank.d196.s14|76-76|.|O
DDI-DrugBank.d196.s15|0-10|Mutagenesis|O
DDI-DrugBank.d196.s15|12-21|Impairment|O
DDI-DrugBank.d196.s15|23-24|of|O
DDI-DrugBank.d196.s15|26-34|Fertility|O
DDI-DrugBank.d196.s15|36-42|PEGASYS|brand
DDI-DrugBank.d196.s15|44-46|may|O
DDI-DrugBank.d196.s15|48-53|impair|O
DDI-DrugBank.d196.s15|55-63|fertility|O
DDI-DrugBank.d196.s15|65-66|in|O
DDI-DrugBank.d196.s15|68-72|women|O
DDI-DrugBank.d196.s15|73-73|.|O
DDI-DrugBank.d196.s16|0-8|Prolonged|O
DDI-DrugBank.d196.s16|10-18|menstrual|O
DDI-DrugBank.d196.s16|20-25|cycles|O
DDI-DrugBank.d196.s16|27-32|and/or|O
DDI-DrugBank.d196.s16|34-43|amenorrhea|O
DDI-DrugBank.d196.s16|45-48|were|O
DDI-DrugBank.d196.s16|50-57|observed|O
DDI-DrugBank.d196.s16|59-60|in|O
DDI-DrugBank.d196.s16|62-67|female|O
DDI-DrugBank.d196.s16|69-78|cynomolgus|O
DDI-DrugBank.d196.s16|80-86|monkeys|O
DDI-DrugBank.d196.s16|88-92|given|O
DDI-DrugBank.d196.s16|94-95|sc|O
DDI-DrugBank.d196.s16|97-106|injections|O
DDI-DrugBank.d196.s16|108-109|of|O
DDI-DrugBank.d196.s16|111-113|600|O
DDI-DrugBank.d196.s16|115-115|m|O
DDI-DrugBank.d196.s16|117-125|g/kg/dose|O
DDI-DrugBank.d196.s16|127-127|(|O
DDI-DrugBank.d196.s16|128-131|7200|O
DDI-DrugBank.d196.s16|133-133|m|O
DDI-DrugBank.d196.s16|135-143|g/m2/dose|O
DDI-DrugBank.d196.s16|144-144|)|O
DDI-DrugBank.d196.s16|146-147|of|O
DDI-DrugBank.d196.s16|149-155|PEGASYS|brand
DDI-DrugBank.d196.s16|157-161|every|O
DDI-DrugBank.d196.s16|163-167|other|O
DDI-DrugBank.d196.s16|169-171|day|O
DDI-DrugBank.d196.s16|173-175|for|O
DDI-DrugBank.d196.s16|177-179|one|O
DDI-DrugBank.d196.s16|181-185|month|O
DDI-DrugBank.d196.s16|186-186|,|O
DDI-DrugBank.d196.s16|188-189|at|O
DDI-DrugBank.d196.s16|191-203|approximately|O
DDI-DrugBank.d196.s16|205-207|180|O
DDI-DrugBank.d196.s16|209-213|times|O
DDI-DrugBank.d196.s16|215-217|the|O
DDI-DrugBank.d196.s16|219-229|recommended|O
DDI-DrugBank.d196.s16|231-236|weekly|O
DDI-DrugBank.d196.s16|238-242|human|O
DDI-DrugBank.d196.s16|244-247|dose|O
DDI-DrugBank.d196.s16|249-251|for|O
DDI-DrugBank.d196.s16|253-253|a|O
DDI-DrugBank.d196.s16|255-256|60|O
DDI-DrugBank.d196.s16|258-259|kg|O
DDI-DrugBank.d196.s16|261-266|person|O
DDI-DrugBank.d196.s16|268-268|(|O
DDI-DrugBank.d196.s16|269-273|based|O
DDI-DrugBank.d196.s16|275-276|on|O
DDI-DrugBank.d196.s16|278-281|body|O
DDI-DrugBank.d196.s16|283-289|surface|O
DDI-DrugBank.d196.s16|291-294|area|O
DDI-DrugBank.d196.s16|295-295|)|O
DDI-DrugBank.d196.s16|296-296|.|O
DDI-DrugBank.d196.s17|0-8|Menstrual|O
DDI-DrugBank.d196.s17|10-14|cycle|O
DDI-DrugBank.d196.s17|16-29|irregularities|O
DDI-DrugBank.d196.s17|31-34|were|O
DDI-DrugBank.d196.s17|36-46|accompanied|O
DDI-DrugBank.d196.s17|48-49|by|O
DDI-DrugBank.d196.s17|51-54|both|O
DDI-DrugBank.d196.s17|56-56|a|O
DDI-DrugBank.d196.s17|58-65|decrease|O
DDI-DrugBank.d196.s17|67-69|and|O
DDI-DrugBank.d196.s17|71-75|delay|O
DDI-DrugBank.d196.s17|77-78|in|O
DDI-DrugBank.d196.s17|80-82|the|O
DDI-DrugBank.d196.s17|84-87|peak|O
DDI-DrugBank.d196.s17|89-91|17b|O
DDI-DrugBank.d196.s17|93-102|-estradiol|O
DDI-DrugBank.d196.s17|104-106|and|O
DDI-DrugBank.d196.s17|108-119|progesterone|O
DDI-DrugBank.d196.s17|121-126|levels|O
DDI-DrugBank.d196.s17|128-136|following|O
DDI-DrugBank.d196.s17|138-151|administration|O
DDI-DrugBank.d196.s17|153-154|of|O
DDI-DrugBank.d196.s17|156-162|PEGASYS|brand
DDI-DrugBank.d196.s17|164-165|to|O
DDI-DrugBank.d196.s17|167-172|female|O
DDI-DrugBank.d196.s17|174-180|monkeys|O
DDI-DrugBank.d196.s17|181-181|.|O
DDI-DrugBank.d196.s18|0-0|A|O
DDI-DrugBank.d196.s18|2-7|return|O
DDI-DrugBank.d196.s18|9-10|to|O
DDI-DrugBank.d196.s18|12-17|normal|O
DDI-DrugBank.d196.s18|19-27|menstrual|O
DDI-DrugBank.d196.s18|29-34|rhythm|O
DDI-DrugBank.d196.s18|36-43|followed|O
DDI-DrugBank.d196.s18|45-53|cessation|O
DDI-DrugBank.d196.s18|55-56|of|O
DDI-DrugBank.d196.s18|58-66|treatment|O
DDI-DrugBank.d196.s18|67-67|.|O
DDI-DrugBank.d196.s19|0-4|Every|O
DDI-DrugBank.d196.s19|6-10|other|O
DDI-DrugBank.d196.s19|12-14|day|O
DDI-DrugBank.d196.s19|16-21|dosing|O
DDI-DrugBank.d196.s19|23-26|with|O
DDI-DrugBank.d196.s19|28-31|100m|O
DDI-DrugBank.d196.s19|33-36|g/kg|O
DDI-DrugBank.d196.s19|38-38|(|O
DDI-DrugBank.d196.s19|39-43|1200m|O
DDI-DrugBank.d196.s19|45-48|g/m2|O
DDI-DrugBank.d196.s19|49-49|)|O
DDI-DrugBank.d196.s19|51-57|PEGASYS|brand
DDI-DrugBank.d196.s19|59-59|(|O
DDI-DrugBank.d196.s19|60-69|equivalent|O
DDI-DrugBank.d196.s19|71-72|to|O
DDI-DrugBank.d196.s19|74-86|approximately|O
DDI-DrugBank.d196.s19|88-89|30|O
DDI-DrugBank.d196.s19|91-95|times|O
DDI-DrugBank.d196.s19|97-99|the|O
DDI-DrugBank.d196.s19|101-111|recommended|O
DDI-DrugBank.d196.s19|113-117|human|O
DDI-DrugBank.d196.s19|119-122|dose|O
DDI-DrugBank.d196.s19|123-123|)|O
DDI-DrugBank.d196.s19|125-127|had|O
DDI-DrugBank.d196.s19|129-130|no|O
DDI-DrugBank.d196.s19|132-138|effects|O
DDI-DrugBank.d196.s19|140-141|on|O
DDI-DrugBank.d196.s19|143-147|cycle|O
DDI-DrugBank.d196.s19|149-156|duration|O
DDI-DrugBank.d196.s19|158-159|or|O
DDI-DrugBank.d196.s19|161-172|reproductive|O
DDI-DrugBank.d196.s19|174-180|hormone|O
DDI-DrugBank.d196.s19|182-187|status|O
DDI-DrugBank.d196.s19|188-188|.|O
DDI-DrugBank.d196.s20|0-2|The|O
DDI-DrugBank.d196.s20|4-10|effects|O
DDI-DrugBank.d196.s20|12-13|of|O
DDI-DrugBank.d196.s20|15-21|PEGASYS|brand
DDI-DrugBank.d196.s20|23-24|on|O
DDI-DrugBank.d196.s20|26-29|male|O
DDI-DrugBank.d196.s20|31-39|fertility|O
DDI-DrugBank.d196.s20|41-44|have|O
DDI-DrugBank.d196.s20|46-48|not|O
DDI-DrugBank.d196.s20|50-53|been|O
DDI-DrugBank.d196.s20|55-61|studied|O
DDI-DrugBank.d196.s20|62-62|.|O
DDI-DrugBank.d196.s21|0-6|However|O
DDI-DrugBank.d196.s21|7-7|,|O
DDI-DrugBank.d196.s21|9-10|no|O
DDI-DrugBank.d196.s21|12-18|adverse|O
DDI-DrugBank.d196.s21|20-26|effects|O
DDI-DrugBank.d196.s21|28-29|on|O
DDI-DrugBank.d196.s21|31-39|fertility|O
DDI-DrugBank.d196.s21|41-44|were|O
DDI-DrugBank.d196.s21|46-53|observed|O
DDI-DrugBank.d196.s21|55-56|in|O
DDI-DrugBank.d196.s21|58-61|male|O
DDI-DrugBank.d196.s21|63-68|Rhesus|O
DDI-DrugBank.d196.s21|70-76|monkeys|O
DDI-DrugBank.d196.s21|78-84|treated|O
DDI-DrugBank.d196.s21|86-89|with|O
DDI-DrugBank.d196.s21|91-103|non-pegylated|O
DDI-DrugBank.d196.s21|105-122|interferon alfa-2a|drug
DDI-DrugBank.d196.s21|124-126|for|O
DDI-DrugBank.d196.s21|128-128|5|O
DDI-DrugBank.d196.s21|130-135|months|O
DDI-DrugBank.d196.s21|137-138|at|O
DDI-DrugBank.d196.s21|140-144|doses|O
DDI-DrugBank.d196.s21|146-147|up|O
DDI-DrugBank.d196.s21|149-150|to|O
DDI-DrugBank.d196.s21|152-153|25|O
DDI-DrugBank.d196.s21|155-155|x|O
DDI-DrugBank.d196.s21|157-159|106|O
DDI-DrugBank.d196.s21|161-169|IU/kg/day|O
DDI-DrugBank.d196.s21|170-170|.|O
DDI-DrugBank.d196.s22|0-8|Pregnancy|O
DDI-DrugBank.d196.s22|10-18|Pregnancy|O
DDI-DrugBank.d196.s22|19-19|:|O
DDI-DrugBank.d196.s22|21-28|Category|O
DDI-DrugBank.d196.s22|30-30|C|O
DDI-DrugBank.d196.s22|32-38|PEGASYS|brand
DDI-DrugBank.d196.s22|40-42|has|O
DDI-DrugBank.d196.s22|44-46|not|O
DDI-DrugBank.d196.s22|48-51|been|O
DDI-DrugBank.d196.s22|53-59|studied|O
DDI-DrugBank.d196.s22|61-63|for|O
DDI-DrugBank.d196.s22|65-67|its|O
DDI-DrugBank.d196.s22|69-79|teratogenic|O
DDI-DrugBank.d196.s22|81-86|effect|O
DDI-DrugBank.d196.s22|87-87|.|O
DDI-DrugBank.d196.s23|0-31|Non-pegylated interferon alfa-2a|drug
DDI-DrugBank.d196.s23|33-41|treatment|O
DDI-DrugBank.d196.s23|43-44|of|O
DDI-DrugBank.d196.s23|46-53|pregnant|O
DDI-DrugBank.d196.s23|55-60|Rhesus|O
DDI-DrugBank.d196.s23|62-68|monkeys|O
DDI-DrugBank.d196.s23|70-71|at|O
DDI-DrugBank.d196.s23|73-85|approximately|O
DDI-DrugBank.d196.s23|87-88|20|O
DDI-DrugBank.d196.s23|90-91|to|O
DDI-DrugBank.d196.s23|93-95|500|O
DDI-DrugBank.d196.s23|97-101|times|O
DDI-DrugBank.d196.s23|103-105|the|O
DDI-DrugBank.d196.s23|107-111|human|O
DDI-DrugBank.d196.s23|113-118|weekly|O
DDI-DrugBank.d196.s23|120-123|dose|O
DDI-DrugBank.d196.s23|125-132|resulted|O
DDI-DrugBank.d196.s23|134-135|in|O
DDI-DrugBank.d196.s23|137-137|a|O
DDI-DrugBank.d196.s23|139-151|statistically|O
DDI-DrugBank.d196.s23|153-163|significant|O
DDI-DrugBank.d196.s23|165-172|increase|O
DDI-DrugBank.d196.s23|174-175|in|O
DDI-DrugBank.d196.s23|177-185|abortions|O
DDI-DrugBank.d196.s23|186-186|.|O
DDI-DrugBank.d196.s24|0-1|No|O
DDI-DrugBank.d196.s24|3-13|teratogenic|O
DDI-DrugBank.d196.s24|15-21|effects|O
DDI-DrugBank.d196.s24|23-26|were|O
DDI-DrugBank.d196.s24|28-31|seen|O
DDI-DrugBank.d196.s24|33-34|in|O
DDI-DrugBank.d196.s24|36-38|the|O
DDI-DrugBank.d196.s24|40-48|offspring|O
DDI-DrugBank.d196.s24|50-58|delivered|O
DDI-DrugBank.d196.s24|60-61|at|O
DDI-DrugBank.d196.s24|63-66|term|O
DDI-DrugBank.d196.s24|67-67|.|O
DDI-DrugBank.d196.s25|0-6|PEGASYS|brand
DDI-DrugBank.d196.s25|8-13|should|O
DDI-DrugBank.d196.s25|15-16|be|O
DDI-DrugBank.d196.s25|18-24|assumed|O
DDI-DrugBank.d196.s25|26-27|to|O
DDI-DrugBank.d196.s25|29-32|have|O
DDI-DrugBank.d196.s25|34-46|abortifacient|O
DDI-DrugBank.d196.s25|48-56|potential|O
DDI-DrugBank.d196.s25|57-57|.|O
DDI-DrugBank.d196.s26|0-4|There|O
DDI-DrugBank.d196.s26|6-8|are|O
DDI-DrugBank.d196.s26|10-11|no|O
DDI-DrugBank.d196.s26|13-20|adequate|O
DDI-DrugBank.d196.s26|22-24|and|O
DDI-DrugBank.d196.s26|26-40|well-controlled|O
DDI-DrugBank.d196.s26|42-48|studies|O
DDI-DrugBank.d196.s26|50-51|of|O
DDI-DrugBank.d196.s26|53-59|PEGASYS|brand
DDI-DrugBank.d196.s26|61-62|in|O
DDI-DrugBank.d196.s26|64-71|pregnant|O
DDI-DrugBank.d196.s26|73-77|women|O
DDI-DrugBank.d196.s26|78-78|.|O
DDI-DrugBank.d196.s27|0-6|PEGASYS|brand
DDI-DrugBank.d196.s27|8-9|is|O
DDI-DrugBank.d196.s27|11-12|to|O
DDI-DrugBank.d196.s27|14-15|be|O
DDI-DrugBank.d196.s27|17-20|used|O
DDI-DrugBank.d196.s27|22-27|during|O
DDI-DrugBank.d196.s27|29-37|pregnancy|O
DDI-DrugBank.d196.s27|39-42|only|O
DDI-DrugBank.d196.s27|44-45|if|O
DDI-DrugBank.d196.s27|47-49|the|O
DDI-DrugBank.d196.s27|51-59|potential|O
DDI-DrugBank.d196.s27|61-67|benefit|O
DDI-DrugBank.d196.s27|69-77|justifies|O
DDI-DrugBank.d196.s27|79-81|the|O
DDI-DrugBank.d196.s27|83-91|potential|O
DDI-DrugBank.d196.s27|93-96|risk|O
DDI-DrugBank.d196.s27|98-99|to|O
DDI-DrugBank.d196.s27|101-103|the|O
DDI-DrugBank.d196.s27|105-109|fetus|O
DDI-DrugBank.d196.s27|110-110|.|O
DDI-DrugBank.d196.s28|0-6|PEGASYS|brand
DDI-DrugBank.d196.s28|8-9|is|O
DDI-DrugBank.d196.s28|11-21|recommended|O
DDI-DrugBank.d196.s28|23-25|for|O
DDI-DrugBank.d196.s28|27-29|use|O
DDI-DrugBank.d196.s28|31-32|in|O
DDI-DrugBank.d196.s28|34-38|women|O
DDI-DrugBank.d196.s28|40-41|of|O
DDI-DrugBank.d196.s28|43-54|childbearing|O
DDI-DrugBank.d196.s28|56-64|potential|O
DDI-DrugBank.d196.s28|66-69|only|O
DDI-DrugBank.d196.s28|71-74|when|O
DDI-DrugBank.d196.s28|76-79|they|O
DDI-DrugBank.d196.s28|81-83|are|O
DDI-DrugBank.d196.s28|85-89|using|O
DDI-DrugBank.d196.s28|91-99|effective|O
DDI-DrugBank.d196.s28|101-113|contraception|O
DDI-DrugBank.d196.s28|115-120|during|O
DDI-DrugBank.d196.s28|122-128|therapy|O
DDI-DrugBank.d196.s28|129-129|.|O
DDI-DrugBank.d196.s29|0-8|Pregnancy|O
DDI-DrugBank.d196.s29|9-9|:|O
DDI-DrugBank.d196.s29|11-18|Category|O
DDI-DrugBank.d196.s29|20-20|X|O
DDI-DrugBank.d196.s29|21-21|:|O
DDI-DrugBank.d196.s29|23-25|Use|O
DDI-DrugBank.d196.s29|27-30|With|O
DDI-DrugBank.d196.s29|32-40|Ribavirin|drug
DDI-DrugBank.d196.s29|42-42|(|O
DDI-DrugBank.d196.s29|43-45|see|O
DDI-DrugBank.d196.s29|47-63|CONTRAINDICATIONS|O
DDI-DrugBank.d196.s29|64-64|)|O
DDI-DrugBank.d196.s29|66-76|Significant|O
DDI-DrugBank.d196.s29|78-88|teratogenic|O
DDI-DrugBank.d196.s29|90-95|and/or|O
DDI-DrugBank.d196.s29|97-107|embryocidal|O
DDI-DrugBank.d196.s29|109-115|effects|O
DDI-DrugBank.d196.s29|117-120|have|O
DDI-DrugBank.d196.s29|122-125|been|O
DDI-DrugBank.d196.s29|127-138|demonstrated|O
DDI-DrugBank.d196.s29|140-141|in|O
DDI-DrugBank.d196.s29|143-145|all|O
DDI-DrugBank.d196.s29|147-152|animal|O
DDI-DrugBank.d196.s29|154-160|species|O
DDI-DrugBank.d196.s29|162-168|exposed|O
DDI-DrugBank.d196.s29|170-171|to|O
DDI-DrugBank.d196.s29|173-181|ribavirin|drug
DDI-DrugBank.d196.s29|182-182|.|O
DDI-DrugBank.d196.s30|0-6|COPEGUS|brand
DDI-DrugBank.d196.s30|8-14|therapy|O
DDI-DrugBank.d196.s30|16-17|is|O
DDI-DrugBank.d196.s30|19-33|contraindicated|O
DDI-DrugBank.d196.s30|35-36|in|O
DDI-DrugBank.d196.s30|38-42|women|O
DDI-DrugBank.d196.s30|44-46|who|O
DDI-DrugBank.d196.s30|48-50|are|O
DDI-DrugBank.d196.s30|52-59|pregnant|O
DDI-DrugBank.d196.s30|61-63|and|O
DDI-DrugBank.d196.s30|65-66|in|O
DDI-DrugBank.d196.s30|68-70|the|O
DDI-DrugBank.d196.s30|72-75|male|O
DDI-DrugBank.d196.s30|77-84|partners|O
DDI-DrugBank.d196.s30|86-87|of|O
DDI-DrugBank.d196.s30|89-93|women|O
DDI-DrugBank.d196.s30|95-97|who|O
DDI-DrugBank.d196.s30|99-101|are|O
DDI-DrugBank.d196.s30|103-110|pregnant|O
DDI-DrugBank.d196.s30|112-112|.|O
DDI-DrugBank.d196.s31|0-1|If|O
DDI-DrugBank.d196.s31|3-11|pregnancy|O
DDI-DrugBank.d196.s31|13-18|occurs|O
DDI-DrugBank.d196.s31|20-21|in|O
DDI-DrugBank.d196.s31|23-23|a|O
DDI-DrugBank.d196.s31|25-31|patient|O
DDI-DrugBank.d196.s31|33-34|or|O
DDI-DrugBank.d196.s31|36-42|partner|O
DDI-DrugBank.d196.s31|44-45|of|O
DDI-DrugBank.d196.s31|47-47|a|O
DDI-DrugBank.d196.s31|49-55|patient|O
DDI-DrugBank.d196.s31|57-62|during|O
DDI-DrugBank.d196.s31|64-72|treatment|O
DDI-DrugBank.d196.s31|74-75|or|O
DDI-DrugBank.d196.s31|77-82|during|O
DDI-DrugBank.d196.s31|84-86|the|O
DDI-DrugBank.d196.s31|88-88|6|O
DDI-DrugBank.d196.s31|90-95|months|O
DDI-DrugBank.d196.s31|97-101|after|O
DDI-DrugBank.d196.s31|103-111|treatment|O
DDI-DrugBank.d196.s31|113-121|cessation|O
DDI-DrugBank.d196.s31|122-122|,|O
DDI-DrugBank.d196.s31|124-127|such|O
DDI-DrugBank.d196.s31|129-133|cases|O
DDI-DrugBank.d196.s31|135-140|should|O
DDI-DrugBank.d196.s31|142-143|be|O
DDI-DrugBank.d196.s31|145-152|reported|O
DDI-DrugBank.d196.s31|154-155|to|O
DDI-DrugBank.d196.s31|157-159|the|O
DDI-DrugBank.d196.s31|161-167|COPEGUS|brand
DDI-DrugBank.d196.s31|169-177|Pregnancy|O
DDI-DrugBank.d196.s31|179-186|Registry|O
DDI-DrugBank.d196.s31|188-189|at|O
DDI-DrugBank.d196.s31|191-204|1-800-526-6367|O
DDI-DrugBank.d196.s31|205-205|.|O
DDI-DrugBank.d196.s32|0-6|Nursing|O
DDI-DrugBank.d196.s32|8-14|Mothers|O
DDI-DrugBank.d196.s32|16-17|It|O
DDI-DrugBank.d196.s32|19-20|is|O
DDI-DrugBank.d196.s32|22-24|not|O
DDI-DrugBank.d196.s32|26-30|known|O
DDI-DrugBank.d196.s32|32-38|whether|O
DDI-DrugBank.d196.s32|40-52|peginterferon|drug
DDI-DrugBank.d196.s32|54-55|or|O
DDI-DrugBank.d196.s32|57-65|ribavirin|drug
DDI-DrugBank.d196.s32|67-68|or|O
DDI-DrugBank.d196.s32|70-72|its|O
DDI-DrugBank.d196.s32|74-83|components|O
DDI-DrugBank.d196.s32|85-87|are|O
DDI-DrugBank.d196.s32|89-96|excreted|O
DDI-DrugBank.d196.s32|98-99|in|O
DDI-DrugBank.d196.s32|101-105|human|O
DDI-DrugBank.d196.s32|107-110|milk|O
DDI-DrugBank.d196.s32|111-111|.|O
DDI-DrugBank.d196.s33|0-2|The|O
DDI-DrugBank.d196.s33|4-9|effect|O
DDI-DrugBank.d196.s33|11-12|of|O
DDI-DrugBank.d196.s33|14-19|orally|O
DDI-DrugBank.d196.s33|21-28|ingested|O
DDI-DrugBank.d196.s33|30-42|peginterferon|drug
DDI-DrugBank.d196.s33|44-45|or|O
DDI-DrugBank.d196.s33|47-55|ribavirin|drug
DDI-DrugBank.d196.s33|57-60|from|O
DDI-DrugBank.d196.s33|62-67|breast|O
DDI-DrugBank.d196.s33|69-72|milk|O
DDI-DrugBank.d196.s33|74-75|on|O
DDI-DrugBank.d196.s33|77-79|the|O
DDI-DrugBank.d196.s33|81-87|nursing|O
DDI-DrugBank.d196.s33|89-94|infant|O
DDI-DrugBank.d196.s33|96-98|has|O
DDI-DrugBank.d196.s33|100-102|not|O
DDI-DrugBank.d196.s33|104-107|been|O
DDI-DrugBank.d196.s33|109-117|evaluated|O
DDI-DrugBank.d196.s33|118-118|.|O
DDI-DrugBank.d196.s34|0-6|Because|O
DDI-DrugBank.d196.s34|8-9|of|O
DDI-DrugBank.d196.s34|11-13|the|O
DDI-DrugBank.d196.s34|15-23|potential|O
DDI-DrugBank.d196.s34|25-27|for|O
DDI-DrugBank.d196.s34|29-35|adverse|O
DDI-DrugBank.d196.s34|37-45|reactions|O
DDI-DrugBank.d196.s34|47-50|from|O
DDI-DrugBank.d196.s34|52-54|the|O
DDI-DrugBank.d196.s34|56-60|drugs|O
DDI-DrugBank.d196.s34|62-63|in|O
DDI-DrugBank.d196.s34|65-71|nursing|O
DDI-DrugBank.d196.s34|73-79|infants|O
DDI-DrugBank.d196.s34|80-80|,|O
DDI-DrugBank.d196.s34|82-82|a|O
DDI-DrugBank.d196.s34|84-91|decision|O
DDI-DrugBank.d196.s34|93-96|must|O
DDI-DrugBank.d196.s34|98-99|be|O
DDI-DrugBank.d196.s34|101-104|made|O
DDI-DrugBank.d196.s34|106-112|whether|O
DDI-DrugBank.d196.s34|114-115|to|O
DDI-DrugBank.d196.s34|117-127|discontinue|O
DDI-DrugBank.d196.s34|129-135|nursing|O
DDI-DrugBank.d196.s34|137-138|or|O
DDI-DrugBank.d196.s34|140-150|discontinue|O
DDI-DrugBank.d196.s34|152-158|PEGASYS|brand
DDI-DrugBank.d196.s34|160-162|and|O
DDI-DrugBank.d196.s34|164-170|COPEGUS|brand
DDI-DrugBank.d196.s34|172-180|treatment|O
DDI-DrugBank.d196.s34|181-181|.|O
DDI-DrugBank.d196.s35|0-8|Pediatric|O
DDI-DrugBank.d196.s35|10-12|Use|O
DDI-DrugBank.d196.s35|14-16|The|O
DDI-DrugBank.d196.s35|18-23|safety|O
DDI-DrugBank.d196.s35|25-27|and|O
DDI-DrugBank.d196.s35|29-41|effectiveness|O
DDI-DrugBank.d196.s35|43-44|of|O
DDI-DrugBank.d196.s35|46-52|PEGASYS|brand
DDI-DrugBank.d196.s35|53-53|,|O
DDI-DrugBank.d196.s35|55-59|alone|O
DDI-DrugBank.d196.s35|61-62|or|O
DDI-DrugBank.d196.s35|64-65|in|O
DDI-DrugBank.d196.s35|67-77|combination|O
DDI-DrugBank.d196.s35|79-82|with|O
DDI-DrugBank.d196.s35|84-90|COPEGUS|brand
DDI-DrugBank.d196.s35|92-93|in|O
DDI-DrugBank.d196.s35|95-102|patients|O
DDI-DrugBank.d196.s35|104-108|below|O
DDI-DrugBank.d196.s35|110-112|the|O
DDI-DrugBank.d196.s35|114-116|age|O
DDI-DrugBank.d196.s35|118-119|of|O
DDI-DrugBank.d196.s35|121-122|18|O
DDI-DrugBank.d196.s35|124-128|years|O
DDI-DrugBank.d196.s35|130-133|have|O
DDI-DrugBank.d196.s35|135-137|not|O
DDI-DrugBank.d196.s35|139-142|been|O
DDI-DrugBank.d196.s35|144-154|established|O
DDI-DrugBank.d196.s35|155-155|.|O
DDI-DrugBank.d196.s36|0-6|PEGASYS|brand
DDI-DrugBank.d196.s36|8-15|contains|O
DDI-DrugBank.d196.s36|31-31|.|O
DDI-DrugBank.d196.s37|15-17|has|O
DDI-DrugBank.d196.s37|19-22|been|O
DDI-DrugBank.d196.s37|24-31|reported|O
DDI-DrugBank.d196.s37|33-34|to|O
DDI-DrugBank.d196.s37|36-37|be|O
DDI-DrugBank.d196.s37|39-48|associated|O
DDI-DrugBank.d196.s37|50-53|with|O
DDI-DrugBank.d196.s37|55-56|an|O
DDI-DrugBank.d196.s37|58-66|increased|O
DDI-DrugBank.d196.s37|68-76|incidence|O
DDI-DrugBank.d196.s37|78-79|of|O
DDI-DrugBank.d196.s37|81-92|neurological|O
DDI-DrugBank.d196.s37|94-96|and|O
DDI-DrugBank.d196.s37|98-102|other|O
DDI-DrugBank.d196.s37|104-116|complications|O
DDI-DrugBank.d196.s37|118-119|in|O
DDI-DrugBank.d196.s37|121-128|neonates|O
DDI-DrugBank.d196.s37|130-132|and|O
DDI-DrugBank.d196.s37|134-140|infants|O
DDI-DrugBank.d196.s37|141-141|,|O
DDI-DrugBank.d196.s37|143-147|which|O
DDI-DrugBank.d196.s37|149-151|are|O
DDI-DrugBank.d196.s37|153-161|sometimes|O
DDI-DrugBank.d196.s37|163-167|fatal|O
DDI-DrugBank.d196.s37|168-168|.|O
DDI-DrugBank.d196.s38|0-8|Geriatric|O
DDI-DrugBank.d196.s38|10-12|Use|O
DDI-DrugBank.d196.s38|14-20|Younger|O
DDI-DrugBank.d196.s38|22-29|patients|O
DDI-DrugBank.d196.s38|31-34|have|O
DDI-DrugBank.d196.s38|36-41|higher|O
DDI-DrugBank.d196.s38|43-51|virologic|O
DDI-DrugBank.d196.s38|53-60|response|O
DDI-DrugBank.d196.s38|62-66|rates|O
DDI-DrugBank.d196.s38|68-71|than|O
DDI-DrugBank.d196.s38|73-77|older|O
DDI-DrugBank.d196.s38|79-86|patients|O
DDI-DrugBank.d196.s38|87-87|.|O
DDI-DrugBank.d196.s39|0-7|Clinical|O
DDI-DrugBank.d196.s39|9-15|studies|O
DDI-DrugBank.d196.s39|17-18|of|O
DDI-DrugBank.d196.s39|20-26|PEGASYS|brand
DDI-DrugBank.d196.s39|28-32|alone|O
DDI-DrugBank.d196.s39|34-35|or|O
DDI-DrugBank.d196.s39|37-38|in|O
DDI-DrugBank.d196.s39|40-50|combination|O
DDI-DrugBank.d196.s39|52-55|with|O
DDI-DrugBank.d196.s39|57-63|COPEGUS|brand
DDI-DrugBank.d196.s39|65-67|did|O
DDI-DrugBank.d196.s39|69-71|not|O
DDI-DrugBank.d196.s39|73-79|include|O
DDI-DrugBank.d196.s39|81-90|sufficient|O
DDI-DrugBank.d196.s39|92-98|numbers|O
DDI-DrugBank.d196.s39|100-101|of|O
DDI-DrugBank.d196.s39|103-110|subjects|O
DDI-DrugBank.d196.s39|112-115|aged|O
DDI-DrugBank.d196.s39|117-118|65|O
DDI-DrugBank.d196.s39|120-121|or|O
DDI-DrugBank.d196.s39|123-126|over|O
DDI-DrugBank.d196.s39|128-129|to|O
DDI-DrugBank.d196.s39|131-139|determine|O
DDI-DrugBank.d196.s39|141-147|whether|O
DDI-DrugBank.d196.s39|149-152|they|O
DDI-DrugBank.d196.s39|154-160|respond|O
DDI-DrugBank.d196.s39|162-172|differently|O
DDI-DrugBank.d196.s39|174-177|from|O
DDI-DrugBank.d196.s39|179-185|younger|O
DDI-DrugBank.d196.s39|187-194|subjects|O
DDI-DrugBank.d196.s39|195-195|.|O
DDI-DrugBank.d196.s40|0-6|Adverse|O
DDI-DrugBank.d196.s40|8-16|reactions|O
DDI-DrugBank.d196.s40|18-24|related|O
DDI-DrugBank.d196.s40|26-27|to|O
DDI-DrugBank.d196.s40|29-33|alpha|drug
DDI-DrugBank.d196.s40|35-45|interferons|O
DDI-DrugBank.d196.s40|46-46|,|O
DDI-DrugBank.d196.s40|48-51|such|O
DDI-DrugBank.d196.s40|53-54|as|O
DDI-DrugBank.d196.s40|56-58|CNS|O
DDI-DrugBank.d196.s40|59-59|,|O
DDI-DrugBank.d196.s40|61-67|cardiac|O
DDI-DrugBank.d196.s40|68-68|,|O
DDI-DrugBank.d196.s40|70-72|and|O
DDI-DrugBank.d196.s40|74-81|systemic|O
DDI-DrugBank.d196.s40|83-83|(|O
DDI-DrugBank.d196.s40|84-85|eg|O
DDI-DrugBank.d196.s40|86-86|,|O
DDI-DrugBank.d196.s40|88-95|flu-like|O
DDI-DrugBank.d196.s40|96-96|)|O
DDI-DrugBank.d196.s40|98-104|effects|O
DDI-DrugBank.d196.s40|106-108|may|O
DDI-DrugBank.d196.s40|110-111|be|O
DDI-DrugBank.d196.s40|113-116|more|O
DDI-DrugBank.d196.s40|118-123|severe|O
DDI-DrugBank.d196.s40|125-126|in|O
DDI-DrugBank.d196.s40|128-130|the|O
DDI-DrugBank.d196.s40|132-138|elderly|O
DDI-DrugBank.d196.s40|140-142|and|O
DDI-DrugBank.d196.s40|144-150|caution|O
DDI-DrugBank.d196.s40|152-157|should|O
DDI-DrugBank.d196.s40|159-160|be|O
DDI-DrugBank.d196.s40|162-170|exercised|O
DDI-DrugBank.d196.s40|172-173|in|O
DDI-DrugBank.d196.s40|175-177|the|O
DDI-DrugBank.d196.s40|179-181|use|O
DDI-DrugBank.d196.s40|183-184|of|O
DDI-DrugBank.d196.s40|186-192|PEGASYS|brand
DDI-DrugBank.d196.s40|194-195|in|O
DDI-DrugBank.d196.s40|197-200|this|O
DDI-DrugBank.d196.s40|202-211|population|O
DDI-DrugBank.d196.s40|212-212|.|O
DDI-DrugBank.d196.s41|0-6|PEGASYS|brand
DDI-DrugBank.d196.s41|8-10|and|O
DDI-DrugBank.d196.s41|12-18|COPEGUS|brand
DDI-DrugBank.d196.s41|20-22|are|O
DDI-DrugBank.d196.s41|24-31|excreted|O
DDI-DrugBank.d196.s41|33-34|by|O
DDI-DrugBank.d196.s41|36-38|the|O
DDI-DrugBank.d196.s41|40-45|kidney|O
DDI-DrugBank.d196.s41|46-46|,|O
DDI-DrugBank.d196.s41|48-50|and|O
DDI-DrugBank.d196.s41|52-54|the|O
DDI-DrugBank.d196.s41|56-59|risk|O
DDI-DrugBank.d196.s41|61-62|of|O
DDI-DrugBank.d196.s41|64-68|toxic|O
DDI-DrugBank.d196.s41|70-78|reactions|O
DDI-DrugBank.d196.s41|80-81|to|O
DDI-DrugBank.d196.s41|83-86|this|O
DDI-DrugBank.d196.s41|88-94|therapy|O
DDI-DrugBank.d196.s41|96-98|may|O
DDI-DrugBank.d196.s41|100-101|be|O
DDI-DrugBank.d196.s41|103-109|greater|O
DDI-DrugBank.d196.s41|111-112|in|O
DDI-DrugBank.d196.s41|114-121|patients|O
DDI-DrugBank.d196.s41|123-126|with|O
DDI-DrugBank.d196.s41|128-135|impaired|O
DDI-DrugBank.d196.s41|137-141|renal|O
DDI-DrugBank.d196.s41|143-150|function|O
DDI-DrugBank.d196.s41|151-151|.|O
DDI-DrugBank.d196.s42|0-6|Because|O
DDI-DrugBank.d196.s42|8-14|elderly|O
DDI-DrugBank.d196.s42|16-23|patients|O
DDI-DrugBank.d196.s42|25-27|are|O
DDI-DrugBank.d196.s42|29-32|more|O
DDI-DrugBank.d196.s42|34-39|likely|O
DDI-DrugBank.d196.s42|41-42|to|O
DDI-DrugBank.d196.s42|44-47|have|O
DDI-DrugBank.d196.s42|49-57|decreased|O
DDI-DrugBank.d196.s42|59-63|renal|O
DDI-DrugBank.d196.s42|65-72|function|O
DDI-DrugBank.d196.s42|73-73|,|O
DDI-DrugBank.d196.s42|75-78|care|O
DDI-DrugBank.d196.s42|80-85|should|O
DDI-DrugBank.d196.s42|87-88|be|O
DDI-DrugBank.d196.s42|90-94|taken|O
DDI-DrugBank.d196.s42|96-97|in|O
DDI-DrugBank.d196.s42|99-102|dose|O
DDI-DrugBank.d196.s42|104-112|selection|O
DDI-DrugBank.d196.s42|114-116|and|O
DDI-DrugBank.d196.s42|118-119|it|O
DDI-DrugBank.d196.s42|121-123|may|O
DDI-DrugBank.d196.s42|125-126|be|O
DDI-DrugBank.d196.s42|128-133|useful|O
DDI-DrugBank.d196.s42|135-136|to|O
DDI-DrugBank.d196.s42|138-144|monitor|O
DDI-DrugBank.d196.s42|146-150|renal|O
DDI-DrugBank.d196.s42|152-159|function|O
DDI-DrugBank.d196.s42|160-160|.|O
DDI-DrugBank.d196.s43|0-6|PEGASYS|brand
DDI-DrugBank.d196.s43|8-13|should|O
DDI-DrugBank.d196.s43|15-16|be|O
DDI-DrugBank.d196.s43|18-21|used|O
DDI-DrugBank.d196.s43|23-26|with|O
DDI-DrugBank.d196.s43|28-34|caution|O
DDI-DrugBank.d196.s43|36-37|in|O
DDI-DrugBank.d196.s43|39-46|patients|O
DDI-DrugBank.d196.s43|48-51|with|O
DDI-DrugBank.d196.s43|53-62|creatinine|O
DDI-DrugBank.d196.s43|64-72|clearance|O
DDI-DrugBank.d196.s43|75-76|50|O
DDI-DrugBank.d196.s43|78-83|mL/min|O
DDI-DrugBank.d196.s43|85-87|and|O
DDI-DrugBank.d196.s43|89-95|COPEGUS|brand
DDI-DrugBank.d196.s43|97-102|should|O
DDI-DrugBank.d196.s43|104-106|not|O
DDI-DrugBank.d196.s43|108-109|be|O
DDI-DrugBank.d196.s43|111-122|administered|O
DDI-DrugBank.d196.s43|124-125|to|O
DDI-DrugBank.d196.s43|127-134|patients|O
DDI-DrugBank.d196.s43|136-139|with|O
DDI-DrugBank.d196.s43|141-150|creatinine|O
DDI-DrugBank.d196.s43|152-160|clearance|O
DDI-DrugBank.d196.s43|163-164|50|O
DDI-DrugBank.d196.s43|166-171|mL/min|O
DDI-DrugBank.d196.s44|0-0|.|O
DDI-MedLine.d120.s0|0-8|Molecular|O
DDI-MedLine.d120.s0|10-14|basis|O
DDI-MedLine.d120.s0|16-18|for|O
DDI-MedLine.d120.s0|20-22|the|O
DDI-MedLine.d120.s0|24-32|selective|O
DDI-MedLine.d120.s0|34-41|toxicity|O
DDI-MedLine.d120.s0|43-44|of|O
DDI-MedLine.d120.s0|46-59|amphotericin B|drug
DDI-MedLine.d120.s0|61-63|for|O
DDI-MedLine.d120.s0|65-69|yeast|O
DDI-MedLine.d120.s0|71-73|and|O
DDI-MedLine.d120.s0|83-85|for|O
DDI-MedLine.d120.s0|87-92|animal|O
DDI-MedLine.d120.s0|94-98|cells|O
DDI-MedLine.d120.s0|99-99|.|O
DDI-MedLine.d120.s1|0-4|Among|O
DDI-MedLine.d120.s1|6-8|the|O
DDI-MedLine.d120.s1|10-28|polyene antibiotics|group
DDI-MedLine.d120.s1|29-29|,|O
DDI-MedLine.d120.s1|31-34|many|O
DDI-MedLine.d120.s1|35-35|,|O
DDI-MedLine.d120.s1|37-40|like|O
DDI-MedLine.d120.s1|49-49|,|O
DDI-MedLine.d120.s1|51-53|can|O
DDI-MedLine.d120.s1|54-56|not|O
DDI-MedLine.d120.s1|58-59|be|O
DDI-MedLine.d120.s1|61-64|used|O
DDI-MedLine.d120.s1|66-75|clinically|O
DDI-MedLine.d120.s1|77-83|because|O
DDI-MedLine.d120.s1|85-88|they|O
DDI-MedLine.d120.s1|90-92|are|O
DDI-MedLine.d120.s1|94-98|toxic|O
DDI-MedLine.d120.s1|99-99|;|O
DDI-MedLine.d120.s2|0-13|amphotericin B|drug
DDI-MedLine.d120.s2|14-14|,|O
DDI-MedLine.d120.s2|16-22|however|O
DDI-MedLine.d120.s2|23-23|,|O
DDI-MedLine.d120.s2|25-26|is|O
DDI-MedLine.d120.s2|28-33|useful|O
DDI-MedLine.d120.s2|35-36|in|O
DDI-MedLine.d120.s2|38-44|therapy|O
DDI-MedLine.d120.s2|46-47|of|O
DDI-MedLine.d120.s2|49-53|human|O
DDI-MedLine.d120.s2|55-60|fungal|O
DDI-MedLine.d120.s2|62-71|infections|O
DDI-MedLine.d120.s2|73-79|because|O
DDI-MedLine.d120.s2|81-82|it|O
DDI-MedLine.d120.s2|84-85|is|O
DDI-MedLine.d120.s2|87-90|less|O
DDI-MedLine.d120.s2|92-96|toxic|O
DDI-MedLine.d120.s2|97-97|.|O
DDI-MedLine.d120.s3|0-3|Both|O
DDI-MedLine.d120.s3|5-7|the|O
DDI-MedLine.d120.s3|9-16|toxicity|O
DDI-MedLine.d120.s3|18-19|of|O
DDI-MedLine.d120.s3|29-31|and|O
DDI-MedLine.d120.s3|33-35|the|O
DDI-MedLine.d120.s3|37-47|therapeutic|O
DDI-MedLine.d120.s3|49-53|value|O
DDI-MedLine.d120.s3|55-56|of|O
DDI-MedLine.d120.s3|58-71|amphotericin B|drug
DDI-MedLine.d120.s3|73-75|can|O
DDI-MedLine.d120.s3|77-78|be|O
DDI-MedLine.d120.s3|80-91|rationalized|O
DDI-MedLine.d120.s3|93-94|at|O
DDI-MedLine.d120.s3|96-98|the|O
DDI-MedLine.d120.s3|100-107|cellular|O
DDI-MedLine.d120.s3|109-111|and|O
DDI-MedLine.d120.s3|113-121|molecular|O
DDI-MedLine.d120.s3|123-127|level|O
DDI-MedLine.d120.s3|129-130|by|O
DDI-MedLine.d120.s3|132-134|the|O
DDI-MedLine.d120.s3|136-144|following|O
DDI-MedLine.d120.s3|146-157|observations|O
DDI-MedLine.d120.s3|158-158|:|O
DDI-MedLine.d120.s3|160-160|(|O
DDI-MedLine.d120.s3|161-161|i|O
DDI-MedLine.d120.s3|162-162|)|O
DDI-MedLine.d120.s3|164-168|these|O
DDI-MedLine.d120.s3|170-188|polyene antibiotics|group
DDI-MedLine.d120.s3|190-195|showed|O
DDI-MedLine.d120.s3|197-208|differential|O
DDI-MedLine.d120.s3|210-216|effects|O
DDI-MedLine.d120.s3|218-219|on|O
DDI-MedLine.d120.s3|221-225|cells|O
DDI-MedLine.d120.s3|226-226|;|O
DDI-MedLine.d120.s4|8-10|was|O
DDI-MedLine.d120.s4|12-15|more|O
DDI-MedLine.d120.s4|17-22|potent|O
DDI-MedLine.d120.s4|24-25|in|O
DDI-MedLine.d120.s4|27-32|lysing|O
DDI-MedLine.d120.s4|34-38|human|O
DDI-MedLine.d120.s4|40-42|red|O
DDI-MedLine.d120.s4|44-48|blood|O
DDI-MedLine.d120.s4|50-54|cells|O
DDI-MedLine.d120.s4|55-55|,|O
DDI-MedLine.d120.s4|57-63|whereas|O
DDI-MedLine.d120.s4|65-78|amphotericin B|drug
DDI-MedLine.d120.s4|80-82|was|O
DDI-MedLine.d120.s4|84-87|more|O
DDI-MedLine.d120.s4|89-94|potent|O
DDI-MedLine.d120.s4|96-97|in|O
DDI-MedLine.d120.s4|99-108|inhibiting|O
DDI-MedLine.d120.s4|110-114|yeast|O
DDI-MedLine.d120.s4|116-119|cell|O
DDI-MedLine.d120.s4|121-126|growth|O
DDI-MedLine.d120.s4|127-127|;|O
DDI-MedLine.d120.s5|0-2|and|O
DDI-MedLine.d120.s5|4-4|(|O
DDI-MedLine.d120.s5|5-6|ii|O
DDI-MedLine.d120.s5|7-7|)|O
DDI-MedLine.d120.s5|9-11|the|O
DDI-MedLine.d120.s5|13-19|effects|O
DDI-MedLine.d120.s5|21-22|of|O
DDI-MedLine.d120.s5|32-35|were|O
DDI-MedLine.d120.s5|37-40|more|O
DDI-MedLine.d120.s5|42-52|efficiently|O
DDI-MedLine.d120.s5|54-62|inhibited|O
DDI-MedLine.d120.s5|64-65|by|O
DDI-MedLine.d120.s5|67-71|added|O
DDI-MedLine.d120.s5|73-83|cholesterol|O
DDI-MedLine.d120.s5|84-84|,|O
DDI-MedLine.d120.s5|86-88|the|O
DDI-MedLine.d120.s5|90-94|major|O
DDI-MedLine.d120.s5|96-103|membrane|O
DDI-MedLine.d120.s5|105-110|sterol|O
DDI-MedLine.d120.s5|112-113|in|O
DDI-MedLine.d120.s5|115-119|human|O
DDI-MedLine.d120.s5|121-125|cells|O
DDI-MedLine.d120.s5|126-126|,|O
DDI-MedLine.d120.s5|128-134|whereas|O
DDI-MedLine.d120.s5|136-138|the|O
DDI-MedLine.d120.s5|140-146|effects|O
DDI-MedLine.d120.s5|148-149|of|O
DDI-MedLine.d120.s5|151-164|amphotericin B|drug
DDI-MedLine.d120.s5|166-169|were|O
DDI-MedLine.d120.s5|171-174|more|O
DDI-MedLine.d120.s5|176-186|efficiently|O
DDI-MedLine.d120.s5|188-196|inhibited|O
DDI-MedLine.d120.s5|198-199|by|O
DDI-MedLine.d120.s5|201-210|ergosterol|O
DDI-MedLine.d120.s5|211-211|,|O
DDI-MedLine.d120.s5|213-215|the|O
DDI-MedLine.d120.s5|217-221|major|O
DDI-MedLine.d120.s5|223-230|membrane|O
DDI-MedLine.d120.s5|232-237|sterol|O
DDI-MedLine.d120.s5|239-240|in|O
DDI-MedLine.d120.s5|242-246|yeast|O
DDI-MedLine.d120.s5|247-247|.|O
DDI-MedLine.d120.s6|0-2|The|O
DDI-MedLine.d120.s6|4-11|simplest|O
DDI-MedLine.d120.s6|13-21|inference|O
DDI-MedLine.d120.s6|23-24|is|O
DDI-MedLine.d120.s6|26-29|that|O
DDI-MedLine.d120.s6|31-33|the|O
DDI-MedLine.d120.s6|35-42|toxicity|O
DDI-MedLine.d120.s6|44-46|and|O
DDI-MedLine.d120.s6|48-60|effectiveness|O
DDI-MedLine.d120.s6|62-63|of|O
DDI-MedLine.d120.s6|65-72|polyenes|O
DDI-MedLine.d120.s6|74-76|are|O
DDI-MedLine.d120.s6|78-87|determined|O
DDI-MedLine.d120.s6|89-90|by|O
DDI-MedLine.d120.s6|92-96|their|O
DDI-MedLine.d120.s6|98-105|relative|O
DDI-MedLine.d120.s6|107-115|avidities|O
DDI-MedLine.d120.s6|117-119|for|O
DDI-MedLine.d120.s6|121-123|the|O
DDI-MedLine.d120.s6|125-135|predominant|O
DDI-MedLine.d120.s6|137-142|sterol|O
DDI-MedLine.d120.s6|144-145|in|O
DDI-MedLine.d120.s6|147-150|cell|O
DDI-MedLine.d120.s6|152-160|membranes|O
DDI-MedLine.d120.s6|161-161|.|O
DDI-DrugBank.d59.s0|0-2|The|O
DDI-DrugBank.d59.s0|4-10|effects|O
DDI-DrugBank.d59.s0|12-13|of|O
DDI-DrugBank.d59.s0|15-21|ERGOMAR|brand
DDI-DrugBank.d59.s0|23-25|may|O
DDI-DrugBank.d59.s0|27-28|be|O
DDI-DrugBank.d59.s0|30-40|potentiated|O
DDI-DrugBank.d59.s0|42-43|by|O
DDI-DrugBank.d59.s0|45-65|triacetyloleandomycin|drug
DDI-DrugBank.d59.s0|67-71|which|O
DDI-DrugBank.d59.s0|73-80|inhibits|O
DDI-DrugBank.d59.s0|82-84|the|O
DDI-DrugBank.d59.s0|86-95|metabolism|O
DDI-DrugBank.d59.s0|97-98|of|O
DDI-DrugBank.d59.s0|100-109|ergotamine|drug
DDI-DrugBank.d59.s0|110-110|.|O
DDI-DrugBank.d59.s1|0-2|The|O
DDI-DrugBank.d59.s1|4-10|pressor|O
DDI-DrugBank.d59.s1|12-18|effects|O
DDI-DrugBank.d59.s1|20-21|of|O
DDI-DrugBank.d59.s1|23-29|ERGOMAR|brand
DDI-DrugBank.d59.s1|31-33|and|O
DDI-DrugBank.d59.s1|35-39|other|O
DDI-DrugBank.d59.s1|41-61|vasoconstrictor drugs|group
DDI-DrugBank.d59.s1|63-65|can|O
DDI-DrugBank.d59.s1|67-73|combine|O
DDI-DrugBank.d59.s1|75-76|to|O
DDI-DrugBank.d59.s1|78-82|cause|O
DDI-DrugBank.d59.s1|84-92|dangerous|O
DDI-DrugBank.d59.s1|94-105|hypertension|O
DDI-DrugBank.d59.s1|106-106|.|O
DDI-DrugBank.d459.s0|0-2|The|O
DDI-DrugBank.d459.s0|4-8|daily|O
DDI-DrugBank.d459.s0|10-13|dose|O
DDI-DrugBank.d459.s0|15-16|of|O
DDI-DrugBank.d459.s0|18-24|ENABLEX|brand
DDI-DrugBank.d459.s0|26-31|should|O
DDI-DrugBank.d459.s0|33-35|not|O
DDI-DrugBank.d459.s0|37-42|exceed|O
DDI-DrugBank.d459.s0|44-46|7.5|O
DDI-DrugBank.d459.s0|48-49|mg|O
DDI-DrugBank.d459.s0|51-54|when|O
DDI-DrugBank.d459.s0|56-69|coadministered|O
DDI-DrugBank.d459.s0|71-74|with|O
DDI-DrugBank.d459.s0|76-81|potent|O
DDI-DrugBank.d459.s0|83-88|CYP3A4|O
DDI-DrugBank.d459.s0|90-99|inhibitors|O
DDI-DrugBank.d459.s0|101-101|(|O
DDI-DrugBank.d459.s0|102-105|e.g.|O
DDI-DrugBank.d459.s0|106-106|,|O
DDI-DrugBank.d459.s0|108-119|ketoconazole|drug
DDI-DrugBank.d459.s0|120-120|,|O
DDI-DrugBank.d459.s0|122-133|itraconazole|drug
DDI-DrugBank.d459.s0|134-134|,|O
DDI-DrugBank.d459.s0|136-144|ritonavir|drug
DDI-DrugBank.d459.s0|145-145|,|O
DDI-DrugBank.d459.s0|147-156|nelfinavir|drug
DDI-DrugBank.d459.s0|157-157|,|O
DDI-DrugBank.d459.s0|159-172|clarithromycin|drug
DDI-DrugBank.d459.s0|174-176|and|O
DDI-DrugBank.d459.s0|178-187|nefazadone|O
DDI-DrugBank.d459.s0|188-188|)|O
DDI-DrugBank.d459.s0|190-190|.|O
DDI-DrugBank.d459.s1|0-6|Caution|O
DDI-DrugBank.d459.s1|8-13|should|O
DDI-DrugBank.d459.s1|15-16|be|O
DDI-DrugBank.d459.s1|18-22|taken|O
DDI-DrugBank.d459.s1|24-27|when|O
DDI-DrugBank.d459.s1|29-35|ENABLEX|brand
DDI-DrugBank.d459.s1|37-38|is|O
DDI-DrugBank.d459.s1|40-43|used|O
DDI-DrugBank.d459.s1|45-57|concomitantly|O
DDI-DrugBank.d459.s1|59-62|with|O
DDI-DrugBank.d459.s1|64-74|medications|O
DDI-DrugBank.d459.s1|76-79|that|O
DDI-DrugBank.d459.s1|81-83|are|O
DDI-DrugBank.d459.s1|85-97|predominantly|O
DDI-DrugBank.d459.s1|99-109|metabolized|O
DDI-DrugBank.d459.s1|111-112|by|O
DDI-DrugBank.d459.s1|114-119|CYP2D6|O
DDI-DrugBank.d459.s1|121-123|and|O
DDI-DrugBank.d459.s1|125-129|which|O
DDI-DrugBank.d459.s1|131-134|have|O
DDI-DrugBank.d459.s1|136-136|a|O
DDI-DrugBank.d459.s1|138-143|narrow|O
DDI-DrugBank.d459.s1|145-155|therapeutic|O
DDI-DrugBank.d459.s1|157-162|window|O
DDI-DrugBank.d459.s1|163-163|,|O
DDI-DrugBank.d459.s1|165-168|such|O
DDI-DrugBank.d459.s1|170-171|as|O
DDI-DrugBank.d459.s1|173-182|flecainide|drug
DDI-DrugBank.d459.s1|183-183|,|O
DDI-DrugBank.d459.s1|185-196|thioridazine|drug
DDI-DrugBank.d459.s1|198-200|and|O
DDI-DrugBank.d459.s1|202-226|tricyclic antidepressants|group
DDI-DrugBank.d459.s1|228-228|(|O
DDI-DrugBank.d459.s1|229-231|see|O
DDI-DrugBank.d459.s1|233-240|CLINICAL|O
DDI-DrugBank.d459.s1|242-253|PHARMACOLOGY|O
DDI-DrugBank.d459.s1|254-254|)|O
DDI-DrugBank.d459.s1|255-255|.|O
DDI-DrugBank.d459.s2|0-2|The|O
DDI-DrugBank.d459.s2|4-14|concomitant|O
DDI-DrugBank.d459.s2|16-18|use|O
DDI-DrugBank.d459.s2|20-21|of|O
DDI-DrugBank.d459.s2|23-29|ENABLEX|brand
DDI-DrugBank.d459.s2|31-34|with|O
DDI-DrugBank.d459.s2|36-40|other|O
DDI-DrugBank.d459.s2|42-63|anticholinergic agents|group
DDI-DrugBank.d459.s2|65-67|may|O
DDI-DrugBank.d459.s2|69-76|increase|O
DDI-DrugBank.d459.s2|78-80|the|O
DDI-DrugBank.d459.s2|82-90|frequency|O
DDI-DrugBank.d459.s2|92-97|and/or|O
DDI-DrugBank.d459.s2|99-106|severity|O
DDI-DrugBank.d459.s2|108-109|of|O
DDI-DrugBank.d459.s2|111-113|dry|O
DDI-DrugBank.d459.s2|115-119|mouth|O
DDI-DrugBank.d459.s2|120-120|,|O
DDI-DrugBank.d459.s2|122-133|constipation|O
DDI-DrugBank.d459.s2|134-134|,|O
DDI-DrugBank.d459.s2|136-142|blurred|O
DDI-DrugBank.d459.s2|144-149|vision|O
DDI-DrugBank.d459.s2|151-153|and|O
DDI-DrugBank.d459.s2|155-159|other|O
DDI-DrugBank.d459.s2|161-175|anticholinergic|O
DDI-DrugBank.d459.s2|177-191|pharmacological|O
DDI-DrugBank.d459.s2|193-199|effects|O
DDI-DrugBank.d459.s2|200-200|.|O
DDI-DrugBank.d459.s3|0-21|Anticholinergic agents|group
DDI-DrugBank.d459.s3|23-25|may|O
DDI-DrugBank.d459.s3|27-37|potentially|O
DDI-DrugBank.d459.s3|39-43|alter|O
DDI-DrugBank.d459.s3|45-47|the|O
DDI-DrugBank.d459.s3|49-58|absorption|O
DDI-DrugBank.d459.s3|60-61|of|O
DDI-DrugBank.d459.s3|63-66|some|O
DDI-DrugBank.d459.s3|68-80|concomitantly|O
DDI-DrugBank.d459.s3|82-93|administered|O
DDI-DrugBank.d459.s3|95-99|drugs|O
DDI-DrugBank.d459.s3|101-103|due|O
DDI-DrugBank.d459.s3|105-106|to|O
DDI-DrugBank.d459.s3|108-114|effects|O
DDI-DrugBank.d459.s3|116-117|on|O
DDI-DrugBank.d459.s3|119-134|gastrointestinal|O
DDI-DrugBank.d459.s3|136-143|motility|O
DDI-DrugBank.d459.s3|144-144|.|O
DDI-DrugBank.d459.s4|0-3|Drug|O
DDI-DrugBank.d459.s4|5-14|Laboratory|O
DDI-DrugBank.d459.s4|16-19|Test|O
DDI-DrugBank.d459.s4|21-32|Interactions|O
DDI-DrugBank.d459.s4|34-45|Interactions|O
DDI-DrugBank.d459.s4|47-53|between|O
DDI-DrugBank.d459.s4|55-65|darifenacin|drug
DDI-DrugBank.d459.s4|67-69|and|O
DDI-DrugBank.d459.s4|71-80|laboratory|O
DDI-DrugBank.d459.s4|82-86|tests|O
DDI-DrugBank.d459.s4|88-91|have|O
DDI-DrugBank.d459.s4|93-95|not|O
DDI-DrugBank.d459.s4|97-100|been|O
DDI-DrugBank.d459.s4|102-108|studied|O
DDI-DrugBank.d459.s4|109-109|.|O
DDI-DrugBank.d609.s0|0-1|An|O
DDI-DrugBank.d609.s0|3-11|inhibitor|O
DDI-DrugBank.d609.s0|13-14|of|O
DDI-DrugBank.d609.s0|16-21|CYP2C8|O
DDI-DrugBank.d609.s0|23-23|(|O
DDI-DrugBank.d609.s0|24-27|such|O
DDI-DrugBank.d609.s0|29-30|as|O
DDI-DrugBank.d609.s0|32-42|gemfibrozil|drug
DDI-DrugBank.d609.s0|43-43|)|O
DDI-DrugBank.d609.s0|45-47|may|O
DDI-DrugBank.d609.s0|49-56|increase|O
DDI-DrugBank.d609.s0|58-60|the|O
DDI-DrugBank.d609.s0|62-64|AUC|O
DDI-DrugBank.d609.s0|66-67|of|O
DDI-DrugBank.d609.s0|69-81|rosiglitazone|drug
DDI-DrugBank.d609.s0|83-85|and|O
DDI-DrugBank.d609.s0|87-88|an|O
DDI-DrugBank.d609.s0|90-96|inducer|O
DDI-DrugBank.d609.s0|98-99|of|O
DDI-DrugBank.d609.s0|101-106|CYP2C8|O
DDI-DrugBank.d609.s0|108-108|(|O
DDI-DrugBank.d609.s0|109-112|such|O
DDI-DrugBank.d609.s0|114-115|as|O
DDI-DrugBank.d609.s0|117-124|rifampin|drug
DDI-DrugBank.d609.s0|125-125|)|O
DDI-DrugBank.d609.s0|127-129|may|O
DDI-DrugBank.d609.s0|131-138|decrease|O
DDI-DrugBank.d609.s0|140-142|the|O
DDI-DrugBank.d609.s0|144-146|AUC|O
DDI-DrugBank.d609.s0|148-149|of|O
DDI-DrugBank.d609.s0|151-163|rosiglitazone|drug
DDI-DrugBank.d609.s0|164-164|.|O
DDI-DrugBank.d609.s1|0-8|Therefore|O
DDI-DrugBank.d609.s1|9-9|,|O
DDI-DrugBank.d609.s1|11-12|if|O
DDI-DrugBank.d609.s1|14-15|an|O
DDI-DrugBank.d609.s1|17-25|inhibitor|O
DDI-DrugBank.d609.s1|27-28|or|O
DDI-DrugBank.d609.s1|30-31|an|O
DDI-DrugBank.d609.s1|33-39|inducer|O
DDI-DrugBank.d609.s1|41-42|of|O
DDI-DrugBank.d609.s1|44-49|CYP2C8|O
DDI-DrugBank.d609.s1|51-52|is|O
DDI-DrugBank.d609.s1|54-60|started|O
DDI-DrugBank.d609.s1|62-63|or|O
DDI-DrugBank.d609.s1|65-71|stopped|O
DDI-DrugBank.d609.s1|73-78|during|O
DDI-DrugBank.d609.s1|80-88|treatment|O
DDI-DrugBank.d609.s1|90-93|with|O
DDI-DrugBank.d609.s1|95-107|rosiglitazone|drug
DDI-DrugBank.d609.s1|108-108|,|O
DDI-DrugBank.d609.s1|110-116|changes|O
DDI-DrugBank.d609.s1|118-119|in|O
DDI-DrugBank.d609.s1|121-128|diabetes|O
DDI-DrugBank.d609.s1|130-138|treatment|O
DDI-DrugBank.d609.s1|140-142|may|O
DDI-DrugBank.d609.s1|144-145|be|O
DDI-DrugBank.d609.s1|147-152|needed|O
DDI-DrugBank.d609.s1|154-158|based|O
DDI-DrugBank.d609.s1|160-163|upon|O
DDI-DrugBank.d609.s1|165-172|clinical|O
DDI-DrugBank.d609.s1|174-181|response|O
DDI-DrugBank.d609.s1|182-182|.|O
DDI-DrugBank.d447.s0|0-14|Drug/Laboratory|O
DDI-DrugBank.d447.s0|16-19|Test|O
DDI-DrugBank.d447.s0|21-32|Interactions|O
DDI-DrugBank.d447.s0|33-33|:|O
DDI-DrugBank.d447.s0|35-35|A|O
DDI-DrugBank.d447.s0|37-50|false-positive|O
DDI-DrugBank.d447.s0|52-59|reaction|O
DDI-DrugBank.d447.s0|61-63|for|O
DDI-DrugBank.d447.s0|65-71|glucose|O
DDI-DrugBank.d447.s0|73-74|in|O
DDI-DrugBank.d447.s0|76-78|the|O
DDI-DrugBank.d447.s0|80-84|urine|O
DDI-DrugBank.d447.s0|86-88|may|O
DDI-DrugBank.d447.s0|90-94|occur|O
DDI-DrugBank.d447.s0|96-99|with|O
DDI-DrugBank.d447.s0|101-106|copper|O
DDI-DrugBank.d447.s0|108-116|reduction|O
DDI-DrugBank.d447.s0|118-122|tests|O
DDI-DrugBank.d447.s0|124-124|(|O
DDI-DrugBank.d447.s0|125-132|Benedict|O
DDI-DrugBank.d447.s0|134-134|s|O
DDI-DrugBank.d447.s0|136-137|or|O
DDI-DrugBank.d447.s0|139-145|Fehling|O
DDI-DrugBank.d447.s0|147-147|s|O
DDI-DrugBank.d447.s0|149-156|solution|O
DDI-DrugBank.d447.s0|158-159|or|O
DDI-DrugBank.d447.s0|161-164|with|O
DDI-DrugBank.d447.s0|166-174|Clinitest|O
DDI-DrugBank.d447.s0|177-183|tablets|O
DDI-DrugBank.d447.s0|184-184|)|O
DDI-DrugBank.d447.s0|186-188|but|O
DDI-DrugBank.d447.s0|190-192|not|O
DDI-DrugBank.d447.s0|194-197|with|O
DDI-DrugBank.d447.s0|199-210|enzyme-based|O
DDI-DrugBank.d447.s0|212-216|tests|O
DDI-DrugBank.d447.s0|218-220|for|O
DDI-DrugBank.d447.s0|222-231|glycosuria|O
DDI-DrugBank.d447.s0|232-232|.|O
DDI-DrugBank.d447.s1|0-1|As|O
DDI-DrugBank.d447.s1|3-3|a|O
DDI-DrugBank.d447.s1|5-18|false-negative|O
DDI-DrugBank.d447.s1|20-25|result|O
DDI-DrugBank.d447.s1|27-29|may|O
DDI-DrugBank.d447.s1|31-35|occur|O
DDI-DrugBank.d447.s1|37-38|in|O
DDI-DrugBank.d447.s1|40-42|the|O
DDI-DrugBank.d447.s1|44-55|ferricyanide|O
DDI-DrugBank.d447.s1|57-60|test|O
DDI-DrugBank.d447.s1|61-61|,|O
DDI-DrugBank.d447.s1|63-64|it|O
DDI-DrugBank.d447.s1|66-67|is|O
DDI-DrugBank.d447.s1|69-79|recommended|O
DDI-DrugBank.d447.s1|81-84|that|O
DDI-DrugBank.d447.s1|86-91|either|O
DDI-DrugBank.d447.s1|93-95|the|O
DDI-DrugBank.d447.s1|97-103|glucose|O
DDI-DrugBank.d447.s1|105-111|oxidase|O
DDI-DrugBank.d447.s1|113-114|or|O
DDI-DrugBank.d447.s1|116-125|hexokinase|O
DDI-DrugBank.d447.s1|127-132|method|O
DDI-DrugBank.d447.s1|134-135|be|O
DDI-DrugBank.d447.s1|137-140|used|O
DDI-DrugBank.d447.s1|142-143|to|O
DDI-DrugBank.d447.s1|145-153|determine|O
DDI-DrugBank.d447.s1|155-159|blood|O
DDI-DrugBank.d447.s1|161-166|plasma|O
DDI-DrugBank.d447.s1|168-174|glucose|O
DDI-DrugBank.d447.s1|176-181|levels|O
DDI-DrugBank.d447.s1|183-184|in|O
DDI-DrugBank.d447.s1|186-193|patients|O
DDI-DrugBank.d447.s1|195-203|receiving|O
DDI-DrugBank.d447.s1|205-214|cefuroxime|drug
DDI-DrugBank.d447.s1|215-215|.|O
DDI-DrugBank.d447.s2|0-9|Cefuroxime|drug
DDI-DrugBank.d447.s2|11-14|does|O
DDI-DrugBank.d447.s2|16-18|not|O
DDI-DrugBank.d447.s2|20-28|interfere|O
DDI-DrugBank.d447.s2|30-33|with|O
DDI-DrugBank.d447.s2|35-37|the|O
DDI-DrugBank.d447.s2|39-43|assay|O
DDI-DrugBank.d447.s2|45-46|of|O
DDI-DrugBank.d447.s2|48-52|serum|O
DDI-DrugBank.d447.s2|54-56|and|O
DDI-DrugBank.d447.s2|58-62|urine|O
DDI-DrugBank.d447.s2|64-73|creatinine|O
DDI-DrugBank.d447.s2|75-76|by|O
DDI-DrugBank.d447.s2|78-80|the|O
DDI-DrugBank.d447.s2|82-89|alkaline|O
DDI-DrugBank.d447.s2|91-97|picrate|O
DDI-DrugBank.d447.s2|99-104|method|O
DDI-DrugBank.d447.s2|105-105|.|O
DDI-DrugBank.d508.s0|0-2|The|O
DDI-DrugBank.d508.s0|4-14|interaction|O
DDI-DrugBank.d508.s0|16-17|of|O
DDI-DrugBank.d508.s0|19-26|Activase|brand
DDI-DrugBank.d508.s0|28-31|with|O
DDI-DrugBank.d508.s0|33-37|other|O
DDI-DrugBank.d508.s0|39-50|cardioactive|O
DDI-DrugBank.d508.s0|52-53|or|O
DDI-DrugBank.d508.s0|55-67|cerebroactive|O
DDI-DrugBank.d508.s0|69-73|drugs|O
DDI-DrugBank.d508.s0|75-77|has|O
DDI-DrugBank.d508.s0|79-81|not|O
DDI-DrugBank.d508.s0|83-86|been|O
DDI-DrugBank.d508.s0|88-94|studied|O
DDI-DrugBank.d508.s0|95-95|.|O
DDI-DrugBank.d508.s1|0-1|In|O
DDI-DrugBank.d508.s1|3-10|addition|O
DDI-DrugBank.d508.s1|12-13|to|O
DDI-DrugBank.d508.s1|15-22|bleeding|O
DDI-DrugBank.d508.s1|24-33|associated|O
DDI-DrugBank.d508.s1|35-38|with|O
DDI-DrugBank.d508.s1|40-46|heparin|drug
DDI-DrugBank.d508.s1|48-50|and|O
DDI-DrugBank.d508.s1|52-72|vitamin K antagonists|group
DDI-DrugBank.d508.s1|73-73|,|O
DDI-DrugBank.d508.s1|75-79|drugs|O
DDI-DrugBank.d508.s1|81-84|that|O
DDI-DrugBank.d508.s1|86-90|alter|O
DDI-DrugBank.d508.s1|92-99|platelet|O
DDI-DrugBank.d508.s1|101-108|function|O
DDI-DrugBank.d508.s1|110-110|(|O
DDI-DrugBank.d508.s1|111-114|such|O
DDI-DrugBank.d508.s1|116-117|as|O
DDI-DrugBank.d508.s1|119-138|acetylsalicylic acid|drug
DDI-DrugBank.d508.s1|139-139|,|O
DDI-DrugBank.d508.s1|141-152|dipyridamole|drug
DDI-DrugBank.d508.s1|154-156|and|O
DDI-DrugBank.d508.s1|158-166|Abciximab|drug
DDI-DrugBank.d508.s1|167-167|)|O
DDI-DrugBank.d508.s1|169-171|may|O
DDI-DrugBank.d508.s1|173-180|increase|O
DDI-DrugBank.d508.s1|182-184|the|O
DDI-DrugBank.d508.s1|186-189|risk|O
DDI-DrugBank.d508.s1|191-192|of|O
DDI-DrugBank.d508.s1|194-201|bleeding|O
DDI-DrugBank.d508.s1|203-204|if|O
DDI-DrugBank.d508.s1|206-217|administered|O
DDI-DrugBank.d508.s1|219-223|prior|O
DDI-DrugBank.d508.s1|225-226|to|O
DDI-DrugBank.d508.s1|227-227|,|O
DDI-DrugBank.d508.s1|229-234|during|O
DDI-DrugBank.d508.s1|235-235|,|O
DDI-DrugBank.d508.s1|237-238|or|O
DDI-DrugBank.d508.s1|240-244|after|O
DDI-DrugBank.d508.s1|246-253|Activase|brand
DDI-DrugBank.d508.s1|255-261|therapy|O
DDI-DrugBank.d508.s1|262-262|.|O
DDI-DrugBank.d508.s2|0-2|Use|O
DDI-DrugBank.d508.s2|4-5|of|O
DDI-DrugBank.d508.s2|7-21|Antithrombotics|group
DDI-DrugBank.d508.s2|7-21|Antithrombotics|group
DDI-DrugBank.d508.s2|31-33|and|O
DDI-DrugBank.d508.s2|35-41|heparin|drug
DDI-DrugBank.d508.s2|43-46|have|O
DDI-DrugBank.d508.s2|48-51|been|O
DDI-DrugBank.d508.s2|53-64|administered|O
DDI-DrugBank.d508.s2|66-78|concomitantly|O
DDI-DrugBank.d508.s2|80-83|with|O
DDI-DrugBank.d508.s2|85-87|and|O
DDI-DrugBank.d508.s2|89-97|following|O
DDI-DrugBank.d508.s2|99-107|infusions|O
DDI-DrugBank.d508.s2|109-110|of|O
DDI-DrugBank.d508.s2|112-119|Activase|brand
DDI-DrugBank.d508.s2|121-122|in|O
DDI-DrugBank.d508.s2|124-126|the|O
DDI-DrugBank.d508.s2|128-137|management|O
DDI-DrugBank.d508.s2|139-140|of|O
DDI-DrugBank.d508.s2|142-146|acute|O
DDI-DrugBank.d508.s2|148-157|myocardial|O
DDI-DrugBank.d508.s2|159-168|infarction|O
DDI-DrugBank.d508.s2|170-171|or|O
DDI-DrugBank.d508.s2|173-181|pulmonary|O
DDI-DrugBank.d508.s2|183-190|embolism|O
DDI-DrugBank.d508.s2|191-191|.|O
DDI-DrugBank.d508.s3|0-6|Because|O
DDI-DrugBank.d508.s3|8-14|heparin|drug
DDI-DrugBank.d508.s3|15-15|,|O
DDI-DrugBank.d508.s3|17-23|aspirin|brand
DDI-DrugBank.d508.s3|24-24|,|O
DDI-DrugBank.d508.s3|26-27|or|O
DDI-DrugBank.d508.s3|29-36|Activase|brand
DDI-DrugBank.d508.s3|38-40|may|O
DDI-DrugBank.d508.s3|42-46|cause|O
DDI-DrugBank.d508.s3|48-55|bleeding|O
DDI-DrugBank.d508.s3|57-69|complications|O
DDI-DrugBank.d508.s3|70-70|,|O
DDI-DrugBank.d508.s3|72-78|careful|O
DDI-DrugBank.d508.s3|80-89|monitoring|O
DDI-DrugBank.d508.s3|91-93|for|O
DDI-DrugBank.d508.s3|95-102|bleeding|O
DDI-DrugBank.d508.s3|104-105|is|O
DDI-DrugBank.d508.s3|107-113|advised|O
DDI-DrugBank.d508.s3|114-114|,|O
DDI-DrugBank.d508.s3|116-125|especially|O
DDI-DrugBank.d508.s3|127-128|at|O
DDI-DrugBank.d508.s3|130-137|arterial|O
DDI-DrugBank.d508.s3|139-146|puncture|O
DDI-DrugBank.d508.s3|148-152|sites|O
DDI-DrugBank.d508.s3|153-153|.|O
DDI-DrugBank.d508.s4|0-2|The|O
DDI-DrugBank.d508.s4|4-14|concomitant|O
DDI-DrugBank.d508.s4|16-18|use|O
DDI-DrugBank.d508.s4|20-21|of|O
DDI-DrugBank.d508.s4|23-29|heparin|drug
DDI-DrugBank.d508.s4|31-32|or|O
DDI-DrugBank.d508.s4|34-40|aspirin|brand
DDI-DrugBank.d508.s4|42-47|during|O
DDI-DrugBank.d508.s4|49-51|the|O
DDI-DrugBank.d508.s4|53-57|first|O
DDI-DrugBank.d508.s4|59-60|24|O
DDI-DrugBank.d508.s4|62-66|hours|O
DDI-DrugBank.d508.s4|68-76|following|O
DDI-DrugBank.d508.s4|78-84|symptom|O
DDI-DrugBank.d508.s4|86-90|onset|O
DDI-DrugBank.d508.s4|92-95|were|O
DDI-DrugBank.d508.s4|97-106|prohibited|O
DDI-DrugBank.d508.s4|108-109|in|O
DDI-DrugBank.d508.s4|111-113|The|O
DDI-DrugBank.d508.s4|115-119|NINDS|O
DDI-DrugBank.d508.s4|121-124|t-PA|O
DDI-DrugBank.d508.s4|126-131|Stroke|O
DDI-DrugBank.d508.s4|133-137|Trial|O
DDI-DrugBank.d508.s4|138-138|.|O
DDI-DrugBank.d508.s5|0-2|The|O
DDI-DrugBank.d508.s5|4-9|safety|O
DDI-DrugBank.d508.s5|11-12|of|O
DDI-DrugBank.d508.s5|14-17|such|O
DDI-DrugBank.d508.s5|19-29|concomitant|O
DDI-DrugBank.d508.s5|31-33|use|O
DDI-DrugBank.d508.s5|35-38|with|O
DDI-DrugBank.d508.s5|40-47|Activase|brand
DDI-DrugBank.d508.s5|49-51|for|O
DDI-DrugBank.d508.s5|53-55|the|O
DDI-DrugBank.d508.s5|57-66|management|O
DDI-DrugBank.d508.s5|68-69|of|O
DDI-DrugBank.d508.s5|71-75|acute|O
DDI-DrugBank.d508.s5|77-84|ischemic|O
DDI-DrugBank.d508.s5|86-91|stroke|O
DDI-DrugBank.d508.s5|93-94|is|O
DDI-DrugBank.d508.s5|96-102|unknown|O
DDI-DrugBank.d508.s5|103-103|.|O
DDI-DrugBank.d738.s0|0-1|Do|O
DDI-DrugBank.d738.s0|3-5|not|O
DDI-DrugBank.d738.s0|7-12|exceed|O
DDI-DrugBank.d738.s0|14-14|a|O
DDI-DrugBank.d738.s0|16-16|5|O
DDI-DrugBank.d738.s0|18-19|mg|O
DDI-DrugBank.d738.s0|21-25|daily|O
DDI-DrugBank.d738.s0|27-30|dose|O
DDI-DrugBank.d738.s0|32-33|of|O
DDI-DrugBank.d738.s0|35-42|VESIcare|brand
DDI-DrugBank.d738.s0|44-47|when|O
DDI-DrugBank.d738.s0|49-60|administered|O
DDI-DrugBank.d738.s0|62-65|with|O
DDI-DrugBank.d738.s0|67-77|therapeutic|O
DDI-DrugBank.d738.s0|79-83|doses|O
DDI-DrugBank.d738.s0|85-86|of|O
DDI-DrugBank.d738.s0|88-99|ketoconazole|drug
DDI-DrugBank.d738.s0|101-102|or|O
DDI-DrugBank.d738.s0|104-108|other|O
DDI-DrugBank.d738.s0|110-115|potent|O
DDI-DrugBank.d738.s0|117-122|CYP3A4|O
DDI-DrugBank.d738.s0|124-133|inhibitors|O
DDI-DrugBank.d738.s0|134-134|.|O
DDI-DrugBank.d738.s1|0-7|Patients|O
DDI-DrugBank.d738.s1|9-12|with|O
DDI-DrugBank.d738.s1|14-23|Congenital|O
DDI-DrugBank.d738.s1|25-26|or|O
DDI-DrugBank.d738.s1|28-35|Acquired|O
DDI-DrugBank.d738.s1|37-38|QT|O
DDI-DrugBank.d738.s1|40-51|Prolongation|O
DDI-DrugBank.d738.s1|53-54|In|O
DDI-DrugBank.d738.s1|56-56|a|O
DDI-DrugBank.d738.s1|58-62|study|O
DDI-DrugBank.d738.s1|64-65|of|O
DDI-DrugBank.d738.s1|67-69|the|O
DDI-DrugBank.d738.s1|71-76|effect|O
DDI-DrugBank.d738.s1|78-79|of|O
DDI-DrugBank.d738.s1|81-91|solifenacin|drug
DDI-DrugBank.d738.s1|93-94|on|O
DDI-DrugBank.d738.s1|96-98|the|O
DDI-DrugBank.d738.s1|100-101|QT|O
DDI-DrugBank.d738.s1|103-110|interval|O
DDI-DrugBank.d738.s1|112-113|in|O
DDI-DrugBank.d738.s1|115-116|76|O
DDI-DrugBank.d738.s1|118-124|healthy|O
DDI-DrugBank.d738.s1|126-130|women|O
DDI-DrugBank.d738.s1|131-131|,|O
DDI-DrugBank.d738.s1|133-135|the|O
DDI-DrugBank.d738.s1|137-138|QT|O
DDI-DrugBank.d738.s1|140-149|prolonging|O
DDI-DrugBank.d738.s1|151-156|effect|O
DDI-DrugBank.d738.s1|158-165|appeared|O
DDI-DrugBank.d738.s1|167-170|less|O
DDI-DrugBank.d738.s1|172-175|with|O
DDI-DrugBank.d738.s1|177-187|solifenacin|drug
DDI-DrugBank.d738.s1|189-190|10|O
DDI-DrugBank.d738.s1|192-193|mg|O
DDI-DrugBank.d738.s1|195-198|than|O
DDI-DrugBank.d738.s1|200-203|with|O
DDI-DrugBank.d738.s1|205-206|30|O
DDI-DrugBank.d738.s1|208-209|mg|O
DDI-DrugBank.d738.s1|211-211|(|O
DDI-DrugBank.d738.s1|212-216|three|O
DDI-DrugBank.d738.s1|218-222|times|O
DDI-DrugBank.d738.s1|224-226|the|O
DDI-DrugBank.d738.s1|228-234|maximum|O
DDI-DrugBank.d738.s1|236-246|recommended|O
DDI-DrugBank.d738.s1|248-251|dose|O
DDI-DrugBank.d738.s1|252-252|)|O
DDI-DrugBank.d738.s1|253-253|,|O
DDI-DrugBank.d738.s1|255-257|and|O
DDI-DrugBank.d738.s1|259-261|the|O
DDI-DrugBank.d738.s1|263-268|effect|O
DDI-DrugBank.d738.s1|270-271|of|O
DDI-DrugBank.d738.s1|273-283|solifenacin|drug
DDI-DrugBank.d738.s1|285-286|30|O
DDI-DrugBank.d738.s1|288-289|mg|O
DDI-DrugBank.d738.s1|291-293|did|O
DDI-DrugBank.d738.s1|295-297|not|O
DDI-DrugBank.d738.s1|299-304|appear|O
DDI-DrugBank.d738.s1|306-307|as|O
DDI-DrugBank.d738.s1|309-313|large|O
DDI-DrugBank.d738.s1|315-316|as|O
DDI-DrugBank.d738.s1|318-321|that|O
DDI-DrugBank.d738.s1|323-324|of|O
DDI-DrugBank.d738.s1|326-328|the|O
DDI-DrugBank.d738.s1|330-337|positive|O
DDI-DrugBank.d738.s1|339-345|control|O
DDI-DrugBank.d738.s1|347-358|moxifloxacin|drug
DDI-DrugBank.d738.s1|360-361|at|O
DDI-DrugBank.d738.s1|363-365|its|O
DDI-DrugBank.d738.s1|367-377|therapeutic|O
DDI-DrugBank.d738.s1|379-382|dose|O
DDI-DrugBank.d738.s1|383-383|.|O
DDI-DrugBank.d738.s2|0-3|This|O
DDI-DrugBank.d738.s2|5-15|observation|O
DDI-DrugBank.d738.s2|17-22|should|O
DDI-DrugBank.d738.s2|24-25|be|O
DDI-DrugBank.d738.s2|27-36|considered|O
DDI-DrugBank.d738.s2|38-39|in|O
DDI-DrugBank.d738.s2|41-48|clinical|O
DDI-DrugBank.d738.s2|50-58|decisions|O
DDI-DrugBank.d738.s2|60-61|to|O
DDI-DrugBank.d738.s2|63-71|prescribe|O
DDI-DrugBank.d738.s2|73-80|VESIcare|brand
DDI-DrugBank.d738.s2|82-84|for|O
DDI-DrugBank.d738.s2|86-93|patients|O
DDI-DrugBank.d738.s2|95-98|with|O
DDI-DrugBank.d738.s2|100-100|a|O
DDI-DrugBank.d738.s2|102-106|known|O
DDI-DrugBank.d738.s2|108-114|history|O
DDI-DrugBank.d738.s2|116-117|of|O
DDI-DrugBank.d738.s2|119-120|QT|O
DDI-DrugBank.d738.s2|122-133|prolongation|O
DDI-DrugBank.d738.s2|135-136|or|O
DDI-DrugBank.d738.s2|138-145|patients|O
DDI-DrugBank.d738.s2|147-149|who|O
DDI-DrugBank.d738.s2|151-153|are|O
DDI-DrugBank.d738.s2|155-160|taking|O
DDI-DrugBank.d738.s2|162-172|medications|O
DDI-DrugBank.d738.s2|174-178|known|O
DDI-DrugBank.d738.s2|180-181|to|O
DDI-DrugBank.d738.s2|183-189|prolong|O
DDI-DrugBank.d738.s2|191-193|the|O
DDI-DrugBank.d738.s2|195-196|QT|O
DDI-DrugBank.d738.s2|198-205|interval|O
DDI-DrugBank.d738.s2|206-206|.|O
DDI-DrugBank.d517.s0|0-11|Tetracycline|drug
DDI-DrugBank.d517.s0|12-12|,|O
DDI-DrugBank.d517.s0|14-14|a|O
DDI-DrugBank.d517.s0|16-40|bacteriostatic antibiotic|group
DDI-DrugBank.d517.s0|41-41|,|O
DDI-DrugBank.d517.s0|43-45|may|O
DDI-DrugBank.d517.s0|47-56|antagonize|O
DDI-DrugBank.d517.s0|58-60|the|O
DDI-DrugBank.d517.s0|62-72|bactercidal|O
DDI-DrugBank.d517.s0|74-79|effect|O
DDI-DrugBank.d517.s0|81-82|of|O
DDI-DrugBank.d517.s0|84-93|penicillin|drug
DDI-DrugBank.d517.s0|95-97|and|O
DDI-DrugBank.d517.s0|99-108|concurrent|O
DDI-DrugBank.d517.s0|110-112|use|O
DDI-DrugBank.d517.s0|114-115|of|O
DDI-DrugBank.d517.s0|117-121|these|O
DDI-DrugBank.d517.s0|123-127|drugs|O
DDI-DrugBank.d517.s0|129-134|should|O
DDI-DrugBank.d517.s0|136-137|be|O
DDI-DrugBank.d517.s0|139-145|avoided|O
DDI-DrugBank.d517.s0|146-146|.|O
DDI-DrugBank.d260.s0|0-9|Probenecid|drug
DDI-DrugBank.d260.s0|11-11|:|O
DDI-DrugBank.d260.s0|13-22|Probenecid|drug
DDI-DrugBank.d260.s0|24-25|is|O
DDI-DrugBank.d260.s0|27-31|known|O
DDI-DrugBank.d260.s0|33-34|to|O
DDI-DrugBank.d260.s0|36-43|interact|O
DDI-DrugBank.d260.s0|45-48|with|O
DDI-DrugBank.d260.s0|50-52|the|O
DDI-DrugBank.d260.s0|54-63|metabolism|O
DDI-DrugBank.d260.s0|65-66|or|O
DDI-DrugBank.d260.s0|68-72|renal|O
DDI-DrugBank.d260.s0|74-80|tubular|O
DDI-DrugBank.d260.s0|82-90|excretion|O
DDI-DrugBank.d260.s0|92-93|of|O
DDI-DrugBank.d260.s0|95-98|many|O
DDI-DrugBank.d260.s0|100-104|drugs|O
DDI-DrugBank.d260.s0|106-106|(|O
DDI-DrugBank.d260.s0|107-110|e.g.|O
DDI-DrugBank.d260.s0|111-111|,|O
DDI-DrugBank.d260.s0|113-125|acetaminophen|drug
DDI-DrugBank.d260.s0|126-126|,|O
DDI-DrugBank.d260.s0|128-136|acyclovir|drug
DDI-DrugBank.d260.s0|137-137|,|O
DDI-DrugBank.d260.s0|139-178|angiotensin-converting enzyme inhibitors|group
DDI-DrugBank.d260.s0|179-179|,|O
DDI-DrugBank.d260.s0|181-199|aminosalicylic acid|drug
DDI-DrugBank.d260.s0|200-200|,|O
DDI-DrugBank.d260.s0|202-213|barbiturates|group
DDI-DrugBank.d260.s0|214-214|,|O
DDI-DrugBank.d260.s0|216-230|benzodiazepines|group
DDI-DrugBank.d260.s0|231-231|,|O
DDI-DrugBank.d260.s0|233-242|bumetanide|drug
DDI-DrugBank.d260.s0|243-243|,|O
DDI-DrugBank.d260.s0|245-254|clofibrate|drug
DDI-DrugBank.d260.s0|255-255|,|O
DDI-DrugBank.d260.s0|257-268|methotrexate|drug
DDI-DrugBank.d260.s0|269-269|,|O
DDI-DrugBank.d260.s0|271-280|famotidine|drug
DDI-DrugBank.d260.s0|281-281|,|O
DDI-DrugBank.d260.s0|283-292|furosemide|drug
DDI-DrugBank.d260.s0|293-293|,|O
DDI-DrugBank.d260.s0|295-324|nonsteroidal anti-inflammatory|group
DDI-DrugBank.d260.s0|326-331|agents|O
DDI-DrugBank.d260.s0|332-332|,|O
DDI-DrugBank.d260.s0|334-345|theophylline|drug
DDI-DrugBank.d260.s0|346-346|,|O
DDI-DrugBank.d260.s0|348-350|and|O
DDI-DrugBank.d260.s0|352-361|zidovudine|drug
DDI-DrugBank.d260.s0|362-362|)|O
DDI-DrugBank.d260.s0|363-363|.|O
DDI-DrugBank.d260.s1|0-10|Concomitant|O
DDI-DrugBank.d260.s1|12-22|medications|O
DDI-DrugBank.d260.s1|24-29|should|O
DDI-DrugBank.d260.s1|31-32|be|O
DDI-DrugBank.d260.s1|34-42|carefully|O
DDI-DrugBank.d260.s1|44-51|assessed|O
DDI-DrugBank.d260.s1|52-52|.|O
DDI-DrugBank.d260.s2|0-9|Zidovudine|drug
DDI-DrugBank.d260.s2|11-16|should|O
DDI-DrugBank.d260.s2|18-23|either|O
DDI-DrugBank.d260.s2|25-26|be|O
DDI-DrugBank.d260.s2|28-38|temporarily|O
DDI-DrugBank.d260.s2|40-51|discontinued|O
DDI-DrugBank.d260.s2|53-54|or|O
DDI-DrugBank.d260.s2|56-64|decreased|O
DDI-DrugBank.d260.s2|66-67|by|O
DDI-DrugBank.d260.s2|69-70|50|O
DDI-DrugBank.d260.s2|71-71|%|O
DDI-DrugBank.d260.s2|73-76|when|O
DDI-DrugBank.d260.s2|78-91|coadministered|O
DDI-DrugBank.d260.s2|93-96|with|O
DDI-DrugBank.d260.s2|98-107|probenecid|drug
DDI-DrugBank.d260.s2|109-110|on|O
DDI-DrugBank.d260.s2|112-114|the|O
DDI-DrugBank.d260.s2|116-118|day|O
DDI-DrugBank.d260.s2|120-121|of|O
DDI-DrugBank.d260.s2|123-129|VISTIDE|brand
DDI-DrugBank.d260.s2|131-138|infusion|O
DDI-DrugBank.d260.s2|139-139|.|O
DDI-DrugBank.d260.s3|0-10|Nephrotoxic|O
DDI-DrugBank.d260.s3|12-17|agents|O
DDI-DrugBank.d260.s3|19-19|:|O
DDI-DrugBank.d260.s3|21-31|Concomitant|O
DDI-DrugBank.d260.s3|33-46|administration|O
DDI-DrugBank.d260.s3|48-49|of|O
DDI-DrugBank.d260.s3|51-57|VISTIDE|brand
DDI-DrugBank.d260.s3|59-61|and|O
DDI-DrugBank.d260.s3|63-68|agents|O
DDI-DrugBank.d260.s3|70-73|with|O
DDI-DrugBank.d260.s3|75-85|nephrotoxic|O
DDI-DrugBank.d260.s3|87-95|potential|O
DDI-DrugBank.d260.s3|97-97|[|O
DDI-DrugBank.d260.s3|98-101|e.g.|O
DDI-DrugBank.d260.s3|102-102|,|O
DDI-DrugBank.d260.s3|104-114|intravenous|O
DDI-DrugBank.d260.s3|116-130|aminoglycosides|group
DDI-DrugBank.d260.s3|132-132|(|O
DDI-DrugBank.d260.s3|133-136|e.g.|O
DDI-DrugBank.d260.s3|137-137|,|O
DDI-DrugBank.d260.s3|139-148|tobramycin|drug
DDI-DrugBank.d260.s3|149-149|,|O
DDI-DrugBank.d260.s3|151-160|gentamicin|drug
DDI-DrugBank.d260.s3|161-161|,|O
DDI-DrugBank.d260.s3|163-165|and|O
DDI-DrugBank.d260.s3|167-174|amikacin|drug
DDI-DrugBank.d260.s3|175-175|)|O
DDI-DrugBank.d260.s3|176-176|,|O
DDI-DrugBank.d260.s3|178-191|amphotericin B|drug
DDI-DrugBank.d260.s3|192-192|,|O
DDI-DrugBank.d260.s3|194-202|foscarnet|drug
DDI-DrugBank.d260.s3|203-203|,|O
DDI-DrugBank.d260.s3|205-215|intravenous|O
DDI-DrugBank.d260.s3|217-227|pentamidine|drug
DDI-DrugBank.d260.s3|228-228|,|O
DDI-DrugBank.d260.s3|230-239|vancomycin|drug
DDI-DrugBank.d260.s3|240-240|,|O
DDI-DrugBank.d260.s3|242-244|and|O
DDI-DrugBank.d260.s3|246-283|non-steroidal anti-inflammatory agents|group
DDI-DrugBank.d260.s3|284-284|]|O
DDI-DrugBank.d260.s3|286-287|is|O
DDI-DrugBank.d260.s3|289-303|contraindicated|O
DDI-DrugBank.d260.s3|304-304|.|O
DDI-DrugBank.d260.s4|0-3|Such|O
DDI-DrugBank.d260.s4|5-10|agents|O
DDI-DrugBank.d260.s4|12-15|must|O
DDI-DrugBank.d260.s4|17-18|be|O
DDI-DrugBank.d260.s4|20-31|discontinued|O
DDI-DrugBank.d260.s4|33-34|at|O
DDI-DrugBank.d260.s4|36-40|least|O
DDI-DrugBank.d260.s4|42-46|seven|O
DDI-DrugBank.d260.s4|48-51|days|O
DDI-DrugBank.d260.s4|53-57|prior|O
DDI-DrugBank.d260.s4|59-60|to|O
DDI-DrugBank.d260.s4|62-69|starting|O
DDI-DrugBank.d260.s4|71-77|therapy|O
DDI-DrugBank.d260.s4|79-82|with|O
DDI-DrugBank.d260.s4|84-90|VISTIDE|brand
DDI-DrugBank.d260.s4|91-91|.|O
DDI-DrugBank.d460.s0|0-1|In|O
DDI-DrugBank.d460.s0|3-7|vitro|O
DDI-DrugBank.d460.s0|9-12|drug|O
DDI-DrugBank.d460.s0|14-23|metabolism|O
DDI-DrugBank.d460.s0|25-31|studies|O
DDI-DrugBank.d460.s0|33-40|indicate|O
DDI-DrugBank.d460.s0|42-45|that|O
DDI-DrugBank.d460.s0|47-53|Starlix|brand
DDI-DrugBank.d460.s0|55-56|is|O
DDI-DrugBank.d460.s0|58-70|predominantly|O
DDI-DrugBank.d460.s0|72-82|metabolized|O
DDI-DrugBank.d460.s0|84-85|by|O
DDI-DrugBank.d460.s0|87-89|the|O
DDI-DrugBank.d460.s0|91-100|cytochrome|O
DDI-DrugBank.d460.s0|102-105|P450|O
DDI-DrugBank.d460.s0|107-113|isozyme|O
DDI-DrugBank.d460.s0|115-120|CYP2C9|O
DDI-DrugBank.d460.s0|122-122|(|O
DDI-DrugBank.d460.s0|123-124|70|O
DDI-DrugBank.d460.s0|125-125|%|O
DDI-DrugBank.d460.s0|126-126|)|O
DDI-DrugBank.d460.s0|128-130|and|O
DDI-DrugBank.d460.s0|132-133|to|O
DDI-DrugBank.d460.s0|135-135|a|O
DDI-DrugBank.d460.s0|137-142|lesser|O
DDI-DrugBank.d460.s0|144-149|extent|O
DDI-DrugBank.d460.s0|151-156|CYP3A4|O
DDI-DrugBank.d460.s0|158-158|(|O
DDI-DrugBank.d460.s0|159-160|30|O
DDI-DrugBank.d460.s0|161-161|%|O
DDI-DrugBank.d460.s0|162-162|)|O
DDI-DrugBank.d460.s0|163-163|.|O
DDI-DrugBank.d460.s1|0-6|Starlix|brand
DDI-DrugBank.d460.s1|8-9|is|O
DDI-DrugBank.d460.s1|11-11|a|O
DDI-DrugBank.d460.s1|13-21|potential|O
DDI-DrugBank.d460.s1|23-31|inhibitor|O
DDI-DrugBank.d460.s1|33-34|of|O
DDI-DrugBank.d460.s1|36-38|the|O
DDI-DrugBank.d460.s1|40-45|CYP2C9|O
DDI-DrugBank.d460.s1|47-55|isoenzyme|O
DDI-DrugBank.d460.s1|57-58|in|O
DDI-DrugBank.d460.s1|60-63|vivo|O
DDI-DrugBank.d460.s1|65-66|as|O
DDI-DrugBank.d460.s1|68-76|indicated|O
DDI-DrugBank.d460.s1|78-79|by|O
DDI-DrugBank.d460.s1|81-83|its|O
DDI-DrugBank.d460.s1|85-91|ability|O
DDI-DrugBank.d460.s1|93-94|to|O
DDI-DrugBank.d460.s1|96-102|inhibit|O
DDI-DrugBank.d460.s1|104-106|the|O
DDI-DrugBank.d460.s1|108-109|in|O
DDI-DrugBank.d460.s1|111-115|vitro|O
DDI-DrugBank.d460.s1|117-126|metabolism|O
DDI-DrugBank.d460.s1|128-129|of|O
DDI-DrugBank.d460.s1|131-141|tolbutamide|drug
DDI-DrugBank.d460.s1|142-142|.|O
DDI-DrugBank.d460.s2|0-9|Inhibition|O
DDI-DrugBank.d460.s2|11-12|of|O
DDI-DrugBank.d460.s2|14-19|CYP3A4|O
DDI-DrugBank.d460.s2|21-29|metabolic|O
DDI-DrugBank.d460.s2|31-39|reactions|O
DDI-DrugBank.d460.s2|41-43|was|O
DDI-DrugBank.d460.s2|45-47|not|O
DDI-DrugBank.d460.s2|49-56|detected|O
DDI-DrugBank.d460.s2|58-59|in|O
DDI-DrugBank.d460.s2|61-62|in|O
DDI-DrugBank.d460.s2|64-68|vitro|O
DDI-DrugBank.d460.s2|70-80|experiments|O
DDI-DrugBank.d460.s2|81-81|.|O
DDI-DrugBank.d460.s3|0-8|Glyburide|drug
DDI-DrugBank.d460.s3|9-9|:|O
DDI-DrugBank.d460.s3|11-12|In|O
DDI-DrugBank.d460.s3|14-14|a|O
DDI-DrugBank.d460.s3|16-25|randomized|O
DDI-DrugBank.d460.s3|26-26|,|O
DDI-DrugBank.d460.s3|28-40|multiple-dose|O
DDI-DrugBank.d460.s3|42-50|crossover|O
DDI-DrugBank.d460.s3|52-56|study|O
DDI-DrugBank.d460.s3|57-57|,|O
DDI-DrugBank.d460.s3|59-66|patients|O
DDI-DrugBank.d460.s3|68-71|with|O
DDI-DrugBank.d460.s3|73-76|Type|O
DDI-DrugBank.d460.s3|78-78|2|O
DDI-DrugBank.d460.s3|80-87|diabetes|O
DDI-DrugBank.d460.s3|89-92|were|O
DDI-DrugBank.d460.s3|94-105|administered|O
DDI-DrugBank.d460.s3|107-109|120|O
DDI-DrugBank.d460.s3|111-112|mg|O
DDI-DrugBank.d460.s3|114-120|Starlix|brand
DDI-DrugBank.d460.s3|122-126|three|O
DDI-DrugBank.d460.s3|128-132|times|O
DDI-DrugBank.d460.s3|134-134|a|O
DDI-DrugBank.d460.s3|136-138|day|O
DDI-DrugBank.d460.s3|140-145|before|O
DDI-DrugBank.d460.s3|147-151|meals|O
DDI-DrugBank.d460.s3|153-155|for|O
DDI-DrugBank.d460.s3|157-157|1|O
DDI-DrugBank.d460.s3|159-161|day|O
DDI-DrugBank.d460.s3|163-164|in|O
DDI-DrugBank.d460.s3|166-176|combination|O
DDI-DrugBank.d460.s3|178-181|with|O
DDI-DrugBank.d460.s3|183-191|glyburide|drug
DDI-DrugBank.d460.s3|193-194|10|O
DDI-DrugBank.d460.s3|196-197|mg|O
DDI-DrugBank.d460.s3|199-203|daily|O
DDI-DrugBank.d460.s3|204-204|.|O
DDI-DrugBank.d460.s4|0-4|There|O
DDI-DrugBank.d460.s4|6-9|were|O
DDI-DrugBank.d460.s4|11-12|no|O
DDI-DrugBank.d460.s4|14-23|clinically|O
DDI-DrugBank.d460.s4|25-32|relevant|O
DDI-DrugBank.d460.s4|34-44|alterations|O
DDI-DrugBank.d460.s4|46-47|in|O
DDI-DrugBank.d460.s4|49-51|the|O
DDI-DrugBank.d460.s4|53-68|pharmacokinetics|O
DDI-DrugBank.d460.s4|70-71|of|O
DDI-DrugBank.d460.s4|73-78|either|O
DDI-DrugBank.d460.s4|80-84|agent|O
DDI-DrugBank.d460.s4|85-85|.|O
DDI-DrugBank.d460.s5|0-8|Metformin|drug
DDI-DrugBank.d460.s5|9-9|:|O
DDI-DrugBank.d460.s5|11-14|When|O
DDI-DrugBank.d460.s5|16-22|Starlix|brand
DDI-DrugBank.d460.s5|24-26|120|O
DDI-DrugBank.d460.s5|28-29|mg|O
DDI-DrugBank.d460.s5|31-35|three|O
DDI-DrugBank.d460.s5|37-41|times|O
DDI-DrugBank.d460.s5|43-47|daily|O
DDI-DrugBank.d460.s5|49-54|before|O
DDI-DrugBank.d460.s5|56-60|meals|O
DDI-DrugBank.d460.s5|62-64|was|O
DDI-DrugBank.d460.s5|66-77|administered|O
DDI-DrugBank.d460.s5|79-80|in|O
DDI-DrugBank.d460.s5|82-92|combination|O
DDI-DrugBank.d460.s5|94-97|with|O
DDI-DrugBank.d460.s5|99-107|metformin|drug
DDI-DrugBank.d460.s5|109-111|500|O
DDI-DrugBank.d460.s5|113-114|mg|O
DDI-DrugBank.d460.s5|116-120|three|O
DDI-DrugBank.d460.s5|122-126|times|O
DDI-DrugBank.d460.s5|128-132|daily|O
DDI-DrugBank.d460.s5|134-135|to|O
DDI-DrugBank.d460.s5|137-144|patients|O
DDI-DrugBank.d460.s5|146-149|with|O
DDI-DrugBank.d460.s5|151-154|Type|O
DDI-DrugBank.d460.s5|156-156|2|O
DDI-DrugBank.d460.s5|158-165|diabetes|O
DDI-DrugBank.d460.s5|166-166|,|O
DDI-DrugBank.d460.s5|168-172|there|O
DDI-DrugBank.d460.s5|174-177|were|O
DDI-DrugBank.d460.s5|179-180|no|O
DDI-DrugBank.d460.s5|182-191|clinically|O
DDI-DrugBank.d460.s5|193-200|relevant|O
DDI-DrugBank.d460.s5|202-208|changes|O
DDI-DrugBank.d460.s5|210-211|in|O
DDI-DrugBank.d460.s5|213-215|the|O
DDI-DrugBank.d460.s5|217-232|pharmacokinetics|O
DDI-DrugBank.d460.s5|234-235|of|O
DDI-DrugBank.d460.s5|237-242|either|O
DDI-DrugBank.d460.s5|244-248|agent|O
DDI-DrugBank.d460.s5|249-249|.|O
DDI-DrugBank.d460.s6|0-6|Digoxin|drug
DDI-DrugBank.d460.s6|7-7|:|O
DDI-DrugBank.d460.s6|9-12|When|O
DDI-DrugBank.d460.s6|14-20|Starlix|brand
DDI-DrugBank.d460.s6|22-24|120|O
DDI-DrugBank.d460.s6|26-27|mg|O
DDI-DrugBank.d460.s6|29-34|before|O
DDI-DrugBank.d460.s6|36-40|meals|O
DDI-DrugBank.d460.s6|42-44|was|O
DDI-DrugBank.d460.s6|46-57|administered|O
DDI-DrugBank.d460.s6|59-60|in|O
DDI-DrugBank.d460.s6|62-72|combination|O
DDI-DrugBank.d460.s6|74-77|with|O
DDI-DrugBank.d460.s6|79-79|a|O
DDI-DrugBank.d460.s6|81-86|single|O
DDI-DrugBank.d460.s6|88-91|1-mg|O
DDI-DrugBank.d460.s6|93-96|dose|O
DDI-DrugBank.d460.s6|98-99|of|O
DDI-DrugBank.d460.s6|101-107|digoxin|drug
DDI-DrugBank.d460.s6|109-110|to|O
DDI-DrugBank.d460.s6|112-118|healthy|O
DDI-DrugBank.d460.s6|120-129|volunteers|O
DDI-DrugBank.d460.s6|130-130|,|O
DDI-DrugBank.d460.s6|132-136|there|O
DDI-DrugBank.d460.s6|138-141|were|O
DDI-DrugBank.d460.s6|143-144|no|O
DDI-DrugBank.d460.s6|146-155|clinically|O
DDI-DrugBank.d460.s6|157-164|relevant|O
DDI-DrugBank.d460.s6|166-172|changes|O
DDI-DrugBank.d460.s6|174-175|in|O
DDI-DrugBank.d460.s6|177-179|the|O
DDI-DrugBank.d460.s6|181-196|pharmacokinetics|O
DDI-DrugBank.d460.s6|198-199|of|O
DDI-DrugBank.d460.s6|201-206|either|O
DDI-DrugBank.d460.s6|208-212|agent|O
DDI-DrugBank.d460.s6|213-213|.|O
DDI-DrugBank.d460.s7|0-7|Warfarin|drug
DDI-DrugBank.d460.s7|8-8|:|O
DDI-DrugBank.d460.s7|10-13|When|O
DDI-DrugBank.d460.s7|15-21|healthy|O
DDI-DrugBank.d460.s7|23-30|subjects|O
DDI-DrugBank.d460.s7|32-35|were|O
DDI-DrugBank.d460.s7|37-48|administered|O
DDI-DrugBank.d460.s7|50-56|Starlix|brand
DDI-DrugBank.d460.s7|58-60|120|O
DDI-DrugBank.d460.s7|62-63|mg|O
DDI-DrugBank.d460.s7|65-69|three|O
DDI-DrugBank.d460.s7|71-75|times|O
DDI-DrugBank.d460.s7|77-81|daily|O
DDI-DrugBank.d460.s7|83-88|before|O
DDI-DrugBank.d460.s7|90-94|meals|O
DDI-DrugBank.d460.s7|96-98|for|O
DDI-DrugBank.d460.s7|100-103|four|O
DDI-DrugBank.d460.s7|105-108|days|O
DDI-DrugBank.d460.s7|110-111|in|O
DDI-DrugBank.d460.s7|113-123|combination|O
DDI-DrugBank.d460.s7|125-128|with|O
DDI-DrugBank.d460.s7|130-130|a|O
DDI-DrugBank.d460.s7|132-137|single|O
DDI-DrugBank.d460.s7|139-142|dose|O
DDI-DrugBank.d460.s7|144-145|of|O
DDI-DrugBank.d460.s7|147-154|warfarin|drug
DDI-DrugBank.d460.s7|156-157|30|O
DDI-DrugBank.d460.s7|159-160|mg|O
DDI-DrugBank.d460.s7|162-163|on|O
DDI-DrugBank.d460.s7|165-167|day|O
DDI-DrugBank.d460.s7|169-169|2|O
DDI-DrugBank.d460.s7|170-170|,|O
DDI-DrugBank.d460.s7|172-176|there|O
DDI-DrugBank.d460.s7|178-181|were|O
DDI-DrugBank.d460.s7|183-184|no|O
DDI-DrugBank.d460.s7|186-196|alterations|O
DDI-DrugBank.d460.s7|198-199|in|O
DDI-DrugBank.d460.s7|201-203|the|O
DDI-DrugBank.d460.s7|205-220|pharmacokinetics|O
DDI-DrugBank.d460.s7|222-223|of|O
DDI-DrugBank.d460.s7|225-230|either|O
DDI-DrugBank.d460.s7|232-236|agent|O
DDI-DrugBank.d460.s7|237-237|.|O
DDI-DrugBank.d460.s8|0-10|Prothrombin|O
DDI-DrugBank.d460.s8|12-15|time|O
DDI-DrugBank.d460.s8|17-19|was|O
DDI-DrugBank.d460.s8|21-23|not|O
DDI-DrugBank.d460.s8|25-32|affected|O
DDI-DrugBank.d460.s8|33-33|.|O
DDI-DrugBank.d460.s9|0-9|Diclofenac|drug
DDI-DrugBank.d460.s9|10-10|:|O
DDI-DrugBank.d460.s9|12-25|Administration|O
DDI-DrugBank.d460.s9|27-28|of|O
DDI-DrugBank.d460.s9|30-36|morning|O
DDI-DrugBank.d460.s9|38-40|and|O
DDI-DrugBank.d460.s9|42-46|lunch|O
DDI-DrugBank.d460.s9|48-52|doses|O
DDI-DrugBank.d460.s9|54-55|of|O
DDI-DrugBank.d460.s9|57-63|Starlix|brand
DDI-DrugBank.d460.s9|65-67|120|O
DDI-DrugBank.d460.s9|69-70|mg|O
DDI-DrugBank.d460.s9|72-73|in|O
DDI-DrugBank.d460.s9|75-85|combination|O
DDI-DrugBank.d460.s9|87-90|with|O
DDI-DrugBank.d460.s9|92-92|a|O
DDI-DrugBank.d460.s9|94-99|single|O
DDI-DrugBank.d460.s9|101-105|75-mg|O
DDI-DrugBank.d460.s9|107-110|dose|O
DDI-DrugBank.d460.s9|112-113|of|O
DDI-DrugBank.d460.s9|115-124|diclofenac|drug
DDI-DrugBank.d460.s9|126-127|in|O
DDI-DrugBank.d460.s9|129-135|healthy|O
DDI-DrugBank.d460.s9|137-146|volunteers|O
DDI-DrugBank.d460.s9|148-155|resulted|O
DDI-DrugBank.d460.s9|157-158|in|O
DDI-DrugBank.d460.s9|160-161|no|O
DDI-DrugBank.d460.s9|163-173|significant|O
DDI-DrugBank.d460.s9|175-181|changes|O
DDI-DrugBank.d460.s9|183-184|to|O
DDI-DrugBank.d460.s9|186-188|the|O
DDI-DrugBank.d460.s9|190-205|pharmacokinetics|O
DDI-DrugBank.d460.s9|207-208|of|O
DDI-DrugBank.d460.s9|210-215|either|O
DDI-DrugBank.d460.s9|217-221|agent|O
DDI-DrugBank.d460.s9|222-222|.|O
DDI-DrugBank.d460.s10|0-10|Nateglinide|drug
DDI-DrugBank.d460.s10|12-13|is|O
DDI-DrugBank.d460.s10|15-20|highly|O
DDI-DrugBank.d460.s10|22-26|bound|O
DDI-DrugBank.d460.s10|28-29|to|O
DDI-DrugBank.d460.s10|31-36|plasma|O
DDI-DrugBank.d460.s10|38-45|proteins|O
DDI-DrugBank.d460.s10|47-47|(|O
DDI-DrugBank.d460.s10|48-49|98|O
DDI-DrugBank.d460.s10|50-50|%|O
DDI-DrugBank.d460.s10|51-51|)|O
DDI-DrugBank.d460.s10|52-52|,|O
DDI-DrugBank.d460.s10|54-59|mainly|O
DDI-DrugBank.d460.s10|61-67|albumin|O
DDI-DrugBank.d460.s10|68-68|.|O
DDI-DrugBank.d460.s11|0-1|In|O
DDI-DrugBank.d460.s11|3-7|vitro|O
DDI-DrugBank.d460.s11|9-20|displacement|O
DDI-DrugBank.d460.s11|22-28|studies|O
DDI-DrugBank.d460.s11|30-33|with|O
DDI-DrugBank.d460.s11|35-40|highly|O
DDI-DrugBank.d460.s11|42-54|protein-bound|O
DDI-DrugBank.d460.s11|56-60|drugs|O
DDI-DrugBank.d460.s11|62-65|such|O
DDI-DrugBank.d460.s11|67-68|as|O
DDI-DrugBank.d460.s11|70-79|furosemide|drug
DDI-DrugBank.d460.s11|80-80|,|O
DDI-DrugBank.d460.s11|82-92|propranolol|drug
DDI-DrugBank.d460.s11|93-93|,|O
DDI-DrugBank.d460.s11|95-103|captopril|drug
DDI-DrugBank.d460.s11|104-104|,|O
DDI-DrugBank.d460.s11|106-116|nicardipine|drug
DDI-DrugBank.d460.s11|117-117|,|O
DDI-DrugBank.d460.s11|119-129|pravastatin|drug
DDI-DrugBank.d460.s11|130-130|,|O
DDI-DrugBank.d460.s11|132-140|glyburide|drug
DDI-DrugBank.d460.s11|141-141|,|O
DDI-DrugBank.d460.s11|143-150|warfarin|drug
DDI-DrugBank.d460.s11|151-151|,|O
DDI-DrugBank.d460.s11|153-161|phenytoin|drug
DDI-DrugBank.d460.s11|162-162|,|O
DDI-DrugBank.d460.s11|164-183|acetylsalicylic acid|drug
DDI-DrugBank.d460.s11|184-184|,|O
DDI-DrugBank.d460.s11|186-196|tolbutamide|drug
DDI-DrugBank.d460.s11|197-197|,|O
DDI-DrugBank.d460.s11|199-201|and|O
DDI-DrugBank.d460.s11|203-211|metformin|drug
DDI-DrugBank.d460.s11|213-218|showed|O
DDI-DrugBank.d460.s11|220-221|no|O
DDI-DrugBank.d460.s11|223-231|influence|O
DDI-DrugBank.d460.s11|233-234|on|O
DDI-DrugBank.d460.s11|236-238|the|O
DDI-DrugBank.d460.s11|240-245|extent|O
DDI-DrugBank.d460.s11|247-248|of|O
DDI-DrugBank.d460.s11|250-260|nateglinide|drug
DDI-DrugBank.d460.s11|262-268|protein|O
DDI-DrugBank.d460.s11|270-276|binding|O
DDI-DrugBank.d460.s11|277-277|.|O
DDI-DrugBank.d460.s12|0-8|Similarly|O
DDI-DrugBank.d460.s12|9-9|,|O
DDI-DrugBank.d460.s12|11-21|nateglinide|drug
DDI-DrugBank.d460.s12|23-25|had|O
DDI-DrugBank.d460.s12|27-28|no|O
DDI-DrugBank.d460.s12|30-38|influence|O
DDI-DrugBank.d460.s12|40-41|on|O
DDI-DrugBank.d460.s12|43-45|the|O
DDI-DrugBank.d460.s12|47-51|serum|O
DDI-DrugBank.d460.s12|53-59|protein|O
DDI-DrugBank.d460.s12|61-67|binding|O
DDI-DrugBank.d460.s12|69-70|of|O
DDI-DrugBank.d460.s12|72-82|propranolol|drug
DDI-DrugBank.d460.s12|83-83|,|O
DDI-DrugBank.d460.s12|85-93|glyburide|drug
DDI-DrugBank.d460.s12|94-94|,|O
DDI-DrugBank.d460.s12|96-106|nicardipine|drug
DDI-DrugBank.d460.s12|107-107|,|O
DDI-DrugBank.d460.s12|109-116|warfarin|drug
DDI-DrugBank.d460.s12|117-117|,|O
DDI-DrugBank.d460.s12|119-127|phenytoin|drug
DDI-DrugBank.d460.s12|128-128|,|O
DDI-DrugBank.d460.s12|130-149|acetylsalicylic acid|drug
DDI-DrugBank.d460.s12|150-150|,|O
DDI-DrugBank.d460.s12|152-154|and|O
DDI-DrugBank.d460.s12|156-166|tolbutamide|drug
DDI-DrugBank.d460.s12|168-169|in|O
DDI-DrugBank.d460.s12|171-175|vitro|O
DDI-DrugBank.d460.s12|177-177|.|O
DDI-DrugBank.d460.s13|0-6|However|O
DDI-DrugBank.d460.s13|7-7|,|O
DDI-DrugBank.d460.s13|9-15|prudent|O
DDI-DrugBank.d460.s13|17-26|evaluation|O
DDI-DrugBank.d460.s13|28-29|of|O
DDI-DrugBank.d460.s13|31-40|individual|O
DDI-DrugBank.d460.s13|42-46|cases|O
DDI-DrugBank.d460.s13|48-49|is|O
DDI-DrugBank.d460.s13|51-59|warranted|O
DDI-DrugBank.d460.s13|61-62|in|O
DDI-DrugBank.d460.s13|64-66|the|O
DDI-DrugBank.d460.s13|68-75|clinical|O
DDI-DrugBank.d460.s13|77-83|setting|O
DDI-DrugBank.d460.s13|84-84|.|O
DDI-DrugBank.d460.s14|0-6|Certain|O
DDI-DrugBank.d460.s14|8-12|drugs|O
DDI-DrugBank.d460.s14|13-13|,|O
DDI-DrugBank.d460.s14|15-23|including|O
DDI-DrugBank.d460.s14|25-61|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d460.s14|63-63|(|O
DDI-DrugBank.d460.s14|64-69|NSAIDs|group
DDI-DrugBank.d460.s14|70-70|)|O
DDI-DrugBank.d460.s14|71-71|,|O
DDI-DrugBank.d460.s14|73-83|salicylates|group
DDI-DrugBank.d460.s14|84-84|,|O
DDI-DrugBank.d460.s14|86-113|monoamine oxidase inhibitors|group
DDI-DrugBank.d460.s14|114-114|,|O
DDI-DrugBank.d460.s14|116-118|and|O
DDI-DrugBank.d460.s14|120-164|non-selective beta-adrenergic-blocking agents|group
DDI-DrugBank.d460.s14|166-168|may|O
DDI-DrugBank.d460.s14|170-179|potentiate|O
DDI-DrugBank.d460.s14|181-183|the|O
DDI-DrugBank.d460.s14|185-196|hypoglycemic|O
DDI-DrugBank.d460.s14|198-203|action|O
DDI-DrugBank.d460.s14|205-206|of|O
DDI-DrugBank.d460.s14|208-214|Starlix|brand
DDI-DrugBank.d460.s14|216-218|and|O
DDI-DrugBank.d460.s14|220-224|other|O
DDI-DrugBank.d460.s14|226-229|oral|O
DDI-DrugBank.d460.s14|231-248|antidiabetic drugs|group
DDI-DrugBank.d460.s14|249-249|.|O
DDI-DrugBank.d460.s15|0-6|Certain|O
DDI-DrugBank.d460.s15|8-12|drugs|O
DDI-DrugBank.d460.s15|14-22|including|O
DDI-DrugBank.d460.s15|24-32|thiazides|group
DDI-DrugBank.d460.s15|33-33|,|O
DDI-DrugBank.d460.s15|35-49|corticosteroids|group
DDI-DrugBank.d460.s15|50-50|,|O
DDI-DrugBank.d460.s15|52-67|thyroid products|group
DDI-DrugBank.d460.s15|68-68|,|O
DDI-DrugBank.d460.s15|70-72|and|O
DDI-DrugBank.d460.s15|74-89|sympathomimetics|group
DDI-DrugBank.d460.s15|91-93|may|O
DDI-DrugBank.d460.s15|95-100|reduce|O
DDI-DrugBank.d460.s15|102-104|the|O
DDI-DrugBank.d460.s15|106-117|hypoglycemic|O
DDI-DrugBank.d460.s15|119-124|action|O
DDI-DrugBank.d460.s15|126-127|of|O
DDI-DrugBank.d460.s15|129-135|Starlix|brand
DDI-DrugBank.d460.s15|137-139|and|O
DDI-DrugBank.d460.s15|141-145|other|O
DDI-DrugBank.d460.s15|147-150|oral|O
DDI-DrugBank.d460.s15|152-169|antidiabetic drugs|group
DDI-DrugBank.d460.s15|170-170|.|O
DDI-DrugBank.d460.s16|0-3|When|O
DDI-DrugBank.d460.s16|5-9|these|O
DDI-DrugBank.d460.s16|11-15|drugs|O
DDI-DrugBank.d460.s16|17-19|are|O
DDI-DrugBank.d460.s16|21-32|administered|O
DDI-DrugBank.d460.s16|34-35|to|O
DDI-DrugBank.d460.s16|37-38|or|O
DDI-DrugBank.d460.s16|40-48|withdrawn|O
DDI-DrugBank.d460.s16|50-53|from|O
DDI-DrugBank.d460.s16|55-62|patients|O
DDI-DrugBank.d460.s16|64-72|receiving|O
DDI-DrugBank.d460.s16|74-80|Starlix|brand
DDI-DrugBank.d460.s16|81-81|,|O
DDI-DrugBank.d460.s16|83-85|the|O
DDI-DrugBank.d460.s16|87-93|patient|O
DDI-DrugBank.d460.s16|95-100|should|O
DDI-DrugBank.d460.s16|102-103|be|O
DDI-DrugBank.d460.s16|105-112|observed|O
DDI-DrugBank.d460.s16|114-120|closely|O
DDI-DrugBank.d460.s16|122-124|for|O
DDI-DrugBank.d460.s16|126-132|changes|O
DDI-DrugBank.d460.s16|134-135|in|O
DDI-DrugBank.d460.s16|137-144|glycemic|O
DDI-DrugBank.d460.s16|146-152|control|O
DDI-DrugBank.d460.s16|153-153|.|O
DDI-DrugBank.d398.s0|0-2|The|O
DDI-DrugBank.d398.s0|4-6|use|O
DDI-DrugBank.d398.s0|8-9|of|O
DDI-DrugBank.d398.s0|11-17|codeine|drug
DDI-DrugBank.d398.s0|19-21|may|O
DDI-DrugBank.d398.s0|23-28|result|O
DDI-DrugBank.d398.s0|30-31|in|O
DDI-DrugBank.d398.s0|33-40|additive|O
DDI-DrugBank.d398.s0|42-44|CNS|O
DDI-DrugBank.d398.s0|46-55|depressant|O
DDI-DrugBank.d398.s0|57-63|effects|O
DDI-DrugBank.d398.s0|65-68|when|O
DDI-DrugBank.d398.s0|70-83|coadministered|O
DDI-DrugBank.d398.s0|85-88|with|O
DDI-DrugBank.d398.s0|90-96|alcohol|drug
DDI-DrugBank.d398.s0|97-97|,|O
DDI-DrugBank.d398.s0|99-112|antihistamines|group
DDI-DrugBank.d398.s0|113-113|,|O
DDI-DrugBank.d398.s0|115-127|psychotropics|group
DDI-DrugBank.d398.s0|129-130|or|O
DDI-DrugBank.d398.s0|132-136|other|O
DDI-DrugBank.d398.s0|138-142|drugs|O
DDI-DrugBank.d398.s0|144-147|that|O
DDI-DrugBank.d398.s0|149-155|produce|O
DDI-DrugBank.d398.s0|157-159|CNS|O
DDI-DrugBank.d398.s0|161-170|depression|O
DDI-DrugBank.d398.s0|171-171|.|O
DDI-DrugBank.d398.s1|0-6|Serious|O
DDI-DrugBank.d398.s1|8-15|toxicity|O
DDI-DrugBank.d398.s1|17-19|may|O
DDI-DrugBank.d398.s1|21-26|result|O
DDI-DrugBank.d398.s1|28-29|if|O
DDI-DrugBank.d398.s1|31-46|dextromethorphan|drug
DDI-DrugBank.d398.s1|48-49|is|O
DDI-DrugBank.d398.s1|51-64|coadministered|O
DDI-DrugBank.d398.s1|66-69|with|O
DDI-DrugBank.d398.s1|71-98|monoamine oxidase inhibitors|group
DDI-DrugBank.d398.s1|100-100|(|O
DDI-DrugBank.d398.s1|101-105|MAOIs|group
DDI-DrugBank.d398.s1|106-106|)|O
DDI-DrugBank.d398.s1|107-107|.|O
DDI-DrugBank.d398.s2|0-2|The|O
DDI-DrugBank.d398.s2|4-6|use|O
DDI-DrugBank.d398.s2|8-9|of|O
DDI-DrugBank.d398.s2|11-39|dextromethorphan hydrobromide|drug
DDI-DrugBank.d398.s2|41-43|may|O
DDI-DrugBank.d398.s2|45-50|result|O
DDI-DrugBank.d398.s2|52-53|in|O
DDI-DrugBank.d398.s2|55-62|additive|O
DDI-DrugBank.d398.s2|64-66|CNS|O
DDI-DrugBank.d398.s2|68-77|depressant|O
DDI-DrugBank.d398.s2|79-85|effects|O
DDI-DrugBank.d398.s2|87-90|when|O
DDI-DrugBank.d398.s2|92-105|coadministered|O
DDI-DrugBank.d398.s2|107-110|with|O
DDI-DrugBank.d398.s2|112-118|alcohol|drug
DDI-DrugBank.d398.s2|119-119|,|O
DDI-DrugBank.d398.s2|121-134|antihistamines|group
DDI-DrugBank.d398.s2|135-135|,|O
DDI-DrugBank.d398.s2|137-149|psychotropics|group
DDI-DrugBank.d398.s2|151-152|or|O
DDI-DrugBank.d398.s2|154-158|other|O
DDI-DrugBank.d398.s2|160-164|drugs|O
DDI-DrugBank.d398.s2|166-169|that|O
DDI-DrugBank.d398.s2|171-177|produce|O
DDI-DrugBank.d398.s2|179-181|CNS|O
DDI-DrugBank.d398.s2|183-192|depression|O
DDI-DrugBank.d398.s2|193-193|.|O
DDI-DrugBank.d140.s0|0-2|The|O
DDI-DrugBank.d140.s0|4-7|risk|O
DDI-DrugBank.d140.s0|9-10|of|O
DDI-DrugBank.d140.s0|12-19|myopathy|O
DDI-DrugBank.d140.s0|21-26|during|O
DDI-DrugBank.d140.s0|28-36|treatment|O
DDI-DrugBank.d140.s0|38-41|with|O
DDI-DrugBank.d140.s0|43-47|drugs|O
DDI-DrugBank.d140.s0|49-50|of|O
DDI-DrugBank.d140.s0|52-55|this|O
DDI-DrugBank.d140.s0|57-61|class|O
DDI-DrugBank.d140.s0|63-64|is|O
DDI-DrugBank.d140.s0|66-74|increased|O
DDI-DrugBank.d140.s0|76-79|with|O
DDI-DrugBank.d140.s0|81-90|concurrent|O
DDI-DrugBank.d140.s0|92-105|administration|O
DDI-DrugBank.d140.s0|107-108|of|O
DDI-DrugBank.d140.s0|110-121|cyclosporine|drug
DDI-DrugBank.d140.s0|122-122|,|O
DDI-DrugBank.d140.s0|124-146|fibric acid derivatives|group
DDI-DrugBank.d140.s0|147-147|,|O
DDI-DrugBank.d140.s0|149-154|niacin|drug
DDI-DrugBank.d140.s0|156-156|(|O
DDI-DrugBank.d140.s0|157-170|nicotinic acid|drug
DDI-DrugBank.d140.s0|171-171|)|O
DDI-DrugBank.d140.s0|172-172|,|O
DDI-DrugBank.d140.s0|174-185|erythromycin|drug
DDI-DrugBank.d140.s0|186-186|,|O
DDI-DrugBank.d140.s0|188-204|azole antifungals|group
DDI-DrugBank.d140.s0|205-205|.|O
DDI-DrugBank.d140.s1|0-6|Antacid|group
DDI-DrugBank.d140.s1|7-7|:|O
DDI-DrugBank.d140.s1|9-12|When|O
DDI-DrugBank.d140.s1|14-25|atorvastatin|drug
DDI-DrugBank.d140.s1|27-29|and|O
DDI-DrugBank.d140.s1|31-39|Maalox TC|brand
DDI-DrugBank.d140.s1|41-50|suspension|O
DDI-DrugBank.d140.s1|52-55|were|O
DDI-DrugBank.d140.s1|57-70|coadministered|O
DDI-DrugBank.d140.s1|71-71|,|O
DDI-DrugBank.d140.s1|73-78|plasma|O
DDI-DrugBank.d140.s1|80-93|concentrations|O
DDI-DrugBank.d140.s1|95-96|of|O
DDI-DrugBank.d140.s1|98-109|atorvastatin|drug
DDI-DrugBank.d140.s1|111-119|decreased|O
DDI-DrugBank.d140.s1|121-133|approximately|O
DDI-DrugBank.d140.s1|135-136|35|O
DDI-DrugBank.d140.s1|137-137|%|O
DDI-DrugBank.d140.s1|138-138|.|O
DDI-DrugBank.d140.s2|0-6|However|O
DDI-DrugBank.d140.s2|7-7|,|O
DDI-DrugBank.d140.s2|9-13|LDL-C|O
DDI-DrugBank.d140.s2|15-23|reduction|O
DDI-DrugBank.d140.s2|25-27|was|O
DDI-DrugBank.d140.s2|29-31|not|O
DDI-DrugBank.d140.s2|33-39|altered|O
DDI-DrugBank.d140.s2|40-40|.|O
DDI-DrugBank.d140.s3|0-9|Antipyrine|drug
DDI-DrugBank.d140.s3|10-10|:|O
DDI-DrugBank.d140.s3|12-18|Because|O
DDI-DrugBank.d140.s3|20-31|atorvastatin|drug
DDI-DrugBank.d140.s3|33-36|does|O
DDI-DrugBank.d140.s3|38-40|not|O
DDI-DrugBank.d140.s3|42-47|affect|O
DDI-DrugBank.d140.s3|49-51|the|O
DDI-DrugBank.d140.s3|53-68|pharmacokinetics|O
DDI-DrugBank.d140.s3|70-71|of|O
DDI-DrugBank.d140.s3|73-82|antipyrine|drug
DDI-DrugBank.d140.s3|83-83|,|O
DDI-DrugBank.d140.s3|85-96|interactions|O
DDI-DrugBank.d140.s3|98-101|with|O
DDI-DrugBank.d140.s3|103-107|other|O
DDI-DrugBank.d140.s3|109-113|drugs|drug
DDI-DrugBank.d140.s3|115-125|metabolized|O
DDI-DrugBank.d140.s3|127-129|via|O
DDI-DrugBank.d140.s3|131-133|the|O
DDI-DrugBank.d140.s3|135-138|same|O
DDI-DrugBank.d140.s3|140-149|cytochrome|O
DDI-DrugBank.d140.s3|151-158|isozymes|O
DDI-DrugBank.d140.s3|160-162|are|O
DDI-DrugBank.d140.s3|164-166|not|O
DDI-DrugBank.d140.s3|168-175|expected|O
DDI-DrugBank.d140.s3|176-176|.|O
DDI-DrugBank.d140.s4|0-9|Colestipol|drug
DDI-DrugBank.d140.s4|10-10|:|O
DDI-DrugBank.d140.s4|12-17|Plasma|O
DDI-DrugBank.d140.s4|19-32|concentrations|O
DDI-DrugBank.d140.s4|34-35|of|O
DDI-DrugBank.d140.s4|37-48|atorvastatin|drug
DDI-DrugBank.d140.s4|50-58|decreased|O
DDI-DrugBank.d140.s4|60-72|approximately|O
DDI-DrugBank.d140.s4|74-75|25|O
DDI-DrugBank.d140.s4|76-76|%|O
DDI-DrugBank.d140.s4|78-81|when|O
DDI-DrugBank.d140.s4|83-92|colestipol|drug
DDI-DrugBank.d140.s4|94-96|and|O
DDI-DrugBank.d140.s4|98-109|atorvastatin|drug
DDI-DrugBank.d140.s4|111-114|were|O
DDI-DrugBank.d140.s4|116-129|coadministered|O
DDI-DrugBank.d140.s4|130-130|.|O
DDI-DrugBank.d140.s5|0-6|However|O
DDI-DrugBank.d140.s5|7-7|,|O
DDI-DrugBank.d140.s5|9-13|LDL-C|O
DDI-DrugBank.d140.s5|15-23|reduction|O
DDI-DrugBank.d140.s5|25-27|was|O
DDI-DrugBank.d140.s5|29-35|greater|O
DDI-DrugBank.d140.s5|37-40|when|O
DDI-DrugBank.d140.s5|42-53|atorvastatin|drug
DDI-DrugBank.d140.s5|55-57|and|O
DDI-DrugBank.d140.s5|59-68|colestipol|drug
DDI-DrugBank.d140.s5|70-73|were|O
DDI-DrugBank.d140.s5|75-88|coadministered|O
DDI-DrugBank.d140.s5|90-93|than|O
DDI-DrugBank.d140.s5|95-98|when|O
DDI-DrugBank.d140.s5|100-105|either|O
DDI-DrugBank.d140.s5|107-110|drug|O
DDI-DrugBank.d140.s5|112-114|was|O
DDI-DrugBank.d140.s5|116-120|given|O
DDI-DrugBank.d140.s5|122-126|alone|O
DDI-DrugBank.d140.s5|127-127|.|O
DDI-DrugBank.d140.s6|0-9|Cimetidine|drug
DDI-DrugBank.d140.s6|10-10|:|O
DDI-DrugBank.d140.s6|12-23|Atorvastatin|drug
DDI-DrugBank.d140.s6|25-30|plasma|O
DDI-DrugBank.d140.s6|32-45|concentrations|O
DDI-DrugBank.d140.s6|47-49|and|O
DDI-DrugBank.d140.s6|51-55|LDL-C|O
DDI-DrugBank.d140.s6|57-65|reduction|O
DDI-DrugBank.d140.s6|67-70|were|O
DDI-DrugBank.d140.s6|72-74|not|O
DDI-DrugBank.d140.s6|76-82|altered|O
DDI-DrugBank.d140.s6|84-85|by|O
DDI-DrugBank.d140.s6|87-102|coadministration|O
DDI-DrugBank.d140.s6|104-105|of|O
DDI-DrugBank.d140.s6|107-116|cimetidine|drug
DDI-DrugBank.d140.s6|117-117|.|O
DDI-DrugBank.d140.s7|0-6|Digoxin|drug
DDI-DrugBank.d140.s7|7-7|:|O
DDI-DrugBank.d140.s7|9-12|When|O
DDI-DrugBank.d140.s7|14-21|multiple|O
DDI-DrugBank.d140.s7|23-27|doses|O
DDI-DrugBank.d140.s7|29-30|of|O
DDI-DrugBank.d140.s7|32-43|atorvastatin|drug
DDI-DrugBank.d140.s7|45-47|and|O
DDI-DrugBank.d140.s7|49-55|digoxin|drug
DDI-DrugBank.d140.s7|57-60|were|O
DDI-DrugBank.d140.s7|62-75|coadministered|O
DDI-DrugBank.d140.s7|76-76|,|O
DDI-DrugBank.d140.s7|78-89|steady-state|O
DDI-DrugBank.d140.s7|91-96|plasma|O
DDI-DrugBank.d140.s7|98-104|digoxin|drug
DDI-DrugBank.d140.s7|106-119|concentrations|O
DDI-DrugBank.d140.s7|121-129|increased|O
DDI-DrugBank.d140.s7|131-132|by|O
DDI-DrugBank.d140.s7|134-146|approximately|O
DDI-DrugBank.d140.s7|148-149|20|O
DDI-DrugBank.d140.s7|150-150|%|O
DDI-DrugBank.d140.s7|151-151|.|O
DDI-DrugBank.d140.s8|0-7|Patients|O
DDI-DrugBank.d140.s8|9-14|taking|O
DDI-DrugBank.d140.s8|16-22|digoxin|drug
DDI-DrugBank.d140.s8|24-29|should|O
DDI-DrugBank.d140.s8|31-32|be|O
DDI-DrugBank.d140.s8|34-42|monitored|O
DDI-DrugBank.d140.s8|44-56|appropriately|O
DDI-DrugBank.d140.s8|57-57|.|O
DDI-DrugBank.d140.s9|0-11|Erythromycin|drug
DDI-DrugBank.d140.s9|12-12|:|O
DDI-DrugBank.d140.s9|14-15|In|O
DDI-DrugBank.d140.s9|17-23|healthy|O
DDI-DrugBank.d140.s9|25-35|individuals|O
DDI-DrugBank.d140.s9|36-36|,|O
DDI-DrugBank.d140.s9|38-43|plasma|O
DDI-DrugBank.d140.s9|45-58|concentrations|O
DDI-DrugBank.d140.s9|60-61|of|O
DDI-DrugBank.d140.s9|63-74|atorvastatin|drug
DDI-DrugBank.d140.s9|76-84|increased|O
DDI-DrugBank.d140.s9|86-98|approximately|O
DDI-DrugBank.d140.s9|100-101|40|O
DDI-DrugBank.d140.s9|102-102|%|O
DDI-DrugBank.d140.s9|104-107|with|O
DDI-DrugBank.d140.s9|109-124|coadministration|O
DDI-DrugBank.d140.s9|126-127|of|O
DDI-DrugBank.d140.s9|129-140|atorvastatin|drug
DDI-DrugBank.d140.s9|142-144|and|O
DDI-DrugBank.d140.s9|146-157|erythromycin|drug
DDI-DrugBank.d140.s9|158-158|,|O
DDI-DrugBank.d140.s9|160-160|a|O
DDI-DrugBank.d140.s9|162-166|known|O
DDI-DrugBank.d140.s9|168-176|inhibitor|O
DDI-DrugBank.d140.s9|178-179|of|O
DDI-DrugBank.d140.s9|181-190|cytochrome|O
DDI-DrugBank.d140.s9|192-195|P450|O
DDI-DrugBank.d140.s9|197-199|3A4|O
DDI-DrugBank.d140.s9|200-200|.|O
DDI-DrugBank.d140.s10|0-3|Oral|O
DDI-DrugBank.d140.s10|5-18|Contraceptives|group
DDI-DrugBank.d140.s10|19-19|:|O
DDI-DrugBank.d140.s10|21-36|Coadministration|O
DDI-DrugBank.d140.s10|38-39|of|O
DDI-DrugBank.d140.s10|41-52|atorvastatin|drug
DDI-DrugBank.d140.s10|54-56|and|O
DDI-DrugBank.d140.s10|58-59|an|O
DDI-DrugBank.d140.s10|61-64|oral|O
DDI-DrugBank.d140.s10|66-78|contraceptive|group
DDI-DrugBank.d140.s10|80-88|increased|O
DDI-DrugBank.d140.s10|90-92|AUC|O
DDI-DrugBank.d140.s10|94-99|values|O
DDI-DrugBank.d140.s10|101-103|for|O
DDI-DrugBank.d140.s10|105-117|norethindrone|drug
DDI-DrugBank.d140.s10|119-121|and|O
DDI-DrugBank.d140.s10|123-139|ethinyl estradiol|drug
DDI-DrugBank.d140.s10|141-142|by|O
DDI-DrugBank.d140.s10|144-156|approximately|O
DDI-DrugBank.d140.s10|158-159|30|O
DDI-DrugBank.d140.s10|160-160|%|O
DDI-DrugBank.d140.s10|162-164|and|O
DDI-DrugBank.d140.s10|166-167|20|O
DDI-DrugBank.d140.s10|168-168|%|O
DDI-DrugBank.d140.s10|169-169|.|O
DDI-DrugBank.d140.s11|0-4|These|O
DDI-DrugBank.d140.s11|6-14|increases|O
DDI-DrugBank.d140.s11|16-21|should|O
DDI-DrugBank.d140.s11|23-24|be|O
DDI-DrugBank.d140.s11|26-35|considered|O
DDI-DrugBank.d140.s11|37-40|when|O
DDI-DrugBank.d140.s11|42-50|selecting|O
DDI-DrugBank.d140.s11|52-53|an|O
DDI-DrugBank.d140.s11|55-58|oral|O
DDI-DrugBank.d140.s11|60-72|contraceptive|group
DDI-DrugBank.d140.s11|74-76|for|O
DDI-DrugBank.d140.s11|78-78|a|O
DDI-DrugBank.d140.s11|80-84|woman|O
DDI-DrugBank.d140.s11|86-91|taking|O
DDI-DrugBank.d140.s11|93-104|atorvastatin|drug
DDI-DrugBank.d140.s11|105-105|.|O
DDI-DrugBank.d140.s12|0-7|Warfarin|drug
DDI-DrugBank.d140.s12|8-8|:|O
DDI-DrugBank.d140.s12|10-21|Atorvastatin|drug
DDI-DrugBank.d140.s12|23-25|had|O
DDI-DrugBank.d140.s12|27-28|no|O
DDI-DrugBank.d140.s12|30-39|clinically|O
DDI-DrugBank.d140.s12|41-51|significant|O
DDI-DrugBank.d140.s12|53-58|effect|O
DDI-DrugBank.d140.s12|60-61|on|O
DDI-DrugBank.d140.s12|63-73|prothrombin|O
DDI-DrugBank.d140.s12|75-78|time|O
DDI-DrugBank.d140.s12|80-83|when|O
DDI-DrugBank.d140.s12|85-96|administered|O
DDI-DrugBank.d140.s12|98-99|to|O
DDI-DrugBank.d140.s12|101-108|patients|O
DDI-DrugBank.d140.s12|110-118|receiving|O
DDI-DrugBank.d140.s12|120-126|chronic|O
DDI-DrugBank.d140.s12|128-135|warfarin|drug
DDI-DrugBank.d140.s12|137-145|treatment|O
DDI-DrugBank.d140.s12|146-146|.|O
DDI-DrugBank.d140.s13|0-8|Endocrine|O
DDI-DrugBank.d140.s13|10-17|Function|O
DDI-DrugBank.d140.s13|19-46|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d140.s13|48-56|interfere|O
DDI-DrugBank.d140.s13|58-61|with|O
DDI-DrugBank.d140.s13|63-73|cholesterol|O
DDI-DrugBank.d140.s13|75-83|synthesis|O
DDI-DrugBank.d140.s13|85-87|and|O
DDI-DrugBank.d140.s13|89-101|theoretically|O
DDI-DrugBank.d140.s13|103-107|might|O
DDI-DrugBank.d140.s13|109-113|blunt|O
DDI-DrugBank.d140.s13|115-121|adrenal|O
DDI-DrugBank.d140.s13|123-128|and/or|O
DDI-DrugBank.d140.s13|130-136|gonadal|O
DDI-DrugBank.d140.s13|138-144|steroid|O
DDI-DrugBank.d140.s13|146-155|production|O
DDI-DrugBank.d140.s13|156-156|.|O
DDI-DrugBank.d140.s14|0-7|Clinical|O
DDI-DrugBank.d140.s14|9-15|studies|O
DDI-DrugBank.d140.s14|17-20|have|O
DDI-DrugBank.d140.s14|22-26|shown|O
DDI-DrugBank.d140.s14|28-31|that|O
DDI-DrugBank.d140.s14|33-44|atorvastatin|drug
DDI-DrugBank.d140.s14|46-49|does|O
DDI-DrugBank.d140.s14|51-53|not|O
DDI-DrugBank.d140.s14|55-60|reduce|O
DDI-DrugBank.d140.s14|62-66|basal|O
DDI-DrugBank.d140.s14|68-73|plasma|O
DDI-DrugBank.d140.s14|75-82|cortisol|O
DDI-DrugBank.d140.s14|84-96|concentration|O
DDI-DrugBank.d140.s14|98-99|or|O
DDI-DrugBank.d140.s14|101-106|impair|O
DDI-DrugBank.d140.s14|108-114|adrenal|O
DDI-DrugBank.d140.s14|116-122|reserve|O
DDI-DrugBank.d140.s14|123-123|.|O
DDI-DrugBank.d140.s15|0-2|The|O
DDI-DrugBank.d140.s15|4-10|effects|O
DDI-DrugBank.d140.s15|12-13|of|O
DDI-DrugBank.d140.s15|15-42|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d140.s15|44-45|on|O
DDI-DrugBank.d140.s15|47-50|male|O
DDI-DrugBank.d140.s15|52-60|fertility|O
DDI-DrugBank.d140.s15|62-65|have|O
DDI-DrugBank.d140.s15|67-69|not|O
DDI-DrugBank.d140.s15|71-74|been|O
DDI-DrugBank.d140.s15|76-82|studied|O
DDI-DrugBank.d140.s15|84-85|in|O
DDI-DrugBank.d140.s15|87-94|adequate|O
DDI-DrugBank.d140.s15|96-102|numbers|O
DDI-DrugBank.d140.s15|104-105|of|O
DDI-DrugBank.d140.s15|107-114|patients|O
DDI-DrugBank.d140.s15|115-115|.|O
DDI-DrugBank.d140.s16|0-2|The|O
DDI-DrugBank.d140.s16|4-10|effects|O
DDI-DrugBank.d140.s16|11-11|,|O
DDI-DrugBank.d140.s16|13-14|if|O
DDI-DrugBank.d140.s16|16-18|any|O
DDI-DrugBank.d140.s16|19-19|,|O
DDI-DrugBank.d140.s16|21-22|on|O
DDI-DrugBank.d140.s16|24-26|the|O
DDI-DrugBank.d140.s16|28-44|pituitary-gonadal|O
DDI-DrugBank.d140.s16|46-49|axis|O
DDI-DrugBank.d140.s16|51-52|in|O
DDI-DrugBank.d140.s16|54-66|premenopausal|O
DDI-DrugBank.d140.s16|68-72|women|O
DDI-DrugBank.d140.s16|74-76|are|O
DDI-DrugBank.d140.s16|78-84|unknown|O
DDI-DrugBank.d140.s16|85-85|.|O
DDI-DrugBank.d140.s17|0-6|Caution|O
DDI-DrugBank.d140.s17|8-13|should|O
DDI-DrugBank.d140.s17|15-16|be|O
DDI-DrugBank.d140.s17|18-26|exercised|O
DDI-DrugBank.d140.s17|28-29|if|O
DDI-DrugBank.d140.s17|31-32|an|O
DDI-DrugBank.d140.s17|34-60|HMG-CoA reductase inhibitor|group
DDI-DrugBank.d140.s17|62-63|is|O
DDI-DrugBank.d140.s17|65-76|administered|O
DDI-DrugBank.d140.s17|78-90|concomitantly|O
DDI-DrugBank.d140.s17|92-95|with|O
DDI-DrugBank.d140.s17|97-101|drugs|O
DDI-DrugBank.d140.s17|103-106|that|O
DDI-DrugBank.d140.s17|108-110|may|O
DDI-DrugBank.d140.s17|112-119|decrease|O
DDI-DrugBank.d140.s17|121-123|the|O
DDI-DrugBank.d140.s17|125-130|levels|O
DDI-DrugBank.d140.s17|132-133|or|O
DDI-DrugBank.d140.s17|135-142|activity|O
DDI-DrugBank.d140.s17|144-145|of|O
DDI-DrugBank.d140.s17|147-156|endogenous|O
DDI-DrugBank.d140.s17|158-164|steroid|O
DDI-DrugBank.d140.s17|166-173|hormones|O
DDI-DrugBank.d140.s17|174-174|,|O
DDI-DrugBank.d140.s17|176-179|such|O
DDI-DrugBank.d140.s17|181-182|as|O
DDI-DrugBank.d140.s17|184-195|ketoconazole|drug
DDI-DrugBank.d140.s17|196-196|,|O
DDI-DrugBank.d140.s17|198-211|spironolactone|drug
DDI-DrugBank.d140.s17|212-212|,|O
DDI-DrugBank.d140.s17|214-216|and|O
DDI-DrugBank.d140.s17|218-227|cimetidine|drug
DDI-DrugBank.d140.s17|228-228|.|O
DDI-DrugBank.d140.s18|0-2|CNS|O
DDI-DrugBank.d140.s18|4-11|Toxicity|O
DDI-DrugBank.d140.s18|13-17|Brain|O
DDI-DrugBank.d140.s18|19-28|hemorrhage|O
DDI-DrugBank.d140.s18|30-32|was|O
DDI-DrugBank.d140.s18|34-37|seen|O
DDI-DrugBank.d140.s18|39-40|in|O
DDI-DrugBank.d140.s18|42-42|a|O
DDI-DrugBank.d140.s18|44-49|female|O
DDI-DrugBank.d140.s18|51-53|dog|O
DDI-DrugBank.d140.s18|55-61|treated|O
DDI-DrugBank.d140.s18|63-65|for|O
DDI-DrugBank.d140.s18|67-67|3|O
DDI-DrugBank.d140.s18|69-74|months|O
DDI-DrugBank.d140.s18|76-77|at|O
DDI-DrugBank.d140.s18|79-81|120|O
DDI-DrugBank.d140.s18|83-91|mg/kg/day|O
DDI-DrugBank.d140.s18|92-92|.|O
DDI-DrugBank.d140.s19|0-4|Brain|O
DDI-DrugBank.d140.s19|6-15|hemorrhage|O
DDI-DrugBank.d140.s19|17-19|and|O
DDI-DrugBank.d140.s19|21-25|optic|O
DDI-DrugBank.d140.s19|27-31|nerve|O
DDI-DrugBank.d140.s19|33-43|vacuolation|O
DDI-DrugBank.d140.s19|45-48|were|O
DDI-DrugBank.d140.s19|50-53|seen|O
DDI-DrugBank.d140.s19|55-56|in|O
DDI-DrugBank.d140.s19|58-64|another|O
DDI-DrugBank.d140.s19|66-71|female|O
DDI-DrugBank.d140.s19|73-75|dog|O
DDI-DrugBank.d140.s19|77-80|that|O
DDI-DrugBank.d140.s19|82-84|was|O
DDI-DrugBank.d140.s19|86-95|sacrificed|O
DDI-DrugBank.d140.s19|97-98|in|O
DDI-DrugBank.d140.s19|100-107|moribund|O
DDI-DrugBank.d140.s19|109-117|condition|O
DDI-DrugBank.d140.s19|119-123|after|O
DDI-DrugBank.d140.s19|125-126|11|O
DDI-DrugBank.d140.s19|128-132|weeks|O
DDI-DrugBank.d140.s19|134-135|of|O
DDI-DrugBank.d140.s19|137-146|escalating|O
DDI-DrugBank.d140.s19|148-152|doses|O
DDI-DrugBank.d140.s19|154-155|up|O
DDI-DrugBank.d140.s19|157-158|to|O
DDI-DrugBank.d140.s19|160-162|280|O
DDI-DrugBank.d140.s19|164-172|mg/kg/day|O
DDI-DrugBank.d140.s19|173-173|.|O
DDI-DrugBank.d140.s20|0-2|The|O
DDI-DrugBank.d140.s20|4-6|120|O
DDI-DrugBank.d140.s20|8-12|mg/kg|O
DDI-DrugBank.d140.s20|14-17|dose|O
DDI-DrugBank.d140.s20|19-26|resulted|O
DDI-DrugBank.d140.s20|28-29|in|O
DDI-DrugBank.d140.s20|31-31|a|O
DDI-DrugBank.d140.s20|33-40|systemic|O
DDI-DrugBank.d140.s20|42-49|exposure|O
DDI-DrugBank.d140.s20|51-63|approximately|O
DDI-DrugBank.d140.s20|65-66|16|O
DDI-DrugBank.d140.s20|68-72|times|O
DDI-DrugBank.d140.s20|74-76|the|O
DDI-DrugBank.d140.s20|78-82|human|O
DDI-DrugBank.d140.s20|84-89|plasma|O
DDI-DrugBank.d140.s20|91-110|area-under-the-curve|O
DDI-DrugBank.d140.s20|112-112|(|O
DDI-DrugBank.d140.s20|113-115|AUC|O
DDI-DrugBank.d140.s20|116-116|,|O
DDI-DrugBank.d140.s20|118-121|0-24|O
DDI-DrugBank.d140.s20|123-127|hours|O
DDI-DrugBank.d140.s20|128-128|)|O
DDI-DrugBank.d140.s20|130-134|based|O
DDI-DrugBank.d140.s20|136-137|on|O
DDI-DrugBank.d140.s20|139-141|the|O
DDI-DrugBank.d140.s20|143-149|maximum|O
DDI-DrugBank.d140.s20|151-155|human|O
DDI-DrugBank.d140.s20|157-160|dose|O
DDI-DrugBank.d140.s20|162-163|of|O
DDI-DrugBank.d140.s20|165-166|80|O
DDI-DrugBank.d140.s20|168-173|mg/day|O
DDI-DrugBank.d140.s20|174-174|.|O
DDI-DrugBank.d140.s21|0-0|A|O
DDI-DrugBank.d140.s21|2-7|single|O
DDI-DrugBank.d140.s21|9-13|tonic|O
DDI-DrugBank.d140.s21|15-24|convulsion|O
DDI-DrugBank.d140.s21|26-28|was|O
DDI-DrugBank.d140.s21|30-33|seen|O
DDI-DrugBank.d140.s21|35-36|in|O
DDI-DrugBank.d140.s21|38-41|each|O
DDI-DrugBank.d140.s21|43-44|of|O
DDI-DrugBank.d140.s21|46-46|2|O
DDI-DrugBank.d140.s21|48-51|male|O
DDI-DrugBank.d140.s21|53-56|dogs|O
DDI-DrugBank.d140.s21|58-58|(|O
DDI-DrugBank.d140.s21|59-61|one|O
DDI-DrugBank.d140.s21|63-69|treated|O
DDI-DrugBank.d140.s21|71-72|at|O
DDI-DrugBank.d140.s21|74-75|10|O
DDI-DrugBank.d140.s21|77-85|mg/kg/day|O
DDI-DrugBank.d140.s21|87-89|and|O
DDI-DrugBank.d140.s21|91-93|one|O
DDI-DrugBank.d140.s21|95-96|at|O
DDI-DrugBank.d140.s21|98-100|120|O
DDI-DrugBank.d140.s21|102-110|mg/kg/day|O
DDI-DrugBank.d140.s21|111-111|)|O
DDI-DrugBank.d140.s21|113-114|in|O
DDI-DrugBank.d140.s21|116-116|a|O
DDI-DrugBank.d140.s21|118-123|2-year|O
DDI-DrugBank.d140.s21|125-129|study|O
DDI-DrugBank.d140.s21|130-130|.|O
DDI-DrugBank.d140.s22|0-1|No|O
DDI-DrugBank.d140.s22|3-5|CNS|O
DDI-DrugBank.d140.s22|7-13|lesions|O
DDI-DrugBank.d140.s22|15-18|have|O
DDI-DrugBank.d140.s22|20-23|been|O
DDI-DrugBank.d140.s22|25-32|observed|O
DDI-DrugBank.d140.s22|34-35|in|O
DDI-DrugBank.d140.s22|37-40|mice|O
DDI-DrugBank.d140.s22|42-46|after|O
DDI-DrugBank.d140.s22|48-54|chronic|O
DDI-DrugBank.d140.s22|56-64|treatment|O
DDI-DrugBank.d140.s22|66-68|for|O
DDI-DrugBank.d140.s22|70-71|up|O
DDI-DrugBank.d140.s22|73-74|to|O
DDI-DrugBank.d140.s22|76-76|2|O
DDI-DrugBank.d140.s22|78-82|years|O
DDI-DrugBank.d140.s22|84-85|at|O
DDI-DrugBank.d140.s22|87-91|doses|O
DDI-DrugBank.d140.s22|93-94|up|O
DDI-DrugBank.d140.s22|96-97|to|O
DDI-DrugBank.d140.s22|99-101|400|O
DDI-DrugBank.d140.s22|103-111|mg/kg/day|O
DDI-DrugBank.d140.s22|113-114|or|O
DDI-DrugBank.d140.s22|116-117|in|O
DDI-DrugBank.d140.s22|119-122|rats|O
DDI-DrugBank.d140.s22|124-125|at|O
DDI-DrugBank.d140.s22|127-131|doses|O
DDI-DrugBank.d140.s22|133-134|up|O
DDI-DrugBank.d140.s22|136-137|to|O
DDI-DrugBank.d140.s22|139-141|100|O
DDI-DrugBank.d140.s22|143-151|mg/kg/day|O
DDI-DrugBank.d140.s22|152-152|.|O
DDI-DrugBank.d140.s23|0-4|These|O
DDI-DrugBank.d140.s23|6-10|doses|O
DDI-DrugBank.d140.s23|12-15|were|O
DDI-DrugBank.d140.s23|17-17|6|O
DDI-DrugBank.d140.s23|19-20|to|O
DDI-DrugBank.d140.s23|22-23|11|O
DDI-DrugBank.d140.s23|25-29|times|O
DDI-DrugBank.d140.s23|31-31|(|O
DDI-DrugBank.d140.s23|32-36|mouse|O
DDI-DrugBank.d140.s23|37-37|)|O
DDI-DrugBank.d140.s23|39-41|and|O
DDI-DrugBank.d140.s23|43-43|8|O
DDI-DrugBank.d140.s23|45-46|to|O
DDI-DrugBank.d140.s23|48-49|16|O
DDI-DrugBank.d140.s23|51-55|times|O
DDI-DrugBank.d140.s23|57-57|(|O
DDI-DrugBank.d140.s23|58-60|rat|O
DDI-DrugBank.d140.s23|61-61|)|O
DDI-DrugBank.d140.s23|63-65|the|O
DDI-DrugBank.d140.s23|67-71|human|O
DDI-DrugBank.d140.s23|73-75|AUC|O
DDI-DrugBank.d140.s23|77-77|(|O
DDI-DrugBank.d140.s23|78-81|0-24|O
DDI-DrugBank.d140.s23|82-82|)|O
DDI-DrugBank.d140.s23|84-88|based|O
DDI-DrugBank.d140.s23|90-91|on|O
DDI-DrugBank.d140.s23|93-95|the|O
DDI-DrugBank.d140.s23|97-103|maximum|O
DDI-DrugBank.d140.s23|105-115|recommended|O
DDI-DrugBank.d140.s23|117-121|human|O
DDI-DrugBank.d140.s23|123-126|dose|O
DDI-DrugBank.d140.s23|128-129|of|O
DDI-DrugBank.d140.s23|131-132|80|O
DDI-DrugBank.d140.s23|134-139|mg/day|O
DDI-DrugBank.d140.s23|140-140|.|O
DDI-DrugBank.d140.s24|0-2|CNS|O
DDI-DrugBank.d140.s24|4-11|vascular|O
DDI-DrugBank.d140.s24|13-19|lesions|O
DDI-DrugBank.d140.s24|20-20|,|O
DDI-DrugBank.d140.s24|22-34|characterized|O
DDI-DrugBank.d140.s24|36-37|by|O
DDI-DrugBank.d140.s24|39-50|perivascular|O
DDI-DrugBank.d140.s24|52-62|hemorrhages|O
DDI-DrugBank.d140.s24|63-63|,|O
DDI-DrugBank.d140.s24|65-69|edema|O
DDI-DrugBank.d140.s24|70-70|,|O
DDI-DrugBank.d140.s24|72-74|and|O
DDI-DrugBank.d140.s24|76-86|mononuclear|O
DDI-DrugBank.d140.s24|88-91|cell|O
DDI-DrugBank.d140.s24|93-104|infiltration|O
DDI-DrugBank.d140.s24|106-107|of|O
DDI-DrugBank.d140.s24|109-120|perivascular|O
DDI-DrugBank.d140.s24|122-127|spaces|O
DDI-DrugBank.d140.s24|128-128|,|O
DDI-DrugBank.d140.s24|130-133|have|O
DDI-DrugBank.d140.s24|135-138|been|O
DDI-DrugBank.d140.s24|140-147|observed|O
DDI-DrugBank.d140.s24|149-150|in|O
DDI-DrugBank.d140.s24|152-155|dogs|O
DDI-DrugBank.d140.s24|157-163|treated|O
DDI-DrugBank.d140.s24|165-168|with|O
DDI-DrugBank.d140.s24|170-174|other|O
DDI-DrugBank.d140.s24|176-182|members|O
DDI-DrugBank.d140.s24|184-185|of|O
DDI-DrugBank.d140.s24|187-190|this|O
DDI-DrugBank.d140.s24|192-196|class|O
DDI-DrugBank.d140.s24|197-197|.|O
DDI-DrugBank.d140.s25|0-0|A|O
DDI-DrugBank.d140.s25|2-11|chemically|O
DDI-DrugBank.d140.s25|13-19|similar|O
DDI-DrugBank.d140.s25|21-24|drug|O
DDI-DrugBank.d140.s25|26-27|in|O
DDI-DrugBank.d140.s25|29-32|this|O
DDI-DrugBank.d140.s25|34-38|class|O
DDI-DrugBank.d140.s25|40-47|produced|O
DDI-DrugBank.d140.s25|49-53|optic|O
DDI-DrugBank.d140.s25|55-59|nerve|O
DDI-DrugBank.d140.s25|61-72|degeneration|O
DDI-DrugBank.d140.s25|74-74|(|O
DDI-DrugBank.d140.s25|75-83|Wallerian|O
DDI-DrugBank.d140.s25|85-96|degeneration|O
DDI-DrugBank.d140.s25|98-99|of|O
DDI-DrugBank.d140.s25|101-116|retinogeniculate|O
DDI-DrugBank.d140.s25|118-123|fibers|O
DDI-DrugBank.d140.s25|124-124|)|O
DDI-DrugBank.d140.s25|126-127|in|O
DDI-DrugBank.d140.s25|129-138|clinically|O
DDI-DrugBank.d140.s25|140-145|normal|O
DDI-DrugBank.d140.s25|147-150|dogs|O
DDI-DrugBank.d140.s25|152-153|in|O
DDI-DrugBank.d140.s25|155-155|a|O
DDI-DrugBank.d140.s25|157-170|dose-dependent|O
DDI-DrugBank.d140.s25|172-178|fashion|O
DDI-DrugBank.d140.s25|180-181|at|O
DDI-DrugBank.d140.s25|183-183|a|O
DDI-DrugBank.d140.s25|185-188|dose|O
DDI-DrugBank.d140.s25|190-193|that|O
DDI-DrugBank.d140.s25|195-202|produced|O
DDI-DrugBank.d140.s25|204-209|plasma|O
DDI-DrugBank.d140.s25|211-214|drug|O
DDI-DrugBank.d140.s25|216-221|levels|O
DDI-DrugBank.d140.s25|223-227|about|O
DDI-DrugBank.d140.s25|229-230|30|O
DDI-DrugBank.d140.s25|232-236|times|O
DDI-DrugBank.d140.s25|238-243|higher|O
DDI-DrugBank.d140.s25|245-248|than|O
DDI-DrugBank.d140.s25|250-252|the|O
DDI-DrugBank.d140.s25|254-257|mean|O
DDI-DrugBank.d140.s25|259-262|drug|O
DDI-DrugBank.d140.s25|264-268|level|O
DDI-DrugBank.d140.s25|270-271|in|O
DDI-DrugBank.d140.s25|273-278|humans|O
DDI-DrugBank.d140.s25|280-285|taking|O
DDI-DrugBank.d140.s25|287-289|the|O
DDI-DrugBank.d140.s25|291-297|highest|O
DDI-DrugBank.d140.s25|299-309|recommended|O
DDI-DrugBank.d140.s25|311-314|dose|O
DDI-DrugBank.d140.s25|315-315|.|O
DDI-MedLine.d72.s0|0-0|[|O
DDI-MedLine.d72.s0|1-13|Pharmacologic|O
DDI-MedLine.d72.s0|15-26|interactions|O
DDI-MedLine.d72.s0|28-29|in|O
DDI-MedLine.d72.s0|31-37|chronic|O
DDI-MedLine.d72.s0|39-48|treatments|O
DDI-MedLine.d72.s0|49-49|:|O
DDI-MedLine.d72.s0|51-60|corrective|O
DDI-MedLine.d72.s0|62-69|measures|O
DDI-MedLine.d72.s0|71-73|for|O
DDI-MedLine.d72.s0|75-77|its|O
DDI-MedLine.d72.s0|79-88|prevention|O
DDI-MedLine.d72.s0|90-91|in|O
DDI-MedLine.d72.s0|93-93|a|O
DDI-MedLine.d72.s0|95-99|basic|O
DDI-MedLine.d72.s0|101-104|area|O
DDI-MedLine.d72.s0|106-107|of|O
DDI-MedLine.d72.s0|109-113|rural|O
DDI-MedLine.d72.s0|115-120|health|O
DDI-MedLine.d72.s0|121-121|]|O
DDI-MedLine.d72.s0|124-133|OBJECTIVES|O
DDI-MedLine.d72.s0|134-134|:|O
DDI-MedLine.d72.s0|136-137|To|O
DDI-MedLine.d72.s0|139-146|identify|O
DDI-MedLine.d72.s0|148-150|the|O
DDI-MedLine.d72.s0|152-166|pharmacological|O
DDI-MedLine.d72.s0|168-179|interactions|O
DDI-MedLine.d72.s0|181-182|of|O
DDI-MedLine.d72.s0|184-191|clinical|O
DDI-MedLine.d72.s0|193-201|relevance|O
DDI-MedLine.d72.s0|203-203|(|O
DDI-MedLine.d72.s0|204-207|PICR|O
DDI-MedLine.d72.s0|208-208|)|O
DDI-MedLine.d72.s0|210-211|in|O
DDI-MedLine.d72.s0|213-215|the|O
DDI-MedLine.d72.s0|217-226|medication|O
DDI-MedLine.d72.s0|228-240|authorization|O
DDI-MedLine.d72.s0|242-246|cards|O
DDI-MedLine.d72.s0|248-248|(|O
DDI-MedLine.d72.s0|249-251|MAC|O
DDI-MedLine.d72.s0|252-252|)|O
DDI-MedLine.d72.s0|254-255|of|O
DDI-MedLine.d72.s0|257-259|the|O
DDI-MedLine.d72.s0|261-271|chronically|O
DDI-MedLine.d72.s0|273-275|ill|O
DDI-MedLine.d72.s0|277-279|and|O
DDI-MedLine.d72.s0|281-282|to|O
DDI-MedLine.d72.s0|284-292|establish|O
DDI-MedLine.d72.s0|294-303|strategies|O
DDI-MedLine.d72.s0|305-306|to|O
DDI-MedLine.d72.s0|308-315|minimise|O
DDI-MedLine.d72.s0|317-321|their|O
DDI-MedLine.d72.s0|323-332|appearance|O
DDI-MedLine.d72.s0|333-333|.|O
DDI-MedLine.d72.s1|0-5|DESIGN|O
DDI-MedLine.d72.s1|6-6|:|O
DDI-MedLine.d72.s1|8-22|Cross-sectional|O
DDI-MedLine.d72.s1|24-34|descriptive|O
DDI-MedLine.d72.s1|36-40|study|O
DDI-MedLine.d72.s1|41-41|.|O
DDI-MedLine.d72.s2|0-6|SETTING|O
DDI-MedLine.d72.s2|7-7|:|O
DDI-MedLine.d72.s2|9-13|Rural|O
DDI-MedLine.d72.s2|15-21|primary|O
DDI-MedLine.d72.s2|23-26|care|O
DDI-MedLine.d72.s2|28-33|centre|O
DDI-MedLine.d72.s2|34-34|.|O
DDI-MedLine.d72.s3|0-7|PATIENTS|O
DDI-MedLine.d72.s3|8-8|:|O
DDI-MedLine.d72.s3|10-15|Random|O
DDI-MedLine.d72.s3|17-22|sample|O
DDI-MedLine.d72.s3|24-25|of|O
DDI-MedLine.d72.s3|27-29|626|O
DDI-MedLine.d72.s3|31-33|MAC|O
DDI-MedLine.d72.s3|35-37|out|O
DDI-MedLine.d72.s3|39-40|of|O
DDI-MedLine.d72.s3|42-42|a|O
DDI-MedLine.d72.s3|44-48|total|O
DDI-MedLine.d72.s3|50-51|of|O
DDI-MedLine.d72.s3|53-56|1306|O
DDI-MedLine.d72.s3|57-57|.|O
DDI-MedLine.d72.s4|0-11|MEASUREMENTS|O
DDI-MedLine.d72.s4|13-15|AND|O
DDI-MedLine.d72.s4|17-20|MAIN|O
DDI-MedLine.d72.s4|22-28|RESULTS|O
DDI-MedLine.d72.s4|29-29|:|O
DDI-MedLine.d72.s4|31-32|In|O
DDI-MedLine.d72.s4|34-41|December|O
DDI-MedLine.d72.s4|43-46|1998|O
DDI-MedLine.d72.s4|47-47|,|O
DDI-MedLine.d72.s4|49-51|the|O
DDI-MedLine.d72.s4|53-61|following|O
DDI-MedLine.d72.s4|63-65|was|O
DDI-MedLine.d72.s4|67-74|gathered|O
DDI-MedLine.d72.s4|76-78|for|O
DDI-MedLine.d72.s4|80-84|every|O
DDI-MedLine.d72.s4|86-88|MAC|O
DDI-MedLine.d72.s4|90-93|with|O
DDI-MedLine.d72.s4|95-98|more|O
DDI-MedLine.d72.s4|100-103|than|O
DDI-MedLine.d72.s4|105-107|one|O
DDI-MedLine.d72.s4|109-112|drug|O
DDI-MedLine.d72.s4|114-122|treatment|O
DDI-MedLine.d72.s4|123-123|:|O
DDI-MedLine.d72.s4|125-127|age|O
DDI-MedLine.d72.s4|128-128|,|O
DDI-MedLine.d72.s4|130-132|sex|O
DDI-MedLine.d72.s4|133-133|,|O
DDI-MedLine.d72.s4|135-140|number|O
DDI-MedLine.d72.s4|142-143|of|O
DDI-MedLine.d72.s4|145-149|drugs|O
DDI-MedLine.d72.s4|150-150|,|O
DDI-MedLine.d72.s4|152-160|intrinsic|O
DDI-MedLine.d72.s4|162-166|value|O
DDI-MedLine.d72.s4|167-167|,|O
DDI-MedLine.d72.s4|169-173|drugs|O
DDI-MedLine.d72.s4|175-184|prescribed|O
DDI-MedLine.d72.s4|185-185|,|O
DDI-MedLine.d72.s4|187-191|daily|O
DDI-MedLine.d72.s4|193-196|dose|O
DDI-MedLine.d72.s4|198-200|and|O
DDI-MedLine.d72.s4|202-216|pharmacological|O
DDI-MedLine.d72.s4|218-229|interactions|O
DDI-MedLine.d72.s4|231-231|(|O
DDI-MedLine.d72.s4|232-233|PI|O
DDI-MedLine.d72.s4|234-234|)|O
DDI-MedLine.d72.s4|235-235|,|O
DDI-MedLine.d72.s4|237-246|classified|O
DDI-MedLine.d72.s4|248-248|(|O
DDI-MedLine.d72.s4|249-253|using|O
DDI-MedLine.d72.s4|255-257|the|O
DDI-MedLine.d72.s4|259-263|scale|O
DDI-MedLine.d72.s4|265-266|of|O
DDI-MedLine.d72.s4|268-274|Hansten|O
DDI-MedLine.d72.s4|276-279|1996|O
DDI-MedLine.d72.s4|280-280|)|O
DDI-MedLine.d72.s4|282-285|into|O
DDI-MedLine.d72.s4|287-291|light|O
DDI-MedLine.d72.s4|293-295|and|O
DDI-MedLine.d72.s4|297-306|clinically|O
DDI-MedLine.d72.s4|308-315|relevant|O
DDI-MedLine.d72.s4|316-316|.|O
DDI-MedLine.d72.s5|0-10|Statistical|O
DDI-MedLine.d72.s5|12-19|analysis|O
DDI-MedLine.d72.s5|20-20|:|O
DDI-MedLine.d72.s5|22-36|Mantel-Haenszel|O
DDI-MedLine.d72.s5|38-38|(|O
DDI-MedLine.d72.s5|39-43|alpha|O
DDI-MedLine.d72.s5|45-45|=|O
DDI-MedLine.d72.s5|47-50|0.05|O
DDI-MedLine.d72.s5|51-51|)|O
DDI-MedLine.d72.s5|52-52|.|O
DDI-MedLine.d72.s6|0-7|Patients|O
DDI-MedLine.d72.s6|8-8|'|O
DDI-MedLine.d72.s6|10-13|mean|O
DDI-MedLine.d72.s6|15-17|age|O
DDI-MedLine.d72.s6|19-21|was|O
DDI-MedLine.d72.s6|23-26|69.1|O
DDI-MedLine.d72.s6|28-28|(|O
DDI-MedLine.d72.s6|29-30|95|O
DDI-MedLine.d72.s6|31-31|%|O
DDI-MedLine.d72.s6|33-34|CI|O
DDI-MedLine.d72.s6|35-35|,|O
DDI-MedLine.d72.s6|37-39|+/-|O
DDI-MedLine.d72.s6|41-43|1.2|O
DDI-MedLine.d72.s6|44-44|)|O
DDI-MedLine.d72.s6|45-45|.|O
DDI-MedLine.d72.s7|0-3|Mean|O
DDI-MedLine.d72.s7|5-10|number|O
DDI-MedLine.d72.s7|12-13|of|O
DDI-MedLine.d72.s7|15-19|drugs|O
DDI-MedLine.d72.s7|21-23|per|O
DDI-MedLine.d72.s7|25-27|MAC|O
DDI-MedLine.d72.s7|29-31|was|O
DDI-MedLine.d72.s7|33-33|4|O
DDI-MedLine.d72.s7|35-35|(|O
DDI-MedLine.d72.s7|36-37|95|O
DDI-MedLine.d72.s7|38-38|%|O
DDI-MedLine.d72.s7|40-41|CI|O
DDI-MedLine.d72.s7|42-42|,|O
DDI-MedLine.d72.s7|44-46|+/-|O
DDI-MedLine.d72.s7|48-50|0.2|O
DDI-MedLine.d72.s7|51-51|)|O
DDI-MedLine.d72.s7|52-52|.|O
DDI-MedLine.d72.s8|0-2|341|O
DDI-MedLine.d72.s8|4-5|PI|O
DDI-MedLine.d72.s8|7-15|affecting|O
DDI-MedLine.d72.s8|17-19|197|O
DDI-MedLine.d72.s8|21-28|patients|O
DDI-MedLine.d72.s8|30-30|(|O
DDI-MedLine.d72.s8|31-34|31.5|O
DDI-MedLine.d72.s8|35-35|%|O
DDI-MedLine.d72.s8|36-36|,|O
DDI-MedLine.d72.s8|38-39|95|O
DDI-MedLine.d72.s8|40-40|%|O
DDI-MedLine.d72.s8|42-43|CI|O
DDI-MedLine.d72.s8|44-44|,|O
DDI-MedLine.d72.s8|46-48|+/-|O
DDI-MedLine.d72.s8|50-52|3.6|O
DDI-MedLine.d72.s8|53-53|)|O
DDI-MedLine.d72.s8|55-58|were|O
DDI-MedLine.d72.s8|60-69|identified|O
DDI-MedLine.d72.s8|70-70|.|O
DDI-MedLine.d72.s9|0-3|24.9|O
DDI-MedLine.d72.s9|4-4|%|O
DDI-MedLine.d72.s9|6-6|(|O
DDI-MedLine.d72.s9|7-8|95|O
DDI-MedLine.d72.s9|9-9|%|O
DDI-MedLine.d72.s9|11-12|CI|O
DDI-MedLine.d72.s9|13-13|,|O
DDI-MedLine.d72.s9|15-17|+/-|O
DDI-MedLine.d72.s9|19-21|4.5|O
DDI-MedLine.d72.s9|22-22|)|O
DDI-MedLine.d72.s9|24-27|were|O
DDI-MedLine.d72.s9|29-32|PICR|O
DDI-MedLine.d72.s9|33-33|,|O
DDI-MedLine.d72.s9|35-42|detected|O
DDI-MedLine.d72.s9|44-45|in|O
DDI-MedLine.d72.s9|47-50|11.7|O
DDI-MedLine.d72.s9|51-51|%|O
DDI-MedLine.d72.s9|53-53|(|O
DDI-MedLine.d72.s9|54-55|95|O
DDI-MedLine.d72.s9|56-56|%|O
DDI-MedLine.d72.s9|58-59|CI|O
DDI-MedLine.d72.s9|60-60|,|O
DDI-MedLine.d72.s9|62-64|+/-|O
DDI-MedLine.d72.s9|66-68|2.5|O
DDI-MedLine.d72.s9|69-69|)|O
DDI-MedLine.d72.s9|71-72|of|O
DDI-MedLine.d72.s9|74-76|the|O
DDI-MedLine.d72.s9|78-80|MAC|O
DDI-MedLine.d72.s9|81-81|.|O
DDI-MedLine.d72.s10|0-2|The|O
DDI-MedLine.d72.s10|4-12|existence|O
DDI-MedLine.d72.s10|14-15|of|O
DDI-MedLine.d72.s10|17-18|PI|O
DDI-MedLine.d72.s10|20-22|was|O
DDI-MedLine.d72.s10|24-30|related|O
DDI-MedLine.d72.s10|32-33|to|O
DDI-MedLine.d72.s10|35-37|the|O
DDI-MedLine.d72.s10|39-44|number|O
DDI-MedLine.d72.s10|46-47|of|O
DDI-MedLine.d72.s10|49-53|drugs|O
DDI-MedLine.d72.s10|55-64|prescribed|O
DDI-MedLine.d72.s10|66-67|to|O
DDI-MedLine.d72.s10|69-72|each|O
DDI-MedLine.d72.s10|74-80|patient|O
DDI-MedLine.d72.s10|82-82|(|O
DDI-MedLine.d72.s10|83-83|p|O
DDI-MedLine.d72.s10|85-85|<|O
DDI-MedLine.d72.s10|87-90|0.01|O
DDI-MedLine.d72.s10|91-91|)|O
DDI-MedLine.d72.s10|92-92|.|O
DDI-MedLine.d72.s11|0-4|There|O
DDI-MedLine.d72.s11|6-9|were|O
DDI-MedLine.d72.s11|11-12|26|O
DDI-MedLine.d72.s11|14-15|PI|O
DDI-MedLine.d72.s11|17-20|with|O
DDI-MedLine.d72.s11|22-26|drugs|O
DDI-MedLine.d72.s11|28-29|of|O
DDI-MedLine.d72.s11|31-33|low|O
DDI-MedLine.d72.s11|35-43|intrinsic|O
DDI-MedLine.d72.s11|45-49|value|O
DDI-MedLine.d72.s11|51-51|(|O
DDI-MedLine.d72.s11|52-54|7.6|O
DDI-MedLine.d72.s11|55-55|%|O
DDI-MedLine.d72.s11|56-56|;|O
DDI-MedLine.d72.s11|58-59|95|O
DDI-MedLine.d72.s11|60-60|%|O
DDI-MedLine.d72.s11|62-63|CI|O
DDI-MedLine.d72.s11|64-64|,|O
DDI-MedLine.d72.s11|66-68|+/-|O
DDI-MedLine.d72.s11|70-72|2.8|O
DDI-MedLine.d72.s11|73-73|)|O
DDI-MedLine.d72.s11|74-74|.|O
DDI-MedLine.d72.s12|0-3|74.1|O
DDI-MedLine.d72.s12|4-4|%|O
DDI-MedLine.d72.s12|6-6|(|O
DDI-MedLine.d72.s12|7-8|95|O
DDI-MedLine.d72.s12|9-9|%|O
DDI-MedLine.d72.s12|11-12|CI|O
DDI-MedLine.d72.s12|13-13|,|O
DDI-MedLine.d72.s12|15-17|+/-|O
DDI-MedLine.d72.s12|19-21|9.3|O
DDI-MedLine.d72.s12|22-22|)|O
DDI-MedLine.d72.s12|24-25|of|O
DDI-MedLine.d72.s12|27-29|the|O
DDI-MedLine.d72.s12|31-35|total|O
DDI-MedLine.d72.s12|37-40|PICR|O
DDI-MedLine.d72.s12|42-46|could|O
DDI-MedLine.d72.s12|48-49|be|O
DDI-MedLine.d72.s12|51-57|avoided|O
DDI-MedLine.d72.s12|59-60|by|O
DDI-MedLine.d72.s12|62-67|simple|O
DDI-MedLine.d72.s12|69-83|recommendations|O
DDI-MedLine.d72.s12|84-84|;|O
DDI-MedLine.d72.s13|0-2|and|O
DDI-MedLine.d72.s13|4-6|the|O
DDI-MedLine.d72.s13|8-16|remaining|O
DDI-MedLine.d72.s13|18-21|25.9|O
DDI-MedLine.d72.s13|22-22|%|O
DDI-MedLine.d72.s13|24-24|(|O
DDI-MedLine.d72.s13|25-26|95|O
DDI-MedLine.d72.s13|27-27|%|O
DDI-MedLine.d72.s13|29-30|CI|O
DDI-MedLine.d72.s13|31-31|,|O
DDI-MedLine.d72.s13|33-35|+/-|O
DDI-MedLine.d72.s13|37-39|9.3|O
DDI-MedLine.d72.s13|40-40|)|O
DDI-MedLine.d72.s13|42-43|by|O
DDI-MedLine.d72.s13|45-54|monitoring|O
DDI-MedLine.d72.s13|56-58|and|O
DDI-MedLine.d72.s13|60-68|follow-up|O
DDI-MedLine.d72.s13|70-71|of|O
DDI-MedLine.d72.s13|73-80|patients|O
DDI-MedLine.d72.s13|81-81|.|O
DDI-MedLine.d72.s14|0-10|CONCLUSIONS|O
DDI-MedLine.d72.s14|11-11|:|O
DDI-MedLine.d72.s14|13-14|It|O
DDI-MedLine.d72.s14|16-17|is|O
DDI-MedLine.d72.s14|19-27|important|O
DDI-MedLine.d72.s14|29-30|to|O
DDI-MedLine.d72.s14|32-39|identify|O
DDI-MedLine.d72.s14|41-43|the|O
DDI-MedLine.d72.s14|45-55|medications|O
DDI-MedLine.d72.s14|57-60|most|O
DDI-MedLine.d72.s14|62-69|commonly|O
DDI-MedLine.d72.s14|71-78|involved|O
DDI-MedLine.d72.s14|80-81|in|O
DDI-MedLine.d72.s14|83-85|the|O
DDI-MedLine.d72.s14|87-90|PICR|O
DDI-MedLine.d72.s14|92-93|so|O
DDI-MedLine.d72.s14|95-96|as|O
DDI-MedLine.d72.s14|98-99|to|O
DDI-MedLine.d72.s14|101-109|establish|O
DDI-MedLine.d72.s14|111-120|corrective|O
DDI-MedLine.d72.s14|122-129|measures|O
DDI-MedLine.d72.s14|131-132|to|O
DDI-MedLine.d72.s14|134-141|minimise|O
DDI-MedLine.d72.s14|143-145|the|O
DDI-MedLine.d72.s14|147-151|risks|O
DDI-MedLine.d72.s14|153-159|arising|O
DDI-MedLine.d72.s14|161-164|from|O
DDI-MedLine.d72.s14|166-173|multiple|O
DDI-MedLine.d72.s14|175-184|medication|O
DDI-MedLine.d72.s14|185-185|.|O
DDI-MedLine.d72.s15|0-3|Four|O
DDI-MedLine.d72.s15|5-15|educational|O
DDI-MedLine.d72.s15|17-24|messages|O
DDI-MedLine.d72.s15|26-31|advise|O
DDI-MedLine.d72.s15|33-34|on|O
DDI-MedLine.d72.s15|36-39|over|O
DDI-MedLine.d72.s15|41-42|60|O
DDI-MedLine.d72.s15|43-43|%|O
DDI-MedLine.d72.s15|45-46|of|O
DDI-MedLine.d72.s15|48-50|the|O
DDI-MedLine.d72.s15|52-55|PICR|O
DDI-MedLine.d72.s15|57-64|detected|O
DDI-MedLine.d72.s15|65-65|.|O
DDI-DrugBank.d2.s0|0-9|PROSTIN E2|brand
DDI-DrugBank.d2.s0|11-13|may|O
DDI-DrugBank.d2.s0|15-21|augment|O
DDI-DrugBank.d2.s0|23-25|the|O
DDI-DrugBank.d2.s0|27-34|activity|O
DDI-DrugBank.d2.s0|36-37|of|O
DDI-DrugBank.d2.s0|39-43|other|O
DDI-DrugBank.d2.s0|45-58|oxytocic drugs|group
DDI-DrugBank.d2.s0|59-59|.|O
DDI-DrugBank.d2.s1|0-10|Concomitant|O
DDI-DrugBank.d2.s1|12-14|use|O
DDI-DrugBank.d2.s1|16-19|with|O
DDI-DrugBank.d2.s1|21-25|other|O
DDI-DrugBank.d2.s1|27-41|oxytocic agents|group
DDI-DrugBank.d2.s1|43-44|is|O
DDI-DrugBank.d2.s1|46-48|not|O
DDI-DrugBank.d2.s1|50-60|recommended|O
DDI-DrugBank.d2.s1|61-61|.|O
DDI-DrugBank.d33.s0|0-7|Although|O
DDI-DrugBank.d33.s0|9-11|the|O
DDI-DrugBank.d33.s0|13-22|occurrence|O
DDI-DrugBank.d33.s0|24-26|has|O
DDI-DrugBank.d33.s0|28-30|not|O
DDI-DrugBank.d33.s0|32-35|been|O
DDI-DrugBank.d33.s0|37-44|reported|O
DDI-DrugBank.d33.s0|46-49|with|O
DDI-DrugBank.d33.s0|51-57|Cefizox|brand
DDI-DrugBank.d33.s0|58-58|,|O
DDI-DrugBank.d33.s0|60-73|nephrotoxicity|O
DDI-DrugBank.d33.s0|75-77|has|O
DDI-DrugBank.d33.s0|79-82|been|O
DDI-DrugBank.d33.s0|84-91|reported|O
DDI-DrugBank.d33.s0|93-101|following|O
DDI-DrugBank.d33.s0|103-113|concomitant|O
DDI-DrugBank.d33.s0|115-128|administration|O
DDI-DrugBank.d33.s0|130-131|of|O
DDI-DrugBank.d33.s0|133-137|other|O
DDI-DrugBank.d33.s0|139-152|cephalosporins|group
DDI-DrugBank.d33.s0|154-156|and|O
DDI-DrugBank.d33.s0|158-172|aminoglycosides|group
DDI-DrugBank.d33.s0|173-173|.|O
DDI-DrugBank.d155.s0|0-1|No|O
DDI-DrugBank.d155.s0|3-13|information|O
DDI-DrugBank.d155.s0|15-23|available|O
DDI-DrugBank.d155.s0|24-24|.|O
DDI-DrugBank.d207.s0|0-9|Substances|O
DDI-DrugBank.d207.s0|11-14|that|O
DDI-DrugBank.d207.s0|16-18|are|O
DDI-DrugBank.d207.s0|20-27|inducers|O
DDI-DrugBank.d207.s0|29-30|of|O
DDI-DrugBank.d207.s0|32-37|CYP3A4|O
DDI-DrugBank.d207.s0|39-46|activity|O
DDI-DrugBank.d207.s0|48-55|increase|O
DDI-DrugBank.d207.s0|57-59|the|O
DDI-DrugBank.d207.s0|61-70|metabolism|O
DDI-DrugBank.d207.s0|72-73|of|O
DDI-DrugBank.d207.s0|75-83|gefitinib|drug
DDI-DrugBank.d207.s0|85-87|and|O
DDI-DrugBank.d207.s0|89-96|decrease|O
DDI-DrugBank.d207.s0|98-100|its|O
DDI-DrugBank.d207.s0|102-107|plasma|O
DDI-DrugBank.d207.s0|109-122|concentrations|O
DDI-DrugBank.d207.s0|123-123|.|O
DDI-DrugBank.d207.s1|0-1|In|O
DDI-DrugBank.d207.s1|3-10|patients|O
DDI-DrugBank.d207.s1|12-20|receiving|O
DDI-DrugBank.d207.s1|22-22|a|O
DDI-DrugBank.d207.s1|24-29|potent|O
DDI-DrugBank.d207.s1|31-36|CYP3A4|O
DDI-DrugBank.d207.s1|38-44|inducer|O
DDI-DrugBank.d207.s1|46-49|such|O
DDI-DrugBank.d207.s1|51-52|as|O
DDI-DrugBank.d207.s1|54-63|rifampicin|drug
DDI-DrugBank.d207.s1|65-66|or|O
DDI-DrugBank.d207.s1|68-76|phenytoin|drug
DDI-DrugBank.d207.s1|77-77|,|O
DDI-DrugBank.d207.s1|79-79|a|O
DDI-DrugBank.d207.s1|81-84|dose|O
DDI-DrugBank.d207.s1|86-93|increase|O
DDI-DrugBank.d207.s1|95-96|to|O
DDI-DrugBank.d207.s1|98-100|500|O
DDI-DrugBank.d207.s1|102-103|mg|O
DDI-DrugBank.d207.s1|105-109|daily|O
DDI-DrugBank.d207.s1|111-116|should|O
DDI-DrugBank.d207.s1|118-119|be|O
DDI-DrugBank.d207.s1|121-130|considered|O
DDI-DrugBank.d207.s1|132-133|in|O
DDI-DrugBank.d207.s1|135-137|the|O
DDI-DrugBank.d207.s1|139-145|absence|O
DDI-DrugBank.d207.s1|147-148|of|O
DDI-DrugBank.d207.s1|150-155|severe|O
DDI-DrugBank.d207.s1|157-163|adverse|O
DDI-DrugBank.d207.s1|165-168|drug|O
DDI-DrugBank.d207.s1|170-177|reaction|O
DDI-DrugBank.d207.s1|178-178|,|O
DDI-DrugBank.d207.s1|180-182|and|O
DDI-DrugBank.d207.s1|184-191|clinical|O
DDI-DrugBank.d207.s1|193-200|response|O
DDI-DrugBank.d207.s1|202-204|and|O
DDI-DrugBank.d207.s1|206-212|adverse|O
DDI-DrugBank.d207.s1|214-219|events|O
DDI-DrugBank.d207.s1|221-226|should|O
DDI-DrugBank.d207.s1|228-229|be|O
DDI-DrugBank.d207.s1|231-239|carefully|O
DDI-DrugBank.d207.s1|241-249|monitored|O
DDI-DrugBank.d207.s1|251-251|(|O
DDI-DrugBank.d207.s1|252-254|see|O
DDI-DrugBank.d207.s1|256-263|CLINICAL|O
DDI-DrugBank.d207.s1|265-303|PHARMACOLOGY-Pharmacokinetics-Drug-Drug|O
DDI-DrugBank.d207.s1|305-316|Interactions|O
DDI-DrugBank.d207.s1|318-320|and|O
DDI-DrugBank.d207.s1|322-327|DOSAGE|O
DDI-DrugBank.d207.s1|329-331|AND|O
DDI-DrugBank.d207.s1|333-353|ADMINISTRATION-Dosage|O
DDI-DrugBank.d207.s1|355-364|Adjustment|O
DDI-DrugBank.d207.s1|366-373|sections|O
DDI-DrugBank.d207.s1|374-374|)|O
DDI-DrugBank.d207.s1|375-375|.|O
DDI-DrugBank.d207.s2|0-12|International|O
DDI-DrugBank.d207.s2|14-23|Normalized|O
DDI-DrugBank.d207.s2|25-29|Ratio|O
DDI-DrugBank.d207.s2|31-31|(|O
DDI-DrugBank.d207.s2|32-34|INR|O
DDI-DrugBank.d207.s2|35-35|)|O
DDI-DrugBank.d207.s2|37-46|elevations|O
DDI-DrugBank.d207.s2|48-53|and/or|O
DDI-DrugBank.d207.s2|55-62|bleeding|O
DDI-DrugBank.d207.s2|64-69|events|O
DDI-DrugBank.d207.s2|71-74|have|O
DDI-DrugBank.d207.s2|76-79|been|O
DDI-DrugBank.d207.s2|81-88|reported|O
DDI-DrugBank.d207.s2|90-91|in|O
DDI-DrugBank.d207.s2|93-96|some|O
DDI-DrugBank.d207.s2|98-105|patients|O
DDI-DrugBank.d207.s2|107-112|taking|O
DDI-DrugBank.d207.s2|114-121|warfarin|drug
DDI-DrugBank.d207.s2|123-127|while|O
DDI-DrugBank.d207.s2|129-130|on|O
DDI-DrugBank.d207.s2|132-137|IRESSA|brand
DDI-DrugBank.d207.s2|139-145|therapy|O
DDI-DrugBank.d207.s2|146-146|.|O
DDI-DrugBank.d207.s3|0-7|Patients|O
DDI-DrugBank.d207.s3|9-14|taking|O
DDI-DrugBank.d207.s3|16-23|warfarin|drug
DDI-DrugBank.d207.s3|25-30|should|O
DDI-DrugBank.d207.s3|32-33|be|O
DDI-DrugBank.d207.s3|35-43|monitored|O
DDI-DrugBank.d207.s3|45-53|regularly|O
DDI-DrugBank.d207.s3|55-57|for|O
DDI-DrugBank.d207.s3|59-65|changes|O
DDI-DrugBank.d207.s3|67-68|in|O
DDI-DrugBank.d207.s3|70-80|prothrombin|O
DDI-DrugBank.d207.s3|82-85|time|O
DDI-DrugBank.d207.s3|87-88|or|O
DDI-DrugBank.d207.s3|90-92|INR|O
DDI-DrugBank.d207.s3|93-93|.|O
DDI-DrugBank.d207.s4|0-9|Substances|O
DDI-DrugBank.d207.s4|11-14|that|O
DDI-DrugBank.d207.s4|16-18|are|O
DDI-DrugBank.d207.s4|20-25|potent|O
DDI-DrugBank.d207.s4|27-36|inhibitors|O
DDI-DrugBank.d207.s4|38-39|of|O
DDI-DrugBank.d207.s4|41-46|CYP3A4|O
DDI-DrugBank.d207.s4|48-55|activity|O
DDI-DrugBank.d207.s4|57-57|(|O
DDI-DrugBank.d207.s4|58-59|eg|O
DDI-DrugBank.d207.s4|60-60|,|O
DDI-DrugBank.d207.s4|62-73|ketoconazole|drug
DDI-DrugBank.d207.s4|75-77|and|O
DDI-DrugBank.d207.s4|79-90|itraconazole|drug
DDI-DrugBank.d207.s4|91-91|)|O
DDI-DrugBank.d207.s4|93-100|decrease|O
DDI-DrugBank.d207.s4|102-110|gefitinib|drug
DDI-DrugBank.d207.s4|112-121|metabolism|O
DDI-DrugBank.d207.s4|123-125|and|O
DDI-DrugBank.d207.s4|127-134|increase|O
DDI-DrugBank.d207.s4|136-144|gefitinib|drug
DDI-DrugBank.d207.s4|146-151|plasma|O
DDI-DrugBank.d207.s4|153-166|concentrations|O
DDI-DrugBank.d207.s4|167-167|.|O
DDI-DrugBank.d207.s5|0-3|This|O
DDI-DrugBank.d207.s5|5-12|increase|O
DDI-DrugBank.d207.s5|14-16|may|O
DDI-DrugBank.d207.s5|18-19|be|O
DDI-DrugBank.d207.s5|21-30|clinically|O
DDI-DrugBank.d207.s5|32-39|relevant|O
DDI-DrugBank.d207.s5|41-42|as|O
DDI-DrugBank.d207.s5|44-50|adverse|O
DDI-DrugBank.d207.s5|52-62|experiences|O
DDI-DrugBank.d207.s5|64-66|are|O
DDI-DrugBank.d207.s5|68-74|related|O
DDI-DrugBank.d207.s5|76-77|to|O
DDI-DrugBank.d207.s5|79-82|dose|O
DDI-DrugBank.d207.s5|84-86|and|O
DDI-DrugBank.d207.s5|88-95|exposure|O
DDI-DrugBank.d207.s5|96-96|;|O
DDI-DrugBank.d207.s6|0-8|therefore|O
DDI-DrugBank.d207.s6|9-9|,|O
DDI-DrugBank.d207.s6|11-17|caution|O
DDI-DrugBank.d207.s6|19-24|should|O
DDI-DrugBank.d207.s6|26-27|be|O
DDI-DrugBank.d207.s6|29-32|used|O
DDI-DrugBank.d207.s6|34-37|when|O
DDI-DrugBank.d207.s6|39-51|administering|O
DDI-DrugBank.d207.s6|53-58|CYP3A4|O
DDI-DrugBank.d207.s6|60-69|inhibitors|O
DDI-DrugBank.d207.s6|71-74|with|O
DDI-DrugBank.d207.s6|76-81|IRESSA|brand
DDI-DrugBank.d207.s6|82-82|.|O
DDI-DrugBank.d207.s7|0-4|Drugs|O
DDI-DrugBank.d207.s7|6-9|that|O
DDI-DrugBank.d207.s7|11-15|cause|O
DDI-DrugBank.d207.s7|17-27|significant|O
DDI-DrugBank.d207.s7|29-37|sustained|O
DDI-DrugBank.d207.s7|39-47|elevation|O
DDI-DrugBank.d207.s7|49-50|in|O
DDI-DrugBank.d207.s7|52-58|gastric|O
DDI-DrugBank.d207.s7|60-61|pH|O
DDI-DrugBank.d207.s7|63-63|(|O
DDI-DrugBank.d207.s7|64-96|histamine H2-receptor antagonists|group
DDI-DrugBank.d207.s7|98-101|such|O
DDI-DrugBank.d207.s7|103-104|as|O
DDI-DrugBank.d207.s7|106-115|ranitidine|drug
DDI-DrugBank.d207.s7|117-118|or|O
DDI-DrugBank.d207.s7|120-129|cimetidine|drug
DDI-DrugBank.d207.s7|130-130|)|O
DDI-DrugBank.d207.s7|132-134|may|O
DDI-DrugBank.d207.s7|136-141|reduce|O
DDI-DrugBank.d207.s7|143-148|plasma|O
DDI-DrugBank.d207.s7|150-163|concentrations|O
DDI-DrugBank.d207.s7|165-166|of|O
DDI-DrugBank.d207.s7|168-173|IRESSA|brand
DDI-DrugBank.d207.s7|175-177|and|O
DDI-DrugBank.d207.s7|179-187|therefore|O
DDI-DrugBank.d207.s7|189-199|potentially|O
DDI-DrugBank.d207.s7|201-203|may|O
DDI-DrugBank.d207.s7|205-210|reduce|O
DDI-DrugBank.d207.s7|212-219|efficacy|O
DDI-DrugBank.d207.s7|220-220|.|O
DDI-DrugBank.d207.s8|0-4|Phase|O
DDI-DrugBank.d207.s8|6-7|II|O
DDI-DrugBank.d207.s8|9-16|clinical|O
DDI-DrugBank.d207.s8|18-22|trial|O
DDI-DrugBank.d207.s8|24-27|data|O
DDI-DrugBank.d207.s8|28-28|,|O
DDI-DrugBank.d207.s8|30-34|where|O
DDI-DrugBank.d207.s8|36-41|IRESSA|brand
DDI-DrugBank.d207.s8|43-45|and|O
DDI-DrugBank.d207.s8|47-57|vinorelbine|drug
DDI-DrugBank.d207.s8|59-62|have|O
DDI-DrugBank.d207.s8|64-67|been|O
DDI-DrugBank.d207.s8|69-72|used|O
DDI-DrugBank.d207.s8|74-86|concomitantly|O
DDI-DrugBank.d207.s8|87-87|,|O
DDI-DrugBank.d207.s8|89-96|indicate|O
DDI-DrugBank.d207.s8|98-101|that|O
DDI-DrugBank.d207.s8|103-108|IRESSA|brand
DDI-DrugBank.d207.s8|110-112|may|O
DDI-DrugBank.d207.s8|114-123|exacerbate|O
DDI-DrugBank.d207.s8|125-127|the|O
DDI-DrugBank.d207.s8|129-139|neutropenic|O
DDI-DrugBank.d207.s8|141-146|effect|O
DDI-DrugBank.d207.s8|148-149|of|O
DDI-DrugBank.d207.s8|151-161|vinorelbine|drug
DDI-DrugBank.d207.s8|162-162|.|O
DDI-DrugBank.d246.s0|0-9|Concurrent|O
DDI-DrugBank.d246.s0|11-13|use|O
DDI-DrugBank.d246.s0|15-16|of|O
DDI-DrugBank.d246.s0|18-28|butorphanol|drug
DDI-DrugBank.d246.s0|30-33|with|O
DDI-DrugBank.d246.s0|35-68|central nervous system depressants|group
DDI-DrugBank.d246.s0|70-70|(|O
DDI-DrugBank.d246.s0|71-74|e.g.|O
DDI-DrugBank.d246.s0|75-75|,|O
DDI-DrugBank.d246.s0|77-83|alcohol|drug
DDI-DrugBank.d246.s0|84-84|,|O
DDI-DrugBank.d246.s0|86-97|barbiturates|group
DDI-DrugBank.d246.s0|98-98|,|O
DDI-DrugBank.d246.s0|100-112|tranquilizers|group
DDI-DrugBank.d246.s0|113-113|,|O
DDI-DrugBank.d246.s0|115-117|and|O
DDI-DrugBank.d246.s0|119-132|antihistamines|group
DDI-DrugBank.d246.s0|133-133|)|O
DDI-DrugBank.d246.s0|135-137|may|O
DDI-DrugBank.d246.s0|139-144|result|O
DDI-DrugBank.d246.s0|146-147|in|O
DDI-DrugBank.d246.s0|149-157|increased|O
DDI-DrugBank.d246.s0|159-191|central nervous system depressant|group
DDI-DrugBank.d246.s0|193-199|effects|O
DDI-DrugBank.d246.s0|200-200|.|O
DDI-DrugBank.d246.s1|0-3|When|O
DDI-DrugBank.d246.s1|5-8|used|O
DDI-DrugBank.d246.s1|10-21|concurrently|O
DDI-DrugBank.d246.s1|23-26|with|O
DDI-DrugBank.d246.s1|28-31|such|O
DDI-DrugBank.d246.s1|33-37|drugs|O
DDI-DrugBank.d246.s1|38-38|,|O
DDI-DrugBank.d246.s1|40-42|the|O
DDI-DrugBank.d246.s1|44-47|dose|O
DDI-DrugBank.d246.s1|49-50|of|O
DDI-DrugBank.d246.s1|52-62|butorphanol|drug
DDI-DrugBank.d246.s1|64-69|should|O
DDI-DrugBank.d246.s1|71-72|be|O
DDI-DrugBank.d246.s1|74-76|the|O
DDI-DrugBank.d246.s1|78-85|smallest|O
DDI-DrugBank.d246.s1|87-95|effective|O
DDI-DrugBank.d246.s1|97-100|dose|O
DDI-DrugBank.d246.s1|102-104|and|O
DDI-DrugBank.d246.s1|106-108|the|O
DDI-DrugBank.d246.s1|110-118|frequency|O
DDI-DrugBank.d246.s1|120-121|of|O
DDI-DrugBank.d246.s1|123-128|dosing|O
DDI-DrugBank.d246.s1|130-136|reduced|O
DDI-DrugBank.d246.s1|138-139|as|O
DDI-DrugBank.d246.s1|141-144|much|O
DDI-DrugBank.d246.s1|146-147|as|O
DDI-DrugBank.d246.s1|149-156|possible|O
DDI-DrugBank.d246.s1|158-161|when|O
DDI-DrugBank.d246.s1|163-174|administered|O
DDI-DrugBank.d246.s1|176-188|concomitantly|O
DDI-DrugBank.d246.s1|190-193|with|O
DDI-DrugBank.d246.s1|195-199|drugs|O
DDI-DrugBank.d246.s1|201-204|that|O
DDI-DrugBank.d246.s1|206-215|potentiate|O
DDI-DrugBank.d246.s1|217-219|the|O
DDI-DrugBank.d246.s1|221-226|action|O
DDI-DrugBank.d246.s1|228-229|of|O
DDI-DrugBank.d246.s1|231-237|opioids|group
DDI-DrugBank.d246.s1|238-238|.|O
DDI-DrugBank.d246.s2|0-1|In|O
DDI-DrugBank.d246.s2|3-9|healthy|O
DDI-DrugBank.d246.s2|11-20|volunteers|O
DDI-DrugBank.d246.s2|21-21|,|O
DDI-DrugBank.d246.s2|23-25|the|O
DDI-DrugBank.d246.s2|27-42|pharmacokinetics|O
DDI-DrugBank.d246.s2|44-45|of|O
DDI-DrugBank.d246.s2|47-47|a|O
DDI-DrugBank.d246.s2|49-52|1-mg|O
DDI-DrugBank.d246.s2|54-57|dose|O
DDI-DrugBank.d246.s2|59-60|of|O
DDI-DrugBank.d246.s2|62-72|butorphanol|drug
DDI-DrugBank.d246.s2|74-85|administered|O
DDI-DrugBank.d246.s2|87-88|as|O
DDI-DrugBank.d246.s2|90-98|STADOL NS|brand
DDI-DrugBank.d246.s2|100-103|were|O
DDI-DrugBank.d246.s2|105-107|not|O
DDI-DrugBank.d246.s2|109-116|affected|O
DDI-DrugBank.d246.s2|118-119|by|O
DDI-DrugBank.d246.s2|121-123|the|O
DDI-DrugBank.d246.s2|125-140|coadministration|O
DDI-DrugBank.d246.s2|142-143|of|O
DDI-DrugBank.d246.s2|145-145|a|O
DDI-DrugBank.d246.s2|147-152|single|O
DDI-DrugBank.d246.s2|154-157|6-mg|O
DDI-DrugBank.d246.s2|159-170|subcutaneous|O
DDI-DrugBank.d246.s2|172-175|dose|O
DDI-DrugBank.d246.s2|177-178|of|O
DDI-DrugBank.d246.s2|180-190|sumatriptan|drug
DDI-DrugBank.d246.s2|191-191|.|O
DDI-DrugBank.d246.s3|0-6|However|O
DDI-DrugBank.d246.s3|7-7|,|O
DDI-DrugBank.d246.s3|9-10|in|O
DDI-DrugBank.d246.s3|12-18|another|O
DDI-DrugBank.d246.s3|20-24|study|O
DDI-DrugBank.d246.s3|26-27|in|O
DDI-DrugBank.d246.s3|29-35|healthy|O
DDI-DrugBank.d246.s3|37-46|volunteers|O
DDI-DrugBank.d246.s3|47-47|,|O
DDI-DrugBank.d246.s3|49-51|the|O
DDI-DrugBank.d246.s3|53-68|pharmacokinetics|O
DDI-DrugBank.d246.s3|70-71|of|O
DDI-DrugBank.d246.s3|73-83|butorphanol|drug
DDI-DrugBank.d246.s3|85-88|were|O
DDI-DrugBank.d246.s3|90-102|significantly|O
DDI-DrugBank.d246.s3|104-110|altered|O
DDI-DrugBank.d246.s3|112-112|(|O
DDI-DrugBank.d246.s3|113-114|29|O
DDI-DrugBank.d246.s3|115-115|%|O
DDI-DrugBank.d246.s3|117-124|decrease|O
DDI-DrugBank.d246.s3|126-127|in|O
DDI-DrugBank.d246.s3|129-131|AUC|O
DDI-DrugBank.d246.s3|133-135|and|O
DDI-DrugBank.d246.s3|137-138|38|O
DDI-DrugBank.d246.s3|139-139|%|O
DDI-DrugBank.d246.s3|141-148|decrease|O
DDI-DrugBank.d246.s3|150-151|in|O
DDI-DrugBank.d246.s3|153-156|Cmax|O
DDI-DrugBank.d246.s3|157-157|)|O
DDI-DrugBank.d246.s3|159-162|when|O
DDI-DrugBank.d246.s3|164-164|a|O
DDI-DrugBank.d246.s3|166-169|1-mg|O
DDI-DrugBank.d246.s3|171-174|dose|O
DDI-DrugBank.d246.s3|176-177|of|O
DDI-DrugBank.d246.s3|179-187|STADOL NS|brand
DDI-DrugBank.d246.s3|189-191|was|O
DDI-DrugBank.d246.s3|193-204|administered|O
DDI-DrugBank.d246.s3|206-206|1|O
DDI-DrugBank.d246.s3|208-213|minute|O
DDI-DrugBank.d246.s3|215-219|after|O
DDI-DrugBank.d246.s3|221-221|a|O
DDI-DrugBank.d246.s3|223-227|20-mg|O
DDI-DrugBank.d246.s3|229-232|dose|O
DDI-DrugBank.d246.s3|234-235|of|O
DDI-DrugBank.d246.s3|237-247|sumatriptan|drug
DDI-DrugBank.d246.s3|249-253|nasal|O
DDI-DrugBank.d246.s3|255-259|spray|O
DDI-DrugBank.d246.s3|260-260|.|O
DDI-DrugBank.d246.s4|0-0|(|O
DDI-DrugBank.d246.s4|1-3|The|O
DDI-DrugBank.d246.s4|5-7|two|O
DDI-DrugBank.d246.s4|9-13|drugs|O
DDI-DrugBank.d246.s4|15-18|were|O
DDI-DrugBank.d246.s4|20-31|administered|O
DDI-DrugBank.d246.s4|33-34|in|O
DDI-DrugBank.d246.s4|36-43|opposite|O
DDI-DrugBank.d246.s4|45-52|nostrils|O
DDI-DrugBank.d246.s4|53-53|.|O
DDI-DrugBank.d246.s4|54-54|)|O
DDI-DrugBank.d246.s5|0-3|When|O
DDI-DrugBank.d246.s5|5-7|the|O
DDI-DrugBank.d246.s5|9-17|STADOL NS|brand
DDI-DrugBank.d246.s5|19-21|was|O
DDI-DrugBank.d246.s5|23-34|administered|O
DDI-DrugBank.d246.s5|36-37|30|O
DDI-DrugBank.d246.s5|39-45|minutes|O
DDI-DrugBank.d246.s5|47-51|after|O
DDI-DrugBank.d246.s5|53-55|the|O
DDI-DrugBank.d246.s5|57-67|sumatriptan|drug
DDI-DrugBank.d246.s5|69-73|nasal|O
DDI-DrugBank.d246.s5|75-79|spray|O
DDI-DrugBank.d246.s5|80-80|,|O
DDI-DrugBank.d246.s5|82-84|the|O
DDI-DrugBank.d246.s5|86-88|AUC|O
DDI-DrugBank.d246.s5|90-91|of|O
DDI-DrugBank.d246.s5|93-103|butorphanol|drug
DDI-DrugBank.d246.s5|105-113|increased|O
DDI-DrugBank.d246.s5|115-116|11|O
DDI-DrugBank.d246.s5|117-117|%|O
DDI-DrugBank.d246.s5|119-121|and|O
DDI-DrugBank.d246.s5|123-126|Cmax|O
DDI-DrugBank.d246.s5|128-136|decreased|O
DDI-DrugBank.d246.s5|138-139|18|O
DDI-DrugBank.d246.s5|140-140|%|O
DDI-DrugBank.d246.s5|141-141|.|O
DDI-DrugBank.d246.s6|0-1|In|O
DDI-DrugBank.d246.s6|3-9|neither|O
DDI-DrugBank.d246.s6|11-14|case|O
DDI-DrugBank.d246.s6|16-19|were|O
DDI-DrugBank.d246.s6|21-23|the|O
DDI-DrugBank.d246.s6|25-40|pharmacokinetics|O
DDI-DrugBank.d246.s6|42-43|of|O
DDI-DrugBank.d246.s6|45-55|sumatriptan|drug
DDI-DrugBank.d246.s6|57-64|affected|O
DDI-DrugBank.d246.s6|66-67|by|O
DDI-DrugBank.d246.s6|69-84|coadministration|O
DDI-DrugBank.d246.s6|86-89|with|O
DDI-DrugBank.d246.s6|91-99|STADOL NS|brand
DDI-DrugBank.d246.s6|100-100|.|O
DDI-DrugBank.d246.s7|0-4|These|O
DDI-DrugBank.d246.s7|6-12|results|O
DDI-DrugBank.d246.s7|14-20|suggest|O
DDI-DrugBank.d246.s7|22-25|that|O
DDI-DrugBank.d246.s7|27-29|the|O
DDI-DrugBank.d246.s7|31-39|analgesic|O
DDI-DrugBank.d246.s7|41-46|effect|O
DDI-DrugBank.d246.s7|48-49|of|O
DDI-DrugBank.d246.s7|51-59|STADOL NS|brand
DDI-DrugBank.d246.s7|61-63|may|O
DDI-DrugBank.d246.s7|65-66|be|O
DDI-DrugBank.d246.s7|68-77|diminished|O
DDI-DrugBank.d246.s7|79-82|when|O
DDI-DrugBank.d246.s7|84-85|it|O
DDI-DrugBank.d246.s7|87-88|is|O
DDI-DrugBank.d246.s7|90-101|administered|O
DDI-DrugBank.d246.s7|103-109|shortly|O
DDI-DrugBank.d246.s7|111-115|after|O
DDI-DrugBank.d246.s7|117-127|sumatriptan|drug
DDI-DrugBank.d246.s7|129-133|nasal|O
DDI-DrugBank.d246.s7|135-139|spray|O
DDI-DrugBank.d246.s7|140-140|,|O
DDI-DrugBank.d246.s7|142-144|but|O
DDI-DrugBank.d246.s7|146-147|by|O
DDI-DrugBank.d246.s7|149-150|30|O
DDI-DrugBank.d246.s7|152-158|minutes|O
DDI-DrugBank.d246.s7|160-162|any|O
DDI-DrugBank.d246.s7|164-167|such|O
DDI-DrugBank.d246.s7|169-177|reduction|O
DDI-DrugBank.d246.s7|179-180|in|O
DDI-DrugBank.d246.s7|182-187|effect|O
DDI-DrugBank.d246.s7|189-194|should|O
DDI-DrugBank.d246.s7|196-197|be|O
DDI-DrugBank.d246.s7|199-205|minimal|O
DDI-DrugBank.d246.s7|206-206|.|O
DDI-DrugBank.d246.s8|0-2|The|O
DDI-DrugBank.d246.s8|4-9|safety|O
DDI-DrugBank.d246.s8|11-12|of|O
DDI-DrugBank.d246.s8|14-18|using|O
DDI-DrugBank.d246.s8|20-28|STADOL NS|brand
DDI-DrugBank.d246.s8|30-32|and|O
DDI-DrugBank.d246.s8|34-40|IMITREX|brand
DDI-DrugBank.d246.s8|42-42|(|O
DDI-DrugBank.d246.s8|43-53|sumatriptan|drug
DDI-DrugBank.d246.s8|54-54|)|O
DDI-DrugBank.d246.s8|56-60|Nasal|O
DDI-DrugBank.d246.s8|62-66|Spray|O
DDI-DrugBank.d246.s8|68-73|during|O
DDI-DrugBank.d246.s8|75-77|the|O
DDI-DrugBank.d246.s8|79-82|same|O
DDI-DrugBank.d246.s8|84-90|episode|O
DDI-DrugBank.d246.s8|92-93|of|O
DDI-DrugBank.d246.s8|95-102|migraine|O
DDI-DrugBank.d246.s8|104-106|has|O
DDI-DrugBank.d246.s8|108-110|not|O
DDI-DrugBank.d246.s8|112-115|been|O
DDI-DrugBank.d246.s8|117-127|established|O
DDI-DrugBank.d246.s8|128-128|.|O
DDI-DrugBank.d246.s9|0-6|However|O
DDI-DrugBank.d246.s9|7-7|,|O
DDI-DrugBank.d246.s9|9-10|it|O
DDI-DrugBank.d246.s9|12-17|should|O
DDI-DrugBank.d246.s9|19-20|be|O
DDI-DrugBank.d246.s9|22-26|noted|O
DDI-DrugBank.d246.s9|28-31|that|O
DDI-DrugBank.d246.s9|33-36|both|O
DDI-DrugBank.d246.s9|38-45|products|O
DDI-DrugBank.d246.s9|47-49|are|O
DDI-DrugBank.d246.s9|51-57|capable|O
DDI-DrugBank.d246.s9|59-60|of|O
DDI-DrugBank.d246.s9|62-70|producing|O
DDI-DrugBank.d246.s9|72-80|transient|O
DDI-DrugBank.d246.s9|82-90|increases|O
DDI-DrugBank.d246.s9|92-93|in|O
DDI-DrugBank.d246.s9|95-99|blood|O
DDI-DrugBank.d246.s9|101-108|pressure|O
DDI-DrugBank.d246.s9|109-109|.|O
DDI-DrugBank.d246.s10|0-2|The|O
DDI-DrugBank.d246.s10|4-19|pharmacokinetics|O
DDI-DrugBank.d246.s10|21-22|of|O
DDI-DrugBank.d246.s10|24-24|a|O
DDI-DrugBank.d246.s10|26-29|1-mg|O
DDI-DrugBank.d246.s10|31-34|dose|O
DDI-DrugBank.d246.s10|36-37|of|O
DDI-DrugBank.d246.s10|39-49|butorphanol|drug
DDI-DrugBank.d246.s10|51-62|administered|O
DDI-DrugBank.d246.s10|64-65|as|O
DDI-DrugBank.d246.s10|67-75|STADOL NS|brand
DDI-DrugBank.d246.s10|77-80|were|O
DDI-DrugBank.d246.s10|82-84|not|O
DDI-DrugBank.d246.s10|86-93|affected|O
DDI-DrugBank.d246.s10|95-96|by|O
DDI-DrugBank.d246.s10|98-100|the|O
DDI-DrugBank.d246.s10|102-117|coadministration|O
DDI-DrugBank.d246.s10|119-120|of|O
DDI-DrugBank.d246.s10|122-131|cimetidine|drug
DDI-DrugBank.d246.s10|133-133|(|O
DDI-DrugBank.d246.s10|134-136|300|O
DDI-DrugBank.d246.s10|138-139|mg|O
DDI-DrugBank.d246.s10|141-143|QID|O
DDI-DrugBank.d246.s10|144-144|)|O
DDI-DrugBank.d246.s10|145-145|.|O
DDI-DrugBank.d246.s11|0-9|Conversely|O
DDI-DrugBank.d246.s11|10-10|,|O
DDI-DrugBank.d246.s11|12-14|the|O
DDI-DrugBank.d246.s11|16-29|administration|O
DDI-DrugBank.d246.s11|31-32|of|O
DDI-DrugBank.d246.s11|34-42|STADOL NS|brand
DDI-DrugBank.d246.s11|44-44|(|O
DDI-DrugBank.d246.s11|45-45|1|O
DDI-DrugBank.d246.s11|47-48|mg|O
DDI-DrugBank.d246.s11|50-60|butorphanol|drug
DDI-DrugBank.d246.s11|62-64|QID|O
DDI-DrugBank.d246.s11|65-65|)|O
DDI-DrugBank.d246.s11|67-69|did|O
DDI-DrugBank.d246.s11|71-73|not|O
DDI-DrugBank.d246.s11|75-79|alter|O
DDI-DrugBank.d246.s11|81-83|the|O
DDI-DrugBank.d246.s11|85-100|pharmacokinetics|O
DDI-DrugBank.d246.s11|102-103|of|O
DDI-DrugBank.d246.s11|105-105|a|O
DDI-DrugBank.d246.s11|107-112|300-mg|O
DDI-DrugBank.d246.s11|114-117|dose|O
DDI-DrugBank.d246.s11|119-120|of|O
DDI-DrugBank.d246.s11|122-131|cimetidine|drug
DDI-DrugBank.d246.s11|132-132|.|O
DDI-DrugBank.d246.s12|0-1|It|O
DDI-DrugBank.d246.s12|3-4|is|O
DDI-DrugBank.d246.s12|6-8|not|O
DDI-DrugBank.d246.s12|10-14|known|O
DDI-DrugBank.d246.s12|16-17|if|O
DDI-DrugBank.d246.s12|19-21|the|O
DDI-DrugBank.d246.s12|23-29|effects|O
DDI-DrugBank.d246.s12|31-32|of|O
DDI-DrugBank.d246.s12|34-44|butorphanol|drug
DDI-DrugBank.d246.s12|46-48|are|O
DDI-DrugBank.d246.s12|50-56|altered|O
DDI-DrugBank.d246.s12|58-59|by|O
DDI-DrugBank.d246.s12|61-71|concomitant|O
DDI-DrugBank.d246.s12|73-83|medications|O
DDI-DrugBank.d246.s12|85-88|that|O
DDI-DrugBank.d246.s12|90-95|affect|O
DDI-DrugBank.d246.s12|97-103|hepatic|O
DDI-DrugBank.d246.s12|105-114|metabolism|O
DDI-DrugBank.d246.s12|116-117|of|O
DDI-DrugBank.d246.s12|119-123|drugs|O
DDI-DrugBank.d246.s12|125-125|(|O
DDI-DrugBank.d246.s12|126-137|erythromycin|drug
DDI-DrugBank.d246.s12|138-138|,|O
DDI-DrugBank.d246.s12|140-143|etc.|O
DDI-DrugBank.d246.s12|144-144|)|O
DDI-DrugBank.d246.s12|145-145|,|O
DDI-DrugBank.d246.s12|147-149|but|O
DDI-DrugBank.d246.s12|151-160|physicians|O
DDI-DrugBank.d246.s12|162-167|should|O
DDI-DrugBank.d246.s12|169-170|be|O
DDI-DrugBank.d246.s12|172-176|alert|O
DDI-DrugBank.d246.s12|178-179|to|O
DDI-DrugBank.d246.s12|181-183|the|O
DDI-DrugBank.d246.s12|185-195|possibility|O
DDI-DrugBank.d246.s12|197-200|that|O
DDI-DrugBank.d246.s12|202-202|a|O
DDI-DrugBank.d246.s12|204-210|smaller|O
DDI-DrugBank.d246.s12|212-218|initial|O
DDI-DrugBank.d246.s12|220-223|dose|O
DDI-DrugBank.d246.s12|225-227|and|O
DDI-DrugBank.d246.s12|229-234|longer|O
DDI-DrugBank.d246.s12|236-244|intervals|O
DDI-DrugBank.d246.s12|246-252|between|O
DDI-DrugBank.d246.s12|254-258|doses|O
DDI-DrugBank.d246.s12|260-262|may|O
DDI-DrugBank.d246.s12|264-265|be|O
DDI-DrugBank.d246.s12|267-272|needed|O
DDI-DrugBank.d246.s12|273-273|.|O
DDI-DrugBank.d246.s13|0-2|The|O
DDI-DrugBank.d246.s13|4-11|fraction|O
DDI-DrugBank.d246.s13|13-14|of|O
DDI-DrugBank.d246.s13|16-24|STADOL NS|brand
DDI-DrugBank.d246.s13|26-33|absorbed|O
DDI-DrugBank.d246.s13|35-36|is|O
DDI-DrugBank.d246.s13|38-47|unaffected|O
DDI-DrugBank.d246.s13|49-50|by|O
DDI-DrugBank.d246.s13|52-54|the|O
DDI-DrugBank.d246.s13|56-66|concomitant|O
DDI-DrugBank.d246.s13|68-81|administration|O
DDI-DrugBank.d246.s13|83-84|of|O
DDI-DrugBank.d246.s13|86-86|a|O
DDI-DrugBank.d246.s13|88-108|nasal vasoconstrictor|group
DDI-DrugBank.d246.s13|110-110|(|O
DDI-DrugBank.d246.s13|111-123|oxymetazoline|drug
DDI-DrugBank.d246.s13|124-124|)|O
DDI-DrugBank.d246.s13|125-125|,|O
DDI-DrugBank.d246.s13|127-129|but|O
DDI-DrugBank.d246.s13|131-133|the|O
DDI-DrugBank.d246.s13|135-138|rate|O
DDI-DrugBank.d246.s13|140-141|of|O
DDI-DrugBank.d246.s13|143-152|absorption|O
DDI-DrugBank.d246.s13|154-155|is|O
DDI-DrugBank.d246.s13|157-165|decreased|O
DDI-DrugBank.d246.s13|166-166|.|O
DDI-DrugBank.d246.s14|0-8|Therefore|O
DDI-DrugBank.d246.s14|9-9|,|O
DDI-DrugBank.d246.s14|11-11|a|O
DDI-DrugBank.d246.s14|13-18|slower|O
DDI-DrugBank.d246.s14|20-24|onset|O
DDI-DrugBank.d246.s14|26-28|can|O
DDI-DrugBank.d246.s14|30-31|be|O
DDI-DrugBank.d246.s14|33-43|anticipated|O
DDI-DrugBank.d246.s14|45-46|if|O
DDI-DrugBank.d246.s14|48-56|STADOL NS|brand
DDI-DrugBank.d246.s14|58-59|is|O
DDI-DrugBank.d246.s14|61-72|administered|O
DDI-DrugBank.d246.s14|74-86|concomitantly|O
DDI-DrugBank.d246.s14|88-91|with|O
DDI-DrugBank.d246.s14|92-92|,|O
DDI-DrugBank.d246.s14|94-95|or|O
DDI-DrugBank.d246.s14|97-107|immediately|O
DDI-DrugBank.d246.s14|109-117|following|O
DDI-DrugBank.d246.s14|118-118|,|O
DDI-DrugBank.d246.s14|120-120|a|O
DDI-DrugBank.d246.s14|122-142|nasal vasoconstrictor|group
DDI-DrugBank.d246.s14|143-143|.|O
DDI-DrugBank.d246.s15|0-1|No|O
DDI-DrugBank.d246.s15|3-13|information|O
DDI-DrugBank.d246.s15|15-16|is|O
DDI-DrugBank.d246.s15|18-26|available|O
DDI-DrugBank.d246.s15|28-32|about|O
DDI-DrugBank.d246.s15|34-36|the|O
DDI-DrugBank.d246.s15|38-40|use|O
DDI-DrugBank.d246.s15|42-43|of|O
DDI-DrugBank.d246.s15|45-55|butorphanol|drug
DDI-DrugBank.d246.s15|57-68|concurrently|O
DDI-DrugBank.d246.s15|70-73|with|O
DDI-DrugBank.d246.s15|75-88|MAO inhibitors|group
DDI-DrugBank.d246.s15|89-89|.|O
DDI-DrugBank.d1.s0|0-3|Drug|O
DDI-DrugBank.d1.s0|5-16|interactions|O
DDI-DrugBank.d1.s0|18-24|between|O
DDI-DrugBank.d1.s0|26-33|NEUPOGEN|brand
DDI-DrugBank.d1.s0|36-38|and|O
DDI-DrugBank.d1.s0|40-44|other|O
DDI-DrugBank.d1.s0|46-50|drugs|O
DDI-DrugBank.d1.s0|52-55|have|O
DDI-DrugBank.d1.s0|57-59|not|O
DDI-DrugBank.d1.s0|61-64|been|O
DDI-DrugBank.d1.s0|66-70|fully|O
DDI-DrugBank.d1.s0|72-80|evaluated|O
DDI-DrugBank.d1.s0|81-81|.|O
DDI-DrugBank.d1.s1|0-4|Drugs|O
DDI-DrugBank.d1.s1|6-10|which|O
DDI-DrugBank.d1.s1|12-14|may|O
DDI-DrugBank.d1.s1|16-25|potentiate|O
DDI-DrugBank.d1.s1|27-29|the|O
DDI-DrugBank.d1.s1|31-37|release|O
DDI-DrugBank.d1.s1|39-40|of|O
DDI-DrugBank.d1.s1|42-52|neutrophils|O
DDI-DrugBank.d1.s1|53-53|,|O
DDI-DrugBank.d1.s1|55-58|such|O
DDI-DrugBank.d1.s1|60-61|as|O
DDI-DrugBank.d1.s1|63-69|lithium|drug
DDI-DrugBank.d1.s1|70-70|,|O
DDI-DrugBank.d1.s1|72-77|should|O
DDI-DrugBank.d1.s1|79-80|be|O
DDI-DrugBank.d1.s1|82-85|used|O
DDI-DrugBank.d1.s1|87-90|with|O
DDI-DrugBank.d1.s1|92-98|caution|O
DDI-DrugBank.d1.s1|99-99|.|O
DDI-DrugBank.d554.s0|0-6|Certain|O
DDI-DrugBank.d554.s0|8-17|antibiotic|group
DDI-DrugBank.d554.s0|18-18|,|O
DDI-DrugBank.d554.s0|20-28|cisplatin|drug
DDI-DrugBank.d554.s0|29-29|,|O
DDI-DrugBank.d554.s0|31-42|cyclosporine|drug
DDI-DrugBank.d554.s0|43-43|,|O
DDI-DrugBank.d554.s0|45-52|diuretic|group
DDI-DrugBank.d554.s0|53-53|,|O
DDI-DrugBank.d554.s0|55-63|foscarnet|drug
DDI-DrugBank.d554.s0|64-64|,|O
DDI-DrugBank.d554.s0|66-68|and|O
DDI-DrugBank.d554.s0|70-77|vaccines|group
DDI-DrugBank.d554.s0|78-78|.|O
DDI-DrugBank.d502.s0|0-7|Ocupress|brand
DDI-DrugBank.d502.s0|9-14|should|O
DDI-DrugBank.d502.s0|16-17|be|O
DDI-DrugBank.d502.s0|19-22|used|O
DDI-DrugBank.d502.s0|24-27|with|O
DDI-DrugBank.d502.s0|29-35|caution|O
DDI-DrugBank.d502.s0|37-38|in|O
DDI-DrugBank.d502.s0|40-47|patients|O
DDI-DrugBank.d502.s0|49-51|who|O
DDI-DrugBank.d502.s0|53-55|are|O
DDI-DrugBank.d502.s0|57-65|receiving|O
DDI-DrugBank.d502.s0|67-67|a|O
DDI-DrugBank.d502.s0|69-98|beta-adrenergic blocking agent|group
DDI-DrugBank.d502.s0|100-105|orally|O
DDI-DrugBank.d502.s0|107-113|because|O
DDI-DrugBank.d502.s0|115-116|of|O
DDI-DrugBank.d502.s0|118-120|the|O
DDI-DrugBank.d502.s0|122-130|potential|O
DDI-DrugBank.d502.s0|132-134|for|O
DDI-DrugBank.d502.s0|136-143|additive|O
DDI-DrugBank.d502.s0|145-151|effects|O
DDI-DrugBank.d502.s0|153-154|on|O
DDI-DrugBank.d502.s0|156-163|systemic|O
DDI-DrugBank.d502.s0|165-177|beta-blockade|O
DDI-DrugBank.d502.s0|178-178|.|O
DDI-DrugBank.d502.s1|0-4|Close|O
DDI-DrugBank.d502.s1|6-16|observation|O
DDI-DrugBank.d502.s1|18-19|of|O
DDI-DrugBank.d502.s1|21-23|the|O
DDI-DrugBank.d502.s1|25-31|patient|O
DDI-DrugBank.d502.s1|33-34|is|O
DDI-DrugBank.d502.s1|36-46|recommended|O
DDI-DrugBank.d502.s1|48-51|when|O
DDI-DrugBank.d502.s1|53-53|a|O
DDI-DrugBank.d502.s1|55-66|beta-blocker|group
DDI-DrugBank.d502.s1|68-69|is|O
DDI-DrugBank.d502.s1|71-82|administered|O
DDI-DrugBank.d502.s1|84-85|to|O
DDI-DrugBank.d502.s1|87-94|patients|O
DDI-DrugBank.d502.s1|96-104|receiving|O
DDI-DrugBank.d502.s1|106-128|catecholamine-depleting|O
DDI-DrugBank.d502.s1|130-134|drugs|O
DDI-DrugBank.d502.s1|136-139|such|O
DDI-DrugBank.d502.s1|141-142|as|O
DDI-DrugBank.d502.s1|144-152|reserpine|drug
DDI-DrugBank.d502.s1|153-153|,|O
DDI-DrugBank.d502.s1|155-161|because|O
DDI-DrugBank.d502.s1|163-164|of|O
DDI-DrugBank.d502.s1|166-173|possible|O
DDI-DrugBank.d502.s1|175-182|additive|O
DDI-DrugBank.d502.s1|184-190|effects|O
DDI-DrugBank.d502.s1|192-194|and|O
DDI-DrugBank.d502.s1|196-198|the|O
DDI-DrugBank.d502.s1|200-209|production|O
DDI-DrugBank.d502.s1|211-212|of|O
DDI-DrugBank.d502.s1|214-224|hypotension|O
DDI-DrugBank.d502.s1|226-231|and/or|O
DDI-DrugBank.d502.s1|233-238|marked|O
DDI-DrugBank.d502.s1|240-250|bradycardia|O
DDI-DrugBank.d502.s1|251-251|,|O
DDI-DrugBank.d502.s1|253-257|which|O
DDI-DrugBank.d502.s1|259-261|may|O
DDI-DrugBank.d502.s1|263-269|produce|O
DDI-DrugBank.d502.s1|271-277|vertigo|O
DDI-DrugBank.d502.s1|278-278|,|O
DDI-DrugBank.d502.s1|280-286|syncope|O
DDI-DrugBank.d502.s1|287-287|,|O
DDI-DrugBank.d502.s1|289-290|or|O
DDI-DrugBank.d502.s1|292-299|postural|O
DDI-DrugBank.d502.s1|301-311|hypotension|O
DDI-DrugBank.d502.s1|312-312|.|O
DDI-MedLine.d126.s0|0-19|Cypermethrin-induced|drug
DDI-MedLine.d126.s0|21-29|oxidative|O
DDI-MedLine.d126.s0|31-36|stress|O
DDI-MedLine.d126.s0|38-39|in|O
DDI-MedLine.d126.s0|41-43|rat|O
DDI-MedLine.d126.s0|45-49|brain|O
DDI-MedLine.d126.s0|51-53|and|O
DDI-MedLine.d126.s0|55-59|liver|O
DDI-MedLine.d126.s0|61-62|is|O
DDI-MedLine.d126.s0|64-72|prevented|O
DDI-MedLine.d126.s0|74-75|by|O
DDI-MedLine.d126.s0|77-85|vitamin E|drug
DDI-MedLine.d126.s0|87-88|or|O
DDI-MedLine.d126.s0|90-100|allopurinol|drug
DDI-MedLine.d126.s0|101-101|.|O
DDI-MedLine.d126.s1|0-10|Considering|O
DDI-MedLine.d126.s1|12-15|that|O
DDI-MedLine.d126.s1|17-19|the|O
DDI-MedLine.d126.s1|21-31|involvement|O
DDI-MedLine.d126.s1|33-34|of|O
DDI-MedLine.d126.s1|36-43|reactive|O
DDI-MedLine.d126.s1|45-50|oxygen|O
DDI-MedLine.d126.s1|52-58|species|O
DDI-MedLine.d126.s1|60-60|(|O
DDI-MedLine.d126.s1|61-63|ROS|O
DDI-MedLine.d126.s1|64-64|)|O
DDI-MedLine.d126.s1|66-68|has|O
DDI-MedLine.d126.s1|70-73|been|O
DDI-MedLine.d126.s1|75-84|implicated|O
DDI-MedLine.d126.s1|86-87|in|O
DDI-MedLine.d126.s1|89-91|the|O
DDI-MedLine.d126.s1|93-100|toxicity|O
DDI-MedLine.d126.s1|102-103|of|O
DDI-MedLine.d126.s1|105-111|various|O
DDI-MedLine.d126.s1|113-122|pesticides|O
DDI-MedLine.d126.s1|123-123|,|O
DDI-MedLine.d126.s1|125-128|this|O
DDI-MedLine.d126.s1|130-134|study|O
DDI-MedLine.d126.s1|136-138|was|O
DDI-MedLine.d126.s1|140-147|designed|O
DDI-MedLine.d126.s1|149-150|to|O
DDI-MedLine.d126.s1|152-162|investigate|O
DDI-MedLine.d126.s1|164-166|the|O
DDI-MedLine.d126.s1|168-178|possibility|O
DDI-MedLine.d126.s1|180-181|of|O
DDI-MedLine.d126.s1|183-191|oxidative|O
DDI-MedLine.d126.s1|193-198|stress|O
DDI-MedLine.d126.s1|200-208|induction|O
DDI-MedLine.d126.s1|210-211|by|O
DDI-MedLine.d126.s1|213-224|cypermethrin|drug
DDI-MedLine.d126.s1|225-225|,|O
DDI-MedLine.d126.s1|227-227|a|O
DDI-MedLine.d126.s1|247-247|.|O
DDI-MedLine.d126.s2|0-5|Either|O
DDI-MedLine.d126.s2|7-12|single|O
DDI-MedLine.d126.s2|14-14|(|O
DDI-MedLine.d126.s2|15-17|170|O
DDI-MedLine.d126.s2|19-23|mg/kg|O
DDI-MedLine.d126.s2|24-24|)|O
DDI-MedLine.d126.s2|26-27|or|O
DDI-MedLine.d126.s2|29-36|repeated|O
DDI-MedLine.d126.s2|38-38|(|O
DDI-MedLine.d126.s2|39-40|75|O
DDI-MedLine.d126.s2|42-46|mg/kg|O
DDI-MedLine.d126.s2|48-50|per|O
DDI-MedLine.d126.s2|52-54|day|O
DDI-MedLine.d126.s2|56-58|for|O
DDI-MedLine.d126.s2|60-60|5|O
DDI-MedLine.d126.s2|62-65|days|O
DDI-MedLine.d126.s2|66-66|)|O
DDI-MedLine.d126.s2|68-71|oral|O
DDI-MedLine.d126.s2|73-86|administration|O
DDI-MedLine.d126.s2|88-89|of|O
DDI-MedLine.d126.s2|91-102|cypermethrin|drug
DDI-MedLine.d126.s2|104-106|was|O
DDI-MedLine.d126.s2|108-112|found|O
DDI-MedLine.d126.s2|114-115|to|O
DDI-MedLine.d126.s2|117-123|produce|O
DDI-MedLine.d126.s2|125-135|significant|O
DDI-MedLine.d126.s2|137-145|oxidative|O
DDI-MedLine.d126.s2|147-152|stress|O
DDI-MedLine.d126.s2|154-155|in|O
DDI-MedLine.d126.s2|157-164|cerebral|O
DDI-MedLine.d126.s2|166-168|and|O
DDI-MedLine.d126.s2|170-176|hepatic|O
DDI-MedLine.d126.s2|178-184|tissues|O
DDI-MedLine.d126.s2|186-187|of|O
DDI-MedLine.d126.s2|189-192|rats|O
DDI-MedLine.d126.s2|193-193|,|O
DDI-MedLine.d126.s2|195-196|as|O
DDI-MedLine.d126.s2|198-200|was|O
DDI-MedLine.d126.s2|202-208|evident|O
DDI-MedLine.d126.s2|210-211|by|O
DDI-MedLine.d126.s2|213-215|the|O
DDI-MedLine.d126.s2|217-225|elevation|O
DDI-MedLine.d126.s2|227-228|of|O
DDI-MedLine.d126.s2|230-232|the|O
DDI-MedLine.d126.s2|234-238|level|O
DDI-MedLine.d126.s2|240-241|of|O
DDI-MedLine.d126.s2|243-256|thiobarbituric|O
DDI-MedLine.d126.s2|258-261|acid|O
DDI-MedLine.d126.s2|263-270|reactive|O
DDI-MedLine.d126.s2|272-281|substances|O
DDI-MedLine.d126.s2|283-283|(|O
DDI-MedLine.d126.s2|284-288|TBARS|O
DDI-MedLine.d126.s2|289-289|)|O
DDI-MedLine.d126.s2|291-292|in|O
DDI-MedLine.d126.s2|294-297|both|O
DDI-MedLine.d126.s2|299-305|tissues|O
DDI-MedLine.d126.s2|306-306|,|O
DDI-MedLine.d126.s2|308-313|either|O
DDI-MedLine.d126.s2|315-315|4|O
DDI-MedLine.d126.s2|317-318|or|O
DDI-MedLine.d126.s2|320-321|24|O
DDI-MedLine.d126.s2|323-323|h|O
DDI-MedLine.d126.s2|325-329|after|O
DDI-MedLine.d126.s2|331-339|treatment|O
DDI-MedLine.d126.s2|340-340|.|O
DDI-MedLine.d126.s3|0-3|Much|O
DDI-MedLine.d126.s3|5-10|higher|O
DDI-MedLine.d126.s3|12-18|changes|O
DDI-MedLine.d126.s3|20-23|were|O
DDI-MedLine.d126.s3|25-32|observed|O
DDI-MedLine.d126.s3|34-35|in|O
DDI-MedLine.d126.s3|37-41|liver|O
DDI-MedLine.d126.s3|42-42|,|O
DDI-MedLine.d126.s3|44-53|increasing|O
DDI-MedLine.d126.s3|55-58|from|O
DDI-MedLine.d126.s3|60-60|a|O
DDI-MedLine.d126.s3|62-66|level|O
DDI-MedLine.d126.s3|68-69|of|O
DDI-MedLine.d126.s3|71-72|60|O
DDI-MedLine.d126.s3|73-73|%|O
DDI-MedLine.d126.s3|75-76|at|O
DDI-MedLine.d126.s3|78-78|4|O
DDI-MedLine.d126.s3|80-80|h|O
DDI-MedLine.d126.s3|82-83|up|O
DDI-MedLine.d126.s3|85-86|to|O
DDI-MedLine.d126.s3|88-93|nearly|O
DDI-MedLine.d126.s3|95-95|4|O
DDI-MedLine.d126.s3|97-101|times|O
DDI-MedLine.d126.s3|103-105|the|O
DDI-MedLine.d126.s3|107-113|control|O
DDI-MedLine.d126.s3|115-116|at|O
DDI-MedLine.d126.s3|118-119|24|O
DDI-MedLine.d126.s3|121-121|h|O
DDI-MedLine.d126.s3|123-125|for|O
DDI-MedLine.d126.s3|127-132|single|O
DDI-MedLine.d126.s3|134-137|dose|O
DDI-MedLine.d126.s3|138-138|.|O
DDI-MedLine.d126.s4|0-6|Reduced|O
DDI-MedLine.d126.s4|8-13|levels|O
DDI-MedLine.d126.s4|15-15|(|O
DDI-MedLine.d126.s4|16-17|up|O
DDI-MedLine.d126.s4|19-20|to|O
DDI-MedLine.d126.s4|22-23|20|O
DDI-MedLine.d126.s4|24-24|%|O
DDI-MedLine.d126.s4|25-25|)|O
DDI-MedLine.d126.s4|27-28|of|O
DDI-MedLine.d126.s4|30-34|total|O
DDI-MedLine.d126.s4|36-46|glutathione|O
DDI-MedLine.d126.s4|48-48|(|O
DDI-MedLine.d126.s4|49-53|total|O
DDI-MedLine.d126.s4|55-57|GSH|O
DDI-MedLine.d126.s4|58-58|)|O
DDI-MedLine.d126.s4|59-59|,|O
DDI-MedLine.d126.s4|61-63|and|O
DDI-MedLine.d126.s4|65-73|elevation|O
DDI-MedLine.d126.s4|75-76|of|O
DDI-MedLine.d126.s4|78-87|conjugated|O
DDI-MedLine.d126.s4|89-94|dienes|O
DDI-MedLine.d126.s4|96-96|(|O
DDI-MedLine.d126.s4|98-110|approximately|O
DDI-MedLine.d126.s4|112-113|60|O
DDI-MedLine.d126.s4|114-114|%|O
DDI-MedLine.d126.s4|116-117|in|O
DDI-MedLine.d126.s4|119-123|liver|O
DDI-MedLine.d126.s4|125-126|by|O
DDI-MedLine.d126.s4|128-133|single|O
DDI-MedLine.d126.s4|135-138|dose|O
DDI-MedLine.d126.s4|140-141|at|O
DDI-MedLine.d126.s4|143-143|4|O
DDI-MedLine.d126.s4|145-145|h|O
DDI-MedLine.d126.s4|146-146|)|O
DDI-MedLine.d126.s4|148-151|also|O
DDI-MedLine.d126.s4|153-161|indicated|O
DDI-MedLine.d126.s4|163-165|the|O
DDI-MedLine.d126.s4|167-174|presence|O
DDI-MedLine.d126.s4|176-177|of|O
DDI-MedLine.d126.s4|179-180|an|O
DDI-MedLine.d126.s4|182-190|oxidative|O
DDI-MedLine.d126.s4|192-197|insult|O
DDI-MedLine.d126.s4|198-198|.|O
DDI-MedLine.d126.s5|0-24|Glutathione-S-transferase|O
DDI-MedLine.d126.s5|26-26|(|O
DDI-MedLine.d126.s5|27-29|GST|O
DDI-MedLine.d126.s5|30-30|)|O
DDI-MedLine.d126.s5|32-39|activity|O
DDI-MedLine.d126.s5|40-40|,|O
DDI-MedLine.d126.s5|42-48|however|O
DDI-MedLine.d126.s5|49-49|,|O
DDI-MedLine.d126.s5|51-53|did|O
DDI-MedLine.d126.s5|55-57|not|O
DDI-MedLine.d126.s5|59-64|differ|O
DDI-MedLine.d126.s5|66-69|from|O
DDI-MedLine.d126.s5|71-77|control|O
DDI-MedLine.d126.s5|79-84|values|O
DDI-MedLine.d126.s5|86-88|for|O
DDI-MedLine.d126.s5|90-92|any|O
DDI-MedLine.d126.s5|94-97|dose|O
DDI-MedLine.d126.s5|99-100|or|O
DDI-MedLine.d126.s5|102-103|at|O
DDI-MedLine.d126.s5|105-107|any|O
DDI-MedLine.d126.s5|109-112|time|O
DDI-MedLine.d126.s5|114-118|point|O
DDI-MedLine.d126.s5|120-121|in|O
DDI-MedLine.d126.s5|123-130|cerebral|O
DDI-MedLine.d126.s5|132-134|and|O
DDI-MedLine.d126.s5|136-142|hepatic|O
DDI-MedLine.d126.s5|144-150|tissues|O
DDI-MedLine.d126.s5|151-151|.|O
DDI-MedLine.d126.s6|0-11|Pretreatment|O
DDI-MedLine.d126.s6|13-14|of|O
DDI-MedLine.d126.s6|16-19|rats|O
DDI-MedLine.d126.s6|21-24|with|O
DDI-MedLine.d126.s6|26-36|allopurinol|drug
DDI-MedLine.d126.s6|38-38|(|O
DDI-MedLine.d126.s6|39-41|100|O
DDI-MedLine.d126.s6|43-47|mg/kg|O
DDI-MedLine.d126.s6|48-48|,|O
DDI-MedLine.d126.s6|50-51|ip|O
DDI-MedLine.d126.s6|52-52|)|O
DDI-MedLine.d126.s6|54-55|or|O
DDI-MedLine.d126.s6|57-65|Vitamin E|drug
DDI-MedLine.d126.s6|67-67|(|O
DDI-MedLine.d126.s6|68-70|100|O
DDI-MedLine.d126.s6|72-76|mg/kg|O
DDI-MedLine.d126.s6|78-80|per|O
DDI-MedLine.d126.s6|82-84|day|O
DDI-MedLine.d126.s6|85-85|,|O
DDI-MedLine.d126.s6|87-88|ig|O
DDI-MedLine.d126.s6|89-89|,|O
DDI-MedLine.d126.s6|91-93|for|O
DDI-MedLine.d126.s6|95-95|3|O
DDI-MedLine.d126.s6|97-100|days|O
DDI-MedLine.d126.s6|102-104|and|O
DDI-MedLine.d126.s6|106-106|a|O
DDI-MedLine.d126.s6|108-111|dose|O
DDI-MedLine.d126.s6|113-114|of|O
DDI-MedLine.d126.s6|116-117|40|O
DDI-MedLine.d126.s6|119-123|mg/kg|O
DDI-MedLine.d126.s6|125-126|on|O
DDI-MedLine.d126.s6|128-130|the|O
DDI-MedLine.d126.s6|132-134|4th|O
DDI-MedLine.d126.s6|136-138|day|O
DDI-MedLine.d126.s6|139-139|)|O
DDI-MedLine.d126.s6|141-148|provided|O
DDI-MedLine.d126.s6|150-160|significant|O
DDI-MedLine.d126.s6|162-171|protection|O
DDI-MedLine.d126.s6|173-179|against|O
DDI-MedLine.d126.s6|181-183|the|O
DDI-MedLine.d126.s6|185-193|elevation|O
DDI-MedLine.d126.s6|195-196|of|O
DDI-MedLine.d126.s6|198-202|TBARS|O
DDI-MedLine.d126.s6|204-209|levels|O
DDI-MedLine.d126.s6|211-212|in|O
DDI-MedLine.d126.s6|214-221|cerebral|O
DDI-MedLine.d126.s6|223-225|and|O
DDI-MedLine.d126.s6|227-233|hepatic|O
DDI-MedLine.d126.s6|235-241|tissues|O
DDI-MedLine.d126.s6|242-242|,|O
DDI-MedLine.d126.s6|244-250|induced|O
DDI-MedLine.d126.s6|252-253|by|O
DDI-MedLine.d126.s6|255-260|single|O
DDI-MedLine.d126.s6|262-265|high|O
DDI-MedLine.d126.s6|267-270|dose|O
DDI-MedLine.d126.s6|272-273|of|O
DDI-MedLine.d126.s6|275-278|oral|O
DDI-MedLine.d126.s6|280-291|cypermethrin|drug
DDI-MedLine.d126.s6|293-306|administration|O
DDI-MedLine.d126.s6|308-313|within|O
DDI-MedLine.d126.s6|315-315|4|O
DDI-MedLine.d126.s6|317-317|h|O
DDI-MedLine.d126.s6|318-318|.|O
DDI-MedLine.d126.s7|0-3|Thus|O
DDI-MedLine.d126.s7|4-4|,|O
DDI-MedLine.d126.s7|6-8|the|O
DDI-MedLine.d126.s7|10-16|results|O
DDI-MedLine.d126.s7|18-24|suggest|O
DDI-MedLine.d126.s7|26-29|that|O
DDI-MedLine.d126.s7|31-42|cypermethrin|drug
DDI-MedLine.d126.s7|44-51|exposure|O
DDI-MedLine.d126.s7|53-54|of|O
DDI-MedLine.d126.s7|56-59|rats|O
DDI-MedLine.d126.s7|61-67|results|O
DDI-MedLine.d126.s7|69-70|in|O
DDI-MedLine.d126.s7|72-75|free|O
DDI-MedLine.d126.s7|77-92|radical-mediated|O
DDI-MedLine.d126.s7|94-99|tissue|O
DDI-MedLine.d126.s7|101-106|damage|O
DDI-MedLine.d126.s7|107-107|,|O
DDI-MedLine.d126.s7|109-110|as|O
DDI-MedLine.d126.s7|112-120|indicated|O
DDI-MedLine.d126.s7|122-123|by|O
DDI-MedLine.d126.s7|125-132|elevated|O
DDI-MedLine.d126.s7|134-141|cerebral|O
DDI-MedLine.d126.s7|143-145|and|O
DDI-MedLine.d126.s7|147-153|hepatic|O
DDI-MedLine.d126.s7|155-159|lipid|O
DDI-MedLine.d126.s7|161-172|peroxidation|O
DDI-MedLine.d126.s7|173-173|,|O
DDI-MedLine.d126.s7|175-179|which|O
DDI-MedLine.d126.s7|181-183|was|O
DDI-MedLine.d126.s7|185-193|prevented|O
DDI-MedLine.d126.s7|195-196|by|O
DDI-MedLine.d126.s7|198-208|allopurinol|drug
DDI-MedLine.d126.s7|210-212|and|O
DDI-MedLine.d126.s7|214-222|Vitamin E|drug
DDI-MedLine.d126.s7|223-223|.|O
DDI-DrugBank.d235.s0|0-8|Substrate|O
DDI-DrugBank.d235.s0|10-11|of|O
DDI-DrugBank.d235.s0|13-18|CYP2D6|O
DDI-DrugBank.d235.s0|20-20|(|O
DDI-DrugBank.d235.s0|21-25|minor|O
DDI-DrugBank.d235.s0|26-26|)|O
DDI-DrugBank.d235.s0|27-27|,|O
DDI-DrugBank.d235.s0|29-31|3A4|O
DDI-DrugBank.d235.s0|33-33|(|O
DDI-DrugBank.d235.s0|34-38|major|O
DDI-DrugBank.d235.s0|39-39|)|O
DDI-DrugBank.d235.s0|40-40|;|O
DDI-DrugBank.d235.s1|0-7|Inhibits|O
DDI-DrugBank.d235.s1|9-14|CYP2D6|O
DDI-DrugBank.d235.s1|16-16|(|O
DDI-DrugBank.d235.s1|17-20|weak|O
DDI-DrugBank.d235.s1|21-21|)|O
DDI-DrugBank.d235.s1|22-22|.|O
DDI-DrugBank.d235.s2|0-8|Increased|O
DDI-DrugBank.d235.s2|10-17|toxicity|O
DDI-DrugBank.d235.s2|19-19|(|O
DDI-DrugBank.d235.s2|20-22|CNS|O
DDI-DrugBank.d235.s2|24-33|depression|O
DDI-DrugBank.d235.s2|34-34|)|O
DDI-DrugBank.d235.s2|35-35|:|O
DDI-DrugBank.d235.s2|37-51|CNS depressants|group
DDI-DrugBank.d235.s2|52-52|,|O
DDI-DrugBank.d235.s2|54-67|MAO inhibitors|group
DDI-DrugBank.d235.s2|68-68|,|O
DDI-DrugBank.d235.s2|70-94|tricyclic antidepressants|group
DDI-DrugBank.d235.s2|95-95|,|O
DDI-DrugBank.d235.s2|97-110|phenothiazines|group
DDI-DrugBank.d235.s2|111-111|.|O
DDI-DrugBank.d235.s3|0-5|CYP3A4|O
DDI-DrugBank.d235.s3|7-16|inhibitors|O
DDI-DrugBank.d235.s3|17-17|:|O
DDI-DrugBank.d235.s3|19-21|May|O
DDI-DrugBank.d235.s3|23-30|increase|O
DDI-DrugBank.d235.s3|32-34|the|O
DDI-DrugBank.d235.s3|36-49|levels/effects|O
DDI-DrugBank.d235.s3|51-52|of|O
DDI-DrugBank.d235.s3|54-69|chlorpheniramine|drug
DDI-DrugBank.d235.s3|70-70|.|O
DDI-DrugBank.d235.s4|0-6|Example|O
DDI-DrugBank.d235.s4|8-17|inhibitors|O
DDI-DrugBank.d235.s4|19-25|include|O
DDI-DrugBank.d235.s4|27-43|azole antifungals|group
DDI-DrugBank.d235.s4|44-44|,|O
DDI-DrugBank.d235.s4|46-58|ciprofloxacin|drug
DDI-DrugBank.d235.s4|59-59|,|O
DDI-DrugBank.d235.s4|61-74|clarithromycin|drug
DDI-DrugBank.d235.s4|75-75|,|O
DDI-DrugBank.d235.s4|77-86|diclofenac|drug
DDI-DrugBank.d235.s4|87-87|,|O
DDI-DrugBank.d235.s4|89-99|doxycycline|drug
DDI-DrugBank.d235.s4|100-100|,|O
DDI-DrugBank.d235.s4|102-113|erythromycin|drug
DDI-DrugBank.d235.s4|114-114|,|O
DDI-DrugBank.d235.s4|116-123|imatinib|drug
DDI-DrugBank.d235.s4|124-124|,|O
DDI-DrugBank.d235.s4|126-134|isoniazid|drug
DDI-DrugBank.d235.s4|135-135|,|O
DDI-DrugBank.d235.s4|137-146|nefazodone|drug
DDI-DrugBank.d235.s4|147-147|,|O
DDI-DrugBank.d235.s4|149-159|nicardipine|drug
DDI-DrugBank.d235.s4|160-160|,|O
DDI-DrugBank.d235.s4|162-169|propofol|drug
DDI-DrugBank.d235.s4|170-170|,|O
DDI-DrugBank.d235.s4|172-190|protease inhibitors|group
DDI-DrugBank.d235.s4|191-191|,|O
DDI-DrugBank.d235.s4|193-201|quinidine|drug
DDI-DrugBank.d235.s4|202-202|,|O
DDI-DrugBank.d235.s4|204-206|and|O
DDI-DrugBank.d235.s4|208-216|verapamil|drug
DDI-DrugBank.d235.s4|217-217|.|O
DDI-DrugBank.d247.s0|0-10|Epinephrine|drug
DDI-DrugBank.d247.s0|12-17|should|O
DDI-DrugBank.d247.s0|19-20|be|O
DDI-DrugBank.d247.s0|22-25|used|O
DDI-DrugBank.d247.s0|27-36|cautiously|O
DDI-DrugBank.d247.s0|38-39|in|O
DDI-DrugBank.d247.s0|41-48|patients|O
DDI-DrugBank.d247.s0|50-53|with|O
DDI-DrugBank.d247.s0|55-69|hyperthyroidism|O
DDI-DrugBank.d247.s0|70-70|,|O
DDI-DrugBank.d247.s0|72-83|hypertension|O
DDI-DrugBank.d247.s0|85-87|and|O
DDI-DrugBank.d247.s0|89-95|cardiac|O
DDI-DrugBank.d247.s0|97-107|arrhythmias|O
DDI-DrugBank.d247.s0|108-108|.|O
DDI-DrugBank.d247.s1|0-2|All|O
DDI-DrugBank.d247.s1|4-15|vasopressors|group
DDI-DrugBank.d247.s1|17-22|should|O
DDI-DrugBank.d247.s1|24-25|be|O
DDI-DrugBank.d247.s1|27-30|used|O
DDI-DrugBank.d247.s1|32-41|cautiously|O
DDI-DrugBank.d247.s1|43-44|in|O
DDI-DrugBank.d247.s1|46-53|patients|O
DDI-DrugBank.d247.s1|55-60|taking|O
DDI-DrugBank.d247.s1|62-95|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d247.s1|96-96|.|O
DDI-DrugBank.d247.s2|0-10|Epinephrine|drug
DDI-DrugBank.d247.s2|12-17|should|O
DDI-DrugBank.d247.s2|19-21|not|O
DDI-DrugBank.d247.s2|23-24|be|O
DDI-DrugBank.d247.s2|26-37|administered|O
DDI-DrugBank.d247.s2|39-51|concomitantly|O
DDI-DrugBank.d247.s2|53-56|with|O
DDI-DrugBank.d247.s2|58-62|other|O
DDI-DrugBank.d247.s2|64-84|sympathomimetic drugs|group
DDI-DrugBank.d247.s2|86-86|(|O
DDI-DrugBank.d247.s2|87-90|such|O
DDI-DrugBank.d247.s2|92-93|as|O
DDI-DrugBank.d247.s2|95-107|isoproterenol|drug
DDI-DrugBank.d247.s2|108-108|)|O
DDI-DrugBank.d247.s2|110-116|because|O
DDI-DrugBank.d247.s2|118-119|of|O
DDI-DrugBank.d247.s2|121-128|possible|O
DDI-DrugBank.d247.s2|130-137|additive|O
DDI-DrugBank.d247.s2|139-145|effects|O
DDI-DrugBank.d247.s2|147-149|and|O
DDI-DrugBank.d247.s2|151-159|increased|O
DDI-DrugBank.d247.s2|161-168|toxicity|O
DDI-DrugBank.d247.s2|169-169|.|O
DDI-DrugBank.d247.s3|0-7|Combined|O
DDI-DrugBank.d247.s3|9-15|effects|O
DDI-DrugBank.d247.s3|17-19|may|O
DDI-DrugBank.d247.s3|21-26|induce|O
DDI-DrugBank.d247.s3|28-34|serious|O
DDI-DrugBank.d247.s3|36-42|cardiac|O
DDI-DrugBank.d247.s3|44-54|arrhythmias|O
DDI-DrugBank.d247.s3|55-55|.|O
DDI-DrugBank.d247.s4|0-3|They|O
DDI-DrugBank.d247.s4|5-7|may|O
DDI-DrugBank.d247.s4|9-10|be|O
DDI-DrugBank.d247.s4|12-23|administered|O
DDI-DrugBank.d247.s4|25-35|alternately|O
DDI-DrugBank.d247.s4|37-40|when|O
DDI-DrugBank.d247.s4|42-44|the|O
DDI-DrugBank.d247.s4|46-54|preceding|O
DDI-DrugBank.d247.s4|56-61|effect|O
DDI-DrugBank.d247.s4|63-64|of|O
DDI-DrugBank.d247.s4|66-70|other|O
DDI-DrugBank.d247.s4|72-75|such|O
DDI-DrugBank.d247.s4|77-80|drug|O
DDI-DrugBank.d247.s4|82-84|has|O
DDI-DrugBank.d247.s4|86-93|subsided|O
DDI-DrugBank.d247.s4|94-94|.|O
DDI-DrugBank.d247.s5|0-13|Administration|O
DDI-DrugBank.d247.s5|15-16|of|O
DDI-DrugBank.d247.s5|18-28|epinephrine|drug
DDI-DrugBank.d247.s5|30-31|to|O
DDI-DrugBank.d247.s5|33-40|patients|O
DDI-DrugBank.d247.s5|42-50|receiving|O
DDI-DrugBank.d247.s5|52-63|cyclopropane|drug
DDI-DrugBank.d247.s5|65-66|or|O
DDI-DrugBank.d247.s5|68-110|halogenated hydrocarbon general anesthetics|group
DDI-DrugBank.d247.s5|112-115|such|O
DDI-DrugBank.d247.s5|117-118|as|O
DDI-DrugBank.d247.s5|120-128|halothane|drug
DDI-DrugBank.d247.s5|130-134|which|O
DDI-DrugBank.d247.s5|136-144|sensitize|O
DDI-DrugBank.d247.s5|146-148|the|O
DDI-DrugBank.d247.s5|150-159|myocardium|O
DDI-DrugBank.d247.s5|160-160|,|O
DDI-DrugBank.d247.s5|162-164|may|O
DDI-DrugBank.d247.s5|166-171|induce|O
DDI-DrugBank.d247.s5|173-179|cardiac|O
DDI-DrugBank.d247.s5|181-192|arrhythmia..|O
DDI-DrugBank.d247.s6|0-3|When|O
DDI-DrugBank.d247.s6|5-15|encountered|O
DDI-DrugBank.d247.s6|16-16|,|O
DDI-DrugBank.d247.s6|18-21|such|O
DDI-DrugBank.d247.s6|23-33|arrhythmias|O
DDI-DrugBank.d247.s6|35-37|may|O
DDI-DrugBank.d247.s6|39-45|respond|O
DDI-DrugBank.d247.s6|47-48|to|O
DDI-DrugBank.d247.s6|50-63|administration|O
DDI-DrugBank.d247.s6|65-66|of|O
DDI-DrugBank.d247.s6|68-68|a|O
DDI-DrugBank.d247.s6|70-98|beta-adrenergic blocking drug|group
DDI-DrugBank.d247.s6|99-99|.|O
DDI-DrugBank.d247.s7|0-10|Epinephrine|drug
DDI-DrugBank.d247.s7|12-15|also|O
DDI-DrugBank.d247.s7|17-22|should|O
DDI-DrugBank.d247.s7|24-25|be|O
DDI-DrugBank.d247.s7|27-30|used|O
DDI-DrugBank.d247.s7|32-41|cautiously|O
DDI-DrugBank.d247.s7|43-46|with|O
DDI-DrugBank.d247.s7|48-52|other|O
DDI-DrugBank.d247.s7|54-58|drugs|O
DDI-DrugBank.d247.s7|60-60|(|O
DDI-DrugBank.d247.s7|61-64|e.g.|O
DDI-DrugBank.d247.s7|65-65|,|O
DDI-DrugBank.d247.s7|67-75|digitalis|group
DDI-DrugBank.d247.s7|76-76|,|O
DDI-DrugBank.d247.s7|78-87|glycosides|group
DDI-DrugBank.d247.s7|88-88|)|O
DDI-DrugBank.d247.s7|90-93|that|O
DDI-DrugBank.d247.s7|95-103|sensitize|O
DDI-DrugBank.d247.s7|105-107|the|O
DDI-DrugBank.d247.s7|109-118|myocardium|O
DDI-DrugBank.d247.s7|120-121|to|O
DDI-DrugBank.d247.s7|123-125|the|O
DDI-DrugBank.d247.s7|127-133|actions|O
DDI-DrugBank.d247.s7|135-136|of|O
DDI-DrugBank.d247.s7|138-158|sympathomimetic drugs|group
DDI-DrugBank.d247.s7|159-159|.|O
DDI-DrugBank.d247.s8|0-14|Diuretic agents|group
DDI-DrugBank.d247.s8|16-18|may|O
DDI-DrugBank.d247.s8|20-27|decrease|O
DDI-DrugBank.d247.s8|29-36|vascular|O
DDI-DrugBank.d247.s8|38-45|response|O
DDI-DrugBank.d247.s8|47-48|to|O
DDI-DrugBank.d247.s8|50-56|pressor|O
DDI-DrugBank.d247.s8|58-62|drugs|O
DDI-DrugBank.d247.s8|64-67|such|O
DDI-DrugBank.d247.s8|69-70|as|O
DDI-DrugBank.d247.s8|72-82|epinephrine|drug
DDI-DrugBank.d247.s8|83-83|.|O
DDI-DrugBank.d247.s9|0-10|Epinephrine|drug
DDI-DrugBank.d247.s9|12-14|may|O
DDI-DrugBank.d247.s9|16-25|antagonize|O
DDI-DrugBank.d247.s9|27-29|the|O
DDI-DrugBank.d247.s9|31-36|neuron|O
DDI-DrugBank.d247.s9|38-45|blockade|O
DDI-DrugBank.d247.s9|47-54|produced|O
DDI-DrugBank.d247.s9|56-57|by|O
DDI-DrugBank.d247.s9|59-70|guanethidine|drug
DDI-DrugBank.d247.s9|72-80|resulting|O
DDI-DrugBank.d247.s9|82-83|in|O
DDI-DrugBank.d247.s9|85-93|decreased|O
DDI-DrugBank.d247.s9|95-110|antihypertensive|O
DDI-DrugBank.d247.s9|112-117|effect|O
DDI-DrugBank.d247.s9|119-121|and|O
DDI-DrugBank.d247.s9|123-131|requiring|O
DDI-DrugBank.d247.s9|133-141|increased|O
DDI-DrugBank.d247.s9|143-148|dosage|O
DDI-DrugBank.d247.s9|150-151|of|O
DDI-DrugBank.d247.s9|153-155|the|O
DDI-DrugBank.d247.s9|157-162|latter|O
DDI-DrugBank.d247.s9|163-163|.|O
DDI-DrugBank.d540.s0|0-1|No|O
DDI-DrugBank.d540.s0|3-8|formal|O
DDI-DrugBank.d540.s0|10-13|drug|O
DDI-DrugBank.d540.s0|15-25|interaction|O
DDI-DrugBank.d540.s0|27-33|studies|O
DDI-DrugBank.d540.s0|35-38|have|O
DDI-DrugBank.d540.s0|40-43|been|O
DDI-DrugBank.d540.s0|45-53|performed|O
DDI-DrugBank.d540.s0|55-58|with|O
DDI-DrugBank.d540.s0|60-68|Cetrotide|brand
DDI-DrugBank.d540.s0|70-70|.|O
DDI-DrugBank.d420.s0|0-7|Antacids|group
DDI-DrugBank.d420.s0|9-9|(|O
DDI-DrugBank.d420.s0|10-18|aluminum-|drug
DDI-DrugBank.d420.s0|20-21|or|O
DDI-DrugBank.d420.s0|23-42|magnesium-containing|drug
DDI-DrugBank.d420.s0|43-43|)|O
DDI-DrugBank.d420.s0|44-44|:|O
DDI-DrugBank.d420.s0|46-56|Concomitant|O
DDI-DrugBank.d420.s0|58-71|administration|O
DDI-DrugBank.d420.s0|73-74|of|O
DDI-DrugBank.d420.s0|76-81|300-mg|O
DDI-DrugBank.d420.s0|83-90|cefdinir|drug
DDI-DrugBank.d420.s0|92-99|capsules|O
DDI-DrugBank.d420.s0|101-104|with|O
DDI-DrugBank.d420.s0|106-107|30|O
DDI-DrugBank.d420.s0|109-110|mL|O
DDI-DrugBank.d420.s0|112-120|Maalox TC|brand
DDI-DrugBank.d420.s0|122-131|suspension|O
DDI-DrugBank.d420.s0|133-139|reduces|O
DDI-DrugBank.d420.s0|141-143|the|O
DDI-DrugBank.d420.s0|145-148|rate|O
DDI-DrugBank.d420.s0|150-150|(|O
DDI-DrugBank.d420.s0|151-154|Cmax|O
DDI-DrugBank.d420.s0|155-155|)|O
DDI-DrugBank.d420.s0|157-159|and|O
DDI-DrugBank.d420.s0|161-166|extent|O
DDI-DrugBank.d420.s0|168-168|(|O
DDI-DrugBank.d420.s0|169-171|AUC|O
DDI-DrugBank.d420.s0|172-172|)|O
DDI-DrugBank.d420.s0|174-175|of|O
DDI-DrugBank.d420.s0|177-186|absorption|O
DDI-DrugBank.d420.s0|188-189|by|O
DDI-DrugBank.d420.s0|191-203|approximately|O
DDI-DrugBank.d420.s0|205-206|40|O
DDI-DrugBank.d420.s0|207-207|%|O
DDI-DrugBank.d420.s0|208-208|.|O
DDI-DrugBank.d420.s1|0-3|Time|O
DDI-DrugBank.d420.s1|5-6|to|O
DDI-DrugBank.d420.s1|8-12|reach|O
DDI-DrugBank.d420.s1|14-17|Cmax|O
DDI-DrugBank.d420.s1|19-20|is|O
DDI-DrugBank.d420.s1|22-25|also|O
DDI-DrugBank.d420.s1|27-35|prolonged|O
DDI-DrugBank.d420.s1|37-38|by|O
DDI-DrugBank.d420.s1|40-40|1|O
DDI-DrugBank.d420.s1|42-45|hour|O
DDI-DrugBank.d420.s1|46-46|.|O
DDI-DrugBank.d420.s2|0-4|There|O
DDI-DrugBank.d420.s2|6-8|are|O
DDI-DrugBank.d420.s2|10-11|no|O
DDI-DrugBank.d420.s2|13-23|significant|O
DDI-DrugBank.d420.s2|25-31|effects|O
DDI-DrugBank.d420.s2|33-34|on|O
DDI-DrugBank.d420.s2|36-43|cefdinir|drug
DDI-DrugBank.d420.s2|45-60|pharmacokinetics|O
DDI-DrugBank.d420.s2|62-63|if|O
DDI-DrugBank.d420.s2|65-67|the|O
DDI-DrugBank.d420.s2|69-75|antacid|group
DDI-DrugBank.d420.s2|77-78|is|O
DDI-DrugBank.d420.s2|80-91|administered|O
DDI-DrugBank.d420.s2|93-93|2|O
DDI-DrugBank.d420.s2|95-99|hours|O
DDI-DrugBank.d420.s2|101-106|before|O
DDI-DrugBank.d420.s2|108-109|or|O
DDI-DrugBank.d420.s2|111-111|2|O
DDI-DrugBank.d420.s2|113-117|hours|O
DDI-DrugBank.d420.s2|119-123|after|O
DDI-DrugBank.d420.s2|125-132|cefdinir|drug
DDI-DrugBank.d420.s2|133-133|.|O
DDI-DrugBank.d420.s3|0-1|If|O
DDI-DrugBank.d420.s3|3-10|antacids|group
DDI-DrugBank.d420.s3|12-14|are|O
DDI-DrugBank.d420.s3|16-23|required|O
DDI-DrugBank.d420.s3|25-30|during|O
DDI-DrugBank.d420.s3|32-38|OMNICEF|brand
DDI-DrugBank.d420.s3|40-46|therapy|O
DDI-DrugBank.d420.s3|47-47|,|O
DDI-DrugBank.d420.s3|49-55|OMNICEF|brand
DDI-DrugBank.d420.s3|57-62|should|O
DDI-DrugBank.d420.s3|64-65|be|O
DDI-DrugBank.d420.s3|67-71|taken|O
DDI-DrugBank.d420.s3|73-74|at|O
DDI-DrugBank.d420.s3|76-80|least|O
DDI-DrugBank.d420.s3|82-82|2|O
DDI-DrugBank.d420.s3|84-88|hours|O
DDI-DrugBank.d420.s3|90-95|before|O
DDI-DrugBank.d420.s3|97-98|or|O
DDI-DrugBank.d420.s3|100-104|after|O
DDI-DrugBank.d420.s3|106-108|the|O
DDI-DrugBank.d420.s3|110-116|antacid|group
DDI-DrugBank.d420.s3|117-117|.|O
DDI-DrugBank.d420.s4|0-9|Probenecid|drug
DDI-DrugBank.d420.s4|10-10|:|O
DDI-DrugBank.d420.s4|12-13|As|O
DDI-DrugBank.d420.s4|15-18|with|O
DDI-DrugBank.d420.s4|20-24|other|O
DDI-DrugBank.d420.s4|26-45|b-lactam antibiotics|group
DDI-DrugBank.d420.s4|46-46|,|O
DDI-DrugBank.d420.s4|48-57|probenecid|drug
DDI-DrugBank.d420.s4|59-66|inhibits|O
DDI-DrugBank.d420.s4|68-70|the|O
DDI-DrugBank.d420.s4|72-76|renal|O
DDI-DrugBank.d420.s4|78-86|excretion|O
DDI-DrugBank.d420.s4|88-89|of|O
DDI-DrugBank.d420.s4|91-98|cefdinir|drug
DDI-DrugBank.d420.s4|99-99|,|O
DDI-DrugBank.d420.s4|101-109|resulting|O
DDI-DrugBank.d420.s4|111-112|in|O
DDI-DrugBank.d420.s4|114-115|an|O
DDI-DrugBank.d420.s4|117-127|approximate|O
DDI-DrugBank.d420.s4|129-136|doubling|O
DDI-DrugBank.d420.s4|138-139|in|O
DDI-DrugBank.d420.s4|141-144|A.C.|O
DDI-DrugBank.d420.s4|146-146|a|O
DDI-DrugBank.d420.s4|148-149|54|O
DDI-DrugBank.d420.s4|150-150|%|O
DDI-DrugBank.d420.s4|152-159|increase|O
DDI-DrugBank.d420.s4|161-162|in|O
DDI-DrugBank.d420.s4|164-167|peak|O
DDI-DrugBank.d420.s4|169-176|cefdinir|drug
DDI-DrugBank.d420.s4|178-183|plasma|O
DDI-DrugBank.d420.s4|185-190|levels|O
DDI-DrugBank.d420.s4|191-191|,|O
DDI-DrugBank.d420.s4|193-195|and|O
DDI-DrugBank.d420.s4|197-197|a|O
DDI-DrugBank.d420.s4|199-200|50|O
DDI-DrugBank.d420.s4|201-201|%|O
DDI-DrugBank.d420.s4|203-214|prolongation|O
DDI-DrugBank.d420.s4|216-217|in|O
DDI-DrugBank.d420.s4|219-221|the|O
DDI-DrugBank.d420.s4|223-230|apparent|O
DDI-DrugBank.d420.s4|232-242|elimination|O
DDI-DrugBank.d420.s4|244-252|half-life|O
DDI-DrugBank.d420.s4|253-253|.|O
DDI-DrugBank.d420.s5|0-15|Iron Supplements|group
DDI-DrugBank.d420.s5|17-19|and|O
DDI-DrugBank.d420.s5|21-25|Foods|O
DDI-DrugBank.d420.s5|27-35|Fortified|O
DDI-DrugBank.d420.s5|37-40|With|O
DDI-DrugBank.d420.s5|42-45|Iron|drug
DDI-DrugBank.d420.s5|47-57|Concomitant|O
DDI-DrugBank.d420.s5|59-72|administration|O
DDI-DrugBank.d420.s5|74-75|of|O
DDI-DrugBank.d420.s5|77-84|cefdinir|drug
DDI-DrugBank.d420.s5|86-89|with|O
DDI-DrugBank.d420.s5|91-91|a|O
DDI-DrugBank.d420.s5|93-103|therapeutic|O
DDI-DrugBank.d420.s5|105-119|iron supplement|group
DDI-DrugBank.d420.s5|121-130|containing|O
DDI-DrugBank.d420.s5|132-133|60|O
DDI-DrugBank.d420.s5|135-136|mg|O
DDI-DrugBank.d420.s5|138-139|of|O
DDI-DrugBank.d420.s5|141-149|elemental|O
DDI-DrugBank.d420.s5|151-154|iron|drug
DDI-DrugBank.d420.s5|156-156|(|O
DDI-DrugBank.d420.s5|157-158|as|O
DDI-DrugBank.d420.s5|160-164|FeSO4|O
DDI-DrugBank.d420.s5|165-165|)|O
DDI-DrugBank.d420.s5|167-168|or|O
DDI-DrugBank.d420.s5|170-177|vitamins|group
DDI-DrugBank.d420.s5|179-190|supplemented|O
DDI-DrugBank.d420.s5|192-195|with|O
DDI-DrugBank.d420.s5|197-198|10|O
DDI-DrugBank.d420.s5|200-201|mg|O
DDI-DrugBank.d420.s5|203-204|of|O
DDI-DrugBank.d420.s5|206-214|elemental|O
DDI-DrugBank.d420.s5|216-219|iron|drug
DDI-DrugBank.d420.s5|221-227|reduced|O
DDI-DrugBank.d420.s5|229-234|extent|O
DDI-DrugBank.d420.s5|236-237|of|O
DDI-DrugBank.d420.s5|239-248|absorption|O
DDI-DrugBank.d420.s5|250-251|by|O
DDI-DrugBank.d420.s5|253-254|80|O
DDI-DrugBank.d420.s5|255-255|%|O
DDI-DrugBank.d420.s5|257-259|and|O
DDI-DrugBank.d420.s5|261-262|31|O
DDI-DrugBank.d420.s5|263-263|%|O
DDI-DrugBank.d420.s5|264-264|,|O
DDI-DrugBank.d420.s5|266-277|respectively|O
DDI-DrugBank.d420.s5|278-278|.|O
DDI-DrugBank.d420.s6|0-1|If|O
DDI-DrugBank.d420.s6|3-18|iron supplements|group
DDI-DrugBank.d420.s6|20-22|are|O
DDI-DrugBank.d420.s6|24-31|required|O
DDI-DrugBank.d420.s6|33-38|during|O
DDI-DrugBank.d420.s6|40-46|OMNICEF|brand
DDI-DrugBank.d420.s6|48-54|therapy|O
DDI-DrugBank.d420.s6|55-55|,|O
DDI-DrugBank.d420.s6|57-63|OMNICEF|brand
DDI-DrugBank.d420.s6|65-70|should|O
DDI-DrugBank.d420.s6|72-73|be|O
DDI-DrugBank.d420.s6|75-79|taken|O
DDI-DrugBank.d420.s6|81-82|at|O
DDI-DrugBank.d420.s6|84-88|least|O
DDI-DrugBank.d420.s6|90-90|2|O
DDI-DrugBank.d420.s6|92-96|hours|O
DDI-DrugBank.d420.s6|98-103|before|O
DDI-DrugBank.d420.s6|105-106|or|O
DDI-DrugBank.d420.s6|108-112|after|O
DDI-DrugBank.d420.s6|114-116|the|O
DDI-DrugBank.d420.s6|118-127|supplement|O
DDI-DrugBank.d420.s6|128-128|.|O
DDI-DrugBank.d420.s7|0-2|The|O
DDI-DrugBank.d420.s7|4-9|effect|O
DDI-DrugBank.d420.s7|11-12|of|O
DDI-DrugBank.d420.s7|14-18|foods|O
DDI-DrugBank.d420.s7|20-25|highly|O
DDI-DrugBank.d420.s7|27-35|fortified|O
DDI-DrugBank.d420.s7|37-40|with|O
DDI-DrugBank.d420.s7|42-50|elemental|O
DDI-DrugBank.d420.s7|57-57|(|O
DDI-DrugBank.d420.s7|58-66|primarily|O
DDI-DrugBank.d420.s7|83-91|breakfast|O
DDI-DrugBank.d420.s7|93-99|cereals|O
DDI-DrugBank.d420.s7|100-100|)|O
DDI-DrugBank.d420.s7|102-103|on|O
DDI-DrugBank.d420.s7|105-112|cefdinir|drug
DDI-DrugBank.d420.s7|114-123|absorption|O
DDI-DrugBank.d420.s7|125-127|has|O
DDI-DrugBank.d420.s7|129-131|not|O
DDI-DrugBank.d420.s7|133-136|been|O
DDI-DrugBank.d420.s7|138-144|studied|O
DDI-DrugBank.d420.s7|145-145|.|O
DDI-DrugBank.d420.s8|0-12|Concomitantly|O
DDI-DrugBank.d420.s8|14-25|administered|O
DDI-DrugBank.d420.s8|42-47|infant|O
DDI-DrugBank.d420.s8|49-55|formula|O
DDI-DrugBank.d420.s8|57-57|(|O
DDI-DrugBank.d420.s8|58-60|2.2|O
DDI-DrugBank.d420.s8|62-63|mg|O
DDI-DrugBank.d420.s8|65-73|elemental|O
DDI-DrugBank.d420.s8|82-83|oz|O
DDI-DrugBank.d420.s8|84-84|)|O
DDI-DrugBank.d420.s8|86-88|has|O
DDI-DrugBank.d420.s8|90-91|no|O
DDI-DrugBank.d420.s8|93-103|significant|O
DDI-DrugBank.d420.s8|105-110|effect|O
DDI-DrugBank.d420.s8|112-113|on|O
DDI-DrugBank.d420.s8|115-122|cefdinir|drug
DDI-DrugBank.d420.s8|124-139|pharmacokinetics|O
DDI-DrugBank.d420.s8|140-140|.|O
DDI-DrugBank.d420.s9|0-8|Therefore|O
DDI-DrugBank.d420.s9|9-9|,|O
DDI-DrugBank.d420.s9|11-17|OMNICEF|brand
DDI-DrugBank.d420.s9|19-21|for|O
DDI-DrugBank.d420.s9|23-26|Oral|O
DDI-DrugBank.d420.s9|28-37|Suspension|O
DDI-DrugBank.d420.s9|39-41|can|O
DDI-DrugBank.d420.s9|43-44|be|O
DDI-DrugBank.d420.s9|46-57|administered|O
DDI-DrugBank.d420.s9|59-62|with|O
DDI-DrugBank.d420.s9|79-84|infant|O
DDI-DrugBank.d420.s9|86-92|formula|O
DDI-DrugBank.d420.s9|93-93|.|O
DDI-DrugBank.d420.s10|0-4|There|O
DDI-DrugBank.d420.s10|6-9|have|O
DDI-DrugBank.d420.s10|11-14|been|O
DDI-DrugBank.d420.s10|16-19|rare|O
DDI-DrugBank.d420.s10|21-27|reports|O
DDI-DrugBank.d420.s10|29-30|of|O
DDI-DrugBank.d420.s10|32-38|reddish|O
DDI-DrugBank.d420.s10|40-45|stools|O
DDI-DrugBank.d420.s10|47-48|in|O
DDI-DrugBank.d420.s10|50-57|patients|O
DDI-DrugBank.d420.s10|59-61|who|O
DDI-DrugBank.d420.s10|63-66|have|O
DDI-DrugBank.d420.s10|68-75|received|O
DDI-DrugBank.d420.s10|77-84|cefdinir|drug
DDI-DrugBank.d420.s10|86-87|in|O
DDI-DrugBank.d420.s10|89-93|Japan|O
DDI-DrugBank.d420.s10|94-94|.|O
DDI-DrugBank.d420.s11|0-2|The|O
DDI-DrugBank.d420.s11|4-10|reddish|O
DDI-DrugBank.d420.s11|12-16|color|O
DDI-DrugBank.d420.s11|18-19|is|O
DDI-DrugBank.d420.s11|21-23|due|O
DDI-DrugBank.d420.s11|25-26|to|O
DDI-DrugBank.d420.s11|28-30|the|O
DDI-DrugBank.d420.s11|32-40|formation|O
DDI-DrugBank.d420.s11|42-43|of|O
DDI-DrugBank.d420.s11|45-45|a|O
DDI-DrugBank.d420.s11|47-59|nonabsorbable|O
DDI-DrugBank.d420.s11|61-67|complex|O
DDI-DrugBank.d420.s11|69-75|between|O
DDI-DrugBank.d420.s11|77-84|cefdinir|drug
DDI-DrugBank.d420.s11|86-87|or|O
DDI-DrugBank.d420.s11|89-91|its|O
DDI-DrugBank.d420.s11|93-101|breakdown|O
DDI-DrugBank.d420.s11|103-110|products|O
DDI-DrugBank.d420.s11|112-114|and|O
DDI-DrugBank.d420.s11|116-119|iron|drug
DDI-DrugBank.d420.s11|121-122|in|O
DDI-DrugBank.d420.s11|124-126|the|O
DDI-DrugBank.d420.s11|128-143|gastrointestinal|O
DDI-DrugBank.d420.s11|145-149|tract|O
DDI-DrugBank.d420.s11|150-150|.|O
DDI-DrugBank.d420.s12|0-14|Drug/Laboratory|O
DDI-DrugBank.d420.s12|16-19|Test|O
DDI-DrugBank.d420.s12|21-32|Interactions|O
DDI-DrugBank.d420.s12|34-34|A|O
DDI-DrugBank.d420.s12|36-49|false-positive|O
DDI-DrugBank.d420.s12|51-58|reaction|O
DDI-DrugBank.d420.s12|60-62|for|O
DDI-DrugBank.d420.s12|64-70|ketones|O
DDI-DrugBank.d420.s12|72-73|in|O
DDI-DrugBank.d420.s12|75-77|the|O
DDI-DrugBank.d420.s12|79-83|urine|O
DDI-DrugBank.d420.s12|85-87|may|O
DDI-DrugBank.d420.s12|89-93|occur|O
DDI-DrugBank.d420.s12|95-98|with|O
DDI-DrugBank.d420.s12|100-104|tests|O
DDI-DrugBank.d420.s12|106-110|using|O
DDI-DrugBank.d420.s12|112-124|nitroprusside|drug
DDI-DrugBank.d420.s12|125-125|,|O
DDI-DrugBank.d420.s12|127-129|but|O
DDI-DrugBank.d420.s12|131-133|not|O
DDI-DrugBank.d420.s12|135-138|with|O
DDI-DrugBank.d420.s12|140-144|those|O
DDI-DrugBank.d420.s12|146-150|using|O
DDI-DrugBank.d420.s12|152-168|nitroferricyanide|drug
DDI-DrugBank.d420.s12|169-169|.|O
DDI-DrugBank.d420.s13|0-2|The|O
DDI-DrugBank.d420.s13|4-17|administration|O
DDI-DrugBank.d420.s13|19-20|of|O
DDI-DrugBank.d420.s13|22-29|cefdinir|drug
DDI-DrugBank.d420.s13|31-33|may|O
DDI-DrugBank.d420.s13|35-40|result|O
DDI-DrugBank.d420.s13|42-43|in|O
DDI-DrugBank.d420.s13|45-45|a|O
DDI-DrugBank.d420.s13|47-60|false-positive|O
DDI-DrugBank.d420.s13|62-69|reaction|O
DDI-DrugBank.d420.s13|71-73|for|O
DDI-DrugBank.d420.s13|75-81|glucose|O
DDI-DrugBank.d420.s13|83-84|in|O
DDI-DrugBank.d420.s13|86-90|urine|O
DDI-DrugBank.d420.s13|92-96|using|O
DDI-DrugBank.d420.s13|98-106|Clinitest|O
DDI-DrugBank.d420.s13|108-108|,|O
DDI-DrugBank.d420.s13|110-117|Benedict|O
DDI-DrugBank.d420.s13|119-119|s|O
DDI-DrugBank.d420.s13|121-128|solution|O
DDI-DrugBank.d420.s13|129-129|,|O
DDI-DrugBank.d420.s13|131-132|or|O
DDI-DrugBank.d420.s13|134-141|Fehlings|O
DDI-DrugBank.d420.s13|143-150|solution|O
DDI-DrugBank.d420.s13|151-151|.|O
DDI-DrugBank.d420.s14|0-1|It|O
DDI-DrugBank.d420.s14|3-4|is|O
DDI-DrugBank.d420.s14|6-16|recommended|O
DDI-DrugBank.d420.s14|18-21|that|O
DDI-DrugBank.d420.s14|23-29|glucose|O
DDI-DrugBank.d420.s14|31-35|tests|O
DDI-DrugBank.d420.s14|37-41|based|O
DDI-DrugBank.d420.s14|43-44|on|O
DDI-DrugBank.d420.s14|46-54|enzymatic|O
DDI-DrugBank.d420.s14|56-62|glucose|O
DDI-DrugBank.d420.s14|64-70|oxidase|O
DDI-DrugBank.d420.s14|72-80|reactions|O
DDI-DrugBank.d420.s14|82-82|(|O
DDI-DrugBank.d420.s14|83-86|such|O
DDI-DrugBank.d420.s14|88-89|as|O
DDI-DrugBank.d420.s14|91-99|Clinistix|O
DDI-DrugBank.d420.s14|102-103|or|O
DDI-DrugBank.d420.s14|105-112|Tes-Tape|O
DDI-DrugBank.d420.s14|114-114|)|O
DDI-DrugBank.d420.s14|116-117|be|O
DDI-DrugBank.d420.s14|119-122|used|O
DDI-DrugBank.d420.s14|123-123|.|O
DDI-DrugBank.d420.s15|0-13|Cephalosporins|group
DDI-DrugBank.d420.s15|15-17|are|O
DDI-DrugBank.d420.s15|19-23|known|O
DDI-DrugBank.d420.s15|25-26|to|O
DDI-DrugBank.d420.s15|28-39|occasionally|O
DDI-DrugBank.d420.s15|41-46|induce|O
DDI-DrugBank.d420.s15|48-48|a|O
DDI-DrugBank.d420.s15|50-57|positive|O
DDI-DrugBank.d420.s15|59-64|direct|O
DDI-DrugBank.d420.s15|66-71|Coombs|O
DDI-DrugBank.d420.s15|74-77|test|O
DDI-DrugBank.d420.s15|78-78|.|O
DDI-MedLine.d104.s0|0-2|The|O
DDI-MedLine.d104.s0|4-10|effects|O
DDI-MedLine.d104.s0|12-13|of|O
DDI-MedLine.d104.s0|22-24|and|O
DDI-MedLine.d104.s0|34-37|upon|O
DDI-MedLine.d104.s0|53-53|(|O
DDI-MedLine.d104.s0|57-57|)|O
DDI-MedLine.d104.s0|58-65|-induced|O
DDI-MedLine.d104.s0|67-76|locomotion|O
DDI-MedLine.d104.s0|78-80|and|O
DDI-MedLine.d104.s0|82-91|behavioral|O
DDI-MedLine.d104.s0|93-99|changes|O
DDI-MedLine.d104.s0|101-102|in|O
DDI-MedLine.d104.s0|104-107|mice|O
DDI-MedLine.d104.s0|108-108|.|O
DDI-MedLine.d104.s1|0-2|The|O
DDI-MedLine.d104.s1|4-13|behavioral|O
DDI-MedLine.d104.s1|15-21|changes|O
DDI-MedLine.d104.s1|23-24|of|O
DDI-MedLine.d104.s1|26-29|mice|O
DDI-MedLine.d104.s1|31-37|induced|O
DDI-MedLine.d104.s1|39-40|by|O
DDI-MedLine.d104.s1|42-46|acute|O
DDI-MedLine.d104.s1|48-50|and|O
DDI-MedLine.d104.s1|52-59|repeated|O
DDI-MedLine.d104.s1|61-63|i.p|O
DDI-MedLine.d104.s1|64-64|.|O
DDI-MedLine.d104.s2|0-8|injection|O
DDI-MedLine.d104.s2|10-11|of|O
DDI-MedLine.d104.s2|27-27|(|O
DDI-MedLine.d104.s2|31-31|)|O
DDI-MedLine.d104.s2|33-36|were|O
DDI-MedLine.d104.s2|38-45|observed|O
DDI-MedLine.d104.s2|47-48|by|O
DDI-MedLine.d104.s2|50-58|measuring|O
DDI-MedLine.d104.s2|60-68|locomotor|O
DDI-MedLine.d104.s2|70-77|activity|O
DDI-MedLine.d104.s2|79-81|and|O
DDI-MedLine.d104.s2|83-93|stereotyped|O
DDI-MedLine.d104.s2|95-102|behavior|O
DDI-MedLine.d104.s2|103-103|.|O
DDI-MedLine.d104.s3|0-3|Then|O
DDI-MedLine.d104.s3|4-4|,|O
DDI-MedLine.d104.s3|6-8|the|O
DDI-MedLine.d104.s3|10-16|effects|O
DDI-MedLine.d104.s3|18-19|of|O
DDI-MedLine.d104.s3|21-32|metabotropic|O
DDI-MedLine.d104.s3|34-42|glutamate|O
DDI-MedLine.d104.s3|44-51|receptor|O
DDI-MedLine.d104.s3|53-53|(|O
DDI-MedLine.d104.s3|54-58|mGluR|O
DDI-MedLine.d104.s3|59-59|)|O
DDI-MedLine.d104.s3|61-68|agonists|O
DDI-MedLine.d104.s3|69-69|,|O
DDI-MedLine.d104.s3|78-80|and|O
DDI-MedLine.d104.s3|89-89|,|O
DDI-MedLine.d104.s3|91-92|on|O
DDI-MedLine.d104.s3|94-96|the|O
DDI-MedLine.d104.s3|98-102|above|O
DDI-MedLine.d104.s3|104-113|behavioral|O
DDI-MedLine.d104.s3|115-121|changes|O
DDI-MedLine.d104.s3|123-129|induced|O
DDI-MedLine.d104.s3|131-132|by|O
DDI-MedLine.d104.s3|138-141|were|O
DDI-MedLine.d104.s3|143-147|found|O
DDI-MedLine.d104.s3|148-148|.|O
DDI-MedLine.d104.s4|0-2|The|O
DDI-MedLine.d104.s4|4-10|effects|O
DDI-MedLine.d104.s4|12-13|of|O
DDI-MedLine.d104.s4|22-25|were|O
DDI-MedLine.d104.s4|27-30|very|O
DDI-MedLine.d104.s4|32-37|strong|O
DDI-MedLine.d104.s4|39-41|and|O
DDI-MedLine.d104.s4|43-52|completely|O
DDI-MedLine.d104.s4|54-62|depressed|O
DDI-MedLine.d104.s4|64-66|the|O
DDI-MedLine.d104.s4|80-94|hyperlocomotion|O
DDI-MedLine.d104.s4|95-95|.|O
DDI-MedLine.d104.s5|0-2|The|O
DDI-MedLine.d104.s5|4-10|effects|O
DDI-MedLine.d104.s5|12-13|of|O
DDI-MedLine.d104.s5|23-26|were|O
DDI-MedLine.d104.s5|28-30|not|O
DDI-MedLine.d104.s5|32-33|so|O
DDI-MedLine.d104.s5|35-40|strong|O
DDI-MedLine.d104.s5|41-41|.|O
DDI-MedLine.d104.s6|0-7|Repeated|O
DDI-MedLine.d104.s6|9-17|injection|O
DDI-MedLine.d104.s6|19-20|of|O
DDI-MedLine.d104.s6|26-28|for|O
DDI-MedLine.d104.s6|30-31|20|O
DDI-MedLine.d104.s6|33-36|days|O
DDI-MedLine.d104.s6|38-41|into|O
DDI-MedLine.d104.s6|43-46|mice|O
DDI-MedLine.d104.s6|48-54|induced|O
DDI-MedLine.d104.s6|56-60|lower|O
DDI-MedLine.d104.s6|62-70|locomotor|O
DDI-MedLine.d104.s6|72-79|activity|O
DDI-MedLine.d104.s6|81-84|than|O
DDI-MedLine.d104.s6|86-89|that|O
DDI-MedLine.d104.s6|91-92|in|O
DDI-MedLine.d104.s6|94-100|acutely|O
DDI-MedLine.d104.s6|102-109|injected|O
DDI-MedLine.d104.s6|111-114|mice|O
DDI-MedLine.d104.s6|115-115|.|O
DDI-MedLine.d104.s7|0-4|These|O
DDI-MedLine.d104.s7|6-15|behavioral|O
DDI-MedLine.d104.s7|17-23|changes|O
DDI-MedLine.d104.s7|25-27|may|O
DDI-MedLine.d104.s7|29-30|be|O
DDI-MedLine.d104.s7|32-38|related|O
DDI-MedLine.d104.s7|40-43|with|O
DDI-MedLine.d104.s7|45-47|the|O
DDI-MedLine.d104.s7|49-56|negative|O
DDI-MedLine.d104.s7|58-65|symptoms|O
DDI-MedLine.d104.s7|67-68|of|O
DDI-MedLine.d104.s7|70-82|schizophrenia|O
DDI-MedLine.d104.s7|83-83|.|O
DDI-MedLine.d104.s8|0-1|In|O
DDI-MedLine.d104.s8|3-7|order|O
DDI-MedLine.d104.s8|9-10|to|O
DDI-MedLine.d104.s8|12-18|examine|O
DDI-MedLine.d104.s8|20-23|some|O
DDI-MedLine.d104.s8|25-33|molecular|O
DDI-MedLine.d104.s8|35-44|mechanisms|O
DDI-MedLine.d104.s8|46-47|of|O
DDI-MedLine.d104.s8|61-70|behavioral|O
DDI-MedLine.d104.s8|72-78|changes|O
DDI-MedLine.d104.s8|79-79|,|O
DDI-MedLine.d104.s8|81-88|Northern|O
DDI-MedLine.d104.s8|90-93|blot|O
DDI-MedLine.d104.s8|95-102|analysis|O
DDI-MedLine.d104.s8|104-105|of|O
DDI-MedLine.d104.s8|107-111|total|O
DDI-MedLine.d104.s8|113-115|RNA|O
DDI-MedLine.d104.s8|117-120|from|O
DDI-MedLine.d104.s8|122-131|prefrontal|O
DDI-MedLine.d104.s8|133-140|cortical|O
DDI-MedLine.d104.s8|142-148|tissues|O
DDI-MedLine.d104.s8|150-151|of|O
DDI-MedLine.d104.s8|153-156|mice|O
DDI-MedLine.d104.s8|158-164|treated|O
DDI-MedLine.d104.s8|166-169|with|O
DDI-MedLine.d104.s8|174-174|,|O
DDI-MedLine.d104.s8|182-182|,|O
DDI-MedLine.d104.s8|184-186|and|O
DDI-MedLine.d104.s8|196-198|was|O
DDI-MedLine.d104.s8|200-206|carried|O
DDI-MedLine.d104.s8|208-210|out|O
DDI-MedLine.d104.s8|211-211|.|O
DDI-DrugBank.d45.s0|0-9|Concurrent|O
DDI-DrugBank.d45.s0|11-24|administration|O
DDI-DrugBank.d45.s0|26-27|of|O
DDI-DrugBank.d45.s0|29-38|etanercept|drug
DDI-DrugBank.d45.s0|40-40|(|O
DDI-DrugBank.d45.s0|41-47|another|O
DDI-DrugBank.d45.s0|49-51|TNF|O
DDI-DrugBank.d45.s0|53-61|-blocking|O
DDI-DrugBank.d45.s0|63-67|agent|O
DDI-DrugBank.d45.s0|68-68|)|O
DDI-DrugBank.d45.s0|70-72|and|O
DDI-DrugBank.d45.s0|74-81|anakinra|drug
DDI-DrugBank.d45.s0|83-83|(|O
DDI-DrugBank.d45.s0|84-85|an|O
DDI-DrugBank.d45.s0|87-110|interleukin-1 antagonist|group
DDI-DrugBank.d45.s0|111-111|)|O
DDI-DrugBank.d45.s0|113-115|has|O
DDI-DrugBank.d45.s0|117-120|been|O
DDI-DrugBank.d45.s0|122-131|associated|O
DDI-DrugBank.d45.s0|133-136|with|O
DDI-DrugBank.d45.s0|138-139|an|O
DDI-DrugBank.d45.s0|141-149|increased|O
DDI-DrugBank.d45.s0|151-154|risk|O
DDI-DrugBank.d45.s0|156-157|of|O
DDI-DrugBank.d45.s0|159-165|serious|O
DDI-DrugBank.d45.s0|167-176|infections|O
DDI-DrugBank.d45.s0|177-177|,|O
DDI-DrugBank.d45.s0|179-181|and|O
DDI-DrugBank.d45.s0|183-191|increased|O
DDI-DrugBank.d45.s0|193-196|risk|O
DDI-DrugBank.d45.s0|198-199|of|O
DDI-DrugBank.d45.s0|201-211|neutropenia|O
DDI-DrugBank.d45.s0|213-215|and|O
DDI-DrugBank.d45.s0|217-218|no|O
DDI-DrugBank.d45.s0|220-229|additional|O
DDI-DrugBank.d45.s0|231-237|benefit|O
DDI-DrugBank.d45.s0|239-246|compared|O
DDI-DrugBank.d45.s0|248-249|to|O
DDI-DrugBank.d45.s0|251-255|these|O
DDI-DrugBank.d45.s0|257-265|medicinal|O
DDI-DrugBank.d45.s0|267-274|products|O
DDI-DrugBank.d45.s0|276-280|alone|O
DDI-DrugBank.d45.s0|281-281|.|O
DDI-DrugBank.d45.s1|0-4|Other|O
DDI-DrugBank.d45.s1|6-25|TNFa-blocking agents|group
DDI-DrugBank.d45.s1|27-27|(|O
DDI-DrugBank.d45.s1|28-36|including|O
DDI-DrugBank.d45.s1|38-45|REMICADE|brand
DDI-DrugBank.d45.s1|46-46|)|O
DDI-DrugBank.d45.s1|48-51|used|O
DDI-DrugBank.d45.s1|53-54|in|O
DDI-DrugBank.d45.s1|56-66|combination|O
DDI-DrugBank.d45.s1|68-71|with|O
DDI-DrugBank.d45.s1|73-80|anakinra|drug
DDI-DrugBank.d45.s1|82-84|may|O
DDI-DrugBank.d45.s1|86-89|also|O
DDI-DrugBank.d45.s1|91-96|result|O
DDI-DrugBank.d45.s1|98-99|in|O
DDI-DrugBank.d45.s1|101-107|similar|O
DDI-DrugBank.d45.s1|109-118|toxicities|O
DDI-DrugBank.d45.s1|119-119|.|O
DDI-DrugBank.d45.s2|0-7|Specific|O
DDI-DrugBank.d45.s2|9-12|drug|O
DDI-DrugBank.d45.s2|14-24|interaction|O
DDI-DrugBank.d45.s2|26-32|studies|O
DDI-DrugBank.d45.s2|33-33|,|O
DDI-DrugBank.d45.s2|35-43|including|O
DDI-DrugBank.d45.s2|45-56|interactions|O
DDI-DrugBank.d45.s2|58-61|with|O
DDI-DrugBank.d45.s2|63-65|MTX|drug
DDI-DrugBank.d45.s2|66-66|,|O
DDI-DrugBank.d45.s2|68-71|have|O
DDI-DrugBank.d45.s2|73-75|not|O
DDI-DrugBank.d45.s2|77-80|been|O
DDI-DrugBank.d45.s2|82-90|conducted|O
DDI-DrugBank.d45.s2|91-91|.|O
DDI-DrugBank.d45.s3|0-2|The|O
DDI-DrugBank.d45.s3|4-11|majority|O
DDI-DrugBank.d45.s3|13-14|of|O
DDI-DrugBank.d45.s3|16-23|patients|O
DDI-DrugBank.d45.s3|25-26|in|O
DDI-DrugBank.d45.s3|28-37|rheumatoid|O
DDI-DrugBank.d45.s3|39-47|arthritis|O
DDI-DrugBank.d45.s3|49-50|or|O
DDI-DrugBank.d45.s3|52-56|Crohn|O
DDI-DrugBank.d45.s3|58-58|s|O
DDI-DrugBank.d45.s3|60-66|disease|O
DDI-DrugBank.d45.s3|68-75|clinical|O
DDI-DrugBank.d45.s3|77-83|studies|O
DDI-DrugBank.d45.s3|85-92|received|O
DDI-DrugBank.d45.s3|94-96|one|O
DDI-DrugBank.d45.s3|98-99|or|O
DDI-DrugBank.d45.s3|101-104|more|O
DDI-DrugBank.d45.s3|106-116|concomitant|O
DDI-DrugBank.d45.s3|118-128|medications|O
DDI-DrugBank.d45.s3|129-129|.|O
DDI-DrugBank.d45.s4|0-1|In|O
DDI-DrugBank.d45.s4|3-12|rheumatoid|O
DDI-DrugBank.d45.s4|14-22|arthritis|O
DDI-DrugBank.d45.s4|23-23|,|O
DDI-DrugBank.d45.s4|25-35|concomitant|O
DDI-DrugBank.d45.s4|37-47|medications|O
DDI-DrugBank.d45.s4|49-55|besides|O
DDI-DrugBank.d45.s4|57-59|MTX|drug
DDI-DrugBank.d45.s4|61-64|were|O
DDI-DrugBank.d45.s4|66-102|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d45.s4|103-103|,|O
DDI-DrugBank.d45.s4|105-114|folic acid|drug
DDI-DrugBank.d45.s4|115-115|,|O
DDI-DrugBank.d45.s4|117-131|corticosteroids|group
DDI-DrugBank.d45.s4|133-138|and/or|O
DDI-DrugBank.d45.s4|140-148|narcotics|group
DDI-DrugBank.d45.s4|149-149|.|O
DDI-DrugBank.d45.s5|0-10|Concomitant|O
DDI-DrugBank.d45.s5|12-16|Crohn|O
DDI-DrugBank.d45.s5|18-18|s|O
DDI-DrugBank.d45.s5|20-26|disease|O
DDI-DrugBank.d45.s5|28-38|medications|O
DDI-DrugBank.d45.s5|40-43|were|O
DDI-DrugBank.d45.s5|45-55|antibiotics|group
DDI-DrugBank.d45.s5|56-56|,|O
DDI-DrugBank.d45.s5|58-67|antivirals|group
DDI-DrugBank.d45.s5|68-68|,|O
DDI-DrugBank.d45.s5|70-84|corticosteroids|group
DDI-DrugBank.d45.s5|85-85|,|O
DDI-DrugBank.d45.s5|87-94|6-MP/AZA|drug
DDI-DrugBank.d45.s5|96-98|and|O
DDI-DrugBank.d45.s5|100-115|aminosalicylates|O
DDI-DrugBank.d45.s5|116-116|.|O
DDI-DrugBank.d45.s6|0-1|In|O
DDI-DrugBank.d45.s6|3-11|psoriatic|O
DDI-DrugBank.d45.s6|13-21|arthritis|O
DDI-DrugBank.d45.s6|23-30|clinical|O
DDI-DrugBank.d45.s6|32-37|trials|O
DDI-DrugBank.d45.s6|38-38|,|O
DDI-DrugBank.d45.s6|40-50|concomitant|O
DDI-DrugBank.d45.s6|52-62|medications|O
DDI-DrugBank.d45.s6|64-71|included|O
DDI-DrugBank.d45.s6|73-75|MTX|drug
DDI-DrugBank.d45.s6|77-78|in|O
DDI-DrugBank.d45.s6|80-92|approximately|O
DDI-DrugBank.d45.s6|94-97|half|O
DDI-DrugBank.d45.s6|99-100|of|O
DDI-DrugBank.d45.s6|102-104|the|O
DDI-DrugBank.d45.s6|106-113|patients|O
DDI-DrugBank.d45.s6|115-116|as|O
DDI-DrugBank.d45.s6|118-121|well|O
DDI-DrugBank.d45.s6|123-124|as|O
DDI-DrugBank.d45.s6|126-162|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d45.s6|163-163|,|O
DDI-DrugBank.d45.s6|165-174|folic acid|drug
DDI-DrugBank.d45.s6|176-178|and|O
DDI-DrugBank.d45.s6|180-194|corticosteroids|group
DDI-DrugBank.d45.s6|195-195|.|O
DDI-DrugBank.d45.s7|0-7|Patients|O
DDI-DrugBank.d45.s7|9-12|with|O
DDI-DrugBank.d45.s7|14-18|Crohn|O
DDI-DrugBank.d45.s7|20-20|s|O
DDI-DrugBank.d45.s7|22-28|disease|O
DDI-DrugBank.d45.s7|30-32|who|O
DDI-DrugBank.d45.s7|34-41|received|O
DDI-DrugBank.d45.s7|43-60|immunosuppressants|group
DDI-DrugBank.d45.s7|62-67|tended|O
DDI-DrugBank.d45.s7|69-70|to|O
DDI-DrugBank.d45.s7|72-81|experience|O
DDI-DrugBank.d45.s7|83-87|fewer|O
DDI-DrugBank.d45.s7|89-96|infusion|O
DDI-DrugBank.d45.s7|98-106|reactions|O
DDI-DrugBank.d45.s7|108-115|compared|O
DDI-DrugBank.d45.s7|117-118|to|O
DDI-DrugBank.d45.s7|120-127|patients|O
DDI-DrugBank.d45.s7|129-130|on|O
DDI-DrugBank.d45.s7|132-133|no|O
DDI-DrugBank.d45.s7|135-152|immunosuppressants|group
DDI-DrugBank.d45.s7|153-153|.|O
DDI-DrugBank.d45.s8|0-4|Serum|O
DDI-DrugBank.d45.s8|6-15|infliximab|drug
DDI-DrugBank.d45.s8|17-30|concentrations|O
DDI-DrugBank.d45.s8|32-39|appeared|O
DDI-DrugBank.d45.s8|41-42|to|O
DDI-DrugBank.d45.s8|44-45|be|O
DDI-DrugBank.d45.s8|47-56|unaffected|O
DDI-DrugBank.d45.s8|58-59|by|O
DDI-DrugBank.d45.s8|61-68|baseline|O
DDI-DrugBank.d45.s8|70-72|use|O
DDI-DrugBank.d45.s8|74-75|of|O
DDI-DrugBank.d45.s8|77-87|medications|O
DDI-DrugBank.d45.s8|89-91|for|O
DDI-DrugBank.d45.s8|93-95|the|O
DDI-DrugBank.d45.s8|97-105|treatment|O
DDI-DrugBank.d45.s8|107-108|of|O
DDI-DrugBank.d45.s8|110-114|Crohn|O
DDI-DrugBank.d45.s8|116-116|s|O
DDI-DrugBank.d45.s8|118-124|disease|O
DDI-DrugBank.d45.s8|126-134|including|O
DDI-DrugBank.d45.s8|136-150|corticosteroids|group
DDI-DrugBank.d45.s8|151-151|,|O
DDI-DrugBank.d45.s8|153-163|antibiotics|group
DDI-DrugBank.d45.s8|165-165|(|O
DDI-DrugBank.d45.s8|166-178|metronidazole|drug
DDI-DrugBank.d45.s8|180-181|or|O
DDI-DrugBank.d45.s8|183-195|ciprofloxacin|drug
DDI-DrugBank.d45.s8|196-196|)|O
DDI-DrugBank.d45.s8|198-200|and|O
DDI-DrugBank.d45.s8|202-217|aminosalicylates|O
DDI-DrugBank.d45.s8|218-218|.|O
DDI-DrugBank.d562.s0|0-7|Elevated|O
DDI-DrugBank.d562.s0|9-14|plasma|O
DDI-DrugBank.d562.s0|16-21|levels|O
DDI-DrugBank.d562.s0|23-24|of|O
DDI-DrugBank.d562.s0|26-37|theophylline|drug
DDI-DrugBank.d562.s0|39-42|have|O
DDI-DrugBank.d562.s0|44-47|been|O
DDI-DrugBank.d562.s0|49-56|reported|O
DDI-DrugBank.d562.s0|58-61|with|O
DDI-DrugBank.d562.s0|63-73|concomitant|O
DDI-DrugBank.d562.s0|75-77|use|O
DDI-DrugBank.d562.s0|79-80|of|O
DDI-DrugBank.d562.s0|82-85|some|O
DDI-DrugBank.d562.s0|87-96|quinolones|group
DDI-DrugBank.d562.s0|97-97|.|O
DDI-DrugBank.d562.s1|0-4|There|O
DDI-DrugBank.d562.s1|6-9|have|O
DDI-DrugBank.d562.s1|11-14|been|O
DDI-DrugBank.d562.s1|16-22|reports|O
DDI-DrugBank.d562.s1|24-25|of|O
DDI-DrugBank.d562.s1|27-46|theophylline-related|drug
DDI-DrugBank.d562.s1|48-59|side-effects|O
DDI-DrugBank.d562.s1|61-62|in|O
DDI-DrugBank.d562.s1|64-71|patients|O
DDI-DrugBank.d562.s1|73-74|on|O
DDI-DrugBank.d562.s1|76-86|concomitant|O
DDI-DrugBank.d562.s1|88-109|theophylline-quinolone|drug
DDI-DrugBank.d562.s1|111-117|therapy|O
DDI-DrugBank.d562.s1|118-118|.|O
DDI-DrugBank.d562.s2|0-8|Therefore|O
DDI-DrugBank.d562.s2|9-9|,|O
DDI-DrugBank.d562.s2|11-20|monitoring|O
DDI-DrugBank.d562.s2|22-23|of|O
DDI-DrugBank.d562.s2|25-36|theophylline|drug
DDI-DrugBank.d562.s2|38-43|plasma|O
DDI-DrugBank.d562.s2|45-50|levels|O
DDI-DrugBank.d562.s2|52-57|should|O
DDI-DrugBank.d562.s2|59-60|be|O
DDI-DrugBank.d562.s2|62-71|considered|O
DDI-DrugBank.d562.s2|73-75|and|O
DDI-DrugBank.d562.s2|77-82|dosage|O
DDI-DrugBank.d562.s2|84-85|of|O
DDI-DrugBank.d562.s2|87-98|theophylline|drug
DDI-DrugBank.d562.s2|100-107|adjusted|O
DDI-DrugBank.d562.s2|109-110|as|O
DDI-DrugBank.d562.s2|112-119|required|O
DDI-DrugBank.d562.s2|120-120|.|O
DDI-DrugBank.d562.s3|0-9|Quinolones|group
DDI-DrugBank.d562.s3|11-14|have|O
DDI-DrugBank.d562.s3|16-19|also|O
DDI-DrugBank.d562.s3|21-24|been|O
DDI-DrugBank.d562.s3|26-30|shown|O
DDI-DrugBank.d562.s3|32-33|to|O
DDI-DrugBank.d562.s3|35-43|interfere|O
DDI-DrugBank.d562.s3|45-48|with|O
DDI-DrugBank.d562.s3|50-52|the|O
DDI-DrugBank.d562.s3|54-63|metabolism|O
DDI-DrugBank.d562.s3|65-66|of|O
DDI-DrugBank.d562.s3|68-75|caffeine|drug
DDI-DrugBank.d562.s3|76-76|.|O
DDI-DrugBank.d562.s4|0-3|This|O
DDI-DrugBank.d562.s4|5-7|may|O
DDI-DrugBank.d562.s4|9-12|lead|O
DDI-DrugBank.d562.s4|14-15|to|O
DDI-DrugBank.d562.s4|17-23|reduced|O
DDI-DrugBank.d562.s4|25-33|clearance|O
DDI-DrugBank.d562.s4|35-36|of|O
DDI-DrugBank.d562.s4|38-45|caffeine|drug
DDI-DrugBank.d562.s4|47-49|and|O
DDI-DrugBank.d562.s4|51-51|a|O
DDI-DrugBank.d562.s4|53-64|prolongation|O
DDI-DrugBank.d562.s4|66-67|of|O
DDI-DrugBank.d562.s4|69-71|its|O
DDI-DrugBank.d562.s4|73-78|plasma|O
DDI-DrugBank.d562.s4|80-88|half-life|O
DDI-DrugBank.d562.s4|89-89|.|O
DDI-DrugBank.d562.s5|0-7|Although|O
DDI-DrugBank.d562.s5|9-12|this|O
DDI-DrugBank.d562.s5|14-24|interaction|O
DDI-DrugBank.d562.s5|26-28|has|O
DDI-DrugBank.d562.s5|30-32|not|O
DDI-DrugBank.d562.s5|34-37|been|O
DDI-DrugBank.d562.s5|39-46|reported|O
DDI-DrugBank.d562.s5|48-51|with|O
DDI-DrugBank.d562.s5|53-61|cinoxacin|drug
DDI-DrugBank.d562.s5|62-62|,|O
DDI-DrugBank.d562.s5|64-70|caution|O
DDI-DrugBank.d562.s5|72-77|should|O
DDI-DrugBank.d562.s5|79-80|be|O
DDI-DrugBank.d562.s5|82-90|exercised|O
DDI-DrugBank.d562.s5|92-95|when|O
DDI-DrugBank.d562.s5|97-105|cinoxacin|drug
DDI-DrugBank.d562.s5|107-108|is|O
DDI-DrugBank.d562.s5|110-114|given|O
DDI-DrugBank.d562.s5|116-128|concomitantly|O
DDI-DrugBank.d562.s5|130-133|with|O
DDI-DrugBank.d562.s5|135-153|caffeine-containing|drug
DDI-DrugBank.d562.s5|155-162|products|O
DDI-DrugBank.d562.s5|163-163|.|O
DDI-DrugBank.d562.s6|0-7|Antacids|group
DDI-DrugBank.d562.s6|9-10|or|O
DDI-DrugBank.d562.s6|12-21|sucralfate|drug
DDI-DrugBank.d562.s6|23-35|substantially|O
DDI-DrugBank.d562.s6|37-45|interfere|O
DDI-DrugBank.d562.s6|47-50|with|O
DDI-DrugBank.d562.s6|52-54|the|O
DDI-DrugBank.d562.s6|56-65|absorption|O
DDI-DrugBank.d562.s6|67-68|of|O
DDI-DrugBank.d562.s6|70-73|some|O
DDI-DrugBank.d562.s6|75-84|quinolones|group
DDI-DrugBank.d562.s6|85-85|,|O
DDI-DrugBank.d562.s6|87-95|resulting|O
DDI-DrugBank.d562.s6|97-98|in|O
DDI-DrugBank.d562.s6|100-102|low|O
DDI-DrugBank.d562.s6|104-108|urine|O
DDI-DrugBank.d562.s6|110-115|levels|O
DDI-DrugBank.d562.s6|116-116|.|O
DDI-DrugBank.d562.s7|0-3|Also|O
DDI-DrugBank.d562.s7|4-4|,|O
DDI-DrugBank.d562.s7|6-16|concomitant|O
DDI-DrugBank.d562.s7|18-31|administration|O
DDI-DrugBank.d562.s7|33-34|of|O
DDI-DrugBank.d562.s7|36-45|quinolones|group
DDI-DrugBank.d562.s7|47-50|with|O
DDI-DrugBank.d562.s7|52-59|products|O
DDI-DrugBank.d562.s7|61-70|containing|O
DDI-DrugBank.d562.s7|72-75|iron|drug
DDI-DrugBank.d562.s7|76-76|,|O
DDI-DrugBank.d562.s7|78-90|multivitamins|group
DDI-DrugBank.d562.s7|92-101|containing|O
DDI-DrugBank.d562.s7|103-106|zinc|drug
DDI-DrugBank.d562.s7|107-107|,|O
DDI-DrugBank.d562.s7|109-110|or|O
DDI-DrugBank.d562.s7|112-116|Videx|brand
DDI-DrugBank.d562.s7|118-118|(|O
DDI-DrugBank.d562.s7|119-128|didanosine|drug
DDI-DrugBank.d562.s7|129-129|)|O
DDI-DrugBank.d562.s7|131-147|chewable/buffered|O
DDI-DrugBank.d562.s7|149-155|tablets|O
DDI-DrugBank.d562.s7|157-158|or|O
DDI-DrugBank.d562.s7|160-162|the|O
DDI-DrugBank.d562.s7|164-172|pediatric|O
DDI-DrugBank.d562.s7|174-179|powder|O
DDI-DrugBank.d562.s7|181-183|for|O
DDI-DrugBank.d562.s7|185-188|oral|O
DDI-DrugBank.d562.s7|190-197|solution|O
DDI-DrugBank.d562.s7|199-201|may|O
DDI-DrugBank.d562.s7|203-208|result|O
DDI-DrugBank.d562.s7|210-211|in|O
DDI-DrugBank.d562.s7|213-215|low|O
DDI-DrugBank.d562.s7|217-221|urine|O
DDI-DrugBank.d562.s7|223-228|levels|O
DDI-DrugBank.d562.s7|229-229|.|O
DDI-DrugBank.d562.s8|0-9|Quinolones|group
DDI-DrugBank.d562.s8|10-10|,|O
DDI-DrugBank.d562.s8|12-20|including|O
DDI-DrugBank.d562.s8|22-30|cinoxacin|drug
DDI-DrugBank.d562.s8|31-31|,|O
DDI-DrugBank.d562.s8|33-35|may|O
DDI-DrugBank.d562.s8|37-43|enhance|O
DDI-DrugBank.d562.s8|45-47|the|O
DDI-DrugBank.d562.s8|49-55|effects|O
DDI-DrugBank.d562.s8|57-58|of|O
DDI-DrugBank.d562.s8|60-63|oral|O
DDI-DrugBank.d562.s8|65-78|anticoagulants|group
DDI-DrugBank.d562.s8|79-79|,|O
DDI-DrugBank.d562.s8|81-84|such|O
DDI-DrugBank.d562.s8|86-87|as|O
DDI-DrugBank.d562.s8|89-96|warfarin|drug
DDI-DrugBank.d562.s8|98-99|or|O
DDI-DrugBank.d562.s8|101-103|its|O
DDI-DrugBank.d562.s8|105-115|derivatives|O
DDI-DrugBank.d562.s8|116-116|.|O
DDI-DrugBank.d562.s9|0-3|When|O
DDI-DrugBank.d562.s9|5-9|these|O
DDI-DrugBank.d562.s9|11-18|products|O
DDI-DrugBank.d562.s9|20-22|are|O
DDI-DrugBank.d562.s9|24-35|administered|O
DDI-DrugBank.d562.s9|37-49|concomitantly|O
DDI-DrugBank.d562.s9|50-50|,|O
DDI-DrugBank.d562.s9|52-62|prothrombin|O
DDI-DrugBank.d562.s9|64-67|time|O
DDI-DrugBank.d562.s9|69-70|or|O
DDI-DrugBank.d562.s9|72-76|other|O
DDI-DrugBank.d562.s9|78-85|suitable|O
DDI-DrugBank.d562.s9|87-97|coagulation|O
DDI-DrugBank.d562.s9|99-103|tests|O
DDI-DrugBank.d562.s9|105-110|should|O
DDI-DrugBank.d562.s9|112-113|be|O
DDI-DrugBank.d562.s9|115-121|closely|O
DDI-DrugBank.d562.s9|123-131|monitored|O
DDI-DrugBank.d562.s9|132-132|.|O
DDI-DrugBank.d562.s10|0-7|Seizures|O
DDI-DrugBank.d562.s10|9-12|have|O
DDI-DrugBank.d562.s10|14-17|been|O
DDI-DrugBank.d562.s10|19-26|reported|O
DDI-DrugBank.d562.s10|28-29|in|O
DDI-DrugBank.d562.s10|31-38|patients|O
DDI-DrugBank.d562.s10|40-45|taking|O
DDI-DrugBank.d562.s10|47-53|another|O
DDI-DrugBank.d562.s10|55-83|quinolone class antimicrobial|group
DDI-DrugBank.d562.s10|85-87|and|O
DDI-DrugBank.d562.s10|89-91|the|O
DDI-DrugBank.d562.s10|93-127|nonsteroidal anti-inflammatory drug|group
DDI-DrugBank.d562.s10|93-127|nonsteroidal anti-inflammatory drug|group
DDI-DrugBank.d562.s10|138-149|concurrently|O
DDI-DrugBank.d562.s10|150-150|.|O
DDI-DrugBank.d562.s11|0-5|Animal|O
DDI-DrugBank.d562.s11|7-13|studies|O
DDI-DrugBank.d562.s11|15-18|also|O
DDI-DrugBank.d562.s11|20-26|suggest|O
DDI-DrugBank.d562.s11|28-29|an|O
DDI-DrugBank.d562.s11|31-39|increased|O
DDI-DrugBank.d562.s11|41-49|potential|O
DDI-DrugBank.d562.s11|51-53|for|O
DDI-DrugBank.d562.s11|55-62|seizures|O
DDI-DrugBank.d562.s11|64-67|when|O
DDI-DrugBank.d562.s11|69-73|these|O
DDI-DrugBank.d562.s11|75-75|2|O
DDI-DrugBank.d562.s11|77-81|drugs|O
DDI-DrugBank.d562.s11|83-85|are|O
DDI-DrugBank.d562.s11|87-91|given|O
DDI-DrugBank.d562.s11|93-105|concomitantly|O
DDI-DrugBank.d562.s11|106-106|.|O
DDI-DrugBank.d562.s12|0-7|Fenbufen|drug
DDI-DrugBank.d562.s12|9-10|is|O
DDI-DrugBank.d562.s12|12-14|not|O
DDI-DrugBank.d562.s12|16-23|approved|O
DDI-DrugBank.d562.s12|25-26|in|O
DDI-DrugBank.d562.s12|28-30|the|O
DDI-DrugBank.d562.s12|32-37|United|O
DDI-DrugBank.d562.s12|39-44|States|O
DDI-DrugBank.d562.s12|46-47|at|O
DDI-DrugBank.d562.s12|49-52|this|O
DDI-DrugBank.d562.s12|54-57|time|O
DDI-DrugBank.d562.s12|58-58|.|O
DDI-DrugBank.d562.s13|0-9|Physicians|O
DDI-DrugBank.d562.s13|11-13|are|O
DDI-DrugBank.d562.s13|15-22|provided|O
DDI-DrugBank.d562.s13|24-27|this|O
DDI-DrugBank.d562.s13|29-39|information|O
DDI-DrugBank.d562.s13|41-42|to|O
DDI-DrugBank.d562.s13|44-51|increase|O
DDI-DrugBank.d562.s13|53-61|awareness|O
DDI-DrugBank.d562.s13|63-64|of|O
DDI-DrugBank.d562.s13|66-68|the|O
DDI-DrugBank.d562.s13|70-78|potential|O
DDI-DrugBank.d562.s13|80-82|for|O
DDI-DrugBank.d562.s13|84-90|serious|O
DDI-DrugBank.d562.s13|92-103|interactions|O
DDI-DrugBank.d562.s13|105-108|when|O
DDI-DrugBank.d562.s13|110-118|cinoxacin|drug
DDI-DrugBank.d562.s13|120-122|and|O
DDI-DrugBank.d562.s13|124-130|certain|O
DDI-DrugBank.d562.s13|132-168|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d562.s13|170-172|are|O
DDI-DrugBank.d562.s13|174-185|administered|O
DDI-DrugBank.d562.s13|187-199|concomitantly|O
DDI-DrugBank.d562.s13|200-200|.|O
DDI-DrugBank.d562.s14|0-7|Elevated|O
DDI-DrugBank.d562.s14|9-20|cyclosporine|drug
DDI-DrugBank.d562.s14|22-26|serum|O
DDI-DrugBank.d562.s14|28-33|levels|O
DDI-DrugBank.d562.s14|35-38|have|O
DDI-DrugBank.d562.s14|40-43|been|O
DDI-DrugBank.d562.s14|45-52|reported|O
DDI-DrugBank.d562.s14|54-57|with|O
DDI-DrugBank.d562.s14|59-61|the|O
DDI-DrugBank.d562.s14|63-73|concomitant|O
DDI-DrugBank.d562.s14|75-77|use|O
DDI-DrugBank.d562.s14|79-80|of|O
DDI-DrugBank.d562.s14|82-91|quinolones|group
DDI-DrugBank.d562.s14|93-95|and|O
DDI-DrugBank.d562.s14|97-108|cyclosporine|drug
DDI-DrugBank.d562.s14|109-109|.|O
DDI-DrugBank.d289.s0|0-7|Bosentan|drug
DDI-DrugBank.d289.s0|9-10|is|O
DDI-DrugBank.d289.s0|12-22|metabolized|O
DDI-DrugBank.d289.s0|24-25|by|O
DDI-DrugBank.d289.s0|27-32|CYP2C9|O
DDI-DrugBank.d289.s0|34-36|and|O
DDI-DrugBank.d289.s0|38-43|CYP3A4|O
DDI-DrugBank.d289.s0|44-44|.|O
DDI-DrugBank.d289.s1|0-9|Inhibition|O
DDI-DrugBank.d289.s1|11-12|of|O
DDI-DrugBank.d289.s1|14-18|these|O
DDI-DrugBank.d289.s1|20-29|isoenzymes|O
DDI-DrugBank.d289.s1|31-33|may|O
DDI-DrugBank.d289.s1|35-42|increase|O
DDI-DrugBank.d289.s1|44-46|the|O
DDI-DrugBank.d289.s1|48-53|plasma|O
DDI-DrugBank.d289.s1|55-67|concentration|O
DDI-DrugBank.d289.s1|69-70|of|O
DDI-DrugBank.d289.s1|72-79|bosentan|drug
DDI-DrugBank.d289.s1|80-80|.|O
DDI-DrugBank.d289.s2|0-7|Bosentan|drug
DDI-DrugBank.d289.s2|9-10|is|O
DDI-DrugBank.d289.s2|12-13|an|O
DDI-DrugBank.d289.s2|15-21|inducer|O
DDI-DrugBank.d289.s2|23-24|of|O
DDI-DrugBank.d289.s2|26-31|CYP3A4|O
DDI-DrugBank.d289.s2|33-35|and|O
DDI-DrugBank.d289.s2|37-42|CYP2C9|O
DDI-DrugBank.d289.s2|43-43|.|O
DDI-DrugBank.d289.s3|0-11|Consequently|O
DDI-DrugBank.d289.s3|12-12|,|O
DDI-DrugBank.d289.s3|14-19|plasma|O
DDI-DrugBank.d289.s3|21-34|concentrations|O
DDI-DrugBank.d289.s3|36-37|of|O
DDI-DrugBank.d289.s3|39-43|drugs|O
DDI-DrugBank.d289.s3|45-55|metabolized|O
DDI-DrugBank.d289.s3|57-58|by|O
DDI-DrugBank.d289.s3|60-64|these|O
DDI-DrugBank.d289.s3|66-68|two|O
DDI-DrugBank.d289.s3|70-79|isoenzymes|O
DDI-DrugBank.d289.s3|81-84|will|O
DDI-DrugBank.d289.s3|86-87|be|O
DDI-DrugBank.d289.s3|89-97|decreased|O
DDI-DrugBank.d289.s3|99-102|when|O
DDI-DrugBank.d289.s3|104-111|TRACLEER|brand
DDI-DrugBank.d289.s3|113-114|is|O
DDI-DrugBank.d289.s3|116-130|co-administered|O
DDI-DrugBank.d289.s3|131-131|.|O
DDI-DrugBank.d289.s4|0-7|Bosentan|drug
DDI-DrugBank.d289.s4|9-11|had|O
DDI-DrugBank.d289.s4|13-14|no|O
DDI-DrugBank.d289.s4|16-23|relevant|O
DDI-DrugBank.d289.s4|25-34|inhibitory|O
DDI-DrugBank.d289.s4|36-41|effect|O
DDI-DrugBank.d289.s4|43-44|on|O
DDI-DrugBank.d289.s4|46-48|any|O
DDI-DrugBank.d289.s4|50-52|CYP|O
DDI-DrugBank.d289.s4|54-63|isoenzymes|O
DDI-DrugBank.d289.s4|65-70|tested|O
DDI-DrugBank.d289.s4|72-72|(|O
DDI-DrugBank.d289.s4|73-78|CYP1A2|O
DDI-DrugBank.d289.s4|79-79|,|O
DDI-DrugBank.d289.s4|81-86|CYP2C9|O
DDI-DrugBank.d289.s4|87-87|,|O
DDI-DrugBank.d289.s4|89-95|CYP2C19|O
DDI-DrugBank.d289.s4|96-96|,|O
DDI-DrugBank.d289.s4|98-103|CYP2D6|O
DDI-DrugBank.d289.s4|104-104|,|O
DDI-DrugBank.d289.s4|106-111|CYP3A4|O
DDI-DrugBank.d289.s4|112-112|)|O
DDI-DrugBank.d289.s4|113-113|.|O
DDI-DrugBank.d289.s5|0-11|Consequently|O
DDI-DrugBank.d289.s5|12-12|,|O
DDI-DrugBank.d289.s5|14-21|TRACLEER|brand
DDI-DrugBank.d289.s5|23-24|is|O
DDI-DrugBank.d289.s5|26-28|not|O
DDI-DrugBank.d289.s5|30-37|expected|O
DDI-DrugBank.d289.s5|39-40|to|O
DDI-DrugBank.d289.s5|42-49|increase|O
DDI-DrugBank.d289.s5|51-53|the|O
DDI-DrugBank.d289.s5|55-60|plasma|O
DDI-DrugBank.d289.s5|62-75|concentrations|O
DDI-DrugBank.d289.s5|77-78|of|O
DDI-DrugBank.d289.s5|80-84|drugs|O
DDI-DrugBank.d289.s5|86-96|metabolized|O
DDI-DrugBank.d289.s5|98-99|by|O
DDI-DrugBank.d289.s5|101-105|these|O
DDI-DrugBank.d289.s5|107-113|enzymes|O
DDI-DrugBank.d289.s5|114-114|.|O
DDI-DrugBank.d289.s6|0-22|Hormonal Contraceptives|group
DDI-DrugBank.d289.s6|23-23|,|O
DDI-DrugBank.d289.s6|25-33|Including|O
DDI-DrugBank.d289.s6|35-38|Oral|O
DDI-DrugBank.d289.s6|39-39|,|O
DDI-DrugBank.d289.s6|41-50|Injectable|O
DDI-DrugBank.d289.s6|51-51|,|O
DDI-DrugBank.d289.s6|53-63|Transdermal|O
DDI-DrugBank.d289.s6|64-64|,|O
DDI-DrugBank.d289.s6|66-68|and|O
DDI-DrugBank.d289.s6|70-80|Implantable|O
DDI-DrugBank.d289.s6|82-95|Contraceptives|group
DDI-DrugBank.d289.s6|96-96|:|O
DDI-DrugBank.d289.s6|98-99|An|O
DDI-DrugBank.d289.s6|101-111|interaction|O
DDI-DrugBank.d289.s6|113-117|study|O
DDI-DrugBank.d289.s6|119-130|demonstrated|O
DDI-DrugBank.d289.s6|132-135|that|O
DDI-DrugBank.d289.s6|137-153|co-administration|O
DDI-DrugBank.d289.s6|155-156|of|O
DDI-DrugBank.d289.s6|158-165|bosentan|drug
DDI-DrugBank.d289.s6|167-169|and|O
DDI-DrugBank.d289.s6|171-173|the|O
DDI-DrugBank.d289.s6|175-178|oral|O
DDI-DrugBank.d289.s6|180-201|hormonal contraceptive|group
DDI-DrugBank.d289.s6|180-201|hormonal contraceptive|group
DDI-DrugBank.d289.s6|215-222|produced|O
DDI-DrugBank.d289.s6|224-230|average|O
DDI-DrugBank.d289.s6|232-240|decreases|O
DDI-DrugBank.d289.s6|242-243|of|O
DDI-DrugBank.d289.s6|245-257|norethindrone|drug
DDI-DrugBank.d289.s6|259-261|and|O
DDI-DrugBank.d289.s6|263-279|ethinyl estradiol|drug
DDI-DrugBank.d289.s6|281-286|levels|O
DDI-DrugBank.d289.s6|288-289|of|O
DDI-DrugBank.d289.s6|291-292|14|O
DDI-DrugBank.d289.s6|293-293|%|O
DDI-DrugBank.d289.s6|295-297|and|O
DDI-DrugBank.d289.s6|299-300|31|O
DDI-DrugBank.d289.s6|301-301|%|O
DDI-DrugBank.d289.s6|302-302|,|O
DDI-DrugBank.d289.s6|304-315|respectively|O
DDI-DrugBank.d289.s6|316-316|.|O
DDI-DrugBank.d289.s7|0-6|However|O
DDI-DrugBank.d289.s7|7-7|,|O
DDI-DrugBank.d289.s7|9-17|decreases|O
DDI-DrugBank.d289.s7|19-20|in|O
DDI-DrugBank.d289.s7|22-29|exposure|O
DDI-DrugBank.d289.s7|31-34|were|O
DDI-DrugBank.d289.s7|36-37|as|O
DDI-DrugBank.d289.s7|39-42|much|O
DDI-DrugBank.d289.s7|44-45|as|O
DDI-DrugBank.d289.s7|47-48|56|O
DDI-DrugBank.d289.s7|49-49|%|O
DDI-DrugBank.d289.s7|51-53|and|O
DDI-DrugBank.d289.s7|55-56|66|O
DDI-DrugBank.d289.s7|57-57|%|O
DDI-DrugBank.d289.s7|58-58|,|O
DDI-DrugBank.d289.s7|60-71|respectively|O
DDI-DrugBank.d289.s7|72-72|,|O
DDI-DrugBank.d289.s7|74-75|in|O
DDI-DrugBank.d289.s7|77-86|individual|O
DDI-DrugBank.d289.s7|88-95|subjects|O
DDI-DrugBank.d289.s7|96-96|.|O
DDI-DrugBank.d289.s8|0-8|Therefore|O
DDI-DrugBank.d289.s8|9-9|,|O
DDI-DrugBank.d289.s8|11-33|hormonal contraceptives|group
DDI-DrugBank.d289.s8|34-34|,|O
DDI-DrugBank.d289.s8|36-44|including|O
DDI-DrugBank.d289.s8|46-49|oral|O
DDI-DrugBank.d289.s8|50-50|,|O
DDI-DrugBank.d289.s8|52-61|injectable|O
DDI-DrugBank.d289.s8|62-62|,|O
DDI-DrugBank.d289.s8|64-74|transdermal|O
DDI-DrugBank.d289.s8|75-75|,|O
DDI-DrugBank.d289.s8|77-79|and|O
DDI-DrugBank.d289.s8|81-91|implantable|O
DDI-DrugBank.d289.s8|93-97|forms|O
DDI-DrugBank.d289.s8|98-98|,|O
DDI-DrugBank.d289.s8|100-102|may|O
DDI-DrugBank.d289.s8|104-106|not|O
DDI-DrugBank.d289.s8|108-109|be|O
DDI-DrugBank.d289.s8|111-118|reliable|O
DDI-DrugBank.d289.s8|120-123|when|O
DDI-DrugBank.d289.s8|125-132|TRACLEER|brand
DDI-DrugBank.d289.s8|134-135|is|O
DDI-DrugBank.d289.s8|137-151|co-administered|O
DDI-DrugBank.d289.s8|152-152|.|O
DDI-DrugBank.d289.s9|0-4|Women|O
DDI-DrugBank.d289.s9|6-11|should|O
DDI-DrugBank.d289.s9|13-20|practice|O
DDI-DrugBank.d289.s9|22-31|additional|O
DDI-DrugBank.d289.s9|33-39|methods|O
DDI-DrugBank.d289.s9|41-42|of|O
DDI-DrugBank.d289.s9|44-56|contraception|O
DDI-DrugBank.d289.s9|58-60|and|O
DDI-DrugBank.d289.s9|62-64|not|O
DDI-DrugBank.d289.s9|66-69|rely|O
DDI-DrugBank.d289.s9|71-72|on|O
DDI-DrugBank.d289.s9|74-81|hormonal|O
DDI-DrugBank.d289.s9|83-95|contraception|O
DDI-DrugBank.d289.s9|97-101|alone|O
DDI-DrugBank.d289.s9|103-106|when|O
DDI-DrugBank.d289.s9|108-113|taking|O
DDI-DrugBank.d289.s9|115-122|TRACLEER|brand
DDI-DrugBank.d289.s9|123-123|.|O
DDI-DrugBank.d289.s10|0-7|Specific|O
DDI-DrugBank.d289.s10|9-19|interaction|O
DDI-DrugBank.d289.s10|21-27|studies|O
DDI-DrugBank.d289.s10|29-32|have|O
DDI-DrugBank.d289.s10|34-45|demonstrated|O
DDI-DrugBank.d289.s10|47-49|the|O
DDI-DrugBank.d289.s10|51-59|following|O
DDI-DrugBank.d289.s10|60-60|:|O
DDI-DrugBank.d289.s10|62-75|Cyclosporine A|drug
DDI-DrugBank.d289.s10|76-76|:|O
DDI-DrugBank.d289.s10|78-83|During|O
DDI-DrugBank.d289.s10|85-87|the|O
DDI-DrugBank.d289.s10|89-93|first|O
DDI-DrugBank.d289.s10|95-97|day|O
DDI-DrugBank.d289.s10|99-100|of|O
DDI-DrugBank.d289.s10|102-112|concomitant|O
DDI-DrugBank.d289.s10|114-127|administration|O
DDI-DrugBank.d289.s10|128-128|,|O
DDI-DrugBank.d289.s10|130-135|trough|O
DDI-DrugBank.d289.s10|137-150|concentrations|O
DDI-DrugBank.d289.s10|152-153|of|O
DDI-DrugBank.d289.s10|155-162|bosentan|drug
DDI-DrugBank.d289.s10|164-167|were|O
DDI-DrugBank.d289.s10|169-177|increased|O
DDI-DrugBank.d289.s10|179-180|by|O
DDI-DrugBank.d289.s10|182-186|about|O
DDI-DrugBank.d289.s10|188-194|30-fold|O
DDI-DrugBank.d289.s10|195-195|.|O
DDI-DrugBank.d289.s11|0-11|Steady-state|O
DDI-DrugBank.d289.s11|13-20|bosentan|drug
DDI-DrugBank.d289.s11|22-27|plasma|O
DDI-DrugBank.d289.s11|29-42|concentrations|O
DDI-DrugBank.d289.s11|44-47|were|O
DDI-DrugBank.d289.s11|49-50|3-|O
DDI-DrugBank.d289.s11|52-53|to|O
DDI-DrugBank.d289.s11|55-60|4-fold|O
DDI-DrugBank.d289.s11|62-67|higher|O
DDI-DrugBank.d289.s11|69-72|than|O
DDI-DrugBank.d289.s11|74-75|in|O
DDI-DrugBank.d289.s11|77-79|the|O
DDI-DrugBank.d289.s11|81-87|absence|O
DDI-DrugBank.d289.s11|89-90|of|O
DDI-DrugBank.d289.s11|92-105|cyclosporine A|drug
DDI-DrugBank.d289.s11|106-106|.|O
DDI-DrugBank.d289.s12|0-2|The|O
DDI-DrugBank.d289.s12|4-14|concomitant|O
DDI-DrugBank.d289.s12|16-29|administration|O
DDI-DrugBank.d289.s12|31-32|of|O
DDI-DrugBank.d289.s12|34-41|bosentan|drug
DDI-DrugBank.d289.s12|43-45|and|O
DDI-DrugBank.d289.s12|47-60|cyclosporine A|drug
DDI-DrugBank.d289.s12|62-63|is|O
DDI-DrugBank.d289.s12|65-79|contraindicated|O
DDI-DrugBank.d289.s12|80-80|.|O
DDI-DrugBank.d289.s13|0-16|Co-administration|O
DDI-DrugBank.d289.s13|18-19|of|O
DDI-DrugBank.d289.s13|21-28|bosentan|drug
DDI-DrugBank.d289.s13|30-38|decreased|O
DDI-DrugBank.d289.s13|40-42|the|O
DDI-DrugBank.d289.s13|44-49|plasma|O
DDI-DrugBank.d289.s13|51-64|concentrations|O
DDI-DrugBank.d289.s13|66-67|of|O
DDI-DrugBank.d289.s13|69-82|cyclosporine A|drug
DDI-DrugBank.d289.s13|84-84|(|O
DDI-DrugBank.d289.s13|85-85|a|O
DDI-DrugBank.d289.s13|87-92|CYP3A4|O
DDI-DrugBank.d289.s13|94-102|substrate|O
DDI-DrugBank.d289.s13|103-103|)|O
DDI-DrugBank.d289.s13|105-106|by|O
DDI-DrugBank.d289.s13|108-120|approximately|O
DDI-DrugBank.d289.s13|122-123|50|O
DDI-DrugBank.d289.s13|124-124|%|O
DDI-DrugBank.d289.s13|125-125|.|O
DDI-DrugBank.d289.s14|0-9|Tacrolimus|drug
DDI-DrugBank.d289.s14|10-10|:|O
DDI-DrugBank.d289.s14|12-28|Co-administration|O
DDI-DrugBank.d289.s14|30-31|of|O
DDI-DrugBank.d289.s14|33-42|tacrolimus|drug
DDI-DrugBank.d289.s14|44-46|and|O
DDI-DrugBank.d289.s14|48-55|bosentan|drug
DDI-DrugBank.d289.s14|57-59|has|O
DDI-DrugBank.d289.s14|61-63|not|O
DDI-DrugBank.d289.s14|65-68|been|O
DDI-DrugBank.d289.s14|70-76|studied|O
DDI-DrugBank.d289.s14|78-79|in|O
DDI-DrugBank.d289.s14|81-83|man|O
DDI-DrugBank.d289.s14|84-84|.|O
DDI-DrugBank.d289.s15|0-16|Co-administration|O
DDI-DrugBank.d289.s15|18-19|of|O
DDI-DrugBank.d289.s15|21-30|tacrolimus|drug
DDI-DrugBank.d289.s15|32-34|and|O
DDI-DrugBank.d289.s15|36-43|bosentan|drug
DDI-DrugBank.d289.s15|45-52|resulted|O
DDI-DrugBank.d289.s15|54-55|in|O
DDI-DrugBank.d289.s15|57-64|markedly|O
DDI-DrugBank.d289.s15|66-74|increased|O
DDI-DrugBank.d289.s15|76-81|plasma|O
DDI-DrugBank.d289.s15|83-96|concentrations|O
DDI-DrugBank.d289.s15|98-99|of|O
DDI-DrugBank.d289.s15|101-108|bosentan|drug
DDI-DrugBank.d289.s15|110-111|in|O
DDI-DrugBank.d289.s15|113-119|animals|O
DDI-DrugBank.d289.s15|120-120|.|O
DDI-DrugBank.d289.s16|0-6|Caution|O
DDI-DrugBank.d289.s16|8-13|should|O
DDI-DrugBank.d289.s16|15-16|be|O
DDI-DrugBank.d289.s16|18-26|exercised|O
DDI-DrugBank.d289.s16|28-29|if|O
DDI-DrugBank.d289.s16|31-40|tacrolimus|drug
DDI-DrugBank.d289.s16|42-44|and|O
DDI-DrugBank.d289.s16|46-53|bosentan|drug
DDI-DrugBank.d289.s16|55-57|are|O
DDI-DrugBank.d289.s16|59-62|used|O
DDI-DrugBank.d289.s16|64-71|together|O
DDI-DrugBank.d289.s16|72-72|.|O
DDI-DrugBank.d289.s17|0-8|Glyburide|drug
DDI-DrugBank.d289.s17|9-9|:|O
DDI-DrugBank.d289.s17|11-12|An|O
DDI-DrugBank.d289.s17|14-22|increased|O
DDI-DrugBank.d289.s17|24-27|risk|O
DDI-DrugBank.d289.s17|29-30|of|O
DDI-DrugBank.d289.s17|32-39|elevated|O
DDI-DrugBank.d289.s17|41-45|liver|O
DDI-DrugBank.d289.s17|47-63|aminotransferases|O
DDI-DrugBank.d289.s17|65-67|was|O
DDI-DrugBank.d289.s17|69-76|observed|O
DDI-DrugBank.d289.s17|78-79|in|O
DDI-DrugBank.d289.s17|81-88|patients|O
DDI-DrugBank.d289.s17|90-98|receiving|O
DDI-DrugBank.d289.s17|100-110|concomitant|O
DDI-DrugBank.d289.s17|112-118|therapy|O
DDI-DrugBank.d289.s17|120-123|with|O
DDI-DrugBank.d289.s17|125-133|glyburide|drug
DDI-DrugBank.d289.s17|134-134|.|O
DDI-DrugBank.d289.s18|0-8|Therefore|O
DDI-DrugBank.d289.s18|9-9|,|O
DDI-DrugBank.d289.s18|11-13|the|O
DDI-DrugBank.d289.s18|15-25|concomitant|O
DDI-DrugBank.d289.s18|27-40|administration|O
DDI-DrugBank.d289.s18|42-43|of|O
DDI-DrugBank.d289.s18|45-52|TRACLEER|brand
DDI-DrugBank.d289.s18|54-56|and|O
DDI-DrugBank.d289.s18|58-66|glyburide|drug
DDI-DrugBank.d289.s18|68-69|is|O
DDI-DrugBank.d289.s18|71-85|contraindicated|O
DDI-DrugBank.d289.s18|86-86|,|O
DDI-DrugBank.d289.s18|88-90|and|O
DDI-DrugBank.d289.s18|92-102|alternative|O
DDI-DrugBank.d289.s18|104-122|hypoglycemic agents|group
DDI-DrugBank.d289.s18|124-129|should|O
DDI-DrugBank.d289.s18|131-132|be|O
DDI-DrugBank.d289.s18|134-143|considered|O
DDI-DrugBank.d289.s18|144-144|.|O
DDI-DrugBank.d289.s19|0-16|Co-administration|O
DDI-DrugBank.d289.s19|18-19|of|O
DDI-DrugBank.d289.s19|21-28|bosentan|drug
DDI-DrugBank.d289.s19|30-38|decreased|O
DDI-DrugBank.d289.s19|40-42|the|O
DDI-DrugBank.d289.s19|44-49|plasma|O
DDI-DrugBank.d289.s19|51-64|concentrations|O
DDI-DrugBank.d289.s19|66-67|of|O
DDI-DrugBank.d289.s19|69-77|glyburide|drug
DDI-DrugBank.d289.s19|79-80|by|O
DDI-DrugBank.d289.s19|82-94|approximately|O
DDI-DrugBank.d289.s19|96-97|40|O
DDI-DrugBank.d289.s19|98-98|%|O
DDI-DrugBank.d289.s19|99-99|.|O
DDI-DrugBank.d289.s20|0-2|The|O
DDI-DrugBank.d289.s20|4-9|plasma|O
DDI-DrugBank.d289.s20|11-24|concentrations|O
DDI-DrugBank.d289.s20|26-27|of|O
DDI-DrugBank.d289.s20|29-36|bosentan|drug
DDI-DrugBank.d289.s20|38-41|were|O
DDI-DrugBank.d289.s20|43-46|also|O
DDI-DrugBank.d289.s20|48-56|decreased|O
DDI-DrugBank.d289.s20|58-59|by|O
DDI-DrugBank.d289.s20|61-73|approximately|O
DDI-DrugBank.d289.s20|75-76|30|O
DDI-DrugBank.d289.s20|77-77|%|O
DDI-DrugBank.d289.s20|78-78|.|O
DDI-DrugBank.d289.s21|0-7|Bosentan|drug
DDI-DrugBank.d289.s21|9-10|is|O
DDI-DrugBank.d289.s21|12-15|also|O
DDI-DrugBank.d289.s21|17-24|expected|O
DDI-DrugBank.d289.s21|26-27|to|O
DDI-DrugBank.d289.s21|29-34|reduce|O
DDI-DrugBank.d289.s21|36-41|plasma|O
DDI-DrugBank.d289.s21|43-56|concentrations|O
DDI-DrugBank.d289.s21|58-59|of|O
DDI-DrugBank.d289.s21|61-65|other|O
DDI-DrugBank.d289.s21|67-70|oral|O
DDI-DrugBank.d289.s21|72-90|hypoglycemic agents|group
DDI-DrugBank.d289.s21|92-95|that|O
DDI-DrugBank.d289.s21|97-99|are|O
DDI-DrugBank.d289.s21|101-113|predominantly|O
DDI-DrugBank.d289.s21|115-125|metabolized|O
DDI-DrugBank.d289.s21|127-128|by|O
DDI-DrugBank.d289.s21|130-135|CYP2C9|O
DDI-DrugBank.d289.s21|137-138|or|O
DDI-DrugBank.d289.s21|140-145|CYP3A4|O
DDI-DrugBank.d289.s21|146-146|.|O
DDI-DrugBank.d289.s22|0-2|The|O
DDI-DrugBank.d289.s22|4-14|possibility|O
DDI-DrugBank.d289.s22|16-17|of|O
DDI-DrugBank.d289.s22|19-26|worsened|O
DDI-DrugBank.d289.s22|28-34|glucose|O
DDI-DrugBank.d289.s22|36-42|control|O
DDI-DrugBank.d289.s22|44-45|in|O
DDI-DrugBank.d289.s22|47-54|patients|O
DDI-DrugBank.d289.s22|56-60|using|O
DDI-DrugBank.d289.s22|62-66|these|O
DDI-DrugBank.d289.s22|68-73|agents|O
DDI-DrugBank.d289.s22|75-80|should|O
DDI-DrugBank.d289.s22|82-83|be|O
DDI-DrugBank.d289.s22|85-94|considered|O
DDI-DrugBank.d289.s22|95-95|.|O
DDI-DrugBank.d289.s23|0-11|Ketoconazole|drug
DDI-DrugBank.d289.s23|12-12|:|O
DDI-DrugBank.d289.s23|14-30|Co-administration|O
DDI-DrugBank.d289.s23|32-33|of|O
DDI-DrugBank.d289.s23|35-42|bosentan|drug
DDI-DrugBank.d289.s23|44-46|125|O
DDI-DrugBank.d289.s23|48-49|mg|O
DDI-DrugBank.d289.s23|51-56|b.i.d.|O
DDI-DrugBank.d289.s23|58-60|and|O
DDI-DrugBank.d289.s23|62-73|ketoconazole|drug
DDI-DrugBank.d289.s23|74-74|,|O
DDI-DrugBank.d289.s23|76-76|a|O
DDI-DrugBank.d289.s23|78-83|potent|O
DDI-DrugBank.d289.s23|85-90|CYP3A4|O
DDI-DrugBank.d289.s23|92-100|inhibitor|O
DDI-DrugBank.d289.s23|101-101|,|O
DDI-DrugBank.d289.s23|103-111|increased|O
DDI-DrugBank.d289.s23|113-115|the|O
DDI-DrugBank.d289.s23|117-122|plasma|O
DDI-DrugBank.d289.s23|124-137|concentrations|O
DDI-DrugBank.d289.s23|139-140|of|O
DDI-DrugBank.d289.s23|142-149|bosentan|drug
DDI-DrugBank.d289.s23|151-152|by|O
DDI-DrugBank.d289.s23|154-166|approximately|O
DDI-DrugBank.d289.s23|168-173|2-fold|O
DDI-DrugBank.d289.s23|174-174|.|O
DDI-DrugBank.d289.s24|0-1|No|O
DDI-DrugBank.d289.s24|3-6|dose|O
DDI-DrugBank.d289.s24|8-17|adjustment|O
DDI-DrugBank.d289.s24|19-20|of|O
DDI-DrugBank.d289.s24|22-29|bosentan|drug
DDI-DrugBank.d289.s24|31-32|is|O
DDI-DrugBank.d289.s24|34-42|necessary|O
DDI-DrugBank.d289.s24|43-43|,|O
DDI-DrugBank.d289.s24|45-47|but|O
DDI-DrugBank.d289.s24|49-57|increased|O
DDI-DrugBank.d289.s24|59-65|effects|O
DDI-DrugBank.d289.s24|67-68|of|O
DDI-DrugBank.d289.s24|70-77|bosentan|drug
DDI-DrugBank.d289.s24|79-84|should|O
DDI-DrugBank.d289.s24|86-87|be|O
DDI-DrugBank.d289.s24|89-98|considered|O
DDI-DrugBank.d289.s24|99-99|.|O
DDI-DrugBank.d289.s25|0-10|Simvastatin|drug
DDI-DrugBank.d289.s25|12-14|and|O
DDI-DrugBank.d289.s25|16-20|Other|O
DDI-DrugBank.d289.s25|22-28|Statins|group
DDI-DrugBank.d289.s25|29-29|:|O
DDI-DrugBank.d289.s25|31-47|Co-administration|O
DDI-DrugBank.d289.s25|49-50|of|O
DDI-DrugBank.d289.s25|52-59|bosentan|drug
DDI-DrugBank.d289.s25|61-69|decreased|O
DDI-DrugBank.d289.s25|71-73|the|O
DDI-DrugBank.d289.s25|75-80|plasma|O
DDI-DrugBank.d289.s25|82-95|concentrations|O
DDI-DrugBank.d289.s25|97-98|of|O
DDI-DrugBank.d289.s25|100-110|simvastatin|drug
DDI-DrugBank.d289.s25|112-112|(|O
DDI-DrugBank.d289.s25|113-113|a|O
DDI-DrugBank.d289.s25|115-120|CYP3A4|O
DDI-DrugBank.d289.s25|122-130|substrate|O
DDI-DrugBank.d289.s25|131-131|)|O
DDI-DrugBank.d289.s25|132-132|,|O
DDI-DrugBank.d289.s25|134-136|and|O
DDI-DrugBank.d289.s25|138-140|its|O
DDI-DrugBank.d289.s25|142-147|active|O
DDI-DrugBank.d289.s25|150-157|-hydroxy|O
DDI-DrugBank.d289.s25|159-162|acid|O
DDI-DrugBank.d289.s25|164-173|metabolite|O
DDI-DrugBank.d289.s25|174-174|,|O
DDI-DrugBank.d289.s25|176-177|by|O
DDI-DrugBank.d289.s25|179-191|approximately|O
DDI-DrugBank.d289.s25|193-194|50|O
DDI-DrugBank.d289.s25|195-195|%|O
DDI-DrugBank.d289.s25|196-196|.|O
DDI-DrugBank.d289.s26|0-2|The|O
DDI-DrugBank.d289.s26|4-9|plasma|O
DDI-DrugBank.d289.s26|11-24|concentrations|O
DDI-DrugBank.d289.s26|26-27|of|O
DDI-DrugBank.d289.s26|29-36|bosentan|drug
DDI-DrugBank.d289.s26|38-41|were|O
DDI-DrugBank.d289.s26|43-45|not|O
DDI-DrugBank.d289.s26|47-54|affected|O
DDI-DrugBank.d289.s26|55-55|.|O
DDI-DrugBank.d289.s27|0-7|Bosentan|drug
DDI-DrugBank.d289.s27|9-10|is|O
DDI-DrugBank.d289.s27|12-15|also|O
DDI-DrugBank.d289.s27|17-24|expected|O
DDI-DrugBank.d289.s27|26-27|to|O
DDI-DrugBank.d289.s27|29-34|reduce|O
DDI-DrugBank.d289.s27|36-41|plasma|O
DDI-DrugBank.d289.s27|43-56|concentrations|O
DDI-DrugBank.d289.s27|58-59|of|O
DDI-DrugBank.d289.s27|61-65|other|O
DDI-DrugBank.d289.s27|67-73|statins|group
DDI-DrugBank.d289.s27|75-78|that|O
DDI-DrugBank.d289.s27|80-83|have|O
DDI-DrugBank.d289.s27|85-95|significant|O
DDI-DrugBank.d289.s27|97-106|metabolism|O
DDI-DrugBank.d289.s27|108-109|by|O
DDI-DrugBank.d289.s27|111-116|CYP3A4|O
DDI-DrugBank.d289.s27|117-117|,|O
DDI-DrugBank.d289.s27|119-122|such|O
DDI-DrugBank.d289.s27|124-125|as|O
DDI-DrugBank.d289.s27|127-136|lovastatin|drug
DDI-DrugBank.d289.s27|138-140|and|O
DDI-DrugBank.d289.s27|142-153|atorvastatin|drug
DDI-DrugBank.d289.s27|154-154|.|O
DDI-DrugBank.d289.s28|0-2|The|O
DDI-DrugBank.d289.s28|4-14|possibility|O
DDI-DrugBank.d289.s28|16-17|of|O
DDI-DrugBank.d289.s28|19-25|reduced|O
DDI-DrugBank.d289.s28|27-32|statin|group
DDI-DrugBank.d289.s28|34-41|efficacy|O
DDI-DrugBank.d289.s28|43-48|should|O
DDI-DrugBank.d289.s28|50-51|be|O
DDI-DrugBank.d289.s28|53-62|considered|O
DDI-DrugBank.d289.s28|63-63|.|O
DDI-DrugBank.d289.s29|0-7|Patients|O
DDI-DrugBank.d289.s29|9-13|using|O
DDI-DrugBank.d289.s29|15-20|CYP3A4|O
DDI-DrugBank.d289.s29|22-32|metabolized|O
DDI-DrugBank.d289.s29|34-40|statins|group
DDI-DrugBank.d289.s29|42-47|should|O
DDI-DrugBank.d289.s29|49-52|have|O
DDI-DrugBank.d289.s29|54-64|cholesterol|O
DDI-DrugBank.d289.s29|66-71|levels|O
DDI-DrugBank.d289.s29|73-81|monitored|O
DDI-DrugBank.d289.s29|83-87|after|O
DDI-DrugBank.d289.s29|89-96|TRACLEER|brand
DDI-DrugBank.d289.s29|98-99|is|O
DDI-DrugBank.d289.s29|101-109|initiated|O
DDI-DrugBank.d289.s29|111-112|to|O
DDI-DrugBank.d289.s29|114-116|see|O
DDI-DrugBank.d289.s29|118-124|whether|O
DDI-DrugBank.d289.s29|126-128|the|O
DDI-DrugBank.d289.s29|130-135|statin|group
DDI-DrugBank.d289.s29|137-140|dose|O
DDI-DrugBank.d289.s29|142-146|needs|O
DDI-DrugBank.d289.s29|148-157|adjustment|O
DDI-DrugBank.d289.s29|158-158|.|O
DDI-DrugBank.d289.s30|0-7|Warfarin|drug
DDI-DrugBank.d289.s30|8-8|:|O
DDI-DrugBank.d289.s30|10-26|Co-administration|O
DDI-DrugBank.d289.s30|28-29|of|O
DDI-DrugBank.d289.s30|31-38|bosentan|drug
DDI-DrugBank.d289.s30|40-42|500|O
DDI-DrugBank.d289.s30|44-45|mg|O
DDI-DrugBank.d289.s30|47-52|b.i.d.|O
DDI-DrugBank.d289.s30|54-56|for|O
DDI-DrugBank.d289.s30|58-58|6|O
DDI-DrugBank.d289.s30|60-63|days|O
DDI-DrugBank.d289.s30|65-73|decreased|O
DDI-DrugBank.d289.s30|75-77|the|O
DDI-DrugBank.d289.s30|79-84|plasma|O
DDI-DrugBank.d289.s30|86-99|concentrations|O
DDI-DrugBank.d289.s30|101-102|of|O
DDI-DrugBank.d289.s30|104-107|both|O
DDI-DrugBank.d289.s30|109-118|S-warfarin|drug
DDI-DrugBank.d289.s30|120-120|(|O
DDI-DrugBank.d289.s30|121-121|a|O
DDI-DrugBank.d289.s30|123-128|CYP2C9|O
DDI-DrugBank.d289.s30|130-138|substrate|O
DDI-DrugBank.d289.s30|139-139|)|O
DDI-DrugBank.d289.s30|141-143|and|O
DDI-DrugBank.d289.s30|145-154|R-warfarin|drug
DDI-DrugBank.d289.s30|156-156|(|O
DDI-DrugBank.d289.s30|157-157|a|O
DDI-DrugBank.d289.s30|159-164|CYP3A4|O
DDI-DrugBank.d289.s30|166-174|substrate|O
DDI-DrugBank.d289.s30|175-175|)|O
DDI-DrugBank.d289.s30|177-178|by|O
DDI-DrugBank.d289.s30|180-181|29|O
DDI-DrugBank.d289.s30|183-185|and|O
DDI-DrugBank.d289.s30|187-188|38|O
DDI-DrugBank.d289.s30|189-189|%|O
DDI-DrugBank.d289.s30|190-190|,|O
DDI-DrugBank.d289.s30|192-203|respectively|O
DDI-DrugBank.d289.s30|204-204|.|O
DDI-DrugBank.d289.s31|0-7|Clinical|O
DDI-DrugBank.d289.s31|9-18|experience|O
DDI-DrugBank.d289.s31|20-23|with|O
DDI-DrugBank.d289.s31|25-35|concomitant|O
DDI-DrugBank.d289.s31|37-50|administration|O
DDI-DrugBank.d289.s31|52-53|of|O
DDI-DrugBank.d289.s31|55-62|bosentan|drug
DDI-DrugBank.d289.s31|64-66|and|O
DDI-DrugBank.d289.s31|68-75|warfarin|drug
DDI-DrugBank.d289.s31|77-78|in|O
DDI-DrugBank.d289.s31|80-87|patients|O
DDI-DrugBank.d289.s31|89-92|with|O
DDI-DrugBank.d289.s31|94-102|pulmonary|O
DDI-DrugBank.d289.s31|104-111|arterial|O
DDI-DrugBank.d289.s31|113-124|hypertension|O
DDI-DrugBank.d289.s31|126-128|did|O
DDI-DrugBank.d289.s31|130-132|not|O
DDI-DrugBank.d289.s31|134-137|show|O
DDI-DrugBank.d289.s31|139-148|clinically|O
DDI-DrugBank.d289.s31|150-157|relevant|O
DDI-DrugBank.d289.s31|159-165|changes|O
DDI-DrugBank.d289.s31|167-168|in|O
DDI-DrugBank.d289.s31|170-172|INR|O
DDI-DrugBank.d289.s31|174-175|or|O
DDI-DrugBank.d289.s31|177-184|warfarin|drug
DDI-DrugBank.d289.s31|186-189|dose|O
DDI-DrugBank.d289.s31|191-191|(|O
DDI-DrugBank.d289.s31|192-199|baseline|O
DDI-DrugBank.d289.s31|201-203|vs.|O
DDI-DrugBank.d289.s31|205-207|end|O
DDI-DrugBank.d289.s31|209-210|of|O
DDI-DrugBank.d289.s31|212-214|the|O
DDI-DrugBank.d289.s31|216-223|clinical|O
DDI-DrugBank.d289.s31|225-231|studies|O
DDI-DrugBank.d289.s31|232-232|)|O
DDI-DrugBank.d289.s31|233-233|,|O
DDI-DrugBank.d289.s31|235-237|and|O
DDI-DrugBank.d289.s31|239-241|the|O
DDI-DrugBank.d289.s31|243-246|need|O
DDI-DrugBank.d289.s31|248-249|to|O
DDI-DrugBank.d289.s31|251-256|change|O
DDI-DrugBank.d289.s31|258-260|the|O
DDI-DrugBank.d289.s31|262-269|warfarin|drug
DDI-DrugBank.d289.s31|271-274|dose|O
DDI-DrugBank.d289.s31|276-281|during|O
DDI-DrugBank.d289.s31|283-285|the|O
DDI-DrugBank.d289.s31|287-292|trials|O
DDI-DrugBank.d289.s31|294-296|due|O
DDI-DrugBank.d289.s31|298-299|to|O
DDI-DrugBank.d289.s31|301-307|changes|O
DDI-DrugBank.d289.s31|309-310|in|O
DDI-DrugBank.d289.s31|312-314|INR|O
DDI-DrugBank.d289.s31|316-317|or|O
DDI-DrugBank.d289.s31|319-321|due|O
DDI-DrugBank.d289.s31|323-324|to|O
DDI-DrugBank.d289.s31|326-332|adverse|O
DDI-DrugBank.d289.s31|334-339|events|O
DDI-DrugBank.d289.s31|341-343|was|O
DDI-DrugBank.d289.s31|345-351|similar|O
DDI-DrugBank.d289.s31|353-357|among|O
DDI-DrugBank.d289.s31|359-367|bosentan-|drug
DDI-DrugBank.d289.s31|369-371|and|O
DDI-DrugBank.d289.s31|373-387|placebo-treated|O
DDI-DrugBank.d289.s31|389-396|patients|O
DDI-DrugBank.d289.s31|397-397|.|O
DDI-DrugBank.d289.s32|0-6|Digoxin|drug
DDI-DrugBank.d289.s32|7-7|,|O
DDI-DrugBank.d289.s32|9-18|Nimodipine|drug
DDI-DrugBank.d289.s32|20-22|and|O
DDI-DrugBank.d289.s32|24-31|Losartan|drug
DDI-DrugBank.d289.s32|32-32|:|O
DDI-DrugBank.d289.s32|34-41|Bosentan|drug
DDI-DrugBank.d289.s32|43-45|has|O
DDI-DrugBank.d289.s32|47-48|no|O
DDI-DrugBank.d289.s32|50-60|significant|O
DDI-DrugBank.d289.s32|62-76|pharmacokinetic|O
DDI-DrugBank.d289.s32|78-89|interactions|O
DDI-DrugBank.d289.s32|91-94|with|O
DDI-DrugBank.d289.s32|96-102|digoxin|drug
DDI-DrugBank.d289.s32|104-106|and|O
DDI-DrugBank.d289.s32|108-117|nimodipine|drug
DDI-DrugBank.d289.s32|118-118|,|O
DDI-DrugBank.d289.s32|120-122|and|O
DDI-DrugBank.d289.s32|124-131|losartan|drug
DDI-DrugBank.d289.s32|133-135|has|O
DDI-DrugBank.d289.s32|137-138|no|O
DDI-DrugBank.d289.s32|140-150|significant|O
DDI-DrugBank.d289.s32|152-157|effect|O
DDI-DrugBank.d289.s32|159-160|on|O
DDI-DrugBank.d289.s32|162-167|plasma|O
DDI-DrugBank.d289.s32|169-174|levels|O
DDI-DrugBank.d289.s32|176-177|of|O
DDI-DrugBank.d289.s32|179-186|bosentan|drug
DDI-DrugBank.d289.s32|187-187|.|O
DDI-DrugBank.d577.s0|0-1|In|O
DDI-DrugBank.d577.s0|3-9|elderly|O
DDI-DrugBank.d577.s0|11-18|patients|O
DDI-DrugBank.d577.s0|20-31|concurrently|O
DDI-DrugBank.d577.s0|33-41|receiving|O
DDI-DrugBank.d577.s0|43-49|certain|O
DDI-DrugBank.d577.s0|51-59|diuretics|group
DDI-DrugBank.d577.s0|60-60|,|O
DDI-DrugBank.d577.s0|62-70|primarily|O
DDI-DrugBank.d577.s0|72-80|thiazides|group
DDI-DrugBank.d577.s0|81-81|,|O
DDI-DrugBank.d577.s0|83-84|an|O
DDI-DrugBank.d577.s0|86-94|increased|O
DDI-DrugBank.d577.s0|96-104|incidence|O
DDI-DrugBank.d577.s0|106-107|of|O
DDI-DrugBank.d577.s0|109-120|thrombopenia|O
DDI-DrugBank.d577.s0|122-125|with|O
DDI-DrugBank.d577.s0|127-133|purpura|O
DDI-DrugBank.d577.s0|135-137|has|O
DDI-DrugBank.d577.s0|139-142|been|O
DDI-DrugBank.d577.s0|144-151|reported|O
DDI-DrugBank.d577.s0|152-152|.|O
DDI-DrugBank.d577.s1|0-1|It|O
DDI-DrugBank.d577.s1|3-5|has|O
DDI-DrugBank.d577.s1|7-10|been|O
DDI-DrugBank.d577.s1|12-19|reported|O
DDI-DrugBank.d577.s1|21-24|that|O
DDI-DrugBank.d577.s1|26-41|sulfamethoxazole|drug
DDI-DrugBank.d577.s1|43-45|may|O
DDI-DrugBank.d577.s1|47-53|prolong|O
DDI-DrugBank.d577.s1|55-57|the|O
DDI-DrugBank.d577.s1|59-69|prothrombin|O
DDI-DrugBank.d577.s1|71-74|time|O
DDI-DrugBank.d577.s1|76-77|in|O
DDI-DrugBank.d577.s1|79-86|patients|O
DDI-DrugBank.d577.s1|88-90|who|O
DDI-DrugBank.d577.s1|92-94|are|O
DDI-DrugBank.d577.s1|96-104|receiving|O
DDI-DrugBank.d577.s1|106-108|the|O
DDI-DrugBank.d577.s1|110-122|anticoagulant|group
DDI-DrugBank.d577.s1|110-122|anticoagulant|group
DDI-DrugBank.d577.s1|132-132|.|O
DDI-DrugBank.d577.s2|0-3|This|O
DDI-DrugBank.d577.s2|5-15|interaction|O
DDI-DrugBank.d577.s2|17-22|should|O
DDI-DrugBank.d577.s2|24-25|be|O
DDI-DrugBank.d577.s2|27-30|kept|O
DDI-DrugBank.d577.s2|32-33|in|O
DDI-DrugBank.d577.s2|35-38|mind|O
DDI-DrugBank.d577.s2|40-43|when|O
DDI-DrugBank.d577.s2|45-52|Gantanol|brand
DDI-DrugBank.d577.s2|54-55|is|O
DDI-DrugBank.d577.s2|57-61|given|O
DDI-DrugBank.d577.s2|63-64|to|O
DDI-DrugBank.d577.s2|66-73|patients|O
DDI-DrugBank.d577.s2|75-81|already|O
DDI-DrugBank.d577.s2|83-84|on|O
DDI-DrugBank.d577.s2|86-98|anticoagulant|O
DDI-DrugBank.d577.s2|100-106|therapy|O
DDI-DrugBank.d577.s2|107-107|,|O
DDI-DrugBank.d577.s2|109-111|and|O
DDI-DrugBank.d577.s2|113-115|the|O
DDI-DrugBank.d577.s2|117-127|coagulation|O
DDI-DrugBank.d577.s2|129-132|time|O
DDI-DrugBank.d577.s2|134-139|should|O
DDI-DrugBank.d577.s2|141-142|be|O
DDI-DrugBank.d577.s2|144-153|reassessed|O
DDI-DrugBank.d577.s2|154-154|.|O
DDI-DrugBank.d577.s3|0-15|Sulfamethoxazole|drug
DDI-DrugBank.d577.s3|17-19|may|O
DDI-DrugBank.d577.s3|21-27|inhibit|O
DDI-DrugBank.d577.s3|29-31|the|O
DDI-DrugBank.d577.s3|33-39|hepatic|O
DDI-DrugBank.d577.s3|41-50|metabolism|O
DDI-DrugBank.d577.s3|52-53|of|O
DDI-DrugBank.d577.s3|55-63|phenytoin|drug
DDI-DrugBank.d577.s3|64-64|.|O
DDI-DrugBank.d577.s4|0-1|At|O
DDI-DrugBank.d577.s4|3-3|a|O
DDI-DrugBank.d577.s4|5-9|1.6-g|O
DDI-DrugBank.d577.s4|11-14|dose|O
DDI-DrugBank.d577.s4|15-15|,|O
DDI-DrugBank.d577.s4|17-32|sulfamethoxazole|drug
DDI-DrugBank.d577.s4|34-41|produced|O
DDI-DrugBank.d577.s4|43-43|a|O
DDI-DrugBank.d577.s4|45-50|slight|O
DDI-DrugBank.d577.s4|52-54|but|O
DDI-DrugBank.d577.s4|56-66|significant|O
DDI-DrugBank.d577.s4|68-75|increase|O
DDI-DrugBank.d577.s4|77-78|in|O
DDI-DrugBank.d577.s4|80-82|the|O
DDI-DrugBank.d577.s4|84-92|half-life|O
DDI-DrugBank.d577.s4|94-95|of|O
DDI-DrugBank.d577.s4|97-105|phenytoin|drug
DDI-DrugBank.d577.s4|107-109|but|O
DDI-DrugBank.d577.s4|111-113|did|O
DDI-DrugBank.d577.s4|115-117|not|O
DDI-DrugBank.d577.s4|119-125|produce|O
DDI-DrugBank.d577.s4|127-127|a|O
DDI-DrugBank.d577.s4|129-141|corresponding|O
DDI-DrugBank.d577.s4|143-150|decrease|O
DDI-DrugBank.d577.s4|152-153|in|O
DDI-DrugBank.d577.s4|155-157|the|O
DDI-DrugBank.d577.s4|159-167|metabolic|O
DDI-DrugBank.d577.s4|169-177|clearance|O
DDI-DrugBank.d577.s4|179-182|rate|O
DDI-DrugBank.d577.s4|183-183|.|O
DDI-DrugBank.d577.s5|0-3|When|O
DDI-DrugBank.d577.s5|5-17|administering|O
DDI-DrugBank.d577.s5|19-23|these|O
DDI-DrugBank.d577.s5|25-29|drugs|O
DDI-DrugBank.d577.s5|31-42|concurrently|O
DDI-DrugBank.d577.s5|43-43|,|O
DDI-DrugBank.d577.s5|45-47|one|O
DDI-DrugBank.d577.s5|49-54|should|O
DDI-DrugBank.d577.s5|56-57|be|O
DDI-DrugBank.d577.s5|59-63|alert|O
DDI-DrugBank.d577.s5|65-67|for|O
DDI-DrugBank.d577.s5|69-76|possible|O
DDI-DrugBank.d577.s5|78-86|excessive|O
DDI-DrugBank.d577.s5|88-96|phenytoin|drug
DDI-DrugBank.d577.s5|98-103|effect|O
DDI-DrugBank.d577.s5|104-104|.|O
DDI-DrugBank.d577.s6|0-11|Sulfonamides|group
DDI-DrugBank.d577.s6|13-15|can|O
DDI-DrugBank.d577.s6|17-20|also|O
DDI-DrugBank.d577.s6|22-29|displace|O
DDI-DrugBank.d577.s6|31-42|methotrexate|drug
DDI-DrugBank.d577.s6|44-47|from|O
DDI-DrugBank.d577.s6|49-54|plasma|O
DDI-DrugBank.d577.s6|56-70|protein-binding|O
DDI-DrugBank.d577.s6|72-76|sites|O
DDI-DrugBank.d577.s6|77-77|,|O
DDI-DrugBank.d577.s6|79-82|thus|O
DDI-DrugBank.d577.s6|84-93|increasing|O
DDI-DrugBank.d577.s6|95-98|free|O
DDI-DrugBank.d577.s6|100-111|methotrexate|drug
DDI-DrugBank.d577.s6|113-126|concentrations|O
DDI-DrugBank.d577.s6|127-127|.|O
DDI-DrugBank.d577.s7|0-2|The|O
DDI-DrugBank.d577.s7|4-11|presence|O
DDI-DrugBank.d577.s7|13-14|of|O
DDI-DrugBank.d577.s7|16-31|sulfamethoxazole|drug
DDI-DrugBank.d577.s7|33-35|may|O
DDI-DrugBank.d577.s7|37-45|interfere|O
DDI-DrugBank.d577.s7|47-50|with|O
DDI-DrugBank.d577.s7|52-54|the|O
DDI-DrugBank.d577.s7|56-59|Jaff|O
DDI-DrugBank.d577.s7|64-71|alkaline|O
DDI-DrugBank.d577.s7|73-79|picrate|O
DDI-DrugBank.d577.s7|81-88|reaction|O
DDI-DrugBank.d577.s7|90-94|assay|O
DDI-DrugBank.d577.s7|96-98|for|O
DDI-DrugBank.d577.s7|100-109|creatinine|O
DDI-DrugBank.d577.s7|110-110|,|O
DDI-DrugBank.d577.s7|112-120|resulting|O
DDI-DrugBank.d577.s7|122-123|in|O
DDI-DrugBank.d577.s7|125-139|overestimations|O
DDI-DrugBank.d577.s7|141-142|of|O
DDI-DrugBank.d577.s7|144-148|about|O
DDI-DrugBank.d577.s7|150-151|10|O
DDI-DrugBank.d577.s7|152-152|%|O
DDI-DrugBank.d577.s7|154-155|in|O
DDI-DrugBank.d577.s7|157-159|the|O
DDI-DrugBank.d577.s7|161-165|range|O
DDI-DrugBank.d577.s7|167-168|of|O
DDI-DrugBank.d577.s7|170-175|normal|O
DDI-DrugBank.d577.s7|177-182|values|O
DDI-DrugBank.d577.s7|183-183|.|O
DDI-MedLine.d36.s0|0-12|Carbamazepine|drug
DDI-MedLine.d36.s0|14-21|overdose|O
DDI-MedLine.d36.s0|23-32|recognized|O
DDI-MedLine.d36.s0|34-35|by|O
DDI-MedLine.d36.s0|37-37|a|O
DDI-MedLine.d36.s0|39-62|tricyclic antidepressant|group
DDI-MedLine.d36.s0|64-68|assay|O
DDI-MedLine.d36.s0|69-69|.|O
DDI-MedLine.d36.s1|0-6|Altered|O
DDI-MedLine.d36.s1|8-13|mental|O
DDI-MedLine.d36.s1|15-20|status|O
DDI-MedLine.d36.s1|22-23|in|O
DDI-MedLine.d36.s1|25-26|an|O
DDI-MedLine.d36.s1|28-37|adolescent|O
DDI-MedLine.d36.s1|39-46|presents|O
DDI-MedLine.d36.s1|48-48|a|O
DDI-MedLine.d36.s1|50-59|diagnostic|O
DDI-MedLine.d36.s1|61-69|challenge|O
DDI-MedLine.d36.s1|70-70|,|O
DDI-MedLine.d36.s1|72-74|and|O
DDI-MedLine.d36.s1|76-78|the|O
DDI-MedLine.d36.s1|80-88|clinician|O
DDI-MedLine.d36.s1|90-96|depends|O
DDI-MedLine.d36.s1|98-99|on|O
DDI-MedLine.d36.s1|101-108|clinical|O
DDI-MedLine.d36.s1|110-119|evaluation|O
DDI-MedLine.d36.s1|121-123|and|O
DDI-MedLine.d36.s1|125-134|laboratory|O
DDI-MedLine.d36.s1|136-142|studies|O
DDI-MedLine.d36.s1|144-145|to|O
DDI-MedLine.d36.s1|147-155|determine|O
DDI-MedLine.d36.s1|157-163|therapy|O
DDI-MedLine.d36.s1|165-167|and|O
DDI-MedLine.d36.s1|169-177|prognosis|O
DDI-MedLine.d36.s1|178-178|.|O
DDI-MedLine.d36.s2|0-1|We|O
DDI-MedLine.d36.s2|3-8|report|O
DDI-MedLine.d36.s2|10-12|the|O
DDI-MedLine.d36.s2|14-17|case|O
DDI-MedLine.d36.s2|19-20|of|O
DDI-MedLine.d36.s2|22-23|an|O
DDI-MedLine.d36.s2|25-34|adolescent|O
DDI-MedLine.d36.s2|36-39|with|O
DDI-MedLine.d36.s2|41-47|altered|O
DDI-MedLine.d36.s2|49-61|consciousness|O
DDI-MedLine.d36.s2|63-68|caused|O
DDI-MedLine.d36.s2|70-71|by|O
DDI-MedLine.d36.s2|73-85|carbamazepine|drug
DDI-MedLine.d36.s2|87-94|overdose|O
DDI-MedLine.d36.s2|96-99|with|O
DDI-MedLine.d36.s2|101-101|a|O
DDI-MedLine.d36.s2|103-110|positive|O
DDI-MedLine.d36.s2|112-135|tricyclic antidepressant|group
DDI-MedLine.d36.s2|137-141|level|O
DDI-MedLine.d36.s2|143-144|to|O
DDI-MedLine.d36.s2|146-150|alert|O
DDI-MedLine.d36.s2|152-161|clinicians|O
DDI-MedLine.d36.s2|163-164|to|O
DDI-MedLine.d36.s2|166-168|the|O
DDI-MedLine.d36.s2|170-185|cross-reactivity|O
DDI-MedLine.d36.s2|187-188|of|O
DDI-MedLine.d36.s2|190-202|carbamazepine|drug
DDI-MedLine.d36.s2|204-207|with|O
DDI-MedLine.d36.s2|209-209|a|O
DDI-MedLine.d36.s2|211-220|toxicology|O
DDI-MedLine.d36.s2|222-227|screen|O
DDI-MedLine.d36.s2|229-231|for|O
DDI-MedLine.d36.s2|233-257|tricyclic antidepressants|group
DDI-MedLine.d36.s2|258-258|.|O
DDI-MedLine.d4.s0|0-0|[|O
DDI-MedLine.d4.s0|1-3|The|O
DDI-MedLine.d4.s0|5-10|effect|O
DDI-MedLine.d4.s0|12-13|of|O
DDI-MedLine.d4.s0|15-24|sandimmune|brand
DDI-MedLine.d4.s0|26-27|on|O
DDI-MedLine.d4.s0|29-31|the|O
DDI-MedLine.d4.s0|33-40|activity|O
DDI-MedLine.d4.s0|42-43|of|O
DDI-MedLine.d4.s0|45-58|mixed-function|O
DDI-MedLine.d4.s0|60-72|mono-oxidases|O
DDI-MedLine.d4.s0|74-75|in|O
DDI-MedLine.d4.s0|77-79|the|O
DDI-MedLine.d4.s0|81-85|liver|O
DDI-MedLine.d4.s0|87-96|microsomes|O
DDI-MedLine.d4.s0|97-97|]|O
DDI-MedLine.d4.s0|100-102|The|O
DDI-MedLine.d4.s0|104-110|effects|O
DDI-MedLine.d4.s0|112-113|of|O
DDI-MedLine.d4.s0|115-117|the|O
DDI-MedLine.d4.s0|119-134|immunodepressant|group
DDI-MedLine.d4.s0|135-136|--|O
DDI-MedLine.d4.s0|137-139|the|O
DDI-MedLine.d4.s0|141-144|drug|O
DDI-MedLine.d4.s0|146-155|sandimmune|brand
DDI-MedLine.d4.s0|156-157|--|O
DDI-MedLine.d4.s0|158-159|on|O
DDI-MedLine.d4.s0|161-167|hepatic|O
DDI-MedLine.d4.s0|169-178|microsomal|O
DDI-MedLine.d4.s0|180-192|monooxygenase|O
DDI-MedLine.d4.s0|194-203|activities|O
DDI-MedLine.d4.s0|205-208|were|O
DDI-MedLine.d4.s0|210-216|studied|O
DDI-MedLine.d4.s0|217-217|.|O
DDI-MedLine.d4.s1|0-2|The|O
DDI-MedLine.d4.s1|4-8|agent|O
DDI-MedLine.d4.s1|10-12|was|O
DDI-MedLine.d4.s1|14-18|found|O
DDI-MedLine.d4.s1|20-21|to|O
DDI-MedLine.d4.s1|23-29|produce|O
DDI-MedLine.d4.s1|31-34|some|O
DDI-MedLine.d4.s1|36-45|inhibiting|O
DDI-MedLine.d4.s1|47-54|activity|O
DDI-MedLine.d4.s1|56-62|against|O
DDI-MedLine.d4.s1|64-70|hepatic|O
DDI-MedLine.d4.s1|72-81|microsomal|O
DDI-MedLine.d4.s1|83-99|7-ethoxycoumarine|O
DDI-MedLine.d4.s1|101-110|deethylase|O
DDI-MedLine.d4.s1|112-113|in|O
DDI-MedLine.d4.s1|115-118|male|O
DDI-MedLine.d4.s1|120-125|Wistar|O
DDI-MedLine.d4.s1|127-130|rats|O
DDI-MedLine.d4.s1|132-133|in|O
DDI-MedLine.d4.s1|135-139|vitro|O
DDI-MedLine.d4.s1|141-143|and|O
DDI-MedLine.d4.s1|145-146|in|O
DDI-MedLine.d4.s1|148-151|vivo|O
DDI-MedLine.d4.s1|153-163|experiments|O
DDI-MedLine.d4.s1|164-164|.|O
DDI-MedLine.d4.s2|0-3|When|O
DDI-MedLine.d4.s2|5-9|given|O
DDI-MedLine.d4.s2|11-12|in|O
DDI-MedLine.d4.s2|14-14|a|O
DDI-MedLine.d4.s2|16-19|dose|O
DDI-MedLine.d4.s2|21-22|of|O
DDI-MedLine.d4.s2|24-25|50|O
DDI-MedLine.d4.s2|27-31|mg/kg|O
DDI-MedLine.d4.s2|32-32|,|O
DDI-MedLine.d4.s2|34-43|sandimmune|brand
DDI-MedLine.d4.s2|45-52|produced|O
DDI-MedLine.d4.s2|54-55|no|O
DDI-MedLine.d4.s2|57-69|statistically|O
DDI-MedLine.d4.s2|71-81|significant|O
DDI-MedLine.d4.s2|83-88|effect|O
DDI-MedLine.d4.s2|90-91|on|O
DDI-MedLine.d4.s2|93-95|the|O
DDI-MedLine.d4.s2|97-104|duration|O
DDI-MedLine.d4.s2|106-107|of|O
DDI-MedLine.d4.s2|109-123|hexanal-induced|O
DDI-MedLine.d4.s2|125-129|sleep|O
DDI-MedLine.d4.s2|131-132|in|O
DDI-MedLine.d4.s2|134-137|mice|O
DDI-MedLine.d4.s2|138-138|.|O
DDI-MedLine.d4.s3|0-2|The|O
DDI-MedLine.d4.s3|4-11|findings|O
DDI-MedLine.d4.s3|13-19|suggest|O
DDI-MedLine.d4.s3|21-24|that|O
DDI-MedLine.d4.s3|26-28|the|O
DDI-MedLine.d4.s3|30-34|agent|O
DDI-MedLine.d4.s3|36-38|has|O
DDI-MedLine.d4.s3|40-45|slight|O
DDI-MedLine.d4.s3|47-53|effects|O
DDI-MedLine.d4.s3|55-56|on|O
DDI-MedLine.d4.s3|58-60|the|O
DDI-MedLine.d4.s3|62-67|tested|O
DDI-MedLine.d4.s3|69-78|activities|O
DDI-MedLine.d4.s3|79-79|.|O
DDI-DrugBank.d239.s0|0-1|No|O
DDI-DrugBank.d239.s0|3-8|trials|O
DDI-DrugBank.d239.s0|10-21|specifically|O
DDI-DrugBank.d239.s0|23-31|examining|O
DDI-DrugBank.d239.s0|33-41|potential|O
DDI-DrugBank.d239.s0|43-46|drug|O
DDI-DrugBank.d239.s0|48-59|interactions|O
DDI-DrugBank.d239.s0|61-64|with|O
DDI-DrugBank.d239.s0|66-73|Natrecor|brand
DDI-DrugBank.d239.s0|75-78|were|O
DDI-DrugBank.d239.s0|80-88|conducted|O
DDI-DrugBank.d239.s0|89-89|,|O
DDI-DrugBank.d239.s0|91-98|although|O
DDI-DrugBank.d239.s0|100-103|many|O
DDI-DrugBank.d239.s0|105-115|concomitant|O
DDI-DrugBank.d239.s0|117-121|drugs|O
DDI-DrugBank.d239.s0|123-126|were|O
DDI-DrugBank.d239.s0|128-131|used|O
DDI-DrugBank.d239.s0|133-134|in|O
DDI-DrugBank.d239.s0|136-143|clinical|O
DDI-DrugBank.d239.s0|145-150|trials|O
DDI-DrugBank.d239.s0|151-151|.|O
DDI-DrugBank.d239.s1|0-1|No|O
DDI-DrugBank.d239.s1|3-6|drug|O
DDI-DrugBank.d239.s1|8-19|interactions|O
DDI-DrugBank.d239.s1|21-24|were|O
DDI-DrugBank.d239.s1|26-33|detected|O
DDI-DrugBank.d239.s1|35-40|except|O
DDI-DrugBank.d239.s1|42-44|for|O
DDI-DrugBank.d239.s1|46-47|an|O
DDI-DrugBank.d239.s1|49-56|increase|O
DDI-DrugBank.d239.s1|58-59|in|O
DDI-DrugBank.d239.s1|61-71|symptomatic|O
DDI-DrugBank.d239.s1|73-83|hypotension|O
DDI-DrugBank.d239.s1|85-86|in|O
DDI-DrugBank.d239.s1|88-95|patients|O
DDI-DrugBank.d239.s1|97-105|receiving|O
DDI-DrugBank.d239.s1|107-110|oral|O
DDI-DrugBank.d239.s1|112-125|ACE inhibitors|group
DDI-DrugBank.d239.s1|126-126|.|O
DDI-DrugBank.d239.s2|0-2|The|O
DDI-DrugBank.d239.s2|4-20|co-administration|O
DDI-DrugBank.d239.s2|22-23|of|O
DDI-DrugBank.d239.s2|25-32|Natrecor|brand
DDI-DrugBank.d239.s2|34-37|with|O
DDI-DrugBank.d239.s2|39-40|IV|O
DDI-DrugBank.d239.s2|42-53|vasodilators|group
DDI-DrugBank.d239.s2|55-58|such|O
DDI-DrugBank.d239.s2|60-61|as|O
DDI-DrugBank.d239.s2|63-75|nitroglycerin|drug
DDI-DrugBank.d239.s2|76-76|,|O
DDI-DrugBank.d239.s2|78-90|nitroprusside|drug
DDI-DrugBank.d239.s2|91-91|,|O
DDI-DrugBank.d239.s2|93-101|milrinone|drug
DDI-DrugBank.d239.s2|102-102|,|O
DDI-DrugBank.d239.s2|104-105|or|O
DDI-DrugBank.d239.s2|107-108|IV|O
DDI-DrugBank.d239.s2|110-123|ACE inhibitors|group
DDI-DrugBank.d239.s2|125-127|has|O
DDI-DrugBank.d239.s2|129-131|not|O
DDI-DrugBank.d239.s2|133-136|been|O
DDI-DrugBank.d239.s2|138-146|evaluated|O
DDI-DrugBank.d239.s2|148-148|(|O
DDI-DrugBank.d239.s2|149-153|these|O
DDI-DrugBank.d239.s2|155-159|drugs|O
DDI-DrugBank.d239.s2|161-164|were|O
DDI-DrugBank.d239.s2|166-168|not|O
DDI-DrugBank.d239.s2|170-184|co-administered|O
DDI-DrugBank.d239.s2|186-189|with|O
DDI-DrugBank.d239.s2|191-198|Natrecor|brand
DDI-DrugBank.d239.s2|200-201|in|O
DDI-DrugBank.d239.s2|203-210|clinical|O
DDI-DrugBank.d239.s2|212-217|trials|O
DDI-DrugBank.d239.s2|218-218|)|O
DDI-DrugBank.d239.s2|219-219|.|O
DDI-DrugBank.d656.s0|0-6|FELDENE|brand
DDI-DrugBank.d656.s0|8-9|is|O
DDI-DrugBank.d656.s0|11-16|highly|O
DDI-DrugBank.d656.s0|18-24|protein|O
DDI-DrugBank.d656.s0|26-30|bound|O
DDI-DrugBank.d656.s0|31-31|,|O
DDI-DrugBank.d656.s0|33-35|and|O
DDI-DrugBank.d656.s0|37-45|therefore|O
DDI-DrugBank.d656.s0|46-46|,|O
DDI-DrugBank.d656.s0|48-52|might|O
DDI-DrugBank.d656.s0|54-55|be|O
DDI-DrugBank.d656.s0|57-64|expected|O
DDI-DrugBank.d656.s0|66-67|to|O
DDI-DrugBank.d656.s0|69-76|displace|O
DDI-DrugBank.d656.s0|78-82|other|O
DDI-DrugBank.d656.s0|84-96|protein-bound|O
DDI-DrugBank.d656.s0|98-102|drugs|O
DDI-DrugBank.d656.s0|103-103|.|O
DDI-DrugBank.d656.s1|0-7|Although|O
DDI-DrugBank.d656.s1|9-12|this|O
DDI-DrugBank.d656.s1|14-16|has|O
DDI-DrugBank.d656.s1|18-20|not|O
DDI-DrugBank.d656.s1|22-29|occurred|O
DDI-DrugBank.d656.s1|31-32|in|O
DDI-DrugBank.d656.s1|34-35|in|O
DDI-DrugBank.d656.s1|37-41|vitro|O
DDI-DrugBank.d656.s1|43-49|studies|O
DDI-DrugBank.d656.s1|51-54|with|O
DDI-DrugBank.d656.s1|56-83|coumarin-type anticoagulants|group
DDI-DrugBank.d656.s1|84-84|,|O
DDI-DrugBank.d656.s1|86-97|interactions|O
DDI-DrugBank.d656.s1|99-102|with|O
DDI-DrugBank.d656.s1|104-131|coumarin-type anticoagulants|group
DDI-DrugBank.d656.s1|133-136|have|O
DDI-DrugBank.d656.s1|138-141|been|O
DDI-DrugBank.d656.s1|143-150|reported|O
DDI-DrugBank.d656.s1|152-155|with|O
DDI-DrugBank.d656.s1|157-163|FELDENE|brand
DDI-DrugBank.d656.s1|165-169|since|O
DDI-DrugBank.d656.s1|171-179|marketing|O
DDI-DrugBank.d656.s1|180-180|,|O
DDI-DrugBank.d656.s1|182-190|therefore|O
DDI-DrugBank.d656.s1|191-191|,|O
DDI-DrugBank.d656.s1|193-202|physicians|O
DDI-DrugBank.d656.s1|204-209|should|O
DDI-DrugBank.d656.s1|211-217|closely|O
DDI-DrugBank.d656.s1|219-225|monitor|O
DDI-DrugBank.d656.s1|227-234|patients|O
DDI-DrugBank.d656.s1|236-238|for|O
DDI-DrugBank.d656.s1|240-240|a|O
DDI-DrugBank.d656.s1|242-247|change|O
DDI-DrugBank.d656.s1|249-250|in|O
DDI-DrugBank.d656.s1|252-257|dosage|O
DDI-DrugBank.d656.s1|259-270|requirements|O
DDI-DrugBank.d656.s1|272-275|when|O
DDI-DrugBank.d656.s1|277-289|administering|O
DDI-DrugBank.d656.s1|291-297|FELDENE|brand
DDI-DrugBank.d656.s1|299-300|to|O
DDI-DrugBank.d656.s1|302-309|patients|O
DDI-DrugBank.d656.s1|311-312|on|O
DDI-DrugBank.d656.s1|314-341|coumarin-type anticoagulants|group
DDI-DrugBank.d656.s1|343-345|and|O
DDI-DrugBank.d656.s1|347-351|other|O
DDI-DrugBank.d656.s1|353-358|highly|O
DDI-DrugBank.d656.s1|360-372|protein-bound|O
DDI-DrugBank.d656.s1|374-378|drugs|O
DDI-DrugBank.d656.s1|379-379|.|O
DDI-DrugBank.d656.s2|0-5|Plasma|O
DDI-DrugBank.d656.s2|7-12|levels|O
DDI-DrugBank.d656.s2|14-15|of|O
DDI-DrugBank.d656.s2|17-25|piroxicam|drug
DDI-DrugBank.d656.s2|27-29|are|O
DDI-DrugBank.d656.s2|31-39|depressed|O
DDI-DrugBank.d656.s2|41-42|to|O
DDI-DrugBank.d656.s2|44-56|approximately|O
DDI-DrugBank.d656.s2|58-59|80|O
DDI-DrugBank.d656.s2|60-60|%|O
DDI-DrugBank.d656.s2|62-63|of|O
DDI-DrugBank.d656.s2|65-69|their|O
DDI-DrugBank.d656.s2|71-76|normal|O
DDI-DrugBank.d656.s2|78-83|values|O
DDI-DrugBank.d656.s2|85-88|when|O
DDI-DrugBank.d656.s2|90-96|FELDENE|brand
DDI-DrugBank.d656.s2|98-99|is|O
DDI-DrugBank.d656.s2|101-112|administered|O
DDI-DrugBank.d656.s2|114-115|in|O
DDI-DrugBank.d656.s2|117-127|conjunction|O
DDI-DrugBank.d656.s2|129-132|with|O
DDI-DrugBank.d656.s2|134-140|aspirin|brand
DDI-DrugBank.d656.s2|142-142|(|O
DDI-DrugBank.d656.s2|143-146|3900|O
DDI-DrugBank.d656.s2|148-153|mg/day|O
DDI-DrugBank.d656.s2|154-154|)|O
DDI-DrugBank.d656.s2|155-155|,|O
DDI-DrugBank.d656.s2|157-159|but|O
DDI-DrugBank.d656.s2|161-171|concomitant|O
DDI-DrugBank.d656.s2|173-186|administration|O
DDI-DrugBank.d656.s2|188-189|of|O
DDI-DrugBank.d656.s2|191-198|antacids|group
DDI-DrugBank.d656.s2|200-202|has|O
DDI-DrugBank.d656.s2|204-205|no|O
DDI-DrugBank.d656.s2|207-212|effect|O
DDI-DrugBank.d656.s2|214-215|on|O
DDI-DrugBank.d656.s2|217-225|piroxicam|drug
DDI-DrugBank.d656.s2|227-232|plasma|O
DDI-DrugBank.d656.s2|234-239|levels|O
DDI-DrugBank.d656.s2|241-241|.|O
DDI-DrugBank.d656.s2|243-279|Nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d656.s2|280-280|,|O
DDI-DrugBank.d656.s2|282-290|including|O
DDI-DrugBank.d656.s2|292-298|FELDENE|brand
DDI-DrugBank.d656.s2|299-299|,|O
DDI-DrugBank.d656.s2|301-304|have|O
DDI-DrugBank.d656.s2|306-309|been|O
DDI-DrugBank.d656.s2|311-318|reported|O
DDI-DrugBank.d656.s2|320-321|to|O
DDI-DrugBank.d656.s2|323-330|increase|O
DDI-DrugBank.d656.s2|332-337|steady|O
DDI-DrugBank.d656.s2|339-343|state|O
DDI-DrugBank.d656.s2|345-350|plasma|O
DDI-DrugBank.d656.s2|352-358|lithium|drug
DDI-DrugBank.d656.s2|360-365|levels|O
DDI-DrugBank.d656.s2|366-366|.|O
DDI-DrugBank.d656.s3|0-1|It|O
DDI-DrugBank.d656.s3|3-4|is|O
DDI-DrugBank.d656.s3|6-16|recommended|O
DDI-DrugBank.d656.s3|18-21|that|O
DDI-DrugBank.d656.s3|23-28|plasma|O
DDI-DrugBank.d656.s3|30-36|lithium|drug
DDI-DrugBank.d656.s3|38-43|levels|O
DDI-DrugBank.d656.s3|45-46|be|O
DDI-DrugBank.d656.s3|48-56|monitored|O
DDI-DrugBank.d656.s3|58-61|when|O
DDI-DrugBank.d656.s3|63-72|initiating|O
DDI-DrugBank.d656.s3|73-73|,|O
DDI-DrugBank.d656.s3|75-83|adjusting|O
DDI-DrugBank.d656.s3|85-87|and|O
DDI-DrugBank.d656.s3|89-101|discontinuing|O
DDI-DrugBank.d656.s3|103-109|FELDENE|brand
DDI-DrugBank.d656.s3|110-110|.|O
DDI-DrugBank.d5.s0|0-2|Few|O
DDI-DrugBank.d5.s0|4-11|systemic|O
DDI-DrugBank.d5.s0|13-16|data|O
DDI-DrugBank.d5.s0|18-21|have|O
DDI-DrugBank.d5.s0|23-26|been|O
DDI-DrugBank.d5.s0|28-36|collected|O
DDI-DrugBank.d5.s0|38-39|on|O
DDI-DrugBank.d5.s0|41-43|the|O
DDI-DrugBank.d5.s0|45-54|metabolism|O
DDI-DrugBank.d5.s0|56-57|of|O
DDI-DrugBank.d5.s0|59-68|WELLBUTRIN|brand
DDI-DrugBank.d5.s0|70-78|following|O
DDI-DrugBank.d5.s0|80-90|concomitant|O
DDI-DrugBank.d5.s0|92-105|administration|O
DDI-DrugBank.d5.s0|107-110|with|O
DDI-DrugBank.d5.s0|112-116|other|O
DDI-DrugBank.d5.s0|118-122|drugs|O
DDI-DrugBank.d5.s0|124-125|or|O
DDI-DrugBank.d5.s0|126-126|,|O
DDI-DrugBank.d5.s0|128-140|alternatively|O
DDI-DrugBank.d5.s0|141-141|,|O
DDI-DrugBank.d5.s0|143-145|the|O
DDI-DrugBank.d5.s0|147-152|effect|O
DDI-DrugBank.d5.s0|154-155|of|O
DDI-DrugBank.d5.s0|157-167|concomitant|O
DDI-DrugBank.d5.s0|169-182|administration|O
DDI-DrugBank.d5.s0|184-185|of|O
DDI-DrugBank.d5.s0|187-196|WELLBUTRIN|brand
DDI-DrugBank.d5.s0|198-199|on|O
DDI-DrugBank.d5.s0|201-203|the|O
DDI-DrugBank.d5.s0|205-214|metabolism|O
DDI-DrugBank.d5.s0|216-217|of|O
DDI-DrugBank.d5.s0|219-223|other|O
DDI-DrugBank.d5.s0|225-229|drugs|O
DDI-DrugBank.d5.s0|230-230|.|O
DDI-DrugBank.d5.s1|0-6|Because|O
DDI-DrugBank.d5.s1|8-16|bupropion|drug
DDI-DrugBank.d5.s1|18-19|is|O
DDI-DrugBank.d5.s1|21-31|extensively|O
DDI-DrugBank.d5.s1|33-43|metabolized|O
DDI-DrugBank.d5.s1|44-44|,|O
DDI-DrugBank.d5.s1|46-48|the|O
DDI-DrugBank.d5.s1|50-65|coadministration|O
DDI-DrugBank.d5.s1|67-68|of|O
DDI-DrugBank.d5.s1|70-74|other|O
DDI-DrugBank.d5.s1|76-80|drugs|O
DDI-DrugBank.d5.s1|82-84|may|O
DDI-DrugBank.d5.s1|86-91|affect|O
DDI-DrugBank.d5.s1|93-95|its|O
DDI-DrugBank.d5.s1|97-104|clinical|O
DDI-DrugBank.d5.s1|106-113|activity|O
DDI-DrugBank.d5.s1|114-114|.|O
DDI-DrugBank.d5.s2|0-1|In|O
DDI-DrugBank.d5.s2|3-7|vitro|O
DDI-DrugBank.d5.s2|9-15|studies|O
DDI-DrugBank.d5.s2|17-24|indicate|O
DDI-DrugBank.d5.s2|26-29|that|O
DDI-DrugBank.d5.s2|31-39|bupropion|drug
DDI-DrugBank.d5.s2|41-42|is|O
DDI-DrugBank.d5.s2|44-52|primarily|O
DDI-DrugBank.d5.s2|54-64|metabolized|O
DDI-DrugBank.d5.s2|66-67|to|O
DDI-DrugBank.d5.s2|86-87|by|O
DDI-DrugBank.d5.s2|89-91|the|O
DDI-DrugBank.d5.s2|93-98|CYP2B6|O
DDI-DrugBank.d5.s2|100-108|isoenzyme|O
DDI-DrugBank.d5.s2|109-109|.|O
DDI-DrugBank.d5.s3|0-8|Therefore|O
DDI-DrugBank.d5.s3|9-9|,|O
DDI-DrugBank.d5.s3|11-13|the|O
DDI-DrugBank.d5.s3|15-23|potential|O
DDI-DrugBank.d5.s3|25-30|exists|O
DDI-DrugBank.d5.s3|32-34|for|O
DDI-DrugBank.d5.s3|36-36|a|O
DDI-DrugBank.d5.s3|38-41|drug|O
DDI-DrugBank.d5.s3|43-53|interaction|O
DDI-DrugBank.d5.s3|55-61|between|O
DDI-DrugBank.d5.s3|63-72|WELLBUTRIN|brand
DDI-DrugBank.d5.s3|74-76|and|O
DDI-DrugBank.d5.s3|78-82|drugs|O
DDI-DrugBank.d5.s3|84-87|that|O
DDI-DrugBank.d5.s3|89-94|affect|O
DDI-DrugBank.d5.s3|96-98|the|O
DDI-DrugBank.d5.s3|100-105|CYP2B6|O
DDI-DrugBank.d5.s3|107-115|isoenzyme|O
DDI-DrugBank.d5.s3|117-117|(|O
DDI-DrugBank.d5.s3|118-121|e.g.|O
DDI-DrugBank.d5.s3|122-122|,|O
DDI-DrugBank.d5.s3|124-135|orphenadrine|drug
DDI-DrugBank.d5.s3|137-139|and|O
DDI-DrugBank.d5.s3|141-156|cyclophosphamide|drug
DDI-DrugBank.d5.s3|157-157|)|O
DDI-DrugBank.d5.s3|158-158|.|O
DDI-DrugBank.d5.s4|0-2|The|O
DDI-DrugBank.d5.s4|24-33|metabolite|O
DDI-DrugBank.d5.s4|35-36|of|O
DDI-DrugBank.d5.s4|38-46|bupropion|drug
DDI-DrugBank.d5.s4|48-51|does|O
DDI-DrugBank.d5.s4|53-55|not|O
DDI-DrugBank.d5.s4|57-62|appear|O
DDI-DrugBank.d5.s4|64-65|to|O
DDI-DrugBank.d5.s4|67-68|be|O
DDI-DrugBank.d5.s4|70-77|produced|O
DDI-DrugBank.d5.s4|79-80|by|O
DDI-DrugBank.d5.s4|82-84|the|O
DDI-DrugBank.d5.s4|86-95|cytochrome|O
DDI-DrugBank.d5.s4|97-100|P450|O
DDI-DrugBank.d5.s4|102-111|isoenzymes|O
DDI-DrugBank.d5.s4|112-112|.|O
DDI-DrugBank.d5.s5|0-2|The|O
DDI-DrugBank.d5.s5|4-10|effects|O
DDI-DrugBank.d5.s5|12-13|of|O
DDI-DrugBank.d5.s5|15-25|concomitant|O
DDI-DrugBank.d5.s5|27-40|administration|O
DDI-DrugBank.d5.s5|42-43|of|O
DDI-DrugBank.d5.s5|45-54|cimetidine|drug
DDI-DrugBank.d5.s5|56-57|on|O
DDI-DrugBank.d5.s5|59-61|the|O
DDI-DrugBank.d5.s5|63-78|pharmacokinetics|O
DDI-DrugBank.d5.s5|80-81|of|O
DDI-DrugBank.d5.s5|83-91|bupropion|drug
DDI-DrugBank.d5.s5|93-95|and|O
DDI-DrugBank.d5.s5|97-99|its|O
DDI-DrugBank.d5.s5|101-106|active|O
DDI-DrugBank.d5.s5|108-118|metabolites|O
DDI-DrugBank.d5.s5|120-123|were|O
DDI-DrugBank.d5.s5|125-131|studied|O
DDI-DrugBank.d5.s5|133-134|in|O
DDI-DrugBank.d5.s5|136-137|24|O
DDI-DrugBank.d5.s5|139-145|healthy|O
DDI-DrugBank.d5.s5|147-151|young|O
DDI-DrugBank.d5.s5|153-156|male|O
DDI-DrugBank.d5.s5|158-167|volunteers|O
DDI-DrugBank.d5.s5|168-168|.|O
DDI-DrugBank.d5.s6|0-8|Following|O
DDI-DrugBank.d5.s6|10-13|oral|O
DDI-DrugBank.d5.s6|15-28|administration|O
DDI-DrugBank.d5.s6|30-31|of|O
DDI-DrugBank.d5.s6|33-35|two|O
DDI-DrugBank.d5.s6|37-42|150-mg|O
DDI-DrugBank.d5.s6|44-60|sustained-release|O
DDI-DrugBank.d5.s6|62-68|tablets|O
DDI-DrugBank.d5.s6|70-73|with|O
DDI-DrugBank.d5.s6|75-77|and|O
DDI-DrugBank.d5.s6|79-85|without|O
DDI-DrugBank.d5.s6|87-89|800|O
DDI-DrugBank.d5.s6|91-92|mg|O
DDI-DrugBank.d5.s6|94-95|of|O
DDI-DrugBank.d5.s6|97-106|cimetidine|drug
DDI-DrugBank.d5.s6|107-107|,|O
DDI-DrugBank.d5.s6|109-111|the|O
DDI-DrugBank.d5.s6|113-128|pharmacokinetics|O
DDI-DrugBank.d5.s6|130-131|of|O
DDI-DrugBank.d5.s6|133-141|bupropion|drug
DDI-DrugBank.d5.s6|143-145|and|O
DDI-DrugBank.d5.s6|164-167|were|O
DDI-DrugBank.d5.s6|169-178|unaffected|O
DDI-DrugBank.d5.s6|179-179|.|O
DDI-DrugBank.d5.s7|0-6|However|O
DDI-DrugBank.d5.s7|7-7|,|O
DDI-DrugBank.d5.s7|9-13|there|O
DDI-DrugBank.d5.s7|15-18|were|O
DDI-DrugBank.d5.s7|20-21|16|O
DDI-DrugBank.d5.s7|22-22|%|O
DDI-DrugBank.d5.s7|24-26|and|O
DDI-DrugBank.d5.s7|28-29|32|O
DDI-DrugBank.d5.s7|30-30|%|O
DDI-DrugBank.d5.s7|32-40|increases|O
DDI-DrugBank.d5.s7|42-43|in|O
DDI-DrugBank.d5.s7|45-47|the|O
DDI-DrugBank.d5.s7|49-51|AUC|O
DDI-DrugBank.d5.s7|53-55|and|O
DDI-DrugBank.d5.s7|57-60|Cmax|O
DDI-DrugBank.d5.s7|61-61|,|O
DDI-DrugBank.d5.s7|63-74|respectively|O
DDI-DrugBank.d5.s7|75-75|,|O
DDI-DrugBank.d5.s7|77-78|of|O
DDI-DrugBank.d5.s7|80-82|the|O
DDI-DrugBank.d5.s7|84-91|combined|O
DDI-DrugBank.d5.s7|93-100|moieties|O
DDI-DrugBank.d5.s7|102-103|of|O
DDI-DrugBank.d5.s7|125-127|and|O
DDI-DrugBank.d5.s7|150-150|.|O
DDI-DrugBank.d5.s8|0-4|While|O
DDI-DrugBank.d5.s8|6-8|not|O
DDI-DrugBank.d5.s8|10-23|systematically|O
DDI-DrugBank.d5.s8|25-31|studied|O
DDI-DrugBank.d5.s8|32-32|,|O
DDI-DrugBank.d5.s8|34-40|certain|O
DDI-DrugBank.d5.s8|42-46|drugs|O
DDI-DrugBank.d5.s8|48-50|may|O
DDI-DrugBank.d5.s8|52-57|induce|O
DDI-DrugBank.d5.s8|59-61|the|O
DDI-DrugBank.d5.s8|63-72|metabolism|O
DDI-DrugBank.d5.s8|74-75|of|O
DDI-DrugBank.d5.s8|77-85|bupropion|drug
DDI-DrugBank.d5.s8|87-87|(|O
DDI-DrugBank.d5.s8|88-91|e.g.|O
DDI-DrugBank.d5.s8|92-92|,|O
DDI-DrugBank.d5.s8|94-106|carbamazepine|drug
DDI-DrugBank.d5.s8|107-107|,|O
DDI-DrugBank.d5.s8|109-121|phenobarbital|drug
DDI-DrugBank.d5.s8|122-122|,|O
DDI-DrugBank.d5.s8|124-132|phenytoin|drug
DDI-DrugBank.d5.s8|133-133|)|O
DDI-DrugBank.d5.s8|134-134|.|O
DDI-DrugBank.d5.s9|0-5|Animal|O
DDI-DrugBank.d5.s9|7-10|data|O
DDI-DrugBank.d5.s9|12-20|indicated|O
DDI-DrugBank.d5.s9|22-25|that|O
DDI-DrugBank.d5.s9|27-35|bupropion|drug
DDI-DrugBank.d5.s9|37-39|may|O
DDI-DrugBank.d5.s9|41-42|be|O
DDI-DrugBank.d5.s9|44-45|an|O
DDI-DrugBank.d5.s9|47-53|inducer|O
DDI-DrugBank.d5.s9|55-56|of|O
DDI-DrugBank.d5.s9|58-74|drug-metabolizing|O
DDI-DrugBank.d5.s9|76-82|enzymes|O
DDI-DrugBank.d5.s9|84-85|in|O
DDI-DrugBank.d5.s9|87-92|humans|O
DDI-DrugBank.d5.s9|93-93|.|O
DDI-DrugBank.d5.s10|0-1|In|O
DDI-DrugBank.d5.s10|3-5|one|O
DDI-DrugBank.d5.s10|7-11|study|O
DDI-DrugBank.d5.s10|12-12|,|O
DDI-DrugBank.d5.s10|14-22|following|O
DDI-DrugBank.d5.s10|24-30|chronic|O
DDI-DrugBank.d5.s10|32-45|administration|O
DDI-DrugBank.d5.s10|47-48|of|O
DDI-DrugBank.d5.s10|50-58|bupropion|drug
DDI-DrugBank.d5.s10|59-59|,|O
DDI-DrugBank.d5.s10|61-63|100|O
DDI-DrugBank.d5.s10|65-66|mg|O
DDI-DrugBank.d5.s10|68-68|3|O
DDI-DrugBank.d5.s10|70-74|times|O
DDI-DrugBank.d5.s10|76-80|daily|O
DDI-DrugBank.d5.s10|82-83|to|O
DDI-DrugBank.d5.s10|85-85|8|O
DDI-DrugBank.d5.s10|87-93|healthy|O
DDI-DrugBank.d5.s10|95-98|male|O
DDI-DrugBank.d5.s10|100-109|volunteers|O
DDI-DrugBank.d5.s10|111-113|for|O
DDI-DrugBank.d5.s10|115-116|14|O
DDI-DrugBank.d5.s10|118-121|days|O
DDI-DrugBank.d5.s10|122-122|,|O
DDI-DrugBank.d5.s10|124-128|there|O
DDI-DrugBank.d5.s10|130-132|was|O
DDI-DrugBank.d5.s10|134-135|no|O
DDI-DrugBank.d5.s10|137-144|evidence|O
DDI-DrugBank.d5.s10|146-147|of|O
DDI-DrugBank.d5.s10|149-157|induction|O
DDI-DrugBank.d5.s10|159-160|of|O
DDI-DrugBank.d5.s10|162-164|its|O
DDI-DrugBank.d5.s10|166-168|own|O
DDI-DrugBank.d5.s10|170-179|metabolism|O
DDI-DrugBank.d5.s10|180-180|.|O
DDI-DrugBank.d5.s11|0-11|Nevertheless|O
DDI-DrugBank.d5.s11|12-12|,|O
DDI-DrugBank.d5.s11|14-18|there|O
DDI-DrugBank.d5.s11|20-22|may|O
DDI-DrugBank.d5.s11|24-25|be|O
DDI-DrugBank.d5.s11|27-29|the|O
DDI-DrugBank.d5.s11|31-39|potential|O
DDI-DrugBank.d5.s11|41-43|for|O
DDI-DrugBank.d5.s11|45-54|clinically|O
DDI-DrugBank.d5.s11|56-64|important|O
DDI-DrugBank.d5.s11|66-76|alterations|O
DDI-DrugBank.d5.s11|78-79|of|O
DDI-DrugBank.d5.s11|81-85|blood|O
DDI-DrugBank.d5.s11|87-92|levels|O
DDI-DrugBank.d5.s11|94-95|of|O
DDI-DrugBank.d5.s11|97-110|coadministered|O
DDI-DrugBank.d5.s11|112-116|drugs|O
DDI-DrugBank.d5.s11|117-117|.|O
DDI-DrugBank.d5.s12|0-4|Drugs|O
DDI-DrugBank.d5.s12|6-16|Metabolized|O
DDI-DrugBank.d5.s12|18-19|by|O
DDI-DrugBank.d5.s12|21-30|Cytochrome|O
DDI-DrugBank.d5.s12|32-39|P450IID6|O
DDI-DrugBank.d5.s12|41-41|(|O
DDI-DrugBank.d5.s12|42-47|CYP2D6|O
DDI-DrugBank.d5.s12|48-48|)|O
DDI-DrugBank.d5.s12|49-49|:|O
DDI-DrugBank.d5.s12|51-54|Many|O
DDI-DrugBank.d5.s12|56-60|drugs|O
DDI-DrugBank.d5.s12|61-61|,|O
DDI-DrugBank.d5.s12|63-71|including|O
DDI-DrugBank.d5.s12|73-76|most|O
DDI-DrugBank.d5.s12|78-92|antidepressants|group
DDI-DrugBank.d5.s12|94-94|(|O
DDI-DrugBank.d5.s12|95-99|SSRIs|O
DDI-DrugBank.d5.s12|100-100|,|O
DDI-DrugBank.d5.s12|102-105|many|O
DDI-DrugBank.d5.s12|107-116|tricyclics|group
DDI-DrugBank.d5.s12|117-117|)|O
DDI-DrugBank.d5.s12|118-118|,|O
DDI-DrugBank.d5.s12|120-132|beta-blockers|group
DDI-DrugBank.d5.s12|133-133|,|O
DDI-DrugBank.d5.s12|135-149|antiarrhythmics|drug
DDI-DrugBank.d5.s12|150-150|,|O
DDI-DrugBank.d5.s12|152-154|and|O
DDI-DrugBank.d5.s12|156-169|antipsychotics|group
DDI-DrugBank.d5.s12|171-173|are|O
DDI-DrugBank.d5.s12|175-185|metabolized|O
DDI-DrugBank.d5.s12|187-188|by|O
DDI-DrugBank.d5.s12|190-192|the|O
DDI-DrugBank.d5.s12|194-199|CYP2D6|O
DDI-DrugBank.d5.s12|201-209|isoenzyme|O
DDI-DrugBank.d5.s12|210-210|.|O
DDI-DrugBank.d5.s13|0-7|Although|O
DDI-DrugBank.d5.s13|9-17|bupropion|drug
DDI-DrugBank.d5.s13|19-20|is|O
DDI-DrugBank.d5.s13|22-24|not|O
DDI-DrugBank.d5.s13|26-36|metabolized|O
DDI-DrugBank.d5.s13|38-39|by|O
DDI-DrugBank.d5.s13|41-44|this|O
DDI-DrugBank.d5.s13|46-54|isoenzyme|O
DDI-DrugBank.d5.s13|55-55|,|O
DDI-DrugBank.d5.s13|57-65|bupropion|drug
DDI-DrugBank.d5.s13|67-69|and|O
DDI-DrugBank.d5.s13|88-90|are|O
DDI-DrugBank.d5.s13|92-101|inhibitors|O
DDI-DrugBank.d5.s13|103-104|of|O
DDI-DrugBank.d5.s13|106-108|the|O
DDI-DrugBank.d5.s13|110-115|CYP2D6|O
DDI-DrugBank.d5.s13|117-125|isoenzyme|O
DDI-DrugBank.d5.s13|127-128|in|O
DDI-DrugBank.d5.s13|130-134|vitro|O
DDI-DrugBank.d5.s13|135-135|.|O
DDI-DrugBank.d5.s14|0-1|In|O
DDI-DrugBank.d5.s14|3-3|a|O
DDI-DrugBank.d5.s14|5-9|study|O
DDI-DrugBank.d5.s14|11-12|of|O
DDI-DrugBank.d5.s14|14-15|15|O
DDI-DrugBank.d5.s14|17-20|male|O
DDI-DrugBank.d5.s14|22-29|subjects|O
DDI-DrugBank.d5.s14|31-31|(|O
DDI-DrugBank.d5.s14|32-35|ages|O
DDI-DrugBank.d5.s14|37-38|19|O
DDI-DrugBank.d5.s14|40-41|to|O
DDI-DrugBank.d5.s14|43-44|35|O
DDI-DrugBank.d5.s14|46-50|years|O
DDI-DrugBank.d5.s14|51-51|)|O
DDI-DrugBank.d5.s14|53-55|who|O
DDI-DrugBank.d5.s14|57-60|were|O
DDI-DrugBank.d5.s14|62-70|extensive|O
DDI-DrugBank.d5.s14|72-83|metabolizers|O
DDI-DrugBank.d5.s14|85-86|of|O
DDI-DrugBank.d5.s14|88-90|the|O
DDI-DrugBank.d5.s14|92-97|CYP2D6|O
DDI-DrugBank.d5.s14|99-107|isoenzyme|O
DDI-DrugBank.d5.s14|108-108|,|O
DDI-DrugBank.d5.s14|110-114|daily|O
DDI-DrugBank.d5.s14|116-120|doses|O
DDI-DrugBank.d5.s14|122-123|of|O
DDI-DrugBank.d5.s14|125-133|bupropion|drug
DDI-DrugBank.d5.s14|135-139|given|O
DDI-DrugBank.d5.s14|141-142|as|O
DDI-DrugBank.d5.s14|144-146|150|O
DDI-DrugBank.d5.s14|148-149|mg|O
DDI-DrugBank.d5.s14|151-155|twice|O
DDI-DrugBank.d5.s14|157-161|daily|O
DDI-DrugBank.d5.s14|163-170|followed|O
DDI-DrugBank.d5.s14|172-173|by|O
DDI-DrugBank.d5.s14|175-175|a|O
DDI-DrugBank.d5.s14|177-182|single|O
DDI-DrugBank.d5.s14|184-187|dose|O
DDI-DrugBank.d5.s14|189-190|of|O
DDI-DrugBank.d5.s14|192-193|50|O
DDI-DrugBank.d5.s14|195-196|mg|O
DDI-DrugBank.d5.s14|198-208|desipramine|drug
DDI-DrugBank.d5.s14|210-218|increased|O
DDI-DrugBank.d5.s14|220-222|the|O
DDI-DrugBank.d5.s14|224-227|Cmax|O
DDI-DrugBank.d5.s14|228-228|,|O
DDI-DrugBank.d5.s14|230-232|AUC|O
DDI-DrugBank.d5.s14|233-233|,|O
DDI-DrugBank.d5.s14|235-237|and|O
DDI-DrugBank.d5.s14|239-242|t1/2|O
DDI-DrugBank.d5.s14|244-245|of|O
DDI-DrugBank.d5.s14|247-257|desipramine|drug
DDI-DrugBank.d5.s14|259-260|by|O
DDI-DrugBank.d5.s14|262-263|an|O
DDI-DrugBank.d5.s14|265-271|average|O
DDI-DrugBank.d5.s14|273-274|of|O
DDI-DrugBank.d5.s14|276-288|approximately|O
DDI-DrugBank.d5.s14|290-291|2-|O
DDI-DrugBank.d5.s14|292-292|,|O
DDI-DrugBank.d5.s14|294-295|5-|O
DDI-DrugBank.d5.s14|297-299|and|O
DDI-DrugBank.d5.s14|301-306|2-fold|O
DDI-DrugBank.d5.s14|307-307|,|O
DDI-DrugBank.d5.s14|309-320|respectively|O
DDI-DrugBank.d5.s14|321-321|.|O
DDI-DrugBank.d5.s15|0-2|The|O
DDI-DrugBank.d5.s15|4-9|effect|O
DDI-DrugBank.d5.s15|11-13|was|O
DDI-DrugBank.d5.s15|15-21|present|O
DDI-DrugBank.d5.s15|23-25|for|O
DDI-DrugBank.d5.s15|27-28|at|O
DDI-DrugBank.d5.s15|30-34|least|O
DDI-DrugBank.d5.s15|36-36|7|O
DDI-DrugBank.d5.s15|38-41|days|O
DDI-DrugBank.d5.s15|43-47|after|O
DDI-DrugBank.d5.s15|49-51|the|O
DDI-DrugBank.d5.s15|53-56|last|O
DDI-DrugBank.d5.s15|58-61|dose|O
DDI-DrugBank.d5.s15|63-64|of|O
DDI-DrugBank.d5.s15|66-74|bupropion|drug
DDI-DrugBank.d5.s15|75-75|.|O
DDI-DrugBank.d5.s16|0-10|Concomitant|O
DDI-DrugBank.d5.s16|12-14|use|O
DDI-DrugBank.d5.s16|16-17|of|O
DDI-DrugBank.d5.s16|19-27|bupropion|drug
DDI-DrugBank.d5.s16|29-32|with|O
DDI-DrugBank.d5.s16|34-38|other|O
DDI-DrugBank.d5.s16|40-44|drugs|O
DDI-DrugBank.d5.s16|46-56|metabolized|O
DDI-DrugBank.d5.s16|58-59|by|O
DDI-DrugBank.d5.s16|61-66|CYP2D6|O
DDI-DrugBank.d5.s16|68-70|has|O
DDI-DrugBank.d5.s16|72-74|not|O
DDI-DrugBank.d5.s16|76-79|been|O
DDI-DrugBank.d5.s16|81-88|formally|O
DDI-DrugBank.d5.s16|90-96|studied|O
DDI-DrugBank.d5.s16|97-97|.|O
DDI-DrugBank.d5.s17|0-8|Therefore|O
DDI-DrugBank.d5.s17|9-9|,|O
DDI-DrugBank.d5.s17|11-27|co-administration|O
DDI-DrugBank.d5.s17|29-30|of|O
DDI-DrugBank.d5.s17|32-40|bupropion|drug
DDI-DrugBank.d5.s17|42-45|with|O
DDI-DrugBank.d5.s17|47-51|drugs|O
DDI-DrugBank.d5.s17|53-56|that|O
DDI-DrugBank.d5.s17|58-60|are|O
DDI-DrugBank.d5.s17|62-72|metabolized|O
DDI-DrugBank.d5.s17|74-75|by|O
DDI-DrugBank.d5.s17|77-82|CYP2D6|O
DDI-DrugBank.d5.s17|84-92|isoenzyme|O
DDI-DrugBank.d5.s17|94-102|including|O
DDI-DrugBank.d5.s17|104-110|certain|O
DDI-DrugBank.d5.s17|112-126|antidepressants|group
DDI-DrugBank.d5.s17|128-128|(|O
DDI-DrugBank.d5.s17|129-132|e.g.|O
DDI-DrugBank.d5.s17|133-133|,|O
DDI-DrugBank.d5.s17|135-147|nortriptyline|drug
DDI-DrugBank.d5.s17|148-148|,|O
DDI-DrugBank.d5.s17|150-159|imipramine|drug
DDI-DrugBank.d5.s17|160-160|,|O
DDI-DrugBank.d5.s17|162-172|desipramine|drug
DDI-DrugBank.d5.s17|173-173|,|O
DDI-DrugBank.d5.s17|175-184|paroxetine|drug
DDI-DrugBank.d5.s17|185-185|,|O
DDI-DrugBank.d5.s17|187-196|fluoxetine|drug
DDI-DrugBank.d5.s17|197-197|,|O
DDI-DrugBank.d5.s17|199-208|sertraline|drug
DDI-DrugBank.d5.s17|209-209|)|O
DDI-DrugBank.d5.s17|210-210|,|O
DDI-DrugBank.d5.s17|212-225|antipsychotics|group
DDI-DrugBank.d5.s17|227-227|(|O
DDI-DrugBank.d5.s17|228-231|e.g.|O
DDI-DrugBank.d5.s17|232-232|,|O
DDI-DrugBank.d5.s17|234-244|haloperidol|drug
DDI-DrugBank.d5.s17|245-245|,|O
DDI-DrugBank.d5.s17|247-257|risperidone|drug
DDI-DrugBank.d5.s17|258-258|,|O
DDI-DrugBank.d5.s17|260-271|thioridazine|drug
DDI-DrugBank.d5.s17|272-272|)|O
DDI-DrugBank.d5.s17|273-273|,|O
DDI-DrugBank.d5.s17|275-287|beta-blockers|group
DDI-DrugBank.d5.s17|289-289|(|O
DDI-DrugBank.d5.s17|290-293|e.g.|O
DDI-DrugBank.d5.s17|294-294|,|O
DDI-DrugBank.d5.s17|296-305|metoprolol|drug
DDI-DrugBank.d5.s17|306-306|)|O
DDI-DrugBank.d5.s17|307-307|,|O
DDI-DrugBank.d5.s17|309-311|and|O
DDI-DrugBank.d5.s17|313-335|Type 1C antiarrhythmics|group
DDI-DrugBank.d5.s17|337-337|(|O
DDI-DrugBank.d5.s17|338-341|e.g.|O
DDI-DrugBank.d5.s17|342-342|,|O
DDI-DrugBank.d5.s17|344-354|propafenone|drug
DDI-DrugBank.d5.s17|355-355|,|O
DDI-DrugBank.d5.s17|357-366|flecainide|drug
DDI-DrugBank.d5.s17|367-367|)|O
DDI-DrugBank.d5.s17|368-368|,|O
DDI-DrugBank.d5.s17|370-375|should|O
DDI-DrugBank.d5.s17|377-378|be|O
DDI-DrugBank.d5.s17|380-389|approached|O
DDI-DrugBank.d5.s17|391-394|with|O
DDI-DrugBank.d5.s17|396-402|caution|O
DDI-DrugBank.d5.s17|404-406|and|O
DDI-DrugBank.d5.s17|408-413|should|O
DDI-DrugBank.d5.s17|415-416|be|O
DDI-DrugBank.d5.s17|418-426|initiated|O
DDI-DrugBank.d5.s17|428-429|at|O
DDI-DrugBank.d5.s17|431-433|the|O
DDI-DrugBank.d5.s17|435-439|lower|O
DDI-DrugBank.d5.s17|441-443|end|O
DDI-DrugBank.d5.s17|445-446|of|O
DDI-DrugBank.d5.s17|448-450|the|O
DDI-DrugBank.d5.s17|452-455|dose|O
DDI-DrugBank.d5.s17|457-461|range|O
DDI-DrugBank.d5.s17|463-464|of|O
DDI-DrugBank.d5.s17|466-468|the|O
DDI-DrugBank.d5.s17|470-480|concomitant|O
DDI-DrugBank.d5.s17|482-491|medication|O
DDI-DrugBank.d5.s17|492-492|.|O
DDI-DrugBank.d5.s18|0-1|If|O
DDI-DrugBank.d5.s18|3-11|bupropion|drug
DDI-DrugBank.d5.s18|13-14|is|O
DDI-DrugBank.d5.s18|16-20|added|O
DDI-DrugBank.d5.s18|22-23|to|O
DDI-DrugBank.d5.s18|25-27|the|O
DDI-DrugBank.d5.s18|29-37|treatment|O
DDI-DrugBank.d5.s18|39-45|regimen|O
DDI-DrugBank.d5.s18|47-48|of|O
DDI-DrugBank.d5.s18|50-50|a|O
DDI-DrugBank.d5.s18|52-58|patient|O
DDI-DrugBank.d5.s18|60-66|already|O
DDI-DrugBank.d5.s18|68-76|receiving|O
DDI-DrugBank.d5.s18|78-78|a|O
DDI-DrugBank.d5.s18|80-83|drug|O
DDI-DrugBank.d5.s18|85-95|metabolized|O
DDI-DrugBank.d5.s18|97-98|by|O
DDI-DrugBank.d5.s18|100-105|CYP2D6|O
DDI-DrugBank.d5.s18|106-106|,|O
DDI-DrugBank.d5.s18|108-110|the|O
DDI-DrugBank.d5.s18|112-115|need|O
DDI-DrugBank.d5.s18|117-118|to|O
DDI-DrugBank.d5.s18|120-127|decrease|O
DDI-DrugBank.d5.s18|129-131|the|O
DDI-DrugBank.d5.s18|133-136|dose|O
DDI-DrugBank.d5.s18|138-139|of|O
DDI-DrugBank.d5.s18|141-143|the|O
DDI-DrugBank.d5.s18|145-152|original|O
DDI-DrugBank.d5.s18|154-163|medication|O
DDI-DrugBank.d5.s18|165-170|should|O
DDI-DrugBank.d5.s18|172-173|be|O
DDI-DrugBank.d5.s18|175-184|considered|O
DDI-DrugBank.d5.s18|185-185|,|O
DDI-DrugBank.d5.s18|187-198|particularly|O
DDI-DrugBank.d5.s18|200-202|for|O
DDI-DrugBank.d5.s18|204-208|those|O
DDI-DrugBank.d5.s18|210-220|concomitant|O
DDI-DrugBank.d5.s18|222-232|medications|O
DDI-DrugBank.d5.s18|234-237|with|O
DDI-DrugBank.d5.s18|239-239|a|O
DDI-DrugBank.d5.s18|241-246|narrow|O
DDI-DrugBank.d5.s18|248-258|therapeutic|O
DDI-DrugBank.d5.s18|260-264|index|O
DDI-DrugBank.d5.s18|265-265|.|O
DDI-DrugBank.d5.s19|0-13|MAO Inhibitors|group
DDI-DrugBank.d5.s19|14-14|:|O
DDI-DrugBank.d5.s19|16-22|Studies|O
DDI-DrugBank.d5.s19|24-25|in|O
DDI-DrugBank.d5.s19|27-33|animals|O
DDI-DrugBank.d5.s19|35-45|demonstrate|O
DDI-DrugBank.d5.s19|47-50|that|O
DDI-DrugBank.d5.s19|52-54|the|O
DDI-DrugBank.d5.s19|56-60|acute|O
DDI-DrugBank.d5.s19|62-69|toxicity|O
DDI-DrugBank.d5.s19|71-72|of|O
DDI-DrugBank.d5.s19|74-82|bupropion|drug
DDI-DrugBank.d5.s19|84-85|is|O
DDI-DrugBank.d5.s19|87-94|enhanced|O
DDI-DrugBank.d5.s19|96-97|by|O
DDI-DrugBank.d5.s19|99-101|the|O
DDI-DrugBank.d5.s19|103-115|MAO inhibitor|group
DDI-DrugBank.d5.s19|103-115|MAO inhibitor|group
DDI-DrugBank.d5.s19|128-128|.|O
DDI-DrugBank.d5.s20|0-7|Levodopa|drug
DDI-DrugBank.d5.s20|9-11|and|O
DDI-DrugBank.d5.s20|13-22|Amantadine|drug
DDI-DrugBank.d5.s20|23-23|:|O
DDI-DrugBank.d5.s20|25-31|Limited|O
DDI-DrugBank.d5.s20|33-40|clinical|O
DDI-DrugBank.d5.s20|42-45|data|O
DDI-DrugBank.d5.s20|47-53|suggest|O
DDI-DrugBank.d5.s20|55-55|a|O
DDI-DrugBank.d5.s20|57-62|higher|O
DDI-DrugBank.d5.s20|64-72|incidence|O
DDI-DrugBank.d5.s20|74-75|of|O
DDI-DrugBank.d5.s20|77-83|adverse|O
DDI-DrugBank.d5.s20|85-95|experiences|O
DDI-DrugBank.d5.s20|97-98|in|O
DDI-DrugBank.d5.s20|100-107|patients|O
DDI-DrugBank.d5.s20|109-117|receiving|O
DDI-DrugBank.d5.s20|119-127|bupropion|drug
DDI-DrugBank.d5.s20|129-140|concurrently|O
DDI-DrugBank.d5.s20|142-145|with|O
DDI-DrugBank.d5.s20|147-152|either|O
DDI-DrugBank.d5.s20|154-161|levodopa|drug
DDI-DrugBank.d5.s20|163-164|or|O
DDI-DrugBank.d5.s20|166-175|amantadine|drug
DDI-DrugBank.d5.s20|176-176|.|O
DDI-DrugBank.d5.s21|0-13|Administration|O
DDI-DrugBank.d5.s21|15-16|of|O
DDI-DrugBank.d5.s21|18-27|WELLBUTRIN|brand
DDI-DrugBank.d5.s21|29-35|Tablets|O
DDI-DrugBank.d5.s21|37-38|to|O
DDI-DrugBank.d5.s21|40-47|patients|O
DDI-DrugBank.d5.s21|49-57|receiving|O
DDI-DrugBank.d5.s21|59-64|either|O
DDI-DrugBank.d5.s21|66-73|levodopa|drug
DDI-DrugBank.d5.s21|75-76|or|O
DDI-DrugBank.d5.s21|78-87|amantadine|drug
DDI-DrugBank.d5.s21|89-100|concurrently|O
DDI-DrugBank.d5.s21|102-107|should|O
DDI-DrugBank.d5.s21|109-110|be|O
DDI-DrugBank.d5.s21|112-121|undertaken|O
DDI-DrugBank.d5.s21|123-126|with|O
DDI-DrugBank.d5.s21|128-134|caution|O
DDI-DrugBank.d5.s21|135-135|,|O
DDI-DrugBank.d5.s21|137-141|using|O
DDI-DrugBank.d5.s21|143-147|small|O
DDI-DrugBank.d5.s21|149-155|initial|O
DDI-DrugBank.d5.s21|157-161|doses|O
DDI-DrugBank.d5.s21|163-165|and|O
DDI-DrugBank.d5.s21|167-171|small|O
DDI-DrugBank.d5.s21|173-179|gradual|O
DDI-DrugBank.d5.s21|181-184|dose|O
DDI-DrugBank.d5.s21|186-194|increases|O
DDI-DrugBank.d5.s21|195-195|.|O
DDI-DrugBank.d5.s22|0-4|Drugs|O
DDI-DrugBank.d5.s22|6-9|that|O
DDI-DrugBank.d5.s22|11-15|Lower|O
DDI-DrugBank.d5.s22|17-23|Seizure|O
DDI-DrugBank.d5.s22|25-33|Threshold|O
DDI-DrugBank.d5.s22|34-34|:|O
DDI-DrugBank.d5.s22|36-45|Concurrent|O
DDI-DrugBank.d5.s22|47-60|administration|O
DDI-DrugBank.d5.s22|62-63|of|O
DDI-DrugBank.d5.s22|65-74|WELLBUTRIN|brand
DDI-DrugBank.d5.s22|76-78|and|O
DDI-DrugBank.d5.s22|80-85|agents|O
DDI-DrugBank.d5.s22|87-87|(|O
DDI-DrugBank.d5.s22|88-91|e.g.|O
DDI-DrugBank.d5.s22|92-92|,|O
DDI-DrugBank.d5.s22|94-107|antipsychotics|group
DDI-DrugBank.d5.s22|108-108|,|O
DDI-DrugBank.d5.s22|110-114|other|O
DDI-DrugBank.d5.s22|116-130|antidepressants|group
DDI-DrugBank.d5.s22|131-131|,|O
DDI-DrugBank.d5.s22|133-144|theophylline|drug
DDI-DrugBank.d5.s22|145-145|,|O
DDI-DrugBank.d5.s22|147-154|systemic|O
DDI-DrugBank.d5.s22|156-163|steroids|group
DDI-DrugBank.d5.s22|164-164|,|O
DDI-DrugBank.d5.s22|166-169|etc.|O
DDI-DrugBank.d5.s22|170-170|)|O
DDI-DrugBank.d5.s22|172-175|that|O
DDI-DrugBank.d5.s22|177-181|lower|O
DDI-DrugBank.d5.s22|183-189|seizure|O
DDI-DrugBank.d5.s22|191-199|threshold|O
DDI-DrugBank.d5.s22|201-206|should|O
DDI-DrugBank.d5.s22|208-209|be|O
DDI-DrugBank.d5.s22|211-220|undertaken|O
DDI-DrugBank.d5.s22|222-225|only|O
DDI-DrugBank.d5.s22|227-230|with|O
DDI-DrugBank.d5.s22|232-238|extreme|O
DDI-DrugBank.d5.s22|240-246|caution|O
DDI-DrugBank.d5.s22|247-247|.|O
DDI-DrugBank.d5.s23|0-2|Low|O
DDI-DrugBank.d5.s23|4-10|initial|O
DDI-DrugBank.d5.s23|12-17|dosing|O
DDI-DrugBank.d5.s23|19-21|and|O
DDI-DrugBank.d5.s23|23-27|small|O
DDI-DrugBank.d5.s23|29-35|gradual|O
DDI-DrugBank.d5.s23|37-40|dose|O
DDI-DrugBank.d5.s23|42-50|increases|O
DDI-DrugBank.d5.s23|52-57|should|O
DDI-DrugBank.d5.s23|59-60|be|O
DDI-DrugBank.d5.s23|62-69|employed|O
DDI-DrugBank.d5.s23|70-70|.|O
DDI-DrugBank.d5.s24|0-7|Nicotine|drug
DDI-DrugBank.d5.s24|9-19|Transdermal|O
DDI-DrugBank.d5.s24|21-26|System|O
DDI-DrugBank.d5.s24|27-27|:|O
DDI-DrugBank.d5.s24|29-29|.|O
DDI-DrugBank.d5.s25|0-6|Alcohol|drug
DDI-DrugBank.d5.s25|7-7|:|O
DDI-DrugBank.d5.s25|9-10|In|O
DDI-DrugBank.d5.s25|12-25|post-marketing|O
DDI-DrugBank.d5.s25|27-36|experience|O
DDI-DrugBank.d5.s25|37-37|,|O
DDI-DrugBank.d5.s25|39-43|there|O
DDI-DrugBank.d5.s25|45-48|have|O
DDI-DrugBank.d5.s25|50-53|been|O
DDI-DrugBank.d5.s25|55-58|rare|O
DDI-DrugBank.d5.s25|60-66|reports|O
DDI-DrugBank.d5.s25|68-69|of|O
DDI-DrugBank.d5.s25|71-77|adverse|O
DDI-DrugBank.d5.s25|79-94|neuropsychiatric|O
DDI-DrugBank.d5.s25|96-101|events|O
DDI-DrugBank.d5.s25|103-104|or|O
DDI-DrugBank.d5.s25|106-112|reduced|O
DDI-DrugBank.d5.s25|114-120|alcohol|drug
DDI-DrugBank.d5.s25|122-130|tolerance|O
DDI-DrugBank.d5.s25|132-133|in|O
DDI-DrugBank.d5.s25|135-142|patients|O
DDI-DrugBank.d5.s25|144-146|who|O
DDI-DrugBank.d5.s25|148-151|were|O
DDI-DrugBank.d5.s25|153-160|drinking|O
DDI-DrugBank.d5.s25|162-168|alcohol|drug
DDI-DrugBank.d5.s25|170-175|during|O
DDI-DrugBank.d5.s25|177-185|treatment|O
DDI-DrugBank.d5.s25|187-190|with|O
DDI-DrugBank.d5.s25|192-201|WELLBUTRIN|brand
DDI-DrugBank.d5.s25|202-202|.|O
DDI-DrugBank.d5.s26|0-2|The|O
DDI-DrugBank.d5.s26|4-14|consumption|O
DDI-DrugBank.d5.s26|16-17|of|O
DDI-DrugBank.d5.s26|19-25|alcohol|drug
DDI-DrugBank.d5.s26|27-32|during|O
DDI-DrugBank.d5.s26|34-42|treatment|O
DDI-DrugBank.d5.s26|44-47|with|O
DDI-DrugBank.d5.s26|49-58|WELLBUTRIN|brand
DDI-DrugBank.d5.s26|60-65|should|O
DDI-DrugBank.d5.s26|67-68|be|O
DDI-DrugBank.d5.s26|70-78|minimized|O
DDI-DrugBank.d5.s26|80-81|or|O
DDI-DrugBank.d5.s26|83-89|avoided|O
DDI-DrugBank.d5.s26|91-91|(|O
DDI-DrugBank.d5.s26|92-95|also|O
DDI-DrugBank.d5.s26|97-99|see|O
DDI-DrugBank.d5.s26|102-102|a|O
DDI-DrugBank.d5.s26|104-108|href=|O
DDI-DrugBank.d5.s26|110-123|bupropz_od.htm|O
DDI-DrugBank.d5.s26|124-124|#|O
DDI-DrugBank.d5.s26|125-126|CI|O
DDI-DrugBank.d5.s26|128-144|CONTRAINDICATIONS|O
DDI-DrugBank.d5.s26|145-145|)|O
DDI-DrugBank.d5.s27|0-0|.|O
DDI-DrugBank.d452.s0|0-13|Administration|O
DDI-DrugBank.d452.s0|15-16|of|O
DDI-DrugBank.d452.s0|18-35|thiazide diuretics|group
DDI-DrugBank.d452.s0|37-38|to|O
DDI-DrugBank.d452.s0|40-54|hypoparathyroid|O
DDI-DrugBank.d452.s0|56-63|patients|O
DDI-DrugBank.d452.s0|65-67|who|O
DDI-DrugBank.d452.s0|69-71|are|O
DDI-DrugBank.d452.s0|73-84|concurrently|O
DDI-DrugBank.d452.s0|86-90|being|O
DDI-DrugBank.d452.s0|92-98|treated|O
DDI-DrugBank.d452.s0|100-103|with|O
DDI-DrugBank.d452.s0|105-122|dihydrotachysterol|drug
DDI-DrugBank.d452.s0|124-126|may|O
DDI-DrugBank.d452.s0|128-132|cause|O
DDI-DrugBank.d452.s0|134-146|hypercalcemia|O
DDI-DrugBank.d452.s0|147-147|.|O
DDI-DrugBank.d613.s0|0-0|A|O
DDI-DrugBank.d613.s0|2-6|study|O
DDI-DrugBank.d613.s0|8-16|published|O
DDI-DrugBank.d613.s0|18-19|in|O
DDI-DrugBank.d613.s0|21-24|2002|O
DDI-DrugBank.d613.s0|26-30|found|O
DDI-DrugBank.d613.s0|32-35|that|O
DDI-DrugBank.d613.s0|37-46|vigabatrin|drug
DDI-DrugBank.d613.s0|48-53|causes|O
DDI-DrugBank.d613.s0|55-55|a|O
DDI-DrugBank.d613.s0|57-69|statistically|O
DDI-DrugBank.d613.s0|71-81|significant|O
DDI-DrugBank.d613.s0|83-90|increase|O
DDI-DrugBank.d613.s0|92-93|in|O
DDI-DrugBank.d613.s0|95-100|plasma|O
DDI-DrugBank.d613.s0|102-110|clearance|O
DDI-DrugBank.d613.s0|112-113|of|O
DDI-DrugBank.d613.s0|115-127|carbamazepine|drug
DDI-DrugBank.d613.s0|128-128|.|O
DDI-DrugBank.d613.s1|0-1|In|O
DDI-DrugBank.d613.s1|3-6|1984|O
DDI-DrugBank.d613.s1|7-7|,|O
DDI-DrugBank.d613.s1|9-11|Drs|O
DDI-DrugBank.d613.s1|13-18|Rimmer|O
DDI-DrugBank.d613.s1|20-22|and|O
DDI-DrugBank.d613.s1|24-30|Richens|O
DDI-DrugBank.d613.s1|32-33|at|O
DDI-DrugBank.d613.s1|35-37|the|O
DDI-DrugBank.d613.s1|39-48|University|O
DDI-DrugBank.d613.s1|50-51|of|O
DDI-DrugBank.d613.s1|53-57|Wales|O
DDI-DrugBank.d613.s1|59-66|reported|O
DDI-DrugBank.d613.s1|68-71|that|O
DDI-DrugBank.d613.s1|73-85|administering|O
DDI-DrugBank.d613.s1|87-96|vigabatrin|drug
DDI-DrugBank.d613.s1|98-101|with|O
DDI-DrugBank.d613.s1|103-111|phenytoin|drug
DDI-DrugBank.d613.s1|113-119|lowered|O
DDI-DrugBank.d613.s1|121-123|the|O
DDI-DrugBank.d613.s1|125-129|serum|O
DDI-DrugBank.d613.s1|131-139|phenytoin|drug
DDI-DrugBank.d613.s1|141-153|concentration|O
DDI-DrugBank.d613.s1|155-156|in|O
DDI-DrugBank.d613.s1|158-165|patients|O
DDI-DrugBank.d613.s1|167-170|with|O
DDI-DrugBank.d613.s1|172-190|treatment-resistant|O
DDI-DrugBank.d613.s1|192-199|epilepsy|O
DDI-DrugBank.d613.s1|200-200|.|O
DDI-DrugBank.d613.s2|0-2|The|O
DDI-DrugBank.d613.s2|4-16|concentration|O
DDI-DrugBank.d613.s2|18-19|of|O
DDI-DrugBank.d613.s2|21-29|phenytoin|drug
DDI-DrugBank.d613.s2|31-35|falls|O
DDI-DrugBank.d613.s2|37-38|to|O
DDI-DrugBank.d613.s2|40-41|23|O
DDI-DrugBank.d613.s2|42-42|%|O
DDI-DrugBank.d613.s2|44-49|within|O
DDI-DrugBank.d613.s2|51-54|five|O
DDI-DrugBank.d613.s2|56-60|weeks|O
DDI-DrugBank.d613.s2|61-61|,|O
DDI-DrugBank.d613.s2|63-71|according|O
DDI-DrugBank.d613.s2|73-74|to|O
DDI-DrugBank.d613.s2|76-77|an|O
DDI-DrugBank.d613.s2|79-88|experiment|O
DDI-DrugBank.d613.s2|90-98|published|O
DDI-DrugBank.d613.s2|100-101|in|O
DDI-DrugBank.d613.s2|103-106|1989|O
DDI-DrugBank.d613.s2|108-109|by|O
DDI-DrugBank.d613.s2|111-113|the|O
DDI-DrugBank.d613.s2|115-118|same|O
DDI-DrugBank.d613.s2|120-122|two|O
DDI-DrugBank.d613.s2|124-133|scientists|O
DDI-DrugBank.d613.s2|135-138|that|O
DDI-DrugBank.d613.s2|140-144|tried|O
DDI-DrugBank.d613.s2|146-148|and|O
DDI-DrugBank.d613.s2|150-155|failed|O
DDI-DrugBank.d613.s2|157-158|to|O
DDI-DrugBank.d613.s2|160-168|elucidate|O
DDI-DrugBank.d613.s2|170-172|the|O
DDI-DrugBank.d613.s2|174-182|mechanism|O
DDI-DrugBank.d613.s2|184-189|behind|O
DDI-DrugBank.d613.s2|191-194|this|O
DDI-DrugBank.d613.s2|196-206|interaction|O
DDI-DrugBank.d613.s2|207-207|.|O
DDI-DrugBank.d277.s0|0-1|In|O
DDI-DrugBank.d277.s0|3-12|evaluating|O
DDI-DrugBank.d277.s0|14-16|the|O
DDI-DrugBank.d277.s0|18-26|potential|O
DDI-DrugBank.d277.s0|28-30|for|O
DDI-DrugBank.d277.s0|32-43|interactions|O
DDI-DrugBank.d277.s0|45-49|among|O
DDI-DrugBank.d277.s0|51-65|co-administered|O
DDI-DrugBank.d277.s0|67-78|antiepilepsy|O
DDI-DrugBank.d277.s0|80-84|drugs|O
DDI-DrugBank.d277.s0|86-86|(|O
DDI-DrugBank.d277.s0|87-90|AEDs|group
DDI-DrugBank.d277.s0|91-91|)|O
DDI-DrugBank.d277.s0|92-92|,|O
DDI-DrugBank.d277.s0|94-100|whether|O
DDI-DrugBank.d277.s0|102-103|or|O
DDI-DrugBank.d277.s0|105-107|not|O
DDI-DrugBank.d277.s0|109-110|an|O
DDI-DrugBank.d277.s0|112-114|AED|group
DDI-DrugBank.d277.s0|116-122|induces|O
DDI-DrugBank.d277.s0|124-125|or|O
DDI-DrugBank.d277.s0|127-130|does|O
DDI-DrugBank.d277.s0|132-134|not|O
DDI-DrugBank.d277.s0|136-141|induce|O
DDI-DrugBank.d277.s0|143-151|metabolic|O
DDI-DrugBank.d277.s0|153-159|enzymes|O
DDI-DrugBank.d277.s0|161-162|is|O
DDI-DrugBank.d277.s0|164-165|an|O
DDI-DrugBank.d277.s0|167-175|important|O
DDI-DrugBank.d277.s0|177-189|consideration|O
DDI-DrugBank.d277.s0|190-190|.|O
DDI-DrugBank.d277.s1|0-8|Phenytoin|drug
DDI-DrugBank.d277.s1|9-9|,|O
DDI-DrugBank.d277.s1|11-23|phenobarbital|drug
DDI-DrugBank.d277.s1|25-27|and|O
DDI-DrugBank.d277.s1|29-41|carbamazepine|drug
DDI-DrugBank.d277.s1|43-45|are|O
DDI-DrugBank.d277.s1|47-48|ge|O
DDI-DrugBank.d277.s1|50-56|nerally|O
DDI-DrugBank.d277.s1|58-67|classified|O
DDI-DrugBank.d277.s1|69-70|as|O
DDI-DrugBank.d277.s1|72-77|enzyme|O
DDI-DrugBank.d277.s1|79-86|inducers|O
DDI-DrugBank.d277.s1|87-87|;|O
DDI-DrugBank.d277.s2|0-8|valproate|drug
DDI-DrugBank.d277.s2|10-12|and|O
DDI-DrugBank.d277.s2|14-23|gabapentin|drug
DDI-DrugBank.d277.s2|25-27|are|O
DDI-DrugBank.d277.s2|29-31|not|O
DDI-DrugBank.d277.s2|32-32|.|O
DDI-DrugBank.d277.s3|0-7|GABITRIL|brand
DDI-DrugBank.d277.s3|9-10|is|O
DDI-DrugBank.d277.s3|12-21|considered|O
DDI-DrugBank.d277.s3|23-24|to|O
DDI-DrugBank.d277.s3|26-27|be|O
DDI-DrugBank.d277.s3|29-29|a|O
DDI-DrugBank.d277.s3|31-40|non-enzyme|O
DDI-DrugBank.d277.s3|42-49|inducing|O
DDI-DrugBank.d277.s3|51-53|AED|group
DDI-DrugBank.d277.s3|54-54|.|O
DDI-DrugBank.d277.s4|0-2|The|O
DDI-DrugBank.d277.s4|4-7|drug|O
DDI-DrugBank.d277.s4|9-19|interaction|O
DDI-DrugBank.d277.s4|21-24|data|O
DDI-DrugBank.d277.s4|26-34|described|O
DDI-DrugBank.d277.s4|36-37|in|O
DDI-DrugBank.d277.s4|39-42|this|O
DDI-DrugBank.d277.s4|44-50|section|O
DDI-DrugBank.d277.s4|52-55|were|O
DDI-DrugBank.d277.s4|57-64|obtained|O
DDI-DrugBank.d277.s4|66-69|from|O
DDI-DrugBank.d277.s4|71-77|studies|O
DDI-DrugBank.d277.s4|79-87|involving|O
DDI-DrugBank.d277.s4|89-94|either|O
DDI-DrugBank.d277.s4|96-102|healthy|O
DDI-DrugBank.d277.s4|104-111|subjects|O
DDI-DrugBank.d277.s4|113-114|or|O
DDI-DrugBank.d277.s4|116-123|patients|O
DDI-DrugBank.d277.s4|125-128|with|O
DDI-DrugBank.d277.s4|130-137|epilepsy|O
DDI-DrugBank.d277.s4|138-138|.|O
DDI-DrugBank.d277.s5|0-6|Effects|O
DDI-DrugBank.d277.s5|8-9|of|O
DDI-DrugBank.d277.s5|11-18|GABITRIL|brand
DDI-DrugBank.d277.s5|20-21|on|O
DDI-DrugBank.d277.s5|23-27|other|O
DDI-DrugBank.d277.s5|29-40|Antiepilepsy|O
DDI-DrugBank.d277.s5|42-46|Drugs|O
DDI-DrugBank.d277.s5|48-48|(|O
DDI-DrugBank.d277.s5|49-52|AEDs|group
DDI-DrugBank.d277.s5|53-53|)|O
DDI-DrugBank.d277.s5|55-55|:|O
DDI-DrugBank.d277.s5|57-65|Phenytoin|drug
DDI-DrugBank.d277.s5|66-66|:|O
DDI-DrugBank.d277.s5|68-76|Tiagabine|drug
DDI-DrugBank.d277.s5|78-80|had|O
DDI-DrugBank.d277.s5|82-83|no|O
DDI-DrugBank.d277.s5|85-90|effect|O
DDI-DrugBank.d277.s5|92-93|on|O
DDI-DrugBank.d277.s5|95-97|the|O
DDI-DrugBank.d277.s5|99-110|steady-state|O
DDI-DrugBank.d277.s5|112-117|plasma|O
DDI-DrugBank.d277.s5|119-132|concentrations|O
DDI-DrugBank.d277.s5|134-135|of|O
DDI-DrugBank.d277.s5|137-145|phenytoin|drug
DDI-DrugBank.d277.s5|147-148|in|O
DDI-DrugBank.d277.s5|150-157|patients|O
DDI-DrugBank.d277.s5|159-162|with|O
DDI-DrugBank.d277.s5|164-171|epilepsy|O
DDI-DrugBank.d277.s5|172-172|.|O
DDI-DrugBank.d277.s6|0-12|Carbamazepine|drug
DDI-DrugBank.d277.s6|13-13|:|O
DDI-DrugBank.d277.s6|15-23|Tiagabine|drug
DDI-DrugBank.d277.s6|25-27|had|O
DDI-DrugBank.d277.s6|29-30|no|O
DDI-DrugBank.d277.s6|32-37|effect|O
DDI-DrugBank.d277.s6|39-40|on|O
DDI-DrugBank.d277.s6|42-44|the|O
DDI-DrugBank.d277.s6|46-57|steady-state|O
DDI-DrugBank.d277.s6|59-64|plasma|O
DDI-DrugBank.d277.s6|66-79|concentrations|O
DDI-DrugBank.d277.s6|81-82|of|O
DDI-DrugBank.d277.s6|84-96|carbamazepine|drug
DDI-DrugBank.d277.s6|98-99|or|O
DDI-DrugBank.d277.s6|101-103|its|O
DDI-DrugBank.d277.s6|105-111|epoxide|O
DDI-DrugBank.d277.s6|113-122|metabolite|O
DDI-DrugBank.d277.s6|124-125|in|O
DDI-DrugBank.d277.s6|127-134|patients|O
DDI-DrugBank.d277.s6|136-139|with|O
DDI-DrugBank.d277.s6|141-148|epilepsy|O
DDI-DrugBank.d277.s6|149-149|.|O
DDI-DrugBank.d277.s7|0-8|Valproate|drug
DDI-DrugBank.d277.s7|9-9|:|O
DDI-DrugBank.d277.s7|11-19|Tiagabine|drug
DDI-DrugBank.d277.s7|21-26|causes|O
DDI-DrugBank.d277.s7|28-28|a|O
DDI-DrugBank.d277.s7|30-35|slight|O
DDI-DrugBank.d277.s7|37-44|decrease|O
DDI-DrugBank.d277.s7|46-46|(|O
DDI-DrugBank.d277.s7|47-51|about|O
DDI-DrugBank.d277.s7|53-54|10|O
DDI-DrugBank.d277.s7|55-55|%|O
DDI-DrugBank.d277.s7|56-56|)|O
DDI-DrugBank.d277.s7|58-59|in|O
DDI-DrugBank.d277.s7|61-72|steady-state|O
DDI-DrugBank.d277.s7|74-82|valproate|drug
DDI-DrugBank.d277.s7|84-97|concentrations|O
DDI-DrugBank.d277.s7|98-98|.|O
DDI-DrugBank.d277.s8|0-12|Phenobarbital|drug
DDI-DrugBank.d277.s8|14-15|or|O
DDI-DrugBank.d277.s8|17-25|Primidone|drug
DDI-DrugBank.d277.s8|27-27|:|O
DDI-DrugBank.d277.s8|29-30|No|O
DDI-DrugBank.d277.s8|32-37|formal|O
DDI-DrugBank.d277.s8|39-53|pharmacokinetic|O
DDI-DrugBank.d277.s8|55-61|studies|O
DDI-DrugBank.d277.s8|63-66|have|O
DDI-DrugBank.d277.s8|68-71|been|O
DDI-DrugBank.d277.s8|73-81|performed|O
DDI-DrugBank.d277.s8|83-91|examining|O
DDI-DrugBank.d277.s8|93-95|the|O
DDI-DrugBank.d277.s8|97-104|addition|O
DDI-DrugBank.d277.s8|106-107|of|O
DDI-DrugBank.d277.s8|109-117|tiagabine|drug
DDI-DrugBank.d277.s8|119-120|to|O
DDI-DrugBank.d277.s8|122-129|regimens|O
DDI-DrugBank.d277.s8|131-140|containing|O
DDI-DrugBank.d277.s8|142-154|phenobarbital|drug
DDI-DrugBank.d277.s8|156-157|or|O
DDI-DrugBank.d277.s8|159-167|primidone|drug
DDI-DrugBank.d277.s8|168-168|.|O
DDI-DrugBank.d277.s9|0-2|The|O
DDI-DrugBank.d277.s9|4-11|addition|O
DDI-DrugBank.d277.s9|13-14|of|O
DDI-DrugBank.d277.s9|16-24|tiagabine|drug
DDI-DrugBank.d277.s9|26-27|in|O
DDI-DrugBank.d277.s9|29-29|a|O
DDI-DrugBank.d277.s9|31-37|limited|O
DDI-DrugBank.d277.s9|39-44|number|O
DDI-DrugBank.d277.s9|46-47|of|O
DDI-DrugBank.d277.s9|49-56|patients|O
DDI-DrugBank.d277.s9|58-59|in|O
DDI-DrugBank.d277.s9|61-65|three|O
DDI-DrugBank.d277.s9|67-81|well-controlled|O
DDI-DrugBank.d277.s9|83-89|studies|O
DDI-DrugBank.d277.s9|91-96|caused|O
DDI-DrugBank.d277.s9|98-99|no|O
DDI-DrugBank.d277.s9|101-110|systematic|O
DDI-DrugBank.d277.s9|112-118|changes|O
DDI-DrugBank.d277.s9|120-121|in|O
DDI-DrugBank.d277.s9|123-135|phenobarbital|drug
DDI-DrugBank.d277.s9|137-138|or|O
DDI-DrugBank.d277.s9|140-148|primidone|drug
DDI-DrugBank.d277.s9|150-163|concentrations|O
DDI-DrugBank.d277.s9|165-168|when|O
DDI-DrugBank.d277.s9|170-177|compared|O
DDI-DrugBank.d277.s9|179-180|to|O
DDI-DrugBank.d277.s9|182-188|placebo|O
DDI-DrugBank.d277.s9|189-189|.|O
DDI-DrugBank.d277.s10|0-6|Effects|O
DDI-DrugBank.d277.s10|8-9|of|O
DDI-DrugBank.d277.s10|11-15|other|O
DDI-DrugBank.d277.s10|17-28|Antiepilepsy|O
DDI-DrugBank.d277.s10|30-34|Drugs|O
DDI-DrugBank.d277.s10|36-36|(|O
DDI-DrugBank.d277.s10|37-40|AEDs|group
DDI-DrugBank.d277.s10|41-41|)|O
DDI-DrugBank.d277.s10|43-44|on|O
DDI-DrugBank.d277.s10|46-53|GABITRIL|brand
DDI-DrugBank.d277.s10|55-55|:|O
DDI-DrugBank.d277.s10|57-69|Carbamazepine|drug
DDI-DrugBank.d277.s10|70-70|:|O
DDI-DrugBank.d277.s10|72-81|Population|O
DDI-DrugBank.d277.s10|83-97|pharmacokinetic|O
DDI-DrugBank.d277.s10|99-106|analyses|O
DDI-DrugBank.d277.s10|108-115|indicate|O
DDI-DrugBank.d277.s10|117-120|that|O
DDI-DrugBank.d277.s10|122-130|tiagabine|drug
DDI-DrugBank.d277.s10|132-140|clearance|O
DDI-DrugBank.d277.s10|142-143|is|O
DDI-DrugBank.d277.s10|145-146|60|O
DDI-DrugBank.d277.s10|147-147|%|O
DDI-DrugBank.d277.s10|149-155|greater|O
DDI-DrugBank.d277.s10|157-158|in|O
DDI-DrugBank.d277.s10|160-167|patients|O
DDI-DrugBank.d277.s10|169-174|taking|O
DDI-DrugBank.d277.s10|176-188|carbamazepine|drug
DDI-DrugBank.d277.s10|190-193|with|O
DDI-DrugBank.d277.s10|195-196|or|O
DDI-DrugBank.d277.s10|198-204|without|O
DDI-DrugBank.d277.s10|206-210|other|O
DDI-DrugBank.d277.s10|212-218|enzyme-|O
DDI-DrugBank.d277.s10|220-227|inducing|O
DDI-DrugBank.d277.s10|229-232|AEDs|group
DDI-DrugBank.d277.s10|233-233|.|O
DDI-DrugBank.d277.s11|0-8|Phenytoin|drug
DDI-DrugBank.d277.s11|9-9|:|O
DDI-DrugBank.d277.s11|11-20|Population|O
DDI-DrugBank.d277.s11|22-36|pharmacokinetic|O
DDI-DrugBank.d277.s11|38-45|analyses|O
DDI-DrugBank.d277.s11|47-54|indicate|O
DDI-DrugBank.d277.s11|56-59|that|O
DDI-DrugBank.d277.s11|61-69|tiagabine|drug
DDI-DrugBank.d277.s11|71-79|clearance|O
DDI-DrugBank.d277.s11|81-82|is|O
DDI-DrugBank.d277.s11|84-85|60|O
DDI-DrugBank.d277.s11|86-86|%|O
DDI-DrugBank.d277.s11|88-94|greater|O
DDI-DrugBank.d277.s11|96-97|in|O
DDI-DrugBank.d277.s11|99-106|patients|O
DDI-DrugBank.d277.s11|108-113|taking|O
DDI-DrugBank.d277.s11|115-123|phenytoin|drug
DDI-DrugBank.d277.s11|125-128|with|O
DDI-DrugBank.d277.s11|130-131|or|O
DDI-DrugBank.d277.s11|133-139|without|O
DDI-DrugBank.d277.s11|141-145|other|O
DDI-DrugBank.d277.s11|147-153|enzyme-|O
DDI-DrugBank.d277.s11|155-162|inducing|O
DDI-DrugBank.d277.s11|164-167|AEDs|group
DDI-DrugBank.d277.s11|168-168|.|O
DDI-DrugBank.d277.s12|0-12|Phenobarbital|drug
DDI-DrugBank.d277.s12|14-14|(|O
DDI-DrugBank.d277.s12|15-23|Primidone|drug
DDI-DrugBank.d277.s12|24-24|)|O
DDI-DrugBank.d277.s12|25-25|:|O
DDI-DrugBank.d277.s12|27-36|Population|O
DDI-DrugBank.d277.s12|38-52|pharmacokinetic|O
DDI-DrugBank.d277.s12|54-61|analyses|O
DDI-DrugBank.d277.s12|63-70|indicate|O
DDI-DrugBank.d277.s12|72-75|that|O
DDI-DrugBank.d277.s12|77-85|tiagabine|drug
DDI-DrugBank.d277.s12|87-95|clearance|O
DDI-DrugBank.d277.s12|97-98|is|O
DDI-DrugBank.d277.s12|100-101|60|O
DDI-DrugBank.d277.s12|102-102|%|O
DDI-DrugBank.d277.s12|104-110|greater|O
DDI-DrugBank.d277.s12|112-113|in|O
DDI-DrugBank.d277.s12|115-122|patients|O
DDI-DrugBank.d277.s12|124-129|taking|O
DDI-DrugBank.d277.s12|131-143|phenobarbital|drug
DDI-DrugBank.d277.s12|145-145|(|O
DDI-DrugBank.d277.s12|146-154|primidone|drug
DDI-DrugBank.d277.s12|155-155|)|O
DDI-DrugBank.d277.s12|157-160|with|O
DDI-DrugBank.d277.s12|162-163|or|O
DDI-DrugBank.d277.s12|165-171|without|O
DDI-DrugBank.d277.s12|173-177|other|O
DDI-DrugBank.d277.s12|179-193|enzyme-inducing|O
DDI-DrugBank.d277.s12|195-198|AEDs|group
DDI-DrugBank.d277.s12|199-199|.|O
DDI-DrugBank.d277.s13|0-8|Valproate|drug
DDI-DrugBank.d277.s13|9-9|:|O
DDI-DrugBank.d277.s13|11-13|The|O
DDI-DrugBank.d277.s13|15-22|addition|O
DDI-DrugBank.d277.s13|24-25|of|O
DDI-DrugBank.d277.s13|27-35|tiagabine|drug
DDI-DrugBank.d277.s13|37-38|to|O
DDI-DrugBank.d277.s13|40-47|patients|O
DDI-DrugBank.d277.s13|49-54|taking|O
DDI-DrugBank.d277.s13|56-64|valproate|drug
DDI-DrugBank.d277.s13|66-76|chronically|O
DDI-DrugBank.d277.s13|78-80|had|O
DDI-DrugBank.d277.s13|82-83|no|O
DDI-DrugBank.d277.s13|85-90|effect|O
DDI-DrugBank.d277.s13|92-93|on|O
DDI-DrugBank.d277.s13|95-103|tiagabine|drug
DDI-DrugBank.d277.s13|105-120|pharmacokinetics|O
DDI-DrugBank.d277.s13|121-121|,|O
DDI-DrugBank.d277.s13|123-125|but|O
DDI-DrugBank.d277.s13|127-135|valproate|drug
DDI-DrugBank.d277.s13|137-149|significantly|O
DDI-DrugBank.d277.s13|151-159|decreased|O
DDI-DrugBank.d277.s13|161-169|tiagabine|drug
DDI-DrugBank.d277.s13|171-177|binding|O
DDI-DrugBank.d277.s13|179-180|in|O
DDI-DrugBank.d277.s13|182-186|vitro|O
DDI-DrugBank.d277.s13|188-191|from|O
DDI-DrugBank.d277.s13|193-196|96.3|O
DDI-DrugBank.d277.s13|198-199|to|O
DDI-DrugBank.d277.s13|201-204|94.8|O
DDI-DrugBank.d277.s13|205-205|%|O
DDI-DrugBank.d277.s13|206-206|,|O
DDI-DrugBank.d277.s13|208-212|which|O
DDI-DrugBank.d277.s13|214-221|resulted|O
DDI-DrugBank.d277.s13|223-224|in|O
DDI-DrugBank.d277.s13|226-227|an|O
DDI-DrugBank.d277.s13|229-236|increase|O
DDI-DrugBank.d277.s13|238-239|of|O
DDI-DrugBank.d277.s13|241-253|approximately|O
DDI-DrugBank.d277.s13|255-256|40|O
DDI-DrugBank.d277.s13|257-257|%|O
DDI-DrugBank.d277.s13|259-260|in|O
DDI-DrugBank.d277.s13|262-264|the|O
DDI-DrugBank.d277.s13|266-269|free|O
DDI-DrugBank.d277.s13|271-279|tiagabine|O
DDI-DrugBank.d277.s13|281-293|concentration|O
DDI-DrugBank.d277.s13|294-294|.|O
DDI-DrugBank.d277.s14|0-2|The|O
DDI-DrugBank.d277.s14|4-11|clinical|O
DDI-DrugBank.d277.s14|13-21|relevance|O
DDI-DrugBank.d277.s14|23-24|of|O
DDI-DrugBank.d277.s14|26-29|this|O
DDI-DrugBank.d277.s14|31-32|in|O
DDI-DrugBank.d277.s14|34-38|vitro|O
DDI-DrugBank.d277.s14|40-46|finding|O
DDI-DrugBank.d277.s14|48-49|is|O
DDI-DrugBank.d277.s14|51-57|unknown|O
DDI-DrugBank.d277.s14|58-58|.|O
DDI-DrugBank.d277.s15|0-10|Interaction|O
DDI-DrugBank.d277.s15|12-13|of|O
DDI-DrugBank.d277.s15|15-22|GABITRIL|brand
DDI-DrugBank.d277.s15|24-27|with|O
DDI-DrugBank.d277.s15|29-33|Other|O
DDI-DrugBank.d277.s15|35-39|Drugs|O
DDI-DrugBank.d277.s15|41-41|:|O
DDI-DrugBank.d277.s15|43-52|Cimetidine|drug
DDI-DrugBank.d277.s15|54-54|:|O
DDI-DrugBank.d277.s15|56-72|Co-administration|O
DDI-DrugBank.d277.s15|74-75|of|O
DDI-DrugBank.d277.s15|77-86|cimetidine|drug
DDI-DrugBank.d277.s15|88-88|(|O
DDI-DrugBank.d277.s15|89-91|800|O
DDI-DrugBank.d277.s15|93-98|mg/day|O
DDI-DrugBank.d277.s15|99-99|)|O
DDI-DrugBank.d277.s15|101-102|to|O
DDI-DrugBank.d277.s15|104-111|patients|O
DDI-DrugBank.d277.s15|113-118|taking|O
DDI-DrugBank.d277.s15|120-128|tiagabine|drug
DDI-DrugBank.d277.s15|130-140|chronically|O
DDI-DrugBank.d277.s15|142-144|had|O
DDI-DrugBank.d277.s15|146-147|no|O
DDI-DrugBank.d277.s15|149-154|effect|O
DDI-DrugBank.d277.s15|156-157|on|O
DDI-DrugBank.d277.s15|159-167|tiagabine|drug
DDI-DrugBank.d277.s15|169-184|pharmacokinetics|O
DDI-DrugBank.d277.s15|185-185|.|O
DDI-DrugBank.d277.s16|0-11|Theophylline|drug
DDI-DrugBank.d277.s16|12-12|:|O
DDI-DrugBank.d277.s16|14-14|A|O
DDI-DrugBank.d277.s16|16-21|single|O
DDI-DrugBank.d277.s16|23-24|10|O
DDI-DrugBank.d277.s16|26-27|mg|O
DDI-DrugBank.d277.s16|29-32|dose|O
DDI-DrugBank.d277.s16|34-35|of|O
DDI-DrugBank.d277.s16|37-45|tiagabine|drug
DDI-DrugBank.d277.s16|47-49|did|O
DDI-DrugBank.d277.s16|51-53|not|O
DDI-DrugBank.d277.s16|55-60|affect|O
DDI-DrugBank.d277.s16|62-64|the|O
DDI-DrugBank.d277.s16|66-81|pharmacokinetics|O
DDI-DrugBank.d277.s16|83-84|of|O
DDI-DrugBank.d277.s16|86-97|theophylline|drug
DDI-DrugBank.d277.s16|99-100|at|O
DDI-DrugBank.d277.s16|102-107|steady|O
DDI-DrugBank.d277.s16|109-113|state|O
DDI-DrugBank.d277.s16|114-114|.|O
DDI-DrugBank.d277.s17|0-7|Warfarin|drug
DDI-DrugBank.d277.s17|8-8|:|O
DDI-DrugBank.d277.s17|10-11|No|O
DDI-DrugBank.d277.s17|13-23|significant|O
DDI-DrugBank.d277.s17|25-35|differences|O
DDI-DrugBank.d277.s17|37-40|were|O
DDI-DrugBank.d277.s17|42-49|observed|O
DDI-DrugBank.d277.s17|51-52|in|O
DDI-DrugBank.d277.s17|54-56|the|O
DDI-DrugBank.d277.s17|58-69|steady-state|O
DDI-DrugBank.d277.s17|71-86|pharmacokinetics|O
DDI-DrugBank.d277.s17|88-89|of|O
DDI-DrugBank.d277.s17|91-100|R-warfarin|drug
DDI-DrugBank.d277.s17|102-103|or|O
DDI-DrugBank.d277.s17|105-114|S-warfarin|drug
DDI-DrugBank.d277.s17|116-119|with|O
DDI-DrugBank.d277.s17|121-123|the|O
DDI-DrugBank.d277.s17|125-132|addition|O
DDI-DrugBank.d277.s17|134-135|of|O
DDI-DrugBank.d277.s17|137-145|tiagabine|drug
DDI-DrugBank.d277.s17|147-151|given|O
DDI-DrugBank.d277.s17|153-154|as|O
DDI-DrugBank.d277.s17|156-156|a|O
DDI-DrugBank.d277.s17|158-163|single|O
DDI-DrugBank.d277.s17|165-168|dose|O
DDI-DrugBank.d277.s17|169-169|.|O
DDI-DrugBank.d277.s18|0-10|Prothrombin|O
DDI-DrugBank.d277.s18|12-16|times|O
DDI-DrugBank.d277.s18|18-21|were|O
DDI-DrugBank.d277.s18|23-25|not|O
DDI-DrugBank.d277.s18|27-34|affected|O
DDI-DrugBank.d277.s18|36-37|by|O
DDI-DrugBank.d277.s18|39-47|tiagabine|drug
DDI-DrugBank.d277.s18|48-48|.|O
DDI-DrugBank.d277.s19|0-6|Digoxin|drug
DDI-DrugBank.d277.s19|7-7|:|O
DDI-DrugBank.d277.s19|9-19|Concomitant|O
DDI-DrugBank.d277.s19|21-34|administration|O
DDI-DrugBank.d277.s19|36-37|of|O
DDI-DrugBank.d277.s19|39-47|tiagabine|drug
DDI-DrugBank.d277.s19|49-51|did|O
DDI-DrugBank.d277.s19|53-55|not|O
DDI-DrugBank.d277.s19|57-62|affect|O
DDI-DrugBank.d277.s19|64-66|the|O
DDI-DrugBank.d277.s19|68-79|steady-state|O
DDI-DrugBank.d277.s19|81-96|pharmacokinetics|O
DDI-DrugBank.d277.s19|98-99|of|O
DDI-DrugBank.d277.s19|101-107|digoxin|drug
DDI-DrugBank.d277.s19|109-110|or|O
DDI-DrugBank.d277.s19|112-114|the|O
DDI-DrugBank.d277.s19|116-119|mean|O
DDI-DrugBank.d277.s19|121-125|daily|O
DDI-DrugBank.d277.s19|127-132|trough|O
DDI-DrugBank.d277.s19|134-138|serum|O
DDI-DrugBank.d277.s19|140-144|level|O
DDI-DrugBank.d277.s19|146-147|of|O
DDI-DrugBank.d277.s19|149-155|digoxin|drug
DDI-DrugBank.d277.s19|156-156|.|O
DDI-DrugBank.d277.s20|0-6|Ethanol|drug
DDI-DrugBank.d277.s20|8-9|or|O
DDI-DrugBank.d277.s20|11-19|Triazolam|drug
DDI-DrugBank.d277.s20|20-20|:|O
DDI-DrugBank.d277.s20|22-23|No|O
DDI-DrugBank.d277.s20|25-35|significant|O
DDI-DrugBank.d277.s20|37-47|differences|O
DDI-DrugBank.d277.s20|49-52|were|O
DDI-DrugBank.d277.s20|54-61|observed|O
DDI-DrugBank.d277.s20|63-64|in|O
DDI-DrugBank.d277.s20|66-68|the|O
DDI-DrugBank.d277.s20|70-85|pharmacokinetics|O
DDI-DrugBank.d277.s20|87-88|of|O
DDI-DrugBank.d277.s20|90-98|triazolam|drug
DDI-DrugBank.d277.s20|100-100|(|O
DDI-DrugBank.d277.s20|101-105|0.125|O
DDI-DrugBank.d277.s20|107-108|mg|O
DDI-DrugBank.d277.s20|109-109|)|O
DDI-DrugBank.d277.s20|111-113|and|O
DDI-DrugBank.d277.s20|115-123|tiagabine|drug
DDI-DrugBank.d277.s20|125-125|(|O
DDI-DrugBank.d277.s20|126-127|10|O
DDI-DrugBank.d277.s20|129-130|mg|O
DDI-DrugBank.d277.s20|131-131|)|O
DDI-DrugBank.d277.s20|133-136|when|O
DDI-DrugBank.d277.s20|138-142|given|O
DDI-DrugBank.d277.s20|144-151|together|O
DDI-DrugBank.d277.s20|153-154|as|O
DDI-DrugBank.d277.s20|156-156|a|O
DDI-DrugBank.d277.s20|158-163|single|O
DDI-DrugBank.d277.s20|165-168|dose|O
DDI-DrugBank.d277.s20|169-169|.|O
DDI-DrugBank.d277.s21|0-2|The|O
DDI-DrugBank.d277.s21|4-19|pharmacokinetics|O
DDI-DrugBank.d277.s21|21-22|of|O
DDI-DrugBank.d277.s21|24-30|ethanol|drug
DDI-DrugBank.d277.s21|32-35|were|O
DDI-DrugBank.d277.s21|37-39|not|O
DDI-DrugBank.d277.s21|41-48|affected|O
DDI-DrugBank.d277.s21|50-51|by|O
DDI-DrugBank.d277.s21|53-65|multiple-dose|O
DDI-DrugBank.d277.s21|67-80|administration|O
DDI-DrugBank.d277.s21|82-83|of|O
DDI-DrugBank.d277.s21|85-93|tiagabine|drug
DDI-DrugBank.d277.s21|94-94|.|O
DDI-DrugBank.d277.s22|0-8|Tiagabine|drug
DDI-DrugBank.d277.s22|10-12|has|O
DDI-DrugBank.d277.s22|14-18|shown|O
DDI-DrugBank.d277.s22|20-21|no|O
DDI-DrugBank.d277.s22|23-32|clinically|O
DDI-DrugBank.d277.s22|34-42|important|O
DDI-DrugBank.d277.s22|44-55|potentiation|O
DDI-DrugBank.d277.s22|57-58|of|O
DDI-DrugBank.d277.s22|60-62|the|O
DDI-DrugBank.d277.s22|64-78|pharmacodynamic|O
DDI-DrugBank.d277.s22|80-86|effects|O
DDI-DrugBank.d277.s22|88-89|of|O
DDI-DrugBank.d277.s22|91-96|triazo|O
DDI-DrugBank.d277.s22|98-100|lam|O
DDI-DrugBank.d277.s22|102-103|or|O
DDI-DrugBank.d277.s22|105-111|alcohol|drug
DDI-DrugBank.d277.s22|112-112|.|O
DDI-DrugBank.d277.s23|0-6|Because|O
DDI-DrugBank.d277.s23|8-9|of|O
DDI-DrugBank.d277.s23|11-13|the|O
DDI-DrugBank.d277.s23|15-22|possible|O
DDI-DrugBank.d277.s23|24-31|additive|O
DDI-DrugBank.d277.s23|33-39|effects|O
DDI-DrugBank.d277.s23|41-42|of|O
DDI-DrugBank.d277.s23|44-48|drugs|O
DDI-DrugBank.d277.s23|50-53|that|O
DDI-DrugBank.d277.s23|55-57|may|O
DDI-DrugBank.d277.s23|59-65|depress|O
DDI-DrugBank.d277.s23|67-69|the|O
DDI-DrugBank.d277.s23|71-77|nervous|O
DDI-DrugBank.d277.s23|79-84|system|O
DDI-DrugBank.d277.s23|85-85|,|O
DDI-DrugBank.d277.s23|87-93|ethanol|drug
DDI-DrugBank.d277.s23|95-96|or|O
DDI-DrugBank.d277.s23|98-106|triazolam|drug
DDI-DrugBank.d277.s23|108-113|should|O
DDI-DrugBank.d277.s23|115-116|be|O
DDI-DrugBank.d277.s23|118-121|used|O
DDI-DrugBank.d277.s23|123-132|cautiously|O
DDI-DrugBank.d277.s23|134-135|in|O
DDI-DrugBank.d277.s23|137-147|combination|O
DDI-DrugBank.d277.s23|149-152|with|O
DDI-DrugBank.d277.s23|154-162|tiagabine|drug
DDI-DrugBank.d277.s23|163-163|.|O
DDI-DrugBank.d277.s24|0-3|Oral|O
DDI-DrugBank.d277.s24|5-18|Contraceptives|group
DDI-DrugBank.d277.s24|19-19|:|O
DDI-DrugBank.d277.s24|21-28|Multiple|O
DDI-DrugBank.d277.s24|30-33|dose|O
DDI-DrugBank.d277.s24|35-48|administration|O
DDI-DrugBank.d277.s24|50-51|of|O
DDI-DrugBank.d277.s24|53-61|tiagabine|drug
DDI-DrugBank.d277.s24|63-63|(|O
DDI-DrugBank.d277.s24|64-64|8|O
DDI-DrugBank.d277.s24|66-71|mg/day|O
DDI-DrugBank.d277.s24|73-83|monotherapy|O
DDI-DrugBank.d277.s24|84-84|)|O
DDI-DrugBank.d277.s24|86-88|did|O
DDI-DrugBank.d277.s24|90-92|not|O
DDI-DrugBank.d277.s24|94-98|alter|O
DDI-DrugBank.d277.s24|100-102|the|O
DDI-DrugBank.d277.s24|104-119|pharmacokinetics|O
DDI-DrugBank.d277.s24|121-122|of|O
DDI-DrugBank.d277.s24|124-127|oral|O
DDI-DrugBank.d277.s24|129-142|contraceptives|group
DDI-DrugBank.d277.s24|144-145|in|O
DDI-DrugBank.d277.s24|147-153|healthy|O
DDI-DrugBank.d277.s24|155-159|women|O
DDI-DrugBank.d277.s24|161-162|of|O
DDI-DrugBank.d277.s24|164-175|childbearing|O
DDI-DrugBank.d277.s24|177-179|age|O
DDI-DrugBank.d277.s24|180-180|.|O
DDI-DrugBank.d277.s25|0-9|Antipyrine|drug
DDI-DrugBank.d277.s25|11-11|:|O
DDI-DrugBank.d277.s25|13-22|Antipyrine|drug
DDI-DrugBank.d277.s25|24-39|pharmacokinetics|O
DDI-DrugBank.d277.s25|41-44|were|O
DDI-DrugBank.d277.s25|46-48|not|O
DDI-DrugBank.d277.s25|50-62|significantly|O
DDI-DrugBank.d277.s25|64-72|different|O
DDI-DrugBank.d277.s25|74-79|before|O
DDI-DrugBank.d277.s25|81-83|and|O
DDI-DrugBank.d277.s25|85-89|after|O
DDI-DrugBank.d277.s25|91-99|tiagabine|drug
DDI-DrugBank.d277.s25|101-113|multiple-dose|O
DDI-DrugBank.d277.s25|115-122|regimens|O
DDI-DrugBank.d277.s25|123-123|.|O
DDI-DrugBank.d277.s26|0-3|This|O
DDI-DrugBank.d277.s26|5-13|indicates|O
DDI-DrugBank.d277.s26|15-18|that|O
DDI-DrugBank.d277.s26|20-28|tiagabine|drug
DDI-DrugBank.d277.s26|30-33|does|O
DDI-DrugBank.d277.s26|35-37|not|O
DDI-DrugBank.d277.s26|39-43|cause|O
DDI-DrugBank.d277.s26|45-53|induction|O
DDI-DrugBank.d277.s26|55-56|or|O
DDI-DrugBank.d277.s26|58-67|inhibition|O
DDI-DrugBank.d277.s26|69-70|of|O
DDI-DrugBank.d277.s26|72-74|the|O
DDI-DrugBank.d277.s26|76-82|hepatic|O
DDI-DrugBank.d277.s26|84-93|microsomal|O
DDI-DrugBank.d277.s26|95-100|enzyme|O
DDI-DrugBank.d277.s26|102-108|systems|O
DDI-DrugBank.d277.s26|110-120|responsible|O
DDI-DrugBank.d277.s26|122-124|for|O
DDI-DrugBank.d277.s26|126-128|the|O
DDI-DrugBank.d277.s26|130-139|metabolism|O
DDI-DrugBank.d277.s26|141-142|of|O
DDI-DrugBank.d277.s26|144-153|antipyrine|drug
DDI-DrugBank.d277.s26|154-154|.|O
DDI-DrugBank.d277.s27|0-10|Interaction|O
DDI-DrugBank.d277.s27|12-13|of|O
DDI-DrugBank.d277.s27|15-22|GABITRIL|brand
DDI-DrugBank.d277.s27|24-27|with|O
DDI-DrugBank.d277.s27|29-34|Highly|O
DDI-DrugBank.d277.s27|36-42|Protein|O
DDI-DrugBank.d277.s27|44-48|Bound|O
DDI-DrugBank.d277.s27|50-54|Drugs|O
DDI-DrugBank.d277.s27|55-55|:|O
DDI-DrugBank.d277.s27|57-58|In|O
DDI-DrugBank.d277.s27|60-64|vitro|O
DDI-DrugBank.d277.s27|66-69|data|O
DDI-DrugBank.d277.s27|71-76|showed|O
DDI-DrugBank.d277.s27|78-81|that|O
DDI-DrugBank.d277.s27|83-91|tiagabine|drug
DDI-DrugBank.d277.s27|93-94|is|O
DDI-DrugBank.d277.s27|96-97|96|O
DDI-DrugBank.d277.s27|98-98|%|O
DDI-DrugBank.d277.s27|100-104|bound|O
DDI-DrugBank.d277.s27|106-107|to|O
DDI-DrugBank.d277.s27|109-113|human|O
DDI-DrugBank.d277.s27|115-120|plasma|O
DDI-DrugBank.d277.s27|122-128|protein|O
DDI-DrugBank.d277.s27|130-132|and|O
DDI-DrugBank.d277.s27|134-142|therefore|O
DDI-DrugBank.d277.s27|144-146|has|O
DDI-DrugBank.d277.s27|148-150|the|O
DDI-DrugBank.d277.s27|152-160|potential|O
DDI-DrugBank.d277.s27|162-163|to|O
DDI-DrugBank.d277.s27|165-172|interact|O
DDI-DrugBank.d277.s27|174-177|with|O
DDI-DrugBank.d277.s27|179-183|other|O
DDI-DrugBank.d277.s27|185-190|highly|O
DDI-DrugBank.d277.s27|192-198|protein|O
DDI-DrugBank.d277.s27|200-204|bound|O
DDI-DrugBank.d277.s27|206-214|compounds|O
DDI-DrugBank.d277.s27|215-215|.|O
DDI-DrugBank.d277.s28|0-3|Such|O
DDI-DrugBank.d277.s28|5-6|an|O
DDI-DrugBank.d277.s28|8-18|interaction|O
DDI-DrugBank.d277.s28|20-22|can|O
DDI-DrugBank.d277.s28|24-34|potentially|O
DDI-DrugBank.d277.s28|36-39|lead|O
DDI-DrugBank.d277.s28|41-42|to|O
DDI-DrugBank.d277.s28|44-49|higher|O
DDI-DrugBank.d277.s28|51-54|free|O
DDI-DrugBank.d277.s28|56-64|fractions|O
DDI-DrugBank.d277.s28|66-67|of|O
DDI-DrugBank.d277.s28|69-74|either|O
DDI-DrugBank.d277.s28|76-84|tiagabine|drug
DDI-DrugBank.d277.s28|86-87|or|O
DDI-DrugBank.d277.s28|89-91|the|O
DDI-DrugBank.d277.s28|93-101|competing|O
DDI-DrugBank.d277.s28|103-106|drug|O
DDI-DrugBank.d277.s28|107-107|.|O
DDI-DrugBank.d377.s0|0-17|Phospholine Iodide|drug
DDI-DrugBank.d377.s0|19-29|potentiates|O
DDI-DrugBank.d377.s0|31-35|other|O
DDI-DrugBank.d377.s0|37-61|cholinesterase inhibitors|group
DDI-DrugBank.d377.s0|63-66|such|O
DDI-DrugBank.d377.s0|68-69|as|O
DDI-DrugBank.d377.s0|71-85|succinylcholine|drug
DDI-DrugBank.d377.s0|87-88|or|O
DDI-DrugBank.d377.s0|106-108|and|O
DDI-DrugBank.d377.s0|120-131|insecticides|O
DDI-DrugBank.d377.s0|132-132|.|O
DDI-DrugBank.d377.s1|0-7|Patients|O
DDI-DrugBank.d377.s1|9-18|undergoing|O
DDI-DrugBank.d377.s1|20-27|systemic|O
DDI-DrugBank.d377.s1|29-46|anticholinesterase|O
DDI-DrugBank.d377.s1|48-56|treatment|O
DDI-DrugBank.d377.s1|58-63|should|O
DDI-DrugBank.d377.s1|65-66|be|O
DDI-DrugBank.d377.s1|68-73|warned|O
DDI-DrugBank.d377.s1|75-76|of|O
DDI-DrugBank.d377.s1|78-80|the|O
DDI-DrugBank.d377.s1|82-89|possible|O
DDI-DrugBank.d377.s1|91-98|additive|O
DDI-DrugBank.d377.s1|100-106|effects|O
DDI-DrugBank.d377.s1|108-109|of|O
DDI-DrugBank.d377.s1|111-128|Phospholine Iodide|drug
DDI-DrugBank.d377.s1|129-129|.|O
DDI-DrugBank.d668.s0|0-7|Although|O
DDI-DrugBank.d668.s0|9-16|specific|O
DDI-DrugBank.d668.s0|18-21|drug|O
DDI-DrugBank.d668.s0|23-24|or|O
DDI-DrugBank.d668.s0|26-29|food|O
DDI-DrugBank.d668.s0|31-42|interactions|O
DDI-DrugBank.d668.s0|44-47|with|O
DDI-DrugBank.d668.s0|49-60|mifepristone|drug
DDI-DrugBank.d668.s0|62-65|have|O
DDI-DrugBank.d668.s0|67-69|not|O
DDI-DrugBank.d668.s0|71-74|been|O
DDI-DrugBank.d668.s0|76-82|studied|O
DDI-DrugBank.d668.s0|83-83|,|O
DDI-DrugBank.d668.s0|85-86|on|O
DDI-DrugBank.d668.s0|88-90|the|O
DDI-DrugBank.d668.s0|92-96|basis|O
DDI-DrugBank.d668.s0|98-99|of|O
DDI-DrugBank.d668.s0|101-104|this|O
DDI-DrugBank.d668.s0|106-109|drug|O
DDI-DrugBank.d668.s0|113-113|s|O
DDI-DrugBank.d668.s0|115-124|metabolism|O
DDI-DrugBank.d668.s0|126-127|by|O
DDI-DrugBank.d668.s0|129-131|CYP|O
DDI-DrugBank.d668.s0|133-135|3A4|O
DDI-DrugBank.d668.s0|136-136|,|O
DDI-DrugBank.d668.s0|138-139|it|O
DDI-DrugBank.d668.s0|141-142|is|O
DDI-DrugBank.d668.s0|144-151|possible|O
DDI-DrugBank.d668.s0|153-156|that|O
DDI-DrugBank.d668.s0|158-169|ketoconazole|drug
DDI-DrugBank.d668.s0|170-170|,|O
DDI-DrugBank.d668.s0|172-183|itraconazole|drug
DDI-DrugBank.d668.s0|184-184|,|O
DDI-DrugBank.d668.s0|186-197|erythromycin|drug
DDI-DrugBank.d668.s0|198-198|,|O
DDI-DrugBank.d668.s0|200-202|and|O
DDI-DrugBank.d668.s0|204-213|grapefruit|O
DDI-DrugBank.d668.s0|215-219|juice|O
DDI-DrugBank.d668.s0|221-223|may|O
DDI-DrugBank.d668.s0|225-231|inhibit|O
DDI-DrugBank.d668.s0|233-235|its|O
DDI-DrugBank.d668.s0|237-246|metabolism|O
DDI-DrugBank.d668.s0|248-248|(|O
DDI-DrugBank.d668.s0|249-258|increasing|O
DDI-DrugBank.d668.s0|260-264|serum|O
DDI-DrugBank.d668.s0|266-271|levels|O
DDI-DrugBank.d668.s0|273-274|of|O
DDI-DrugBank.d668.s0|276-287|mifepristone|drug
DDI-DrugBank.d668.s0|288-288|)|O
DDI-DrugBank.d668.s0|289-289|.|O
DDI-DrugBank.d668.s1|0-10|Furthermore|O
DDI-DrugBank.d668.s1|11-11|,|O
DDI-DrugBank.d668.s1|13-20|rifampin|drug
DDI-DrugBank.d668.s1|21-21|,|O
DDI-DrugBank.d668.s1|23-35|dexamethasone|drug
DDI-DrugBank.d668.s1|36-36|,|O
DDI-DrugBank.d668.s1|38-39|St|O
DDI-DrugBank.d668.s1|40-40|.|O
DDI-DrugBank.d668.s2|0-3|John|O
DDI-DrugBank.d668.s2|7-7|s|O
DDI-DrugBank.d668.s2|9-12|Wort|O
DDI-DrugBank.d668.s2|13-13|,|O
DDI-DrugBank.d668.s2|15-17|and|O
DDI-DrugBank.d668.s2|19-25|certain|O
DDI-DrugBank.d668.s2|27-41|anticonvulsants|group
DDI-DrugBank.d668.s2|43-43|(|O
DDI-DrugBank.d668.s2|44-52|phenytoin|drug
DDI-DrugBank.d668.s2|53-53|,|O
DDI-DrugBank.d668.s2|55-67|phenobarbital|drug
DDI-DrugBank.d668.s2|68-68|,|O
DDI-DrugBank.d668.s2|70-82|carbamazepine|drug
DDI-DrugBank.d668.s2|83-83|)|O
DDI-DrugBank.d668.s2|85-87|may|O
DDI-DrugBank.d668.s2|89-94|induce|O
DDI-DrugBank.d668.s2|96-107|mifepristone|drug
DDI-DrugBank.d668.s2|109-118|metabolism|O
DDI-DrugBank.d668.s2|120-120|(|O
DDI-DrugBank.d668.s2|121-128|lowering|O
DDI-DrugBank.d668.s2|130-134|serum|O
DDI-DrugBank.d668.s2|136-141|levels|O
DDI-DrugBank.d668.s2|143-144|of|O
DDI-DrugBank.d668.s2|146-157|mifepristone|drug
DDI-DrugBank.d668.s2|158-158|)|O
DDI-DrugBank.d668.s2|159-159|.|O
DDI-DrugBank.d668.s3|0-4|Based|O
DDI-DrugBank.d668.s3|6-7|on|O
DDI-DrugBank.d668.s3|9-10|in|O
DDI-DrugBank.d668.s3|12-16|vitro|O
DDI-DrugBank.d668.s3|18-27|inhibition|O
DDI-DrugBank.d668.s3|29-39|information|O
DDI-DrugBank.d668.s3|40-40|,|O
DDI-DrugBank.d668.s3|42-57|coadministration|O
DDI-DrugBank.d668.s3|59-60|of|O
DDI-DrugBank.d668.s3|62-73|mifepristone|drug
DDI-DrugBank.d668.s3|75-77|may|O
DDI-DrugBank.d668.s3|79-82|lead|O
DDI-DrugBank.d668.s3|84-85|to|O
DDI-DrugBank.d668.s3|87-88|an|O
DDI-DrugBank.d668.s3|90-97|increase|O
DDI-DrugBank.d668.s3|99-100|in|O
DDI-DrugBank.d668.s3|102-106|serum|O
DDI-DrugBank.d668.s3|108-113|levels|O
DDI-DrugBank.d668.s3|115-116|of|O
DDI-DrugBank.d668.s3|118-122|drugs|O
DDI-DrugBank.d668.s3|124-127|that|O
DDI-DrugBank.d668.s3|129-131|are|O
DDI-DrugBank.d668.s3|133-135|CYP|O
DDI-DrugBank.d668.s3|137-139|3A4|O
DDI-DrugBank.d668.s3|141-150|substrates|O
DDI-DrugBank.d668.s3|151-151|.|O
DDI-DrugBank.d668.s4|0-2|Due|O
DDI-DrugBank.d668.s4|4-5|to|O
DDI-DrugBank.d668.s4|7-9|the|O
DDI-DrugBank.d668.s4|11-14|slow|O
DDI-DrugBank.d668.s4|16-26|elimination|O
DDI-DrugBank.d668.s4|28-29|of|O
DDI-DrugBank.d668.s4|31-42|mifepristone|drug
DDI-DrugBank.d668.s4|44-47|from|O
DDI-DrugBank.d668.s4|49-51|the|O
DDI-DrugBank.d668.s4|53-56|body|O
DDI-DrugBank.d668.s4|57-57|,|O
DDI-DrugBank.d668.s4|59-62|such|O
DDI-DrugBank.d668.s4|64-74|interaction|O
DDI-DrugBank.d668.s4|76-78|may|O
DDI-DrugBank.d668.s4|80-81|be|O
DDI-DrugBank.d668.s4|83-90|observed|O
DDI-DrugBank.d668.s4|92-94|for|O
DDI-DrugBank.d668.s4|96-96|a|O
DDI-DrugBank.d668.s4|98-106|prolonged|O
DDI-DrugBank.d668.s4|108-113|period|O
DDI-DrugBank.d668.s4|115-119|after|O
DDI-DrugBank.d668.s4|121-123|its|O
DDI-DrugBank.d668.s4|125-138|administration|O
DDI-DrugBank.d668.s4|139-139|.|O
DDI-DrugBank.d668.s5|0-8|Therefore|O
DDI-DrugBank.d668.s5|9-9|,|O
DDI-DrugBank.d668.s5|11-17|caution|O
DDI-DrugBank.d668.s5|19-24|should|O
DDI-DrugBank.d668.s5|26-27|be|O
DDI-DrugBank.d668.s5|29-37|exercised|O
DDI-DrugBank.d668.s5|39-42|when|O
DDI-DrugBank.d668.s5|44-55|mifepristone|drug
DDI-DrugBank.d668.s5|57-58|is|O
DDI-DrugBank.d668.s5|60-71|administered|O
DDI-DrugBank.d668.s5|73-76|with|O
DDI-DrugBank.d668.s5|78-82|drugs|O
DDI-DrugBank.d668.s5|84-87|that|O
DDI-DrugBank.d668.s5|89-91|are|O
DDI-DrugBank.d668.s5|93-95|CYP|O
DDI-DrugBank.d668.s5|97-99|3A4|O
DDI-DrugBank.d668.s5|101-110|substrates|O
DDI-DrugBank.d668.s5|112-114|and|O
DDI-DrugBank.d668.s5|116-119|have|O
DDI-DrugBank.d668.s5|121-126|narrow|O
DDI-DrugBank.d668.s5|128-138|therapeutic|O
DDI-DrugBank.d668.s5|140-144|range|O
DDI-DrugBank.d668.s5|145-145|,|O
DDI-DrugBank.d668.s5|147-155|including|O
DDI-DrugBank.d668.s5|157-160|some|O
DDI-DrugBank.d668.s5|162-167|agents|O
DDI-DrugBank.d668.s5|169-172|used|O
DDI-DrugBank.d668.s5|174-179|during|O
DDI-DrugBank.d668.s5|181-187|general|O
DDI-DrugBank.d668.s5|189-198|anesthesia|O
DDI-DrugBank.d668.s5|199-199|.|O
DDI-MedLine.d19.s0|0-10|Anaesthesia|O
DDI-MedLine.d19.s0|12-14|and|O
DDI-MedLine.d19.s0|16-18|the|O
DDI-MedLine.d19.s0|20-28|epileptic|O
DDI-MedLine.d19.s0|30-36|pateint|O
DDI-MedLine.d19.s0|37-37|.|O
DDI-MedLine.d19.s1|0-0|A|O
DDI-MedLine.d19.s1|2-7|review|O
DDI-MedLine.d19.s1|8-8|.|O
DDI-MedLine.d19.s2|0-0|A|O
DDI-MedLine.d19.s2|2-7|review|O
DDI-MedLine.d19.s2|9-10|is|O
DDI-MedLine.d19.s2|12-20|presented|O
DDI-MedLine.d19.s2|22-23|of|O
DDI-MedLine.d19.s2|25-28|some|O
DDI-MedLine.d19.s2|30-31|of|O
DDI-MedLine.d19.s2|33-35|the|O
DDI-MedLine.d19.s2|37-44|problems|O
DDI-MedLine.d19.s2|46-49|that|O
DDI-MedLine.d19.s2|51-53|may|O
DDI-MedLine.d19.s2|55-59|arise|O
DDI-MedLine.d19.s2|61-62|in|O
DDI-MedLine.d19.s2|64-74|association|O
DDI-MedLine.d19.s2|76-79|with|O
DDI-MedLine.d19.s2|81-91|anaesthesia|O
DDI-MedLine.d19.s2|93-95|for|O
DDI-MedLine.d19.s2|97-105|epileptic|O
DDI-MedLine.d19.s2|107-114|patients|O
DDI-MedLine.d19.s2|115-115|.|O
DDI-MedLine.d19.s3|0-4|There|O
DDI-MedLine.d19.s3|6-7|is|O
DDI-MedLine.d19.s3|9-11|the|O
DDI-MedLine.d19.s3|13-23|possibility|O
DDI-MedLine.d19.s3|25-26|of|O
DDI-MedLine.d19.s3|28-40|precipitating|O
DDI-MedLine.d19.s3|42-55|anticonvulsant|O
DDI-MedLine.d19.s3|57-60|drug|O
DDI-MedLine.d19.s3|62-69|toxicity|O
DDI-MedLine.d19.s3|70-70|.|O
DDI-MedLine.d19.s4|0-7|Numerous|O
DDI-MedLine.d19.s4|9-12|drug|O
DDI-MedLine.d19.s4|14-25|interactions|O
DDI-MedLine.d19.s4|27-29|are|O
DDI-MedLine.d19.s4|31-38|possible|O
DDI-MedLine.d19.s4|40-43|with|O
DDI-MedLine.d19.s4|45-48|some|O
DDI-MedLine.d19.s4|50-70|anticonvulsant agents|group
DDI-MedLine.d19.s4|71-71|,|O
DDI-MedLine.d19.s4|73-76|such|O
DDI-MedLine.d19.s4|78-79|as|O
DDI-MedLine.d19.s4|81-94|phenobarbitone|drug
DDI-MedLine.d19.s4|96-98|and|O
DDI-MedLine.d19.s4|100-108|phenytoin|drug
DDI-MedLine.d19.s4|109-109|,|O
DDI-MedLine.d19.s4|111-115|which|O
DDI-MedLine.d19.s4|117-122|affect|O
DDI-MedLine.d19.s4|124-130|hepatic|O
DDI-MedLine.d19.s4|132-141|microsomal|O
DDI-MedLine.d19.s4|143-148|enzyme|O
DDI-MedLine.d19.s4|150-156|systems|O
DDI-MedLine.d19.s4|157-157|.|O
DDI-MedLine.d19.s5|0-4|There|O
DDI-MedLine.d19.s5|6-7|is|O
DDI-MedLine.d19.s5|9-11|the|O
DDI-MedLine.d19.s5|13-16|risk|O
DDI-MedLine.d19.s5|18-19|of|O
DDI-MedLine.d19.s5|21-31|convulsions|O
DDI-MedLine.d19.s5|33-41|occurring|O
DDI-MedLine.d19.s5|43-44|in|O
DDI-MedLine.d19.s5|46-56|susceptible|O
DDI-MedLine.d19.s5|58-65|patients|O
DDI-MedLine.d19.s5|67-75|following|O
DDI-MedLine.d19.s5|77-79|the|O
DDI-MedLine.d19.s5|81-83|use|O
DDI-MedLine.d19.s5|85-86|of|O
DDI-MedLine.d19.s5|88-90|the|O
DDI-MedLine.d19.s5|92-94|new|O
DDI-MedLine.d19.s5|96-113|anaesthetic agents|group
DDI-MedLine.d19.s5|115-119|which|O
DDI-MedLine.d19.s5|121-123|are|O
DDI-MedLine.d19.s5|125-131|capable|O
DDI-MedLine.d19.s5|133-134|of|O
DDI-MedLine.d19.s5|136-143|inducing|O
DDI-MedLine.d19.s5|145-147|CNS|O
DDI-MedLine.d19.s5|149-160|excitability|O
DDI-MedLine.d19.s5|161-161|.|O
DDI-DrugBank.d650.s0|0-19|Dopamine antagonists|group
DDI-DrugBank.d650.s0|20-20|,|O
DDI-DrugBank.d650.s0|22-25|such|O
DDI-DrugBank.d650.s0|27-28|as|O
DDI-DrugBank.d650.s0|30-32|the|O
DDI-DrugBank.d650.s0|34-45|neuroleptics|group
DDI-DrugBank.d650.s0|47-47|(|O
DDI-DrugBank.d650.s0|48-61|phenothiazines|group
DDI-DrugBank.d650.s0|62-62|,|O
DDI-DrugBank.d650.s0|64-77|butyrophenones|group
DDI-DrugBank.d650.s0|78-78|,|O
DDI-DrugBank.d650.s0|80-92|thioxanthines|group
DDI-DrugBank.d650.s0|94-94|)|O
DDI-DrugBank.d650.s0|96-97|or|O
DDI-DrugBank.d650.s0|99-112|metoclopramide|drug
DDI-DrugBank.d650.s0|113-113|,|O
DDI-DrugBank.d650.s0|115-124|ordinarily|O
DDI-DrugBank.d650.s0|126-131|should|O
DDI-DrugBank.d650.s0|133-135|not|O
DDI-DrugBank.d650.s0|137-138|be|O
DDI-DrugBank.d650.s0|140-151|administered|O
DDI-DrugBank.d650.s0|153-164|concurrently|O
DDI-DrugBank.d650.s0|166-169|with|O
DDI-DrugBank.d650.s0|171-176|Permax|brand
DDI-DrugBank.d650.s0|178-178|(|O
DDI-DrugBank.d650.s0|179-179|a|O
DDI-DrugBank.d650.s0|181-196|dopamine agonist|group
DDI-DrugBank.d650.s0|197-197|)|O
DDI-DrugBank.d650.s0|198-198|;|O
DDI-DrugBank.d650.s1|0-4|these|O
DDI-DrugBank.d650.s1|6-11|agents|O
DDI-DrugBank.d650.s1|13-15|may|O
DDI-DrugBank.d650.s1|17-24|diminish|O
DDI-DrugBank.d650.s1|26-28|the|O
DDI-DrugBank.d650.s1|30-42|effectiveness|O
DDI-DrugBank.d650.s1|44-45|of|O
DDI-DrugBank.d650.s1|47-52|Permax|brand
DDI-DrugBank.d650.s1|53-53|.|O
DDI-DrugBank.d650.s2|0-6|Because|O
DDI-DrugBank.d650.s2|8-25|pergolide mesylate|drug
DDI-DrugBank.d650.s2|27-28|is|O
DDI-DrugBank.d650.s2|30-42|approximately|O
DDI-DrugBank.d650.s2|44-45|90|O
DDI-DrugBank.d650.s2|46-46|%|O
DDI-DrugBank.d650.s2|48-52|bound|O
DDI-DrugBank.d650.s2|54-55|to|O
DDI-DrugBank.d650.s2|57-62|plasma|O
DDI-DrugBank.d650.s2|64-71|proteins|O
DDI-DrugBank.d650.s2|72-72|,|O
DDI-DrugBank.d650.s2|74-80|caution|O
DDI-DrugBank.d650.s2|82-87|should|O
DDI-DrugBank.d650.s2|89-90|be|O
DDI-DrugBank.d650.s2|92-100|exercised|O
DDI-DrugBank.d650.s2|102-103|if|O
DDI-DrugBank.d650.s2|105-122|pergolide mesylate|drug
DDI-DrugBank.d650.s2|124-125|is|O
DDI-DrugBank.d650.s2|127-140|coadministered|O
DDI-DrugBank.d650.s2|142-145|with|O
DDI-DrugBank.d650.s2|147-151|other|O
DDI-DrugBank.d650.s2|153-157|drugs|O
DDI-DrugBank.d650.s2|159-163|known|O
DDI-DrugBank.d650.s2|165-166|to|O
DDI-DrugBank.d650.s2|168-173|affect|O
DDI-DrugBank.d650.s2|175-181|protein|O
DDI-DrugBank.d650.s2|183-189|binding|O
DDI-DrugBank.d650.s2|190-190|.|O
DDI-DrugBank.d481.s0|0-3|Milk|O
DDI-DrugBank.d481.s0|4-4|,|O
DDI-DrugBank.d481.s0|6-9|milk|O
DDI-DrugBank.d481.s0|11-18|products|O
DDI-DrugBank.d481.s0|19-19|,|O
DDI-DrugBank.d481.s0|21-23|and|O
DDI-DrugBank.d481.s0|25-36|calcium-rich|drug
DDI-DrugBank.d481.s0|38-42|foods|O
DDI-DrugBank.d481.s0|44-45|or|O
DDI-DrugBank.d481.s0|47-51|drugs|O
DDI-DrugBank.d481.s0|53-55|may|O
DDI-DrugBank.d481.s0|57-62|impair|O
DDI-DrugBank.d481.s0|64-66|the|O
DDI-DrugBank.d481.s0|68-77|absorption|O
DDI-DrugBank.d481.s0|79-80|of|O
DDI-DrugBank.d481.s0|82-86|EMCYT|brand
DDI-DrugBank.d481.s0|87-87|.|O
DDI-DrugBank.d254.s0|0-4|Other|O
DDI-DrugBank.d254.s0|6-25|CNS depressant drugs|group
DDI-DrugBank.d254.s0|27-27|(|O
DDI-DrugBank.d254.s0|28-31|e.g.|O
DDI-DrugBank.d254.s0|33-44|barbiturates|group
DDI-DrugBank.d254.s0|45-45|,|O
DDI-DrugBank.d254.s0|47-59|tranquilizers|group
DDI-DrugBank.d254.s0|60-60|,|O
DDI-DrugBank.d254.s0|62-68|opioids|group
DDI-DrugBank.d254.s0|70-72|and|O
DDI-DrugBank.d254.s0|74-80|general|O
DDI-DrugBank.d254.s0|82-92|anesthetics|group
DDI-DrugBank.d254.s0|93-93|)|O
DDI-DrugBank.d254.s0|95-98|have|O
DDI-DrugBank.d254.s0|100-107|additive|O
DDI-DrugBank.d254.s0|109-110|or|O
DDI-DrugBank.d254.s0|112-123|potentiating|O
DDI-DrugBank.d254.s0|125-131|effects|O
DDI-DrugBank.d254.s0|133-136|with|O
DDI-DrugBank.d254.s0|138-145|INAPSINE|brand
DDI-DrugBank.d254.s0|146-146|.|O
DDI-DrugBank.d254.s1|0-3|When|O
DDI-DrugBank.d254.s1|5-12|patients|O
DDI-DrugBank.d254.s1|14-17|have|O
DDI-DrugBank.d254.s1|19-26|received|O
DDI-DrugBank.d254.s1|28-31|such|O
DDI-DrugBank.d254.s1|33-37|drugs|O
DDI-DrugBank.d254.s1|38-38|,|O
DDI-DrugBank.d254.s1|40-42|the|O
DDI-DrugBank.d254.s1|44-47|dose|O
DDI-DrugBank.d254.s1|49-50|of|O
DDI-DrugBank.d254.s1|52-59|INAPSINE|brand
DDI-DrugBank.d254.s1|61-68|required|O
DDI-DrugBank.d254.s1|70-73|will|O
DDI-DrugBank.d254.s1|75-76|be|O
DDI-DrugBank.d254.s1|78-81|less|O
DDI-DrugBank.d254.s1|83-86|than|O
DDI-DrugBank.d254.s1|88-92|usual|O
DDI-DrugBank.d254.s1|93-93|.|O
DDI-DrugBank.d254.s2|0-8|Following|O
DDI-DrugBank.d254.s2|10-12|the|O
DDI-DrugBank.d254.s2|14-27|administration|O
DDI-DrugBank.d254.s2|29-30|of|O
DDI-DrugBank.d254.s2|32-39|INAPSINE|brand
DDI-DrugBank.d254.s2|40-40|,|O
DDI-DrugBank.d254.s2|42-44|the|O
DDI-DrugBank.d254.s2|46-49|dose|O
DDI-DrugBank.d254.s2|51-52|of|O
DDI-DrugBank.d254.s2|54-58|other|O
DDI-DrugBank.d254.s2|60-79|CNS depressant drugs|group
DDI-DrugBank.d254.s2|81-86|should|O
DDI-DrugBank.d254.s2|88-89|be|O
DDI-DrugBank.d254.s2|91-97|reduced|O
DDI-DrugBank.d254.s2|98-98|.|O
DDI-DrugBank.d280.s0|0-1|No|O
DDI-DrugBank.d280.s0|3-10|specific|O
DDI-DrugBank.d280.s0|12-22|information|O
DDI-DrugBank.d280.s0|24-32|available|O
DDI-DrugBank.d280.s1|0-0|.|O
DDI-MedLine.d6.s0|0-14|Pharmacokinetic|O
DDI-MedLine.d6.s0|16-22|profile|O
DDI-MedLine.d6.s0|24-25|of|O
DDI-MedLine.d6.s0|27-34|etodolac|drug
DDI-MedLine.d6.s0|36-37|in|O
DDI-MedLine.d6.s0|39-45|special|O
DDI-MedLine.d6.s0|47-57|populations|O
DDI-MedLine.d6.s0|58-58|.|O
DDI-MedLine.d6.s1|0-2|The|O
DDI-MedLine.d6.s1|4-19|pharmacokinetics|O
DDI-MedLine.d6.s1|21-22|of|O
DDI-MedLine.d6.s1|24-31|etodolac|drug
DDI-MedLine.d6.s1|33-34|in|O
DDI-MedLine.d6.s1|36-42|healthy|O
DDI-MedLine.d6.s1|44-49|normal|O
DDI-MedLine.d6.s1|51-60|volunteers|O
DDI-MedLine.d6.s1|62-64|has|O
DDI-MedLine.d6.s1|66-69|been|O
DDI-MedLine.d6.s1|71-81|extensively|O
DDI-MedLine.d6.s1|83-89|studied|O
DDI-MedLine.d6.s1|91-93|and|O
DDI-MedLine.d6.s1|95-96|is|O
DDI-MedLine.d6.s1|98-101|well|O
DDI-MedLine.d6.s1|103-111|described|O
DDI-MedLine.d6.s1|112-112|.|O
DDI-MedLine.d6.s2|0-7|Etodolac|drug
DDI-MedLine.d6.s2|9-10|is|O
DDI-MedLine.d6.s2|12-24|characterised|O
DDI-MedLine.d6.s2|26-27|by|O
DDI-MedLine.d6.s2|29-29|a|O
DDI-MedLine.d6.s2|31-34|high|O
DDI-MedLine.d6.s2|36-39|oral|O
DDI-MedLine.d6.s2|41-55|bioavailability|O
DDI-MedLine.d6.s2|56-56|,|O
DDI-MedLine.d6.s2|58-60|low|O
DDI-MedLine.d6.s2|62-70|clearance|O
DDI-MedLine.d6.s2|71-71|,|O
DDI-MedLine.d6.s2|73-73|a|O
DDI-MedLine.d6.s2|75-79|small|O
DDI-MedLine.d6.s2|81-86|volume|O
DDI-MedLine.d6.s2|88-89|of|O
DDI-MedLine.d6.s2|91-102|distribution|O
DDI-MedLine.d6.s2|103-103|,|O
DDI-MedLine.d6.s2|105-107|and|O
DDI-MedLine.d6.s2|109-109|a|O
DDI-MedLine.d6.s2|111-116|7-hour|O
DDI-MedLine.d6.s2|118-126|half-life|O
DDI-MedLine.d6.s2|127-127|.|O
DDI-MedLine.d6.s3|0-1|It|O
DDI-MedLine.d6.s3|3-4|is|O
DDI-MedLine.d6.s3|6-16|essentially|O
DDI-MedLine.d6.s3|18-27|completely|O
DDI-MedLine.d6.s3|29-39|metabolised|O
DDI-MedLine.d6.s3|40-40|,|O
DDI-MedLine.d6.s3|42-50|therefore|O
DDI-MedLine.d6.s3|52-57|little|O
DDI-MedLine.d6.s3|59-60|is|O
DDI-MedLine.d6.s3|62-69|excreted|O
DDI-MedLine.d6.s3|71-79|unchanged|O
DDI-MedLine.d6.s3|80-80|.|O
DDI-MedLine.d6.s4|0-7|Etodolac|drug
DDI-MedLine.d6.s4|9-10|is|O
DDI-MedLine.d6.s4|12-17|highly|O
DDI-MedLine.d6.s4|19-25|protein|O
DDI-MedLine.d6.s4|27-31|bound|O
DDI-MedLine.d6.s4|32-32|.|O
DDI-MedLine.d6.s5|0-1|To|O
DDI-MedLine.d6.s5|3-13|investigate|O
DDI-MedLine.d6.s5|15-17|the|O
DDI-MedLine.d6.s5|19-24|effect|O
DDI-MedLine.d6.s5|26-27|of|O
DDI-MedLine.d6.s5|29-35|disease|O
DDI-MedLine.d6.s5|37-42|states|O
DDI-MedLine.d6.s5|44-45|or|O
DDI-MedLine.d6.s5|47-57|concomitant|O
DDI-MedLine.d6.s5|59-62|drug|O
DDI-MedLine.d6.s5|64-77|administration|O
DDI-MedLine.d6.s5|79-80|on|O
DDI-MedLine.d6.s5|82-82|a|O
DDI-MedLine.d6.s5|84-90|patient|O
DDI-MedLine.d6.s5|91-92|'s|O
DDI-MedLine.d6.s5|94-101|response|O
DDI-MedLine.d6.s5|103-104|to|O
DDI-MedLine.d6.s5|106-113|etodolac|drug
DDI-MedLine.d6.s5|114-114|,|O
DDI-MedLine.d6.s5|116-125|additional|O
DDI-MedLine.d6.s5|127-141|pharmacokinetic|O
DDI-MedLine.d6.s5|143-149|studies|O
DDI-MedLine.d6.s5|151-154|were|O
DDI-MedLine.d6.s5|156-162|carried|O
DDI-MedLine.d6.s5|164-166|out|O
DDI-MedLine.d6.s5|168-169|in|O
DDI-MedLine.d6.s5|171-177|special|O
DDI-MedLine.d6.s5|179-189|populations|O
DDI-MedLine.d6.s5|190-190|.|O
DDI-MedLine.d6.s6|0-4|Since|O
DDI-MedLine.d6.s6|6-13|etodolac|drug
DDI-MedLine.d6.s6|15-17|has|O
DDI-MedLine.d6.s6|19-19|a|O
DDI-MedLine.d6.s6|21-32|well-defined|O
DDI-MedLine.d6.s6|34-64|pharmacokinetic-pharmacodynamic|O
DDI-MedLine.d6.s6|66-77|relationship|O
DDI-MedLine.d6.s6|78-78|,|O
DDI-MedLine.d6.s6|80-90|measurement|O
DDI-MedLine.d6.s6|92-93|of|O
DDI-MedLine.d6.s6|95-109|pharmacokinetic|O
DDI-MedLine.d6.s6|111-120|parameters|O
DDI-MedLine.d6.s6|122-123|is|O
DDI-MedLine.d6.s6|125-134|clinically|O
DDI-MedLine.d6.s6|136-143|relevant|O
DDI-MedLine.d6.s6|144-144|.|O
DDI-MedLine.d6.s7|0-3|Data|O
DDI-MedLine.d6.s7|5-8|from|O
DDI-MedLine.d6.s7|10-16|studies|O
DDI-MedLine.d6.s7|18-19|to|O
DDI-MedLine.d6.s7|21-24|date|O
DDI-MedLine.d6.s7|26-29|show|O
DDI-MedLine.d6.s7|31-34|that|O
DDI-MedLine.d6.s7|36-42|disease|O
DDI-MedLine.d6.s7|44-49|states|O
DDI-MedLine.d6.s7|50-50|,|O
DDI-MedLine.d6.s7|52-61|underlying|O
DDI-MedLine.d6.s7|63-72|conditions|O
DDI-MedLine.d6.s7|73-73|,|O
DDI-MedLine.d6.s7|75-77|and|O
DDI-MedLine.d6.s7|79-91|concomitantly|O
DDI-MedLine.d6.s7|93-104|administered|O
DDI-MedLine.d6.s7|106-111|highly|O
DDI-MedLine.d6.s7|113-125|protein-bound|O
DDI-MedLine.d6.s7|127-131|drugs|O
DDI-MedLine.d6.s7|133-136|have|O
DDI-MedLine.d6.s7|138-148|essentially|O
DDI-MedLine.d6.s7|150-151|no|O
DDI-MedLine.d6.s7|153-158|effect|O
DDI-MedLine.d6.s7|160-161|on|O
DDI-MedLine.d6.s7|163-170|etodolac|drug
DDI-MedLine.d6.s7|172-187|pharmacokinetics|O
DDI-MedLine.d6.s7|188-188|.|O
DDI-MedLine.d6.s8|0-8|Therefore|O
DDI-MedLine.d6.s8|9-9|,|O
DDI-MedLine.d6.s8|11-18|etodolac|drug
DDI-MedLine.d6.s8|20-22|can|O
DDI-MedLine.d6.s8|24-32|generally|O
DDI-MedLine.d6.s8|34-35|be|O
DDI-MedLine.d6.s8|37-41|given|O
DDI-MedLine.d6.s8|43-49|without|O
DDI-MedLine.d6.s8|51-53|the|O
DDI-MedLine.d6.s8|55-58|need|O
DDI-MedLine.d6.s8|60-62|for|O
DDI-MedLine.d6.s8|64-69|dosage|O
DDI-MedLine.d6.s8|71-83|modifications|O
DDI-MedLine.d6.s8|85-86|in|O
DDI-MedLine.d6.s8|88-94|special|O
DDI-MedLine.d6.s8|96-106|populations|O
DDI-MedLine.d6.s8|108-111|such|O
DDI-MedLine.d6.s8|113-114|as|O
DDI-MedLine.d6.s8|116-128|uncompromised|O
DDI-MedLine.d6.s8|130-136|elderly|O
DDI-MedLine.d6.s8|138-145|patients|O
DDI-MedLine.d6.s8|146-146|,|O
DDI-MedLine.d6.s8|148-152|those|O
DDI-MedLine.d6.s8|154-157|with|O
DDI-MedLine.d6.s8|159-166|moderate|O
DDI-MedLine.d6.s8|168-172|renal|O
DDI-MedLine.d6.s8|174-183|impairment|O
DDI-MedLine.d6.s8|184-184|,|O
DDI-MedLine.d6.s8|186-188|and|O
DDI-MedLine.d6.s8|190-197|patients|O
DDI-MedLine.d6.s8|199-202|with|O
DDI-MedLine.d6.s8|204-209|stable|O
DDI-MedLine.d6.s8|211-217|hepatic|O
DDI-MedLine.d6.s8|219-225|disease|O
DDI-MedLine.d6.s8|226-226|.|O
DDI-DrugBank.d493.s0|0-11|Methotrexate|drug
DDI-DrugBank.d493.s0|12-12|:|O
DDI-DrugBank.d493.s0|14-19|HUMIRA|brand
DDI-DrugBank.d493.s0|21-23|has|O
DDI-DrugBank.d493.s0|25-28|been|O
DDI-DrugBank.d493.s0|30-36|studied|O
DDI-DrugBank.d493.s0|38-39|in|O
DDI-DrugBank.d493.s0|41-50|rheumatoid|O
DDI-DrugBank.d493.s0|52-60|arthritis|O
DDI-DrugBank.d493.s0|62-69|patients|O
DDI-DrugBank.d493.s0|71-76|taking|O
DDI-DrugBank.d493.s0|78-88|concomitant|O
DDI-DrugBank.d493.s0|90-92|MTX|drug
DDI-DrugBank.d493.s0|93-93|.|O
DDI-DrugBank.d493.s1|0-2|The|O
DDI-DrugBank.d493.s1|4-7|data|O
DDI-DrugBank.d493.s1|9-10|do|O
DDI-DrugBank.d493.s1|12-14|not|O
DDI-DrugBank.d493.s1|16-22|suggest|O
DDI-DrugBank.d493.s1|24-26|the|O
DDI-DrugBank.d493.s1|28-31|need|O
DDI-DrugBank.d493.s1|33-35|for|O
DDI-DrugBank.d493.s1|37-40|dose|O
DDI-DrugBank.d493.s1|42-51|adjustment|O
DDI-DrugBank.d493.s1|53-54|of|O
DDI-DrugBank.d493.s1|56-61|either|O
DDI-DrugBank.d493.s1|63-68|HUMIRA|brand
DDI-DrugBank.d493.s1|70-71|or|O
DDI-DrugBank.d493.s1|73-75|MTX|drug
DDI-DrugBank.d493.s1|76-76|.|O
DDI-DrugBank.d493.s2|0-7|Anakinra|drug
DDI-DrugBank.d493.s2|8-8|:|O
DDI-DrugBank.d493.s2|10-19|Concurrent|O
DDI-DrugBank.d493.s2|21-34|administration|O
DDI-DrugBank.d493.s2|36-37|of|O
DDI-DrugBank.d493.s2|39-46|anakinra|drug
DDI-DrugBank.d493.s2|48-48|(|O
DDI-DrugBank.d493.s2|49-50|an|O
DDI-DrugBank.d493.s2|52-75|interleukin-1 antagonist|group
DDI-DrugBank.d493.s2|76-76|)|O
DDI-DrugBank.d493.s2|78-80|and|O
DDI-DrugBank.d493.s2|82-88|another|O
DDI-DrugBank.d493.s2|90-107|TNF-blocking agent|group
DDI-DrugBank.d493.s2|109-111|has|O
DDI-DrugBank.d493.s2|113-116|been|O
DDI-DrugBank.d493.s2|118-127|associated|O
DDI-DrugBank.d493.s2|129-132|with|O
DDI-DrugBank.d493.s2|134-135|an|O
DDI-DrugBank.d493.s2|137-145|increased|O
DDI-DrugBank.d493.s2|147-150|risk|O
DDI-DrugBank.d493.s2|152-153|of|O
DDI-DrugBank.d493.s2|155-161|serious|O
DDI-DrugBank.d493.s2|163-172|infections|O
DDI-DrugBank.d493.s2|173-173|,|O
DDI-DrugBank.d493.s2|175-176|an|O
DDI-DrugBank.d493.s2|178-186|increased|O
DDI-DrugBank.d493.s2|188-191|risk|O
DDI-DrugBank.d493.s2|193-194|of|O
DDI-DrugBank.d493.s2|196-206|neutropenia|O
DDI-DrugBank.d493.s2|208-210|and|O
DDI-DrugBank.d493.s2|212-213|no|O
DDI-DrugBank.d493.s2|215-224|additional|O
DDI-DrugBank.d493.s2|226-232|benefit|O
DDI-DrugBank.d493.s2|234-241|compared|O
DDI-DrugBank.d493.s2|243-244|to|O
DDI-DrugBank.d493.s2|246-250|these|O
DDI-DrugBank.d493.s2|252-260|medicinal|O
DDI-DrugBank.d493.s2|262-269|products|O
DDI-DrugBank.d493.s2|271-275|alone|O
DDI-DrugBank.d493.s2|276-276|.|O
DDI-DrugBank.d493.s3|0-2|The|O
DDI-DrugBank.d493.s3|4-9|safety|O
DDI-DrugBank.d493.s3|11-13|and|O
DDI-DrugBank.d493.s3|15-22|efficacy|O
DDI-DrugBank.d493.s3|24-25|of|O
DDI-DrugBank.d493.s3|27-34|anakinra|drug
DDI-DrugBank.d493.s3|36-39|used|O
DDI-DrugBank.d493.s3|41-42|in|O
DDI-DrugBank.d493.s3|44-54|combination|O
DDI-DrugBank.d493.s3|56-59|with|O
DDI-DrugBank.d493.s3|61-66|HUMIRA|brand
DDI-DrugBank.d493.s3|68-70|has|O
DDI-DrugBank.d493.s3|72-74|not|O
DDI-DrugBank.d493.s3|76-79|been|O
DDI-DrugBank.d493.s3|81-87|studied|O
DDI-DrugBank.d493.s3|88-88|.|O
DDI-DrugBank.d493.s4|0-8|Therefore|O
DDI-DrugBank.d493.s4|10-12|the|O
DDI-DrugBank.d493.s4|13-13|,|O
DDI-DrugBank.d493.s4|15-25|combination|O
DDI-DrugBank.d493.s4|27-28|of|O
DDI-DrugBank.d493.s4|30-37|anakinra|drug
DDI-DrugBank.d493.s4|39-42|with|O
DDI-DrugBank.d493.s4|44-48|other|O
DDI-DrugBank.d493.s4|50-68|TNF-blocking agents|group
DDI-DrugBank.d493.s4|69-69|,|O
DDI-DrugBank.d493.s4|71-79|including|O
DDI-DrugBank.d493.s4|81-86|HUMIRA|brand
DDI-DrugBank.d493.s4|87-87|,|O
DDI-DrugBank.d493.s4|89-91|may|O
DDI-DrugBank.d493.s4|93-96|also|O
DDI-DrugBank.d493.s4|98-103|result|O
DDI-DrugBank.d493.s4|105-105|i|O
DDI-DrugBank.d493.s4|107-107|n|O
DDI-DrugBank.d493.s4|109-115|similar|O
DDI-DrugBank.d493.s4|117-126|toxicities|O
DDI-DrugBank.d493.s4|127-127|.|O
DDI-DrugBank.d248.s0|0-2|May|O
DDI-DrugBank.d248.s0|4-11|interact|O
DDI-DrugBank.d248.s0|13-26|anticoagulants|group
DDI-DrugBank.d248.s0|28-28|(|O
DDI-DrugBank.d248.s0|29-35|altered|O
DDI-DrugBank.d248.s0|37-56|hypo-prothrombinemic|O
DDI-DrugBank.d248.s0|58-63|effect|O
DDI-DrugBank.d248.s0|64-64|)|O
DDI-DrugBank.d248.s0|65-65|,|O
DDI-DrugBank.d248.s0|67-78|barbiturates|group
DDI-DrugBank.d248.s0|79-79|,|O
DDI-DrugBank.d248.s0|81-88|rifampin|drug
DDI-DrugBank.d248.s0|90-92|and|O
DDI-DrugBank.d248.s0|94-98|other|O
DDI-DrugBank.d248.s0|100-107|inducers|O
DDI-DrugBank.d248.s0|109-110|of|O
DDI-DrugBank.d248.s0|112-118|hepatic|O
DDI-DrugBank.d248.s0|120-129|microsomal|O
DDI-DrugBank.d248.s0|131-136|enzyme|O
DDI-DrugBank.d248.s0|138-146|oxidation|O
DDI-DrugBank.d248.s0|148-153|system|O
DDI-DrugBank.d248.s0|155-155|(|O
DDI-DrugBank.d248.s0|156-164|decreased|O
DDI-DrugBank.d248.s0|166-171|effect|O
DDI-DrugBank.d248.s0|173-174|of|O
DDI-DrugBank.d248.s0|176-193|diethylstilbestrol|drug
DDI-DrugBank.d248.s0|194-194|)|O
DDI-DrugBank.d248.s0|195-195|,|O
DDI-DrugBank.d248.s0|197-211|corticosteroids|group
DDI-DrugBank.d248.s0|213-213|(|O
DDI-DrugBank.d248.s0|214-222|increased|O
DDI-DrugBank.d248.s0|224-229|effect|O
DDI-DrugBank.d248.s0|231-232|of|O
DDI-DrugBank.d248.s0|234-248|corticosteroids|group
DDI-DrugBank.d248.s0|249-249|)|O
DDI-DrugBank.d248.s0|250-250|.|O
DDI-DrugBank.d659.s0|0-7|Although|O
DDI-DrugBank.d659.s0|9-9|a|O
DDI-DrugBank.d659.s0|11-16|causal|O
DDI-DrugBank.d659.s0|18-29|relationship|O
DDI-DrugBank.d659.s0|31-33|has|O
DDI-DrugBank.d659.s0|35-37|not|O
DDI-DrugBank.d659.s0|39-42|been|O
DDI-DrugBank.d659.s0|44-54|established|O
DDI-DrugBank.d659.s0|55-55|,|O
DDI-DrugBank.d659.s0|57-61|there|O
DDI-DrugBank.d659.s0|63-66|have|O
DDI-DrugBank.d659.s0|68-71|been|O
DDI-DrugBank.d659.s0|73-79|reports|O
DDI-DrugBank.d659.s0|81-82|of|O
DDI-DrugBank.d659.s0|84-91|bleeding|O
DDI-DrugBank.d659.s0|93-98|and/or|O
DDI-DrugBank.d659.s0|100-108|prolonged|O
DDI-DrugBank.d659.s0|110-120|prothrombin|O
DDI-DrugBank.d659.s0|122-125|time|O
DDI-DrugBank.d659.s0|127-128|in|O
DDI-DrugBank.d659.s0|130-137|patients|O
DDI-DrugBank.d659.s0|139-145|treated|O
DDI-DrugBank.d659.s0|147-150|with|O
DDI-DrugBank.d659.s0|152-158|TRENTAL|brand
DDI-DrugBank.d659.s0|160-163|with|O
DDI-DrugBank.d659.s0|165-167|and|O
DDI-DrugBank.d659.s0|169-175|without|O
DDI-DrugBank.d659.s0|177-190|anticoagulants|group
DDI-DrugBank.d659.s0|192-193|or|O
DDI-DrugBank.d659.s0|195-225|platelet aggregation inhibitors|group
DDI-DrugBank.d659.s0|226-226|.|O
DDI-DrugBank.d659.s1|0-7|Patients|O
DDI-DrugBank.d659.s1|9-10|on|O
DDI-DrugBank.d659.s1|12-19|Warfarin|drug
DDI-DrugBank.d659.s1|21-26|should|O
DDI-DrugBank.d659.s1|28-31|have|O
DDI-DrugBank.d659.s1|33-36|more|O
DDI-DrugBank.d659.s1|38-45|frequent|O
DDI-DrugBank.d659.s1|47-56|monitoring|O
DDI-DrugBank.d659.s1|58-59|of|O
DDI-DrugBank.d659.s1|61-71|prothrombin|O
DDI-DrugBank.d659.s1|73-77|times|O
DDI-DrugBank.d659.s1|78-78|,|O
DDI-DrugBank.d659.s1|80-84|while|O
DDI-DrugBank.d659.s1|86-93|patients|O
DDI-DrugBank.d659.s1|95-98|with|O
DDI-DrugBank.d659.s1|100-104|other|O
DDI-DrugBank.d659.s1|106-109|risk|O
DDI-DrugBank.d659.s1|111-117|factors|O
DDI-DrugBank.d659.s1|119-129|complicated|O
DDI-DrugBank.d659.s1|131-132|by|O
DDI-DrugBank.d659.s1|134-143|hemorrhage|O
DDI-DrugBank.d659.s1|145-145|(|O
DDI-DrugBank.d659.s1|146-149|e.g.|O
DDI-DrugBank.d659.s1|150-150|,|O
DDI-DrugBank.d659.s1|152-157|recent|O
DDI-DrugBank.d659.s1|159-165|surgery|O
DDI-DrugBank.d659.s1|166-166|,|O
DDI-DrugBank.d659.s1|168-173|peptic|O
DDI-DrugBank.d659.s1|175-184|ulceration|O
DDI-DrugBank.d659.s1|185-185|)|O
DDI-DrugBank.d659.s1|187-192|should|O
DDI-DrugBank.d659.s1|194-197|have|O
DDI-DrugBank.d659.s1|199-206|periodic|O
DDI-DrugBank.d659.s1|208-219|examinations|O
DDI-DrugBank.d659.s1|221-223|for|O
DDI-DrugBank.d659.s1|225-232|bleeding|O
DDI-DrugBank.d659.s1|234-242|including|O
DDI-DrugBank.d659.s1|244-253|hematocrit|O
DDI-DrugBank.d659.s1|255-260|and/or|O
DDI-DrugBank.d659.s1|262-271|hemoglobin|O
DDI-DrugBank.d659.s1|272-272|.|O
DDI-DrugBank.d659.s2|0-10|Concomitant|O
DDI-DrugBank.d659.s2|12-25|administration|O
DDI-DrugBank.d659.s2|27-28|of|O
DDI-DrugBank.d659.s2|30-36|TRENTAL|brand
DDI-DrugBank.d659.s2|38-40|and|O
DDI-DrugBank.d659.s2|42-64|theophylline-containing|drug
DDI-DrugBank.d659.s2|66-70|drugs|O
DDI-DrugBank.d659.s2|72-76|leads|O
DDI-DrugBank.d659.s2|78-79|to|O
DDI-DrugBank.d659.s2|81-89|increased|O
DDI-DrugBank.d659.s2|91-102|theophylline|drug
DDI-DrugBank.d659.s2|104-109|levels|O
DDI-DrugBank.d659.s2|111-113|and|O
DDI-DrugBank.d659.s2|115-126|theophylline|drug
DDI-DrugBank.d659.s2|128-135|toxicity|O
DDI-DrugBank.d659.s2|137-138|in|O
DDI-DrugBank.d659.s2|140-143|some|O
DDI-DrugBank.d659.s2|145-155|individuals|O
DDI-DrugBank.d659.s2|156-156|.|O
DDI-DrugBank.d659.s3|0-3|Such|O
DDI-DrugBank.d659.s3|5-12|patients|O
DDI-DrugBank.d659.s3|14-19|should|O
DDI-DrugBank.d659.s3|21-22|be|O
DDI-DrugBank.d659.s3|24-30|closely|O
DDI-DrugBank.d659.s3|32-40|monitored|O
DDI-DrugBank.d659.s3|42-44|for|O
DDI-DrugBank.d659.s3|46-50|signs|O
DDI-DrugBank.d659.s3|52-53|of|O
DDI-DrugBank.d659.s3|55-62|toxicity|O
DDI-DrugBank.d659.s3|64-66|and|O
DDI-DrugBank.d659.s3|68-71|have|O
DDI-DrugBank.d659.s3|73-77|their|O
DDI-DrugBank.d659.s3|79-90|theophylline|drug
DDI-DrugBank.d659.s3|92-97|dosage|O
DDI-DrugBank.d659.s3|99-106|adjusted|O
DDI-DrugBank.d659.s3|108-109|as|O
DDI-DrugBank.d659.s3|111-119|necessary|O
DDI-DrugBank.d659.s3|120-120|.|O
DDI-DrugBank.d659.s4|0-6|TRENTAL|brand
DDI-DrugBank.d659.s4|8-10|has|O
DDI-DrugBank.d659.s4|12-15|been|O
DDI-DrugBank.d659.s4|17-20|used|O
DDI-DrugBank.d659.s4|22-33|concurrently|O
DDI-DrugBank.d659.s4|35-38|with|O
DDI-DrugBank.d659.s4|40-61|antihypertensive drugs|group
DDI-DrugBank.d659.s4|62-62|,|O
DDI-DrugBank.d659.s4|64-76|beta blockers|group
DDI-DrugBank.d659.s4|77-77|,|O
DDI-DrugBank.d659.s4|79-87|digitalis|group
DDI-DrugBank.d659.s4|88-88|,|O
DDI-DrugBank.d659.s4|90-98|diuretics|group
DDI-DrugBank.d659.s4|99-99|,|O
DDI-DrugBank.d659.s4|101-119|antidiabetic agents|group
DDI-DrugBank.d659.s4|120-120|,|O
DDI-DrugBank.d659.s4|122-124|and|O
DDI-DrugBank.d659.s4|126-140|antiarrhythmics|group
DDI-DrugBank.d659.s4|141-141|,|O
DDI-DrugBank.d659.s4|143-149|without|O
DDI-DrugBank.d659.s4|151-158|observed|O
DDI-DrugBank.d659.s4|160-167|problems|O
DDI-DrugBank.d659.s4|168-168|.|O
DDI-DrugBank.d659.s5|0-4|Small|O
DDI-DrugBank.d659.s5|6-14|decreases|O
DDI-DrugBank.d659.s5|16-17|in|O
DDI-DrugBank.d659.s5|19-23|blood|O
DDI-DrugBank.d659.s5|25-32|pressure|O
DDI-DrugBank.d659.s5|34-37|have|O
DDI-DrugBank.d659.s5|39-42|been|O
DDI-DrugBank.d659.s5|44-51|observed|O
DDI-DrugBank.d659.s5|53-54|in|O
DDI-DrugBank.d659.s5|56-59|some|O
DDI-DrugBank.d659.s5|61-68|patients|O
DDI-DrugBank.d659.s5|70-76|treated|O
DDI-DrugBank.d659.s5|78-81|with|O
DDI-DrugBank.d659.s5|83-89|TRENTAL|brand
DDI-DrugBank.d659.s5|90-90|;|O
DDI-DrugBank.d659.s6|0-7|periodic|O
DDI-DrugBank.d659.s6|9-16|systemic|O
DDI-DrugBank.d659.s6|18-22|blood|O
DDI-DrugBank.d659.s6|24-31|pressure|O
DDI-DrugBank.d659.s6|33-42|monitoring|O
DDI-DrugBank.d659.s6|44-45|is|O
DDI-DrugBank.d659.s6|47-57|recommended|O
DDI-DrugBank.d659.s6|59-61|for|O
DDI-DrugBank.d659.s6|63-70|patients|O
DDI-DrugBank.d659.s6|72-80|receiving|O
DDI-DrugBank.d659.s6|82-92|concomitant|O
DDI-DrugBank.d659.s6|94-109|antihypertensive|O
DDI-DrugBank.d659.s6|111-117|therapy|O
DDI-DrugBank.d659.s6|118-118|.|O
DDI-DrugBank.d659.s7|0-1|If|O
DDI-DrugBank.d659.s7|3-11|indicated|O
DDI-DrugBank.d659.s7|12-12|,|O
DDI-DrugBank.d659.s7|14-19|dosage|O
DDI-DrugBank.d659.s7|21-22|of|O
DDI-DrugBank.d659.s7|24-26|the|O
DDI-DrugBank.d659.s7|28-50|antihypertensive agents|group
DDI-DrugBank.d659.s7|52-57|should|O
DDI-DrugBank.d659.s7|59-60|be|O
DDI-DrugBank.d659.s7|62-68|reduced|O
DDI-DrugBank.d659.s7|69-69|.|O
DDI-DrugBank.d652.s0|0-2|The|O
DDI-DrugBank.d652.s0|4-10|effects|O
DDI-DrugBank.d652.s0|12-13|of|O
DDI-DrugBank.d652.s0|15-28|metoclopramide|drug
DDI-DrugBank.d652.s0|30-31|on|O
DDI-DrugBank.d652.s0|33-48|gastrointestinal|O
DDI-DrugBank.d652.s0|50-57|motility|O
DDI-DrugBank.d652.s0|59-61|are|O
DDI-DrugBank.d652.s0|63-73|antagonized|O
DDI-DrugBank.d652.s0|75-76|by|O
DDI-DrugBank.d652.s0|78-98|anticholinergic drugs|group
DDI-DrugBank.d652.s0|100-102|and|O
DDI-DrugBank.d652.s0|104-122|narcotic analgesics|group
DDI-DrugBank.d652.s0|123-123|.|O
DDI-DrugBank.d652.s1|0-7|Additive|O
DDI-DrugBank.d652.s1|9-16|sedative|O
DDI-DrugBank.d652.s1|18-24|effects|O
DDI-DrugBank.d652.s1|26-28|can|O
DDI-DrugBank.d652.s1|30-34|occur|O
DDI-DrugBank.d652.s1|36-39|when|O
DDI-DrugBank.d652.s1|41-54|metoclopramide|drug
DDI-DrugBank.d652.s1|56-57|is|O
DDI-DrugBank.d652.s1|59-63|given|O
DDI-DrugBank.d652.s1|65-68|with|O
DDI-DrugBank.d652.s1|70-76|alcohol|drug
DDI-DrugBank.d652.s1|77-77|,|O
DDI-DrugBank.d652.s1|79-87|sedatives|group
DDI-DrugBank.d652.s1|88-88|,|O
DDI-DrugBank.d652.s1|90-98|hypnotics|group
DDI-DrugBank.d652.s1|99-99|,|O
DDI-DrugBank.d652.s1|101-109|narcotics|group
DDI-DrugBank.d652.s1|110-110|,|O
DDI-DrugBank.d652.s1|112-113|or|O
DDI-DrugBank.d652.s1|115-127|tranquilizers|group
DDI-DrugBank.d652.s1|128-128|.|O
DDI-DrugBank.d652.s2|0-2|The|O
DDI-DrugBank.d652.s2|4-10|finding|O
DDI-DrugBank.d652.s2|12-15|that|O
DDI-DrugBank.d652.s2|17-30|metoclopramide|drug
DDI-DrugBank.d652.s2|32-39|releases|O
DDI-DrugBank.d652.s2|41-54|catecholamines|O
DDI-DrugBank.d652.s2|56-57|in|O
DDI-DrugBank.d652.s2|59-66|patients|O
DDI-DrugBank.d652.s2|68-71|with|O
DDI-DrugBank.d652.s2|73-81|essential|O
DDI-DrugBank.d652.s2|83-94|hypertension|O
DDI-DrugBank.d652.s2|96-103|suggests|O
DDI-DrugBank.d652.s2|105-108|that|O
DDI-DrugBank.d652.s2|110-111|it|O
DDI-DrugBank.d652.s2|113-118|should|O
DDI-DrugBank.d652.s2|120-121|be|O
DDI-DrugBank.d652.s2|123-126|used|O
DDI-DrugBank.d652.s2|128-137|cautiously|O
DDI-DrugBank.d652.s2|138-138|,|O
DDI-DrugBank.d652.s2|140-141|if|O
DDI-DrugBank.d652.s2|143-144|at|O
DDI-DrugBank.d652.s2|146-148|all|O
DDI-DrugBank.d652.s2|149-149|,|O
DDI-DrugBank.d652.s2|151-152|in|O
DDI-DrugBank.d652.s2|154-161|patients|O
DDI-DrugBank.d652.s2|163-171|receiving|O
DDI-DrugBank.d652.s2|173-201|monoamine oxi-dase inhibitors|group
DDI-DrugBank.d652.s2|202-202|.|O
DDI-DrugBank.d652.s3|0-9|Absorption|O
DDI-DrugBank.d652.s3|11-12|of|O
DDI-DrugBank.d652.s3|14-18|drugs|O
DDI-DrugBank.d652.s3|20-23|from|O
DDI-DrugBank.d652.s3|25-27|the|O
DDI-DrugBank.d652.s3|29-35|stomach|O
DDI-DrugBank.d652.s3|37-39|may|O
DDI-DrugBank.d652.s3|41-42|be|O
DDI-DrugBank.d652.s3|44-53|diminished|O
DDI-DrugBank.d652.s3|55-55|(|O
DDI-DrugBank.d652.s3|56-59|e.g.|O
DDI-DrugBank.d652.s3|60-60|,|O
DDI-DrugBank.d652.s3|62-68|digoxin|drug
DDI-DrugBank.d652.s3|69-69|)|O
DDI-DrugBank.d652.s3|71-72|by|O
DDI-DrugBank.d652.s3|74-87|metoclopramide|drug
DDI-DrugBank.d652.s3|88-88|,|O
DDI-DrugBank.d652.s3|90-96|whereas|O
DDI-DrugBank.d652.s3|98-100|the|O
DDI-DrugBank.d652.s3|102-105|rate|O
DDI-DrugBank.d652.s3|107-112|and/or|O
DDI-DrugBank.d652.s3|114-119|extent|O
DDI-DrugBank.d652.s3|121-122|of|O
DDI-DrugBank.d652.s3|124-133|absorption|O
DDI-DrugBank.d652.s3|135-136|of|O
DDI-DrugBank.d652.s3|138-142|drugs|O
DDI-DrugBank.d652.s3|144-147|from|O
DDI-DrugBank.d652.s3|149-151|the|O
DDI-DrugBank.d652.s3|153-157|small|O
DDI-DrugBank.d652.s3|159-163|bowel|O
DDI-DrugBank.d652.s3|165-167|may|O
DDI-DrugBank.d652.s3|169-170|be|O
DDI-DrugBank.d652.s3|172-180|increased|O
DDI-DrugBank.d652.s3|182-182|(|O
DDI-DrugBank.d652.s3|183-186|e.g.|O
DDI-DrugBank.d652.s3|187-187|,|O
DDI-DrugBank.d652.s3|189-201|acetaminophen|drug
DDI-DrugBank.d652.s3|202-202|,|O
DDI-DrugBank.d652.s3|204-215|tetracycline|drug
DDI-DrugBank.d652.s3|216-216|,|O
DDI-DrugBank.d652.s3|218-225|levodopa|drug
DDI-DrugBank.d652.s3|226-226|,|O
DDI-DrugBank.d652.s3|228-234|ethanol|drug
DDI-DrugBank.d652.s3|235-235|,|O
DDI-DrugBank.d652.s3|237-248|cyclosporine|drug
DDI-DrugBank.d652.s3|249-249|)|O
DDI-DrugBank.d652.s3|250-250|.|O
DDI-DrugBank.d652.s4|0-12|Gastroparesis|O
DDI-DrugBank.d652.s4|14-14|(|O
DDI-DrugBank.d652.s4|15-21|gastric|O
DDI-DrugBank.d652.s4|23-28|stasis|O
DDI-DrugBank.d652.s4|29-29|)|O
DDI-DrugBank.d652.s4|31-33|may|O
DDI-DrugBank.d652.s4|35-36|be|O
DDI-DrugBank.d652.s4|38-48|responsible|O
DDI-DrugBank.d652.s4|50-52|for|O
DDI-DrugBank.d652.s4|54-57|poor|O
DDI-DrugBank.d652.s4|59-66|diabetic|O
DDI-DrugBank.d652.s4|68-74|control|O
DDI-DrugBank.d652.s4|76-77|in|O
DDI-DrugBank.d652.s4|79-82|some|O
DDI-DrugBank.d652.s4|84-91|patients|O
DDI-DrugBank.d652.s4|92-92|.|O
DDI-DrugBank.d652.s5|0-10|Exogenously|O
DDI-DrugBank.d652.s5|12-23|administered|O
DDI-DrugBank.d652.s5|25-31|insulin|drug
DDI-DrugBank.d652.s5|33-35|may|O
DDI-DrugBank.d652.s5|37-41|begin|O
DDI-DrugBank.d652.s5|43-44|to|O
DDI-DrugBank.d652.s5|46-48|act|O
DDI-DrugBank.d652.s5|50-55|before|O
DDI-DrugBank.d652.s5|57-60|food|O
DDI-DrugBank.d652.s5|62-64|has|O
DDI-DrugBank.d652.s5|66-69|left|O
DDI-DrugBank.d652.s5|71-73|the|O
DDI-DrugBank.d652.s5|75-81|stomach|O
DDI-DrugBank.d652.s5|83-85|and|O
DDI-DrugBank.d652.s5|87-90|lead|O
DDI-DrugBank.d652.s5|92-93|to|O
DDI-DrugBank.d652.s5|95-106|hypoglycemia|O
DDI-DrugBank.d652.s5|107-107|.|O
DDI-DrugBank.d652.s6|0-6|Because|O
DDI-DrugBank.d652.s6|8-10|the|O
DDI-DrugBank.d652.s6|12-17|action|O
DDI-DrugBank.d652.s6|19-20|of|O
DDI-DrugBank.d652.s6|22-35|metoclopramide|drug
DDI-DrugBank.d652.s6|37-40|will|O
DDI-DrugBank.d652.s6|42-50|influence|O
DDI-DrugBank.d652.s6|52-54|the|O
DDI-DrugBank.d652.s6|56-63|delivery|O
DDI-DrugBank.d652.s6|65-66|of|O
DDI-DrugBank.d652.s6|68-71|food|O
DDI-DrugBank.d652.s6|73-74|to|O
DDI-DrugBank.d652.s6|76-78|the|O
DDI-DrugBank.d652.s6|80-89|intestines|O
DDI-DrugBank.d652.s6|91-93|and|O
DDI-DrugBank.d652.s6|95-98|thus|O
DDI-DrugBank.d652.s6|100-102|the|O
DDI-DrugBank.d652.s6|104-107|rate|O
DDI-DrugBank.d652.s6|109-110|of|O
DDI-DrugBank.d652.s6|112-121|absorption|O
DDI-DrugBank.d652.s6|122-122|,|O
DDI-DrugBank.d652.s6|124-130|insulin|drug
DDI-DrugBank.d652.s6|132-137|dosage|O
DDI-DrugBank.d652.s6|139-140|or|O
DDI-DrugBank.d652.s6|142-147|timing|O
DDI-DrugBank.d652.s6|149-150|of|O
DDI-DrugBank.d652.s6|152-157|dosage|O
DDI-DrugBank.d652.s6|159-161|may|O
DDI-DrugBank.d652.s6|163-169|require|O
DDI-DrugBank.d652.s6|171-180|adjustment|O
DDI-DrugBank.d652.s6|181-181|.|O
DDI-DrugBank.d72.s0|0-11|Itraconazole|drug
DDI-DrugBank.d72.s0|13-21|decreases|O
DDI-DrugBank.d72.s0|23-30|busulfan|drug
DDI-DrugBank.d72.s0|32-40|clearance|O
DDI-DrugBank.d72.s0|42-43|by|O
DDI-DrugBank.d72.s0|45-46|up|O
DDI-DrugBank.d72.s0|48-49|to|O
DDI-DrugBank.d72.s0|51-52|25|O
DDI-DrugBank.d72.s0|53-53|%|O
DDI-DrugBank.d72.s0|54-54|,|O
DDI-DrugBank.d72.s0|56-58|and|O
DDI-DrugBank.d72.s0|60-62|may|O
DDI-DrugBank.d72.s0|64-70|produce|O
DDI-DrugBank.d72.s0|72-75|AUCs|O
DDI-DrugBank.d72.s0|79-82|1500|O
DDI-DrugBank.d72.s0|85-85|M|O
DDI-DrugBank.d72.s0|87-89|min|O
DDI-DrugBank.d72.s0|91-92|in|O
DDI-DrugBank.d72.s0|94-97|some|O
DDI-DrugBank.d72.s0|99-106|patients|O
DDI-DrugBank.d72.s0|107-107|.|O
DDI-DrugBank.d72.s1|0-10|Fluconazole|drug
DDI-DrugBank.d72.s1|11-11|,|O
DDI-DrugBank.d72.s1|13-15|and|O
DDI-DrugBank.d72.s1|17-19|the|O
DDI-DrugBank.d72.s1|21-37|5-HT3 antiemetics|group
DDI-DrugBank.d72.s1|21-37|5-HT3 antiemetics|group
DDI-DrugBank.d72.s1|51-51|(|O
DDI-DrugBank.d72.s1|52-57|Zofran|brand
DDI-DrugBank.d72.s1|58-58|)|O
DDI-DrugBank.d72.s1|60-62|and|O
DDI-DrugBank.d72.s1|64-74|granisetron|drug
DDI-DrugBank.d72.s1|76-76|(|O
DDI-DrugBank.d72.s1|77-82|Kytril|brand
DDI-DrugBank.d72.s1|83-83|)|O
DDI-DrugBank.d72.s1|85-88|have|O
DDI-DrugBank.d72.s1|90-92|all|O
DDI-DrugBank.d72.s1|94-97|been|O
DDI-DrugBank.d72.s1|99-102|used|O
DDI-DrugBank.d72.s1|104-107|with|O
DDI-DrugBank.d72.s1|109-116|BUSULFEX|brand
DDI-DrugBank.d72.s1|117-117|.|O
DDI-DrugBank.d72.s2|0-8|Phenytoin|drug
DDI-DrugBank.d72.s2|10-18|increases|O
DDI-DrugBank.d72.s2|20-22|the|O
DDI-DrugBank.d72.s2|24-32|clearance|O
DDI-DrugBank.d72.s2|34-35|of|O
DDI-DrugBank.d72.s2|37-44|busulfan|drug
DDI-DrugBank.d72.s2|46-47|by|O
DDI-DrugBank.d72.s2|49-50|15|O
DDI-DrugBank.d72.s2|51-51|%|O
DDI-DrugBank.d72.s2|53-54|or|O
DDI-DrugBank.d72.s2|56-59|more|O
DDI-DrugBank.d72.s2|60-60|,|O
DDI-DrugBank.d72.s2|62-69|possibly|O
DDI-DrugBank.d72.s2|71-73|due|O
DDI-DrugBank.d72.s2|75-76|to|O
DDI-DrugBank.d72.s2|78-80|the|O
DDI-DrugBank.d72.s2|82-90|induction|O
DDI-DrugBank.d72.s2|92-93|of|O
DDI-DrugBank.d72.s2|95-119|glutathione-S-transferase|O
DDI-DrugBank.d72.s2|120-120|.|O
DDI-DrugBank.d72.s3|0-4|Since|O
DDI-DrugBank.d72.s3|6-8|the|O
DDI-DrugBank.d72.s3|10-25|pharmacokinetics|O
DDI-DrugBank.d72.s3|27-28|of|O
DDI-DrugBank.d72.s3|30-37|BUSULFEX|brand
DDI-DrugBank.d72.s3|39-42|were|O
DDI-DrugBank.d72.s3|44-50|studied|O
DDI-DrugBank.d72.s3|52-53|in|O
DDI-DrugBank.d72.s3|55-62|patients|O
DDI-DrugBank.d72.s3|64-70|treated|O
DDI-DrugBank.d72.s3|72-75|with|O
DDI-DrugBank.d72.s3|77-85|phenytoin|drug
DDI-DrugBank.d72.s3|86-86|,|O
DDI-DrugBank.d72.s3|88-90|the|O
DDI-DrugBank.d72.s3|92-100|clearance|O
DDI-DrugBank.d72.s3|102-103|of|O
DDI-DrugBank.d72.s3|105-112|BUSULFEX|brand
DDI-DrugBank.d72.s3|114-115|at|O
DDI-DrugBank.d72.s3|117-119|the|O
DDI-DrugBank.d72.s3|121-131|recommended|O
DDI-DrugBank.d72.s3|133-136|dose|O
DDI-DrugBank.d72.s3|138-140|may|O
DDI-DrugBank.d72.s3|142-143|be|O
DDI-DrugBank.d72.s3|145-149|lower|O
DDI-DrugBank.d72.s3|151-153|and|O
DDI-DrugBank.d72.s3|155-162|exposure|O
DDI-DrugBank.d72.s3|164-164|(|O
DDI-DrugBank.d72.s3|165-167|AUC|O
DDI-DrugBank.d72.s3|168-168|)|O
DDI-DrugBank.d72.s3|170-175|higher|O
DDI-DrugBank.d72.s3|177-178|in|O
DDI-DrugBank.d72.s3|180-187|patients|O
DDI-DrugBank.d72.s3|189-191|not|O
DDI-DrugBank.d72.s3|193-199|treated|O
DDI-DrugBank.d72.s3|201-204|with|O
DDI-DrugBank.d72.s3|206-214|phenytoin|drug
DDI-DrugBank.d72.s3|215-215|.|O
DDI-DrugBank.d72.s4|0-6|Because|O
DDI-DrugBank.d72.s4|8-15|busulfan|drug
DDI-DrugBank.d72.s4|17-18|is|O
DDI-DrugBank.d72.s4|20-29|eliminated|O
DDI-DrugBank.d72.s4|31-34|from|O
DDI-DrugBank.d72.s4|36-38|the|O
DDI-DrugBank.d72.s4|40-43|body|O
DDI-DrugBank.d72.s4|45-47|via|O
DDI-DrugBank.d72.s4|49-59|conjugation|O
DDI-DrugBank.d72.s4|61-64|with|O
DDI-DrugBank.d72.s4|66-76|glutathione|O
DDI-DrugBank.d72.s4|77-77|,|O
DDI-DrugBank.d72.s4|79-81|use|O
DDI-DrugBank.d72.s4|83-84|of|O
DDI-DrugBank.d72.s4|86-98|acetaminophen|drug
DDI-DrugBank.d72.s4|100-104|prior|O
DDI-DrugBank.d72.s4|106-107|to|O
DDI-DrugBank.d72.s4|109-109|(|O
DDI-DrugBank.d72.s4|111-112|72|O
DDI-DrugBank.d72.s4|114-118|hours|O
DDI-DrugBank.d72.s4|119-119|)|O
DDI-DrugBank.d72.s4|121-122|or|O
DDI-DrugBank.d72.s4|124-133|concurrent|O
DDI-DrugBank.d72.s4|135-138|with|O
DDI-DrugBank.d72.s4|140-147|BUSULFEX|brand
DDI-DrugBank.d72.s4|149-151|may|O
DDI-DrugBank.d72.s4|153-158|result|O
DDI-DrugBank.d72.s4|160-161|in|O
DDI-DrugBank.d72.s4|163-169|reduced|O
DDI-DrugBank.d72.s4|171-178|busulfan|drug
DDI-DrugBank.d72.s4|180-188|clearance|O
DDI-DrugBank.d72.s4|190-194|based|O
DDI-DrugBank.d72.s4|196-199|upon|O
DDI-DrugBank.d72.s4|201-203|the|O
DDI-DrugBank.d72.s4|205-209|known|O
DDI-DrugBank.d72.s4|211-218|property|O
DDI-DrugBank.d72.s4|220-221|of|O
DDI-DrugBank.d72.s4|223-235|acetaminophen|drug
DDI-DrugBank.d72.s4|237-238|to|O
DDI-DrugBank.d72.s4|240-247|decrease|O
DDI-DrugBank.d72.s4|249-259|glutathione|O
DDI-DrugBank.d72.s4|261-266|levels|O
DDI-DrugBank.d72.s4|268-269|in|O
DDI-DrugBank.d72.s4|271-273|the|O
DDI-DrugBank.d72.s4|275-279|blood|O
DDI-DrugBank.d72.s4|281-283|and|O
DDI-DrugBank.d72.s4|285-291|tissues|O
DDI-DrugBank.d72.s4|292-292|.|O
DDI-DrugBank.d422.s0|0-22|Catecholamine-depleting|O
DDI-DrugBank.d422.s0|24-28|drugs|O
DDI-DrugBank.d422.s0|29-29|,|O
DDI-DrugBank.d422.s0|31-34|e.g.|O
DDI-DrugBank.d422.s0|35-35|,|O
DDI-DrugBank.d422.s0|37-45|reserpine|drug
DDI-DrugBank.d422.s0|46-46|,|O
DDI-DrugBank.d422.s0|48-50|may|O
DDI-DrugBank.d422.s0|52-55|have|O
DDI-DrugBank.d422.s0|57-58|an|O
DDI-DrugBank.d422.s0|60-67|additive|O
DDI-DrugBank.d422.s0|69-74|effect|O
DDI-DrugBank.d422.s0|76-79|when|O
DDI-DrugBank.d422.s0|81-85|given|O
DDI-DrugBank.d422.s0|87-90|with|O
DDI-DrugBank.d422.s0|92-111|beta blocking agents|group
DDI-DrugBank.d422.s0|112-112|.|O
DDI-DrugBank.d422.s1|0-7|Patients|O
DDI-DrugBank.d422.s1|9-15|treated|O
DDI-DrugBank.d422.s1|17-28|concurrently|O
DDI-DrugBank.d422.s1|30-33|with|O
DDI-DrugBank.d422.s1|35-43|BREVIBLOC|brand
DDI-DrugBank.d422.s1|45-45|(|O
DDI-DrugBank.d422.s1|46-56|esmolol HCl|drug
DDI-DrugBank.d422.s1|57-57|)|O
DDI-DrugBank.d422.s1|59-61|and|O
DDI-DrugBank.d422.s1|63-63|a|O
DDI-DrugBank.d422.s1|65-77|catecholamine|O
DDI-DrugBank.d422.s1|79-86|depletor|O
DDI-DrugBank.d422.s1|88-93|should|O
DDI-DrugBank.d422.s1|95-103|therefore|O
DDI-DrugBank.d422.s1|105-106|be|O
DDI-DrugBank.d422.s1|108-114|closely|O
DDI-DrugBank.d422.s1|116-123|observed|O
DDI-DrugBank.d422.s1|125-127|for|O
DDI-DrugBank.d422.s1|129-136|evidence|O
DDI-DrugBank.d422.s1|138-139|of|O
DDI-DrugBank.d422.s1|141-151|hypotension|O
DDI-DrugBank.d422.s1|153-154|or|O
DDI-DrugBank.d422.s1|156-161|marked|O
DDI-DrugBank.d422.s1|163-173|bradycardia|O
DDI-DrugBank.d422.s1|174-174|,|O
DDI-DrugBank.d422.s1|176-180|which|O
DDI-DrugBank.d422.s1|182-184|may|O
DDI-DrugBank.d422.s1|186-191|result|O
DDI-DrugBank.d422.s1|193-194|in|O
DDI-DrugBank.d422.s1|196-202|vertigo|O
DDI-DrugBank.d422.s1|203-203|,|O
DDI-DrugBank.d422.s1|205-211|syncope|O
DDI-DrugBank.d422.s1|212-212|,|O
DDI-DrugBank.d422.s1|214-215|or|O
DDI-DrugBank.d422.s1|217-224|postural|O
DDI-DrugBank.d422.s1|226-236|hypotension|O
DDI-DrugBank.d422.s1|237-237|.|O
DDI-DrugBank.d422.s2|0-0|A|O
DDI-DrugBank.d422.s2|2-6|study|O
DDI-DrugBank.d422.s2|8-9|of|O
DDI-DrugBank.d422.s2|11-21|interaction|O
DDI-DrugBank.d422.s2|23-29|between|O
DDI-DrugBank.d422.s2|31-39|BREVIBLOC|brand
DDI-DrugBank.d422.s2|41-43|and|O
DDI-DrugBank.d422.s2|45-52|warfarin|drug
DDI-DrugBank.d422.s2|54-59|showed|O
DDI-DrugBank.d422.s2|61-64|that|O
DDI-DrugBank.d422.s2|66-76|concomitant|O
DDI-DrugBank.d422.s2|78-91|administration|O
DDI-DrugBank.d422.s2|93-94|of|O
DDI-DrugBank.d422.s2|96-104|BREVIBLOC|brand
DDI-DrugBank.d422.s2|106-108|and|O
DDI-DrugBank.d422.s2|110-117|warfarin|drug
DDI-DrugBank.d422.s2|119-122|does|O
DDI-DrugBank.d422.s2|124-126|not|O
DDI-DrugBank.d422.s2|128-132|alter|O
DDI-DrugBank.d422.s2|134-141|warfarin|drug
DDI-DrugBank.d422.s2|143-148|plasma|O
DDI-DrugBank.d422.s2|150-155|levels|O
DDI-DrugBank.d422.s2|156-156|.|O
DDI-DrugBank.d422.s3|0-8|BREVIBLOC|brand
DDI-DrugBank.d422.s3|10-23|concentrations|O
DDI-DrugBank.d422.s3|25-28|were|O
DDI-DrugBank.d422.s3|30-40|equivocally|O
DDI-DrugBank.d422.s3|42-47|higher|O
DDI-DrugBank.d422.s3|49-52|when|O
DDI-DrugBank.d422.s3|54-58|given|O
DDI-DrugBank.d422.s3|60-63|with|O
DDI-DrugBank.d422.s3|65-72|warfarin|drug
DDI-DrugBank.d422.s3|73-73|,|O
DDI-DrugBank.d422.s3|75-77|but|O
DDI-DrugBank.d422.s3|79-82|this|O
DDI-DrugBank.d422.s3|84-85|is|O
DDI-DrugBank.d422.s3|87-89|not|O
DDI-DrugBank.d422.s3|91-96|likely|O
DDI-DrugBank.d422.s3|98-99|to|O
DDI-DrugBank.d422.s3|101-102|be|O
DDI-DrugBank.d422.s3|104-113|clinically|O
DDI-DrugBank.d422.s3|115-123|important|O
DDI-DrugBank.d422.s3|124-124|.|O
DDI-DrugBank.d422.s4|0-3|When|O
DDI-DrugBank.d422.s4|5-11|digoxin|drug
DDI-DrugBank.d422.s4|13-15|and|O
DDI-DrugBank.d422.s4|17-25|BREVIBLOC|brand
DDI-DrugBank.d422.s4|27-30|were|O
DDI-DrugBank.d422.s4|32-44|concomitantly|O
DDI-DrugBank.d422.s4|46-57|administered|O
DDI-DrugBank.d422.s4|59-71|intravenously|O
DDI-DrugBank.d422.s4|73-74|to|O
DDI-DrugBank.d422.s4|76-81|normal|O
DDI-DrugBank.d422.s4|83-92|volunteers|O
DDI-DrugBank.d422.s4|93-93|,|O
DDI-DrugBank.d422.s4|95-99|there|O
DDI-DrugBank.d422.s4|101-103|was|O
DDI-DrugBank.d422.s4|105-105|a|O
DDI-DrugBank.d422.s4|107-111|10-20|O
DDI-DrugBank.d422.s4|112-112|%|O
DDI-DrugBank.d422.s4|114-121|increase|O
DDI-DrugBank.d422.s4|123-124|in|O
DDI-DrugBank.d422.s4|126-132|digoxin|drug
DDI-DrugBank.d422.s4|134-138|blood|O
DDI-DrugBank.d422.s4|140-145|levels|O
DDI-DrugBank.d422.s4|147-148|at|O
DDI-DrugBank.d422.s4|150-153|some|O
DDI-DrugBank.d422.s4|155-158|time|O
DDI-DrugBank.d422.s4|160-165|points|O
DDI-DrugBank.d422.s4|166-166|.|O
DDI-DrugBank.d422.s5|0-6|Digoxin|drug
DDI-DrugBank.d422.s5|8-10|did|O
DDI-DrugBank.d422.s5|12-14|not|O
DDI-DrugBank.d422.s5|16-21|affect|O
DDI-DrugBank.d422.s5|23-31|BREVIBLOC|brand
DDI-DrugBank.d422.s5|33-48|pharmacokinetics|O
DDI-DrugBank.d422.s5|49-49|.|O
DDI-DrugBank.d422.s6|0-3|When|O
DDI-DrugBank.d422.s6|5-15|intravenous|O
DDI-DrugBank.d422.s6|17-24|morphine|drug
DDI-DrugBank.d422.s6|26-28|and|O
DDI-DrugBank.d422.s6|30-38|BREVIBLOC|brand
DDI-DrugBank.d422.s6|40-43|were|O
DDI-DrugBank.d422.s6|45-57|concomitantly|O
DDI-DrugBank.d422.s6|59-70|administered|O
DDI-DrugBank.d422.s6|72-73|in|O
DDI-DrugBank.d422.s6|75-80|normal|O
DDI-DrugBank.d422.s6|82-89|subjects|O
DDI-DrugBank.d422.s6|90-90|,|O
DDI-DrugBank.d422.s6|92-93|no|O
DDI-DrugBank.d422.s6|95-100|effect|O
DDI-DrugBank.d422.s6|102-103|on|O
DDI-DrugBank.d422.s6|105-112|morphine|drug
DDI-DrugBank.d422.s6|114-118|blood|O
DDI-DrugBank.d422.s6|120-125|levels|O
DDI-DrugBank.d422.s6|127-129|was|O
DDI-DrugBank.d422.s6|131-134|seen|O
DDI-DrugBank.d422.s6|135-135|,|O
DDI-DrugBank.d422.s6|137-139|but|O
DDI-DrugBank.d422.s6|141-149|BREVIBLOC|brand
DDI-DrugBank.d422.s6|151-162|steady-state|O
DDI-DrugBank.d422.s6|164-168|blood|O
DDI-DrugBank.d422.s6|170-175|levels|O
DDI-DrugBank.d422.s6|177-180|were|O
DDI-DrugBank.d422.s6|182-190|increased|O
DDI-DrugBank.d422.s6|192-193|by|O
DDI-DrugBank.d422.s6|195-196|46|O
DDI-DrugBank.d422.s6|197-197|%|O
DDI-DrugBank.d422.s6|199-200|in|O
DDI-DrugBank.d422.s6|202-204|the|O
DDI-DrugBank.d422.s6|206-213|presence|O
DDI-DrugBank.d422.s6|215-216|of|O
DDI-DrugBank.d422.s6|218-225|morphine|drug
DDI-DrugBank.d422.s6|226-226|.|O
DDI-DrugBank.d422.s7|0-1|No|O
DDI-DrugBank.d422.s7|3-7|other|O
DDI-DrugBank.d422.s7|9-23|pharmacokinetic|O
DDI-DrugBank.d422.s7|25-34|parameters|O
DDI-DrugBank.d422.s7|36-39|were|O
DDI-DrugBank.d422.s7|41-47|changed|O
DDI-DrugBank.d422.s7|48-48|.|O
DDI-DrugBank.d422.s8|0-2|The|O
DDI-DrugBank.d422.s8|4-9|effect|O
DDI-DrugBank.d422.s8|11-12|of|O
DDI-DrugBank.d422.s8|14-22|BREVIBLOC|drug
DDI-DrugBank.d422.s8|24-25|on|O
DDI-DrugBank.d422.s8|27-29|the|O
DDI-DrugBank.d422.s8|31-38|duration|O
DDI-DrugBank.d422.s8|40-41|of|O
DDI-DrugBank.d422.s8|43-65|succinylcholine-induced|drug
DDI-DrugBank.d422.s8|67-79|neuromuscular|O
DDI-DrugBank.d422.s8|81-88|blockade|O
DDI-DrugBank.d422.s8|90-92|was|O
DDI-DrugBank.d422.s8|94-100|studied|O
DDI-DrugBank.d422.s8|102-103|in|O
DDI-DrugBank.d422.s8|105-112|patients|O
DDI-DrugBank.d422.s8|114-123|undergoing|O
DDI-DrugBank.d422.s8|125-131|surgery|O
DDI-DrugBank.d422.s8|132-132|.|O
DDI-DrugBank.d422.s9|0-2|The|O
DDI-DrugBank.d422.s9|4-8|onset|O
DDI-DrugBank.d422.s9|10-11|of|O
DDI-DrugBank.d422.s9|13-25|neuromuscular|O
DDI-DrugBank.d422.s9|27-34|blockade|O
DDI-DrugBank.d422.s9|36-37|by|O
DDI-DrugBank.d422.s9|39-53|succinylcholine|drug
DDI-DrugBank.d422.s9|55-57|was|O
DDI-DrugBank.d422.s9|59-68|unaffected|O
DDI-DrugBank.d422.s9|70-71|by|O
DDI-DrugBank.d422.s9|73-81|BREVIBLOC|brand
DDI-DrugBank.d422.s9|82-82|,|O
DDI-DrugBank.d422.s9|84-86|but|O
DDI-DrugBank.d422.s9|88-90|the|O
DDI-DrugBank.d422.s9|92-99|duration|O
DDI-DrugBank.d422.s9|101-102|of|O
DDI-DrugBank.d422.s9|104-116|neuromuscular|O
DDI-DrugBank.d422.s9|118-125|blockade|O
DDI-DrugBank.d422.s9|127-129|was|O
DDI-DrugBank.d422.s9|131-139|prolonged|O
DDI-DrugBank.d422.s9|141-144|from|O
DDI-DrugBank.d422.s9|146-146|5|O
DDI-DrugBank.d422.s9|148-154|minutes|O
DDI-DrugBank.d422.s9|156-157|to|O
DDI-DrugBank.d422.s9|159-159|8|O
DDI-DrugBank.d422.s9|161-167|minutes|O
DDI-DrugBank.d422.s9|168-168|.|O
DDI-DrugBank.d422.s10|0-7|Although|O
DDI-DrugBank.d422.s10|9-11|the|O
DDI-DrugBank.d422.s10|13-24|interactions|O
DDI-DrugBank.d422.s10|26-33|observed|O
DDI-DrugBank.d422.s10|35-36|in|O
DDI-DrugBank.d422.s10|38-42|these|O
DDI-DrugBank.d422.s10|44-50|studies|O
DDI-DrugBank.d422.s10|52-53|do|O
DDI-DrugBank.d422.s10|55-57|not|O
DDI-DrugBank.d422.s10|59-64|appear|O
DDI-DrugBank.d422.s10|66-67|to|O
DDI-DrugBank.d422.s10|69-70|be|O
DDI-DrugBank.d422.s10|72-73|of|O
DDI-DrugBank.d422.s10|75-79|major|O
DDI-DrugBank.d422.s10|81-88|clinical|O
DDI-DrugBank.d422.s10|90-99|importance|O
DDI-DrugBank.d422.s10|100-100|,|O
DDI-DrugBank.d422.s10|102-110|BREVIBLOC|brand
DDI-DrugBank.d422.s10|112-117|should|O
DDI-DrugBank.d422.s10|119-120|be|O
DDI-DrugBank.d422.s10|122-129|titrated|O
DDI-DrugBank.d422.s10|131-134|with|O
DDI-DrugBank.d422.s10|136-142|caution|O
DDI-DrugBank.d422.s10|144-145|in|O
DDI-DrugBank.d422.s10|147-154|patients|O
DDI-DrugBank.d422.s10|156-160|being|O
DDI-DrugBank.d422.s10|162-168|treated|O
DDI-DrugBank.d422.s10|170-181|concurrently|O
DDI-DrugBank.d422.s10|183-186|with|O
DDI-DrugBank.d422.s10|188-194|digoxin|drug
DDI-DrugBank.d422.s10|195-195|,|O
DDI-DrugBank.d422.s10|197-204|morphine|drug
DDI-DrugBank.d422.s10|205-205|,|O
DDI-DrugBank.d422.s10|207-221|succinylcholine|drug
DDI-DrugBank.d422.s10|223-224|or|O
DDI-DrugBank.d422.s10|226-233|warfarin|drug
DDI-DrugBank.d422.s10|234-234|.|O
DDI-DrugBank.d422.s11|0-4|While|O
DDI-DrugBank.d422.s11|6-11|taking|O
DDI-DrugBank.d422.s11|13-25|beta blockers|group
DDI-DrugBank.d422.s11|26-26|,|O
DDI-DrugBank.d422.s11|28-35|patients|O
DDI-DrugBank.d422.s11|37-40|with|O
DDI-DrugBank.d422.s11|42-42|a|O
DDI-DrugBank.d422.s11|44-50|history|O
DDI-DrugBank.d422.s11|52-53|of|O
DDI-DrugBank.d422.s11|55-60|severe|O
DDI-DrugBank.d422.s11|62-73|anaphylactic|O
DDI-DrugBank.d422.s11|75-82|reaction|O
DDI-DrugBank.d422.s11|84-85|to|O
DDI-DrugBank.d422.s11|87-87|a|O
DDI-DrugBank.d422.s11|89-95|variety|O
DDI-DrugBank.d422.s11|97-98|of|O
DDI-DrugBank.d422.s11|100-108|allergens|O
DDI-DrugBank.d422.s11|110-112|may|O
DDI-DrugBank.d422.s11|114-115|be|O
DDI-DrugBank.d422.s11|117-120|more|O
DDI-DrugBank.d422.s11|122-129|reactive|O
DDI-DrugBank.d422.s11|131-132|to|O
DDI-DrugBank.d422.s11|134-141|repeated|O
DDI-DrugBank.d422.s11|143-151|challenge|O
DDI-DrugBank.d422.s11|152-152|,|O
DDI-DrugBank.d422.s11|154-159|either|O
DDI-DrugBank.d422.s11|161-170|accidental|O
DDI-DrugBank.d422.s11|171-171|,|O
DDI-DrugBank.d422.s11|173-182|diagnostic|O
DDI-DrugBank.d422.s11|183-183|,|O
DDI-DrugBank.d422.s11|185-186|or|O
DDI-DrugBank.d422.s11|188-198|therapeutic|O
DDI-DrugBank.d422.s11|199-199|.|O
DDI-DrugBank.d422.s12|0-3|Such|O
DDI-DrugBank.d422.s12|5-12|patients|O
DDI-DrugBank.d422.s12|14-16|may|O
DDI-DrugBank.d422.s12|18-19|be|O
DDI-DrugBank.d422.s12|21-32|unresponsive|O
DDI-DrugBank.d422.s12|34-35|to|O
DDI-DrugBank.d422.s12|37-39|the|O
DDI-DrugBank.d422.s12|41-45|usual|O
DDI-DrugBank.d422.s12|47-51|doses|O
DDI-DrugBank.d422.s12|53-54|of|O
DDI-DrugBank.d422.s12|56-66|epinephrine|drug
DDI-DrugBank.d422.s12|68-71|used|O
DDI-DrugBank.d422.s12|73-74|to|O
DDI-DrugBank.d422.s12|76-80|treat|O
DDI-DrugBank.d422.s12|82-89|allergic|O
DDI-DrugBank.d422.s12|91-98|reaction|O
DDI-DrugBank.d422.s12|99-99|.|O
DDI-DrugBank.d422.s13|0-6|Caution|O
DDI-DrugBank.d422.s13|8-13|should|O
DDI-DrugBank.d422.s13|15-16|be|O
DDI-DrugBank.d422.s13|18-26|exercised|O
DDI-DrugBank.d422.s13|28-31|when|O
DDI-DrugBank.d422.s13|33-43|considering|O
DDI-DrugBank.d422.s13|45-47|the|O
DDI-DrugBank.d422.s13|49-51|use|O
DDI-DrugBank.d422.s13|53-54|of|O
DDI-DrugBank.d422.s13|56-64|BREVIBLOC|brand
DDI-DrugBank.d422.s13|66-68|and|O
DDI-DrugBank.d422.s13|70-78|verapamil|drug
DDI-DrugBank.d422.s13|80-81|in|O
DDI-DrugBank.d422.s13|83-90|patients|O
DDI-DrugBank.d422.s13|92-95|with|O
DDI-DrugBank.d422.s13|97-105|depressed|O
DDI-DrugBank.d422.s13|107-116|myocardial|O
DDI-DrugBank.d422.s13|118-125|function|O
DDI-DrugBank.d422.s13|126-126|.|O
DDI-DrugBank.d422.s14|0-4|Fatal|O
DDI-DrugBank.d422.s14|6-12|cardiac|O
DDI-DrugBank.d422.s14|14-20|arrests|O
DDI-DrugBank.d422.s14|22-25|have|O
DDI-DrugBank.d422.s14|27-34|occurred|O
DDI-DrugBank.d422.s14|36-37|in|O
DDI-DrugBank.d422.s14|39-46|patients|O
DDI-DrugBank.d422.s14|48-56|receiving|O
DDI-DrugBank.d422.s14|58-61|both|O
DDI-DrugBank.d422.s14|63-67|drugs|O
DDI-DrugBank.d422.s14|68-68|.|O
DDI-DrugBank.d422.s15|0-11|Additionally|O
DDI-DrugBank.d422.s15|12-12|,|O
DDI-DrugBank.d422.s15|14-22|BREVIBLOC|brand
DDI-DrugBank.d422.s15|24-29|should|O
DDI-DrugBank.d422.s15|31-33|not|O
DDI-DrugBank.d422.s15|35-36|be|O
DDI-DrugBank.d422.s15|38-41|used|O
DDI-DrugBank.d422.s15|43-44|to|O
DDI-DrugBank.d422.s15|46-52|control|O
DDI-DrugBank.d422.s15|54-69|supraventricular|O
DDI-DrugBank.d422.s15|71-81|tachycardia|O
DDI-DrugBank.d422.s15|83-84|in|O
DDI-DrugBank.d422.s15|86-88|the|O
DDI-DrugBank.d422.s15|90-97|presence|O
DDI-DrugBank.d422.s15|99-100|of|O
DDI-DrugBank.d422.s15|102-107|agents|O
DDI-DrugBank.d422.s15|109-113|which|O
DDI-DrugBank.d422.s15|115-117|are|O
DDI-DrugBank.d422.s15|119-134|vasoconstrictive|O
DDI-DrugBank.d422.s15|136-138|and|O
DDI-DrugBank.d422.s15|140-148|inotropic|O
DDI-DrugBank.d422.s15|150-153|such|O
DDI-DrugBank.d422.s15|155-156|as|O
DDI-DrugBank.d422.s15|158-165|dopamine|drug
DDI-DrugBank.d422.s15|166-166|,|O
DDI-DrugBank.d422.s15|168-178|epinephrine|drug
DDI-DrugBank.d422.s15|179-179|,|O
DDI-DrugBank.d422.s15|181-183|and|O
DDI-DrugBank.d422.s15|185-198|norepinephrine|drug
DDI-DrugBank.d422.s15|200-206|because|O
DDI-DrugBank.d422.s15|208-209|of|O
DDI-DrugBank.d422.s15|211-213|the|O
DDI-DrugBank.d422.s15|215-220|danger|O
DDI-DrugBank.d422.s15|222-223|of|O
DDI-DrugBank.d422.s15|225-232|blocking|O
DDI-DrugBank.d422.s15|234-240|cardiac|O
DDI-DrugBank.d422.s15|242-254|contractility|O
DDI-DrugBank.d422.s15|256-259|when|O
DDI-DrugBank.d422.s15|261-268|systemic|O
DDI-DrugBank.d422.s15|270-277|vascular|O
DDI-DrugBank.d422.s15|279-288|resistance|O
DDI-DrugBank.d422.s15|290-291|is|O
DDI-DrugBank.d422.s15|293-296|high|O
DDI-DrugBank.d422.s15|297-297|.|O
DDI-DrugBank.d542.s0|0-11|Interactions|O
DDI-DrugBank.d542.s0|13-15|for|O
DDI-DrugBank.d542.s0|17-26|Vitamin B3|drug
DDI-DrugBank.d542.s0|28-28|(|O
DDI-DrugBank.d542.s0|29-34|Niacin|drug
DDI-DrugBank.d542.s0|35-35|)|O
DDI-DrugBank.d542.s0|36-36|:|O
DDI-DrugBank.d542.s0|38-53|Antihypertensive|group
DDI-DrugBank.d542.s0|55-61|Therapy|O
DDI-DrugBank.d542.s0|62-62|:|O
DDI-DrugBank.d542.s0|64-77|Nicotinic acid|drug
DDI-DrugBank.d542.s0|79-81|may|O
DDI-DrugBank.d542.s0|83-92|potentiate|O
DDI-DrugBank.d542.s0|94-96|the|O
DDI-DrugBank.d542.s0|98-104|effects|O
DDI-DrugBank.d542.s0|106-107|of|O
DDI-DrugBank.d542.s0|109-134|ganglionic blocking agents|group
DDI-DrugBank.d542.s0|136-138|and|O
DDI-DrugBank.d542.s0|140-149|vasoactive|O
DDI-DrugBank.d542.s0|151-155|drugs|O
DDI-DrugBank.d542.s0|157-165|resulting|O
DDI-DrugBank.d542.s0|167-168|in|O
DDI-DrugBank.d542.s0|170-177|postural|O
DDI-DrugBank.d542.s0|179-189|hypotension|O
DDI-DrugBank.d542.s0|190-190|.|O
DDI-DrugBank.d542.s1|0-6|Aspirin|brand
DDI-DrugBank.d542.s1|7-7|:|O
DDI-DrugBank.d542.s1|9-19|Concomitant|O
DDI-DrugBank.d542.s1|21-27|aspirin|brand
DDI-DrugBank.d542.s1|29-31|may|O
DDI-DrugBank.d542.s1|33-40|decrease|O
DDI-DrugBank.d542.s1|42-44|the|O
DDI-DrugBank.d542.s1|46-54|metabolic|O
DDI-DrugBank.d542.s1|56-64|clearance|O
DDI-DrugBank.d542.s1|66-67|of|O
DDI-DrugBank.d542.s1|69-82|nicotinic acid|drug
DDI-DrugBank.d542.s1|83-83|.|O
DDI-DrugBank.d542.s2|0-2|The|O
DDI-DrugBank.d542.s2|4-11|clinical|O
DDI-DrugBank.d542.s2|13-21|relevance|O
DDI-DrugBank.d542.s2|23-24|of|O
DDI-DrugBank.d542.s2|26-29|this|O
DDI-DrugBank.d542.s2|31-37|finding|O
DDI-DrugBank.d542.s2|39-40|is|O
DDI-DrugBank.d542.s2|42-48|unclear|O
DDI-DrugBank.d542.s2|49-49|.|O
DDI-DrugBank.d542.s3|0-4|Other|O
DDI-DrugBank.d542.s3|5-5|:|O
DDI-DrugBank.d542.s3|7-17|Concomitant|O
DDI-DrugBank.d542.s3|19-25|alcohol|drug
DDI-DrugBank.d542.s3|27-28|or|O
DDI-DrugBank.d542.s3|30-32|hot|O
DDI-DrugBank.d542.s3|34-39|drinks|O
DDI-DrugBank.d542.s3|41-43|may|O
DDI-DrugBank.d542.s3|45-52|increase|O
DDI-DrugBank.d542.s3|54-56|the|O
DDI-DrugBank.d542.s3|58-61|side|O
DDI-DrugBank.d542.s3|63-69|effects|O
DDI-DrugBank.d542.s3|71-72|of|O
DDI-DrugBank.d542.s3|74-81|flushing|O
DDI-DrugBank.d542.s3|83-85|and|O
DDI-DrugBank.d542.s3|87-94|pruritus|O
DDI-DrugBank.d542.s3|96-98|and|O
DDI-DrugBank.d542.s3|100-105|should|O
DDI-DrugBank.d542.s3|107-108|be|O
DDI-DrugBank.d542.s3|110-116|avoided|O
DDI-DrugBank.d542.s3|118-119|at|O
DDI-DrugBank.d542.s3|121-123|the|O
DDI-DrugBank.d542.s3|125-128|time|O
DDI-DrugBank.d542.s3|130-131|of|O
DDI-DrugBank.d542.s3|133-136|drug|O
DDI-DrugBank.d542.s3|138-146|ingestion|O
DDI-DrugBank.d542.s3|147-147|.|O
DDI-DrugBank.d686.s0|0-12|Thiabendazole|drug
DDI-DrugBank.d686.s0|14-16|may|O
DDI-DrugBank.d686.s0|18-24|compete|O
DDI-DrugBank.d686.s0|26-29|with|O
DDI-DrugBank.d686.s0|31-35|other|O
DDI-DrugBank.d686.s0|37-41|drugs|O
DDI-DrugBank.d686.s0|42-42|,|O
DDI-DrugBank.d686.s0|44-47|such|O
DDI-DrugBank.d686.s0|49-50|as|O
DDI-DrugBank.d686.s0|52-63|theophylline|drug
DDI-DrugBank.d686.s0|64-64|,|O
DDI-DrugBank.d686.s0|66-68|for|O
DDI-DrugBank.d686.s0|70-74|sites|O
DDI-DrugBank.d686.s0|76-77|of|O
DDI-DrugBank.d686.s0|79-88|metabolism|O
DDI-DrugBank.d686.s0|90-91|in|O
DDI-DrugBank.d686.s0|93-95|the|O
DDI-DrugBank.d686.s0|97-101|liver|O
DDI-DrugBank.d686.s0|102-102|,|O
DDI-DrugBank.d686.s0|104-107|thus|O
DDI-DrugBank.d686.s0|109-117|elevating|O
DDI-DrugBank.d686.s0|119-121|the|O
DDI-DrugBank.d686.s0|123-127|serum|O
DDI-DrugBank.d686.s0|129-134|levels|O
DDI-DrugBank.d686.s0|136-137|of|O
DDI-DrugBank.d686.s0|139-142|such|O
DDI-DrugBank.d686.s0|144-152|compounds|O
DDI-DrugBank.d686.s0|154-155|to|O
DDI-DrugBank.d686.s0|157-167|potentially|O
DDI-DrugBank.d686.s0|169-173|toxic|O
DDI-DrugBank.d686.s0|175-180|levels|O
DDI-DrugBank.d686.s0|181-181|.|O
DDI-DrugBank.d686.s1|0-8|Therefore|O
DDI-DrugBank.d686.s1|9-9|,|O
DDI-DrugBank.d686.s1|11-14|when|O
DDI-DrugBank.d686.s1|16-26|concomitant|O
DDI-DrugBank.d686.s1|28-30|use|O
DDI-DrugBank.d686.s1|32-33|of|O
DDI-DrugBank.d686.s1|35-47|thiabendazole|drug
DDI-DrugBank.d686.s1|49-51|and|O
DDI-DrugBank.d686.s1|53-72|xanthine derivatives|group
DDI-DrugBank.d686.s1|74-75|is|O
DDI-DrugBank.d686.s1|77-87|anticipated|O
DDI-DrugBank.d686.s1|88-88|,|O
DDI-DrugBank.d686.s1|90-91|it|O
DDI-DrugBank.d686.s1|93-95|may|O
DDI-DrugBank.d686.s1|97-98|be|O
DDI-DrugBank.d686.s1|100-108|necessary|O
DDI-DrugBank.d686.s1|110-111|to|O
DDI-DrugBank.d686.s1|113-119|monitor|O
DDI-DrugBank.d686.s1|121-125|blood|O
DDI-DrugBank.d686.s1|127-132|levels|O
DDI-DrugBank.d686.s1|134-139|and/or|O
DDI-DrugBank.d686.s1|141-146|reduce|O
DDI-DrugBank.d686.s1|148-150|the|O
DDI-DrugBank.d686.s1|152-157|dosage|O
DDI-DrugBank.d686.s1|159-160|of|O
DDI-DrugBank.d686.s1|162-165|such|O
DDI-DrugBank.d686.s1|167-175|compounds|O
DDI-DrugBank.d686.s1|176-176|.|O
DDI-DrugBank.d686.s2|0-3|Such|O
DDI-DrugBank.d686.s2|5-15|concomitant|O
DDI-DrugBank.d686.s2|17-19|use|O
DDI-DrugBank.d686.s2|21-26|should|O
DDI-DrugBank.d686.s2|28-29|be|O
DDI-DrugBank.d686.s2|31-42|administered|O
DDI-DrugBank.d686.s2|44-48|under|O
DDI-DrugBank.d686.s2|50-56|careful|O
DDI-DrugBank.d686.s2|58-64|medical|O
DDI-DrugBank.d686.s2|66-76|supervision|O
DDI-DrugBank.d686.s2|77-77|.|O
DDI-DrugBank.d18.s0|0-6|Tablets|O
DDI-DrugBank.d18.s0|7-7|:|O
DDI-DrugBank.d18.s0|9-11|The|O
DDI-DrugBank.d18.s0|13-27|benzodiazepines|group
DDI-DrugBank.d18.s0|28-28|,|O
DDI-DrugBank.d18.s0|30-38|including|O
DDI-DrugBank.d18.s0|40-48|lorazepam|drug
DDI-DrugBank.d18.s0|49-49|,|O
DDI-DrugBank.d18.s0|51-57|produce|O
DDI-DrugBank.d18.s0|59-72|CNS-depressant|O
DDI-DrugBank.d18.s0|74-80|effects|O
DDI-DrugBank.d18.s0|82-85|when|O
DDI-DrugBank.d18.s0|87-98|administered|O
DDI-DrugBank.d18.s0|100-103|with|O
DDI-DrugBank.d18.s0|105-108|such|O
DDI-DrugBank.d18.s0|110-120|medications|O
DDI-DrugBank.d18.s0|122-123|as|O
DDI-DrugBank.d18.s0|125-136|barbiturates|group
DDI-DrugBank.d18.s0|138-139|or|O
DDI-DrugBank.d18.s0|141-147|alcohol|drug
DDI-DrugBank.d18.s0|148-148|.|O
DDI-DrugBank.d18.s1|0-8|Injection|O
DDI-DrugBank.d18.s1|9-9|:|O
DDI-DrugBank.d18.s1|11-19|Lorazepam|drug
DDI-DrugBank.d18.s1|21-29|injection|O
DDI-DrugBank.d18.s1|30-30|,|O
DDI-DrugBank.d18.s1|32-35|like|O
DDI-DrugBank.d18.s1|37-41|other|O
DDI-DrugBank.d18.s1|43-52|injectable|O
DDI-DrugBank.d18.s1|54-68|benzodiazepines|group
DDI-DrugBank.d18.s1|69-69|,|O
DDI-DrugBank.d18.s1|71-78|produces|O
DDI-DrugBank.d18.s1|80-89|depression|O
DDI-DrugBank.d18.s1|91-92|of|O
DDI-DrugBank.d18.s1|94-96|the|O
DDI-DrugBank.d18.s1|98-104|central|O
DDI-DrugBank.d18.s1|106-112|nervous|O
DDI-DrugBank.d18.s1|114-119|system|O
DDI-DrugBank.d18.s1|121-124|when|O
DDI-DrugBank.d18.s1|126-137|administered|O
DDI-DrugBank.d18.s1|139-142|with|O
DDI-DrugBank.d18.s1|144-156|ethyl alcohol|drug
DDI-DrugBank.d18.s1|157-157|,|O
DDI-DrugBank.d18.s1|159-172|phenothiazines|group
DDI-DrugBank.d18.s1|173-173|,|O
DDI-DrugBank.d18.s1|175-186|barbiturates|group
DDI-DrugBank.d18.s1|187-187|,|O
DDI-DrugBank.d18.s1|189-202|MAO inhibitors|group
DDI-DrugBank.d18.s1|203-203|,|O
DDI-DrugBank.d18.s1|205-207|and|O
DDI-DrugBank.d18.s1|209-213|other|O
DDI-DrugBank.d18.s1|215-234|antidepressants.When|group
DDI-DrugBank.d18.s1|215-234|antidepressants.When|group
DDI-DrugBank.d18.s1|248-249|is|O
DDI-DrugBank.d18.s1|251-254|used|O
DDI-DrugBank.d18.s1|256-268|concomitantly|O
DDI-DrugBank.d18.s1|270-273|with|O
DDI-DrugBank.d18.s1|275-284|injectable|O
DDI-DrugBank.d18.s1|286-294|lorazepam|drug
DDI-DrugBank.d18.s1|295-295|,|O
DDI-DrugBank.d18.s1|297-298|an|O
DDI-DrugBank.d18.s1|300-308|increased|O
DDI-DrugBank.d18.s1|310-318|incidence|O
DDI-DrugBank.d18.s1|320-321|of|O
DDI-DrugBank.d18.s1|323-330|sedation|O
DDI-DrugBank.d18.s1|331-331|,|O
DDI-DrugBank.d18.s1|333-346|hallucinations|O
DDI-DrugBank.d18.s1|347-347|,|O
DDI-DrugBank.d18.s1|349-351|and|O
DDI-DrugBank.d18.s1|353-362|irrational|O
DDI-DrugBank.d18.s1|364-371|behavior|O
DDI-DrugBank.d18.s1|373-375|has|O
DDI-DrugBank.d18.s1|377-380|been|O
DDI-DrugBank.d18.s1|382-389|observed|O
DDI-DrugBank.d18.s1|390-390|.|O
DDI-DrugBank.d10.s0|0-11|Interactions|O
DDI-DrugBank.d10.s0|13-19|between|O
DDI-DrugBank.d10.s0|21-29|Betaseron|brand
DDI-DrugBank.d10.s0|31-33|and|O
DDI-DrugBank.d10.s0|35-39|other|O
DDI-DrugBank.d10.s0|41-45|drugs|O
DDI-DrugBank.d10.s0|47-50|have|O
DDI-DrugBank.d10.s0|52-54|not|O
DDI-DrugBank.d10.s0|56-59|been|O
DDI-DrugBank.d10.s0|61-65|fully|O
DDI-DrugBank.d10.s0|67-75|evaluated|O
DDI-DrugBank.d10.s0|76-76|.|O
DDI-DrugBank.d10.s1|0-7|Although|O
DDI-DrugBank.d10.s1|9-15|studies|O
DDI-DrugBank.d10.s1|17-24|designed|O
DDI-DrugBank.d10.s1|26-27|to|O
DDI-DrugBank.d10.s1|29-35|examine|O
DDI-DrugBank.d10.s1|37-40|drug|O
DDI-DrugBank.d10.s1|42-53|interactions|O
DDI-DrugBank.d10.s1|55-58|have|O
DDI-DrugBank.d10.s1|60-62|not|O
DDI-DrugBank.d10.s1|64-67|been|O
DDI-DrugBank.d10.s1|69-72|done|O
DDI-DrugBank.d10.s1|73-73|,|O
DDI-DrugBank.d10.s1|75-76|it|O
DDI-DrugBank.d10.s1|78-80|was|O
DDI-DrugBank.d10.s1|82-86|noted|O
DDI-DrugBank.d10.s1|88-91|that|O
DDI-DrugBank.d10.s1|93-106|corticosteroid|group
DDI-DrugBank.d10.s1|108-109|or|O
DDI-DrugBank.d10.s1|111-114|ACTH|drug
DDI-DrugBank.d10.s1|116-124|treatment|O
DDI-DrugBank.d10.s1|126-127|of|O
DDI-DrugBank.d10.s1|129-136|relapses|O
DDI-DrugBank.d10.s1|138-140|for|O
DDI-DrugBank.d10.s1|142-148|periods|O
DDI-DrugBank.d10.s1|150-151|of|O
DDI-DrugBank.d10.s1|153-154|up|O
DDI-DrugBank.d10.s1|156-157|to|O
DDI-DrugBank.d10.s1|159-160|28|O
DDI-DrugBank.d10.s1|162-165|days|O
DDI-DrugBank.d10.s1|167-169|has|O
DDI-DrugBank.d10.s1|171-174|been|O
DDI-DrugBank.d10.s1|176-187|administered|O
DDI-DrugBank.d10.s1|189-190|to|O
DDI-DrugBank.d10.s1|192-199|patients|O
DDI-DrugBank.d10.s1|201-201|(|O
DDI-DrugBank.d10.s1|202-206|N=180|O
DDI-DrugBank.d10.s1|207-207|)|O
DDI-DrugBank.d10.s1|209-217|receiving|O
DDI-DrugBank.d10.s1|219-227|Betaseron|brand
DDI-DrugBank.d10.s1|228-228|.|O
DDI-DrugBank.d10.s2|0-8|Betaseron|brand
DDI-DrugBank.d10.s2|10-23|administration|O
DDI-DrugBank.d10.s2|25-26|to|O
DDI-DrugBank.d10.s2|28-32|three|O
DDI-DrugBank.d10.s2|34-39|cancer|O
DDI-DrugBank.d10.s2|41-48|patients|O
DDI-DrugBank.d10.s2|50-53|over|O
DDI-DrugBank.d10.s2|55-55|a|O
DDI-DrugBank.d10.s2|57-60|dose|O
DDI-DrugBank.d10.s2|62-66|range|O
DDI-DrugBank.d10.s2|68-69|of|O
DDI-DrugBank.d10.s2|71-75|0.025|O
DDI-DrugBank.d10.s2|77-78|mg|O
DDI-DrugBank.d10.s2|80-81|to|O
DDI-DrugBank.d10.s2|83-85|2.2|O
DDI-DrugBank.d10.s2|87-88|mg|O
DDI-DrugBank.d10.s2|90-92|led|O
DDI-DrugBank.d10.s2|94-95|to|O
DDI-DrugBank.d10.s2|97-97|a|O
DDI-DrugBank.d10.s2|99-112|dose-dependent|O
DDI-DrugBank.d10.s2|114-123|inhibition|O
DDI-DrugBank.d10.s2|125-126|of|O
DDI-DrugBank.d10.s2|128-137|antipyrine|drug
DDI-DrugBank.d10.s2|139-152|elimination.14|O
DDI-DrugBank.d10.s2|154-156|The|O
DDI-DrugBank.d10.s2|158-163|effect|O
DDI-DrugBank.d10.s2|165-166|of|O
DDI-DrugBank.d10.s2|168-180|alternate-day|O
DDI-DrugBank.d10.s2|182-195|administration|O
DDI-DrugBank.d10.s2|197-198|of|O
DDI-DrugBank.d10.s2|200-203|0.25|O
DDI-DrugBank.d10.s2|205-206|mg|O
DDI-DrugBank.d10.s2|208-209|of|O
DDI-DrugBank.d10.s2|211-219|Betaseron|brand
DDI-DrugBank.d10.s2|221-222|on|O
DDI-DrugBank.d10.s2|224-227|drug|O
DDI-DrugBank.d10.s2|229-238|metabolism|O
DDI-DrugBank.d10.s2|240-241|in|O
DDI-DrugBank.d10.s2|243-244|MS|O
DDI-DrugBank.d10.s2|246-253|patients|O
DDI-DrugBank.d10.s2|255-256|is|O
DDI-DrugBank.d10.s2|258-264|unknown|O
DDI-DrugBank.d10.s2|265-265|.|O
DDI-MedLine.d110.s0|23-23|(|O
DDI-MedLine.d110.s0|29-29|)|O
DDI-MedLine.d110.s0|31-33|and|O
DDI-MedLine.d110.s0|43-43|:|O
DDI-MedLine.d110.s0|45-54|comparison|O
DDI-MedLine.d110.s0|56-57|of|O
DDI-MedLine.d110.s0|59-71|antiaddictive|O
DDI-MedLine.d110.s0|73-80|efficacy|O
DDI-MedLine.d110.s0|81-81|,|O
DDI-MedLine.d110.s0|83-90|toxicity|O
DDI-MedLine.d110.s0|91-91|,|O
DDI-MedLine.d110.s0|93-95|and|O
DDI-MedLine.d110.s0|97-106|mechanisms|O
DDI-MedLine.d110.s0|108-109|of|O
DDI-MedLine.d110.s0|111-116|action|O
DDI-MedLine.d110.s0|117-117|.|O
DDI-MedLine.d110.s1|5-5|,|O
DDI-MedLine.d110.s1|7-7|a|O
DDI-MedLine.d110.s1|9-13|novel|O
DDI-MedLine.d110.s1|15-19|iboga|O
DDI-MedLine.d110.s1|21-28|alkaloid|O
DDI-MedLine.d110.s1|30-37|congener|O
DDI-MedLine.d110.s1|38-38|,|O
DDI-MedLine.d110.s1|40-41|is|O
DDI-MedLine.d110.s1|43-47|being|O
DDI-MedLine.d110.s1|49-57|developed|O
DDI-MedLine.d110.s1|59-60|as|O
DDI-MedLine.d110.s1|62-62|a|O
DDI-MedLine.d110.s1|64-72|potential|O
DDI-MedLine.d110.s1|74-82|treatment|O
DDI-MedLine.d110.s1|84-86|for|O
DDI-MedLine.d110.s1|88-95|multiple|O
DDI-MedLine.d110.s1|97-101|forms|O
DDI-MedLine.d110.s1|103-104|of|O
DDI-MedLine.d110.s1|106-109|drug|O
DDI-MedLine.d110.s1|111-115|abuse|O
DDI-MedLine.d110.s1|116-116|.|O
DDI-MedLine.d110.s2|0-3|Like|O
DDI-MedLine.d110.s2|14-14|(|O
DDI-MedLine.d110.s2|15-16|40|O
DDI-MedLine.d110.s2|18-22|mg/kg|O
DDI-MedLine.d110.s2|23-23|)|O
DDI-MedLine.d110.s2|24-24|,|O
DDI-MedLine.d110.s2|32-32|(|O
DDI-MedLine.d110.s2|33-34|40|O
DDI-MedLine.d110.s2|36-40|mg/kg|O
DDI-MedLine.d110.s2|41-41|)|O
DDI-MedLine.d110.s2|43-51|decreases|O
DDI-MedLine.d110.s2|53-55|the|O
DDI-MedLine.d110.s2|57-67|intravenous|O
DDI-MedLine.d110.s2|69-87|self-administration|O
DDI-MedLine.d110.s2|89-90|of|O
DDI-MedLine.d110.s2|92-99|morphine|drug
DDI-MedLine.d110.s2|101-103|and|O
DDI-MedLine.d110.s2|105-111|cocaine|drug
DDI-MedLine.d110.s2|113-115|and|O
DDI-MedLine.d110.s2|117-119|the|O
DDI-MedLine.d110.s2|121-124|oral|O
DDI-MedLine.d110.s2|126-144|self-administration|O
DDI-MedLine.d110.s2|146-147|of|O
DDI-MedLine.d110.s2|149-155|ethanol|drug
DDI-MedLine.d110.s2|157-159|and|O
DDI-MedLine.d110.s2|161-168|nicotine|drug
DDI-MedLine.d110.s2|170-171|in|O
DDI-MedLine.d110.s2|173-176|rats|O
DDI-MedLine.d110.s2|177-177|;|O
DDI-MedLine.d110.s3|0-5|unlike|O
DDI-MedLine.d110.s3|15-15|,|O
DDI-MedLine.d110.s3|23-26|does|O
DDI-MedLine.d110.s3|28-30|not|O
DDI-MedLine.d110.s3|32-37|affect|O
DDI-MedLine.d110.s3|39-48|responding|O
DDI-MedLine.d110.s3|50-52|for|O
DDI-MedLine.d110.s3|54-54|a|O
DDI-MedLine.d110.s3|56-62|nondrug|O
DDI-MedLine.d110.s3|64-73|reinforcer|O
DDI-MedLine.d110.s3|75-75|(|O
DDI-MedLine.d110.s3|76-80|water|O
DDI-MedLine.d110.s3|81-81|)|O
DDI-MedLine.d110.s3|82-82|.|O
DDI-MedLine.d110.s4|0-3|Both|O
DDI-MedLine.d110.s4|14-16|and|O
DDI-MedLine.d110.s4|24-33|ameliorate|O
DDI-MedLine.d110.s4|35-40|opioid|group
DDI-MedLine.d110.s4|42-51|withdrawal|O
DDI-MedLine.d110.s4|53-57|signs|O
DDI-MedLine.d110.s4|58-58|.|O
DDI-MedLine.d110.s5|0-3|Both|O
DDI-MedLine.d110.s5|14-16|and|O
DDI-MedLine.d110.s5|24-31|decrease|O
DDI-MedLine.d110.s5|33-45|extracellular|O
DDI-MedLine.d110.s5|47-52|levels|O
DDI-MedLine.d110.s5|54-55|of|O
DDI-MedLine.d110.s5|57-64|dopamine|O
DDI-MedLine.d110.s5|66-67|in|O
DDI-MedLine.d110.s5|69-71|the|O
DDI-MedLine.d110.s5|73-79|nucleus|O
DDI-MedLine.d110.s5|81-89|accumbens|O
DDI-MedLine.d110.s5|90-90|,|O
DDI-MedLine.d110.s5|92-94|but|O
DDI-MedLine.d110.s5|96-99|only|O
DDI-MedLine.d110.s5|110-118|increases|O
DDI-MedLine.d110.s5|120-132|extracellular|O
DDI-MedLine.d110.s5|134-139|levels|O
DDI-MedLine.d110.s5|141-142|of|O
DDI-MedLine.d110.s5|144-152|serotonin|O
DDI-MedLine.d110.s5|154-155|in|O
DDI-MedLine.d110.s5|157-159|the|O
DDI-MedLine.d110.s5|161-167|nucleus|O
DDI-MedLine.d110.s5|169-177|accumbens|O
DDI-MedLine.d110.s5|178-178|.|O
DDI-MedLine.d110.s6|0-3|Both|O
DDI-MedLine.d110.s6|14-16|and|O
DDI-MedLine.d110.s6|24-28|block|O
DDI-MedLine.d110.s6|30-45|morphine-induced|drug
DDI-MedLine.d110.s6|47-49|and|O
DDI-MedLine.d110.s6|51-66|nicotine-induced|drug
DDI-MedLine.d110.s6|68-75|dopamine|O
DDI-MedLine.d110.s6|77-83|release|O
DDI-MedLine.d110.s6|85-86|in|O
DDI-MedLine.d110.s6|88-90|the|O
DDI-MedLine.d110.s6|92-98|nucleus|O
DDI-MedLine.d110.s6|100-108|accumbens|O
DDI-MedLine.d110.s6|109-109|;|O
DDI-MedLine.d110.s7|0-3|only|O
DDI-MedLine.d110.s7|14-21|enhances|O
DDI-MedLine.d110.s7|23-37|cocaine-induced|drug
DDI-MedLine.d110.s7|39-47|increases|O
DDI-MedLine.d110.s7|49-50|in|O
DDI-MedLine.d110.s7|52-59|accumbal|O
DDI-MedLine.d110.s7|61-68|dopamine|O
DDI-MedLine.d110.s7|69-69|.|O
DDI-MedLine.d110.s8|0-3|Both|O
DDI-MedLine.d110.s8|14-16|and|O
DDI-MedLine.d110.s8|24-30|enhance|O
DDI-MedLine.d110.s8|32-34|the|O
DDI-MedLine.d110.s8|36-44|locomotor|O
DDI-MedLine.d110.s8|46-51|and/or|O
DDI-MedLine.d110.s8|53-63|stereotypic|O
DDI-MedLine.d110.s8|65-71|effects|O
DDI-MedLine.d110.s8|73-74|of|O
DDI-MedLine.d110.s8|76-85|stimulants|O
DDI-MedLine.d110.s8|86-86|.|O
DDI-MedLine.d110.s9|9-18|attenuates|O
DDI-MedLine.d110.s9|19-19|,|O
DDI-MedLine.d110.s9|21-23|but|O
DDI-MedLine.d110.s9|31-41|potentiates|O
DDI-MedLine.d110.s9|42-42|,|O
DDI-MedLine.d110.s9|44-46|the|O
DDI-MedLine.d110.s9|48-52|acute|O
DDI-MedLine.d110.s9|54-62|locomotor|O
DDI-MedLine.d110.s9|64-70|effects|O
DDI-MedLine.d110.s9|72-73|of|O
DDI-MedLine.d110.s9|75-82|morphine|drug
DDI-MedLine.d110.s9|83-83|;|O
DDI-MedLine.d110.s10|0-3|both|O
DDI-MedLine.d110.s10|5-13|compounds|O
DDI-MedLine.d110.s10|15-23|attenuate|O
DDI-MedLine.d110.s10|25-40|morphine-induced|drug
DDI-MedLine.d110.s10|42-51|locomotion|O
DDI-MedLine.d110.s10|53-54|in|O
DDI-MedLine.d110.s10|56-75|morphine-experienced|drug
DDI-MedLine.d110.s10|77-80|rats|O
DDI-MedLine.d110.s10|81-81|.|O
DDI-MedLine.d110.s11|9-16|produces|O
DDI-MedLine.d110.s11|18-22|whole|O
DDI-MedLine.d110.s11|24-27|body|O
DDI-MedLine.d110.s11|29-35|tremors|O
DDI-MedLine.d110.s11|37-39|and|O
DDI-MedLine.d110.s11|40-40|,|O
DDI-MedLine.d110.s11|42-43|at|O
DDI-MedLine.d110.s11|45-48|high|O
DDI-MedLine.d110.s11|50-54|doses|O
DDI-MedLine.d110.s11|56-56|(|O
DDI-MedLine.d110.s11|57-57|>|O
DDI-MedLine.d110.s11|59-60|or|O
DDI-MedLine.d110.s11|62-62|=|O
DDI-MedLine.d110.s11|64-66|100|O
DDI-MedLine.d110.s11|68-72|mg/kg|O
DDI-MedLine.d110.s11|73-73|)|O
DDI-MedLine.d110.s11|74-74|,|O
DDI-MedLine.d110.s11|76-85|cerebellar|O
DDI-MedLine.d110.s11|87-92|damage|O
DDI-MedLine.d110.s11|93-93|;|O
DDI-MedLine.d110.s12|6-9|does|O
DDI-MedLine.d110.s12|11-13|not|O
DDI-MedLine.d110.s12|15-21|produce|O
DDI-MedLine.d110.s12|23-27|these|O
DDI-MedLine.d110.s12|29-35|effects|O
DDI-MedLine.d110.s12|36-36|.|O
DDI-MedLine.d110.s13|8-8|,|O
DDI-MedLine.d110.s13|10-12|but|O
DDI-MedLine.d110.s13|14-16|not|O
DDI-MedLine.d110.s13|23-23|,|O
DDI-MedLine.d110.s13|25-33|decreases|O
DDI-MedLine.d110.s13|35-39|heart|O
DDI-MedLine.d110.s13|41-44|rate|O
DDI-MedLine.d110.s13|46-47|at|O
DDI-MedLine.d110.s13|49-52|high|O
DDI-MedLine.d110.s13|54-58|doses|O
DDI-MedLine.d110.s13|59-59|.|O
DDI-MedLine.d110.s14|0-4|While|O
DDI-MedLine.d110.s14|12-14|and|O
DDI-MedLine.d110.s14|25-28|have|O
DDI-MedLine.d110.s14|30-36|similar|O
DDI-MedLine.d110.s14|38-47|affinities|O
DDI-MedLine.d110.s14|49-51|for|O
DDI-MedLine.d110.s14|53-57|kappa|O
DDI-MedLine.d110.s14|59-64|opioid|O
DDI-MedLine.d110.s14|66-68|and|O
DDI-MedLine.d110.s14|70-77|possibly|O
DDI-MedLine.d110.s14|79-87|nicotinic|O
DDI-MedLine.d110.s14|89-97|receptors|O
DDI-MedLine.d110.s14|98-98|,|O
DDI-MedLine.d110.s14|106-108|has|O
DDI-MedLine.d110.s14|110-113|much|O
DDI-MedLine.d110.s14|115-119|lower|O
DDI-MedLine.d110.s14|121-130|affinities|O
DDI-MedLine.d110.s14|132-135|than|O
DDI-MedLine.d110.s14|146-148|for|O
DDI-MedLine.d110.s14|150-153|NMDA|O
DDI-MedLine.d110.s14|155-157|and|O
DDI-MedLine.d110.s14|159-165|sigma-2|O
DDI-MedLine.d110.s14|167-175|receptors|O
DDI-MedLine.d110.s14|176-176|,|O
DDI-MedLine.d110.s14|178-183|sodium|O
DDI-MedLine.d110.s14|185-192|channels|O
DDI-MedLine.d110.s14|193-193|,|O
DDI-MedLine.d110.s14|195-197|and|O
DDI-MedLine.d110.s14|199-201|the|O
DDI-MedLine.d110.s14|203-206|5-HT|O
DDI-MedLine.d110.s14|208-218|transporter|O
DDI-MedLine.d110.s14|219-219|.|O
DDI-MedLine.d110.s15|0-3|Both|O
DDI-MedLine.d110.s15|11-13|and|O
DDI-MedLine.d110.s15|24-26|are|O
DDI-MedLine.d110.s15|28-38|sequestered|O
DDI-MedLine.d110.s15|40-41|in|O
DDI-MedLine.d110.s15|43-45|fat|O
DDI-MedLine.d110.s15|47-49|and|O
DDI-MedLine.d110.s15|50-50|,|O
DDI-MedLine.d110.s15|52-55|like|O
DDI-MedLine.d110.s15|65-65|,|O
DDI-MedLine.d110.s15|73-80|probably|O
DDI-MedLine.d110.s15|82-84|has|O
DDI-MedLine.d110.s15|86-87|an|O
DDI-MedLine.d110.s15|89-94|active|O
DDI-MedLine.d110.s15|96-105|metabolite|O
DDI-MedLine.d110.s15|106-106|.|O
DDI-MedLine.d110.s16|0-2|The|O
DDI-MedLine.d110.s16|4-7|data|O
DDI-MedLine.d110.s16|9-15|suggest|O
DDI-MedLine.d110.s16|17-20|that|O
DDI-MedLine.d110.s16|28-30|has|O
DDI-MedLine.d110.s16|32-32|a|O
DDI-MedLine.d110.s16|34-41|narrower|O
DDI-MedLine.d110.s16|43-50|spectrum|O
DDI-MedLine.d110.s16|52-53|of|O
DDI-MedLine.d110.s16|55-61|actions|O
DDI-MedLine.d110.s16|63-65|and|O
DDI-MedLine.d110.s16|67-70|will|O
DDI-MedLine.d110.s16|72-75|have|O
DDI-MedLine.d110.s16|77-77|a|O
DDI-MedLine.d110.s16|79-91|substantially|O
DDI-MedLine.d110.s16|93-99|greater|O
DDI-MedLine.d110.s16|101-111|therapeutic|O
DDI-MedLine.d110.s16|113-117|index|O
DDI-MedLine.d110.s16|119-122|than|O
DDI-MedLine.d110.s16|132-132|.|O
DDI-DrugBank.d565.s0|0-2|Due|O
DDI-DrugBank.d565.s0|4-5|to|O
DDI-DrugBank.d565.s0|7-9|the|O
DDI-DrugBank.d565.s0|11-19|potential|O
DDI-DrugBank.d565.s0|21-23|for|O
DDI-DrugBank.d565.s0|25-32|additive|O
DDI-DrugBank.d565.s0|34-40|effects|O
DDI-DrugBank.d565.s0|41-41|,|O
DDI-DrugBank.d565.s0|43-49|caution|O
DDI-DrugBank.d565.s0|51-53|and|O
DDI-DrugBank.d565.s0|55-61|careful|O
DDI-DrugBank.d565.s0|63-71|titration|O
DDI-DrugBank.d565.s0|73-75|are|O
DDI-DrugBank.d565.s0|77-85|warranted|O
DDI-DrugBank.d565.s0|87-88|in|O
DDI-DrugBank.d565.s0|90-97|patients|O
DDI-DrugBank.d565.s0|99-107|receiving|O
DDI-DrugBank.d565.s0|109-131|diltiazem hydrochloride|drug
DDI-DrugBank.d565.s0|133-145|concomitantly|O
DDI-DrugBank.d565.s0|147-150|with|O
DDI-DrugBank.d565.s0|152-156|other|O
DDI-DrugBank.d565.s0|158-163|agents|O
DDI-DrugBank.d565.s0|165-169|known|O
DDI-DrugBank.d565.s0|171-172|to|O
DDI-DrugBank.d565.s0|174-179|affect|O
DDI-DrugBank.d565.s0|181-187|cardiac|O
DDI-DrugBank.d565.s0|189-201|contractility|O
DDI-DrugBank.d565.s0|203-208|and/or|O
DDI-DrugBank.d565.s0|210-219|conduction|O
DDI-DrugBank.d565.s0|220-220|.|O
DDI-DrugBank.d565.s1|0-12|Pharmacologic|O
DDI-DrugBank.d565.s1|14-20|studies|O
DDI-DrugBank.d565.s1|22-29|indicate|O
DDI-DrugBank.d565.s1|31-34|that|O
DDI-DrugBank.d565.s1|36-40|there|O
DDI-DrugBank.d565.s1|42-44|may|O
DDI-DrugBank.d565.s1|46-47|be|O
DDI-DrugBank.d565.s1|49-56|additive|O
DDI-DrugBank.d565.s1|58-64|effects|O
DDI-DrugBank.d565.s1|66-67|in|O
DDI-DrugBank.d565.s1|69-78|prolonging|O
DDI-DrugBank.d565.s1|80-81|AV|O
DDI-DrugBank.d565.s1|83-92|conduction|O
DDI-DrugBank.d565.s1|94-97|when|O
DDI-DrugBank.d565.s1|99-103|using|O
DDI-DrugBank.d565.s1|105-117|beta-blockers|group
DDI-DrugBank.d565.s1|119-120|or|O
DDI-DrugBank.d565.s1|122-130|digitalis|group
DDI-DrugBank.d565.s1|132-144|concomitantly|O
DDI-DrugBank.d565.s1|146-149|with|O
DDI-DrugBank.d565.s1|151-156|Tiazac|brand
DDI-DrugBank.d565.s1|157-157|.|O
DDI-DrugBank.d565.s2|0-1|As|O
DDI-DrugBank.d565.s2|3-6|with|O
DDI-DrugBank.d565.s2|8-10|all|O
DDI-DrugBank.d565.s2|12-16|drugs|O
DDI-DrugBank.d565.s2|17-17|,|O
DDI-DrugBank.d565.s2|19-22|care|O
DDI-DrugBank.d565.s2|24-29|should|O
DDI-DrugBank.d565.s2|31-32|be|O
DDI-DrugBank.d565.s2|34-42|exercised|O
DDI-DrugBank.d565.s2|44-47|when|O
DDI-DrugBank.d565.s2|49-56|treating|O
DDI-DrugBank.d565.s2|58-65|patients|O
DDI-DrugBank.d565.s2|67-70|with|O
DDI-DrugBank.d565.s2|72-79|multiple|O
DDI-DrugBank.d565.s2|81-91|medications|O
DDI-DrugBank.d565.s2|92-92|.|O
DDI-DrugBank.d565.s3|0-8|Diltiazem|drug
DDI-DrugBank.d565.s3|10-11|is|O
DDI-DrugBank.d565.s3|13-16|both|O
DDI-DrugBank.d565.s3|18-18|a|O
DDI-DrugBank.d565.s3|20-28|substrate|O
DDI-DrugBank.d565.s3|30-32|and|O
DDI-DrugBank.d565.s3|34-35|an|O
DDI-DrugBank.d565.s3|37-45|inhibitor|O
DDI-DrugBank.d565.s3|47-48|of|O
DDI-DrugBank.d565.s3|50-52|the|O
DDI-DrugBank.d565.s3|54-63|cytochrome|O
DDI-DrugBank.d565.s3|65-69|P-450|O
DDI-DrugBank.d565.s3|71-73|3A4|O
DDI-DrugBank.d565.s3|75-80|enzyme|O
DDI-DrugBank.d565.s3|82-87|system|O
DDI-DrugBank.d565.s3|88-88|.|O
DDI-DrugBank.d565.s4|0-4|Other|O
DDI-DrugBank.d565.s4|6-10|drugs|O
DDI-DrugBank.d565.s4|12-15|that|O
DDI-DrugBank.d565.s4|17-19|are|O
DDI-DrugBank.d565.s4|21-28|specific|O
DDI-DrugBank.d565.s4|30-39|substrates|O
DDI-DrugBank.d565.s4|40-40|,|O
DDI-DrugBank.d565.s4|42-51|inhibitors|O
DDI-DrugBank.d565.s4|52-52|,|O
DDI-DrugBank.d565.s4|54-55|or|O
DDI-DrugBank.d565.s4|57-64|inducers|O
DDI-DrugBank.d565.s4|66-67|of|O
DDI-DrugBank.d565.s4|69-71|the|O
DDI-DrugBank.d565.s4|73-78|enzyme|O
DDI-DrugBank.d565.s4|80-85|system|O
DDI-DrugBank.d565.s4|87-89|may|O
DDI-DrugBank.d565.s4|91-94|have|O
DDI-DrugBank.d565.s4|96-96|a|O
DDI-DrugBank.d565.s4|98-108|significant|O
DDI-DrugBank.d565.s4|110-115|impact|O
DDI-DrugBank.d565.s4|117-118|on|O
DDI-DrugBank.d565.s4|120-122|the|O
DDI-DrugBank.d565.s4|124-131|efficacy|O
DDI-DrugBank.d565.s4|133-135|and|O
DDI-DrugBank.d565.s4|137-140|side|O
DDI-DrugBank.d565.s4|142-147|effect|O
DDI-DrugBank.d565.s4|149-155|profile|O
DDI-DrugBank.d565.s4|157-158|of|O
DDI-DrugBank.d565.s4|160-168|diltiazem|drug
DDI-DrugBank.d565.s4|169-169|.|O
DDI-DrugBank.d565.s5|0-7|Patients|O
DDI-DrugBank.d565.s5|9-14|taking|O
DDI-DrugBank.d565.s5|16-20|other|O
DDI-DrugBank.d565.s5|22-26|drugs|O
DDI-DrugBank.d565.s5|28-31|that|O
DDI-DrugBank.d565.s5|33-35|are|O
DDI-DrugBank.d565.s5|37-46|substrates|O
DDI-DrugBank.d565.s5|48-49|of|O
DDI-DrugBank.d565.s5|51-56|CYP450|O
DDI-DrugBank.d565.s5|58-60|3A4|O
DDI-DrugBank.d565.s5|61-61|,|O
DDI-DrugBank.d565.s5|63-72|especially|O
DDI-DrugBank.d565.s5|74-81|patients|O
DDI-DrugBank.d565.s5|83-86|with|O
DDI-DrugBank.d565.s5|88-92|renal|O
DDI-DrugBank.d565.s5|94-99|and/or|O
DDI-DrugBank.d565.s5|101-107|hepatic|O
DDI-DrugBank.d565.s5|109-118|impairment|O
DDI-DrugBank.d565.s5|119-119|,|O
DDI-DrugBank.d565.s5|121-123|may|O
DDI-DrugBank.d565.s5|125-131|require|O
DDI-DrugBank.d565.s5|133-138|dosage|O
DDI-DrugBank.d565.s5|140-149|adjustment|O
DDI-DrugBank.d565.s5|151-154|when|O
DDI-DrugBank.d565.s5|156-163|starting|O
DDI-DrugBank.d565.s5|165-166|or|O
DDI-DrugBank.d565.s5|168-175|stopping|O
DDI-DrugBank.d565.s5|177-189|concomitantly|O
DDI-DrugBank.d565.s5|191-202|administered|O
DDI-DrugBank.d565.s5|204-212|diltiazem|drug
DDI-DrugBank.d565.s5|214-215|in|O
DDI-DrugBank.d565.s5|217-221|order|O
DDI-DrugBank.d565.s5|223-224|to|O
DDI-DrugBank.d565.s5|226-233|maintain|O
DDI-DrugBank.d565.s5|235-241|optimum|O
DDI-DrugBank.d565.s5|243-253|therapeutic|O
DDI-DrugBank.d565.s5|255-259|blood|O
DDI-DrugBank.d565.s5|261-266|levels|O
DDI-DrugBank.d565.s5|267-267|.|O
DDI-DrugBank.d565.s7|0-9|Controlled|O
DDI-DrugBank.d565.s7|11-13|and|O
DDI-DrugBank.d565.s7|15-26|uncontrolled|O
DDI-DrugBank.d565.s7|28-35|domestic|O
DDI-DrugBank.d565.s7|37-43|studies|O
DDI-DrugBank.d565.s7|45-51|suggest|O
DDI-DrugBank.d565.s7|53-56|that|O
DDI-DrugBank.d565.s7|58-68|concomitant|O
DDI-DrugBank.d565.s7|70-72|use|O
DDI-DrugBank.d565.s7|74-75|of|O
DDI-DrugBank.d565.s7|77-99|diltiazem hydrochloride|drug
DDI-DrugBank.d565.s7|101-103|and|O
DDI-DrugBank.d565.s7|105-117|beta-blockers|group
DDI-DrugBank.d565.s7|119-120|is|O
DDI-DrugBank.d565.s7|122-128|usually|O
DDI-DrugBank.d565.s7|130-133|well|O
DDI-DrugBank.d565.s7|135-143|tolerated|O
DDI-DrugBank.d565.s7|144-144|,|O
DDI-DrugBank.d565.s7|146-148|but|O
DDI-DrugBank.d565.s7|150-158|available|O
DDI-DrugBank.d565.s7|160-163|data|O
DDI-DrugBank.d565.s7|165-167|are|O
DDI-DrugBank.d565.s7|169-171|not|O
DDI-DrugBank.d565.s7|173-182|sufficient|O
DDI-DrugBank.d565.s7|184-185|to|O
DDI-DrugBank.d565.s7|187-193|predict|O
DDI-DrugBank.d565.s7|195-197|the|O
DDI-DrugBank.d565.s7|199-205|effects|O
DDI-DrugBank.d565.s7|207-208|of|O
DDI-DrugBank.d565.s7|210-220|concomitant|O
DDI-DrugBank.d565.s7|222-230|treatment|O
DDI-DrugBank.d565.s7|232-233|in|O
DDI-DrugBank.d565.s7|235-242|patients|O
DDI-DrugBank.d565.s7|244-247|with|O
DDI-DrugBank.d565.s7|249-252|left|O
DDI-DrugBank.d565.s7|254-264|ventricular|O
DDI-DrugBank.d565.s7|266-276|dysfunction|O
DDI-DrugBank.d565.s7|278-279|or|O
DDI-DrugBank.d565.s7|281-287|cardiac|O
DDI-DrugBank.d565.s7|289-298|conduction|O
DDI-DrugBank.d565.s7|300-312|abnormalities|O
DDI-DrugBank.d565.s7|313-313|.|O
DDI-DrugBank.d565.s8|0-13|Administration|O
DDI-DrugBank.d565.s8|15-16|of|O
DDI-DrugBank.d565.s8|18-40|diltiazem hydrochloride|drug
DDI-DrugBank.d565.s8|42-54|concomitantly|O
DDI-DrugBank.d565.s8|56-59|with|O
DDI-DrugBank.d565.s8|61-71|propranolol|drug
DDI-DrugBank.d565.s8|73-74|in|O
DDI-DrugBank.d565.s8|76-79|five|O
DDI-DrugBank.d565.s8|81-86|normal|O
DDI-DrugBank.d565.s8|88-97|volunteers|O
DDI-DrugBank.d565.s8|99-106|resulted|O
DDI-DrugBank.d565.s8|108-109|in|O
DDI-DrugBank.d565.s8|111-119|increased|O
DDI-DrugBank.d565.s8|121-131|propranolol|drug
DDI-DrugBank.d565.s8|133-138|levels|O
DDI-DrugBank.d565.s8|140-141|in|O
DDI-DrugBank.d565.s8|143-145|all|O
DDI-DrugBank.d565.s8|147-154|subjects|O
DDI-DrugBank.d565.s8|156-158|and|O
DDI-DrugBank.d565.s8|160-174|bioavailability|O
DDI-DrugBank.d565.s8|176-177|of|O
DDI-DrugBank.d565.s8|179-189|propranolol|drug
DDI-DrugBank.d565.s8|191-193|was|O
DDI-DrugBank.d565.s8|195-203|increased|O
DDI-DrugBank.d565.s8|205-217|approximately|O
DDI-DrugBank.d565.s8|219-220|50|O
DDI-DrugBank.d565.s8|221-221|%|O
DDI-DrugBank.d565.s8|222-222|.|O
DDI-DrugBank.d565.s9|0-1|In|O
DDI-DrugBank.d565.s9|3-7|vitro|O
DDI-DrugBank.d565.s9|8-8|,|O
DDI-DrugBank.d565.s9|10-20|propranolol|drug
DDI-DrugBank.d565.s9|22-28|appears|O
DDI-DrugBank.d565.s9|30-31|to|O
DDI-DrugBank.d565.s9|33-34|be|O
DDI-DrugBank.d565.s9|36-44|displaced|O
DDI-DrugBank.d565.s9|46-49|from|O
DDI-DrugBank.d565.s9|51-53|its|O
DDI-DrugBank.d565.s9|55-61|binding|O
DDI-DrugBank.d565.s9|63-67|sites|O
DDI-DrugBank.d565.s9|69-70|by|O
DDI-DrugBank.d565.s9|72-80|diltiazem|drug
DDI-DrugBank.d565.s9|81-81|.|O
DDI-DrugBank.d565.s10|0-1|If|O
DDI-DrugBank.d565.s10|3-13|combination|O
DDI-DrugBank.d565.s10|15-21|therapy|O
DDI-DrugBank.d565.s10|23-24|is|O
DDI-DrugBank.d565.s10|26-34|initiated|O
DDI-DrugBank.d565.s10|36-37|or|O
DDI-DrugBank.d565.s10|39-47|withdrawn|O
DDI-DrugBank.d565.s10|49-50|in|O
DDI-DrugBank.d565.s10|52-62|conjunction|O
DDI-DrugBank.d565.s10|64-67|with|O
DDI-DrugBank.d565.s10|69-79|propranolol|drug
DDI-DrugBank.d565.s10|80-80|,|O
DDI-DrugBank.d565.s10|82-83|an|O
DDI-DrugBank.d565.s10|85-94|adjustment|O
DDI-DrugBank.d565.s10|96-97|in|O
DDI-DrugBank.d565.s10|99-101|the|O
DDI-DrugBank.d565.s10|103-113|propranolol|drug
DDI-DrugBank.d565.s10|115-118|dose|O
DDI-DrugBank.d565.s10|120-122|may|O
DDI-DrugBank.d565.s10|124-125|be|O
DDI-DrugBank.d565.s10|127-135|warranted|O
DDI-DrugBank.d565.s10|136-136|.|O
DDI-DrugBank.d565.s12|0-0|A|O
DDI-DrugBank.d565.s12|2-6|study|O
DDI-DrugBank.d565.s12|8-9|in|O
DDI-DrugBank.d565.s12|11-13|six|O
DDI-DrugBank.d565.s12|15-21|healthy|O
DDI-DrugBank.d565.s12|23-32|volunteers|O
DDI-DrugBank.d565.s12|34-36|has|O
DDI-DrugBank.d565.s12|38-42|shown|O
DDI-DrugBank.d565.s12|44-44|a|O
DDI-DrugBank.d565.s12|46-56|significant|O
DDI-DrugBank.d565.s12|58-65|increase|O
DDI-DrugBank.d565.s12|67-68|in|O
DDI-DrugBank.d565.s12|70-73|peak|O
DDI-DrugBank.d565.s12|75-83|diltiazem|drug
DDI-DrugBank.d565.s12|85-90|plasma|O
DDI-DrugBank.d565.s12|92-97|levels|O
DDI-DrugBank.d565.s12|99-99|(|O
DDI-DrugBank.d565.s12|100-101|58|O
DDI-DrugBank.d565.s12|102-102|%|O
DDI-DrugBank.d565.s12|103-103|)|O
DDI-DrugBank.d565.s12|105-107|and|O
DDI-DrugBank.d565.s12|109-111|AUC|O
DDI-DrugBank.d565.s12|113-113|(|O
DDI-DrugBank.d565.s12|114-115|53|O
DDI-DrugBank.d565.s12|116-116|%|O
DDI-DrugBank.d565.s12|117-117|)|O
DDI-DrugBank.d565.s12|119-123|after|O
DDI-DrugBank.d565.s12|125-125|a|O
DDI-DrugBank.d565.s12|127-132|1-week|O
DDI-DrugBank.d565.s12|134-139|course|O
DDI-DrugBank.d565.s12|141-142|of|O
DDI-DrugBank.d565.s12|144-153|cimetidine|drug
DDI-DrugBank.d565.s12|155-158|1200|O
DDI-DrugBank.d565.s12|160-165|mg/day|O
DDI-DrugBank.d565.s12|167-169|and|O
DDI-DrugBank.d565.s12|171-171|a|O
DDI-DrugBank.d565.s12|173-178|single|O
DDI-DrugBank.d565.s12|180-183|dose|O
DDI-DrugBank.d565.s12|185-186|of|O
DDI-DrugBank.d565.s12|188-196|diltiazem|drug
DDI-DrugBank.d565.s12|198-201|60mg|O
DDI-DrugBank.d565.s12|202-202|.|O
DDI-DrugBank.d565.s13|0-9|Ranitidine|drug
DDI-DrugBank.d565.s13|11-18|produced|O
DDI-DrugBank.d565.s13|20-26|smaller|O
DDI-DrugBank.d565.s13|27-27|,|O
DDI-DrugBank.d565.s13|29-42|nonsignificant|O
DDI-DrugBank.d565.s13|44-52|increases|O
DDI-DrugBank.d565.s13|53-53|.|O
DDI-DrugBank.d565.s14|0-2|The|O
DDI-DrugBank.d565.s14|4-9|effect|O
DDI-DrugBank.d565.s14|11-13|may|O
DDI-DrugBank.d565.s14|15-16|be|O
DDI-DrugBank.d565.s14|18-25|mediated|O
DDI-DrugBank.d565.s14|27-28|by|O
DDI-DrugBank.d565.s14|30-40|cimetidines|drug
DDI-DrugBank.d565.s14|42-46|known|O
DDI-DrugBank.d565.s14|48-57|inhibition|O
DDI-DrugBank.d565.s14|59-60|of|O
DDI-DrugBank.d565.s14|62-68|hepatic|O
DDI-DrugBank.d565.s14|70-79|cytochrome|O
DDI-DrugBank.d565.s14|81-85|P-450|O
DDI-DrugBank.d565.s14|86-86|,|O
DDI-DrugBank.d565.s14|88-90|the|O
DDI-DrugBank.d565.s14|92-97|enzyme|O
DDI-DrugBank.d565.s14|99-104|system|O
DDI-DrugBank.d565.s14|106-116|responsible|O
DDI-DrugBank.d565.s14|118-120|for|O
DDI-DrugBank.d565.s14|122-124|the|O
DDI-DrugBank.d565.s14|126-135|first-pass|O
DDI-DrugBank.d565.s14|137-146|metabolism|O
DDI-DrugBank.d565.s14|148-149|of|O
DDI-DrugBank.d565.s14|151-159|diltiazem|drug
DDI-DrugBank.d565.s14|160-160|.|O
DDI-DrugBank.d565.s15|0-7|Patients|O
DDI-DrugBank.d565.s15|9-17|currently|O
DDI-DrugBank.d565.s15|19-27|receiving|O
DDI-DrugBank.d565.s15|29-37|diltiazem|drug
DDI-DrugBank.d565.s15|39-45|therapy|O
DDI-DrugBank.d565.s15|47-52|should|O
DDI-DrugBank.d565.s15|54-55|be|O
DDI-DrugBank.d565.s15|57-65|carefully|O
DDI-DrugBank.d565.s15|67-75|monitored|O
DDI-DrugBank.d565.s15|77-79|for|O
DDI-DrugBank.d565.s15|81-81|a|O
DDI-DrugBank.d565.s15|83-88|change|O
DDI-DrugBank.d565.s15|90-91|in|O
DDI-DrugBank.d565.s15|93-107|pharmacological|O
DDI-DrugBank.d565.s15|109-114|effect|O
DDI-DrugBank.d565.s15|116-119|when|O
DDI-DrugBank.d565.s15|121-130|initiating|O
DDI-DrugBank.d565.s15|132-134|and|O
DDI-DrugBank.d565.s15|136-148|discontinuing|O
DDI-DrugBank.d565.s15|150-156|therapy|O
DDI-DrugBank.d565.s15|158-161|with|O
DDI-DrugBank.d565.s15|163-172|cimetidine|drug
DDI-DrugBank.d565.s15|173-173|.|O
DDI-DrugBank.d565.s16|0-1|An|O
DDI-DrugBank.d565.s16|3-12|adjustment|O
DDI-DrugBank.d565.s16|14-15|in|O
DDI-DrugBank.d565.s16|17-19|the|O
DDI-DrugBank.d565.s16|21-29|diltiazem|drug
DDI-DrugBank.d565.s16|31-34|dose|O
DDI-DrugBank.d565.s16|36-38|may|O
DDI-DrugBank.d565.s16|40-41|be|O
DDI-DrugBank.d565.s16|43-51|warranted|O
DDI-DrugBank.d565.s16|52-52|.|O
DDI-DrugBank.d565.s18|0-13|Administration|O
DDI-DrugBank.d565.s18|15-16|of|O
DDI-DrugBank.d565.s18|18-40|diltiazem hydrochloride|drug
DDI-DrugBank.d565.s18|42-45|with|O
DDI-DrugBank.d565.s18|47-53|digoxin|drug
DDI-DrugBank.d565.s18|55-56|in|O
DDI-DrugBank.d565.s18|58-59|24|O
DDI-DrugBank.d565.s18|61-67|healthy|O
DDI-DrugBank.d565.s18|69-72|male|O
DDI-DrugBank.d565.s18|74-81|subjects|O
DDI-DrugBank.d565.s18|83-91|increased|O
DDI-DrugBank.d565.s18|93-98|plasma|O
DDI-DrugBank.d565.s18|100-106|digoxin|drug
DDI-DrugBank.d565.s18|108-121|concentrations|O
DDI-DrugBank.d565.s18|123-135|approximately|O
DDI-DrugBank.d565.s18|137-138|20|O
DDI-DrugBank.d565.s18|139-139|%|O
DDI-DrugBank.d565.s18|140-140|.|O
DDI-DrugBank.d565.s19|0-6|Another|O
DDI-DrugBank.d565.s19|8-19|investigator|O
DDI-DrugBank.d565.s19|21-25|found|O
DDI-DrugBank.d565.s19|27-28|no|O
DDI-DrugBank.d565.s19|30-37|increase|O
DDI-DrugBank.d565.s19|39-40|in|O
DDI-DrugBank.d565.s19|42-48|digoxin|drug
DDI-DrugBank.d565.s19|50-55|levels|O
DDI-DrugBank.d565.s19|57-58|in|O
DDI-DrugBank.d565.s19|60-61|12|O
DDI-DrugBank.d565.s19|63-70|patients|O
DDI-DrugBank.d565.s19|72-75|with|O
DDI-DrugBank.d565.s19|77-84|coronary|O
DDI-DrugBank.d565.s19|86-91|artery|O
DDI-DrugBank.d565.s19|93-99|disease|O
DDI-DrugBank.d565.s19|100-100|.|O
DDI-DrugBank.d565.s20|0-4|Since|O
DDI-DrugBank.d565.s20|6-10|there|O
DDI-DrugBank.d565.s20|12-15|have|O
DDI-DrugBank.d565.s20|17-20|been|O
DDI-DrugBank.d565.s20|22-32|conflicting|O
DDI-DrugBank.d565.s20|34-40|results|O
DDI-DrugBank.d565.s20|42-50|regarding|O
DDI-DrugBank.d565.s20|52-54|the|O
DDI-DrugBank.d565.s20|56-61|effect|O
DDI-DrugBank.d565.s20|63-64|of|O
DDI-DrugBank.d565.s20|66-72|digoxin|drug
DDI-DrugBank.d565.s20|74-79|levels|O
DDI-DrugBank.d565.s20|80-80|,|O
DDI-DrugBank.d565.s20|82-83|it|O
DDI-DrugBank.d565.s20|85-86|is|O
DDI-DrugBank.d565.s20|88-98|recommended|O
DDI-DrugBank.d565.s20|100-103|that|O
DDI-DrugBank.d565.s20|105-111|digoxin|drug
DDI-DrugBank.d565.s20|113-118|levels|O
DDI-DrugBank.d565.s20|120-121|be|O
DDI-DrugBank.d565.s20|123-131|monitored|O
DDI-DrugBank.d565.s20|133-136|when|O
DDI-DrugBank.d565.s20|138-147|initiating|O
DDI-DrugBank.d565.s20|148-148|,|O
DDI-DrugBank.d565.s20|150-158|adjusting|O
DDI-DrugBank.d565.s20|159-159|,|O
DDI-DrugBank.d565.s20|161-163|and|O
DDI-DrugBank.d565.s20|165-177|discontinuing|O
DDI-DrugBank.d565.s20|179-201|diltiazem hydrochloride|drug
DDI-DrugBank.d565.s20|203-209|therapy|O
DDI-DrugBank.d565.s20|211-212|to|O
DDI-DrugBank.d565.s20|214-218|avoid|O
DDI-DrugBank.d565.s20|220-227|possible|O
DDI-DrugBank.d565.s20|229-233|over-|O
DDI-DrugBank.d565.s20|235-236|or|O
DDI-DrugBank.d565.s20|238-257|under-digitalization|O
DDI-DrugBank.d565.s20|258-258|.|O
DDI-DrugBank.d565.s22|0-2|The|O
DDI-DrugBank.d565.s22|4-13|depression|O
DDI-DrugBank.d565.s22|15-16|of|O
DDI-DrugBank.d565.s22|18-24|cardiac|O
DDI-DrugBank.d565.s22|26-38|contractility|O
DDI-DrugBank.d565.s22|39-39|,|O
DDI-DrugBank.d565.s22|41-52|conductivity|O
DDI-DrugBank.d565.s22|53-53|,|O
DDI-DrugBank.d565.s22|55-57|and|O
DDI-DrugBank.d565.s22|59-70|automaticity|O
DDI-DrugBank.d565.s22|72-73|as|O
DDI-DrugBank.d565.s22|75-78|well|O
DDI-DrugBank.d565.s22|80-81|as|O
DDI-DrugBank.d565.s22|83-85|the|O
DDI-DrugBank.d565.s22|87-94|vascular|O
DDI-DrugBank.d565.s22|96-103|dilation|O
DDI-DrugBank.d565.s22|105-114|associated|O
DDI-DrugBank.d565.s22|116-119|with|O
DDI-DrugBank.d565.s22|121-131|anesthetics|group
DDI-DrugBank.d565.s22|133-135|may|O
DDI-DrugBank.d565.s22|137-138|be|O
DDI-DrugBank.d565.s22|140-150|potentiated|O
DDI-DrugBank.d565.s22|152-153|by|O
DDI-DrugBank.d565.s22|155-178|calcium channel blockers|group
DDI-DrugBank.d565.s22|179-179|.|O
DDI-DrugBank.d565.s23|0-3|When|O
DDI-DrugBank.d565.s23|5-8|used|O
DDI-DrugBank.d565.s23|10-22|concomitantly|O
DDI-DrugBank.d565.s23|23-23|,|O
DDI-DrugBank.d565.s23|25-35|anesthetics|group
DDI-DrugBank.d565.s23|37-39|and|O
DDI-DrugBank.d565.s23|41-64|calcium channel blockers|group
DDI-DrugBank.d565.s23|66-71|should|O
DDI-DrugBank.d565.s23|73-74|be|O
DDI-DrugBank.d565.s23|76-83|titrated|O
DDI-DrugBank.d565.s23|85-93|carefully|O
DDI-DrugBank.d565.s23|94-94|.|O
DDI-DrugBank.d565.s25|0-0|A|O
DDI-DrugBank.d565.s25|2-16|pharmacokinetic|O
DDI-DrugBank.d565.s25|18-28|interaction|O
DDI-DrugBank.d565.s25|30-36|between|O
DDI-DrugBank.d565.s25|38-46|diltiazem|drug
DDI-DrugBank.d565.s25|48-50|and|O
DDI-DrugBank.d565.s25|52-63|cyclosporine|drug
DDI-DrugBank.d565.s25|65-67|has|O
DDI-DrugBank.d565.s25|69-72|been|O
DDI-DrugBank.d565.s25|74-81|observed|O
DDI-DrugBank.d565.s25|83-88|during|O
DDI-DrugBank.d565.s25|90-96|studies|O
DDI-DrugBank.d565.s25|98-106|involving|O
DDI-DrugBank.d565.s25|108-112|renal|O
DDI-DrugBank.d565.s25|114-116|and|O
DDI-DrugBank.d565.s25|118-124|cardiac|O
DDI-DrugBank.d565.s25|126-135|transplant|O
DDI-DrugBank.d565.s25|137-144|patients|O
DDI-DrugBank.d565.s25|145-145|.|O
DDI-DrugBank.d565.s26|0-1|In|O
DDI-DrugBank.d565.s26|3-7|renal|O
DDI-DrugBank.d565.s26|9-11|and|O
DDI-DrugBank.d565.s26|13-19|cardiac|O
DDI-DrugBank.d565.s26|21-30|transplant|O
DDI-DrugBank.d565.s26|32-41|recipients|O
DDI-DrugBank.d565.s26|42-42|,|O
DDI-DrugBank.d565.s26|44-44|a|O
DDI-DrugBank.d565.s26|46-54|reduction|O
DDI-DrugBank.d565.s26|56-57|of|O
DDI-DrugBank.d565.s26|59-70|cyclosporine|drug
DDI-DrugBank.d565.s26|72-75|dose|O
DDI-DrugBank.d565.s26|77-83|ranging|O
DDI-DrugBank.d565.s26|85-88|from|O
DDI-DrugBank.d565.s26|90-91|15|O
DDI-DrugBank.d565.s26|92-92|%|O
DDI-DrugBank.d565.s26|94-95|to|O
DDI-DrugBank.d565.s26|97-98|48|O
DDI-DrugBank.d565.s26|99-99|%|O
DDI-DrugBank.d565.s26|101-103|was|O
DDI-DrugBank.d565.s26|105-113|necessary|O
DDI-DrugBank.d565.s26|115-116|to|O
DDI-DrugBank.d565.s26|118-125|maintain|O
DDI-DrugBank.d565.s26|127-138|cyclosporine|drug
DDI-DrugBank.d565.s26|140-145|trough|O
DDI-DrugBank.d565.s26|147-160|concentrations|O
DDI-DrugBank.d565.s26|162-168|similar|O
DDI-DrugBank.d565.s26|170-171|to|O
DDI-DrugBank.d565.s26|173-177|those|O
DDI-DrugBank.d565.s26|179-182|seen|O
DDI-DrugBank.d565.s26|184-188|prior|O
DDI-DrugBank.d565.s26|190-191|to|O
DDI-DrugBank.d565.s26|193-195|the|O
DDI-DrugBank.d565.s26|197-204|addition|O
DDI-DrugBank.d565.s26|206-207|of|O
DDI-DrugBank.d565.s26|209-217|diltiazem|drug
DDI-DrugBank.d565.s26|218-218|.|O
DDI-DrugBank.d565.s27|0-1|If|O
DDI-DrugBank.d565.s27|3-7|these|O
DDI-DrugBank.d565.s27|9-14|agents|O
DDI-DrugBank.d565.s27|16-18|are|O
DDI-DrugBank.d565.s27|20-21|to|O
DDI-DrugBank.d565.s27|23-24|be|O
DDI-DrugBank.d565.s27|26-37|administered|O
DDI-DrugBank.d565.s27|39-50|concurrently|O
DDI-DrugBank.d565.s27|51-51|,|O
DDI-DrugBank.d565.s27|53-64|cyclosporine|drug
DDI-DrugBank.d565.s27|66-79|concentrations|O
DDI-DrugBank.d565.s27|81-86|should|O
DDI-DrugBank.d565.s27|88-89|be|O
DDI-DrugBank.d565.s27|91-99|monitored|O
DDI-DrugBank.d565.s27|100-100|,|O
DDI-DrugBank.d565.s27|102-111|especially|O
DDI-DrugBank.d565.s27|113-116|when|O
DDI-DrugBank.d565.s27|118-126|diltiazem|drug
DDI-DrugBank.d565.s27|128-134|therapy|O
DDI-DrugBank.d565.s27|136-137|is|O
DDI-DrugBank.d565.s27|139-147|initiated|O
DDI-DrugBank.d565.s27|148-148|,|O
DDI-DrugBank.d565.s27|150-157|adjusted|O
DDI-DrugBank.d565.s27|158-158|,|O
DDI-DrugBank.d565.s27|160-161|or|O
DDI-DrugBank.d565.s27|163-174|discontinued|O
DDI-DrugBank.d565.s27|175-175|.|O
DDI-DrugBank.d565.s28|0-2|The|O
DDI-DrugBank.d565.s28|4-9|effect|O
DDI-DrugBank.d565.s28|11-12|of|O
DDI-DrugBank.d565.s28|14-25|cyclosporine|drug
DDI-DrugBank.d565.s28|27-28|on|O
DDI-DrugBank.d565.s28|30-38|diltiazem|drug
DDI-DrugBank.d565.s28|40-45|plasma|O
DDI-DrugBank.d565.s28|47-60|concentrations|O
DDI-DrugBank.d565.s28|62-64|has|O
DDI-DrugBank.d565.s28|66-68|not|O
DDI-DrugBank.d565.s28|70-73|been|O
DDI-DrugBank.d565.s28|75-83|evaluated|O
DDI-DrugBank.d565.s28|84-84|.|O
DDI-DrugBank.d565.s30|0-10|Concomitant|O
DDI-DrugBank.d565.s30|12-25|administration|O
DDI-DrugBank.d565.s30|27-28|of|O
DDI-DrugBank.d565.s30|30-38|diltiazem|drug
DDI-DrugBank.d565.s30|40-43|with|O
DDI-DrugBank.d565.s30|45-57|carbamazepine|drug
DDI-DrugBank.d565.s30|59-61|has|O
DDI-DrugBank.d565.s30|63-66|been|O
DDI-DrugBank.d565.s30|68-75|reported|O
DDI-DrugBank.d565.s30|77-78|to|O
DDI-DrugBank.d565.s30|80-85|result|O
DDI-DrugBank.d565.s30|87-88|in|O
DDI-DrugBank.d565.s30|90-97|elevated|O
DDI-DrugBank.d565.s30|99-103|serum|O
DDI-DrugBank.d565.s30|105-110|levels|O
DDI-DrugBank.d565.s30|112-113|of|O
DDI-DrugBank.d565.s30|115-127|carbamazepine|drug
DDI-DrugBank.d565.s30|129-129|(|O
DDI-DrugBank.d565.s30|130-131|40|O
DDI-DrugBank.d565.s30|132-132|%|O
DDI-DrugBank.d565.s30|134-135|to|O
DDI-DrugBank.d565.s30|137-138|72|O
DDI-DrugBank.d565.s30|139-139|%|O
DDI-DrugBank.d565.s30|141-148|increase|O
DDI-DrugBank.d565.s30|149-149|)|O
DDI-DrugBank.d565.s30|150-150|,|O
DDI-DrugBank.d565.s30|152-160|resulting|O
DDI-DrugBank.d565.s30|162-163|in|O
DDI-DrugBank.d565.s30|165-172|toxicity|O
DDI-DrugBank.d565.s30|174-175|in|O
DDI-DrugBank.d565.s30|177-180|some|O
DDI-DrugBank.d565.s30|182-186|cases|O
DDI-DrugBank.d565.s30|187-187|.|O
DDI-DrugBank.d565.s31|0-7|Patients|O
DDI-DrugBank.d565.s31|9-17|receiving|O
DDI-DrugBank.d565.s31|19-23|these|O
DDI-DrugBank.d565.s31|25-29|drugs|O
DDI-DrugBank.d565.s31|31-42|concurrently|O
DDI-DrugBank.d565.s31|44-49|should|O
DDI-DrugBank.d565.s31|51-52|be|O
DDI-DrugBank.d565.s31|54-62|monitored|O
DDI-DrugBank.d565.s31|64-66|for|O
DDI-DrugBank.d565.s31|68-68|a|O
DDI-DrugBank.d565.s31|70-78|potential|O
DDI-DrugBank.d565.s31|80-83|drug|O
DDI-DrugBank.d565.s31|85-95|interaction|O
DDI-DrugBank.d565.s31|96-96|.|O
DDI-DrugBank.d565.s33|0-6|Studies|O
DDI-DrugBank.d565.s33|8-13|showed|O
DDI-DrugBank.d565.s33|15-18|that|O
DDI-DrugBank.d565.s33|20-28|diltiazem|drug
DDI-DrugBank.d565.s33|30-38|increased|O
DDI-DrugBank.d565.s33|40-42|the|O
DDI-DrugBank.d565.s33|44-46|AUC|O
DDI-DrugBank.d565.s33|48-49|of|O
DDI-DrugBank.d565.s33|51-59|midazolam|drug
DDI-DrugBank.d565.s33|61-63|and|O
DDI-DrugBank.d565.s33|65-73|triazolam|drug
DDI-DrugBank.d565.s33|75-76|by|O
DDI-DrugBank.d565.s33|78-80|3-4|O
DDI-DrugBank.d565.s33|82-85|fold|O
DDI-DrugBank.d565.s33|87-89|and|O
DDI-DrugBank.d565.s33|91-93|the|O
DDI-DrugBank.d565.s33|95-98|Cmax|O
DDI-DrugBank.d565.s33|100-101|by|O
DDI-DrugBank.d565.s33|103-108|2-fold|O
DDI-DrugBank.d565.s33|109-109|,|O
DDI-DrugBank.d565.s33|111-118|compared|O
DDI-DrugBank.d565.s33|120-121|to|O
DDI-DrugBank.d565.s33|123-129|placebo|O
DDI-DrugBank.d565.s33|130-130|.|O
DDI-DrugBank.d565.s34|0-2|The|O
DDI-DrugBank.d565.s34|4-14|elimination|O
DDI-DrugBank.d565.s34|16-19|half|O
DDI-DrugBank.d565.s34|21-24|life|O
DDI-DrugBank.d565.s34|26-27|of|O
DDI-DrugBank.d565.s34|29-37|midazolam|drug
DDI-DrugBank.d565.s34|39-41|and|O
DDI-DrugBank.d565.s34|43-51|triazolam|drug
DDI-DrugBank.d565.s34|53-56|also|O
DDI-DrugBank.d565.s34|58-66|increased|O
DDI-DrugBank.d565.s34|68-68|(|O
DDI-DrugBank.d565.s34|69-75|1.5-2.5|O
DDI-DrugBank.d565.s34|77-80|fold|O
DDI-DrugBank.d565.s34|81-81|)|O
DDI-DrugBank.d565.s34|83-88|during|O
DDI-DrugBank.d565.s34|90-105|coadministration|O
DDI-DrugBank.d565.s34|107-110|with|O
DDI-DrugBank.d565.s34|112-120|diltiazem|drug
DDI-DrugBank.d565.s34|121-121|.|O
DDI-DrugBank.d565.s35|0-4|These|O
DDI-DrugBank.d565.s35|6-20|pharmacokinetic|O
DDI-DrugBank.d565.s35|22-28|effects|O
DDI-DrugBank.d565.s35|30-33|seen|O
DDI-DrugBank.d565.s35|35-40|during|O
DDI-DrugBank.d565.s35|42-50|diltiazem|drug
DDI-DrugBank.d565.s35|52-67|coadministration|O
DDI-DrugBank.d565.s35|69-71|can|O
DDI-DrugBank.d565.s35|73-78|result|O
DDI-DrugBank.d565.s35|80-81|in|O
DDI-DrugBank.d565.s35|83-91|increased|O
DDI-DrugBank.d565.s35|93-100|clinical|O
DDI-DrugBank.d565.s35|102-108|effects|O
DDI-DrugBank.d565.s35|110-110|(|O
DDI-DrugBank.d565.s35|111-114|e.g.|O
DDI-DrugBank.d565.s35|115-115|,|O
DDI-DrugBank.d565.s35|117-125|prolonged|O
DDI-DrugBank.d565.s35|127-134|sodation|O
DDI-DrugBank.d565.s35|135-135|)|O
DDI-DrugBank.d565.s35|136-137|of|O
DDI-DrugBank.d565.s35|139-142|both|O
DDI-DrugBank.d565.s35|144-152|midazolam|drug
DDI-DrugBank.d565.s35|154-156|and|O
DDI-DrugBank.d565.s35|158-166|triazolam|drug
DDI-DrugBank.d565.s35|167-167|.|O
DDI-DrugBank.d565.s37|0-1|In|O
DDI-DrugBank.d565.s37|3-3|a|O
DDI-DrugBank.d565.s37|5-15|ten-subject|O
DDI-DrugBank.d565.s37|17-21|study|O
DDI-DrugBank.d565.s37|22-22|,|O
DDI-DrugBank.d565.s37|24-39|coadministration|O
DDI-DrugBank.d565.s37|41-42|of|O
DDI-DrugBank.d565.s37|44-52|diltiazem|drug
DDI-DrugBank.d565.s37|54-54|(|O
DDI-DrugBank.d565.s37|55-57|120|O
DDI-DrugBank.d565.s37|59-60|mg|O
DDI-DrugBank.d565.s37|62-64|bid|O
DDI-DrugBank.d565.s37|65-65|)|O
DDI-DrugBank.d565.s37|67-70|with|O
DDI-DrugBank.d565.s37|72-81|lovastatin|drug
DDI-DrugBank.d565.s37|83-90|resulted|O
DDI-DrugBank.d565.s37|92-93|in|O
DDI-DrugBank.d565.s37|95-95|a|O
DDI-DrugBank.d565.s37|97-99|3-4|O
DDI-DrugBank.d565.s37|101-105|times|O
DDI-DrugBank.d565.s37|107-114|increase|O
DDI-DrugBank.d565.s37|116-117|in|O
DDI-DrugBank.d565.s37|119-122|mean|O
DDI-DrugBank.d565.s37|124-133|lovastatin|drug
DDI-DrugBank.d565.s37|135-137|AUC|O
DDI-DrugBank.d565.s37|139-141|and|O
DDI-DrugBank.d565.s37|143-146|Cmax|O
DDI-DrugBank.d565.s37|148-150|vs.|O
DDI-DrugBank.d565.s37|152-161|lovastatin|drug
DDI-DrugBank.d565.s37|163-167|alone|O
DDI-DrugBank.d565.s37|168-168|;|O
DDI-DrugBank.d565.s38|0-1|no|O
DDI-DrugBank.d565.s38|3-8|change|O
DDI-DrugBank.d565.s38|10-11|in|O
DDI-DrugBank.d565.s38|13-23|pravastatin|drug
DDI-DrugBank.d565.s38|25-27|AUC|O
DDI-DrugBank.d565.s38|29-31|and|O
DDI-DrugBank.d565.s38|33-36|Cmax|O
DDI-DrugBank.d565.s38|38-40|was|O
DDI-DrugBank.d565.s38|42-49|observed|O
DDI-DrugBank.d565.s38|51-56|during|O
DDI-DrugBank.d565.s38|58-66|diltiazem|drug
DDI-DrugBank.d565.s38|68-83|coadministration|O
DDI-DrugBank.d565.s38|84-84|.|O
DDI-DrugBank.d565.s39|0-8|Diltiazem|drug
DDI-DrugBank.d565.s39|10-15|plasma|O
DDI-DrugBank.d565.s39|17-22|levels|O
DDI-DrugBank.d565.s39|24-27|were|O
DDI-DrugBank.d565.s39|29-31|not|O
DDI-DrugBank.d565.s39|33-45|significantly|O
DDI-DrugBank.d565.s39|47-54|affected|O
DDI-DrugBank.d565.s39|56-57|by|O
DDI-DrugBank.d565.s39|59-68|lovastatin|drug
DDI-DrugBank.d565.s39|70-71|or|O
DDI-DrugBank.d565.s39|73-83|pravastatin|drug
DDI-DrugBank.d565.s39|84-84|.|O
DDI-DrugBank.d565.s41|0-15|Coadministration|O
DDI-DrugBank.d565.s41|17-18|of|O
DDI-DrugBank.d565.s41|20-27|rifampin|drug
DDI-DrugBank.d565.s41|29-32|with|O
DDI-DrugBank.d565.s41|34-42|diltiazem|drug
DDI-DrugBank.d565.s41|44-50|lowered|O
DDI-DrugBank.d565.s41|52-54|the|O
DDI-DrugBank.d565.s41|56-64|diltiazem|drug
DDI-DrugBank.d565.s41|66-71|plasma|O
DDI-DrugBank.d565.s41|73-86|concentrations|O
DDI-DrugBank.d565.s41|88-89|to|O
DDI-DrugBank.d565.s41|91-102|undetectable|O
DDI-DrugBank.d565.s41|104-109|levels|O
DDI-DrugBank.d565.s41|110-110|.|O
DDI-DrugBank.d565.s42|0-15|Coadministration|O
DDI-DrugBank.d565.s42|17-18|of|O
DDI-DrugBank.d565.s42|20-28|diltiazem|drug
DDI-DrugBank.d565.s42|30-33|with|O
DDI-DrugBank.d565.s42|35-42|rifampin|drug
DDI-DrugBank.d565.s42|44-45|or|O
DDI-DrugBank.d565.s42|47-49|any|O
DDI-DrugBank.d565.s42|51-55|known|O
DDI-DrugBank.d565.s42|57-62|CYP3A4|O
DDI-DrugBank.d565.s42|64-70|inducer|O
DDI-DrugBank.d565.s42|72-77|should|O
DDI-DrugBank.d565.s42|79-80|be|O
DDI-DrugBank.d565.s42|82-88|avoided|O
DDI-DrugBank.d565.s42|90-93|when|O
DDI-DrugBank.d565.s42|95-102|possible|O
DDI-DrugBank.d565.s42|103-103|,|O
DDI-DrugBank.d565.s42|105-107|and|O
DDI-DrugBank.d565.s42|109-119|alternative|O
DDI-DrugBank.d565.s42|121-127|therapy|O
DDI-DrugBank.d565.s42|129-138|considered|O
DDI-DrugBank.d565.s42|139-139|.|O
DDI-DrugBank.d384.s0|0-11|Interactions|O
DDI-DrugBank.d384.s0|13-15|for|O
DDI-DrugBank.d384.s0|17-35|vitamin D analogues|group
DDI-DrugBank.d384.s0|37-37|(|O
DDI-DrugBank.d384.s0|38-47|Vitamin D2|drug
DDI-DrugBank.d384.s0|48-48|,|O
DDI-DrugBank.d384.s0|50-59|Vitamin D3|drug
DDI-DrugBank.d384.s0|60-60|,|O
DDI-DrugBank.d384.s0|62-71|Calcitriol|drug
DDI-DrugBank.d384.s0|72-72|,|O
DDI-DrugBank.d384.s0|74-76|and|O
DDI-DrugBank.d384.s0|78-86|Calcidiol|drug
DDI-DrugBank.d384.s0|87-87|)|O
DDI-DrugBank.d384.s0|88-88|:|O
DDI-DrugBank.d384.s0|90-103|Cholestyramine|drug
DDI-DrugBank.d384.s0|104-104|:|O
DDI-DrugBank.d384.s0|106-119|Cholestyramine|drug
DDI-DrugBank.d384.s0|121-123|has|O
DDI-DrugBank.d384.s0|125-128|been|O
DDI-DrugBank.d384.s0|130-137|reported|O
DDI-DrugBank.d384.s0|139-140|to|O
DDI-DrugBank.d384.s0|142-147|reduce|O
DDI-DrugBank.d384.s0|149-158|intestinal|O
DDI-DrugBank.d384.s0|160-169|absorption|O
DDI-DrugBank.d384.s0|171-172|of|O
DDI-DrugBank.d384.s0|174-193|fat soluble vitamins|group
DDI-DrugBank.d384.s0|194-194|;|O
DDI-DrugBank.d384.s1|0-1|as|O
DDI-DrugBank.d384.s1|3-6|such|O
DDI-DrugBank.d384.s1|8-9|it|O
DDI-DrugBank.d384.s1|11-13|may|O
DDI-DrugBank.d384.s1|15-20|impair|O
DDI-DrugBank.d384.s1|22-31|intestinal|O
DDI-DrugBank.d384.s1|33-42|absorption|O
DDI-DrugBank.d384.s1|44-45|of|O
DDI-DrugBank.d384.s1|47-49|any|O
DDI-DrugBank.d384.s1|51-52|of|O
DDI-DrugBank.d384.s1|54-62|vitamin D|group
DDI-DrugBank.d384.s1|63-63|.|O
DDI-DrugBank.d384.s2|0-22|Phenytoin/Phenobarbital|drug
DDI-DrugBank.d384.s2|23-23|:|O
DDI-DrugBank.d384.s2|25-27|The|O
DDI-DrugBank.d384.s2|29-44|coadministration|O
DDI-DrugBank.d384.s2|46-47|of|O
DDI-DrugBank.d384.s2|49-57|phenytoin|drug
DDI-DrugBank.d384.s2|59-60|or|O
DDI-DrugBank.d384.s2|62-74|phenobarbital|drug
DDI-DrugBank.d384.s2|76-79|will|O
DDI-DrugBank.d384.s2|81-83|not|O
DDI-DrugBank.d384.s2|85-90|affect|O
DDI-DrugBank.d384.s2|92-97|plasma|O
DDI-DrugBank.d384.s2|99-112|concentrations|O
DDI-DrugBank.d384.s2|114-115|of|O
DDI-DrugBank.d384.s2|117-125|vitamin D|group
DDI-DrugBank.d384.s2|126-126|,|O
DDI-DrugBank.d384.s2|128-130|but|O
DDI-DrugBank.d384.s2|132-134|may|O
DDI-DrugBank.d384.s2|136-141|reduce|O
DDI-DrugBank.d384.s2|143-152|endogenous|O
DDI-DrugBank.d384.s2|154-159|plasma|O
DDI-DrugBank.d384.s2|161-166|levels|O
DDI-DrugBank.d384.s2|168-169|of|O
DDI-DrugBank.d384.s2|171-195|calcitriol/ergocalcitriol|drug
DDI-DrugBank.d384.s2|197-198|by|O
DDI-DrugBank.d384.s2|200-211|accelerating|O
DDI-DrugBank.d384.s2|213-222|metabolism|O
DDI-DrugBank.d384.s2|223-223|.|O
DDI-DrugBank.d384.s3|0-4|Since|O
DDI-DrugBank.d384.s3|6-10|blood|O
DDI-DrugBank.d384.s3|12-16|level|O
DDI-DrugBank.d384.s3|18-19|of|O
DDI-DrugBank.d384.s3|21-45|calcitriol/ergocalcitriol|drug
DDI-DrugBank.d384.s3|47-50|will|O
DDI-DrugBank.d384.s3|52-53|be|O
DDI-DrugBank.d384.s3|55-61|reduced|O
DDI-DrugBank.d384.s3|62-62|,|O
DDI-DrugBank.d384.s3|64-69|higher|O
DDI-DrugBank.d384.s3|71-75|doses|O
DDI-DrugBank.d384.s3|77-78|of|O
DDI-DrugBank.d384.s3|80-88|Rocaltrol|brand
DDI-DrugBank.d384.s3|90-92|may|O
DDI-DrugBank.d384.s3|94-95|be|O
DDI-DrugBank.d384.s3|97-105|necessary|O
DDI-DrugBank.d384.s3|107-108|if|O
DDI-DrugBank.d384.s3|110-114|these|O
DDI-DrugBank.d384.s3|116-120|drugs|O
DDI-DrugBank.d384.s3|122-124|are|O
DDI-DrugBank.d384.s3|126-137|administered|O
DDI-DrugBank.d384.s3|139-152|simultaneously|O
DDI-DrugBank.d384.s3|153-153|.|O
DDI-DrugBank.d384.s4|0-8|Thiazides|group
DDI-DrugBank.d384.s4|9-9|:|O
DDI-DrugBank.d384.s4|11-19|Thiazides|group
DDI-DrugBank.d384.s4|21-23|are|O
DDI-DrugBank.d384.s4|25-29|known|O
DDI-DrugBank.d384.s4|31-32|to|O
DDI-DrugBank.d384.s4|34-39|induce|O
DDI-DrugBank.d384.s4|41-53|hypercalcemia|O
DDI-DrugBank.d384.s4|55-56|by|O
DDI-DrugBank.d384.s4|58-60|the|O
DDI-DrugBank.d384.s4|62-70|reduction|O
DDI-DrugBank.d384.s4|72-73|of|O
DDI-DrugBank.d384.s4|75-81|calcium|drug
DDI-DrugBank.d384.s4|83-91|excretion|O
DDI-DrugBank.d384.s4|93-94|in|O
DDI-DrugBank.d384.s4|96-100|urine|O
DDI-DrugBank.d384.s4|101-101|.|O
DDI-DrugBank.d384.s5|0-3|Some|O
DDI-DrugBank.d384.s5|5-11|reports|O
DDI-DrugBank.d384.s5|13-16|have|O
DDI-DrugBank.d384.s5|18-22|shown|O
DDI-DrugBank.d384.s5|24-27|that|O
DDI-DrugBank.d384.s5|29-31|the|O
DDI-DrugBank.d384.s5|33-43|concomitant|O
DDI-DrugBank.d384.s5|45-58|administration|O
DDI-DrugBank.d384.s5|60-61|of|O
DDI-DrugBank.d384.s5|63-71|thiazides|group
DDI-DrugBank.d384.s5|73-76|with|O
DDI-DrugBank.d384.s5|78-86|vitamin D|group
DDI-DrugBank.d384.s5|88-93|causes|O
DDI-DrugBank.d384.s5|95-107|hypercalcemia|O
DDI-DrugBank.d384.s5|108-108|.|O
DDI-DrugBank.d384.s6|0-8|Therefore|O
DDI-DrugBank.d384.s6|9-9|,|O
DDI-DrugBank.d384.s6|11-20|precaution|O
DDI-DrugBank.d384.s6|22-27|should|O
DDI-DrugBank.d384.s6|29-30|be|O
DDI-DrugBank.d384.s6|32-36|taken|O
DDI-DrugBank.d384.s6|38-41|when|O
DDI-DrugBank.d384.s6|43-58|coadministration|O
DDI-DrugBank.d384.s6|60-61|is|O
DDI-DrugBank.d384.s6|63-71|necessary|O
DDI-DrugBank.d384.s6|72-72|.|O
DDI-DrugBank.d384.s7|0-8|Digitalis|group
DDI-DrugBank.d384.s7|9-9|:|O
DDI-DrugBank.d384.s7|11-19|Vitamin D|group
DDI-DrugBank.d384.s7|21-26|dosage|O
DDI-DrugBank.d384.s7|28-31|must|O
DDI-DrugBank.d384.s7|33-34|be|O
DDI-DrugBank.d384.s7|36-45|determined|O
DDI-DrugBank.d384.s7|47-50|with|O
DDI-DrugBank.d384.s7|52-55|care|O
DDI-DrugBank.d384.s7|57-58|in|O
DDI-DrugBank.d384.s7|60-67|patients|O
DDI-DrugBank.d384.s7|69-78|undergoing|O
DDI-DrugBank.d384.s7|80-88|treatment|O
DDI-DrugBank.d384.s7|90-93|with|O
DDI-DrugBank.d384.s7|95-103|digitalis|group
DDI-DrugBank.d384.s7|104-104|,|O
DDI-DrugBank.d384.s7|106-107|as|O
DDI-DrugBank.d384.s7|109-121|hypercalcemia|O
DDI-DrugBank.d384.s7|123-124|in|O
DDI-DrugBank.d384.s7|126-129|such|O
DDI-DrugBank.d384.s7|131-138|patients|O
DDI-DrugBank.d384.s7|140-142|may|O
DDI-DrugBank.d384.s7|144-154|precipitate|O
DDI-DrugBank.d384.s7|156-162|cardiac|O
DDI-DrugBank.d384.s7|164-174|arrhythmias|O
DDI-DrugBank.d384.s7|175-175|.|O
DDI-DrugBank.d384.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d384.s8|12-12|:|O
DDI-DrugBank.d384.s8|14-25|Ketoconazole|drug
DDI-DrugBank.d384.s8|27-29|may|O
DDI-DrugBank.d384.s8|31-37|inhibit|O
DDI-DrugBank.d384.s8|39-42|both|O
DDI-DrugBank.d384.s8|44-52|synthetic|O
DDI-DrugBank.d384.s8|54-56|and|O
DDI-DrugBank.d384.s8|58-66|catabolic|O
DDI-DrugBank.d384.s8|68-74|enzymes|O
DDI-DrugBank.d384.s8|76-77|of|O
DDI-DrugBank.d384.s8|79-87|vitamin D|group
DDI-DrugBank.d384.s8|88-88|.|O
DDI-DrugBank.d384.s9|0-9|Reductions|O
DDI-DrugBank.d384.s9|11-12|in|O
DDI-DrugBank.d384.s9|14-18|serum|O
DDI-DrugBank.d384.s9|20-29|endogenous|O
DDI-DrugBank.d384.s9|31-37|vitamin|O
DDI-DrugBank.d384.s9|39-39|D|O
DDI-DrugBank.d384.s9|41-54|concentrations|O
DDI-DrugBank.d384.s9|56-59|have|O
DDI-DrugBank.d384.s9|61-64|been|O
DDI-DrugBank.d384.s9|66-73|observed|O
DDI-DrugBank.d384.s9|75-83|following|O
DDI-DrugBank.d384.s9|85-87|the|O
DDI-DrugBank.d384.s9|89-102|administration|O
DDI-DrugBank.d384.s9|104-105|of|O
DDI-DrugBank.d384.s9|107-109|300|O
DDI-DrugBank.d384.s9|111-116|mg/day|O
DDI-DrugBank.d384.s9|118-119|to|O
DDI-DrugBank.d384.s9|121-124|1200|O
DDI-DrugBank.d384.s9|126-131|mg/day|O
DDI-DrugBank.d384.s9|133-144|ketoconazole|drug
DDI-DrugBank.d384.s9|146-148|for|O
DDI-DrugBank.d384.s9|150-150|a|O
DDI-DrugBank.d384.s9|152-155|week|O
DDI-DrugBank.d384.s9|157-158|to|O
DDI-DrugBank.d384.s9|160-166|healthy|O
DDI-DrugBank.d384.s9|168-170|men|O
DDI-DrugBank.d384.s9|171-171|.|O
DDI-DrugBank.d384.s10|0-6|However|O
DDI-DrugBank.d384.s10|7-7|,|O
DDI-DrugBank.d384.s10|9-10|in|O
DDI-DrugBank.d384.s10|12-15|vivo|O
DDI-DrugBank.d384.s10|17-20|drug|O
DDI-DrugBank.d384.s10|22-32|interaction|O
DDI-DrugBank.d384.s10|34-40|studies|O
DDI-DrugBank.d384.s10|42-43|of|O
DDI-DrugBank.d384.s10|45-56|ketoconazole|drug
DDI-DrugBank.d384.s10|58-61|with|O
DDI-DrugBank.d384.s10|63-71|vitamin D|group
DDI-DrugBank.d384.s10|73-76|have|O
DDI-DrugBank.d384.s10|78-80|not|O
DDI-DrugBank.d384.s10|82-85|been|O
DDI-DrugBank.d384.s10|87-98|investigated|O
DDI-DrugBank.d384.s10|99-99|.|O
DDI-DrugBank.d384.s11|0-14|Corticosteroids|group
DDI-DrugBank.d384.s11|15-15|:|O
DDI-DrugBank.d384.s11|17-17|A|O
DDI-DrugBank.d384.s11|19-30|relationship|O
DDI-DrugBank.d384.s11|32-33|of|O
DDI-DrugBank.d384.s11|35-44|functional|O
DDI-DrugBank.d384.s11|46-55|antagonism|O
DDI-DrugBank.d384.s11|57-62|exists|O
DDI-DrugBank.d384.s11|64-70|between|O
DDI-DrugBank.d384.s11|72-90|vitamin D analogues|group
DDI-DrugBank.d384.s11|91-91|,|O
DDI-DrugBank.d384.s11|93-97|which|O
DDI-DrugBank.d384.s11|99-105|promote|O
DDI-DrugBank.d384.s11|107-113|calcium|O
DDI-DrugBank.d384.s11|115-124|absorption|O
DDI-DrugBank.d384.s11|125-125|,|O
DDI-DrugBank.d384.s11|127-129|and|O
DDI-DrugBank.d384.s11|131-145|corticosteroids|group
DDI-DrugBank.d384.s11|146-146|,|O
DDI-DrugBank.d384.s11|148-152|which|O
DDI-DrugBank.d384.s11|154-160|inhibit|O
DDI-DrugBank.d384.s11|162-168|calcium|O
DDI-DrugBank.d384.s11|170-179|absorption|O
DDI-DrugBank.d384.s11|180-180|.|O
DDI-DrugBank.d384.s12|0-16|Phosphate-Binding|O
DDI-DrugBank.d384.s12|18-23|Agents|O
DDI-DrugBank.d384.s12|24-24|:|O
DDI-DrugBank.d384.s12|26-30|Since|O
DDI-DrugBank.d384.s12|32-40|vitamin D|group
DDI-DrugBank.d384.s12|42-45|also|O
DDI-DrugBank.d384.s12|47-49|has|O
DDI-DrugBank.d384.s12|51-52|an|O
DDI-DrugBank.d384.s12|54-59|effect|O
DDI-DrugBank.d384.s12|61-62|on|O
DDI-DrugBank.d384.s12|64-72|phosphate|O
DDI-DrugBank.d384.s12|74-82|transport|O
DDI-DrugBank.d384.s12|84-85|in|O
DDI-DrugBank.d384.s12|87-89|the|O
DDI-DrugBank.d384.s12|91-99|intestine|O
DDI-DrugBank.d384.s12|100-100|,|O
DDI-DrugBank.d384.s12|102-108|kidneys|O
DDI-DrugBank.d384.s12|110-112|and|O
DDI-DrugBank.d384.s12|114-118|bones|O
DDI-DrugBank.d384.s12|119-119|,|O
DDI-DrugBank.d384.s12|121-123|the|O
DDI-DrugBank.d384.s12|125-130|dosage|O
DDI-DrugBank.d384.s12|132-133|of|O
DDI-DrugBank.d384.s12|135-151|phosphate-binding|O
DDI-DrugBank.d384.s12|153-158|agents|O
DDI-DrugBank.d384.s12|160-163|must|O
DDI-DrugBank.d384.s12|165-166|be|O
DDI-DrugBank.d384.s12|168-175|adjusted|O
DDI-DrugBank.d384.s12|177-178|in|O
DDI-DrugBank.d384.s12|180-189|accordance|O
DDI-DrugBank.d384.s12|191-194|with|O
DDI-DrugBank.d384.s12|196-198|the|O
DDI-DrugBank.d384.s12|200-204|serum|O
DDI-DrugBank.d384.s12|206-214|phosphate|O
DDI-DrugBank.d384.s12|216-228|concentration|O
DDI-DrugBank.d384.s12|229-229|.|O
DDI-DrugBank.d384.s13|0-8|Vitamin D|group
DDI-DrugBank.d384.s13|9-9|:|O
DDI-DrugBank.d384.s13|11-13|The|O
DDI-DrugBank.d384.s13|15-30|coadministration|O
DDI-DrugBank.d384.s13|32-33|of|O
DDI-DrugBank.d384.s13|35-37|any|O
DDI-DrugBank.d384.s13|39-40|of|O
DDI-DrugBank.d384.s13|42-44|the|O
DDI-DrugBank.d384.s13|46-64|vitamin D analogues|group
DDI-DrugBank.d384.s13|66-71|should|O
DDI-DrugBank.d384.s13|73-74|be|O
DDI-DrugBank.d384.s13|76-82|avoided|O
DDI-DrugBank.d384.s13|84-85|as|O
DDI-DrugBank.d384.s13|87-90|this|O
DDI-DrugBank.d384.s13|92-96|could|O
DDI-DrugBank.d384.s13|98-103|create|O
DDI-DrugBank.d384.s13|105-112|possible|O
DDI-DrugBank.d384.s13|114-121|additive|O
DDI-DrugBank.d384.s13|123-129|effects|O
DDI-DrugBank.d384.s13|131-133|and|O
DDI-DrugBank.d384.s13|135-147|hypercalcemia|O
DDI-DrugBank.d384.s13|148-148|.|O
DDI-DrugBank.d384.s14|0-6|Calcium|drug
DDI-DrugBank.d384.s14|8-18|Supplements|O
DDI-DrugBank.d384.s14|19-19|:|O
DDI-DrugBank.d384.s14|21-32|Uncontrolled|O
DDI-DrugBank.d384.s14|34-39|intake|O
DDI-DrugBank.d384.s14|41-42|of|O
DDI-DrugBank.d384.s14|44-53|additional|O
DDI-DrugBank.d384.s14|55-72|calcium-containing|drug
DDI-DrugBank.d384.s14|74-85|preparations|O
DDI-DrugBank.d384.s14|87-92|should|O
DDI-DrugBank.d384.s14|94-95|be|O
DDI-DrugBank.d384.s14|97-103|avoided|O
DDI-DrugBank.d384.s14|104-104|.|O
DDI-DrugBank.d384.s15|0-8|Magnesium|drug
DDI-DrugBank.d384.s15|9-9|:|O
DDI-DrugBank.d384.s15|11-30|Magnesium-containing|drug
DDI-DrugBank.d384.s15|32-43|preparations|O
DDI-DrugBank.d384.s15|45-45|(|O
DDI-DrugBank.d384.s15|46-47|eg|O
DDI-DrugBank.d384.s15|48-48|,|O
DDI-DrugBank.d384.s15|50-57|antacids|group
DDI-DrugBank.d384.s15|58-58|)|O
DDI-DrugBank.d384.s15|60-62|may|O
DDI-DrugBank.d384.s15|64-68|cause|O
DDI-DrugBank.d384.s15|70-84|hypermagnesemia|O
DDI-DrugBank.d384.s15|86-88|and|O
DDI-DrugBank.d384.s15|90-95|should|O
DDI-DrugBank.d384.s15|97-105|therefore|O
DDI-DrugBank.d384.s15|107-109|not|O
DDI-DrugBank.d384.s15|111-112|be|O
DDI-DrugBank.d384.s15|114-118|taken|O
DDI-DrugBank.d384.s15|120-125|during|O
DDI-DrugBank.d384.s15|127-133|therapy|O
DDI-DrugBank.d384.s15|135-138|with|O
DDI-DrugBank.d384.s15|140-148|vitamin D|group
DDI-DrugBank.d384.s15|150-151|by|O
DDI-DrugBank.d384.s15|153-160|patients|O
DDI-DrugBank.d384.s15|162-163|on|O
DDI-DrugBank.d384.s15|165-171|chronic|O
DDI-DrugBank.d384.s15|173-177|renal|O
DDI-DrugBank.d384.s15|179-186|dialysis|O
DDI-DrugBank.d384.s15|187-187|.|O
DDI-DrugBank.d24.s0|0-1|No|O
DDI-DrugBank.d24.s0|3-13|information|O
DDI-DrugBank.d24.s0|15-16|is|O
DDI-DrugBank.d24.s0|18-26|available|O
DDI-DrugBank.d24.s0|27-27|.|O
DDI-DrugBank.d494.s0|0-10|Concomitant|O
DDI-DrugBank.d494.s0|12-14|use|O
DDI-DrugBank.d494.s0|16-19|with|O
DDI-DrugBank.d494.s0|21-25|other|O
DDI-DrugBank.d494.s0|27-44|calcium-containing|drug
DDI-DrugBank.d494.s0|46-54|medicines|O
DDI-DrugBank.d494.s0|56-56|(|O
DDI-DrugBank.d494.s0|57-65|including|O
DDI-DrugBank.d494.s0|67-74|antacids|group
DDI-DrugBank.d494.s0|75-75|)|O
DDI-DrugBank.d494.s0|77-79|may|O
DDI-DrugBank.d494.s0|81-85|cause|O
DDI-DrugBank.d494.s0|87-89|too|O
DDI-DrugBank.d494.s0|91-94|much|O
DDI-DrugBank.d494.s0|96-102|calcium|drug
DDI-DrugBank.d494.s0|104-105|in|O
DDI-DrugBank.d494.s0|107-109|the|O
DDI-DrugBank.d494.s0|111-115|blood|O
DDI-DrugBank.d494.s0|117-118|or|O
DDI-DrugBank.d494.s0|120-124|urine|O
DDI-DrugBank.d494.s0|125-125|,|O
DDI-DrugBank.d494.s0|127-131|which|O
DDI-DrugBank.d494.s0|133-135|may|O
DDI-DrugBank.d494.s0|137-144|increase|O
DDI-DrugBank.d494.s0|146-148|the|O
DDI-DrugBank.d494.s0|150-155|chance|O
DDI-DrugBank.d494.s0|157-158|of|O
DDI-DrugBank.d494.s0|160-163|side|O
DDI-DrugBank.d494.s0|165-171|effects|O
DDI-DrugBank.d494.s0|172-172|.|O
DDI-DrugBank.d494.s1|0-4|Using|O
DDI-DrugBank.d494.s1|6-20|calcium acetate|drug
DDI-DrugBank.d494.s1|22-25|with|O
DDI-DrugBank.d494.s1|27-46|digitalis glycosides|group
DDI-DrugBank.d494.s1|48-48|(|O
DDI-DrugBank.d494.s1|49-53|heart|O
DDI-DrugBank.d494.s1|55-62|medicine|O
DDI-DrugBank.d494.s1|63-63|)|O
DDI-DrugBank.d494.s1|65-67|may|O
DDI-DrugBank.d494.s1|69-73|cause|O
DDI-DrugBank.d494.s1|75-87|hypercalcemia|O
DDI-DrugBank.d494.s1|89-89|(|O
DDI-DrugBank.d494.s1|90-92|too|O
DDI-DrugBank.d494.s1|94-97|much|O
DDI-DrugBank.d494.s1|99-105|calcium|drug
DDI-DrugBank.d494.s1|107-108|in|O
DDI-DrugBank.d494.s1|110-112|the|O
DDI-DrugBank.d494.s1|114-118|blood|O
DDI-DrugBank.d494.s1|119-119|)|O
DDI-DrugBank.d494.s1|120-120|,|O
DDI-DrugBank.d494.s1|122-126|which|O
DDI-DrugBank.d494.s1|128-132|could|O
DDI-DrugBank.d494.s1|134-141|increase|O
DDI-DrugBank.d494.s1|143-145|the|O
DDI-DrugBank.d494.s1|147-152|chance|O
DDI-DrugBank.d494.s1|154-155|of|O
DDI-DrugBank.d494.s1|157-166|developing|O
DDI-DrugBank.d494.s1|168-169|an|O
DDI-DrugBank.d494.s1|171-179|irregular|O
DDI-DrugBank.d494.s1|181-189|heartbeat|O
DDI-DrugBank.d494.s1|190-190|.|O
DDI-DrugBank.d288.s0|0-1|In|O
DDI-DrugBank.d288.s0|3-3|a|O
DDI-DrugBank.d288.s0|5-9|Phase|O
DDI-DrugBank.d288.s0|11-11|I|O
DDI-DrugBank.d288.s0|13-17|trial|O
DDI-DrugBank.d288.s0|19-23|using|O
DDI-DrugBank.d288.s0|25-34|escalating|O
DDI-DrugBank.d288.s0|36-40|doses|O
DDI-DrugBank.d288.s0|42-43|of|O
DDI-DrugBank.d288.s0|45-49|TAXOL|brand
DDI-DrugBank.d288.s0|51-51|(|O
DDI-DrugBank.d288.s0|52-58|110-200|O
DDI-DrugBank.d288.s0|60-64|mg/m2|O
DDI-DrugBank.d288.s0|65-65|)|O
DDI-DrugBank.d288.s0|67-69|and|O
DDI-DrugBank.d288.s0|71-79|cisplatin|drug
DDI-DrugBank.d288.s0|81-81|(|O
DDI-DrugBank.d288.s0|82-83|50|O
DDI-DrugBank.d288.s0|85-86|or|O
DDI-DrugBank.d288.s0|88-89|75|O
DDI-DrugBank.d288.s0|91-95|mg/m2|O
DDI-DrugBank.d288.s0|96-96|)|O
DDI-DrugBank.d288.s0|98-102|given|O
DDI-DrugBank.d288.s0|104-105|as|O
DDI-DrugBank.d288.s0|107-116|sequential|O
DDI-DrugBank.d288.s0|118-126|infusions|O
DDI-DrugBank.d288.s0|127-127|,|O
DDI-DrugBank.d288.s0|129-144|myelosuppression|O
DDI-DrugBank.d288.s0|146-148|was|O
DDI-DrugBank.d288.s0|150-153|more|O
DDI-DrugBank.d288.s0|155-162|profound|O
DDI-DrugBank.d288.s0|164-167|when|O
DDI-DrugBank.d288.s0|169-173|TAXOL|brand
DDI-DrugBank.d288.s0|175-177|was|O
DDI-DrugBank.d288.s0|179-183|given|O
DDI-DrugBank.d288.s0|185-189|after|O
DDI-DrugBank.d288.s0|191-199|cisplatin|drug
DDI-DrugBank.d288.s0|201-204|than|O
DDI-DrugBank.d288.s0|206-209|with|O
DDI-DrugBank.d288.s0|211-213|the|O
DDI-DrugBank.d288.s0|215-223|alternate|O
DDI-DrugBank.d288.s0|225-232|sequence|O
DDI-DrugBank.d288.s0|234-234|(|O
DDI-DrugBank.d288.s0|235-236|ie|O
DDI-DrugBank.d288.s0|237-237|,|O
DDI-DrugBank.d288.s0|239-243|TAXOL|brand
DDI-DrugBank.d288.s0|245-250|before|O
DDI-DrugBank.d288.s0|252-260|cisplatin|drug
DDI-DrugBank.d288.s0|261-261|)|O
DDI-DrugBank.d288.s0|262-262|.|O
DDI-DrugBank.d288.s1|0-14|Pharmacokinetic|O
DDI-DrugBank.d288.s1|16-19|data|O
DDI-DrugBank.d288.s1|21-24|from|O
DDI-DrugBank.d288.s1|26-30|these|O
DDI-DrugBank.d288.s1|32-39|patients|O
DDI-DrugBank.d288.s1|41-52|demonstrated|O
DDI-DrugBank.d288.s1|54-54|a|O
DDI-DrugBank.d288.s1|56-63|decrease|O
DDI-DrugBank.d288.s1|65-66|in|O
DDI-DrugBank.d288.s1|68-77|paclitaxel|drug
DDI-DrugBank.d288.s1|79-87|clearance|O
DDI-DrugBank.d288.s1|89-90|of|O
DDI-DrugBank.d288.s1|92-104|approximately|O
DDI-DrugBank.d288.s1|106-107|33|O
DDI-DrugBank.d288.s1|108-108|%|O
DDI-DrugBank.d288.s1|110-113|when|O
DDI-DrugBank.d288.s1|115-119|TAXOL|brand
DDI-DrugBank.d288.s1|121-123|was|O
DDI-DrugBank.d288.s1|125-136|administered|O
DDI-DrugBank.d288.s1|138-146|following|O
DDI-DrugBank.d288.s1|148-156|cisplatin|drug
DDI-DrugBank.d288.s1|157-157|.|O
DDI-DrugBank.d288.s2|0-2|The|O
DDI-DrugBank.d288.s2|4-13|metabolism|O
DDI-DrugBank.d288.s2|15-16|of|O
DDI-DrugBank.d288.s2|18-22|TAXOL|brand
DDI-DrugBank.d288.s2|24-25|is|O
DDI-DrugBank.d288.s2|27-35|catalyzed|O
DDI-DrugBank.d288.s2|37-38|by|O
DDI-DrugBank.d288.s2|40-49|cytochrome|O
DDI-DrugBank.d288.s2|51-54|P450|O
DDI-DrugBank.d288.s2|56-66|isoen-zymes|O
DDI-DrugBank.d288.s2|68-73|CYP2C8|O
DDI-DrugBank.d288.s2|75-77|and|O
DDI-DrugBank.d288.s2|79-84|CYP3A4|O
DDI-DrugBank.d288.s2|85-85|.|O
DDI-DrugBank.d288.s3|0-1|In|O
DDI-DrugBank.d288.s3|3-5|the|O
DDI-DrugBank.d288.s3|7-13|absence|O
DDI-DrugBank.d288.s3|15-16|of|O
DDI-DrugBank.d288.s3|18-23|formal|O
DDI-DrugBank.d288.s3|25-32|clinical|O
DDI-DrugBank.d288.s3|34-37|drug|O
DDI-DrugBank.d288.s3|39-49|interaction|O
DDI-DrugBank.d288.s3|51-57|studies|O
DDI-DrugBank.d288.s3|58-58|,|O
DDI-DrugBank.d288.s3|60-66|caution|O
DDI-DrugBank.d288.s3|68-73|should|O
DDI-DrugBank.d288.s3|75-76|be|O
DDI-DrugBank.d288.s3|78-86|exercised|O
DDI-DrugBank.d288.s3|88-91|when|O
DDI-DrugBank.d288.s3|93-105|administering|O
DDI-DrugBank.d288.s3|107-111|TAXOL|brand
DDI-DrugBank.d288.s3|113-125|concomitantly|O
DDI-DrugBank.d288.s3|127-130|with|O
DDI-DrugBank.d288.s3|132-136|known|O
DDI-DrugBank.d288.s3|138-147|substrates|O
DDI-DrugBank.d288.s3|149-150|or|O
DDI-DrugBank.d288.s3|152-161|inhibitors|O
DDI-DrugBank.d288.s3|163-164|of|O
DDI-DrugBank.d288.s3|166-168|the|O
DDI-DrugBank.d288.s3|170-179|cytochrome|O
DDI-DrugBank.d288.s3|181-184|P450|O
DDI-DrugBank.d288.s3|186-195|isoenzymes|O
DDI-DrugBank.d288.s3|197-202|CYP2C8|O
DDI-DrugBank.d288.s3|204-206|and|O
DDI-DrugBank.d288.s3|208-213|CYP3A4|O
DDI-DrugBank.d288.s3|214-214|.|O
DDI-DrugBank.d288.s4|0-8|Potential|O
DDI-DrugBank.d288.s4|10-21|interactions|O
DDI-DrugBank.d288.s4|23-29|between|O
DDI-DrugBank.d288.s4|31-35|TAXOL|brand
DDI-DrugBank.d288.s4|36-36|,|O
DDI-DrugBank.d288.s4|38-38|a|O
DDI-DrugBank.d288.s4|40-48|substrate|O
DDI-DrugBank.d288.s4|50-51|of|O
DDI-DrugBank.d288.s4|53-58|CYP3A4|O
DDI-DrugBank.d288.s4|59-59|,|O
DDI-DrugBank.d288.s4|61-63|and|O
DDI-DrugBank.d288.s4|65-83|protease inhibitors|group
DDI-DrugBank.d288.s4|85-85|(|O
DDI-DrugBank.d288.s4|86-94|ritonavir|drug
DDI-DrugBank.d288.s4|95-95|,|O
DDI-DrugBank.d288.s4|97-106|saquinavir|drug
DDI-DrugBank.d288.s4|107-107|,|O
DDI-DrugBank.d288.s4|109-117|indinavir|drug
DDI-DrugBank.d288.s4|118-118|,|O
DDI-DrugBank.d288.s4|120-122|and|O
DDI-DrugBank.d288.s4|124-133|nelfinavir|drug
DDI-DrugBank.d288.s4|134-134|)|O
DDI-DrugBank.d288.s4|135-135|,|O
DDI-DrugBank.d288.s4|137-141|which|O
DDI-DrugBank.d288.s4|143-145|are|O
DDI-DrugBank.d288.s4|147-156|substrates|O
DDI-DrugBank.d288.s4|158-163|and/or|O
DDI-DrugBank.d288.s4|165-174|inhibitors|O
DDI-DrugBank.d288.s4|176-177|of|O
DDI-DrugBank.d288.s4|179-184|CYP3A4|O
DDI-DrugBank.d288.s4|185-185|,|O
DDI-DrugBank.d288.s4|187-190|have|O
DDI-DrugBank.d288.s4|192-194|not|O
DDI-DrugBank.d288.s4|196-199|been|O
DDI-DrugBank.d288.s4|201-209|evaluated|O
DDI-DrugBank.d288.s4|211-212|in|O
DDI-DrugBank.d288.s4|214-221|clinical|O
DDI-DrugBank.d288.s4|223-228|trials|O
DDI-DrugBank.d288.s4|229-229|.|O
DDI-DrugBank.d288.s5|0-6|Reports|O
DDI-DrugBank.d288.s5|8-9|in|O
DDI-DrugBank.d288.s5|11-13|the|O
DDI-DrugBank.d288.s5|15-24|literature|O
DDI-DrugBank.d288.s5|26-32|suggest|O
DDI-DrugBank.d288.s5|34-37|that|O
DDI-DrugBank.d288.s5|39-44|plasma|O
DDI-DrugBank.d288.s5|46-51|levels|O
DDI-DrugBank.d288.s5|53-54|of|O
DDI-DrugBank.d288.s5|56-66|doxorubicin|drug
DDI-DrugBank.d288.s5|68-68|(|O
DDI-DrugBank.d288.s5|69-71|and|O
DDI-DrugBank.d288.s5|73-75|its|O
DDI-DrugBank.d288.s5|77-82|active|O
DDI-DrugBank.d288.s5|84-93|metabolite|O
DDI-DrugBank.d288.s5|108-108|)|O
DDI-DrugBank.d288.s5|110-112|may|O
DDI-DrugBank.d288.s5|114-115|be|O
DDI-DrugBank.d288.s5|117-125|increased|O
DDI-DrugBank.d288.s5|127-130|when|O
DDI-DrugBank.d288.s5|132-141|paclitaxel|drug
DDI-DrugBank.d288.s5|143-145|and|O
DDI-DrugBank.d288.s5|147-157|doxorubicin|drug
DDI-DrugBank.d288.s5|159-161|are|O
DDI-DrugBank.d288.s5|163-166|used|O
DDI-DrugBank.d288.s5|168-169|in|O
DDI-DrugBank.d288.s5|171-181|combination|O
DDI-DrugBank.d288.s5|182-182|.|O
DDI-DrugBank.d288.s6|0-9|Hematology|O
DDI-DrugBank.d288.s6|10-10|:|O
DDI-DrugBank.d288.s6|12-16|TAXOL|brand
DDI-DrugBank.d288.s6|18-24|therapy|O
DDI-DrugBank.d288.s6|26-31|should|O
DDI-DrugBank.d288.s6|33-35|not|O
DDI-DrugBank.d288.s6|37-38|be|O
DDI-DrugBank.d288.s6|40-51|administered|O
DDI-DrugBank.d288.s6|53-54|to|O
DDI-DrugBank.d288.s6|56-63|patients|O
DDI-DrugBank.d288.s6|65-68|with|O
DDI-DrugBank.d288.s6|70-77|baseline|O
DDI-DrugBank.d288.s6|79-88|neutrophil|O
DDI-DrugBank.d288.s6|90-95|counts|O
DDI-DrugBank.d288.s6|97-98|of|O
DDI-DrugBank.d288.s6|100-103|less|O
DDI-DrugBank.d288.s6|105-108|than|O
DDI-DrugBank.d288.s6|110-114|1,500|O
DDI-DrugBank.d288.s6|116-124|cells/mm3|O
DDI-DrugBank.d288.s6|125-125|.|O
DDI-DrugBank.d288.s7|0-1|In|O
DDI-DrugBank.d288.s7|3-7|order|O
DDI-DrugBank.d288.s7|9-10|to|O
DDI-DrugBank.d288.s7|12-18|monitor|O
DDI-DrugBank.d288.s7|20-22|the|O
DDI-DrugBank.d288.s7|24-33|occurrence|O
DDI-DrugBank.d288.s7|35-36|of|O
DDI-DrugBank.d288.s7|38-50|myelotoxicity|O
DDI-DrugBank.d288.s7|51-51|,|O
DDI-DrugBank.d288.s7|53-54|it|O
DDI-DrugBank.d288.s7|56-57|is|O
DDI-DrugBank.d288.s7|59-69|recommended|O
DDI-DrugBank.d288.s7|71-74|that|O
DDI-DrugBank.d288.s7|76-83|frequent|O
DDI-DrugBank.d288.s7|85-94|peripheral|O
DDI-DrugBank.d288.s7|96-100|blood|O
DDI-DrugBank.d288.s7|102-105|cell|O
DDI-DrugBank.d288.s7|107-112|counts|O
DDI-DrugBank.d288.s7|114-115|be|O
DDI-DrugBank.d288.s7|117-125|performed|O
DDI-DrugBank.d288.s7|127-128|on|O
DDI-DrugBank.d288.s7|130-132|all|O
DDI-DrugBank.d288.s7|134-141|patients|O
DDI-DrugBank.d288.s7|143-151|receiving|O
DDI-DrugBank.d288.s7|153-157|TAXOL|brand
DDI-DrugBank.d288.s7|158-158|.|O
DDI-DrugBank.d288.s8|0-7|Patients|O
DDI-DrugBank.d288.s8|9-14|should|O
DDI-DrugBank.d288.s8|16-18|not|O
DDI-DrugBank.d288.s8|20-21|be|O
DDI-DrugBank.d288.s8|23-32|re-treated|O
DDI-DrugBank.d288.s8|34-37|with|O
DDI-DrugBank.d288.s8|39-48|subsequent|O
DDI-DrugBank.d288.s8|50-55|cycles|O
DDI-DrugBank.d288.s8|57-58|of|O
DDI-DrugBank.d288.s8|60-64|TAXOL|brand
DDI-DrugBank.d288.s8|66-70|until|O
DDI-DrugBank.d288.s8|72-82|neutrophils|O
DDI-DrugBank.d288.s8|84-90|recover|O
DDI-DrugBank.d288.s8|92-93|to|O
DDI-DrugBank.d288.s8|95-95|a|O
DDI-DrugBank.d288.s8|97-101|level|O
DDI-DrugBank.d288.s8|104-107|1500|O
DDI-DrugBank.d288.s8|109-117|cells/mm3|O
DDI-DrugBank.d288.s8|119-121|and|O
DDI-DrugBank.d288.s8|123-131|platelets|O
DDI-DrugBank.d288.s8|133-139|recover|O
DDI-DrugBank.d288.s8|141-142|to|O
DDI-DrugBank.d288.s8|144-144|a|O
DDI-DrugBank.d288.s8|146-150|level|O
DDI-DrugBank.d288.s8|153-159|100,000|O
DDI-DrugBank.d288.s8|161-169|cells/mm3|O
DDI-DrugBank.d288.s8|170-170|.|O
DDI-DrugBank.d288.s9|0-1|In|O
DDI-DrugBank.d288.s9|3-5|the|O
DDI-DrugBank.d288.s9|7-10|case|O
DDI-DrugBank.d288.s9|12-13|of|O
DDI-DrugBank.d288.s9|15-20|severe|O
DDI-DrugBank.d288.s9|22-32|neutropenia|O
DDI-DrugBank.d288.s9|34-34|(|O
DDI-DrugBank.d288.s9|36-38|500|O
DDI-DrugBank.d288.s9|40-48|cells/mm3|O
DDI-DrugBank.d288.s9|50-52|for|O
DDI-DrugBank.d288.s9|54-58|seven|O
DDI-DrugBank.d288.s9|60-63|days|O
DDI-DrugBank.d288.s9|65-66|or|O
DDI-DrugBank.d288.s9|68-71|more|O
DDI-DrugBank.d288.s9|72-72|)|O
DDI-DrugBank.d288.s9|74-79|during|O
DDI-DrugBank.d288.s9|81-81|a|O
DDI-DrugBank.d288.s9|83-88|course|O
DDI-DrugBank.d288.s9|90-91|of|O
DDI-DrugBank.d288.s9|93-97|TAXOL|brand
DDI-DrugBank.d288.s9|99-105|therapy|O
DDI-DrugBank.d288.s9|106-106|,|O
DDI-DrugBank.d288.s9|108-108|a|O
DDI-DrugBank.d288.s9|110-111|20|O
DDI-DrugBank.d288.s9|112-112|%|O
DDI-DrugBank.d288.s9|114-122|reduction|O
DDI-DrugBank.d288.s9|124-125|in|O
DDI-DrugBank.d288.s9|127-130|dose|O
DDI-DrugBank.d288.s9|132-134|for|O
DDI-DrugBank.d288.s9|136-145|subsequent|O
DDI-DrugBank.d288.s9|147-153|courses|O
DDI-DrugBank.d288.s9|155-156|of|O
DDI-DrugBank.d288.s9|158-164|therapy|O
DDI-DrugBank.d288.s9|166-167|is|O
DDI-DrugBank.d288.s9|169-179|recommended|O
DDI-DrugBank.d288.s9|180-180|.|O
DDI-DrugBank.d288.s10|0-2|For|O
DDI-DrugBank.d288.s10|4-11|patients|O
DDI-DrugBank.d288.s10|13-16|with|O
DDI-DrugBank.d288.s10|18-25|advanced|O
DDI-DrugBank.d288.s10|27-29|HIV|O
DDI-DrugBank.d288.s10|31-37|disease|O
DDI-DrugBank.d288.s10|39-41|and|O
DDI-DrugBank.d288.s10|43-51|poor-risk|O
DDI-DrugBank.d288.s10|53-64|AIDS-related|O
DDI-DrugBank.d288.s10|66-71|Kaposi|O
DDI-DrugBank.d288.s10|73-73|s|O
DDI-DrugBank.d288.s10|75-81|sarcoma|O
DDI-DrugBank.d288.s10|82-82|,|O
DDI-DrugBank.d288.s10|84-88|TAXOL|brand
DDI-DrugBank.d288.s10|89-89|,|O
DDI-DrugBank.d288.s10|91-92|at|O
DDI-DrugBank.d288.s10|94-96|the|O
DDI-DrugBank.d288.s10|98-108|recommended|O
DDI-DrugBank.d288.s10|110-113|dose|O
DDI-DrugBank.d288.s10|115-117|for|O
DDI-DrugBank.d288.s10|119-122|this|O
DDI-DrugBank.d288.s10|124-130|disease|O
DDI-DrugBank.d288.s10|131-131|,|O
DDI-DrugBank.d288.s10|133-135|can|O
DDI-DrugBank.d288.s10|137-138|be|O
DDI-DrugBank.d288.s10|140-148|initiated|O
DDI-DrugBank.d288.s10|150-152|and|O
DDI-DrugBank.d288.s10|154-161|repeated|O
DDI-DrugBank.d288.s10|163-164|if|O
DDI-DrugBank.d288.s10|166-168|the|O
DDI-DrugBank.d288.s10|170-179|neutrophil|O
DDI-DrugBank.d288.s10|181-185|count|O
DDI-DrugBank.d288.s10|187-188|is|O
DDI-DrugBank.d288.s10|190-191|at|O
DDI-DrugBank.d288.s10|193-197|least|O
DDI-DrugBank.d288.s10|199-202|1000|O
DDI-DrugBank.d288.s10|204-212|cells/mm3|O
DDI-DrugBank.d288.s10|213-213|.|O
DDI-DrugBank.d288.s11|0-15|Hypersensitivity|O
DDI-DrugBank.d288.s11|17-25|Reactions|O
DDI-DrugBank.d288.s11|26-26|:|O
DDI-DrugBank.d288.s11|28-35|Patients|O
DDI-DrugBank.d288.s11|37-40|with|O
DDI-DrugBank.d288.s11|42-42|a|O
DDI-DrugBank.d288.s11|44-50|history|O
DDI-DrugBank.d288.s11|52-53|of|O
DDI-DrugBank.d288.s11|55-60|severe|O
DDI-DrugBank.d288.s11|62-77|hypersensitivity|O
DDI-DrugBank.d288.s11|79-87|reactions|O
DDI-DrugBank.d288.s11|89-90|to|O
DDI-DrugBank.d288.s11|92-99|products|O
DDI-DrugBank.d288.s11|101-110|containing|O
DDI-DrugBank.d288.s11|112-120|Cremophor|O
DDI-DrugBank.d288.s11|123-124|EL|O
DDI-DrugBank.d288.s11|126-126|(|O
DDI-DrugBank.d288.s11|127-128|eg|O
DDI-DrugBank.d288.s11|129-129|,|O
DDI-DrugBank.d288.s11|131-141|cyclosporin|drug
DDI-DrugBank.d288.s11|143-145|for|O
DDI-DrugBank.d288.s11|147-155|injection|O
DDI-DrugBank.d288.s11|157-167|concentrate|O
DDI-DrugBank.d288.s11|169-171|and|O
DDI-DrugBank.d288.s11|173-182|teniposide|drug
DDI-DrugBank.d288.s11|184-186|for|O
DDI-DrugBank.d288.s11|188-196|injection|O
DDI-DrugBank.d288.s11|198-208|concentrate|O
DDI-DrugBank.d288.s11|209-209|)|O
DDI-DrugBank.d288.s11|211-216|should|O
DDI-DrugBank.d288.s11|218-220|not|O
DDI-DrugBank.d288.s11|222-223|be|O
DDI-DrugBank.d288.s11|225-231|treated|O
DDI-DrugBank.d288.s11|233-236|with|O
DDI-DrugBank.d288.s11|238-242|TAXOL|brand
DDI-DrugBank.d288.s11|243-243|.|O
DDI-DrugBank.d288.s12|0-1|In|O
DDI-DrugBank.d288.s12|3-7|order|O
DDI-DrugBank.d288.s12|9-10|to|O
DDI-DrugBank.d288.s12|12-16|avoid|O
DDI-DrugBank.d288.s12|18-20|the|O
DDI-DrugBank.d288.s12|22-31|occurrence|O
DDI-DrugBank.d288.s12|33-34|of|O
DDI-DrugBank.d288.s12|36-41|severe|O
DDI-DrugBank.d288.s12|43-58|hypersensitivity|O
DDI-DrugBank.d288.s12|60-68|reactions|O
DDI-DrugBank.d288.s12|69-69|,|O
DDI-DrugBank.d288.s12|71-73|all|O
DDI-DrugBank.d288.s12|75-82|patients|O
DDI-DrugBank.d288.s12|84-90|treated|O
DDI-DrugBank.d288.s12|92-95|with|O
DDI-DrugBank.d288.s12|97-101|TAXOL|brand
DDI-DrugBank.d288.s12|103-108|should|O
DDI-DrugBank.d288.s12|110-111|be|O
DDI-DrugBank.d288.s12|113-124|premedicated|O
DDI-DrugBank.d288.s12|126-129|with|O
DDI-DrugBank.d288.s12|131-145|corticosteroids|group
DDI-DrugBank.d288.s12|147-147|(|O
DDI-DrugBank.d288.s12|148-151|such|O
DDI-DrugBank.d288.s12|153-154|as|O
DDI-DrugBank.d288.s12|156-168|dexamethasone|drug
DDI-DrugBank.d288.s12|169-169|)|O
DDI-DrugBank.d288.s12|170-170|,|O
DDI-DrugBank.d288.s12|172-187|diphen-hydramine|O
DDI-DrugBank.d288.s12|189-191|and|O
DDI-DrugBank.d288.s12|193-206|H2 antagonists|group
DDI-DrugBank.d288.s12|208-208|(|O
DDI-DrugBank.d288.s12|209-212|such|O
DDI-DrugBank.d288.s12|214-215|as|O
DDI-DrugBank.d288.s12|217-226|cimetidine|drug
DDI-DrugBank.d288.s12|228-229|or|O
DDI-DrugBank.d288.s12|231-240|ranitidine|drug
DDI-DrugBank.d288.s12|241-241|)|O
DDI-DrugBank.d288.s12|242-242|.|O
DDI-DrugBank.d288.s13|0-4|Minor|O
DDI-DrugBank.d288.s13|6-13|symptoms|O
DDI-DrugBank.d288.s13|15-18|such|O
DDI-DrugBank.d288.s13|20-21|as|O
DDI-DrugBank.d288.s13|23-30|flushing|O
DDI-DrugBank.d288.s13|31-31|,|O
DDI-DrugBank.d288.s13|33-36|skin|O
DDI-DrugBank.d288.s13|38-46|reactions|O
DDI-DrugBank.d288.s13|47-47|,|O
DDI-DrugBank.d288.s13|49-55|dyspnea|O
DDI-DrugBank.d288.s13|56-56|,|O
DDI-DrugBank.d288.s13|58-68|hypotension|O
DDI-DrugBank.d288.s13|69-69|,|O
DDI-DrugBank.d288.s13|71-72|or|O
DDI-DrugBank.d288.s13|74-84|tachycardia|O
DDI-DrugBank.d288.s13|86-87|do|O
DDI-DrugBank.d288.s13|89-91|not|O
DDI-DrugBank.d288.s13|93-99|require|O
DDI-DrugBank.d288.s13|101-112|interruption|O
DDI-DrugBank.d288.s13|114-115|of|O
DDI-DrugBank.d288.s13|117-123|therapy|O
DDI-DrugBank.d288.s13|124-124|.|O
DDI-DrugBank.d288.s14|0-6|However|O
DDI-DrugBank.d288.s14|7-7|,|O
DDI-DrugBank.d288.s14|9-14|severe|O
DDI-DrugBank.d288.s14|16-24|reactions|O
DDI-DrugBank.d288.s14|25-25|,|O
DDI-DrugBank.d288.s14|27-30|such|O
DDI-DrugBank.d288.s14|32-33|as|O
DDI-DrugBank.d288.s14|35-45|hypotension|O
DDI-DrugBank.d288.s14|47-55|requiring|O
DDI-DrugBank.d288.s14|57-65|treatment|O
DDI-DrugBank.d288.s14|66-66|,|O
DDI-DrugBank.d288.s14|68-74|dyspnea|O
DDI-DrugBank.d288.s14|76-84|requiring|O
DDI-DrugBank.d288.s14|86-100|bronchodilators|group
DDI-DrugBank.d288.s14|101-101|,|O
DDI-DrugBank.d288.s14|103-112|angioedema|O
DDI-DrugBank.d288.s14|113-113|,|O
DDI-DrugBank.d288.s14|115-116|or|O
DDI-DrugBank.d288.s14|118-128|generalized|O
DDI-DrugBank.d288.s14|130-138|urticaria|O
DDI-DrugBank.d288.s14|140-146|require|O
DDI-DrugBank.d288.s14|148-156|immediate|O
DDI-DrugBank.d288.s14|158-172|discontinuation|O
DDI-DrugBank.d288.s14|174-175|of|O
DDI-DrugBank.d288.s14|177-181|TAXOL|brand
DDI-DrugBank.d288.s14|183-185|and|O
DDI-DrugBank.d288.s14|187-196|aggressive|O
DDI-DrugBank.d288.s14|198-208|symptomatic|O
DDI-DrugBank.d288.s14|210-216|therapy|O
DDI-DrugBank.d288.s14|217-217|.|O
DDI-DrugBank.d288.s15|0-7|Patients|O
DDI-DrugBank.d288.s15|9-11|who|O
DDI-DrugBank.d288.s15|13-16|have|O
DDI-DrugBank.d288.s15|18-26|developed|O
DDI-DrugBank.d288.s15|28-33|severe|O
DDI-DrugBank.d288.s15|35-50|hypersensitivity|O
DDI-DrugBank.d288.s15|52-60|reactions|O
DDI-DrugBank.d288.s15|62-67|should|O
DDI-DrugBank.d288.s15|69-71|not|O
DDI-DrugBank.d288.s15|73-74|be|O
DDI-DrugBank.d288.s15|76-87|rechallenged|O
DDI-DrugBank.d288.s15|89-92|with|O
DDI-DrugBank.d288.s15|94-98|TAXOL|brand
DDI-DrugBank.d288.s15|99-99|.|O
DDI-DrugBank.d288.s16|0-13|Cardiovascular|O
DDI-DrugBank.d288.s16|14-14|:|O
DDI-DrugBank.d288.s16|16-26|Hypotension|O
DDI-DrugBank.d288.s16|27-27|,|O
DDI-DrugBank.d288.s16|29-39|bradycardia|O
DDI-DrugBank.d288.s16|40-40|,|O
DDI-DrugBank.d288.s16|42-44|and|O
DDI-DrugBank.d288.s16|46-57|hypertension|O
DDI-DrugBank.d288.s16|59-62|have|O
DDI-DrugBank.d288.s16|64-67|been|O
DDI-DrugBank.d288.s16|69-76|observed|O
DDI-DrugBank.d288.s16|78-83|during|O
DDI-DrugBank.d288.s16|85-98|administration|O
DDI-DrugBank.d288.s16|100-101|of|O
DDI-DrugBank.d288.s16|103-107|TAXOL|brand
DDI-DrugBank.d288.s16|108-108|,|O
DDI-DrugBank.d288.s16|110-112|but|O
DDI-DrugBank.d288.s16|114-122|generally|O
DDI-DrugBank.d288.s16|124-125|do|O
DDI-DrugBank.d288.s16|127-129|not|O
DDI-DrugBank.d288.s16|131-137|require|O
DDI-DrugBank.d288.s16|139-147|treatment|O
DDI-DrugBank.d288.s16|148-148|.|O
DDI-DrugBank.d288.s17|0-11|Occasionally|O
DDI-DrugBank.d288.s17|13-17|TAXOL|brand
DDI-DrugBank.d288.s17|19-27|infusions|O
DDI-DrugBank.d288.s17|29-32|must|O
DDI-DrugBank.d288.s17|34-35|be|O
DDI-DrugBank.d288.s17|37-47|interrupted|O
DDI-DrugBank.d288.s17|49-50|or|O
DDI-DrugBank.d288.s17|52-63|discontinued|O
DDI-DrugBank.d288.s17|65-71|because|O
DDI-DrugBank.d288.s17|73-74|of|O
DDI-DrugBank.d288.s17|76-82|initial|O
DDI-DrugBank.d288.s17|84-85|or|O
DDI-DrugBank.d288.s17|87-95|recurrent|O
DDI-DrugBank.d288.s17|97-108|hypertension|O
DDI-DrugBank.d288.s17|109-109|.|O
DDI-DrugBank.d288.s18|0-7|Frequent|O
DDI-DrugBank.d288.s18|9-13|vital|O
DDI-DrugBank.d288.s18|15-18|sign|O
DDI-DrugBank.d288.s18|20-29|monitoring|O
DDI-DrugBank.d288.s18|30-30|,|O
DDI-DrugBank.d288.s18|32-43|particularly|O
DDI-DrugBank.d288.s18|45-50|during|O
DDI-DrugBank.d288.s18|52-54|the|O
DDI-DrugBank.d288.s18|56-60|first|O
DDI-DrugBank.d288.s18|62-65|hour|O
DDI-DrugBank.d288.s18|67-68|of|O
DDI-DrugBank.d288.s18|70-74|TAXOL|brand
DDI-DrugBank.d288.s18|76-83|infusion|O
DDI-DrugBank.d288.s18|84-84|,|O
DDI-DrugBank.d288.s18|86-87|is|O
DDI-DrugBank.d288.s18|89-99|recommended|O
DDI-DrugBank.d288.s18|100-100|.|O
DDI-DrugBank.d288.s19|0-9|Continuous|O
DDI-DrugBank.d288.s19|11-17|cardiac|O
DDI-DrugBank.d288.s19|19-28|monitoring|O
DDI-DrugBank.d288.s19|30-31|is|O
DDI-DrugBank.d288.s19|33-35|not|O
DDI-DrugBank.d288.s19|37-44|required|O
DDI-DrugBank.d288.s19|46-51|except|O
DDI-DrugBank.d288.s19|53-55|for|O
DDI-DrugBank.d288.s19|57-64|patients|O
DDI-DrugBank.d288.s19|66-69|with|O
DDI-DrugBank.d288.s19|71-77|serious|O
DDI-DrugBank.d288.s19|79-88|conduction|O
DDI-DrugBank.d288.s19|90-102|abnormalities|O
DDI-DrugBank.d288.s19|103-103|.|O
DDI-DrugBank.d288.s20|0-6|Nervous|O
DDI-DrugBank.d288.s20|8-13|System|O
DDI-DrugBank.d288.s20|14-14|:|O
DDI-DrugBank.d288.s20|16-23|Although|O
DDI-DrugBank.d288.s20|25-27|the|O
DDI-DrugBank.d288.s20|29-38|occurrence|O
DDI-DrugBank.d288.s20|40-41|of|O
DDI-DrugBank.d288.s20|43-52|peripheral|O
DDI-DrugBank.d288.s20|54-63|neuropathy|O
DDI-DrugBank.d288.s20|65-66|is|O
DDI-DrugBank.d288.s20|68-75|frequent|O
DDI-DrugBank.d288.s20|76-76|,|O
DDI-DrugBank.d288.s20|78-80|the|O
DDI-DrugBank.d288.s20|82-92|development|O
DDI-DrugBank.d288.s20|94-95|of|O
DDI-DrugBank.d288.s20|97-102|severe|O
DDI-DrugBank.d288.s20|104-117|symptomatology|O
DDI-DrugBank.d288.s20|119-120|is|O
DDI-DrugBank.d288.s20|122-128|unusual|O
DDI-DrugBank.d288.s20|130-132|and|O
DDI-DrugBank.d288.s20|134-141|requires|O
DDI-DrugBank.d288.s20|143-143|a|O
DDI-DrugBank.d288.s20|145-148|dose|O
DDI-DrugBank.d288.s20|150-158|reduction|O
DDI-DrugBank.d288.s20|160-161|of|O
DDI-DrugBank.d288.s20|163-164|20|O
DDI-DrugBank.d288.s20|165-165|%|O
DDI-DrugBank.d288.s20|167-169|for|O
DDI-DrugBank.d288.s20|171-173|all|O
DDI-DrugBank.d288.s20|175-191|subsequentcourses|O
DDI-DrugBank.d288.s20|193-194|of|O
DDI-DrugBank.d288.s20|196-200|TAXOL|brand
DDI-DrugBank.d288.s20|201-201|.|O
DDI-DrugBank.d288.s21|0-4|TAXOL|brand
DDI-DrugBank.d288.s21|6-13|contains|O
DDI-DrugBank.d288.s21|15-24|dehydrated|O
DDI-DrugBank.d288.s21|26-32|alcohol|O
DDI-DrugBank.d288.s21|34-36|USP|O
DDI-DrugBank.d288.s21|37-37|,|O
DDI-DrugBank.d288.s21|39-41|396|O
DDI-DrugBank.d288.s21|43-47|mg/mL|O
DDI-DrugBank.d288.s21|48-48|;|O
DDI-DrugBank.d288.s22|0-12|consideration|O
DDI-DrugBank.d288.s22|14-19|should|O
DDI-DrugBank.d288.s22|21-22|be|O
DDI-DrugBank.d288.s22|24-28|given|O
DDI-DrugBank.d288.s22|30-31|to|O
DDI-DrugBank.d288.s22|33-40|possible|O
DDI-DrugBank.d288.s22|42-44|CNS|O
DDI-DrugBank.d288.s22|46-48|and|O
DDI-DrugBank.d288.s22|50-54|other|O
DDI-DrugBank.d288.s22|56-62|effects|O
DDI-DrugBank.d288.s22|64-65|of|O
DDI-DrugBank.d288.s22|67-73|alcohol|drug
DDI-DrugBank.d288.s22|74-74|.|O
DDI-DrugBank.d288.s23|0-6|Hepatic|O
DDI-DrugBank.d288.s23|7-7|:|O
DDI-DrugBank.d288.s23|9-13|There|O
DDI-DrugBank.d288.s23|15-16|is|O
DDI-DrugBank.d288.s23|18-24|limited|O
DDI-DrugBank.d288.s23|26-33|evidence|O
DDI-DrugBank.d288.s23|35-38|that|O
DDI-DrugBank.d288.s23|40-42|the|O
DDI-DrugBank.d288.s23|44-56|myelotoxicity|O
DDI-DrugBank.d288.s23|58-59|of|O
DDI-DrugBank.d288.s23|61-65|TAXOL|brand
DDI-DrugBank.d288.s23|67-69|may|O
DDI-DrugBank.d288.s23|71-72|be|O
DDI-DrugBank.d288.s23|74-84|exacerbated|O
DDI-DrugBank.d288.s23|86-87|in|O
DDI-DrugBank.d288.s23|89-96|patients|O
DDI-DrugBank.d288.s23|98-101|with|O
DDI-DrugBank.d288.s23|103-107|serum|O
DDI-DrugBank.d288.s23|109-113|total|O
DDI-DrugBank.d288.s23|115-123|bilirubin|O
DDI-DrugBank.d288.s23|126-126|2|O
DDI-DrugBank.d288.s23|128-132|times|O
DDI-DrugBank.d288.s23|134-136|ULN|O
DDI-DrugBank.d288.s23|137-137|.|O
DDI-DrugBank.d288.s24|0-6|Extreme|O
DDI-DrugBank.d288.s24|8-14|caution|O
DDI-DrugBank.d288.s24|16-21|should|O
DDI-DrugBank.d288.s24|23-24|be|O
DDI-DrugBank.d288.s24|26-34|exercised|O
DDI-DrugBank.d288.s24|36-39|when|O
DDI-DrugBank.d288.s24|41-53|administering|O
DDI-DrugBank.d288.s24|55-59|TAXOL|brand
DDI-DrugBank.d288.s24|61-62|to|O
DDI-DrugBank.d288.s24|64-67|such|O
DDI-DrugBank.d288.s24|69-76|patients|O
DDI-DrugBank.d288.s24|77-77|,|O
DDI-DrugBank.d288.s24|79-82|with|O
DDI-DrugBank.d288.s24|84-87|dose|O
DDI-DrugBank.d288.s24|89-97|reduction|O
DDI-DrugBank.d288.s24|99-100|as|O
DDI-DrugBank.d288.s24|102-112|recommended|O
DDI-DrugBank.d288.s24|114-115|in|O
DDI-DrugBank.d288.s24|117-122|DOSAGE|O
DDI-DrugBank.d288.s24|124-126|AND|O
DDI-DrugBank.d288.s24|128-141|ADMINISTRATION|O
DDI-DrugBank.d288.s24|142-142|,|O
DDI-DrugBank.d288.s24|144-148|Table|O
DDI-DrugBank.d288.s24|150-151|17|O
DDI-DrugBank.d288.s24|152-152|.|O
DDI-DrugBank.d288.s25|0-12|InjectionSite|O
DDI-DrugBank.d288.s25|14-21|Reaction|O
DDI-DrugBank.d288.s25|22-22|:|O
DDI-DrugBank.d288.s25|24-32|Injection|O
DDI-DrugBank.d288.s25|34-37|site|O
DDI-DrugBank.d288.s25|39-47|reactions|O
DDI-DrugBank.d288.s25|48-48|,|O
DDI-DrugBank.d288.s25|50-58|including|O
DDI-DrugBank.d288.s25|60-68|reactions|O
DDI-DrugBank.d288.s25|70-78|secondary|O
DDI-DrugBank.d288.s25|80-81|to|O
DDI-DrugBank.d288.s25|83-95|extravasation|O
DDI-DrugBank.d288.s25|96-96|,|O
DDI-DrugBank.d288.s25|98-101|were|O
DDI-DrugBank.d288.s25|103-109|usually|O
DDI-DrugBank.d288.s25|111-114|mild|O
DDI-DrugBank.d288.s25|116-118|and|O
DDI-DrugBank.d288.s25|120-128|consisted|O
DDI-DrugBank.d288.s25|130-131|of|O
DDI-DrugBank.d288.s25|133-140|erythema|O
DDI-DrugBank.d288.s25|141-141|,|O
DDI-DrugBank.d288.s25|143-152|tenderness|O
DDI-DrugBank.d288.s25|153-153|,|O
DDI-DrugBank.d288.s25|155-158|skin|O
DDI-DrugBank.d288.s25|160-172|discoloration|O
DDI-DrugBank.d288.s25|173-173|,|O
DDI-DrugBank.d288.s25|175-176|or|O
DDI-DrugBank.d288.s25|178-185|swelling|O
DDI-DrugBank.d288.s25|187-188|at|O
DDI-DrugBank.d288.s25|190-192|the|O
DDI-DrugBank.d288.s25|194-202|injection|O
DDI-DrugBank.d288.s25|204-207|site|O
DDI-DrugBank.d288.s25|208-208|.|O
DDI-DrugBank.d288.s26|0-4|These|O
DDI-DrugBank.d288.s26|6-14|reactions|O
DDI-DrugBank.d288.s26|16-19|have|O
DDI-DrugBank.d288.s26|21-24|been|O
DDI-DrugBank.d288.s26|26-33|observed|O
DDI-DrugBank.d288.s26|35-38|more|O
DDI-DrugBank.d288.s26|40-49|frequently|O
DDI-DrugBank.d288.s26|51-54|with|O
DDI-DrugBank.d288.s26|56-58|the|O
DDI-DrugBank.d288.s26|60-66|24-hour|O
DDI-DrugBank.d288.s26|68-75|infusion|O
DDI-DrugBank.d288.s26|77-80|than|O
DDI-DrugBank.d288.s26|82-85|with|O
DDI-DrugBank.d288.s26|87-89|the|O
DDI-DrugBank.d288.s26|91-96|3-hour|O
DDI-DrugBank.d288.s26|98-105|infusion|O
DDI-DrugBank.d288.s26|106-106|.|O
DDI-DrugBank.d288.s27|0-9|Recurrence|O
DDI-DrugBank.d288.s27|11-12|of|O
DDI-DrugBank.d288.s27|14-17|skin|O
DDI-DrugBank.d288.s27|19-27|reactions|O
DDI-DrugBank.d288.s27|29-30|at|O
DDI-DrugBank.d288.s27|32-32|a|O
DDI-DrugBank.d288.s27|34-37|site|O
DDI-DrugBank.d288.s27|39-40|of|O
DDI-DrugBank.d288.s27|42-49|previous|O
DDI-DrugBank.d288.s27|51-63|extravasation|O
DDI-DrugBank.d288.s27|65-73|following|O
DDI-DrugBank.d288.s27|75-88|administration|O
DDI-DrugBank.d288.s27|90-91|of|O
DDI-DrugBank.d288.s27|93-97|TAXOL|brand
DDI-DrugBank.d288.s27|99-100|at|O
DDI-DrugBank.d288.s27|102-102|a|O
DDI-DrugBank.d288.s27|104-112|different|O
DDI-DrugBank.d288.s27|114-117|site|O
DDI-DrugBank.d288.s27|118-118|,|O
DDI-DrugBank.d288.s27|120-121|ie|O
DDI-DrugBank.d288.s27|122-122|,|O
DDI-DrugBank.d288.s27|124-129|recall|O
DDI-DrugBank.d288.s27|130-130|,|O
DDI-DrugBank.d288.s27|132-134|has|O
DDI-DrugBank.d288.s27|136-139|been|O
DDI-DrugBank.d288.s27|141-148|reported|O
DDI-DrugBank.d288.s27|150-155|rarely|O
DDI-DrugBank.d288.s27|156-156|.|O
DDI-DrugBank.d288.s28|0-3|Rare|O
DDI-DrugBank.d288.s28|5-11|reports|O
DDI-DrugBank.d288.s28|13-14|of|O
DDI-DrugBank.d288.s28|16-19|more|O
DDI-DrugBank.d288.s28|21-26|severe|O
DDI-DrugBank.d288.s28|28-33|events|O
DDI-DrugBank.d288.s28|35-38|such|O
DDI-DrugBank.d288.s28|40-41|as|O
DDI-DrugBank.d288.s28|43-51|phlebitis|O
DDI-DrugBank.d288.s28|52-52|,|O
DDI-DrugBank.d288.s28|54-63|cellulitis|O
DDI-DrugBank.d288.s28|64-64|,|O
DDI-DrugBank.d288.s28|66-75|induration|O
DDI-DrugBank.d288.s28|76-76|,|O
DDI-DrugBank.d288.s28|78-81|skin|O
DDI-DrugBank.d288.s28|83-93|exfoliation|O
DDI-DrugBank.d288.s28|94-94|,|O
DDI-DrugBank.d288.s28|96-103|necrosis|O
DDI-DrugBank.d288.s28|104-104|,|O
DDI-DrugBank.d288.s28|106-108|and|O
DDI-DrugBank.d288.s28|110-117|fibrosis|O
DDI-DrugBank.d288.s28|119-122|have|O
DDI-DrugBank.d288.s28|124-127|been|O
DDI-DrugBank.d288.s28|129-136|received|O
DDI-DrugBank.d288.s28|138-139|as|O
DDI-DrugBank.d288.s28|141-144|part|O
DDI-DrugBank.d288.s28|146-147|of|O
DDI-DrugBank.d288.s28|149-151|the|O
DDI-DrugBank.d288.s28|153-162|continuing|O
DDI-DrugBank.d288.s28|164-175|surveillance|O
DDI-DrugBank.d288.s28|177-178|of|O
DDI-DrugBank.d288.s28|180-184|TAXOL|brand
DDI-DrugBank.d288.s28|186-191|safety|O
DDI-DrugBank.d288.s28|192-192|.|O
DDI-DrugBank.d288.s29|0-1|In|O
DDI-DrugBank.d288.s29|3-6|some|O
DDI-DrugBank.d288.s29|8-12|cases|O
DDI-DrugBank.d288.s29|14-16|the|O
DDI-DrugBank.d288.s29|18-22|onset|O
DDI-DrugBank.d288.s29|24-25|of|O
DDI-DrugBank.d288.s29|27-29|the|O
DDI-DrugBank.d288.s29|31-39|injection|O
DDI-DrugBank.d288.s29|41-44|site|O
DDI-DrugBank.d288.s29|46-53|reaction|O
DDI-DrugBank.d288.s29|55-60|either|O
DDI-DrugBank.d288.s29|62-69|occurred|O
DDI-DrugBank.d288.s29|71-76|during|O
DDI-DrugBank.d288.s29|78-78|a|O
DDI-DrugBank.d288.s29|80-88|prolonged|O
DDI-DrugBank.d288.s29|90-97|infusion|O
DDI-DrugBank.d288.s29|99-100|or|O
DDI-DrugBank.d288.s29|102-104|was|O
DDI-DrugBank.d288.s29|106-112|delayed|O
DDI-DrugBank.d288.s29|114-115|by|O
DDI-DrugBank.d288.s29|117-117|a|O
DDI-DrugBank.d288.s29|119-122|week|O
DDI-DrugBank.d288.s29|124-125|to|O
DDI-DrugBank.d288.s29|127-129|ten|O
DDI-DrugBank.d288.s29|131-134|days|O
DDI-DrugBank.d288.s29|135-135|.|O
DDI-DrugBank.d288.s30|0-0|A|O
DDI-DrugBank.d288.s30|2-9|specific|O
DDI-DrugBank.d288.s30|11-19|treatment|O
DDI-DrugBank.d288.s30|21-23|for|O
DDI-DrugBank.d288.s30|25-37|extravasation|O
DDI-DrugBank.d288.s30|39-47|reactions|O
DDI-DrugBank.d288.s30|49-50|is|O
DDI-DrugBank.d288.s30|52-58|unknown|O
DDI-DrugBank.d288.s30|60-61|at|O
DDI-DrugBank.d288.s30|63-66|this|O
DDI-DrugBank.d288.s30|68-71|time|O
DDI-DrugBank.d288.s30|72-72|.|O
DDI-DrugBank.d288.s31|0-4|Given|O
DDI-DrugBank.d288.s31|6-8|the|O
DDI-DrugBank.d288.s31|10-20|possibility|O
DDI-DrugBank.d288.s31|22-23|of|O
DDI-DrugBank.d288.s31|25-37|extravasation|O
DDI-DrugBank.d288.s31|38-38|,|O
DDI-DrugBank.d288.s31|40-41|it|O
DDI-DrugBank.d288.s31|43-44|is|O
DDI-DrugBank.d288.s31|46-54|advisable|O
DDI-DrugBank.d288.s31|56-57|to|O
DDI-DrugBank.d288.s31|59-65|closely|O
DDI-DrugBank.d288.s31|67-73|monitor|O
DDI-DrugBank.d288.s31|75-77|the|O
DDI-DrugBank.d288.s31|79-86|infusion|O
DDI-DrugBank.d288.s31|88-91|site|O
DDI-DrugBank.d288.s31|93-95|for|O
DDI-DrugBank.d288.s31|97-104|possible|O
DDI-DrugBank.d288.s31|106-117|infiltration|O
DDI-DrugBank.d288.s31|119-124|during|O
DDI-DrugBank.d288.s31|126-129|drug|O
DDI-DrugBank.d288.s31|131-144|administration|O
DDI-DrugBank.d288.s31|145-145|.|O
DDI-DrugBank.d79.s0|0-2|The|O
DDI-DrugBank.d79.s0|4-13|absorption|O
DDI-DrugBank.d79.s0|15-16|of|O
DDI-DrugBank.d79.s0|18-28|lymecycline|drug
DDI-DrugBank.d79.s0|30-32|may|O
DDI-DrugBank.d79.s0|34-35|be|O
DDI-DrugBank.d79.s0|37-44|affected|O
DDI-DrugBank.d79.s0|46-47|by|O
DDI-DrugBank.d79.s0|49-51|the|O
DDI-DrugBank.d79.s0|53-64|simultaneous|O
DDI-DrugBank.d79.s0|66-79|administration|O
DDI-DrugBank.d79.s0|81-82|of|O
DDI-DrugBank.d79.s0|84-94|indigestion|O
DDI-DrugBank.d79.s0|96-103|remedies|O
DDI-DrugBank.d79.s0|104-104|,|O
DDI-DrugBank.d79.s0|106-109|iron|drug
DDI-DrugBank.d79.s0|111-112|or|O
DDI-DrugBank.d79.s0|114-117|zinc|drug
DDI-DrugBank.d79.s0|119-129|supplements|O
DDI-DrugBank.d79.s0|130-130|.|O
DDI-DrugBank.d79.s1|0-3|Oral|O
DDI-DrugBank.d79.s1|5-18|contraceptives|group
DDI-DrugBank.d79.s1|20-22|may|O
DDI-DrugBank.d79.s1|24-25|be|O
DDI-DrugBank.d79.s1|27-30|less|O
DDI-DrugBank.d79.s1|32-40|effective|O
DDI-DrugBank.d79.s1|42-46|while|O
DDI-DrugBank.d79.s1|48-50|you|O
DDI-DrugBank.d79.s1|52-54|are|O
DDI-DrugBank.d79.s1|56-61|taking|O
DDI-DrugBank.d79.s1|63-73|lymecycline|drug
DDI-DrugBank.d79.s1|74-74|.|O
DDI-DrugBank.d60.s0|0-13|Administration|O
DDI-DrugBank.d60.s0|15-16|of|O
DDI-DrugBank.d60.s0|18-26|0.1-mg/kg|O
DDI-DrugBank.d60.s0|28-28|(|O
DDI-DrugBank.d60.s0|29-29|2|O
DDI-DrugBank.d60.s0|31-31|x|O
DDI-DrugBank.d60.s0|33-36|ED95|O
DDI-DrugBank.d60.s0|37-37|)|O
DDI-DrugBank.d60.s0|39-44|NIMBEX|brand
DDI-DrugBank.d60.s0|46-47|at|O
DDI-DrugBank.d60.s0|49-50|10|O
DDI-DrugBank.d60.s0|51-51|%|O
DDI-DrugBank.d60.s0|53-54|or|O
DDI-DrugBank.d60.s0|56-57|95|O
DDI-DrugBank.d60.s0|58-58|%|O
DDI-DrugBank.d60.s0|60-67|recovery|O
DDI-DrugBank.d60.s0|69-77|following|O
DDI-DrugBank.d60.s0|79-80|an|O
DDI-DrugBank.d60.s0|82-91|intubating|O
DDI-DrugBank.d60.s0|93-96|dose|O
DDI-DrugBank.d60.s0|98-99|of|O
DDI-DrugBank.d60.s0|101-115|succinylcholine|drug
DDI-DrugBank.d60.s0|117-117|(|O
DDI-DrugBank.d60.s0|118-118|1|O
DDI-DrugBank.d60.s0|120-124|mg/kg|O
DDI-DrugBank.d60.s0|125-125|)|O
DDI-DrugBank.d60.s0|127-134|produced|O
DDI-DrugBank.d60.s0|137-138|95|O
DDI-DrugBank.d60.s0|139-139|%|O
DDI-DrugBank.d60.s0|141-153|neuromuscular|O
DDI-DrugBank.d60.s0|155-159|block|O
DDI-DrugBank.d60.s0|160-160|.|O
DDI-DrugBank.d60.s1|0-2|The|O
DDI-DrugBank.d60.s1|4-7|time|O
DDI-DrugBank.d60.s1|9-10|to|O
DDI-DrugBank.d60.s1|12-16|onset|O
DDI-DrugBank.d60.s1|18-19|of|O
DDI-DrugBank.d60.s1|21-27|maximum|O
DDI-DrugBank.d60.s1|29-33|block|O
DDI-DrugBank.d60.s1|35-43|following|O
DDI-DrugBank.d60.s1|45-50|NIMBEX|brand
DDI-DrugBank.d60.s1|52-53|is|O
DDI-DrugBank.d60.s1|55-67|approximately|O
DDI-DrugBank.d60.s1|69-69|2|O
DDI-DrugBank.d60.s1|71-77|minutes|O
DDI-DrugBank.d60.s1|79-84|faster|O
DDI-DrugBank.d60.s1|86-89|with|O
DDI-DrugBank.d60.s1|91-95|prior|O
DDI-DrugBank.d60.s1|97-110|administration|O
DDI-DrugBank.d60.s1|112-113|of|O
DDI-DrugBank.d60.s1|115-129|succinylcholine|drug
DDI-DrugBank.d60.s1|130-130|.|O
DDI-DrugBank.d60.s2|0-4|Prior|O
DDI-DrugBank.d60.s2|6-19|administration|O
DDI-DrugBank.d60.s2|21-22|of|O
DDI-DrugBank.d60.s2|24-38|succinylcholine|drug
DDI-DrugBank.d60.s2|40-42|had|O
DDI-DrugBank.d60.s2|44-45|no|O
DDI-DrugBank.d60.s2|47-52|effect|O
DDI-DrugBank.d60.s2|54-55|on|O
DDI-DrugBank.d60.s2|57-59|the|O
DDI-DrugBank.d60.s2|61-68|duration|O
DDI-DrugBank.d60.s2|70-71|of|O
DDI-DrugBank.d60.s2|73-85|neuromuscular|O
DDI-DrugBank.d60.s2|87-91|block|O
DDI-DrugBank.d60.s2|93-101|following|O
DDI-DrugBank.d60.s2|103-109|initial|O
DDI-DrugBank.d60.s2|111-112|or|O
DDI-DrugBank.d60.s2|114-124|maintenance|O
DDI-DrugBank.d60.s2|126-130|bolus|O
DDI-DrugBank.d60.s2|132-136|doses|O
DDI-DrugBank.d60.s2|138-139|of|O
DDI-DrugBank.d60.s2|141-146|NIMBEX|brand
DDI-DrugBank.d60.s2|147-147|.|O
DDI-DrugBank.d60.s3|0-7|Infusion|O
DDI-DrugBank.d60.s3|9-20|requirements|O
DDI-DrugBank.d60.s3|22-23|of|O
DDI-DrugBank.d60.s3|25-30|NIMBEX|brand
DDI-DrugBank.d60.s3|32-33|in|O
DDI-DrugBank.d60.s3|35-42|patients|O
DDI-DrugBank.d60.s3|44-55|administered|O
DDI-DrugBank.d60.s3|57-71|succinylcholine|drug
DDI-DrugBank.d60.s3|73-77|prior|O
DDI-DrugBank.d60.s3|79-80|to|O
DDI-DrugBank.d60.s3|82-90|infusions|O
DDI-DrugBank.d60.s3|92-93|of|O
DDI-DrugBank.d60.s3|95-100|NIMBEX|brand
DDI-DrugBank.d60.s3|102-105|were|O
DDI-DrugBank.d60.s3|107-116|comparable|O
DDI-DrugBank.d60.s3|118-119|to|O
DDI-DrugBank.d60.s3|121-122|or|O
DDI-DrugBank.d60.s3|124-131|slightly|O
DDI-DrugBank.d60.s3|133-139|greater|O
DDI-DrugBank.d60.s3|141-144|than|O
DDI-DrugBank.d60.s3|146-149|when|O
DDI-DrugBank.d60.s3|151-165|succinylcholine|drug
DDI-DrugBank.d60.s3|167-169|was|O
DDI-DrugBank.d60.s3|171-173|not|O
DDI-DrugBank.d60.s3|175-186|administered|O
DDI-DrugBank.d60.s3|187-187|.|O
DDI-DrugBank.d60.s4|0-2|The|O
DDI-DrugBank.d60.s4|4-6|use|O
DDI-DrugBank.d60.s4|8-9|of|O
DDI-DrugBank.d60.s4|11-16|NIMBEX|brand
DDI-DrugBank.d60.s4|18-23|before|O
DDI-DrugBank.d60.s4|25-39|succinylcholine|drug
DDI-DrugBank.d60.s4|41-42|to|O
DDI-DrugBank.d60.s4|44-52|attenuate|O
DDI-DrugBank.d60.s4|54-57|some|O
DDI-DrugBank.d60.s4|59-60|of|O
DDI-DrugBank.d60.s4|62-64|the|O
DDI-DrugBank.d60.s4|66-69|side|O
DDI-DrugBank.d60.s4|71-77|effects|O
DDI-DrugBank.d60.s4|79-80|of|O
DDI-DrugBank.d60.s4|82-96|succinylcholine|drug
DDI-DrugBank.d60.s4|98-100|has|O
DDI-DrugBank.d60.s4|102-104|not|O
DDI-DrugBank.d60.s4|106-109|been|O
DDI-DrugBank.d60.s4|111-117|studied|O
DDI-DrugBank.d60.s4|118-118|.|O
DDI-DrugBank.d60.s5|0-7|Although|O
DDI-DrugBank.d60.s5|9-11|not|O
DDI-DrugBank.d60.s5|13-19|studied|O
DDI-DrugBank.d60.s5|21-34|systematically|O
DDI-DrugBank.d60.s5|36-37|in|O
DDI-DrugBank.d60.s5|39-46|clinical|O
DDI-DrugBank.d60.s5|48-53|trials|O
DDI-DrugBank.d60.s5|54-54|,|O
DDI-DrugBank.d60.s5|56-57|no|O
DDI-DrugBank.d60.s5|59-62|drug|O
DDI-DrugBank.d60.s5|64-75|interactions|O
DDI-DrugBank.d60.s5|77-80|were|O
DDI-DrugBank.d60.s5|82-89|observed|O
DDI-DrugBank.d60.s5|91-94|when|O
DDI-DrugBank.d60.s5|96-105|vecuronium|drug
DDI-DrugBank.d60.s5|106-106|,|O
DDI-DrugBank.d60.s5|108-118|pancuronium|drug
DDI-DrugBank.d60.s5|119-119|,|O
DDI-DrugBank.d60.s5|121-122|or|O
DDI-DrugBank.d60.s5|124-133|atracurium|drug
DDI-DrugBank.d60.s5|135-138|were|O
DDI-DrugBank.d60.s5|140-151|administered|O
DDI-DrugBank.d60.s5|153-161|following|O
DDI-DrugBank.d60.s5|163-169|varying|O
DDI-DrugBank.d60.s5|171-177|degrees|O
DDI-DrugBank.d60.s5|179-180|of|O
DDI-DrugBank.d60.s5|182-189|recovery|O
DDI-DrugBank.d60.s5|191-194|from|O
DDI-DrugBank.d60.s5|196-201|single|O
DDI-DrugBank.d60.s5|203-207|doses|O
DDI-DrugBank.d60.s5|209-210|or|O
DDI-DrugBank.d60.s5|212-220|infusions|O
DDI-DrugBank.d60.s5|222-223|of|O
DDI-DrugBank.d60.s5|225-230|NIMBEX|brand
DDI-DrugBank.d60.s5|231-231|.|O
DDI-DrugBank.d60.s6|0-9|Isoflurane|drug
DDI-DrugBank.d60.s6|11-12|or|O
DDI-DrugBank.d60.s6|14-22|enflurane|drug
DDI-DrugBank.d60.s6|24-35|administered|O
DDI-DrugBank.d60.s6|37-40|with|O
DDI-DrugBank.d60.s6|42-61|nitrous oxide/oxygen|drug
DDI-DrugBank.d60.s6|63-64|to|O
DDI-DrugBank.d60.s6|66-72|achieve|O
DDI-DrugBank.d60.s6|74-77|1.25|O
DDI-DrugBank.d60.s6|79-81|MAC|O
DDI-DrugBank.d60.s6|83-83|[|O
DDI-DrugBank.d60.s6|84-90|Minimum|O
DDI-DrugBank.d60.s6|92-99|Alveolar|O
DDI-DrugBank.d60.s6|101-113|Concentration|O
DDI-DrugBank.d60.s6|114-114|]|O
DDI-DrugBank.d60.s6|116-118|may|O
DDI-DrugBank.d60.s6|120-126|prolong|O
DDI-DrugBank.d60.s6|128-130|the|O
DDI-DrugBank.d60.s6|132-141|clinically|O
DDI-DrugBank.d60.s6|143-151|effective|O
DDI-DrugBank.d60.s6|153-160|duration|O
DDI-DrugBank.d60.s6|162-163|of|O
DDI-DrugBank.d60.s6|165-170|action|O
DDI-DrugBank.d60.s6|172-173|of|O
DDI-DrugBank.d60.s6|175-181|initial|O
DDI-DrugBank.d60.s6|183-185|and|O
DDI-DrugBank.d60.s6|187-197|maintenance|O
DDI-DrugBank.d60.s6|199-203|doses|O
DDI-DrugBank.d60.s6|205-206|of|O
DDI-DrugBank.d60.s6|208-213|NIMBEX|brand
DDI-DrugBank.d60.s6|215-217|and|O
DDI-DrugBank.d60.s6|219-226|decrease|O
DDI-DrugBank.d60.s6|228-230|the|O
DDI-DrugBank.d60.s6|232-239|required|O
DDI-DrugBank.d60.s6|241-248|infusion|O
DDI-DrugBank.d60.s6|250-253|rate|O
DDI-DrugBank.d60.s6|255-256|of|O
DDI-DrugBank.d60.s6|258-263|NIMBEX|brand
DDI-DrugBank.d60.s6|264-264|.|O
DDI-DrugBank.d60.s7|0-2|The|O
DDI-DrugBank.d60.s7|4-12|magnitude|O
DDI-DrugBank.d60.s7|14-15|of|O
DDI-DrugBank.d60.s7|17-21|these|O
DDI-DrugBank.d60.s7|23-29|effects|O
DDI-DrugBank.d60.s7|31-33|may|O
DDI-DrugBank.d60.s7|35-40|depend|O
DDI-DrugBank.d60.s7|42-43|on|O
DDI-DrugBank.d60.s7|45-47|the|O
DDI-DrugBank.d60.s7|49-56|duration|O
DDI-DrugBank.d60.s7|58-59|of|O
DDI-DrugBank.d60.s7|61-74|administration|O
DDI-DrugBank.d60.s7|76-77|of|O
DDI-DrugBank.d60.s7|79-81|the|O
DDI-DrugBank.d60.s7|83-90|volatile|O
DDI-DrugBank.d60.s7|92-97|agents|O
DDI-DrugBank.d60.s7|98-98|.|O
DDI-DrugBank.d60.s8|0-6|Fifteen|O
DDI-DrugBank.d60.s8|8-9|to|O
DDI-DrugBank.d60.s8|11-12|30|O
DDI-DrugBank.d60.s8|14-20|minutes|O
DDI-DrugBank.d60.s8|22-23|of|O
DDI-DrugBank.d60.s8|25-32|exposure|O
DDI-DrugBank.d60.s8|34-35|to|O
DDI-DrugBank.d60.s8|37-40|1.25|O
DDI-DrugBank.d60.s8|42-44|MAC|O
DDI-DrugBank.d60.s8|46-55|isoflurane|drug
DDI-DrugBank.d60.s8|57-58|or|O
DDI-DrugBank.d60.s8|60-68|enflurane|drug
DDI-DrugBank.d60.s8|70-72|had|O
DDI-DrugBank.d60.s8|74-80|minimal|O
DDI-DrugBank.d60.s8|82-88|effects|O
DDI-DrugBank.d60.s8|90-91|on|O
DDI-DrugBank.d60.s8|93-95|the|O
DDI-DrugBank.d60.s8|97-104|duration|O
DDI-DrugBank.d60.s8|106-107|of|O
DDI-DrugBank.d60.s8|109-114|action|O
DDI-DrugBank.d60.s8|116-117|of|O
DDI-DrugBank.d60.s8|119-125|initial|O
DDI-DrugBank.d60.s8|127-131|doses|O
DDI-DrugBank.d60.s8|133-134|of|O
DDI-DrugBank.d60.s8|136-141|NIMBEX|brand
DDI-DrugBank.d60.s8|143-145|and|O
DDI-DrugBank.d60.s8|147-155|therefore|O
DDI-DrugBank.d60.s8|156-156|,|O
DDI-DrugBank.d60.s8|158-159|no|O
DDI-DrugBank.d60.s8|161-170|adjustment|O
DDI-DrugBank.d60.s8|172-173|to|O
DDI-DrugBank.d60.s8|175-177|the|O
DDI-DrugBank.d60.s8|179-185|initial|O
DDI-DrugBank.d60.s8|187-190|dose|O
DDI-DrugBank.d60.s8|192-197|should|O
DDI-DrugBank.d60.s8|199-200|be|O
DDI-DrugBank.d60.s8|202-210|necessary|O
DDI-DrugBank.d60.s8|212-215|when|O
DDI-DrugBank.d60.s8|217-222|NIMBEX|brand
DDI-DrugBank.d60.s8|224-225|is|O
DDI-DrugBank.d60.s8|227-238|administered|O
DDI-DrugBank.d60.s8|240-246|shortly|O
DDI-DrugBank.d60.s8|248-252|after|O
DDI-DrugBank.d60.s8|254-263|initiation|O
DDI-DrugBank.d60.s8|265-266|of|O
DDI-DrugBank.d60.s8|268-275|volatile|O
DDI-DrugBank.d60.s8|277-282|agents|O
DDI-DrugBank.d60.s8|283-283|.|O
DDI-DrugBank.d60.s9|0-1|In|O
DDI-DrugBank.d60.s9|3-6|long|O
DDI-DrugBank.d60.s9|8-15|surgical|O
DDI-DrugBank.d60.s9|17-26|procedures|O
DDI-DrugBank.d60.s9|28-33|during|O
DDI-DrugBank.d60.s9|35-43|enflurane|drug
DDI-DrugBank.d60.s9|45-46|or|O
DDI-DrugBank.d60.s9|48-57|isoflurane|drug
DDI-DrugBank.d60.s9|59-68|anesthesia|O
DDI-DrugBank.d60.s9|69-69|,|O
DDI-DrugBank.d60.s9|71-74|less|O
DDI-DrugBank.d60.s9|76-83|frequent|O
DDI-DrugBank.d60.s9|85-95|maintenance|O
DDI-DrugBank.d60.s9|97-102|dosing|O
DDI-DrugBank.d60.s9|103-103|,|O
DDI-DrugBank.d60.s9|105-109|lower|O
DDI-DrugBank.d60.s9|111-121|maintenance|O
DDI-DrugBank.d60.s9|123-127|doses|O
DDI-DrugBank.d60.s9|128-128|,|O
DDI-DrugBank.d60.s9|130-131|or|O
DDI-DrugBank.d60.s9|133-139|reduced|O
DDI-DrugBank.d60.s9|141-148|infusion|O
DDI-DrugBank.d60.s9|150-154|rates|O
DDI-DrugBank.d60.s9|156-157|of|O
DDI-DrugBank.d60.s9|159-164|NIMBEX|brand
DDI-DrugBank.d60.s9|166-168|may|O
DDI-DrugBank.d60.s9|170-171|be|O
DDI-DrugBank.d60.s9|173-181|necessary|O
DDI-DrugBank.d60.s9|182-182|.|O
DDI-DrugBank.d60.s10|0-2|The|O
DDI-DrugBank.d60.s10|4-10|average|O
DDI-DrugBank.d60.s10|12-19|infusion|O
DDI-DrugBank.d60.s10|21-24|rate|O
DDI-DrugBank.d60.s10|26-36|requirement|O
DDI-DrugBank.d60.s10|38-40|may|O
DDI-DrugBank.d60.s10|42-43|be|O
DDI-DrugBank.d60.s10|45-53|decreased|O
DDI-DrugBank.d60.s10|55-56|by|O
DDI-DrugBank.d60.s10|58-59|as|O
DDI-DrugBank.d60.s10|61-64|much|O
DDI-DrugBank.d60.s10|66-67|as|O
DDI-DrugBank.d60.s10|69-70|30|O
DDI-DrugBank.d60.s10|71-71|%|O
DDI-DrugBank.d60.s10|73-74|to|O
DDI-DrugBank.d60.s10|76-77|40|O
DDI-DrugBank.d60.s10|78-78|%|O
DDI-DrugBank.d60.s10|79-79|.|O
DDI-DrugBank.d60.s11|0-1|In|O
DDI-DrugBank.d60.s11|3-10|clinical|O
DDI-DrugBank.d60.s11|12-18|studies|O
DDI-DrugBank.d60.s11|20-27|propofol|drug
DDI-DrugBank.d60.s11|29-31|had|O
DDI-DrugBank.d60.s11|33-34|no|O
DDI-DrugBank.d60.s11|36-41|effect|O
DDI-DrugBank.d60.s11|43-44|on|O
DDI-DrugBank.d60.s11|46-48|the|O
DDI-DrugBank.d60.s11|50-57|duration|O
DDI-DrugBank.d60.s11|59-60|of|O
DDI-DrugBank.d60.s11|62-67|action|O
DDI-DrugBank.d60.s11|69-70|or|O
DDI-DrugBank.d60.s11|72-77|dosing|O
DDI-DrugBank.d60.s11|79-90|requirements|O
DDI-DrugBank.d60.s11|92-94|for|O
DDI-DrugBank.d60.s11|96-101|NIMBEX|brand
DDI-DrugBank.d60.s11|102-102|.|O
DDI-DrugBank.d60.s12|0-4|Other|O
DDI-DrugBank.d60.s12|6-10|drugs|O
DDI-DrugBank.d60.s12|12-16|which|O
DDI-DrugBank.d60.s12|18-20|may|O
DDI-DrugBank.d60.s12|22-28|enhance|O
DDI-DrugBank.d60.s12|30-32|the|O
DDI-DrugBank.d60.s12|34-46|neuromuscular|O
DDI-DrugBank.d60.s12|48-55|blocking|O
DDI-DrugBank.d60.s12|57-62|action|O
DDI-DrugBank.d60.s12|64-65|of|O
DDI-DrugBank.d60.s12|67-88|nondepolarizing agents|group
DDI-DrugBank.d60.s12|90-93|such|O
DDI-DrugBank.d60.s12|95-96|as|O
DDI-DrugBank.d60.s12|98-103|NIMBEX|brand
DDI-DrugBank.d60.s12|105-111|include|O
DDI-DrugBank.d60.s12|113-119|certain|O
DDI-DrugBank.d60.s12|121-131|antibiotics|group
DDI-DrugBank.d60.s12|133-133|(|O
DDI-DrugBank.d60.s12|134-135|e.|O
DDI-DrugBank.d60.s12|137-138|g.|O
DDI-DrugBank.d60.s12|139-139|,|O
DDI-DrugBank.d60.s12|141-155|aminoglycosides|group
DDI-DrugBank.d60.s12|156-156|,|O
DDI-DrugBank.d60.s12|158-170|tetracyclines|group
DDI-DrugBank.d60.s12|171-171|,|O
DDI-DrugBank.d60.s12|173-182|bacitracin|drug
DDI-DrugBank.d60.s12|183-183|,|O
DDI-DrugBank.d60.s12|185-194|polymyxins|group
DDI-DrugBank.d60.s12|195-195|,|O
DDI-DrugBank.d60.s12|197-206|lincomycin|drug
DDI-DrugBank.d60.s12|207-207|,|O
DDI-DrugBank.d60.s12|209-219|clindamycin|drug
DDI-DrugBank.d60.s12|220-220|,|O
DDI-DrugBank.d60.s12|222-229|colistin|drug
DDI-DrugBank.d60.s12|230-230|,|O
DDI-DrugBank.d60.s12|232-234|and|O
DDI-DrugBank.d60.s12|236-256|sodium colistemethate|drug
DDI-DrugBank.d60.s12|257-257|)|O
DDI-DrugBank.d60.s12|258-258|,|O
DDI-DrugBank.d60.s12|260-268|magnesium|group
DDI-DrugBank.d60.s12|270-274|salts|O
DDI-DrugBank.d60.s12|275-275|,|O
DDI-DrugBank.d60.s12|277-283|lithium|drug
DDI-DrugBank.d60.s12|284-284|,|O
DDI-DrugBank.d60.s12|286-290|local|O
DDI-DrugBank.d60.s12|292-302|anesthetics|group
DDI-DrugBank.d60.s12|303-303|,|O
DDI-DrugBank.d60.s12|305-316|procainamide|drug
DDI-DrugBank.d60.s12|317-317|,|O
DDI-DrugBank.d60.s12|319-321|and|O
DDI-DrugBank.d60.s12|323-331|quinidine|drug
DDI-DrugBank.d60.s12|332-332|.|O
DDI-DrugBank.d60.s13|0-9|Resistance|O
DDI-DrugBank.d60.s13|11-12|to|O
DDI-DrugBank.d60.s13|14-16|the|O
DDI-DrugBank.d60.s13|18-30|neuromuscular|O
DDI-DrugBank.d60.s13|32-39|blocking|O
DDI-DrugBank.d60.s13|41-46|action|O
DDI-DrugBank.d60.s13|48-49|of|O
DDI-DrugBank.d60.s13|51-95|nondepolarizing neuromuscular blocking agents|group
DDI-DrugBank.d60.s13|97-99|has|O
DDI-DrugBank.d60.s13|101-104|been|O
DDI-DrugBank.d60.s13|106-117|demonstrated|O
DDI-DrugBank.d60.s13|119-120|in|O
DDI-DrugBank.d60.s13|122-129|patients|O
DDI-DrugBank.d60.s13|131-141|chronically|O
DDI-DrugBank.d60.s13|143-154|administered|O
DDI-DrugBank.d60.s13|156-164|phenytoin|drug
DDI-DrugBank.d60.s13|166-167|or|O
DDI-DrugBank.d60.s13|169-181|carbamazepine|drug
DDI-DrugBank.d60.s13|182-182|.|O
DDI-DrugBank.d60.s14|0-4|While|O
DDI-DrugBank.d60.s14|6-8|the|O
DDI-DrugBank.d60.s14|10-16|effects|O
DDI-DrugBank.d60.s14|18-19|of|O
DDI-DrugBank.d60.s14|21-27|chronic|O
DDI-DrugBank.d60.s14|29-37|phenytoin|drug
DDI-DrugBank.d60.s14|39-40|or|O
DDI-DrugBank.d60.s14|42-54|carbamazepine|drug
DDI-DrugBank.d60.s14|56-62|therapy|O
DDI-DrugBank.d60.s14|64-65|on|O
DDI-DrugBank.d60.s14|67-69|the|O
DDI-DrugBank.d60.s14|71-76|action|O
DDI-DrugBank.d60.s14|78-79|of|O
DDI-DrugBank.d60.s14|81-86|NIMBEX|brand
DDI-DrugBank.d60.s14|88-90|are|O
DDI-DrugBank.d60.s14|92-98|unknown|O
DDI-DrugBank.d60.s14|99-99|,|O
DDI-DrugBank.d60.s14|101-108|slightly|O
DDI-DrugBank.d60.s14|110-116|shorter|O
DDI-DrugBank.d60.s14|118-126|durations|O
DDI-DrugBank.d60.s14|128-129|of|O
DDI-DrugBank.d60.s14|131-143|neuromuscular|O
DDI-DrugBank.d60.s14|145-149|block|O
DDI-DrugBank.d60.s14|151-153|may|O
DDI-DrugBank.d60.s14|155-156|be|O
DDI-DrugBank.d60.s14|158-168|anticipated|O
DDI-DrugBank.d60.s14|170-172|and|O
DDI-DrugBank.d60.s14|174-181|infusion|O
DDI-DrugBank.d60.s14|183-186|rate|O
DDI-DrugBank.d60.s14|188-199|requirements|O
DDI-DrugBank.d60.s14|201-203|may|O
DDI-DrugBank.d60.s14|205-206|be|O
DDI-DrugBank.d60.s14|208-213|higher|O
DDI-DrugBank.d60.s14|214-214|.|O
DDI-DrugBank.d60.s15|0-14|Drug/Laboratory|O
DDI-DrugBank.d60.s15|16-19|Test|O
DDI-DrugBank.d60.s15|21-32|Interactions|O
DDI-DrugBank.d60.s15|34-37|None|O
DDI-DrugBank.d60.s15|39-43|known|O
DDI-DrugBank.d60.s15|44-44|.|O
DDI-DrugBank.d304.s0|0-2|May|O
DDI-DrugBank.d304.s0|4-11|interact|O
DDI-DrugBank.d304.s0|13-16|with|O
DDI-DrugBank.d304.s0|18-20|the|O
DDI-DrugBank.d304.s0|22-30|following|O
DDI-DrugBank.d304.s0|31-31|:|O
DDI-DrugBank.d304.s0|33-46|cholestyramine|drug
DDI-DrugBank.d304.s0|47-47|,|O
DDI-DrugBank.d304.s0|49-58|colestipol|drug
DDI-DrugBank.d304.s0|60-60|(|O
DDI-DrugBank.d304.s0|61-63|use|O
DDI-DrugBank.d304.s0|65-68|with|O
DDI-DrugBank.d304.s0|70-87|thiazide diuretics|group
DDI-DrugBank.d304.s0|89-91|may|O
DDI-DrugBank.d304.s0|93-99|prevent|O
DDI-DrugBank.d304.s0|101-103|the|O
DDI-DrugBank.d304.s0|105-112|diuretic|group
DDI-DrugBank.d304.s0|114-117|from|O
DDI-DrugBank.d304.s0|119-125|working|O
DDI-DrugBank.d304.s0|127-134|properly|O
DDI-DrugBank.d304.s0|135-135|;|O
DDI-MedLine.d127.s0|0-4|Serum|O
DDI-MedLine.d127.s0|6-12|digoxin|drug
DDI-MedLine.d127.s0|14-19|levels|O
DDI-MedLine.d127.s0|21-25|using|O
DDI-MedLine.d127.s0|27-28|an|O
DDI-MedLine.d127.s0|30-42|125I-labelled|O
DDI-MedLine.d127.s0|44-50|antigen|O
DDI-MedLine.d127.s0|51-51|:|O
DDI-MedLine.d127.s0|53-62|Validation|O
DDI-MedLine.d127.s0|64-65|of|O
DDI-MedLine.d127.s0|67-72|method|O
DDI-MedLine.d127.s0|74-76|and|O
DDI-MedLine.d127.s0|78-89|observations|O
DDI-MedLine.d127.s0|91-92|on|O
DDI-MedLine.d127.s0|94-100|cardiac|O
DDI-MedLine.d127.s0|102-109|patients|O
DDI-MedLine.d127.s0|110-110|.|O
DDI-MedLine.d127.s1|0-0|1|O
DDI-MedLine.d127.s1|1-1|.|O
DDI-MedLine.d127.s2|0-13|Determinations|O
DDI-MedLine.d127.s2|15-16|of|O
DDI-MedLine.d127.s2|18-22|serum|O
DDI-MedLine.d127.s2|24-30|digoxin|drug
DDI-MedLine.d127.s2|32-37|levels|O
DDI-MedLine.d127.s2|39-47|utilizing|O
DDI-MedLine.d127.s2|49-60|commercially|O
DDI-MedLine.d127.s2|62-70|available|O
DDI-MedLine.d127.s2|72-75|kits|O
DDI-MedLine.d127.s2|77-80|with|O
DDI-MedLine.d127.s2|82-83|an|O
DDI-MedLine.d127.s2|85-97|125I-labelled|O
DDI-MedLine.d127.s2|99-105|antigen|O
DDI-MedLine.d127.s2|107-110|were|O
DDI-MedLine.d127.s2|112-118|precise|O
DDI-MedLine.d127.s2|120-122|and|O
DDI-MedLine.d127.s2|124-126|not|O
DDI-MedLine.d127.s2|128-137|materially|O
DDI-MedLine.d127.s2|139-147|different|O
DDI-MedLine.d127.s2|149-152|from|O
DDI-MedLine.d127.s2|154-160|results|O
DDI-MedLine.d127.s2|162-169|obtained|O
DDI-MedLine.d127.s2|171-174|with|O
DDI-MedLine.d127.s2|176-176|a|O
DDI-MedLine.d127.s2|178-188|3H-labelled|O
DDI-MedLine.d127.s2|190-196|antigen|O
DDI-MedLine.d127.s2|197-197|.|O
DDI-MedLine.d127.s3|0-0|2|O
DDI-MedLine.d127.s3|1-1|.|O
DDI-MedLine.d127.s4|0-1|In|O
DDI-MedLine.d127.s4|3-7|order|O
DDI-MedLine.d127.s4|9-10|to|O
DDI-MedLine.d127.s4|12-22|approximate|O
DDI-MedLine.d127.s4|24-26|the|O
DDI-MedLine.d127.s4|28-33|steady|O
DDI-MedLine.d127.s4|35-39|state|O
DDI-MedLine.d127.s4|41-45|level|O
DDI-MedLine.d127.s4|46-46|,|O
DDI-MedLine.d127.s4|48-52|serum|O
DDI-MedLine.d127.s4|54-60|digoxin|drug
DDI-MedLine.d127.s4|62-67|levels|O
DDI-MedLine.d127.s4|69-74|should|O
DDI-MedLine.d127.s4|76-77|be|O
DDI-MedLine.d127.s4|79-83|drawn|O
DDI-MedLine.d127.s4|85-90|either|O
DDI-MedLine.d127.s4|92-97|before|O
DDI-MedLine.d127.s4|99-100|or|O
DDI-MedLine.d127.s4|102-103|at|O
DDI-MedLine.d127.s4|105-109|least|O
DDI-MedLine.d127.s4|111-113|six|O
DDI-MedLine.d127.s4|115-119|hours|O
DDI-MedLine.d127.s4|121-129|following|O
DDI-MedLine.d127.s4|131-133|the|O
DDI-MedLine.d127.s4|135-148|administration|O
DDI-MedLine.d127.s4|150-151|of|O
DDI-MedLine.d127.s4|153-154|an|O
DDI-MedLine.d127.s4|156-159|oral|O
DDI-MedLine.d127.s4|161-166|tablet|O
DDI-MedLine.d127.s4|167-167|.|O
DDI-MedLine.d127.s5|0-0|3|O
DDI-MedLine.d127.s5|1-1|.|O
DDI-MedLine.d127.s6|0-12|Concomitantly|O
DDI-MedLine.d127.s6|14-18|given|O
DDI-MedLine.d127.s6|20-37|thiazide diuretics|group
DDI-MedLine.d127.s6|39-41|did|O
DDI-MedLine.d127.s6|43-45|not|O
DDI-MedLine.d127.s6|47-55|interfere|O
DDI-MedLine.d127.s6|57-60|with|O
DDI-MedLine.d127.s6|62-64|the|O
DDI-MedLine.d127.s6|66-75|absorption|O
DDI-MedLine.d127.s6|77-78|of|O
DDI-MedLine.d127.s6|80-80|a|O
DDI-MedLine.d127.s6|82-87|tablet|O
DDI-MedLine.d127.s6|89-90|of|O
DDI-MedLine.d127.s6|92-98|digoxin|drug
DDI-MedLine.d127.s6|99-99|.|O
DDI-MedLine.d127.s7|0-0|4|O
DDI-MedLine.d127.s7|1-1|.|O
DDI-MedLine.d127.s8|0-1|In|O
DDI-MedLine.d127.s8|3-5|the|O
DDI-MedLine.d127.s8|7-17|digitalized|O
DDI-MedLine.d127.s8|19-25|patient|O
DDI-MedLine.d127.s8|26-26|,|O
DDI-MedLine.d127.s8|28-31|slow|O
DDI-MedLine.d127.s8|33-43|alterations|O
DDI-MedLine.d127.s8|45-46|in|O
DDI-MedLine.d127.s8|48-52|serum|O
DDI-MedLine.d127.s8|54-59|levels|O
DDI-MedLine.d127.s8|61-65|after|O
DDI-MedLine.d127.s8|67-70|oral|O
DDI-MedLine.d127.s8|72-85|administration|O
DDI-MedLine.d127.s8|87-94|appeared|O
DDI-MedLine.d127.s8|96-99|well|O
DDI-MedLine.d127.s8|101-110|correlated|O
DDI-MedLine.d127.s8|112-115|with|O
DDI-MedLine.d127.s8|116-116|,|O
DDI-MedLine.d127.s8|118-119|at|O
DDI-MedLine.d127.s8|121-125|least|O
DDI-MedLine.d127.s8|126-126|,|O
DDI-MedLine.d127.s8|128-130|the|O
DDI-MedLine.d127.s8|132-139|negative|O
DDI-MedLine.d127.s8|141-152|chronotropic|O
DDI-MedLine.d127.s8|154-160|effects|O
DDI-MedLine.d127.s8|162-163|of|O
DDI-MedLine.d127.s8|165-167|the|O
DDI-MedLine.d127.s8|169-172|drug|O
DDI-MedLine.d127.s8|173-173|.|O
DDI-MedLine.d127.s9|0-0|5|O
DDI-MedLine.d127.s9|1-1|.|O
DDI-MedLine.d127.s10|0-6|Maximal|O
DDI-MedLine.d127.s10|8-15|exercise|O
DDI-MedLine.d127.s10|17-23|testing|O
DDI-MedLine.d127.s10|24-24|,|O
DDI-MedLine.d127.s10|26-26|a|O
DDI-MedLine.d127.s10|28-35|maneuver|O
DDI-MedLine.d127.s10|37-41|often|O
DDI-MedLine.d127.s10|43-49|applied|O
DDI-MedLine.d127.s10|51-52|to|O
DDI-MedLine.d127.s10|54-60|cardiac|O
DDI-MedLine.d127.s10|62-69|patients|O
DDI-MedLine.d127.s10|70-70|,|O
DDI-MedLine.d127.s10|72-75|does|O
DDI-MedLine.d127.s10|77-79|not|O
DDI-MedLine.d127.s10|81-93|significantly|O
DDI-MedLine.d127.s10|95-99|alter|O
DDI-MedLine.d127.s10|101-103|the|O
DDI-MedLine.d127.s10|105-109|serum|O
DDI-MedLine.d127.s10|111-117|digoxin|drug
DDI-MedLine.d127.s10|119-123|level|O
DDI-MedLine.d127.s10|124-124|.|O
DDI-DrugBank.d498.s0|0-6|Certain|O
DDI-DrugBank.d498.s0|8-18|antibiotics|group
DDI-DrugBank.d498.s0|19-19|,|O
DDI-DrugBank.d498.s0|21-30|especially|O
DDI-DrugBank.d498.s0|32-39|neomycin|drug
DDI-DrugBank.d498.s0|40-40|,|O
DDI-DrugBank.d498.s0|42-53|streptomycin|drug
DDI-DrugBank.d498.s0|55-57|and|O
DDI-DrugBank.d498.s0|59-67|kanamycin|drug
DDI-DrugBank.d498.s0|68-68|,|O
DDI-DrugBank.d498.s0|70-73|have|O
DDI-DrugBank.d498.s0|75-75|a|O
DDI-DrugBank.d498.s0|77-80|mild|O
DDI-DrugBank.d498.s0|82-84|but|O
DDI-DrugBank.d498.s0|86-93|definite|O
DDI-DrugBank.d498.s0|95-109|nondepolarizing|O
DDI-DrugBank.d498.s0|111-118|blocking|O
DDI-DrugBank.d498.s0|120-125|action|O
DDI-DrugBank.d498.s0|127-131|which|O
DDI-DrugBank.d498.s0|133-135|may|O
DDI-DrugBank.d498.s0|137-146|accentuate|O
DDI-DrugBank.d498.s0|148-160|neuromuscular|O
DDI-DrugBank.d498.s0|162-166|block|O
DDI-DrugBank.d498.s0|167-167|.|O
DDI-DrugBank.d498.s1|0-4|These|O
DDI-DrugBank.d498.s1|6-16|antibiotics|group
DDI-DrugBank.d498.s1|18-23|should|O
DDI-DrugBank.d498.s1|25-26|be|O
DDI-DrugBank.d498.s1|28-31|used|O
DDI-DrugBank.d498.s1|33-34|in|O
DDI-DrugBank.d498.s1|36-38|the|O
DDI-DrugBank.d498.s1|40-49|myasthenic|O
DDI-DrugBank.d498.s1|51-57|patient|O
DDI-DrugBank.d498.s1|59-62|only|O
DDI-DrugBank.d498.s1|64-68|where|O
DDI-DrugBank.d498.s1|70-79|definitely|O
DDI-DrugBank.d498.s1|81-89|indicated|O
DDI-DrugBank.d498.s1|90-90|,|O
DDI-DrugBank.d498.s1|92-94|and|O
DDI-DrugBank.d498.s1|96-99|then|O
DDI-DrugBank.d498.s1|101-107|careful|O
DDI-DrugBank.d498.s1|109-118|adjustment|O
DDI-DrugBank.d498.s1|120-125|should|O
DDI-DrugBank.d498.s1|127-128|be|O
DDI-DrugBank.d498.s1|130-133|made|O
DDI-DrugBank.d498.s1|135-136|of|O
DDI-DrugBank.d498.s1|138-147|adjunctive|O
DDI-DrugBank.d498.s1|149-166|anticholinesterase|group
DDI-DrugBank.d498.s1|168-173|dosage|O
DDI-DrugBank.d498.s1|174-174|.|O
DDI-DrugBank.d498.s2|0-4|Local|O
DDI-DrugBank.d498.s2|6-8|and|O
DDI-DrugBank.d498.s2|10-13|some|O
DDI-DrugBank.d498.s2|15-21|general|O
DDI-DrugBank.d498.s2|23-33|anesthetics|group
DDI-DrugBank.d498.s2|34-34|,|O
DDI-DrugBank.d498.s2|36-56|antiarrhythmic agents|group
DDI-DrugBank.d498.s2|58-60|and|O
DDI-DrugBank.d498.s2|62-66|other|O
DDI-DrugBank.d498.s2|68-72|drugs|O
DDI-DrugBank.d498.s2|74-77|that|O
DDI-DrugBank.d498.s2|79-87|interfere|O
DDI-DrugBank.d498.s2|89-92|with|O
DDI-DrugBank.d498.s2|94-106|neuromuscular|O
DDI-DrugBank.d498.s2|108-119|transmission|O
DDI-DrugBank.d498.s2|121-126|should|O
DDI-DrugBank.d498.s2|128-129|be|O
DDI-DrugBank.d498.s2|131-134|used|O
DDI-DrugBank.d498.s2|136-145|cautiously|O
DDI-DrugBank.d498.s2|146-146|,|O
DDI-DrugBank.d498.s2|148-149|if|O
DDI-DrugBank.d498.s2|151-152|at|O
DDI-DrugBank.d498.s2|154-156|all|O
DDI-DrugBank.d498.s2|157-157|,|O
DDI-DrugBank.d498.s2|159-160|in|O
DDI-DrugBank.d498.s2|162-169|patients|O
DDI-DrugBank.d498.s2|171-174|with|O
DDI-DrugBank.d498.s2|176-185|myasthenia|O
DDI-DrugBank.d498.s2|187-192|gravis|O
DDI-DrugBank.d498.s2|193-193|;|O
DDI-DrugBank.d498.s3|0-2|the|O
DDI-DrugBank.d498.s3|4-7|dose|O
DDI-DrugBank.d498.s3|9-10|of|O
DDI-DrugBank.d498.s3|12-21|Prostigmin|brand
DDI-DrugBank.d498.s3|23-25|may|O
DDI-DrugBank.d498.s3|27-30|have|O
DDI-DrugBank.d498.s3|32-33|to|O
DDI-DrugBank.d498.s3|35-36|be|O
DDI-DrugBank.d498.s3|38-46|increased|O
DDI-DrugBank.d498.s3|48-58|accordingly|O
DDI-DrugBank.d498.s3|59-59|.|O
DDI-DrugBank.d779.s0|0-3|When|O
DDI-DrugBank.d779.s0|5-14|methyldopa|drug
DDI-DrugBank.d779.s0|16-17|is|O
DDI-DrugBank.d779.s0|19-22|used|O
DDI-DrugBank.d779.s0|24-27|with|O
DDI-DrugBank.d779.s0|29-33|other|O
DDI-DrugBank.d779.s0|35-56|antihypertensive drugs|group
DDI-DrugBank.d779.s0|57-57|,|O
DDI-DrugBank.d779.s0|59-70|potentiation|O
DDI-DrugBank.d779.s0|72-73|of|O
DDI-DrugBank.d779.s0|75-90|antihypertensive|O
DDI-DrugBank.d779.s0|92-97|effect|O
DDI-DrugBank.d779.s0|99-101|may|O
DDI-DrugBank.d779.s0|103-107|occur|O
DDI-DrugBank.d779.s0|108-108|.|O
DDI-DrugBank.d779.s1|0-7|Patients|O
DDI-DrugBank.d779.s1|9-14|should|O
DDI-DrugBank.d779.s1|16-17|be|O
DDI-DrugBank.d779.s1|19-26|followed|O
DDI-DrugBank.d779.s1|28-36|carefully|O
DDI-DrugBank.d779.s1|38-39|to|O
DDI-DrugBank.d779.s1|41-46|detect|O
DDI-DrugBank.d779.s1|48-51|side|O
DDI-DrugBank.d779.s1|53-61|reactions|O
DDI-DrugBank.d779.s1|63-64|or|O
DDI-DrugBank.d779.s1|66-72|unusual|O
DDI-DrugBank.d779.s1|74-87|manifestations|O
DDI-DrugBank.d779.s1|89-90|of|O
DDI-DrugBank.d779.s1|92-95|drug|O
DDI-DrugBank.d779.s1|97-108|idiosyncrasy|O
DDI-DrugBank.d779.s1|109-109|.|O
DDI-DrugBank.d779.s2|0-7|Patients|O
DDI-DrugBank.d779.s2|9-11|may|O
DDI-DrugBank.d779.s2|13-19|require|O
DDI-DrugBank.d779.s2|21-27|reduced|O
DDI-DrugBank.d779.s2|29-33|doses|O
DDI-DrugBank.d779.s2|35-36|of|O
DDI-DrugBank.d779.s2|38-48|anesthetics|group
DDI-DrugBank.d779.s2|50-53|when|O
DDI-DrugBank.d779.s2|55-56|on|O
DDI-DrugBank.d779.s2|58-67|methyldopa|drug
DDI-DrugBank.d779.s2|68-68|.|O
DDI-DrugBank.d779.s3|0-1|If|O
DDI-DrugBank.d779.s3|3-13|hypotension|O
DDI-DrugBank.d779.s3|15-18|does|O
DDI-DrugBank.d779.s3|20-24|occur|O
DDI-DrugBank.d779.s3|26-31|during|O
DDI-DrugBank.d779.s3|33-42|anesthesia|O
DDI-DrugBank.d779.s3|43-43|,|O
DDI-DrugBank.d779.s3|45-46|it|O
DDI-DrugBank.d779.s3|48-54|usually|O
DDI-DrugBank.d779.s3|56-58|can|O
DDI-DrugBank.d779.s3|60-61|be|O
DDI-DrugBank.d779.s3|63-72|controlled|O
DDI-DrugBank.d779.s3|74-75|by|O
DDI-DrugBank.d779.s3|77-88|vasopressors|group
DDI-DrugBank.d779.s3|89-89|.|O
DDI-DrugBank.d779.s4|0-2|The|O
DDI-DrugBank.d779.s4|4-13|adrenergic|O
DDI-DrugBank.d779.s4|15-23|receptors|O
DDI-DrugBank.d779.s4|25-30|remain|O
DDI-DrugBank.d779.s4|32-40|sensitive|O
DDI-DrugBank.d779.s4|42-47|during|O
DDI-DrugBank.d779.s4|49-57|treatment|O
DDI-DrugBank.d779.s4|59-62|with|O
DDI-DrugBank.d779.s4|64-73|methyldopa|drug
DDI-DrugBank.d779.s4|74-74|.|O
DDI-DrugBank.d779.s5|0-3|When|O
DDI-DrugBank.d779.s5|5-14|methyldopa|drug
DDI-DrugBank.d779.s5|16-18|and|O
DDI-DrugBank.d779.s5|20-26|lithium|drug
DDI-DrugBank.d779.s5|28-30|are|O
DDI-DrugBank.d779.s5|32-36|given|O
DDI-DrugBank.d779.s5|38-50|concomitantly|O
DDI-DrugBank.d779.s5|52-54|the|O
DDI-DrugBank.d779.s5|56-62|patient|O
DDI-DrugBank.d779.s5|64-69|should|O
DDI-DrugBank.d779.s5|71-72|be|O
DDI-DrugBank.d779.s5|74-82|carefully|O
DDI-DrugBank.d779.s5|84-92|monitored|O
DDI-DrugBank.d779.s5|94-96|for|O
DDI-DrugBank.d779.s5|98-105|symptoms|O
DDI-DrugBank.d779.s5|107-108|of|O
DDI-DrugBank.d779.s5|110-116|lithium|drug
DDI-DrugBank.d779.s5|118-125|toxicity|O
DDI-DrugBank.d779.s5|126-126|.|O
DDI-DrugBank.d779.s6|0-3|Read|O
DDI-DrugBank.d779.s6|5-7|the|O
DDI-DrugBank.d779.s6|9-16|circular|O
DDI-DrugBank.d779.s6|18-20|for|O
DDI-DrugBank.d779.s6|22-28|lithium|drug
DDI-DrugBank.d779.s6|30-41|preparations|O
DDI-DrugBank.d779.s6|42-42|.|O
DDI-DrugBank.d779.s7|0-6|Several|O
DDI-DrugBank.d779.s7|8-14|studies|O
DDI-DrugBank.d779.s7|16-26|demonstrate|O
DDI-DrugBank.d779.s7|28-28|a|O
DDI-DrugBank.d779.s7|30-37|decrease|O
DDI-DrugBank.d779.s7|39-40|in|O
DDI-DrugBank.d779.s7|42-44|the|O
DDI-DrugBank.d779.s7|46-60|bioavailability|O
DDI-DrugBank.d779.s7|62-63|of|O
DDI-DrugBank.d779.s7|65-74|methyldopa|drug
DDI-DrugBank.d779.s7|76-79|when|O
DDI-DrugBank.d779.s7|81-82|it|O
DDI-DrugBank.d779.s7|84-85|is|O
DDI-DrugBank.d779.s7|87-94|ingested|O
DDI-DrugBank.d779.s7|96-99|with|O
DDI-DrugBank.d779.s7|101-115|ferrous sulfate|drug
DDI-DrugBank.d779.s7|117-118|or|O
DDI-DrugBank.d779.s7|120-136|ferrous gluconate|drug
DDI-DrugBank.d779.s7|137-137|.|O
DDI-DrugBank.d779.s8|0-3|This|O
DDI-DrugBank.d779.s8|5-7|may|O
DDI-DrugBank.d779.s8|9-17|adversely|O
DDI-DrugBank.d779.s8|19-24|affect|O
DDI-DrugBank.d779.s8|26-30|blood|O
DDI-DrugBank.d779.s8|32-39|pressure|O
DDI-DrugBank.d779.s8|41-47|control|O
DDI-DrugBank.d779.s8|49-50|in|O
DDI-DrugBank.d779.s8|52-59|patients|O
DDI-DrugBank.d779.s8|61-67|treated|O
DDI-DrugBank.d779.s8|69-72|with|O
DDI-DrugBank.d779.s8|74-83|methyldopa|drug
DDI-DrugBank.d779.s8|84-84|.|O
DDI-DrugBank.d779.s9|0-15|Coadministration|O
DDI-DrugBank.d779.s9|17-18|of|O
DDI-DrugBank.d779.s9|20-29|methyldopa|drug
DDI-DrugBank.d779.s9|31-34|with|O
DDI-DrugBank.d779.s9|36-50|ferrous sulfate|drug
DDI-DrugBank.d779.s9|52-53|or|O
DDI-DrugBank.d779.s9|55-71|ferrous gluconate|drug
DDI-DrugBank.d779.s9|73-74|is|O
DDI-DrugBank.d779.s9|76-78|not|O
DDI-DrugBank.d779.s9|80-90|recommended|O
DDI-DrugBank.d779.s9|91-91|.|O
DDI-DrugBank.d779.s10|0-33|Monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d779.s10|34-34|:|O
DDI-DrugBank.d779.s10|36-38|See|O
DDI-DrugBank.d779.s10|40-56|CONTRAINDICATIONS|O
DDI-DrugBank.d779.s10|57-57|.|O
DDI-DrugBank.d779.s11|0-14|Drug/Laboratory|O
DDI-DrugBank.d779.s11|16-19|Test|O
DDI-DrugBank.d779.s11|21-32|Interactions|O
DDI-DrugBank.d779.s11|34-43|Methyldopa|drug
DDI-DrugBank.d779.s11|45-47|may|O
DDI-DrugBank.d779.s11|49-57|interfere|O
DDI-DrugBank.d779.s11|59-62|with|O
DDI-DrugBank.d779.s11|64-74|measurement|O
DDI-DrugBank.d779.s11|76-77|of|O
DDI-DrugBank.d779.s11|78-78|:|O
DDI-DrugBank.d779.s11|80-86|urinary|O
DDI-DrugBank.d779.s11|88-91|uric|O
DDI-DrugBank.d779.s11|93-96|acid|O
DDI-DrugBank.d779.s11|98-99|by|O
DDI-DrugBank.d779.s11|101-103|the|O
DDI-DrugBank.d779.s11|105-120|phosphotungstate|O
DDI-DrugBank.d779.s11|122-127|method|O
DDI-DrugBank.d779.s11|128-128|,|O
DDI-DrugBank.d779.s11|130-134|serum|O
DDI-DrugBank.d779.s11|136-145|creatinine|O
DDI-DrugBank.d779.s11|147-148|by|O
DDI-DrugBank.d779.s11|150-152|the|O
DDI-DrugBank.d779.s11|154-161|alkaline|O
DDI-DrugBank.d779.s11|163-169|picrate|O
DDI-DrugBank.d779.s11|171-176|method|O
DDI-DrugBank.d779.s11|177-177|,|O
DDI-DrugBank.d779.s11|179-181|and|O
DDI-DrugBank.d779.s11|183-186|SGOT|O
DDI-DrugBank.d779.s11|188-189|by|O
DDI-DrugBank.d779.s11|191-202|colorimetric|O
DDI-DrugBank.d779.s11|204-210|methods|O
DDI-DrugBank.d779.s11|211-211|.|O
DDI-DrugBank.d779.s12|0-11|Interference|O
DDI-DrugBank.d779.s12|13-16|with|O
DDI-DrugBank.d779.s12|18-35|spectrophotometric|O
DDI-DrugBank.d779.s12|37-43|methods|O
DDI-DrugBank.d779.s12|45-47|for|O
DDI-DrugBank.d779.s12|49-52|SGOT|O
DDI-DrugBank.d779.s12|54-61|analysis|O
DDI-DrugBank.d779.s12|63-65|has|O
DDI-DrugBank.d779.s12|67-69|not|O
DDI-DrugBank.d779.s12|71-74|been|O
DDI-DrugBank.d779.s12|76-83|reported|O
DDI-DrugBank.d779.s12|84-84|.|O
DDI-DrugBank.d779.s13|0-4|Since|O
DDI-DrugBank.d779.s13|6-15|methyldopa|drug
DDI-DrugBank.d779.s13|17-22|causes|O
DDI-DrugBank.d779.s13|24-35|fluorescence|O
DDI-DrugBank.d779.s13|37-38|in|O
DDI-DrugBank.d779.s13|40-44|urine|O
DDI-DrugBank.d779.s13|46-52|samples|O
DDI-DrugBank.d779.s13|54-55|at|O
DDI-DrugBank.d779.s13|57-59|the|O
DDI-DrugBank.d779.s13|61-64|same|O
DDI-DrugBank.d779.s13|66-69|wave|O
DDI-DrugBank.d779.s13|71-77|lengths|O
DDI-DrugBank.d779.s13|79-80|as|O
DDI-DrugBank.d779.s13|82-95|catecholamines|O
DDI-DrugBank.d779.s13|96-96|,|O
DDI-DrugBank.d779.s13|98-104|falsely|O
DDI-DrugBank.d779.s13|106-109|high|O
DDI-DrugBank.d779.s13|111-116|levels|O
DDI-DrugBank.d779.s13|118-119|of|O
DDI-DrugBank.d779.s13|121-127|urinary|O
DDI-DrugBank.d779.s13|129-142|catecholamines|O
DDI-DrugBank.d779.s13|144-146|may|O
DDI-DrugBank.d779.s13|148-149|be|O
DDI-DrugBank.d779.s13|151-158|reported|O
DDI-DrugBank.d779.s13|159-159|.|O
DDI-DrugBank.d779.s14|0-3|This|O
DDI-DrugBank.d779.s14|5-8|will|O
DDI-DrugBank.d779.s14|10-18|interfere|O
DDI-DrugBank.d779.s14|20-23|with|O
DDI-DrugBank.d779.s14|25-27|the|O
DDI-DrugBank.d779.s14|29-37|diagnosis|O
DDI-DrugBank.d779.s14|39-40|of|O
DDI-DrugBank.d779.s14|42-57|pheochromocytoma|O
DDI-DrugBank.d779.s14|58-58|.|O
DDI-DrugBank.d779.s15|0-1|It|O
DDI-DrugBank.d779.s15|3-4|is|O
DDI-DrugBank.d779.s15|6-14|important|O
DDI-DrugBank.d779.s15|16-17|to|O
DDI-DrugBank.d779.s15|19-27|recognize|O
DDI-DrugBank.d779.s15|29-32|this|O
DDI-DrugBank.d779.s15|34-43|phenomenon|O
DDI-DrugBank.d779.s15|45-50|before|O
DDI-DrugBank.d779.s15|52-52|a|O
DDI-DrugBank.d779.s15|54-60|patient|O
DDI-DrugBank.d779.s15|62-65|with|O
DDI-DrugBank.d779.s15|67-67|a|O
DDI-DrugBank.d779.s15|69-76|possible|O
DDI-DrugBank.d779.s15|78-93|pheochromocytoma|O
DDI-DrugBank.d779.s15|95-96|is|O
DDI-DrugBank.d779.s15|98-106|subjected|O
DDI-DrugBank.d779.s15|108-109|to|O
DDI-DrugBank.d779.s15|111-117|surgery|O
DDI-DrugBank.d779.s15|118-118|.|O
DDI-DrugBank.d779.s16|0-9|Methyldopa|drug
DDI-DrugBank.d779.s16|11-14|does|O
DDI-DrugBank.d779.s16|16-18|not|O
DDI-DrugBank.d779.s16|20-28|interfere|O
DDI-DrugBank.d779.s16|30-33|with|O
DDI-DrugBank.d779.s16|35-45|measurement|O
DDI-DrugBank.d779.s16|47-48|of|O
DDI-DrugBank.d779.s16|54-54|(|O
DDI-DrugBank.d779.s16|76-76|)|O
DDI-DrugBank.d779.s16|77-77|,|O
DDI-DrugBank.d779.s16|79-79|a|O
DDI-DrugBank.d779.s16|81-84|test|O
DDI-DrugBank.d779.s16|86-88|for|O
DDI-DrugBank.d779.s16|90-105|pheochromocytoma|O
DDI-DrugBank.d779.s16|106-106|,|O
DDI-DrugBank.d779.s16|108-109|by|O
DDI-DrugBank.d779.s16|111-115|those|O
DDI-DrugBank.d779.s16|117-123|methods|O
DDI-DrugBank.d779.s16|125-129|which|O
DDI-DrugBank.d779.s16|131-137|convert|O
DDI-DrugBank.d779.s16|143-144|to|O
DDI-DrugBank.d779.s16|154-154|.|O
DDI-DrugBank.d779.s17|0-9|Methyldopa|drug
DDI-DrugBank.d779.s17|11-12|is|O
DDI-DrugBank.d779.s17|14-16|not|O
DDI-DrugBank.d779.s17|18-28|recommended|O
DDI-DrugBank.d779.s17|30-32|for|O
DDI-DrugBank.d779.s17|34-36|the|O
DDI-DrugBank.d779.s17|38-46|treatment|O
DDI-DrugBank.d779.s17|48-49|of|O
DDI-DrugBank.d779.s17|51-58|patients|O
DDI-DrugBank.d779.s17|60-63|with|O
DDI-DrugBank.d779.s17|65-80|pheochromocytoma|O
DDI-DrugBank.d779.s17|81-81|.|O
DDI-DrugBank.d779.s18|0-5|Rarely|O
DDI-DrugBank.d779.s18|6-6|,|O
DDI-DrugBank.d779.s18|8-11|when|O
DDI-DrugBank.d779.s18|13-17|urine|O
DDI-DrugBank.d779.s18|19-20|is|O
DDI-DrugBank.d779.s18|22-28|exposed|O
DDI-DrugBank.d779.s18|30-31|to|O
DDI-DrugBank.d779.s18|33-35|air|O
DDI-DrugBank.d779.s18|37-41|after|O
DDI-DrugBank.d779.s18|43-49|voiding|O
DDI-DrugBank.d779.s18|50-50|,|O
DDI-DrugBank.d779.s18|52-53|it|O
DDI-DrugBank.d779.s18|55-57|may|O
DDI-DrugBank.d779.s18|59-64|darken|O
DDI-DrugBank.d779.s18|66-72|because|O
DDI-DrugBank.d779.s18|74-75|of|O
DDI-DrugBank.d779.s18|77-85|breakdown|O
DDI-DrugBank.d779.s18|87-88|of|O
DDI-DrugBank.d779.s18|90-99|methyldopa|drug
DDI-DrugBank.d779.s18|101-102|or|O
DDI-DrugBank.d779.s18|104-106|its|O
DDI-DrugBank.d779.s18|108-118|metabolites|O
DDI-DrugBank.d779.s18|119-119|.|O
DDI-DrugBank.d689.s0|0-11|Vasopressors|group
DDI-DrugBank.d689.s0|12-12|,|O
DDI-DrugBank.d689.s0|14-25|particularly|O
DDI-DrugBank.d689.s0|27-37|metaraminol|drug
DDI-DrugBank.d689.s0|38-38|,|O
DDI-DrugBank.d689.s0|40-42|may|O
DDI-DrugBank.d689.s0|44-48|cause|O
DDI-DrugBank.d689.s0|50-56|serious|O
DDI-DrugBank.d689.s0|58-64|cardiac|O
DDI-DrugBank.d689.s0|66-76|arrhythmias|O
DDI-DrugBank.d689.s0|78-83|during|O
DDI-DrugBank.d689.s0|85-93|halothane|drug
DDI-DrugBank.d689.s0|95-104|anesthesia|O
DDI-DrugBank.d689.s0|106-108|and|O
DDI-DrugBank.d689.s0|110-118|therefore|O
DDI-DrugBank.d689.s0|120-125|should|O
DDI-DrugBank.d689.s0|127-128|be|O
DDI-DrugBank.d689.s0|130-133|used|O
DDI-DrugBank.d689.s0|135-138|only|O
DDI-DrugBank.d689.s0|140-143|with|O
DDI-DrugBank.d689.s0|145-149|great|O
DDI-DrugBank.d689.s0|151-157|caution|O
DDI-DrugBank.d689.s0|159-160|or|O
DDI-DrugBank.d689.s0|162-164|not|O
DDI-DrugBank.d689.s0|166-167|at|O
DDI-DrugBank.d689.s0|169-171|all|O
DDI-DrugBank.d689.s0|172-172|.|O
DDI-DrugBank.d689.s1|0-13|MAO Inhibitors|group
DDI-DrugBank.d689.s1|15-15|-|O
DDI-DrugBank.d689.s1|17-19|The|O
DDI-DrugBank.d689.s1|21-27|pressor|O
DDI-DrugBank.d689.s1|29-34|effect|O
DDI-DrugBank.d689.s1|36-37|of|O
DDI-DrugBank.d689.s1|39-68|sympathomimetic pressor amines|group
DDI-DrugBank.d689.s1|70-71|is|O
DDI-DrugBank.d689.s1|73-80|markedly|O
DDI-DrugBank.d689.s1|82-92|potentiated|O
DDI-DrugBank.d689.s1|94-95|in|O
DDI-DrugBank.d689.s1|97-104|patients|O
DDI-DrugBank.d689.s1|106-114|receiving|O
DDI-DrugBank.d689.s1|116-143|monoamine oxidase inhibitors|group
DDI-DrugBank.d689.s1|145-145|(|O
DDI-DrugBank.d689.s1|146-149|MAOI|group
DDI-DrugBank.d689.s1|150-150|)|O
DDI-DrugBank.d689.s1|151-151|.|O
DDI-DrugBank.d689.s2|0-8|Therefore|O
DDI-DrugBank.d689.s2|9-9|,|O
DDI-DrugBank.d689.s2|11-14|when|O
DDI-DrugBank.d689.s2|16-25|initiating|O
DDI-DrugBank.d689.s2|27-33|pressor|O
DDI-DrugBank.d689.s2|35-41|therapy|O
DDI-DrugBank.d689.s2|43-44|in|O
DDI-DrugBank.d689.s2|46-50|these|O
DDI-DrugBank.d689.s2|52-59|patients|O
DDI-DrugBank.d689.s2|60-60|,|O
DDI-DrugBank.d689.s2|62-64|the|O
DDI-DrugBank.d689.s2|66-72|initial|O
DDI-DrugBank.d689.s2|74-77|dose|O
DDI-DrugBank.d689.s2|79-84|should|O
DDI-DrugBank.d689.s2|86-87|be|O
DDI-DrugBank.d689.s2|89-93|small|O
DDI-DrugBank.d689.s2|95-97|and|O
DDI-DrugBank.d689.s2|99-102|used|O
DDI-DrugBank.d689.s2|104-107|with|O
DDI-DrugBank.d689.s2|109-111|due|O
DDI-DrugBank.d689.s2|113-119|caution|O
DDI-DrugBank.d689.s2|120-120|.|O
DDI-DrugBank.d689.s3|0-2|The|O
DDI-DrugBank.d689.s3|4-10|pressor|O
DDI-DrugBank.d689.s3|12-19|response|O
DDI-DrugBank.d689.s3|21-22|of|O
DDI-DrugBank.d689.s3|24-40|adrenergic agents|group
DDI-DrugBank.d689.s3|42-44|may|O
DDI-DrugBank.d689.s3|46-49|also|O
DDI-DrugBank.d689.s3|51-52|be|O
DDI-DrugBank.d689.s3|54-64|potentiated|O
DDI-DrugBank.d689.s3|66-67|by|O
DDI-DrugBank.d689.s3|69-93|tricyclic antidepressants|group
DDI-DrugBank.d689.s3|94-94|.|O
DDI-DrugBank.d596.s0|0-8|Drug-Drug|O
DDI-DrugBank.d596.s0|10-21|Interactions|O
DDI-DrugBank.d596.s0|23-28|Effect|O
DDI-DrugBank.d596.s0|30-31|of|O
DDI-DrugBank.d596.s0|33-38|Exelon|brand
DDI-DrugBank.d596.s0|43-43|(|O
DDI-DrugBank.d596.s0|44-64|rivastigmine tartrate|drug
DDI-DrugBank.d596.s0|65-65|)|O
DDI-DrugBank.d596.s0|67-68|on|O
DDI-DrugBank.d596.s0|70-72|the|O
DDI-DrugBank.d596.s0|74-83|Metabolism|O
DDI-DrugBank.d596.s0|85-86|of|O
DDI-DrugBank.d596.s0|88-92|Other|O
DDI-DrugBank.d596.s0|94-98|Drugs|O
DDI-DrugBank.d596.s0|99-99|:|O
DDI-DrugBank.d596.s0|101-112|Rivastigmine|drug
DDI-DrugBank.d596.s0|114-115|is|O
DDI-DrugBank.d596.s0|117-125|primarily|O
DDI-DrugBank.d596.s0|127-137|metabolized|O
DDI-DrugBank.d596.s0|139-145|through|O
DDI-DrugBank.d596.s0|147-156|hydrolysis|O
DDI-DrugBank.d596.s0|158-159|by|O
DDI-DrugBank.d596.s0|161-169|esterases|O
DDI-DrugBank.d596.s0|170-170|.|O
DDI-DrugBank.d596.s1|0-6|Minimal|O
DDI-DrugBank.d596.s1|8-17|metabolism|O
DDI-DrugBank.d596.s1|19-24|occurs|O
DDI-DrugBank.d596.s1|26-28|via|O
DDI-DrugBank.d596.s1|30-32|the|O
DDI-DrugBank.d596.s1|34-38|major|O
DDI-DrugBank.d596.s1|40-49|cytochrome|O
DDI-DrugBank.d596.s1|51-54|P450|O
DDI-DrugBank.d596.s1|56-65|isoenzymes|O
DDI-DrugBank.d596.s1|66-66|.|O
DDI-DrugBank.d596.s2|0-4|Based|O
DDI-DrugBank.d596.s2|6-7|on|O
DDI-DrugBank.d596.s2|9-10|in|O
DDI-DrugBank.d596.s2|12-16|vitro|O
DDI-DrugBank.d596.s2|18-24|studies|O
DDI-DrugBank.d596.s2|25-25|,|O
DDI-DrugBank.d596.s2|27-28|no|O
DDI-DrugBank.d596.s2|30-44|pharmacokinetic|O
DDI-DrugBank.d596.s2|46-49|drug|O
DDI-DrugBank.d596.s2|51-62|interactions|O
DDI-DrugBank.d596.s2|64-67|with|O
DDI-DrugBank.d596.s2|69-73|drugs|O
DDI-DrugBank.d596.s2|75-85|metabolized|O
DDI-DrugBank.d596.s2|87-88|by|O
DDI-DrugBank.d596.s2|90-92|the|O
DDI-DrugBank.d596.s2|94-102|following|O
DDI-DrugBank.d596.s2|104-112|isoenzyme|O
DDI-DrugBank.d596.s2|114-120|systems|O
DDI-DrugBank.d596.s2|122-124|are|O
DDI-DrugBank.d596.s2|126-133|expected|O
DDI-DrugBank.d596.s2|134-134|:|O
DDI-DrugBank.d596.s2|136-141|CYP1A2|O
DDI-DrugBank.d596.s2|142-142|,|O
DDI-DrugBank.d596.s2|144-149|CYP2D6|O
DDI-DrugBank.d596.s2|150-150|,|O
DDI-DrugBank.d596.s2|152-159|CYP3A4/5|O
DDI-DrugBank.d596.s2|160-160|,|O
DDI-DrugBank.d596.s2|162-167|CYP2E1|O
DDI-DrugBank.d596.s2|168-168|,|O
DDI-DrugBank.d596.s2|170-175|CYP2C9|O
DDI-DrugBank.d596.s2|176-176|,|O
DDI-DrugBank.d596.s2|178-183|CYP2C8|O
DDI-DrugBank.d596.s2|184-184|,|O
DDI-DrugBank.d596.s2|186-187|or|O
DDI-DrugBank.d596.s2|189-195|CYP2C19|O
DDI-DrugBank.d596.s2|196-196|.|O
DDI-DrugBank.d596.s3|0-1|No|O
DDI-DrugBank.d596.s3|3-17|pharmacokinetic|O
DDI-DrugBank.d596.s3|19-29|interaction|O
DDI-DrugBank.d596.s3|31-33|was|O
DDI-DrugBank.d596.s3|35-42|observed|O
DDI-DrugBank.d596.s3|44-50|between|O
DDI-DrugBank.d596.s3|52-63|rivastigmine|drug
DDI-DrugBank.d596.s3|65-67|and|O
DDI-DrugBank.d596.s3|69-75|digoxin|drug
DDI-DrugBank.d596.s3|76-76|,|O
DDI-DrugBank.d596.s3|78-85|warfarin|drug
DDI-DrugBank.d596.s3|86-86|,|O
DDI-DrugBank.d596.s3|88-95|diazepam|drug
DDI-DrugBank.d596.s3|96-96|,|O
DDI-DrugBank.d596.s3|98-99|or|O
DDI-DrugBank.d596.s3|101-110|fluoxetine|drug
DDI-DrugBank.d596.s3|112-113|in|O
DDI-DrugBank.d596.s3|115-121|studies|O
DDI-DrugBank.d596.s3|123-124|in|O
DDI-DrugBank.d596.s3|126-132|healthy|O
DDI-DrugBank.d596.s3|134-143|volunteers|O
DDI-DrugBank.d596.s3|144-144|.|O
DDI-DrugBank.d596.s4|0-2|The|O
DDI-DrugBank.d596.s4|4-12|elevation|O
DDI-DrugBank.d596.s4|14-15|of|O
DDI-DrugBank.d596.s4|17-27|prothrombin|O
DDI-DrugBank.d596.s4|29-32|time|O
DDI-DrugBank.d596.s4|34-40|induced|O
DDI-DrugBank.d596.s4|42-43|by|O
DDI-DrugBank.d596.s4|45-52|warfarin|drug
DDI-DrugBank.d596.s4|54-55|is|O
DDI-DrugBank.d596.s4|57-59|not|O
DDI-DrugBank.d596.s4|61-68|affected|O
DDI-DrugBank.d596.s4|70-71|by|O
DDI-DrugBank.d596.s4|73-86|administration|O
DDI-DrugBank.d596.s4|88-89|of|O
DDI-DrugBank.d596.s4|91-96|Exelon|brand
DDI-DrugBank.d596.s4|97-97|.|O
DDI-DrugBank.d596.s5|0-5|Effect|O
DDI-DrugBank.d596.s5|7-8|of|O
DDI-DrugBank.d596.s5|10-14|Other|O
DDI-DrugBank.d596.s5|16-20|Drugs|O
DDI-DrugBank.d596.s5|22-23|on|O
DDI-DrugBank.d596.s5|25-27|the|O
DDI-DrugBank.d596.s5|29-38|Metabolism|O
DDI-DrugBank.d596.s5|40-41|of|O
DDI-DrugBank.d596.s5|43-48|Exelon|brand
DDI-DrugBank.d596.s5|49-49|:|O
DDI-DrugBank.d596.s5|51-55|Drugs|O
DDI-DrugBank.d596.s5|57-60|that|O
DDI-DrugBank.d596.s5|62-67|induce|O
DDI-DrugBank.d596.s5|69-70|or|O
DDI-DrugBank.d596.s5|72-78|inhibit|O
DDI-DrugBank.d596.s5|80-85|CYP450|O
DDI-DrugBank.d596.s5|87-96|metabolism|O
DDI-DrugBank.d596.s5|98-100|are|O
DDI-DrugBank.d596.s5|102-104|not|O
DDI-DrugBank.d596.s5|106-113|expected|O
DDI-DrugBank.d596.s5|115-116|to|O
DDI-DrugBank.d596.s5|118-122|alter|O
DDI-DrugBank.d596.s5|124-126|the|O
DDI-DrugBank.d596.s5|128-137|metabolism|O
DDI-DrugBank.d596.s5|139-140|of|O
DDI-DrugBank.d596.s5|142-153|rivastigmine|drug
DDI-DrugBank.d596.s5|154-154|.|O
DDI-DrugBank.d596.s6|0-5|Single|O
DDI-DrugBank.d596.s6|7-10|dose|O
DDI-DrugBank.d596.s6|12-26|pharmacokinetic|O
DDI-DrugBank.d596.s6|28-34|studies|O
DDI-DrugBank.d596.s6|36-47|demonstrated|O
DDI-DrugBank.d596.s6|49-52|that|O
DDI-DrugBank.d596.s6|54-56|the|O
DDI-DrugBank.d596.s6|58-67|metabolism|O
DDI-DrugBank.d596.s6|69-70|of|O
DDI-DrugBank.d596.s6|72-83|rivastigmine|drug
DDI-DrugBank.d596.s6|85-86|is|O
DDI-DrugBank.d596.s6|88-90|not|O
DDI-DrugBank.d596.s6|92-104|significantly|O
DDI-DrugBank.d596.s6|106-113|affected|O
DDI-DrugBank.d596.s6|115-116|by|O
DDI-DrugBank.d596.s6|118-127|concurrent|O
DDI-DrugBank.d596.s6|129-142|administration|O
DDI-DrugBank.d596.s6|144-145|of|O
DDI-DrugBank.d596.s6|147-153|digoxin|drug
DDI-DrugBank.d596.s6|154-154|,|O
DDI-DrugBank.d596.s6|156-163|warfarin|drug
DDI-DrugBank.d596.s6|164-164|,|O
DDI-DrugBank.d596.s6|166-173|diazepam|drug
DDI-DrugBank.d596.s6|174-174|,|O
DDI-DrugBank.d596.s6|176-177|or|O
DDI-DrugBank.d596.s6|179-188|fluoxetine|drug
DDI-DrugBank.d596.s6|189-189|.|O
DDI-DrugBank.d596.s7|0-9|Population|O
DDI-DrugBank.d596.s7|11-12|PK|O
DDI-DrugBank.d596.s7|14-21|analysis|O
DDI-DrugBank.d596.s7|23-26|with|O
DDI-DrugBank.d596.s7|28-28|a|O
DDI-DrugBank.d596.s7|30-37|database|O
DDI-DrugBank.d596.s7|39-40|of|O
DDI-DrugBank.d596.s7|42-44|625|O
DDI-DrugBank.d596.s7|46-53|patients|O
DDI-DrugBank.d596.s7|55-60|showed|O
DDI-DrugBank.d596.s7|62-65|that|O
DDI-DrugBank.d596.s7|67-69|the|O
DDI-DrugBank.d596.s7|71-86|pharmacokinetics|O
DDI-DrugBank.d596.s7|88-89|of|O
DDI-DrugBank.d596.s7|91-102|rivastigmine|drug
DDI-DrugBank.d596.s7|104-107|were|O
DDI-DrugBank.d596.s7|109-111|not|O
DDI-DrugBank.d596.s7|113-122|influenced|O
DDI-DrugBank.d596.s7|124-125|by|O
DDI-DrugBank.d596.s7|127-134|commonly|O
DDI-DrugBank.d596.s7|136-145|prescribed|O
DDI-DrugBank.d596.s7|147-157|medications|O
DDI-DrugBank.d596.s7|159-162|such|O
DDI-DrugBank.d596.s7|164-165|as|O
DDI-DrugBank.d596.s7|167-174|antacids|group
DDI-DrugBank.d596.s7|176-176|(|O
DDI-DrugBank.d596.s7|177-180|n=77|O
DDI-DrugBank.d596.s7|181-181|)|O
DDI-DrugBank.d596.s7|182-182|,|O
DDI-DrugBank.d596.s7|184-200|antihypertensives|group
DDI-DrugBank.d596.s7|202-202|(|O
DDI-DrugBank.d596.s7|203-206|n=72|O
DDI-DrugBank.d596.s7|207-207|)|O
DDI-DrugBank.d596.s7|208-208|,|O
DDI-DrugBank.d596.s7|210-233|calcium channel blockers|group
DDI-DrugBank.d596.s7|235-235|(|O
DDI-DrugBank.d596.s7|236-239|n=75|O
DDI-DrugBank.d596.s7|240-240|)|O
DDI-DrugBank.d596.s7|241-241|,|O
DDI-DrugBank.d596.s7|243-255|antidiabetics|group
DDI-DrugBank.d596.s7|257-257|(|O
DDI-DrugBank.d596.s7|258-261|n=21|O
DDI-DrugBank.d596.s7|262-262|)|O
DDI-DrugBank.d596.s7|263-263|,|O
DDI-DrugBank.d596.s7|265-300|nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d596.s7|302-302|(|O
DDI-DrugBank.d596.s7|303-306|n=79|O
DDI-DrugBank.d596.s7|307-307|)|O
DDI-DrugBank.d596.s7|308-308|,|O
DDI-DrugBank.d596.s7|310-318|estrogens|group
DDI-DrugBank.d596.s7|320-320|(|O
DDI-DrugBank.d596.s7|321-324|n=70|O
DDI-DrugBank.d596.s7|325-325|)|O
DDI-DrugBank.d596.s7|326-326|,|O
DDI-DrugBank.d596.s7|328-348|salicylate analgesics|group
DDI-DrugBank.d596.s7|350-350|(|O
DDI-DrugBank.d596.s7|351-355|n=177|O
DDI-DrugBank.d596.s7|356-356|)|O
DDI-DrugBank.d596.s7|357-357|,|O
DDI-DrugBank.d596.s7|359-370|antianginals|group
DDI-DrugBank.d596.s7|372-372|(|O
DDI-DrugBank.d596.s7|373-376|n=35|O
DDI-DrugBank.d596.s7|377-377|)|O
DDI-DrugBank.d596.s7|378-378|,|O
DDI-DrugBank.d596.s7|380-382|and|O
DDI-DrugBank.d596.s7|384-397|antihistamines|group
DDI-DrugBank.d596.s7|399-399|(|O
DDI-DrugBank.d596.s7|400-403|n=15|O
DDI-DrugBank.d596.s7|404-404|)|O
DDI-DrugBank.d596.s7|405-405|.|O
DDI-DrugBank.d596.s8|0-2|Use|O
DDI-DrugBank.d596.s8|4-7|with|O
DDI-DrugBank.d596.s8|9-24|Anticholinergics|group
DDI-DrugBank.d596.s8|25-25|:|O
DDI-DrugBank.d596.s8|27-33|Because|O
DDI-DrugBank.d596.s8|35-36|of|O
DDI-DrugBank.d596.s8|38-42|their|O
DDI-DrugBank.d596.s8|44-52|mechanism|O
DDI-DrugBank.d596.s8|54-55|of|O
DDI-DrugBank.d596.s8|57-62|action|O
DDI-DrugBank.d596.s8|63-63|,|O
DDI-DrugBank.d596.s8|65-89|cholinesterase inhibitors|group
DDI-DrugBank.d596.s8|91-94|have|O
DDI-DrugBank.d596.s8|96-98|the|O
DDI-DrugBank.d596.s8|100-108|potential|O
DDI-DrugBank.d596.s8|110-111|to|O
DDI-DrugBank.d596.s8|113-121|interfere|O
DDI-DrugBank.d596.s8|123-126|with|O
DDI-DrugBank.d596.s8|128-130|the|O
DDI-DrugBank.d596.s8|132-139|activity|O
DDI-DrugBank.d596.s8|141-142|of|O
DDI-DrugBank.d596.s8|144-170|anticholinergic medications|group
DDI-DrugBank.d596.s8|171-171|.|O
DDI-DrugBank.d596.s9|0-2|Use|O
DDI-DrugBank.d596.s9|4-7|with|O
DDI-DrugBank.d596.s9|9-23|Cholinomimetics|group
DDI-DrugBank.d596.s9|25-27|and|O
DDI-DrugBank.d596.s9|29-33|Other|O
DDI-DrugBank.d596.s9|35-59|Cholinesterase Inhibitors|group
DDI-DrugBank.d596.s9|60-60|:|O
DDI-DrugBank.d596.s9|62-62|A|O
DDI-DrugBank.d596.s9|64-74|synergistic|O
DDI-DrugBank.d596.s9|76-81|effect|O
DDI-DrugBank.d596.s9|83-85|may|O
DDI-DrugBank.d596.s9|87-88|be|O
DDI-DrugBank.d596.s9|90-97|expected|O
DDI-DrugBank.d596.s9|99-102|when|O
DDI-DrugBank.d596.s9|104-128|cholinesterase inhibitors|group
DDI-DrugBank.d596.s9|130-132|are|O
DDI-DrugBank.d596.s9|134-138|given|O
DDI-DrugBank.d596.s9|140-151|concurrently|O
DDI-DrugBank.d596.s9|153-156|with|O
DDI-DrugBank.d596.s9|158-172|succinylcholine|drug
DDI-DrugBank.d596.s9|173-173|,|O
DDI-DrugBank.d596.s9|175-181|similar|O
DDI-DrugBank.d596.s9|183-211|neuromuscular blocking agents|group
DDI-DrugBank.d596.s9|213-214|or|O
DDI-DrugBank.d596.s9|216-235|cholinergic agonists|group
DDI-DrugBank.d596.s9|237-240|such|O
DDI-DrugBank.d596.s9|242-243|as|O
DDI-DrugBank.d596.s9|245-255|bethanechol|drug
DDI-DrugBank.d596.s9|256-256|.|O
DDI-DrugBank.d394.s0|0-2|The|O
DDI-DrugBank.d394.s0|4-14|hypotensive|O
DDI-DrugBank.d394.s0|16-21|effect|O
DDI-DrugBank.d394.s0|23-24|of|O
DDI-DrugBank.d394.s0|26-45|sodium nitroprusside|drug
DDI-DrugBank.d394.s0|47-48|is|O
DDI-DrugBank.d394.s0|50-58|augmented|O
DDI-DrugBank.d394.s0|60-61|by|O
DDI-DrugBank.d394.s0|63-66|that|O
DDI-DrugBank.d394.s0|68-69|of|O
DDI-DrugBank.d394.s0|71-74|most|O
DDI-DrugBank.d394.s0|76-80|other|O
DDI-DrugBank.d394.s0|82-98|hypotensive drugs|group
DDI-DrugBank.d394.s0|99-99|,|O
DDI-DrugBank.d394.s0|101-109|including|O
DDI-DrugBank.d394.s0|111-136|ganglionic blocking agents|group
DDI-DrugBank.d394.s0|137-137|,|O
DDI-DrugBank.d394.s0|139-146|negative|O
DDI-DrugBank.d394.s0|148-156|inotropic|O
DDI-DrugBank.d394.s0|158-163|agents|O
DDI-DrugBank.d394.s0|164-164|,|O
DDI-DrugBank.d394.s0|166-168|and|O
DDI-DrugBank.d394.s0|170-176|inhaled|O
DDI-DrugBank.d394.s0|178-188|anesthetics|group
DDI-DrugBank.d394.s0|189-189|.|O
DDI-DrugBank.d234.s0|0-10|Interaction|O
DDI-DrugBank.d234.s0|12-15|with|O
DDI-DrugBank.d234.s0|17-50|central nervous system depressants|group
DDI-DrugBank.d234.s0|52-56|other|O
DDI-DrugBank.d234.s0|58-61|than|O
DDI-DrugBank.d234.s0|63-77|benzodiazepines|group
DDI-DrugBank.d234.s0|79-81|has|O
DDI-DrugBank.d234.s0|83-85|not|O
DDI-DrugBank.d234.s0|87-90|been|O
DDI-DrugBank.d234.s0|92-103|specifically|O
DDI-DrugBank.d234.s0|105-111|studied|O
DDI-DrugBank.d234.s0|112-112|;|O
DDI-DrugBank.d234.s1|0-6|however|O
DDI-DrugBank.d234.s1|7-7|,|O
DDI-DrugBank.d234.s1|9-10|no|O
DDI-DrugBank.d234.s1|12-22|deleterious|O
DDI-DrugBank.d234.s1|24-35|interactions|O
DDI-DrugBank.d234.s1|37-40|were|O
DDI-DrugBank.d234.s1|42-45|seen|O
DDI-DrugBank.d234.s1|47-50|when|O
DDI-DrugBank.d234.s1|52-60|ROMAZICON|brand
DDI-DrugBank.d234.s1|62-64|was|O
DDI-DrugBank.d234.s1|66-77|administered|O
DDI-DrugBank.d234.s1|79-83|after|O
DDI-DrugBank.d234.s1|85-93|narcotics|group
DDI-DrugBank.d234.s1|94-94|,|O
DDI-DrugBank.d234.s1|96-107|inhalational|O
DDI-DrugBank.d234.s1|109-119|anesthetics|group
DDI-DrugBank.d234.s1|120-120|,|O
DDI-DrugBank.d234.s1|122-137|muscle relaxants|group
DDI-DrugBank.d234.s1|139-141|and|O
DDI-DrugBank.d234.s1|143-148|muscle|O
DDI-DrugBank.d234.s1|150-157|relaxant|O
DDI-DrugBank.d234.s1|159-169|antagonists|O
DDI-DrugBank.d234.s1|171-182|administered|O
DDI-DrugBank.d234.s1|184-185|in|O
DDI-DrugBank.d234.s1|187-197|conjunction|O
DDI-DrugBank.d234.s1|199-202|with|O
DDI-DrugBank.d234.s1|204-211|sedation|O
DDI-DrugBank.d234.s1|213-214|or|O
DDI-DrugBank.d234.s1|216-225|anesthesia|O
DDI-DrugBank.d234.s1|226-226|.|O
DDI-DrugBank.d234.s2|0-9|Particular|O
DDI-DrugBank.d234.s2|11-17|caution|O
DDI-DrugBank.d234.s2|19-20|is|O
DDI-DrugBank.d234.s2|22-30|necessary|O
DDI-DrugBank.d234.s2|32-35|when|O
DDI-DrugBank.d234.s2|37-41|using|O
DDI-DrugBank.d234.s2|43-51|ROMAZICON|brand
DDI-DrugBank.d234.s2|53-54|in|O
DDI-DrugBank.d234.s2|56-60|cases|O
DDI-DrugBank.d234.s2|62-63|of|O
DDI-DrugBank.d234.s2|65-69|mixed|O
DDI-DrugBank.d234.s2|71-74|drug|O
DDI-DrugBank.d234.s2|76-85|overdosage|O
DDI-DrugBank.d234.s2|87-91|since|O
DDI-DrugBank.d234.s2|93-95|the|O
DDI-DrugBank.d234.s2|97-101|toxic|O
DDI-DrugBank.d234.s2|103-109|effects|O
DDI-DrugBank.d234.s2|111-111|(|O
DDI-DrugBank.d234.s2|112-115|such|O
DDI-DrugBank.d234.s2|117-118|as|O
DDI-DrugBank.d234.s2|120-130|convulsions|O
DDI-DrugBank.d234.s2|132-134|and|O
DDI-DrugBank.d234.s2|136-142|cardiac|O
DDI-DrugBank.d234.s2|144-155|dysrhythmias|O
DDI-DrugBank.d234.s2|156-156|)|O
DDI-DrugBank.d234.s2|158-159|of|O
DDI-DrugBank.d234.s2|161-165|other|O
DDI-DrugBank.d234.s2|167-171|drugs|O
DDI-DrugBank.d234.s2|173-177|taken|O
DDI-DrugBank.d234.s2|179-180|in|O
DDI-DrugBank.d234.s2|182-189|overdose|O
DDI-DrugBank.d234.s2|191-191|(|O
DDI-DrugBank.d234.s2|192-201|especially|O
DDI-DrugBank.d234.s2|203-224|cyclic antidepressants|group
DDI-DrugBank.d234.s2|225-225|)|O
DDI-DrugBank.d234.s2|227-229|may|O
DDI-DrugBank.d234.s2|231-236|emerge|O
DDI-DrugBank.d234.s2|238-241|with|O
DDI-DrugBank.d234.s2|243-245|the|O
DDI-DrugBank.d234.s2|247-254|reversal|O
DDI-DrugBank.d234.s2|256-257|of|O
DDI-DrugBank.d234.s2|259-261|the|O
DDI-DrugBank.d234.s2|263-276|benzodiazepine|group
DDI-DrugBank.d234.s2|278-283|effect|O
DDI-DrugBank.d234.s2|285-286|by|O
DDI-DrugBank.d234.s2|288-297|flumazenil|drug
DDI-DrugBank.d234.s2|298-298|.|O
DDI-DrugBank.d234.s3|0-2|The|O
DDI-DrugBank.d234.s3|4-6|use|O
DDI-DrugBank.d234.s3|8-9|of|O
DDI-DrugBank.d234.s3|11-19|ROMAZICON|brand
DDI-DrugBank.d234.s3|21-22|is|O
DDI-DrugBank.d234.s3|24-26|not|O
DDI-DrugBank.d234.s3|28-38|recommended|O
DDI-DrugBank.d234.s3|40-41|in|O
DDI-DrugBank.d234.s3|43-51|epileptic|O
DDI-DrugBank.d234.s3|53-60|patients|O
DDI-DrugBank.d234.s3|62-64|who|O
DDI-DrugBank.d234.s3|66-69|have|O
DDI-DrugBank.d234.s3|71-74|been|O
DDI-DrugBank.d234.s3|76-84|receiving|O
DDI-DrugBank.d234.s3|86-99|benzodiazepine|O
DDI-DrugBank.d234.s3|101-109|treatment|O
DDI-DrugBank.d234.s3|111-113|for|O
DDI-DrugBank.d234.s3|115-115|a|O
DDI-DrugBank.d234.s3|117-125|prolonged|O
DDI-DrugBank.d234.s3|127-132|period|O
DDI-DrugBank.d234.s3|133-133|.|O
DDI-DrugBank.d234.s4|0-7|Although|O
DDI-DrugBank.d234.s4|9-17|ROMAZICON|brand
DDI-DrugBank.d234.s4|19-24|exerts|O
DDI-DrugBank.d234.s4|26-26|a|O
DDI-DrugBank.d234.s4|28-33|slight|O
DDI-DrugBank.d234.s4|35-43|intrinsic|O
DDI-DrugBank.d234.s4|45-58|anticonvulsant|O
DDI-DrugBank.d234.s4|60-65|effect|O
DDI-DrugBank.d234.s4|66-66|,|O
DDI-DrugBank.d234.s4|68-70|its|O
DDI-DrugBank.d234.s4|72-77|abrupt|O
DDI-DrugBank.d234.s4|79-89|suppression|O
DDI-DrugBank.d234.s4|91-92|of|O
DDI-DrugBank.d234.s4|94-96|the|O
DDI-DrugBank.d234.s4|98-107|protective|O
DDI-DrugBank.d234.s4|109-114|effect|O
DDI-DrugBank.d234.s4|116-117|of|O
DDI-DrugBank.d234.s4|119-119|a|O
DDI-DrugBank.d234.s4|121-134|benzodiazepine|group
DDI-DrugBank.d234.s4|136-142|agonist|O
DDI-DrugBank.d234.s4|144-146|can|O
DDI-DrugBank.d234.s4|148-151|give|O
DDI-DrugBank.d234.s4|153-156|rise|O
DDI-DrugBank.d234.s4|158-159|to|O
DDI-DrugBank.d234.s4|161-171|convulsions|O
DDI-DrugBank.d234.s4|173-174|in|O
DDI-DrugBank.d234.s4|176-184|epileptic|O
DDI-DrugBank.d234.s4|186-193|patients|O
DDI-DrugBank.d234.s4|194-194|.|O
DDI-DrugBank.d234.s5|0-8|ROMAZICON|brand
DDI-DrugBank.d234.s5|10-15|blocks|O
DDI-DrugBank.d234.s5|17-19|the|O
DDI-DrugBank.d234.s5|21-27|central|O
DDI-DrugBank.d234.s5|29-35|effects|O
DDI-DrugBank.d234.s5|37-38|of|O
DDI-DrugBank.d234.s5|40-54|benzodiazepines|group
DDI-DrugBank.d234.s5|56-57|by|O
DDI-DrugBank.d234.s5|59-69|competitive|O
DDI-DrugBank.d234.s5|71-81|interaction|O
DDI-DrugBank.d234.s5|83-84|at|O
DDI-DrugBank.d234.s5|86-88|the|O
DDI-DrugBank.d234.s5|90-97|receptor|O
DDI-DrugBank.d234.s5|99-103|level|O
DDI-DrugBank.d234.s5|104-104|.|O
DDI-DrugBank.d234.s6|0-2|The|O
DDI-DrugBank.d234.s6|4-10|effects|O
DDI-DrugBank.d234.s6|12-13|of|O
DDI-DrugBank.d234.s6|15-31|nonbenzodiazepine|O
DDI-DrugBank.d234.s6|33-40|agonists|O
DDI-DrugBank.d234.s6|42-43|at|O
DDI-DrugBank.d234.s6|45-58|benzodiazepine|O
DDI-DrugBank.d234.s6|60-68|receptors|O
DDI-DrugBank.d234.s6|69-69|,|O
DDI-DrugBank.d234.s6|71-74|such|O
DDI-DrugBank.d234.s6|76-77|as|O
DDI-DrugBank.d234.s6|79-87|zopiclone|drug
DDI-DrugBank.d234.s6|88-88|,|O
DDI-DrugBank.d234.s6|90-108|triazolopyridazines|O
DDI-DrugBank.d234.s6|110-112|and|O
DDI-DrugBank.d234.s6|114-119|others|O
DDI-DrugBank.d234.s6|120-120|,|O
DDI-DrugBank.d234.s6|122-124|are|O
DDI-DrugBank.d234.s6|126-129|also|O
DDI-DrugBank.d234.s6|131-137|blocked|O
DDI-DrugBank.d234.s6|139-140|by|O
DDI-DrugBank.d234.s6|142-150|ROMAZICON|brand
DDI-DrugBank.d234.s6|151-151|.|O
DDI-DrugBank.d234.s7|0-2|The|O
DDI-DrugBank.d234.s7|4-19|pharmacokinetics|O
DDI-DrugBank.d234.s7|21-22|of|O
DDI-DrugBank.d234.s7|24-38|benzodiazepines|group
DDI-DrugBank.d234.s7|40-42|are|O
DDI-DrugBank.d234.s7|44-52|unaltered|O
DDI-DrugBank.d234.s7|54-55|in|O
DDI-DrugBank.d234.s7|57-59|the|O
DDI-DrugBank.d234.s7|61-68|presence|O
DDI-DrugBank.d234.s7|70-71|of|O
DDI-DrugBank.d234.s7|73-82|flumazenil|drug
DDI-DrugBank.d234.s7|84-86|and|O
DDI-DrugBank.d234.s7|88-91|vice|O
DDI-DrugBank.d234.s7|93-97|versa|O
DDI-DrugBank.d234.s7|98-98|.|O
DDI-DrugBank.d234.s8|0-4|There|O
DDI-DrugBank.d234.s8|6-7|is|O
DDI-DrugBank.d234.s8|9-10|no|O
DDI-DrugBank.d234.s8|12-26|pharmacokinetic|O
DDI-DrugBank.d234.s8|28-38|interaction|O
DDI-DrugBank.d234.s8|40-46|between|O
DDI-DrugBank.d234.s8|48-54|ethanol|drug
DDI-DrugBank.d234.s8|56-58|and|O
DDI-DrugBank.d234.s8|60-69|flumazenil|drug
DDI-DrugBank.d234.s8|70-70|.|O
DDI-DrugBank.d234.s9|0-2|Use|O
DDI-DrugBank.d234.s9|4-5|in|O
DDI-DrugBank.d234.s9|7-16|Ambulatory|O
DDI-DrugBank.d234.s9|18-25|Patients|O
DDI-DrugBank.d234.s9|27-29|The|O
DDI-DrugBank.d234.s9|31-37|effects|O
DDI-DrugBank.d234.s9|39-40|of|O
DDI-DrugBank.d234.s9|42-50|ROMAZICON|brand
DDI-DrugBank.d234.s9|52-54|may|O
DDI-DrugBank.d234.s9|56-59|wear|O
DDI-DrugBank.d234.s9|61-63|off|O
DDI-DrugBank.d234.s9|65-70|before|O
DDI-DrugBank.d234.s9|72-72|a|O
DDI-DrugBank.d234.s9|74-99|long-acting benzodiazepine|group
DDI-DrugBank.d234.s9|101-102|is|O
DDI-DrugBank.d234.s9|104-113|completely|O
DDI-DrugBank.d234.s9|115-121|cleared|O
DDI-DrugBank.d234.s9|123-126|from|O
DDI-DrugBank.d234.s9|128-130|the|O
DDI-DrugBank.d234.s9|132-135|body|O
DDI-DrugBank.d234.s9|136-136|.|O
DDI-DrugBank.d234.s10|0-1|In|O
DDI-DrugBank.d234.s10|3-9|general|O
DDI-DrugBank.d234.s10|10-10|,|O
DDI-DrugBank.d234.s10|12-13|if|O
DDI-DrugBank.d234.s10|15-15|a|O
DDI-DrugBank.d234.s10|17-23|patient|O
DDI-DrugBank.d234.s10|25-29|shows|O
DDI-DrugBank.d234.s10|31-32|no|O
DDI-DrugBank.d234.s10|34-38|signs|O
DDI-DrugBank.d234.s10|40-41|of|O
DDI-DrugBank.d234.s10|43-50|sedation|O
DDI-DrugBank.d234.s10|52-57|within|O
DDI-DrugBank.d234.s10|59-59|2|O
DDI-DrugBank.d234.s10|61-65|hours|O
DDI-DrugBank.d234.s10|67-71|after|O
DDI-DrugBank.d234.s10|73-73|a|O
DDI-DrugBank.d234.s10|75-78|1-mg|O
DDI-DrugBank.d234.s10|80-83|dose|O
DDI-DrugBank.d234.s10|85-86|of|O
DDI-DrugBank.d234.s10|88-97|flumazenil|drug
DDI-DrugBank.d234.s10|98-98|,|O
DDI-DrugBank.d234.s10|100-106|serious|O
DDI-DrugBank.d234.s10|108-117|resedation|O
DDI-DrugBank.d234.s10|119-120|at|O
DDI-DrugBank.d234.s10|122-122|a|O
DDI-DrugBank.d234.s10|124-128|later|O
DDI-DrugBank.d234.s10|130-133|time|O
DDI-DrugBank.d234.s10|135-136|is|O
DDI-DrugBank.d234.s10|138-145|unlikely|O
DDI-DrugBank.d234.s10|146-146|.|O
DDI-DrugBank.d234.s11|0-1|An|O
DDI-DrugBank.d234.s11|3-10|adequate|O
DDI-DrugBank.d234.s11|12-17|period|O
DDI-DrugBank.d234.s11|19-20|of|O
DDI-DrugBank.d234.s11|22-32|observation|O
DDI-DrugBank.d234.s11|34-37|must|O
DDI-DrugBank.d234.s11|39-40|be|O
DDI-DrugBank.d234.s11|42-49|provided|O
DDI-DrugBank.d234.s11|51-53|for|O
DDI-DrugBank.d234.s11|55-57|any|O
DDI-DrugBank.d234.s11|59-65|patient|O
DDI-DrugBank.d234.s11|67-68|in|O
DDI-DrugBank.d234.s11|70-73|whom|O
DDI-DrugBank.d234.s11|75-80|either|O
DDI-DrugBank.d234.s11|82-108|long-acting benzodiazepines|group
DDI-DrugBank.d234.s11|110-110|(|O
DDI-DrugBank.d234.s11|111-114|such|O
DDI-DrugBank.d234.s11|116-117|as|O
DDI-DrugBank.d234.s11|119-126|diazepam|drug
DDI-DrugBank.d234.s11|127-127|)|O
DDI-DrugBank.d234.s11|129-130|or|O
DDI-DrugBank.d234.s11|132-136|large|O
DDI-DrugBank.d234.s11|138-142|doses|O
DDI-DrugBank.d234.s11|144-145|of|O
DDI-DrugBank.d234.s11|147-174|short-acting benzodiazepines|group
DDI-DrugBank.d234.s11|176-176|(|O
DDI-DrugBank.d234.s11|177-180|such|O
DDI-DrugBank.d234.s11|182-183|as|O
DDI-DrugBank.d234.s11|186-187|10|O
DDI-DrugBank.d234.s11|189-190|mg|O
DDI-DrugBank.d234.s11|192-193|of|O
DDI-DrugBank.d234.s11|195-203|midazolam|drug
DDI-DrugBank.d234.s11|204-204|)|O
DDI-DrugBank.d234.s11|206-209|have|O
DDI-DrugBank.d234.s11|211-214|been|O
DDI-DrugBank.d234.s11|216-219|used|O
DDI-DrugBank.d234.s11|220-220|.|O
DDI-DrugBank.d234.s12|0-6|Because|O
DDI-DrugBank.d234.s12|8-9|of|O
DDI-DrugBank.d234.s12|11-13|the|O
DDI-DrugBank.d234.s12|15-23|increased|O
DDI-DrugBank.d234.s12|25-28|risk|O
DDI-DrugBank.d234.s12|30-31|of|O
DDI-DrugBank.d234.s12|33-39|adverse|O
DDI-DrugBank.d234.s12|41-49|reactions|O
DDI-DrugBank.d234.s12|51-52|in|O
DDI-DrugBank.d234.s12|54-61|patients|O
DDI-DrugBank.d234.s12|63-65|who|O
DDI-DrugBank.d234.s12|67-70|have|O
DDI-DrugBank.d234.s12|72-75|been|O
DDI-DrugBank.d234.s12|77-82|taking|O
DDI-DrugBank.d234.s12|84-98|benzodiazepines|group
DDI-DrugBank.d234.s12|100-101|on|O
DDI-DrugBank.d234.s12|103-103|a|O
DDI-DrugBank.d234.s12|105-111|regular|O
DDI-DrugBank.d234.s12|113-117|basis|O
DDI-DrugBank.d234.s12|118-118|,|O
DDI-DrugBank.d234.s12|120-121|it|O
DDI-DrugBank.d234.s12|123-124|is|O
DDI-DrugBank.d234.s12|126-137|particularly|O
DDI-DrugBank.d234.s12|139-147|important|O
DDI-DrugBank.d234.s12|149-152|that|O
DDI-DrugBank.d234.s12|154-163|physicians|O
DDI-DrugBank.d234.s12|165-169|query|O
DDI-DrugBank.d234.s12|171-178|patients|O
DDI-DrugBank.d234.s12|180-181|or|O
DDI-DrugBank.d234.s12|183-187|their|O
DDI-DrugBank.d234.s12|189-197|guardians|O
DDI-DrugBank.d234.s12|199-207|carefully|O
DDI-DrugBank.d234.s12|209-213|about|O
DDI-DrugBank.d234.s12|215-228|benzodiazepine|group
DDI-DrugBank.d234.s12|229-229|,|O
DDI-DrugBank.d234.s12|231-237|alcohol|drug
DDI-DrugBank.d234.s12|239-241|and|O
DDI-DrugBank.d234.s12|243-250|sedative|group
DDI-DrugBank.d234.s12|252-254|use|O
DDI-DrugBank.d234.s12|256-257|as|O
DDI-DrugBank.d234.s12|259-262|part|O
DDI-DrugBank.d234.s12|264-265|of|O
DDI-DrugBank.d234.s12|267-269|the|O
DDI-DrugBank.d234.s12|271-277|history|O
DDI-DrugBank.d234.s12|279-283|prior|O
DDI-DrugBank.d234.s12|285-286|to|O
DDI-DrugBank.d234.s12|288-290|any|O
DDI-DrugBank.d234.s12|292-300|procedure|O
DDI-DrugBank.d234.s12|302-303|in|O
DDI-DrugBank.d234.s12|305-309|which|O
DDI-DrugBank.d234.s12|311-313|the|O
DDI-DrugBank.d234.s12|315-317|use|O
DDI-DrugBank.d234.s12|319-320|of|O
DDI-DrugBank.d234.s12|322-330|ROMAZICON|brand
DDI-DrugBank.d234.s12|332-333|is|O
DDI-DrugBank.d234.s12|335-341|planned|O
DDI-DrugBank.d234.s12|342-342|.|O
DDI-DrugBank.d595.s0|0-8|Additives|O
DDI-DrugBank.d595.s0|10-12|may|O
DDI-DrugBank.d595.s0|14-15|be|O
DDI-DrugBank.d595.s0|17-28|incompatible|O
DDI-DrugBank.d595.s0|29-29|;|O
DDI-DrugBank.d595.s1|0-13|norepinephrine|drug
DDI-DrugBank.d595.s1|15-17|and|O
DDI-DrugBank.d595.s1|19-28|dobutamine|drug
DDI-DrugBank.d595.s1|30-32|are|O
DDI-DrugBank.d595.s1|34-45|incompatible|O
DDI-DrugBank.d595.s1|47-50|with|O
DDI-DrugBank.d595.s1|52-69|sodium bicarbonate|drug
DDI-DrugBank.d595.s1|71-78|solution|O
DDI-DrugBank.d595.s1|79-79|.|O
DDI-DrugBank.d595.s2|0-2|The|O
DDI-DrugBank.d595.s2|4-11|addition|O
DDI-DrugBank.d595.s2|13-14|of|O
DDI-DrugBank.d595.s2|16-33|sodium bicarbonate|drug
DDI-DrugBank.d595.s2|35-36|to|O
DDI-DrugBank.d595.s2|38-47|parenteral|O
DDI-DrugBank.d595.s2|49-57|solutions|O
DDI-DrugBank.d595.s2|59-68|containing|O
DDI-DrugBank.d595.s2|70-76|calcium|drug
DDI-DrugBank.d595.s2|78-83|should|O
DDI-DrugBank.d595.s2|85-86|be|O
DDI-DrugBank.d595.s2|88-94|avoided|O
DDI-DrugBank.d595.s2|95-95|,|O
DDI-DrugBank.d595.s2|97-102|except|O
DDI-DrugBank.d595.s2|104-108|where|O
DDI-DrugBank.d595.s2|110-122|compatibility|O
DDI-DrugBank.d595.s2|124-126|has|O
DDI-DrugBank.d595.s2|128-131|been|O
DDI-DrugBank.d595.s2|133-142|previously|O
DDI-DrugBank.d595.s2|144-154|established|O
DDI-DrugBank.d595.s2|155-155|.|O
DDI-DrugBank.d595.s3|0-12|Precipitation|O
DDI-DrugBank.d595.s3|14-15|or|O
DDI-DrugBank.d595.s3|17-20|haze|O
DDI-DrugBank.d595.s3|22-24|may|O
DDI-DrugBank.d595.s3|26-31|result|O
DDI-DrugBank.d595.s3|33-36|from|O
DDI-DrugBank.d595.s3|38-43|sodium|O
DDI-DrugBank.d595.s3|45-63|bicarbonate-calcium|O
DDI-DrugBank.d595.s3|65-74|admixtures|O
DDI-DrugBank.d595.s3|75-75|.|O
DDI-DrugBank.d595.s4|0-3|NOTE|O
DDI-DrugBank.d595.s4|4-4|:|O
DDI-DrugBank.d595.s4|6-7|Do|O
DDI-DrugBank.d595.s4|9-11|not|O
DDI-DrugBank.d595.s4|13-15|use|O
DDI-DrugBank.d595.s4|17-19|the|O
DDI-DrugBank.d595.s4|21-29|injection|O
DDI-DrugBank.d595.s4|31-32|if|O
DDI-DrugBank.d595.s4|34-35|it|O
DDI-DrugBank.d595.s4|37-44|contains|O
DDI-DrugBank.d595.s4|46-56|precipitate|O
DDI-DrugBank.d595.s4|57-57|.|O
DDI-DrugBank.d595.s5|0-8|Additives|O
DDI-DrugBank.d595.s5|10-12|may|O
DDI-DrugBank.d595.s5|14-15|be|O
DDI-DrugBank.d595.s5|17-28|incompatible|O
DDI-DrugBank.d595.s5|29-29|.|O
DDI-DrugBank.d595.s6|0-6|Consult|O
DDI-DrugBank.d595.s6|8-11|with|O
DDI-DrugBank.d595.s6|13-22|pharmacist|O
DDI-DrugBank.d595.s6|23-23|,|O
DDI-DrugBank.d595.s6|25-26|if|O
DDI-DrugBank.d595.s6|28-36|available|O
DDI-DrugBank.d595.s6|37-37|.|O
DDI-DrugBank.d595.s7|0-3|When|O
DDI-DrugBank.d595.s7|5-15|introducing|O
DDI-DrugBank.d595.s7|17-25|additives|O
DDI-DrugBank.d595.s7|26-26|,|O
DDI-DrugBank.d595.s7|28-30|use|O
DDI-DrugBank.d595.s7|32-38|aseptic|O
DDI-DrugBank.d595.s7|40-48|technique|O
DDI-DrugBank.d595.s7|49-49|,|O
DDI-DrugBank.d595.s7|51-53|mix|O
DDI-DrugBank.d595.s7|55-64|thoroughly|O
DDI-DrugBank.d595.s7|66-68|and|O
DDI-DrugBank.d595.s7|70-71|do|O
DDI-DrugBank.d595.s7|73-75|not|O
DDI-DrugBank.d595.s7|77-81|store|O
DDI-DrugBank.d595.s7|82-82|.|O
DDI-DrugBank.d183.s0|0-1|No|O
DDI-DrugBank.d183.s0|3-8|formal|O
DDI-DrugBank.d183.s0|10-25|drug-interaction|O
DDI-DrugBank.d183.s0|27-33|studies|O
DDI-DrugBank.d183.s0|35-38|have|O
DDI-DrugBank.d183.s0|40-43|been|O
DDI-DrugBank.d183.s0|45-53|performed|O
DDI-DrugBank.d183.s0|54-54|,|O
DDI-DrugBank.d183.s0|56-58|and|O
DDI-DrugBank.d183.s0|60-60|a|O
DDI-DrugBank.d183.s0|62-71|clinically|O
DDI-DrugBank.d183.s0|73-83|significant|O
DDI-DrugBank.d183.s0|85-95|interaction|O
DDI-DrugBank.d183.s0|97-100|with|O
DDI-DrugBank.d183.s0|102-106|other|O
DDI-DrugBank.d183.s0|108-118|medications|O
DDI-DrugBank.d183.s0|120-123|used|O
DDI-DrugBank.d183.s0|125-126|in|O
DDI-DrugBank.d183.s0|128-130|the|O
DDI-DrugBank.d183.s0|132-140|treatment|O
DDI-DrugBank.d183.s0|142-143|of|O
DDI-DrugBank.d183.s0|145-151|hypoxic|O
DDI-DrugBank.d183.s0|153-163|respiratory|O
DDI-DrugBank.d183.s0|165-171|failure|O
DDI-DrugBank.d183.s0|173-175|can|O
DDI-DrugBank.d183.s0|176-178|not|O
DDI-DrugBank.d183.s0|180-181|be|O
DDI-DrugBank.d183.s0|183-190|excluded|O
DDI-DrugBank.d183.s0|192-196|based|O
DDI-DrugBank.d183.s0|198-199|on|O
DDI-DrugBank.d183.s0|201-203|the|O
DDI-DrugBank.d183.s0|205-213|available|O
DDI-DrugBank.d183.s0|215-218|data|O
DDI-DrugBank.d183.s0|219-219|.|O
DDI-DrugBank.d183.s1|0-5|INOmax|brand
DDI-DrugBank.d183.s1|7-9|has|O
DDI-DrugBank.d183.s1|11-14|been|O
DDI-DrugBank.d183.s1|16-27|administered|O
DDI-DrugBank.d183.s1|29-32|with|O
DDI-DrugBank.d183.s1|34-43|tolazoline|drug
DDI-DrugBank.d183.s1|44-44|,|O
DDI-DrugBank.d183.s1|46-53|dopamine|drug
DDI-DrugBank.d183.s1|54-54|,|O
DDI-DrugBank.d183.s1|56-65|dobutamine|drug
DDI-DrugBank.d183.s1|66-66|,|O
DDI-DrugBank.d183.s1|68-75|steroids|group
DDI-DrugBank.d183.s1|76-76|,|O
DDI-DrugBank.d183.s1|78-87|surfactant|drug
DDI-DrugBank.d183.s1|88-88|,|O
DDI-DrugBank.d183.s1|90-92|and|O
DDI-DrugBank.d183.s1|94-107|high-frequency|O
DDI-DrugBank.d183.s1|109-119|ventilation|O
DDI-DrugBank.d183.s1|120-120|.|O
DDI-DrugBank.d183.s2|0-7|Although|O
DDI-DrugBank.d183.s2|9-13|there|O
DDI-DrugBank.d183.s2|15-17|are|O
DDI-DrugBank.d183.s2|19-20|no|O
DDI-DrugBank.d183.s2|22-26|study|O
DDI-DrugBank.d183.s2|28-31|data|O
DDI-DrugBank.d183.s2|33-34|to|O
DDI-DrugBank.d183.s2|36-43|evaluate|O
DDI-DrugBank.d183.s2|45-47|the|O
DDI-DrugBank.d183.s2|49-59|possibility|O
DDI-DrugBank.d183.s2|60-60|,|O
DDI-DrugBank.d183.s2|62-89|nitric oxide donor compounds|group
DDI-DrugBank.d183.s2|90-90|,|O
DDI-DrugBank.d183.s2|92-100|including|O
DDI-DrugBank.d183.s2|102-121|sodium nitroprusside|drug
DDI-DrugBank.d183.s2|123-125|and|O
DDI-DrugBank.d183.s2|127-139|nitroglycerin|drug
DDI-DrugBank.d183.s2|140-140|,|O
DDI-DrugBank.d183.s2|142-144|may|O
DDI-DrugBank.d183.s2|146-149|have|O
DDI-DrugBank.d183.s2|151-152|an|O
DDI-DrugBank.d183.s2|154-161|additive|O
DDI-DrugBank.d183.s2|163-168|effect|O
DDI-DrugBank.d183.s2|170-173|with|O
DDI-DrugBank.d183.s2|175-180|INOmax|brand
DDI-DrugBank.d183.s2|182-183|on|O
DDI-DrugBank.d183.s2|185-187|the|O
DDI-DrugBank.d183.s2|189-192|risk|O
DDI-DrugBank.d183.s2|194-195|of|O
DDI-DrugBank.d183.s2|197-206|developing|O
DDI-DrugBank.d183.s2|208-224|methemoglobinemia|O
DDI-DrugBank.d183.s2|225-225|.|O
DDI-DrugBank.d183.s3|0-1|An|O
DDI-DrugBank.d183.s3|3-13|association|O
DDI-DrugBank.d183.s3|15-21|between|O
DDI-DrugBank.d183.s3|23-32|prilocaine|drug
DDI-DrugBank.d183.s3|34-36|and|O
DDI-DrugBank.d183.s3|38-39|an|O
DDI-DrugBank.d183.s3|41-49|increased|O
DDI-DrugBank.d183.s3|51-54|risk|O
DDI-DrugBank.d183.s3|56-57|of|O
DDI-DrugBank.d183.s3|59-77|methaemoglobinaemia|O
DDI-DrugBank.d183.s3|78-78|,|O
DDI-DrugBank.d183.s3|80-91|particularly|O
DDI-DrugBank.d183.s3|93-94|in|O
DDI-DrugBank.d183.s3|96-102|infants|O
DDI-DrugBank.d183.s3|103-103|,|O
DDI-DrugBank.d183.s3|105-107|has|O
DDI-DrugBank.d183.s3|109-120|specifically|O
DDI-DrugBank.d183.s3|122-125|been|O
DDI-DrugBank.d183.s3|127-135|described|O
DDI-DrugBank.d183.s3|137-138|in|O
DDI-DrugBank.d183.s3|140-140|a|O
DDI-DrugBank.d183.s3|142-151|literature|O
DDI-DrugBank.d183.s3|153-156|case|O
DDI-DrugBank.d183.s3|158-163|report|O
DDI-DrugBank.d183.s3|164-164|.|O
DDI-DrugBank.d183.s4|0-3|This|O
DDI-DrugBank.d183.s4|5-8|risk|O
DDI-DrugBank.d183.s4|10-11|is|O
DDI-DrugBank.d183.s4|13-19|present|O
DDI-DrugBank.d183.s4|21-27|whether|O
DDI-DrugBank.d183.s4|29-31|the|O
DDI-DrugBank.d183.s4|33-37|drugs|O
DDI-DrugBank.d183.s4|39-41|are|O
DDI-DrugBank.d183.s4|43-54|administered|O
DDI-DrugBank.d183.s4|56-57|as|O
DDI-DrugBank.d183.s4|59-62|oral|O
DDI-DrugBank.d183.s4|63-63|,|O
DDI-DrugBank.d183.s4|65-74|parenteral|O
DDI-DrugBank.d183.s4|75-75|,|O
DDI-DrugBank.d183.s4|77-78|or|O
DDI-DrugBank.d183.s4|80-86|topical|O
DDI-DrugBank.d183.s4|88-99|formulations|O
DDI-DrugBank.d183.s4|100-100|.|O
DDI-DrugBank.d518.s0|0-8|Prolonged|O
DDI-DrugBank.d518.s0|10-17|recovery|O
DDI-DrugBank.d518.s0|19-22|time|O
DDI-DrugBank.d518.s0|24-26|may|O
DDI-DrugBank.d518.s0|28-32|occur|O
DDI-DrugBank.d518.s0|34-35|if|O
DDI-DrugBank.d518.s0|37-48|barbiturates|group
DDI-DrugBank.d518.s0|50-55|and/or|O
DDI-DrugBank.d518.s0|57-65|narcotics|group
DDI-DrugBank.d518.s0|67-69|are|O
DDI-DrugBank.d518.s0|71-74|used|O
DDI-DrugBank.d518.s0|76-87|concurrently|O
DDI-DrugBank.d518.s0|89-92|with|O
DDI-DrugBank.d518.s0|94-101|ketamine|drug
DDI-DrugBank.d518.s0|102-102|.|O
DDI-DrugBank.d518.s1|0-7|Ketamine|drug
DDI-DrugBank.d518.s1|9-10|is|O
DDI-DrugBank.d518.s1|12-21|clinically|O
DDI-DrugBank.d518.s1|23-32|compatible|O
DDI-DrugBank.d518.s1|34-37|with|O
DDI-DrugBank.d518.s1|39-41|the|O
DDI-DrugBank.d518.s1|43-50|commonly|O
DDI-DrugBank.d518.s1|52-55|used|O
DDI-DrugBank.d518.s1|57-63|general|O
DDI-DrugBank.d518.s1|65-67|and|O
DDI-DrugBank.d518.s1|69-73|local|O
DDI-DrugBank.d518.s1|75-91|anesthetic agents|group
DDI-DrugBank.d518.s1|93-96|when|O
DDI-DrugBank.d518.s1|98-99|an|O
DDI-DrugBank.d518.s1|101-108|adequate|O
DDI-DrugBank.d518.s1|110-120|respiratory|O
DDI-DrugBank.d518.s1|122-129|exchange|O
DDI-DrugBank.d518.s1|131-132|is|O
DDI-DrugBank.d518.s1|134-143|maintained|O
DDI-DrugBank.d518.s1|144-144|.|O
DDI-DrugBank.d111.s0|0-27|Non-selective MAO inhibitors|group
DDI-DrugBank.d111.s0|29-37|including|O
DDI-DrugBank.d111.s0|39-61|tranylcypromine sulfate|drug
DDI-DrugBank.d111.s0|62-62|,|O
DDI-DrugBank.d111.s0|64-81|phenelzine sulfate|drug
DDI-DrugBank.d111.s0|82-82|,|O
DDI-DrugBank.d111.s0|84-86|and|O
DDI-DrugBank.d111.s0|88-96|pargyline|drug
DDI-DrugBank.d111.s0|98-100|HC1|O
DDI-DrugBank.d111.s0|101-101|:|O
DDI-DrugBank.d111.s0|103-113|Concomitant|O
DDI-DrugBank.d111.s0|115-117|use|O
DDI-DrugBank.d111.s0|119-120|of|O
DDI-DrugBank.d111.s0|122-131|L-tyrosine|drug
DDI-DrugBank.d111.s0|133-135|and|O
DDI-DrugBank.d111.s0|137-149|non-selective|O
DDI-DrugBank.d111.s0|151-164|MAO inhibitors|group
DDI-DrugBank.d111.s0|166-168|may|O
DDI-DrugBank.d111.s0|170-174|cause|O
DDI-DrugBank.d111.s0|176-187|hypertension|O
DDI-DrugBank.d111.s0|188-188|.|O
DDI-DrugBank.d135.s0|0-6|Effects|O
DDI-DrugBank.d135.s0|8-9|of|O
DDI-DrugBank.d135.s0|11-19|Lapatinib|drug
DDI-DrugBank.d135.s0|21-22|on|O
DDI-DrugBank.d135.s0|24-27|Drug|O
DDI-DrugBank.d135.s0|29-40|Metabolizing|O
DDI-DrugBank.d135.s0|42-48|Enzymes|O
DDI-DrugBank.d135.s0|50-52|and|O
DDI-DrugBank.d135.s0|54-57|Drug|O
DDI-DrugBank.d135.s0|59-67|Transport|O
DDI-DrugBank.d135.s0|69-75|Systems|O
DDI-DrugBank.d135.s0|77-85|Lapatinib|drug
DDI-DrugBank.d135.s0|87-94|inhibits|O
DDI-DrugBank.d135.s0|96-101|CYP3A4|O
DDI-DrugBank.d135.s0|103-105|and|O
DDI-DrugBank.d135.s0|107-112|CYP2C8|O
DDI-DrugBank.d135.s0|114-115|in|O
DDI-DrugBank.d135.s0|117-121|vitro|O
DDI-DrugBank.d135.s0|123-124|at|O
DDI-DrugBank.d135.s0|126-135|clinically|O
DDI-DrugBank.d135.s0|137-144|relevant|O
DDI-DrugBank.d135.s0|146-159|concentrations|O
DDI-DrugBank.d135.s0|160-160|.|O
DDI-DrugBank.d135.s1|0-6|Caution|O
DDI-DrugBank.d135.s1|8-13|should|O
DDI-DrugBank.d135.s1|15-16|be|O
DDI-DrugBank.d135.s1|18-26|exercised|O
DDI-DrugBank.d135.s1|28-30|and|O
DDI-DrugBank.d135.s1|32-35|dose|O
DDI-DrugBank.d135.s1|37-45|reduction|O
DDI-DrugBank.d135.s1|47-48|of|O
DDI-DrugBank.d135.s1|50-52|the|O
DDI-DrugBank.d135.s1|54-64|concomitant|O
DDI-DrugBank.d135.s1|66-74|substrate|O
DDI-DrugBank.d135.s1|76-79|drug|O
DDI-DrugBank.d135.s1|81-86|should|O
DDI-DrugBank.d135.s1|88-89|be|O
DDI-DrugBank.d135.s1|91-100|considered|O
DDI-DrugBank.d135.s1|102-105|when|O
DDI-DrugBank.d135.s1|107-112|dosing|O
DDI-DrugBank.d135.s1|114-122|lapatinib|drug
DDI-DrugBank.d135.s1|124-135|concurrently|O
DDI-DrugBank.d135.s1|137-140|with|O
DDI-DrugBank.d135.s1|142-152|medications|O
DDI-DrugBank.d135.s1|154-157|with|O
DDI-DrugBank.d135.s1|159-164|narrow|O
DDI-DrugBank.d135.s1|166-176|therapeutic|O
DDI-DrugBank.d135.s1|178-184|windows|O
DDI-DrugBank.d135.s1|186-189|that|O
DDI-DrugBank.d135.s1|191-193|are|O
DDI-DrugBank.d135.s1|195-204|substrates|O
DDI-DrugBank.d135.s1|206-207|of|O
DDI-DrugBank.d135.s1|209-214|CYP3A4|O
DDI-DrugBank.d135.s1|216-217|or|O
DDI-DrugBank.d135.s1|219-224|CYP2C8|O
DDI-DrugBank.d135.s1|225-225|.|O
DDI-DrugBank.d135.s2|0-8|Lapatinib|drug
DDI-DrugBank.d135.s2|10-12|did|O
DDI-DrugBank.d135.s2|14-16|not|O
DDI-DrugBank.d135.s2|18-30|significantly|O
DDI-DrugBank.d135.s2|32-38|inhibit|O
DDI-DrugBank.d135.s2|40-42|the|O
DDI-DrugBank.d135.s2|44-52|following|O
DDI-DrugBank.d135.s2|54-60|enzymes|O
DDI-DrugBank.d135.s2|62-63|in|O
DDI-DrugBank.d135.s2|65-69|human|O
DDI-DrugBank.d135.s2|71-75|liver|O
DDI-DrugBank.d135.s2|77-86|microsomes|O
DDI-DrugBank.d135.s2|87-87|:|O
DDI-DrugBank.d135.s2|89-94|CYP1A2|O
DDI-DrugBank.d135.s2|95-95|,|O
DDI-DrugBank.d135.s2|97-102|CYP2C9|O
DDI-DrugBank.d135.s2|103-103|,|O
DDI-DrugBank.d135.s2|105-111|CYP2C19|O
DDI-DrugBank.d135.s2|112-112|,|O
DDI-DrugBank.d135.s2|114-116|and|O
DDI-DrugBank.d135.s2|118-123|CYP2D6|O
DDI-DrugBank.d135.s2|125-126|or|O
DDI-DrugBank.d135.s2|128-130|UGT|O
DDI-DrugBank.d135.s2|132-138|enzymes|O
DDI-DrugBank.d135.s2|140-141|in|O
DDI-DrugBank.d135.s2|143-147|vitro|O
DDI-DrugBank.d135.s2|148-148|,|O
DDI-DrugBank.d135.s2|150-156|however|O
DDI-DrugBank.d135.s2|157-157|,|O
DDI-DrugBank.d135.s2|159-161|the|O
DDI-DrugBank.d135.s2|163-170|clinical|O
DDI-DrugBank.d135.s2|172-183|significance|O
DDI-DrugBank.d135.s2|185-186|is|O
DDI-DrugBank.d135.s2|188-194|unknown|O
DDI-DrugBank.d135.s2|195-195|.|O
DDI-DrugBank.d135.s3|0-8|Lapatinib|drug
DDI-DrugBank.d135.s3|10-17|inhibits|O
DDI-DrugBank.d135.s3|19-23|human|O
DDI-DrugBank.d135.s3|25-38|P-glycoprotein|O
DDI-DrugBank.d135.s3|39-39|.|O
DDI-DrugBank.d135.s4|0-1|If|O
DDI-DrugBank.d135.s4|3-8|TYKERB|brand
DDI-DrugBank.d135.s4|10-11|is|O
DDI-DrugBank.d135.s4|13-24|administered|O
DDI-DrugBank.d135.s4|26-29|with|O
DDI-DrugBank.d135.s4|31-35|drugs|O
DDI-DrugBank.d135.s4|37-40|that|O
DDI-DrugBank.d135.s4|42-44|are|O
DDI-DrugBank.d135.s4|46-55|substrates|O
DDI-DrugBank.d135.s4|57-58|of|O
DDI-DrugBank.d135.s4|60-62|Pgp|O
DDI-DrugBank.d135.s4|63-63|,|O
DDI-DrugBank.d135.s4|65-73|increased|O
DDI-DrugBank.d135.s4|75-88|concentrations|O
DDI-DrugBank.d135.s4|90-91|of|O
DDI-DrugBank.d135.s4|93-95|the|O
DDI-DrugBank.d135.s4|97-105|substrate|O
DDI-DrugBank.d135.s4|107-110|drug|O
DDI-DrugBank.d135.s4|112-114|are|O
DDI-DrugBank.d135.s4|116-121|likely|O
DDI-DrugBank.d135.s4|122-122|,|O
DDI-DrugBank.d135.s4|124-126|and|O
DDI-DrugBank.d135.s4|128-134|caution|O
DDI-DrugBank.d135.s4|136-141|should|O
DDI-DrugBank.d135.s4|143-144|be|O
DDI-DrugBank.d135.s4|146-154|exercised|O
DDI-DrugBank.d135.s4|155-155|.|O
DDI-DrugBank.d135.s5|0-4|Drugs|O
DDI-DrugBank.d135.s5|6-9|that|O
DDI-DrugBank.d135.s5|11-17|Inhibit|O
DDI-DrugBank.d135.s5|19-20|or|O
DDI-DrugBank.d135.s5|22-27|Induce|O
DDI-DrugBank.d135.s5|29-38|Cytochrome|O
DDI-DrugBank.d135.s5|40-43|P450|O
DDI-DrugBank.d135.s5|45-47|3A4|O
DDI-DrugBank.d135.s5|49-55|Enzymes|O
DDI-DrugBank.d135.s5|57-65|Lapatinib|drug
DDI-DrugBank.d135.s5|67-75|undergoes|O
DDI-DrugBank.d135.s5|77-85|extensive|O
DDI-DrugBank.d135.s5|87-96|metabolism|O
DDI-DrugBank.d135.s5|98-99|by|O
DDI-DrugBank.d135.s5|101-106|CYP3A4|O
DDI-DrugBank.d135.s5|107-107|,|O
DDI-DrugBank.d135.s5|109-111|and|O
DDI-DrugBank.d135.s5|113-123|concomitant|O
DDI-DrugBank.d135.s5|125-138|administration|O
DDI-DrugBank.d135.s5|140-141|of|O
DDI-DrugBank.d135.s5|143-148|strong|O
DDI-DrugBank.d135.s5|150-159|inhibitors|O
DDI-DrugBank.d135.s5|161-162|or|O
DDI-DrugBank.d135.s5|164-171|inducers|O
DDI-DrugBank.d135.s5|173-174|of|O
DDI-DrugBank.d135.s5|176-181|CYP3A4|O
DDI-DrugBank.d135.s5|183-187|alter|O
DDI-DrugBank.d135.s5|189-197|lapatinib|drug
DDI-DrugBank.d135.s5|199-212|concentrations|O
DDI-DrugBank.d135.s5|214-226|significantly|O
DDI-DrugBank.d135.s5|227-227|.|O
DDI-DrugBank.d135.s6|0-3|Dose|O
DDI-DrugBank.d135.s6|5-14|adjustment|O
DDI-DrugBank.d135.s6|16-17|of|O
DDI-DrugBank.d135.s6|19-27|lapatinib|drug
DDI-DrugBank.d135.s6|29-34|should|O
DDI-DrugBank.d135.s6|36-37|be|O
DDI-DrugBank.d135.s6|39-48|considered|O
DDI-DrugBank.d135.s6|50-52|for|O
DDI-DrugBank.d135.s6|54-61|patients|O
DDI-DrugBank.d135.s6|63-65|who|O
DDI-DrugBank.d135.s6|67-70|must|O
DDI-DrugBank.d135.s6|72-78|receive|O
DDI-DrugBank.d135.s6|80-90|concomitant|O
DDI-DrugBank.d135.s6|92-97|strong|O
DDI-DrugBank.d135.s6|99-108|inhibitors|O
DDI-DrugBank.d135.s6|110-111|or|O
DDI-DrugBank.d135.s6|113-123|concomitant|O
DDI-DrugBank.d135.s6|125-130|strong|O
DDI-DrugBank.d135.s6|132-139|inducers|O
DDI-DrugBank.d135.s6|141-142|of|O
DDI-DrugBank.d135.s6|144-149|CYP3A4|O
DDI-DrugBank.d135.s6|151-157|enzymes|O
DDI-DrugBank.d135.s6|158-158|.|O
DDI-DrugBank.d135.s7|0-11|Ketoconazole|drug
DDI-DrugBank.d135.s7|12-12|:|O
DDI-DrugBank.d135.s7|14-15|In|O
DDI-DrugBank.d135.s7|17-23|healthy|O
DDI-DrugBank.d135.s7|25-32|subjects|O
DDI-DrugBank.d135.s7|34-42|receiving|O
DDI-DrugBank.d135.s7|44-55|ketoconazole|drug
DDI-DrugBank.d135.s7|56-56|,|O
DDI-DrugBank.d135.s7|58-58|a|O
DDI-DrugBank.d135.s7|60-65|CYP3A4|O
DDI-DrugBank.d135.s7|67-75|inhibitor|O
DDI-DrugBank.d135.s7|76-76|,|O
DDI-DrugBank.d135.s7|78-79|at|O
DDI-DrugBank.d135.s7|81-83|200|O
DDI-DrugBank.d135.s7|85-86|mg|O
DDI-DrugBank.d135.s7|88-92|twice|O
DDI-DrugBank.d135.s7|94-98|daily|O
DDI-DrugBank.d135.s7|100-102|for|O
DDI-DrugBank.d135.s7|104-104|7|O
DDI-DrugBank.d135.s7|106-109|days|O
DDI-DrugBank.d135.s7|110-110|,|O
DDI-DrugBank.d135.s7|112-119|systemic|O
DDI-DrugBank.d135.s7|121-128|exposure|O
DDI-DrugBank.d135.s7|130-130|(|O
DDI-DrugBank.d135.s7|131-133|AUC|O
DDI-DrugBank.d135.s7|134-134|)|O
DDI-DrugBank.d135.s7|136-137|to|O
DDI-DrugBank.d135.s7|139-147|lapatinib|drug
DDI-DrugBank.d135.s7|149-151|was|O
DDI-DrugBank.d135.s7|153-161|increased|O
DDI-DrugBank.d135.s7|163-164|to|O
DDI-DrugBank.d135.s7|166-178|approximately|O
DDI-DrugBank.d135.s7|180-187|3.6-fold|O
DDI-DrugBank.d135.s7|189-190|of|O
DDI-DrugBank.d135.s7|192-198|control|O
DDI-DrugBank.d135.s7|200-202|and|O
DDI-DrugBank.d135.s7|204-212|half-life|O
DDI-DrugBank.d135.s7|214-222|increased|O
DDI-DrugBank.d135.s7|224-225|to|O
DDI-DrugBank.d135.s7|227-234|1.7-fold|O
DDI-DrugBank.d135.s7|236-237|of|O
DDI-DrugBank.d135.s7|239-245|control|O
DDI-DrugBank.d135.s7|246-246|.|O
DDI-DrugBank.d135.s8|0-12|Carbamazepine|drug
DDI-DrugBank.d135.s8|13-13|:|O
DDI-DrugBank.d135.s8|15-16|In|O
DDI-DrugBank.d135.s8|18-24|healthy|O
DDI-DrugBank.d135.s8|26-33|subjects|O
DDI-DrugBank.d135.s8|35-43|receiving|O
DDI-DrugBank.d135.s8|45-47|the|O
DDI-DrugBank.d135.s8|49-54|CYP3A4|O
DDI-DrugBank.d135.s8|56-62|inducer|O
DDI-DrugBank.d135.s8|63-63|,|O
DDI-DrugBank.d135.s8|65-77|carbamazepine|drug
DDI-DrugBank.d135.s8|78-78|,|O
DDI-DrugBank.d135.s8|80-81|at|O
DDI-DrugBank.d135.s8|83-85|100|O
DDI-DrugBank.d135.s8|87-88|mg|O
DDI-DrugBank.d135.s8|90-94|twice|O
DDI-DrugBank.d135.s8|96-100|daily|O
DDI-DrugBank.d135.s8|102-104|for|O
DDI-DrugBank.d135.s8|106-106|3|O
DDI-DrugBank.d135.s8|108-111|days|O
DDI-DrugBank.d135.s8|113-115|and|O
DDI-DrugBank.d135.s8|117-119|200|O
DDI-DrugBank.d135.s8|121-122|mg|O
DDI-DrugBank.d135.s8|124-128|twice|O
DDI-DrugBank.d135.s8|130-134|daily|O
DDI-DrugBank.d135.s8|136-138|for|O
DDI-DrugBank.d135.s8|140-141|17|O
DDI-DrugBank.d135.s8|143-146|days|O
DDI-DrugBank.d135.s8|147-147|,|O
DDI-DrugBank.d135.s8|149-156|systemic|O
DDI-DrugBank.d135.s8|158-165|exposure|O
DDI-DrugBank.d135.s8|167-167|(|O
DDI-DrugBank.d135.s8|168-170|AUC|O
DDI-DrugBank.d135.s8|171-171|)|O
DDI-DrugBank.d135.s8|173-174|to|O
DDI-DrugBank.d135.s8|176-184|lapatinib|drug
DDI-DrugBank.d135.s8|186-188|was|O
DDI-DrugBank.d135.s8|190-198|decreased|O
DDI-DrugBank.d135.s8|200-212|approximately|O
DDI-DrugBank.d135.s8|214-215|72|O
DDI-DrugBank.d135.s8|216-216|%|O
DDI-DrugBank.d135.s8|217-217|.|O
DDI-DrugBank.d135.s9|0-4|Drugs|O
DDI-DrugBank.d135.s9|6-9|that|O
DDI-DrugBank.d135.s9|11-17|Inhibit|O
DDI-DrugBank.d135.s9|19-22|Drug|O
DDI-DrugBank.d135.s9|24-32|Transport|O
DDI-DrugBank.d135.s9|34-40|Systems|O
DDI-DrugBank.d135.s9|42-50|Lapatinib|drug
DDI-DrugBank.d135.s9|52-53|is|O
DDI-DrugBank.d135.s9|55-55|a|O
DDI-DrugBank.d135.s9|57-65|substrate|O
DDI-DrugBank.d135.s9|67-68|of|O
DDI-DrugBank.d135.s9|70-72|the|O
DDI-DrugBank.d135.s9|74-79|efflux|O
DDI-DrugBank.d135.s9|81-91|transporter|O
DDI-DrugBank.d135.s9|93-106|P-glycoprotein|O
DDI-DrugBank.d135.s9|108-108|(|O
DDI-DrugBank.d135.s9|109-111|Pgp|O
DDI-DrugBank.d135.s9|112-112|,|O
DDI-DrugBank.d135.s9|114-118|ABCB1|O
DDI-DrugBank.d135.s9|119-119|)|O
DDI-DrugBank.d135.s9|120-120|.|O
DDI-DrugBank.d135.s10|0-1|If|O
DDI-DrugBank.d135.s10|3-8|TYKERB|brand
DDI-DrugBank.d135.s10|10-11|is|O
DDI-DrugBank.d135.s10|13-24|administered|O
DDI-DrugBank.d135.s10|26-29|with|O
DDI-DrugBank.d135.s10|31-35|drugs|O
DDI-DrugBank.d135.s10|37-40|that|O
DDI-DrugBank.d135.s10|42-48|inhibit|O
DDI-DrugBank.d135.s10|50-52|Pgp|O
DDI-DrugBank.d135.s10|53-53|,|O
DDI-DrugBank.d135.s10|55-63|increased|O
DDI-DrugBank.d135.s10|65-78|concentrations|O
DDI-DrugBank.d135.s10|80-81|of|O
DDI-DrugBank.d135.s10|83-91|lapatinib|drug
DDI-DrugBank.d135.s10|93-95|are|O
DDI-DrugBank.d135.s10|97-102|likely|O
DDI-DrugBank.d135.s10|103-103|,|O
DDI-DrugBank.d135.s10|105-107|and|O
DDI-DrugBank.d135.s10|109-115|caution|O
DDI-DrugBank.d135.s10|117-122|should|O
DDI-DrugBank.d135.s10|124-125|be|O
DDI-DrugBank.d135.s10|127-135|exercised|O
DDI-DrugBank.d135.s10|136-136|.|O
DDI-DrugBank.d135.s11|0-4|Other|O
DDI-DrugBank.d135.s11|6-17|Chemotherapy|O
DDI-DrugBank.d135.s11|19-24|Agents|O
DDI-DrugBank.d135.s11|26-27|In|O
DDI-DrugBank.d135.s11|29-29|a|O
DDI-DrugBank.d135.s11|31-38|separate|O
DDI-DrugBank.d135.s11|40-44|study|O
DDI-DrugBank.d135.s11|45-45|,|O
DDI-DrugBank.d135.s11|47-57|concomitant|O
DDI-DrugBank.d135.s11|59-72|administration|O
DDI-DrugBank.d135.s11|74-75|of|O
DDI-DrugBank.d135.s11|77-85|lapatinib|drug
DDI-DrugBank.d135.s11|87-90|with|O
DDI-DrugBank.d135.s11|92-103|capecitabine|drug
DDI-DrugBank.d135.s11|105-107|did|O
DDI-DrugBank.d135.s11|109-111|not|O
DDI-DrugBank.d135.s11|113-124|meaningfully|O
DDI-DrugBank.d135.s11|126-130|alter|O
DDI-DrugBank.d135.s11|132-134|the|O
DDI-DrugBank.d135.s11|136-151|pharmacokinetics|O
DDI-DrugBank.d135.s11|153-154|of|O
DDI-DrugBank.d135.s11|156-161|either|O
DDI-DrugBank.d135.s11|163-167|agent|O
DDI-DrugBank.d135.s11|169-169|(|O
DDI-DrugBank.d135.s11|170-171|or|O
DDI-DrugBank.d135.s11|173-175|the|O
DDI-DrugBank.d135.s11|177-187|metabolites|O
DDI-DrugBank.d135.s11|189-190|of|O
DDI-DrugBank.d135.s11|192-203|capecitabine|drug
DDI-DrugBank.d135.s11|204-204|)|O
DDI-DrugBank.d135.s11|205-205|.|O
DDI-DrugBank.d184.s0|0-11|Interactions|O
DDI-DrugBank.d184.s0|13-15|may|O
DDI-DrugBank.d184.s0|17-21|occur|O
DDI-DrugBank.d184.s0|23-26|with|O
DDI-DrugBank.d184.s0|28-30|the|O
DDI-DrugBank.d184.s0|32-40|following|O
DDI-DrugBank.d184.s0|41-41|:|O
DDI-DrugBank.d184.s0|43-58|adrenocorticoids|O
DDI-DrugBank.d184.s0|60-60|(|O
DDI-DrugBank.d184.s0|61-74|cortisone-like|O
DDI-DrugBank.d184.s0|76-83|medicine|O
DDI-DrugBank.d184.s0|84-84|)|O
DDI-DrugBank.d184.s0|85-85|,|O
DDI-DrugBank.d184.s0|87-100|anticoagulants|group
DDI-DrugBank.d184.s0|102-102|(|O
DDI-DrugBank.d184.s0|103-107|blood|group
DDI-DrugBank.d184.s0|109-116|thinners|O
DDI-DrugBank.d184.s0|117-117|)|O
DDI-DrugBank.d184.s0|118-118|,|O
DDI-DrugBank.d184.s0|120-132|carbamazepine|drug
DDI-DrugBank.d184.s0|133-133|,|O
DDI-DrugBank.d184.s0|135-147|corticotropin|drug
DDI-DrugBank.d184.s0|149-149|(|O
DDI-DrugBank.d184.s0|150-161|barbiturates|group
DDI-DrugBank.d184.s0|163-165|may|O
DDI-DrugBank.d184.s0|167-174|decrease|O
DDI-DrugBank.d184.s0|176-178|the|O
DDI-DrugBank.d184.s0|180-186|effects|O
DDI-DrugBank.d184.s0|188-189|of|O
DDI-DrugBank.d184.s0|191-195|these|O
DDI-DrugBank.d184.s0|197-205|medicines|O
DDI-DrugBank.d184.s0|206-206|)|O
DDI-DrugBank.d184.s0|207-207|,|O
DDI-DrugBank.d184.s0|209-248|central nervous system ( CNS ) depressants|group
DDI-DrugBank.d184.s0|250-250|(|O
DDI-DrugBank.d184.s0|251-255|using|O
DDI-DrugBank.d184.s0|257-261|these|O
DDI-DrugBank.d184.s0|263-271|medicines|O
DDI-DrugBank.d184.s0|273-276|with|O
DDI-DrugBank.d184.s0|278-289|barbiturates|group
DDI-DrugBank.d184.s0|291-293|may|O
DDI-DrugBank.d184.s0|295-300|result|O
DDI-DrugBank.d184.s0|302-303|in|O
DDI-DrugBank.d184.s0|305-313|increased|O
DDI-DrugBank.d184.s0|315-317|CNS|O
DDI-DrugBank.d184.s0|319-328|depressant|O
DDI-DrugBank.d184.s0|330-336|effects|O
DDI-DrugBank.d184.s0|337-337|)|O
DDI-DrugBank.d184.s0|338-338|,|O
DDI-DrugBank.d184.s0|340-356|divalproex sodium|drug
DDI-DrugBank.d184.s0|357-357|,|O
DDI-DrugBank.d184.s0|359-371|valproic acid|drug
DDI-DrugBank.d184.s0|373-373|(|O
DDI-DrugBank.d184.s0|374-378|using|O
DDI-DrugBank.d184.s0|380-384|these|O
DDI-DrugBank.d184.s0|386-394|medicines|O
DDI-DrugBank.d184.s0|396-399|with|O
DDI-DrugBank.d184.s0|401-412|barbiturates|group
DDI-DrugBank.d184.s0|414-416|may|O
DDI-DrugBank.d184.s0|418-423|change|O
DDI-DrugBank.d184.s0|425-427|the|O
DDI-DrugBank.d184.s0|429-434|amount|O
DDI-DrugBank.d184.s0|436-437|of|O
DDI-DrugBank.d184.s0|439-444|either|O
DDI-DrugBank.d184.s0|446-453|medicine|O
DDI-DrugBank.d184.s0|455-458|that|O
DDI-DrugBank.d184.s0|460-462|you|O
DDI-DrugBank.d184.s0|464-467|need|O
DDI-DrugBank.d184.s0|469-470|to|O
DDI-DrugBank.d184.s0|472-475|take|O
DDI-DrugBank.d184.s0|476-476|)|O
DDI-DrugBank.d184.s0|477-477|,|O
DDI-DrugBank.d184.s0|479-481|and|O
DDI-DrugBank.d184.s0|483-486|oral|O
DDI-DrugBank.d184.s0|488-501|contraceptives|group
DDI-DrugBank.d184.s0|503-512|containing|O
DDI-DrugBank.d184.s0|514-522|estrogens|group
DDI-DrugBank.d184.s0|524-524|(|O
DDI-DrugBank.d184.s0|525-536|barbiturates|group
DDI-DrugBank.d184.s0|538-540|may|O
DDI-DrugBank.d184.s0|542-549|decrease|O
DDI-DrugBank.d184.s0|551-553|the|O
DDI-DrugBank.d184.s0|555-567|effectiveness|O
DDI-DrugBank.d184.s0|569-570|of|O
DDI-DrugBank.d184.s0|572-576|these|O
DDI-DrugBank.d184.s0|578-581|oral|O
DDI-DrugBank.d184.s0|583-596|contraceptives|group
DDI-DrugBank.d184.s0|597-597|,|O
DDI-DrugBank.d184.s0|599-601|and|O
DDI-DrugBank.d184.s0|603-605|you|O
DDI-DrugBank.d184.s0|607-609|may|O
DDI-DrugBank.d184.s0|611-614|need|O
DDI-DrugBank.d184.s0|616-617|to|O
DDI-DrugBank.d184.s0|619-624|change|O
DDI-DrugBank.d184.s0|626-627|to|O
DDI-DrugBank.d184.s0|629-629|a|O
DDI-DrugBank.d184.s0|631-639|different|O
DDI-DrugBank.d184.s0|641-644|type|O
DDI-DrugBank.d184.s0|646-647|of|O
DDI-DrugBank.d184.s0|649-653|birth|O
DDI-DrugBank.d184.s0|655-661|control|O
DDI-DrugBank.d184.s0|662-662|)|O
DDI-DrugBank.d184.s0|663-663|.|O
DDI-DrugBank.d536.s0|0-6|Certain|O
DDI-DrugBank.d536.s0|8-12|drugs|O
DDI-DrugBank.d536.s0|14-17|tend|O
DDI-DrugBank.d536.s0|19-20|to|O
DDI-DrugBank.d536.s0|22-28|produce|O
DDI-DrugBank.d536.s0|30-42|hyperglycemia|O
DDI-DrugBank.d536.s0|44-46|and|O
DDI-DrugBank.d536.s0|48-50|may|O
DDI-DrugBank.d536.s0|52-55|lead|O
DDI-DrugBank.d536.s0|57-58|to|O
DDI-DrugBank.d536.s0|60-63|loss|O
DDI-DrugBank.d536.s0|65-66|of|O
DDI-DrugBank.d536.s0|68-72|blood|O
DDI-DrugBank.d536.s0|74-80|glucose|O
DDI-DrugBank.d536.s0|82-88|control|O
DDI-DrugBank.d536.s0|89-89|.|O
DDI-DrugBank.d536.s1|0-4|These|O
DDI-DrugBank.d536.s1|6-10|drugs|O
DDI-DrugBank.d536.s1|12-18|include|O
DDI-DrugBank.d536.s1|20-22|the|O
DDI-DrugBank.d536.s1|24-32|thiazides|group
DDI-DrugBank.d536.s1|34-36|and|O
DDI-DrugBank.d536.s1|38-42|other|O
DDI-DrugBank.d536.s1|44-52|diuretics|group
DDI-DrugBank.d536.s1|53-53|,|O
DDI-DrugBank.d536.s1|55-69|corticosteroids|group
DDI-DrugBank.d536.s1|70-70|,|O
DDI-DrugBank.d536.s1|72-85|phenothiazines|group
DDI-DrugBank.d536.s1|86-86|,|O
DDI-DrugBank.d536.s1|88-103|thyroid products|group
DDI-DrugBank.d536.s1|104-104|,|O
DDI-DrugBank.d536.s1|106-114|estrogens|group
DDI-DrugBank.d536.s1|115-115|,|O
DDI-DrugBank.d536.s1|117-120|oral|O
DDI-DrugBank.d536.s1|122-135|contraceptives|group
DDI-DrugBank.d536.s1|136-136|,|O
DDI-DrugBank.d536.s1|138-146|phenytoin|drug
DDI-DrugBank.d536.s1|147-147|,|O
DDI-DrugBank.d536.s1|149-162|nicotinic acid|drug
DDI-DrugBank.d536.s1|163-163|,|O
DDI-DrugBank.d536.s1|165-180|sympathomimetics|group
DDI-DrugBank.d536.s1|181-181|,|O
DDI-DrugBank.d536.s1|183-212|calcium channel-blocking drugs|group
DDI-DrugBank.d536.s1|213-213|,|O
DDI-DrugBank.d536.s1|215-217|and|O
DDI-DrugBank.d536.s1|219-227|isoniazid|drug
DDI-DrugBank.d536.s1|228-228|.|O
DDI-DrugBank.d536.s2|0-3|When|O
DDI-DrugBank.d536.s2|5-8|such|O
DDI-DrugBank.d536.s2|10-14|drugs|O
DDI-DrugBank.d536.s2|16-18|are|O
DDI-DrugBank.d536.s2|20-31|administered|O
DDI-DrugBank.d536.s2|33-34|to|O
DDI-DrugBank.d536.s2|36-36|a|O
DDI-DrugBank.d536.s2|38-44|patient|O
DDI-DrugBank.d536.s2|46-54|receiving|O
DDI-DrugBank.d536.s2|56-63|Acarbose|drug
DDI-DrugBank.d536.s2|64-64|,|O
DDI-DrugBank.d536.s2|66-68|the|O
DDI-DrugBank.d536.s2|70-76|patient|O
DDI-DrugBank.d536.s2|78-83|should|O
DDI-DrugBank.d536.s2|85-86|be|O
DDI-DrugBank.d536.s2|88-94|closely|O
DDI-DrugBank.d536.s2|96-103|observed|O
DDI-DrugBank.d536.s2|105-107|for|O
DDI-DrugBank.d536.s2|109-112|loss|O
DDI-DrugBank.d536.s2|114-115|of|O
DDI-DrugBank.d536.s2|117-121|blood|O
DDI-DrugBank.d536.s2|123-129|glucose|O
DDI-DrugBank.d536.s2|131-137|control|O
DDI-DrugBank.d536.s2|138-138|.|O
DDI-DrugBank.d536.s3|0-3|When|O
DDI-DrugBank.d536.s3|5-8|such|O
DDI-DrugBank.d536.s3|10-14|drugs|O
DDI-DrugBank.d536.s3|16-18|are|O
DDI-DrugBank.d536.s3|20-28|withdrawn|O
DDI-DrugBank.d536.s3|30-33|from|O
DDI-DrugBank.d536.s3|35-42|patients|O
DDI-DrugBank.d536.s3|44-52|receiving|O
DDI-DrugBank.d536.s3|54-61|Acarbose|drug
DDI-DrugBank.d536.s3|63-64|in|O
DDI-DrugBank.d536.s3|66-76|combination|O
DDI-DrugBank.d536.s3|78-81|with|O
DDI-DrugBank.d536.s3|83-95|sulfonylureas|group
DDI-DrugBank.d536.s3|97-98|or|O
DDI-DrugBank.d536.s3|100-106|insulin|drug
DDI-DrugBank.d536.s3|107-107|,|O
DDI-DrugBank.d536.s3|109-116|patients|O
DDI-DrugBank.d536.s3|118-123|should|O
DDI-DrugBank.d536.s3|125-126|be|O
DDI-DrugBank.d536.s3|128-135|observed|O
DDI-DrugBank.d536.s3|137-143|closely|O
DDI-DrugBank.d536.s3|145-147|for|O
DDI-DrugBank.d536.s3|149-151|any|O
DDI-DrugBank.d536.s3|153-160|evidence|O
DDI-DrugBank.d536.s3|162-163|of|O
DDI-DrugBank.d536.s3|165-176|hypoglycemia|O
DDI-DrugBank.d536.s3|177-177|.|O
DDI-DrugBank.d536.s4|0-20|Intestinal adsorbents|group
DDI-DrugBank.d536.s4|22-22|(|O
DDI-DrugBank.d536.s4|23-24|e.|O
DDI-DrugBank.d536.s4|26-27|g.|O
DDI-DrugBank.d536.s4|28-28|,|O
DDI-DrugBank.d536.s4|30-37|charcoal|drug
DDI-DrugBank.d536.s4|38-38|)|O
DDI-DrugBank.d536.s4|40-42|and|O
DDI-DrugBank.d536.s4|44-72|digestive enzyme preparations|group
DDI-DrugBank.d536.s4|74-83|containing|O
DDI-DrugBank.d536.s4|85-106|carbohydrate-splitting|O
DDI-DrugBank.d536.s4|108-114|enzymes|O
DDI-DrugBank.d536.s4|116-116|(|O
DDI-DrugBank.d536.s4|117-118|e.|O
DDI-DrugBank.d536.s4|120-121|g.|O
DDI-DrugBank.d536.s4|122-122|,|O
DDI-DrugBank.d536.s4|124-130|amylase|drug
DDI-DrugBank.d536.s4|131-131|,|O
DDI-DrugBank.d536.s4|133-142|pancreatin|drug
DDI-DrugBank.d536.s4|143-143|)|O
DDI-DrugBank.d536.s4|145-147|may|O
DDI-DrugBank.d536.s4|149-154|reduce|O
DDI-DrugBank.d536.s4|156-158|the|O
DDI-DrugBank.d536.s4|160-165|effect|O
DDI-DrugBank.d536.s4|167-168|of|O
DDI-DrugBank.d536.s4|170-177|Acarbose|drug
DDI-DrugBank.d536.s4|179-181|and|O
DDI-DrugBank.d536.s4|183-188|should|O
DDI-DrugBank.d536.s4|190-192|not|O
DDI-DrugBank.d536.s4|194-195|be|O
DDI-DrugBank.d536.s4|197-201|taken|O
DDI-DrugBank.d536.s4|203-215|concomitantly|O
DDI-DrugBank.d536.s4|216-216|.|O
DDI-DrugBank.d536.s5|0-7|Acarbose|drug
DDI-DrugBank.d536.s5|9-11|has|O
DDI-DrugBank.d536.s5|13-16|been|O
DDI-DrugBank.d536.s5|18-22|shown|O
DDI-DrugBank.d536.s5|24-25|to|O
DDI-DrugBank.d536.s5|27-32|change|O
DDI-DrugBank.d536.s5|34-36|the|O
DDI-DrugBank.d536.s5|38-52|bioavailabillty|O
DDI-DrugBank.d536.s5|54-60|digoxin|drug
DDI-DrugBank.d536.s5|62-65|when|O
DDI-DrugBank.d536.s5|67-70|they|O
DDI-DrugBank.d536.s5|72-74|are|O
DDI-DrugBank.d536.s5|76-90|co-administered|O
DDI-DrugBank.d536.s5|91-91|,|O
DDI-DrugBank.d536.s5|93-97|which|O
DDI-DrugBank.d536.s5|99-101|may|O
DDI-DrugBank.d536.s5|103-109|require|O
DDI-DrugBank.d536.s5|111-117|digoxin|drug
DDI-DrugBank.d536.s5|119-122|dose|O
DDI-DrugBank.d536.s5|124-133|adjustment|O
DDI-DrugBank.d536.s5|134-134|.|O
DDI-DrugBank.d536.s6|0-6|Studies|O
DDI-DrugBank.d536.s6|8-9|in|O
DDI-DrugBank.d536.s6|11-17|healthy|O
DDI-DrugBank.d536.s6|19-28|volunteers|O
DDI-DrugBank.d536.s6|30-33|have|O
DDI-DrugBank.d536.s6|35-39|shown|O
DDI-DrugBank.d536.s6|41-44|that|O
DDI-DrugBank.d536.s6|46-53|Acarbose|drug
DDI-DrugBank.d536.s6|55-57|has|O
DDI-DrugBank.d536.s6|59-60|no|O
DDI-DrugBank.d536.s6|62-67|effect|O
DDI-DrugBank.d536.s6|69-70|on|O
DDI-DrugBank.d536.s6|72-77|either|O
DDI-DrugBank.d536.s6|79-81|the|O
DDI-DrugBank.d536.s6|83-98|pharmacokinetics|O
DDI-DrugBank.d536.s6|100-101|or|O
DDI-DrugBank.d536.s6|103-118|pharmacodynamics|O
DDI-DrugBank.d536.s6|120-121|of|O
DDI-DrugBank.d536.s6|123-129|digoxin|drug
DDI-DrugBank.d536.s6|130-130|,|O
DDI-DrugBank.d536.s6|132-141|nifedipine|drug
DDI-DrugBank.d536.s6|142-142|,|O
DDI-DrugBank.d536.s6|144-154|propranolol|drug
DDI-DrugBank.d536.s6|155-155|,|O
DDI-DrugBank.d536.s6|157-158|or|O
DDI-DrugBank.d536.s6|160-169|ranitidine|drug
DDI-DrugBank.d536.s6|170-170|.|O
DDI-DrugBank.d536.s7|0-7|Acarbose|drug
DDI-DrugBank.d536.s7|9-11|did|O
DDI-DrugBank.d536.s7|13-15|not|O
DDI-DrugBank.d536.s7|17-25|interfere|O
DDI-DrugBank.d536.s7|27-30|with|O
DDI-DrugBank.d536.s7|32-34|the|O
DDI-DrugBank.d536.s7|36-45|absorption|O
DDI-DrugBank.d536.s7|47-48|or|O
DDI-DrugBank.d536.s7|50-60|disposition|O
DDI-DrugBank.d536.s7|62-63|of|O
DDI-DrugBank.d536.s7|65-67|the|O
DDI-DrugBank.d536.s7|69-80|sulfonylurea|drug
DDI-DrugBank.d536.s7|69-80|sulfonylurea|drug
DDI-DrugBank.d536.s7|92-93|in|O
DDI-DrugBank.d536.s7|95-102|diabetic|O
DDI-DrugBank.d536.s7|104-111|patients|O
DDI-DrugBank.d536.s7|112-112|.|O
DDI-DrugBank.d536.s8|0-7|Acarbose|drug
DDI-DrugBank.d536.s8|9-11|may|O
DDI-DrugBank.d536.s8|13-18|affect|O
DDI-DrugBank.d536.s8|20-26|digoxin|drug
DDI-DrugBank.d536.s8|28-42|bioavailabillty|O
DDI-DrugBank.d536.s8|44-46|and|O
DDI-DrugBank.d536.s8|48-50|may|O
DDI-DrugBank.d536.s8|52-58|require|O
DDI-DrugBank.d536.s8|60-63|dose|O
DDI-DrugBank.d536.s8|65-74|adjustment|O
DDI-DrugBank.d536.s8|76-77|of|O
DDI-DrugBank.d536.s8|79-85|digoxin|drug
DDI-DrugBank.d536.s8|87-88|by|O
DDI-DrugBank.d536.s8|90-91|16|O
DDI-DrugBank.d536.s8|92-92|%|O
DDI-DrugBank.d536.s8|94-94|(|O
DDI-DrugBank.d536.s8|95-96|90|O
DDI-DrugBank.d536.s8|97-97|%|O
DDI-DrugBank.d536.s8|99-108|confidence|O
DDI-DrugBank.d536.s8|110-117|interval|O
DDI-DrugBank.d536.s8|118-118|:|O
DDI-DrugBank.d536.s8|120-123|8-23|O
DDI-DrugBank.d536.s8|124-124|%|O
DDI-DrugBank.d536.s8|125-125|)|O
DDI-DrugBank.d536.s8|126-126|,|O
DDI-DrugBank.d536.s8|128-135|decrease|O
DDI-DrugBank.d536.s8|137-140|mean|O
DDI-DrugBank.d536.s8|142-142|C|O
DDI-DrugBank.d536.s8|144-146|max|O
DDI-DrugBank.d536.s8|148-154|digoxin|drug
DDI-DrugBank.d536.s8|156-157|by|O
DDI-DrugBank.d536.s8|159-160|26|O
DDI-DrugBank.d536.s8|161-161|%|O
DDI-DrugBank.d536.s8|163-163|(|O
DDI-DrugBank.d536.s8|164-165|90|O
DDI-DrugBank.d536.s8|166-166|%|O
DDI-DrugBank.d536.s8|168-177|confidence|O
DDI-DrugBank.d536.s8|179-186|interval|O
DDI-DrugBank.d536.s8|187-187|:|O
DDI-DrugBank.d536.s8|189-193|16-34|O
DDI-DrugBank.d536.s8|194-194|%|O
DDI-DrugBank.d536.s8|195-195|)|O
DDI-DrugBank.d536.s8|197-199|and|O
DDI-DrugBank.d536.s8|201-208|decrease|O
DDI-DrugBank.d536.s8|210-213|mean|O
DDI-DrugBank.d536.s8|215-220|trough|O
DDI-DrugBank.d536.s8|222-235|concentrations|O
DDI-DrugBank.d536.s8|237-238|of|O
DDI-DrugBank.d536.s8|240-246|digoxin|drug
DDI-DrugBank.d536.s8|248-249|by|O
DDI-DrugBank.d536.s8|251-251|9|O
DDI-DrugBank.d536.s8|252-252|%|O
DDI-DrugBank.d536.s8|254-254|(|O
DDI-DrugBank.d536.s8|255-256|90|O
DDI-DrugBank.d536.s8|257-257|%|O
DDI-DrugBank.d536.s8|259-268|confidence|O
DDI-DrugBank.d536.s8|270-274|limit|O
DDI-DrugBank.d536.s8|275-275|:|O
DDI-DrugBank.d536.s8|277-278|19|O
DDI-DrugBank.d536.s8|279-279|%|O
DDI-DrugBank.d536.s8|281-288|decrease|O
DDI-DrugBank.d536.s8|290-291|to|O
DDI-DrugBank.d536.s8|293-293|2|O
DDI-DrugBank.d536.s8|294-294|%|O
DDI-DrugBank.d536.s8|296-303|increase|O
DDI-DrugBank.d536.s8|304-304|)|O
DDI-DrugBank.d536.s8|305-305|.|O
DDI-DrugBank.d536.s9|0-2|The|O
DDI-DrugBank.d536.s9|4-9|amount|O
DDI-DrugBank.d536.s9|11-12|of|O
DDI-DrugBank.d536.s9|14-22|metformin|drug
DDI-DrugBank.d536.s9|24-31|absorbed|O
DDI-DrugBank.d536.s9|33-37|while|O
DDI-DrugBank.d536.s9|39-44|taking|O
DDI-DrugBank.d536.s9|46-53|Acarbose|drug
DDI-DrugBank.d536.s9|55-57|was|O
DDI-DrugBank.d536.s9|59-71|bioequivalent|O
DDI-DrugBank.d536.s9|73-74|to|O
DDI-DrugBank.d536.s9|76-78|the|O
DDI-DrugBank.d536.s9|80-85|amount|O
DDI-DrugBank.d536.s9|87-94|absorbed|O
DDI-DrugBank.d536.s9|96-99|when|O
DDI-DrugBank.d536.s9|101-106|taking|O
DDI-DrugBank.d536.s9|108-114|placebo|O
DDI-DrugBank.d536.s9|115-115|,|O
DDI-DrugBank.d536.s9|117-118|as|O
DDI-DrugBank.d536.s9|120-128|indicated|O
DDI-DrugBank.d536.s9|130-131|by|O
DDI-DrugBank.d536.s9|133-135|the|O
DDI-DrugBank.d536.s9|137-142|plasma|O
DDI-DrugBank.d536.s9|144-146|AUC|O
DDI-DrugBank.d536.s9|148-153|values|O
DDI-DrugBank.d536.s9|154-154|.|O
DDI-DrugBank.d536.s10|0-6|However|O
DDI-DrugBank.d536.s10|7-7|,|O
DDI-DrugBank.d536.s10|9-11|the|O
DDI-DrugBank.d536.s10|13-16|peak|O
DDI-DrugBank.d536.s10|18-23|plasma|O
DDI-DrugBank.d536.s10|25-29|level|O
DDI-DrugBank.d536.s10|31-32|of|O
DDI-DrugBank.d536.s10|34-42|metformin|drug
DDI-DrugBank.d536.s10|44-46|was|O
DDI-DrugBank.d536.s10|48-54|reduced|O
DDI-DrugBank.d536.s10|56-57|by|O
DDI-DrugBank.d536.s10|59-71|approximately|O
DDI-DrugBank.d536.s10|73-74|20|O
DDI-DrugBank.d536.s10|75-75|%|O
DDI-DrugBank.d536.s10|77-80|when|O
DDI-DrugBank.d536.s10|82-87|taking|O
DDI-DrugBank.d536.s10|89-96|Acarbose|drug
DDI-DrugBank.d536.s10|98-100|due|O
DDI-DrugBank.d536.s10|102-103|to|O
DDI-DrugBank.d536.s10|105-105|a|O
DDI-DrugBank.d536.s10|107-112|slight|O
DDI-DrugBank.d536.s10|114-118|delay|O
DDI-DrugBank.d536.s10|120-121|in|O
DDI-DrugBank.d536.s10|123-125|the|O
DDI-DrugBank.d536.s10|127-136|absorption|O
DDI-DrugBank.d536.s10|138-139|of|O
DDI-DrugBank.d536.s10|141-149|metformin|drug
DDI-DrugBank.d536.s10|150-150|.|O
DDI-DrugBank.d536.s11|0-4|There|O
DDI-DrugBank.d536.s11|6-7|is|O
DDI-DrugBank.d536.s11|9-14|little|O
DDI-DrugBank.d536.s11|16-17|if|O
DDI-DrugBank.d536.s11|19-21|any|O
DDI-DrugBank.d536.s11|23-32|clinically|O
DDI-DrugBank.d536.s11|34-44|significant|O
DDI-DrugBank.d536.s11|46-56|interaction|O
DDI-DrugBank.d536.s11|58-64|between|O
DDI-DrugBank.d536.s11|66-73|Acarbose|drug
DDI-DrugBank.d536.s11|75-77|and|O
DDI-DrugBank.d536.s11|79-87|metformin|drug
DDI-DrugBank.d536.s11|88-88|.|O
DDI-DrugBank.d211.s0|0-3|When|O
DDI-DrugBank.d211.s0|5-16|administered|O
DDI-DrugBank.d211.s0|18-29|concurrently|O
DDI-DrugBank.d211.s0|30-30|,|O
DDI-DrugBank.d211.s0|32-34|the|O
DDI-DrugBank.d211.s0|36-44|following|O
DDI-DrugBank.d211.s0|46-50|drugs|O
DDI-DrugBank.d211.s0|52-54|may|O
DDI-DrugBank.d211.s0|56-63|interact|O
DDI-DrugBank.d211.s0|65-68|with|O
DDI-DrugBank.d211.s0|70-79|ampicillin|drug
DDI-DrugBank.d211.s0|80-80|.|O
DDI-DrugBank.d211.s1|0-10|Allopurinol|drug
DDI-DrugBank.d211.s1|11-11|:|O
DDI-DrugBank.d211.s1|13-21|Increased|O
DDI-DrugBank.d211.s1|23-33|possibility|O
DDI-DrugBank.d211.s1|35-36|of|O
DDI-DrugBank.d211.s1|38-41|skin|O
DDI-DrugBank.d211.s1|43-46|rash|O
DDI-DrugBank.d211.s1|47-47|,|O
DDI-DrugBank.d211.s1|49-60|particularly|O
DDI-DrugBank.d211.s1|62-63|in|O
DDI-DrugBank.d211.s1|65-77|hyperuricemic|O
DDI-DrugBank.d211.s1|79-86|patients|O
DDI-DrugBank.d211.s1|88-90|may|O
DDI-DrugBank.d211.s1|92-96|occur|O
DDI-DrugBank.d211.s1|97-97|.|O
DDI-DrugBank.d211.s2|0-25|Bacteriostatic Antibiotics|group
DDI-DrugBank.d211.s2|26-26|:|O
DDI-DrugBank.d211.s2|28-42|Chloramphenicol|drug
DDI-DrugBank.d211.s2|43-43|,|O
DDI-DrugBank.d211.s2|45-57|erythromycins|drug
DDI-DrugBank.d211.s2|58-58|,|O
DDI-DrugBank.d211.s2|60-71|sulfonamides|group
DDI-DrugBank.d211.s2|72-72|,|O
DDI-DrugBank.d211.s2|74-75|or|O
DDI-DrugBank.d211.s2|77-89|tetracyclines|group
DDI-DrugBank.d211.s2|91-93|may|O
DDI-DrugBank.d211.s2|95-103|interfere|O
DDI-DrugBank.d211.s2|105-108|with|O
DDI-DrugBank.d211.s2|110-112|the|O
DDI-DrugBank.d211.s2|114-125|bactericidal|O
DDI-DrugBank.d211.s2|127-132|effect|O
DDI-DrugBank.d211.s2|134-135|of|O
DDI-DrugBank.d211.s2|137-147|penicillins|group
DDI-DrugBank.d211.s2|148-148|.|O
DDI-DrugBank.d211.s3|0-3|This|O
DDI-DrugBank.d211.s3|5-7|has|O
DDI-DrugBank.d211.s3|9-12|been|O
DDI-DrugBank.d211.s3|14-25|demonstrated|O
DDI-DrugBank.d211.s3|27-28|in|O
DDI-DrugBank.d211.s3|30-33|view|O
DDI-DrugBank.d211.s3|34-34|,|O
DDI-DrugBank.d211.s3|36-42|however|O
DDI-DrugBank.d211.s3|43-43|,|O
DDI-DrugBank.d211.s3|45-47|the|O
DDI-DrugBank.d211.s3|49-56|clinical|O
DDI-DrugBank.d211.s3|58-69|significance|O
DDI-DrugBank.d211.s3|71-72|of|O
DDI-DrugBank.d211.s3|74-77|this|O
DDI-DrugBank.d211.s3|79-89|interaction|O
DDI-DrugBank.d211.s3|91-92|is|O
DDI-DrugBank.d211.s3|94-96|not|O
DDI-DrugBank.d211.s3|98-101|well|O
DDI-DrugBank.d211.s3|103-112|documented|O
DDI-DrugBank.d211.s3|113-113|.|O
DDI-DrugBank.d211.s4|0-3|Oral|O
DDI-DrugBank.d211.s4|5-18|Contraceptives|group
DDI-DrugBank.d211.s4|19-19|:|O
DDI-DrugBank.d211.s4|21-23|May|O
DDI-DrugBank.d211.s4|25-26|be|O
DDI-DrugBank.d211.s4|28-31|less|O
DDI-DrugBank.d211.s4|33-41|effective|O
DDI-DrugBank.d211.s4|43-45|and|O
DDI-DrugBank.d211.s4|47-55|increased|O
DDI-DrugBank.d211.s4|57-68|breakthrough|O
DDI-DrugBank.d211.s4|70-77|bleeding|O
DDI-DrugBank.d211.s4|79-81|may|O
DDI-DrugBank.d211.s4|83-87|occur|O
DDI-DrugBank.d211.s4|88-88|.|O
DDI-DrugBank.d211.s5|0-9|Probenecid|drug
DDI-DrugBank.d211.s5|10-10|:|O
DDI-DrugBank.d211.s5|12-14|May|O
DDI-DrugBank.d211.s5|16-23|decrease|O
DDI-DrugBank.d211.s5|25-29|renal|O
DDI-DrugBank.d211.s5|31-37|tubular|O
DDI-DrugBank.d211.s5|39-47|secretion|O
DDI-DrugBank.d211.s5|49-50|of|O
DDI-DrugBank.d211.s5|52-61|ampicillin|drug
DDI-DrugBank.d211.s5|63-71|resulting|O
DDI-DrugBank.d211.s5|73-74|in|O
DDI-DrugBank.d211.s5|76-84|increased|O
DDI-DrugBank.d211.s5|86-90|blood|O
DDI-DrugBank.d211.s5|92-97|levels|O
DDI-DrugBank.d211.s5|99-104|and/or|O
DDI-DrugBank.d211.s5|106-115|ampicillin|drug
DDI-DrugBank.d211.s5|117-124|toxicity|O
DDI-DrugBank.d211.s5|125-125|.|O
DDI-DrugBank.d211.s6|0-14|Drug/Laboratory|O
DDI-DrugBank.d211.s6|16-19|Test|O
DDI-DrugBank.d211.s6|21-31|Interaction|O
DDI-DrugBank.d211.s6|33-37|After|O
DDI-DrugBank.d211.s6|39-47|treatment|O
DDI-DrugBank.d211.s6|49-52|with|O
DDI-DrugBank.d211.s6|54-63|ampicillin|drug
DDI-DrugBank.d211.s6|64-64|,|O
DDI-DrugBank.d211.s6|66-66|a|O
DDI-DrugBank.d211.s6|68-81|false-positive|O
DDI-DrugBank.d211.s6|83-90|reaction|O
DDI-DrugBank.d211.s6|92-94|for|O
DDI-DrugBank.d211.s6|96-102|glucose|O
DDI-DrugBank.d211.s6|104-105|in|O
DDI-DrugBank.d211.s6|107-109|the|O
DDI-DrugBank.d211.s6|111-115|urine|O
DDI-DrugBank.d211.s6|117-119|may|O
DDI-DrugBank.d211.s6|121-125|occur|O
DDI-DrugBank.d211.s6|127-130|with|O
DDI-DrugBank.d211.s6|147-151|tests|O
DDI-DrugBank.d211.s6|153-153|(|O
DDI-DrugBank.d211.s6|154-162|Benedicts|O
DDI-DrugBank.d211.s6|164-171|solution|O
DDI-DrugBank.d211.s6|172-172|,|O
DDI-DrugBank.d211.s6|174-181|Fehlings|O
DDI-DrugBank.d211.s6|183-190|solution|O
DDI-DrugBank.d211.s6|191-191|,|O
DDI-DrugBank.d211.s6|193-194|or|O
DDI-DrugBank.d211.s6|196-204|Clinitest|O
DDI-DrugBank.d211.s6|206-212|tablets|O
DDI-DrugBank.d211.s6|213-213|)|O
DDI-DrugBank.d211.s6|215-217|but|O
DDI-DrugBank.d211.s6|219-221|not|O
DDI-DrugBank.d211.s6|223-226|with|O
DDI-DrugBank.d211.s6|228-233|enzyme|O
DDI-DrugBank.d211.s6|235-239|based|O
DDI-DrugBank.d211.s6|241-245|tests|O
DDI-DrugBank.d211.s6|247-250|such|O
DDI-DrugBank.d211.s6|252-253|as|O
DDI-DrugBank.d211.s6|255-263|Clinistix|O
DDI-DrugBank.d211.s6|265-267|and|O
DDI-DrugBank.d211.s6|269-275|Glucose|O
DDI-DrugBank.d211.s6|277-285|Enzymatic|O
DDI-DrugBank.d211.s6|287-290|Test|O
DDI-DrugBank.d211.s6|292-296|Strip|O
DDI-DrugBank.d211.s6|298-300|USP|O
DDI-DrugBank.d211.s6|301-301|.|O
DDI-DrugBank.d75.s0|0-6|Limited|O
DDI-DrugBank.d75.s0|8-9|PK|O
DDI-DrugBank.d75.s0|11-16|and/or|O
DDI-DrugBank.d75.s0|18-19|PD|O
DDI-DrugBank.d75.s0|21-27|studies|O
DDI-DrugBank.d75.s0|29-41|investigating|O
DDI-DrugBank.d75.s0|43-50|possible|O
DDI-DrugBank.d75.s0|52-63|interactions|O
DDI-DrugBank.d75.s0|65-71|between|O
DDI-DrugBank.d75.s0|73-82|anagrelide|drug
DDI-DrugBank.d75.s0|84-86|and|O
DDI-DrugBank.d75.s0|88-92|other|O
DDI-DrugBank.d75.s0|94-102|medicinal|O
DDI-DrugBank.d75.s0|104-111|products|O
DDI-DrugBank.d75.s0|113-116|have|O
DDI-DrugBank.d75.s0|118-121|been|O
DDI-DrugBank.d75.s0|123-131|conducted|O
DDI-DrugBank.d75.s0|132-132|.|O
DDI-DrugBank.d75.s1|0-1|In|O
DDI-DrugBank.d75.s1|3-6|vivo|O
DDI-DrugBank.d75.s1|8-18|interaction|O
DDI-DrugBank.d75.s1|20-26|studies|O
DDI-DrugBank.d75.s1|28-29|in|O
DDI-DrugBank.d75.s1|31-36|humans|O
DDI-DrugBank.d75.s1|38-41|have|O
DDI-DrugBank.d75.s1|43-54|demonstrated|O
DDI-DrugBank.d75.s1|56-59|that|O
DDI-DrugBank.d75.s1|61-67|digoxin|drug
DDI-DrugBank.d75.s1|69-71|and|O
DDI-DrugBank.d75.s1|73-80|warfarin|drug
DDI-DrugBank.d75.s1|82-83|do|O
DDI-DrugBank.d75.s1|85-87|not|O
DDI-DrugBank.d75.s1|89-94|affect|O
DDI-DrugBank.d75.s1|96-98|the|O
DDI-DrugBank.d75.s1|100-101|PK|O
DDI-DrugBank.d75.s1|103-112|properties|O
DDI-DrugBank.d75.s1|114-115|of|O
DDI-DrugBank.d75.s1|117-126|anagrelide|drug
DDI-DrugBank.d75.s1|127-127|,|O
DDI-DrugBank.d75.s1|129-131|nor|O
DDI-DrugBank.d75.s1|133-136|does|O
DDI-DrugBank.d75.s1|138-147|anagrelide|drug
DDI-DrugBank.d75.s1|149-154|affect|O
DDI-DrugBank.d75.s1|156-158|the|O
DDI-DrugBank.d75.s1|160-161|PK|O
DDI-DrugBank.d75.s1|163-172|properties|O
DDI-DrugBank.d75.s1|174-175|of|O
DDI-DrugBank.d75.s1|177-183|digoxin|drug
DDI-DrugBank.d75.s1|185-186|or|O
DDI-DrugBank.d75.s1|188-195|warfarin|drug
DDI-DrugBank.d75.s1|196-196|.|O
DDI-DrugBank.d75.s2|0-7|Although|O
DDI-DrugBank.d75.s2|9-18|additional|O
DDI-DrugBank.d75.s2|20-23|drug|O
DDI-DrugBank.d75.s2|25-35|interaction|O
DDI-DrugBank.d75.s2|37-43|studies|O
DDI-DrugBank.d75.s2|45-48|have|O
DDI-DrugBank.d75.s2|50-52|not|O
DDI-DrugBank.d75.s2|54-57|been|O
DDI-DrugBank.d75.s2|59-67|conducted|O
DDI-DrugBank.d75.s2|68-68|,|O
DDI-DrugBank.d75.s2|70-72|the|O
DDI-DrugBank.d75.s2|74-77|most|O
DDI-DrugBank.d75.s2|79-84|common|O
DDI-DrugBank.d75.s2|86-96|medications|O
DDI-DrugBank.d75.s2|98-101|used|O
DDI-DrugBank.d75.s2|103-115|concomitantly|O
DDI-DrugBank.d75.s2|117-120|with|O
DDI-DrugBank.d75.s2|122-131|anagrelide|drug
DDI-DrugBank.d75.s2|133-134|in|O
DDI-DrugBank.d75.s2|136-143|clinical|O
DDI-DrugBank.d75.s2|145-150|trials|O
DDI-DrugBank.d75.s2|152-155|were|O
DDI-DrugBank.d75.s2|157-163|aspirin|brand
DDI-DrugBank.d75.s2|164-164|,|O
DDI-DrugBank.d75.s2|166-178|acetaminophen|drug
DDI-DrugBank.d75.s2|179-179|,|O
DDI-DrugBank.d75.s2|181-190|furosemide|drug
DDI-DrugBank.d75.s2|191-191|,|O
DDI-DrugBank.d75.s2|193-196|iron|drug
DDI-DrugBank.d75.s2|197-197|,|O
DDI-DrugBank.d75.s2|199-208|ranitidine|drug
DDI-DrugBank.d75.s2|209-209|,|O
DDI-DrugBank.d75.s2|211-221|hydroxyurea|drug
DDI-DrugBank.d75.s2|222-222|,|O
DDI-DrugBank.d75.s2|224-226|and|O
DDI-DrugBank.d75.s2|228-238|allopurinol|drug
DDI-DrugBank.d75.s2|239-239|.|O
DDI-DrugBank.d75.s3|0-4|There|O
DDI-DrugBank.d75.s3|6-7|is|O
DDI-DrugBank.d75.s3|9-10|no|O
DDI-DrugBank.d75.s3|12-19|clinical|O
DDI-DrugBank.d75.s3|21-28|evidence|O
DDI-DrugBank.d75.s3|30-31|to|O
DDI-DrugBank.d75.s3|33-39|suggest|O
DDI-DrugBank.d75.s3|41-44|that|O
DDI-DrugBank.d75.s3|46-55|anagrelide|drug
DDI-DrugBank.d75.s3|57-65|interacts|O
DDI-DrugBank.d75.s3|67-70|with|O
DDI-DrugBank.d75.s3|72-74|any|O
DDI-DrugBank.d75.s3|76-77|of|O
DDI-DrugBank.d75.s3|79-83|these|O
DDI-DrugBank.d75.s3|85-93|compounds|O
DDI-DrugBank.d75.s3|94-94|.|O
DDI-DrugBank.d75.s4|0-1|An|O
DDI-DrugBank.d75.s4|3-4|in|O
DDI-DrugBank.d75.s4|6-9|vivo|O
DDI-DrugBank.d75.s4|11-21|interaction|O
DDI-DrugBank.d75.s4|23-27|study|O
DDI-DrugBank.d75.s4|29-30|in|O
DDI-DrugBank.d75.s4|32-37|humans|O
DDI-DrugBank.d75.s4|39-50|demonstrated|O
DDI-DrugBank.d75.s4|52-55|that|O
DDI-DrugBank.d75.s4|57-57|a|O
DDI-DrugBank.d75.s4|59-64|single|O
DDI-DrugBank.d75.s4|66-68|1mg|O
DDI-DrugBank.d75.s4|70-73|dose|O
DDI-DrugBank.d75.s4|75-76|of|O
DDI-DrugBank.d75.s4|78-87|anagrelide|drug
DDI-DrugBank.d75.s4|89-100|administered|O
DDI-DrugBank.d75.s4|102-114|concomitantly|O
DDI-DrugBank.d75.s4|116-119|with|O
DDI-DrugBank.d75.s4|121-121|a|O
DDI-DrugBank.d75.s4|123-128|single|O
DDI-DrugBank.d75.s4|130-132|900|O
DDI-DrugBank.d75.s4|134-135|mg|O
DDI-DrugBank.d75.s4|137-140|dose|O
DDI-DrugBank.d75.s4|142-143|of|O
DDI-DrugBank.d75.s4|145-151|aspirin|brand
DDI-DrugBank.d75.s4|153-155|was|O
DDI-DrugBank.d75.s4|157-165|generally|O
DDI-DrugBank.d75.s4|167-170|well|O
DDI-DrugBank.d75.s4|172-180|tolerated|O
DDI-DrugBank.d75.s4|181-181|.|O
DDI-DrugBank.d75.s5|0-4|There|O
DDI-DrugBank.d75.s5|6-8|was|O
DDI-DrugBank.d75.s5|10-11|no|O
DDI-DrugBank.d75.s5|13-18|effect|O
DDI-DrugBank.d75.s5|20-21|on|O
DDI-DrugBank.d75.s5|23-30|bleeding|O
DDI-DrugBank.d75.s5|32-35|time|O
DDI-DrugBank.d75.s5|36-36|,|O
DDI-DrugBank.d75.s5|38-39|PT|O
DDI-DrugBank.d75.s5|41-42|or|O
DDI-DrugBank.d75.s5|44-47|aPTT|O
DDI-DrugBank.d75.s5|48-48|.|O
DDI-DrugBank.d75.s6|0-1|No|O
DDI-DrugBank.d75.s6|3-12|clinically|O
DDI-DrugBank.d75.s6|14-21|relevant|O
DDI-DrugBank.d75.s6|23-37|pharmacokinetic|O
DDI-DrugBank.d75.s6|39-50|interactions|O
DDI-DrugBank.d75.s6|52-58|between|O
DDI-DrugBank.d75.s6|60-69|anagrelide|drug
DDI-DrugBank.d75.s6|71-73|and|O
DDI-DrugBank.d75.s6|75-94|acetylsalicylic acid|drug
DDI-DrugBank.d75.s6|96-99|were|O
DDI-DrugBank.d75.s6|101-108|observed|O
DDI-DrugBank.d75.s6|109-109|.|O
DDI-DrugBank.d75.s7|0-1|In|O
DDI-DrugBank.d75.s7|3-6|that|O
DDI-DrugBank.d75.s7|8-11|same|O
DDI-DrugBank.d75.s7|13-17|study|O
DDI-DrugBank.d75.s7|18-18|,|O
DDI-DrugBank.d75.s7|20-26|aspirin|brand
DDI-DrugBank.d75.s7|28-32|alone|O
DDI-DrugBank.d75.s7|34-41|produced|O
DDI-DrugBank.d75.s7|43-43|a|O
DDI-DrugBank.d75.s7|45-50|marked|O
DDI-DrugBank.d75.s7|52-61|inhibition|O
DDI-DrugBank.d75.s7|63-64|in|O
DDI-DrugBank.d75.s7|66-73|platelet|O
DDI-DrugBank.d75.s7|75-85|aggregation|O
DDI-DrugBank.d75.s7|87-88|ex|O
DDI-DrugBank.d75.s7|90-93|vivo|O
DDI-DrugBank.d75.s7|94-94|.|O
DDI-DrugBank.d75.s8|0-9|Anagrelide|drug
DDI-DrugBank.d75.s8|11-15|alone|O
DDI-DrugBank.d75.s8|17-19|had|O
DDI-DrugBank.d75.s8|21-22|no|O
DDI-DrugBank.d75.s8|24-29|effect|O
DDI-DrugBank.d75.s8|31-32|on|O
DDI-DrugBank.d75.s8|34-41|platelet|O
DDI-DrugBank.d75.s8|43-53|aggregation|O
DDI-DrugBank.d75.s8|54-54|,|O
DDI-DrugBank.d75.s8|56-58|but|O
DDI-DrugBank.d75.s8|60-62|did|O
DDI-DrugBank.d75.s8|64-71|slightly|O
DDI-DrugBank.d75.s8|73-79|enhance|O
DDI-DrugBank.d75.s8|81-83|the|O
DDI-DrugBank.d75.s8|85-94|inhibition|O
DDI-DrugBank.d75.s8|96-97|of|O
DDI-DrugBank.d75.s8|99-106|platelet|O
DDI-DrugBank.d75.s8|108-118|aggregation|O
DDI-DrugBank.d75.s8|120-121|by|O
DDI-DrugBank.d75.s8|123-129|aspirin|brand
DDI-DrugBank.d75.s8|130-130|.|O
DDI-DrugBank.d75.s9|0-9|Anagrelide|drug
DDI-DrugBank.d75.s9|11-12|is|O
DDI-DrugBank.d75.s9|14-24|metabolized|O
DDI-DrugBank.d75.s9|26-27|at|O
DDI-DrugBank.d75.s9|29-33|least|O
DDI-DrugBank.d75.s9|35-36|in|O
DDI-DrugBank.d75.s9|38-41|part|O
DDI-DrugBank.d75.s9|43-44|by|O
DDI-DrugBank.d75.s9|46-51|CYP1A2|O
DDI-DrugBank.d75.s9|52-52|.|O
DDI-DrugBank.d75.s10|0-1|It|O
DDI-DrugBank.d75.s10|3-4|is|O
DDI-DrugBank.d75.s10|6-10|known|O
DDI-DrugBank.d75.s10|12-15|that|O
DDI-DrugBank.d75.s10|17-22|CYP1A2|O
DDI-DrugBank.d75.s10|24-25|is|O
DDI-DrugBank.d75.s10|27-35|inhibited|O
DDI-DrugBank.d75.s10|37-38|by|O
DDI-DrugBank.d75.s10|40-46|several|O
DDI-DrugBank.d75.s10|48-56|medicinal|O
DDI-DrugBank.d75.s10|58-65|products|O
DDI-DrugBank.d75.s10|66-66|,|O
DDI-DrugBank.d75.s10|68-76|including|O
DDI-DrugBank.d75.s10|78-88|fluvoxamine|drug
DDI-DrugBank.d75.s10|89-89|,|O
DDI-DrugBank.d75.s10|91-93|and|O
DDI-DrugBank.d75.s10|95-98|such|O
DDI-DrugBank.d75.s10|100-108|medicinal|O
DDI-DrugBank.d75.s10|110-117|products|O
DDI-DrugBank.d75.s10|119-123|could|O
DDI-DrugBank.d75.s10|125-137|theoretically|O
DDI-DrugBank.d75.s10|139-147|adversely|O
DDI-DrugBank.d75.s10|149-157|influence|O
DDI-DrugBank.d75.s10|159-161|the|O
DDI-DrugBank.d75.s10|163-171|clearance|O
DDI-DrugBank.d75.s10|173-174|of|O
DDI-DrugBank.d75.s10|176-185|anagrelide|drug
DDI-DrugBank.d75.s10|186-186|.|O
DDI-DrugBank.d75.s11|0-9|Anagrelide|drug
DDI-DrugBank.d75.s11|11-22|demonstrates|O
DDI-DrugBank.d75.s11|24-27|some|O
DDI-DrugBank.d75.s11|29-35|limited|O
DDI-DrugBank.d75.s11|37-46|inhibitory|O
DDI-DrugBank.d75.s11|48-55|activity|O
DDI-DrugBank.d75.s11|57-63|towards|O
DDI-DrugBank.d75.s11|65-70|CYP1A2|O
DDI-DrugBank.d75.s11|72-76|which|O
DDI-DrugBank.d75.s11|78-80|may|O
DDI-DrugBank.d75.s11|82-88|present|O
DDI-DrugBank.d75.s11|90-90|a|O
DDI-DrugBank.d75.s11|92-102|theoretical|O
DDI-DrugBank.d75.s11|104-112|potential|O
DDI-DrugBank.d75.s11|114-116|for|O
DDI-DrugBank.d75.s11|118-128|interaction|O
DDI-DrugBank.d75.s11|130-133|with|O
DDI-DrugBank.d75.s11|135-139|other|O
DDI-DrugBank.d75.s11|141-154|coadministered|O
DDI-DrugBank.d75.s11|156-164|medicinal|O
DDI-DrugBank.d75.s11|166-173|products|O
DDI-DrugBank.d75.s11|175-181|sharing|O
DDI-DrugBank.d75.s11|183-186|that|O
DDI-DrugBank.d75.s11|188-196|clearance|O
DDI-DrugBank.d75.s11|198-206|mechanism|O
DDI-DrugBank.d75.s11|208-210|e.g|O
DDI-DrugBank.d75.s11|211-211|.|O
DDI-DrugBank.d75.s12|0-9|Anagrelide|drug
DDI-DrugBank.d75.s12|11-22|demonstrates|O
DDI-DrugBank.d75.s12|24-27|some|O
DDI-DrugBank.d75.s12|29-35|limited|O
DDI-DrugBank.d75.s12|37-46|inhibitory|O
DDI-DrugBank.d75.s12|48-55|activity|O
DDI-DrugBank.d75.s12|57-63|towards|O
DDI-DrugBank.d75.s12|65-70|CYP1A2|O
DDI-DrugBank.d75.s12|72-76|which|O
DDI-DrugBank.d75.s12|78-80|may|O
DDI-DrugBank.d75.s12|82-88|present|O
DDI-DrugBank.d75.s12|90-90|a|O
DDI-DrugBank.d75.s12|92-102|theoretical|O
DDI-DrugBank.d75.s12|104-112|potential|O
DDI-DrugBank.d75.s12|114-116|for|O
DDI-DrugBank.d75.s12|118-128|interaction|O
DDI-DrugBank.d75.s12|130-133|with|O
DDI-DrugBank.d75.s12|135-139|other|O
DDI-DrugBank.d75.s12|141-154|coadministered|O
DDI-DrugBank.d75.s12|156-164|medicinal|O
DDI-DrugBank.d75.s12|166-173|products|O
DDI-DrugBank.d75.s12|175-181|sharing|O
DDI-DrugBank.d75.s12|183-186|that|O
DDI-DrugBank.d75.s12|188-196|clearance|O
DDI-DrugBank.d75.s12|198-206|mechanism|O
DDI-DrugBank.d75.s12|208-211|e.g.|O
DDI-DrugBank.d75.s12|213-224|theophylline|drug
DDI-DrugBank.d75.s12|225-225|.|O
DDI-DrugBank.d75.s13|0-9|Anagrelide|drug
DDI-DrugBank.d75.s13|11-12|is|O
DDI-DrugBank.d75.s13|14-15|an|O
DDI-DrugBank.d75.s13|17-25|inhibitor|O
DDI-DrugBank.d75.s13|27-28|of|O
DDI-DrugBank.d75.s13|30-35|cyclic|O
DDI-DrugBank.d75.s13|37-39|AMP|O
DDI-DrugBank.d75.s13|41-43|PDE|O
DDI-DrugBank.d75.s13|45-47|III|O
DDI-DrugBank.d75.s13|48-48|.|O
DDI-DrugBank.d75.s14|0-2|The|O
DDI-DrugBank.d75.s14|4-10|effects|O
DDI-DrugBank.d75.s14|12-13|of|O
DDI-DrugBank.d75.s14|15-23|medicinal|O
DDI-DrugBank.d75.s14|25-32|products|O
DDI-DrugBank.d75.s14|34-37|with|O
DDI-DrugBank.d75.s14|39-45|similar|O
DDI-DrugBank.d75.s14|47-56|properties|O
DDI-DrugBank.d75.s14|58-61|such|O
DDI-DrugBank.d75.s14|63-64|as|O
DDI-DrugBank.d75.s14|66-74|inotropes|O
DDI-DrugBank.d75.s14|76-84|milrinone|drug
DDI-DrugBank.d75.s14|85-85|,|O
DDI-DrugBank.d75.s14|87-95|enoximone|drug
DDI-DrugBank.d75.s14|96-96|,|O
DDI-DrugBank.d75.s14|98-105|amrinone|drug
DDI-DrugBank.d75.s14|106-106|,|O
DDI-DrugBank.d75.s14|118-120|and|O
DDI-DrugBank.d75.s14|122-131|cilostazol|drug
DDI-DrugBank.d75.s14|133-135|may|O
DDI-DrugBank.d75.s14|137-138|be|O
DDI-DrugBank.d75.s14|140-150|exacerbated|O
DDI-DrugBank.d75.s14|152-153|by|O
DDI-DrugBank.d75.s14|155-164|anagrelide|drug
DDI-DrugBank.d75.s14|165-165|.|O
DDI-DrugBank.d75.s15|0-4|There|O
DDI-DrugBank.d75.s15|6-7|is|O
DDI-DrugBank.d75.s15|9-9|a|O
DDI-DrugBank.d75.s15|11-16|single|O
DDI-DrugBank.d75.s15|18-21|case|O
DDI-DrugBank.d75.s15|23-28|report|O
DDI-DrugBank.d75.s15|29-29|,|O
DDI-DrugBank.d75.s15|31-35|which|O
DDI-DrugBank.d75.s15|37-44|suggests|O
DDI-DrugBank.d75.s15|46-49|that|O
DDI-DrugBank.d75.s15|51-60|sucralfate|drug
DDI-DrugBank.d75.s15|62-64|may|O
DDI-DrugBank.d75.s15|66-74|interfere|O
DDI-DrugBank.d75.s15|76-79|with|O
DDI-DrugBank.d75.s15|81-90|anagrelide|drug
DDI-DrugBank.d75.s15|92-101|absorption|O
DDI-DrugBank.d75.s15|102-102|.|O
DDI-DrugBank.d75.s16|0-3|Food|O
DDI-DrugBank.d75.s16|5-7|has|O
DDI-DrugBank.d75.s16|9-10|no|O
DDI-DrugBank.d75.s16|12-21|clinically|O
DDI-DrugBank.d75.s16|23-33|significant|O
DDI-DrugBank.d75.s16|35-40|effect|O
DDI-DrugBank.d75.s16|42-43|on|O
DDI-DrugBank.d75.s16|45-47|the|O
DDI-DrugBank.d75.s16|49-63|bioavailability|O
DDI-DrugBank.d75.s16|65-66|of|O
DDI-DrugBank.d75.s16|68-77|anagrelide|drug
DDI-DrugBank.d75.s16|78-78|.|O
DDI-DrugBank.d471.s0|0-10|Mineral oil|drug
DDI-DrugBank.d471.s0|12-21|interferes|O
DDI-DrugBank.d471.s0|23-26|with|O
DDI-DrugBank.d471.s0|28-30|the|O
DDI-DrugBank.d471.s0|32-41|absorption|O
DDI-DrugBank.d471.s0|43-44|of|O
DDI-DrugBank.d471.s0|46-65|fat-soluble vitamins|group
DDI-DrugBank.d471.s0|66-66|,|O
DDI-DrugBank.d471.s0|68-76|including|O
DDI-DrugBank.d471.s0|78-99|vitamin D preparations|group
DDI-DrugBank.d471.s0|100-100|.|O
DDI-DrugBank.d471.s1|0-13|Administration|O
DDI-DrugBank.d471.s1|15-16|of|O
DDI-DrugBank.d471.s1|18-35|thiazide diuretics|group
DDI-DrugBank.d471.s1|37-38|to|O
DDI-DrugBank.d471.s1|40-54|hypoparathyroid|O
DDI-DrugBank.d471.s1|56-63|patients|O
DDI-DrugBank.d471.s1|65-67|who|O
DDI-DrugBank.d471.s1|69-71|are|O
DDI-DrugBank.d471.s1|73-84|concurrently|O
DDI-DrugBank.d471.s1|86-90|being|O
DDI-DrugBank.d471.s1|92-98|treated|O
DDI-DrugBank.d471.s1|100-103|with|O
DDI-DrugBank.d471.s1|105-118|ergocalciferol|drug
DDI-DrugBank.d471.s1|120-122|may|O
DDI-DrugBank.d471.s1|124-128|cause|O
DDI-DrugBank.d471.s1|130-142|hypercalcemia|O
DDI-DrugBank.d471.s1|143-143|.|O
DDI-DrugBank.d52.s0|0-10|Concomitant|O
DDI-DrugBank.d52.s0|12-20|treatment|O
DDI-DrugBank.d52.s0|22-25|with|O
DDI-DrugBank.d52.s0|27-39|thrombolytics|group
DDI-DrugBank.d52.s0|41-41|(|O
DDI-DrugBank.d52.s0|42-43|eg|O
DDI-DrugBank.d52.s0|44-44|,|O
DDI-DrugBank.d52.s0|46-50|rt-PA|O
DDI-DrugBank.d52.s0|52-53|or|O
DDI-DrugBank.d52.s0|55-67|streptokinase|drug
DDI-DrugBank.d52.s0|68-68|)|O
DDI-DrugBank.d52.s0|70-72|may|O
DDI-DrugBank.d52.s0|73-73|:|O
DDI-DrugBank.d52.s0|75-75|-|O
DDI-DrugBank.d52.s0|77-84|increase|O
DDI-DrugBank.d52.s0|86-88|the|O
DDI-DrugBank.d52.s0|90-93|risk|O
DDI-DrugBank.d52.s0|95-96|of|O
DDI-DrugBank.d52.s0|98-105|bleeding|O
DDI-DrugBank.d52.s0|107-119|complications|O
DDI-DrugBank.d52.s0|121-121|-|O
DDI-DrugBank.d52.s0|123-134|considerably|O
DDI-DrugBank.d52.s0|136-142|enhance|O
DDI-DrugBank.d52.s0|144-146|the|O
DDI-DrugBank.d52.s0|148-153|effect|O
DDI-DrugBank.d52.s0|155-156|of|O
DDI-DrugBank.d52.s0|158-165|REFLUDAN|brand
DDI-DrugBank.d52.s0|167-168|on|O
DDI-DrugBank.d52.s0|170-173|aPTT|O
DDI-DrugBank.d52.s0|175-186|prolongation|O
DDI-DrugBank.d52.s1|0-10|Concomitant|O
DDI-DrugBank.d52.s1|12-20|treatment|O
DDI-DrugBank.d52.s1|22-25|with|O
DDI-DrugBank.d52.s1|27-46|coumarin derivatives|group
DDI-DrugBank.d52.s1|48-48|(|O
DDI-DrugBank.d52.s1|49-69|vitamin K antagonists|group
DDI-DrugBank.d52.s1|70-70|)|O
DDI-DrugBank.d52.s1|72-74|and|O
DDI-DrugBank.d52.s1|76-80|drugs|O
DDI-DrugBank.d52.s1|82-85|that|O
DDI-DrugBank.d52.s1|87-92|affect|O
DDI-DrugBank.d52.s1|94-101|platelet|O
DDI-DrugBank.d52.s1|103-110|function|O
DDI-DrugBank.d52.s1|112-114|may|O
DDI-DrugBank.d52.s1|116-119|also|O
DDI-DrugBank.d52.s1|121-128|increase|O
DDI-DrugBank.d52.s1|130-132|the|O
DDI-DrugBank.d52.s1|134-137|risk|O
DDI-DrugBank.d52.s1|139-140|of|O
DDI-DrugBank.d52.s1|142-149|bleeding|O
DDI-DrugBank.d52.s1|150-150|.|O
DDI-DrugBank.d300.s0|0-1|No|O
DDI-DrugBank.d300.s0|3-8|formal|O
DDI-DrugBank.d300.s0|10-13|drug|O
DDI-DrugBank.d300.s0|15-25|interaction|O
DDI-DrugBank.d300.s0|27-33|studies|O
DDI-DrugBank.d300.s0|35-38|have|O
DDI-DrugBank.d300.s0|40-43|been|O
DDI-DrugBank.d300.s0|45-53|conducted|O
DDI-DrugBank.d300.s0|54-54|.|O
DDI-DrugBank.d364.s0|0-6|Because|O
DDI-DrugBank.d364.s0|8-16|alosetron|drug
DDI-DrugBank.d364.s0|18-19|is|O
DDI-DrugBank.d364.s0|21-31|metabolized|O
DDI-DrugBank.d364.s0|33-34|by|O
DDI-DrugBank.d364.s0|36-36|a|O
DDI-DrugBank.d364.s0|38-44|variety|O
DDI-DrugBank.d364.s0|46-47|of|O
DDI-DrugBank.d364.s0|49-55|hepatic|O
DDI-DrugBank.d364.s0|57-59|CYP|O
DDI-DrugBank.d364.s0|61-77|drug-metabolizing|O
DDI-DrugBank.d364.s0|79-85|enzymes|O
DDI-DrugBank.d364.s0|86-86|,|O
DDI-DrugBank.d364.s0|88-95|inducers|O
DDI-DrugBank.d364.s0|97-98|or|O
DDI-DrugBank.d364.s0|100-109|inhibitors|O
DDI-DrugBank.d364.s0|111-112|of|O
DDI-DrugBank.d364.s0|114-118|these|O
DDI-DrugBank.d364.s0|120-126|enzymes|O
DDI-DrugBank.d364.s0|128-130|may|O
DDI-DrugBank.d364.s0|132-137|change|O
DDI-DrugBank.d364.s0|139-141|the|O
DDI-DrugBank.d364.s0|143-151|clearance|O
DDI-DrugBank.d364.s0|153-154|of|O
DDI-DrugBank.d364.s0|156-164|alosetron|drug
DDI-DrugBank.d364.s0|165-165|.|O
DDI-DrugBank.d364.s1|0-10|Fluvoxamine|drug
DDI-DrugBank.d364.s1|12-13|is|O
DDI-DrugBank.d364.s1|15-15|a|O
DDI-DrugBank.d364.s1|17-21|known|O
DDI-DrugBank.d364.s1|23-28|strong|O
DDI-DrugBank.d364.s1|30-38|inhibitor|O
DDI-DrugBank.d364.s1|40-41|of|O
DDI-DrugBank.d364.s1|43-48|CYP1A2|O
DDI-DrugBank.d364.s1|50-52|and|O
DDI-DrugBank.d364.s1|54-57|also|O
DDI-DrugBank.d364.s1|59-66|inhibits|O
DDI-DrugBank.d364.s1|68-73|CYP3A4|O
DDI-DrugBank.d364.s1|74-74|,|O
DDI-DrugBank.d364.s1|76-81|CYP2C9|O
DDI-DrugBank.d364.s1|82-82|,|O
DDI-DrugBank.d364.s1|84-86|and|O
DDI-DrugBank.d364.s1|88-94|CYP2C19|O
DDI-DrugBank.d364.s1|95-95|.|O
DDI-DrugBank.d364.s2|0-1|In|O
DDI-DrugBank.d364.s2|3-3|a|O
DDI-DrugBank.d364.s2|5-19|pharmacokinetic|O
DDI-DrugBank.d364.s2|21-25|study|O
DDI-DrugBank.d364.s2|26-26|,|O
DDI-DrugBank.d364.s2|28-29|40|O
DDI-DrugBank.d364.s2|31-37|healthy|O
DDI-DrugBank.d364.s2|39-44|female|O
DDI-DrugBank.d364.s2|46-53|subjects|O
DDI-DrugBank.d364.s2|55-62|received|O
DDI-DrugBank.d364.s2|64-74|fluvoxamine|drug
DDI-DrugBank.d364.s2|76-77|in|O
DDI-DrugBank.d364.s2|79-88|escalating|O
DDI-DrugBank.d364.s2|90-94|doses|O
DDI-DrugBank.d364.s2|96-99|from|O
DDI-DrugBank.d364.s2|101-102|50|O
DDI-DrugBank.d364.s2|104-105|to|O
DDI-DrugBank.d364.s2|107-109|200|O
DDI-DrugBank.d364.s2|111-112|mg|O
DDI-DrugBank.d364.s2|114-116|per|O
DDI-DrugBank.d364.s2|118-120|day|O
DDI-DrugBank.d364.s2|122-124|for|O
DDI-DrugBank.d364.s2|126-127|16|O
DDI-DrugBank.d364.s2|129-132|days|O
DDI-DrugBank.d364.s2|133-133|,|O
DDI-DrugBank.d364.s2|135-138|with|O
DDI-DrugBank.d364.s2|140-155|coadministration|O
DDI-DrugBank.d364.s2|157-158|of|O
DDI-DrugBank.d364.s2|160-168|alosetron|drug
DDI-DrugBank.d364.s2|170-170|1|O
DDI-DrugBank.d364.s2|172-173|mg|O
DDI-DrugBank.d364.s2|175-176|on|O
DDI-DrugBank.d364.s2|178-180|the|O
DDI-DrugBank.d364.s2|182-185|last|O
DDI-DrugBank.d364.s2|187-189|day|O
DDI-DrugBank.d364.s2|190-190|.|O
DDI-DrugBank.d364.s3|0-10|Fluvoxamine|drug
DDI-DrugBank.d364.s3|12-20|increased|O
DDI-DrugBank.d364.s3|22-25|mean|O
DDI-DrugBank.d364.s3|27-35|alosetron|drug
DDI-DrugBank.d364.s3|37-42|plasma|O
DDI-DrugBank.d364.s3|44-57|concentrations|O
DDI-DrugBank.d364.s3|59-59|(|O
DDI-DrugBank.d364.s3|60-62|AUC|O
DDI-DrugBank.d364.s3|63-63|)|O
DDI-DrugBank.d364.s3|65-77|approximately|O
DDI-DrugBank.d364.s3|79-84|6-fold|O
DDI-DrugBank.d364.s3|86-88|and|O
DDI-DrugBank.d364.s3|90-98|prolonged|O
DDI-DrugBank.d364.s3|100-102|the|O
DDI-DrugBank.d364.s3|104-112|half-life|O
DDI-DrugBank.d364.s3|114-115|by|O
DDI-DrugBank.d364.s3|117-129|approximately|O
DDI-DrugBank.d364.s3|131-136|3-fold|O
DDI-DrugBank.d364.s3|137-137|.|O
DDI-DrugBank.d364.s4|0-10|Concomitant|O
DDI-DrugBank.d364.s4|12-25|administration|O
DDI-DrugBank.d364.s4|27-28|of|O
DDI-DrugBank.d364.s4|30-38|alosetron|drug
DDI-DrugBank.d364.s4|40-42|and|O
DDI-DrugBank.d364.s4|44-54|fluvoxamine|drug
DDI-DrugBank.d364.s4|56-57|is|O
DDI-DrugBank.d364.s4|59-73|contraindicated|O
DDI-DrugBank.d364.s4|74-74|.|O
DDI-DrugBank.d364.s5|0-10|Concomitant|O
DDI-DrugBank.d364.s5|12-25|administration|O
DDI-DrugBank.d364.s5|27-28|of|O
DDI-DrugBank.d364.s5|30-38|alosetron|drug
DDI-DrugBank.d364.s5|40-42|and|O
DDI-DrugBank.d364.s5|44-51|moderate|O
DDI-DrugBank.d364.s5|53-58|CYP1A2|O
DDI-DrugBank.d364.s5|60-69|inhibitors|O
DDI-DrugBank.d364.s5|70-70|,|O
DDI-DrugBank.d364.s5|72-80|including|O
DDI-DrugBank.d364.s5|82-102|quinolone antibiotics|group
DDI-DrugBank.d364.s5|104-106|and|O
DDI-DrugBank.d364.s5|108-117|cimetidine|drug
DDI-DrugBank.d364.s5|118-118|,|O
DDI-DrugBank.d364.s5|120-122|has|O
DDI-DrugBank.d364.s5|124-126|not|O
DDI-DrugBank.d364.s5|128-131|been|O
DDI-DrugBank.d364.s5|133-141|evaluated|O
DDI-DrugBank.d364.s5|142-142|,|O
DDI-DrugBank.d364.s5|144-146|but|O
DDI-DrugBank.d364.s5|148-153|should|O
DDI-DrugBank.d364.s5|155-156|be|O
DDI-DrugBank.d364.s5|158-164|avoided|O
DDI-DrugBank.d364.s5|166-171|unless|O
DDI-DrugBank.d364.s5|173-182|clinically|O
DDI-DrugBank.d364.s5|184-192|necessary|O
DDI-DrugBank.d364.s5|194-200|because|O
DDI-DrugBank.d364.s5|202-203|of|O
DDI-DrugBank.d364.s5|205-211|similar|O
DDI-DrugBank.d364.s5|213-221|potential|O
DDI-DrugBank.d364.s5|223-226|drug|O
DDI-DrugBank.d364.s5|228-239|interactions|O
DDI-DrugBank.d364.s5|240-240|.|O
DDI-DrugBank.d364.s6|0-11|Ketoconazole|drug
DDI-DrugBank.d364.s6|13-14|is|O
DDI-DrugBank.d364.s6|16-16|a|O
DDI-DrugBank.d364.s6|18-22|known|O
DDI-DrugBank.d364.s6|24-29|strong|O
DDI-DrugBank.d364.s6|31-39|inhibitor|O
DDI-DrugBank.d364.s6|41-42|of|O
DDI-DrugBank.d364.s6|44-49|CYP3A4|O
DDI-DrugBank.d364.s6|50-50|.|O
DDI-DrugBank.d364.s7|0-1|In|O
DDI-DrugBank.d364.s7|3-3|a|O
DDI-DrugBank.d364.s7|5-19|pharmacokinetic|O
DDI-DrugBank.d364.s7|21-25|study|O
DDI-DrugBank.d364.s7|26-26|,|O
DDI-DrugBank.d364.s7|28-29|38|O
DDI-DrugBank.d364.s7|31-37|healthy|O
DDI-DrugBank.d364.s7|39-44|female|O
DDI-DrugBank.d364.s7|46-53|subjects|O
DDI-DrugBank.d364.s7|55-62|received|O
DDI-DrugBank.d364.s7|64-75|ketoconazole|drug
DDI-DrugBank.d364.s7|77-79|200|O
DDI-DrugBank.d364.s7|81-82|mg|O
DDI-DrugBank.d364.s7|84-88|twice|O
DDI-DrugBank.d364.s7|90-94|daily|O
DDI-DrugBank.d364.s7|96-98|for|O
DDI-DrugBank.d364.s7|100-100|7|O
DDI-DrugBank.d364.s7|102-105|days|O
DDI-DrugBank.d364.s7|106-106|,|O
DDI-DrugBank.d364.s7|108-111|with|O
DDI-DrugBank.d364.s7|113-128|coadministration|O
DDI-DrugBank.d364.s7|130-131|of|O
DDI-DrugBank.d364.s7|133-141|alosetron|drug
DDI-DrugBank.d364.s7|143-143|1|O
DDI-DrugBank.d364.s7|145-146|mg|O
DDI-DrugBank.d364.s7|148-149|on|O
DDI-DrugBank.d364.s7|151-153|the|O
DDI-DrugBank.d364.s7|155-158|last|O
DDI-DrugBank.d364.s7|160-162|day|O
DDI-DrugBank.d364.s7|163-163|.|O
DDI-DrugBank.d364.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d364.s8|13-21|increased|O
DDI-DrugBank.d364.s8|23-26|mean|O
DDI-DrugBank.d364.s8|28-36|alosetron|drug
DDI-DrugBank.d364.s8|38-43|plasma|O
DDI-DrugBank.d364.s8|45-58|concentrations|O
DDI-DrugBank.d364.s8|60-60|(|O
DDI-DrugBank.d364.s8|61-63|AUC|O
DDI-DrugBank.d364.s8|64-64|)|O
DDI-DrugBank.d364.s8|66-67|by|O
DDI-DrugBank.d364.s8|69-70|29|O
DDI-DrugBank.d364.s8|71-71|%|O
DDI-DrugBank.d364.s8|72-72|.|O
DDI-DrugBank.d364.s9|0-6|Caution|O
DDI-DrugBank.d364.s9|8-13|should|O
DDI-DrugBank.d364.s9|15-16|be|O
DDI-DrugBank.d364.s9|18-21|used|O
DDI-DrugBank.d364.s9|23-26|when|O
DDI-DrugBank.d364.s9|28-36|alosetron|drug
DDI-DrugBank.d364.s9|38-40|and|O
DDI-DrugBank.d364.s9|42-53|ketoconazole|drug
DDI-DrugBank.d364.s9|55-57|are|O
DDI-DrugBank.d364.s9|59-70|administered|O
DDI-DrugBank.d364.s9|72-84|concomitantly|O
DDI-DrugBank.d364.s9|85-85|.|O
DDI-DrugBank.d364.s10|0-15|Coadministration|O
DDI-DrugBank.d364.s10|17-18|of|O
DDI-DrugBank.d364.s10|20-28|alosetron|drug
DDI-DrugBank.d364.s10|30-32|and|O
DDI-DrugBank.d364.s10|34-39|strong|O
DDI-DrugBank.d364.s10|41-46|CYP3A4|O
DDI-DrugBank.d364.s10|48-57|inhibitors|O
DDI-DrugBank.d364.s10|58-58|,|O
DDI-DrugBank.d364.s10|60-63|such|O
DDI-DrugBank.d364.s10|65-66|as|O
DDI-DrugBank.d364.s10|68-81|clarithromycin|drug
DDI-DrugBank.d364.s10|82-82|,|O
DDI-DrugBank.d364.s10|84-96|telithromycin|drug
DDI-DrugBank.d364.s10|97-97|,|O
DDI-DrugBank.d364.s10|99-117|protease inhibitors|group
DDI-DrugBank.d364.s10|118-118|,|O
DDI-DrugBank.d364.s10|120-131|voriconazole|drug
DDI-DrugBank.d364.s10|132-132|,|O
DDI-DrugBank.d364.s10|134-136|and|O
DDI-DrugBank.d364.s10|138-149|itraconazole|drug
DDI-DrugBank.d364.s10|151-153|has|O
DDI-DrugBank.d364.s10|155-157|not|O
DDI-DrugBank.d364.s10|159-162|been|O
DDI-DrugBank.d364.s10|164-172|evaluated|O
DDI-DrugBank.d364.s10|174-176|but|O
DDI-DrugBank.d364.s10|178-183|should|O
DDI-DrugBank.d364.s10|185-186|be|O
DDI-DrugBank.d364.s10|188-197|undertaken|O
DDI-DrugBank.d364.s10|199-202|with|O
DDI-DrugBank.d364.s10|204-210|caution|O
DDI-DrugBank.d364.s10|212-218|because|O
DDI-DrugBank.d364.s10|220-221|of|O
DDI-DrugBank.d364.s10|223-229|similar|O
DDI-DrugBank.d364.s10|231-239|potential|O
DDI-DrugBank.d364.s10|241-244|drug|O
DDI-DrugBank.d364.s10|246-257|interactions|O
DDI-DrugBank.d364.s10|258-258|.|O
DDI-DrugBank.d364.s11|0-2|The|O
DDI-DrugBank.d364.s11|4-9|effect|O
DDI-DrugBank.d364.s11|11-12|of|O
DDI-DrugBank.d364.s11|14-22|induction|O
DDI-DrugBank.d364.s11|24-25|or|O
DDI-DrugBank.d364.s11|27-36|inhibition|O
DDI-DrugBank.d364.s11|38-39|of|O
DDI-DrugBank.d364.s11|41-45|other|O
DDI-DrugBank.d364.s11|47-54|pathways|O
DDI-DrugBank.d364.s11|56-57|on|O
DDI-DrugBank.d364.s11|59-66|exposure|O
DDI-DrugBank.d364.s11|68-69|to|O
DDI-DrugBank.d364.s11|71-79|alosetron|drug
DDI-DrugBank.d364.s11|81-83|and|O
DDI-DrugBank.d364.s11|85-87|its|O
DDI-DrugBank.d364.s11|89-99|metabolites|O
DDI-DrugBank.d364.s11|101-102|is|O
DDI-DrugBank.d364.s11|104-106|not|O
DDI-DrugBank.d364.s11|108-112|known|O
DDI-DrugBank.d364.s11|113-113|.|O
DDI-DrugBank.d364.s12|0-1|In|O
DDI-DrugBank.d364.s12|3-7|vitro|O
DDI-DrugBank.d364.s12|9-13|human|O
DDI-DrugBank.d364.s12|15-19|liver|O
DDI-DrugBank.d364.s12|21-29|microsome|O
DDI-DrugBank.d364.s12|31-37|studies|O
DDI-DrugBank.d364.s12|39-41|and|O
DDI-DrugBank.d364.s12|43-44|an|O
DDI-DrugBank.d364.s12|46-47|in|O
DDI-DrugBank.d364.s12|49-52|vivo|O
DDI-DrugBank.d364.s12|54-62|metabolic|O
DDI-DrugBank.d364.s12|64-68|probe|O
DDI-DrugBank.d364.s12|70-74|study|O
DDI-DrugBank.d364.s12|76-87|demonstrated|O
DDI-DrugBank.d364.s12|89-92|that|O
DDI-DrugBank.d364.s12|94-102|alosetron|drug
DDI-DrugBank.d364.s12|104-106|did|O
DDI-DrugBank.d364.s12|108-110|not|O
DDI-DrugBank.d364.s12|112-118|inhibit|O
DDI-DrugBank.d364.s12|120-122|CYP|O
DDI-DrugBank.d364.s12|124-130|enzymes|O
DDI-DrugBank.d364.s12|132-134|2D6|O
DDI-DrugBank.d364.s12|135-135|,|O
DDI-DrugBank.d364.s12|137-139|3A4|O
DDI-DrugBank.d364.s12|140-140|,|O
DDI-DrugBank.d364.s12|142-144|2C9|O
DDI-DrugBank.d364.s12|145-145|,|O
DDI-DrugBank.d364.s12|147-148|or|O
DDI-DrugBank.d364.s12|150-153|2C19|O
DDI-DrugBank.d364.s12|154-154|.|O
DDI-DrugBank.d364.s13|0-1|In|O
DDI-DrugBank.d364.s13|3-7|vitro|O
DDI-DrugBank.d364.s13|8-8|,|O
DDI-DrugBank.d364.s13|10-11|at|O
DDI-DrugBank.d364.s13|13-17|total|O
DDI-DrugBank.d364.s13|19-22|drug|O
DDI-DrugBank.d364.s13|24-37|concentrations|O
DDI-DrugBank.d364.s13|39-45|27-fold|O
DDI-DrugBank.d364.s13|47-52|higher|O
DDI-DrugBank.d364.s13|54-57|than|O
DDI-DrugBank.d364.s13|59-62|peak|O
DDI-DrugBank.d364.s13|64-69|plasma|O
DDI-DrugBank.d364.s13|71-84|concentrations|O
DDI-DrugBank.d364.s13|86-93|observed|O
DDI-DrugBank.d364.s13|95-98|with|O
DDI-DrugBank.d364.s13|100-102|the|O
DDI-DrugBank.d364.s13|104-107|1-mg|O
DDI-DrugBank.d364.s13|109-114|dosage|O
DDI-DrugBank.d364.s13|115-115|,|O
DDI-DrugBank.d364.s13|117-125|alosetron|drug
DDI-DrugBank.d364.s13|127-135|inhibited|O
DDI-DrugBank.d364.s13|137-139|CYP|O
DDI-DrugBank.d364.s13|141-147|enzymes|O
DDI-DrugBank.d364.s13|149-151|1A2|O
DDI-DrugBank.d364.s13|153-153|(|O
DDI-DrugBank.d364.s13|154-155|60|O
DDI-DrugBank.d364.s13|156-156|%|O
DDI-DrugBank.d364.s13|157-157|)|O
DDI-DrugBank.d364.s13|159-161|and|O
DDI-DrugBank.d364.s13|163-165|2E1|O
DDI-DrugBank.d364.s13|167-167|(|O
DDI-DrugBank.d364.s13|168-169|50|O
DDI-DrugBank.d364.s13|170-170|%|O
DDI-DrugBank.d364.s13|171-171|)|O
DDI-DrugBank.d364.s13|172-172|.|O
DDI-DrugBank.d364.s14|0-1|In|O
DDI-DrugBank.d364.s14|3-4|an|O
DDI-DrugBank.d364.s14|6-7|in|O
DDI-DrugBank.d364.s14|9-12|vivo|O
DDI-DrugBank.d364.s14|14-22|metabolic|O
DDI-DrugBank.d364.s14|24-28|probe|O
DDI-DrugBank.d364.s14|30-34|study|O
DDI-DrugBank.d364.s14|35-35|,|O
DDI-DrugBank.d364.s14|37-45|alosetron|drug
DDI-DrugBank.d364.s14|47-49|did|O
DDI-DrugBank.d364.s14|51-53|not|O
DDI-DrugBank.d364.s14|55-61|inhibit|O
DDI-DrugBank.d364.s14|63-68|CYP2E1|O
DDI-DrugBank.d364.s14|70-72|but|O
DDI-DrugBank.d364.s14|74-76|did|O
DDI-DrugBank.d364.s14|78-84|produce|O
DDI-DrugBank.d364.s14|86-87|30|O
DDI-DrugBank.d364.s14|88-88|%|O
DDI-DrugBank.d364.s14|90-99|inhibition|O
DDI-DrugBank.d364.s14|101-102|of|O
DDI-DrugBank.d364.s14|104-107|both|O
DDI-DrugBank.d364.s14|109-114|CYP1A2|O
DDI-DrugBank.d364.s14|116-118|and|O
DDI-DrugBank.d364.s14|120-138|N-acetyltransferase|O
DDI-DrugBank.d364.s14|139-139|.|O
DDI-DrugBank.d364.s15|0-7|Although|O
DDI-DrugBank.d364.s15|9-11|not|O
DDI-DrugBank.d364.s15|13-19|studied|O
DDI-DrugBank.d364.s15|21-24|with|O
DDI-DrugBank.d364.s15|26-34|alosetron|drug
DDI-DrugBank.d364.s15|35-35|,|O
DDI-DrugBank.d364.s15|37-46|inhibition|O
DDI-DrugBank.d364.s15|48-49|of|O
DDI-DrugBank.d364.s15|51-69|N-acetyltransferase|O
DDI-DrugBank.d364.s15|71-73|may|O
DDI-DrugBank.d364.s15|75-78|have|O
DDI-DrugBank.d364.s15|80-89|clinically|O
DDI-DrugBank.d364.s15|91-98|relevant|O
DDI-DrugBank.d364.s15|100-111|consequences|O
DDI-DrugBank.d364.s15|113-115|for|O
DDI-DrugBank.d364.s15|117-121|drugs|O
DDI-DrugBank.d364.s15|123-126|such|O
DDI-DrugBank.d364.s15|128-129|as|O
DDI-DrugBank.d364.s15|131-139|isoniazid|drug
DDI-DrugBank.d364.s15|140-140|,|O
DDI-DrugBank.d364.s15|142-153|procainamide|drug
DDI-DrugBank.d364.s15|154-154|,|O
DDI-DrugBank.d364.s15|156-158|and|O
DDI-DrugBank.d364.s15|160-170|hydralazine|drug
DDI-DrugBank.d364.s15|171-171|.|O
DDI-DrugBank.d364.s16|0-2|The|O
DDI-DrugBank.d364.s16|4-9|effect|O
DDI-DrugBank.d364.s16|11-12|on|O
DDI-DrugBank.d364.s16|14-19|CYP1A2|O
DDI-DrugBank.d364.s16|21-23|was|O
DDI-DrugBank.d364.s16|25-32|explored|O
DDI-DrugBank.d364.s16|34-40|further|O
DDI-DrugBank.d364.s16|42-43|in|O
DDI-DrugBank.d364.s16|45-45|a|O
DDI-DrugBank.d364.s16|47-54|clinical|O
DDI-DrugBank.d364.s16|56-66|interaction|O
DDI-DrugBank.d364.s16|68-72|study|O
DDI-DrugBank.d364.s16|74-77|with|O
DDI-DrugBank.d364.s16|79-90|theophylline|drug
DDI-DrugBank.d364.s16|92-94|and|O
DDI-DrugBank.d364.s16|96-97|no|O
DDI-DrugBank.d364.s16|99-104|effect|O
DDI-DrugBank.d364.s16|106-107|on|O
DDI-DrugBank.d364.s16|109-118|metabolism|O
DDI-DrugBank.d364.s16|120-122|was|O
DDI-DrugBank.d364.s16|124-131|observed|O
DDI-DrugBank.d364.s16|132-132|.|O
DDI-DrugBank.d364.s17|0-6|Another|O
DDI-DrugBank.d364.s17|8-12|study|O
DDI-DrugBank.d364.s17|14-19|showed|O
DDI-DrugBank.d364.s17|21-24|that|O
DDI-DrugBank.d364.s17|26-34|alosetron|drug
DDI-DrugBank.d364.s17|36-38|had|O
DDI-DrugBank.d364.s17|40-41|no|O
DDI-DrugBank.d364.s17|43-52|clinically|O
DDI-DrugBank.d364.s17|54-64|significant|O
DDI-DrugBank.d364.s17|66-71|effect|O
DDI-DrugBank.d364.s17|73-74|on|O
DDI-DrugBank.d364.s17|76-81|plasma|O
DDI-DrugBank.d364.s17|83-96|concentrations|O
DDI-DrugBank.d364.s17|98-99|of|O
DDI-DrugBank.d364.s17|101-103|the|O
DDI-DrugBank.d364.s17|105-108|oral|O
DDI-DrugBank.d364.s17|110-129|contraceptive agents|group
DDI-DrugBank.d364.s17|110-129|contraceptive agents|group
DDI-DrugBank.d364.s17|139-147|estradiol|drug
DDI-DrugBank.d364.s17|149-151|and|O
DDI-DrugBank.d364.s17|153-166|levonorgestrel|drug
DDI-DrugBank.d364.s17|168-168|(|O
DDI-DrugBank.d364.s17|169-174|CYP3A4|O
DDI-DrugBank.d364.s17|176-185|substrates|O
DDI-DrugBank.d364.s17|186-186|)|O
DDI-DrugBank.d364.s17|187-187|.|O
DDI-DrugBank.d364.s18|0-0|A|O
DDI-DrugBank.d364.s18|2-9|clinical|O
DDI-DrugBank.d364.s18|11-21|interaction|O
DDI-DrugBank.d364.s18|23-27|study|O
DDI-DrugBank.d364.s18|29-31|was|O
DDI-DrugBank.d364.s18|33-36|also|O
DDI-DrugBank.d364.s18|38-46|conducted|O
DDI-DrugBank.d364.s18|48-51|with|O
DDI-DrugBank.d364.s18|53-61|alosetron|drug
DDI-DrugBank.d364.s18|63-65|and|O
DDI-DrugBank.d364.s18|67-69|the|O
DDI-DrugBank.d364.s18|71-76|CYP3A4|O
DDI-DrugBank.d364.s18|78-86|substrate|O
DDI-DrugBank.d364.s18|88-96|cisapride|drug
DDI-DrugBank.d364.s18|97-97|.|O
DDI-DrugBank.d364.s19|0-1|No|O
DDI-DrugBank.d364.s19|3-13|significant|O
DDI-DrugBank.d364.s19|15-21|effects|O
DDI-DrugBank.d364.s19|23-24|on|O
DDI-DrugBank.d364.s19|26-34|cisapride|drug
DDI-DrugBank.d364.s19|36-45|metabolism|O
DDI-DrugBank.d364.s19|47-48|or|O
DDI-DrugBank.d364.s19|50-51|QT|O
DDI-DrugBank.d364.s19|53-60|interval|O
DDI-DrugBank.d364.s19|62-65|were|O
DDI-DrugBank.d364.s19|67-71|noted|O
DDI-DrugBank.d364.s19|72-72|.|O
DDI-DrugBank.d364.s20|0-2|The|O
DDI-DrugBank.d364.s20|4-9|effect|O
DDI-DrugBank.d364.s20|11-12|of|O
DDI-DrugBank.d364.s20|14-22|alosetron|drug
DDI-DrugBank.d364.s20|24-25|on|O
DDI-DrugBank.d364.s20|27-35|monoamine|O
DDI-DrugBank.d364.s20|37-44|oxidases|O
DDI-DrugBank.d364.s20|46-48|and|O
DDI-DrugBank.d364.s20|50-51|on|O
DDI-DrugBank.d364.s20|53-62|intestinal|O
DDI-DrugBank.d364.s20|64-68|first|O
DDI-DrugBank.d364.s20|70-73|pass|O
DDI-DrugBank.d364.s20|75-83|secondary|O
DDI-DrugBank.d364.s20|85-86|to|O
DDI-DrugBank.d364.s20|88-91|high|O
DDI-DrugBank.d364.s20|93-104|intraluminal|O
DDI-DrugBank.d364.s20|106-119|concentrations|O
DDI-DrugBank.d364.s20|121-124|have|O
DDI-DrugBank.d364.s20|126-128|not|O
DDI-DrugBank.d364.s20|130-133|been|O
DDI-DrugBank.d364.s20|135-142|examined|O
DDI-DrugBank.d364.s20|143-143|.|O
DDI-DrugBank.d364.s21|0-4|Based|O
DDI-DrugBank.d364.s21|6-7|on|O
DDI-DrugBank.d364.s21|9-11|the|O
DDI-DrugBank.d364.s21|13-17|above|O
DDI-DrugBank.d364.s21|19-22|data|O
DDI-DrugBank.d364.s21|24-27|from|O
DDI-DrugBank.d364.s21|29-30|in|O
DDI-DrugBank.d364.s21|32-36|vitro|O
DDI-DrugBank.d364.s21|38-40|and|O
DDI-DrugBank.d364.s21|42-43|in|O
DDI-DrugBank.d364.s21|45-48|vivo|O
DDI-DrugBank.d364.s21|50-56|studies|O
DDI-DrugBank.d364.s21|57-57|,|O
DDI-DrugBank.d364.s21|59-60|it|O
DDI-DrugBank.d364.s21|62-63|is|O
DDI-DrugBank.d364.s21|65-72|unlikely|O
DDI-DrugBank.d364.s21|74-77|that|O
DDI-DrugBank.d364.s21|79-87|alosetron|drug
DDI-DrugBank.d364.s21|89-92|will|O
DDI-DrugBank.d364.s21|94-100|inhibit|O
DDI-DrugBank.d364.s21|102-104|the|O
DDI-DrugBank.d364.s21|106-112|hepatic|O
DDI-DrugBank.d364.s21|114-122|metabolic|O
DDI-DrugBank.d364.s21|124-132|clearance|O
DDI-DrugBank.d364.s21|134-135|of|O
DDI-DrugBank.d364.s21|137-141|drugs|O
DDI-DrugBank.d364.s21|143-153|metabolized|O
DDI-DrugBank.d364.s21|155-156|by|O
DDI-DrugBank.d364.s21|158-160|the|O
DDI-DrugBank.d364.s21|162-166|major|O
DDI-DrugBank.d364.s21|168-170|CYP|O
DDI-DrugBank.d364.s21|172-177|enzyme|O
DDI-DrugBank.d364.s21|179-181|3A4|O
DDI-DrugBank.d364.s21|182-182|,|O
DDI-DrugBank.d364.s21|184-185|as|O
DDI-DrugBank.d364.s21|187-190|well|O
DDI-DrugBank.d364.s21|192-193|as|O
DDI-DrugBank.d364.s21|195-197|the|O
DDI-DrugBank.d364.s21|199-201|CYP|O
DDI-DrugBank.d364.s21|203-209|enzymes|O
DDI-DrugBank.d364.s21|211-213|2D6|O
DDI-DrugBank.d364.s21|214-214|,|O
DDI-DrugBank.d364.s21|216-218|2C9|O
DDI-DrugBank.d364.s21|219-219|,|O
DDI-DrugBank.d364.s21|221-224|2C19|O
DDI-DrugBank.d364.s21|225-225|,|O
DDI-DrugBank.d364.s21|227-229|2E1|O
DDI-DrugBank.d364.s21|230-230|,|O
DDI-DrugBank.d364.s21|232-233|or|O
DDI-DrugBank.d364.s21|235-237|1A2|O
DDI-DrugBank.d364.s21|238-238|.|O
DDI-DrugBank.d364.s22|0-8|Alosetron|drug
DDI-DrugBank.d364.s22|10-13|does|O
DDI-DrugBank.d364.s22|15-17|not|O
DDI-DrugBank.d364.s22|19-24|appear|O
DDI-DrugBank.d364.s22|26-27|to|O
DDI-DrugBank.d364.s22|29-34|induce|O
DDI-DrugBank.d364.s22|36-38|the|O
DDI-DrugBank.d364.s22|40-44|major|O
DDI-DrugBank.d364.s22|46-55|cytochrome|O
DDI-DrugBank.d364.s22|57-60|P450|O
DDI-DrugBank.d364.s22|62-62|(|O
DDI-DrugBank.d364.s22|63-65|CYP|O
DDI-DrugBank.d364.s22|66-66|)|O
DDI-DrugBank.d364.s22|68-71|drug|O
DDI-DrugBank.d364.s22|73-84|metabolizing|O
DDI-DrugBank.d364.s22|86-91|enzyme|O
DDI-DrugBank.d364.s22|93-94|3A|O
DDI-DrugBank.d364.s22|95-95|.|O
DDI-DrugBank.d364.s23|0-8|Alosetron|drug
DDI-DrugBank.d364.s23|10-13|also|O
DDI-DrugBank.d364.s23|15-18|does|O
DDI-DrugBank.d364.s23|20-22|not|O
DDI-DrugBank.d364.s23|24-29|appear|O
DDI-DrugBank.d364.s23|31-32|to|O
DDI-DrugBank.d364.s23|34-39|induce|O
DDI-DrugBank.d364.s23|41-43|CYP|O
DDI-DrugBank.d364.s23|45-51|enzymes|O
DDI-DrugBank.d364.s23|53-55|2E1|O
DDI-DrugBank.d364.s23|57-58|or|O
DDI-DrugBank.d364.s23|60-63|2C19|O
DDI-DrugBank.d364.s23|64-64|.|O
DDI-DrugBank.d364.s24|0-1|It|O
DDI-DrugBank.d364.s24|3-4|is|O
DDI-DrugBank.d364.s24|6-8|not|O
DDI-DrugBank.d364.s24|10-14|known|O
DDI-DrugBank.d364.s24|16-22|whether|O
DDI-DrugBank.d364.s24|24-32|alosetron|drug
DDI-DrugBank.d364.s24|34-38|might|O
DDI-DrugBank.d364.s24|40-45|induce|O
DDI-DrugBank.d364.s24|47-51|other|O
DDI-DrugBank.d364.s24|53-59|enzymes|O
DDI-DrugBank.d364.s24|60-60|.|O
DDI-MedLine.d52.s0|0-10|Restoration|O
DDI-MedLine.d52.s0|12-13|of|O
DDI-MedLine.d52.s0|15-24|vancomycin|drug
DDI-MedLine.d52.s0|26-39|susceptibility|O
DDI-MedLine.d52.s0|41-42|in|O
DDI-MedLine.d52.s0|44-55|Enterococcus|O
DDI-MedLine.d52.s0|57-64|faecalis|O
DDI-MedLine.d52.s0|66-67|by|O
DDI-MedLine.d52.s0|69-82|antiresistance|O
DDI-MedLine.d52.s0|84-94|determinant|O
DDI-MedLine.d52.s0|96-99|gene|O
DDI-MedLine.d52.s0|101-108|transfer|O
DDI-MedLine.d52.s0|109-109|.|O
DDI-MedLine.d52.s1|0-1|We|O
DDI-MedLine.d52.s1|3-10|assessed|O
DDI-MedLine.d52.s1|12-14|the|O
DDI-MedLine.d52.s1|16-22|ability|O
DDI-MedLine.d52.s1|24-25|of|O
DDI-MedLine.d52.s1|27-30|gene|O
DDI-MedLine.d52.s1|32-39|transfer|O
DDI-MedLine.d52.s1|41-42|to|O
DDI-MedLine.d52.s1|44-50|reverse|O
DDI-MedLine.d52.s1|52-61|vancomycin|drug
DDI-MedLine.d52.s1|63-72|resistance|O
DDI-MedLine.d52.s1|74-75|in|O
DDI-MedLine.d52.s1|77-81|class|O
DDI-MedLine.d52.s1|83-83|A|O
DDI-MedLine.d52.s1|85-85|(|O
DDI-MedLine.d52.s1|86-89|VanA|O
DDI-MedLine.d52.s1|90-90|)|O
DDI-MedLine.d52.s1|92-113|glycopeptide-resistant|O
DDI-MedLine.d52.s1|115-126|Enterococcus|O
DDI-MedLine.d52.s1|128-135|faecalis|O
DDI-MedLine.d52.s1|136-136|.|O
DDI-MedLine.d52.s2|0-10|Recombinant|O
DDI-MedLine.d52.s2|12-18|shuttle|O
DDI-MedLine.d52.s2|20-26|vectors|O
DDI-MedLine.d52.s2|28-37|containing|O
DDI-MedLine.d52.s2|39-39|a|O
DDI-MedLine.d52.s2|41-44|vanH|O
DDI-MedLine.d52.s2|46-58|promoter-vanA|O
DDI-MedLine.d52.s2|60-68|antisense|O
DDI-MedLine.d52.s2|70-73|gene|O
DDI-MedLine.d52.s2|75-82|cassette|O
DDI-MedLine.d52.s2|84-88|fully|O
DDI-MedLine.d52.s2|90-97|restored|O
DDI-MedLine.d52.s2|99-108|vancomycin|drug
DDI-MedLine.d52.s2|110-123|susceptibility|O
DDI-MedLine.d52.s2|125-131|through|O
DDI-MedLine.d52.s2|133-133|a|O
DDI-MedLine.d52.s2|135-142|combined|O
DDI-MedLine.d52.s2|144-158|transcriptional|O
DDI-MedLine.d52.s2|160-168|activator|O
DDI-MedLine.d52.s2|170-176|binding|O
DDI-MedLine.d52.s2|178-183|domain|O
DDI-MedLine.d52.s2|185-189|decoy|O
DDI-MedLine.d52.s2|191-193|and|O
DDI-MedLine.d52.s2|195-203|inducible|O
DDI-MedLine.d52.s2|205-208|vanA|O
DDI-MedLine.d52.s2|210-218|antisense|O
DDI-MedLine.d52.s2|220-222|RNA|O
DDI-MedLine.d52.s2|224-229|effect|O
DDI-MedLine.d52.s2|230-230|.|O
DDI-DrugBank.d271.s0|0-12|Physiological|O
DDI-DrugBank.d271.s0|14-20|changes|O
DDI-DrugBank.d271.s0|22-30|resulting|O
DDI-DrugBank.d271.s0|32-35|from|O
DDI-DrugBank.d271.s0|37-43|smoking|O
DDI-DrugBank.d271.s0|45-53|cessation|O
DDI-DrugBank.d271.s0|54-54|,|O
DDI-DrugBank.d271.s0|56-59|with|O
DDI-DrugBank.d271.s0|61-62|or|O
DDI-DrugBank.d271.s0|64-70|without|O
DDI-DrugBank.d271.s0|72-79|nicotine|drug
DDI-DrugBank.d271.s0|81-91|replacement|O
DDI-DrugBank.d271.s0|92-92|,|O
DDI-DrugBank.d271.s0|94-96|may|O
DDI-DrugBank.d271.s0|98-102|alter|O
DDI-DrugBank.d271.s0|104-106|the|O
DDI-DrugBank.d271.s0|108-123|pharmacokinetics|O
DDI-DrugBank.d271.s0|125-126|of|O
DDI-DrugBank.d271.s0|128-134|certain|O
DDI-DrugBank.d271.s0|136-146|concomitant|O
DDI-DrugBank.d271.s0|148-158|medications|O
DDI-DrugBank.d271.s0|159-159|,|O
DDI-DrugBank.d271.s0|161-164|such|O
DDI-DrugBank.d271.s0|166-167|as|O
DDI-DrugBank.d271.s0|169-193|tricyclic antidepressants|group
DDI-DrugBank.d271.s0|195-197|and|O
DDI-DrugBank.d271.s0|199-210|theophylline|drug
DDI-DrugBank.d271.s0|211-211|.|O
DDI-DrugBank.d271.s1|0-4|Doses|O
DDI-DrugBank.d271.s1|6-7|of|O
DDI-DrugBank.d271.s1|9-13|these|O
DDI-DrugBank.d271.s1|15-17|and|O
DDI-DrugBank.d271.s1|19-25|perhaps|O
DDI-DrugBank.d271.s1|27-31|other|O
DDI-DrugBank.d271.s1|33-43|medications|O
DDI-DrugBank.d271.s1|45-47|may|O
DDI-DrugBank.d271.s1|49-52|need|O
DDI-DrugBank.d271.s1|54-55|to|O
DDI-DrugBank.d271.s1|57-58|be|O
DDI-DrugBank.d271.s1|60-67|adjusted|O
DDI-DrugBank.d271.s1|69-70|in|O
DDI-DrugBank.d271.s1|72-79|patients|O
DDI-DrugBank.d271.s1|81-83|who|O
DDI-DrugBank.d271.s1|85-96|successfully|O
DDI-DrugBank.d271.s1|98-101|quit|O
DDI-DrugBank.d271.s1|103-109|smoking|O
DDI-DrugBank.d271.s1|110-110|.|O
DDI-MedLine.d54.s0|0-10|Cholinergic|O
DDI-MedLine.d54.s0|12-15|role|O
DDI-MedLine.d54.s0|17-18|in|O
DDI-MedLine.d54.s0|20-26|alcohol|drug
DDI-MedLine.d54.s0|27-28|'s|O
DDI-MedLine.d54.s0|30-36|effects|O
DDI-MedLine.d54.s0|38-39|on|O
DDI-MedLine.d54.s0|41-46|evoked|O
DDI-MedLine.d54.s0|48-57|potentials|O
DDI-MedLine.d54.s0|59-60|in|O
DDI-MedLine.d54.s0|62-67|visual|O
DDI-MedLine.d54.s0|69-74|cortex|O
DDI-MedLine.d54.s0|76-77|of|O
DDI-MedLine.d54.s0|79-81|the|O
DDI-MedLine.d54.s0|83-88|albino|O
DDI-MedLine.d54.s0|90-92|rat|O
DDI-MedLine.d54.s0|93-93|.|O
DDI-MedLine.d54.s1|0-5|Photic|O
DDI-MedLine.d54.s1|7-12|evoked|O
DDI-MedLine.d54.s1|14-23|potentials|O
DDI-MedLine.d54.s1|25-28|were|O
DDI-MedLine.d54.s1|30-37|recorded|O
DDI-MedLine.d54.s1|39-42|from|O
DDI-MedLine.d54.s1|44-46|the|O
DDI-MedLine.d54.s1|48-53|visual|O
DDI-MedLine.d54.s1|55-60|cortex|O
DDI-MedLine.d54.s1|62-63|of|O
DDI-MedLine.d54.s1|65-75|chronically|O
DDI-MedLine.d54.s1|77-85|implanted|O
DDI-MedLine.d54.s1|87-92|albino|O
DDI-MedLine.d54.s1|94-97|rats|O
DDI-MedLine.d54.s1|98-98|.|O
DDI-MedLine.d54.s2|0-4|Since|O
DDI-MedLine.d54.s2|6-11|photic|O
DDI-MedLine.d54.s2|13-18|evoked|O
DDI-MedLine.d54.s2|20-28|potential|O
DDI-MedLine.d54.s2|30-39|components|O
DDI-MedLine.d54.s2|41-43|are|O
DDI-MedLine.d54.s2|45-59|representations|O
DDI-MedLine.d54.s2|61-62|of|O
DDI-MedLine.d54.s2|64-69|neural|O
DDI-MedLine.d54.s2|71-78|pathways|O
DDI-MedLine.d54.s2|80-84|which|O
DDI-MedLine.d54.s2|86-88|are|O
DDI-MedLine.d54.s2|90-98|activated|O
DDI-MedLine.d54.s2|100-105|during|O
DDI-MedLine.d54.s2|107-112|photic|O
DDI-MedLine.d54.s2|114-124|stimulation|O
DDI-MedLine.d54.s2|125-125|,|O
DDI-MedLine.d54.s2|127-131|study|O
DDI-MedLine.d54.s2|133-134|of|O
DDI-MedLine.d54.s2|136-138|the|O
DDI-MedLine.d54.s2|140-146|effects|O
DDI-MedLine.d54.s2|148-149|of|O
DDI-MedLine.d54.s2|151-157|alcohol|drug
DDI-MedLine.d54.s2|159-160|on|O
DDI-MedLine.d54.s2|162-166|these|O
DDI-MedLine.d54.s2|168-177|components|O
DDI-MedLine.d54.s2|179-181|may|O
DDI-MedLine.d54.s2|183-186|help|O
DDI-MedLine.d54.s2|188-189|to|O
DDI-MedLine.d54.s2|191-195|trace|O
DDI-MedLine.d54.s2|197-204|pathways|O
DDI-MedLine.d54.s2|206-210|which|O
DDI-MedLine.d54.s2|212-214|are|O
DDI-MedLine.d54.s2|216-223|affected|O
DDI-MedLine.d54.s2|225-226|by|O
DDI-MedLine.d54.s2|228-234|alcohol|drug
DDI-MedLine.d54.s2|235-235|.|O
DDI-MedLine.d54.s3|0-1|In|O
DDI-MedLine.d54.s3|3-5|the|O
DDI-MedLine.d54.s3|7-13|present|O
DDI-MedLine.d54.s3|15-19|study|O
DDI-MedLine.d54.s3|20-20|,|O
DDI-MedLine.d54.s3|22-27|evoked|O
DDI-MedLine.d54.s3|29-38|potentials|O
DDI-MedLine.d54.s3|40-43|were|O
DDI-MedLine.d54.s3|45-52|recorded|O
DDI-MedLine.d54.s3|54-55|at|O
DDI-MedLine.d54.s3|57-57|5|O
DDI-MedLine.d54.s3|58-58|,|O
DDI-MedLine.d54.s3|60-61|20|O
DDI-MedLine.d54.s3|62-62|,|O
DDI-MedLine.d54.s3|64-66|and|O
DDI-MedLine.d54.s3|68-69|40|O
DDI-MedLine.d54.s3|71-73|min|O
DDI-MedLine.d54.s3|75-83|following|O
DDI-MedLine.d54.s3|85-86|IP|O
DDI-MedLine.d54.s3|88-97|injections|O
DDI-MedLine.d54.s3|99-100|of|O
DDI-MedLine.d54.s3|102-107|saline|O
DDI-MedLine.d54.s3|108-108|,|O
DDI-MedLine.d54.s3|110-116|ethanol|drug
DDI-MedLine.d54.s3|118-118|(|O
DDI-MedLine.d54.s3|119-121|2.0|O
DDI-MedLine.d54.s3|123-126|g/kg|O
DDI-MedLine.d54.s3|127-127|)|O
DDI-MedLine.d54.s3|128-128|,|O
DDI-MedLine.d54.s3|130-142|physostigmine|drug
DDI-MedLine.d54.s3|144-144|(|O
DDI-MedLine.d54.s3|145-147|0.6|O
DDI-MedLine.d54.s3|149-153|mg/kg|O
DDI-MedLine.d54.s3|154-154|)|O
DDI-MedLine.d54.s3|156-157|or|O
DDI-MedLine.d54.s3|159-166|atropine|drug
DDI-MedLine.d54.s3|168-168|(|O
DDI-MedLine.d54.s3|169-172|15.0|O
DDI-MedLine.d54.s3|174-178|mg/kg|O
DDI-MedLine.d54.s3|179-179|)|O
DDI-MedLine.d54.s3|181-182|on|O
DDI-MedLine.d54.s3|184-191|separate|O
DDI-MedLine.d54.s3|193-196|days|O
DDI-MedLine.d54.s3|197-197|.|O
DDI-MedLine.d54.s4|0-6|Ethanol|drug
DDI-MedLine.d54.s4|8-16|depressed|O
DDI-MedLine.d54.s4|18-20|the|O
DDI-MedLine.d54.s4|22-31|amplitudes|O
DDI-MedLine.d54.s4|33-34|of|O
DDI-MedLine.d54.s4|36-39|most|O
DDI-MedLine.d54.s4|41-46|evoked|O
DDI-MedLine.d54.s4|48-56|potential|O
DDI-MedLine.d54.s4|58-67|components|O
DDI-MedLine.d54.s4|69-70|in|O
DDI-MedLine.d54.s4|72-81|comparison|O
DDI-MedLine.d54.s4|83-84|to|O
DDI-MedLine.d54.s4|86-91|saline|O
DDI-MedLine.d54.s4|93-106|administration|O
DDI-MedLine.d54.s4|107-107|.|O
DDI-MedLine.d54.s5|0-8|Component|O
DDI-MedLine.d54.s5|10-11|P2|O
DDI-MedLine.d54.s5|12-12|,|O
DDI-MedLine.d54.s5|14-20|however|O
DDI-MedLine.d54.s5|21-21|,|O
DDI-MedLine.d54.s5|23-25|was|O
DDI-MedLine.d54.s5|27-35|increased|O
DDI-MedLine.d54.s5|37-38|in|O
DDI-MedLine.d54.s5|40-48|amplitude|O
DDI-MedLine.d54.s5|49-49|.|O
DDI-MedLine.d54.s6|0-12|Physostigmine|drug
DDI-MedLine.d54.s6|14-20|briefly|O
DDI-MedLine.d54.s6|22-28|reduced|O
DDI-MedLine.d54.s6|30-32|the|O
DDI-MedLine.d54.s6|34-42|amplitude|O
DDI-MedLine.d54.s6|44-45|of|O
DDI-MedLine.d54.s6|47-50|most|O
DDI-MedLine.d54.s6|52-61|components|O
DDI-MedLine.d54.s6|62-62|,|O
DDI-MedLine.d54.s6|64-72|including|O
DDI-MedLine.d54.s6|74-75|P2|O
DDI-MedLine.d54.s6|76-76|.|O
DDI-MedLine.d54.s7|0-1|In|O
DDI-MedLine.d54.s7|3-10|contrast|O
DDI-MedLine.d54.s7|11-11|,|O
DDI-MedLine.d54.s7|13-20|atropine|drug
DDI-MedLine.d54.s7|22-30|increased|O
DDI-MedLine.d54.s7|32-34|the|O
DDI-MedLine.d54.s7|36-45|amplitudes|O
DDI-MedLine.d54.s7|47-48|of|O
DDI-MedLine.d54.s7|50-59|components|O
DDI-MedLine.d54.s7|61-62|P1|O
DDI-MedLine.d54.s7|64-66|and|O
DDI-MedLine.d54.s7|68-69|P2|O
DDI-MedLine.d54.s7|70-70|,|O
DDI-MedLine.d54.s7|72-76|while|O
DDI-MedLine.d54.s7|78-87|decreasing|O
DDI-MedLine.d54.s7|89-98|components|O
DDI-MedLine.d54.s7|100-101|N1|O
DDI-MedLine.d54.s7|102-102|,|O
DDI-MedLine.d54.s7|104-105|N2|O
DDI-MedLine.d54.s7|107-109|and|O
DDI-MedLine.d54.s7|111-112|N3|O
DDI-MedLine.d54.s7|114-116|for|O
DDI-MedLine.d54.s7|118-124|varying|O
DDI-MedLine.d54.s7|126-134|durations|O
DDI-MedLine.d54.s7|136-137|of|O
DDI-MedLine.d54.s7|139-142|time|O
DDI-MedLine.d54.s7|143-143|.|O
DDI-MedLine.d54.s8|0-12|Physostigmine|drug
DDI-MedLine.d54.s8|14-25|pretreatment|O
DDI-MedLine.d54.s8|27-35|augmented|O
DDI-MedLine.d54.s8|37-39|the|O
DDI-MedLine.d54.s8|41-50|depressant|O
DDI-MedLine.d54.s8|52-57|effect|O
DDI-MedLine.d54.s8|59-60|of|O
DDI-MedLine.d54.s8|62-68|alcohol|drug
DDI-MedLine.d54.s8|70-71|on|O
DDI-MedLine.d54.s8|73-75|the|O
DDI-MedLine.d54.s8|77-81|early|O
DDI-MedLine.d54.s8|83-92|components|O
DDI-MedLine.d54.s8|94-95|P1|O
DDI-MedLine.d54.s8|97-99|and|O
DDI-MedLine.d54.s8|101-102|N1|O
DDI-MedLine.d54.s8|103-103|,|O
DDI-MedLine.d54.s8|105-109|while|O
DDI-MedLine.d54.s8|111-121|attenuating|O
DDI-MedLine.d54.s8|123-129|alcohol|drug
DDI-MedLine.d54.s8|130-131|'s|O
DDI-MedLine.d54.s8|133-141|influence|O
DDI-MedLine.d54.s8|143-144|on|O
DDI-MedLine.d54.s8|146-155|components|O
DDI-MedLine.d54.s8|157-158|P2|O
DDI-MedLine.d54.s8|160-162|and|O
DDI-MedLine.d54.s8|164-165|P3|O
DDI-MedLine.d54.s8|166-166|.|O
DDI-MedLine.d54.s9|0-11|Pretreatment|O
DDI-MedLine.d54.s9|13-16|with|O
DDI-MedLine.d54.s9|18-25|atropine|drug
DDI-MedLine.d54.s9|27-34|likewise|O
DDI-MedLine.d54.s9|36-42|further|O
DDI-MedLine.d54.s9|44-50|reduced|O
DDI-MedLine.d54.s9|52-54|the|O
DDI-MedLine.d54.s9|56-65|amplitudes|O
DDI-MedLine.d54.s9|67-68|of|O
DDI-MedLine.d54.s9|70-79|components|O
DDI-MedLine.d54.s9|81-82|P1|O
DDI-MedLine.d54.s9|84-86|and|O
DDI-MedLine.d54.s9|88-89|N1|O
DDI-MedLine.d54.s9|90-90|,|O
DDI-MedLine.d54.s9|92-94|and|O
DDI-MedLine.d54.s9|96-103|produced|O
DDI-MedLine.d54.s9|105-105|a|O
DDI-MedLine.d54.s9|107-113|similar|O
DDI-MedLine.d54.s9|115-120|effect|O
DDI-MedLine.d54.s9|122-123|on|O
DDI-MedLine.d54.s9|125-133|component|O
DDI-MedLine.d54.s9|135-136|N3|O
DDI-MedLine.d54.s9|137-137|.|O
DDI-MedLine.d54.s10|0-7|Atropine|drug
DDI-MedLine.d54.s10|8-8|,|O
DDI-MedLine.d54.s10|10-15|either|O
DDI-MedLine.d54.s10|17-21|alone|O
DDI-MedLine.d54.s10|23-24|or|O
DDI-MedLine.d54.s10|26-27|in|O
DDI-MedLine.d54.s10|29-39|combination|O
DDI-MedLine.d54.s10|41-44|with|O
DDI-MedLine.d54.s10|46-52|alcohol|drug
DDI-MedLine.d54.s10|53-53|,|O
DDI-MedLine.d54.s10|55-62|produced|O
DDI-MedLine.d54.s10|64-76|approximately|O
DDI-MedLine.d54.s10|78-80|the|O
DDI-MedLine.d54.s10|82-85|same|O
DDI-MedLine.d54.s10|87-92|degree|O
DDI-MedLine.d54.s10|94-95|of|O
DDI-MedLine.d54.s10|97-107|enhancement|O
DDI-MedLine.d54.s10|109-110|of|O
DDI-MedLine.d54.s10|112-120|component|O
DDI-MedLine.d54.s10|122-123|P2|O
DDI-MedLine.d54.s10|124-124|.|O
DDI-MedLine.d54.s11|0-1|In|O
DDI-MedLine.d54.s11|3-12|comparison|O
DDI-MedLine.d54.s11|14-15|to|O
DDI-MedLine.d54.s11|17-22|saline|O
DDI-MedLine.d54.s11|24-29|values|O
DDI-MedLine.d54.s11|30-30|,|O
DDI-MedLine.d54.s11|32-34|all|O
DDI-MedLine.d54.s11|36-40|three|O
DDI-MedLine.d54.s11|42-47|agents|O
DDI-MedLine.d54.s11|49-56|produced|O
DDI-MedLine.d54.s11|58-65|reliable|O
DDI-MedLine.d54.s11|67-75|increases|O
DDI-MedLine.d54.s11|77-78|in|O
DDI-MedLine.d54.s11|80-83|peak|O
DDI-MedLine.d54.s11|85-91|latency|O
DDI-MedLine.d54.s11|93-95|for|O
DDI-MedLine.d54.s11|97-100|most|O
DDI-MedLine.d54.s11|102-103|of|O
DDI-MedLine.d54.s11|105-107|the|O
DDI-MedLine.d54.s11|109-118|components|O
DDI-MedLine.d54.s11|119-119|,|O
DDI-MedLine.d54.s11|121-124|with|O
DDI-MedLine.d54.s11|126-129|only|O
DDI-MedLine.d54.s11|131-132|N3|O
DDI-MedLine.d54.s11|134-140|showing|O
DDI-MedLine.d54.s11|142-143|no|O
DDI-MedLine.d54.s11|145-151|effects|O
DDI-MedLine.d54.s11|152-152|.|O
DDI-MedLine.d54.s12|0-2|The|O
DDI-MedLine.d54.s12|4-12|amplitude|O
DDI-MedLine.d54.s12|14-17|data|O
DDI-MedLine.d54.s12|19-22|from|O
DDI-MedLine.d54.s12|24-27|this|O
DDI-MedLine.d54.s12|29-33|study|O
DDI-MedLine.d54.s12|35-41|suggest|O
DDI-MedLine.d54.s12|43-46|that|O
DDI-MedLine.d54.s12|48-54|ethanol|drug
DDI-MedLine.d54.s12|55-56|'s|O
DDI-MedLine.d54.s12|58-69|augmentation|O
DDI-MedLine.d54.s12|71-72|of|O
DDI-MedLine.d54.s12|74-82|component|O
DDI-MedLine.d54.s12|84-85|P2|O
DDI-MedLine.d54.s12|87-89|may|O
DDI-MedLine.d54.s12|91-96|result|O
DDI-MedLine.d54.s12|97-97|,|O
DDI-MedLine.d54.s12|99-100|at|O
DDI-MedLine.d54.s12|102-106|least|O
DDI-MedLine.d54.s12|108-109|in|O
DDI-MedLine.d54.s12|111-114|part|O
DDI-MedLine.d54.s12|115-115|,|O
DDI-MedLine.d54.s12|117-120|from|O
DDI-MedLine.d54.s12|122-132|alterations|O
DDI-MedLine.d54.s12|134-135|in|O
DDI-MedLine.d54.s12|137-147|cholinergic|O
DDI-MedLine.d54.s12|149-157|functions|O
DDI-MedLine.d54.s12|158-158|.|O
DDI-DrugBank.d696.s0|0-11|Methysergide|drug
DDI-DrugBank.d696.s0|13-15|may|O
DDI-DrugBank.d696.s0|17-23|reverse|O
DDI-DrugBank.d696.s0|25-27|the|O
DDI-DrugBank.d696.s0|29-37|analgesic|O
DDI-DrugBank.d696.s0|39-46|activity|O
DDI-DrugBank.d696.s0|48-49|of|O
DDI-DrugBank.d696.s0|51-69|narcotic analgesics|group
DDI-DrugBank.d696.s0|70-70|.|O
DDI-DrugBank.d696.s1|0-9|Concurrent|O
DDI-DrugBank.d696.s1|11-13|use|O
DDI-DrugBank.d696.s1|15-18|with|O
DDI-DrugBank.d696.s1|20-41|vasoconstrictor agents|group
DDI-DrugBank.d696.s1|43-51|including|O
DDI-DrugBank.d696.s1|53-67|ergot alkaloids|group
DDI-DrugBank.d696.s1|68-68|,|O
DDI-DrugBank.d696.s1|70-80|sumatriptan|drug
DDI-DrugBank.d696.s1|81-81|,|O
DDI-DrugBank.d696.s1|83-85|and|O
DDI-DrugBank.d696.s1|87-94|nicotine|drug
DDI-DrugBank.d696.s1|96-96|(|O
DDI-DrugBank.d696.s1|97-100|e.g.|O
DDI-DrugBank.d696.s1|102-108|smoking|O
DDI-DrugBank.d696.s1|109-109|)|O
DDI-DrugBank.d696.s1|111-113|may|O
DDI-DrugBank.d696.s1|115-120|result|O
DDI-DrugBank.d696.s1|122-123|in|O
DDI-DrugBank.d696.s1|125-132|enhanced|O
DDI-DrugBank.d696.s1|134-149|vasoconstriction|O
DDI-DrugBank.d696.s1|150-150|.|O
DDI-MedLine.d24.s0|0-8|Excretion|O
DDI-MedLine.d24.s0|10-11|of|O
DDI-MedLine.d24.s0|13-22|thioethers|O
DDI-MedLine.d24.s0|24-25|in|O
DDI-MedLine.d24.s0|27-31|urine|O
DDI-MedLine.d24.s0|33-37|after|O
DDI-MedLine.d24.s0|39-46|exposure|O
DDI-MedLine.d24.s0|48-49|to|O
DDI-MedLine.d24.s0|51-63|electrophilic|O
DDI-MedLine.d24.s0|65-73|chemicals|O
DDI-MedLine.d24.s0|74-74|.|O
DDI-MedLine.d24.s1|0-12|Electrophilic|O
DDI-MedLine.d24.s1|14-19|agents|O
DDI-MedLine.d24.s1|20-21|--|O
DDI-MedLine.d24.s1|22-22|a|O
DDI-MedLine.d24.s1|24-28|class|O
DDI-MedLine.d24.s1|30-31|of|O
DDI-MedLine.d24.s1|33-41|chemicals|O
DDI-MedLine.d24.s1|43-46|that|O
DDI-MedLine.d24.s1|48-55|includes|O
DDI-MedLine.d24.s1|57-60|most|O
DDI-MedLine.d24.s1|62-70|genotoxic|O
DDI-MedLine.d24.s1|72-80|compounds|O
DDI-MedLine.d24.s1|81-82|--|O
DDI-MedLine.d24.s1|83-85|can|O
DDI-MedLine.d24.s1|87-88|be|O
DDI-MedLine.d24.s1|90-100|inactivated|O
DDI-MedLine.d24.s1|102-103|by|O
DDI-MedLine.d24.s1|105-112|reaction|O
DDI-MedLine.d24.s1|114-117|with|O
DDI-MedLine.d24.s1|119-129|glutathione|O
DDI-MedLine.d24.s1|131-132|or|O
DDI-MedLine.d24.s1|134-138|other|O
DDI-MedLine.d24.s1|140-149|SH-bearing|O
DDI-MedLine.d24.s1|151-159|molecules|O
DDI-MedLine.d24.s1|160-160|.|O
DDI-MedLine.d24.s2|0-2|The|O
DDI-MedLine.d24.s2|4-13|conjugates|O
DDI-MedLine.d24.s2|15-16|so|O
DDI-MedLine.d24.s2|18-23|formed|O
DDI-MedLine.d24.s2|25-29|often|O
DDI-MedLine.d24.s2|31-36|appear|O
DDI-MedLine.d24.s2|38-39|in|O
DDI-MedLine.d24.s2|41-43|the|O
DDI-MedLine.d24.s2|45-49|urine|O
DDI-MedLine.d24.s2|51-52|as|O
DDI-MedLine.d24.s2|54-64|mercapturic|O
DDI-MedLine.d24.s2|66-70|acids|O
DDI-MedLine.d24.s2|72-73|or|O
DDI-MedLine.d24.s2|75-79|other|O
DDI-MedLine.d24.s2|81-89|thioether|O
DDI-MedLine.d24.s2|91-98|products|O
DDI-MedLine.d24.s2|99-99|.|O
DDI-MedLine.d24.s3|0-3|This|O
DDI-MedLine.d24.s3|5-9|paper|O
DDI-MedLine.d24.s3|11-20|critically|O
DDI-MedLine.d24.s3|22-28|reviews|O
DDI-MedLine.d24.s3|30-32|the|O
DDI-MedLine.d24.s3|34-44|suitability|O
DDI-MedLine.d24.s3|46-47|of|O
DDI-MedLine.d24.s3|49-51|the|O
DDI-MedLine.d24.s3|53-59|urinary|O
DDI-MedLine.d24.s3|61-69|thioether|O
DDI-MedLine.d24.s3|71-75|assay|O
DDI-MedLine.d24.s3|77-78|as|O
DDI-MedLine.d24.s3|80-80|a|O
DDI-MedLine.d24.s3|82-87|method|O
DDI-MedLine.d24.s3|89-91|for|O
DDI-MedLine.d24.s3|93-95|the|O
DDI-MedLine.d24.s3|97-105|detection|O
DDI-MedLine.d24.s3|107-108|of|O
DDI-MedLine.d24.s3|110-117|exposure|O
DDI-MedLine.d24.s3|119-120|to|O
DDI-MedLine.d24.s3|122-134|electrophilic|O
DDI-MedLine.d24.s3|136-141|agents|O
DDI-MedLine.d24.s3|143-144|or|O
DDI-MedLine.d24.s3|146-150|their|O
DDI-MedLine.d24.s3|152-161|precursors|O
DDI-MedLine.d24.s3|162-162|.|O
DDI-MedLine.d24.s4|0-1|In|O
DDI-MedLine.d24.s4|3-10|practice|O
DDI-MedLine.d24.s4|11-11|,|O
DDI-MedLine.d24.s4|13-15|the|O
DDI-MedLine.d24.s4|17-24|greatest|O
DDI-MedLine.d24.s4|26-30|value|O
DDI-MedLine.d24.s4|32-33|of|O
DDI-MedLine.d24.s4|35-37|the|O
DDI-MedLine.d24.s4|39-47|thioether|O
DDI-MedLine.d24.s4|49-53|assay|O
DDI-MedLine.d24.s4|55-61|appears|O
DDI-MedLine.d24.s4|63-64|to|O
DDI-MedLine.d24.s4|66-68|lie|O
DDI-MedLine.d24.s4|70-71|in|O
DDI-MedLine.d24.s4|73-75|its|O
DDI-MedLine.d24.s4|77-82|signal|O
DDI-MedLine.d24.s4|84-91|function|O
DDI-MedLine.d24.s4|92-92|.|O
DDI-MedLine.d24.s5|0-3|This|O
DDI-MedLine.d24.s5|5-6|is|O
DDI-MedLine.d24.s5|8-19|demonstrated|O
DDI-MedLine.d24.s5|21-23|for|O
DDI-MedLine.d24.s5|25-33|cigarette|O
DDI-MedLine.d24.s5|35-41|smokers|O
DDI-MedLine.d24.s5|43-45|and|O
DDI-MedLine.d24.s5|47-56|industrial|O
DDI-MedLine.d24.s5|58-64|workers|O
DDI-MedLine.d24.s5|66-73|involved|O
DDI-MedLine.d24.s5|75-76|in|O
DDI-MedLine.d24.s5|78-85|chemical|O
DDI-MedLine.d24.s5|87-91|waste|O
DDI-MedLine.d24.s5|93-104|incineration|O
DDI-MedLine.d24.s5|105-105|.|O
DDI-MedLine.d24.s6|0-7|Whenever|O
DDI-MedLine.d24.s6|9-17|increased|O
DDI-MedLine.d24.s6|19-27|thioether|O
DDI-MedLine.d24.s6|29-37|excretion|O
DDI-MedLine.d24.s6|39-40|is|O
DDI-MedLine.d24.s6|42-49|observed|O
DDI-MedLine.d24.s6|50-50|,|O
DDI-MedLine.d24.s6|52-53|it|O
DDI-MedLine.d24.s6|55-56|is|O
DDI-MedLine.d24.s6|58-63|likely|O
DDI-MedLine.d24.s6|65-66|to|O
DDI-MedLine.d24.s6|68-69|be|O
DDI-MedLine.d24.s6|71-73|due|O
DDI-MedLine.d24.s6|75-76|to|O
DDI-MedLine.d24.s6|78-85|exposure|O
DDI-MedLine.d24.s6|87-88|to|O
DDI-MedLine.d24.s6|90-92|one|O
DDI-MedLine.d24.s6|94-95|or|O
DDI-MedLine.d24.s6|97-100|more|O
DDI-MedLine.d24.s6|102-108|suspect|O
DDI-MedLine.d24.s6|110-118|compounds|O
DDI-MedLine.d24.s6|119-119|.|O
DDI-MedLine.d24.s7|0-6|However|O
DDI-MedLine.d24.s7|7-7|,|O
DDI-MedLine.d24.s7|9-12|when|O
DDI-MedLine.d24.s7|14-16|the|O
DDI-MedLine.d24.s7|18-26|thioether|O
DDI-MedLine.d24.s7|28-40|concentration|O
DDI-MedLine.d24.s7|42-47|ranges|O
DDI-MedLine.d24.s7|49-54|within|O
DDI-MedLine.d24.s7|56-58|the|O
DDI-MedLine.d24.s7|60-65|limits|O
DDI-MedLine.d24.s7|67-68|of|O
DDI-MedLine.d24.s7|70-72|the|O
DDI-MedLine.d24.s7|74-79|normal|O
DDI-MedLine.d24.s7|81-85|value|O
DDI-MedLine.d24.s7|86-86|,|O
DDI-MedLine.d24.s7|88-90|one|O
DDI-MedLine.d24.s7|92-95|must|O
DDI-MedLine.d24.s7|97-99|not|O
DDI-MedLine.d24.s7|101-108|conclude|O
DDI-MedLine.d24.s7|110-113|that|O
DDI-MedLine.d24.s7|115-119|there|O
DDI-MedLine.d24.s7|121-122|is|O
DDI-MedLine.d24.s7|124-125|no|O
DDI-MedLine.d24.s7|126-126|,|O
DDI-MedLine.d24.s7|128-129|or|O
DDI-MedLine.d24.s7|131-140|negligible|O
DDI-MedLine.d24.s7|141-141|,|O
DDI-MedLine.d24.s7|143-150|exposure|O
DDI-MedLine.d24.s7|151-151|.|O
DDI-MedLine.d24.s8|0-3|More|O
DDI-MedLine.d24.s8|5-12|specific|O
DDI-MedLine.d24.s8|14-25|applications|O
DDI-MedLine.d24.s8|27-28|of|O
DDI-MedLine.d24.s8|30-32|the|O
DDI-MedLine.d24.s8|34-38|assay|O
DDI-MedLine.d24.s8|40-41|of|O
DDI-MedLine.d24.s8|43-46|thio|O
DDI-MedLine.d24.s8|48-56|compounds|O
DDI-MedLine.d24.s8|58-59|in|O
DDI-MedLine.d24.s8|61-65|urine|O
DDI-MedLine.d24.s8|67-71|allow|O
DDI-MedLine.d24.s8|73-83|development|O
DDI-MedLine.d24.s8|85-86|of|O
DDI-MedLine.d24.s8|88-96|selective|O
DDI-MedLine.d24.s8|98-104|methods|O
DDI-MedLine.d24.s8|106-109|that|O
DDI-MedLine.d24.s8|111-113|may|O
DDI-MedLine.d24.s8|115-116|be|O
DDI-MedLine.d24.s8|118-123|useful|O
DDI-MedLine.d24.s8|125-127|for|O
DDI-MedLine.d24.s8|129-138|biological|O
DDI-MedLine.d24.s8|140-149|monitoring|O
DDI-MedLine.d24.s8|150-150|.|O
DDI-DrugBank.d380.s0|0-12|Buprenorphine|drug
DDI-DrugBank.d380.s0|14-15|is|O
DDI-DrugBank.d380.s0|17-27|metabolized|O
DDI-DrugBank.d380.s0|29-30|to|O
DDI-DrugBank.d380.s0|49-50|by|O
DDI-DrugBank.d380.s0|52-61|cytochrome|O
DDI-DrugBank.d380.s0|63-65|CYP|O
DDI-DrugBank.d380.s0|67-69|3A4|O
DDI-DrugBank.d380.s0|70-70|.|O
DDI-DrugBank.d380.s1|0-6|Because|O
DDI-DrugBank.d380.s1|8-10|CYP|O
DDI-DrugBank.d380.s1|12-14|3A4|O
DDI-DrugBank.d380.s1|16-25|inhibitors|O
DDI-DrugBank.d380.s1|27-29|may|O
DDI-DrugBank.d380.s1|31-38|increase|O
DDI-DrugBank.d380.s1|40-45|plasma|O
DDI-DrugBank.d380.s1|47-60|concentrations|O
DDI-DrugBank.d380.s1|62-63|of|O
DDI-DrugBank.d380.s1|65-77|buprenorphine|drug
DDI-DrugBank.d380.s1|78-78|,|O
DDI-DrugBank.d380.s1|80-87|patients|O
DDI-DrugBank.d380.s1|89-95|already|O
DDI-DrugBank.d380.s1|97-98|on|O
DDI-DrugBank.d380.s1|100-102|CYP|O
DDI-DrugBank.d380.s1|104-106|3A4|O
DDI-DrugBank.d380.s1|108-117|inhibitors|O
DDI-DrugBank.d380.s1|119-122|such|O
DDI-DrugBank.d380.s1|124-125|as|O
DDI-DrugBank.d380.s1|127-143|azole antifungals|group
DDI-DrugBank.d380.s1|145-145|(|O
DDI-DrugBank.d380.s1|146-148|e.g|O
DDI-DrugBank.d380.s1|149-149|.|O
DDI-DrugBank.d380.s2|0-11|ketoconazole|drug
DDI-DrugBank.d380.s2|12-12|)|O
DDI-DrugBank.d380.s2|13-13|,|O
DDI-DrugBank.d380.s2|15-35|macrolide antibiotics|group
DDI-DrugBank.d380.s2|37-37|(|O
DDI-DrugBank.d380.s2|38-41|e.g.|O
DDI-DrugBank.d380.s2|43-54|erythromycin|drug
DDI-DrugBank.d380.s2|55-55|)|O
DDI-DrugBank.d380.s2|56-56|,|O
DDI-DrugBank.d380.s2|58-60|and|O
DDI-DrugBank.d380.s2|62-84|HIV protease inhibitors|group
DDI-DrugBank.d380.s2|86-86|(|O
DDI-DrugBank.d380.s2|87-90|e.g.|O
DDI-DrugBank.d380.s2|92-100|ritonavir|drug
DDI-DrugBank.d380.s2|101-101|,|O
DDI-DrugBank.d380.s2|103-111|indinavir|drug
DDI-DrugBank.d380.s2|113-115|and|O
DDI-DrugBank.d380.s2|117-126|saquinavir|drug
DDI-DrugBank.d380.s2|127-127|)|O
DDI-DrugBank.d380.s2|129-134|should|O
DDI-DrugBank.d380.s2|136-139|have|O
DDI-DrugBank.d380.s2|141-145|their|O
DDI-DrugBank.d380.s2|147-150|dose|O
DDI-DrugBank.d380.s2|152-153|of|O
DDI-DrugBank.d380.s2|155-161|SUBUTEX|brand
DDI-DrugBank.d380.s2|163-164|or|O
DDI-DrugBank.d380.s2|166-173|SUBOXONE|brand
DDI-DrugBank.d380.s2|175-182|adjusted|O
DDI-DrugBank.d380.s2|183-183|.|O
DDI-DrugBank.d380.s3|0-4|Based|O
DDI-DrugBank.d380.s3|6-7|on|O
DDI-DrugBank.d380.s3|9-17|anecdotal|O
DDI-DrugBank.d380.s3|19-25|reports|O
DDI-DrugBank.d380.s3|26-26|,|O
DDI-DrugBank.d380.s3|28-32|there|O
DDI-DrugBank.d380.s3|34-36|may|O
DDI-DrugBank.d380.s3|38-39|be|O
DDI-DrugBank.d380.s3|41-42|an|O
DDI-DrugBank.d380.s3|44-54|interaction|O
DDI-DrugBank.d380.s3|56-62|between|O
DDI-DrugBank.d380.s3|64-76|buprenorphine|drug
DDI-DrugBank.d380.s3|78-80|and|O
DDI-DrugBank.d380.s3|82-96|benzodiazepines|group
DDI-DrugBank.d380.s3|97-97|.|O
DDI-DrugBank.d380.s4|0-4|There|O
DDI-DrugBank.d380.s4|6-9|have|O
DDI-DrugBank.d380.s4|11-14|been|O
DDI-DrugBank.d380.s4|16-16|a|O
DDI-DrugBank.d380.s4|18-23|number|O
DDI-DrugBank.d380.s4|25-26|of|O
DDI-DrugBank.d380.s4|28-34|reports|O
DDI-DrugBank.d380.s4|36-37|in|O
DDI-DrugBank.d380.s4|39-41|the|O
DDI-DrugBank.d380.s4|43-56|post-marketing|O
DDI-DrugBank.d380.s4|58-67|experience|O
DDI-DrugBank.d380.s4|69-70|of|O
DDI-DrugBank.d380.s4|72-75|coma|O
DDI-DrugBank.d380.s4|77-79|and|O
DDI-DrugBank.d380.s4|81-85|death|O
DDI-DrugBank.d380.s4|87-96|associated|O
DDI-DrugBank.d380.s4|98-101|with|O
DDI-DrugBank.d380.s4|103-105|the|O
DDI-DrugBank.d380.s4|107-117|concomitant|O
DDI-DrugBank.d380.s4|119-129|intravenous|O
DDI-DrugBank.d380.s4|131-136|misuse|O
DDI-DrugBank.d380.s4|138-139|of|O
DDI-DrugBank.d380.s4|141-153|buprenorphine|drug
DDI-DrugBank.d380.s4|155-157|and|O
DDI-DrugBank.d380.s4|159-173|benzodiazepines|drug
DDI-DrugBank.d380.s4|175-176|by|O
DDI-DrugBank.d380.s4|178-184|addicts|O
DDI-DrugBank.d380.s4|185-185|.|O
DDI-DrugBank.d380.s5|0-1|In|O
DDI-DrugBank.d380.s5|3-6|many|O
DDI-DrugBank.d380.s5|8-9|of|O
DDI-DrugBank.d380.s5|11-15|these|O
DDI-DrugBank.d380.s5|17-21|cases|O
DDI-DrugBank.d380.s5|22-22|,|O
DDI-DrugBank.d380.s5|24-36|buprenorphine|drug
DDI-DrugBank.d380.s5|38-40|was|O
DDI-DrugBank.d380.s5|42-48|misused|O
DDI-DrugBank.d380.s5|50-51|by|O
DDI-DrugBank.d380.s5|53-66|self-injection|O
DDI-DrugBank.d380.s5|68-69|of|O
DDI-DrugBank.d380.s5|71-77|crushed|O
DDI-DrugBank.d380.s5|79-85|SUBUTEX|brand
DDI-DrugBank.d380.s5|87-93|tablets|O
DDI-DrugBank.d380.s5|94-94|.|O
DDI-DrugBank.d380.s6|0-6|SUBUTEX|brand
DDI-DrugBank.d380.s6|8-10|and|O
DDI-DrugBank.d380.s6|12-19|SUBOXONE|brand
DDI-DrugBank.d380.s6|21-26|should|O
DDI-DrugBank.d380.s6|28-29|be|O
DDI-DrugBank.d380.s6|31-40|prescribed|O
DDI-DrugBank.d380.s6|42-45|with|O
DDI-DrugBank.d380.s6|47-53|caution|O
DDI-DrugBank.d380.s6|55-56|to|O
DDI-DrugBank.d380.s6|58-65|patients|O
DDI-DrugBank.d380.s6|67-68|on|O
DDI-DrugBank.d380.s6|70-84|benzodiazepines|group
DDI-DrugBank.d380.s6|86-87|or|O
DDI-DrugBank.d380.s6|89-93|other|O
DDI-DrugBank.d380.s6|95-99|drugs|O
DDI-DrugBank.d380.s6|101-104|that|O
DDI-DrugBank.d380.s6|106-108|act|O
DDI-DrugBank.d380.s6|110-111|on|O
DDI-DrugBank.d380.s6|113-115|the|O
DDI-DrugBank.d380.s6|117-123|central|O
DDI-DrugBank.d380.s6|125-131|nervous|O
DDI-DrugBank.d380.s6|133-138|system|O
DDI-DrugBank.d380.s6|139-139|,|O
DDI-DrugBank.d380.s6|141-150|regardless|O
DDI-DrugBank.d380.s6|152-153|of|O
DDI-DrugBank.d380.s6|155-161|whether|O
DDI-DrugBank.d380.s6|163-167|these|O
DDI-DrugBank.d380.s6|169-173|drugs|O
DDI-DrugBank.d380.s6|175-177|are|O
DDI-DrugBank.d380.s6|179-183|taken|O
DDI-DrugBank.d380.s6|185-186|on|O
DDI-DrugBank.d380.s6|188-190|the|O
DDI-DrugBank.d380.s6|192-197|advice|O
DDI-DrugBank.d380.s6|199-200|of|O
DDI-DrugBank.d380.s6|202-202|a|O
DDI-DrugBank.d380.s6|204-212|physician|O
DDI-DrugBank.d380.s6|214-215|or|O
DDI-DrugBank.d380.s6|217-219|are|O
DDI-DrugBank.d380.s6|221-225|taken|O
DDI-DrugBank.d380.s6|227-228|as|O
DDI-DrugBank.d380.s6|230-234|drugs|O
DDI-DrugBank.d380.s6|236-237|of|O
DDI-DrugBank.d380.s6|239-243|abuse|O
DDI-DrugBank.d380.s6|244-244|.|O
DDI-DrugBank.d380.s7|0-7|Patients|O
DDI-DrugBank.d380.s7|9-14|should|O
DDI-DrugBank.d380.s7|16-17|be|O
DDI-DrugBank.d380.s7|19-24|warned|O
DDI-DrugBank.d380.s7|26-27|of|O
DDI-DrugBank.d380.s7|29-31|the|O
DDI-DrugBank.d380.s7|33-41|potential|O
DDI-DrugBank.d380.s7|43-48|danger|O
DDI-DrugBank.d380.s7|50-51|of|O
DDI-DrugBank.d380.s7|53-55|the|O
DDI-DrugBank.d380.s7|57-67|intravenous|O
DDI-DrugBank.d380.s7|69-87|self-administration|O
DDI-DrugBank.d380.s7|89-90|of|O
DDI-DrugBank.d380.s7|92-106|benzodiazepines|group
DDI-DrugBank.d380.s7|108-112|while|O
DDI-DrugBank.d380.s7|114-118|under|O
DDI-DrugBank.d380.s7|120-128|treatment|O
DDI-DrugBank.d380.s7|130-133|with|O
DDI-DrugBank.d380.s7|135-142|SUBOXONE|brand
DDI-DrugBank.d380.s7|144-145|or|O
DDI-DrugBank.d380.s7|147-153|SUBUTEX|brand
DDI-DrugBank.d380.s7|154-154|.|O
DDI-DrugBank.d534.s0|0-1|No|O
DDI-DrugBank.d534.s0|3-8|formal|O
DDI-DrugBank.d534.s0|10-13|drug|O
DDI-DrugBank.d534.s0|15-25|interaction|O
DDI-DrugBank.d534.s0|27-33|studies|O
DDI-DrugBank.d534.s0|35-36|of|O
DDI-DrugBank.d534.s0|38-44|Aranesp|brand
DDI-DrugBank.d534.s0|47-50|have|O
DDI-DrugBank.d534.s0|52-55|been|O
DDI-DrugBank.d534.s0|57-65|performed|O
DDI-DrugBank.d534.s0|66-66|.|O
DDI-DrugBank.d301.s0|0-0|D|O
DDI-DrugBank.d301.s0|1-1|.|O
DDI-DrugBank.d301.s1|0-3|Drug|O
DDI-DrugBank.d301.s1|5-7|and|O
DDI-DrugBank.d301.s1|9-18|Laboratory|O
DDI-DrugBank.d301.s1|20-23|Test|O
DDI-DrugBank.d301.s1|25-36|Interactions|O
DDI-DrugBank.d301.s1|38-38|1|O
DDI-DrugBank.d301.s1|39-39|.|O
DDI-DrugBank.d301.s2|0-10|Accelerated|O
DDI-DrugBank.d301.s2|12-22|prothrombin|O
DDI-DrugBank.d301.s2|24-27|time|O
DDI-DrugBank.d301.s2|28-28|,|O
DDI-DrugBank.d301.s2|30-36|partial|O
DDI-DrugBank.d301.s2|38-51|thromboplastin|O
DDI-DrugBank.d301.s2|53-56|time|O
DDI-DrugBank.d301.s2|57-57|,|O
DDI-DrugBank.d301.s2|59-61|and|O
DDI-DrugBank.d301.s2|63-70|platelet|O
DDI-DrugBank.d301.s2|72-82|aggregation|O
DDI-DrugBank.d301.s2|84-87|time|O
DDI-DrugBank.d301.s2|88-88|;|O
DDI-DrugBank.d301.s3|0-8|increased|O
DDI-DrugBank.d301.s3|10-17|platelet|O
DDI-DrugBank.d301.s3|19-23|count|O
DDI-DrugBank.d301.s3|24-24|;|O
DDI-DrugBank.d301.s4|0-8|increased|O
DDI-DrugBank.d301.s4|10-16|factors|O
DDI-DrugBank.d301.s4|18-19|II|O
DDI-DrugBank.d301.s4|20-20|,|O
DDI-DrugBank.d301.s4|22-24|VII|O
DDI-DrugBank.d301.s4|26-32|antigen|O
DDI-DrugBank.d301.s4|33-33|,|O
DDI-DrugBank.d301.s4|35-38|VIII|O
DDI-DrugBank.d301.s4|40-46|antigen|O
DDI-DrugBank.d301.s4|47-47|,|O
DDI-DrugBank.d301.s4|49-52|VIII|O
DDI-DrugBank.d301.s4|54-62|coagulant|O
DDI-DrugBank.d301.s4|64-71|activity|O
DDI-DrugBank.d301.s4|72-72|,|O
DDI-DrugBank.d301.s4|74-75|IX|O
DDI-DrugBank.d301.s4|76-76|,|O
DDI-DrugBank.d301.s4|78-78|X|O
DDI-DrugBank.d301.s4|79-79|,|O
DDI-DrugBank.d301.s4|81-83|XII|O
DDI-DrugBank.d301.s4|84-84|,|O
DDI-DrugBank.d301.s4|86-90|VII-X|O
DDI-DrugBank.d301.s4|92-98|complex|O
DDI-DrugBank.d301.s4|99-99|,|O
DDI-DrugBank.d301.s4|101-108|II-VII-X|O
DDI-DrugBank.d301.s4|110-116|complex|O
DDI-DrugBank.d301.s4|117-117|,|O
DDI-DrugBank.d301.s4|119-121|and|O
DDI-DrugBank.d301.s4|123-142|beta-thromboglobulin|O
DDI-DrugBank.d301.s4|143-143|;|O
DDI-DrugBank.d301.s5|0-8|decreased|O
DDI-DrugBank.d301.s5|10-15|levels|O
DDI-DrugBank.d301.s5|17-18|of|O
DDI-DrugBank.d301.s5|20-30|anti-factor|O
DDI-DrugBank.d301.s5|32-33|Xa|O
DDI-DrugBank.d301.s5|35-37|and|O
DDI-DrugBank.d301.s5|39-50|antithrombin|O
DDI-DrugBank.d301.s5|52-54|III|O
DDI-DrugBank.d301.s5|55-55|,|O
DDI-DrugBank.d301.s5|57-65|decreased|O
DDI-DrugBank.d301.s5|67-78|antithrombin|O
DDI-DrugBank.d301.s5|80-82|III|O
DDI-DrugBank.d301.s5|84-91|activity|O
DDI-DrugBank.d301.s5|92-92|;|O
DDI-DrugBank.d301.s6|0-8|increased|O
DDI-DrugBank.d301.s6|10-15|levels|O
DDI-DrugBank.d301.s6|17-18|of|O
DDI-DrugBank.d301.s6|20-29|fibrinogen|O
DDI-DrugBank.d301.s6|31-33|and|O
DDI-DrugBank.d301.s6|35-44|fibrinogen|O
DDI-DrugBank.d301.s6|46-53|activity|O
DDI-DrugBank.d301.s6|54-54|;|O
DDI-DrugBank.d301.s7|0-8|increased|O
DDI-DrugBank.d301.s7|10-20|plasminogen|O
DDI-DrugBank.d301.s7|22-28|antigen|O
DDI-DrugBank.d301.s7|30-32|and|O
DDI-DrugBank.d301.s7|34-41|activity|O
DDI-DrugBank.d301.s7|42-42|.|O
DDI-DrugBank.d301.s8|0-0|2|O
DDI-DrugBank.d301.s8|1-1|.|O
DDI-DrugBank.d301.s9|0-8|Increased|O
DDI-DrugBank.d301.s9|10-24|thyroid-binding|O
DDI-DrugBank.d301.s9|26-33|globulin|O
DDI-DrugBank.d301.s9|35-35|(|O
DDI-DrugBank.d301.s9|36-38|TBG|O
DDI-DrugBank.d301.s9|39-39|)|O
DDI-DrugBank.d301.s9|41-47|leading|O
DDI-DrugBank.d301.s9|49-50|to|O
DDI-DrugBank.d301.s9|52-60|increased|O
DDI-DrugBank.d301.s9|62-72|circulating|O
DDI-DrugBank.d301.s9|74-78|total|O
DDI-DrugBank.d301.s9|80-86|thyroid|O
DDI-DrugBank.d301.s9|88-94|hormone|O
DDI-DrugBank.d301.s9|96-101|levels|O
DDI-DrugBank.d301.s9|102-102|,|O
DDI-DrugBank.d301.s9|104-105|as|O
DDI-DrugBank.d301.s9|107-114|measured|O
DDI-DrugBank.d301.s9|116-117|by|O
DDI-DrugBank.d301.s9|119-131|protein-bound|O
DDI-DrugBank.d301.s9|133-138|iodine|O
DDI-DrugBank.d301.s9|140-140|(|O
DDI-DrugBank.d301.s9|141-143|PBI|O
DDI-DrugBank.d301.s9|144-144|)|O
DDI-DrugBank.d301.s9|145-145|,|O
DDI-DrugBank.d301.s9|147-148|T4|O
DDI-DrugBank.d301.s9|150-155|levels|O
DDI-DrugBank.d301.s9|157-157|(|O
DDI-DrugBank.d301.s9|158-159|by|O
DDI-DrugBank.d301.s9|161-166|column|O
DDI-DrugBank.d301.s9|168-169|or|O
DDI-DrugBank.d301.s9|171-172|by|O
DDI-DrugBank.d301.s9|174-189|radioimmunoassay|O
DDI-DrugBank.d301.s9|190-190|)|O
DDI-DrugBank.d301.s9|192-193|or|O
DDI-DrugBank.d301.s9|195-196|T3|O
DDI-DrugBank.d301.s9|198-203|levels|O
DDI-DrugBank.d301.s9|205-206|by|O
DDI-DrugBank.d301.s9|208-223|radioimmunoassay|O
DDI-DrugBank.d301.s9|224-224|.|O
DDI-DrugBank.d301.s10|0-1|T3|O
DDI-DrugBank.d301.s10|3-7|resin|O
DDI-DrugBank.d301.s10|9-14|uptake|O
DDI-DrugBank.d301.s10|16-17|is|O
DDI-DrugBank.d301.s10|19-27|decreased|O
DDI-DrugBank.d301.s10|28-28|,|O
DDI-DrugBank.d301.s10|30-39|reflecting|O
DDI-DrugBank.d301.s10|41-43|the|O
DDI-DrugBank.d301.s10|45-52|elevated|O
DDI-DrugBank.d301.s10|54-56|TBG|O
DDI-DrugBank.d301.s10|57-57|.|O
DDI-DrugBank.d301.s11|0-3|Free|O
DDI-DrugBank.d301.s11|5-6|T4|O
DDI-DrugBank.d301.s11|8-10|and|O
DDI-DrugBank.d301.s11|12-13|T3|O
DDI-DrugBank.d301.s11|15-28|concentrations|O
DDI-DrugBank.d301.s11|30-32|are|O
DDI-DrugBank.d301.s11|34-42|unaltered|O
DDI-DrugBank.d301.s11|43-43|.|O
DDI-DrugBank.d301.s12|0-7|Patients|O
DDI-DrugBank.d301.s12|9-10|on|O
DDI-DrugBank.d301.s12|12-18|thyroid|O
DDI-DrugBank.d301.s12|20-30|replacement|O
DDI-DrugBank.d301.s12|32-38|therapy|O
DDI-DrugBank.d301.s12|40-42|may|O
DDI-DrugBank.d301.s12|44-50|require|O
DDI-DrugBank.d301.s12|52-57|higher|O
DDI-DrugBank.d301.s12|59-63|doses|O
DDI-DrugBank.d301.s12|65-66|of|O
DDI-DrugBank.d301.s12|68-82|thyroid hormone|group
DDI-DrugBank.d301.s12|83-83|.|O
DDI-DrugBank.d301.s13|0-0|3|O
DDI-DrugBank.d301.s13|1-1|.|O
DDI-DrugBank.d301.s14|0-4|Other|O
DDI-DrugBank.d301.s14|6-12|binding|O
DDI-DrugBank.d301.s14|14-21|proteins|O
DDI-DrugBank.d301.s14|23-25|may|O
DDI-DrugBank.d301.s14|27-28|be|O
DDI-DrugBank.d301.s14|30-37|elevated|O
DDI-DrugBank.d301.s14|39-40|in|O
DDI-DrugBank.d301.s14|42-46|serum|O
DDI-DrugBank.d301.s14|47-47|,|O
DDI-DrugBank.d301.s14|49-52|i.e.|O
DDI-DrugBank.d301.s14|53-53|,|O
DDI-DrugBank.d301.s14|55-68|corticosteroid|O
DDI-DrugBank.d301.s14|70-76|binding|O
DDI-DrugBank.d301.s14|78-85|globulin|O
DDI-DrugBank.d301.s14|87-87|(|O
DDI-DrugBank.d301.s14|88-90|CBG|O
DDI-DrugBank.d301.s14|91-91|)|O
DDI-DrugBank.d301.s14|92-92|,|O
DDI-DrugBank.d301.s14|94-96|sex|O
DDI-DrugBank.d301.s14|98-112|hormone-binding|O
DDI-DrugBank.d301.s14|114-121|globulin|O
DDI-DrugBank.d301.s14|123-123|(|O
DDI-DrugBank.d301.s14|124-127|SHBG|O
DDI-DrugBank.d301.s14|128-128|)|O
DDI-DrugBank.d301.s14|129-129|,|O
DDI-DrugBank.d301.s14|131-137|leading|O
DDI-DrugBank.d301.s14|139-140|to|O
DDI-DrugBank.d301.s14|142-150|increased|O
DDI-DrugBank.d301.s14|152-156|total|O
DDI-DrugBank.d301.s14|158-168|circulating|O
DDI-DrugBank.d301.s14|170-184|corticosteroids|group
DDI-DrugBank.d301.s14|186-188|and|O
DDI-DrugBank.d301.s14|190-201|sex steroids|group
DDI-DrugBank.d301.s14|202-202|,|O
DDI-DrugBank.d301.s14|204-215|respectively|O
DDI-DrugBank.d301.s14|216-216|.|O
DDI-DrugBank.d301.s15|0-3|Free|O
DDI-DrugBank.d301.s15|5-11|hormone|O
DDI-DrugBank.d301.s15|13-26|concentrations|O
DDI-DrugBank.d301.s15|28-30|may|O
DDI-DrugBank.d301.s15|32-33|be|O
DDI-DrugBank.d301.s15|35-43|decreased|O
DDI-DrugBank.d301.s15|44-44|.|O
DDI-DrugBank.d301.s16|0-4|Other|O
DDI-DrugBank.d301.s16|6-11|plasma|O
DDI-DrugBank.d301.s16|13-20|proteins|O
DDI-DrugBank.d301.s16|22-24|may|O
DDI-DrugBank.d301.s16|26-27|be|O
DDI-DrugBank.d301.s16|29-37|increased|O
DDI-DrugBank.d301.s16|39-39|(|O
DDI-DrugBank.d301.s16|40-60|angiotensinogen/renin|O
DDI-DrugBank.d301.s16|62-70|substrate|O
DDI-DrugBank.d301.s16|71-71|,|O
DDI-DrugBank.d301.s16|73-91|alpha-1-antitrypsin|O
DDI-DrugBank.d301.s16|92-92|,|O
DDI-DrugBank.d301.s16|94-106|ceruloplasmin|O
DDI-DrugBank.d301.s16|107-107|)|O
DDI-DrugBank.d301.s16|108-108|.|O
DDI-DrugBank.d301.s17|0-0|4|O
DDI-DrugBank.d301.s17|1-1|.|O
DDI-DrugBank.d301.s18|0-8|Increased|O
DDI-DrugBank.d301.s18|10-15|plasma|O
DDI-DrugBank.d301.s18|17-19|HDL|O
DDI-DrugBank.d301.s18|21-23|and|O
DDI-DrugBank.d301.s18|25-28|HDL2|O
DDI-DrugBank.d301.s18|30-40|cholesterol|O
DDI-DrugBank.d301.s18|42-52|subfraction|O
DDI-DrugBank.d301.s18|54-67|concentrations|O
DDI-DrugBank.d301.s18|68-68|,|O
DDI-DrugBank.d301.s18|70-76|reduced|O
DDI-DrugBank.d301.s18|78-80|LDL|O
DDI-DrugBank.d301.s18|82-92|cholesterol|O
DDI-DrugBank.d301.s18|94-106|concentration|O
DDI-DrugBank.d301.s18|107-107|,|O
DDI-DrugBank.d301.s18|109-117|increased|O
DDI-DrugBank.d301.s18|119-130|triglyceride|O
DDI-DrugBank.d301.s18|132-137|levels|O
DDI-DrugBank.d301.s18|138-138|.|O
DDI-DrugBank.d301.s19|0-0|5|O
DDI-DrugBank.d301.s19|1-1|.|O
DDI-DrugBank.d301.s20|0-7|Impaired|O
DDI-DrugBank.d301.s20|9-15|glucose|O
DDI-DrugBank.d301.s20|17-25|tolerance|O
DDI-DrugBank.d301.s20|26-26|.|O
DDI-DrugBank.d301.s21|0-0|6|O
DDI-DrugBank.d301.s21|1-1|.|O
DDI-DrugBank.d301.s22|0-6|Reduced|O
DDI-DrugBank.d301.s22|8-15|response|O
DDI-DrugBank.d301.s22|17-18|to|O
DDI-DrugBank.d301.s22|20-29|metyrapone|O
DDI-DrugBank.d301.s22|31-34|test|O
DDI-DrugBank.d301.s22|35-35|.|O
DDI-MedLine.d70.s0|0-7|Toxicity|O
DDI-MedLine.d70.s0|9-10|of|O
DDI-MedLine.d70.s0|12-18|cadmium|O
DDI-MedLine.d70.s0|20-22|and|O
DDI-MedLine.d70.s0|24-27|zinc|drug
DDI-MedLine.d70.s0|29-30|to|O
DDI-MedLine.d70.s0|32-40|miracidia|O
DDI-MedLine.d70.s0|42-43|of|O
DDI-MedLine.d70.s0|45-55|Schistosoma|O
DDI-MedLine.d70.s0|57-63|mansoni|O
DDI-MedLine.d70.s0|64-64|.|O
DDI-MedLine.d70.s1|0-2|The|O
DDI-MedLine.d70.s1|4-11|specific|O
DDI-MedLine.d70.s1|13-22|objectives|O
DDI-MedLine.d70.s1|24-25|of|O
DDI-MedLine.d70.s1|27-30|this|O
DDI-MedLine.d70.s1|32-36|study|O
DDI-MedLine.d70.s1|38-41|were|O
DDI-MedLine.d70.s1|43-44|to|O
DDI-MedLine.d70.s1|46-54|elucidate|O
DDI-MedLine.d70.s1|56-60|metal|O
DDI-MedLine.d70.s1|62-69|toxicity|O
DDI-MedLine.d70.s1|71-72|to|O
DDI-MedLine.d70.s1|74-81|hatching|O
DDI-MedLine.d70.s1|82-82|,|O
DDI-MedLine.d70.s1|84-91|survival|O
DDI-MedLine.d70.s1|93-95|and|O
DDI-MedLine.d70.s1|97-105|avoidance|O
DDI-MedLine.d70.s1|107-115|behaviour|O
DDI-MedLine.d70.s1|117-118|of|O
DDI-MedLine.d70.s1|120-130|Schistosoma|O
DDI-MedLine.d70.s1|132-138|mansoni|O
DDI-MedLine.d70.s1|140-148|miracidia|O
DDI-MedLine.d70.s1|149-149|.|O
DDI-MedLine.d70.s2|0-2|The|O
DDI-MedLine.d70.s2|4-11|toxicity|O
DDI-MedLine.d70.s2|13-14|of|O
DDI-MedLine.d70.s2|16-22|cadmium|O
DDI-MedLine.d70.s2|23-23|,|O
DDI-MedLine.d70.s2|25-28|zinc|drug
DDI-MedLine.d70.s2|29-29|,|O
DDI-MedLine.d70.s2|31-33|and|O
DDI-MedLine.d70.s2|35-46|cadmium/zinc|O
DDI-MedLine.d70.s2|48-55|mixtures|O
DDI-MedLine.d70.s2|57-58|at|O
DDI-MedLine.d70.s2|60-73|concentrations|O
DDI-MedLine.d70.s2|75-81|ranging|O
DDI-MedLine.d70.s2|83-86|from|O
DDI-MedLine.d70.s2|88-92|10000|O
DDI-MedLine.d70.s2|94-95|to|O
DDI-MedLine.d70.s2|97-98|10|O
DDI-MedLine.d70.s2|100-107|microg/l|O
DDI-MedLine.d70.s2|109-111|was|O
DDI-MedLine.d70.s2|113-124|investigated|O
DDI-MedLine.d70.s2|125-125|.|O
DDI-MedLine.d70.s3|0-4|Metal|O
DDI-MedLine.d70.s3|6-12|mixture|O
DDI-MedLine.d70.s3|14-21|toxicity|O
DDI-MedLine.d70.s3|23-35|investigation|O
DDI-MedLine.d70.s3|37-39|was|O
DDI-MedLine.d70.s3|41-50|undertaken|O
DDI-MedLine.d70.s3|52-55|with|O
DDI-MedLine.d70.s3|57-61|equal|O
DDI-MedLine.d70.s3|63-76|concentrations|O
DDI-MedLine.d70.s3|78-79|of|O
DDI-MedLine.d70.s3|81-83|the|O
DDI-MedLine.d70.s3|85-90|metals|O
DDI-MedLine.d70.s3|91-91|.|O
DDI-MedLine.d70.s4|0-2|The|O
DDI-MedLine.d70.s4|4-11|hatching|O
DDI-MedLine.d70.s4|13-14|of|O
DDI-MedLine.d70.s4|16-24|miracidia|O
DDI-MedLine.d70.s4|26-29|from|O
DDI-MedLine.d70.s4|31-34|eggs|O
DDI-MedLine.d70.s4|36-38|was|O
DDI-MedLine.d70.s4|40-48|inhibited|O
DDI-MedLine.d70.s4|50-51|by|O
DDI-MedLine.d70.s4|53-66|concentrations|O
DDI-MedLine.d70.s4|68-69|of|O
DDI-MedLine.d70.s4|71-80|1000-10000|O
DDI-MedLine.d70.s4|82-89|microg/l|O
DDI-MedLine.d70.s4|91-92|of|O
DDI-MedLine.d70.s4|94-99|single|O
DDI-MedLine.d70.s4|101-106|metals|O
DDI-MedLine.d70.s4|107-107|.|O
DDI-MedLine.d70.s5|0-4|Metal|O
DDI-MedLine.d70.s5|6-13|mixtures|O
DDI-MedLine.d70.s5|15-17|had|O
DDI-MedLine.d70.s5|19-20|no|O
DDI-MedLine.d70.s5|22-27|effect|O
DDI-MedLine.d70.s5|29-30|on|O
DDI-MedLine.d70.s5|32-34|egg|drug
DDI-MedLine.d70.s5|36-43|hatching|O
DDI-MedLine.d70.s5|44-44|.|O
DDI-MedLine.d70.s6|0-7|Survival|O
DDI-MedLine.d70.s6|9-10|of|O
DDI-MedLine.d70.s6|12-20|miracidia|O
DDI-MedLine.d70.s6|22-24|was|O
DDI-MedLine.d70.s6|26-32|reduced|O
DDI-MedLine.d70.s6|34-35|by|O
DDI-MedLine.d70.s6|37-46|increasing|O
DDI-MedLine.d70.s6|48-52|metal|O
DDI-MedLine.d70.s6|54-66|concentration|O
DDI-MedLine.d70.s6|68-73|except|O
DDI-MedLine.d70.s6|75-76|at|O
DDI-MedLine.d70.s6|78-91|concentrations|O
DDI-MedLine.d70.s6|93-94|of|O
DDI-MedLine.d70.s6|96-97|10|O
DDI-MedLine.d70.s6|99-106|microg/l|O
DDI-MedLine.d70.s6|108-110|for|O
DDI-MedLine.d70.s6|112-117|single|O
DDI-MedLine.d70.s6|119-123|metal|O
DDI-MedLine.d70.s6|125-132|toxicity|O
DDI-MedLine.d70.s6|134-138|where|O
DDI-MedLine.d70.s6|140-147|survival|O
DDI-MedLine.d70.s6|149-151|was|O
DDI-MedLine.d70.s6|153-161|increased|O
DDI-MedLine.d70.s6|163-167|above|O
DDI-MedLine.d70.s6|169-171|the|O
DDI-MedLine.d70.s6|173-179|control|O
DDI-MedLine.d70.s6|180-180|.|O
DDI-MedLine.d70.s7|0-8|Miracidia|O
DDI-MedLine.d70.s7|10-21|demonstrated|O
DDI-MedLine.d70.s7|23-23|a|O
DDI-MedLine.d70.s7|25-29|rapid|O
DDI-MedLine.d70.s7|31-39|avoidance|O
DDI-MedLine.d70.s7|41-49|behaviour|O
DDI-MedLine.d70.s7|51-54|when|O
DDI-MedLine.d70.s7|56-62|briefly|O
DDI-MedLine.d70.s7|64-70|exposed|O
DDI-MedLine.d70.s7|72-73|to|O
DDI-MedLine.d70.s7|75-79|heavy|O
DDI-MedLine.d70.s7|81-86|metals|O
DDI-MedLine.d70.s7|87-87|.|O
DDI-MedLine.d70.s8|0-2|The|O
DDI-MedLine.d70.s8|4-13|mechanisms|O
DDI-MedLine.d70.s8|15-16|of|O
DDI-MedLine.d70.s8|18-22|metal|O
DDI-MedLine.d70.s8|24-31|toxicity|O
DDI-MedLine.d70.s8|33-34|to|O
DDI-MedLine.d70.s8|36-44|miracidia|O
DDI-MedLine.d70.s8|46-48|are|O
DDI-MedLine.d70.s8|50-56|briefly|O
DDI-MedLine.d70.s8|58-66|discussed|O
DDI-MedLine.d70.s8|67-67|.|O
DDI-DrugBank.d62.s0|0-17|Dexbrompheniramine|drug
DDI-DrugBank.d62.s0|19-21|can|O
DDI-DrugBank.d62.s0|23-30|interact|O
DDI-DrugBank.d62.s0|32-35|with|O
DDI-DrugBank.d62.s0|37-43|alcohol|drug
DDI-DrugBank.d62.s0|45-46|or|O
DDI-DrugBank.d62.s0|48-52|other|O
DDI-DrugBank.d62.s0|54-68|CNS depressants|group
DDI-DrugBank.d62.s0|70-70|(|O
DDI-DrugBank.d62.s0|71-73|may|O
DDI-DrugBank.d62.s0|75-84|potentiate|O
DDI-DrugBank.d62.s0|86-88|the|O
DDI-DrugBank.d62.s0|90-92|CNS|O
DDI-DrugBank.d62.s0|94-103|depressant|O
DDI-DrugBank.d62.s0|105-111|effects|O
DDI-DrugBank.d62.s0|113-114|of|O
DDI-DrugBank.d62.s0|116-121|either|O
DDI-DrugBank.d62.s0|123-127|these|O
DDI-DrugBank.d62.s0|129-139|medications|O
DDI-DrugBank.d62.s0|141-142|or|O
DDI-DrugBank.d62.s0|144-157|antihistamines|group
DDI-DrugBank.d62.s0|158-158|)|O
DDI-DrugBank.d62.s0|159-159|,|O
DDI-DrugBank.d62.s0|161-176|anticholinergics|group
DDI-DrugBank.d62.s0|178-179|or|O
DDI-DrugBank.d62.s0|181-185|other|O
DDI-DrugBank.d62.s0|187-197|medications|O
DDI-DrugBank.d62.s0|199-202|with|O
DDI-DrugBank.d62.s0|204-218|anticholinergic|O
DDI-DrugBank.d62.s0|220-227|activity|O
DDI-DrugBank.d62.s0|229-229|(|O
DDI-DrugBank.d62.s0|230-244|anticholinergic|O
DDI-DrugBank.d62.s0|246-252|effects|O
DDI-DrugBank.d62.s0|254-256|may|O
DDI-DrugBank.d62.s0|258-259|be|O
DDI-DrugBank.d62.s0|261-271|potentiated|O
DDI-DrugBank.d62.s0|273-276|when|O
DDI-DrugBank.d62.s0|278-282|these|O
DDI-DrugBank.d62.s0|284-294|medications|O
DDI-DrugBank.d62.s0|296-298|are|O
DDI-DrugBank.d62.s0|300-303|used|O
DDI-DrugBank.d62.s0|305-316|concurrently|O
DDI-DrugBank.d62.s0|318-321|with|O
DDI-DrugBank.d62.s0|323-336|antihistamines|group
DDI-DrugBank.d62.s0|337-337|)|O
DDI-DrugBank.d62.s0|338-338|,|O
DDI-DrugBank.d62.s0|340-342|and|O
DDI-DrugBank.d62.s0|344-377|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d62.s0|379-379|(|O
DDI-DrugBank.d62.s0|380-389|concurrent|O
DDI-DrugBank.d62.s0|391-393|use|O
DDI-DrugBank.d62.s0|395-398|with|O
DDI-DrugBank.d62.s0|400-413|antihistamines|group
DDI-DrugBank.d62.s0|415-417|may|O
DDI-DrugBank.d62.s0|419-425|prolong|O
DDI-DrugBank.d62.s0|427-429|and|O
DDI-DrugBank.d62.s0|431-439|intensify|O
DDI-DrugBank.d62.s0|441-443|the|O
DDI-DrugBank.d62.s0|445-459|anticholinergic|O
DDI-DrugBank.d62.s0|461-463|and|O
DDI-DrugBank.d62.s0|465-467|CNS|O
DDI-DrugBank.d62.s0|469-478|depressant|O
DDI-DrugBank.d62.s0|480-486|effects|O
DDI-DrugBank.d62.s0|488-489|of|O
DDI-DrugBank.d62.s0|491-504|antihistamines|group
DDI-DrugBank.d62.s0|505-505|)|O
DDI-DrugBank.d62.s0|506-506|.|O
DDI-DrugBank.d85.s0|0-2|The|O
DDI-DrugBank.d85.s0|4-6|use|O
DDI-DrugBank.d85.s0|8-9|of|O
DDI-DrugBank.d85.s0|11-16|NSAIDs|group
DDI-DrugBank.d85.s0|18-19|in|O
DDI-DrugBank.d85.s0|21-28|patients|O
DDI-DrugBank.d85.s0|30-32|who|O
DDI-DrugBank.d85.s0|34-36|are|O
DDI-DrugBank.d85.s0|38-46|receiving|O
DDI-DrugBank.d85.s0|48-61|ACE inhibitors|group
DDI-DrugBank.d85.s0|63-65|may|O
DDI-DrugBank.d85.s0|67-76|potentiate|O
DDI-DrugBank.d85.s0|78-82|renal|O
DDI-DrugBank.d85.s0|84-90|disease|O
DDI-DrugBank.d85.s0|92-97|states|O
DDI-DrugBank.d85.s0|98-98|.|O
DDI-DrugBank.d85.s1|0-1|In|O
DDI-DrugBank.d85.s1|3-7|vitro|O
DDI-DrugBank.d85.s1|9-15|studies|O
DDI-DrugBank.d85.s1|17-20|have|O
DDI-DrugBank.d85.s1|22-26|shown|O
DDI-DrugBank.d85.s1|28-31|that|O
DDI-DrugBank.d85.s1|33-40|naproxen|drug
DDI-DrugBank.d85.s1|42-46|anion|O
DDI-DrugBank.d85.s1|47-47|,|O
DDI-DrugBank.d85.s1|49-55|because|O
DDI-DrugBank.d85.s1|57-58|of|O
DDI-DrugBank.d85.s1|60-62|its|O
DDI-DrugBank.d85.s1|64-71|affinity|O
DDI-DrugBank.d85.s1|73-75|for|O
DDI-DrugBank.d85.s1|77-83|protein|O
DDI-DrugBank.d85.s1|84-84|,|O
DDI-DrugBank.d85.s1|86-88|may|O
DDI-DrugBank.d85.s1|90-97|displace|O
DDI-DrugBank.d85.s1|99-102|from|O
DDI-DrugBank.d85.s1|104-108|their|O
DDI-DrugBank.d85.s1|110-116|binding|O
DDI-DrugBank.d85.s1|118-122|sites|O
DDI-DrugBank.d85.s1|124-128|other|O
DDI-DrugBank.d85.s1|130-134|drugs|O
DDI-DrugBank.d85.s1|136-140|which|O
DDI-DrugBank.d85.s1|142-144|are|O
DDI-DrugBank.d85.s1|146-149|also|O
DDI-DrugBank.d85.s1|151-163|albumin-bound|O
DDI-DrugBank.d85.s1|165-165|.|O
DDI-DrugBank.d85.s2|0-12|Theoretically|O
DDI-DrugBank.d85.s2|13-13|,|O
DDI-DrugBank.d85.s2|15-17|the|O
DDI-DrugBank.d85.s2|19-26|naproxen|drug
DDI-DrugBank.d85.s2|28-32|anion|O
DDI-DrugBank.d85.s2|34-39|itself|O
DDI-DrugBank.d85.s2|41-45|could|O
DDI-DrugBank.d85.s2|47-54|likewise|O
DDI-DrugBank.d85.s2|56-57|be|O
DDI-DrugBank.d85.s2|59-67|displaced|O
DDI-DrugBank.d85.s2|68-68|.|O
DDI-DrugBank.d85.s3|0-9|Short-term|O
DDI-DrugBank.d85.s3|11-20|controlled|O
DDI-DrugBank.d85.s3|22-28|studies|O
DDI-DrugBank.d85.s3|30-35|failed|O
DDI-DrugBank.d85.s3|37-38|to|O
DDI-DrugBank.d85.s3|40-43|show|O
DDI-DrugBank.d85.s3|45-48|that|O
DDI-DrugBank.d85.s3|50-55|taking|O
DDI-DrugBank.d85.s3|57-59|the|O
DDI-DrugBank.d85.s3|61-64|drug|O
DDI-DrugBank.d85.s3|66-78|significantly|O
DDI-DrugBank.d85.s3|80-86|affects|O
DDI-DrugBank.d85.s3|88-98|prothrombin|O
DDI-DrugBank.d85.s3|100-104|times|O
DDI-DrugBank.d85.s3|106-109|when|O
DDI-DrugBank.d85.s3|111-122|administered|O
DDI-DrugBank.d85.s3|124-125|to|O
DDI-DrugBank.d85.s3|127-137|individuals|O
DDI-DrugBank.d85.s3|139-140|on|O
DDI-DrugBank.d85.s3|142-169|coumarin-type anticoagulants|group
DDI-DrugBank.d85.s3|170-170|.|O
DDI-DrugBank.d85.s4|0-6|Caution|O
DDI-DrugBank.d85.s4|8-9|is|O
DDI-DrugBank.d85.s4|11-17|advised|O
DDI-DrugBank.d85.s4|19-29|nonetheless|O
DDI-DrugBank.d85.s4|30-30|,|O
DDI-DrugBank.d85.s4|32-36|since|O
DDI-DrugBank.d85.s4|38-49|interactions|O
DDI-DrugBank.d85.s4|51-54|have|O
DDI-DrugBank.d85.s4|56-59|been|O
DDI-DrugBank.d85.s4|61-64|seen|O
DDI-DrugBank.d85.s4|66-69|with|O
DDI-DrugBank.d85.s4|71-75|other|O
DDI-DrugBank.d85.s4|77-88|nonsteroidal|O
DDI-DrugBank.d85.s4|90-95|agents|O
DDI-DrugBank.d85.s4|97-98|of|O
DDI-DrugBank.d85.s4|100-103|this|O
DDI-DrugBank.d85.s4|105-109|class|O
DDI-DrugBank.d85.s4|110-110|.|O
DDI-DrugBank.d85.s5|0-8|Similarly|O
DDI-DrugBank.d85.s5|9-9|,|O
DDI-DrugBank.d85.s5|11-18|patients|O
DDI-DrugBank.d85.s5|20-28|receiving|O
DDI-DrugBank.d85.s5|30-32|the|O
DDI-DrugBank.d85.s5|34-37|drug|O
DDI-DrugBank.d85.s5|39-41|and|O
DDI-DrugBank.d85.s5|43-43|a|O
DDI-DrugBank.d85.s5|45-53|hydantoin|group
DDI-DrugBank.d85.s5|54-54|,|O
DDI-DrugBank.d85.s5|56-66|sulfonamide|group
DDI-DrugBank.d85.s5|68-69|or|O
DDI-DrugBank.d85.s5|71-82|sulfonylurea|group
DDI-DrugBank.d85.s5|84-89|should|O
DDI-DrugBank.d85.s5|91-92|be|O
DDI-DrugBank.d85.s5|94-101|observed|O
DDI-DrugBank.d85.s5|103-105|for|O
DDI-DrugBank.d85.s5|107-111|signs|O
DDI-DrugBank.d85.s5|113-114|of|O
DDI-DrugBank.d85.s5|116-123|toxicity|O
DDI-DrugBank.d85.s5|125-126|to|O
DDI-DrugBank.d85.s5|128-132|these|O
DDI-DrugBank.d85.s5|134-138|drugs|O
DDI-DrugBank.d85.s5|139-139|.|O
DDI-DrugBank.d85.s6|0-10|Concomitant|O
DDI-DrugBank.d85.s6|12-25|administration|O
DDI-DrugBank.d85.s6|27-28|of|O
DDI-DrugBank.d85.s6|30-37|naproxen|drug
DDI-DrugBank.d85.s6|39-41|and|O
DDI-DrugBank.d85.s6|43-49|aspirin|brand
DDI-DrugBank.d85.s6|51-52|is|O
DDI-DrugBank.d85.s6|54-56|not|O
DDI-DrugBank.d85.s6|58-68|recommended|O
DDI-DrugBank.d85.s6|70-76|because|O
DDI-DrugBank.d85.s6|78-85|naproxen|drug
DDI-DrugBank.d85.s6|87-88|is|O
DDI-DrugBank.d85.s6|90-98|displaced|O
DDI-DrugBank.d85.s6|100-103|from|O
DDI-DrugBank.d85.s6|105-107|its|O
DDI-DrugBank.d85.s6|109-115|binding|O
DDI-DrugBank.d85.s6|117-121|sites|O
DDI-DrugBank.d85.s6|123-128|during|O
DDI-DrugBank.d85.s6|130-132|the|O
DDI-DrugBank.d85.s6|134-144|concomitant|O
DDI-DrugBank.d85.s6|146-159|administration|O
DDI-DrugBank.d85.s6|161-162|of|O
DDI-DrugBank.d85.s6|164-170|aspirin|brand
DDI-DrugBank.d85.s6|171-171|,|O
DDI-DrugBank.d85.s6|173-181|resulting|O
DDI-DrugBank.d85.s6|183-184|in|O
DDI-DrugBank.d85.s6|186-190|lower|O
DDI-DrugBank.d85.s6|192-197|plasma|O
DDI-DrugBank.d85.s6|199-212|concentrations|O
DDI-DrugBank.d85.s6|214-216|and|O
DDI-DrugBank.d85.s6|218-221|peak|O
DDI-DrugBank.d85.s6|223-228|plasma|O
DDI-DrugBank.d85.s6|230-235|levels|O
DDI-DrugBank.d85.s6|236-236|.|O
DDI-DrugBank.d85.s7|0-2|The|O
DDI-DrugBank.d85.s7|4-14|natriuretic|O
DDI-DrugBank.d85.s7|16-21|effect|O
DDI-DrugBank.d85.s7|23-24|of|O
DDI-DrugBank.d85.s7|26-35|furosemide|drug
DDI-DrugBank.d85.s7|37-39|has|O
DDI-DrugBank.d85.s7|41-44|been|O
DDI-DrugBank.d85.s7|46-53|reported|O
DDI-DrugBank.d85.s7|55-56|to|O
DDI-DrugBank.d85.s7|58-59|be|O
DDI-DrugBank.d85.s7|61-69|inhibited|O
DDI-DrugBank.d85.s7|71-72|by|O
DDI-DrugBank.d85.s7|74-77|some|O
DDI-DrugBank.d85.s7|79-83|drugs|O
DDI-DrugBank.d85.s7|85-86|of|O
DDI-DrugBank.d85.s7|88-91|this|O
DDI-DrugBank.d85.s7|93-97|class|O
DDI-DrugBank.d85.s7|98-98|.|O
DDI-DrugBank.d85.s8|0-9|Inhibition|O
DDI-DrugBank.d85.s8|11-12|of|O
DDI-DrugBank.d85.s8|14-18|renal|O
DDI-DrugBank.d85.s8|20-26|lithium|drug
DDI-DrugBank.d85.s8|28-36|clearance|O
DDI-DrugBank.d85.s8|38-44|leading|O
DDI-DrugBank.d85.s8|46-47|to|O
DDI-DrugBank.d85.s8|49-57|increases|O
DDI-DrugBank.d85.s8|59-60|in|O
DDI-DrugBank.d85.s8|62-67|plasma|O
DDI-DrugBank.d85.s8|69-75|lithium|drug
DDI-DrugBank.d85.s8|77-90|concentrations|O
DDI-DrugBank.d85.s8|92-94|has|O
DDI-DrugBank.d85.s8|96-99|also|O
DDI-DrugBank.d85.s8|101-104|been|O
DDI-DrugBank.d85.s8|106-113|reported|O
DDI-DrugBank.d85.s8|114-114|.|O
DDI-DrugBank.d85.s9|0-7|Naproxen|drug
DDI-DrugBank.d85.s9|9-11|and|O
DDI-DrugBank.d85.s9|13-17|other|O
DDI-DrugBank.d85.s9|19-24|NSAIDs|group
DDI-DrugBank.d85.s9|26-28|can|O
DDI-DrugBank.d85.s9|30-35|reduce|O
DDI-DrugBank.d85.s9|37-39|the|O
DDI-DrugBank.d85.s9|41-56|antihypertensive|O
DDI-DrugBank.d85.s9|58-63|effect|O
DDI-DrugBank.d85.s9|65-66|of|O
DDI-DrugBank.d85.s9|68-78|propranolol|drug
DDI-DrugBank.d85.s9|80-82|and|O
DDI-DrugBank.d85.s9|84-88|other|O
DDI-DrugBank.d85.s9|90-102|beta-blockers|group
DDI-DrugBank.d85.s9|103-103|.|O
DDI-DrugBank.d85.s10|0-9|Probenecid|drug
DDI-DrugBank.d85.s10|11-15|given|O
DDI-DrugBank.d85.s10|17-28|concurrently|O
DDI-DrugBank.d85.s10|30-38|increases|O
DDI-DrugBank.d85.s10|40-47|naproxen|drug
DDI-DrugBank.d85.s10|49-53|anion|O
DDI-DrugBank.d85.s10|55-60|plasma|O
DDI-DrugBank.d85.s10|62-67|levels|O
DDI-DrugBank.d85.s10|69-71|and|O
DDI-DrugBank.d85.s10|73-79|extends|O
DDI-DrugBank.d85.s10|81-83|its|O
DDI-DrugBank.d85.s10|85-90|plasma|O
DDI-DrugBank.d85.s10|92-100|half-life|O
DDI-DrugBank.d85.s10|102-114|significantly|O
DDI-DrugBank.d85.s10|115-115|.|O
DDI-DrugBank.d85.s11|0-6|Caution|O
DDI-DrugBank.d85.s11|8-13|should|O
DDI-DrugBank.d85.s11|15-16|be|O
DDI-DrugBank.d85.s11|18-21|used|O
DDI-DrugBank.d85.s11|23-24|if|O
DDI-DrugBank.d85.s11|26-33|naproxen|drug
DDI-DrugBank.d85.s11|35-36|is|O
DDI-DrugBank.d85.s11|38-49|administered|O
DDI-DrugBank.d85.s11|51-63|concomitantly|O
DDI-DrugBank.d85.s11|65-68|with|O
DDI-DrugBank.d85.s11|70-81|methotrexate|drug
DDI-DrugBank.d85.s11|82-82|.|O
DDI-DrugBank.d85.s12|0-7|Naproxen|drug
DDI-DrugBank.d85.s12|8-8|,|O
DDI-DrugBank.d85.s12|10-24|naproxen sodium|drug
DDI-DrugBank.d85.s12|26-28|and|O
DDI-DrugBank.d85.s12|30-34|other|O
DDI-DrugBank.d85.s12|36-41|NSAIDs|group
DDI-DrugBank.d85.s12|43-46|have|O
DDI-DrugBank.d85.s12|48-51|been|O
DDI-DrugBank.d85.s12|53-60|reported|O
DDI-DrugBank.d85.s12|62-63|to|O
DDI-DrugBank.d85.s12|65-70|reduce|O
DDI-DrugBank.d85.s12|72-74|the|O
DDI-DrugBank.d85.s12|76-82|tubular|O
DDI-DrugBank.d85.s12|84-92|secretion|O
DDI-DrugBank.d85.s12|94-95|of|O
DDI-DrugBank.d85.s12|97-108|methotrexate|drug
DDI-DrugBank.d85.s12|110-111|in|O
DDI-DrugBank.d85.s12|113-114|an|O
DDI-DrugBank.d85.s12|116-121|animal|O
DDI-DrugBank.d85.s12|123-127|model|O
DDI-DrugBank.d85.s12|128-128|,|O
DDI-DrugBank.d85.s12|130-137|possibly|O
DDI-DrugBank.d85.s12|139-148|increasing|O
DDI-DrugBank.d85.s12|150-152|the|O
DDI-DrugBank.d85.s12|154-161|toxicity|O
DDI-DrugBank.d85.s12|163-164|of|O
DDI-DrugBank.d85.s12|166-177|methotrexate|drug
DDI-DrugBank.d85.s12|178-178|.|O
DDI-DrugBank.d85.s13|0-14|Drug/Laboratory|O
DDI-DrugBank.d85.s13|16-19|Test|O
DDI-DrugBank.d85.s13|21-32|Interactions|O
DDI-DrugBank.d85.s13|34-41|Naproxen|drug
DDI-DrugBank.d85.s13|43-45|may|O
DDI-DrugBank.d85.s13|47-54|decrease|O
DDI-DrugBank.d85.s13|56-63|platelet|O
DDI-DrugBank.d85.s13|65-75|aggregation|O
DDI-DrugBank.d85.s13|77-79|and|O
DDI-DrugBank.d85.s13|81-87|prolong|O
DDI-DrugBank.d85.s13|89-96|bleeding|O
DDI-DrugBank.d85.s13|98-101|time|O
DDI-DrugBank.d85.s13|102-102|.|O
DDI-DrugBank.d85.s14|0-3|This|O
DDI-DrugBank.d85.s14|5-10|effect|O
DDI-DrugBank.d85.s14|12-17|should|O
DDI-DrugBank.d85.s14|19-20|be|O
DDI-DrugBank.d85.s14|22-25|kept|O
DDI-DrugBank.d85.s14|27-28|in|O
DDI-DrugBank.d85.s14|30-33|mind|O
DDI-DrugBank.d85.s14|35-38|when|O
DDI-DrugBank.d85.s14|40-47|bleeding|O
DDI-DrugBank.d85.s14|49-53|times|O
DDI-DrugBank.d85.s14|55-57|are|O
DDI-DrugBank.d85.s14|59-68|determined|O
DDI-DrugBank.d85.s14|69-69|.|O
DDI-DrugBank.d85.s15|0-2|The|O
DDI-DrugBank.d85.s15|4-17|administration|O
DDI-DrugBank.d85.s15|19-20|of|O
DDI-DrugBank.d85.s15|22-29|naproxen|drug
DDI-DrugBank.d85.s15|31-33|may|O
DDI-DrugBank.d85.s15|35-40|result|O
DDI-DrugBank.d85.s15|42-43|in|O
DDI-DrugBank.d85.s15|45-53|increased|O
DDI-DrugBank.d85.s15|55-61|urinary|O
DDI-DrugBank.d85.s15|63-68|values|O
DDI-DrugBank.d85.s15|70-72|for|O
DDI-DrugBank.d85.s15|74-85|17-ketogenic|O
DDI-DrugBank.d85.s15|87-94|steroids|O
DDI-DrugBank.d85.s15|96-102|because|O
DDI-DrugBank.d85.s15|104-105|of|O
DDI-DrugBank.d85.s15|107-108|an|O
DDI-DrugBank.d85.s15|110-120|interaction|O
DDI-DrugBank.d85.s15|122-128|between|O
DDI-DrugBank.d85.s15|130-132|the|O
DDI-DrugBank.d85.s15|134-137|drug|O
DDI-DrugBank.d85.s15|139-144|and/or|O
DDI-DrugBank.d85.s15|146-148|its|O
DDI-DrugBank.d85.s15|150-160|metabolites|O
DDI-DrugBank.d85.s15|162-165|with|O
DDI-DrugBank.d85.s15|167-182|m-dinitrobenzene|O
DDI-DrugBank.d85.s15|184-187|used|O
DDI-DrugBank.d85.s15|189-190|in|O
DDI-DrugBank.d85.s15|192-195|this|O
DDI-DrugBank.d85.s15|197-201|assay|O
DDI-DrugBank.d85.s15|202-202|.|O
DDI-DrugBank.d85.s16|0-7|Although|O
DDI-DrugBank.d85.s16|9-33|17-hydroxy-corticosteroid|O
DDI-DrugBank.d85.s16|35-46|measurements|O
DDI-DrugBank.d85.s16|48-48|(|O
DDI-DrugBank.d85.s16|49-61|Porter-Silber|O
DDI-DrugBank.d85.s16|63-66|test|O
DDI-DrugBank.d85.s16|67-67|)|O
DDI-DrugBank.d85.s16|69-70|do|O
DDI-DrugBank.d85.s16|72-74|not|O
DDI-DrugBank.d85.s16|76-81|appear|O
DDI-DrugBank.d85.s16|83-84|to|O
DDI-DrugBank.d85.s16|86-87|be|O
DDI-DrugBank.d85.s16|89-101|artifactually|O
DDI-DrugBank.d85.s16|103-109|altered|O
DDI-DrugBank.d85.s16|110-110|,|O
DDI-DrugBank.d85.s16|112-113|it|O
DDI-DrugBank.d85.s16|115-116|is|O
DDI-DrugBank.d85.s16|118-126|suggested|O
DDI-DrugBank.d85.s16|128-131|that|O
DDI-DrugBank.d85.s16|133-139|therapy|O
DDI-DrugBank.d85.s16|141-144|with|O
DDI-DrugBank.d85.s16|146-153|naproxen|drug
DDI-DrugBank.d85.s16|155-156|be|O
DDI-DrugBank.d85.s16|158-168|temporarily|O
DDI-DrugBank.d85.s16|170-181|discontinued|O
DDI-DrugBank.d85.s16|183-184|72|O
DDI-DrugBank.d85.s16|186-190|hours|O
DDI-DrugBank.d85.s16|192-197|before|O
DDI-DrugBank.d85.s16|199-205|adrenal|O
DDI-DrugBank.d85.s16|207-214|function|O
DDI-DrugBank.d85.s16|216-220|tests|O
DDI-DrugBank.d85.s16|222-224|are|O
DDI-DrugBank.d85.s16|226-234|performed|O
DDI-DrugBank.d85.s16|236-237|if|O
DDI-DrugBank.d85.s16|239-241|the|O
DDI-DrugBank.d85.s16|243-255|Porter-Silber|O
DDI-DrugBank.d85.s16|257-260|test|O
DDI-DrugBank.d85.s16|262-263|is|O
DDI-DrugBank.d85.s16|265-266|to|O
DDI-DrugBank.d85.s16|268-269|be|O
DDI-DrugBank.d85.s16|271-274|used|O
DDI-DrugBank.d85.s16|275-275|.|O
DDI-DrugBank.d85.s17|0-7|Naproxen|drug
DDI-DrugBank.d85.s17|9-11|may|O
DDI-DrugBank.d85.s17|13-21|interfere|O
DDI-DrugBank.d85.s17|23-26|with|O
DDI-DrugBank.d85.s17|28-31|some|O
DDI-DrugBank.d85.s17|33-39|urinary|O
DDI-DrugBank.d85.s17|41-46|assays|O
DDI-DrugBank.d85.s17|48-49|of|O
DDI-DrugBank.d85.s17|51-59|5-hydroxy|O
DDI-DrugBank.d85.s17|61-72|indoleacetic|O
DDI-DrugBank.d85.s17|74-77|acid|O
DDI-DrugBank.d85.s17|79-79|(|O
DDI-DrugBank.d85.s17|80-84|5HIAA|O
DDI-DrugBank.d85.s17|85-85|)|O
DDI-DrugBank.d85.s17|86-86|.|O
DDI-DrugBank.d559.s0|0-2|The|O
DDI-DrugBank.d559.s0|4-6|CNS|O
DDI-DrugBank.d559.s0|8-14|effects|O
DDI-DrugBank.d559.s0|16-17|of|O
DDI-DrugBank.d559.s0|19-28|butalbital|drug
DDI-DrugBank.d559.s0|30-32|may|O
DDI-DrugBank.d559.s0|34-35|be|O
DDI-DrugBank.d559.s0|37-44|enhanced|O
DDI-DrugBank.d559.s0|46-47|by|O
DDI-DrugBank.d559.s0|49-82|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d559.s0|83-83|.|O
DDI-DrugBank.d559.s1|0-9|Butalbital|drug
DDI-DrugBank.d559.s1|10-10|,|O
DDI-DrugBank.d559.s1|12-24|acetaminophen|drug
DDI-DrugBank.d559.s1|26-28|and|O
DDI-DrugBank.d559.s1|30-37|caffeine|drug
DDI-DrugBank.d559.s1|39-41|may|O
DDI-DrugBank.d559.s1|43-49|enhance|O
DDI-DrugBank.d559.s1|51-53|the|O
DDI-DrugBank.d559.s1|55-61|effects|O
DDI-DrugBank.d559.s1|63-64|of|O
DDI-DrugBank.d559.s1|65-65|:|O
DDI-DrugBank.d559.s1|67-71|other|O
DDI-DrugBank.d559.s1|73-80|narcotic|group
DDI-DrugBank.d559.s1|82-91|analgesics|O
DDI-DrugBank.d559.s1|92-92|,|O
DDI-DrugBank.d559.s1|94-100|alcohol|drug
DDI-DrugBank.d559.s1|101-101|,|O
DDI-DrugBank.d559.s1|103-109|general|O
DDI-DrugBank.d559.s1|111-121|anesthetics|group
DDI-DrugBank.d559.s1|122-122|,|O
DDI-DrugBank.d559.s1|124-136|tranquilizers|group
DDI-DrugBank.d559.s1|138-141|such|O
DDI-DrugBank.d559.s1|143-144|as|O
DDI-DrugBank.d559.s1|146-161|chlordiazepoxide|drug
DDI-DrugBank.d559.s1|162-162|,|O
DDI-DrugBank.d559.s1|164-181|sedative-hypnotics|group
DDI-DrugBank.d559.s1|182-182|,|O
DDI-DrugBank.d559.s1|184-185|or|O
DDI-DrugBank.d559.s1|187-191|other|O
DDI-DrugBank.d559.s1|193-207|CNS depressants|group
DDI-DrugBank.d559.s1|208-208|,|O
DDI-DrugBank.d559.s1|210-216|causing|O
DDI-DrugBank.d559.s1|218-226|increased|O
DDI-DrugBank.d559.s1|228-230|CNS|O
DDI-DrugBank.d559.s1|232-241|depression|O
DDI-DrugBank.d559.s1|242-242|.|O
DDI-DrugBank.d559.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d559.s2|16-19|Test|O
DDI-DrugBank.d559.s2|21-32|Interactions|O
DDI-DrugBank.d559.s2|34-46|Acetaminophen|drug
DDI-DrugBank.d559.s2|48-50|may|O
DDI-DrugBank.d559.s2|52-58|produce|O
DDI-DrugBank.d559.s2|60-73|false-positive|O
DDI-DrugBank.d559.s2|75-78|test|O
DDI-DrugBank.d559.s2|80-86|results|O
DDI-DrugBank.d559.s2|88-90|for|O
DDI-DrugBank.d559.s2|92-98|urinary|O
DDI-DrugBank.d559.s2|100-120|5-hydroxyindoleacetic|O
DDI-DrugBank.d559.s2|122-125|acid|O
DDI-DrugBank.d559.s2|126-126|.|O
DDI-DrugBank.d191.s0|0-4|There|O
DDI-DrugBank.d191.s0|6-7|is|O
DDI-DrugBank.d191.s0|9-10|no|O
DDI-DrugBank.d191.s0|12-16|known|O
DDI-DrugBank.d191.s0|18-21|drug|O
DDI-DrugBank.d191.s0|23-34|interference|O
DDI-DrugBank.d191.s0|36-39|with|O
DDI-DrugBank.d191.s0|41-48|standard|O
DDI-DrugBank.d191.s0|50-57|clinical|O
DDI-DrugBank.d191.s0|59-68|laboratory|O
DDI-DrugBank.d191.s0|70-74|tests|O
DDI-DrugBank.d191.s0|75-75|.|O
DDI-DrugBank.d191.s1|0-7|Steroids|group
DDI-DrugBank.d191.s1|9-15|enhance|O
DDI-DrugBank.d191.s1|17-19|the|O
DDI-DrugBank.d191.s1|21-25|renal|O
DDI-DrugBank.d191.s1|27-34|toxicity|O
DDI-DrugBank.d191.s1|36-37|of|O
DDI-DrugBank.d191.s1|39-62|edetate calcium disodium|drug
DDI-DrugBank.d191.s1|64-65|in|O
DDI-DrugBank.d191.s1|67-74|animals.|O
DDI-DrugBank.d191.s1|76-76|7|O
DDI-DrugBank.d191.s1|78-101|Edetate calcium disodium|drug
DDI-DrugBank.d191.s1|103-112|interferes|O
DDI-DrugBank.d191.s1|114-117|with|O
DDI-DrugBank.d191.s1|119-121|the|O
DDI-DrugBank.d191.s1|123-128|action|O
DDI-DrugBank.d191.s1|130-131|of|O
DDI-DrugBank.d191.s1|133-144|zinc insulin|drug
DDI-DrugBank.d191.s1|146-157|preparations|O
DDI-DrugBank.d191.s1|159-160|by|O
DDI-DrugBank.d191.s1|162-170|chelating|O
DDI-DrugBank.d191.s1|172-174|the|O
DDI-DrugBank.d191.s1|176-180|zinc.|drug
DDI-DrugBank.d191.s1|182-182|7|O
DDI-DrugBank.d225.s0|0-8|Immediate|O
DDI-DrugBank.d225.s0|10-12|and|O
DDI-DrugBank.d225.s0|14-21|Extended|O
DDI-DrugBank.d225.s0|23-29|Release|O
DDI-DrugBank.d225.s0|31-37|Tablets|O
DDI-DrugBank.d225.s0|39-41|The|O
DDI-DrugBank.d225.s0|43-54|hypoglycemic|O
DDI-DrugBank.d225.s0|56-61|action|O
DDI-DrugBank.d225.s0|63-64|of|O
DDI-DrugBank.d225.s0|66-78|sulfonylureas|group
DDI-DrugBank.d225.s0|80-82|may|O
DDI-DrugBank.d225.s0|84-85|be|O
DDI-DrugBank.d225.s0|87-97|potentiated|O
DDI-DrugBank.d225.s0|99-100|by|O
DDI-DrugBank.d225.s0|102-108|certain|O
DDI-DrugBank.d225.s0|110-114|drugs|O
DDI-DrugBank.d225.s0|116-124|including|O
DDI-DrugBank.d225.s0|126-162|nonsteroidal anti-inflammatory agents|group
DDI-DrugBank.d225.s0|163-163|,|O
DDI-DrugBank.d225.s0|165-168|some|O
DDI-DrugBank.d225.s0|170-175|azoles|group
DDI-DrugBank.d225.s0|177-179|and|O
DDI-DrugBank.d225.s0|181-185|other|O
DDI-DrugBank.d225.s0|187-191|drugs|O
DDI-DrugBank.d225.s0|193-196|that|O
DDI-DrugBank.d225.s0|198-200|are|O
DDI-DrugBank.d225.s0|202-207|highly|O
DDI-DrugBank.d225.s0|209-215|protein|O
DDI-DrugBank.d225.s0|217-221|bound|O
DDI-DrugBank.d225.s0|222-222|,|O
DDI-DrugBank.d225.s0|224-234|salicylates|group
DDI-DrugBank.d225.s0|235-235|,|O
DDI-DrugBank.d225.s0|237-248|sulfonamides|group
DDI-DrugBank.d225.s0|249-249|,|O
DDI-DrugBank.d225.s0|251-265|chloramphenicol|drug
DDI-DrugBank.d225.s0|266-266|,|O
DDI-DrugBank.d225.s0|268-277|probenecid|drug
DDI-DrugBank.d225.s0|278-278|,|O
DDI-DrugBank.d225.s0|280-288|coumarins|group
DDI-DrugBank.d225.s0|289-289|,|O
DDI-DrugBank.d225.s0|291-318|monoamine oxidase inhibitors|group
DDI-DrugBank.d225.s0|319-319|,|O
DDI-DrugBank.d225.s0|321-323|and|O
DDI-DrugBank.d225.s0|325-355|beta adrenergic blocking agents|group
DDI-DrugBank.d225.s0|356-356|.|O
DDI-DrugBank.d225.s1|0-3|When|O
DDI-DrugBank.d225.s1|5-8|such|O
DDI-DrugBank.d225.s1|10-14|drugs|O
DDI-DrugBank.d225.s1|16-18|are|O
DDI-DrugBank.d225.s1|20-31|administered|O
DDI-DrugBank.d225.s1|33-34|to|O
DDI-DrugBank.d225.s1|36-36|a|O
DDI-DrugBank.d225.s1|38-44|patient|O
DDI-DrugBank.d225.s1|46-54|receiving|O
DDI-DrugBank.d225.s1|56-64|glipizide|drug
DDI-DrugBank.d225.s1|65-65|,|O
DDI-DrugBank.d225.s1|67-69|the|O
DDI-DrugBank.d225.s1|71-77|patient|O
DDI-DrugBank.d225.s1|79-84|should|O
DDI-DrugBank.d225.s1|86-87|be|O
DDI-DrugBank.d225.s1|89-96|observed|O
DDI-DrugBank.d225.s1|98-104|closely|O
DDI-DrugBank.d225.s1|106-108|for|O
DDI-DrugBank.d225.s1|110-121|hypoglycemia|O
DDI-DrugBank.d225.s1|122-122|.|O
DDI-DrugBank.d225.s2|0-3|When|O
DDI-DrugBank.d225.s2|5-8|such|O
DDI-DrugBank.d225.s2|10-14|drugs|O
DDI-DrugBank.d225.s2|16-18|are|O
DDI-DrugBank.d225.s2|20-28|withdrawn|O
DDI-DrugBank.d225.s2|30-33|from|O
DDI-DrugBank.d225.s2|35-35|a|O
DDI-DrugBank.d225.s2|37-43|patient|O
DDI-DrugBank.d225.s2|45-53|receiving|O
DDI-DrugBank.d225.s2|55-63|glipizide|drug
DDI-DrugBank.d225.s2|64-64|,|O
DDI-DrugBank.d225.s2|66-68|the|O
DDI-DrugBank.d225.s2|70-76|patient|O
DDI-DrugBank.d225.s2|78-83|should|O
DDI-DrugBank.d225.s2|85-86|be|O
DDI-DrugBank.d225.s2|88-95|observed|O
DDI-DrugBank.d225.s2|97-103|closely|O
DDI-DrugBank.d225.s2|105-107|for|O
DDI-DrugBank.d225.s2|109-112|loss|O
DDI-DrugBank.d225.s2|114-115|of|O
DDI-DrugBank.d225.s2|117-123|control|O
DDI-DrugBank.d225.s2|124-124|.|O
DDI-DrugBank.d225.s3|0-1|In|O
DDI-DrugBank.d225.s3|3-7|vitro|O
DDI-DrugBank.d225.s3|9-15|binding|O
DDI-DrugBank.d225.s3|17-23|studies|O
DDI-DrugBank.d225.s3|25-28|with|O
DDI-DrugBank.d225.s3|30-34|human|O
DDI-DrugBank.d225.s3|36-40|serum|O
DDI-DrugBank.d225.s3|42-49|proteins|O
DDI-DrugBank.d225.s3|51-58|indicate|O
DDI-DrugBank.d225.s3|60-63|that|O
DDI-DrugBank.d225.s3|65-73|glipizide|drug
DDI-DrugBank.d225.s3|75-79|binds|O
DDI-DrugBank.d225.s3|81-91|differently|O
DDI-DrugBank.d225.s3|93-96|than|O
DDI-DrugBank.d225.s3|98-108|tolbutamide|drug
DDI-DrugBank.d225.s3|110-112|and|O
DDI-DrugBank.d225.s3|114-117|does|O
DDI-DrugBank.d225.s3|119-121|not|O
DDI-DrugBank.d225.s3|123-130|interact|O
DDI-DrugBank.d225.s3|132-135|with|O
DDI-DrugBank.d225.s3|137-146|salicylate|group
DDI-DrugBank.d225.s3|148-149|or|O
DDI-DrugBank.d225.s3|151-159|dicumarol|drug
DDI-DrugBank.d225.s3|160-160|.|O
DDI-DrugBank.d225.s4|0-6|However|O
DDI-DrugBank.d225.s4|7-7|,|O
DDI-DrugBank.d225.s4|9-15|caution|O
DDI-DrugBank.d225.s4|17-20|must|O
DDI-DrugBank.d225.s4|22-23|be|O
DDI-DrugBank.d225.s4|25-33|exercised|O
DDI-DrugBank.d225.s4|35-36|in|O
DDI-DrugBank.d225.s4|38-50|extrapolating|O
DDI-DrugBank.d225.s4|52-56|these|O
DDI-DrugBank.d225.s4|58-65|findings|O
DDI-DrugBank.d225.s4|67-68|to|O
DDI-DrugBank.d225.s4|70-72|the|O
DDI-DrugBank.d225.s4|74-81|clinical|O
DDI-DrugBank.d225.s4|83-91|situation|O
DDI-DrugBank.d225.s4|93-95|and|O
DDI-DrugBank.d225.s4|97-98|in|O
DDI-DrugBank.d225.s4|100-102|the|O
DDI-DrugBank.d225.s4|104-106|use|O
DDI-DrugBank.d225.s4|108-109|of|O
DDI-DrugBank.d225.s4|111-119|glipizide|drug
DDI-DrugBank.d225.s4|121-124|with|O
DDI-DrugBank.d225.s4|126-130|these|O
DDI-DrugBank.d225.s4|132-136|drugs|O
DDI-DrugBank.d225.s4|137-137|.|O
DDI-DrugBank.d225.s5|0-6|Certain|O
DDI-DrugBank.d225.s5|8-12|drugs|O
DDI-DrugBank.d225.s5|14-17|tend|O
DDI-DrugBank.d225.s5|19-20|to|O
DDI-DrugBank.d225.s5|22-28|produce|O
DDI-DrugBank.d225.s5|30-42|hyperglycemia|O
DDI-DrugBank.d225.s5|44-46|and|O
DDI-DrugBank.d225.s5|48-50|may|O
DDI-DrugBank.d225.s5|52-55|lead|O
DDI-DrugBank.d225.s5|57-58|to|O
DDI-DrugBank.d225.s5|60-63|loss|O
DDI-DrugBank.d225.s5|65-66|of|O
DDI-DrugBank.d225.s5|68-74|control|O
DDI-DrugBank.d225.s5|75-75|.|O
DDI-DrugBank.d225.s6|0-4|These|O
DDI-DrugBank.d225.s6|6-10|drugs|O
DDI-DrugBank.d225.s6|12-18|include|O
DDI-DrugBank.d225.s6|20-22|the|O
DDI-DrugBank.d225.s6|24-32|thiazides|group
DDI-DrugBank.d225.s6|34-36|and|O
DDI-DrugBank.d225.s6|38-42|other|O
DDI-DrugBank.d225.s6|44-52|diuretics|group
DDI-DrugBank.d225.s6|53-53|,|O
DDI-DrugBank.d225.s6|55-69|corticosteroids|group
DDI-DrugBank.d225.s6|70-70|,|O
DDI-DrugBank.d225.s6|72-85|phenothiazines|group
DDI-DrugBank.d225.s6|86-86|,|O
DDI-DrugBank.d225.s6|88-103|thyroid products|group
DDI-DrugBank.d225.s6|104-104|,|O
DDI-DrugBank.d225.s6|106-114|estrogens|group
DDI-DrugBank.d225.s6|115-115|,|O
DDI-DrugBank.d225.s6|117-120|oral|O
DDI-DrugBank.d225.s6|122-135|contraceptives|group
DDI-DrugBank.d225.s6|136-136|,|O
DDI-DrugBank.d225.s6|138-146|phenytoin|drug
DDI-DrugBank.d225.s6|147-147|,|O
DDI-DrugBank.d225.s6|149-162|nicotinic acid|drug
DDI-DrugBank.d225.s6|163-163|,|O
DDI-DrugBank.d225.s6|165-180|sympathomimetics|group
DDI-DrugBank.d225.s6|181-181|,|O
DDI-DrugBank.d225.s6|183-212|calcium channel blocking drugs|group
DDI-DrugBank.d225.s6|213-213|,|O
DDI-DrugBank.d225.s6|215-217|and|O
DDI-DrugBank.d225.s6|219-227|isoniazid|drug
DDI-DrugBank.d225.s6|228-228|.|O
DDI-DrugBank.d225.s7|0-3|When|O
DDI-DrugBank.d225.s7|5-8|such|O
DDI-DrugBank.d225.s7|10-14|drugs|O
DDI-DrugBank.d225.s7|16-18|are|O
DDI-DrugBank.d225.s7|20-31|administered|O
DDI-DrugBank.d225.s7|33-34|to|O
DDI-DrugBank.d225.s7|36-36|a|O
DDI-DrugBank.d225.s7|38-44|patient|O
DDI-DrugBank.d225.s7|46-54|receiving|O
DDI-DrugBank.d225.s7|56-64|glipizide|drug
DDI-DrugBank.d225.s7|65-65|,|O
DDI-DrugBank.d225.s7|67-69|the|O
DDI-DrugBank.d225.s7|71-77|patient|O
DDI-DrugBank.d225.s7|79-84|should|O
DDI-DrugBank.d225.s7|86-87|be|O
DDI-DrugBank.d225.s7|89-95|closely|O
DDI-DrugBank.d225.s7|97-104|observed|O
DDI-DrugBank.d225.s7|106-108|for|O
DDI-DrugBank.d225.s7|110-113|loss|O
DDI-DrugBank.d225.s7|115-116|of|O
DDI-DrugBank.d225.s7|118-124|control|O
DDI-DrugBank.d225.s7|125-125|.|O
DDI-DrugBank.d225.s8|0-3|When|O
DDI-DrugBank.d225.s8|5-8|such|O
DDI-DrugBank.d225.s8|10-14|drugs|O
DDI-DrugBank.d225.s8|16-18|are|O
DDI-DrugBank.d225.s8|20-28|withdrawn|O
DDI-DrugBank.d225.s8|30-33|from|O
DDI-DrugBank.d225.s8|35-35|a|O
DDI-DrugBank.d225.s8|37-43|patient|O
DDI-DrugBank.d225.s8|45-53|receiving|O
DDI-DrugBank.d225.s8|55-63|glipizide|drug
DDI-DrugBank.d225.s8|64-64|,|O
DDI-DrugBank.d225.s8|66-68|the|O
DDI-DrugBank.d225.s8|70-76|patient|O
DDI-DrugBank.d225.s8|78-83|should|O
DDI-DrugBank.d225.s8|85-86|be|O
DDI-DrugBank.d225.s8|88-95|observed|O
DDI-DrugBank.d225.s8|97-103|closely|O
DDI-DrugBank.d225.s8|105-107|for|O
DDI-DrugBank.d225.s8|109-120|hypoglycemia|O
DDI-DrugBank.d225.s8|121-121|.|O
DDI-DrugBank.d225.s9|0-0|A|O
DDI-DrugBank.d225.s9|2-10|potential|O
DDI-DrugBank.d225.s9|12-22|interaction|O
DDI-DrugBank.d225.s9|24-30|between|O
DDI-DrugBank.d225.s9|32-35|oral|O
DDI-DrugBank.d225.s9|37-46|miconazole|drug
DDI-DrugBank.d225.s9|48-50|and|O
DDI-DrugBank.d225.s9|52-55|oral|O
DDI-DrugBank.d225.s9|57-75|hypoglycemic agents|group
DDI-DrugBank.d225.s9|77-83|leading|O
DDI-DrugBank.d225.s9|85-86|to|O
DDI-DrugBank.d225.s9|88-93|severe|O
DDI-DrugBank.d225.s9|95-106|hypoglycemia|O
DDI-DrugBank.d225.s9|108-110|has|O
DDI-DrugBank.d225.s9|112-115|been|O
DDI-DrugBank.d225.s9|117-124|reported|O
DDI-DrugBank.d225.s9|125-125|.|O
DDI-DrugBank.d225.s10|0-6|Whether|O
DDI-DrugBank.d225.s10|8-11|this|O
DDI-DrugBank.d225.s10|13-23|interaction|O
DDI-DrugBank.d225.s10|25-28|also|O
DDI-DrugBank.d225.s10|30-35|occurs|O
DDI-DrugBank.d225.s10|37-40|with|O
DDI-DrugBank.d225.s10|42-44|the|O
DDI-DrugBank.d225.s10|46-56|intravenous|O
DDI-DrugBank.d225.s10|57-57|,|O
DDI-DrugBank.d225.s10|59-65|topical|O
DDI-DrugBank.d225.s10|66-66|,|O
DDI-DrugBank.d225.s10|68-69|or|O
DDI-DrugBank.d225.s10|71-77|vaginal|O
DDI-DrugBank.d225.s10|79-90|preparations|O
DDI-DrugBank.d225.s10|92-93|of|O
DDI-DrugBank.d225.s10|95-104|miconazole|drug
DDI-DrugBank.d225.s10|106-107|is|O
DDI-DrugBank.d225.s10|109-111|not|O
DDI-DrugBank.d225.s10|113-117|known|O
DDI-DrugBank.d225.s10|118-118|.|O
DDI-DrugBank.d225.s11|0-2|The|O
DDI-DrugBank.d225.s11|4-9|effect|O
DDI-DrugBank.d225.s11|11-12|of|O
DDI-DrugBank.d225.s11|14-24|concomitant|O
DDI-DrugBank.d225.s11|26-39|administration|O
DDI-DrugBank.d225.s11|41-42|of|O
DDI-DrugBank.d225.s11|44-54|fluconazole|drug
DDI-DrugBank.d225.s11|56-58|and|O
DDI-DrugBank.d225.s11|60-68|glipizide|drug
DDI-DrugBank.d225.s11|70-72|has|O
DDI-DrugBank.d225.s11|74-77|been|O
DDI-DrugBank.d225.s11|79-90|demonstrated|O
DDI-DrugBank.d225.s11|92-93|in|O
DDI-DrugBank.d225.s11|95-95|a|O
DDI-DrugBank.d225.s11|97-114|placebo-controlled|O
DDI-DrugBank.d225.s11|116-124|crossover|O
DDI-DrugBank.d225.s11|126-130|study|O
DDI-DrugBank.d225.s11|132-133|in|O
DDI-DrugBank.d225.s11|135-140|normal|O
DDI-DrugBank.d225.s11|142-151|volunteers|O
DDI-DrugBank.d225.s11|152-152|.|O
DDI-DrugBank.d225.s12|0-2|All|O
DDI-DrugBank.d225.s12|4-11|subjects|O
DDI-DrugBank.d225.s12|13-20|received|O
DDI-DrugBank.d225.s12|22-30|glipizide|drug
DDI-DrugBank.d225.s12|32-36|alone|O
DDI-DrugBank.d225.s12|38-40|and|O
DDI-DrugBank.d225.s12|42-50|following|O
DDI-DrugBank.d225.s12|52-60|treatment|O
DDI-DrugBank.d225.s12|62-65|with|O
DDI-DrugBank.d225.s12|67-69|100|O
DDI-DrugBank.d225.s12|71-72|mg|O
DDI-DrugBank.d225.s12|74-75|of|O
DDI-DrugBank.d225.s12|77-87|fluconazole|drug
DDI-DrugBank.d225.s12|89-90|as|O
DDI-DrugBank.d225.s12|92-92|a|O
DDI-DrugBank.d225.s12|94-99|single|O
DDI-DrugBank.d225.s12|101-105|daily|O
DDI-DrugBank.d225.s12|107-110|oral|O
DDI-DrugBank.d225.s12|112-115|dose|O
DDI-DrugBank.d225.s12|117-119|for|O
DDI-DrugBank.d225.s12|121-125|seven|O
DDI-DrugBank.d225.s12|127-130|days|O
DDI-DrugBank.d225.s12|131-131|.|O
DDI-DrugBank.d225.s13|0-2|The|O
DDI-DrugBank.d225.s13|4-7|mean|O
DDI-DrugBank.d225.s13|9-18|percentage|O
DDI-DrugBank.d225.s13|20-27|increase|O
DDI-DrugBank.d225.s13|29-30|in|O
DDI-DrugBank.d225.s13|32-34|the|O
DDI-DrugBank.d225.s13|36-44|glipizide|drug
DDI-DrugBank.d225.s13|46-48|AUC|O
DDI-DrugBank.d225.s13|50-54|after|O
DDI-DrugBank.d225.s13|56-66|fluconazole|drug
DDI-DrugBank.d225.s13|68-81|administration|O
DDI-DrugBank.d225.s13|83-85|was|O
DDI-DrugBank.d225.s13|87-90|56.9|O
DDI-DrugBank.d225.s13|91-91|%|O
DDI-DrugBank.d225.s13|93-93|(|O
DDI-DrugBank.d225.s13|94-98|range|O
DDI-DrugBank.d225.s13|99-99|:|O
DDI-DrugBank.d225.s13|101-102|35|O
DDI-DrugBank.d225.s13|104-105|to|O
DDI-DrugBank.d225.s13|107-108|81|O
DDI-DrugBank.d225.s13|109-109|)|O
DDI-DrugBank.d225.s13|110-110|.|O
DDI-DrugBank.d431.s0|0-11|Lansoprazole|drug
DDI-DrugBank.d431.s0|13-14|is|O
DDI-DrugBank.d431.s0|16-26|metabolized|O
DDI-DrugBank.d431.s0|28-34|through|O
DDI-DrugBank.d431.s0|36-38|the|O
DDI-DrugBank.d431.s0|40-49|cytochrome|O
DDI-DrugBank.d431.s0|51-54|P450|O
DDI-DrugBank.d431.s0|56-61|system|O
DDI-DrugBank.d431.s0|62-62|,|O
DDI-DrugBank.d431.s0|64-75|specifically|O
DDI-DrugBank.d431.s0|77-83|through|O
DDI-DrugBank.d431.s0|85-87|the|O
DDI-DrugBank.d431.s0|89-93|CYP3A|O
DDI-DrugBank.d431.s0|95-97|and|O
DDI-DrugBank.d431.s0|99-105|CYP2C19|O
DDI-DrugBank.d431.s0|107-114|isozymes|O
DDI-DrugBank.d431.s0|115-115|.|O
DDI-DrugBank.d431.s1|0-6|Studies|O
DDI-DrugBank.d431.s1|8-11|have|O
DDI-DrugBank.d431.s1|13-17|shown|O
DDI-DrugBank.d431.s1|19-22|that|O
DDI-DrugBank.d431.s1|24-35|lansoprazole|drug
DDI-DrugBank.d431.s1|37-40|does|O
DDI-DrugBank.d431.s1|42-44|not|O
DDI-DrugBank.d431.s1|46-49|have|O
DDI-DrugBank.d431.s1|51-60|clinically|O
DDI-DrugBank.d431.s1|62-72|significant|O
DDI-DrugBank.d431.s1|74-85|interactions|O
DDI-DrugBank.d431.s1|87-90|with|O
DDI-DrugBank.d431.s1|92-96|other|O
DDI-DrugBank.d431.s1|98-102|drugs|O
DDI-DrugBank.d431.s1|104-114|metabolized|O
DDI-DrugBank.d431.s1|116-117|by|O
DDI-DrugBank.d431.s1|119-121|the|O
DDI-DrugBank.d431.s1|123-132|cytochrome|O
DDI-DrugBank.d431.s1|134-137|P450|O
DDI-DrugBank.d431.s1|139-144|system|O
DDI-DrugBank.d431.s1|145-145|,|O
DDI-DrugBank.d431.s1|147-150|such|O
DDI-DrugBank.d431.s1|152-153|as|O
DDI-DrugBank.d431.s1|155-162|warfarin|drug
DDI-DrugBank.d431.s1|163-163|,|O
DDI-DrugBank.d431.s1|165-174|antipyrine|drug
DDI-DrugBank.d431.s1|175-175|,|O
DDI-DrugBank.d431.s1|177-188|indomethacin|drug
DDI-DrugBank.d431.s1|189-189|,|O
DDI-DrugBank.d431.s1|191-199|ibuprofen|drug
DDI-DrugBank.d431.s1|200-200|,|O
DDI-DrugBank.d431.s1|202-210|phenytoin|drug
DDI-DrugBank.d431.s1|211-211|,|O
DDI-DrugBank.d431.s1|213-223|propranolol|drug
DDI-DrugBank.d431.s1|224-224|,|O
DDI-DrugBank.d431.s1|226-235|prednisone|drug
DDI-DrugBank.d431.s1|236-236|,|O
DDI-DrugBank.d431.s1|238-245|diazepam|drug
DDI-DrugBank.d431.s1|246-246|,|O
DDI-DrugBank.d431.s1|248-261|clarithromycin|drug
DDI-DrugBank.d431.s1|262-262|,|O
DDI-DrugBank.d431.s1|264-265|or|O
DDI-DrugBank.d431.s1|267-277|terfenadine|drug
DDI-DrugBank.d431.s1|279-280|in|O
DDI-DrugBank.d431.s1|282-288|healthy|O
DDI-DrugBank.d431.s1|290-297|subjects|O
DDI-DrugBank.d431.s1|298-298|.|O
DDI-DrugBank.d431.s2|0-4|These|O
DDI-DrugBank.d431.s2|6-14|compounds|O
DDI-DrugBank.d431.s2|16-18|are|O
DDI-DrugBank.d431.s2|20-30|metabolized|O
DDI-DrugBank.d431.s2|32-38|through|O
DDI-DrugBank.d431.s2|40-46|various|O
DDI-DrugBank.d431.s2|48-57|cytochrome|O
DDI-DrugBank.d431.s2|59-62|P450|O
DDI-DrugBank.d431.s2|64-71|isozymes|O
DDI-DrugBank.d431.s2|73-81|including|O
DDI-DrugBank.d431.s2|83-88|CYP1A2|O
DDI-DrugBank.d431.s2|89-89|,|O
DDI-DrugBank.d431.s2|91-96|CYP2C9|O
DDI-DrugBank.d431.s2|97-97|,|O
DDI-DrugBank.d431.s2|99-105|CYP2C19|O
DDI-DrugBank.d431.s2|106-106|,|O
DDI-DrugBank.d431.s2|108-113|CYP2D6|O
DDI-DrugBank.d431.s2|114-114|,|O
DDI-DrugBank.d431.s2|116-118|and|O
DDI-DrugBank.d431.s2|120-124|CYP3A|O
DDI-DrugBank.d431.s2|125-125|.|O
DDI-DrugBank.d431.s3|0-3|When|O
DDI-DrugBank.d431.s3|5-16|lansoprazole|drug
DDI-DrugBank.d431.s3|18-20|was|O
DDI-DrugBank.d431.s3|22-33|administered|O
DDI-DrugBank.d431.s3|35-47|concomitantly|O
DDI-DrugBank.d431.s3|49-52|with|O
DDI-DrugBank.d431.s3|54-65|theophylline|drug
DDI-DrugBank.d431.s3|67-67|(|O
DDI-DrugBank.d431.s3|68-73|CYP1A2|O
DDI-DrugBank.d431.s3|74-74|,|O
DDI-DrugBank.d431.s3|76-80|CYP3A|O
DDI-DrugBank.d431.s3|81-81|)|O
DDI-DrugBank.d431.s3|82-82|,|O
DDI-DrugBank.d431.s3|84-84|a|O
DDI-DrugBank.d431.s3|86-90|minor|O
DDI-DrugBank.d431.s3|92-99|increase|O
DDI-DrugBank.d431.s3|101-101|(|O
DDI-DrugBank.d431.s3|102-103|10|O
DDI-DrugBank.d431.s3|104-104|%|O
DDI-DrugBank.d431.s3|105-105|)|O
DDI-DrugBank.d431.s3|107-108|in|O
DDI-DrugBank.d431.s3|110-112|the|O
DDI-DrugBank.d431.s3|114-122|clearance|O
DDI-DrugBank.d431.s3|124-125|of|O
DDI-DrugBank.d431.s3|127-138|theophylline|drug
DDI-DrugBank.d431.s3|140-142|was|O
DDI-DrugBank.d431.s3|144-147|seen|O
DDI-DrugBank.d431.s3|148-148|.|O
DDI-DrugBank.d431.s4|0-6|Because|O
DDI-DrugBank.d431.s4|8-10|the|O
DDI-DrugBank.d431.s4|12-16|small|O
DDI-DrugBank.d431.s4|18-26|magnitude|O
DDI-DrugBank.d431.s4|28-30|and|O
DDI-DrugBank.d431.s4|32-34|the|O
DDI-DrugBank.d431.s4|36-44|direction|O
DDI-DrugBank.d431.s4|46-47|of|O
DDI-DrugBank.d431.s4|49-51|the|O
DDI-DrugBank.d431.s4|53-58|effect|O
DDI-DrugBank.d431.s4|60-61|on|O
DDI-DrugBank.d431.s4|63-74|theophylline|drug
DDI-DrugBank.d431.s4|76-84|clearance|O
DDI-DrugBank.d431.s4|85-85|,|O
DDI-DrugBank.d431.s4|87-90|this|O
DDI-DrugBank.d431.s4|92-102|interaction|O
DDI-DrugBank.d431.s4|104-105|is|O
DDI-DrugBank.d431.s4|107-114|unlikely|O
DDI-DrugBank.d431.s4|116-117|to|O
DDI-DrugBank.d431.s4|119-120|be|O
DDI-DrugBank.d431.s4|122-129|clinical|O
DDI-DrugBank.d431.s4|131-137|concern|O
DDI-DrugBank.d431.s4|138-138|.|O
DDI-DrugBank.d431.s5|0-10|Nonetheless|O
DDI-DrugBank.d431.s5|11-11|,|O
DDI-DrugBank.d431.s5|13-22|individual|O
DDI-DrugBank.d431.s5|24-31|patients|O
DDI-DrugBank.d431.s5|33-35|may|O
DDI-DrugBank.d431.s5|37-43|require|O
DDI-DrugBank.d431.s5|45-54|additional|O
DDI-DrugBank.d431.s5|56-64|titration|O
DDI-DrugBank.d431.s5|66-67|of|O
DDI-DrugBank.d431.s5|69-73|their|O
DDI-DrugBank.d431.s5|75-86|theophylline|drug
DDI-DrugBank.d431.s5|88-93|dosage|O
DDI-DrugBank.d431.s5|95-98|when|O
DDI-DrugBank.d431.s5|100-111|lansoprazole|drug
DDI-DrugBank.d431.s5|113-114|is|O
DDI-DrugBank.d431.s5|116-122|started|O
DDI-DrugBank.d431.s5|124-125|or|O
DDI-DrugBank.d431.s5|127-133|stopped|O
DDI-DrugBank.d431.s5|135-136|to|O
DDI-DrugBank.d431.s5|138-143|ensure|O
DDI-DrugBank.d431.s5|145-154|clinically|O
DDI-DrugBank.d431.s5|156-164|effective|O
DDI-DrugBank.d431.s5|166-170|blood|O
DDI-DrugBank.d431.s5|172-177|levels|O
DDI-DrugBank.d431.s5|178-178|.|O
DDI-DrugBank.d431.s6|0-11|Lansoprazole|drug
DDI-DrugBank.d431.s6|13-15|has|O
DDI-DrugBank.d431.s6|17-20|also|O
DDI-DrugBank.d431.s6|22-25|been|O
DDI-DrugBank.d431.s6|27-31|shown|O
DDI-DrugBank.d431.s6|33-34|to|O
DDI-DrugBank.d431.s6|36-39|have|O
DDI-DrugBank.d431.s6|41-42|no|O
DDI-DrugBank.d431.s6|44-53|clinically|O
DDI-DrugBank.d431.s6|55-65|significant|O
DDI-DrugBank.d431.s6|67-77|interaction|O
DDI-DrugBank.d431.s6|79-82|with|O
DDI-DrugBank.d431.s6|84-94|amoxicillin|drug
DDI-DrugBank.d431.s6|95-95|.|O
DDI-DrugBank.d431.s7|0-1|In|O
DDI-DrugBank.d431.s7|3-3|a|O
DDI-DrugBank.d431.s7|5-15|single-dose|O
DDI-DrugBank.d431.s7|17-25|crossover|O
DDI-DrugBank.d431.s7|27-31|study|O
DDI-DrugBank.d431.s7|33-41|examining|O
DDI-DrugBank.d431.s7|43-54|lansoprazole|drug
DDI-DrugBank.d431.s7|56-57|30|O
DDI-DrugBank.d431.s7|59-60|mg|O
DDI-DrugBank.d431.s7|62-64|and|O
DDI-DrugBank.d431.s7|66-75|omeprazole|drug
DDI-DrugBank.d431.s7|77-78|20|O
DDI-DrugBank.d431.s7|80-81|mg|O
DDI-DrugBank.d431.s7|83-86|each|O
DDI-DrugBank.d431.s7|88-99|administered|O
DDI-DrugBank.d431.s7|101-105|alone|O
DDI-DrugBank.d431.s7|107-109|and|O
DDI-DrugBank.d431.s7|111-123|concomitantly|O
DDI-DrugBank.d431.s7|125-128|with|O
DDI-DrugBank.d431.s7|130-139|sucralfate|drug
DDI-DrugBank.d431.s7|141-141|1|O
DDI-DrugBank.d431.s7|143-146|gram|O
DDI-DrugBank.d431.s7|147-147|,|O
DDI-DrugBank.d431.s7|149-158|absorption|O
DDI-DrugBank.d431.s7|160-161|of|O
DDI-DrugBank.d431.s7|163-165|the|O
DDI-DrugBank.d431.s7|167-188|proton pump inhibitors|group
DDI-DrugBank.d431.s7|190-192|was|O
DDI-DrugBank.d431.s7|194-200|delayed|O
DDI-DrugBank.d431.s7|202-204|and|O
DDI-DrugBank.d431.s7|206-210|their|O
DDI-DrugBank.d431.s7|212-226|bioavailability|O
DDI-DrugBank.d431.s7|228-230|was|O
DDI-DrugBank.d431.s7|232-238|reduced|O
DDI-DrugBank.d431.s7|240-241|by|O
DDI-DrugBank.d431.s7|243-244|17|O
DDI-DrugBank.d431.s7|245-245|%|O
DDI-DrugBank.d431.s7|247-249|and|O
DDI-DrugBank.d431.s7|251-252|16|O
DDI-DrugBank.d431.s7|253-253|%|O
DDI-DrugBank.d431.s7|254-254|,|O
DDI-DrugBank.d431.s7|256-267|respectively|O
DDI-DrugBank.d431.s7|268-268|,|O
DDI-DrugBank.d431.s7|270-273|when|O
DDI-DrugBank.d431.s7|275-286|administered|O
DDI-DrugBank.d431.s7|288-300|concomitantly|O
DDI-DrugBank.d431.s7|302-305|with|O
DDI-DrugBank.d431.s7|307-316|sucralfate|drug
DDI-DrugBank.d431.s7|317-317|.|O
DDI-DrugBank.d431.s8|0-8|Therefore|O
DDI-DrugBank.d431.s8|9-9|,|O
DDI-DrugBank.d431.s8|11-32|proton pump inhibitors|group
DDI-DrugBank.d431.s8|34-39|should|O
DDI-DrugBank.d431.s8|41-42|be|O
DDI-DrugBank.d431.s8|44-48|taken|O
DDI-DrugBank.d431.s8|50-51|at|O
DDI-DrugBank.d431.s8|53-57|least|O
DDI-DrugBank.d431.s8|59-60|30|O
DDI-DrugBank.d431.s8|62-68|minutes|O
DDI-DrugBank.d431.s8|70-74|prior|O
DDI-DrugBank.d431.s8|76-77|to|O
DDI-DrugBank.d431.s8|79-88|sucralfate|drug
DDI-DrugBank.d431.s8|89-89|.|O
DDI-DrugBank.d431.s9|0-1|In|O
DDI-DrugBank.d431.s9|3-10|clinical|O
DDI-DrugBank.d431.s9|12-17|trials|O
DDI-DrugBank.d431.s9|18-18|,|O
DDI-DrugBank.d431.s9|20-27|antacids|group
DDI-DrugBank.d431.s9|29-32|were|O
DDI-DrugBank.d431.s9|34-45|administered|O
DDI-DrugBank.d431.s9|47-59|concomitantly|O
DDI-DrugBank.d431.s9|61-64|with|O
DDI-DrugBank.d431.s9|66-77|lansoprazole|drug
DDI-DrugBank.d431.s9|79-93|delayed-release|O
DDI-DrugBank.d431.s9|95-102|capsules|O
DDI-DrugBank.d431.s9|103-103|;|O
DDI-DrugBank.d431.s10|0-3|this|O
DDI-DrugBank.d431.s10|5-7|did|O
DDI-DrugBank.d431.s10|9-11|not|O
DDI-DrugBank.d431.s10|13-21|interfere|O
DDI-DrugBank.d431.s10|23-26|with|O
DDI-DrugBank.d431.s10|28-30|its|O
DDI-DrugBank.d431.s10|32-37|effect|O
DDI-DrugBank.d431.s10|38-38|.|O
DDI-DrugBank.d431.s11|0-11|Lansoprazole|drug
DDI-DrugBank.d431.s11|13-18|causes|O
DDI-DrugBank.d431.s11|20-20|a|O
DDI-DrugBank.d431.s11|22-29|profound|O
DDI-DrugBank.d431.s11|31-33|and|O
DDI-DrugBank.d431.s11|35-38|long|O
DDI-DrugBank.d431.s11|40-46|lasting|O
DDI-DrugBank.d431.s11|48-57|inhibition|O
DDI-DrugBank.d431.s11|59-60|of|O
DDI-DrugBank.d431.s11|62-68|gastric|O
DDI-DrugBank.d431.s11|70-73|acid|O
DDI-DrugBank.d431.s11|75-83|secretion|O
DDI-DrugBank.d431.s11|84-84|;|O
DDI-DrugBank.d431.s12|0-8|therefore|O
DDI-DrugBank.d431.s12|9-9|,|O
DDI-DrugBank.d431.s12|11-12|it|O
DDI-DrugBank.d431.s12|14-15|is|O
DDI-DrugBank.d431.s12|17-29|theoretically|O
DDI-DrugBank.d431.s12|31-38|possible|O
DDI-DrugBank.d431.s12|40-43|that|O
DDI-DrugBank.d431.s12|45-56|lansoprazole|drug
DDI-DrugBank.d431.s12|58-60|may|O
DDI-DrugBank.d431.s12|62-70|interfere|O
DDI-DrugBank.d431.s12|72-75|with|O
DDI-DrugBank.d431.s12|77-79|the|O
DDI-DrugBank.d431.s12|81-90|absorption|O
DDI-DrugBank.d431.s12|92-93|of|O
DDI-DrugBank.d431.s12|95-99|drugs|O
DDI-DrugBank.d431.s12|101-105|where|O
DDI-DrugBank.d431.s12|107-113|gastric|O
DDI-DrugBank.d431.s12|115-116|pH|O
DDI-DrugBank.d431.s12|118-119|is|O
DDI-DrugBank.d431.s12|121-122|an|O
DDI-DrugBank.d431.s12|124-132|important|O
DDI-DrugBank.d431.s12|134-144|determinant|O
DDI-DrugBank.d431.s12|146-147|of|O
DDI-DrugBank.d431.s12|149-163|bioavailability|O
DDI-DrugBank.d431.s12|165-165|(|O
DDI-DrugBank.d431.s12|166-169|e.g.|O
DDI-DrugBank.d431.s12|171-182|ketoconazole|drug
DDI-DrugBank.d431.s12|183-183|,|O
DDI-DrugBank.d431.s12|185-194|ampicillin|drug
DDI-DrugBank.d431.s12|196-201|esters|O
DDI-DrugBank.d431.s12|202-202|,|O
DDI-DrugBank.d431.s12|204-207|iron|drug
DDI-DrugBank.d431.s12|209-213|salts|O
DDI-DrugBank.d431.s12|214-214|,|O
DDI-DrugBank.d431.s12|216-222|digoxin|drug
DDI-DrugBank.d431.s12|223-223|)|O
DDI-DrugBank.d431.s12|224-224|.|O
DDI-MedLine.d18.s0|0-3|Note|O
DDI-MedLine.d18.s0|4-4|:|O
DDI-MedLine.d18.s0|6-16|dissolution|O
DDI-MedLine.d18.s0|18-19|of|O
DDI-MedLine.d18.s0|21-27|aerosol|O
DDI-MedLine.d18.s0|29-37|particles|O
DDI-MedLine.d18.s0|39-40|of|O
DDI-MedLine.d18.s0|42-51|budesonide|drug
DDI-MedLine.d18.s0|53-54|in|O
DDI-MedLine.d18.s0|56-63|Survanta|brand
DDI-MedLine.d18.s0|64-64|,|O
DDI-MedLine.d18.s0|66-66|a|O
DDI-MedLine.d18.s0|68-72|model|O
DDI-MedLine.d18.s0|74-88|lung surfactant|group
DDI-MedLine.d18.s0|89-89|.|O
DDI-MedLine.d18.s1|0-2|The|O
DDI-MedLine.d18.s1|4-9|effect|O
DDI-MedLine.d18.s1|11-12|of|O
DDI-MedLine.d18.s1|14-14|a|O
DDI-MedLine.d18.s1|16-35|pulmonary surfactant|group
DDI-MedLine.d18.s1|37-43|extract|O
DDI-MedLine.d18.s1|45-48|from|O
DDI-MedLine.d18.s1|50-55|bovine|O
DDI-MedLine.d18.s1|57-60|lung|O
DDI-MedLine.d18.s1|61-61|,|O
DDI-MedLine.d18.s1|63-70|Survanta|brand
DDI-MedLine.d18.s1|71-71|,|O
DDI-MedLine.d18.s1|73-74|on|O
DDI-MedLine.d18.s1|76-78|the|O
DDI-MedLine.d18.s1|80-90|dissolution|O
DDI-MedLine.d18.s1|92-95|rate|O
DDI-MedLine.d18.s1|97-98|of|O
DDI-MedLine.d18.s1|100-106|aerosol|O
DDI-MedLine.d18.s1|108-116|particles|O
DDI-MedLine.d18.s1|118-119|of|O
DDI-MedLine.d18.s1|121-130|budesonide|drug
DDI-MedLine.d18.s1|132-134|was|O
DDI-MedLine.d18.s1|136-145|determined|O
DDI-MedLine.d18.s1|146-146|.|O
DDI-MedLine.d18.s2|0-6|Aerosol|O
DDI-MedLine.d18.s2|8-16|particles|O
DDI-MedLine.d18.s2|18-19|of|O
DDI-MedLine.d18.s2|21-30|budesonide|drug
DDI-MedLine.d18.s2|32-35|were|O
DDI-MedLine.d18.s2|37-45|generated|O
DDI-MedLine.d18.s2|47-50|from|O
DDI-MedLine.d18.s2|52-53|an|O
DDI-MedLine.d18.s2|55-61|ethanol|drug
DDI-MedLine.d18.s2|63-70|solution|O
DDI-MedLine.d18.s2|71-71|,|O
DDI-MedLine.d18.s2|73-77|dried|O
DDI-MedLine.d18.s2|78-78|,|O
DDI-MedLine.d18.s2|80-82|and|O
DDI-MedLine.d18.s2|84-92|collected|O
DDI-MedLine.d18.s2|94-95|by|O
DDI-MedLine.d18.s2|97-97|a|O
DDI-MedLine.d18.s2|99-105|cascade|O
DDI-MedLine.d18.s2|107-114|impactor|O
DDI-MedLine.d18.s2|116-118|for|O
DDI-MedLine.d18.s2|120-135|characterization|O
DDI-MedLine.d18.s2|137-138|or|O
DDI-MedLine.d18.s2|140-141|by|O
DDI-MedLine.d18.s2|143-143|a|O
DDI-MedLine.d18.s2|145-150|liquid|O
DDI-MedLine.d18.s2|152-159|impinger|O
DDI-MedLine.d18.s2|161-163|for|O
DDI-MedLine.d18.s2|165-175|dissolution|O
DDI-MedLine.d18.s2|177-187|experiments|O
DDI-MedLine.d18.s2|188-188|.|O
DDI-MedLine.d18.s3|0-5|Powder|O
DDI-MedLine.d18.s3|7-11|x-ray|O
DDI-MedLine.d18.s3|13-23|diffraction|O
DDI-MedLine.d18.s3|24-24|,|O
DDI-MedLine.d18.s3|26-37|differential|O
DDI-MedLine.d18.s3|39-46|scanning|O
DDI-MedLine.d18.s3|48-58|calorimetry|O
DDI-MedLine.d18.s3|59-59|,|O
DDI-MedLine.d18.s3|61-72|differential|O
DDI-MedLine.d18.s3|74-80|thermal|O
DDI-MedLine.d18.s3|82-89|analysis|O
DDI-MedLine.d18.s3|90-90|,|O
DDI-MedLine.d18.s3|92-94|and|O
DDI-MedLine.d18.s3|96-103|scanning|O
DDI-MedLine.d18.s3|105-112|electron|O
DDI-MedLine.d18.s3|114-123|microscopy|O
DDI-MedLine.d18.s3|125-128|were|O
DDI-MedLine.d18.s3|130-133|used|O
DDI-MedLine.d18.s3|135-136|to|O
DDI-MedLine.d18.s3|138-149|characterize|O
DDI-MedLine.d18.s3|151-153|the|O
DDI-MedLine.d18.s3|155-161|aerosol|O
DDI-MedLine.d18.s3|163-171|particles|O
DDI-MedLine.d18.s3|173-175|and|O
DDI-MedLine.d18.s3|177-184|starting|O
DDI-MedLine.d18.s3|186-193|material|O
DDI-MedLine.d18.s3|194-194|.|O
DDI-MedLine.d18.s4|0-1|No|O
DDI-MedLine.d18.s4|3-8|change|O
DDI-MedLine.d18.s4|10-11|in|O
DDI-MedLine.d18.s4|13-17|phase|O
DDI-MedLine.d18.s4|19-21|was|O
DDI-MedLine.d18.s4|23-30|detected|O
DDI-MedLine.d18.s4|31-31|,|O
DDI-MedLine.d18.s4|33-40|although|O
DDI-MedLine.d18.s4|42-44|the|O
DDI-MedLine.d18.s4|46-52|aerosol|O
DDI-MedLine.d18.s4|54-62|particles|O
DDI-MedLine.d18.s4|64-71|appeared|O
DDI-MedLine.d18.s4|73-74|to|O
DDI-MedLine.d18.s4|76-82|contain|O
DDI-MedLine.d18.s4|84-91|residual|O
DDI-MedLine.d18.s4|93-99|solvent|group
DDI-MedLine.d18.s4|100-100|.|O
DDI-MedLine.d18.s5|0-2|The|O
DDI-MedLine.d18.s5|4-14|dissolution|O
DDI-MedLine.d18.s5|16-19|rate|O
DDI-MedLine.d18.s5|21-22|of|O
DDI-MedLine.d18.s5|24-26|the|O
DDI-MedLine.d18.s5|28-34|aerosol|O
DDI-MedLine.d18.s5|36-44|particles|O
DDI-MedLine.d18.s5|46-47|in|O
DDI-MedLine.d18.s5|49-54|saline|O
DDI-MedLine.d18.s5|56-58|was|O
DDI-MedLine.d18.s5|60-62|low|O
DDI-MedLine.d18.s5|64-66|and|O
DDI-MedLine.d18.s5|68-75|variable|O
DDI-MedLine.d18.s5|76-76|.|O
DDI-MedLine.d18.s6|0-7|Survanta|brand
DDI-MedLine.d18.s6|9-17|increased|O
DDI-MedLine.d18.s6|19-21|the|O
DDI-MedLine.d18.s6|23-28|extent|O
DDI-MedLine.d18.s6|30-31|of|O
DDI-MedLine.d18.s6|33-43|dissolution|O
DDI-MedLine.d18.s6|45-46|of|O
DDI-MedLine.d18.s6|48-57|budesonide|drug
DDI-MedLine.d18.s6|59-60|in|O
DDI-MedLine.d18.s6|62-71|proportion|O
DDI-MedLine.d18.s6|73-74|to|O
DDI-MedLine.d18.s6|76-78|the|O
DDI-MedLine.d18.s6|80-84|added|O
DDI-MedLine.d18.s6|86-98|concentration|O
DDI-MedLine.d18.s6|99-99|,|O
DDI-MedLine.d18.s6|101-105|which|O
DDI-MedLine.d18.s6|107-109|was|O
DDI-MedLine.d18.s6|111-114|also|O
DDI-MedLine.d18.s6|116-123|verified|O
DDI-MedLine.d18.s6|125-126|by|O
DDI-MedLine.d18.s6|128-138|equilibrium|O
DDI-MedLine.d18.s6|140-153|solubilization|O
DDI-MedLine.d18.s6|155-161|studies|O
DDI-MedLine.d18.s6|162-162|.|O
DDI-MedLine.d18.s7|0-7|Survanta|brand
DDI-MedLine.d18.s7|9-12|also|O
DDI-MedLine.d18.s7|14-22|increased|O
DDI-MedLine.d18.s7|24-27|rate|O
DDI-MedLine.d18.s7|29-30|of|O
DDI-MedLine.d18.s7|32-42|dissolution|O
DDI-MedLine.d18.s7|43-43|,|O
DDI-MedLine.d18.s7|45-46|in|O
DDI-MedLine.d18.s7|48-48|a|O
DDI-MedLine.d18.s7|50-55|manner|O
DDI-MedLine.d18.s7|57-63|similar|O
DDI-MedLine.d18.s7|65-66|to|O
DDI-MedLine.d18.s7|90-90|.|O
DDI-MedLine.d18.s8|0-7|Analysis|O
DDI-MedLine.d18.s8|9-10|of|O
DDI-MedLine.d18.s8|12-14|the|O
DDI-MedLine.d18.s8|16-28|concentration|O
DDI-MedLine.d18.s8|30-31|of|O
DDI-MedLine.d18.s8|33-42|budesonide|drug
DDI-MedLine.d18.s8|44-52|following|O
DDI-MedLine.d18.s8|54-72|ultracentrifugation|O
DDI-MedLine.d18.s8|74-82|indicated|O
DDI-MedLine.d18.s8|84-87|that|O
DDI-MedLine.d18.s8|89-93|there|O
DDI-MedLine.d18.s8|95-96|is|O
DDI-MedLine.d18.s8|98-102|rapid|O
DDI-MedLine.d18.s8|104-116|equilibration|O
DDI-MedLine.d18.s8|118-119|of|O
DDI-MedLine.d18.s8|121-130|budesonide|drug
DDI-MedLine.d18.s8|132-138|between|O
DDI-MedLine.d18.s8|140-142|the|O
DDI-MedLine.d18.s8|144-151|Survanta|brand
DDI-MedLine.d18.s8|153-155|and|O
DDI-MedLine.d18.s8|157-163|aqueous|O
DDI-MedLine.d18.s8|165-169|phase|O
DDI-MedLine.d18.s8|170-170|.|O
DDI-MedLine.d18.s9|0-4|These|O
DDI-MedLine.d18.s9|6-12|results|O
DDI-MedLine.d18.s9|14-17|show|O
DDI-MedLine.d18.s9|19-22|that|O
DDI-MedLine.d18.s9|24-38|lung surfactant|group
DDI-MedLine.d18.s9|40-42|has|O
DDI-MedLine.d18.s9|44-46|the|O
DDI-MedLine.d18.s9|48-56|potential|O
DDI-MedLine.d18.s9|58-59|of|O
DDI-MedLine.d18.s9|61-69|enhancing|O
DDI-MedLine.d18.s9|71-73|the|O
DDI-MedLine.d18.s9|75-78|rate|O
DDI-MedLine.d18.s9|80-82|and|O
DDI-MedLine.d18.s9|84-89|extent|O
DDI-MedLine.d18.s9|91-92|of|O
DDI-MedLine.d18.s9|94-104|dissolution|O
DDI-MedLine.d18.s9|106-107|of|O
DDI-MedLine.d18.s9|109-113|drugs|O
DDI-MedLine.d18.s9|115-126|administered|O
DDI-MedLine.d18.s9|128-129|to|O
DDI-MedLine.d18.s9|131-133|the|O
DDI-MedLine.d18.s9|135-138|lung|O
DDI-MedLine.d18.s9|139-139|.|O
DDI-DrugBank.d677.s0|0-13|Phenothiazines|group
DDI-DrugBank.d677.s0|15-17|are|O
DDI-DrugBank.d677.s0|19-25|capable|O
DDI-DrugBank.d677.s0|27-28|of|O
DDI-DrugBank.d677.s0|30-41|potentiating|O
DDI-DrugBank.d677.s0|43-57|CNS depressants|group
DDI-DrugBank.d677.s0|59-59|(|O
DDI-DrugBank.d677.s0|60-63|e.g.|O
DDI-DrugBank.d677.s0|64-64|,|O
DDI-DrugBank.d677.s0|66-77|barbiturates|group
DDI-DrugBank.d677.s0|78-78|,|O
DDI-DrugBank.d677.s0|80-90|anesthetics|group
DDI-DrugBank.d677.s0|91-91|,|O
DDI-DrugBank.d677.s0|93-99|opiates|group
DDI-DrugBank.d677.s0|100-100|,|O
DDI-DrugBank.d677.s0|102-108|alcohol|drug
DDI-DrugBank.d677.s0|109-109|,|O
DDI-DrugBank.d677.s0|111-113|etc|O
DDI-DrugBank.d677.s0|114-114|.|O
DDI-DrugBank.d677.s0|115-115|)|O
DDI-DrugBank.d677.s1|0-1|as|O
DDI-DrugBank.d677.s1|3-6|well|O
DDI-DrugBank.d677.s1|8-9|as|O
DDI-DrugBank.d677.s1|11-18|atropine|drug
DDI-DrugBank.d677.s1|20-22|and|O
DDI-DrugBank.d677.s1|48-48|.|O
DDI-DrugBank.d547.s0|0-1|No|O
DDI-DrugBank.d547.s0|3-13|significant|O
DDI-DrugBank.d547.s0|15-18|drug|O
DDI-DrugBank.d547.s0|20-31|interactions|O
DDI-DrugBank.d547.s0|33-36|have|O
DDI-DrugBank.d547.s0|38-41|been|O
DDI-DrugBank.d547.s0|43-50|reported|O
DDI-DrugBank.d547.s0|52-53|in|O
DDI-DrugBank.d547.s0|55-61|studies|O
DDI-DrugBank.d547.s0|63-64|of|O
DDI-DrugBank.d547.s0|66-86|candesartan cilexetil|drug
DDI-DrugBank.d547.s0|88-92|given|O
DDI-DrugBank.d547.s0|94-97|with|O
DDI-DrugBank.d547.s0|99-103|other|O
DDI-DrugBank.d547.s0|105-109|drugs|O
DDI-DrugBank.d547.s0|111-114|such|O
DDI-DrugBank.d547.s0|116-117|as|O
DDI-DrugBank.d547.s0|119-127|glyburide|drug
DDI-DrugBank.d547.s0|128-128|,|O
DDI-DrugBank.d547.s0|130-139|nifedipine|drug
DDI-DrugBank.d547.s0|140-140|,|O
DDI-DrugBank.d547.s0|142-148|digoxin|drug
DDI-DrugBank.d547.s0|149-149|,|O
DDI-DrugBank.d547.s0|151-158|warfarin|drug
DDI-DrugBank.d547.s0|159-159|,|O
DDI-DrugBank.d547.s0|161-179|hydrochlorothiazide|drug
DDI-DrugBank.d547.s0|180-180|,|O
DDI-DrugBank.d547.s0|182-184|and|O
DDI-DrugBank.d547.s0|186-189|oral|O
DDI-DrugBank.d547.s0|191-204|contraceptives|group
DDI-DrugBank.d547.s0|206-207|in|O
DDI-DrugBank.d547.s0|209-215|healthy|O
DDI-DrugBank.d547.s0|217-226|volunteers|O
DDI-DrugBank.d547.s0|227-227|,|O
DDI-DrugBank.d547.s0|229-230|or|O
DDI-DrugBank.d547.s0|232-236|given|O
DDI-DrugBank.d547.s0|238-241|with|O
DDI-DrugBank.d547.s0|243-251|enalapril|drug
DDI-DrugBank.d547.s0|253-254|to|O
DDI-DrugBank.d547.s0|256-263|patients|O
DDI-DrugBank.d547.s0|265-268|with|O
DDI-DrugBank.d547.s0|270-274|heart|O
DDI-DrugBank.d547.s0|276-282|failure|O
DDI-DrugBank.d547.s0|284-284|(|O
DDI-DrugBank.d547.s0|285-288|NYHA|O
DDI-DrugBank.d547.s0|290-294|class|O
DDI-DrugBank.d547.s0|296-297|II|O
DDI-DrugBank.d547.s0|299-301|and|O
DDI-DrugBank.d547.s0|303-305|III|O
DDI-DrugBank.d547.s0|306-306|)|O
DDI-DrugBank.d547.s0|307-307|.|O
DDI-DrugBank.d547.s1|0-6|Because|O
DDI-DrugBank.d547.s1|8-18|candesartan|drug
DDI-DrugBank.d547.s1|20-21|is|O
DDI-DrugBank.d547.s1|23-25|not|O
DDI-DrugBank.d547.s1|27-39|significantly|O
DDI-DrugBank.d547.s1|41-51|metabolized|O
DDI-DrugBank.d547.s1|53-54|by|O
DDI-DrugBank.d547.s1|56-58|the|O
DDI-DrugBank.d547.s1|60-69|cytochrome|O
DDI-DrugBank.d547.s1|71-74|P450|O
DDI-DrugBank.d547.s1|76-81|system|O
DDI-DrugBank.d547.s1|83-85|and|O
DDI-DrugBank.d547.s1|87-88|at|O
DDI-DrugBank.d547.s1|90-100|therapeutic|O
DDI-DrugBank.d547.s1|102-115|concentrations|O
DDI-DrugBank.d547.s1|117-119|has|O
DDI-DrugBank.d547.s1|121-122|no|O
DDI-DrugBank.d547.s1|124-130|effects|O
DDI-DrugBank.d547.s1|132-133|on|O
DDI-DrugBank.d547.s1|135-138|P450|O
DDI-DrugBank.d547.s1|140-146|enzymes|O
DDI-DrugBank.d547.s1|147-147|,|O
DDI-DrugBank.d547.s1|149-160|interactions|O
DDI-DrugBank.d547.s1|162-165|with|O
DDI-DrugBank.d547.s1|167-171|drugs|O
DDI-DrugBank.d547.s1|173-176|that|O
DDI-DrugBank.d547.s1|178-184|inhibit|O
DDI-DrugBank.d547.s1|186-187|or|O
DDI-DrugBank.d547.s1|189-191|are|O
DDI-DrugBank.d547.s1|193-203|metabolized|O
DDI-DrugBank.d547.s1|205-206|by|O
DDI-DrugBank.d547.s1|208-212|those|O
DDI-DrugBank.d547.s1|214-220|enzymes|O
DDI-DrugBank.d547.s1|222-226|would|O
DDI-DrugBank.d547.s1|228-230|not|O
DDI-DrugBank.d547.s1|232-233|be|O
DDI-DrugBank.d547.s1|235-242|expected|O
DDI-DrugBank.d547.s1|243-243|.|O
DDI-DrugBank.d547.s2|0-6|Lithium|drug
DDI-DrugBank.d547.s2|8-17|Reversible|O
DDI-DrugBank.d547.s2|19-27|increases|O
DDI-DrugBank.d547.s2|29-30|in|O
DDI-DrugBank.d547.s2|32-36|serum|O
DDI-DrugBank.d547.s2|38-44|lithium|drug
DDI-DrugBank.d547.s2|46-59|concentrations|O
DDI-DrugBank.d547.s2|61-63|and|O
DDI-DrugBank.d547.s2|65-72|toxicity|O
DDI-DrugBank.d547.s2|74-77|have|O
DDI-DrugBank.d547.s2|79-82|been|O
DDI-DrugBank.d547.s2|84-91|reported|O
DDI-DrugBank.d547.s2|93-98|during|O
DDI-DrugBank.d547.s2|100-110|concomitant|O
DDI-DrugBank.d547.s2|112-125|administration|O
DDI-DrugBank.d547.s2|127-128|of|O
DDI-DrugBank.d547.s2|130-136|lithium|drug
DDI-DrugBank.d547.s2|138-141|with|O
DDI-DrugBank.d547.s2|143-156|ACE inhibitors|group
DDI-DrugBank.d547.s2|157-157|,|O
DDI-DrugBank.d547.s2|159-161|and|O
DDI-DrugBank.d547.s2|163-166|with|O
DDI-DrugBank.d547.s2|168-171|some|O
DDI-DrugBank.d547.s2|173-207|angiotensin II receptor antagonists|group
DDI-DrugBank.d547.s2|208-208|.|O
DDI-DrugBank.d547.s3|0-1|An|O
DDI-DrugBank.d547.s3|3-10|increase|O
DDI-DrugBank.d547.s3|12-13|in|O
DDI-DrugBank.d547.s3|15-19|serum|O
DDI-DrugBank.d547.s3|21-27|lithium|drug
DDI-DrugBank.d547.s3|29-41|concentration|O
DDI-DrugBank.d547.s3|43-45|has|O
DDI-DrugBank.d547.s3|47-50|been|O
DDI-DrugBank.d547.s3|52-59|reported|O
DDI-DrugBank.d547.s3|61-66|during|O
DDI-DrugBank.d547.s3|68-78|concomitant|O
DDI-DrugBank.d547.s3|80-93|administration|O
DDI-DrugBank.d547.s3|95-96|of|O
DDI-DrugBank.d547.s3|98-104|lithium|drug
DDI-DrugBank.d547.s3|106-109|with|O
DDI-DrugBank.d547.s3|111-117|ATACAND|brand
DDI-DrugBank.d547.s3|118-118|,|O
DDI-DrugBank.d547.s3|120-121|so|O
DDI-DrugBank.d547.s3|123-129|careful|O
DDI-DrugBank.d547.s3|131-140|monitoring|O
DDI-DrugBank.d547.s3|142-143|of|O
DDI-DrugBank.d547.s3|145-149|serum|O
DDI-DrugBank.d547.s3|151-157|lithium|drug
DDI-DrugBank.d547.s3|159-164|levels|O
DDI-DrugBank.d547.s3|166-167|is|O
DDI-DrugBank.d547.s3|169-179|recommended|O
DDI-DrugBank.d547.s3|181-186|during|O
DDI-DrugBank.d547.s3|188-198|concomitant|O
DDI-DrugBank.d547.s3|200-202|use|O
DDI-DrugBank.d547.s3|203-203|.|O
DDI-MedLine.d16.s0|0-10|Interaction|O
DDI-MedLine.d16.s0|12-13|of|O
DDI-MedLine.d16.s0|15-22|ketamine|drug
DDI-MedLine.d16.s0|24-26|and|O
DDI-MedLine.d16.s0|28-36|halothane|drug
DDI-MedLine.d16.s0|38-39|in|O
DDI-MedLine.d16.s0|41-44|rats|O
DDI-MedLine.d16.s0|45-45|.|O
DDI-MedLine.d16.s1|0-2|The|O
DDI-MedLine.d16.s1|4-14|interaction|O
DDI-MedLine.d16.s1|16-17|of|O
DDI-MedLine.d16.s1|19-33|intramuscularly|O
DDI-MedLine.d16.s1|35-42|injected|O
DDI-MedLine.d16.s1|44-51|ketamine|drug
DDI-MedLine.d16.s1|53-55|and|O
DDI-MedLine.d16.s1|57-59|its|O
DDI-MedLine.d16.s1|61-74|N-demethylated|O
DDI-MedLine.d16.s1|76-85|metabolite|O
DDI-MedLine.d16.s1|87-87|(|O
DDI-MedLine.d16.s1|88-97|metabolite|O
DDI-MedLine.d16.s1|99-99|I|O
DDI-MedLine.d16.s1|100-100|)|O
DDI-MedLine.d16.s1|102-105|with|O
DDI-MedLine.d16.s1|107-115|halothane|drug
DDI-MedLine.d16.s1|117-119|was|O
DDI-MedLine.d16.s1|121-129|evaluated|O
DDI-MedLine.d16.s1|131-132|in|O
DDI-MedLine.d16.s1|134-137|rats|O
DDI-MedLine.d16.s1|138-138|.|O
DDI-MedLine.d16.s2|0-3|Five|O
DDI-MedLine.d16.s2|4-4|,|O
DDI-MedLine.d16.s2|6-7|10|O
DDI-MedLine.d16.s2|8-8|,|O
DDI-MedLine.d16.s2|10-11|20|O
DDI-MedLine.d16.s2|12-12|,|O
DDI-MedLine.d16.s2|14-15|or|O
DDI-MedLine.d16.s2|17-18|50|O
DDI-MedLine.d16.s2|20-24|mg/kg|O
DDI-MedLine.d16.s2|26-27|of|O
DDI-MedLine.d16.s2|29-36|ketamine|drug
DDI-MedLine.d16.s2|38-42|alone|O
DDI-MedLine.d16.s2|44-45|or|O
DDI-MedLine.d16.s2|47-48|20|O
DDI-MedLine.d16.s2|49-49|,|O
DDI-MedLine.d16.s2|51-52|50|O
DDI-MedLine.d16.s2|53-53|,|O
DDI-MedLine.d16.s2|55-56|or|O
DDI-MedLine.d16.s2|58-60|100|O
DDI-MedLine.d16.s2|62-66|mg/kg|O
DDI-MedLine.d16.s2|68-69|of|O
DDI-MedLine.d16.s2|71-80|metabolite|O
DDI-MedLine.d16.s2|82-82|I|O
DDI-MedLine.d16.s2|84-88|alone|O
DDI-MedLine.d16.s2|90-97|produced|O
DDI-MedLine.d16.s2|99-102|less|O
DDI-MedLine.d16.s2|104-107|than|O
DDI-MedLine.d16.s2|109-110|10|O
DDI-MedLine.d16.s2|112-118|minutes|O
DDI-MedLine.d16.s2|120-121|of|O
DDI-MedLine.d16.s2|123-130|hypnosis|O
DDI-MedLine.d16.s2|131-131|.|O
DDI-MedLine.d16.s3|0-6|However|O
DDI-MedLine.d16.s3|7-7|,|O
DDI-MedLine.d16.s3|9-17|halothane|drug
DDI-MedLine.d16.s3|19-28|anesthetic|O
DDI-MedLine.d16.s3|30-40|requirement|O
DDI-MedLine.d16.s3|42-42|(|O
DDI-MedLine.d16.s3|43-46|i.e.|O
DDI-MedLine.d16.s3|47-47|,|O
DDI-MedLine.d16.s3|49-51|MAC|O
DDI-MedLine.d16.s3|52-52|)|O
DDI-MedLine.d16.s3|54-56|was|O
DDI-MedLine.d16.s3|58-66|depressed|O
DDI-MedLine.d16.s3|68-69|in|O
DDI-MedLine.d16.s3|71-71|a|O
DDI-MedLine.d16.s3|73-86|dose-dependent|O
DDI-MedLine.d16.s3|88-94|fashion|O
DDI-MedLine.d16.s3|96-97|as|O
DDI-MedLine.d16.s3|99-102|much|O
DDI-MedLine.d16.s3|104-105|as|O
DDI-MedLine.d16.s3|107-108|56|O
DDI-MedLine.d16.s3|109-109|%|O
DDI-MedLine.d16.s3|111-113|1-2|O
DDI-MedLine.d16.s3|115-119|hours|O
DDI-MedLine.d16.s3|121-123|and|O
DDI-MedLine.d16.s3|125-126|as|O
DDI-MedLine.d16.s3|128-131|much|O
DDI-MedLine.d16.s3|133-134|as|O
DDI-MedLine.d16.s3|136-137|14|O
DDI-MedLine.d16.s3|138-138|%|O
DDI-MedLine.d16.s3|140-142|5-6|O
DDI-MedLine.d16.s3|144-148|hours|O
DDI-MedLine.d16.s3|150-154|after|O
DDI-MedLine.d16.s3|156-164|injection|O
DDI-MedLine.d16.s3|166-167|of|O
DDI-MedLine.d16.s3|169-176|ketamine|drug
DDI-MedLine.d16.s3|177-177|,|O
DDI-MedLine.d16.s3|179-180|50|O
DDI-MedLine.d16.s3|182-186|mg/kg|O
DDI-MedLine.d16.s3|187-187|,|O
DDI-MedLine.d16.s3|189-190|im|O
DDI-MedLine.d16.s3|191-191|.|O
DDI-MedLine.d16.s4|0-2|The|O
DDI-MedLine.d16.s4|4-12|reduction|O
DDI-MedLine.d16.s4|14-15|in|O
DDI-MedLine.d16.s4|17-19|MAC|O
DDI-MedLine.d16.s4|21-23|was|O
DDI-MedLine.d16.s4|25-34|correlated|O
DDI-MedLine.d16.s4|36-39|with|O
DDI-MedLine.d16.s4|41-45|brain|O
DDI-MedLine.d16.s4|47-52|levels|O
DDI-MedLine.d16.s4|54-55|of|O
DDI-MedLine.d16.s4|57-64|ketamine|drug
DDI-MedLine.d16.s4|66-67|or|O
DDI-MedLine.d16.s4|69-78|metabolite|O
DDI-MedLine.d16.s4|80-80|I|O
DDI-MedLine.d16.s4|81-81|,|O
DDI-MedLine.d16.s4|83-92|suggesting|O
DDI-MedLine.d16.s4|94-94|a|O
DDI-MedLine.d16.s4|96-103|ketamine|drug
DDI-MedLine.d16.s4|104-104|:|O
DDI-MedLine.d16.s4|105-114|metabolite|O
DDI-MedLine.d16.s4|116-116|I|O
DDI-MedLine.d16.s4|118-124|potency|O
DDI-MedLine.d16.s4|126-131|ration|O
DDI-MedLine.d16.s4|133-134|of|O
DDI-MedLine.d16.s4|136-138|3:1|O
DDI-MedLine.d16.s4|139-139|.|O
DDI-MedLine.d16.s5|0-2|The|O
DDI-MedLine.d16.s5|4-12|half-life|O
DDI-MedLine.d16.s5|14-15|of|O
DDI-MedLine.d16.s5|17-24|ketamine|drug
DDI-MedLine.d16.s5|26-27|in|O
DDI-MedLine.d16.s5|29-34|plasma|O
DDI-MedLine.d16.s5|36-38|and|O
DDI-MedLine.d16.s5|40-44|brain|O
DDI-MedLine.d16.s5|46-48|was|O
DDI-MedLine.d16.s5|50-55|longer|O
DDI-MedLine.d16.s5|57-58|in|O
DDI-MedLine.d16.s5|60-62|the|O
DDI-MedLine.d16.s5|64-71|presence|O
DDI-MedLine.d16.s5|73-74|of|O
DDI-MedLine.d16.s5|76-84|halothane|drug
DDI-MedLine.d16.s5|86-89|than|O
DDI-MedLine.d16.s5|91-94|when|O
DDI-MedLine.d16.s5|96-103|ketamine|drug
DDI-MedLine.d16.s5|105-107|was|O
DDI-MedLine.d16.s5|109-113|given|O
DDI-MedLine.d16.s5|115-119|alone|O
DDI-MedLine.d16.s5|120-120|.|O
DDI-MedLine.d16.s6|0-1|It|O
DDI-MedLine.d16.s6|3-4|is|O
DDI-MedLine.d16.s6|6-14|concluded|O
DDI-MedLine.d16.s6|16-19|that|O
DDI-MedLine.d16.s6|21-28|ketamine|drug
DDI-MedLine.d16.s6|30-31|is|O
DDI-MedLine.d16.s6|33-35|not|O
DDI-MedLine.d16.s6|37-37|a|O
DDI-MedLine.d16.s6|39-50|short-acting|O
DDI-MedLine.d16.s6|52-55|drug|O
DDI-MedLine.d16.s6|57-59|and|O
DDI-MedLine.d16.s6|61-64|that|O
DDI-MedLine.d16.s6|66-76|concomitant|O
DDI-MedLine.d16.s6|78-80|use|O
DDI-MedLine.d16.s6|82-85|with|O
DDI-MedLine.d16.s6|87-95|halothane|drug
DDI-MedLine.d16.s6|97-101|would|O
DDI-MedLine.d16.s6|103-104|be|O
DDI-MedLine.d16.s6|106-113|expected|O
DDI-MedLine.d16.s6|115-116|to|O
DDI-MedLine.d16.s6|118-124|prolong|O
DDI-MedLine.d16.s6|126-132|further|O
DDI-MedLine.d16.s6|134-136|the|O
DDI-MedLine.d16.s6|138-145|duration|O
DDI-MedLine.d16.s6|147-148|of|O
DDI-MedLine.d16.s6|150-152|its|O
DDI-MedLine.d16.s6|154-159|action|O
DDI-MedLine.d16.s6|161-162|on|O
DDI-MedLine.d16.s6|164-166|the|O
DDI-MedLine.d16.s6|168-174|central|O
DDI-MedLine.d16.s6|176-182|nervous|O
DDI-MedLine.d16.s6|184-189|system|O
DDI-MedLine.d16.s6|190-190|.|O
DDI-MedLine.d48.s0|0-11|Modification|O
DDI-MedLine.d48.s0|13-14|of|O
DDI-MedLine.d48.s0|16-22|surface|O
DDI-MedLine.d48.s0|24-32|histidine|O
DDI-MedLine.d48.s0|34-41|residues|O
DDI-MedLine.d48.s0|43-51|abolishes|O
DDI-MedLine.d48.s0|53-55|the|O
DDI-MedLine.d48.s0|57-65|cytotoxic|O
DDI-MedLine.d48.s0|67-74|activity|O
DDI-MedLine.d48.s0|76-77|of|O
DDI-MedLine.d48.s0|108-108|.|O
DDI-MedLine.d48.s1|30-37|displays|O
DDI-MedLine.d48.s1|39-42|both|O
DDI-MedLine.d48.s1|44-52|cytotoxic|O
DDI-MedLine.d48.s1|54-56|and|O
DDI-MedLine.d48.s1|58-68|enterotoxic|O
DDI-MedLine.d48.s1|70-79|activities|O
DDI-MedLine.d48.s1|80-80|.|O
DDI-MedLine.d48.s2|0-1|It|O
DDI-MedLine.d48.s2|3-5|has|O
DDI-MedLine.d48.s2|7-14|recently|O
DDI-MedLine.d48.s2|16-19|been|O
DDI-MedLine.d48.s2|21-32|demonstrated|O
DDI-MedLine.d48.s2|34-37|that|O
DDI-MedLine.d48.s2|47-52|exerts|O
DDI-MedLine.d48.s2|54-56|its|O
DDI-MedLine.d48.s2|58-66|cytotoxic|O
DDI-MedLine.d48.s2|68-73|effect|O
DDI-MedLine.d48.s2|75-76|by|O
DDI-MedLine.d48.s2|78-80|the|O
DDI-MedLine.d48.s2|82-94|glucosylation|O
DDI-MedLine.d48.s2|96-97|of|O
DDI-MedLine.d48.s2|99-101|the|O
DDI-MedLine.d48.s2|103-107|small|O
DDI-MedLine.d48.s2|109-119|GTP-binding|O
DDI-MedLine.d48.s2|121-128|proteins|O
DDI-MedLine.d48.s2|130-131|of|O
DDI-MedLine.d48.s2|133-135|the|O
DDI-MedLine.d48.s2|137-139|Rho|O
DDI-MedLine.d48.s2|141-146|family|O
DDI-MedLine.d48.s2|147-147|.|O
DDI-MedLine.d48.s3|21-21|,|O
DDI-MedLine.d48.s3|23-24|at|O
DDI-MedLine.d48.s3|26-27|pH|O
DDI-MedLine.d48.s3|29-31|7.0|O
DDI-MedLine.d48.s3|32-32|,|O
DDI-MedLine.d48.s3|34-36|was|O
DDI-MedLine.d48.s3|38-41|used|O
DDI-MedLine.d48.s3|43-44|to|O
DDI-MedLine.d48.s3|46-55|chemically|O
DDI-MedLine.d48.s3|57-62|modify|O
DDI-MedLine.d48.s3|64-70|exposed|O
DDI-MedLine.d48.s3|72-80|histidine|O
DDI-MedLine.d48.s3|82-89|residues|O
DDI-MedLine.d48.s3|91-92|on|O
DDI-MedLine.d48.s3|101-101|.|O
DDI-MedLine.d48.s4|0-11|Modification|O
DDI-MedLine.d48.s4|13-14|of|O
DDI-MedLine.d48.s4|24-27|with|O
DDI-MedLine.d48.s4|51-59|abolished|O
DDI-MedLine.d48.s4|61-64|both|O
DDI-MedLine.d48.s4|66-68|its|O
DDI-MedLine.d48.s4|70-78|cytotoxic|O
DDI-MedLine.d48.s4|80-87|activity|O
DDI-MedLine.d48.s4|89-91|and|O
DDI-MedLine.d48.s4|93-95|the|O
DDI-MedLine.d48.s4|97-103|ability|O
DDI-MedLine.d48.s4|105-106|of|O
DDI-MedLine.d48.s4|108-110|the|O
DDI-MedLine.d48.s4|112-116|toxin|O
DDI-MedLine.d48.s4|118-119|to|O
DDI-MedLine.d48.s4|121-124|bind|O
DDI-MedLine.d48.s4|126-137|Zn-Sepharose|O
DDI-MedLine.d48.s4|139-141|gel|O
DDI-MedLine.d48.s4|142-142|.|O
DDI-MedLine.d48.s5|0-8|Treatment|O
DDI-MedLine.d48.s5|10-11|of|O
DDI-MedLine.d48.s5|21-24|with|O
DDI-MedLine.d48.s5|26-26|[|O
DDI-MedLine.d48.s5|27-27|(|O
DDI-MedLine.d48.s5|28-29|14|O
DDI-MedLine.d48.s5|30-30|)|O
DDI-MedLine.d48.s5|31-31|C|O
DDI-MedLine.d48.s5|32-32|]|O
DDI-MedLine.d48.s5|33-40|-diethyl|O
DDI-MedLine.d48.s5|56-63|revealed|O
DDI-MedLine.d48.s5|65-77|concentration|O
DDI-MedLine.d48.s5|79-87|dependent|O
DDI-MedLine.d48.s5|89-97|labelling|O
DDI-MedLine.d48.s5|99-100|of|O
DDI-MedLine.d48.s5|102-110|histidine|O
DDI-MedLine.d48.s5|112-119|residues|O
DDI-MedLine.d48.s5|121-122|on|O
DDI-MedLine.d48.s5|124-126|the|O
DDI-MedLine.d48.s5|128-132|toxin|O
DDI-MedLine.d48.s5|134-142|molecules|O
DDI-MedLine.d48.s5|143-143|.|O
DDI-MedLine.d48.s6|0-2|The|O
DDI-MedLine.d48.s6|4-10|effects|O
DDI-MedLine.d48.s6|12-13|of|O
DDI-MedLine.d48.s6|37-41|could|O
DDI-MedLine.d48.s6|43-44|be|O
DDI-MedLine.d48.s6|46-53|reversed|O
DDI-MedLine.d48.s6|55-56|by|O
DDI-MedLine.d48.s6|72-80|treatment|O
DDI-MedLine.d48.s6|81-81|.|O
DDI-MedLine.d48.s7|0-4|These|O
DDI-MedLine.d48.s7|6-9|data|O
DDI-MedLine.d48.s7|11-17|suggest|O
DDI-MedLine.d48.s7|19-21|the|O
DDI-MedLine.d48.s7|23-30|modified|O
DDI-MedLine.d48.s7|32-40|histidine|O
DDI-MedLine.d48.s7|42-49|residues|O
DDI-MedLine.d48.s7|51-52|on|O
DDI-MedLine.d48.s7|62-64|are|O
DDI-MedLine.d48.s7|66-73|critical|O
DDI-MedLine.d48.s7|75-76|to|O
DDI-MedLine.d48.s7|78-80|its|O
DDI-MedLine.d48.s7|82-90|cytotoxic|O
DDI-MedLine.d48.s7|92-99|activity|O
DDI-MedLine.d48.s7|100-100|.|O
DDI-MedLine.d48.s8|0-8|Histidine|O
DDI-MedLine.d48.s8|10-21|modification|O
DDI-MedLine.d48.s8|23-25|had|O
DDI-MedLine.d48.s8|27-28|no|O
DDI-MedLine.d48.s8|30-35|effect|O
DDI-MedLine.d48.s8|37-38|on|O
DDI-MedLine.d48.s8|40-42|the|O
DDI-MedLine.d48.s8|44-51|glucosyl|O
DDI-MedLine.d48.s8|53-63|transferase|O
DDI-MedLine.d48.s8|65-70|enzyme|O
DDI-MedLine.d48.s8|72-79|activity|O
DDI-MedLine.d48.s8|81-82|of|O
DDI-MedLine.d48.s8|91-91|.|O
DDI-MedLine.d48.s9|0-6|However|O
DDI-MedLine.d48.s9|7-7|,|O
DDI-MedLine.d48.s9|9-20|modification|O
DDI-MedLine.d48.s9|22-30|abolished|O
DDI-MedLine.d48.s9|32-34|the|O
DDI-MedLine.d48.s9|36-40|'cold|O
DDI-MedLine.d48.s9|41-41|'|O
DDI-MedLine.d48.s9|43-49|binding|O
DDI-MedLine.d48.s9|51-52|of|O
DDI-MedLine.d48.s9|54-58|toxin|O
DDI-MedLine.d48.s9|60-61|to|O
DDI-MedLine.d48.s9|63-68|bovine|O
DDI-MedLine.d48.s9|70-82|thyroglobulin|O
DDI-MedLine.d48.s9|84-85|in|O
DDI-MedLine.d48.s9|87-88|an|O
DDI-MedLine.d48.s9|90-94|ELISA|O
DDI-MedLine.d48.s9|96-98|and|O
DDI-MedLine.d48.s9|100-106|reduced|O
DDI-MedLine.d48.s9|108-113|ligand|O
DDI-MedLine.d48.s9|115-121|binding|O
DDI-MedLine.d48.s9|123-130|activity|O
DDI-MedLine.d48.s9|132-133|in|O
DDI-MedLine.d48.s9|135-135|a|O
DDI-MedLine.d48.s9|137-142|rabbit|O
DDI-MedLine.d48.s9|144-154|erythrocyte|O
DDI-MedLine.d48.s9|156-172|haemagglutination|O
DDI-MedLine.d48.s9|174-178|assay|O
DDI-MedLine.d48.s9|179-179|.|O
DDI-MedLine.d48.s10|0-2|The|O
DDI-MedLine.d48.s10|4-7|data|O
DDI-MedLine.d48.s10|9-15|suggest|O
DDI-MedLine.d48.s10|17-20|that|O
DDI-MedLine.d48.s10|22-24|the|O
DDI-MedLine.d48.s10|26-34|histidine|O
DDI-MedLine.d48.s10|36-43|residues|O
DDI-MedLine.d48.s10|45-47|may|O
DDI-MedLine.d48.s10|49-50|be|O
DDI-MedLine.d48.s10|52-58|crucial|O
DDI-MedLine.d48.s10|60-61|to|O
DDI-MedLine.d48.s10|63-65|the|O
DDI-MedLine.d48.s10|67-82|receptor-binding|O
DDI-MedLine.d48.s10|84-91|activity|O
DDI-MedLine.d48.s10|93-94|of|O
DDI-MedLine.d48.s10|103-103|.|O
DDI-MedLine.d48.s11|0-6|Exposed|O
DDI-MedLine.d48.s11|8-17|histidines|O
DDI-MedLine.d48.s11|19-20|on|O
DDI-MedLine.d48.s11|30-32|are|O
DDI-MedLine.d48.s11|34-42|available|O
DDI-MedLine.d48.s11|44-46|for|O
DDI-MedLine.d48.s11|48-51|zinc|drug
DDI-MedLine.d48.s11|53-61|chelation|O
DDI-MedLine.d48.s11|62-62|,|O
DDI-MedLine.d48.s11|64-66|and|O
DDI-MedLine.d48.s11|68-72|these|O
DDI-MedLine.d48.s11|74-77|have|O
DDI-MedLine.d48.s11|79-82|been|O
DDI-MedLine.d48.s11|84-92|exploited|O
DDI-MedLine.d48.s11|94-95|in|O
DDI-MedLine.d48.s11|97-99|the|O
DDI-MedLine.d48.s11|101-111|development|O
DDI-MedLine.d48.s11|113-114|of|O
DDI-MedLine.d48.s11|116-116|a|O
DDI-MedLine.d48.s11|118-122|novel|O
DDI-MedLine.d48.s11|124-135|purification|O
DDI-MedLine.d48.s11|137-144|protocol|O
DDI-MedLine.d48.s11|146-148|for|O
DDI-MedLine.d48.s11|158-162|using|O
DDI-MedLine.d48.s11|164-177|zinc-chelating|drug
DDI-MedLine.d48.s11|179-192|chromatography|O
DDI-MedLine.d48.s11|193-193|.|O
DDI-MedLine.d114.s0|0-9|Inhibitory|O
DDI-MedLine.d114.s0|11-17|effects|O
DDI-MedLine.d114.s0|19-20|of|O
DDI-MedLine.d114.s0|36-37|on|O
DDI-MedLine.d114.s0|39-46|inositol|O
DDI-MedLine.d114.s0|48-50|1,4|O
DDI-MedLine.d114.s0|51-51|,|O
DDI-MedLine.d114.s0|53-75|5-trisphosphate-induced|O
DDI-MedLine.d114.s0|77-85|responses|O
DDI-MedLine.d114.s0|87-88|in|O
DDI-MedLine.d114.s0|90-92|rat|O
DDI-MedLine.d114.s0|94-107|megakaryocytes|O
DDI-MedLine.d114.s0|108-108|.|O
DDI-MedLine.d114.s1|0-2|The|O
DDI-MedLine.d114.s1|4-10|effects|O
DDI-MedLine.d114.s1|12-13|of|O
DDI-MedLine.d114.s1|29-29|(|O
DDI-MedLine.d114.s1|32-32|)|O
DDI-MedLine.d114.s1|34-35|on|O
DDI-MedLine.d114.s1|66-66|(|O
DDI-MedLine.d114.s1|74-74|)|O
DDI-MedLine.d114.s1|75-82|-induced|O
DDI-MedLine.d114.s1|84-92|responses|O
DDI-MedLine.d114.s1|94-97|were|O
DDI-MedLine.d114.s1|99-105|studied|O
DDI-MedLine.d114.s1|107-108|in|O
DDI-MedLine.d114.s1|110-112|rat|O
DDI-MedLine.d114.s1|114-117|bone|O
DDI-MedLine.d114.s1|119-124|marrow|O
DDI-MedLine.d114.s1|126-139|megakaryocytes|O
DDI-MedLine.d114.s1|141-144|with|O
DDI-MedLine.d114.s1|146-148|the|O
DDI-MedLine.d114.s1|150-160|patch-clamp|O
DDI-MedLine.d114.s1|162-171|whole-cell|O
DDI-MedLine.d114.s1|173-181|recording|O
DDI-MedLine.d114.s1|183-191|technique|O
DDI-MedLine.d114.s1|193-194|in|O
DDI-MedLine.d114.s1|196-206|combination|O
DDI-MedLine.d114.s1|208-211|with|O
DDI-MedLine.d114.s1|213-218|fura-2|O
DDI-MedLine.d114.s1|220-235|microfluorometry|O
DDI-MedLine.d114.s1|236-236|.|O
DDI-MedLine.d114.s2|0-7|Internal|O
DDI-MedLine.d114.s2|9-19|application|O
DDI-MedLine.d114.s2|21-22|of|O
DDI-MedLine.d114.s2|32-32|(|O
DDI-MedLine.d114.s2|33-35|100|O
DDI-MedLine.d114.s2|37-42|microM|O
DDI-MedLine.d114.s2|43-43|)|O
DDI-MedLine.d114.s2|45-53|increased|O
DDI-MedLine.d114.s2|55-67|intracellular|O
DDI-MedLine.d114.s2|69-70|Ca|O
DDI-MedLine.d114.s2|71-71|(|O
DDI-MedLine.d114.s2|72-73|2+|O
DDI-MedLine.d114.s2|74-74|)|O
DDI-MedLine.d114.s2|76-88|concentration|O
DDI-MedLine.d114.s2|90-90|(|O
DDI-MedLine.d114.s2|91-91|[|O
DDI-MedLine.d114.s2|92-93|Ca|O
DDI-MedLine.d114.s2|94-94|(|O
DDI-MedLine.d114.s2|95-96|2+|O
DDI-MedLine.d114.s2|97-97|)|O
DDI-MedLine.d114.s2|98-98|]|O
DDI-MedLine.d114.s2|99-99|(|O
DDI-MedLine.d114.s2|100-100|i|O
DDI-MedLine.d114.s2|101-101|)|O
DDI-MedLine.d114.s2|102-102|)|O
DDI-MedLine.d114.s2|104-106|and|O
DDI-MedLine.d114.s2|108-116|activated|O
DDI-MedLine.d114.s2|118-120|the|O
DDI-MedLine.d114.s2|122-123|Ca|O
DDI-MedLine.d114.s2|124-124|(|O
DDI-MedLine.d114.s2|125-126|2+|O
DDI-MedLine.d114.s2|127-127|)|O
DDI-MedLine.d114.s2|128-137|-dependent|O
DDI-MedLine.d114.s2|139-139|K|O
DDI-MedLine.d114.s2|140-140|(|O
DDI-MedLine.d114.s2|141-141|+|O
DDI-MedLine.d114.s2|142-142|)|O
DDI-MedLine.d114.s2|144-150|current|O
DDI-MedLine.d114.s2|151-151|.|O
DDI-MedLine.d114.s3|0-12|Administering|O
DDI-MedLine.d114.s3|22-29|together|O
DDI-MedLine.d114.s3|31-34|with|O
DDI-MedLine.d114.s3|39-39|(|O
DDI-MedLine.d114.s3|40-46|100-500|O
DDI-MedLine.d114.s3|48-53|microM|O
DDI-MedLine.d114.s3|54-54|)|O
DDI-MedLine.d114.s3|56-64|inhibited|O
DDI-MedLine.d114.s3|66-69|InsP|O
DDI-MedLine.d114.s3|70-70|(|O
DDI-MedLine.d114.s3|71-71|3|O
DDI-MedLine.d114.s3|72-72|)|O
DDI-MedLine.d114.s3|73-80|-induced|O
DDI-MedLine.d114.s3|82-90|responses|O
DDI-MedLine.d114.s3|92-92|(|O
DDI-MedLine.d114.s3|93-96|both|O
DDI-MedLine.d114.s3|98-99|Ca|O
DDI-MedLine.d114.s3|100-100|(|O
DDI-MedLine.d114.s3|101-102|2+|O
DDI-MedLine.d114.s3|103-103|)|O
DDI-MedLine.d114.s3|105-107|and|O
DDI-MedLine.d114.s3|109-115|current|O
DDI-MedLine.d114.s3|117-125|responses|O
DDI-MedLine.d114.s3|126-126|)|O
DDI-MedLine.d114.s3|128-129|in|O
DDI-MedLine.d114.s3|131-131|a|O
DDI-MedLine.d114.s3|133-146|dose-dependent|O
DDI-MedLine.d114.s3|148-154|fashion|O
DDI-MedLine.d114.s3|155-155|.|O
DDI-MedLine.d114.s4|0-11|Pretreatment|O
DDI-MedLine.d114.s4|13-14|of|O
DDI-MedLine.d114.s4|16-29|megakaryocytes|O
DDI-MedLine.d114.s4|31-34|with|O
DDI-MedLine.d114.s4|36-48|extracellular|O
DDI-MedLine.d114.s4|53-53|(|O
DDI-MedLine.d114.s4|54-55|50|O
DDI-MedLine.d114.s4|57-62|microM|O
DDI-MedLine.d114.s4|63-63|)|O
DDI-MedLine.d114.s4|65-68|also|O
DDI-MedLine.d114.s4|70-78|inhibited|O
DDI-MedLine.d114.s4|87-94|-induced|O
DDI-MedLine.d114.s4|96-104|responses|O
DDI-MedLine.d114.s4|105-105|.|O
DDI-MedLine.d114.s5|0-12|Intracellular|O
DDI-MedLine.d114.s5|14-16|and|O
DDI-MedLine.d114.s5|18-30|extracellular|O
DDI-MedLine.d114.s5|32-42|application|O
DDI-MedLine.d114.s5|44-45|of|O
DDI-MedLine.d114.s5|50-56|reduced|O
DDI-MedLine.d114.s5|58-68|ADP-induced|O
DDI-MedLine.d114.s5|70-78|increases|O
DDI-MedLine.d114.s5|80-81|in|O
DDI-MedLine.d114.s5|83-83|[|O
DDI-MedLine.d114.s5|84-85|Ca|O
DDI-MedLine.d114.s5|86-86|(|O
DDI-MedLine.d114.s5|87-88|2+|O
DDI-MedLine.d114.s5|89-89|)|O
DDI-MedLine.d114.s5|90-90|]|O
DDI-MedLine.d114.s5|91-91|(|O
DDI-MedLine.d114.s5|92-92|i|O
DDI-MedLine.d114.s5|93-93|)|O
DDI-MedLine.d114.s5|94-94|.|O
DDI-MedLine.d114.s6|0-1|In|O
DDI-MedLine.d114.s6|3-10|contrast|O
DDI-MedLine.d114.s6|11-11|,|O
DDI-MedLine.d114.s6|13-14|in|O
DDI-MedLine.d114.s6|16-23|isolated|O
DDI-MedLine.d114.s6|25-30|single|O
DDI-MedLine.d114.s6|32-41|pancreatic|O
DDI-MedLine.d114.s6|43-48|acinar|O
DDI-MedLine.d114.s6|50-54|cells|O
DDI-MedLine.d114.s6|55-55|,|O
DDI-MedLine.d114.s6|60-62|had|O
DDI-MedLine.d114.s6|64-65|no|O
DDI-MedLine.d114.s6|67-72|effect|O
DDI-MedLine.d114.s6|74-75|on|O
DDI-MedLine.d114.s6|84-91|-induced|O
DDI-MedLine.d114.s6|93-101|responses|O
DDI-MedLine.d114.s6|102-102|.|O
DDI-MedLine.d114.s7|0-4|Taken|O
DDI-MedLine.d114.s7|6-13|together|O
DDI-MedLine.d114.s7|14-14|,|O
DDI-MedLine.d114.s7|16-20|these|O
DDI-MedLine.d114.s7|22-28|results|O
DDI-MedLine.d114.s7|30-36|suggest|O
DDI-MedLine.d114.s7|38-41|that|O
DDI-MedLine.d114.s7|43-45|the|O
DDI-MedLine.d114.s7|47-50|site|O
DDI-MedLine.d114.s7|52-53|of|O
DDI-MedLine.d114.s7|55-57|the|O
DDI-MedLine.d114.s7|59-68|inhibitory|O
DDI-MedLine.d114.s7|70-75|action|O
DDI-MedLine.d114.s7|77-78|of|O
DDI-MedLine.d114.s7|83-84|is|O
DDI-MedLine.d114.s7|86-87|at|O
DDI-MedLine.d114.s7|89-91|the|O
DDI-MedLine.d114.s7|93-96|InsP|O
DDI-MedLine.d114.s7|97-97|(|O
DDI-MedLine.d114.s7|98-98|3|O
DDI-MedLine.d114.s7|99-99|)|O
DDI-MedLine.d114.s7|101-108|receptor|O
DDI-MedLine.d114.s7|109-109|,|O
DDI-MedLine.d114.s7|111-112|or|O
DDI-MedLine.d114.s7|114-116|its|O
DDI-MedLine.d114.s7|118-124|closely|O
DDI-MedLine.d114.s7|126-135|associated|O
DDI-MedLine.d114.s7|137-144|proteins|O
DDI-MedLine.d114.s7|145-145|.|O
DDI-MedLine.d114.s8|0-1|In|O
DDI-MedLine.d114.s8|3-10|addition|O
DDI-MedLine.d114.s8|11-11|,|O
DDI-MedLine.d114.s8|13-14|we|O
DDI-MedLine.d114.s8|16-19|have|O
DDI-MedLine.d114.s8|21-25|shown|O
DDI-MedLine.d114.s8|27-30|that|O
DDI-MedLine.d114.s8|35-36|is|O
DDI-MedLine.d114.s8|38-38|a|O
DDI-MedLine.d114.s8|40-45|useful|O
DDI-MedLine.d114.s8|47-61|pharmacological|O
DDI-MedLine.d114.s8|63-66|tool|O
DDI-MedLine.d114.s8|68-71|with|O
DDI-MedLine.d114.s8|73-77|which|O
DDI-MedLine.d114.s8|79-80|to|O
DDI-MedLine.d114.s8|82-88|examine|O
DDI-MedLine.d114.s8|90-92|the|O
DDI-MedLine.d114.s8|101-109|-mediated|O
DDI-MedLine.d114.s8|111-119|responses|O
DDI-MedLine.d114.s8|121-122|of|O
DDI-MedLine.d114.s8|124-137|megakaryocytes|O
DDI-MedLine.d114.s8|138-138|.|O
DDI-MedLine.d89.s0|0-10|Therapeutic|O
DDI-MedLine.d89.s0|12-15|drug|O
DDI-MedLine.d89.s0|17-26|monitoring|O
DDI-MedLine.d89.s0|28-30|can|O
DDI-MedLine.d89.s0|32-36|avoid|O
DDI-MedLine.d89.s0|38-47|iatrogenic|O
DDI-MedLine.d89.s0|49-59|alterations|O
DDI-MedLine.d89.s0|61-66|caused|O
DDI-MedLine.d89.s0|68-69|by|O
DDI-MedLine.d89.s0|71-99|99mTc-methylene diphosphonate|drug
DDI-MedLine.d89.s0|101-101|(|O
DDI-MedLine.d89.s0|102-104|MDP|O
DDI-MedLine.d89.s0|105-105|)|O
DDI-MedLine.d89.s0|106-116|-gentamicin|drug
DDI-MedLine.d89.s0|118-128|interaction|O
DDI-MedLine.d89.s0|129-129|.|O
DDI-MedLine.d89.s1|0-9|Gentamicin|drug
DDI-MedLine.d89.s1|11-12|is|O
DDI-MedLine.d89.s1|14-15|an|O
DDI-MedLine.d89.s1|17-41|aminoglycoside antibiotic|group
DDI-MedLine.d89.s1|43-46|used|O
DDI-MedLine.d89.s1|48-49|to|O
DDI-MedLine.d89.s1|51-55|treat|O
DDI-MedLine.d89.s1|57-57|a|O
DDI-MedLine.d89.s1|59-62|wide|O
DDI-MedLine.d89.s1|64-70|variety|O
DDI-MedLine.d89.s1|72-73|of|O
DDI-MedLine.d89.s1|75-84|infections|O
DDI-MedLine.d89.s1|86-91|caused|O
DDI-MedLine.d89.s1|93-94|by|O
DDI-MedLine.d89.s1|96-108|gram-negative|O
DDI-MedLine.d89.s1|110-118|organisms|O
DDI-MedLine.d89.s1|119-119|,|O
DDI-MedLine.d89.s1|121-123|but|O
DDI-MedLine.d89.s1|125-126|it|O
DDI-MedLine.d89.s1|128-129|is|O
DDI-MedLine.d89.s1|131-141|potentially|O
DDI-MedLine.d89.s1|143-147|toxic|O
DDI-MedLine.d89.s1|149-150|to|O
DDI-MedLine.d89.s1|152-154|the|O
DDI-MedLine.d89.s1|156-162|kidneys|O
DDI-MedLine.d89.s1|163-163|.|O
DDI-MedLine.d89.s2|0-2|Due|O
DDI-MedLine.d89.s2|4-5|to|O
DDI-MedLine.d89.s2|7-9|its|O
DDI-MedLine.d89.s2|11-24|nephrotoxicity|O
DDI-MedLine.d89.s2|25-25|,|O
DDI-MedLine.d89.s2|27-36|gentamicin|drug
DDI-MedLine.d89.s2|38-40|may|O
DDI-MedLine.d89.s2|42-46|cause|O
DDI-MedLine.d89.s2|48-55|abnormal|O
DDI-MedLine.d89.s2|57-61|renal|O
DDI-MedLine.d89.s2|63-68|uptake|O
DDI-MedLine.d89.s2|70-71|to|O
DDI-MedLine.d89.s2|73-74|be|O
DDI-MedLine.d89.s2|76-79|seen|O
DDI-MedLine.d89.s2|81-82|on|O
DDI-MedLine.d89.s2|84-92|99mTc-MDP|drug
DDI-MedLine.d89.s2|94-97|bone|O
DDI-MedLine.d89.s2|99-110|scintigraphy|O
DDI-MedLine.d89.s2|111-111|.|O
DDI-MedLine.d89.s3|0-2|The|O
DDI-MedLine.d89.s3|4-11|presence|O
DDI-MedLine.d89.s3|13-14|of|O
DDI-MedLine.d89.s3|16-18|the|O
DDI-MedLine.d89.s3|20-38|radiopharmaceutical|group
DDI-MedLine.d89.s3|40-41|in|O
DDI-MedLine.d89.s3|43-45|the|O
DDI-MedLine.d89.s3|47-53|kidneys|O
DDI-MedLine.d89.s3|54-54|,|O
DDI-MedLine.d89.s3|56-60|along|O
DDI-MedLine.d89.s3|62-65|with|O
DDI-MedLine.d89.s3|67-68|an|O
DDI-MedLine.d89.s3|70-77|increase|O
DDI-MedLine.d89.s3|79-80|in|O
DDI-MedLine.d89.s3|82-86|renal|O
DDI-MedLine.d89.s3|88-96|retention|O
DDI-MedLine.d89.s3|97-97|,|O
DDI-MedLine.d89.s3|99-102|tend|O
DDI-MedLine.d89.s3|104-105|to|O
DDI-MedLine.d89.s3|107-113|produce|O
DDI-MedLine.d89.s3|115-127|scintigraphic|O
DDI-MedLine.d89.s3|129-135|results|O
DDI-MedLine.d89.s3|137-140|that|O
DDI-MedLine.d89.s3|142-148|falsely|O
DDI-MedLine.d89.s3|150-157|identify|O
DDI-MedLine.d89.s3|159-173|characteristics|O
DDI-MedLine.d89.s3|175-181|related|O
DDI-MedLine.d89.s3|183-184|to|O
DDI-MedLine.d89.s3|186-193|diseases|O
DDI-MedLine.d89.s3|195-198|such|O
DDI-MedLine.d89.s3|200-201|as|O
DDI-MedLine.d89.s3|203-207|renal|O
DDI-MedLine.d89.s3|209-216|vascular|O
DDI-MedLine.d89.s3|217-217|,|O
DDI-MedLine.d89.s3|219-220|or|O
DDI-MedLine.d89.s3|222-228|urinary|O
DDI-MedLine.d89.s3|230-234|tract|O
DDI-MedLine.d89.s3|236-246|obstruction|O
DDI-MedLine.d89.s3|247-247|,|O
DDI-MedLine.d89.s3|249-251|and|O
DDI-MedLine.d89.s3|253-256|even|O
DDI-MedLine.d89.s3|258-262|renal|O
DDI-MedLine.d89.s3|264-269|cancer|O
DDI-MedLine.d89.s3|270-270|.|O
DDI-MedLine.d89.s4|0-1|An|O
DDI-MedLine.d89.s4|3-9|altered|O
DDI-MedLine.d89.s4|11-25|biodistribution|O
DDI-MedLine.d89.s4|27-29|may|O
DDI-MedLine.d89.s4|31-37|provide|O
DDI-MedLine.d89.s4|39-48|misleading|O
DDI-MedLine.d89.s4|50-60|information|O
DDI-MedLine.d89.s4|62-65|that|O
DDI-MedLine.d89.s4|67-69|can|O
DDI-MedLine.d89.s4|71-76|either|O
DDI-MedLine.d89.s4|78-81|mask|O
DDI-MedLine.d89.s4|83-84|or|O
DDI-MedLine.d89.s4|86-90|mimic|O
DDI-MedLine.d89.s4|92-98|certain|O
DDI-MedLine.d89.s4|100-106|disease|O
DDI-MedLine.d89.s4|108-115|symptoms|O
DDI-MedLine.d89.s4|116-116|.|O
DDI-MedLine.d89.s5|0-0|A|O
DDI-MedLine.d89.s5|2-7|method|O
DDI-MedLine.d89.s5|9-10|to|O
DDI-MedLine.d89.s5|12-19|maximize|O
DDI-MedLine.d89.s5|21-23|the|O
DDI-MedLine.d89.s5|25-35|therapeutic|O
DDI-MedLine.d89.s5|37-43|benefit|O
DDI-MedLine.d89.s5|45-46|of|O
DDI-MedLine.d89.s5|48-57|gentamicin|drug
DDI-MedLine.d89.s5|59-63|while|O
DDI-MedLine.d89.s5|65-74|minimizing|O
DDI-MedLine.d89.s5|76-78|the|O
DDI-MedLine.d89.s5|80-83|risk|O
DDI-MedLine.d89.s5|85-86|of|O
DDI-MedLine.d89.s5|88-101|nephrotoxicity|O
DDI-MedLine.d89.s5|103-105|and|O
DDI-MedLine.d89.s5|107-109|the|O
DDI-MedLine.d89.s5|111-120|appearance|O
DDI-MedLine.d89.s5|122-123|of|O
DDI-MedLine.d89.s5|125-125|a|O
DDI-MedLine.d89.s5|127-129|hot|O
DDI-MedLine.d89.s5|131-136|kidney|O
DDI-MedLine.d89.s5|138-139|on|O
DDI-MedLine.d89.s5|141-152|scintigraphy|O
DDI-MedLine.d89.s5|154-155|is|O
DDI-MedLine.d89.s5|157-165|desirable|O
DDI-MedLine.d89.s5|166-166|.|O
DDI-MedLine.d89.s6|0-5|Serial|O
DDI-MedLine.d89.s6|7-21|pharmacokinetic|O
DDI-MedLine.d89.s6|23-28|dosing|O
DDI-MedLine.d89.s6|30-32|has|O
DDI-MedLine.d89.s6|34-37|been|O
DDI-MedLine.d89.s6|39-46|proposed|O
DDI-MedLine.d89.s6|48-49|as|O
DDI-MedLine.d89.s6|51-51|a|O
DDI-MedLine.d89.s6|53-58|method|O
DDI-MedLine.d89.s6|60-61|to|O
DDI-MedLine.d89.s6|63-72|accomplish|O
DDI-MedLine.d89.s6|74-77|this|O
DDI-MedLine.d89.s6|79-82|goal|O
DDI-MedLine.d89.s6|83-83|.|O
DDI-MedLine.d89.s7|0-10|Therapeutic|O
DDI-MedLine.d89.s7|12-15|drug|O
DDI-MedLine.d89.s7|17-26|monitoring|O
DDI-MedLine.d89.s7|28-28|(|O
DDI-MedLine.d89.s7|29-31|TDM|O
DDI-MedLine.d89.s7|32-32|)|O
DDI-MedLine.d89.s7|34-35|of|O
DDI-MedLine.d89.s7|37-46|gentamicin|drug
DDI-MedLine.d89.s7|48-54|therapy|O
DDI-MedLine.d89.s7|55-55|,|O
DDI-MedLine.d89.s7|57-59|and|O
DDI-MedLine.d89.s7|61-64|bone|O
DDI-MedLine.d89.s7|66-77|scintigraphy|O
DDI-MedLine.d89.s7|79-87|employing|O
DDI-MedLine.d89.s7|89-97|99mTc-MDP|drug
DDI-MedLine.d89.s7|99-100|as|O
DDI-MedLine.d89.s7|102-104|the|O
DDI-MedLine.d89.s7|106-124|radiopharmaceutical|group
DDI-MedLine.d89.s7|126-128|was|O
DDI-MedLine.d89.s7|130-136|carried|O
DDI-MedLine.d89.s7|138-140|out|O
DDI-MedLine.d89.s7|142-143|in|O
DDI-MedLine.d89.s7|145-146|22|O
DDI-MedLine.d89.s7|148-155|patients|O
DDI-MedLine.d89.s7|156-156|.|O
DDI-MedLine.d89.s8|0-2|The|O
DDI-MedLine.d89.s8|4-7|data|O
DDI-MedLine.d89.s8|9-17|presented|O
DDI-MedLine.d89.s8|19-22|here|O
DDI-MedLine.d89.s8|24-34|demonstrate|O
DDI-MedLine.d89.s8|36-39|that|O
DDI-MedLine.d89.s8|41-44|with|O
DDI-MedLine.d89.s8|46-51|serial|O
DDI-MedLine.d89.s8|53-67|pharmacokinetic|O
DDI-MedLine.d89.s8|69-74|dosing|O
DDI-MedLine.d89.s8|76-77|of|O
DDI-MedLine.d89.s8|79-88|gentamicin|drug
DDI-MedLine.d89.s8|89-89|,|O
DDI-MedLine.d89.s8|91-93|the|O
DDI-MedLine.d89.s8|95-104|iatrogenic|O
DDI-MedLine.d89.s8|106-115|alteration|O
DDI-MedLine.d89.s8|117-122|caused|O
DDI-MedLine.d89.s8|124-125|by|O
DDI-MedLine.d89.s8|127-136|gentamicin|drug
DDI-MedLine.d89.s8|138-144|therapy|O
DDI-MedLine.d89.s8|146-148|can|O
DDI-MedLine.d89.s8|150-151|be|O
DDI-MedLine.d89.s8|153-159|avoided|O
DDI-MedLine.d89.s8|160-160|.|O
DDI-DrugBank.d64.s0|0-7|Addition|O
DDI-DrugBank.d64.s0|9-10|or|O
DDI-DrugBank.d64.s0|12-19|deletion|O
DDI-DrugBank.d64.s0|21-22|of|O
DDI-DrugBank.d64.s0|24-26|any|O
DDI-DrugBank.d64.s0|28-31|drug|O
DDI-DrugBank.d64.s0|33-36|from|O
DDI-DrugBank.d64.s0|38-40|the|O
DDI-DrugBank.d64.s0|42-52|therapeutic|O
DDI-DrugBank.d64.s0|54-60|regimen|O
DDI-DrugBank.d64.s0|62-63|of|O
DDI-DrugBank.d64.s0|65-72|patients|O
DDI-DrugBank.d64.s0|74-82|receiving|O
DDI-DrugBank.d64.s0|84-87|oral|O
DDI-DrugBank.d64.s0|89-102|anticoagulants|group
DDI-DrugBank.d64.s0|104-106|may|O
DDI-DrugBank.d64.s0|108-113|affect|O
DDI-DrugBank.d64.s0|115-121|patient|O
DDI-DrugBank.d64.s0|123-130|response|O
DDI-DrugBank.d64.s0|132-133|to|O
DDI-DrugBank.d64.s0|135-137|the|O
DDI-DrugBank.d64.s0|139-151|anticoagulant|group
DDI-DrugBank.d64.s0|152-152|.|O
DDI-DrugBank.d64.s1|0-7|Frequent|O
DDI-DrugBank.d64.s1|9-21|determination|O
DDI-DrugBank.d64.s1|23-24|of|O
DDI-DrugBank.d64.s1|26-36|prothrombin|O
DDI-DrugBank.d64.s1|38-41|time|O
DDI-DrugBank.d64.s1|43-45|and|O
DDI-DrugBank.d64.s1|47-51|close|O
DDI-DrugBank.d64.s1|53-62|monitoring|O
DDI-DrugBank.d64.s1|64-65|of|O
DDI-DrugBank.d64.s1|67-69|the|O
DDI-DrugBank.d64.s1|71-77|patient|O
DDI-DrugBank.d64.s1|79-80|is|O
DDI-DrugBank.d64.s1|82-90|essential|O
DDI-DrugBank.d64.s1|92-93|to|O
DDI-DrugBank.d64.s1|95-103|ascertain|O
DDI-DrugBank.d64.s1|105-108|when|O
DDI-DrugBank.d64.s1|110-119|adjustment|O
DDI-DrugBank.d64.s1|121-122|of|O
DDI-DrugBank.d64.s1|124-129|dosage|O
DDI-DrugBank.d64.s1|131-132|of|O
DDI-DrugBank.d64.s1|134-146|anticoagulant|group
DDI-DrugBank.d64.s1|148-150|may|O
DDI-DrugBank.d64.s1|152-153|be|O
DDI-DrugBank.d64.s1|155-160|needed|O
DDI-DrugBank.d64.s1|161-161|.|O
DDI-DrugBank.d64.s2|0-6|Because|O
DDI-DrugBank.d64.s2|8-9|of|O
DDI-DrugBank.d64.s2|11-13|the|O
DDI-DrugBank.d64.s2|15-25|variability|O
DDI-DrugBank.d64.s2|27-28|of|O
DDI-DrugBank.d64.s2|30-39|individual|O
DDI-DrugBank.d64.s2|41-47|patient|O
DDI-DrugBank.d64.s2|49-56|response|O
DDI-DrugBank.d64.s2|57-57|,|O
DDI-DrugBank.d64.s2|59-66|multiple|O
DDI-DrugBank.d64.s2|68-78|interacting|O
DDI-DrugBank.d64.s2|80-89|mechanisms|O
DDI-DrugBank.d64.s2|91-94|with|O
DDI-DrugBank.d64.s2|96-99|some|O
DDI-DrugBank.d64.s2|101-105|drugs|O
DDI-DrugBank.d64.s2|106-106|,|O
DDI-DrugBank.d64.s2|108-110|the|O
DDI-DrugBank.d64.s2|112-121|dependency|O
DDI-DrugBank.d64.s2|123-124|of|O
DDI-DrugBank.d64.s2|126-128|the|O
DDI-DrugBank.d64.s2|130-135|extent|O
DDI-DrugBank.d64.s2|137-138|of|O
DDI-DrugBank.d64.s2|140-142|the|O
DDI-DrugBank.d64.s2|144-154|interaction|O
DDI-DrugBank.d64.s2|156-157|on|O
DDI-DrugBank.d64.s2|159-161|the|O
DDI-DrugBank.d64.s2|163-168|dosage|O
DDI-DrugBank.d64.s2|170-172|and|O
DDI-DrugBank.d64.s2|174-181|duration|O
DDI-DrugBank.d64.s2|183-184|of|O
DDI-DrugBank.d64.s2|186-192|therapy|O
DDI-DrugBank.d64.s2|193-193|,|O
DDI-DrugBank.d64.s2|195-197|and|O
DDI-DrugBank.d64.s2|199-201|the|O
DDI-DrugBank.d64.s2|203-210|possible|O
DDI-DrugBank.d64.s2|212-225|administration|O
DDI-DrugBank.d64.s2|227-228|of|O
DDI-DrugBank.d64.s2|230-236|several|O
DDI-DrugBank.d64.s2|238-248|interacting|O
DDI-DrugBank.d64.s2|250-254|drugs|O
DDI-DrugBank.d64.s2|256-269|simultaneously|O
DDI-DrugBank.d64.s2|270-270|,|O
DDI-DrugBank.d64.s2|272-273|it|O
DDI-DrugBank.d64.s2|275-276|is|O
DDI-DrugBank.d64.s2|278-286|difficult|O
DDI-DrugBank.d64.s2|288-289|to|O
DDI-DrugBank.d64.s2|291-297|predict|O
DDI-DrugBank.d64.s2|299-301|the|O
DDI-DrugBank.d64.s2|303-311|direction|O
DDI-DrugBank.d64.s2|313-315|and|O
DDI-DrugBank.d64.s2|317-322|degree|O
DDI-DrugBank.d64.s2|324-325|of|O
DDI-DrugBank.d64.s2|327-329|the|O
DDI-DrugBank.d64.s2|331-338|ultimate|O
DDI-DrugBank.d64.s2|340-345|effect|O
DDI-DrugBank.d64.s2|347-348|of|O
DDI-DrugBank.d64.s2|350-360|concomitant|O
DDI-DrugBank.d64.s2|362-372|medications|O
DDI-DrugBank.d64.s2|374-375|on|O
DDI-DrugBank.d64.s2|377-389|anticoagulant|group
DDI-DrugBank.d64.s2|391-398|response|O
DDI-DrugBank.d64.s2|399-399|.|O
DDI-DrugBank.d64.s3|0-2|For|O
DDI-DrugBank.d64.s3|4-10|example|O
DDI-DrugBank.d64.s3|11-11|,|O
DDI-DrugBank.d64.s3|13-17|since|O
DDI-DrugBank.d64.s3|19-32|cholestyramine|drug
DDI-DrugBank.d64.s3|34-36|may|O
DDI-DrugBank.d64.s3|38-43|reduce|O
DDI-DrugBank.d64.s3|45-47|the|O
DDI-DrugBank.d64.s3|49-64|gastrointestinal|O
DDI-DrugBank.d64.s3|66-75|absorption|O
DDI-DrugBank.d64.s3|77-78|of|O
DDI-DrugBank.d64.s3|80-83|both|O
DDI-DrugBank.d64.s3|85-87|the|O
DDI-DrugBank.d64.s3|89-92|oral|O
DDI-DrugBank.d64.s3|94-107|anticoagulants|group
DDI-DrugBank.d64.s3|109-111|and|O
DDI-DrugBank.d64.s3|113-121|vitamin K|group
DDI-DrugBank.d64.s3|122-122|,|O
DDI-DrugBank.d64.s3|124-126|the|O
DDI-DrugBank.d64.s3|128-130|net|O
DDI-DrugBank.d64.s3|132-138|effects|O
DDI-DrugBank.d64.s3|140-142|are|O
DDI-DrugBank.d64.s3|144-156|unpredictable|O
DDI-DrugBank.d64.s3|157-157|.|O
DDI-DrugBank.d64.s4|0-14|Chloral hydrate|drug
DDI-DrugBank.d64.s4|16-18|may|O
DDI-DrugBank.d64.s4|20-24|cause|O
DDI-DrugBank.d64.s4|26-27|an|O
DDI-DrugBank.d64.s4|29-37|increased|O
DDI-DrugBank.d64.s4|39-49|prothrombin|O
DDI-DrugBank.d64.s4|51-58|response|O
DDI-DrugBank.d64.s4|60-61|by|O
DDI-DrugBank.d64.s4|63-72|displacing|O
DDI-DrugBank.d64.s4|74-76|the|O
DDI-DrugBank.d64.s4|78-90|anticoagulant|group
DDI-DrugBank.d64.s4|92-95|from|O
DDI-DrugBank.d64.s4|97-103|protein|O
DDI-DrugBank.d64.s4|105-111|binding|O
DDI-DrugBank.d64.s4|113-117|sites|O
DDI-DrugBank.d64.s4|119-120|or|O
DDI-DrugBank.d64.s4|122-122|a|O
DDI-DrugBank.d64.s4|124-133|diminished|O
DDI-DrugBank.d64.s4|135-145|prothrombin|O
DDI-DrugBank.d64.s4|147-154|response|O
DDI-DrugBank.d64.s4|156-162|through|O
DDI-DrugBank.d64.s4|164-172|increased|O
DDI-DrugBank.d64.s4|174-183|metabolism|O
DDI-DrugBank.d64.s4|185-186|of|O
DDI-DrugBank.d64.s4|188-190|the|O
DDI-DrugBank.d64.s4|192-198|unbound|O
DDI-DrugBank.d64.s4|200-203|drug|O
DDI-DrugBank.d64.s4|205-206|by|O
DDI-DrugBank.d64.s4|208-214|hepatic|O
DDI-DrugBank.d64.s4|216-221|enzyme|O
DDI-DrugBank.d64.s4|223-231|induction|O
DDI-DrugBank.d64.s4|232-232|,|O
DDI-DrugBank.d64.s4|234-237|thus|O
DDI-DrugBank.d64.s4|239-245|leading|O
DDI-DrugBank.d64.s4|247-248|to|O
DDI-DrugBank.d64.s4|250-262|inter-patient|O
DDI-DrugBank.d64.s4|264-272|variation|O
DDI-DrugBank.d64.s4|274-275|in|O
DDI-DrugBank.d64.s4|277-284|ultimate|O
DDI-DrugBank.d64.s4|286-296|prothrombin|O
DDI-DrugBank.d64.s4|298-303|effect|O
DDI-DrugBank.d64.s4|304-304|.|O
DDI-DrugBank.d64.s5|0-1|An|O
DDI-DrugBank.d64.s5|3-13|interacting|O
DDI-DrugBank.d64.s5|15-18|drug|O
DDI-DrugBank.d64.s5|20-24|which|O
DDI-DrugBank.d64.s5|26-30|leads|O
DDI-DrugBank.d64.s5|32-33|to|O
DDI-DrugBank.d64.s5|35-35|a|O
DDI-DrugBank.d64.s5|37-44|decrease|O
DDI-DrugBank.d64.s5|46-47|in|O
DDI-DrugBank.d64.s5|49-59|prothrombin|O
DDI-DrugBank.d64.s5|61-64|time|O
DDI-DrugBank.d64.s5|66-78|necessitating|O
DDI-DrugBank.d64.s5|80-81|an|O
DDI-DrugBank.d64.s5|83-91|increased|O
DDI-DrugBank.d64.s5|93-96|dose|O
DDI-DrugBank.d64.s5|98-99|of|O
DDI-DrugBank.d64.s5|101-104|oral|O
DDI-DrugBank.d64.s5|106-118|anticoagulant|group
DDI-DrugBank.d64.s5|120-121|to|O
DDI-DrugBank.d64.s5|123-130|maintain|O
DDI-DrugBank.d64.s5|132-133|an|O
DDI-DrugBank.d64.s5|135-142|adequate|O
DDI-DrugBank.d64.s5|144-149|degree|O
DDI-DrugBank.d64.s5|151-152|of|O
DDI-DrugBank.d64.s5|154-168|anticoagulation|O
DDI-DrugBank.d64.s5|170-172|may|O
DDI-DrugBank.d64.s5|173-173|,|O
DDI-DrugBank.d64.s5|175-176|if|O
DDI-DrugBank.d64.s5|178-185|abruptly|O
DDI-DrugBank.d64.s5|187-198|discontinued|O
DDI-DrugBank.d64.s5|199-199|,|O
DDI-DrugBank.d64.s5|201-208|increase|O
DDI-DrugBank.d64.s5|210-212|the|O
DDI-DrugBank.d64.s5|214-217|risk|O
DDI-DrugBank.d64.s5|219-220|of|O
DDI-DrugBank.d64.s5|222-231|subsequent|O
DDI-DrugBank.d64.s5|233-240|bleeding|O
DDI-DrugBank.d64.s5|241-241|.|O
DDI-DrugBank.d64.s6|0-4|Drugs|O
DDI-DrugBank.d64.s6|6-9|that|O
DDI-DrugBank.d64.s6|11-14|have|O
DDI-DrugBank.d64.s6|16-19|been|O
DDI-DrugBank.d64.s6|21-28|reported|O
DDI-DrugBank.d64.s6|30-31|to|O
DDI-DrugBank.d64.s6|33-40|diminish|O
DDI-DrugBank.d64.s6|42-45|oral|O
DDI-DrugBank.d64.s6|47-59|anticoagulant|group
DDI-DrugBank.d64.s6|61-68|response|O
DDI-DrugBank.d64.s6|69-69|,|O
DDI-DrugBank.d64.s6|71-72|ie|O
DDI-DrugBank.d64.s6|73-73|,|O
DDI-DrugBank.d64.s6|75-83|decreased|O
DDI-DrugBank.d64.s6|85-96|prothrom-bin|O
DDI-DrugBank.d64.s6|98-101|time|O
DDI-DrugBank.d64.s6|103-110|response|O
DDI-DrugBank.d64.s6|111-111|,|O
DDI-DrugBank.d64.s6|113-114|in|O
DDI-DrugBank.d64.s6|116-118|man|O
DDI-DrugBank.d64.s6|120-132|significantly|O
DDI-DrugBank.d64.s6|134-140|include|O
DDI-DrugBank.d64.s6|141-141|:|O
DDI-DrugBank.d64.s6|143-165|adrenocortical steroids|group
DDI-DrugBank.d64.s6|166-166|;|O
DDI-DrugBank.d64.s7|0-7|alcohol*|drug
DDI-DrugBank.d64.s7|8-8|;|O
DDI-DrugBank.d64.s8|0-7|antacids|group
DDI-DrugBank.d64.s8|8-8|;|O
DDI-DrugBank.d64.s9|0-13|antihistamines|group
DDI-DrugBank.d64.s9|14-14|;|O
DDI-DrugBank.d64.s10|0-11|barbiturates|group
DDI-DrugBank.d64.s10|12-12|;|O
DDI-DrugBank.d64.s11|0-12|carbamazepine|drug
DDI-DrugBank.d64.s11|13-13|;|O
DDI-DrugBank.d64.s12|0-6|chloral|drug
DDI-DrugBank.d64.s12|8-15|hydrate*|O
DDI-DrugBank.d64.s12|16-16|;|O
DDI-DrugBank.d64.s13|0-15|chlordiazepoxide|drug
DDI-DrugBank.d64.s13|16-16|;|O
DDI-DrugBank.d64.s14|0-13|cholestyramine|drug
DDI-DrugBank.d64.s14|14-14|;|O
DDI-DrugBank.d64.s15|0-3|diet|O
DDI-DrugBank.d64.s15|5-8|high|O
DDI-DrugBank.d64.s15|10-11|in|O
DDI-DrugBank.d64.s15|13-21|vitamin K|group
DDI-DrugBank.d64.s15|22-22|;|O
DDI-DrugBank.d64.s16|0-9|diuretics*|group
DDI-DrugBank.d64.s16|10-10|;|O
DDI-DrugBank.d64.s17|0-12|ethchlorvynol|drug
DDI-DrugBank.d64.s17|13-13|;|O
DDI-DrugBank.d64.s18|0-11|glutethimide|drug
DDI-DrugBank.d64.s18|12-12|;|O
DDI-DrugBank.d64.s19|0-11|griseofulvin|drug
DDI-DrugBank.d64.s19|12-12|;|O
DDI-DrugBank.d64.s20|0-10|haloperidol|drug
DDI-DrugBank.d64.s20|11-11|;|O
DDI-DrugBank.d64.s21|0-10|meprobamate|drug
DDI-DrugBank.d64.s21|11-11|;|O
DDI-DrugBank.d64.s22|0-3|oral|O
DDI-DrugBank.d64.s22|5-18|contraceptives|group
DDI-DrugBank.d64.s22|19-19|;|O
DDI-DrugBank.d64.s23|0-10|paraldehyde|drug
DDI-DrugBank.d64.s23|11-11|;|O
DDI-DrugBank.d64.s24|0-8|primidone|drug
DDI-DrugBank.d64.s24|9-9|;|O
DDI-DrugBank.d64.s25|0-10|ranitidine*|drug
DDI-DrugBank.d64.s25|11-11|;|O
DDI-DrugBank.d64.s26|0-7|rifampin|drug
DDI-DrugBank.d64.s26|8-8|;|O
DDI-DrugBank.d64.s27|0-9|unreliable|O
DDI-DrugBank.d64.s27|11-21|prothrombin|O
DDI-DrugBank.d64.s27|23-26|time|O
DDI-DrugBank.d64.s27|28-41|determinations|O
DDI-DrugBank.d64.s27|42-42|;|O
DDI-DrugBank.d64.s28|0-8|vitamin C|drug
DDI-DrugBank.d64.s28|9-9|;|O
DDI-DrugBank.d64.s29|0-4|Drugs|O
DDI-DrugBank.d64.s29|6-9|that|O
DDI-DrugBank.d64.s29|11-14|have|O
DDI-DrugBank.d64.s29|16-19|been|O
DDI-DrugBank.d64.s29|21-28|reported|O
DDI-DrugBank.d64.s29|30-31|to|O
DDI-DrugBank.d64.s29|33-40|diminish|O
DDI-DrugBank.d64.s29|42-45|oral|O
DDI-DrugBank.d64.s29|47-59|anticoagulant|group
DDI-DrugBank.d64.s29|61-68|response|O
DDI-DrugBank.d64.s29|69-69|,|O
DDI-DrugBank.d64.s29|71-72|ie|O
DDI-DrugBank.d64.s29|73-73|,|O
DDI-DrugBank.d64.s29|75-83|decreased|O
DDI-DrugBank.d64.s29|85-96|prothrom-bin|O
DDI-DrugBank.d64.s29|98-101|time|O
DDI-DrugBank.d64.s29|103-110|response|O
DDI-DrugBank.d64.s29|111-111|,|O
DDI-DrugBank.d64.s29|113-114|in|O
DDI-DrugBank.d64.s29|116-118|man|O
DDI-DrugBank.d64.s29|120-132|significantly|O
DDI-DrugBank.d64.s29|134-140|include|O
DDI-DrugBank.d64.s29|141-141|:|O
DDI-DrugBank.d64.s29|143-165|adrenocortical steroids|group
DDI-DrugBank.d64.s29|166-166|;|O
DDI-DrugBank.d64.s29|167-174|alcohol*|drug
DDI-DrugBank.d64.s29|175-175|;|O
DDI-DrugBank.d64.s29|176-183|antacids|group
DDI-DrugBank.d64.s29|184-184|;|O
DDI-DrugBank.d64.s29|185-198|antihistamines|group
DDI-DrugBank.d64.s29|199-199|;|O
DDI-DrugBank.d64.s29|200-211|barbiturates|group
DDI-DrugBank.d64.s29|212-212|;|O
DDI-DrugBank.d64.s29|213-225|carbamazepine|drug
DDI-DrugBank.d64.s29|226-226|;|O
DDI-DrugBank.d64.s29|227-233|chloral|drug
DDI-DrugBank.d64.s29|235-242|hydrate*|O
DDI-DrugBank.d64.s29|243-243|;|O
DDI-DrugBank.d64.s29|244-259|chlordiazepoxide|drug
DDI-DrugBank.d64.s29|260-260|;|O
DDI-DrugBank.d64.s29|261-274|cholestyramine|drug
DDI-DrugBank.d64.s29|275-275|;|O
DDI-DrugBank.d64.s29|276-279|diet|O
DDI-DrugBank.d64.s29|281-284|high|O
DDI-DrugBank.d64.s29|286-287|in|O
DDI-DrugBank.d64.s29|289-297|vitamin K|group
DDI-DrugBank.d64.s29|298-298|;|O
DDI-DrugBank.d64.s29|299-308|diuretics*|group
DDI-DrugBank.d64.s29|309-309|;|O
DDI-DrugBank.d64.s29|310-322|ethchlorvynol|drug
DDI-DrugBank.d64.s29|323-323|;|O
DDI-DrugBank.d64.s29|324-335|glutethimide|drug
DDI-DrugBank.d64.s29|336-336|;|O
DDI-DrugBank.d64.s29|337-348|griseofulvin|drug
DDI-DrugBank.d64.s29|349-349|;|O
DDI-DrugBank.d64.s29|350-360|haloperidol|drug
DDI-DrugBank.d64.s29|361-361|;|O
DDI-DrugBank.d64.s29|362-372|meprobamate|drug
DDI-DrugBank.d64.s29|373-373|;|O
DDI-DrugBank.d64.s29|374-377|oral|O
DDI-DrugBank.d64.s29|379-392|contraceptives|group
DDI-DrugBank.d64.s29|393-393|;|O
DDI-DrugBank.d64.s29|394-404|paraldehyde|drug
DDI-DrugBank.d64.s29|405-405|;|O
DDI-DrugBank.d64.s29|406-414|primidone|drug
DDI-DrugBank.d64.s29|415-415|;|O
DDI-DrugBank.d64.s29|416-426|ranitidine*|drug
DDI-DrugBank.d64.s29|427-427|;|O
DDI-DrugBank.d64.s29|428-435|rifampin|drug
DDI-DrugBank.d64.s29|436-436|;|O
DDI-DrugBank.d64.s29|437-446|unreliable|O
DDI-DrugBank.d64.s29|448-458|prothrombin|O
DDI-DrugBank.d64.s29|460-463|time|O
DDI-DrugBank.d64.s29|465-478|determinations|O
DDI-DrugBank.d64.s29|479-479|;|O
DDI-DrugBank.d64.s29|480-488|vitamin C|drug
DDI-DrugBank.d64.s29|489-489|;|O
DDI-DrugBank.d64.s29|490-504|warfarin sodium|drug
DDI-DrugBank.d64.s29|506-517|under-dosage|O
DDI-DrugBank.d64.s29|518-518|.|O
DDI-DrugBank.d64.s30|0-4|Drugs|O
DDI-DrugBank.d64.s30|6-9|that|O
DDI-DrugBank.d64.s30|11-20|reportedly|O
DDI-DrugBank.d64.s30|22-24|may|O
DDI-DrugBank.d64.s30|26-33|increase|O
DDI-DrugBank.d64.s30|35-38|oral|O
DDI-DrugBank.d64.s30|40-52|anticoagulant|group
DDI-DrugBank.d64.s30|54-61|response|O
DDI-DrugBank.d64.s30|62-62|,|O
DDI-DrugBank.d64.s30|64-65|ie|O
DDI-DrugBank.d64.s30|66-66|,|O
DDI-DrugBank.d64.s30|68-76|increased|O
DDI-DrugBank.d64.s30|78-88|prothrombin|O
DDI-DrugBank.d64.s30|90-97|response|O
DDI-DrugBank.d64.s30|98-98|,|O
DDI-DrugBank.d64.s30|100-101|in|O
DDI-DrugBank.d64.s30|103-105|man|O
DDI-DrugBank.d64.s30|107-113|include|O
DDI-DrugBank.d64.s30|114-114|:|O
DDI-DrugBank.d64.s30|115-122|alcohol*|drug
DDI-DrugBank.d64.s30|123-123|;|O
DDI-DrugBank.d64.s31|0-10|allopurinol|drug
DDI-DrugBank.d64.s31|11-11|;|O
DDI-DrugBank.d64.s32|0-18|aminosalicylic acid|drug
DDI-DrugBank.d64.s32|19-19|;|O
DDI-DrugBank.d64.s33|0-9|amiodarone|drug
DDI-DrugBank.d64.s33|10-10|;|O
DDI-DrugBank.d64.s34|0-16|anabolic steroids|group
DDI-DrugBank.d64.s34|17-17|;|O
DDI-DrugBank.d64.s35|0-10|antibiotics|group
DDI-DrugBank.d64.s35|11-11|;|O
DDI-DrugBank.d64.s36|0-9|bromelains|drug
DDI-DrugBank.d64.s36|10-10|;|O
DDI-DrugBank.d64.s37|0-6|chloral|drug
DDI-DrugBank.d64.s37|8-15|hydrate*|O
DDI-DrugBank.d64.s37|16-16|;|O
DDI-DrugBank.d64.s38|0-13|chlorpropamide|drug
DDI-DrugBank.d64.s38|14-14|;|O
DDI-DrugBank.d64.s39|0-11|chymotrypsin|drug
DDI-DrugBank.d64.s39|12-12|;|O
DDI-DrugBank.d64.s40|0-9|cimetidine|drug
DDI-DrugBank.d64.s40|10-10|;|O
DDI-DrugBank.d64.s41|0-9|cinchophen|drug
DDI-DrugBank.d64.s41|10-10|;|O
DDI-DrugBank.d64.s42|0-9|clofibrate|drug
DDI-DrugBank.d64.s42|10-10|;|O
DDI-DrugBank.d64.s43|0-6|dextran|drug
DDI-DrugBank.d64.s43|7-7|;|O
DDI-DrugBank.d64.s44|0-14|dextrothyroxine|drug
DDI-DrugBank.d64.s44|15-15|;|O
DDI-DrugBank.d64.s45|0-8|diazoxide|drug
DDI-DrugBank.d64.s45|9-9|;|O
DDI-DrugBank.d64.s46|0-6|dietary|O
DDI-DrugBank.d64.s46|8-19|deficiencies|O
DDI-DrugBank.d64.s46|20-20|;|O
DDI-DrugBank.d64.s47|0-9|diflunisal|drug
DDI-DrugBank.d64.s47|10-10|;|O
DDI-DrugBank.d64.s48|0-9|diuretics*|group
DDI-DrugBank.d64.s48|10-10|;|O
DDI-DrugBank.d64.s49|0-9|disulfiram|drug
DDI-DrugBank.d64.s49|10-10|;|O
DDI-DrugBank.d64.s50|0-4|drugs|O
DDI-DrugBank.d64.s50|6-14|affecting|O
DDI-DrugBank.d64.s50|16-20|blood|O
DDI-DrugBank.d64.s50|22-29|elements|O
DDI-DrugBank.d64.s50|30-30|;|O
DDI-DrugBank.d64.s51|0-14|ethacrynic acid|drug
DDI-DrugBank.d64.s51|15-15|;|O
DDI-DrugBank.d64.s52|0-9|fenoprofen|drug
DDI-DrugBank.d64.s52|10-10|;|O
DDI-DrugBank.d64.s53|0-7|glucagon|drug
DDI-DrugBank.d64.s53|8-8|;|O
DDI-DrugBank.d64.s54|0-10|hepatotoxic|O
DDI-DrugBank.d64.s54|12-16|drugs|O
DDI-DrugBank.d64.s54|17-17|;|O
DDI-DrugBank.d64.s55|0-8|ibuprofen|drug
DDI-DrugBank.d64.s55|9-9|;|O
DDI-DrugBank.d64.s56|0-11|indomethacin|drug
DDI-DrugBank.d64.s56|12-12|;|O
DDI-DrugBank.d64.s57|0-22|influenza virus vaccine|group
DDI-DrugBank.d64.s57|23-23|;|O
DDI-DrugBank.d64.s58|0-9|inhalation|O
DDI-DrugBank.d64.s58|11-21|anesthetics|group
DDI-DrugBank.d64.s58|22-22|;|O
DDI-DrugBank.d64.s59|0-13|mefenamic acid|drug
DDI-DrugBank.d64.s59|14-14|;|O
DDI-DrugBank.d64.s60|0-9|methyldopa|drug
DDI-DrugBank.d64.s60|10-10|;|O
DDI-DrugBank.d64.s61|0-14|methylphenidate|drug
DDI-DrugBank.d64.s61|15-15|;|O
DDI-DrugBank.d64.s62|0-12|metronidazole|drug
DDI-DrugBank.d64.s62|13-13|;|O
DDI-DrugBank.d64.s63|0-9|miconazole|drug
DDI-DrugBank.d64.s63|10-10|;|O
DDI-DrugBank.d64.s64|0-27|monoamine oxidase inhibitors|group
DDI-DrugBank.d64.s64|28-28|;|O
DDI-DrugBank.d64.s65|0-13|nalidixic acid|drug
DDI-DrugBank.d64.s65|14-14|;|O
DDI-DrugBank.d64.s66|0-7|naproxen|drug
DDI-DrugBank.d64.s66|8-8|;|O
DDI-DrugBank.d64.s67|0-12|oxolinic acid|drug
DDI-DrugBank.d64.s67|13-13|;|O
DDI-DrugBank.d64.s68|0-14|oxyphenbutazone|drug
DDI-DrugBank.d64.s68|15-15|;|O
DDI-DrugBank.d64.s69|0-13|pentoxifylline|drug
DDI-DrugBank.d64.s69|14-14|;|O
DDI-DrugBank.d64.s70|0-13|phenylbutazone|drug
DDI-DrugBank.d64.s70|14-14|;|O
DDI-DrugBank.d64.s71|12-12|;|O
DDI-DrugBank.d64.s72|0-8|phenytoin|drug
DDI-DrugBank.d64.s72|9-9|;|O
DDI-DrugBank.d64.s73|0-8|prolonged|O
DDI-DrugBank.d64.s73|10-12|hot|O
DDI-DrugBank.d64.s73|14-20|weather|O
DDI-DrugBank.d64.s73|21-21|;|O
DDI-DrugBank.d64.s74|0-18|prolonged narcotics|group
DDI-DrugBank.d64.s74|19-19|;|O
DDI-DrugBank.d64.s75|0-10|pyrazolones|group
DDI-DrugBank.d64.s75|11-11|;|O
DDI-DrugBank.d64.s76|0-8|quinidine|drug
DDI-DrugBank.d64.s76|9-9|;|O
DDI-DrugBank.d64.s77|0-6|quinine|drug
DDI-DrugBank.d64.s77|7-7|;|O
DDI-DrugBank.d64.s78|0-10|ranitidine*|drug
DDI-DrugBank.d64.s78|11-11|;|O
DDI-DrugBank.d64.s79|0-10|salicylates|group
DDI-DrugBank.d64.s79|11-11|;|O
DDI-DrugBank.d64.s79|12-25|sulfinpyrazone|drug
DDI-DrugBank.d64.s79|26-26|;|O
DDI-DrugBank.d64.s80|0-11|sulfonamides|group
DDI-DrugBank.d64.s80|12-12|,|O
DDI-DrugBank.d64.s80|14-17|long|O
DDI-DrugBank.d64.s80|19-24|acting|O
DDI-DrugBank.d64.s80|25-25|;|O
DDI-DrugBank.d64.s81|0-7|sulindac|drug
DDI-DrugBank.d64.s81|8-8|;|O
DDI-DrugBank.d64.s82|0-12|thyroid drugs|group
DDI-DrugBank.d64.s82|13-13|;|O
DDI-DrugBank.d64.s83|0-10|tolbutamide|drug
DDI-DrugBank.d64.s83|11-11|;|O
DDI-DrugBank.d64.s84|0-15|triclofos sodium|drug
DDI-DrugBank.d64.s84|16-16|;|O
DDI-DrugBank.d64.s85|0-28|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d64.s85|29-29|;|O
DDI-DrugBank.d64.s86|0-9|unreliable|O
DDI-DrugBank.d64.s86|11-21|prothrombin|O
DDI-DrugBank.d64.s86|23-26|time|O
DDI-DrugBank.d64.s86|28-41|determinations|O
DDI-DrugBank.d64.s86|42-42|;|O
DDI-DrugBank.d64.s87|0-4|Drugs|O
DDI-DrugBank.d64.s87|6-9|that|O
DDI-DrugBank.d64.s87|11-20|reportedly|O
DDI-DrugBank.d64.s87|22-24|may|O
DDI-DrugBank.d64.s87|26-33|increase|O
DDI-DrugBank.d64.s87|35-38|oral|O
DDI-DrugBank.d64.s87|40-52|anticoagulant|group
DDI-DrugBank.d64.s87|54-61|response|O
DDI-DrugBank.d64.s87|62-62|,|O
DDI-DrugBank.d64.s87|64-65|ie|O
DDI-DrugBank.d64.s87|66-66|,|O
DDI-DrugBank.d64.s87|68-76|increased|O
DDI-DrugBank.d64.s87|78-88|prothrombin|O
DDI-DrugBank.d64.s87|90-97|response|O
DDI-DrugBank.d64.s87|98-98|,|O
DDI-DrugBank.d64.s87|100-101|in|O
DDI-DrugBank.d64.s87|103-105|man|O
DDI-DrugBank.d64.s87|107-113|include|O
DDI-DrugBank.d64.s87|114-114|:|O
DDI-DrugBank.d64.s87|115-122|alcohol*|drug
DDI-DrugBank.d64.s87|123-123|;|O
DDI-DrugBank.d64.s87|124-134|allopurinol|drug
DDI-DrugBank.d64.s87|135-135|;|O
DDI-DrugBank.d64.s87|136-154|aminosalicylic acid|drug
DDI-DrugBank.d64.s87|155-155|;|O
DDI-DrugBank.d64.s87|156-165|amiodarone|drug
DDI-DrugBank.d64.s87|166-166|;|O
DDI-DrugBank.d64.s87|167-183|anabolic steroids|group
DDI-DrugBank.d64.s87|184-184|;|O
DDI-DrugBank.d64.s87|185-195|antibiotics|group
DDI-DrugBank.d64.s87|196-196|;|O
DDI-DrugBank.d64.s87|197-206|bromelains|drug
DDI-DrugBank.d64.s87|207-207|;|O
DDI-DrugBank.d64.s87|208-214|chloral|drug
DDI-DrugBank.d64.s87|216-223|hydrate*|O
DDI-DrugBank.d64.s87|224-224|;|O
DDI-DrugBank.d64.s87|225-238|chlorpropamide|drug
DDI-DrugBank.d64.s87|239-239|;|O
DDI-DrugBank.d64.s87|240-251|chymotrypsin|drug
DDI-DrugBank.d64.s87|252-252|;|O
DDI-DrugBank.d64.s87|253-262|cimetidine|drug
DDI-DrugBank.d64.s87|263-263|;|O
DDI-DrugBank.d64.s87|264-273|cinchophen|drug
DDI-DrugBank.d64.s87|274-274|;|O
DDI-DrugBank.d64.s87|275-284|clofibrate|drug
DDI-DrugBank.d64.s87|285-285|;|O
DDI-DrugBank.d64.s87|286-292|dextran|drug
DDI-DrugBank.d64.s87|293-293|;|O
DDI-DrugBank.d64.s87|294-308|dextrothyroxine|drug
DDI-DrugBank.d64.s87|309-309|;|O
DDI-DrugBank.d64.s87|310-318|diazoxide|drug
DDI-DrugBank.d64.s87|319-319|;|O
DDI-DrugBank.d64.s87|320-326|dietary|O
DDI-DrugBank.d64.s87|328-339|deficiencies|O
DDI-DrugBank.d64.s87|340-340|;|O
DDI-DrugBank.d64.s87|341-350|diflunisal|drug
DDI-DrugBank.d64.s87|351-351|;|O
DDI-DrugBank.d64.s87|352-361|disulfiram|drug
DDI-DrugBank.d64.s87|362-362|;|O
DDI-DrugBank.d64.s87|363-367|drugs|O
DDI-DrugBank.d64.s87|369-377|affecting|O
DDI-DrugBank.d64.s87|379-383|blood|O
DDI-DrugBank.d64.s87|385-392|elements|O
DDI-DrugBank.d64.s87|393-393|;|O
DDI-DrugBank.d64.s87|394-408|ethacrynic acid|drug
DDI-DrugBank.d64.s87|409-409|;|O
DDI-DrugBank.d64.s87|410-419|fenoprofen|drug
DDI-DrugBank.d64.s87|420-420|;|O
DDI-DrugBank.d64.s87|421-428|glucagon|drug
DDI-DrugBank.d64.s87|429-429|;|O
DDI-DrugBank.d64.s87|430-440|hepatotoxic|O
DDI-DrugBank.d64.s87|442-446|drugs|O
DDI-DrugBank.d64.s87|447-447|;|O
DDI-DrugBank.d64.s87|448-456|ibuprofen|drug
DDI-DrugBank.d64.s87|457-457|;|O
DDI-DrugBank.d64.s87|458-469|indomethacin|drug
DDI-DrugBank.d64.s87|470-470|;|O
DDI-DrugBank.d64.s87|471-493|influenza virus vaccine|group
DDI-DrugBank.d64.s87|494-494|;|O
DDI-DrugBank.d64.s87|495-504|inhalation|O
DDI-DrugBank.d64.s87|506-516|anesthetics|group
DDI-DrugBank.d64.s87|517-517|;|O
DDI-DrugBank.d64.s87|518-531|mefenamic acid|drug
DDI-DrugBank.d64.s87|532-532|;|O
DDI-DrugBank.d64.s87|533-542|methyldopa|drug
DDI-DrugBank.d64.s87|543-543|;|O
DDI-DrugBank.d64.s87|544-558|methylphenidate|drug
DDI-DrugBank.d64.s87|559-559|;|O
DDI-DrugBank.d64.s87|560-572|metronidazole|drug
DDI-DrugBank.d64.s87|573-573|;|O
DDI-DrugBank.d64.s87|574-583|miconazole|drug
DDI-DrugBank.d64.s87|584-584|;|O
DDI-DrugBank.d64.s87|585-612|monoamine oxidase inhibitors|group
DDI-DrugBank.d64.s87|613-613|;|O
DDI-DrugBank.d64.s87|614-627|nalidixic acid|drug
DDI-DrugBank.d64.s87|628-628|;|O
DDI-DrugBank.d64.s87|629-636|naproxen|drug
DDI-DrugBank.d64.s87|637-637|;|O
DDI-DrugBank.d64.s87|638-650|oxolinic acid|drug
DDI-DrugBank.d64.s87|651-651|;|O
DDI-DrugBank.d64.s87|652-666|oxyphenbutazone|drug
DDI-DrugBank.d64.s87|667-667|;|O
DDI-DrugBank.d64.s87|668-681|pentoxifylline|drug
DDI-DrugBank.d64.s87|682-682|;|O
DDI-DrugBank.d64.s87|683-696|phenylbutazone|drug
DDI-DrugBank.d64.s87|697-697|;|O
DDI-DrugBank.d64.s87|710-710|;|O
DDI-DrugBank.d64.s87|711-719|phenytoin|drug
DDI-DrugBank.d64.s87|720-720|;|O
DDI-DrugBank.d64.s87|721-729|prolonged|O
DDI-DrugBank.d64.s87|731-733|hot|O
DDI-DrugBank.d64.s87|735-741|weather|O
DDI-DrugBank.d64.s87|742-742|;|O
DDI-DrugBank.d64.s87|743-761|prolonged narcotics|group
DDI-DrugBank.d64.s87|762-762|;|O
DDI-DrugBank.d64.s87|763-773|pyrazolones|group
DDI-DrugBank.d64.s87|774-774|;|O
DDI-DrugBank.d64.s87|775-783|quinidine|drug
DDI-DrugBank.d64.s87|784-784|;|O
DDI-DrugBank.d64.s87|785-791|quinine|drug
DDI-DrugBank.d64.s87|792-792|;|O
DDI-DrugBank.d64.s87|793-803|ranitidine*|drug
DDI-DrugBank.d64.s87|804-804|;|O
DDI-DrugBank.d64.s87|805-815|salicylates|group
DDI-DrugBank.d64.s87|816-816|;|O
DDI-DrugBank.d64.s87|817-830|sulfinpyrazone|drug
DDI-DrugBank.d64.s87|831-831|;|O
DDI-DrugBank.d64.s87|832-843|sulfonamides|group
DDI-DrugBank.d64.s87|844-844|,|O
DDI-DrugBank.d64.s87|846-849|long|O
DDI-DrugBank.d64.s87|851-856|acting|O
DDI-DrugBank.d64.s87|857-857|;|O
DDI-DrugBank.d64.s87|858-865|sulindac|drug
DDI-DrugBank.d64.s87|866-866|;|O
DDI-DrugBank.d64.s87|867-879|thyroid drugs|group
DDI-DrugBank.d64.s87|880-880|;|O
DDI-DrugBank.d64.s87|881-891|tolbutamide|drug
DDI-DrugBank.d64.s87|892-892|;|O
DDI-DrugBank.d64.s87|893-908|triclofos sodium|drug
DDI-DrugBank.d64.s87|909-909|;|O
DDI-DrugBank.d64.s87|910-938|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d64.s87|939-939|;|O
DDI-DrugBank.d64.s87|940-949|unreliable|O
DDI-DrugBank.d64.s87|951-961|prothrombin|O
DDI-DrugBank.d64.s87|963-966|time|O
DDI-DrugBank.d64.s87|968-981|determinations|O
DDI-DrugBank.d64.s87|982-982|;|O
DDI-DrugBank.d64.s87|983-997|warfarin sodium|drug
DDI-DrugBank.d64.s87|999-1008|overdosage|O
DDI-DrugBank.d64.s87|1009-1009|.|O
DDI-DrugBank.d64.s88|0-3|Oral|O
DDI-DrugBank.d64.s88|5-18|anticoagulants|group
DDI-DrugBank.d64.s88|20-22|may|O
DDI-DrugBank.d64.s88|24-33|potentiate|O
DDI-DrugBank.d64.s88|35-37|the|O
DDI-DrugBank.d64.s88|39-50|hypoglycemic|O
DDI-DrugBank.d64.s88|52-57|action|O
DDI-DrugBank.d64.s88|59-60|of|O
DDI-DrugBank.d64.s88|62-80|hypoglycemic agents|group
DDI-DrugBank.d64.s88|81-81|,|O
DDI-DrugBank.d64.s88|83-84|eg|O
DDI-DrugBank.d64.s88|85-85|,|O
DDI-DrugBank.d64.s88|87-97|tolbutamide|drug
DDI-DrugBank.d64.s88|99-101|and|O
DDI-DrugBank.d64.s88|103-116|chlorpropamide|drug
DDI-DrugBank.d64.s88|117-117|,|O
DDI-DrugBank.d64.s88|119-120|by|O
DDI-DrugBank.d64.s88|122-131|inhibiting|O
DDI-DrugBank.d64.s88|133-137|their|O
DDI-DrugBank.d64.s88|139-148|metabolism|O
DDI-DrugBank.d64.s88|150-151|in|O
DDI-DrugBank.d64.s88|153-155|the|O
DDI-DrugBank.d64.s88|157-161|liver|O
DDI-DrugBank.d64.s88|162-162|.|O
DDI-DrugBank.d64.s89|0-6|Because|O
DDI-DrugBank.d64.s89|8-11|oral|O
DDI-DrugBank.d64.s89|13-26|anticoagulants|group
DDI-DrugBank.d64.s89|28-30|may|O
DDI-DrugBank.d64.s89|32-40|interfere|O
DDI-DrugBank.d64.s89|42-45|with|O
DDI-DrugBank.d64.s89|47-49|the|O
DDI-DrugBank.d64.s89|51-57|hepatic|O
DDI-DrugBank.d64.s89|59-68|metabolism|O
DDI-DrugBank.d64.s89|70-71|of|O
DDI-DrugBank.d64.s89|73-81|phenytoin|drug
DDI-DrugBank.d64.s89|82-82|,|O
DDI-DrugBank.d64.s89|84-88|toxic|O
DDI-DrugBank.d64.s89|90-95|levels|O
DDI-DrugBank.d64.s89|97-98|of|O
DDI-DrugBank.d64.s89|100-102|the|O
DDI-DrugBank.d64.s89|104-117|anticonvulsant|group
DDI-DrugBank.d64.s89|119-121|may|O
DDI-DrugBank.d64.s89|123-127|occur|O
DDI-DrugBank.d64.s89|129-132|when|O
DDI-DrugBank.d64.s89|134-135|an|O
DDI-DrugBank.d64.s89|137-140|oral|O
DDI-DrugBank.d64.s89|142-154|anticoagulant|group
DDI-DrugBank.d64.s89|156-158|and|O
DDI-DrugBank.d64.s89|160-168|phenytoin|drug
DDI-DrugBank.d64.s89|170-172|are|O
DDI-DrugBank.d64.s89|174-185|administered|O
DDI-DrugBank.d64.s89|187-198|concurrently|O
DDI-DrugBank.d64.s89|199-199|.|O
DDI-DrugBank.d64.s90|0-4|Drugs|O
DDI-DrugBank.d64.s90|6-9|that|O
DDI-DrugBank.d64.s90|11-16|reduce|O
DDI-DrugBank.d64.s90|18-20|the|O
DDI-DrugBank.d64.s90|22-27|number|O
DDI-DrugBank.d64.s90|29-30|of|O
DDI-DrugBank.d64.s90|32-36|blood|O
DDI-DrugBank.d64.s90|38-46|platelets|O
DDI-DrugBank.d64.s90|48-49|by|O
DDI-DrugBank.d64.s90|51-57|causing|O
DDI-DrugBank.d64.s90|59-62|bone|O
DDI-DrugBank.d64.s90|64-69|marrow|O
DDI-DrugBank.d64.s90|71-80|depression|O
DDI-DrugBank.d64.s90|82-82|(|O
DDI-DrugBank.d64.s90|83-86|such|O
DDI-DrugBank.d64.s90|88-89|as|O
DDI-DrugBank.d64.s90|91-111|antineoplastic agents|group
DDI-DrugBank.d64.s90|112-112|)|O
DDI-DrugBank.d64.s90|114-115|or|O
DDI-DrugBank.d64.s90|117-121|drugs|O
DDI-DrugBank.d64.s90|123-127|which|O
DDI-DrugBank.d64.s90|129-135|inhibit|O
DDI-DrugBank.d64.s90|137-144|platelet|O
DDI-DrugBank.d64.s90|146-153|function|O
DDI-DrugBank.d64.s90|155-155|(|O
DDI-DrugBank.d64.s90|156-157|eg|O
DDI-DrugBank.d64.s90|158-158|,|O
DDI-DrugBank.d64.s90|160-166|aspirin|brand
DDI-DrugBank.d64.s90|168-170|and|O
DDI-DrugBank.d64.s90|172-176|other|O
DDI-DrugBank.d64.s90|178-214|non-steroidal anti-inflammatory drugs|group
DDI-DrugBank.d64.s90|215-215|,|O
DDI-DrugBank.d64.s90|217-228|dipyridamole|drug
DDI-DrugBank.d64.s90|229-229|,|O
DDI-DrugBank.d64.s90|231-246|hydrochloroquine|drug
DDI-DrugBank.d64.s90|247-247|,|O
DDI-DrugBank.d64.s90|249-258|clofibrate|drug
DDI-DrugBank.d64.s90|259-259|,|O
DDI-DrugBank.d64.s90|261-267|dextran|drug
DDI-DrugBank.d64.s90|268-268|)|O
DDI-DrugBank.d64.s90|270-272|may|O
DDI-DrugBank.d64.s90|274-281|increase|O
DDI-DrugBank.d64.s90|283-285|the|O
DDI-DrugBank.d64.s90|287-294|bleeding|O
DDI-DrugBank.d64.s90|296-303|tendency|O
DDI-DrugBank.d64.s90|305-312|produced|O
DDI-DrugBank.d64.s90|314-315|by|O
DDI-DrugBank.d64.s90|317-330|anticoagulants|group
DDI-DrugBank.d64.s90|332-338|without|O
DDI-DrugBank.d64.s90|340-347|altering|O
DDI-DrugBank.d64.s90|349-359|prothrombin|O
DDI-DrugBank.d64.s90|361-364|time|O
DDI-DrugBank.d64.s90|366-379|determinations|O
DDI-DrugBank.d64.s90|380-380|.|O
DDI-DrugBank.d64.s91|0-2|The|O
DDI-DrugBank.d64.s91|4-13|beneficial|O
DDI-DrugBank.d64.s91|15-21|effects|O
DDI-DrugBank.d64.s91|23-24|on|O
DDI-DrugBank.d64.s91|26-33|arterial|O
DDI-DrugBank.d64.s91|35-42|thrombus|O
DDI-DrugBank.d64.s91|44-52|formation|O
DDI-DrugBank.d64.s91|54-57|from|O
DDI-DrugBank.d64.s91|59-66|combined|O
DDI-DrugBank.d64.s91|68-74|therapy|O
DDI-DrugBank.d64.s91|76-79|with|O
DDI-DrugBank.d64.s91|81-92|antiplatelet|group
DDI-DrugBank.d64.s91|94-96|and|O
DDI-DrugBank.d64.s91|98-121|anticoagulant medication|group
DDI-DrugBank.d64.s91|123-126|must|O
DDI-DrugBank.d64.s91|128-129|be|O
DDI-DrugBank.d64.s91|131-137|weighed|O
DDI-DrugBank.d64.s91|139-145|against|O
DDI-DrugBank.d64.s91|147-148|an|O
DDI-DrugBank.d64.s91|150-158|increased|O
DDI-DrugBank.d64.s91|160-163|risk|O
DDI-DrugBank.d64.s91|165-166|of|O
DDI-DrugBank.d64.s91|168-175|inducing|O
DDI-DrugBank.d64.s91|177-186|hemorrhage|O
DDI-DrugBank.d64.s91|187-187|.|O
DDI-DrugBank.d64.s92|0-9|*Increased|O
DDI-DrugBank.d64.s92|11-13|and|O
DDI-DrugBank.d64.s92|15-23|decreased|O
DDI-DrugBank.d64.s92|25-35|prothrombin|O
DDI-DrugBank.d64.s92|37-40|time|O
DDI-DrugBank.d64.s92|42-50|responses|O
DDI-DrugBank.d64.s92|52-55|have|O
DDI-DrugBank.d64.s92|57-60|been|O
DDI-DrugBank.d64.s92|62-69|reported|O
DDI-DrugBank.d64.s92|70-70|.|O
DDI-DrugBank.d64.s93|0-14|Drug/Laboratory|O
DDI-DrugBank.d64.s93|16-19|Test|O
DDI-DrugBank.d64.s93|21-33|Interferences|O
DDI-DrugBank.d64.s93|34-34|:|O
DDI-DrugBank.d64.s93|36-44|Dicumarol|drug
DDI-DrugBank.d64.s93|46-48|and|O
DDI-DrugBank.d64.s93|50-75|indanedione anticoagulants|group
DDI-DrugBank.d64.s93|76-76|,|O
DDI-DrugBank.d64.s93|78-86|including|O
DDI-DrugBank.d64.s93|88-98|anisindione|drug
DDI-DrugBank.d64.s93|99-99|,|O
DDI-DrugBank.d64.s93|101-102|or|O
DDI-DrugBank.d64.s93|104-108|their|O
DDI-DrugBank.d64.s93|110-120|metabolites|O
DDI-DrugBank.d64.s93|122-124|may|O
DDI-DrugBank.d64.s93|126-130|color|O
DDI-DrugBank.d64.s93|132-139|alkaline|O
DDI-DrugBank.d64.s93|141-145|urine|O
DDI-DrugBank.d64.s93|147-156|red-orange|O
DDI-DrugBank.d64.s93|157-157|,|O
DDI-DrugBank.d64.s93|159-163|which|O
DDI-DrugBank.d64.s93|165-167|may|O
DDI-DrugBank.d64.s93|169-177|interfere|O
DDI-DrugBank.d64.s93|179-182|with|O
DDI-DrugBank.d64.s93|184-205|spectrophotometrically|O
DDI-DrugBank.d64.s93|207-216|determined|O
DDI-DrugBank.d64.s93|218-224|urinary|O
DDI-DrugBank.d64.s93|226-235|laboratory|O
DDI-DrugBank.d64.s93|237-241|tests|O
DDI-DrugBank.d64.s93|242-242|.|O
DDI-DrugBank.d64.s94|0-2|The|O
DDI-DrugBank.d64.s94|4-8|color|O
DDI-DrugBank.d64.s94|10-17|reverses|O
DDI-DrugBank.d64.s94|19-22|when|O
DDI-DrugBank.d64.s94|24-26|the|O
DDI-DrugBank.d64.s94|28-31|test|O
DDI-DrugBank.d64.s94|33-38|sample|O
DDI-DrugBank.d64.s94|40-41|is|O
DDI-DrugBank.d64.s94|43-51|acidified|O
DDI-DrugBank.d64.s94|53-54|in|O
DDI-DrugBank.d64.s94|56-60|vitro|O
DDI-DrugBank.d64.s94|62-63|to|O
DDI-DrugBank.d64.s94|65-65|a|O
DDI-DrugBank.d64.s94|67-68|pH|O
DDI-DrugBank.d64.s94|70-74|below|O
DDI-DrugBank.d64.s94|76-76|4|O
DDI-DrugBank.d64.s94|77-77|.|O
DDI-DrugBank.d174.s0|0-1|In|O
DDI-DrugBank.d174.s0|3-7|vitro|O
DDI-DrugBank.d174.s0|9-15|studies|O
DDI-DrugBank.d174.s0|17-20|have|O
DDI-DrugBank.d174.s0|22-26|shown|O
DDI-DrugBank.d174.s0|28-31|that|O
DDI-DrugBank.d174.s0|32-32|,|O
DDI-DrugBank.d174.s0|34-40|because|O
DDI-DrugBank.d174.s0|42-43|of|O
DDI-DrugBank.d174.s0|45-47|its|O
DDI-DrugBank.d174.s0|49-56|affinity|O
DDI-DrugBank.d174.s0|58-60|for|O
DDI-DrugBank.d174.s0|62-68|protein|O
DDI-DrugBank.d174.s0|69-69|,|O
DDI-DrugBank.d174.s0|76-78|may|O
DDI-DrugBank.d174.s0|80-87|displace|O
DDI-DrugBank.d174.s0|89-93|other|O
DDI-DrugBank.d174.s0|95-107|protein-bound|O
DDI-DrugBank.d174.s0|109-113|drugs|O
DDI-DrugBank.d174.s0|115-118|from|O
DDI-DrugBank.d174.s0|120-124|their|O
DDI-DrugBank.d174.s0|126-132|binding|O
DDI-DrugBank.d174.s0|134-137|site|O
DDI-DrugBank.d174.s0|138-138|.|O
DDI-DrugBank.d174.s1|0-6|Caution|O
DDI-DrugBank.d174.s1|8-13|should|O
DDI-DrugBank.d174.s1|15-16|be|O
DDI-DrugBank.d174.s1|18-26|exercised|O
DDI-DrugBank.d174.s1|28-31|when|O
DDI-DrugBank.d174.s1|33-45|administering|O
DDI-DrugBank.d174.s1|47-56|nabumetone|drug
DDI-DrugBank.d174.s1|58-61|with|O
DDI-DrugBank.d174.s1|63-70|warfarin|drug
DDI-DrugBank.d174.s1|72-76|since|O
DDI-DrugBank.d174.s1|78-89|interactions|O
DDI-DrugBank.d174.s1|91-94|have|O
DDI-DrugBank.d174.s1|96-99|been|O
DDI-DrugBank.d174.s1|101-104|seen|O
DDI-DrugBank.d174.s1|106-109|with|O
DDI-DrugBank.d174.s1|111-115|other|O
DDI-DrugBank.d174.s1|117-122|NSAIDs|group
DDI-DrugBank.d174.s1|123-123|.|O
DDI-DrugBank.d174.s2|0-10|Concomitant|O
DDI-DrugBank.d174.s2|12-25|administration|O
DDI-DrugBank.d174.s2|27-28|of|O
DDI-DrugBank.d174.s2|30-31|an|O
DDI-DrugBank.d174.s2|33-51|aluminum-containing|drug
DDI-DrugBank.d174.s2|33-51|aluminum-containing|drug
DDI-DrugBank.d174.s2|61-63|had|O
DDI-DrugBank.d174.s2|65-66|no|O
DDI-DrugBank.d174.s2|68-78|significant|O
DDI-DrugBank.d174.s2|80-85|effect|O
DDI-DrugBank.d174.s2|87-88|in|O
DDI-DrugBank.d174.s2|90-92|the|O
DDI-DrugBank.d174.s2|94-108|bioavailability|O
DDI-DrugBank.d174.s2|110-111|of|O
DDI-DrugBank.d174.s2|117-117|.|O
DDI-DrugBank.d174.s3|0-3|When|O
DDI-DrugBank.d174.s3|5-16|administered|O
DDI-DrugBank.d174.s3|18-21|with|O
DDI-DrugBank.d174.s3|23-26|food|O
DDI-DrugBank.d174.s3|28-29|or|O
DDI-DrugBank.d174.s3|31-34|milk|O
DDI-DrugBank.d174.s3|35-35|,|O
DDI-DrugBank.d174.s3|37-41|there|O
DDI-DrugBank.d174.s3|43-44|is|O
DDI-DrugBank.d174.s3|46-49|more|O
DDI-DrugBank.d174.s3|51-55|rapid|O
DDI-DrugBank.d174.s3|57-66|absorption|O
DDI-DrugBank.d174.s3|67-67|;|O
DDI-DrugBank.d174.s4|0-6|however|O
DDI-DrugBank.d174.s4|7-7|,|O
DDI-DrugBank.d174.s4|9-11|the|O
DDI-DrugBank.d174.s4|13-17|total|O
DDI-DrugBank.d174.s4|19-24|amount|O
DDI-DrugBank.d174.s4|26-27|of|O
DDI-DrugBank.d174.s4|34-35|in|O
DDI-DrugBank.d174.s4|37-39|the|O
DDI-DrugBank.d174.s4|41-46|plasma|O
DDI-DrugBank.d174.s4|48-49|is|O
DDI-DrugBank.d174.s4|51-59|unchanged|O
DDI-DrugBank.d174.s4|61-61|.|O
DDI-DrugBank.d611.s0|0-4|Other|O
DDI-DrugBank.d611.s0|6-44|beta adrenergic aerosol bronchodilators|group
DDI-DrugBank.d611.s0|46-51|should|O
DDI-DrugBank.d611.s0|53-55|not|O
DDI-DrugBank.d611.s0|57-58|be|O
DDI-DrugBank.d611.s0|60-63|used|O
DDI-DrugBank.d611.s0|65-77|concomitantly|O
DDI-DrugBank.d611.s0|79-82|with|O
DDI-DrugBank.d611.s0|84-90|Alupent|brand
DDI-DrugBank.d611.s0|95-95|(|O
DDI-DrugBank.d611.s0|96-117|metaproterenol sulfate|drug
DDI-DrugBank.d611.s0|119-121|USP|O
DDI-DrugBank.d611.s0|122-122|)|O
DDI-DrugBank.d611.s0|124-130|because|O
DDI-DrugBank.d611.s0|132-135|they|O
DDI-DrugBank.d611.s0|137-139|may|O
DDI-DrugBank.d611.s0|141-144|have|O
DDI-DrugBank.d611.s0|146-153|additive|O
DDI-DrugBank.d611.s0|155-161|effects|O
DDI-DrugBank.d611.s0|162-162|.|O
DDI-DrugBank.d611.s1|0-23|Beta adrenergic agonists|group
DDI-DrugBank.d611.s1|25-30|should|O
DDI-DrugBank.d611.s1|32-33|be|O
DDI-DrugBank.d611.s1|35-46|administered|O
DDI-DrugBank.d611.s1|48-51|with|O
DDI-DrugBank.d611.s1|53-59|caution|O
DDI-DrugBank.d611.s1|61-62|to|O
DDI-DrugBank.d611.s1|64-71|patients|O
DDI-DrugBank.d611.s1|73-77|being|O
DDI-DrugBank.d611.s1|79-85|treated|O
DDI-DrugBank.d611.s1|87-90|with|O
DDI-DrugBank.d611.s1|92-119|monoamine oxidase inhibitors|group
DDI-DrugBank.d611.s1|121-122|or|O
DDI-DrugBank.d611.s1|124-148|tricyclic antidepressants|group
DDI-DrugBank.d611.s1|149-149|,|O
DDI-DrugBank.d611.s1|151-155|since|O
DDI-DrugBank.d611.s1|157-159|the|O
DDI-DrugBank.d611.s1|161-166|action|O
DDI-DrugBank.d611.s1|168-169|of|O
DDI-DrugBank.d611.s1|171-194|beta adrenergic agonists|group
DDI-DrugBank.d611.s1|196-197|on|O
DDI-DrugBank.d611.s1|199-201|the|O
DDI-DrugBank.d611.s1|203-210|vascular|O
DDI-DrugBank.d611.s1|212-217|system|O
DDI-DrugBank.d611.s1|219-221|may|O
DDI-DrugBank.d611.s1|223-224|be|O
DDI-DrugBank.d611.s1|226-236|potentiated|O
DDI-DrugBank.d611.s1|237-237|.|O
DDI-MedLine.d33.s0|0-11|Determinants|O
DDI-MedLine.d33.s0|13-14|of|O
DDI-MedLine.d33.s0|16-23|cellular|O
DDI-MedLine.d33.s0|25-35|sensitivity|O
DDI-MedLine.d33.s0|37-38|to|O
DDI-MedLine.d33.s0|40-78|topoisomerase-targeting antitumor drugs|group
DDI-MedLine.d33.s0|79-79|.|O
DDI-MedLine.d33.s1|0-1|It|O
DDI-MedLine.d33.s1|3-4|is|O
DDI-MedLine.d33.s1|6-8|now|O
DDI-MedLine.d33.s1|10-14|clear|O
DDI-MedLine.d33.s1|16-19|that|O
DDI-MedLine.d33.s1|21-33|topoisomerase|O
DDI-MedLine.d33.s1|35-42|activity|O
DDI-MedLine.d33.s1|44-48|level|O
DDI-MedLine.d33.s1|50-51|is|O
DDI-MedLine.d33.s1|53-54|an|O
DDI-MedLine.d33.s1|56-64|important|O
DDI-MedLine.d33.s1|66-76|determinant|O
DDI-MedLine.d33.s1|78-79|of|O
DDI-MedLine.d33.s1|81-91|sensitivity|O
DDI-MedLine.d33.s1|93-94|to|O
DDI-MedLine.d33.s1|96-99|topo|O
DDI-MedLine.d33.s1|101-105|drugs|O
DDI-MedLine.d33.s1|106-106|.|O
DDI-MedLine.d33.s2|0-2|The|O
DDI-MedLine.d33.s2|4-13|regulation|O
DDI-MedLine.d33.s2|15-16|of|O
DDI-MedLine.d33.s2|18-31|topoisomerases|O
DDI-MedLine.d33.s2|33-34|is|O
DDI-MedLine.d33.s2|36-37|no|O
DDI-MedLine.d33.s2|39-43|doubt|O
DDI-MedLine.d33.s2|45-51|complex|O
DDI-MedLine.d33.s2|53-55|and|O
DDI-MedLine.d33.s2|57-68|multifaceted|O
DDI-MedLine.d33.s2|70-72|and|O
DDI-MedLine.d33.s2|74-75|is|O
DDI-MedLine.d33.s2|77-84|probably|O
DDI-MedLine.d33.s2|86-97|accomplished|O
DDI-MedLine.d33.s2|99-105|through|O
DDI-MedLine.d33.s2|107-116|redundancy|O
DDI-MedLine.d33.s2|118-119|at|O
DDI-MedLine.d33.s2|121-124|many|O
DDI-MedLine.d33.s2|126-132|control|O
DDI-MedLine.d33.s2|134-139|levels|O
DDI-MedLine.d33.s2|140-140|.|O
DDI-MedLine.d33.s3|0-2|The|O
DDI-MedLine.d33.s3|4-12|mechanism|O
DDI-MedLine.d33.s3|13-13|(|O
DDI-MedLine.d33.s3|14-14|s|O
DDI-MedLine.d33.s3|15-15|)|O
DDI-MedLine.d33.s3|17-18|of|O
DDI-MedLine.d33.s3|20-26|altered|O
DDI-MedLine.d33.s3|28-31|topo|O
DDI-MedLine.d33.s3|33-33|I|O
DDI-MedLine.d33.s3|35-44|expression|O
DDI-MedLine.d33.s3|46-47|in|O
DDI-MedLine.d33.s3|49-55|certain|O
DDI-MedLine.d33.s3|57-61|tumor|O
DDI-MedLine.d33.s3|63-67|types|O
DDI-MedLine.d33.s3|69-70|is|O
DDI-MedLine.d33.s3|72-78|unknown|O
DDI-MedLine.d33.s3|79-79|,|O
DDI-MedLine.d33.s3|81-83|but|O
DDI-MedLine.d33.s3|85-87|may|O
DDI-MedLine.d33.s3|89-90|be|O
DDI-MedLine.d33.s3|92-98|related|O
DDI-MedLine.d33.s3|100-101|to|O
DDI-MedLine.d33.s3|103-105|the|O
DDI-MedLine.d33.s3|107-113|central|O
DDI-MedLine.d33.s3|115-124|importance|O
DDI-MedLine.d33.s3|126-127|of|O
DDI-MedLine.d33.s3|129-142|topoisomerases|O
DDI-MedLine.d33.s3|144-145|in|O
DDI-MedLine.d33.s3|147-159|proliferating|O
DDI-MedLine.d33.s3|161-164|cell|O
DDI-MedLine.d33.s3|166-174|functions|O
DDI-MedLine.d33.s3|176-176|(|O
DDI-MedLine.d33.s3|177-189|transcription|O
DDI-MedLine.d33.s3|190-190|,|O
DDI-MedLine.d33.s3|192-202|replication|O
DDI-MedLine.d33.s3|203-203|,|O
DDI-MedLine.d33.s3|205-208|etc.|O
DDI-MedLine.d33.s3|209-209|)|O
DDI-MedLine.d33.s3|210-210|,|O
DDI-MedLine.d33.s3|212-214|and|O
DDI-MedLine.d33.s3|216-218|the|O
DDI-MedLine.d33.s3|220-227|aberrant|O
DDI-MedLine.d33.s3|229-231|and|O
DDI-MedLine.d33.s3|233-239|chronic|O
DDI-MedLine.d33.s3|241-250|activation|O
DDI-MedLine.d33.s3|252-253|of|O
DDI-MedLine.d33.s3|255-259|these|O
DDI-MedLine.d33.s3|261-269|functions|O
DDI-MedLine.d33.s3|271-272|as|O
DDI-MedLine.d33.s3|274-274|a|O
DDI-MedLine.d33.s3|276-281|result|O
DDI-MedLine.d33.s3|283-284|of|O
DDI-MedLine.d33.s3|286-293|specific|O
DDI-MedLine.d33.s3|295-305|tumorigenic|O
DDI-MedLine.d33.s3|307-317|alterations|O
DDI-MedLine.d33.s3|318-318|.|O
DDI-MedLine.d33.s4|0-4|Small|O
DDI-MedLine.d33.s4|6-16|differences|O
DDI-MedLine.d33.s4|18-19|in|O
DDI-MedLine.d33.s4|21-31|sensitivity|O
DDI-MedLine.d33.s4|33-34|to|O
DDI-MedLine.d33.s4|36-47|chemotherapy|O
DDI-MedLine.d33.s4|49-51|can|O
DDI-MedLine.d33.s4|53-56|have|O
DDI-MedLine.d33.s4|58-58|a|O
DDI-MedLine.d33.s4|60-67|dramatic|O
DDI-MedLine.d33.s4|69-74|effect|O
DDI-MedLine.d33.s4|76-77|on|O
DDI-MedLine.d33.s4|79-82|cure|O
DDI-MedLine.d33.s4|84-88|rates|O
DDI-MedLine.d33.s4|89-89|,|O
DDI-MedLine.d33.s4|91-93|and|O
DDI-MedLine.d33.s4|95-103|therefore|O
DDI-MedLine.d33.s4|105-110|subtle|O
DDI-MedLine.d33.s4|112-115|cell|O
DDI-MedLine.d33.s4|117-129|type-specific|O
DDI-MedLine.d33.s4|131-141|differences|O
DDI-MedLine.d33.s4|143-145|may|O
DDI-MedLine.d33.s4|147-148|be|O
DDI-MedLine.d33.s4|150-158|important|O
DDI-MedLine.d33.s4|160-171|determinants|O
DDI-MedLine.d33.s4|173-174|of|O
DDI-MedLine.d33.s4|176-179|drug|O
DDI-MedLine.d33.s4|181-191|sensitivity|O
DDI-MedLine.d33.s4|192-192|.|O
DDI-MedLine.d33.s5|0-6|Whether|O
DDI-MedLine.d33.s5|8-15|abnormal|O
DDI-MedLine.d33.s5|17-29|topoisomerase|O
DDI-MedLine.d33.s5|31-38|quantity|O
DDI-MedLine.d33.s5|40-42|and|O
DDI-MedLine.d33.s5|44-51|specific|O
DDI-MedLine.d33.s5|53-60|activity|O
DDI-MedLine.d33.s5|62-64|are|O
DDI-MedLine.d33.s5|66-75|associated|O
DDI-MedLine.d33.s5|77-80|with|O
DDI-MedLine.d33.s5|82-91|resistance|O
DDI-MedLine.d33.s5|93-94|or|O
DDI-MedLine.d33.s5|96-106|sensitivity|O
DDI-MedLine.d33.s5|108-109|to|O
DDI-MedLine.d33.s5|111-132|topoisomerase-targeted|O
DDI-MedLine.d33.s5|134-145|chemotherapy|O
DDI-MedLine.d33.s5|147-148|in|O
DDI-MedLine.d33.s5|150-152|the|O
DDI-MedLine.d33.s5|154-159|clinic|O
DDI-MedLine.d33.s5|161-162|is|O
DDI-MedLine.d33.s5|164-166|now|O
DDI-MedLine.d33.s5|168-172|being|O
DDI-MedLine.d33.s5|174-180|studied|O
DDI-MedLine.d33.s5|181-181|.|O
DDI-MedLine.d33.s6|0-11|Determinants|O
DDI-MedLine.d33.s6|13-22|downstream|O
DDI-MedLine.d33.s6|24-25|of|O
DDI-MedLine.d33.s6|27-35|cleavable|O
DDI-MedLine.d33.s6|37-43|complex|O
DDI-MedLine.d33.s6|45-53|formation|O
DDI-MedLine.d33.s6|55-58|that|O
DDI-MedLine.d33.s6|60-65|affect|O
DDI-MedLine.d33.s6|67-69|the|O
DDI-MedLine.d33.s6|71-81|sensitivity|O
DDI-MedLine.d33.s6|83-84|of|O
DDI-MedLine.d33.s6|86-90|tumor|O
DDI-MedLine.d33.s6|92-97|versus|O
DDI-MedLine.d33.s6|99-104|normal|O
DDI-MedLine.d33.s6|106-110|cells|O
DDI-MedLine.d33.s6|112-113|to|O
DDI-MedLine.d33.s6|115-118|topo|O
DDI-MedLine.d33.s6|120-124|drugs|O
DDI-MedLine.d33.s6|126-127|in|O
DDI-MedLine.d33.s6|129-138|particular|O
DDI-MedLine.d33.s6|140-142|and|O
DDI-MedLine.d33.s6|144-155|DNA-damaging|O
DDI-MedLine.d33.s6|157-162|agents|O
DDI-MedLine.d33.s6|164-165|in|O
DDI-MedLine.d33.s6|167-173|general|O
DDI-MedLine.d33.s6|175-177|are|O
DDI-MedLine.d33.s6|179-184|little|O
DDI-MedLine.d33.s6|186-190|known|O
DDI-MedLine.d33.s6|191-191|.|O
DDI-MedLine.d33.s7|0-2|The|O
DDI-MedLine.d33.s7|4-7|goal|O
DDI-MedLine.d33.s7|9-10|of|O
DDI-MedLine.d33.s7|12-20|enhancing|O
DDI-MedLine.d33.s7|22-30|selective|O
DDI-MedLine.d33.s7|32-36|tumor|O
DDI-MedLine.d33.s7|38-41|cell|O
DDI-MedLine.d33.s7|43-49|killing|O
DDI-MedLine.d33.s7|51-58|relative|O
DDI-MedLine.d33.s7|60-61|to|O
DDI-MedLine.d33.s7|63-65|the|O
DDI-MedLine.d33.s7|67-72|normal|O
DDI-MedLine.d33.s7|74-78|cells|O
DDI-MedLine.d33.s7|80-83|that|O
DDI-MedLine.d33.s7|85-87|are|O
DDI-MedLine.d33.s7|89-92|dose|O
DDI-MedLine.d33.s7|94-101|limiting|O
DDI-MedLine.d33.s7|103-105|may|O
DDI-MedLine.d33.s7|107-108|be|O
DDI-MedLine.d33.s7|110-117|achieved|O
DDI-MedLine.d33.s7|119-124|either|O
DDI-MedLine.d33.s7|126-127|by|O
DDI-MedLine.d33.s7|129-138|overcoming|O
DDI-MedLine.d33.s7|140-144|tumor|O
DDI-MedLine.d33.s7|146-149|cell|O
DDI-MedLine.d33.s7|151-160|resistance|O
DDI-MedLine.d33.s7|162-163|or|O
DDI-MedLine.d33.s7|165-166|by|O
DDI-MedLine.d33.s7|168-177|protecting|O
DDI-MedLine.d33.s7|179-184|normal|O
DDI-MedLine.d33.s7|186-190|cells|O
DDI-MedLine.d33.s7|191-191|.|O
DDI-MedLine.d33.s8|0-3|Both|O
DDI-MedLine.d33.s8|5-6|of|O
DDI-MedLine.d33.s8|8-12|these|O
DDI-MedLine.d33.s8|14-23|strategies|O
DDI-MedLine.d33.s8|25-28|will|O
DDI-MedLine.d33.s8|30-35|become|O
DDI-MedLine.d33.s8|37-40|more|O
DDI-MedLine.d33.s8|42-49|feasible|O
DDI-MedLine.d33.s8|51-52|as|O
DDI-MedLine.d33.s8|54-61|specific|O
DDI-MedLine.d33.s8|63-71|molecular|O
DDI-MedLine.d33.s8|73-83|differences|O
DDI-MedLine.d33.s8|85-91|between|O
DDI-MedLine.d33.s8|93-97|tumor|O
DDI-MedLine.d33.s8|99-101|and|O
DDI-MedLine.d33.s8|103-108|normal|O
DDI-MedLine.d33.s8|110-114|cells|O
DDI-MedLine.d33.s8|116-118|are|O
DDI-MedLine.d33.s8|120-124|being|O
DDI-MedLine.d33.s8|126-132|rapidly|O
DDI-MedLine.d33.s8|134-143|identified|O
DDI-MedLine.d33.s8|145-147|and|O
DDI-MedLine.d33.s8|149-151|new|O
DDI-MedLine.d33.s8|153-163|combination|O
DDI-MedLine.d33.s8|165-173|therapies|O
DDI-MedLine.d33.s8|175-178|that|O
DDI-MedLine.d33.s8|180-183|take|O
DDI-MedLine.d33.s8|185-193|advantage|O
DDI-MedLine.d33.s8|195-196|of|O
DDI-MedLine.d33.s8|198-202|these|O
DDI-MedLine.d33.s8|204-214|differences|O
DDI-MedLine.d33.s8|216-218|are|O
DDI-MedLine.d33.s8|220-224|being|O
DDI-MedLine.d33.s8|226-233|designed|O
DDI-MedLine.d33.s8|235-237|and|O
DDI-MedLine.d33.s8|239-244|tested|O
DDI-MedLine.d33.s8|245-245|.|O
DDI-DrugBank.d309.s0|0-7|Additive|O
DDI-DrugBank.d309.s0|9-11|CNS|O
DDI-DrugBank.d309.s0|13-22|depression|O
DDI-DrugBank.d309.s0|24-26|may|O
DDI-DrugBank.d309.s0|28-32|occur|O
DDI-DrugBank.d309.s0|34-37|when|O
DDI-DrugBank.d309.s0|39-52|antihistamines|group
DDI-DrugBank.d309.s0|54-56|are|O
DDI-DrugBank.d309.s0|58-69|administered|O
DDI-DrugBank.d309.s0|71-83|concomitantly|O
DDI-DrugBank.d309.s0|85-88|with|O
DDI-DrugBank.d309.s0|90-94|other|O
DDI-DrugBank.d309.s0|96-110|CNS depressants|group
DDI-DrugBank.d309.s0|112-120|including|O
DDI-DrugBank.d309.s0|122-133|barbiturates|group
DDI-DrugBank.d309.s0|134-134|,|O
DDI-DrugBank.d309.s0|136-148|tranquilizers|group
DDI-DrugBank.d309.s0|149-149|,|O
DDI-DrugBank.d309.s0|151-153|and|O
DDI-DrugBank.d309.s0|155-161|alcohol|drug
DDI-DrugBank.d309.s0|162-162|.|O
DDI-DrugBank.d309.s1|0-7|Patients|O
DDI-DrugBank.d309.s1|9-17|receiving|O
DDI-DrugBank.d309.s1|19-32|antihistamines|group
DDI-DrugBank.d309.s1|34-39|should|O
DDI-DrugBank.d309.s1|41-42|be|O
DDI-DrugBank.d309.s1|44-50|advised|O
DDI-DrugBank.d309.s1|52-58|against|O
DDI-DrugBank.d309.s1|60-62|the|O
DDI-DrugBank.d309.s1|64-73|concurrent|O
DDI-DrugBank.d309.s1|75-77|use|O
DDI-DrugBank.d309.s1|79-80|of|O
DDI-DrugBank.d309.s1|82-86|other|O
DDI-DrugBank.d309.s1|88-107|CNS depressant drugs|group
DDI-DrugBank.d309.s1|108-108|.|O
DDI-DrugBank.d309.s2|0-33|Monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d309.s2|35-41|prolong|O
DDI-DrugBank.d309.s2|43-45|and|O
DDI-DrugBank.d309.s2|47-55|intensify|O
DDI-DrugBank.d309.s2|57-59|the|O
DDI-DrugBank.d309.s2|61-75|anticholinergic|O
DDI-DrugBank.d309.s2|77-83|effects|O
DDI-DrugBank.d309.s2|85-86|of|O
DDI-DrugBank.d309.s2|88-101|antihistamines|group
DDI-DrugBank.d309.s2|102-102|.|O
DDI-DrugBank.d782.s0|0-8|Vindesine|drug
DDI-DrugBank.d782.s0|10-12|can|O
DDI-DrugBank.d782.s0|14-21|interact|O
DDI-DrugBank.d782.s0|23-26|with|O
DDI-DrugBank.d782.s0|28-30|the|O
DDI-DrugBank.d782.s0|32-36|drugs|O
DDI-DrugBank.d782.s0|38-39|of|O
DDI-DrugBank.d782.s0|41-43|the|O
DDI-DrugBank.d782.s0|45-53|following|O
DDI-DrugBank.d782.s0|55-64|categories|O
DDI-DrugBank.d782.s0|65-65|:|O
DDI-DrugBank.d782.s0|68-68|-|O
DDI-DrugBank.d782.s0|70-74|Blood|O
DDI-DrugBank.d782.s0|76-84|dyscrasia|O
DDI-DrugBank.d782.s0|85-85|:|O
DDI-DrugBank.d782.s0|87-89|can|O
DDI-DrugBank.d782.s0|91-95|cause|O
DDI-DrugBank.d782.s0|97-109|unpredictable|O
DDI-DrugBank.d782.s0|111-123|myelotoxicity|O
DDI-DrugBank.d782.s0|125-125|-|O
DDI-DrugBank.d782.s0|127-130|Bone|O
DDI-DrugBank.d782.s0|132-137|marrow|O
DDI-DrugBank.d782.s0|139-149|depressants|O
DDI-DrugBank.d782.s0|150-150|:|O
DDI-DrugBank.d782.s0|152-154|can|O
DDI-DrugBank.d782.s0|156-160|cause|O
DDI-DrugBank.d782.s0|162-162|a|O
DDI-DrugBank.d782.s0|164-174|predictable|O
DDI-DrugBank.d782.s0|176-187|dose-related|O
DDI-DrugBank.d782.s0|189-201|myelotoxicity|O
DDI-DrugBank.d782.s0|203-203|-|O
DDI-DrugBank.d782.s0|205-213|Radiation|O
DDI-DrugBank.d782.s0|215-221|therapy|O
DDI-DrugBank.d782.s0|222-222|:|O
DDI-DrugBank.d782.s0|224-226|may|O
DDI-DrugBank.d782.s0|228-232|cause|O
DDI-DrugBank.d782.s0|234-239|marrow|O
DDI-DrugBank.d782.s0|241-250|depression|O
DDI-DrugBank.d782.s0|252-252|-|O
DDI-DrugBank.d782.s0|254-263|Neurotoxic|O
DDI-DrugBank.d782.s0|265-275|medications|O
DDI-DrugBank.d782.s0|276-276|:|O
DDI-DrugBank.d782.s0|278-280|can|O
DDI-DrugBank.d782.s0|282-286|cause|O
DDI-DrugBank.d782.s0|288-297|neurologic|O
DDI-DrugBank.d782.s0|299-306|toxicity|O
DDI-DrugBank.d782.s0|308-308|-|O
DDI-DrugBank.d782.s0|310-318|Phenytoin|drug
DDI-DrugBank.d782.s0|319-319|:|O
DDI-DrugBank.d782.s0|321-323|can|O
DDI-DrugBank.d782.s0|325-332|increase|O
DDI-DrugBank.d782.s0|334-340|seizure|O
DDI-DrugBank.d782.s0|342-349|activity|O
DDI-DrugBank.d782.s0|351-351|-|O
DDI-DrugBank.d782.s0|353-371|Live virus vaccines|group
DDI-DrugBank.d782.s0|372-372|:|O
DDI-DrugBank.d782.s0|374-376|may|O
DDI-DrugBank.d782.s0|378-387|potentiate|O
DDI-DrugBank.d782.s0|389-391|the|O
DDI-DrugBank.d782.s0|393-403|replication|O
DDI-DrugBank.d782.s0|405-406|of|O
DDI-DrugBank.d782.s0|408-410|the|O
DDI-DrugBank.d782.s0|412-418|vaccine|drug
DDI-DrugBank.d782.s0|420-424|virus|O
DDI-DrugBank.d782.s0|425-425|,|O
DDI-DrugBank.d782.s0|427-429|may|O
DDI-DrugBank.d782.s0|431-438|increase|O
DDI-DrugBank.d782.s0|440-442|the|O
DDI-DrugBank.d782.s0|444-447|side|O
DDI-DrugBank.d782.s0|449-455|effects|O
DDI-DrugBank.d782.s0|457-458|of|O
DDI-DrugBank.d782.s0|460-462|the|O
DDI-DrugBank.d782.s0|464-474|vaccination|O
DDI-DrugBank.d782.s0|475-475|,|O
DDI-DrugBank.d782.s0|477-479|and|O
DDI-DrugBank.d782.s0|481-488|decrease|O
DDI-DrugBank.d782.s0|490-496|patient|O
DDI-DrugBank.d782.s0|497-498|'s|O
DDI-DrugBank.d782.s0|500-507|response|O
DDI-DrugBank.d782.s0|509-510|to|O
DDI-DrugBank.d782.s0|512-514|the|O
DDI-DrugBank.d782.s0|516-522|vaccine|O
DDI-DrugBank.d782.s0|524-524|-|O
DDI-DrugBank.d782.s0|526-536|Mitomycin-C|drug
DDI-DrugBank.d782.s0|537-537|:|O
DDI-DrugBank.d782.s0|539-541|may|O
DDI-DrugBank.d782.s0|543-547|cause|O
DDI-DrugBank.d782.s0|549-557|shortness|O
DDI-DrugBank.d782.s0|559-560|of|O
DDI-DrugBank.d782.s0|562-567|breath|O
DDI-DrugBank.d782.s0|569-571|and|O
DDI-DrugBank.d782.s0|573-584|bronchospasm|O
DDI-DrugBank.d782.s0|586-586|-|O
DDI-DrugBank.d782.s0|588-608|Killed virus vaccines|group
DDI-DrugBank.d782.s0|609-609|:|O
DDI-DrugBank.d782.s0|611-613|may|O
DDI-DrugBank.d782.s0|615-622|decrease|O
DDI-DrugBank.d782.s0|624-630|patient|O
DDI-DrugBank.d782.s0|631-632|'s|O
DDI-DrugBank.d782.s0|634-641|response|O
DDI-DrugBank.d782.s0|643-644|to|O
DDI-DrugBank.d782.s0|646-648|the|O
DDI-DrugBank.d180.s0|0-8|Digitalis|group
DDI-DrugBank.d180.s0|10-17|toxicity|O
DDI-DrugBank.d180.s0|19-21|may|O
DDI-DrugBank.d180.s0|23-24|be|O
DDI-DrugBank.d180.s0|26-35|aggravated|O
DDI-DrugBank.d180.s0|37-38|by|O
DDI-DrugBank.d180.s0|40-42|the|O
DDI-DrugBank.d180.s0|44-50|initial|O
DDI-DrugBank.d180.s0|52-58|release|O
DDI-DrugBank.d180.s0|60-61|of|O
DDI-DrugBank.d180.s0|63-76|norepinephrine|O
DDI-DrugBank.d180.s0|78-83|caused|O
DDI-DrugBank.d180.s0|85-86|by|O
DDI-DrugBank.d180.s0|88-105|Bretylium Tosylate|drug
DDI-DrugBank.d180.s0|107-115|Injection|O
DDI-DrugBank.d180.s0|116-116|.|O
DDI-DrugBank.d180.s1|0-2|The|O
DDI-DrugBank.d180.s1|4-10|pressor|O
DDI-DrugBank.d180.s1|12-18|effects|O
DDI-DrugBank.d180.s1|20-21|of|O
DDI-DrugBank.d180.s1|23-36|catecholamines|group
DDI-DrugBank.d180.s1|38-41|such|O
DDI-DrugBank.d180.s1|43-44|as|O
DDI-DrugBank.d180.s1|46-53|dopamine|drug
DDI-DrugBank.d180.s1|55-56|or|O
DDI-DrugBank.d180.s1|58-71|norepinephrine|drug
DDI-DrugBank.d180.s1|73-75|are|O
DDI-DrugBank.d180.s1|77-84|enhanced|O
DDI-DrugBank.d180.s1|86-87|by|O
DDI-DrugBank.d180.s1|89-106|Bretylium Tosylate|drug
DDI-DrugBank.d180.s1|107-107|.|O
DDI-DrugBank.d180.s2|0-3|When|O
DDI-DrugBank.d180.s2|5-18|catecholamines|group
DDI-DrugBank.d180.s2|20-22|are|O
DDI-DrugBank.d180.s2|24-35|administered|O
DDI-DrugBank.d180.s2|36-36|,|O
DDI-DrugBank.d180.s2|38-43|dilute|O
DDI-DrugBank.d180.s2|45-53|solutions|O
DDI-DrugBank.d180.s2|55-60|should|O
DDI-DrugBank.d180.s2|62-63|be|O
DDI-DrugBank.d180.s2|65-68|used|O
DDI-DrugBank.d180.s2|70-72|and|O
DDI-DrugBank.d180.s2|74-78|blood|O
DDI-DrugBank.d180.s2|80-87|pressure|O
DDI-DrugBank.d180.s2|89-94|should|O
DDI-DrugBank.d180.s2|96-97|be|O
DDI-DrugBank.d180.s2|99-107|monitored|O
DDI-DrugBank.d180.s2|109-115|closely|O
DDI-DrugBank.d180.s2|116-116|.|O
DDI-DrugBank.d180.s3|0-7|Although|O
DDI-DrugBank.d180.s3|9-13|there|O
DDI-DrugBank.d180.s3|15-16|is|O
DDI-DrugBank.d180.s3|18-23|little|O
DDI-DrugBank.d180.s3|25-33|published|O
DDI-DrugBank.d180.s3|35-45|information|O
DDI-DrugBank.d180.s3|47-48|on|O
DDI-DrugBank.d180.s3|50-60|concomitant|O
DDI-DrugBank.d180.s3|62-75|administration|O
DDI-DrugBank.d180.s3|77-78|of|O
DDI-DrugBank.d180.s3|80-88|lidocaine|drug
DDI-DrugBank.d180.s3|90-92|and|O
DDI-DrugBank.d180.s3|94-111|Bretylium Tosylate|drug
DDI-DrugBank.d180.s3|112-112|,|O
DDI-DrugBank.d180.s3|114-118|these|O
DDI-DrugBank.d180.s3|120-124|drugs|O
DDI-DrugBank.d180.s3|126-128|are|O
DDI-DrugBank.d180.s3|130-134|often|O
DDI-DrugBank.d180.s3|136-147|administered|O
DDI-DrugBank.d180.s3|149-160|concurrently|O
DDI-DrugBank.d180.s3|162-168|without|O
DDI-DrugBank.d180.s3|170-172|any|O
DDI-DrugBank.d180.s3|174-181|evidence|O
DDI-DrugBank.d180.s3|183-184|of|O
DDI-DrugBank.d180.s3|186-197|interactions|O
DDI-DrugBank.d180.s3|199-207|resulting|O
DDI-DrugBank.d180.s3|209-210|in|O
DDI-DrugBank.d180.s3|212-218|adverse|O
DDI-DrugBank.d180.s3|220-226|effects|O
DDI-DrugBank.d180.s3|228-229|or|O
DDI-DrugBank.d180.s3|231-240|diminished|O
DDI-DrugBank.d180.s3|242-249|efficacy|O
DDI-DrugBank.d180.s3|250-250|.|O
DDI-DrugBank.d720.s0|0-15|Ergot-containing|group
DDI-DrugBank.d720.s0|17-21|drugs|O
DDI-DrugBank.d720.s0|23-26|have|O
DDI-DrugBank.d720.s0|28-31|been|O
DDI-DrugBank.d720.s0|33-40|reported|O
DDI-DrugBank.d720.s0|42-43|to|O
DDI-DrugBank.d720.s0|45-49|cause|O
DDI-DrugBank.d720.s0|51-59|prolonged|O
DDI-DrugBank.d720.s0|61-71|vasospastic|O
DDI-DrugBank.d720.s0|73-81|reactions|O
DDI-DrugBank.d720.s0|82-82|.|O
DDI-DrugBank.d720.s1|0-6|Because|O
DDI-DrugBank.d720.s1|8-12|there|O
DDI-DrugBank.d720.s1|14-15|is|O
DDI-DrugBank.d720.s1|17-17|a|O
DDI-DrugBank.d720.s1|19-29|theoretical|O
DDI-DrugBank.d720.s1|31-35|basis|O
DDI-DrugBank.d720.s1|37-40|that|O
DDI-DrugBank.d720.s1|42-46|these|O
DDI-DrugBank.d720.s1|48-54|effects|O
DDI-DrugBank.d720.s1|56-58|may|O
DDI-DrugBank.d720.s1|60-61|be|O
DDI-DrugBank.d720.s1|63-70|additive|O
DDI-DrugBank.d720.s1|71-71|,|O
DDI-DrugBank.d720.s1|73-75|use|O
DDI-DrugBank.d720.s1|77-78|of|O
DDI-DrugBank.d720.s1|80-100|ergotamine-containing|drug
DDI-DrugBank.d720.s1|102-103|or|O
DDI-DrugBank.d720.s1|105-126|ergot-type medications|group
DDI-DrugBank.d720.s1|128-128|(|O
DDI-DrugBank.d720.s1|129-132|like|O
DDI-DrugBank.d720.s1|134-150|dihydroergotamine|drug
DDI-DrugBank.d720.s1|152-153|or|O
DDI-DrugBank.d720.s1|155-166|methysergide|drug
DDI-DrugBank.d720.s1|167-167|)|O
DDI-DrugBank.d720.s1|169-171|and|O
DDI-DrugBank.d720.s1|173-183|sumatriptan|drug
DDI-DrugBank.d720.s1|185-190|within|O
DDI-DrugBank.d720.s1|192-193|24|O
DDI-DrugBank.d720.s1|195-199|hours|O
DDI-DrugBank.d720.s1|201-202|of|O
DDI-DrugBank.d720.s1|204-207|each|O
DDI-DrugBank.d720.s1|209-213|other|O
DDI-DrugBank.d720.s1|215-220|should|O
DDI-DrugBank.d720.s1|222-223|be|O
DDI-DrugBank.d720.s1|225-231|avoided|O
DDI-DrugBank.d720.s1|232-232|.|O
DDI-DrugBank.d720.s2|0-15|MAO-A inhibitors|group
DDI-DrugBank.d720.s2|17-22|reduce|O
DDI-DrugBank.d720.s2|24-34|sumatriptan|drug
DDI-DrugBank.d720.s2|36-44|clearance|O
DDI-DrugBank.d720.s2|45-45|,|O
DDI-DrugBank.d720.s2|47-59|significantly|O
DDI-DrugBank.d720.s2|61-70|increasing|O
DDI-DrugBank.d720.s2|72-79|systemic|O
DDI-DrugBank.d720.s2|81-88|exposure|O
DDI-DrugBank.d720.s2|89-89|.|O
DDI-DrugBank.d720.s3|0-8|Therefore|O
DDI-DrugBank.d720.s3|9-9|,|O
DDI-DrugBank.d720.s3|11-13|the|O
DDI-DrugBank.d720.s3|15-17|use|O
DDI-DrugBank.d720.s3|19-20|of|O
DDI-DrugBank.d720.s3|22-42|sumatriptan succinate|drug
DDI-DrugBank.d720.s3|44-50|tablets|O
DDI-DrugBank.d720.s3|52-53|in|O
DDI-DrugBank.d720.s3|55-62|patients|O
DDI-DrugBank.d720.s3|64-72|receiving|O
DDI-DrugBank.d720.s3|74-89|MAO-A inhibitors|group
DDI-DrugBank.d720.s3|91-92|is|O
DDI-DrugBank.d720.s3|94-108|contraindicated|O
DDI-DrugBank.d720.s3|110-110|.|O
DDI-DrugBank.d720.s3|112-150|Selective serotonin reuptake inhibitors|group
DDI-DrugBank.d720.s3|152-152|(|O
DDI-DrugBank.d720.s3|153-157|SSRIs|group
DDI-DrugBank.d720.s3|158-158|)|O
DDI-DrugBank.d720.s3|160-160|(|O
DDI-DrugBank.d720.s3|161-164|e.g.|O
DDI-DrugBank.d720.s3|165-165|,|O
DDI-DrugBank.d720.s3|167-176|fluoxetine|drug
DDI-DrugBank.d720.s3|177-177|,|O
DDI-DrugBank.d720.s3|179-189|fluvoxamine|drug
DDI-DrugBank.d720.s3|190-190|,|O
DDI-DrugBank.d720.s3|192-201|paroxetine|drug
DDI-DrugBank.d720.s3|202-202|,|O
DDI-DrugBank.d720.s3|204-213|sertraline|drug
DDI-DrugBank.d720.s3|214-214|)|O
DDI-DrugBank.d720.s3|216-219|have|O
DDI-DrugBank.d720.s3|221-224|been|O
DDI-DrugBank.d720.s3|226-233|reported|O
DDI-DrugBank.d720.s3|234-234|,|O
DDI-DrugBank.d720.s3|236-241|rarely|O
DDI-DrugBank.d720.s3|242-242|,|O
DDI-DrugBank.d720.s3|244-245|to|O
DDI-DrugBank.d720.s3|247-251|cause|O
DDI-DrugBank.d720.s3|253-260|weakness|O
DDI-DrugBank.d720.s3|261-261|,|O
DDI-DrugBank.d720.s3|263-275|hyperreflexia|O
DDI-DrugBank.d720.s3|276-276|,|O
DDI-DrugBank.d720.s3|278-280|and|O
DDI-DrugBank.d720.s3|282-295|incoordination|O
DDI-DrugBank.d720.s3|297-300|when|O
DDI-DrugBank.d720.s3|302-315|coadministered|O
DDI-DrugBank.d720.s3|317-320|with|O
DDI-DrugBank.d720.s3|322-332|sumatriptan|drug
DDI-DrugBank.d720.s3|333-333|.|O
DDI-DrugBank.d720.s4|0-1|If|O
DDI-DrugBank.d720.s4|3-13|concomitant|O
DDI-DrugBank.d720.s4|15-23|treatment|O
DDI-DrugBank.d720.s4|25-28|with|O
DDI-DrugBank.d720.s4|30-40|sumatriptan|drug
DDI-DrugBank.d720.s4|42-44|and|O
DDI-DrugBank.d720.s4|46-47|an|O
DDI-DrugBank.d720.s4|49-52|SSRI|group
DDI-DrugBank.d720.s4|54-55|is|O
DDI-DrugBank.d720.s4|57-66|clinically|O
DDI-DrugBank.d720.s4|68-76|warranted|O
DDI-DrugBank.d720.s4|77-77|,|O
DDI-DrugBank.d720.s4|79-89|appropriate|O
DDI-DrugBank.d720.s4|91-101|observation|O
DDI-DrugBank.d720.s4|103-104|of|O
DDI-DrugBank.d720.s4|106-108|the|O
DDI-DrugBank.d720.s4|110-116|patient|O
DDI-DrugBank.d720.s4|118-119|is|O
DDI-DrugBank.d720.s4|121-127|advised|O
DDI-DrugBank.d720.s4|128-128|.|O
DDI-DrugBank.d750.s0|0-10|Concomitant|O
DDI-DrugBank.d750.s0|12-14|use|O
DDI-DrugBank.d750.s0|16-17|of|O
DDI-DrugBank.d750.s0|19-25|alcohol|drug
DDI-DrugBank.d750.s0|27-30|with|O
DDI-DrugBank.d750.s0|32-56|phentermine hydrochloride|drug
DDI-DrugBank.d750.s0|58-60|may|O
DDI-DrugBank.d750.s0|62-67|result|O
DDI-DrugBank.d750.s0|69-70|in|O
DDI-DrugBank.d750.s0|72-73|an|O
DDI-DrugBank.d750.s0|75-81|adverse|O
DDI-DrugBank.d750.s0|83-86|drug|O
DDI-DrugBank.d750.s0|88-98|interaction|O
DDI-DrugBank.d750.s0|99-99|.|O
DDI-MedLine.d80.s0|0-13|Progestin-only|O
DDI-MedLine.d80.s0|15-18|oral|O
DDI-MedLine.d80.s0|20-32|contraception|O
DDI-MedLine.d80.s0|33-33|:|O
DDI-MedLine.d80.s0|35-35|a|O
DDI-MedLine.d80.s0|37-49|comprehensive|O
DDI-MedLine.d80.s0|51-56|review|O
DDI-MedLine.d80.s0|57-57|.|O
DDI-MedLine.d80.s1|0-1|In|O
DDI-MedLine.d80.s1|3-7|order|O
DDI-MedLine.d80.s1|9-10|to|O
DDI-MedLine.d80.s1|12-18|provide|O
DDI-MedLine.d80.s1|20-30|information|O
DDI-MedLine.d80.s1|32-34|for|O
DDI-MedLine.d80.s1|36-38|the|O
DDI-MedLine.d80.s1|40-50|appropriate|O
DDI-MedLine.d80.s1|52-58|package|O
DDI-MedLine.d80.s1|60-65|insert|O
DDI-MedLine.d80.s1|67-74|labeling|O
DDI-MedLine.d80.s1|76-77|of|O
DDI-MedLine.d80.s1|79-112|progestin-only oral contraceptives|group
DDI-MedLine.d80.s1|114-114|(|O
DDI-MedLine.d80.s1|115-117|POC|group
DDI-MedLine.d80.s1|118-118|)|O
DDI-MedLine.d80.s1|120-121|in|O
DDI-MedLine.d80.s1|123-125|the|O
DDI-MedLine.d80.s1|127-128|US|O
DDI-MedLine.d80.s1|129-129|,|O
DDI-MedLine.d80.s1|131-131|a|O
DDI-MedLine.d80.s1|133-145|comprehensive|O
DDI-MedLine.d80.s1|147-152|review|O
DDI-MedLine.d80.s1|154-156|was|O
DDI-MedLine.d80.s1|158-161|made|O
DDI-MedLine.d80.s1|163-164|of|O
DDI-MedLine.d80.s1|166-175|norgestrel|drug
DDI-MedLine.d80.s1|177-177|(|O
DDI-MedLine.d80.s1|178-182|0.075|O
DDI-MedLine.d80.s1|184-185|mg|O
DDI-MedLine.d80.s1|186-186|)|O
DDI-MedLine.d80.s1|188-190|and|O
DDI-MedLine.d80.s1|192-204|norethindrone|drug
DDI-MedLine.d80.s1|206-206|(|O
DDI-MedLine.d80.s1|207-210|0.35|O
DDI-MedLine.d80.s1|212-213|mg|O
DDI-MedLine.d80.s1|214-214|)|O
DDI-MedLine.d80.s1|215-215|,|O
DDI-MedLine.d80.s1|217-220|with|O
DDI-MedLine.d80.s1|222-224|the|O
DDI-MedLine.d80.s1|226-233|clinical|O
DDI-MedLine.d80.s1|235-245|differences|O
DDI-MedLine.d80.s1|247-255|indicated|O
DDI-MedLine.d80.s1|257-261|where|O
DDI-MedLine.d80.s1|263-272|applicable|O
DDI-MedLine.d80.s1|273-273|.|O
DDI-MedLine.d80.s2|0-2|The|O
DDI-MedLine.d80.s2|4-7|goal|O
DDI-MedLine.d80.s2|9-10|of|O
DDI-MedLine.d80.s2|12-15|this|O
DDI-MedLine.d80.s2|17-22|review|O
DDI-MedLine.d80.s2|24-26|was|O
DDI-MedLine.d80.s2|28-29|to|O
DDI-MedLine.d80.s2|31-34|cite|O
DDI-MedLine.d80.s2|36-42|primary|O
DDI-MedLine.d80.s2|44-50|sources|O
DDI-MedLine.d80.s2|52-54|for|O
DDI-MedLine.d80.s2|56-64|virtually|O
DDI-MedLine.d80.s2|66-68|all|O
DDI-MedLine.d80.s2|70-77|research|O
DDI-MedLine.d80.s2|79-86|specific|O
DDI-MedLine.d80.s2|88-89|to|O
DDI-MedLine.d80.s2|91-94|POPs|O
DDI-MedLine.d80.s2|96-100|since|O
DDI-MedLine.d80.s2|102-105|1975|O
DDI-MedLine.d80.s2|106-106|.|O
DDI-MedLine.d80.s3|0-10|Conclusions|O
DDI-MedLine.d80.s3|12-14|and|O
DDI-MedLine.d80.s3|16-18|the|O
DDI-MedLine.d80.s3|20-24|types|O
DDI-MedLine.d80.s3|26-27|of|O
DDI-MedLine.d80.s3|29-35|studies|O
DDI-MedLine.d80.s3|37-41|which|O
DDI-MedLine.d80.s3|43-49|support|O
DDI-MedLine.d80.s3|51-55|these|O
DDI-MedLine.d80.s3|57-67|conclusions|O
DDI-MedLine.d80.s3|69-71|are|O
DDI-MedLine.d80.s3|73-77|given|O
DDI-MedLine.d80.s3|79-81|for|O
DDI-MedLine.d80.s3|83-86|each|O
DDI-MedLine.d80.s3|88-92|major|O
DDI-MedLine.d80.s3|94-100|section|O
DDI-MedLine.d80.s3|101-101|.|O
DDI-MedLine.d80.s4|0-2|The|O
DDI-MedLine.d80.s4|4-15|introductory|O
DDI-MedLine.d80.s4|17-23|chapter|O
DDI-MedLine.d80.s4|25-33|discusses|O
DDI-MedLine.d80.s4|35-37|the|O
DDI-MedLine.d80.s4|39-48|advantages|O
DDI-MedLine.d80.s4|50-52|and|O
DDI-MedLine.d80.s4|54-66|disadvantages|O
DDI-MedLine.d80.s4|68-69|of|O
DDI-MedLine.d80.s4|71-74|POCs|group
DDI-MedLine.d80.s4|76-78|and|O
DDI-MedLine.d80.s4|80-82|the|O
DDI-MedLine.d80.s4|84-92|magnitude|O
DDI-MedLine.d80.s4|94-96|and|O
DDI-MedLine.d80.s4|98-107|prevalence|O
DDI-MedLine.d80.s4|109-110|of|O
DDI-MedLine.d80.s4|112-116|their|O
DDI-MedLine.d80.s4|118-120|use|O
DDI-MedLine.d80.s4|121-121|.|O
DDI-MedLine.d80.s5|0-5|Future|O
DDI-MedLine.d80.s5|7-12|trends|O
DDI-MedLine.d80.s5|14-16|are|O
DDI-MedLine.d80.s5|18-21|also|O
DDI-MedLine.d80.s5|23-31|predicted|O
DDI-MedLine.d80.s5|32-32|.|O
DDI-MedLine.d80.s6|0-6|Chapter|O
DDI-MedLine.d80.s6|8-8|2|O
DDI-MedLine.d80.s6|10-18|considers|O
DDI-MedLine.d80.s6|20-22|the|O
DDI-MedLine.d80.s6|24-27|mode|O
DDI-MedLine.d80.s6|29-30|of|O
DDI-MedLine.d80.s6|32-37|action|O
DDI-MedLine.d80.s6|38-38|,|O
DDI-MedLine.d80.s6|40-48|including|O
DDI-MedLine.d80.s6|50-58|ovulation|O
DDI-MedLine.d80.s6|60-69|prevention|O
DDI-MedLine.d80.s6|70-70|;|O
DDI-MedLine.d80.s7|0-10|suppression|O
DDI-MedLine.d80.s7|12-13|of|O
DDI-MedLine.d80.s7|15-22|midcycle|O
DDI-MedLine.d80.s7|24-35|gonadotropin|O
DDI-MedLine.d80.s7|37-41|peaks|O
DDI-MedLine.d80.s7|42-42|;|O
DDI-MedLine.d80.s8|0-6|changes|O
DDI-MedLine.d80.s8|8-9|in|O
DDI-MedLine.d80.s8|11-18|cervical|O
DDI-MedLine.d80.s8|20-24|mucus|O
DDI-MedLine.d80.s8|25-25|,|O
DDI-MedLine.d80.s8|27-29|the|O
DDI-MedLine.d80.s8|31-41|endometrium|O
DDI-MedLine.d80.s8|42-42|,|O
DDI-MedLine.d80.s8|44-46|and|O
DDI-MedLine.d80.s8|48-50|the|O
DDI-MedLine.d80.s8|52-60|fallopian|O
DDI-MedLine.d80.s8|62-66|tubes|O
DDI-MedLine.d80.s8|67-67|;|O
DDI-MedLine.d80.s9|0-2|and|O
DDI-MedLine.d80.s9|4-11|clinical|O
DDI-MedLine.d80.s9|13-24|implications|O
DDI-MedLine.d80.s9|25-25|.|O
DDI-MedLine.d80.s10|0-6|Chapter|O
DDI-MedLine.d80.s10|8-8|3|O
DDI-MedLine.d80.s10|10-15|covers|O
DDI-MedLine.d80.s10|17-28|pharmacology|O
DDI-MedLine.d80.s10|30-30|(|O
DDI-MedLine.d80.s10|31-46|pharmacokinetics|O
DDI-MedLine.d80.s10|47-47|,|O
DDI-MedLine.d80.s10|49-64|pharmacodynamics|O
DDI-MedLine.d80.s10|66-68|and|O
DDI-MedLine.d80.s10|70-76|potency|O
DDI-MedLine.d80.s10|77-77|,|O
DDI-MedLine.d80.s10|79-81|and|O
DDI-MedLine.d80.s10|83-90|clinical|O
DDI-MedLine.d80.s10|92-103|implications|O
DDI-MedLine.d80.s10|104-104|)|O
DDI-MedLine.d80.s10|105-105|.|O
DDI-MedLine.d80.s11|0-2|The|O
DDI-MedLine.d80.s11|4-7|next|O
DDI-MedLine.d80.s11|9-15|chapter|O
DDI-MedLine.d80.s11|17-24|presents|O
DDI-MedLine.d80.s11|26-36|information|O
DDI-MedLine.d80.s11|38-39|on|O
DDI-MedLine.d80.s11|41-48|efficacy|O
DDI-MedLine.d80.s11|50-52|and|O
DDI-MedLine.d80.s11|54-62|pregnancy|O
DDI-MedLine.d80.s11|64-71|outcomes|O
DDI-MedLine.d80.s11|73-74|in|O
DDI-MedLine.d80.s11|76-80|terms|O
DDI-MedLine.d80.s11|82-83|of|O
DDI-MedLine.d80.s11|85-93|pregnancy|O
DDI-MedLine.d80.s11|95-99|rates|O
DDI-MedLine.d80.s11|100-100|,|O
DDI-MedLine.d80.s11|102-111|compliance|O
DDI-MedLine.d80.s11|113-115|and|O
DDI-MedLine.d80.s11|117-124|efficacy|O
DDI-MedLine.d80.s11|125-125|,|O
DDI-MedLine.d80.s11|127-133|ectopic|O
DDI-MedLine.d80.s11|135-145|pregnancies|O
DDI-MedLine.d80.s11|146-146|,|O
DDI-MedLine.d80.s11|148-150|the|O
DDI-MedLine.d80.s11|152-158|outcome|O
DDI-MedLine.d80.s11|160-161|of|O
DDI-MedLine.d80.s11|163-173|pregnancies|O
DDI-MedLine.d80.s11|175-183|conceived|O
DDI-MedLine.d80.s11|185-189|while|O
DDI-MedLine.d80.s11|191-195|using|O
DDI-MedLine.d80.s11|197-200|POCs|group
DDI-MedLine.d80.s11|201-201|,|O
DDI-MedLine.d80.s11|203-205|and|O
DDI-MedLine.d80.s11|207-215|fertility|O
DDI-MedLine.d80.s11|217-225|following|O
DDI-MedLine.d80.s11|227-241|discontinuation|O
DDI-MedLine.d80.s11|242-242|.|O
DDI-MedLine.d80.s12|0-6|Chapter|O
DDI-MedLine.d80.s12|8-8|5|O
DDI-MedLine.d80.s12|10-16|focuses|O
DDI-MedLine.d80.s12|18-19|on|O
DDI-MedLine.d80.s12|21-29|metabolic|O
DDI-MedLine.d80.s12|31-37|effects|O
DDI-MedLine.d80.s12|38-38|,|O
DDI-MedLine.d80.s12|40-51|specifically|O
DDI-MedLine.d80.s12|53-57|lipid|O
DDI-MedLine.d80.s12|59-68|metabolism|O
DDI-MedLine.d80.s12|69-69|,|O
DDI-MedLine.d80.s12|71-82|carbohydrate|O
DDI-MedLine.d80.s12|84-93|metabolism|O
DDI-MedLine.d80.s12|95-97|and|O
DDI-MedLine.d80.s12|99-106|diabetes|O
DDI-MedLine.d80.s12|107-107|,|O
DDI-MedLine.d80.s12|109-119|coagulation|O
DDI-MedLine.d80.s12|121-127|factors|O
DDI-MedLine.d80.s12|128-128|,|O
DDI-MedLine.d80.s12|130-132|and|O
DDI-MedLine.d80.s12|134-138|blood|O
DDI-MedLine.d80.s12|140-147|pressure|O
DDI-MedLine.d80.s12|148-148|.|O
DDI-MedLine.d80.s13|0-13|Cardiovascular|O
DDI-MedLine.d80.s13|15-21|disease|O
DDI-MedLine.d80.s13|23-24|is|O
DDI-MedLine.d80.s13|26-35|considered|O
DDI-MedLine.d80.s13|37-38|in|O
DDI-MedLine.d80.s13|40-42|the|O
DDI-MedLine.d80.s13|44-47|next|O
DDI-MedLine.d80.s13|49-55|chapter|O
DDI-MedLine.d80.s13|56-56|,|O
DDI-MedLine.d80.s13|58-60|and|O
DDI-MedLine.d80.s13|62-68|chapter|O
DDI-MedLine.d80.s13|70-70|7|O
DDI-MedLine.d80.s13|72-79|presents|O
DDI-MedLine.d80.s13|81-88|findings|O
DDI-MedLine.d80.s13|90-91|on|O
DDI-MedLine.d80.s13|93-103|endometrial|O
DDI-MedLine.d80.s13|104-104|,|O
DDI-MedLine.d80.s13|106-112|ovarian|O
DDI-MedLine.d80.s13|113-113|,|O
DDI-MedLine.d80.s13|115-122|cervical|O
DDI-MedLine.d80.s13|123-123|,|O
DDI-MedLine.d80.s13|125-130|breast|O
DDI-MedLine.d80.s13|131-131|,|O
DDI-MedLine.d80.s13|133-135|and|O
DDI-MedLine.d80.s13|137-141|other|O
DDI-MedLine.d80.s13|143-149|cancers|O
DDI-MedLine.d80.s13|150-150|.|O
DDI-MedLine.d80.s14|0-0|A|O
DDI-MedLine.d80.s14|2-5|host|O
DDI-MedLine.d80.s14|7-8|of|O
DDI-MedLine.d80.s14|10-14|other|O
DDI-MedLine.d80.s14|16-22|medical|O
DDI-MedLine.d80.s14|24-37|considerations|O
DDI-MedLine.d80.s14|39-41|are|O
DDI-MedLine.d80.s14|43-51|discussed|O
DDI-MedLine.d80.s14|53-54|in|O
DDI-MedLine.d80.s14|56-62|chapter|O
DDI-MedLine.d80.s14|64-64|8|O
DDI-MedLine.d80.s14|65-65|,|O
DDI-MedLine.d80.s14|67-75|including|O
DDI-MedLine.d80.s14|77-86|persistent|O
DDI-MedLine.d80.s14|88-94|ovarian|O
DDI-MedLine.d80.s14|96-104|follicles|O
DDI-MedLine.d80.s14|105-105|;|O
DDI-MedLine.d80.s15|0-11|reproductive|O
DDI-MedLine.d80.s15|13-17|tract|O
DDI-MedLine.d80.s15|19-28|infections|O
DDI-MedLine.d80.s15|29-29|;|O
DDI-MedLine.d80.s16|0-7|abnormal|O
DDI-MedLine.d80.s16|9-15|vaginal|O
DDI-MedLine.d80.s16|17-24|bleeding|O
DDI-MedLine.d80.s16|25-25|;|O
DDI-MedLine.d80.s17|0-6|uterine|O
DDI-MedLine.d80.s17|8-15|fibroids|O
DDI-MedLine.d80.s17|16-16|;|O
DDI-MedLine.d80.s18|0-10|gestational|O
DDI-MedLine.d80.s18|12-24|trophoblastic|O
DDI-MedLine.d80.s18|26-32|disease|O
DDI-MedLine.d80.s18|33-33|;|O
DDI-MedLine.d80.s19|0-5|benign|O
DDI-MedLine.d80.s19|7-12|breast|O
DDI-MedLine.d80.s19|14-20|disease|O
DDI-MedLine.d80.s19|21-21|;|O
DDI-MedLine.d80.s20|0-7|diseases|O
DDI-MedLine.d80.s20|9-10|of|O
DDI-MedLine.d80.s20|12-14|the|O
DDI-MedLine.d80.s20|16-20|liver|O
DDI-MedLine.d80.s20|21-21|,|O
DDI-MedLine.d80.s20|23-33|gallbladder|O
DDI-MedLine.d80.s20|34-34|,|O
DDI-MedLine.d80.s20|36-38|and|O
DDI-MedLine.d80.s20|40-44|bowel|O
DDI-MedLine.d80.s20|45-45|;|O
DDI-MedLine.d80.s21|0-8|endocrine|O
DDI-MedLine.d80.s21|10-20|dysfunction|O
DDI-MedLine.d80.s21|21-21|;|O
DDI-MedLine.d80.s22|0-7|epilepsy|O
DDI-MedLine.d80.s22|8-8|;|O
DDI-MedLine.d80.s23|0-3|bone|O
DDI-MedLine.d80.s23|5-11|density|O
DDI-MedLine.d80.s23|12-12|;|O
DDI-MedLine.d80.s24|0-5|sickle|O
DDI-MedLine.d80.s24|7-10|cell|O
DDI-MedLine.d80.s24|12-18|disease|O
DDI-MedLine.d80.s24|19-19|;|O
DDI-MedLine.d80.s25|0-5|ocular|O
DDI-MedLine.d80.s25|7-13|effects|O
DDI-MedLine.d80.s25|14-14|;|O
DDI-MedLine.d80.s26|0-6|surgery|O
DDI-MedLine.d80.s26|7-7|;|O
DDI-MedLine.d80.s27|0-2|and|O
DDI-MedLine.d80.s27|4-11|overdose|O
DDI-MedLine.d80.s27|12-12|.|O
DDI-MedLine.d80.s28|0-2|The|O
DDI-MedLine.d80.s28|4-7|last|O
DDI-MedLine.d80.s28|9-9|4|O
DDI-MedLine.d80.s28|11-18|chapters|O
DDI-MedLine.d80.s28|20-24|cover|O
DDI-MedLine.d80.s28|26-37|interactions|O
DDI-MedLine.d80.s28|39-42|with|O
DDI-MedLine.d80.s28|44-48|drugs|O
DDI-MedLine.d80.s28|50-52|and|O
DDI-MedLine.d80.s28|54-63|laboratory|O
DDI-MedLine.d80.s28|65-69|tests|O
DDI-MedLine.d80.s28|70-70|,|O
DDI-MedLine.d80.s28|72-77|common|O
DDI-MedLine.d80.s28|79-82|side|O
DDI-MedLine.d80.s28|84-90|effects|O
DDI-MedLine.d80.s28|91-91|,|O
DDI-MedLine.d80.s28|93-98|breast|O
DDI-MedLine.d80.s28|100-106|feeding|O
DDI-MedLine.d80.s28|107-107|,|O
DDI-MedLine.d80.s28|109-111|and|O
DDI-MedLine.d80.s28|113-121|effective|O
DDI-MedLine.d80.s28|123-125|use|O
DDI-MedLine.d80.s28|127-128|of|O
DDI-MedLine.d80.s28|130-133|POCs|group
DDI-MedLine.d80.s28|134-134|.|O
DDI-MedLine.d80.s29|0-10|Information|O
DDI-MedLine.d80.s29|12-13|on|O
DDI-MedLine.d80.s29|15-25|precautions|O
DDI-MedLine.d80.s29|27-29|and|O
DDI-MedLine.d80.s29|31-47|contraindications|O
DDI-MedLine.d80.s29|48-48|,|O
DDI-MedLine.d80.s29|50-60|indications|O
DDI-MedLine.d80.s29|61-61|,|O
DDI-MedLine.d80.s29|63-65|use|O
DDI-MedLine.d80.s29|67-78|instructions|O
DDI-MedLine.d80.s29|79-79|,|O
DDI-MedLine.d80.s29|81-83|and|O
DDI-MedLine.d80.s29|85-96|instructions|O
DDI-MedLine.d80.s29|98-100|for|O
DDI-MedLine.d80.s29|102-112|appropriate|O
DDI-MedLine.d80.s29|114-120|actions|O
DDI-MedLine.d80.s29|122-126|after|O
DDI-MedLine.d80.s29|128-134|missing|O
DDI-MedLine.d80.s29|136-136|a|O
DDI-MedLine.d80.s29|138-141|pill|O
DDI-MedLine.d80.s29|143-144|is|O
DDI-MedLine.d80.s29|146-153|appended|O
DDI-MedLine.d80.s29|154-154|.|O
DDI-DrugBank.d113.s0|0-7|Warfarin|drug
DDI-DrugBank.d113.s0|8-8|:|O
DDI-DrugBank.d113.s0|10-29|Meclofenamate sodium|drug
DDI-DrugBank.d113.s0|31-38|enhances|O
DDI-DrugBank.d113.s0|40-42|the|O
DDI-DrugBank.d113.s0|44-49|effect|O
DDI-DrugBank.d113.s0|51-52|of|O
DDI-DrugBank.d113.s0|54-61|warfarin|drug
DDI-DrugBank.d113.s0|62-62|.|O
DDI-DrugBank.d113.s1|0-8|Therefore|O
DDI-DrugBank.d113.s1|9-9|,|O
DDI-DrugBank.d113.s1|11-14|when|O
DDI-DrugBank.d113.s1|16-35|meclofenamate sodium|drug
DDI-DrugBank.d113.s1|37-38|is|O
DDI-DrugBank.d113.s1|40-44|given|O
DDI-DrugBank.d113.s1|46-47|to|O
DDI-DrugBank.d113.s1|49-49|a|O
DDI-DrugBank.d113.s1|51-57|patient|O
DDI-DrugBank.d113.s1|59-67|receiving|O
DDI-DrugBank.d113.s1|69-76|warfarin|drug
DDI-DrugBank.d113.s1|77-77|,|O
DDI-DrugBank.d113.s1|79-81|the|O
DDI-DrugBank.d113.s1|83-88|dosage|O
DDI-DrugBank.d113.s1|90-91|of|O
DDI-DrugBank.d113.s1|93-100|warfarin|drug
DDI-DrugBank.d113.s1|102-107|should|O
DDI-DrugBank.d113.s1|109-110|be|O
DDI-DrugBank.d113.s1|112-118|reduced|O
DDI-DrugBank.d113.s1|120-121|to|O
DDI-DrugBank.d113.s1|123-129|prevent|O
DDI-DrugBank.d113.s1|131-139|excessive|O
DDI-DrugBank.d113.s1|141-152|prolongation|O
DDI-DrugBank.d113.s1|154-155|of|O
DDI-DrugBank.d113.s1|157-159|the|O
DDI-DrugBank.d113.s1|161-171|prothrombin|O
DDI-DrugBank.d113.s1|173-176|time|O
DDI-DrugBank.d113.s1|177-177|.|O
DDI-DrugBank.d113.s2|0-6|Aspirin|brand
DDI-DrugBank.d113.s2|7-7|:|O
DDI-DrugBank.d113.s2|9-18|Concurrent|O
DDI-DrugBank.d113.s2|20-33|administration|O
DDI-DrugBank.d113.s2|35-36|of|O
DDI-DrugBank.d113.s2|38-44|aspirin|brand
DDI-DrugBank.d113.s2|46-48|may|O
DDI-DrugBank.d113.s2|50-54|lower|O
DDI-DrugBank.d113.s2|56-75|meclofenamate sodium|drug
DDI-DrugBank.d113.s2|77-82|plasma|O
DDI-DrugBank.d113.s2|84-89|levels|O
DDI-DrugBank.d113.s2|90-90|,|O
DDI-DrugBank.d113.s2|92-99|possibly|O
DDI-DrugBank.d113.s2|101-102|by|O
DDI-DrugBank.d113.s2|104-112|competing|O
DDI-DrugBank.d113.s2|114-116|for|O
DDI-DrugBank.d113.s2|118-132|protein-binding|O
DDI-DrugBank.d113.s2|134-138|sites|O
DDI-DrugBank.d113.s2|139-139|.|O
DDI-DrugBank.d113.s3|0-2|The|O
DDI-DrugBank.d113.s3|4-10|urinary|O
DDI-DrugBank.d113.s3|12-20|excretion|O
DDI-DrugBank.d113.s3|22-23|of|O
DDI-DrugBank.d113.s3|25-44|meclofenamate sodium|drug
DDI-DrugBank.d113.s3|46-47|is|O
DDI-DrugBank.d113.s3|49-58|unaffected|O
DDI-DrugBank.d113.s3|60-61|by|O
DDI-DrugBank.d113.s3|63-69|aspirin|brand
DDI-DrugBank.d113.s3|70-70|,|O
DDI-DrugBank.d113.s3|72-81|indicating|O
DDI-DrugBank.d113.s3|83-84|no|O
DDI-DrugBank.d113.s3|86-91|change|O
DDI-DrugBank.d113.s3|93-94|in|O
DDI-DrugBank.d113.s3|96-115|meclofenamate sodium|drug
DDI-DrugBank.d113.s3|117-126|absorption|O
DDI-DrugBank.d113.s3|127-127|.|O
DDI-DrugBank.d113.s4|0-19|Meclofenamate sodium|drug
DDI-DrugBank.d113.s4|21-24|does|O
DDI-DrugBank.d113.s4|26-28|not|O
DDI-DrugBank.d113.s4|30-35|affect|O
DDI-DrugBank.d113.s4|37-41|serum|O
DDI-DrugBank.d113.s4|43-52|salicylate|group
DDI-DrugBank.d113.s4|54-59|levels|O
DDI-DrugBank.d113.s4|60-60|.|O
DDI-DrugBank.d113.s5|0-6|Greater|O
DDI-DrugBank.d113.s5|8-12|fecal|O
DDI-DrugBank.d113.s5|14-18|blood|O
DDI-DrugBank.d113.s5|20-23|loss|O
DDI-DrugBank.d113.s5|25-31|results|O
DDI-DrugBank.d113.s5|33-36|from|O
DDI-DrugBank.d113.s5|38-48|concomitant|O
DDI-DrugBank.d113.s5|50-63|administration|O
DDI-DrugBank.d113.s5|65-66|of|O
DDI-DrugBank.d113.s5|68-71|both|O
DDI-DrugBank.d113.s5|73-77|drugs|O
DDI-DrugBank.d113.s5|79-82|than|O
DDI-DrugBank.d113.s5|84-87|from|O
DDI-DrugBank.d113.s5|89-94|either|O
DDI-DrugBank.d113.s5|96-99|drug|O
DDI-DrugBank.d113.s5|101-105|alone|O
DDI-DrugBank.d113.s5|106-106|.|O
DDI-DrugBank.d113.s6|0-11|Propoxyphene|drug
DDI-DrugBank.d113.s6|12-12|:|O
DDI-DrugBank.d113.s6|14-16|The|O
DDI-DrugBank.d113.s6|18-27|concurrent|O
DDI-DrugBank.d113.s6|29-42|administration|O
DDI-DrugBank.d113.s6|44-45|of|O
DDI-DrugBank.d113.s6|47-72|propoxyphene hydrochloride|drug
DDI-DrugBank.d113.s6|74-77|does|O
DDI-DrugBank.d113.s6|79-81|not|O
DDI-DrugBank.d113.s6|83-88|affect|O
DDI-DrugBank.d113.s6|90-92|the|O
DDI-DrugBank.d113.s6|94-108|bioavailability|O
DDI-DrugBank.d113.s6|110-111|of|O
DDI-DrugBank.d113.s6|113-132|meclofenamate sodium|drug
DDI-DrugBank.d113.s6|133-133|.|O
DDI-DrugBank.d113.s7|0-7|Antacids|group
DDI-DrugBank.d113.s7|8-8|:|O
DDI-DrugBank.d113.s7|10-20|Concomitant|O
DDI-DrugBank.d113.s7|22-35|administration|O
DDI-DrugBank.d113.s7|37-38|of|O
DDI-DrugBank.d113.s7|40-47|aluminum|drug
DDI-DrugBank.d113.s7|49-51|and|O
DDI-DrugBank.d113.s7|53-61|magnesium|drug
DDI-DrugBank.d113.s7|63-72|hydroxides|O
DDI-DrugBank.d113.s7|74-77|does|O
DDI-DrugBank.d113.s7|79-81|not|O
DDI-DrugBank.d113.s7|83-91|interfere|O
DDI-DrugBank.d113.s7|93-96|with|O
DDI-DrugBank.d113.s7|98-107|absorption|O
DDI-DrugBank.d113.s7|109-110|of|O
DDI-DrugBank.d113.s7|112-131|meclofenamate sodium|drug
DDI-DrugBank.d113.s7|132-132|.|O
DDI-DrugBank.d385.s0|0-1|It|O
DDI-DrugBank.d385.s0|3-4|is|O
DDI-DrugBank.d385.s0|6-8|not|O
DDI-DrugBank.d385.s0|10-14|known|O
DDI-DrugBank.d385.s0|16-17|if|O
DDI-DrugBank.d385.s0|19-26|REGRANEX|brand
DDI-DrugBank.d385.s0|28-30|Gel|O
DDI-DrugBank.d385.s0|32-40|interacts|O
DDI-DrugBank.d385.s0|42-45|with|O
DDI-DrugBank.d385.s0|47-51|other|O
DDI-DrugBank.d385.s0|53-59|topical|O
DDI-DrugBank.d385.s0|61-71|medications|O
DDI-DrugBank.d385.s0|73-79|applied|O
DDI-DrugBank.d385.s0|81-82|to|O
DDI-DrugBank.d385.s0|84-86|the|O
DDI-DrugBank.d385.s0|88-92|ulcer|O
DDI-DrugBank.d385.s0|94-97|site|O
DDI-DrugBank.d385.s0|98-98|.|O
DDI-DrugBank.d385.s1|0-2|The|O
DDI-DrugBank.d385.s1|4-6|use|O
DDI-DrugBank.d385.s1|8-9|of|O
DDI-DrugBank.d385.s1|11-18|REGRANEX|brand
DDI-DrugBank.d385.s1|20-22|Gel|O
DDI-DrugBank.d385.s1|24-27|with|O
DDI-DrugBank.d385.s1|29-33|other|O
DDI-DrugBank.d385.s1|35-41|topical|O
DDI-DrugBank.d385.s1|43-47|drugs|O
DDI-DrugBank.d385.s1|49-51|has|O
DDI-DrugBank.d385.s1|53-55|not|O
DDI-DrugBank.d385.s1|57-60|been|O
DDI-DrugBank.d385.s1|62-68|studied|O
DDI-DrugBank.d385.s1|69-69|.|O
DDI-DrugBank.d31.s0|0-13|MAO inhibitors|group
DDI-DrugBank.d31.s0|15-20|should|O
DDI-DrugBank.d31.s0|22-23|be|O
DDI-DrugBank.d31.s0|25-28|used|O
DDI-DrugBank.d31.s0|30-33|with|O
DDI-DrugBank.d31.s0|35-41|caution|O
DDI-DrugBank.d31.s0|43-44|in|O
DDI-DrugBank.d31.s0|46-53|patients|O
DDI-DrugBank.d31.s0|55-63|receiving|O
DDI-DrugBank.d31.s0|65-75|hydralazine|drug
DDI-DrugBank.d31.s0|76-76|.|O
DDI-DrugBank.d31.s1|0-3|When|O
DDI-DrugBank.d31.s1|5-9|other|O
DDI-DrugBank.d31.s1|11-16|potent|O
DDI-DrugBank.d31.s1|18-25|parental|O
DDI-DrugBank.d31.s1|27-48|antihypertensive drugs|group
DDI-DrugBank.d31.s1|49-49|,|O
DDI-DrugBank.d31.s1|51-54|such|O
DDI-DrugBank.d31.s1|56-57|as|O
DDI-DrugBank.d31.s1|59-67|diazoxide|drug
DDI-DrugBank.d31.s1|68-68|,|O
DDI-DrugBank.d31.s1|70-72|are|O
DDI-DrugBank.d31.s1|74-77|used|O
DDI-DrugBank.d31.s1|79-80|in|O
DDI-DrugBank.d31.s1|82-92|combination|O
DDI-DrugBank.d31.s1|94-97|with|O
DDI-DrugBank.d31.s1|99-109|hydralazine|drug
DDI-DrugBank.d31.s1|110-110|,|O
DDI-DrugBank.d31.s1|112-119|patients|O
DDI-DrugBank.d31.s1|121-126|should|O
DDI-DrugBank.d31.s1|128-129|be|O
DDI-DrugBank.d31.s1|131-142|continuously|O
DDI-DrugBank.d31.s1|144-151|observed|O
DDI-DrugBank.d31.s1|153-155|for|O
DDI-DrugBank.d31.s1|157-163|several|O
DDI-DrugBank.d31.s1|165-169|hours|O
DDI-DrugBank.d31.s1|171-173|for|O
DDI-DrugBank.d31.s1|175-177|any|O
DDI-DrugBank.d31.s1|179-187|excessive|O
DDI-DrugBank.d31.s1|189-192|fall|O
DDI-DrugBank.d31.s1|194-195|in|O
DDI-DrugBank.d31.s1|197-201|blood|O
DDI-DrugBank.d31.s1|203-210|pressure|O
DDI-DrugBank.d31.s1|211-211|.|O
DDI-DrugBank.d31.s2|0-7|Profound|O
DDI-DrugBank.d31.s2|9-19|hypotensive|O
DDI-DrugBank.d31.s2|21-28|episodes|O
DDI-DrugBank.d31.s2|30-32|may|O
DDI-DrugBank.d31.s2|34-38|occur|O
DDI-DrugBank.d31.s2|40-43|when|O
DDI-DrugBank.d31.s2|45-53|diazoxide|drug
DDI-DrugBank.d31.s2|55-63|infection|O
DDI-DrugBank.d31.s2|65-67|and|O
DDI-DrugBank.d31.s2|69-79|hydralazine|drug
DDI-DrugBank.d31.s2|81-83|are|O
DDI-DrugBank.d31.s2|85-88|used|O
DDI-DrugBank.d31.s2|90-102|concomitantly|O
DDI-DrugBank.d31.s2|103-103|.|O
DDI-DrugBank.d31.s3|0-12|Beta-blockers|group
DDI-DrugBank.d31.s3|14-14|(|O
DDI-DrugBank.d31.s3|15-24|metoprolol|drug
DDI-DrugBank.d31.s3|25-25|,|O
DDI-DrugBank.d31.s3|27-37|propranolol|drug
DDI-DrugBank.d31.s3|38-38|)|O
DDI-DrugBank.d31.s3|40-44|serum|O
DDI-DrugBank.d31.s3|46-59|concentrations|O
DDI-DrugBank.d31.s3|61-63|and|O
DDI-DrugBank.d31.s3|65-77|pharmacologic|O
DDI-DrugBank.d31.s3|79-85|effects|O
DDI-DrugBank.d31.s3|87-89|may|O
DDI-DrugBank.d31.s3|91-92|be|O
DDI-DrugBank.d31.s3|94-102|increased|O
DDI-DrugBank.d31.s3|103-103|.|O
DDI-DrugBank.d31.s4|0-6|Monitor|O
DDI-DrugBank.d31.s4|8-21|cardiovascular|O
DDI-DrugBank.d31.s4|23-28|status|O
DDI-DrugBank.d31.s4|29-29|.|O
DDI-DrugBank.d31.s5|0-10|Propranolol|drug
DDI-DrugBank.d31.s5|12-20|increases|O
DDI-DrugBank.d31.s5|22-33|hydralazines|drug
DDI-DrugBank.d31.s5|35-39|serum|O
DDI-DrugBank.d31.s5|41-54|concentrations|O
DDI-DrugBank.d31.s5|55-55|.|O
DDI-DrugBank.d31.s6|0-9|Acebutolol|drug
DDI-DrugBank.d31.s6|10-10|,|O
DDI-DrugBank.d31.s6|12-19|atenolol|drug
DDI-DrugBank.d31.s6|20-20|,|O
DDI-DrugBank.d31.s6|22-24|and|O
DDI-DrugBank.d31.s6|26-32|nadolol|drug
DDI-DrugBank.d31.s6|34-34|(|O
DDI-DrugBank.d31.s6|35-37|low|O
DDI-DrugBank.d31.s6|39-45|hepatic|O
DDI-DrugBank.d31.s6|47-55|clearance|O
DDI-DrugBank.d31.s6|57-58|or|O
DDI-DrugBank.d31.s6|60-61|no|O
DDI-DrugBank.d31.s6|63-72|first-pass|O
DDI-DrugBank.d31.s6|74-83|metabolism|O
DDI-DrugBank.d31.s6|84-84|)|O
DDI-DrugBank.d31.s6|86-88|are|O
DDI-DrugBank.d31.s6|90-97|unlikely|O
DDI-DrugBank.d31.s6|99-100|to|O
DDI-DrugBank.d31.s6|102-103|be|O
DDI-DrugBank.d31.s6|105-112|affected|O
DDI-DrugBank.d31.s6|113-113|.|O
DDI-DrugBank.d31.s7|0-5|NSAIDs|group
DDI-DrugBank.d31.s7|7-9|may|O
DDI-DrugBank.d31.s7|11-18|decrease|O
DDI-DrugBank.d31.s7|20-22|the|O
DDI-DrugBank.d31.s7|24-34|hemodynamic|O
DDI-DrugBank.d31.s7|36-42|effects|O
DDI-DrugBank.d31.s7|44-45|of|O
DDI-DrugBank.d31.s7|47-57|hydralazine|drug
DDI-DrugBank.d31.s7|58-58|;|O
DDI-DrugBank.d31.s8|0-4|avoid|O
DDI-DrugBank.d31.s8|6-8|use|O
DDI-DrugBank.d31.s8|10-11|if|O
DDI-DrugBank.d31.s8|13-20|possible|O
DDI-DrugBank.d31.s8|22-23|or|O
DDI-DrugBank.d31.s8|25-31|closely|O
DDI-DrugBank.d31.s8|33-39|monitor|O
DDI-DrugBank.d31.s8|41-54|cardiovascular|O
DDI-DrugBank.d31.s8|56-61|status|O
DDI-DrugBank.d31.s8|63-64|at|O
DDI-DrugBank.d31.s8|66-68|the|O
DDI-DrugBank.d31.s8|70-72|end|O
DDI-DrugBank.d31.s8|74-75|of|O
DDI-DrugBank.d31.s8|77-80|drug|O
DDI-DrugBank.d31.s8|82-93|interactions|O
DDI-MedLine.d217.s0|0-10|Interaction|O
DDI-MedLine.d217.s0|12-13|of|O
DDI-MedLine.d217.s0|15-23|celecoxib|drug
DDI-MedLine.d217.s0|25-28|with|O
DDI-MedLine.d217.s0|30-38|different|O
DDI-MedLine.d217.s0|40-56|anti-cancer drugs|group
DDI-MedLine.d217.s0|58-59|is|O
DDI-MedLine.d217.s0|61-72|antagonistic|O
DDI-MedLine.d217.s0|74-75|in|O
DDI-MedLine.d217.s0|77-82|breast|O
DDI-MedLine.d217.s0|84-86|but|O
DDI-MedLine.d217.s0|88-90|not|O
DDI-MedLine.d217.s0|92-93|in|O
DDI-MedLine.d217.s0|95-99|other|O
DDI-MedLine.d217.s0|101-106|cancer|O
DDI-MedLine.d217.s0|108-112|cells|O
DDI-MedLine.d217.s0|113-113|.|O
DDI-MedLine.d217.s1|0-8|Celecoxib|drug
DDI-MedLine.d217.s1|9-9|,|O
DDI-MedLine.d217.s1|11-12|an|O
DDI-MedLine.d217.s1|14-22|inhibitor|O
DDI-MedLine.d217.s1|24-25|of|O
DDI-MedLine.d217.s1|27-42|cyclooxygenase-2|O
DDI-MedLine.d217.s1|43-43|,|O
DDI-MedLine.d217.s1|45-46|is|O
DDI-MedLine.d217.s1|48-52|being|O
DDI-MedLine.d217.s1|54-65|investigated|O
DDI-MedLine.d217.s1|67-69|for|O
DDI-MedLine.d217.s1|71-81|enhancement|O
DDI-MedLine.d217.s1|83-84|of|O
DDI-MedLine.d217.s1|86-97|chemotherapy|O
DDI-MedLine.d217.s1|99-106|efficacy|O
DDI-MedLine.d217.s1|108-109|in|O
DDI-MedLine.d217.s1|111-116|cancer|O
DDI-MedLine.d217.s1|118-125|clinical|O
DDI-MedLine.d217.s1|127-132|trials|O
DDI-MedLine.d217.s1|133-133|.|O
DDI-MedLine.d217.s2|0-3|This|O
DDI-MedLine.d217.s2|5-9|study|O
DDI-MedLine.d217.s2|11-22|investigates|O
DDI-MedLine.d217.s2|24-26|the|O
DDI-MedLine.d217.s2|28-34|ability|O
DDI-MedLine.d217.s2|36-37|of|O
DDI-MedLine.d217.s2|39-65|cyclooxygenase-2 inhibitors|group
DDI-MedLine.d217.s2|67-68|to|O
DDI-MedLine.d217.s2|70-78|sensitize|O
DDI-MedLine.d217.s2|80-84|cells|O
DDI-MedLine.d217.s2|86-89|from|O
DDI-MedLine.d217.s2|91-99|different|O
DDI-MedLine.d217.s2|101-107|origins|O
DDI-MedLine.d217.s2|109-110|to|O
DDI-MedLine.d217.s2|112-118|several|O
DDI-MedLine.d217.s2|120-142|chemotherapeutic agents|group
DDI-MedLine.d217.s2|143-143|.|O
DDI-MedLine.d217.s3|0-2|The|O
DDI-MedLine.d217.s3|4-9|effect|O
DDI-MedLine.d217.s3|11-12|of|O
DDI-MedLine.d217.s3|14-16|the|O
DDI-MedLine.d217.s3|18-21|drug|O
DDI-MedLine.d217.s3|22-23|'s|O
DDI-MedLine.d217.s3|25-33|mechanism|O
DDI-MedLine.d217.s3|35-36|of|O
DDI-MedLine.d217.s3|38-43|action|O
DDI-MedLine.d217.s3|45-47|and|O
DDI-MedLine.d217.s3|49-56|sequence|O
DDI-MedLine.d217.s3|58-59|of|O
DDI-MedLine.d217.s3|61-74|administration|O
DDI-MedLine.d217.s3|76-78|are|O
DDI-MedLine.d217.s3|80-83|also|O
DDI-MedLine.d217.s3|85-96|investigated|O
DDI-MedLine.d217.s3|97-97|.|O
DDI-MedLine.d217.s4|0-2|The|O
DDI-MedLine.d217.s4|4-14|sensitivity|O
DDI-MedLine.d217.s4|15-15|,|O
DDI-MedLine.d217.s4|17-20|cell|O
DDI-MedLine.d217.s4|22-26|cycle|O
DDI-MedLine.d217.s4|27-27|,|O
DDI-MedLine.d217.s4|29-37|apoptosis|O
DDI-MedLine.d217.s4|39-41|and|O
DDI-MedLine.d217.s4|43-45|DNA|O
DDI-MedLine.d217.s4|47-52|damage|O
DDI-MedLine.d217.s4|54-55|of|O
DDI-MedLine.d217.s4|57-60|five|O
DDI-MedLine.d217.s4|62-70|different|O
DDI-MedLine.d217.s4|72-77|cancer|O
DDI-MedLine.d217.s4|79-82|cell|O
DDI-MedLine.d217.s4|84-88|lines|O
DDI-MedLine.d217.s4|90-90|(|O
DDI-MedLine.d217.s4|91-94|HeLa|O
DDI-MedLine.d217.s4|95-95|,|O
DDI-MedLine.d217.s4|97-102|HCT116|O
DDI-MedLine.d217.s4|103-103|,|O
DDI-MedLine.d217.s4|105-109|HepG2|O
DDI-MedLine.d217.s4|110-110|,|O
DDI-MedLine.d217.s4|112-115|MCF7|O
DDI-MedLine.d217.s4|117-119|and|O
DDI-MedLine.d217.s4|121-124|U251|O
DDI-MedLine.d217.s4|125-125|)|O
DDI-MedLine.d217.s4|127-128|to|O
DDI-MedLine.d217.s4|130-133|5-FU|drug
DDI-MedLine.d217.s4|134-134|,|O
DDI-MedLine.d217.s4|136-144|cisplatin|drug
DDI-MedLine.d217.s4|145-145|,|O
DDI-MedLine.d217.s4|147-157|doxorubicin|drug
DDI-MedLine.d217.s4|159-161|and|O
DDI-MedLine.d217.s4|163-171|etoposide|drug
DDI-MedLine.d217.s4|163-171|etoposide|drug
DDI-MedLine.d217.s4|185-193|following|O
DDI-MedLine.d217.s4|195-203|different|O
DDI-MedLine.d217.s4|205-214|incubation|O
DDI-MedLine.d217.s4|216-224|schedules|O
DDI-MedLine.d217.s4|226-229|were|O
DDI-MedLine.d217.s4|231-238|analyzed|O
DDI-MedLine.d217.s4|239-239|.|O
DDI-MedLine.d217.s5|0-1|We|O
DDI-MedLine.d217.s5|3-7|found|O
DDI-MedLine.d217.s5|9-18|antagonism|O
DDI-MedLine.d217.s5|20-26|between|O
DDI-MedLine.d217.s5|28-36|celecoxib|drug
DDI-MedLine.d217.s5|38-40|and|O
DDI-MedLine.d217.s5|42-44|the|O
DDI-MedLine.d217.s5|46-49|four|O
DDI-MedLine.d217.s5|51-55|drugs|O
DDI-MedLine.d217.s5|57-58|in|O
DDI-MedLine.d217.s5|60-62|the|O
DDI-MedLine.d217.s5|64-69|breast|O
DDI-MedLine.d217.s5|71-76|cancer|O
DDI-MedLine.d217.s5|78-82|cells|O
DDI-MedLine.d217.s5|84-87|MCF7|O
DDI-MedLine.d217.s5|89-97|following|O
DDI-MedLine.d217.s5|99-101|all|O
DDI-MedLine.d217.s5|103-112|incubation|O
DDI-MedLine.d217.s5|114-122|schedules|O
DDI-MedLine.d217.s5|124-126|and|O
DDI-MedLine.d217.s5|128-134|between|O
DDI-MedLine.d217.s5|136-144|celecoxib|drug
DDI-MedLine.d217.s5|146-148|and|O
DDI-MedLine.d217.s5|150-160|doxorubicin|drug
DDI-MedLine.d217.s5|162-163|in|O
DDI-MedLine.d217.s5|165-167|all|O
DDI-MedLine.d217.s5|169-172|cell|O
DDI-MedLine.d217.s5|174-178|lines|O
DDI-MedLine.d217.s5|180-185|except|O
DDI-MedLine.d217.s5|187-189|for|O
DDI-MedLine.d217.s5|191-193|two|O
DDI-MedLine.d217.s5|195-206|combinations|O
DDI-MedLine.d217.s5|208-209|in|O
DDI-MedLine.d217.s5|211-216|HCT116|O
DDI-MedLine.d217.s5|218-222|cells|O
DDI-MedLine.d217.s5|223-223|.|O
DDI-MedLine.d217.s6|0-8|Celecoxib|drug
DDI-MedLine.d217.s6|10-13|with|O
DDI-MedLine.d217.s6|15-17|the|O
DDI-MedLine.d217.s6|19-23|other|O
DDI-MedLine.d217.s6|25-29|three|O
DDI-MedLine.d217.s6|31-35|drugs|O
DDI-MedLine.d217.s6|37-38|in|O
DDI-MedLine.d217.s6|40-42|the|O
DDI-MedLine.d217.s6|44-52|remaining|O
DDI-MedLine.d217.s6|54-57|four|O
DDI-MedLine.d217.s6|59-62|cell|O
DDI-MedLine.d217.s6|64-68|lines|O
DDI-MedLine.d217.s6|70-77|resulted|O
DDI-MedLine.d217.s6|79-80|in|O
DDI-MedLine.d217.s6|82-89|variable|O
DDI-MedLine.d217.s6|91-102|interactions|O
DDI-MedLine.d217.s6|103-103|.|O
DDI-MedLine.d217.s7|0-10|Mechanistic|O
DDI-MedLine.d217.s7|12-25|investigations|O
DDI-MedLine.d217.s7|27-34|revealed|O
DDI-MedLine.d217.s7|36-39|that|O
DDI-MedLine.d217.s7|41-49|celecoxib|drug
DDI-MedLine.d217.s7|51-56|exerts|O
DDI-MedLine.d217.s7|58-66|different|O
DDI-MedLine.d217.s7|68-76|molecular|O
DDI-MedLine.d217.s7|78-84|effects|O
DDI-MedLine.d217.s7|86-87|in|O
DDI-MedLine.d217.s7|89-97|different|O
DDI-MedLine.d217.s7|99-103|cells|O
DDI-MedLine.d217.s7|104-104|.|O
DDI-MedLine.d217.s8|0-1|In|O
DDI-MedLine.d217.s8|3-6|some|O
DDI-MedLine.d217.s8|8-12|lines|O
DDI-MedLine.d217.s8|13-13|,|O
DDI-MedLine.d217.s8|15-16|it|O
DDI-MedLine.d217.s8|18-26|abrogates|O
DDI-MedLine.d217.s8|28-30|the|O
DDI-MedLine.d217.s8|32-43|drug-induced|O
DDI-MedLine.d217.s8|45-48|G2/M|O
DDI-MedLine.d217.s8|50-55|arrest|O
DDI-MedLine.d217.s8|57-65|enhancing|O
DDI-MedLine.d217.s8|67-76|pre-mature|O
DDI-MedLine.d217.s8|78-82|entry|O
DDI-MedLine.d217.s8|84-87|into|O
DDI-MedLine.d217.s8|89-95|mitosis|O
DDI-MedLine.d217.s8|97-100|with|O
DDI-MedLine.d217.s8|102-108|damaged|O
DDI-MedLine.d217.s8|110-112|DNA|O
DDI-MedLine.d217.s8|114-117|thus|O
DDI-MedLine.d217.s8|119-128|increasing|O
DDI-MedLine.d217.s8|130-138|apoptosis|O
DDI-MedLine.d217.s8|140-142|and|O
DDI-MedLine.d217.s8|144-152|resulting|O
DDI-MedLine.d217.s8|154-155|in|O
DDI-MedLine.d217.s8|157-165|synergism|O
DDI-MedLine.d217.s8|166-166|.|O
DDI-MedLine.d217.s9|0-1|In|O
DDI-MedLine.d217.s9|3-7|other|O
DDI-MedLine.d217.s9|9-13|cells|O
DDI-MedLine.d217.s9|14-14|,|O
DDI-MedLine.d217.s9|16-17|it|O
DDI-MedLine.d217.s9|19-26|enhances|O
DDI-MedLine.d217.s9|28-39|drug-induced|O
DDI-MedLine.d217.s9|41-44|G2/M|O
DDI-MedLine.d217.s9|46-51|arrest|O
DDI-MedLine.d217.s9|53-60|allowing|O
DDI-MedLine.d217.s9|62-65|time|O
DDI-MedLine.d217.s9|67-68|to|O
DDI-MedLine.d217.s9|70-75|repair|O
DDI-MedLine.d217.s9|77-88|drug-induced|O
DDI-MedLine.d217.s9|90-92|DNA|O
DDI-MedLine.d217.s9|94-99|damage|O
DDI-MedLine.d217.s9|101-106|before|O
DDI-MedLine.d217.s9|108-112|entry|O
DDI-MedLine.d217.s9|114-117|into|O
DDI-MedLine.d217.s9|119-125|mitosis|O
DDI-MedLine.d217.s9|127-129|and|O
DDI-MedLine.d217.s9|131-140|decreasing|O
DDI-MedLine.d217.s9|142-145|cell|O
DDI-MedLine.d217.s9|147-151|death|O
DDI-MedLine.d217.s9|153-161|resulting|O
DDI-MedLine.d217.s9|163-164|in|O
DDI-MedLine.d217.s9|166-175|antagonism|O
DDI-MedLine.d217.s9|176-176|.|O
DDI-MedLine.d217.s10|0-1|In|O
DDI-MedLine.d217.s10|3-6|some|O
DDI-MedLine.d217.s10|8-18|synergistic|O
DDI-MedLine.d217.s10|20-31|combinations|O
DDI-MedLine.d217.s10|32-32|,|O
DDI-MedLine.d217.s10|34-50|celecoxib-induced|O
DDI-MedLine.d217.s10|52-61|abrogation|O
DDI-MedLine.d217.s10|63-64|of|O
DDI-MedLine.d217.s10|66-69|G2/M|O
DDI-MedLine.d217.s10|71-76|arrest|O
DDI-MedLine.d217.s10|78-80|was|O
DDI-MedLine.d217.s10|82-84|not|O
DDI-MedLine.d217.s10|86-95|associated|O
DDI-MedLine.d217.s10|97-100|with|O
DDI-MedLine.d217.s10|102-110|apoptosis|O
DDI-MedLine.d217.s10|112-114|but|O
DDI-MedLine.d217.s10|116-124|permanent|O
DDI-MedLine.d217.s10|126-131|arrest|O
DDI-MedLine.d217.s10|133-134|in|O
DDI-MedLine.d217.s10|136-137|G1|O
DDI-MedLine.d217.s10|139-143|phase|O
DDI-MedLine.d217.s10|144-144|.|O
DDI-MedLine.d217.s11|0-4|These|O
DDI-MedLine.d217.s11|6-12|results|O
DDI-MedLine.d217.s11|13-13|,|O
DDI-MedLine.d217.s11|15-16|if|O
DDI-MedLine.d217.s11|18-26|confirmed|O
DDI-MedLine.d217.s11|28-34|in-vivo|O
DDI-MedLine.d217.s11|35-35|,|O
DDI-MedLine.d217.s11|37-44|indicate|O
DDI-MedLine.d217.s11|46-49|that|O
DDI-MedLine.d217.s11|51-59|celecoxib|drug
DDI-MedLine.d217.s11|61-62|is|O
DDI-MedLine.d217.s11|64-66|not|O
DDI-MedLine.d217.s11|68-68|a|O
DDI-MedLine.d217.s11|70-77|suitable|O
DDI-MedLine.d217.s11|79-93|chemosensitizer|O
DDI-MedLine.d217.s11|95-97|for|O
DDI-MedLine.d217.s11|99-104|breast|O
DDI-MedLine.d217.s11|106-111|cancer|O
DDI-MedLine.d217.s11|113-114|or|O
DDI-MedLine.d217.s11|116-119|with|O
DDI-MedLine.d217.s11|121-131|doxorubicin|drug
DDI-MedLine.d217.s11|133-135|for|O
DDI-MedLine.d217.s11|137-141|other|O
DDI-MedLine.d217.s11|143-149|cancers|O
DDI-MedLine.d217.s11|150-150|.|O
DDI-MedLine.d217.s12|0-7|Moreover|O
DDI-MedLine.d217.s12|8-8|,|O
DDI-MedLine.d217.s12|10-20|combination|O
DDI-MedLine.d217.s12|22-23|of|O
DDI-MedLine.d217.s12|25-33|celecoxib|drug
DDI-MedLine.d217.s12|35-38|with|O
DDI-MedLine.d217.s12|40-44|other|O
DDI-MedLine.d217.s12|46-50|drugs|O
DDI-MedLine.d217.s12|52-57|should|O
DDI-MedLine.d217.s12|59-60|be|O
DDI-MedLine.d217.s12|62-69|tailored|O
DDI-MedLine.d217.s12|71-72|to|O
DDI-MedLine.d217.s12|74-76|the|O
DDI-MedLine.d217.s12|78-82|tumor|O
DDI-MedLine.d217.s12|84-87|type|O
DDI-MedLine.d217.s12|88-88|,|O
DDI-MedLine.d217.s12|90-93|drug|O
DDI-MedLine.d217.s12|95-97|and|O
DDI-MedLine.d217.s12|99-112|administration|O
DDI-MedLine.d217.s12|114-121|schedule|O
DDI-MedLine.d217.s12|122-122|.|O
DDI-DrugBank.d139.s0|0-13|Broad-Spectrum|group
DDI-DrugBank.d139.s0|15-40|Antibiotics-Broad-spectrum|O
DDI-DrugBank.d139.s0|42-52|antibiotics|group
DDI-DrugBank.d139.s0|54-56|may|O
DDI-DrugBank.d139.s0|58-66|sterilize|O
DDI-DrugBank.d139.s0|68-70|the|O
DDI-DrugBank.d139.s0|72-76|bowel|O
DDI-DrugBank.d139.s0|78-80|and|O
DDI-DrugBank.d139.s0|82-89|decrease|O
DDI-DrugBank.d139.s0|91-93|the|O
DDI-DrugBank.d139.s0|95-103|vitamin K|group
DDI-DrugBank.d139.s0|105-116|contribution|O
DDI-DrugBank.d139.s0|118-119|to|O
DDI-DrugBank.d139.s0|121-123|the|O
DDI-DrugBank.d139.s0|125-128|body|O
DDI-DrugBank.d139.s0|130-131|by|O
DDI-DrugBank.d139.s0|133-135|the|O
DDI-DrugBank.d139.s0|137-146|intestinal|O
DDI-DrugBank.d139.s0|148-157|microflora|O
DDI-DrugBank.d139.s0|158-158|.|O
DDI-DrugBank.d139.s1|0-28|Cephalosporins-Cephalosporins|group
DDI-DrugBank.d139.s1|30-39|containing|O
DDI-DrugBank.d139.s1|41-44|side|O
DDI-DrugBank.d139.s1|46-51|chains|O
DDI-DrugBank.d139.s1|53-54|of|O
DDI-DrugBank.d139.s1|56-76|N-methylthiotetrazole|O
DDI-DrugBank.d139.s1|78-78|(|O
DDI-DrugBank.d139.s1|79-89|cefmenoxime|drug
DDI-DrugBank.d139.s1|90-90|,|O
DDI-DrugBank.d139.s1|92-103|cefoperazone|drug
DDI-DrugBank.d139.s1|104-104|,|O
DDI-DrugBank.d139.s1|106-114|cefotetan|drug
DDI-DrugBank.d139.s1|115-115|,|O
DDI-DrugBank.d139.s1|117-127|cefamandole|drug
DDI-DrugBank.d139.s1|128-128|,|O
DDI-DrugBank.d139.s1|130-138|latamoxef|drug
DDI-DrugBank.d139.s1|139-139|)|O
DDI-DrugBank.d139.s1|141-142|or|O
DDI-DrugBank.d139.s1|144-160|methylthiadiazole|O
DDI-DrugBank.d139.s1|162-162|(|O
DDI-DrugBank.d139.s1|163-171|cefazolin|drug
DDI-DrugBank.d139.s1|172-172|)|O
DDI-DrugBank.d139.s1|174-176|can|O
DDI-DrugBank.d139.s1|178-182|cause|O
DDI-DrugBank.d139.s1|184-190|vitamin|O
DDI-DrugBank.d139.s1|192-192|K|O
DDI-DrugBank.d139.s1|194-203|deficiency|O
DDI-DrugBank.d139.s1|205-207|and|O
DDI-DrugBank.d139.s1|209-227|hypoprothrombinemia|O
DDI-DrugBank.d139.s1|228-228|.|O
DDI-DrugBank.d139.s2|0-4|These|O
DDI-DrugBank.d139.s2|6-19|cephalosporins|group
DDI-DrugBank.d139.s2|21-23|are|O
DDI-DrugBank.d139.s2|25-34|inhibitors|O
DDI-DrugBank.d139.s2|36-37|of|O
DDI-DrugBank.d139.s2|39-45|hepatic|O
DDI-DrugBank.d139.s2|47-53|vitamin|O
DDI-DrugBank.d139.s2|55-55|K|O
DDI-DrugBank.d139.s2|57-63|epoxide|O
DDI-DrugBank.d139.s2|65-73|reductase|O
DDI-DrugBank.d139.s2|74-74|.|O
DDI-DrugBank.d139.s3|0-25|Cholestyramine-Concomitant|drug
DDI-DrugBank.d139.s3|27-32|intake|O
DDI-DrugBank.d139.s3|34-35|of|O
DDI-DrugBank.d139.s3|37-50|cholestyramine|drug
DDI-DrugBank.d139.s3|52-54|and|O
DDI-DrugBank.d139.s3|56-64|vitamin K|group
DDI-DrugBank.d139.s3|66-68|may|O
DDI-DrugBank.d139.s3|70-75|reduce|O
DDI-DrugBank.d139.s3|77-79|the|O
DDI-DrugBank.d139.s3|81-90|absorption|O
DDI-DrugBank.d139.s3|92-93|of|O
DDI-DrugBank.d139.s3|95-103|vitamin K|group
DDI-DrugBank.d139.s3|104-104|.|O
DDI-DrugBank.d139.s4|0-21|Colestipol-Concomitant|drug
DDI-DrugBank.d139.s4|23-28|intake|O
DDI-DrugBank.d139.s4|30-31|of|O
DDI-DrugBank.d139.s4|33-42|colestipol|drug
DDI-DrugBank.d139.s4|44-46|and|O
DDI-DrugBank.d139.s4|48-56|vitamin K|group
DDI-DrugBank.d139.s4|58-60|may|O
DDI-DrugBank.d139.s4|62-67|reduce|O
DDI-DrugBank.d139.s4|69-71|the|O
DDI-DrugBank.d139.s4|73-82|absorption|O
DDI-DrugBank.d139.s4|84-85|of|O
DDI-DrugBank.d139.s4|87-95|vitamin K|group
DDI-DrugBank.d139.s4|96-96|.|O
DDI-DrugBank.d139.s5|8-22|Oil-Concomitant|O
DDI-DrugBank.d139.s5|24-29|intake|O
DDI-DrugBank.d139.s5|31-32|of|O
DDI-DrugBank.d139.s5|46-48|and|O
DDI-DrugBank.d139.s5|50-58|vitamin K|group
DDI-DrugBank.d139.s5|60-62|may|O
DDI-DrugBank.d139.s5|64-69|reduce|O
DDI-DrugBank.d139.s5|71-73|the|O
DDI-DrugBank.d139.s5|75-84|absorption|O
DDI-DrugBank.d139.s5|86-87|of|O
DDI-DrugBank.d139.s5|89-97|vitamin K|group
DDI-DrugBank.d139.s5|98-98|.|O
DDI-DrugBank.d139.s6|0-16|Orlistat-Orlistat|drug
DDI-DrugBank.d139.s6|18-20|may|O
DDI-DrugBank.d139.s6|22-29|decrease|O
DDI-DrugBank.d139.s6|31-33|the|O
DDI-DrugBank.d139.s6|35-44|absorption|O
DDI-DrugBank.d139.s6|46-47|of|O
DDI-DrugBank.d139.s6|49-57|vitamin K|group
DDI-DrugBank.d139.s6|58-58|.|O
DDI-DrugBank.d139.s7|0-22|Salicylates-Salicylates|group
DDI-DrugBank.d139.s7|24-25|in|O
DDI-DrugBank.d139.s7|27-31|large|O
DDI-DrugBank.d139.s7|33-37|doses|O
DDI-DrugBank.d139.s7|39-41|may|O
DDI-DrugBank.d139.s7|43-49|inhibit|O
DDI-DrugBank.d139.s7|51-57|vitamin|O
DDI-DrugBank.d139.s7|59-59|K|O
DDI-DrugBank.d139.s7|61-67|epoxide|O
DDI-DrugBank.d139.s7|69-77|reductase|O
DDI-DrugBank.d139.s7|79-87|resulting|O
DDI-DrugBank.d139.s7|89-90|in|O
DDI-DrugBank.d139.s7|92-98|vitamin|O
DDI-DrugBank.d139.s7|100-100|K|O
DDI-DrugBank.d139.s7|102-111|deficiency|O
DDI-DrugBank.d139.s7|112-112|.|O
DDI-DrugBank.d139.s8|0-15|Warfarin-Vitamin|drug
DDI-DrugBank.d139.s8|17-17|K|group
DDI-DrugBank.d139.s8|19-21|can|O
DDI-DrugBank.d139.s8|23-32|antagonize|O
DDI-DrugBank.d139.s8|34-36|the|O
DDI-DrugBank.d139.s8|38-43|effect|O
DDI-DrugBank.d139.s8|45-46|of|O
DDI-DrugBank.d492.s0|0-13|MAO inhibitors|group
DDI-DrugBank.d492.s0|15-21|prolong|O
DDI-DrugBank.d492.s0|23-25|and|O
DDI-DrugBank.d492.s0|27-35|intensify|O
DDI-DrugBank.d492.s0|37-39|the|O
DDI-DrugBank.d492.s0|41-55|anticholinergic|O
DDI-DrugBank.d492.s0|57-63|effects|O
DDI-DrugBank.d492.s0|65-66|of|O
DDI-DrugBank.d492.s0|68-81|antihistamines|group
DDI-DrugBank.d492.s0|82-82|.|O
DDI-DrugBank.d492.s1|0-13|Antihistamines|group
DDI-DrugBank.d492.s1|15-17|may|O
DDI-DrugBank.d492.s1|19-22|have|O
DDI-DrugBank.d492.s1|24-31|additive|O
DDI-DrugBank.d492.s1|33-39|effects|O
DDI-DrugBank.d492.s1|41-44|with|O
DDI-DrugBank.d492.s1|46-52|alcohol|drug
DDI-DrugBank.d492.s1|54-56|and|O
DDI-DrugBank.d492.s1|58-62|other|O
DDI-DrugBank.d492.s1|64-78|CNS depressants|group
DDI-DrugBank.d492.s1|79-79|,|O
DDI-DrugBank.d492.s1|81-84|e.g.|O
DDI-DrugBank.d492.s1|85-85|,|O
DDI-DrugBank.d492.s1|87-95|hypnotics|group
DDI-DrugBank.d492.s1|96-96|,|O
DDI-DrugBank.d492.s1|98-106|sedatives|group
DDI-DrugBank.d492.s1|107-107|,|O
DDI-DrugBank.d492.s1|109-121|tranquilizers|group
DDI-DrugBank.d492.s1|122-122|,|O
DDI-DrugBank.d492.s1|124-141|antianxiety agents|group
DDI-DrugBank.d492.s1|142-142|.|O
DDI-DrugBank.d638.s0|0-6|Ritalin|brand
DDI-DrugBank.d638.s0|8-10|may|O
DDI-DrugBank.d638.s0|12-19|decrease|O
DDI-DrugBank.d638.s0|21-23|the|O
DDI-DrugBank.d638.s0|25-35|hypotensive|O
DDI-DrugBank.d638.s0|37-42|effect|O
DDI-DrugBank.d638.s0|44-45|of|O
DDI-DrugBank.d638.s0|47-58|guanethidine|drug
DDI-DrugBank.d638.s0|59-59|.|O
DDI-DrugBank.d638.s1|0-2|Use|O
DDI-DrugBank.d638.s1|4-13|cautiously|O
DDI-DrugBank.d638.s1|15-18|with|O
DDI-DrugBank.d638.s1|20-26|pressor|O
DDI-DrugBank.d638.s1|28-33|agents|O
DDI-DrugBank.d638.s1|34-34|.|O
DDI-DrugBank.d638.s2|0-4|Human|O
DDI-DrugBank.d638.s2|6-18|pharmacologic|O
DDI-DrugBank.d638.s2|20-26|studies|O
DDI-DrugBank.d638.s2|28-31|have|O
DDI-DrugBank.d638.s2|33-37|shown|O
DDI-DrugBank.d638.s2|39-42|that|O
DDI-DrugBank.d638.s2|44-50|Ritalin|brand
DDI-DrugBank.d638.s2|52-54|may|O
DDI-DrugBank.d638.s2|56-62|inhibit|O
DDI-DrugBank.d638.s2|64-66|the|O
DDI-DrugBank.d638.s2|68-77|metabolism|O
DDI-DrugBank.d638.s2|79-80|of|O
DDI-DrugBank.d638.s2|82-104|coumarin anticoagulants|group
DDI-DrugBank.d638.s2|105-105|,|O
DDI-DrugBank.d638.s2|107-121|anticonvulsants|group
DDI-DrugBank.d638.s2|123-123|(|O
DDI-DrugBank.d638.s2|124-136|phenobarbital|drug
DDI-DrugBank.d638.s2|137-137|,|O
DDI-DrugBank.d638.s2|139-155|diphenylhydantoin|drug
DDI-DrugBank.d638.s2|156-156|,|O
DDI-DrugBank.d638.s2|158-166|primidone|drug
DDI-DrugBank.d638.s2|167-167|)|O
DDI-DrugBank.d638.s2|168-168|,|O
DDI-DrugBank.d638.s2|170-183|phenylbutazone|drug
DDI-DrugBank.d638.s2|184-184|,|O
DDI-DrugBank.d638.s2|186-188|and|O
DDI-DrugBank.d638.s2|190-204|tricyclic drugs|group
DDI-DrugBank.d638.s2|206-206|(|O
DDI-DrugBank.d638.s2|207-216|imipramine|drug
DDI-DrugBank.d638.s2|217-217|,|O
DDI-DrugBank.d638.s2|219-230|clomipramine|drug
DDI-DrugBank.d638.s2|231-231|,|O
DDI-DrugBank.d638.s2|233-243|desipramine|drug
DDI-DrugBank.d638.s2|244-244|)|O
DDI-DrugBank.d638.s2|245-245|.|O
DDI-DrugBank.d638.s3|0-7|Downward|O
DDI-DrugBank.d638.s3|9-14|dosage|O
DDI-DrugBank.d638.s3|16-26|adjustments|O
DDI-DrugBank.d638.s3|28-29|of|O
DDI-DrugBank.d638.s3|31-35|these|O
DDI-DrugBank.d638.s3|37-41|drugs|O
DDI-DrugBank.d638.s3|43-45|may|O
DDI-DrugBank.d638.s3|47-48|be|O
DDI-DrugBank.d638.s3|50-57|required|O
DDI-DrugBank.d638.s3|59-62|when|O
DDI-DrugBank.d638.s3|64-68|given|O
DDI-DrugBank.d638.s3|70-82|concomitantly|O
DDI-DrugBank.d638.s3|84-87|with|O
DDI-DrugBank.d638.s3|89-95|Ritalin|brand
DDI-DrugBank.d638.s3|96-96|.|O
DDI-DrugBank.d638.s4|0-6|Serious|O
DDI-DrugBank.d638.s4|8-14|adverse|O
DDI-DrugBank.d638.s4|16-21|events|O
DDI-DrugBank.d638.s4|23-26|have|O
DDI-DrugBank.d638.s4|28-31|been|O
DDI-DrugBank.d638.s4|33-40|reported|O
DDI-DrugBank.d638.s4|42-43|in|O
DDI-DrugBank.d638.s4|45-55|concomitant|O
DDI-DrugBank.d638.s4|57-59|use|O
DDI-DrugBank.d638.s4|61-64|with|O
DDI-DrugBank.d638.s4|66-74|clonidine|drug
DDI-DrugBank.d638.s4|75-75|,|O
DDI-DrugBank.d638.s4|77-84|although|O
DDI-DrugBank.d638.s4|86-87|no|O
DDI-DrugBank.d638.s4|89-97|causality|O
DDI-DrugBank.d638.s4|99-101|for|O
DDI-DrugBank.d638.s4|103-105|the|O
DDI-DrugBank.d638.s4|107-117|combination|O
DDI-DrugBank.d638.s4|119-121|has|O
DDI-DrugBank.d638.s4|123-126|been|O
DDI-DrugBank.d638.s4|128-138|established|O
DDI-DrugBank.d638.s4|139-139|.|O
DDI-DrugBank.d638.s5|0-2|The|O
DDI-DrugBank.d638.s5|4-9|safety|O
DDI-DrugBank.d638.s5|11-12|of|O
DDI-DrugBank.d638.s5|14-18|using|O
DDI-DrugBank.d638.s5|20-34|methylphenidate|drug
DDI-DrugBank.d638.s5|36-37|in|O
DDI-DrugBank.d638.s5|39-49|combination|O
DDI-DrugBank.d638.s5|51-54|with|O
DDI-DrugBank.d638.s5|56-64|clonidine|drug
DDI-DrugBank.d638.s5|66-67|or|O
DDI-DrugBank.d638.s5|69-73|other|O
DDI-DrugBank.d638.s5|75-83|centrally|O
DDI-DrugBank.d638.s5|85-90|acting|O
DDI-DrugBank.d638.s5|92-107|alpha-2 agonists|group
DDI-DrugBank.d638.s5|109-111|has|O
DDI-DrugBank.d638.s5|113-115|not|O
DDI-DrugBank.d638.s5|117-120|been|O
DDI-DrugBank.d638.s5|122-133|systemically|O
DDI-DrugBank.d638.s5|135-143|evaluated|O
DDI-DrugBank.d638.s5|144-144|.|O
DDI-DrugBank.d230.s0|0-9|LABORATORY|O
DDI-DrugBank.d230.s0|11-14|TEST|O
DDI-DrugBank.d230.s0|16-23|FINDINGS|O
DDI-DrugBank.d230.s0|25-36|Asymptomatic|O
DDI-DrugBank.d230.s0|37-37|,|O
DDI-DrugBank.d230.s0|39-48|transitory|O
DDI-DrugBank.d230.s0|50-56|changes|O
DDI-DrugBank.d230.s0|58-59|in|O
DDI-DrugBank.d230.s0|61-65|serum|O
DDI-DrugBank.d230.s0|67-70|iron|O
DDI-DrugBank.d230.s0|72-75|have|O
DDI-DrugBank.d230.s0|77-80|been|O
DDI-DrugBank.d230.s0|82-89|observed|O
DDI-DrugBank.d230.s0|90-90|.|O
DDI-DrugBank.d230.s1|0-2|The|O
DDI-DrugBank.d230.s1|4-11|clinical|O
DDI-DrugBank.d230.s1|13-24|significance|O
DDI-DrugBank.d230.s1|26-27|is|O
DDI-DrugBank.d230.s1|29-35|unknown|O
DDI-DrugBank.d230.s1|36-36|.|O
DDI-DrugBank.d230.s2|0-7|Omniscan|brand
DDI-DrugBank.d230.s2|9-18|interferes|O
DDI-DrugBank.d230.s2|20-23|with|O
DDI-DrugBank.d230.s2|25-29|serum|O
DDI-DrugBank.d230.s2|31-37|calcium|O
DDI-DrugBank.d230.s2|39-50|measurements|O
DDI-DrugBank.d230.s2|52-55|with|O
DDI-DrugBank.d230.s2|57-60|some|O
DDI-DrugBank.d230.s2|62-73|colorimetric|O
DDI-DrugBank.d230.s2|75-75|(|O
DDI-DrugBank.d230.s2|76-89|complexometric|O
DDI-DrugBank.d230.s2|90-90|)|O
DDI-DrugBank.d230.s2|92-98|methods|O
DDI-DrugBank.d230.s2|100-107|commonly|O
DDI-DrugBank.d230.s2|109-112|used|O
DDI-DrugBank.d230.s2|114-115|in|O
DDI-DrugBank.d230.s2|117-125|hospitals|O
DDI-DrugBank.d230.s2|126-126|,|O
DDI-DrugBank.d230.s2|128-136|resulting|O
DDI-DrugBank.d230.s2|138-139|in|O
DDI-DrugBank.d230.s2|141-145|serum|O
DDI-DrugBank.d230.s2|147-153|calcium|O
DDI-DrugBank.d230.s2|155-168|concentrations|O
DDI-DrugBank.d230.s2|170-174|lower|O
DDI-DrugBank.d230.s2|176-179|than|O
DDI-DrugBank.d230.s2|181-183|the|O
DDI-DrugBank.d230.s2|185-188|true|O
DDI-DrugBank.d230.s2|190-195|values|O
DDI-DrugBank.d230.s2|196-196|.|O
DDI-DrugBank.d230.s3|0-3|Thus|O
DDI-DrugBank.d230.s3|4-4|,|O
DDI-DrugBank.d230.s3|6-7|it|O
DDI-DrugBank.d230.s3|9-10|is|O
DDI-DrugBank.d230.s3|12-22|recommended|O
DDI-DrugBank.d230.s3|24-26|not|O
DDI-DrugBank.d230.s3|28-29|to|O
DDI-DrugBank.d230.s3|31-33|use|O
DDI-DrugBank.d230.s3|35-38|such|O
DDI-DrugBank.d230.s3|40-46|methods|O
DDI-DrugBank.d230.s3|48-50|for|O
DDI-DrugBank.d230.s3|52-56|12-24|O
DDI-DrugBank.d230.s3|58-62|hours|O
DDI-DrugBank.d230.s3|64-68|after|O
DDI-DrugBank.d230.s3|70-83|administration|O
DDI-DrugBank.d230.s3|85-86|of|O
DDI-DrugBank.d230.s3|88-95|Omniscan|brand
DDI-DrugBank.d230.s3|96-96|.|O
DDI-DrugBank.d230.s4|0-1|If|O
DDI-DrugBank.d230.s4|3-6|such|O
DDI-DrugBank.d230.s4|8-19|measurements|O
DDI-DrugBank.d230.s4|21-23|are|O
DDI-DrugBank.d230.s4|25-33|necessary|O
DDI-DrugBank.d230.s4|34-34|,|O
DDI-DrugBank.d230.s4|36-38|the|O
DDI-DrugBank.d230.s4|40-42|use|O
DDI-DrugBank.d230.s4|44-45|of|O
DDI-DrugBank.d230.s4|47-51|other|O
DDI-DrugBank.d230.s4|53-59|methods|O
DDI-DrugBank.d230.s4|61-62|is|O
DDI-DrugBank.d230.s4|64-74|recommended|O
DDI-DrugBank.d230.s4|75-75|.|O
DDI-DrugBank.d230.s5|0-2|All|O
DDI-DrugBank.d230.s5|4-11|patients|O
DDI-DrugBank.d230.s5|13-14|in|O
DDI-DrugBank.d230.s5|16-19|whom|O
DDI-DrugBank.d230.s5|21-24|this|O
DDI-DrugBank.d230.s5|26-31|effect|O
DDI-DrugBank.d230.s5|33-35|was|O
DDI-DrugBank.d230.s5|37-44|observed|O
DDI-DrugBank.d230.s5|46-53|remained|O
DDI-DrugBank.d230.s5|55-66|asymptomatic|O
DDI-DrugBank.d230.s5|67-67|.|O
DDI-DrugBank.d507.s0|0-2|The|O
DDI-DrugBank.d507.s0|4-12|potential|O
DDI-DrugBank.d507.s0|14-16|for|O
DDI-DrugBank.d507.s0|18-26|increased|O
DDI-DrugBank.d507.s0|28-35|sedation|O
DDI-DrugBank.d507.s0|37-40|when|O
DDI-DrugBank.d507.s0|42-51|guanfacine|drug
DDI-DrugBank.d507.s0|53-54|is|O
DDI-DrugBank.d507.s0|56-60|given|O
DDI-DrugBank.d507.s0|62-65|with|O
DDI-DrugBank.d507.s0|67-71|other|O
DDI-DrugBank.d507.s0|73-91|CNS-depressant drug|group
DDI-DrugBank.d507.s0|93-98|should|O
DDI-DrugBank.d507.s0|100-101|be|O
DDI-DrugBank.d507.s0|103-113|appreciated|O
DDI-DrugBank.d507.s0|114-114|.|O
DDI-DrugBank.d507.s1|0-2|The|O
DDI-DrugBank.d507.s1|4-17|administration|O
DDI-DrugBank.d507.s1|19-20|of|O
DDI-DrugBank.d507.s1|22-31|guanfacine|drug
DDI-DrugBank.d507.s1|33-45|concomitantly|O
DDI-DrugBank.d507.s1|47-50|with|O
DDI-DrugBank.d507.s1|52-56|known|O
DDI-DrugBank.d507.s1|58-67|microsomal|O
DDI-DrugBank.d507.s1|69-74|enzyme|O
DDI-DrugBank.d507.s1|76-82|inducer|O
DDI-DrugBank.d507.s1|84-84|(|O
DDI-DrugBank.d507.s1|85-97|phenobarbital|drug
DDI-DrugBank.d507.s1|99-100|or|O
DDI-DrugBank.d507.s1|102-110|phenytoin|drug
DDI-DrugBank.d507.s1|111-111|)|O
DDI-DrugBank.d507.s1|113-114|to|O
DDI-DrugBank.d507.s1|116-118|two|O
DDI-DrugBank.d507.s1|120-127|patients|O
DDI-DrugBank.d507.s1|129-132|with|O
DDI-DrugBank.d507.s1|134-138|renal|O
DDI-DrugBank.d507.s1|140-149|impairment|O
DDI-DrugBank.d507.s1|151-160|reportedly|O
DDI-DrugBank.d507.s1|162-169|resulted|O
DDI-DrugBank.d507.s1|171-172|in|O
DDI-DrugBank.d507.s1|174-184|significant|O
DDI-DrugBank.d507.s1|186-195|reductions|O
DDI-DrugBank.d507.s1|197-198|in|O
DDI-DrugBank.d507.s1|200-210|elimination|O
DDI-DrugBank.d507.s1|212-220|half-life|O
DDI-DrugBank.d507.s1|222-224|and|O
DDI-DrugBank.d507.s1|226-231|plasma|O
DDI-DrugBank.d507.s1|233-245|concentration|O
DDI-DrugBank.d507.s1|246-246|.|O
DDI-DrugBank.d507.s2|0-1|In|O
DDI-DrugBank.d507.s2|3-6|such|O
DDI-DrugBank.d507.s2|8-12|cases|O
DDI-DrugBank.d507.s2|13-13|,|O
DDI-DrugBank.d507.s2|15-23|therefore|O
DDI-DrugBank.d507.s2|24-24|,|O
DDI-DrugBank.d507.s2|26-29|more|O
DDI-DrugBank.d507.s2|31-38|frequent|O
DDI-DrugBank.d507.s2|40-45|dosing|O
DDI-DrugBank.d507.s2|47-49|may|O
DDI-DrugBank.d507.s2|51-52|be|O
DDI-DrugBank.d507.s2|54-61|required|O
DDI-DrugBank.d507.s2|63-64|to|O
DDI-DrugBank.d507.s2|66-72|achieve|O
DDI-DrugBank.d507.s2|74-75|or|O
DDI-DrugBank.d507.s2|77-84|maintain|O
DDI-DrugBank.d507.s2|86-88|the|O
DDI-DrugBank.d507.s2|90-96|desired|O
DDI-DrugBank.d507.s2|98-108|hypotensive|O
DDI-DrugBank.d507.s2|110-117|response|O
DDI-DrugBank.d507.s2|118-118|.|O
DDI-DrugBank.d507.s3|0-6|Further|O
DDI-DrugBank.d507.s3|7-7|,|O
DDI-DrugBank.d507.s3|9-10|if|O
DDI-DrugBank.d507.s3|12-21|guanfacine|drug
DDI-DrugBank.d507.s3|23-24|is|O
DDI-DrugBank.d507.s3|26-27|to|O
DDI-DrugBank.d507.s3|29-30|be|O
DDI-DrugBank.d507.s3|32-43|discontinued|O
DDI-DrugBank.d507.s3|45-46|in|O
DDI-DrugBank.d507.s3|48-51|such|O
DDI-DrugBank.d507.s3|53-60|patients|O
DDI-DrugBank.d507.s3|61-61|,|O
DDI-DrugBank.d507.s3|63-69|careful|O
DDI-DrugBank.d507.s3|71-78|tapering|O
DDI-DrugBank.d507.s3|80-81|of|O
DDI-DrugBank.d507.s3|83-85|the|O
DDI-DrugBank.d507.s3|87-92|dosage|O
DDI-DrugBank.d507.s3|94-96|may|O
DDI-DrugBank.d507.s3|98-99|be|O
DDI-DrugBank.d507.s3|101-109|necessary|O
DDI-DrugBank.d507.s3|111-112|in|O
DDI-DrugBank.d507.s3|114-118|order|O
DDI-DrugBank.d507.s3|120-121|to|O
DDI-DrugBank.d507.s3|123-127|avoid|O
DDI-DrugBank.d507.s3|129-135|rebound|O
DDI-DrugBank.d507.s3|137-145|phenomena|O
DDI-DrugBank.d507.s3|146-146|.|O
DDI-DrugBank.d507.s4|0-3|TCAs|group
DDI-DrugBank.d507.s4|5-12|decrease|O
DDI-DrugBank.d507.s4|14-16|the|O
DDI-DrugBank.d507.s4|18-28|hypotensive|O
DDI-DrugBank.d507.s4|30-35|effect|O
DDI-DrugBank.d507.s4|37-38|of|O
DDI-DrugBank.d507.s4|40-49|guanfacine|drug
DDI-DrugBank.d507.s4|50-50|.|O
DDI-DrugBank.d507.s5|0-31|Noncardioselective beta-blockers|group
DDI-DrugBank.d507.s5|33-33|(|O
DDI-DrugBank.d507.s5|34-40|nadolol|drug
DDI-DrugBank.d507.s5|41-41|,|O
DDI-DrugBank.d507.s5|42-52|porpranolol|O
DDI-DrugBank.d507.s5|53-53|,|O
DDI-DrugBank.d507.s5|54-60|timolol|drug
DDI-DrugBank.d507.s5|61-61|)|O
DDI-DrugBank.d507.s5|63-65|may|O
DDI-DrugBank.d507.s5|67-76|exacerbate|O
DDI-DrugBank.d507.s5|78-84|rebound|O
DDI-DrugBank.d507.s5|86-97|hypertension|O
DDI-DrugBank.d507.s5|99-102|when|O
DDI-DrugBank.d507.s5|104-113|guanfacine|drug
DDI-DrugBank.d507.s5|115-116|is|O
DDI-DrugBank.d507.s5|118-126|withdrawn|O
DDI-DrugBank.d507.s5|127-127|.|O
DDI-DrugBank.d507.s6|0-2|The|O
DDI-DrugBank.d507.s6|4-15|beta-blocker|group
DDI-DrugBank.d507.s6|17-22|should|O
DDI-DrugBank.d507.s6|24-25|be|O
DDI-DrugBank.d507.s6|27-35|withdrawn|O
DDI-DrugBank.d507.s6|37-41|first|O
DDI-DrugBank.d507.s6|42-42|.|O
DDI-DrugBank.d507.s7|0-2|The|O
DDI-DrugBank.d507.s7|4-10|gradual|O
DDI-DrugBank.d507.s7|12-21|withdrawal|O
DDI-DrugBank.d507.s7|23-24|of|O
DDI-DrugBank.d507.s7|26-34|guafacine|drug
DDI-DrugBank.d507.s7|36-37|or|O
DDI-DrugBank.d507.s7|39-39|a|O
DDI-DrugBank.d507.s7|41-68|cardioselective beta-blocker|group
DDI-DrugBank.d507.s7|70-74|could|O
DDI-DrugBank.d507.s7|76-77|be|O
DDI-DrugBank.d507.s7|79-89|substituted|O
DDI-DrugBank.d507.s7|90-90|.|O
DDI-DrugBank.d507.s8|0-13|Anticoagulants|group
DDI-DrugBank.d507.s8|14-14|:|O
DDI-DrugBank.d507.s8|16-18|Ten|O
DDI-DrugBank.d507.s8|20-27|patients|O
DDI-DrugBank.d507.s8|29-31|who|O
DDI-DrugBank.d507.s8|33-36|were|O
DDI-DrugBank.d507.s8|38-47|stabilized|O
DDI-DrugBank.d507.s8|49-50|on|O
DDI-DrugBank.d507.s8|52-55|oral|O
DDI-DrugBank.d507.s8|57-70|anticoagulants|group
DDI-DrugBank.d507.s8|72-75|were|O
DDI-DrugBank.d507.s8|77-81|given|O
DDI-DrugBank.d507.s8|83-92|guanfacine|drug
DDI-DrugBank.d507.s8|93-93|,|O
DDI-DrugBank.d507.s8|95-97|1-2|O
DDI-DrugBank.d507.s8|99-104|mg/day|O
DDI-DrugBank.d507.s8|105-105|,|O
DDI-DrugBank.d507.s8|107-109|for|O
DDI-DrugBank.d507.s8|111-111|4|O
DDI-DrugBank.d507.s8|113-117|weeks|O
DDI-DrugBank.d507.s8|118-118|.|O
DDI-DrugBank.d507.s9|0-1|No|O
DDI-DrugBank.d507.s9|3-9|changes|O
DDI-DrugBank.d507.s9|11-14|were|O
DDI-DrugBank.d507.s9|16-23|observed|O
DDI-DrugBank.d507.s9|25-26|in|O
DDI-DrugBank.d507.s9|28-30|the|O
DDI-DrugBank.d507.s9|32-37|degree|O
DDI-DrugBank.d507.s9|39-40|of|O
DDI-DrugBank.d507.s9|42-56|anticoagulation|O
DDI-DrugBank.d507.s9|57-57|.|O
DDI-DrugBank.d507.s10|0-1|In|O
DDI-DrugBank.d507.s10|3-9|several|O
DDI-DrugBank.d507.s10|11-25|well-controlled|O
DDI-DrugBank.d507.s10|27-33|studies|O
DDI-DrugBank.d507.s10|34-34|,|O
DDI-DrugBank.d507.s10|36-45|guanfacine|drug
DDI-DrugBank.d507.s10|47-49|was|O
DDI-DrugBank.d507.s10|51-62|administered|O
DDI-DrugBank.d507.s10|64-71|together|O
DDI-DrugBank.d507.s10|73-76|with|O
DDI-DrugBank.d507.s10|78-86|diuretics|group
DDI-DrugBank.d507.s10|88-91|with|O
DDI-DrugBank.d507.s10|93-94|no|O
DDI-DrugBank.d507.s10|96-99|drug|O
DDI-DrugBank.d507.s10|101-112|interactions|O
DDI-DrugBank.d507.s10|114-121|reported|O
DDI-DrugBank.d507.s10|122-122|.|O
DDI-DrugBank.d507.s11|0-1|In|O
DDI-DrugBank.d507.s11|3-5|the|O
DDI-DrugBank.d507.s11|7-15|long-term|O
DDI-DrugBank.d507.s11|17-22|safety|O
DDI-DrugBank.d507.s11|24-30|studies|O
DDI-DrugBank.d507.s11|31-31|,|O
DDI-DrugBank.d507.s11|33-42|guanfacine|drug
DDI-DrugBank.d507.s11|44-46|was|O
DDI-DrugBank.d507.s11|48-52|given|O
DDI-DrugBank.d507.s11|54-66|concomitantly|O
DDI-DrugBank.d507.s11|68-71|with|O
DDI-DrugBank.d507.s11|73-76|many|O
DDI-DrugBank.d507.s11|78-82|drugs|O
DDI-DrugBank.d507.s11|84-90|without|O
DDI-DrugBank.d507.s11|92-99|evidence|O
DDI-DrugBank.d507.s11|101-102|of|O
DDI-DrugBank.d507.s11|104-106|any|O
DDI-DrugBank.d507.s11|108-119|interactions|O
DDI-DrugBank.d507.s11|120-120|.|O
DDI-DrugBank.d507.s12|0-2|The|O
DDI-DrugBank.d507.s12|4-12|principal|O
DDI-DrugBank.d507.s12|14-18|drugs|O
DDI-DrugBank.d507.s12|20-24|given|O
DDI-DrugBank.d507.s12|26-26|(|O
DDI-DrugBank.d507.s12|27-32|number|O
DDI-DrugBank.d507.s12|34-35|of|O
DDI-DrugBank.d507.s12|37-44|patients|O
DDI-DrugBank.d507.s12|46-47|in|O
DDI-DrugBank.d507.s12|49-59|parentheses|O
DDI-DrugBank.d507.s12|60-60|)|O
DDI-DrugBank.d507.s12|62-65|were|O
DDI-DrugBank.d507.s12|66-66|:|O
DDI-DrugBank.d507.s12|68-85|cardiac glycosides|group
DDI-DrugBank.d507.s12|87-87|(|O
DDI-DrugBank.d507.s12|88-90|115|O
DDI-DrugBank.d507.s12|91-91|)|O
DDI-DrugBank.d507.s12|92-92|,|O
DDI-DrugBank.d507.s12|94-102|sedatives|group
DDI-DrugBank.d507.s12|104-106|and|O
DDI-DrugBank.d507.s12|108-116|hypnotics|group
DDI-DrugBank.d507.s12|118-118|(|O
DDI-DrugBank.d507.s12|119-121|103|O
DDI-DrugBank.d507.s12|122-122|)|O
DDI-DrugBank.d507.s12|123-123|,|O
DDI-DrugBank.d507.s12|125-145|coronary vasodilators|group
DDI-DrugBank.d507.s12|147-147|(|O
DDI-DrugBank.d507.s12|148-149|52|O
DDI-DrugBank.d507.s12|150-150|)|O
DDI-DrugBank.d507.s12|151-151|,|O
DDI-DrugBank.d507.s12|153-156|oral|O
DDI-DrugBank.d507.s12|158-170|hypoglycemics|group
DDI-DrugBank.d507.s12|172-172|(|O
DDI-DrugBank.d507.s12|173-174|45|O
DDI-DrugBank.d507.s12|175-175|)|O
DDI-DrugBank.d507.s12|176-176|,|O
DDI-DrugBank.d507.s12|178-182|cough|O
DDI-DrugBank.d507.s12|184-186|and|O
DDI-DrugBank.d507.s12|188-191|cold|O
DDI-DrugBank.d507.s12|193-204|preparations|O
DDI-DrugBank.d507.s12|206-206|(|O
DDI-DrugBank.d507.s12|207-208|45|O
DDI-DrugBank.d507.s12|209-209|)|O
DDI-DrugBank.d507.s12|210-210|,|O
DDI-DrugBank.d507.s12|212-217|NSAIDs|group
DDI-DrugBank.d507.s12|219-219|(|O
DDI-DrugBank.d507.s12|220-221|38|O
DDI-DrugBank.d507.s12|222-222|)|O
DDI-DrugBank.d507.s12|223-223|,|O
DDI-DrugBank.d507.s12|225-243|antihyperlipidemics|group
DDI-DrugBank.d507.s12|245-245|(|O
DDI-DrugBank.d507.s12|246-247|29|O
DDI-DrugBank.d507.s12|248-248|)|O
DDI-DrugBank.d507.s12|249-249|,|O
DDI-DrugBank.d507.s12|251-264|antigout drugs|group
DDI-DrugBank.d507.s12|266-266|(|O
DDI-DrugBank.d507.s12|267-268|24|O
DDI-DrugBank.d507.s12|269-269|)|O
DDI-DrugBank.d507.s12|270-270|,|O
DDI-DrugBank.d507.s12|272-275|oral|O
DDI-DrugBank.d507.s12|277-290|contraceptives|group
DDI-DrugBank.d507.s12|292-292|(|O
DDI-DrugBank.d507.s12|293-294|18|O
DDI-DrugBank.d507.s12|295-295|)|O
DDI-DrugBank.d507.s12|296-296|,|O
DDI-DrugBank.d507.s12|298-312|bronchodilators|group
DDI-DrugBank.d507.s12|314-314|(|O
DDI-DrugBank.d507.s12|315-316|13|O
DDI-DrugBank.d507.s12|317-317|)|O
DDI-DrugBank.d507.s12|318-318|,|O
DDI-DrugBank.d507.s12|320-326|insulin|drug
DDI-DrugBank.d507.s12|328-328|(|O
DDI-DrugBank.d507.s12|329-330|10|O
DDI-DrugBank.d507.s12|331-331|)|O
DDI-DrugBank.d507.s12|332-332|,|O
DDI-DrugBank.d507.s12|334-336|and|O
DDI-DrugBank.d507.s12|338-350|beta blockers|group
DDI-DrugBank.d507.s12|352-352|(|O
DDI-DrugBank.d507.s12|353-354|10|O
DDI-DrugBank.d507.s12|355-355|)|O
DDI-DrugBank.d507.s12|356-356|.|O
DDI-DrugBank.d507.s13|0-9|Laboratory|O
DDI-DrugBank.d507.s13|11-14|Test|O
DDI-DrugBank.d507.s13|16-17|In|O
DDI-DrugBank.d507.s13|19-26|clinical|O
DDI-DrugBank.d507.s13|28-33|trials|O
DDI-DrugBank.d507.s13|34-34|,|O
DDI-DrugBank.d507.s13|36-37|no|O
DDI-DrugBank.d507.s13|39-48|clinically|O
DDI-DrugBank.d507.s13|50-57|relevant|O
DDI-DrugBank.d507.s13|59-68|laboratory|O
DDI-DrugBank.d507.s13|70-73|test|O
DDI-DrugBank.d507.s13|75-87|abnormalities|O
DDI-DrugBank.d507.s13|89-92|were|O
DDI-DrugBank.d507.s13|94-103|identified|O
DDI-DrugBank.d507.s13|105-106|as|O
DDI-DrugBank.d507.s13|108-115|causally|O
DDI-DrugBank.d507.s13|117-123|related|O
DDI-DrugBank.d507.s13|125-126|to|O
DDI-DrugBank.d507.s13|128-131|drug|O
DDI-DrugBank.d507.s13|133-138|during|O
DDI-DrugBank.d507.s13|140-149|short-term|O
DDI-DrugBank.d507.s13|151-159|treatment|O
DDI-DrugBank.d507.s13|161-164|with|O
DDI-DrugBank.d507.s13|166-175|guanfacine|drug
DDI-DrugBank.d507.s13|176-176|.|O
DDI-DrugBank.d507.s14|0-14|Drug/Laboratory|O
DDI-DrugBank.d507.s14|16-19|Test|O
DDI-DrugBank.d507.s14|21-32|Interactions|O
DDI-DrugBank.d507.s14|34-35|No|O
DDI-DrugBank.d507.s14|37-46|laboratory|O
DDI-DrugBank.d507.s14|48-51|test|O
DDI-DrugBank.d507.s14|53-65|abnormalities|O
DDI-DrugBank.d507.s14|67-73|related|O
DDI-DrugBank.d507.s14|75-76|to|O
DDI-DrugBank.d507.s14|78-80|the|O
DDI-DrugBank.d507.s14|82-84|use|O
DDI-DrugBank.d507.s14|86-87|of|O
DDI-DrugBank.d507.s14|89-98|guanfacine|drug
DDI-DrugBank.d507.s14|100-103|have|O
DDI-DrugBank.d507.s14|105-108|been|O
DDI-DrugBank.d507.s14|110-119|identified|O
DDI-DrugBank.d507.s14|120-120|.|O
DDI-MedLine.d10.s0|0-5|Herbal|O
DDI-MedLine.d10.s0|7-14|remedies|O
DDI-MedLine.d10.s0|15-15|,|O
DDI-MedLine.d10.s0|17-29|nephropathies|O
DDI-MedLine.d10.s0|30-30|,|O
DDI-MedLine.d10.s0|32-34|and|O
DDI-MedLine.d10.s0|36-40|renal|O
DDI-MedLine.d10.s0|42-48|disease|O
DDI-MedLine.d10.s0|49-49|.|O
DDI-MedLine.d10.s1|0-2|The|O
DDI-MedLine.d10.s1|4-6|use|O
DDI-MedLine.d10.s1|8-9|of|O
DDI-MedLine.d10.s1|11-16|herbal|O
DDI-MedLine.d10.s1|18-25|remedies|O
DDI-MedLine.d10.s1|27-28|is|O
DDI-MedLine.d10.s1|30-37|becoming|O
DDI-MedLine.d10.s1|39-50|increasingly|O
DDI-MedLine.d10.s1|52-58|popular|O
DDI-MedLine.d10.s1|60-61|in|O
DDI-MedLine.d10.s1|63-65|the|O
DDI-MedLine.d10.s1|67-72|United|O
DDI-MedLine.d10.s1|74-79|States|O
DDI-MedLine.d10.s1|80-80|.|O
DDI-MedLine.d10.s2|0-7|Research|O
DDI-MedLine.d10.s2|9-11|has|O
DDI-MedLine.d10.s2|13-17|shown|O
DDI-MedLine.d10.s2|19-22|that|O
DDI-MedLine.d10.s2|24-29|herbal|O
DDI-MedLine.d10.s2|31-36|remedy|O
DDI-MedLine.d10.s2|38-40|use|O
DDI-MedLine.d10.s2|42-44|may|O
DDI-MedLine.d10.s2|46-47|be|O
DDI-MedLine.d10.s2|49-58|associated|O
DDI-MedLine.d10.s2|60-63|with|O
DDI-MedLine.d10.s2|65-69|acute|O
DDI-MedLine.d10.s2|71-75|renal|O
DDI-MedLine.d10.s2|77-83|failure|O
DDI-MedLine.d10.s2|84-84|.|O
DDI-MedLine.d10.s3|0-1|In|O
DDI-MedLine.d10.s3|3-10|addition|O
DDI-MedLine.d10.s3|11-11|,|O
DDI-MedLine.d10.s3|13-15|the|O
DDI-MedLine.d10.s3|17-19|use|O
DDI-MedLine.d10.s3|21-22|of|O
DDI-MedLine.d10.s3|24-29|herbal|O
DDI-MedLine.d10.s3|31-38|remedies|O
DDI-MedLine.d10.s3|40-42|may|O
DDI-MedLine.d10.s3|44-45|be|O
DDI-MedLine.d10.s3|47-57|detrimental|O
DDI-MedLine.d10.s3|59-61|for|O
DDI-MedLine.d10.s3|63-65|the|O
DDI-MedLine.d10.s3|67-73|patient|O
DDI-MedLine.d10.s3|75-78|with|O
DDI-MedLine.d10.s3|80-90|compromised|O
DDI-MedLine.d10.s3|92-96|renal|O
DDI-MedLine.d10.s3|98-105|function|O
DDI-MedLine.d10.s3|106-106|.|O
DDI-MedLine.d10.s4|0-7|Patients|O
DDI-MedLine.d10.s4|9-12|with|O
DDI-MedLine.d10.s4|14-18|renal|O
DDI-MedLine.d10.s4|20-32|insufficiency|O
DDI-MedLine.d10.s4|34-35|or|O
DDI-MedLine.d10.s4|37-41|renal|O
DDI-MedLine.d10.s4|43-49|failure|O
DDI-MedLine.d10.s4|51-53|may|O
DDI-MedLine.d10.s4|55-56|be|O
DDI-MedLine.d10.s4|58-59|at|O
DDI-MedLine.d10.s4|61-64|risk|O
DDI-MedLine.d10.s4|66-68|for|O
DDI-MedLine.d10.s4|70-76|further|O
DDI-MedLine.d10.s4|78-83|kidney|O
DDI-MedLine.d10.s4|85-90|damage|O
DDI-MedLine.d10.s4|92-93|as|O
DDI-MedLine.d10.s4|95-98|well|O
DDI-MedLine.d10.s4|100-101|as|O
DDI-MedLine.d10.s4|103-115|complications|O
DDI-MedLine.d10.s4|117-123|related|O
DDI-MedLine.d10.s4|125-126|to|O
DDI-MedLine.d10.s4|128-139|interactions|O
DDI-MedLine.d10.s4|141-142|of|O
DDI-MedLine.d10.s4|144-149|herbal|O
DDI-MedLine.d10.s4|151-158|remedies|O
DDI-MedLine.d10.s4|160-163|with|O
DDI-MedLine.d10.s4|165-171|complex|O
DDI-MedLine.d10.s4|173-177|renal|O
DDI-MedLine.d10.s4|179-185|therapy|O
DDI-MedLine.d10.s4|187-194|regimens|O
DDI-MedLine.d10.s4|195-195|.|O
DDI-MedLine.d10.s5|0-3|This|O
DDI-MedLine.d10.s5|5-11|article|O
DDI-MedLine.d10.s5|13-16|will|O
DDI-MedLine.d10.s5|18-25|describe|O
DDI-MedLine.d10.s5|27-29|the|O
DDI-MedLine.d10.s5|31-40|escalating|O
DDI-MedLine.d10.s5|42-44|use|O
DDI-MedLine.d10.s5|46-47|of|O
DDI-MedLine.d10.s5|49-54|herbal|O
DDI-MedLine.d10.s5|56-62|therapy|O
DDI-MedLine.d10.s5|64-66|and|O
DDI-MedLine.d10.s5|68-70|the|O
DDI-MedLine.d10.s5|72-78|hazards|O
DDI-MedLine.d10.s5|80-81|of|O
DDI-MedLine.d10.s5|83-88|herbal|O
DDI-MedLine.d10.s5|90-95|remedy|O
DDI-MedLine.d10.s5|97-99|use|O
DDI-MedLine.d10.s5|101-105|among|O
DDI-MedLine.d10.s5|107-114|patients|O
DDI-MedLine.d10.s5|115-115|.|O
DDI-DrugBank.d157.s0|0-7|Clinical|O
DDI-DrugBank.d157.s0|9-19|interaction|O
DDI-DrugBank.d157.s0|21-27|studies|O
DDI-DrugBank.d157.s0|29-32|with|O
DDI-DrugBank.d157.s0|34-43|cimetidine|drug
DDI-DrugBank.d157.s0|45-47|and|O
DDI-DrugBank.d157.s0|49-56|warfarin|drug
DDI-DrugBank.d157.s0|58-66|indicated|O
DDI-DrugBank.d157.s0|68-71|that|O
DDI-DrugBank.d157.s0|73-75|the|O
DDI-DrugBank.d157.s0|77-92|coadministration|O
DDI-DrugBank.d157.s0|94-95|of|O
DDI-DrugBank.d157.s0|97-102|Femara|brand
DDI-DrugBank.d157.s0|104-107|with|O
DDI-DrugBank.d157.s0|109-113|these|O
DDI-DrugBank.d157.s0|115-119|drugs|O
DDI-DrugBank.d157.s0|121-124|does|O
DDI-DrugBank.d157.s0|126-128|not|O
DDI-DrugBank.d157.s0|130-135|result|O
DDI-DrugBank.d157.s0|137-138|in|O
DDI-DrugBank.d157.s0|140-150|clinically-|O
DDI-DrugBank.d157.s0|152-162|significant|O
DDI-DrugBank.d157.s0|164-167|drug|O
DDI-DrugBank.d157.s0|169-180|interactions|O
DDI-DrugBank.d157.s0|181-181|.|O
DDI-DrugBank.d157.s1|0-0|(|O
DDI-DrugBank.d157.s1|1-3|See|O
DDI-DrugBank.d157.s1|5-12|CLINICAL|O
DDI-DrugBank.d157.s1|14-25|PHARMACOLOGY|O
DDI-DrugBank.d157.s1|26-26|)|O
DDI-DrugBank.d157.s1|28-43|Coadministration|O
DDI-DrugBank.d157.s1|45-46|of|O
DDI-DrugBank.d157.s1|48-53|Femara|brand
DDI-DrugBank.d157.s1|55-57|and|O
DDI-DrugBank.d157.s1|59-67|tamoxifen|drug
DDI-DrugBank.d157.s1|69-70|20|O
DDI-DrugBank.d157.s1|72-73|mg|O
DDI-DrugBank.d157.s1|75-79|daily|O
DDI-DrugBank.d157.s1|81-88|resulted|O
DDI-DrugBank.d157.s1|90-91|in|O
DDI-DrugBank.d157.s1|93-93|a|O
DDI-DrugBank.d157.s1|95-103|reduction|O
DDI-DrugBank.d157.s1|105-106|of|O
DDI-DrugBank.d157.s1|108-116|letrozole|drug
DDI-DrugBank.d157.s1|118-123|plasma|O
DDI-DrugBank.d157.s1|125-130|levels|O
DDI-DrugBank.d157.s1|132-133|by|O
DDI-DrugBank.d157.s1|135-136|38|O
DDI-DrugBank.d157.s1|137-137|%|O
DDI-DrugBank.d157.s1|139-140|on|O
DDI-DrugBank.d157.s1|142-148|average|O
DDI-DrugBank.d157.s1|149-149|.|O
DDI-DrugBank.d157.s2|0-4|There|O
DDI-DrugBank.d157.s2|6-7|is|O
DDI-DrugBank.d157.s2|9-10|no|O
DDI-DrugBank.d157.s2|12-19|clinical|O
DDI-DrugBank.d157.s2|21-30|experience|O
DDI-DrugBank.d157.s2|32-33|to|O
DDI-DrugBank.d157.s2|35-38|date|O
DDI-DrugBank.d157.s2|40-41|on|O
DDI-DrugBank.d157.s2|43-45|the|O
DDI-DrugBank.d157.s2|47-49|use|O
DDI-DrugBank.d157.s2|51-52|of|O
DDI-DrugBank.d157.s2|54-59|Femara|brand
DDI-DrugBank.d157.s2|61-62|in|O
DDI-DrugBank.d157.s2|64-74|combination|O
DDI-DrugBank.d157.s2|76-79|with|O
DDI-DrugBank.d157.s2|81-85|other|O
DDI-DrugBank.d157.s2|87-96|anticancer|O
DDI-DrugBank.d157.s2|98-103|agents|O
DDI-DrugBank.d157.s2|104-104|.|O
DDI-DrugBank.d157.s3|0-14|Drug/Laboratory|O
DDI-DrugBank.d157.s3|16-32|Test-Interactions|O
DDI-DrugBank.d157.s3|34-37|None|O
DDI-DrugBank.d157.s3|39-46|observed|O
DDI-DrugBank.d157.s3|47-47|.|O
DDI-DrugBank.d67.s0|0-1|In|O
DDI-DrugBank.d67.s0|3-5|two|O
DDI-DrugBank.d67.s0|7-16|controlled|O
DDI-DrugBank.d67.s0|18-26|crossover|O
DDI-DrugBank.d67.s0|28-35|clinical|O
DDI-DrugBank.d67.s0|37-48|pharmacology|O
DDI-DrugBank.d67.s0|50-56|studies|O
DDI-DrugBank.d67.s0|58-59|in|O
DDI-DrugBank.d67.s0|61-67|healthy|O
DDI-DrugBank.d67.s0|69-72|male|O
DDI-DrugBank.d67.s0|74-74|(|O
DDI-DrugBank.d67.s0|75-78|n=12|O
DDI-DrugBank.d67.s0|80-81|in|O
DDI-DrugBank.d67.s0|83-86|each|O
DDI-DrugBank.d67.s0|88-92|study|O
DDI-DrugBank.d67.s0|93-93|)|O
DDI-DrugBank.d67.s0|95-95|a|O
DDI-DrugBank.d67.s0|97-98|nd|O
DDI-DrugBank.d67.s0|100-105|female|O
DDI-DrugBank.d67.s0|107-107|(|O
DDI-DrugBank.d67.s0|108-111|n=12|O
DDI-DrugBank.d67.s0|113-114|in|O
DDI-DrugBank.d67.s0|116-119|each|O
DDI-DrugBank.d67.s0|121-125|study|O
DDI-DrugBank.d67.s0|126-126|)|O
DDI-DrugBank.d67.s0|128-137|volunteers|O
DDI-DrugBank.d67.s0|138-138|,|O
DDI-DrugBank.d67.s0|140-152|desloratadine|drug
DDI-DrugBank.d67.s0|154-156|7.5|O
DDI-DrugBank.d67.s0|158-159|mg|O
DDI-DrugBank.d67.s0|161-161|(|O
DDI-DrugBank.d67.s0|162-164|1.5|O
DDI-DrugBank.d67.s0|166-170|times|O
DDI-DrugBank.d67.s0|172-174|the|O
DDI-DrugBank.d67.s0|176-180|daily|O
DDI-DrugBank.d67.s0|182-185|dose|O
DDI-DrugBank.d67.s0|186-186|)|O
DDI-DrugBank.d67.s0|188-191|once|O
DDI-DrugBank.d67.s0|193-197|daily|O
DDI-DrugBank.d67.s0|199-201|was|O
DDI-DrugBank.d67.s0|203-216|coadministered|O
DDI-DrugBank.d67.s0|218-221|with|O
DDI-DrugBank.d67.s0|223-234|erythromycin|drug
DDI-DrugBank.d67.s0|236-238|500|O
DDI-DrugBank.d67.s0|240-241|mg|O
DDI-DrugBank.d67.s0|243-247|every|O
DDI-DrugBank.d67.s0|249-249|8|O
DDI-DrugBank.d67.s0|251-255|hours|O
DDI-DrugBank.d67.s0|257-258|or|O
DDI-DrugBank.d67.s0|260-271|ketoconazole|drug
DDI-DrugBank.d67.s0|273-275|200|O
DDI-DrugBank.d67.s0|277-278|mg|O
DDI-DrugBank.d67.s0|280-284|every|O
DDI-DrugBank.d67.s0|286-287|12|O
DDI-DrugBank.d67.s0|289-293|hours|O
DDI-DrugBank.d67.s0|295-297|for|O
DDI-DrugBank.d67.s0|299-300|10|O
DDI-DrugBank.d67.s0|302-305|days|O
DDI-DrugBank.d67.s0|306-306|.|O
DDI-DrugBank.d67.s1|0-1|In|O
DDI-DrugBank.d67.s1|3-7|three|O
DDI-DrugBank.d67.s1|9-16|separate|O
DDI-DrugBank.d67.s1|18-27|controlled|O
DDI-DrugBank.d67.s1|28-28|,|O
DDI-DrugBank.d67.s1|30-37|parallel|O
DDI-DrugBank.d67.s1|39-43|group|O
DDI-DrugBank.d67.s1|45-52|clinical|O
DDI-DrugBank.d67.s1|54-65|pharmacology|O
DDI-DrugBank.d67.s1|67-73|studies|O
DDI-DrugBank.d67.s1|74-74|,|O
DDI-DrugBank.d67.s1|76-88|desloratadine|drug
DDI-DrugBank.d67.s1|90-91|at|O
DDI-DrugBank.d67.s1|93-95|the|O
DDI-DrugBank.d67.s1|97-104|clinical|O
DDI-DrugBank.d67.s1|106-109|dose|O
DDI-DrugBank.d67.s1|111-112|of|O
DDI-DrugBank.d67.s1|114-114|5|O
DDI-DrugBank.d67.s1|116-117|mg|O
DDI-DrugBank.d67.s1|119-121|has|O
DDI-DrugBank.d67.s1|123-126|been|O
DDI-DrugBank.d67.s1|128-141|coadministered|O
DDI-DrugBank.d67.s1|143-146|with|O
DDI-DrugBank.d67.s1|148-159|azithromycin|drug
DDI-DrugBank.d67.s1|161-163|500|O
DDI-DrugBank.d67.s1|165-166|mg|O
DDI-DrugBank.d67.s1|168-175|followed|O
DDI-DrugBank.d67.s1|177-178|by|O
DDI-DrugBank.d67.s1|180-182|250|O
DDI-DrugBank.d67.s1|184-185|mg|O
DDI-DrugBank.d67.s1|187-190|once|O
DDI-DrugBank.d67.s1|192-196|daily|O
DDI-DrugBank.d67.s1|198-200|for|O
DDI-DrugBank.d67.s1|202-202|4|O
DDI-DrugBank.d67.s1|204-207|days|O
DDI-DrugBank.d67.s1|209-209|(|O
DDI-DrugBank.d67.s1|210-213|n=18|O
DDI-DrugBank.d67.s1|214-214|)|O
DDI-DrugBank.d67.s1|216-217|or|O
DDI-DrugBank.d67.s1|219-222|with|O
DDI-DrugBank.d67.s1|224-233|fluoxetine|drug
DDI-DrugBank.d67.s1|235-236|20|O
DDI-DrugBank.d67.s1|238-239|mg|O
DDI-DrugBank.d67.s1|241-244|once|O
DDI-DrugBank.d67.s1|246-250|daily|O
DDI-DrugBank.d67.s1|252-254|for|O
DDI-DrugBank.d67.s1|256-256|7|O
DDI-DrugBank.d67.s1|258-261|days|O
DDI-DrugBank.d67.s1|263-267|after|O
DDI-DrugBank.d67.s1|269-269|a|O
DDI-DrugBank.d67.s1|271-272|23|O
DDI-DrugBank.d67.s1|274-276|day|O
DDI-DrugBank.d67.s1|278-289|pretreatment|O
DDI-DrugBank.d67.s1|291-296|period|O
DDI-DrugBank.d67.s1|298-301|with|O
DDI-DrugBank.d67.s1|303-312|fluoxetine|drug
DDI-DrugBank.d67.s1|314-314|(|O
DDI-DrugBank.d67.s1|315-318|n=18|O
DDI-DrugBank.d67.s1|319-319|)|O
DDI-DrugBank.d67.s1|321-322|or|O
DDI-DrugBank.d67.s1|324-327|with|O
DDI-DrugBank.d67.s1|329-338|cimetidine|drug
DDI-DrugBank.d67.s1|340-342|600|O
DDI-DrugBank.d67.s1|344-345|mg|O
DDI-DrugBank.d67.s1|347-351|every|O
DDI-DrugBank.d67.s1|353-354|12|O
DDI-DrugBank.d67.s1|356-360|hours|O
DDI-DrugBank.d67.s1|362-364|for|O
DDI-DrugBank.d67.s1|366-367|14|O
DDI-DrugBank.d67.s1|369-372|days|O
DDI-DrugBank.d67.s1|374-374|(|O
DDI-DrugBank.d67.s1|375-378|n=18|O
DDI-DrugBank.d67.s1|379-379|)|O
DDI-DrugBank.d67.s1|381-385|under|O
DDI-DrugBank.d67.s1|387-392|steady|O
DDI-DrugBank.d67.s1|394-398|state|O
DDI-DrugBank.d67.s1|400-409|conditions|O
DDI-DrugBank.d67.s1|411-412|to|O
DDI-DrugBank.d67.s1|414-419|normal|O
DDI-DrugBank.d67.s1|421-427|healthy|O
DDI-DrugBank.d67.s1|429-432|male|O
DDI-DrugBank.d67.s1|434-436|and|O
DDI-DrugBank.d67.s1|438-443|female|O
DDI-DrugBank.d67.s1|445-454|volunteers|O
DDI-DrugBank.d67.s1|455-455|.|O
DDI-DrugBank.d67.s2|0-7|Although|O
DDI-DrugBank.d67.s2|9-17|increased|O
DDI-DrugBank.d67.s2|19-24|plasma|O
DDI-DrugBank.d67.s2|26-39|concentrations|O
DDI-DrugBank.d67.s2|41-41|(|O
DDI-DrugBank.d67.s2|42-42|C|O
DDI-DrugBank.d67.s2|44-46|max|O
DDI-DrugBank.d67.s2|48-50|and|O
DDI-DrugBank.d67.s2|52-54|AUC|O
DDI-DrugBank.d67.s2|56-59|0-24|O
DDI-DrugBank.d67.s2|61-63|hrs|O
DDI-DrugBank.d67.s2|64-64|)|O
DDI-DrugBank.d67.s2|66-67|of|O
DDI-DrugBank.d67.s2|69-81|desloratadine|drug
DDI-DrugBank.d67.s2|83-85|and|O
DDI-DrugBank.d67.s2|110-113|were|O
DDI-DrugBank.d67.s2|115-122|observed|O
DDI-DrugBank.d67.s2|124-124|,|O
DDI-DrugBank.d67.s2|126-130|there|O
DDI-DrugBank.d67.s2|132-135|were|O
DDI-DrugBank.d67.s2|137-138|no|O
DDI-DrugBank.d67.s2|140-149|clinically|O
DDI-DrugBank.d67.s2|151-158|relevant|O
DDI-DrugBank.d67.s2|160-166|changes|O
DDI-DrugBank.d67.s2|168-169|in|O
DDI-DrugBank.d67.s2|171-173|the|O
DDI-DrugBank.d67.s2|175-180|safety|O
DDI-DrugBank.d67.s2|182-188|profile|O
DDI-DrugBank.d67.s2|190-191|of|O
DDI-DrugBank.d67.s2|193-205|desloratadine|drug
DDI-DrugBank.d67.s2|206-206|,|O
DDI-DrugBank.d67.s2|208-209|as|O
DDI-DrugBank.d67.s2|211-218|assessed|O
DDI-DrugBank.d67.s2|220-221|by|O
DDI-DrugBank.d67.s2|223-242|electrocardiographic|O
DDI-DrugBank.d67.s2|244-253|parameters|O
DDI-DrugBank.d67.s2|255-255|(|O
DDI-DrugBank.d67.s2|256-264|including|O
DDI-DrugBank.d67.s2|266-268|the|O
DDI-DrugBank.d67.s2|270-278|corrected|O
DDI-DrugBank.d67.s2|280-281|QT|O
DDI-DrugBank.d67.s2|283-290|interval|O
DDI-DrugBank.d67.s2|291-291|)|O
DDI-DrugBank.d67.s2|292-292|,|O
DDI-DrugBank.d67.s2|294-301|clinical|O
DDI-DrugBank.d67.s2|303-312|laboratory|O
DDI-DrugBank.d67.s2|314-318|tests|O
DDI-DrugBank.d67.s2|319-319|,|O
DDI-DrugBank.d67.s2|321-325|vital|O
DDI-DrugBank.d67.s2|327-331|signs|O
DDI-DrugBank.d67.s2|332-332|,|O
DDI-DrugBank.d67.s2|334-336|and|O
DDI-DrugBank.d67.s2|338-344|adverse|O
DDI-DrugBank.d67.s2|346-351|events|O
DDI-DrugBank.d67.s2|352-352|.|O
DDI-DrugBank.d67.s3|0-4|Table|O
DDI-DrugBank.d67.s3|6-6|1|O
DDI-DrugBank.d67.s3|8-14|Changes|O
DDI-DrugBank.d67.s3|16-17|in|O
DDI-DrugBank.d67.s3|19-31|Desloratadine|drug
DDI-DrugBank.d67.s3|33-35|and|O
DDI-DrugBank.d67.s3|60-75|Pharmacokinetics|O
DDI-DrugBank.d67.s3|77-78|in|O
DDI-DrugBank.d67.s3|80-86|Healthy|O
DDI-DrugBank.d67.s3|88-91|Male|O
DDI-DrugBank.d67.s3|93-95|and|O
DDI-DrugBank.d67.s3|97-102|Female|O
DDI-DrugBank.d67.s3|104-113|Volunteers|O
DDI-DrugBank.d67.s7|0-0|C|O
DDI-DrugBank.d67.s7|2-4|max|O
DDI-DrugBank.d67.s7|6-8|AUC|O
DDI-DrugBank.d67.s7|10-13|0-24|O
DDI-DrugBank.d67.s7|15-17|hrs|O
DDI-DrugBank.d67.s7|19-19|C|O
DDI-DrugBank.d67.s7|21-23|max|O
DDI-DrugBank.d67.s7|25-27|AUC|O
DDI-DrugBank.d67.s7|29-32|0-24|O
DDI-DrugBank.d67.s7|34-36|hrs|O
DDI-DrugBank.d67.s9|0-0|(|O
DDI-DrugBank.d67.s9|1-3|500|O
DDI-DrugBank.d67.s9|5-6|mg|O
DDI-DrugBank.d67.s9|8-10|Q8h|O
DDI-DrugBank.d67.s9|11-11|)|O
DDI-DrugBank.d67.s10|0-2|+24|O
DDI-DrugBank.d67.s10|3-3|%|O
DDI-DrugBank.d67.s10|5-7|+14|O
DDI-DrugBank.d67.s10|8-8|%|O
DDI-DrugBank.d67.s10|10-12|+43|O
DDI-DrugBank.d67.s10|13-13|%|O
DDI-DrugBank.d67.s10|15-17|+40|O
DDI-DrugBank.d67.s10|18-18|%|O
DDI-DrugBank.d67.s12|0-0|(|O
DDI-DrugBank.d67.s12|1-3|200|O
DDI-DrugBank.d67.s12|5-6|mg|O
DDI-DrugBank.d67.s12|8-11|Q12h|O
DDI-DrugBank.d67.s12|12-12|)|O
DDI-DrugBank.d67.s13|0-2|+45|O
DDI-DrugBank.d67.s13|3-3|%|O
DDI-DrugBank.d67.s13|5-7|+39|O
DDI-DrugBank.d67.s13|8-8|%|O
DDI-DrugBank.d67.s13|10-12|+43|O
DDI-DrugBank.d67.s13|13-13|%|O
DDI-DrugBank.d67.s13|15-17|+72|O
DDI-DrugBank.d67.s13|18-18|%|O
DDI-DrugBank.d67.s15|0-0|(|O
DDI-DrugBank.d67.s15|1-3|500|O
DDI-DrugBank.d67.s15|5-6|mg|O
DDI-DrugBank.d67.s15|8-10|day|O
DDI-DrugBank.d67.s15|12-12|1|O
DDI-DrugBank.d67.s15|13-13|,|O
DDI-DrugBank.d67.s15|15-17|250|O
DDI-DrugBank.d67.s15|19-20|mg|O
DDI-DrugBank.d67.s15|22-23|QD|O
DDI-DrugBank.d67.s15|27-27|4|O
DDI-DrugBank.d67.s15|29-32|days|O
DDI-DrugBank.d67.s15|33-33|)|O
DDI-DrugBank.d67.s16|0-2|+15|O
DDI-DrugBank.d67.s16|3-3|%|O
DDI-DrugBank.d67.s16|5-6|+5|O
DDI-DrugBank.d67.s16|7-7|%|O
DDI-DrugBank.d67.s16|9-11|+15|O
DDI-DrugBank.d67.s16|12-12|%|O
DDI-DrugBank.d67.s16|14-15|+4|O
DDI-DrugBank.d67.s16|16-16|%|O
DDI-DrugBank.d67.s18|0-0|(|O
DDI-DrugBank.d67.s18|1-2|20|O
DDI-DrugBank.d67.s18|4-5|mg|O
DDI-DrugBank.d67.s18|7-8|QD|O
DDI-DrugBank.d67.s18|9-9|)|O
DDI-DrugBank.d67.s19|0-2|+15|O
DDI-DrugBank.d67.s19|3-3|%|O
DDI-DrugBank.d67.s19|5-6|+0|O
DDI-DrugBank.d67.s19|7-7|%|O
DDI-DrugBank.d67.s19|9-11|+17|O
DDI-DrugBank.d67.s19|12-12|%|O
DDI-DrugBank.d67.s19|14-16|+13|O
DDI-DrugBank.d67.s19|17-17|%|O
DDI-DrugBank.d67.s21|0-0|(|O
DDI-DrugBank.d67.s21|1-3|600|O
DDI-DrugBank.d67.s21|5-6|mg|O
DDI-DrugBank.d67.s21|8-11|Q12h|O
DDI-DrugBank.d67.s21|12-12|)|O
DDI-DrugBank.d67.s22|0-2|+12|O
DDI-DrugBank.d67.s22|3-3|%|O
DDI-DrugBank.d67.s22|5-7|+19|O
DDI-DrugBank.d67.s22|8-8|%|O
DDI-DrugBank.d67.s22|10-12|-11|O
DDI-DrugBank.d67.s22|13-13|%|O
DDI-DrugBank.d67.s22|16-17|-3|O
DDI-DrugBank.d67.s22|18-18|%|O
DDI-MedLine.d8.s0|0-1|In|O
DDI-MedLine.d8.s0|3-7|vitro|O
DDI-MedLine.d8.s0|9-16|activity|O
DDI-MedLine.d8.s0|18-19|of|O
DDI-MedLine.d8.s0|29-29|,|O
DDI-MedLine.d8.s0|31-36|either|O
DDI-MedLine.d8.s0|38-43|singly|O
DDI-MedLine.d8.s0|45-46|or|O
DDI-MedLine.d8.s0|48-49|in|O
DDI-MedLine.d8.s0|51-61|combination|O
DDI-MedLine.d8.s0|63-66|with|O
DDI-MedLine.d8.s0|68-76|ofloxacin|drug
DDI-MedLine.d8.s0|77-77|,|O
DDI-MedLine.d8.s0|79-85|against|O
DDI-MedLine.d8.s0|87-99|Mycobacterium|O
DDI-MedLine.d8.s0|101-108|ulcerans|O
DDI-MedLine.d8.s0|109-109|.|O
DDI-MedLine.d8.s1|0-2|The|O
DDI-MedLine.d8.s1|4-16|antimicrobial|O
DDI-MedLine.d8.s1|18-23|effect|O
DDI-MedLine.d8.s1|25-26|of|O
DDI-MedLine.d8.s1|28-28|a|O
DDI-MedLine.d8.s1|50-50|,|O
DDI-MedLine.d8.s1|60-60|,|O
DDI-MedLine.d8.s1|62-67|either|O
DDI-MedLine.d8.s1|69-73|alone|O
DDI-MedLine.d8.s1|75-76|or|O
DDI-MedLine.d8.s1|78-79|in|O
DDI-MedLine.d8.s1|81-91|combination|O
DDI-MedLine.d8.s1|93-96|with|O
DDI-MedLine.d8.s1|98-106|ofloxacin|drug
DDI-MedLine.d8.s1|107-107|,|O
DDI-MedLine.d8.s1|109-111|was|O
DDI-MedLine.d8.s1|113-121|evaluated|O
DDI-MedLine.d8.s1|123-124|in|O
DDI-MedLine.d8.s1|126-130|vitro|O
DDI-MedLine.d8.s1|132-138|against|O
DDI-MedLine.d8.s1|140-142|two|O
DDI-MedLine.d8.s1|144-147|type|O
DDI-MedLine.d8.s1|149-155|strains|O
DDI-MedLine.d8.s1|157-159|and|O
DDI-MedLine.d8.s1|161-163|six|O
DDI-MedLine.d8.s1|165-172|clinical|O
DDI-MedLine.d8.s1|174-181|isolates|O
DDI-MedLine.d8.s1|183-184|of|O
DDI-MedLine.d8.s1|186-198|Mycobacterium|O
DDI-MedLine.d8.s1|200-207|ulcerans|O
DDI-MedLine.d8.s1|208-208|.|O
DDI-MedLine.d8.s2|0-5|Growth|O
DDI-MedLine.d8.s2|7-8|of|O
DDI-MedLine.d8.s2|10-10|M|O
DDI-MedLine.d8.s2|11-11|.|O
DDI-MedLine.d8.s3|0-7|ulcerans|O
DDI-MedLine.d8.s3|9-11|was|O
DDI-MedLine.d8.s3|13-20|measured|O
DDI-MedLine.d8.s3|22-23|by|O
DDI-MedLine.d8.s3|25-29|plate|O
DDI-MedLine.d8.s3|31-36|counts|O
DDI-MedLine.d8.s3|38-40|and|O
DDI-MedLine.d8.s3|42-44|the|O
DDI-MedLine.d8.s3|46-51|BACTEC|O
DDI-MedLine.d8.s3|53-63|radiometric|O
DDI-MedLine.d8.s3|65-70|method|O
DDI-MedLine.d8.s3|71-71|.|O
DDI-MedLine.d8.s4|0-2|The|O
DDI-MedLine.d8.s4|4-10|minimal|O
DDI-MedLine.d8.s4|12-21|inhibitory|O
DDI-MedLine.d8.s4|23-35|concentration|O
DDI-MedLine.d8.s4|37-38|as|O
DDI-MedLine.d8.s4|40-43|well|O
DDI-MedLine.d8.s4|45-46|as|O
DDI-MedLine.d8.s4|48-54|minimal|O
DDI-MedLine.d8.s4|56-67|bactericidal|O
DDI-MedLine.d8.s4|69-81|concentration|O
DDI-MedLine.d8.s4|83-84|of|O
DDI-MedLine.d8.s4|95-101|against|O
DDI-MedLine.d8.s4|103-103|M|O
DDI-MedLine.d8.s4|104-104|.|O
DDI-MedLine.d8.s5|0-7|ulcerans|O
DDI-MedLine.d8.s5|9-11|was|O
DDI-MedLine.d8.s5|13-19|between|O
DDI-MedLine.d8.s5|21-25|0.012|O
DDI-MedLine.d8.s5|27-29|and|O
DDI-MedLine.d8.s5|31-35|0.025|O
DDI-MedLine.d8.s5|37-40|mg/l|O
DDI-MedLine.d8.s5|41-41|,|O
DDI-MedLine.d8.s5|43-47|while|O
DDI-MedLine.d8.s5|49-61|corresponding|O
DDI-MedLine.d8.s5|63-68|values|O
DDI-MedLine.d8.s5|70-72|for|O
DDI-MedLine.d8.s5|74-83|rifampicin|drug
DDI-MedLine.d8.s5|85-87|and|O
DDI-MedLine.d8.s5|89-97|rifabutin|drug
DDI-MedLine.d8.s5|99-102|were|O
DDI-MedLine.d8.s5|104-105|in|O
DDI-MedLine.d8.s5|107-109|the|O
DDI-MedLine.d8.s5|111-115|range|O
DDI-MedLine.d8.s5|117-118|of|O
DDI-MedLine.d8.s5|120-126|0.1-0.8|O
DDI-MedLine.d8.s5|128-131|mg/l|O
DDI-MedLine.d8.s5|133-135|and|O
DDI-MedLine.d8.s5|137-143|0.1-0.4|O
DDI-MedLine.d8.s5|145-148|mg/l|O
DDI-MedLine.d8.s5|150-161|respectively|O
DDI-MedLine.d8.s5|162-162|.|O
DDI-MedLine.d8.s6|0-3|When|O
DDI-MedLine.d8.s6|5-12|combined|O
DDI-MedLine.d8.s6|14-17|with|O
DDI-MedLine.d8.s6|19-27|ofloxacin|drug
DDI-MedLine.d8.s6|28-28|,|O
DDI-MedLine.d8.s6|39-47|exhibited|O
DDI-MedLine.d8.s6|49-54|strong|O
DDI-MedLine.d8.s6|56-66|synergistic|O
DDI-MedLine.d8.s6|68-75|activity|O
DDI-MedLine.d8.s6|77-81|while|O
DDI-MedLine.d8.s6|83-86|only|O
DDI-MedLine.d8.s6|88-95|additive|O
DDI-MedLine.d8.s6|97-103|effects|O
DDI-MedLine.d8.s6|105-108|were|O
DDI-MedLine.d8.s6|110-117|observed|O
DDI-MedLine.d8.s6|119-122|with|O
DDI-MedLine.d8.s6|124-126|the|O
DDI-MedLine.d8.s6|128-138|combination|O
DDI-MedLine.d8.s6|140-141|of|O
DDI-MedLine.d8.s6|143-152|rifampicin|drug
DDI-MedLine.d8.s6|154-154|(|O
DDI-MedLine.d8.s6|155-156|or|O
DDI-MedLine.d8.s6|158-166|rifabutin|drug
DDI-MedLine.d8.s6|167-167|)|O
DDI-MedLine.d8.s6|169-171|and|O
DDI-MedLine.d8.s6|173-181|ofloxacin|drug
DDI-MedLine.d8.s6|182-182|.|O
DDI-MedLine.d8.s7|0-4|These|O
DDI-MedLine.d8.s7|6-12|results|O
DDI-MedLine.d8.s7|14-20|suggest|O
DDI-MedLine.d8.s7|22-25|that|O
DDI-MedLine.d8.s7|36-38|has|O
DDI-MedLine.d8.s7|40-40|a|O
DDI-MedLine.d8.s7|42-46|great|O
DDI-MedLine.d8.s7|48-56|potential|O
DDI-MedLine.d8.s7|58-59|in|O
DDI-MedLine.d8.s7|61-63|the|O
DDI-MedLine.d8.s7|65-73|treatment|O
DDI-MedLine.d8.s7|75-76|of|O
DDI-MedLine.d8.s7|78-78|M|O
DDI-MedLine.d8.s7|79-79|.|O
DDI-MedLine.d8.s8|0-7|ulcerans|O
DDI-MedLine.d8.s8|9-17|infection|O
DDI-MedLine.d8.s8|18-18|.|O
DDI-DrugBank.d43.s0|0-15|Coadministration|O
DDI-DrugBank.d43.s0|17-18|of|O
DDI-DrugBank.d43.s0|20-24|VIDEX|brand
DDI-DrugBank.d43.s0|26-29|with|O
DDI-DrugBank.d43.s0|31-35|drugs|O
DDI-DrugBank.d43.s0|37-40|that|O
DDI-DrugBank.d43.s0|42-44|are|O
DDI-DrugBank.d43.s0|46-50|known|O
DDI-DrugBank.d43.s0|52-53|to|O
DDI-DrugBank.d43.s0|55-59|cause|O
DDI-DrugBank.d43.s0|61-72|pancreatitis|O
DDI-DrugBank.d43.s0|74-76|may|O
DDI-DrugBank.d43.s0|78-85|increase|O
DDI-DrugBank.d43.s0|87-89|the|O
DDI-DrugBank.d43.s0|91-94|risk|O
DDI-DrugBank.d43.s0|96-97|of|O
DDI-DrugBank.d43.s0|99-102|this|O
DDI-DrugBank.d43.s0|104-111|toxicity|O
DDI-DrugBank.d43.s0|113-113|(|O
DDI-DrugBank.d43.s0|114-116|see|O
DDI-DrugBank.d43.s0|118-125|WARNINGS|O
DDI-DrugBank.d43.s0|126-126|)|O
DDI-DrugBank.d43.s0|128-130|and|O
DDI-DrugBank.d43.s0|132-137|should|O
DDI-DrugBank.d43.s0|139-140|be|O
DDI-DrugBank.d43.s0|142-145|done|O
DDI-DrugBank.d43.s0|147-150|with|O
DDI-DrugBank.d43.s0|152-158|extreme|O
DDI-DrugBank.d43.s0|160-166|caution|O
DDI-DrugBank.d43.s0|167-167|,|O
DDI-DrugBank.d43.s0|169-172|only|O
DDI-DrugBank.d43.s0|174-175|if|O
DDI-DrugBank.d43.s0|177-181|other|O
DDI-DrugBank.d43.s0|183-194|alternatives|O
DDI-DrugBank.d43.s0|196-198|are|O
DDI-DrugBank.d43.s0|200-202|not|O
DDI-DrugBank.d43.s0|204-212|available|O
DDI-DrugBank.d43.s0|213-213|,|O
DDI-DrugBank.d43.s0|215-217|and|O
DDI-DrugBank.d43.s0|219-222|only|O
DDI-DrugBank.d43.s0|224-225|if|O
DDI-DrugBank.d43.s0|227-233|clearly|O
DDI-DrugBank.d43.s0|235-243|indicated|O
DDI-DrugBank.d43.s0|244-244|.|O
DDI-DrugBank.d43.s1|0-9|Neuropathy|O
DDI-DrugBank.d43.s1|11-13|has|O
DDI-DrugBank.d43.s1|15-22|occurred|O
DDI-DrugBank.d43.s1|24-27|more|O
DDI-DrugBank.d43.s1|29-38|frequently|O
DDI-DrugBank.d43.s1|40-41|in|O
DDI-DrugBank.d43.s1|43-50|patients|O
DDI-DrugBank.d43.s1|52-55|with|O
DDI-DrugBank.d43.s1|57-57|a|O
DDI-DrugBank.d43.s1|59-65|history|O
DDI-DrugBank.d43.s1|67-68|of|O
DDI-DrugBank.d43.s1|70-79|neuropathy|O
DDI-DrugBank.d43.s1|81-82|or|O
DDI-DrugBank.d43.s1|84-93|neurotoxic|O
DDI-DrugBank.d43.s1|95-98|drug|O
DDI-DrugBank.d43.s1|100-106|therapy|O
DDI-DrugBank.d43.s1|107-107|,|O
DDI-DrugBank.d43.s1|109-117|including|O
DDI-DrugBank.d43.s1|119-127|stavudine|drug
DDI-DrugBank.d43.s1|128-128|,|O
DDI-DrugBank.d43.s1|130-132|and|O
DDI-DrugBank.d43.s1|134-138|these|O
DDI-DrugBank.d43.s1|140-147|patients|O
DDI-DrugBank.d43.s1|149-151|may|O
DDI-DrugBank.d43.s1|153-154|be|O
DDI-DrugBank.d43.s1|156-157|at|O
DDI-DrugBank.d43.s1|159-167|increased|O
DDI-DrugBank.d43.s1|169-172|risk|O
DDI-DrugBank.d43.s1|174-175|of|O
DDI-DrugBank.d43.s1|177-186|neuropathy|O
DDI-DrugBank.d43.s1|188-193|during|O
DDI-DrugBank.d43.s1|195-199|VIDEX|brand
DDI-DrugBank.d43.s1|201-207|therapy|O
DDI-DrugBank.d43.s1|209-209|(|O
DDI-DrugBank.d43.s1|210-212|see|O
DDI-DrugBank.d43.s1|214-220|ADVERSE|O
DDI-DrugBank.d43.s1|222-230|REACTIONS|O
DDI-DrugBank.d43.s1|231-231|)|O
DDI-DrugBank.d43.s1|232-232|.|O
DDI-DrugBank.d43.s2|0-10|Allopurinol|drug
DDI-DrugBank.d43.s2|11-11|:|O
DDI-DrugBank.d43.s2|13-15|The|O
DDI-DrugBank.d43.s2|17-19|AUC|O
DDI-DrugBank.d43.s2|21-22|of|O
DDI-DrugBank.d43.s2|24-33|didanosine|drug
DDI-DrugBank.d43.s2|35-37|was|O
DDI-DrugBank.d43.s2|39-47|increased|O
DDI-DrugBank.d43.s2|49-53|about|O
DDI-DrugBank.d43.s2|55-60|4-fold|O
DDI-DrugBank.d43.s2|62-65|when|O
DDI-DrugBank.d43.s2|67-77|allopurinol|drug
DDI-DrugBank.d43.s2|79-80|at|O
DDI-DrugBank.d43.s2|82-84|300|O
DDI-DrugBank.d43.s2|86-91|mg/day|O
DDI-DrugBank.d43.s2|93-95|was|O
DDI-DrugBank.d43.s2|97-110|coadministered|O
DDI-DrugBank.d43.s2|112-115|with|O
DDI-DrugBank.d43.s2|117-117|a|O
DDI-DrugBank.d43.s2|119-124|single|O
DDI-DrugBank.d43.s2|126-131|200-mg|O
DDI-DrugBank.d43.s2|133-136|dose|O
DDI-DrugBank.d43.s2|138-139|of|O
DDI-DrugBank.d43.s2|141-145|VIDEX|brand
DDI-DrugBank.d43.s2|147-148|to|O
DDI-DrugBank.d43.s2|150-152|two|O
DDI-DrugBank.d43.s2|154-161|patients|O
DDI-DrugBank.d43.s2|163-166|with|O
DDI-DrugBank.d43.s2|168-172|renal|O
DDI-DrugBank.d43.s2|174-183|impairment|O
DDI-DrugBank.d43.s2|185-185|(|O
DDI-DrugBank.d43.s2|186-192|CLcr=15|O
DDI-DrugBank.d43.s2|194-196|and|O
DDI-DrugBank.d43.s2|198-199|18|O
DDI-DrugBank.d43.s2|201-206|mL/min|O
DDI-DrugBank.d43.s2|207-207|)|O
DDI-DrugBank.d43.s2|208-208|.|O
DDI-DrugBank.d43.s3|0-2|The|O
DDI-DrugBank.d43.s3|4-10|effects|O
DDI-DrugBank.d43.s3|12-13|of|O
DDI-DrugBank.d43.s3|15-25|allopurinol|drug
DDI-DrugBank.d43.s3|27-28|on|O
DDI-DrugBank.d43.s3|30-39|didanosine|drug
DDI-DrugBank.d43.s3|41-56|pharmacokinetics|O
DDI-DrugBank.d43.s3|58-59|in|O
DDI-DrugBank.d43.s3|61-68|subjects|O
DDI-DrugBank.d43.s3|70-73|with|O
DDI-DrugBank.d43.s3|75-80|normal|O
DDI-DrugBank.d43.s3|82-86|renal|O
DDI-DrugBank.d43.s3|88-95|function|O
DDI-DrugBank.d43.s3|97-99|are|O
DDI-DrugBank.d43.s3|101-103|not|O
DDI-DrugBank.d43.s3|105-109|known|O
DDI-DrugBank.d43.s3|110-110|.|O
DDI-DrugBank.d43.s4|0-7|Antacids|group
DDI-DrugBank.d43.s4|8-8|:|O
DDI-DrugBank.d43.s4|10-20|Concomitant|O
DDI-DrugBank.d43.s4|22-35|administration|O
DDI-DrugBank.d43.s4|37-38|of|O
DDI-DrugBank.d43.s4|40-47|antacids|group
DDI-DrugBank.d43.s4|49-58|containing|O
DDI-DrugBank.d43.s4|60-68|magnesium|drug
DDI-DrugBank.d43.s4|70-71|or|O
DDI-DrugBank.d43.s4|73-80|aluminum|drug
DDI-DrugBank.d43.s4|82-85|with|O
DDI-DrugBank.d43.s4|87-91|VIDEX|brand
DDI-DrugBank.d43.s4|93-112|Chewable/Dispersible|O
DDI-DrugBank.d43.s4|114-121|Buffered|O
DDI-DrugBank.d43.s4|123-129|Tablets|O
DDI-DrugBank.d43.s4|131-132|or|O
DDI-DrugBank.d43.s4|134-142|Pediatric|O
DDI-DrugBank.d43.s4|144-149|Powder|O
DDI-DrugBank.d43.s4|151-153|for|O
DDI-DrugBank.d43.s4|155-158|Oral|O
DDI-DrugBank.d43.s4|160-167|Solution|O
DDI-DrugBank.d43.s4|169-171|may|O
DDI-DrugBank.d43.s4|173-182|potentiate|O
DDI-DrugBank.d43.s4|184-190|adverse|O
DDI-DrugBank.d43.s4|192-197|events|O
DDI-DrugBank.d43.s4|199-208|associated|O
DDI-DrugBank.d43.s4|210-213|with|O
DDI-DrugBank.d43.s4|215-217|the|O
DDI-DrugBank.d43.s4|219-225|antacid|group
DDI-DrugBank.d43.s4|227-236|components|O
DDI-DrugBank.d43.s4|237-237|.|O
DDI-DrugBank.d43.s5|0-4|Drugs|O
DDI-DrugBank.d43.s5|6-10|Whose|O
DDI-DrugBank.d43.s5|12-21|Absorption|O
DDI-DrugBank.d43.s5|23-25|Can|O
DDI-DrugBank.d43.s5|27-28|Be|O
DDI-DrugBank.d43.s5|30-37|Affected|O
DDI-DrugBank.d43.s5|39-40|by|O
DDI-DrugBank.d43.s5|42-44|the|O
DDI-DrugBank.d43.s5|46-50|Level|O
DDI-DrugBank.d43.s5|52-53|of|O
DDI-DrugBank.d43.s5|55-61|Acidity|O
DDI-DrugBank.d43.s5|63-64|in|O
DDI-DrugBank.d43.s5|66-68|the|O
DDI-DrugBank.d43.s5|70-76|Stomach|O
DDI-DrugBank.d43.s5|77-77|:|O
DDI-DrugBank.d43.s5|79-83|Drugs|O
DDI-DrugBank.d43.s5|85-88|such|O
DDI-DrugBank.d43.s5|90-91|as|O
DDI-DrugBank.d43.s5|93-104|ketoconazole|drug
DDI-DrugBank.d43.s5|106-108|and|O
DDI-DrugBank.d43.s5|110-121|itraconazole|drug
DDI-DrugBank.d43.s5|123-128|should|O
DDI-DrugBank.d43.s5|130-131|be|O
DDI-DrugBank.d43.s5|133-144|administered|O
DDI-DrugBank.d43.s5|146-147|at|O
DDI-DrugBank.d43.s5|149-153|least|O
DDI-DrugBank.d43.s5|155-155|2|O
DDI-DrugBank.d43.s5|157-161|hours|O
DDI-DrugBank.d43.s5|163-167|prior|O
DDI-DrugBank.d43.s5|169-170|to|O
DDI-DrugBank.d43.s5|172-177|dosing|O
DDI-DrugBank.d43.s5|179-182|with|O
DDI-DrugBank.d43.s5|184-188|VIDEX|brand
DDI-DrugBank.d43.s5|189-189|.|O
DDI-DrugBank.d43.s6|0-10|Ganciclovir|drug
DDI-DrugBank.d43.s6|11-11|:|O
DDI-DrugBank.d43.s6|13-26|Administration|O
DDI-DrugBank.d43.s6|28-29|of|O
DDI-DrugBank.d43.s6|31-35|VIDEX|brand
DDI-DrugBank.d43.s6|37-37|2|O
DDI-DrugBank.d43.s6|39-43|hours|O
DDI-DrugBank.d43.s6|45-49|prior|O
DDI-DrugBank.d43.s6|51-52|to|O
DDI-DrugBank.d43.s6|54-55|or|O
DDI-DrugBank.d43.s6|57-66|concurrent|O
DDI-DrugBank.d43.s6|68-71|with|O
DDI-DrugBank.d43.s6|73-76|oral|O
DDI-DrugBank.d43.s6|78-88|ganciclovir|drug
DDI-DrugBank.d43.s6|90-92|was|O
DDI-DrugBank.d43.s6|94-103|associated|O
DDI-DrugBank.d43.s6|105-108|with|O
DDI-DrugBank.d43.s6|110-110|a|O
DDI-DrugBank.d43.s6|112-114|111|O
DDI-DrugBank.d43.s6|116-116|(|O
DDI-DrugBank.d43.s6|117-119|114|O
DDI-DrugBank.d43.s6|120-120|)|O
DDI-DrugBank.d43.s6|121-121|%|O
DDI-DrugBank.d43.s6|123-130|increase|O
DDI-DrugBank.d43.s6|132-133|in|O
DDI-DrugBank.d43.s6|135-137|the|O
DDI-DrugBank.d43.s6|139-150|steady-state|O
DDI-DrugBank.d43.s6|152-154|AUC|O
DDI-DrugBank.d43.s6|156-157|of|O
DDI-DrugBank.d43.s6|159-168|didanosine|drug
DDI-DrugBank.d43.s6|170-170|(|O
DDI-DrugBank.d43.s6|171-171|n|O
DDI-DrugBank.d43.s6|173-173|=|O
DDI-DrugBank.d43.s6|175-176|12|O
DDI-DrugBank.d43.s6|177-177|)|O
DDI-DrugBank.d43.s6|178-178|.|O
DDI-DrugBank.d43.s7|0-0|A|O
DDI-DrugBank.d43.s7|2-3|21|O
DDI-DrugBank.d43.s7|5-5|(|O
DDI-DrugBank.d43.s7|6-7|17|O
DDI-DrugBank.d43.s7|8-8|)|O
DDI-DrugBank.d43.s7|9-9|%|O
DDI-DrugBank.d43.s7|11-18|decrease|O
DDI-DrugBank.d43.s7|20-21|in|O
DDI-DrugBank.d43.s7|23-25|the|O
DDI-DrugBank.d43.s7|27-38|steady-state|O
DDI-DrugBank.d43.s7|40-42|AUC|O
DDI-DrugBank.d43.s7|44-45|of|O
DDI-DrugBank.d43.s7|47-57|ganciclovir|drug
DDI-DrugBank.d43.s7|59-61|was|O
DDI-DrugBank.d43.s7|63-70|observed|O
DDI-DrugBank.d43.s7|72-75|when|O
DDI-DrugBank.d43.s7|77-81|VIDEX|brand
DDI-DrugBank.d43.s7|83-85|was|O
DDI-DrugBank.d43.s7|87-98|administered|O
DDI-DrugBank.d43.s7|100-100|2|O
DDI-DrugBank.d43.s7|102-106|hours|O
DDI-DrugBank.d43.s7|108-112|prior|O
DDI-DrugBank.d43.s7|114-115|to|O
DDI-DrugBank.d43.s7|117-127|ganciclovir|drug
DDI-DrugBank.d43.s7|128-128|,|O
DDI-DrugBank.d43.s7|130-132|but|O
DDI-DrugBank.d43.s7|134-136|not|O
DDI-DrugBank.d43.s7|138-141|when|O
DDI-DrugBank.d43.s7|143-145|the|O
DDI-DrugBank.d43.s7|147-149|two|O
DDI-DrugBank.d43.s7|151-155|drugs|O
DDI-DrugBank.d43.s7|157-160|were|O
DDI-DrugBank.d43.s7|162-173|administered|O
DDI-DrugBank.d43.s7|175-188|simultaneously|O
DDI-DrugBank.d43.s7|190-190|(|O
DDI-DrugBank.d43.s7|191-191|n|O
DDI-DrugBank.d43.s7|193-193|=|O
DDI-DrugBank.d43.s7|195-196|12|O
DDI-DrugBank.d43.s7|197-197|)|O
DDI-DrugBank.d43.s7|198-198|.|O
DDI-DrugBank.d43.s8|0-8|Quinolone|group
DDI-DrugBank.d43.s8|10-20|Antibiotics|O
DDI-DrugBank.d43.s8|21-21|:|O
DDI-DrugBank.d43.s8|23-27|VIDEX|brand
DDI-DrugBank.d43.s8|29-34|should|O
DDI-DrugBank.d43.s8|36-37|be|O
DDI-DrugBank.d43.s8|39-50|administered|O
DDI-DrugBank.d43.s8|52-53|at|O
DDI-DrugBank.d43.s8|55-59|least|O
DDI-DrugBank.d43.s8|61-61|2|O
DDI-DrugBank.d43.s8|63-67|hours|O
DDI-DrugBank.d43.s8|69-73|after|O
DDI-DrugBank.d43.s8|75-76|or|O
DDI-DrugBank.d43.s8|78-78|6|O
DDI-DrugBank.d43.s8|80-84|hours|O
DDI-DrugBank.d43.s8|86-91|before|O
DDI-DrugBank.d43.s8|93-98|dosing|O
DDI-DrugBank.d43.s8|100-103|with|O
DDI-DrugBank.d43.s8|105-117|ciprofloxacin|drug
DDI-DrugBank.d43.s8|119-125|because|O
DDI-DrugBank.d43.s8|127-132|plasma|O
DDI-DrugBank.d43.s8|134-147|concentrations|O
DDI-DrugBank.d43.s8|149-150|of|O
DDI-DrugBank.d43.s8|152-164|ciprofloxacin|drug
DDI-DrugBank.d43.s8|166-168|are|O
DDI-DrugBank.d43.s8|170-178|decreased|O
DDI-DrugBank.d43.s8|180-183|when|O
DDI-DrugBank.d43.s8|185-196|administered|O
DDI-DrugBank.d43.s8|198-201|with|O
DDI-DrugBank.d43.s8|203-210|antacids|group
DDI-DrugBank.d43.s8|212-221|containing|O
DDI-DrugBank.d43.s8|223-231|magnesium|drug
DDI-DrugBank.d43.s8|232-232|,|O
DDI-DrugBank.d43.s8|234-240|calcium|drug
DDI-DrugBank.d43.s8|241-241|,|O
DDI-DrugBank.d43.s8|243-244|or|O
DDI-DrugBank.d43.s8|246-253|aluminum|drug
DDI-DrugBank.d43.s8|254-254|.|O
DDI-DrugBank.d43.s9|0-1|In|O
DDI-DrugBank.d43.s9|3-7|eight|O
DDI-DrugBank.d43.s9|9-20|HIV-infected|O
DDI-DrugBank.d43.s9|22-29|patients|O
DDI-DrugBank.d43.s9|30-30|,|O
DDI-DrugBank.d43.s9|32-34|the|O
DDI-DrugBank.d43.s9|36-47|steady-state|O
DDI-DrugBank.d43.s9|49-51|AUC|O
DDI-DrugBank.d43.s9|53-54|of|O
DDI-DrugBank.d43.s9|56-68|ciprofloxacin|drug
DDI-DrugBank.d43.s9|70-72|was|O
DDI-DrugBank.d43.s9|74-82|decreased|O
DDI-DrugBank.d43.s9|84-85|an|O
DDI-DrugBank.d43.s9|87-93|average|O
DDI-DrugBank.d43.s9|95-96|of|O
DDI-DrugBank.d43.s9|98-99|26|O
DDI-DrugBank.d43.s9|100-100|%|O
DDI-DrugBank.d43.s9|102-102|(|O
DDI-DrugBank.d43.s9|103-104|95|O
DDI-DrugBank.d43.s9|105-105|%|O
DDI-DrugBank.d43.s9|107-108|CI|O
DDI-DrugBank.d43.s9|110-110|=|O
DDI-DrugBank.d43.s9|112-113|14|O
DDI-DrugBank.d43.s9|114-114|%|O
DDI-DrugBank.d43.s9|115-115|,|O
DDI-DrugBank.d43.s9|117-118|37|O
DDI-DrugBank.d43.s9|119-119|%|O
DDI-DrugBank.d43.s9|120-120|)|O
DDI-DrugBank.d43.s9|122-125|when|O
DDI-DrugBank.d43.s9|127-139|ciprofloxacin|drug
DDI-DrugBank.d43.s9|141-143|was|O
DDI-DrugBank.d43.s9|145-156|administered|O
DDI-DrugBank.d43.s9|158-158|2|O
DDI-DrugBank.d43.s9|160-164|hours|O
DDI-DrugBank.d43.s9|166-170|prior|O
DDI-DrugBank.d43.s9|172-173|to|O
DDI-DrugBank.d43.s9|175-175|a|O
DDI-DrugBank.d43.s9|177-184|marketed|O
DDI-DrugBank.d43.s9|186-205|chewable/dispersible|O
DDI-DrugBank.d43.s9|207-212|tablet|O
DDI-DrugBank.d43.s9|214-224|formulation|O
DDI-DrugBank.d43.s9|226-227|of|O
DDI-DrugBank.d43.s9|229-233|VIDEX|brand
DDI-DrugBank.d43.s9|234-234|.|O
DDI-DrugBank.d43.s10|0-2|The|O
DDI-DrugBank.d43.s10|4-6|AUC|O
DDI-DrugBank.d43.s10|8-9|of|O
DDI-DrugBank.d43.s10|11-23|ciprofloxacin|drug
DDI-DrugBank.d43.s10|25-27|was|O
DDI-DrugBank.d43.s10|29-37|decreased|O
DDI-DrugBank.d43.s10|39-40|an|O
DDI-DrugBank.d43.s10|42-48|average|O
DDI-DrugBank.d43.s10|50-51|of|O
DDI-DrugBank.d43.s10|53-59|15-fold|O
DDI-DrugBank.d43.s10|61-62|in|O
DDI-DrugBank.d43.s10|64-65|12|O
DDI-DrugBank.d43.s10|67-73|healthy|O
DDI-DrugBank.d43.s10|75-82|subjects|O
DDI-DrugBank.d43.s10|84-88|given|O
DDI-DrugBank.d43.s10|90-102|ciprofloxacin|drug
DDI-DrugBank.d43.s10|104-106|and|O
DDI-DrugBank.d43.s10|108-125|didanosine-placebo|drug
DDI-DrugBank.d43.s10|127-133|tablets|O
DDI-DrugBank.d43.s10|135-146|concurrently|O
DDI-DrugBank.d43.s10|147-147|.|O
DDI-DrugBank.d43.s11|0-1|In|O
DDI-DrugBank.d43.s11|3-3|a|O
DDI-DrugBank.d43.s11|5-10|single|O
DDI-DrugBank.d43.s11|12-18|subject|O
DDI-DrugBank.d43.s11|20-24|given|O
DDI-DrugBank.d43.s11|26-28|one|O
DDI-DrugBank.d43.s11|30-33|dose|O
DDI-DrugBank.d43.s11|35-36|of|O
DDI-DrugBank.d43.s11|38-50|ciprofloxacin|drug
DDI-DrugBank.d43.s11|52-52|2|O
DDI-DrugBank.d43.s11|54-58|hours|O
DDI-DrugBank.d43.s11|60-64|after|O
DDI-DrugBank.d43.s11|66-66|a|O
DDI-DrugBank.d43.s11|68-71|dose|O
DDI-DrugBank.d43.s11|73-74|of|O
DDI-DrugBank.d43.s11|76-93|didanosine-placebo|drug
DDI-DrugBank.d43.s11|95-101|tablets|O
DDI-DrugBank.d43.s11|102-102|,|O
DDI-DrugBank.d43.s11|104-104|a|O
DDI-DrugBank.d43.s11|106-112|greater|O
DDI-DrugBank.d43.s11|114-117|than|O
DDI-DrugBank.d43.s11|119-120|50|O
DDI-DrugBank.d43.s11|121-121|%|O
DDI-DrugBank.d43.s11|123-131|reduction|O
DDI-DrugBank.d43.s11|133-134|in|O
DDI-DrugBank.d43.s11|136-138|the|O
DDI-DrugBank.d43.s11|140-142|AUC|O
DDI-DrugBank.d43.s11|144-145|of|O
DDI-DrugBank.d43.s11|147-159|ciprofloxacin|drug
DDI-DrugBank.d43.s11|161-163|was|O
DDI-DrugBank.d43.s11|165-172|observed|O
DDI-DrugBank.d43.s11|173-173|.|O
DDI-DrugBank.d43.s12|0-5|Plasma|O
DDI-DrugBank.d43.s12|7-20|concentrations|O
DDI-DrugBank.d43.s12|22-23|of|O
DDI-DrugBank.d43.s12|25-45|quinolone antibiotics|group
DDI-DrugBank.d43.s12|47-49|are|O
DDI-DrugBank.d43.s12|51-59|decreased|O
DDI-DrugBank.d43.s12|61-64|when|O
DDI-DrugBank.d43.s12|66-77|administered|O
DDI-DrugBank.d43.s12|79-82|with|O
DDI-DrugBank.d43.s12|84-91|antacids|group
DDI-DrugBank.d43.s12|93-102|containing|O
DDI-DrugBank.d43.s12|104-112|magnesium|drug
DDI-DrugBank.d43.s12|113-113|,|O
DDI-DrugBank.d43.s12|115-121|calcium|drug
DDI-DrugBank.d43.s12|122-122|,|O
DDI-DrugBank.d43.s12|124-125|or|O
DDI-DrugBank.d43.s12|127-134|aluminum|drug
DDI-DrugBank.d43.s12|135-135|.|O
DDI-DrugBank.d43.s13|0-2|The|O
DDI-DrugBank.d43.s13|4-10|optimal|O
DDI-DrugBank.d43.s13|12-17|dosing|O
DDI-DrugBank.d43.s13|19-26|interval|O
DDI-DrugBank.d43.s13|28-30|for|O
DDI-DrugBank.d43.s13|32-47|coadministration|O
DDI-DrugBank.d43.s13|49-52|with|O
DDI-DrugBank.d43.s13|54-58|VIDEX|brand
DDI-DrugBank.d43.s13|60-65|should|O
DDI-DrugBank.d43.s13|67-68|be|O
DDI-DrugBank.d43.s13|70-79|determined|O
DDI-DrugBank.d43.s13|81-82|by|O
DDI-DrugBank.d43.s13|84-93|consulting|O
DDI-DrugBank.d43.s13|95-97|the|O
DDI-DrugBank.d43.s13|99-109|appropriate|O
DDI-DrugBank.d43.s13|111-119|quinolone|group
DDI-DrugBank.d43.s13|121-127|package|O
DDI-DrugBank.d43.s13|129-134|insert|O
DDI-DrugBank.d43.s13|135-135|.|O
DDI-DrugBank.d43.s14|0-11|Interactions|O
DDI-DrugBank.d43.s14|13-16|with|O
DDI-DrugBank.d43.s14|18-22|Other|O
DDI-DrugBank.d43.s14|24-43|Antiretroviral Drugs|group
DDI-DrugBank.d43.s14|44-44|:|O
DDI-DrugBank.d43.s14|46-56|Significant|O
DDI-DrugBank.d43.s14|58-66|decreases|O
DDI-DrugBank.d43.s14|68-69|in|O
DDI-DrugBank.d43.s14|71-73|the|O
DDI-DrugBank.d43.s14|75-77|AUC|O
DDI-DrugBank.d43.s14|79-80|of|O
DDI-DrugBank.d43.s14|82-92|delavirdine|drug
DDI-DrugBank.d43.s14|94-94|(|O
DDI-DrugBank.d43.s14|95-96|20|O
DDI-DrugBank.d43.s14|97-97|%|O
DDI-DrugBank.d43.s14|98-98|)|O
DDI-DrugBank.d43.s14|100-102|and|O
DDI-DrugBank.d43.s14|104-112|indinavir|drug
DDI-DrugBank.d43.s14|114-114|(|O
DDI-DrugBank.d43.s14|115-116|84|O
DDI-DrugBank.d43.s14|117-117|%|O
DDI-DrugBank.d43.s14|118-118|)|O
DDI-DrugBank.d43.s14|120-127|occurred|O
DDI-DrugBank.d43.s14|129-137|following|O
DDI-DrugBank.d43.s14|139-150|simultaneous|O
DDI-DrugBank.d43.s14|152-165|administration|O
DDI-DrugBank.d43.s14|167-168|of|O
DDI-DrugBank.d43.s14|170-174|these|O
DDI-DrugBank.d43.s14|176-181|agents|O
DDI-DrugBank.d43.s14|183-186|with|O
DDI-DrugBank.d43.s14|188-192|VIDEX|brand
DDI-DrugBank.d43.s14|193-193|.|O
DDI-DrugBank.d43.s15|0-1|To|O
DDI-DrugBank.d43.s15|3-7|avoid|O
DDI-DrugBank.d43.s15|9-12|this|O
DDI-DrugBank.d43.s15|14-24|interaction|O
DDI-DrugBank.d43.s15|25-25|,|O
DDI-DrugBank.d43.s15|27-37|delavirdine|drug
DDI-DrugBank.d43.s15|39-40|or|O
DDI-DrugBank.d43.s15|42-50|indinavir|drug
DDI-DrugBank.d43.s15|52-57|should|O
DDI-DrugBank.d43.s15|59-60|be|O
DDI-DrugBank.d43.s15|62-66|given|O
DDI-DrugBank.d43.s15|68-68|1|O
DDI-DrugBank.d43.s15|70-73|hour|O
DDI-DrugBank.d43.s15|75-79|prior|O
DDI-DrugBank.d43.s15|81-82|to|O
DDI-DrugBank.d43.s15|84-89|dosing|O
DDI-DrugBank.d43.s15|91-94|with|O
DDI-DrugBank.d43.s15|96-100|VIDEX|brand
DDI-DrugBank.d43.s15|101-101|.|O
DDI-DrugBank.d43.s16|0-2|The|O
DDI-DrugBank.d43.s16|4-19|pharmacokinetics|O
DDI-DrugBank.d43.s16|21-22|of|O
DDI-DrugBank.d43.s16|24-33|nelfinavir|drug
DDI-DrugBank.d43.s16|35-37|are|O
DDI-DrugBank.d43.s16|39-41|not|O
DDI-DrugBank.d43.s16|43-49|altered|O
DDI-DrugBank.d43.s16|51-52|to|O
DDI-DrugBank.d43.s16|54-54|a|O
DDI-DrugBank.d43.s16|56-65|clinically|O
DDI-DrugBank.d43.s16|67-77|significant|O
DDI-DrugBank.d43.s16|79-84|degree|O
DDI-DrugBank.d43.s16|86-89|when|O
DDI-DrugBank.d43.s16|91-92|it|O
DDI-DrugBank.d43.s16|94-95|is|O
DDI-DrugBank.d43.s16|97-108|administered|O
DDI-DrugBank.d43.s16|110-113|with|O
DDI-DrugBank.d43.s16|115-115|a|O
DDI-DrugBank.d43.s16|117-121|light|O
DDI-DrugBank.d43.s16|123-126|meal|O
DDI-DrugBank.d43.s16|128-128|1|O
DDI-DrugBank.d43.s16|130-133|hour|O
DDI-DrugBank.d43.s16|135-139|after|O
DDI-DrugBank.d43.s16|141-145|VIDEX|brand
DDI-DrugBank.d43.s16|146-146|.|O
DDI-MedLine.d213.s0|0-1|In|O
DDI-MedLine.d213.s0|3-6|vivo|O
DDI-MedLine.d213.s0|8-12|CYP3A|O
DDI-MedLine.d213.s0|14-21|activity|O
DDI-MedLine.d213.s0|23-24|is|O
DDI-MedLine.d213.s0|26-38|significantly|O
DDI-MedLine.d213.s0|40-44|lower|O
DDI-MedLine.d213.s0|46-47|in|O
DDI-MedLine.d213.s0|49-68|cyclosporine-treated|drug
DDI-MedLine.d213.s0|70-71|as|O
DDI-MedLine.d213.s0|73-80|compared|O
DDI-MedLine.d213.s0|82-85|with|O
DDI-MedLine.d213.s0|87-104|tacrolimus-treated|drug
DDI-MedLine.d213.s0|106-110|renal|O
DDI-MedLine.d213.s0|112-120|allograft|O
DDI-MedLine.d213.s0|122-131|recipients|O
DDI-MedLine.d213.s0|132-132|.|O
DDI-MedLine.d213.s1|0-1|In|O
DDI-MedLine.d213.s1|3-7|vitro|O
DDI-MedLine.d213.s1|9-15|studies|O
DDI-MedLine.d213.s1|17-20|have|O
DDI-MedLine.d213.s1|22-31|identified|O
DDI-MedLine.d213.s1|33-44|cyclosporine|drug
DDI-MedLine.d213.s1|46-48|and|O
DDI-MedLine.d213.s1|50-59|tacrolimus|drug
DDI-MedLine.d213.s1|61-62|as|O
DDI-MedLine.d213.s1|64-68|CYP3A|O
DDI-MedLine.d213.s1|70-79|inhibitors|O
DDI-MedLine.d213.s1|80-80|.|O
DDI-MedLine.d213.s2|0-1|In|O
DDI-MedLine.d213.s2|3-5|the|O
DDI-MedLine.d213.s2|7-13|current|O
DDI-MedLine.d213.s2|15-19|study|O
DDI-MedLine.d213.s2|21-22|in|O
DDI-MedLine.d213.s2|24-28|renal|O
DDI-MedLine.d213.s2|30-38|allograft|O
DDI-MedLine.d213.s2|40-49|recipients|O
DDI-MedLine.d213.s2|50-50|,|O
DDI-MedLine.d213.s2|52-53|we|O
DDI-MedLine.d213.s2|55-58|used|O
DDI-MedLine.d213.s2|60-72|intravenously|O
DDI-MedLine.d213.s2|74-76|and|O
DDI-MedLine.d213.s2|78-83|orally|O
DDI-MedLine.d213.s2|85-96|administered|O
DDI-MedLine.d213.s2|98-106|midazolam|drug
DDI-MedLine.d213.s2|108-109|as|O
DDI-MedLine.d213.s2|111-111|a|O
DDI-MedLine.d213.s2|113-116|drug|O
DDI-MedLine.d213.s2|118-122|probe|O
DDI-MedLine.d213.s2|124-125|to|O
DDI-MedLine.d213.s2|127-132|assess|O
DDI-MedLine.d213.s2|134-140|whether|O
DDI-MedLine.d213.s2|142-144|the|O
DDI-MedLine.d213.s2|146-150|study|O
DDI-MedLine.d213.s2|152-156|drugs|O
DDI-MedLine.d213.s2|158-159|at|O
DDI-MedLine.d213.s2|161-165|doses|O
DDI-MedLine.d213.s2|167-170|that|O
DDI-MedLine.d213.s2|172-174|are|O
DDI-MedLine.d213.s2|176-184|generally|O
DDI-MedLine.d213.s2|186-189|used|O
DDI-MedLine.d213.s2|191-192|in|O
DDI-MedLine.d213.s2|194-201|clinical|O
DDI-MedLine.d213.s2|203-210|practice|O
DDI-MedLine.d213.s2|212-215|have|O
DDI-MedLine.d213.s2|217-228|differential|O
DDI-MedLine.d213.s2|230-236|effects|O
DDI-MedLine.d213.s2|238-239|on|O
DDI-MedLine.d213.s2|241-242|in|O
DDI-MedLine.d213.s2|244-247|vivo|O
DDI-MedLine.d213.s2|249-255|hepatic|O
DDI-MedLine.d213.s2|257-259|and|O
DDI-MedLine.d213.s2|261-270|first-pass|O
DDI-MedLine.d213.s2|272-276|CYP3A|O
DDI-MedLine.d213.s2|278-287|activities|O
DDI-MedLine.d213.s2|288-288|.|O
DDI-MedLine.d213.s3|0-7|Systemic|O
DDI-MedLine.d213.s3|9-11|and|O
DDI-MedLine.d213.s3|13-20|apparent|O
DDI-MedLine.d213.s3|22-25|oral|O
DDI-MedLine.d213.s3|27-35|midazolam|drug
DDI-MedLine.d213.s3|37-45|clearance|O
DDI-MedLine.d213.s3|47-50|were|O
DDI-MedLine.d213.s3|52-53|24|O
DDI-MedLine.d213.s3|54-54|%|O
DDI-MedLine.d213.s3|56-56|(|O
DDI-MedLine.d213.s3|57-59|269|O
DDI-MedLine.d213.s3|64-65|73|O
DDI-MedLine.d213.s3|67-69|vs.|O
DDI-MedLine.d213.s3|71-73|354|O
DDI-MedLine.d213.s3|78-80|102|O
DDI-MedLine.d213.s3|83-88|ml/min|O
DDI-MedLine.d213.s3|89-89|,|O
DDI-MedLine.d213.s3|91-91|P|O
DDI-MedLine.d213.s3|93-93|=|O
DDI-MedLine.d213.s3|95-99|0.022|O
DDI-MedLine.d213.s3|100-100|)|O
DDI-MedLine.d213.s3|102-104|and|O
DDI-MedLine.d213.s3|106-107|31|O
DDI-MedLine.d213.s3|108-108|%|O
DDI-MedLine.d213.s3|110-110|(|O
DDI-MedLine.d213.s3|111-113|479|O
DDI-MedLine.d213.s3|118-120|190|O
DDI-MedLine.d213.s3|122-124|vs.|O
DDI-MedLine.d213.s3|126-128|688|O
DDI-MedLine.d213.s3|133-135|265|O
DDI-MedLine.d213.s3|138-143|ml/min|O
DDI-MedLine.d213.s3|144-144|,|O
DDI-MedLine.d213.s3|146-146|P|O
DDI-MedLine.d213.s3|148-148|=|O
DDI-MedLine.d213.s3|150-154|0.013|O
DDI-MedLine.d213.s3|155-155|)|O
DDI-MedLine.d213.s3|156-156|,|O
DDI-MedLine.d213.s3|158-169|respectively|O
DDI-MedLine.d213.s3|170-170|,|O
DDI-MedLine.d213.s3|172-176|lower|O
DDI-MedLine.d213.s3|178-179|in|O
DDI-MedLine.d213.s3|181-200|cyclosporine-treated|drug
DDI-MedLine.d213.s3|202-209|patients|O
DDI-MedLine.d213.s3|211-211|(|O
DDI-MedLine.d213.s3|212-212|n|O
DDI-MedLine.d213.s3|214-214|=|O
DDI-MedLine.d213.s3|216-217|20|O
DDI-MedLine.d213.s3|218-218|)|O
DDI-MedLine.d213.s3|220-223|than|O
DDI-MedLine.d213.s3|225-226|in|O
DDI-MedLine.d213.s3|228-234|matched|O
DDI-MedLine.d213.s3|236-253|tacrolimus-treated|drug
DDI-MedLine.d213.s3|255-262|patients|O
DDI-MedLine.d213.s3|264-264|(|O
DDI-MedLine.d213.s3|265-265|n|O
DDI-MedLine.d213.s3|267-267|=|O
DDI-MedLine.d213.s3|269-270|20|O
DDI-MedLine.d213.s3|271-271|)|O
DDI-MedLine.d213.s3|272-272|.|O
DDI-MedLine.d213.s4|0-2|The|O
DDI-MedLine.d213.s4|4-9|latter|O
DDI-MedLine.d213.s4|11-19|displayed|O
DDI-MedLine.d213.s4|21-29|midazolam|drug
DDI-MedLine.d213.s4|31-40|clearances|O
DDI-MedLine.d213.s4|42-48|similar|O
DDI-MedLine.d213.s4|50-51|to|O
DDI-MedLine.d213.s4|53-57|those|O
DDI-MedLine.d213.s4|59-60|in|O
DDI-MedLine.d213.s4|62-64|two|O
DDI-MedLine.d213.s4|66-71|larger|O
DDI-MedLine.d213.s4|73-79|cohorts|O
DDI-MedLine.d213.s4|81-82|of|O
DDI-MedLine.d213.s4|84-93|nonmatched|O
DDI-MedLine.d213.s4|95-112|tacrolimus-treated|drug
DDI-MedLine.d213.s4|114-121|patients|O
DDI-MedLine.d213.s4|123-123|(|O
DDI-MedLine.d213.s4|124-124|n|O
DDI-MedLine.d213.s4|126-126|=|O
DDI-MedLine.d213.s4|128-129|58|O
DDI-MedLine.d213.s4|131-133|and|O
DDI-MedLine.d213.s4|135-135|n|O
DDI-MedLine.d213.s4|137-137|=|O
DDI-MedLine.d213.s4|139-140|80|O
DDI-MedLine.d213.s4|141-141|)|O
DDI-MedLine.d213.s4|143-145|and|O
DDI-MedLine.d213.s4|147-148|to|O
DDI-MedLine.d213.s4|150-154|those|O
DDI-MedLine.d213.s4|156-164|receiving|O
DDI-MedLine.d213.s4|166-166|a|O
DDI-MedLine.d213.s4|168-178|calcineurin|group
DDI-MedLine.d213.s4|180-193|inhibitor-free|O
DDI-MedLine.d213.s4|195-201|regimen|O
DDI-MedLine.d213.s4|203-203|(|O
DDI-MedLine.d213.s4|204-204|n|O
DDI-MedLine.d213.s4|206-206|=|O
DDI-MedLine.d213.s4|208-208|6|O
DDI-MedLine.d213.s4|209-209|)|O
DDI-MedLine.d213.s4|210-210|.|O
DDI-MedLine.d213.s5|0-3|This|O
DDI-MedLine.d213.s5|5-11|implies|O
DDI-MedLine.d213.s5|13-16|that|O
DDI-MedLine.d213.s5|18-19|in|O
DDI-MedLine.d213.s5|21-24|vivo|O
DDI-MedLine.d213.s5|26-32|hepatic|O
DDI-MedLine.d213.s5|34-36|and|O
DDI-MedLine.d213.s5|38-47|first-pass|O
DDI-MedLine.d213.s5|49-53|CYP3A|O
DDI-MedLine.d213.s5|55-64|activities|O
DDI-MedLine.d213.s5|66-68|are|O
DDI-MedLine.d213.s5|70-82|significantly|O
DDI-MedLine.d213.s5|84-88|lower|O
DDI-MedLine.d213.s5|90-91|in|O
DDI-MedLine.d213.s5|93-100|patients|O
DDI-MedLine.d213.s5|102-110|receiving|O
DDI-MedLine.d213.s5|112-123|cyclosporine|drug
DDI-MedLine.d213.s5|125-128|than|O
DDI-MedLine.d213.s5|130-131|in|O
DDI-MedLine.d213.s5|133-137|those|O
DDI-MedLine.d213.s5|139-147|receiving|O
DDI-MedLine.d213.s5|149-158|tacrolimus|drug
DDI-MedLine.d213.s5|159-159|,|O
DDI-MedLine.d213.s5|161-170|indicating|O
DDI-MedLine.d213.s5|172-175|that|O
DDI-MedLine.d213.s5|176-176|,|O
DDI-MedLine.d213.s5|178-179|at|O
DDI-MedLine.d213.s5|181-183|the|O
DDI-MedLine.d213.s5|185-189|doses|O
DDI-MedLine.d213.s5|191-199|generally|O
DDI-MedLine.d213.s5|201-204|used|O
DDI-MedLine.d213.s5|206-207|in|O
DDI-MedLine.d213.s5|209-216|clinical|O
DDI-MedLine.d213.s5|218-225|practice|O
DDI-MedLine.d213.s5|226-226|,|O
DDI-MedLine.d213.s5|228-239|cyclosporine|drug
DDI-MedLine.d213.s5|241-242|is|O
DDI-MedLine.d213.s5|244-246|the|O
DDI-MedLine.d213.s5|248-255|stronger|O
DDI-MedLine.d213.s5|257-258|of|O
DDI-MedLine.d213.s5|260-262|the|O
DDI-MedLine.d213.s5|264-266|two|O
DDI-MedLine.d213.s5|268-271|with|O
DDI-MedLine.d213.s5|273-279|respect|O
DDI-MedLine.d213.s5|281-282|to|O
DDI-MedLine.d213.s5|284-288|CYP3A|O
DDI-MedLine.d213.s5|290-299|inhibition|O
DDI-MedLine.d213.s5|300-300|.|O
DDI-MedLine.d213.s6|0-3|This|O
DDI-MedLine.d213.s6|5-15|observation|O
DDI-MedLine.d213.s6|17-19|has|O
DDI-MedLine.d213.s6|21-29|important|O
DDI-MedLine.d213.s6|31-42|implications|O
DDI-MedLine.d213.s6|44-45|in|O
DDI-MedLine.d213.s6|47-49|the|O
DDI-MedLine.d213.s6|51-57|context|O
DDI-MedLine.d213.s6|59-60|of|O
DDI-MedLine.d213.s6|62-70|drug-drug|O
DDI-MedLine.d213.s6|72-83|interactions|O
DDI-MedLine.d213.s6|85-86|in|O
DDI-MedLine.d213.s6|88-97|transplant|O
DDI-MedLine.d213.s6|99-108|recipients|O
DDI-MedLine.d213.s6|109-109|.|O
DDI-MedLine.d42.s0|0-17|Sildenafil citrate|drug
DDI-MedLine.d42.s0|18-18|:|O
DDI-MedLine.d42.s0|20-20|a|O
DDI-MedLine.d42.s0|22-32|therapeutic|O
DDI-MedLine.d42.s0|34-39|update|O
DDI-MedLine.d42.s0|40-40|.|O
DDI-MedLine.d42.s1|0-9|BACKGROUND|O
DDI-MedLine.d42.s1|10-10|:|O
DDI-MedLine.d42.s1|12-16|Since|O
DDI-MedLine.d42.s1|18-20|its|O
DDI-MedLine.d42.s1|22-29|approval|O
DDI-MedLine.d42.s1|31-32|by|O
DDI-MedLine.d42.s1|34-36|the|O
DDI-MedLine.d42.s1|38-39|US|O
DDI-MedLine.d42.s1|41-44|Food|O
DDI-MedLine.d42.s1|46-48|and|O
DDI-MedLine.d42.s1|50-53|Drug|O
DDI-MedLine.d42.s1|55-68|Administration|O
DDI-MedLine.d42.s1|70-71|in|O
DDI-MedLine.d42.s1|73-77|March|O
DDI-MedLine.d42.s1|79-82|1998|O
DDI-MedLine.d42.s1|83-83|,|O
DDI-MedLine.d42.s1|85-102|sildenafil citrate|drug
DDI-MedLine.d42.s1|104-106|has|O
DDI-MedLine.d42.s1|108-111|been|O
DDI-MedLine.d42.s1|113-116|used|O
DDI-MedLine.d42.s1|118-119|by|O
DDI-MedLine.d42.s1|121-128|millions|O
DDI-MedLine.d42.s1|130-131|of|O
DDI-MedLine.d42.s1|133-135|men|O
DDI-MedLine.d42.s1|137-139|for|O
DDI-MedLine.d42.s1|141-143|the|O
DDI-MedLine.d42.s1|145-153|treatment|O
DDI-MedLine.d42.s1|155-156|of|O
DDI-MedLine.d42.s1|158-165|erectile|O
DDI-MedLine.d42.s1|167-177|dysfunction|O
DDI-MedLine.d42.s1|178-178|.|O
DDI-MedLine.d42.s2|0-5|Recent|O
DDI-MedLine.d42.s2|7-13|studies|O
DDI-MedLine.d42.s2|15-17|and|O
DDI-MedLine.d42.s2|19-27|consensus|O
DDI-MedLine.d42.s2|29-35|reports|O
DDI-MedLine.d42.s2|37-40|have|O
DDI-MedLine.d42.s2|42-49|expanded|O
DDI-MedLine.d42.s2|51-53|our|O
DDI-MedLine.d42.s2|55-67|understanding|O
DDI-MedLine.d42.s2|69-70|of|O
DDI-MedLine.d42.s2|72-74|its|O
DDI-MedLine.d42.s2|76-83|efficacy|O
DDI-MedLine.d42.s2|84-84|,|O
DDI-MedLine.d42.s2|86-91|safety|O
DDI-MedLine.d42.s2|92-92|,|O
DDI-MedLine.d42.s2|94-110|contraindications|O
DDI-MedLine.d42.s2|111-111|,|O
DDI-MedLine.d42.s2|113-115|and|O
DDI-MedLine.d42.s2|117-120|drug|O
DDI-MedLine.d42.s2|122-133|interactions|O
DDI-MedLine.d42.s2|134-134|.|O
DDI-MedLine.d42.s3|0-8|OBJECTIVE|O
DDI-MedLine.d42.s3|9-9|:|O
DDI-MedLine.d42.s3|11-14|This|O
DDI-MedLine.d42.s3|16-20|paper|O
DDI-MedLine.d42.s3|22-28|reviews|O
DDI-MedLine.d42.s3|30-35|recent|O
DDI-MedLine.d42.s3|37-43|studies|O
DDI-MedLine.d42.s3|45-46|of|O
DDI-MedLine.d42.s3|48-50|the|O
DDI-MedLine.d42.s3|52-59|efficacy|O
DDI-MedLine.d42.s3|61-62|of|O
DDI-MedLine.d42.s3|64-73|sildenafil|drug
DDI-MedLine.d42.s3|74-74|,|O
DDI-MedLine.d42.s3|76-78|its|O
DDI-MedLine.d42.s3|80-86|adverse|O
DDI-MedLine.d42.s3|88-94|effects|O
DDI-MedLine.d42.s3|96-98|and|O
DDI-MedLine.d42.s3|100-103|drug|O
DDI-MedLine.d42.s3|105-116|interactions|O
DDI-MedLine.d42.s3|117-117|,|O
DDI-MedLine.d42.s3|119-121|and|O
DDI-MedLine.d42.s3|123-135|socioeconomic|O
DDI-MedLine.d42.s3|137-143|factors|O
DDI-MedLine.d42.s3|145-152|involved|O
DDI-MedLine.d42.s3|154-155|in|O
DDI-MedLine.d42.s3|157-159|its|O
DDI-MedLine.d42.s3|161-163|use|O
DDI-MedLine.d42.s3|164-164|,|O
DDI-MedLine.d42.s3|166-169|with|O
DDI-MedLine.d42.s3|171-171|a|O
DDI-MedLine.d42.s3|173-177|focus|O
DDI-MedLine.d42.s3|179-180|on|O
DDI-MedLine.d42.s3|182-189|specific|O
DDI-MedLine.d42.s3|191-197|patient|O
DDI-MedLine.d42.s3|199-209|populations|O
DDI-MedLine.d42.s3|211-211|(|O
DDI-MedLine.d42.s3|212-219|prostate|O
DDI-MedLine.d42.s3|221-226|cancer|O
DDI-MedLine.d42.s3|227-227|,|O
DDI-MedLine.d42.s3|229-236|diabetes|O
DDI-MedLine.d42.s3|238-245|mellitus|O
DDI-MedLine.d42.s3|246-246|,|O
DDI-MedLine.d42.s3|248-255|ischemic|O
DDI-MedLine.d42.s3|257-261|heart|O
DDI-MedLine.d42.s3|263-269|disease|O
DDI-MedLine.d42.s3|270-270|,|O
DDI-MedLine.d42.s3|272-277|spinal|O
DDI-MedLine.d42.s3|279-282|cord|O
DDI-MedLine.d42.s3|284-291|injuries|O
DDI-MedLine.d42.s3|292-292|,|O
DDI-MedLine.d42.s3|294-303|neurologic|O
DDI-MedLine.d42.s3|305-313|disorders|O
DDI-MedLine.d42.s3|314-314|)|O
DDI-MedLine.d42.s3|315-315|.|O
DDI-MedLine.d42.s4|0-6|METHODS|O
DDI-MedLine.d42.s4|7-7|:|O
DDI-MedLine.d42.s4|9-16|Clinical|O
DDI-MedLine.d42.s4|18-24|studies|O
DDI-MedLine.d42.s4|25-25|,|O
DDI-MedLine.d42.s4|27-30|case|O
DDI-MedLine.d42.s4|32-38|reports|O
DDI-MedLine.d42.s4|39-39|,|O
DDI-MedLine.d42.s4|41-43|and|O
DDI-MedLine.d42.s4|45-56|commentaries|O
DDI-MedLine.d42.s4|58-60|and|O
DDI-MedLine.d42.s4|62-71|editorials|O
DDI-MedLine.d42.s4|73-82|concerning|O
DDI-MedLine.d42.s4|84-93|sildenafil|drug
DDI-MedLine.d42.s4|95-103|published|O
DDI-MedLine.d42.s4|105-106|in|O
DDI-MedLine.d42.s4|108-110|the|O
DDI-MedLine.d42.s4|112-124|international|O
DDI-MedLine.d42.s4|126-135|literature|O
DDI-MedLine.d42.s4|137-143|between|O
DDI-MedLine.d42.s4|145-151|January|O
DDI-MedLine.d42.s4|153-156|1999|O
DDI-MedLine.d42.s4|158-160|and|O
DDI-MedLine.d42.s4|162-167|August|O
DDI-MedLine.d42.s4|169-172|2000|O
DDI-MedLine.d42.s4|174-177|were|O
DDI-MedLine.d42.s4|179-188|identified|O
DDI-MedLine.d42.s4|190-196|through|O
DDI-MedLine.d42.s4|198-205|searches|O
DDI-MedLine.d42.s4|207-208|of|O
DDI-MedLine.d42.s4|210-216|MEDLINE|O
DDI-MedLine.d42.s4|217-217|,|O
DDI-MedLine.d42.s4|219-228|PREMEDLINE|O
DDI-MedLine.d42.s4|229-229|,|O
DDI-MedLine.d42.s4|231-233|and|O
DDI-MedLine.d42.s4|235-247|International|O
DDI-MedLine.d42.s4|249-262|Pharmaceutical|O
DDI-MedLine.d42.s4|264-272|Abstracts|O
DDI-MedLine.d42.s4|273-273|,|O
DDI-MedLine.d42.s4|275-279|using|O
DDI-MedLine.d42.s4|281-283|the|O
DDI-MedLine.d42.s4|285-289|terms|O
DDI-MedLine.d42.s4|291-300|sildenafil|drug
DDI-MedLine.d42.s4|301-301|,|O
DDI-MedLine.d42.s4|303-308|Viagra|brand
DDI-MedLine.d42.s4|309-309|,|O
DDI-MedLine.d42.s4|311-313|and|O
DDI-MedLine.d42.s4|315-322|erectile|O
DDI-MedLine.d42.s4|324-334|dysfunction|O
DDI-MedLine.d42.s4|335-335|.|O
DDI-MedLine.d42.s5|0-6|RESULTS|O
DDI-MedLine.d42.s5|7-7|:|O
DDI-MedLine.d42.s5|9-18|Sildenafil|drug
DDI-MedLine.d42.s5|20-22|has|O
DDI-MedLine.d42.s5|24-35|demonstrated|O
DDI-MedLine.d42.s5|37-49|effectiveness|O
DDI-MedLine.d42.s5|51-52|in|O
DDI-MedLine.d42.s5|54-56|men|O
DDI-MedLine.d42.s5|58-61|with|O
DDI-MedLine.d42.s5|63-70|erectile|O
DDI-MedLine.d42.s5|72-82|dysfunction|O
DDI-MedLine.d42.s5|84-93|associated|O
DDI-MedLine.d42.s5|95-98|with|O
DDI-MedLine.d42.s5|100-112|prostatectomy|O
DDI-MedLine.d42.s5|113-113|,|O
DDI-MedLine.d42.s5|115-123|radiation|O
DDI-MedLine.d42.s5|125-131|therapy|O
DDI-MedLine.d42.s5|132-132|,|O
DDI-MedLine.d42.s5|134-141|diabetes|O
DDI-MedLine.d42.s5|143-150|mellitus|O
DDI-MedLine.d42.s5|151-151|,|O
DDI-MedLine.d42.s5|153-159|certain|O
DDI-MedLine.d42.s5|161-170|neurologic|O
DDI-MedLine.d42.s5|172-180|disorders|O
DDI-MedLine.d42.s5|181-181|,|O
DDI-MedLine.d42.s5|183-185|and|O
DDI-MedLine.d42.s5|187-190|drug|O
DDI-MedLine.d42.s5|192-198|therapy|O
DDI-MedLine.d42.s5|200-200|(|O
DDI-MedLine.d42.s5|201-202|eg|O
DDI-MedLine.d42.s5|203-203|,|O
DDI-MedLine.d42.s5|205-243|selective serotonin reuptake inhibitors|group
DDI-MedLine.d42.s5|245-245|[|O
DDI-MedLine.d42.s5|246-250|SSRIs|group
DDI-MedLine.d42.s5|251-251|]|O
DDI-MedLine.d42.s5|252-252|)|O
DDI-MedLine.d42.s5|253-253|.|O
DDI-MedLine.d42.s6|0-1|It|O
DDI-MedLine.d42.s6|3-5|has|O
DDI-MedLine.d42.s6|7-9|not|O
DDI-MedLine.d42.s6|11-14|been|O
DDI-MedLine.d42.s6|16-17|as|O
DDI-MedLine.d42.s6|19-27|effective|O
DDI-MedLine.d42.s6|29-30|in|O
DDI-MedLine.d42.s6|32-36|women|O
DDI-MedLine.d42.s6|38-41|with|O
DDI-MedLine.d42.s6|43-48|sexual|O
DDI-MedLine.d42.s6|50-60|dysfunction|O
DDI-MedLine.d42.s6|61-61|,|O
DDI-MedLine.d42.s6|63-66|with|O
DDI-MedLine.d42.s6|68-70|the|O
DDI-MedLine.d42.s6|72-80|exception|O
DDI-MedLine.d42.s6|82-83|of|O
DDI-MedLine.d42.s6|85-99|SSRI-associated|group
DDI-MedLine.d42.s6|101-106|sexual|O
DDI-MedLine.d42.s6|108-118|dysfunction|O
DDI-MedLine.d42.s6|119-119|.|O
DDI-MedLine.d42.s7|0-3|Some|O
DDI-MedLine.d42.s7|5-13|disorders|O
DDI-MedLine.d42.s7|15-23|unrelated|O
DDI-MedLine.d42.s7|25-26|to|O
DDI-MedLine.d42.s7|28-33|sexual|O
DDI-MedLine.d42.s7|35-45|dysfunction|O
DDI-MedLine.d42.s7|47-47|(|O
DDI-MedLine.d42.s7|48-49|eg|O
DDI-MedLine.d42.s7|50-50|,|O
DDI-MedLine.d42.s7|52-61|esophageal|O
DDI-MedLine.d42.s7|63-70|motility|O
DDI-MedLine.d42.s7|72-82|dysfunction|O
DDI-MedLine.d42.s7|83-83|)|O
DDI-MedLine.d42.s7|85-87|may|O
DDI-MedLine.d42.s7|89-92|also|O
DDI-MedLine.d42.s7|94-100|respond|O
DDI-MedLine.d42.s7|102-103|to|O
DDI-MedLine.d42.s7|105-114|sildenafil|drug
DDI-MedLine.d42.s7|115-115|.|O
DDI-MedLine.d42.s8|0-1|In|O
DDI-MedLine.d42.s8|3-5|the|O
DDI-MedLine.d42.s8|7-13|general|O
DDI-MedLine.d42.s8|15-24|population|O
DDI-MedLine.d42.s8|25-25|,|O
DDI-MedLine.d42.s8|27-36|sildenafil|drug
DDI-MedLine.d42.s8|38-39|is|O
DDI-MedLine.d42.s8|41-50|considered|O
DDI-MedLine.d42.s8|52-53|to|O
DDI-MedLine.d42.s8|55-58|have|O
DDI-MedLine.d42.s8|60-61|an|O
DDI-MedLine.d42.s8|63-72|acceptable|O
DDI-MedLine.d42.s8|74-85|tolerability|O
DDI-MedLine.d42.s8|87-93|profile|O
DDI-MedLine.d42.s8|94-94|;|O
DDI-MedLine.d42.s9|0-6|however|O
DDI-MedLine.d42.s9|7-7|,|O
DDI-MedLine.d42.s9|9-16|patients|O
DDI-MedLine.d42.s9|18-21|with|O
DDI-MedLine.d42.s9|23-30|moderate|O
DDI-MedLine.d42.s9|32-33|to|O
DDI-MedLine.d42.s9|35-40|severe|O
DDI-MedLine.d42.s9|42-55|cardiovascular|O
DDI-MedLine.d42.s9|57-63|disease|O
DDI-MedLine.d42.s9|65-66|or|O
DDI-MedLine.d42.s9|68-72|those|O
DDI-MedLine.d42.s9|74-79|taking|O
DDI-MedLine.d42.s9|81-87|nitrate|group
DDI-MedLine.d42.s9|89-95|therapy|O
DDI-MedLine.d42.s9|97-99|are|O
DDI-MedLine.d42.s9|101-102|at|O
DDI-MedLine.d42.s9|104-112|increased|O
DDI-MedLine.d42.s9|114-117|risk|O
DDI-MedLine.d42.s9|119-121|for|O
DDI-MedLine.d42.s9|123-133|potentially|O
DDI-MedLine.d42.s9|135-141|serious|O
DDI-MedLine.d42.s9|143-156|cardiovascular|O
DDI-MedLine.d42.s9|158-164|adverse|O
DDI-MedLine.d42.s9|166-172|effects|O
DDI-MedLine.d42.s9|174-177|with|O
DDI-MedLine.d42.s9|179-188|sildenafil|drug
DDI-MedLine.d42.s9|190-196|therapy|O
DDI-MedLine.d42.s9|197-197|.|O
DDI-MedLine.d42.s10|0-1|In|O
DDI-MedLine.d42.s10|3-10|addition|O
DDI-MedLine.d42.s10|11-11|,|O
DDI-MedLine.d42.s10|13-20|patients|O
DDI-MedLine.d42.s10|22-27|taking|O
DDI-MedLine.d42.s10|29-33|drugs|O
DDI-MedLine.d42.s10|35-38|that|O
DDI-MedLine.d42.s10|40-46|inhibit|O
DDI-MedLine.d42.s10|48-50|the|O
DDI-MedLine.d42.s10|52-61|cytochrome|O
DDI-MedLine.d42.s10|63-66|P450|O
DDI-MedLine.d42.s10|68-70|3A4|O
DDI-MedLine.d42.s10|72-78|isozyme|O
DDI-MedLine.d42.s10|79-79|,|O
DDI-MedLine.d42.s10|81-85|which|O
DDI-MedLine.d42.s10|87-97|metabolizes|O
DDI-MedLine.d42.s10|99-108|sildenafil|drug
DDI-MedLine.d42.s10|109-109|,|O
DDI-MedLine.d42.s10|111-113|may|O
DDI-MedLine.d42.s10|115-124|experience|O
DDI-MedLine.d42.s10|126-134|increased|O
DDI-MedLine.d42.s10|136-139|drug|O
DDI-MedLine.d42.s10|141-154|concentrations|O
DDI-MedLine.d42.s10|156-158|and|O
DDI-MedLine.d42.s10|160-167|possible|O
DDI-MedLine.d42.s10|169-176|toxicity|O
DDI-MedLine.d42.s10|178-181|from|O
DDI-MedLine.d42.s10|183-188|normal|O
DDI-MedLine.d42.s10|190-194|doses|O
DDI-MedLine.d42.s10|196-197|of|O
DDI-MedLine.d42.s10|199-208|sildenafil|drug
DDI-MedLine.d42.s10|209-209|.|O
DDI-MedLine.d42.s11|0-10|CONCLUSIONS|O
DDI-MedLine.d42.s11|11-11|:|O
DDI-MedLine.d42.s11|13-22|Sildenafil|drug
DDI-MedLine.d42.s11|24-25|is|O
DDI-MedLine.d42.s11|27-28|an|O
DDI-MedLine.d42.s11|30-38|effective|O
DDI-MedLine.d42.s11|40-49|first-line|O
DDI-MedLine.d42.s11|51-57|therapy|O
DDI-MedLine.d42.s11|59-61|for|O
DDI-MedLine.d42.s11|63-70|erectile|O
DDI-MedLine.d42.s11|72-82|dysfunction|O
DDI-MedLine.d42.s11|84-85|in|O
DDI-MedLine.d42.s11|87-89|men|O
DDI-MedLine.d42.s11|90-90|.|O
DDI-MedLine.d42.s12|0-2|The|O
DDI-MedLine.d42.s12|4-11|decision|O
DDI-MedLine.d42.s12|13-14|to|O
DDI-MedLine.d42.s12|16-24|prescribe|O
DDI-MedLine.d42.s12|26-29|this|O
DDI-MedLine.d42.s12|31-35|agent|O
DDI-MedLine.d42.s12|37-42|should|O
DDI-MedLine.d42.s12|44-50|include|O
DDI-MedLine.d42.s12|52-55|such|O
DDI-MedLine.d42.s12|57-70|considerations|O
DDI-MedLine.d42.s12|72-73|as|O
DDI-MedLine.d42.s12|75-77|the|O
DDI-MedLine.d42.s12|79-95|cost-risk-benefit|O
DDI-MedLine.d42.s12|97-103|balance|O
DDI-MedLine.d42.s12|104-104|,|O
DDI-MedLine.d42.s12|106-112|patient|O
DDI-MedLine.d42.s12|114-119|access|O
DDI-MedLine.d42.s12|120-120|,|O
DDI-MedLine.d42.s12|122-125|drug|O
DDI-MedLine.d42.s12|127-138|distribution|O
DDI-MedLine.d42.s12|140-147|pathways|O
DDI-MedLine.d42.s12|148-148|,|O
DDI-MedLine.d42.s12|150-152|and|O
DDI-MedLine.d42.s12|154-165|prescription|O
DDI-MedLine.d42.s12|167-170|drug|O
DDI-MedLine.d42.s12|172-179|coverage|O
DDI-MedLine.d42.s12|180-180|.|O
DDI-MedLine.d50.s0|0-12|Ascorbic acid|drug
DDI-MedLine.d50.s0|14-16|and|O
DDI-MedLine.d50.s0|18-20|the|O
DDI-MedLine.d50.s0|22-27|common|O
DDI-MedLine.d50.s0|29-32|cold|O
DDI-MedLine.d50.s0|33-33|.|O
DDI-MedLine.d50.s1|0-9|Evaluation|O
DDI-MedLine.d50.s1|11-12|of|O
DDI-MedLine.d50.s1|14-16|its|O
DDI-MedLine.d50.s1|18-25|efficacy|O
DDI-MedLine.d50.s1|27-29|and|O
DDI-MedLine.d50.s1|31-38|toxicity|O
DDI-MedLine.d50.s1|39-39|.|O
DDI-MedLine.d50.s2|0-1|We|O
DDI-MedLine.d50.s2|3-10|reviewed|O
DDI-MedLine.d50.s2|12-14|the|O
DDI-MedLine.d50.s2|16-23|clinical|O
DDI-MedLine.d50.s2|25-28|data|O
DDI-MedLine.d50.s2|30-37|relating|O
DDI-MedLine.d50.s2|39-40|to|O
DDI-MedLine.d50.s2|42-44|the|O
DDI-MedLine.d50.s2|46-53|efficacy|O
DDI-MedLine.d50.s2|55-57|and|O
DDI-MedLine.d50.s2|59-64|safety|O
DDI-MedLine.d50.s2|66-67|of|O
DDI-MedLine.d50.s2|69-81|pharmacologic|O
DDI-MedLine.d50.s2|83-87|doses|O
DDI-MedLine.d50.s2|89-90|of|O
DDI-MedLine.d50.s2|92-104|ascorbic acid|drug
DDI-MedLine.d50.s2|106-107|in|O
DDI-MedLine.d50.s2|109-111|the|O
DDI-MedLine.d50.s2|113-122|prevention|O
DDI-MedLine.d50.s2|124-126|and|O
DDI-MedLine.d50.s2|128-136|treatment|O
DDI-MedLine.d50.s2|138-139|of|O
DDI-MedLine.d50.s2|141-143|the|O
DDI-MedLine.d50.s2|145-150|common|O
DDI-MedLine.d50.s2|152-155|cold|O
DDI-MedLine.d50.s2|156-156|.|O
DDI-MedLine.d50.s3|0-7|Although|O
DDI-MedLine.d50.s3|9-11|one|O
DDI-MedLine.d50.s3|13-17|study|O
DDI-MedLine.d50.s3|19-29|tentatively|O
DDI-MedLine.d50.s3|31-38|supports|O
DDI-MedLine.d50.s3|40-42|the|O
DDI-MedLine.d50.s3|44-53|hypothesis|O
DDI-MedLine.d50.s3|55-58|that|O
DDI-MedLine.d50.s3|60-63|such|O
DDI-MedLine.d50.s3|65-69|doses|O
DDI-MedLine.d50.s3|71-72|of|O
DDI-MedLine.d50.s3|74-86|ascorbic acid|drug
DDI-MedLine.d50.s3|88-90|may|O
DDI-MedLine.d50.s3|92-93|be|O
DDI-MedLine.d50.s3|95-105|efficacious|O
DDI-MedLine.d50.s3|106-106|,|O
DDI-MedLine.d50.s3|108-108|a|O
DDI-MedLine.d50.s3|110-115|second|O
DDI-MedLine.d50.s3|117-121|study|O
DDI-MedLine.d50.s3|123-124|by|O
DDI-MedLine.d50.s3|126-128|the|O
DDI-MedLine.d50.s3|130-133|same|O
DDI-MedLine.d50.s3|135-139|group|O
DDI-MedLine.d50.s3|141-143|did|O
DDI-MedLine.d50.s3|145-147|not|O
DDI-MedLine.d50.s3|149-155|confirm|O
DDI-MedLine.d50.s3|157-159|the|O
DDI-MedLine.d50.s3|161-171|significant|O
DDI-MedLine.d50.s3|173-180|findings|O
DDI-MedLine.d50.s3|181-181|,|O
DDI-MedLine.d50.s3|183-185|and|O
DDI-MedLine.d50.s3|187-188|no|O
DDI-MedLine.d50.s3|190-194|clear|O
DDI-MedLine.d50.s3|195-195|,|O
DDI-MedLine.d50.s3|197-208|reproducible|O
DDI-MedLine.d50.s3|210-216|pattern|O
DDI-MedLine.d50.s3|218-219|of|O
DDI-MedLine.d50.s3|221-228|efficacy|O
DDI-MedLine.d50.s3|230-232|has|O
DDI-MedLine.d50.s3|234-240|emerged|O
DDI-MedLine.d50.s3|242-245|from|O
DDI-MedLine.d50.s3|247-249|the|O
DDI-MedLine.d50.s3|251-256|review|O
DDI-MedLine.d50.s3|258-259|of|O
DDI-MedLine.d50.s3|261-263|all|O
DDI-MedLine.d50.s3|265-267|the|O
DDI-MedLine.d50.s3|269-276|evidence|O
DDI-MedLine.d50.s3|277-277|.|O
DDI-MedLine.d50.s4|0-8|Similarly|O
DDI-MedLine.d50.s4|9-9|,|O
DDI-MedLine.d50.s4|11-15|there|O
DDI-MedLine.d50.s4|17-18|is|O
DDI-MedLine.d50.s4|20-28|currently|O
DDI-MedLine.d50.s4|30-35|little|O
DDI-MedLine.d50.s4|37-44|adequate|O
DDI-MedLine.d50.s4|46-53|evidence|O
DDI-MedLine.d50.s4|55-56|on|O
DDI-MedLine.d50.s4|58-63|either|O
DDI-MedLine.d50.s4|65-67|the|O
DDI-MedLine.d50.s4|69-76|presence|O
DDI-MedLine.d50.s4|78-79|or|O
DDI-MedLine.d50.s4|81-83|the|O
DDI-MedLine.d50.s4|85-91|absence|O
DDI-MedLine.d50.s4|93-94|of|O
DDI-MedLine.d50.s4|96-102|serious|O
DDI-MedLine.d50.s4|104-110|adverse|O
DDI-MedLine.d50.s4|112-120|reactions|O
DDI-MedLine.d50.s4|122-123|to|O
DDI-MedLine.d50.s4|125-128|such|O
DDI-MedLine.d50.s4|130-134|doses|O
DDI-MedLine.d50.s4|136-137|of|O
DDI-MedLine.d50.s4|139-151|ascorbic acid|drug
DDI-MedLine.d50.s4|152-152|,|O
DDI-MedLine.d50.s4|154-161|although|O
DDI-MedLine.d50.s4|163-166|many|O
DDI-MedLine.d50.s4|168-171|such|O
DDI-MedLine.d50.s4|173-181|reactions|O
DDI-MedLine.d50.s4|183-186|have|O
DDI-MedLine.d50.s4|188-191|been|O
DDI-MedLine.d50.s4|193-204|hypothesized|O
DDI-MedLine.d50.s4|205-205|.|O
DDI-MedLine.d50.s5|0-2|The|O
DDI-MedLine.d50.s5|4-15|unrestricted|O
DDI-MedLine.d50.s5|17-19|use|O
DDI-MedLine.d50.s5|21-22|of|O
DDI-MedLine.d50.s5|24-36|ascorbic acid|drug
DDI-MedLine.d50.s5|38-40|for|O
DDI-MedLine.d50.s5|42-46|these|O
DDI-MedLine.d50.s5|48-55|purposes|O
DDI-MedLine.d50.s5|57-59|can|O
DDI-MedLine.d50.s5|60-62|not|O
DDI-MedLine.d50.s5|64-65|be|O
DDI-MedLine.d50.s5|67-75|advocated|O
DDI-MedLine.d50.s5|77-78|on|O
DDI-MedLine.d50.s5|80-82|the|O
DDI-MedLine.d50.s5|84-88|basis|O
DDI-MedLine.d50.s5|90-91|of|O
DDI-MedLine.d50.s5|93-95|the|O
DDI-MedLine.d50.s5|97-104|evidence|O
DDI-MedLine.d50.s5|106-114|currently|O
DDI-MedLine.d50.s5|116-124|available|O
DDI-MedLine.d50.s5|125-125|.|O
DDI-DrugBank.d63.s0|0-33|Monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d63.s0|35-38|such|O
DDI-DrugBank.d63.s0|40-41|as|O
DDI-DrugBank.d63.s0|43-55|isocarboxazid|drug
DDI-DrugBank.d63.s0|57-57|(|O
DDI-DrugBank.d63.s0|58-61|e.g.|O
DDI-DrugBank.d63.s0|62-62|,|O
DDI-DrugBank.d63.s0|64-70|Marplan|brand
DDI-DrugBank.d63.s0|71-71|)|O
DDI-DrugBank.d63.s0|72-72|,|O
DDI-DrugBank.d63.s0|74-83|phenelzine|drug
DDI-DrugBank.d63.s0|85-85|(|O
DDI-DrugBank.d63.s0|86-89|e.g.|O
DDI-DrugBank.d63.s0|90-90|,|O
DDI-DrugBank.d63.s0|92-97|Nardil|brand
DDI-DrugBank.d63.s0|98-98|)|O
DDI-DrugBank.d63.s0|99-99|,|O
DDI-DrugBank.d63.s0|101-112|procarbazine|drug
DDI-DrugBank.d63.s0|114-114|(|O
DDI-DrugBank.d63.s0|115-118|e.g.|O
DDI-DrugBank.d63.s0|119-119|,|O
DDI-DrugBank.d63.s0|121-128|Matulane|brand
DDI-DrugBank.d63.s0|129-129|)|O
DDI-DrugBank.d63.s0|130-130|,|O
DDI-DrugBank.d63.s0|132-141|selegiline|drug
DDI-DrugBank.d63.s0|143-143|(|O
DDI-DrugBank.d63.s0|144-147|e.g.|O
DDI-DrugBank.d63.s0|148-148|,|O
DDI-DrugBank.d63.s0|150-157|Eldepryl|brand
DDI-DrugBank.d63.s0|158-158|)|O
DDI-DrugBank.d63.s0|159-159|,|O
DDI-DrugBank.d63.s0|161-163|and|O
DDI-DrugBank.d63.s0|165-179|tranylcypromine|drug
DDI-DrugBank.d63.s0|181-181|(|O
DDI-DrugBank.d63.s0|182-185|e.g.|O
DDI-DrugBank.d63.s0|186-186|,|O
DDI-DrugBank.d63.s0|188-194|Parnate|brand
DDI-DrugBank.d63.s0|195-195|)|O
DDI-DrugBank.d63.s0|196-196|:|O
DDI-DrugBank.d63.s0|198-202|Using|O
DDI-DrugBank.d63.s0|204-208|these|O
DDI-DrugBank.d63.s0|210-218|medicines|O
DDI-DrugBank.d63.s0|220-223|with|O
DDI-DrugBank.d63.s0|225-236|L-tryptophan|drug
DDI-DrugBank.d63.s0|238-240|may|O
DDI-DrugBank.d63.s0|242-249|increase|O
DDI-DrugBank.d63.s0|251-253|the|O
DDI-DrugBank.d63.s0|255-260|chance|O
DDI-DrugBank.d63.s0|262-263|of|O
DDI-DrugBank.d63.s0|265-268|side|O
DDI-DrugBank.d63.s0|270-276|effects|O
DDI-DrugBank.d63.s0|277-277|.|O
DDI-DrugBank.d474.s0|0-5|Unless|O
DDI-DrugBank.d474.s0|7-12|really|O
DDI-DrugBank.d474.s0|14-19|needed|O
DDI-DrugBank.d474.s0|20-20|,|O
DDI-DrugBank.d474.s0|22-27|agents|O
DDI-DrugBank.d474.s0|29-33|which|O
DDI-DrugBank.d474.s0|35-37|may|O
DDI-DrugBank.d474.s0|39-45|enhance|O
DDI-DrugBank.d474.s0|47-49|the|O
DDI-DrugBank.d474.s0|51-54|risk|O
DDI-DrugBank.d474.s0|56-57|of|O
DDI-DrugBank.d474.s0|59-68|hemorrhage|O
DDI-DrugBank.d474.s0|70-75|should|O
DDI-DrugBank.d474.s0|77-78|be|O
DDI-DrugBank.d474.s0|80-91|discontinued|O
DDI-DrugBank.d474.s0|93-97|prior|O
DDI-DrugBank.d474.s0|99-100|to|O
DDI-DrugBank.d474.s0|102-111|initiation|O
DDI-DrugBank.d474.s0|113-114|of|O
DDI-DrugBank.d474.s0|116-122|Lovenox|brand
DDI-DrugBank.d474.s0|124-132|Injection|O
DDI-DrugBank.d474.s0|134-140|therapy|O
DDI-DrugBank.d474.s0|141-141|.|O
DDI-DrugBank.d474.s1|0-4|These|O
DDI-DrugBank.d474.s1|6-11|agents|O
DDI-DrugBank.d474.s1|13-19|include|O
DDI-DrugBank.d474.s1|21-31|medications|O
DDI-DrugBank.d474.s1|33-36|such|O
DDI-DrugBank.d474.s1|38-39|as|O
DDI-DrugBank.d474.s1|40-40|:|O
DDI-DrugBank.d474.s1|42-55|anticoagulants|group
DDI-DrugBank.d474.s1|56-56|,|O
DDI-DrugBank.d474.s1|58-76|platelet inhibitors|group
DDI-DrugBank.d474.s1|78-86|including|O
DDI-DrugBank.d474.s1|88-107|acetylsalicylic acid|drug
DDI-DrugBank.d474.s1|108-108|,|O
DDI-DrugBank.d474.s1|110-121|sali-cylates|O
DDI-DrugBank.d474.s1|122-122|,|O
DDI-DrugBank.d474.s1|124-129|NSAIDs|group
DDI-DrugBank.d474.s1|131-131|(|O
DDI-DrugBank.d474.s1|132-140|including|O
DDI-DrugBank.d474.s1|142-163|ketorolac tromethamine|drug
DDI-DrugBank.d474.s1|164-164|)|O
DDI-DrugBank.d474.s1|165-165|,|O
DDI-DrugBank.d474.s1|167-178|dipyridamole|drug
DDI-DrugBank.d474.s1|179-179|,|O
DDI-DrugBank.d474.s1|181-182|or|O
DDI-DrugBank.d474.s1|184-197|sulfinpyrazone|drug
DDI-DrugBank.d474.s1|198-198|.|O
DDI-DrugBank.d474.s2|0-1|If|O
DDI-DrugBank.d474.s2|3-19|co-administration|O
DDI-DrugBank.d474.s2|21-22|is|O
DDI-DrugBank.d474.s2|24-32|essential|O
DDI-DrugBank.d474.s2|33-33|,|O
DDI-DrugBank.d474.s2|35-41|conduct|O
DDI-DrugBank.d474.s2|43-47|close|O
DDI-DrugBank.d474.s2|49-56|clinical|O
DDI-DrugBank.d474.s2|58-60|and|O
DDI-DrugBank.d474.s2|62-71|laboratory|O
DDI-DrugBank.d474.s2|73-82|monitoring|O
DDI-DrugBank.d474.s3|0-0|.|O
DDI-DrugBank.d478.s0|0-15|Ergot-containing|group
DDI-DrugBank.d478.s0|17-21|drugs|O
DDI-DrugBank.d478.s0|23-26|have|O
DDI-DrugBank.d478.s0|28-31|been|O
DDI-DrugBank.d478.s0|33-40|reported|O
DDI-DrugBank.d478.s0|42-43|to|O
DDI-DrugBank.d478.s0|45-49|cause|O
DDI-DrugBank.d478.s0|51-59|prolonged|O
DDI-DrugBank.d478.s0|61-71|vasospastic|O
DDI-DrugBank.d478.s0|73-81|reactions|O
DDI-DrugBank.d478.s0|82-82|.|O
DDI-DrugBank.d478.s1|0-6|Because|O
DDI-DrugBank.d478.s1|8-12|there|O
DDI-DrugBank.d478.s1|14-15|is|O
DDI-DrugBank.d478.s1|17-17|a|O
DDI-DrugBank.d478.s1|19-29|theoretical|O
DDI-DrugBank.d478.s1|31-35|basis|O
DDI-DrugBank.d478.s1|37-40|that|O
DDI-DrugBank.d478.s1|42-46|these|O
DDI-DrugBank.d478.s1|48-54|effects|O
DDI-DrugBank.d478.s1|56-58|may|O
DDI-DrugBank.d478.s1|60-61|be|O
DDI-DrugBank.d478.s1|63-70|additive|O
DDI-DrugBank.d478.s1|71-71|,|O
DDI-DrugBank.d478.s1|73-75|use|O
DDI-DrugBank.d478.s1|77-78|of|O
DDI-DrugBank.d478.s1|80-100|ergotamine-containing|drug
DDI-DrugBank.d478.s1|102-103|or|O
DDI-DrugBank.d478.s1|105-126|ergot-type medications|group
DDI-DrugBank.d478.s1|128-128|(|O
DDI-DrugBank.d478.s1|129-132|like|O
DDI-DrugBank.d478.s1|134-150|dihydroergotamine|drug
DDI-DrugBank.d478.s1|152-153|or|O
DDI-DrugBank.d478.s1|155-166|methysergide|drug
DDI-DrugBank.d478.s1|167-167|)|O
DDI-DrugBank.d478.s1|169-171|and|O
DDI-DrugBank.d478.s1|173-183|naratriptan|drug
DDI-DrugBank.d478.s1|185-190|within|O
DDI-DrugBank.d478.s1|192-193|24|O
DDI-DrugBank.d478.s1|195-199|hours|O
DDI-DrugBank.d478.s1|201-202|is|O
DDI-DrugBank.d478.s1|204-218|contraindicated|O
DDI-DrugBank.d478.s1|219-219|.|O
DDI-DrugBank.d478.s2|0-2|The|O
DDI-DrugBank.d478.s2|4-17|administration|O
DDI-DrugBank.d478.s2|19-20|of|O
DDI-DrugBank.d478.s2|22-32|naratriptan|drug
DDI-DrugBank.d478.s2|34-37|with|O
DDI-DrugBank.d478.s2|39-43|other|O
DDI-DrugBank.d478.s2|45-58|5-HT1 agonists|group
DDI-DrugBank.d478.s2|60-62|has|O
DDI-DrugBank.d478.s2|64-66|not|O
DDI-DrugBank.d478.s2|68-71|been|O
DDI-DrugBank.d478.s2|73-81|evaluated|O
DDI-DrugBank.d478.s2|83-84|in|O
DDI-DrugBank.d478.s2|86-93|migraine|O
DDI-DrugBank.d478.s2|95-102|patients|O
DDI-DrugBank.d478.s2|103-103|.|O
DDI-DrugBank.d478.s3|0-6|Because|O
DDI-DrugBank.d478.s3|8-12|their|O
DDI-DrugBank.d478.s3|14-24|vasospastic|O
DDI-DrugBank.d478.s3|26-32|effects|O
DDI-DrugBank.d478.s3|34-36|may|O
DDI-DrugBank.d478.s3|38-39|be|O
DDI-DrugBank.d478.s3|41-48|additive|O
DDI-DrugBank.d478.s3|49-49|,|O
DDI-DrugBank.d478.s3|51-66|coadministration|O
DDI-DrugBank.d478.s3|68-69|of|O
DDI-DrugBank.d478.s3|71-81|naratriptan|drug
DDI-DrugBank.d478.s3|83-85|and|O
DDI-DrugBank.d478.s3|87-91|other|O
DDI-DrugBank.d478.s3|93-106|5-HT1 agonists|group
DDI-DrugBank.d478.s3|108-113|within|O
DDI-DrugBank.d478.s3|115-116|24|O
DDI-DrugBank.d478.s3|118-122|hours|O
DDI-DrugBank.d478.s3|124-125|of|O
DDI-DrugBank.d478.s3|127-130|each|O
DDI-DrugBank.d478.s3|132-136|other|O
DDI-DrugBank.d478.s3|138-139|is|O
DDI-DrugBank.d478.s3|141-143|not|O
DDI-DrugBank.d478.s3|145-155|recommended|O
DDI-DrugBank.d478.s3|156-156|.|O
DDI-DrugBank.d478.s4|0-38|Selective serotonin reuptake inhibitors|group
DDI-DrugBank.d478.s4|40-40|(|O
DDI-DrugBank.d478.s4|41-45|SSRIs|group
DDI-DrugBank.d478.s4|46-46|)|O
DDI-DrugBank.d478.s4|48-48|(|O
DDI-DrugBank.d478.s4|49-52|e.g.|O
DDI-DrugBank.d478.s4|53-53|,|O
DDI-DrugBank.d478.s4|55-64|fluoxetine|drug
DDI-DrugBank.d478.s4|65-65|,|O
DDI-DrugBank.d478.s4|67-77|fluvoxamine|drug
DDI-DrugBank.d478.s4|78-78|,|O
DDI-DrugBank.d478.s4|80-89|paroxetine|drug
DDI-DrugBank.d478.s4|90-90|,|O
DDI-DrugBank.d478.s4|92-101|sertraline|drug
DDI-DrugBank.d478.s4|102-102|)|O
DDI-DrugBank.d478.s4|104-107|have|O
DDI-DrugBank.d478.s4|109-112|been|O
DDI-DrugBank.d478.s4|114-121|reported|O
DDI-DrugBank.d478.s4|122-122|,|O
DDI-DrugBank.d478.s4|124-129|rarely|O
DDI-DrugBank.d478.s4|130-130|,|O
DDI-DrugBank.d478.s4|132-133|to|O
DDI-DrugBank.d478.s4|135-139|cause|O
DDI-DrugBank.d478.s4|141-148|weakness|O
DDI-DrugBank.d478.s4|149-149|,|O
DDI-DrugBank.d478.s4|151-163|hyperreflexia|O
DDI-DrugBank.d478.s4|164-164|,|O
DDI-DrugBank.d478.s4|166-168|and|O
DDI-DrugBank.d478.s4|170-183|incoordination|O
DDI-DrugBank.d478.s4|185-188|when|O
DDI-DrugBank.d478.s4|190-203|coadministered|O
DDI-DrugBank.d478.s4|205-208|with|O
DDI-DrugBank.d478.s4|210-214|5-HTv|O
DDI-DrugBank.d478.s4|216-223|agonists|O
DDI-DrugBank.d478.s4|224-224|.|O
DDI-DrugBank.d478.s5|0-1|If|O
DDI-DrugBank.d478.s5|3-13|concomitant|O
DDI-DrugBank.d478.s5|15-23|treatment|O
DDI-DrugBank.d478.s5|25-28|with|O
DDI-DrugBank.d478.s5|30-40|naratriptan|drug
DDI-DrugBank.d478.s5|42-44|and|O
DDI-DrugBank.d478.s5|46-47|an|O
DDI-DrugBank.d478.s5|49-52|SSRI|group
DDI-DrugBank.d478.s5|54-55|is|O
DDI-DrugBank.d478.s5|57-66|clinically|O
DDI-DrugBank.d478.s5|68-76|warranted|O
DDI-DrugBank.d478.s5|77-77|,|O
DDI-DrugBank.d478.s5|79-89|appropriate|O
DDI-DrugBank.d478.s5|91-101|observation|O
DDI-DrugBank.d478.s5|103-104|of|O
DDI-DrugBank.d478.s5|106-108|the|O
DDI-DrugBank.d478.s5|110-116|patient|O
DDI-DrugBank.d478.s5|118-119|is|O
DDI-DrugBank.d478.s5|121-127|advised|O
DDI-DrugBank.d478.s5|128-128|.|O
DDI-DrugBank.d478.s6|0-4|Drug/|O
DDI-DrugBank.d478.s6|6-15|Laboratory|O
DDI-DrugBank.d478.s6|17-20|Test|O
DDI-DrugBank.d478.s6|22-33|Interactions|O
DDI-DrugBank.d478.s6|35-40|AMERGE|brand
DDI-DrugBank.d478.s6|42-48|Tablets|O
DDI-DrugBank.d478.s6|50-52|are|O
DDI-DrugBank.d478.s6|54-56|not|O
DDI-DrugBank.d478.s6|58-62|known|O
DDI-DrugBank.d478.s6|64-65|to|O
DDI-DrugBank.d478.s6|67-75|interfere|O
DDI-DrugBank.d478.s6|77-80|with|O
DDI-DrugBank.d478.s6|82-89|commonly|O
DDI-DrugBank.d478.s6|91-98|employed|O
DDI-DrugBank.d478.s6|100-107|clinical|O
DDI-DrugBank.d478.s6|109-118|laboratory|O
DDI-DrugBank.d478.s6|120-124|tests|O
DDI-DrugBank.d478.s6|125-125|.|O
DDI-DrugBank.d77.s0|0-1|In|O
DDI-DrugBank.d77.s0|3-12|occasional|O
DDI-DrugBank.d77.s0|14-24|susceptible|O
DDI-DrugBank.d77.s0|26-33|patients|O
DDI-DrugBank.d77.s0|35-36|or|O
DDI-DrugBank.d77.s0|38-39|in|O
DDI-DrugBank.d77.s0|41-45|those|O
DDI-DrugBank.d77.s0|47-55|receiving|O
DDI-DrugBank.d77.s0|57-77|anticholinergic drugs|group
DDI-DrugBank.d77.s0|79-79|(|O
DDI-DrugBank.d77.s0|80-88|including|O
DDI-DrugBank.d77.s0|90-105|antiparkinsonism|O
DDI-DrugBank.d77.s0|107-112|agents|O
DDI-DrugBank.d77.s0|113-113|)|O
DDI-DrugBank.d77.s0|115-116|in|O
DDI-DrugBank.d77.s0|118-125|addition|O
DDI-DrugBank.d77.s0|126-126|,|O
DDI-DrugBank.d77.s0|128-130|the|O
DDI-DrugBank.d77.s0|132-144|atropine-like|O
DDI-DrugBank.d77.s0|146-152|effects|O
DDI-DrugBank.d77.s0|154-156|may|O
DDI-DrugBank.d77.s0|158-163|become|O
DDI-DrugBank.d77.s0|165-168|more|O
DDI-DrugBank.d77.s0|170-179|pronounced|O
DDI-DrugBank.d77.s0|181-181|(|O
DDI-DrugBank.d77.s0|182-185|e.g.|O
DDI-DrugBank.d77.s0|186-186|,|O
DDI-DrugBank.d77.s0|188-196|paralytic|O
DDI-DrugBank.d77.s0|198-202|ileus|O
DDI-DrugBank.d77.s0|203-203|)|O
DDI-DrugBank.d77.s0|204-204|.|O
DDI-DrugBank.d77.s1|0-4|Close|O
DDI-DrugBank.d77.s1|6-16|supervision|O
DDI-DrugBank.d77.s1|18-20|and|O
DDI-DrugBank.d77.s1|22-28|careful|O
DDI-DrugBank.d77.s1|30-39|adjustment|O
DDI-DrugBank.d77.s1|41-42|of|O
DDI-DrugBank.d77.s1|44-49|dosage|O
DDI-DrugBank.d77.s1|51-52|is|O
DDI-DrugBank.d77.s1|54-61|required|O
DDI-DrugBank.d77.s1|63-66|when|O
DDI-DrugBank.d77.s1|68-71|this|O
DDI-DrugBank.d77.s1|73-76|drug|O
DDI-DrugBank.d77.s1|78-79|is|O
DDI-DrugBank.d77.s1|81-92|administered|O
DDI-DrugBank.d77.s1|94-106|concomitantly|O
DDI-DrugBank.d77.s1|108-111|with|O
DDI-DrugBank.d77.s1|113-133|anticholinergic drugs|group
DDI-DrugBank.d77.s1|134-134|.|O
DDI-DrugBank.d77.s2|0-4|Avoid|O
DDI-DrugBank.d77.s2|6-8|the|O
DDI-DrugBank.d77.s2|10-12|use|O
DDI-DrugBank.d77.s2|14-15|of|O
DDI-DrugBank.d77.s2|17-28|preparations|O
DDI-DrugBank.d77.s2|30-33|such|O
DDI-DrugBank.d77.s2|35-36|as|O
DDI-DrugBank.d77.s2|38-50|decongestants|group
DDI-DrugBank.d77.s2|52-54|and|O
DDI-DrugBank.d77.s2|56-60|local|O
DDI-DrugBank.d77.s2|62-72|anesthetics|group
DDI-DrugBank.d77.s2|74-78|which|O
DDI-DrugBank.d77.s2|80-86|contain|O
DDI-DrugBank.d77.s2|88-90|any|O
DDI-DrugBank.d77.s2|92-112|sympathomimetic amine|group
DDI-DrugBank.d77.s2|114-114|(|O
DDI-DrugBank.d77.s2|115-118|e.g.|O
DDI-DrugBank.d77.s2|119-119|,|O
DDI-DrugBank.d77.s2|121-131|epinephrine|drug
DDI-DrugBank.d77.s2|132-132|,|O
DDI-DrugBank.d77.s2|134-147|norepinephrine|drug
DDI-DrugBank.d77.s2|148-148|)|O
DDI-DrugBank.d77.s2|149-149|,|O
DDI-DrugBank.d77.s2|151-155|since|O
DDI-DrugBank.d77.s2|157-158|it|O
DDI-DrugBank.d77.s2|160-162|has|O
DDI-DrugBank.d77.s2|164-167|been|O
DDI-DrugBank.d77.s2|169-176|reported|O
DDI-DrugBank.d77.s2|178-181|that|O
DDI-DrugBank.d77.s2|183-207|tricyclic antidepressants|group
DDI-DrugBank.d77.s2|209-211|can|O
DDI-DrugBank.d77.s2|213-222|potentiate|O
DDI-DrugBank.d77.s2|224-226|the|O
DDI-DrugBank.d77.s2|228-234|effects|O
DDI-DrugBank.d77.s2|236-237|of|O
DDI-DrugBank.d77.s2|239-252|catecholamines|O
DDI-DrugBank.d77.s2|253-253|.|O
DDI-DrugBank.d77.s3|0-6|Caution|O
DDI-DrugBank.d77.s3|8-13|should|O
DDI-DrugBank.d77.s3|15-16|be|O
DDI-DrugBank.d77.s3|18-26|exercised|O
DDI-DrugBank.d77.s3|28-31|when|O
DDI-DrugBank.d77.s3|33-56|imipramine hydrochloride|drug
DDI-DrugBank.d77.s3|58-59|is|O
DDI-DrugBank.d77.s3|61-64|used|O
DDI-DrugBank.d77.s3|66-69|with|O
DDI-DrugBank.d77.s3|71-76|agents|O
DDI-DrugBank.d77.s3|78-81|that|O
DDI-DrugBank.d77.s3|83-87|lower|O
DDI-DrugBank.d77.s3|89-93|blood|O
DDI-DrugBank.d77.s3|95-102|pressure|O
DDI-DrugBank.d77.s3|103-103|.|O
DDI-DrugBank.d77.s4|0-23|Imipramine hydrochloride|drug
DDI-DrugBank.d77.s4|25-27|may|O
DDI-DrugBank.d77.s4|29-38|potentiate|O
DDI-DrugBank.d77.s4|40-42|the|O
DDI-DrugBank.d77.s4|44-50|effects|O
DDI-DrugBank.d77.s4|52-53|of|O
DDI-DrugBank.d77.s4|55-74|CNS depressant drugs|group
DDI-DrugBank.d77.s4|75-75|.|O
DDI-DrugBank.d77.s5|0-2|The|O
DDI-DrugBank.d77.s5|4-9|plasma|O
DDI-DrugBank.d77.s5|11-23|concentration|O
DDI-DrugBank.d77.s5|25-26|of|O
DDI-DrugBank.d77.s5|28-37|imipramine|drug
DDI-DrugBank.d77.s5|39-41|may|O
DDI-DrugBank.d77.s5|43-50|increase|O
DDI-DrugBank.d77.s5|52-55|when|O
DDI-DrugBank.d77.s5|57-59|the|O
DDI-DrugBank.d77.s5|61-64|drug|O
DDI-DrugBank.d77.s5|66-67|is|O
DDI-DrugBank.d77.s5|69-73|given|O
DDI-DrugBank.d77.s5|75-87|concomitantly|O
DDI-DrugBank.d77.s5|89-92|with|O
DDI-DrugBank.d77.s5|94-100|hepatic|O
DDI-DrugBank.d77.s5|102-107|enzyme|O
DDI-DrugBank.d77.s5|109-118|inhibitors|O
DDI-DrugBank.d77.s5|120-120|(|O
DDI-DrugBank.d77.s5|121-124|e.g.|O
DDI-DrugBank.d77.s5|125-125|,|O
DDI-DrugBank.d77.s5|127-136|cimetidine|drug
DDI-DrugBank.d77.s5|137-137|,|O
DDI-DrugBank.d77.s5|139-148|fluoxetine|drug
DDI-DrugBank.d77.s5|149-149|)|O
DDI-DrugBank.d77.s5|151-153|and|O
DDI-DrugBank.d77.s5|155-162|decrease|O
DDI-DrugBank.d77.s5|164-165|by|O
DDI-DrugBank.d77.s5|167-177|concomitant|O
DDI-DrugBank.d77.s5|179-192|administration|O
DDI-DrugBank.d77.s5|194-195|of|O
DDI-DrugBank.d77.s5|197-203|hepatic|O
DDI-DrugBank.d77.s5|205-210|enzyme|O
DDI-DrugBank.d77.s5|212-219|inducers|O
DDI-DrugBank.d77.s5|221-221|(|O
DDI-DrugBank.d77.s5|222-225|e.g.|O
DDI-DrugBank.d77.s5|226-226|,|O
DDI-DrugBank.d77.s5|228-239|barbiturates|group
DDI-DrugBank.d77.s5|240-240|,|O
DDI-DrugBank.d77.s5|242-250|phenytoin|drug
DDI-DrugBank.d77.s5|251-251|)|O
DDI-DrugBank.d77.s5|252-252|,|O
DDI-DrugBank.d77.s5|254-256|and|O
DDI-DrugBank.d77.s5|258-267|adjustment|O
DDI-DrugBank.d77.s5|269-270|of|O
DDI-DrugBank.d77.s5|272-274|the|O
DDI-DrugBank.d77.s5|276-281|dosage|O
DDI-DrugBank.d77.s5|283-284|of|O
DDI-DrugBank.d77.s5|286-295|imipramine|drug
DDI-DrugBank.d77.s5|297-299|may|O
DDI-DrugBank.d77.s5|301-309|therefore|O
DDI-DrugBank.d77.s5|311-312|be|O
DDI-DrugBank.d77.s5|314-322|necessary|O
DDI-DrugBank.d77.s5|323-323|.|O
DDI-DrugBank.d77.s6|0-4|Drugs|O
DDI-DrugBank.d77.s6|6-16|Metabolized|O
DDI-DrugBank.d77.s6|18-19|by|O
DDI-DrugBank.d77.s6|21-24|P450|O
DDI-DrugBank.d77.s6|26-28|2D6|O
DDI-DrugBank.d77.s6|30-32|The|O
DDI-DrugBank.d77.s6|34-44|biochemical|O
DDI-DrugBank.d77.s6|46-53|activity|O
DDI-DrugBank.d77.s6|55-56|of|O
DDI-DrugBank.d77.s6|58-60|the|O
DDI-DrugBank.d77.s6|62-65|drug|O
DDI-DrugBank.d77.s6|67-78|metabolizing|O
DDI-DrugBank.d77.s6|80-86|isozyme|O
DDI-DrugBank.d77.s6|88-97|cytochrome|O
DDI-DrugBank.d77.s6|99-102|P450|O
DDI-DrugBank.d77.s6|104-106|2D6|O
DDI-DrugBank.d77.s6|108-108|(|O
DDI-DrugBank.d77.s6|109-119|debrisoquin|O
DDI-DrugBank.d77.s6|121-131|hydroxylase|O
DDI-DrugBank.d77.s6|132-132|)|O
DDI-DrugBank.d77.s6|134-135|is|O
DDI-DrugBank.d77.s6|137-143|reduced|O
DDI-DrugBank.d77.s6|145-146|in|O
DDI-DrugBank.d77.s6|148-148|a|O
DDI-DrugBank.d77.s6|150-155|subset|O
DDI-DrugBank.d77.s6|157-158|of|O
DDI-DrugBank.d77.s6|160-162|the|O
DDI-DrugBank.d77.s6|164-172|caucasian|O
DDI-DrugBank.d77.s6|174-183|population|O
DDI-DrugBank.d77.s6|185-185|(|O
DDI-DrugBank.d77.s6|186-190|about|O
DDI-DrugBank.d77.s6|192-192|7|O
DDI-DrugBank.d77.s6|194-195|to|O
DDI-DrugBank.d77.s6|197-198|10|O
DDI-DrugBank.d77.s6|199-199|%|O
DDI-DrugBank.d77.s6|201-202|of|O
DDI-DrugBank.d77.s6|204-213|caucasians|O
DDI-DrugBank.d77.s6|215-217|are|O
DDI-DrugBank.d77.s6|219-220|so|O
DDI-DrugBank.d77.s6|222-227|called|O
DDI-DrugBank.d77.s6|229-232|poor|O
DDI-DrugBank.d77.s6|234-245|metabolizers|O
DDI-DrugBank.d77.s6|246-246|)|O
DDI-DrugBank.d77.s6|247-247|;|O
DDI-DrugBank.d77.s7|0-7|reliable|O
DDI-DrugBank.d77.s7|9-17|estimates|O
DDI-DrugBank.d77.s7|19-20|of|O
DDI-DrugBank.d77.s7|22-24|the|O
DDI-DrugBank.d77.s7|26-35|prevalence|O
DDI-DrugBank.d77.s7|37-38|of|O
DDI-DrugBank.d77.s7|40-46|reduced|O
DDI-DrugBank.d77.s7|48-51|P450|O
DDI-DrugBank.d77.s7|53-55|2D6|O
DDI-DrugBank.d77.s7|57-63|isozyme|O
DDI-DrugBank.d77.s7|65-72|activity|O
DDI-DrugBank.d77.s7|74-78|among|O
DDI-DrugBank.d77.s7|80-84|Asian|O
DDI-DrugBank.d77.s7|85-85|,|O
DDI-DrugBank.d77.s7|87-93|African|O
DDI-DrugBank.d77.s7|95-97|and|O
DDI-DrugBank.d77.s7|99-103|other|O
DDI-DrugBank.d77.s7|105-115|populations|O
DDI-DrugBank.d77.s7|117-119|are|O
DDI-DrugBank.d77.s7|121-123|not|O
DDI-DrugBank.d77.s7|125-127|yet|O
DDI-DrugBank.d77.s7|129-137|available|O
DDI-DrugBank.d77.s7|138-138|.|O
DDI-DrugBank.d77.s8|0-3|Poor|O
DDI-DrugBank.d77.s8|5-16|metabolizers|O
DDI-DrugBank.d77.s8|18-21|have|O
DDI-DrugBank.d77.s8|23-28|higher|O
DDI-DrugBank.d77.s8|30-33|than|O
DDI-DrugBank.d77.s8|35-42|expected|O
DDI-DrugBank.d77.s8|44-49|plasma|O
DDI-DrugBank.d77.s8|51-64|concentrations|O
DDI-DrugBank.d77.s8|66-67|of|O
DDI-DrugBank.d77.s8|69-93|tricyclic antidepressants|group
DDI-DrugBank.d77.s8|95-95|(|O
DDI-DrugBank.d77.s8|96-99|TCAs|group
DDI-DrugBank.d77.s8|100-100|)|O
DDI-DrugBank.d77.s8|102-105|when|O
DDI-DrugBank.d77.s8|107-111|given|O
DDI-DrugBank.d77.s8|113-117|usual|O
DDI-DrugBank.d77.s8|119-123|doses|O
DDI-DrugBank.d77.s8|124-124|.|O
DDI-DrugBank.d77.s9|0-8|Depending|O
DDI-DrugBank.d77.s9|10-11|on|O
DDI-DrugBank.d77.s9|13-15|the|O
DDI-DrugBank.d77.s9|17-24|fraction|O
DDI-DrugBank.d77.s9|26-27|of|O
DDI-DrugBank.d77.s9|29-32|drug|O
DDI-DrugBank.d77.s9|34-44|metabolized|O
DDI-DrugBank.d77.s9|46-47|by|O
DDI-DrugBank.d77.s9|49-52|P450|O
DDI-DrugBank.d77.s9|54-56|2D6|O
DDI-DrugBank.d77.s9|57-57|,|O
DDI-DrugBank.d77.s9|59-61|the|O
DDI-DrugBank.d77.s9|63-70|increase|O
DDI-DrugBank.d77.s9|72-73|in|O
DDI-DrugBank.d77.s9|75-80|plasma|O
DDI-DrugBank.d77.s9|82-94|concentration|O
DDI-DrugBank.d77.s9|96-98|may|O
DDI-DrugBank.d77.s9|100-101|be|O
DDI-DrugBank.d77.s9|103-107|small|O
DDI-DrugBank.d77.s9|108-108|,|O
DDI-DrugBank.d77.s9|110-111|or|O
DDI-DrugBank.d77.s9|113-117|quite|O
DDI-DrugBank.d77.s9|119-123|large|O
DDI-DrugBank.d77.s9|125-125|(|O
DDI-DrugBank.d77.s9|126-131|8-fold|O
DDI-DrugBank.d77.s9|133-140|increase|O
DDI-DrugBank.d77.s9|142-143|in|O
DDI-DrugBank.d77.s9|145-150|plasma|O
DDI-DrugBank.d77.s9|152-154|AUC|O
DDI-DrugBank.d77.s9|156-157|of|O
DDI-DrugBank.d77.s9|159-161|the|O
DDI-DrugBank.d77.s9|163-165|TCA|group
DDI-DrugBank.d77.s9|166-166|)|O
DDI-DrugBank.d77.s9|167-167|.|O
DDI-DrugBank.d77.s10|0-1|In|O
DDI-DrugBank.d77.s10|3-10|addition|O
DDI-DrugBank.d77.s10|11-11|,|O
DDI-DrugBank.d77.s10|13-19|certain|O
DDI-DrugBank.d77.s10|21-25|drugs|O
DDI-DrugBank.d77.s10|27-33|inhibit|O
DDI-DrugBank.d77.s10|35-37|the|O
DDI-DrugBank.d77.s10|39-46|activity|O
DDI-DrugBank.d77.s10|48-49|of|O
DDI-DrugBank.d77.s10|51-54|this|O
DDI-DrugBank.d77.s10|56-62|isozyme|O
DDI-DrugBank.d77.s10|64-66|and|O
DDI-DrugBank.d77.s10|68-71|make|O
DDI-DrugBank.d77.s10|73-78|normal|O
DDI-DrugBank.d77.s10|80-91|metabolizers|O
DDI-DrugBank.d77.s10|93-100|resemble|O
DDI-DrugBank.d77.s10|102-104|p.o|O
DDI-DrugBank.d77.s10|105-105|.|O
DDI-DrugBank.d77.s11|0-11|metabolizers|O
DDI-DrugBank.d77.s11|12-12|.|O
DDI-DrugBank.d77.s12|0-1|An|O
DDI-DrugBank.d77.s12|3-12|individual|O
DDI-DrugBank.d77.s12|14-16|who|O
DDI-DrugBank.d77.s12|18-19|is|O
DDI-DrugBank.d77.s12|21-26|stable|O
DDI-DrugBank.d77.s12|28-29|on|O
DDI-DrugBank.d77.s12|31-31|a|O
DDI-DrugBank.d77.s12|33-37|given|O
DDI-DrugBank.d77.s12|39-42|dose|O
DDI-DrugBank.d77.s12|44-45|of|O
DDI-DrugBank.d77.s12|47-49|TCA|group
DDI-DrugBank.d77.s12|51-53|may|O
DDI-DrugBank.d77.s12|55-60|become|O
DDI-DrugBank.d77.s12|62-69|abruptly|O
DDI-DrugBank.d77.s12|71-75|toxic|O
DDI-DrugBank.d77.s12|77-80|when|O
DDI-DrugBank.d77.s12|82-86|given|O
DDI-DrugBank.d77.s12|88-90|one|O
DDI-DrugBank.d77.s12|92-93|of|O
DDI-DrugBank.d77.s12|95-99|these|O
DDI-DrugBank.d77.s12|101-110|inhibiting|O
DDI-DrugBank.d77.s12|112-116|drugs|O
DDI-DrugBank.d77.s12|118-119|as|O
DDI-DrugBank.d77.s12|121-131|concomitant|O
DDI-DrugBank.d77.s12|133-139|therapy|O
DDI-DrugBank.d77.s12|140-140|.|O
DDI-DrugBank.d77.s13|0-2|The|O
DDI-DrugBank.d77.s13|4-8|drugs|O
DDI-DrugBank.d77.s13|10-13|that|O
DDI-DrugBank.d77.s13|15-21|inhibit|O
DDI-DrugBank.d77.s13|23-32|cytochrome|O
DDI-DrugBank.d77.s13|34-37|P450|O
DDI-DrugBank.d77.s13|39-41|2D6|O
DDI-DrugBank.d77.s13|43-49|include|O
DDI-DrugBank.d77.s13|51-54|some|O
DDI-DrugBank.d77.s13|56-59|that|O
DDI-DrugBank.d77.s13|61-63|are|O
DDI-DrugBank.d77.s13|65-67|not|O
DDI-DrugBank.d77.s13|69-79|metabolized|O
DDI-DrugBank.d77.s13|81-82|by|O
DDI-DrugBank.d77.s13|84-86|the|O
DDI-DrugBank.d77.s13|88-93|enzyme|O
DDI-DrugBank.d77.s13|95-95|(|O
DDI-DrugBank.d77.s13|96-104|quinidine|drug
DDI-DrugBank.d77.s13|105-105|;|O
DDI-DrugBank.d77.s14|0-9|cimetidine|drug
DDI-DrugBank.d77.s14|10-10|)|O
DDI-DrugBank.d77.s14|12-14|and|O
DDI-DrugBank.d77.s14|16-19|many|O
DDI-DrugBank.d77.s14|21-24|that|O
DDI-DrugBank.d77.s14|26-28|are|O
DDI-DrugBank.d77.s14|30-39|substrates|O
DDI-DrugBank.d77.s14|41-43|for|O
DDI-DrugBank.d77.s14|45-48|P450|O
DDI-DrugBank.d77.s14|50-52|2D6|O
DDI-DrugBank.d77.s14|54-54|(|O
DDI-DrugBank.d77.s14|55-58|many|O
DDI-DrugBank.d77.s14|60-64|other|O
DDI-DrugBank.d77.s14|66-80|antidepressants|group
DDI-DrugBank.d77.s14|81-81|,|O
DDI-DrugBank.d77.s14|83-96|phenothiazines|group
DDI-DrugBank.d77.s14|97-97|,|O
DDI-DrugBank.d77.s14|99-101|and|O
DDI-DrugBank.d77.s14|103-105|the|O
DDI-DrugBank.d77.s14|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d77.s14|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d77.s14|143-145|and|O
DDI-DrugBank.d77.s14|147-156|flecainide|drug
DDI-DrugBank.d77.s14|157-157|)|O
DDI-DrugBank.d77.s14|158-158|.|O
DDI-DrugBank.d77.s15|0-4|While|O
DDI-DrugBank.d77.s15|6-8|all|O
DDI-DrugBank.d77.s15|10-12|the|O
DDI-DrugBank.d77.s15|14-52|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d77.s15|54-54|(|O
DDI-DrugBank.d77.s15|55-59|SSRIs|group
DDI-DrugBank.d77.s15|60-60|)|O
DDI-DrugBank.d77.s15|61-61|,|O
DDI-DrugBank.d77.s15|63-64|e.|O
DDI-DrugBank.d77.s15|66-67|g.|O
DDI-DrugBank.d77.s15|68-68|,|O
DDI-DrugBank.d77.s15|70-79|fluoxetine|drug
DDI-DrugBank.d77.s15|80-80|,|O
DDI-DrugBank.d77.s15|82-91|sertraline|drug
DDI-DrugBank.d77.s15|92-92|,|O
DDI-DrugBank.d77.s15|94-96|and|O
DDI-DrugBank.d77.s15|98-107|paroxetine|drug
DDI-DrugBank.d77.s15|108-108|,|O
DDI-DrugBank.d77.s15|110-116|inhibit|O
DDI-DrugBank.d77.s15|118-121|P450|O
DDI-DrugBank.d77.s15|123-125|2D6|O
DDI-DrugBank.d77.s15|126-126|,|O
DDI-DrugBank.d77.s15|128-131|they|O
DDI-DrugBank.d77.s15|133-135|may|O
DDI-DrugBank.d77.s15|137-140|vary|O
DDI-DrugBank.d77.s15|142-143|in|O
DDI-DrugBank.d77.s15|145-147|the|O
DDI-DrugBank.d77.s15|149-154|extent|O
DDI-DrugBank.d77.s15|156-157|of|O
DDI-DrugBank.d77.s15|159-168|inhibition|O
DDI-DrugBank.d77.s15|169-169|.|O
DDI-DrugBank.d77.s16|0-2|The|O
DDI-DrugBank.d77.s16|4-9|extent|O
DDI-DrugBank.d77.s16|11-12|to|O
DDI-DrugBank.d77.s16|14-18|which|O
DDI-DrugBank.d77.s16|20-27|SSRI-TCA|group
DDI-DrugBank.d77.s16|29-40|interactions|O
DDI-DrugBank.d77.s16|42-44|may|O
DDI-DrugBank.d77.s16|46-49|pose|O
DDI-DrugBank.d77.s16|51-58|clinical|O
DDI-DrugBank.d77.s16|60-67|problems|O
DDI-DrugBank.d77.s16|69-72|will|O
DDI-DrugBank.d77.s16|74-79|depend|O
DDI-DrugBank.d77.s16|81-82|on|O
DDI-DrugBank.d77.s16|84-86|the|O
DDI-DrugBank.d77.s16|88-93|degree|O
DDI-DrugBank.d77.s16|95-96|of|O
DDI-DrugBank.d77.s16|98-107|inhibition|O
DDI-DrugBank.d77.s16|108-108|,|O
DDI-DrugBank.d77.s16|110-112|and|O
DDI-DrugBank.d77.s16|114-116|the|O
DDI-DrugBank.d77.s16|118-133|pharmacokinetics|O
DDI-DrugBank.d77.s16|135-136|of|O
DDI-DrugBank.d77.s16|138-140|the|O
DDI-DrugBank.d77.s16|142-145|SSRI|group
DDI-DrugBank.d77.s16|147-154|involved|O
DDI-DrugBank.d77.s16|155-155|.|O
DDI-DrugBank.d77.s17|0-11|Nevertheless|O
DDI-DrugBank.d77.s17|12-12|,|O
DDI-DrugBank.d77.s17|14-20|caution|O
DDI-DrugBank.d77.s17|22-23|is|O
DDI-DrugBank.d77.s17|25-33|indicated|O
DDI-DrugBank.d77.s17|35-36|in|O
DDI-DrugBank.d77.s17|38-40|the|O
DDI-DrugBank.d77.s17|42-58|co-administration|O
DDI-DrugBank.d77.s17|60-61|of|O
DDI-DrugBank.d77.s17|63-66|TCA5|O
DDI-DrugBank.d77.s17|68-71|with|O
DDI-DrugBank.d77.s17|73-75|any|O
DDI-DrugBank.d77.s17|77-78|of|O
DDI-DrugBank.d77.s17|80-82|the|O
DDI-DrugBank.d77.s17|84-88|SSRIs|group
DDI-DrugBank.d77.s17|90-92|and|O
DDI-DrugBank.d77.s17|94-97|also|O
DDI-DrugBank.d77.s17|99-100|in|O
DDI-DrugBank.d77.s17|102-110|switching|O
DDI-DrugBank.d77.s17|112-115|from|O
DDI-DrugBank.d77.s17|117-119|one|O
DDI-DrugBank.d77.s17|121-125|class|O
DDI-DrugBank.d77.s17|127-128|to|O
DDI-DrugBank.d77.s17|130-132|the|O
DDI-DrugBank.d77.s17|134-138|other|O
DDI-DrugBank.d77.s17|139-139|.|O
DDI-DrugBank.d77.s18|0-1|Of|O
DDI-DrugBank.d77.s18|3-12|particular|O
DDI-DrugBank.d77.s18|14-23|importance|O
DDI-DrugBank.d77.s18|24-24|,|O
DDI-DrugBank.d77.s18|26-35|sufficient|O
DDI-DrugBank.d77.s18|37-40|time|O
DDI-DrugBank.d77.s18|42-45|must|O
DDI-DrugBank.d77.s18|47-52|elapse|O
DDI-DrugBank.d77.s18|54-59|before|O
DDI-DrugBank.d77.s18|61-70|initiating|O
DDI-DrugBank.d77.s18|72-74|TCA|O
DDI-DrugBank.d77.s18|76-84|treatment|O
DDI-DrugBank.d77.s18|86-87|in|O
DDI-DrugBank.d77.s18|89-89|a|O
DDI-DrugBank.d77.s18|91-97|patient|O
DDI-DrugBank.d77.s18|99-103|being|O
DDI-DrugBank.d77.s18|105-113|withdrawn|O
DDI-DrugBank.d77.s18|115-118|from|O
DDI-DrugBank.d77.s18|120-129|fluoxetine|drug
DDI-DrugBank.d77.s18|130-130|,|O
DDI-DrugBank.d77.s18|132-136|given|O
DDI-DrugBank.d77.s18|138-140|the|O
DDI-DrugBank.d77.s18|142-145|long|O
DDI-DrugBank.d77.s18|147-155|half-life|O
DDI-DrugBank.d77.s18|157-158|of|O
DDI-DrugBank.d77.s18|160-162|the|O
DDI-DrugBank.d77.s18|164-169|parent|O
DDI-DrugBank.d77.s18|171-173|and|O
DDI-DrugBank.d77.s18|175-180|active|O
DDI-DrugBank.d77.s18|182-191|metabolite|O
DDI-DrugBank.d77.s18|193-193|(|O
DDI-DrugBank.d77.s18|194-195|at|O
DDI-DrugBank.d77.s18|197-201|least|O
DDI-DrugBank.d77.s18|203-203|5|O
DDI-DrugBank.d77.s18|205-209|weeks|O
DDI-DrugBank.d77.s18|211-213|may|O
DDI-DrugBank.d77.s18|215-216|be|O
DDI-DrugBank.d77.s18|218-226|necessary|O
DDI-DrugBank.d77.s18|227-227|)|O
DDI-DrugBank.d77.s18|228-228|.|O
DDI-DrugBank.d77.s19|0-10|Concomitant|O
DDI-DrugBank.d77.s19|12-14|use|O
DDI-DrugBank.d77.s19|16-17|of|O
DDI-DrugBank.d77.s19|19-43|tricyclic antidepressants|group
DDI-DrugBank.d77.s19|45-48|with|O
DDI-DrugBank.d77.s19|50-54|drugs|O
DDI-DrugBank.d77.s19|56-59|that|O
DDI-DrugBank.d77.s19|61-63|can|O
DDI-DrugBank.d77.s19|65-71|inhibit|O
DDI-DrugBank.d77.s19|73-82|cytochrome|O
DDI-DrugBank.d77.s19|84-87|P450|O
DDI-DrugBank.d77.s19|89-91|2D6|O
DDI-DrugBank.d77.s19|93-95|may|O
DDI-DrugBank.d77.s19|97-103|require|O
DDI-DrugBank.d77.s19|105-109|lower|O
DDI-DrugBank.d77.s19|111-115|doses|O
DDI-DrugBank.d77.s19|117-120|than|O
DDI-DrugBank.d77.s19|122-128|usually|O
DDI-DrugBank.d77.s19|130-139|prescribed|O
DDI-DrugBank.d77.s19|141-143|for|O
DDI-DrugBank.d77.s19|145-150|either|O
DDI-DrugBank.d77.s19|152-154|the|O
DDI-DrugBank.d77.s19|156-179|tricyclic antidepressant|group
DDI-DrugBank.d77.s19|181-182|or|O
DDI-DrugBank.d77.s19|184-186|the|O
DDI-DrugBank.d77.s19|188-192|other|O
DDI-DrugBank.d77.s19|194-197|drug|O
DDI-DrugBank.d77.s19|198-198|.|O
DDI-DrugBank.d77.s20|0-10|Furthermore|O
DDI-DrugBank.d77.s20|11-11|,|O
DDI-DrugBank.d77.s20|13-20|whenever|O
DDI-DrugBank.d77.s20|22-24|one|O
DDI-DrugBank.d77.s20|26-27|of|O
DDI-DrugBank.d77.s20|29-33|these|O
DDI-DrugBank.d77.s20|35-39|other|O
DDI-DrugBank.d77.s20|41-45|drugs|O
DDI-DrugBank.d77.s20|47-48|is|O
DDI-DrugBank.d77.s20|50-58|withdrawn|O
DDI-DrugBank.d77.s20|60-63|from|O
DDI-DrugBank.d77.s20|65-73|cotherapy|O
DDI-DrugBank.d77.s20|74-74|,|O
DDI-DrugBank.d77.s20|76-77|an|O
DDI-DrugBank.d77.s20|79-87|increased|O
DDI-DrugBank.d77.s20|89-92|dose|O
DDI-DrugBank.d77.s20|94-95|of|O
DDI-DrugBank.d77.s20|97-120|tricyclic antidepressant|group
DDI-DrugBank.d77.s20|122-124|may|O
DDI-DrugBank.d77.s20|126-127|be|O
DDI-DrugBank.d77.s20|129-136|required|O
DDI-DrugBank.d77.s20|137-137|.|O
DDI-DrugBank.d77.s21|0-1|It|O
DDI-DrugBank.d77.s21|3-4|is|O
DDI-DrugBank.d77.s21|6-14|desirable|O
DDI-DrugBank.d77.s21|16-17|to|O
DDI-DrugBank.d77.s21|19-25|monitor|O
DDI-DrugBank.d77.s21|27-29|TCA|group
DDI-DrugBank.d77.s21|31-36|plasma|O
DDI-DrugBank.d77.s21|38-43|levels|O
DDI-DrugBank.d77.s21|45-52|whenever|O
DDI-DrugBank.d77.s21|54-54|a|O
DDI-DrugBank.d77.s21|56-58|TCA|group
DDI-DrugBank.d77.s21|60-61|is|O
DDI-DrugBank.d77.s21|63-67|going|O
DDI-DrugBank.d77.s21|69-70|to|O
DDI-DrugBank.d77.s21|72-73|be|O
DDI-DrugBank.d77.s21|75-89|co-administered|O
DDI-DrugBank.d77.s21|91-94|with|O
DDI-DrugBank.d77.s21|96-102|another|O
DDI-DrugBank.d77.s21|104-107|drug|O
DDI-DrugBank.d77.s21|109-113|known|O
DDI-DrugBank.d77.s21|115-116|to|O
DDI-DrugBank.d77.s21|118-119|be|O
DDI-DrugBank.d77.s21|121-122|an|O
DDI-DrugBank.d77.s21|124-132|inhibitor|O
DDI-DrugBank.d77.s21|134-135|of|O
DDI-DrugBank.d77.s21|137-140|P450|O
DDI-DrugBank.d77.s21|142-144|2D6|O
DDI-DrugBank.d77.s21|145-145|.|O
DDI-DrugBank.d608.s0|0-2|The|O
DDI-DrugBank.d608.s0|4-5|in|O
DDI-DrugBank.d608.s0|7-11|vitro|O
DDI-DrugBank.d608.s0|13-19|binding|O
DDI-DrugBank.d608.s0|21-22|of|O
DDI-DrugBank.d608.s0|24-31|warfarin|drug
DDI-DrugBank.d608.s0|33-34|to|O
DDI-DrugBank.d608.s0|36-40|human|O
DDI-DrugBank.d608.s0|42-47|plasma|O
DDI-DrugBank.d608.s0|49-56|proteins|O
DDI-DrugBank.d608.s0|58-59|is|O
DDI-DrugBank.d608.s0|61-70|unaffected|O
DDI-DrugBank.d608.s0|72-73|by|O
DDI-DrugBank.d608.s0|75-82|tolmetin|drug
DDI-DrugBank.d608.s0|83-83|,|O
DDI-DrugBank.d608.s0|85-87|and|O
DDI-DrugBank.d608.s0|89-96|tolmetin|drug
DDI-DrugBank.d608.s0|98-101|does|O
DDI-DrugBank.d608.s0|103-105|not|O
DDI-DrugBank.d608.s0|107-111|alter|O
DDI-DrugBank.d608.s0|113-115|the|O
DDI-DrugBank.d608.s0|117-127|prothrombin|O
DDI-DrugBank.d608.s0|129-132|time|O
DDI-DrugBank.d608.s0|134-135|of|O
DDI-DrugBank.d608.s0|137-142|normal|O
DDI-DrugBank.d608.s0|144-153|volunteers|O
DDI-DrugBank.d608.s0|154-154|.|O
DDI-DrugBank.d608.s1|0-6|However|O
DDI-DrugBank.d608.s1|7-7|,|O
DDI-DrugBank.d608.s1|9-17|increased|O
DDI-DrugBank.d608.s1|19-29|prothrombin|O
DDI-DrugBank.d608.s1|31-34|time|O
DDI-DrugBank.d608.s1|36-38|and|O
DDI-DrugBank.d608.s1|40-47|bleeding|O
DDI-DrugBank.d608.s1|49-52|have|O
DDI-DrugBank.d608.s1|54-57|been|O
DDI-DrugBank.d608.s1|59-66|reported|O
DDI-DrugBank.d608.s1|68-69|in|O
DDI-DrugBank.d608.s1|71-78|patients|O
DDI-DrugBank.d608.s1|80-81|on|O
DDI-DrugBank.d608.s1|83-93|concomitant|O
DDI-DrugBank.d608.s1|95-102|TOLECTIN|brand
DDI-DrugBank.d608.s1|104-106|and|O
DDI-DrugBank.d608.s1|108-115|warfarin|drug
DDI-DrugBank.d608.s1|117-123|therapy|O
DDI-DrugBank.d608.s1|124-124|.|O
DDI-DrugBank.d608.s2|0-8|Therefore|O
DDI-DrugBank.d608.s2|9-9|,|O
DDI-DrugBank.d608.s2|11-17|caution|O
DDI-DrugBank.d608.s2|19-24|should|O
DDI-DrugBank.d608.s2|26-27|be|O
DDI-DrugBank.d608.s2|29-37|exercised|O
DDI-DrugBank.d608.s2|39-42|when|O
DDI-DrugBank.d608.s2|44-56|administering|O
DDI-DrugBank.d608.s2|58-65|TOLECTIN|brand
DDI-DrugBank.d608.s2|67-68|to|O
DDI-DrugBank.d608.s2|70-77|patients|O
DDI-DrugBank.d608.s2|79-80|on|O
DDI-DrugBank.d608.s2|82-95|anticoagulants|group
DDI-DrugBank.d608.s2|96-96|.|O
DDI-DrugBank.d608.s3|0-1|In|O
DDI-DrugBank.d608.s3|3-7|adult|O
DDI-DrugBank.d608.s3|9-16|diabetic|O
DDI-DrugBank.d608.s3|18-25|patients|O
DDI-DrugBank.d608.s3|27-31|under|O
DDI-DrugBank.d608.s3|33-41|treatment|O
DDI-DrugBank.d608.s3|43-46|with|O
DDI-DrugBank.d608.s3|48-53|either|O
DDI-DrugBank.d608.s3|55-67|sulfonylureas|group
DDI-DrugBank.d608.s3|69-70|or|O
DDI-DrugBank.d608.s3|72-78|insulin|drug
DDI-DrugBank.d608.s3|80-84|there|O
DDI-DrugBank.d608.s3|86-87|is|O
DDI-DrugBank.d608.s3|89-90|no|O
DDI-DrugBank.d608.s3|92-97|change|O
DDI-DrugBank.d608.s3|99-100|in|O
DDI-DrugBank.d608.s3|102-104|the|O
DDI-DrugBank.d608.s3|106-113|clinical|O
DDI-DrugBank.d608.s3|115-121|effects|O
DDI-DrugBank.d608.s3|123-124|of|O
DDI-DrugBank.d608.s3|126-131|either|O
DDI-DrugBank.d608.s3|133-140|TOLECTIN|brand
DDI-DrugBank.d608.s3|142-143|or|O
DDI-DrugBank.d608.s3|145-147|the|O
DDI-DrugBank.d608.s3|149-167|hypoglycemic agents|group
DDI-DrugBank.d608.s3|168-168|.|O
DDI-DrugBank.d608.s4|0-6|Caution|O
DDI-DrugBank.d608.s4|8-13|should|O
DDI-DrugBank.d608.s4|15-16|be|O
DDI-DrugBank.d608.s4|18-21|used|O
DDI-DrugBank.d608.s4|23-24|if|O
DDI-DrugBank.d608.s4|26-33|TOLECTIN|brand
DDI-DrugBank.d608.s4|35-36|is|O
DDI-DrugBank.d608.s4|38-49|administered|O
DDI-DrugBank.d608.s4|51-63|concomitantly|O
DDI-DrugBank.d608.s4|65-68|with|O
DDI-DrugBank.d608.s4|70-81|methotrexate|drug
DDI-DrugBank.d608.s4|82-82|.|O
DDI-DrugBank.d608.s5|0-7|TOLECTIN|brand
DDI-DrugBank.d608.s5|9-11|and|O
DDI-DrugBank.d608.s5|13-17|other|O
DDI-DrugBank.d608.s5|19-54|nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d608.s5|56-59|have|O
DDI-DrugBank.d608.s5|61-64|been|O
DDI-DrugBank.d608.s5|66-73|reported|O
DDI-DrugBank.d608.s5|75-76|to|O
DDI-DrugBank.d608.s5|78-83|reduce|O
DDI-DrugBank.d608.s5|85-87|the|O
DDI-DrugBank.d608.s5|89-95|tubular|O
DDI-DrugBank.d608.s5|97-105|secretion|O
DDI-DrugBank.d608.s5|107-108|of|O
DDI-DrugBank.d608.s5|110-121|methotrexate|drug
DDI-DrugBank.d608.s5|123-124|in|O
DDI-DrugBank.d608.s5|126-127|an|O
DDI-DrugBank.d608.s5|129-134|animal|O
DDI-DrugBank.d608.s5|136-140|model|O
DDI-DrugBank.d608.s5|141-141|,|O
DDI-DrugBank.d608.s5|143-150|possibly|O
DDI-DrugBank.d608.s5|152-160|enhancing|O
DDI-DrugBank.d608.s5|162-164|the|O
DDI-DrugBank.d608.s5|166-173|toxicity|O
DDI-DrugBank.d608.s5|175-176|of|O
DDI-DrugBank.d608.s5|178-189|methotrexate|drug
DDI-DrugBank.d608.s5|190-190|.|O
DDI-DrugBank.d608.s6|0-9|Laboratory|O
DDI-DrugBank.d608.s6|11-15|Tests|O
DDI-DrugBank.d608.s6|17-23|Because|O
DDI-DrugBank.d608.s6|25-31|serious|O
DDI-DrugBank.d608.s6|33-34|GI|O
DDI-DrugBank.d608.s6|36-40|tract|O
DDI-DrugBank.d608.s6|42-51|ulceration|O
DDI-DrugBank.d608.s6|53-55|and|O
DDI-DrugBank.d608.s6|57-64|bleeding|O
DDI-DrugBank.d608.s6|66-68|can|O
DDI-DrugBank.d608.s6|70-74|occur|O
DDI-DrugBank.d608.s6|76-82|without|O
DDI-DrugBank.d608.s6|84-90|warning|O
DDI-DrugBank.d608.s6|92-99|symptoms|O
DDI-DrugBank.d608.s6|100-100|,|O
DDI-DrugBank.d608.s6|102-111|physicians|O
DDI-DrugBank.d608.s6|113-118|should|O
DDI-DrugBank.d608.s6|120-125|follow|O
DDI-DrugBank.d608.s6|127-137|chronically|O
DDI-DrugBank.d608.s6|139-145|treated|O
DDI-DrugBank.d608.s6|147-154|patients|O
DDI-DrugBank.d608.s6|156-158|for|O
DDI-DrugBank.d608.s6|160-162|the|O
DDI-DrugBank.d608.s6|164-168|signs|O
DDI-DrugBank.d608.s6|170-172|and|O
DDI-DrugBank.d608.s6|174-181|symptoms|O
DDI-DrugBank.d608.s6|183-184|of|O
DDI-DrugBank.d608.s6|186-195|ulceration|O
DDI-DrugBank.d608.s6|197-199|and|O
DDI-DrugBank.d608.s6|201-208|bleeding|O
DDI-DrugBank.d608.s6|210-212|and|O
DDI-DrugBank.d608.s6|214-219|should|O
DDI-DrugBank.d608.s6|221-226|inform|O
DDI-DrugBank.d608.s6|228-231|them|O
DDI-DrugBank.d608.s6|233-234|of|O
DDI-DrugBank.d608.s6|236-238|the|O
DDI-DrugBank.d608.s6|240-249|importance|O
DDI-DrugBank.d608.s6|251-252|of|O
DDI-DrugBank.d608.s6|254-257|this|O
DDI-DrugBank.d608.s6|259-267|follow-up|O
DDI-DrugBank.d608.s6|268-268|.|O
DDI-DrugBank.d727.s0|0-9|Zidovudine|drug
DDI-DrugBank.d727.s0|11-23|competitively|O
DDI-DrugBank.d727.s0|25-32|inhibits|O
DDI-DrugBank.d727.s0|34-36|the|O
DDI-DrugBank.d727.s0|38-50|intracellular|O
DDI-DrugBank.d727.s0|52-66|phosphorylation|O
DDI-DrugBank.d727.s0|68-69|of|O
DDI-DrugBank.d727.s0|71-79|stavudine|drug
DDI-DrugBank.d727.s0|80-80|.|O
DDI-DrugBank.d727.s1|0-8|Therefore|O
DDI-DrugBank.d727.s1|9-9|,|O
DDI-DrugBank.d727.s1|11-13|use|O
DDI-DrugBank.d727.s1|15-16|of|O
DDI-DrugBank.d727.s1|18-27|zidovudine|drug
DDI-DrugBank.d727.s1|29-30|in|O
DDI-DrugBank.d727.s1|32-42|combination|O
DDI-DrugBank.d727.s1|44-47|with|O
DDI-DrugBank.d727.s1|49-53|ZERIT|brand
DDI-DrugBank.d727.s1|55-60|should|O
DDI-DrugBank.d727.s1|62-63|be|O
DDI-DrugBank.d727.s1|65-71|avoided|O
DDI-DrugBank.d727.s1|72-72|.|O
DDI-DrugBank.d727.s2|0-1|In|O
DDI-DrugBank.d727.s2|3-7|vitro|O
DDI-DrugBank.d727.s2|9-12|data|O
DDI-DrugBank.d727.s2|14-21|indicate|O
DDI-DrugBank.d727.s2|23-26|that|O
DDI-DrugBank.d727.s2|28-30|the|O
DDI-DrugBank.d727.s2|32-46|phosphorylation|O
DDI-DrugBank.d727.s2|48-49|of|O
DDI-DrugBank.d727.s2|51-59|stavudine|drug
DDI-DrugBank.d727.s2|61-62|is|O
DDI-DrugBank.d727.s2|64-67|also|O
DDI-DrugBank.d727.s2|69-77|inhibited|O
DDI-DrugBank.d727.s2|79-80|at|O
DDI-DrugBank.d727.s2|82-89|relevant|O
DDI-DrugBank.d727.s2|91-104|concentrations|O
DDI-DrugBank.d727.s2|106-107|by|O
DDI-DrugBank.d727.s2|109-119|doxorubicin|drug
DDI-DrugBank.d727.s2|121-123|and|O
DDI-DrugBank.d727.s2|125-133|ribavirin|drug
DDI-DrugBank.d727.s2|134-134|.|O
DDI-DrugBank.d727.s3|0-2|The|O
DDI-DrugBank.d727.s3|4-11|clinical|O
DDI-DrugBank.d727.s3|13-24|significance|O
DDI-DrugBank.d727.s3|26-27|of|O
DDI-DrugBank.d727.s3|29-33|these|O
DDI-DrugBank.d727.s3|35-36|in|O
DDI-DrugBank.d727.s3|38-42|vitro|O
DDI-DrugBank.d727.s3|44-55|interactions|O
DDI-DrugBank.d727.s3|57-58|is|O
DDI-DrugBank.d727.s3|60-66|unknown|O
DDI-DrugBank.d727.s3|67-67|;|O
DDI-DrugBank.d727.s4|0-8|therefore|O
DDI-DrugBank.d727.s4|9-9|,|O
DDI-DrugBank.d727.s4|11-21|concomitant|O
DDI-DrugBank.d727.s4|23-25|use|O
DDI-DrugBank.d727.s4|27-28|of|O
DDI-DrugBank.d727.s4|30-38|stavudine|drug
DDI-DrugBank.d727.s4|40-43|with|O
DDI-DrugBank.d727.s4|45-50|either|O
DDI-DrugBank.d727.s4|52-53|of|O
DDI-DrugBank.d727.s4|55-59|these|O
DDI-DrugBank.d727.s4|61-65|drugs|O
DDI-DrugBank.d727.s4|67-72|should|O
DDI-DrugBank.d727.s4|74-75|be|O
DDI-DrugBank.d727.s4|77-86|undertaken|O
DDI-DrugBank.d727.s4|88-91|with|O
DDI-DrugBank.d727.s4|93-99|caution|O
DDI-DrugBank.d727.s4|100-100|.|O
DDI-DrugBank.d512.s0|0-5|and/or|O
DDI-DrugBank.d512.s0|7-21|Drug/Laboratory|O
DDI-DrugBank.d512.s0|23-26|Test|O
DDI-DrugBank.d512.s0|28-39|Interactions|O
DDI-DrugBank.d512.s0|41-43|See|O
DDI-DrugBank.d512.s0|45-52|CLINICAL|O
DDI-DrugBank.d512.s0|54-65|PHARMACOLOGY|O
DDI-DrugBank.d512.s0|66-66|,|O
DDI-DrugBank.d512.s0|68-83|Pharmacokinetics|O
DDI-DrugBank.d512.s0|85-87|and|O
DDI-DrugBank.d512.s0|89-92|Drug|O
DDI-DrugBank.d512.s0|94-105|Interactions|O
DDI-DrugBank.d512.s0|106-106|.|O
DDI-DrugBank.d512.s1|0-5|Effect|O
DDI-DrugBank.d512.s1|7-8|of|O
DDI-DrugBank.d512.s1|10-17|Sensipar|brand
DDI-DrugBank.d512.s1|19-20|on|O
DDI-DrugBank.d512.s1|22-26|other|O
DDI-DrugBank.d512.s1|28-32|drugs|O
DDI-DrugBank.d512.s1|33-33|:|O
DDI-DrugBank.d512.s1|35-39|Drugs|O
DDI-DrugBank.d512.s1|41-51|metabolized|O
DDI-DrugBank.d512.s1|53-54|by|O
DDI-DrugBank.d512.s1|56-65|cytochrome|O
DDI-DrugBank.d512.s1|67-70|P450|O
DDI-DrugBank.d512.s1|72-74|2D6|O
DDI-DrugBank.d512.s1|76-76|(|O
DDI-DrugBank.d512.s1|77-82|CYP2D6|O
DDI-DrugBank.d512.s1|83-83|)|O
DDI-DrugBank.d512.s1|84-84|:|O
DDI-DrugBank.d512.s1|86-93|Sensipar|brand
DDI-DrugBank.d512.s1|96-97|is|O
DDI-DrugBank.d512.s1|99-99|a|O
DDI-DrugBank.d512.s1|101-106|strong|O
DDI-DrugBank.d512.s1|108-109|in|O
DDI-DrugBank.d512.s1|111-115|vitro|O
DDI-DrugBank.d512.s1|117-125|inhibitor|O
DDI-DrugBank.d512.s1|127-128|of|O
DDI-DrugBank.d512.s1|130-135|CYP2D6|O
DDI-DrugBank.d512.s1|136-136|.|O
DDI-DrugBank.d512.s2|0-8|Therefore|O
DDI-DrugBank.d512.s2|9-9|,|O
DDI-DrugBank.d512.s2|11-14|dose|O
DDI-DrugBank.d512.s2|16-26|adjustments|O
DDI-DrugBank.d512.s2|28-29|of|O
DDI-DrugBank.d512.s2|31-41|concomitant|O
DDI-DrugBank.d512.s2|43-53|medications|O
DDI-DrugBank.d512.s2|55-58|that|O
DDI-DrugBank.d512.s2|60-62|are|O
DDI-DrugBank.d512.s2|64-76|predominantly|O
DDI-DrugBank.d512.s2|78-88|metabolized|O
DDI-DrugBank.d512.s2|90-91|by|O
DDI-DrugBank.d512.s2|93-98|CYP2D6|O
DDI-DrugBank.d512.s2|100-102|and|O
DDI-DrugBank.d512.s2|104-107|have|O
DDI-DrugBank.d512.s2|109-109|a|O
DDI-DrugBank.d512.s2|111-116|narrow|O
DDI-DrugBank.d512.s2|118-128|therapeutic|O
DDI-DrugBank.d512.s2|130-134|index|O
DDI-DrugBank.d512.s2|136-136|(|O
DDI-DrugBank.d512.s2|137-140|e.g.|O
DDI-DrugBank.d512.s2|141-141|,|O
DDI-DrugBank.d512.s2|143-152|flecainide|drug
DDI-DrugBank.d512.s2|153-153|,|O
DDI-DrugBank.d512.s2|155-165|vinblastine|drug
DDI-DrugBank.d512.s2|166-166|,|O
DDI-DrugBank.d512.s2|168-179|thioridazine|drug
DDI-DrugBank.d512.s2|181-183|and|O
DDI-DrugBank.d512.s2|185-188|most|O
DDI-DrugBank.d512.s2|190-214|tricyclic antidepressants|group
DDI-DrugBank.d512.s2|215-215|)|O
DDI-DrugBank.d512.s2|217-219|may|O
DDI-DrugBank.d512.s2|221-222|be|O
DDI-DrugBank.d512.s2|224-231|required|O
DDI-DrugBank.d512.s2|232-232|.|O
DDI-DrugBank.d512.s3|0-12|Amitriptyline|drug
DDI-DrugBank.d512.s3|13-13|:|O
DDI-DrugBank.d512.s3|15-24|Concurrent|O
DDI-DrugBank.d512.s3|26-39|administration|O
DDI-DrugBank.d512.s3|41-42|of|O
DDI-DrugBank.d512.s3|44-45|25|O
DDI-DrugBank.d512.s3|47-48|mg|O
DDI-DrugBank.d512.s3|50-51|or|O
DDI-DrugBank.d512.s3|53-55|100|O
DDI-DrugBank.d512.s3|57-58|mg|O
DDI-DrugBank.d512.s3|60-69|cinacalcet|drug
DDI-DrugBank.d512.s3|71-74|with|O
DDI-DrugBank.d512.s3|76-77|50|O
DDI-DrugBank.d512.s3|79-80|mg|O
DDI-DrugBank.d512.s3|82-94|amitriptyline|drug
DDI-DrugBank.d512.s3|96-104|increased|O
DDI-DrugBank.d512.s3|106-118|amitriptyline|drug
DDI-DrugBank.d512.s3|120-127|exposure|O
DDI-DrugBank.d512.s3|129-131|and|O
DDI-DrugBank.d512.s3|147-147|(|O
DDI-DrugBank.d512.s3|148-153|active|O
DDI-DrugBank.d512.s3|155-164|metabolite|O
DDI-DrugBank.d512.s3|165-165|)|O
DDI-DrugBank.d512.s3|167-174|exposure|O
DDI-DrugBank.d512.s3|176-177|by|O
DDI-DrugBank.d512.s3|179-191|approximately|O
DDI-DrugBank.d512.s3|193-194|20|O
DDI-DrugBank.d512.s3|195-195|%|O
DDI-DrugBank.d512.s3|197-198|in|O
DDI-DrugBank.d512.s3|200-205|CYP2D6|O
DDI-DrugBank.d512.s3|207-215|extensive|O
DDI-DrugBank.d512.s3|217-228|metabolizers|O
DDI-DrugBank.d512.s3|229-229|.|O
DDI-DrugBank.d512.s4|0-5|Effect|O
DDI-DrugBank.d512.s4|7-8|of|O
DDI-DrugBank.d512.s4|10-14|other|O
DDI-DrugBank.d512.s4|16-20|drugs|O
DDI-DrugBank.d512.s4|22-23|on|O
DDI-DrugBank.d512.s4|25-32|Sensipar|brand
DDI-DrugBank.d512.s4|34-34|:|O
DDI-DrugBank.d512.s4|36-43|Sensipar|brand
DDI-DrugBank.d512.s4|46-47|is|O
DDI-DrugBank.d512.s4|49-59|metabolized|O
DDI-DrugBank.d512.s4|61-62|by|O
DDI-DrugBank.d512.s4|64-71|multiple|O
DDI-DrugBank.d512.s4|73-82|cytochrome|O
DDI-DrugBank.d512.s4|84-87|P450|O
DDI-DrugBank.d512.s4|89-95|enzymes|O
DDI-DrugBank.d512.s4|96-96|,|O
DDI-DrugBank.d512.s4|98-106|primarily|O
DDI-DrugBank.d512.s4|108-113|CYP3A4|O
DDI-DrugBank.d512.s4|114-114|,|O
DDI-DrugBank.d512.s4|116-121|CYP2D6|O
DDI-DrugBank.d512.s4|122-122|,|O
DDI-DrugBank.d512.s4|124-126|and|O
DDI-DrugBank.d512.s4|128-133|CYP1A2|O
DDI-DrugBank.d512.s4|134-134|.|O
DDI-DrugBank.d512.s5|0-11|Ketoconazole|drug
DDI-DrugBank.d512.s5|12-12|:|O
DDI-DrugBank.d512.s5|14-21|Sensipar|brand
DDI-DrugBank.d512.s5|23-24|is|O
DDI-DrugBank.d512.s5|26-36|metabolized|O
DDI-DrugBank.d512.s5|38-39|in|O
DDI-DrugBank.d512.s5|41-44|part|O
DDI-DrugBank.d512.s5|46-47|by|O
DDI-DrugBank.d512.s5|49-54|CYP3A4|O
DDI-DrugBank.d512.s5|55-55|.|O
DDI-DrugBank.d512.s6|0-16|Co-administration|O
DDI-DrugBank.d512.s6|18-19|of|O
DDI-DrugBank.d512.s6|21-32|ketoconazole|drug
DDI-DrugBank.d512.s6|33-33|,|O
DDI-DrugBank.d512.s6|35-35|a|O
DDI-DrugBank.d512.s6|37-42|strong|O
DDI-DrugBank.d512.s6|44-52|inhibitor|O
DDI-DrugBank.d512.s6|54-55|of|O
DDI-DrugBank.d512.s6|57-62|CYP3A4|O
DDI-DrugBank.d512.s6|63-63|,|O
DDI-DrugBank.d512.s6|65-73|increased|O
DDI-DrugBank.d512.s6|75-84|cinacalcet|drug
DDI-DrugBank.d512.s6|86-93|exposure|O
DDI-DrugBank.d512.s6|95-103|following|O
DDI-DrugBank.d512.s6|105-105|a|O
DDI-DrugBank.d512.s6|107-112|single|O
DDI-DrugBank.d512.s6|114-115|90|O
DDI-DrugBank.d512.s6|117-118|mg|O
DDI-DrugBank.d512.s6|120-123|dose|O
DDI-DrugBank.d512.s6|125-126|of|O
DDI-DrugBank.d512.s6|128-135|Sensipar|brand
DDI-DrugBank.d512.s6|137-138|by|O
DDI-DrugBank.d512.s6|140-142|2.3|O
DDI-DrugBank.d512.s6|144-147|fold|O
DDI-DrugBank.d512.s6|148-148|.|O
DDI-DrugBank.d512.s7|0-3|Dose|O
DDI-DrugBank.d512.s7|5-14|adjustment|O
DDI-DrugBank.d512.s7|16-17|of|O
DDI-DrugBank.d512.s7|19-26|Sensipar|brand
DDI-DrugBank.d512.s7|28-30|may|O
DDI-DrugBank.d512.s7|32-33|be|O
DDI-DrugBank.d512.s7|35-42|required|O
DDI-DrugBank.d512.s7|44-46|and|O
DDI-DrugBank.d512.s7|48-50|PTH|O
DDI-DrugBank.d512.s7|52-54|and|O
DDI-DrugBank.d512.s7|56-60|serum|O
DDI-DrugBank.d512.s7|62-68|calcium|O
DDI-DrugBank.d512.s7|70-83|concentrations|O
DDI-DrugBank.d512.s7|85-90|should|O
DDI-DrugBank.d512.s7|92-93|be|O
DDI-DrugBank.d512.s7|95-101|closely|O
DDI-DrugBank.d512.s7|103-111|monitored|O
DDI-DrugBank.d512.s7|113-114|if|O
DDI-DrugBank.d512.s7|116-116|a|O
DDI-DrugBank.d512.s7|118-124|patient|O
DDI-DrugBank.d512.s7|126-134|initiates|O
DDI-DrugBank.d512.s7|136-137|or|O
DDI-DrugBank.d512.s7|139-150|discontinues|O
DDI-DrugBank.d512.s7|152-158|therapy|O
DDI-DrugBank.d512.s7|160-163|with|O
DDI-DrugBank.d512.s7|165-165|a|O
DDI-DrugBank.d512.s7|167-172|strong|O
DDI-DrugBank.d512.s7|174-179|CYP3A4|O
DDI-DrugBank.d512.s7|181-189|inhibitor|O
DDI-DrugBank.d512.s7|191-191|(|O
DDI-DrugBank.d512.s7|192-195|e.g.|O
DDI-DrugBank.d512.s7|196-196|,|O
DDI-DrugBank.d512.s7|198-209|ketoconazole|drug
DDI-DrugBank.d512.s7|210-210|,|O
DDI-DrugBank.d512.s7|212-223|erythromycin|drug
DDI-DrugBank.d512.s7|224-224|,|O
DDI-DrugBank.d512.s7|226-237|itraconazole|drug
DDI-DrugBank.d512.s7|238-238|;|O
DDI-DrugBank.d512.s8|0-2|see|O
DDI-DrugBank.d512.s8|4-9|DOSAGE|O
DDI-DrugBank.d512.s8|11-13|AND|O
DDI-DrugBank.d512.s8|15-28|ADMINISTRATION|O
DDI-DrugBank.d512.s8|29-29|)|O
DDI-DrugBank.d512.s8|30-30|.|O
DDI-DrugBank.d305.s0|0-7|Dantrium|brand
DDI-DrugBank.d305.s0|9-10|is|O
DDI-DrugBank.d305.s0|12-22|metabolized|O
DDI-DrugBank.d305.s0|24-25|by|O
DDI-DrugBank.d305.s0|27-29|the|O
DDI-DrugBank.d305.s0|31-35|liver|O
DDI-DrugBank.d305.s0|36-36|,|O
DDI-DrugBank.d305.s0|38-40|and|O
DDI-DrugBank.d305.s0|42-43|it|O
DDI-DrugBank.d305.s0|45-46|is|O
DDI-DrugBank.d305.s0|48-60|theoretically|O
DDI-DrugBank.d305.s0|62-69|possible|O
DDI-DrugBank.d305.s0|71-74|that|O
DDI-DrugBank.d305.s0|76-78|its|O
DDI-DrugBank.d305.s0|80-89|metabolism|O
DDI-DrugBank.d305.s0|91-93|may|O
DDI-DrugBank.d305.s0|95-96|be|O
DDI-DrugBank.d305.s0|98-105|enhanced|O
DDI-DrugBank.d305.s0|107-108|by|O
DDI-DrugBank.d305.s0|110-114|drugs|O
DDI-DrugBank.d305.s0|116-120|known|O
DDI-DrugBank.d305.s0|122-123|to|O
DDI-DrugBank.d305.s0|125-130|induce|O
DDI-DrugBank.d305.s0|132-138|hepatic|O
DDI-DrugBank.d305.s0|140-149|microsomal|O
DDI-DrugBank.d305.s0|151-157|enzymes|O
DDI-DrugBank.d305.s0|158-158|.|O
DDI-DrugBank.d305.s1|0-6|However|O
DDI-DrugBank.d305.s1|7-7|,|O
DDI-DrugBank.d305.s1|9-15|neither|O
DDI-DrugBank.d305.s1|17-29|phenobarbital|drug
DDI-DrugBank.d305.s1|31-33|nor|O
DDI-DrugBank.d305.s1|35-42|diazepam|drug
DDI-DrugBank.d305.s1|44-50|appears|O
DDI-DrugBank.d305.s1|52-53|to|O
DDI-DrugBank.d305.s1|55-60|affect|O
DDI-DrugBank.d305.s1|62-69|Dantrium|brand
DDI-DrugBank.d305.s1|71-80|metabolism|O
DDI-DrugBank.d305.s1|81-81|.|O
DDI-DrugBank.d305.s2|0-6|Binding|O
DDI-DrugBank.d305.s2|8-9|to|O
DDI-DrugBank.d305.s2|11-16|plasma|O
DDI-DrugBank.d305.s2|18-24|protein|O
DDI-DrugBank.d305.s2|26-27|is|O
DDI-DrugBank.d305.s2|29-31|not|O
DDI-DrugBank.d305.s2|33-45|significantly|O
DDI-DrugBank.d305.s2|47-53|altered|O
DDI-DrugBank.d305.s2|55-56|by|O
DDI-DrugBank.d305.s2|58-65|diazepam|drug
DDI-DrugBank.d305.s2|66-66|,|O
DDI-DrugBank.d305.s2|68-84|diphenylhydantoin|drug
DDI-DrugBank.d305.s2|85-85|,|O
DDI-DrugBank.d305.s2|87-88|or|O
DDI-DrugBank.d305.s2|90-103|phenylbutazone|drug
DDI-DrugBank.d305.s2|104-104|.|O
DDI-DrugBank.d305.s3|0-6|Binding|O
DDI-DrugBank.d305.s3|8-9|to|O
DDI-DrugBank.d305.s3|11-16|plasma|O
DDI-DrugBank.d305.s3|18-25|proteins|O
DDI-DrugBank.d305.s3|27-28|is|O
DDI-DrugBank.d305.s3|30-36|reduced|O
DDI-DrugBank.d305.s3|38-39|by|O
DDI-DrugBank.d305.s3|41-48|warfarin|drug
DDI-DrugBank.d305.s3|50-52|and|O
DDI-DrugBank.d305.s3|54-63|clotibrate|O
DDI-DrugBank.d305.s3|65-67|and|O
DDI-DrugBank.d305.s3|69-77|increased|O
DDI-DrugBank.d305.s3|79-80|by|O
DDI-DrugBank.d305.s3|82-92|tolbutamide|drug
DDI-DrugBank.d305.s3|93-93|.|O
DDI-DrugBank.d305.s4|0-13|Cardiovascular|O
DDI-DrugBank.d305.s4|15-22|collapse|O
DDI-DrugBank.d305.s4|24-25|in|O
DDI-DrugBank.d305.s4|27-34|patients|O
DDI-DrugBank.d305.s4|36-42|treated|O
DDI-DrugBank.d305.s4|44-57|simultaneously|O
DDI-DrugBank.d305.s4|59-62|with|O
DDI-DrugBank.d305.s4|64-72|varapamil|O
DDI-DrugBank.d305.s4|74-76|and|O
DDI-DrugBank.d305.s4|78-94|dantrolene sodium|drug
DDI-DrugBank.d305.s4|96-97|is|O
DDI-DrugBank.d305.s4|99-102|rare|O
DDI-DrugBank.d305.s4|103-103|.|O
DDI-DrugBank.d305.s5|0-2|The|O
DDI-DrugBank.d305.s5|4-14|combination|O
DDI-DrugBank.d305.s5|16-17|of|O
DDI-DrugBank.d305.s5|19-29|therapeutic|O
DDI-DrugBank.d305.s5|31-35|doses|O
DDI-DrugBank.d305.s5|37-38|of|O
DDI-DrugBank.d305.s5|40-50|intravenous|O
DDI-DrugBank.d305.s5|52-68|dantrolene sodium|drug
DDI-DrugBank.d305.s5|70-72|and|O
DDI-DrugBank.d305.s5|74-82|verapamil|drug
DDI-DrugBank.d305.s5|84-85|in|O
DDI-DrugBank.d305.s5|87-95|halothane|drug
DDI-DrugBank.d305.s5|97-108|a-chloralose|O
DDI-DrugBank.d305.s5|110-121|anesthetized|O
DDI-DrugBank.d305.s5|123-127|swine|O
DDI-DrugBank.d305.s5|129-131|has|O
DDI-DrugBank.d305.s5|133-140|resulted|O
DDI-DrugBank.d305.s5|142-143|in|O
DDI-DrugBank.d305.s5|145-155|ventricular|O
DDI-DrugBank.d305.s5|157-168|fibrillation|O
DDI-DrugBank.d305.s5|170-172|and|O
DDI-DrugBank.d305.s5|174-187|cardiovascular|O
DDI-DrugBank.d305.s5|189-196|collapse|O
DDI-DrugBank.d305.s5|198-199|in|O
DDI-DrugBank.d305.s5|201-211|association|O
DDI-DrugBank.d305.s5|213-216|with|O
DDI-DrugBank.d305.s5|218-223|marked|O
DDI-DrugBank.d305.s5|225-236|hyperkalemia|O
DDI-DrugBank.d305.s5|237-237|.|O
DDI-DrugBank.d305.s6|0-1|It|O
DDI-DrugBank.d305.s6|3-4|is|O
DDI-DrugBank.d305.s6|6-16|recommended|O
DDI-DrugBank.d305.s6|18-21|that|O
DDI-DrugBank.d305.s6|23-25|the|O
DDI-DrugBank.d305.s6|27-37|combination|O
DDI-DrugBank.d305.s6|39-40|of|O
DDI-DrugBank.d305.s6|42-52|intravenous|O
DDI-DrugBank.d305.s6|54-70|dantrolene sodium|drug
DDI-DrugBank.d305.s6|72-74|and|O
DDI-DrugBank.d305.s6|76-99|calcium channel blockers|group
DDI-DrugBank.d305.s6|100-100|,|O
DDI-DrugBank.d305.s6|102-105|such|O
DDI-DrugBank.d305.s6|107-108|as|O
DDI-DrugBank.d305.s6|110-118|verapamil|drug
DDI-DrugBank.d305.s6|119-119|,|O
DDI-DrugBank.d305.s6|121-123|not|O
DDI-DrugBank.d305.s6|125-126|be|O
DDI-DrugBank.d305.s6|128-131|used|O
DDI-DrugBank.d305.s6|133-140|together|O
DDI-DrugBank.d305.s6|142-147|during|O
DDI-DrugBank.d305.s6|149-151|the|O
DDI-DrugBank.d305.s6|153-162|management|O
DDI-DrugBank.d305.s6|164-165|of|O
DDI-DrugBank.d305.s6|167-175|malignant|O
DDI-DrugBank.d305.s6|177-188|hyperthermia|O
DDI-DrugBank.d305.s6|190-195|crisis|O
DDI-DrugBank.d305.s6|197-201|until|O
DDI-DrugBank.d305.s6|203-205|the|O
DDI-DrugBank.d305.s6|207-215|relevance|O
DDI-DrugBank.d305.s6|217-218|of|O
DDI-DrugBank.d305.s6|220-224|these|O
DDI-DrugBank.d305.s6|226-233|findings|O
DDI-DrugBank.d305.s6|235-236|to|O
DDI-DrugBank.d305.s6|238-243|humans|O
DDI-DrugBank.d305.s6|245-246|is|O
DDI-DrugBank.d305.s6|248-258|established|O
DDI-DrugBank.d305.s6|259-259|.|O
DDI-DrugBank.d305.s7|0-13|Administration|O
DDI-DrugBank.d305.s7|15-16|of|O
DDI-DrugBank.d305.s7|18-27|dantrolene|drug
DDI-DrugBank.d305.s7|29-31|may|O
DDI-DrugBank.d305.s7|33-42|potentiate|O
DDI-DrugBank.d305.s7|44-61|vecuronium-induced|drug
DDI-DrugBank.d305.s7|63-75|neuromuscular|O
DDI-DrugBank.d305.s7|77-81|block|O
DDI-DrugBank.d305.s7|82-82|.|O
DDI-DrugBank.d741.s0|0-1|In|O
DDI-DrugBank.d741.s0|3-3|a|O
DDI-DrugBank.d741.s0|5-19|pharmacokinetic|O
DDI-DrugBank.d741.s0|21-25|study|O
DDI-DrugBank.d741.s0|27-28|of|O
DDI-DrugBank.d741.s0|30-31|18|O
DDI-DrugBank.d741.s0|33-39|chronic|O
DDI-DrugBank.d741.s0|41-49|hepatitis|O
DDI-DrugBank.d741.s0|51-51|C|O
DDI-DrugBank.d741.s0|53-60|patients|O
DDI-DrugBank.d741.s0|62-74|concomitantly|O
DDI-DrugBank.d741.s0|76-84|receiving|O
DDI-DrugBank.d741.s0|86-94|methadone|drug
DDI-DrugBank.d741.s0|95-95|,|O
DDI-DrugBank.d741.s0|97-105|treatment|O
DDI-DrugBank.d741.s0|107-110|with|O
DDI-DrugBank.d741.s0|112-121|PEG-Intron|brand
DDI-DrugBank.d741.s0|123-126|once|O
DDI-DrugBank.d741.s0|128-133|weekly|O
DDI-DrugBank.d741.s0|135-137|for|O
DDI-DrugBank.d741.s0|139-139|4|O
DDI-DrugBank.d741.s0|141-145|weeks|O
DDI-DrugBank.d741.s0|147-149|was|O
DDI-DrugBank.d741.s0|151-160|associated|O
DDI-DrugBank.d741.s0|162-165|with|O
DDI-DrugBank.d741.s0|167-167|a|O
DDI-DrugBank.d741.s0|169-172|mean|O
DDI-DrugBank.d741.s0|174-181|increase|O
DDI-DrugBank.d741.s0|183-184|of|O
DDI-DrugBank.d741.s0|186-187|16|O
DDI-DrugBank.d741.s0|188-188|%|O
DDI-DrugBank.d741.s0|190-191|in|O
DDI-DrugBank.d741.s0|193-201|methadone|drug
DDI-DrugBank.d741.s0|203-205|AUC|O
DDI-DrugBank.d741.s0|206-206|;|O
DDI-DrugBank.d741.s1|0-1|in|O
DDI-DrugBank.d741.s1|3-3|2|O
DDI-DrugBank.d741.s1|5-7|out|O
DDI-DrugBank.d741.s1|9-10|of|O
DDI-DrugBank.d741.s1|12-13|18|O
DDI-DrugBank.d741.s1|15-22|patients|O
DDI-DrugBank.d741.s1|23-23|,|O
DDI-DrugBank.d741.s1|25-33|methadone|drug
DDI-DrugBank.d741.s1|35-37|AUC|O
DDI-DrugBank.d741.s1|39-45|doubled|O
DDI-DrugBank.d741.s1|46-46|.|O
DDI-DrugBank.d741.s2|0-2|The|O
DDI-DrugBank.d741.s2|4-11|clinical|O
DDI-DrugBank.d741.s2|13-24|significance|O
DDI-DrugBank.d741.s2|26-27|of|O
DDI-DrugBank.d741.s2|29-32|this|O
DDI-DrugBank.d741.s2|34-40|finding|O
DDI-DrugBank.d741.s2|42-43|is|O
DDI-DrugBank.d741.s2|45-51|unknown|O
DDI-DrugBank.d741.s2|52-52|;|O
DDI-DrugBank.d741.s3|0-6|however|O
DDI-DrugBank.d741.s3|7-7|,|O
DDI-DrugBank.d741.s3|9-16|patients|O
DDI-DrugBank.d741.s3|18-23|should|O
DDI-DrugBank.d741.s3|25-26|be|O
DDI-DrugBank.d741.s3|28-36|monitored|O
DDI-DrugBank.d741.s3|38-40|for|O
DDI-DrugBank.d741.s3|42-44|the|O
DDI-DrugBank.d741.s3|46-50|signs|O
DDI-DrugBank.d741.s3|52-54|and|O
DDI-DrugBank.d741.s3|56-63|symptoms|O
DDI-DrugBank.d741.s3|65-66|of|O
DDI-DrugBank.d741.s3|68-76|increased|O
DDI-DrugBank.d741.s3|78-85|narcotic|O
DDI-DrugBank.d741.s3|87-92|effect|O
DDI-DrugBank.d741.s3|93-93|.|O
DDI-DrugBank.d188.s0|0-9|Concurrent|O
DDI-DrugBank.d188.s0|11-24|administration|O
DDI-DrugBank.d188.s0|26-27|of|O
DDI-DrugBank.d188.s0|29-35|HEXALEN|brand
DDI-DrugBank.d188.s0|37-39|and|O
DDI-DrugBank.d188.s0|41-82|antidepressants of the MAO inhibitor class|group
DDI-DrugBank.d188.s0|84-86|may|O
DDI-DrugBank.d188.s0|88-92|cause|O
DDI-DrugBank.d188.s0|94-99|severe|O
DDI-DrugBank.d188.s0|101-111|orthostatic|O
DDI-DrugBank.d188.s0|113-134|hypotension.Cimetidine|drug
DDI-DrugBank.d188.s0|135-135|,|O
DDI-DrugBank.d188.s0|137-138|an|O
DDI-DrugBank.d188.s0|140-148|inhibitor|O
DDI-DrugBank.d188.s0|150-151|of|O
DDI-DrugBank.d188.s0|153-162|microsomal|O
DDI-DrugBank.d188.s0|164-167|drug|O
DDI-DrugBank.d188.s0|169-178|metabolism|O
DDI-DrugBank.d188.s0|179-179|,|O
DDI-DrugBank.d188.s0|181-189|increased|O
DDI-DrugBank.d188.s0|191-202|altretamines|drug
DDI-DrugBank.d188.s0|204-212|half-life|O
DDI-DrugBank.d188.s0|214-216|and|O
DDI-DrugBank.d188.s0|218-225|toxicity|O
DDI-DrugBank.d188.s0|227-228|in|O
DDI-DrugBank.d188.s0|230-230|a|O
DDI-DrugBank.d188.s0|232-234|rat|O
DDI-DrugBank.d188.s0|236-240|model|O
DDI-DrugBank.d188.s0|241-241|.|O
DDI-DrugBank.d188.s1|0-3|Data|O
DDI-DrugBank.d188.s1|5-8|from|O
DDI-DrugBank.d188.s1|10-10|a|O
DDI-DrugBank.d188.s1|12-21|randomized|O
DDI-DrugBank.d188.s1|23-27|trial|O
DDI-DrugBank.d188.s1|29-30|of|O
DDI-DrugBank.d188.s1|32-38|HEXALEN|brand
DDI-DrugBank.d188.s1|40-42|and|O
DDI-DrugBank.d188.s1|44-52|cisplatin|drug
DDI-DrugBank.d188.s1|54-57|plus|O
DDI-DrugBank.d188.s1|59-60|or|O
DDI-DrugBank.d188.s1|62-66|minus|O
DDI-DrugBank.d188.s1|68-77|pyridoxine|drug
DDI-DrugBank.d188.s1|79-80|in|O
DDI-DrugBank.d188.s1|82-88|ovarian|O
DDI-DrugBank.d188.s1|90-95|cancer|O
DDI-DrugBank.d188.s1|97-105|indicated|O
DDI-DrugBank.d188.s1|107-110|that|O
DDI-DrugBank.d188.s1|112-121|pyridoxine|drug
DDI-DrugBank.d188.s1|123-135|significantly|O
DDI-DrugBank.d188.s1|137-143|reduced|O
DDI-DrugBank.d188.s1|145-157|neurotoxicity|O
DDI-DrugBank.d188.s1|158-158|;|O
DDI-DrugBank.d188.s2|0-6|however|O
DDI-DrugBank.d188.s2|7-7|,|O
DDI-DrugBank.d188.s2|9-10|it|O
DDI-DrugBank.d188.s2|12-20|adversely|O
DDI-DrugBank.d188.s2|22-29|affected|O
DDI-DrugBank.d188.s2|31-38|response|O
DDI-DrugBank.d188.s2|40-47|duration|O
DDI-DrugBank.d188.s2|49-58|suggesting|O
DDI-DrugBank.d188.s2|60-63|that|O
DDI-DrugBank.d188.s2|65-74|pyridoxine|drug
DDI-DrugBank.d188.s2|76-81|should|O
DDI-DrugBank.d188.s2|83-85|not|O
DDI-DrugBank.d188.s2|87-88|be|O
DDI-DrugBank.d188.s2|90-101|administered|O
DDI-DrugBank.d188.s2|103-106|with|O
DDI-DrugBank.d188.s2|108-114|HEXALEN|brand
DDI-DrugBank.d188.s2|116-121|and/or|O
DDI-DrugBank.d604.s0|0-10|Thalidomide|drug
DDI-DrugBank.d604.s0|12-14|has|O
DDI-DrugBank.d604.s0|16-19|been|O
DDI-DrugBank.d604.s0|21-28|reported|O
DDI-DrugBank.d604.s0|30-31|to|O
DDI-DrugBank.d604.s0|33-39|enhance|O
DDI-DrugBank.d604.s0|41-43|the|O
DDI-DrugBank.d604.s0|45-52|sedative|O
DDI-DrugBank.d604.s0|54-61|activity|O
DDI-DrugBank.d604.s0|63-64|of|O
DDI-DrugBank.d604.s0|66-77|barbiturates|group
DDI-DrugBank.d604.s0|78-78|,|O
DDI-DrugBank.d604.s0|80-86|alcohol|drug
DDI-DrugBank.d604.s0|87-87|,|O
DDI-DrugBank.d604.s0|89-102|chlorpromazine|drug
DDI-DrugBank.d604.s0|103-103|,|O
DDI-DrugBank.d604.s0|105-107|and|O
DDI-DrugBank.d604.s0|109-117|reserpine|drug
DDI-DrugBank.d604.s0|118-118|.|O
DDI-DrugBank.d604.s1|0-9|Peripheral|O
DDI-DrugBank.d604.s1|11-20|Neuropathy|O
DDI-DrugBank.d604.s1|21-21|:|O
DDI-DrugBank.d604.s1|23-33|Medications|O
DDI-DrugBank.d604.s1|35-39|known|O
DDI-DrugBank.d604.s1|41-42|to|O
DDI-DrugBank.d604.s1|44-45|be|O
DDI-DrugBank.d604.s1|47-56|associated|O
DDI-DrugBank.d604.s1|58-61|with|O
DDI-DrugBank.d604.s1|63-72|peripheral|O
DDI-DrugBank.d604.s1|74-83|neuropathy|O
DDI-DrugBank.d604.s1|85-90|should|O
DDI-DrugBank.d604.s1|92-93|be|O
DDI-DrugBank.d604.s1|95-98|used|O
DDI-DrugBank.d604.s1|100-103|with|O
DDI-DrugBank.d604.s1|105-111|caution|O
DDI-DrugBank.d604.s1|113-114|in|O
DDI-DrugBank.d604.s1|116-123|patients|O
DDI-DrugBank.d604.s1|125-133|receiving|O
DDI-DrugBank.d604.s1|135-145|thalidomide|drug
DDI-DrugBank.d604.s1|146-146|.|O
DDI-DrugBank.d604.s2|0-3|Oral|O
DDI-DrugBank.d604.s2|5-18|Contraceptives|group
DDI-DrugBank.d604.s2|19-19|:|O
DDI-DrugBank.d604.s2|21-22|In|O
DDI-DrugBank.d604.s2|24-25|10|O
DDI-DrugBank.d604.s2|27-33|healthy|O
DDI-DrugBank.d604.s2|35-39|women|O
DDI-DrugBank.d604.s2|40-40|,|O
DDI-DrugBank.d604.s2|42-44|the|O
DDI-DrugBank.d604.s2|46-60|pharmacokinetic|O
DDI-DrugBank.d604.s2|62-69|profiles|O
DDI-DrugBank.d604.s2|71-72|of|O
DDI-DrugBank.d604.s2|74-86|norethindrone|drug
DDI-DrugBank.d604.s2|88-90|and|O
DDI-DrugBank.d604.s2|92-108|ethinyl estradiol|drug
DDI-DrugBank.d604.s2|110-118|following|O
DDI-DrugBank.d604.s2|120-133|administration|O
DDI-DrugBank.d604.s2|135-136|of|O
DDI-DrugBank.d604.s2|138-138|a|O
DDI-DrugBank.d604.s2|140-145|single|O
DDI-DrugBank.d604.s2|147-150|dose|O
DDI-DrugBank.d604.s2|152-161|containing|O
DDI-DrugBank.d604.s2|163-165|1.0|O
DDI-DrugBank.d604.s2|167-168|mg|O
DDI-DrugBank.d604.s2|170-171|of|O
DDI-DrugBank.d604.s2|173-193|norethindrone acetate|drug
DDI-DrugBank.d604.s2|195-197|and|O
DDI-DrugBank.d604.s2|199-200|75|O
DDI-DrugBank.d604.s2|205-205|g|O
DDI-DrugBank.d604.s2|207-208|of|O
DDI-DrugBank.d604.s2|210-226|ethinyl estradiol|drug
DDI-DrugBank.d604.s2|228-231|were|O
DDI-DrugBank.d604.s2|233-239|studied|O
DDI-DrugBank.d604.s2|240-240|.|O
DDI-DrugBank.d604.s3|0-2|The|O
DDI-DrugBank.d604.s3|4-10|results|O
DDI-DrugBank.d604.s3|12-15|were|O
DDI-DrugBank.d604.s3|17-23|similar|O
DDI-DrugBank.d604.s3|25-28|with|O
DDI-DrugBank.d604.s3|30-32|and|O
DDI-DrugBank.d604.s3|34-40|without|O
DDI-DrugBank.d604.s3|42-57|coadministration|O
DDI-DrugBank.d604.s3|59-60|of|O
DDI-DrugBank.d604.s3|62-72|thalidomide|drug
DDI-DrugBank.d604.s3|74-76|200|O
DDI-DrugBank.d604.s3|78-83|mg/day|O
DDI-DrugBank.d604.s3|85-86|to|O
DDI-DrugBank.d604.s3|88-99|steady-state|O
DDI-DrugBank.d604.s3|101-106|levels|O
DDI-DrugBank.d604.s3|107-107|.|O
DDI-DrugBank.d604.s4|0-8|Important|O
DDI-DrugBank.d604.s4|10-24|Non-Thalidomide|drug
DDI-DrugBank.d604.s4|26-29|Drug|O
DDI-DrugBank.d604.s4|31-42|Interactions|O
DDI-DrugBank.d604.s4|44-48|Drugs|O
DDI-DrugBank.d604.s4|50-53|That|O
DDI-DrugBank.d604.s4|55-63|Interfere|O
DDI-DrugBank.d604.s4|65-68|with|O
DDI-DrugBank.d604.s4|70-92|Hormonal Contraceptives|group
DDI-DrugBank.d604.s4|93-93|:|O
DDI-DrugBank.d604.s4|95-105|Concomitant|O
DDI-DrugBank.d604.s4|107-109|use|O
DDI-DrugBank.d604.s4|111-112|of|O
DDI-DrugBank.d604.s4|114-136|HIV-protease inhibitors|group
DDI-DrugBank.d604.s4|137-137|,|O
DDI-DrugBank.d604.s4|139-150|griseofulvin|drug
DDI-DrugBank.d604.s4|151-151|,|O
DDI-DrugBank.d604.s4|153-161|modafinil|drug
DDI-DrugBank.d604.s4|162-162|,|O
DDI-DrugBank.d604.s4|164-174|penicillins|group
DDI-DrugBank.d604.s4|175-175|,|O
DDI-DrugBank.d604.s4|177-184|rifampin|drug
DDI-DrugBank.d604.s4|185-185|,|O
DDI-DrugBank.d604.s4|187-195|rifabutin|drug
DDI-DrugBank.d604.s4|196-196|,|O
DDI-DrugBank.d604.s4|198-206|phenytoin|drug
DDI-DrugBank.d604.s4|207-207|,|O
DDI-DrugBank.d604.s4|209-221|carbamazepine|drug
DDI-DrugBank.d604.s4|222-222|,|O
DDI-DrugBank.d604.s4|224-225|or|O
DDI-DrugBank.d604.s4|227-233|certain|O
DDI-DrugBank.d604.s4|235-240|herbal|O
DDI-DrugBank.d604.s4|242-252|supplements|O
DDI-DrugBank.d604.s4|254-257|such|O
DDI-DrugBank.d604.s4|259-260|as|O
DDI-DrugBank.d604.s4|262-263|St|O
DDI-DrugBank.d604.s4|264-264|.|O
DDI-DrugBank.d604.s5|12-15|with|O
DDI-DrugBank.d604.s5|17-45|hormonal contraceptive agents|group
DDI-DrugBank.d604.s5|47-49|may|O
DDI-DrugBank.d604.s5|51-56|reduce|O
DDI-DrugBank.d604.s5|58-60|the|O
DDI-DrugBank.d604.s5|62-74|effectiveness|O
DDI-DrugBank.d604.s5|76-77|of|O
DDI-DrugBank.d604.s5|79-81|the|O
DDI-DrugBank.d604.s5|83-95|contraception|O
DDI-DrugBank.d604.s5|97-99|and|O
DDI-DrugBank.d604.s5|101-102|up|O
DDI-DrugBank.d604.s5|104-105|to|O
DDI-DrugBank.d604.s5|107-109|one|O
DDI-DrugBank.d604.s5|111-115|month|O
DDI-DrugBank.d604.s5|117-121|after|O
DDI-DrugBank.d604.s5|123-137|discontinuation|O
DDI-DrugBank.d604.s5|139-140|of|O
DDI-DrugBank.d604.s5|142-146|these|O
DDI-DrugBank.d604.s5|148-158|concomitant|O
DDI-DrugBank.d604.s5|160-168|therapies|O
DDI-DrugBank.d604.s5|169-169|.|O
DDI-DrugBank.d604.s6|0-8|Therefore|O
DDI-DrugBank.d604.s6|9-9|,|O
DDI-DrugBank.d604.s6|11-15|women|O
DDI-DrugBank.d604.s6|17-25|requiring|O
DDI-DrugBank.d604.s6|27-35|treatment|O
DDI-DrugBank.d604.s6|37-40|with|O
DDI-DrugBank.d604.s6|42-44|one|O
DDI-DrugBank.d604.s6|46-47|or|O
DDI-DrugBank.d604.s6|49-52|more|O
DDI-DrugBank.d604.s6|54-55|of|O
DDI-DrugBank.d604.s6|57-61|these|O
DDI-DrugBank.d604.s6|63-67|drugs|O
DDI-DrugBank.d604.s6|69-72|must|O
DDI-DrugBank.d604.s6|74-76|use|O
DDI-DrugBank.d604.s6|78-80|two|O
DDI-DrugBank.d604.s6|82-86|OTHER|O
DDI-DrugBank.d604.s6|88-96|effective|O
DDI-DrugBank.d604.s6|98-99|or|O
DDI-DrugBank.d604.s6|101-106|highly|O
DDI-DrugBank.d604.s6|108-116|effective|O
DDI-DrugBank.d604.s6|118-124|methods|O
DDI-DrugBank.d604.s6|126-127|of|O
DDI-DrugBank.d604.s6|129-141|contraception|O
DDI-DrugBank.d604.s6|143-144|or|O
DDI-DrugBank.d604.s6|146-152|abstain|O
DDI-DrugBank.d604.s6|154-157|from|O
DDI-DrugBank.d604.s6|159-170|heterosexual|O
DDI-DrugBank.d604.s6|172-177|sexual|O
DDI-DrugBank.d604.s6|179-185|contact|O
DDI-DrugBank.d604.s6|187-191|while|O
DDI-DrugBank.d604.s6|193-198|taking|O
DDI-DrugBank.d604.s6|200-210|thalidomide|drug
DDI-DrugBank.d604.s6|211-211|.|O
DDI-DrugBank.d584.s0|0-13|Anticoagulants|group
DDI-DrugBank.d584.s0|0-31|Anticoagulants steroids|group
DDI-DrugBank.d584.s0|33-35|may|O
DDI-DrugBank.d584.s0|37-44|increase|O
DDI-DrugBank.d584.s0|46-56|sensitivity|O
DDI-DrugBank.d584.s0|58-59|to|O
DDI-DrugBank.d584.s0|61-64|oral|O
DDI-DrugBank.d584.s0|66-79|anticoagulants|group
DDI-DrugBank.d584.s0|80-80|.|O
DDI-DrugBank.d584.s1|0-5|Dosage|O
DDI-DrugBank.d584.s1|7-8|of|O
DDI-DrugBank.d584.s1|10-12|the|O
DDI-DrugBank.d584.s1|14-26|anticoagulant|group
DDI-DrugBank.d584.s1|28-30|may|O
DDI-DrugBank.d584.s1|32-35|have|O
DDI-DrugBank.d584.s1|37-38|to|O
DDI-DrugBank.d584.s1|40-41|be|O
DDI-DrugBank.d584.s1|43-51|decreased|O
DDI-DrugBank.d584.s1|53-54|in|O
DDI-DrugBank.d584.s1|56-60|order|O
DDI-DrugBank.d584.s1|62-63|to|O
DDI-DrugBank.d584.s1|65-72|maintain|O
DDI-DrugBank.d584.s1|74-80|desired|O
DDI-DrugBank.d584.s1|82-92|prothrombin|O
DDI-DrugBank.d584.s1|94-97|time|O
DDI-DrugBank.d584.s1|98-98|.|O
DDI-DrugBank.d584.s2|0-7|Patients|O
DDI-DrugBank.d584.s2|9-17|receiving|O
DDI-DrugBank.d584.s2|19-22|oral|O
DDI-DrugBank.d584.s2|24-36|anticoagulant|O
DDI-DrugBank.d584.s2|38-44|therapy|O
DDI-DrugBank.d584.s2|46-52|require|O
DDI-DrugBank.d584.s2|54-58|close|O
DDI-DrugBank.d584.s2|60-69|monitoring|O
DDI-DrugBank.d584.s2|70-70|,|O
DDI-DrugBank.d584.s2|72-81|especially|O
DDI-DrugBank.d584.s2|83-86|when|O
DDI-DrugBank.d584.s2|88-104|anabolic steroids|group
DDI-DrugBank.d584.s2|106-108|are|O
DDI-DrugBank.d584.s2|110-116|started|O
DDI-DrugBank.d584.s2|118-119|or|O
DDI-DrugBank.d584.s2|121-127|stopped|O
DDI-DrugBank.d584.s2|128-128|.|O
DDI-DrugBank.d584.s3|0-7|Warfarin|drug
DDI-DrugBank.d584.s3|8-8|:|O
DDI-DrugBank.d584.s3|10-10|A|O
DDI-DrugBank.d584.s3|12-20|multidose|O
DDI-DrugBank.d584.s3|22-26|study|O
DDI-DrugBank.d584.s3|28-29|of|O
DDI-DrugBank.d584.s3|31-41|oxandrolone|drug
DDI-DrugBank.d584.s3|42-42|,|O
DDI-DrugBank.d584.s3|44-48|given|O
DDI-DrugBank.d584.s3|50-51|as|O
DDI-DrugBank.d584.s3|53-53|5|O
DDI-DrugBank.d584.s3|55-56|or|O
DDI-DrugBank.d584.s3|58-59|10|O
DDI-DrugBank.d584.s3|61-62|mg|O
DDI-DrugBank.d584.s3|64-66|BID|O
DDI-DrugBank.d584.s3|68-69|in|O
DDI-DrugBank.d584.s3|71-72|15|O
DDI-DrugBank.d584.s3|74-80|healthy|O
DDI-DrugBank.d584.s3|82-89|subjects|O
DDI-DrugBank.d584.s3|91-102|concurrently|O
DDI-DrugBank.d584.s3|104-110|treated|O
DDI-DrugBank.d584.s3|112-115|with|O
DDI-DrugBank.d584.s3|117-124|warfarin|drug
DDI-DrugBank.d584.s3|125-125|,|O
DDI-DrugBank.d584.s3|127-134|resulted|O
DDI-DrugBank.d584.s3|136-137|in|O
DDI-DrugBank.d584.s3|139-139|a|O
DDI-DrugBank.d584.s3|141-144|mean|O
DDI-DrugBank.d584.s3|146-153|increase|O
DDI-DrugBank.d584.s3|155-156|in|O
DDI-DrugBank.d584.s3|158-167|S-warfarin|drug
DDI-DrugBank.d584.s3|169-177|half-life|O
DDI-DrugBank.d584.s3|179-182|from|O
DDI-DrugBank.d584.s3|184-185|26|O
DDI-DrugBank.d584.s3|187-188|to|O
DDI-DrugBank.d584.s3|190-191|48|O
DDI-DrugBank.d584.s3|193-197|hours|O
DDI-DrugBank.d584.s3|199-201|and|O
DDI-DrugBank.d584.s3|203-205|AUC|O
DDI-DrugBank.d584.s3|207-210|from|O
DDI-DrugBank.d584.s3|212-215|4.55|O
DDI-DrugBank.d584.s3|217-218|to|O
DDI-DrugBank.d584.s3|220-224|12.08|O
DDI-DrugBank.d584.s3|226-233|ng*hr/mL|O
DDI-DrugBank.d584.s3|234-234|:|O
DDI-DrugBank.d584.s3|236-242|similar|O
DDI-DrugBank.d584.s3|244-252|increases|O
DDI-DrugBank.d584.s3|254-255|in|O
DDI-DrugBank.d584.s3|257-266|R-warfarin|drug
DDI-DrugBank.d584.s3|268-276|half-life|O
DDI-DrugBank.d584.s3|278-280|and|O
DDI-DrugBank.d584.s3|282-284|AUC|O
DDI-DrugBank.d584.s3|286-289|were|O
DDI-DrugBank.d584.s3|291-294|also|O
DDI-DrugBank.d584.s3|296-303|detected|O
DDI-DrugBank.d584.s3|304-304|.|O
DDI-DrugBank.d584.s4|0-10|Microscopic|O
DDI-DrugBank.d584.s4|12-20|hematuria|O
DDI-DrugBank.d584.s4|22-22|(|O
DDI-DrugBank.d584.s4|23-26|9/15|O
DDI-DrugBank.d584.s4|27-27|)|O
DDI-DrugBank.d584.s4|29-31|and|O
DDI-DrugBank.d584.s4|33-40|gingival|O
DDI-DrugBank.d584.s4|42-49|bleeding|O
DDI-DrugBank.d584.s4|51-51|(|O
DDI-DrugBank.d584.s4|52-55|1/15|O
DDI-DrugBank.d584.s4|56-56|)|O
DDI-DrugBank.d584.s4|58-61|were|O
DDI-DrugBank.d584.s4|63-66|also|O
DDI-DrugBank.d584.s4|68-75|observed|O
DDI-DrugBank.d584.s4|76-76|.|O
DDI-DrugBank.d584.s5|0-0|A|O
DDI-DrugBank.d584.s5|2-9|5.5-fold|O
DDI-DrugBank.d584.s5|11-18|decrease|O
DDI-DrugBank.d584.s5|20-21|in|O
DDI-DrugBank.d584.s5|23-25|the|O
DDI-DrugBank.d584.s5|27-30|mean|O
DDI-DrugBank.d584.s5|32-39|warfarin|drug
DDI-DrugBank.d584.s5|41-44|dose|O
DDI-DrugBank.d584.s5|46-49|from|O
DDI-DrugBank.d584.s5|51-54|6.13|O
DDI-DrugBank.d584.s5|56-61|mg/day|O
DDI-DrugBank.d584.s5|63-64|to|O
DDI-DrugBank.d584.s5|66-69|1.13|O
DDI-DrugBank.d584.s5|71-76|mg/day|O
DDI-DrugBank.d584.s5|78-78|(|O
DDI-DrugBank.d584.s5|79-91|approximately|O
DDI-DrugBank.d584.s5|93-97|80-85|O
DDI-DrugBank.d584.s5|98-98|%|O
DDI-DrugBank.d584.s5|100-108|reduction|O
DDI-DrugBank.d584.s5|110-111|of|O
DDI-DrugBank.d584.s5|113-120|warfarin|drug
DDI-DrugBank.d584.s5|122-125|dose|O
DDI-DrugBank.d584.s5|126-126|)|O
DDI-DrugBank.d584.s5|127-127|,|O
DDI-DrugBank.d584.s5|129-131|was|O
DDI-DrugBank.d584.s5|133-141|necessary|O
DDI-DrugBank.d584.s5|143-144|to|O
DDI-DrugBank.d584.s5|146-153|maintain|O
DDI-DrugBank.d584.s5|155-155|a|O
DDI-DrugBank.d584.s5|157-162|target|O
DDI-DrugBank.d584.s5|164-166|INR|O
DDI-DrugBank.d584.s5|168-169|of|O
DDI-DrugBank.d584.s5|171-173|1.5|O
DDI-DrugBank.d584.s5|174-174|.|O
DDI-DrugBank.d584.s6|0-3|When|O
DDI-DrugBank.d584.s6|5-15|oxandrolone|drug
DDI-DrugBank.d584.s6|17-23|therapy|O
DDI-DrugBank.d584.s6|25-26|is|O
DDI-DrugBank.d584.s6|28-36|initiated|O
DDI-DrugBank.d584.s6|38-39|in|O
DDI-DrugBank.d584.s6|41-41|a|O
DDI-DrugBank.d584.s6|43-49|patient|O
DDI-DrugBank.d584.s6|51-57|already|O
DDI-DrugBank.d584.s6|59-67|receiving|O
DDI-DrugBank.d584.s6|69-77|treatment|O
DDI-DrugBank.d584.s6|79-82|with|O
DDI-DrugBank.d584.s6|84-91|warfarin|drug
DDI-DrugBank.d584.s6|92-92|,|O
DDI-DrugBank.d584.s6|94-96|the|O
DDI-DrugBank.d584.s6|98-100|INR|O
DDI-DrugBank.d584.s6|102-103|or|O
DDI-DrugBank.d584.s6|105-115|prothrombin|O
DDI-DrugBank.d584.s6|117-120|time|O
DDI-DrugBank.d584.s6|122-122|(|O
DDI-DrugBank.d584.s6|123-124|PT|O
DDI-DrugBank.d584.s6|125-125|)|O
DDI-DrugBank.d584.s6|127-132|should|O
DDI-DrugBank.d584.s6|134-135|be|O
DDI-DrugBank.d584.s6|137-145|monitored|O
DDI-DrugBank.d584.s6|147-153|closely|O
DDI-DrugBank.d584.s6|155-157|and|O
DDI-DrugBank.d584.s6|159-161|the|O
DDI-DrugBank.d584.s6|163-166|dose|O
DDI-DrugBank.d584.s6|168-169|of|O
DDI-DrugBank.d584.s6|171-178|warfarin|drug
DDI-DrugBank.d584.s6|180-187|adjusted|O
DDI-DrugBank.d584.s6|189-190|as|O
DDI-DrugBank.d584.s6|192-200|necessary|O
DDI-DrugBank.d584.s6|202-206|until|O
DDI-DrugBank.d584.s6|208-208|a|O
DDI-DrugBank.d584.s6|210-215|stable|O
DDI-DrugBank.d584.s6|217-222|target|O
DDI-DrugBank.d584.s6|224-226|INR|O
DDI-DrugBank.d584.s6|228-229|or|O
DDI-DrugBank.d584.s6|231-232|PT|O
DDI-DrugBank.d584.s6|234-236|has|O
DDI-DrugBank.d584.s6|238-241|been|O
DDI-DrugBank.d584.s6|243-250|achieved|O
DDI-DrugBank.d584.s6|251-251|.|O
DDI-DrugBank.d584.s7|0-10|Furthermore|O
DDI-DrugBank.d584.s7|11-11|,|O
DDI-DrugBank.d584.s7|13-14|in|O
DDI-DrugBank.d584.s7|16-23|patients|O
DDI-DrugBank.d584.s7|25-33|receiving|O
DDI-DrugBank.d584.s7|35-38|both|O
DDI-DrugBank.d584.s7|40-44|drugs|O
DDI-DrugBank.d584.s7|45-45|,|O
DDI-DrugBank.d584.s7|47-53|careful|O
DDI-DrugBank.d584.s7|55-64|monitoring|O
DDI-DrugBank.d584.s7|66-67|of|O
DDI-DrugBank.d584.s7|69-71|the|O
DDI-DrugBank.d584.s7|73-75|INR|O
DDI-DrugBank.d584.s7|77-78|or|O
DDI-DrugBank.d584.s7|80-81|PT|O
DDI-DrugBank.d584.s7|82-82|,|O
DDI-DrugBank.d584.s7|84-86|and|O
DDI-DrugBank.d584.s7|88-97|adjustment|O
DDI-DrugBank.d584.s7|99-100|of|O
DDI-DrugBank.d584.s7|102-104|the|O
DDI-DrugBank.d584.s7|106-113|warfarin|drug
DDI-DrugBank.d584.s7|115-120|dosage|O
DDI-DrugBank.d584.s7|122-123|if|O
DDI-DrugBank.d584.s7|125-133|indicated|O
DDI-DrugBank.d584.s7|135-137|are|O
DDI-DrugBank.d584.s7|139-149|recommended|O
DDI-DrugBank.d584.s7|151-154|when|O
DDI-DrugBank.d584.s7|156-158|the|O
DDI-DrugBank.d584.s7|160-170|oxandrolone|drug
DDI-DrugBank.d584.s7|172-175|dose|O
DDI-DrugBank.d584.s7|177-178|is|O
DDI-DrugBank.d584.s7|180-186|changed|O
DDI-DrugBank.d584.s7|188-189|or|O
DDI-DrugBank.d584.s7|191-202|discontinued|O
DDI-DrugBank.d584.s7|203-203|.|O
DDI-DrugBank.d584.s8|0-7|Patients|O
DDI-DrugBank.d584.s8|9-14|should|O
DDI-DrugBank.d584.s8|16-17|be|O
DDI-DrugBank.d584.s8|19-25|closely|O
DDI-DrugBank.d584.s8|27-35|monitored|O
DDI-DrugBank.d584.s8|37-39|for|O
DDI-DrugBank.d584.s8|41-45|signs|O
DDI-DrugBank.d584.s8|47-49|and|O
DDI-DrugBank.d584.s8|51-58|symptoms|O
DDI-DrugBank.d584.s8|60-61|of|O
DDI-DrugBank.d584.s8|63-68|occult|O
DDI-DrugBank.d584.s8|70-77|bleeding|O
DDI-DrugBank.d584.s8|78-78|.|O
DDI-DrugBank.d584.s9|0-3|Oral|O
DDI-DrugBank.d584.s9|5-23|hypoglycemic agents|group
DDI-DrugBank.d584.s9|5-23|hypoglycemic agents|group
DDI-DrugBank.d584.s9|37-39|may|O
DDI-DrugBank.d584.s9|41-47|inhibit|O
DDI-DrugBank.d584.s9|49-51|the|O
DDI-DrugBank.d584.s9|53-62|metabolism|O
DDI-DrugBank.d584.s9|64-65|of|O
DDI-DrugBank.d584.s9|67-70|oral|O
DDI-DrugBank.d584.s9|72-90|hypoglycemic agents|group
DDI-DrugBank.d584.s9|91-91|.|O
DDI-DrugBank.d584.s10|0-15|Adrenal steroids|group
DDI-DrugBank.d584.s10|17-18|or|O
DDI-DrugBank.d584.s10|20-23|ACTH|drug
DDI-DrugBank.d584.s10|25-26|In|O
DDI-DrugBank.d584.s10|28-35|patients|O
DDI-DrugBank.d584.s10|37-40|with|O
DDI-DrugBank.d584.s10|42-46|edema|O
DDI-DrugBank.d584.s10|47-47|,|O
DDI-DrugBank.d584.s10|49-59|concomitant|O
DDI-DrugBank.d584.s10|61-74|administration|O
DDI-DrugBank.d584.s10|76-79|with|O
DDI-DrugBank.d584.s10|81-105|adrenal cortical steroids|group
DDI-DrugBank.d584.s10|107-108|or|O
DDI-DrugBank.d584.s10|110-113|ACTH|drug
DDI-DrugBank.d584.s10|115-117|may|O
DDI-DrugBank.d584.s10|119-126|increase|O
DDI-DrugBank.d584.s10|128-130|the|O
DDI-DrugBank.d584.s10|132-136|edema|O
DDI-DrugBank.d584.s10|137-137|.|O
DDI-DrugBank.d584.s11|0-14|Drug/Laboratory|O
DDI-DrugBank.d584.s11|16-19|test|O
DDI-DrugBank.d584.s11|21-32|interactions|O
DDI-DrugBank.d584.s11|34-50|Anabolic steroids|drug
DDI-DrugBank.d584.s11|52-54|may|O
DDI-DrugBank.d584.s11|56-63|decrease|O
DDI-DrugBank.d584.s11|65-70|levels|O
DDI-DrugBank.d584.s11|72-73|of|O
DDI-DrugBank.d584.s11|75-91|thyroxine-binding|O
DDI-DrugBank.d584.s11|93-100|globulin|O
DDI-DrugBank.d584.s11|101-101|,|O
DDI-DrugBank.d584.s11|103-111|resulting|O
DDI-DrugBank.d584.s11|113-114|in|O
DDI-DrugBank.d584.s11|116-124|decreased|O
DDI-DrugBank.d584.s11|126-130|total|O
DDI-DrugBank.d584.s11|132-133|T4|O
DDI-DrugBank.d584.s11|135-139|serum|O
DDI-DrugBank.d584.s11|141-146|levels|O
DDI-DrugBank.d584.s11|148-150|and|O
DDI-DrugBank.d584.s11|152-160|increased|O
DDI-DrugBank.d584.s11|162-166|resin|O
DDI-DrugBank.d584.s11|168-173|uptake|O
DDI-DrugBank.d584.s11|175-176|of|O
DDI-DrugBank.d584.s11|178-179|T3|O
DDI-DrugBank.d584.s11|181-183|and|O
DDI-DrugBank.d584.s11|185-186|T4|O
DDI-DrugBank.d584.s11|187-187|.|O
DDI-DrugBank.d584.s12|0-3|Free|O
DDI-DrugBank.d584.s12|5-11|thyroid|O
DDI-DrugBank.d584.s12|13-19|hormone|O
DDI-DrugBank.d584.s12|21-26|levels|O
DDI-DrugBank.d584.s12|28-33|remain|O
DDI-DrugBank.d584.s12|35-43|unchanged|O
DDI-DrugBank.d584.s12|44-44|.|O
DDI-DrugBank.d584.s13|0-1|In|O
DDI-DrugBank.d584.s13|3-10|addition|O
DDI-DrugBank.d584.s13|11-11|,|O
DDI-DrugBank.d584.s13|13-13|a|O
DDI-DrugBank.d584.s13|15-22|decrease|O
DDI-DrugBank.d584.s13|24-25|in|O
DDI-DrugBank.d584.s13|27-29|PBI|O
DDI-DrugBank.d584.s13|31-33|and|O
DDI-DrugBank.d584.s13|35-45|radioactive|O
DDI-DrugBank.d584.s13|47-52|iodine|O
DDI-DrugBank.d584.s13|54-59|uptake|O
DDI-DrugBank.d584.s13|61-63|may|O
DDI-DrugBank.d584.s13|65-69|occur|O
DDI-DrugBank.d584.s13|70-70|.|O
DDI-DrugBank.d376.s0|0-2|May|O
DDI-DrugBank.d376.s0|4-11|interact|O
DDI-DrugBank.d376.s0|13-16|with|O
DDI-DrugBank.d376.s0|18-26|addictive|O
DDI-DrugBank.d376.s0|28-38|medications|O
DDI-DrugBank.d376.s0|39-39|,|O
DDI-DrugBank.d376.s0|41-50|especially|O
DDI-DrugBank.d376.s0|52-91|central nervous system ( CNS ) depressants|group
DDI-DrugBank.d376.s0|93-96|with|O
DDI-DrugBank.d376.s0|98-108|habituating|O
DDI-DrugBank.d376.s0|110-118|potential|O
DDI-DrugBank.d376.s0|120-120|(|O
DDI-DrugBank.d376.s0|121-129|prolonged|O
DDI-DrugBank.d376.s0|131-140|concurrent|O
DDI-DrugBank.d376.s0|142-144|use|O
DDI-DrugBank.d376.s0|146-148|may|O
DDI-DrugBank.d376.s0|150-157|increase|O
DDI-DrugBank.d376.s0|159-161|the|O
DDI-DrugBank.d376.s0|163-166|risk|O
DDI-DrugBank.d376.s0|168-169|of|O
DDI-DrugBank.d376.s0|171-181|habituation|O
DDI-DrugBank.d376.s0|182-182|)|O
DDI-DrugBank.d376.s0|183-183|,|O
DDI-DrugBank.d376.s0|185-191|alcohol|drug
DDI-DrugBank.d376.s0|193-194|or|O
DDI-DrugBank.d376.s0|196-198|CNS|O
DDI-DrugBank.d376.s0|200-209|depression|O
DDI-DrugBank.d376.s0|211-219|producing|O
DDI-DrugBank.d376.s0|221-231|medications|O
DDI-DrugBank.d376.s0|233-233|(|O
DDI-DrugBank.d376.s0|234-243|concurrent|O
DDI-DrugBank.d376.s0|245-247|use|O
DDI-DrugBank.d376.s0|249-251|may|O
DDI-DrugBank.d376.s0|253-260|increase|O
DDI-DrugBank.d376.s0|262-264|the|O
DDI-DrugBank.d376.s0|266-268|CNS|O
DDI-DrugBank.d376.s0|270-279|depressant|O
DDI-DrugBank.d376.s0|281-287|effects|O
DDI-DrugBank.d376.s0|289-290|of|O
DDI-DrugBank.d376.s0|292-297|either|O
DDI-DrugBank.d376.s0|299-303|these|O
DDI-DrugBank.d376.s0|305-315|medications|O
DDI-DrugBank.d376.s0|317-318|or|O
DDI-DrugBank.d376.s0|320-329|ethinamate|drug
DDI-DrugBank.d376.s0|330-330|)|O
DDI-DrugBank.d376.s0|331-331|.|O
DDI-DrugBank.d114.s0|0-8|PROLEUKIN|brand
DDI-DrugBank.d114.s0|10-12|may|O
DDI-DrugBank.d114.s0|14-19|affect|O
DDI-DrugBank.d114.s0|21-27|central|O
DDI-DrugBank.d114.s0|29-35|nervous|O
DDI-DrugBank.d114.s0|37-44|function|O
DDI-DrugBank.d114.s0|45-45|.|O
DDI-DrugBank.d114.s1|0-8|Therefore|O
DDI-DrugBank.d114.s1|9-9|,|O
DDI-DrugBank.d114.s1|11-22|interactions|O
DDI-DrugBank.d114.s1|24-28|could|O
DDI-DrugBank.d114.s1|30-34|occur|O
DDI-DrugBank.d114.s1|36-44|following|O
DDI-DrugBank.d114.s1|46-56|concomitant|O
DDI-DrugBank.d114.s1|58-71|administration|O
DDI-DrugBank.d114.s1|73-74|of|O
DDI-DrugBank.d114.s1|76-93|psychotropic drugs|group
DDI-DrugBank.d114.s1|95-95|(|O
DDI-DrugBank.d114.s1|96-99|e.g.|O
DDI-DrugBank.d114.s1|100-100|,|O
DDI-DrugBank.d114.s1|102-110|narcotics|group
DDI-DrugBank.d114.s1|111-111|,|O
DDI-DrugBank.d114.s1|113-122|analgesics|group
DDI-DrugBank.d114.s1|123-123|,|O
DDI-DrugBank.d114.s1|125-135|antiemetics|group
DDI-DrugBank.d114.s1|136-136|,|O
DDI-DrugBank.d114.s1|138-146|sedatives|group
DDI-DrugBank.d114.s1|147-147|,|O
DDI-DrugBank.d114.s1|149-161|tranquilizers|group
DDI-DrugBank.d114.s1|162-162|)|O
DDI-DrugBank.d114.s1|163-163|.|O
DDI-DrugBank.d114.s2|0-9|Concurrent|O
DDI-DrugBank.d114.s2|11-24|administration|O
DDI-DrugBank.d114.s2|26-27|of|O
DDI-DrugBank.d114.s2|29-33|drugs|O
DDI-DrugBank.d114.s2|35-44|possessing|O
DDI-DrugBank.d114.s2|46-56|nephrotoxic|O
DDI-DrugBank.d114.s2|58-58|(|O
DDI-DrugBank.d114.s2|59-62|e.g.|O
DDI-DrugBank.d114.s2|63-63|,|O
DDI-DrugBank.d114.s2|65-79|aminoglycosides|group
DDI-DrugBank.d114.s2|80-80|,|O
DDI-DrugBank.d114.s2|82-93|indomethacin|drug
DDI-DrugBank.d114.s2|94-94|)|O
DDI-DrugBank.d114.s2|95-95|,|O
DDI-DrugBank.d114.s2|97-106|myelotoxic|O
DDI-DrugBank.d114.s2|108-108|(|O
DDI-DrugBank.d114.s2|109-112|e.g.|O
DDI-DrugBank.d114.s2|113-113|,|O
DDI-DrugBank.d114.s2|115-123|cytotoxic|group
DDI-DrugBank.d114.s2|125-136|chemotherapy|O
DDI-DrugBank.d114.s2|137-137|)|O
DDI-DrugBank.d114.s2|138-138|,|O
DDI-DrugBank.d114.s2|140-150|cardiotoxic|O
DDI-DrugBank.d114.s2|152-152|(|O
DDI-DrugBank.d114.s2|153-156|e.g.|O
DDI-DrugBank.d114.s2|157-157|,|O
DDI-DrugBank.d114.s2|159-169|doxorubicin|drug
DDI-DrugBank.d114.s2|170-170|)|O
DDI-DrugBank.d114.s2|172-173|or|O
DDI-DrugBank.d114.s2|175-185|hepatotoxic|O
DDI-DrugBank.d114.s2|187-187|(|O
DDI-DrugBank.d114.s2|188-191|e.g.|O
DDI-DrugBank.d114.s2|192-192|,|O
DDI-DrugBank.d114.s2|194-205|methotrexate|drug
DDI-DrugBank.d114.s2|206-206|,|O
DDI-DrugBank.d114.s2|208-219|asparaginase|drug
DDI-DrugBank.d114.s2|220-220|)|O
DDI-DrugBank.d114.s2|222-228|effects|O
DDI-DrugBank.d114.s2|230-233|with|O
DDI-DrugBank.d114.s2|235-243|PROLEUKIN|brand
DDI-DrugBank.d114.s2|245-247|may|O
DDI-DrugBank.d114.s2|249-256|increase|O
DDI-DrugBank.d114.s2|258-265|toxicity|O
DDI-DrugBank.d114.s2|267-268|in|O
DDI-DrugBank.d114.s2|270-274|these|O
DDI-DrugBank.d114.s2|276-280|organ|O
DDI-DrugBank.d114.s2|282-288|systems|O
DDI-DrugBank.d114.s2|289-289|.|O
DDI-DrugBank.d114.s3|0-2|The|O
DDI-DrugBank.d114.s3|4-9|safety|O
DDI-DrugBank.d114.s3|11-13|and|O
DDI-DrugBank.d114.s3|15-22|efficacy|O
DDI-DrugBank.d114.s3|24-25|of|O
DDI-DrugBank.d114.s3|27-35|PROLEUKIN|brand
DDI-DrugBank.d114.s3|37-38|in|O
DDI-DrugBank.d114.s3|40-50|combination|O
DDI-DrugBank.d114.s3|52-55|with|O
DDI-DrugBank.d114.s3|57-59|any|O
DDI-DrugBank.d114.s3|61-81|antineoplastic agents|group
DDI-DrugBank.d114.s3|83-86|have|O
DDI-DrugBank.d114.s3|88-90|not|O
DDI-DrugBank.d114.s3|92-95|been|O
DDI-DrugBank.d114.s3|97-107|established|O
DDI-DrugBank.d114.s3|108-108|.|O
DDI-DrugBank.d114.s4|0-1|In|O
DDI-DrugBank.d114.s4|3-10|addition|O
DDI-DrugBank.d114.s4|11-11|,|O
DDI-DrugBank.d114.s4|13-19|reduced|O
DDI-DrugBank.d114.s4|21-26|kidney|O
DDI-DrugBank.d114.s4|28-30|and|O
DDI-DrugBank.d114.s4|32-36|liver|O
DDI-DrugBank.d114.s4|38-45|function|O
DDI-DrugBank.d114.s4|47-55|secondary|O
DDI-DrugBank.d114.s4|57-58|to|O
DDI-DrugBank.d114.s4|60-68|PROLEUKIN|brand
DDI-DrugBank.d114.s4|70-78|treatment|O
DDI-DrugBank.d114.s4|80-82|may|O
DDI-DrugBank.d114.s4|84-88|delay|O
DDI-DrugBank.d114.s4|90-100|elimination|O
DDI-DrugBank.d114.s4|102-103|of|O
DDI-DrugBank.d114.s4|105-115|concomitant|O
DDI-DrugBank.d114.s4|117-127|medications|O
DDI-DrugBank.d114.s4|129-131|and|O
DDI-DrugBank.d114.s4|133-140|increase|O
DDI-DrugBank.d114.s4|142-144|the|O
DDI-DrugBank.d114.s4|146-149|risk|O
DDI-DrugBank.d114.s4|151-152|of|O
DDI-DrugBank.d114.s4|154-160|adverse|O
DDI-DrugBank.d114.s4|162-167|events|O
DDI-DrugBank.d114.s4|169-172|from|O
DDI-DrugBank.d114.s4|174-178|those|O
DDI-DrugBank.d114.s4|180-184|drugs|O
DDI-DrugBank.d114.s4|185-185|.|O
DDI-DrugBank.d114.s5|0-15|Hypersensitivity|O
DDI-DrugBank.d114.s5|17-25|reactions|O
DDI-DrugBank.d114.s5|27-30|have|O
DDI-DrugBank.d114.s5|32-35|been|O
DDI-DrugBank.d114.s5|37-44|reported|O
DDI-DrugBank.d114.s5|46-47|in|O
DDI-DrugBank.d114.s5|49-56|patients|O
DDI-DrugBank.d114.s5|58-66|receiving|O
DDI-DrugBank.d114.s5|68-78|combination|O
DDI-DrugBank.d114.s5|80-87|regimens|O
DDI-DrugBank.d114.s5|89-98|containing|O
DDI-DrugBank.d114.s5|100-109|sequential|O
DDI-DrugBank.d114.s5|111-114|high|O
DDI-DrugBank.d114.s5|116-119|dose|O
DDI-DrugBank.d114.s5|121-129|PROLEUKIN|brand
DDI-DrugBank.d114.s5|131-133|and|O
DDI-DrugBank.d114.s5|135-155|antineoplastic agents|group
DDI-DrugBank.d114.s5|156-156|,|O
DDI-DrugBank.d114.s5|158-169|specifically|O
DDI-DrugBank.d114.s5|170-170|,|O
DDI-DrugBank.d114.s5|172-182|dacarbazine|drug
DDI-DrugBank.d114.s5|183-183|,|O
DDI-DrugBank.d114.s5|185-196|cis-platinum|drug
DDI-DrugBank.d114.s5|197-197|,|O
DDI-DrugBank.d114.s5|199-207|tamoxifen|drug
DDI-DrugBank.d114.s5|209-211|and|O
DDI-DrugBank.d114.s5|213-227|interferon-alfa|drug
DDI-DrugBank.d114.s5|228-228|.|O
DDI-DrugBank.d114.s6|0-4|These|O
DDI-DrugBank.d114.s6|6-14|reactions|O
DDI-DrugBank.d114.s6|16-24|consisted|O
DDI-DrugBank.d114.s6|26-27|of|O
DDI-DrugBank.d114.s6|29-36|erythema|O
DDI-DrugBank.d114.s6|37-37|,|O
DDI-DrugBank.d114.s6|39-46|pruritus|O
DDI-DrugBank.d114.s6|47-47|,|O
DDI-DrugBank.d114.s6|49-51|and|O
DDI-DrugBank.d114.s6|53-63|hypotension|O
DDI-DrugBank.d114.s6|65-67|and|O
DDI-DrugBank.d114.s6|69-76|occurred|O
DDI-DrugBank.d114.s6|78-83|within|O
DDI-DrugBank.d114.s6|85-89|hours|O
DDI-DrugBank.d114.s6|91-92|of|O
DDI-DrugBank.d114.s6|94-107|administration|O
DDI-DrugBank.d114.s6|109-110|of|O
DDI-DrugBank.d114.s6|112-123|chemotherapy|O
DDI-DrugBank.d114.s6|124-124|.|O
DDI-DrugBank.d114.s7|0-4|These|O
DDI-DrugBank.d114.s7|6-11|events|O
DDI-DrugBank.d114.s7|13-20|required|O
DDI-DrugBank.d114.s7|22-28|medical|O
DDI-DrugBank.d114.s7|30-41|intervention|O
DDI-DrugBank.d114.s7|43-44|in|O
DDI-DrugBank.d114.s7|46-49|some|O
DDI-DrugBank.d114.s7|51-58|patients|O
DDI-DrugBank.d114.s7|59-59|.|O
DDI-DrugBank.d114.s8|0-9|Myocardial|O
DDI-DrugBank.d114.s8|11-16|injury|O
DDI-DrugBank.d114.s8|17-17|,|O
DDI-DrugBank.d114.s8|19-27|including|O
DDI-DrugBank.d114.s8|29-38|myocardial|O
DDI-DrugBank.d114.s8|40-49|infarction|O
DDI-DrugBank.d114.s8|50-50|,|O
DDI-DrugBank.d114.s8|52-62|myocarditis|O
DDI-DrugBank.d114.s8|63-63|,|O
DDI-DrugBank.d114.s8|65-75|ventricular|O
DDI-DrugBank.d114.s8|77-87|hypokinesia|O
DDI-DrugBank.d114.s8|88-88|,|O
DDI-DrugBank.d114.s8|90-92|and|O
DDI-DrugBank.d114.s8|94-99|severe|O
DDI-DrugBank.d114.s8|101-114|rhabdomyolysis|O
DDI-DrugBank.d114.s8|116-121|appear|O
DDI-DrugBank.d114.s8|123-124|to|O
DDI-DrugBank.d114.s8|126-127|be|O
DDI-DrugBank.d114.s8|129-137|increased|O
DDI-DrugBank.d114.s8|139-140|in|O
DDI-DrugBank.d114.s8|142-149|patients|O
DDI-DrugBank.d114.s8|151-159|receiving|O
DDI-DrugBank.d114.s8|161-169|PROLEUKIN|brand
DDI-DrugBank.d114.s8|171-173|and|O
DDI-DrugBank.d114.s8|175-189|interferon-alfa|drug
DDI-DrugBank.d114.s8|191-202|concurrently|O
DDI-DrugBank.d114.s8|203-203|.|O
DDI-DrugBank.d114.s9|0-11|Exacerbation|O
DDI-DrugBank.d114.s9|13-14|or|O
DDI-DrugBank.d114.s9|16-18|the|O
DDI-DrugBank.d114.s9|20-26|initial|O
DDI-DrugBank.d114.s9|28-39|presentation|O
DDI-DrugBank.d114.s9|41-42|of|O
DDI-DrugBank.d114.s9|44-44|a|O
DDI-DrugBank.d114.s9|46-51|number|O
DDI-DrugBank.d114.s9|53-54|of|O
DDI-DrugBank.d114.s9|56-65|autoimmune|O
DDI-DrugBank.d114.s9|67-69|and|O
DDI-DrugBank.d114.s9|71-82|inflammatory|O
DDI-DrugBank.d114.s9|84-92|disorders|O
DDI-DrugBank.d114.s9|94-96|has|O
DDI-DrugBank.d114.s9|98-101|been|O
DDI-DrugBank.d114.s9|103-110|observed|O
DDI-DrugBank.d114.s9|112-120|following|O
DDI-DrugBank.d114.s9|122-131|concurrent|O
DDI-DrugBank.d114.s9|133-135|use|O
DDI-DrugBank.d114.s9|137-138|of|O
DDI-DrugBank.d114.s9|140-154|interferon-alfa|drug
DDI-DrugBank.d114.s9|156-158|and|O
DDI-DrugBank.d114.s9|160-168|PROLEUKIN|brand
DDI-DrugBank.d114.s9|169-169|,|O
DDI-DrugBank.d114.s9|171-179|including|O
DDI-DrugBank.d114.s9|181-190|crescentic|O
DDI-DrugBank.d114.s9|192-194|IgA|O
DDI-DrugBank.d114.s9|196-213|glomerulonephritis|O
DDI-DrugBank.d114.s9|214-214|,|O
DDI-DrugBank.d114.s9|216-227|oculo-bulbar|O
DDI-DrugBank.d114.s9|229-238|myasthenia|O
DDI-DrugBank.d114.s9|240-245|gravis|O
DDI-DrugBank.d114.s9|246-246|,|O
DDI-DrugBank.d114.s9|248-259|inflammatory|O
DDI-DrugBank.d114.s9|261-269|arthritis|O
DDI-DrugBank.d114.s9|270-270|,|O
DDI-DrugBank.d114.s9|272-282|thyroiditis|O
DDI-DrugBank.d114.s9|283-283|,|O
DDI-DrugBank.d114.s9|285-291|bullous|O
DDI-DrugBank.d114.s9|293-302|pemphigoid|O
DDI-DrugBank.d114.s9|303-303|,|O
DDI-DrugBank.d114.s9|305-307|and|O
DDI-DrugBank.d114.s9|309-323|Stevens-Johnson|O
DDI-DrugBank.d114.s9|325-332|syndrome|O
DDI-DrugBank.d114.s9|333-333|.|O
DDI-DrugBank.d114.s10|0-7|Although|O
DDI-DrugBank.d114.s10|9-23|glucocorticoids|group
DDI-DrugBank.d114.s10|25-28|have|O
DDI-DrugBank.d114.s10|30-33|been|O
DDI-DrugBank.d114.s10|35-39|shown|O
DDI-DrugBank.d114.s10|41-42|to|O
DDI-DrugBank.d114.s10|44-49|reduce|O
DDI-DrugBank.d114.s10|51-67|PROLEUKIN-induced|brand
DDI-DrugBank.d114.s10|69-72|side|O
DDI-DrugBank.d114.s10|74-80|effects|O
DDI-DrugBank.d114.s10|82-90|including|O
DDI-DrugBank.d114.s10|92-96|fever|O
DDI-DrugBank.d114.s10|97-97|,|O
DDI-DrugBank.d114.s10|99-103|renal|O
DDI-DrugBank.d114.s10|105-117|insufficiency|O
DDI-DrugBank.d114.s10|118-118|,|O
DDI-DrugBank.d114.s10|120-137|hyperbilirubinemia|O
DDI-DrugBank.d114.s10|138-138|,|O
DDI-DrugBank.d114.s10|140-148|confusion|O
DDI-DrugBank.d114.s10|149-149|,|O
DDI-DrugBank.d114.s10|151-153|and|O
DDI-DrugBank.d114.s10|155-161|dyspnea|O
DDI-DrugBank.d114.s10|162-162|,|O
DDI-DrugBank.d114.s10|164-174|concomitant|O
DDI-DrugBank.d114.s10|176-189|administration|O
DDI-DrugBank.d114.s10|191-192|of|O
DDI-DrugBank.d114.s10|194-198|these|O
DDI-DrugBank.d114.s10|200-205|agents|O
DDI-DrugBank.d114.s10|207-210|with|O
DDI-DrugBank.d114.s10|212-220|PROLEUKIN|brand
DDI-DrugBank.d114.s10|222-224|may|O
DDI-DrugBank.d114.s10|226-231|reduce|O
DDI-DrugBank.d114.s10|233-235|the|O
DDI-DrugBank.d114.s10|237-245|antitumor|O
DDI-DrugBank.d114.s10|247-259|effectiveness|O
DDI-DrugBank.d114.s10|261-262|of|O
DDI-DrugBank.d114.s10|264-272|PROLEUKIN|brand
DDI-DrugBank.d114.s10|274-276|and|O
DDI-DrugBank.d114.s10|278-281|thus|O
DDI-DrugBank.d114.s10|283-288|should|O
DDI-DrugBank.d114.s10|290-291|be|O
DDI-DrugBank.d114.s10|293-300|avoided.|O
DDI-DrugBank.d114.s10|302-303|12|O
DDI-DrugBank.d114.s10|305-317|Beta-blockers|group
DDI-DrugBank.d114.s10|319-321|and|O
DDI-DrugBank.d114.s10|323-327|other|O
DDI-DrugBank.d114.s10|329-345|antihypertensives|group
DDI-DrugBank.d114.s10|347-349|may|O
DDI-DrugBank.d114.s10|351-360|potentiate|O
DDI-DrugBank.d114.s10|362-364|the|O
DDI-DrugBank.d114.s10|366-376|hypotension|O
DDI-DrugBank.d114.s10|378-381|seen|O
DDI-DrugBank.d114.s10|383-386|with|O
DDI-DrugBank.d114.s10|388-396|PROLEUKIN|brand
DDI-DrugBank.d114.s10|397-397|.|O
DDI-DrugBank.d114.s11|0-6|Delayed|O
DDI-DrugBank.d114.s11|8-14|Adverse|O
DDI-DrugBank.d114.s11|16-24|Reactions|O
DDI-DrugBank.d114.s11|26-27|to|O
DDI-DrugBank.d114.s11|29-52|Iodinated Contrast Media|group
DDI-DrugBank.d114.s11|53-53|:|O
DDI-DrugBank.d114.s11|55-55|A|O
DDI-DrugBank.d114.s11|57-62|review|O
DDI-DrugBank.d114.s11|64-65|of|O
DDI-DrugBank.d114.s11|67-69|the|O
DDI-DrugBank.d114.s11|71-80|literature|O
DDI-DrugBank.d114.s11|82-89|revealed|O
DDI-DrugBank.d114.s11|91-94|that|O
DDI-DrugBank.d114.s11|96-99|12.6|O
DDI-DrugBank.d114.s11|100-100|%|O
DDI-DrugBank.d114.s11|102-102|(|O
DDI-DrugBank.d114.s11|103-107|range|O
DDI-DrugBank.d114.s11|109-113|11-28|O
DDI-DrugBank.d114.s11|114-114|%|O
DDI-DrugBank.d114.s11|115-115|)|O
DDI-DrugBank.d114.s11|117-118|of|O
DDI-DrugBank.d114.s11|120-122|501|O
DDI-DrugBank.d114.s11|124-131|patients|O
DDI-DrugBank.d114.s11|133-139|treated|O
DDI-DrugBank.d114.s11|141-144|with|O
DDI-DrugBank.d114.s11|146-152|various|O
DDI-DrugBank.d114.s11|154-166|interleukin-2|drug
DDI-DrugBank.d114.s11|168-177|containing|O
DDI-DrugBank.d114.s11|179-186|regimens|O
DDI-DrugBank.d114.s11|188-190|who|O
DDI-DrugBank.d114.s11|192-195|were|O
DDI-DrugBank.d114.s11|197-208|subsequently|O
DDI-DrugBank.d114.s11|210-221|administered|O
DDI-DrugBank.d114.s11|223-259|radiographic iodinated contrast media|group
DDI-DrugBank.d114.s11|261-271|experienced|O
DDI-DrugBank.d114.s11|273-277|acute|O
DDI-DrugBank.d114.s11|278-278|,|O
DDI-DrugBank.d114.s11|280-287|atypical|O
DDI-DrugBank.d114.s11|289-295|adverse|O
DDI-DrugBank.d114.s11|297-305|reactions|O
DDI-DrugBank.d114.s11|306-306|.|O
DDI-DrugBank.d114.s12|0-2|The|O
DDI-DrugBank.d114.s12|4-8|onset|O
DDI-DrugBank.d114.s12|10-11|of|O
DDI-DrugBank.d114.s12|13-20|symptoms|O
DDI-DrugBank.d114.s12|22-28|usually|O
DDI-DrugBank.d114.s12|30-37|occurred|O
DDI-DrugBank.d114.s12|39-44|within|O
DDI-DrugBank.d114.s12|46-50|hours|O
DDI-DrugBank.d114.s12|52-52|(|O
DDI-DrugBank.d114.s12|53-56|most|O
DDI-DrugBank.d114.s12|58-65|commonly|O
DDI-DrugBank.d114.s12|67-67|1|O
DDI-DrugBank.d114.s12|69-70|to|O
DDI-DrugBank.d114.s12|72-72|4|O
DDI-DrugBank.d114.s12|74-78|hours|O
DDI-DrugBank.d114.s12|79-79|)|O
DDI-DrugBank.d114.s12|81-89|following|O
DDI-DrugBank.d114.s12|91-93|the|O
DDI-DrugBank.d114.s12|95-108|administration|O
DDI-DrugBank.d114.s12|110-111|of|O
DDI-DrugBank.d114.s12|113-120|contrast|O
DDI-DrugBank.d114.s12|122-126|media|O
DDI-DrugBank.d114.s12|127-127|.|O
DDI-DrugBank.d114.s13|0-4|These|O
DDI-DrugBank.d114.s13|6-14|reactions|O
DDI-DrugBank.d114.s13|16-22|include|O
DDI-DrugBank.d114.s13|24-28|fever|O
DDI-DrugBank.d114.s13|29-29|,|O
DDI-DrugBank.d114.s13|31-36|chills|O
DDI-DrugBank.d114.s13|37-37|,|O
DDI-DrugBank.d114.s13|39-44|nausea|O
DDI-DrugBank.d114.s13|45-45|,|O
DDI-DrugBank.d114.s13|47-54|vomiting|O
DDI-DrugBank.d114.s13|55-55|,|O
DDI-DrugBank.d114.s13|57-64|pruritus|O
DDI-DrugBank.d114.s13|65-65|,|O
DDI-DrugBank.d114.s13|67-70|rash|O
DDI-DrugBank.d114.s13|71-71|,|O
DDI-DrugBank.d114.s13|73-80|diarrhea|O
DDI-DrugBank.d114.s13|81-81|,|O
DDI-DrugBank.d114.s13|83-93|hypotension|O
DDI-DrugBank.d114.s13|94-94|,|O
DDI-DrugBank.d114.s13|96-100|edema|O
DDI-DrugBank.d114.s13|101-101|,|O
DDI-DrugBank.d114.s13|103-105|and|O
DDI-DrugBank.d114.s13|107-114|oliguria|O
DDI-DrugBank.d114.s13|115-115|.|O
DDI-DrugBank.d114.s14|0-3|Some|O
DDI-DrugBank.d114.s14|5-14|clinicians|O
DDI-DrugBank.d114.s14|16-19|have|O
DDI-DrugBank.d114.s14|21-25|noted|O
DDI-DrugBank.d114.s14|27-30|that|O
DDI-DrugBank.d114.s14|32-36|these|O
DDI-DrugBank.d114.s14|38-46|reactions|O
DDI-DrugBank.d114.s14|48-55|resemble|O
DDI-DrugBank.d114.s14|57-59|the|O
DDI-DrugBank.d114.s14|61-69|immediate|O
DDI-DrugBank.d114.s14|71-74|side|O
DDI-DrugBank.d114.s14|76-82|effects|O
DDI-DrugBank.d114.s14|84-89|caused|O
DDI-DrugBank.d114.s14|91-92|by|O
DDI-DrugBank.d114.s14|94-106|interleukin-2|drug
DDI-DrugBank.d114.s14|108-121|administration|O
DDI-DrugBank.d114.s14|122-122|,|O
DDI-DrugBank.d114.s14|124-130|however|O
DDI-DrugBank.d114.s14|132-134|the|O
DDI-DrugBank.d114.s14|136-140|cause|O
DDI-DrugBank.d114.s14|142-143|of|O
DDI-DrugBank.d114.s14|145-152|contrast|O
DDI-DrugBank.d114.s14|154-162|reactions|O
DDI-DrugBank.d114.s14|164-168|after|O
DDI-DrugBank.d114.s14|170-182|interleukin-2|O
DDI-DrugBank.d114.s14|184-190|therapy|O
DDI-DrugBank.d114.s14|192-193|is|O
DDI-DrugBank.d114.s14|195-201|unknown|O
DDI-DrugBank.d114.s14|202-202|.|O
DDI-DrugBank.d114.s15|0-3|Most|O
DDI-DrugBank.d114.s15|5-10|events|O
DDI-DrugBank.d114.s15|12-15|were|O
DDI-DrugBank.d114.s15|17-24|reported|O
DDI-DrugBank.d114.s15|26-27|to|O
DDI-DrugBank.d114.s15|29-33|occur|O
DDI-DrugBank.d114.s15|35-38|when|O
DDI-DrugBank.d114.s15|40-47|contrast|O
DDI-DrugBank.d114.s15|49-53|media|O
DDI-DrugBank.d114.s15|55-57|was|O
DDI-DrugBank.d114.s15|59-63|given|O
DDI-DrugBank.d114.s15|65-70|within|O
DDI-DrugBank.d114.s15|72-72|4|O
DDI-DrugBank.d114.s15|74-78|weeks|O
DDI-DrugBank.d114.s15|80-84|after|O
DDI-DrugBank.d114.s15|86-88|the|O
DDI-DrugBank.d114.s15|90-93|last|O
DDI-DrugBank.d114.s15|95-98|dose|O
DDI-DrugBank.d114.s15|100-101|of|O
DDI-DrugBank.d114.s15|103-115|interleukin-2|drug
DDI-DrugBank.d114.s15|116-116|.|O
DDI-DrugBank.d114.s16|0-4|These|O
DDI-DrugBank.d114.s16|6-11|events|O
DDI-DrugBank.d114.s16|13-16|were|O
DDI-DrugBank.d114.s16|18-21|also|O
DDI-DrugBank.d114.s16|23-30|reported|O
DDI-DrugBank.d114.s16|32-33|to|O
DDI-DrugBank.d114.s16|35-39|occur|O
DDI-DrugBank.d114.s16|41-44|when|O
DDI-DrugBank.d114.s16|46-53|contrast|O
DDI-DrugBank.d114.s16|55-59|media|O
DDI-DrugBank.d114.s16|61-63|was|O
DDI-DrugBank.d114.s16|65-69|given|O
DDI-DrugBank.d114.s16|71-77|several|O
DDI-DrugBank.d114.s16|79-84|months|O
DDI-DrugBank.d114.s16|86-90|after|O
DDI-DrugBank.d114.s16|92-104|interleukin-2|drug
DDI-DrugBank.d114.s16|106-114|treatment|O
DDI-DrugBank.d114.s16|115-115|.|O
DDI-DrugBank.d784.s0|0-2|The|O
DDI-DrugBank.d784.s0|4-14|concomitant|O
DDI-DrugBank.d784.s0|16-18|use|O
DDI-DrugBank.d784.s0|20-21|of|O
DDI-DrugBank.d784.s0|23-32|oxybutynin|drug
DDI-DrugBank.d784.s0|34-37|with|O
DDI-DrugBank.d784.s0|39-43|other|O
DDI-DrugBank.d784.s0|45-65|anticholinergic drugs|group
DDI-DrugBank.d784.s0|67-68|or|O
DDI-DrugBank.d784.s0|70-73|with|O
DDI-DrugBank.d784.s0|75-79|other|O
DDI-DrugBank.d784.s0|81-86|agents|O
DDI-DrugBank.d784.s0|88-92|which|O
DDI-DrugBank.d784.s0|94-100|produce|O
DDI-DrugBank.d784.s0|102-104|dry|O
DDI-DrugBank.d784.s0|106-110|mouth|O
DDI-DrugBank.d784.s0|111-111|,|O
DDI-DrugBank.d784.s0|113-124|constipation|O
DDI-DrugBank.d784.s0|125-125|,|O
DDI-DrugBank.d784.s0|127-136|somnolence|O
DDI-DrugBank.d784.s0|138-138|(|O
DDI-DrugBank.d784.s0|139-148|drowsiness|O
DDI-DrugBank.d784.s0|149-149|)|O
DDI-DrugBank.d784.s0|150-150|,|O
DDI-DrugBank.d784.s0|152-157|and/or|O
DDI-DrugBank.d784.s0|159-163|other|O
DDI-DrugBank.d784.s0|165-184|anticholinergic-like|O
DDI-DrugBank.d784.s0|186-192|effects|O
DDI-DrugBank.d784.s0|194-196|may|O
DDI-DrugBank.d784.s0|198-205|increase|O
DDI-DrugBank.d784.s0|207-209|the|O
DDI-DrugBank.d784.s0|211-219|frequency|O
DDI-DrugBank.d784.s0|221-226|and/or|O
DDI-DrugBank.d784.s0|228-235|severity|O
DDI-DrugBank.d784.s0|237-238|of|O
DDI-DrugBank.d784.s0|240-243|such|O
DDI-DrugBank.d784.s0|245-251|effects|O
DDI-DrugBank.d784.s0|252-252|.|O
DDI-DrugBank.d784.s1|0-21|Anticholinergic agents|group
DDI-DrugBank.d784.s1|23-25|may|O
DDI-DrugBank.d784.s1|27-37|potentially|O
DDI-DrugBank.d784.s1|39-43|alter|O
DDI-DrugBank.d784.s1|45-47|the|O
DDI-DrugBank.d784.s1|49-58|absorption|O
DDI-DrugBank.d784.s1|60-61|of|O
DDI-DrugBank.d784.s1|63-66|some|O
DDI-DrugBank.d784.s1|68-80|concomitantly|O
DDI-DrugBank.d784.s1|82-93|administered|O
DDI-DrugBank.d784.s1|95-99|drugs|O
DDI-DrugBank.d784.s1|101-103|due|O
DDI-DrugBank.d784.s1|105-106|to|O
DDI-DrugBank.d784.s1|108-122|anticholinergic|O
DDI-DrugBank.d784.s1|124-130|effects|O
DDI-DrugBank.d784.s1|132-133|on|O
DDI-DrugBank.d784.s1|135-150|gastrointestinal|O
DDI-DrugBank.d784.s1|152-159|motility|O
DDI-DrugBank.d784.s1|160-160|.|O
DDI-DrugBank.d784.s2|0-3|This|O
DDI-DrugBank.d784.s2|5-7|may|O
DDI-DrugBank.d784.s2|9-10|be|O
DDI-DrugBank.d784.s2|12-13|of|O
DDI-DrugBank.d784.s2|15-21|concern|O
DDI-DrugBank.d784.s2|23-25|for|O
DDI-DrugBank.d784.s2|27-31|drugs|O
DDI-DrugBank.d784.s2|33-36|with|O
DDI-DrugBank.d784.s2|38-38|a|O
DDI-DrugBank.d784.s2|40-45|narrow|O
DDI-DrugBank.d784.s2|47-57|therapeutic|O
DDI-DrugBank.d784.s2|59-63|index|O
DDI-DrugBank.d784.s2|64-64|.|O
DDI-DrugBank.d784.s3|0-3|Mean|O
DDI-DrugBank.d784.s3|5-23|oxybutynin chloride|drug
DDI-DrugBank.d784.s3|25-30|plasma|O
DDI-DrugBank.d784.s3|32-45|concentrations|O
DDI-DrugBank.d784.s3|47-50|were|O
DDI-DrugBank.d784.s3|52-64|approximately|O
DDI-DrugBank.d784.s3|66-66|2|O
DDI-DrugBank.d784.s3|68-71|fold|O
DDI-DrugBank.d784.s3|73-78|higher|O
DDI-DrugBank.d784.s3|80-83|when|O
DDI-DrugBank.d784.s3|85-95|DITROPAN XL|brand
DDI-DrugBank.d784.s3|97-99|was|O
DDI-DrugBank.d784.s3|101-112|administered|O
DDI-DrugBank.d784.s3|114-117|with|O
DDI-DrugBank.d784.s3|119-130|ketoconazole|drug
DDI-DrugBank.d784.s3|131-131|,|O
DDI-DrugBank.d784.s3|133-133|a|O
DDI-DrugBank.d784.s3|135-140|potent|O
DDI-DrugBank.d784.s3|142-147|CYP3A4|O
DDI-DrugBank.d784.s3|149-157|inhibitor|O
DDI-DrugBank.d784.s3|158-158|.|O
DDI-DrugBank.d784.s4|0-4|Other|O
DDI-DrugBank.d784.s4|6-15|inhibitors|O
DDI-DrugBank.d784.s4|17-18|of|O
DDI-DrugBank.d784.s4|20-22|the|O
DDI-DrugBank.d784.s4|24-33|cytochrome|O
DDI-DrugBank.d784.s4|35-38|P450|O
DDI-DrugBank.d784.s4|40-42|3A4|O
DDI-DrugBank.d784.s4|44-49|enzyme|O
DDI-DrugBank.d784.s4|51-56|system|O
DDI-DrugBank.d784.s4|57-57|,|O
DDI-DrugBank.d784.s4|59-62|such|O
DDI-DrugBank.d784.s4|64-65|as|O
DDI-DrugBank.d784.s4|67-84|antimycotic agents|group
DDI-DrugBank.d784.s4|86-86|(|O
DDI-DrugBank.d784.s4|87-90|e.g.|O
DDI-DrugBank.d784.s4|91-91|,|O
DDI-DrugBank.d784.s4|93-104|itraconazole|drug
DDI-DrugBank.d784.s4|106-108|and|O
DDI-DrugBank.d784.s4|110-119|miconazole|drug
DDI-DrugBank.d784.s4|120-120|)|O
DDI-DrugBank.d784.s4|122-123|or|O
DDI-DrugBank.d784.s4|125-145|macrolide antibiotics|group
DDI-DrugBank.d784.s4|147-147|(|O
DDI-DrugBank.d784.s4|148-151|e.g.|O
DDI-DrugBank.d784.s4|152-152|,|O
DDI-DrugBank.d784.s4|154-165|erythromycin|drug
DDI-DrugBank.d784.s4|167-169|and|O
DDI-DrugBank.d784.s4|171-184|clarithromycin|drug
DDI-DrugBank.d784.s4|185-185|)|O
DDI-DrugBank.d784.s4|186-186|,|O
DDI-DrugBank.d784.s4|188-190|may|O
DDI-DrugBank.d784.s4|192-196|alter|O
DDI-DrugBank.d784.s4|198-207|oxybutynin|drug
DDI-DrugBank.d784.s4|209-212|mean|O
DDI-DrugBank.d784.s4|214-228|pharmacokinetic|O
DDI-DrugBank.d784.s4|230-239|parameters|O
DDI-DrugBank.d784.s4|241-241|(|O
DDI-DrugBank.d784.s4|242-245|i.e.|O
DDI-DrugBank.d784.s4|246-246|,|O
DDI-DrugBank.d784.s4|248-251|Cmax|O
DDI-DrugBank.d784.s4|253-255|and|O
DDI-DrugBank.d784.s4|257-259|AUC|O
DDI-DrugBank.d784.s4|260-260|)|O
DDI-DrugBank.d784.s4|261-261|.|O
DDI-DrugBank.d784.s5|0-2|The|O
DDI-DrugBank.d784.s5|4-11|clinical|O
DDI-DrugBank.d784.s5|13-21|relevance|O
DDI-DrugBank.d784.s5|23-24|of|O
DDI-DrugBank.d784.s5|26-29|such|O
DDI-DrugBank.d784.s5|31-39|potential|O
DDI-DrugBank.d784.s5|41-52|interactions|O
DDI-DrugBank.d784.s5|54-55|is|O
DDI-DrugBank.d784.s5|57-59|not|O
DDI-DrugBank.d784.s5|61-65|known|O
DDI-DrugBank.d784.s5|66-66|.|O
DDI-DrugBank.d784.s6|0-6|Caution|O
DDI-DrugBank.d784.s6|8-13|should|O
DDI-DrugBank.d784.s6|15-16|be|O
DDI-DrugBank.d784.s6|18-21|used|O
DDI-DrugBank.d784.s6|23-26|when|O
DDI-DrugBank.d784.s6|28-31|such|O
DDI-DrugBank.d784.s6|33-37|drugs|O
DDI-DrugBank.d784.s6|39-41|are|O
DDI-DrugBank.d784.s6|43-57|co-administered|O
DDI-DrugBank.d784.s6|58-58|.|O
DDI-DrugBank.d784.s7|0-9|Concurrent|O
DDI-DrugBank.d784.s7|11-19|ingestion|O
DDI-DrugBank.d784.s7|21-22|of|O
DDI-DrugBank.d784.s7|24-30|antacid|group
DDI-DrugBank.d784.s7|32-32|(|O
DDI-DrugBank.d784.s7|33-34|20|O
DDI-DrugBank.d784.s7|36-37|mL|O
DDI-DrugBank.d784.s7|39-40|of|O
DDI-DrugBank.d784.s7|42-48|antacid|group
DDI-DrugBank.d784.s7|50-59|containing|O
DDI-DrugBank.d784.s7|61-78|aluminum hydroxide|drug
DDI-DrugBank.d784.s7|79-79|,|O
DDI-DrugBank.d784.s7|81-99|magnesium hydroxide|drug
DDI-DrugBank.d784.s7|100-100|,|O
DDI-DrugBank.d784.s7|102-104|and|O
DDI-DrugBank.d784.s7|106-116|simethicone|drug
DDI-DrugBank.d784.s7|117-117|)|O
DDI-DrugBank.d784.s7|119-121|did|O
DDI-DrugBank.d784.s7|123-125|not|O
DDI-DrugBank.d784.s7|127-139|significantly|O
DDI-DrugBank.d784.s7|141-146|affect|O
DDI-DrugBank.d784.s7|148-150|the|O
DDI-DrugBank.d784.s7|152-159|exposure|O
DDI-DrugBank.d784.s7|161-162|of|O
DDI-DrugBank.d784.s7|164-173|oxybutynin|drug
DDI-DrugBank.d784.s7|175-176|or|O
DDI-DrugBank.d784.s7|196-196|.|O
DDI-MedLine.d35.s0|0-0|[|O
DDI-MedLine.d35.s0|1-10|Importance|O
DDI-MedLine.d35.s0|12-13|of|O
DDI-MedLine.d35.s0|15-30|pharmacogenetics|O
DDI-MedLine.d35.s0|31-31|]|O
DDI-MedLine.d35.s0|34-49|Pharmacogenetics|O
DDI-MedLine.d35.s0|51-55|deals|O
DDI-MedLine.d35.s0|57-60|with|O
DDI-MedLine.d35.s0|62-64|the|O
DDI-MedLine.d35.s0|66-76|differences|O
DDI-MedLine.d35.s0|78-79|in|O
DDI-MedLine.d35.s0|81-86|effect|O
DDI-MedLine.d35.s0|88-89|of|O
DDI-MedLine.d35.s0|91-95|drugs|O
DDI-MedLine.d35.s0|97-102|caused|O
DDI-MedLine.d35.s0|104-105|by|O
DDI-MedLine.d35.s0|107-113|genetic|O
DDI-MedLine.d35.s0|115-123|variation|O
DDI-MedLine.d35.s0|124-124|.|O
DDI-MedLine.d35.s1|0-10|Differences|O
DDI-MedLine.d35.s1|12-14|can|O
DDI-MedLine.d35.s1|16-20|occur|O
DDI-MedLine.d35.s1|22-23|in|O
DDI-MedLine.d35.s1|25-35|therapeutic|O
DDI-MedLine.d35.s1|37-42|effect|O
DDI-MedLine.d35.s1|44-46|and|O
DDI-MedLine.d35.s1|48-49|in|O
DDI-MedLine.d35.s1|51-57|adverse|O
DDI-MedLine.d35.s1|59-64|events|O
DDI-MedLine.d35.s1|65-65|.|O
DDI-MedLine.d35.s2|0-6|Genetic|O
DDI-MedLine.d35.s2|8-16|variation|O
DDI-MedLine.d35.s2|18-19|in|O
DDI-MedLine.d35.s2|21-30|metabolism|O
DDI-MedLine.d35.s2|32-34|may|O
DDI-MedLine.d35.s2|36-41|result|O
DDI-MedLine.d35.s2|43-44|in|O
DDI-MedLine.d35.s2|46-49|high|O
DDI-MedLine.d35.s2|51-64|concentrations|O
DDI-MedLine.d35.s2|66-67|of|O
DDI-MedLine.d35.s2|69-73|drugs|O
DDI-MedLine.d35.s2|75-77|and|O
DDI-MedLine.d35.s2|79-80|an|O
DDI-MedLine.d35.s2|82-90|increased|O
DDI-MedLine.d35.s2|92-95|risk|O
DDI-MedLine.d35.s2|97-98|of|O
DDI-MedLine.d35.s2|100-106|adverse|O
DDI-MedLine.d35.s2|108-114|effects|O
DDI-MedLine.d35.s2|116-117|in|O
DDI-MedLine.d35.s2|119-122|slow|O
DDI-MedLine.d35.s2|124-135|metabolizers|O
DDI-MedLine.d35.s2|136-136|,|O
DDI-MedLine.d35.s2|138-142|which|O
DDI-MedLine.d35.s2|144-145|is|O
DDI-MedLine.d35.s2|147-155|important|O
DDI-MedLine.d35.s2|157-160|when|O
DDI-MedLine.d35.s2|162-166|using|O
DDI-MedLine.d35.s2|168-170|for|O
DDI-MedLine.d35.s2|172-178|example|O
DDI-MedLine.d35.s2|180-194|antidepressants|group
DDI-MedLine.d35.s2|196-197|or|O
DDI-MedLine.d35.s2|199-210|chemotherapy|O
DDI-MedLine.d35.s2|211-211|.|O
DDI-MedLine.d35.s3|0-6|Genetic|O
DDI-MedLine.d35.s3|8-16|variation|O
DDI-MedLine.d35.s3|18-21|also|O
DDI-MedLine.d35.s3|23-28|occurs|O
DDI-MedLine.d35.s3|30-31|in|O
DDI-MedLine.d35.s3|33-40|proteins|O
DDI-MedLine.d35.s3|42-52|interacting|O
DDI-MedLine.d35.s3|54-57|with|O
DDI-MedLine.d35.s3|59-63|drugs|O
DDI-MedLine.d35.s3|64-64|,|O
DDI-MedLine.d35.s3|66-70|which|O
DDI-MedLine.d35.s3|72-74|may|O
DDI-MedLine.d35.s3|76-81|change|O
DDI-MedLine.d35.s3|83-85|the|O
DDI-MedLine.d35.s3|87-92|effect|O
DDI-MedLine.d35.s3|94-95|of|O
DDI-MedLine.d35.s3|97-99|e.g|O
DDI-MedLine.d35.s3|100-100|.|O
DDI-MedLine.d35.s4|0-5|asthma|O
DDI-MedLine.d35.s4|7-11|drugs|O
DDI-MedLine.d35.s4|13-15|and|O
DDI-MedLine.d35.s4|17-30|antipsychotics|group
DDI-MedLine.d35.s4|31-31|.|O
DDI-MedLine.d35.s5|0-2|The|O
DDI-MedLine.d35.s5|4-12|selection|O
DDI-MedLine.d35.s5|14-15|of|O
DDI-MedLine.d35.s5|17-21|drugs|O
DDI-MedLine.d35.s5|23-25|and|O
DDI-MedLine.d35.s5|27-31|their|O
DDI-MedLine.d35.s5|33-39|dosages|O
DDI-MedLine.d35.s5|41-43|may|O
DDI-MedLine.d35.s5|45-46|be|O
DDI-MedLine.d35.s5|48-55|improved|O
DDI-MedLine.d35.s5|56-56|,|O
DDI-MedLine.d35.s5|58-60|and|O
DDI-MedLine.d35.s5|62-64|the|O
DDI-MedLine.d35.s5|66-71|number|O
DDI-MedLine.d35.s5|73-74|of|O
DDI-MedLine.d35.s5|76-82|adverse|O
DDI-MedLine.d35.s5|84-90|effects|O
DDI-MedLine.d35.s5|92-98|reduced|O
DDI-MedLine.d35.s5|100-101|by|O
DDI-MedLine.d35.s5|103-117|pharmacogenetic|O
DDI-MedLine.d35.s5|119-132|investigations|O
DDI-MedLine.d35.s5|133-133|.|O
DDI-MedLine.d35.s6|0-6|However|O
DDI-MedLine.d35.s6|7-7|,|O
DDI-MedLine.d35.s6|9-10|it|O
DDI-MedLine.d35.s6|12-14|may|O
DDI-MedLine.d35.s6|16-17|be|O
DDI-MedLine.d35.s6|19-27|important|O
DDI-MedLine.d35.s6|29-32|also|O
DDI-MedLine.d35.s6|34-35|in|O
DDI-MedLine.d35.s6|37-40|case|O
DDI-MedLine.d35.s6|42-43|of|O
DDI-MedLine.d35.s6|45-51|medical|O
DDI-MedLine.d35.s6|53-64|examinations|O
DDI-MedLine.d35.s6|66-68|for|O
DDI-MedLine.d35.s6|70-79|insurances|O
DDI-MedLine.d35.s6|81-83|and|O
DDI-MedLine.d35.s6|85-87|job|O
DDI-MedLine.d35.s6|89-100|appointments|O
DDI-MedLine.d35.s6|101-101|,|O
DDI-MedLine.d35.s6|103-107|since|O
DDI-MedLine.d35.s6|109-112|some|O
DDI-MedLine.d35.s6|114-121|patients|O
DDI-MedLine.d35.s6|123-125|may|O
DDI-MedLine.d35.s6|127-130|turn|O
DDI-MedLine.d35.s6|132-134|out|O
DDI-MedLine.d35.s6|136-137|to|O
DDI-MedLine.d35.s6|139-142|need|O
DDI-MedLine.d35.s6|144-152|expensive|O
DDI-MedLine.d35.s6|154-158|drugs|O
DDI-MedLine.d35.s6|160-161|or|O
DDI-MedLine.d35.s6|163-164|to|O
DDI-MedLine.d35.s6|166-167|be|O
DDI-MedLine.d35.s6|169-179|susceptible|O
DDI-MedLine.d35.s6|181-182|to|O
DDI-MedLine.d35.s6|184-184|a|O
DDI-MedLine.d35.s6|186-192|certain|O
DDI-MedLine.d35.s6|194-200|disease|O
DDI-MedLine.d35.s6|201-201|.|O
DDI-MedLine.d35.s7|0-8|Therefore|O
DDI-MedLine.d35.s7|9-9|,|O
DDI-MedLine.d35.s7|11-13|the|O
DDI-MedLine.d35.s7|15-17|use|O
DDI-MedLine.d35.s7|19-20|of|O
DDI-MedLine.d35.s7|22-28|genetic|O
DDI-MedLine.d35.s7|30-33|data|O
DDI-MedLine.d35.s7|35-36|in|O
DDI-MedLine.d35.s7|38-42|these|O
DDI-MedLine.d35.s7|44-52|instances|O
DDI-MedLine.d35.s7|54-56|has|O
DDI-MedLine.d35.s7|58-59|to|O
DDI-MedLine.d35.s7|61-62|be|O
DDI-MedLine.d35.s7|64-72|regulated|O
DDI-MedLine.d35.s7|73-73|.|O
DDI-DrugBank.d510.s0|0-2|The|O
DDI-DrugBank.d510.s0|4-13|concurrent|O
DDI-DrugBank.d510.s0|15-17|use|O
DDI-DrugBank.d510.s0|19-20|of|O
DDI-DrugBank.d510.s0|22-28|Robinul|brand
DDI-DrugBank.d510.s0|30-38|Injection|O
DDI-DrugBank.d510.s0|40-43|with|O
DDI-DrugBank.d510.s0|45-49|other|O
DDI-DrugBank.d510.s0|51-66|anticholinergics|group
DDI-DrugBank.d510.s0|68-69|or|O
DDI-DrugBank.d510.s0|71-81|medications|O
DDI-DrugBank.d510.s0|83-86|with|O
DDI-DrugBank.d510.s0|88-102|anticholinergic|O
DDI-DrugBank.d510.s0|104-111|activity|O
DDI-DrugBank.d510.s0|112-112|,|O
DDI-DrugBank.d510.s0|114-117|such|O
DDI-DrugBank.d510.s0|119-120|as|O
DDI-DrugBank.d510.s0|122-135|phenothiazines|group
DDI-DrugBank.d510.s0|136-136|,|O
DDI-DrugBank.d510.s0|138-156|antiparkinson drugs|group
DDI-DrugBank.d510.s0|157-157|,|O
DDI-DrugBank.d510.s0|159-160|or|O
DDI-DrugBank.d510.s0|162-186|tricyclic antidepressants|group
DDI-DrugBank.d510.s0|187-187|,|O
DDI-DrugBank.d510.s0|189-191|may|O
DDI-DrugBank.d510.s0|193-201|intensify|O
DDI-DrugBank.d510.s0|203-205|the|O
DDI-DrugBank.d510.s0|207-220|antimuscarinic|O
DDI-DrugBank.d510.s0|222-228|effects|O
DDI-DrugBank.d510.s0|230-232|and|O
DDI-DrugBank.d510.s0|234-236|may|O
DDI-DrugBank.d510.s0|238-243|result|O
DDI-DrugBank.d510.s0|245-246|in|O
DDI-DrugBank.d510.s0|248-249|an|O
DDI-DrugBank.d510.s0|251-258|increase|O
DDI-DrugBank.d510.s0|260-261|in|O
DDI-DrugBank.d510.s0|263-277|anticholinergic|O
DDI-DrugBank.d510.s0|279-282|side|O
DDI-DrugBank.d510.s0|284-290|effects|O
DDI-DrugBank.d510.s0|291-291|.|O
DDI-DrugBank.d510.s1|0-10|Concomitant|O
DDI-DrugBank.d510.s1|12-25|administration|O
DDI-DrugBank.d510.s1|27-28|of|O
DDI-DrugBank.d510.s1|30-36|Robinul|brand
DDI-DrugBank.d510.s1|38-46|Injection|O
DDI-DrugBank.d510.s1|48-50|and|O
DDI-DrugBank.d510.s1|52-69|potassium chloride|drug
DDI-DrugBank.d510.s1|71-72|in|O
DDI-DrugBank.d510.s1|74-74|a|O
DDI-DrugBank.d510.s1|76-78|wax|O
DDI-DrugBank.d510.s1|80-85|matrix|O
DDI-DrugBank.d510.s1|87-89|may|O
DDI-DrugBank.d510.s1|91-98|increase|O
DDI-DrugBank.d510.s1|100-102|the|O
DDI-DrugBank.d510.s1|104-111|severity|O
DDI-DrugBank.d510.s1|113-114|of|O
DDI-DrugBank.d510.s1|116-124|potassium|O
DDI-DrugBank.d510.s1|126-141|chloride-induced|O
DDI-DrugBank.d510.s1|143-158|gastrointestinal|O
DDI-DrugBank.d510.s1|160-166|lesions|O
DDI-DrugBank.d510.s1|168-169|as|O
DDI-DrugBank.d510.s1|171-171|a|O
DDI-DrugBank.d510.s1|173-178|result|O
DDI-DrugBank.d510.s1|180-181|of|O
DDI-DrugBank.d510.s1|183-183|a|O
DDI-DrugBank.d510.s1|185-190|slower|O
DDI-DrugBank.d510.s1|192-207|gastrointestinal|O
DDI-DrugBank.d510.s1|209-215|transit|O
DDI-DrugBank.d510.s1|217-220|time|O
DDI-DrugBank.d510.s1|221-221|.|O
DDI-DrugBank.d355.s0|0-8|Androgens|group
DDI-DrugBank.d355.s0|10-12|may|O
DDI-DrugBank.d355.s0|14-21|increase|O
DDI-DrugBank.d355.s0|23-33|sensitivity|O
DDI-DrugBank.d355.s0|35-36|to|O
DDI-DrugBank.d355.s0|38-41|oral|O
DDI-DrugBank.d355.s0|43-56|anticoagulahts|O
DDI-DrugBank.d355.s0|57-57|.|O
DDI-DrugBank.d355.s1|0-5|Dosage|O
DDI-DrugBank.d355.s1|7-8|of|O
DDI-DrugBank.d355.s1|10-12|the|O
DDI-DrugBank.d355.s1|14-26|anticoagulant|group
DDI-DrugBank.d355.s1|28-30|may|O
DDI-DrugBank.d355.s1|32-38|require|O
DDI-DrugBank.d355.s1|40-48|reduction|O
DDI-DrugBank.d355.s1|50-51|in|O
DDI-DrugBank.d355.s1|53-57|order|O
DDI-DrugBank.d355.s1|59-60|to|O
DDI-DrugBank.d355.s1|62-69|maintain|O
DDI-DrugBank.d355.s1|71-82|satisfactory|O
DDI-DrugBank.d355.s1|84-94|therapeutic|O
DDI-DrugBank.d355.s1|96-114|hypoprothrombinemia|O
DDI-DrugBank.d355.s1|115-115|.|O
DDI-DrugBank.d355.s2|0-9|Concurrent|O
DDI-DrugBank.d355.s2|11-24|administration|O
DDI-DrugBank.d355.s2|26-27|of|O
DDI-DrugBank.d355.s2|29-43|oxyphenbutazone|drug
DDI-DrugBank.d355.s2|45-47|and|O
DDI-DrugBank.d355.s2|49-57|androgens|group
DDI-DrugBank.d355.s2|59-61|may|O
DDI-DrugBank.d355.s2|63-68|result|O
DDI-DrugBank.d355.s2|70-71|in|O
DDI-DrugBank.d355.s2|73-80|elevated|O
DDI-DrugBank.d355.s2|82-86|serum|O
DDI-DrugBank.d355.s2|88-93|levels|O
DDI-DrugBank.d355.s2|95-96|of|O
DDI-DrugBank.d355.s2|98-112|oxyphenbutazone|drug
DDI-DrugBank.d355.s2|113-113|.|O
DDI-DrugBank.d355.s3|0-1|In|O
DDI-DrugBank.d355.s3|3-10|diabetic|O
DDI-DrugBank.d355.s3|12-19|patients|O
DDI-DrugBank.d355.s3|20-20|,|O
DDI-DrugBank.d355.s3|22-24|the|O
DDI-DrugBank.d355.s3|26-34|metabolic|O
DDI-DrugBank.d355.s3|36-42|effects|O
DDI-DrugBank.d355.s3|44-45|of|O
DDI-DrugBank.d355.s3|47-55|androgens|group
DDI-DrugBank.d355.s3|57-59|may|O
DDI-DrugBank.d355.s3|61-68|decrease|O
DDI-DrugBank.d355.s3|70-74|blood|O
DDI-DrugBank.d355.s3|76-82|glucose|O
DDI-DrugBank.d355.s3|84-86|and|O
DDI-DrugBank.d355.s3|88-96|therefore|O
DDI-DrugBank.d355.s3|97-97|,|O
DDI-DrugBank.d355.s3|99-105|insulin|drug
DDI-DrugBank.d355.s3|107-118|requirements|O
DDI-DrugBank.d355.s3|119-119|.|O
DDI-MedLine.d17.s0|0-1|In|O
DDI-MedLine.d17.s0|3-7|vitro|O
DDI-MedLine.d17.s0|9-19|interaction|O
DDI-MedLine.d17.s0|21-22|of|O
DDI-MedLine.d17.s0|24-44|prostaglandin F2alpha|drug
DDI-MedLine.d17.s0|46-48|and|O
DDI-MedLine.d17.s0|50-57|oxytocin|drug
DDI-MedLine.d17.s0|59-60|in|O
DDI-MedLine.d17.s0|62-70|placental|O
DDI-MedLine.d17.s0|72-78|vessels|O
DDI-MedLine.d17.s0|79-79|.|O
DDI-MedLine.d17.s1|0-2|The|O
DDI-MedLine.d17.s1|4-14|interaction|O
DDI-MedLine.d17.s1|16-17|of|O
DDI-MedLine.d17.s1|19-39|prostaglandin F2alpha|drug
DDI-MedLine.d17.s1|41-43|and|O
DDI-MedLine.d17.s1|45-53|synthetic|O
DDI-MedLine.d17.s1|55-62|oxytocin|drug
DDI-MedLine.d17.s1|64-65|on|O
DDI-MedLine.d17.s1|67-75|placental|O
DDI-MedLine.d17.s1|77-83|vessels|O
DDI-MedLine.d17.s1|85-87|was|O
DDI-MedLine.d17.s1|89-95|studied|O
DDI-MedLine.d17.s1|97-98|in|O
DDI-MedLine.d17.s1|100-104|vitro|O
DDI-MedLine.d17.s1|105-105|.|O
DDI-MedLine.d17.s2|0-9|Resistance|O
DDI-MedLine.d17.s2|11-13|was|O
DDI-MedLine.d17.s2|15-22|measured|O
DDI-MedLine.d17.s2|24-27|near|O
DDI-MedLine.d17.s2|29-31|the|O
DDI-MedLine.d17.s2|33-41|placental|O
DDI-MedLine.d17.s2|43-48|margin|O
DDI-MedLine.d17.s2|50-54|after|O
DDI-MedLine.d17.s2|56-66|spontaneous|O
DDI-MedLine.d17.s2|68-71|term|O
DDI-MedLine.d17.s2|73-80|delivery|O
DDI-MedLine.d17.s2|81-81|.|O
DDI-MedLine.d17.s3|0-1|In|O
DDI-MedLine.d17.s3|3-7|seven|O
DDI-MedLine.d17.s3|9-19|experiments|O
DDI-MedLine.d17.s3|21-29|reactions|O
DDI-MedLine.d17.s3|31-32|to|O
DDI-MedLine.d17.s3|34-47|norepinephrine|drug
DDI-MedLine.d17.s3|49-51|and|O
DDI-MedLine.d17.s3|53-60|oxytocin|drug
DDI-MedLine.d17.s3|62-65|were|O
DDI-MedLine.d17.s3|67-75|PGF2alpha|drug
DDI-MedLine.d17.s3|76-76|.|O
DDI-MedLine.d17.s4|0-8|PGF2alpha|drug
DDI-MedLine.d17.s4|10-17|produced|O
DDI-MedLine.d17.s4|19-31|significantly|O
DDI-MedLine.d17.s4|33-41|increased|O
DDI-MedLine.d17.s4|43-58|vasoconstriction|O
DDI-MedLine.d17.s4|60-64|after|O
DDI-MedLine.d17.s4|66-66|a|O
DDI-MedLine.d17.s4|68-73|single|O
DDI-MedLine.d17.s4|75-88|administration|O
DDI-MedLine.d17.s4|90-91|of|O
DDI-MedLine.d17.s4|93-100|oxytocin|drug
DDI-MedLine.d17.s4|101-101|.|O
DDI-MedLine.d17.s5|0-1|In|O
DDI-MedLine.d17.s5|3-7|eight|O
DDI-MedLine.d17.s5|9-19|experiments|O
DDI-MedLine.d17.s5|21-23|the|O
DDI-MedLine.d17.s5|25-33|perfusion|O
DDI-MedLine.d17.s5|35-40|medium|O
DDI-MedLine.d17.s5|42-50|contained|O
DDI-MedLine.d17.s5|52-59|oxytocin|drug
DDI-MedLine.d17.s5|60-60|.|O
DDI-MedLine.d17.s6|0-4|There|O
DDI-MedLine.d17.s6|6-8|was|O
DDI-MedLine.d17.s6|10-11|no|O
DDI-MedLine.d17.s6|13-18|change|O
DDI-MedLine.d17.s6|20-24|after|O
DDI-MedLine.d17.s6|26-26|a|O
DDI-MedLine.d17.s6|28-33|single|O
DDI-MedLine.d17.s6|35-38|dose|O
DDI-MedLine.d17.s6|40-41|of|O
DDI-MedLine.d17.s6|43-51|PGF2alpha|drug
DDI-MedLine.d17.s6|52-52|.|O
DDI-MedLine.d17.s7|0-2|The|O
DDI-MedLine.d17.s7|4-11|reaction|O
DDI-MedLine.d17.s7|13-17|after|O
DDI-MedLine.d17.s7|19-32|norepinephrine|drug
DDI-MedLine.d17.s7|34-41|remained|O
DDI-MedLine.d17.s7|43-45|the|O
DDI-MedLine.d17.s7|47-50|same|O
DDI-MedLine.d17.s7|52-53|in|O
DDI-MedLine.d17.s7|55-58|both|O
DDI-MedLine.d17.s7|60-65|groups|O
DDI-MedLine.d17.s7|67-68|of|O
DDI-MedLine.d17.s7|70-80|experiments|O
DDI-MedLine.d17.s7|81-81|.|O
DDI-MedLine.d17.s8|0-4|There|O
DDI-MedLine.d17.s8|6-7|is|O
DDI-MedLine.d17.s8|9-12|thus|O
DDI-MedLine.d17.s8|14-15|an|O
DDI-MedLine.d17.s8|17-27|enhancement|O
DDI-MedLine.d17.s8|29-34|effect|O
DDI-MedLine.d17.s9|0-4|There|O
DDI-MedLine.d17.s9|6-7|is|O
DDI-MedLine.d17.s9|9-12|thus|O
DDI-MedLine.d17.s9|14-15|an|O
DDI-MedLine.d17.s9|17-27|enhancement|O
DDI-MedLine.d17.s9|29-34|effect|O
DDI-MedLine.d17.s9|36-37|of|O
DDI-MedLine.d17.s9|39-47|PGF2alpha|drug
DDI-MedLine.d17.s9|49-52|upon|O
DDI-MedLine.d17.s9|54-56|the|O
DDI-MedLine.d17.s9|58-65|reaction|O
DDI-MedLine.d17.s9|67-68|of|O
DDI-MedLine.d17.s9|70-78|placental|O
DDI-MedLine.d17.s9|80-86|vessels|O
DDI-MedLine.d17.s9|88-89|to|O
DDI-MedLine.d17.s9|91-98|oxytocin|drug
DDI-MedLine.d17.s9|100-101|in|O
DDI-MedLine.d17.s9|103-107|vitro|O
DDI-MedLine.d17.s9|108-108|.|O
DDI-DrugBank.d606.s0|0-13|MAO inhibitors|group
DDI-DrugBank.d606.s0|15-17|and|O
DDI-DrugBank.d606.s0|19-42|beta adrenergic blockers|group
DDI-DrugBank.d606.s0|44-51|increase|O
DDI-DrugBank.d606.s0|53-55|the|O
DDI-DrugBank.d606.s0|57-63|effects|O
DDI-DrugBank.d606.s0|65-66|of|O
DDI-DrugBank.d606.s0|68-82|pseudoephedrine|drug
DDI-DrugBank.d606.s0|83-83|.|O
DDI-DrugBank.d606.s1|0-15|Sympathomimetics|group
DDI-DrugBank.d606.s1|17-19|may|O
DDI-DrugBank.d606.s1|21-26|reduce|O
DDI-DrugBank.d606.s1|28-30|the|O
DDI-DrugBank.d606.s1|32-47|antihypertensive|O
DDI-DrugBank.d606.s1|49-55|effects|O
DDI-DrugBank.d606.s1|57-58|of|O
DDI-DrugBank.d606.s1|60-69|methyldopa|drug
DDI-DrugBank.d606.s1|70-70|,|O
DDI-DrugBank.d606.s1|72-83|mecamylamine|drug
DDI-DrugBank.d606.s1|84-84|,|O
DDI-DrugBank.d606.s1|86-94|reserpine|drug
DDI-DrugBank.d606.s1|96-98|and|O
DDI-DrugBank.d606.s1|100-117|veratrum alkaloids|group
DDI-DrugBank.d606.s1|118-118|.|O
DDI-MedLine.d7.s0|0-7|Enhanced|O
DDI-MedLine.d7.s0|9-20|theophylline|drug
DDI-MedLine.d7.s0|22-30|clearance|O
DDI-MedLine.d7.s0|32-40|secondary|O
DDI-MedLine.d7.s0|42-43|to|O
DDI-MedLine.d7.s0|45-53|phenytoin|drug
DDI-MedLine.d7.s0|55-61|therapy|O
DDI-MedLine.d7.s0|62-62|.|O
DDI-MedLine.d7.s1|0-3|This|O
DDI-MedLine.d7.s1|5-10|report|O
DDI-MedLine.d7.s1|12-20|describes|O
DDI-MedLine.d7.s1|22-24|two|O
DDI-MedLine.d7.s1|26-30|cases|O
DDI-MedLine.d7.s1|32-33|in|O
DDI-MedLine.d7.s1|35-39|which|O
DDI-MedLine.d7.s1|41-52|theophylline|drug
DDI-MedLine.d7.s1|54-62|clearance|O
DDI-MedLine.d7.s1|64-74|accelerated|O
DDI-MedLine.d7.s1|76-83|markedly|O
DDI-MedLine.d7.s1|85-88|with|O
DDI-MedLine.d7.s1|90-100|concomitant|O
DDI-MedLine.d7.s1|102-110|phenytoin|drug
DDI-MedLine.d7.s1|112-125|administration|O
DDI-MedLine.d7.s1|126-126|.|O
DDI-MedLine.d7.s2|0-6|Maximum|O
DDI-MedLine.d7.s2|8-17|calculated|O
DDI-MedLine.d7.s2|19-30|theophylline|drug
DDI-MedLine.d7.s2|32-40|clearance|O
DDI-MedLine.d7.s2|42-47|ranged|O
DDI-MedLine.d7.s2|49-52|from|O
DDI-MedLine.d7.s2|54-54|2|O
DDI-MedLine.d7.s2|56-58|1/2|O
DDI-MedLine.d7.s2|60-61|to|O
DDI-MedLine.d7.s2|63-63|3|O
DDI-MedLine.d7.s2|65-67|1/2|O
DDI-MedLine.d7.s2|69-73|times|O
DDI-MedLine.d7.s2|75-82|baseline|O
DDI-MedLine.d7.s2|83-83|.|O
DDI-MedLine.d7.s3|0-4|Onset|O
DDI-MedLine.d7.s3|6-7|of|O
DDI-MedLine.d7.s3|9-11|the|O
DDI-MedLine.d7.s3|13-23|interaction|O
DDI-MedLine.d7.s3|25-29|began|O
DDI-MedLine.d7.s3|31-36|within|O
DDI-MedLine.d7.s3|38-41|five|O
DDI-MedLine.d7.s3|43-46|days|O
DDI-MedLine.d7.s3|48-49|of|O
DDI-MedLine.d7.s3|51-59|beginning|O
DDI-MedLine.d7.s3|61-70|concurrent|O
DDI-MedLine.d7.s3|72-78|therapy|O
DDI-MedLine.d7.s3|79-79|.|O
DDI-MedLine.d7.s4|0-3|With|O
DDI-MedLine.d7.s4|5-12|combined|O
DDI-MedLine.d7.s4|14-16|use|O
DDI-MedLine.d7.s4|17-17|,|O
DDI-MedLine.d7.s4|19-28|clinicians|O
DDI-MedLine.d7.s4|30-35|should|O
DDI-MedLine.d7.s4|37-38|be|O
DDI-MedLine.d7.s4|40-44|aware|O
DDI-MedLine.d7.s4|45-45|,|O
DDI-MedLine.d7.s4|47-50|when|O
DDI-MedLine.d7.s4|52-60|phenytoin|drug
DDI-MedLine.d7.s4|62-63|is|O
DDI-MedLine.d7.s4|65-69|added|O
DDI-MedLine.d7.s4|70-70|,|O
DDI-MedLine.d7.s4|72-73|of|O
DDI-MedLine.d7.s4|75-77|the|O
DDI-MedLine.d7.s4|79-87|potential|O
DDI-MedLine.d7.s4|89-91|for|O
DDI-MedLine.d7.s4|93-106|reexacerbation|O
DDI-MedLine.d7.s4|108-109|of|O
DDI-MedLine.d7.s4|111-119|pulmonary|O
DDI-MedLine.d7.s4|121-134|symptomatology|O
DDI-MedLine.d7.s4|136-138|due|O
DDI-MedLine.d7.s4|140-141|to|O
DDI-MedLine.d7.s4|143-149|lowered|O
DDI-MedLine.d7.s4|151-155|serum|O
DDI-MedLine.d7.s4|157-168|theophylline|drug
DDI-MedLine.d7.s4|170-183|concentrations|O
DDI-MedLine.d7.s4|184-184|.|O
DDI-DrugBank.d35.s0|0-11|Interactions|O
DDI-DrugBank.d35.s0|13-15|may|O
DDI-DrugBank.d35.s0|17-21|occur|O
DDI-DrugBank.d35.s0|23-29|between|O
DDI-DrugBank.d35.s0|31-33|EPA|drug
DDI-DrugBank.d35.s0|35-45|supplements|O
DDI-DrugBank.d35.s0|47-49|and|O
DDI-DrugBank.d35.s0|51-57|aspirin|brand
DDI-DrugBank.d35.s0|59-61|and|O
DDI-DrugBank.d35.s0|63-67|other|O
DDI-DrugBank.d35.s0|69-105|non-steroidal anti-inflammatory drugs|group
DDI-DrugBank.d35.s0|107-109|and|O
DDI-DrugBank.d35.s0|111-115|herbs|O
DDI-DrugBank.d35.s0|117-120|such|O
DDI-DrugBank.d35.s0|122-123|as|O
DDI-DrugBank.d35.s0|125-130|garlic|O
DDI-DrugBank.d35.s0|132-132|(|O
DDI-DrugBank.d35.s0|133-138|Allium|O
DDI-DrugBank.d35.s0|140-146|sativum|O
DDI-DrugBank.d35.s0|147-147|)|O
DDI-DrugBank.d35.s0|149-151|and|O
DDI-DrugBank.d35.s0|153-158|ginkgo|drug
DDI-DrugBank.d35.s0|160-160|(|O
DDI-DrugBank.d35.s0|161-173|Ginkgo biloba|drug
DDI-DrugBank.d35.s0|174-174|)|O
DDI-DrugBank.d35.s0|175-175|.|O
DDI-DrugBank.d35.s1|0-3|Such|O
DDI-DrugBank.d35.s1|5-16|interactions|O
DDI-DrugBank.d35.s1|18-22|might|O
DDI-DrugBank.d35.s1|24-25|be|O
DDI-DrugBank.d35.s1|27-36|manifested|O
DDI-DrugBank.d35.s1|38-39|by|O
DDI-DrugBank.d35.s1|41-49|increased|O
DDI-DrugBank.d35.s1|51-64|susceptibility|O
DDI-DrugBank.d35.s1|66-67|to|O
DDI-DrugBank.d35.s1|69-76|bruising|O
DDI-DrugBank.d35.s1|77-77|,|O
DDI-DrugBank.d35.s1|79-88|nosebleeds|O
DDI-DrugBank.d35.s1|89-89|,|O
DDI-DrugBank.d35.s1|91-100|hemoptysis|O
DDI-DrugBank.d35.s1|101-101|,|O
DDI-DrugBank.d35.s1|103-113|hematemesis|O
DDI-DrugBank.d35.s1|114-114|,|O
DDI-DrugBank.d35.s1|116-124|hematuria|O
DDI-DrugBank.d35.s1|126-128|and|O
DDI-DrugBank.d35.s1|130-134|blood|O
DDI-DrugBank.d35.s1|136-137|in|O
DDI-DrugBank.d35.s1|139-141|the|O
DDI-DrugBank.d35.s1|143-147|stool|O
DDI-DrugBank.d35.s1|148-148|.|O
DDI-DrugBank.d35.s2|0-3|Most|O
DDI-DrugBank.d35.s2|5-7|who|O
DDI-DrugBank.d35.s2|9-12|take|O
DDI-DrugBank.d35.s2|14-16|EPA|drug
DDI-DrugBank.d35.s2|18-28|supplements|O
DDI-DrugBank.d35.s2|30-32|and|O
DDI-DrugBank.d35.s2|34-36|the|O
DDI-DrugBank.d35.s2|38-42|above|O
DDI-DrugBank.d35.s2|44-48|drugs|O
DDI-DrugBank.d35.s2|50-51|or|O
DDI-DrugBank.d35.s2|53-57|herbs|O
DDI-DrugBank.d35.s2|59-60|do|O
DDI-DrugBank.d35.s2|62-64|not|O
DDI-DrugBank.d35.s2|66-71|suffer|O
DDI-DrugBank.d35.s2|73-76|from|O
DDI-DrugBank.d35.s2|78-82|these|O
DDI-DrugBank.d35.s2|84-91|problems|O
DDI-DrugBank.d35.s2|93-95|and|O
DDI-DrugBank.d35.s2|97-98|if|O
DDI-DrugBank.d35.s2|100-103|they|O
DDI-DrugBank.d35.s2|105-109|occur|O
DDI-DrugBank.d35.s2|110-110|,|O
DDI-DrugBank.d35.s2|112-115|they|O
DDI-DrugBank.d35.s2|117-119|are|O
DDI-DrugBank.d35.s2|121-124|rare|O
DDI-DrugBank.d35.s2|125-125|.|O
DDI-DrugBank.d35.s3|0-1|If|O
DDI-DrugBank.d35.s3|3-6|they|O
DDI-DrugBank.d35.s3|8-9|do|O
DDI-DrugBank.d35.s3|11-15|occur|O
DDI-DrugBank.d35.s3|16-16|,|O
DDI-DrugBank.d35.s3|18-20|the|O
DDI-DrugBank.d35.s3|22-24|EPA|drug
DDI-DrugBank.d35.s3|26-29|dose|O
DDI-DrugBank.d35.s3|31-36|should|O
DDI-DrugBank.d35.s3|38-39|be|O
DDI-DrugBank.d35.s3|41-47|lowered|O
DDI-DrugBank.d35.s3|49-50|or|O
DDI-DrugBank.d35.s3|52-63|discontinued|O
DDI-DrugBank.d35.s3|64-64|.|O
DDI-DrugBank.d35.s4|0-10|Conflicting|O
DDI-DrugBank.d35.s4|12-18|results|O
DDI-DrugBank.d35.s4|20-23|have|O
DDI-DrugBank.d35.s4|25-28|been|O
DDI-DrugBank.d35.s4|30-37|reported|O
DDI-DrugBank.d35.s4|39-47|regarding|O
DDI-DrugBank.d35.s4|49-51|the|O
DDI-DrugBank.d35.s4|53-59|effects|O
DDI-DrugBank.d35.s4|61-62|of|O
DDI-DrugBank.d35.s4|64-66|EPA|drug
DDI-DrugBank.d35.s4|68-78|supplements|O
DDI-DrugBank.d35.s4|80-81|on|O
DDI-DrugBank.d35.s4|83-90|glycemic|O
DDI-DrugBank.d35.s4|92-98|control|O
DDI-DrugBank.d35.s4|100-101|in|O
DDI-DrugBank.d35.s4|103-115|non-diabetics|O
DDI-DrugBank.d35.s4|117-120|with|O
DDI-DrugBank.d35.s4|122-128|glucose|O
DDI-DrugBank.d35.s4|130-140|intolerance|O
DDI-DrugBank.d35.s4|141-141|,|O
DDI-DrugBank.d35.s4|143-145|and|O
DDI-DrugBank.d35.s4|147-151|those|O
DDI-DrugBank.d35.s4|153-156|with|O
DDI-DrugBank.d35.s4|158-161|type|O
DDI-DrugBank.d35.s4|163-163|2|O
DDI-DrugBank.d35.s4|165-172|diabetes|O
DDI-DrugBank.d35.s4|173-173|.|O
DDI-DrugBank.d35.s5|0-3|Some|O
DDI-DrugBank.d35.s5|5-9|early|O
DDI-DrugBank.d35.s5|11-17|studies|O
DDI-DrugBank.d35.s5|19-27|indicated|O
DDI-DrugBank.d35.s5|29-32|that|O
DDI-DrugBank.d35.s5|34-36|EPA|drug
DDI-DrugBank.d35.s5|38-48|supplements|O
DDI-DrugBank.d35.s5|50-54|might|O
DDI-DrugBank.d35.s5|56-59|have|O
DDI-DrugBank.d35.s5|61-71|detrimental|O
DDI-DrugBank.d35.s5|73-79|effects|O
DDI-DrugBank.d35.s5|81-82|in|O
DDI-DrugBank.d35.s5|84-88|those|O
DDI-DrugBank.d35.s5|90-95|groups|O
DDI-DrugBank.d35.s5|96-96|.|O
DDI-DrugBank.d35.s6|0-5|Recent|O
DDI-DrugBank.d35.s6|6-6|,|O
DDI-DrugBank.d35.s6|8-13|better|O
DDI-DrugBank.d35.s6|15-22|designed|O
DDI-DrugBank.d35.s6|24-30|studies|O
DDI-DrugBank.d35.s6|32-35|have|O
DDI-DrugBank.d35.s6|37-39|not|O
DDI-DrugBank.d35.s6|41-48|reported|O
DDI-DrugBank.d35.s6|50-54|these|O
DDI-DrugBank.d35.s6|56-62|adverse|O
DDI-DrugBank.d35.s6|64-70|effects|O
DDI-DrugBank.d35.s6|71-71|.|O
DDI-DrugBank.d35.s7|0-4|There|O
DDI-DrugBank.d35.s7|6-7|is|O
DDI-DrugBank.d35.s7|9-10|no|O
DDI-DrugBank.d35.s7|12-19|evidence|O
DDI-DrugBank.d35.s7|21-24|that|O
DDI-DrugBank.d35.s7|26-28|EPA|drug
DDI-DrugBank.d35.s7|30-40|supplements|O
DDI-DrugBank.d35.s7|42-45|have|O
DDI-DrugBank.d35.s7|47-57|detrimental|O
DDI-DrugBank.d35.s7|59-65|effects|O
DDI-DrugBank.d35.s7|67-68|on|O
DDI-DrugBank.d35.s7|70-76|glucose|O
DDI-DrugBank.d35.s7|78-86|tolerance|O
DDI-DrugBank.d35.s7|87-87|,|O
DDI-DrugBank.d35.s7|89-95|insulin|O
DDI-DrugBank.d35.s7|97-105|secretion|O
DDI-DrugBank.d35.s7|107-108|or|O
DDI-DrugBank.d35.s7|110-116|insulin|O
DDI-DrugBank.d35.s7|118-127|resistance|O
DDI-DrugBank.d35.s7|129-130|in|O
DDI-DrugBank.d35.s7|132-143|non-diabetic|O
DDI-DrugBank.d35.s7|145-152|subjects|O
DDI-DrugBank.d35.s7|153-153|.|O
DDI-DrugBank.d35.s8|0-8|Diabetics|O
DDI-DrugBank.d35.s8|10-15|should|O
DDI-DrugBank.d35.s8|17-23|discuss|O
DDI-DrugBank.d35.s8|25-27|the|O
DDI-DrugBank.d35.s8|29-31|use|O
DDI-DrugBank.d35.s8|33-34|of|O
DDI-DrugBank.d35.s8|36-40|these|O
DDI-DrugBank.d35.s8|42-52|supplements|O
DDI-DrugBank.d35.s8|54-57|with|O
DDI-DrugBank.d35.s8|59-63|their|O
DDI-DrugBank.d35.s8|65-74|physicians|O
DDI-DrugBank.d35.s8|76-78|and|O
DDI-DrugBank.d35.s8|80-83|note|O
DDI-DrugBank.d35.s8|85-86|if|O
DDI-DrugBank.d35.s8|88-90|the|O
DDI-DrugBank.d35.s8|92-102|supplements|O
DDI-DrugBank.d35.s8|104-109|affect|O
DDI-DrugBank.d35.s8|111-115|their|O
DDI-DrugBank.d35.s8|117-124|glycemic|O
DDI-DrugBank.d35.s8|126-132|control|O
DDI-DrugBank.d35.s8|133-133|.|O
DDI-DrugBank.d35.s9|0-8|Diabetics|O
DDI-DrugBank.d35.s9|10-12|who|O
DDI-DrugBank.d35.s9|14-17|take|O
DDI-DrugBank.d35.s9|19-21|EPA|drug
DDI-DrugBank.d35.s9|23-33|supplements|O
DDI-DrugBank.d35.s9|35-40|should|O
DDI-DrugBank.d35.s9|42-43|be|O
DDI-DrugBank.d35.s9|45-53|monitored|O
DDI-DrugBank.d35.s9|55-56|by|O
DDI-DrugBank.d35.s9|58-62|their|O
DDI-DrugBank.d35.s9|64-73|physicians|O
DDI-DrugBank.d35.s9|74-74|.|O
DDI-MedLine.d84.s0|0-12|Antimicrobial|O
DDI-MedLine.d84.s0|14-21|activity|O
DDI-MedLine.d84.s0|23-24|of|O
DDI-MedLine.d84.s0|52-56|alone|O
DDI-MedLine.d84.s0|58-60|and|O
DDI-MedLine.d84.s0|62-63|in|O
DDI-MedLine.d84.s0|65-75|combination|O
DDI-MedLine.d84.s0|77-80|with|O
DDI-MedLine.d84.s0|82-85|some|O
DDI-MedLine.d84.s0|87-97|antibiotics|group
DDI-MedLine.d84.s0|98-98|.|O
DDI-MedLine.d84.s1|0-12|Antimicrobial|O
DDI-MedLine.d84.s1|14-21|activity|O
DDI-MedLine.d84.s1|23-24|of|O
DDI-MedLine.d84.s1|29-29|(|O
DDI-MedLine.d84.s1|30-32|the|O
DDI-MedLine.d84.s1|34-40|aqueous|O
DDI-MedLine.d84.s1|42-48|extract|O
DDI-MedLine.d84.s1|50-53|from|O
DDI-MedLine.d84.s1|55-57|the|O
DDI-MedLine.d84.s1|59-69|carpophores|O
DDI-MedLine.d84.s1|71-72|of|O
DDI-MedLine.d84.s1|74-82|Ganoderma|O
DDI-MedLine.d84.s1|84-90|lucidum|O
DDI-MedLine.d84.s1|92-92|(|O
DDI-MedLine.d84.s1|93-94|FR|O
DDI-MedLine.d84.s1|95-95|)|O
DDI-MedLine.d84.s1|96-100|KARST|O
DDI-MedLine.d84.s1|101-101|)|O
DDI-MedLine.d84.s1|103-105|was|O
DDI-MedLine.d84.s1|107-112|tested|O
DDI-MedLine.d84.s1|114-115|in|O
DDI-MedLine.d84.s1|117-121|vitro|O
DDI-MedLine.d84.s1|123-129|against|O
DDI-MedLine.d84.s1|131-134|Gram|O
DDI-MedLine.d84.s1|136-143|positive|O
DDI-MedLine.d84.s1|145-147|and|O
DDI-MedLine.d84.s1|149-152|Gram|O
DDI-MedLine.d84.s1|154-161|negative|O
DDI-MedLine.d84.s1|163-170|bacteria|O
DDI-MedLine.d84.s1|172-173|by|O
DDI-MedLine.d84.s1|175-180|serial|O
DDI-MedLine.d84.s1|182-186|broth|O
DDI-MedLine.d84.s1|188-195|dilution|O
DDI-MedLine.d84.s1|197-202|method|O
DDI-MedLine.d84.s1|203-203|,|O
DDI-MedLine.d84.s1|205-207|and|O
DDI-MedLine.d84.s1|209-211|the|O
DDI-MedLine.d84.s1|213-225|antimicrobial|O
DDI-MedLine.d84.s1|227-234|activity|O
DDI-MedLine.d84.s1|236-238|was|O
DDI-MedLine.d84.s1|240-248|expressed|O
DDI-MedLine.d84.s1|250-251|by|O
DDI-MedLine.d84.s1|253-259|minimal|O
DDI-MedLine.d84.s1|261-270|inhibitory|O
DDI-MedLine.d84.s1|272-284|concentration|O
DDI-MedLine.d84.s1|286-286|(|O
DDI-MedLine.d84.s1|287-289|MIC|O
DDI-MedLine.d84.s1|290-290|)|O
DDI-MedLine.d84.s1|291-291|.|O
DDI-MedLine.d84.s2|0-4|Among|O
DDI-MedLine.d84.s2|6-12|fifteen|O
DDI-MedLine.d84.s2|14-20|species|O
DDI-MedLine.d84.s2|22-23|of|O
DDI-MedLine.d84.s2|25-32|bacteria|O
DDI-MedLine.d84.s2|34-39|tested|O
DDI-MedLine.d84.s2|40-40|,|O
DDI-MedLine.d84.s2|42-44|the|O
DDI-MedLine.d84.s2|46-58|antimicrobial|O
DDI-MedLine.d84.s2|60-67|activity|O
DDI-MedLine.d84.s2|69-70|of|O
DDI-MedLine.d84.s2|75-77|was|O
DDI-MedLine.d84.s2|79-81|the|O
DDI-MedLine.d84.s2|83-86|most|O
DDI-MedLine.d84.s2|88-93|potent|O
DDI-MedLine.d84.s2|95-101|against|O
DDI-MedLine.d84.s2|103-113|Micrococcus|O
DDI-MedLine.d84.s2|115-120|luteus|O
DDI-MedLine.d84.s2|122-122|(|O
DDI-MedLine.d84.s2|123-125|MIC|O
DDI-MedLine.d84.s2|126-126|,|O
DDI-MedLine.d84.s2|128-131|0.75|O
DDI-MedLine.d84.s2|133-137|mg/ml|O
DDI-MedLine.d84.s2|138-138|)|O
DDI-MedLine.d84.s2|139-139|.|O
DDI-MedLine.d84.s3|0-1|To|O
DDI-MedLine.d84.s3|3-13|investigate|O
DDI-MedLine.d84.s3|15-17|the|O
DDI-MedLine.d84.s3|19-25|effects|O
DDI-MedLine.d84.s3|27-28|of|O
DDI-MedLine.d84.s3|30-42|antimicrobial|O
DDI-MedLine.d84.s3|44-55|combinations|O
DDI-MedLine.d84.s3|57-58|of|O
DDI-MedLine.d84.s3|63-66|with|O
DDI-MedLine.d84.s3|68-71|four|O
DDI-MedLine.d84.s3|73-77|kinds|O
DDI-MedLine.d84.s3|79-80|of|O
DDI-MedLine.d84.s3|82-92|antibiotics|group
DDI-MedLine.d84.s3|94-94|(|O
DDI-MedLine.d84.s3|95-104|ampicillin|drug
DDI-MedLine.d84.s3|105-105|,|O
DDI-MedLine.d84.s3|107-115|cefazolin|drug
DDI-MedLine.d84.s3|116-116|,|O
DDI-MedLine.d84.s3|118-132|oxytetracycline|drug
DDI-MedLine.d84.s3|134-136|and|O
DDI-MedLine.d84.s3|138-152|chloramphenicol|drug
DDI-MedLine.d84.s3|153-153|)|O
DDI-MedLine.d84.s3|154-154|,|O
DDI-MedLine.d84.s3|156-158|the|O
DDI-MedLine.d84.s3|160-169|fractional|O
DDI-MedLine.d84.s3|171-180|inhibitory|O
DDI-MedLine.d84.s3|182-194|concentration|O
DDI-MedLine.d84.s3|196-200|index|O
DDI-MedLine.d84.s3|202-202|(|O
DDI-MedLine.d84.s3|203-206|FICI|O
DDI-MedLine.d84.s3|207-207|)|O
DDI-MedLine.d84.s3|209-211|was|O
DDI-MedLine.d84.s3|213-222|determined|O
DDI-MedLine.d84.s3|224-225|by|O
DDI-MedLine.d84.s3|227-238|checkerboard|O
DDI-MedLine.d84.s3|240-244|assay|O
DDI-MedLine.d84.s3|246-248|for|O
DDI-MedLine.d84.s3|250-253|each|O
DDI-MedLine.d84.s3|255-260|strain|O
DDI-MedLine.d84.s3|261-261|.|O
DDI-MedLine.d84.s4|0-2|The|O
DDI-MedLine.d84.s4|4-16|antimicrobial|O
DDI-MedLine.d84.s4|18-29|combinations|O
DDI-MedLine.d84.s4|31-32|of|O
DDI-MedLine.d84.s4|37-40|with|O
DDI-MedLine.d84.s4|42-45|four|O
DDI-MedLine.d84.s4|47-57|antibiotics|group
DDI-MedLine.d84.s4|59-66|resulted|O
DDI-MedLine.d84.s4|68-69|in|O
DDI-MedLine.d84.s4|71-78|additive|O
DDI-MedLine.d84.s4|80-85|effect|O
DDI-MedLine.d84.s4|87-88|in|O
DDI-MedLine.d84.s4|90-93|most|O
DDI-MedLine.d84.s4|95-103|instances|O
DDI-MedLine.d84.s4|104-104|,|O
DDI-MedLine.d84.s4|106-114|synergism|O
DDI-MedLine.d84.s4|116-117|in|O
DDI-MedLine.d84.s4|119-121|two|O
DDI-MedLine.d84.s4|123-131|instances|O
DDI-MedLine.d84.s4|132-132|,|O
DDI-MedLine.d84.s4|134-136|and|O
DDI-MedLine.d84.s4|138-147|antagonism|O
DDI-MedLine.d84.s4|149-150|in|O
DDI-MedLine.d84.s4|152-154|two|O
DDI-MedLine.d84.s4|156-164|instances|O
DDI-MedLine.d84.s4|165-165|.|O
DDI-MedLine.d84.s5|0-8|Synergism|O
DDI-MedLine.d84.s5|10-12|was|O
DDI-MedLine.d84.s5|14-21|observed|O
DDI-MedLine.d84.s5|23-26|when|O
DDI-MedLine.d84.s5|31-33|was|O
DDI-MedLine.d84.s5|35-42|combined|O
DDI-MedLine.d84.s5|44-47|with|O
DDI-MedLine.d84.s5|49-57|cefazolin|drug
DDI-MedLine.d84.s5|59-65|against|O
DDI-MedLine.d84.s5|67-74|Bacillus|O
DDI-MedLine.d84.s5|76-83|subtilis|O
DDI-MedLine.d84.s5|85-87|and|O
DDI-MedLine.d84.s5|89-98|Klebsiella|O
DDI-MedLine.d84.s5|100-106|oxytoca|O
DDI-MedLine.d84.s5|107-107|.|O
DDI-DrugBank.d753.s0|0-2|The|O
DDI-DrugBank.d753.s0|4-14|concomitant|O
DDI-DrugBank.d753.s0|16-18|use|O
DDI-DrugBank.d753.s0|20-21|of|O
DDI-DrugBank.d753.s0|23-27|other|O
DDI-DrugBank.d753.s0|29-43|CNS depressants|group
DDI-DrugBank.d753.s0|45-53|including|O
DDI-DrugBank.d753.s0|55-63|sedatives|group
DDI-DrugBank.d753.s0|64-64|,|O
DDI-DrugBank.d753.s0|66-74|hypnotics|group
DDI-DrugBank.d753.s0|75-75|,|O
DDI-DrugBank.d753.s0|77-89|tranquilizers|group
DDI-DrugBank.d753.s0|90-90|,|O
DDI-DrugBank.d753.s0|92-98|general|O
DDI-DrugBank.d753.s0|100-110|anesthetics|group
DDI-DrugBank.d753.s0|111-111|,|O
DDI-DrugBank.d753.s0|113-126|phenothiazines|group
DDI-DrugBank.d753.s0|127-127|,|O
DDI-DrugBank.d753.s0|129-133|other|O
DDI-DrugBank.d753.s0|135-141|opioids|group
DDI-DrugBank.d753.s0|142-142|,|O
DDI-DrugBank.d753.s0|144-168|tricyclic antidepressants|group
DDI-DrugBank.d753.s0|169-169|,|O
DDI-DrugBank.d753.s0|171-204|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d753.s0|205-205|,|O
DDI-DrugBank.d753.s0|207-209|and|O
DDI-DrugBank.d753.s0|211-217|alcohol|drug
DDI-DrugBank.d753.s0|219-221|may|O
DDI-DrugBank.d753.s0|223-229|produce|O
DDI-DrugBank.d753.s0|231-238|additive|O
DDI-DrugBank.d753.s0|240-242|CNS|O
DDI-DrugBank.d753.s0|244-253|depressant|O
DDI-DrugBank.d753.s0|255-261|effects|O
DDI-DrugBank.d753.s0|262-262|.|O
DDI-DrugBank.d753.s1|0-3|When|O
DDI-DrugBank.d753.s1|5-8|such|O
DDI-DrugBank.d753.s1|10-17|combined|O
DDI-DrugBank.d753.s1|19-25|therapy|O
DDI-DrugBank.d753.s1|27-28|is|O
DDI-DrugBank.d753.s1|30-41|contemplated|O
DDI-DrugBank.d753.s1|42-42|,|O
DDI-DrugBank.d753.s1|44-46|the|O
DDI-DrugBank.d753.s1|48-51|dose|O
DDI-DrugBank.d753.s1|53-54|of|O
DDI-DrugBank.d753.s1|56-58|one|O
DDI-DrugBank.d753.s1|60-61|or|O
DDI-DrugBank.d753.s1|63-66|both|O
DDI-DrugBank.d753.s1|68-73|agents|O
DDI-DrugBank.d753.s1|75-80|should|O
DDI-DrugBank.d753.s1|82-83|be|O
DDI-DrugBank.d753.s1|85-91|reduced|O
DDI-DrugBank.d753.s1|92-92|.|O
DDI-DrugBank.d753.s2|0-15|Anticholinergics|group
DDI-DrugBank.d753.s2|17-18|or|O
DDI-DrugBank.d753.s2|20-24|other|O
DDI-DrugBank.d753.s2|26-36|medications|O
DDI-DrugBank.d753.s2|38-41|with|O
DDI-DrugBank.d753.s2|43-57|anticholinergic|O
DDI-DrugBank.d753.s2|59-66|activity|O
DDI-DrugBank.d753.s2|68-71|when|O
DDI-DrugBank.d753.s2|73-76|used|O
DDI-DrugBank.d753.s2|78-89|concurrently|O
DDI-DrugBank.d753.s2|91-94|with|O
DDI-DrugBank.d753.s2|96-112|opioid analgesics|group
DDI-DrugBank.d753.s2|114-116|may|O
DDI-DrugBank.d753.s2|118-123|result|O
DDI-DrugBank.d753.s2|125-126|in|O
DDI-DrugBank.d753.s2|128-136|increased|O
DDI-DrugBank.d753.s2|138-141|risk|O
DDI-DrugBank.d753.s2|143-144|of|O
DDI-DrugBank.d753.s2|146-152|urinary|O
DDI-DrugBank.d753.s2|154-162|retention|O
DDI-DrugBank.d753.s2|164-169|and/or|O
DDI-DrugBank.d753.s2|171-176|severe|O
DDI-DrugBank.d753.s2|178-189|constipation|O
DDI-DrugBank.d753.s2|190-190|,|O
DDI-DrugBank.d753.s2|192-196|which|O
DDI-DrugBank.d753.s2|198-200|may|O
DDI-DrugBank.d753.s2|202-205|lead|O
DDI-DrugBank.d753.s2|207-208|to|O
DDI-DrugBank.d753.s2|210-218|paralytic|O
DDI-DrugBank.d753.s2|220-224|ileus|O
DDI-DrugBank.d753.s2|225-225|.|O
DDI-DrugBank.d753.s3|0-1|It|O
DDI-DrugBank.d753.s3|3-5|has|O
DDI-DrugBank.d753.s3|7-10|been|O
DDI-DrugBank.d753.s3|12-19|reported|O
DDI-DrugBank.d753.s3|21-24|that|O
DDI-DrugBank.d753.s3|26-28|the|O
DDI-DrugBank.d753.s3|30-38|incidence|O
DDI-DrugBank.d753.s3|40-41|of|O
DDI-DrugBank.d753.s3|43-53|bradycardia|O
DDI-DrugBank.d753.s3|55-57|was|O
DDI-DrugBank.d753.s3|59-67|increased|O
DDI-DrugBank.d753.s3|69-72|when|O
DDI-DrugBank.d753.s3|74-84|oxymorphone|drug
DDI-DrugBank.d753.s3|86-88|was|O
DDI-DrugBank.d753.s3|90-97|combined|O
DDI-DrugBank.d753.s3|99-102|with|O
DDI-DrugBank.d753.s3|104-111|propofol|drug
DDI-DrugBank.d753.s3|113-115|for|O
DDI-DrugBank.d753.s3|117-125|induction|O
DDI-DrugBank.d753.s3|127-128|of|O
DDI-DrugBank.d753.s3|130-139|anesthesia|O
DDI-DrugBank.d753.s3|140-140|.|O
DDI-DrugBank.d753.s4|0-1|In|O
DDI-DrugBank.d753.s4|3-10|addition|O
DDI-DrugBank.d753.s4|11-11|,|O
DDI-DrugBank.d753.s4|13-15|CNS|O
DDI-DrugBank.d753.s4|17-24|toxicity|O
DDI-DrugBank.d753.s4|26-28|has|O
DDI-DrugBank.d753.s4|30-33|been|O
DDI-DrugBank.d753.s4|35-42|reported|O
DDI-DrugBank.d753.s4|44-44|(|O
DDI-DrugBank.d753.s4|45-53|confusion|O
DDI-DrugBank.d753.s4|54-54|,|O
DDI-DrugBank.d753.s4|56-69|disorientation|O
DDI-DrugBank.d753.s4|70-70|,|O
DDI-DrugBank.d753.s4|72-82|respiratory|O
DDI-DrugBank.d753.s4|84-93|depression|O
DDI-DrugBank.d753.s4|94-94|,|O
DDI-DrugBank.d753.s4|96-100|apnea|O
DDI-DrugBank.d753.s4|101-101|,|O
DDI-DrugBank.d753.s4|103-110|seizures|O
DDI-DrugBank.d753.s4|111-111|)|O
DDI-DrugBank.d753.s4|113-121|following|O
DDI-DrugBank.d753.s4|123-138|coadministration|O
DDI-DrugBank.d753.s4|140-141|of|O
DDI-DrugBank.d753.s4|143-152|cimetidine|drug
DDI-DrugBank.d753.s4|154-157|with|O
DDI-DrugBank.d753.s4|159-175|opioid analgesics|group
DDI-DrugBank.d753.s4|176-176|;|O
DDI-DrugBank.d753.s5|0-1|no|O
DDI-DrugBank.d753.s5|3-11|clear-cut|O
DDI-DrugBank.d753.s5|13-17|cause|O
DDI-DrugBank.d753.s5|19-21|and|O
DDI-DrugBank.d753.s5|23-28|effect|O
DDI-DrugBank.d753.s5|30-41|relationship|O
DDI-DrugBank.d753.s5|43-45|was|O
DDI-DrugBank.d753.s5|47-57|established|O
DDI-DrugBank.d753.s5|58-58|.|O
DDI-MedLine.d3.s0|0-14|Pharmacokinetic|O
DDI-MedLine.d3.s0|16-26|Interaction|O
DDI-MedLine.d3.s0|28-34|between|O
DDI-MedLine.d3.s0|36-45|amprenavir|drug
DDI-MedLine.d3.s0|47-49|and|O
DDI-MedLine.d3.s0|51-59|rifabutin|drug
DDI-MedLine.d3.s0|61-62|or|O
DDI-MedLine.d3.s0|64-71|rifampin|drug
DDI-MedLine.d3.s0|73-74|in|O
DDI-MedLine.d3.s0|76-82|healthy|O
DDI-MedLine.d3.s0|84-88|males|O
DDI-MedLine.d3.s0|89-89|.|O
DDI-MedLine.d3.s1|0-2|The|O
DDI-MedLine.d3.s1|4-12|objective|O
DDI-MedLine.d3.s1|14-15|of|O
DDI-MedLine.d3.s1|17-20|this|O
DDI-MedLine.d3.s1|22-26|study|O
DDI-MedLine.d3.s1|28-30|was|O
DDI-MedLine.d3.s1|32-33|to|O
DDI-MedLine.d3.s1|35-43|determine|O
DDI-MedLine.d3.s1|45-46|if|O
DDI-MedLine.d3.s1|48-52|there|O
DDI-MedLine.d3.s1|54-55|is|O
DDI-MedLine.d3.s1|57-57|a|O
DDI-MedLine.d3.s1|59-73|pharmacokinetic|O
DDI-MedLine.d3.s1|75-85|interaction|O
DDI-MedLine.d3.s1|87-90|when|O
DDI-MedLine.d3.s1|92-101|amprenavir|drug
DDI-MedLine.d3.s1|103-104|is|O
DDI-MedLine.d3.s1|106-110|given|O
DDI-MedLine.d3.s1|112-115|with|O
DDI-MedLine.d3.s1|117-125|rifabutin|drug
DDI-MedLine.d3.s1|127-128|or|O
DDI-MedLine.d3.s1|130-137|rifampin|drug
DDI-MedLine.d3.s1|139-141|and|O
DDI-MedLine.d3.s1|143-144|to|O
DDI-MedLine.d3.s1|146-154|determine|O
DDI-MedLine.d3.s1|156-158|the|O
DDI-MedLine.d3.s1|160-166|effects|O
DDI-MedLine.d3.s1|168-169|of|O
DDI-MedLine.d3.s1|171-175|these|O
DDI-MedLine.d3.s1|177-181|drugs|O
DDI-MedLine.d3.s1|183-184|on|O
DDI-MedLine.d3.s1|186-188|the|O
DDI-MedLine.d3.s1|190-201|erythromycin|O
DDI-MedLine.d3.s1|203-208|breath|O
DDI-MedLine.d3.s1|210-213|test|O
DDI-MedLine.d3.s1|215-215|(|O
DDI-MedLine.d3.s1|216-220|ERMBT|O
DDI-MedLine.d3.s1|221-221|)|O
DDI-MedLine.d3.s1|222-222|.|O
DDI-MedLine.d3.s2|0-10|Twenty-four|O
DDI-MedLine.d3.s2|12-18|healthy|O
DDI-MedLine.d3.s2|20-23|male|O
DDI-MedLine.d3.s2|25-32|subjects|O
DDI-MedLine.d3.s2|34-37|were|O
DDI-MedLine.d3.s2|39-48|randomized|O
DDI-MedLine.d3.s2|50-51|to|O
DDI-MedLine.d3.s2|53-55|one|O
DDI-MedLine.d3.s2|57-58|of|O
DDI-MedLine.d3.s2|60-62|two|O
DDI-MedLine.d3.s2|64-70|cohorts|O
DDI-MedLine.d3.s2|71-71|.|O
DDI-MedLine.d3.s3|0-2|All|O
DDI-MedLine.d3.s3|4-11|subjects|O
DDI-MedLine.d3.s3|13-20|received|O
DDI-MedLine.d3.s3|22-31|amprenavir|drug
DDI-MedLine.d3.s3|33-33|(|O
DDI-MedLine.d3.s3|34-38|1,200|O
DDI-MedLine.d3.s3|40-41|mg|O
DDI-MedLine.d3.s3|43-47|twice|O
DDI-MedLine.d3.s3|49-49|a|O
DDI-MedLine.d3.s3|51-53|day|O
DDI-MedLine.d3.s3|54-54|)|O
DDI-MedLine.d3.s3|56-58|for|O
DDI-MedLine.d3.s3|60-60|4|O
DDI-MedLine.d3.s3|62-65|days|O
DDI-MedLine.d3.s3|66-66|,|O
DDI-MedLine.d3.s3|68-75|followed|O
DDI-MedLine.d3.s3|77-78|by|O
DDI-MedLine.d3.s3|80-80|a|O
DDI-MedLine.d3.s3|82-86|7-day|O
DDI-MedLine.d3.s3|88-94|washout|O
DDI-MedLine.d3.s3|96-101|period|O
DDI-MedLine.d3.s3|102-102|,|O
DDI-MedLine.d3.s3|104-111|followed|O
DDI-MedLine.d3.s3|113-114|by|O
DDI-MedLine.d3.s3|116-121|either|O
DDI-MedLine.d3.s3|123-131|rifabutin|drug
DDI-MedLine.d3.s3|133-133|(|O
DDI-MedLine.d3.s3|134-136|300|O
DDI-MedLine.d3.s3|138-139|mg|O
DDI-MedLine.d3.s3|141-144|once|O
DDI-MedLine.d3.s3|146-146|a|O
DDI-MedLine.d3.s3|148-150|day|O
DDI-MedLine.d3.s3|152-152|[|O
DDI-MedLine.d3.s3|153-154|QD|O
DDI-MedLine.d3.s3|155-155|]|O
DDI-MedLine.d3.s3|156-156|)|O
DDI-MedLine.d3.s3|158-158|(|O
DDI-MedLine.d3.s3|159-164|cohort|O
DDI-MedLine.d3.s3|166-166|1|O
DDI-MedLine.d3.s3|167-167|)|O
DDI-MedLine.d3.s3|169-170|or|O
DDI-MedLine.d3.s3|172-179|rifampin|drug
DDI-MedLine.d3.s3|181-181|(|O
DDI-MedLine.d3.s3|182-184|600|O
DDI-MedLine.d3.s3|186-187|mg|O
DDI-MedLine.d3.s3|189-190|QD|O
DDI-MedLine.d3.s3|191-191|)|O
DDI-MedLine.d3.s3|193-193|(|O
DDI-MedLine.d3.s3|194-199|cohort|O
DDI-MedLine.d3.s3|201-201|2|O
DDI-MedLine.d3.s3|202-202|)|O
DDI-MedLine.d3.s3|204-206|for|O
DDI-MedLine.d3.s3|208-209|14|O
DDI-MedLine.d3.s3|211-214|days|O
DDI-MedLine.d3.s3|215-215|.|O
DDI-MedLine.d3.s4|0-5|Cohort|O
DDI-MedLine.d3.s4|7-7|1|O
DDI-MedLine.d3.s4|9-12|then|O
DDI-MedLine.d3.s4|14-21|received|O
DDI-MedLine.d3.s4|23-32|amprenavir|drug
DDI-MedLine.d3.s4|34-37|plus|O
DDI-MedLine.d3.s4|39-47|rifabutin|drug
DDI-MedLine.d3.s4|49-51|for|O
DDI-MedLine.d3.s4|53-54|10|O
DDI-MedLine.d3.s4|56-59|days|O
DDI-MedLine.d3.s4|60-60|,|O
DDI-MedLine.d3.s4|62-64|and|O
DDI-MedLine.d3.s4|66-71|cohort|O
DDI-MedLine.d3.s4|73-73|2|O
DDI-MedLine.d3.s4|75-82|received|O
DDI-MedLine.d3.s4|84-93|amprenavir|drug
DDI-MedLine.d3.s4|95-98|plus|O
DDI-MedLine.d3.s4|100-107|rifampin|drug
DDI-MedLine.d3.s4|109-111|for|O
DDI-MedLine.d3.s4|113-113|4|O
DDI-MedLine.d3.s4|115-118|days|O
DDI-MedLine.d3.s4|119-119|.|O
DDI-MedLine.d3.s5|0-5|Serial|O
DDI-MedLine.d3.s5|7-12|plasma|O
DDI-MedLine.d3.s5|14-16|and|O
DDI-MedLine.d3.s5|18-22|urine|O
DDI-MedLine.d3.s5|24-30|samples|O
DDI-MedLine.d3.s5|32-34|for|O
DDI-MedLine.d3.s5|36-46|measurement|O
DDI-MedLine.d3.s5|48-49|of|O
DDI-MedLine.d3.s5|51-60|amprenavir|drug
DDI-MedLine.d3.s5|61-61|,|O
DDI-MedLine.d3.s5|63-71|rifabutin|drug
DDI-MedLine.d3.s5|72-72|,|O
DDI-MedLine.d3.s5|74-76|and|O
DDI-MedLine.d3.s5|78-85|rifampin|drug
DDI-MedLine.d3.s5|87-89|and|O
DDI-MedLine.d3.s5|91-95|their|O
DDI-MedLine.d3.s5|123-123|,|O
DDI-MedLine.d3.s5|125-128|were|O
DDI-MedLine.d3.s5|130-137|measured|O
DDI-MedLine.d3.s5|139-140|by|O
DDI-MedLine.d3.s5|142-157|high-performance|O
DDI-MedLine.d3.s5|159-164|liquid|O
DDI-MedLine.d3.s5|166-179|chromatography|O
DDI-MedLine.d3.s5|180-180|.|O
DDI-MedLine.d3.s6|0-8|Rifabutin|drug
DDI-MedLine.d3.s6|10-12|did|O
DDI-MedLine.d3.s6|14-16|not|O
DDI-MedLine.d3.s6|18-30|significantly|O
DDI-MedLine.d3.s6|32-37|affect|O
DDI-MedLine.d3.s6|39-48|amprenavir|drug
DDI-MedLine.d3.s6|49-50|'s|O
DDI-MedLine.d3.s6|52-67|pharmacokinetics|O
DDI-MedLine.d3.s6|68-68|.|O
DDI-MedLine.d3.s7|0-9|Amprenavir|drug
DDI-MedLine.d3.s7|11-23|significantly|O
DDI-MedLine.d3.s7|25-33|increased|O
DDI-MedLine.d3.s7|35-37|the|O
DDI-MedLine.d3.s7|39-42|area|O
DDI-MedLine.d3.s7|44-48|under|O
DDI-MedLine.d3.s7|50-52|the|O
DDI-MedLine.d3.s7|54-58|curve|O
DDI-MedLine.d3.s7|60-61|at|O
DDI-MedLine.d3.s7|63-68|steady|O
DDI-MedLine.d3.s7|70-74|state|O
DDI-MedLine.d3.s7|76-76|(|O
DDI-MedLine.d3.s7|77-79|AUC|O
DDI-MedLine.d3.s7|80-80|(|O
DDI-MedLine.d3.s7|81-82|ss|O
DDI-MedLine.d3.s7|83-83|)|O
DDI-MedLine.d3.s7|84-84|)|O
DDI-MedLine.d3.s7|86-87|of|O
DDI-MedLine.d3.s7|89-97|rifabutin|drug
DDI-MedLine.d3.s7|99-100|by|O
DDI-MedLine.d3.s7|102-110|2.93-fold|O
DDI-MedLine.d3.s7|112-114|and|O
DDI-MedLine.d3.s7|116-118|the|O
DDI-MedLine.d3.s7|120-122|AUC|O
DDI-MedLine.d3.s7|123-123|(|O
DDI-MedLine.d3.s7|124-125|ss|O
DDI-MedLine.d3.s7|126-126|)|O
DDI-MedLine.d3.s7|128-129|of|O
DDI-MedLine.d3.s7|155-156|by|O
DDI-MedLine.d3.s7|158-166|13.3-fold|O
DDI-MedLine.d3.s7|167-167|.|O
DDI-MedLine.d3.s8|0-7|Rifampin|drug
DDI-MedLine.d3.s8|9-21|significantly|O
DDI-MedLine.d3.s8|23-31|decreased|O
DDI-MedLine.d3.s8|33-35|the|O
DDI-MedLine.d3.s8|37-39|AUC|O
DDI-MedLine.d3.s8|40-40|(|O
DDI-MedLine.d3.s8|41-42|ss|O
DDI-MedLine.d3.s8|43-43|)|O
DDI-MedLine.d3.s8|45-46|of|O
DDI-MedLine.d3.s8|48-57|amprenavir|drug
DDI-MedLine.d3.s8|59-60|by|O
DDI-MedLine.d3.s8|62-63|82|O
DDI-MedLine.d3.s8|64-64|%|O
DDI-MedLine.d3.s8|65-65|,|O
DDI-MedLine.d3.s8|67-69|but|O
DDI-MedLine.d3.s8|71-80|amprenavir|drug
DDI-MedLine.d3.s8|82-84|had|O
DDI-MedLine.d3.s8|86-87|no|O
DDI-MedLine.d3.s8|89-94|effect|O
DDI-MedLine.d3.s8|96-97|on|O
DDI-MedLine.d3.s8|99-106|rifampin|drug
DDI-MedLine.d3.s8|108-123|pharmacokinetics|O
DDI-MedLine.d3.s8|124-124|.|O
DDI-MedLine.d3.s9|0-9|Amprenavir|drug
DDI-MedLine.d3.s9|11-19|decreased|O
DDI-MedLine.d3.s9|21-23|the|O
DDI-MedLine.d3.s9|25-31|results|O
DDI-MedLine.d3.s9|33-34|of|O
DDI-MedLine.d3.s9|36-38|the|O
DDI-MedLine.d3.s9|40-44|ERMBT|O
DDI-MedLine.d3.s9|46-47|by|O
DDI-MedLine.d3.s9|49-50|83|O
DDI-MedLine.d3.s9|51-51|%|O
DDI-MedLine.d3.s9|52-52|.|O
DDI-MedLine.d3.s10|0-2|The|O
DDI-MedLine.d3.s10|4-10|results|O
DDI-MedLine.d3.s10|12-13|of|O
DDI-MedLine.d3.s10|15-17|the|O
DDI-MedLine.d3.s10|19-23|ERMBT|O
DDI-MedLine.d3.s10|25-29|after|O
DDI-MedLine.d3.s10|31-31|2|O
DDI-MedLine.d3.s10|33-37|weeks|O
DDI-MedLine.d3.s10|39-40|of|O
DDI-MedLine.d3.s10|42-50|rifabutin|drug
DDI-MedLine.d3.s10|52-54|and|O
DDI-MedLine.d3.s10|56-63|rifampin|drug
DDI-MedLine.d3.s10|65-71|therapy|O
DDI-MedLine.d3.s10|73-76|were|O
DDI-MedLine.d3.s10|78-86|increased|O
DDI-MedLine.d3.s10|88-90|187|O
DDI-MedLine.d3.s10|92-94|and|O
DDI-MedLine.d3.s10|96-98|156|O
DDI-MedLine.d3.s10|99-99|%|O
DDI-MedLine.d3.s10|100-100|,|O
DDI-MedLine.d3.s10|102-113|respectively|O
DDI-MedLine.d3.s10|114-114|.|O
DDI-MedLine.d3.s11|0-9|Amprenavir|drug
DDI-MedLine.d3.s11|11-14|plus|O
DDI-MedLine.d3.s11|16-23|rifampin|drug
DDI-MedLine.d3.s11|25-27|was|O
DDI-MedLine.d3.s11|29-32|well|O
DDI-MedLine.d3.s11|34-42|tolerated|O
DDI-MedLine.d3.s11|43-43|.|O
DDI-MedLine.d3.s12|0-9|Amprenavir|drug
DDI-MedLine.d3.s12|11-14|plus|O
DDI-MedLine.d3.s12|16-24|rifabutin|drug
DDI-MedLine.d3.s12|26-28|was|O
DDI-MedLine.d3.s12|30-35|poorly|O
DDI-MedLine.d3.s12|37-45|tolerated|O
DDI-MedLine.d3.s12|46-46|,|O
DDI-MedLine.d3.s12|48-50|and|O
DDI-MedLine.d3.s12|52-52|5|O
DDI-MedLine.d3.s12|54-55|of|O
DDI-MedLine.d3.s12|57-58|11|O
DDI-MedLine.d3.s12|60-67|subjects|O
DDI-MedLine.d3.s12|69-80|discontinued|O
DDI-MedLine.d3.s12|82-88|therapy|O
DDI-MedLine.d3.s12|89-89|.|O
DDI-MedLine.d3.s13|0-7|Rifampin|drug
DDI-MedLine.d3.s13|9-16|markedly|O
DDI-MedLine.d3.s13|18-26|increases|O
DDI-MedLine.d3.s13|28-30|the|O
DDI-MedLine.d3.s13|32-40|metabolic|O
DDI-MedLine.d3.s13|42-50|clearance|O
DDI-MedLine.d3.s13|52-53|of|O
DDI-MedLine.d3.s13|55-64|amprenavir|drug
DDI-MedLine.d3.s13|65-65|,|O
DDI-MedLine.d3.s13|67-69|and|O
DDI-MedLine.d3.s13|71-86|coadministration|O
DDI-MedLine.d3.s13|88-89|is|O
DDI-MedLine.d3.s13|91-105|contraindicated|O
DDI-MedLine.d3.s13|106-106|.|O
DDI-MedLine.d3.s14|0-9|Amprenavir|drug
DDI-MedLine.d3.s14|11-23|significantly|O
DDI-MedLine.d3.s14|25-33|decreases|O
DDI-MedLine.d3.s14|35-43|clearance|O
DDI-MedLine.d3.s14|45-46|of|O
DDI-MedLine.d3.s14|48-56|rifabutin|drug
DDI-MedLine.d3.s14|58-60|and|O
DDI-MedLine.d3.s14|85-85|,|O
DDI-MedLine.d3.s14|87-89|and|O
DDI-MedLine.d3.s14|91-93|the|O
DDI-MedLine.d3.s14|95-105|combination|O
DDI-MedLine.d3.s14|107-108|is|O
DDI-MedLine.d3.s14|110-115|poorly|O
DDI-MedLine.d3.s14|117-125|tolerated|O
DDI-MedLine.d3.s14|126-126|.|O
DDI-MedLine.d3.s15|0-9|Amprenavir|drug
DDI-MedLine.d3.s15|11-18|inhibits|O
DDI-MedLine.d3.s15|20-22|the|O
DDI-MedLine.d3.s15|24-28|ERMBT|O
DDI-MedLine.d3.s15|29-29|,|O
DDI-MedLine.d3.s15|31-33|and|O
DDI-MedLine.d3.s15|35-42|rifampin|drug
DDI-MedLine.d3.s15|44-46|and|O
DDI-MedLine.d3.s15|48-56|rifabutin|drug
DDI-MedLine.d3.s15|58-60|are|O
DDI-MedLine.d3.s15|62-71|equipotent|O
DDI-MedLine.d3.s15|73-80|inducers|O
DDI-MedLine.d3.s15|82-83|of|O
DDI-MedLine.d3.s15|85-87|the|O
DDI-MedLine.d3.s15|89-93|ERMBT|O
DDI-MedLine.d3.s15|94-94|.|O
DDI-DrugBank.d408.s0|0-1|No|O
DDI-DrugBank.d408.s0|3-8|formal|O
DDI-DrugBank.d408.s0|10-13|drug|O
DDI-DrugBank.d408.s0|15-25|interaction|O
DDI-DrugBank.d408.s0|27-33|studies|O
DDI-DrugBank.d408.s0|35-38|have|O
DDI-DrugBank.d408.s0|40-43|been|O
DDI-DrugBank.d408.s0|45-53|performed|O
DDI-DrugBank.d408.s0|55-58|with|O
DDI-DrugBank.d408.s0|60-66|ZEVALIN|brand
DDI-DrugBank.d408.s0|67-67|.|O
DDI-DrugBank.d408.s1|0-2|Due|O
DDI-DrugBank.d408.s1|4-5|to|O
DDI-DrugBank.d408.s1|7-9|the|O
DDI-DrugBank.d408.s1|11-18|frequent|O
DDI-DrugBank.d408.s1|20-29|occurrence|O
DDI-DrugBank.d408.s1|31-32|of|O
DDI-DrugBank.d408.s1|34-39|severe|O
DDI-DrugBank.d408.s1|41-43|and|O
DDI-DrugBank.d408.s1|45-53|prolonged|O
DDI-DrugBank.d408.s1|55-70|thrombocytopenia|O
DDI-DrugBank.d408.s1|71-71|,|O
DDI-DrugBank.d408.s1|73-75|the|O
DDI-DrugBank.d408.s1|77-85|potential|O
DDI-DrugBank.d408.s1|87-94|benefits|O
DDI-DrugBank.d408.s1|96-97|of|O
DDI-DrugBank.d408.s1|99-109|medications|O
DDI-DrugBank.d408.s1|111-115|which|O
DDI-DrugBank.d408.s1|117-125|interfere|O
DDI-DrugBank.d408.s1|127-130|with|O
DDI-DrugBank.d408.s1|132-139|platelet|O
DDI-DrugBank.d408.s1|141-148|function|O
DDI-DrugBank.d408.s1|150-155|and/or|O
DDI-DrugBank.d408.s1|157-171|anticoagulation|O
DDI-DrugBank.d408.s1|173-178|should|O
DDI-DrugBank.d408.s1|180-181|be|O
DDI-DrugBank.d408.s1|183-189|weighed|O
DDI-DrugBank.d408.s1|191-197|against|O
DDI-DrugBank.d408.s1|199-201|the|O
DDI-DrugBank.d408.s1|203-211|potential|O
DDI-DrugBank.d408.s1|213-221|increased|O
DDI-DrugBank.d408.s1|223-227|risks|O
DDI-DrugBank.d408.s1|229-230|of|O
DDI-DrugBank.d408.s1|232-239|bleeding|O
DDI-DrugBank.d408.s1|241-243|and|O
DDI-DrugBank.d408.s1|245-254|hemorrhage|O
DDI-DrugBank.d408.s1|255-255|.|O
DDI-DrugBank.d408.s2|0-7|Patients|O
DDI-DrugBank.d408.s2|9-17|receiving|O
DDI-DrugBank.d408.s2|19-29|medications|O
DDI-DrugBank.d408.s2|31-34|that|O
DDI-DrugBank.d408.s2|36-44|interfere|O
DDI-DrugBank.d408.s2|46-49|with|O
DDI-DrugBank.d408.s2|51-58|platelet|O
DDI-DrugBank.d408.s2|60-67|function|O
DDI-DrugBank.d408.s2|69-70|or|O
DDI-DrugBank.d408.s2|72-82|coagulation|O
DDI-DrugBank.d408.s2|84-89|should|O
DDI-DrugBank.d408.s2|91-94|have|O
DDI-DrugBank.d408.s2|96-99|more|O
DDI-DrugBank.d408.s2|101-108|frequent|O
DDI-DrugBank.d408.s2|110-119|laboratory|O
DDI-DrugBank.d408.s2|121-130|monitoring|O
DDI-DrugBank.d408.s2|132-134|for|O
DDI-DrugBank.d408.s2|136-151|thrombocytopenia|O
DDI-DrugBank.d408.s2|152-152|.|O
DDI-DrugBank.d408.s3|0-1|In|O
DDI-DrugBank.d408.s3|3-10|addition|O
DDI-DrugBank.d408.s3|11-11|,|O
DDI-DrugBank.d408.s3|13-15|the|O
DDI-DrugBank.d408.s3|17-27|transfusion|O
DDI-DrugBank.d408.s3|29-37|practices|O
DDI-DrugBank.d408.s3|39-41|for|O
DDI-DrugBank.d408.s3|43-46|such|O
DDI-DrugBank.d408.s3|48-55|patients|O
DDI-DrugBank.d408.s3|57-59|may|O
DDI-DrugBank.d408.s3|61-64|need|O
DDI-DrugBank.d408.s3|66-67|to|O
DDI-DrugBank.d408.s3|69-70|be|O
DDI-DrugBank.d408.s3|72-79|modified|O
DDI-DrugBank.d408.s3|81-85|given|O
DDI-DrugBank.d408.s3|87-89|the|O
DDI-DrugBank.d408.s3|91-99|increased|O
DDI-DrugBank.d408.s3|101-104|risk|O
DDI-DrugBank.d408.s3|106-107|of|O
DDI-DrugBank.d408.s3|109-116|bleeding|O
DDI-DrugBank.d408.s3|117-117|.|O
DDI-DrugBank.d408.s4|0-7|Patients|O
DDI-DrugBank.d408.s4|9-10|in|O
DDI-DrugBank.d408.s4|12-19|clinical|O
DDI-DrugBank.d408.s4|21-27|studies|O
DDI-DrugBank.d408.s4|29-32|were|O
DDI-DrugBank.d408.s4|34-43|prohibited|O
DDI-DrugBank.d408.s4|45-48|from|O
DDI-DrugBank.d408.s4|50-58|receiving|O
DDI-DrugBank.d408.s4|60-65|growth|O
DDI-DrugBank.d408.s4|67-72|factor|O
DDI-DrugBank.d408.s4|74-82|treatment|O
DDI-DrugBank.d408.s4|84-86|for|O
DDI-DrugBank.d408.s4|88-88|2|O
DDI-DrugBank.d408.s4|90-94|weeks|O
DDI-DrugBank.d408.s4|96-100|prior|O
DDI-DrugBank.d408.s4|102-103|to|O
DDI-DrugBank.d408.s4|105-107|the|O
DDI-DrugBank.d408.s4|109-115|ZEVALIN|brand
DDI-DrugBank.d408.s4|117-127|therapeutic|O
DDI-DrugBank.d408.s4|129-135|regimen|O
DDI-DrugBank.d408.s4|137-138|as|O
DDI-DrugBank.d408.s4|140-143|well|O
DDI-DrugBank.d408.s4|145-146|as|O
DDI-DrugBank.d408.s4|148-150|for|O
DDI-DrugBank.d408.s4|152-152|2|O
DDI-DrugBank.d408.s4|154-158|weeks|O
DDI-DrugBank.d408.s4|160-168|following|O
DDI-DrugBank.d408.s4|170-179|completion|O
DDI-DrugBank.d408.s4|181-182|of|O
DDI-DrugBank.d408.s4|184-186|the|O
DDI-DrugBank.d408.s4|188-194|regimen|O
DDI-DrugBank.d408.s4|195-195|.|O
DDI-DrugBank.d88.s0|0-6|Antacid|group
DDI-DrugBank.d88.s0|7-7|:|O
DDI-DrugBank.d88.s0|9-11|The|O
DDI-DrugBank.d88.s0|13-18|effect|O
DDI-DrugBank.d88.s0|20-21|of|O
DDI-DrugBank.d88.s0|23-24|an|O
DDI-DrugBank.d88.s0|26-33|aluminum|drug
DDI-DrugBank.d88.s0|35-44|hydroxide-|O
DDI-DrugBank.d88.s0|46-48|and|O
DDI-DrugBank.d88.s0|50-58|magnesium|drug
DDI-DrugBank.d88.s0|60-79|hydroxide-containing|O
DDI-DrugBank.d88.s0|81-87|antacid|group
DDI-DrugBank.d88.s0|89-89|(|O
DDI-DrugBank.d88.s0|90-95|Maalox|brand
DDI-DrugBank.d88.s0|96-96|)|O
DDI-DrugBank.d88.s0|97-97|*|O
DDI-DrugBank.d88.s0|99-100|on|O
DDI-DrugBank.d88.s0|102-104|the|O
DDI-DrugBank.d88.s0|106-121|pharmacokinetics|O
DDI-DrugBank.d88.s0|123-124|of|O
DDI-DrugBank.d88.s0|126-137|capecitabine|drug
DDI-DrugBank.d88.s0|139-141|was|O
DDI-DrugBank.d88.s0|143-154|investigated|O
DDI-DrugBank.d88.s0|156-157|in|O
DDI-DrugBank.d88.s0|159-160|12|O
DDI-DrugBank.d88.s0|162-167|cancer|O
DDI-DrugBank.d88.s0|169-176|patients|O
DDI-DrugBank.d88.s0|177-177|.|O
DDI-DrugBank.d88.s1|0-4|There|O
DDI-DrugBank.d88.s1|6-8|was|O
DDI-DrugBank.d88.s1|10-10|a|O
DDI-DrugBank.d88.s1|12-16|small|O
DDI-DrugBank.d88.s1|18-25|increase|O
DDI-DrugBank.d88.s1|27-28|in|O
DDI-DrugBank.d88.s1|30-35|plasma|O
DDI-DrugBank.d88.s1|37-50|concentrations|O
DDI-DrugBank.d88.s1|52-53|of|O
DDI-DrugBank.d88.s1|55-66|capecitabine|drug
DDI-DrugBank.d88.s1|68-70|and|O
DDI-DrugBank.d88.s1|72-74|one|O
DDI-DrugBank.d88.s1|76-85|metabolite|O
DDI-DrugBank.d88.s1|87-87|(|O
DDI-DrugBank.d88.s1|94-94|)|O
DDI-DrugBank.d88.s1|95-95|;|O
DDI-DrugBank.d88.s2|0-4|there|O
DDI-DrugBank.d88.s2|6-8|was|O
DDI-DrugBank.d88.s2|10-11|no|O
DDI-DrugBank.d88.s2|13-18|effect|O
DDI-DrugBank.d88.s2|20-21|on|O
DDI-DrugBank.d88.s2|23-25|the|O
DDI-DrugBank.d88.s2|27-27|3|O
DDI-DrugBank.d88.s2|29-33|major|O
DDI-DrugBank.d88.s2|35-45|metabolites|O
DDI-DrugBank.d88.s2|47-47|(|O
DDI-DrugBank.d88.s2|54-54|,|O
DDI-DrugBank.d88.s2|61-63|and|O
DDI-DrugBank.d88.s2|69-69|)|O
DDI-DrugBank.d88.s2|70-70|.|O
DDI-DrugBank.d88.s3|0-22|Coumarin Anticoagulants|group
DDI-DrugBank.d88.s3|24-30|Altered|O
DDI-DrugBank.d88.s3|32-42|coagulation|O
DDI-DrugBank.d88.s3|44-53|parameters|O
DDI-DrugBank.d88.s3|55-60|and/or|O
DDI-DrugBank.d88.s3|62-69|bleeding|O
DDI-DrugBank.d88.s3|71-74|have|O
DDI-DrugBank.d88.s3|76-79|been|O
DDI-DrugBank.d88.s3|81-88|reported|O
DDI-DrugBank.d88.s3|90-91|in|O
DDI-DrugBank.d88.s3|93-100|patients|O
DDI-DrugBank.d88.s3|102-107|taking|O
DDI-DrugBank.d88.s3|109-120|capecitabine|drug
DDI-DrugBank.d88.s3|122-134|concomitantly|O
DDI-DrugBank.d88.s3|136-139|with|O
DDI-DrugBank.d88.s3|141-174|coumarin-derivative anticoagulants|group
DDI-DrugBank.d88.s3|176-179|such|O
DDI-DrugBank.d88.s3|181-182|as|O
DDI-DrugBank.d88.s3|184-191|warfarin|drug
DDI-DrugBank.d88.s3|193-195|and|O
DDI-DrugBank.d88.s3|197-209|phenprocoumon|drug
DDI-DrugBank.d88.s3|210-210|.|O
DDI-DrugBank.d88.s4|0-7|Patients|O
DDI-DrugBank.d88.s4|9-14|taking|O
DDI-DrugBank.d88.s4|16-49|coumarin-derivative anticoagulants|group
DDI-DrugBank.d88.s4|51-63|concomitantly|O
DDI-DrugBank.d88.s4|65-68|with|O
DDI-DrugBank.d88.s4|70-81|capecitabine|drug
DDI-DrugBank.d88.s4|83-88|should|O
DDI-DrugBank.d88.s4|90-91|be|O
DDI-DrugBank.d88.s4|93-101|monitored|O
DDI-DrugBank.d88.s4|103-111|regularly|O
DDI-DrugBank.d88.s4|113-115|for|O
DDI-DrugBank.d88.s4|117-127|alterations|O
DDI-DrugBank.d88.s4|129-130|in|O
DDI-DrugBank.d88.s4|132-136|their|O
DDI-DrugBank.d88.s4|138-148|coagulation|O
DDI-DrugBank.d88.s4|150-159|parameters|O
DDI-DrugBank.d88.s4|161-161|(|O
DDI-DrugBank.d88.s4|162-163|PT|O
DDI-DrugBank.d88.s4|165-166|or|O
DDI-DrugBank.d88.s4|168-170|INR|O
DDI-DrugBank.d88.s4|171-171|)|O
DDI-DrugBank.d88.s4|172-172|.|O
DDI-DrugBank.d88.s5|0-9|Leucovorin|drug
DDI-DrugBank.d88.s5|10-10|:|O
DDI-DrugBank.d88.s5|12-14|The|O
DDI-DrugBank.d88.s5|16-28|concentration|O
DDI-DrugBank.d88.s5|30-31|of|O
DDI-DrugBank.d88.s5|33-46|5-fluorouracil|drug
DDI-DrugBank.d88.s5|48-49|is|O
DDI-DrugBank.d88.s5|51-59|increased|O
DDI-DrugBank.d88.s5|61-63|and|O
DDI-DrugBank.d88.s5|65-67|its|O
DDI-DrugBank.d88.s5|69-76|toxicity|O
DDI-DrugBank.d88.s5|78-80|may|O
DDI-DrugBank.d88.s5|82-83|be|O
DDI-DrugBank.d88.s5|85-92|enhanced|O
DDI-DrugBank.d88.s5|94-95|by|O
DDI-DrugBank.d88.s5|97-106|leucovorin|drug
DDI-DrugBank.d88.s5|107-107|.|O
DDI-DrugBank.d88.s6|0-5|Deaths|O
DDI-DrugBank.d88.s6|7-10|from|O
DDI-DrugBank.d88.s6|12-17|severe|O
DDI-DrugBank.d88.s6|19-31|enterocolitis|O
DDI-DrugBank.d88.s6|32-32|,|O
DDI-DrugBank.d88.s6|34-41|diarrhea|O
DDI-DrugBank.d88.s6|42-42|,|O
DDI-DrugBank.d88.s6|44-46|and|O
DDI-DrugBank.d88.s6|48-58|dehydration|O
DDI-DrugBank.d88.s6|60-63|have|O
DDI-DrugBank.d88.s6|65-68|been|O
DDI-DrugBank.d88.s6|70-77|reported|O
DDI-DrugBank.d88.s6|79-80|in|O
DDI-DrugBank.d88.s6|82-88|elderly|O
DDI-DrugBank.d88.s6|90-97|patients|O
DDI-DrugBank.d88.s6|99-107|receiving|O
DDI-DrugBank.d88.s6|109-114|weekly|O
DDI-DrugBank.d88.s6|116-125|leucovorin|drug
DDI-DrugBank.d88.s6|127-129|and|O
DDI-DrugBank.d88.s6|131-142|fluorouracil|drug
DDI-DrugBank.d88.s6|143-143|.|O
DDI-DrugBank.d642.s0|0-10|Prothrombin|O
DDI-DrugBank.d642.s0|12-15|time|O
DDI-DrugBank.d642.s0|17-18|or|O
DDI-DrugBank.d642.s0|20-24|other|O
DDI-DrugBank.d642.s0|26-33|suitable|O
DDI-DrugBank.d642.s0|35-49|anticoagulation|O
DDI-DrugBank.d642.s0|51-54|test|O
DDI-DrugBank.d642.s0|56-61|should|O
DDI-DrugBank.d642.s0|63-64|be|O
DDI-DrugBank.d642.s0|66-74|monitored|O
DDI-DrugBank.d642.s0|76-77|if|O
DDI-DrugBank.d642.s0|79-89|tigecycline|drug
DDI-DrugBank.d642.s0|91-92|is|O
DDI-DrugBank.d642.s0|94-105|administered|O
DDI-DrugBank.d642.s0|107-110|with|O
DDI-DrugBank.d642.s0|112-119|warfarin|drug
DDI-DrugBank.d642.s0|120-120|.|O
DDI-DrugBank.d642.s1|0-9|Concurrent|O
DDI-DrugBank.d642.s1|11-13|use|O
DDI-DrugBank.d642.s1|15-16|of|O
DDI-DrugBank.d642.s1|18-36|antibacterial drugs|group
DDI-DrugBank.d642.s1|38-41|with|O
DDI-DrugBank.d642.s1|43-46|oral|O
DDI-DrugBank.d642.s1|48-61|contraceptives|group
DDI-DrugBank.d642.s1|63-65|may|O
DDI-DrugBank.d642.s1|67-72|render|O
DDI-DrugBank.d642.s1|74-77|oral|O
DDI-DrugBank.d642.s1|79-92|contraceptives|group
DDI-DrugBank.d642.s1|94-97|less|O
DDI-DrugBank.d642.s1|99-107|effective|O
DDI-DrugBank.d642.s1|108-108|.|O
DDI-DrugBank.d642.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d642.s2|16-19|Test|O
DDI-DrugBank.d642.s2|21-32|Interactions|O
DDI-DrugBank.d642.s2|35-39|There|O
DDI-DrugBank.d642.s2|41-43|are|O
DDI-DrugBank.d642.s2|45-46|no|O
DDI-DrugBank.d642.s2|48-55|reported|O
DDI-DrugBank.d642.s2|57-71|drug-laboratory|O
DDI-DrugBank.d642.s2|73-76|test|O
DDI-DrugBank.d642.s2|78-89|interactions|O
DDI-DrugBank.d642.s2|90-90|.|O
DDI-DrugBank.d426.s0|0-15|Ergot-containing|O
DDI-DrugBank.d426.s0|17-21|drugs|O
DDI-DrugBank.d426.s0|23-26|have|O
DDI-DrugBank.d426.s0|28-31|been|O
DDI-DrugBank.d426.s0|33-40|reported|O
DDI-DrugBank.d426.s0|42-43|to|O
DDI-DrugBank.d426.s0|45-49|cause|O
DDI-DrugBank.d426.s0|51-59|prolonged|O
DDI-DrugBank.d426.s0|61-71|vasospastic|O
DDI-DrugBank.d426.s0|73-81|reactions|O
DDI-DrugBank.d426.s0|82-82|.|O
DDI-DrugBank.d426.s1|0-2|Due|O
DDI-DrugBank.d426.s1|4-5|to|O
DDI-DrugBank.d426.s1|7-7|a|O
DDI-DrugBank.d426.s1|9-19|theoretical|O
DDI-DrugBank.d426.s1|21-24|risk|O
DDI-DrugBank.d426.s1|26-27|of|O
DDI-DrugBank.d426.s1|29-29|a|O
DDI-DrugBank.d426.s1|31-45|pharmacodynamic|O
DDI-DrugBank.d426.s1|47-57|interaction|O
DDI-DrugBank.d426.s1|58-58|,|O
DDI-DrugBank.d426.s1|60-62|use|O
DDI-DrugBank.d426.s1|64-65|of|O
DDI-DrugBank.d426.s1|67-87|ergotamine-containing|drug
DDI-DrugBank.d426.s1|89-90|or|O
DDI-DrugBank.d426.s1|92-113|ergot-type medications|group
DDI-DrugBank.d426.s1|115-115|(|O
DDI-DrugBank.d426.s1|116-119|like|O
DDI-DrugBank.d426.s1|121-137|dihydroergotamine|drug
DDI-DrugBank.d426.s1|139-140|or|O
DDI-DrugBank.d426.s1|142-153|methysergide|drug
DDI-DrugBank.d426.s1|154-154|)|O
DDI-DrugBank.d426.s1|156-158|and|O
DDI-DrugBank.d426.s1|160-164|FROVA|brand
DDI-DrugBank.d426.s1|166-171|within|O
DDI-DrugBank.d426.s1|173-174|24|O
DDI-DrugBank.d426.s1|176-180|hours|O
DDI-DrugBank.d426.s1|182-183|of|O
DDI-DrugBank.d426.s1|185-188|each|O
DDI-DrugBank.d426.s1|190-194|other|O
DDI-DrugBank.d426.s1|196-201|should|O
DDI-DrugBank.d426.s1|203-204|be|O
DDI-DrugBank.d426.s1|206-212|avoided|O
DDI-DrugBank.d426.s1|214-214|(|O
DDI-DrugBank.d426.s1|215-217|see|O
DDI-DrugBank.d426.s1|220-220|a|O
DDI-DrugBank.d426.s1|222-226|href=|O
DDI-DrugBank.d426.s1|228-239|frova_od.htm|O
DDI-DrugBank.d426.s1|240-240|#|O
DDI-DrugBank.d426.s1|241-242|CI|O
DDI-DrugBank.d426.s1|244-260|CONTRAINDICATIONS|O
DDI-DrugBank.d426.s1|261-261|)|O
DDI-DrugBank.d426.s1|262-262|.|O
DDI-DrugBank.d426.s2|0-10|Concomitant|O
DDI-DrugBank.d426.s2|12-14|use|O
DDI-DrugBank.d426.s2|16-17|of|O
DDI-DrugBank.d426.s2|19-23|other|O
DDI-DrugBank.d426.s2|25-33|5-HT1B/1D|O
DDI-DrugBank.d426.s2|35-42|agonists|O
DDI-DrugBank.d426.s2|44-49|within|O
DDI-DrugBank.d426.s2|51-52|24|O
DDI-DrugBank.d426.s2|54-58|hours|O
DDI-DrugBank.d426.s2|60-61|of|O
DDI-DrugBank.d426.s2|63-67|FROVA|brand
DDI-DrugBank.d426.s2|69-77|treatment|O
DDI-DrugBank.d426.s2|79-80|is|O
DDI-DrugBank.d426.s2|82-84|not|O
DDI-DrugBank.d426.s2|86-96|recommended|O
DDI-DrugBank.d426.s2|97-97|.|O
DDI-DrugBank.d426.s3|0-38|Selective serotonin reuptake inhibitors|group
DDI-DrugBank.d426.s3|40-40|(|O
DDI-DrugBank.d426.s3|41-45|SSRIs|group
DDI-DrugBank.d426.s3|46-46|)|O
DDI-DrugBank.d426.s3|48-48|(|O
DDI-DrugBank.d426.s3|49-52|e.g.|O
DDI-DrugBank.d426.s3|53-53|,|O
DDI-DrugBank.d426.s3|55-64|fluoxetine|drug
DDI-DrugBank.d426.s3|65-65|,|O
DDI-DrugBank.d426.s3|67-77|fluvoxamine|drug
DDI-DrugBank.d426.s3|78-78|,|O
DDI-DrugBank.d426.s3|80-89|paroxetine|drug
DDI-DrugBank.d426.s3|90-90|,|O
DDI-DrugBank.d426.s3|92-101|sertraline|drug
DDI-DrugBank.d426.s3|102-102|)|O
DDI-DrugBank.d426.s3|104-107|have|O
DDI-DrugBank.d426.s3|109-112|been|O
DDI-DrugBank.d426.s3|114-121|reported|O
DDI-DrugBank.d426.s3|122-122|,|O
DDI-DrugBank.d426.s3|124-129|rarely|O
DDI-DrugBank.d426.s3|130-130|,|O
DDI-DrugBank.d426.s3|132-133|to|O
DDI-DrugBank.d426.s3|135-139|cause|O
DDI-DrugBank.d426.s3|141-148|weakness|O
DDI-DrugBank.d426.s3|149-149|,|O
DDI-DrugBank.d426.s3|151-163|hyperreflexia|O
DDI-DrugBank.d426.s3|164-164|,|O
DDI-DrugBank.d426.s3|166-168|and|O
DDI-DrugBank.d426.s3|170-183|incoordination|O
DDI-DrugBank.d426.s3|185-188|when|O
DDI-DrugBank.d426.s3|190-203|coadministered|O
DDI-DrugBank.d426.s3|205-208|with|O
DDI-DrugBank.d426.s3|210-223|5-HT1 agonists|group
DDI-DrugBank.d426.s3|224-224|.|O
DDI-DrugBank.d426.s4|0-1|If|O
DDI-DrugBank.d426.s4|3-13|concomitant|O
DDI-DrugBank.d426.s4|15-23|treatment|O
DDI-DrugBank.d426.s4|25-28|with|O
DDI-DrugBank.d426.s4|30-41|frovatriptan|drug
DDI-DrugBank.d426.s4|43-45|and|O
DDI-DrugBank.d426.s4|47-48|an|O
DDI-DrugBank.d426.s4|50-53|SSRI|group
DDI-DrugBank.d426.s4|55-56|is|O
DDI-DrugBank.d426.s4|58-67|clinically|O
DDI-DrugBank.d426.s4|69-77|warranted|O
DDI-DrugBank.d426.s4|78-78|,|O
DDI-DrugBank.d426.s4|80-90|appropriate|O
DDI-DrugBank.d426.s4|92-102|observation|O
DDI-DrugBank.d426.s4|104-105|of|O
DDI-DrugBank.d426.s4|107-109|the|O
DDI-DrugBank.d426.s4|111-117|patient|O
DDI-DrugBank.d426.s4|119-120|is|O
DDI-DrugBank.d426.s4|122-128|advised|O
DDI-DrugBank.d426.s4|129-129|.|O
DDI-DrugBank.d426.s5|0-14|Drug/Laboratory|O
DDI-DrugBank.d426.s5|16-19|Test|O
DDI-DrugBank.d426.s5|21-32|Interactions|O
DDI-DrugBank.d426.s5|34-38|FROVA|brand
DDI-DrugBank.d426.s5|40-41|is|O
DDI-DrugBank.d426.s5|43-45|not|O
DDI-DrugBank.d426.s5|47-51|known|O
DDI-DrugBank.d426.s5|53-54|to|O
DDI-DrugBank.d426.s5|56-64|interfere|O
DDI-DrugBank.d426.s5|66-69|with|O
DDI-DrugBank.d426.s5|71-78|commonly|O
DDI-DrugBank.d426.s5|80-87|employed|O
DDI-DrugBank.d426.s5|89-96|clinical|O
DDI-DrugBank.d426.s5|98-107|laboratory|O
DDI-DrugBank.d426.s5|109-113|tests|O
DDI-DrugBank.d426.s5|114-114|.|O
DDI-MedLine.d30.s0|0-14|Stereoselective|O
DDI-MedLine.d30.s0|16-25|behavioral|O
DDI-MedLine.d30.s0|27-33|effects|O
DDI-MedLine.d30.s0|35-36|of|O
DDI-MedLine.d30.s0|59-60|in|O
DDI-MedLine.d30.s0|62-68|pigeons|O
DDI-MedLine.d30.s0|70-72|and|O
DDI-MedLine.d30.s0|74-81|squirrel|O
DDI-MedLine.d30.s0|83-89|monkeys|O
DDI-MedLine.d30.s0|90-90|.|O
DDI-MedLine.d30.s1|0-2|The|O
DDI-MedLine.d30.s1|4-13|behavioral|O
DDI-MedLine.d30.s1|15-21|effects|O
DDI-MedLine.d30.s1|23-24|of|O
DDI-MedLine.d30.s1|26-28|the|O
DDI-MedLine.d30.s1|30-42|stereoisomers|O
DDI-MedLine.d30.s1|44-45|of|O
DDI-MedLine.d30.s1|68-68|(|O
DDI-MedLine.d30.s1|73-73|)|O
DDI-MedLine.d30.s1|75-78|were|O
DDI-MedLine.d30.s1|80-87|compared|O
DDI-MedLine.d30.s1|89-92|with|O
DDI-MedLine.d30.s1|94-98|those|O
DDI-MedLine.d30.s1|100-101|of|O
DDI-MedLine.d30.s1|117-117|(|O
DDI-MedLine.d30.s1|121-121|)|O
DDI-MedLine.d30.s1|123-124|in|O
DDI-MedLine.d30.s1|126-132|pigeons|O
DDI-MedLine.d30.s1|134-136|and|O
DDI-MedLine.d30.s1|138-145|squirrel|O
DDI-MedLine.d30.s1|147-153|monkeys|O
DDI-MedLine.d30.s1|155-164|responding|O
DDI-MedLine.d30.s1|166-170|under|O
DDI-MedLine.d30.s1|172-172|a|O
DDI-MedLine.d30.s1|174-181|multiple|O
DDI-MedLine.d30.s1|183-196|fixed-interval|O
DDI-MedLine.d30.s1|198-208|fixed-ratio|O
DDI-MedLine.d30.s1|210-210|(|O
DDI-MedLine.d30.s1|211-212|FI|O
DDI-MedLine.d30.s1|214-215|FR|O
DDI-MedLine.d30.s1|216-216|)|O
DDI-MedLine.d30.s1|218-225|schedule|O
DDI-MedLine.d30.s1|227-228|of|O
DDI-MedLine.d30.s1|230-233|food|O
DDI-MedLine.d30.s1|235-246|presentation|O
DDI-MedLine.d30.s1|247-247|.|O
DDI-MedLine.d30.s2|0-11|Intermediate|O
DDI-MedLine.d30.s2|13-17|doses|O
DDI-MedLine.d30.s2|19-20|of|O
DDI-MedLine.d30.s2|31-32|or|O
DDI-MedLine.d30.s2|38-45|produced|O
DDI-MedLine.d30.s2|47-55|transient|O
DDI-MedLine.d30.s2|57-65|increases|O
DDI-MedLine.d30.s2|67-68|in|O
DDI-MedLine.d30.s2|70-71|FI|O
DDI-MedLine.d30.s2|73-82|responding|O
DDI-MedLine.d30.s2|84-85|in|O
DDI-MedLine.d30.s2|87-93|monkeys|O
DDI-MedLine.d30.s2|95-97|and|O
DDI-MedLine.d30.s2|99-107|sustained|O
DDI-MedLine.d30.s2|109-117|increases|O
DDI-MedLine.d30.s2|119-120|in|O
DDI-MedLine.d30.s2|122-123|FI|O
DDI-MedLine.d30.s2|125-134|responding|O
DDI-MedLine.d30.s2|136-137|in|O
DDI-MedLine.d30.s2|139-145|pigeons|O
DDI-MedLine.d30.s2|146-146|;|O
DDI-MedLine.d30.s3|0-5|higher|O
DDI-MedLine.d30.s3|7-11|doses|O
DDI-MedLine.d30.s3|13-21|decreased|O
DDI-MedLine.d30.s3|23-24|FI|O
DDI-MedLine.d30.s3|26-28|and|O
DDI-MedLine.d30.s3|30-31|FR|O
DDI-MedLine.d30.s3|33-42|responding|O
DDI-MedLine.d30.s3|44-45|in|O
DDI-MedLine.d30.s3|47-50|both|O
DDI-MedLine.d30.s3|52-58|species|O
DDI-MedLine.d30.s3|59-59|.|O
DDI-MedLine.d30.s4|0-1|In|O
DDI-MedLine.d30.s4|3-10|contrast|O
DDI-MedLine.d30.s4|12-13|to|O
DDI-MedLine.d30.s4|15-17|its|O
DDI-MedLine.d30.s4|19-28|enantiomer|O
DDI-MedLine.d30.s4|29-29|,|O
DDI-MedLine.d30.s4|40-45|failed|O
DDI-MedLine.d30.s4|47-48|to|O
DDI-MedLine.d30.s4|50-57|increase|O
DDI-MedLine.d30.s4|59-60|FI|O
DDI-MedLine.d30.s4|62-71|responding|O
DDI-MedLine.d30.s4|73-85|significantly|O
DDI-MedLine.d30.s4|87-88|in|O
DDI-MedLine.d30.s4|90-95|either|O
DDI-MedLine.d30.s4|97-103|species|O
DDI-MedLine.d30.s4|104-104|;|O
DDI-MedLine.d30.s5|0-1|at|O
DDI-MedLine.d30.s5|3-6|high|O
DDI-MedLine.d30.s5|8-12|doses|O
DDI-MedLine.d30.s5|13-13|,|O
DDI-MedLine.d30.s5|24-32|decreased|O
DDI-MedLine.d30.s5|34-35|FI|O
DDI-MedLine.d30.s5|37-39|and|O
DDI-MedLine.d30.s5|41-42|FR|O
DDI-MedLine.d30.s5|44-53|responding|O
DDI-MedLine.d30.s5|54-54|.|O
DDI-MedLine.d30.s6|0-1|In|O
DDI-MedLine.d30.s6|3-9|monkeys|O
DDI-MedLine.d30.s6|10-10|,|O
DDI-MedLine.d30.s6|21-23|was|O
DDI-MedLine.d30.s6|25-29|about|O
DDI-MedLine.d30.s6|31-32|10|O
DDI-MedLine.d30.s6|34-38|times|O
DDI-MedLine.d30.s6|40-43|more|O
DDI-MedLine.d30.s6|45-50|potent|O
DDI-MedLine.d30.s6|52-55|than|O
DDI-MedLine.d30.s6|66-67|in|O
DDI-MedLine.d30.s6|69-78|decreasing|O
DDI-MedLine.d30.s6|80-89|responding|O
DDI-MedLine.d30.s6|90-90|,|O
DDI-MedLine.d30.s6|92-98|whereas|O
DDI-MedLine.d30.s6|100-101|in|O
DDI-MedLine.d30.s6|103-109|pigeons|O
DDI-MedLine.d30.s6|120-122|was|O
DDI-MedLine.d30.s6|124-128|about|O
DDI-MedLine.d30.s6|130-139|equipotent|O
DDI-MedLine.d30.s6|141-144|with|O
DDI-MedLine.d30.s6|154-154|.|O
DDI-MedLine.d30.s7|0-1|In|O
DDI-MedLine.d30.s7|3-6|both|O
DDI-MedLine.d30.s7|8-14|species|O
DDI-MedLine.d30.s7|15-15|,|O
DDI-MedLine.d30.s7|25-25|,|O
DDI-MedLine.d30.s7|27-29|but|O
DDI-MedLine.d30.s7|31-33|not|O
DDI-MedLine.d30.s7|43-43|,|O
DDI-MedLine.d30.s7|45-55|antagonized|O
DDI-MedLine.d30.s7|57-59|the|O
DDI-MedLine.d30.s7|61-75|rate-decreasing|O
DDI-MedLine.d30.s7|77-83|effects|O
DDI-MedLine.d30.s7|85-86|of|O
DDI-MedLine.d30.s7|88-95|morphine|drug
DDI-MedLine.d30.s7|97-98|on|O
DDI-MedLine.d30.s7|100-101|FI|O
DDI-MedLine.d30.s7|103-105|and|O
DDI-MedLine.d30.s7|107-108|FR|O
DDI-MedLine.d30.s7|110-119|responding|O
DDI-MedLine.d30.s7|120-120|.|O
DDI-MedLine.d30.s8|0-1|In|O
DDI-MedLine.d30.s8|3-9|monkeys|O
DDI-MedLine.d30.s8|10-10|,|O
DDI-MedLine.d30.s8|12-14|the|O
DDI-MedLine.d30.s8|16-22|effects|O
DDI-MedLine.d30.s8|24-25|of|O
DDI-MedLine.d30.s8|35-35|,|O
DDI-MedLine.d30.s8|37-39|but|O
DDI-MedLine.d30.s8|41-43|not|O
DDI-MedLine.d30.s8|54-55|or|O
DDI-MedLine.d30.s8|60-60|,|O
DDI-MedLine.d30.s8|62-65|were|O
DDI-MedLine.d30.s8|67-77|antagonized|O
DDI-MedLine.d30.s8|79-80|by|O
DDI-MedLine.d30.s8|82-89|naloxone|drug
DDI-MedLine.d30.s8|90-90|;|O
DDI-MedLine.d30.s9|0-2|the|O
DDI-MedLine.d30.s9|4-8|doses|O
DDI-MedLine.d30.s9|10-11|of|O
DDI-MedLine.d30.s9|13-20|naloxone|drug
DDI-MedLine.d30.s9|22-29|required|O
DDI-MedLine.d30.s9|31-32|to|O
DDI-MedLine.d30.s9|34-43|antagonize|O
DDI-MedLine.d30.s9|45-47|the|O
DDI-MedLine.d30.s9|49-55|effects|O
DDI-MedLine.d30.s9|57-58|of|O
DDI-MedLine.d30.s9|69-72|were|O
DDI-MedLine.d30.s9|74-77|more|O
DDI-MedLine.d30.s9|79-82|than|O
DDI-MedLine.d30.s9|84-86|100|O
DDI-MedLine.d30.s9|88-92|times|O
DDI-MedLine.d30.s9|94-99|higher|O
DDI-MedLine.d30.s9|101-104|than|O
DDI-MedLine.d30.s9|106-110|those|O
DDI-MedLine.d30.s9|112-119|required|O
DDI-MedLine.d30.s9|121-122|to|O
DDI-MedLine.d30.s9|124-133|antagonize|O
DDI-MedLine.d30.s9|135-137|the|O
DDI-MedLine.d30.s9|139-145|effects|O
DDI-MedLine.d30.s9|147-148|of|O
DDI-MedLine.d30.s9|150-157|morphine|drug
DDI-MedLine.d30.s9|158-158|.|O
DDI-MedLine.d30.s10|0-1|In|O
DDI-MedLine.d30.s10|3-9|pigeons|O
DDI-MedLine.d30.s10|10-10|,|O
DDI-MedLine.d30.s10|12-19|naloxone|drug
DDI-MedLine.d30.s10|21-23|did|O
DDI-MedLine.d30.s10|25-27|not|O
DDI-MedLine.d30.s10|29-42|systematically|O
DDI-MedLine.d30.s10|44-48|alter|O
DDI-MedLine.d30.s10|50-52|the|O
DDI-MedLine.d30.s10|54-60|effects|O
DDI-MedLine.d30.s10|62-63|of|O
DDI-MedLine.d30.s10|73-73|,|O
DDI-MedLine.d30.s10|84-85|or|O
DDI-MedLine.d30.s10|90-90|.|O
DDI-MedLine.d30.s11|0-10|Haloperidol|drug
DDI-MedLine.d30.s11|12-18|reduced|O
DDI-MedLine.d30.s11|20-21|or|O
DDI-MedLine.d30.s11|23-32|eliminated|O
DDI-MedLine.d30.s11|34-36|the|O
DDI-MedLine.d30.s11|38-46|increases|O
DDI-MedLine.d30.s11|48-49|in|O
DDI-MedLine.d30.s11|51-52|FI|O
DDI-MedLine.d30.s11|54-63|responding|O
DDI-MedLine.d30.s11|65-72|produced|O
DDI-MedLine.d30.s11|74-75|by|O
DDI-MedLine.d30.s11|77-88|intermediate|O
DDI-MedLine.d30.s11|90-94|doses|O
DDI-MedLine.d30.s11|96-97|of|O
DDI-MedLine.d30.s11|99-104|either|O
DDI-MedLine.d30.s11|115-116|or|O
DDI-MedLine.d30.s11|122-123|in|O
DDI-MedLine.d30.s11|125-131|pigeons|O
DDI-MedLine.d30.s11|132-132|,|O
DDI-MedLine.d30.s11|134-136|but|O
DDI-MedLine.d30.s11|138-140|did|O
DDI-MedLine.d30.s11|142-144|not|O
DDI-MedLine.d30.s11|146-155|antagonize|O
DDI-MedLine.d30.s11|157-159|the|O
DDI-MedLine.d30.s11|161-169|decreases|O
DDI-MedLine.d30.s11|171-172|in|O
DDI-MedLine.d30.s11|174-175|FI|O
DDI-MedLine.d30.s11|177-178|or|O
DDI-MedLine.d30.s11|180-181|FR|O
DDI-MedLine.d30.s11|183-192|responding|O
DDI-MedLine.d30.s11|194-201|produced|O
DDI-MedLine.d30.s11|203-204|by|O
DDI-MedLine.d30.s11|206-209|high|O
DDI-MedLine.d30.s11|211-215|doses|O
DDI-MedLine.d30.s11|217-218|of|O
DDI-MedLine.d30.s11|220-222|PCP|O
DDI-MedLine.d30.s11|224-225|or|O
DDI-MedLine.d30.s11|227-232|either|O
DDI-MedLine.d30.s11|234-245|stereoisomer|O
DDI-MedLine.d30.s11|247-248|of|O
DDI-MedLine.d30.s11|254-254|.|O
DDI-MedLine.d30.s12|0-2|The|O
DDI-MedLine.d30.s12|4-10|results|O
DDI-MedLine.d30.s12|12-22|demonstrate|O
DDI-MedLine.d30.s12|24-24|a|O
DDI-MedLine.d30.s12|26-29|high|O
DDI-MedLine.d30.s12|31-36|degree|O
DDI-MedLine.d30.s12|38-39|of|O
DDI-MedLine.d30.s12|41-57|stereoselectivity|O
DDI-MedLine.d30.s12|59-60|in|O
DDI-MedLine.d30.s12|62-64|the|O
DDI-MedLine.d30.s12|66-75|behavioral|O
DDI-MedLine.d30.s12|77-83|effects|O
DDI-MedLine.d30.s12|85-86|of|O
DDI-MedLine.d30.s12|92-92|.|O
DDI-MedLine.d30.s13|0-2|The|O
DDI-MedLine.d30.s13|4-15|levorotatory|O
DDI-MedLine.d30.s13|17-22|isomer|O
DDI-MedLine.d30.s13|24-26|had|O
DDI-MedLine.d30.s13|28-44|opioid-antagonist|O
DDI-MedLine.d30.s13|46-48|and|O
DDI-MedLine.d30.s13|50-59|non-opioid|O
DDI-MedLine.d30.s13|61-67|agonist|O
DDI-MedLine.d30.s13|69-75|effects|O
DDI-MedLine.d30.s13|77-78|in|O
DDI-MedLine.d30.s13|80-86|pigeons|O
DDI-MedLine.d30.s13|88-90|and|O
DDI-MedLine.d30.s13|92-96|mixed|O
DDI-MedLine.d30.s13|98-103|opioid|O
DDI-MedLine.d30.s13|105-122|agonist-antagonist|O
DDI-MedLine.d30.s13|124-130|effects|O
DDI-MedLine.d30.s13|132-133|in|O
DDI-MedLine.d30.s13|135-141|monkeys|O
DDI-MedLine.d30.s13|142-142|.|O
DDI-MedLine.d30.s14|0-2|The|O
DDI-MedLine.d30.s14|4-17|dextrorotatory|O
DDI-MedLine.d30.s14|19-24|isomer|O
DDI-MedLine.d30.s14|25-25|,|O
DDI-MedLine.d30.s14|27-28|on|O
DDI-MedLine.d30.s14|30-32|the|O
DDI-MedLine.d30.s14|34-38|other|O
DDI-MedLine.d30.s14|40-43|hand|O
DDI-MedLine.d30.s14|44-44|,|O
DDI-MedLine.d30.s14|46-48|had|O
DDI-MedLine.d30.s14|50-56|effects|O
DDI-MedLine.d30.s14|58-64|similar|O
DDI-MedLine.d30.s14|66-67|to|O
DDI-MedLine.d30.s14|69-73|those|O
DDI-MedLine.d30.s14|75-76|of|O
DDI-MedLine.d30.s14|82-83|in|O
DDI-MedLine.d30.s14|85-88|both|O
DDI-MedLine.d30.s14|90-96|species|O
DDI-MedLine.d30.s14|97-97|.|O
DDI-MedLine.d121.s0|0-0|[|O
DDI-MedLine.d121.s0|1-11|Hippocampus|O
DDI-MedLine.d121.s0|13-14|as|O
DDI-MedLine.d121.s0|16-26|interaction|O
DDI-MedLine.d121.s0|28-32|sites|O
DDI-MedLine.d121.s0|34-40|between|O
DDI-MedLine.d121.s0|42-49|cerebral|O
DDI-MedLine.d121.s0|51-56|memory|O
DDI-MedLine.d121.s0|58-64|systems|O
DDI-MedLine.d121.s0|65-65|]|O
DDI-MedLine.d121.s0|67-70|Most|O
DDI-MedLine.d121.s0|72-73|of|O
DDI-MedLine.d121.s0|75-77|the|O
DDI-MedLine.d121.s0|79-85|current|O
DDI-MedLine.d121.s0|87-94|theories|O
DDI-MedLine.d121.s0|96-101|assume|O
DDI-MedLine.d121.s0|103-106|that|O
DDI-MedLine.d121.s0|108-112|there|O
DDI-MedLine.d121.s0|114-116|are|O
DDI-MedLine.d121.s0|118-125|multiple|O
DDI-MedLine.d121.s0|127-131|forms|O
DDI-MedLine.d121.s0|133-134|of|O
DDI-MedLine.d121.s0|136-141|memory|O
DDI-MedLine.d121.s0|143-146|that|O
DDI-MedLine.d121.s0|148-150|are|O
DDI-MedLine.d121.s0|152-160|supported|O
DDI-MedLine.d121.s0|162-163|by|O
DDI-MedLine.d121.s0|165-172|separate|O
DDI-MedLine.d121.s0|174-178|brain|O
DDI-MedLine.d121.s0|180-186|systems|O
DDI-MedLine.d121.s0|188-190|and|O
DDI-MedLine.d121.s0|192-195|have|O
DDI-MedLine.d121.s0|197-205|different|O
DDI-MedLine.d121.s0|207-221|characteristics|O
DDI-MedLine.d121.s0|222-222|.|O
DDI-MedLine.d121.s1|0-6|Animals|O
DDI-MedLine.d121.s1|8-14|studies|O
DDI-MedLine.d121.s1|16-17|on|O
DDI-MedLine.d121.s1|19-21|the|O
DDI-MedLine.d121.s1|23-29|various|O
DDI-MedLine.d121.s1|31-41|dual-memory|O
DDI-MedLine.d121.s1|43-50|theories|O
DDI-MedLine.d121.s1|52-55|have|O
DDI-MedLine.d121.s1|57-60|been|O
DDI-MedLine.d121.s1|62-68|carried|O
DDI-MedLine.d121.s1|70-72|out|O
DDI-MedLine.d121.s1|74-79|mainly|O
DDI-MedLine.d121.s1|81-82|on|O
DDI-MedLine.d121.s1|84-86|the|O
DDI-MedLine.d121.s1|88-92|basis|O
DDI-MedLine.d121.s1|94-95|of|O
DDI-MedLine.d121.s1|97-107|hippocampal|O
DDI-MedLine.d121.s1|109-114|system|O
DDI-MedLine.d121.s1|116-123|function|O
DDI-MedLine.d121.s1|124-124|.|O
DDI-MedLine.d121.s2|0-11|Specifically|O
DDI-MedLine.d121.s2|12-12|,|O
DDI-MedLine.d121.s2|14-17|they|O
DDI-MedLine.d121.s2|19-22|have|O
DDI-MedLine.d121.s2|24-30|focused|O
DDI-MedLine.d121.s2|32-33|on|O
DDI-MedLine.d121.s2|35-41|aspects|O
DDI-MedLine.d121.s2|43-44|of|O
DDI-MedLine.d121.s2|46-53|learning|O
DDI-MedLine.d121.s2|55-57|and|O
DDI-MedLine.d121.s2|59-64|memory|O
DDI-MedLine.d121.s2|66-69|that|O
DDI-MedLine.d121.s2|71-73|are|O
DDI-MedLine.d121.s2|75-82|impaired|O
DDI-MedLine.d121.s2|84-84|(|O
DDI-MedLine.d121.s2|85-87|vs.|O
DDI-MedLine.d121.s2|89-94|spared|O
DDI-MedLine.d121.s2|95-95|)|O
DDI-MedLine.d121.s2|97-98|by|O
DDI-MedLine.d121.s2|100-106|lesions|O
DDI-MedLine.d121.s2|108-109|of|O
DDI-MedLine.d121.s2|111-113|the|O
DDI-MedLine.d121.s2|115-125|hippocampal|O
DDI-MedLine.d121.s2|127-135|formation|O
DDI-MedLine.d121.s2|136-136|.|O
DDI-MedLine.d121.s3|0-6|However|O
DDI-MedLine.d121.s3|7-7|,|O
DDI-MedLine.d121.s3|9-13|there|O
DDI-MedLine.d121.s3|15-17|are|O
DDI-MedLine.d121.s3|19-25|several|O
DDI-MedLine.d121.s3|27-35|instances|O
DDI-MedLine.d121.s3|37-38|in|O
DDI-MedLine.d121.s3|40-42|the|O
DDI-MedLine.d121.s3|44-49|animal|O
DDI-MedLine.d121.s3|51-60|literature|O
DDI-MedLine.d121.s3|62-68|showing|O
DDI-MedLine.d121.s3|70-73|that|O
DDI-MedLine.d121.s3|75-85|hippocampal|O
DDI-MedLine.d121.s3|87-93|lesions|O
DDI-MedLine.d121.s3|95-102|actually|O
DDI-MedLine.d121.s3|104-111|produced|O
DDI-MedLine.d121.s3|113-120|enhanced|O
DDI-MedLine.d121.s3|122-129|learning|O
DDI-MedLine.d121.s3|131-133|and|O
DDI-MedLine.d121.s3|135-140|memory|O
DDI-MedLine.d121.s3|142-149|function|O
DDI-MedLine.d121.s3|150-150|.|O
DDI-MedLine.d121.s4|0-7|Moreover|O
DDI-MedLine.d121.s4|8-8|,|O
DDI-MedLine.d121.s4|10-12|the|O
DDI-MedLine.d121.s4|14-24|acquisition|O
DDI-MedLine.d121.s4|26-27|of|O
DDI-MedLine.d121.s4|29-33|tasks|O
DDI-MedLine.d121.s4|35-38|that|O
DDI-MedLine.d121.s4|40-42|are|O
DDI-MedLine.d121.s4|44-54|facilitated|O
DDI-MedLine.d121.s4|56-57|by|O
DDI-MedLine.d121.s4|59-69|hippocampal|O
DDI-MedLine.d121.s4|71-77|lesions|O
DDI-MedLine.d121.s4|79-79|(|O
DDI-MedLine.d121.s4|80-81|or|O
DDI-MedLine.d121.s4|83-93|dysfunction|O
DDI-MedLine.d121.s4|94-94|)|O
DDI-MedLine.d121.s4|96-97|is|O
DDI-MedLine.d121.s4|99-110|nevertheless|O
DDI-MedLine.d121.s4|112-121|associated|O
DDI-MedLine.d121.s4|122-122|,|O
DDI-MedLine.d121.s4|124-125|in|O
DDI-MedLine.d121.s4|127-132|intact|O
DDI-MedLine.d121.s4|134-141|subjects|O
DDI-MedLine.d121.s4|142-142|,|O
DDI-MedLine.d121.s4|144-147|with|O
DDI-MedLine.d121.s4|149-156|specific|O
DDI-MedLine.d121.s4|158-172|neurobiological|O
DDI-MedLine.d121.s4|174-184|alterations|O
DDI-MedLine.d121.s4|186-187|in|O
DDI-MedLine.d121.s4|189-191|the|O
DDI-MedLine.d121.s4|193-203|hippocampus|O
DDI-MedLine.d121.s4|204-204|.|O
DDI-MedLine.d121.s5|0-3|This|O
DDI-MedLine.d121.s5|5-11|problem|O
DDI-MedLine.d121.s5|13-15|has|O
DDI-MedLine.d121.s5|17-20|been|O
DDI-MedLine.d121.s5|22-29|analysed|O
DDI-MedLine.d121.s5|31-35|using|O
DDI-MedLine.d121.s5|37-39|two|O
DDI-MedLine.d121.s5|41-49|different|O
DDI-MedLine.d121.s5|51-55|tasks|O
DDI-MedLine.d121.s5|57-58|in|O
DDI-MedLine.d121.s5|60-63|mice|O
DDI-MedLine.d121.s5|64-64|:|O
DDI-MedLine.d121.s5|66-66|a|O
DDI-MedLine.d121.s5|68-76|bar-press|O
DDI-MedLine.d121.s5|78-89|conditioning|O
DDI-MedLine.d121.s5|91-93|and|O
DDI-MedLine.d121.s5|95-95|a|O
DDI-MedLine.d121.s5|97-103|spatial|O
DDI-MedLine.d121.s5|105-118|discrimination|O
DDI-MedLine.d121.s5|120-123|task|O
DDI-MedLine.d121.s5|124-124|.|O
DDI-MedLine.d121.s6|0-6|Results|O
DDI-MedLine.d121.s6|8-13|showed|O
DDI-MedLine.d121.s6|15-18|that|O
DDI-MedLine.d121.s6|19-19|,|O
DDI-MedLine.d121.s6|21-29|depending|O
DDI-MedLine.d121.s6|31-32|on|O
DDI-MedLine.d121.s6|34-36|the|O
DDI-MedLine.d121.s6|38-41|task|O
DDI-MedLine.d121.s6|43-52|considered|O
DDI-MedLine.d121.s6|53-53|,|O
DDI-MedLine.d121.s6|55-57|the|O
DDI-MedLine.d121.s6|59-62|same|O
DDI-MedLine.d121.s6|64-78|pharmacological|O
DDI-MedLine.d121.s6|80-88|treatment|O
DDI-MedLine.d121.s6|90-97|produced|O
DDI-MedLine.d121.s6|99-104|either|O
DDI-MedLine.d121.s6|106-106|a|O
DDI-MedLine.d121.s6|108-119|facilitation|O
DDI-MedLine.d121.s6|121-122|or|O
DDI-MedLine.d121.s6|124-125|an|O
DDI-MedLine.d121.s6|127-136|impairment|O
DDI-MedLine.d121.s6|138-139|of|O
DDI-MedLine.d121.s6|141-151|acquisition|O
DDI-MedLine.d121.s6|152-152|.|O
DDI-MedLine.d121.s7|0-7|Moreover|O
DDI-MedLine.d121.s7|8-8|,|O
DDI-MedLine.d121.s7|10-13|each|O
DDI-MedLine.d121.s7|15-18|task|O
DDI-MedLine.d121.s7|20-26|induced|O
DDI-MedLine.d121.s7|28-38|significant|O
DDI-MedLine.d121.s7|40-50|alterations|O
DDI-MedLine.d121.s7|52-53|in|O
DDI-MedLine.d121.s7|55-65|hippocampal|O
DDI-MedLine.d121.s7|67-75|adenylate|O
DDI-MedLine.d121.s7|77-83|cyclase|O
DDI-MedLine.d121.s7|85-92|activity|O
DDI-MedLine.d121.s7|94-96|but|O
DDI-MedLine.d121.s7|98-99|in|O
DDI-MedLine.d121.s7|101-108|opposite|O
DDI-MedLine.d121.s7|110-119|directions|O
DDI-MedLine.d121.s7|120-120|.|O
DDI-MedLine.d121.s8|0-7|Together|O
DDI-MedLine.d121.s8|9-12|with|O
DDI-MedLine.d121.s8|14-21|previous|O
DDI-MedLine.d121.s8|23-30|findings|O
DDI-MedLine.d121.s8|31-31|,|O
DDI-MedLine.d121.s8|33-37|these|O
DDI-MedLine.d121.s8|39-45|results|O
DDI-MedLine.d121.s8|47-53|suggest|O
DDI-MedLine.d121.s8|55-58|that|O
DDI-MedLine.d121.s8|60-62|the|O
DDI-MedLine.d121.s8|64-74|hippocampus|O
DDI-MedLine.d121.s8|76-77|is|O
DDI-MedLine.d121.s8|79-86|involved|O
DDI-MedLine.d121.s8|88-89|in|O
DDI-MedLine.d121.s8|91-94|both|O
DDI-MedLine.d121.s8|96-98|the|O
DDI-MedLine.d121.s8|100-108|so-called|O
DDI-MedLine.d121.s8|110-110|"|O
DDI-MedLine.d121.s8|111-131|hippocampal-dependent|O
DDI-MedLine.d121.s8|132-132|"|O
DDI-MedLine.d121.s9|0-0|"|O
DDI-MedLine.d121.s9|1-23|hippocampal-independent|O
DDI-MedLine.d121.s9|24-24|"|O
DDI-MedLine.d121.s10|0-4|forms|O
DDI-MedLine.d121.s10|6-7|of|O
DDI-MedLine.d121.s10|9-14|memory|O
DDI-MedLine.d121.s10|15-15|.|O
DDI-MedLine.d121.s11|0-1|It|O
DDI-MedLine.d121.s11|3-4|is|O
DDI-MedLine.d121.s11|6-15|postulated|O
DDI-MedLine.d121.s11|17-20|that|O
DDI-MedLine.d121.s11|22-25|some|O
DDI-MedLine.d121.s11|27-28|of|O
DDI-MedLine.d121.s11|30-32|the|O
DDI-MedLine.d121.s11|34-41|observed|O
DDI-MedLine.d121.s11|43-58|training-induced|O
DDI-MedLine.d121.s11|60-74|neurobiological|O
DDI-MedLine.d121.s11|76-86|alterations|O
DDI-MedLine.d121.s11|88-92|might|O
DDI-MedLine.d121.s11|94-100|reflect|O
DDI-MedLine.d121.s11|102-104|the|O
DDI-MedLine.d121.s11|106-116|interaction|O
DDI-MedLine.d121.s11|118-124|between|O
DDI-MedLine.d121.s11|126-128|two|O
DDI-MedLine.d121.s11|130-130|(|O
DDI-MedLine.d121.s11|131-132|or|O
DDI-MedLine.d121.s11|134-137|more|O
DDI-MedLine.d121.s11|138-138|)|O
DDI-MedLine.d121.s11|140-148|competing|O
DDI-MedLine.d121.s11|150-155|memory|O
DDI-MedLine.d121.s11|157-163|systems|O
DDI-MedLine.d121.s11|165-166|at|O
DDI-MedLine.d121.s11|168-170|the|O
DDI-MedLine.d121.s11|172-182|hippocampal|O
DDI-MedLine.d121.s11|184-188|level|O
DDI-MedLine.d121.s11|189-189|.|O
DDI-MedLine.d121.s12|0-3|Thus|O
DDI-MedLine.d121.s12|4-4|,|O
DDI-MedLine.d121.s12|6-7|in|O
DDI-MedLine.d121.s12|9-16|addition|O
DDI-MedLine.d121.s12|18-19|to|O
DDI-MedLine.d121.s12|21-23|its|O
DDI-MedLine.d121.s12|25-32|proposed|O
DDI-MedLine.d121.s12|34-41|specific|O
DDI-MedLine.d121.s12|43-53|information|O
DDI-MedLine.d121.s12|55-64|processing|O
DDI-MedLine.d121.s12|66-74|functions|O
DDI-MedLine.d121.s12|76-76|(|O
DDI-MedLine.d121.s12|77-80|i.e.|O
DDI-MedLine.d121.s12|81-81|,|O
DDI-MedLine.d121.s12|83-92|relational|O
DDI-MedLine.d121.s12|93-93|)|O
DDI-MedLine.d121.s12|94-94|,|O
DDI-MedLine.d121.s12|96-98|the|O
DDI-MedLine.d121.s12|100-110|hippocampus|O
DDI-MedLine.d121.s12|112-116|would|O
DDI-MedLine.d121.s12|118-121|play|O
DDI-MedLine.d121.s12|123-123|a|O
DDI-MedLine.d121.s12|125-128|role|O
DDI-MedLine.d121.s12|130-131|in|O
DDI-MedLine.d121.s12|133-142|addressing|O
DDI-MedLine.d121.s12|144-154|information|O
DDI-MedLine.d121.s12|156-157|to|O
DDI-MedLine.d121.s12|159-161|the|O
DDI-MedLine.d121.s12|163-167|brain|O
DDI-MedLine.d121.s12|169-174|memory|O
DDI-MedLine.d121.s12|176-181|system|O
DDI-MedLine.d121.s12|183-186|that|O
DDI-MedLine.d121.s12|187-187|,|O
DDI-MedLine.d121.s12|189-190|in|O
DDI-MedLine.d121.s12|192-192|a|O
DDI-MedLine.d121.s12|194-198|given|O
DDI-MedLine.d121.s12|200-208|situation|O
DDI-MedLine.d121.s12|209-209|,|O
DDI-MedLine.d121.s12|211-213|has|O
DDI-MedLine.d121.s12|215-217|the|O
DDI-MedLine.d121.s12|219-222|best|O
DDI-MedLine.d121.s12|224-231|adaptive|O
DDI-MedLine.d121.s12|233-238|value.|O
DDI-MedLine.d121.s12|239-239|(|O
DDI-MedLine.d121.s12|240-247|ABSTRACT|O
DDI-MedLine.d121.s12|249-257|TRUNCATED|O
DDI-MedLine.d121.s12|259-260|AT|O
DDI-MedLine.d121.s12|262-264|250|O
DDI-MedLine.d121.s12|266-270|WORDS|O
DDI-MedLine.d121.s12|271-271|)|O
DDI-DrugBank.d56.s0|0-5|Taking|O
DDI-DrugBank.d56.s0|7-18|amyl nitrite|drug
DDI-DrugBank.d56.s0|20-24|after|O
DDI-DrugBank.d56.s0|26-33|drinking|O
DDI-DrugBank.d56.s0|35-41|alcohol|drug
DDI-DrugBank.d56.s0|43-45|may|O
DDI-DrugBank.d56.s0|47-52|worsen|O
DDI-DrugBank.d56.s0|54-57|side|O
DDI-DrugBank.d56.s0|59-65|effects|O
DDI-DrugBank.d56.s0|67-69|and|O
DDI-DrugBank.d56.s0|71-73|may|O
DDI-DrugBank.d56.s0|75-79|cause|O
DDI-DrugBank.d56.s0|81-86|severe|O
DDI-DrugBank.d56.s0|88-98|hypotension|O
DDI-DrugBank.d56.s0|100-102|and|O
DDI-DrugBank.d56.s0|104-117|cardiovascular|O
DDI-DrugBank.d56.s0|119-126|collapse|O
DDI-DrugBank.d56.s0|127-127|.|O
DDI-DrugBank.d532.s0|0-5|Formal|O
DDI-DrugBank.d532.s0|7-10|drug|O
DDI-DrugBank.d532.s0|12-22|interaction|O
DDI-DrugBank.d532.s0|24-30|studies|O
DDI-DrugBank.d532.s0|32-35|with|O
DDI-DrugBank.d532.s0|37-45|Abciximab|drug
DDI-DrugBank.d532.s0|47-50|have|O
DDI-DrugBank.d532.s0|52-54|not|O
DDI-DrugBank.d532.s0|56-59|been|O
DDI-DrugBank.d532.s0|61-69|conducted|O
DDI-DrugBank.d532.s0|70-70|.|O
DDI-DrugBank.d532.s1|0-8|Abciximab|drug
DDI-DrugBank.d532.s1|10-12|has|O
DDI-DrugBank.d532.s1|14-17|been|O
DDI-DrugBank.d532.s1|19-30|administered|O
DDI-DrugBank.d532.s1|32-33|to|O
DDI-DrugBank.d532.s1|35-42|patients|O
DDI-DrugBank.d532.s1|44-47|with|O
DDI-DrugBank.d532.s1|49-56|ischemic|O
DDI-DrugBank.d532.s1|58-62|heart|O
DDI-DrugBank.d532.s1|64-70|disease|O
DDI-DrugBank.d532.s1|72-78|treated|O
DDI-DrugBank.d532.s1|80-92|concomitantly|O
DDI-DrugBank.d532.s1|94-97|with|O
DDI-DrugBank.d532.s1|99-99|a|O
DDI-DrugBank.d532.s1|101-105|broad|O
DDI-DrugBank.d532.s1|107-111|range|O
DDI-DrugBank.d532.s1|113-114|of|O
DDI-DrugBank.d532.s1|116-126|medications|O
DDI-DrugBank.d532.s1|128-131|used|O
DDI-DrugBank.d532.s1|133-134|in|O
DDI-DrugBank.d532.s1|136-138|the|O
DDI-DrugBank.d532.s1|140-148|treatment|O
DDI-DrugBank.d532.s1|150-151|of|O
DDI-DrugBank.d532.s1|153-158|angina|O
DDI-DrugBank.d532.s1|160-169|myocardial|O
DDI-DrugBank.d532.s1|171-180|infarction|O
DDI-DrugBank.d532.s1|182-184|and|O
DDI-DrugBank.d532.s1|186-197|hypertension|O
DDI-DrugBank.d532.s1|198-198|.|O
DDI-DrugBank.d532.s2|0-4|These|O
DDI-DrugBank.d532.s2|6-16|medications|O
DDI-DrugBank.d532.s2|18-21|have|O
DDI-DrugBank.d532.s2|23-30|included|O
DDI-DrugBank.d532.s2|32-38|heparin|drug
DDI-DrugBank.d532.s2|39-39|,|O
DDI-DrugBank.d532.s2|41-48|warfarin|drug
DDI-DrugBank.d532.s2|49-49|,|O
DDI-DrugBank.d532.s2|51-83|beta-adrenergic receptor blockers|group
DDI-DrugBank.d532.s2|84-84|,|O
DDI-DrugBank.d532.s2|86-112|calcium channel antagonists|group
DDI-DrugBank.d532.s2|113-113|,|O
DDI-DrugBank.d532.s2|115-154|angiotensin converting enzyme inhibitors|group
DDI-DrugBank.d532.s2|155-155|,|O
DDI-DrugBank.d532.s2|157-167|intravenous|O
DDI-DrugBank.d532.s2|169-171|and|O
DDI-DrugBank.d532.s2|173-176|oral|O
DDI-DrugBank.d532.s2|178-185|nitrates|group
DDI-DrugBank.d532.s2|186-186|,|O
DDI-DrugBank.d532.s2|188-198|ticlopidine|drug
DDI-DrugBank.d532.s2|199-199|,|O
DDI-DrugBank.d532.s2|201-203|and|O
DDI-DrugBank.d532.s2|205-211|aspirin|brand
DDI-DrugBank.d532.s2|212-212|.|O
DDI-DrugBank.d532.s3|0-6|Heparin|drug
DDI-DrugBank.d532.s3|7-7|,|O
DDI-DrugBank.d532.s3|9-13|other|O
DDI-DrugBank.d532.s3|15-28|anticoagulants|group
DDI-DrugBank.d532.s3|29-29|,|O
DDI-DrugBank.d532.s3|31-43|thrombolytics|group
DDI-DrugBank.d532.s3|44-44|,|O
DDI-DrugBank.d532.s3|46-48|and|O
DDI-DrugBank.d532.s3|50-69|anti platelet agents|group
DDI-DrugBank.d532.s3|71-73|are|O
DDI-DrugBank.d532.s3|75-84|associated|O
DDI-DrugBank.d532.s3|86-89|with|O
DDI-DrugBank.d532.s3|91-92|an|O
DDI-DrugBank.d532.s3|94-101|increase|O
DDI-DrugBank.d532.s3|103-104|in|O
DDI-DrugBank.d532.s3|106-113|bleeding|O
DDI-DrugBank.d532.s3|114-114|.|O
DDI-DrugBank.d532.s4|0-7|Patients|O
DDI-DrugBank.d532.s4|9-12|with|O
DDI-DrugBank.d532.s4|14-17|HACA|O
DDI-DrugBank.d532.s4|19-24|titers|O
DDI-DrugBank.d532.s4|26-28|may|O
DDI-DrugBank.d532.s4|30-33|have|O
DDI-DrugBank.d532.s4|35-42|allergic|O
DDI-DrugBank.d532.s4|44-45|or|O
DDI-DrugBank.d532.s4|47-62|hypersensitivity|O
DDI-DrugBank.d532.s4|64-72|reactions|O
DDI-DrugBank.d532.s4|74-77|when|O
DDI-DrugBank.d532.s4|79-85|treated|O
DDI-DrugBank.d532.s4|87-90|with|O
DDI-DrugBank.d532.s4|92-96|other|O
DDI-DrugBank.d532.s4|98-107|diagnostic|group
DDI-DrugBank.d532.s4|109-110|or|O
DDI-DrugBank.d532.s4|112-144|therapeutic monoclonal antibodies|group
DDI-DrugBank.d532.s4|145-145|.|O
DDI-DrugBank.d216.s0|0-9|CNS-Active|O
DDI-DrugBank.d216.s0|11-15|Drugs|O
DDI-DrugBank.d216.s0|17-23|Ethanol|drug
DDI-DrugBank.d216.s0|25-26|An|O
DDI-DrugBank.d216.s0|28-35|additive|O
DDI-DrugBank.d216.s0|37-42|effect|O
DDI-DrugBank.d216.s0|44-45|on|O
DDI-DrugBank.d216.s0|47-57|psychomotor|O
DDI-DrugBank.d216.s0|59-69|performance|O
DDI-DrugBank.d216.s0|71-73|was|O
DDI-DrugBank.d216.s0|75-78|seen|O
DDI-DrugBank.d216.s0|80-83|with|O
DDI-DrugBank.d216.s0|85-100|coadministration|O
DDI-DrugBank.d216.s0|102-103|of|O
DDI-DrugBank.d216.s0|105-115|eszopiclone|drug
DDI-DrugBank.d216.s0|117-119|and|O
DDI-DrugBank.d216.s0|121-127|ethanol|drug
DDI-DrugBank.d216.s0|129-132|0.70|O
DDI-DrugBank.d216.s0|134-137|g/kg|O
DDI-DrugBank.d216.s0|139-141|for|O
DDI-DrugBank.d216.s0|143-144|up|O
DDI-DrugBank.d216.s0|146-147|to|O
DDI-DrugBank.d216.s0|149-149|4|O
DDI-DrugBank.d216.s0|151-155|hours|O
DDI-DrugBank.d216.s0|157-161|after|O
DDI-DrugBank.d216.s0|163-169|ethanol|drug
DDI-DrugBank.d216.s0|171-184|administration|O
DDI-DrugBank.d216.s0|185-185|.|O
DDI-DrugBank.d216.s1|0-9|Paroxetine|drug
DDI-DrugBank.d216.s1|10-10|:|O
DDI-DrugBank.d216.s1|12-27|Coadministration|O
DDI-DrugBank.d216.s1|29-30|of|O
DDI-DrugBank.d216.s1|32-37|single|O
DDI-DrugBank.d216.s1|39-43|doses|O
DDI-DrugBank.d216.s1|45-46|of|O
DDI-DrugBank.d216.s1|48-58|eszopiclone|drug
DDI-DrugBank.d216.s1|60-60|3|O
DDI-DrugBank.d216.s1|62-63|mg|O
DDI-DrugBank.d216.s1|65-67|and|O
DDI-DrugBank.d216.s1|69-78|paroxetine|drug
DDI-DrugBank.d216.s1|80-81|20|O
DDI-DrugBank.d216.s1|83-84|mg|O
DDI-DrugBank.d216.s1|86-90|daily|O
DDI-DrugBank.d216.s1|92-94|for|O
DDI-DrugBank.d216.s1|96-96|7|O
DDI-DrugBank.d216.s1|98-101|days|O
DDI-DrugBank.d216.s1|103-110|produced|O
DDI-DrugBank.d216.s1|112-113|no|O
DDI-DrugBank.d216.s1|115-129|pharmacokinetic|O
DDI-DrugBank.d216.s1|131-132|or|O
DDI-DrugBank.d216.s1|134-148|pharmacodynamic|O
DDI-DrugBank.d216.s1|150-160|interaction|O
DDI-DrugBank.d216.s1|161-161|.|O
DDI-DrugBank.d216.s2|0-8|Lorazepam|drug
DDI-DrugBank.d216.s2|9-9|:|O
DDI-DrugBank.d216.s2|11-26|Coadministration|O
DDI-DrugBank.d216.s2|28-29|of|O
DDI-DrugBank.d216.s2|31-36|single|O
DDI-DrugBank.d216.s2|38-42|doses|O
DDI-DrugBank.d216.s2|44-45|of|O
DDI-DrugBank.d216.s2|47-57|eszopiclone|drug
DDI-DrugBank.d216.s2|59-59|3|O
DDI-DrugBank.d216.s2|61-62|mg|O
DDI-DrugBank.d216.s2|64-66|and|O
DDI-DrugBank.d216.s2|68-76|lorazepam|drug
DDI-DrugBank.d216.s2|78-78|2|O
DDI-DrugBank.d216.s2|80-81|mg|O
DDI-DrugBank.d216.s2|83-85|did|O
DDI-DrugBank.d216.s2|87-89|not|O
DDI-DrugBank.d216.s2|91-94|have|O
DDI-DrugBank.d216.s2|96-105|clinically|O
DDI-DrugBank.d216.s2|107-114|relevant|O
DDI-DrugBank.d216.s2|116-122|effects|O
DDI-DrugBank.d216.s2|124-125|on|O
DDI-DrugBank.d216.s2|127-129|the|O
DDI-DrugBank.d216.s2|131-146|pharmacodynamics|O
DDI-DrugBank.d216.s2|148-149|or|O
DDI-DrugBank.d216.s2|151-166|pharmacokinetics|O
DDI-DrugBank.d216.s2|168-169|of|O
DDI-DrugBank.d216.s2|171-176|either|O
DDI-DrugBank.d216.s2|178-181|drug|O
DDI-DrugBank.d216.s2|182-182|.|O
DDI-DrugBank.d216.s3|0-9|Olanzapine|drug
DDI-DrugBank.d216.s3|10-10|:|O
DDI-DrugBank.d216.s3|12-27|Coadministration|O
DDI-DrugBank.d216.s3|29-30|of|O
DDI-DrugBank.d216.s3|32-42|eszopiclone|drug
DDI-DrugBank.d216.s3|44-44|3|O
DDI-DrugBank.d216.s3|46-47|mg|O
DDI-DrugBank.d216.s3|49-51|and|O
DDI-DrugBank.d216.s3|53-62|olanzapine|drug
DDI-DrugBank.d216.s3|64-65|10|O
DDI-DrugBank.d216.s3|67-68|mg|O
DDI-DrugBank.d216.s3|70-77|produced|O
DDI-DrugBank.d216.s3|79-79|a|O
DDI-DrugBank.d216.s3|81-88|decrease|O
DDI-DrugBank.d216.s3|90-91|in|O
DDI-DrugBank.d216.s3|93-96|DSST|O
DDI-DrugBank.d216.s3|98-103|scores|O
DDI-DrugBank.d216.s3|104-104|.|O
DDI-DrugBank.d216.s4|0-2|The|O
DDI-DrugBank.d216.s4|4-14|interaction|O
DDI-DrugBank.d216.s4|16-18|was|O
DDI-DrugBank.d216.s4|20-34|pharmacodynamic|O
DDI-DrugBank.d216.s4|35-35|;|O
DDI-DrugBank.d216.s5|0-4|there|O
DDI-DrugBank.d216.s5|6-8|was|O
DDI-DrugBank.d216.s5|10-11|no|O
DDI-DrugBank.d216.s5|13-22|alteration|O
DDI-DrugBank.d216.s5|24-25|in|O
DDI-DrugBank.d216.s5|27-29|the|O
DDI-DrugBank.d216.s5|31-46|pharmacokinetics|O
DDI-DrugBank.d216.s5|48-49|of|O
DDI-DrugBank.d216.s5|51-56|either|O
DDI-DrugBank.d216.s5|58-61|drug|O
DDI-DrugBank.d216.s5|62-62|.|O
DDI-DrugBank.d216.s6|0-4|Drugs|O
DDI-DrugBank.d216.s6|6-9|That|O
DDI-DrugBank.d216.s6|11-17|Inhibit|O
DDI-DrugBank.d216.s6|19-24|CYP3A4|O
DDI-DrugBank.d216.s6|26-26|(|O
DDI-DrugBank.d216.s6|27-38|Ketoconazole|drug
DDI-DrugBank.d216.s6|39-39|)|O
DDI-DrugBank.d216.s6|41-46|CYP3A4|O
DDI-DrugBank.d216.s6|48-49|is|O
DDI-DrugBank.d216.s6|51-51|a|O
DDI-DrugBank.d216.s6|53-57|major|O
DDI-DrugBank.d216.s6|59-67|metabolic|O
DDI-DrugBank.d216.s6|69-75|pathway|O
DDI-DrugBank.d216.s6|77-79|for|O
DDI-DrugBank.d216.s6|81-91|elimination|O
DDI-DrugBank.d216.s6|93-94|of|O
DDI-DrugBank.d216.s6|96-106|eszopiclone|drug
DDI-DrugBank.d216.s6|107-107|.|O
DDI-DrugBank.d216.s7|0-2|The|O
DDI-DrugBank.d216.s7|4-6|AUC|O
DDI-DrugBank.d216.s7|8-9|of|O
DDI-DrugBank.d216.s7|11-21|eszopiclone|drug
DDI-DrugBank.d216.s7|23-25|was|O
DDI-DrugBank.d216.s7|27-35|increased|O
DDI-DrugBank.d216.s7|37-44|2.2-fold|O
DDI-DrugBank.d216.s7|46-47|by|O
DDI-DrugBank.d216.s7|49-64|coadministration|O
DDI-DrugBank.d216.s7|66-67|of|O
DDI-DrugBank.d216.s7|69-80|ketoconazole|drug
DDI-DrugBank.d216.s7|81-81|,|O
DDI-DrugBank.d216.s7|83-83|a|O
DDI-DrugBank.d216.s7|85-90|potent|O
DDI-DrugBank.d216.s7|92-100|inhibitor|O
DDI-DrugBank.d216.s7|102-103|of|O
DDI-DrugBank.d216.s7|105-110|CYP3A4|O
DDI-DrugBank.d216.s7|111-111|,|O
DDI-DrugBank.d216.s7|113-115|400|O
DDI-DrugBank.d216.s7|117-118|mg|O
DDI-DrugBank.d216.s7|120-124|daily|O
DDI-DrugBank.d216.s7|126-128|for|O
DDI-DrugBank.d216.s7|130-130|5|O
DDI-DrugBank.d216.s7|132-135|days|O
DDI-DrugBank.d216.s7|136-136|.|O
DDI-DrugBank.d216.s8|0-3|Cmax|O
DDI-DrugBank.d216.s8|5-7|and|O
DDI-DrugBank.d216.s8|9-12|t1/2|O
DDI-DrugBank.d216.s8|14-17|were|O
DDI-DrugBank.d216.s8|19-27|increased|O
DDI-DrugBank.d216.s8|29-36|1.4-fold|O
DDI-DrugBank.d216.s8|38-40|and|O
DDI-DrugBank.d216.s8|42-49|1.3-fold|O
DDI-DrugBank.d216.s8|50-50|,|O
DDI-DrugBank.d216.s8|52-63|respectively|O
DDI-DrugBank.d216.s8|64-64|.|O
DDI-DrugBank.d216.s9|0-4|Other|O
DDI-DrugBank.d216.s9|6-11|strong|O
DDI-DrugBank.d216.s9|13-22|inhibitors|O
DDI-DrugBank.d216.s9|24-25|of|O
DDI-DrugBank.d216.s9|27-32|CYP3A4|O
DDI-DrugBank.d216.s9|34-34|(|O
DDI-DrugBank.d216.s9|35-38|e.g.|O
DDI-DrugBank.d216.s9|39-39|,|O
DDI-DrugBank.d216.s9|41-52|itraconazole|drug
DDI-DrugBank.d216.s9|53-53|,|O
DDI-DrugBank.d216.s9|55-68|clarithromycin|drug
DDI-DrugBank.d216.s9|69-69|,|O
DDI-DrugBank.d216.s9|71-80|nefazodone|drug
DDI-DrugBank.d216.s9|81-81|,|O
DDI-DrugBank.d216.s9|83-96|troleandomycin|drug
DDI-DrugBank.d216.s9|97-97|,|O
DDI-DrugBank.d216.s9|99-107|ritonavir|drug
DDI-DrugBank.d216.s9|108-108|,|O
DDI-DrugBank.d216.s9|110-119|nelfinavir|drug
DDI-DrugBank.d216.s9|120-120|)|O
DDI-DrugBank.d216.s9|122-126|would|O
DDI-DrugBank.d216.s9|128-129|be|O
DDI-DrugBank.d216.s9|131-138|expected|O
DDI-DrugBank.d216.s9|140-141|to|O
DDI-DrugBank.d216.s9|143-148|behave|O
DDI-DrugBank.d216.s9|150-158|similarly|O
DDI-DrugBank.d216.s9|159-159|.|O
DDI-DrugBank.d216.s10|0-4|Drugs|O
DDI-DrugBank.d216.s10|6-9|That|O
DDI-DrugBank.d216.s10|11-16|Induce|O
DDI-DrugBank.d216.s10|18-23|CYP3A4|O
DDI-DrugBank.d216.s10|25-25|(|O
DDI-DrugBank.d216.s10|26-35|Rifampicin|drug
DDI-DrugBank.d216.s10|36-36|)|O
DDI-DrugBank.d216.s10|38-44|Racemic|O
DDI-DrugBank.d216.s10|46-54|zopiclone|drug
DDI-DrugBank.d216.s10|56-63|exposure|O
DDI-DrugBank.d216.s10|65-67|was|O
DDI-DrugBank.d216.s10|69-77|decreased|O
DDI-DrugBank.d216.s10|79-80|80|O
DDI-DrugBank.d216.s10|81-81|%|O
DDI-DrugBank.d216.s10|83-84|by|O
DDI-DrugBank.d216.s10|86-96|concomitant|O
DDI-DrugBank.d216.s10|98-102|useof|O
DDI-DrugBank.d216.s10|104-113|rifampicin|drug
DDI-DrugBank.d216.s10|114-114|,|O
DDI-DrugBank.d216.s10|116-116|a|O
DDI-DrugBank.d216.s10|118-123|potent|O
DDI-DrugBank.d216.s10|125-131|inducer|O
DDI-DrugBank.d216.s10|133-134|of|O
DDI-DrugBank.d216.s10|136-141|CYP3A4|O
DDI-DrugBank.d216.s10|142-142|.|O
DDI-DrugBank.d216.s11|0-0|A|O
DDI-DrugBank.d216.s11|2-8|similar|O
DDI-DrugBank.d216.s11|10-15|effect|O
DDI-DrugBank.d216.s11|17-21|would|O
DDI-DrugBank.d216.s11|23-24|be|O
DDI-DrugBank.d216.s11|26-33|expected|O
DDI-DrugBank.d216.s11|35-38|with|O
DDI-DrugBank.d216.s11|40-50|eszopiclone|drug
DDI-DrugBank.d216.s11|51-51|.|O
DDI-DrugBank.d216.s12|0-4|Drugs|O
DDI-DrugBank.d216.s12|6-11|Highly|O
DDI-DrugBank.d216.s12|13-17|Bound|O
DDI-DrugBank.d216.s12|19-20|To|O
DDI-DrugBank.d216.s12|22-27|Plasma|O
DDI-DrugBank.d216.s12|29-35|Protein|O
DDI-DrugBank.d216.s12|37-47|Eszopiclone|drug
DDI-DrugBank.d216.s12|49-50|is|O
DDI-DrugBank.d216.s12|52-54|not|O
DDI-DrugBank.d216.s12|56-61|highly|O
DDI-DrugBank.d216.s12|63-67|bound|O
DDI-DrugBank.d216.s12|69-70|to|O
DDI-DrugBank.d216.s12|72-77|plasma|O
DDI-DrugBank.d216.s12|79-86|proteins|O
DDI-DrugBank.d216.s12|88-88|(|O
DDI-DrugBank.d216.s12|89-93|52-59|O
DDI-DrugBank.d216.s12|94-94|%|O
DDI-DrugBank.d216.s12|96-100|bound|O
DDI-DrugBank.d216.s12|101-101|)|O
DDI-DrugBank.d216.s12|102-102|;|O
DDI-DrugBank.d216.s13|0-8|therefore|O
DDI-DrugBank.d216.s13|9-9|,|O
DDI-DrugBank.d216.s13|11-13|the|O
DDI-DrugBank.d216.s13|15-25|disposition|O
DDI-DrugBank.d216.s13|27-28|of|O
DDI-DrugBank.d216.s13|30-40|eszopiclone|drug
DDI-DrugBank.d216.s13|42-43|is|O
DDI-DrugBank.d216.s13|45-47|not|O
DDI-DrugBank.d216.s13|49-56|expected|O
DDI-DrugBank.d216.s13|58-59|to|O
DDI-DrugBank.d216.s13|61-62|be|O
DDI-DrugBank.d216.s13|64-72|sensitive|O
DDI-DrugBank.d216.s13|74-75|to|O
DDI-DrugBank.d216.s13|77-87|alterations|O
DDI-DrugBank.d216.s13|89-90|in|O
DDI-DrugBank.d216.s13|92-98|protein|O
DDI-DrugBank.d216.s13|100-106|binding|O
DDI-DrugBank.d216.s13|107-107|.|O
DDI-DrugBank.d216.s14|0-13|Administration|O
DDI-DrugBank.d216.s14|15-16|of|O
DDI-DrugBank.d216.s14|18-28|eszopiclone|drug
DDI-DrugBank.d216.s14|30-30|3|O
DDI-DrugBank.d216.s14|32-33|mg|O
DDI-DrugBank.d216.s14|35-36|to|O
DDI-DrugBank.d216.s14|38-38|a|O
DDI-DrugBank.d216.s14|40-46|patient|O
DDI-DrugBank.d216.s14|48-53|taking|O
DDI-DrugBank.d216.s14|55-61|another|O
DDI-DrugBank.d216.s14|63-66|drug|O
DDI-DrugBank.d216.s14|68-71|that|O
DDI-DrugBank.d216.s14|73-74|is|O
DDI-DrugBank.d216.s14|76-81|highly|O
DDI-DrugBank.d216.s14|83-95|protein-bound|O
DDI-DrugBank.d216.s14|97-101|would|O
DDI-DrugBank.d216.s14|103-105|not|O
DDI-DrugBank.d216.s14|107-108|be|O
DDI-DrugBank.d216.s14|110-117|expected|O
DDI-DrugBank.d216.s14|119-120|to|O
DDI-DrugBank.d216.s14|122-126|cause|O
DDI-DrugBank.d216.s14|128-129|an|O
DDI-DrugBank.d216.s14|131-140|alteration|O
DDI-DrugBank.d216.s14|142-143|in|O
DDI-DrugBank.d216.s14|145-147|the|O
DDI-DrugBank.d216.s14|149-152|free|O
DDI-DrugBank.d216.s14|154-166|concentration|O
DDI-DrugBank.d216.s14|168-169|of|O
DDI-DrugBank.d216.s14|171-176|either|O
DDI-DrugBank.d216.s14|178-181|drug|O
DDI-DrugBank.d216.s14|182-182|.|O
DDI-DrugBank.d216.s15|0-4|Drugs|O
DDI-DrugBank.d216.s15|6-9|With|O
DDI-DrugBank.d216.s15|11-11|A|O
DDI-DrugBank.d216.s15|13-18|Narrow|O
DDI-DrugBank.d216.s15|20-30|Therapeutic|O
DDI-DrugBank.d216.s15|32-36|Index|O
DDI-DrugBank.d216.s15|38-44|Digoxin|drug
DDI-DrugBank.d216.s15|46-46|A|O
DDI-DrugBank.d216.s15|48-53|single|O
DDI-DrugBank.d216.s15|55-58|dose|O
DDI-DrugBank.d216.s15|60-61|of|O
DDI-DrugBank.d216.s15|63-73|eszopiclone|drug
DDI-DrugBank.d216.s15|75-75|3|O
DDI-DrugBank.d216.s15|77-78|mg|O
DDI-DrugBank.d216.s15|80-82|did|O
DDI-DrugBank.d216.s15|84-86|not|O
DDI-DrugBank.d216.s15|88-93|affect|O
DDI-DrugBank.d216.s15|95-97|the|O
DDI-DrugBank.d216.s15|99-114|pharmacokinetics|O
DDI-DrugBank.d216.s15|116-117|of|O
DDI-DrugBank.d216.s15|119-125|digoxin|drug
DDI-DrugBank.d216.s15|127-134|measured|O
DDI-DrugBank.d216.s15|136-137|at|O
DDI-DrugBank.d216.s15|139-144|steady|O
DDI-DrugBank.d216.s15|146-150|state|O
DDI-DrugBank.d216.s15|152-160|following|O
DDI-DrugBank.d216.s15|162-167|dosing|O
DDI-DrugBank.d216.s15|169-170|of|O
DDI-DrugBank.d216.s15|172-174|0.5|O
DDI-DrugBank.d216.s15|176-177|mg|O
DDI-DrugBank.d216.s15|179-183|twice|O
DDI-DrugBank.d216.s15|185-189|daily|O
DDI-DrugBank.d216.s15|191-193|for|O
DDI-DrugBank.d216.s15|195-197|one|O
DDI-DrugBank.d216.s15|199-201|day|O
DDI-DrugBank.d216.s15|203-205|and|O
DDI-DrugBank.d216.s15|207-210|0.25|O
DDI-DrugBank.d216.s15|212-213|mg|O
DDI-DrugBank.d216.s15|215-219|daily|O
DDI-DrugBank.d216.s15|221-223|for|O
DDI-DrugBank.d216.s15|225-227|the|O
DDI-DrugBank.d216.s15|229-232|next|O
DDI-DrugBank.d216.s15|234-234|6|O
DDI-DrugBank.d216.s15|236-239|days|O
DDI-DrugBank.d216.s15|240-240|.|O
DDI-DrugBank.d216.s16|0-7|Warfarin|drug
DDI-DrugBank.d216.s16|8-8|:|O
DDI-DrugBank.d216.s16|10-20|Eszopiclone|drug
DDI-DrugBank.d216.s16|22-22|3|O
DDI-DrugBank.d216.s16|24-25|mg|O
DDI-DrugBank.d216.s16|27-38|administered|O
DDI-DrugBank.d216.s16|40-44|daily|O
DDI-DrugBank.d216.s16|46-48|for|O
DDI-DrugBank.d216.s16|50-50|5|O
DDI-DrugBank.d216.s16|52-55|days|O
DDI-DrugBank.d216.s16|57-59|did|O
DDI-DrugBank.d216.s16|61-63|not|O
DDI-DrugBank.d216.s16|65-70|affect|O
DDI-DrugBank.d216.s16|72-74|the|O
DDI-DrugBank.d216.s16|76-91|pharmacokinetics|O
DDI-DrugBank.d216.s16|93-94|of|O
DDI-DrugBank.d216.s16|96-98|( R )|drug
DDI-DrugBank.d216.s16|99-99|-|O
DDI-DrugBank.d216.s16|101-102|or|O
DDI-DrugBank.d216.s16|104-115|( S ) -warfarin|drug
DDI-DrugBank.d216.s16|116-116|,|O
DDI-DrugBank.d216.s16|118-120|nor|O
DDI-DrugBank.d216.s16|122-125|were|O
DDI-DrugBank.d216.s16|127-131|there|O
DDI-DrugBank.d216.s16|133-135|any|O
DDI-DrugBank.d216.s16|137-143|changes|O
DDI-DrugBank.d216.s16|145-146|in|O
DDI-DrugBank.d216.s16|148-150|the|O
DDI-DrugBank.d216.s16|152-166|pharmacodynamic|O
DDI-DrugBank.d216.s16|168-174|profile|O
DDI-DrugBank.d216.s16|176-176|(|O
DDI-DrugBank.d216.s16|177-187|prothrombin|O
DDI-DrugBank.d216.s16|189-192|time|O
DDI-DrugBank.d216.s16|193-193|)|O
DDI-DrugBank.d216.s16|195-203|following|O
DDI-DrugBank.d216.s16|205-205|a|O
DDI-DrugBank.d216.s16|207-212|single|O
DDI-DrugBank.d216.s16|214-215|25|O
DDI-DrugBank.d216.s16|217-218|mg|O
DDI-DrugBank.d216.s16|220-223|oral|O
DDI-DrugBank.d216.s16|225-228|dose|O
DDI-DrugBank.d216.s16|230-231|of|O
DDI-DrugBank.d216.s17|0-0|.|O
DDI-DrugBank.d537.s0|0-10|Bentiromide|drug
DDI-DrugBank.d537.s0|12-14|may|O
DDI-DrugBank.d537.s0|16-23|interact|O
DDI-DrugBank.d537.s0|25-28|with|O
DDI-DrugBank.d537.s0|30-42|acetaminophen|drug
DDI-DrugBank.d537.s0|44-44|(|O
DDI-DrugBank.d537.s0|45-48|e.g.|O
DDI-DrugBank.d537.s0|49-49|,|O
DDI-DrugBank.d537.s0|51-57|Tylenol|brand
DDI-DrugBank.d537.s0|58-58|)|O
DDI-DrugBank.d537.s0|59-59|,|O
DDI-DrugBank.d537.s0|61-75|chloramphenicol|drug
DDI-DrugBank.d537.s0|77-77|(|O
DDI-DrugBank.d537.s0|78-81|e.g.|O
DDI-DrugBank.d537.s0|82-82|,|O
DDI-DrugBank.d537.s0|84-96|Chloromycetin|brand
DDI-DrugBank.d537.s0|97-97|)|O
DDI-DrugBank.d537.s0|98-98|,|O
DDI-DrugBank.d537.s0|100-104|local|O
DDI-DrugBank.d537.s0|106-116|anesthetics|group
DDI-DrugBank.d537.s0|118-118|(|O
DDI-DrugBank.d537.s0|119-122|e.g.|O
DDI-DrugBank.d537.s0|123-123|,|O
DDI-DrugBank.d537.s0|125-134|benzocaine|drug
DDI-DrugBank.d537.s0|136-138|and|O
DDI-DrugBank.d537.s0|140-148|lidocaine|drug
DDI-DrugBank.d537.s0|149-149|)|O
DDI-DrugBank.d537.s0|150-150|,|O
DDI-DrugBank.d537.s0|175-175|(|O
DDI-DrugBank.d537.s0|180-180|)|O
DDI-DrugBank.d537.s0|181-191|-containing|O
DDI-DrugBank.d537.s0|193-204|preparations|O
DDI-DrugBank.d537.s0|206-206|(|O
DDI-DrugBank.d537.s0|207-210|e.g.|O
DDI-DrugBank.d537.s0|211-211|,|O
DDI-DrugBank.d537.s0|213-222|sunscreens|O
DDI-DrugBank.d537.s0|224-226|and|O
DDI-DrugBank.d537.s0|228-231|some|O
DDI-DrugBank.d537.s0|233-245|multivitamins|group
DDI-DrugBank.d537.s0|246-246|)|O
DDI-DrugBank.d537.s0|247-247|,|O
DDI-DrugBank.d537.s0|249-260|procainamide|drug
DDI-DrugBank.d537.s0|262-262|(|O
DDI-DrugBank.d537.s0|263-266|e.g.|O
DDI-DrugBank.d537.s0|267-267|,|O
DDI-DrugBank.d537.s0|269-277|Pronestyl|brand
DDI-DrugBank.d537.s0|278-278|)|O
DDI-DrugBank.d537.s0|279-279|,|O
DDI-DrugBank.d537.s0|281-292|sulfonamides|group
DDI-DrugBank.d537.s0|294-294|(|O
DDI-DrugBank.d537.s0|295-299|sulfa|O
DDI-DrugBank.d537.s0|301-309|medicines|O
DDI-DrugBank.d537.s0|310-310|)|O
DDI-DrugBank.d537.s0|311-311|,|O
DDI-DrugBank.d537.s0|313-330|thiazide diuretics|group
DDI-DrugBank.d537.s0|332-332|(|O
DDI-DrugBank.d537.s0|333-335|use|O
DDI-DrugBank.d537.s0|337-338|of|O
DDI-DrugBank.d537.s0|340-344|these|O
DDI-DrugBank.d537.s0|346-354|medicines|O
DDI-DrugBank.d537.s0|356-361|during|O
DDI-DrugBank.d537.s0|363-365|the|O
DDI-DrugBank.d537.s0|367-370|test|O
DDI-DrugBank.d537.s0|372-377|period|O
DDI-DrugBank.d537.s0|379-382|will|O
DDI-DrugBank.d537.s0|384-389|affect|O
DDI-DrugBank.d537.s0|391-393|the|O
DDI-DrugBank.d537.s0|395-398|test|O
DDI-DrugBank.d537.s0|400-406|results|O
DDI-DrugBank.d537.s0|407-407|)|O
DDI-DrugBank.d537.s0|408-408|,|O
DDI-DrugBank.d537.s0|410-412|and|O
DDI-DrugBank.d537.s0|414-423|pancreatic|O
DDI-DrugBank.d537.s0|425-435|supplements|O
DDI-DrugBank.d537.s0|437-437|(|O
DDI-DrugBank.d537.s0|438-440|use|O
DDI-DrugBank.d537.s0|442-443|of|O
DDI-DrugBank.d537.s0|445-454|pancreatic|O
DDI-DrugBank.d537.s0|456-466|supplements|O
DDI-DrugBank.d537.s0|468-470|may|O
DDI-DrugBank.d537.s0|472-475|give|O
DDI-DrugBank.d537.s0|477-481|false|O
DDI-DrugBank.d537.s0|483-486|test|O
DDI-DrugBank.d537.s0|488-494|results|O
DDI-DrugBank.d537.s0|495-495|)|O
DDI-DrugBank.d537.s0|496-496|.|O
DDI-MedLine.d105.s0|0-3|Lack|O
DDI-MedLine.d105.s0|5-6|of|O
DDI-MedLine.d105.s0|8-9|an|O
DDI-MedLine.d105.s0|11-16|effect|O
DDI-MedLine.d105.s0|18-19|of|O
DDI-MedLine.d105.s0|21-32|azithromycin|drug
DDI-MedLine.d105.s0|34-35|on|O
DDI-MedLine.d105.s0|37-39|the|O
DDI-MedLine.d105.s0|41-51|disposition|O
DDI-MedLine.d105.s0|53-54|of|O
DDI-MedLine.d105.s0|56-65|zidovudine|drug
DDI-MedLine.d105.s0|67-69|and|O
DDI-MedLine.d105.s0|71-84|dideoxyinosine|drug
DDI-MedLine.d105.s0|86-87|in|O
DDI-MedLine.d105.s0|89-100|HIV-infected|O
DDI-MedLine.d105.s0|102-109|patients|O
DDI-MedLine.d105.s0|110-110|.|O
DDI-MedLine.d105.s1|0-2|Two|O
DDI-MedLine.d105.s1|4-10|studies|O
DDI-MedLine.d105.s1|12-15|were|O
DDI-MedLine.d105.s1|17-25|conducted|O
DDI-MedLine.d105.s1|27-28|in|O
DDI-MedLine.d105.s1|30-41|HIV-infected|O
DDI-MedLine.d105.s1|43-50|subjects|O
DDI-MedLine.d105.s1|52-53|to|O
DDI-MedLine.d105.s1|55-60|assess|O
DDI-MedLine.d105.s1|62-64|the|O
DDI-MedLine.d105.s1|66-74|potential|O
DDI-MedLine.d105.s1|76-78|for|O
DDI-MedLine.d105.s1|80-91|azithromycin|drug
DDI-MedLine.d105.s1|93-94|to|O
DDI-MedLine.d105.s1|96-103|interact|O
DDI-MedLine.d105.s1|105-108|with|O
DDI-MedLine.d105.s1|110-119|zidovudine|drug
DDI-MedLine.d105.s1|121-123|and|O
DDI-MedLine.d105.s1|125-138|dideoxyinosine|drug
DDI-MedLine.d105.s1|139-139|.|O
DDI-MedLine.d105.s2|0-3|Both|O
DDI-MedLine.d105.s2|5-11|studies|O
DDI-MedLine.d105.s2|13-16|used|O
DDI-MedLine.d105.s2|18-19|12|O
DDI-MedLine.d105.s2|21-28|subjects|O
DDI-MedLine.d105.s2|29-29|.|O
DDI-MedLine.d105.s3|0-2|The|O
DDI-MedLine.d105.s3|4-13|zidovudine|drug
DDI-MedLine.d105.s3|15-19|study|O
DDI-MedLine.d105.s3|21-25|dosed|O
DDI-MedLine.d105.s3|27-34|subjects|O
DDI-MedLine.d105.s3|36-39|with|O
DDI-MedLine.d105.s3|41-44|1200|O
DDI-MedLine.d105.s3|46-51|mg/day|O
DDI-MedLine.d105.s3|53-54|of|O
DDI-MedLine.d105.s3|56-67|azithromycin|drug
DDI-MedLine.d105.s3|69-69|(|O
DDI-MedLine.d105.s3|70-70|n|O
DDI-MedLine.d105.s3|72-72|=|O
DDI-MedLine.d105.s3|74-74|7|O
DDI-MedLine.d105.s3|75-75|)|O
DDI-MedLine.d105.s3|77-77|(|O
DDI-MedLine.d105.s3|78-82|later|O
DDI-MedLine.d105.s3|84-90|changed|O
DDI-MedLine.d105.s3|92-93|to|O
DDI-MedLine.d105.s3|95-97|600|O
DDI-MedLine.d105.s3|99-104|mg/day|O
DDI-MedLine.d105.s3|106-106|[|O
DDI-MedLine.d105.s3|107-107|n|O
DDI-MedLine.d105.s3|109-109|=|O
DDI-MedLine.d105.s3|111-111|5|O
DDI-MedLine.d105.s3|112-112|]|O
DDI-MedLine.d105.s3|113-113|)|O
DDI-MedLine.d105.s3|115-117|for|O
DDI-MedLine.d105.s3|119-122|Days|O
DDI-MedLine.d105.s3|124-124|8|O
DDI-MedLine.d105.s3|126-127|to|O
DDI-MedLine.d105.s3|129-130|21|O
DDI-MedLine.d105.s3|132-133|of|O
DDI-MedLine.d105.s3|135-135|a|O
DDI-MedLine.d105.s3|137-142|21-day|O
DDI-MedLine.d105.s3|144-149|course|O
DDI-MedLine.d105.s3|151-152|of|O
DDI-MedLine.d105.s3|154-156|100|O
DDI-MedLine.d105.s3|158-159|mg|O
DDI-MedLine.d105.s3|160-160|,|O
DDI-MedLine.d105.s3|162-165|five|O
DDI-MedLine.d105.s3|167-175|times/day|O
DDI-MedLine.d105.s3|177-178|of|O
DDI-MedLine.d105.s3|180-189|zidovudine|drug
DDI-MedLine.d105.s3|190-190|.|O
DDI-MedLine.d105.s4|0-7|Subjects|O
DDI-MedLine.d105.s4|9-15|treated|O
DDI-MedLine.d105.s4|17-20|with|O
DDI-MedLine.d105.s4|22-24|200|O
DDI-MedLine.d105.s4|26-27|mg|O
DDI-MedLine.d105.s4|29-30|of|O
DDI-MedLine.d105.s4|32-45|dideoxyinosine|drug
DDI-MedLine.d105.s4|47-51|twice|O
DDI-MedLine.d105.s4|53-57|daily|O
DDI-MedLine.d105.s4|59-61|for|O
DDI-MedLine.d105.s4|63-64|21|O
DDI-MedLine.d105.s4|66-69|days|O
DDI-MedLine.d105.s4|71-78|received|O
DDI-MedLine.d105.s4|80-83|1200|O
DDI-MedLine.d105.s4|85-86|mg|O
DDI-MedLine.d105.s4|88-89|of|O
DDI-MedLine.d105.s4|91-102|azithromycin|drug
DDI-MedLine.d105.s4|104-105|or|O
DDI-MedLine.d105.s4|107-108|an|O
DDI-MedLine.d105.s4|110-119|equivalent|O
DDI-MedLine.d105.s4|121-126|amount|O
DDI-MedLine.d105.s4|128-129|of|O
DDI-MedLine.d105.s4|131-141|placebo/day|O
DDI-MedLine.d105.s4|143-145|for|O
DDI-MedLine.d105.s4|147-150|Days|O
DDI-MedLine.d105.s4|152-152|8|O
DDI-MedLine.d105.s4|154-155|to|O
DDI-MedLine.d105.s4|157-158|21|O
DDI-MedLine.d105.s4|159-159|.|O
DDI-MedLine.d105.s5|0-13|Antiretroviral|group
DDI-MedLine.d105.s5|15-20|plasma|O
DDI-MedLine.d105.s5|22-24|and|O
DDI-MedLine.d105.s5|26-30|urine|O
DDI-MedLine.d105.s5|32-39|sampling|O
DDI-MedLine.d105.s5|41-44|were|O
DDI-MedLine.d105.s5|46-54|conducted|O
DDI-MedLine.d105.s5|56-57|on|O
DDI-MedLine.d105.s5|59-62|Days|O
DDI-MedLine.d105.s5|64-64|1|O
DDI-MedLine.d105.s5|65-65|,|O
DDI-MedLine.d105.s5|67-67|7|O
DDI-MedLine.d105.s5|68-68|,|O
DDI-MedLine.d105.s5|70-72|and|O
DDI-MedLine.d105.s5|74-75|21|O
DDI-MedLine.d105.s5|77-79|for|O
DDI-MedLine.d105.s5|81-90|zidovudine|drug
DDI-MedLine.d105.s5|92-94|and|O
DDI-MedLine.d105.s5|96-97|on|O
DDI-MedLine.d105.s5|99-102|Days|O
DDI-MedLine.d105.s5|104-104|7|O
DDI-MedLine.d105.s5|106-108|and|O
DDI-MedLine.d105.s5|110-111|21|O
DDI-MedLine.d105.s5|113-115|for|O
DDI-MedLine.d105.s5|117-130|dideoxyinosine|drug
DDI-MedLine.d105.s5|131-131|.|O
DDI-MedLine.d105.s6|0-9|Peripheral|O
DDI-MedLine.d105.s6|11-21|mononuclear|O
DDI-MedLine.d105.s6|23-27|cells|O
DDI-MedLine.d105.s6|29-32|were|O
DDI-MedLine.d105.s6|34-37|also|O
DDI-MedLine.d105.s6|39-47|collected|O
DDI-MedLine.d105.s6|49-51|for|O
DDI-MedLine.d105.s6|53-64|quantitation|O
DDI-MedLine.d105.s6|66-67|of|O
DDI-MedLine.d105.s6|69-82|phosphorylated|O
DDI-MedLine.d105.s6|84-93|zidovudine|drug
DDI-MedLine.d105.s6|94-94|.|O
DDI-MedLine.d105.s7|0-11|Azithromycin|drug
DDI-MedLine.d105.s7|13-15|had|O
DDI-MedLine.d105.s7|17-18|no|O
DDI-MedLine.d105.s7|20-30|significant|O
DDI-MedLine.d105.s7|32-37|impact|O
DDI-MedLine.d105.s7|39-40|on|O
DDI-MedLine.d105.s7|42-44|the|O
DDI-MedLine.d105.s7|46-49|Cmax|O
DDI-MedLine.d105.s7|51-53|and|O
DDI-MedLine.d105.s7|55-57|AUC|O
DDI-MedLine.d105.s7|59-60|of|O
DDI-MedLine.d105.s7|62-71|zidovudine|drug
DDI-MedLine.d105.s7|72-72|,|O
DDI-MedLine.d105.s7|74-81|although|O
DDI-MedLine.d105.s7|83-84|it|O
DDI-MedLine.d105.s7|86-98|significantly|O
DDI-MedLine.d105.s7|100-108|decreased|O
DDI-MedLine.d105.s7|110-112|the|O
DDI-MedLine.d105.s7|114-123|zidovudine|drug
DDI-MedLine.d105.s7|125-128|tmax|O
DDI-MedLine.d105.s7|130-131|by|O
DDI-MedLine.d105.s7|133-134|44|O
DDI-MedLine.d105.s7|135-135|%|O
DDI-MedLine.d105.s7|137-139|and|O
DDI-MedLine.d105.s7|141-149|increased|O
DDI-MedLine.d105.s7|151-153|the|O
DDI-MedLine.d105.s7|155-167|intracellular|O
DDI-MedLine.d105.s7|169-176|exposure|O
DDI-MedLine.d105.s7|178-179|to|O
DDI-MedLine.d105.s7|181-194|phosphorylated|O
DDI-MedLine.d105.s7|196-205|zidovudine|drug
DDI-MedLine.d105.s7|207-208|by|O
DDI-MedLine.d105.s7|210-212|110|O
DDI-MedLine.d105.s7|213-213|%|O
DDI-MedLine.d105.s7|214-214|.|O
DDI-MedLine.d105.s8|0-11|Azithromycin|drug
DDI-MedLine.d105.s8|13-15|had|O
DDI-MedLine.d105.s8|17-18|no|O
DDI-MedLine.d105.s8|20-30|significant|O
DDI-MedLine.d105.s8|32-37|effect|O
DDI-MedLine.d105.s8|39-40|on|O
DDI-MedLine.d105.s8|42-55|dideoxyinosine|drug
DDI-MedLine.d105.s8|57-72|pharmacokinetics|O
DDI-MedLine.d105.s8|73-73|.|O
DDI-MedLine.d105.s9|0-4|Based|O
DDI-MedLine.d105.s9|6-7|on|O
DDI-MedLine.d105.s9|9-11|the|O
DDI-MedLine.d105.s9|13-19|results|O
DDI-MedLine.d105.s9|21-22|of|O
DDI-MedLine.d105.s9|24-28|these|O
DDI-MedLine.d105.s9|30-36|studies|O
DDI-MedLine.d105.s9|37-37|,|O
DDI-MedLine.d105.s9|39-40|it|O
DDI-MedLine.d105.s9|42-43|is|O
DDI-MedLine.d105.s9|45-53|concluded|O
DDI-MedLine.d105.s9|55-58|that|O
DDI-MedLine.d105.s9|60-71|azithromycin|drug
DDI-MedLine.d105.s9|73-75|may|O
DDI-MedLine.d105.s9|77-78|be|O
DDI-MedLine.d105.s9|80-85|safely|O
DDI-MedLine.d105.s9|87-100|coadministered|O
DDI-MedLine.d105.s9|102-105|with|O
DDI-MedLine.d105.s9|107-110|both|O
DDI-MedLine.d105.s9|112-121|zidovudine|drug
DDI-MedLine.d105.s9|123-125|and|O
DDI-MedLine.d105.s9|127-140|dideoxyinosine|drug
DDI-MedLine.d105.s9|141-141|.|O
DDI-DrugBank.d771.s0|0-2|The|O
DDI-DrugBank.d771.s0|4-13|absorption|O
DDI-DrugBank.d771.s0|15-16|of|O
DDI-DrugBank.d771.s0|18-21|oral|O
DDI-DrugBank.d771.s0|23-33|medications|O
DDI-DrugBank.d771.s0|35-37|may|O
DDI-DrugBank.d771.s0|39-40|be|O
DDI-DrugBank.d771.s0|42-50|decreased|O
DDI-DrugBank.d771.s0|52-57|during|O
DDI-DrugBank.d771.s0|59-61|the|O
DDI-DrugBank.d771.s0|63-72|concurrent|O
DDI-DrugBank.d771.s0|74-76|use|O
DDI-DrugBank.d771.s0|78-79|of|O
DDI-DrugBank.d771.s0|81-91|scopolamine|drug
DDI-DrugBank.d771.s0|93-99|because|O
DDI-DrugBank.d771.s0|101-102|of|O
DDI-DrugBank.d771.s0|104-112|decreased|O
DDI-DrugBank.d771.s0|114-120|gastric|O
DDI-DrugBank.d771.s0|122-129|motility|O
DDI-DrugBank.d771.s0|131-133|and|O
DDI-DrugBank.d771.s0|135-141|delayed|O
DDI-DrugBank.d771.s0|143-149|gastric|O
DDI-DrugBank.d771.s0|151-158|emptying|O
DDI-DrugBank.d771.s0|159-159|.|O
DDI-DrugBank.d771.s1|0-10|Scopolamine|drug
DDI-DrugBank.d771.s1|12-17|should|O
DDI-DrugBank.d771.s1|19-20|be|O
DDI-DrugBank.d771.s1|22-25|used|O
DDI-DrugBank.d771.s1|27-30|with|O
DDI-DrugBank.d771.s1|32-35|care|O
DDI-DrugBank.d771.s1|37-38|in|O
DDI-DrugBank.d771.s1|40-47|patients|O
DDI-DrugBank.d771.s1|49-54|taking|O
DDI-DrugBank.d771.s1|56-60|other|O
DDI-DrugBank.d771.s1|62-66|drugs|O
DDI-DrugBank.d771.s1|68-71|that|O
DDI-DrugBank.d771.s1|73-75|are|O
DDI-DrugBank.d771.s1|77-83|capable|O
DDI-DrugBank.d771.s1|85-86|of|O
DDI-DrugBank.d771.s1|88-94|causing|O
DDI-DrugBank.d771.s1|96-98|CNS|O
DDI-DrugBank.d771.s1|100-106|effects|O
DDI-DrugBank.d771.s1|108-111|such|O
DDI-DrugBank.d771.s1|113-114|as|O
DDI-DrugBank.d771.s1|116-124|sedatives|group
DDI-DrugBank.d771.s1|125-125|,|O
DDI-DrugBank.d771.s1|127-139|tranquilizers|group
DDI-DrugBank.d771.s1|140-140|,|O
DDI-DrugBank.d771.s1|142-143|or|O
DDI-DrugBank.d771.s1|145-151|alcohol|drug
DDI-DrugBank.d771.s1|152-152|.|O
DDI-DrugBank.d771.s2|0-6|Special|O
DDI-DrugBank.d771.s2|8-16|attention|O
DDI-DrugBank.d771.s2|18-23|should|O
DDI-DrugBank.d771.s2|25-26|be|O
DDI-DrugBank.d771.s2|28-31|paid|O
DDI-DrugBank.d771.s2|33-34|to|O
DDI-DrugBank.d771.s2|36-44|potential|O
DDI-DrugBank.d771.s2|46-57|interactions|O
DDI-DrugBank.d771.s2|59-62|with|O
DDI-DrugBank.d771.s2|64-68|drugs|O
DDI-DrugBank.d771.s2|70-75|having|O
DDI-DrugBank.d771.s2|77-91|anticholinergic|O
DDI-DrugBank.d771.s2|93-102|properties|O
DDI-DrugBank.d771.s2|103-103|;|O
DDI-DrugBank.d771.s3|0-3|e.g.|O
DDI-DrugBank.d771.s3|4-4|,|O
DDI-DrugBank.d771.s3|6-10|other|O
DDI-DrugBank.d771.s3|12-31|belladonna alkaloids|group
DDI-DrugBank.d771.s3|32-32|,|O
DDI-DrugBank.d771.s3|34-47|antihistamines|group
DDI-DrugBank.d771.s3|49-49|(|O
DDI-DrugBank.d771.s3|50-58|including|O
DDI-DrugBank.d771.s3|60-68|meclizine|drug
DDI-DrugBank.d771.s3|69-69|)|O
DDI-DrugBank.d771.s3|70-70|,|O
DDI-DrugBank.d771.s3|72-96|tricyclic antidepressants|group
DDI-DrugBank.d771.s3|97-97|,|O
DDI-DrugBank.d771.s3|99-101|and|O
DDI-DrugBank.d771.s3|103-118|muscle relaxants|group
DDI-DrugBank.d771.s3|119-119|.|O
DDI-DrugBank.d771.s4|0-9|Laboratory|O
DDI-DrugBank.d771.s4|11-14|Test|O
DDI-DrugBank.d771.s4|16-27|Interactions|O
DDI-DrugBank.d771.s4|29-39|Scopolamine|drug
DDI-DrugBank.d771.s4|41-44|will|O
DDI-DrugBank.d771.s4|46-54|interfere|O
DDI-DrugBank.d771.s4|56-59|with|O
DDI-DrugBank.d771.s4|61-63|the|O
DDI-DrugBank.d771.s4|65-71|gastric|O
DDI-DrugBank.d771.s4|73-81|secretion|O
DDI-DrugBank.d771.s4|83-86|test|O
DDI-DrugBank.d771.s4|87-87|.|O
DDI-DrugBank.d374.s0|0-8|Auranofin|drug
DDI-DrugBank.d374.s0|10-15|should|O
DDI-DrugBank.d374.s0|17-18|be|O
DDI-DrugBank.d374.s0|20-26|avoided|O
DDI-DrugBank.d374.s0|28-29|by|O
DDI-DrugBank.d374.s0|31-38|patients|O
DDI-DrugBank.d374.s0|40-43|with|O
DDI-DrugBank.d374.s0|45-45|a|O
DDI-DrugBank.d374.s0|47-53|history|O
DDI-DrugBank.d374.s0|55-56|of|O
DDI-DrugBank.d374.s0|58-64|serious|O
DDI-DrugBank.d374.s0|66-73|reaction|O
DDI-DrugBank.d374.s0|75-76|to|O
DDI-DrugBank.d374.s0|78-80|any|O
DDI-DrugBank.d374.s0|82-96|gold medication|group
DDI-DrugBank.d374.s0|97-97|,|O
DDI-DrugBank.d374.s0|99-107|including|O
DDI-DrugBank.d374.s0|109-116|Solganal|brand
DDI-DrugBank.d374.s0|118-120|and|O
DDI-DrugBank.d374.s0|122-132|Myochrysine|brand
DDI-DrugBank.d374.s0|133-133|.|O
DDI-DrugBank.d374.s1|0-8|Auranofin|drug
DDI-DrugBank.d374.s1|10-15|should|O
DDI-DrugBank.d374.s1|17-19|not|O
DDI-DrugBank.d374.s1|21-22|be|O
DDI-DrugBank.d374.s1|24-27|used|O
DDI-DrugBank.d374.s1|29-36|together|O
DDI-DrugBank.d374.s1|38-41|with|O
DDI-DrugBank.d374.s1|43-55|penicillamine|drug
DDI-DrugBank.d374.s1|57-57|(|O
DDI-DrugBank.d374.s1|58-62|Depen|brand
DDI-DrugBank.d374.s1|63-63|,|O
DDI-DrugBank.d374.s1|65-73|Cuprimine|brand
DDI-DrugBank.d374.s1|74-74|)|O
DDI-DrugBank.d374.s1|75-75|,|O
DDI-DrugBank.d374.s1|77-83|another|O
DDI-DrugBank.d374.s1|85-93|arthritis|O
DDI-DrugBank.d374.s1|95-104|medication|O
DDI-DrugBank.d374.s1|105-105|.|O
DDI-DrugBank.d374.s2|0-1|It|O
DDI-DrugBank.d374.s2|3-8|should|O
DDI-DrugBank.d374.s2|10-13|also|O
DDI-DrugBank.d374.s2|15-16|be|O
DDI-DrugBank.d374.s2|18-24|avoided|O
DDI-DrugBank.d374.s2|26-27|in|O
DDI-DrugBank.d374.s2|29-36|patients|O
DDI-DrugBank.d374.s2|38-41|with|O
DDI-DrugBank.d374.s2|43-47|blood|O
DDI-DrugBank.d374.s2|48-48|,|O
DDI-DrugBank.d374.s2|50-54|liver|O
DDI-DrugBank.d374.s2|56-57|or|O
DDI-DrugBank.d374.s2|59-64|kidney|O
DDI-DrugBank.d374.s2|66-73|diseases|O
DDI-DrugBank.d374.s2|74-74|,|O
DDI-DrugBank.d374.s2|76-81|recent|O
DDI-DrugBank.d374.s2|83-91|radiation|O
DDI-DrugBank.d374.s2|93-101|treatment|O
DDI-DrugBank.d374.s2|102-102|,|O
DDI-DrugBank.d374.s2|104-105|or|O
DDI-DrugBank.d374.s2|107-118|uncontrolled|O
DDI-DrugBank.d374.s2|120-127|diabetes|O
DDI-DrugBank.d374.s2|128-128|.|O
DDI-DrugBank.d374.s3|0-7|Patients|O
DDI-DrugBank.d374.s3|9-14|should|O
DDI-DrugBank.d374.s3|16-21|report|O
DDI-DrugBank.d374.s3|23-24|to|O
DDI-DrugBank.d374.s3|26-30|their|O
DDI-DrugBank.d374.s3|32-44|practitioners|O
DDI-DrugBank.d374.s3|46-48|any|O
DDI-DrugBank.d374.s3|50-52|new|O
DDI-DrugBank.d374.s3|54-59|rashes|O
DDI-DrugBank.d374.s3|60-60|,|O
DDI-DrugBank.d374.s3|62-68|itching|O
DDI-DrugBank.d374.s3|69-69|,|O
DDI-DrugBank.d374.s3|71-75|mouth|O
DDI-DrugBank.d374.s3|77-81|sores|O
DDI-DrugBank.d374.s3|82-82|,|O
DDI-DrugBank.d374.s3|84-85|or|O
DDI-DrugBank.d374.s3|87-93|unusual|O
DDI-DrugBank.d374.s3|95-99|taste|O
DDI-DrugBank.d374.s3|101-105|while|O
DDI-DrugBank.d374.s3|107-112|taking|O
DDI-DrugBank.d374.s3|114-122|auranofin|drug
DDI-DrugBank.d374.s3|123-123|.|O
DDI-DrugBank.d374.s4|0-3|Gold|group
DDI-DrugBank.d374.s4|5-6|is|O
DDI-DrugBank.d374.s4|8-15|excreted|O
DDI-DrugBank.d374.s4|17-22|slowly|O
DDI-DrugBank.d374.s4|24-27|from|O
DDI-DrugBank.d374.s4|29-31|the|O
DDI-DrugBank.d374.s4|33-36|body|O
DDI-DrugBank.d374.s4|37-37|.|O
DDI-DrugBank.d374.s5|0-5|Safety|O
DDI-DrugBank.d374.s5|7-9|and|O
DDI-DrugBank.d374.s5|11-23|effectiveness|O
DDI-DrugBank.d374.s5|25-26|in|O
DDI-DrugBank.d374.s5|28-35|children|O
DDI-DrugBank.d374.s5|37-39|has|O
DDI-DrugBank.d374.s5|41-43|not|O
DDI-DrugBank.d374.s5|45-48|been|O
DDI-DrugBank.d374.s5|50-60|established|O
DDI-DrugBank.d374.s5|61-61|.|O
DDI-DrugBank.d500.s0|0-6|Because|O
DDI-DrugBank.d500.s0|8-20|tetracyclines|group
DDI-DrugBank.d500.s0|22-25|have|O
DDI-DrugBank.d500.s0|27-30|been|O
DDI-DrugBank.d500.s0|32-36|shown|O
DDI-DrugBank.d500.s0|38-39|to|O
DDI-DrugBank.d500.s0|41-47|depress|O
DDI-DrugBank.d500.s0|49-54|plasma|O
DDI-DrugBank.d500.s0|56-66|prothrombin|O
DDI-DrugBank.d500.s0|68-75|activity|O
DDI-DrugBank.d500.s0|76-76|,|O
DDI-DrugBank.d500.s0|78-85|patients|O
DDI-DrugBank.d500.s0|87-89|who|O
DDI-DrugBank.d500.s0|91-93|are|O
DDI-DrugBank.d500.s0|95-96|on|O
DDI-DrugBank.d500.s0|98-110|anticoagulant|group
DDI-DrugBank.d500.s0|112-118|therapy|O
DDI-DrugBank.d500.s0|120-122|may|O
DDI-DrugBank.d500.s0|124-130|require|O
DDI-DrugBank.d500.s0|132-139|downward|O
DDI-DrugBank.d500.s0|141-150|adjustment|O
DDI-DrugBank.d500.s0|152-153|of|O
DDI-DrugBank.d500.s0|155-159|their|O
DDI-DrugBank.d500.s0|161-173|anticoagulant|group
DDI-DrugBank.d500.s0|175-180|dosage|O
DDI-DrugBank.d500.s0|181-181|.|O
DDI-DrugBank.d500.s1|0-4|Since|O
DDI-DrugBank.d500.s1|6-19|bacteriostatic|O
DDI-DrugBank.d500.s1|21-25|drugs|O
DDI-DrugBank.d500.s1|27-29|may|O
DDI-DrugBank.d500.s1|31-39|interfere|O
DDI-DrugBank.d500.s1|41-44|with|O
DDI-DrugBank.d500.s1|46-48|the|O
DDI-DrugBank.d500.s1|50-61|bactericidal|O
DDI-DrugBank.d500.s1|63-68|action|O
DDI-DrugBank.d500.s1|70-71|of|O
DDI-DrugBank.d500.s1|73-82|penicillin|drug
DDI-DrugBank.d500.s1|83-83|,|O
DDI-DrugBank.d500.s1|85-86|it|O
DDI-DrugBank.d500.s1|88-89|is|O
DDI-DrugBank.d500.s1|91-99|advisable|O
DDI-DrugBank.d500.s1|101-102|to|O
DDI-DrugBank.d500.s1|104-108|avoid|O
DDI-DrugBank.d500.s1|110-115|giving|O
DDI-DrugBank.d500.s1|117-129|tetracyclines|group
DDI-DrugBank.d500.s1|131-132|in|O
DDI-DrugBank.d500.s1|134-144|conjunction|O
DDI-DrugBank.d500.s1|146-149|with|O
DDI-DrugBank.d500.s1|151-160|penicillin|group
DDI-DrugBank.d500.s1|161-161|.|O
DDI-DrugBank.d500.s2|0-9|Absorption|O
DDI-DrugBank.d500.s2|11-12|of|O
DDI-DrugBank.d500.s2|14-26|tetracyclines|group
DDI-DrugBank.d500.s2|28-29|is|O
DDI-DrugBank.d500.s2|31-38|impaired|O
DDI-DrugBank.d500.s2|40-41|by|O
DDI-DrugBank.d500.s2|43-50|antacids|group
DDI-DrugBank.d500.s2|52-61|containing|O
DDI-DrugBank.d500.s2|63-70|aluminum|drug
DDI-DrugBank.d500.s2|71-71|,|O
DDI-DrugBank.d500.s2|73-79|calcium|drug
DDI-DrugBank.d500.s2|80-80|,|O
DDI-DrugBank.d500.s2|82-83|or|O
DDI-DrugBank.d500.s2|85-93|magnesium|drug
DDI-DrugBank.d500.s2|94-94|,|O
DDI-DrugBank.d500.s2|96-98|and|O
DDI-DrugBank.d500.s2|100-114|iron-containing|drug
DDI-DrugBank.d500.s2|116-127|preparations|O
DDI-DrugBank.d500.s2|128-128|.|O
DDI-DrugBank.d500.s3|0-9|Absorption|O
DDI-DrugBank.d500.s3|11-12|of|O
DDI-DrugBank.d500.s3|14-25|tetracycline|drug
DDI-DrugBank.d500.s3|27-28|is|O
DDI-DrugBank.d500.s3|30-37|impaired|O
DDI-DrugBank.d500.s3|39-40|by|O
DDI-DrugBank.d500.s3|42-62|bismuth subsalicylate|drug
DDI-DrugBank.d500.s3|63-63|.|O
DDI-DrugBank.d500.s4|0-11|Barbiturates|group
DDI-DrugBank.d500.s4|12-12|,|O
DDI-DrugBank.d500.s4|14-26|carbamazepine|drug
DDI-DrugBank.d500.s4|27-27|,|O
DDI-DrugBank.d500.s4|29-31|and|O
DDI-DrugBank.d500.s4|33-41|phenytoin|drug
DDI-DrugBank.d500.s4|43-50|decrease|O
DDI-DrugBank.d500.s4|52-54|the|O
DDI-DrugBank.d500.s4|56-64|half-life|O
DDI-DrugBank.d500.s4|66-67|of|O
DDI-DrugBank.d500.s4|69-79|doxycycline|drug
DDI-DrugBank.d500.s4|80-80|.|O
DDI-DrugBank.d500.s5|0-2|The|O
DDI-DrugBank.d500.s5|4-13|concurrent|O
DDI-DrugBank.d500.s5|15-17|use|O
DDI-DrugBank.d500.s5|19-20|of|O
DDI-DrugBank.d500.s5|22-33|tetracycline|drug
DDI-DrugBank.d500.s5|35-37|and|O
DDI-DrugBank.d500.s5|39-47|Penthrane|brand
DDI-DrugBank.d500.s5|49-49|(|O
DDI-DrugBank.d500.s5|50-63|methoxyflurane|drug
DDI-DrugBank.d500.s5|64-64|)|O
DDI-DrugBank.d500.s5|66-68|has|O
DDI-DrugBank.d500.s5|70-73|been|O
DDI-DrugBank.d500.s5|75-82|reported|O
DDI-DrugBank.d500.s5|84-85|to|O
DDI-DrugBank.d500.s5|87-92|result|O
DDI-DrugBank.d500.s5|94-95|in|O
DDI-DrugBank.d500.s5|97-101|fatal|O
DDI-DrugBank.d500.s5|103-107|renal|O
DDI-DrugBank.d500.s5|109-116|toxicity|O
DDI-DrugBank.d500.s5|117-117|.|O
DDI-DrugBank.d500.s6|0-9|Concurrent|O
DDI-DrugBank.d500.s6|11-13|use|O
DDI-DrugBank.d500.s6|15-16|of|O
DDI-DrugBank.d500.s6|18-29|tetracycline|drug
DDI-DrugBank.d500.s6|31-33|may|O
DDI-DrugBank.d500.s6|35-40|render|O
DDI-DrugBank.d500.s6|42-45|oral|O
DDI-DrugBank.d500.s6|47-60|contraceptives|group
DDI-DrugBank.d500.s6|62-65|less|O
DDI-DrugBank.d500.s6|67-75|effective|O
DDI-DrugBank.d500.s6|76-76|.|O
DDI-DrugBank.d500.s7|0-14|Drug/Laboratory|O
DDI-DrugBank.d500.s7|16-19|Test|O
DDI-DrugBank.d500.s7|21-32|Interactions|O
DDI-DrugBank.d500.s7|34-38|False|O
DDI-DrugBank.d500.s7|40-49|elevations|O
DDI-DrugBank.d500.s7|51-52|of|O
DDI-DrugBank.d500.s7|54-60|urinary|O
DDI-DrugBank.d500.s7|62-74|catecholamine|O
DDI-DrugBank.d500.s7|76-81|levels|O
DDI-DrugBank.d500.s7|83-85|may|O
DDI-DrugBank.d500.s7|87-91|occur|O
DDI-DrugBank.d500.s7|93-95|due|O
DDI-DrugBank.d500.s7|97-98|to|O
DDI-DrugBank.d500.s7|100-111|interference|O
DDI-DrugBank.d500.s7|113-116|with|O
DDI-DrugBank.d500.s7|118-120|the|O
DDI-DrugBank.d500.s7|122-133|fluorescence|O
DDI-DrugBank.d500.s7|135-138|test|O
DDI-DrugBank.d500.s7|139-139|.|O
DDI-DrugBank.d265.s0|0-13|Chlorthalidone|drug
DDI-DrugBank.d265.s0|15-17|may|O
DDI-DrugBank.d265.s0|19-21|add|O
DDI-DrugBank.d265.s0|23-24|to|O
DDI-DrugBank.d265.s0|26-27|or|O
DDI-DrugBank.d265.s0|29-38|potentiate|O
DDI-DrugBank.d265.s0|40-42|the|O
DDI-DrugBank.d265.s0|44-49|action|O
DDI-DrugBank.d265.s0|51-52|of|O
DDI-DrugBank.d265.s0|54-58|other|O
DDI-DrugBank.d265.s0|60-81|antihypertensive drugs|group
DDI-DrugBank.d265.s0|82-82|.|O
DDI-DrugBank.d265.s1|0-11|Potentiation|O
DDI-DrugBank.d265.s1|13-18|occurs|O
DDI-DrugBank.d265.s1|20-23|with|O
DDI-DrugBank.d265.s1|25-71|ganglionic peripheral adrenergic blocking drugs|group
DDI-DrugBank.d265.s1|72-72|.|O
DDI-DrugBank.d265.s2|0-9|Medication|O
DDI-DrugBank.d265.s2|11-14|such|O
DDI-DrugBank.d265.s2|16-17|as|O
DDI-DrugBank.d265.s2|19-27|digitalis|group
DDI-DrugBank.d265.s2|29-31|may|O
DDI-DrugBank.d265.s2|33-36|also|O
DDI-DrugBank.d265.s2|38-46|influence|O
DDI-DrugBank.d265.s2|48-52|serum|O
DDI-DrugBank.d265.s2|54-65|electrolytes|O
DDI-DrugBank.d265.s2|66-66|.|O
DDI-DrugBank.d265.s3|0-6|Warning|O
DDI-DrugBank.d265.s3|8-12|signs|O
DDI-DrugBank.d265.s3|13-13|,|O
DDI-DrugBank.d265.s3|15-26|irrespective|O
DDI-DrugBank.d265.s3|28-29|of|O
DDI-DrugBank.d265.s3|31-35|cause|O
DDI-DrugBank.d265.s3|36-36|,|O
DDI-DrugBank.d265.s3|38-40|are|O
DDI-DrugBank.d265.s3|41-41|:|O
DDI-DrugBank.d265.s3|43-49|dryness|O
DDI-DrugBank.d265.s3|51-52|of|O
DDI-DrugBank.d265.s3|54-58|mouth|O
DDI-DrugBank.d265.s3|59-59|,|O
DDI-DrugBank.d265.s3|61-66|thirst|O
DDI-DrugBank.d265.s3|67-67|,|O
DDI-DrugBank.d265.s3|69-76|weakness|O
DDI-DrugBank.d265.s3|77-77|,|O
DDI-DrugBank.d265.s3|79-86|lethargy|O
DDI-DrugBank.d265.s3|87-87|,|O
DDI-DrugBank.d265.s3|89-98|drowsiness|O
DDI-DrugBank.d265.s3|99-99|,|O
DDI-DrugBank.d265.s3|101-112|restlessness|O
DDI-DrugBank.d265.s3|113-113|,|O
DDI-DrugBank.d265.s3|115-120|muscle|O
DDI-DrugBank.d265.s3|122-126|pains|O
DDI-DrugBank.d265.s3|128-129|or|O
DDI-DrugBank.d265.s3|131-136|cramps|O
DDI-DrugBank.d265.s3|137-137|,|O
DDI-DrugBank.d265.s3|139-146|muscular|O
DDI-DrugBank.d265.s3|148-154|fatigue|O
DDI-DrugBank.d265.s3|155-155|,|O
DDI-DrugBank.d265.s3|157-167|hypotension|O
DDI-DrugBank.d265.s3|168-168|,|O
DDI-DrugBank.d265.s3|170-177|oliguria|O
DDI-DrugBank.d265.s3|178-178|,|O
DDI-DrugBank.d265.s3|180-190|tachycardia|O
DDI-DrugBank.d265.s3|191-191|,|O
DDI-DrugBank.d265.s3|193-195|and|O
DDI-DrugBank.d265.s3|197-212|gastrointestinal|O
DDI-DrugBank.d265.s3|214-225|disturbances|O
DDI-DrugBank.d265.s3|227-230|such|O
DDI-DrugBank.d265.s3|232-233|as|O
DDI-DrugBank.d265.s3|235-240|nausea|O
DDI-DrugBank.d265.s3|242-244|and|O
DDI-DrugBank.d265.s3|246-253|vomiting|O
DDI-DrugBank.d265.s3|254-254|.|O
DDI-DrugBank.d265.s4|0-6|Insulin|drug
DDI-DrugBank.d265.s4|8-19|requirements|O
DDI-DrugBank.d265.s4|21-22|in|O
DDI-DrugBank.d265.s4|24-31|diabetic|O
DDI-DrugBank.d265.s4|33-40|patients|O
DDI-DrugBank.d265.s4|42-44|may|O
DDI-DrugBank.d265.s4|46-47|be|O
DDI-DrugBank.d265.s4|49-57|increased|O
DDI-DrugBank.d265.s4|58-58|,|O
DDI-DrugBank.d265.s4|60-68|decreased|O
DDI-DrugBank.d265.s4|69-69|,|O
DDI-DrugBank.d265.s4|71-72|or|O
DDI-DrugBank.d265.s4|74-82|unchanged|O
DDI-DrugBank.d265.s4|83-83|.|O
DDI-DrugBank.d265.s5|0-5|Higher|O
DDI-DrugBank.d265.s5|7-12|dosage|O
DDI-DrugBank.d265.s5|14-15|of|O
DDI-DrugBank.d265.s5|17-20|oral|O
DDI-DrugBank.d265.s5|22-40|hypoglycemic agents|group
DDI-DrugBank.d265.s5|42-44|may|O
DDI-DrugBank.d265.s5|46-47|be|O
DDI-DrugBank.d265.s5|49-56|required|O
DDI-DrugBank.d265.s5|57-57|.|O
DDI-DrugBank.d265.s6|0-5|Latent|O
DDI-DrugBank.d265.s6|7-14|diabetes|O
DDI-DrugBank.d265.s6|16-23|mellitus|O
DDI-DrugBank.d265.s6|25-27|may|O
DDI-DrugBank.d265.s6|29-34|become|O
DDI-DrugBank.d265.s6|36-43|manifest|O
DDI-DrugBank.d265.s6|45-50|during|O
DDI-DrugBank.d265.s6|52-65|chlorthalidone|drug
DDI-DrugBank.d265.s6|67-80|administration|O
DDI-DrugBank.d265.s6|81-81|.|O
DDI-DrugBank.d265.s7|0-13|Chlorthalidone|drug
DDI-DrugBank.d265.s7|15-17|and|O
DDI-DrugBank.d265.s7|19-25|related|O
DDI-DrugBank.d265.s7|27-31|drugs|O
DDI-DrugBank.d265.s7|33-35|may|O
DDI-DrugBank.d265.s7|37-44|increase|O
DDI-DrugBank.d265.s7|46-48|the|O
DDI-DrugBank.d265.s7|50-63|responsiveness|O
DDI-DrugBank.d265.s7|65-66|to|O
DDI-DrugBank.d265.s7|68-79|tubocurarine|drug
DDI-DrugBank.d265.s7|80-80|.|O
DDI-DrugBank.d265.s8|0-13|Chlorthalidone|drug
DDI-DrugBank.d265.s8|15-17|and|O
DDI-DrugBank.d265.s8|19-25|related|O
DDI-DrugBank.d265.s8|27-31|drugs|O
DDI-DrugBank.d265.s8|33-35|may|O
DDI-DrugBank.d265.s8|37-44|decrease|O
DDI-DrugBank.d265.s8|46-53|arterial|O
DDI-DrugBank.d265.s8|55-68|responsiveness|O
DDI-DrugBank.d265.s8|70-71|to|O
DDI-DrugBank.d265.s8|73-86|norepinephrine|drug
DDI-DrugBank.d265.s8|87-87|.|O
DDI-DrugBank.d265.s9|0-3|This|O
DDI-DrugBank.d265.s9|5-14|diminution|O
DDI-DrugBank.d265.s9|16-17|is|O
DDI-DrugBank.d265.s9|19-21|not|O
DDI-DrugBank.d265.s9|23-32|sufficient|O
DDI-DrugBank.d265.s9|34-35|to|O
DDI-DrugBank.d265.s9|37-44|preclude|O
DDI-DrugBank.d265.s9|46-58|effectiveness|O
DDI-DrugBank.d265.s9|60-61|of|O
DDI-DrugBank.d265.s9|63-65|the|O
DDI-DrugBank.d265.s9|67-73|pressor|O
DDI-DrugBank.d265.s9|75-79|agent|O
DDI-DrugBank.d265.s9|81-83|for|O
DDI-DrugBank.d265.s9|85-95|therapeutic|O
DDI-DrugBank.d265.s9|97-99|use|O
DDI-DrugBank.d265.s9|100-100|.|O
DDI-DrugBank.d629.s0|0-3|Oral|O
DDI-DrugBank.d629.s0|5-17|metronidazole|drug
DDI-DrugBank.d629.s0|19-21|has|O
DDI-DrugBank.d629.s0|23-26|been|O
DDI-DrugBank.d629.s0|28-35|reported|O
DDI-DrugBank.d629.s0|37-38|to|O
DDI-DrugBank.d629.s0|40-49|potentiate|O
DDI-DrugBank.d629.s0|51-53|the|O
DDI-DrugBank.d629.s0|55-67|anticoagulant|O
DDI-DrugBank.d629.s0|69-74|effect|O
DDI-DrugBank.d629.s0|76-77|of|O
DDI-DrugBank.d629.s0|79-86|coumarin|group
DDI-DrugBank.d629.s0|88-90|and|O
DDI-DrugBank.d629.s0|92-99|warfarin|drug
DDI-DrugBank.d629.s0|100-100|,|O
DDI-DrugBank.d629.s0|102-110|resulting|O
DDI-DrugBank.d629.s0|112-113|in|O
DDI-DrugBank.d629.s0|115-115|a|O
DDI-DrugBank.d629.s0|117-128|prolongation|O
DDI-DrugBank.d629.s0|130-131|of|O
DDI-DrugBank.d629.s0|133-143|prothrombin|O
DDI-DrugBank.d629.s0|145-148|time|O
DDI-DrugBank.d629.s0|149-149|.|O
DDI-DrugBank.d629.s1|0-3|Drug|O
DDI-DrugBank.d629.s1|5-16|interactions|O
DDI-DrugBank.d629.s1|18-23|should|O
DDI-DrugBank.d629.s1|25-26|be|O
DDI-DrugBank.d629.s1|28-31|kept|O
DDI-DrugBank.d629.s1|33-34|in|O
DDI-DrugBank.d629.s1|36-39|mind|O
DDI-DrugBank.d629.s1|41-44|when|O
DDI-DrugBank.d629.s1|46-53|METROGEL|brand
DDI-DrugBank.d629.s1|55-55|(|O
DDI-DrugBank.d629.s1|56-68|metronidazole|drug
DDI-DrugBank.d629.s1|70-72|gel|O
DDI-DrugBank.d629.s1|73-73|)|O
DDI-DrugBank.d629.s1|74-74|,|O
DDI-DrugBank.d629.s1|76-76|1|O
DDI-DrugBank.d629.s1|77-77|%|O
DDI-DrugBank.d629.s1|79-80|is|O
DDI-DrugBank.d629.s1|82-91|prescribed|O
DDI-DrugBank.d629.s1|93-95|for|O
DDI-DrugBank.d629.s1|97-104|patients|O
DDI-DrugBank.d629.s1|106-108|who|O
DDI-DrugBank.d629.s1|110-112|are|O
DDI-DrugBank.d629.s1|114-122|receiving|O
DDI-DrugBank.d629.s1|124-136|anticoagulant|O
DDI-DrugBank.d629.s1|138-146|treatment|O
DDI-DrugBank.d629.s1|147-147|,|O
DDI-DrugBank.d629.s1|149-156|although|O
DDI-DrugBank.d629.s1|158-161|they|O
DDI-DrugBank.d629.s1|163-165|are|O
DDI-DrugBank.d629.s1|167-170|less|O
DDI-DrugBank.d629.s1|172-177|likely|O
DDI-DrugBank.d629.s1|179-180|to|O
DDI-DrugBank.d629.s1|182-186|occur|O
DDI-DrugBank.d629.s1|188-191|with|O
DDI-DrugBank.d629.s1|193-199|topical|O
DDI-DrugBank.d629.s1|201-213|metronidazole|drug
DDI-DrugBank.d629.s1|215-228|administration|O
DDI-DrugBank.d629.s1|230-236|because|O
DDI-DrugBank.d629.s1|238-239|of|O
DDI-DrugBank.d629.s1|241-243|low|O
DDI-DrugBank.d629.s1|245-254|absorption|O
DDI-DrugBank.d629.s1|255-255|.|O
DDI-MedLine.d58.s0|0-5|Effect|O
DDI-MedLine.d58.s0|7-8|of|O
DDI-MedLine.d58.s0|23-24|on|O
DDI-MedLine.d58.s0|26-42|voltage-dependent|O
DDI-MedLine.d58.s0|44-45|Ca|O
DDI-MedLine.d58.s0|46-46|(|O
DDI-MedLine.d58.s0|47-48|2+|O
DDI-MedLine.d58.s0|49-49|)|O
DDI-MedLine.d58.s0|51-57|channel|O
DDI-MedLine.d58.s0|59-66|subtypes|O
DDI-MedLine.d58.s0|68-69|in|O
DDI-MedLine.d58.s0|71-76|bovine|O
DDI-MedLine.d58.s0|78-87|chromaffin|O
DDI-MedLine.d58.s0|89-93|cells|O
DDI-MedLine.d58.s0|94-94|.|O
DDI-MedLine.d58.s1|0-1|In|O
DDI-MedLine.d58.s1|3-10|previous|O
DDI-MedLine.d58.s1|12-18|reports|O
DDI-MedLine.d58.s1|20-21|we|O
DDI-MedLine.d58.s1|23-26|have|O
DDI-MedLine.d58.s1|28-32|shown|O
DDI-MedLine.d58.s1|34-37|that|O
DDI-MedLine.d58.s1|52-58|inhibit|O
DDI-MedLine.d58.s1|60-63|high|O
DDI-MedLine.d58.s1|65-73|threshold|O
DDI-MedLine.d58.s1|75-91|voltage-dependent|O
DDI-MedLine.d58.s1|93-94|Ca|O
DDI-MedLine.d58.s1|95-95|(|O
DDI-MedLine.d58.s1|96-97|2+|O
DDI-MedLine.d58.s1|98-98|)|O
DDI-MedLine.d58.s1|100-107|channels|O
DDI-MedLine.d58.s1|109-110|in|O
DDI-MedLine.d58.s1|112-119|neuronal|O
DDI-MedLine.d58.s1|121-125|cells|O
DDI-MedLine.d58.s1|126-126|.|O
DDI-MedLine.d58.s2|0-6|However|O
DDI-MedLine.d58.s2|7-7|,|O
DDI-MedLine.d58.s2|9-13|these|O
DDI-MedLine.d58.s2|15-21|studies|O
DDI-MedLine.d58.s2|23-25|did|O
DDI-MedLine.d58.s2|27-29|not|O
DDI-MedLine.d58.s2|31-34|show|O
DDI-MedLine.d58.s2|36-42|whether|O
DDI-MedLine.d58.s2|65-74|inhibition|O
DDI-MedLine.d58.s2|76-77|of|O
DDI-MedLine.d58.s2|79-80|Ca|O
DDI-MedLine.d58.s2|81-81|(|O
DDI-MedLine.d58.s2|82-83|2+|O
DDI-MedLine.d58.s2|84-84|)|O
DDI-MedLine.d58.s2|86-93|currents|O
DDI-MedLine.d58.s2|95-107|discriminates|O
DDI-MedLine.d58.s2|109-113|among|O
DDI-MedLine.d58.s2|115-117|the|O
DDI-MedLine.d58.s2|119-125|various|O
DDI-MedLine.d58.s2|127-128|Ca|O
DDI-MedLine.d58.s2|129-129|(|O
DDI-MedLine.d58.s2|130-131|2+|O
DDI-MedLine.d58.s2|132-132|)|O
DDI-MedLine.d58.s2|134-140|channel|O
DDI-MedLine.d58.s2|142-149|subtypes|O
DDI-MedLine.d58.s2|150-150|,|O
DDI-MedLine.d58.s2|152-159|although|O
DDI-MedLine.d58.s2|161-162|it|O
DDI-MedLine.d58.s2|164-165|is|O
DDI-MedLine.d58.s2|167-171|known|O
DDI-MedLine.d58.s2|173-176|that|O
DDI-MedLine.d58.s2|178-182|there|O
DDI-MedLine.d58.s2|184-186|are|O
DDI-MedLine.d58.s2|188-189|at|O
DDI-MedLine.d58.s2|191-195|least|O
DDI-MedLine.d58.s2|197-200|five|O
DDI-MedLine.d58.s2|202-210|different|O
DDI-MedLine.d58.s2|212-213|Ca|O
DDI-MedLine.d58.s2|214-214|(|O
DDI-MedLine.d58.s2|215-216|2+|O
DDI-MedLine.d58.s2|217-217|)|O
DDI-MedLine.d58.s2|219-225|channel|O
DDI-MedLine.d58.s2|227-234|subtypes|O
DDI-MedLine.d58.s2|236-237|in|O
DDI-MedLine.d58.s2|239-246|neuronal|O
DDI-MedLine.d58.s2|248-252|cells|O
DDI-MedLine.d58.s2|253-253|.|O
DDI-MedLine.d58.s3|0-1|In|O
DDI-MedLine.d58.s3|3-6|this|O
DDI-MedLine.d58.s3|8-12|study|O
DDI-MedLine.d58.s3|14-15|we|O
DDI-MedLine.d58.s3|17-28|investigated|O
DDI-MedLine.d58.s3|30-32|the|O
DDI-MedLine.d58.s3|34-39|effect|O
DDI-MedLine.d58.s3|41-42|of|O
DDI-MedLine.d58.s3|57-58|on|O
DDI-MedLine.d58.s3|60-63|high|O
DDI-MedLine.d58.s3|65-73|threshold|O
DDI-MedLine.d58.s3|75-91|voltage-dependent|O
DDI-MedLine.d58.s3|93-94|Ca|O
DDI-MedLine.d58.s3|95-95|(|O
DDI-MedLine.d58.s3|96-97|2+|O
DDI-MedLine.d58.s3|98-98|)|O
DDI-MedLine.d58.s3|100-106|channel|O
DDI-MedLine.d58.s3|108-115|subtypes|O
DDI-MedLine.d58.s3|117-121|using|O
DDI-MedLine.d58.s3|123-127|their|O
DDI-MedLine.d58.s3|129-161|selective Ca ( 2+ ) channel blockers|group
DDI-MedLine.d58.s3|129-161|selective Ca ( 2+ ) channel blockers|group
DDI-MedLine.d58.s3|174-174|(|O
DDI-MedLine.d58.s3|175-180|L-type|O
DDI-MedLine.d58.s3|181-181|)|O
DDI-MedLine.d58.s3|182-182|,|O
DDI-MedLine.d58.s3|205-205|(|O
DDI-MedLine.d58.s3|206-211|N-type|O
DDI-MedLine.d58.s3|212-212|)|O
DDI-MedLine.d58.s3|213-213|,|O
DDI-MedLine.d58.s3|215-216|or|O
DDI-MedLine.d58.s3|237-237|(|O
DDI-MedLine.d58.s3|238-243|P-type|O
DDI-MedLine.d58.s3|244-244|)|O
DDI-MedLine.d58.s3|246-247|in|O
DDI-MedLine.d58.s3|249-254|bovine|O
DDI-MedLine.d58.s3|256-265|chromaffin|O
DDI-MedLine.d58.s3|267-271|cells|O
DDI-MedLine.d58.s3|272-272|.|O
DDI-MedLine.d58.s4|0-1|We|O
DDI-MedLine.d58.s4|3-7|could|O
DDI-MedLine.d58.s4|9-15|observe|O
DDI-MedLine.d58.s4|17-20|that|O
DDI-MedLine.d58.s4|35-43|inhibited|O
DDI-MedLine.d58.s4|45-48|high|O
DDI-MedLine.d58.s4|50-58|threshold|O
DDI-MedLine.d58.s4|60-76|voltage-dependent|O
DDI-MedLine.d58.s4|78-79|Ca|O
DDI-MedLine.d58.s4|80-80|(|O
DDI-MedLine.d58.s4|81-82|2+|O
DDI-MedLine.d58.s4|83-83|)|O
DDI-MedLine.d58.s4|85-92|currents|O
DDI-MedLine.d58.s4|94-95|in|O
DDI-MedLine.d58.s4|97-97|a|O
DDI-MedLine.d58.s4|99-112|dose-dependent|O
DDI-MedLine.d58.s4|114-119|manner|O
DDI-MedLine.d58.s4|120-120|.|O
DDI-MedLine.d58.s5|0-2|The|O
DDI-MedLine.d58.s5|4-5|IC|O
DDI-MedLine.d58.s5|6-6|(|O
DDI-MedLine.d58.s5|7-8|50|O
DDI-MedLine.d58.s5|9-9|)|O
DDI-MedLine.d58.s5|11-13|was|O
DDI-MedLine.d58.s5|15-19|about|O
DDI-MedLine.d58.s5|21-23|120|O
DDI-MedLine.d58.s5|25-36|microgram/ml|O
DDI-MedLine.d58.s5|37-37|.|O
DDI-MedLine.d58.s6|0-9|Nimodipine|drug
DDI-MedLine.d58.s6|11-13|had|O
DDI-MedLine.d58.s6|15-16|no|O
DDI-MedLine.d58.s6|18-23|effect|O
DDI-MedLine.d58.s6|25-26|on|O
DDI-MedLine.d58.s6|41-48|response|O
DDI-MedLine.d58.s6|49-49|.|O
DDI-MedLine.d58.s7|0-4|These|O
DDI-MedLine.d58.s7|6-9|data|O
DDI-MedLine.d58.s7|11-17|suggest|O
DDI-MedLine.d58.s7|19-22|that|O
DDI-MedLine.d58.s7|37-39|are|O
DDI-MedLine.d58.s7|41-50|negatively|O
DDI-MedLine.d58.s7|52-58|coupled|O
DDI-MedLine.d58.s7|60-61|to|O
DDI-MedLine.d58.s7|63-67|three|O
DDI-MedLine.d58.s7|69-73|types|O
DDI-MedLine.d58.s7|75-76|of|O
DDI-MedLine.d58.s7|78-84|calcium|O
DDI-MedLine.d58.s7|86-93|channels|O
DDI-MedLine.d58.s7|95-96|in|O
DDI-MedLine.d58.s7|98-103|bovine|O
DDI-MedLine.d58.s7|105-114|chromaffin|O
DDI-MedLine.d58.s7|116-119|cell|O
DDI-MedLine.d58.s7|120-120|,|O
DDI-MedLine.d58.s7|122-130|including|O
DDI-MedLine.d58.s7|132-133|an|O
DDI-MedLine.d58.s7|151-164|GVIA-sensitive|O
DDI-MedLine.d58.s7|166-166|(|O
DDI-MedLine.d58.s7|167-172|N-type|O
DDI-MedLine.d58.s7|173-173|)|O
DDI-MedLine.d58.s7|175-181|channel|O
DDI-MedLine.d58.s7|182-182|,|O
DDI-MedLine.d58.s7|184-185|an|O
DDI-MedLine.d58.s7|202-214|IVA-sensitive|O
DDI-MedLine.d58.s7|216-216|(|O
DDI-MedLine.d58.s7|217-222|P-type|O
DDI-MedLine.d58.s7|223-223|)|O
DDI-MedLine.d58.s7|225-231|channel|O
DDI-MedLine.d58.s7|233-235|and|O
DDI-MedLine.d58.s7|237-262|nimodipine/omega-conotoxin|drug
DDI-MedLine.d58.s7|264-282|GVIA/omega-agatoxin|O
DDI-MedLine.d58.s7|284-296|VIA-resistant|O
DDI-MedLine.d58.s7|298-298|(|O
DDI-MedLine.d58.s7|299-309|presumptive|O
DDI-MedLine.d58.s7|311-316|Q-type|O
DDI-MedLine.d58.s7|317-317|)|O
DDI-MedLine.d58.s7|319-325|channel|O
DDI-MedLine.d58.s7|326-326|.|O
DDI-MedLine.d58.s8|0-3|Thus|O
DDI-MedLine.d58.s8|4-4|,|O
DDI-MedLine.d58.s8|6-8|the|O
DDI-MedLine.d58.s8|10-18|selective|O
DDI-MedLine.d58.s8|20-29|regulation|O
DDI-MedLine.d58.s8|31-32|of|O
DDI-MedLine.d58.s8|34-50|voltage-dependent|O
DDI-MedLine.d58.s8|52-53|Ca|O
DDI-MedLine.d58.s8|54-54|(|O
DDI-MedLine.d58.s8|55-56|2+|O
DDI-MedLine.d58.s8|57-57|)|O
DDI-MedLine.d58.s8|59-66|subtypes|O
DDI-MedLine.d58.s8|68-69|by|O
DDI-MedLine.d58.s8|84-85|in|O
DDI-MedLine.d58.s8|87-92|bovine|O
DDI-MedLine.d58.s8|94-103|chromaffin|O
DDI-MedLine.d58.s8|105-108|cell|O
DDI-MedLine.d58.s8|110-114|could|O
DDI-MedLine.d58.s8|116-117|be|O
DDI-MedLine.d58.s8|119-121|the|O
DDI-MedLine.d58.s8|123-130|cellular|O
DDI-MedLine.d58.s8|132-136|basis|O
DDI-MedLine.d58.s8|138-139|of|O
DDI-MedLine.d58.s8|141-150|antistress|O
DDI-MedLine.d58.s8|152-158|effects|O
DDI-MedLine.d58.s8|160-166|induced|O
DDI-MedLine.d58.s8|168-169|by|O
DDI-MedLine.d58.s8|171-177|ginseng|drug
DDI-MedLine.d58.s8|178-178|.|O
DDI-DrugBank.d399.s0|0-10|Preliminary|O
DDI-DrugBank.d399.s0|12-15|data|O
DDI-DrugBank.d399.s0|17-21|which|O
DDI-DrugBank.d399.s0|23-29|suggest|O
DDI-DrugBank.d399.s0|31-34|that|O
DDI-DrugBank.d399.s0|36-42|dapsone|drug
DDI-DrugBank.d399.s0|44-46|may|O
DDI-DrugBank.d399.s0|48-54|inhibit|O
DDI-DrugBank.d399.s0|56-58|the|O
DDI-DrugBank.d399.s0|60-76|anti-inflammatory|O
DDI-DrugBank.d399.s0|78-85|activity|O
DDI-DrugBank.d399.s0|87-88|of|O
DDI-DrugBank.d399.s0|90-97|Lamprene|brand
DDI-DrugBank.d399.s0|99-102|have|O
DDI-DrugBank.d399.s0|104-106|not|O
DDI-DrugBank.d399.s0|108-111|been|O
DDI-DrugBank.d399.s0|113-121|confirmed|O
DDI-DrugBank.d399.s0|122-122|.|O
DDI-DrugBank.d399.s1|0-1|If|O
DDI-DrugBank.d399.s1|3-20|leprosy-associated|O
DDI-DrugBank.d399.s1|22-33|inflammatory|O
DDI-DrugBank.d399.s1|35-43|reactions|O
DDI-DrugBank.d399.s1|45-51|develop|O
DDI-DrugBank.d399.s1|53-54|in|O
DDI-DrugBank.d399.s1|56-63|patients|O
DDI-DrugBank.d399.s1|65-69|being|O
DDI-DrugBank.d399.s1|71-77|treated|O
DDI-DrugBank.d399.s1|79-82|with|O
DDI-DrugBank.d399.s1|84-90|dapsone|drug
DDI-DrugBank.d399.s1|92-94|and|O
DDI-DrugBank.d399.s1|96-106|clofazimine|drug
DDI-DrugBank.d399.s1|107-107|,|O
DDI-DrugBank.d399.s1|109-110|it|O
DDI-DrugBank.d399.s1|112-113|is|O
DDI-DrugBank.d399.s1|115-119|still|O
DDI-DrugBank.d399.s1|121-129|advisable|O
DDI-DrugBank.d399.s1|131-132|to|O
DDI-DrugBank.d399.s1|134-141|continue|O
DDI-DrugBank.d399.s1|143-151|treatment|O
DDI-DrugBank.d399.s1|153-156|with|O
DDI-DrugBank.d399.s1|158-161|both|O
DDI-DrugBank.d399.s1|163-167|drugs|O
DDI-DrugBank.d399.s1|168-168|.|O
DDI-DrugBank.d516.s0|0-11|Theophylline|drug
DDI-DrugBank.d516.s0|12-12|:|O
DDI-DrugBank.d516.s0|14-15|In|O
DDI-DrugBank.d516.s0|17-21|three|O
DDI-DrugBank.d516.s0|23-37|pharmacokinetic|O
DDI-DrugBank.d516.s0|39-45|studies|O
DDI-DrugBank.d516.s0|47-55|including|O
DDI-DrugBank.d516.s0|57-58|46|O
DDI-DrugBank.d516.s0|60-65|normal|O
DDI-DrugBank.d516.s0|66-66|,|O
DDI-DrugBank.d516.s0|68-74|healthy|O
DDI-DrugBank.d516.s0|76-83|subjects|O
DDI-DrugBank.d516.s0|84-84|,|O
DDI-DrugBank.d516.s0|86-97|theophylline|drug
DDI-DrugBank.d516.s0|99-107|clearance|O
DDI-DrugBank.d516.s0|109-111|and|O
DDI-DrugBank.d516.s0|113-125|concentration|O
DDI-DrugBank.d516.s0|127-130|were|O
DDI-DrugBank.d516.s0|132-134|not|O
DDI-DrugBank.d516.s0|136-148|significantly|O
DDI-DrugBank.d516.s0|150-156|altered|O
DDI-DrugBank.d516.s0|158-159|by|O
DDI-DrugBank.d516.s0|161-163|the|O
DDI-DrugBank.d516.s0|165-172|addition|O
DDI-DrugBank.d516.s0|174-175|of|O
DDI-DrugBank.d516.s0|177-188|lomefloxacin|drug
DDI-DrugBank.d516.s0|189-189|.|O
DDI-DrugBank.d516.s1|0-1|In|O
DDI-DrugBank.d516.s1|3-10|clinical|O
DDI-DrugBank.d516.s1|12-18|studies|O
DDI-DrugBank.d516.s1|20-24|where|O
DDI-DrugBank.d516.s1|26-33|patients|O
DDI-DrugBank.d516.s1|35-38|were|O
DDI-DrugBank.d516.s1|40-41|on|O
DDI-DrugBank.d516.s1|43-49|chronic|O
DDI-DrugBank.d516.s1|51-62|theophylline|drug
DDI-DrugBank.d516.s1|64-70|therapy|O
DDI-DrugBank.d516.s1|71-71|,|O
DDI-DrugBank.d516.s1|73-84|lomefloxacin|drug
DDI-DrugBank.d516.s1|86-88|had|O
DDI-DrugBank.d516.s1|90-91|no|O
DDI-DrugBank.d516.s1|93-102|measurable|O
DDI-DrugBank.d516.s1|104-109|effect|O
DDI-DrugBank.d516.s1|111-112|on|O
DDI-DrugBank.d516.s1|114-116|the|O
DDI-DrugBank.d516.s1|118-121|mean|O
DDI-DrugBank.d516.s1|123-134|distribution|O
DDI-DrugBank.d516.s1|136-137|of|O
DDI-DrugBank.d516.s1|139-150|theophylline|drug
DDI-DrugBank.d516.s1|152-165|concentrations|O
DDI-DrugBank.d516.s1|167-168|or|O
DDI-DrugBank.d516.s1|170-172|the|O
DDI-DrugBank.d516.s1|174-177|mean|O
DDI-DrugBank.d516.s1|179-187|estimates|O
DDI-DrugBank.d516.s1|189-190|of|O
DDI-DrugBank.d516.s1|192-203|theophylline|drug
DDI-DrugBank.d516.s1|205-213|clearance|O
DDI-DrugBank.d516.s1|214-214|.|O
DDI-DrugBank.d516.s2|0-5|Though|O
DDI-DrugBank.d516.s2|7-16|individual|O
DDI-DrugBank.d516.s2|18-29|theophylline|drug
DDI-DrugBank.d516.s2|31-36|levels|O
DDI-DrugBank.d516.s2|38-47|fluctuated|O
DDI-DrugBank.d516.s2|48-48|,|O
DDI-DrugBank.d516.s2|50-54|there|O
DDI-DrugBank.d516.s2|56-59|were|O
DDI-DrugBank.d516.s2|61-62|no|O
DDI-DrugBank.d516.s2|64-73|clinically|O
DDI-DrugBank.d516.s2|75-85|significant|O
DDI-DrugBank.d516.s2|87-94|symptoms|O
DDI-DrugBank.d516.s2|96-97|of|O
DDI-DrugBank.d516.s2|99-102|drug|O
DDI-DrugBank.d516.s2|104-115|inter-action|O
DDI-DrugBank.d516.s2|116-116|.|O
DDI-DrugBank.d516.s3|0-7|Antacids|group
DDI-DrugBank.d516.s3|9-11|and|O
DDI-DrugBank.d516.s3|13-22|sucralfate|drug
DDI-DrugBank.d516.s3|23-23|:|O
DDI-DrugBank.d516.s3|25-34|Sucralfate|drug
DDI-DrugBank.d516.s3|36-38|and|O
DDI-DrugBank.d516.s3|40-47|antacids|group
DDI-DrugBank.d516.s3|49-58|containing|O
DDI-DrugBank.d516.s3|60-68|magnesium|drug
DDI-DrugBank.d516.s3|70-71|or|O
DDI-DrugBank.d516.s3|73-80|aluminum|drug
DDI-DrugBank.d516.s3|81-81|,|O
DDI-DrugBank.d516.s3|83-84|as|O
DDI-DrugBank.d516.s3|86-89|well|O
DDI-DrugBank.d516.s3|91-92|as|O
DDI-DrugBank.d516.s3|94-105|formulations|O
DDI-DrugBank.d516.s3|107-116|containing|O
DDI-DrugBank.d516.s3|118-125|divalent|O
DDI-DrugBank.d516.s3|127-129|and|O
DDI-DrugBank.d516.s3|131-139|trivalent|O
DDI-DrugBank.d516.s3|141-147|cations|O
DDI-DrugBank.d516.s3|149-152|such|O
DDI-DrugBank.d516.s3|154-155|as|O
DDI-DrugBank.d516.s3|157-161|Videx|brand
DDI-DrugBank.d516.s3|164-164|(|O
DDI-DrugBank.d516.s3|165-174|didanosine|drug
DDI-DrugBank.d516.s3|175-175|)|O
DDI-DrugBank.d516.s3|176-176|,|O
DDI-DrugBank.d516.s3|178-194|chewable/buffered|O
DDI-DrugBank.d516.s3|196-202|tablets|O
DDI-DrugBank.d516.s3|204-205|or|O
DDI-DrugBank.d516.s3|207-209|the|O
DDI-DrugBank.d516.s3|211-219|pediatric|O
DDI-DrugBank.d516.s3|221-226|powder|O
DDI-DrugBank.d516.s3|228-230|for|O
DDI-DrugBank.d516.s3|232-235|oral|O
DDI-DrugBank.d516.s3|237-244|solution|O
DDI-DrugBank.d516.s3|246-248|can|O
DDI-DrugBank.d516.s3|250-253|form|O
DDI-DrugBank.d516.s3|255-263|chelation|O
DDI-DrugBank.d516.s3|265-273|complexes|O
DDI-DrugBank.d516.s3|275-278|with|O
DDI-DrugBank.d516.s3|280-291|lomefloxacin|drug
DDI-DrugBank.d516.s3|293-295|and|O
DDI-DrugBank.d516.s3|297-305|interfere|O
DDI-DrugBank.d516.s3|307-310|with|O
DDI-DrugBank.d516.s3|312-314|its|O
DDI-DrugBank.d516.s3|316-330|bioavailability|O
DDI-DrugBank.d516.s3|331-331|.|O
DDI-DrugBank.d516.s4|0-9|Sucralfate|drug
DDI-DrugBank.d516.s4|11-22|administered|O
DDI-DrugBank.d516.s4|24-24|2|O
DDI-DrugBank.d516.s4|26-30|hours|O
DDI-DrugBank.d516.s4|32-37|before|O
DDI-DrugBank.d516.s4|39-50|lomefloxacin|drug
DDI-DrugBank.d516.s4|52-59|resulted|O
DDI-DrugBank.d516.s4|61-62|in|O
DDI-DrugBank.d516.s4|64-64|a|O
DDI-DrugBank.d516.s4|66-71|slower|O
DDI-DrugBank.d516.s4|73-82|absorption|O
DDI-DrugBank.d516.s4|84-84|(|O
DDI-DrugBank.d516.s4|85-88|mean|O
DDI-DrugBank.d516.s4|90-90|C|O
DDI-DrugBank.d516.s4|92-94|max|O
DDI-DrugBank.d516.s4|96-104|decreased|O
DDI-DrugBank.d516.s4|106-107|by|O
DDI-DrugBank.d516.s4|109-110|30|O
DDI-DrugBank.d516.s4|111-111|%|O
DDI-DrugBank.d516.s4|113-115|and|O
DDI-DrugBank.d516.s4|117-120|mean|O
DDI-DrugBank.d516.s4|122-122|T|O
DDI-DrugBank.d516.s4|124-126|max|O
DDI-DrugBank.d516.s4|128-136|increased|O
DDI-DrugBank.d516.s4|138-139|by|O
DDI-DrugBank.d516.s4|141-141|1|O
DDI-DrugBank.d516.s4|143-146|hour|O
DDI-DrugBank.d516.s4|147-147|)|O
DDI-DrugBank.d516.s4|149-151|and|O
DDI-DrugBank.d516.s4|153-153|a|O
DDI-DrugBank.d516.s4|155-160|lesser|O
DDI-DrugBank.d516.s4|162-167|extent|O
DDI-DrugBank.d516.s4|169-170|of|O
DDI-DrugBank.d516.s4|172-181|absorption|O
DDI-DrugBank.d516.s4|183-183|(|O
DDI-DrugBank.d516.s4|184-187|mean|O
DDI-DrugBank.d516.s4|189-191|AUC|O
DDI-DrugBank.d516.s4|193-201|decreased|O
DDI-DrugBank.d516.s4|203-204|by|O
DDI-DrugBank.d516.s4|206-218|approximately|O
DDI-DrugBank.d516.s4|220-221|25|O
DDI-DrugBank.d516.s4|222-222|%|O
DDI-DrugBank.d516.s4|223-223|)|O
DDI-DrugBank.d516.s4|224-224|.|O
DDI-DrugBank.d516.s5|0-9|Magnesium-|drug
DDI-DrugBank.d516.s5|11-13|and|O
DDI-DrugBank.d516.s5|15-33|aluminum-containing|drug
DDI-DrugBank.d516.s5|15-33|aluminum-containing|drug
DDI-DrugBank.d516.s5|43-43|,|O
DDI-DrugBank.d516.s5|45-56|administered|O
DDI-DrugBank.d516.s5|58-70|concomitantly|O
DDI-DrugBank.d516.s5|72-75|with|O
DDI-DrugBank.d516.s5|77-88|lomefloxacin|drug
DDI-DrugBank.d516.s5|89-89|,|O
DDI-DrugBank.d516.s5|91-103|significantly|O
DDI-DrugBank.d516.s5|105-113|decreased|O
DDI-DrugBank.d516.s5|115-117|the|O
DDI-DrugBank.d516.s5|119-133|bioavailability|O
DDI-DrugBank.d516.s5|135-135|(|O
DDI-DrugBank.d516.s5|136-137|48|O
DDI-DrugBank.d516.s5|138-138|%|O
DDI-DrugBank.d516.s5|139-139|)|O
DDI-DrugBank.d516.s5|141-142|of|O
DDI-DrugBank.d516.s5|144-155|lomefloxacin|drug
DDI-DrugBank.d516.s5|156-156|.|O
DDI-DrugBank.d516.s6|0-9|Separating|O
DDI-DrugBank.d516.s6|11-13|the|O
DDI-DrugBank.d516.s6|15-19|doses|O
DDI-DrugBank.d516.s6|21-22|of|O
DDI-DrugBank.d516.s6|24-30|antacid|group
DDI-DrugBank.d516.s6|32-34|and|O
DDI-DrugBank.d516.s6|36-47|lomefloxacin|drug
DDI-DrugBank.d516.s6|49-57|minimizes|O
DDI-DrugBank.d516.s6|59-62|this|O
DDI-DrugBank.d516.s6|64-71|decrease|O
DDI-DrugBank.d516.s6|73-74|in|O
DDI-DrugBank.d516.s6|76-90|bioavailability|O
DDI-DrugBank.d516.s6|91-91|;|O
DDI-DrugBank.d516.s7|0-8|therefore|O
DDI-DrugBank.d516.s7|9-9|,|O
DDI-DrugBank.d516.s7|11-24|administration|O
DDI-DrugBank.d516.s7|26-27|of|O
DDI-DrugBank.d516.s7|29-33|these|O
DDI-DrugBank.d516.s7|35-40|agents|O
DDI-DrugBank.d516.s7|42-47|should|O
DDI-DrugBank.d516.s7|49-55|precede|O
DDI-DrugBank.d516.s7|57-68|lomefloxacin|drug
DDI-DrugBank.d516.s7|70-75|dosing|O
DDI-DrugBank.d516.s7|77-78|by|O
DDI-DrugBank.d516.s7|80-80|4|O
DDI-DrugBank.d516.s7|82-86|hours|O
DDI-DrugBank.d516.s7|88-89|or|O
DDI-DrugBank.d516.s7|91-96|follow|O
DDI-DrugBank.d516.s7|98-109|lomefloxacin|drug
DDI-DrugBank.d516.s7|111-116|dosing|O
DDI-DrugBank.d516.s7|118-119|by|O
DDI-DrugBank.d516.s7|121-122|at|O
DDI-DrugBank.d516.s7|124-128|least|O
DDI-DrugBank.d516.s7|130-130|2|O
DDI-DrugBank.d516.s7|132-136|hours|O
DDI-DrugBank.d516.s7|137-137|.|O
DDI-DrugBank.d516.s8|0-7|Caffeine|drug
DDI-DrugBank.d516.s8|8-8|:|O
DDI-DrugBank.d516.s8|10-12|Two|O
DDI-DrugBank.d516.s8|14-20|hundred|O
DDI-DrugBank.d516.s8|22-23|mg|O
DDI-DrugBank.d516.s8|25-26|of|O
DDI-DrugBank.d516.s8|28-35|caffeine|drug
DDI-DrugBank.d516.s8|37-37|(|O
DDI-DrugBank.d516.s8|38-47|equivalent|O
DDI-DrugBank.d516.s8|49-50|to|O
DDI-DrugBank.d516.s8|52-52|1|O
DDI-DrugBank.d516.s8|54-55|to|O
DDI-DrugBank.d516.s8|57-57|3|O
DDI-DrugBank.d516.s8|59-62|cups|O
DDI-DrugBank.d516.s8|64-65|of|O
DDI-DrugBank.d516.s8|67-74|American|O
DDI-DrugBank.d516.s8|76-81|coffee|O
DDI-DrugBank.d516.s8|82-82|)|O
DDI-DrugBank.d516.s8|84-86|was|O
DDI-DrugBank.d516.s8|88-99|administered|O
DDI-DrugBank.d516.s8|101-102|to|O
DDI-DrugBank.d516.s8|104-105|16|O
DDI-DrugBank.d516.s8|107-112|normal|O
DDI-DrugBank.d516.s8|113-113|,|O
DDI-DrugBank.d516.s8|115-121|healthy|O
DDI-DrugBank.d516.s8|123-132|volunteers|O
DDI-DrugBank.d516.s8|134-136|who|O
DDI-DrugBank.d516.s8|138-140|had|O
DDI-DrugBank.d516.s8|142-149|achieved|O
DDI-DrugBank.d516.s8|151-162|steady-state|O
DDI-DrugBank.d516.s8|164-168|blood|O
DDI-DrugBank.d516.s8|170-183|concentrations|O
DDI-DrugBank.d516.s8|185-186|of|O
DDI-DrugBank.d516.s8|188-199|lomefloxacin|drug
DDI-DrugBank.d516.s8|201-205|after|O
DDI-DrugBank.d516.s8|207-211|being|O
DDI-DrugBank.d516.s8|213-217|dosed|O
DDI-DrugBank.d516.s8|219-220|at|O
DDI-DrugBank.d516.s8|222-224|400|O
DDI-DrugBank.d516.s8|226-227|mg|O
DDI-DrugBank.d516.s8|229-230|qd|O
DDI-DrugBank.d516.s8|231-231|.|O
DDI-DrugBank.d516.s9|0-3|This|O
DDI-DrugBank.d516.s9|5-7|did|O
DDI-DrugBank.d516.s9|9-11|not|O
DDI-DrugBank.d516.s9|13-18|result|O
DDI-DrugBank.d516.s9|20-21|in|O
DDI-DrugBank.d516.s9|23-25|any|O
DDI-DrugBank.d516.s9|27-39|statistically|O
DDI-DrugBank.d516.s9|41-42|or|O
DDI-DrugBank.d516.s9|44-53|clinically|O
DDI-DrugBank.d516.s9|55-62|relevant|O
DDI-DrugBank.d516.s9|64-70|changes|O
DDI-DrugBank.d516.s9|72-73|in|O
DDI-DrugBank.d516.s9|75-77|the|O
DDI-DrugBank.d516.s9|79-93|pharmacokinetic|O
DDI-DrugBank.d516.s9|95-104|parameters|O
DDI-DrugBank.d516.s9|106-107|of|O
DDI-DrugBank.d516.s9|109-114|either|O
DDI-DrugBank.d516.s9|116-123|caffeine|drug
DDI-DrugBank.d516.s9|125-126|or|O
DDI-DrugBank.d516.s9|128-130|its|O
DDI-DrugBank.d516.s9|132-136|major|O
DDI-DrugBank.d516.s9|138-147|metabolite|O
DDI-DrugBank.d516.s9|148-148|,|O
DDI-DrugBank.d516.s9|162-162|.|O
DDI-DrugBank.d516.s10|0-1|No|O
DDI-DrugBank.d516.s10|3-6|data|O
DDI-DrugBank.d516.s10|8-10|are|O
DDI-DrugBank.d516.s10|12-20|available|O
DDI-DrugBank.d516.s10|22-23|on|O
DDI-DrugBank.d516.s10|25-33|potential|O
DDI-DrugBank.d516.s10|35-46|interactions|O
DDI-DrugBank.d516.s10|48-49|in|O
DDI-DrugBank.d516.s10|51-61|individuals|O
DDI-DrugBank.d516.s10|63-65|who|O
DDI-DrugBank.d516.s10|67-73|consume|O
DDI-DrugBank.d516.s10|75-81|greater|O
DDI-DrugBank.d516.s10|83-86|than|O
DDI-DrugBank.d516.s10|88-90|200|O
DDI-DrugBank.d516.s10|92-93|mg|O
DDI-DrugBank.d516.s10|95-96|of|O
DDI-DrugBank.d516.s10|98-105|caffeine|drug
DDI-DrugBank.d516.s10|107-109|per|O
DDI-DrugBank.d516.s10|111-113|day|O
DDI-DrugBank.d516.s10|115-116|or|O
DDI-DrugBank.d516.s10|118-119|in|O
DDI-DrugBank.d516.s10|121-125|those|O
DDI-DrugBank.d516.s10|126-126|,|O
DDI-DrugBank.d516.s10|128-131|such|O
DDI-DrugBank.d516.s10|133-134|as|O
DDI-DrugBank.d516.s10|136-138|the|O
DDI-DrugBank.d516.s10|140-148|geriatric|O
DDI-DrugBank.d516.s10|150-159|population|O
DDI-DrugBank.d516.s10|160-160|,|O
DDI-DrugBank.d516.s10|162-164|who|O
DDI-DrugBank.d516.s10|166-168|are|O
DDI-DrugBank.d516.s10|170-178|generally|O
DDI-DrugBank.d516.s10|180-187|believed|O
DDI-DrugBank.d516.s10|189-190|to|O
DDI-DrugBank.d516.s10|192-193|be|O
DDI-DrugBank.d516.s10|195-198|more|O
DDI-DrugBank.d516.s10|200-210|susceptible|O
DDI-DrugBank.d516.s10|212-213|to|O
DDI-DrugBank.d516.s10|215-217|the|O
DDI-DrugBank.d516.s10|219-229|development|O
DDI-DrugBank.d516.s10|231-232|of|O
DDI-DrugBank.d516.s10|234-245|drug-induced|O
DDI-DrugBank.d516.s10|247-257|CNS-related|O
DDI-DrugBank.d516.s10|259-265|adverse|O
DDI-DrugBank.d516.s10|267-273|effects|O
DDI-DrugBank.d516.s10|274-274|.|O
DDI-DrugBank.d516.s11|0-4|Other|O
DDI-DrugBank.d516.s11|6-15|quinolones|group
DDI-DrugBank.d516.s11|17-20|have|O
DDI-DrugBank.d516.s11|22-33|demonstrated|O
DDI-DrugBank.d516.s11|35-42|moderate|O
DDI-DrugBank.d516.s11|44-45|to|O
DDI-DrugBank.d516.s11|47-52|marked|O
DDI-DrugBank.d516.s11|54-65|interference|O
DDI-DrugBank.d516.s11|67-70|with|O
DDI-DrugBank.d516.s11|72-74|the|O
DDI-DrugBank.d516.s11|76-85|metabolism|O
DDI-DrugBank.d516.s11|87-88|of|O
DDI-DrugBank.d516.s11|90-97|caffeine|drug
DDI-DrugBank.d516.s11|98-98|,|O
DDI-DrugBank.d516.s11|100-108|resulting|O
DDI-DrugBank.d516.s11|110-111|in|O
DDI-DrugBank.d516.s11|113-113|a|O
DDI-DrugBank.d516.s11|115-121|reduced|O
DDI-DrugBank.d516.s11|123-131|clearance|O
DDI-DrugBank.d516.s11|132-132|,|O
DDI-DrugBank.d516.s11|134-134|a|O
DDI-DrugBank.d516.s11|136-147|prolongation|O
DDI-DrugBank.d516.s11|149-150|of|O
DDI-DrugBank.d516.s11|152-157|plasma|O
DDI-DrugBank.d516.s11|159-167|half-life|O
DDI-DrugBank.d516.s11|168-168|,|O
DDI-DrugBank.d516.s11|170-172|and|O
DDI-DrugBank.d516.s11|174-175|an|O
DDI-DrugBank.d516.s11|177-184|increase|O
DDI-DrugBank.d516.s11|186-187|in|O
DDI-DrugBank.d516.s11|189-196|symptoms|O
DDI-DrugBank.d516.s11|198-201|that|O
DDI-DrugBank.d516.s11|203-211|accompany|O
DDI-DrugBank.d516.s11|213-216|high|O
DDI-DrugBank.d516.s11|218-223|levels|O
DDI-DrugBank.d516.s11|225-226|of|O
DDI-DrugBank.d516.s11|228-235|caffeine|drug
DDI-DrugBank.d516.s11|236-236|.|O
DDI-DrugBank.d516.s12|0-9|Cimetidine|drug
DDI-DrugBank.d516.s12|10-10|:|O
DDI-DrugBank.d516.s12|12-21|Cimetidine|drug
DDI-DrugBank.d516.s12|23-25|has|O
DDI-DrugBank.d516.s12|27-30|been|O
DDI-DrugBank.d516.s12|32-43|demonstrated|O
DDI-DrugBank.d516.s12|45-46|to|O
DDI-DrugBank.d516.s12|48-56|interfere|O
DDI-DrugBank.d516.s12|58-61|with|O
DDI-DrugBank.d516.s12|63-65|the|O
DDI-DrugBank.d516.s12|67-77|elimination|O
DDI-DrugBank.d516.s12|79-80|of|O
DDI-DrugBank.d516.s12|82-86|other|O
DDI-DrugBank.d516.s12|88-97|quinolones|group
DDI-DrugBank.d516.s12|98-98|.|O
DDI-DrugBank.d516.s13|0-3|This|O
DDI-DrugBank.d516.s13|5-16|interference|O
DDI-DrugBank.d516.s13|18-20|has|O
DDI-DrugBank.d516.s13|22-29|resulted|O
DDI-DrugBank.d516.s13|31-32|in|O
DDI-DrugBank.d516.s13|34-44|significant|O
DDI-DrugBank.d516.s13|46-54|increases|O
DDI-DrugBank.d516.s13|56-57|in|O
DDI-DrugBank.d516.s13|59-67|half-life|O
DDI-DrugBank.d516.s13|69-71|and|O
DDI-DrugBank.d516.s13|73-75|AUC|O
DDI-DrugBank.d516.s13|76-76|.|O
DDI-DrugBank.d516.s14|0-2|The|O
DDI-DrugBank.d516.s14|4-14|interaction|O
DDI-DrugBank.d516.s14|16-22|between|O
DDI-DrugBank.d516.s14|24-35|lomefloxacin|drug
DDI-DrugBank.d516.s14|37-39|and|O
DDI-DrugBank.d516.s14|41-50|cimetidine|drug
DDI-DrugBank.d516.s14|52-54|has|O
DDI-DrugBank.d516.s14|56-58|not|O
DDI-DrugBank.d516.s14|60-63|been|O
DDI-DrugBank.d516.s14|65-71|studied|O
DDI-DrugBank.d516.s14|72-72|.|O
DDI-DrugBank.d516.s15|0-11|Cyclosporine|drug
DDI-DrugBank.d516.s15|12-12|:|O
DDI-DrugBank.d516.s15|14-21|Elevated|O
DDI-DrugBank.d516.s15|23-27|serum|O
DDI-DrugBank.d516.s15|29-34|levels|O
DDI-DrugBank.d516.s15|36-37|of|O
DDI-DrugBank.d516.s15|39-50|cyclosporine|drug
DDI-DrugBank.d516.s15|52-55|have|O
DDI-DrugBank.d516.s15|57-60|been|O
DDI-DrugBank.d516.s15|62-69|reported|O
DDI-DrugBank.d516.s15|71-74|with|O
DDI-DrugBank.d516.s15|76-86|concomitant|O
DDI-DrugBank.d516.s15|88-90|use|O
DDI-DrugBank.d516.s15|92-93|of|O
DDI-DrugBank.d516.s15|95-106|cyclosporine|drug
DDI-DrugBank.d516.s15|108-111|with|O
DDI-DrugBank.d516.s15|113-117|other|O
DDI-DrugBank.d516.s15|119-125|members|O
DDI-DrugBank.d516.s15|127-128|of|O
DDI-DrugBank.d516.s15|130-132|the|O
DDI-DrugBank.d516.s15|134-148|quinolone class|group
DDI-DrugBank.d516.s15|149-149|.|O
DDI-DrugBank.d516.s16|0-10|Interaction|O
DDI-DrugBank.d516.s16|12-18|between|O
DDI-DrugBank.d516.s16|20-31|lomefloxacin|drug
DDI-DrugBank.d516.s16|33-35|and|O
DDI-DrugBank.d516.s16|37-48|cyclosporine|drug
DDI-DrugBank.d516.s16|50-52|has|O
DDI-DrugBank.d516.s16|54-56|not|O
DDI-DrugBank.d516.s16|58-61|been|O
DDI-DrugBank.d516.s16|63-69|studied|O
DDI-DrugBank.d516.s16|70-70|.|O
DDI-DrugBank.d516.s17|0-9|Omeprazole|drug
DDI-DrugBank.d516.s17|10-10|:|O
DDI-DrugBank.d516.s17|12-13|No|O
DDI-DrugBank.d516.s17|15-24|clinically|O
DDI-DrugBank.d516.s17|26-36|significant|O
DDI-DrugBank.d516.s17|38-44|changes|O
DDI-DrugBank.d516.s17|46-47|in|O
DDI-DrugBank.d516.s17|49-60|lomefloxacin|drug
DDI-DrugBank.d516.s17|62-77|pharmacokinetics|O
DDI-DrugBank.d516.s17|79-79|(|O
DDI-DrugBank.d516.s17|80-82|AUC|O
DDI-DrugBank.d516.s17|83-83|,|O
DDI-DrugBank.d516.s17|85-85|C|O
DDI-DrugBank.d516.s17|87-89|max|O
DDI-DrugBank.d516.s17|91-91|,|O
DDI-DrugBank.d516.s17|93-94|or|O
DDI-DrugBank.d516.s17|96-96|T|O
DDI-DrugBank.d516.s17|98-100|max|O
DDI-DrugBank.d516.s17|102-102|)|O
DDI-DrugBank.d516.s17|104-107|were|O
DDI-DrugBank.d516.s17|109-116|observed|O
DDI-DrugBank.d516.s17|118-121|when|O
DDI-DrugBank.d516.s17|123-123|a|O
DDI-DrugBank.d516.s17|125-130|single|O
DDI-DrugBank.d516.s17|132-135|dose|O
DDI-DrugBank.d516.s17|137-138|of|O
DDI-DrugBank.d516.s17|140-151|lomefloxacin|drug
DDI-DrugBank.d516.s17|153-155|400|O
DDI-DrugBank.d516.s17|157-158|mg|O
DDI-DrugBank.d516.s17|160-162|was|O
DDI-DrugBank.d516.s17|164-168|given|O
DDI-DrugBank.d516.s17|170-174|after|O
DDI-DrugBank.d516.s17|176-183|multiple|O
DDI-DrugBank.d516.s17|185-189|doses|O
DDI-DrugBank.d516.s17|191-192|of|O
DDI-DrugBank.d516.s17|194-203|omeprazole|drug
DDI-DrugBank.d516.s17|205-205|(|O
DDI-DrugBank.d516.s17|206-207|20|O
DDI-DrugBank.d516.s17|209-210|mg|O
DDI-DrugBank.d516.s17|212-213|qd|O
DDI-DrugBank.d516.s17|214-214|)|O
DDI-DrugBank.d516.s17|216-217|in|O
DDI-DrugBank.d516.s17|219-220|13|O
DDI-DrugBank.d516.s17|222-228|healthy|O
DDI-DrugBank.d516.s17|230-239|volunteers|O
DDI-DrugBank.d516.s17|240-240|.|O
DDI-DrugBank.d516.s18|0-6|Changes|O
DDI-DrugBank.d516.s18|8-9|in|O
DDI-DrugBank.d516.s18|11-20|omeprazole|drug
DDI-DrugBank.d516.s18|22-37|pharmacokinetics|O
DDI-DrugBank.d516.s18|39-42|were|O
DDI-DrugBank.d516.s18|44-46|not|O
DDI-DrugBank.d516.s18|48-54|studied|O
DDI-DrugBank.d516.s18|55-55|.|O
DDI-DrugBank.d516.s19|0-8|Phenytoin|drug
DDI-DrugBank.d516.s19|9-9|:|O
DDI-DrugBank.d516.s19|11-12|No|O
DDI-DrugBank.d516.s19|14-24|significant|O
DDI-DrugBank.d516.s19|26-36|differences|O
DDI-DrugBank.d516.s19|38-41|were|O
DDI-DrugBank.d516.s19|43-50|observed|O
DDI-DrugBank.d516.s19|52-53|in|O
DDI-DrugBank.d516.s19|55-58|mean|O
DDI-DrugBank.d516.s19|60-68|phenytoin|drug
DDI-DrugBank.d516.s19|70-72|AUC|O
DDI-DrugBank.d516.s19|73-73|,|O
DDI-DrugBank.d516.s19|75-75|C|O
DDI-DrugBank.d516.s19|77-79|max|O
DDI-DrugBank.d516.s19|81-81|,|O
DDI-DrugBank.d516.s19|83-83|C|O
DDI-DrugBank.d516.s19|85-87|min|O
DDI-DrugBank.d516.s19|89-90|or|O
DDI-DrugBank.d516.s19|92-92|T|O
DDI-DrugBank.d516.s19|94-96|max|O
DDI-DrugBank.d516.s19|98-98|(|O
DDI-DrugBank.d516.s19|99-106|although|O
DDI-DrugBank.d516.s19|108-108|C|O
DDI-DrugBank.d516.s19|110-112|max|O
DDI-DrugBank.d516.s19|114-122|increased|O
DDI-DrugBank.d516.s19|124-125|by|O
DDI-DrugBank.d516.s19|127-128|11|O
DDI-DrugBank.d516.s19|129-129|%|O
DDI-DrugBank.d516.s19|130-130|)|O
DDI-DrugBank.d516.s19|132-135|when|O
DDI-DrugBank.d516.s19|137-144|extended|O
DDI-DrugBank.d516.s19|146-161|phenytoin sodium|drug
DDI-DrugBank.d516.s19|163-170|capsules|O
DDI-DrugBank.d516.s19|172-172|(|O
DDI-DrugBank.d516.s19|173-175|100|O
DDI-DrugBank.d516.s19|177-178|mg|O
DDI-DrugBank.d516.s19|180-182|tid|O
DDI-DrugBank.d516.s19|183-183|)|O
DDI-DrugBank.d516.s19|185-188|were|O
DDI-DrugBank.d516.s19|190-203|coadministered|O
DDI-DrugBank.d516.s19|205-208|with|O
DDI-DrugBank.d516.s19|210-221|lomefloxacin|drug
DDI-DrugBank.d516.s19|223-223|(|O
DDI-DrugBank.d516.s19|224-226|400|O
DDI-DrugBank.d516.s19|228-229|mg|O
DDI-DrugBank.d516.s19|231-232|qd|O
DDI-DrugBank.d516.s19|233-233|)|O
DDI-DrugBank.d516.s19|235-237|for|O
DDI-DrugBank.d516.s19|239-242|five|O
DDI-DrugBank.d516.s19|244-247|days|O
DDI-DrugBank.d516.s19|249-250|in|O
DDI-DrugBank.d516.s19|252-253|15|O
DDI-DrugBank.d516.s19|255-261|healthy|O
DDI-DrugBank.d516.s19|263-267|males|O
DDI-DrugBank.d516.s19|268-268|.|O
DDI-DrugBank.d516.s20|0-11|Lomefloxacin|drug
DDI-DrugBank.d516.s20|13-14|is|O
DDI-DrugBank.d516.s20|16-23|unlikely|O
DDI-DrugBank.d516.s20|25-26|to|O
DDI-DrugBank.d516.s20|28-31|have|O
DDI-DrugBank.d516.s20|33-33|a|O
DDI-DrugBank.d516.s20|35-45|significant|O
DDI-DrugBank.d516.s20|47-52|effect|O
DDI-DrugBank.d516.s20|54-55|on|O
DDI-DrugBank.d516.s20|57-65|phenytoin|drug
DDI-DrugBank.d516.s20|67-76|metabolism|O
DDI-DrugBank.d516.s20|77-77|.|O
DDI-DrugBank.d516.s21|0-9|Probenecid|drug
DDI-DrugBank.d516.s21|10-10|:|O
DDI-DrugBank.d516.s21|12-21|Probenecid|drug
DDI-DrugBank.d516.s21|23-27|slows|O
DDI-DrugBank.d516.s21|29-31|the|O
DDI-DrugBank.d516.s21|33-37|renal|O
DDI-DrugBank.d516.s21|39-49|elimination|O
DDI-DrugBank.d516.s21|51-52|of|O
DDI-DrugBank.d516.s21|54-66|lome-floxacin|O
DDI-DrugBank.d516.s21|67-67|.|O
DDI-DrugBank.d516.s22|0-1|An|O
DDI-DrugBank.d516.s22|3-10|increase|O
DDI-DrugBank.d516.s22|12-13|of|O
DDI-DrugBank.d516.s22|15-16|63|O
DDI-DrugBank.d516.s22|17-17|%|O
DDI-DrugBank.d516.s22|19-20|in|O
DDI-DrugBank.d516.s22|22-24|the|O
DDI-DrugBank.d516.s22|26-29|mean|O
DDI-DrugBank.d516.s22|31-33|AUC|O
DDI-DrugBank.d516.s22|35-37|and|O
DDI-DrugBank.d516.s22|39-47|increases|O
DDI-DrugBank.d516.s22|49-50|of|O
DDI-DrugBank.d516.s22|52-53|50|O
DDI-DrugBank.d516.s22|54-54|%|O
DDI-DrugBank.d516.s22|56-58|and|O
DDI-DrugBank.d516.s22|60-60|4|O
DDI-DrugBank.d516.s22|61-61|%|O
DDI-DrugBank.d516.s22|62-62|,|O
DDI-DrugBank.d516.s22|64-75|respectively|O
DDI-DrugBank.d516.s22|76-76|,|O
DDI-DrugBank.d516.s22|78-79|in|O
DDI-DrugBank.d516.s22|81-83|the|O
DDI-DrugBank.d516.s22|85-88|mean|O
DDI-DrugBank.d516.s22|90-90|T|O
DDI-DrugBank.d516.s22|92-94|max|O
DDI-DrugBank.d516.s22|96-98|and|O
DDI-DrugBank.d516.s22|100-103|mean|O
DDI-DrugBank.d516.s22|105-105|C|O
DDI-DrugBank.d516.s22|107-109|max|O
DDI-DrugBank.d516.s22|111-114|were|O
DDI-DrugBank.d516.s22|116-120|noted|O
DDI-DrugBank.d516.s22|122-123|in|O
DDI-DrugBank.d516.s22|125-125|1|O
DDI-DrugBank.d516.s22|127-131|study|O
DDI-DrugBank.d516.s22|133-134|of|O
DDI-DrugBank.d516.s22|136-136|6|O
DDI-DrugBank.d516.s22|138-148|individuals|O
DDI-DrugBank.d516.s22|149-149|.|O
DDI-DrugBank.d516.s23|0-10|Terfenadine|drug
DDI-DrugBank.d516.s23|11-11|:|O
DDI-DrugBank.d516.s23|13-14|No|O
DDI-DrugBank.d516.s23|16-25|clinically|O
DDI-DrugBank.d516.s23|27-37|significant|O
DDI-DrugBank.d516.s23|39-45|changes|O
DDI-DrugBank.d516.s23|47-54|occurred|O
DDI-DrugBank.d516.s23|56-57|in|O
DDI-DrugBank.d516.s23|59-63|heart|O
DDI-DrugBank.d516.s23|65-68|rate|O
DDI-DrugBank.d516.s23|70-71|or|O
DDI-DrugBank.d516.s23|73-81|corrected|O
DDI-DrugBank.d516.s23|83-84|QT|O
DDI-DrugBank.d516.s23|86-94|intervals|O
DDI-DrugBank.d516.s23|95-95|,|O
DDI-DrugBank.d516.s23|97-98|or|O
DDI-DrugBank.d516.s23|100-101|in|O
DDI-DrugBank.d516.s23|103-113|terfenadine|drug
DDI-DrugBank.d516.s23|115-124|metabolite|O
DDI-DrugBank.d516.s23|126-127|or|O
DDI-DrugBank.d516.s23|129-140|lomefloxacin|drug
DDI-DrugBank.d516.s23|142-157|pharmacokinetics|O
DDI-DrugBank.d516.s23|158-158|,|O
DDI-DrugBank.d516.s23|160-165|during|O
DDI-DrugBank.d516.s23|167-176|concurrent|O
DDI-DrugBank.d516.s23|178-191|administration|O
DDI-DrugBank.d516.s23|193-194|of|O
DDI-DrugBank.d516.s23|196-207|lomefloxacin|drug
DDI-DrugBank.d516.s23|209-211|and|O
DDI-DrugBank.d516.s23|213-223|terfenadine|drug
DDI-DrugBank.d516.s23|225-226|at|O
DDI-DrugBank.d516.s23|228-239|steady-state|O
DDI-DrugBank.d516.s23|241-242|in|O
DDI-DrugBank.d516.s23|244-245|28|O
DDI-DrugBank.d516.s23|247-253|healthy|O
DDI-DrugBank.d516.s23|255-259|males|O
DDI-DrugBank.d516.s23|260-260|.|O
DDI-DrugBank.d516.s24|0-7|Warfarin|drug
DDI-DrugBank.d516.s24|8-8|:|O
DDI-DrugBank.d516.s24|10-19|Quinolones|group
DDI-DrugBank.d516.s24|21-23|may|O
DDI-DrugBank.d516.s24|25-31|enhance|O
DDI-DrugBank.d516.s24|33-35|the|O
DDI-DrugBank.d516.s24|37-43|effects|O
DDI-DrugBank.d516.s24|45-46|of|O
DDI-DrugBank.d516.s24|48-50|the|O
DDI-DrugBank.d516.s24|52-55|oral|O
DDI-DrugBank.d516.s24|57-69|anticoagulant|group
DDI-DrugBank.d516.s24|70-70|,|O
DDI-DrugBank.d516.s24|72-79|warfarin|drug
DDI-DrugBank.d516.s24|80-80|,|O
DDI-DrugBank.d516.s24|82-83|or|O
DDI-DrugBank.d516.s24|85-87|its|O
DDI-DrugBank.d516.s24|89-99|derivatives|O
DDI-DrugBank.d516.s24|100-100|.|O
DDI-DrugBank.d516.s25|0-3|When|O
DDI-DrugBank.d516.s25|5-9|these|O
DDI-DrugBank.d516.s25|11-18|products|O
DDI-DrugBank.d516.s25|20-22|are|O
DDI-DrugBank.d516.s25|24-35|administered|O
DDI-DrugBank.d516.s25|37-49|concomitantly|O
DDI-DrugBank.d516.s25|50-50|,|O
DDI-DrugBank.d516.s25|52-62|prothrombin|O
DDI-DrugBank.d516.s25|64-65|or|O
DDI-DrugBank.d516.s25|67-71|other|O
DDI-DrugBank.d516.s25|73-80|suitable|O
DDI-DrugBank.d516.s25|82-92|coagulation|O
DDI-DrugBank.d516.s25|94-98|tests|O
DDI-DrugBank.d516.s25|100-105|should|O
DDI-DrugBank.d516.s25|107-108|be|O
DDI-DrugBank.d516.s25|110-118|monitored|O
DDI-DrugBank.d516.s25|120-126|closely|O
DDI-DrugBank.d516.s25|127-127|.|O
DDI-DrugBank.d516.s26|0-6|However|O
DDI-DrugBank.d516.s26|7-7|,|O
DDI-DrugBank.d516.s26|9-10|no|O
DDI-DrugBank.d516.s26|12-21|clinically|O
DDI-DrugBank.d516.s26|23-24|or|O
DDI-DrugBank.d516.s26|26-38|statistically|O
DDI-DrugBank.d516.s26|40-50|significant|O
DDI-DrugBank.d516.s26|52-62|differences|O
DDI-DrugBank.d516.s26|64-65|in|O
DDI-DrugBank.d516.s26|67-77|prothrombin|O
DDI-DrugBank.d516.s26|79-82|time|O
DDI-DrugBank.d516.s26|84-88|ratio|O
DDI-DrugBank.d516.s26|90-91|or|O
DDI-DrugBank.d516.s26|93-100|warfarin|drug
DDI-DrugBank.d516.s26|102-111|enantiomer|O
DDI-DrugBank.d516.s26|113-128|pharmacokinetics|O
DDI-DrugBank.d516.s26|130-133|were|O
DDI-DrugBank.d516.s26|135-142|observed|O
DDI-DrugBank.d516.s26|144-145|in|O
DDI-DrugBank.d516.s26|147-147|a|O
DDI-DrugBank.d516.s26|149-153|small|O
DDI-DrugBank.d516.s26|155-159|study|O
DDI-DrugBank.d516.s26|161-162|of|O
DDI-DrugBank.d516.s26|164-164|7|O
DDI-DrugBank.d516.s26|166-172|healthy|O
DDI-DrugBank.d516.s26|174-178|males|O
DDI-DrugBank.d516.s26|180-182|who|O
DDI-DrugBank.d516.s26|184-191|received|O
DDI-DrugBank.d516.s26|193-196|both|O
DDI-DrugBank.d516.s26|198-205|warfarin|drug
DDI-DrugBank.d516.s26|207-209|and|O
DDI-DrugBank.d516.s26|211-222|lomefloxacin|drug
DDI-DrugBank.d516.s26|224-228|under|O
DDI-DrugBank.d516.s26|230-241|steady-state|O
DDI-DrugBank.d516.s26|243-252|conditions|O
DDI-DrugBank.d516.s26|253-253|.|O
DDI-DrugBank.d645.s0|0-1|In|O
DDI-DrugBank.d645.s0|3-7|vitro|O
DDI-DrugBank.d645.s0|9-15|studies|O
DDI-DrugBank.d645.s0|17-20|with|O
DDI-DrugBank.d645.s0|22-26|human|O
DDI-DrugBank.d645.s0|28-32|liver|O
DDI-DrugBank.d645.s0|34-43|microsomes|O
DDI-DrugBank.d645.s0|45-50|showed|O
DDI-DrugBank.d645.s0|52-55|that|O
DDI-DrugBank.d645.s0|57-67|terbinafine|drug
DDI-DrugBank.d645.s0|69-72|does|O
DDI-DrugBank.d645.s0|74-76|not|O
DDI-DrugBank.d645.s0|78-84|inhibit|O
DDI-DrugBank.d645.s0|86-88|the|O
DDI-DrugBank.d645.s0|90-99|metabolism|O
DDI-DrugBank.d645.s0|101-102|of|O
DDI-DrugBank.d645.s0|104-114|tolbutamide|drug
DDI-DrugBank.d645.s0|115-115|,|O
DDI-DrugBank.d645.s0|117-132|ethinylestradiol|drug
DDI-DrugBank.d645.s0|133-133|,|O
DDI-DrugBank.d645.s0|149-149|,|O
DDI-DrugBank.d645.s0|151-153|and|O
DDI-DrugBank.d645.s0|155-166|cyclosporine|drug
DDI-DrugBank.d645.s0|167-167|.|O
DDI-DrugBank.d645.s1|0-1|In|O
DDI-DrugBank.d645.s1|3-7|vitro|O
DDI-DrugBank.d645.s1|9-15|studies|O
DDI-DrugBank.d645.s1|17-20|have|O
DDI-DrugBank.d645.s1|22-25|also|O
DDI-DrugBank.d645.s1|27-31|shown|O
DDI-DrugBank.d645.s1|33-36|that|O
DDI-DrugBank.d645.s1|38-48|terbinafine|drug
DDI-DrugBank.d645.s1|50-57|inhibits|O
DDI-DrugBank.d645.s1|59-73|CYP2D6-mediated|O
DDI-DrugBank.d645.s1|75-84|metabolism|O
DDI-DrugBank.d645.s1|85-85|.|O
DDI-DrugBank.d645.s2|0-3|This|O
DDI-DrugBank.d645.s2|5-7|may|O
DDI-DrugBank.d645.s2|9-10|be|O
DDI-DrugBank.d645.s2|12-13|of|O
DDI-DrugBank.d645.s2|15-22|clinical|O
DDI-DrugBank.d645.s2|24-32|relevance|O
DDI-DrugBank.d645.s2|34-36|for|O
DDI-DrugBank.d645.s2|38-46|compounds|O
DDI-DrugBank.d645.s2|48-60|predominantly|O
DDI-DrugBank.d645.s2|62-72|metabolized|O
DDI-DrugBank.d645.s2|74-75|by|O
DDI-DrugBank.d645.s2|77-80|this|O
DDI-DrugBank.d645.s2|82-87|enzyme|O
DDI-DrugBank.d645.s2|88-88|,|O
DDI-DrugBank.d645.s2|90-93|such|O
DDI-DrugBank.d645.s2|95-96|as|O
DDI-DrugBank.d645.s2|98-122|tricyclic antidepressants|group
DDI-DrugBank.d645.s2|123-123|,|O
DDI-DrugBank.d645.s2|128-136|-blockers|O
DDI-DrugBank.d645.s2|137-137|,|O
DDI-DrugBank.d645.s2|139-177|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d645.s2|179-179|(|O
DDI-DrugBank.d645.s2|180-184|SSRIs|group
DDI-DrugBank.d645.s2|185-185|)|O
DDI-DrugBank.d645.s2|186-186|,|O
DDI-DrugBank.d645.s2|188-190|and|O
DDI-DrugBank.d645.s2|192-235|monoamine oxidase inhibitors ( MAO-Is ) Type B|group
DDI-DrugBank.d645.s2|236-236|,|O
DDI-DrugBank.d645.s2|238-239|if|O
DDI-DrugBank.d645.s2|241-244|they|O
DDI-DrugBank.d645.s2|246-249|have|O
DDI-DrugBank.d645.s2|251-251|a|O
DDI-DrugBank.d645.s2|253-258|narrow|O
DDI-DrugBank.d645.s2|260-270|therapeutic|O
DDI-DrugBank.d645.s2|272-277|window|O
DDI-DrugBank.d645.s2|278-278|.|O
DDI-DrugBank.d645.s3|0-1|In|O
DDI-DrugBank.d645.s3|3-6|vivo|O
DDI-DrugBank.d645.s3|8-16|drug-drug|O
DDI-DrugBank.d645.s3|18-28|interaction|O
DDI-DrugBank.d645.s3|30-36|studies|O
DDI-DrugBank.d645.s3|38-46|conducted|O
DDI-DrugBank.d645.s3|48-49|in|O
DDI-DrugBank.d645.s3|51-56|normal|O
DDI-DrugBank.d645.s3|58-66|volunteer|O
DDI-DrugBank.d645.s3|68-75|subjects|O
DDI-DrugBank.d645.s3|77-82|showed|O
DDI-DrugBank.d645.s3|84-87|that|O
DDI-DrugBank.d645.s3|89-99|terbinafine|drug
DDI-DrugBank.d645.s3|101-104|does|O
DDI-DrugBank.d645.s3|106-108|not|O
DDI-DrugBank.d645.s3|110-115|affect|O
DDI-DrugBank.d645.s3|117-119|the|O
DDI-DrugBank.d645.s3|121-129|clearance|O
DDI-DrugBank.d645.s3|131-132|of|O
DDI-DrugBank.d645.s3|134-143|antipyrine|drug
DDI-DrugBank.d645.s3|145-146|or|O
DDI-DrugBank.d645.s3|148-154|digoxin|drug
DDI-DrugBank.d645.s3|155-155|.|O
DDI-DrugBank.d645.s4|0-10|Terbinafine|drug
DDI-DrugBank.d645.s4|12-20|decreases|O
DDI-DrugBank.d645.s4|22-24|the|O
DDI-DrugBank.d645.s4|26-34|clearance|O
DDI-DrugBank.d645.s4|36-37|of|O
DDI-DrugBank.d645.s4|39-46|caffeine|drug
DDI-DrugBank.d645.s4|48-49|by|O
DDI-DrugBank.d645.s4|51-52|19|O
DDI-DrugBank.d645.s4|53-53|%|O
DDI-DrugBank.d645.s4|54-54|.|O
DDI-DrugBank.d645.s5|0-10|Terbinafine|drug
DDI-DrugBank.d645.s5|12-20|increases|O
DDI-DrugBank.d645.s5|22-24|the|O
DDI-DrugBank.d645.s5|26-34|clearance|O
DDI-DrugBank.d645.s5|36-37|of|O
DDI-DrugBank.d645.s5|39-50|cyclosporine|drug
DDI-DrugBank.d645.s5|52-53|by|O
DDI-DrugBank.d645.s5|55-56|15|O
DDI-DrugBank.d645.s5|57-57|%|O
DDI-DrugBank.d645.s5|58-58|.|O
DDI-DrugBank.d645.s6|0-4|There|O
DDI-DrugBank.d645.s6|6-9|have|O
DDI-DrugBank.d645.s6|11-14|been|O
DDI-DrugBank.d645.s6|16-26|spontaneous|O
DDI-DrugBank.d645.s6|28-34|reports|O
DDI-DrugBank.d645.s6|36-37|of|O
DDI-DrugBank.d645.s6|39-46|increase|O
DDI-DrugBank.d645.s6|48-49|or|O
DDI-DrugBank.d645.s6|51-58|decrease|O
DDI-DrugBank.d645.s6|60-61|in|O
DDI-DrugBank.d645.s6|63-73|prothrombin|O
DDI-DrugBank.d645.s6|75-79|times|O
DDI-DrugBank.d645.s6|81-82|in|O
DDI-DrugBank.d645.s6|84-91|patients|O
DDI-DrugBank.d645.s6|93-105|concomitantly|O
DDI-DrugBank.d645.s6|107-112|taking|O
DDI-DrugBank.d645.s6|114-117|oral|O
DDI-DrugBank.d645.s6|119-129|terbinafine|drug
DDI-DrugBank.d645.s6|131-133|and|O
DDI-DrugBank.d645.s6|135-142|warfarin|drug
DDI-DrugBank.d645.s6|143-143|,|O
DDI-DrugBank.d645.s6|145-151|however|O
DDI-DrugBank.d645.s6|152-152|,|O
DDI-DrugBank.d645.s6|154-154|a|O
DDI-DrugBank.d645.s6|156-161|causal|O
DDI-DrugBank.d645.s6|163-174|relationship|O
DDI-DrugBank.d645.s6|176-182|between|O
DDI-DrugBank.d645.s6|184-190|LAMISIL|brand
DDI-DrugBank.d645.s6|195-201|Tablets|O
DDI-DrugBank.d645.s6|203-205|and|O
DDI-DrugBank.d645.s6|207-211|these|O
DDI-DrugBank.d645.s6|213-219|changes|O
DDI-DrugBank.d645.s6|221-223|has|O
DDI-DrugBank.d645.s6|225-227|not|O
DDI-DrugBank.d645.s6|229-232|been|O
DDI-DrugBank.d645.s6|234-244|established|O
DDI-DrugBank.d645.s6|245-245|.|O
DDI-DrugBank.d645.s7|0-10|Terbinafine|drug
DDI-DrugBank.d645.s7|12-20|clearance|O
DDI-DrugBank.d645.s7|22-23|is|O
DDI-DrugBank.d645.s7|25-33|increased|O
DDI-DrugBank.d645.s7|35-37|100|O
DDI-DrugBank.d645.s7|38-38|%|O
DDI-DrugBank.d645.s7|40-41|by|O
DDI-DrugBank.d645.s7|43-50|rifampin|drug
DDI-DrugBank.d645.s7|51-51|,|O
DDI-DrugBank.d645.s7|53-53|a|O
DDI-DrugBank.d645.s7|55-60|CyP450|O
DDI-DrugBank.d645.s7|62-67|enzyme|O
DDI-DrugBank.d645.s7|69-75|inducer|O
DDI-DrugBank.d645.s7|76-76|,|O
DDI-DrugBank.d645.s7|78-80|and|O
DDI-DrugBank.d645.s7|82-90|decreased|O
DDI-DrugBank.d645.s7|92-93|33|O
DDI-DrugBank.d645.s7|94-94|%|O
DDI-DrugBank.d645.s7|96-97|by|O
DDI-DrugBank.d645.s7|99-108|cimetidine|drug
DDI-DrugBank.d645.s7|109-109|,|O
DDI-DrugBank.d645.s7|111-111|a|O
DDI-DrugBank.d645.s7|113-118|CyP450|O
DDI-DrugBank.d645.s7|120-125|enzyme|O
DDI-DrugBank.d645.s7|127-135|inhibitor|O
DDI-DrugBank.d645.s7|136-136|.|O
DDI-DrugBank.d645.s8|0-10|Terbinafine|drug
DDI-DrugBank.d645.s8|12-20|clearance|O
DDI-DrugBank.d645.s8|22-23|is|O
DDI-DrugBank.d645.s8|25-34|unaffected|O
DDI-DrugBank.d645.s8|36-37|by|O
DDI-DrugBank.d645.s8|39-50|cyclosporine|drug
DDI-DrugBank.d645.s8|51-51|.|O
DDI-DrugBank.d645.s9|0-4|There|O
DDI-DrugBank.d645.s9|6-7|is|O
DDI-DrugBank.d645.s9|9-10|no|O
DDI-DrugBank.d645.s9|12-22|information|O
DDI-DrugBank.d645.s9|24-32|available|O
DDI-DrugBank.d645.s9|34-37|from|O
DDI-DrugBank.d645.s9|39-46|adequate|O
DDI-DrugBank.d645.s9|48-56|drug-drug|O
DDI-DrugBank.d645.s9|58-68|interaction|O
DDI-DrugBank.d645.s9|70-76|studies|O
DDI-DrugBank.d645.s9|78-81|with|O
DDI-DrugBank.d645.s9|83-85|the|O
DDI-DrugBank.d645.s9|87-95|following|O
DDI-DrugBank.d645.s9|97-103|classes|O
DDI-DrugBank.d645.s9|105-106|of|O
DDI-DrugBank.d645.s9|108-112|drugs|O
DDI-DrugBank.d645.s9|113-113|:|O
DDI-DrugBank.d645.s9|115-118|oral|O
DDI-DrugBank.d645.s9|120-133|contraceptives|group
DDI-DrugBank.d645.s9|134-134|,|O
DDI-DrugBank.d645.s9|136-142|hormone|O
DDI-DrugBank.d645.s9|144-154|replacement|O
DDI-DrugBank.d645.s9|156-164|therapies|O
DDI-DrugBank.d645.s9|165-165|,|O
DDI-DrugBank.d645.s9|167-179|hypoglycemics|group
DDI-DrugBank.d645.s9|180-180|,|O
DDI-DrugBank.d645.s9|182-194|theophyllines|drug
DDI-DrugBank.d645.s9|195-195|,|O
DDI-DrugBank.d645.s9|197-206|phenytoins|drug
DDI-DrugBank.d645.s9|207-207|,|O
DDI-DrugBank.d645.s9|209-226|thiazide diuretics|group
DDI-DrugBank.d645.s9|227-227|,|O
DDI-DrugBank.d645.s9|229-241|beta blockers|group
DDI-DrugBank.d645.s9|242-242|,|O
DDI-DrugBank.d645.s9|244-246|and|O
DDI-DrugBank.d645.s9|248-271|calcium channel blockers|group
DDI-DrugBank.d645.s9|272-272|.|O
DDI-DrugBank.d463.s0|0-1|It|O
DDI-DrugBank.d463.s0|3-4|is|O
DDI-DrugBank.d463.s0|6-16|recommended|O
DDI-DrugBank.d463.s0|18-21|that|O
DDI-DrugBank.d463.s0|23-45|buspirone hydrochloride|drug
DDI-DrugBank.d463.s0|47-49|not|O
DDI-DrugBank.d463.s0|51-52|be|O
DDI-DrugBank.d463.s0|54-57|used|O
DDI-DrugBank.d463.s0|59-71|concomitantly|O
DDI-DrugBank.d463.s0|73-76|with|O
DDI-DrugBank.d463.s0|78-91|MAO inhibitors|group
DDI-DrugBank.d463.s0|93-99|Because|O
DDI-DrugBank.d463.s0|101-103|the|O
DDI-DrugBank.d463.s0|105-111|effects|O
DDI-DrugBank.d463.s0|113-114|of|O
DDI-DrugBank.d463.s0|116-126|concomitant|O
DDI-DrugBank.d463.s0|128-141|administration|O
DDI-DrugBank.d463.s0|143-144|of|O
DDI-DrugBank.d463.s0|146-158|buspirone HCl|drug
DDI-DrugBank.d463.s0|160-163|with|O
DDI-DrugBank.d463.s0|165-168|most|O
DDI-DrugBank.d463.s0|170-174|other|O
DDI-DrugBank.d463.s0|176-193|psychotropic drugs|group
DDI-DrugBank.d463.s0|195-198|have|O
DDI-DrugBank.d463.s0|200-202|not|O
DDI-DrugBank.d463.s0|204-207|been|O
DDI-DrugBank.d463.s0|209-215|studied|O
DDI-DrugBank.d463.s0|216-216|,|O
DDI-DrugBank.d463.s0|218-220|the|O
DDI-DrugBank.d463.s0|222-232|concomitant|O
DDI-DrugBank.d463.s0|234-236|use|O
DDI-DrugBank.d463.s0|238-239|of|O
DDI-DrugBank.d463.s0|241-253|buspirone HCl|drug
DDI-DrugBank.d463.s0|255-258|with|O
DDI-DrugBank.d463.s0|260-264|other|O
DDI-DrugBank.d463.s0|266-275|CNS-active|O
DDI-DrugBank.d463.s0|277-281|drugs|O
DDI-DrugBank.d463.s0|283-288|should|O
DDI-DrugBank.d463.s0|290-291|be|O
DDI-DrugBank.d463.s0|293-302|approached|O
DDI-DrugBank.d463.s0|304-307|with|O
DDI-DrugBank.d463.s0|309-315|caution|O
DDI-DrugBank.d463.s0|316-316|.|O
DDI-DrugBank.d463.s1|0-4|There|O
DDI-DrugBank.d463.s1|6-7|is|O
DDI-DrugBank.d463.s1|9-11|one|O
DDI-DrugBank.d463.s1|13-18|report|O
DDI-DrugBank.d463.s1|20-29|suggesting|O
DDI-DrugBank.d463.s1|31-34|that|O
DDI-DrugBank.d463.s1|36-38|the|O
DDI-DrugBank.d463.s1|40-50|concomitant|O
DDI-DrugBank.d463.s1|52-54|use|O
DDI-DrugBank.d463.s1|56-57|of|O
DDI-DrugBank.d463.s1|59-81|trazodone hydrochloride|drug
DDI-DrugBank.d463.s1|83-83|(|O
DDI-DrugBank.d463.s1|84-90|Desyrel|brand
DDI-DrugBank.d463.s1|91-91|)|O
DDI-DrugBank.d463.s1|93-95|and|O
DDI-DrugBank.d463.s1|97-109|buspirone HCl|drug
DDI-DrugBank.d463.s1|111-113|may|O
DDI-DrugBank.d463.s1|115-118|have|O
DDI-DrugBank.d463.s1|120-125|caused|O
DDI-DrugBank.d463.s1|127-128|3-|O
DDI-DrugBank.d463.s1|130-131|to|O
DDI-DrugBank.d463.s1|133-138|6-fold|O
DDI-DrugBank.d463.s1|140-149|elevations|O
DDI-DrugBank.d463.s1|151-152|on|O
DDI-DrugBank.d463.s1|154-157|SGPT|O
DDI-DrugBank.d463.s1|159-159|(|O
DDI-DrugBank.d463.s1|160-162|ALT|O
DDI-DrugBank.d463.s1|163-163|)|O
DDI-DrugBank.d463.s1|165-166|in|O
DDI-DrugBank.d463.s1|168-168|a|O
DDI-DrugBank.d463.s1|170-172|few|O
DDI-DrugBank.d463.s1|174-181|patients|O
DDI-DrugBank.d463.s1|182-182|.|O
DDI-DrugBank.d463.s2|0-1|In|O
DDI-DrugBank.d463.s2|3-3|a|O
DDI-DrugBank.d463.s2|5-11|similar|O
DDI-DrugBank.d463.s2|13-17|study|O
DDI-DrugBank.d463.s2|18-18|,|O
DDI-DrugBank.d463.s2|20-29|attempting|O
DDI-DrugBank.d463.s2|31-32|to|O
DDI-DrugBank.d463.s2|34-42|replicate|O
DDI-DrugBank.d463.s2|44-47|this|O
DDI-DrugBank.d463.s2|49-55|finding|O
DDI-DrugBank.d463.s2|56-56|,|O
DDI-DrugBank.d463.s2|58-59|no|O
DDI-DrugBank.d463.s2|61-71|interactive|O
DDI-DrugBank.d463.s2|73-78|effect|O
DDI-DrugBank.d463.s2|80-81|on|O
DDI-DrugBank.d463.s2|83-89|hepatic|O
DDI-DrugBank.d463.s2|91-103|transaminases|O
DDI-DrugBank.d463.s2|105-107|was|O
DDI-DrugBank.d463.s2|109-118|identified|O
DDI-DrugBank.d463.s2|119-119|.|O
DDI-DrugBank.d463.s3|0-1|In|O
DDI-DrugBank.d463.s3|3-3|a|O
DDI-DrugBank.d463.s3|5-9|study|O
DDI-DrugBank.d463.s3|11-12|in|O
DDI-DrugBank.d463.s3|14-19|normal|O
DDI-DrugBank.d463.s3|21-30|volunteers|O
DDI-DrugBank.d463.s3|31-31|,|O
DDI-DrugBank.d463.s3|33-43|concomitant|O
DDI-DrugBank.d463.s3|45-58|administration|O
DDI-DrugBank.d463.s3|60-61|of|O
DDI-DrugBank.d463.s3|63-75|buspirone HCl|drug
DDI-DrugBank.d463.s3|77-79|and|O
DDI-DrugBank.d463.s3|81-91|haloperidol|drug
DDI-DrugBank.d463.s3|93-100|resulted|O
DDI-DrugBank.d463.s3|102-103|in|O
DDI-DrugBank.d463.s3|105-113|increased|O
DDI-DrugBank.d463.s3|115-119|serum|O
DDI-DrugBank.d463.s3|121-131|haloperidol|drug
DDI-DrugBank.d463.s3|133-146|concentrations|O
DDI-DrugBank.d463.s3|147-147|.|O
DDI-DrugBank.d463.s4|0-2|The|O
DDI-DrugBank.d463.s4|4-11|clinical|O
DDI-DrugBank.d463.s4|13-24|significance|O
DDI-DrugBank.d463.s4|26-27|of|O
DDI-DrugBank.d463.s4|29-32|this|O
DDI-DrugBank.d463.s4|34-40|finding|O
DDI-DrugBank.d463.s4|42-43|is|O
DDI-DrugBank.d463.s4|45-47|not|O
DDI-DrugBank.d463.s4|49-53|clear|O
DDI-DrugBank.d463.s4|54-54|.|O
DDI-DrugBank.d463.s5|0-1|In|O
DDI-DrugBank.d463.s5|3-7|vitro|O
DDI-DrugBank.d463.s5|8-8|,|O
DDI-DrugBank.d463.s5|10-18|buspirone|drug
DDI-DrugBank.d463.s5|20-23|does|O
DDI-DrugBank.d463.s5|25-27|not|O
DDI-DrugBank.d463.s5|29-36|displace|O
DDI-DrugBank.d463.s5|38-44|tightly|O
DDI-DrugBank.d463.s5|46-50|bound|O
DDI-DrugBank.d463.s5|52-56|drugs|O
DDI-DrugBank.d463.s5|58-61|like|O
DDI-DrugBank.d463.s5|63-71|phenytoin|drug
DDI-DrugBank.d463.s5|72-72|,|O
DDI-DrugBank.d463.s5|74-84|propranolol|drug
DDI-DrugBank.d463.s5|85-85|,|O
DDI-DrugBank.d463.s5|87-89|and|O
DDI-DrugBank.d463.s5|91-98|warfarin|drug
DDI-DrugBank.d463.s5|100-103|from|O
DDI-DrugBank.d463.s5|105-109|serum|O
DDI-DrugBank.d463.s5|111-118|proteins|O
DDI-DrugBank.d463.s5|119-119|.|O
DDI-DrugBank.d463.s6|0-6|However|O
DDI-DrugBank.d463.s6|7-7|,|O
DDI-DrugBank.d463.s6|9-13|there|O
DDI-DrugBank.d463.s6|15-17|has|O
DDI-DrugBank.d463.s6|19-22|been|O
DDI-DrugBank.d463.s6|24-26|one|O
DDI-DrugBank.d463.s6|28-33|report|O
DDI-DrugBank.d463.s6|35-36|of|O
DDI-DrugBank.d463.s6|38-46|prolonged|O
DDI-DrugBank.d463.s6|48-58|prothrombin|O
DDI-DrugBank.d463.s6|60-63|time|O
DDI-DrugBank.d463.s6|65-68|when|O
DDI-DrugBank.d463.s6|70-78|buspirone|drug
DDI-DrugBank.d463.s6|80-82|was|O
DDI-DrugBank.d463.s6|84-88|added|O
DDI-DrugBank.d463.s6|90-91|to|O
DDI-DrugBank.d463.s6|93-95|the|O
DDI-DrugBank.d463.s6|97-103|regimen|O
DDI-DrugBank.d463.s6|105-106|of|O
DDI-DrugBank.d463.s6|108-108|a|O
DDI-DrugBank.d463.s6|110-116|patient|O
DDI-DrugBank.d463.s6|118-124|treated|O
DDI-DrugBank.d463.s6|126-129|with|O
DDI-DrugBank.d463.s6|131-138|warfarin|drug
DDI-DrugBank.d463.s6|139-139|.|O
DDI-DrugBank.d463.s7|0-2|The|O
DDI-DrugBank.d463.s7|4-10|patient|O
DDI-DrugBank.d463.s7|12-14|was|O
DDI-DrugBank.d463.s7|16-19|also|O
DDI-DrugBank.d463.s7|21-31|chronically|O
DDI-DrugBank.d463.s7|33-41|receiving|O
DDI-DrugBank.d463.s7|43-51|phenytoin|drug
DDI-DrugBank.d463.s7|52-52|,|O
DDI-DrugBank.d463.s7|54-66|phenobarbital|drug
DDI-DrugBank.d463.s7|67-67|,|O
DDI-DrugBank.d463.s7|69-75|digoxin|drug
DDI-DrugBank.d463.s7|76-76|,|O
DDI-DrugBank.d463.s7|78-80|and|O
DDI-DrugBank.d463.s7|82-101|levothyroxine sodium|drug
DDI-DrugBank.d463.s7|102-102|.|O
DDI-DrugBank.d463.s8|0-1|In|O
DDI-DrugBank.d463.s8|3-7|vitro|O
DDI-DrugBank.d463.s8|8-8|,|O
DDI-DrugBank.d463.s8|10-18|buspirone|drug
DDI-DrugBank.d463.s8|20-22|may|O
DDI-DrugBank.d463.s8|24-31|displace|O
DDI-DrugBank.d463.s8|33-36|less|O
DDI-DrugBank.d463.s8|38-43|firmly|O
DDI-DrugBank.d463.s8|45-49|bound|O
DDI-DrugBank.d463.s8|51-55|drugs|O
DDI-DrugBank.d463.s8|57-60|like|O
DDI-DrugBank.d463.s8|62-68|digoxin|drug
DDI-DrugBank.d463.s8|69-69|.|O
DDI-DrugBank.d463.s9|0-2|The|O
DDI-DrugBank.d463.s9|4-11|clinical|O
DDI-DrugBank.d463.s9|13-24|significance|O
DDI-DrugBank.d463.s9|26-27|of|O
DDI-DrugBank.d463.s9|29-32|this|O
DDI-DrugBank.d463.s9|34-41|property|O
DDI-DrugBank.d463.s9|43-44|is|O
DDI-DrugBank.d463.s9|46-52|unknown|O
DDI-DrugBank.d463.s9|53-53|.|O
DDI-DrugBank.d709.s0|0-10|Concomitant|O
DDI-DrugBank.d709.s0|12-25|administration|O
DDI-DrugBank.d709.s0|27-42|contra-indicated|O
DDI-DrugBank.d709.s0|43-43|:|O
DDI-DrugBank.d709.s0|46-46|-|O
DDI-DrugBank.d709.s0|48-63|Vasoconstrictive|O
DDI-DrugBank.d709.s0|65-79|ergot alkaloids|group
DDI-DrugBank.d709.s0|80-80|.|O
DDI-DrugBank.d709.s1|0-10|Concomitant|O
DDI-DrugBank.d709.s1|12-26|administrations|O
DDI-DrugBank.d709.s1|28-30|not|O
DDI-DrugBank.d709.s1|32-42|recommended|O
DDI-DrugBank.d709.s1|43-43|:|O
DDI-DrugBank.d709.s1|46-46|-|O
DDI-DrugBank.d709.s1|48-58|Terfenadine|drug
DDI-DrugBank.d709.s1|60-62|and|O
DDI-DrugBank.d709.s1|64-73|astemizole|drug
DDI-DrugBank.d709.s1|74-74|:|O
DDI-DrugBank.d709.s1|76-82|Certain|O
DDI-DrugBank.d709.s1|84-93|macrolides|group
DDI-DrugBank.d709.s1|95-102|interact|O
DDI-DrugBank.d709.s1|104-107|with|O
DDI-DrugBank.d709.s1|109-119|terfenadine|drug
DDI-DrugBank.d709.s1|121-123|and|O
DDI-DrugBank.d709.s1|125-134|astemizole|drug
DDI-DrugBank.d709.s1|136-142|leading|O
DDI-DrugBank.d709.s1|144-145|to|O
DDI-DrugBank.d709.s1|147-155|increased|O
DDI-DrugBank.d709.s1|157-161|serum|O
DDI-DrugBank.d709.s1|163-176|concentrations|O
DDI-DrugBank.d709.s1|178-179|of|O
DDI-DrugBank.d709.s1|181-183|the|O
DDI-DrugBank.d709.s1|185-190|latter|O
DDI-DrugBank.d709.s1|191-191|.|O
DDI-DrugBank.d709.s2|0-3|This|O
DDI-DrugBank.d709.s2|5-7|may|O
DDI-DrugBank.d709.s2|9-14|result|O
DDI-DrugBank.d709.s2|16-17|in|O
DDI-DrugBank.d709.s2|19-24|severe|O
DDI-DrugBank.d709.s2|26-36|ventricular|O
DDI-DrugBank.d709.s2|38-47|arrhythmia|O
DDI-DrugBank.d709.s2|48-48|,|O
DDI-DrugBank.d709.s2|50-58|typically|O
DDI-DrugBank.d709.s2|60-67|torsades|O
DDI-DrugBank.d709.s2|69-70|de|O
DDI-DrugBank.d709.s2|72-77|pointe|O
DDI-DrugBank.d709.s2|78-78|.|O
DDI-DrugBank.d709.s3|0-7|Although|O
DDI-DrugBank.d709.s3|9-12|such|O
DDI-DrugBank.d709.s3|14-14|a|O
DDI-DrugBank.d709.s3|16-23|reaction|O
DDI-DrugBank.d709.s3|25-27|has|O
DDI-DrugBank.d709.s3|29-31|not|O
DDI-DrugBank.d709.s3|33-36|been|O
DDI-DrugBank.d709.s3|38-49|demonstrated|O
DDI-DrugBank.d709.s3|51-54|with|O
DDI-DrugBank.d709.s3|56-68|roxithromycin|drug
DDI-DrugBank.d709.s3|69-69|,|O
DDI-DrugBank.d709.s3|71-81|concomitant|O
DDI-DrugBank.d709.s3|83-96|administration|O
DDI-DrugBank.d709.s3|98-99|of|O
DDI-DrugBank.d709.s3|101-113|roxithromycin|drug
DDI-DrugBank.d709.s3|115-118|with|O
DDI-DrugBank.d709.s3|120-130|terfenadine|drug
DDI-DrugBank.d709.s3|132-133|or|O
DDI-DrugBank.d709.s3|135-144|astemizole|drug
DDI-DrugBank.d709.s3|146-147|is|O
DDI-DrugBank.d709.s3|149-151|not|O
DDI-DrugBank.d709.s3|153-163|recommended|O
DDI-DrugBank.d709.s3|164-164|.|O
DDI-DrugBank.d709.s4|0-0|-|O
DDI-DrugBank.d709.s4|2-10|Cisapride|drug
DDI-DrugBank.d709.s4|11-11|,|O
DDI-DrugBank.d709.s4|13-20|pimozide|drug
DDI-DrugBank.d709.s4|21-21|:|O
DDI-DrugBank.d709.s4|23-27|Other|O
DDI-DrugBank.d709.s4|29-33|drugs|O
DDI-DrugBank.d709.s4|35-38|such|O
DDI-DrugBank.d709.s4|40-41|as|O
DDI-DrugBank.d709.s4|43-51|cisapride|drug
DDI-DrugBank.d709.s4|53-54|or|O
DDI-DrugBank.d709.s4|56-63|pimozide|drug
DDI-DrugBank.d709.s4|64-64|,|O
DDI-DrugBank.d709.s4|66-70|which|O
DDI-DrugBank.d709.s4|72-74|are|O
DDI-DrugBank.d709.s4|76-86|metabolised|O
DDI-DrugBank.d709.s4|88-89|by|O
DDI-DrugBank.d709.s4|91-97|hepatic|O
DDI-DrugBank.d709.s4|99-103|CYP3A|O
DDI-DrugBank.d709.s4|105-112|isozymes|O
DDI-DrugBank.d709.s4|114-117|have|O
DDI-DrugBank.d709.s4|119-122|been|O
DDI-DrugBank.d709.s4|124-133|associated|O
DDI-DrugBank.d709.s4|135-138|with|O
DDI-DrugBank.d709.s4|140-141|QT|O
DDI-DrugBank.d709.s4|143-150|interval|O
DDI-DrugBank.d709.s4|152-163|prolongation|O
DDI-DrugBank.d709.s4|165-170|and/or|O
DDI-DrugBank.d709.s4|172-178|cardiac|O
DDI-DrugBank.d709.s4|180-189|arrythmias|O
DDI-DrugBank.d709.s4|191-191|(|O
DDI-DrugBank.d709.s4|192-200|typically|O
DDI-DrugBank.d709.s4|202-209|torsades|O
DDI-DrugBank.d709.s4|211-212|de|O
DDI-DrugBank.d709.s4|214-219|pointe|O
DDI-DrugBank.d709.s4|220-220|)|O
DDI-DrugBank.d709.s4|222-223|as|O
DDI-DrugBank.d709.s4|225-225|a|O
DDI-DrugBank.d709.s4|227-232|result|O
DDI-DrugBank.d709.s4|234-235|of|O
DDI-DrugBank.d709.s4|237-244|increase|O
DDI-DrugBank.d709.s4|246-247|in|O
DDI-DrugBank.d709.s4|249-253|their|O
DDI-DrugBank.d709.s4|255-259|serum|O
DDI-DrugBank.d709.s4|261-265|level|O
DDI-DrugBank.d709.s4|267-276|subsequent|O
DDI-DrugBank.d709.s4|278-279|to|O
DDI-DrugBank.d709.s4|281-291|interaction|O
DDI-DrugBank.d709.s4|293-296|with|O
DDI-DrugBank.d709.s4|298-308|significant|O
DDI-DrugBank.d709.s4|310-319|inhibitors|O
DDI-DrugBank.d709.s4|321-322|of|O
DDI-DrugBank.d709.s4|324-326|the|O
DDI-DrugBank.d709.s4|328-334|isozyme|O
DDI-DrugBank.d709.s4|335-335|,|O
DDI-DrugBank.d709.s4|337-345|including|O
DDI-DrugBank.d709.s4|347-350|some|O
DDI-DrugBank.d709.s4|352-375|macrolide antibacterials|group
DDI-DrugBank.d709.s4|376-376|.|O
DDI-DrugBank.d709.s5|0-7|Although|O
DDI-DrugBank.d709.s5|9-12|such|O
DDI-DrugBank.d709.s5|14-14|a|O
DDI-DrugBank.d709.s5|16-19|risk|O
DDI-DrugBank.d709.s5|21-22|is|O
DDI-DrugBank.d709.s5|24-26|not|O
DDI-DrugBank.d709.s5|28-35|verified|O
DDI-DrugBank.d709.s5|37-39|for|O
DDI-DrugBank.d709.s5|41-53|roxithromycin|drug
DDI-DrugBank.d709.s5|54-54|,|O
DDI-DrugBank.d709.s5|56-66|combination|O
DDI-DrugBank.d709.s5|68-69|of|O
DDI-DrugBank.d709.s5|71-83|roxithromycin|drug
DDI-DrugBank.d709.s5|85-88|with|O
DDI-DrugBank.d709.s5|90-93|such|O
DDI-DrugBank.d709.s5|95-99|drugs|O
DDI-DrugBank.d709.s5|101-102|is|O
DDI-DrugBank.d709.s5|104-106|not|O
DDI-DrugBank.d709.s5|108-118|recommended|O
DDI-DrugBank.d709.s5|119-119|.|O
DDI-MedLine.d76.s0|32-32|:|O
DDI-MedLine.d76.s0|34-35|in|O
DDI-MedLine.d76.s0|37-41|vitro|O
DDI-MedLine.d76.s0|43-52|evaluation|O
DDI-MedLine.d76.s0|54-55|of|O
DDI-MedLine.d76.s0|57-59|its|O
DDI-MedLine.d76.s0|61-70|permeation|O
DDI-MedLine.d76.s0|72-80|enhancing|O
DDI-MedLine.d76.s0|82-87|effect|O
DDI-MedLine.d76.s0|89-90|on|O
DDI-MedLine.d76.s0|92-98|peptide|O
DDI-MedLine.d76.s0|100-104|drugs|O
DDI-MedLine.d76.s0|105-105|.|O
DDI-MedLine.d76.s1|0-2|The|O
DDI-MedLine.d76.s1|4-10|purpose|O
DDI-MedLine.d76.s1|12-13|of|O
DDI-MedLine.d76.s1|15-18|this|O
DDI-MedLine.d76.s1|20-24|study|O
DDI-MedLine.d76.s1|26-28|was|O
DDI-MedLine.d76.s1|30-31|to|O
DDI-MedLine.d76.s1|33-40|evaluate|O
DDI-MedLine.d76.s1|42-44|the|O
DDI-MedLine.d76.s1|46-51|effect|O
DDI-MedLine.d76.s1|53-54|of|O
DDI-MedLine.d76.s1|86-86|(|O
DDI-MedLine.d76.s1|92-92|)|O
DDI-MedLine.d76.s1|94-96|and|O
DDI-MedLine.d76.s1|130-130|(|O
DDI-MedLine.d76.s1|138-138|)|O
DDI-MedLine.d76.s1|140-149|conjugates|O
DDI-MedLine.d76.s1|151-152|on|O
DDI-MedLine.d76.s1|154-156|the|O
DDI-MedLine.d76.s1|158-167|intestinal|O
DDI-MedLine.d76.s1|169-178|permeation|O
DDI-MedLine.d76.s1|180-181|of|O
DDI-MedLine.d76.s1|183-200|sodium fluorescein|drug
DDI-MedLine.d76.s1|202-202|(|O
DDI-MedLine.d76.s1|203-207|NaFlu|drug
DDI-MedLine.d76.s1|208-208|)|O
DDI-MedLine.d76.s1|210-212|and|O
DDI-MedLine.d76.s1|214-218|model|O
DDI-MedLine.d76.s1|220-226|peptide|O
DDI-MedLine.d76.s1|228-232|drugs|O
DDI-MedLine.d76.s1|233-233|,|O
DDI-MedLine.d76.s1|235-244|bacitracin|drug
DDI-MedLine.d76.s1|246-248|and|O
DDI-MedLine.d76.s1|250-256|insulin|drug
DDI-MedLine.d76.s1|257-257|.|O
DDI-MedLine.d76.s2|0-7|Cysteine|drug
DDI-MedLine.d76.s2|9-11|was|O
DDI-MedLine.d76.s2|13-22|covalently|O
DDI-MedLine.d76.s2|24-29|linked|O
DDI-MedLine.d76.s2|31-32|to|O
DDI-MedLine.d76.s2|34-45|carbodiimide|O
DDI-MedLine.d76.s2|47-55|activated|O
DDI-MedLine.d76.s2|62-62|.|O
DDI-MedLine.d76.s3|0-9|Iodometric|O
DDI-MedLine.d76.s3|11-19|titration|O
DDI-MedLine.d76.s3|21-22|of|O
DDI-MedLine.d76.s3|24-26|the|O
DDI-MedLine.d76.s3|28-34|polymer|O
DDI-MedLine.d76.s3|36-45|conjugates|O
DDI-MedLine.d76.s3|47-49|was|O
DDI-MedLine.d76.s3|51-54|used|O
DDI-MedLine.d76.s3|56-57|to|O
DDI-MedLine.d76.s3|59-67|determine|O
DDI-MedLine.d76.s3|69-71|the|O
DDI-MedLine.d76.s3|73-78|extent|O
DDI-MedLine.d76.s3|80-81|of|O
DDI-MedLine.d76.s3|83-93|immobilised|O
DDI-MedLine.d76.s3|95-102|cysteine|drug
DDI-MedLine.d76.s3|103-103|.|O
DDI-MedLine.d76.s4|0-9|Permeation|O
DDI-MedLine.d76.s4|11-17|studies|O
DDI-MedLine.d76.s4|19-22|were|O
DDI-MedLine.d76.s4|24-32|performed|O
DDI-MedLine.d76.s4|34-35|on|O
DDI-MedLine.d76.s4|37-42|guinea|O
DDI-MedLine.d76.s4|44-46|pig|O
DDI-MedLine.d76.s4|48-52|small|O
DDI-MedLine.d76.s4|54-63|intestinal|O
DDI-MedLine.d76.s4|65-70|mucosa|O
DDI-MedLine.d76.s4|72-78|mounted|O
DDI-MedLine.d76.s4|80-81|in|O
DDI-MedLine.d76.s4|83-93|Ussing-type|O
DDI-MedLine.d76.s4|95-101|chamber|O
DDI-MedLine.d76.s4|102-102|.|O
DDI-MedLine.d76.s5|0-9|Unmodified|O
DDI-MedLine.d76.s5|17-17|(|O
DDI-MedLine.d76.s5|18-18|1|O
DDI-MedLine.d76.s5|19-19|%|O
DDI-MedLine.d76.s5|21-23|m/v|O
DDI-MedLine.d76.s5|24-24|)|O
DDI-MedLine.d76.s5|26-38|significantly|O
DDI-MedLine.d76.s5|40-47|improved|O
DDI-MedLine.d76.s5|49-51|the|O
DDI-MedLine.d76.s5|53-61|transport|O
DDI-MedLine.d76.s5|63-67|ratio|O
DDI-MedLine.d76.s5|69-69|(|O
DDI-MedLine.d76.s5|70-71|R=|O
DDI-MedLine.d76.s5|73-73|P|O
DDI-MedLine.d76.s5|74-74|(|O
DDI-MedLine.d76.s5|75-77|app|O
DDI-MedLine.d76.s5|78-78|)|O
DDI-MedLine.d76.s5|80-87|polymer/|O
DDI-MedLine.d76.s5|89-89|P|O
DDI-MedLine.d76.s5|90-90|(|O
DDI-MedLine.d76.s5|91-93|app|O
DDI-MedLine.d76.s5|94-94|)|O
DDI-MedLine.d76.s5|96-102|control|O
DDI-MedLine.d76.s5|103-103|)|O
DDI-MedLine.d76.s5|105-106|of|O
DDI-MedLine.d76.s5|108-112|NaFlu|drug
DDI-MedLine.d76.s5|114-115|to|O
DDI-MedLine.d76.s5|117-119|1.3|O
DDI-MedLine.d76.s5|121-123|and|O
DDI-MedLine.d76.s5|125-125|1|O
DDI-MedLine.d76.s5|126-126|%|O
DDI-MedLine.d76.s5|128-128|(|O
DDI-MedLine.d76.s5|129-131|m/v|O
DDI-MedLine.d76.s5|132-132|)|O
DDI-MedLine.d76.s5|140-149|conjugated|O
DDI-MedLine.d76.s5|151-154|with|O
DDI-MedLine.d76.s5|156-163|cysteine|drug
DDI-MedLine.d76.s5|165-171|further|O
DDI-MedLine.d76.s5|173-180|enhanced|O
DDI-MedLine.d76.s5|182-184|the|O
DDI-MedLine.d76.s5|186-195|permeation|O
DDI-MedLine.d76.s5|196-196|.|O
DDI-MedLine.d76.s6|0-7|Cysteine|drug
DDI-MedLine.d76.s6|9-19|conjugation|O
DDI-MedLine.d76.s6|21-22|at|O
DDI-MedLine.d76.s6|24-26|3.6|O
DDI-MedLine.d76.s6|27-27|,|O
DDI-MedLine.d76.s6|29-31|5.3|O
DDI-MedLine.d76.s6|33-35|and|O
DDI-MedLine.d76.s6|37-39|7.3|O
DDI-MedLine.d76.s6|40-40|%|O
DDI-MedLine.d76.s6|42-42|(|O
DDI-MedLine.d76.s6|43-45|m/m|O
DDI-MedLine.d76.s6|46-46|)|O
DDI-MedLine.d76.s6|48-55|resulted|O
DDI-MedLine.d76.s6|57-58|in|O
DDI-MedLine.d76.s6|60-67|R-values|O
DDI-MedLine.d76.s6|69-70|of|O
DDI-MedLine.d76.s6|72-74|1.4|O
DDI-MedLine.d76.s6|75-75|,|O
DDI-MedLine.d76.s6|77-79|1.7|O
DDI-MedLine.d76.s6|81-83|and|O
DDI-MedLine.d76.s6|85-87|1.8|O
DDI-MedLine.d76.s6|88-88|,|O
DDI-MedLine.d76.s6|90-101|respectively|O
DDI-MedLine.d76.s6|102-102|.|O
DDI-MedLine.d76.s7|0-9|Decreasing|O
DDI-MedLine.d76.s7|11-13|the|O
DDI-MedLine.d76.s7|15-27|concentration|O
DDI-MedLine.d76.s7|29-30|of|O
DDI-MedLine.d76.s7|39-39|,|O
DDI-MedLine.d76.s7|41-50|exhibiting|O
DDI-MedLine.d76.s7|52-54|7.3|O
DDI-MedLine.d76.s7|55-55|%|O
DDI-MedLine.d76.s7|57-57|(|O
DDI-MedLine.d76.s7|58-60|m/m|O
DDI-MedLine.d76.s7|61-61|)|O
DDI-MedLine.d76.s7|63-64|of|O
DDI-MedLine.d76.s7|66-76|immobilised|O
DDI-MedLine.d76.s7|78-85|cysteine|drug
DDI-MedLine.d76.s7|87-87|(|O
DDI-MedLine.d76.s7|88-97|CMC-Cys7.3|O
DDI-MedLine.d76.s7|98-98|)|O
DDI-MedLine.d76.s7|100-103|from|O
DDI-MedLine.d76.s7|105-105|1|O
DDI-MedLine.d76.s7|106-106|%|O
DDI-MedLine.d76.s7|108-108|(|O
DDI-MedLine.d76.s7|109-111|m/v|O
DDI-MedLine.d76.s7|112-112|)|O
DDI-MedLine.d76.s7|114-115|to|O
DDI-MedLine.d76.s7|117-119|0.5|O
DDI-MedLine.d76.s7|120-120|%|O
DDI-MedLine.d76.s7|122-122|(|O
DDI-MedLine.d76.s7|123-125|m/v|O
DDI-MedLine.d76.s7|126-126|)|O
DDI-MedLine.d76.s7|128-136|decreased|O
DDI-MedLine.d76.s7|138-140|the|O
DDI-MedLine.d76.s7|142-148|R-value|O
DDI-MedLine.d76.s7|150-151|of|O
DDI-MedLine.d76.s7|153-157|NaFlu|drug
DDI-MedLine.d76.s7|159-162|from|O
DDI-MedLine.d76.s7|164-166|1.8|O
DDI-MedLine.d76.s7|168-169|to|O
DDI-MedLine.d76.s7|171-173|1.2|O
DDI-MedLine.d76.s7|174-174|.|O
DDI-MedLine.d76.s8|6-7|at|O
DDI-MedLine.d76.s8|9-9|1|O
DDI-MedLine.d76.s8|10-10|%|O
DDI-MedLine.d76.s8|12-12|(|O
DDI-MedLine.d76.s8|13-15|m/v|O
DDI-MedLine.d76.s8|16-16|)|O
DDI-MedLine.d76.s8|18-19|in|O
DDI-MedLine.d76.s8|21-23|the|O
DDI-MedLine.d76.s8|25-32|presence|O
DDI-MedLine.d76.s8|34-35|of|O
DDI-MedLine.d76.s8|37-40|free|O
DDI-MedLine.d76.s8|42-49|cysteine|drug
DDI-MedLine.d76.s8|51-53|had|O
DDI-MedLine.d76.s8|55-56|no|O
DDI-MedLine.d76.s8|58-68|significant|O
DDI-MedLine.d76.s8|70-75|effect|O
DDI-MedLine.d76.s8|77-78|on|O
DDI-MedLine.d76.s8|80-82|the|O
DDI-MedLine.d76.s8|84-90|R-value|O
DDI-MedLine.d76.s8|92-93|of|O
DDI-MedLine.d76.s8|95-99|NaFlu|drug
DDI-MedLine.d76.s8|101-108|compared|O
DDI-MedLine.d76.s8|110-111|to|O
DDI-MedLine.d76.s8|119-123|alone|O
DDI-MedLine.d76.s8|124-124|.|O
DDI-MedLine.d76.s9|0-10|Formulation|O
DDI-MedLine.d76.s9|12-13|of|O
DDI-MedLine.d76.s9|15-26|fluorescence|O
DDI-MedLine.d76.s9|28-35|labelled|O
DDI-MedLine.d76.s9|37-46|bacitracin|drug
DDI-MedLine.d76.s9|48-50|and|O
DDI-MedLine.d76.s9|52-58|insulin|drug
DDI-MedLine.d76.s9|60-61|in|O
DDI-MedLine.d76.s9|63-74|unconjugated|O
DDI-MedLine.d76.s9|82-82|(|O
DDI-MedLine.d76.s9|83-83|1|O
DDI-MedLine.d76.s9|84-84|%|O
DDI-MedLine.d76.s9|86-88|m/v|O
DDI-MedLine.d76.s9|89-89|)|O
DDI-MedLine.d76.s9|91-93|did|O
DDI-MedLine.d76.s9|95-97|not|O
DDI-MedLine.d76.s9|99-111|significantly|O
DDI-MedLine.d76.s9|113-119|improve|O
DDI-MedLine.d76.s9|121-123|the|O
DDI-MedLine.d76.s9|125-134|permeation|O
DDI-MedLine.d76.s9|135-135|,|O
DDI-MedLine.d76.s9|137-143|however|O
DDI-MedLine.d76.s9|145-146|in|O
DDI-MedLine.d76.s9|148-150|the|O
DDI-MedLine.d76.s9|152-159|presence|O
DDI-MedLine.d76.s9|161-162|of|O
DDI-MedLine.d76.s9|164-164|1|O
DDI-MedLine.d76.s9|165-165|%|O
DDI-MedLine.d76.s9|167-167|(|O
DDI-MedLine.d76.s9|168-170|m/v|O
DDI-MedLine.d76.s9|171-171|)|O
DDI-MedLine.d76.s9|184-184|a|O
DDI-MedLine.d76.s9|186-198|significantly|O
DDI-MedLine.d76.s9|200-207|improved|O
DDI-MedLine.d76.s9|209-218|permeation|O
DDI-MedLine.d76.s9|220-222|was|O
DDI-MedLine.d76.s9|224-231|observed|O
DDI-MedLine.d76.s9|233-233|(|O
DDI-MedLine.d76.s9|234-235|R=|O
DDI-MedLine.d76.s9|237-239|1.3|O
DDI-MedLine.d76.s9|240-240|)|O
DDI-MedLine.d76.s9|241-241|.|O
DDI-MedLine.d76.s10|0-10|Conjugation|O
DDI-MedLine.d76.s10|12-13|at|O
DDI-MedLine.d76.s10|21-24|with|O
DDI-MedLine.d76.s10|26-33|cysteine|drug
DDI-MedLine.d76.s10|35-42|moieties|O
DDI-MedLine.d76.s10|44-56|significantly|O
DDI-MedLine.d76.s10|58-65|improves|O
DDI-MedLine.d76.s10|67-69|the|O
DDI-MedLine.d76.s10|71-80|intestinal|O
DDI-MedLine.d76.s10|82-91|permeation|O
DDI-MedLine.d76.s10|93-94|of|O
DDI-MedLine.d76.s10|96-98|the|O
DDI-MedLine.d76.s10|100-110|hydrophilic|O
DDI-MedLine.d76.s10|112-119|molecule|O
DDI-MedLine.d76.s10|121-125|NaFlu|drug
DDI-MedLine.d76.s10|127-129|and|O
DDI-MedLine.d76.s10|131-133|the|O
DDI-MedLine.d76.s10|135-139|model|O
DDI-MedLine.d76.s10|141-147|peptide|O
DDI-MedLine.d76.s10|149-153|drugs|O
DDI-MedLine.d76.s10|155-164|bacitracin|drug
DDI-MedLine.d76.s10|166-168|and|O
DDI-MedLine.d76.s10|170-176|insulin|drug
DDI-MedLine.d76.s10|178-179|in|O
DDI-MedLine.d76.s10|181-185|vitro|O
DDI-MedLine.d76.s10|186-186|,|O
DDI-MedLine.d76.s10|188-196|therefore|O
DDI-MedLine.d76.s10|198-201|this|O
DDI-MedLine.d76.s10|203-212|conjugated|O
DDI-MedLine.d76.s10|214-219|system|O
DDI-MedLine.d76.s10|221-225|maybe|O
DDI-MedLine.d76.s10|227-232|useful|O
DDI-MedLine.d76.s10|234-236|for|O
DDI-MedLine.d76.s10|238-244|peroral|O
DDI-MedLine.d76.s10|246-259|administration|O
DDI-MedLine.d76.s10|261-262|of|O
DDI-MedLine.d76.s10|264-270|peptide|O
DDI-MedLine.d76.s10|272-276|drugs|O
DDI-MedLine.d76.s10|278-279|in|O
DDI-MedLine.d76.s10|281-283|the|O
DDI-MedLine.d76.s10|285-290|future|O
DDI-MedLine.d76.s10|291-291|.|O
DDI-DrugBank.d637.s0|0-2|Use|O
DDI-DrugBank.d637.s0|4-7|with|O
DDI-DrugBank.d637.s0|9-13|Other|O
DDI-DrugBank.d637.s0|15-48|Central Nervous System Depressants|group
DDI-DrugBank.d637.s0|49-49|:|O
DDI-DrugBank.d637.s0|51-53|The|O
DDI-DrugBank.d637.s0|55-64|depressant|O
DDI-DrugBank.d637.s0|66-72|effects|O
DDI-DrugBank.d637.s0|74-75|of|O
DDI-DrugBank.d637.s0|77-84|morphine|drug
DDI-DrugBank.d637.s0|86-88|are|O
DDI-DrugBank.d637.s0|90-100|potentiated|O
DDI-DrugBank.d637.s0|102-103|by|O
DDI-DrugBank.d637.s0|105-107|the|O
DDI-DrugBank.d637.s0|109-116|presence|O
DDI-DrugBank.d637.s0|118-119|of|O
DDI-DrugBank.d637.s0|121-125|other|O
DDI-DrugBank.d637.s0|127-141|CNS depressants|group
DDI-DrugBank.d637.s0|143-146|such|O
DDI-DrugBank.d637.s0|148-149|as|O
DDI-DrugBank.d637.s0|151-157|alcohol|drug
DDI-DrugBank.d637.s0|158-158|,|O
DDI-DrugBank.d637.s0|160-168|sedatives|group
DDI-DrugBank.d637.s0|169-169|,|O
DDI-DrugBank.d637.s0|171-185|antihistaminics|group
DDI-DrugBank.d637.s0|186-186|,|O
DDI-DrugBank.d637.s0|188-189|or|O
DDI-DrugBank.d637.s0|191-208|psychotropic drugs|group
DDI-DrugBank.d637.s0|209-209|.|O
DDI-DrugBank.d637.s1|0-2|Use|O
DDI-DrugBank.d637.s1|4-5|of|O
DDI-DrugBank.d637.s1|7-18|neuroleptics|group
DDI-DrugBank.d637.s1|20-21|in|O
DDI-DrugBank.d637.s1|23-33|conjunction|O
DDI-DrugBank.d637.s1|35-38|with|O
DDI-DrugBank.d637.s1|40-43|oral|O
DDI-DrugBank.d637.s1|45-52|morphine|drug
DDI-DrugBank.d637.s1|54-56|may|O
DDI-DrugBank.d637.s1|58-65|increase|O
DDI-DrugBank.d637.s1|67-69|the|O
DDI-DrugBank.d637.s1|71-74|risk|O
DDI-DrugBank.d637.s1|76-77|of|O
DDI-DrugBank.d637.s1|79-89|respiratory|O
DDI-DrugBank.d637.s1|91-100|depression|O
DDI-DrugBank.d637.s1|101-101|,|O
DDI-DrugBank.d637.s1|103-113|hypotension|O
DDI-DrugBank.d637.s1|115-117|and|O
DDI-DrugBank.d637.s1|119-126|profound|O
DDI-DrugBank.d637.s1|128-135|sedation|O
DDI-DrugBank.d637.s1|137-138|or|O
DDI-DrugBank.d637.s1|140-143|coma|O
DDI-DrugBank.d637.s1|144-144|.|O
DDI-DrugBank.d637.s2|0-10|Interaction|O
DDI-DrugBank.d637.s2|12-15|with|O
DDI-DrugBank.d637.s2|17-58|Mixed Agonist/Antagonist Opioid Analgesics|group
DDI-DrugBank.d637.s2|59-59|:|O
DDI-DrugBank.d637.s2|61-89|Agonist/antagonist analgesics|group
DDI-DrugBank.d637.s2|91-91|(|O
DDI-DrugBank.d637.s2|92-95|i.e.|O
DDI-DrugBank.d637.s2|96-96|,|O
DDI-DrugBank.d637.s2|98-108|pentazocine|drug
DDI-DrugBank.d637.s2|109-109|,|O
DDI-DrugBank.d637.s2|111-120|nalbuphine|drug
DDI-DrugBank.d637.s2|121-121|,|O
DDI-DrugBank.d637.s2|123-133|butorphanol|drug
DDI-DrugBank.d637.s2|134-134|,|O
DDI-DrugBank.d637.s2|136-137|or|O
DDI-DrugBank.d637.s2|139-151|buprenorphine|drug
DDI-DrugBank.d637.s2|152-152|)|O
DDI-DrugBank.d637.s2|154-159|should|O
DDI-DrugBank.d637.s2|161-163|NOT|O
DDI-DrugBank.d637.s2|165-166|be|O
DDI-DrugBank.d637.s2|168-179|administered|O
DDI-DrugBank.d637.s2|181-182|to|O
DDI-DrugBank.d637.s2|184-191|patients|O
DDI-DrugBank.d637.s2|193-195|who|O
DDI-DrugBank.d637.s2|197-200|have|O
DDI-DrugBank.d637.s2|202-209|received|O
DDI-DrugBank.d637.s2|211-212|or|O
DDI-DrugBank.d637.s2|214-216|are|O
DDI-DrugBank.d637.s2|218-226|receiving|O
DDI-DrugBank.d637.s2|228-228|a|O
DDI-DrugBank.d637.s2|230-235|course|O
DDI-DrugBank.d637.s2|237-238|of|O
DDI-DrugBank.d637.s2|240-246|therapy|O
DDI-DrugBank.d637.s2|248-251|with|O
DDI-DrugBank.d637.s2|253-253|a|O
DDI-DrugBank.d637.s2|255-259|proof|O
DDI-DrugBank.d637.s2|261-284|opioid agonist analgesic|group
DDI-DrugBank.d637.s2|285-285|.|O
DDI-DrugBank.d637.s3|0-1|In|O
DDI-DrugBank.d637.s3|3-7|these|O
DDI-DrugBank.d637.s3|9-16|patients|O
DDI-DrugBank.d637.s3|17-17|,|O
DDI-DrugBank.d637.s3|19-21|the|O
DDI-DrugBank.d637.s3|23-27|mixed|O
DDI-DrugBank.d637.s3|29-46|agonist/antagonist|O
DDI-DrugBank.d637.s3|48-50|may|O
DDI-DrugBank.d637.s3|52-56|alter|O
DDI-DrugBank.d637.s3|58-60|the|O
DDI-DrugBank.d637.s3|62-70|analgesic|O
DDI-DrugBank.d637.s3|72-77|effect|O
DDI-DrugBank.d637.s3|79-80|or|O
DDI-DrugBank.d637.s3|82-84|may|O
DDI-DrugBank.d637.s3|86-96|precipitate|O
DDI-DrugBank.d637.s3|98-107|withdrawal|O
DDI-DrugBank.d637.s3|109-116|symptoms|O
DDI-DrugBank.d637.s3|117-117|.|O
DDI-DrugBank.d142.s0|0-7|Additive|O
DDI-DrugBank.d142.s0|9-15|adverse|O
DDI-DrugBank.d142.s0|17-23|effects|O
DDI-DrugBank.d142.s0|25-33|resulting|O
DDI-DrugBank.d142.s0|35-38|from|O
DDI-DrugBank.d142.s0|40-50|cholinergic|O
DDI-DrugBank.d142.s0|52-59|blockade|O
DDI-DrugBank.d142.s0|61-63|may|O
DDI-DrugBank.d142.s0|65-69|occur|O
DDI-DrugBank.d142.s0|71-74|when|O
DDI-DrugBank.d142.s0|76-81|LEVSIN|brand
DDI-DrugBank.d142.s0|83-84|is|O
DDI-DrugBank.d142.s0|86-97|administered|O
DDI-DrugBank.d142.s0|99-111|concomitantly|O
DDI-DrugBank.d142.s0|113-116|with|O
DDI-DrugBank.d142.s0|118-122|other|O
DDI-DrugBank.d142.s0|124-138|antimuscarinics|group
DDI-DrugBank.d142.s0|139-139|,|O
DDI-DrugBank.d142.s0|141-150|amantadine|drug
DDI-DrugBank.d142.s0|151-151|,|O
DDI-DrugBank.d142.s0|153-163|haloperidol|drug
DDI-DrugBank.d142.s0|164-164|,|O
DDI-DrugBank.d142.s0|166-179|phenothiazines|group
DDI-DrugBank.d142.s0|180-180|,|O
DDI-DrugBank.d142.s0|182-215|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d142.s0|216-216|,|O
DDI-DrugBank.d142.s0|218-242|tricyclic antidepressants|group
DDI-DrugBank.d142.s0|244-245|or|O
DDI-DrugBank.d142.s0|247-250|some|O
DDI-DrugBank.d142.s0|252-265|antihistamines|group
DDI-DrugBank.d142.s0|266-266|.|O
DDI-DrugBank.d142.s1|0-7|Antacids|group
DDI-DrugBank.d142.s1|9-11|may|O
DDI-DrugBank.d142.s1|13-21|interfere|O
DDI-DrugBank.d142.s1|23-26|with|O
DDI-DrugBank.d142.s1|28-30|the|O
DDI-DrugBank.d142.s1|32-41|absorption|O
DDI-DrugBank.d142.s1|43-44|of|O
DDI-DrugBank.d142.s1|46-51|LEVSIN|brand
DDI-DrugBank.d142.s1|52-52|.|O
DDI-DrugBank.d142.s2|0-9|Administer|O
DDI-DrugBank.d142.s2|11-16|LEVSIN|brand
DDI-DrugBank.d142.s2|18-23|before|O
DDI-DrugBank.d142.s2|25-29|meals|O
DDI-DrugBank.d142.s2|30-30|;|O
DDI-DrugBank.d142.s3|0-7|antacids|group
DDI-DrugBank.d142.s3|9-13|after|O
DDI-DrugBank.d142.s3|15-19|meals|O
DDI-DrugBank.d142.s3|20-20|.|O
DDI-DrugBank.d275.s0|0-1|No|O
DDI-DrugBank.d275.s0|3-11|drug-drug|O
DDI-DrugBank.d275.s0|13-23|interaction|O
DDI-DrugBank.d275.s0|25-31|studies|O
DDI-DrugBank.d275.s0|33-34|in|O
DDI-DrugBank.d275.s0|36-40|human|O
DDI-DrugBank.d275.s0|42-49|subjects|O
DDI-DrugBank.d275.s0|51-54|have|O
DDI-DrugBank.d275.s0|56-59|been|O
DDI-DrugBank.d275.s0|61-69|conducted|O
DDI-DrugBank.d275.s0|70-70|.|O
DDI-DrugBank.d275.s1|0-10|Toxicologic|O
DDI-DrugBank.d275.s1|12-14|and|O
DDI-DrugBank.d275.s1|16-28|toxicokinetic|O
DDI-DrugBank.d275.s1|30-36|studies|O
DDI-DrugBank.d275.s1|38-39|in|O
DDI-DrugBank.d275.s1|41-44|rats|O
DDI-DrugBank.d275.s1|46-48|did|O
DDI-DrugBank.d275.s1|50-52|not|O
DDI-DrugBank.d275.s1|54-64|demonstrate|O
DDI-DrugBank.d275.s1|66-68|any|O
DDI-DrugBank.d275.s1|70-80|alterations|O
DDI-DrugBank.d275.s1|82-83|in|O
DDI-DrugBank.d275.s1|85-87|the|O
DDI-DrugBank.d275.s1|89-97|clearance|O
DDI-DrugBank.d275.s1|99-100|or|O
DDI-DrugBank.d275.s1|102-112|toxicologic|O
DDI-DrugBank.d275.s1|114-120|profile|O
DDI-DrugBank.d275.s1|122-123|of|O
DDI-DrugBank.d275.s1|125-130|either|O
DDI-DrugBank.d275.s1|132-143|methotrexate|drug
DDI-DrugBank.d275.s1|145-146|or|O
DDI-DrugBank.d275.s1|148-154|Kineret|brand
DDI-DrugBank.d275.s1|156-159|when|O
DDI-DrugBank.d275.s1|161-163|the|O
DDI-DrugBank.d275.s1|165-167|two|O
DDI-DrugBank.d275.s1|169-174|agents|O
DDI-DrugBank.d275.s1|176-179|were|O
DDI-DrugBank.d275.s1|181-192|administered|O
DDI-DrugBank.d275.s1|194-201|together|O
DDI-DrugBank.d275.s1|202-202|.|O
DDI-DrugBank.d275.s2|0-1|In|O
DDI-DrugBank.d275.s2|3-3|a|O
DDI-DrugBank.d275.s2|5-9|study|O
DDI-DrugBank.d275.s2|11-12|in|O
DDI-DrugBank.d275.s2|14-18|which|O
DDI-DrugBank.d275.s2|20-27|patients|O
DDI-DrugBank.d275.s2|29-32|with|O
DDI-DrugBank.d275.s2|34-39|active|O
DDI-DrugBank.d275.s2|41-42|RA|O
DDI-DrugBank.d275.s2|44-47|were|O
DDI-DrugBank.d275.s2|49-55|treated|O
DDI-DrugBank.d275.s2|57-59|for|O
DDI-DrugBank.d275.s2|61-62|up|O
DDI-DrugBank.d275.s2|64-65|to|O
DDI-DrugBank.d275.s2|67-68|24|O
DDI-DrugBank.d275.s2|70-74|weeks|O
DDI-DrugBank.d275.s2|76-79|with|O
DDI-DrugBank.d275.s2|81-90|concurrent|O
DDI-DrugBank.d275.s2|92-98|Kineret|brand
DDI-DrugBank.d275.s2|100-102|and|O
DDI-DrugBank.d275.s2|104-113|etanercept|drug
DDI-DrugBank.d275.s2|115-121|therapy|O
DDI-DrugBank.d275.s2|122-122|,|O
DDI-DrugBank.d275.s2|124-124|a|O
DDI-DrugBank.d275.s2|126-126|7|O
DDI-DrugBank.d275.s2|127-127|%|O
DDI-DrugBank.d275.s2|129-132|rate|O
DDI-DrugBank.d275.s2|134-135|of|O
DDI-DrugBank.d275.s2|137-143|serious|O
DDI-DrugBank.d275.s2|145-154|infections|O
DDI-DrugBank.d275.s2|156-158|was|O
DDI-DrugBank.d275.s2|160-167|observed|O
DDI-DrugBank.d275.s2|168-168|,|O
DDI-DrugBank.d275.s2|170-174|which|O
DDI-DrugBank.d275.s2|176-178|was|O
DDI-DrugBank.d275.s2|180-185|higher|O
DDI-DrugBank.d275.s2|187-190|than|O
DDI-DrugBank.d275.s2|192-195|that|O
DDI-DrugBank.d275.s2|197-204|observed|O
DDI-DrugBank.d275.s2|206-209|with|O
DDI-DrugBank.d275.s2|211-220|etanercept|drug
DDI-DrugBank.d275.s2|222-226|alone|O
DDI-DrugBank.d275.s2|228-228|(|O
DDI-DrugBank.d275.s2|229-229|0|O
DDI-DrugBank.d275.s2|230-230|%|O
DDI-DrugBank.d275.s2|231-231|)|O
DDI-DrugBank.d275.s2|232-232|.|O
DDI-DrugBank.d275.s3|0-2|Two|O
DDI-DrugBank.d275.s3|4-10|percent|O
DDI-DrugBank.d275.s3|12-13|of|O
DDI-DrugBank.d275.s3|15-22|patients|O
DDI-DrugBank.d275.s3|24-30|treated|O
DDI-DrugBank.d275.s3|32-43|concurrently|O
DDI-DrugBank.d275.s3|45-48|with|O
DDI-DrugBank.d275.s3|50-56|Kineret|brand
DDI-DrugBank.d275.s3|58-60|and|O
DDI-DrugBank.d275.s3|62-71|etanercept|drug
DDI-DrugBank.d275.s3|73-81|developed|O
DDI-DrugBank.d275.s3|83-93|neutropenia|O
DDI-DrugBank.d275.s3|95-95|(|O
DDI-DrugBank.d275.s3|96-98|ANC|O
DDI-DrugBank.d275.s3|101-101|1|O
DDI-DrugBank.d275.s3|103-103|x|O
DDI-DrugBank.d275.s3|105-109|109/L|O
DDI-DrugBank.d275.s3|110-110|)|O
DDI-DrugBank.d275.s3|111-111|.|O
DDI-MedLine.d98.s0|0-9|Behavioral|O
DDI-MedLine.d98.s0|11-19|responses|O
DDI-MedLine.d98.s0|21-22|to|O
DDI-MedLine.d98.s0|24-31|repeated|O
DDI-MedLine.d98.s0|33-39|cocaine|drug
DDI-MedLine.d98.s0|41-48|exposure|O
DDI-MedLine.d98.s0|50-51|in|O
DDI-MedLine.d98.s0|53-56|mice|O
DDI-MedLine.d98.s0|58-68|selectively|O
DDI-MedLine.d98.s0|70-73|bred|O
DDI-MedLine.d98.s0|75-77|for|O
DDI-MedLine.d98.s0|79-90|differential|O
DDI-MedLine.d98.s0|92-102|sensitivity|O
DDI-MedLine.d98.s0|104-105|to|O
DDI-MedLine.d98.s0|107-119|pentobarbital|drug
DDI-MedLine.d98.s0|120-120|.|O
DDI-MedLine.d98.s1|0-3|Mice|O
DDI-MedLine.d98.s1|5-8|from|O
DDI-MedLine.d98.s1|10-12|the|O
DDI-MedLine.d98.s1|14-17|20th|O
DDI-MedLine.d98.s1|19-28|generation|O
DDI-MedLine.d98.s1|30-31|of|O
DDI-MedLine.d98.s1|33-37|three|O
DDI-MedLine.d98.s1|39-43|lines|O
DDI-MedLine.d98.s1|45-55|divergently|O
DDI-MedLine.d98.s1|57-64|selected|O
DDI-MedLine.d98.s1|66-68|for|O
DDI-MedLine.d98.s1|70-77|response|O
DDI-MedLine.d98.s1|79-80|to|O
DDI-MedLine.d98.s1|82-102|pentobarbital-induced|drug
DDI-MedLine.d98.s1|104-111|sedation|O
DDI-MedLine.d98.s1|113-117|times|O
DDI-MedLine.d98.s1|119-119|[|O
DDI-MedLine.d98.s1|120-132|long-sedation|O
DDI-MedLine.d98.s1|134-137|time|O
DDI-MedLine.d98.s1|139-139|(|O
DDI-MedLine.d98.s1|140-142|LST|O
DDI-MedLine.d98.s1|143-143|)|O
DDI-MedLine.d98.s1|144-144|,|O
DDI-MedLine.d98.s1|146-150|short|O
DDI-MedLine.d98.s1|152-159|sedation|O
DDI-MedLine.d98.s1|161-164|time|O
DDI-MedLine.d98.s1|166-166|(|O
DDI-MedLine.d98.s1|167-169|SST|O
DDI-MedLine.d98.s1|170-170|)|O
DDI-MedLine.d98.s1|171-171|,|O
DDI-MedLine.d98.s1|173-175|and|O
DDI-MedLine.d98.s1|177-184|randomly|O
DDI-MedLine.d98.s1|186-189|bred|O
DDI-MedLine.d98.s1|191-197|control|O
DDI-MedLine.d98.s1|199-199|(|O
DDI-MedLine.d98.s1|200-202|RBC|O
DDI-MedLine.d98.s1|203-203|)|O
DDI-MedLine.d98.s1|204-204|]|O
DDI-MedLine.d98.s1|206-209|were|O
DDI-MedLine.d98.s1|211-214|used|O
DDI-MedLine.d98.s1|216-217|to|O
DDI-MedLine.d98.s1|219-223|study|O
DDI-MedLine.d98.s1|225-239|cocaine-induced|drug
DDI-MedLine.d98.s1|241-250|behavioral|O
DDI-MedLine.d98.s1|252-264|sensitization|O
DDI-MedLine.d98.s1|265-265|.|O
DDI-MedLine.d98.s2|0-4|These|O
DDI-MedLine.d98.s2|6-10|lines|O
DDI-MedLine.d98.s2|12-17|showed|O
DDI-MedLine.d98.s2|19-26|variable|O
DDI-MedLine.d98.s2|28-34|degrees|O
DDI-MedLine.d98.s2|36-37|of|O
DDI-MedLine.d98.s2|39-47|locomotor|O
DDI-MedLine.d98.s2|49-58|activities|O
DDI-MedLine.d98.s2|60-61|in|O
DDI-MedLine.d98.s2|63-70|response|O
DDI-MedLine.d98.s2|72-73|to|O
DDI-MedLine.d98.s2|75-81|cocaine|drug
DDI-MedLine.d98.s2|82-82|.|O
DDI-MedLine.d98.s3|0-1|At|O
DDI-MedLine.d98.s3|3-3|a|O
DDI-MedLine.d98.s3|5-7|low|O
DDI-MedLine.d98.s3|9-15|cocaine|drug
DDI-MedLine.d98.s3|17-20|dose|O
DDI-MedLine.d98.s3|22-24|and|O
DDI-MedLine.d98.s3|26-29|long|O
DDI-MedLine.d98.s3|31-40|withdrawal|O
DDI-MedLine.d98.s3|42-47|period|O
DDI-MedLine.d98.s3|49-49|(|O
DDI-MedLine.d98.s3|50-51|10|O
DDI-MedLine.d98.s3|53-57|mg/kg|O
DDI-MedLine.d98.s3|58-58|,|O
DDI-MedLine.d98.s3|60-64|twice|O
DDI-MedLine.d98.s3|66-66|a|O
DDI-MedLine.d98.s3|68-70|day|O
DDI-MedLine.d98.s3|72-74|for|O
DDI-MedLine.d98.s3|76-76|5|O
DDI-MedLine.d98.s3|78-81|days|O
DDI-MedLine.d98.s3|83-90|followed|O
DDI-MedLine.d98.s3|92-93|by|O
DDI-MedLine.d98.s3|95-95|a|O
DDI-MedLine.d98.s3|97-102|14-day|O
DDI-MedLine.d98.s3|104-113|withdrawal|O
DDI-MedLine.d98.s3|114-114|)|O
DDI-MedLine.d98.s3|115-115|,|O
DDI-MedLine.d98.s3|117-119|the|O
DDI-MedLine.d98.s3|121-123|LST|O
DDI-MedLine.d98.s3|125-128|mice|O
DDI-MedLine.d98.s3|130-135|showed|O
DDI-MedLine.d98.s3|137-145|tolerance|O
DDI-MedLine.d98.s3|147-157|development|O
DDI-MedLine.d98.s3|158-158|.|O
DDI-MedLine.d98.s4|0-1|In|O
DDI-MedLine.d98.s4|3-10|response|O
DDI-MedLine.d98.s4|12-13|to|O
DDI-MedLine.d98.s4|15-21|cocaine|drug
DDI-MedLine.d98.s4|22-22|,|O
DDI-MedLine.d98.s4|24-26|the|O
DDI-MedLine.d98.s4|28-36|locomotor|O
DDI-MedLine.d98.s4|38-47|activities|O
DDI-MedLine.d98.s4|49-50|of|O
DDI-MedLine.d98.s4|52-54|the|O
DDI-MedLine.d98.s4|56-58|SST|O
DDI-MedLine.d98.s4|60-63|were|O
DDI-MedLine.d98.s4|65-67|not|O
DDI-MedLine.d98.s4|69-81|significantly|O
DDI-MedLine.d98.s4|83-91|different|O
DDI-MedLine.d98.s4|93-96|from|O
DDI-MedLine.d98.s4|98-100|the|O
DDI-MedLine.d98.s4|102-104|RBC|O
DDI-MedLine.d98.s4|106-110|group|O
DDI-MedLine.d98.s4|111-111|.|O
DDI-MedLine.d98.s5|0-1|At|O
DDI-MedLine.d98.s5|3-3|a|O
DDI-MedLine.d98.s5|5-10|higher|O
DDI-MedLine.d98.s5|12-15|dose|O
DDI-MedLine.d98.s5|17-19|and|O
DDI-MedLine.d98.s5|21-21|a|O
DDI-MedLine.d98.s5|23-29|shorter|O
DDI-MedLine.d98.s5|31-40|withdrawal|O
DDI-MedLine.d98.s5|42-47|period|O
DDI-MedLine.d98.s5|49-49|(|O
DDI-MedLine.d98.s5|50-51|20|O
DDI-MedLine.d98.s5|53-57|mg/kg|O
DDI-MedLine.d98.s5|58-58|,|O
DDI-MedLine.d98.s5|60-64|daily|O
DDI-MedLine.d98.s5|66-68|for|O
DDI-MedLine.d98.s5|70-70|7|O
DDI-MedLine.d98.s5|72-75|days|O
DDI-MedLine.d98.s5|77-84|followed|O
DDI-MedLine.d98.s5|86-87|by|O
DDI-MedLine.d98.s5|89-89|a|O
DDI-MedLine.d98.s5|91-95|3-day|O
DDI-MedLine.d98.s5|97-106|withdrawal|O
DDI-MedLine.d98.s5|107-107|)|O
DDI-MedLine.d98.s5|108-108|,|O
DDI-MedLine.d98.s5|110-112|the|O
DDI-MedLine.d98.s5|114-116|SST|O
DDI-MedLine.d98.s5|118-121|mice|O
DDI-MedLine.d98.s5|123-128|showed|O
DDI-MedLine.d98.s5|130-139|behavioral|O
DDI-MedLine.d98.s5|141-153|sensitization|O
DDI-MedLine.d98.s5|155-161|similar|O
DDI-MedLine.d98.s5|163-164|to|O
DDI-MedLine.d98.s5|166-168|the|O
DDI-MedLine.d98.s5|170-172|RBC|O
DDI-MedLine.d98.s5|174-177|mice|O
DDI-MedLine.d98.s5|178-178|,|O
DDI-MedLine.d98.s5|180-182|but|O
DDI-MedLine.d98.s5|184-186|the|O
DDI-MedLine.d98.s5|188-190|LST|O
DDI-MedLine.d98.s5|192-195|mice|O
DDI-MedLine.d98.s5|197-199|did|O
DDI-MedLine.d98.s5|201-203|not|O
DDI-MedLine.d98.s5|205-211|develop|O
DDI-MedLine.d98.s5|213-225|sensitization|O
DDI-MedLine.d98.s5|226-226|.|O
DDI-MedLine.d98.s6|0-2|The|O
DDI-MedLine.d98.s6|4-12|different|O
DDI-MedLine.d98.s6|14-22|responses|O
DDI-MedLine.d98.s6|24-25|in|O
DDI-MedLine.d98.s6|27-35|locomotor|O
DDI-MedLine.d98.s6|37-44|activity|O
DDI-MedLine.d98.s6|46-52|induced|O
DDI-MedLine.d98.s6|54-55|by|O
DDI-MedLine.d98.s6|57-63|cocaine|drug
DDI-MedLine.d98.s6|65-71|suggest|O
DDI-MedLine.d98.s6|73-76|that|O
DDI-MedLine.d98.s6|78-84|genetic|O
DDI-MedLine.d98.s6|86-92|factors|O
DDI-MedLine.d98.s6|94-96|may|O
DDI-MedLine.d98.s6|98-101|play|O
DDI-MedLine.d98.s6|103-103|a|O
DDI-MedLine.d98.s6|105-108|role|O
DDI-MedLine.d98.s6|110-111|in|O
DDI-MedLine.d98.s6|113-123|determining|O
DDI-MedLine.d98.s6|125-127|the|O
DDI-MedLine.d98.s6|129-137|magnitude|O
DDI-MedLine.d98.s6|139-140|of|O
DDI-MedLine.d98.s6|142-149|response|O
DDI-MedLine.d98.s6|151-152|to|O
DDI-MedLine.d98.s6|154-157|this|O
DDI-MedLine.d98.s6|159-162|drug|O
DDI-MedLine.d98.s6|163-163|.|O
DDI-MedLine.d98.s7|0-7|Dopamine|O
DDI-MedLine.d98.s7|9-9|(|O
DDI-MedLine.d98.s7|10-11|DA|O
DDI-MedLine.d98.s7|12-12|)|O
DDI-MedLine.d98.s7|14-19|levels|O
DDI-MedLine.d98.s7|21-23|did|O
DDI-MedLine.d98.s7|25-27|not|O
DDI-MedLine.d98.s7|29-34|differ|O
DDI-MedLine.d98.s7|36-48|significantly|O
DDI-MedLine.d98.s7|50-51|in|O
DDI-MedLine.d98.s7|53-58|either|O
DDI-MedLine.d98.s7|60-67|striatum|O
DDI-MedLine.d98.s7|69-69|(|O
DDI-MedLine.d98.s7|70-72|STR|O
DDI-MedLine.d98.s7|73-73|)|O
DDI-MedLine.d98.s7|75-76|or|O
DDI-MedLine.d98.s7|78-84|nucleus|O
DDI-MedLine.d98.s7|86-94|accumbens|O
DDI-MedLine.d98.s7|96-96|(|O
DDI-MedLine.d98.s7|97-99|NAC|O
DDI-MedLine.d98.s7|100-100|)|O
DDI-MedLine.d98.s7|102-104|for|O
DDI-MedLine.d98.s7|106-108|the|O
DDI-MedLine.d98.s7|110-124|cocaine-treated|drug
DDI-MedLine.d98.s7|126-132|animals|O
DDI-MedLine.d98.s7|134-135|to|O
DDI-MedLine.d98.s7|137-141|their|O
DDI-MedLine.d98.s7|143-155|corresponding|O
DDI-MedLine.d98.s7|157-170|saline-treated|O
DDI-MedLine.d98.s7|172-179|controls|O
DDI-MedLine.d98.s7|180-180|.|O
DDI-MedLine.d98.s8|0-2|The|O
DDI-MedLine.d98.s8|4-11|affinity|O
DDI-MedLine.d98.s8|13-13|(|O
DDI-MedLine.d98.s8|14-15|Kd|O
DDI-MedLine.d98.s8|16-16|)|O
DDI-MedLine.d98.s8|18-19|of|O
DDI-MedLine.d98.s8|21-22|D2|O
DDI-MedLine.d98.s8|24-25|in|O
DDI-MedLine.d98.s8|27-29|the|O
DDI-MedLine.d98.s8|31-33|NAC|O
DDI-MedLine.d98.s8|35-43|decreased|O
DDI-MedLine.d98.s8|45-57|significantly|O
DDI-MedLine.d98.s8|58-58|,|O
DDI-MedLine.d98.s8|60-66|without|O
DDI-MedLine.d98.s8|68-74|changes|O
DDI-MedLine.d98.s8|76-77|in|O
DDI-MedLine.d98.s8|79-85|density|O
DDI-MedLine.d98.s8|87-87|(|O
DDI-MedLine.d98.s8|88-91|Bmax|O
DDI-MedLine.d98.s8|92-92|)|O
DDI-MedLine.d98.s8|93-93|,|O
DDI-MedLine.d98.s8|95-96|in|O
DDI-MedLine.d98.s8|98-100|the|O
DDI-MedLine.d98.s8|102-116|cocaine-treated|drug
DDI-MedLine.d98.s8|118-120|SST|O
DDI-MedLine.d98.s8|122-124|and|O
DDI-MedLine.d98.s8|126-128|RBC|O
DDI-MedLine.d98.s8|130-133|mice|O
DDI-MedLine.d98.s8|134-134|.|O
DDI-MedLine.d98.s9|0-1|On|O
DDI-MedLine.d98.s9|3-5|the|O
DDI-MedLine.d98.s9|7-11|other|O
DDI-MedLine.d98.s9|13-16|hand|O
DDI-MedLine.d98.s9|17-17|,|O
DDI-MedLine.d98.s9|19-21|the|O
DDI-MedLine.d98.s9|23-29|density|O
DDI-MedLine.d98.s9|31-32|of|O
DDI-MedLine.d98.s9|34-35|D2|O
DDI-MedLine.d98.s9|37-43|binding|O
DDI-MedLine.d98.s9|45-49|sites|O
DDI-MedLine.d98.s9|51-52|in|O
DDI-MedLine.d98.s9|54-56|the|O
DDI-MedLine.d98.s9|58-60|SST|O
DDI-MedLine.d98.s9|62-64|and|O
DDI-MedLine.d98.s9|66-68|the|O
DDI-MedLine.d98.s9|70-72|RBC|O
DDI-MedLine.d98.s9|74-77|mice|O
DDI-MedLine.d98.s9|79-80|in|O
DDI-MedLine.d98.s9|82-84|the|O
DDI-MedLine.d98.s9|86-88|STR|O
DDI-MedLine.d98.s9|90-92|was|O
DDI-MedLine.d98.s9|94-106|significantly|O
DDI-MedLine.d98.s9|108-116|increased|O
DDI-MedLine.d98.s9|118-119|in|O
DDI-MedLine.d98.s9|121-135|cocaine-treated|drug
DDI-MedLine.d98.s9|137-142|groups|O
DDI-MedLine.d98.s9|144-150|without|O
DDI-MedLine.d98.s9|152-157|change|O
DDI-MedLine.d98.s9|159-160|in|O
DDI-MedLine.d98.s9|162-163|Kd|O
DDI-MedLine.d98.s9|164-164|.|O
DDI-MedLine.d98.s10|0-2|The|O
DDI-MedLine.d98.s10|4-6|LST|O
DDI-MedLine.d98.s10|8-11|mice|O
DDI-MedLine.d98.s10|13-15|did|O
DDI-MedLine.d98.s10|17-19|not|O
DDI-MedLine.d98.s10|21-24|show|O
DDI-MedLine.d98.s10|26-28|any|O
DDI-MedLine.d98.s10|30-36|changes|O
DDI-MedLine.d98.s10|38-39|in|O
DDI-MedLine.d98.s10|41-43|the|O
DDI-MedLine.d98.s10|45-46|Kd|O
DDI-MedLine.d98.s10|48-50|and|O
DDI-MedLine.d98.s10|52-55|Bmax|O
DDI-MedLine.d98.s10|57-58|in|O
DDI-MedLine.d98.s10|60-65|either|O
DDI-MedLine.d98.s10|67-69|the|O
DDI-MedLine.d98.s10|71-73|STR|O
DDI-MedLine.d98.s10|75-76|or|O
DDI-MedLine.d98.s10|78-80|the|O
DDI-MedLine.d98.s10|82-84|NAC|O
DDI-MedLine.d98.s10|85-85|.|O
DDI-MedLine.d98.s11|0-4|Taken|O
DDI-MedLine.d98.s11|6-13|together|O
DDI-MedLine.d98.s11|14-14|,|O
DDI-MedLine.d98.s11|16-20|these|O
DDI-MedLine.d98.s11|22-29|findings|O
DDI-MedLine.d98.s11|31-37|suggest|O
DDI-MedLine.d98.s11|39-42|that|O
DDI-MedLine.d98.s11|44-46|the|O
DDI-MedLine.d98.s11|48-54|changes|O
DDI-MedLine.d98.s11|56-57|in|O
DDI-MedLine.d98.s11|59-61|the|O
DDI-MedLine.d98.s11|63-64|Kd|O
DDI-MedLine.d98.s11|66-67|of|O
DDI-MedLine.d98.s11|69-70|D2|O
DDI-MedLine.d98.s11|72-73|in|O
DDI-MedLine.d98.s11|75-77|the|O
DDI-MedLine.d98.s11|79-81|NAC|O
DDI-MedLine.d98.s11|83-85|and|O
DDI-MedLine.d98.s11|87-89|the|O
DDI-MedLine.d98.s11|91-94|Bmax|O
DDI-MedLine.d98.s11|96-97|of|O
DDI-MedLine.d98.s11|99-100|D2|O
DDI-MedLine.d98.s11|102-103|in|O
DDI-MedLine.d98.s11|105-107|the|O
DDI-MedLine.d98.s11|109-111|STR|O
DDI-MedLine.d98.s11|113-115|may|O
DDI-MedLine.d98.s11|117-126|contribute|O
DDI-MedLine.d98.s11|128-129|to|O
DDI-MedLine.d98.s11|131-133|the|O
DDI-MedLine.d98.s11|135-145|differences|O
DDI-MedLine.d98.s11|147-148|in|O
DDI-MedLine.d98.s11|150-158|locomotor|O
DDI-MedLine.d98.s11|160-168|responses|O
DDI-MedLine.d98.s11|170-171|to|O
DDI-MedLine.d98.s11|173-179|cocaine|drug
DDI-MedLine.d98.s11|181-188|exposure|O
DDI-MedLine.d98.s11|190-191|in|O
DDI-MedLine.d98.s11|193-197|these|O
DDI-MedLine.d98.s11|199-203|mouse|O
DDI-MedLine.d98.s11|205-209|lines|O
DDI-MedLine.d98.s11|210-210|.|O
DDI-DrugBank.d257.s0|0-11|Interactions|O
DDI-DrugBank.d257.s0|13-16|with|O
DDI-DrugBank.d257.s0|18-22|Other|O
DDI-DrugBank.d257.s0|24-26|CNS|O
DDI-DrugBank.d257.s0|28-33|Agents|O
DDI-DrugBank.d257.s0|34-34|:|O
DDI-DrugBank.d257.s0|36-45|Concurrent|O
DDI-DrugBank.d257.s0|47-49|use|O
DDI-DrugBank.d257.s0|51-52|of|O
DDI-DrugBank.d257.s0|54-66|Levo-Dromoran|brand
DDI-DrugBank.d257.s0|68-71|with|O
DDI-DrugBank.d257.s0|73-75|all|O
DDI-DrugBank.d257.s0|77-110|central nervous system depressants|group
DDI-DrugBank.d257.s0|112-112|(|O
DDI-DrugBank.d257.s0|113-114|eg|O
DDI-DrugBank.d257.s0|115-115|,|O
DDI-DrugBank.d257.s0|117-123|alcohol|drug
DDI-DrugBank.d257.s0|124-124|,|O
DDI-DrugBank.d257.s0|126-134|sedatives|group
DDI-DrugBank.d257.s0|135-135|,|O
DDI-DrugBank.d257.s0|137-145|hypnotics|group
DDI-DrugBank.d257.s0|146-146|,|O
DDI-DrugBank.d257.s0|148-152|other|O
DDI-DrugBank.d257.s0|154-160|opioids|group
DDI-DrugBank.d257.s0|161-161|,|O
DDI-DrugBank.d257.s0|163-169|general|O
DDI-DrugBank.d257.s0|171-181|anesthetics|group
DDI-DrugBank.d257.s0|182-182|,|O
DDI-DrugBank.d257.s0|184-195|barbiturates|group
DDI-DrugBank.d257.s0|196-196|,|O
DDI-DrugBank.d257.s0|198-222|tricyclic antidepressants|group
DDI-DrugBank.d257.s0|223-223|,|O
DDI-DrugBank.d257.s0|225-238|phenothiazines|group
DDI-DrugBank.d257.s0|239-239|,|O
DDI-DrugBank.d257.s0|241-253|tranquilizers|group
DDI-DrugBank.d257.s0|254-254|,|O
DDI-DrugBank.d257.s0|256-280|skeletal muscle relaxants|group
DDI-DrugBank.d257.s0|282-284|and|O
DDI-DrugBank.d257.s0|286-299|antihistamines|group
DDI-DrugBank.d257.s0|300-300|)|O
DDI-DrugBank.d257.s0|302-304|may|O
DDI-DrugBank.d257.s0|306-311|result|O
DDI-DrugBank.d257.s0|313-314|in|O
DDI-DrugBank.d257.s0|316-323|additive|O
DDI-DrugBank.d257.s0|325-331|central|O
DDI-DrugBank.d257.s0|333-339|nervous|O
DDI-DrugBank.d257.s0|341-346|system|O
DDI-DrugBank.d257.s0|348-357|depressant|O
DDI-DrugBank.d257.s0|359-365|effects|O
DDI-DrugBank.d257.s0|366-366|.|O
DDI-DrugBank.d257.s1|0-10|Respiratory|O
DDI-DrugBank.d257.s1|12-21|depression|O
DDI-DrugBank.d257.s1|22-22|,|O
DDI-DrugBank.d257.s1|24-34|hypotension|O
DDI-DrugBank.d257.s1|35-35|,|O
DDI-DrugBank.d257.s1|37-39|and|O
DDI-DrugBank.d257.s1|41-48|profound|O
DDI-DrugBank.d257.s1|50-57|sedation|O
DDI-DrugBank.d257.s1|59-60|or|O
DDI-DrugBank.d257.s1|62-65|coma|O
DDI-DrugBank.d257.s1|67-69|may|O
DDI-DrugBank.d257.s1|71-75|occur|O
DDI-DrugBank.d257.s1|76-76|.|O
DDI-DrugBank.d257.s2|0-3|When|O
DDI-DrugBank.d257.s2|5-8|such|O
DDI-DrugBank.d257.s2|10-17|combined|O
DDI-DrugBank.d257.s2|19-25|therapy|O
DDI-DrugBank.d257.s2|27-28|is|O
DDI-DrugBank.d257.s2|30-41|contemplated|O
DDI-DrugBank.d257.s2|42-42|,|O
DDI-DrugBank.d257.s2|44-46|the|O
DDI-DrugBank.d257.s2|48-51|dose|O
DDI-DrugBank.d257.s2|53-54|of|O
DDI-DrugBank.d257.s2|56-58|one|O
DDI-DrugBank.d257.s2|60-61|or|O
DDI-DrugBank.d257.s2|63-66|both|O
DDI-DrugBank.d257.s2|68-73|agents|O
DDI-DrugBank.d257.s2|75-80|should|O
DDI-DrugBank.d257.s2|82-83|be|O
DDI-DrugBank.d257.s2|85-91|reduced|O
DDI-DrugBank.d257.s2|92-92|.|O
DDI-DrugBank.d257.s3|0-7|Although|O
DDI-DrugBank.d257.s3|9-10|no|O
DDI-DrugBank.d257.s3|12-22|interaction|O
DDI-DrugBank.d257.s3|24-30|between|O
DDI-DrugBank.d257.s3|32-45|MAO inhibitors|group
DDI-DrugBank.d257.s3|47-49|and|O
DDI-DrugBank.d257.s3|51-63|Levo-Dromoran|brand
DDI-DrugBank.d257.s3|65-67|has|O
DDI-DrugBank.d257.s3|69-72|been|O
DDI-DrugBank.d257.s3|74-81|observed|O
DDI-DrugBank.d257.s3|82-82|,|O
DDI-DrugBank.d257.s3|84-85|it|O
DDI-DrugBank.d257.s3|87-88|is|O
DDI-DrugBank.d257.s3|90-92|not|O
DDI-DrugBank.d257.s3|94-104|recommended|O
DDI-DrugBank.d257.s3|106-108|for|O
DDI-DrugBank.d257.s3|110-112|use|O
DDI-DrugBank.d257.s3|114-117|with|O
DDI-DrugBank.d257.s3|119-132|MAO inhibitors|group
DDI-DrugBank.d257.s3|133-133|.|O
DDI-DrugBank.d257.s4|0-3|Most|O
DDI-DrugBank.d257.s4|5-9|cases|O
DDI-DrugBank.d257.s4|11-12|of|O
DDI-DrugBank.d257.s4|14-20|serious|O
DDI-DrugBank.d257.s4|22-23|or|O
DDI-DrugBank.d257.s4|25-29|fatal|O
DDI-DrugBank.d257.s4|31-37|adverse|O
DDI-DrugBank.d257.s4|39-44|events|O
DDI-DrugBank.d257.s4|46-54|involving|O
DDI-DrugBank.d257.s4|56-68|Levo-Dromoran|brand
DDI-DrugBank.d257.s4|70-77|reported|O
DDI-DrugBank.d257.s4|79-80|to|O
DDI-DrugBank.d257.s4|82-84|the|O
DDI-DrugBank.d257.s4|86-97|manufacturer|O
DDI-DrugBank.d257.s4|99-100|or|O
DDI-DrugBank.d257.s4|102-104|the|O
DDI-DrugBank.d257.s4|106-108|FDA|O
DDI-DrugBank.d257.s4|110-113|have|O
DDI-DrugBank.d257.s4|115-122|involved|O
DDI-DrugBank.d257.s4|124-129|either|O
DDI-DrugBank.d257.s4|131-133|the|O
DDI-DrugBank.d257.s4|135-148|administration|O
DDI-DrugBank.d257.s4|150-151|of|O
DDI-DrugBank.d257.s4|153-157|large|O
DDI-DrugBank.d257.s4|159-165|initial|O
DDI-DrugBank.d257.s4|167-171|doses|O
DDI-DrugBank.d257.s4|173-174|or|O
DDI-DrugBank.d257.s4|176-178|too|O
DDI-DrugBank.d257.s4|180-187|frequent|O
DDI-DrugBank.d257.s4|189-193|doses|O
DDI-DrugBank.d257.s4|195-196|of|O
DDI-DrugBank.d257.s4|198-200|the|O
DDI-DrugBank.d257.s4|202-205|drug|O
DDI-DrugBank.d257.s4|207-208|to|O
DDI-DrugBank.d257.s4|210-218|nonopioid|O
DDI-DrugBank.d257.s4|220-227|tolerant|O
DDI-DrugBank.d257.s4|229-236|patients|O
DDI-DrugBank.d257.s4|237-237|,|O
DDI-DrugBank.d257.s4|239-240|or|O
DDI-DrugBank.d257.s4|242-244|the|O
DDI-DrugBank.d257.s4|246-257|simultaneous|O
DDI-DrugBank.d257.s4|259-272|administration|O
DDI-DrugBank.d257.s4|274-275|of|O
DDI-DrugBank.d257.s4|277-287|levorphanol|drug
DDI-DrugBank.d257.s4|289-292|with|O
DDI-DrugBank.d257.s4|294-298|other|O
DDI-DrugBank.d257.s4|300-304|drugs|O
DDI-DrugBank.d257.s4|306-314|affecting|O
DDI-DrugBank.d257.s4|316-326|respiration|O
DDI-DrugBank.d257.s4|327-327|.|O
DDI-DrugBank.d257.s5|0-2|The|O
DDI-DrugBank.d257.s5|4-10|initial|O
DDI-DrugBank.d257.s5|12-15|dose|O
DDI-DrugBank.d257.s5|17-18|of|O
DDI-DrugBank.d257.s5|20-30|levorphanol|drug
DDI-DrugBank.d257.s5|32-37|should|O
DDI-DrugBank.d257.s5|39-40|be|O
DDI-DrugBank.d257.s5|42-48|reduced|O
DDI-DrugBank.d257.s5|50-51|by|O
DDI-DrugBank.d257.s5|53-65|approximately|O
DDI-DrugBank.d257.s5|67-68|50|O
DDI-DrugBank.d257.s5|69-69|%|O
DDI-DrugBank.d257.s5|71-72|or|O
DDI-DrugBank.d257.s5|74-77|more|O
DDI-DrugBank.d257.s5|79-82|when|O
DDI-DrugBank.d257.s5|84-85|it|O
DDI-DrugBank.d257.s5|87-88|is|O
DDI-DrugBank.d257.s5|90-94|given|O
DDI-DrugBank.d257.s5|96-97|to|O
DDI-DrugBank.d257.s5|99-106|patients|O
DDI-DrugBank.d257.s5|108-112|along|O
DDI-DrugBank.d257.s5|114-117|with|O
DDI-DrugBank.d257.s5|119-125|another|O
DDI-DrugBank.d257.s5|127-130|drug|O
DDI-DrugBank.d257.s5|132-140|affecting|O
DDI-DrugBank.d257.s5|142-152|respiration|O
DDI-DrugBank.d257.s5|153-153|.|O
DDI-DrugBank.d257.s6|0-11|Interactions|O
DDI-DrugBank.d257.s6|13-16|with|O
DDI-DrugBank.d257.s6|18-59|Mixed Agonist/Antagonist Opioid Analgesics|group
DDI-DrugBank.d257.s6|60-60|:|O
DDI-DrugBank.d257.s6|62-90|Agonist/antagonist analgesics|group
DDI-DrugBank.d257.s6|92-92|(|O
DDI-DrugBank.d257.s6|93-94|eg|O
DDI-DrugBank.d257.s6|95-95|,|O
DDI-DrugBank.d257.s6|97-107|pentazocine|drug
DDI-DrugBank.d257.s6|108-108|,|O
DDI-DrugBank.d257.s6|110-119|nalbuphine|drug
DDI-DrugBank.d257.s6|120-120|,|O
DDI-DrugBank.d257.s6|122-132|butorphanol|drug
DDI-DrugBank.d257.s6|133-133|,|O
DDI-DrugBank.d257.s6|135-142|dezocine|drug
DDI-DrugBank.d257.s6|144-146|and|O
DDI-DrugBank.d257.s6|148-160|buprenorphine|drug
DDI-DrugBank.d257.s6|161-161|)|O
DDI-DrugBank.d257.s6|163-168|should|O
DDI-DrugBank.d257.s6|170-172|NOT|O
DDI-DrugBank.d257.s6|174-175|be|O
DDI-DrugBank.d257.s6|177-188|administered|O
DDI-DrugBank.d257.s6|190-191|to|O
DDI-DrugBank.d257.s6|193-193|a|O
DDI-DrugBank.d257.s6|195-201|patient|O
DDI-DrugBank.d257.s6|203-205|who|O
DDI-DrugBank.d257.s6|207-209|has|O
DDI-DrugBank.d257.s6|211-218|received|O
DDI-DrugBank.d257.s6|220-221|or|O
DDI-DrugBank.d257.s6|223-224|is|O
DDI-DrugBank.d257.s6|226-234|receiving|O
DDI-DrugBank.d257.s6|236-236|a|O
DDI-DrugBank.d257.s6|238-243|course|O
DDI-DrugBank.d257.s6|245-246|of|O
DDI-DrugBank.d257.s6|248-254|therapy|O
DDI-DrugBank.d257.s6|256-259|with|O
DDI-DrugBank.d257.s6|261-261|a|O
DDI-DrugBank.d257.s6|263-291|pure agonist opioid analgesic|group
DDI-DrugBank.d257.s6|293-296|such|O
DDI-DrugBank.d257.s6|298-299|as|O
DDI-DrugBank.d257.s6|301-313|Levo-Dromoran|brand
DDI-DrugBank.d257.s6|314-314|.|O
DDI-DrugBank.d257.s7|0-1|In|O
DDI-DrugBank.d257.s7|3-18|opioid-dependent|group
DDI-DrugBank.d257.s7|20-27|patients|O
DDI-DrugBank.d257.s7|28-28|,|O
DDI-DrugBank.d257.s7|30-64|mixed agonist/antagonist analgesics|group
DDI-DrugBank.d257.s7|66-68|may|O
DDI-DrugBank.d257.s7|70-80|precipitate|O
DDI-DrugBank.d257.s7|82-91|withdrawal|O
DDI-DrugBank.d257.s7|93-100|symptoms|O
DDI-DrugBank.d257.s7|101-101|.|O
DDI-MedLine.d69.s0|0-11|Differential|O
DDI-MedLine.d69.s0|13-22|regulation|O
DDI-MedLine.d69.s0|24-25|of|O
DDI-MedLine.d69.s0|27-34|tyrosine|O
DDI-MedLine.d69.s0|36-50|phosphorylation|O
DDI-MedLine.d69.s0|52-53|in|O
DDI-MedLine.d69.s0|55-59|tumor|O
DDI-MedLine.d69.s0|61-65|cells|O
DDI-MedLine.d69.s0|67-68|by|O
DDI-MedLine.d69.s0|85-85|,|O
DDI-MedLine.d69.s0|87-87|a|O
DDI-MedLine.d69.s0|89-99|homodimeric|O
DDI-MedLine.d69.s0|101-111|disintegrin|O
DDI-MedLine.d69.s0|112-112|,|O
DDI-MedLine.d69.s0|114-116|and|O
DDI-MedLine.d69.s0|118-126|monomeric|O
DDI-MedLine.d69.s0|128-139|disintegrins|O
DDI-MedLine.d69.s0|152-154|and|O
DDI-MedLine.d69.s0|166-166|.|O
DDI-MedLine.d69.s1|0-2|The|O
DDI-MedLine.d69.s1|4-14|homodimeric|O
DDI-MedLine.d69.s1|16-26|disintegrin|O
DDI-MedLine.d69.s1|44-46|was|O
DDI-MedLine.d69.s1|48-55|compared|O
DDI-MedLine.d69.s1|57-64|directly|O
DDI-MedLine.d69.s1|66-67|to|O
DDI-MedLine.d69.s1|69-71|the|O
DDI-MedLine.d69.s1|73-81|monomeric|O
DDI-MedLine.d69.s1|83-94|disintegrins|O
DDI-MedLine.d69.s1|107-109|and|O
DDI-MedLine.d69.s1|122-124|for|O
DDI-MedLine.d69.s1|126-128|the|O
DDI-MedLine.d69.s1|130-136|ability|O
DDI-MedLine.d69.s1|138-139|to|O
DDI-MedLine.d69.s1|141-146|affect|O
DDI-MedLine.d69.s1|148-154|protein|O
DDI-MedLine.d69.s1|156-163|tyrosine|O
DDI-MedLine.d69.s1|165-179|phosphorylation|O
DDI-MedLine.d69.s1|181-182|in|O
DDI-MedLine.d69.s1|184-188|tumor|O
DDI-MedLine.d69.s1|190-194|cells|O
DDI-MedLine.d69.s1|195-195|.|O
DDI-MedLine.d69.s2|0-1|It|O
DDI-MedLine.d69.s2|3-5|was|O
DDI-MedLine.d69.s2|7-14|observed|O
DDI-MedLine.d69.s2|16-19|that|O
DDI-MedLine.d69.s2|37-39|had|O
DDI-MedLine.d69.s2|41-41|a|O
DDI-MedLine.d69.s2|43-50|dramatic|O
DDI-MedLine.d69.s2|52-57|effect|O
DDI-MedLine.d69.s2|59-60|on|O
DDI-MedLine.d69.s2|62-64|the|O
DDI-MedLine.d69.s2|66-73|tyrosine|O
DDI-MedLine.d69.s2|75-89|phosphorylation|O
DDI-MedLine.d69.s2|91-96|status|O
DDI-MedLine.d69.s2|98-99|of|O
DDI-MedLine.d69.s2|101-107|several|O
DDI-MedLine.d69.s2|109-116|proteins|O
DDI-MedLine.d69.s2|118-119|in|O
DDI-MedLine.d69.s2|121-123|T24|O
DDI-MedLine.d69.s2|125-129|human|O
DDI-MedLine.d69.s2|131-137|bladder|O
DDI-MedLine.d69.s2|139-144|cancer|O
DDI-MedLine.d69.s2|146-150|cells|O
DDI-MedLine.d69.s2|151-151|,|O
DDI-MedLine.d69.s2|153-161|including|O
DDI-MedLine.d69.s2|163-168|robust|O
DDI-MedLine.d69.s2|170-178|induction|O
DDI-MedLine.d69.s2|180-181|of|O
DDI-MedLine.d69.s2|183-197|phosphorylation|O
DDI-MedLine.d69.s2|199-200|of|O
DDI-MedLine.d69.s2|202-209|proteins|O
DDI-MedLine.d69.s2|211-212|in|O
DDI-MedLine.d69.s2|214-216|the|O
DDI-MedLine.d69.s2|218-222|range|O
DDI-MedLine.d69.s2|224-225|of|O
DDI-MedLine.d69.s2|227-233|120-140|O
DDI-MedLine.d69.s2|235-237|kDa|O
DDI-MedLine.d69.s2|238-238|.|O
DDI-MedLine.d69.s3|11-15|alone|O
DDI-MedLine.d69.s3|17-19|had|O
DDI-MedLine.d69.s3|21-22|no|O
DDI-MedLine.d69.s3|24-29|effect|O
DDI-MedLine.d69.s3|31-32|on|O
DDI-MedLine.d69.s3|34-41|tyrosine|O
DDI-MedLine.d69.s3|43-57|phosphorylation|O
DDI-MedLine.d69.s3|59-60|in|O
DDI-MedLine.d69.s3|62-64|T24|O
DDI-MedLine.d69.s3|66-70|cells|O
DDI-MedLine.d69.s3|71-71|,|O
DDI-MedLine.d69.s3|73-75|but|O
DDI-MedLine.d69.s3|77-92|dose-dependently|O
DDI-MedLine.d69.s3|94-101|inhibits|O
DDI-MedLine.d69.s3|103-105|the|O
DDI-MedLine.d69.s3|107-113|effects|O
DDI-MedLine.d69.s3|115-116|of|O
DDI-MedLine.d69.s3|134-137|when|O
DDI-MedLine.d69.s3|139-142|both|O
DDI-MedLine.d69.s3|144-146|are|O
DDI-MedLine.d69.s3|148-152|added|O
DDI-MedLine.d69.s3|154-167|simultaneously|O
DDI-MedLine.d69.s3|168-168|.|O
DDI-MedLine.d69.s4|0-4|Among|O
DDI-MedLine.d69.s4|6-8|the|O
DDI-MedLine.d69.s4|10-17|proteins|O
DDI-MedLine.d69.s4|19-22|that|O
DDI-MedLine.d69.s4|24-30|undergo|O
DDI-MedLine.d69.s4|32-39|tyrosine|O
DDI-MedLine.d69.s4|41-55|phosphorylation|O
DDI-MedLine.d69.s4|57-58|in|O
DDI-MedLine.d69.s4|60-67|response|O
DDI-MedLine.d69.s4|69-70|to|O
DDI-MedLine.d69.s4|88-96|treatment|O
DDI-MedLine.d69.s4|98-99|is|O
DDI-MedLine.d69.s4|101-103|CAS|O
DDI-MedLine.d69.s4|104-104|,|O
DDI-MedLine.d69.s4|106-106|a|O
DDI-MedLine.d69.s4|108-110|130|O
DDI-MedLine.d69.s4|112-114|kDa|O
DDI-MedLine.d69.s4|116-122|adapter|O
DDI-MedLine.d69.s4|124-130|protein|O
DDI-MedLine.d69.s4|132-139|involved|O
DDI-MedLine.d69.s4|141-142|in|O
DDI-MedLine.d69.s4|144-151|integrin|O
DDI-MedLine.d69.s4|153-161|signaling|O
DDI-MedLine.d69.s4|162-162|.|O
DDI-MedLine.d69.s5|11-15|alone|O
DDI-MedLine.d69.s5|17-19|was|O
DDI-MedLine.d69.s5|21-25|found|O
DDI-MedLine.d69.s5|27-28|to|O
DDI-MedLine.d69.s5|30-33|have|O
DDI-MedLine.d69.s5|35-36|no|O
DDI-MedLine.d69.s5|38-43|effect|O
DDI-MedLine.d69.s5|45-46|on|O
DDI-MedLine.d69.s5|48-50|CAS|O
DDI-MedLine.d69.s5|51-51|,|O
DDI-MedLine.d69.s5|53-55|but|O
DDI-MedLine.d69.s5|57-59|can|O
DDI-MedLine.d69.s5|61-70|completely|O
DDI-MedLine.d69.s5|72-76|block|O
DDI-MedLine.d69.s5|102-116|phosphorylation|O
DDI-MedLine.d69.s5|118-119|of|O
DDI-MedLine.d69.s5|121-124|this|O
DDI-MedLine.d69.s5|126-132|protein|O
DDI-MedLine.d69.s5|134-135|in|O
DDI-MedLine.d69.s5|137-146|MDA-MB-435|O
DDI-MedLine.d69.s5|148-152|cells|O
DDI-MedLine.d69.s5|153-153|.|O
DDI-MedLine.d69.s6|0-4|These|O
DDI-MedLine.d69.s6|6-17|observations|O
DDI-MedLine.d69.s6|19-26|strongly|O
DDI-MedLine.d69.s6|28-34|suggest|O
DDI-MedLine.d69.s6|36-39|that|O
DDI-MedLine.d69.s6|41-43|the|O
DDI-MedLine.d69.s6|45-55|homodimeric|O
DDI-MedLine.d69.s6|57-65|structure|O
DDI-MedLine.d69.s6|67-68|of|O
DDI-MedLine.d69.s6|86-97|functionally|O
DDI-MedLine.d69.s6|99-111|distinguishes|O
DDI-MedLine.d69.s6|113-114|it|O
DDI-MedLine.d69.s6|116-119|from|O
DDI-MedLine.d69.s6|121-125|other|O
DDI-MedLine.d69.s6|127-135|monomeric|O
DDI-MedLine.d69.s6|137-143|members|O
DDI-MedLine.d69.s6|145-146|of|O
DDI-MedLine.d69.s6|148-150|the|O
DDI-MedLine.d69.s6|152-162|disintegrin|O
DDI-MedLine.d69.s6|164-169|family|O
DDI-MedLine.d69.s6|170-170|.|O
DDI-DrugBank.d726.s0|13-14|is|O
DDI-DrugBank.d726.s0|16-18|not|O
DDI-DrugBank.d726.s0|20-27|expected|O
DDI-DrugBank.d726.s0|29-30|to|O
DDI-DrugBank.d726.s0|32-38|inhibit|O
DDI-DrugBank.d726.s0|40-42|the|O
DDI-DrugBank.d726.s0|44-52|clearance|O
DDI-DrugBank.d726.s0|54-55|of|O
DDI-DrugBank.d726.s0|57-61|drugs|O
DDI-DrugBank.d726.s0|63-73|metabolized|O
DDI-DrugBank.d726.s0|75-76|by|O
DDI-DrugBank.d726.s0|78-87|cytochrome|O
DDI-DrugBank.d726.s0|89-92|P450|O
DDI-DrugBank.d726.s0|94-100|enzymes|O
DDI-DrugBank.d726.s0|102-107|CYP1A2|O
DDI-DrugBank.d726.s0|108-108|,|O
DDI-DrugBank.d726.s0|110-115|CYP2A6|O
DDI-DrugBank.d726.s0|116-116|,|O
DDI-DrugBank.d726.s0|118-123|CYP2B6|O
DDI-DrugBank.d726.s0|124-124|,|O
DDI-DrugBank.d726.s0|126-131|CYP2C8|O
DDI-DrugBank.d726.s0|132-132|,|O
DDI-DrugBank.d726.s0|134-139|CYP2C9|O
DDI-DrugBank.d726.s0|140-140|,|O
DDI-DrugBank.d726.s0|142-148|CYP2C19|O
DDI-DrugBank.d726.s0|149-149|,|O
DDI-DrugBank.d726.s0|151-156|CYP2D6|O
DDI-DrugBank.d726.s0|158-163|CYP2E1|O
DDI-DrugBank.d726.s0|165-166|or|O
DDI-DrugBank.d726.s0|168-172|CYP3A|O
DDI-DrugBank.d726.s0|174-176|nor|O
DDI-DrugBank.d726.s0|178-183|induce|O
DDI-DrugBank.d726.s0|185-187|the|O
DDI-DrugBank.d726.s0|189-197|clearance|O
DDI-DrugBank.d726.s0|199-200|of|O
DDI-DrugBank.d726.s0|202-206|drugs|O
DDI-DrugBank.d726.s0|208-218|metabolized|O
DDI-DrugBank.d726.s0|220-221|by|O
DDI-DrugBank.d726.s0|223-228|CYP2B6|O
DDI-DrugBank.d726.s0|229-229|,|O
DDI-DrugBank.d726.s0|231-236|CYP2C9|O
DDI-DrugBank.d726.s0|238-239|or|O
DDI-DrugBank.d726.s0|241-245|CYP3A|O
DDI-DrugBank.d726.s0|246-246|.|O
DDI-DrugBank.d726.s1|0-0|A|O
DDI-DrugBank.d726.s1|2-9|multiple|O
DDI-DrugBank.d726.s1|11-14|dose|O
DDI-DrugBank.d726.s1|16-24|drug-drug|O
DDI-DrugBank.d726.s1|26-36|interaction|O
DDI-DrugBank.d726.s1|38-42|study|O
DDI-DrugBank.d726.s1|44-55|demonstrated|O
DDI-DrugBank.d726.s1|57-60|that|O
DDI-DrugBank.d726.s1|62-73|ketoconazole|drug
DDI-DrugBank.d726.s1|75-87|approximately|O
DDI-DrugBank.d726.s1|89-95|doubled|O
DDI-DrugBank.d726.s1|97-108|paricalcitol|drug
DDI-DrugBank.d726.s1|110-114|AUC0-|O
DDI-DrugBank.d726.s1|118-118|.|O
DDI-DrugBank.d726.s1|120-124|Since|O
DDI-DrugBank.d726.s1|126-137|paricalcitol|drug
DDI-DrugBank.d726.s1|139-140|is|O
DDI-DrugBank.d726.s1|142-150|partially|O
DDI-DrugBank.d726.s1|152-162|metabolized|O
DDI-DrugBank.d726.s1|164-165|by|O
DDI-DrugBank.d726.s1|167-171|CYP3A|O
DDI-DrugBank.d726.s1|173-175|and|O
DDI-DrugBank.d726.s1|177-188|ketoconazole|drug
DDI-DrugBank.d726.s1|190-191|le|O
DDI-DrugBank.d726.s1|193-194|is|O
DDI-DrugBank.d726.s1|196-200|known|O
DDI-DrugBank.d726.s1|202-203|to|O
DDI-DrugBank.d726.s1|205-206|be|O
DDI-DrugBank.d726.s1|208-208|a|O
DDI-DrugBank.d726.s1|210-215|strong|O
DDI-DrugBank.d726.s1|217-225|inhibitor|O
DDI-DrugBank.d726.s1|227-228|of|O
DDI-DrugBank.d726.s1|230-239|cytochrome|O
DDI-DrugBank.d726.s1|241-244|P450|O
DDI-DrugBank.d726.s1|246-247|3A|O
DDI-DrugBank.d726.s1|249-254|enzyme|O
DDI-DrugBank.d726.s1|255-255|,|O
DDI-DrugBank.d726.s1|257-260|care|O
DDI-DrugBank.d726.s1|262-267|should|O
DDI-DrugBank.d726.s1|269-270|be|O
DDI-DrugBank.d726.s1|272-276|taken|O
DDI-DrugBank.d726.s1|278-282|while|O
DDI-DrugBank.d726.s1|284-289|dosing|O
DDI-DrugBank.d726.s1|291-302|paricalcitol|drug
DDI-DrugBank.d726.s1|304-307|with|O
DDI-DrugBank.d726.s1|309-320|ketoconazole|drug
DDI-DrugBank.d726.s1|322-324|and|O
DDI-DrugBank.d726.s1|326-330|other|O
DDI-DrugBank.d726.s1|332-337|strong|O
DDI-DrugBank.d726.s1|339-342|P450|O
DDI-DrugBank.d726.s1|344-345|3A|O
DDI-DrugBank.d726.s1|347-356|inhibitors|O
DDI-DrugBank.d726.s1|358-366|including|O
DDI-DrugBank.d726.s1|368-377|atazanavir|drug
DDI-DrugBank.d726.s1|378-378|,|O
DDI-DrugBank.d726.s1|380-393|clarithromycin|drug
DDI-DrugBank.d726.s1|394-394|,|O
DDI-DrugBank.d726.s1|396-404|indinavir|drug
DDI-DrugBank.d726.s1|405-405|,|O
DDI-DrugBank.d726.s1|407-418|itraconazole|drug
DDI-DrugBank.d726.s1|419-419|,|O
DDI-DrugBank.d726.s1|421-430|nefazodone|drug
DDI-DrugBank.d726.s1|431-431|,|O
DDI-DrugBank.d726.s1|433-442|nelfinavir|drug
DDI-DrugBank.d726.s1|443-443|,|O
DDI-DrugBank.d726.s1|445-453|ritonavir|drug
DDI-DrugBank.d726.s1|454-454|,|O
DDI-DrugBank.d726.s1|456-465|saquinavir|drug
DDI-DrugBank.d726.s1|466-466|,|O
DDI-DrugBank.d726.s1|468-480|telithromycin|drug
DDI-DrugBank.d726.s1|482-483|or|O
DDI-DrugBank.d726.s1|485-496|voriconazole|drug
DDI-DrugBank.d726.s1|497-497|.|O
DDI-DrugBank.d726.s2|0-3|Dose|O
DDI-DrugBank.d726.s2|5-14|adjustment|O
DDI-DrugBank.d726.s2|16-17|of|O
DDI-DrugBank.d726.s2|19-25|Zemplar|brand
DDI-DrugBank.d726.s2|27-34|Capsules|O
DDI-DrugBank.d726.s2|36-38|may|O
DDI-DrugBank.d726.s2|40-41|be|O
DDI-DrugBank.d726.s2|43-50|required|O
DDI-DrugBank.d726.s2|51-51|,|O
DDI-DrugBank.d726.s2|53-55|and|O
DDI-DrugBank.d726.s2|57-60|iPTH|O
DDI-DrugBank.d726.s2|62-64|and|O
DDI-DrugBank.d726.s2|66-70|serum|O
DDI-DrugBank.d726.s2|72-78|calcium|O
DDI-DrugBank.d726.s2|80-93|concentrations|O
DDI-DrugBank.d726.s2|95-100|should|O
DDI-DrugBank.d726.s2|102-103|be|O
DDI-DrugBank.d726.s2|105-111|closely|O
DDI-DrugBank.d726.s2|113-121|monitored|O
DDI-DrugBank.d726.s2|123-124|if|O
DDI-DrugBank.d726.s2|126-126|a|O
DDI-DrugBank.d726.s2|128-134|patient|O
DDI-DrugBank.d726.s2|136-144|initiates|O
DDI-DrugBank.d726.s2|146-147|or|O
DDI-DrugBank.d726.s2|149-160|discontinues|O
DDI-DrugBank.d726.s2|162-168|therapy|O
DDI-DrugBank.d726.s2|170-173|with|O
DDI-DrugBank.d726.s2|175-175|a|O
DDI-DrugBank.d726.s2|177-182|strong|O
DDI-DrugBank.d726.s2|184-189|CYP3A4|O
DDI-DrugBank.d726.s2|191-199|inhibitor|O
DDI-DrugBank.d726.s2|201-204|such|O
DDI-DrugBank.d726.s2|206-207|as|O
DDI-DrugBank.d726.s2|209-220|ketoconazole|drug
DDI-DrugBank.d726.s2|221-221|.|O
DDI-DrugBank.d726.s3|0-4|Drugs|O
DDI-DrugBank.d726.s3|6-9|that|O
DDI-DrugBank.d726.s3|11-16|impair|O
DDI-DrugBank.d726.s3|18-27|intestinal|O
DDI-DrugBank.d726.s3|29-38|absorption|O
DDI-DrugBank.d726.s3|40-41|of|O
DDI-DrugBank.d726.s3|43-62|fat-soluble vitamins|group
DDI-DrugBank.d726.s3|63-63|,|O
DDI-DrugBank.d726.s3|65-68|such|O
DDI-DrugBank.d726.s3|70-71|as|O
DDI-DrugBank.d726.s3|73-86|cholestyramine|drug
DDI-DrugBank.d726.s3|87-87|,|O
DDI-DrugBank.d726.s3|89-91|may|O
DDI-DrugBank.d726.s3|93-101|interfere|O
DDI-DrugBank.d726.s3|103-106|with|O
DDI-DrugBank.d726.s3|108-110|the|O
DDI-DrugBank.d726.s3|112-121|absorption|O
DDI-DrugBank.d726.s3|123-124|of|O
DDI-DrugBank.d726.s3|126-132|Zemplar|brand
DDI-DrugBank.d726.s3|134-141|Capsules|O
DDI-DrugBank.d726.s3|142-142|.|O
DDI-DrugBank.d199.s0|0-13|Metoclopramide|drug
DDI-DrugBank.d199.s0|14-14|:|O
DDI-DrugBank.d199.s0|16-19|When|O
DDI-DrugBank.d199.s0|21-34|coadministered|O
DDI-DrugBank.d199.s0|36-39|with|O
DDI-DrugBank.d199.s0|41-47|MONUROL|brand
DDI-DrugBank.d199.s0|48-48|,|O
DDI-DrugBank.d199.s0|50-63|metoclopramide|drug
DDI-DrugBank.d199.s0|64-64|,|O
DDI-DrugBank.d199.s0|66-66|a|O
DDI-DrugBank.d199.s0|68-71|drug|O
DDI-DrugBank.d199.s0|73-77|which|O
DDI-DrugBank.d199.s0|79-87|increases|O
DDI-DrugBank.d199.s0|89-104|gastrointestinal|O
DDI-DrugBank.d199.s0|106-113|motility|O
DDI-DrugBank.d199.s0|114-114|,|O
DDI-DrugBank.d199.s0|116-121|lowers|O
DDI-DrugBank.d199.s0|123-125|the|O
DDI-DrugBank.d199.s0|127-131|serum|O
DDI-DrugBank.d199.s0|133-145|concentration|O
DDI-DrugBank.d199.s0|147-149|and|O
DDI-DrugBank.d199.s0|151-157|urinary|O
DDI-DrugBank.d199.s0|159-167|excretion|O
DDI-DrugBank.d199.s0|169-170|of|O
DDI-DrugBank.d199.s0|172-181|fosfomycin|drug
DDI-DrugBank.d199.s0|182-182|.|O
DDI-DrugBank.d199.s1|0-4|Other|O
DDI-DrugBank.d199.s1|6-10|drugs|O
DDI-DrugBank.d199.s1|12-15|that|O
DDI-DrugBank.d199.s1|17-24|increase|O
DDI-DrugBank.d199.s1|26-41|gastrointestinal|O
DDI-DrugBank.d199.s1|43-50|motility|O
DDI-DrugBank.d199.s1|52-54|may|O
DDI-DrugBank.d199.s1|56-62|produce|O
DDI-DrugBank.d199.s1|64-70|similar|O
DDI-DrugBank.d199.s1|72-78|effects|O
DDI-DrugBank.d199.s1|79-79|.|O
DDI-DrugBank.d199.s2|0-9|Cimetidine|drug
DDI-DrugBank.d199.s2|10-10|:|O
DDI-DrugBank.d199.s2|12-21|Cimetidine|drug
DDI-DrugBank.d199.s2|23-26|does|O
DDI-DrugBank.d199.s2|28-30|not|O
DDI-DrugBank.d199.s2|32-37|affect|O
DDI-DrugBank.d199.s2|39-41|the|O
DDI-DrugBank.d199.s2|43-58|pharmacokinetics|O
DDI-DrugBank.d199.s2|60-61|of|O
DDI-DrugBank.d199.s2|63-72|fosfomycin|drug
DDI-DrugBank.d199.s2|74-77|when|O
DDI-DrugBank.d199.s2|79-92|coadministered|O
DDI-DrugBank.d199.s2|94-97|with|O
DDI-DrugBank.d199.s2|99-105|MONUROL|brand
DDI-DrugBank.d199.s2|106-106|.|O
DDI-DrugBank.d233.s0|0-2|Use|O
DDI-DrugBank.d233.s0|4-7|with|O
DDI-DrugBank.d233.s0|9-19|Allopurinol|drug
DDI-DrugBank.d233.s0|20-20|:|O
DDI-DrugBank.d233.s0|22-24|The|O
DDI-DrugBank.d233.s0|26-34|principal|O
DDI-DrugBank.d233.s0|36-42|pathway|O
DDI-DrugBank.d233.s0|44-46|for|O
DDI-DrugBank.d233.s0|48-61|detoxification|O
DDI-DrugBank.d233.s0|63-64|of|O
DDI-DrugBank.d233.s0|66-77|azathioprine|drug
DDI-DrugBank.d233.s0|79-80|is|O
DDI-DrugBank.d233.s0|82-90|inhibited|O
DDI-DrugBank.d233.s0|92-93|by|O
DDI-DrugBank.d233.s0|95-105|allopurinol|drug
DDI-DrugBank.d233.s0|106-106|.|O
DDI-DrugBank.d233.s1|0-7|Patients|O
DDI-DrugBank.d233.s1|9-17|receiving|O
DDI-DrugBank.d233.s1|19-30|azathioprine|drug
DDI-DrugBank.d233.s1|32-34|and|O
DDI-DrugBank.d233.s1|36-46|allopurinol|drug
DDI-DrugBank.d233.s1|48-60|concomitantly|O
DDI-DrugBank.d233.s1|62-67|should|O
DDI-DrugBank.d233.s1|69-72|have|O
DDI-DrugBank.d233.s1|74-74|a|O
DDI-DrugBank.d233.s1|76-79|dose|O
DDI-DrugBank.d233.s1|81-89|reduction|O
DDI-DrugBank.d233.s1|91-92|of|O
DDI-DrugBank.d233.s1|94-105|azathioprine|drug
DDI-DrugBank.d233.s1|106-106|,|O
DDI-DrugBank.d233.s1|108-109|to|O
DDI-DrugBank.d233.s1|111-123|approximately|O
DDI-DrugBank.d233.s1|125-127|1/3|O
DDI-DrugBank.d233.s1|129-130|to|O
DDI-DrugBank.d233.s1|132-134|1/4|O
DDI-DrugBank.d233.s1|136-138|the|O
DDI-DrugBank.d233.s1|140-144|usual|O
DDI-DrugBank.d233.s1|146-149|dose|O
DDI-DrugBank.d233.s1|150-150|.|O
DDI-DrugBank.d233.s2|0-2|Use|O
DDI-DrugBank.d233.s2|4-7|with|O
DDI-DrugBank.d233.s2|9-13|Other|O
DDI-DrugBank.d233.s2|15-20|Agents|O
DDI-DrugBank.d233.s2|22-30|Affecting|O
DDI-DrugBank.d233.s2|32-42|Myelopoesis|O
DDI-DrugBank.d233.s2|43-43|:|O
DDI-DrugBank.d233.s2|45-49|Drugs|O
DDI-DrugBank.d233.s2|51-55|which|O
DDI-DrugBank.d233.s2|57-59|may|O
DDI-DrugBank.d233.s2|61-66|affect|O
DDI-DrugBank.d233.s2|68-76|leukocyte|O
DDI-DrugBank.d233.s2|78-87|production|O
DDI-DrugBank.d233.s2|88-88|,|O
DDI-DrugBank.d233.s2|90-98|including|O
DDI-DrugBank.d233.s2|100-113|co-trimoxazole|brand
DDI-DrugBank.d233.s2|114-114|,|O
DDI-DrugBank.d233.s2|116-118|may|O
DDI-DrugBank.d233.s2|120-123|lead|O
DDI-DrugBank.d233.s2|125-126|to|O
DDI-DrugBank.d233.s2|128-138|exaggerated|O
DDI-DrugBank.d233.s2|140-149|leukopenia|O
DDI-DrugBank.d233.s2|150-150|,|O
DDI-DrugBank.d233.s2|152-161|especially|O
DDI-DrugBank.d233.s2|163-164|in|O
DDI-DrugBank.d233.s2|166-170|renal|O
DDI-DrugBank.d233.s2|172-181|transplant|O
DDI-DrugBank.d233.s2|183-192|recipients|O
DDI-DrugBank.d233.s2|193-193|.|O
DDI-DrugBank.d233.s3|0-2|Use|O
DDI-DrugBank.d233.s3|4-7|with|O
DDI-DrugBank.d233.s3|9-48|Angiotensln Converting Enzyme Inhibitors|group
DDI-DrugBank.d233.s3|49-49|:|O
DDI-DrugBank.d233.s3|51-53|The|O
DDI-DrugBank.d233.s3|55-57|use|O
DDI-DrugBank.d233.s3|59-60|of|O
DDI-DrugBank.d233.s3|62-101|angiotensin converting enzyme inhibitors|group
DDI-DrugBank.d233.s3|103-104|to|O
DDI-DrugBank.d233.s3|106-112|control|O
DDI-DrugBank.d233.s3|114-125|hypertension|O
DDI-DrugBank.d233.s3|127-128|in|O
DDI-DrugBank.d233.s3|130-137|patients|O
DDI-DrugBank.d233.s3|139-140|on|O
DDI-DrugBank.d233.s3|142-153|azathioprine|drug
DDI-DrugBank.d233.s3|155-157|has|O
DDI-DrugBank.d233.s3|159-162|been|O
DDI-DrugBank.d233.s3|164-171|reported|O
DDI-DrugBank.d233.s3|173-174|to|O
DDI-DrugBank.d233.s3|176-181|induce|O
DDI-DrugBank.d233.s3|183-188|severe|O
DDI-DrugBank.d233.s3|190-199|leukopenia|O
DDI-DrugBank.d233.s3|200-200|.|O
DDI-DrugBank.d428.s0|0-6|ELLENCE|brand
DDI-DrugBank.d428.s0|8-11|when|O
DDI-DrugBank.d428.s0|13-16|used|O
DDI-DrugBank.d428.s0|18-19|in|O
DDI-DrugBank.d428.s0|21-31|combination|O
DDI-DrugBank.d428.s0|33-36|with|O
DDI-DrugBank.d428.s0|38-42|other|O
DDI-DrugBank.d428.s0|44-52|cytotoxic|O
DDI-DrugBank.d428.s0|54-58|drugs|O
DDI-DrugBank.d428.s0|60-62|may|O
DDI-DrugBank.d428.s0|64-67|show|O
DDI-DrugBank.d428.s0|69-80|on-treatment|O
DDI-DrugBank.d428.s0|82-89|additive|O
DDI-DrugBank.d428.s0|91-98|toxicity|O
DDI-DrugBank.d428.s0|99-99|,|O
DDI-DrugBank.d428.s0|101-110|especially|O
DDI-DrugBank.d428.s0|112-122|hematologic|O
DDI-DrugBank.d428.s0|124-126|and|O
DDI-DrugBank.d428.s0|128-143|gastrointestinal|O
DDI-DrugBank.d428.s0|145-151|effects|O
DDI-DrugBank.d428.s0|152-152|.|O
DDI-DrugBank.d428.s1|0-10|Concomitant|O
DDI-DrugBank.d428.s1|12-14|use|O
DDI-DrugBank.d428.s1|16-17|of|O
DDI-DrugBank.d428.s1|19-25|ELLENCE|brand
DDI-DrugBank.d428.s1|27-30|with|O
DDI-DrugBank.d428.s1|32-36|other|O
DDI-DrugBank.d428.s1|38-49|cardioactive|O
DDI-DrugBank.d428.s1|51-59|compounds|O
DDI-DrugBank.d428.s1|61-64|that|O
DDI-DrugBank.d428.s1|66-70|could|O
DDI-DrugBank.d428.s1|72-76|cause|O
DDI-DrugBank.d428.s1|78-82|heart|O
DDI-DrugBank.d428.s1|84-90|failure|O
DDI-DrugBank.d428.s1|92-92|(|O
DDI-DrugBank.d428.s1|93-96|e.g.|O
DDI-DrugBank.d428.s1|97-97|,|O
DDI-DrugBank.d428.s1|99-122|calcium channel blockers|group
DDI-DrugBank.d428.s1|123-123|)|O
DDI-DrugBank.d428.s1|124-124|,|O
DDI-DrugBank.d428.s1|126-133|requires|O
DDI-DrugBank.d428.s1|135-139|close|O
DDI-DrugBank.d428.s1|141-150|monitoring|O
DDI-DrugBank.d428.s1|152-153|of|O
DDI-DrugBank.d428.s1|155-161|cardiac|O
DDI-DrugBank.d428.s1|163-170|function|O
DDI-DrugBank.d428.s1|172-181|throughout|O
DDI-DrugBank.d428.s1|183-191|treatment|O
DDI-DrugBank.d428.s1|192-192|.|O
DDI-DrugBank.d428.s2|0-4|There|O
DDI-DrugBank.d428.s2|6-8|are|O
DDI-DrugBank.d428.s2|10-12|few|O
DDI-DrugBank.d428.s2|14-17|data|O
DDI-DrugBank.d428.s2|19-27|regarding|O
DDI-DrugBank.d428.s2|29-31|the|O
DDI-DrugBank.d428.s2|33-48|coadministration|O
DDI-DrugBank.d428.s2|50-51|of|O
DDI-DrugBank.d428.s2|53-61|radiation|O
DDI-DrugBank.d428.s2|63-69|therapy|O
DDI-DrugBank.d428.s2|71-73|and|O
DDI-DrugBank.d428.s2|75-84|epirubicin|drug
DDI-DrugBank.d428.s2|85-85|.|O
DDI-DrugBank.d428.s3|0-1|In|O
DDI-DrugBank.d428.s3|3-10|adjuvant|O
DDI-DrugBank.d428.s3|12-17|trials|O
DDI-DrugBank.d428.s3|19-20|of|O
DDI-DrugBank.d428.s3|22-42|epirubicin-containing|drug
DDI-DrugBank.d428.s3|44-50|CEF-120|O
DDI-DrugBank.d428.s3|52-53|or|O
DDI-DrugBank.d428.s3|55-61|FEC-100|O
DDI-DrugBank.d428.s3|63-76|chemotherapies|O
DDI-DrugBank.d428.s3|77-77|,|O
DDI-DrugBank.d428.s3|79-84|breast|O
DDI-DrugBank.d428.s3|86-96|irradiation|O
DDI-DrugBank.d428.s3|98-100|was|O
DDI-DrugBank.d428.s3|102-108|delayed|O
DDI-DrugBank.d428.s3|110-114|until|O
DDI-DrugBank.d428.s3|116-120|after|O
DDI-DrugBank.d428.s3|122-133|chemotherapy|O
DDI-DrugBank.d428.s3|135-137|was|O
DDI-DrugBank.d428.s3|139-147|completed|O
DDI-DrugBank.d428.s3|148-148|.|O
DDI-DrugBank.d428.s4|0-3|This|O
DDI-DrugBank.d428.s4|5-12|practice|O
DDI-DrugBank.d428.s4|14-21|resulted|O
DDI-DrugBank.d428.s4|23-24|in|O
DDI-DrugBank.d428.s4|26-27|no|O
DDI-DrugBank.d428.s4|29-36|apparent|O
DDI-DrugBank.d428.s4|38-45|increase|O
DDI-DrugBank.d428.s4|47-48|in|O
DDI-DrugBank.d428.s4|50-54|local|O
DDI-DrugBank.d428.s4|56-61|breast|O
DDI-DrugBank.d428.s4|63-68|cancer|O
DDI-DrugBank.d428.s4|70-79|recurrence|O
DDI-DrugBank.d428.s4|81-88|relative|O
DDI-DrugBank.d428.s4|90-91|to|O
DDI-DrugBank.d428.s4|93-101|published|O
DDI-DrugBank.d428.s4|103-110|accounts|O
DDI-DrugBank.d428.s4|112-113|in|O
DDI-DrugBank.d428.s4|115-117|the|O
DDI-DrugBank.d428.s4|119-128|literature|O
DDI-DrugBank.d428.s4|129-129|.|O
DDI-DrugBank.d428.s5|0-0|A|O
DDI-DrugBank.d428.s5|2-6|small|O
DDI-DrugBank.d428.s5|8-13|number|O
DDI-DrugBank.d428.s5|15-16|of|O
DDI-DrugBank.d428.s5|18-25|patients|O
DDI-DrugBank.d428.s5|27-34|received|O
DDI-DrugBank.d428.s5|36-51|epirubicin-based|drug
DDI-DrugBank.d428.s5|53-64|chemotherapy|O
DDI-DrugBank.d428.s5|66-78|concomitantly|O
DDI-DrugBank.d428.s5|80-83|with|O
DDI-DrugBank.d428.s5|85-93|radiation|O
DDI-DrugBank.d428.s5|95-101|therapy|O
DDI-DrugBank.d428.s5|103-105|but|O
DDI-DrugBank.d428.s5|107-109|had|O
DDI-DrugBank.d428.s5|111-122|chemotherapy|O
DDI-DrugBank.d428.s5|124-134|interrupted|O
DDI-DrugBank.d428.s5|136-137|in|O
DDI-DrugBank.d428.s5|139-143|order|O
DDI-DrugBank.d428.s5|145-146|to|O
DDI-DrugBank.d428.s5|148-152|avoid|O
DDI-DrugBank.d428.s5|154-162|potential|O
DDI-DrugBank.d428.s5|164-174|overlapping|O
DDI-DrugBank.d428.s5|176-185|toxicities|O
DDI-DrugBank.d428.s5|186-186|.|O
DDI-DrugBank.d428.s6|0-1|It|O
DDI-DrugBank.d428.s6|3-4|is|O
DDI-DrugBank.d428.s6|6-11|likely|O
DDI-DrugBank.d428.s6|13-16|that|O
DDI-DrugBank.d428.s6|18-20|use|O
DDI-DrugBank.d428.s6|22-23|of|O
DDI-DrugBank.d428.s6|25-34|epirubicin|drug
DDI-DrugBank.d428.s6|36-39|with|O
DDI-DrugBank.d428.s6|41-52|radiotherapy|O
DDI-DrugBank.d428.s6|54-56|may|O
DDI-DrugBank.d428.s6|58-66|sensitize|O
DDI-DrugBank.d428.s6|68-74|tissues|O
DDI-DrugBank.d428.s6|76-77|to|O
DDI-DrugBank.d428.s6|79-81|the|O
DDI-DrugBank.d428.s6|83-91|cytotoxic|O
DDI-DrugBank.d428.s6|93-99|actions|O
DDI-DrugBank.d428.s6|101-102|of|O
DDI-DrugBank.d428.s6|104-114|irradiation|O
DDI-DrugBank.d428.s6|115-115|.|O
DDI-DrugBank.d428.s7|0-13|Administration|O
DDI-DrugBank.d428.s7|15-16|of|O
DDI-DrugBank.d428.s7|18-24|ELLENCE|brand
DDI-DrugBank.d428.s7|26-30|after|O
DDI-DrugBank.d428.s7|32-39|previous|O
DDI-DrugBank.d428.s7|41-49|radiation|O
DDI-DrugBank.d428.s7|51-57|therapy|O
DDI-DrugBank.d428.s7|59-61|may|O
DDI-DrugBank.d428.s7|63-68|induce|O
DDI-DrugBank.d428.s7|70-71|an|O
DDI-DrugBank.d428.s7|73-84|inflammatory|O
DDI-DrugBank.d428.s7|86-91|recall|O
DDI-DrugBank.d428.s7|93-100|reaction|O
DDI-DrugBank.d428.s7|102-103|at|O
DDI-DrugBank.d428.s7|105-107|the|O
DDI-DrugBank.d428.s7|109-112|site|O
DDI-DrugBank.d428.s7|114-115|of|O
DDI-DrugBank.d428.s7|117-119|the|O
DDI-DrugBank.d428.s7|121-131|irradiation|O
DDI-DrugBank.d428.s7|132-132|.|O
DDI-DrugBank.d428.s8|0-9|Epirubicin|drug
DDI-DrugBank.d428.s8|11-12|is|O
DDI-DrugBank.d428.s8|14-24|extensively|O
DDI-DrugBank.d428.s8|26-36|metabolized|O
DDI-DrugBank.d428.s8|38-39|by|O
DDI-DrugBank.d428.s8|41-43|the|O
DDI-DrugBank.d428.s8|45-49|liver|O
DDI-DrugBank.d428.s8|50-50|.|O
DDI-DrugBank.d428.s9|0-6|Changes|O
DDI-DrugBank.d428.s9|8-9|in|O
DDI-DrugBank.d428.s9|11-17|hepatic|O
DDI-DrugBank.d428.s9|19-26|function|O
DDI-DrugBank.d428.s9|28-34|induced|O
DDI-DrugBank.d428.s9|36-37|by|O
DDI-DrugBank.d428.s9|39-49|concomitant|O
DDI-DrugBank.d428.s9|51-59|therapies|O
DDI-DrugBank.d428.s9|61-63|may|O
DDI-DrugBank.d428.s9|65-70|affect|O
DDI-DrugBank.d428.s9|72-81|epirubicin|drug
DDI-DrugBank.d428.s9|83-92|metabolism|O
DDI-DrugBank.d428.s9|93-93|,|O
DDI-DrugBank.d428.s9|95-110|pharmacokinetics|O
DDI-DrugBank.d428.s9|111-111|,|O
DDI-DrugBank.d428.s9|113-123|therapeutic|O
DDI-DrugBank.d428.s9|125-132|efficacy|O
DDI-DrugBank.d428.s9|133-133|,|O
DDI-DrugBank.d428.s9|135-140|and/or|O
DDI-DrugBank.d428.s9|142-149|toxicity|O
DDI-DrugBank.d428.s9|150-150|.|O
DDI-DrugBank.d428.s10|0-9|Cimetidine|drug
DDI-DrugBank.d428.s10|11-19|increased|O
DDI-DrugBank.d428.s10|21-23|the|O
DDI-DrugBank.d428.s10|25-27|AUC|O
DDI-DrugBank.d428.s10|29-30|of|O
DDI-DrugBank.d428.s10|32-41|epirubicin|drug
DDI-DrugBank.d428.s10|43-44|by|O
DDI-DrugBank.d428.s10|46-47|50|O
DDI-DrugBank.d428.s10|48-48|%|O
DDI-DrugBank.d428.s10|49-49|.|O
DDI-DrugBank.d428.s11|0-9|Cimetidine|drug
DDI-DrugBank.d428.s11|11-19|treatment|O
DDI-DrugBank.d428.s11|21-26|should|O
DDI-DrugBank.d428.s11|28-29|be|O
DDI-DrugBank.d428.s11|31-37|stopped|O
DDI-DrugBank.d428.s11|39-44|during|O
DDI-DrugBank.d428.s11|46-54|treatment|O
DDI-DrugBank.d428.s11|56-59|with|O
DDI-DrugBank.d428.s11|61-67|ELLENCE|brand
DDI-DrugBank.d428.s11|68-68|.|O
DDI-DrugBank.d428.s12|0-14|Drug-Laboratory|O
DDI-DrugBank.d428.s12|16-19|Test|O
DDI-DrugBank.d428.s12|21-32|Interactions|O
DDI-DrugBank.d428.s12|34-38|There|O
DDI-DrugBank.d428.s12|40-42|are|O
DDI-DrugBank.d428.s12|44-45|no|O
DDI-DrugBank.d428.s12|47-51|known|O
DDI-DrugBank.d428.s12|53-64|interactions|O
DDI-DrugBank.d428.s12|66-72|between|O
DDI-DrugBank.d428.s12|74-80|ELLENCE|brand
DDI-DrugBank.d428.s12|82-84|and|O
DDI-DrugBank.d428.s12|86-95|laboratory|O
DDI-DrugBank.d428.s12|97-101|tests|O
DDI-DrugBank.d428.s12|102-102|.|O
DDI-DrugBank.d313.s0|0-0|A|O
DDI-DrugBank.d313.s0|2-7|number|O
DDI-DrugBank.d313.s0|9-10|of|O
DDI-DrugBank.d313.s0|12-21|substances|O
DDI-DrugBank.d313.s0|23-28|affect|O
DDI-DrugBank.d313.s0|30-36|glucose|O
DDI-DrugBank.d313.s0|38-47|metabolism|O
DDI-DrugBank.d313.s0|49-51|and|O
DDI-DrugBank.d313.s0|53-55|may|O
DDI-DrugBank.d313.s0|57-63|require|O
DDI-DrugBank.d313.s0|65-71|insulin|drug
DDI-DrugBank.d313.s0|73-76|dose|O
DDI-DrugBank.d313.s0|78-87|adjustment|O
DDI-DrugBank.d313.s0|89-91|and|O
DDI-DrugBank.d313.s0|93-104|particularly|O
DDI-DrugBank.d313.s0|106-110|close|O
DDI-DrugBank.d313.s0|112-121|monitoring|O
DDI-DrugBank.d313.s0|122-122|.|O
DDI-DrugBank.d313.s1|0-2|The|O
DDI-DrugBank.d313.s1|4-12|following|O
DDI-DrugBank.d313.s1|14-16|are|O
DDI-DrugBank.d313.s1|18-25|examples|O
DDI-DrugBank.d313.s1|27-28|of|O
DDI-DrugBank.d313.s1|30-39|substances|O
DDI-DrugBank.d313.s1|41-44|that|O
DDI-DrugBank.d313.s1|46-48|may|O
DDI-DrugBank.d313.s1|50-57|increase|O
DDI-DrugBank.d313.s1|59-61|the|O
DDI-DrugBank.d313.s1|63-84|blood-glucose-lowering|O
DDI-DrugBank.d313.s1|86-91|effect|O
DDI-DrugBank.d313.s1|93-95|and|O
DDI-DrugBank.d313.s1|97-110|susceptibility|O
DDI-DrugBank.d313.s1|112-113|to|O
DDI-DrugBank.d313.s1|115-126|hypoglycemia|O
DDI-DrugBank.d313.s1|127-127|:|O
DDI-DrugBank.d313.s1|129-132|oral|O
DDI-DrugBank.d313.s1|134-154|antidiabetic products|group
DDI-DrugBank.d313.s1|155-155|,|O
DDI-DrugBank.d313.s1|157-170|ACE inhibitors|group
DDI-DrugBank.d313.s1|171-171|,|O
DDI-DrugBank.d313.s1|173-184|disopyramide|drug
DDI-DrugBank.d313.s1|185-185|,|O
DDI-DrugBank.d313.s1|187-194|fibrates|group
DDI-DrugBank.d313.s1|195-195|,|O
DDI-DrugBank.d313.s1|197-206|fluoxetine|drug
DDI-DrugBank.d313.s1|207-207|,|O
DDI-DrugBank.d313.s1|209-242|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d313.s1|243-243|,|O
DDI-DrugBank.d313.s1|245-256|propoxyphene|drug
DDI-DrugBank.d313.s1|257-257|,|O
DDI-DrugBank.d313.s1|259-269|salicylates|group
DDI-DrugBank.d313.s1|270-270|,|O
DDI-DrugBank.d313.s1|272-290|somatostatin analog|group
DDI-DrugBank.d313.s1|292-292|(|O
DDI-DrugBank.d313.s1|293-296|e.g.|O
DDI-DrugBank.d313.s1|297-297|,|O
DDI-DrugBank.d313.s1|299-308|octreotide|drug
DDI-DrugBank.d313.s1|309-309|)|O
DDI-DrugBank.d313.s1|310-310|,|O
DDI-DrugBank.d313.s1|312-334|sulfonamide antibiotics|group
DDI-DrugBank.d313.s1|335-335|.|O
DDI-DrugBank.d313.s2|0-2|The|O
DDI-DrugBank.d313.s2|4-12|following|O
DDI-DrugBank.d313.s2|14-16|are|O
DDI-DrugBank.d313.s2|18-25|examples|O
DDI-DrugBank.d313.s2|27-28|of|O
DDI-DrugBank.d313.s2|30-39|substances|O
DDI-DrugBank.d313.s2|41-44|that|O
DDI-DrugBank.d313.s2|46-48|may|O
DDI-DrugBank.d313.s2|50-55|reduce|O
DDI-DrugBank.d313.s2|57-59|the|O
DDI-DrugBank.d313.s2|61-82|blood-glucose-lowering|O
DDI-DrugBank.d313.s2|84-89|effect|O
DDI-DrugBank.d313.s2|90-90|:|O
DDI-DrugBank.d313.s2|92-106|corticosteroids|group
DDI-DrugBank.d313.s2|107-107|,|O
DDI-DrugBank.d313.s2|109-114|niacin|drug
DDI-DrugBank.d313.s2|115-115|,|O
DDI-DrugBank.d313.s2|117-123|danazol|drug
DDI-DrugBank.d313.s2|124-124|,|O
DDI-DrugBank.d313.s2|126-134|diuretics|group
DDI-DrugBank.d313.s2|135-135|,|O
DDI-DrugBank.d313.s2|137-158|sympathomimetic agents|group
DDI-DrugBank.d313.s2|160-160|(|O
DDI-DrugBank.d313.s2|161-164|e.g.|O
DDI-DrugBank.d313.s2|165-165|,|O
DDI-DrugBank.d313.s2|167-177|epinephrine|drug
DDI-DrugBank.d313.s2|178-178|,|O
DDI-DrugBank.d313.s2|180-189|salbutamol|drug
DDI-DrugBank.d313.s2|190-190|,|O
DDI-DrugBank.d313.s2|192-202|terbutaline|drug
DDI-DrugBank.d313.s2|203-203|)|O
DDI-DrugBank.d313.s2|204-204|,|O
DDI-DrugBank.d313.s2|206-214|isoniazid|drug
DDI-DrugBank.d313.s2|215-215|,|O
DDI-DrugBank.d313.s2|217-241|phenothiazine derivatives|group
DDI-DrugBank.d313.s2|242-242|,|O
DDI-DrugBank.d313.s2|244-253|somatropin|drug
DDI-DrugBank.d313.s2|254-254|,|O
DDI-DrugBank.d313.s2|256-271|thyroid hormones|group
DDI-DrugBank.d313.s2|272-272|,|O
DDI-DrugBank.d313.s2|274-282|estrogens|group
DDI-DrugBank.d313.s2|283-283|,|O
DDI-DrugBank.d313.s2|285-296|progestogens|group
DDI-DrugBank.d313.s2|298-298|(|O
DDI-DrugBank.d313.s2|299-302|e.g.|O
DDI-DrugBank.d313.s2|303-303|,|O
DDI-DrugBank.d313.s2|305-306|in|O
DDI-DrugBank.d313.s2|308-311|oral|O
DDI-DrugBank.d313.s2|313-326|contraceptives|group
DDI-DrugBank.d313.s2|327-327|)|O
DDI-DrugBank.d313.s2|328-328|.|O
DDI-DrugBank.d313.s3|0-12|Beta-blockers|group
DDI-DrugBank.d313.s3|13-13|,|O
DDI-DrugBank.d313.s3|15-23|clonidine|drug
DDI-DrugBank.d313.s3|24-24|,|O
DDI-DrugBank.d313.s3|26-32|lithium|drug
DDI-DrugBank.d313.s3|34-38|salts|O
DDI-DrugBank.d313.s3|39-39|,|O
DDI-DrugBank.d313.s3|41-43|and|O
DDI-DrugBank.d313.s3|45-51|alcohol|drug
DDI-DrugBank.d313.s3|53-55|may|O
DDI-DrugBank.d313.s3|57-62|either|O
DDI-DrugBank.d313.s3|64-73|potentiate|O
DDI-DrugBank.d313.s3|75-76|or|O
DDI-DrugBank.d313.s3|78-83|weaken|O
DDI-DrugBank.d313.s3|85-87|the|O
DDI-DrugBank.d313.s3|89-110|blood-glucose-lowering|O
DDI-DrugBank.d313.s3|112-117|effect|O
DDI-DrugBank.d313.s3|119-120|of|O
DDI-DrugBank.d313.s3|122-128|insulin|drug
DDI-DrugBank.d313.s3|129-129|.|O
DDI-DrugBank.d313.s4|0-10|Pentamidine|drug
DDI-DrugBank.d313.s4|12-14|may|O
DDI-DrugBank.d313.s4|16-20|cause|O
DDI-DrugBank.d313.s4|22-33|hypoglycemia|O
DDI-DrugBank.d313.s4|34-34|,|O
DDI-DrugBank.d313.s4|36-40|which|O
DDI-DrugBank.d313.s4|42-44|may|O
DDI-DrugBank.d313.s4|46-54|sometimes|O
DDI-DrugBank.d313.s4|56-57|be|O
DDI-DrugBank.d313.s4|59-66|followed|O
DDI-DrugBank.d313.s4|68-69|by|O
DDI-DrugBank.d313.s4|71-83|hyperglycemia|O
DDI-DrugBank.d313.s4|84-84|.|O
DDI-DrugBank.d313.s5|0-1|In|O
DDI-DrugBank.d313.s5|3-10|addition|O
DDI-DrugBank.d313.s5|11-11|,|O
DDI-DrugBank.d313.s5|13-17|under|O
DDI-DrugBank.d313.s5|19-21|the|O
DDI-DrugBank.d313.s5|23-31|influence|O
DDI-DrugBank.d313.s5|33-34|of|O
DDI-DrugBank.d313.s5|36-48|sympatholytic|O
DDI-DrugBank.d313.s5|50-58|medicinal|O
DDI-DrugBank.d313.s5|60-67|products|O
DDI-DrugBank.d313.s5|69-72|such|O
DDI-DrugBank.d313.s5|74-75|as|O
DDI-DrugBank.d313.s5|77-89|beta-blockers|group
DDI-DrugBank.d313.s5|90-90|,|O
DDI-DrugBank.d313.s5|92-100|clonidine|drug
DDI-DrugBank.d313.s5|101-101|,|O
DDI-DrugBank.d313.s5|103-114|guanethidine|drug
DDI-DrugBank.d313.s5|115-115|,|O
DDI-DrugBank.d313.s5|117-119|and|O
DDI-DrugBank.d313.s5|121-129|reserpine|drug
DDI-DrugBank.d313.s5|130-130|,|O
DDI-DrugBank.d313.s5|132-134|the|O
DDI-DrugBank.d313.s5|136-140|signs|O
DDI-DrugBank.d313.s5|142-143|of|O
DDI-DrugBank.d313.s5|145-156|hypoglycemia|O
DDI-DrugBank.d313.s5|158-160|may|O
DDI-DrugBank.d313.s5|162-163|be|O
DDI-DrugBank.d313.s5|165-171|reduced|O
DDI-DrugBank.d313.s5|173-174|or|O
DDI-DrugBank.d313.s5|176-181|absent|O
DDI-DrugBank.d313.s5|182-182|.|O
DDI-DrugBank.d313.s6|0-5|Mixing|O
DDI-DrugBank.d313.s6|7-8|of|O
DDI-DrugBank.d313.s7|0-0|A|O
DDI-DrugBank.d313.s7|2-9|clinical|O
DDI-DrugBank.d313.s7|11-15|study|O
DDI-DrugBank.d313.s7|17-18|in|O
DDI-DrugBank.d313.s7|20-26|healthy|O
DDI-DrugBank.d313.s7|28-31|male|O
DDI-DrugBank.d313.s7|33-42|volunteers|O
DDI-DrugBank.d313.s7|44-44|(|O
DDI-DrugBank.d313.s7|45-48|n=24|O
DDI-DrugBank.d313.s7|49-49|)|O
DDI-DrugBank.d313.s7|51-62|demonstrated|O
DDI-DrugBank.d313.s7|64-67|that|O
DDI-DrugBank.d313.s7|69-74|mixing|O
DDI-DrugBank.d313.s7|76-82|NovoLog|brand
DDI-DrugBank.d313.s7|84-87|with|O
DDI-DrugBank.d313.s7|89-105|NPH human insulin|drug
DDI-DrugBank.d313.s7|107-117|immediately|O
DDI-DrugBank.d313.s7|119-124|before|O
DDI-DrugBank.d313.s7|126-134|injection|O
DDI-DrugBank.d313.s7|136-143|produced|O
DDI-DrugBank.d313.s7|145-148|some|O
DDI-DrugBank.d313.s7|150-160|attenuation|O
DDI-DrugBank.d313.s7|162-163|in|O
DDI-DrugBank.d313.s7|165-167|the|O
DDI-DrugBank.d313.s7|169-172|peak|O
DDI-DrugBank.d313.s7|174-186|concentration|O
DDI-DrugBank.d313.s7|188-189|of|O
DDI-DrugBank.d313.s7|191-197|NovoLog|brand
DDI-DrugBank.d313.s7|198-198|,|O
DDI-DrugBank.d313.s7|200-202|but|O
DDI-DrugBank.d313.s7|204-207|that|O
DDI-DrugBank.d313.s7|209-211|the|O
DDI-DrugBank.d313.s7|213-216|time|O
DDI-DrugBank.d313.s7|218-219|to|O
DDI-DrugBank.d313.s7|221-224|peak|O
DDI-DrugBank.d313.s7|226-228|and|O
DDI-DrugBank.d313.s7|230-232|the|O
DDI-DrugBank.d313.s7|234-238|total|O
DDI-DrugBank.d313.s7|240-254|bioavailability|O
DDI-DrugBank.d313.s7|256-257|of|O
DDI-DrugBank.d313.s7|259-265|NovoLog|brand
DDI-DrugBank.d313.s7|267-270|were|O
DDI-DrugBank.d313.s7|272-274|not|O
DDI-DrugBank.d313.s7|276-288|significantly|O
DDI-DrugBank.d313.s7|290-297|affected|O
DDI-DrugBank.d313.s7|298-298|.|O
DDI-DrugBank.d313.s8|0-1|If|O
DDI-DrugBank.d313.s8|3-9|NovoLog|brand
DDI-DrugBank.d313.s8|11-12|is|O
DDI-DrugBank.d313.s8|14-18|mixed|O
DDI-DrugBank.d313.s8|20-23|with|O
DDI-DrugBank.d313.s8|25-41|NPH human insulin|drug
DDI-DrugBank.d313.s8|42-42|,|O
DDI-DrugBank.d313.s8|44-50|NovoLog|brand
DDI-DrugBank.d313.s8|52-57|should|O
DDI-DrugBank.d313.s8|59-60|be|O
DDI-DrugBank.d313.s8|62-66|drawn|O
DDI-DrugBank.d313.s8|68-71|into|O
DDI-DrugBank.d313.s8|73-75|the|O
DDI-DrugBank.d313.s8|77-83|syringe|O
DDI-DrugBank.d313.s8|85-89|first|O
DDI-DrugBank.d313.s8|90-90|.|O
DDI-DrugBank.d313.s9|0-2|The|O
DDI-DrugBank.d313.s9|4-12|injection|O
DDI-DrugBank.d313.s9|14-19|should|O
DDI-DrugBank.d313.s9|21-22|be|O
DDI-DrugBank.d313.s9|24-27|made|O
DDI-DrugBank.d313.s9|29-39|immediately|O
DDI-DrugBank.d313.s9|41-45|after|O
DDI-DrugBank.d313.s9|47-52|mixing|O
DDI-DrugBank.d313.s9|53-53|.|O
DDI-DrugBank.d313.s10|0-6|Because|O
DDI-DrugBank.d313.s10|8-12|there|O
DDI-DrugBank.d313.s10|14-16|are|O
DDI-DrugBank.d313.s10|18-19|no|O
DDI-DrugBank.d313.s10|21-24|data|O
DDI-DrugBank.d313.s10|26-27|on|O
DDI-DrugBank.d313.s10|29-31|the|O
DDI-DrugBank.d313.s10|33-45|compatibility|O
DDI-DrugBank.d313.s10|47-48|of|O
DDI-DrugBank.d313.s10|50-56|NovoLog|brand
DDI-DrugBank.d313.s10|58-60|and|O
DDI-DrugBank.d313.s10|62-72|crystalline|O
DDI-DrugBank.d313.s10|74-85|zinc insulin|drug
DDI-DrugBank.d313.s10|87-98|preparations|O
DDI-DrugBank.d313.s10|99-99|,|O
DDI-DrugBank.d313.s10|101-107|NovoLog|brand
DDI-DrugBank.d313.s10|109-114|should|O
DDI-DrugBank.d313.s10|116-118|not|O
DDI-DrugBank.d313.s10|120-121|be|O
DDI-DrugBank.d313.s10|123-127|mixed|O
DDI-DrugBank.d313.s10|129-132|with|O
DDI-DrugBank.d313.s10|134-138|these|O
DDI-DrugBank.d313.s10|140-151|preparations|O
DDI-DrugBank.d313.s10|152-152|.|O
DDI-DrugBank.d313.s11|0-2|The|O
DDI-DrugBank.d313.s11|4-10|effects|O
DDI-DrugBank.d313.s11|12-13|of|O
DDI-DrugBank.d313.s11|15-20|mixing|O
DDI-DrugBank.d313.s11|22-28|NovoLog|brand
DDI-DrugBank.d313.s11|30-33|with|O
DDI-DrugBank.d313.s11|35-42|insulins|group
DDI-DrugBank.d313.s11|44-45|of|O
DDI-DrugBank.d313.s11|47-52|animal|O
DDI-DrugBank.d313.s11|54-59|source|O
DDI-DrugBank.d313.s11|61-62|or|O
DDI-DrugBank.d313.s11|64-70|insulin|drug
DDI-DrugBank.d313.s11|72-83|preparations|O
DDI-DrugBank.d313.s11|85-92|produced|O
DDI-DrugBank.d313.s11|94-95|by|O
DDI-DrugBank.d313.s11|97-101|other|O
DDI-DrugBank.d313.s11|103-115|manufacturers|O
DDI-DrugBank.d313.s11|117-120|have|O
DDI-DrugBank.d313.s11|122-124|not|O
DDI-DrugBank.d313.s11|126-129|been|O
DDI-DrugBank.d313.s11|131-137|studied|O
DDI-DrugBank.d313.s11|139-139|.|O
DDI-DrugBank.d313.s12|0-7|Mixtures|O
DDI-DrugBank.d313.s12|9-14|should|O
DDI-DrugBank.d313.s12|16-18|not|O
DDI-DrugBank.d313.s12|20-21|be|O
DDI-DrugBank.d313.s12|23-34|administered|O
DDI-DrugBank.d313.s12|36-48|intravenously|O
DDI-DrugBank.d313.s12|49-49|.|O
DDI-DrugBank.d313.s13|0-3|When|O
DDI-DrugBank.d313.s13|5-8|used|O
DDI-DrugBank.d313.s13|10-11|in|O
DDI-DrugBank.d313.s13|13-20|external|O
DDI-DrugBank.d313.s13|22-33|subcutaneous|O
DDI-DrugBank.d313.s13|35-42|infusion|O
DDI-DrugBank.d313.s13|44-48|pumps|O
DDI-DrugBank.d313.s13|50-52|for|O
DDI-DrugBank.d313.s13|54-60|insulin|drug
DDI-DrugBank.d313.s13|61-61|,|O
DDI-DrugBank.d313.s13|63-69|NovoLog|brand
DDI-DrugBank.d313.s13|71-76|should|O
DDI-DrugBank.d313.s13|78-80|not|O
DDI-DrugBank.d313.s13|82-83|be|O
DDI-DrugBank.d313.s13|85-89|mixed|O
DDI-DrugBank.d313.s13|91-94|with|O
DDI-DrugBank.d313.s13|96-98|any|O
DDI-DrugBank.d313.s13|100-104|other|O
DDI-DrugBank.d313.s13|106-113|insulins|group
DDI-DrugBank.d313.s13|115-116|or|O
DDI-DrugBank.d313.s13|118-124|diluent|O
DDI-DrugBank.d313.s13|125-125|.|O
DDI-DrugBank.d169.s0|0-6|Results|O
DDI-DrugBank.d169.s0|8-11|from|O
DDI-DrugBank.d169.s0|13-17|human|O
DDI-DrugBank.d169.s0|19-20|in|O
DDI-DrugBank.d169.s0|22-26|vitro|O
DDI-DrugBank.d169.s0|28-37|metabolism|O
DDI-DrugBank.d169.s0|39-45|studies|O
DDI-DrugBank.d169.s0|47-49|and|O
DDI-DrugBank.d169.s0|51-61|nonclinical|O
DDI-DrugBank.d169.s0|63-69|studies|O
DDI-DrugBank.d169.s0|71-74|show|O
DDI-DrugBank.d169.s0|76-79|that|O
DDI-DrugBank.d169.s0|81-88|REVLIMID|brand
DDI-DrugBank.d169.s0|91-91|(|O
DDI-DrugBank.d169.s0|92-103|lenalidomide|drug
DDI-DrugBank.d169.s0|104-104|)|O
DDI-DrugBank.d169.s0|106-107|is|O
DDI-DrugBank.d169.s0|109-115|neither|O
DDI-DrugBank.d169.s0|117-127|metabolized|O
DDI-DrugBank.d169.s0|129-130|by|O
DDI-DrugBank.d169.s0|132-134|nor|O
DDI-DrugBank.d169.s0|136-143|inhibits|O
DDI-DrugBank.d169.s0|145-146|or|O
DDI-DrugBank.d169.s0|148-154|induces|O
DDI-DrugBank.d169.s0|156-158|the|O
DDI-DrugBank.d169.s0|160-169|cytochrome|O
DDI-DrugBank.d169.s0|171-174|P450|O
DDI-DrugBank.d169.s0|176-182|pathway|O
DDI-DrugBank.d169.s0|184-193|suggesting|O
DDI-DrugBank.d169.s0|195-198|that|O
DDI-DrugBank.d169.s0|200-211|lenalidomide|drug
DDI-DrugBank.d169.s0|213-214|is|O
DDI-DrugBank.d169.s0|216-218|not|O
DDI-DrugBank.d169.s0|220-225|likely|O
DDI-DrugBank.d169.s0|227-228|to|O
DDI-DrugBank.d169.s0|230-234|cause|O
DDI-DrugBank.d169.s0|236-237|or|O
DDI-DrugBank.d169.s0|239-240|be|O
DDI-DrugBank.d169.s0|242-248|subject|O
DDI-DrugBank.d169.s0|250-251|to|O
DDI-DrugBank.d169.s0|253-262|P450-based|O
DDI-DrugBank.d169.s0|264-272|metabolic|O
DDI-DrugBank.d169.s0|274-277|drug|O
DDI-DrugBank.d169.s0|279-290|interactions|O
DDI-DrugBank.d169.s0|292-293|in|O
DDI-DrugBank.d169.s0|295-297|man|O
DDI-DrugBank.d169.s0|298-298|.|O
DDI-DrugBank.d169.s1|0-16|Co-administration|O
DDI-DrugBank.d169.s1|18-19|of|O
DDI-DrugBank.d169.s1|21-28|multiple|O
DDI-DrugBank.d169.s1|30-34|doses|O
DDI-DrugBank.d169.s1|36-37|of|O
DDI-DrugBank.d169.s1|39-40|10|O
DDI-DrugBank.d169.s1|42-43|mg|O
DDI-DrugBank.d169.s1|45-46|of|O
DDI-DrugBank.d169.s1|48-59|lenalidomide|drug
DDI-DrugBank.d169.s1|61-63|had|O
DDI-DrugBank.d169.s1|65-66|no|O
DDI-DrugBank.d169.s1|68-73|effect|O
DDI-DrugBank.d169.s1|75-76|on|O
DDI-DrugBank.d169.s1|78-80|the|O
DDI-DrugBank.d169.s1|82-87|single|O
DDI-DrugBank.d169.s1|89-92|dose|O
DDI-DrugBank.d169.s1|94-109|pharmacokinetics|O
DDI-DrugBank.d169.s1|111-112|of|O
DDI-DrugBank.d169.s1|114-115|R-|drug
DDI-DrugBank.d169.s1|117-119|and|O
DDI-DrugBank.d169.s1|121-131|S- warfarin|drug
DDI-DrugBank.d169.s1|132-132|.|O
DDI-DrugBank.d169.s2|0-16|Co-administration|O
DDI-DrugBank.d169.s2|18-19|of|O
DDI-DrugBank.d169.s2|21-26|single|O
DDI-DrugBank.d169.s2|28-32|25-mg|O
DDI-DrugBank.d169.s2|34-37|dose|O
DDI-DrugBank.d169.s2|39-46|warfarin|drug
DDI-DrugBank.d169.s2|48-50|had|O
DDI-DrugBank.d169.s2|52-53|no|O
DDI-DrugBank.d169.s2|55-60|effect|O
DDI-DrugBank.d169.s2|62-63|on|O
DDI-DrugBank.d169.s2|65-67|the|O
DDI-DrugBank.d169.s2|69-84|pharmacokinetics|O
DDI-DrugBank.d169.s2|86-87|of|O
DDI-DrugBank.d169.s2|89-93|total|O
DDI-DrugBank.d169.s2|95-106|lenalidomide|drug
DDI-DrugBank.d169.s2|107-107|.|O
DDI-DrugBank.d169.s3|0-7|Expected|O
DDI-DrugBank.d169.s3|9-15|changes|O
DDI-DrugBank.d169.s3|17-18|in|O
DDI-DrugBank.d169.s3|20-29|laboratory|O
DDI-DrugBank.d169.s3|31-41|assessments|O
DDI-DrugBank.d169.s3|43-44|of|O
DDI-DrugBank.d169.s3|46-47|PT|O
DDI-DrugBank.d169.s3|49-51|and|O
DDI-DrugBank.d169.s3|53-55|INR|O
DDI-DrugBank.d169.s3|57-60|were|O
DDI-DrugBank.d169.s3|62-69|observed|O
DDI-DrugBank.d169.s3|71-75|after|O
DDI-DrugBank.d169.s3|77-84|warfarin|drug
DDI-DrugBank.d169.s3|86-99|administration|O
DDI-DrugBank.d169.s3|100-100|,|O
DDI-DrugBank.d169.s3|102-104|but|O
DDI-DrugBank.d169.s3|106-110|these|O
DDI-DrugBank.d169.s3|112-118|changes|O
DDI-DrugBank.d169.s3|120-123|were|O
DDI-DrugBank.d169.s3|125-127|not|O
DDI-DrugBank.d169.s3|129-136|affected|O
DDI-DrugBank.d169.s3|138-139|by|O
DDI-DrugBank.d169.s3|141-151|concomitant|O
DDI-DrugBank.d169.s3|153-164|lenalidomide|drug
DDI-DrugBank.d169.s3|166-179|administration|O
DDI-DrugBank.d169.s3|180-180|.|O
DDI-DrugBank.d40.s0|0-1|No|O
DDI-DrugBank.d40.s0|3-7|drugs|O
DDI-DrugBank.d40.s0|9-11|are|O
DDI-DrugBank.d40.s0|13-17|known|O
DDI-DrugBank.d40.s0|19-20|to|O
DDI-DrugBank.d40.s0|22-30|interfere|O
DDI-DrugBank.d40.s0|32-35|with|O
DDI-DrugBank.d40.s0|37-39|the|O
DDI-DrugBank.d40.s0|41-50|conversion|O
DDI-DrugBank.d40.s0|52-53|of|O
DDI-DrugBank.d40.s0|55-66|fosphenytoin|drug
DDI-DrugBank.d40.s0|68-69|to|O
DDI-DrugBank.d40.s0|71-79|phenytoin|drug
DDI-DrugBank.d40.s0|80-80|.|O
DDI-DrugBank.d40.s1|0-9|Conversion|O
DDI-DrugBank.d40.s1|11-15|could|O
DDI-DrugBank.d40.s1|17-18|be|O
DDI-DrugBank.d40.s1|20-27|affected|O
DDI-DrugBank.d40.s1|29-30|by|O
DDI-DrugBank.d40.s1|32-42|alterations|O
DDI-DrugBank.d40.s1|44-45|in|O
DDI-DrugBank.d40.s1|47-49|the|O
DDI-DrugBank.d40.s1|51-55|level|O
DDI-DrugBank.d40.s1|57-58|of|O
DDI-DrugBank.d40.s1|60-70|phosphatase|O
DDI-DrugBank.d40.s1|72-79|activity|O
DDI-DrugBank.d40.s1|80-80|,|O
DDI-DrugBank.d40.s1|82-84|but|O
DDI-DrugBank.d40.s1|86-90|given|O
DDI-DrugBank.d40.s1|92-94|the|O
DDI-DrugBank.d40.s1|96-104|abundance|O
DDI-DrugBank.d40.s1|106-108|and|O
DDI-DrugBank.d40.s1|110-113|wide|O
DDI-DrugBank.d40.s1|115-126|distribution|O
DDI-DrugBank.d40.s1|128-129|of|O
DDI-DrugBank.d40.s1|131-142|phosphatases|O
DDI-DrugBank.d40.s1|144-145|in|O
DDI-DrugBank.d40.s1|147-149|the|O
DDI-DrugBank.d40.s1|151-154|body|O
DDI-DrugBank.d40.s1|156-157|it|O
DDI-DrugBank.d40.s1|159-160|is|O
DDI-DrugBank.d40.s1|162-169|unlikely|O
DDI-DrugBank.d40.s1|171-174|that|O
DDI-DrugBank.d40.s1|176-180|drugs|O
DDI-DrugBank.d40.s1|182-186|would|O
DDI-DrugBank.d40.s1|188-193|affect|O
DDI-DrugBank.d40.s1|195-198|this|O
DDI-DrugBank.d40.s1|200-207|activity|O
DDI-DrugBank.d40.s1|209-214|enough|O
DDI-DrugBank.d40.s1|216-217|to|O
DDI-DrugBank.d40.s1|219-224|affect|O
DDI-DrugBank.d40.s1|226-235|conversion|O
DDI-DrugBank.d40.s1|237-238|of|O
DDI-DrugBank.d40.s1|240-251|fosphenytoin|drug
DDI-DrugBank.d40.s1|253-254|to|O
DDI-DrugBank.d40.s1|256-264|phenytoin|drug
DDI-DrugBank.d40.s1|265-265|.|O
DDI-DrugBank.d40.s2|0-4|Drugs|O
DDI-DrugBank.d40.s2|6-11|highly|O
DDI-DrugBank.d40.s2|13-17|bound|O
DDI-DrugBank.d40.s2|19-20|to|O
DDI-DrugBank.d40.s2|22-28|albumin|O
DDI-DrugBank.d40.s2|30-34|could|O
DDI-DrugBank.d40.s2|36-43|increase|O
DDI-DrugBank.d40.s2|45-47|the|O
DDI-DrugBank.d40.s2|49-55|unbound|O
DDI-DrugBank.d40.s2|57-64|fraction|O
DDI-DrugBank.d40.s2|66-67|of|O
DDI-DrugBank.d40.s2|69-80|fosphenytoin|drug
DDI-DrugBank.d40.s2|81-81|.|O
DDI-DrugBank.d40.s3|0-7|Although|O
DDI-DrugBank.d40.s3|8-8|,|O
DDI-DrugBank.d40.s3|10-11|it|O
DDI-DrugBank.d40.s3|13-14|is|O
DDI-DrugBank.d40.s3|16-22|unknown|O
DDI-DrugBank.d40.s3|24-30|whether|O
DDI-DrugBank.d40.s3|32-35|this|O
DDI-DrugBank.d40.s3|37-41|could|O
DDI-DrugBank.d40.s3|43-48|result|O
DDI-DrugBank.d40.s3|50-51|in|O
DDI-DrugBank.d40.s3|53-62|clinically|O
DDI-DrugBank.d40.s3|64-74|significant|O
DDI-DrugBank.d40.s3|76-82|effects|O
DDI-DrugBank.d40.s3|83-83|,|O
DDI-DrugBank.d40.s3|85-91|caution|O
DDI-DrugBank.d40.s3|93-94|is|O
DDI-DrugBank.d40.s3|96-102|advised|O
DDI-DrugBank.d40.s3|104-107|when|O
DDI-DrugBank.d40.s3|109-121|administering|O
DDI-DrugBank.d40.s3|123-129|Cerebyx|brand
DDI-DrugBank.d40.s3|131-134|with|O
DDI-DrugBank.d40.s3|136-140|other|O
DDI-DrugBank.d40.s3|142-146|drugs|O
DDI-DrugBank.d40.s3|148-151|that|O
DDI-DrugBank.d40.s3|153-165|significantly|O
DDI-DrugBank.d40.s3|167-170|bind|O
DDI-DrugBank.d40.s3|172-173|to|O
DDI-DrugBank.d40.s3|175-179|serum|O
DDI-DrugBank.d40.s3|181-187|albumin|O
DDI-DrugBank.d40.s3|188-188|.|O
DDI-DrugBank.d40.s4|0-2|The|O
DDI-DrugBank.d40.s4|4-19|pharmacokinetics|O
DDI-DrugBank.d40.s4|21-23|and|O
DDI-DrugBank.d40.s4|25-31|protein|O
DDI-DrugBank.d40.s4|33-39|binding|O
DDI-DrugBank.d40.s4|41-42|of|O
DDI-DrugBank.d40.s4|44-55|fosphenytoin|drug
DDI-DrugBank.d40.s4|56-56|,|O
DDI-DrugBank.d40.s4|58-66|phenytoin|drug
DDI-DrugBank.d40.s4|67-67|,|O
DDI-DrugBank.d40.s4|69-71|and|O
DDI-DrugBank.d40.s4|73-80|diazepam|drug
DDI-DrugBank.d40.s4|82-85|were|O
DDI-DrugBank.d40.s4|87-89|not|O
DDI-DrugBank.d40.s4|91-97|altered|O
DDI-DrugBank.d40.s4|99-102|when|O
DDI-DrugBank.d40.s4|104-111|diazepam|drug
DDI-DrugBank.d40.s4|113-115|and|O
DDI-DrugBank.d40.s4|117-123|Cerebyx|brand
DDI-DrugBank.d40.s4|125-128|were|O
DDI-DrugBank.d40.s4|130-141|concurrently|O
DDI-DrugBank.d40.s4|143-154|administered|O
DDI-DrugBank.d40.s4|156-157|in|O
DDI-DrugBank.d40.s4|159-164|single|O
DDI-DrugBank.d40.s4|166-175|submaximal|O
DDI-DrugBank.d40.s4|177-181|doses|O
DDI-DrugBank.d40.s4|182-182|.|O
DDI-DrugBank.d40.s5|0-2|The|O
DDI-DrugBank.d40.s5|4-7|most|O
DDI-DrugBank.d40.s5|9-19|significant|O
DDI-DrugBank.d40.s5|21-24|drug|O
DDI-DrugBank.d40.s5|26-37|interactions|O
DDI-DrugBank.d40.s5|39-47|following|O
DDI-DrugBank.d40.s5|49-62|administration|O
DDI-DrugBank.d40.s5|64-65|of|O
DDI-DrugBank.d40.s5|67-73|Cerebyx|brand
DDI-DrugBank.d40.s5|75-77|are|O
DDI-DrugBank.d40.s5|79-86|expected|O
DDI-DrugBank.d40.s5|88-89|to|O
DDI-DrugBank.d40.s5|91-95|occur|O
DDI-DrugBank.d40.s5|97-100|with|O
DDI-DrugBank.d40.s5|102-106|drugs|O
DDI-DrugBank.d40.s5|108-111|that|O
DDI-DrugBank.d40.s5|113-120|interact|O
DDI-DrugBank.d40.s5|122-125|with|O
DDI-DrugBank.d40.s5|127-135|phenytoin|drug
DDI-DrugBank.d40.s5|136-136|.|O
DDI-DrugBank.d40.s6|0-8|Phenytoin|drug
DDI-DrugBank.d40.s6|10-11|is|O
DDI-DrugBank.d40.s6|13-23|extensively|O
DDI-DrugBank.d40.s6|25-29|bound|O
DDI-DrugBank.d40.s6|31-32|to|O
DDI-DrugBank.d40.s6|34-38|serum|O
DDI-DrugBank.d40.s6|40-45|plasma|O
DDI-DrugBank.d40.s6|47-54|proteins|O
DDI-DrugBank.d40.s6|56-58|and|O
DDI-DrugBank.d40.s6|60-61|is|O
DDI-DrugBank.d40.s6|63-67|prone|O
DDI-DrugBank.d40.s6|69-70|to|O
DDI-DrugBank.d40.s6|72-82|competitive|O
DDI-DrugBank.d40.s6|84-95|displacement|O
DDI-DrugBank.d40.s6|96-96|.|O
DDI-DrugBank.d40.s7|0-8|Phenytoin|drug
DDI-DrugBank.d40.s7|10-11|is|O
DDI-DrugBank.d40.s7|13-23|metabolized|O
DDI-DrugBank.d40.s7|25-26|by|O
DDI-DrugBank.d40.s7|28-34|hepatic|O
DDI-DrugBank.d40.s7|36-45|cytochrome|O
DDI-DrugBank.d40.s7|47-50|P450|O
DDI-DrugBank.d40.s7|52-58|enzymes|O
DDI-DrugBank.d40.s7|60-62|and|O
DDI-DrugBank.d40.s7|64-65|is|O
DDI-DrugBank.d40.s7|67-78|particularly|O
DDI-DrugBank.d40.s7|80-90|susceptible|O
DDI-DrugBank.d40.s7|92-93|to|O
DDI-DrugBank.d40.s7|95-104|inhibitory|O
DDI-DrugBank.d40.s7|106-109|drug|O
DDI-DrugBank.d40.s7|111-122|interactions|O
DDI-DrugBank.d40.s7|124-130|because|O
DDI-DrugBank.d40.s7|132-133|it|O
DDI-DrugBank.d40.s7|135-136|is|O
DDI-DrugBank.d40.s7|138-144|subject|O
DDI-DrugBank.d40.s7|146-147|to|O
DDI-DrugBank.d40.s7|149-157|saturable|O
DDI-DrugBank.d40.s7|159-168|metabolism|O
DDI-DrugBank.d40.s7|169-169|.|O
DDI-DrugBank.d40.s8|0-9|Inhibition|O
DDI-DrugBank.d40.s8|11-12|of|O
DDI-DrugBank.d40.s8|14-23|metabolism|O
DDI-DrugBank.d40.s8|25-27|may|O
DDI-DrugBank.d40.s8|29-35|produce|O
DDI-DrugBank.d40.s8|37-47|significant|O
DDI-DrugBank.d40.s8|49-57|increases|O
DDI-DrugBank.d40.s8|59-60|in|O
DDI-DrugBank.d40.s8|62-72|circulating|O
DDI-DrugBank.d40.s8|74-82|phenytoin|drug
DDI-DrugBank.d40.s8|84-97|concentrations|O
DDI-DrugBank.d40.s8|99-101|and|O
DDI-DrugBank.d40.s8|103-109|enhance|O
DDI-DrugBank.d40.s8|111-113|the|O
DDI-DrugBank.d40.s8|115-118|risk|O
DDI-DrugBank.d40.s8|120-121|of|O
DDI-DrugBank.d40.s8|123-126|drug|O
DDI-DrugBank.d40.s8|128-135|toxicity|O
DDI-DrugBank.d40.s8|136-136|.|O
DDI-DrugBank.d40.s9|0-8|Phenytoin|drug
DDI-DrugBank.d40.s9|10-11|is|O
DDI-DrugBank.d40.s9|13-13|a|O
DDI-DrugBank.d40.s9|15-20|potent|O
DDI-DrugBank.d40.s9|22-28|inducer|O
DDI-DrugBank.d40.s9|30-31|of|O
DDI-DrugBank.d40.s9|33-39|hepatic|O
DDI-DrugBank.d40.s9|41-57|drug-metabolizing|O
DDI-DrugBank.d40.s9|59-65|enzymes|O
DDI-DrugBank.d40.s9|66-66|.|O
DDI-DrugBank.d40.s10|0-2|The|O
DDI-DrugBank.d40.s10|4-7|most|O
DDI-DrugBank.d40.s10|9-16|commonly|O
DDI-DrugBank.d40.s10|18-26|occurring|O
DDI-DrugBank.d40.s10|28-31|drug|O
DDI-DrugBank.d40.s10|33-44|interactions|O
DDI-DrugBank.d40.s10|46-48|are|O
DDI-DrugBank.d40.s10|50-55|listed|O
DDI-DrugBank.d40.s10|57-61|below|O
DDI-DrugBank.d40.s10|62-62|:|O
DDI-DrugBank.d40.s10|64-64|-|O
DDI-DrugBank.d40.s10|66-70|Drugs|O
DDI-DrugBank.d40.s10|72-75|that|O
DDI-DrugBank.d40.s10|77-79|may|O
DDI-DrugBank.d40.s10|81-88|increase|O
DDI-DrugBank.d40.s10|90-95|plasma|O
DDI-DrugBank.d40.s10|97-105|phenytoin|drug
DDI-DrugBank.d40.s10|107-120|concentrations|O
DDI-DrugBank.d40.s10|122-128|include|O
DDI-DrugBank.d40.s10|129-129|:|O
DDI-DrugBank.d40.s10|131-135|acute|O
DDI-DrugBank.d40.s10|137-143|alcohol|drug
DDI-DrugBank.d40.s10|145-150|intake|O
DDI-DrugBank.d40.s10|151-151|,|O
DDI-DrugBank.d40.s10|153-162|amiodarone|drug
DDI-DrugBank.d40.s10|163-163|,|O
DDI-DrugBank.d40.s10|165-179|chboramphenicol|O
DDI-DrugBank.d40.s10|180-180|,|O
DDI-DrugBank.d40.s10|182-197|chlordiazepoxide|drug
DDI-DrugBank.d40.s10|198-198|,|O
DDI-DrugBank.d40.s10|200-209|cimetidine|drug
DDI-DrugBank.d40.s10|210-210|,|O
DDI-DrugBank.d40.s10|212-219|diazepam|drug
DDI-DrugBank.d40.s10|220-220|,|O
DDI-DrugBank.d40.s10|222-230|dicumarol|drug
DDI-DrugBank.d40.s10|231-231|,|O
DDI-DrugBank.d40.s10|233-242|disulfiram|drug
DDI-DrugBank.d40.s10|243-243|,|O
DDI-DrugBank.d40.s10|245-253|estrogens|group
DDI-DrugBank.d40.s10|254-254|,|O
DDI-DrugBank.d40.s10|256-267|ethosuximide|drug
DDI-DrugBank.d40.s10|268-268|,|O
DDI-DrugBank.d40.s10|270-279|fluoxetine|drug
DDI-DrugBank.d40.s10|280-280|,|O
DDI-DrugBank.d40.s10|282-295|H2-antagonists|group
DDI-DrugBank.d40.s10|296-296|,|O
DDI-DrugBank.d40.s10|298-306|halothane|drug
DDI-DrugBank.d40.s10|307-307|,|O
DDI-DrugBank.d40.s10|309-317|isoniazid|drug
DDI-DrugBank.d40.s10|318-318|,|O
DDI-DrugBank.d40.s10|320-334|methylphenidate|drug
DDI-DrugBank.d40.s10|335-335|,|O
DDI-DrugBank.d40.s10|337-350|phenothiazines|group
DDI-DrugBank.d40.s10|351-351|,|O
DDI-DrugBank.d40.s10|353-366|phenylbutazone|drug
DDI-DrugBank.d40.s10|367-367|,|O
DDI-DrugBank.d40.s10|369-379|salicylates|group
DDI-DrugBank.d40.s10|380-380|,|O
DDI-DrugBank.d40.s10|382-393|succinimides|group
DDI-DrugBank.d40.s10|394-394|,|O
DDI-DrugBank.d40.s10|396-407|sulfonamides|group
DDI-DrugBank.d40.s10|408-408|,|O
DDI-DrugBank.d40.s10|410-420|tolbutamide|drug
DDI-DrugBank.d40.s10|421-421|,|O
DDI-DrugBank.d40.s11|0-0|.|O
DDI-DrugBank.d40.s12|0-0|-|O
DDI-DrugBank.d40.s12|2-6|Drugs|O
DDI-DrugBank.d40.s12|8-11|that|O
DDI-DrugBank.d40.s12|13-15|may|O
DDI-DrugBank.d40.s12|17-24|decrease|O
DDI-DrugBank.d40.s12|26-31|plasma|O
DDI-DrugBank.d40.s12|33-41|phenytoin|drug
DDI-DrugBank.d40.s12|43-56|concentrations|O
DDI-DrugBank.d40.s12|58-64|include|O
DDI-DrugBank.d40.s12|65-65|:|O
DDI-DrugBank.d40.s12|67-79|carbamazepine|drug
DDI-DrugBank.d40.s12|80-80|,|O
DDI-DrugBank.d40.s12|82-88|chronic|O
DDI-DrugBank.d40.s12|90-96|alcohol|drug
DDI-DrugBank.d40.s12|98-102|abuse|O
DDI-DrugBank.d40.s12|103-103|,|O
DDI-DrugBank.d40.s13|0-0|.|O
DDI-DrugBank.d40.s14|0-0|-|O
DDI-DrugBank.d40.s14|2-6|Drugs|O
DDI-DrugBank.d40.s14|8-11|that|O
DDI-DrugBank.d40.s14|13-15|may|O
DDI-DrugBank.d40.s14|17-22|either|O
DDI-DrugBank.d40.s14|24-31|increase|O
DDI-DrugBank.d40.s14|33-34|or|O
DDI-DrugBank.d40.s14|36-43|decrease|O
DDI-DrugBank.d40.s14|45-50|plasma|O
DDI-DrugBank.d40.s14|52-60|phenytoin|drug
DDI-DrugBank.d40.s14|62-75|concentrations|O
DDI-DrugBank.d40.s14|77-83|include|O
DDI-DrugBank.d40.s14|84-84|:|O
DDI-DrugBank.d40.s14|86-98|phenobarbital|drug
DDI-DrugBank.d40.s14|99-99|,|O
DDI-DrugBank.d40.s14|101-108|vaiproic|O
DDI-DrugBank.d40.s14|110-113|acid|O
DDI-DrugBank.d40.s14|114-114|,|O
DDI-DrugBank.d40.s14|116-118|and|O
DDI-DrugBank.d40.s14|120-135|sodium valproate|drug
DDI-DrugBank.d40.s14|136-136|.|O
DDI-DrugBank.d40.s15|0-8|Similarly|O
DDI-DrugBank.d40.s15|9-9|,|O
DDI-DrugBank.d40.s15|11-13|the|O
DDI-DrugBank.d40.s15|15-21|effects|O
DDI-DrugBank.d40.s15|23-24|of|O
DDI-DrugBank.d40.s15|26-34|phenytoin|drug
DDI-DrugBank.d40.s15|36-37|on|O
DDI-DrugBank.d40.s15|39-51|phenobarbital|drug
DDI-DrugBank.d40.s15|52-52|,|O
DDI-DrugBank.d40.s15|54-66|valproic acid|drug
DDI-DrugBank.d40.s15|68-70|and|O
DDI-DrugBank.d40.s15|72-77|sodium|O
DDI-DrugBank.d40.s15|79-84|plasma|O
DDI-DrugBank.d40.s15|86-94|valproate|drug
DDI-DrugBank.d40.s15|96-109|concentrations|O
DDI-DrugBank.d40.s15|111-113|are|O
DDI-DrugBank.d40.s15|115-127|unpredictable|O
DDI-DrugBank.d40.s16|0-0|.|O
DDI-DrugBank.d40.s17|0-0|-|O
DDI-DrugBank.d40.s17|2-9|Although|O
DDI-DrugBank.d40.s17|11-13|not|O
DDI-DrugBank.d40.s17|15-15|a|O
DDI-DrugBank.d40.s17|17-20|true|O
DDI-DrugBank.d40.s17|22-25|drug|O
DDI-DrugBank.d40.s17|27-37|interaction|O
DDI-DrugBank.d40.s17|38-38|,|O
DDI-DrugBank.d40.s17|40-64|tricyclic antidepressants|group
DDI-DrugBank.d40.s17|66-68|may|O
DDI-DrugBank.d40.s17|70-80|precipitate|O
DDI-DrugBank.d40.s17|82-89|seizures|O
DDI-DrugBank.d40.s17|91-92|in|O
DDI-DrugBank.d40.s17|94-104|susceptible|O
DDI-DrugBank.d40.s17|106-113|patients|O
DDI-DrugBank.d40.s17|115-117|and|O
DDI-DrugBank.d40.s17|119-125|Cerebyx|brand
DDI-DrugBank.d40.s17|127-132|dosage|O
DDI-DrugBank.d40.s17|134-136|may|O
DDI-DrugBank.d40.s17|138-141|need|O
DDI-DrugBank.d40.s17|143-144|to|O
DDI-DrugBank.d40.s17|146-147|be|O
DDI-DrugBank.d40.s17|149-156|adjusted|O
DDI-DrugBank.d40.s18|0-0|.|O
DDI-DrugBank.d40.s19|0-0|-|O
DDI-DrugBank.d40.s19|2-6|Drugs|O
DDI-DrugBank.d40.s19|8-12|whose|O
DDI-DrugBank.d40.s19|14-21|efficacy|O
DDI-DrugBank.d40.s19|23-24|is|O
DDI-DrugBank.d40.s19|26-33|impaired|O
DDI-DrugBank.d40.s19|35-36|by|O
DDI-DrugBank.d40.s19|38-46|phenytoin|drug
DDI-DrugBank.d40.s19|48-54|include|O
DDI-DrugBank.d40.s19|55-55|:|O
DDI-DrugBank.d40.s19|57-70|anticoagulants|group
DDI-DrugBank.d40.s19|71-71|,|O
DDI-DrugBank.d40.s19|73-87|corticosteroids|group
DDI-DrugBank.d40.s19|88-88|,|O
DDI-DrugBank.d40.s19|90-97|coumarin|group
DDI-DrugBank.d40.s19|98-98|,|O
DDI-DrugBank.d40.s19|100-108|digitoxin|drug
DDI-DrugBank.d40.s19|109-109|,|O
DDI-DrugBank.d40.s19|111-121|doxycycline|drug
DDI-DrugBank.d40.s19|122-122|,|O
DDI-DrugBank.d40.s19|124-132|estrogens|group
DDI-DrugBank.d40.s19|133-133|,|O
DDI-DrugBank.d40.s19|135-144|furosemide|drug
DDI-DrugBank.d40.s19|145-145|,|O
DDI-DrugBank.d40.s19|147-150|oral|O
DDI-DrugBank.d40.s19|152-165|contraceptives|group
DDI-DrugBank.d40.s19|166-166|,|O
DDI-DrugBank.d40.s19|168-175|rifampin|drug
DDI-DrugBank.d40.s19|176-176|,|O
DDI-DrugBank.d40.s19|178-186|quinidine|drug
DDI-DrugBank.d40.s19|187-187|,|O
DDI-DrugBank.d40.s19|189-200|theophylline|drug
DDI-DrugBank.d40.s19|201-201|,|O
DDI-DrugBank.d40.s19|203-211|vitamin D|group
DDI-DrugBank.d40.s19|212-212|.|O
DDI-DrugBank.d40.s20|0-9|Monitoring|O
DDI-DrugBank.d40.s20|11-12|of|O
DDI-DrugBank.d40.s20|14-19|plasma|O
DDI-DrugBank.d40.s20|21-29|phenytoin|drug
DDI-DrugBank.d40.s20|31-44|concentrations|O
DDI-DrugBank.d40.s20|46-48|may|O
DDI-DrugBank.d40.s20|50-51|be|O
DDI-DrugBank.d40.s20|53-59|helpful|O
DDI-DrugBank.d40.s20|61-64|when|O
DDI-DrugBank.d40.s20|66-73|possible|O
DDI-DrugBank.d40.s20|75-78|drug|O
DDI-DrugBank.d40.s20|80-91|interactions|O
DDI-DrugBank.d40.s20|93-95|are|O
DDI-DrugBank.d40.s20|97-105|suspected|O
DDI-DrugBank.d40.s20|106-106|.|O
DDI-DrugBank.d40.s21|0-14|Drug/Laboratory|O
DDI-DrugBank.d40.s21|16-19|Test|O
DDI-DrugBank.d40.s21|21-32|Interactions|O
DDI-DrugBank.d40.s21|34-42|Phenytoin|drug
DDI-DrugBank.d40.s21|44-46|may|O
DDI-DrugBank.d40.s21|48-55|decrease|O
DDI-DrugBank.d40.s21|57-61|serum|O
DDI-DrugBank.d40.s21|63-76|concentrations|O
DDI-DrugBank.d40.s21|78-79|of|O
DDI-DrugBank.d40.s21|81-82|14|O
DDI-DrugBank.d40.s21|83-83|.|O
DDI-DrugBank.d40.s22|0-1|It|O
DDI-DrugBank.d40.s22|3-5|may|O
DDI-DrugBank.d40.s22|7-10|also|O
DDI-DrugBank.d40.s22|12-18|produce|O
DDI-DrugBank.d40.s22|20-32|artifactually|O
DDI-DrugBank.d40.s22|34-36|low|O
DDI-DrugBank.d40.s22|38-44|results|O
DDI-DrugBank.d40.s22|46-47|in|O
DDI-DrugBank.d40.s22|49-61|dexamethasone|O
DDI-DrugBank.d40.s22|63-64|or|O
DDI-DrugBank.d40.s22|66-75|metyrapone|O
DDI-DrugBank.d40.s22|77-81|tests|O
DDI-DrugBank.d40.s22|82-82|.|O
DDI-DrugBank.d40.s23|0-8|Phenytoin|drug
DDI-DrugBank.d40.s23|10-12|may|O
DDI-DrugBank.d40.s23|14-17|also|O
DDI-DrugBank.d40.s23|19-23|cause|O
DDI-DrugBank.d40.s23|25-33|increased|O
DDI-DrugBank.d40.s23|35-39|serum|O
DDI-DrugBank.d40.s23|41-54|concentrations|O
DDI-DrugBank.d40.s23|56-57|of|O
DDI-DrugBank.d40.s23|59-65|glucose|O
DDI-DrugBank.d40.s23|66-66|,|O
DDI-DrugBank.d40.s23|68-75|alkaline|O
DDI-DrugBank.d40.s23|77-87|phosphatase|O
DDI-DrugBank.d40.s23|88-88|,|O
DDI-DrugBank.d40.s23|90-92|and|O
DDI-DrugBank.d40.s23|94-98|gamma|O
DDI-DrugBank.d40.s23|100-107|glutamyl|O
DDI-DrugBank.d40.s23|109-122|transpeptidase|O
DDI-DrugBank.d40.s23|124-124|(|O
DDI-DrugBank.d40.s23|125-127|GGT|O
DDI-DrugBank.d40.s23|128-128|)|O
DDI-DrugBank.d40.s23|129-129|.|O
DDI-DrugBank.d40.s24|0-3|Care|O
DDI-DrugBank.d40.s24|5-10|should|O
DDI-DrugBank.d40.s24|12-13|be|O
DDI-DrugBank.d40.s24|15-19|taken|O
DDI-DrugBank.d40.s24|21-24|when|O
DDI-DrugBank.d40.s24|26-30|using|O
DDI-DrugBank.d40.s24|32-47|immunoanalytical|O
DDI-DrugBank.d40.s24|49-55|methods|O
DDI-DrugBank.d40.s24|57-58|to|O
DDI-DrugBank.d40.s24|60-66|measure|O
DDI-DrugBank.d40.s24|68-73|plasma|O
DDI-DrugBank.d40.s24|75-83|phenytoin|drug
DDI-DrugBank.d40.s24|85-98|concentrations|O
DDI-DrugBank.d40.s24|100-108|following|O
DDI-DrugBank.d40.s24|110-116|Cerebyx|brand
DDI-DrugBank.d40.s24|118-131|administration|O
DDI-DrugBank.d40.s24|132-132|.|O
DDI-DrugBank.d4.s0|0-8|Synergism|O
DDI-DrugBank.d4.s0|10-16|between|O
DDI-DrugBank.d4.s0|18-41|xanthine bronchodilators|group
DDI-DrugBank.d4.s0|43-43|(|O
DDI-DrugBank.d4.s0|44-47|e.g.|O
DDI-DrugBank.d4.s0|48-48|,|O
DDI-DrugBank.d4.s0|50-61|theophylline|drug
DDI-DrugBank.d4.s0|62-62|)|O
DDI-DrugBank.d4.s0|63-63|,|O
DDI-DrugBank.d4.s0|65-73|ephedrine|drug
DDI-DrugBank.d4.s0|74-74|,|O
DDI-DrugBank.d4.s0|76-78|and|O
DDI-DrugBank.d4.s0|80-84|other|O
DDI-DrugBank.d4.s0|86-116|sympathomimetic bronchodilators|group
DDI-DrugBank.d4.s0|118-120|has|O
DDI-DrugBank.d4.s0|122-125|been|O
DDI-DrugBank.d4.s0|127-134|reported|O
DDI-DrugBank.d4.s0|135-135|.|O
DDI-DrugBank.d4.s1|0-3|This|O
DDI-DrugBank.d4.s1|5-10|should|O
DDI-DrugBank.d4.s1|12-13|be|O
DDI-DrugBank.d4.s1|15-24|considered|O
DDI-DrugBank.d4.s1|26-33|whenever|O
DDI-DrugBank.d4.s1|35-39|these|O
DDI-DrugBank.d4.s1|41-46|agents|O
DDI-DrugBank.d4.s1|48-50|are|O
DDI-DrugBank.d4.s1|52-61|prescribed|O
DDI-DrugBank.d4.s1|63-75|concomitantly|O
DDI-DrugBank.d4.s1|76-76|.|O
DDI-DrugBank.d4.s2|0-9|Concurrent|O
DDI-DrugBank.d4.s2|11-24|administration|O
DDI-DrugBank.d4.s2|26-27|of|O
DDI-DrugBank.d4.s2|29-38|dyphylline|drug
DDI-DrugBank.d4.s2|40-42|and|O
DDI-DrugBank.d4.s2|44-53|probenecid|drug
DDI-DrugBank.d4.s2|54-54|,|O
DDI-DrugBank.d4.s2|56-60|which|O
DDI-DrugBank.d4.s2|62-69|competes|O
DDI-DrugBank.d4.s2|71-73|for|O
DDI-DrugBank.d4.s2|75-81|tubular|O
DDI-DrugBank.d4.s2|83-91|secretion|O
DDI-DrugBank.d4.s2|92-92|,|O
DDI-DrugBank.d4.s2|94-96|has|O
DDI-DrugBank.d4.s2|98-101|been|O
DDI-DrugBank.d4.s2|103-107|shown|O
DDI-DrugBank.d4.s2|109-110|to|O
DDI-DrugBank.d4.s2|112-119|increase|O
DDI-DrugBank.d4.s2|121-123|the|O
DDI-DrugBank.d4.s2|125-130|plasma|O
DDI-DrugBank.d4.s2|132-140|half-life|O
DDI-DrugBank.d4.s2|142-143|of|O
DDI-DrugBank.d4.s2|145-154|dyphylline|drug
DDI-DrugBank.d4.s2|156-156|.|O
DDI-DrugBank.d7.s0|0-2|The|O
DDI-DrugBank.d7.s0|4-7|rate|O
DDI-DrugBank.d7.s0|9-10|of|O
DDI-DrugBank.d7.s0|12-21|metabolism|O
DDI-DrugBank.d7.s0|23-25|and|O
DDI-DrugBank.d7.s0|27-29|the|O
DDI-DrugBank.d7.s0|31-40|leukopenic|O
DDI-DrugBank.d7.s0|42-49|activity|O
DDI-DrugBank.d7.s0|51-52|of|O
DDI-DrugBank.d7.s0|54-69|cyclophosphamide|drug
DDI-DrugBank.d7.s0|71-80|reportedly|O
DDI-DrugBank.d7.s0|82-84|are|O
DDI-DrugBank.d7.s0|86-94|increased|O
DDI-DrugBank.d7.s0|96-97|by|O
DDI-DrugBank.d7.s0|99-105|chronic|O
DDI-DrugBank.d7.s0|107-120|administration|O
DDI-DrugBank.d7.s0|122-123|of|O
DDI-DrugBank.d7.s0|125-128|high|O
DDI-DrugBank.d7.s0|130-134|doses|O
DDI-DrugBank.d7.s0|136-137|of|O
DDI-DrugBank.d7.s0|139-151|phenobarbital|drug
DDI-DrugBank.d7.s0|152-152|.|O
DDI-DrugBank.d7.s1|0-2|The|O
DDI-DrugBank.d7.s1|4-12|physician|O
DDI-DrugBank.d7.s1|14-19|should|O
DDI-DrugBank.d7.s1|21-22|be|O
DDI-DrugBank.d7.s1|24-28|alert|O
DDI-DrugBank.d7.s1|30-32|for|O
DDI-DrugBank.d7.s1|34-41|possible|O
DDI-DrugBank.d7.s1|43-50|combined|O
DDI-DrugBank.d7.s1|52-55|drug|O
DDI-DrugBank.d7.s1|57-63|actions|O
DDI-DrugBank.d7.s1|64-64|,|O
DDI-DrugBank.d7.s1|66-74|desirable|O
DDI-DrugBank.d7.s1|76-77|or|O
DDI-DrugBank.d7.s1|79-89|undesirable|O
DDI-DrugBank.d7.s1|90-90|,|O
DDI-DrugBank.d7.s1|92-100|involving|O
DDI-DrugBank.d7.s1|102-117|cyclophosphamide|drug
DDI-DrugBank.d7.s1|119-122|even|O
DDI-DrugBank.d7.s1|124-129|though|O
DDI-DrugBank.d7.s1|131-146|cyclophosphamide|drug
DDI-DrugBank.d7.s1|148-150|has|O
DDI-DrugBank.d7.s1|152-155|been|O
DDI-DrugBank.d7.s1|157-160|used|O
DDI-DrugBank.d7.s1|162-173|successfully|O
DDI-DrugBank.d7.s1|175-186|concurrently|O
DDI-DrugBank.d7.s1|188-191|with|O
DDI-DrugBank.d7.s1|193-197|other|O
DDI-DrugBank.d7.s1|199-203|drugs|O
DDI-DrugBank.d7.s1|204-204|,|O
DDI-DrugBank.d7.s1|206-214|including|O
DDI-DrugBank.d7.s1|216-220|other|O
DDI-DrugBank.d7.s1|222-230|cytotoxic|O
DDI-DrugBank.d7.s1|232-236|drugs|O
DDI-DrugBank.d7.s1|237-237|.|O
DDI-DrugBank.d7.s2|0-15|Cyclophosphamide|drug
DDI-DrugBank.d7.s2|17-25|treatment|O
DDI-DrugBank.d7.s2|26-26|,|O
DDI-DrugBank.d7.s2|28-32|which|O
DDI-DrugBank.d7.s2|34-39|causes|O
DDI-DrugBank.d7.s2|41-41|a|O
DDI-DrugBank.d7.s2|43-48|marked|O
DDI-DrugBank.d7.s2|50-52|and|O
DDI-DrugBank.d7.s2|54-63|persistent|O
DDI-DrugBank.d7.s2|65-74|inhibition|O
DDI-DrugBank.d7.s2|76-77|of|O
DDI-DrugBank.d7.s2|79-92|cholinesterase|O
DDI-DrugBank.d7.s2|94-101|activity|O
DDI-DrugBank.d7.s2|102-102|,|O
DDI-DrugBank.d7.s2|104-114|potentiates|O
DDI-DrugBank.d7.s2|116-118|the|O
DDI-DrugBank.d7.s2|120-125|effect|O
DDI-DrugBank.d7.s2|127-128|of|O
DDI-DrugBank.d7.s2|130-153|succinylcholine chloride|drug
DDI-DrugBank.d7.s2|154-154|.|O
DDI-DrugBank.d7.s3|0-1|If|O
DDI-DrugBank.d7.s3|3-3|a|O
DDI-DrugBank.d7.s3|5-11|patient|O
DDI-DrugBank.d7.s3|13-15|has|O
DDI-DrugBank.d7.s3|17-20|been|O
DDI-DrugBank.d7.s3|22-28|treated|O
DDI-DrugBank.d7.s3|30-33|with|O
DDI-DrugBank.d7.s3|35-50|cyclophosphamide|drug
DDI-DrugBank.d7.s3|52-57|within|O
DDI-DrugBank.d7.s3|59-60|10|O
DDI-DrugBank.d7.s3|62-65|days|O
DDI-DrugBank.d7.s3|67-68|of|O
DDI-DrugBank.d7.s3|70-76|general|O
DDI-DrugBank.d7.s3|78-87|anesthesia|O
DDI-DrugBank.d7.s3|88-88|,|O
DDI-DrugBank.d7.s3|90-92|the|O
DDI-DrugBank.d7.s3|94-109|anesthesiologist|O
DDI-DrugBank.d7.s3|111-116|should|O
DDI-DrugBank.d7.s3|118-119|be|O
DDI-DrugBank.d7.s3|121-127|alerted|O
DDI-DrugBank.d7.s3|128-128|.|O
DDI-DrugBank.d360.s0|0-6|Reduced|O
DDI-DrugBank.d360.s0|8-15|efficacy|O
DDI-DrugBank.d360.s0|17-19|and|O
DDI-DrugBank.d360.s0|21-29|increased|O
DDI-DrugBank.d360.s0|31-39|incidence|O
DDI-DrugBank.d360.s0|41-42|of|O
DDI-DrugBank.d360.s0|44-55|breakthrough|O
DDI-DrugBank.d360.s0|57-64|bleeding|O
DDI-DrugBank.d360.s0|66-68|and|O
DDI-DrugBank.d360.s0|70-78|menstrual|O
DDI-DrugBank.d360.s0|80-93|irregularities|O
DDI-DrugBank.d360.s0|95-98|have|O
DDI-DrugBank.d360.s0|100-103|been|O
DDI-DrugBank.d360.s0|105-114|associated|O
DDI-DrugBank.d360.s0|116-119|with|O
DDI-DrugBank.d360.s0|121-131|concomitant|O
DDI-DrugBank.d360.s0|133-135|use|O
DDI-DrugBank.d360.s0|137-138|of|O
DDI-DrugBank.d360.s0|140-147|rifampin|drug
DDI-DrugBank.d360.s0|148-148|.|O
DDI-DrugBank.d360.s1|0-0|A|O
DDI-DrugBank.d360.s1|2-8|similar|O
DDI-DrugBank.d360.s1|10-20|association|O
DDI-DrugBank.d360.s1|21-21|,|O
DDI-DrugBank.d360.s1|23-28|though|O
DDI-DrugBank.d360.s1|30-33|less|O
DDI-DrugBank.d360.s1|35-40|marked|O
DDI-DrugBank.d360.s1|41-41|,|O
DDI-DrugBank.d360.s1|43-45|has|O
DDI-DrugBank.d360.s1|47-50|been|O
DDI-DrugBank.d360.s1|52-60|suggested|O
DDI-DrugBank.d360.s1|62-65|with|O
DDI-DrugBank.d360.s1|67-78|barbiturates|group
DDI-DrugBank.d360.s1|79-79|,|O
DDI-DrugBank.d360.s1|81-94|phenylbutazone|drug
DDI-DrugBank.d360.s1|95-95|,|O
DDI-DrugBank.d360.s1|97-112|phenytoin sodium|drug
DDI-DrugBank.d360.s1|113-113|,|O
DDI-DrugBank.d360.s1|115-127|carbamazepine|drug
DDI-DrugBank.d360.s1|128-128|,|O
DDI-DrugBank.d360.s1|130-141|griseofulvin|drug
DDI-DrugBank.d360.s1|142-142|,|O
DDI-DrugBank.d360.s1|144-153|topiramate|drug
DDI-DrugBank.d360.s1|154-154|,|O
DDI-DrugBank.d360.s1|156-158|and|O
DDI-DrugBank.d360.s1|160-167|possibly|O
DDI-DrugBank.d360.s1|169-172|with|O
DDI-DrugBank.d360.s1|174-183|ampicillin|drug
DDI-DrugBank.d360.s1|185-187|and|O
DDI-DrugBank.d360.s1|189-201|tetracyclines|group
DDI-DrugBank.d360.s1|203-204|72|O
DDI-DrugBank.d360.s1|205-205|.|O
DDI-DrugBank.d360.s2|0-0|A|O
DDI-DrugBank.d360.s2|2-9|possible|O
DDI-DrugBank.d360.s2|11-21|interaction|O
DDI-DrugBank.d360.s2|23-25|has|O
DDI-DrugBank.d360.s2|27-30|been|O
DDI-DrugBank.d360.s2|32-40|suggested|O
DDI-DrugBank.d360.s2|42-45|with|O
DDI-DrugBank.d360.s2|47-69|hormonal contraceptives|group
DDI-DrugBank.d360.s2|71-73|and|O
DDI-DrugBank.d360.s2|75-77|the|O
DDI-DrugBank.d360.s2|79-84|herbal|O
DDI-DrugBank.d360.s2|86-95|supplement|O
DDI-DrugBank.d360.s2|97-99|St.|O
DDI-DrugBank.d360.s2|101-105|Johns|O
DDI-DrugBank.d360.s2|107-110|Wort|O
DDI-DrugBank.d360.s2|112-116|based|O
DDI-DrugBank.d360.s2|118-119|on|O
DDI-DrugBank.d360.s2|121-124|some|O
DDI-DrugBank.d360.s2|126-132|reports|O
DDI-DrugBank.d360.s2|134-135|of|O
DDI-DrugBank.d360.s2|137-140|oral|O
DDI-DrugBank.d360.s2|142-154|contraceptive|group
DDI-DrugBank.d360.s2|156-160|users|O
DDI-DrugBank.d360.s2|162-173|experiencing|O
DDI-DrugBank.d360.s2|175-186|breakthrough|O
DDI-DrugBank.d360.s2|188-195|bleeding|O
DDI-DrugBank.d360.s2|197-203|shortly|O
DDI-DrugBank.d360.s2|205-209|after|O
DDI-DrugBank.d360.s2|211-218|starting|O
DDI-DrugBank.d360.s2|220-222|St.|O
DDI-DrugBank.d360.s2|224-228|Johns|O
DDI-DrugBank.d360.s2|230-233|Wort|O
DDI-DrugBank.d360.s2|234-234|.|O
DDI-DrugBank.d360.s3|0-10|Pregnancies|O
DDI-DrugBank.d360.s3|12-15|have|O
DDI-DrugBank.d360.s3|17-20|been|O
DDI-DrugBank.d360.s3|22-29|reported|O
DDI-DrugBank.d360.s3|31-32|by|O
DDI-DrugBank.d360.s3|34-38|users|O
DDI-DrugBank.d360.s3|40-41|of|O
DDI-DrugBank.d360.s3|43-74|combined hormonal contraceptives|group
DDI-DrugBank.d360.s3|76-78|who|O
DDI-DrugBank.d360.s3|80-83|also|O
DDI-DrugBank.d360.s3|85-88|used|O
DDI-DrugBank.d360.s3|90-93|some|O
DDI-DrugBank.d360.s3|95-98|form|O
DDI-DrugBank.d360.s3|100-101|of|O
DDI-DrugBank.d360.s3|103-105|St.|O
DDI-DrugBank.d360.s3|107-111|Johns|O
DDI-DrugBank.d360.s3|113-116|Wort|O
DDI-DrugBank.d360.s3|117-117|.|O
DDI-DrugBank.d360.s4|0-9|Healthcare|O
DDI-DrugBank.d360.s4|11-21|prescribers|O
DDI-DrugBank.d360.s4|23-25|are|O
DDI-DrugBank.d360.s4|27-33|advised|O
DDI-DrugBank.d360.s4|35-36|to|O
DDI-DrugBank.d360.s4|38-44|consult|O
DDI-DrugBank.d360.s4|46-48|the|O
DDI-DrugBank.d360.s4|50-56|package|O
DDI-DrugBank.d360.s4|58-64|inserts|O
DDI-DrugBank.d360.s4|66-67|of|O
DDI-DrugBank.d360.s4|69-78|medication|O
DDI-DrugBank.d360.s4|80-91|administered|O
DDI-DrugBank.d360.s4|93-105|concomitantly|O
DDI-DrugBank.d360.s4|107-110|with|O
DDI-DrugBank.d360.s4|112-115|oral|O
DDI-DrugBank.d360.s4|117-130|contraceptives|group
DDI-DrugBank.d360.s4|131-131|.|O
DDI-DrugBank.d505.s0|0-1|No|O
DDI-DrugBank.d505.s0|3-17|pharmacokinetic|O
DDI-DrugBank.d505.s0|19-27|drug-drug|O
DDI-DrugBank.d505.s0|29-39|interaction|O
DDI-DrugBank.d505.s0|41-47|studies|O
DDI-DrugBank.d505.s0|49-52|were|O
DDI-DrugBank.d505.s0|54-62|conducted|O
DDI-DrugBank.d505.s0|64-67|with|O
DDI-DrugBank.d505.s0|69-78|PERSANTINE|brand
DDI-DrugBank.d505.s0|81-81|(|O
DDI-DrugBank.d505.s0|82-93|dipyridamole|drug
DDI-DrugBank.d505.s0|95-97|USP|O
DDI-DrugBank.d505.s0|98-98|)|O
DDI-DrugBank.d505.s0|100-106|Tablets|O
DDI-DrugBank.d505.s0|107-107|.|O
DDI-DrugBank.d505.s1|0-2|The|O
DDI-DrugBank.d505.s1|4-12|following|O
DDI-DrugBank.d505.s1|14-24|information|O
DDI-DrugBank.d505.s1|26-28|was|O
DDI-DrugBank.d505.s1|30-37|obtained|O
DDI-DrugBank.d505.s1|39-42|from|O
DDI-DrugBank.d505.s1|44-46|the|O
DDI-DrugBank.d505.s1|48-57|literature|O
DDI-DrugBank.d505.s1|58-58|.|O
DDI-DrugBank.d505.s2|0-8|Adenosine|drug
DDI-DrugBank.d505.s2|9-9|:|O
DDI-DrugBank.d505.s2|11-22|Dipyridamole|drug
DDI-DrugBank.d505.s2|24-26|has|O
DDI-DrugBank.d505.s2|28-31|been|O
DDI-DrugBank.d505.s2|33-40|reported|O
DDI-DrugBank.d505.s2|42-43|to|O
DDI-DrugBank.d505.s2|45-52|increase|O
DDI-DrugBank.d505.s2|54-56|the|O
DDI-DrugBank.d505.s2|58-63|plasma|O
DDI-DrugBank.d505.s2|65-70|levels|O
DDI-DrugBank.d505.s2|72-74|and|O
DDI-DrugBank.d505.s2|76-89|cardiovascular|O
DDI-DrugBank.d505.s2|91-97|effects|O
DDI-DrugBank.d505.s2|99-100|of|O
DDI-DrugBank.d505.s2|102-110|adenosine|drug
DDI-DrugBank.d505.s2|111-111|.|O
DDI-DrugBank.d505.s3|0-9|Adjustment|O
DDI-DrugBank.d505.s3|11-12|of|O
DDI-DrugBank.d505.s3|14-22|adenosine|drug
DDI-DrugBank.d505.s3|24-29|dosage|O
DDI-DrugBank.d505.s3|31-33|may|O
DDI-DrugBank.d505.s3|35-36|be|O
DDI-DrugBank.d505.s3|38-46|necessary|O
DDI-DrugBank.d505.s3|47-47|.|O
DDI-DrugBank.d505.s4|0-24|Cholinesterase Inhibitors|group
DDI-DrugBank.d505.s4|25-25|:|O
DDI-DrugBank.d505.s4|27-38|Dipyridamole|drug
DDI-DrugBank.d505.s4|40-42|may|O
DDI-DrugBank.d505.s4|44-53|counteract|O
DDI-DrugBank.d505.s4|55-57|the|O
DDI-DrugBank.d505.s4|59-76|anticholinesterase|O
DDI-DrugBank.d505.s4|78-83|effect|O
DDI-DrugBank.d505.s4|85-86|of|O
DDI-DrugBank.d505.s4|88-112|cholinesterase inhibitors|group
DDI-DrugBank.d505.s4|113-113|,|O
DDI-DrugBank.d505.s4|115-121|thereby|O
DDI-DrugBank.d505.s4|123-133|potentially|O
DDI-DrugBank.d505.s4|135-145|aggravating|O
DDI-DrugBank.d505.s4|147-156|myasthenia|O
DDI-DrugBank.d505.s4|158-163|gravis|O
DDI-DrugBank.d505.s4|164-164|.|O
DDI-DrugBank.d375.s0|0-2|The|O
DDI-DrugBank.d375.s0|4-12|potential|O
DDI-DrugBank.d375.s0|14-16|for|O
DDI-DrugBank.d375.s0|18-21|drug|O
DDI-DrugBank.d375.s0|23-34|interactions|O
DDI-DrugBank.d375.s0|36-39|with|O
DDI-DrugBank.d375.s0|41-47|EMTRIVA|brand
DDI-DrugBank.d375.s0|49-51|has|O
DDI-DrugBank.d375.s0|53-56|been|O
DDI-DrugBank.d375.s0|58-64|studied|O
DDI-DrugBank.d375.s0|66-67|in|O
DDI-DrugBank.d375.s0|69-79|combination|O
DDI-DrugBank.d375.s0|81-84|with|O
DDI-DrugBank.d375.s0|86-94|indinavir|drug
DDI-DrugBank.d375.s0|95-95|,|O
DDI-DrugBank.d375.s0|97-105|stavudine|drug
DDI-DrugBank.d375.s0|106-106|,|O
DDI-DrugBank.d375.s0|108-118|famciclovir|drug
DDI-DrugBank.d375.s0|119-119|,|O
DDI-DrugBank.d375.s0|121-123|and|O
DDI-DrugBank.d375.s0|125-153|tenofovir disoproxil fumarate|drug
DDI-DrugBank.d375.s0|154-154|.|O
DDI-DrugBank.d375.s1|0-4|There|O
DDI-DrugBank.d375.s1|6-9|were|O
DDI-DrugBank.d375.s1|11-12|no|O
DDI-DrugBank.d375.s1|14-23|clinically|O
DDI-DrugBank.d375.s1|25-35|significant|O
DDI-DrugBank.d375.s1|37-40|drug|O
DDI-DrugBank.d375.s1|42-53|interactions|O
DDI-DrugBank.d375.s1|55-57|for|O
DDI-DrugBank.d375.s1|59-61|any|O
DDI-DrugBank.d375.s1|63-64|of|O
DDI-DrugBank.d375.s1|66-70|these|O
DDI-DrugBank.d375.s1|72-76|drugs|O
DDI-DrugBank.d375.s2|0-0|.|O
DDI-MedLine.d106.s0|0-7|Clinical|O
DDI-MedLine.d106.s0|9-20|implications|O
DDI-MedLine.d106.s0|22-23|of|O
DDI-MedLine.d106.s0|25-32|warfarin|drug
DDI-MedLine.d106.s0|34-45|interactions|O
DDI-MedLine.d106.s0|47-50|with|O
DDI-MedLine.d106.s0|52-55|five|O
DDI-MedLine.d106.s0|57-65|sedatives|group
DDI-MedLine.d106.s0|66-66|.|O
DDI-MedLine.d106.s1|0-2|The|O
DDI-MedLine.d106.s1|4-12|intensity|O
DDI-MedLine.d106.s1|13-13|,|O
DDI-MedLine.d106.s1|15-24|uniformity|O
DDI-MedLine.d106.s1|26-28|and|O
DDI-MedLine.d106.s1|30-33|time|O
DDI-MedLine.d106.s1|35-40|course|O
DDI-MedLine.d106.s1|42-43|of|O
DDI-MedLine.d106.s1|45-57|anticoagulant|group
DDI-MedLine.d106.s1|59-70|interference|O
DDI-MedLine.d106.s1|72-73|by|O
DDI-MedLine.d106.s1|75-87|phenobarbital|drug
DDI-MedLine.d106.s1|88-88|,|O
DDI-MedLine.d106.s1|90-101|secobarbital|drug
DDI-MedLine.d106.s1|102-102|,|O
DDI-MedLine.d106.s1|104-115|glutethimide|drug
DDI-MedLine.d106.s1|116-116|,|O
DDI-MedLine.d106.s1|118-132|chloral hydrate|drug
DDI-MedLine.d106.s1|134-136|and|O
DDI-MedLine.d106.s1|138-149|methaqualone|drug
DDI-MedLine.d106.s1|151-154|were|O
DDI-MedLine.d106.s1|156-169|systematically|O
DDI-MedLine.d106.s1|171-182|investigated|O
DDI-MedLine.d106.s1|184-185|in|O
DDI-MedLine.d106.s1|187-188|16|O
DDI-MedLine.d106.s1|190-197|patients|O
DDI-MedLine.d106.s1|199-207|receiving|O
DDI-MedLine.d106.s1|209-216|coumarin|group
DDI-MedLine.d106.s1|218-224|therapy|O
DDI-MedLine.d106.s1|225-225|.|O
DDI-MedLine.d106.s2|0-3|Each|O
DDI-MedLine.d106.s2|5-11|subject|O
DDI-MedLine.d106.s2|13-20|received|O
DDI-MedLine.d106.s2|22-23|an|O
DDI-MedLine.d106.s2|25-38|individualized|O
DDI-MedLine.d106.s2|40-44|fixed|O
DDI-MedLine.d106.s2|46-50|daily|O
DDI-MedLine.d106.s2|52-55|dose|O
DDI-MedLine.d106.s2|57-58|of|O
DDI-MedLine.d106.s2|60-67|warfarin|drug
DDI-MedLine.d106.s2|69-71|and|O
DDI-MedLine.d106.s2|73-78|served|O
DDI-MedLine.d106.s2|80-81|as|O
DDI-MedLine.d106.s2|83-85|his|O
DDI-MedLine.d106.s2|87-89|own|O
DDI-MedLine.d106.s2|91-94|pre-|O
DDI-MedLine.d106.s2|96-98|and|O
DDI-MedLine.d106.s2|100-111|postsedative|O
DDI-MedLine.d106.s2|113-121|treatment|O
DDI-MedLine.d106.s2|123-129|control|O
DDI-MedLine.d106.s2|130-130|.|O
DDI-MedLine.d106.s3|0-10|Prothrombin|O
DDI-MedLine.d106.s3|12-16|times|O
DDI-MedLine.d106.s3|18-21|were|O
DDI-MedLine.d106.s3|23-30|measured|O
DDI-MedLine.d106.s3|32-35|four|O
DDI-MedLine.d106.s3|37-41|times|O
DDI-MedLine.d106.s3|43-48|weekly|O
DDI-MedLine.d106.s3|50-55|during|O
DDI-MedLine.d106.s3|57-60|five|O
DDI-MedLine.d106.s3|62-70|long-term|O
DDI-MedLine.d106.s3|72-82|experiments|O
DDI-MedLine.d106.s3|83-83|.|O
DDI-MedLine.d106.s4|0-12|Anticoagulant|O
DDI-MedLine.d106.s4|14-23|inhibition|O
DDI-MedLine.d106.s4|25-27|was|O
DDI-MedLine.d106.s4|29-36|observed|O
DDI-MedLine.d106.s4|38-43|during|O
DDI-MedLine.d106.s4|45-47|the|O
DDI-MedLine.d106.s4|49-62|administration|O
DDI-MedLine.d106.s4|64-65|of|O
DDI-MedLine.d106.s4|67-79|phenobarbital|drug
DDI-MedLine.d106.s4|80-80|,|O
DDI-MedLine.d106.s4|82-93|secobarbital|drug
DDI-MedLine.d106.s4|95-97|and|O
DDI-MedLine.d106.s4|99-110|glutethimide|drug
DDI-MedLine.d106.s4|111-111|;|O
DDI-MedLine.d106.s5|0-4|there|O
DDI-MedLine.d106.s5|6-8|was|O
DDI-MedLine.d106.s5|10-11|no|O
DDI-MedLine.d106.s5|13-23|significant|O
DDI-MedLine.d106.s5|25-30|change|O
DDI-MedLine.d106.s5|32-33|in|O
DDI-MedLine.d106.s5|35-45|prothrombin|O
DDI-MedLine.d106.s5|47-50|test|O
DDI-MedLine.d106.s5|52-58|results|O
DDI-MedLine.d106.s5|60-65|during|O
DDI-MedLine.d106.s5|67-69|the|O
DDI-MedLine.d106.s5|71-76|trials|O
DDI-MedLine.d106.s5|78-79|of|O
DDI-MedLine.d106.s5|81-95|chloral hydrate|drug
DDI-MedLine.d106.s5|97-99|and|O
DDI-MedLine.d106.s5|101-112|methaqualone|drug
DDI-MedLine.d106.s5|113-113|.|O
DDI-MedLine.d106.s6|0-11|Barbiturates|group
DDI-MedLine.d106.s6|13-15|and|O
DDI-MedLine.d106.s6|17-28|glutethimide|drug
DDI-MedLine.d106.s6|30-35|should|O
DDI-MedLine.d106.s6|37-39|not|O
DDI-MedLine.d106.s6|41-42|be|O
DDI-MedLine.d106.s6|44-55|administered|O
DDI-MedLine.d106.s6|57-58|to|O
DDI-MedLine.d106.s6|60-67|patients|O
DDI-MedLine.d106.s6|69-77|receiving|O
DDI-MedLine.d106.s6|79-92|coumarin drugs|group
DDI-MedLine.d106.s6|93-93|.|O
DDI-MedLine.d106.s7|0-2|The|O
DDI-MedLine.d106.s7|4-13|concurrent|O
DDI-MedLine.d106.s7|15-17|use|O
DDI-MedLine.d106.s7|19-20|of|O
DDI-MedLine.d106.s7|22-26|drugs|O
DDI-MedLine.d106.s7|28-31|from|O
DDI-MedLine.d106.s7|33-37|these|O
DDI-MedLine.d106.s7|39-44|groups|O
DDI-MedLine.d106.s7|46-47|is|O
DDI-MedLine.d106.s7|49-58|decreasing|O
DDI-MedLine.d106.s7|60-68|according|O
DDI-MedLine.d106.s7|70-71|to|O
DDI-MedLine.d106.s7|73-73|a|O
DDI-MedLine.d106.s7|75-80|survey|O
DDI-MedLine.d106.s7|82-83|of|O
DDI-MedLine.d106.s7|85-87|200|O
DDI-MedLine.d106.s7|89-96|hospital|O
DDI-MedLine.d106.s7|98-104|medical|O
DDI-MedLine.d106.s7|106-112|records|O
DDI-MedLine.d106.s7|113-113|.|O
DDI-MedLine.d106.s8|0-14|Chloral hydrate|drug
DDI-MedLine.d106.s8|16-18|and|O
DDI-MedLine.d106.s8|20-31|methaqualone|drug
DDI-MedLine.d106.s8|33-40|interact|O
DDI-MedLine.d106.s8|42-58|pharmacologically|O
DDI-MedLine.d106.s8|60-63|with|O
DDI-MedLine.d106.s8|65-70|orally|O
DDI-MedLine.d106.s8|72-83|administered|O
DDI-MedLine.d106.s8|85-104|anticoagulant agents|group
DDI-MedLine.d106.s8|105-105|,|O
DDI-MedLine.d106.s8|107-109|but|O
DDI-MedLine.d106.s8|111-113|the|O
DDI-MedLine.d106.s8|115-120|effect|O
DDI-MedLine.d106.s8|122-123|is|O
DDI-MedLine.d106.s8|125-127|not|O
DDI-MedLine.d106.s8|129-138|clinically|O
DDI-MedLine.d106.s8|140-150|significant|O
DDI-MedLine.d106.s8|151-151|.|O
DDI-MedLine.d106.s9|0-1|It|O
DDI-MedLine.d106.s9|3-4|is|O
DDI-MedLine.d106.s9|6-14|concluded|O
DDI-MedLine.d106.s9|16-19|that|O
DDI-MedLine.d106.s9|21-35|chloral hydrate|drug
DDI-MedLine.d106.s9|37-39|and|O
DDI-MedLine.d106.s9|41-52|methaqualone|drug
DDI-MedLine.d106.s9|54-56|may|O
DDI-MedLine.d106.s9|58-59|be|O
DDI-MedLine.d106.s9|61-72|administered|O
DDI-MedLine.d106.s9|74-79|safely|O
DDI-MedLine.d106.s9|81-87|without|O
DDI-MedLine.d106.s9|89-98|additional|O
DDI-MedLine.d106.s9|100-106|caution|O
DDI-MedLine.d106.s9|108-109|in|O
DDI-MedLine.d106.s9|111-121|prothrombin|O
DDI-MedLine.d106.s9|123-126|test|O
DDI-MedLine.d106.s9|128-137|monitoring|O
DDI-MedLine.d106.s9|139-144|during|O
DDI-MedLine.d106.s9|146-149|oral|O
DDI-MedLine.d106.s9|151-163|anticoagulant|group
DDI-MedLine.d106.s9|165-171|therapy|O
DDI-MedLine.d106.s9|172-172|.|O
DDI-MedLine.d125.s0|0-2|The|O
DDI-MedLine.d125.s0|4-7|mode|O
DDI-MedLine.d125.s0|9-10|of|O
DDI-MedLine.d125.s0|12-16|toxic|O
DDI-MedLine.d125.s0|18-23|action|O
DDI-MedLine.d125.s0|25-26|of|O
DDI-MedLine.d125.s0|28-30|the|O
DDI-MedLine.d125.s0|32-40|pesticide|O
DDI-MedLine.d125.s0|49-49|:|O
DDI-MedLine.d125.s0|51-53|the|O
DDI-MedLine.d125.s0|55-64|metabolism|O
DDI-MedLine.d125.s0|66-67|of|O
DDI-MedLine.d125.s0|89-90|to|O
DDI-MedLine.d125.s0|117-117|.|O
DDI-MedLine.d125.s1|0-2|The|O
DDI-MedLine.d125.s1|4-14|biochemical|O
DDI-MedLine.d125.s1|16-25|toxicology|O
DDI-MedLine.d125.s1|27-28|of|O
DDI-MedLine.d125.s1|49-49|,|O
DDI-MedLine.d125.s1|51-51|a|O
DDI-MedLine.d125.s1|53-57|known|O
DDI-MedLine.d125.s1|59-68|metabolite|O
DDI-MedLine.d125.s1|70-71|of|O
DDI-MedLine.d125.s1|73-75|the|O
DDI-MedLine.d125.s1|77-81|major|O
DDI-MedLine.d125.s1|83-92|ingredient|O
DDI-MedLine.d125.s1|94-95|of|O
DDI-MedLine.d125.s1|97-99|the|O
DDI-MedLine.d125.s1|101-109|pesticide|O
DDI-MedLine.d125.s1|119-119|(|O
DDI-MedLine.d125.s1|143-143|)|O
DDI-MedLine.d125.s1|144-144|,|O
DDI-MedLine.d125.s1|146-148|was|O
DDI-MedLine.d125.s1|150-161|investigated|O
DDI-MedLine.d125.s1|163-164|in|O
DDI-MedLine.d125.s1|166-169|vivo|O
DDI-MedLine.d125.s1|171-173|and|O
DDI-MedLine.d125.s1|175-176|in|O
DDI-MedLine.d125.s1|178-182|vitro|O
DDI-MedLine.d125.s1|183-183|.|O
DDI-MedLine.d125.s2|0-2|Rat|O
DDI-MedLine.d125.s2|4-9|kidney|O
DDI-MedLine.d125.s2|11-21|homogenates|O
DDI-MedLine.d125.s2|23-34|supplemented|O
DDI-MedLine.d125.s2|36-39|with|O
DDI-MedLine.d125.s2|41-48|coenzyme|O
DDI-MedLine.d125.s2|50-50|A|O
DDI-MedLine.d125.s2|51-51|,|O
DDI-MedLine.d125.s2|53-55|ATP|O
DDI-MedLine.d125.s2|56-56|,|O
DDI-MedLine.d125.s2|58-69|oxaloacetate|O
DDI-MedLine.d125.s2|70-70|,|O
DDI-MedLine.d125.s2|72-74|and|O
DDI-MedLine.d125.s2|76-79|Mg2+|O
DDI-MedLine.d125.s2|81-89|converted|O
DDI-MedLine.d125.s2|111-112|to|O
DDI-MedLine.d125.s2|140-141|in|O
DDI-MedLine.d125.s2|143-147|vitro|O
DDI-MedLine.d125.s2|148-148|.|O
DDI-MedLine.d125.s3|0-13|Administration|O
DDI-MedLine.d125.s3|15-16|of|O
DDI-MedLine.d125.s3|38-38|(|O
DDI-MedLine.d125.s3|39-41|100|O
DDI-MedLine.d125.s3|43-44|mg|O
DDI-MedLine.d125.s3|46-47|kg|O
DDI-MedLine.d125.s3|48-48|(|O
DDI-MedLine.d125.s3|49-50|-1|O
DDI-MedLine.d125.s3|51-51|)|O
DDI-MedLine.d125.s3|53-56|body|O
DDI-MedLine.d125.s3|58-63|weight|O
DDI-MedLine.d125.s3|64-64|)|O
DDI-MedLine.d125.s3|66-67|to|O
DDI-MedLine.d125.s3|69-72|rats|O
DDI-MedLine.d125.s3|74-75|in|O
DDI-MedLine.d125.s3|77-80|vivo|O
DDI-MedLine.d125.s3|82-89|resulted|O
DDI-MedLine.d125.s3|91-92|in|O
DDI-MedLine.d125.s3|120-128|synthesis|O
DDI-MedLine.d125.s3|130-131|in|O
DDI-MedLine.d125.s3|133-135|the|O
DDI-MedLine.d125.s3|137-142|kidney|O
DDI-MedLine.d125.s3|143-143|,|O
DDI-MedLine.d125.s3|145-149|which|O
DDI-MedLine.d125.s3|151-153|was|O
DDI-MedLine.d125.s3|155-162|preceded|O
DDI-MedLine.d125.s3|164-165|by|O
DDI-MedLine.d125.s3|167-168|an|O
DDI-MedLine.d125.s3|170-178|elevation|O
DDI-MedLine.d125.s3|180-181|in|O
DDI-MedLine.d125.s3|183-190|fluoride|O
DDI-MedLine.d125.s3|192-197|levels|O
DDI-MedLine.d125.s3|199-201|and|O
DDI-MedLine.d125.s3|203-210|followed|O
DDI-MedLine.d125.s3|212-213|by|O
DDI-MedLine.d125.s3|215-221|citrate|O
DDI-MedLine.d125.s3|223-234|accumulation|O
DDI-MedLine.d125.s3|235-235|.|O
DDI-MedLine.d125.s4|0-6|Animals|O
DDI-MedLine.d125.s4|8-12|dosed|O
DDI-MedLine.d125.s4|14-17|with|O
DDI-MedLine.d125.s4|39-41|did|O
DDI-MedLine.d125.s4|43-45|not|O
DDI-MedLine.d125.s4|47-53|display|O
DDI-MedLine.d125.s4|55-57|the|O
DDI-MedLine.d125.s4|59-61|2-3|O
DDI-MedLine.d125.s4|63-66|hour|O
DDI-MedLine.d125.s4|68-70|lag|O
DDI-MedLine.d125.s4|72-76|phase|O
DDI-MedLine.d125.s4|78-79|in|O
DDI-MedLine.d125.s4|81-86|either|O
DDI-MedLine.d125.s4|114-122|synthesis|O
DDI-MedLine.d125.s4|124-125|or|O
DDI-MedLine.d125.s4|127-128|in|O
DDI-MedLine.d125.s4|130-136|citrate|O
DDI-MedLine.d125.s4|138-140|and|O
DDI-MedLine.d125.s4|142-149|fluoride|O
DDI-MedLine.d125.s4|151-162|accumulation|O
DDI-MedLine.d125.s4|164-177|characteristic|O
DDI-MedLine.d125.s4|179-180|of|O
DDI-MedLine.d125.s4|182-188|animals|O
DDI-MedLine.d125.s4|190-194|dosed|O
DDI-MedLine.d125.s4|196-199|with|O
DDI-MedLine.d125.s4|224-224|.|O
DDI-MedLine.d125.s5|0-1|We|O
DDI-MedLine.d125.s5|3-13|demonstrate|O
DDI-MedLine.d125.s5|15-18|that|O
DDI-MedLine.d125.s5|20-22|the|O
DDI-MedLine.d125.s5|24-33|conversion|O
DDI-MedLine.d125.s5|35-36|of|O
DDI-MedLine.d125.s5|62-63|to|O
DDI-MedLine.d125.s5|85-86|by|O
DDI-MedLine.d125.s5|88-89|an|O
DDI-MedLine.d125.s5|91-104|NAD+-dependent|O
DDI-MedLine.d125.s5|106-114|oxidation|O
DDI-MedLine.d125.s5|116-117|is|O
DDI-MedLine.d125.s5|119-121|the|O
DDI-MedLine.d125.s5|123-135|rate-limiting|O
DDI-MedLine.d125.s5|137-140|step|O
DDI-MedLine.d125.s5|142-143|in|O
DDI-MedLine.d125.s5|145-147|the|O
DDI-MedLine.d125.s5|149-157|synthesis|O
DDI-MedLine.d125.s5|159-160|of|O
DDI-MedLine.d125.s5|162-164|the|O
DDI-MedLine.d125.s5|166-170|toxic|O
DDI-MedLine.d125.s5|172-178|product|O
DDI-MedLine.d125.s5|179-179|,|O
DDI-MedLine.d125.s5|207-210|from|O
DDI-MedLine.d125.s5|235-235|.|O
DDI-MedLine.d125.s6|0-4|Prior|O
DDI-MedLine.d125.s6|6-19|administration|O
DDI-MedLine.d125.s6|21-22|of|O
DDI-MedLine.d125.s6|24-39|4-methylpyrazole|drug
DDI-MedLine.d125.s6|41-41|(|O
DDI-MedLine.d125.s6|42-43|90|O
DDI-MedLine.d125.s6|45-46|mg|O
DDI-MedLine.d125.s6|48-49|kg|O
DDI-MedLine.d125.s6|50-50|(|O
DDI-MedLine.d125.s6|51-52|-1|O
DDI-MedLine.d125.s6|53-53|)|O
DDI-MedLine.d125.s6|55-58|body|O
DDI-MedLine.d125.s6|60-65|weight|O
DDI-MedLine.d125.s6|66-66|)|O
DDI-MedLine.d125.s6|68-70|was|O
DDI-MedLine.d125.s6|72-76|shown|O
DDI-MedLine.d125.s6|78-79|to|O
DDI-MedLine.d125.s6|81-87|prevent|O
DDI-MedLine.d125.s6|89-91|the|O
DDI-MedLine.d125.s6|93-102|conversion|O
DDI-MedLine.d125.s6|104-105|of|O
DDI-MedLine.d125.s6|131-131|(|O
DDI-MedLine.d125.s6|132-134|100|O
DDI-MedLine.d125.s6|136-137|mg|O
DDI-MedLine.d125.s6|139-140|kg|O
DDI-MedLine.d125.s6|141-141|(|O
DDI-MedLine.d125.s6|142-143|-1|O
DDI-MedLine.d125.s6|144-144|)|O
DDI-MedLine.d125.s6|146-149|body|O
DDI-MedLine.d125.s6|151-156|weight|O
DDI-MedLine.d125.s6|157-157|)|O
DDI-MedLine.d125.s6|159-160|to|O
DDI-MedLine.d125.s6|188-189|in|O
DDI-MedLine.d125.s6|191-194|vivo|O
DDI-MedLine.d125.s6|196-198|and|O
DDI-MedLine.d125.s6|200-201|to|O
DDI-MedLine.d125.s6|203-211|eliminate|O
DDI-MedLine.d125.s6|213-215|the|O
DDI-MedLine.d125.s6|217-224|fluoride|O
DDI-MedLine.d125.s6|226-228|and|O
DDI-MedLine.d125.s6|230-236|citrate|O
DDI-MedLine.d125.s6|238-247|elevations|O
DDI-MedLine.d125.s6|249-252|seen|O
DDI-MedLine.d125.s6|254-255|in|O
DDI-MedLine.d125.s6|293-299|animals|O
DDI-MedLine.d125.s6|300-300|.|O
DDI-MedLine.d125.s7|0-6|However|O
DDI-MedLine.d125.s7|7-7|,|O
DDI-MedLine.d125.s7|9-22|administration|O
DDI-MedLine.d125.s7|24-25|of|O
DDI-MedLine.d125.s7|27-42|4-methylpyrazole|drug
DDI-MedLine.d125.s7|44-44|(|O
DDI-MedLine.d125.s7|45-46|90|O
DDI-MedLine.d125.s7|48-49|mg|O
DDI-MedLine.d125.s7|51-52|kg|O
DDI-MedLine.d125.s7|53-53|(|O
DDI-MedLine.d125.s7|54-55|-1|O
DDI-MedLine.d125.s7|56-56|)|O
DDI-MedLine.d125.s7|58-61|body|O
DDI-MedLine.d125.s7|63-68|weight|O
DDI-MedLine.d125.s7|69-69|)|O
DDI-MedLine.d125.s7|71-72|to|O
DDI-MedLine.d125.s7|74-77|rats|O
DDI-MedLine.d125.s7|79-79|2|O
DDI-MedLine.d125.s7|81-85|hours|O
DDI-MedLine.d125.s7|87-91|prior|O
DDI-MedLine.d125.s7|93-94|to|O
DDI-MedLine.d125.s7|116-116|(|O
DDI-MedLine.d125.s7|117-119|100|O
DDI-MedLine.d125.s7|121-122|mg|O
DDI-MedLine.d125.s7|124-125|kg|O
DDI-MedLine.d125.s7|126-126|(|O
DDI-MedLine.d125.s7|127-128|-1|O
DDI-MedLine.d125.s7|129-129|)|O
DDI-MedLine.d125.s7|131-134|body|O
DDI-MedLine.d125.s7|136-141|weight|O
DDI-MedLine.d125.s7|142-142|)|O
DDI-MedLine.d125.s7|144-146|was|O
DDI-MedLine.d125.s7|148-158|ineffective|O
DDI-MedLine.d125.s7|160-161|in|O
DDI-MedLine.d125.s7|163-172|preventing|O
DDI-MedLine.d125.s7|200-208|synthesis|O
DDI-MedLine.d125.s7|210-212|and|O
DDI-MedLine.d125.s7|214-216|did|O
DDI-MedLine.d125.s7|218-220|not|O
DDI-MedLine.d125.s7|222-229|diminish|O
DDI-MedLine.d125.s7|231-238|fluoride|O
DDI-MedLine.d125.s7|240-241|or|O
DDI-MedLine.d125.s7|243-249|citrate|O
DDI-MedLine.d125.s7|251-262|accumulation|O
DDI-MedLine.d125.s7|264-265|in|O
DDI-MedLine.d125.s7|267-270|vivo|O
DDI-MedLine.d125.s7|271-271|.|O
DDI-MedLine.d125.s8|0-1|We|O
DDI-MedLine.d125.s8|3-10|conclude|O
DDI-MedLine.d125.s8|12-15|that|O
DDI-MedLine.d125.s8|17-19|the|O
DDI-MedLine.d125.s8|21-32|prophylactic|O
DDI-MedLine.d125.s8|34-36|and|O
DDI-MedLine.d125.s8|38-46|antidotal|O
DDI-MedLine.d125.s8|48-57|properties|O
DDI-MedLine.d125.s8|59-60|of|O
DDI-MedLine.d125.s8|62-77|4-methylpyrazole|drug
DDI-MedLine.d125.s8|79-82|seen|O
DDI-MedLine.d125.s8|84-85|in|O
DDI-MedLine.d125.s8|87-93|animals|O
DDI-MedLine.d125.s8|95-101|treated|O
DDI-MedLine.d125.s8|103-106|with|O
DDI-MedLine.d125.s8|132-137|derive|O
DDI-MedLine.d125.s8|139-142|from|O
DDI-MedLine.d125.s8|144-146|its|O
DDI-MedLine.d125.s8|148-155|capacity|O
DDI-MedLine.d125.s8|157-158|to|O
DDI-MedLine.d125.s8|160-166|inhibit|O
DDI-MedLine.d125.s8|168-170|the|O
DDI-MedLine.d125.s8|172-185|NAD+-dependent|O
DDI-MedLine.d125.s8|187-195|oxidation|O
DDI-MedLine.d125.s8|197-207|responsible|O
DDI-MedLine.d125.s8|209-211|for|O
DDI-MedLine.d125.s8|213-222|converting|O
DDI-MedLine.d125.s8|248-249|to|O
DDI-MedLine.d125.s8|271-272|in|O
DDI-MedLine.d125.s8|274-276|the|O
DDI-MedLine.d125.s8|278-286|committed|O
DDI-MedLine.d125.s8|288-291|step|O
DDI-MedLine.d125.s8|293-294|of|O
DDI-MedLine.d125.s8|296-298|the|O
DDI-MedLine.d125.s8|300-304|toxic|O
DDI-MedLine.d125.s8|306-312|pathway|O
DDI-MedLine.d125.s8|313-313|.|O
DDI-DrugBank.d117.s0|0-10|Concomitant|O
DDI-DrugBank.d117.s0|12-14|use|O
DDI-DrugBank.d117.s0|16-19|with|O
DDI-DrugBank.d117.s0|21-24|iron|group
DDI-DrugBank.d117.s0|26-36|supplements|O
DDI-DrugBank.d117.s0|38-40|may|O
DDI-DrugBank.d117.s0|42-47|result|O
DDI-DrugBank.d117.s0|49-50|in|O
DDI-DrugBank.d117.s0|52-54|the|O
DDI-DrugBank.d117.s0|56-62|reduced|O
DDI-DrugBank.d117.s0|64-73|absorption|O
DDI-DrugBank.d117.s0|75-76|of|O
DDI-DrugBank.d117.s0|78-81|iron|drug
DDI-DrugBank.d117.s0|82-82|.|O
DDI-MedLine.d57.s0|0-8|Analgesic|O
DDI-MedLine.d57.s0|10-16|effects|O
DDI-MedLine.d57.s0|18-19|of|O
DDI-MedLine.d57.s0|21-35|antihistaminics|group
DDI-MedLine.d57.s0|36-36|.|O
DDI-MedLine.d57.s1|0-2|The|O
DDI-MedLine.d57.s1|4-13|literature|O
DDI-MedLine.d57.s1|15-22|provides|O
DDI-MedLine.d57.s1|24-35|considerable|O
DDI-MedLine.d57.s1|37-44|evidence|O
DDI-MedLine.d57.s1|46-55|indicating|O
DDI-MedLine.d57.s1|57-60|that|O
DDI-MedLine.d57.s1|62-68|several|O
DDI-MedLine.d57.s1|69-69|,|O
DDI-MedLine.d57.s1|71-73|but|O
DDI-MedLine.d57.s1|75-77|not|O
DDI-MedLine.d57.s1|79-81|all|O
DDI-MedLine.d57.s1|83-97|antihistaminics|group
DDI-MedLine.d57.s1|98-98|,|O
DDI-MedLine.d57.s1|100-102|are|O
DDI-MedLine.d57.s1|104-109|indeed|O
DDI-MedLine.d57.s1|111-126|analgesic agents|group
DDI-MedLine.d57.s1|128-130|and|O
DDI-MedLine.d57.s1|132-135|some|O
DDI-MedLine.d57.s1|137-139|are|O
DDI-MedLine.d57.s1|141-159|analgesic adjuvants|group
DDI-MedLine.d57.s1|161-162|as|O
DDI-MedLine.d57.s1|164-167|well|O
DDI-MedLine.d57.s1|168-168|.|O
DDI-MedLine.d57.s2|0-4|Those|O
DDI-MedLine.d57.s2|6-8|for|O
DDI-MedLine.d57.s2|10-14|which|O
DDI-MedLine.d57.s2|16-28|effectiveness|O
DDI-MedLine.d57.s2|30-31|is|O
DDI-MedLine.d57.s2|33-40|reported|O
DDI-MedLine.d57.s2|42-49|includes|O
DDI-MedLine.d57.s2|51-65|diphenhydramine|drug
DDI-MedLine.d57.s2|66-66|,|O
DDI-MedLine.d57.s2|68-78|hydroxyzine|drug
DDI-MedLine.d57.s2|79-79|,|O
DDI-MedLine.d57.s2|81-92|orphenadrine|drug
DDI-MedLine.d57.s2|93-93|,|O
DDI-MedLine.d57.s2|95-104|pyrilamine|drug
DDI-MedLine.d57.s2|105-105|,|O
DDI-MedLine.d57.s2|123-123|,|O
DDI-MedLine.d57.s2|125-136|promethazine|drug
DDI-MedLine.d57.s2|137-137|,|O
DDI-MedLine.d57.s2|139-150|methdilazine|drug
DDI-MedLine.d57.s2|151-151|,|O
DDI-MedLine.d57.s2|153-155|and|O
DDI-MedLine.d57.s2|157-170|tripelennamine|drug
DDI-MedLine.d57.s2|171-171|.|O
DDI-MedLine.d57.s3|0-2|The|O
DDI-MedLine.d57.s3|4-11|proposed|O
DDI-MedLine.d57.s3|13-22|mechanisms|O
DDI-MedLine.d57.s3|24-25|of|O
DDI-MedLine.d57.s3|27-35|analgesic|O
DDI-MedLine.d57.s3|37-42|action|O
DDI-MedLine.d57.s3|44-45|of|O
DDI-MedLine.d57.s3|47-61|antihistaminics|group
DDI-MedLine.d57.s3|63-65|are|O
DDI-MedLine.d57.s3|67-74|reviewed|O
DDI-MedLine.d57.s3|76-78|and|O
DDI-MedLine.d57.s3|80-88|discussed|O
DDI-MedLine.d57.s3|89-89|.|O
DDI-MedLine.d57.s4|0-2|The|O
DDI-MedLine.d57.s4|4-13|literature|O
DDI-MedLine.d57.s4|15-22|suggests|O
DDI-MedLine.d57.s4|24-27|that|O
DDI-MedLine.d57.s4|29-32|more|O
DDI-MedLine.d57.s4|34-37|than|O
DDI-MedLine.d57.s4|39-41|one|O
DDI-MedLine.d57.s4|43-51|mechanism|O
DDI-MedLine.d57.s4|53-54|of|O
DDI-MedLine.d57.s4|56-61|action|O
DDI-MedLine.d57.s4|63-68|exists|O
DDI-MedLine.d57.s4|70-72|for|O
DDI-MedLine.d57.s4|74-77|them|O
DDI-MedLine.d57.s4|78-78|.|O
DDI-MedLine.d57.s5|0-4|There|O
DDI-MedLine.d57.s5|6-7|is|O
DDI-MedLine.d57.s5|9-20|considerable|O
DDI-MedLine.d57.s5|22-29|evidence|O
DDI-MedLine.d57.s5|31-40|suggesting|O
DDI-MedLine.d57.s5|42-45|that|O
DDI-MedLine.d57.s5|47-59|histaminergic|O
DDI-MedLine.d57.s5|61-63|and|O
DDI-MedLine.d57.s5|65-78|serotoninergic|O
DDI-MedLine.d57.s5|80-86|central|O
DDI-MedLine.d57.s5|88-95|pathways|O
DDI-MedLine.d57.s5|97-99|are|O
DDI-MedLine.d57.s5|101-108|involved|O
DDI-MedLine.d57.s5|110-111|in|O
DDI-MedLine.d57.s5|113-123|nociception|O
DDI-MedLine.d57.s5|125-127|and|O
DDI-MedLine.d57.s5|129-132|that|O
DDI-MedLine.d57.s5|134-147|antihistaminic|group
DDI-MedLine.d57.s5|149-153|drugs|O
DDI-MedLine.d57.s5|155-157|can|O
DDI-MedLine.d57.s5|159-166|modulate|O
DDI-MedLine.d57.s5|168-172|their|O
DDI-MedLine.d57.s5|174-182|responses|O
DDI-MedLine.d57.s5|184-184|(|O
DDI-MedLine.d57.s5|185-185|1|O
DDI-MedLine.d57.s5|186-186|)|O
DDI-MedLine.d57.s5|187-187|.|O
DDI-MedLine.d57.s6|0-2|The|O
DDI-MedLine.d57.s6|4-11|evidence|O
DDI-MedLine.d57.s6|13-15|for|O
DDI-MedLine.d57.s6|17-17|a|O
DDI-MedLine.d57.s6|19-22|role|O
DDI-MedLine.d57.s6|24-26|for|O
DDI-MedLine.d57.s6|28-41|norepinephrine|O
DDI-MedLine.d57.s6|43-45|and|O
DDI-MedLine.d57.s6|47-54|dopamine|O
DDI-MedLine.d57.s6|56-58|and|O
DDI-MedLine.d57.s6|60-62|the|O
DDI-MedLine.d57.s6|64-70|effects|O
DDI-MedLine.d57.s6|72-73|of|O
DDI-MedLine.d57.s6|75-89|antihistaminics|group
DDI-MedLine.d57.s6|91-92|on|O
DDI-MedLine.d57.s6|94-97|them|O
DDI-MedLine.d57.s6|99-101|are|O
DDI-MedLine.d57.s6|103-106|less|O
DDI-MedLine.d57.s6|108-111|well|O
DDI-MedLine.d57.s6|113-123|established|O
DDI-MedLine.d57.s6|124-124|.|O
DDI-MedLine.d57.s7|0-4|Still|O
DDI-MedLine.d57.s7|6-10|other|O
DDI-MedLine.d57.s7|12-19|pathways|O
DDI-MedLine.d57.s7|21-24|have|O
DDI-MedLine.d57.s7|26-29|been|O
DDI-MedLine.d57.s7|31-38|proposed|O
DDI-MedLine.d57.s7|39-39|.|O
DDI-MedLine.d57.s8|0-0|A|O
DDI-MedLine.d57.s8|2-8|greater|O
DDI-MedLine.d57.s8|10-22|understanding|O
DDI-MedLine.d57.s8|24-25|of|O
DDI-MedLine.d57.s8|27-30|pain|O
DDI-MedLine.d57.s8|32-41|mechanisms|O
DDI-MedLine.d57.s8|43-46|will|O
DDI-MedLine.d57.s8|48-50|aid|O
DDI-MedLine.d57.s8|52-53|in|O
DDI-MedLine.d57.s8|55-65|elucidating|O
DDI-MedLine.d57.s8|67-69|the|O
DDI-MedLine.d57.s8|71-74|role|O
DDI-MedLine.d57.s8|76-77|of|O
DDI-MedLine.d57.s8|79-93|antihistaminics|group
DDI-MedLine.d57.s8|95-96|in|O
DDI-MedLine.d57.s8|98-106|analgesia|O
DDI-MedLine.d57.s8|107-107|.|O
DDI-DrugBank.d209.s0|0-1|No|O
DDI-DrugBank.d209.s0|3-6|drug|O
DDI-DrugBank.d209.s0|8-19|interactions|O
DDI-DrugBank.d209.s0|21-22|of|O
DDI-DrugBank.d209.s0|24-31|clinical|O
DDI-DrugBank.d209.s0|33-42|importance|O
DDI-DrugBank.d209.s0|44-47|have|O
DDI-DrugBank.d209.s0|49-52|been|O
DDI-DrugBank.d209.s0|54-63|identified|O
DDI-DrugBank.d209.s0|64-64|.|O
DDI-DrugBank.d209.s1|0-10|Finasteride|drug
DDI-DrugBank.d209.s1|12-15|does|O
DDI-DrugBank.d209.s1|17-19|not|O
DDI-DrugBank.d209.s1|21-26|appear|O
DDI-DrugBank.d209.s1|28-29|to|O
DDI-DrugBank.d209.s1|31-36|affect|O
DDI-DrugBank.d209.s1|38-40|the|O
DDI-DrugBank.d209.s1|42-51|cytochrome|O
DDI-DrugBank.d209.s1|53-63|P450-linked|O
DDI-DrugBank.d209.s1|65-81|drug-metabolizing|O
DDI-DrugBank.d209.s1|83-88|enzyme|O
DDI-DrugBank.d209.s1|90-95|system|O
DDI-DrugBank.d209.s1|96-96|.|O
DDI-DrugBank.d209.s2|0-8|Compounds|O
DDI-DrugBank.d209.s2|10-13|that|O
DDI-DrugBank.d209.s2|15-18|have|O
DDI-DrugBank.d209.s2|20-23|been|O
DDI-DrugBank.d209.s2|25-30|tested|O
DDI-DrugBank.d209.s2|32-33|in|O
DDI-DrugBank.d209.s2|35-37|man|O
DDI-DrugBank.d209.s2|39-45|include|O
DDI-DrugBank.d209.s2|47-56|antipyrine|drug
DDI-DrugBank.d209.s2|57-57|,|O
DDI-DrugBank.d209.s2|59-65|digoxin|drug
DDI-DrugBank.d209.s2|66-66|,|O
DDI-DrugBank.d209.s2|68-78|propranolol|drug
DDI-DrugBank.d209.s2|79-79|,|O
DDI-DrugBank.d209.s2|81-92|theophylline|drug
DDI-DrugBank.d209.s2|93-93|,|O
DDI-DrugBank.d209.s2|95-97|and|O
DDI-DrugBank.d209.s2|99-106|warfarin|drug
DDI-DrugBank.d209.s2|108-110|and|O
DDI-DrugBank.d209.s2|112-113|no|O
DDI-DrugBank.d209.s2|115-124|clinically|O
DDI-DrugBank.d209.s2|126-135|meaningful|O
DDI-DrugBank.d209.s2|137-148|interactions|O
DDI-DrugBank.d209.s2|150-153|were|O
DDI-DrugBank.d209.s2|155-159|found|O
DDI-DrugBank.d209.s2|160-160|.|O
DDI-DrugBank.d209.s3|0-4|Other|O
DDI-DrugBank.d209.s3|6-16|concomitant|O
DDI-DrugBank.d209.s3|18-24|therapy|O
DDI-DrugBank.d209.s3|26-33|Although|O
DDI-DrugBank.d209.s3|35-42|specific|O
DDI-DrugBank.d209.s3|44-54|interaction|O
DDI-DrugBank.d209.s3|56-62|studies|O
DDI-DrugBank.d209.s3|64-67|were|O
DDI-DrugBank.d209.s3|69-71|not|O
DDI-DrugBank.d209.s3|73-81|performed|O
DDI-DrugBank.d209.s3|82-82|,|O
DDI-DrugBank.d209.s3|84-94|finasteride|drug
DDI-DrugBank.d209.s3|96-100|doses|O
DDI-DrugBank.d209.s3|102-103|of|O
DDI-DrugBank.d209.s3|105-105|1|O
DDI-DrugBank.d209.s3|107-108|mg|O
DDI-DrugBank.d209.s3|110-111|or|O
DDI-DrugBank.d209.s3|113-116|more|O
DDI-DrugBank.d209.s3|118-121|were|O
DDI-DrugBank.d209.s3|123-135|concomitantly|O
DDI-DrugBank.d209.s3|137-140|used|O
DDI-DrugBank.d209.s3|142-143|in|O
DDI-DrugBank.d209.s3|145-152|clinical|O
DDI-DrugBank.d209.s3|154-160|studies|O
DDI-DrugBank.d209.s3|162-165|with|O
DDI-DrugBank.d209.s3|167-179|acetaminophen|drug
DDI-DrugBank.d209.s3|180-180|,|O
DDI-DrugBank.d209.s3|182-201|acetylsalicylic acid|drug
DDI-DrugBank.d209.s3|202-202|,|O
DDI-DrugBank.d209.s3|204-213|a-blockers|O
DDI-DrugBank.d209.s3|214-214|,|O
DDI-DrugBank.d209.s3|216-225|analgesics|group
DDI-DrugBank.d209.s3|226-226|,|O
DDI-DrugBank.d209.s3|228-273|angiotensin-converting enzyme ( ACE ) inhibitors|group
DDI-DrugBank.d209.s3|274-274|,|O
DDI-DrugBank.d209.s3|276-290|anticonvulsants|group
DDI-DrugBank.d209.s3|291-291|,|O
DDI-DrugBank.d209.s3|293-307|benzodiazepines|group
DDI-DrugBank.d209.s3|308-308|,|O
DDI-DrugBank.d209.s3|310-322|beta blockers|group
DDI-DrugBank.d209.s3|323-323|,|O
DDI-DrugBank.d209.s3|325-348|calcium-channel blockers|group
DDI-DrugBank.d209.s3|349-349|,|O
DDI-DrugBank.d209.s3|351-357|cardiac|O
DDI-DrugBank.d209.s3|359-366|nitrates|group
DDI-DrugBank.d209.s3|367-367|,|O
DDI-DrugBank.d209.s3|369-377|diuretics|group
DDI-DrugBank.d209.s3|378-378|,|O
DDI-DrugBank.d209.s3|380-393|H2 antagonists|group
DDI-DrugBank.d209.s3|394-394|,|O
DDI-DrugBank.d209.s3|396-423|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d209.s3|424-424|,|O
DDI-DrugBank.d209.s3|426-460|prostaglandin synthetase inhibitors|group
DDI-DrugBank.d209.s3|462-462|(|O
DDI-DrugBank.d209.s3|463-466|also|O
DDI-DrugBank.d209.s3|468-475|referred|O
DDI-DrugBank.d209.s3|477-478|to|O
DDI-DrugBank.d209.s3|480-481|as|O
DDI-DrugBank.d209.s3|483-488|NSAIDs|group
DDI-DrugBank.d209.s3|489-489|)|O
DDI-DrugBank.d209.s3|490-490|,|O
DDI-DrugBank.d209.s3|492-494|and|O
DDI-DrugBank.d209.s3|496-520|quinolone anti-infectives|group
DDI-DrugBank.d209.s3|522-528|without|O
DDI-DrugBank.d209.s3|530-537|evidence|O
DDI-DrugBank.d209.s3|539-540|of|O
DDI-DrugBank.d209.s3|542-551|clinically|O
DDI-DrugBank.d209.s3|553-563|significant|O
DDI-DrugBank.d209.s3|565-571|adverse|O
DDI-DrugBank.d209.s3|573-584|interactions|O
DDI-DrugBank.d209.s3|585-585|.|O
DDI-DrugBank.d209.s4|0-14|Drug/Laboratory|O
DDI-DrugBank.d209.s4|16-19|Test|O
DDI-DrugBank.d209.s4|21-32|Interactions|O
DDI-DrugBank.d209.s4|34-44|Finasteride|drug
DDI-DrugBank.d209.s4|46-48|had|O
DDI-DrugBank.d209.s4|50-51|no|O
DDI-DrugBank.d209.s4|53-58|effect|O
DDI-DrugBank.d209.s4|60-61|on|O
DDI-DrugBank.d209.s4|63-73|circulating|O
DDI-DrugBank.d209.s4|75-80|levels|O
DDI-DrugBank.d209.s4|82-83|of|O
DDI-DrugBank.d209.s4|85-92|cortisol|O
DDI-DrugBank.d209.s4|93-93|,|O
DDI-DrugBank.d209.s4|95-113|thyroid-stimulating|O
DDI-DrugBank.d209.s4|115-121|hormone|O
DDI-DrugBank.d209.s4|122-122|,|O
DDI-DrugBank.d209.s4|124-125|or|O
DDI-DrugBank.d209.s4|127-135|thyroxine|O
DDI-DrugBank.d209.s4|136-136|,|O
DDI-DrugBank.d209.s4|138-140|nor|O
DDI-DrugBank.d209.s4|142-144|did|O
DDI-DrugBank.d209.s4|146-147|it|O
DDI-DrugBank.d209.s4|149-154|affect|O
DDI-DrugBank.d209.s4|156-158|the|O
DDI-DrugBank.d209.s4|160-165|plasma|O
DDI-DrugBank.d209.s4|167-171|lipid|O
DDI-DrugBank.d209.s4|173-179|profile|O
DDI-DrugBank.d209.s4|181-181|(|O
DDI-DrugBank.d209.s4|182-185|e.g.|O
DDI-DrugBank.d209.s4|186-186|,|O
DDI-DrugBank.d209.s4|188-192|total|O
DDI-DrugBank.d209.s4|194-204|cholesterol|O
DDI-DrugBank.d209.s4|205-205|,|O
DDI-DrugBank.d209.s4|207-217|low-density|O
DDI-DrugBank.d209.s4|219-230|lipoproteins|O
DDI-DrugBank.d209.s4|231-231|,|O
DDI-DrugBank.d209.s4|233-244|high-density|O
DDI-DrugBank.d209.s4|246-257|lipoproteins|O
DDI-DrugBank.d209.s4|259-261|and|O
DDI-DrugBank.d209.s4|263-275|triglycerides|O
DDI-DrugBank.d209.s4|276-276|)|O
DDI-DrugBank.d209.s4|278-279|or|O
DDI-DrugBank.d209.s4|281-284|bone|O
DDI-DrugBank.d209.s4|286-292|mineral|O
DDI-DrugBank.d209.s4|294-300|density|O
DDI-DrugBank.d209.s4|301-301|.|O
DDI-DrugBank.d209.s5|0-1|In|O
DDI-DrugBank.d209.s5|3-9|studies|O
DDI-DrugBank.d209.s5|11-14|with|O
DDI-DrugBank.d209.s5|16-26|finasteride|drug
DDI-DrugBank.d209.s5|27-27|,|O
DDI-DrugBank.d209.s5|29-30|no|O
DDI-DrugBank.d209.s5|32-41|clinically|O
DDI-DrugBank.d209.s5|43-52|meaningful|O
DDI-DrugBank.d209.s5|54-60|changes|O
DDI-DrugBank.d209.s5|62-63|in|O
DDI-DrugBank.d209.s5|65-75|luteinizing|O
DDI-DrugBank.d209.s5|77-83|hormone|O
DDI-DrugBank.d209.s5|85-85|(|O
DDI-DrugBank.d209.s5|86-87|LH|O
DDI-DrugBank.d209.s5|88-88|)|O
DDI-DrugBank.d209.s5|89-89|,|O
DDI-DrugBank.d209.s5|91-110|follicle-stimulating|O
DDI-DrugBank.d209.s5|112-118|hormone|O
DDI-DrugBank.d209.s5|120-120|(|O
DDI-DrugBank.d209.s5|121-123|FSH|O
DDI-DrugBank.d209.s5|124-124|)|O
DDI-DrugBank.d209.s5|126-127|or|O
DDI-DrugBank.d209.s5|129-137|prolactin|O
DDI-DrugBank.d209.s5|139-142|were|O
DDI-DrugBank.d209.s5|144-151|detected|O
DDI-DrugBank.d209.s5|152-152|.|O
DDI-DrugBank.d209.s6|0-1|In|O
DDI-DrugBank.d209.s6|3-9|healthy|O
DDI-DrugBank.d209.s6|11-20|volunteers|O
DDI-DrugBank.d209.s6|21-21|,|O
DDI-DrugBank.d209.s6|23-31|treatment|O
DDI-DrugBank.d209.s6|33-36|with|O
DDI-DrugBank.d209.s6|38-48|finasteride|drug
DDI-DrugBank.d209.s6|50-52|did|O
DDI-DrugBank.d209.s6|54-56|not|O
DDI-DrugBank.d209.s6|58-62|alter|O
DDI-DrugBank.d209.s6|64-66|the|O
DDI-DrugBank.d209.s6|68-75|response|O
DDI-DrugBank.d209.s6|77-78|of|O
DDI-DrugBank.d209.s6|80-81|LH|O
DDI-DrugBank.d209.s6|83-85|and|O
DDI-DrugBank.d209.s6|87-89|FSH|O
DDI-DrugBank.d209.s6|91-92|to|O
DDI-DrugBank.d209.s6|94-115|gonadotropin-releasing|O
DDI-DrugBank.d209.s6|117-123|hormone|O
DDI-DrugBank.d209.s6|125-134|indicating|O
DDI-DrugBank.d209.s6|136-139|that|O
DDI-DrugBank.d209.s6|141-143|the|O
DDI-DrugBank.d209.s6|145-177|hypothalamic-pituitary-testicular|O
DDI-DrugBank.d209.s6|179-182|axis|O
DDI-DrugBank.d209.s6|184-186|was|O
DDI-DrugBank.d209.s6|188-190|not|O
DDI-DrugBank.d209.s6|192-199|affected|O
DDI-DrugBank.d209.s6|200-200|.|O
DDI-DrugBank.d209.s7|0-1|In|O
DDI-DrugBank.d209.s7|3-10|clinical|O
DDI-DrugBank.d209.s7|12-18|studies|O
DDI-DrugBank.d209.s7|20-23|with|O
DDI-DrugBank.d209.s7|25-32|PROPECIA|brand
DDI-DrugBank.d209.s7|34-34|(|O
DDI-DrugBank.d209.s7|35-45|finasteride|drug
DDI-DrugBank.d209.s7|46-46|,|O
DDI-DrugBank.d209.s7|48-48|1|O
DDI-DrugBank.d209.s7|50-51|mg|O
DDI-DrugBank.d209.s7|52-52|)|O
DDI-DrugBank.d209.s7|54-55|in|O
DDI-DrugBank.d209.s7|57-59|men|O
DDI-DrugBank.d209.s7|61-65|18-41|O
DDI-DrugBank.d209.s7|67-71|years|O
DDI-DrugBank.d209.s7|73-74|of|O
DDI-DrugBank.d209.s7|76-78|age|O
DDI-DrugBank.d209.s7|79-79|,|O
DDI-DrugBank.d209.s7|81-83|the|O
DDI-DrugBank.d209.s7|85-88|mean|O
DDI-DrugBank.d209.s7|90-94|value|O
DDI-DrugBank.d209.s7|96-97|of|O
DDI-DrugBank.d209.s7|99-103|serum|O
DDI-DrugBank.d209.s7|105-121|prostate-specific|O
DDI-DrugBank.d209.s7|123-129|antigen|O
DDI-DrugBank.d209.s7|131-131|(|O
DDI-DrugBank.d209.s7|132-134|PSA|O
DDI-DrugBank.d209.s7|135-135|)|O
DDI-DrugBank.d209.s7|137-145|decreased|O
DDI-DrugBank.d209.s7|147-150|from|O
DDI-DrugBank.d209.s7|152-154|0.7|O
DDI-DrugBank.d209.s7|156-160|ng/mL|O
DDI-DrugBank.d209.s7|162-163|at|O
DDI-DrugBank.d209.s7|165-172|baseline|O
DDI-DrugBank.d209.s7|174-175|to|O
DDI-DrugBank.d209.s7|177-179|0.5|O
DDI-DrugBank.d209.s7|181-185|ng/mL|O
DDI-DrugBank.d209.s7|187-188|at|O
DDI-DrugBank.d209.s7|190-194|Month|O
DDI-DrugBank.d209.s7|196-197|12|O
DDI-DrugBank.d209.s7|198-198|.|O
DDI-DrugBank.d209.s8|0-6|Further|O
DDI-DrugBank.d209.s8|7-7|,|O
DDI-DrugBank.d209.s8|9-10|in|O
DDI-DrugBank.d209.s8|12-19|clinical|O
DDI-DrugBank.d209.s8|21-27|studies|O
DDI-DrugBank.d209.s8|29-32|with|O
DDI-DrugBank.d209.s8|34-40|PROSCAR|brand
DDI-DrugBank.d209.s8|42-42|(|O
DDI-DrugBank.d209.s8|43-53|finasteride|drug
DDI-DrugBank.d209.s8|54-54|,|O
DDI-DrugBank.d209.s8|56-56|5|O
DDI-DrugBank.d209.s8|58-59|mg|O
DDI-DrugBank.d209.s8|60-60|)|O
DDI-DrugBank.d209.s8|62-65|when|O
DDI-DrugBank.d209.s8|67-70|used|O
DDI-DrugBank.d209.s8|72-73|in|O
DDI-DrugBank.d209.s8|75-79|older|O
DDI-DrugBank.d209.s8|81-83|men|O
DDI-DrugBank.d209.s8|85-87|who|O
DDI-DrugBank.d209.s8|89-92|have|O
DDI-DrugBank.d209.s8|94-99|benign|O
DDI-DrugBank.d209.s8|101-109|prostatic|O
DDI-DrugBank.d209.s8|111-121|hyperplasia|O
DDI-DrugBank.d209.s8|123-123|(|O
DDI-DrugBank.d209.s8|124-126|BPH|O
DDI-DrugBank.d209.s8|127-127|)|O
DDI-DrugBank.d209.s8|128-128|,|O
DDI-DrugBank.d209.s8|130-132|PSA|O
DDI-DrugBank.d209.s8|134-139|levels|O
DDI-DrugBank.d209.s8|141-143|are|O
DDI-DrugBank.d209.s8|145-153|decreased|O
DDI-DrugBank.d209.s8|155-156|by|O
DDI-DrugBank.d209.s8|158-170|approximately|O
DDI-DrugBank.d209.s8|172-173|50|O
DDI-DrugBank.d209.s8|174-174|%|O
DDI-DrugBank.d209.s8|175-175|.|O
DDI-DrugBank.d209.s9|0-4|These|O
DDI-DrugBank.d209.s9|6-13|findings|O
DDI-DrugBank.d209.s9|15-20|should|O
DDI-DrugBank.d209.s9|22-23|be|O
DDI-DrugBank.d209.s9|25-29|taken|O
DDI-DrugBank.d209.s9|31-34|into|O
DDI-DrugBank.d209.s9|36-42|account|O
DDI-DrugBank.d209.s9|44-46|for|O
DDI-DrugBank.d209.s9|48-53|proper|O
DDI-DrugBank.d209.s9|55-68|interpretation|O
DDI-DrugBank.d209.s9|70-71|of|O
DDI-DrugBank.d209.s9|73-77|serum|O
DDI-DrugBank.d209.s9|79-81|PSA|O
DDI-DrugBank.d209.s9|83-86|when|O
DDI-DrugBank.d209.s9|88-97|evaluating|O
DDI-DrugBank.d209.s9|99-101|men|O
DDI-DrugBank.d209.s9|103-109|treated|O
DDI-DrugBank.d209.s9|111-114|with|O
DDI-DrugBank.d209.s9|116-126|finasteride|drug
DDI-DrugBank.d209.s9|127-127|.|O
DDI-MedLine.d227.s0|0-8|Ephedrine|drug
DDI-MedLine.d227.s0|10-17|enhances|O
DDI-MedLine.d227.s0|19-21|the|O
DDI-MedLine.d227.s0|23-37|antinociceptive|O
DDI-MedLine.d227.s0|39-44|effect|O
DDI-MedLine.d227.s0|46-47|of|O
DDI-MedLine.d227.s0|49-63|dexmedetomidine|drug
DDI-MedLine.d227.s0|65-66|in|O
DDI-MedLine.d227.s0|68-71|mice|O
DDI-MedLine.d227.s0|72-72|.|O
DDI-MedLine.d227.s1|0-14|Dexmedetomidine|drug
DDI-MedLine.d227.s1|15-15|,|O
DDI-MedLine.d227.s1|17-17|a|O
DDI-MedLine.d227.s1|19-24|highly|O
DDI-MedLine.d227.s1|26-34|selective|O
DDI-MedLine.d227.s1|36-55|alpha-2-adrenoceptor|O
DDI-MedLine.d227.s1|57-63|agonist|O
DDI-MedLine.d227.s1|64-64|,|O
DDI-MedLine.d227.s1|66-68|was|O
DDI-MedLine.d227.s1|70-77|recently|O
DDI-MedLine.d227.s1|79-88|introduced|O
DDI-MedLine.d227.s1|90-93|into|O
DDI-MedLine.d227.s1|95-102|clinical|O
DDI-MedLine.d227.s1|104-111|practice|O
DDI-MedLine.d227.s1|113-115|for|O
DDI-MedLine.d227.s1|117-119|its|O
DDI-MedLine.d227.s1|121-128|sedative|O
DDI-MedLine.d227.s1|130-132|and|O
DDI-MedLine.d227.s1|134-142|analgesic|O
DDI-MedLine.d227.s1|144-153|properties|O
DDI-MedLine.d227.s1|154-154|.|O
DDI-MedLine.d227.s2|0-2|The|O
DDI-MedLine.d227.s2|4-10|purpose|O
DDI-MedLine.d227.s2|12-13|of|O
DDI-MedLine.d227.s2|15-18|this|O
DDI-MedLine.d227.s2|20-24|study|O
DDI-MedLine.d227.s2|26-28|was|O
DDI-MedLine.d227.s2|30-31|to|O
DDI-MedLine.d227.s2|33-40|evaluate|O
DDI-MedLine.d227.s2|42-48|whether|O
DDI-MedLine.d227.s2|50-52|the|O
DDI-MedLine.d227.s2|54-68|psychostimulant|O
DDI-MedLine.d227.s2|70-73|drug|O
DDI-MedLine.d227.s2|75-83|ephedrine|drug
DDI-MedLine.d227.s2|85-87|has|O
DDI-MedLine.d227.s2|89-91|any|O
DDI-MedLine.d227.s2|93-98|effect|O
DDI-MedLine.d227.s2|100-101|on|O
DDI-MedLine.d227.s2|103-125|dexmedetomidine-induced|drug
DDI-MedLine.d227.s2|127-141|antinociception|O
DDI-MedLine.d227.s2|143-145|and|O
DDI-MedLine.d227.s2|147-155|locomotor|O
DDI-MedLine.d227.s2|157-165|inhibitor|O
DDI-MedLine.d227.s2|167-174|activity|O
DDI-MedLine.d227.s2|176-177|in|O
DDI-MedLine.d227.s2|179-182|mice|O
DDI-MedLine.d227.s2|184-185|in|O
DDI-MedLine.d227.s2|187-191|acute|O
DDI-MedLine.d227.s2|193-203|application|O
DDI-MedLine.d227.s2|204-204|.|O
DDI-MedLine.d227.s3|0-1|In|O
DDI-MedLine.d227.s3|3-6|both|O
DDI-MedLine.d227.s3|8-12|sexes|O
DDI-MedLine.d227.s3|14-15|of|O
DDI-MedLine.d227.s3|17-21|swiss|O
DDI-MedLine.d227.s3|23-28|albino|O
DDI-MedLine.d227.s3|30-33|mice|O
DDI-MedLine.d227.s3|34-34|;|O
DDI-MedLine.d227.s4|0-14|antinociception|O
DDI-MedLine.d227.s4|16-18|was|O
DDI-MedLine.d227.s4|20-27|assessed|O
DDI-MedLine.d227.s4|29-32|with|O
DDI-MedLine.d227.s4|34-42|hot-plate|O
DDI-MedLine.d227.s4|44-47|test|O
DDI-MedLine.d227.s4|49-51|and|O
DDI-MedLine.d227.s4|53-55|the|O
DDI-MedLine.d227.s4|57-65|locomotor|O
DDI-MedLine.d227.s4|66-66|,|O
DDI-MedLine.d227.s4|68-78|exploratory|O
DDI-MedLine.d227.s4|80-89|activities|O
DDI-MedLine.d227.s4|91-94|were|O
DDI-MedLine.d227.s4|96-103|assessed|O
DDI-MedLine.d227.s4|105-108|with|O
DDI-MedLine.d227.s4|110-114|holed|O
DDI-MedLine.d227.s4|116-119|open|O
DDI-MedLine.d227.s4|121-125|field|O
DDI-MedLine.d227.s4|127-130|test|O
DDI-MedLine.d227.s4|131-131|.|O
DDI-MedLine.d227.s5|0-2|The|O
DDI-MedLine.d227.s5|4-10|animals|O
DDI-MedLine.d227.s5|12-15|were|O
DDI-MedLine.d227.s5|17-24|received|O
DDI-MedLine.d227.s5|25-25|;|O
DDI-MedLine.d227.s6|0-5|saline|O
DDI-MedLine.d227.s6|7-7|+|O
DDI-MedLine.d227.s6|9-14|saline|O
DDI-MedLine.d227.s6|15-15|,|O
DDI-MedLine.d227.s6|17-25|ephedrine|drug
DDI-MedLine.d227.s6|27-27|(|O
DDI-MedLine.d227.s6|28-29|10|O
DDI-MedLine.d227.s6|33-37|mg/kg|O
DDI-MedLine.d227.s6|38-38|)|O
DDI-MedLine.d227.s6|40-40|+|O
DDI-MedLine.d227.s6|42-47|saline|O
DDI-MedLine.d227.s6|48-48|,|O
DDI-MedLine.d227.s6|50-55|saline|O
DDI-MedLine.d227.s6|57-57|+|O
DDI-MedLine.d227.s6|59-73|dexmedetomidine|drug
DDI-MedLine.d227.s6|75-75|(|O
DDI-MedLine.d227.s6|76-77|15|O
DDI-MedLine.d227.s6|83-86|g/kg|O
DDI-MedLine.d227.s6|87-87|)|O
DDI-MedLine.d227.s6|89-91|and|O
DDI-MedLine.d227.s6|93-101|ephedrine|drug
DDI-MedLine.d227.s6|103-103|(|O
DDI-MedLine.d227.s6|104-105|10|O
DDI-MedLine.d227.s6|109-113|mg/kg|O
DDI-MedLine.d227.s6|114-114|)|O
DDI-MedLine.d227.s6|116-116|+|O
DDI-MedLine.d227.s6|118-132|dexmedetomidine|drug
DDI-MedLine.d227.s6|134-134|(|O
DDI-MedLine.d227.s6|135-136|15|O
DDI-MedLine.d227.s6|142-145|g/kg|O
DDI-MedLine.d227.s6|146-146|)|O
DDI-MedLine.d227.s6|147-147|,|O
DDI-MedLine.d227.s6|149-165|intraperitoneally|O
DDI-MedLine.d227.s6|166-166|,|O
DDI-MedLine.d227.s6|168-169|30|O
DDI-MedLine.d227.s6|171-173|min|O
DDI-MedLine.d227.s6|175-180|before|O
DDI-MedLine.d227.s6|182-184|hot|O
DDI-MedLine.d227.s6|186-190|plate|O
DDI-MedLine.d227.s6|192-193|or|O
DDI-MedLine.d227.s6|195-199|holed|O
DDI-MedLine.d227.s6|201-204|open|O
DDI-MedLine.d227.s6|206-210|field|O
DDI-MedLine.d227.s6|212-216|tests|O
DDI-MedLine.d227.s6|217-217|.|O
DDI-MedLine.d227.s7|0-1|In|O
DDI-MedLine.d227.s7|3-5|the|O
DDI-MedLine.d227.s7|7-9|hot|O
DDI-MedLine.d227.s7|11-15|plate|O
DDI-MedLine.d227.s7|17-20|test|O
DDI-MedLine.d227.s7|22-23|in|O
DDI-MedLine.d227.s7|25-28|mice|O
DDI-MedLine.d227.s7|29-29|,|O
DDI-MedLine.d227.s7|31-47|co-administration|O
DDI-MedLine.d227.s7|49-50|of|O
DDI-MedLine.d227.s7|52-53|15|O
DDI-MedLine.d227.s7|59-62|g/kg|O
DDI-MedLine.d227.s7|64-78|dexmedetomidine|drug
DDI-MedLine.d227.s7|80-83|with|O
DDI-MedLine.d227.s7|85-86|10|O
DDI-MedLine.d227.s7|90-94|mg/kg|O
DDI-MedLine.d227.s7|96-104|ephedrine|drug
DDI-MedLine.d227.s7|106-122|intraperitoneally|O
DDI-MedLine.d227.s7|124-126|not|O
DDI-MedLine.d227.s7|128-131|only|O
DDI-MedLine.d227.s7|133-140|enhanced|O
DDI-MedLine.d227.s7|141-141|,|O
DDI-MedLine.d227.s7|143-145|but|O
DDI-MedLine.d227.s7|147-150|also|O
DDI-MedLine.d227.s7|152-160|prolonged|O
DDI-MedLine.d227.s7|162-164|the|O
DDI-MedLine.d227.s7|166-173|duration|O
DDI-MedLine.d227.s7|175-176|of|O
DDI-MedLine.d227.s7|178-192|antinociception|O
DDI-MedLine.d227.s7|194-200|induced|O
DDI-MedLine.d227.s7|202-203|by|O
DDI-MedLine.d227.s7|205-219|dexmedetomidine|drug
DDI-MedLine.d227.s7|220-220|.|O
DDI-MedLine.d227.s8|0-1|At|O
DDI-MedLine.d227.s8|3-5|the|O
DDI-MedLine.d227.s8|7-10|same|O
DDI-MedLine.d227.s8|12-15|time|O
DDI-MedLine.d227.s8|16-16|,|O
DDI-MedLine.d227.s8|18-20|the|O
DDI-MedLine.d227.s8|22-30|locomotor|O
DDI-MedLine.d227.s8|32-41|inhibitory|O
DDI-MedLine.d227.s8|43-48|effect|O
DDI-MedLine.d227.s8|50-51|of|O
DDI-MedLine.d227.s8|53-67|dexmedetomidine|drug
DDI-MedLine.d227.s8|69-71|was|O
DDI-MedLine.d227.s8|73-84|counteracted|O
DDI-MedLine.d227.s8|86-87|by|O
DDI-MedLine.d227.s8|89-97|ephedrine|drug
DDI-MedLine.d227.s8|98-98|.|O
DDI-MedLine.d227.s9|0-1|We|O
DDI-MedLine.d227.s9|3-11|concluded|O
DDI-MedLine.d227.s9|13-16|that|O
DDI-MedLine.d227.s9|18-20|the|O
DDI-MedLine.d227.s9|22-29|combined|O
DDI-MedLine.d227.s9|31-44|administration|O
DDI-MedLine.d227.s9|46-47|of|O
DDI-MedLine.d227.s9|49-63|dexmedetomidine|drug
DDI-MedLine.d227.s9|65-68|with|O
DDI-MedLine.d227.s9|70-78|ephedrine|drug
DDI-MedLine.d227.s9|80-82|may|O
DDI-MedLine.d227.s9|84-87|have|O
DDI-MedLine.d227.s9|89-98|beneficial|O
DDI-MedLine.d227.s9|100-106|effects|O
DDI-MedLine.d227.s9|108-109|in|O
DDI-MedLine.d227.s9|111-113|the|O
DDI-MedLine.d227.s9|115-123|treatment|O
DDI-MedLine.d227.s9|125-126|of|O
DDI-MedLine.d227.s9|128-131|pain|O
DDI-MedLine.d227.s9|133-139|without|O
DDI-MedLine.d227.s9|141-147|causing|O
DDI-MedLine.d227.s9|149-156|sedation|O
DDI-MedLine.d227.s9|157-157|,|O
DDI-MedLine.d227.s9|159-163|which|O
DDI-MedLine.d227.s9|165-170|limits|O
DDI-MedLine.d227.s9|172-174|the|O
DDI-MedLine.d227.s9|176-178|use|O
DDI-MedLine.d227.s9|180-181|of|O
DDI-MedLine.d227.s9|183-197|dexmedetomidine|drug
DDI-MedLine.d227.s9|199-200|as|O
DDI-MedLine.d227.s9|202-203|an|O
DDI-MedLine.d227.s9|205-213|analgesic|group
DDI-MedLine.d227.s9|215-216|in|O
DDI-MedLine.d227.s9|218-223|humans|O
DDI-MedLine.d227.s9|224-224|.|O
DDI-DrugBank.d666.s0|0-22|Catecholamine-depleting|O
DDI-DrugBank.d666.s0|24-28|drugs|O
DDI-DrugBank.d666.s0|30-30|(|O
DDI-DrugBank.d666.s0|31-34|e.g.|O
DDI-DrugBank.d666.s0|35-35|,|O
DDI-DrugBank.d666.s0|37-45|reserpine|drug
DDI-DrugBank.d666.s0|46-46|)|O
DDI-DrugBank.d666.s0|48-50|may|O
DDI-DrugBank.d666.s0|52-55|have|O
DDI-DrugBank.d666.s0|57-58|an|O
DDI-DrugBank.d666.s0|60-67|additive|O
DDI-DrugBank.d666.s0|69-74|effect|O
DDI-DrugBank.d666.s0|76-79|when|O
DDI-DrugBank.d666.s0|81-85|given|O
DDI-DrugBank.d666.s0|87-90|with|O
DDI-DrugBank.d666.s0|92-111|beta-blocking agents|group
DDI-DrugBank.d666.s0|112-112|.|O
DDI-DrugBank.d666.s1|0-7|Patients|O
DDI-DrugBank.d666.s1|9-17|receiving|O
DDI-DrugBank.d666.s1|19-26|pindolol|drug
DDI-DrugBank.d666.s1|28-31|plus|O
DDI-DrugBank.d666.s1|33-33|a|O
DDI-DrugBank.d666.s1|35-57|catecholamine-depleting|O
DDI-DrugBank.d666.s1|59-63|agent|O
DDI-DrugBank.d666.s1|65-70|should|O
DDI-DrugBank.d666.s1|71-71|,|O
DDI-DrugBank.d666.s1|73-81|therefore|O
DDI-DrugBank.d666.s1|82-82|,|O
DDI-DrugBank.d666.s1|84-85|be|O
DDI-DrugBank.d666.s1|87-93|closely|O
DDI-DrugBank.d666.s1|95-102|observed|O
DDI-DrugBank.d666.s1|104-106|for|O
DDI-DrugBank.d666.s1|108-115|evidence|O
DDI-DrugBank.d666.s1|117-118|of|O
DDI-DrugBank.d666.s1|120-130|hypotension|O
DDI-DrugBank.d666.s1|132-137|and/or|O
DDI-DrugBank.d666.s1|139-144|marked|O
DDI-DrugBank.d666.s1|146-156|bradycardia|O
DDI-DrugBank.d666.s1|158-162|which|O
DDI-DrugBank.d666.s1|164-166|may|O
DDI-DrugBank.d666.s1|168-174|produce|O
DDI-DrugBank.d666.s1|176-182|vertigo|O
DDI-DrugBank.d666.s1|183-183|,|O
DDI-DrugBank.d666.s1|185-191|syncope|O
DDI-DrugBank.d666.s1|192-192|,|O
DDI-DrugBank.d666.s1|194-195|or|O
DDI-DrugBank.d666.s1|197-204|postural|O
DDI-DrugBank.d666.s1|206-216|hypotension|O
DDI-DrugBank.d666.s1|217-217|.|O
DDI-DrugBank.d666.s2|0-7|Pindolol|drug
DDI-DrugBank.d666.s2|9-11|has|O
DDI-DrugBank.d666.s2|13-16|been|O
DDI-DrugBank.d666.s2|18-21|used|O
DDI-DrugBank.d666.s2|23-26|with|O
DDI-DrugBank.d666.s2|28-28|a|O
DDI-DrugBank.d666.s2|30-36|variety|O
DDI-DrugBank.d666.s2|38-39|of|O
DDI-DrugBank.d666.s2|41-63|antihypertensive agents|group
DDI-DrugBank.d666.s2|64-64|,|O
DDI-DrugBank.d666.s2|66-74|including|O
DDI-DrugBank.d666.s2|76-94|hydrochlorothiazide|drug
DDI-DrugBank.d666.s2|95-95|,|O
DDI-DrugBank.d666.s2|97-107|hydralazine|drug
DDI-DrugBank.d666.s2|108-108|,|O
DDI-DrugBank.d666.s2|110-112|and|O
DDI-DrugBank.d666.s2|114-125|guanethidine|drug
DDI-DrugBank.d666.s2|127-133|without|O
DDI-DrugBank.d666.s2|135-144|unexpected|O
DDI-DrugBank.d666.s2|146-152|adverse|O
DDI-DrugBank.d666.s2|154-165|interactions|O
DDI-DrugBank.d666.s2|166-166|.|O
DDI-DrugBank.d666.s3|0-7|Pindolol|drug
DDI-DrugBank.d666.s3|9-11|has|O
DDI-DrugBank.d666.s3|13-16|been|O
DDI-DrugBank.d666.s3|18-22|shown|O
DDI-DrugBank.d666.s3|24-25|to|O
DDI-DrugBank.d666.s3|27-34|increase|O
DDI-DrugBank.d666.s3|36-40|serum|O
DDI-DrugBank.d666.s3|42-53|thioridazine|drug
DDI-DrugBank.d666.s3|55-60|levels|O
DDI-DrugBank.d666.s3|62-65|when|O
DDI-DrugBank.d666.s3|67-70|both|O
DDI-DrugBank.d666.s3|72-76|drugs|O
DDI-DrugBank.d666.s3|78-80|are|O
DDI-DrugBank.d666.s3|82-96|co-administered|O
DDI-DrugBank.d666.s3|97-97|.|O
DDI-DrugBank.d666.s4|0-7|Pindolol|drug
DDI-DrugBank.d666.s4|9-14|levels|O
DDI-DrugBank.d666.s4|16-18|may|O
DDI-DrugBank.d666.s4|20-23|also|O
DDI-DrugBank.d666.s4|25-26|be|O
DDI-DrugBank.d666.s4|28-36|increased|O
DDI-DrugBank.d666.s4|38-41|with|O
DDI-DrugBank.d666.s4|43-46|this|O
DDI-DrugBank.d666.s4|48-58|combination|O
DDI-DrugBank.d666.s4|59-59|.|O
DDI-DrugBank.d666.s5|0-3|Risk|O
DDI-DrugBank.d666.s5|5-6|of|O
DDI-DrugBank.d666.s5|8-19|anaphylactic|O
DDI-DrugBank.d666.s5|21-28|reaction|O
DDI-DrugBank.d666.s5|29-29|:|O
DDI-DrugBank.d666.s5|31-35|While|O
DDI-DrugBank.d666.s5|37-42|taking|O
DDI-DrugBank.d666.s5|44-56|beta blockers|group
DDI-DrugBank.d666.s5|57-57|,|O
DDI-DrugBank.d666.s5|59-66|patients|O
DDI-DrugBank.d666.s5|68-71|with|O
DDI-DrugBank.d666.s5|73-73|a|O
DDI-DrugBank.d666.s5|75-81|history|O
DDI-DrugBank.d666.s5|83-84|of|O
DDI-DrugBank.d666.s5|86-91|severe|O
DDI-DrugBank.d666.s5|93-104|anaphylactic|O
DDI-DrugBank.d666.s5|106-113|reaction|O
DDI-DrugBank.d666.s5|115-116|to|O
DDI-DrugBank.d666.s5|118-118|a|O
DDI-DrugBank.d666.s5|120-126|variety|O
DDI-DrugBank.d666.s5|128-129|of|O
DDI-DrugBank.d666.s5|131-139|allergens|O
DDI-DrugBank.d666.s5|141-143|may|O
DDI-DrugBank.d666.s5|145-146|be|O
DDI-DrugBank.d666.s5|148-151|more|O
DDI-DrugBank.d666.s5|153-160|reactive|O
DDI-DrugBank.d666.s5|162-163|to|O
DDI-DrugBank.d666.s5|165-172|repeated|O
DDI-DrugBank.d666.s5|174-182|challenge|O
DDI-DrugBank.d666.s5|183-183|,|O
DDI-DrugBank.d666.s5|185-190|either|O
DDI-DrugBank.d666.s5|192-201|accidental|O
DDI-DrugBank.d666.s5|202-202|,|O
DDI-DrugBank.d666.s5|204-213|diagnostic|O
DDI-DrugBank.d666.s5|214-214|,|O
DDI-DrugBank.d666.s5|216-217|or|O
DDI-DrugBank.d666.s5|219-229|therapeutic|O
DDI-DrugBank.d666.s5|230-230|.|O
DDI-DrugBank.d666.s6|0-3|Such|O
DDI-DrugBank.d666.s6|5-12|patients|O
DDI-DrugBank.d666.s6|14-16|may|O
DDI-DrugBank.d666.s6|18-19|be|O
DDI-DrugBank.d666.s6|21-32|unresponsive|O
DDI-DrugBank.d666.s6|34-35|to|O
DDI-DrugBank.d666.s6|37-39|the|O
DDI-DrugBank.d666.s6|41-45|usual|O
DDI-DrugBank.d666.s6|47-51|doses|O
DDI-DrugBank.d666.s6|53-54|of|O
DDI-DrugBank.d666.s6|56-66|epinephrine|drug
DDI-DrugBank.d666.s6|68-71|used|O
DDI-DrugBank.d666.s6|73-74|to|O
DDI-DrugBank.d666.s6|76-80|treat|O
DDI-DrugBank.d666.s6|82-89|allergic|O
DDI-DrugBank.d666.s6|91-99|reactions|O
DDI-DrugBank.d666.s6|100-100|.|O
DDI-DrugBank.d631.s0|0-12|Pyrimethamine|drug
DDI-DrugBank.d631.s0|14-16|may|O
DDI-DrugBank.d631.s0|18-19|be|O
DDI-DrugBank.d631.s0|21-24|used|O
DDI-DrugBank.d631.s0|26-29|with|O
DDI-DrugBank.d631.s0|31-42|sulfonamides|group
DDI-DrugBank.d631.s0|43-43|,|O
DDI-DrugBank.d631.s0|45-51|quinine|drug
DDI-DrugBank.d631.s0|53-55|and|O
DDI-DrugBank.d631.s0|57-61|other|O
DDI-DrugBank.d631.s0|63-75|antimalarials|group
DDI-DrugBank.d631.s0|76-76|,|O
DDI-DrugBank.d631.s0|78-80|and|O
DDI-DrugBank.d631.s0|82-85|with|O
DDI-DrugBank.d631.s0|87-91|other|O
DDI-DrugBank.d631.s0|93-103|antibiotics|group
DDI-DrugBank.d631.s0|104-104|.|O
DDI-DrugBank.d631.s1|0-1|If|O
DDI-DrugBank.d631.s1|3-7|signs|O
DDI-DrugBank.d631.s1|9-10|of|O
DDI-DrugBank.d631.s1|12-17|folate|O
DDI-DrugBank.d631.s1|19-28|deficiency|O
DDI-DrugBank.d631.s1|30-36|develop|O
DDI-DrugBank.d631.s1|37-37|,|O
DDI-DrugBank.d631.s1|39-51|pyrimethamine|drug
DDI-DrugBank.d631.s1|53-58|should|O
DDI-DrugBank.d631.s1|60-61|be|O
DDI-DrugBank.d631.s1|63-74|discontinued|O
DDI-DrugBank.d631.s1|75-75|.|O
DDI-DrugBank.d631.s2|0-11|Folinic acid|drug
DDI-DrugBank.d631.s2|13-13|(|O
DDI-DrugBank.d631.s2|14-23|leucovorin|drug
DDI-DrugBank.d631.s2|24-24|)|O
DDI-DrugBank.d631.s2|26-31|should|O
DDI-DrugBank.d631.s2|33-34|be|O
DDI-DrugBank.d631.s2|36-47|administered|O
DDI-DrugBank.d631.s2|49-53|until|O
DDI-DrugBank.d631.s2|55-60|normal|O
DDI-DrugBank.d631.s2|62-74|hematopoiesis|O
DDI-DrugBank.d631.s2|76-77|is|O
DDI-DrugBank.d631.s2|79-86|restored|O
DDI-DrugBank.d631.s2|87-87|.|O
DDI-DrugBank.d631.s3|0-3|Mild|O
DDI-DrugBank.d631.s3|5-18|hepatotoxicity|O
DDI-DrugBank.d631.s3|20-22|has|O
DDI-DrugBank.d631.s3|24-27|been|O
DDI-DrugBank.d631.s3|29-36|reported|O
DDI-DrugBank.d631.s3|38-39|in|O
DDI-DrugBank.d631.s3|41-44|some|O
DDI-DrugBank.d631.s3|46-53|patients|O
DDI-DrugBank.d631.s3|55-58|when|O
DDI-DrugBank.d631.s3|60-68|lorazepam|drug
DDI-DrugBank.d631.s3|70-72|and|O
DDI-DrugBank.d631.s3|74-86|pyrimethamine|drug
DDI-DrugBank.d631.s3|88-91|were|O
DDI-DrugBank.d631.s3|93-104|administered|O
DDI-DrugBank.d631.s3|106-118|concomitantly|O
DDI-DrugBank.d631.s3|119-119|.|O
DDI-DrugBank.d228.s0|0-3|Oral|O
DDI-DrugBank.d228.s0|5-9|doses|O
DDI-DrugBank.d228.s0|11-12|of|O
DDI-DrugBank.d228.s0|14-20|Antizol|brand
DDI-DrugBank.d228.s0|22-22|(|O
DDI-DrugBank.d228.s0|23-27|10-20|O
DDI-DrugBank.d228.s0|29-33|mg/kg|O
DDI-DrugBank.d228.s0|34-34|)|O
DDI-DrugBank.d228.s0|35-35|,|O
DDI-DrugBank.d228.s0|37-39|via|O
DDI-DrugBank.d228.s0|41-47|alcohol|O
DDI-DrugBank.d228.s0|49-61|dehydrogenase|O
DDI-DrugBank.d228.s0|63-72|inhibition|O
DDI-DrugBank.d228.s0|73-73|,|O
DDI-DrugBank.d228.s0|75-87|significantly|O
DDI-DrugBank.d228.s0|89-95|reduced|O
DDI-DrugBank.d228.s0|97-99|the|O
DDI-DrugBank.d228.s0|101-104|rate|O
DDI-DrugBank.d228.s0|106-107|of|O
DDI-DrugBank.d228.s0|109-119|elimination|O
DDI-DrugBank.d228.s0|121-122|of|O
DDI-DrugBank.d228.s0|124-130|ethanol|drug
DDI-DrugBank.d228.s0|132-132|(|O
DDI-DrugBank.d228.s0|133-134|by|O
DDI-DrugBank.d228.s0|136-148|approximately|O
DDI-DrugBank.d228.s0|150-151|40|O
DDI-DrugBank.d228.s0|152-152|%|O
DDI-DrugBank.d228.s0|153-153|)|O
DDI-DrugBank.d228.s0|155-159|given|O
DDI-DrugBank.d228.s0|161-162|to|O
DDI-DrugBank.d228.s0|164-170|healthy|O
DDI-DrugBank.d228.s0|172-181|volunteers|O
DDI-DrugBank.d228.s0|183-184|in|O
DDI-DrugBank.d228.s0|186-193|moderate|O
DDI-DrugBank.d228.s0|195-199|doses|O
DDI-DrugBank.d228.s0|200-200|.|O
DDI-DrugBank.d228.s1|0-8|Similarly|O
DDI-DrugBank.d228.s1|9-9|,|O
DDI-DrugBank.d228.s1|11-17|ethanol|drug
DDI-DrugBank.d228.s1|19-27|decreased|O
DDI-DrugBank.d228.s1|29-31|the|O
DDI-DrugBank.d228.s1|33-36|rate|O
DDI-DrugBank.d228.s1|38-39|of|O
DDI-DrugBank.d228.s1|41-51|elimination|O
DDI-DrugBank.d228.s1|53-54|of|O
DDI-DrugBank.d228.s1|56-62|Antizol|brand
DDI-DrugBank.d228.s1|64-64|(|O
DDI-DrugBank.d228.s1|65-66|by|O
DDI-DrugBank.d228.s1|68-80|approximately|O
DDI-DrugBank.d228.s1|82-83|50|O
DDI-DrugBank.d228.s1|84-84|%|O
DDI-DrugBank.d228.s1|85-85|)|O
DDI-DrugBank.d228.s1|87-88|by|O
DDI-DrugBank.d228.s1|90-92|the|O
DDI-DrugBank.d228.s1|94-97|same|O
DDI-DrugBank.d228.s1|99-107|mechanism|O
DDI-DrugBank.d228.s1|108-108|.|O
DDI-DrugBank.d228.s2|0-9|Reciprocal|O
DDI-DrugBank.d228.s2|11-22|interactions|O
DDI-DrugBank.d228.s2|24-26|may|O
DDI-DrugBank.d228.s2|28-32|occur|O
DDI-DrugBank.d228.s2|34-37|with|O
DDI-DrugBank.d228.s2|39-49|concomitant|O
DDI-DrugBank.d228.s2|51-53|use|O
DDI-DrugBank.d228.s2|55-56|of|O
DDI-DrugBank.d228.s2|58-64|Antizol|brand
DDI-DrugBank.d228.s2|66-68|and|O
DDI-DrugBank.d228.s2|70-74|drugs|O
DDI-DrugBank.d228.s2|76-79|that|O
DDI-DrugBank.d228.s2|81-88|increase|O
DDI-DrugBank.d228.s2|90-91|or|O
DDI-DrugBank.d228.s2|93-99|inhibit|O
DDI-DrugBank.d228.s2|101-103|the|O
DDI-DrugBank.d228.s2|105-114|cytochrome|O
DDI-DrugBank.d228.s2|116-119|P450|O
DDI-DrugBank.d228.s2|121-126|system|O
DDI-DrugBank.d228.s2|128-128|(|O
DDI-DrugBank.d228.s2|129-132|e.g.|O
DDI-DrugBank.d228.s2|133-133|,|O
DDI-DrugBank.d228.s2|135-143|phenytoin|drug
DDI-DrugBank.d228.s2|144-144|,|O
DDI-DrugBank.d228.s2|146-158|carbamazepine|drug
DDI-DrugBank.d228.s2|159-159|,|O
DDI-DrugBank.d228.s2|161-170|cimetidine|drug
DDI-DrugBank.d228.s2|171-171|,|O
DDI-DrugBank.d228.s2|173-184|ketoconazole|drug
DDI-DrugBank.d228.s2|185-185|)|O
DDI-DrugBank.d228.s2|186-186|,|O
DDI-DrugBank.d228.s2|188-193|though|O
DDI-DrugBank.d228.s2|195-198|this|O
DDI-DrugBank.d228.s2|200-202|has|O
DDI-DrugBank.d228.s2|204-206|not|O
DDI-DrugBank.d228.s2|208-211|been|O
DDI-DrugBank.d228.s2|213-219|studied|O
DDI-DrugBank.d228.s3|0-0|.|O
DDI-DrugBank.d137.s0|0-7|Nitrates|group
DDI-DrugBank.d137.s0|8-8|:|O
DDI-DrugBank.d137.s0|10-12|The|O
DDI-DrugBank.d137.s0|14-24|concomitant|O
DDI-DrugBank.d137.s0|26-28|use|O
DDI-DrugBank.d137.s0|30-31|of|O
DDI-DrugBank.d137.s0|33-40|Bepridil|drug
DDI-DrugBank.d137.s0|42-45|with|O
DDI-DrugBank.d137.s0|47-51|long-|O
DDI-DrugBank.d137.s0|53-55|and|O
DDI-DrugBank.d137.s0|57-68|short-acting|O
DDI-DrugBank.d137.s0|70-77|nitrates|group
DDI-DrugBank.d137.s0|79-81|has|O
DDI-DrugBank.d137.s0|83-86|been|O
DDI-DrugBank.d137.s0|88-93|safely|O
DDI-DrugBank.d137.s0|95-103|tolerated|O
DDI-DrugBank.d137.s0|105-106|in|O
DDI-DrugBank.d137.s0|108-115|patients|O
DDI-DrugBank.d137.s0|117-120|with|O
DDI-DrugBank.d137.s0|122-127|stable|O
DDI-DrugBank.d137.s0|129-134|angina|O
DDI-DrugBank.d137.s0|136-143|pectoris|O
DDI-DrugBank.d137.s0|144-144|.|O
DDI-DrugBank.d137.s1|0-9|Sublingual|O
DDI-DrugBank.d137.s1|11-23|nitroglycerin|drug
DDI-DrugBank.d137.s1|25-27|may|O
DDI-DrugBank.d137.s1|29-30|be|O
DDI-DrugBank.d137.s1|32-36|taken|O
DDI-DrugBank.d137.s1|38-39|if|O
DDI-DrugBank.d137.s1|41-49|necessary|O
DDI-DrugBank.d137.s1|51-53|for|O
DDI-DrugBank.d137.s1|55-57|the|O
DDI-DrugBank.d137.s1|59-65|control|O
DDI-DrugBank.d137.s1|67-68|of|O
DDI-DrugBank.d137.s1|70-74|acute|O
DDI-DrugBank.d137.s1|76-81|angina|O
DDI-DrugBank.d137.s1|83-89|attacks|O
DDI-DrugBank.d137.s1|91-96|during|O
DDI-DrugBank.d137.s1|98-105|Bepridil|drug
DDI-DrugBank.d137.s1|107-113|therapy|O
DDI-DrugBank.d137.s1|114-114|.|O
DDI-DrugBank.d137.s2|0-19|Beta-blocking Agents|group
DDI-DrugBank.d137.s2|20-20|:|O
DDI-DrugBank.d137.s2|22-24|The|O
DDI-DrugBank.d137.s2|26-36|concomitant|O
DDI-DrugBank.d137.s2|38-40|use|O
DDI-DrugBank.d137.s2|42-43|of|O
DDI-DrugBank.d137.s2|45-52|Bepridil|drug
DDI-DrugBank.d137.s2|54-56|and|O
DDI-DrugBank.d137.s2|58-77|beta-blocking agents|group
DDI-DrugBank.d137.s2|79-81|has|O
DDI-DrugBank.d137.s2|83-86|been|O
DDI-DrugBank.d137.s2|88-91|well|O
DDI-DrugBank.d137.s2|93-101|tolerated|O
DDI-DrugBank.d137.s2|103-104|in|O
DDI-DrugBank.d137.s2|106-113|patients|O
DDI-DrugBank.d137.s2|115-118|with|O
DDI-DrugBank.d137.s2|120-125|stable|O
DDI-DrugBank.d137.s2|127-132|angina|O
DDI-DrugBank.d137.s2|133-133|.|O
DDI-DrugBank.d137.s3|0-8|Available|O
DDI-DrugBank.d137.s3|10-13|data|O
DDI-DrugBank.d137.s3|15-17|are|O
DDI-DrugBank.d137.s3|19-21|not|O
DDI-DrugBank.d137.s3|23-32|sufficient|O
DDI-DrugBank.d137.s3|33-33|,|O
DDI-DrugBank.d137.s3|35-41|however|O
DDI-DrugBank.d137.s3|42-42|,|O
DDI-DrugBank.d137.s3|44-45|to|O
DDI-DrugBank.d137.s3|47-53|predict|O
DDI-DrugBank.d137.s3|55-57|the|O
DDI-DrugBank.d137.s3|59-65|effects|O
DDI-DrugBank.d137.s3|67-68|of|O
DDI-DrugBank.d137.s3|70-80|concomitant|O
DDI-DrugBank.d137.s3|82-91|medication|O
DDI-DrugBank.d137.s3|93-94|on|O
DDI-DrugBank.d137.s3|96-103|patients|O
DDI-DrugBank.d137.s3|105-108|with|O
DDI-DrugBank.d137.s3|110-117|impaired|O
DDI-DrugBank.d137.s3|119-129|ventricular|O
DDI-DrugBank.d137.s3|131-138|function|O
DDI-DrugBank.d137.s3|140-141|or|O
DDI-DrugBank.d137.s3|143-149|cardiac|O
DDI-DrugBank.d137.s3|151-160|conduction|O
DDI-DrugBank.d137.s3|162-174|abnormalities|O
DDI-DrugBank.d137.s3|175-175|.|O
DDI-DrugBank.d137.s4|0-6|Digoxin|drug
DDI-DrugBank.d137.s4|7-7|:|O
DDI-DrugBank.d137.s4|9-10|In|O
DDI-DrugBank.d137.s4|12-21|controlled|O
DDI-DrugBank.d137.s4|23-29|studies|O
DDI-DrugBank.d137.s4|31-32|in|O
DDI-DrugBank.d137.s4|34-40|healthy|O
DDI-DrugBank.d137.s4|42-51|volunteers|O
DDI-DrugBank.d137.s4|52-52|,|O
DDI-DrugBank.d137.s4|54-75|bepridil hydrochloride|drug
DDI-DrugBank.d137.s4|77-82|either|O
DDI-DrugBank.d137.s4|84-86|had|O
DDI-DrugBank.d137.s4|88-89|no|O
DDI-DrugBank.d137.s4|91-96|effect|O
DDI-DrugBank.d137.s4|98-98|(|O
DDI-DrugBank.d137.s4|99-101|one|O
DDI-DrugBank.d137.s4|103-107|study|O
DDI-DrugBank.d137.s4|108-108|)|O
DDI-DrugBank.d137.s4|110-111|or|O
DDI-DrugBank.d137.s4|113-115|was|O
DDI-DrugBank.d137.s4|117-126|associated|O
DDI-DrugBank.d137.s4|128-131|with|O
DDI-DrugBank.d137.s4|133-138|modest|O
DDI-DrugBank.d137.s4|140-148|increases|O
DDI-DrugBank.d137.s4|149-149|,|O
DDI-DrugBank.d137.s4|151-155|about|O
DDI-DrugBank.d137.s4|157-158|30|O
DDI-DrugBank.d137.s4|159-159|%|O
DDI-DrugBank.d137.s4|161-161|(|O
DDI-DrugBank.d137.s4|162-164|two|O
DDI-DrugBank.d137.s4|166-172|studies|O
DDI-DrugBank.d137.s4|173-173|)|O
DDI-DrugBank.d137.s4|175-176|in|O
DDI-DrugBank.d137.s4|178-189|steady-state|O
DDI-DrugBank.d137.s4|191-195|serum|O
DDI-DrugBank.d137.s4|197-203|digoxin|drug
DDI-DrugBank.d137.s4|205-218|concentrations|O
DDI-DrugBank.d137.s4|219-219|.|O
DDI-DrugBank.d137.s5|0-6|Limited|O
DDI-DrugBank.d137.s5|8-15|clinical|O
DDI-DrugBank.d137.s5|17-20|data|O
DDI-DrugBank.d137.s5|22-23|in|O
DDI-DrugBank.d137.s5|25-30|angina|O
DDI-DrugBank.d137.s5|32-39|patients|O
DDI-DrugBank.d137.s5|41-49|receiving|O
DDI-DrugBank.d137.s5|51-61|concomitant|O
DDI-DrugBank.d137.s5|63-84|bepridil hydrochloride|drug
DDI-DrugBank.d137.s5|86-88|and|O
DDI-DrugBank.d137.s5|90-96|digoxin|drug
DDI-DrugBank.d137.s5|98-104|therapy|O
DDI-DrugBank.d137.s5|106-113|indicate|O
DDI-DrugBank.d137.s5|115-116|no|O
DDI-DrugBank.d137.s5|118-128|discernible|O
DDI-DrugBank.d137.s5|130-136|changes|O
DDI-DrugBank.d137.s5|138-139|in|O
DDI-DrugBank.d137.s5|141-145|serum|O
DDI-DrugBank.d137.s5|147-153|digoxin|O
DDI-DrugBank.d137.s5|155-160|levels|O
DDI-DrugBank.d137.s5|161-161|.|O
DDI-DrugBank.d137.s6|0-8|Available|O
DDI-DrugBank.d137.s6|10-13|data|O
DDI-DrugBank.d137.s6|15-17|are|O
DDI-DrugBank.d137.s6|19-25|neither|O
DDI-DrugBank.d137.s6|27-36|sufficient|O
DDI-DrugBank.d137.s6|38-39|to|O
DDI-DrugBank.d137.s6|41-44|rule|O
DDI-DrugBank.d137.s6|46-48|out|O
DDI-DrugBank.d137.s6|50-57|possible|O
DDI-DrugBank.d137.s6|59-67|increases|O
DDI-DrugBank.d137.s6|69-70|in|O
DDI-DrugBank.d137.s6|72-76|serum|O
DDI-DrugBank.d137.s6|78-84|digoxin|drug
DDI-DrugBank.d137.s6|86-89|with|O
DDI-DrugBank.d137.s6|91-101|concomitant|O
DDI-DrugBank.d137.s6|103-111|treatment|O
DDI-DrugBank.d137.s6|113-114|in|O
DDI-DrugBank.d137.s6|116-119|some|O
DDI-DrugBank.d137.s6|121-128|patients|O
DDI-DrugBank.d137.s6|129-129|,|O
DDI-DrugBank.d137.s6|131-133|nor|O
DDI-DrugBank.d137.s6|135-139|other|O
DDI-DrugBank.d137.s6|141-148|possible|O
DDI-DrugBank.d137.s6|150-161|interactions|O
DDI-DrugBank.d137.s6|162-162|,|O
DDI-DrugBank.d137.s6|164-175|particularly|O
DDI-DrugBank.d137.s6|177-178|in|O
DDI-DrugBank.d137.s6|180-187|patients|O
DDI-DrugBank.d137.s6|189-192|with|O
DDI-DrugBank.d137.s6|194-200|cardiac|O
DDI-DrugBank.d137.s6|202-211|conduction|O
DDI-DrugBank.d137.s6|213-225|abnormalities|O
DDI-DrugBank.d137.s6|227-227|(|O
DDI-DrugBank.d137.s6|228-231|Also|O
DDI-DrugBank.d137.s6|233-235|see|O
DDI-DrugBank.d137.s6|237-244|WARNINGS|O
DDI-DrugBank.d137.s6|246-255|Congestive|O
DDI-DrugBank.d137.s6|257-261|Heart|O
DDI-DrugBank.d137.s6|263-269|Failure|O
DDI-DrugBank.d137.s6|270-270|)|O
DDI-DrugBank.d137.s6|271-271|.|O
DDI-DrugBank.d137.s7|0-3|Oral|O
DDI-DrugBank.d137.s7|5-17|Hypoglycemics|group
DDI-DrugBank.d137.s7|18-18|:|O
DDI-DrugBank.d137.s7|20-27|Bepridil|drug
DDI-DrugBank.d137.s7|29-31|has|O
DDI-DrugBank.d137.s7|33-36|been|O
DDI-DrugBank.d137.s7|38-43|safely|O
DDI-DrugBank.d137.s7|45-48|used|O
DDI-DrugBank.d137.s7|50-51|in|O
DDI-DrugBank.d137.s7|53-60|diabetic|O
DDI-DrugBank.d137.s7|62-69|patients|O
DDI-DrugBank.d137.s7|71-77|without|O
DDI-DrugBank.d137.s7|79-91|significantly|O
DDI-DrugBank.d137.s7|93-100|lowering|O
DDI-DrugBank.d137.s7|102-106|their|O
DDI-DrugBank.d137.s7|108-112|blood|O
DDI-DrugBank.d137.s7|114-120|glucose|O
DDI-DrugBank.d137.s7|122-127|levels|O
DDI-DrugBank.d137.s7|129-130|or|O
DDI-DrugBank.d137.s7|132-139|altering|O
DDI-DrugBank.d137.s7|141-145|their|O
DDI-DrugBank.d137.s7|147-150|need|O
DDI-DrugBank.d137.s7|152-154|for|O
DDI-DrugBank.d137.s7|156-162|insulin|drug
DDI-DrugBank.d137.s7|164-165|or|O
DDI-DrugBank.d137.s7|167-170|oral|O
DDI-DrugBank.d137.s7|172-190|hypoglycemic agents|group
DDI-DrugBank.d137.s7|191-191|.|O
DDI-DrugBank.d137.s8|0-6|General|O
DDI-DrugBank.d137.s8|8-19|Interactions|O
DDI-DrugBank.d137.s8|20-20|:|O
DDI-DrugBank.d137.s8|22-28|Certain|O
DDI-DrugBank.d137.s8|30-34|drugs|O
DDI-DrugBank.d137.s8|36-40|could|O
DDI-DrugBank.d137.s8|42-49|increase|O
DDI-DrugBank.d137.s8|51-53|the|O
DDI-DrugBank.d137.s8|55-64|likelihood|O
DDI-DrugBank.d137.s8|66-67|of|O
DDI-DrugBank.d137.s8|69-79|potentially|O
DDI-DrugBank.d137.s8|81-87|serious|O
DDI-DrugBank.d137.s8|89-95|adverse|O
DDI-DrugBank.d137.s8|97-103|effects|O
DDI-DrugBank.d137.s8|105-108|with|O
DDI-DrugBank.d137.s8|110-131|bepridil hydrochloride|drug
DDI-DrugBank.d137.s8|132-132|.|O
DDI-DrugBank.d137.s9|0-1|In|O
DDI-DrugBank.d137.s9|3-9|general|O
DDI-DrugBank.d137.s9|10-10|,|O
DDI-DrugBank.d137.s9|12-16|these|O
DDI-DrugBank.d137.s9|18-20|are|O
DDI-DrugBank.d137.s9|22-26|drugs|O
DDI-DrugBank.d137.s9|28-31|that|O
DDI-DrugBank.d137.s9|33-36|have|O
DDI-DrugBank.d137.s9|38-40|one|O
DDI-DrugBank.d137.s9|42-43|or|O
DDI-DrugBank.d137.s9|45-48|more|O
DDI-DrugBank.d137.s9|50-62|pharmacologic|O
DDI-DrugBank.d137.s9|64-73|activities|O
DDI-DrugBank.d137.s9|75-81|similar|O
DDI-DrugBank.d137.s9|83-84|to|O
DDI-DrugBank.d137.s9|86-107|bepridil hydrochloride|drug
DDI-DrugBank.d137.s9|108-108|,|O
DDI-DrugBank.d137.s9|110-118|including|O
DDI-DrugBank.d137.s9|120-141|anti-arrhythmic agents|group
DDI-DrugBank.d137.s9|143-146|such|O
DDI-DrugBank.d137.s9|148-149|as|O
DDI-DrugBank.d137.s9|151-159|quinidine|drug
DDI-DrugBank.d137.s9|161-163|and|O
DDI-DrugBank.d137.s9|165-176|procainamide|drug
DDI-DrugBank.d137.s9|177-177|,|O
DDI-DrugBank.d137.s9|179-196|cardiac glycosides|group
DDI-DrugBank.d137.s9|198-200|and|O
DDI-DrugBank.d137.s9|202-227|tricyclic anti-depressants|group
DDI-DrugBank.d137.s9|228-228|.|O
DDI-DrugBank.d137.s10|0-15|Anti-arrhythmics|group
DDI-DrugBank.d137.s10|17-19|and|O
DDI-DrugBank.d137.s10|21-46|tricyclic anti-depressants|group
DDI-DrugBank.d137.s10|48-52|could|O
DDI-DrugBank.d137.s10|54-63|exaggerate|O
DDI-DrugBank.d137.s10|65-67|the|O
DDI-DrugBank.d137.s10|69-80|prolongation|O
DDI-DrugBank.d137.s10|82-83|of|O
DDI-DrugBank.d137.s10|85-87|the|O
DDI-DrugBank.d137.s10|89-90|QT|O
DDI-DrugBank.d137.s10|92-99|interval|O
DDI-DrugBank.d137.s10|101-108|observed|O
DDI-DrugBank.d137.s10|110-113|with|O
DDI-DrugBank.d137.s10|115-136|bepridil hydrochloride|drug
DDI-DrugBank.d137.s10|137-137|.|O
DDI-DrugBank.d137.s11|0-17|Cardiac glycosides|group
DDI-DrugBank.d137.s11|19-23|could|O
DDI-DrugBank.d137.s11|25-34|exaggerate|O
DDI-DrugBank.d137.s11|36-38|the|O
DDI-DrugBank.d137.s11|40-49|depression|O
DDI-DrugBank.d137.s11|51-52|of|O
DDI-DrugBank.d137.s11|54-55|AV|O
DDI-DrugBank.d137.s11|57-61|nodal|O
DDI-DrugBank.d137.s11|63-72|conduction|O
DDI-DrugBank.d137.s11|74-81|observed|O
DDI-DrugBank.d137.s11|83-86|with|O
DDI-DrugBank.d137.s11|88-109|bepridil hydrochloride|drug
DDI-DrugBank.d137.s11|110-110|.|O
DDI-DrugBank.d126.s0|0-3|Drug|O
DDI-DrugBank.d126.s0|5-15|interaction|O
DDI-DrugBank.d126.s0|17-23|studies|O
DDI-DrugBank.d126.s0|25-28|with|O
DDI-DrugBank.d126.s0|30-39|decitabine|drug
DDI-DrugBank.d126.s0|41-44|have|O
DDI-DrugBank.d126.s0|46-48|not|O
DDI-DrugBank.d126.s0|50-53|been|O
DDI-DrugBank.d126.s0|55-63|conducted|O
DDI-DrugBank.d126.s0|64-64|.|O
DDI-DrugBank.d126.s1|0-1|In|O
DDI-DrugBank.d126.s1|3-7|vitro|O
DDI-DrugBank.d126.s1|9-15|studies|O
DDI-DrugBank.d126.s1|17-18|in|O
DDI-DrugBank.d126.s1|20-24|human|O
DDI-DrugBank.d126.s1|26-30|liver|O
DDI-DrugBank.d126.s1|32-41|microsomes|O
DDI-DrugBank.d126.s1|43-49|suggest|O
DDI-DrugBank.d126.s1|51-54|that|O
DDI-DrugBank.d126.s1|56-65|decitabine|drug
DDI-DrugBank.d126.s1|67-68|is|O
DDI-DrugBank.d126.s1|70-77|unlikely|O
DDI-DrugBank.d126.s1|79-80|to|O
DDI-DrugBank.d126.s1|82-88|inhibit|O
DDI-DrugBank.d126.s1|90-91|or|O
DDI-DrugBank.d126.s1|93-98|induce|O
DDI-DrugBank.d126.s1|100-109|cytochrome|O
DDI-DrugBank.d126.s1|111-114|P450|O
DDI-DrugBank.d126.s1|116-122|enzymes|O
DDI-DrugBank.d126.s1|123-123|.|O
DDI-DrugBank.d126.s2|0-1|In|O
DDI-DrugBank.d126.s2|3-7|vitro|O
DDI-DrugBank.d126.s2|9-18|metabolism|O
DDI-DrugBank.d126.s2|20-26|studies|O
DDI-DrugBank.d126.s2|28-31|have|O
DDI-DrugBank.d126.s2|33-41|suggested|O
DDI-DrugBank.d126.s2|43-46|that|O
DDI-DrugBank.d126.s2|48-57|decitabine|drug
DDI-DrugBank.d126.s2|59-60|is|O
DDI-DrugBank.d126.s2|62-64|not|O
DDI-DrugBank.d126.s2|66-66|a|O
DDI-DrugBank.d126.s2|68-76|substrate|O
DDI-DrugBank.d126.s2|78-80|for|O
DDI-DrugBank.d126.s2|82-84|the|O
DDI-DrugBank.d126.s2|86-90|human|O
DDI-DrugBank.d126.s2|92-96|liver|O
DDI-DrugBank.d126.s2|98-107|cytochrome|O
DDI-DrugBank.d126.s2|109-112|P450|O
DDI-DrugBank.d126.s2|114-120|enzymes|O
DDI-DrugBank.d126.s2|121-121|.|O
DDI-DrugBank.d126.s3|0-1|As|O
DDI-DrugBank.d126.s3|3-8|plasma|O
DDI-DrugBank.d126.s3|10-16|protein|O
DDI-DrugBank.d126.s3|18-24|binding|O
DDI-DrugBank.d126.s3|26-27|of|O
DDI-DrugBank.d126.s3|29-38|decitabine|drug
DDI-DrugBank.d126.s3|40-41|is|O
DDI-DrugBank.d126.s3|43-52|negligible|O
DDI-DrugBank.d126.s3|54-54|(|O
DDI-DrugBank.d126.s3|56-56|1|O
DDI-DrugBank.d126.s3|57-57|%|O
DDI-DrugBank.d126.s3|58-58|)|O
DDI-DrugBank.d126.s3|59-59|,|O
DDI-DrugBank.d126.s3|61-72|interactions|O
DDI-DrugBank.d126.s3|74-76|due|O
DDI-DrugBank.d126.s3|78-79|to|O
DDI-DrugBank.d126.s3|81-92|displacement|O
DDI-DrugBank.d126.s3|94-95|of|O
DDI-DrugBank.d126.s3|97-100|more|O
DDI-DrugBank.d126.s3|102-107|highly|O
DDI-DrugBank.d126.s3|109-115|protein|O
DDI-DrugBank.d126.s3|117-121|bound|O
DDI-DrugBank.d126.s3|123-127|drugs|O
DDI-DrugBank.d126.s3|129-132|from|O
DDI-DrugBank.d126.s3|134-139|plasma|O
DDI-DrugBank.d126.s3|141-148|proteins|O
DDI-DrugBank.d126.s3|150-152|are|O
DDI-DrugBank.d126.s3|154-156|not|O
DDI-DrugBank.d126.s3|158-165|expected|O
DDI-DrugBank.d126.s3|166-166|.|O
DDI-MedLine.d163.s0|0-1|In|O
DDI-MedLine.d163.s0|3-7|vitro|O
DDI-MedLine.d163.s0|9-16|activity|O
DDI-MedLine.d163.s0|18-19|of|O
DDI-MedLine.d163.s0|21-31|minocycline|drug
DDI-MedLine.d163.s0|33-40|combined|O
DDI-MedLine.d163.s0|42-45|with|O
DDI-MedLine.d163.s0|47-56|fosfomycin|drug
DDI-MedLine.d163.s0|58-64|against|O
DDI-MedLine.d163.s0|66-73|clinical|O
DDI-MedLine.d163.s0|75-82|isolates|O
DDI-MedLine.d163.s0|84-85|of|O
DDI-MedLine.d163.s0|87-107|methicillin-resistant|drug
DDI-MedLine.d163.s0|109-122|Staphylococcus|O
DDI-MedLine.d163.s0|124-129|aureus|O
DDI-MedLine.d163.s0|130-130|.|O
DDI-MedLine.d163.s1|0-3|This|O
DDI-MedLine.d163.s1|5-9|study|O
DDI-MedLine.d163.s1|11-15|aimed|O
DDI-MedLine.d163.s1|17-18|to|O
DDI-MedLine.d163.s1|20-27|evaluate|O
DDI-MedLine.d163.s1|29-31|the|O
DDI-MedLine.d163.s1|33-34|in|O
DDI-MedLine.d163.s1|36-40|vitro|O
DDI-MedLine.d163.s1|42-49|activity|O
DDI-MedLine.d163.s1|51-52|of|O
DDI-MedLine.d163.s1|54-64|minocycline|drug
DDI-MedLine.d163.s1|66-73|combined|O
DDI-MedLine.d163.s1|75-78|with|O
DDI-MedLine.d163.s1|80-89|fosfomycin|drug
DDI-MedLine.d163.s1|91-97|against|O
DDI-MedLine.d163.s1|99-106|isolates|O
DDI-MedLine.d163.s1|108-109|of|O
DDI-MedLine.d163.s1|111-131|methicillin-resistant|drug
DDI-MedLine.d163.s1|133-146|Staphylococcus|O
DDI-MedLine.d163.s1|148-153|aureus|O
DDI-MedLine.d163.s1|155-155|(|O
DDI-MedLine.d163.s1|156-159|MRSA|O
DDI-MedLine.d163.s1|160-160|)|O
DDI-MedLine.d163.s1|161-161|.|O
DDI-MedLine.d163.s2|0-0|A|O
DDI-MedLine.d163.s2|2-6|total|O
DDI-MedLine.d163.s2|8-9|of|O
DDI-MedLine.d163.s2|11-12|87|O
DDI-MedLine.d163.s2|14-21|clinical|O
DDI-MedLine.d163.s2|23-30|isolates|O
DDI-MedLine.d163.s2|32-33|of|O
DDI-MedLine.d163.s2|35-38|MRSA|O
DDI-MedLine.d163.s2|40-48|collected|O
DDI-MedLine.d163.s2|50-53|from|O
DDI-MedLine.d163.s2|55-59|three|O
DDI-MedLine.d163.s2|61-67|Chinese|O
DDI-MedLine.d163.s2|69-77|hospitals|O
DDI-MedLine.d163.s2|79-82|were|O
DDI-MedLine.d163.s2|84-91|included|O
DDI-MedLine.d163.s2|93-94|in|O
DDI-MedLine.d163.s2|96-98|the|O
DDI-MedLine.d163.s2|100-104|study|O
DDI-MedLine.d163.s2|105-105|.|O
DDI-MedLine.d163.s3|0-2|The|O
DDI-MedLine.d163.s3|4-15|checkerboard|O
DDI-MedLine.d163.s3|17-22|method|O
DDI-MedLine.d163.s3|24-27|with|O
DDI-MedLine.d163.s3|29-41|determination|O
DDI-MedLine.d163.s3|43-44|of|O
DDI-MedLine.d163.s3|46-48|the|O
DDI-MedLine.d163.s3|50-59|fractional|O
DDI-MedLine.d163.s3|61-62|IC|O
DDI-MedLine.d163.s3|64-68|index|O
DDI-MedLine.d163.s3|70-70|(|O
DDI-MedLine.d163.s3|71-74|FICI|O
DDI-MedLine.d163.s3|75-75|)|O
DDI-MedLine.d163.s3|77-79|was|O
DDI-MedLine.d163.s3|81-84|used|O
DDI-MedLine.d163.s3|86-87|to|O
DDI-MedLine.d163.s3|89-97|determine|O
DDI-MedLine.d163.s3|99-105|whether|O
DDI-MedLine.d163.s3|107-116|antibiotic|group
DDI-MedLine.d163.s3|118-129|combinations|O
DDI-MedLine.d163.s3|131-133|act|O
DDI-MedLine.d163.s3|135-149|synergistically|O
DDI-MedLine.d163.s3|151-157|against|O
DDI-MedLine.d163.s3|159-163|these|O
DDI-MedLine.d163.s3|165-172|isolates|O
DDI-MedLine.d163.s3|173-173|.|O
DDI-MedLine.d163.s4|0-2|The|O
DDI-MedLine.d163.s4|4-17|susceptibility|O
DDI-MedLine.d163.s4|19-25|results|O
DDI-MedLine.d163.s4|27-29|for|O
DDI-MedLine.d163.s4|31-41|minocycline|drug
DDI-MedLine.d163.s4|43-45|and|O
DDI-MedLine.d163.s4|47-56|fosfomycin|drug
DDI-MedLine.d163.s4|58-61|were|O
DDI-MedLine.d163.s4|63-73|interpreted|O
DDI-MedLine.d163.s4|75-83|according|O
DDI-MedLine.d163.s4|85-86|to|O
DDI-MedLine.d163.s4|88-90|the|O
DDI-MedLine.d163.s4|92-95|most|O
DDI-MedLine.d163.s4|97-104|relevant|O
DDI-MedLine.d163.s4|106-113|criteria|O
DDI-MedLine.d163.s4|114-114|.|O
DDI-MedLine.d163.s5|0-2|The|O
DDI-MedLine.d163.s5|4-10|results|O
DDI-MedLine.d163.s5|12-23|demonstrated|O
DDI-MedLine.d163.s5|25-27|the|O
DDI-MedLine.d163.s5|29-37|following|O
DDI-MedLine.d163.s5|39-50|interactions|O
DDI-MedLine.d163.s5|51-51|:|O
DDI-MedLine.d163.s5|53-54|76|O
DDI-MedLine.d163.s5|56-63|isolates|O
DDI-MedLine.d163.s5|65-65|(|O
DDI-MedLine.d163.s5|66-69|87.4|O
DDI-MedLine.d163.s5|70-70|%|O
DDI-MedLine.d163.s5|71-71|)|O
DDI-MedLine.d163.s5|73-78|showed|O
DDI-MedLine.d163.s5|80-90|synergistic|O
DDI-MedLine.d163.s5|92-103|interactions|O
DDI-MedLine.d163.s5|105-105|(|O
DDI-MedLine.d163.s5|106-109|FICI|O
DDI-MedLine.d163.s5|113-115|0.5|O
DDI-MedLine.d163.s5|116-116|)|O
DDI-MedLine.d163.s5|118-120|and|O
DDI-MedLine.d163.s5|122-123|11|O
DDI-MedLine.d163.s5|125-132|isolates|O
DDI-MedLine.d163.s5|134-134|(|O
DDI-MedLine.d163.s5|135-138|12.6|O
DDI-MedLine.d163.s5|139-139|%|O
DDI-MedLine.d163.s5|140-140|)|O
DDI-MedLine.d163.s5|142-147|showed|O
DDI-MedLine.d163.s5|149-159|indifferent|O
DDI-MedLine.d163.s5|161-172|interactions|O
DDI-MedLine.d163.s5|174-174|(|O
DDI-MedLine.d163.s5|175-177|0.5|O
DDI-MedLine.d163.s5|178-178|&|O
DDI-MedLine.d163.s5|179-180|lt|O
DDI-MedLine.d163.s5|181-181|;|O
DDI-MedLine.d163.s5|182-185|FICI|O
DDI-MedLine.d163.s5|186-186|&|O
DDI-MedLine.d163.s5|187-188|lt|O
DDI-MedLine.d163.s5|189-189|;|O
DDI-MedLine.d163.s5|190-190|4|O
DDI-MedLine.d163.s5|191-191|)|O
DDI-MedLine.d163.s5|192-192|.|O
DDI-MedLine.d163.s6|0-1|No|O
DDI-MedLine.d163.s6|3-14|antagonistic|O
DDI-MedLine.d163.s6|16-27|interactions|O
DDI-MedLine.d163.s6|29-29|(|O
DDI-MedLine.d163.s6|30-33|FICI|O
DDI-MedLine.d163.s6|37-37|4|O
DDI-MedLine.d163.s6|38-38|)|O
DDI-MedLine.d163.s6|40-43|were|O
DDI-MedLine.d163.s6|45-52|observed|O
DDI-MedLine.d163.s6|53-53|.|O
DDI-MedLine.d163.s7|0-2|The|O
DDI-MedLine.d163.s7|4-14|combination|O
DDI-MedLine.d163.s7|16-17|of|O
DDI-MedLine.d163.s7|19-29|minocycline|drug
DDI-MedLine.d163.s7|31-33|and|O
DDI-MedLine.d163.s7|35-44|fosfomycin|drug
DDI-MedLine.d163.s7|46-48|can|O
DDI-MedLine.d163.s7|50-51|be|O
DDI-MedLine.d163.s7|53-63|synergistic|O
DDI-MedLine.d163.s7|65-71|against|O
DDI-MedLine.d163.s7|73-76|MRSA|O
DDI-MedLine.d163.s7|77-77|.|O
DDI-MedLine.d163.s8|0-6|Further|O
DDI-MedLine.d163.s8|8-14|studies|O
DDI-MedLine.d163.s8|16-18|are|O
DDI-MedLine.d163.s8|20-27|required|O
DDI-MedLine.d163.s8|29-30|to|O
DDI-MedLine.d163.s8|32-40|determine|O
DDI-MedLine.d163.s8|42-44|the|O
DDI-MedLine.d163.s8|46-54|potential|O
DDI-MedLine.d163.s8|56-63|clinical|O
DDI-MedLine.d163.s8|65-68|role|O
DDI-MedLine.d163.s8|70-71|of|O
DDI-MedLine.d163.s8|73-76|this|O
DDI-MedLine.d163.s8|78-88|combination|O
DDI-MedLine.d163.s8|90-96|regimen|O
DDI-MedLine.d163.s8|98-99|as|O
DDI-MedLine.d163.s8|101-101|a|O
DDI-MedLine.d163.s8|103-113|therapeutic|O
DDI-MedLine.d163.s8|115-125|alternative|O
DDI-MedLine.d163.s8|127-129|for|O
DDI-MedLine.d163.s8|131-137|certain|O
DDI-MedLine.d163.s8|139-143|types|O
DDI-MedLine.d163.s8|145-146|of|O
DDI-MedLine.d163.s8|148-151|MRSA|O
DDI-MedLine.d163.s8|153-162|infections|O
DDI-MedLine.d163.s8|163-163|.|O
DDI-DrugBank.d284.s0|0-1|If|O
DDI-DrugBank.d284.s0|3-12|additional|O
DDI-DrugBank.d284.s0|14-29|adrenergic drugs|group
DDI-DrugBank.d284.s0|31-33|are|O
DDI-DrugBank.d284.s0|35-36|to|O
DDI-DrugBank.d284.s0|38-39|be|O
DDI-DrugBank.d284.s0|41-52|administered|O
DDI-DrugBank.d284.s0|54-55|by|O
DDI-DrugBank.d284.s0|57-59|any|O
DDI-DrugBank.d284.s0|61-65|route|O
DDI-DrugBank.d284.s0|66-66|,|O
DDI-DrugBank.d284.s0|68-71|they|O
DDI-DrugBank.d284.s0|73-78|should|O
DDI-DrugBank.d284.s0|80-81|be|O
DDI-DrugBank.d284.s0|83-86|used|O
DDI-DrugBank.d284.s0|88-91|with|O
DDI-DrugBank.d284.s0|93-99|caution|O
DDI-DrugBank.d284.s0|101-107|because|O
DDI-DrugBank.d284.s0|109-111|the|O
DDI-DrugBank.d284.s0|113-129|pharmacologically|O
DDI-DrugBank.d284.s0|131-141|predictable|O
DDI-DrugBank.d284.s0|143-153|sympathetic|O
DDI-DrugBank.d284.s0|155-161|effects|O
DDI-DrugBank.d284.s0|163-164|of|O
DDI-DrugBank.d284.s0|166-172|BROVANA|brand
DDI-DrugBank.d284.s0|174-176|may|O
DDI-DrugBank.d284.s0|178-179|be|O
DDI-DrugBank.d284.s0|181-191|potentiated|O
DDI-DrugBank.d284.s0|192-192|.|O
DDI-DrugBank.d284.s1|0-3|When|O
DDI-DrugBank.d284.s1|5-14|paroxetine|drug
DDI-DrugBank.d284.s1|15-15|,|O
DDI-DrugBank.d284.s1|17-17|a|O
DDI-DrugBank.d284.s1|19-24|potent|O
DDI-DrugBank.d284.s1|26-34|inhibitor|O
DDI-DrugBank.d284.s1|36-37|of|O
DDI-DrugBank.d284.s1|39-44|CYP2D6|O
DDI-DrugBank.d284.s1|45-45|,|O
DDI-DrugBank.d284.s1|47-49|was|O
DDI-DrugBank.d284.s1|51-65|co-administered|O
DDI-DrugBank.d284.s1|67-70|with|O
DDI-DrugBank.d284.s1|72-78|BROVANA|brand
DDI-DrugBank.d284.s1|80-81|at|O
DDI-DrugBank.d284.s1|83-94|steady-state|O
DDI-DrugBank.d284.s1|95-95|,|O
DDI-DrugBank.d284.s1|97-104|exposure|O
DDI-DrugBank.d284.s1|106-107|to|O
DDI-DrugBank.d284.s1|109-114|either|O
DDI-DrugBank.d284.s1|116-119|drug|O
DDI-DrugBank.d284.s1|121-123|was|O
DDI-DrugBank.d284.s1|125-127|not|O
DDI-DrugBank.d284.s1|129-135|altered|O
DDI-DrugBank.d284.s1|136-136|.|O
DDI-DrugBank.d284.s2|0-5|Dosage|O
DDI-DrugBank.d284.s2|7-17|adjustments|O
DDI-DrugBank.d284.s2|19-20|of|O
DDI-DrugBank.d284.s2|22-28|BROVANA|brand
DDI-DrugBank.d284.s2|30-32|are|O
DDI-DrugBank.d284.s2|34-36|not|O
DDI-DrugBank.d284.s2|38-46|necessary|O
DDI-DrugBank.d284.s2|48-51|when|O
DDI-DrugBank.d284.s2|53-55|the|O
DDI-DrugBank.d284.s2|57-60|drug|O
DDI-DrugBank.d284.s2|62-63|is|O
DDI-DrugBank.d284.s2|65-69|given|O
DDI-DrugBank.d284.s2|71-83|concomitantly|O
DDI-DrugBank.d284.s2|85-88|with|O
DDI-DrugBank.d284.s2|90-95|potent|O
DDI-DrugBank.d284.s2|97-102|CYP2D6|O
DDI-DrugBank.d284.s2|104-113|inhibitors|O
DDI-DrugBank.d284.s2|114-114|.|O
DDI-DrugBank.d284.s3|0-10|Concomitant|O
DDI-DrugBank.d284.s3|12-20|treatment|O
DDI-DrugBank.d284.s3|22-25|with|O
DDI-DrugBank.d284.s3|27-41|methylxanthines|group
DDI-DrugBank.d284.s3|43-43|(|O
DDI-DrugBank.d284.s3|44-56|aminophylline|drug
DDI-DrugBank.d284.s3|57-57|,|O
DDI-DrugBank.d284.s3|59-70|theophylline|drug
DDI-DrugBank.d284.s3|71-71|)|O
DDI-DrugBank.d284.s3|72-72|,|O
DDI-DrugBank.d284.s3|74-81|steroids|group
DDI-DrugBank.d284.s3|82-82|,|O
DDI-DrugBank.d284.s3|84-85|or|O
DDI-DrugBank.d284.s3|87-95|diuretics|group
DDI-DrugBank.d284.s3|97-99|may|O
DDI-DrugBank.d284.s3|101-110|potentiate|O
DDI-DrugBank.d284.s3|112-114|any|O
DDI-DrugBank.d284.s3|116-126|hypokalemic|O
DDI-DrugBank.d284.s3|128-133|effect|O
DDI-DrugBank.d284.s3|135-136|of|O
DDI-DrugBank.d284.s3|138-156|adrenergic agonists|group
DDI-DrugBank.d284.s3|157-157|.|O
DDI-DrugBank.d284.s4|0-2|The|O
DDI-DrugBank.d284.s4|4-6|ECG|O
DDI-DrugBank.d284.s4|8-14|changes|O
DDI-DrugBank.d284.s4|16-21|and/or|O
DDI-DrugBank.d284.s4|23-33|hypokalemia|O
DDI-DrugBank.d284.s4|35-38|that|O
DDI-DrugBank.d284.s4|40-42|may|O
DDI-DrugBank.d284.s4|44-49|result|O
DDI-DrugBank.d284.s4|51-54|from|O
DDI-DrugBank.d284.s4|56-58|the|O
DDI-DrugBank.d284.s4|60-73|administration|O
DDI-DrugBank.d284.s4|75-76|of|O
DDI-DrugBank.d284.s4|78-108|non-potassium sparing diuretics|group
DDI-DrugBank.d284.s4|110-110|(|O
DDI-DrugBank.d284.s4|111-114|such|O
DDI-DrugBank.d284.s4|116-117|as|O
DDI-DrugBank.d284.s4|119-122|loop|group
DDI-DrugBank.d284.s4|124-125|or|O
DDI-DrugBank.d284.s4|127-144|thiazide diuretics|group
DDI-DrugBank.d284.s4|145-145|)|O
DDI-DrugBank.d284.s4|147-149|can|O
DDI-DrugBank.d284.s4|151-152|be|O
DDI-DrugBank.d284.s4|154-160|acutely|O
DDI-DrugBank.d284.s4|162-169|worsened|O
DDI-DrugBank.d284.s4|171-172|by|O
DDI-DrugBank.d284.s4|174-186|beta-agonists|group
DDI-DrugBank.d284.s4|187-187|,|O
DDI-DrugBank.d284.s4|189-198|especially|O
DDI-DrugBank.d284.s4|200-203|when|O
DDI-DrugBank.d284.s4|205-207|the|O
DDI-DrugBank.d284.s4|209-219|recommended|O
DDI-DrugBank.d284.s4|221-224|dose|O
DDI-DrugBank.d284.s4|226-227|of|O
DDI-DrugBank.d284.s4|229-231|the|O
DDI-DrugBank.d284.s4|233-244|beta-agonist|group
DDI-DrugBank.d284.s4|246-247|is|O
DDI-DrugBank.d284.s4|249-256|exceeded|O
DDI-DrugBank.d284.s4|257-257|.|O
DDI-DrugBank.d284.s5|0-7|Although|O
DDI-DrugBank.d284.s5|9-11|the|O
DDI-DrugBank.d284.s5|13-20|clinical|O
DDI-DrugBank.d284.s5|22-33|significance|O
DDI-DrugBank.d284.s5|35-36|of|O
DDI-DrugBank.d284.s5|38-42|these|O
DDI-DrugBank.d284.s5|44-50|effects|O
DDI-DrugBank.d284.s5|52-53|is|O
DDI-DrugBank.d284.s5|55-57|not|O
DDI-DrugBank.d284.s5|59-63|known|O
DDI-DrugBank.d284.s5|64-64|,|O
DDI-DrugBank.d284.s5|66-72|caution|O
DDI-DrugBank.d284.s5|74-75|is|O
DDI-DrugBank.d284.s5|77-83|advised|O
DDI-DrugBank.d284.s5|85-86|in|O
DDI-DrugBank.d284.s5|88-90|the|O
DDI-DrugBank.d284.s5|92-108|co-administration|O
DDI-DrugBank.d284.s5|110-111|of|O
DDI-DrugBank.d284.s5|113-125|beta-agonists|group
DDI-DrugBank.d284.s5|127-130|with|O
DDI-DrugBank.d284.s5|132-162|non-potassium sparing diuretics|group
DDI-DrugBank.d284.s5|163-163|.|O
DDI-DrugBank.d284.s6|0-6|BROVANA|brand
DDI-DrugBank.d284.s6|7-7|,|O
DDI-DrugBank.d284.s6|9-10|as|O
DDI-DrugBank.d284.s6|12-15|with|O
DDI-DrugBank.d284.s6|17-21|other|O
DDI-DrugBank.d284.s6|23-36|beta2-agonists|group
DDI-DrugBank.d284.s6|37-37|,|O
DDI-DrugBank.d284.s6|39-44|should|O
DDI-DrugBank.d284.s6|46-47|be|O
DDI-DrugBank.d284.s6|49-60|administered|O
DDI-DrugBank.d284.s6|62-65|with|O
DDI-DrugBank.d284.s6|67-73|extreme|O
DDI-DrugBank.d284.s6|75-81|caution|O
DDI-DrugBank.d284.s6|83-84|to|O
DDI-DrugBank.d284.s6|86-93|patients|O
DDI-DrugBank.d284.s6|95-99|being|O
DDI-DrugBank.d284.s6|101-107|treated|O
DDI-DrugBank.d284.s6|109-112|with|O
DDI-DrugBank.d284.s6|114-141|monoamine oxidase inhibitors|group
DDI-DrugBank.d284.s6|142-142|,|O
DDI-DrugBank.d284.s6|144-168|tricyclic antidepressants|group
DDI-DrugBank.d284.s6|169-169|,|O
DDI-DrugBank.d284.s6|171-172|or|O
DDI-DrugBank.d284.s6|174-178|drugs|O
DDI-DrugBank.d284.s6|180-184|known|O
DDI-DrugBank.d284.s6|186-187|to|O
DDI-DrugBank.d284.s6|189-195|prolong|O
DDI-DrugBank.d284.s6|197-199|the|O
DDI-DrugBank.d284.s6|201-203|QTc|O
DDI-DrugBank.d284.s6|205-212|interval|O
DDI-DrugBank.d284.s6|214-220|because|O
DDI-DrugBank.d284.s6|222-224|the|O
DDI-DrugBank.d284.s6|226-231|action|O
DDI-DrugBank.d284.s6|233-234|of|O
DDI-DrugBank.d284.s6|236-254|adrenergic agonists|group
DDI-DrugBank.d284.s6|256-257|on|O
DDI-DrugBank.d284.s6|259-261|the|O
DDI-DrugBank.d284.s6|263-276|cardiovascular|O
DDI-DrugBank.d284.s6|278-283|system|O
DDI-DrugBank.d284.s6|285-287|may|O
DDI-DrugBank.d284.s6|289-290|be|O
DDI-DrugBank.d284.s6|292-302|potentiated|O
DDI-DrugBank.d284.s6|304-305|by|O
DDI-DrugBank.d284.s6|307-311|these|O
DDI-DrugBank.d284.s6|313-318|agents|O
DDI-DrugBank.d284.s6|319-319|.|O
DDI-DrugBank.d284.s7|0-4|Drugs|O
DDI-DrugBank.d284.s7|6-9|that|O
DDI-DrugBank.d284.s7|11-13|are|O
DDI-DrugBank.d284.s7|15-19|known|O
DDI-DrugBank.d284.s7|21-22|to|O
DDI-DrugBank.d284.s7|24-30|prolong|O
DDI-DrugBank.d284.s7|32-34|the|O
DDI-DrugBank.d284.s7|36-38|QTc|O
DDI-DrugBank.d284.s7|40-47|interval|O
DDI-DrugBank.d284.s7|49-52|have|O
DDI-DrugBank.d284.s7|54-55|an|O
DDI-DrugBank.d284.s7|57-65|increased|O
DDI-DrugBank.d284.s7|67-70|risk|O
DDI-DrugBank.d284.s7|72-73|of|O
DDI-DrugBank.d284.s7|75-85|ventricular|O
DDI-DrugBank.d284.s7|87-97|arrhythmias|O
DDI-DrugBank.d284.s7|98-98|.|O
DDI-DrugBank.d284.s8|0-2|The|O
DDI-DrugBank.d284.s8|4-13|concurrent|O
DDI-DrugBank.d284.s8|15-17|use|O
DDI-DrugBank.d284.s8|19-20|of|O
DDI-DrugBank.d284.s8|22-34|intravenously|O
DDI-DrugBank.d284.s8|36-37|or|O
DDI-DrugBank.d284.s8|39-44|orally|O
DDI-DrugBank.d284.s8|46-57|administered|O
DDI-DrugBank.d284.s8|59-73|methylxanthines|group
DDI-DrugBank.d284.s8|75-75|(|O
DDI-DrugBank.d284.s8|76-79|e.g.|O
DDI-DrugBank.d284.s8|80-80|,|O
DDI-DrugBank.d284.s8|82-94|aminophylline|drug
DDI-DrugBank.d284.s8|95-95|,|O
DDI-DrugBank.d284.s8|97-108|theophylline|drug
DDI-DrugBank.d284.s8|109-109|)|O
DDI-DrugBank.d284.s8|111-112|by|O
DDI-DrugBank.d284.s8|114-121|patients|O
DDI-DrugBank.d284.s8|123-131|receiving|O
DDI-DrugBank.d284.s8|133-139|BROVANA|brand
DDI-DrugBank.d284.s8|141-143|has|O
DDI-DrugBank.d284.s8|145-147|not|O
DDI-DrugBank.d284.s8|149-152|been|O
DDI-DrugBank.d284.s8|154-163|completely|O
DDI-DrugBank.d284.s8|165-173|evaluated|O
DDI-DrugBank.d284.s8|174-174|.|O
DDI-DrugBank.d284.s9|0-1|In|O
DDI-DrugBank.d284.s9|3-5|two|O
DDI-DrugBank.d284.s9|7-14|combined|O
DDI-DrugBank.d284.s9|16-22|12-week|O
DDI-DrugBank.d284.s9|24-30|placebo|O
DDI-DrugBank.d284.s9|32-41|controlled|O
DDI-DrugBank.d284.s9|43-48|trials|O
DDI-DrugBank.d284.s9|50-53|that|O
DDI-DrugBank.d284.s9|55-62|included|O
DDI-DrugBank.d284.s9|64-70|BROVANA|brand
DDI-DrugBank.d284.s9|72-76|doses|O
DDI-DrugBank.d284.s9|78-79|of|O
DDI-DrugBank.d284.s9|81-82|15|O
DDI-DrugBank.d284.s9|84-86|mcg|O
DDI-DrugBank.d284.s9|88-92|twice|O
DDI-DrugBank.d284.s9|94-98|daily|O
DDI-DrugBank.d284.s9|99-99|,|O
DDI-DrugBank.d284.s9|101-102|25|O
DDI-DrugBank.d284.s9|104-106|mcg|O
DDI-DrugBank.d284.s9|108-112|twice|O
DDI-DrugBank.d284.s9|114-118|daily|O
DDI-DrugBank.d284.s9|119-119|,|O
DDI-DrugBank.d284.s9|121-123|and|O
DDI-DrugBank.d284.s9|125-126|50|O
DDI-DrugBank.d284.s9|128-130|mcg|O
DDI-DrugBank.d284.s9|132-135|once|O
DDI-DrugBank.d284.s9|137-141|daily|O
DDI-DrugBank.d284.s9|142-142|,|O
DDI-DrugBank.d284.s9|144-145|54|O
DDI-DrugBank.d284.s9|147-148|of|O
DDI-DrugBank.d284.s9|150-152|873|O
DDI-DrugBank.d284.s9|154-160|BROVANA|brand
DDI-DrugBank.d284.s9|162-169|-treated|O
DDI-DrugBank.d284.s9|171-178|subjects|O
DDI-DrugBank.d284.s9|180-187|received|O
DDI-DrugBank.d284.s9|189-199|concomitant|O
DDI-DrugBank.d284.s9|201-212|theophylline|drug
DDI-DrugBank.d284.s9|214-215|at|O
DDI-DrugBank.d284.s9|217-221|study|O
DDI-DrugBank.d284.s9|223-227|entry|O
DDI-DrugBank.d284.s9|228-228|.|O
DDI-DrugBank.d284.s10|0-1|In|O
DDI-DrugBank.d284.s10|3-3|a|O
DDI-DrugBank.d284.s10|5-12|12-month|O
DDI-DrugBank.d284.s10|14-23|controlled|O
DDI-DrugBank.d284.s10|25-29|trial|O
DDI-DrugBank.d284.s10|31-34|that|O
DDI-DrugBank.d284.s10|36-43|included|O
DDI-DrugBank.d284.s10|45-45|a|O
DDI-DrugBank.d284.s10|47-48|50|O
DDI-DrugBank.d284.s10|50-52|mcg|O
DDI-DrugBank.d284.s10|54-57|once|O
DDI-DrugBank.d284.s10|59-63|daily|O
DDI-DrugBank.d284.s10|65-71|BROVANA|brand
DDI-DrugBank.d284.s10|73-76|dose|O
DDI-DrugBank.d284.s10|77-77|,|O
DDI-DrugBank.d284.s10|79-80|30|O
DDI-DrugBank.d284.s10|82-83|of|O
DDI-DrugBank.d284.s10|85-87|the|O
DDI-DrugBank.d284.s10|89-91|528|O
DDI-DrugBank.d284.s10|93-99|BROVANA|brand
DDI-DrugBank.d284.s10|101-108|-treated|O
DDI-DrugBank.d284.s10|110-117|subjects|O
DDI-DrugBank.d284.s10|119-126|received|O
DDI-DrugBank.d284.s10|128-138|concomitant|O
DDI-DrugBank.d284.s10|140-151|theophylline|drug
DDI-DrugBank.d284.s10|153-154|at|O
DDI-DrugBank.d284.s10|156-160|study|O
DDI-DrugBank.d284.s10|162-166|entry|O
DDI-DrugBank.d284.s10|167-167|.|O
DDI-DrugBank.d284.s11|0-1|In|O
DDI-DrugBank.d284.s11|3-7|these|O
DDI-DrugBank.d284.s11|9-14|trials|O
DDI-DrugBank.d284.s11|15-15|,|O
DDI-DrugBank.d284.s11|17-21|heart|O
DDI-DrugBank.d284.s11|23-26|rate|O
DDI-DrugBank.d284.s11|28-30|and|O
DDI-DrugBank.d284.s11|32-39|systolic|O
DDI-DrugBank.d284.s11|41-45|blood|O
DDI-DrugBank.d284.s11|47-54|pressure|O
DDI-DrugBank.d284.s11|56-59|were|O
DDI-DrugBank.d284.s11|61-73|approximately|O
DDI-DrugBank.d284.s11|75-77|2-3|O
DDI-DrugBank.d284.s11|79-81|bpm|O
DDI-DrugBank.d284.s11|83-85|and|O
DDI-DrugBank.d284.s11|87-89|6-8|O
DDI-DrugBank.d284.s11|91-92|mm|O
DDI-DrugBank.d284.s11|94-95|Hg|O
DDI-DrugBank.d284.s11|97-102|higher|O
DDI-DrugBank.d284.s11|103-103|,|O
DDI-DrugBank.d284.s11|105-116|respectively|O
DDI-DrugBank.d284.s11|117-117|,|O
DDI-DrugBank.d284.s11|119-120|in|O
DDI-DrugBank.d284.s11|122-129|subjects|O
DDI-DrugBank.d284.s11|131-132|on|O
DDI-DrugBank.d284.s11|134-144|concomitant|O
DDI-DrugBank.d284.s11|146-157|theophylline|drug
DDI-DrugBank.d284.s11|159-166|compared|O
DDI-DrugBank.d284.s11|168-171|with|O
DDI-DrugBank.d284.s11|173-175|the|O
DDI-DrugBank.d284.s11|177-183|overall|O
DDI-DrugBank.d284.s11|185-194|population|O
DDI-DrugBank.d284.s11|195-195|.|O
DDI-DrugBank.d284.s12|0-35|Beta-adrenergic receptor antagonists|group
DDI-DrugBank.d284.s12|37-37|(|O
DDI-DrugBank.d284.s12|38-50|beta-blockers|group
DDI-DrugBank.d284.s12|51-51|)|O
DDI-DrugBank.d284.s12|53-55|and|O
DDI-DrugBank.d284.s12|57-63|BROVANA|brand
DDI-DrugBank.d284.s12|65-67|may|O
DDI-DrugBank.d284.s12|69-77|interfere|O
DDI-DrugBank.d284.s12|79-82|with|O
DDI-DrugBank.d284.s12|84-86|the|O
DDI-DrugBank.d284.s12|88-93|effect|O
DDI-DrugBank.d284.s12|95-96|of|O
DDI-DrugBank.d284.s12|98-101|each|O
DDI-DrugBank.d284.s12|103-107|other|O
DDI-DrugBank.d284.s12|109-112|when|O
DDI-DrugBank.d284.s12|114-125|administered|O
DDI-DrugBank.d284.s12|127-138|concurrently|O
DDI-DrugBank.d284.s12|139-139|.|O
DDI-DrugBank.d284.s13|0-12|Beta-blockers|group
DDI-DrugBank.d284.s13|14-16|not|O
DDI-DrugBank.d284.s13|18-21|only|O
DDI-DrugBank.d284.s13|23-27|block|O
DDI-DrugBank.d284.s13|29-31|the|O
DDI-DrugBank.d284.s13|33-43|therapeutic|O
DDI-DrugBank.d284.s13|45-51|effects|O
DDI-DrugBank.d284.s13|53-54|of|O
DDI-DrugBank.d284.s13|56-68|beta-agonists|group
DDI-DrugBank.d284.s13|69-69|,|O
DDI-DrugBank.d284.s13|71-73|but|O
DDI-DrugBank.d284.s13|75-77|may|O
DDI-DrugBank.d284.s13|79-85|produce|O
DDI-DrugBank.d284.s13|87-92|severe|O
DDI-DrugBank.d284.s13|94-105|bronchospasm|O
DDI-DrugBank.d284.s13|107-108|in|O
DDI-DrugBank.d284.s13|110-113|COPD|O
DDI-DrugBank.d284.s13|115-122|patients|O
DDI-DrugBank.d284.s13|123-123|.|O
DDI-DrugBank.d284.s14|0-8|Therefore|O
DDI-DrugBank.d284.s14|9-9|,|O
DDI-DrugBank.d284.s14|11-18|patients|O
DDI-DrugBank.d284.s14|20-23|with|O
DDI-DrugBank.d284.s14|25-28|COPD|O
DDI-DrugBank.d284.s14|30-35|should|O
DDI-DrugBank.d284.s14|37-39|not|O
DDI-DrugBank.d284.s14|41-48|normally|O
DDI-DrugBank.d284.s14|50-51|be|O
DDI-DrugBank.d284.s14|53-59|treated|O
DDI-DrugBank.d284.s14|61-64|with|O
DDI-DrugBank.d284.s14|66-78|beta-blockers|group
DDI-DrugBank.d284.s14|79-79|.|O
DDI-DrugBank.d284.s15|0-6|However|O
DDI-DrugBank.d284.s15|7-7|,|O
DDI-DrugBank.d284.s15|9-13|under|O
DDI-DrugBank.d284.s15|15-21|certain|O
DDI-DrugBank.d284.s15|23-35|circumstances|O
DDI-DrugBank.d284.s15|36-36|,|O
DDI-DrugBank.d284.s15|38-41|e.g.|O
DDI-DrugBank.d284.s15|42-42|,|O
DDI-DrugBank.d284.s15|44-45|as|O
DDI-DrugBank.d284.s15|47-57|prophylaxis|O
DDI-DrugBank.d284.s15|59-63|after|O
DDI-DrugBank.d284.s15|65-74|myocardial|O
DDI-DrugBank.d284.s15|76-85|infarction|O
DDI-DrugBank.d284.s15|86-86|,|O
DDI-DrugBank.d284.s15|88-92|there|O
DDI-DrugBank.d284.s15|94-96|may|O
DDI-DrugBank.d284.s15|98-99|be|O
DDI-DrugBank.d284.s15|101-102|no|O
DDI-DrugBank.d284.s15|104-113|acceptable|O
DDI-DrugBank.d284.s15|115-126|alternatives|O
DDI-DrugBank.d284.s15|128-129|to|O
DDI-DrugBank.d284.s15|131-133|the|O
DDI-DrugBank.d284.s15|135-137|use|O
DDI-DrugBank.d284.s15|139-140|of|O
DDI-DrugBank.d284.s15|142-154|beta-blockers|group
DDI-DrugBank.d284.s15|156-157|in|O
DDI-DrugBank.d284.s15|159-166|patients|O
DDI-DrugBank.d284.s15|168-171|with|O
DDI-DrugBank.d284.s15|173-176|COPD|O
DDI-DrugBank.d284.s15|177-177|.|O
DDI-DrugBank.d284.s16|0-1|In|O
DDI-DrugBank.d284.s16|3-6|this|O
DDI-DrugBank.d284.s16|8-14|setting|O
DDI-DrugBank.d284.s16|15-15|,|O
DDI-DrugBank.d284.s16|17-45|cardioselective beta-blockers|group
DDI-DrugBank.d284.s16|47-51|could|O
DDI-DrugBank.d284.s16|53-54|be|O
DDI-DrugBank.d284.s16|56-65|considered|O
DDI-DrugBank.d284.s16|66-66|,|O
DDI-DrugBank.d284.s16|68-75|although|O
DDI-DrugBank.d284.s16|77-80|they|O
DDI-DrugBank.d284.s16|82-87|should|O
DDI-DrugBank.d284.s16|89-90|be|O
DDI-DrugBank.d284.s16|92-103|administered|O
DDI-DrugBank.d284.s16|105-108|with|O
DDI-DrugBank.d284.s16|110-116|caution|O
DDI-DrugBank.d284.s16|117-117|.|O
DDI-DrugBank.d296.s0|0-28|Diphenhydramine hydrochloride|drug
DDI-DrugBank.d296.s0|30-32|has|O
DDI-DrugBank.d296.s0|34-41|additive|O
DDI-DrugBank.d296.s0|43-49|effects|O
DDI-DrugBank.d296.s0|51-54|with|O
DDI-DrugBank.d296.s0|56-62|alcohol|drug
DDI-DrugBank.d296.s0|64-66|and|O
DDI-DrugBank.d296.s0|68-72|other|O
DDI-DrugBank.d296.s0|74-88|CNS depressants|group
DDI-DrugBank.d296.s0|90-90|(|O
DDI-DrugBank.d296.s0|91-99|hypnotics|group
DDI-DrugBank.d296.s0|100-100|,|O
DDI-DrugBank.d296.s0|102-110|sedatives|group
DDI-DrugBank.d296.s0|111-111|,|O
DDI-DrugBank.d296.s0|113-125|tranquilizers|group
DDI-DrugBank.d296.s0|126-126|,|O
DDI-DrugBank.d296.s0|128-130|etc|O
DDI-DrugBank.d296.s0|131-131|)|O
DDI-DrugBank.d296.s0|132-132|.|O
DDI-DrugBank.d296.s1|0-13|MAO inhibitors|group
DDI-DrugBank.d296.s1|15-21|prolong|O
DDI-DrugBank.d296.s1|23-25|and|O
DDI-DrugBank.d296.s1|27-35|intensify|O
DDI-DrugBank.d296.s1|37-39|the|O
DDI-DrugBank.d296.s1|41-55|anticholinergic|O
DDI-DrugBank.d296.s1|57-57|(|O
DDI-DrugBank.d296.s1|58-63|drying|O
DDI-DrugBank.d296.s1|64-64|)|O
DDI-DrugBank.d296.s1|66-72|effects|O
DDI-DrugBank.d296.s1|74-75|of|O
DDI-DrugBank.d296.s1|77-90|antihistamines|group
DDI-DrugBank.d296.s1|91-91|.|O
DDI-MedLine.d209.s0|0-8|Tamoxifen|drug
DDI-MedLine.d209.s0|10-12|and|O
DDI-MedLine.d209.s0|14-16|CYP|O
DDI-MedLine.d209.s0|18-20|2D6|O
DDI-MedLine.d209.s0|22-31|inhibitors|O
DDI-MedLine.d209.s0|32-32|:|O
DDI-MedLine.d209.s0|34-40|caution|O
DDI-MedLine.d209.s0|41-41|.|O
DDI-MedLine.d209.s1|0-8|Tamoxifen|drug
DDI-MedLine.d209.s1|9-9|,|O
DDI-MedLine.d209.s1|11-12|an|O
DDI-MedLine.d209.s1|14-32|estrogen antagonist|group
DDI-MedLine.d209.s1|33-33|,|O
DDI-MedLine.d209.s1|35-36|is|O
DDI-MedLine.d209.s1|38-40|the|O
DDI-MedLine.d209.s1|42-49|standard|O
DDI-MedLine.d209.s1|51-57|hormone|O
DDI-MedLine.d209.s1|59-67|treatment|O
DDI-MedLine.d209.s1|69-71|for|O
DDI-MedLine.d209.s1|73-78|breast|O
DDI-MedLine.d209.s1|80-85|cancer|O
DDI-MedLine.d209.s1|86-86|.|O
DDI-MedLine.d209.s2|0-1|It|O
DDI-MedLine.d209.s2|3-4|is|O
DDI-MedLine.d209.s2|6-16|extensively|O
DDI-MedLine.d209.s2|18-28|transformed|O
DDI-MedLine.d209.s2|30-33|into|O
DDI-MedLine.d209.s2|35-37|its|O
DDI-MedLine.d209.s2|39-44|active|O
DDI-MedLine.d209.s2|46-56|metabolites|O
DDI-MedLine.d209.s2|58-59|by|O
DDI-MedLine.d209.s2|61-63|the|O
DDI-MedLine.d209.s2|65-74|cytochrome|O
DDI-MedLine.d209.s2|76-79|P450|O
DDI-MedLine.d209.s2|81-86|enzyme|O
DDI-MedLine.d209.s2|88-93|system|O
DDI-MedLine.d209.s2|94-94|,|O
DDI-MedLine.d209.s2|96-105|especially|O
DDI-MedLine.d209.s2|107-110|into|O
DDI-MedLine.d209.s2|122-123|by|O
DDI-MedLine.d209.s2|125-133|isoenzyme|O
DDI-MedLine.d209.s2|135-137|CYP|O
DDI-MedLine.d209.s2|139-141|2D6|O
DDI-MedLine.d209.s2|142-142|.|O
DDI-MedLine.d209.s3|0-16|Co-administration|O
DDI-MedLine.d209.s3|18-19|of|O
DDI-MedLine.d209.s3|21-29|tamoxifen|drug
DDI-MedLine.d209.s3|31-34|with|O
DDI-MedLine.d209.s3|36-44|isoenzyme|O
DDI-MedLine.d209.s3|46-48|CYP|O
DDI-MedLine.d209.s3|50-52|2D6|O
DDI-MedLine.d209.s3|54-63|inhibitors|O
DDI-MedLine.d209.s3|65-71|reduces|O
DDI-MedLine.d209.s3|73-76|this|O
DDI-MedLine.d209.s3|78-87|metabolism|O
DDI-MedLine.d209.s3|88-88|.|O
DDI-MedLine.d209.s4|0-60|Selective serotonin reuptake inhibitor ( SSRI ) antidepressants|group
DDI-MedLine.d209.s4|62-68|inhibit|O
DDI-MedLine.d209.s4|70-78|isoenzyme|O
DDI-MedLine.d209.s4|80-82|CYP|O
DDI-MedLine.d209.s4|84-86|2D6|O
DDI-MedLine.d209.s4|87-87|.|O
DDI-MedLine.d209.s5|0-9|Paroxetine|drug
DDI-MedLine.d209.s5|11-13|and|O
DDI-MedLine.d209.s5|15-24|fluoxetine|drug
DDI-MedLine.d209.s5|26-31|reduce|O
DDI-MedLine.d209.s5|33-35|the|O
DDI-MedLine.d209.s5|37-42|plasma|O
DDI-MedLine.d209.s5|44-56|concentration|O
DDI-MedLine.d209.s5|58-59|of|O
DDI-MedLine.d209.s5|71-72|by|O
DDI-MedLine.d209.s5|74-78|about|O
DDI-MedLine.d209.s5|80-81|50|O
DDI-MedLine.d209.s5|82-82|%|O
DDI-MedLine.d209.s5|83-83|.|O
DDI-MedLine.d209.s6|0-2|Two|O
DDI-MedLine.d209.s6|4-18|epidemiological|O
DDI-MedLine.d209.s6|20-26|studies|O
DDI-MedLine.d209.s6|28-36|involving|O
DDI-MedLine.d209.s6|38-42|about|O
DDI-MedLine.d209.s6|44-47|3700|O
DDI-MedLine.d209.s6|49-53|women|O
DDI-MedLine.d209.s6|55-58|have|O
DDI-MedLine.d209.s6|60-64|shown|O
DDI-MedLine.d209.s6|66-66|a|O
DDI-MedLine.d209.s6|68-71|link|O
DDI-MedLine.d209.s6|73-79|between|O
DDI-MedLine.d209.s6|81-83|the|O
DDI-MedLine.d209.s6|85-87|use|O
DDI-MedLine.d209.s6|89-90|of|O
DDI-MedLine.d209.s6|92-111|SSRI antidepressants|group
DDI-MedLine.d209.s6|113-115|and|O
DDI-MedLine.d209.s6|117-118|an|O
DDI-MedLine.d209.s6|120-128|increased|O
DDI-MedLine.d209.s6|130-138|frequency|O
DDI-MedLine.d209.s6|140-141|of|O
DDI-MedLine.d209.s6|143-148|breast|O
DDI-MedLine.d209.s6|150-155|cancer|O
DDI-MedLine.d209.s6|157-166|recurrence|O
DDI-MedLine.d209.s6|167-167|.|O
DDI-MedLine.d209.s7|0-4|Other|O
DDI-MedLine.d209.s7|6-12|studies|O
DDI-MedLine.d209.s7|13-13|,|O
DDI-MedLine.d209.s7|15-18|with|O
DDI-MedLine.d209.s7|20-20|a|O
DDI-MedLine.d209.s7|22-26|lower|O
DDI-MedLine.d209.s7|28-32|level|O
DDI-MedLine.d209.s7|34-35|of|O
DDI-MedLine.d209.s7|37-44|evidence|O
DDI-MedLine.d209.s7|45-45|,|O
DDI-MedLine.d209.s7|47-50|were|O
DDI-MedLine.d209.s7|52-55|less|O
DDI-MedLine.d209.s7|57-66|convincing|O
DDI-MedLine.d209.s7|67-67|.|O
DDI-MedLine.d209.s8|0-6|Studies|O
DDI-MedLine.d209.s8|8-9|of|O
DDI-MedLine.d209.s8|11-15|other|O
DDI-MedLine.d209.s8|17-25|isoenzyme|O
DDI-MedLine.d209.s8|27-29|CYP|O
DDI-MedLine.d209.s8|31-33|2D6|O
DDI-MedLine.d209.s8|35-44|inhibitors|O
DDI-MedLine.d209.s8|46-51|showed|O
DDI-MedLine.d209.s8|53-54|no|O
DDI-MedLine.d209.s8|56-63|increase|O
DDI-MedLine.d209.s8|65-66|in|O
DDI-MedLine.d209.s8|68-70|the|O
DDI-MedLine.d209.s8|72-75|risk|O
DDI-MedLine.d209.s8|77-78|of|O
DDI-MedLine.d209.s8|80-85|breast|O
DDI-MedLine.d209.s8|87-92|cancer|O
DDI-MedLine.d209.s8|94-103|recurrence|O
DDI-MedLine.d209.s8|104-104|,|O
DDI-MedLine.d209.s8|106-108|but|O
DDI-MedLine.d209.s8|110-113|they|O
DDI-MedLine.d209.s8|115-120|lacked|O
DDI-MedLine.d209.s8|122-132|statistical|O
DDI-MedLine.d209.s8|134-138|power|O
DDI-MedLine.d209.s8|139-139|.|O
DDI-MedLine.d209.s9|0-1|It|O
DDI-MedLine.d209.s9|3-4|is|O
DDI-MedLine.d209.s9|6-11|better|O
DDI-MedLine.d209.s9|13-14|to|O
DDI-MedLine.d209.s9|16-20|avoid|O
DDI-MedLine.d209.s9|22-32|prescribing|O
DDI-MedLine.d209.s9|34-42|isoenzyme|O
DDI-MedLine.d209.s9|44-46|CYP|O
DDI-MedLine.d209.s9|48-50|2D6|O
DDI-MedLine.d209.s9|52-61|inhibitors|O
DDI-MedLine.d209.s9|63-64|to|O
DDI-MedLine.d209.s9|66-70|women|O
DDI-MedLine.d209.s9|72-78|treated|O
DDI-MedLine.d209.s9|80-83|with|O
DDI-MedLine.d209.s9|85-93|tamoxifen|drug
DDI-MedLine.d209.s9|95-97|for|O
DDI-MedLine.d209.s9|99-104|breast|O
DDI-MedLine.d209.s9|106-111|cancer|O
DDI-MedLine.d209.s9|112-112|,|O
DDI-MedLine.d209.s9|114-123|especially|O
DDI-MedLine.d209.s9|125-144|SSRI antidepressants|group
DDI-MedLine.d209.s9|146-149|such|O
DDI-MedLine.d209.s9|151-152|as|O
DDI-MedLine.d209.s9|154-163|paroxetine|drug
DDI-MedLine.d209.s9|165-167|and|O
DDI-MedLine.d209.s9|169-178|fluoxetine|drug
DDI-MedLine.d209.s9|179-179|.|O
DDI-MedLine.d209.s10|0-9|Depression|O
DDI-MedLine.d209.s10|11-14|does|O
DDI-MedLine.d209.s10|16-18|not|O
DDI-MedLine.d209.s10|20-25|always|O
DDI-MedLine.d209.s10|27-33|require|O
DDI-MedLine.d209.s10|35-53|antidepressant drug|group
DDI-MedLine.d209.s10|55-61|therapy|O
DDI-MedLine.d209.s10|62-62|,|O
DDI-MedLine.d209.s10|64-66|and|O
DDI-MedLine.d209.s10|68-82|antidepressants|group
DDI-MedLine.d209.s10|84-87|have|O
DDI-MedLine.d209.s10|89-90|no|O
DDI-MedLine.d209.s10|92-97|proven|O
DDI-MedLine.d209.s10|99-108|preventive|O
DDI-MedLine.d209.s10|110-115|impact|O
DDI-MedLine.d209.s10|117-118|on|O
DDI-MedLine.d209.s10|120-122|hot|O
DDI-MedLine.d209.s10|124-130|flushes|O
DDI-MedLine.d209.s10|132-137|linked|O
DDI-MedLine.d209.s10|139-140|to|O
DDI-MedLine.d209.s10|142-144|the|O
DDI-MedLine.d209.s10|146-154|menopause|O
DDI-MedLine.d209.s10|155-155|.|O
DDI-MedLine.d209.s11|0-1|If|O
DDI-MedLine.d209.s11|3-4|in|O
DDI-MedLine.d209.s11|6-12|certain|O
DDI-MedLine.d209.s11|14-18|cases|O
DDI-MedLine.d209.s11|19-19|,|O
DDI-MedLine.d209.s11|21-22|an|O
DDI-MedLine.d209.s11|24-37|antidepressant|group
DDI-MedLine.d209.s11|39-40|is|O
DDI-MedLine.d209.s11|42-51|considered|O
DDI-MedLine.d209.s11|53-61|necessary|O
DDI-MedLine.d209.s11|62-62|,|O
DDI-MedLine.d209.s11|64-65|it|O
DDI-MedLine.d209.s11|67-69|may|O
DDI-MedLine.d209.s11|71-72|be|O
DDI-MedLine.d209.s11|74-82|advisable|O
DDI-MedLine.d209.s11|84-85|to|O
DDI-MedLine.d209.s11|87-93|replace|O
DDI-MedLine.d209.s11|95-103|tamoxifen|drug
DDI-MedLine.d209.s11|105-108|with|O
DDI-MedLine.d209.s11|110-120|anastrozole|drug
DDI-MedLine.d209.s11|121-121|.|O
DDI-DrugBank.d699.s0|0-10|Mequitazine|drug
DDI-DrugBank.d699.s0|12-14|can|O
DDI-DrugBank.d699.s0|16-23|interact|O
DDI-DrugBank.d699.s0|25-28|with|O
DDI-DrugBank.d699.s0|30-43|CNS depressant|group
DDI-DrugBank.d699.s0|44-44|,|O
DDI-DrugBank.d699.s0|46-61|antichlolinergic|group
DDI-DrugBank.d699.s0|62-62|,|O
DDI-DrugBank.d699.s0|64-66|TCA|group
DDI-DrugBank.d699.s0|67-67|,|O
DDI-DrugBank.d699.s0|69-73|MAOIs|group
DDI-DrugBank.d699.s0|74-74|,|O
DDI-DrugBank.d699.s0|76-78|and|O
DDI-DrugBank.d699.s0|80-86|alcohol|drug
DDI-DrugBank.d699.s0|87-87|.|O
DDI-DrugBank.d711.s0|0-6|Because|O
DDI-DrugBank.d711.s0|8-20|tetracyclines|group
DDI-DrugBank.d711.s0|22-25|have|O
DDI-DrugBank.d711.s0|27-30|been|O
DDI-DrugBank.d711.s0|32-36|shown|O
DDI-DrugBank.d711.s0|38-39|to|O
DDI-DrugBank.d711.s0|41-47|depress|O
DDI-DrugBank.d711.s0|49-54|plasma|O
DDI-DrugBank.d711.s0|56-66|prothrombin|O
DDI-DrugBank.d711.s0|68-75|activity|O
DDI-DrugBank.d711.s0|76-76|,|O
DDI-DrugBank.d711.s0|78-85|patients|O
DDI-DrugBank.d711.s0|87-89|who|O
DDI-DrugBank.d711.s0|91-93|are|O
DDI-DrugBank.d711.s0|95-96|on|O
DDI-DrugBank.d711.s0|98-110|anticoagulant|group
DDI-DrugBank.d711.s0|112-118|therapy|O
DDI-DrugBank.d711.s0|120-122|may|O
DDI-DrugBank.d711.s0|124-130|require|O
DDI-DrugBank.d711.s0|132-139|downward|O
DDI-DrugBank.d711.s0|141-150|adjustment|O
DDI-DrugBank.d711.s0|152-153|of|O
DDI-DrugBank.d711.s0|155-159|their|O
DDI-DrugBank.d711.s0|161-173|anticoagulant|group
DDI-DrugBank.d711.s0|175-180|dosage|O
DDI-DrugBank.d711.s0|181-181|.|O
DDI-DrugBank.d711.s1|0-4|Since|O
DDI-DrugBank.d711.s1|6-19|bacteriostatic|O
DDI-DrugBank.d711.s1|21-25|drugs|O
DDI-DrugBank.d711.s1|27-29|may|O
DDI-DrugBank.d711.s1|31-39|interfere|O
DDI-DrugBank.d711.s1|41-44|with|O
DDI-DrugBank.d711.s1|46-48|the|O
DDI-DrugBank.d711.s1|50-61|bactericidal|O
DDI-DrugBank.d711.s1|63-68|action|O
DDI-DrugBank.d711.s1|70-71|of|O
DDI-DrugBank.d711.s1|73-82|penicillin|drug
DDI-DrugBank.d711.s1|83-83|,|O
DDI-DrugBank.d711.s1|85-86|it|O
DDI-DrugBank.d711.s1|88-89|is|O
DDI-DrugBank.d711.s1|91-99|advisable|O
DDI-DrugBank.d711.s1|101-102|to|O
DDI-DrugBank.d711.s1|104-108|avoid|O
DDI-DrugBank.d711.s1|110-115|giving|O
DDI-DrugBank.d711.s1|117-140|tetracycline class drugs|group
DDI-DrugBank.d711.s1|142-143|in|O
DDI-DrugBank.d711.s1|145-155|conjunction|O
DDI-DrugBank.d711.s1|157-160|with|O
DDI-DrugBank.d711.s1|162-171|penicillin|drug
DDI-DrugBank.d711.s1|172-172|.|O
DDI-DrugBank.d711.s2|0-9|Absorption|O
DDI-DrugBank.d711.s2|11-12|of|O
DDI-DrugBank.d711.s2|14-26|tetracyclines|group
DDI-DrugBank.d711.s2|28-29|is|O
DDI-DrugBank.d711.s2|31-38|impaired|O
DDI-DrugBank.d711.s2|40-41|by|O
DDI-DrugBank.d711.s2|43-50|antacids|group
DDI-DrugBank.d711.s2|52-61|containing|O
DDI-DrugBank.d711.s2|63-70|aluminum|drug
DDI-DrugBank.d711.s2|71-71|,|O
DDI-DrugBank.d711.s2|73-79|calcium|drug
DDI-DrugBank.d711.s2|81-82|or|O
DDI-DrugBank.d711.s2|84-92|magnesium|drug
DDI-DrugBank.d711.s2|93-93|,|O
DDI-DrugBank.d711.s2|95-97|and|O
DDI-DrugBank.d711.s2|99-113|iron-containing|drug
DDI-DrugBank.d711.s2|115-126|preparations|O
DDI-DrugBank.d711.s2|127-127|.|O
DDI-DrugBank.d711.s3|0-2|The|O
DDI-DrugBank.d711.s3|4-13|concurrent|O
DDI-DrugBank.d711.s3|15-17|use|O
DDI-DrugBank.d711.s3|19-20|of|O
DDI-DrugBank.d711.s3|22-33|tetracycline|group
DDI-DrugBank.d711.s3|35-37|and|O
DDI-DrugBank.d711.s3|39-52|methoxyflurane|drug
DDI-DrugBank.d711.s3|54-56|has|O
DDI-DrugBank.d711.s3|58-61|been|O
DDI-DrugBank.d711.s3|63-70|reported|O
DDI-DrugBank.d711.s3|72-73|to|O
DDI-DrugBank.d711.s3|75-80|result|O
DDI-DrugBank.d711.s3|82-83|in|O
DDI-DrugBank.d711.s3|85-89|fatal|O
DDI-DrugBank.d711.s3|91-95|renal|O
DDI-DrugBank.d711.s3|97-104|toxicity|O
DDI-DrugBank.d711.s3|105-105|.|O
DDI-DrugBank.d711.s4|0-9|Concurrent|O
DDI-DrugBank.d711.s4|11-13|use|O
DDI-DrugBank.d711.s4|15-16|of|O
DDI-DrugBank.d711.s4|18-30|tetracyclines|group
DDI-DrugBank.d711.s4|32-35|with|O
DDI-DrugBank.d711.s4|37-40|oral|O
DDI-DrugBank.d711.s4|42-55|contraceptives|group
DDI-DrugBank.d711.s4|57-59|may|O
DDI-DrugBank.d711.s4|61-66|render|O
DDI-DrugBank.d711.s4|68-71|oral|O
DDI-DrugBank.d711.s4|73-86|contraceptives|group
DDI-DrugBank.d711.s4|88-91|less|O
DDI-DrugBank.d711.s4|93-101|effective|O
DDI-DrugBank.d711.s4|102-102|.|O
DDI-MedLine.d88.s0|0-2|The|O
DDI-MedLine.d88.s0|4-10|effects|O
DDI-MedLine.d88.s0|12-13|of|O
DDI-MedLine.d88.s0|15-30|chlordiazepoxide|drug
DDI-MedLine.d88.s0|31-31|,|O
DDI-MedLine.d88.s0|33-43|amphetamine|drug
DDI-MedLine.d88.s0|45-47|and|O
DDI-MedLine.d88.s0|49-55|cocaine|drug
DDI-MedLine.d88.s0|57-58|on|O
DDI-MedLine.d88.s0|60-68|bar-press|O
DDI-MedLine.d88.s0|70-77|behavior|O
DDI-MedLine.d88.s0|79-80|in|O
DDI-MedLine.d88.s0|82-87|normal|O
DDI-MedLine.d88.s0|89-91|and|O
DDI-MedLine.d88.s0|93-103|genetically|O
DDI-MedLine.d88.s0|105-111|nervous|O
DDI-MedLine.d88.s0|113-116|dogs|O
DDI-MedLine.d88.s0|117-117|.|O
DDI-MedLine.d88.s1|0-6|Studies|O
DDI-MedLine.d88.s1|8-9|on|O
DDI-MedLine.d88.s1|11-13|two|O
DDI-MedLine.d88.s1|15-21|strains|O
DDI-MedLine.d88.s1|23-24|of|O
DDI-MedLine.d88.s1|26-32|pointer|O
DDI-MedLine.d88.s1|34-37|dogs|O
DDI-MedLine.d88.s1|39-42|have|O
DDI-MedLine.d88.s1|44-55|demonstrated|O
DDI-MedLine.d88.s1|57-60|that|O
DDI-MedLine.d88.s1|62-75|administration|O
DDI-MedLine.d88.s1|77-78|of|O
DDI-MedLine.d88.s1|80-80|a|O
DDI-MedLine.d88.s1|82-95|benzodiazepine|group
DDI-MedLine.d88.s1|97-97|(|O
DDI-MedLine.d88.s1|98-113|chlordiazepoxide|drug
DDI-MedLine.d88.s1|114-114|)|O
DDI-MedLine.d88.s1|116-126|facilitates|O
DDI-MedLine.d88.s1|128-138|acquisition|O
DDI-MedLine.d88.s1|140-141|of|O
DDI-MedLine.d88.s1|143-155|goal-directed|O
DDI-MedLine.d88.s1|157-164|behavior|O
DDI-MedLine.d88.s1|166-167|in|O
DDI-MedLine.d88.s1|169-169|"|O
DDI-MedLine.d88.s1|170-180|genetically|O
DDI-MedLine.d88.s1|182-188|nervous|O
DDI-MedLine.d88.s1|189-189|"|O
DDI-MedLine.d88.s2|0-7|subjects|O
DDI-MedLine.d88.s2|8-8|.|O
DDI-MedLine.d88.s3|0-8|Continued|O
DDI-MedLine.d88.s3|10-21|admistration|O
DDI-MedLine.d88.s3|23-24|of|O
DDI-MedLine.d88.s3|26-28|the|O
DDI-MedLine.d88.s3|30-33|drug|O
DDI-MedLine.d88.s3|35-36|is|O
DDI-MedLine.d88.s3|38-45|required|O
DDI-MedLine.d88.s3|47-48|to|O
DDI-MedLine.d88.s3|50-57|maintain|O
DDI-MedLine.d88.s3|59-66|barpress|O
DDI-MedLine.d88.s3|68-75|response|O
DDI-MedLine.d88.s3|77-78|in|O
DDI-MedLine.d88.s3|80-83|this|O
DDI-MedLine.d88.s3|85-90|strain|O
DDI-MedLine.d88.s3|92-93|of|O
DDI-MedLine.d88.s3|95-98|dogs|O
DDI-MedLine.d88.s3|99-99|.|O
DDI-MedLine.d88.s4|0-2|The|O
DDI-MedLine.d88.s4|4-14|concomitant|O
DDI-MedLine.d88.s4|16-29|administration|O
DDI-MedLine.d88.s4|31-32|of|O
DDI-MedLine.d88.s4|34-39|either|O
DDI-MedLine.d88.s4|41-47|cocaine|drug
DDI-MedLine.d88.s4|49-50|or|O
DDI-MedLine.d88.s4|52-62|amphetamine|drug
DDI-MedLine.d88.s4|63-63|,|O
DDI-MedLine.d88.s4|65-73|compounds|O
DDI-MedLine.d88.s4|75-79|which|O
DDI-MedLine.d88.s4|81-87|inhibit|O
DDI-MedLine.d88.s4|89-96|neuronal|O
DDI-MedLine.d88.s4|98-105|reuptake|O
DDI-MedLine.d88.s4|107-108|of|O
DDI-MedLine.d88.s4|110-123|norepinephrine|O
DDI-MedLine.d88.s4|124-124|,|O
DDI-MedLine.d88.s4|126-133|disrupts|O
DDI-MedLine.d88.s4|135-137|the|O
DDI-MedLine.d88.s4|139-148|behavioral|O
DDI-MedLine.d88.s4|150-157|response|O
DDI-MedLine.d88.s4|159-160|of|O
DDI-MedLine.d88.s4|162-164|the|O
DDI-MedLine.d88.s4|166-176|genetically|O
DDI-MedLine.d88.s4|178-184|nervous|O
DDI-MedLine.d88.s4|186-193|E-strain|O
DDI-MedLine.d88.s4|195-202|subjects|O
DDI-MedLine.d88.s4|204-205|to|O
DDI-MedLine.d88.s4|207-207|a|O
DDI-MedLine.d88.s4|209-211|far|O
DDI-MedLine.d88.s4|213-219|greater|O
DDI-MedLine.d88.s4|221-226|extent|O
DDI-MedLine.d88.s4|228-231|than|O
DDI-MedLine.d88.s4|233-235|the|O
DDI-MedLine.d88.s4|237-242|stable|O
DDI-MedLine.d88.s4|244-251|A-strain|O
DDI-MedLine.d88.s4|253-260|subjects|O
DDI-MedLine.d88.s4|261-261|.|O
DDI-MedLine.d88.s5|0-1|It|O
DDI-MedLine.d88.s5|3-4|is|O
DDI-MedLine.d88.s5|6-9|also|O
DDI-MedLine.d88.s5|11-15|shown|O
DDI-MedLine.d88.s5|17-20|that|O
DDI-MedLine.d88.s5|22-26|after|O
DDI-MedLine.d88.s5|28-29|14|O
DDI-MedLine.d88.s5|31-34|days|O
DDI-MedLine.d88.s5|36-37|of|O
DDI-MedLine.d88.s5|39-43|daily|O
DDI-MedLine.d88.s5|45-58|administration|O
DDI-MedLine.d88.s5|60-61|of|O
DDI-MedLine.d88.s5|63-78|chlordiazepoxide|drug
DDI-MedLine.d88.s5|79-79|,|O
DDI-MedLine.d88.s5|81-90|withdrawal|O
DDI-MedLine.d88.s5|92-93|of|O
DDI-MedLine.d88.s5|95-97|the|O
DDI-MedLine.d88.s5|99-102|drug|O
DDI-MedLine.d88.s5|104-106|not|O
DDI-MedLine.d88.s5|108-111|only|O
DDI-MedLine.d88.s5|113-122|re-results|O
DDI-MedLine.d88.s5|124-125|in|O
DDI-MedLine.d88.s5|127-132|almost|O
DDI-MedLine.d88.s5|134-141|complete|O
DDI-MedLine.d88.s5|143-146|loss|O
DDI-MedLine.d88.s5|148-149|of|O
DDI-MedLine.d88.s5|151-159|bar-press|O
DDI-MedLine.d88.s5|161-168|response|O
DDI-MedLine.d88.s5|170-171|in|O
DDI-MedLine.d88.s5|173-175|the|O
DDI-MedLine.d88.s5|177-184|E-strain|O
DDI-MedLine.d88.s5|186-193|subjects|O
DDI-MedLine.d88.s5|195-197|but|O
DDI-MedLine.d88.s5|199-202|also|O
DDI-MedLine.d88.s5|204-210|results|O
DDI-MedLine.d88.s5|212-213|in|O
DDI-MedLine.d88.s5|215-215|a|O
DDI-MedLine.d88.s5|217-225|temporary|O
DDI-MedLine.d88.s5|227-234|decrease|O
DDI-MedLine.d88.s5|236-237|in|O
DDI-MedLine.d88.s5|239-241|the|O
DDI-MedLine.d88.s5|243-250|acquired|O
DDI-MedLine.d88.s5|252-261|behavioral|O
DDI-MedLine.d88.s5|263-270|response|O
DDI-MedLine.d88.s5|272-273|of|O
DDI-MedLine.d88.s5|275-277|the|O
DDI-MedLine.d88.s5|279-284|stable|O
DDI-MedLine.d88.s5|286-293|A-strain|O
DDI-MedLine.d88.s5|295-302|subjects|O
DDI-MedLine.d88.s5|303-303|.|O
DDI-DrugBank.d563.s0|0-6|Special|O
DDI-DrugBank.d563.s0|8-20|consideration|O
DDI-DrugBank.d563.s0|22-27|should|O
DDI-DrugBank.d563.s0|29-30|be|O
DDI-DrugBank.d563.s0|32-36|given|O
DDI-DrugBank.d563.s0|38-39|to|O
DDI-DrugBank.d563.s0|41-43|the|O
DDI-DrugBank.d563.s0|45-58|administration|O
DDI-DrugBank.d563.s0|60-61|of|O
DDI-DrugBank.d563.s0|63-68|ETHYOL|brand
DDI-DrugBank.d563.s0|70-71|in|O
DDI-DrugBank.d563.s0|73-80|patients|O
DDI-DrugBank.d563.s0|82-90|receiving|O
DDI-DrugBank.d563.s0|92-119|antihypertensive medications|group
DDI-DrugBank.d563.s0|121-122|or|O
DDI-DrugBank.d563.s0|124-128|other|O
DDI-DrugBank.d563.s0|130-134|drugs|O
DDI-DrugBank.d563.s0|136-139|that|O
DDI-DrugBank.d563.s0|141-145|could|O
DDI-DrugBank.d563.s0|147-151|cause|O
DDI-DrugBank.d563.s0|153-154|or|O
DDI-DrugBank.d563.s0|156-165|potentiate|O
DDI-DrugBank.d563.s0|167-177|hypotension|O
DDI-DrugBank.d563.s0|178-178|.|O
DDI-MedLine.d211.s0|0-4|Phase|O
DDI-MedLine.d211.s0|6-6|I|O
DDI-MedLine.d211.s0|8-12|trial|O
DDI-MedLine.d211.s0|14-15|of|O
DDI-MedLine.d211.s0|17-28|lenalidomide|drug
DDI-MedLine.d211.s0|30-32|and|O
DDI-MedLine.d211.s0|34-40|CCI-779|drug
DDI-MedLine.d211.s0|42-43|in|O
DDI-MedLine.d211.s0|45-52|patients|O
DDI-MedLine.d211.s0|54-57|with|O
DDI-MedLine.d211.s0|59-66|relapsed|O
DDI-MedLine.d211.s0|68-75|multiple|O
DDI-MedLine.d211.s0|77-83|myeloma|O
DDI-MedLine.d211.s0|84-84|:|O
DDI-MedLine.d211.s0|86-93|evidence|O
DDI-MedLine.d211.s0|95-97|for|O
DDI-MedLine.d211.s0|99-118|lenalidomide-CCI-779|drug
DDI-MedLine.d211.s0|120-130|interaction|O
DDI-MedLine.d211.s0|132-134|via|O
DDI-MedLine.d211.s0|136-149|P-glycoprotein|O
DDI-MedLine.d211.s0|150-150|.|O
DDI-MedLine.d211.s1|0-7|Multiple|O
DDI-MedLine.d211.s1|9-15|myeloma|O
DDI-MedLine.d211.s1|17-17|(|O
DDI-MedLine.d211.s1|18-19|MM|O
DDI-MedLine.d211.s1|20-20|)|O
DDI-MedLine.d211.s1|22-23|is|O
DDI-MedLine.d211.s1|25-26|an|O
DDI-MedLine.d211.s1|28-36|incurable|O
DDI-MedLine.d211.s1|38-48|plasma-cell|O
DDI-MedLine.d211.s1|50-57|neoplasm|O
DDI-MedLine.d211.s1|59-61|for|O
DDI-MedLine.d211.s1|63-67|which|O
DDI-MedLine.d211.s1|69-72|most|O
DDI-MedLine.d211.s1|74-83|treatments|O
DDI-MedLine.d211.s1|85-91|involve|O
DDI-MedLine.d211.s1|93-93|a|O
DDI-MedLine.d211.s1|95-105|therapeutic|O
DDI-MedLine.d211.s1|107-111|agent|O
DDI-MedLine.d211.s1|113-120|combined|O
DDI-MedLine.d211.s1|122-125|with|O
DDI-MedLine.d211.s1|127-139|dexamethasone|drug
DDI-MedLine.d211.s1|140-140|.|O
DDI-MedLine.d211.s2|0-2|The|O
DDI-MedLine.d211.s2|4-14|preclinical|O
DDI-MedLine.d211.s2|16-26|combination|O
DDI-MedLine.d211.s2|28-29|of|O
DDI-MedLine.d211.s2|31-42|lenalidomide|drug
DDI-MedLine.d211.s2|44-47|with|O
DDI-MedLine.d211.s2|49-51|the|O
DDI-MedLine.d211.s2|53-56|mTOR|O
DDI-MedLine.d211.s2|58-66|inhibitor|O
DDI-MedLine.d211.s2|68-74|CCI-779|drug
DDI-MedLine.d211.s2|76-78|has|O
DDI-MedLine.d211.s2|80-88|displayed|O
DDI-MedLine.d211.s2|90-96|synergy|O
DDI-MedLine.d211.s2|98-99|in|O
DDI-MedLine.d211.s2|101-105|vitro|O
DDI-MedLine.d211.s2|107-109|and|O
DDI-MedLine.d211.s2|111-120|represents|O
DDI-MedLine.d211.s2|122-122|a|O
DDI-MedLine.d211.s2|124-128|novel|O
DDI-MedLine.d211.s2|130-140|combination|O
DDI-MedLine.d211.s2|142-143|in|O
DDI-MedLine.d211.s2|145-146|MM|O
DDI-MedLine.d211.s2|147-147|.|O
DDI-DrugBank.d430.s0|0-10|Intravenous|O
DDI-DrugBank.d430.s0|12-21|ranitidine|drug
DDI-DrugBank.d430.s0|23-25|was|O
DDI-DrugBank.d430.s0|27-31|shown|O
DDI-DrugBank.d430.s0|33-34|to|O
DDI-DrugBank.d430.s0|36-41|double|O
DDI-DrugBank.d430.s0|43-45|the|O
DDI-DrugBank.d430.s0|47-61|bioavailability|O
DDI-DrugBank.d430.s0|63-64|of|O
DDI-DrugBank.d430.s0|66-69|oral|O
DDI-DrugBank.d430.s0|71-81|alendronate|drug
DDI-DrugBank.d430.s0|82-82|.|O
DDI-DrugBank.d430.s1|0-2|The|O
DDI-DrugBank.d430.s1|4-11|clinical|O
DDI-DrugBank.d430.s1|13-24|significance|O
DDI-DrugBank.d430.s1|26-27|of|O
DDI-DrugBank.d430.s1|29-32|this|O
DDI-DrugBank.d430.s1|34-42|increased|O
DDI-DrugBank.d430.s1|44-58|bioavailability|O
DDI-DrugBank.d430.s1|60-62|and|O
DDI-DrugBank.d430.s1|64-70|whether|O
DDI-DrugBank.d430.s1|72-78|similar|O
DDI-DrugBank.d430.s1|80-88|increases|O
DDI-DrugBank.d430.s1|90-93|will|O
DDI-DrugBank.d430.s1|95-99|occur|O
DDI-DrugBank.d430.s1|101-102|in|O
DDI-DrugBank.d430.s1|104-111|patients|O
DDI-DrugBank.d430.s1|113-117|given|O
DDI-DrugBank.d430.s1|119-122|oral|O
DDI-DrugBank.d430.s1|124-137|H2-antagonists|group
DDI-DrugBank.d430.s1|139-140|is|O
DDI-DrugBank.d430.s1|142-148|unknown|O
DDI-DrugBank.d430.s1|149-149|;|O
DDI-DrugBank.d430.s2|0-1|no|O
DDI-DrugBank.d430.s2|3-7|other|O
DDI-DrugBank.d430.s2|9-16|specific|O
DDI-DrugBank.d430.s2|18-21|drug|O
DDI-DrugBank.d430.s2|23-33|interaction|O
DDI-DrugBank.d430.s2|35-41|studies|O
DDI-DrugBank.d430.s2|43-46|were|O
DDI-DrugBank.d430.s2|48-56|performed|O
DDI-DrugBank.d430.s2|57-57|.|O
DDI-DrugBank.d430.s3|0-7|Products|O
DDI-DrugBank.d430.s3|9-18|containing|O
DDI-DrugBank.d430.s3|20-26|calcium|drug
DDI-DrugBank.d430.s3|28-30|and|O
DDI-DrugBank.d430.s3|32-36|other|O
DDI-DrugBank.d430.s3|38-56|multivalent cations|drug
DDI-DrugBank.d430.s3|58-63|likely|O
DDI-DrugBank.d430.s3|65-68|will|O
DDI-DrugBank.d430.s3|70-78|interfere|O
DDI-DrugBank.d430.s3|80-83|with|O
DDI-DrugBank.d430.s3|85-94|absorption|O
DDI-DrugBank.d430.s3|96-97|of|O
DDI-DrugBank.d430.s3|99-109|alendronate|drug
DDI-DrugBank.d430.s3|110-110|.|O
DDI-MedLine.d51.s0|0-6|Effects|O
DDI-MedLine.d51.s0|8-9|of|O
DDI-MedLine.d51.s0|11-30|xanthine derivatives|group
DDI-MedLine.d51.s0|32-33|in|O
DDI-MedLine.d51.s0|35-35|a|O
DDI-MedLine.d51.s0|37-46|light/dark|O
DDI-MedLine.d51.s0|48-51|test|O
DDI-MedLine.d51.s0|53-54|in|O
DDI-MedLine.d51.s0|56-59|mice|O
DDI-MedLine.d51.s0|61-63|and|O
DDI-MedLine.d51.s0|65-67|the|O
DDI-MedLine.d51.s0|69-80|contribution|O
DDI-MedLine.d51.s0|82-83|of|O
DDI-MedLine.d51.s0|85-93|adenosine|O
DDI-MedLine.d51.s0|95-103|receptors|O
DDI-MedLine.d51.s0|104-104|.|O
DDI-MedLine.d51.s1|0-1|We|O
DDI-MedLine.d51.s1|3-14|investigated|O
DDI-MedLine.d51.s1|16-18|the|O
DDI-MedLine.d51.s1|20-26|effects|O
DDI-MedLine.d51.s1|28-29|of|O
DDI-MedLine.d51.s1|31-39|adenosine|O
DDI-MedLine.d51.s1|41-48|receptor|O
DDI-MedLine.d51.s1|50-60|antagonists|O
DDI-MedLine.d51.s1|61-61|,|O
DDI-MedLine.d51.s1|63-70|caffeine|drug
DDI-MedLine.d51.s1|71-71|,|O
DDI-MedLine.d51.s1|73-84|theophylline|drug
DDI-MedLine.d51.s1|85-85|,|O
DDI-MedLine.d51.s1|107-107|,|O
DDI-MedLine.d51.s1|109-111|and|O
DDI-MedLine.d51.s1|148-148|(|O
DDI-MedLine.d51.s1|154-154|)|O
DDI-MedLine.d51.s1|155-155|,|O
DDI-MedLine.d51.s1|157-158|in|O
DDI-MedLine.d51.s1|160-160|a|O
DDI-MedLine.d51.s1|162-171|light/dark|O
DDI-MedLine.d51.s1|173-176|test|O
DDI-MedLine.d51.s1|178-179|in|O
DDI-MedLine.d51.s1|181-184|mice|O
DDI-MedLine.d51.s1|185-185|.|O
DDI-MedLine.d51.s2|0-2|All|O
DDI-MedLine.d51.s2|4-14|antagonists|O
DDI-MedLine.d51.s2|16-24|decreased|O
DDI-MedLine.d51.s2|26-28|the|O
DDI-MedLine.d51.s2|30-33|time|O
DDI-MedLine.d51.s2|35-39|spent|O
DDI-MedLine.d51.s2|41-42|in|O
DDI-MedLine.d51.s2|44-46|the|O
DDI-MedLine.d51.s2|48-52|light|O
DDI-MedLine.d51.s2|54-57|zone|O
DDI-MedLine.d51.s2|59-60|in|O
DDI-MedLine.d51.s2|62-65|this|O
DDI-MedLine.d51.s2|67-70|test|O
DDI-MedLine.d51.s2|71-71|,|O
DDI-MedLine.d51.s2|73-77|which|O
DDI-MedLine.d51.s2|79-87|suggested|O
DDI-MedLine.d51.s2|89-92|that|O
DDI-MedLine.d51.s2|94-98|these|O
DDI-MedLine.d51.s2|100-108|compounds|O
DDI-MedLine.d51.s2|110-113|have|O
DDI-MedLine.d51.s2|115-124|anxiogenic|O
DDI-MedLine.d51.s2|126-132|effects|O
DDI-MedLine.d51.s2|133-133|.|O
DDI-MedLine.d51.s3|0-2|The|O
DDI-MedLine.d51.s3|4-13|anxiogenic|O
DDI-MedLine.d51.s3|15-21|effects|O
DDI-MedLine.d51.s3|23-24|of|O
DDI-MedLine.d51.s3|26-37|theophylline|drug
DDI-MedLine.d51.s3|39-42|were|O
DDI-MedLine.d51.s3|44-50|reduced|O
DDI-MedLine.d51.s3|52-53|by|O
DDI-MedLine.d51.s3|55-66|pretreatment|O
DDI-MedLine.d51.s3|68-71|with|O
DDI-MedLine.d51.s3|82-82|,|O
DDI-MedLine.d51.s3|84-85|an|O
DDI-MedLine.d51.s3|87-98|A2-selective|O
DDI-MedLine.d51.s3|100-106|agonist|O
DDI-MedLine.d51.s3|107-107|,|O
DDI-MedLine.d51.s3|109-111|but|O
DDI-MedLine.d51.s3|113-115|not|O
DDI-MedLine.d51.s3|117-118|by|O
DDI-MedLine.d51.s3|144-144|(|O
DDI-MedLine.d51.s3|148-148|)|O
DDI-MedLine.d51.s3|149-149|,|O
DDI-MedLine.d51.s3|151-152|an|O
DDI-MedLine.d51.s3|154-165|A1-selective|O
DDI-MedLine.d51.s3|167-173|agonist|O
DDI-MedLine.d51.s3|174-174|.|O
DDI-MedLine.d51.s4|0-6|However|O
DDI-MedLine.d51.s4|7-7|,|O
DDI-MedLine.d51.s4|9-11|the|O
DDI-MedLine.d51.s4|13-22|antagonism|O
DDI-MedLine.d51.s4|24-25|of|O
DDI-MedLine.d51.s4|27-29|the|O
DDI-MedLine.d51.s4|31-50|theophylline-induced|drug
DDI-MedLine.d51.s4|52-61|anxiogenic|O
DDI-MedLine.d51.s4|63-69|effects|O
DDI-MedLine.d51.s4|71-72|by|O
DDI-MedLine.d51.s4|83-85|was|O
DDI-MedLine.d51.s4|87-90|only|O
DDI-MedLine.d51.s4|92-99|observed|O
DDI-MedLine.d51.s4|101-102|in|O
DDI-MedLine.d51.s4|104-106|the|O
DDI-MedLine.d51.s4|108-111|time|O
DDI-MedLine.d51.s4|113-117|spent|O
DDI-MedLine.d51.s4|119-120|in|O
DDI-MedLine.d51.s4|122-124|the|O
DDI-MedLine.d51.s4|126-130|light|O
DDI-MedLine.d51.s4|132-135|zone|O
DDI-MedLine.d51.s4|136-136|,|O
DDI-MedLine.d51.s4|138-140|and|O
DDI-MedLine.d51.s4|156-165|anxiogenic|O
DDI-MedLine.d51.s4|167-173|effects|O
DDI-MedLine.d51.s4|175-178|were|O
DDI-MedLine.d51.s4|180-186|neither|O
DDI-MedLine.d51.s4|188-195|reversed|O
DDI-MedLine.d51.s4|197-198|by|O
DDI-MedLine.d51.s4|200-208|CGS 21680|drug
DDI-MedLine.d51.s4|210-212|nor|O
DDI-MedLine.d51.s4|214-215|by|O
DDI-MedLine.d51.s4|220-220|.|O
DDI-MedLine.d51.s5|0-6|Finally|O
DDI-MedLine.d51.s5|7-7|,|O
DDI-MedLine.d51.s5|9-10|it|O
DDI-MedLine.d51.s5|12-13|is|O
DDI-MedLine.d51.s5|15-21|notable|O
DDI-MedLine.d51.s5|23-26|that|O
DDI-MedLine.d51.s5|28-43|xanthine-derived|O
DDI-MedLine.d51.s5|45-53|adenosine|O
DDI-MedLine.d51.s5|55-65|antagonists|O
DDI-MedLine.d51.s5|67-72|tested|O
DDI-MedLine.d51.s5|74-77|here|O
DDI-MedLine.d51.s5|79-86|commonly|O
DDI-MedLine.d51.s5|88-93|showed|O
DDI-MedLine.d51.s5|95-104|anxiogenic|O
DDI-MedLine.d51.s5|106-112|effects|O
DDI-MedLine.d51.s5|114-115|in|O
DDI-MedLine.d51.s5|117-119|the|O
DDI-MedLine.d51.s5|121-130|light/dark|O
DDI-MedLine.d51.s5|132-135|test|O
DDI-MedLine.d51.s5|137-138|in|O
DDI-MedLine.d51.s5|140-143|mice|O
DDI-MedLine.d51.s5|144-144|.|O
DDI-MedLine.d51.s6|0-1|It|O
DDI-MedLine.d51.s6|3-4|is|O
DDI-MedLine.d51.s6|6-14|suggested|O
DDI-MedLine.d51.s6|16-19|that|O
DDI-MedLine.d51.s6|21-25|there|O
DDI-MedLine.d51.s6|27-28|is|O
DDI-MedLine.d51.s6|30-30|a|O
DDI-MedLine.d51.s6|32-36|minor|O
DDI-MedLine.d51.s6|38-49|contribution|O
DDI-MedLine.d51.s6|51-52|of|O
DDI-MedLine.d51.s6|54-62|adenosine|O
DDI-MedLine.d51.s6|64-72|receptors|O
DDI-MedLine.d51.s6|74-75|to|O
DDI-MedLine.d51.s6|77-81|these|O
DDI-MedLine.d51.s6|83-89|effects|O
DDI-MedLine.d51.s6|90-90|,|O
DDI-MedLine.d51.s6|92-99|although|O
DDI-MedLine.d51.s6|101-120|theophylline-induced|drug
DDI-MedLine.d51.s6|122-131|anxiogenic|O
DDI-MedLine.d51.s6|133-139|effects|O
DDI-MedLine.d51.s6|141-144|were|O
DDI-MedLine.d51.s6|146-156|antagonized|O
DDI-MedLine.d51.s6|158-159|by|O
DDI-MedLine.d51.s6|161-162|an|O
DDI-MedLine.d51.s6|164-165|A2|O
DDI-MedLine.d51.s6|167-174|receptor|O
DDI-MedLine.d51.s6|176-182|agonist|O
DDI-MedLine.d51.s6|183-183|.|O
DDI-MedLine.d94.s0|0-7|Evidence|O
DDI-MedLine.d94.s0|9-11|for|O
DDI-MedLine.d94.s0|13-21|reduction|O
DDI-MedLine.d94.s0|23-24|of|O
DDI-MedLine.d94.s0|26-39|norepinephrine|drug
DDI-MedLine.d94.s0|41-46|uptake|O
DDI-MedLine.d94.s0|48-52|sites|O
DDI-MedLine.d94.s0|54-55|in|O
DDI-MedLine.d94.s0|57-59|the|O
DDI-MedLine.d94.s0|61-67|failing|O
DDI-MedLine.d94.s0|69-73|human|O
DDI-MedLine.d94.s0|75-79|heart|O
DDI-MedLine.d94.s0|80-80|.|O
DDI-MedLine.d94.s1|0-9|OBJECTIVES|O
DDI-MedLine.d94.s1|10-10|.|O
DDI-MedLine.d94.s2|0-3|This|O
DDI-MedLine.d94.s2|5-9|study|O
DDI-MedLine.d94.s2|11-22|investigated|O
DDI-MedLine.d94.s2|24-26|the|O
DDI-MedLine.d94.s2|28-31|role|O
DDI-MedLine.d94.s2|33-34|of|O
DDI-MedLine.d94.s2|36-43|neuronal|O
DDI-MedLine.d94.s2|45-50|uptake|O
DDI-MedLine.d94.s2|52-53|of|O
DDI-MedLine.d94.s2|55-68|norepinephrine|drug
DDI-MedLine.d94.s2|70-70|(|O
DDI-MedLine.d94.s2|71-78|uptake-1|O
DDI-MedLine.d94.s2|79-79|)|O
DDI-MedLine.d94.s2|81-82|in|O
DDI-MedLine.d94.s2|84-88|human|O
DDI-MedLine.d94.s2|90-94|heart|O
DDI-MedLine.d94.s2|96-102|failure|O
DDI-MedLine.d94.s2|104-105|as|O
DDI-MedLine.d94.s2|107-107|a|O
DDI-MedLine.d94.s2|109-113|local|O
DDI-MedLine.d94.s2|115-120|factor|O
DDI-MedLine.d94.s2|122-124|for|O
DDI-MedLine.d94.s2|126-133|altering|O
DDI-MedLine.d94.s2|135-148|concentrations|O
DDI-MedLine.d94.s2|150-151|of|O
DDI-MedLine.d94.s2|153-166|norepinephrine|O
DDI-MedLine.d94.s2|168-169|at|O
DDI-MedLine.d94.s2|171-173|the|O
DDI-MedLine.d94.s2|175-181|cardiac|O
DDI-MedLine.d94.s2|183-189|myocyte|O
DDI-MedLine.d94.s2|191-199|membranes|O
DDI-MedLine.d94.s2|200-200|.|O
DDI-MedLine.d94.s3|0-9|BACKGROUND|O
DDI-MedLine.d94.s3|10-10|.|O
DDI-MedLine.d94.s4|0-6|Several|O
DDI-MedLine.d94.s4|8-22|beta-adrenergic|O
DDI-MedLine.d94.s4|24-36|neuroeffector|O
DDI-MedLine.d94.s4|38-44|defects|O
DDI-MedLine.d94.s4|46-50|occur|O
DDI-MedLine.d94.s4|52-53|in|O
DDI-MedLine.d94.s4|55-59|heart|O
DDI-MedLine.d94.s4|61-67|failure|O
DDI-MedLine.d94.s4|68-68|.|O
DDI-MedLine.d94.s5|0-6|Whether|O
DDI-MedLine.d94.s5|8-9|an|O
DDI-MedLine.d94.s5|11-20|alteration|O
DDI-MedLine.d94.s5|22-23|in|O
DDI-MedLine.d94.s5|25-38|norepinephrine|drug
DDI-MedLine.d94.s5|40-47|uptake-1|O
DDI-MedLine.d94.s5|49-54|occurs|O
DDI-MedLine.d94.s5|56-57|is|O
DDI-MedLine.d94.s5|59-63|still|O
DDI-MedLine.d94.s5|65-74|unresolved|O
DDI-MedLine.d94.s5|75-75|.|O
DDI-MedLine.d94.s6|0-6|METHODS|O
DDI-MedLine.d94.s6|7-7|.|O
DDI-MedLine.d94.s7|0-2|The|O
DDI-MedLine.d94.s7|4-7|role|O
DDI-MedLine.d94.s7|9-10|of|O
DDI-MedLine.d94.s7|12-25|norepinephrine|drug
DDI-MedLine.d94.s7|27-34|uptake-1|O
DDI-MedLine.d94.s7|36-38|was|O
DDI-MedLine.d94.s7|40-46|studied|O
DDI-MedLine.d94.s7|48-49|in|O
DDI-MedLine.d94.s7|51-62|electrically|O
DDI-MedLine.d94.s7|64-73|stimulated|O
DDI-MedLine.d94.s7|75-75|(|O
DDI-MedLine.d94.s7|76-76|1|O
DDI-MedLine.d94.s7|78-79|Hz|O
DDI-MedLine.d94.s7|80-80|,|O
DDI-MedLine.d94.s7|82-83|37|O
DDI-MedLine.d94.s7|85-91|degrees|O
DDI-MedLine.d94.s7|93-93|C|O
DDI-MedLine.d94.s7|94-94|)|O
DDI-MedLine.d94.s7|96-100|human|O
DDI-MedLine.d94.s7|102-112|ventricular|O
DDI-MedLine.d94.s7|114-120|cardiac|O
DDI-MedLine.d94.s7|122-133|preparations|O
DDI-MedLine.d94.s7|135-137|and|O
DDI-MedLine.d94.s7|139-146|isolated|O
DDI-MedLine.d94.s7|148-157|myocardial|O
DDI-MedLine.d94.s7|159-167|membranes|O
DDI-MedLine.d94.s7|168-168|.|O
DDI-MedLine.d94.s8|0-6|RESULTS|O
DDI-MedLine.d94.s8|7-7|.|O
DDI-MedLine.d94.s9|0-2|The|O
DDI-MedLine.d94.s9|4-16|effectiveness|O
DDI-MedLine.d94.s9|18-19|of|O
DDI-MedLine.d94.s9|21-34|norepinephrine|drug
DDI-MedLine.d94.s9|36-37|in|O
DDI-MedLine.d94.s9|39-48|increasing|O
DDI-MedLine.d94.s9|50-52|the|O
DDI-MedLine.d94.s9|54-58|force|O
DDI-MedLine.d94.s9|60-61|of|O
DDI-MedLine.d94.s9|63-73|contraction|O
DDI-MedLine.d94.s9|75-77|was|O
DDI-MedLine.d94.s9|79-87|decreased|O
DDI-MedLine.d94.s9|89-90|in|O
DDI-MedLine.d94.s9|92-99|relation|O
DDI-MedLine.d94.s9|101-102|to|O
DDI-MedLine.d94.s9|104-106|the|O
DDI-MedLine.d94.s9|108-113|degree|O
DDI-MedLine.d94.s9|115-116|of|O
DDI-MedLine.d94.s9|118-122|heart|O
DDI-MedLine.d94.s9|124-130|failure|O
DDI-MedLine.d94.s9|131-131|.|O
DDI-MedLine.d94.s10|0-1|In|O
DDI-MedLine.d94.s10|3-10|contrast|O
DDI-MedLine.d94.s10|11-11|,|O
DDI-MedLine.d94.s10|13-15|the|O
DDI-MedLine.d94.s10|17-23|potency|O
DDI-MedLine.d94.s10|25-26|of|O
DDI-MedLine.d94.s10|28-41|norepinephrine|drug
DDI-MedLine.d94.s10|43-45|was|O
DDI-MedLine.d94.s10|47-55|increased|O
DDI-MedLine.d94.s10|57-58|in|O
DDI-MedLine.d94.s10|60-66|failing|O
DDI-MedLine.d94.s10|68-73|hearts|O
DDI-MedLine.d94.s10|75-75|(|O
DDI-MedLine.d94.s10|76-78|New|O
DDI-MedLine.d94.s10|80-83|York|O
DDI-MedLine.d94.s10|85-89|Heart|O
DDI-MedLine.d94.s10|91-101|Association|O
DDI-MedLine.d94.s10|103-112|functional|O
DDI-MedLine.d94.s10|114-118|class|O
DDI-MedLine.d94.s10|120-121|IV|O
DDI-MedLine.d94.s10|122-122|)|O
DDI-MedLine.d94.s10|124-125|in|O
DDI-MedLine.d94.s10|127-134|relation|O
DDI-MedLine.d94.s10|136-137|to|O
DDI-MedLine.d94.s10|139-141|the|O
DDI-MedLine.d94.s10|143-156|concentrations|O
DDI-MedLine.d94.s10|158-166|producing|O
DDI-MedLine.d94.s10|168-169|50|O
DDI-MedLine.d94.s10|170-170|%|O
DDI-MedLine.d94.s10|172-173|of|O
DDI-MedLine.d94.s10|175-177|the|O
DDI-MedLine.d94.s10|179-185|maximal|O
DDI-MedLine.d94.s10|187-192|effect|O
DDI-MedLine.d94.s10|194-194|(|O
DDI-MedLine.d94.s10|195-198|EC50|O
DDI-MedLine.d94.s10|199-199|)|O
DDI-MedLine.d94.s10|200-200|.|O
DDI-MedLine.d94.s11|0-2|The|O
DDI-MedLine.d94.s11|4-7|EC50|O
DDI-MedLine.d94.s11|9-14|values|O
DDI-MedLine.d94.s11|16-18|for|O
DDI-MedLine.d94.s11|20-32|isoproterenol|drug
DDI-MedLine.d94.s11|33-33|,|O
DDI-MedLine.d94.s11|35-39|which|O
DDI-MedLine.d94.s11|41-42|is|O
DDI-MedLine.d94.s11|44-46|not|O
DDI-MedLine.d94.s11|48-48|a|O
DDI-MedLine.d94.s11|50-58|substrate|O
DDI-MedLine.d94.s11|60-62|for|O
DDI-MedLine.d94.s11|64-77|norepinephrine|drug
DDI-MedLine.d94.s11|79-86|uptake-1|O
DDI-MedLine.d94.s11|87-87|,|O
DDI-MedLine.d94.s11|89-92|were|O
DDI-MedLine.d94.s11|94-100|reduced|O
DDI-MedLine.d94.s11|102-103|in|O
DDI-MedLine.d94.s11|105-114|myocardium|O
DDI-MedLine.d94.s11|116-117|in|O
DDI-MedLine.d94.s11|119-128|functional|O
DDI-MedLine.d94.s11|130-136|classes|O
DDI-MedLine.d94.s11|138-139|II|O
DDI-MedLine.d94.s11|141-142|to|O
DDI-MedLine.d94.s11|144-146|III|O
DDI-MedLine.d94.s11|148-150|and|O
DDI-MedLine.d94.s11|152-153|IV|O
DDI-MedLine.d94.s11|155-162|compared|O
DDI-MedLine.d94.s11|164-167|with|O
DDI-MedLine.d94.s11|169-173|those|O
DDI-MedLine.d94.s11|175-176|in|O
DDI-MedLine.d94.s11|178-187|nonfailing|O
DDI-MedLine.d94.s11|189-198|myocardium|O
DDI-MedLine.d94.s11|199-199|.|O
DDI-MedLine.d94.s12|0-2|The|O
DDI-MedLine.d94.s12|4-9|uptake|O
DDI-MedLine.d94.s12|11-20|inhibitors|O
DDI-MedLine.d94.s12|22-28|cocaine|drug
DDI-MedLine.d94.s12|30-32|and|O
DDI-MedLine.d94.s12|34-44|desipramine|drug
DDI-MedLine.d94.s12|46-46|(|O
DDI-MedLine.d94.s12|47-47|3|O
DDI-MedLine.d94.s12|49-59|mumol/liter|O
DDI-MedLine.d94.s12|60-60|)|O
DDI-MedLine.d94.s12|62-72|potentiated|O
DDI-MedLine.d94.s12|74-76|the|O
DDI-MedLine.d94.s12|78-85|positive|O
DDI-MedLine.d94.s12|87-95|inotropic|O
DDI-MedLine.d94.s12|97-103|effects|O
DDI-MedLine.d94.s12|105-106|of|O
DDI-MedLine.d94.s12|108-121|norepinephrine|drug
DDI-MedLine.d94.s12|123-124|in|O
DDI-MedLine.d94.s12|126-135|nonfailing|O
DDI-MedLine.d94.s12|137-146|myocardium|O
DDI-MedLine.d94.s12|148-148|(|O
DDI-MedLine.d94.s12|149-149|p|O
DDI-MedLine.d94.s12|151-151|<|O
DDI-MedLine.d94.s12|153-156|0.05|O
DDI-MedLine.d94.s12|157-157|)|O
DDI-MedLine.d94.s12|159-161|but|O
DDI-MedLine.d94.s12|163-165|not|O
DDI-MedLine.d94.s12|167-168|in|O
DDI-MedLine.d94.s12|170-179|functional|O
DDI-MedLine.d94.s12|181-185|class|O
DDI-MedLine.d94.s12|187-188|IV|O
DDI-MedLine.d94.s12|190-199|myocardium|O
DDI-MedLine.d94.s12|200-200|.|O
DDI-MedLine.d94.s13|0-10|Radioligand|O
DDI-MedLine.d94.s13|12-18|binding|O
DDI-MedLine.d94.s13|20-30|experiments|O
DDI-MedLine.d94.s13|32-36|using|O
DDI-MedLine.d94.s13|38-40|the|O
DDI-MedLine.d94.s13|42-47|uptake|O
DDI-MedLine.d94.s13|49-57|inhibitor|O
DDI-MedLine.d94.s13|59-68|hydrogen-3|O
DDI-MedLine.d94.s13|70-77|mazindol|drug
DDI-MedLine.d94.s13|79-86|revealed|O
DDI-MedLine.d94.s13|88-88|a|O
DDI-MedLine.d94.s13|90-100|significant|O
DDI-MedLine.d94.s13|102-109|decrease|O
DDI-MedLine.d94.s13|111-112|by|O
DDI-MedLine.d94.s13|114-126|approximately|O
DDI-MedLine.d94.s13|128-129|30|O
DDI-MedLine.d94.s13|130-130|%|O
DDI-MedLine.d94.s13|132-133|in|O
DDI-MedLine.d94.s13|135-148|norepinephrine|drug
DDI-MedLine.d94.s13|150-157|uptake-1|O
DDI-MedLine.d94.s13|159-165|carrier|O
DDI-MedLine.d94.s13|167-173|density|O
DDI-MedLine.d94.s13|175-176|in|O
DDI-MedLine.d94.s13|178-187|functional|O
DDI-MedLine.d94.s13|189-195|classes|O
DDI-MedLine.d94.s13|197-198|II|O
DDI-MedLine.d94.s13|200-201|to|O
DDI-MedLine.d94.s13|203-205|III|O
DDI-MedLine.d94.s13|207-209|and|O
DDI-MedLine.d94.s13|211-212|IV|O
DDI-MedLine.d94.s13|214-223|myocardium|O
DDI-MedLine.d94.s13|225-230|versus|O
DDI-MedLine.d94.s13|232-241|nonfailing|O
DDI-MedLine.d94.s13|243-252|myocardium|O
DDI-MedLine.d94.s13|254-254|(|O
DDI-MedLine.d94.s13|255-255|p|O
DDI-MedLine.d94.s13|257-257|<|O
DDI-MedLine.d94.s13|259-262|0.05|O
DDI-MedLine.d94.s13|263-263|)|O
DDI-MedLine.d94.s13|264-264|.|O
DDI-MedLine.d94.s14|0-10|CONCLUSIONS|O
DDI-MedLine.d94.s14|11-11|.|O
DDI-MedLine.d94.s15|0-1|In|O
DDI-MedLine.d94.s15|3-7|human|O
DDI-MedLine.d94.s15|9-13|heart|O
DDI-MedLine.d94.s15|15-21|failure|O
DDI-MedLine.d94.s15|22-22|,|O
DDI-MedLine.d94.s15|24-28|there|O
DDI-MedLine.d94.s15|30-31|is|O
DDI-MedLine.d94.s15|33-33|a|O
DDI-MedLine.d94.s15|35-45|presynaptic|O
DDI-MedLine.d94.s15|47-52|defect|O
DDI-MedLine.d94.s15|54-55|in|O
DDI-MedLine.d94.s15|57-59|the|O
DDI-MedLine.d94.s15|61-71|sympathetic|O
DDI-MedLine.d94.s15|73-79|nervous|O
DDI-MedLine.d94.s15|81-86|system|O
DDI-MedLine.d94.s15|87-87|,|O
DDI-MedLine.d94.s15|89-95|leading|O
DDI-MedLine.d94.s15|97-98|to|O
DDI-MedLine.d94.s15|100-106|reduced|O
DDI-MedLine.d94.s15|108-115|uptake-1|O
DDI-MedLine.d94.s15|117-124|activity|O
DDI-MedLine.d94.s15|125-125|.|O
DDI-MedLine.d94.s16|0-3|This|O
DDI-MedLine.d94.s16|5-10|defect|O
DDI-MedLine.d94.s16|12-13|in|O
DDI-MedLine.d94.s16|15-17|the|O
DDI-MedLine.d94.s16|19-25|failing|O
DDI-MedLine.d94.s16|27-31|heart|O
DDI-MedLine.d94.s16|33-35|can|O
DDI-MedLine.d94.s16|37-38|be|O
DDI-MedLine.d94.s16|40-47|mimicked|O
DDI-MedLine.d94.s16|49-50|by|O
DDI-MedLine.d94.s16|52-54|the|O
DDI-MedLine.d94.s16|56-62|effects|O
DDI-MedLine.d94.s16|64-65|of|O
DDI-MedLine.d94.s16|67-72|uptake|O
DDI-MedLine.d94.s16|74-81|blocking|O
DDI-MedLine.d94.s16|83-88|agents|O
DDI-MedLine.d94.s16|89-89|,|O
DDI-MedLine.d94.s16|91-94|such|O
DDI-MedLine.d94.s16|96-97|as|O
DDI-MedLine.d94.s16|99-105|cocaine|drug
DDI-MedLine.d94.s16|107-109|and|O
DDI-MedLine.d94.s16|111-121|desipramine|drug
DDI-MedLine.d94.s16|122-122|,|O
DDI-MedLine.d94.s16|124-125|in|O
DDI-MedLine.d94.s16|127-129|the|O
DDI-MedLine.d94.s16|131-140|nonfailing|O
DDI-MedLine.d94.s16|142-146|heart|O
DDI-MedLine.d94.s16|148-151|only|O
DDI-MedLine.d94.s16|152-152|.|O
DDI-MedLine.d94.s17|0-10|Compromised|O
DDI-MedLine.d94.s17|12-25|norepinephrine|drug
DDI-MedLine.d94.s17|27-34|uptake-1|O
DDI-MedLine.d94.s17|36-37|in|O
DDI-MedLine.d94.s17|39-48|functional|O
DDI-MedLine.d94.s17|50-54|class|O
DDI-MedLine.d94.s17|56-57|IV|O
DDI-MedLine.d94.s17|59-61|can|O
DDI-MedLine.d94.s17|62-64|not|O
DDI-MedLine.d94.s17|66-67|be|O
DDI-MedLine.d94.s17|69-75|further|O
DDI-MedLine.d94.s17|77-85|increased|O
DDI-MedLine.d94.s17|87-88|by|O
DDI-MedLine.d94.s17|90-96|cocaine|drug
DDI-MedLine.d94.s17|98-100|and|O
DDI-MedLine.d94.s17|102-112|desipramine|drug
DDI-MedLine.d94.s17|113-113|.|O
DDI-MedLine.d94.s18|0-2|The|O
DDI-MedLine.d94.s18|4-19|pathophysiologic|O
DDI-MedLine.d94.s18|21-32|consequences|O
DDI-MedLine.d94.s18|34-38|could|O
DDI-MedLine.d94.s18|40-41|be|O
DDI-MedLine.d94.s18|43-44|an|O
DDI-MedLine.d94.s18|46-54|increased|O
DDI-MedLine.d94.s18|56-63|synaptic|O
DDI-MedLine.d94.s18|65-77|concentration|O
DDI-MedLine.d94.s18|79-80|of|O
DDI-MedLine.d94.s18|82-95|norepinephrine|drug
DDI-MedLine.d94.s18|97-108|predisposing|O
DDI-MedLine.d94.s18|110-111|to|O
DDI-MedLine.d94.s18|113-120|adenylyl|O
DDI-MedLine.d94.s18|122-128|cyclase|O
DDI-MedLine.d94.s18|130-144|desensitization|O
DDI-MedLine.d94.s18|145-145|.|O
DDI-DrugBank.d327.s0|0-4|There|O
DDI-DrugBank.d327.s0|6-9|have|O
DDI-DrugBank.d327.s0|11-14|been|O
DDI-DrugBank.d327.s0|16-23|isolated|O
DDI-DrugBank.d327.s0|25-31|reports|O
DDI-DrugBank.d327.s0|33-34|of|O
DDI-DrugBank.d327.s0|36-43|patients|O
DDI-DrugBank.d327.s0|45-56|experiencing|O
DDI-DrugBank.d327.s0|58-66|increases|O
DDI-DrugBank.d327.s0|68-69|in|O
DDI-DrugBank.d327.s0|71-75|their|O
DDI-DrugBank.d327.s0|77-87|prothrombin|O
DDI-DrugBank.d327.s0|89-93|times|O
DDI-DrugBank.d327.s0|95-98|when|O
DDI-DrugBank.d327.s0|100-109|etidronate|drug
DDI-DrugBank.d327.s0|111-113|was|O
DDI-DrugBank.d327.s0|115-119|added|O
DDI-DrugBank.d327.s0|121-122|to|O
DDI-DrugBank.d327.s0|124-131|warfarin|drug
DDI-DrugBank.d327.s0|133-139|therapy|O
DDI-DrugBank.d327.s0|140-140|.|O
DDI-DrugBank.d327.s1|0-2|The|O
DDI-DrugBank.d327.s1|4-11|majority|O
DDI-DrugBank.d327.s1|13-14|of|O
DDI-DrugBank.d327.s1|16-20|these|O
DDI-DrugBank.d327.s1|22-28|reports|O
DDI-DrugBank.d327.s1|30-38|concerned|O
DDI-DrugBank.d327.s1|40-47|variable|O
DDI-DrugBank.d327.s1|49-58|elevations|O
DDI-DrugBank.d327.s1|60-61|in|O
DDI-DrugBank.d327.s1|63-73|prothrombin|O
DDI-DrugBank.d327.s1|75-79|times|O
DDI-DrugBank.d327.s1|81-87|without|O
DDI-DrugBank.d327.s1|89-98|clinically|O
DDI-DrugBank.d327.s1|100-110|significant|O
DDI-DrugBank.d327.s1|112-119|sequelae|O
DDI-DrugBank.d327.s1|120-120|.|O
DDI-DrugBank.d327.s2|0-7|Although|O
DDI-DrugBank.d327.s2|9-11|the|O
DDI-DrugBank.d327.s2|13-21|relevance|O
DDI-DrugBank.d327.s2|23-24|of|O
DDI-DrugBank.d327.s2|26-30|these|O
DDI-DrugBank.d327.s2|32-38|reports|O
DDI-DrugBank.d327.s2|40-42|and|O
DDI-DrugBank.d327.s2|44-46|any|O
DDI-DrugBank.d327.s2|48-56|mechanism|O
DDI-DrugBank.d327.s2|58-59|of|O
DDI-DrugBank.d327.s2|61-71|coagulation|O
DDI-DrugBank.d327.s2|73-83|alterations|O
DDI-DrugBank.d327.s2|85-86|is|O
DDI-DrugBank.d327.s2|88-94|unclear|O
DDI-DrugBank.d327.s2|95-95|,|O
DDI-DrugBank.d327.s2|97-104|patients|O
DDI-DrugBank.d327.s2|106-107|on|O
DDI-DrugBank.d327.s2|109-116|warfarin|drug
DDI-DrugBank.d327.s2|118-123|should|O
DDI-DrugBank.d327.s2|125-128|have|O
DDI-DrugBank.d327.s2|130-134|their|O
DDI-DrugBank.d327.s2|136-146|prothrombin|O
DDI-DrugBank.d327.s2|148-151|time|O
DDI-DrugBank.d327.s2|153-161|monitored|O
DDI-DrugBank.d327.s2|162-162|.|O
DDI-DrugBank.d568.s0|0-2|CNS|O
DDI-DrugBank.d568.s0|4-8|Drugs|O
DDI-DrugBank.d568.s0|10-10|-|O
DDI-DrugBank.d568.s0|12-16|Given|O
DDI-DrugBank.d568.s0|18-20|the|O
DDI-DrugBank.d568.s0|22-28|primary|O
DDI-DrugBank.d568.s0|30-32|CNS|O
DDI-DrugBank.d568.s0|34-40|effects|O
DDI-DrugBank.d568.s0|42-43|of|O
DDI-DrugBank.d568.s0|45-56|escitalopram|drug
DDI-DrugBank.d568.s0|57-57|,|O
DDI-DrugBank.d568.s0|59-65|caution|O
DDI-DrugBank.d568.s0|67-72|should|O
DDI-DrugBank.d568.s0|74-75|be|O
DDI-DrugBank.d568.s0|77-80|used|O
DDI-DrugBank.d568.s0|82-85|when|O
DDI-DrugBank.d568.s0|87-88|it|O
DDI-DrugBank.d568.s0|90-91|is|O
DDI-DrugBank.d568.s0|93-97|taken|O
DDI-DrugBank.d568.s0|99-100|in|O
DDI-DrugBank.d568.s0|102-112|combination|O
DDI-DrugBank.d568.s0|114-117|with|O
DDI-DrugBank.d568.s0|119-123|other|O
DDI-DrugBank.d568.s0|125-133|centrally|O
DDI-DrugBank.d568.s0|135-140|acting|O
DDI-DrugBank.d568.s0|142-146|drugs|O
DDI-DrugBank.d568.s0|147-147|.|O
DDI-DrugBank.d568.s1|0-6|Alcohol|drug
DDI-DrugBank.d568.s1|8-8|-|O
DDI-DrugBank.d568.s1|10-17|Although|O
DDI-DrugBank.d568.s1|19-25|LEXAPRO|brand
DDI-DrugBank.d568.s1|27-29|did|O
DDI-DrugBank.d568.s1|31-33|not|O
DDI-DrugBank.d568.s1|35-44|potentiate|O
DDI-DrugBank.d568.s1|46-48|the|O
DDI-DrugBank.d568.s1|50-58|cognitive|O
DDI-DrugBank.d568.s1|60-62|and|O
DDI-DrugBank.d568.s1|64-68|motor|O
DDI-DrugBank.d568.s1|70-76|effects|O
DDI-DrugBank.d568.s1|78-79|of|O
DDI-DrugBank.d568.s1|81-87|alcohol|drug
DDI-DrugBank.d568.s1|89-90|in|O
DDI-DrugBank.d568.s1|92-92|a|O
DDI-DrugBank.d568.s1|94-101|clinical|O
DDI-DrugBank.d568.s1|103-107|trial|O
DDI-DrugBank.d568.s1|108-108|,|O
DDI-DrugBank.d568.s1|110-111|as|O
DDI-DrugBank.d568.s1|113-116|with|O
DDI-DrugBank.d568.s1|118-122|other|O
DDI-DrugBank.d568.s1|124-147|psychotropic medications|group
DDI-DrugBank.d568.s1|148-148|,|O
DDI-DrugBank.d568.s1|150-152|the|O
DDI-DrugBank.d568.s1|154-156|use|O
DDI-DrugBank.d568.s1|158-159|of|O
DDI-DrugBank.d568.s1|161-167|alcohol|drug
DDI-DrugBank.d568.s1|169-170|by|O
DDI-DrugBank.d568.s1|172-179|patients|O
DDI-DrugBank.d568.s1|181-186|taking|O
DDI-DrugBank.d568.s1|188-194|LEXAPRO|brand
DDI-DrugBank.d568.s1|196-197|is|O
DDI-DrugBank.d568.s1|199-201|not|O
DDI-DrugBank.d568.s1|203-213|recommended|O
DDI-DrugBank.d568.s1|214-214|.|O
DDI-DrugBank.d568.s2|0-27|Monoamine Oxidase Inhibitors|group
DDI-DrugBank.d568.s2|29-29|(|O
DDI-DrugBank.d568.s2|30-34|MAOIs|group
DDI-DrugBank.d568.s2|35-35|)|O
DDI-DrugBank.d568.s3|0-4|Drugs|O
DDI-DrugBank.d568.s3|6-9|That|O
DDI-DrugBank.d568.s3|11-19|Interfere|O
DDI-DrugBank.d568.s3|21-24|With|O
DDI-DrugBank.d568.s3|26-35|Hemostasis|O
DDI-DrugBank.d568.s3|37-37|(|O
DDI-DrugBank.d568.s3|38-43|NSAIDs|group
DDI-DrugBank.d568.s3|44-44|,|O
DDI-DrugBank.d568.s3|46-52|Aspirin|brand
DDI-DrugBank.d568.s3|53-53|,|O
DDI-DrugBank.d568.s3|55-62|Warfarin|drug
DDI-DrugBank.d568.s3|63-63|,|O
DDI-DrugBank.d568.s3|65-67|etc|O
DDI-DrugBank.d568.s3|68-68|.|O
DDI-DrugBank.d568.s3|69-69|)|O
DDI-DrugBank.d568.s4|0-8|Serotonin|O
DDI-DrugBank.d568.s4|10-16|release|O
DDI-DrugBank.d568.s4|18-19|by|O
DDI-DrugBank.d568.s4|21-29|platelets|O
DDI-DrugBank.d568.s4|31-35|plays|O
DDI-DrugBank.d568.s4|37-38|an|O
DDI-DrugBank.d568.s4|40-48|important|O
DDI-DrugBank.d568.s4|50-53|role|O
DDI-DrugBank.d568.s4|55-56|in|O
DDI-DrugBank.d568.s4|58-67|hemostasis|O
DDI-DrugBank.d568.s4|68-68|.|O
DDI-DrugBank.d568.s5|0-14|Epidemiological|O
DDI-DrugBank.d568.s5|16-22|studies|O
DDI-DrugBank.d568.s5|24-25|of|O
DDI-DrugBank.d568.s5|27-29|the|O
DDI-DrugBank.d568.s5|31-42|case-control|O
DDI-DrugBank.d568.s5|44-46|and|O
DDI-DrugBank.d568.s5|48-53|cohort|O
DDI-DrugBank.d568.s5|55-60|design|O
DDI-DrugBank.d568.s5|62-65|that|O
DDI-DrugBank.d568.s5|67-70|have|O
DDI-DrugBank.d568.s5|72-83|demonstrated|O
DDI-DrugBank.d568.s5|85-86|an|O
DDI-DrugBank.d568.s5|88-98|association|O
DDI-DrugBank.d568.s5|100-106|between|O
DDI-DrugBank.d568.s5|108-110|use|O
DDI-DrugBank.d568.s5|112-113|of|O
DDI-DrugBank.d568.s5|115-132|psychotropic drugs|group
DDI-DrugBank.d568.s5|134-137|that|O
DDI-DrugBank.d568.s5|139-147|interfere|O
DDI-DrugBank.d568.s5|149-152|with|O
DDI-DrugBank.d568.s5|154-162|serotonin|O
DDI-DrugBank.d568.s5|164-171|reuptake|O
DDI-DrugBank.d568.s5|173-175|and|O
DDI-DrugBank.d568.s5|177-179|the|O
DDI-DrugBank.d568.s5|181-190|occurrence|O
DDI-DrugBank.d568.s5|192-193|of|O
DDI-DrugBank.d568.s5|195-199|upper|O
DDI-DrugBank.d568.s5|201-216|gastrointestinal|O
DDI-DrugBank.d568.s5|218-225|bleeding|O
DDI-DrugBank.d568.s5|227-230|have|O
DDI-DrugBank.d568.s5|232-235|also|O
DDI-DrugBank.d568.s5|237-241|shown|O
DDI-DrugBank.d568.s5|243-246|that|O
DDI-DrugBank.d568.s5|248-257|concurrent|O
DDI-DrugBank.d568.s5|259-261|use|O
DDI-DrugBank.d568.s5|263-264|of|O
DDI-DrugBank.d568.s5|266-267|an|O
DDI-DrugBank.d568.s5|269-273|NSAID|group
DDI-DrugBank.d568.s5|275-276|or|O
DDI-DrugBank.d568.s5|278-284|aspirin|brand
DDI-DrugBank.d568.s5|286-296|potentiated|O
DDI-DrugBank.d568.s5|298-300|the|O
DDI-DrugBank.d568.s5|302-305|risk|O
DDI-DrugBank.d568.s5|307-308|of|O
DDI-DrugBank.d568.s5|310-317|bleeding|O
DDI-DrugBank.d568.s5|318-318|.|O
DDI-DrugBank.d568.s6|0-3|Thus|O
DDI-DrugBank.d568.s6|4-4|,|O
DDI-DrugBank.d568.s6|6-13|patients|O
DDI-DrugBank.d568.s6|15-20|should|O
DDI-DrugBank.d568.s6|22-23|be|O
DDI-DrugBank.d568.s6|25-33|cautioned|O
DDI-DrugBank.d568.s6|35-39|about|O
DDI-DrugBank.d568.s6|41-43|the|O
DDI-DrugBank.d568.s6|45-47|use|O
DDI-DrugBank.d568.s6|49-50|of|O
DDI-DrugBank.d568.s6|52-55|such|O
DDI-DrugBank.d568.s6|57-61|drugs|O
DDI-DrugBank.d568.s6|63-74|concurrently|O
DDI-DrugBank.d568.s6|76-79|with|O
DDI-DrugBank.d568.s6|81-87|LEXAPRO|brand
DDI-DrugBank.d568.s6|88-88|.|O
DDI-DrugBank.d568.s7|0-9|Cimetidine|drug
DDI-DrugBank.d568.s7|11-11|-|O
DDI-DrugBank.d568.s7|13-14|In|O
DDI-DrugBank.d568.s7|16-23|subjects|O
DDI-DrugBank.d568.s7|25-27|who|O
DDI-DrugBank.d568.s7|29-31|had|O
DDI-DrugBank.d568.s7|33-40|received|O
DDI-DrugBank.d568.s7|42-43|21|O
DDI-DrugBank.d568.s7|45-48|days|O
DDI-DrugBank.d568.s7|50-51|of|O
DDI-DrugBank.d568.s7|53-54|40|O
DDI-DrugBank.d568.s7|56-61|mg/day|O
DDI-DrugBank.d568.s7|63-69|racemic|O
DDI-DrugBank.d568.s7|71-80|citalopram|drug
DDI-DrugBank.d568.s7|81-81|,|O
DDI-DrugBank.d568.s7|83-90|combined|O
DDI-DrugBank.d568.s7|92-105|administration|O
DDI-DrugBank.d568.s7|107-108|of|O
DDI-DrugBank.d568.s7|110-112|400|O
DDI-DrugBank.d568.s7|114-119|mg/day|O
DDI-DrugBank.d568.s7|121-130|cimetidine|drug
DDI-DrugBank.d568.s7|132-134|for|O
DDI-DrugBank.d568.s7|136-136|8|O
DDI-DrugBank.d568.s7|138-141|days|O
DDI-DrugBank.d568.s7|143-150|resulted|O
DDI-DrugBank.d568.s7|152-153|in|O
DDI-DrugBank.d568.s7|155-156|an|O
DDI-DrugBank.d568.s7|158-165|increase|O
DDI-DrugBank.d568.s7|167-168|in|O
DDI-DrugBank.d568.s7|170-179|citalopram|drug
DDI-DrugBank.d568.s7|181-183|AUC|O
DDI-DrugBank.d568.s7|185-187|and|O
DDI-DrugBank.d568.s7|189-192|Cmax|O
DDI-DrugBank.d568.s7|194-195|of|O
DDI-DrugBank.d568.s7|197-198|43|O
DDI-DrugBank.d568.s7|199-199|%|O
DDI-DrugBank.d568.s7|201-203|and|O
DDI-DrugBank.d568.s7|205-206|39|O
DDI-DrugBank.d568.s7|207-207|%|O
DDI-DrugBank.d568.s7|208-208|,|O
DDI-DrugBank.d568.s7|210-221|respectively|O
DDI-DrugBank.d568.s7|222-222|.|O
DDI-DrugBank.d568.s8|0-2|The|O
DDI-DrugBank.d568.s8|4-11|clinical|O
DDI-DrugBank.d568.s8|13-24|significance|O
DDI-DrugBank.d568.s8|26-27|of|O
DDI-DrugBank.d568.s8|29-33|these|O
DDI-DrugBank.d568.s8|35-42|findings|O
DDI-DrugBank.d568.s8|44-45|is|O
DDI-DrugBank.d568.s8|47-53|unknown|O
DDI-DrugBank.d568.s8|54-54|.|O
DDI-DrugBank.d568.s9|0-6|Digoxin|drug
DDI-DrugBank.d568.s9|8-8|-|O
DDI-DrugBank.d568.s9|10-11|In|O
DDI-DrugBank.d568.s9|13-20|subjects|O
DDI-DrugBank.d568.s9|22-24|who|O
DDI-DrugBank.d568.s9|26-28|had|O
DDI-DrugBank.d568.s9|30-37|received|O
DDI-DrugBank.d568.s9|39-40|21|O
DDI-DrugBank.d568.s9|42-45|days|O
DDI-DrugBank.d568.s9|47-48|of|O
DDI-DrugBank.d568.s9|50-51|40|O
DDI-DrugBank.d568.s9|53-58|mg/day|O
DDI-DrugBank.d568.s9|60-66|racemic|O
DDI-DrugBank.d568.s9|68-77|citalopram|drug
DDI-DrugBank.d568.s9|78-78|,|O
DDI-DrugBank.d568.s9|80-87|combined|O
DDI-DrugBank.d568.s9|89-102|administration|O
DDI-DrugBank.d568.s9|104-105|of|O
DDI-DrugBank.d568.s9|107-116|citalopram|drug
DDI-DrugBank.d568.s9|118-120|and|O
DDI-DrugBank.d568.s9|122-128|digoxin|drug
DDI-DrugBank.d568.s9|130-130|(|O
DDI-DrugBank.d568.s9|131-136|single|O
DDI-DrugBank.d568.s9|138-141|dose|O
DDI-DrugBank.d568.s9|143-144|of|O
DDI-DrugBank.d568.s9|146-146|1|O
DDI-DrugBank.d568.s9|148-149|mg|O
DDI-DrugBank.d568.s9|150-150|)|O
DDI-DrugBank.d568.s9|152-154|did|O
DDI-DrugBank.d568.s9|156-158|not|O
DDI-DrugBank.d568.s9|160-172|significantly|O
DDI-DrugBank.d568.s9|174-179|affect|O
DDI-DrugBank.d568.s9|181-183|the|O
DDI-DrugBank.d568.s9|185-200|pharmacokinetics|O
DDI-DrugBank.d568.s9|202-203|of|O
DDI-DrugBank.d568.s9|205-210|either|O
DDI-DrugBank.d568.s9|212-221|citalopram|drug
DDI-DrugBank.d568.s9|223-224|or|O
DDI-DrugBank.d568.s9|226-232|digoxin|drug
DDI-DrugBank.d568.s9|233-233|.|O
DDI-DrugBank.d568.s10|0-6|Lithium|drug
DDI-DrugBank.d568.s10|8-8|-|O
DDI-DrugBank.d568.s10|10-25|Coadministration|O
DDI-DrugBank.d568.s10|27-28|of|O
DDI-DrugBank.d568.s10|30-36|racemic|O
DDI-DrugBank.d568.s10|38-47|citalopram|drug
DDI-DrugBank.d568.s10|49-49|(|O
DDI-DrugBank.d568.s10|50-51|40|O
DDI-DrugBank.d568.s10|53-58|mg/day|O
DDI-DrugBank.d568.s10|60-62|for|O
DDI-DrugBank.d568.s10|64-65|10|O
DDI-DrugBank.d568.s10|67-70|days|O
DDI-DrugBank.d568.s10|71-71|)|O
DDI-DrugBank.d568.s10|73-75|and|O
DDI-DrugBank.d568.s10|77-83|lithium|drug
DDI-DrugBank.d568.s10|85-85|(|O
DDI-DrugBank.d568.s10|86-87|30|O
DDI-DrugBank.d568.s10|89-96|mmol/day|O
DDI-DrugBank.d568.s10|98-100|for|O
DDI-DrugBank.d568.s10|102-102|5|O
DDI-DrugBank.d568.s10|104-107|days|O
DDI-DrugBank.d568.s10|108-108|)|O
DDI-DrugBank.d568.s10|110-112|had|O
DDI-DrugBank.d568.s10|114-115|no|O
DDI-DrugBank.d568.s10|117-127|significant|O
DDI-DrugBank.d568.s10|129-134|effect|O
DDI-DrugBank.d568.s10|136-137|on|O
DDI-DrugBank.d568.s10|139-141|the|O
DDI-DrugBank.d568.s10|143-158|pharmacokinetics|O
DDI-DrugBank.d568.s10|160-161|of|O
DDI-DrugBank.d568.s10|163-172|citalopram|drug
DDI-DrugBank.d568.s10|174-175|or|O
DDI-DrugBank.d568.s10|177-183|lithium|drug
DDI-DrugBank.d568.s10|184-184|.|O
DDI-DrugBank.d568.s11|0-11|Nevertheless|O
DDI-DrugBank.d568.s11|12-12|,|O
DDI-DrugBank.d568.s11|14-19|plasma|O
DDI-DrugBank.d568.s11|21-27|lithium|drug
DDI-DrugBank.d568.s11|29-34|levels|O
DDI-DrugBank.d568.s11|36-41|should|O
DDI-DrugBank.d568.s11|43-44|be|O
DDI-DrugBank.d568.s11|46-54|monitored|O
DDI-DrugBank.d568.s11|56-59|with|O
DDI-DrugBank.d568.s11|61-71|appropriate|O
DDI-DrugBank.d568.s11|73-82|adjustment|O
DDI-DrugBank.d568.s11|84-85|to|O
DDI-DrugBank.d568.s11|87-89|the|O
DDI-DrugBank.d568.s11|91-97|lithium|drug
DDI-DrugBank.d568.s11|99-102|dose|O
DDI-DrugBank.d568.s11|104-105|in|O
DDI-DrugBank.d568.s11|107-116|accordance|O
DDI-DrugBank.d568.s11|118-121|with|O
DDI-DrugBank.d568.s11|123-130|standard|O
DDI-DrugBank.d568.s11|132-139|clinical|O
DDI-DrugBank.d568.s11|141-148|practice|O
DDI-DrugBank.d568.s11|149-149|.|O
DDI-DrugBank.d568.s12|0-6|Because|O
DDI-DrugBank.d568.s12|8-14|lithium|drug
DDI-DrugBank.d568.s12|16-18|may|O
DDI-DrugBank.d568.s12|20-26|enhance|O
DDI-DrugBank.d568.s12|28-30|the|O
DDI-DrugBank.d568.s12|32-43|serotonergic|O
DDI-DrugBank.d568.s12|45-51|effects|O
DDI-DrugBank.d568.s12|53-54|of|O
DDI-DrugBank.d568.s12|56-67|escitalopram|drug
DDI-DrugBank.d568.s12|68-68|,|O
DDI-DrugBank.d568.s12|70-76|caution|O
DDI-DrugBank.d568.s12|78-83|should|O
DDI-DrugBank.d568.s12|85-86|be|O
DDI-DrugBank.d568.s12|88-96|exercised|O
DDI-DrugBank.d568.s12|98-101|when|O
DDI-DrugBank.d568.s12|103-109|LEXAPRO|brand
DDI-DrugBank.d568.s12|111-113|and|O
DDI-DrugBank.d568.s12|115-121|lithium|drug
DDI-DrugBank.d568.s12|123-125|are|O
DDI-DrugBank.d568.s12|127-140|coadministered|O
DDI-DrugBank.d568.s12|141-141|.|O
DDI-DrugBank.d568.s13|0-7|Pimozide|drug
DDI-DrugBank.d568.s13|9-11|and|O
DDI-DrugBank.d568.s13|13-18|Celexa|brand
DDI-DrugBank.d568.s13|20-20|-|O
DDI-DrugBank.d568.s13|22-23|In|O
DDI-DrugBank.d568.s13|25-25|a|O
DDI-DrugBank.d568.s13|27-36|controlled|O
DDI-DrugBank.d568.s13|38-42|study|O
DDI-DrugBank.d568.s13|43-43|,|O
DDI-DrugBank.d568.s13|45-45|a|O
DDI-DrugBank.d568.s13|47-52|single|O
DDI-DrugBank.d568.s13|54-57|dose|O
DDI-DrugBank.d568.s13|59-60|of|O
DDI-DrugBank.d568.s13|62-69|pimozide|drug
DDI-DrugBank.d568.s13|71-71|2|O
DDI-DrugBank.d568.s13|73-74|mg|O
DDI-DrugBank.d568.s13|76-90|co-administered|O
DDI-DrugBank.d568.s13|92-95|with|O
DDI-DrugBank.d568.s13|97-103|racemic|O
DDI-DrugBank.d568.s13|105-114|citalopram|drug
DDI-DrugBank.d568.s13|116-117|40|O
DDI-DrugBank.d568.s13|119-120|mg|O
DDI-DrugBank.d568.s13|122-126|given|O
DDI-DrugBank.d568.s13|128-131|once|O
DDI-DrugBank.d568.s13|133-137|daily|O
DDI-DrugBank.d568.s13|139-141|for|O
DDI-DrugBank.d568.s13|143-144|11|O
DDI-DrugBank.d568.s13|146-149|days|O
DDI-DrugBank.d568.s13|151-153|was|O
DDI-DrugBank.d568.s13|155-164|associated|O
DDI-DrugBank.d568.s13|166-169|with|O
DDI-DrugBank.d568.s13|171-171|a|O
DDI-DrugBank.d568.s13|173-176|mean|O
DDI-DrugBank.d568.s13|178-185|increase|O
DDI-DrugBank.d568.s13|187-188|in|O
DDI-DrugBank.d568.s13|190-192|QTc|O
DDI-DrugBank.d568.s13|194-199|values|O
DDI-DrugBank.d568.s13|201-202|of|O
DDI-DrugBank.d568.s13|204-216|approximately|O
DDI-DrugBank.d568.s13|218-219|10|O
DDI-DrugBank.d568.s13|221-224|msec|O
DDI-DrugBank.d568.s13|226-233|compared|O
DDI-DrugBank.d568.s13|235-236|to|O
DDI-DrugBank.d568.s13|238-245|pimozide|drug
DDI-DrugBank.d568.s13|247-251|given|O
DDI-DrugBank.d568.s13|253-257|alone|O
DDI-DrugBank.d568.s13|258-258|.|O
DDI-DrugBank.d568.s14|0-6|Racemic|O
DDI-DrugBank.d568.s14|8-17|citalopram|drug
DDI-DrugBank.d568.s14|19-21|did|O
DDI-DrugBank.d568.s14|23-25|not|O
DDI-DrugBank.d568.s14|27-31|alter|O
DDI-DrugBank.d568.s14|33-35|the|O
DDI-DrugBank.d568.s14|37-40|mean|O
DDI-DrugBank.d568.s14|42-44|AUC|O
DDI-DrugBank.d568.s14|46-47|or|O
DDI-DrugBank.d568.s14|49-52|Cmax|O
DDI-DrugBank.d568.s14|54-55|of|O
DDI-DrugBank.d568.s14|57-64|pimozide|drug
DDI-DrugBank.d568.s14|65-65|.|O
DDI-DrugBank.d568.s15|0-2|The|O
DDI-DrugBank.d568.s15|4-12|mechanism|O
DDI-DrugBank.d568.s15|14-15|of|O
DDI-DrugBank.d568.s15|17-20|this|O
DDI-DrugBank.d568.s15|22-36|pharmacodynamic|O
DDI-DrugBank.d568.s15|38-48|interaction|O
DDI-DrugBank.d568.s15|50-51|is|O
DDI-DrugBank.d568.s15|53-55|not|O
DDI-DrugBank.d568.s15|57-61|known|O
DDI-DrugBank.d568.s15|62-62|.|O
DDI-DrugBank.d568.s16|0-10|Sumatriptan|drug
DDI-DrugBank.d568.s16|12-12|-|O
DDI-DrugBank.d568.s16|14-18|There|O
DDI-DrugBank.d568.s16|20-23|have|O
DDI-DrugBank.d568.s16|25-28|been|O
DDI-DrugBank.d568.s16|30-33|rare|O
DDI-DrugBank.d568.s16|35-47|postmarketing|O
DDI-DrugBank.d568.s16|49-55|reports|O
DDI-DrugBank.d568.s16|57-66|describing|O
DDI-DrugBank.d568.s16|68-75|patients|O
DDI-DrugBank.d568.s16|77-80|with|O
DDI-DrugBank.d568.s16|82-89|weakness|O
DDI-DrugBank.d568.s16|90-90|,|O
DDI-DrugBank.d568.s16|92-104|hyperreflexia|O
DDI-DrugBank.d568.s16|105-105|,|O
DDI-DrugBank.d568.s16|107-109|and|O
DDI-DrugBank.d568.s16|111-124|incoordination|O
DDI-DrugBank.d568.s16|126-134|following|O
DDI-DrugBank.d568.s16|136-138|the|O
DDI-DrugBank.d568.s16|140-142|use|O
DDI-DrugBank.d568.s16|144-145|of|O
DDI-DrugBank.d568.s16|147-147|a|O
DDI-DrugBank.d568.s16|149-186|selective serotonin reuptake inhibitor|group
DDI-DrugBank.d568.s16|188-188|(|O
DDI-DrugBank.d568.s16|189-192|SSRI|group
DDI-DrugBank.d568.s16|193-193|)|O
DDI-DrugBank.d568.s16|195-197|and|O
DDI-DrugBank.d568.s16|199-209|sumatriptan|drug
DDI-DrugBank.d568.s16|210-210|.|O
DDI-DrugBank.d568.s17|0-1|If|O
DDI-DrugBank.d568.s17|3-13|concomitant|O
DDI-DrugBank.d568.s17|15-23|treatment|O
DDI-DrugBank.d568.s17|25-28|with|O
DDI-DrugBank.d568.s17|30-40|sumatriptan|drug
DDI-DrugBank.d568.s17|42-44|and|O
DDI-DrugBank.d568.s17|46-47|an|O
DDI-DrugBank.d568.s17|49-52|SSRI|group
DDI-DrugBank.d568.s17|54-54|(|O
DDI-DrugBank.d568.s17|55-58|e.g.|O
DDI-DrugBank.d568.s17|59-59|,|O
DDI-DrugBank.d568.s17|61-70|fluoxetine|drug
DDI-DrugBank.d568.s17|71-71|,|O
DDI-DrugBank.d568.s17|73-83|fluvoxamine|drug
DDI-DrugBank.d568.s17|84-84|,|O
DDI-DrugBank.d568.s17|86-95|paroxetine|drug
DDI-DrugBank.d568.s17|96-96|,|O
DDI-DrugBank.d568.s17|98-107|sertraline|drug
DDI-DrugBank.d568.s17|108-108|,|O
DDI-DrugBank.d568.s17|110-119|citalopram|drug
DDI-DrugBank.d568.s17|120-120|,|O
DDI-DrugBank.d568.s17|122-133|escitalopram|drug
DDI-DrugBank.d568.s17|134-134|)|O
DDI-DrugBank.d568.s17|136-137|is|O
DDI-DrugBank.d568.s17|139-148|clinically|O
DDI-DrugBank.d568.s17|150-158|warranted|O
DDI-DrugBank.d568.s17|159-159|,|O
DDI-DrugBank.d568.s17|161-171|appropriate|O
DDI-DrugBank.d568.s17|173-183|observation|O
DDI-DrugBank.d568.s17|185-186|of|O
DDI-DrugBank.d568.s17|188-190|the|O
DDI-DrugBank.d568.s17|192-198|patient|O
DDI-DrugBank.d568.s17|200-201|is|O
DDI-DrugBank.d568.s17|203-209|advised|O
DDI-DrugBank.d568.s17|210-210|.|O
DDI-DrugBank.d568.s18|0-11|Theophylline|drug
DDI-DrugBank.d568.s18|13-13|-|O
DDI-DrugBank.d568.s18|15-22|Combined|O
DDI-DrugBank.d568.s18|24-37|administration|O
DDI-DrugBank.d568.s18|39-40|of|O
DDI-DrugBank.d568.s18|42-48|racemic|O
DDI-DrugBank.d568.s18|50-59|citalopram|drug
DDI-DrugBank.d568.s18|61-61|(|O
DDI-DrugBank.d568.s18|62-63|40|O
DDI-DrugBank.d568.s18|65-70|mg/day|O
DDI-DrugBank.d568.s18|72-74|for|O
DDI-DrugBank.d568.s18|76-77|21|O
DDI-DrugBank.d568.s18|79-82|days|O
DDI-DrugBank.d568.s18|83-83|)|O
DDI-DrugBank.d568.s18|85-87|and|O
DDI-DrugBank.d568.s18|89-91|the|O
DDI-DrugBank.d568.s18|93-98|CYP1A2|O
DDI-DrugBank.d568.s18|100-108|substrate|O
DDI-DrugBank.d568.s18|110-121|theophylline|drug
DDI-DrugBank.d568.s18|123-123|(|O
DDI-DrugBank.d568.s18|124-129|single|O
DDI-DrugBank.d568.s18|131-134|dose|O
DDI-DrugBank.d568.s18|136-137|of|O
DDI-DrugBank.d568.s18|139-141|300|O
DDI-DrugBank.d568.s18|143-144|mg|O
DDI-DrugBank.d568.s18|145-145|)|O
DDI-DrugBank.d568.s18|147-149|did|O
DDI-DrugBank.d568.s18|151-153|not|O
DDI-DrugBank.d568.s18|155-160|affect|O
DDI-DrugBank.d568.s18|162-164|the|O
DDI-DrugBank.d568.s18|166-181|pharmacokinetics|O
DDI-DrugBank.d568.s18|183-184|of|O
DDI-DrugBank.d568.s18|186-197|theophylline|drug
DDI-DrugBank.d568.s18|198-198|.|O
DDI-DrugBank.d568.s19|0-2|The|O
DDI-DrugBank.d568.s19|4-9|effect|O
DDI-DrugBank.d568.s19|11-12|of|O
DDI-DrugBank.d568.s19|14-25|theophylline|drug
DDI-DrugBank.d568.s19|27-28|on|O
DDI-DrugBank.d568.s19|30-32|the|O
DDI-DrugBank.d568.s19|34-49|pharmacokinetics|O
DDI-DrugBank.d568.s19|51-52|of|O
DDI-DrugBank.d568.s19|54-63|citalopram|drug
DDI-DrugBank.d568.s19|65-67|was|O
DDI-DrugBank.d568.s19|69-71|not|O
DDI-DrugBank.d568.s19|73-81|evaluated|O
DDI-DrugBank.d568.s19|82-82|.|O
DDI-DrugBank.d568.s20|0-7|Warfarin|drug
DDI-DrugBank.d568.s20|9-9|-|O
DDI-DrugBank.d568.s20|11-24|Administration|O
DDI-DrugBank.d568.s20|26-27|of|O
DDI-DrugBank.d568.s20|29-30|40|O
DDI-DrugBank.d568.s20|32-37|mg/day|O
DDI-DrugBank.d568.s20|39-45|racemic|O
DDI-DrugBank.d568.s20|47-56|citalopram|drug
DDI-DrugBank.d568.s20|58-60|for|O
DDI-DrugBank.d568.s20|62-63|21|O
DDI-DrugBank.d568.s20|65-68|days|O
DDI-DrugBank.d568.s20|70-72|did|O
DDI-DrugBank.d568.s20|74-76|not|O
DDI-DrugBank.d568.s20|78-83|affect|O
DDI-DrugBank.d568.s20|85-87|the|O
DDI-DrugBank.d568.s20|89-104|pharmacokinetics|O
DDI-DrugBank.d568.s20|106-107|of|O
DDI-DrugBank.d568.s20|109-116|warfarin|drug
DDI-DrugBank.d568.s20|117-117|,|O
DDI-DrugBank.d568.s20|119-119|a|O
DDI-DrugBank.d568.s20|121-126|CYP3A4|O
DDI-DrugBank.d568.s20|128-136|substrate|O
DDI-DrugBank.d568.s20|137-137|.|O
DDI-DrugBank.d568.s21|0-10|Prothrombin|O
DDI-DrugBank.d568.s21|12-15|time|O
DDI-DrugBank.d568.s21|17-19|was|O
DDI-DrugBank.d568.s21|21-29|increased|O
DDI-DrugBank.d568.s21|31-32|by|O
DDI-DrugBank.d568.s21|34-34|5|O
DDI-DrugBank.d568.s21|35-35|%|O
DDI-DrugBank.d568.s21|36-36|,|O
DDI-DrugBank.d568.s21|38-40|the|O
DDI-DrugBank.d568.s21|42-49|clinical|O
DDI-DrugBank.d568.s21|51-62|significance|O
DDI-DrugBank.d568.s21|64-65|of|O
DDI-DrugBank.d568.s21|67-71|which|O
DDI-DrugBank.d568.s21|73-74|is|O
DDI-DrugBank.d568.s21|76-82|unknown|O
DDI-DrugBank.d568.s21|83-83|.|O
DDI-DrugBank.d568.s22|0-12|Carbamazepine|drug
DDI-DrugBank.d568.s22|14-14|-|O
DDI-DrugBank.d568.s22|16-23|Combined|O
DDI-DrugBank.d568.s22|25-38|administration|O
DDI-DrugBank.d568.s22|40-41|of|O
DDI-DrugBank.d568.s22|43-49|racemic|O
DDI-DrugBank.d568.s22|51-60|citalopram|drug
DDI-DrugBank.d568.s22|62-62|(|O
DDI-DrugBank.d568.s22|63-64|40|O
DDI-DrugBank.d568.s22|66-71|mg/day|O
DDI-DrugBank.d568.s22|73-75|for|O
DDI-DrugBank.d568.s22|77-78|14|O
DDI-DrugBank.d568.s22|80-83|days|O
DDI-DrugBank.d568.s22|84-84|)|O
DDI-DrugBank.d568.s22|86-88|and|O
DDI-DrugBank.d568.s22|90-102|carbamazepine|drug
DDI-DrugBank.d568.s22|104-104|(|O
DDI-DrugBank.d568.s22|105-112|titrated|O
DDI-DrugBank.d568.s22|114-115|to|O
DDI-DrugBank.d568.s22|117-119|400|O
DDI-DrugBank.d568.s22|121-126|mg/day|O
DDI-DrugBank.d568.s22|128-130|for|O
DDI-DrugBank.d568.s22|132-133|35|O
DDI-DrugBank.d568.s22|135-138|days|O
DDI-DrugBank.d568.s22|139-139|)|O
DDI-DrugBank.d568.s22|141-143|did|O
DDI-DrugBank.d568.s22|145-147|not|O
DDI-DrugBank.d568.s22|149-161|significantly|O
DDI-DrugBank.d568.s22|163-168|affect|O
DDI-DrugBank.d568.s22|170-172|the|O
DDI-DrugBank.d568.s22|174-189|pharmacokinetics|O
DDI-DrugBank.d568.s22|191-192|of|O
DDI-DrugBank.d568.s22|194-206|carbamazepine|drug
DDI-DrugBank.d568.s22|207-207|,|O
DDI-DrugBank.d568.s22|209-209|a|O
DDI-DrugBank.d568.s22|211-216|CYP3A4|O
DDI-DrugBank.d568.s22|218-226|substrate|O
DDI-DrugBank.d568.s22|227-227|.|O
DDI-DrugBank.d568.s23|0-7|Although|O
DDI-DrugBank.d568.s23|9-14|trough|O
DDI-DrugBank.d568.s23|16-25|citalopram|drug
DDI-DrugBank.d568.s23|27-32|plasma|O
DDI-DrugBank.d568.s23|34-39|levels|O
DDI-DrugBank.d568.s23|41-44|were|O
DDI-DrugBank.d568.s23|46-55|unaffected|O
DDI-DrugBank.d568.s23|56-56|,|O
DDI-DrugBank.d568.s23|58-62|given|O
DDI-DrugBank.d568.s23|64-66|the|O
DDI-DrugBank.d568.s23|68-82|enzyme-inducing|O
DDI-DrugBank.d568.s23|84-93|properties|O
DDI-DrugBank.d568.s23|95-96|of|O
DDI-DrugBank.d568.s23|98-110|carbamazepine|drug
DDI-DrugBank.d568.s23|111-111|,|O
DDI-DrugBank.d568.s23|113-115|the|O
DDI-DrugBank.d568.s23|117-127|possibility|O
DDI-DrugBank.d568.s23|129-132|that|O
DDI-DrugBank.d568.s23|134-146|carbamazepine|drug
DDI-DrugBank.d568.s23|148-152|might|O
DDI-DrugBank.d568.s23|154-161|increase|O
DDI-DrugBank.d568.s23|163-165|the|O
DDI-DrugBank.d568.s23|167-175|clearance|O
DDI-DrugBank.d568.s23|177-178|of|O
DDI-DrugBank.d568.s23|180-191|escitalopram|drug
DDI-DrugBank.d568.s23|193-198|should|O
DDI-DrugBank.d568.s23|200-201|be|O
DDI-DrugBank.d568.s23|203-212|considered|O
DDI-DrugBank.d568.s23|214-215|if|O
DDI-DrugBank.d568.s23|217-219|the|O
DDI-DrugBank.d568.s23|221-223|two|O
DDI-DrugBank.d568.s23|225-229|drugs|O
DDI-DrugBank.d568.s23|231-233|are|O
DDI-DrugBank.d568.s23|235-248|coadministered|O
DDI-DrugBank.d568.s23|249-249|.|O
DDI-DrugBank.d568.s24|0-8|Triazolam|drug
DDI-DrugBank.d568.s24|10-10|-|O
DDI-DrugBank.d568.s24|12-19|Combined|O
DDI-DrugBank.d568.s24|21-34|administration|O
DDI-DrugBank.d568.s24|36-37|of|O
DDI-DrugBank.d568.s24|39-45|racemic|O
DDI-DrugBank.d568.s24|47-56|citalopram|drug
DDI-DrugBank.d568.s24|58-58|(|O
DDI-DrugBank.d568.s24|59-66|titrated|O
DDI-DrugBank.d568.s24|68-69|to|O
DDI-DrugBank.d568.s24|71-72|40|O
DDI-DrugBank.d568.s24|74-79|mg/day|O
DDI-DrugBank.d568.s24|81-83|for|O
DDI-DrugBank.d568.s24|85-86|28|O
DDI-DrugBank.d568.s24|88-91|days|O
DDI-DrugBank.d568.s24|92-92|)|O
DDI-DrugBank.d568.s24|94-96|and|O
DDI-DrugBank.d568.s24|98-100|the|O
DDI-DrugBank.d568.s24|102-107|CYP3A4|O
DDI-DrugBank.d568.s24|109-117|substrate|O
DDI-DrugBank.d568.s24|119-127|triazolam|drug
DDI-DrugBank.d568.s24|129-129|(|O
DDI-DrugBank.d568.s24|130-135|single|O
DDI-DrugBank.d568.s24|137-140|dose|O
DDI-DrugBank.d568.s24|142-143|of|O
DDI-DrugBank.d568.s24|145-148|0.25|O
DDI-DrugBank.d568.s24|150-151|mg|O
DDI-DrugBank.d568.s24|152-152|)|O
DDI-DrugBank.d568.s24|154-156|did|O
DDI-DrugBank.d568.s24|158-160|not|O
DDI-DrugBank.d568.s24|162-174|significantly|O
DDI-DrugBank.d568.s24|176-181|affect|O
DDI-DrugBank.d568.s24|183-185|the|O
DDI-DrugBank.d568.s24|187-202|pharmacokinetics|O
DDI-DrugBank.d568.s24|204-205|of|O
DDI-DrugBank.d568.s24|207-212|either|O
DDI-DrugBank.d568.s24|214-223|citalopram|drug
DDI-DrugBank.d568.s24|225-226|or|O
DDI-DrugBank.d568.s24|228-236|triazolam|drug
DDI-DrugBank.d568.s24|237-237|.|O
DDI-DrugBank.d568.s25|0-11|Ketoconazole|drug
DDI-DrugBank.d568.s25|13-13|-|O
DDI-DrugBank.d568.s25|15-22|Combined|O
DDI-DrugBank.d568.s25|24-37|administration|O
DDI-DrugBank.d568.s25|39-40|of|O
DDI-DrugBank.d568.s25|42-48|racemic|O
DDI-DrugBank.d568.s25|50-59|citalopram|drug
DDI-DrugBank.d568.s25|61-61|(|O
DDI-DrugBank.d568.s25|62-63|40|O
DDI-DrugBank.d568.s25|65-66|mg|O
DDI-DrugBank.d568.s25|67-67|)|O
DDI-DrugBank.d568.s25|69-71|and|O
DDI-DrugBank.d568.s25|73-84|ketoconazole|drug
DDI-DrugBank.d568.s25|86-86|(|O
DDI-DrugBank.d568.s25|87-89|200|O
DDI-DrugBank.d568.s25|91-92|mg|O
DDI-DrugBank.d568.s25|93-93|)|O
DDI-DrugBank.d568.s25|95-103|decreased|O
DDI-DrugBank.d568.s25|105-107|the|O
DDI-DrugBank.d568.s25|109-112|Cmax|O
DDI-DrugBank.d568.s25|114-116|and|O
DDI-DrugBank.d568.s25|118-120|AUC|O
DDI-DrugBank.d568.s25|122-123|of|O
DDI-DrugBank.d568.s25|125-136|ketoconazole|drug
DDI-DrugBank.d568.s25|138-139|by|O
DDI-DrugBank.d568.s25|141-142|21|O
DDI-DrugBank.d568.s25|143-143|%|O
DDI-DrugBank.d568.s25|145-147|and|O
DDI-DrugBank.d568.s25|149-150|10|O
DDI-DrugBank.d568.s25|151-151|%|O
DDI-DrugBank.d568.s25|152-152|,|O
DDI-DrugBank.d568.s25|154-165|respectively|O
DDI-DrugBank.d568.s25|166-166|,|O
DDI-DrugBank.d568.s25|168-170|and|O
DDI-DrugBank.d568.s25|172-174|did|O
DDI-DrugBank.d568.s25|176-178|not|O
DDI-DrugBank.d568.s25|180-192|significantly|O
DDI-DrugBank.d568.s25|194-199|affect|O
DDI-DrugBank.d568.s25|201-203|the|O
DDI-DrugBank.d568.s25|205-220|pharmacokinetics|O
DDI-DrugBank.d568.s25|222-223|of|O
DDI-DrugBank.d568.s25|225-234|citalopram|drug
DDI-DrugBank.d568.s25|235-235|.|O
DDI-DrugBank.d568.s26|0-8|Ritonavir|drug
DDI-DrugBank.d568.s26|10-10|-|O
DDI-DrugBank.d568.s26|12-19|Combined|O
DDI-DrugBank.d568.s26|21-34|administration|O
DDI-DrugBank.d568.s26|36-37|of|O
DDI-DrugBank.d568.s26|39-39|a|O
DDI-DrugBank.d568.s26|41-46|single|O
DDI-DrugBank.d568.s26|48-51|dose|O
DDI-DrugBank.d568.s26|53-54|of|O
DDI-DrugBank.d568.s26|56-64|ritonavir|drug
DDI-DrugBank.d568.s26|66-66|(|O
DDI-DrugBank.d568.s26|67-69|600|O
DDI-DrugBank.d568.s26|71-72|mg|O
DDI-DrugBank.d568.s26|73-73|)|O
DDI-DrugBank.d568.s26|74-74|,|O
DDI-DrugBank.d568.s26|76-79|both|O
DDI-DrugBank.d568.s26|81-81|a|O
DDI-DrugBank.d568.s26|83-88|CYP3A4|O
DDI-DrugBank.d568.s26|90-98|substrate|O
DDI-DrugBank.d568.s26|100-102|and|O
DDI-DrugBank.d568.s26|104-104|a|O
DDI-DrugBank.d568.s26|106-111|potent|O
DDI-DrugBank.d568.s26|113-121|inhibitor|O
DDI-DrugBank.d568.s26|123-124|of|O
DDI-DrugBank.d568.s26|126-131|CYP3A4|O
DDI-DrugBank.d568.s26|132-132|,|O
DDI-DrugBank.d568.s26|134-136|and|O
DDI-DrugBank.d568.s26|138-149|escitalopram|drug
DDI-DrugBank.d568.s26|151-151|(|O
DDI-DrugBank.d568.s26|152-153|20|O
DDI-DrugBank.d568.s26|155-156|mg|O
DDI-DrugBank.d568.s26|157-157|)|O
DDI-DrugBank.d568.s26|159-161|did|O
DDI-DrugBank.d568.s26|163-165|not|O
DDI-DrugBank.d568.s26|167-172|affect|O
DDI-DrugBank.d568.s26|174-176|the|O
DDI-DrugBank.d568.s26|178-193|pharmacokinetics|O
DDI-DrugBank.d568.s26|195-196|of|O
DDI-DrugBank.d568.s26|198-203|either|O
DDI-DrugBank.d568.s26|205-213|ritonavir|drug
DDI-DrugBank.d568.s26|215-216|or|O
DDI-DrugBank.d568.s26|218-229|escitalopram|drug
DDI-DrugBank.d568.s26|230-230|.|O
DDI-DrugBank.d568.s27|0-5|CYP3A4|O
DDI-DrugBank.d568.s27|7-9|and|O
DDI-DrugBank.d568.s27|11-15|-2C19|O
DDI-DrugBank.d568.s27|17-26|Inhibitors|O
DDI-DrugBank.d568.s27|28-28|-|O
DDI-DrugBank.d568.s27|30-31|In|O
DDI-DrugBank.d568.s27|33-37|vitro|O
DDI-DrugBank.d568.s27|39-45|studies|O
DDI-DrugBank.d568.s27|47-55|indicated|O
DDI-DrugBank.d568.s27|57-60|that|O
DDI-DrugBank.d568.s27|62-67|CYP3A4|O
DDI-DrugBank.d568.s27|69-71|and|O
DDI-DrugBank.d568.s27|73-77|-2C19|O
DDI-DrugBank.d568.s27|79-81|are|O
DDI-DrugBank.d568.s27|83-85|the|O
DDI-DrugBank.d568.s27|87-93|primary|O
DDI-DrugBank.d568.s27|95-101|enzymes|O
DDI-DrugBank.d568.s27|103-110|involved|O
DDI-DrugBank.d568.s27|112-113|in|O
DDI-DrugBank.d568.s27|115-117|the|O
DDI-DrugBank.d568.s27|119-128|metabolism|O
DDI-DrugBank.d568.s27|130-131|of|O
DDI-DrugBank.d568.s27|133-144|escitalopram|drug
DDI-DrugBank.d568.s27|145-145|.|O
DDI-DrugBank.d568.s28|0-6|However|O
DDI-DrugBank.d568.s28|7-7|,|O
DDI-DrugBank.d568.s28|9-24|coadministration|O
DDI-DrugBank.d568.s28|26-27|of|O
DDI-DrugBank.d568.s28|29-40|escitalopram|drug
DDI-DrugBank.d568.s28|42-42|(|O
DDI-DrugBank.d568.s28|43-44|20|O
DDI-DrugBank.d568.s28|46-47|mg|O
DDI-DrugBank.d568.s28|48-48|)|O
DDI-DrugBank.d568.s28|50-52|and|O
DDI-DrugBank.d568.s28|54-62|ritonavir|drug
DDI-DrugBank.d568.s28|64-64|(|O
DDI-DrugBank.d568.s28|65-67|600|O
DDI-DrugBank.d568.s28|69-70|mg|O
DDI-DrugBank.d568.s28|71-71|)|O
DDI-DrugBank.d568.s28|72-72|,|O
DDI-DrugBank.d568.s28|74-74|a|O
DDI-DrugBank.d568.s28|76-81|potent|O
DDI-DrugBank.d568.s28|83-91|inhibitor|O
DDI-DrugBank.d568.s28|93-94|of|O
DDI-DrugBank.d568.s28|96-101|CYP3A4|O
DDI-DrugBank.d568.s28|102-102|,|O
DDI-DrugBank.d568.s28|104-106|did|O
DDI-DrugBank.d568.s28|108-110|not|O
DDI-DrugBank.d568.s28|112-124|significantly|O
DDI-DrugBank.d568.s28|126-131|affect|O
DDI-DrugBank.d568.s28|133-135|the|O
DDI-DrugBank.d568.s28|137-152|pharmacokinetics|O
DDI-DrugBank.d568.s28|154-155|of|O
DDI-DrugBank.d568.s28|157-168|escitalopram|drug
DDI-DrugBank.d568.s28|169-169|.|O
DDI-DrugBank.d568.s29|0-6|Because|O
DDI-DrugBank.d568.s29|8-19|escitalopram|drug
DDI-DrugBank.d568.s29|21-22|is|O
DDI-DrugBank.d568.s29|24-34|metabolized|O
DDI-DrugBank.d568.s29|36-37|by|O
DDI-DrugBank.d568.s29|39-46|multiple|O
DDI-DrugBank.d568.s29|48-53|enzyme|O
DDI-DrugBank.d568.s29|55-61|systems|O
DDI-DrugBank.d568.s29|62-62|,|O
DDI-DrugBank.d568.s29|64-73|inhibition|O
DDI-DrugBank.d568.s29|75-76|of|O
DDI-DrugBank.d568.s29|78-78|a|O
DDI-DrugBank.d568.s29|80-85|single|O
DDI-DrugBank.d568.s29|87-92|enzyme|O
DDI-DrugBank.d568.s29|94-96|may|O
DDI-DrugBank.d568.s29|98-100|not|O
DDI-DrugBank.d568.s29|102-112|appreciably|O
DDI-DrugBank.d568.s29|114-121|decrease|O
DDI-DrugBank.d568.s29|123-134|escitalopram|drug
DDI-DrugBank.d568.s29|136-144|clearance|O
DDI-DrugBank.d568.s29|145-145|.|O
DDI-DrugBank.d568.s30|0-4|Drugs|O
DDI-DrugBank.d568.s30|6-16|Metabolized|O
DDI-DrugBank.d568.s30|18-19|by|O
DDI-DrugBank.d568.s30|21-30|Cytochrome|O
DDI-DrugBank.d568.s30|32-38|P4502D6|O
DDI-DrugBank.d568.s30|40-40|-|O
DDI-DrugBank.d568.s30|42-43|In|O
DDI-DrugBank.d568.s30|45-49|vitro|O
DDI-DrugBank.d568.s30|51-57|studies|O
DDI-DrugBank.d568.s30|59-61|did|O
DDI-DrugBank.d568.s30|63-65|not|O
DDI-DrugBank.d568.s30|67-72|reveal|O
DDI-DrugBank.d568.s30|74-75|an|O
DDI-DrugBank.d568.s30|77-86|inhibitory|O
DDI-DrugBank.d568.s30|88-93|effect|O
DDI-DrugBank.d568.s30|95-96|of|O
DDI-DrugBank.d568.s30|98-109|escitalopram|drug
DDI-DrugBank.d568.s30|111-112|on|O
DDI-DrugBank.d568.s30|114-119|CYP2D6|O
DDI-DrugBank.d568.s30|120-120|.|O
DDI-DrugBank.d568.s31|0-1|In|O
DDI-DrugBank.d568.s31|3-10|addition|O
DDI-DrugBank.d568.s31|11-11|,|O
DDI-DrugBank.d568.s31|13-18|steady|O
DDI-DrugBank.d568.s31|20-24|state|O
DDI-DrugBank.d568.s31|26-31|levels|O
DDI-DrugBank.d568.s31|33-34|of|O
DDI-DrugBank.d568.s31|36-42|racemic|O
DDI-DrugBank.d568.s31|44-53|citalopram|drug
DDI-DrugBank.d568.s31|55-58|were|O
DDI-DrugBank.d568.s31|60-62|not|O
DDI-DrugBank.d568.s31|64-76|significantly|O
DDI-DrugBank.d568.s31|78-86|different|O
DDI-DrugBank.d568.s31|88-89|in|O
DDI-DrugBank.d568.s31|91-94|poor|O
DDI-DrugBank.d568.s31|96-107|metabolizers|O
DDI-DrugBank.d568.s31|109-111|and|O
DDI-DrugBank.d568.s31|113-121|extensive|O
DDI-DrugBank.d568.s31|123-128|CYP2D6|O
DDI-DrugBank.d568.s31|130-141|metabolizers|O
DDI-DrugBank.d568.s31|143-147|after|O
DDI-DrugBank.d568.s31|149-161|multiple-dose|O
DDI-DrugBank.d568.s31|163-176|administration|O
DDI-DrugBank.d568.s31|178-179|of|O
DDI-DrugBank.d568.s31|181-190|citalopram|drug
DDI-DrugBank.d568.s31|191-191|,|O
DDI-DrugBank.d568.s31|193-202|suggesting|O
DDI-DrugBank.d568.s31|204-207|that|O
DDI-DrugBank.d568.s31|209-224|coadministration|O
DDI-DrugBank.d568.s31|225-225|,|O
DDI-DrugBank.d568.s31|227-230|with|O
DDI-DrugBank.d568.s31|232-243|escitalopram|drug
DDI-DrugBank.d568.s31|244-244|,|O
DDI-DrugBank.d568.s31|246-247|of|O
DDI-DrugBank.d568.s31|249-249|a|O
DDI-DrugBank.d568.s31|251-254|drug|O
DDI-DrugBank.d568.s31|256-259|that|O
DDI-DrugBank.d568.s31|261-268|inhibits|O
DDI-DrugBank.d568.s31|270-275|CYP2D6|O
DDI-DrugBank.d568.s31|276-276|,|O
DDI-DrugBank.d568.s31|278-279|is|O
DDI-DrugBank.d568.s31|281-288|unlikely|O
DDI-DrugBank.d568.s31|290-291|to|O
DDI-DrugBank.d568.s31|293-296|have|O
DDI-DrugBank.d568.s31|298-307|clinically|O
DDI-DrugBank.d568.s31|309-319|significant|O
DDI-DrugBank.d568.s31|321-327|effects|O
DDI-DrugBank.d568.s31|329-330|on|O
DDI-DrugBank.d568.s31|332-343|escitalopram|drug
DDI-DrugBank.d568.s31|345-354|metabolism|O
DDI-DrugBank.d568.s31|355-355|.|O
DDI-DrugBank.d568.s32|0-6|However|O
DDI-DrugBank.d568.s32|7-7|,|O
DDI-DrugBank.d568.s32|9-13|there|O
DDI-DrugBank.d568.s32|15-17|are|O
DDI-DrugBank.d568.s32|19-25|limited|O
DDI-DrugBank.d568.s32|27-28|in|O
DDI-DrugBank.d568.s32|30-33|vivo|O
DDI-DrugBank.d568.s32|35-38|data|O
DDI-DrugBank.d568.s32|40-49|suggesting|O
DDI-DrugBank.d568.s32|51-51|a|O
DDI-DrugBank.d568.s32|53-58|modest|O
DDI-DrugBank.d568.s32|60-65|CYP2D6|O
DDI-DrugBank.d568.s32|67-76|inhibitory|O
DDI-DrugBank.d568.s32|78-83|effect|O
DDI-DrugBank.d568.s32|85-87|for|O
DDI-DrugBank.d568.s32|89-100|escitalopram|drug
DDI-DrugBank.d568.s32|101-101|,|O
DDI-DrugBank.d568.s32|103-106|i.e.|O
DDI-DrugBank.d568.s32|107-107|,|O
DDI-DrugBank.d568.s32|109-124|coadministration|O
DDI-DrugBank.d568.s32|126-127|of|O
DDI-DrugBank.d568.s32|129-140|escitalopram|drug
DDI-DrugBank.d568.s32|142-142|(|O
DDI-DrugBank.d568.s32|143-144|20|O
DDI-DrugBank.d568.s32|146-151|mg/day|O
DDI-DrugBank.d568.s32|153-155|for|O
DDI-DrugBank.d568.s32|157-158|21|O
DDI-DrugBank.d568.s32|160-163|days|O
DDI-DrugBank.d568.s32|164-164|)|O
DDI-DrugBank.d568.s32|166-169|with|O
DDI-DrugBank.d568.s32|171-173|the|O
DDI-DrugBank.d568.s32|175-198|tricyclic antidepressant|group
DDI-DrugBank.d568.s32|175-198|tricyclic antidepressant|group
DDI-DrugBank.d568.s32|212-212|(|O
DDI-DrugBank.d568.s32|213-218|single|O
DDI-DrugBank.d568.s32|220-223|dose|O
DDI-DrugBank.d568.s32|225-226|of|O
DDI-DrugBank.d568.s32|228-229|50|O
DDI-DrugBank.d568.s32|231-232|mg|O
DDI-DrugBank.d568.s32|233-233|)|O
DDI-DrugBank.d568.s32|234-234|,|O
DDI-DrugBank.d568.s32|236-236|a|O
DDI-DrugBank.d568.s32|238-246|substrate|O
DDI-DrugBank.d568.s32|248-250|for|O
DDI-DrugBank.d568.s32|252-257|CYP2D6|O
DDI-DrugBank.d568.s32|258-258|,|O
DDI-DrugBank.d568.s32|260-267|resulted|O
DDI-DrugBank.d568.s32|269-270|in|O
DDI-DrugBank.d568.s32|272-272|a|O
DDI-DrugBank.d568.s32|274-275|40|O
DDI-DrugBank.d568.s32|276-276|%|O
DDI-DrugBank.d568.s32|278-285|increase|O
DDI-DrugBank.d568.s32|287-288|in|O
DDI-DrugBank.d568.s32|290-293|Cmax|O
DDI-DrugBank.d568.s32|295-297|and|O
DDI-DrugBank.d568.s32|299-299|a|O
DDI-DrugBank.d568.s32|301-303|100|O
DDI-DrugBank.d568.s32|304-304|%|O
DDI-DrugBank.d568.s32|306-313|increase|O
DDI-DrugBank.d568.s32|315-316|in|O
DDI-DrugBank.d568.s32|318-320|AUC|O
DDI-DrugBank.d568.s32|322-323|of|O
DDI-DrugBank.d568.s32|325-335|desipramine|drug
DDI-DrugBank.d568.s32|336-336|.|O
DDI-DrugBank.d568.s33|0-2|The|O
DDI-DrugBank.d568.s33|4-11|clinical|O
DDI-DrugBank.d568.s33|13-24|significance|O
DDI-DrugBank.d568.s33|26-27|of|O
DDI-DrugBank.d568.s33|29-32|this|O
DDI-DrugBank.d568.s33|34-40|finding|O
DDI-DrugBank.d568.s33|42-43|is|O
DDI-DrugBank.d568.s33|45-51|unknown|O
DDI-DrugBank.d568.s33|52-52|.|O
DDI-DrugBank.d568.s34|0-11|Nevertheless|O
DDI-DrugBank.d568.s34|12-12|,|O
DDI-DrugBank.d568.s34|14-20|caution|O
DDI-DrugBank.d568.s34|22-23|is|O
DDI-DrugBank.d568.s34|25-33|indicated|O
DDI-DrugBank.d568.s34|35-36|in|O
DDI-DrugBank.d568.s34|38-40|the|O
DDI-DrugBank.d568.s34|42-57|coadministration|O
DDI-DrugBank.d568.s34|59-60|of|O
DDI-DrugBank.d568.s34|62-73|escitalopram|drug
DDI-DrugBank.d568.s34|75-77|and|O
DDI-DrugBank.d568.s34|79-83|drugs|O
DDI-DrugBank.d568.s34|85-95|metabolized|O
DDI-DrugBank.d568.s34|97-98|by|O
DDI-DrugBank.d568.s34|100-105|CYP2D6|O
DDI-DrugBank.d568.s34|106-106|.|O
DDI-DrugBank.d568.s35|0-9|Metoprolol|drug
DDI-DrugBank.d568.s35|11-11|-|O
DDI-DrugBank.d568.s35|13-26|Administration|O
DDI-DrugBank.d568.s35|28-29|of|O
DDI-DrugBank.d568.s35|31-32|20|O
DDI-DrugBank.d568.s35|34-39|mg/day|O
DDI-DrugBank.d568.s35|41-47|LEXAPRO|brand
DDI-DrugBank.d568.s35|49-51|for|O
DDI-DrugBank.d568.s35|53-54|21|O
DDI-DrugBank.d568.s35|56-59|days|O
DDI-DrugBank.d568.s35|61-62|in|O
DDI-DrugBank.d568.s35|64-70|healthy|O
DDI-DrugBank.d568.s35|72-81|volunteers|O
DDI-DrugBank.d568.s35|83-90|resulted|O
DDI-DrugBank.d568.s35|92-93|in|O
DDI-DrugBank.d568.s35|95-95|a|O
DDI-DrugBank.d568.s35|97-98|50|O
DDI-DrugBank.d568.s35|99-99|%|O
DDI-DrugBank.d568.s35|101-108|increase|O
DDI-DrugBank.d568.s35|110-111|in|O
DDI-DrugBank.d568.s35|113-116|Cmax|O
DDI-DrugBank.d568.s35|118-120|and|O
DDI-DrugBank.d568.s35|122-123|82|O
DDI-DrugBank.d568.s35|124-124|%|O
DDI-DrugBank.d568.s35|126-133|increase|O
DDI-DrugBank.d568.s35|135-136|in|O
DDI-DrugBank.d568.s35|138-140|AUC|O
DDI-DrugBank.d568.s35|142-143|of|O
DDI-DrugBank.d568.s35|145-147|the|O
DDI-DrugBank.d568.s35|149-171|beta-adrenergic blocker|group
DDI-DrugBank.d568.s35|149-171|beta-adrenergic blocker|group
DDI-DrugBank.d568.s35|184-184|(|O
DDI-DrugBank.d568.s35|185-189|given|O
DDI-DrugBank.d568.s35|191-192|in|O
DDI-DrugBank.d568.s35|194-194|a|O
DDI-DrugBank.d568.s35|196-201|single|O
DDI-DrugBank.d568.s35|203-206|dose|O
DDI-DrugBank.d568.s35|208-209|of|O
DDI-DrugBank.d568.s35|211-213|100|O
DDI-DrugBank.d568.s35|215-216|mg|O
DDI-DrugBank.d568.s35|217-217|)|O
DDI-DrugBank.d568.s35|218-218|.|O
DDI-DrugBank.d568.s36|0-8|Increased|O
DDI-DrugBank.d568.s36|10-19|metoprolol|drug
DDI-DrugBank.d568.s36|21-26|plasma|O
DDI-DrugBank.d568.s36|28-33|levels|O
DDI-DrugBank.d568.s36|35-38|have|O
DDI-DrugBank.d568.s36|40-43|been|O
DDI-DrugBank.d568.s36|45-54|associated|O
DDI-DrugBank.d568.s36|56-59|with|O
DDI-DrugBank.d568.s36|61-69|decreased|O
DDI-DrugBank.d568.s36|71-87|cardioselectivity|O
DDI-DrugBank.d568.s36|88-88|.|O
DDI-DrugBank.d568.s37|0-15|Coadministration|O
DDI-DrugBank.d568.s37|17-18|of|O
DDI-DrugBank.d568.s37|20-26|LEXAPRO|brand
DDI-DrugBank.d568.s37|28-30|and|O
DDI-DrugBank.d568.s37|32-41|metoprolol|drug
DDI-DrugBank.d568.s37|43-45|had|O
DDI-DrugBank.d568.s37|47-48|no|O
DDI-DrugBank.d568.s37|50-59|clinically|O
DDI-DrugBank.d568.s37|61-71|significant|O
DDI-DrugBank.d568.s37|73-79|effects|O
DDI-DrugBank.d568.s37|81-82|on|O
DDI-DrugBank.d568.s37|84-88|blood|O
DDI-DrugBank.d568.s37|90-97|pressure|O
DDI-DrugBank.d568.s37|99-100|or|O
DDI-DrugBank.d568.s37|102-106|heart|O
DDI-DrugBank.d568.s37|108-111|rate|O
DDI-DrugBank.d568.s37|112-112|.|O
DDI-DrugBank.d568.s38|0-16|Electroconvulsive|O
DDI-DrugBank.d568.s38|18-24|Therapy|O
DDI-DrugBank.d568.s38|26-26|(|O
DDI-DrugBank.d568.s38|27-29|ECT|O
DDI-DrugBank.d568.s38|30-30|)|O
DDI-DrugBank.d568.s38|32-32|-|O
DDI-DrugBank.d568.s38|34-38|There|O
DDI-DrugBank.d568.s38|40-42|are|O
DDI-DrugBank.d568.s38|44-45|no|O
DDI-DrugBank.d568.s38|47-54|clinical|O
DDI-DrugBank.d568.s38|56-62|studies|O
DDI-DrugBank.d568.s38|64-65|of|O
DDI-DrugBank.d568.s38|67-69|the|O
DDI-DrugBank.d568.s38|71-78|combined|O
DDI-DrugBank.d568.s38|80-82|use|O
DDI-DrugBank.d568.s38|84-85|of|O
DDI-DrugBank.d568.s38|87-89|ECT|O
DDI-DrugBank.d568.s38|91-93|and|O
DDI-DrugBank.d568.s38|95-106|escitalopram|drug
DDI-DrugBank.d568.s38|107-107|.|O
DDI-DrugBank.d568.s39|0-10|Concomitant|O
DDI-DrugBank.d568.s39|12-25|Administration|O
DDI-DrugBank.d568.s39|27-30|with|O
DDI-DrugBank.d568.s39|32-38|Racemic|O
DDI-DrugBank.d568.s39|40-49|Citalopram|drug
DDI-DrugBank.d568.s39|40-49|Citalopram|drug
DDI-DrugBank.d568.s39|62-62|-|O
DDI-DrugBank.d568.s39|64-68|Since|O
DDI-DrugBank.d568.s39|70-81|escitalopram|drug
DDI-DrugBank.d568.s39|83-84|is|O
DDI-DrugBank.d568.s39|86-88|the|O
DDI-DrugBank.d568.s39|90-95|active|O
DDI-DrugBank.d568.s39|97-102|isomer|O
DDI-DrugBank.d568.s39|104-105|of|O
DDI-DrugBank.d568.s39|107-113|racemic|O
DDI-DrugBank.d568.s39|115-124|citalopram|drug
DDI-DrugBank.d568.s39|126-126|(|O
DDI-DrugBank.d568.s39|127-132|Celexa|brand
DDI-DrugBank.d568.s39|133-133|)|O
DDI-DrugBank.d568.s39|134-134|,|O
DDI-DrugBank.d568.s39|136-138|the|O
DDI-DrugBank.d568.s39|140-142|two|O
DDI-DrugBank.d568.s39|144-149|agents|O
DDI-DrugBank.d568.s39|151-156|should|O
DDI-DrugBank.d568.s39|158-160|not|O
DDI-DrugBank.d568.s39|162-163|be|O
DDI-DrugBank.d568.s39|165-178|coadministered|O
DDI-DrugBank.d568.s39|179-179|.|O
DDI-DrugBank.d82.s0|0-1|In|O
DDI-DrugBank.d82.s0|3-8|normal|O
DDI-DrugBank.d82.s0|10-19|volunteers|O
DDI-DrugBank.d82.s0|21-29|receiving|O
DDI-DrugBank.d82.s0|31-42|indomethacin|drug
DDI-DrugBank.d82.s0|43-43|,|O
DDI-DrugBank.d82.s0|45-47|the|O
DDI-DrugBank.d82.s0|49-62|administration|O
DDI-DrugBank.d82.s0|64-65|of|O
DDI-DrugBank.d82.s0|67-76|diflunisal|drug
DDI-DrugBank.d82.s0|78-86|decreased|O
DDI-DrugBank.d82.s0|88-90|the|O
DDI-DrugBank.d82.s0|92-96|renal|O
DDI-DrugBank.d82.s0|98-106|clearance|O
DDI-DrugBank.d82.s0|108-110|and|O
DDI-DrugBank.d82.s0|112-124|significantly|O
DDI-DrugBank.d82.s0|126-134|increased|O
DDI-DrugBank.d82.s0|136-138|the|O
DDI-DrugBank.d82.s0|140-145|plasma|O
DDI-DrugBank.d82.s0|147-152|levels|O
DDI-DrugBank.d82.s0|154-155|of|O
DDI-DrugBank.d82.s0|157-168|indomethacin|drug
DDI-DrugBank.d82.s0|169-169|.|O
DDI-DrugBank.d82.s1|0-1|In|O
DDI-DrugBank.d82.s1|3-6|some|O
DDI-DrugBank.d82.s1|8-15|patients|O
DDI-DrugBank.d82.s1|16-16|,|O
DDI-DrugBank.d82.s1|18-25|combined|O
DDI-DrugBank.d82.s1|27-29|use|O
DDI-DrugBank.d82.s1|31-32|of|O
DDI-DrugBank.d82.s1|34-40|INDOCIN|brand
DDI-DrugBank.d82.s1|42-44|and|O
DDI-DrugBank.d82.s1|46-55|diflunisal|drug
DDI-DrugBank.d82.s1|57-59|has|O
DDI-DrugBank.d82.s1|61-64|been|O
DDI-DrugBank.d82.s1|66-75|associated|O
DDI-DrugBank.d82.s1|77-80|with|O
DDI-DrugBank.d82.s1|82-86|fatal|O
DDI-DrugBank.d82.s1|88-103|gastrointestinal|O
DDI-DrugBank.d82.s1|105-114|hemorrhage|O
DDI-DrugBank.d82.s1|115-115|.|O
DDI-DrugBank.d82.s2|0-8|Therefore|O
DDI-DrugBank.d82.s2|9-9|,|O
DDI-DrugBank.d82.s2|11-20|diflunisal|drug
DDI-DrugBank.d82.s2|22-24|and|O
DDI-DrugBank.d82.s2|26-32|INDOCIN|brand
DDI-DrugBank.d82.s2|34-39|should|O
DDI-DrugBank.d82.s2|41-43|not|O
DDI-DrugBank.d82.s2|45-46|be|O
DDI-DrugBank.d82.s2|48-51|used|O
DDI-DrugBank.d82.s2|53-65|concomitantly|O
DDI-DrugBank.d82.s2|66-66|.|O
DDI-DrugBank.d82.s3|0-1|In|O
DDI-DrugBank.d82.s3|3-3|a|O
DDI-DrugBank.d82.s3|5-9|study|O
DDI-DrugBank.d82.s3|11-12|in|O
DDI-DrugBank.d82.s3|14-19|normal|O
DDI-DrugBank.d82.s3|21-30|volunteers|O
DDI-DrugBank.d82.s3|31-31|,|O
DDI-DrugBank.d82.s3|33-34|it|O
DDI-DrugBank.d82.s3|36-38|was|O
DDI-DrugBank.d82.s3|40-44|found|O
DDI-DrugBank.d82.s3|46-49|that|O
DDI-DrugBank.d82.s3|51-57|chronic|O
DDI-DrugBank.d82.s3|59-68|concurrent|O
DDI-DrugBank.d82.s3|70-83|administration|O
DDI-DrugBank.d82.s3|85-86|of|O
DDI-DrugBank.d82.s3|88-90|3.6|O
DDI-DrugBank.d82.s3|92-92|g|O
DDI-DrugBank.d82.s3|94-95|of|O
DDI-DrugBank.d82.s3|97-103|aspirin|brand
DDI-DrugBank.d82.s3|105-107|per|O
DDI-DrugBank.d82.s3|109-111|day|O
DDI-DrugBank.d82.s3|113-121|decreases|O
DDI-DrugBank.d82.s3|123-134|indomethacin|drug
DDI-DrugBank.d82.s3|136-140|blood|O
DDI-DrugBank.d82.s3|142-147|levels|O
DDI-DrugBank.d82.s3|149-161|approximately|O
DDI-DrugBank.d82.s3|163-164|20|O
DDI-DrugBank.d82.s3|165-165|%|O
DDI-DrugBank.d82.s3|166-166|.|O
DDI-DrugBank.d82.s4|0-2|The|O
DDI-DrugBank.d82.s4|4-14|concomitant|O
DDI-DrugBank.d82.s4|16-18|use|O
DDI-DrugBank.d82.s4|20-21|of|O
DDI-DrugBank.d82.s4|23-29|INDOCIN|brand
DDI-DrugBank.d82.s4|31-34|with|O
DDI-DrugBank.d82.s4|36-40|other|O
DDI-DrugBank.d82.s4|42-47|NSAIDs|group
DDI-DrugBank.d82.s4|49-50|is|O
DDI-DrugBank.d82.s4|52-54|not|O
DDI-DrugBank.d82.s4|56-66|recommended|O
DDI-DrugBank.d82.s4|68-70|due|O
DDI-DrugBank.d82.s4|72-73|to|O
DDI-DrugBank.d82.s4|75-77|the|O
DDI-DrugBank.d82.s4|79-87|increased|O
DDI-DrugBank.d82.s4|89-99|possibility|O
DDI-DrugBank.d82.s4|101-102|of|O
DDI-DrugBank.d82.s4|104-119|gastrointestinal|O
DDI-DrugBank.d82.s4|121-128|toxicity|O
DDI-DrugBank.d82.s4|129-129|,|O
DDI-DrugBank.d82.s4|131-134|with|O
DDI-DrugBank.d82.s4|136-141|little|O
DDI-DrugBank.d82.s4|143-144|or|O
DDI-DrugBank.d82.s4|146-147|no|O
DDI-DrugBank.d82.s4|149-156|increase|O
DDI-DrugBank.d82.s4|158-159|in|O
DDI-DrugBank.d82.s4|161-168|efficacy|O
DDI-DrugBank.d82.s4|169-169|.|O
DDI-DrugBank.d82.s5|0-7|Clinical|O
DDI-DrugBank.d82.s5|9-15|studies|O
DDI-DrugBank.d82.s5|17-20|have|O
DDI-DrugBank.d82.s5|22-26|shown|O
DDI-DrugBank.d82.s5|28-31|that|O
DDI-DrugBank.d82.s5|33-39|INDOCIN|brand
DDI-DrugBank.d82.s5|41-44|does|O
DDI-DrugBank.d82.s5|46-48|not|O
DDI-DrugBank.d82.s5|50-58|influence|O
DDI-DrugBank.d82.s5|60-62|the|O
DDI-DrugBank.d82.s5|64-82|hypoprothrombinemia|O
DDI-DrugBank.d82.s5|84-91|produced|O
DDI-DrugBank.d82.s5|93-94|by|O
DDI-DrugBank.d82.s5|96-109|anticoagulants|group
DDI-DrugBank.d82.s5|110-110|.|O
DDI-DrugBank.d82.s6|0-6|However|O
DDI-DrugBank.d82.s6|7-7|,|O
DDI-DrugBank.d82.s6|9-12|when|O
DDI-DrugBank.d82.s6|14-16|any|O
DDI-DrugBank.d82.s6|18-27|additional|O
DDI-DrugBank.d82.s6|29-32|drug|O
DDI-DrugBank.d82.s6|33-33|,|O
DDI-DrugBank.d82.s6|35-43|including|O
DDI-DrugBank.d82.s6|45-51|INDOCIN|brand
DDI-DrugBank.d82.s6|52-52|,|O
DDI-DrugBank.d82.s6|54-55|is|O
DDI-DrugBank.d82.s6|57-61|added|O
DDI-DrugBank.d82.s6|63-64|to|O
DDI-DrugBank.d82.s6|66-68|the|O
DDI-DrugBank.d82.s6|70-78|treatment|O
DDI-DrugBank.d82.s6|80-81|of|O
DDI-DrugBank.d82.s6|83-90|patients|O
DDI-DrugBank.d82.s6|92-93|on|O
DDI-DrugBank.d82.s6|95-107|anticoagulant|group
DDI-DrugBank.d82.s6|109-115|therapy|O
DDI-DrugBank.d82.s6|116-116|,|O
DDI-DrugBank.d82.s6|118-120|the|O
DDI-DrugBank.d82.s6|122-129|patients|O
DDI-DrugBank.d82.s6|131-136|should|O
DDI-DrugBank.d82.s6|138-139|be|O
DDI-DrugBank.d82.s6|141-148|observed|O
DDI-DrugBank.d82.s6|150-152|for|O
DDI-DrugBank.d82.s6|154-164|alterations|O
DDI-DrugBank.d82.s6|166-167|of|O
DDI-DrugBank.d82.s6|169-171|the|O
DDI-DrugBank.d82.s6|173-183|prothrombin|O
DDI-DrugBank.d82.s6|185-188|time|O
DDI-DrugBank.d82.s6|189-189|.|O
DDI-DrugBank.d82.s7|0-1|In|O
DDI-DrugBank.d82.s7|3-16|post-marketing|O
DDI-DrugBank.d82.s7|18-27|experience|O
DDI-DrugBank.d82.s7|28-28|,|O
DDI-DrugBank.d82.s7|30-37|bleeding|O
DDI-DrugBank.d82.s7|39-41|has|O
DDI-DrugBank.d82.s7|43-46|been|O
DDI-DrugBank.d82.s7|48-55|reported|O
DDI-DrugBank.d82.s7|57-58|in|O
DDI-DrugBank.d82.s7|60-67|patients|O
DDI-DrugBank.d82.s7|69-70|on|O
DDI-DrugBank.d82.s7|72-82|concomitant|O
DDI-DrugBank.d82.s7|84-92|treatment|O
DDI-DrugBank.d82.s7|94-97|with|O
DDI-DrugBank.d82.s7|99-112|anticoagulants|group
DDI-DrugBank.d82.s7|114-116|and|O
DDI-DrugBank.d82.s7|118-124|INDOCIN|brand
DDI-DrugBank.d82.s7|125-125|.|O
DDI-DrugBank.d82.s8|0-6|Caution|O
DDI-DrugBank.d82.s8|8-13|should|O
DDI-DrugBank.d82.s8|15-16|be|O
DDI-DrugBank.d82.s8|18-26|exercised|O
DDI-DrugBank.d82.s8|28-31|when|O
DDI-DrugBank.d82.s8|33-39|INDOCIN|brand
DDI-DrugBank.d82.s8|41-43|and|O
DDI-DrugBank.d82.s8|45-58|anticoagulants|group
DDI-DrugBank.d82.s8|60-62|are|O
DDI-DrugBank.d82.s8|64-75|administered|O
DDI-DrugBank.d82.s8|77-89|concomitantly|O
DDI-DrugBank.d82.s8|90-90|.|O
DDI-DrugBank.d82.s9|0-3|When|O
DDI-DrugBank.d82.s9|5-11|INDOCIN|brand
DDI-DrugBank.d82.s9|13-14|is|O
DDI-DrugBank.d82.s9|16-20|given|O
DDI-DrugBank.d82.s9|22-23|to|O
DDI-DrugBank.d82.s9|25-32|patients|O
DDI-DrugBank.d82.s9|34-42|receiving|O
DDI-DrugBank.d82.s9|44-53|probenecid|drug
DDI-DrugBank.d82.s9|54-54|,|O
DDI-DrugBank.d82.s9|56-58|the|O
DDI-DrugBank.d82.s9|60-65|plasma|O
DDI-DrugBank.d82.s9|67-72|levels|O
DDI-DrugBank.d82.s9|74-75|of|O
DDI-DrugBank.d82.s9|77-88|indomethacin|drug
DDI-DrugBank.d82.s9|90-92|are|O
DDI-DrugBank.d82.s9|94-99|likely|O
DDI-DrugBank.d82.s9|101-102|to|O
DDI-DrugBank.d82.s9|104-105|be|O
DDI-DrugBank.d82.s9|107-115|increased|O
DDI-DrugBank.d82.s9|116-116|.|O
DDI-DrugBank.d82.s10|0-8|Therefore|O
DDI-DrugBank.d82.s10|9-9|,|O
DDI-DrugBank.d82.s10|11-11|a|O
DDI-DrugBank.d82.s10|13-17|lower|O
DDI-DrugBank.d82.s10|19-23|total|O
DDI-DrugBank.d82.s10|25-29|daily|O
DDI-DrugBank.d82.s10|31-36|dosage|O
DDI-DrugBank.d82.s10|38-39|of|O
DDI-DrugBank.d82.s10|41-47|INDOCIN|brand
DDI-DrugBank.d82.s10|49-51|may|O
DDI-DrugBank.d82.s10|53-59|produce|O
DDI-DrugBank.d82.s10|61-61|a|O
DDI-DrugBank.d82.s10|63-74|satisfactory|O
DDI-DrugBank.d82.s10|76-86|therapeutic|O
DDI-DrugBank.d82.s10|88-93|effect|O
DDI-DrugBank.d82.s10|94-94|.|O
DDI-DrugBank.d82.s11|0-3|When|O
DDI-DrugBank.d82.s11|5-13|increases|O
DDI-DrugBank.d82.s11|15-16|in|O
DDI-DrugBank.d82.s11|18-20|the|O
DDI-DrugBank.d82.s11|22-25|dose|O
DDI-DrugBank.d82.s11|27-28|of|O
DDI-DrugBank.d82.s11|30-36|INDOCIN|brand
DDI-DrugBank.d82.s11|38-40|are|O
DDI-DrugBank.d82.s11|42-45|made|O
DDI-DrugBank.d82.s11|46-46|,|O
DDI-DrugBank.d82.s11|48-51|they|O
DDI-DrugBank.d82.s11|53-58|should|O
DDI-DrugBank.d82.s11|60-61|be|O
DDI-DrugBank.d82.s11|63-66|made|O
DDI-DrugBank.d82.s11|68-76|carefully|O
DDI-DrugBank.d82.s11|78-80|and|O
DDI-DrugBank.d82.s11|82-83|in|O
DDI-DrugBank.d82.s11|85-89|small|O
DDI-DrugBank.d82.s11|91-100|increments|O
DDI-DrugBank.d82.s11|101-101|.|O
DDI-DrugBank.d82.s12|0-6|Caution|O
DDI-DrugBank.d82.s12|8-13|should|O
DDI-DrugBank.d82.s12|15-16|be|O
DDI-DrugBank.d82.s12|18-21|used|O
DDI-DrugBank.d82.s12|23-24|if|O
DDI-DrugBank.d82.s12|26-32|INDOCIN|brand
DDI-DrugBank.d82.s12|34-35|is|O
DDI-DrugBank.d82.s12|37-48|administered|O
DDI-DrugBank.d82.s12|50-63|simultaneously|O
DDI-DrugBank.d82.s12|65-68|with|O
DDI-DrugBank.d82.s12|70-81|methotrexate|drug
DDI-DrugBank.d82.s12|82-82|.|O
DDI-DrugBank.d82.s13|0-6|INDOCIN|brand
DDI-DrugBank.d82.s13|8-10|has|O
DDI-DrugBank.d82.s13|12-15|been|O
DDI-DrugBank.d82.s13|17-24|reported|O
DDI-DrugBank.d82.s13|26-27|to|O
DDI-DrugBank.d82.s13|29-36|decrease|O
DDI-DrugBank.d82.s13|38-40|the|O
DDI-DrugBank.d82.s13|42-48|tubular|O
DDI-DrugBank.d82.s13|50-58|secretion|O
DDI-DrugBank.d82.s13|60-61|of|O
DDI-DrugBank.d82.s13|63-74|methotrexate|drug
DDI-DrugBank.d82.s13|76-78|and|O
DDI-DrugBank.d82.s13|80-81|to|O
DDI-DrugBank.d82.s13|83-92|potentiate|O
DDI-DrugBank.d82.s13|94-96|its|O
DDI-DrugBank.d82.s13|98-105|toxicity|O
DDI-DrugBank.d82.s13|106-106|.|O
DDI-DrugBank.d82.s14|0-13|Administration|O
DDI-DrugBank.d82.s14|15-16|of|O
DDI-DrugBank.d82.s14|18-54|non-steroidal anti-inflammatory drugs|group
DDI-DrugBank.d82.s14|56-68|concomitantly|O
DDI-DrugBank.d82.s14|70-73|with|O
DDI-DrugBank.d82.s14|75-86|cyclosporine|drug
DDI-DrugBank.d82.s14|88-90|has|O
DDI-DrugBank.d82.s14|92-95|been|O
DDI-DrugBank.d82.s14|97-106|associated|O
DDI-DrugBank.d82.s14|108-111|with|O
DDI-DrugBank.d82.s14|113-114|an|O
DDI-DrugBank.d82.s14|116-123|increase|O
DDI-DrugBank.d82.s14|125-126|in|O
DDI-DrugBank.d82.s14|128-147|cyclosporine-induced|drug
DDI-DrugBank.d82.s14|149-156|toxicity|O
DDI-DrugBank.d82.s14|157-157|,|O
DDI-DrugBank.d82.s14|159-166|possibly|O
DDI-DrugBank.d82.s14|168-170|due|O
DDI-DrugBank.d82.s14|172-173|to|O
DDI-DrugBank.d82.s14|175-183|decreased|O
DDI-DrugBank.d82.s14|185-193|synthesis|O
DDI-DrugBank.d82.s14|195-196|of|O
DDI-DrugBank.d82.s14|198-202|renal|O
DDI-DrugBank.d82.s14|204-215|prostacyclin|O
DDI-DrugBank.d82.s14|216-216|.|O
DDI-DrugBank.d82.s15|0-5|NSAIDs|group
DDI-DrugBank.d82.s15|7-12|should|O
DDI-DrugBank.d82.s15|14-15|be|O
DDI-DrugBank.d82.s15|17-20|used|O
DDI-DrugBank.d82.s15|22-25|with|O
DDI-DrugBank.d82.s15|27-33|caution|O
DDI-DrugBank.d82.s15|35-36|in|O
DDI-DrugBank.d82.s15|38-45|patients|O
DDI-DrugBank.d82.s15|47-52|taking|O
DDI-DrugBank.d82.s15|54-65|cyclosporine|drug
DDI-DrugBank.d82.s15|66-66|,|O
DDI-DrugBank.d82.s15|68-70|and|O
DDI-DrugBank.d82.s15|72-76|renal|O
DDI-DrugBank.d82.s15|78-85|function|O
DDI-DrugBank.d82.s15|87-92|should|O
DDI-DrugBank.d82.s15|94-95|be|O
DDI-DrugBank.d82.s15|97-105|carefully|O
DDI-DrugBank.d82.s15|107-115|monitored|O
DDI-DrugBank.d82.s15|116-116|.|O
DDI-DrugBank.d82.s16|0-7|Capsules|O
DDI-DrugBank.d82.s16|9-15|INDOCIN|brand
DDI-DrugBank.d82.s16|17-18|50|O
DDI-DrugBank.d82.s16|20-21|mg|O
DDI-DrugBank.d82.s16|23-28|t.i.d.|O
DDI-DrugBank.d82.s16|30-37|produced|O
DDI-DrugBank.d82.s16|39-39|a|O
DDI-DrugBank.d82.s16|41-50|clinically|O
DDI-DrugBank.d82.s16|52-59|relevant|O
DDI-DrugBank.d82.s16|61-69|elevation|O
DDI-DrugBank.d82.s16|71-72|of|O
DDI-DrugBank.d82.s16|74-79|plasma|O
DDI-DrugBank.d82.s16|81-87|lithium|drug
DDI-DrugBank.d82.s16|89-91|and|O
DDI-DrugBank.d82.s16|93-101|reduction|O
DDI-DrugBank.d82.s16|103-104|in|O
DDI-DrugBank.d82.s16|106-110|renal|O
DDI-DrugBank.d82.s16|112-118|lithium|drug
DDI-DrugBank.d82.s16|120-128|clearance|O
DDI-DrugBank.d82.s16|130-131|in|O
DDI-DrugBank.d82.s16|133-143|psychiatric|O
DDI-DrugBank.d82.s16|145-152|patients|O
DDI-DrugBank.d82.s16|154-156|and|O
DDI-DrugBank.d82.s16|158-163|normal|O
DDI-DrugBank.d82.s16|165-172|subjects|O
DDI-DrugBank.d82.s16|174-177|with|O
DDI-DrugBank.d82.s16|179-184|steady|O
DDI-DrugBank.d82.s16|186-190|state|O
DDI-DrugBank.d82.s16|192-197|plasma|O
DDI-DrugBank.d82.s16|199-205|lithium|drug
DDI-DrugBank.d82.s16|207-220|concentrations|O
DDI-DrugBank.d82.s16|221-221|.|O
DDI-DrugBank.d82.s17|0-3|This|O
DDI-DrugBank.d82.s17|5-10|effect|O
DDI-DrugBank.d82.s17|12-14|has|O
DDI-DrugBank.d82.s17|16-19|been|O
DDI-DrugBank.d82.s17|21-30|attributed|O
DDI-DrugBank.d82.s17|32-33|to|O
DDI-DrugBank.d82.s17|35-44|inhibition|O
DDI-DrugBank.d82.s17|46-47|of|O
DDI-DrugBank.d82.s17|49-61|prostaglandin|O
DDI-DrugBank.d82.s17|63-71|synthesis|O
DDI-DrugBank.d82.s17|72-72|.|O
DDI-DrugBank.d82.s18|0-1|As|O
DDI-DrugBank.d82.s18|3-3|a|O
DDI-DrugBank.d82.s18|5-15|consequence|O
DDI-DrugBank.d82.s18|16-16|,|O
DDI-DrugBank.d82.s18|18-21|when|O
DDI-DrugBank.d82.s18|23-29|INDOCIN|brand
DDI-DrugBank.d82.s18|31-33|and|O
DDI-DrugBank.d82.s18|35-41|lithium|drug
DDI-DrugBank.d82.s18|43-45|are|O
DDI-DrugBank.d82.s18|47-51|given|O
DDI-DrugBank.d82.s18|53-65|concomitantly|O
DDI-DrugBank.d82.s18|66-66|,|O
DDI-DrugBank.d82.s18|68-70|the|O
DDI-DrugBank.d82.s18|72-78|patient|O
DDI-DrugBank.d82.s18|80-85|should|O
DDI-DrugBank.d82.s18|87-88|be|O
DDI-DrugBank.d82.s18|90-98|carefully|O
DDI-DrugBank.d82.s18|100-107|observed|O
DDI-DrugBank.d82.s18|109-111|for|O
DDI-DrugBank.d82.s18|113-117|signs|O
DDI-DrugBank.d82.s18|119-120|of|O
DDI-DrugBank.d82.s18|122-128|lithium|drug
DDI-DrugBank.d82.s18|130-137|toxicity|O
DDI-DrugBank.d82.s18|138-138|.|O
DDI-DrugBank.d82.s19|0-0|(|O
DDI-DrugBank.d82.s19|1-4|Read|O
DDI-DrugBank.d82.s19|6-14|circulars|O
DDI-DrugBank.d82.s19|16-18|for|O
DDI-DrugBank.d82.s19|20-26|lithium|drug
DDI-DrugBank.d82.s19|28-39|preparations|O
DDI-DrugBank.d82.s19|41-46|before|O
DDI-DrugBank.d82.s19|48-50|use|O
DDI-DrugBank.d82.s19|52-53|of|O
DDI-DrugBank.d82.s19|55-58|such|O
DDI-DrugBank.d82.s19|60-70|concomitant|O
DDI-DrugBank.d82.s19|72-78|therapy|O
DDI-DrugBank.d82.s19|79-79|.|O
DDI-DrugBank.d82.s19|80-80|)|O
DDI-DrugBank.d82.s20|0-1|In|O
DDI-DrugBank.d82.s20|3-10|addition|O
DDI-DrugBank.d82.s20|11-11|,|O
DDI-DrugBank.d82.s20|13-15|the|O
DDI-DrugBank.d82.s20|17-25|frequency|O
DDI-DrugBank.d82.s20|27-28|of|O
DDI-DrugBank.d82.s20|30-39|monitoring|O
DDI-DrugBank.d82.s20|41-45|serum|O
DDI-DrugBank.d82.s20|47-53|lithium|drug
DDI-DrugBank.d82.s20|55-67|concentration|O
DDI-DrugBank.d82.s20|69-74|should|O
DDI-DrugBank.d82.s20|76-77|be|O
DDI-DrugBank.d82.s20|79-87|increased|O
DDI-DrugBank.d82.s20|89-90|at|O
DDI-DrugBank.d82.s20|92-94|the|O
DDI-DrugBank.d82.s20|96-101|outset|O
DDI-DrugBank.d82.s20|103-104|of|O
DDI-DrugBank.d82.s20|106-109|such|O
DDI-DrugBank.d82.s20|111-121|combination|O
DDI-DrugBank.d82.s20|123-126|drug|O
DDI-DrugBank.d82.s20|128-136|treatment|O
DDI-DrugBank.d82.s20|137-137|.|O
DDI-DrugBank.d82.s21|0-6|INDOCIN|brand
DDI-DrugBank.d82.s21|8-12|given|O
DDI-DrugBank.d82.s21|14-26|concomitantly|O
DDI-DrugBank.d82.s21|28-31|with|O
DDI-DrugBank.d82.s21|33-39|digoxin|drug
DDI-DrugBank.d82.s21|41-43|has|O
DDI-DrugBank.d82.s21|45-48|been|O
DDI-DrugBank.d82.s21|50-57|reported|O
DDI-DrugBank.d82.s21|59-60|to|O
DDI-DrugBank.d82.s21|62-69|increase|O
DDI-DrugBank.d82.s21|71-73|the|O
DDI-DrugBank.d82.s21|75-79|serum|O
DDI-DrugBank.d82.s21|81-93|concentration|O
DDI-DrugBank.d82.s21|95-97|and|O
DDI-DrugBank.d82.s21|99-105|prolong|O
DDI-DrugBank.d82.s21|107-109|the|O
DDI-DrugBank.d82.s21|111-119|half-life|O
DDI-DrugBank.d82.s21|121-122|of|O
DDI-DrugBank.d82.s21|124-130|digoxin|drug
DDI-DrugBank.d82.s21|131-131|.|O
DDI-DrugBank.d82.s22|0-8|Therefore|O
DDI-DrugBank.d82.s22|9-9|,|O
DDI-DrugBank.d82.s22|11-14|when|O
DDI-DrugBank.d82.s22|16-22|INDOCIN|brand
DDI-DrugBank.d82.s22|24-26|and|O
DDI-DrugBank.d82.s22|28-34|digoxin|drug
DDI-DrugBank.d82.s22|36-38|are|O
DDI-DrugBank.d82.s22|40-43|used|O
DDI-DrugBank.d82.s22|45-57|concomitantly|O
DDI-DrugBank.d82.s22|58-58|,|O
DDI-DrugBank.d82.s22|60-64|serum|O
DDI-DrugBank.d82.s22|66-72|digoxin|drug
DDI-DrugBank.d82.s22|74-79|levels|O
DDI-DrugBank.d82.s22|81-86|should|O
DDI-DrugBank.d82.s22|88-89|be|O
DDI-DrugBank.d82.s22|91-97|closely|O
DDI-DrugBank.d82.s22|99-107|monitored|O
DDI-DrugBank.d82.s22|108-108|.|O
DDI-DrugBank.d82.s23|0-1|In|O
DDI-DrugBank.d82.s23|3-6|some|O
DDI-DrugBank.d82.s23|8-15|patients|O
DDI-DrugBank.d82.s23|16-16|,|O
DDI-DrugBank.d82.s23|18-20|the|O
DDI-DrugBank.d82.s23|22-35|administration|O
DDI-DrugBank.d82.s23|37-38|of|O
DDI-DrugBank.d82.s23|40-46|INDOCIN|brand
DDI-DrugBank.d82.s23|48-50|can|O
DDI-DrugBank.d82.s23|52-57|reduce|O
DDI-DrugBank.d82.s23|59-61|the|O
DDI-DrugBank.d82.s23|63-70|diuretic|O
DDI-DrugBank.d82.s23|71-71|,|O
DDI-DrugBank.d82.s23|73-83|natriuretic|O
DDI-DrugBank.d82.s23|84-84|,|O
DDI-DrugBank.d82.s23|86-88|and|O
DDI-DrugBank.d82.s23|90-105|antihypertensive|O
DDI-DrugBank.d82.s23|107-113|effects|O
DDI-DrugBank.d82.s23|115-116|of|O
DDI-DrugBank.d82.s23|118-121|loop|group
DDI-DrugBank.d82.s23|122-122|,|O
DDI-DrugBank.d82.s23|124-140|potassium-sparing|group
DDI-DrugBank.d82.s23|141-141|,|O
DDI-DrugBank.d82.s23|143-145|and|O
DDI-DrugBank.d82.s23|147-164|thiazide diuretics|group
DDI-DrugBank.d82.s23|165-165|.|O
DDI-DrugBank.d82.s24|0-8|Therefore|O
DDI-DrugBank.d82.s24|9-9|,|O
DDI-DrugBank.d82.s24|11-14|when|O
DDI-DrugBank.d82.s24|16-22|INDOCIN|brand
DDI-DrugBank.d82.s24|24-26|and|O
DDI-DrugBank.d82.s24|28-34|INDOCIN|brand
DDI-DrugBank.d82.s24|35-35|.|O
DDI-DrugBank.d82.s25|0-0|(|O
DDI-DrugBank.d82.s25|1-12|Indomethacin|drug
DDI-DrugBank.d82.s25|13-13|)|O
DDI-DrugBank.d82.s25|15-23|diuretics|group
DDI-DrugBank.d82.s25|25-27|are|O
DDI-DrugBank.d82.s25|29-32|used|O
DDI-DrugBank.d82.s25|34-46|concomitantly|O
DDI-DrugBank.d82.s25|47-47|,|O
DDI-DrugBank.d82.s25|49-51|the|O
DDI-DrugBank.d82.s25|53-59|patient|O
DDI-DrugBank.d82.s25|61-66|should|O
DDI-DrugBank.d82.s25|68-69|be|O
DDI-DrugBank.d82.s25|71-78|observed|O
DDI-DrugBank.d82.s25|80-86|closely|O
DDI-DrugBank.d82.s25|88-89|to|O
DDI-DrugBank.d82.s25|91-99|determine|O
DDI-DrugBank.d82.s25|101-102|if|O
DDI-DrugBank.d82.s25|104-106|the|O
DDI-DrugBank.d82.s25|108-114|desired|O
DDI-DrugBank.d82.s25|116-121|effect|O
DDI-DrugBank.d82.s25|123-124|of|O
DDI-DrugBank.d82.s25|126-128|the|O
DDI-DrugBank.d82.s25|130-137|diuretic|group
DDI-DrugBank.d82.s25|139-140|is|O
DDI-DrugBank.d82.s25|142-149|obtained|O
DDI-DrugBank.d82.s25|150-150|.|O
DDI-DrugBank.d82.s26|0-6|INDOCIN|brand
DDI-DrugBank.d82.s26|8-14|reduces|O
DDI-DrugBank.d82.s26|16-20|basal|O
DDI-DrugBank.d82.s26|22-27|plasma|O
DDI-DrugBank.d82.s26|29-33|renin|O
DDI-DrugBank.d82.s26|35-42|activity|O
DDI-DrugBank.d82.s26|44-44|(|O
DDI-DrugBank.d82.s26|45-47|PRA|O
DDI-DrugBank.d82.s26|48-48|)|O
DDI-DrugBank.d82.s26|49-49|,|O
DDI-DrugBank.d82.s26|51-52|as|O
DDI-DrugBank.d82.s26|54-57|well|O
DDI-DrugBank.d82.s26|59-60|as|O
DDI-DrugBank.d82.s26|62-66|those|O
DDI-DrugBank.d82.s26|68-77|elevations|O
DDI-DrugBank.d82.s26|79-80|of|O
DDI-DrugBank.d82.s26|82-84|PRA|O
DDI-DrugBank.d82.s26|86-92|induced|O
DDI-DrugBank.d82.s26|94-95|by|O
DDI-DrugBank.d82.s26|97-106|furosemide|drug
DDI-DrugBank.d82.s26|108-121|administration|O
DDI-DrugBank.d82.s26|122-122|,|O
DDI-DrugBank.d82.s26|124-125|or|O
DDI-DrugBank.d82.s26|127-130|salt|O
DDI-DrugBank.d82.s26|132-133|or|O
DDI-DrugBank.d82.s26|135-140|volume|O
DDI-DrugBank.d82.s26|142-150|depletion|O
DDI-DrugBank.d82.s26|151-151|.|O
DDI-DrugBank.d82.s27|0-4|These|O
DDI-DrugBank.d82.s27|6-10|facts|O
DDI-DrugBank.d82.s27|12-17|should|O
DDI-DrugBank.d82.s27|19-20|be|O
DDI-DrugBank.d82.s27|22-31|considered|O
DDI-DrugBank.d82.s27|33-36|when|O
DDI-DrugBank.d82.s27|38-47|evaluating|O
DDI-DrugBank.d82.s27|49-54|plasma|O
DDI-DrugBank.d82.s27|56-60|renin|O
DDI-DrugBank.d82.s27|62-69|activity|O
DDI-DrugBank.d82.s27|71-72|in|O
DDI-DrugBank.d82.s27|74-85|hypertensive|O
DDI-DrugBank.d82.s27|87-94|patients|O
DDI-DrugBank.d82.s27|95-95|.|O
DDI-DrugBank.d82.s28|0-1|It|O
DDI-DrugBank.d82.s28|3-5|has|O
DDI-DrugBank.d82.s28|7-10|been|O
DDI-DrugBank.d82.s28|12-19|reported|O
DDI-DrugBank.d82.s28|21-24|that|O
DDI-DrugBank.d82.s28|26-28|the|O
DDI-DrugBank.d82.s28|30-37|addition|O
DDI-DrugBank.d82.s28|39-40|of|O
DDI-DrugBank.d82.s28|42-52|triamterene|drug
DDI-DrugBank.d82.s28|54-55|to|O
DDI-DrugBank.d82.s28|57-57|a|O
DDI-DrugBank.d82.s28|59-69|maintenance|O
DDI-DrugBank.d82.s28|71-78|schedule|O
DDI-DrugBank.d82.s28|80-81|of|O
DDI-DrugBank.d82.s28|83-89|INDOCIN|brand
DDI-DrugBank.d82.s28|91-98|resulted|O
DDI-DrugBank.d82.s28|100-101|in|O
DDI-DrugBank.d82.s28|103-112|reversible|O
DDI-DrugBank.d82.s28|114-118|acute|O
DDI-DrugBank.d82.s28|120-124|renal|O
DDI-DrugBank.d82.s28|126-132|failure|O
DDI-DrugBank.d82.s28|134-135|in|O
DDI-DrugBank.d82.s28|137-139|two|O
DDI-DrugBank.d82.s28|141-142|of|O
DDI-DrugBank.d82.s28|144-147|four|O
DDI-DrugBank.d82.s28|149-155|healthy|O
DDI-DrugBank.d82.s28|157-166|volunteers|O
DDI-DrugBank.d82.s28|167-167|.|O
DDI-DrugBank.d82.s29|0-6|INDOCIN|brand
DDI-DrugBank.d82.s29|8-10|and|O
DDI-DrugBank.d82.s29|12-22|triamterene|drug
DDI-DrugBank.d82.s29|24-29|should|O
DDI-DrugBank.d82.s29|31-33|not|O
DDI-DrugBank.d82.s29|35-36|be|O
DDI-DrugBank.d82.s29|38-49|administered|O
DDI-DrugBank.d82.s29|51-58|together|O
DDI-DrugBank.d82.s29|59-59|.|O
DDI-DrugBank.d82.s30|0-6|INDOCIN|brand
DDI-DrugBank.d82.s30|8-10|and|O
DDI-DrugBank.d82.s30|12-38|potassium-sparing diuretics|group
DDI-DrugBank.d82.s30|40-43|each|O
DDI-DrugBank.d82.s30|45-47|may|O
DDI-DrugBank.d82.s30|49-50|be|O
DDI-DrugBank.d82.s30|52-61|associated|O
DDI-DrugBank.d82.s30|63-66|with|O
DDI-DrugBank.d82.s30|68-76|increased|O
DDI-DrugBank.d82.s30|78-82|serum|O
DDI-DrugBank.d82.s30|84-92|potassium|O
DDI-DrugBank.d82.s30|94-99|levels|O
DDI-DrugBank.d82.s30|100-100|.|O
DDI-DrugBank.d82.s31|0-2|The|O
DDI-DrugBank.d82.s31|4-12|potential|O
DDI-DrugBank.d82.s31|14-20|effects|O
DDI-DrugBank.d82.s31|22-23|of|O
DDI-DrugBank.d82.s31|25-31|INDOCIN|brand
DDI-DrugBank.d82.s31|33-35|and|O
DDI-DrugBank.d82.s31|37-63|potassium-sparing diuretics|group
DDI-DrugBank.d82.s31|65-66|on|O
DDI-DrugBank.d82.s31|68-76|potassium|O
DDI-DrugBank.d82.s31|78-85|kinetics|O
DDI-DrugBank.d82.s31|87-89|and|O
DDI-DrugBank.d82.s31|91-95|renal|O
DDI-DrugBank.d82.s31|97-104|function|O
DDI-DrugBank.d82.s31|106-111|should|O
DDI-DrugBank.d82.s31|113-114|be|O
DDI-DrugBank.d82.s31|116-125|considered|O
DDI-DrugBank.d82.s31|127-130|when|O
DDI-DrugBank.d82.s31|132-136|these|O
DDI-DrugBank.d82.s31|138-143|agents|O
DDI-DrugBank.d82.s31|145-147|are|O
DDI-DrugBank.d82.s31|149-160|administered|O
DDI-DrugBank.d82.s31|162-173|concurrently|O
DDI-DrugBank.d82.s31|174-174|.|O
DDI-DrugBank.d82.s32|0-3|Most|O
DDI-DrugBank.d82.s32|5-6|of|O
DDI-DrugBank.d82.s32|8-10|the|O
DDI-DrugBank.d82.s32|12-16|above|O
DDI-DrugBank.d82.s32|18-24|effects|O
DDI-DrugBank.d82.s32|26-35|concerning|O
DDI-DrugBank.d82.s32|37-45|diuretics|group
DDI-DrugBank.d82.s32|47-50|have|O
DDI-DrugBank.d82.s32|52-55|been|O
DDI-DrugBank.d82.s32|57-66|attributed|O
DDI-DrugBank.d82.s32|67-67|,|O
DDI-DrugBank.d82.s32|69-70|at|O
DDI-DrugBank.d82.s32|72-76|least|O
DDI-DrugBank.d82.s32|78-79|in|O
DDI-DrugBank.d82.s32|81-84|part|O
DDI-DrugBank.d82.s32|85-85|,|O
DDI-DrugBank.d82.s32|87-88|to|O
DDI-DrugBank.d82.s32|90-99|mechanisms|O
DDI-DrugBank.d82.s32|101-109|involving|O
DDI-DrugBank.d82.s32|111-120|inhibition|O
DDI-DrugBank.d82.s32|122-123|of|O
DDI-DrugBank.d82.s32|125-137|prostaglandin|O
DDI-DrugBank.d82.s32|139-147|synthesis|O
DDI-DrugBank.d82.s32|149-150|by|O
DDI-DrugBank.d82.s32|152-158|INDOCIN|brand
DDI-DrugBank.d82.s32|159-159|.|O
DDI-DrugBank.d82.s33|0-7|Blunting|O
DDI-DrugBank.d82.s33|9-10|of|O
DDI-DrugBank.d82.s33|12-14|the|O
DDI-DrugBank.d82.s33|16-31|antihypertensive|O
DDI-DrugBank.d82.s33|33-38|effect|O
DDI-DrugBank.d82.s33|40-41|of|O
DDI-DrugBank.d82.s33|43-75|beta-adrenoceptor blocking agents|group
DDI-DrugBank.d82.s33|77-78|by|O
DDI-DrugBank.d82.s33|80-115|non-steroidal antiinflammatory drugs|group
DDI-DrugBank.d82.s33|117-125|including|O
DDI-DrugBank.d82.s33|127-133|INDOCIN|brand
DDI-DrugBank.d82.s33|135-137|has|O
DDI-DrugBank.d82.s33|139-142|been|O
DDI-DrugBank.d82.s33|144-151|reported|O
DDI-DrugBank.d82.s33|152-152|.|O
DDI-DrugBank.d82.s34|0-8|Therefore|O
DDI-DrugBank.d82.s34|9-9|,|O
DDI-DrugBank.d82.s34|11-14|when|O
DDI-DrugBank.d82.s34|16-20|using|O
DDI-DrugBank.d82.s34|22-26|these|O
DDI-DrugBank.d82.s34|28-35|blocking|O
DDI-DrugBank.d82.s34|37-42|agents|O
DDI-DrugBank.d82.s34|44-45|to|O
DDI-DrugBank.d82.s34|47-51|treat|O
DDI-DrugBank.d82.s34|53-64|hypertension|O
DDI-DrugBank.d82.s34|65-65|,|O
DDI-DrugBank.d82.s34|67-74|patients|O
DDI-DrugBank.d82.s34|76-81|should|O
DDI-DrugBank.d82.s34|83-84|be|O
DDI-DrugBank.d82.s34|86-93|observed|O
DDI-DrugBank.d82.s34|95-103|carefully|O
DDI-DrugBank.d82.s34|105-106|in|O
DDI-DrugBank.d82.s34|108-112|order|O
DDI-DrugBank.d82.s34|114-115|to|O
DDI-DrugBank.d82.s34|117-123|confirm|O
DDI-DrugBank.d82.s34|125-128|that|O
DDI-DrugBank.d82.s34|130-132|the|O
DDI-DrugBank.d82.s34|134-140|desired|O
DDI-DrugBank.d82.s34|142-152|therapeutic|O
DDI-DrugBank.d82.s34|154-159|effect|O
DDI-DrugBank.d82.s34|161-163|has|O
DDI-DrugBank.d82.s34|165-168|been|O
DDI-DrugBank.d82.s34|170-177|obtained|O
DDI-DrugBank.d82.s34|178-178|.|O
DDI-DrugBank.d82.s35|0-6|INDOCIN|brand
DDI-DrugBank.d82.s35|8-10|can|O
DDI-DrugBank.d82.s35|12-17|reduce|O
DDI-DrugBank.d82.s35|19-21|the|O
DDI-DrugBank.d82.s35|23-38|antihypertensive|O
DDI-DrugBank.d82.s35|40-46|effects|O
DDI-DrugBank.d82.s35|48-49|of|O
DDI-DrugBank.d82.s35|51-59|captopril|drug
DDI-DrugBank.d82.s35|61-63|and|O
DDI-DrugBank.d82.s35|65-72|losartan|drug
DDI-DrugBank.d82.s35|73-73|.|O
DDI-DrugBank.d82.s36|0-13|False-negative|O
DDI-DrugBank.d82.s36|15-21|results|O
DDI-DrugBank.d82.s36|23-24|in|O
DDI-DrugBank.d82.s36|26-28|the|O
DDI-DrugBank.d82.s36|30-42|dexamethasone|O
DDI-DrugBank.d82.s36|44-54|suppression|O
DDI-DrugBank.d82.s36|56-59|test|O
DDI-DrugBank.d82.s36|61-61|(|O
DDI-DrugBank.d82.s36|62-64|DST|O
DDI-DrugBank.d82.s36|65-65|)|O
DDI-DrugBank.d82.s36|67-68|in|O
DDI-DrugBank.d82.s36|70-77|patients|O
DDI-DrugBank.d82.s36|79-83|being|O
DDI-DrugBank.d82.s36|85-91|treated|O
DDI-DrugBank.d82.s36|93-96|with|O
DDI-DrugBank.d82.s36|98-104|INDOCIN|brand
DDI-DrugBank.d82.s36|106-109|have|O
DDI-DrugBank.d82.s36|111-114|been|O
DDI-DrugBank.d82.s36|116-123|reported|O
DDI-DrugBank.d82.s36|124-124|.|O
DDI-DrugBank.d82.s37|0-3|Thus|O
DDI-DrugBank.d82.s37|4-4|,|O
DDI-DrugBank.d82.s37|6-12|results|O
DDI-DrugBank.d82.s37|14-15|of|O
DDI-DrugBank.d82.s37|17-19|the|O
DDI-DrugBank.d82.s37|21-23|DST|O
DDI-DrugBank.d82.s37|25-30|should|O
DDI-DrugBank.d82.s37|32-33|be|O
DDI-DrugBank.d82.s37|35-45|interpreted|O
DDI-DrugBank.d82.s37|47-50|with|O
DDI-DrugBank.d82.s37|52-58|caution|O
DDI-DrugBank.d82.s37|60-61|in|O
DDI-DrugBank.d82.s37|63-67|these|O
DDI-DrugBank.d82.s37|69-76|patients|O
DDI-DrugBank.d82.s37|77-77|.|O
DDI-DrugBank.d94.s0|0-9|Clinically|O
DDI-DrugBank.d94.s0|11-20|meaningful|O
DDI-DrugBank.d94.s0|22-25|drug|O
DDI-DrugBank.d94.s0|27-38|interactions|O
DDI-DrugBank.d94.s0|40-43|have|O
DDI-DrugBank.d94.s0|45-52|occurred|O
DDI-DrugBank.d94.s0|54-57|with|O
DDI-DrugBank.d94.s0|59-69|concomitant|O
DDI-DrugBank.d94.s0|71-81|medications|O
DDI-DrugBank.d94.s0|83-85|and|O
DDI-DrugBank.d94.s0|87-93|include|O
DDI-DrugBank.d94.s0|94-94|,|O
DDI-DrugBank.d94.s0|96-98|but|O
DDI-DrugBank.d94.s0|100-102|are|O
DDI-DrugBank.d94.s0|104-106|not|O
DDI-DrugBank.d94.s0|108-114|limited|O
DDI-DrugBank.d94.s0|116-117|to|O
DDI-DrugBank.d94.s0|119-121|the|O
DDI-DrugBank.d94.s0|123-131|following|O
DDI-DrugBank.d94.s0|132-132|:|O
DDI-DrugBank.d94.s0|134-139|Agents|O
DDI-DrugBank.d94.s0|141-146|Highly|O
DDI-DrugBank.d94.s0|148-152|Bound|O
DDI-DrugBank.d94.s0|154-155|to|O
DDI-DrugBank.d94.s0|157-162|Plasma|O
DDI-DrugBank.d94.s0|164-170|Protein|O
DDI-DrugBank.d94.s0|172-184|Carbamazepine|drug
DDI-DrugBank.d94.s0|186-187|is|O
DDI-DrugBank.d94.s0|189-191|not|O
DDI-DrugBank.d94.s0|193-198|highly|O
DDI-DrugBank.d94.s0|200-204|bound|O
DDI-DrugBank.d94.s0|206-207|to|O
DDI-DrugBank.d94.s0|209-214|plasma|O
DDI-DrugBank.d94.s0|216-223|proteins|O
DDI-DrugBank.d94.s0|224-224|;|O
DDI-DrugBank.d94.s1|0-8|therefore|O
DDI-DrugBank.d94.s1|9-9|,|O
DDI-DrugBank.d94.s1|11-24|administration|O
DDI-DrugBank.d94.s1|26-27|of|O
DDI-DrugBank.d94.s1|29-37|EQUETROTM|brand
DDI-DrugBank.d94.s1|39-40|to|O
DDI-DrugBank.d94.s1|42-42|a|O
DDI-DrugBank.d94.s1|44-50|patient|O
DDI-DrugBank.d94.s1|52-57|taking|O
DDI-DrugBank.d94.s1|59-65|another|O
DDI-DrugBank.d94.s1|67-70|drug|O
DDI-DrugBank.d94.s1|72-75|that|O
DDI-DrugBank.d94.s1|77-78|is|O
DDI-DrugBank.d94.s1|80-85|highly|O
DDI-DrugBank.d94.s1|87-93|protein|O
DDI-DrugBank.d94.s1|95-99|bound|O
DDI-DrugBank.d94.s1|101-106|should|O
DDI-DrugBank.d94.s1|108-110|not|O
DDI-DrugBank.d94.s1|112-116|cause|O
DDI-DrugBank.d94.s1|118-126|increased|O
DDI-DrugBank.d94.s1|128-131|free|O
DDI-DrugBank.d94.s1|133-146|concentrations|O
DDI-DrugBank.d94.s1|148-149|of|O
DDI-DrugBank.d94.s1|151-153|the|O
DDI-DrugBank.d94.s1|155-159|other|O
DDI-DrugBank.d94.s1|161-164|drug|O
DDI-DrugBank.d94.s1|165-165|.|O
DDI-DrugBank.d94.s2|0-5|Agents|O
DDI-DrugBank.d94.s2|7-10|that|O
DDI-DrugBank.d94.s2|12-18|Inhibit|O
DDI-DrugBank.d94.s2|20-29|Cytochrome|O
DDI-DrugBank.d94.s2|31-34|P450|O
DDI-DrugBank.d94.s2|36-45|Isoenzymes|O
DDI-DrugBank.d94.s2|47-52|and/or|O
DDI-DrugBank.d94.s2|54-60|Epoxide|O
DDI-DrugBank.d94.s2|62-70|Hydrolase|O
DDI-DrugBank.d94.s2|72-84|Carbamazepine|drug
DDI-DrugBank.d94.s2|86-87|is|O
DDI-DrugBank.d94.s2|89-99|metabolized|O
DDI-DrugBank.d94.s2|101-106|mainly|O
DDI-DrugBank.d94.s2|108-109|by|O
DDI-DrugBank.d94.s2|111-120|cytochrome|O
DDI-DrugBank.d94.s2|122-125|P450|O
DDI-DrugBank.d94.s2|127-127|(|O
DDI-DrugBank.d94.s2|128-130|CYP|O
DDI-DrugBank.d94.s2|131-131|)|O
DDI-DrugBank.d94.s2|133-135|3A4|O
DDI-DrugBank.d94.s2|137-138|to|O
DDI-DrugBank.d94.s2|140-142|the|O
DDI-DrugBank.d94.s2|144-149|active|O
DDI-DrugBank.d94.s2|151-177|carbamazepine 10,11-epoxide|drug
DDI-DrugBank.d94.s2|178-178|,|O
DDI-DrugBank.d94.s2|180-184|which|O
DDI-DrugBank.d94.s2|186-187|is|O
DDI-DrugBank.d94.s2|189-195|further|O
DDI-DrugBank.d94.s2|197-207|metabolized|O
DDI-DrugBank.d94.s2|209-210|to|O
DDI-DrugBank.d94.s2|212-214|the|O
DDI-DrugBank.d94.s2|216-225|trans-diol|O
DDI-DrugBank.d94.s2|227-228|by|O
DDI-DrugBank.d94.s2|230-236|epoxide|O
DDI-DrugBank.d94.s2|238-246|hydrolase|O
DDI-DrugBank.d94.s2|247-247|.|O
DDI-DrugBank.d94.s3|0-8|Therefore|O
DDI-DrugBank.d94.s3|9-9|,|O
DDI-DrugBank.d94.s3|11-13|the|O
DDI-DrugBank.d94.s3|15-23|potential|O
DDI-DrugBank.d94.s3|25-30|exists|O
DDI-DrugBank.d94.s3|32-34|for|O
DDI-DrugBank.d94.s3|36-46|interaction|O
DDI-DrugBank.d94.s3|48-54|between|O
DDI-DrugBank.d94.s3|56-68|carbamazepine|drug
DDI-DrugBank.d94.s3|70-72|and|O
DDI-DrugBank.d94.s3|74-76|any|O
DDI-DrugBank.d94.s3|78-82|agent|O
DDI-DrugBank.d94.s3|84-87|that|O
DDI-DrugBank.d94.s3|89-96|inhibits|O
DDI-DrugBank.d94.s3|98-103|CYP3A4|O
DDI-DrugBank.d94.s3|105-110|and/or|O
DDI-DrugBank.d94.s3|112-118|epoxide|O
DDI-DrugBank.d94.s3|120-128|hydrolase|O
DDI-DrugBank.d94.s3|129-129|.|O
DDI-DrugBank.d94.s4|0-5|Agents|O
DDI-DrugBank.d94.s4|7-10|that|O
DDI-DrugBank.d94.s4|12-14|are|O
DDI-DrugBank.d94.s4|16-21|CYP3A4|O
DDI-DrugBank.d94.s4|23-32|inhibitors|O
DDI-DrugBank.d94.s4|34-37|that|O
DDI-DrugBank.d94.s4|39-42|have|O
DDI-DrugBank.d94.s4|44-47|been|O
DDI-DrugBank.d94.s4|49-53|found|O
DDI-DrugBank.d94.s4|54-54|,|O
DDI-DrugBank.d94.s4|56-57|or|O
DDI-DrugBank.d94.s4|59-61|are|O
DDI-DrugBank.d94.s4|63-70|expected|O
DDI-DrugBank.d94.s4|71-71|,|O
DDI-DrugBank.d94.s4|73-74|to|O
DDI-DrugBank.d94.s4|76-83|increase|O
DDI-DrugBank.d94.s4|85-90|plasma|O
DDI-DrugBank.d94.s4|92-97|levels|O
DDI-DrugBank.d94.s4|99-100|of|O
DDI-DrugBank.d94.s4|102-110|EQUETROTM|brand
DDI-DrugBank.d94.s4|112-114|are|O
DDI-DrugBank.d94.s4|116-118|the|O
DDI-DrugBank.d94.s4|120-128|following|O
DDI-DrugBank.d94.s4|129-129|:|O
DDI-DrugBank.d94.s4|131-143|Acetazolamide|drug
DDI-DrugBank.d94.s4|144-144|,|O
DDI-DrugBank.d94.s4|146-162|azole antifungals|group
DDI-DrugBank.d94.s4|163-163|,|O
DDI-DrugBank.d94.s4|165-174|cimetidine|drug
DDI-DrugBank.d94.s4|175-175|,|O
DDI-DrugBank.d94.s4|177-190|clarithromycin|drug
DDI-DrugBank.d94.s4|191-191|(|O
DDI-DrugBank.d94.s4|192-192|1|O
DDI-DrugBank.d94.s4|193-193|)|O
DDI-DrugBank.d94.s4|194-194|,|O
DDI-DrugBank.d94.s4|196-207|dalfopristin|drug
DDI-DrugBank.d94.s4|208-208|,|O
DDI-DrugBank.d94.s4|210-216|danazol|drug
DDI-DrugBank.d94.s4|217-217|,|O
DDI-DrugBank.d94.s4|219-229|delavirdine|drug
DDI-DrugBank.d94.s4|230-230|,|O
DDI-DrugBank.d94.s4|232-240|diltiazem|drug
DDI-DrugBank.d94.s4|241-241|,|O
DDI-DrugBank.d94.s4|243-254|erythromycin|drug
DDI-DrugBank.d94.s4|255-255|(|O
DDI-DrugBank.d94.s4|256-256|1|O
DDI-DrugBank.d94.s4|257-257|)|O
DDI-DrugBank.d94.s4|258-258|,|O
DDI-DrugBank.d94.s4|260-269|fluoxetine|drug
DDI-DrugBank.d94.s4|270-270|,|O
DDI-DrugBank.d94.s4|272-282|fluvoxamine|drug
DDI-DrugBank.d94.s4|283-283|,|O
DDI-DrugBank.d94.s4|285-294|grapefruit|O
DDI-DrugBank.d94.s4|296-300|juice|O
DDI-DrugBank.d94.s4|301-301|,|O
DDI-DrugBank.d94.s4|303-311|isoniazid|drug
DDI-DrugBank.d94.s4|312-312|,|O
DDI-DrugBank.d94.s4|314-325|itraconazole|drug
DDI-DrugBank.d94.s4|326-326|,|O
DDI-DrugBank.d94.s4|328-339|ketoconazole|drug
DDI-DrugBank.d94.s4|340-340|,|O
DDI-DrugBank.d94.s4|342-351|loratadine|drug
DDI-DrugBank.d94.s4|352-352|,|O
DDI-DrugBank.d94.s4|354-363|nefazodone|drug
DDI-DrugBank.d94.s4|364-364|,|O
DDI-DrugBank.d94.s4|366-376|niacinamide|drug
DDI-DrugBank.d94.s4|377-377|,|O
DDI-DrugBank.d94.s4|379-390|nicotinamide|drug
DDI-DrugBank.d94.s4|391-391|,|O
DDI-DrugBank.d94.s4|393-411|protease inhibitors|group
DDI-DrugBank.d94.s4|412-412|,|O
DDI-DrugBank.d94.s4|414-425|propoxyphene|drug
DDI-DrugBank.d94.s4|426-426|,|O
DDI-DrugBank.d94.s4|428-434|quinine|drug
DDI-DrugBank.d94.s4|435-435|,|O
DDI-DrugBank.d94.s4|437-448|quinupristin|drug
DDI-DrugBank.d94.s4|449-449|,|O
DDI-DrugBank.d94.s4|451-464|troleandomycin|drug
DDI-DrugBank.d94.s4|465-465|,|O
DDI-DrugBank.d94.s4|467-475|valproate|drug
DDI-DrugBank.d94.s4|476-476|(|O
DDI-DrugBank.d94.s4|477-477|1|O
DDI-DrugBank.d94.s4|478-478|)|O
DDI-DrugBank.d94.s4|479-479|,|O
DDI-DrugBank.d94.s4|481-489|verapamil|drug
DDI-DrugBank.d94.s4|490-490|,|O
DDI-DrugBank.d94.s4|492-499|zileuton|drug
DDI-DrugBank.d94.s4|500-500|.|O
DDI-DrugBank.d94.s5|0-3|Thus|O
DDI-DrugBank.d94.s5|4-4|,|O
DDI-DrugBank.d94.s5|6-7|if|O
DDI-DrugBank.d94.s5|9-9|a|O
DDI-DrugBank.d94.s5|11-17|patient|O
DDI-DrugBank.d94.s5|19-21|has|O
DDI-DrugBank.d94.s5|23-26|been|O
DDI-DrugBank.d94.s5|28-35|titrated|O
DDI-DrugBank.d94.s5|37-38|to|O
DDI-DrugBank.d94.s5|40-40|a|O
DDI-DrugBank.d94.s5|42-47|stable|O
DDI-DrugBank.d94.s5|49-54|dosage|O
DDI-DrugBank.d94.s5|56-57|of|O
DDI-DrugBank.d94.s5|59-67|EQUETROTM|brand
DDI-DrugBank.d94.s5|68-68|,|O
DDI-DrugBank.d94.s5|70-72|and|O
DDI-DrugBank.d94.s5|74-77|then|O
DDI-DrugBank.d94.s5|79-84|begins|O
DDI-DrugBank.d94.s5|86-86|a|O
DDI-DrugBank.d94.s5|88-93|course|O
DDI-DrugBank.d94.s5|95-96|of|O
DDI-DrugBank.d94.s5|98-106|treatment|O
DDI-DrugBank.d94.s5|108-111|with|O
DDI-DrugBank.d94.s5|113-115|one|O
DDI-DrugBank.d94.s5|117-118|of|O
DDI-DrugBank.d94.s5|120-124|these|O
DDI-DrugBank.d94.s5|126-131|CYP3A4|O
DDI-DrugBank.d94.s5|133-134|or|O
DDI-DrugBank.d94.s5|136-142|epoxide|O
DDI-DrugBank.d94.s5|144-152|hydrolase|O
DDI-DrugBank.d94.s5|154-163|inhibitors|O
DDI-DrugBank.d94.s5|164-164|,|O
DDI-DrugBank.d94.s5|166-167|it|O
DDI-DrugBank.d94.s5|169-170|is|O
DDI-DrugBank.d94.s5|172-181|reasonable|O
DDI-DrugBank.d94.s5|183-184|to|O
DDI-DrugBank.d94.s5|186-191|expect|O
DDI-DrugBank.d94.s5|193-196|that|O
DDI-DrugBank.d94.s5|198-198|a|O
DDI-DrugBank.d94.s5|200-203|dose|O
DDI-DrugBank.d94.s5|205-213|reduction|O
DDI-DrugBank.d94.s5|215-217|for|O
DDI-DrugBank.d94.s5|219-227|EQUETROTM|brand
DDI-DrugBank.d94.s5|229-231|may|O
DDI-DrugBank.d94.s5|233-234|be|O
DDI-DrugBank.d94.s5|236-244|necessary|O
DDI-DrugBank.d94.s5|245-245|.|O
DDI-DrugBank.d94.s6|0-5|Agents|O
DDI-DrugBank.d94.s6|7-10|that|O
DDI-DrugBank.d94.s6|12-17|Induce|O
DDI-DrugBank.d94.s6|19-28|Cytochrome|O
DDI-DrugBank.d94.s6|30-33|P450|O
DDI-DrugBank.d94.s6|35-44|Isoenzymes|O
DDI-DrugBank.d94.s6|46-58|Carbamazepine|drug
DDI-DrugBank.d94.s6|60-61|is|O
DDI-DrugBank.d94.s6|63-73|metabolized|O
DDI-DrugBank.d94.s6|75-76|by|O
DDI-DrugBank.d94.s6|78-83|CYP3A4|O
DDI-DrugBank.d94.s6|84-84|.|O
DDI-DrugBank.d94.s7|0-8|Therefore|O
DDI-DrugBank.d94.s7|9-9|,|O
DDI-DrugBank.d94.s7|11-13|the|O
DDI-DrugBank.d94.s7|15-23|potential|O
DDI-DrugBank.d94.s7|25-30|exists|O
DDI-DrugBank.d94.s7|32-34|for|O
DDI-DrugBank.d94.s7|36-46|interaction|O
DDI-DrugBank.d94.s7|48-54|between|O
DDI-DrugBank.d94.s7|56-68|carbamazepine|drug
DDI-DrugBank.d94.s7|70-72|and|O
DDI-DrugBank.d94.s7|74-76|any|O
DDI-DrugBank.d94.s7|78-82|agent|O
DDI-DrugBank.d94.s7|84-87|that|O
DDI-DrugBank.d94.s7|89-95|induces|O
DDI-DrugBank.d94.s7|97-102|CYP3A4|O
DDI-DrugBank.d94.s7|103-103|.|O
DDI-DrugBank.d94.s8|0-5|Agents|O
DDI-DrugBank.d94.s8|7-10|that|O
DDI-DrugBank.d94.s8|12-14|are|O
DDI-DrugBank.d94.s8|16-18|CYP|O
DDI-DrugBank.d94.s8|20-27|inducers|O
DDI-DrugBank.d94.s8|29-32|that|O
DDI-DrugBank.d94.s8|34-37|have|O
DDI-DrugBank.d94.s8|39-42|been|O
DDI-DrugBank.d94.s8|44-48|found|O
DDI-DrugBank.d94.s8|49-49|,|O
DDI-DrugBank.d94.s8|51-52|or|O
DDI-DrugBank.d94.s8|54-56|are|O
DDI-DrugBank.d94.s8|58-65|expected|O
DDI-DrugBank.d94.s8|66-66|,|O
DDI-DrugBank.d94.s8|68-69|to|O
DDI-DrugBank.d94.s8|71-78|decrease|O
DDI-DrugBank.d94.s8|80-85|plasma|O
DDI-DrugBank.d94.s8|87-92|levels|O
DDI-DrugBank.d94.s8|94-95|of|O
DDI-DrugBank.d94.s8|97-105|EQUETROTM|brand
DDI-DrugBank.d94.s8|107-109|are|O
DDI-DrugBank.d94.s8|111-113|the|O
DDI-DrugBank.d94.s8|115-123|following|O
DDI-DrugBank.d94.s8|124-124|:|O
DDI-DrugBank.d94.s8|126-134|Cisplatin|drug
DDI-DrugBank.d94.s8|135-135|,|O
DDI-DrugBank.d94.s8|137-151|doxorubicin HCL|drug
DDI-DrugBank.d94.s8|152-152|,|O
DDI-DrugBank.d94.s8|154-162|felbamate|drug
DDI-DrugBank.d94.s8|163-163|,|O
DDI-DrugBank.d94.s8|165-172|rifampin|drug
DDI-DrugBank.d94.s8|173-173|,|O
DDI-DrugBank.d94.s8|175-187|phenobarbital|drug
DDI-DrugBank.d94.s8|188-188|,|O
DDI-DrugBank.d94.s8|190-198|Phenytoin|drug
DDI-DrugBank.d94.s8|199-199|(|O
DDI-DrugBank.d94.s8|200-200|2|O
DDI-DrugBank.d94.s8|201-201|)|O
DDI-DrugBank.d94.s8|202-202|,|O
DDI-DrugBank.d94.s8|204-212|primidone|drug
DDI-DrugBank.d94.s8|213-213|,|O
DDI-DrugBank.d94.s8|215-226|methsuximide|drug
DDI-DrugBank.d94.s8|227-227|,|O
DDI-DrugBank.d94.s8|229-231|and|O
DDI-DrugBank.d94.s8|233-244|theophylline|drug
DDI-DrugBank.d94.s8|246-249|Thus|O
DDI-DrugBank.d94.s8|250-250|,|O
DDI-DrugBank.d94.s8|252-253|if|O
DDI-DrugBank.d94.s8|255-255|a|O
DDI-DrugBank.d94.s8|257-263|patient|O
DDI-DrugBank.d94.s8|265-267|has|O
DDI-DrugBank.d94.s8|269-272|been|O
DDI-DrugBank.d94.s8|274-281|titrated|O
DDI-DrugBank.d94.s8|283-284|to|O
DDI-DrugBank.d94.s8|286-286|a|O
DDI-DrugBank.d94.s8|288-293|stable|O
DDI-DrugBank.d94.s8|295-300|dosage|O
DDI-DrugBank.d94.s8|302-303|on|O
DDI-DrugBank.d94.s8|305-313|EQUETROTM|brand
DDI-DrugBank.d94.s8|314-314|,|O
DDI-DrugBank.d94.s8|316-318|and|O
DDI-DrugBank.d94.s8|320-323|then|O
DDI-DrugBank.d94.s8|325-330|begins|O
DDI-DrugBank.d94.s8|332-332|a|O
DDI-DrugBank.d94.s8|334-339|course|O
DDI-DrugBank.d94.s8|341-342|of|O
DDI-DrugBank.d94.s8|344-352|treatment|O
DDI-DrugBank.d94.s8|354-357|with|O
DDI-DrugBank.d94.s8|359-361|one|O
DDI-DrugBank.d94.s8|363-364|of|O
DDI-DrugBank.d94.s8|366-370|these|O
DDI-DrugBank.d94.s8|372-377|CYP3A4|O
DDI-DrugBank.d94.s8|379-386|inducers|O
DDI-DrugBank.d94.s8|387-387|,|O
DDI-DrugBank.d94.s8|389-390|it|O
DDI-DrugBank.d94.s8|392-393|is|O
DDI-DrugBank.d94.s8|395-404|reasonable|O
DDI-DrugBank.d94.s8|406-407|to|O
DDI-DrugBank.d94.s8|409-414|expect|O
DDI-DrugBank.d94.s8|416-419|that|O
DDI-DrugBank.d94.s8|421-421|a|O
DDI-DrugBank.d94.s8|423-426|dose|O
DDI-DrugBank.d94.s8|428-435|increase|O
DDI-DrugBank.d94.s8|437-439|for|O
DDI-DrugBank.d94.s8|441-449|EQUETROTM|brand
DDI-DrugBank.d94.s8|451-453|may|O
DDI-DrugBank.d94.s8|455-456|be|O
DDI-DrugBank.d94.s8|458-466|necessary|O
DDI-DrugBank.d94.s8|467-467|.|O
DDI-DrugBank.d94.s9|0-5|Agents|O
DDI-DrugBank.d94.s9|7-10|with|O
DDI-DrugBank.d94.s9|12-20|Decreased|O
DDI-DrugBank.d94.s9|22-27|Levels|O
DDI-DrugBank.d94.s9|29-30|in|O
DDI-DrugBank.d94.s9|32-34|the|O
DDI-DrugBank.d94.s9|36-43|Presence|O
DDI-DrugBank.d94.s9|45-46|of|O
DDI-DrugBank.d94.s9|48-60|Carbamazepine|drug
DDI-DrugBank.d94.s9|62-64|due|O
DDI-DrugBank.d94.s9|66-67|to|O
DDI-DrugBank.d94.s9|69-77|Induction|O
DDI-DrugBank.d94.s9|79-80|of|O
DDI-DrugBank.d94.s9|82-91|Cytochrome|O
DDI-DrugBank.d94.s9|93-96|P450|O
DDI-DrugBank.d94.s9|98-104|Enzymes|O
DDI-DrugBank.d94.s9|106-118|Carbamazepine|drug
DDI-DrugBank.d94.s9|120-121|is|O
DDI-DrugBank.d94.s9|123-127|known|O
DDI-DrugBank.d94.s9|129-130|to|O
DDI-DrugBank.d94.s9|132-137|induce|O
DDI-DrugBank.d94.s9|139-144|CYP1A2|O
DDI-DrugBank.d94.s9|146-148|and|O
DDI-DrugBank.d94.s9|150-155|CYP3A4|O
DDI-DrugBank.d94.s9|156-156|.|O
DDI-DrugBank.d94.s10|0-8|Therefore|O
DDI-DrugBank.d94.s10|9-9|,|O
DDI-DrugBank.d94.s10|11-13|the|O
DDI-DrugBank.d94.s10|15-23|potential|O
DDI-DrugBank.d94.s10|25-30|exists|O
DDI-DrugBank.d94.s10|32-34|for|O
DDI-DrugBank.d94.s10|36-46|interaction|O
DDI-DrugBank.d94.s10|48-54|between|O
DDI-DrugBank.d94.s10|56-68|carbamazepine|drug
DDI-DrugBank.d94.s10|70-72|and|O
DDI-DrugBank.d94.s10|74-76|any|O
DDI-DrugBank.d94.s10|78-82|agent|O
DDI-DrugBank.d94.s10|84-94|metabolized|O
DDI-DrugBank.d94.s10|96-97|by|O
DDI-DrugBank.d94.s10|99-101|one|O
DDI-DrugBank.d94.s10|103-103|(|O
DDI-DrugBank.d94.s10|104-105|or|O
DDI-DrugBank.d94.s10|107-110|more|O
DDI-DrugBank.d94.s10|111-111|)|O
DDI-DrugBank.d94.s10|113-114|of|O
DDI-DrugBank.d94.s10|116-120|these|O
DDI-DrugBank.d94.s10|122-128|enzymes|O
DDI-DrugBank.d94.s10|129-129|.|O
DDI-DrugBank.d94.s11|0-5|Agents|O
DDI-DrugBank.d94.s11|7-10|that|O
DDI-DrugBank.d94.s11|12-15|have|O
DDI-DrugBank.d94.s11|17-20|been|O
DDI-DrugBank.d94.s11|22-26|found|O
DDI-DrugBank.d94.s11|27-27|,|O
DDI-DrugBank.d94.s11|29-30|or|O
DDI-DrugBank.d94.s11|32-34|are|O
DDI-DrugBank.d94.s11|36-43|expected|O
DDI-DrugBank.d94.s11|45-46|to|O
DDI-DrugBank.d94.s11|48-51|have|O
DDI-DrugBank.d94.s11|53-61|decreased|O
DDI-DrugBank.d94.s11|63-68|plasma|O
DDI-DrugBank.d94.s11|70-75|levels|O
DDI-DrugBank.d94.s11|77-78|in|O
DDI-DrugBank.d94.s11|80-82|the|O
DDI-DrugBank.d94.s11|84-91|presence|O
DDI-DrugBank.d94.s11|93-94|of|O
DDI-DrugBank.d94.s11|96-104|EQUETROTM|brand
DDI-DrugBank.d94.s11|106-108|due|O
DDI-DrugBank.d94.s11|110-111|to|O
DDI-DrugBank.d94.s11|113-121|induction|O
DDI-DrugBank.d94.s11|123-124|of|O
DDI-DrugBank.d94.s11|126-128|CYP|O
DDI-DrugBank.d94.s11|130-136|enzymes|O
DDI-DrugBank.d94.s11|138-140|are|O
DDI-DrugBank.d94.s11|142-144|the|O
DDI-DrugBank.d94.s11|146-154|following|O
DDI-DrugBank.d94.s11|155-155|:|O
DDI-DrugBank.d94.s11|157-169|Acetaminophen|drug
DDI-DrugBank.d94.s11|170-170|,|O
DDI-DrugBank.d94.s11|172-181|alprazolam|drug
DDI-DrugBank.d94.s11|182-182|,|O
DDI-DrugBank.d94.s11|184-196|amitriptyline|drug
DDI-DrugBank.d94.s11|197-197|,|O
DDI-DrugBank.d94.s11|199-207|bupropion|drug
DDI-DrugBank.d94.s11|208-208|,|O
DDI-DrugBank.d94.s11|210-218|buspirone|drug
DDI-DrugBank.d94.s11|219-219|,|O
DDI-DrugBank.d94.s11|221-230|citalopram|drug
DDI-DrugBank.d94.s11|231-231|,|O
DDI-DrugBank.d94.s11|233-240|clobazam|drug
DDI-DrugBank.d94.s11|241-241|,|O
DDI-DrugBank.d94.s11|243-252|clonazepam|drug
DDI-DrugBank.d94.s11|253-253|,|O
DDI-DrugBank.d94.s11|255-263|clozapine|drug
DDI-DrugBank.d94.s11|264-264|,|O
DDI-DrugBank.d94.s11|266-276|cyclosporin|drug
DDI-DrugBank.d94.s11|277-277|,|O
DDI-DrugBank.d94.s11|279-289|delavirdine|drug
DDI-DrugBank.d94.s11|290-290|,|O
DDI-DrugBank.d94.s11|292-302|desipramine|drug
DDI-DrugBank.d94.s11|303-303|,|O
DDI-DrugBank.d94.s11|305-312|diazepam|drug
DDI-DrugBank.d94.s11|313-313|,|O
DDI-DrugBank.d94.s11|315-323|dicumarol|drug
DDI-DrugBank.d94.s11|324-324|,|O
DDI-DrugBank.d94.s11|326-336|doxycycline|drug
DDI-DrugBank.d94.s11|337-337|,|O
DDI-DrugBank.d94.s11|339-350|ethosuximide|drug
DDI-DrugBank.d94.s11|351-351|,|O
DDI-DrugBank.d94.s11|353-361|felbamate|drug
DDI-DrugBank.d94.s11|362-362|,|O
DDI-DrugBank.d94.s11|364-373|felodipine|drug
DDI-DrugBank.d94.s11|374-374|,|O
DDI-DrugBank.d94.s11|376-390|glucocorticoids|group
DDI-DrugBank.d94.s11|391-391|,|O
DDI-DrugBank.d94.s11|393-403|haloperidol|drug
DDI-DrugBank.d94.s11|404-404|,|O
DDI-DrugBank.d94.s11|406-417|itraconazole|drug
DDI-DrugBank.d94.s11|418-418|,|O
DDI-DrugBank.d94.s11|420-430|lamotrigine|drug
DDI-DrugBank.d94.s11|431-431|,|O
DDI-DrugBank.d94.s11|433-445|levothyroxine|drug
DDI-DrugBank.d94.s11|446-446|,|O
DDI-DrugBank.d94.s11|448-456|lorazepam|drug
DDI-DrugBank.d94.s11|457-457|,|O
DDI-DrugBank.d94.s11|459-467|methadone|drug
DDI-DrugBank.d94.s11|468-468|,|O
DDI-DrugBank.d94.s11|470-478|midazolam|drug
DDI-DrugBank.d94.s11|479-479|,|O
DDI-DrugBank.d94.s11|481-491|mirtazapine|drug
DDI-DrugBank.d94.s11|492-492|,|O
DDI-DrugBank.d94.s11|494-506|nortriptyline|drug
DDI-DrugBank.d94.s11|507-507|,|O
DDI-DrugBank.d94.s11|509-518|olanzapine|drug
DDI-DrugBank.d94.s11|519-519|,|O
DDI-DrugBank.d94.s11|521-524|oral|O
DDI-DrugBank.d94.s11|526-539|contraceptives|group
DDI-DrugBank.d94.s11|540-540|(|O
DDI-DrugBank.d94.s11|541-541|3|O
DDI-DrugBank.d94.s11|542-542|)|O
DDI-DrugBank.d94.s11|543-543|,|O
DDI-DrugBank.d94.s11|545-557|oxcarbazepine|drug
DDI-DrugBank.d94.s11|558-558|,|O
DDI-DrugBank.d94.s11|560-568|Phenytoin|drug
DDI-DrugBank.d94.s11|569-569|(|O
DDI-DrugBank.d94.s11|570-570|4|O
DDI-DrugBank.d94.s11|571-571|)|O
DDI-DrugBank.d94.s11|572-572|,|O
DDI-DrugBank.d94.s11|574-585|praziquantel|drug
DDI-DrugBank.d94.s11|586-586|,|O
DDI-DrugBank.d94.s11|588-606|protease inhibitors|group
DDI-DrugBank.d94.s11|607-607|,|O
DDI-DrugBank.d94.s11|609-618|quetiapine|drug
DDI-DrugBank.d94.s11|619-619|,|O
DDI-DrugBank.d94.s11|621-631|risperidone|drug
DDI-DrugBank.d94.s11|632-632|,|O
DDI-DrugBank.d94.s11|634-645|theophylline|drug
DDI-DrugBank.d94.s11|646-646|,|O
DDI-DrugBank.d94.s11|648-657|topiramate|drug
DDI-DrugBank.d94.s11|658-658|,|O
DDI-DrugBank.d94.s11|660-668|tiagabine|drug
DDI-DrugBank.d94.s11|669-669|,|O
DDI-DrugBank.d94.s11|671-678|tramadol|drug
DDI-DrugBank.d94.s11|679-679|,|O
DDI-DrugBank.d94.s11|681-689|triazolam|drug
DDI-DrugBank.d94.s11|690-690|,|O
DDI-DrugBank.d94.s11|692-700|valproate|drug
DDI-DrugBank.d94.s11|701-701|,|O
DDI-DrugBank.d94.s11|703-710|warfarin|drug
DDI-DrugBank.d94.s11|711-711|(|O
DDI-DrugBank.d94.s11|712-712|5|O
DDI-DrugBank.d94.s11|713-713|)|O
DDI-DrugBank.d94.s11|715-715|,|O
DDI-DrugBank.d94.s11|717-727|ziprasidone|drug
DDI-DrugBank.d94.s11|728-728|,|O
DDI-DrugBank.d94.s11|730-732|and|O
DDI-DrugBank.d94.s11|734-743|zonisamide|drug
DDI-DrugBank.d94.s11|744-744|.|O
DDI-DrugBank.d94.s12|0-3|Thus|O
DDI-DrugBank.d94.s12|4-4|,|O
DDI-DrugBank.d94.s12|6-7|if|O
DDI-DrugBank.d94.s12|9-9|a|O
DDI-DrugBank.d94.s12|11-17|patient|O
DDI-DrugBank.d94.s12|19-21|has|O
DDI-DrugBank.d94.s12|23-26|been|O
DDI-DrugBank.d94.s12|28-35|titrated|O
DDI-DrugBank.d94.s12|37-38|to|O
DDI-DrugBank.d94.s12|40-40|a|O
DDI-DrugBank.d94.s12|42-47|stable|O
DDI-DrugBank.d94.s12|49-54|dosage|O
DDI-DrugBank.d94.s12|56-57|on|O
DDI-DrugBank.d94.s12|59-61|one|O
DDI-DrugBank.d94.s12|63-64|of|O
DDI-DrugBank.d94.s12|66-68|the|O
DDI-DrugBank.d94.s12|70-75|agents|O
DDI-DrugBank.d94.s12|77-78|in|O
DDI-DrugBank.d94.s12|80-83|this|O
DDI-DrugBank.d94.s12|85-92|category|O
DDI-DrugBank.d94.s12|93-93|,|O
DDI-DrugBank.d94.s12|95-97|and|O
DDI-DrugBank.d94.s12|99-102|then|O
DDI-DrugBank.d94.s12|104-109|begins|O
DDI-DrugBank.d94.s12|111-111|a|O
DDI-DrugBank.d94.s12|113-118|course|O
DDI-DrugBank.d94.s12|120-121|of|O
DDI-DrugBank.d94.s12|123-131|treatment|O
DDI-DrugBank.d94.s12|133-136|with|O
DDI-DrugBank.d94.s12|138-146|EQUETROTM|brand
DDI-DrugBank.d94.s12|147-147|,|O
DDI-DrugBank.d94.s12|149-150|it|O
DDI-DrugBank.d94.s12|152-153|is|O
DDI-DrugBank.d94.s12|155-164|reasonable|O
DDI-DrugBank.d94.s12|166-167|to|O
DDI-DrugBank.d94.s12|169-174|expect|O
DDI-DrugBank.d94.s12|176-179|that|O
DDI-DrugBank.d94.s12|181-181|a|O
DDI-DrugBank.d94.s12|183-186|dose|O
DDI-DrugBank.d94.s12|188-195|increase|O
DDI-DrugBank.d94.s12|197-199|for|O
DDI-DrugBank.d94.s12|201-203|the|O
DDI-DrugBank.d94.s12|205-215|concomitant|O
DDI-DrugBank.d94.s12|217-221|agent|O
DDI-DrugBank.d94.s12|223-225|may|O
DDI-DrugBank.d94.s12|227-228|be|O
DDI-DrugBank.d94.s12|230-238|necessary|O
DDI-DrugBank.d94.s12|239-239|.|O
DDI-DrugBank.d94.s13|0-5|Agents|O
DDI-DrugBank.d94.s13|7-10|with|O
DDI-DrugBank.d94.s13|12-20|Increased|O
DDI-DrugBank.d94.s13|22-27|Levels|O
DDI-DrugBank.d94.s13|29-30|in|O
DDI-DrugBank.d94.s13|32-34|the|O
DDI-DrugBank.d94.s13|36-43|Presence|O
DDI-DrugBank.d94.s13|45-46|of|O
DDI-DrugBank.d94.s13|48-60|Carbamazepine|drug
DDI-DrugBank.d94.s13|61-61|:|O
DDI-DrugBank.d94.s13|63-71|EQUETROTM|brand
DDI-DrugBank.d94.s13|73-81|increases|O
DDI-DrugBank.d94.s13|83-85|the|O
DDI-DrugBank.d94.s13|87-92|plasma|O
DDI-DrugBank.d94.s13|94-99|levels|O
DDI-DrugBank.d94.s13|101-102|of|O
DDI-DrugBank.d94.s13|104-106|the|O
DDI-DrugBank.d94.s13|108-116|following|O
DDI-DrugBank.d94.s13|118-123|agents|O
DDI-DrugBank.d94.s13|124-124|:|O
DDI-DrugBank.d94.s13|126-141|Clomipramine HCl|drug
DDI-DrugBank.d94.s13|142-142|,|O
DDI-DrugBank.d94.s13|144-152|Phenytoin|drug
DDI-DrugBank.d94.s13|153-153|(|O
DDI-DrugBank.d94.s13|154-154|6|O
DDI-DrugBank.d94.s13|155-155|)|O
DDI-DrugBank.d94.s13|156-156|,|O
DDI-DrugBank.d94.s13|158-160|and|O
DDI-DrugBank.d94.s13|162-170|primidone|drug
DDI-DrugBank.d94.s13|172-175|Thus|O
DDI-DrugBank.d94.s13|176-176|,|O
DDI-DrugBank.d94.s13|178-179|if|O
DDI-DrugBank.d94.s13|181-181|a|O
DDI-DrugBank.d94.s13|183-189|patient|O
DDI-DrugBank.d94.s13|191-193|has|O
DDI-DrugBank.d94.s13|195-198|been|O
DDI-DrugBank.d94.s13|200-207|titrated|O
DDI-DrugBank.d94.s13|209-210|to|O
DDI-DrugBank.d94.s13|212-212|a|O
DDI-DrugBank.d94.s13|214-219|stable|O
DDI-DrugBank.d94.s13|221-226|dosage|O
DDI-DrugBank.d94.s13|228-229|on|O
DDI-DrugBank.d94.s13|231-233|one|O
DDI-DrugBank.d94.s13|235-236|of|O
DDI-DrugBank.d94.s13|238-240|the|O
DDI-DrugBank.d94.s13|242-247|agents|O
DDI-DrugBank.d94.s13|249-250|in|O
DDI-DrugBank.d94.s13|252-255|this|O
DDI-DrugBank.d94.s13|257-264|category|O
DDI-DrugBank.d94.s13|265-265|,|O
DDI-DrugBank.d94.s13|267-269|and|O
DDI-DrugBank.d94.s13|271-274|then|O
DDI-DrugBank.d94.s13|276-281|begins|O
DDI-DrugBank.d94.s13|283-283|a|O
DDI-DrugBank.d94.s13|285-290|course|O
DDI-DrugBank.d94.s13|292-293|of|O
DDI-DrugBank.d94.s13|295-297|the|O
DDI-DrugBank.d94.s13|299-307|treatment|O
DDI-DrugBank.d94.s13|309-312|with|O
DDI-DrugBank.d94.s13|314-322|EQUETROTM|brand
DDI-DrugBank.d94.s13|323-323|,|O
DDI-DrugBank.d94.s13|325-326|it|O
DDI-DrugBank.d94.s13|328-329|is|O
DDI-DrugBank.d94.s13|331-340|reasonable|O
DDI-DrugBank.d94.s13|342-343|to|O
DDI-DrugBank.d94.s13|345-350|expect|O
DDI-DrugBank.d94.s13|352-355|that|O
DDI-DrugBank.d94.s13|357-357|a|O
DDI-DrugBank.d94.s13|359-362|dose|O
DDI-DrugBank.d94.s13|364-371|decrease|O
DDI-DrugBank.d94.s13|373-375|for|O
DDI-DrugBank.d94.s13|377-379|the|O
DDI-DrugBank.d94.s13|381-391|concomitant|O
DDI-DrugBank.d94.s13|393-397|agent|O
DDI-DrugBank.d94.s13|399-401|may|O
DDI-DrugBank.d94.s13|403-404|be|O
DDI-DrugBank.d94.s13|406-414|necessary|O
DDI-DrugBank.d94.s13|415-415|.|O
DDI-DrugBank.d94.s14|0-30|Pharmacological/Pharmacodynamic|O
DDI-DrugBank.d94.s14|32-43|Interactions|O
DDI-DrugBank.d94.s14|45-48|with|O
DDI-DrugBank.d94.s14|50-62|Carbamazepine|drug
DDI-DrugBank.d94.s14|64-74|Concomitant|O
DDI-DrugBank.d94.s14|76-89|administration|O
DDI-DrugBank.d94.s14|91-92|of|O
DDI-DrugBank.d94.s14|94-106|carbamazepine|drug
DDI-DrugBank.d94.s14|108-110|and|O
DDI-DrugBank.d94.s14|112-118|lithium|drug
DDI-DrugBank.d94.s14|120-122|may|O
DDI-DrugBank.d94.s14|124-131|increase|O
DDI-DrugBank.d94.s14|133-135|the|O
DDI-DrugBank.d94.s14|137-140|risk|O
DDI-DrugBank.d94.s14|142-143|of|O
DDI-DrugBank.d94.s14|145-154|neurotoxic|O
DDI-DrugBank.d94.s14|156-159|side|O
DDI-DrugBank.d94.s14|161-167|effects|O
DDI-DrugBank.d94.s14|168-168|.|O
DDI-DrugBank.d94.s15|0-4|Given|O
DDI-DrugBank.d94.s15|6-8|the|O
DDI-DrugBank.d94.s15|10-23|anticonvulsant|O
DDI-DrugBank.d94.s15|25-34|properties|O
DDI-DrugBank.d94.s15|36-37|of|O
DDI-DrugBank.d94.s15|39-51|carbamazepine|drug
DDI-DrugBank.d94.s15|52-52|,|O
DDI-DrugBank.d94.s15|54-62|EQUETROTM|brand
DDI-DrugBank.d94.s15|64-66|may|O
DDI-DrugBank.d94.s15|68-73|reduce|O
DDI-DrugBank.d94.s15|75-77|the|O
DDI-DrugBank.d94.s15|79-85|thyroid|O
DDI-DrugBank.d94.s15|87-94|function|O
DDI-DrugBank.d94.s15|96-97|as|O
DDI-DrugBank.d94.s15|99-101|has|O
DDI-DrugBank.d94.s15|103-106|been|O
DDI-DrugBank.d94.s15|108-115|reported|O
DDI-DrugBank.d94.s15|117-120|with|O
DDI-DrugBank.d94.s15|122-126|other|O
DDI-DrugBank.d94.s15|128-142|anticonvulsants|group
DDI-DrugBank.d94.s15|143-143|.|O
DDI-DrugBank.d94.s16|0-11|Additionally|O
DDI-DrugBank.d94.s16|12-12|,|O
DDI-DrugBank.d94.s16|14-32|anti-malarial drugs|group
DDI-DrugBank.d94.s16|33-33|,|O
DDI-DrugBank.d94.s16|35-38|such|O
DDI-DrugBank.d94.s16|40-41|as|O
DDI-DrugBank.d94.s16|43-53|chloroquine|drug
DDI-DrugBank.d94.s16|55-57|and|O
DDI-DrugBank.d94.s16|59-68|mefloquine|drug
DDI-DrugBank.d94.s16|69-69|,|O
DDI-DrugBank.d94.s16|71-73|may|O
DDI-DrugBank.d94.s16|75-84|antagonize|O
DDI-DrugBank.d94.s16|86-88|the|O
DDI-DrugBank.d94.s16|90-97|activity|O
DDI-DrugBank.d94.s16|99-100|of|O
DDI-DrugBank.d94.s16|102-114|carbamazepine|drug
DDI-DrugBank.d94.s16|115-115|.|O
DDI-DrugBank.d94.s17|0-3|Thus|O
DDI-DrugBank.d94.s17|5-6|if|O
DDI-DrugBank.d94.s17|8-8|a|O
DDI-DrugBank.d94.s17|10-16|patient|O
DDI-DrugBank.d94.s17|18-20|has|O
DDI-DrugBank.d94.s17|22-25|been|O
DDI-DrugBank.d94.s17|27-34|titrated|O
DDI-DrugBank.d94.s17|36-37|to|O
DDI-DrugBank.d94.s17|39-39|a|O
DDI-DrugBank.d94.s17|41-46|stable|O
DDI-DrugBank.d94.s17|48-53|dosage|O
DDI-DrugBank.d94.s17|55-56|on|O
DDI-DrugBank.d94.s17|58-60|one|O
DDI-DrugBank.d94.s17|62-63|of|O
DDI-DrugBank.d94.s17|65-67|the|O
DDI-DrugBank.d94.s17|69-74|agents|O
DDI-DrugBank.d94.s17|76-77|in|O
DDI-DrugBank.d94.s17|79-82|this|O
DDI-DrugBank.d94.s17|84-91|category|O
DDI-DrugBank.d94.s17|92-92|,|O
DDI-DrugBank.d94.s17|94-96|and|O
DDI-DrugBank.d94.s17|98-101|then|O
DDI-DrugBank.d94.s17|103-108|begins|O
DDI-DrugBank.d94.s17|110-110|a|O
DDI-DrugBank.d94.s17|112-117|course|O
DDI-DrugBank.d94.s17|119-120|of|O
DDI-DrugBank.d94.s17|122-130|treatment|O
DDI-DrugBank.d94.s17|132-135|with|O
DDI-DrugBank.d94.s17|137-145|EQUETROTM|brand
DDI-DrugBank.d94.s17|146-146|,|O
DDI-DrugBank.d94.s17|148-149|it|O
DDI-DrugBank.d94.s17|151-152|is|O
DDI-DrugBank.d94.s17|154-163|reasonable|O
DDI-DrugBank.d94.s17|165-166|to|O
DDI-DrugBank.d94.s17|168-173|expect|O
DDI-DrugBank.d94.s17|175-178|that|O
DDI-DrugBank.d94.s17|180-180|a|O
DDI-DrugBank.d94.s17|182-185|dose|O
DDI-DrugBank.d94.s17|187-196|adjustment|O
DDI-DrugBank.d94.s17|198-200|may|O
DDI-DrugBank.d94.s17|202-203|be|O
DDI-DrugBank.d94.s17|205-213|necessary|O
DDI-DrugBank.d94.s17|214-214|.|O
DDI-DrugBank.d94.s18|0-6|Because|O
DDI-DrugBank.d94.s18|8-9|of|O
DDI-DrugBank.d94.s18|11-13|its|O
DDI-DrugBank.d94.s18|15-21|primary|O
DDI-DrugBank.d94.s18|23-25|CNS|O
DDI-DrugBank.d94.s18|27-32|effect|O
DDI-DrugBank.d94.s18|33-33|,|O
DDI-DrugBank.d94.s18|35-41|caution|O
DDI-DrugBank.d94.s18|43-48|should|O
DDI-DrugBank.d94.s18|50-51|be|O
DDI-DrugBank.d94.s18|53-56|used|O
DDI-DrugBank.d94.s18|58-61|when|O
DDI-DrugBank.d94.s18|63-71|EQUETROTM|brand
DDI-DrugBank.d94.s18|73-74|is|O
DDI-DrugBank.d94.s18|76-80|taken|O
DDI-DrugBank.d94.s18|82-85|with|O
DDI-DrugBank.d94.s18|87-91|other|O
DDI-DrugBank.d94.s18|93-114|centrally acting drugs|group
DDI-DrugBank.d94.s18|116-118|and|O
DDI-DrugBank.d94.s18|120-126|alcohol|drug
DDI-DrugBank.d94.s18|127-127|.|O
DDI-DrugBank.d261.s0|0-11|Tetracycline|drug
DDI-DrugBank.d261.s0|12-12|,|O
DDI-DrugBank.d261.s0|14-14|a|O
DDI-DrugBank.d261.s0|16-40|bacteriostatic antibiotic|group
DDI-DrugBank.d261.s0|41-41|,|O
DDI-DrugBank.d261.s0|43-45|may|O
DDI-DrugBank.d261.s0|47-56|antagonize|O
DDI-DrugBank.d261.s0|58-60|the|O
DDI-DrugBank.d261.s0|62-73|bactericidal|O
DDI-DrugBank.d261.s0|75-80|effect|O
DDI-DrugBank.d261.s0|82-83|of|O
DDI-DrugBank.d261.s0|85-94|penicillin|drug
DDI-DrugBank.d261.s0|96-98|and|O
DDI-DrugBank.d261.s0|100-109|concurrent|O
DDI-DrugBank.d261.s0|111-113|use|O
DDI-DrugBank.d261.s0|115-116|of|O
DDI-DrugBank.d261.s0|118-122|these|O
DDI-DrugBank.d261.s0|124-128|drugs|O
DDI-DrugBank.d261.s0|130-135|should|O
DDI-DrugBank.d261.s0|137-138|be|O
DDI-DrugBank.d261.s0|140-146|avoided|O
DDI-DrugBank.d261.s0|147-147|.|O
DDI-MedLine.d140.s0|0-11|Longitudinal|O
DDI-MedLine.d140.s0|13-22|assessment|O
DDI-MedLine.d140.s0|24-25|of|O
DDI-MedLine.d140.s0|27-36|everolimus|drug
DDI-MedLine.d140.s0|38-39|in|O
DDI-MedLine.d140.s0|41-42|de|O
DDI-MedLine.d140.s0|44-47|novo|O
DDI-MedLine.d140.s0|49-53|renal|O
DDI-MedLine.d140.s0|55-64|transplant|O
DDI-MedLine.d140.s0|66-75|recipients|O
DDI-MedLine.d140.s0|77-80|over|O
DDI-MedLine.d140.s0|82-84|the|O
DDI-MedLine.d140.s0|86-90|first|O
DDI-MedLine.d140.s0|92-106|post-transplant|O
DDI-MedLine.d140.s0|108-111|year|O
DDI-MedLine.d140.s0|112-112|:|O
DDI-MedLine.d140.s0|114-129|pharmacokinetics|O
DDI-MedLine.d140.s0|130-130|,|O
DDI-MedLine.d140.s0|132-148|exposure-response|O
DDI-MedLine.d140.s0|150-162|relationships|O
DDI-MedLine.d140.s0|163-163|,|O
DDI-MedLine.d140.s0|165-167|and|O
DDI-MedLine.d140.s0|169-177|influence|O
DDI-MedLine.d140.s0|179-180|on|O
DDI-MedLine.d140.s0|182-193|cyclosporine|drug
DDI-MedLine.d140.s0|194-194|.|O
DDI-MedLine.d140.s1|0-8|OBJECTIVE|O
DDI-MedLine.d140.s1|9-9|:|O
DDI-MedLine.d140.s1|11-13|Our|O
DDI-MedLine.d140.s1|15-23|objective|O
DDI-MedLine.d140.s1|25-27|was|O
DDI-MedLine.d140.s1|29-30|to|O
DDI-MedLine.d140.s1|32-43|characterize|O
DDI-MedLine.d140.s1|45-47|the|O
DDI-MedLine.d140.s1|49-60|steady-state|O
DDI-MedLine.d140.s1|62-77|pharmacokinetics|O
DDI-MedLine.d140.s1|79-80|of|O
DDI-MedLine.d140.s1|82-91|everolimus|drug
DDI-MedLine.d140.s1|93-95|and|O
DDI-MedLine.d140.s1|97-108|cyclosporine|drug
DDI-MedLine.d140.s1|110-110|(|O
DDI-MedLine.d140.s1|111-113|INN|O
DDI-MedLine.d140.s1|114-114|,|O
DDI-MedLine.d140.s1|116-126|ciclosporin|drug
DDI-MedLine.d140.s1|127-127|)|O
DDI-MedLine.d140.s1|129-132|when|O
DDI-MedLine.d140.s1|134-147|coadministered|O
DDI-MedLine.d140.s1|149-150|in|O
DDI-MedLine.d140.s1|152-153|de|O
DDI-MedLine.d140.s1|155-158|novo|O
DDI-MedLine.d140.s1|160-165|kidney|O
DDI-MedLine.d140.s1|167-175|allograft|O
DDI-MedLine.d140.s1|177-186|recipients|O
DDI-MedLine.d140.s1|188-193|during|O
DDI-MedLine.d140.s1|195-197|the|O
DDI-MedLine.d140.s1|199-203|first|O
DDI-MedLine.d140.s1|205-208|year|O
DDI-MedLine.d140.s1|210-214|after|O
DDI-MedLine.d140.s1|216-230|transplantation|O
DDI-MedLine.d140.s1|231-231|.|O
DDI-MedLine.d140.s2|0-5|METHOD|O
DDI-MedLine.d140.s2|6-6|:|O
DDI-MedLine.d140.s2|8-11|This|O
DDI-MedLine.d140.s2|13-17|study|O
DDI-MedLine.d140.s2|19-21|was|O
DDI-MedLine.d140.s2|23-23|a|O
DDI-MedLine.d140.s2|25-35|multicenter|O
DDI-MedLine.d140.s2|37-46|randomized|O
DDI-MedLine.d140.s2|48-59|double-blind|O
DDI-MedLine.d140.s2|61-65|study|O
DDI-MedLine.d140.s2|67-68|of|O
DDI-MedLine.d140.s2|70-72|101|O
DDI-MedLine.d140.s2|74-81|patients|O
DDI-MedLine.d140.s2|83-85|who|O
DDI-MedLine.d140.s2|87-90|were|O
DDI-MedLine.d140.s2|92-99|randomly|O
DDI-MedLine.d140.s2|101-108|assigned|O
DDI-MedLine.d140.s2|110-114|1:1:1|O
DDI-MedLine.d140.s2|116-117|to|O
DDI-MedLine.d140.s2|119-125|receive|O
DDI-MedLine.d140.s2|127-136|everolimus|drug
DDI-MedLine.d140.s2|138-144|tablets|O
DDI-MedLine.d140.s2|146-147|at|O
DDI-MedLine.d140.s2|149-153|doses|O
DDI-MedLine.d140.s2|155-156|of|O
DDI-MedLine.d140.s2|158-160|0.5|O
DDI-MedLine.d140.s2|162-163|mg|O
DDI-MedLine.d140.s2|164-164|,|O
DDI-MedLine.d140.s2|166-166|1|O
DDI-MedLine.d140.s2|168-169|mg|O
DDI-MedLine.d140.s2|170-170|,|O
DDI-MedLine.d140.s2|172-173|or|O
DDI-MedLine.d140.s2|175-175|2|O
DDI-MedLine.d140.s2|177-178|mg|O
DDI-MedLine.d140.s2|180-184|twice|O
DDI-MedLine.d140.s2|186-190|daily|O
DDI-MedLine.d140.s2|192-195|with|O
DDI-MedLine.d140.s2|197-208|cyclosporine|drug
DDI-MedLine.d140.s2|210-212|and|O
DDI-MedLine.d140.s2|214-223|prednisone|drug
DDI-MedLine.d140.s2|224-224|.|O
DDI-MedLine.d140.s3|0-4|Blood|O
DDI-MedLine.d140.s3|6-13|sampling|O
DDI-MedLine.d140.s3|15-17|for|O
DDI-MedLine.d140.s3|19-21|the|O
DDI-MedLine.d140.s3|23-38|pharmacokinetics|O
DDI-MedLine.d140.s3|40-41|of|O
DDI-MedLine.d140.s3|43-52|everolimus|drug
DDI-MedLine.d140.s3|54-56|and|O
DDI-MedLine.d140.s3|58-69|cyclosporine|drug
DDI-MedLine.d140.s3|71-73|was|O
DDI-MedLine.d140.s3|75-83|performed|O
DDI-MedLine.d140.s3|85-86|on|O
DDI-MedLine.d140.s3|88-90|day|O
DDI-MedLine.d140.s3|92-92|1|O
DDI-MedLine.d140.s3|93-93|,|O
DDI-MedLine.d140.s3|95-96|on|O
DDI-MedLine.d140.s3|98-102|weeks|O
DDI-MedLine.d140.s3|104-104|1|O
DDI-MedLine.d140.s3|105-105|,|O
DDI-MedLine.d140.s3|107-107|2|O
DDI-MedLine.d140.s3|108-108|,|O
DDI-MedLine.d140.s3|110-110|3|O
DDI-MedLine.d140.s3|111-111|,|O
DDI-MedLine.d140.s3|113-115|and|O
DDI-MedLine.d140.s3|117-117|4|O
DDI-MedLine.d140.s3|118-118|,|O
DDI-MedLine.d140.s3|120-122|and|O
DDI-MedLine.d140.s3|124-125|on|O
DDI-MedLine.d140.s3|127-132|months|O
DDI-MedLine.d140.s3|134-134|2|O
DDI-MedLine.d140.s3|135-135|,|O
DDI-MedLine.d140.s3|137-137|3|O
DDI-MedLine.d140.s3|138-138|,|O
DDI-MedLine.d140.s3|140-140|6|O
DDI-MedLine.d140.s3|141-141|,|O
DDI-MedLine.d140.s3|143-143|9|O
DDI-MedLine.d140.s3|144-144|,|O
DDI-MedLine.d140.s3|146-148|and|O
DDI-MedLine.d140.s3|150-151|12|O
DDI-MedLine.d140.s3|152-152|.|O
DDI-MedLine.d140.s4|0-9|Everolimus|drug
DDI-MedLine.d140.s4|11-30|dose-proportionality|O
DDI-MedLine.d140.s4|32-34|and|O
DDI-MedLine.d140.s4|36-44|stability|O
DDI-MedLine.d140.s4|46-49|over|O
DDI-MedLine.d140.s4|51-54|time|O
DDI-MedLine.d140.s4|56-59|were|O
DDI-MedLine.d140.s4|61-68|assessed|O
DDI-MedLine.d140.s4|70-71|in|O
DDI-MedLine.d140.s4|73-75|the|O
DDI-MedLine.d140.s4|77-83|context|O
DDI-MedLine.d140.s4|85-86|of|O
DDI-MedLine.d140.s4|88-93|linear|O
DDI-MedLine.d140.s4|95-104|regression|O
DDI-MedLine.d140.s4|106-108|and|O
DDI-MedLine.d140.s4|110-114|ANOVA|O
DDI-MedLine.d140.s4|116-121|models|O
DDI-MedLine.d140.s4|122-122|.|O
DDI-MedLine.d140.s5|0-9|Everolimus|drug
DDI-MedLine.d140.s5|11-27|exposure-response|O
DDI-MedLine.d140.s5|29-41|relationships|O
DDI-MedLine.d140.s5|43-49|between|O
DDI-MedLine.d140.s5|51-54|area|O
DDI-MedLine.d140.s5|56-60|under|O
DDI-MedLine.d140.s5|62-64|the|O
DDI-MedLine.d140.s5|66-70|blood|O
DDI-MedLine.d140.s5|72-89|concentration-time|O
DDI-MedLine.d140.s5|91-95|curve|O
DDI-MedLine.d140.s5|97-97|(|O
DDI-MedLine.d140.s5|98-100|AUC|O
DDI-MedLine.d140.s5|101-101|)|O
DDI-MedLine.d140.s5|103-105|and|O
DDI-MedLine.d140.s5|107-113|changes|O
DDI-MedLine.d140.s5|115-116|in|O
DDI-MedLine.d140.s5|118-126|platelets|O
DDI-MedLine.d140.s5|127-127|,|O
DDI-MedLine.d140.s5|129-138|leukocytes|O
DDI-MedLine.d140.s5|139-139|,|O
DDI-MedLine.d140.s5|141-143|and|O
DDI-MedLine.d140.s5|145-150|lipids|O
DDI-MedLine.d140.s5|152-155|were|O
DDI-MedLine.d140.s5|157-164|explored|O
DDI-MedLine.d140.s5|166-169|with|O
DDI-MedLine.d140.s5|171-173|the|O
DDI-MedLine.d140.s5|175-187|median-effect|O
DDI-MedLine.d140.s5|189-193|model|O
DDI-MedLine.d140.s5|194-194|.|O
DDI-MedLine.d140.s6|0-8|Potential|O
DDI-MedLine.d140.s6|10-20|differences|O
DDI-MedLine.d140.s6|22-23|in|O
DDI-MedLine.d140.s6|25-36|cyclosporine|drug
DDI-MedLine.d140.s6|38-43|dosing|O
DDI-MedLine.d140.s6|45-47|and|O
DDI-MedLine.d140.s6|49-64|pharmacokinetics|O
DDI-MedLine.d140.s6|66-67|at|O
DDI-MedLine.d140.s6|69-77|different|O
DDI-MedLine.d140.s6|79-84|levels|O
DDI-MedLine.d140.s6|86-87|of|O
DDI-MedLine.d140.s6|89-98|everolimus|drug
DDI-MedLine.d140.s6|100-107|exposure|O
DDI-MedLine.d140.s6|109-112|were|O
DDI-MedLine.d140.s6|114-121|assessed|O
DDI-MedLine.d140.s6|123-124|in|O
DDI-MedLine.d140.s6|126-128|the|O
DDI-MedLine.d140.s6|130-136|context|O
DDI-MedLine.d140.s6|138-139|of|O
DDI-MedLine.d140.s6|141-145|ANOVA|O
DDI-MedLine.d140.s6|146-146|.|O
DDI-MedLine.d140.s7|0-6|RESULTS|O
DDI-MedLine.d140.s7|7-7|:|O
DDI-MedLine.d140.s7|9-18|Everolimus|drug
DDI-MedLine.d140.s7|20-25|steady|O
DDI-MedLine.d140.s7|27-31|state|O
DDI-MedLine.d140.s7|33-35|was|O
DDI-MedLine.d140.s7|37-43|reached|O
DDI-MedLine.d140.s7|45-46|on|O
DDI-MedLine.d140.s7|48-49|or|O
DDI-MedLine.d140.s7|51-56|before|O
DDI-MedLine.d140.s7|58-60|day|O
DDI-MedLine.d140.s7|62-62|7|O
DDI-MedLine.d140.s7|63-63|,|O
DDI-MedLine.d140.s7|65-68|with|O
DDI-MedLine.d140.s7|70-70|a|O
DDI-MedLine.d140.s7|72-77|median|O
DDI-MedLine.d140.s7|79-84|3-fold|O
DDI-MedLine.d140.s7|86-97|accumulation|O
DDI-MedLine.d140.s7|99-100|of|O
DDI-MedLine.d140.s7|102-105|drug|O
DDI-MedLine.d140.s7|107-114|exposure|O
DDI-MedLine.d140.s7|116-123|compared|O
DDI-MedLine.d140.s7|125-128|with|O
DDI-MedLine.d140.s7|130-133|that|O
DDI-MedLine.d140.s7|135-139|after|O
DDI-MedLine.d140.s7|141-143|the|O
DDI-MedLine.d140.s7|145-149|first|O
DDI-MedLine.d140.s7|151-163|postoperative|O
DDI-MedLine.d140.s7|165-168|dose|O
DDI-MedLine.d140.s7|169-169|.|O
DDI-MedLine.d140.s8|0-3|Both|O
DDI-MedLine.d140.s8|5-16|steady-state|O
DDI-MedLine.d140.s8|18-24|maximum|O
DDI-MedLine.d140.s8|26-38|concentration|O
DDI-MedLine.d140.s8|40-42|and|O
DDI-MedLine.d140.s8|44-46|AUC|O
DDI-MedLine.d140.s8|48-51|were|O
DDI-MedLine.d140.s8|53-56|dose|O
DDI-MedLine.d140.s8|58-69|proportional|O
DDI-MedLine.d140.s8|71-74|over|O
DDI-MedLine.d140.s8|76-78|the|O
DDI-MedLine.d140.s8|80-83|full|O
DDI-MedLine.d140.s8|85-88|dose|O
DDI-MedLine.d140.s8|90-94|range|O
DDI-MedLine.d140.s8|96-99|when|O
DDI-MedLine.d140.s8|101-108|assessed|O
DDI-MedLine.d140.s8|110-111|on|O
DDI-MedLine.d140.s8|113-115|day|O
DDI-MedLine.d140.s8|117-117|1|O
DDI-MedLine.d140.s8|118-118|,|O
DDI-MedLine.d140.s8|120-121|as|O
DDI-MedLine.d140.s8|123-126|well|O
DDI-MedLine.d140.s8|128-129|as|O
DDI-MedLine.d140.s8|131-133|for|O
DDI-MedLine.d140.s8|135-137|the|O
DDI-MedLine.d140.s8|139-142|full|O
DDI-MedLine.d140.s8|144-151|duration|O
DDI-MedLine.d140.s8|153-154|of|O
DDI-MedLine.d140.s8|156-158|the|O
DDI-MedLine.d140.s8|160-164|study|O
DDI-MedLine.d140.s8|166-167|at|O
DDI-MedLine.d140.s8|169-174|steady|O
DDI-MedLine.d140.s8|176-180|state|O
DDI-MedLine.d140.s8|181-181|.|O
DDI-MedLine.d140.s9|0-4|There|O
DDI-MedLine.d140.s9|6-8|was|O
DDI-MedLine.d140.s9|10-17|evidence|O
DDI-MedLine.d140.s9|19-21|for|O
DDI-MedLine.d140.s9|23-34|longitudinal|O
DDI-MedLine.d140.s9|36-44|stability|O
DDI-MedLine.d140.s9|46-47|in|O
DDI-MedLine.d140.s9|49-51|AUC|O
DDI-MedLine.d140.s9|53-54|of|O
DDI-MedLine.d140.s9|56-65|everolimus|drug
DDI-MedLine.d140.s9|67-72|during|O
DDI-MedLine.d140.s9|74-76|the|O
DDI-MedLine.d140.s9|78-83|course|O
DDI-MedLine.d140.s9|85-86|of|O
DDI-MedLine.d140.s9|88-90|the|O
DDI-MedLine.d140.s9|92-96|study|O
DDI-MedLine.d140.s9|97-97|.|O
DDI-MedLine.d140.s10|0-2|The|O
DDI-MedLine.d140.s10|4-18|interindividual|O
DDI-MedLine.d140.s10|20-34|pharmacokinetic|O
DDI-MedLine.d140.s10|36-46|variability|O
DDI-MedLine.d140.s10|48-50|for|O
DDI-MedLine.d140.s10|52-54|AUC|O
DDI-MedLine.d140.s10|56-58|was|O
DDI-MedLine.d140.s10|60-63|85.4|O
DDI-MedLine.d140.s10|64-64|%|O
DDI-MedLine.d140.s10|66-68|and|O
DDI-MedLine.d140.s10|70-84|intraindividual|O
DDI-MedLine.d140.s10|85-85|,|O
DDI-MedLine.d140.s10|87-99|interoccasion|O
DDI-MedLine.d140.s10|101-111|variability|O
DDI-MedLine.d140.s10|113-115|was|O
DDI-MedLine.d140.s10|117-120|40.8|O
DDI-MedLine.d140.s10|121-121|%|O
DDI-MedLine.d140.s10|122-122|.|O
DDI-MedLine.d140.s11|0-2|Age|O
DDI-MedLine.d140.s11|4-4|(|O
DDI-MedLine.d140.s11|5-9|range|O
DDI-MedLine.d140.s11|10-10|,|O
DDI-MedLine.d140.s11|12-16|17-69|O
DDI-MedLine.d140.s11|18-22|years|O
DDI-MedLine.d140.s11|23-23|)|O
DDI-MedLine.d140.s11|24-24|,|O
DDI-MedLine.d140.s11|26-31|weight|O
DDI-MedLine.d140.s11|33-33|(|O
DDI-MedLine.d140.s11|34-38|range|O
DDI-MedLine.d140.s11|39-39|,|O
DDI-MedLine.d140.s11|41-46|49-106|O
DDI-MedLine.d140.s11|48-49|kg|O
DDI-MedLine.d140.s11|50-50|)|O
DDI-MedLine.d140.s11|51-51|,|O
DDI-MedLine.d140.s11|53-55|and|O
DDI-MedLine.d140.s11|57-59|sex|O
DDI-MedLine.d140.s11|61-61|(|O
DDI-MedLine.d140.s11|62-63|65|O
DDI-MedLine.d140.s11|65-67|men|O
DDI-MedLine.d140.s11|69-71|and|O
DDI-MedLine.d140.s11|73-74|36|O
DDI-MedLine.d140.s11|76-80|women|O
DDI-MedLine.d140.s11|81-81|)|O
DDI-MedLine.d140.s11|83-86|were|O
DDI-MedLine.d140.s11|88-90|not|O
DDI-MedLine.d140.s11|92-102|significant|O
DDI-MedLine.d140.s11|104-115|contributors|O
DDI-MedLine.d140.s11|117-118|to|O
DDI-MedLine.d140.s11|120-130|variability|O
DDI-MedLine.d140.s11|131-131|.|O
DDI-MedLine.d140.s12|0-4|There|O
DDI-MedLine.d140.s12|6-8|was|O
DDI-MedLine.d140.s12|10-11|an|O
DDI-MedLine.d140.s12|13-22|increasing|O
DDI-MedLine.d140.s12|24-32|incidence|O
DDI-MedLine.d140.s12|34-35|of|O
DDI-MedLine.d140.s12|37-45|transient|O
DDI-MedLine.d140.s12|47-62|thrombocytopenia|O
DDI-MedLine.d140.s12|64-64|(|O
DDI-MedLine.d140.s12|65-66|or|O
DDI-MedLine.d140.s12|68-71|=100|O
DDI-MedLine.d140.s12|73-73|x|O
DDI-MedLine.d140.s12|75-76|10|O
DDI-MedLine.d140.s12|77-77|(|O
DDI-MedLine.d140.s12|78-78|9|O
DDI-MedLine.d140.s12|79-79|)|O
DDI-MedLine.d140.s12|80-81|/L|O
DDI-MedLine.d140.s12|82-82|)|O
DDI-MedLine.d140.s12|84-87|with|O
DDI-MedLine.d140.s12|89-98|increasing|O
DDI-MedLine.d140.s12|100-109|everolimus|drug
DDI-MedLine.d140.s12|111-113|AUC|O
DDI-MedLine.d140.s12|115-115|(|O
DDI-MedLine.d140.s12|116-116|P|O
DDI-MedLine.d140.s12|118-118|=|O
DDI-MedLine.d140.s12|120-122|.03|O
DDI-MedLine.d140.s12|123-123|)|O
DDI-MedLine.d140.s12|124-124|.|O
DDI-MedLine.d140.s13|0-11|Cyclosporine|drug
DDI-MedLine.d140.s13|13-17|doses|O
DDI-MedLine.d140.s13|18-18|,|O
DDI-MedLine.d140.s13|20-25|trough|O
DDI-MedLine.d140.s13|27-40|concentrations|O
DDI-MedLine.d140.s13|41-41|,|O
DDI-MedLine.d140.s13|43-45|and|O
DDI-MedLine.d140.s13|47-49|AUC|O
DDI-MedLine.d140.s13|51-59|exhibited|O
DDI-MedLine.d140.s13|61-67|similar|O
DDI-MedLine.d140.s13|69-76|temporal|O
DDI-MedLine.d140.s13|78-85|patterns|O
DDI-MedLine.d140.s13|87-92|during|O
DDI-MedLine.d140.s13|94-96|the|O
DDI-MedLine.d140.s13|98-103|course|O
DDI-MedLine.d140.s13|105-106|of|O
DDI-MedLine.d140.s13|108-110|the|O
DDI-MedLine.d140.s13|112-116|study|O
DDI-MedLine.d140.s13|118-127|regardless|O
DDI-MedLine.d140.s13|129-130|of|O
DDI-MedLine.d140.s13|132-134|the|O
DDI-MedLine.d140.s13|136-150|co-administered|O
DDI-MedLine.d140.s13|152-161|everolimus|drug
DDI-MedLine.d140.s13|163-166|dose|O
DDI-MedLine.d140.s13|168-172|level|O
DDI-MedLine.d140.s13|174-174|(|O
DDI-MedLine.d140.s13|175-175|P|O
DDI-MedLine.d140.s13|177-177|=|O
DDI-MedLine.d140.s13|179-181|.13|O
DDI-MedLine.d140.s13|182-182|,|O
DDI-MedLine.d140.s13|184-186|.82|O
DDI-MedLine.d140.s13|187-187|,|O
DDI-MedLine.d140.s13|189-191|and|O
DDI-MedLine.d140.s13|193-195|.76|O
DDI-MedLine.d140.s13|196-196|,|O
DDI-MedLine.d140.s13|198-209|respectively|O
DDI-MedLine.d140.s13|210-210|)|O
DDI-MedLine.d140.s13|211-211|.|O
DDI-MedLine.d140.s14|0-10|CONCLUSIONS|O
DDI-MedLine.d140.s14|11-11|:|O
DDI-MedLine.d140.s14|13-22|Everolimus|drug
DDI-MedLine.d140.s14|24-32|exhibited|O
DDI-MedLine.d140.s14|34-50|dose-proportional|O
DDI-MedLine.d140.s14|51-51|,|O
DDI-MedLine.d140.s14|53-58|stable|O
DDI-MedLine.d140.s14|60-67|exposure|O
DDI-MedLine.d140.s14|69-74|during|O
DDI-MedLine.d140.s14|76-78|the|O
DDI-MedLine.d140.s14|80-84|first|O
DDI-MedLine.d140.s14|86-100|post-transplant|O
DDI-MedLine.d140.s14|102-105|year|O
DDI-MedLine.d140.s14|106-106|.|O
DDI-MedLine.d140.s15|0-2|For|O
DDI-MedLine.d140.s15|4-4|a|O
DDI-MedLine.d140.s15|6-11|4-fold|O
DDI-MedLine.d140.s15|13-17|range|O
DDI-MedLine.d140.s15|19-20|of|O
DDI-MedLine.d140.s15|22-31|everolimus|drug
DDI-MedLine.d140.s15|33-37|doses|O
DDI-MedLine.d140.s15|39-43|there|O
DDI-MedLine.d140.s15|45-48|were|O
DDI-MedLine.d140.s15|50-51|no|O
DDI-MedLine.d140.s15|53-64|differential|O
DDI-MedLine.d140.s15|66-72|effects|O
DDI-MedLine.d140.s15|74-75|on|O
DDI-MedLine.d140.s15|77-88|cyclosporine|drug
DDI-MedLine.d140.s15|90-95|dosing|O
DDI-MedLine.d140.s15|97-98|or|O
DDI-MedLine.d140.s15|100-115|pharmacokinetics|O
DDI-MedLine.d140.s15|116-116|.|O
DDI-DrugBank.d389.s0|0-13|Antihistamines|group
DDI-DrugBank.d389.s0|15-17|may|O
DDI-DrugBank.d389.s0|19-25|enhance|O
DDI-DrugBank.d389.s0|27-29|the|O
DDI-DrugBank.d389.s0|31-37|effects|O
DDI-DrugBank.d389.s0|39-40|of|O
DDI-DrugBank.d389.s0|42-66|tricyclic antidepressants|group
DDI-DrugBank.d389.s0|67-67|,|O
DDI-DrugBank.d389.s0|69-80|barbiturates|group
DDI-DrugBank.d389.s0|81-81|,|O
DDI-DrugBank.d389.s0|83-89|alcohol|drug
DDI-DrugBank.d389.s0|90-90|,|O
DDI-DrugBank.d389.s0|92-94|and|O
DDI-DrugBank.d389.s0|96-100|other|O
DDI-DrugBank.d389.s0|102-116|CNS depressants|group
DDI-DrugBank.d389.s0|117-117|.|O
DDI-DrugBank.d389.s1|0-13|MAO inhibitors|group
DDI-DrugBank.d389.s1|15-21|prolong|O
DDI-DrugBank.d389.s1|23-25|and|O
DDI-DrugBank.d389.s1|27-35|intensify|O
DDI-DrugBank.d389.s1|37-39|the|O
DDI-DrugBank.d389.s1|41-55|anticholinergic|O
DDI-DrugBank.d389.s1|57-63|effects|O
DDI-DrugBank.d389.s1|65-66|of|O
DDI-DrugBank.d389.s1|68-81|antihistamines|group
DDI-DrugBank.d389.s1|82-82|.|O
DDI-DrugBank.d389.s2|0-21|Sympathomimetic amines|group
DDI-DrugBank.d389.s2|23-25|may|O
DDI-DrugBank.d389.s2|27-32|reduce|O
DDI-DrugBank.d389.s2|34-36|the|O
DDI-DrugBank.d389.s2|38-53|antihypertensive|O
DDI-DrugBank.d389.s2|55-61|effects|O
DDI-DrugBank.d389.s2|63-64|of|O
DDI-DrugBank.d389.s2|66-74|reserpine|drug
DDI-DrugBank.d389.s2|75-75|,|O
DDI-DrugBank.d389.s2|77-94|veratrum alkaloids|group
DDI-DrugBank.d389.s2|95-95|,|O
DDI-DrugBank.d389.s2|97-106|methyldopa|drug
DDI-DrugBank.d389.s2|108-110|and|O
DDI-DrugBank.d389.s2|112-123|mecamylamine|drug
DDI-DrugBank.d389.s2|124-124|.|O
DDI-DrugBank.d389.s3|0-6|Effects|O
DDI-DrugBank.d389.s3|8-9|of|O
DDI-DrugBank.d389.s3|11-26|sympathomimetics|group
DDI-DrugBank.d389.s3|28-30|are|O
DDI-DrugBank.d389.s3|32-40|increased|O
DDI-DrugBank.d389.s3|42-45|with|O
DDI-DrugBank.d389.s3|47-60|MAO inhibitors|group
DDI-DrugBank.d389.s3|62-64|and|O
DDI-DrugBank.d389.s3|66-89|beta adrenergic blockers|group
DDI-DrugBank.d389.s3|90-90|.|O
DDI-DrugBank.d151.s0|0-9|Folic acid|drug
DDI-DrugBank.d151.s0|11-12|in|O
DDI-DrugBank.d151.s0|14-18|large|O
DDI-DrugBank.d151.s0|20-26|amounts|O
DDI-DrugBank.d151.s0|28-30|may|O
DDI-DrugBank.d151.s0|32-41|counteract|O
DDI-DrugBank.d151.s0|43-45|the|O
DDI-DrugBank.d151.s0|47-59|antiepileptic|O
DDI-DrugBank.d151.s0|61-66|effect|O
DDI-DrugBank.d151.s0|68-69|of|O
DDI-DrugBank.d151.s0|71-83|phenobarbital|drug
DDI-DrugBank.d151.s0|84-84|,|O
DDI-DrugBank.d151.s0|86-94|phenytoin|drug
DDI-DrugBank.d151.s0|96-98|and|O
DDI-DrugBank.d151.s0|100-108|primidone|drug
DDI-DrugBank.d151.s0|109-109|,|O
DDI-DrugBank.d151.s0|111-113|and|O
DDI-DrugBank.d151.s0|115-122|increase|O
DDI-DrugBank.d151.s0|124-126|the|O
DDI-DrugBank.d151.s0|128-136|frequency|O
DDI-DrugBank.d151.s0|138-139|of|O
DDI-DrugBank.d151.s0|141-148|seizures|O
DDI-DrugBank.d151.s0|150-151|in|O
DDI-DrugBank.d151.s0|153-163|susceptible|O
DDI-DrugBank.d151.s0|165-173|pediatric|O
DDI-DrugBank.d151.s0|175-182|patients|O
DDI-DrugBank.d151.s0|183-183|.|O
DDI-DrugBank.d151.s1|0-10|Preliminary|O
DDI-DrugBank.d151.s1|12-17|animal|O
DDI-DrugBank.d151.s1|19-21|and|O
DDI-DrugBank.d151.s1|23-27|human|O
DDI-DrugBank.d151.s1|29-35|studies|O
DDI-DrugBank.d151.s1|37-40|have|O
DDI-DrugBank.d151.s1|42-46|shown|O
DDI-DrugBank.d151.s1|48-51|that|O
DDI-DrugBank.d151.s1|53-57|small|O
DDI-DrugBank.d151.s1|59-68|quantities|O
DDI-DrugBank.d151.s1|70-71|of|O
DDI-DrugBank.d151.s1|73-84|systemically|O
DDI-DrugBank.d151.s1|86-97|administered|O
DDI-DrugBank.d151.s1|99-108|leucovorin|drug
DDI-DrugBank.d151.s1|110-114|enter|O
DDI-DrugBank.d151.s1|116-118|the|O
DDI-DrugBank.d151.s1|120-122|CSF|O
DDI-DrugBank.d151.s1|124-132|primarily|O
DDI-DrugBank.d151.s1|134-135|as|O
DDI-DrugBank.d151.s1|137-161|5-methyltetrahydro-folate|O
DDI-DrugBank.d151.s1|163-165|and|O
DDI-DrugBank.d151.s1|166-166|,|O
DDI-DrugBank.d151.s1|168-169|in|O
DDI-DrugBank.d151.s1|171-176|humans|O
DDI-DrugBank.d151.s1|177-177|,|O
DDI-DrugBank.d151.s1|179-184|remain|O
DDI-DrugBank.d151.s1|186-186|1|O
DDI-DrugBank.d151.s1|188-189|to|O
DDI-DrugBank.d151.s1|191-191|3|O
DDI-DrugBank.d151.s1|193-198|orders|O
DDI-DrugBank.d151.s1|200-201|of|O
DDI-DrugBank.d151.s1|203-211|magnitude|O
DDI-DrugBank.d151.s1|213-217|lower|O
DDI-DrugBank.d151.s1|219-222|than|O
DDI-DrugBank.d151.s1|224-226|the|O
DDI-DrugBank.d151.s1|228-232|usual|O
DDI-DrugBank.d151.s1|234-245|methotrexate|drug
DDI-DrugBank.d151.s1|247-260|concentrations|O
DDI-DrugBank.d151.s1|262-270|following|O
DDI-DrugBank.d151.s1|272-282|intrathecal|O
DDI-DrugBank.d151.s1|284-297|administration|O
DDI-DrugBank.d151.s1|298-298|.|O
DDI-DrugBank.d151.s2|0-6|However|O
DDI-DrugBank.d151.s2|7-7|,|O
DDI-DrugBank.d151.s2|9-12|high|O
DDI-DrugBank.d151.s2|14-18|doses|O
DDI-DrugBank.d151.s2|20-21|of|O
DDI-DrugBank.d151.s2|23-32|leucovorin|drug
DDI-DrugBank.d151.s2|34-36|may|O
DDI-DrugBank.d151.s2|38-43|reduce|O
DDI-DrugBank.d151.s2|45-47|the|O
DDI-DrugBank.d151.s2|49-56|efficacy|O
DDI-DrugBank.d151.s2|58-59|of|O
DDI-DrugBank.d151.s2|61-73|intrathecally|O
DDI-DrugBank.d151.s2|75-86|administered|O
DDI-DrugBank.d151.s2|88-99|methotrexate|drug
DDI-DrugBank.d151.s2|100-100|.|O
DDI-DrugBank.d151.s3|0-9|Leucovorin|drug
DDI-DrugBank.d151.s3|11-13|may|O
DDI-DrugBank.d151.s3|15-21|enhance|O
DDI-DrugBank.d151.s3|23-25|the|O
DDI-DrugBank.d151.s3|27-34|toxicity|O
DDI-DrugBank.d151.s3|36-37|of|O
DDI-DrugBank.d151.s3|39-52|5-fluorouracil|drug
DDI-DrugBank.d151.s3|53-53|.|O
DDI-DrugBank.d21.s0|0-5|Tissue|O
DDI-DrugBank.d21.s0|7-13|culture|O
DDI-DrugBank.d21.s0|15-17|and|O
DDI-DrugBank.d21.s0|19-24|animal|O
DDI-DrugBank.d21.s0|26-32|studies|O
DDI-DrugBank.d21.s0|34-41|indicate|O
DDI-DrugBank.d21.s0|43-46|that|O
DDI-DrugBank.d21.s0|48-53|ELSPAR|brand
DDI-DrugBank.d21.s0|55-57|can|O
DDI-DrugBank.d21.s0|59-66|diminish|O
DDI-DrugBank.d21.s0|68-69|or|O
DDI-DrugBank.d21.s0|71-77|abolish|O
DDI-DrugBank.d21.s0|79-81|the|O
DDI-DrugBank.d21.s0|83-88|effect|O
DDI-DrugBank.d21.s0|90-91|of|O
DDI-DrugBank.d21.s0|93-104|methotrexate|drug
DDI-DrugBank.d21.s0|106-107|on|O
DDI-DrugBank.d21.s0|109-117|malignant|O
DDI-DrugBank.d21.s0|119-126|cells.14|O
DDI-DrugBank.d21.s0|128-131|This|O
DDI-DrugBank.d21.s0|133-138|effect|O
DDI-DrugBank.d21.s0|140-141|on|O
DDI-DrugBank.d21.s0|143-154|methotrexate|drug
DDI-DrugBank.d21.s0|156-163|activity|O
DDI-DrugBank.d21.s0|165-172|persists|O
DDI-DrugBank.d21.s0|174-175|as|O
DDI-DrugBank.d21.s0|177-180|long|O
DDI-DrugBank.d21.s0|182-183|as|O
DDI-DrugBank.d21.s0|185-190|plasma|O
DDI-DrugBank.d21.s0|192-201|asparagine|O
DDI-DrugBank.d21.s0|203-208|levels|O
DDI-DrugBank.d21.s0|210-212|are|O
DDI-DrugBank.d21.s0|214-223|suppressed|O
DDI-DrugBank.d21.s0|224-224|.|O
DDI-DrugBank.d21.s1|0-4|These|O
DDI-DrugBank.d21.s1|6-12|results|O
DDI-DrugBank.d21.s1|14-18|would|O
DDI-DrugBank.d21.s1|20-23|seem|O
DDI-DrugBank.d21.s1|25-26|to|O
DDI-DrugBank.d21.s1|28-34|dictate|O
DDI-DrugBank.d21.s1|36-42|against|O
DDI-DrugBank.d21.s1|44-46|the|O
DDI-DrugBank.d21.s1|48-55|clinical|O
DDI-DrugBank.d21.s1|57-59|use|O
DDI-DrugBank.d21.s1|61-62|of|O
DDI-DrugBank.d21.s1|64-75|methotrexate|drug
DDI-DrugBank.d21.s1|77-80|with|O
DDI-DrugBank.d21.s1|82-87|ELSPAR|brand
DDI-DrugBank.d21.s1|88-88|,|O
DDI-DrugBank.d21.s1|90-91|or|O
DDI-DrugBank.d21.s1|93-98|during|O
DDI-DrugBank.d21.s1|100-102|the|O
DDI-DrugBank.d21.s1|104-109|period|O
DDI-DrugBank.d21.s1|111-119|following|O
DDI-DrugBank.d21.s1|121-126|ELSPAR|brand
DDI-DrugBank.d21.s1|128-134|therapy|O
DDI-DrugBank.d21.s1|136-139|when|O
DDI-DrugBank.d21.s1|141-146|plasma|O
DDI-DrugBank.d21.s1|148-157|asparagine|O
DDI-DrugBank.d21.s1|159-164|levels|O
DDI-DrugBank.d21.s1|166-168|are|O
DDI-DrugBank.d21.s1|170-174|below|O
DDI-DrugBank.d21.s1|176-181|normal|O
DDI-DrugBank.d21.s1|182-182|.|O
DDI-DrugBank.d503.s0|0-14|Chlorprothixene|drug
DDI-DrugBank.d503.s0|16-18|may|O
DDI-DrugBank.d503.s0|20-27|increase|O
DDI-DrugBank.d503.s0|29-31|the|O
DDI-DrugBank.d503.s0|33-44|plasma-level|O
DDI-DrugBank.d503.s0|46-47|of|O
DDI-DrugBank.d503.s0|49-61|concomitantly|O
DDI-DrugBank.d503.s0|63-67|given|O
DDI-DrugBank.d503.s0|69-75|lithium|drug
DDI-DrugBank.d503.s0|76-76|.|O
DDI-DrugBank.d503.s1|0-1|In|O
DDI-DrugBank.d503.s1|3-7|order|O
DDI-DrugBank.d503.s1|9-10|to|O
DDI-DrugBank.d503.s1|12-16|avoid|O
DDI-DrugBank.d503.s1|18-24|lithium|drug
DDI-DrugBank.d503.s1|26-37|intoxication|O
DDI-DrugBank.d503.s1|38-38|,|O
DDI-DrugBank.d503.s1|40-46|lithium|drug
DDI-DrugBank.d503.s1|48-53|plasma|O
DDI-DrugBank.d503.s1|55-60|levels|O
DDI-DrugBank.d503.s1|62-67|should|O
DDI-DrugBank.d503.s1|69-70|be|O
DDI-DrugBank.d503.s1|72-80|monitored|O
DDI-DrugBank.d503.s1|82-88|closely|O
DDI-DrugBank.d503.s1|89-89|.|O
DDI-DrugBank.d503.s2|0-1|If|O
DDI-DrugBank.d503.s2|3-17|chlorprothixene|drug
DDI-DrugBank.d503.s2|19-20|is|O
DDI-DrugBank.d503.s2|22-26|given|O
DDI-DrugBank.d503.s2|28-40|concomitantly|O
DDI-DrugBank.d503.s2|42-45|with|O
DDI-DrugBank.d503.s2|47-53|opioids|group
DDI-DrugBank.d503.s2|54-54|,|O
DDI-DrugBank.d503.s2|56-58|the|O
DDI-DrugBank.d503.s2|60-65|opioid|group
DDI-DrugBank.d503.s2|67-70|dose|O
DDI-DrugBank.d503.s2|72-77|should|O
DDI-DrugBank.d503.s2|79-80|be|O
DDI-DrugBank.d503.s2|82-88|reduced|O
DDI-DrugBank.d503.s2|90-90|(|O
DDI-DrugBank.d503.s2|91-92|by|O
DDI-DrugBank.d503.s2|94-100|approx.|O
DDI-DrugBank.d503.s2|102-103|50|O
DDI-DrugBank.d503.s2|104-104|%|O
DDI-DrugBank.d503.s2|105-105|)|O
DDI-DrugBank.d503.s2|106-106|,|O
DDI-DrugBank.d503.s2|108-114|because|O
DDI-DrugBank.d503.s2|116-130|chlorprothixene|drug
DDI-DrugBank.d503.s2|132-140|amplifies|O
DDI-DrugBank.d503.s2|142-144|the|O
DDI-DrugBank.d503.s2|146-156|therapeutic|O
DDI-DrugBank.d503.s2|158-164|actions|O
DDI-DrugBank.d503.s2|166-168|and|O
DDI-DrugBank.d503.s2|170-181|side-effects|O
DDI-DrugBank.d503.s2|183-184|of|O
DDI-DrugBank.d503.s2|186-192|opioids|group
DDI-DrugBank.d503.s2|194-202|massively|O
DDI-DrugBank.d503.s2|203-203|.|O
DDI-DrugBank.d503.s3|0-4|Avoid|O
DDI-DrugBank.d503.s3|6-8|the|O
DDI-DrugBank.d503.s3|10-20|concomitant|O
DDI-DrugBank.d503.s3|22-24|use|O
DDI-DrugBank.d503.s3|26-27|of|O
DDI-DrugBank.d503.s3|29-43|chlorprothixene|drug
DDI-DrugBank.d503.s3|45-47|and|O
DDI-DrugBank.d503.s3|49-56|tramadol|drug
DDI-DrugBank.d503.s3|58-58|(|O
DDI-DrugBank.d503.s3|59-64|Ultram|brand
DDI-DrugBank.d503.s3|65-65|)|O
DDI-DrugBank.d503.s3|66-66|.|O
DDI-DrugBank.d503.s4|0-6|Massive|O
DDI-DrugBank.d503.s4|8-15|seizures|O
DDI-DrugBank.d503.s4|17-19|may|O
DDI-DrugBank.d503.s4|21-22|be|O
DDI-DrugBank.d503.s4|24-34|encountered|O
DDI-DrugBank.d503.s4|36-39|with|O
DDI-DrugBank.d503.s4|41-44|this|O
DDI-DrugBank.d503.s4|46-56|combination|O
DDI-DrugBank.d503.s4|57-57|.|O
DDI-DrugBank.d503.s5|0-7|Consider|O
DDI-DrugBank.d503.s5|9-16|additive|O
DDI-DrugBank.d503.s5|18-25|sedative|O
DDI-DrugBank.d503.s5|27-33|effects|O
DDI-DrugBank.d503.s5|35-37|and|O
DDI-DrugBank.d503.s5|39-49|confusional|O
DDI-DrugBank.d503.s5|51-56|states|O
DDI-DrugBank.d503.s5|58-59|to|O
DDI-DrugBank.d503.s5|61-66|emerge|O
DDI-DrugBank.d503.s5|67-67|,|O
DDI-DrugBank.d503.s5|69-70|if|O
DDI-DrugBank.d503.s5|72-86|chlorprothixene|drug
DDI-DrugBank.d503.s5|88-89|is|O
DDI-DrugBank.d503.s5|91-95|given|O
DDI-DrugBank.d503.s5|97-100|with|O
DDI-DrugBank.d503.s5|102-116|benzodiazepines|group
DDI-DrugBank.d503.s5|118-119|or|O
DDI-DrugBank.d503.s5|121-131|barbituates|group
DDI-DrugBank.d503.s5|132-132|.|O
DDI-DrugBank.d503.s6|0-5|Choose|O
DDI-DrugBank.d503.s6|7-16|particular|O
DDI-DrugBank.d503.s6|18-20|low|O
DDI-DrugBank.d503.s6|22-26|doses|O
DDI-DrugBank.d503.s6|28-29|of|O
DDI-DrugBank.d503.s6|31-35|these|O
DDI-DrugBank.d503.s6|37-41|drugs|O
DDI-DrugBank.d503.s6|42-42|.|O
DDI-DrugBank.d503.s7|0-4|Exert|O
DDI-DrugBank.d503.s7|6-15|particular|O
DDI-DrugBank.d503.s7|17-23|caution|O
DDI-DrugBank.d503.s7|25-26|in|O
DDI-DrugBank.d503.s7|28-36|combining|O
DDI-DrugBank.d503.s7|38-52|chlorprothixene|drug
DDI-DrugBank.d503.s7|54-57|with|O
DDI-DrugBank.d503.s7|59-63|other|O
DDI-DrugBank.d503.s7|65-85|anticholinergic drugs|group
DDI-DrugBank.d503.s7|87-87|(|O
DDI-DrugBank.d503.s7|88-112|tricyclic antidepressants|group
DDI-DrugBank.d503.s7|114-116|and|O
DDI-DrugBank.d503.s7|118-140|antiparkinsonian agents|group
DDI-DrugBank.d503.s7|141-141|)|O
DDI-DrugBank.d503.s7|142-142|:|O
DDI-DrugBank.d503.s7|144-155|Particularly|O
DDI-DrugBank.d503.s7|157-159|the|O
DDI-DrugBank.d503.s7|161-167|elderly|O
DDI-DrugBank.d503.s7|169-171|may|O
DDI-DrugBank.d503.s7|173-179|develop|O
DDI-DrugBank.d503.s7|181-188|delirium|O
DDI-DrugBank.d503.s7|189-189|,|O
DDI-DrugBank.d503.s7|191-194|high|O
DDI-DrugBank.d503.s7|196-200|fever|O
DDI-DrugBank.d503.s7|201-201|,|O
DDI-DrugBank.d503.s7|203-208|severe|O
DDI-DrugBank.d503.s7|210-220|obstipation|O
DDI-DrugBank.d503.s7|221-221|,|O
DDI-DrugBank.d503.s7|223-226|even|O
DDI-DrugBank.d503.s7|228-232|ileus|O
DDI-DrugBank.d503.s7|234-236|and|O
DDI-DrugBank.d503.s7|238-245|glaucoma|O
DDI-DrugBank.d503.s7|246-246|.|O
DDI-DrugBank.d680.s0|0-11|Pantoprazole|drug
DDI-DrugBank.d680.s0|13-14|is|O
DDI-DrugBank.d680.s0|16-26|metabolized|O
DDI-DrugBank.d680.s0|28-34|through|O
DDI-DrugBank.d680.s0|36-38|the|O
DDI-DrugBank.d680.s0|40-49|cytochrome|O
DDI-DrugBank.d680.s0|51-54|P450|O
DDI-DrugBank.d680.s0|56-61|system|O
DDI-DrugBank.d680.s0|62-62|,|O
DDI-DrugBank.d680.s0|64-72|primarily|O
DDI-DrugBank.d680.s0|74-76|the|O
DDI-DrugBank.d680.s0|78-84|CYP2C19|O
DDI-DrugBank.d680.s0|86-88|and|O
DDI-DrugBank.d680.s0|90-95|CYP3A4|O
DDI-DrugBank.d680.s0|97-104|isozymes|O
DDI-DrugBank.d680.s0|105-105|,|O
DDI-DrugBank.d680.s0|107-109|and|O
DDI-DrugBank.d680.s0|111-122|subsequently|O
DDI-DrugBank.d680.s0|124-132|undergoes|O
DDI-DrugBank.d680.s0|134-138|Phase|O
DDI-DrugBank.d680.s0|140-141|II|O
DDI-DrugBank.d680.s0|143-153|conjugation|O
DDI-DrugBank.d680.s0|154-154|.|O
DDI-DrugBank.d680.s1|0-4|Based|O
DDI-DrugBank.d680.s1|6-7|on|O
DDI-DrugBank.d680.s1|9-15|studies|O
DDI-DrugBank.d680.s1|17-26|evaluating|O
DDI-DrugBank.d680.s1|28-35|possible|O
DDI-DrugBank.d680.s1|37-48|interactions|O
DDI-DrugBank.d680.s1|50-51|of|O
DDI-DrugBank.d680.s1|53-64|pantoprazole|drug
DDI-DrugBank.d680.s1|66-69|with|O
DDI-DrugBank.d680.s1|71-75|other|O
DDI-DrugBank.d680.s1|77-81|drugs|O
DDI-DrugBank.d680.s1|82-82|,|O
DDI-DrugBank.d680.s1|84-85|no|O
DDI-DrugBank.d680.s1|87-92|dosage|O
DDI-DrugBank.d680.s1|94-103|adjustment|O
DDI-DrugBank.d680.s1|105-106|is|O
DDI-DrugBank.d680.s1|108-113|needed|O
DDI-DrugBank.d680.s1|115-118|with|O
DDI-DrugBank.d680.s1|120-130|concomitant|O
DDI-DrugBank.d680.s1|132-134|use|O
DDI-DrugBank.d680.s1|136-137|of|O
DDI-DrugBank.d680.s1|139-141|the|O
DDI-DrugBank.d680.s1|143-151|following|O
DDI-DrugBank.d680.s1|152-152|:|O
DDI-DrugBank.d680.s1|154-165|theophylline|drug
DDI-DrugBank.d680.s1|166-166|,|O
DDI-DrugBank.d680.s1|168-176|cisapride|drug
DDI-DrugBank.d680.s1|177-177|,|O
DDI-DrugBank.d680.s1|179-188|antipyrine|drug
DDI-DrugBank.d680.s1|189-189|,|O
DDI-DrugBank.d680.s1|191-198|caffeine|drug
DDI-DrugBank.d680.s1|199-199|,|O
DDI-DrugBank.d680.s1|201-213|carbamazepine|drug
DDI-DrugBank.d680.s1|214-214|,|O
DDI-DrugBank.d680.s1|216-223|diazepam|drug
DDI-DrugBank.d680.s1|225-225|(|O
DDI-DrugBank.d680.s1|226-228|and|O
DDI-DrugBank.d680.s1|230-232|its|O
DDI-DrugBank.d680.s1|234-239|active|O
DDI-DrugBank.d680.s1|241-250|metabolite|O
DDI-DrugBank.d680.s1|251-251|,|O
DDI-DrugBank.d680.s1|270-270|)|O
DDI-DrugBank.d680.s1|271-271|,|O
DDI-DrugBank.d680.s1|273-282|diclofenac|drug
DDI-DrugBank.d680.s1|283-283|,|O
DDI-DrugBank.d680.s1|285-292|naproxen|drug
DDI-DrugBank.d680.s1|293-293|,|O
DDI-DrugBank.d680.s1|295-303|piroxicam|drug
DDI-DrugBank.d680.s1|304-304|,|O
DDI-DrugBank.d680.s1|306-312|digoxin|drug
DDI-DrugBank.d680.s1|313-313|,|O
DDI-DrugBank.d680.s1|315-321|ethanol|drug
DDI-DrugBank.d680.s1|322-322|,|O
DDI-DrugBank.d680.s1|324-332|glyburide|drug
DDI-DrugBank.d680.s1|333-333|,|O
DDI-DrugBank.d680.s1|335-336|an|O
DDI-DrugBank.d680.s1|338-341|oral|O
DDI-DrugBank.d680.s1|343-355|contraceptive|group
DDI-DrugBank.d680.s1|357-357|(|O
DDI-DrugBank.d680.s1|358-389|levonorgestrel/ethinyl estradiol|drug
DDI-DrugBank.d680.s1|390-390|)|O
DDI-DrugBank.d680.s1|391-391|,|O
DDI-DrugBank.d680.s1|393-402|metoprolol|drug
DDI-DrugBank.d680.s1|403-403|,|O
DDI-DrugBank.d680.s1|405-414|nifedipine|drug
DDI-DrugBank.d680.s1|415-415|,|O
DDI-DrugBank.d680.s1|417-425|phenytoin|drug
DDI-DrugBank.d680.s1|426-426|,|O
DDI-DrugBank.d680.s1|428-435|warfarin|drug
DDI-DrugBank.d680.s1|436-436|,|O
DDI-DrugBank.d680.s1|438-446|midazolam|drug
DDI-DrugBank.d680.s1|447-447|,|O
DDI-DrugBank.d680.s1|449-462|clarithromycin|drug
DDI-DrugBank.d680.s1|463-463|,|O
DDI-DrugBank.d680.s1|465-477|metronidazole|drug
DDI-DrugBank.d680.s1|478-478|,|O
DDI-DrugBank.d680.s1|480-481|or|O
DDI-DrugBank.d680.s1|483-493|amoxicillin|drug
DDI-DrugBank.d680.s1|494-494|.|O
DDI-DrugBank.d680.s2|0-9|Clinically|O
DDI-DrugBank.d680.s2|11-18|relevant|O
DDI-DrugBank.d680.s2|20-31|interactions|O
DDI-DrugBank.d680.s2|33-34|of|O
DDI-DrugBank.d680.s2|36-47|pantoprazole|drug
DDI-DrugBank.d680.s2|49-52|with|O
DDI-DrugBank.d680.s2|54-58|other|O
DDI-DrugBank.d680.s2|60-64|drugs|O
DDI-DrugBank.d680.s2|66-69|with|O
DDI-DrugBank.d680.s2|71-73|the|O
DDI-DrugBank.d680.s2|75-78|same|O
DDI-DrugBank.d680.s2|80-88|metabolic|O
DDI-DrugBank.d680.s2|90-97|pathways|O
DDI-DrugBank.d680.s2|99-101|are|O
DDI-DrugBank.d680.s2|103-105|not|O
DDI-DrugBank.d680.s2|107-114|expected|O
DDI-DrugBank.d680.s2|115-115|.|O
DDI-DrugBank.d680.s3|0-8|Therefore|O
DDI-DrugBank.d680.s3|9-9|,|O
DDI-DrugBank.d680.s3|11-14|when|O
DDI-DrugBank.d680.s3|16-29|coadministered|O
DDI-DrugBank.d680.s3|31-34|with|O
DDI-DrugBank.d680.s3|36-47|pantoprazole|drug
DDI-DrugBank.d680.s3|48-48|,|O
DDI-DrugBank.d680.s3|50-59|adjustment|O
DDI-DrugBank.d680.s3|61-62|of|O
DDI-DrugBank.d680.s3|64-66|the|O
DDI-DrugBank.d680.s3|68-73|dosage|O
DDI-DrugBank.d680.s3|75-76|of|O
DDI-DrugBank.d680.s3|78-89|pantoprazole|drug
DDI-DrugBank.d680.s3|91-92|or|O
DDI-DrugBank.d680.s3|94-95|of|O
DDI-DrugBank.d680.s3|97-100|such|O
DDI-DrugBank.d680.s3|102-106|drugs|O
DDI-DrugBank.d680.s3|108-110|may|O
DDI-DrugBank.d680.s3|112-114|not|O
DDI-DrugBank.d680.s3|116-117|be|O
DDI-DrugBank.d680.s3|119-127|necessary|O
DDI-DrugBank.d680.s3|128-128|.|O
DDI-DrugBank.d680.s4|0-4|There|O
DDI-DrugBank.d680.s4|6-8|was|O
DDI-DrugBank.d680.s4|10-13|also|O
DDI-DrugBank.d680.s4|15-16|no|O
DDI-DrugBank.d680.s4|18-28|interaction|O
DDI-DrugBank.d680.s4|30-33|with|O
DDI-DrugBank.d680.s4|35-47|concomitantly|O
DDI-DrugBank.d680.s4|49-60|administered|O
DDI-DrugBank.d680.s4|62-69|antacids|group
DDI-DrugBank.d680.s4|70-70|.|O
DDI-DrugBank.d680.s5|0-4|There|O
DDI-DrugBank.d680.s5|6-9|have|O
DDI-DrugBank.d680.s5|11-14|been|O
DDI-DrugBank.d680.s5|16-28|postmarketing|O
DDI-DrugBank.d680.s5|30-36|reports|O
DDI-DrugBank.d680.s5|38-39|of|O
DDI-DrugBank.d680.s5|41-49|increased|O
DDI-DrugBank.d680.s5|51-53|INR|O
DDI-DrugBank.d680.s5|55-57|and|O
DDI-DrugBank.d680.s5|59-69|prothrombin|O
DDI-DrugBank.d680.s5|71-74|time|O
DDI-DrugBank.d680.s5|76-77|in|O
DDI-DrugBank.d680.s5|79-86|patients|O
DDI-DrugBank.d680.s5|88-96|receiving|O
DDI-DrugBank.d680.s5|98-119|proton pump inhibitors|group
DDI-DrugBank.d680.s5|120-120|,|O
DDI-DrugBank.d680.s5|122-130|including|O
DDI-DrugBank.d680.s5|132-143|pantoprazole|drug
DDI-DrugBank.d680.s5|144-144|,|O
DDI-DrugBank.d680.s5|146-148|and|O
DDI-DrugBank.d680.s5|150-157|warfarin|drug
DDI-DrugBank.d680.s5|159-171|concomitantly|O
DDI-DrugBank.d680.s5|172-172|.|O
DDI-DrugBank.d680.s6|0-8|Increases|O
DDI-DrugBank.d680.s6|10-11|in|O
DDI-DrugBank.d680.s6|13-15|INR|O
DDI-DrugBank.d680.s6|17-19|and|O
DDI-DrugBank.d680.s6|21-31|prothrombin|O
DDI-DrugBank.d680.s6|33-36|time|O
DDI-DrugBank.d680.s6|38-40|may|O
DDI-DrugBank.d680.s6|42-45|lead|O
DDI-DrugBank.d680.s6|47-48|to|O
DDI-DrugBank.d680.s6|50-57|abnormal|O
DDI-DrugBank.d680.s6|59-66|bleeding|O
DDI-DrugBank.d680.s6|68-70|and|O
DDI-DrugBank.d680.s6|72-75|even|O
DDI-DrugBank.d680.s6|77-81|death|O
DDI-DrugBank.d680.s6|82-82|.|O
DDI-DrugBank.d680.s7|0-7|Patients|O
DDI-DrugBank.d680.s7|9-15|treated|O
DDI-DrugBank.d680.s7|17-20|with|O
DDI-DrugBank.d680.s7|22-43|proton pump inhibitors|group
DDI-DrugBank.d680.s7|45-47|and|O
DDI-DrugBank.d680.s7|49-56|warfarin|drug
DDI-DrugBank.d680.s7|58-70|concomitantly|O
DDI-DrugBank.d680.s7|72-77|should|O
DDI-DrugBank.d680.s7|79-80|be|O
DDI-DrugBank.d680.s7|82-90|monitored|O
DDI-DrugBank.d680.s7|92-94|for|O
DDI-DrugBank.d680.s7|96-104|increases|O
DDI-DrugBank.d680.s7|106-107|in|O
DDI-DrugBank.d680.s7|109-111|INR|O
DDI-DrugBank.d680.s7|113-115|and|O
DDI-DrugBank.d680.s7|117-127|prothrombin|O
DDI-DrugBank.d680.s7|129-132|time|O
DDI-DrugBank.d680.s7|133-133|.|O
DDI-DrugBank.d680.s8|0-6|Because|O
DDI-DrugBank.d680.s8|8-9|of|O
DDI-DrugBank.d680.s8|11-18|profound|O
DDI-DrugBank.d680.s8|20-22|and|O
DDI-DrugBank.d680.s8|24-27|long|O
DDI-DrugBank.d680.s8|29-35|lasting|O
DDI-DrugBank.d680.s8|37-46|inhibition|O
DDI-DrugBank.d680.s8|48-49|of|O
DDI-DrugBank.d680.s8|51-57|gastric|O
DDI-DrugBank.d680.s8|59-62|acid|O
DDI-DrugBank.d680.s8|64-72|secretion|O
DDI-DrugBank.d680.s8|73-73|,|O
DDI-DrugBank.d680.s8|75-86|pantoprazole|drug
DDI-DrugBank.d680.s8|88-90|may|O
DDI-DrugBank.d680.s8|92-100|interfere|O
DDI-DrugBank.d680.s8|102-105|with|O
DDI-DrugBank.d680.s8|107-116|absorption|O
DDI-DrugBank.d680.s8|118-119|of|O
DDI-DrugBank.d680.s8|121-125|drugs|O
DDI-DrugBank.d680.s8|127-131|where|O
DDI-DrugBank.d680.s8|133-139|gastric|O
DDI-DrugBank.d680.s8|141-142|pH|O
DDI-DrugBank.d680.s8|144-145|is|O
DDI-DrugBank.d680.s8|147-148|an|O
DDI-DrugBank.d680.s8|150-158|important|O
DDI-DrugBank.d680.s8|160-170|determinant|O
DDI-DrugBank.d680.s8|172-173|of|O
DDI-DrugBank.d680.s8|175-179|their|O
DDI-DrugBank.d680.s8|181-195|bioavailability|O
DDI-DrugBank.d680.s8|197-197|(|O
DDI-DrugBank.d680.s8|198-199|eg|O
DDI-DrugBank.d680.s8|200-200|,|O
DDI-DrugBank.d680.s8|202-213|ketoconazole|drug
DDI-DrugBank.d680.s8|214-214|,|O
DDI-DrugBank.d680.s8|216-225|ampicillin|drug
DDI-DrugBank.d680.s8|227-232|esters|O
DDI-DrugBank.d680.s8|233-233|,|O
DDI-DrugBank.d680.s8|235-237|and|O
DDI-DrugBank.d680.s8|239-242|iron|drug
DDI-DrugBank.d680.s8|244-248|salts|O
DDI-DrugBank.d680.s8|249-249|)|O
DDI-DrugBank.d680.s8|250-250|.|O
DDI-DrugBank.d680.s9|0-9|Laboratory|O
DDI-DrugBank.d680.s9|11-15|Tests|O
DDI-DrugBank.d680.s9|17-21|There|O
DDI-DrugBank.d680.s9|23-26|have|O
DDI-DrugBank.d680.s9|28-31|been|O
DDI-DrugBank.d680.s9|33-39|reports|O
DDI-DrugBank.d680.s9|41-42|of|O
DDI-DrugBank.d680.s9|44-57|false-positive|O
DDI-DrugBank.d680.s9|59-63|urine|O
DDI-DrugBank.d680.s9|65-73|screening|O
DDI-DrugBank.d680.s9|75-79|tests|O
DDI-DrugBank.d680.s9|81-83|for|O
DDI-DrugBank.d680.s9|85-104|tetrahydrocannabinol|drug
DDI-DrugBank.d680.s9|106-106|(|O
DDI-DrugBank.d680.s9|107-109|THC|drug
DDI-DrugBank.d680.s9|110-110|)|O
DDI-DrugBank.d680.s9|112-113|in|O
DDI-DrugBank.d680.s9|115-122|patients|O
DDI-DrugBank.d680.s9|124-132|receiving|O
DDI-DrugBank.d680.s9|134-137|most|O
DDI-DrugBank.d680.s9|139-160|proton pump inhibitors|group
DDI-DrugBank.d680.s9|161-161|,|O
DDI-DrugBank.d680.s9|163-171|including|O
DDI-DrugBank.d680.s9|173-184|pantoprazole|drug
DDI-DrugBank.d680.s9|185-185|.|O
DDI-DrugBank.d680.s10|0-1|An|O
DDI-DrugBank.d680.s10|3-13|alternative|O
DDI-DrugBank.d680.s10|15-26|confirmatory|O
DDI-DrugBank.d680.s10|28-33|method|O
DDI-DrugBank.d680.s10|35-40|should|O
DDI-DrugBank.d680.s10|42-43|be|O
DDI-DrugBank.d680.s10|45-54|considered|O
DDI-DrugBank.d680.s10|56-57|to|O
DDI-DrugBank.d680.s10|59-64|verify|O
DDI-DrugBank.d680.s10|66-73|positive|O
DDI-DrugBank.d680.s10|75-81|results|O
DDI-DrugBank.d680.s10|82-82|.|O
DDI-DrugBank.d455.s0|0-1|In|O
DDI-DrugBank.d455.s0|3-7|vitro|O
DDI-DrugBank.d455.s0|9-15|studies|O
DDI-DrugBank.d455.s0|17-18|of|O
DDI-DrugBank.d455.s0|20-24|human|O
DDI-DrugBank.d455.s0|26-28|CYP|O
DDI-DrugBank.d455.s0|30-36|enzymes|O
DDI-DrugBank.d455.s0|38-43|showed|O
DDI-DrugBank.d455.s0|45-48|that|O
DDI-DrugBank.d455.s0|50-59|entacapone|drug
DDI-DrugBank.d455.s0|61-69|inhibited|O
DDI-DrugBank.d455.s0|71-73|the|O
DDI-DrugBank.d455.s0|75-77|CYP|O
DDI-DrugBank.d455.s0|79-85|enzymes|O
DDI-DrugBank.d455.s0|87-89|1A2|O
DDI-DrugBank.d455.s0|90-90|,|O
DDI-DrugBank.d455.s0|92-94|2A6|O
DDI-DrugBank.d455.s0|95-95|,|O
DDI-DrugBank.d455.s0|97-99|2C9|O
DDI-DrugBank.d455.s0|100-100|,|O
DDI-DrugBank.d455.s0|102-105|2C19|O
DDI-DrugBank.d455.s0|106-106|,|O
DDI-DrugBank.d455.s0|108-110|2D6|O
DDI-DrugBank.d455.s0|111-111|,|O
DDI-DrugBank.d455.s0|113-115|2E1|O
DDI-DrugBank.d455.s0|117-119|and|O
DDI-DrugBank.d455.s0|121-122|3A|O
DDI-DrugBank.d455.s0|124-127|only|O
DDI-DrugBank.d455.s0|129-130|at|O
DDI-DrugBank.d455.s0|132-135|very|O
DDI-DrugBank.d455.s0|137-140|high|O
DDI-DrugBank.d455.s0|142-155|concentrations|O
DDI-DrugBank.d455.s0|157-157|(|O
DDI-DrugBank.d455.s0|158-161|IC50|O
DDI-DrugBank.d455.s0|163-166|from|O
DDI-DrugBank.d455.s0|168-170|200|O
DDI-DrugBank.d455.s0|172-173|to|O
DDI-DrugBank.d455.s0|175-178|over|O
DDI-DrugBank.d455.s0|180-183|1000|O
DDI-DrugBank.d455.s0|185-186|uM|O
DDI-DrugBank.d455.s0|187-187|;|O
DDI-DrugBank.d455.s1|0-1|an|O
DDI-DrugBank.d455.s1|3-6|oral|O
DDI-DrugBank.d455.s1|8-10|200|O
DDI-DrugBank.d455.s1|12-13|mg|O
DDI-DrugBank.d455.s1|15-18|dose|O
DDI-DrugBank.d455.s1|20-27|achieves|O
DDI-DrugBank.d455.s1|29-29|a|O
DDI-DrugBank.d455.s1|31-37|highest|O
DDI-DrugBank.d455.s1|39-43|level|O
DDI-DrugBank.d455.s1|45-46|of|O
DDI-DrugBank.d455.s1|48-60|approximately|O
DDI-DrugBank.d455.s1|62-62|5|O
DDI-DrugBank.d455.s1|64-65|uM|O
DDI-DrugBank.d455.s1|67-68|in|O
DDI-DrugBank.d455.s1|70-75|people|O
DDI-DrugBank.d455.s1|76-76|)|O
DDI-DrugBank.d455.s1|77-77|;|O
DDI-DrugBank.d455.s2|0-4|these|O
DDI-DrugBank.d455.s2|6-12|enzymes|O
DDI-DrugBank.d455.s2|14-18|would|O
DDI-DrugBank.d455.s2|20-28|therefore|O
DDI-DrugBank.d455.s2|30-32|not|O
DDI-DrugBank.d455.s2|34-35|be|O
DDI-DrugBank.d455.s2|37-44|expected|O
DDI-DrugBank.d455.s2|46-47|to|O
DDI-DrugBank.d455.s2|49-50|be|O
DDI-DrugBank.d455.s2|52-60|inhibited|O
DDI-DrugBank.d455.s2|62-63|in|O
DDI-DrugBank.d455.s2|65-72|clinical|O
DDI-DrugBank.d455.s2|74-76|use|O
DDI-DrugBank.d455.s2|77-77|.|O
DDI-DrugBank.d455.s3|0-6|Protein|O
DDI-DrugBank.d455.s3|8-14|Binding|O
DDI-DrugBank.d455.s3|15-15|:|O
DDI-DrugBank.d455.s3|17-26|Entacapone|drug
DDI-DrugBank.d455.s3|28-29|is|O
DDI-DrugBank.d455.s3|31-36|highly|O
DDI-DrugBank.d455.s3|38-44|protein|O
DDI-DrugBank.d455.s3|46-50|bound|O
DDI-DrugBank.d455.s3|52-52|(|O
DDI-DrugBank.d455.s3|53-54|98|O
DDI-DrugBank.d455.s3|55-55|%|O
DDI-DrugBank.d455.s3|56-56|)|O
DDI-DrugBank.d455.s3|57-57|.|O
DDI-DrugBank.d455.s4|0-1|In|O
DDI-DrugBank.d455.s4|3-7|vitro|O
DDI-DrugBank.d455.s4|9-15|studies|O
DDI-DrugBank.d455.s4|17-20|have|O
DDI-DrugBank.d455.s4|22-26|shown|O
DDI-DrugBank.d455.s4|28-29|no|O
DDI-DrugBank.d455.s4|31-37|binding|O
DDI-DrugBank.d455.s4|39-50|displacement|O
DDI-DrugBank.d455.s4|52-58|between|O
DDI-DrugBank.d455.s4|60-69|entacapone|drug
DDI-DrugBank.d455.s4|71-73|and|O
DDI-DrugBank.d455.s4|75-79|other|O
DDI-DrugBank.d455.s4|81-86|highly|O
DDI-DrugBank.d455.s4|88-92|bound|O
DDI-DrugBank.d455.s4|94-98|drugs|O
DDI-DrugBank.d455.s4|99-99|,|O
DDI-DrugBank.d455.s4|101-104|such|O
DDI-DrugBank.d455.s4|106-107|as|O
DDI-DrugBank.d455.s4|109-116|warfarin|drug
DDI-DrugBank.d455.s4|117-117|,|O
DDI-DrugBank.d455.s4|119-132|salicylic acid|drug
DDI-DrugBank.d455.s4|133-133|,|O
DDI-DrugBank.d455.s4|135-148|phenylbutazone|drug
DDI-DrugBank.d455.s4|149-149|,|O
DDI-DrugBank.d455.s4|151-153|and|O
DDI-DrugBank.d455.s4|155-162|diazepam|drug
DDI-DrugBank.d455.s4|163-163|.|O
DDI-DrugBank.d455.s5|0-4|Drugs|O
DDI-DrugBank.d455.s5|6-16|Metabolized|O
DDI-DrugBank.d455.s5|18-19|by|O
DDI-DrugBank.d455.s5|21-48|Catechol-O-methyltransferase|O
DDI-DrugBank.d455.s5|50-50|(|O
DDI-DrugBank.d455.s5|51-54|COMT|O
DDI-DrugBank.d455.s5|55-55|)|O
DDI-DrugBank.d455.s5|56-56|:|O
DDI-DrugBank.d455.s5|58-64|Hormone|O
DDI-DrugBank.d455.s5|66-71|levels|O
DDI-DrugBank.d455.s5|72-72|:|O
DDI-DrugBank.d455.s5|74-81|Levodopa|drug
DDI-DrugBank.d455.s5|83-84|is|O
DDI-DrugBank.d455.s5|86-90|known|O
DDI-DrugBank.d455.s5|92-93|to|O
DDI-DrugBank.d455.s5|95-101|depress|O
DDI-DrugBank.d455.s5|103-111|prolactin|O
DDI-DrugBank.d455.s5|113-121|secretion|O
DDI-DrugBank.d455.s5|123-125|and|O
DDI-DrugBank.d455.s5|127-134|increase|O
DDI-DrugBank.d455.s5|136-141|growth|O
DDI-DrugBank.d455.s5|143-149|hormone|O
DDI-DrugBank.d455.s5|151-156|levels|O
DDI-DrugBank.d455.s5|157-157|.|O
DDI-DrugBank.d455.s6|0-8|Treatment|O
DDI-DrugBank.d455.s6|10-13|with|O
DDI-DrugBank.d455.s6|15-24|entacapone|drug
DDI-DrugBank.d455.s6|26-39|coadministered|O
DDI-DrugBank.d455.s6|41-44|with|O
DDI-DrugBank.d455.s6|46-58|levodopa/dopa|drug
DDI-DrugBank.d455.s6|60-82|decarboxylase inhibitor|group
DDI-DrugBank.d455.s6|84-87|does|O
DDI-DrugBank.d455.s6|89-91|not|O
DDI-DrugBank.d455.s6|93-98|change|O
DDI-DrugBank.d455.s6|100-104|these|O
DDI-DrugBank.d455.s6|106-112|effects|O
DDI-DrugBank.d455.s6|113-113|.|O
DDI-DrugBank.d455.s7|0-1|No|O
DDI-DrugBank.d455.s7|3-13|interaction|O
DDI-DrugBank.d455.s7|15-17|was|O
DDI-DrugBank.d455.s7|19-23|noted|O
DDI-DrugBank.d455.s7|25-28|with|O
DDI-DrugBank.d455.s7|30-32|the|O
DDI-DrugBank.d455.s7|34-48|MAO-B inhibitor|group
DDI-DrugBank.d455.s7|34-48|MAO-B inhibitor|group
DDI-DrugBank.d455.s7|61-62|in|O
DDI-DrugBank.d455.s7|64-66|two|O
DDI-DrugBank.d455.s7|68-80|multiple-dose|O
DDI-DrugBank.d455.s7|82-92|interaction|O
DDI-DrugBank.d455.s7|94-100|studies|O
DDI-DrugBank.d455.s7|102-105|when|O
DDI-DrugBank.d455.s7|107-116|entacapone|drug
DDI-DrugBank.d455.s7|118-120|was|O
DDI-DrugBank.d455.s7|122-135|coadministered|O
DDI-DrugBank.d455.s7|137-140|with|O
DDI-DrugBank.d455.s7|142-142|a|O
DDI-DrugBank.d455.s7|144-156|levodopa/dopa|drug
DDI-DrugBank.d455.s7|158-180|decarboxylase inhibitor|group
DDI-DrugBank.d455.s7|182-182|(|O
DDI-DrugBank.d455.s7|183-186|n=29|O
DDI-DrugBank.d455.s7|187-187|)|O
DDI-DrugBank.d455.s7|188-188|.|O
DDI-DrugBank.d455.s8|0-3|More|O
DDI-DrugBank.d455.s8|5-8|than|O
DDI-DrugBank.d455.s8|10-12|600|O
DDI-DrugBank.d455.s8|14-23|Parkinsons|O
DDI-DrugBank.d455.s8|25-31|disease|O
DDI-DrugBank.d455.s8|33-40|patients|O
DDI-DrugBank.d455.s8|42-43|in|O
DDI-DrugBank.d455.s8|45-52|clinical|O
DDI-DrugBank.d455.s8|54-59|trials|O
DDI-DrugBank.d455.s8|61-64|have|O
DDI-DrugBank.d455.s8|66-69|used|O
DDI-DrugBank.d455.s8|71-80|selegiline|drug
DDI-DrugBank.d455.s8|82-83|in|O
DDI-DrugBank.d455.s8|85-95|combination|O
DDI-DrugBank.d455.s8|97-100|with|O
DDI-DrugBank.d455.s8|102-111|entacapone|drug
DDI-DrugBank.d455.s8|113-115|and|O
DDI-DrugBank.d455.s8|117-129|levodopa/dopa|drug
DDI-DrugBank.d455.s8|131-153|decarboxylase inhibitor|group
DDI-DrugBank.d455.s8|154-154|.|O
DDI-DrugBank.d455.s9|0-1|As|O
DDI-DrugBank.d455.s9|3-6|most|O
DDI-DrugBank.d455.s9|8-17|entacapone|drug
DDI-DrugBank.d455.s9|19-27|excretion|O
DDI-DrugBank.d455.s9|29-30|is|O
DDI-DrugBank.d455.s9|32-34|via|O
DDI-DrugBank.d455.s9|36-38|the|O
DDI-DrugBank.d455.s9|40-43|bile|O
DDI-DrugBank.d455.s9|44-44|,|O
DDI-DrugBank.d455.s9|46-52|caution|O
DDI-DrugBank.d455.s9|54-59|should|O
DDI-DrugBank.d455.s9|61-62|be|O
DDI-DrugBank.d455.s9|64-72|exercised|O
DDI-DrugBank.d455.s9|74-77|when|O
DDI-DrugBank.d455.s9|79-83|drugs|O
DDI-DrugBank.d455.s9|85-89|known|O
DDI-DrugBank.d455.s9|91-92|to|O
DDI-DrugBank.d455.s9|94-102|interfere|O
DDI-DrugBank.d455.s9|104-107|with|O
DDI-DrugBank.d455.s9|109-115|biliary|O
DDI-DrugBank.d455.s9|117-125|excretion|O
DDI-DrugBank.d455.s9|126-126|,|O
DDI-DrugBank.d455.s9|128-142|glucuronidation|O
DDI-DrugBank.d455.s9|143-143|,|O
DDI-DrugBank.d455.s9|145-147|and|O
DDI-DrugBank.d455.s9|149-158|intestinal|O
DDI-DrugBank.d455.s9|160-177|beta-glucuronidase|O
DDI-DrugBank.d455.s9|179-181|are|O
DDI-DrugBank.d455.s9|183-187|given|O
DDI-DrugBank.d455.s9|189-200|concurrently|O
DDI-DrugBank.d455.s9|202-205|with|O
DDI-DrugBank.d455.s9|207-216|entacapone|drug
DDI-DrugBank.d455.s9|217-217|.|O
DDI-DrugBank.d455.s10|0-4|These|O
DDI-DrugBank.d455.s10|6-12|include|O
DDI-DrugBank.d455.s10|14-23|probenecid|drug
DDI-DrugBank.d455.s10|24-24|,|O
DDI-DrugBank.d455.s10|26-39|cholestyramine|drug
DDI-DrugBank.d455.s10|40-40|,|O
DDI-DrugBank.d455.s10|42-44|and|O
DDI-DrugBank.d455.s10|46-49|some|O
DDI-DrugBank.d455.s10|51-61|antibiotics|group
DDI-DrugBank.d455.s10|63-63|(|O
DDI-DrugBank.d455.s10|64-67|e.g.|O
DDI-DrugBank.d455.s10|69-80|erythromycin|drug
DDI-DrugBank.d455.s10|81-81|,|O
DDI-DrugBank.d455.s10|83-93|rifamipicin|O
DDI-DrugBank.d455.s10|94-94|,|O
DDI-DrugBank.d455.s10|96-105|ampicillin|drug
DDI-DrugBank.d455.s10|107-109|and|O
DDI-DrugBank.d455.s10|111-125|chloramphenicol|drug
DDI-DrugBank.d455.s10|126-126|)|O
DDI-DrugBank.d455.s10|127-127|.|O
DDI-DrugBank.d455.s11|0-1|No|O
DDI-DrugBank.d455.s11|3-13|interaction|O
DDI-DrugBank.d455.s11|15-18|with|O
DDI-DrugBank.d455.s11|20-22|the|O
DDI-DrugBank.d455.s11|24-47|tricyclic antidepressant|group
DDI-DrugBank.d455.s11|24-47|tricyclic antidepressant|group
DDI-DrugBank.d455.s11|60-62|was|O
DDI-DrugBank.d455.s11|64-68|shown|O
DDI-DrugBank.d455.s11|70-71|in|O
DDI-DrugBank.d455.s11|73-73|a|O
DDI-DrugBank.d455.s11|75-85|single-dose|O
DDI-DrugBank.d455.s11|87-91|study|O
DDI-DrugBank.d455.s11|93-96|with|O
DDI-DrugBank.d455.s11|98-107|entacapone|drug
DDI-DrugBank.d455.s11|109-115|without|O
DDI-DrugBank.d455.s11|117-130|coadministered|O
DDI-DrugBank.d455.s11|132-158|levodopa/dopa-decarboxylase|drug
DDI-DrugBank.d455.s11|160-168|inhibitor|group
DDI-DrugBank.d455.s11|169-169|.|O
DDI-MedLine.d130.s0|0-8|High-dose|O
DDI-MedLine.d130.s0|10-18|cisplatin|drug
DDI-MedLine.d130.s0|20-23|with|O
DDI-MedLine.d130.s0|25-42|sodium thiosulfate|drug
DDI-MedLine.d130.s0|44-53|protection|O
DDI-MedLine.d130.s0|54-54|.|O
DDI-MedLine.d130.s1|0-13|Nephrotoxicity|O
DDI-MedLine.d130.s1|15-24|frequently|O
DDI-MedLine.d130.s1|26-31|limits|O
DDI-MedLine.d130.s1|33-35|the|O
DDI-MedLine.d130.s1|37-40|dose|O
DDI-MedLine.d130.s1|42-43|of|O
DDI-MedLine.d130.s1|45-53|cisplatin|drug
DDI-MedLine.d130.s1|55-56|to|O
DDI-MedLine.d130.s1|58-61|less|O
DDI-MedLine.d130.s1|63-66|than|O
DDI-MedLine.d130.s1|68-70|120|O
DDI-MedLine.d130.s1|72-76|mg/m2|O
DDI-MedLine.d130.s1|78-80|per|O
DDI-MedLine.d130.s1|82-90|injection|O
DDI-MedLine.d130.s1|91-91|.|O
DDI-MedLine.d130.s2|0-17|Sodium thiosulfate|drug
DDI-MedLine.d130.s2|19-20|is|O
DDI-MedLine.d130.s2|22-22|a|O
DDI-MedLine.d130.s2|24-35|neutralizing|O
DDI-MedLine.d130.s2|37-41|agent|O
DDI-MedLine.d130.s2|43-45|for|O
DDI-MedLine.d130.s2|47-55|cisplatin|drug
DDI-MedLine.d130.s2|57-60|that|O
DDI-MedLine.d130.s2|62-69|protects|O
DDI-MedLine.d130.s2|71-77|against|O
DDI-MedLine.d130.s2|79-83|renal|O
DDI-MedLine.d130.s2|85-90|damage|O
DDI-MedLine.d130.s2|91-91|.|O
DDI-MedLine.d130.s3|0-1|To|O
DDI-MedLine.d130.s3|3-11|determine|O
DDI-MedLine.d130.s3|13-19|whether|O
DDI-MedLine.d130.s3|21-29|injection|O
DDI-MedLine.d130.s3|31-32|of|O
DDI-MedLine.d130.s3|34-44|thiosulfate|drug
DDI-MedLine.d130.s3|46-50|would|O
DDI-MedLine.d130.s3|52-57|permit|O
DDI-MedLine.d130.s3|59-64|larger|O
DDI-MedLine.d130.s3|66-70|doses|O
DDI-MedLine.d130.s3|72-73|of|O
DDI-MedLine.d130.s3|75-83|cisplatin|drug
DDI-MedLine.d130.s3|85-86|to|O
DDI-MedLine.d130.s3|88-89|be|O
DDI-MedLine.d130.s3|91-102|administered|O
DDI-MedLine.d130.s3|103-103|,|O
DDI-MedLine.d130.s3|105-105|a|O
DDI-MedLine.d130.s3|107-111|fixed|O
DDI-MedLine.d130.s3|113-120|9.9-g/m2|O
DDI-MedLine.d130.s3|122-125|dose|O
DDI-MedLine.d130.s3|127-128|of|O
DDI-MedLine.d130.s3|130-140|thiosulfate|drug
DDI-MedLine.d130.s3|142-144|was|O
DDI-MedLine.d130.s3|146-150|given|O
DDI-MedLine.d130.s3|152-164|intravenously|O
DDI-MedLine.d130.s3|166-169|over|O
DDI-MedLine.d130.s3|171-175|three|O
DDI-MedLine.d130.s3|177-181|hours|O
DDI-MedLine.d130.s3|183-194|concurrently|O
DDI-MedLine.d130.s3|196-199|with|O
DDI-MedLine.d130.s3|201-210|escalating|O
DDI-MedLine.d130.s3|212-216|doses|O
DDI-MedLine.d130.s3|218-219|of|O
DDI-MedLine.d130.s3|221-229|cisplatin|drug
DDI-MedLine.d130.s3|230-230|.|O
DDI-MedLine.d130.s4|0-8|Cisplatin|drug
DDI-MedLine.d130.s4|10-12|was|O
DDI-MedLine.d130.s4|14-25|administered|O
DDI-MedLine.d130.s4|27-30|over|O
DDI-MedLine.d130.s4|32-34|the|O
DDI-MedLine.d130.s4|36-39|last|O
DDI-MedLine.d130.s4|41-43|two|O
DDI-MedLine.d130.s4|45-49|hours|O
DDI-MedLine.d130.s4|51-52|of|O
DDI-MedLine.d130.s4|54-56|the|O
DDI-MedLine.d130.s4|58-68|thiosulfate|drug
DDI-MedLine.d130.s4|70-77|infusion|O
DDI-MedLine.d130.s4|78-78|.|O
DDI-MedLine.d130.s5|0-4|Using|O
DDI-MedLine.d130.s5|6-9|this|O
DDI-MedLine.d130.s5|11-19|technique|O
DDI-MedLine.d130.s5|20-20|,|O
DDI-MedLine.d130.s5|22-23|it|O
DDI-MedLine.d130.s5|25-27|was|O
DDI-MedLine.d130.s5|29-36|possible|O
DDI-MedLine.d130.s5|38-39|to|O
DDI-MedLine.d130.s5|41-48|escalate|O
DDI-MedLine.d130.s5|50-52|the|O
DDI-MedLine.d130.s5|54-62|cisplatin|drug
DDI-MedLine.d130.s5|64-67|dose|O
DDI-MedLine.d130.s5|69-70|to|O
DDI-MedLine.d130.s5|72-74|225|O
DDI-MedLine.d130.s5|76-80|mg/m2|O
DDI-MedLine.d130.s5|82-87|before|O
DDI-MedLine.d130.s5|89-101|dose-limiting|O
DDI-MedLine.d130.s5|103-112|toxicities|O
DDI-MedLine.d130.s5|114-117|were|O
DDI-MedLine.d130.s5|119-129|encountered|O
DDI-MedLine.d130.s5|130-130|.|O
DDI-MedLine.d130.s6|0-9|Comparison|O
DDI-MedLine.d130.s6|11-12|of|O
DDI-MedLine.d130.s6|14-22|cisplatin|drug
DDI-MedLine.d130.s6|24-39|pharmacokinetics|O
DDI-MedLine.d130.s6|41-42|in|O
DDI-MedLine.d130.s6|44-51|patients|O
DDI-MedLine.d130.s6|53-59|treated|O
DDI-MedLine.d130.s6|61-64|with|O
DDI-MedLine.d130.s6|66-70|202.5|O
DDI-MedLine.d130.s6|72-76|mg/m2|O
DDI-MedLine.d130.s6|78-81|plus|O
DDI-MedLine.d130.s6|83-93|thiosulfate|drug
DDI-MedLine.d130.s6|95-96|to|O
DDI-MedLine.d130.s6|98-102|those|O
DDI-MedLine.d130.s6|104-105|in|O
DDI-MedLine.d130.s6|107-114|patients|O
DDI-MedLine.d130.s6|116-122|treated|O
DDI-MedLine.d130.s6|124-127|with|O
DDI-MedLine.d130.s6|129-131|100|O
DDI-MedLine.d130.s6|133-137|mg/m2|O
DDI-MedLine.d130.s6|139-145|without|O
DDI-MedLine.d130.s6|147-157|thiosulfate|drug
DDI-MedLine.d130.s6|159-167|indicated|O
DDI-MedLine.d130.s6|169-172|that|O
DDI-MedLine.d130.s6|174-178|there|O
DDI-MedLine.d130.s6|180-183|were|O
DDI-MedLine.d130.s6|185-186|no|O
DDI-MedLine.d130.s6|188-194|changes|O
DDI-MedLine.d130.s6|196-197|in|O
DDI-MedLine.d130.s6|199-201|the|O
DDI-MedLine.d130.s6|203-213|elimination|O
DDI-MedLine.d130.s6|215-218|rate|O
DDI-MedLine.d130.s6|220-227|constant|O
DDI-MedLine.d130.s6|228-228|,|O
DDI-MedLine.d130.s6|230-235|volume|O
DDI-MedLine.d130.s6|237-238|of|O
DDI-MedLine.d130.s6|240-251|distribution|O
DDI-MedLine.d130.s6|252-252|,|O
DDI-MedLine.d130.s6|254-255|or|O
DDI-MedLine.d130.s6|257-261|total|O
DDI-MedLine.d130.s6|263-266|body|O
DDI-MedLine.d130.s6|268-276|clearance|O
DDI-MedLine.d130.s6|278-279|of|O
DDI-MedLine.d130.s6|281-289|cisplatin|drug
DDI-MedLine.d130.s6|290-290|.|O
DDI-MedLine.d130.s7|0-2|The|O
DDI-MedLine.d130.s7|4-8|total|O
DDI-MedLine.d130.s7|10-13|drug|O
DDI-MedLine.d130.s7|15-22|exposure|O
DDI-MedLine.d130.s7|24-26|for|O
DDI-MedLine.d130.s7|28-30|the|O
DDI-MedLine.d130.s7|32-37|plasma|O
DDI-MedLine.d130.s7|39-41|was|O
DDI-MedLine.d130.s7|43-55|approximately|O
DDI-MedLine.d130.s7|57-63|twofold|O
DDI-MedLine.d130.s7|65-66|at|O
DDI-MedLine.d130.s7|68-70|the|O
DDI-MedLine.d130.s7|72-77|higher|O
DDI-MedLine.d130.s7|79-87|cisplatin|drug
DDI-MedLine.d130.s7|89-92|dose|O
DDI-MedLine.d130.s7|93-93|.|O
DDI-MedLine.d130.s8|0-3|This|O
DDI-MedLine.d130.s8|5-9|study|O
DDI-MedLine.d130.s8|11-22|demonstrates|O
DDI-MedLine.d130.s8|24-27|that|O
DDI-MedLine.d130.s8|29-38|concurrent|O
DDI-MedLine.d130.s8|40-53|administration|O
DDI-MedLine.d130.s8|55-56|of|O
DDI-MedLine.d130.s8|58-68|thiosulfate|drug
DDI-MedLine.d130.s8|70-76|permits|O
DDI-MedLine.d130.s8|78-79|at|O
DDI-MedLine.d130.s8|81-85|least|O
DDI-MedLine.d130.s8|87-87|a|O
DDI-MedLine.d130.s8|89-95|twofold|O
DDI-MedLine.d130.s8|97-104|increase|O
DDI-MedLine.d130.s8|106-107|in|O
DDI-MedLine.d130.s8|109-112|dose|O
DDI-MedLine.d130.s8|114-116|and|O
DDI-MedLine.d130.s8|118-122|total|O
DDI-MedLine.d130.s8|124-131|exposure|O
DDI-MedLine.d130.s8|133-134|to|O
DDI-MedLine.d130.s8|136-144|cisplatin|drug
DDI-MedLine.d130.s8|145-145|.|O
DDI-DrugBank.d479.s0|0-2|The|O
DDI-DrugBank.d479.s0|4-15|vasodilating|O
DDI-DrugBank.d479.s0|17-23|effects|O
DDI-DrugBank.d479.s0|25-26|of|O
DDI-DrugBank.d479.s0|28-49|isosorbide mononitrate|drug
DDI-DrugBank.d479.s0|51-53|may|O
DDI-DrugBank.d479.s0|55-56|be|O
DDI-DrugBank.d479.s0|58-65|additive|O
DDI-DrugBank.d479.s0|67-70|with|O
DDI-DrugBank.d479.s0|72-76|those|O
DDI-DrugBank.d479.s0|78-79|of|O
DDI-DrugBank.d479.s0|81-85|other|O
DDI-DrugBank.d479.s0|87-98|vasodilators|group
DDI-DrugBank.d479.s0|99-99|.|O
DDI-DrugBank.d479.s1|0-6|Alcohol|drug
DDI-DrugBank.d479.s1|7-7|,|O
DDI-DrugBank.d479.s1|9-10|in|O
DDI-DrugBank.d479.s1|12-21|particular|O
DDI-DrugBank.d479.s1|22-22|,|O
DDI-DrugBank.d479.s1|24-26|has|O
DDI-DrugBank.d479.s1|28-31|been|O
DDI-DrugBank.d479.s1|33-37|found|O
DDI-DrugBank.d479.s1|39-40|to|O
DDI-DrugBank.d479.s1|42-48|exhibit|O
DDI-DrugBank.d479.s1|50-57|additive|O
DDI-DrugBank.d479.s1|59-65|effects|O
DDI-DrugBank.d479.s1|67-68|of|O
DDI-DrugBank.d479.s1|70-73|this|O
DDI-DrugBank.d479.s1|75-81|variety|O
DDI-DrugBank.d479.s1|82-82|.|O
DDI-DrugBank.d479.s2|0-5|Marked|O
DDI-DrugBank.d479.s2|7-17|symptomatic|O
DDI-DrugBank.d479.s2|19-29|orthostatic|O
DDI-DrugBank.d479.s2|31-41|hypotension|O
DDI-DrugBank.d479.s2|43-45|has|O
DDI-DrugBank.d479.s2|47-50|been|O
DDI-DrugBank.d479.s2|52-59|reported|O
DDI-DrugBank.d479.s2|61-64|when|O
DDI-DrugBank.d479.s2|66-89|calcium channel blockers|group
DDI-DrugBank.d479.s2|91-93|and|O
DDI-DrugBank.d479.s2|95-110|organic nitrates|group
DDI-DrugBank.d479.s2|112-115|were|O
DDI-DrugBank.d479.s2|117-120|used|O
DDI-DrugBank.d479.s2|122-123|in|O
DDI-DrugBank.d479.s2|125-135|combination|O
DDI-DrugBank.d479.s2|136-136|.|O
DDI-DrugBank.d479.s3|0-3|Dose|O
DDI-DrugBank.d479.s3|5-15|adjustments|O
DDI-DrugBank.d479.s3|17-18|of|O
DDI-DrugBank.d479.s3|20-25|either|O
DDI-DrugBank.d479.s3|27-31|class|O
DDI-DrugBank.d479.s3|33-34|of|O
DDI-DrugBank.d479.s3|36-41|agents|O
DDI-DrugBank.d479.s3|43-45|may|O
DDI-DrugBank.d479.s3|47-48|be|O
DDI-DrugBank.d479.s3|50-58|necessary|O
DDI-DrugBank.d479.s3|59-59|.|O
DDI-MedLine.d135.s0|0-11|Combinations|O
DDI-MedLine.d135.s0|13-14|of|O
DDI-MedLine.d135.s0|16-24|clozapine|drug
DDI-MedLine.d135.s0|26-28|and|O
DDI-MedLine.d135.s0|43-43|:|O
DDI-MedLine.d135.s0|45-51|effects|O
DDI-MedLine.d135.s0|53-54|on|O
DDI-MedLine.d135.s0|56-59|drug|O
DDI-MedLine.d135.s0|61-74|discrimination|O
DDI-MedLine.d135.s0|76-78|and|O
DDI-MedLine.d135.s0|80-89|behavioral|O
DDI-MedLine.d135.s0|91-100|inhibition|O
DDI-MedLine.d135.s0|102-103|in|O
DDI-MedLine.d135.s0|105-108|rats|O
DDI-MedLine.d135.s0|109-109|.|O
DDI-MedLine.d135.s1|14-14|(|O
DDI-MedLine.d135.s1|18-18|)|O
DDI-MedLine.d135.s1|20-27|produces|O
DDI-MedLine.d135.s1|29-43|psychotomimetic|O
DDI-MedLine.d135.s1|45-51|effects|O
DDI-MedLine.d135.s1|53-54|in|O
DDI-MedLine.d135.s1|56-61|humans|O
DDI-MedLine.d135.s1|63-66|that|O
DDI-MedLine.d135.s1|68-75|resemble|O
DDI-MedLine.d135.s1|77-89|schizophrenia|O
DDI-MedLine.d135.s1|91-98|symptoms|O
DDI-MedLine.d135.s1|99-99|.|O
DDI-MedLine.d135.s2|0-1|In|O
DDI-MedLine.d135.s2|3-4|an|O
DDI-MedLine.d135.s2|6-11|effort|O
DDI-MedLine.d135.s2|13-14|to|O
DDI-MedLine.d135.s2|16-21|screen|O
DDI-MedLine.d135.s2|23-31|compounds|O
DDI-MedLine.d135.s2|33-35|for|O
DDI-MedLine.d135.s2|37-49|antipsychotic|O
DDI-MedLine.d135.s2|51-58|activity|O
DDI-MedLine.d135.s2|59-59|,|O
DDI-MedLine.d135.s2|61-71|preclinical|O
DDI-MedLine.d135.s2|73-83|researchers|O
DDI-MedLine.d135.s2|85-88|have|O
DDI-MedLine.d135.s2|90-101|investigated|O
DDI-MedLine.d135.s2|103-109|whether|O
DDI-MedLine.d135.s2|111-115|these|O
DDI-MedLine.d135.s2|117-125|compounds|O
DDI-MedLine.d135.s2|127-131|block|O
DDI-MedLine.d135.s2|145-153|behaviors|O
DDI-MedLine.d135.s2|155-156|in|O
DDI-MedLine.d135.s2|158-164|animals|O
DDI-MedLine.d135.s2|165-165|.|O
DDI-MedLine.d135.s3|0-1|In|O
DDI-MedLine.d135.s3|3-5|the|O
DDI-MedLine.d135.s3|7-13|present|O
DDI-MedLine.d135.s3|15-19|study|O
DDI-MedLine.d135.s3|20-20|,|O
DDI-MedLine.d135.s3|22-24|the|O
DDI-MedLine.d135.s3|26-47|atypical antipsychotic|group
DDI-MedLine.d135.s3|26-47|atypical antipsychotic|group
DDI-MedLine.d135.s3|59-61|was|O
DDI-MedLine.d135.s3|63-68|tested|O
DDI-MedLine.d135.s3|70-71|in|O
DDI-MedLine.d135.s3|73-83|combination|O
DDI-MedLine.d135.s3|85-88|with|O
DDI-MedLine.d135.s3|90-91|an|O
DDI-MedLine.d135.s3|93-98|active|O
DDI-MedLine.d135.s3|100-103|dose|O
DDI-MedLine.d135.s3|105-106|of|O
DDI-MedLine.d135.s3|112-113|in|O
DDI-MedLine.d135.s3|115-123|two-lever|O
DDI-MedLine.d135.s3|125-128|drug|O
DDI-MedLine.d135.s3|130-143|discrimination|O
DDI-MedLine.d135.s3|145-147|and|O
DDI-MedLine.d135.s3|149-153|mixed|O
DDI-MedLine.d135.s3|155-175|signalled-unsignalled|O
DDI-MedLine.d135.s3|177-215|differential-reinforcement-of-low-rates|O
DDI-MedLine.d135.s3|217-217|(|O
DDI-MedLine.d135.s3|218-220|DRL|O
DDI-MedLine.d135.s3|221-221|)|O
DDI-MedLine.d135.s3|223-232|procedures|O
DDI-MedLine.d135.s3|233-233|.|O
DDI-MedLine.d135.s4|4-11|produced|O
DDI-MedLine.d135.s4|13-23|distinctive|O
DDI-MedLine.d135.s4|25-31|effects|O
DDI-MedLine.d135.s4|33-34|in|O
DDI-MedLine.d135.s4|36-39|each|O
DDI-MedLine.d135.s4|41-44|task|O
DDI-MedLine.d135.s4|45-45|:|O
DDI-MedLine.d135.s4|47-48|it|O
DDI-MedLine.d135.s4|50-60|substituted|O
DDI-MedLine.d135.s4|62-64|for|O
DDI-MedLine.d135.s4|66-68|the|O
DDI-MedLine.d135.s4|70-77|training|O
DDI-MedLine.d135.s4|79-82|dose|O
DDI-MedLine.d135.s4|84-85|in|O
DDI-MedLine.d135.s4|91-104|discrimination|O
DDI-MedLine.d135.s4|106-108|and|O
DDI-MedLine.d135.s4|110-111|it|O
DDI-MedLine.d135.s4|113-121|increased|O
DDI-MedLine.d135.s4|123-125|the|O
DDI-MedLine.d135.s4|127-132|number|O
DDI-MedLine.d135.s4|134-135|of|O
DDI-MedLine.d135.s4|137-145|responses|O
DDI-MedLine.d135.s4|147-150|with|O
DDI-MedLine.d135.s4|152-156|short|O
DDI-MedLine.d135.s4|158-158|(|O
DDI-MedLine.d135.s4|159-159|<|O
DDI-MedLine.d135.s4|160-160|3|O
DDI-MedLine.d135.s4|162-162|s|O
DDI-MedLine.d135.s4|163-163|)|O
DDI-MedLine.d135.s4|165-177|interresponse|O
DDI-MedLine.d135.s4|179-183|times|O
DDI-MedLine.d135.s4|185-186|as|O
DDI-MedLine.d135.s4|188-191|well|O
DDI-MedLine.d135.s4|193-194|as|O
DDI-MedLine.d135.s4|196-205|increasing|O
DDI-MedLine.d135.s4|207-213|overall|O
DDI-MedLine.d135.s4|215-222|response|O
DDI-MedLine.d135.s4|224-228|rates|O
DDI-MedLine.d135.s4|230-231|in|O
DDI-MedLine.d135.s4|233-235|the|O
DDI-MedLine.d135.s4|237-239|DRL|O
DDI-MedLine.d135.s4|241-248|schedule|O
DDI-MedLine.d135.s4|249-249|.|O
DDI-MedLine.d135.s5|0-4|Acute|O
DDI-MedLine.d135.s5|6-11|dosing|O
DDI-MedLine.d135.s5|13-16|with|O
DDI-MedLine.d135.s5|18-26|clozapine|drug
DDI-MedLine.d135.s5|28-33|failed|O
DDI-MedLine.d135.s5|35-36|to|O
DDI-MedLine.d135.s5|38-42|alter|O
DDI-MedLine.d135.s5|44-46|the|O
DDI-MedLine.d135.s5|48-57|behavioral|O
DDI-MedLine.d135.s5|59-65|effects|O
DDI-MedLine.d135.s5|67-68|of|O
DDI-MedLine.d135.s5|74-75|in|O
DDI-MedLine.d135.s5|77-82|either|O
DDI-MedLine.d135.s5|84-92|procedure|O
DDI-MedLine.d135.s5|94-97|even|O
DDI-MedLine.d135.s5|99-102|when|O
DDI-MedLine.d135.s5|104-109|tested|O
DDI-MedLine.d135.s5|111-112|up|O
DDI-MedLine.d135.s5|114-115|to|O
DDI-MedLine.d135.s5|117-121|doses|O
DDI-MedLine.d135.s5|123-126|that|O
DDI-MedLine.d135.s5|128-135|produced|O
DDI-MedLine.d135.s5|137-151|pharmacological|O
DDI-MedLine.d135.s5|153-159|effects|O
DDI-MedLine.d135.s5|161-165|alone|O
DDI-MedLine.d135.s5|166-166|.|O
DDI-MedLine.d135.s6|0-4|These|O
DDI-MedLine.d135.s6|6-12|results|O
DDI-MedLine.d135.s6|14-20|suggest|O
DDI-MedLine.d135.s6|22-25|that|O
DDI-MedLine.d135.s6|27-31|acute|O
DDI-MedLine.d135.s6|33-38|dosing|O
DDI-MedLine.d135.s6|40-43|with|O
DDI-MedLine.d135.s6|45-53|clozapine|drug
DDI-MedLine.d135.s6|55-59|would|O
DDI-MedLine.d135.s6|61-63|not|O
DDI-MedLine.d135.s6|65-70|affect|O
DDI-MedLine.d135.s6|72-80|behaviors|O
DDI-MedLine.d135.s6|82-85|most|O
DDI-MedLine.d135.s6|87-93|closely|O
DDI-MedLine.d135.s6|95-104|associated|O
DDI-MedLine.d135.s6|106-109|with|O
DDI-MedLine.d135.s6|115-126|intoxication|O
DDI-MedLine.d135.s6|127-127|.|O
DDI-MedLine.d135.s7|0-6|Further|O
DDI-MedLine.d135.s7|7-7|,|O
DDI-MedLine.d135.s7|9-12|they|O
DDI-MedLine.d135.s7|14-18|bring|O
DDI-MedLine.d135.s7|20-23|into|O
DDI-MedLine.d135.s7|25-32|question|O
DDI-MedLine.d135.s7|34-36|the|O
DDI-MedLine.d135.s7|38-44|utility|O
DDI-MedLine.d135.s7|46-47|of|O
DDI-MedLine.d135.s7|49-53|using|O
DDI-MedLine.d135.s7|59-69|combination|O
DDI-MedLine.d135.s7|71-80|procedures|O
DDI-MedLine.d135.s7|82-83|in|O
DDI-MedLine.d135.s7|85-91|animals|O
DDI-MedLine.d135.s7|93-94|to|O
DDI-MedLine.d135.s7|96-101|screen|O
DDI-MedLine.d135.s7|103-105|for|O
DDI-MedLine.d135.s7|107-119|antipsychotic|O
DDI-MedLine.d135.s7|121-129|potential|O
DDI-MedLine.d135.s7|130-130|.|O
DDI-MedLine.d135.s8|0-4|Since|O
DDI-MedLine.d135.s8|6-12|chronic|O
DDI-MedLine.d135.s8|14-19|dosing|O
DDI-MedLine.d135.s8|21-22|is|O
DDI-MedLine.d135.s8|24-31|required|O
DDI-MedLine.d135.s8|33-35|for|O
DDI-MedLine.d135.s8|37-47|therapeutic|O
DDI-MedLine.d135.s8|49-56|efficacy|O
DDI-MedLine.d135.s8|58-59|of|O
DDI-MedLine.d135.s8|61-74|antipsychotics|group
DDI-MedLine.d135.s8|75-75|,|O
DDI-MedLine.d135.s8|77-82|future|O
DDI-MedLine.d135.s8|84-90|studies|O
DDI-MedLine.d135.s8|92-97|should|O
DDI-MedLine.d135.s8|99-103|focus|O
DDI-MedLine.d135.s8|105-106|on|O
DDI-MedLine.d135.s8|108-120|investigation|O
DDI-MedLine.d135.s8|122-123|of|O
DDI-MedLine.d135.s8|125-131|chronic|O
DDI-MedLine.d135.s8|133-138|dosing|O
DDI-MedLine.d135.s8|140-146|effects|O
DDI-MedLine.d135.s8|148-149|of|O
DDI-MedLine.d135.s8|151-155|these|O
DDI-MedLine.d135.s8|157-161|drugs|O
DDI-MedLine.d135.s8|163-164|in|O
DDI-MedLine.d135.s8|166-176|combination|O
DDI-MedLine.d135.s8|178-181|with|O
DDI-MedLine.d135.s8|186-186|.|O
DDI-DrugBank.d315.s0|0-6|Digoxin|drug
DDI-DrugBank.d315.s0|7-7|:|O
DDI-DrugBank.d315.s0|9-24|Coadministration|O
DDI-DrugBank.d315.s0|26-27|of|O
DDI-DrugBank.d315.s0|29-35|digoxin|drug
DDI-DrugBank.d315.s0|36-36|,|O
DDI-DrugBank.d315.s0|38-38|a|O
DDI-DrugBank.d315.s0|40-53|P-glycoprotein|O
DDI-DrugBank.d315.s0|55-63|substrate|O
DDI-DrugBank.d315.s0|64-64|,|O
DDI-DrugBank.d315.s0|66-69|with|O
DDI-DrugBank.d315.s0|71-74|oral|O
DDI-DrugBank.d315.s0|76-85|conivaptan|drug
DDI-DrugBank.d315.s0|87-94|resulted|O
DDI-DrugBank.d315.s0|96-97|in|O
DDI-DrugBank.d315.s0|99-99|a|O
DDI-DrugBank.d315.s0|101-109|reduction|O
DDI-DrugBank.d315.s0|111-112|in|O
DDI-DrugBank.d315.s0|114-122|clearance|O
DDI-DrugBank.d315.s0|124-126|and|O
DDI-DrugBank.d315.s0|128-129|an|O
DDI-DrugBank.d315.s0|131-138|increase|O
DDI-DrugBank.d315.s0|140-141|in|O
DDI-DrugBank.d315.s0|143-149|digoxin|drug
DDI-DrugBank.d315.s0|151-154|Cmax|O
DDI-DrugBank.d315.s0|156-158|and|O
DDI-DrugBank.d315.s0|160-162|AUC|O
DDI-DrugBank.d315.s0|164-169|values|O
DDI-DrugBank.d315.s0|170-170|.|O
DDI-DrugBank.d315.s1|0-8|Therefore|O
DDI-DrugBank.d315.s1|9-9|,|O
DDI-DrugBank.d315.s1|11-12|if|O
DDI-DrugBank.d315.s1|14-20|digoxin|drug
DDI-DrugBank.d315.s1|22-23|is|O
DDI-DrugBank.d315.s1|25-36|administered|O
DDI-DrugBank.d315.s1|38-41|with|O
DDI-DrugBank.d315.s1|43-50|VAPRISOL|brand
DDI-DrugBank.d315.s1|51-51|,|O
DDI-DrugBank.d315.s1|53-55|the|O
DDI-DrugBank.d315.s1|57-65|clinician|O
DDI-DrugBank.d315.s1|67-72|should|O
DDI-DrugBank.d315.s1|74-75|be|O
DDI-DrugBank.d315.s1|77-81|alert|O
DDI-DrugBank.d315.s1|83-84|to|O
DDI-DrugBank.d315.s1|86-88|the|O
DDI-DrugBank.d315.s1|90-100|possibility|O
DDI-DrugBank.d315.s1|102-103|of|O
DDI-DrugBank.d315.s1|105-113|increases|O
DDI-DrugBank.d315.s1|115-116|in|O
DDI-DrugBank.d315.s1|118-124|digoxin|drug
DDI-DrugBank.d315.s1|126-131|levels|O
DDI-DrugBank.d315.s1|132-132|.|O
DDI-DrugBank.d6.s0|0-2|The|O
DDI-DrugBank.d6.s0|4-9|action|O
DDI-DrugBank.d6.s0|11-12|of|O
DDI-DrugBank.d6.s0|14-28|nondepolarizing|O
DDI-DrugBank.d6.s0|30-38|relaxants|O
DDI-DrugBank.d6.s0|40-41|is|O
DDI-DrugBank.d6.s0|43-51|augmented|O
DDI-DrugBank.d6.s0|53-54|by|O
DDI-DrugBank.d6.s0|56-64|Enflurane|drug
DDI-DrugBank.d6.s0|65-65|.|O
DDI-DrugBank.d6.s1|0-3|Less|O
DDI-DrugBank.d6.s1|5-8|than|O
DDI-DrugBank.d6.s1|10-12|the|O
DDI-DrugBank.d6.s1|14-18|usual|O
DDI-DrugBank.d6.s1|20-26|amounts|O
DDI-DrugBank.d6.s1|28-29|of|O
DDI-DrugBank.d6.s1|31-35|these|O
DDI-DrugBank.d6.s1|37-45|medicines|O
DDI-DrugBank.d6.s1|47-52|should|O
DDI-DrugBank.d6.s1|54-55|be|O
DDI-DrugBank.d6.s1|57-60|used|O
DDI-DrugBank.d6.s1|61-61|.|O
DDI-DrugBank.d6.s2|0-1|If|O
DDI-DrugBank.d6.s2|3-5|the|O
DDI-DrugBank.d6.s2|7-11|usual|O
DDI-DrugBank.d6.s2|13-19|amounts|O
DDI-DrugBank.d6.s2|21-22|of|O
DDI-DrugBank.d6.s2|24-38|nondepolarizing|O
DDI-DrugBank.d6.s2|40-48|relaxants|O
DDI-DrugBank.d6.s2|50-52|are|O
DDI-DrugBank.d6.s2|54-58|given|O
DDI-DrugBank.d6.s2|59-59|,|O
DDI-DrugBank.d6.s2|61-63|the|O
DDI-DrugBank.d6.s2|65-68|time|O
DDI-DrugBank.d6.s2|70-72|for|O
DDI-DrugBank.d6.s2|74-81|recovery|O
DDI-DrugBank.d6.s2|83-86|from|O
DDI-DrugBank.d6.s2|88-100|neuromuscular|O
DDI-DrugBank.d6.s2|102-109|blockade|O
DDI-DrugBank.d6.s2|111-114|will|O
DDI-DrugBank.d6.s2|116-117|be|O
DDI-DrugBank.d6.s2|119-124|longer|O
DDI-DrugBank.d6.s2|126-127|in|O
DDI-DrugBank.d6.s2|129-131|the|O
DDI-DrugBank.d6.s2|133-140|presence|O
DDI-DrugBank.d6.s2|142-143|of|O
DDI-DrugBank.d6.s2|145-153|Enflurane|drug
DDI-DrugBank.d6.s2|155-158|than|O
DDI-DrugBank.d6.s2|160-163|when|O
DDI-DrugBank.d6.s2|165-173|halothane|drug
DDI-DrugBank.d6.s2|175-176|or|O
DDI-DrugBank.d6.s2|178-190|nitrous oxide|drug
DDI-DrugBank.d6.s2|192-195|with|O
DDI-DrugBank.d6.s2|197-197|a|O
DDI-DrugBank.d6.s2|199-206|balanced|O
DDI-DrugBank.d6.s2|208-216|technique|O
DDI-DrugBank.d6.s2|218-220|are|O
DDI-DrugBank.d6.s2|222-225|used|O
DDI-DrugBank.d6.s2|226-226|.|O
DDI-MedLine.d55.s0|0-8|Increased|O
DDI-MedLine.d55.s0|10-23|hepatotoxicity|O
DDI-MedLine.d55.s0|25-26|of|O
DDI-MedLine.d55.s0|28-40|acetaminophen|drug
DDI-MedLine.d55.s0|42-43|by|O
DDI-MedLine.d55.s0|45-55|concomitant|O
DDI-MedLine.d55.s0|57-70|administration|O
DDI-MedLine.d55.s0|72-73|of|O
DDI-MedLine.d55.s0|75-82|caffeine|drug
DDI-MedLine.d55.s0|84-85|in|O
DDI-MedLine.d55.s0|87-89|the|O
DDI-MedLine.d55.s0|91-93|rat|O
DDI-MedLine.d55.s0|94-94|.|O
DDI-MedLine.d55.s1|0-4|Since|O
DDI-MedLine.d55.s1|6-13|caffeine|drug
DDI-MedLine.d55.s1|15-16|is|O
DDI-MedLine.d55.s1|18-27|frequently|O
DDI-MedLine.d55.s1|29-43|co-administered|O
DDI-MedLine.d55.s1|45-48|with|O
DDI-MedLine.d55.s1|50-62|acetaminophen|drug
DDI-MedLine.d55.s1|63-63|,|O
DDI-MedLine.d55.s1|65-66|it|O
DDI-MedLine.d55.s1|68-69|is|O
DDI-MedLine.d55.s1|71-72|of|O
DDI-MedLine.d55.s1|74-81|clinical|O
DDI-MedLine.d55.s1|83-90|interest|O
DDI-MedLine.d55.s1|92-93|to|O
DDI-MedLine.d55.s1|95-99|study|O
DDI-MedLine.d55.s1|101-103|the|O
DDI-MedLine.d55.s1|105-110|effect|O
DDI-MedLine.d55.s1|112-113|of|O
DDI-MedLine.d55.s1|115-122|caffeine|drug
DDI-MedLine.d55.s1|124-125|on|O
DDI-MedLine.d55.s1|127-129|the|O
DDI-MedLine.d55.s1|131-144|hepatotoxicity|O
DDI-MedLine.d55.s1|146-147|of|O
DDI-MedLine.d55.s1|149-161|acetaminophen|drug
DDI-MedLine.d55.s1|162-162|.|O
DDI-MedLine.d55.s2|0-1|In|O
DDI-MedLine.d55.s2|3-6|male|O
DDI-MedLine.d55.s2|8-21|Sprague-Dawley|O
DDI-MedLine.d55.s2|23-26|rats|O
DDI-MedLine.d55.s2|28-33|fasted|O
DDI-MedLine.d55.s2|35-37|for|O
DDI-MedLine.d55.s2|39-40|18|O
DDI-MedLine.d55.s2|42-42|h|O
DDI-MedLine.d55.s2|43-43|,|O
DDI-MedLine.d55.s2|45-55|concomitant|O
DDI-MedLine.d55.s2|57-70|administration|O
DDI-MedLine.d55.s2|72-73|of|O
DDI-MedLine.d55.s2|75-82|caffeine|drug
DDI-MedLine.d55.s2|84-84|(|O
DDI-MedLine.d55.s2|85-87|0.1|O
DDI-MedLine.d55.s2|89-92|g/kg|O
DDI-MedLine.d55.s2|93-93|,|O
DDI-MedLine.d55.s2|95-97|i.p|O
DDI-MedLine.d55.s2|98-98|.|O
DDI-MedLine.d55.s2|99-99|)|O
DDI-MedLine.d55.s3|0-1|as|O
DDI-MedLine.d55.s3|3-8|judged|O
DDI-MedLine.d55.s3|10-11|by|O
DDI-MedLine.d55.s3|13-21|increased|O
DDI-MedLine.d55.s3|23-27|serum|O
DDI-MedLine.d55.s3|29-34|enzyme|O
DDI-MedLine.d55.s3|36-45|activities|O
DDI-MedLine.d55.s3|47-49|and|O
DDI-MedLine.d55.s3|51-59|increased|O
DDI-MedLine.d55.s3|61-69|incidence|O
DDI-MedLine.d55.s3|71-72|of|O
DDI-MedLine.d55.s3|74-80|hepatic|O
DDI-MedLine.d55.s3|82-89|necrosis|O
DDI-MedLine.d55.s3|90-90|.|O
DDI-MedLine.d55.s4|0-6|Careful|O
DDI-MedLine.d55.s4|8-19|observations|O
DDI-MedLine.d55.s4|21-22|on|O
DDI-MedLine.d55.s4|24-37|hepatotoxicity|O
DDI-MedLine.d55.s4|39-41|are|O
DDI-MedLine.d55.s4|43-51|suggested|O
DDI-MedLine.d55.s4|53-56|when|O
DDI-MedLine.d55.s4|58-70|acetaminophen|drug
DDI-MedLine.d55.s4|72-73|is|O
DDI-MedLine.d55.s4|75-84|prescribed|O
DDI-MedLine.d55.s4|86-89|with|O
DDI-MedLine.d55.s4|91-98|caffeine|drug
DDI-MedLine.d55.s4|99-99|.|O
DDI-DrugBank.d417.s0|0-9|Netilmicin|drug
DDI-DrugBank.d417.s0|11-16|should|O
DDI-DrugBank.d417.s0|18-20|not|O
DDI-DrugBank.d417.s0|22-23|be|O
DDI-DrugBank.d417.s0|25-36|administered|O
DDI-DrugBank.d417.s0|38-50|concomitantly|O
DDI-DrugBank.d417.s0|52-55|with|O
DDI-DrugBank.d417.s0|57-62|potent|O
DDI-DrugBank.d417.s0|64-77|loop diuretics|group
DDI-DrugBank.d417.s0|79-82|such|O
DDI-DrugBank.d417.s0|84-85|as|O
DDI-DrugBank.d417.s0|87-96|furosemide|drug
DDI-DrugBank.d417.s0|98-100|and|O
DDI-DrugBank.d417.s0|102-116|ethacrynic acid|drug
DDI-DrugBank.d417.s0|118-119|as|O
DDI-DrugBank.d417.s0|121-123|the|O
DDI-DrugBank.d417.s0|125-133|potential|O
DDI-DrugBank.d417.s0|135-137|for|O
DDI-DrugBank.d417.s0|139-149|ototoxicity|O
DDI-DrugBank.d417.s0|151-152|is|O
DDI-DrugBank.d417.s0|154-161|enhanced|O
DDI-DrugBank.d417.s0|163-164|by|O
DDI-DrugBank.d417.s0|166-168|the|O
DDI-DrugBank.d417.s0|170-180|combination|O
DDI-DrugBank.d417.s0|181-181|.|O
DDI-DrugBank.d722.s0|0-4|There|O
DDI-DrugBank.d722.s0|6-7|is|O
DDI-DrugBank.d722.s0|9-15|usually|O
DDI-DrugBank.d722.s0|17-24|complete|O
DDI-DrugBank.d722.s0|26-41|cross-resistance|O
DDI-DrugBank.d722.s0|43-49|between|O
DDI-DrugBank.d722.s0|51-60|PURINETHOL|brand
DDI-DrugBank.d722.s0|62-62|(|O
DDI-DrugBank.d722.s0|63-76|mercaptopurine|drug
DDI-DrugBank.d722.s0|77-77|)|O
DDI-DrugBank.d722.s0|79-81|and|O
DDI-DrugBank.d722.s0|83-89|TABLOID|brand
DDI-DrugBank.d722.s0|91-95|brand|O
DDI-DrugBank.d722.s0|97-107|Thioguanine|drug
DDI-DrugBank.d722.s0|108-108|.|O
DDI-DrugBank.d722.s1|0-1|As|O
DDI-DrugBank.d722.s1|3-7|there|O
DDI-DrugBank.d722.s1|9-10|is|O
DDI-DrugBank.d722.s1|12-13|in|O
DDI-DrugBank.d722.s1|15-19|vitro|O
DDI-DrugBank.d722.s1|21-28|evidence|O
DDI-DrugBank.d722.s1|30-33|that|O
DDI-DrugBank.d722.s1|35-61|aminosalicylate derivatives|group
DDI-DrugBank.d722.s1|63-63|(|O
DDI-DrugBank.d722.s1|64-67|e.g.|O
DDI-DrugBank.d722.s1|68-68|,|O
DDI-DrugBank.d722.s1|70-79|olsalazine|drug
DDI-DrugBank.d722.s1|80-80|,|O
DDI-DrugBank.d722.s1|82-91|mesalazine|drug
DDI-DrugBank.d722.s1|92-92|,|O
DDI-DrugBank.d722.s1|94-95|or|O
DDI-DrugBank.d722.s1|97-110|sulphasalazine|drug
DDI-DrugBank.d722.s1|111-111|)|O
DDI-DrugBank.d722.s1|113-119|inhibit|O
DDI-DrugBank.d722.s1|121-123|the|O
DDI-DrugBank.d722.s1|125-128|TPMT|O
DDI-DrugBank.d722.s1|130-135|enzyme|O
DDI-DrugBank.d722.s1|136-136|,|O
DDI-DrugBank.d722.s1|138-141|they|O
DDI-DrugBank.d722.s1|143-148|should|O
DDI-DrugBank.d722.s1|150-151|be|O
DDI-DrugBank.d722.s1|153-164|administered|O
DDI-DrugBank.d722.s1|166-169|with|O
DDI-DrugBank.d722.s1|171-177|caution|O
DDI-DrugBank.d722.s1|179-180|to|O
DDI-DrugBank.d722.s1|182-189|patients|O
DDI-DrugBank.d722.s1|191-199|receiving|O
DDI-DrugBank.d722.s1|201-210|concurrent|O
DDI-DrugBank.d722.s1|212-222|thioguanine|drug
DDI-DrugBank.d722.s1|224-230|therapy|O
DDI-DrugBank.d722.s1|231-231|.|O
DDI-DrugBank.d414.s0|0-6|Lithium|drug
DDI-DrugBank.d414.s0|8-16|generally|O
DDI-DrugBank.d414.s0|18-23|should|O
DDI-DrugBank.d414.s0|25-27|not|O
DDI-DrugBank.d414.s0|29-30|be|O
DDI-DrugBank.d414.s0|32-36|given|O
DDI-DrugBank.d414.s0|38-41|with|O
DDI-DrugBank.d414.s0|43-51|diuretics|group
DDI-DrugBank.d414.s0|53-59|because|O
DDI-DrugBank.d414.s0|61-64|they|O
DDI-DrugBank.d414.s0|66-71|reduce|O
DDI-DrugBank.d414.s0|73-75|its|O
DDI-DrugBank.d414.s0|77-81|renal|O
DDI-DrugBank.d414.s0|83-91|clearance|O
DDI-DrugBank.d414.s0|93-95|and|O
DDI-DrugBank.d414.s0|97-99|add|O
DDI-DrugBank.d414.s0|101-101|a|O
DDI-DrugBank.d414.s0|103-106|high|O
DDI-DrugBank.d414.s0|108-111|risk|O
DDI-DrugBank.d414.s0|113-114|of|O
DDI-DrugBank.d414.s0|116-122|lithium|drug
DDI-DrugBank.d414.s0|124-131|toxicity|O
DDI-DrugBank.d414.s0|132-132|.|O
DDI-DrugBank.d414.s1|0-3|Read|O
DDI-DrugBank.d414.s1|5-13|circulars|O
DDI-DrugBank.d414.s1|15-17|for|O
DDI-DrugBank.d414.s1|19-25|lithium|drug
DDI-DrugBank.d414.s1|27-38|preparations|O
DDI-DrugBank.d414.s1|40-45|before|O
DDI-DrugBank.d414.s1|47-49|use|O
DDI-DrugBank.d414.s1|51-52|of|O
DDI-DrugBank.d414.s1|54-57|such|O
DDI-DrugBank.d414.s1|59-69|concomitant|O
DDI-DrugBank.d414.s1|71-77|therapy|O
DDI-DrugBank.d414.s1|78-78|.|O
DDI-DrugBank.d414.s2|0-6|EDECRIN|brand
DDI-DrugBank.d414.s2|8-10|may|O
DDI-DrugBank.d414.s2|12-19|increase|O
DDI-DrugBank.d414.s2|21-23|the|O
DDI-DrugBank.d414.s2|25-32|ototoxic|O
DDI-DrugBank.d414.s2|34-42|potential|O
DDI-DrugBank.d414.s2|44-45|of|O
DDI-DrugBank.d414.s2|47-51|other|O
DDI-DrugBank.d414.s2|53-57|drugs|O
DDI-DrugBank.d414.s2|59-62|such|O
DDI-DrugBank.d414.s2|64-65|as|O
DDI-DrugBank.d414.s2|67-80|aminoglycoside|group
DDI-DrugBank.d414.s2|82-84|and|O
DDI-DrugBank.d414.s2|86-89|some|O
DDI-DrugBank.d414.s2|91-115|cephalosporin antibiotics|group
DDI-DrugBank.d414.s2|116-116|.|O
DDI-DrugBank.d414.s3|0-4|Their|O
DDI-DrugBank.d414.s3|6-15|concurrent|O
DDI-DrugBank.d414.s3|17-19|use|O
DDI-DrugBank.d414.s3|21-26|should|O
DDI-DrugBank.d414.s3|28-29|be|O
DDI-DrugBank.d414.s3|31-37|avoided|O
DDI-DrugBank.d414.s3|38-38|.|O
DDI-DrugBank.d414.s4|0-0|A|O
DDI-DrugBank.d414.s4|2-7|number|O
DDI-DrugBank.d414.s4|9-10|of|O
DDI-DrugBank.d414.s4|12-16|drugs|O
DDI-DrugBank.d414.s4|17-17|,|O
DDI-DrugBank.d414.s4|19-27|including|O
DDI-DrugBank.d414.s4|29-43|ethacrynic acid|drug
DDI-DrugBank.d414.s4|44-44|,|O
DDI-DrugBank.d414.s4|46-49|have|O
DDI-DrugBank.d414.s4|51-54|been|O
DDI-DrugBank.d414.s4|56-60|shown|O
DDI-DrugBank.d414.s4|62-63|to|O
DDI-DrugBank.d414.s4|65-72|displace|O
DDI-DrugBank.d414.s4|74-81|warfarin|drug
DDI-DrugBank.d414.s4|83-86|from|O
DDI-DrugBank.d414.s4|88-93|plasma|O
DDI-DrugBank.d414.s4|95-101|protein|O
DDI-DrugBank.d414.s4|102-102|;|O
DDI-DrugBank.d414.s5|0-0|a|O
DDI-DrugBank.d414.s5|2-10|reduction|O
DDI-DrugBank.d414.s5|12-13|in|O
DDI-DrugBank.d414.s5|15-17|the|O
DDI-DrugBank.d414.s5|19-23|usual|O
DDI-DrugBank.d414.s5|25-37|anticoagulant|group
DDI-DrugBank.d414.s5|39-44|dosage|O
DDI-DrugBank.d414.s5|46-48|may|O
DDI-DrugBank.d414.s5|50-51|be|O
DDI-DrugBank.d414.s5|53-60|required|O
DDI-DrugBank.d414.s5|62-63|in|O
DDI-DrugBank.d414.s5|65-72|patients|O
DDI-DrugBank.d414.s5|74-82|receiving|O
DDI-DrugBank.d414.s5|84-87|both|O
DDI-DrugBank.d414.s5|89-93|drugs|O
DDI-DrugBank.d414.s5|94-94|.|O
DDI-DrugBank.d414.s6|0-1|In|O
DDI-DrugBank.d414.s6|3-6|some|O
DDI-DrugBank.d414.s6|8-15|patients|O
DDI-DrugBank.d414.s6|16-16|,|O
DDI-DrugBank.d414.s6|18-20|the|O
DDI-DrugBank.d414.s6|22-35|administration|O
DDI-DrugBank.d414.s6|37-38|of|O
DDI-DrugBank.d414.s6|40-40|a|O
DDI-DrugBank.d414.s6|42-78|non- steroidal antiinflammatory agent|group
DDI-DrugBank.d414.s6|80-82|can|O
DDI-DrugBank.d414.s6|84-89|reduce|O
DDI-DrugBank.d414.s6|91-93|the|O
DDI-DrugBank.d414.s6|95-102|diuretic|O
DDI-DrugBank.d414.s6|103-103|,|O
DDI-DrugBank.d414.s6|105-115|natriuretic|O
DDI-DrugBank.d414.s6|116-116|,|O
DDI-DrugBank.d414.s6|118-120|and|O
DDI-DrugBank.d414.s6|122-137|antihypertensive|O
DDI-DrugBank.d414.s6|139-145|effects|O
DDI-DrugBank.d414.s6|147-148|of|O
DDI-DrugBank.d414.s6|150-153|loop|group
DDI-DrugBank.d414.s6|154-154|,|O
DDI-DrugBank.d414.s6|156-173|potassium- sparing|group
DDI-DrugBank.d414.s6|175-177|and|O
DDI-DrugBank.d414.s6|179-196|thiazide diuretics|group
DDI-DrugBank.d414.s6|197-197|.|O
DDI-DrugBank.d414.s7|0-8|Therefore|O
DDI-DrugBank.d414.s7|9-9|,|O
DDI-DrugBank.d414.s7|11-14|when|O
DDI-DrugBank.d414.s7|16-22|EDECRIN|brand
DDI-DrugBank.d414.s7|24-26|and|O
DDI-DrugBank.d414.s7|28-67|non- steroidal anti- inflammatory agents|group
DDI-DrugBank.d414.s7|69-71|are|O
DDI-DrugBank.d414.s7|73-76|used|O
DDI-DrugBank.d414.s7|78-90|concomitantly|O
DDI-DrugBank.d414.s7|91-91|,|O
DDI-DrugBank.d414.s7|93-95|the|O
DDI-DrugBank.d414.s7|97-103|patient|O
DDI-DrugBank.d414.s7|105-110|should|O
DDI-DrugBank.d414.s7|112-113|be|O
DDI-DrugBank.d414.s7|115-122|observed|O
DDI-DrugBank.d414.s7|124-130|closely|O
DDI-DrugBank.d414.s7|132-133|to|O
DDI-DrugBank.d414.s7|135-143|determine|O
DDI-DrugBank.d414.s7|145-146|if|O
DDI-DrugBank.d414.s7|148-150|the|O
DDI-DrugBank.d414.s7|152-158|desired|O
DDI-DrugBank.d414.s7|160-165|effect|O
DDI-DrugBank.d414.s7|167-168|of|O
DDI-DrugBank.d414.s7|170-172|the|O
DDI-DrugBank.d414.s7|174-181|diuretic|group
DDI-DrugBank.d414.s7|183-184|is|O
DDI-DrugBank.d414.s7|186-193|obtained|O
DDI-DrugBank.d414.s7|194-194|.|O
DDI-DrugBank.d572.s0|0-13|Cholestyramine|drug
DDI-DrugBank.d572.s0|14-14|:|O
DDI-DrugBank.d572.s0|16-26|Concomitant|O
DDI-DrugBank.d572.s0|28-41|cholestyramine|drug
DDI-DrugBank.d572.s0|43-56|administration|O
DDI-DrugBank.d572.s0|58-66|decreased|O
DDI-DrugBank.d572.s0|68-70|the|O
DDI-DrugBank.d572.s0|72-75|mean|O
DDI-DrugBank.d572.s0|77-79|AUC|O
DDI-DrugBank.d572.s0|81-82|of|O
DDI-DrugBank.d572.s0|84-88|total|O
DDI-DrugBank.d572.s0|90-98|ezetimibe|drug
DDI-DrugBank.d572.s0|100-112|approximately|O
DDI-DrugBank.d572.s0|114-115|55|O
DDI-DrugBank.d572.s0|116-116|%|O
DDI-DrugBank.d572.s0|117-117|.|O
DDI-DrugBank.d572.s1|0-2|The|O
DDI-DrugBank.d572.s1|4-14|incremental|O
DDI-DrugBank.d572.s1|16-20|LDL-C|O
DDI-DrugBank.d572.s1|22-30|reduction|O
DDI-DrugBank.d572.s1|32-34|due|O
DDI-DrugBank.d572.s1|36-37|to|O
DDI-DrugBank.d572.s1|39-44|adding|O
DDI-DrugBank.d572.s1|46-54|ezetimibe|drug
DDI-DrugBank.d572.s1|56-57|to|O
DDI-DrugBank.d572.s1|59-72|cholestyramine|drug
DDI-DrugBank.d572.s1|74-76|may|O
DDI-DrugBank.d572.s1|78-79|be|O
DDI-DrugBank.d572.s1|81-87|reduced|O
DDI-DrugBank.d572.s1|89-90|by|O
DDI-DrugBank.d572.s1|92-95|this|O
DDI-DrugBank.d572.s1|97-107|interaction|O
DDI-DrugBank.d572.s1|108-108|.|O
DDI-DrugBank.d572.s2|0-7|Fibrates|group
DDI-DrugBank.d572.s2|8-8|:|O
DDI-DrugBank.d572.s2|10-12|The|O
DDI-DrugBank.d572.s2|14-19|safety|O
DDI-DrugBank.d572.s2|21-23|and|O
DDI-DrugBank.d572.s2|25-37|effectiveness|O
DDI-DrugBank.d572.s2|39-40|of|O
DDI-DrugBank.d572.s2|42-50|ezetimibe|drug
DDI-DrugBank.d572.s2|52-63|administered|O
DDI-DrugBank.d572.s2|65-68|with|O
DDI-DrugBank.d572.s2|70-77|fibrates|group
DDI-DrugBank.d572.s2|79-82|have|O
DDI-DrugBank.d572.s2|84-86|not|O
DDI-DrugBank.d572.s2|88-91|been|O
DDI-DrugBank.d572.s2|93-103|established|O
DDI-DrugBank.d572.s2|104-104|.|O
DDI-DrugBank.d572.s3|0-7|Fibrates|group
DDI-DrugBank.d572.s3|9-11|may|O
DDI-DrugBank.d572.s3|13-20|increase|O
DDI-DrugBank.d572.s3|22-32|cholesterol|O
DDI-DrugBank.d572.s3|34-42|excretion|O
DDI-DrugBank.d572.s3|44-47|into|O
DDI-DrugBank.d572.s3|49-51|the|O
DDI-DrugBank.d572.s3|53-56|bile|O
DDI-DrugBank.d572.s3|57-57|,|O
DDI-DrugBank.d572.s3|59-65|leading|O
DDI-DrugBank.d572.s3|67-68|to|O
DDI-DrugBank.d572.s3|70-83|cholelithiasis|O
DDI-DrugBank.d572.s3|84-84|.|O
DDI-DrugBank.d572.s4|0-1|In|O
DDI-DrugBank.d572.s4|3-3|a|O
DDI-DrugBank.d572.s4|5-15|preclinical|O
DDI-DrugBank.d572.s4|17-21|study|O
DDI-DrugBank.d572.s4|23-24|in|O
DDI-DrugBank.d572.s4|26-29|dogs|O
DDI-DrugBank.d572.s4|30-30|,|O
DDI-DrugBank.d572.s4|32-40|ezetimibe|drug
DDI-DrugBank.d572.s4|42-50|increased|O
DDI-DrugBank.d572.s4|52-62|cholesterol|O
DDI-DrugBank.d572.s4|64-65|in|O
DDI-DrugBank.d572.s4|67-69|the|O
DDI-DrugBank.d572.s4|71-81|gallbladder|O
DDI-DrugBank.d572.s4|83-86|bile|O
DDI-DrugBank.d572.s4|87-87|.|O
DDI-DrugBank.d572.s5|0-16|Co-administration|O
DDI-DrugBank.d572.s5|18-19|of|O
DDI-DrugBank.d572.s5|21-25|ZETIA|brand
DDI-DrugBank.d572.s5|27-30|with|O
DDI-DrugBank.d572.s5|32-39|fibrates|group
DDI-DrugBank.d572.s5|41-42|is|O
DDI-DrugBank.d572.s5|44-46|not|O
DDI-DrugBank.d572.s5|48-58|recommended|O
DDI-DrugBank.d572.s5|60-64|until|O
DDI-DrugBank.d572.s5|66-68|use|O
DDI-DrugBank.d572.s5|70-71|in|O
DDI-DrugBank.d572.s5|73-80|patients|O
DDI-DrugBank.d572.s5|82-83|is|O
DDI-DrugBank.d572.s5|85-91|studied|O
DDI-DrugBank.d572.s5|92-92|.|O
DDI-DrugBank.d572.s6|0-10|Fenofibrate|drug
DDI-DrugBank.d572.s6|11-11|:|O
DDI-DrugBank.d572.s6|13-14|In|O
DDI-DrugBank.d572.s6|16-16|a|O
DDI-DrugBank.d572.s6|18-32|pharmacokinetic|O
DDI-DrugBank.d572.s6|34-38|study|O
DDI-DrugBank.d572.s6|39-39|,|O
DDI-DrugBank.d572.s6|41-51|concomitant|O
DDI-DrugBank.d572.s6|53-63|fenofibrate|drug
DDI-DrugBank.d572.s6|65-78|administration|O
DDI-DrugBank.d572.s6|80-88|increased|O
DDI-DrugBank.d572.s6|90-94|total|O
DDI-DrugBank.d572.s6|96-104|ezetimibe|drug
DDI-DrugBank.d572.s6|106-119|concentrations|O
DDI-DrugBank.d572.s6|121-133|approximately|O
DDI-DrugBank.d572.s6|135-142|1.5-fold|O
DDI-DrugBank.d572.s6|143-143|.|O
DDI-DrugBank.d572.s7|0-10|Gemfibrozil|drug
DDI-DrugBank.d572.s7|11-11|:|O
DDI-DrugBank.d572.s7|13-14|In|O
DDI-DrugBank.d572.s7|16-16|a|O
DDI-DrugBank.d572.s7|18-32|pharmacokinetic|O
DDI-DrugBank.d572.s7|34-38|study|O
DDI-DrugBank.d572.s7|39-39|,|O
DDI-DrugBank.d572.s7|41-51|concomitant|O
DDI-DrugBank.d572.s7|53-63|gemfibrozil|drug
DDI-DrugBank.d572.s7|65-78|administration|O
DDI-DrugBank.d572.s7|80-88|increased|O
DDI-DrugBank.d572.s7|90-94|total|O
DDI-DrugBank.d572.s7|96-104|ezetimibe|drug
DDI-DrugBank.d572.s7|106-119|concentrations|O
DDI-DrugBank.d572.s7|121-133|approximately|O
DDI-DrugBank.d572.s7|135-142|1.7-fold|O
DDI-DrugBank.d572.s7|143-143|.|O
DDI-DrugBank.d572.s8|0-27|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d572.s8|28-28|:|O
DDI-DrugBank.d572.s8|30-31|No|O
DDI-DrugBank.d572.s8|33-42|clinically|O
DDI-DrugBank.d572.s8|44-54|significant|O
DDI-DrugBank.d572.s8|56-70|pharmacokinetic|O
DDI-DrugBank.d572.s8|72-83|interactions|O
DDI-DrugBank.d572.s8|85-88|were|O
DDI-DrugBank.d572.s8|90-93|seen|O
DDI-DrugBank.d572.s8|95-98|when|O
DDI-DrugBank.d572.s8|100-108|ezetimibe|drug
DDI-DrugBank.d572.s8|110-112|was|O
DDI-DrugBank.d572.s8|114-128|co-administered|O
DDI-DrugBank.d572.s8|130-133|with|O
DDI-DrugBank.d572.s8|135-146|atorvastatin|drug
DDI-DrugBank.d572.s8|147-147|,|O
DDI-DrugBank.d572.s8|149-159|simvastatin|drug
DDI-DrugBank.d572.s8|160-160|,|O
DDI-DrugBank.d572.s8|162-172|pravastatin|drug
DDI-DrugBank.d572.s8|173-173|,|O
DDI-DrugBank.d572.s8|175-184|lovastatin|drug
DDI-DrugBank.d572.s8|185-185|,|O
DDI-DrugBank.d572.s8|187-188|or|O
DDI-DrugBank.d572.s8|190-200|fluvastatin|drug
DDI-DrugBank.d572.s8|201-201|.|O
DDI-DrugBank.d572.s9|0-11|Cyclosporine|drug
DDI-DrugBank.d572.s9|12-12|:|O
DDI-DrugBank.d572.s9|14-16|The|O
DDI-DrugBank.d572.s9|18-22|total|O
DDI-DrugBank.d572.s9|24-32|ezetimibe|drug
DDI-DrugBank.d572.s9|34-38|level|O
DDI-DrugBank.d572.s9|40-48|increased|O
DDI-DrugBank.d572.s9|50-56|12-fold|O
DDI-DrugBank.d572.s9|58-59|in|O
DDI-DrugBank.d572.s9|61-63|one|O
DDI-DrugBank.d572.s9|65-69|renal|O
DDI-DrugBank.d572.s9|71-80|transplant|O
DDI-DrugBank.d572.s9|82-88|patient|O
DDI-DrugBank.d572.s9|90-98|receiving|O
DDI-DrugBank.d572.s9|100-107|multiple|O
DDI-DrugBank.d572.s9|109-119|medications|O
DDI-DrugBank.d572.s9|120-120|,|O
DDI-DrugBank.d572.s9|122-130|including|O
DDI-DrugBank.d572.s9|132-143|cyclosporine|drug
DDI-DrugBank.d572.s9|144-144|.|O
DDI-DrugBank.d572.s10|0-7|Patients|O
DDI-DrugBank.d572.s10|9-11|who|O
DDI-DrugBank.d572.s10|13-16|take|O
DDI-DrugBank.d572.s10|18-21|both|O
DDI-DrugBank.d572.s10|23-31|ezetimibe|drug
DDI-DrugBank.d572.s10|33-35|and|O
DDI-DrugBank.d572.s10|37-48|cyclosporine|drug
DDI-DrugBank.d572.s10|50-55|should|O
DDI-DrugBank.d572.s10|57-58|be|O
DDI-DrugBank.d572.s10|60-68|carefully|O
DDI-DrugBank.d572.s10|70-78|monitored|O
DDI-DrugBank.d572.s10|79-79|.|O
DDI-DrugBank.d572.s11|0-13|Carcinogenesis|O
DDI-DrugBank.d572.s11|14-14|,|O
DDI-DrugBank.d572.s11|16-26|Mutagenesis|O
DDI-DrugBank.d572.s11|27-27|,|O
DDI-DrugBank.d572.s11|29-38|Impairment|O
DDI-DrugBank.d572.s11|40-41|of|O
DDI-DrugBank.d572.s11|43-51|Fertility|O
DDI-DrugBank.d572.s11|53-53|A|O
DDI-DrugBank.d572.s11|55-62|104-week|O
DDI-DrugBank.d572.s11|64-70|dietary|O
DDI-DrugBank.d572.s11|72-86|carcinogenicity|O
DDI-DrugBank.d572.s11|88-92|study|O
DDI-DrugBank.d572.s11|94-97|with|O
DDI-DrugBank.d572.s11|99-107|ezetimibe|drug
DDI-DrugBank.d572.s11|109-111|was|O
DDI-DrugBank.d572.s11|113-121|conducted|O
DDI-DrugBank.d572.s11|123-124|in|O
DDI-DrugBank.d572.s11|126-129|rats|O
DDI-DrugBank.d572.s11|131-132|at|O
DDI-DrugBank.d572.s11|134-138|doses|O
DDI-DrugBank.d572.s11|140-141|up|O
DDI-DrugBank.d572.s11|143-144|to|O
DDI-DrugBank.d572.s11|146-149|1500|O
DDI-DrugBank.d572.s11|151-159|mg/kg/day|O
DDI-DrugBank.d572.s11|161-161|(|O
DDI-DrugBank.d572.s11|162-166|males|O
DDI-DrugBank.d572.s11|167-167|)|O
DDI-DrugBank.d572.s11|169-171|and|O
DDI-DrugBank.d572.s11|173-175|500|O
DDI-DrugBank.d572.s11|177-185|mg/kg/day|O
DDI-DrugBank.d572.s11|187-187|(|O
DDI-DrugBank.d572.s11|188-194|females|O
DDI-DrugBank.d572.s11|195-195|)|O
DDI-DrugBank.d572.s11|197-197|(|O
DDI-DrugBank.d572.s11|198-200|~20|O
DDI-DrugBank.d572.s11|202-206|times|O
DDI-DrugBank.d572.s11|208-210|the|O
DDI-DrugBank.d572.s11|212-216|human|O
DDI-DrugBank.d572.s11|218-225|exposure|O
DDI-DrugBank.d572.s11|227-228|at|O
DDI-DrugBank.d572.s11|230-231|10|O
DDI-DrugBank.d572.s11|233-234|mg|O
DDI-DrugBank.d572.s11|236-240|daily|O
DDI-DrugBank.d572.s11|242-246|based|O
DDI-DrugBank.d572.s11|248-249|on|O
DDI-DrugBank.d572.s11|251-259|AUC0-24hr|O
DDI-DrugBank.d572.s11|261-263|for|O
DDI-DrugBank.d572.s11|265-269|total|O
DDI-DrugBank.d572.s11|271-279|ezetimibe|drug
DDI-DrugBank.d572.s11|280-280|)|O
DDI-DrugBank.d572.s11|281-281|.|O
DDI-DrugBank.d572.s12|0-0|A|O
DDI-DrugBank.d572.s12|2-9|104-week|O
DDI-DrugBank.d572.s12|11-17|dietary|O
DDI-DrugBank.d572.s12|19-33|carcinogenicity|O
DDI-DrugBank.d572.s12|35-39|study|O
DDI-DrugBank.d572.s12|41-44|with|O
DDI-DrugBank.d572.s12|46-54|ezetimibe|drug
DDI-DrugBank.d572.s12|56-58|was|O
DDI-DrugBank.d572.s12|60-63|also|O
DDI-DrugBank.d572.s12|65-73|conducted|O
DDI-DrugBank.d572.s12|75-76|in|O
DDI-DrugBank.d572.s12|78-81|mice|O
DDI-DrugBank.d572.s12|83-84|at|O
DDI-DrugBank.d572.s12|86-90|doses|O
DDI-DrugBank.d572.s12|92-93|up|O
DDI-DrugBank.d572.s12|95-96|to|O
DDI-DrugBank.d572.s12|98-100|500|O
DDI-DrugBank.d572.s12|102-110|mg/kg/day|O
DDI-DrugBank.d572.s12|112-112|(|O
DDI-DrugBank.d572.s12|113-113|>|O
DDI-DrugBank.d572.s12|114-116|150|O
DDI-DrugBank.d572.s12|118-122|times|O
DDI-DrugBank.d572.s12|124-126|the|O
DDI-DrugBank.d572.s12|128-132|human|O
DDI-DrugBank.d572.s12|134-141|exposure|O
DDI-DrugBank.d572.s12|143-144|at|O
DDI-DrugBank.d572.s12|146-147|10|O
DDI-DrugBank.d572.s12|149-150|mg|O
DDI-DrugBank.d572.s12|152-156|daily|O
DDI-DrugBank.d572.s12|158-162|based|O
DDI-DrugBank.d572.s12|164-165|on|O
DDI-DrugBank.d572.s12|167-175|AUC0-24hr|O
DDI-DrugBank.d572.s12|177-179|for|O
DDI-DrugBank.d572.s12|181-185|total|O
DDI-DrugBank.d572.s12|187-195|ezetimibe|drug
DDI-DrugBank.d572.s12|196-196|)|O
DDI-DrugBank.d572.s12|197-197|.|O
DDI-DrugBank.d572.s13|0-4|There|O
DDI-DrugBank.d572.s13|6-9|were|O
DDI-DrugBank.d572.s13|11-12|no|O
DDI-DrugBank.d572.s13|14-26|statistically|O
DDI-DrugBank.d572.s13|28-38|significant|O
DDI-DrugBank.d572.s13|40-48|increases|O
DDI-DrugBank.d572.s13|50-51|in|O
DDI-DrugBank.d572.s13|53-57|tumor|O
DDI-DrugBank.d572.s13|59-68|incidences|O
DDI-DrugBank.d572.s13|70-71|in|O
DDI-DrugBank.d572.s13|73-84|drug-treated|O
DDI-DrugBank.d572.s13|86-89|rats|O
DDI-DrugBank.d572.s13|91-92|or|O
DDI-DrugBank.d572.s13|94-97|mice|O
DDI-DrugBank.d572.s13|98-98|.|O
DDI-DrugBank.d572.s14|0-1|No|O
DDI-DrugBank.d572.s14|3-10|evidence|O
DDI-DrugBank.d572.s14|12-13|of|O
DDI-DrugBank.d572.s14|15-26|mutagenicity|O
DDI-DrugBank.d572.s14|28-30|was|O
DDI-DrugBank.d572.s14|32-39|observed|O
DDI-DrugBank.d572.s14|41-42|in|O
DDI-DrugBank.d572.s14|44-48|vitro|O
DDI-DrugBank.d572.s14|50-51|in|O
DDI-DrugBank.d572.s14|53-53|a|O
DDI-DrugBank.d572.s14|55-63|microbial|O
DDI-DrugBank.d572.s14|65-76|mutagenicity|O
DDI-DrugBank.d572.s14|78-78|(|O
DDI-DrugBank.d572.s14|79-82|Ames|O
DDI-DrugBank.d572.s14|83-83|)|O
DDI-DrugBank.d572.s14|85-88|test|O
DDI-DrugBank.d572.s14|90-93|with|O
DDI-DrugBank.d572.s14|95-104|Salmonella|O
DDI-DrugBank.d572.s14|106-116|typhimurium|O
DDI-DrugBank.d572.s14|118-120|and|O
DDI-DrugBank.d572.s14|122-132|Escherichia|O
DDI-DrugBank.d572.s14|134-137|coli|O
DDI-DrugBank.d572.s14|139-142|with|O
DDI-DrugBank.d572.s14|144-145|or|O
DDI-DrugBank.d572.s14|147-153|without|O
DDI-DrugBank.d572.s14|155-163|metabolic|O
DDI-DrugBank.d572.s14|165-174|activation|O
DDI-DrugBank.d572.s14|175-175|.|O
DDI-DrugBank.d572.s15|0-1|No|O
DDI-DrugBank.d572.s15|3-10|evidence|O
DDI-DrugBank.d572.s15|12-13|of|O
DDI-DrugBank.d572.s15|15-28|clastogenicity|O
DDI-DrugBank.d572.s15|30-32|was|O
DDI-DrugBank.d572.s15|34-41|observed|O
DDI-DrugBank.d572.s15|43-44|in|O
DDI-DrugBank.d572.s15|46-50|vitro|O
DDI-DrugBank.d572.s15|52-53|in|O
DDI-DrugBank.d572.s15|55-55|a|O
DDI-DrugBank.d572.s15|57-67|chromosomal|O
DDI-DrugBank.d572.s15|69-78|aberration|O
DDI-DrugBank.d572.s15|80-84|assay|O
DDI-DrugBank.d572.s15|86-87|in|O
DDI-DrugBank.d572.s15|89-93|human|O
DDI-DrugBank.d572.s15|95-104|peripheral|O
DDI-DrugBank.d572.s15|106-110|blood|O
DDI-DrugBank.d572.s15|112-122|lymphocytes|O
DDI-DrugBank.d572.s15|124-127|with|O
DDI-DrugBank.d572.s15|129-130|or|O
DDI-DrugBank.d572.s15|132-138|without|O
DDI-DrugBank.d572.s15|140-148|metabolic|O
DDI-DrugBank.d572.s15|150-159|activation|O
DDI-DrugBank.d572.s15|160-160|.|O
DDI-DrugBank.d572.s16|0-1|In|O
DDI-DrugBank.d572.s16|3-10|addition|O
DDI-DrugBank.d572.s16|11-11|,|O
DDI-DrugBank.d572.s16|13-17|there|O
DDI-DrugBank.d572.s16|19-21|was|O
DDI-DrugBank.d572.s16|23-24|no|O
DDI-DrugBank.d572.s16|26-33|evidence|O
DDI-DrugBank.d572.s16|35-36|of|O
DDI-DrugBank.d572.s16|38-49|genotoxicity|O
DDI-DrugBank.d572.s16|51-52|in|O
DDI-DrugBank.d572.s16|54-56|the|O
DDI-DrugBank.d572.s16|58-59|in|O
DDI-DrugBank.d572.s16|61-64|vivo|O
DDI-DrugBank.d572.s16|66-70|mouse|O
DDI-DrugBank.d572.s16|72-83|micronucleus|O
DDI-DrugBank.d572.s16|85-88|test|O
DDI-DrugBank.d572.s16|89-89|.|O
DDI-DrugBank.d572.s17|0-1|In|O
DDI-DrugBank.d572.s17|3-6|oral|O
DDI-DrugBank.d572.s17|8-8|(|O
DDI-DrugBank.d572.s17|9-14|gavage|O
DDI-DrugBank.d572.s17|15-15|)|O
DDI-DrugBank.d572.s17|17-25|fertility|O
DDI-DrugBank.d572.s17|27-33|studies|O
DDI-DrugBank.d572.s17|35-36|of|O
DDI-DrugBank.d572.s17|38-46|ezetimibe|drug
DDI-DrugBank.d572.s17|48-56|conducted|O
DDI-DrugBank.d572.s17|58-59|in|O
DDI-DrugBank.d572.s17|61-64|rats|O
DDI-DrugBank.d572.s17|65-65|,|O
DDI-DrugBank.d572.s17|67-71|there|O
DDI-DrugBank.d572.s17|73-75|was|O
DDI-DrugBank.d572.s17|77-78|no|O
DDI-DrugBank.d572.s17|80-87|evidence|O
DDI-DrugBank.d572.s17|89-90|of|O
DDI-DrugBank.d572.s17|92-103|reproductive|O
DDI-DrugBank.d572.s17|105-112|toxicity|O
DDI-DrugBank.d572.s17|114-115|at|O
DDI-DrugBank.d572.s17|117-121|doses|O
DDI-DrugBank.d572.s17|123-124|up|O
DDI-DrugBank.d572.s17|126-127|to|O
DDI-DrugBank.d572.s17|129-132|1000|O
DDI-DrugBank.d572.s17|134-142|mg/kg/day|O
DDI-DrugBank.d572.s17|144-145|in|O
DDI-DrugBank.d572.s17|147-150|male|O
DDI-DrugBank.d572.s17|152-153|or|O
DDI-DrugBank.d572.s17|155-160|female|O
DDI-DrugBank.d572.s17|162-165|rats|O
DDI-DrugBank.d572.s17|167-167|(|O
DDI-DrugBank.d572.s17|168-169|~7|O
DDI-DrugBank.d572.s17|171-175|times|O
DDI-DrugBank.d572.s17|177-179|the|O
DDI-DrugBank.d572.s17|181-185|human|O
DDI-DrugBank.d572.s17|187-194|exposure|O
DDI-DrugBank.d572.s17|196-197|at|O
DDI-DrugBank.d572.s17|199-200|10|O
DDI-DrugBank.d572.s17|202-203|mg|O
DDI-DrugBank.d572.s17|205-209|daily|O
DDI-DrugBank.d572.s17|211-215|based|O
DDI-DrugBank.d572.s17|217-218|on|O
DDI-DrugBank.d572.s17|220-228|AUC0-24hr|O
DDI-DrugBank.d572.s17|230-232|for|O
DDI-DrugBank.d572.s17|234-238|total|O
DDI-DrugBank.d572.s17|240-248|ezetimibe|drug
DDI-DrugBank.d572.s17|249-249|)|O
DDI-DrugBank.d572.s17|250-250|.|O
DDI-DrugBank.d572.s18|0-8|Pregnancy|O
DDI-DrugBank.d572.s18|10-18|Pregnancy|O
DDI-DrugBank.d572.s18|20-27|Category|O
DDI-DrugBank.d572.s18|28-28|:|O
DDI-DrugBank.d572.s18|30-30|C|O
DDI-DrugBank.d572.s18|32-36|There|O
DDI-DrugBank.d572.s18|38-40|are|O
DDI-DrugBank.d572.s18|42-43|no|O
DDI-DrugBank.d572.s18|45-52|adequate|O
DDI-DrugBank.d572.s18|54-56|and|O
DDI-DrugBank.d572.s18|58-72|well-controlled|O
DDI-DrugBank.d572.s18|74-80|studies|O
DDI-DrugBank.d572.s18|82-83|of|O
DDI-DrugBank.d572.s18|85-93|ezetimibe|drug
DDI-DrugBank.d572.s18|95-96|in|O
DDI-DrugBank.d572.s18|98-105|pregnant|O
DDI-DrugBank.d572.s18|107-111|women|O
DDI-DrugBank.d572.s18|112-112|.|O
DDI-DrugBank.d572.s19|0-8|Ezetimibe|drug
DDI-DrugBank.d572.s19|10-15|should|O
DDI-DrugBank.d572.s19|17-18|be|O
DDI-DrugBank.d572.s19|20-23|used|O
DDI-DrugBank.d572.s19|25-30|during|O
DDI-DrugBank.d572.s19|32-40|pregnancy|O
DDI-DrugBank.d572.s19|42-45|only|O
DDI-DrugBank.d572.s19|47-48|if|O
DDI-DrugBank.d572.s19|50-52|the|O
DDI-DrugBank.d572.s19|54-62|potential|O
DDI-DrugBank.d572.s19|64-70|benefit|O
DDI-DrugBank.d572.s19|72-80|justifies|O
DDI-DrugBank.d572.s19|82-84|the|O
DDI-DrugBank.d572.s19|86-89|risk|O
DDI-DrugBank.d572.s19|91-92|to|O
DDI-DrugBank.d572.s19|94-96|the|O
DDI-DrugBank.d572.s19|98-102|fetus|O
DDI-DrugBank.d572.s19|103-103|.|O
DDI-DrugBank.d572.s20|0-1|In|O
DDI-DrugBank.d572.s20|3-6|oral|O
DDI-DrugBank.d572.s20|8-8|(|O
DDI-DrugBank.d572.s20|9-14|gavage|O
DDI-DrugBank.d572.s20|15-15|)|O
DDI-DrugBank.d572.s20|17-28|embryo-fetal|O
DDI-DrugBank.d572.s20|30-40|development|O
DDI-DrugBank.d572.s20|42-48|studies|O
DDI-DrugBank.d572.s20|50-51|of|O
DDI-DrugBank.d572.s20|53-61|ezetimibe|drug
DDI-DrugBank.d572.s20|63-71|conducted|O
DDI-DrugBank.d572.s20|73-74|in|O
DDI-DrugBank.d572.s20|76-79|rats|O
DDI-DrugBank.d572.s20|81-83|and|O
DDI-DrugBank.d572.s20|85-91|rabbits|O
DDI-DrugBank.d572.s20|93-98|during|O
DDI-DrugBank.d572.s20|100-112|organogenesis|O
DDI-DrugBank.d572.s20|113-113|,|O
DDI-DrugBank.d572.s20|115-119|there|O
DDI-DrugBank.d572.s20|121-123|was|O
DDI-DrugBank.d572.s20|125-126|no|O
DDI-DrugBank.d572.s20|128-135|evidence|O
DDI-DrugBank.d572.s20|137-138|of|O
DDI-DrugBank.d572.s20|140-151|embryolethal|O
DDI-DrugBank.d572.s20|153-159|effects|O
DDI-DrugBank.d572.s20|161-162|at|O
DDI-DrugBank.d572.s20|164-166|the|O
DDI-DrugBank.d572.s20|168-172|doses|O
DDI-DrugBank.d572.s20|174-179|tested|O
DDI-DrugBank.d572.s20|181-181|(|O
DDI-DrugBank.d572.s20|182-184|250|O
DDI-DrugBank.d572.s20|185-185|,|O
DDI-DrugBank.d572.s20|187-189|500|O
DDI-DrugBank.d572.s20|190-190|,|O
DDI-DrugBank.d572.s20|192-195|1000|O
DDI-DrugBank.d572.s20|197-205|mg/kg/day|O
DDI-DrugBank.d572.s20|206-206|)|O
DDI-DrugBank.d572.s20|207-207|.|O
DDI-DrugBank.d572.s21|0-1|In|O
DDI-DrugBank.d572.s21|3-6|rats|O
DDI-DrugBank.d572.s21|7-7|,|O
DDI-DrugBank.d572.s21|9-17|increased|O
DDI-DrugBank.d572.s21|19-28|incidences|O
DDI-DrugBank.d572.s21|30-31|of|O
DDI-DrugBank.d572.s21|33-38|common|O
DDI-DrugBank.d572.s21|40-44|fetal|O
DDI-DrugBank.d572.s21|46-53|skeletal|O
DDI-DrugBank.d572.s21|55-62|findings|O
DDI-DrugBank.d572.s21|64-64|(|O
DDI-DrugBank.d572.s21|65-69|extra|O
DDI-DrugBank.d572.s21|71-74|pair|O
DDI-DrugBank.d572.s21|76-77|of|O
DDI-DrugBank.d572.s21|79-86|thoracic|O
DDI-DrugBank.d572.s21|88-91|ribs|O
DDI-DrugBank.d572.s21|92-92|,|O
DDI-DrugBank.d572.s21|94-103|unossified|O
DDI-DrugBank.d572.s21|105-112|cervical|O
DDI-DrugBank.d572.s21|114-122|vertebral|O
DDI-DrugBank.d572.s21|124-129|centra|O
DDI-DrugBank.d572.s21|130-130|,|O
DDI-DrugBank.d572.s21|132-140|shortened|O
DDI-DrugBank.d572.s21|142-145|ribs|O
DDI-DrugBank.d572.s21|146-146|)|O
DDI-DrugBank.d572.s21|148-151|were|O
DDI-DrugBank.d572.s21|153-160|observed|O
DDI-DrugBank.d572.s21|162-163|at|O
DDI-DrugBank.d572.s21|165-168|1000|O
DDI-DrugBank.d572.s21|170-178|mg/kg/day|O
DDI-DrugBank.d572.s21|180-180|(|O
DDI-DrugBank.d572.s21|181-183|~10|O
DDI-DrugBank.d572.s21|185-189|times|O
DDI-DrugBank.d572.s21|191-193|the|O
DDI-DrugBank.d572.s21|195-199|human|O
DDI-DrugBank.d572.s21|201-208|exposure|O
DDI-DrugBank.d572.s21|210-211|at|O
DDI-DrugBank.d572.s21|213-214|10|O
DDI-DrugBank.d572.s21|216-217|mg|O
DDI-DrugBank.d572.s21|219-223|daily|O
DDI-DrugBank.d572.s21|225-229|based|O
DDI-DrugBank.d572.s21|231-232|on|O
DDI-DrugBank.d572.s21|234-242|AUC0-24hr|O
DDI-DrugBank.d572.s21|244-246|for|O
DDI-DrugBank.d572.s21|248-252|total|O
DDI-DrugBank.d572.s21|254-262|ezetimibe|drug
DDI-DrugBank.d572.s21|263-263|)|O
DDI-DrugBank.d572.s21|264-264|.|O
DDI-DrugBank.d572.s22|0-1|In|O
DDI-DrugBank.d572.s22|3-9|rabbits|O
DDI-DrugBank.d572.s22|11-17|treated|O
DDI-DrugBank.d572.s22|19-22|with|O
DDI-DrugBank.d572.s22|24-32|ezetimibe|drug
DDI-DrugBank.d572.s22|33-33|,|O
DDI-DrugBank.d572.s22|35-36|an|O
DDI-DrugBank.d572.s22|38-46|increased|O
DDI-DrugBank.d572.s22|48-56|incidence|O
DDI-DrugBank.d572.s22|58-59|of|O
DDI-DrugBank.d572.s22|61-65|extra|O
DDI-DrugBank.d572.s22|67-74|thoracic|O
DDI-DrugBank.d572.s22|76-79|ribs|O
DDI-DrugBank.d572.s22|81-83|was|O
DDI-DrugBank.d572.s22|85-92|observed|O
DDI-DrugBank.d572.s22|94-95|at|O
DDI-DrugBank.d572.s22|97-100|1000|O
DDI-DrugBank.d572.s22|102-110|mg/kg/day|O
DDI-DrugBank.d572.s22|112-112|(|O
DDI-DrugBank.d572.s22|113-115|150|O
DDI-DrugBank.d572.s22|117-121|times|O
DDI-DrugBank.d572.s22|123-125|the|O
DDI-DrugBank.d572.s22|127-131|human|O
DDI-DrugBank.d572.s22|133-140|exposure|O
DDI-DrugBank.d572.s22|142-143|at|O
DDI-DrugBank.d572.s22|145-146|10|O
DDI-DrugBank.d572.s22|148-149|mg|O
DDI-DrugBank.d572.s22|151-155|daily|O
DDI-DrugBank.d572.s22|157-161|based|O
DDI-DrugBank.d572.s22|163-164|on|O
DDI-DrugBank.d572.s22|166-174|AUC0-24hr|O
DDI-DrugBank.d572.s22|176-178|for|O
DDI-DrugBank.d572.s22|180-184|total|O
DDI-DrugBank.d572.s22|186-194|ezetimibe|drug
DDI-DrugBank.d572.s22|195-195|)|O
DDI-DrugBank.d572.s22|196-196|.|O
DDI-DrugBank.d572.s23|0-8|Ezetimibe|drug
DDI-DrugBank.d572.s23|10-16|crossed|O
DDI-DrugBank.d572.s23|18-20|the|O
DDI-DrugBank.d572.s23|22-29|placenta|O
DDI-DrugBank.d572.s23|31-34|when|O
DDI-DrugBank.d572.s23|36-43|pregnant|O
DDI-DrugBank.d572.s23|45-48|rats|O
DDI-DrugBank.d572.s23|50-52|and|O
DDI-DrugBank.d572.s23|54-60|rabbits|O
DDI-DrugBank.d572.s23|62-65|were|O
DDI-DrugBank.d572.s23|67-71|given|O
DDI-DrugBank.d572.s23|73-80|multiple|O
DDI-DrugBank.d572.s23|82-85|oral|O
DDI-DrugBank.d572.s23|87-91|doses|O
DDI-DrugBank.d572.s23|92-92|.|O
DDI-DrugBank.d572.s24|0-7|Multiple|O
DDI-DrugBank.d572.s24|9-12|dose|O
DDI-DrugBank.d572.s24|14-20|studies|O
DDI-DrugBank.d572.s24|22-23|of|O
DDI-DrugBank.d572.s24|25-33|ezetimibe|drug
DDI-DrugBank.d572.s24|35-39|given|O
DDI-DrugBank.d572.s24|41-42|in|O
DDI-DrugBank.d572.s24|44-54|combination|O
DDI-DrugBank.d572.s24|56-59|with|O
DDI-DrugBank.d572.s24|61-88|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d572.s24|90-90|(|O
DDI-DrugBank.d572.s24|91-97|statins|group
DDI-DrugBank.d572.s24|98-98|)|O
DDI-DrugBank.d572.s24|100-101|in|O
DDI-DrugBank.d572.s24|103-106|rats|O
DDI-DrugBank.d572.s24|108-110|and|O
DDI-DrugBank.d572.s24|112-118|rabbits|O
DDI-DrugBank.d572.s24|120-125|during|O
DDI-DrugBank.d572.s24|127-139|organogenesis|O
DDI-DrugBank.d572.s24|141-146|result|O
DDI-DrugBank.d572.s24|148-149|in|O
DDI-DrugBank.d572.s24|151-156|higher|O
DDI-DrugBank.d572.s24|158-166|ezetimibe|drug
DDI-DrugBank.d572.s24|168-170|and|O
DDI-DrugBank.d572.s24|172-177|statin|O
DDI-DrugBank.d572.s24|179-187|exposures|O
DDI-DrugBank.d572.s24|188-188|.|O
DDI-DrugBank.d572.s25|0-11|Reproductive|O
DDI-DrugBank.d572.s25|13-20|findings|O
DDI-DrugBank.d572.s25|22-26|occur|O
DDI-DrugBank.d572.s25|28-29|at|O
DDI-DrugBank.d572.s25|31-35|lower|O
DDI-DrugBank.d572.s25|37-41|doses|O
DDI-DrugBank.d572.s25|43-44|in|O
DDI-DrugBank.d572.s25|46-56|combination|O
DDI-DrugBank.d572.s25|58-64|therapy|O
DDI-DrugBank.d572.s25|66-73|compared|O
DDI-DrugBank.d572.s25|75-76|to|O
DDI-DrugBank.d572.s25|78-88|monotherapy|O
DDI-DrugBank.d572.s25|89-89|.|O
DDI-DrugBank.d572.s26|0-2|All|O
DDI-DrugBank.d572.s26|4-31|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d572.s26|33-35|are|O
DDI-DrugBank.d572.s26|37-51|contraindicated|O
DDI-DrugBank.d572.s26|53-54|in|O
DDI-DrugBank.d572.s26|56-63|pregnant|O
DDI-DrugBank.d572.s26|65-67|and|O
DDI-DrugBank.d572.s26|69-75|nursing|O
DDI-DrugBank.d572.s26|77-81|women|O
DDI-DrugBank.d572.s26|82-82|.|O
DDI-DrugBank.d572.s27|0-3|When|O
DDI-DrugBank.d572.s27|5-9|ZETIA|brand
DDI-DrugBank.d572.s27|11-12|is|O
DDI-DrugBank.d572.s27|14-25|administered|O
DDI-DrugBank.d572.s27|27-30|with|O
DDI-DrugBank.d572.s27|32-33|an|O
DDI-DrugBank.d572.s27|35-61|HMG-CoA reductase inhibitor|group
DDI-DrugBank.d572.s27|63-64|in|O
DDI-DrugBank.d572.s27|66-66|a|O
DDI-DrugBank.d572.s27|68-72|woman|O
DDI-DrugBank.d572.s27|74-75|of|O
DDI-DrugBank.d572.s27|77-88|childbearing|O
DDI-DrugBank.d572.s27|90-98|potential|O
DDI-DrugBank.d572.s27|99-99|,|O
DDI-DrugBank.d572.s27|101-105|refer|O
DDI-DrugBank.d572.s27|107-108|to|O
DDI-DrugBank.d572.s27|110-112|the|O
DDI-DrugBank.d572.s27|114-122|pregnancy|O
DDI-DrugBank.d572.s27|124-131|category|O
DDI-DrugBank.d572.s27|133-135|and|O
DDI-DrugBank.d572.s27|137-143|package|O
DDI-DrugBank.d572.s27|145-152|labeling|O
DDI-DrugBank.d572.s27|154-156|for|O
DDI-DrugBank.d572.s27|158-160|the|O
DDI-DrugBank.d572.s27|162-188|HMG-CoA reductase inhibitor|drug
DDI-DrugBank.d572.s27|189-189|.|O
DDI-DrugBank.d572.s28|0-4|Labor|O
DDI-DrugBank.d572.s28|6-8|and|O
DDI-DrugBank.d572.s28|10-17|Delivery|O
DDI-DrugBank.d572.s28|19-21|The|O
DDI-DrugBank.d572.s28|23-29|effects|O
DDI-DrugBank.d572.s28|31-32|of|O
DDI-DrugBank.d572.s28|34-38|ZETIA|brand
DDI-DrugBank.d572.s28|40-41|on|O
DDI-DrugBank.d572.s28|43-47|labor|O
DDI-DrugBank.d572.s28|49-51|and|O
DDI-DrugBank.d572.s28|53-60|delivery|O
DDI-DrugBank.d572.s28|62-63|in|O
DDI-DrugBank.d572.s28|65-72|pregnant|O
DDI-DrugBank.d572.s28|74-78|women|O
DDI-DrugBank.d572.s28|80-82|are|O
DDI-DrugBank.d572.s28|84-90|unknown|O
DDI-DrugBank.d572.s28|91-91|.|O
DDI-DrugBank.d572.s29|0-6|Nursing|O
DDI-DrugBank.d572.s29|8-14|Mothers|O
DDI-DrugBank.d572.s29|16-17|In|O
DDI-DrugBank.d572.s29|19-21|rat|O
DDI-DrugBank.d572.s29|23-29|studies|O
DDI-DrugBank.d572.s29|30-30|,|O
DDI-DrugBank.d572.s29|32-39|exposure|O
DDI-DrugBank.d572.s29|41-42|to|O
DDI-DrugBank.d572.s29|44-48|total|O
DDI-DrugBank.d572.s29|50-58|ezetimibe|drug
DDI-DrugBank.d572.s29|60-61|in|O
DDI-DrugBank.d572.s29|63-69|nursing|O
DDI-DrugBank.d572.s29|71-74|pups|O
DDI-DrugBank.d572.s29|76-78|was|O
DDI-DrugBank.d572.s29|80-81|up|O
DDI-DrugBank.d572.s29|83-84|to|O
DDI-DrugBank.d572.s29|86-89|half|O
DDI-DrugBank.d572.s29|91-92|of|O
DDI-DrugBank.d572.s29|94-97|that|O
DDI-DrugBank.d572.s29|99-106|observed|O
DDI-DrugBank.d572.s29|108-109|in|O
DDI-DrugBank.d572.s29|111-118|maternal|O
DDI-DrugBank.d572.s29|120-125|plasma|O
DDI-DrugBank.d572.s29|126-126|.|O
DDI-DrugBank.d572.s30|0-1|It|O
DDI-DrugBank.d572.s30|3-4|is|O
DDI-DrugBank.d572.s30|6-8|not|O
DDI-DrugBank.d572.s30|10-14|known|O
DDI-DrugBank.d572.s30|16-22|whether|O
DDI-DrugBank.d572.s30|24-32|ezetimibe|drug
DDI-DrugBank.d572.s30|34-35|is|O
DDI-DrugBank.d572.s30|37-44|excreted|O
DDI-DrugBank.d572.s30|46-49|into|O
DDI-DrugBank.d572.s30|51-55|human|O
DDI-DrugBank.d572.s30|57-62|breast|O
DDI-DrugBank.d572.s30|64-67|milk|O
DDI-DrugBank.d572.s30|68-68|;|O
DDI-DrugBank.d572.s31|0-8|therefore|O
DDI-DrugBank.d572.s31|9-9|,|O
DDI-DrugBank.d572.s31|11-15|ZETIA|brand
DDI-DrugBank.d572.s31|17-22|should|O
DDI-DrugBank.d572.s31|24-26|not|O
DDI-DrugBank.d572.s31|28-29|be|O
DDI-DrugBank.d572.s31|31-34|used|O
DDI-DrugBank.d572.s31|36-37|in|O
DDI-DrugBank.d572.s31|39-45|nursing|O
DDI-DrugBank.d572.s31|47-53|mothers|O
DDI-DrugBank.d572.s31|55-60|unless|O
DDI-DrugBank.d572.s31|62-64|the|O
DDI-DrugBank.d572.s31|66-74|potential|O
DDI-DrugBank.d572.s31|76-82|benefit|O
DDI-DrugBank.d572.s31|84-92|justifies|O
DDI-DrugBank.d572.s31|94-96|the|O
DDI-DrugBank.d572.s31|98-106|potential|O
DDI-DrugBank.d572.s31|108-111|risk|O
DDI-DrugBank.d572.s31|113-114|to|O
DDI-DrugBank.d572.s31|116-118|the|O
DDI-DrugBank.d572.s31|120-125|infant|O
DDI-DrugBank.d572.s31|126-126|.|O
DDI-DrugBank.d572.s32|0-8|Pediatric|O
DDI-DrugBank.d572.s32|10-12|Use|O
DDI-DrugBank.d572.s32|14-16|The|O
DDI-DrugBank.d572.s32|18-33|pharmacokinetics|O
DDI-DrugBank.d572.s32|35-36|of|O
DDI-DrugBank.d572.s32|38-42|ZETIA|brand
DDI-DrugBank.d572.s32|44-45|in|O
DDI-DrugBank.d572.s32|47-57|adolescents|O
DDI-DrugBank.d572.s32|59-59|(|O
DDI-DrugBank.d572.s32|60-61|10|O
DDI-DrugBank.d572.s32|63-64|to|O
DDI-DrugBank.d572.s32|66-67|18|O
DDI-DrugBank.d572.s32|69-73|years|O
DDI-DrugBank.d572.s32|74-74|)|O
DDI-DrugBank.d572.s32|76-79|have|O
DDI-DrugBank.d572.s32|81-84|been|O
DDI-DrugBank.d572.s32|86-90|shown|O
DDI-DrugBank.d572.s32|92-93|to|O
DDI-DrugBank.d572.s32|95-96|be|O
DDI-DrugBank.d572.s32|98-104|similar|O
DDI-DrugBank.d572.s32|106-107|to|O
DDI-DrugBank.d572.s32|109-112|that|O
DDI-DrugBank.d572.s32|114-115|in|O
DDI-DrugBank.d572.s32|117-122|adults|O
DDI-DrugBank.d572.s32|123-123|.|O
DDI-DrugBank.d572.s33|0-8|Treatment|O
DDI-DrugBank.d572.s33|10-19|experience|O
DDI-DrugBank.d572.s33|21-24|with|O
DDI-DrugBank.d572.s33|26-30|ZETIA|brand
DDI-DrugBank.d572.s33|32-33|in|O
DDI-DrugBank.d572.s33|35-37|the|O
DDI-DrugBank.d572.s33|39-47|pediatric|O
DDI-DrugBank.d572.s33|49-58|population|O
DDI-DrugBank.d572.s33|60-61|is|O
DDI-DrugBank.d572.s33|63-69|limited|O
DDI-DrugBank.d572.s33|71-72|to|O
DDI-DrugBank.d572.s33|74-74|4|O
DDI-DrugBank.d572.s33|76-83|patients|O
DDI-DrugBank.d572.s33|85-85|(|O
DDI-DrugBank.d572.s33|86-86|9|O
DDI-DrugBank.d572.s33|88-89|to|O
DDI-DrugBank.d572.s33|91-92|17|O
DDI-DrugBank.d572.s33|94-98|years|O
DDI-DrugBank.d572.s33|99-99|)|O
DDI-DrugBank.d572.s33|101-102|in|O
DDI-DrugBank.d572.s33|104-106|the|O
DDI-DrugBank.d572.s33|108-121|sitosterolemia|O
DDI-DrugBank.d572.s33|123-127|study|O
DDI-DrugBank.d572.s33|129-131|and|O
DDI-DrugBank.d572.s33|133-133|5|O
DDI-DrugBank.d572.s33|135-142|patients|O
DDI-DrugBank.d572.s33|144-144|(|O
DDI-DrugBank.d572.s33|145-146|11|O
DDI-DrugBank.d572.s33|148-149|to|O
DDI-DrugBank.d572.s33|151-152|17|O
DDI-DrugBank.d572.s33|154-158|years|O
DDI-DrugBank.d572.s33|159-159|)|O
DDI-DrugBank.d572.s33|161-162|in|O
DDI-DrugBank.d572.s33|164-166|the|O
DDI-DrugBank.d572.s33|168-171|HoFH|O
DDI-DrugBank.d572.s33|173-177|study|O
DDI-DrugBank.d572.s33|178-178|.|O
DDI-DrugBank.d572.s34|0-8|Treatment|O
DDI-DrugBank.d572.s34|10-13|with|O
DDI-DrugBank.d572.s34|15-19|ZETIA|brand
DDI-DrugBank.d572.s34|21-22|in|O
DDI-DrugBank.d572.s34|24-31|children|O
DDI-DrugBank.d572.s34|33-33|(|O
DDI-DrugBank.d572.s34|34-34|<|O
DDI-DrugBank.d572.s34|35-36|10|O
DDI-DrugBank.d572.s34|38-42|years|O
DDI-DrugBank.d572.s34|43-43|)|O
DDI-DrugBank.d572.s34|45-46|is|O
DDI-DrugBank.d572.s34|48-50|not|O
DDI-DrugBank.d572.s34|52-62|recommended|O
DDI-DrugBank.d572.s34|63-63|.|O
DDI-DrugBank.d572.s35|0-8|Geriatric|O
DDI-DrugBank.d572.s35|10-12|Use|O
DDI-DrugBank.d572.s35|14-15|Of|O
DDI-DrugBank.d572.s35|17-19|the|O
DDI-DrugBank.d572.s35|21-28|patients|O
DDI-DrugBank.d572.s35|30-32|who|O
DDI-DrugBank.d572.s35|34-41|received|O
DDI-DrugBank.d572.s35|43-47|ZETIA|brand
DDI-DrugBank.d572.s35|49-50|in|O
DDI-DrugBank.d572.s35|52-59|clinical|O
DDI-DrugBank.d572.s35|61-67|studies|O
DDI-DrugBank.d572.s35|68-68|,|O
DDI-DrugBank.d572.s35|70-72|948|O
DDI-DrugBank.d572.s35|74-77|were|O
DDI-DrugBank.d572.s35|79-80|65|O
DDI-DrugBank.d572.s35|82-84|and|O
DDI-DrugBank.d572.s35|86-90|older|O
DDI-DrugBank.d572.s35|92-92|(|O
DDI-DrugBank.d572.s35|93-96|this|O
DDI-DrugBank.d572.s35|98-105|included|O
DDI-DrugBank.d572.s35|107-109|206|O
DDI-DrugBank.d572.s35|111-113|who|O
DDI-DrugBank.d572.s35|115-118|were|O
DDI-DrugBank.d572.s35|120-121|75|O
DDI-DrugBank.d572.s35|123-125|and|O
DDI-DrugBank.d572.s35|127-131|older|O
DDI-DrugBank.d572.s35|132-132|)|O
DDI-DrugBank.d572.s35|133-133|.|O
DDI-DrugBank.d572.s36|0-2|The|O
DDI-DrugBank.d572.s36|4-16|effectiveness|O
DDI-DrugBank.d572.s36|18-20|and|O
DDI-DrugBank.d572.s36|22-27|safety|O
DDI-DrugBank.d572.s36|29-30|of|O
DDI-DrugBank.d572.s36|32-36|ZETIA|brand
DDI-DrugBank.d572.s36|38-41|were|O
DDI-DrugBank.d572.s36|43-49|similar|O
DDI-DrugBank.d572.s36|51-57|between|O
DDI-DrugBank.d572.s36|59-63|these|O
DDI-DrugBank.d572.s36|65-72|patients|O
DDI-DrugBank.d572.s36|74-76|and|O
DDI-DrugBank.d572.s36|78-84|younger|O
DDI-DrugBank.d572.s36|86-93|subjects|O
DDI-DrugBank.d572.s36|94-94|.|O
DDI-DrugBank.d572.s37|0-6|Greater|O
DDI-DrugBank.d572.s37|8-18|sensitivity|O
DDI-DrugBank.d572.s37|20-21|of|O
DDI-DrugBank.d572.s37|23-26|some|O
DDI-DrugBank.d572.s37|28-32|older|O
DDI-DrugBank.d572.s37|34-44|individuals|O
DDI-DrugBank.d572.s37|46-48|can|O
DDI-DrugBank.d572.s37|49-51|not|O
DDI-DrugBank.d572.s37|53-54|be|O
DDI-DrugBank.d572.s37|56-60|ruled|O
DDI-DrugBank.d572.s37|62-64|out|O
DDI-DrugBank.d572.s37|65-65|.|O
DDI-DrugBank.d490.s0|0-0|)|O
DDI-DrugBank.d490.s2|0-7|Clinical|O
DDI-DrugBank.d490.s2|9-18|Laboratory|O
DDI-DrugBank.d490.s4|0-8|increased|O
DDI-DrugBank.d490.s4|10-17|creatine|O
DDI-DrugBank.d490.s5|0-7|positive|O
DDI-DrugBank.d490.s5|9-19|antinuclear|O
DDI-DrugBank.d490.s7|0-12|phosphokinase|O
DDI-DrugBank.d490.s8|0-7|antibody|O
DDI-DrugBank.d490.s10|0-8|increased|O
DDI-DrugBank.d490.s10|10-18|bilirubin|O
DDI-DrugBank.d490.s13|0-8|increased|O
DDI-DrugBank.d490.s13|10-14|liver|O
DDI-DrugBank.d490.s16|0-12|transaminases|O
DDI-DrugBank.d490.s16|14-14|(|O
DDI-DrugBank.d490.s16|15-17|AST|O
DDI-DrugBank.d490.s19|0-0|(|O
DDI-DrugBank.d490.s19|1-4|SGOT|O
DDI-DrugBank.d490.s19|5-5|)|O
DDI-DrugBank.d490.s19|6-6|,|O
DDI-DrugBank.d490.s19|8-10|ALT|O
DDI-DrugBank.d490.s19|12-12|(|O
DDI-DrugBank.d490.s19|13-16|SGPT|O
DDI-DrugBank.d490.s19|17-17|)|O
DDI-DrugBank.d490.s22|0-8|increased|O
DDI-DrugBank.d490.s22|10-17|alkaline|O
DDI-DrugBank.d490.s25|0-9|phophatase|O
DDI-DrugBank.d490.s27|0-12|Hematopoietic|O
DDI-DrugBank.d490.s28|0-5|anemia|O
DDI-DrugBank.d490.s29|0-15|thrombocytopenia|O
DDI-DrugBank.d490.s31|0-9|leukopenia|O
DDI-DrugBank.d490.s34|0-3|bone|O
DDI-DrugBank.d490.s34|5-10|marrow|O
DDI-DrugBank.d490.s34|12-21|hypoplasia|O
DDI-DrugBank.d490.s37|0-11|eosinophilia|O
DDI-DrugBank.d490.s39|0-10|Immunologic|O
DDI-DrugBank.d490.s40|0-9|angioedema|O
DDI-DrugBank.d490.s41|0-10|anaphylaxis|O
DDI-DrugBank.d490.s43|0-8|laryngeal|O
DDI-DrugBank.d490.s43|10-14|edema|O
DDI-DrugBank.d490.s44|0-9|Lupus-like|O
DDI-DrugBank.d490.s44|11-18|syndrome|O
DDI-DrugBank.d490.s46|0-8|urticaria|O
DDI-DrugBank.d490.s47|0-9|vasculitis|O
DDI-DrugBank.d490.s48|0-12|Integumentary|O
DDI-DrugBank.d490.s49|0-10|exfoliative|O
DDI-DrugBank.d490.s49|12-21|dermatitis|O
DDI-DrugBank.d490.s50|0-7|alopecia|O
DDI-DrugBank.d490.s52|0-3|rash|O
DDI-DrugBank.d490.s55|0-9|dermatitis|O
DDI-DrugBank.d490.s58|0-7|pruritus|O
DDI-DrugBank.d643.s0|0-8|Melatonin|drug
DDI-DrugBank.d643.s0|10-12|may|O
DDI-DrugBank.d643.s0|14-21|interact|O
DDI-DrugBank.d643.s0|23-26|with|O
DDI-DrugBank.d643.s0|28-30|the|O
DDI-DrugBank.d643.s0|32-40|following|O
DDI-DrugBank.d643.s0|42-46|drugs|O
DDI-DrugBank.d643.s0|47-47|:|O
DDI-DrugBank.d643.s0|49-55|aspirin|brand
DDI-DrugBank.d643.s0|57-59|and|O
DDI-DrugBank.d643.s0|61-65|other|O
DDI-DrugBank.d643.s0|67-72|NSAIDs|group
DDI-DrugBank.d643.s0|74-74|(|O
DDI-DrugBank.d643.s0|75-77|may|O
DDI-DrugBank.d643.s0|79-83|lower|O
DDI-DrugBank.d643.s0|85-93|melatonin|drug
DDI-DrugBank.d643.s0|95-100|levels|O
DDI-DrugBank.d643.s0|101-101|)|O
DDI-DrugBank.d643.s0|102-102|,|O
DDI-DrugBank.d643.s0|104-114|fluvoxamine|drug
DDI-DrugBank.d643.s0|116-116|(|O
DDI-DrugBank.d643.s0|117-131|bioavailability|O
DDI-DrugBank.d643.s0|133-134|of|O
DDI-DrugBank.d643.s0|136-139|oral|O
DDI-DrugBank.d643.s0|141-149|melatonin|drug
DDI-DrugBank.d643.s0|151-152|is|O
DDI-DrugBank.d643.s0|154-162|increased|O
DDI-DrugBank.d643.s0|164-167|with|O
DDI-DrugBank.d643.s0|169-184|coadministration|O
DDI-DrugBank.d643.s0|185-185|)|O
DDI-DrugBank.d643.s0|186-186|,|O
DDI-DrugBank.d643.s0|188-200|beta blockers|group
DDI-DrugBank.d643.s0|202-202|(|O
DDI-DrugBank.d643.s0|203-205|may|O
DDI-DrugBank.d643.s0|207-214|decrease|O
DDI-DrugBank.d643.s0|216-224|melatonin|drug
DDI-DrugBank.d643.s0|226-231|levels|O
DDI-DrugBank.d643.s0|232-232|)|O
DDI-DrugBank.d643.s0|233-233|,|O
DDI-DrugBank.d643.s0|235-244|fluoxetine|drug
DDI-DrugBank.d643.s0|246-246|(|O
DDI-DrugBank.d643.s0|247-253|reports|O
DDI-DrugBank.d643.s0|255-256|of|O
DDI-DrugBank.d643.s0|258-266|psychotic|O
DDI-DrugBank.d643.s0|268-275|episodes|O
DDI-DrugBank.d643.s0|277-280|when|O
DDI-DrugBank.d643.s0|282-295|coadministered|O
DDI-DrugBank.d643.s0|296-296|)|O
DDI-DrugBank.d643.s0|297-297|,|O
DDI-DrugBank.d643.s0|299-307|progestin|group
DDI-DrugBank.d643.s0|309-309|(|O
DDI-DrugBank.d643.s0|310-325|coadministration|O
DDI-DrugBank.d643.s0|327-328|of|O
DDI-DrugBank.d643.s0|330-338|melatonin|drug
DDI-DrugBank.d643.s0|340-343|with|O
DDI-DrugBank.d643.s0|345-353|progestin|group
DDI-DrugBank.d643.s0|355-357|can|O
DDI-DrugBank.d643.s0|359-365|inhibit|O
DDI-DrugBank.d643.s0|367-373|ovarian|O
DDI-DrugBank.d643.s0|375-382|function|O
DDI-DrugBank.d643.s0|384-385|in|O
DDI-DrugBank.d643.s0|387-391|women|O
DDI-DrugBank.d643.s0|392-392|)|O
DDI-DrugBank.d643.s0|393-393|,|O
DDI-DrugBank.d643.s0|395-409|benzodiazepenes|group
DDI-DrugBank.d643.s0|411-413|and|O
DDI-DrugBank.d643.s0|415-419|other|O
DDI-DrugBank.d643.s0|421-428|sedating|O
DDI-DrugBank.d643.s0|430-434|drugs|O
DDI-DrugBank.d643.s0|436-436|(|O
DDI-DrugBank.d643.s0|437-439|may|O
DDI-DrugBank.d643.s0|441-446|result|O
DDI-DrugBank.d643.s0|448-449|in|O
DDI-DrugBank.d643.s0|451-458|additive|O
DDI-DrugBank.d643.s0|460-467|sedation|O
DDI-DrugBank.d643.s0|469-471|and|O
DDI-DrugBank.d643.s0|473-474|an|O
DDI-DrugBank.d643.s0|476-484|increased|O
DDI-DrugBank.d643.s0|486-494|incidence|O
DDI-DrugBank.d643.s0|496-497|of|O
DDI-DrugBank.d643.s0|499-505|adverse|O
DDI-DrugBank.d643.s0|507-513|effects|O
DDI-DrugBank.d643.s0|514-514|)|O
DDI-DrugBank.d643.s0|515-515|,|O
DDI-DrugBank.d643.s0|517-519|and|O
DDI-DrugBank.d643.s0|521-535|corticosteroids|group
DDI-DrugBank.d643.s0|537-537|(|O
DDI-DrugBank.d643.s0|538-553|coadministration|O
DDI-DrugBank.d643.s0|555-556|of|O
DDI-DrugBank.d643.s0|558-566|melatonin|drug
DDI-DrugBank.d643.s0|568-570|and|O
DDI-DrugBank.d643.s0|572-586|corticosteroids|group
DDI-DrugBank.d643.s0|588-590|may|O
DDI-DrugBank.d643.s0|592-600|interfere|O
DDI-DrugBank.d643.s0|602-605|with|O
DDI-DrugBank.d643.s0|607-609|the|O
DDI-DrugBank.d643.s0|611-618|efficacy|O
DDI-DrugBank.d643.s0|620-621|of|O
DDI-DrugBank.d643.s0|623-625|the|O
DDI-DrugBank.d643.s0|627-641|corticosteroids|group
DDI-DrugBank.d643.s0|642-642|)|O
DDI-DrugBank.d643.s0|643-643|.|O
DDI-DrugBank.d15.s0|0-1|In|O
DDI-DrugBank.d15.s0|3-10|clinical|O
DDI-DrugBank.d15.s0|12-18|studies|O
DDI-DrugBank.d15.s0|20-28|performed|O
DDI-DrugBank.d15.s0|30-33|with|O
DDI-DrugBank.d15.s0|35-46|Fondaparinux|drug
DDI-DrugBank.d15.s0|47-47|,|O
DDI-DrugBank.d15.s0|49-51|the|O
DDI-DrugBank.d15.s0|53-63|concomitant|O
DDI-DrugBank.d15.s0|65-67|use|O
DDI-DrugBank.d15.s0|69-70|of|O
DDI-DrugBank.d15.s0|72-75|oral|O
DDI-DrugBank.d15.s0|77-90|anticoagulants|group
DDI-DrugBank.d15.s0|92-92|(|O
DDI-DrugBank.d15.s0|93-100|warfarin|drug
DDI-DrugBank.d15.s0|101-101|)|O
DDI-DrugBank.d15.s0|102-102|,|O
DDI-DrugBank.d15.s0|104-122|platelet inhibitors|group
DDI-DrugBank.d15.s0|124-124|(|O
DDI-DrugBank.d15.s0|125-144|acetylsalicylic acid|drug
DDI-DrugBank.d15.s0|145-145|)|O
DDI-DrugBank.d15.s0|146-146|,|O
DDI-DrugBank.d15.s0|148-153|NSAIDs|group
DDI-DrugBank.d15.s0|155-155|(|O
DDI-DrugBank.d15.s0|156-164|piroxicam|drug
DDI-DrugBank.d15.s0|165-165|)|O
DDI-DrugBank.d15.s0|166-166|,|O
DDI-DrugBank.d15.s0|168-170|and|O
DDI-DrugBank.d15.s0|172-178|digoxin|drug
DDI-DrugBank.d15.s0|180-182|did|O
DDI-DrugBank.d15.s0|184-186|not|O
DDI-DrugBank.d15.s0|188-200|significantly|O
DDI-DrugBank.d15.s0|202-207|affect|O
DDI-DrugBank.d15.s0|209-211|the|O
DDI-DrugBank.d15.s0|213-245|pharmacokinetics/pharmacodynamics|O
DDI-DrugBank.d15.s0|247-248|of|O
DDI-DrugBank.d15.s0|250-268|fondaparinux sodium|drug
DDI-DrugBank.d15.s0|269-269|.|O
DDI-DrugBank.d15.s1|0-1|In|O
DDI-DrugBank.d15.s1|3-10|addition|O
DDI-DrugBank.d15.s1|11-11|,|O
DDI-DrugBank.d15.s1|13-24|Fondaparinux|drug
DDI-DrugBank.d15.s1|26-32|neither|O
DDI-DrugBank.d15.s1|34-43|influenced|O
DDI-DrugBank.d15.s1|45-47|the|O
DDI-DrugBank.d15.s1|49-64|pharmacodynamics|O
DDI-DrugBank.d15.s1|66-67|of|O
DDI-DrugBank.d15.s1|69-76|warfarin|drug
DDI-DrugBank.d15.s1|77-77|,|O
DDI-DrugBank.d15.s1|79-98|acetylsalicylic acid|drug
DDI-DrugBank.d15.s1|99-99|,|O
DDI-DrugBank.d15.s1|101-109|piroxicam|drug
DDI-DrugBank.d15.s1|110-110|,|O
DDI-DrugBank.d15.s1|112-114|and|O
DDI-DrugBank.d15.s1|116-122|digoxin|drug
DDI-DrugBank.d15.s1|123-123|,|O
DDI-DrugBank.d15.s1|125-127|nor|O
DDI-DrugBank.d15.s1|129-131|the|O
DDI-DrugBank.d15.s1|133-148|pharmacokinetics|O
DDI-DrugBank.d15.s1|150-151|of|O
DDI-DrugBank.d15.s1|153-159|digoxin|drug
DDI-DrugBank.d15.s1|161-162|at|O
DDI-DrugBank.d15.s1|164-169|steady|O
DDI-DrugBank.d15.s1|171-175|state|O
DDI-DrugBank.d15.s1|176-176|.|O
DDI-DrugBank.d15.s2|0-5|Agents|O
DDI-DrugBank.d15.s2|7-10|that|O
DDI-DrugBank.d15.s2|12-14|may|O
DDI-DrugBank.d15.s2|16-22|enhance|O
DDI-DrugBank.d15.s2|24-26|the|O
DDI-DrugBank.d15.s2|28-31|risk|O
DDI-DrugBank.d15.s2|33-34|of|O
DDI-DrugBank.d15.s2|36-45|hemorrhage|O
DDI-DrugBank.d15.s2|47-52|should|O
DDI-DrugBank.d15.s2|54-55|be|O
DDI-DrugBank.d15.s2|57-68|discontinued|O
DDI-DrugBank.d15.s2|70-74|prior|O
DDI-DrugBank.d15.s2|76-77|to|O
DDI-DrugBank.d15.s2|79-88|initiation|O
DDI-DrugBank.d15.s2|90-91|of|O
DDI-DrugBank.d15.s2|93-104|Fondaparinux|drug
DDI-DrugBank.d15.s2|106-112|therapy|O
DDI-DrugBank.d15.s2|113-113|.|O
DDI-DrugBank.d15.s3|0-1|If|O
DDI-DrugBank.d15.s3|3-19|co-administration|O
DDI-DrugBank.d15.s3|21-22|is|O
DDI-DrugBank.d15.s3|24-32|essential|O
DDI-DrugBank.d15.s3|33-33|,|O
DDI-DrugBank.d15.s3|35-39|close|O
DDI-DrugBank.d15.s3|41-50|monitoring|O
DDI-DrugBank.d15.s3|52-54|may|O
DDI-DrugBank.d15.s3|56-57|be|O
DDI-DrugBank.d15.s3|59-69|appropriate|O
DDI-DrugBank.d15.s3|70-70|.|O
DDI-DrugBank.d15.s4|0-1|In|O
DDI-DrugBank.d15.s4|3-4|an|O
DDI-DrugBank.d15.s4|6-7|in|O
DDI-DrugBank.d15.s4|9-13|vitro|O
DDI-DrugBank.d15.s4|15-19|study|O
DDI-DrugBank.d15.s4|21-22|in|O
DDI-DrugBank.d15.s4|24-28|human|O
DDI-DrugBank.d15.s4|30-34|liver|O
DDI-DrugBank.d15.s4|36-45|microsomes|O
DDI-DrugBank.d15.s4|46-46|,|O
DDI-DrugBank.d15.s4|48-57|inhibition|O
DDI-DrugBank.d15.s4|59-60|of|O
DDI-DrugBank.d15.s4|62-67|CYP2A6|O
DDI-DrugBank.d15.s4|69-81|hydroxylation|O
DDI-DrugBank.d15.s4|83-84|of|O
DDI-DrugBank.d15.s4|86-93|coumarin|group
DDI-DrugBank.d15.s4|95-96|by|O
DDI-DrugBank.d15.s4|98-109|fondaparinux|drug
DDI-DrugBank.d15.s4|111-111|(|O
DDI-DrugBank.d15.s4|112-114|200|O
DDI-DrugBank.d15.s4|116-116|m|O
DDI-DrugBank.d15.s4|118-118|m|O
DDI-DrugBank.d15.s4|120-120|M|O
DDI-DrugBank.d15.s4|122-125|i.e.|O
DDI-DrugBank.d15.s4|126-126|,|O
DDI-DrugBank.d15.s4|128-130|350|O
DDI-DrugBank.d15.s4|132-135|mg/L|O
DDI-DrugBank.d15.s4|136-136|)|O
DDI-DrugBank.d15.s4|138-140|was|O
DDI-DrugBank.d15.s4|142-146|17-28|O
DDI-DrugBank.d15.s4|147-147|%|O
DDI-DrugBank.d15.s4|148-148|.|O
DDI-DrugBank.d15.s5|0-9|Inhibition|O
DDI-DrugBank.d15.s5|11-12|of|O
DDI-DrugBank.d15.s5|14-16|the|O
DDI-DrugBank.d15.s5|18-22|other|O
DDI-DrugBank.d15.s5|24-31|isozymes|O
DDI-DrugBank.d15.s5|33-41|evaluated|O
DDI-DrugBank.d15.s5|43-43|(|O
DDI-DrugBank.d15.s5|44-47|CYPs|O
DDI-DrugBank.d15.s5|49-51|2A1|O
DDI-DrugBank.d15.s5|52-52|,|O
DDI-DrugBank.d15.s5|54-56|2C9|O
DDI-DrugBank.d15.s5|57-57|,|O
DDI-DrugBank.d15.s5|59-62|2C19|O
DDI-DrugBank.d15.s5|63-63|,|O
DDI-DrugBank.d15.s5|65-67|2D6|O
DDI-DrugBank.d15.s5|68-68|,|O
DDI-DrugBank.d15.s5|70-72|3A4|O
DDI-DrugBank.d15.s5|73-73|,|O
DDI-DrugBank.d15.s5|75-77|and|O
DDI-DrugBank.d15.s5|79-81|3E1|O
DDI-DrugBank.d15.s5|82-82|)|O
DDI-DrugBank.d15.s5|84-86|was|O
DDI-DrugBank.d15.s5|88-91|0-16|O
DDI-DrugBank.d15.s5|92-92|%|O
DDI-DrugBank.d15.s5|93-93|.|O
DDI-DrugBank.d15.s6|0-4|Since|O
DDI-DrugBank.d15.s6|6-17|fondaparinux|drug
DDI-DrugBank.d15.s6|19-22|does|O
DDI-DrugBank.d15.s6|24-26|not|O
DDI-DrugBank.d15.s6|28-35|markedly|O
DDI-DrugBank.d15.s6|37-43|inhibit|O
DDI-DrugBank.d15.s6|45-51|CYP450s|O
DDI-DrugBank.d15.s6|53-53|(|O
DDI-DrugBank.d15.s6|54-59|CYP1A2|O
DDI-DrugBank.d15.s6|60-60|,|O
DDI-DrugBank.d15.s6|62-67|CYP2A6|O
DDI-DrugBank.d15.s6|68-68|,|O
DDI-DrugBank.d15.s6|70-75|CYP2C9|O
DDI-DrugBank.d15.s6|76-76|,|O
DDI-DrugBank.d15.s6|78-84|CYP2C19|O
DDI-DrugBank.d15.s6|85-85|,|O
DDI-DrugBank.d15.s6|87-92|CYP2D6|O
DDI-DrugBank.d15.s6|93-93|,|O
DDI-DrugBank.d15.s6|95-100|CYP2E1|O
DDI-DrugBank.d15.s6|101-101|,|O
DDI-DrugBank.d15.s6|103-104|or|O
DDI-DrugBank.d15.s6|106-111|CYP3A4|O
DDI-DrugBank.d15.s6|112-112|)|O
DDI-DrugBank.d15.s6|114-115|in|O
DDI-DrugBank.d15.s6|117-121|vitro|O
DDI-DrugBank.d15.s6|122-122|,|O
DDI-DrugBank.d15.s6|124-142|fondaparinux sodium|drug
DDI-DrugBank.d15.s6|144-145|is|O
DDI-DrugBank.d15.s6|147-149|not|O
DDI-DrugBank.d15.s6|151-158|expected|O
DDI-DrugBank.d15.s6|160-161|to|O
DDI-DrugBank.d15.s6|163-175|significantly|O
DDI-DrugBank.d15.s6|177-184|interact|O
DDI-DrugBank.d15.s6|186-189|with|O
DDI-DrugBank.d15.s6|191-195|other|O
DDI-DrugBank.d15.s6|197-201|drugs|O
DDI-DrugBank.d15.s6|203-204|in|O
DDI-DrugBank.d15.s6|206-209|vivo|O
DDI-DrugBank.d15.s6|211-212|by|O
DDI-DrugBank.d15.s6|214-223|inhibition|O
DDI-DrugBank.d15.s6|225-226|of|O
DDI-DrugBank.d15.s6|228-237|metabolism|O
DDI-DrugBank.d15.s6|239-246|mediated|O
DDI-DrugBank.d15.s6|248-249|by|O
DDI-DrugBank.d15.s6|251-255|these|O
DDI-DrugBank.d15.s6|257-264|isozymes|O
DDI-DrugBank.d15.s6|265-265|.|O
DDI-DrugBank.d15.s7|0-4|Since|O
DDI-DrugBank.d15.s7|6-24|fondaparinux sodium|drug
DDI-DrugBank.d15.s7|26-29|does|O
DDI-DrugBank.d15.s7|31-33|not|O
DDI-DrugBank.d15.s7|35-38|bind|O
DDI-DrugBank.d15.s7|40-52|significantly|O
DDI-DrugBank.d15.s7|54-55|to|O
DDI-DrugBank.d15.s7|57-62|plasma|O
DDI-DrugBank.d15.s7|64-71|proteins|O
DDI-DrugBank.d15.s7|73-77|other|O
DDI-DrugBank.d15.s7|79-82|than|O
DDI-DrugBank.d15.s7|84-88|ATIII|O
DDI-DrugBank.d15.s7|89-89|,|O
DDI-DrugBank.d15.s7|91-92|no|O
DDI-DrugBank.d15.s7|94-97|drug|O
DDI-DrugBank.d15.s7|99-110|interactions|O
DDI-DrugBank.d15.s7|112-113|by|O
DDI-DrugBank.d15.s7|115-129|protein-binding|O
DDI-DrugBank.d15.s7|131-142|displacement|O
DDI-DrugBank.d15.s7|144-146|are|O
DDI-DrugBank.d15.s7|148-155|expected|O
DDI-DrugBank.d15.s7|156-156|.|O
DDI-DrugBank.d571.s0|0-1|No|O
DDI-DrugBank.d571.s0|3-8|formal|O
DDI-DrugBank.d571.s0|10-13|drug|O
DDI-DrugBank.d571.s0|15-25|interaction|O
DDI-DrugBank.d571.s0|27-33|studies|O
DDI-DrugBank.d571.s0|35-38|have|O
DDI-DrugBank.d571.s0|40-43|been|O
DDI-DrugBank.d571.s0|45-53|conducted|O
DDI-DrugBank.d571.s0|55-58|with|O
DDI-DrugBank.d571.s0|60-66|VELCADE|brand
DDI-DrugBank.d571.s0|67-67|.|O
DDI-DrugBank.d571.s1|0-1|In|O
DDI-DrugBank.d571.s1|3-7|vitro|O
DDI-DrugBank.d571.s1|9-15|studies|O
DDI-DrugBank.d571.s1|17-20|with|O
DDI-DrugBank.d571.s1|22-26|human|O
DDI-DrugBank.d571.s1|28-32|liver|O
DDI-DrugBank.d571.s1|34-43|microsomes|O
DDI-DrugBank.d571.s1|45-52|indicate|O
DDI-DrugBank.d571.s1|54-57|that|O
DDI-DrugBank.d571.s1|59-68|bortezomib|drug
DDI-DrugBank.d571.s1|70-71|is|O
DDI-DrugBank.d571.s1|73-81|primarily|O
DDI-DrugBank.d571.s1|83-83|a|O
DDI-DrugBank.d571.s1|85-93|substrate|O
DDI-DrugBank.d571.s1|95-97|for|O
DDI-DrugBank.d571.s1|99-108|cytochrome|O
DDI-DrugBank.d571.s1|110-113|P450|O
DDI-DrugBank.d571.s1|115-117|3A4|O
DDI-DrugBank.d571.s1|118-118|,|O
DDI-DrugBank.d571.s1|120-123|2C19|O
DDI-DrugBank.d571.s1|124-124|,|O
DDI-DrugBank.d571.s1|126-128|and|O
DDI-DrugBank.d571.s1|130-132|1A2|O
DDI-DrugBank.d571.s1|133-133|.|O
DDI-DrugBank.d571.s2|0-7|Patients|O
DDI-DrugBank.d571.s2|9-11|who|O
DDI-DrugBank.d571.s2|13-15|are|O
DDI-DrugBank.d571.s2|17-29|concomitantly|O
DDI-DrugBank.d571.s2|31-39|receiving|O
DDI-DrugBank.d571.s2|41-47|VELCADE|brand
DDI-DrugBank.d571.s2|49-51|and|O
DDI-DrugBank.d571.s2|53-57|drugs|O
DDI-DrugBank.d571.s2|59-62|that|O
DDI-DrugBank.d571.s2|64-66|are|O
DDI-DrugBank.d571.s2|68-77|inhibitors|O
DDI-DrugBank.d571.s2|79-80|or|O
DDI-DrugBank.d571.s2|82-89|inducers|O
DDI-DrugBank.d571.s2|91-92|of|O
DDI-DrugBank.d571.s2|94-103|cytochrome|O
DDI-DrugBank.d571.s2|105-108|P450|O
DDI-DrugBank.d571.s2|110-112|3A4|O
DDI-DrugBank.d571.s2|114-119|should|O
DDI-DrugBank.d571.s2|121-122|be|O
DDI-DrugBank.d571.s2|124-130|closely|O
DDI-DrugBank.d571.s2|132-140|monitored|O
DDI-DrugBank.d571.s2|142-144|for|O
DDI-DrugBank.d571.s2|146-151|either|O
DDI-DrugBank.d571.s2|153-162|toxicities|O
DDI-DrugBank.d571.s2|164-165|or|O
DDI-DrugBank.d571.s2|167-173|reduced|O
DDI-DrugBank.d571.s2|175-182|efficacy|O
DDI-DrugBank.d571.s2|184-184|.|O
DDI-DrugBank.d571.s3|0-5|During|O
DDI-DrugBank.d571.s3|7-14|clinical|O
DDI-DrugBank.d571.s3|16-21|trials|O
DDI-DrugBank.d571.s3|22-22|,|O
DDI-DrugBank.d571.s3|24-35|hypoglycemia|O
DDI-DrugBank.d571.s3|37-39|and|O
DDI-DrugBank.d571.s3|41-53|hyperglycemia|O
DDI-DrugBank.d571.s3|55-58|were|O
DDI-DrugBank.d571.s3|60-67|reported|O
DDI-DrugBank.d571.s3|69-70|in|O
DDI-DrugBank.d571.s3|72-79|diabetic|O
DDI-DrugBank.d571.s3|81-88|patients|O
DDI-DrugBank.d571.s3|90-98|receiving|O
DDI-DrugBank.d571.s3|100-103|oral|O
DDI-DrugBank.d571.s3|105-117|hypoglycemics|group
DDI-DrugBank.d571.s3|118-118|.|O
DDI-DrugBank.d571.s4|0-7|Patients|O
DDI-DrugBank.d571.s4|9-10|on|O
DDI-DrugBank.d571.s4|12-15|oral|O
DDI-DrugBank.d571.s4|17-35|antidiabetic agents|group
DDI-DrugBank.d571.s4|37-45|receiving|O
DDI-DrugBank.d571.s4|47-53|VELCADE|brand
DDI-DrugBank.d571.s4|55-63|treatment|O
DDI-DrugBank.d571.s4|65-67|may|O
DDI-DrugBank.d571.s4|69-75|require|O
DDI-DrugBank.d571.s4|77-81|close|O
DDI-DrugBank.d571.s4|83-92|monitoring|O
DDI-DrugBank.d571.s4|94-95|of|O
DDI-DrugBank.d571.s4|97-101|their|O
DDI-DrugBank.d571.s4|103-107|blood|O
DDI-DrugBank.d571.s4|109-115|glucose|O
DDI-DrugBank.d571.s4|117-122|levels|O
DDI-DrugBank.d571.s4|124-126|and|O
DDI-DrugBank.d571.s4|128-137|adjustment|O
DDI-DrugBank.d571.s4|139-140|of|O
DDI-DrugBank.d571.s4|142-144|the|O
DDI-DrugBank.d571.s4|146-149|dose|O
DDI-DrugBank.d571.s4|151-152|of|O
DDI-DrugBank.d571.s4|154-158|their|O
DDI-DrugBank.d571.s4|160-182|antidiabetic medication|group
DDI-DrugBank.d571.s4|183-183|.|O
DDI-DrugBank.d571.s5|0-3|Drug|O
DDI-DrugBank.d571.s5|5-14|Laboratory|O
DDI-DrugBank.d571.s5|16-19|Test|O
DDI-DrugBank.d571.s5|21-32|Interactions|O
DDI-DrugBank.d571.s5|34-37|None|O
DDI-DrugBank.d571.s5|39-43|known|O
DDI-DrugBank.d571.s5|44-44|.|O
DDI-DrugBank.d670.s0|0-8|Potential|O
DDI-DrugBank.d670.s0|10-12|for|O
DDI-DrugBank.d670.s0|14-19|INVEGA|brand
DDI-DrugBank.d670.s0|24-25|to|O
DDI-DrugBank.d670.s0|27-32|Affect|O
DDI-DrugBank.d670.s0|34-38|Other|O
DDI-DrugBank.d670.s0|40-44|Drugs|O
DDI-DrugBank.d670.s0|46-57|Paliperidone|drug
DDI-DrugBank.d670.s0|59-60|is|O
DDI-DrugBank.d670.s0|62-64|not|O
DDI-DrugBank.d670.s0|66-73|expected|O
DDI-DrugBank.d670.s0|75-76|to|O
DDI-DrugBank.d670.s0|78-82|cause|O
DDI-DrugBank.d670.s0|84-93|clinically|O
DDI-DrugBank.d670.s0|95-103|important|O
DDI-DrugBank.d670.s0|105-119|pharmacokinetic|O
DDI-DrugBank.d670.s0|121-132|interactions|O
DDI-DrugBank.d670.s0|134-137|with|O
DDI-DrugBank.d670.s0|139-143|drugs|O
DDI-DrugBank.d670.s0|145-148|that|O
DDI-DrugBank.d670.s0|150-152|are|O
DDI-DrugBank.d670.s0|154-164|metabolized|O
DDI-DrugBank.d670.s0|166-167|by|O
DDI-DrugBank.d670.s0|169-178|cytochrome|O
DDI-DrugBank.d670.s0|180-183|P450|O
DDI-DrugBank.d670.s0|185-192|isozymes|O
DDI-DrugBank.d670.s0|193-193|.|O
DDI-DrugBank.d670.s1|0-1|In|O
DDI-DrugBank.d670.s1|3-7|vitro|O
DDI-DrugBank.d670.s1|9-15|studies|O
DDI-DrugBank.d670.s1|17-18|in|O
DDI-DrugBank.d670.s1|20-24|human|O
DDI-DrugBank.d670.s1|26-30|liver|O
DDI-DrugBank.d670.s1|32-41|microsomes|O
DDI-DrugBank.d670.s1|43-48|showed|O
DDI-DrugBank.d670.s1|50-53|that|O
DDI-DrugBank.d670.s1|55-66|paliperidone|drug
DDI-DrugBank.d670.s1|68-71|does|O
DDI-DrugBank.d670.s1|73-75|not|O
DDI-DrugBank.d670.s1|77-89|substantially|O
DDI-DrugBank.d670.s1|91-97|inhibit|O
DDI-DrugBank.d670.s1|99-101|the|O
DDI-DrugBank.d670.s1|103-112|metabolism|O
DDI-DrugBank.d670.s1|114-115|of|O
DDI-DrugBank.d670.s1|117-121|drugs|O
DDI-DrugBank.d670.s1|123-133|metabolized|O
DDI-DrugBank.d670.s1|135-136|by|O
DDI-DrugBank.d670.s1|138-147|cytochrome|O
DDI-DrugBank.d670.s1|149-152|P450|O
DDI-DrugBank.d670.s1|154-161|isozymes|O
DDI-DrugBank.d670.s1|162-162|,|O
DDI-DrugBank.d670.s1|164-172|including|O
DDI-DrugBank.d670.s1|174-179|CYP1A2|O
DDI-DrugBank.d670.s1|180-180|,|O
DDI-DrugBank.d670.s1|182-187|CYP2A6|O
DDI-DrugBank.d670.s1|188-188|,|O
DDI-DrugBank.d670.s1|190-200|CYP2C8/9/10|O
DDI-DrugBank.d670.s1|201-201|,|O
DDI-DrugBank.d670.s1|203-208|CYP2D6|O
DDI-DrugBank.d670.s1|209-209|,|O
DDI-DrugBank.d670.s1|211-216|CYP2E1|O
DDI-DrugBank.d670.s1|217-217|,|O
DDI-DrugBank.d670.s1|219-224|CYP3A4|O
DDI-DrugBank.d670.s1|225-225|,|O
DDI-DrugBank.d670.s1|227-229|and|O
DDI-DrugBank.d670.s1|231-236|CYP3A5|O
DDI-DrugBank.d670.s1|237-237|.|O
DDI-DrugBank.d670.s2|0-8|Therefore|O
DDI-DrugBank.d670.s2|9-9|,|O
DDI-DrugBank.d670.s2|11-22|paliperidone|drug
DDI-DrugBank.d670.s2|24-25|is|O
DDI-DrugBank.d670.s2|27-29|not|O
DDI-DrugBank.d670.s2|31-38|expected|O
DDI-DrugBank.d670.s2|40-41|to|O
DDI-DrugBank.d670.s2|43-49|inhibit|O
DDI-DrugBank.d670.s2|51-59|clearance|O
DDI-DrugBank.d670.s2|61-62|of|O
DDI-DrugBank.d670.s2|64-68|drugs|O
DDI-DrugBank.d670.s2|70-73|that|O
DDI-DrugBank.d670.s2|75-77|are|O
DDI-DrugBank.d670.s2|79-89|metabolized|O
DDI-DrugBank.d670.s2|91-92|by|O
DDI-DrugBank.d670.s2|94-98|these|O
DDI-DrugBank.d670.s2|100-108|metabolic|O
DDI-DrugBank.d670.s2|110-117|pathways|O
DDI-DrugBank.d670.s2|119-120|in|O
DDI-DrugBank.d670.s2|122-122|a|O
DDI-DrugBank.d670.s2|124-133|clinically|O
DDI-DrugBank.d670.s2|135-142|relevant|O
DDI-DrugBank.d670.s2|144-149|manner|O
DDI-DrugBank.d670.s2|150-150|.|O
DDI-DrugBank.d670.s3|0-11|Paliperidone|drug
DDI-DrugBank.d670.s3|13-14|is|O
DDI-DrugBank.d670.s3|16-19|also|O
DDI-DrugBank.d670.s3|21-23|not|O
DDI-DrugBank.d670.s3|25-32|expected|O
DDI-DrugBank.d670.s3|34-35|to|O
DDI-DrugBank.d670.s3|37-40|have|O
DDI-DrugBank.d670.s3|42-47|enzyme|O
DDI-DrugBank.d670.s3|49-56|inducing|O
DDI-DrugBank.d670.s3|58-67|properties|O
DDI-DrugBank.d670.s3|68-68|.|O
DDI-DrugBank.d670.s4|0-1|At|O
DDI-DrugBank.d670.s4|3-13|therapeutic|O
DDI-DrugBank.d670.s4|15-28|concentrations|O
DDI-DrugBank.d670.s4|29-29|,|O
DDI-DrugBank.d670.s4|31-42|paliperidone|drug
DDI-DrugBank.d670.s4|44-46|did|O
DDI-DrugBank.d670.s4|48-50|not|O
DDI-DrugBank.d670.s4|52-58|inhibit|O
DDI-DrugBank.d670.s4|60-73|P-glycoprotein|O
DDI-DrugBank.d670.s4|74-74|.|O
DDI-DrugBank.d670.s5|0-11|Paliperidone|drug
DDI-DrugBank.d670.s5|13-14|is|O
DDI-DrugBank.d670.s5|16-24|therefore|O
DDI-DrugBank.d670.s5|26-28|not|O
DDI-DrugBank.d670.s5|30-37|expected|O
DDI-DrugBank.d670.s5|39-40|to|O
DDI-DrugBank.d670.s5|42-48|inhibit|O
DDI-DrugBank.d670.s5|50-72|P-glycoprotein-mediated|O
DDI-DrugBank.d670.s5|74-82|transport|O
DDI-DrugBank.d670.s5|84-85|of|O
DDI-DrugBank.d670.s5|87-91|other|O
DDI-DrugBank.d670.s5|93-97|drugs|O
DDI-DrugBank.d670.s5|99-100|in|O
DDI-DrugBank.d670.s5|102-102|a|O
DDI-DrugBank.d670.s5|104-113|clinically|O
DDI-DrugBank.d670.s5|115-122|relevant|O
DDI-DrugBank.d670.s5|124-129|manner|O
DDI-DrugBank.d670.s5|130-130|.|O
DDI-DrugBank.d670.s6|0-4|Given|O
DDI-DrugBank.d670.s6|6-8|the|O
DDI-DrugBank.d670.s6|10-16|primary|O
DDI-DrugBank.d670.s6|18-20|CNS|O
DDI-DrugBank.d670.s6|22-28|effects|O
DDI-DrugBank.d670.s6|30-31|of|O
DDI-DrugBank.d670.s6|33-44|paliperidone|drug
DDI-DrugBank.d670.s6|45-45|,|O
DDI-DrugBank.d670.s6|47-52|INVEGA|brand
DDI-DrugBank.d670.s6|57-62|should|O
DDI-DrugBank.d670.s6|64-65|be|O
DDI-DrugBank.d670.s6|67-70|used|O
DDI-DrugBank.d670.s6|72-75|with|O
DDI-DrugBank.d670.s6|77-83|caution|O
DDI-DrugBank.d670.s6|85-86|in|O
DDI-DrugBank.d670.s6|88-98|combination|O
DDI-DrugBank.d670.s6|100-103|with|O
DDI-DrugBank.d670.s6|105-109|other|O
DDI-DrugBank.d670.s6|111-132|centrally acting drugs|group
DDI-DrugBank.d670.s6|134-136|and|O
DDI-DrugBank.d670.s6|138-144|alcohol|drug
DDI-DrugBank.d670.s6|145-145|.|O
DDI-DrugBank.d670.s7|0-11|Paliperidone|drug
DDI-DrugBank.d670.s7|13-15|may|O
DDI-DrugBank.d670.s7|17-26|antagonize|O
DDI-DrugBank.d670.s7|28-30|the|O
DDI-DrugBank.d670.s7|32-37|effect|O
DDI-DrugBank.d670.s7|39-40|of|O
DDI-DrugBank.d670.s7|42-49|levodopa|drug
DDI-DrugBank.d670.s7|51-53|and|O
DDI-DrugBank.d670.s7|55-59|other|O
DDI-DrugBank.d670.s7|61-77|dopamine agonists|group
DDI-DrugBank.d670.s7|78-78|.|O
DDI-DrugBank.d670.s8|0-6|Because|O
DDI-DrugBank.d670.s8|8-9|of|O
DDI-DrugBank.d670.s8|11-13|its|O
DDI-DrugBank.d670.s8|15-23|potential|O
DDI-DrugBank.d670.s8|25-27|for|O
DDI-DrugBank.d670.s8|29-36|inducing|O
DDI-DrugBank.d670.s8|38-48|orthostatic|O
DDI-DrugBank.d670.s8|50-60|hypotension|O
DDI-DrugBank.d670.s8|61-61|,|O
DDI-DrugBank.d670.s8|63-64|an|O
DDI-DrugBank.d670.s8|66-73|additive|O
DDI-DrugBank.d670.s8|75-80|effect|O
DDI-DrugBank.d670.s8|82-84|may|O
DDI-DrugBank.d670.s8|86-87|be|O
DDI-DrugBank.d670.s8|89-96|observed|O
DDI-DrugBank.d670.s8|98-101|when|O
DDI-DrugBank.d670.s8|103-108|INVEGA|brand
DDI-DrugBank.d670.s8|113-114|is|O
DDI-DrugBank.d670.s8|116-127|administered|O
DDI-DrugBank.d670.s8|129-132|with|O
DDI-DrugBank.d670.s8|134-138|other|O
DDI-DrugBank.d670.s8|140-150|therapeutic|O
DDI-DrugBank.d670.s8|152-157|agents|O
DDI-DrugBank.d670.s8|159-162|that|O
DDI-DrugBank.d670.s8|164-167|have|O
DDI-DrugBank.d670.s8|169-172|this|O
DDI-DrugBank.d670.s8|174-182|potential|O
DDI-DrugBank.d670.s8|183-183|.|O
DDI-DrugBank.d670.s9|0-8|Potential|O
DDI-DrugBank.d670.s9|10-12|for|O
DDI-DrugBank.d670.s9|14-18|Other|O
DDI-DrugBank.d670.s9|20-24|Drugs|O
DDI-DrugBank.d670.s9|26-27|to|O
DDI-DrugBank.d670.s9|29-34|Affect|O
DDI-DrugBank.d670.s9|36-41|INVEGA|brand
DDI-DrugBank.d670.s9|36-41|INVEGA|brand
DDI-DrugBank.d670.s9|59-60|is|O
DDI-DrugBank.d670.s9|62-64|not|O
DDI-DrugBank.d670.s9|66-66|a|O
DDI-DrugBank.d670.s9|68-76|substrate|O
DDI-DrugBank.d670.s9|78-79|of|O
DDI-DrugBank.d670.s9|81-86|CYP1A2|O
DDI-DrugBank.d670.s9|87-87|,|O
DDI-DrugBank.d670.s9|89-94|CYP2A6|O
DDI-DrugBank.d670.s9|95-95|,|O
DDI-DrugBank.d670.s9|97-102|CYP2C9|O
DDI-DrugBank.d670.s9|103-103|,|O
DDI-DrugBank.d670.s9|105-107|and|O
DDI-DrugBank.d670.s9|109-115|CYP2C19|O
DDI-DrugBank.d670.s9|116-116|,|O
DDI-DrugBank.d670.s9|118-119|so|O
DDI-DrugBank.d670.s9|121-124|that|O
DDI-DrugBank.d670.s9|126-127|an|O
DDI-DrugBank.d670.s9|129-139|interaction|O
DDI-DrugBank.d670.s9|141-144|with|O
DDI-DrugBank.d670.s9|146-155|inhibitors|O
DDI-DrugBank.d670.s9|157-158|or|O
DDI-DrugBank.d670.s9|160-167|inducers|O
DDI-DrugBank.d670.s9|169-170|of|O
DDI-DrugBank.d670.s9|172-176|these|O
DDI-DrugBank.d670.s9|178-185|isozymes|O
DDI-DrugBank.d670.s9|187-188|is|O
DDI-DrugBank.d670.s9|190-197|unlikely|O
DDI-DrugBank.d670.s9|198-198|.|O
DDI-DrugBank.d670.s10|0-4|While|O
DDI-DrugBank.d670.s10|6-7|in|O
DDI-DrugBank.d670.s10|9-13|vitro|O
DDI-DrugBank.d670.s10|15-21|studies|O
DDI-DrugBank.d670.s10|23-30|indicate|O
DDI-DrugBank.d670.s10|32-35|that|O
DDI-DrugBank.d670.s10|37-42|CYP2D6|O
DDI-DrugBank.d670.s10|44-46|and|O
DDI-DrugBank.d670.s10|48-53|CYP3A4|O
DDI-DrugBank.d670.s10|55-57|may|O
DDI-DrugBank.d670.s10|59-60|be|O
DDI-DrugBank.d670.s10|62-70|minimally|O
DDI-DrugBank.d670.s10|72-79|involved|O
DDI-DrugBank.d670.s10|81-82|in|O
DDI-DrugBank.d670.s10|84-95|paliperidone|drug
DDI-DrugBank.d670.s10|97-106|metabolism|O
DDI-DrugBank.d670.s10|107-107|,|O
DDI-DrugBank.d670.s10|109-110|in|O
DDI-DrugBank.d670.s10|112-115|vivo|O
DDI-DrugBank.d670.s10|117-123|studies|O
DDI-DrugBank.d670.s10|125-126|do|O
DDI-DrugBank.d670.s10|128-130|not|O
DDI-DrugBank.d670.s10|132-135|show|O
DDI-DrugBank.d670.s10|137-145|decreased|O
DDI-DrugBank.d670.s10|147-157|elimination|O
DDI-DrugBank.d670.s10|159-160|by|O
DDI-DrugBank.d670.s10|162-166|these|O
DDI-DrugBank.d670.s10|168-175|isozymes|O
DDI-DrugBank.d670.s10|177-179|and|O
DDI-DrugBank.d670.s10|181-184|they|O
DDI-DrugBank.d670.s10|186-195|contribute|O
DDI-DrugBank.d670.s10|197-198|to|O
DDI-DrugBank.d670.s10|200-203|only|O
DDI-DrugBank.d670.s10|205-205|a|O
DDI-DrugBank.d670.s10|207-211|small|O
DDI-DrugBank.d670.s10|213-220|fraction|O
DDI-DrugBank.d670.s10|222-223|of|O
DDI-DrugBank.d670.s10|225-229|total|O
DDI-DrugBank.d670.s10|231-234|body|O
DDI-DrugBank.d670.s10|236-244|clearance|O
DDI-DrugBank.d670.s10|245-245|.|O
DDI-DrugBank.d353.s0|0-6|Ethanol|drug
DDI-DrugBank.d353.s0|7-7|:|O
DDI-DrugBank.d353.s0|8-15|Clinical|O
DDI-DrugBank.d353.s0|17-24|evidence|O
DDI-DrugBank.d353.s0|26-28|has|O
DDI-DrugBank.d353.s0|30-34|shown|O
DDI-DrugBank.d353.s0|36-39|that|O
DDI-DrugBank.d353.s0|41-50|etretinate|drug
DDI-DrugBank.d353.s0|52-54|can|O
DDI-DrugBank.d353.s0|56-57|be|O
DDI-DrugBank.d353.s0|59-64|formed|O
DDI-DrugBank.d353.s0|66-69|with|O
DDI-DrugBank.d353.s0|71-80|concurrent|O
DDI-DrugBank.d353.s0|82-90|ingestion|O
DDI-DrugBank.d353.s0|92-93|of|O
DDI-DrugBank.d353.s0|95-103|acitretin|drug
DDI-DrugBank.d353.s0|105-107|and|O
DDI-DrugBank.d353.s0|109-115|ethanol|drug
DDI-DrugBank.d353.s0|116-116|.|O
DDI-DrugBank.d353.s1|0-12|Glibenclamide|drug
DDI-DrugBank.d353.s1|13-13|:|O
DDI-DrugBank.d353.s1|15-16|In|O
DDI-DrugBank.d353.s1|18-18|a|O
DDI-DrugBank.d353.s1|20-24|study|O
DDI-DrugBank.d353.s1|26-27|of|O
DDI-DrugBank.d353.s1|29-29|7|O
DDI-DrugBank.d353.s1|31-37|healthy|O
DDI-DrugBank.d353.s1|39-42|male|O
DDI-DrugBank.d353.s1|44-53|volunteers|O
DDI-DrugBank.d353.s1|54-54|,|O
DDI-DrugBank.d353.s1|56-64|acitretin|drug
DDI-DrugBank.d353.s1|66-74|treatment|O
DDI-DrugBank.d353.s1|76-86|potentiated|O
DDI-DrugBank.d353.s1|88-90|the|O
DDI-DrugBank.d353.s1|92-96|blood|O
DDI-DrugBank.d353.s1|98-104|glucose|O
DDI-DrugBank.d353.s1|106-113|lowering|O
DDI-DrugBank.d353.s1|115-120|effect|O
DDI-DrugBank.d353.s1|122-123|of|O
DDI-DrugBank.d353.s1|125-137|glibenclamide|drug
DDI-DrugBank.d353.s1|139-139|(|O
DDI-DrugBank.d353.s1|140-140|a|O
DDI-DrugBank.d353.s1|142-153|sulfonylurea|group
DDI-DrugBank.d353.s1|155-161|similar|O
DDI-DrugBank.d353.s1|163-164|to|O
DDI-DrugBank.d353.s1|166-179|chlorpropamide|drug
DDI-DrugBank.d353.s1|180-180|)|O
DDI-DrugBank.d353.s1|182-183|in|O
DDI-DrugBank.d353.s1|185-185|3|O
DDI-DrugBank.d353.s1|187-188|of|O
DDI-DrugBank.d353.s1|190-192|the|O
DDI-DrugBank.d353.s1|194-194|7|O
DDI-DrugBank.d353.s1|196-203|subjects|O
DDI-DrugBank.d353.s1|204-204|.|O
DDI-DrugBank.d353.s2|0-8|Repeating|O
DDI-DrugBank.d353.s2|10-12|the|O
DDI-DrugBank.d353.s2|14-18|study|O
DDI-DrugBank.d353.s2|20-23|with|O
DDI-DrugBank.d353.s2|25-25|6|O
DDI-DrugBank.d353.s2|27-33|healthy|O
DDI-DrugBank.d353.s2|35-38|male|O
DDI-DrugBank.d353.s2|40-49|volunteers|O
DDI-DrugBank.d353.s2|51-52|in|O
DDI-DrugBank.d353.s2|54-56|the|O
DDI-DrugBank.d353.s2|58-64|absence|O
DDI-DrugBank.d353.s2|66-67|of|O
DDI-DrugBank.d353.s2|69-81|glibenclamide|drug
DDI-DrugBank.d353.s2|83-85|did|O
DDI-DrugBank.d353.s2|87-89|not|O
DDI-DrugBank.d353.s2|91-96|detect|O
DDI-DrugBank.d353.s2|98-99|an|O
DDI-DrugBank.d353.s2|101-106|effect|O
DDI-DrugBank.d353.s2|108-109|of|O
DDI-DrugBank.d353.s2|111-119|acitretin|drug
DDI-DrugBank.d353.s2|121-122|on|O
DDI-DrugBank.d353.s2|124-130|glucose|O
DDI-DrugBank.d353.s2|132-140|tolerance|O
DDI-DrugBank.d353.s2|141-141|.|O
DDI-DrugBank.d353.s3|0-6|Careful|O
DDI-DrugBank.d353.s3|8-18|supervision|O
DDI-DrugBank.d353.s3|20-21|of|O
DDI-DrugBank.d353.s3|23-30|diabetic|O
DDI-DrugBank.d353.s3|32-39|patients|O
DDI-DrugBank.d353.s3|41-45|under|O
DDI-DrugBank.d353.s3|47-55|treatment|O
DDI-DrugBank.d353.s3|57-60|with|O
DDI-DrugBank.d353.s3|62-70|Soriatane|brand
DDI-DrugBank.d353.s3|72-73|is|O
DDI-DrugBank.d353.s3|75-85|recommended|O
DDI-DrugBank.d353.s3|86-86|.|O
DDI-DrugBank.d353.s4|0-22|Hormonal Contraceptives|group
DDI-DrugBank.d353.s4|23-23|:|O
DDI-DrugBank.d353.s4|25-26|It|O
DDI-DrugBank.d353.s4|28-30|has|O
DDI-DrugBank.d353.s4|32-34|not|O
DDI-DrugBank.d353.s4|36-39|been|O
DDI-DrugBank.d353.s4|41-51|established|O
DDI-DrugBank.d353.s4|53-54|if|O
DDI-DrugBank.d353.s4|56-60|there|O
DDI-DrugBank.d353.s4|62-63|is|O
DDI-DrugBank.d353.s4|65-65|a|O
DDI-DrugBank.d353.s4|67-81|pharmacokinetic|O
DDI-DrugBank.d353.s4|83-93|interaction|O
DDI-DrugBank.d353.s4|95-101|between|O
DDI-DrugBank.d353.s4|103-111|acitretin|drug
DDI-DrugBank.d353.s4|113-115|and|O
DDI-DrugBank.d353.s4|117-144|combined oral contraceptives|group
DDI-DrugBank.d353.s4|145-145|.|O
DDI-DrugBank.d353.s5|0-6|However|O
DDI-DrugBank.d353.s5|7-7|,|O
DDI-DrugBank.d353.s5|9-10|it|O
DDI-DrugBank.d353.s5|12-14|has|O
DDI-DrugBank.d353.s5|16-19|been|O
DDI-DrugBank.d353.s5|21-31|established|O
DDI-DrugBank.d353.s5|33-36|that|O
DDI-DrugBank.d353.s5|38-46|acitretin|drug
DDI-DrugBank.d353.s5|48-57|interferes|O
DDI-DrugBank.d353.s5|59-62|with|O
DDI-DrugBank.d353.s5|64-66|the|O
DDI-DrugBank.d353.s5|68-80|contraceptive|O
DDI-DrugBank.d353.s5|82-87|effect|O
DDI-DrugBank.d353.s5|89-90|of|O
DDI-DrugBank.d353.s5|92-101|microdosed|O
DDI-DrugBank.d353.s5|103-111|progestin|drug
DDI-DrugBank.d353.s5|113-120|minipill|O
DDI-DrugBank.d353.s5|122-133|preparations|O
DDI-DrugBank.d353.s5|134-134|.|O
DDI-DrugBank.d353.s6|0-9|Microdosed|O
DDI-DrugBank.d353.s6|11-18|minipill|O
DDI-DrugBank.d353.s6|20-28|progestin|drug
DDI-DrugBank.d353.s6|30-41|preparations|O
DDI-DrugBank.d353.s6|43-45|are|O
DDI-DrugBank.d353.s6|47-49|not|O
DDI-DrugBank.d353.s6|51-61|recommended|O
DDI-DrugBank.d353.s6|63-65|for|O
DDI-DrugBank.d353.s6|67-69|use|O
DDI-DrugBank.d353.s6|71-74|with|O
DDI-DrugBank.d353.s6|76-84|Soriatane|drug
DDI-DrugBank.d353.s6|85-85|.|O
DDI-DrugBank.d353.s7|0-1|It|O
DDI-DrugBank.d353.s7|3-4|is|O
DDI-DrugBank.d353.s7|6-8|not|O
DDI-DrugBank.d353.s7|10-14|known|O
DDI-DrugBank.d353.s7|16-22|whether|O
DDI-DrugBank.d353.s7|24-28|other|O
DDI-DrugBank.d353.s7|30-58|progestational contraceptives|group
DDI-DrugBank.d353.s7|59-59|,|O
DDI-DrugBank.d353.s7|61-64|such|O
DDI-DrugBank.d353.s7|66-67|as|O
DDI-DrugBank.d353.s7|69-76|implants|O
DDI-DrugBank.d353.s7|78-80|and|O
DDI-DrugBank.d353.s7|82-92|injectables|O
DDI-DrugBank.d353.s7|93-93|,|O
DDI-DrugBank.d353.s7|95-97|are|O
DDI-DrugBank.d353.s7|99-106|adequate|O
DDI-DrugBank.d353.s7|108-114|methods|O
DDI-DrugBank.d353.s7|116-117|of|O
DDI-DrugBank.d353.s7|119-131|contraception|O
DDI-DrugBank.d353.s7|133-138|during|O
DDI-DrugBank.d353.s7|140-148|acitretin|drug
DDI-DrugBank.d353.s7|150-156|therapy|O
DDI-DrugBank.d353.s7|157-157|.|O
DDI-DrugBank.d353.s8|0-11|Methotrexate|drug
DDI-DrugBank.d353.s8|12-12|:|O
DDI-DrugBank.d353.s8|14-15|An|O
DDI-DrugBank.d353.s8|17-25|increased|O
DDI-DrugBank.d353.s8|27-30|risk|O
DDI-DrugBank.d353.s8|32-33|of|O
DDI-DrugBank.d353.s8|35-43|hepatitis|O
DDI-DrugBank.d353.s8|45-47|has|O
DDI-DrugBank.d353.s8|49-52|been|O
DDI-DrugBank.d353.s8|54-61|reported|O
DDI-DrugBank.d353.s8|63-64|to|O
DDI-DrugBank.d353.s8|66-71|result|O
DDI-DrugBank.d353.s8|73-76|from|O
DDI-DrugBank.d353.s8|78-85|combined|O
DDI-DrugBank.d353.s8|87-89|use|O
DDI-DrugBank.d353.s8|91-92|of|O
DDI-DrugBank.d353.s8|94-105|methotrexate|drug
DDI-DrugBank.d353.s8|107-109|and|O
DDI-DrugBank.d353.s8|111-120|etretinate|drug
DDI-DrugBank.d353.s8|121-121|.|O
DDI-DrugBank.d353.s9|0-11|Consequently|O
DDI-DrugBank.d353.s9|12-12|,|O
DDI-DrugBank.d353.s9|14-16|the|O
DDI-DrugBank.d353.s9|18-28|combination|O
DDI-DrugBank.d353.s9|30-31|of|O
DDI-DrugBank.d353.s9|33-44|methotrexate|drug
DDI-DrugBank.d353.s9|46-49|with|O
DDI-DrugBank.d353.s9|51-59|acitretin|drug
DDI-DrugBank.d353.s9|61-62|is|O
DDI-DrugBank.d353.s9|64-67|also|O
DDI-DrugBank.d353.s9|69-83|contraindicated|O
DDI-DrugBank.d353.s9|84-84|.|O
DDI-DrugBank.d353.s10|0-8|Phenytoin|drug
DDI-DrugBank.d353.s10|9-9|:|O
DDI-DrugBank.d353.s10|11-12|If|O
DDI-DrugBank.d353.s10|14-22|acitretin|drug
DDI-DrugBank.d353.s10|24-25|is|O
DDI-DrugBank.d353.s10|27-31|given|O
DDI-DrugBank.d353.s10|33-44|concurrently|O
DDI-DrugBank.d353.s10|46-49|with|O
DDI-DrugBank.d353.s10|51-59|phenytoin|drug
DDI-DrugBank.d353.s10|60-60|,|O
DDI-DrugBank.d353.s10|62-64|the|O
DDI-DrugBank.d353.s10|66-72|protein|O
DDI-DrugBank.d353.s10|74-80|binding|O
DDI-DrugBank.d353.s10|82-83|of|O
DDI-DrugBank.d353.s10|85-93|phenytoin|drug
DDI-DrugBank.d353.s10|95-97|may|O
DDI-DrugBank.d353.s10|99-100|be|O
DDI-DrugBank.d353.s10|102-108|reduced|O
DDI-DrugBank.d353.s10|109-109|.|O
DDI-DrugBank.d353.s11|0-12|Tetracyclines|group
DDI-DrugBank.d353.s11|13-13|:|O
DDI-DrugBank.d353.s11|15-19|Since|O
DDI-DrugBank.d353.s11|21-24|both|O
DDI-DrugBank.d353.s11|26-34|acitretin|drug
DDI-DrugBank.d353.s11|36-38|and|O
DDI-DrugBank.d353.s11|40-52|tetracyclines|group
DDI-DrugBank.d353.s11|54-56|can|O
DDI-DrugBank.d353.s11|58-62|cause|O
DDI-DrugBank.d353.s11|64-72|increased|O
DDI-DrugBank.d353.s11|74-85|intracranial|O
DDI-DrugBank.d353.s11|87-94|pressure|O
DDI-DrugBank.d353.s11|95-95|,|O
DDI-DrugBank.d353.s11|97-101|their|O
DDI-DrugBank.d353.s11|103-110|combined|O
DDI-DrugBank.d353.s11|112-114|use|O
DDI-DrugBank.d353.s11|116-117|is|O
DDI-DrugBank.d353.s11|119-133|contraindicated|O
DDI-DrugBank.d353.s11|134-134|.|O
DDI-DrugBank.d353.s12|0-8|Vitamin A|group
DDI-DrugBank.d353.s12|10-12|and|O
DDI-DrugBank.d353.s12|14-17|oral|O
DDI-DrugBank.d353.s12|19-27|retinoids|group
DDI-DrugBank.d353.s12|28-28|:|O
DDI-DrugBank.d353.s12|30-40|Concomitant|O
DDI-DrugBank.d353.s12|42-55|administration|O
DDI-DrugBank.d353.s12|57-58|of|O
DDI-DrugBank.d353.s12|60-68|vitamin A|group
DDI-DrugBank.d353.s12|70-75|and/or|O
DDI-DrugBank.d353.s12|77-81|other|O
DDI-DrugBank.d353.s12|83-86|oral|O
DDI-DrugBank.d353.s12|88-96|retinoids|group
DDI-DrugBank.d353.s12|98-101|with|O
DDI-DrugBank.d353.s12|103-111|acitretin|drug
DDI-DrugBank.d353.s12|113-116|must|O
DDI-DrugBank.d353.s12|118-119|be|O
DDI-DrugBank.d353.s12|121-127|avoided|O
DDI-DrugBank.d353.s12|129-135|because|O
DDI-DrugBank.d353.s12|137-138|of|O
DDI-DrugBank.d353.s12|140-142|the|O
DDI-DrugBank.d353.s12|144-147|risk|O
DDI-DrugBank.d353.s12|149-150|of|O
DDI-DrugBank.d353.s12|152-167|hypervitaminosis|O
DDI-DrugBank.d353.s12|169-169|A|O
DDI-DrugBank.d353.s12|170-170|.|O
DDI-DrugBank.d353.s13|0-4|Other|O
DDI-DrugBank.d353.s13|5-5|:|O
DDI-DrugBank.d353.s13|7-11|There|O
DDI-DrugBank.d353.s13|13-19|appears|O
DDI-DrugBank.d353.s13|21-22|to|O
DDI-DrugBank.d353.s13|24-25|be|O
DDI-DrugBank.d353.s13|27-28|no|O
DDI-DrugBank.d353.s13|30-44|pharmacokinetic|O
DDI-DrugBank.d353.s13|46-56|interaction|O
DDI-DrugBank.d353.s13|58-64|between|O
DDI-DrugBank.d353.s13|66-74|acitretin|drug
DDI-DrugBank.d353.s13|76-78|and|O
DDI-DrugBank.d353.s13|80-89|cimetidine|drug
DDI-DrugBank.d353.s13|90-90|,|O
DDI-DrugBank.d353.s13|92-98|digoxin|drug
DDI-DrugBank.d353.s13|99-99|,|O
DDI-DrugBank.d353.s13|101-102|or|O
DDI-DrugBank.d353.s13|104-112|glyburide|drug
DDI-DrugBank.d353.s13|113-113|.|O
DDI-DrugBank.d353.s14|0-13|Investigations|O
DDI-DrugBank.d353.s14|15-18|into|O
DDI-DrugBank.d353.s14|20-22|the|O
DDI-DrugBank.d353.s14|24-29|effect|O
DDI-DrugBank.d353.s14|31-32|of|O
DDI-DrugBank.d353.s14|34-42|acitretin|drug
DDI-DrugBank.d353.s14|44-45|on|O
DDI-DrugBank.d353.s14|47-49|the|O
DDI-DrugBank.d353.s14|51-57|protein|O
DDI-DrugBank.d353.s14|59-65|binding|O
DDI-DrugBank.d353.s14|67-68|of|O
DDI-DrugBank.d353.s14|70-104|anticoagulants of the coumarin type|group
DDI-DrugBank.d353.s14|106-106|(|O
DDI-DrugBank.d353.s14|107-114|warfarin|drug
DDI-DrugBank.d353.s14|115-115|)|O
DDI-DrugBank.d353.s14|117-124|revealed|O
DDI-DrugBank.d353.s14|126-127|no|O
DDI-DrugBank.d353.s14|129-139|interaction|O
DDI-DrugBank.d353.s14|140-140|.|O
DDI-DrugBank.d353.s15|0-9|Laboratory|O
DDI-DrugBank.d353.s15|11-15|Tests|O
DDI-DrugBank.d353.s15|17-18|If|O
DDI-DrugBank.d353.s15|20-30|significant|O
DDI-DrugBank.d353.s15|32-39|abnormal|O
DDI-DrugBank.d353.s15|41-50|laboratory|O
DDI-DrugBank.d353.s15|52-58|results|O
DDI-DrugBank.d353.s15|60-62|are|O
DDI-DrugBank.d353.s15|64-71|obtained|O
DDI-DrugBank.d353.s15|72-72|,|O
DDI-DrugBank.d353.s15|74-79|either|O
DDI-DrugBank.d353.s15|81-86|dosage|O
DDI-DrugBank.d353.s15|88-96|reduction|O
DDI-DrugBank.d353.s15|98-101|with|O
DDI-DrugBank.d353.s15|103-109|careful|O
DDI-DrugBank.d353.s15|111-120|monitoring|O
DDI-DrugBank.d353.s15|122-123|or|O
DDI-DrugBank.d353.s15|125-133|treatment|O
DDI-DrugBank.d353.s15|135-149|discontinuation|O
DDI-DrugBank.d353.s15|151-152|is|O
DDI-DrugBank.d353.s15|154-164|recommended|O
DDI-DrugBank.d353.s15|165-165|,|O
DDI-DrugBank.d353.s15|167-175|depending|O
DDI-DrugBank.d353.s15|177-178|on|O
DDI-DrugBank.d353.s15|180-187|clinical|O
DDI-DrugBank.d353.s15|189-197|judgement|O
DDI-DrugBank.d353.s15|198-198|.|O
DDI-DrugBank.d353.s16|0-4|Blood|O
DDI-DrugBank.d353.s16|6-10|Sugar|O
DDI-DrugBank.d353.s16|11-11|:|O
DDI-DrugBank.d353.s16|13-16|Some|O
DDI-DrugBank.d353.s16|18-25|patients|O
DDI-DrugBank.d353.s16|27-35|receiving|O
DDI-DrugBank.d353.s16|37-45|retinoids|group
DDI-DrugBank.d353.s16|47-50|have|O
DDI-DrugBank.d353.s16|52-62|experienced|O
DDI-DrugBank.d353.s16|64-71|problems|O
DDI-DrugBank.d353.s16|73-76|with|O
DDI-DrugBank.d353.s16|78-82|blood|O
DDI-DrugBank.d353.s16|84-88|sugar|O
DDI-DrugBank.d353.s16|90-96|control|O
DDI-DrugBank.d353.s16|97-97|.|O
DDI-DrugBank.d353.s17|0-1|In|O
DDI-DrugBank.d353.s17|3-10|addition|O
DDI-DrugBank.d353.s17|11-11|,|O
DDI-DrugBank.d353.s17|13-15|new|O
DDI-DrugBank.d353.s17|17-21|cases|O
DDI-DrugBank.d353.s17|23-24|of|O
DDI-DrugBank.d353.s17|26-33|diabetes|O
DDI-DrugBank.d353.s17|35-38|have|O
DDI-DrugBank.d353.s17|40-43|been|O
DDI-DrugBank.d353.s17|45-53|diagnosed|O
DDI-DrugBank.d353.s17|55-60|during|O
DDI-DrugBank.d353.s17|62-69|retinoid|group
DDI-DrugBank.d353.s17|71-77|therapy|O
DDI-DrugBank.d353.s17|78-78|,|O
DDI-DrugBank.d353.s17|80-88|including|O
DDI-DrugBank.d353.s17|90-97|diabetic|O
DDI-DrugBank.d353.s17|99-110|ketoacidosis|O
DDI-DrugBank.d353.s17|111-111|.|O
DDI-DrugBank.d353.s18|0-1|In|O
DDI-DrugBank.d353.s18|3-11|diabetics|O
DDI-DrugBank.d353.s18|12-12|,|O
DDI-DrugBank.d353.s18|14-24|blood-sugar|O
DDI-DrugBank.d353.s18|26-31|levels|O
DDI-DrugBank.d353.s18|33-38|should|O
DDI-DrugBank.d353.s18|40-41|be|O
DDI-DrugBank.d353.s18|43-51|monitored|O
DDI-DrugBank.d353.s18|53-56|very|O
DDI-DrugBank.d353.s18|58-66|carefully|O
DDI-DrugBank.d353.s18|67-67|.|O
DDI-DrugBank.d353.s19|0-5|Lipids|O
DDI-DrugBank.d353.s19|6-6|:|O
DDI-DrugBank.d353.s19|8-9|In|O
DDI-DrugBank.d353.s19|11-18|clinical|O
DDI-DrugBank.d353.s19|20-26|studies|O
DDI-DrugBank.d353.s19|27-27|,|O
DDI-DrugBank.d353.s19|29-31|the|O
DDI-DrugBank.d353.s19|33-41|incidence|O
DDI-DrugBank.d353.s19|43-44|of|O
DDI-DrugBank.d353.s19|46-65|hypertriglyceridemia|O
DDI-DrugBank.d353.s19|67-69|was|O
DDI-DrugBank.d353.s19|71-72|66|O
DDI-DrugBank.d353.s19|73-73|%|O
DDI-DrugBank.d353.s19|74-74|,|O
DDI-DrugBank.d353.s19|76-95|hypercholesterolemia|O
DDI-DrugBank.d353.s19|97-99|was|O
DDI-DrugBank.d353.s19|101-102|33|O
DDI-DrugBank.d353.s19|103-103|%|O
DDI-DrugBank.d353.s19|105-107|and|O
DDI-DrugBank.d353.s19|109-112|that|O
DDI-DrugBank.d353.s19|114-115|of|O
DDI-DrugBank.d353.s19|117-125|decreased|O
DDI-DrugBank.d353.s19|127-129|HDL|O
DDI-DrugBank.d353.s19|131-133|was|O
DDI-DrugBank.d353.s19|135-136|40|O
DDI-DrugBank.d353.s19|137-137|%|O
DDI-DrugBank.d353.s19|138-138|.|O
DDI-DrugBank.d353.s20|0-11|Pretreatment|O
DDI-DrugBank.d353.s20|13-15|and|O
DDI-DrugBank.d353.s20|17-25|follow-up|O
DDI-DrugBank.d353.s20|27-38|measurements|O
DDI-DrugBank.d353.s20|40-45|should|O
DDI-DrugBank.d353.s20|47-48|be|O
DDI-DrugBank.d353.s20|50-57|obtained|O
DDI-DrugBank.d353.s20|59-63|under|O
DDI-DrugBank.d353.s20|65-71|fasting|O
DDI-DrugBank.d353.s20|73-82|conditions|O
DDI-DrugBank.d353.s20|83-83|.|O
DDI-DrugBank.d353.s21|0-1|It|O
DDI-DrugBank.d353.s21|3-4|is|O
DDI-DrugBank.d353.s21|6-16|recommended|O
DDI-DrugBank.d353.s21|18-21|that|O
DDI-DrugBank.d353.s21|23-27|these|O
DDI-DrugBank.d353.s21|29-33|tests|O
DDI-DrugBank.d353.s21|35-36|be|O
DDI-DrugBank.d353.s21|38-46|performed|O
DDI-DrugBank.d353.s21|48-53|weekly|O
DDI-DrugBank.d353.s21|55-56|or|O
DDI-DrugBank.d353.s21|58-62|every|O
DDI-DrugBank.d353.s21|64-68|other|O
DDI-DrugBank.d353.s21|70-73|week|O
DDI-DrugBank.d353.s21|75-79|until|O
DDI-DrugBank.d353.s21|81-83|the|O
DDI-DrugBank.d353.s21|85-89|lipid|O
DDI-DrugBank.d353.s21|91-98|response|O
DDI-DrugBank.d353.s21|100-101|to|O
DDI-DrugBank.d353.s21|103-111|Soriatane|brand
DDI-DrugBank.d353.s21|113-115|has|O
DDI-DrugBank.d353.s21|117-126|stabilized|O
DDI-DrugBank.d353.s21|127-127|.|O
DDI-DrugBank.d353.s22|0-4|Liver|O
DDI-DrugBank.d353.s22|6-13|Function|O
DDI-DrugBank.d353.s22|15-19|Tests|O
DDI-DrugBank.d353.s22|20-20|:|O
DDI-DrugBank.d353.s22|22-31|Elevations|O
DDI-DrugBank.d353.s22|33-34|of|O
DDI-DrugBank.d353.s22|36-38|AST|O
DDI-DrugBank.d353.s22|40-40|(|O
DDI-DrugBank.d353.s22|41-44|SGOT|O
DDI-DrugBank.d353.s22|45-45|)|O
DDI-DrugBank.d353.s22|46-46|,|O
DDI-DrugBank.d353.s22|48-50|ALT|O
DDI-DrugBank.d353.s22|52-52|(|O
DDI-DrugBank.d353.s22|53-56|SGPT|O
DDI-DrugBank.d353.s22|57-57|)|O
DDI-DrugBank.d353.s22|59-60|or|O
DDI-DrugBank.d353.s22|62-64|LDH|O
DDI-DrugBank.d353.s22|66-69|were|O
DDI-DrugBank.d353.s22|71-81|experienced|O
DDI-DrugBank.d353.s22|83-84|by|O
DDI-DrugBank.d353.s22|86-98|approximately|O
DDI-DrugBank.d353.s22|100-100|1|O
DDI-DrugBank.d353.s22|102-103|in|O
DDI-DrugBank.d353.s22|105-105|3|O
DDI-DrugBank.d353.s22|107-114|patients|O
DDI-DrugBank.d353.s22|116-122|treated|O
DDI-DrugBank.d353.s22|124-127|with|O
DDI-DrugBank.d353.s22|129-137|Soriatane|brand
DDI-DrugBank.d353.s22|138-138|.|O
DDI-DrugBank.d353.s23|0-1|It|O
DDI-DrugBank.d353.s23|3-4|is|O
DDI-DrugBank.d353.s23|6-16|recommended|O
DDI-DrugBank.d353.s23|18-21|that|O
DDI-DrugBank.d353.s23|23-27|these|O
DDI-DrugBank.d353.s23|29-33|tests|O
DDI-DrugBank.d353.s23|35-36|be|O
DDI-DrugBank.d353.s23|38-46|performed|O
DDI-DrugBank.d353.s23|48-52|prior|O
DDI-DrugBank.d353.s23|54-55|to|O
DDI-DrugBank.d353.s23|57-66|initiation|O
DDI-DrugBank.d353.s23|68-69|of|O
DDI-DrugBank.d353.s23|71-79|Soriatane|brand
DDI-DrugBank.d353.s23|81-87|therapy|O
DDI-DrugBank.d353.s23|88-88|,|O
DDI-DrugBank.d353.s23|90-91|at|O
DDI-DrugBank.d353.s23|93-94|1-|O
DDI-DrugBank.d353.s23|96-97|to|O
DDI-DrugBank.d353.s23|99-104|2-week|O
DDI-DrugBank.d353.s23|106-114|intervals|O
DDI-DrugBank.d353.s23|116-120|until|O
DDI-DrugBank.d353.s23|122-127|stable|O
DDI-DrugBank.d353.s23|129-131|and|O
DDI-DrugBank.d353.s23|133-142|thereafter|O
DDI-DrugBank.d353.s23|144-145|at|O
DDI-DrugBank.d353.s23|147-155|intervals|O
DDI-DrugBank.d353.s23|157-158|as|O
DDI-DrugBank.d353.s23|160-169|clinically|O
DDI-DrugBank.d353.s23|171-179|indicated|O
DDI-DrugBank.d353.s23|180-180|.|O
DDI-DrugBank.d451.s0|0-3|Drug|O
DDI-DrugBank.d451.s0|5-16|interactions|O
DDI-DrugBank.d451.s0|18-21|with|O
DDI-DrugBank.d451.s0|23-40|clomiphene citrate|drug
DDI-DrugBank.d451.s0|42-48|tablets|O
DDI-DrugBank.d451.s0|50-52|USP|O
DDI-DrugBank.d451.s0|54-57|have|O
DDI-DrugBank.d451.s0|59-61|not|O
DDI-DrugBank.d451.s0|63-66|been|O
DDI-DrugBank.d451.s0|68-77|documented|O
DDI-DrugBank.d451.s0|78-78|.|O
DDI-DrugBank.d150.s0|0-7|FLEXERIL|brand
DDI-DrugBank.d150.s0|9-11|may|O
DDI-DrugBank.d150.s0|13-16|have|O
DDI-DrugBank.d150.s0|18-33|life-threatening|O
DDI-DrugBank.d150.s0|35-46|interactions|O
DDI-DrugBank.d150.s0|48-51|with|O
DDI-DrugBank.d150.s0|53-66|MAO inhibitors|group
DDI-DrugBank.d150.s0|67-67|.|O
DDI-DrugBank.d150.s1|0-7|FLEXERIL|brand
DDI-DrugBank.d150.s1|9-11|may|O
DDI-DrugBank.d150.s1|13-19|enhance|O
DDI-DrugBank.d150.s1|21-23|the|O
DDI-DrugBank.d150.s1|25-31|effects|O
DDI-DrugBank.d150.s1|33-34|of|O
DDI-DrugBank.d150.s1|36-42|alcohol|drug
DDI-DrugBank.d150.s1|43-43|,|O
DDI-DrugBank.d150.s1|45-56|barbiturates|group
DDI-DrugBank.d150.s1|57-57|,|O
DDI-DrugBank.d150.s1|59-61|and|O
DDI-DrugBank.d150.s1|63-67|other|O
DDI-DrugBank.d150.s1|69-83|CNS depressants|group
DDI-DrugBank.d150.s1|84-84|.|O
DDI-DrugBank.d150.s2|0-24|Tricyclic antidepressants|group
DDI-DrugBank.d150.s2|26-28|may|O
DDI-DrugBank.d150.s2|30-34|block|O
DDI-DrugBank.d150.s2|36-38|the|O
DDI-DrugBank.d150.s2|40-55|antihypertensive|O
DDI-DrugBank.d150.s2|57-62|action|O
DDI-DrugBank.d150.s2|64-65|of|O
DDI-DrugBank.d150.s2|67-78|guanethidine|drug
DDI-DrugBank.d150.s2|80-82|and|O
DDI-DrugBank.d150.s2|84-92|similarly|O
DDI-DrugBank.d150.s2|94-99|acting|O
DDI-DrugBank.d150.s2|101-109|compounds|O
DDI-DrugBank.d150.s2|110-110|.|O
DDI-DrugBank.d150.s3|0-24|Tricyclic antidepressants|group
DDI-DrugBank.d150.s3|26-28|may|O
DDI-DrugBank.d150.s3|30-36|enhance|O
DDI-DrugBank.d150.s3|38-40|the|O
DDI-DrugBank.d150.s3|42-48|seizure|O
DDI-DrugBank.d150.s3|50-53|risk|O
DDI-DrugBank.d150.s3|55-56|in|O
DDI-DrugBank.d150.s3|58-65|patients|O
DDI-DrugBank.d150.s3|67-72|taking|O
DDI-DrugBank.d150.s4|0-0|.|O
DDI-MedLine.d129.s0|0-20|Green tea polyphenols|drug
DDI-MedLine.d129.s0|22-23|as|O
DDI-MedLine.d129.s0|25-30|potent|O
DDI-MedLine.d129.s0|32-40|enhancers|drug
DDI-MedLine.d129.s0|42-43|of|O
DDI-MedLine.d129.s0|45-66|glucocorticoid-induced|O
DDI-MedLine.d129.s0|68-72|mouse|O
DDI-MedLine.d129.s0|74-80|mammary|O
DDI-MedLine.d129.s0|82-86|tumor|O
DDI-MedLine.d129.s0|88-92|virus|O
DDI-MedLine.d129.s0|94-97|gene|O
DDI-MedLine.d129.s0|99-108|expression|O
DDI-MedLine.d129.s0|109-109|.|O
DDI-MedLine.d129.s1|0-2|The|O
DDI-MedLine.d129.s1|4-9|effect|O
DDI-MedLine.d129.s1|11-12|of|O
DDI-MedLine.d129.s1|14-20|natural|O
DDI-MedLine.d129.s1|22-24|and|O
DDI-MedLine.d129.s1|26-34|synthetic|O
DDI-MedLine.d129.s1|36-42|galloyl|O
DDI-MedLine.d129.s1|44-49|esters|O
DDI-MedLine.d129.s1|51-52|on|O
DDI-MedLine.d129.s1|54-75|glucocorticoid-induced|O
DDI-MedLine.d129.s1|77-80|gene|O
DDI-MedLine.d129.s1|82-91|expression|O
DDI-MedLine.d129.s1|93-95|was|O
DDI-MedLine.d129.s1|97-105|evaluated|O
DDI-MedLine.d129.s1|107-108|by|O
DDI-MedLine.d129.s1|110-114|using|O
DDI-MedLine.d129.s1|116-118|rat|O
DDI-MedLine.d129.s1|120-129|fibroblast|O
DDI-MedLine.d129.s1|131-133|3Y1|O
DDI-MedLine.d129.s1|135-139|cells|O
DDI-MedLine.d129.s1|141-146|stably|O
DDI-MedLine.d129.s1|148-158|transfected|O
DDI-MedLine.d129.s1|160-163|with|O
DDI-MedLine.d129.s1|165-165|a|O
DDI-MedLine.d129.s1|167-176|luciferase|O
DDI-MedLine.d129.s1|178-185|reporter|O
DDI-MedLine.d129.s1|187-190|gene|O
DDI-MedLine.d129.s1|192-196|under|O
DDI-MedLine.d129.s1|198-200|the|O
DDI-MedLine.d129.s1|202-216|transcriptional|O
DDI-MedLine.d129.s1|218-227|regulation|O
DDI-MedLine.d129.s1|229-230|of|O
DDI-MedLine.d129.s1|232-234|the|O
DDI-MedLine.d129.s1|236-240|mouse|O
DDI-MedLine.d129.s1|242-248|mammary|O
DDI-MedLine.d129.s1|250-254|tumor|O
DDI-MedLine.d129.s1|256-260|virus|O
DDI-MedLine.d129.s1|262-269|promoter|drug
DDI-MedLine.d129.s1|270-270|.|O
DDI-MedLine.d129.s2|0-2|The|O
DDI-MedLine.d129.s2|4-25|glucocorticoid-induced|O
DDI-MedLine.d129.s2|27-30|gene|O
DDI-MedLine.d129.s2|32-44|transcription|O
DDI-MedLine.d129.s2|46-48|was|O
DDI-MedLine.d129.s2|50-57|strongly|O
DDI-MedLine.d129.s2|59-68|suppressed|O
DDI-MedLine.d129.s2|70-71|by|O
DDI-MedLine.d129.s2|73-81|synthetic|O
DDI-MedLine.d129.s2|83-87|alkyl|O
DDI-MedLine.d129.s2|89-94|esters|O
DDI-MedLine.d129.s2|95-95|;|O
DDI-MedLine.d129.s3|0-16|n-dodecyl gallate|drug
DDI-MedLine.d129.s3|18-23|showed|O
DDI-MedLine.d129.s3|25-27|the|O
DDI-MedLine.d129.s3|29-32|most|O
DDI-MedLine.d129.s3|34-39|potent|O
DDI-MedLine.d129.s3|41-50|inhibition|O
DDI-MedLine.d129.s3|52-52|(|O
DDI-MedLine.d129.s3|53-54|66|O
DDI-MedLine.d129.s3|55-55|%|O
DDI-MedLine.d129.s3|57-66|inhibition|O
DDI-MedLine.d129.s3|68-69|at|O
DDI-MedLine.d129.s3|71-72|10|O
DDI-MedLine.d129.s3|74-79|microM|O
DDI-MedLine.d129.s3|80-80|)|O
DDI-MedLine.d129.s3|81-81|,|O
DDI-MedLine.d129.s3|83-87|which|O
DDI-MedLine.d129.s3|89-91|was|O
DDI-MedLine.d129.s3|93-95|far|O
DDI-MedLine.d129.s3|97-100|more|O
DDI-MedLine.d129.s3|102-107|potent|O
DDI-MedLine.d129.s3|109-112|than|O
DDI-MedLine.d129.s3|114-117|that|O
DDI-MedLine.d129.s3|119-120|of|O
DDI-MedLine.d129.s3|122-126|crude|O
DDI-MedLine.d129.s3|128-138|tannic acid|drug
DDI-MedLine.d129.s3|139-139|.|O
DDI-MedLine.d129.s4|0-6|n-Octyl|O
DDI-MedLine.d129.s4|8-10|and|O
DDI-MedLine.d129.s4|12-18|n-cetyl|O
DDI-MedLine.d129.s4|20-26|gallate|O
DDI-MedLine.d129.s4|28-31|also|O
DDI-MedLine.d129.s4|33-38|showed|O
DDI-MedLine.d129.s4|40-43|good|O
DDI-MedLine.d129.s4|45-54|inhibition|O
DDI-MedLine.d129.s4|55-55|,|O
DDI-MedLine.d129.s4|57-61|while|O
DDI-MedLine.d129.s4|63-68|gallic|O
DDI-MedLine.d129.s4|70-73|acid|O
DDI-MedLine.d129.s4|75-80|itself|O
DDI-MedLine.d129.s4|82-84|was|O
DDI-MedLine.d129.s4|86-88|not|O
DDI-MedLine.d129.s4|90-91|so|O
DDI-MedLine.d129.s4|93-98|active|O
DDI-MedLine.d129.s4|99-99|,|O
DDI-MedLine.d129.s4|101-110|suggesting|O
DDI-MedLine.d129.s4|112-115|that|O
DDI-MedLine.d129.s4|117-119|the|O
DDI-MedLine.d129.s4|121-128|presence|O
DDI-MedLine.d129.s4|130-131|of|O
DDI-MedLine.d129.s4|133-143|hydrophobic|O
DDI-MedLine.d129.s4|145-148|side|O
DDI-MedLine.d129.s4|150-154|chain|O
DDI-MedLine.d129.s4|156-157|is|O
DDI-MedLine.d129.s4|159-167|important|O
DDI-MedLine.d129.s4|169-171|for|O
DDI-MedLine.d129.s4|173-175|the|O
DDI-MedLine.d129.s4|177-187|suppressive|O
DDI-MedLine.d129.s4|189-194|effect|O
DDI-MedLine.d129.s4|195-195|.|O
DDI-MedLine.d129.s5|0-1|On|O
DDI-MedLine.d129.s5|3-5|the|O
DDI-MedLine.d129.s5|7-11|other|O
DDI-MedLine.d129.s5|13-16|hand|O
DDI-MedLine.d129.s5|17-17|,|O
DDI-MedLine.d129.s5|19-30|surprisingly|O
DDI-MedLine.d129.s5|31-31|,|O
DDI-MedLine.d129.s5|33-56|green tea gallocatechins|drug
DDI-MedLine.d129.s5|57-57|,|O
DDI-MedLine.d129.s5|59-59|(|O
DDI-MedLine.d129.s5|60-60|-|O
DDI-MedLine.d129.s5|61-61|)|O
DDI-MedLine.d129.s5|62-90|-epigallocatechin-3-O-gallate|O
DDI-MedLine.d129.s5|92-94|and|O
DDI-MedLine.d129.s5|96-107|theasinensin|O
DDI-MedLine.d129.s5|109-109|A|O
DDI-MedLine.d129.s5|110-110|,|O
DDI-MedLine.d129.s5|112-119|potently|O
DDI-MedLine.d129.s5|121-128|enhanced|O
DDI-MedLine.d129.s5|130-132|the|O
DDI-MedLine.d129.s5|134-141|promoter|O
DDI-MedLine.d129.s5|143-150|activity|O
DDI-MedLine.d129.s5|152-152|(|O
DDI-MedLine.d129.s5|153-155|182|O
DDI-MedLine.d129.s5|157-159|and|O
DDI-MedLine.d129.s5|161-163|247|O
DDI-MedLine.d129.s5|164-164|%|O
DDI-MedLine.d129.s5|166-173|activity|O
DDI-MedLine.d129.s5|175-176|at|O
DDI-MedLine.d129.s5|178-178|1|O
DDI-MedLine.d129.s5|180-185|microM|O
DDI-MedLine.d129.s5|186-186|,|O
DDI-MedLine.d129.s5|188-199|respectively|O
DDI-MedLine.d129.s5|200-200|)|O
DDI-MedLine.d129.s5|201-201|.|O
DDI-MedLine.d129.s6|0-2|The|O
DDI-MedLine.d129.s6|4-13|regulation|O
DDI-MedLine.d129.s6|15-16|of|O
DDI-MedLine.d129.s6|18-20|the|O
DDI-MedLine.d129.s6|22-26|level|O
DDI-MedLine.d129.s6|28-29|of|O
DDI-MedLine.d129.s6|31-33|the|O
DDI-MedLine.d129.s6|35-56|glucocorticoid-induced|O
DDI-MedLine.d129.s6|58-61|gene|O
DDI-MedLine.d129.s6|63-72|expression|O
DDI-MedLine.d129.s6|74-75|by|O
DDI-MedLine.d129.s6|77-79|the|O
DDI-MedLine.d129.s6|81-93|antioxidative|O
DDI-MedLine.d129.s6|95-102|gallates|O
DDI-MedLine.d129.s6|104-105|is|O
DDI-MedLine.d129.s6|107-108|of|O
DDI-MedLine.d129.s6|110-114|great|O
DDI-MedLine.d129.s6|116-123|interest|O
DDI-MedLine.d129.s6|125-128|from|O
DDI-MedLine.d129.s6|130-130|a|O
DDI-MedLine.d129.s6|132-142|therapeutic|O
DDI-MedLine.d129.s6|144-148|point|O
DDI-MedLine.d129.s6|150-151|of|O
DDI-MedLine.d129.s6|153-156|view|O
DDI-MedLine.d129.s6|157-157|.|O
DDI-DrugBank.d444.s0|0-2|The|O
DDI-DrugBank.d444.s0|4-6|use|O
DDI-DrugBank.d444.s0|8-9|of|O
DDI-DrugBank.d444.s0|11-17|FLUDARA|brand
DDI-DrugBank.d444.s0|19-21|FOR|O
DDI-DrugBank.d444.s0|23-31|INJECTION|O
DDI-DrugBank.d444.s0|33-34|in|O
DDI-DrugBank.d444.s0|36-46|combination|O
DDI-DrugBank.d444.s0|48-51|with|O
DDI-DrugBank.d444.s0|53-63|pentostatin|drug
DDI-DrugBank.d444.s0|65-66|is|O
DDI-DrugBank.d444.s0|68-70|not|O
DDI-DrugBank.d444.s0|72-82|recommended|O
DDI-DrugBank.d444.s0|84-86|due|O
DDI-DrugBank.d444.s0|88-89|to|O
DDI-DrugBank.d444.s0|91-93|the|O
DDI-DrugBank.d444.s0|95-98|risk|O
DDI-DrugBank.d444.s0|100-101|of|O
DDI-DrugBank.d444.s0|103-108|severe|O
DDI-DrugBank.d444.s0|110-118|pulmonary|O
DDI-DrugBank.d444.s0|120-127|toxicity|O
DDI-DrugBank.d444.s0|128-128|.|O
DDI-DrugBank.d221.s0|0-2|The|O
DDI-DrugBank.d221.s0|4-7|risk|O
DDI-DrugBank.d221.s0|9-10|of|O
DDI-DrugBank.d221.s0|12-12|a|O
DDI-DrugBank.d221.s0|14-22|potential|O
DDI-DrugBank.d221.s0|24-34|interaction|O
DDI-DrugBank.d221.s0|36-42|between|O
DDI-DrugBank.d221.s0|44-52|NovoSeven|brand
DDI-DrugBank.d221.s0|54-56|and|O
DDI-DrugBank.d221.s0|58-75|coagulation factor|group
DDI-DrugBank.d221.s0|77-88|concentrates|O
DDI-DrugBank.d221.s0|90-92|has|O
DDI-DrugBank.d221.s0|94-96|not|O
DDI-DrugBank.d221.s0|98-101|been|O
DDI-DrugBank.d221.s0|103-112|adequately|O
DDI-DrugBank.d221.s0|114-122|evaluated|O
DDI-DrugBank.d221.s0|124-125|in|O
DDI-DrugBank.d221.s0|127-137|preclinical|O
DDI-DrugBank.d221.s0|139-140|or|O
DDI-DrugBank.d221.s0|142-149|clinical|O
DDI-DrugBank.d221.s0|151-157|studies|O
DDI-DrugBank.d221.s0|158-158|.|O
DDI-DrugBank.d221.s1|0-11|Simultaneous|O
DDI-DrugBank.d221.s1|13-15|use|O
DDI-DrugBank.d221.s1|17-18|of|O
DDI-DrugBank.d221.s1|20-61|activated prothrombin complex concentrates|group
DDI-DrugBank.d221.s1|63-64|or|O
DDI-DrugBank.d221.s1|66-97|prothrombin complex concentrates|group
DDI-DrugBank.d221.s1|99-104|should|O
DDI-DrugBank.d221.s1|106-107|be|O
DDI-DrugBank.d221.s1|109-115|avoided|O
DDI-DrugBank.d221.s1|116-116|.|O
DDI-DrugBank.d221.s2|0-7|Although|O
DDI-DrugBank.d221.s2|9-11|the|O
DDI-DrugBank.d221.s2|13-20|specific|O
DDI-DrugBank.d221.s2|22-25|drug|O
DDI-DrugBank.d221.s2|27-37|interaction|O
DDI-DrugBank.d221.s2|39-41|was|O
DDI-DrugBank.d221.s2|43-45|not|O
DDI-DrugBank.d221.s2|47-53|studied|O
DDI-DrugBank.d221.s2|55-56|in|O
DDI-DrugBank.d221.s2|58-58|a|O
DDI-DrugBank.d221.s2|60-67|clinical|O
DDI-DrugBank.d221.s2|69-73|trial|O
DDI-DrugBank.d221.s2|74-74|,|O
DDI-DrugBank.d221.s2|76-80|there|O
DDI-DrugBank.d221.s2|82-85|have|O
DDI-DrugBank.d221.s2|87-90|been|O
DDI-DrugBank.d221.s2|92-95|more|O
DDI-DrugBank.d221.s2|97-100|than|O
DDI-DrugBank.d221.s2|102-103|50|O
DDI-DrugBank.d221.s2|105-112|episodes|O
DDI-DrugBank.d221.s2|114-115|of|O
DDI-DrugBank.d221.s2|117-127|concomitant|O
DDI-DrugBank.d221.s2|129-131|use|O
DDI-DrugBank.d221.s2|133-134|of|O
DDI-DrugBank.d221.s2|136-151|antifibrinolytic|O
DDI-DrugBank.d221.s2|153-161|therapies|O
DDI-DrugBank.d221.s2|163-163|(|O
DDI-DrugBank.d221.s2|164-167|i.e.|O
DDI-DrugBank.d221.s2|168-168|,|O
DDI-DrugBank.d221.s2|170-184|tranexamic acid|drug
DDI-DrugBank.d221.s2|185-185|,|O
DDI-DrugBank.d221.s2|187-203|aminocaproic acid|drug
DDI-DrugBank.d221.s2|204-204|)|O
DDI-DrugBank.d221.s2|206-208|and|O
DDI-DrugBank.d221.s2|210-218|NovoSeven|brand
DDI-DrugBank.d221.s2|219-219|.|O
DDI-DrugBank.d221.s3|0-8|NovoSeven|brand
DDI-DrugBank.d221.s3|10-15|should|O
DDI-DrugBank.d221.s3|17-19|not|O
DDI-DrugBank.d221.s3|21-22|be|O
DDI-DrugBank.d221.s3|24-28|mixed|O
DDI-DrugBank.d221.s3|30-33|with|O
DDI-DrugBank.d221.s3|35-42|infusion|O
DDI-DrugBank.d221.s3|44-52|solutions|O
DDI-DrugBank.d221.s3|54-58|until|O
DDI-DrugBank.d221.s3|60-67|clinical|O
DDI-DrugBank.d221.s3|69-72|data|O
DDI-DrugBank.d221.s3|74-76|are|O
DDI-DrugBank.d221.s3|78-86|available|O
DDI-DrugBank.d221.s3|88-89|to|O
DDI-DrugBank.d221.s3|91-96|direct|O
DDI-DrugBank.d221.s3|98-101|this|O
DDI-DrugBank.d221.s3|103-105|use|O
DDI-DrugBank.d221.s3|106-106|.|O
DDI-MedLine.d128.s0|0-7|Analysis|O
DDI-MedLine.d128.s0|9-10|of|O
DDI-MedLine.d128.s0|40-49|E2-induced|O
DDI-MedLine.d128.s0|51-58|diarrhea|O
DDI-MedLine.d128.s0|60-61|in|O
DDI-MedLine.d128.s0|63-74|cecectomized|O
DDI-MedLine.d128.s0|76-79|rats|O
DDI-MedLine.d128.s0|80-80|.|O
DDI-MedLine.d128.s1|0-2|The|O
DDI-MedLine.d128.s1|35-35|(|O
DDI-MedLine.d128.s1|42-42|)|O
DDI-MedLine.d128.s1|43-50|-induced|O
DDI-MedLine.d128.s1|52-59|diarrhea|O
DDI-MedLine.d128.s1|61-63|was|O
DDI-MedLine.d128.s1|65-72|analyzed|O
DDI-MedLine.d128.s1|74-75|in|O
DDI-MedLine.d128.s1|77-88|cecectomized|O
DDI-MedLine.d128.s1|90-93|rats|O
DDI-MedLine.d128.s1|95-102|prepared|O
DDI-MedLine.d128.s1|104-105|by|O
DDI-MedLine.d128.s1|107-115|resecting|O
DDI-MedLine.d128.s1|117-119|the|O
DDI-MedLine.d128.s1|121-125|cecum|O
DDI-MedLine.d128.s1|127-129|and|O
DDI-MedLine.d128.s1|131-133|its|O
DDI-MedLine.d128.s1|135-145|vasculature|O
DDI-MedLine.d128.s1|147-153|without|O
DDI-MedLine.d128.s1|155-164|disturbing|O
DDI-MedLine.d128.s1|166-168|the|O
DDI-MedLine.d128.s1|170-178|ileocecal|O
DDI-MedLine.d128.s1|180-187|junction|O
DDI-MedLine.d128.s1|188-188|.|O
DDI-MedLine.d128.s2|7-7|(|O
DDI-MedLine.d128.s2|8-14|0.1-1.0|O
DDI-MedLine.d128.s2|16-20|mg/kg|O
DDI-MedLine.d128.s2|21-21|,|O
DDI-MedLine.d128.s2|23-25|p.o|O
DDI-MedLine.d128.s2|26-26|.|O
DDI-MedLine.d128.s2|27-27|)|O
DDI-MedLine.d128.s3|0-15|dose-dependently|O
DDI-MedLine.d128.s3|17-25|increased|O
DDI-MedLine.d128.s3|27-29|the|O
DDI-MedLine.d128.s3|31-36|number|O
DDI-MedLine.d128.s3|38-39|of|O
DDI-MedLine.d128.s3|41-50|defecation|O
DDI-MedLine.d128.s3|52-59|episodes|O
DDI-MedLine.d128.s3|61-63|and|O
DDI-MedLine.d128.s3|65-71|induced|O
DDI-MedLine.d128.s3|73-73|a|O
DDI-MedLine.d128.s3|75-78|soft|O
DDI-MedLine.d128.s3|80-82|and|O
DDI-MedLine.d128.s3|84-89|watery|O
DDI-MedLine.d128.s3|91-95|stool|O
DDI-MedLine.d128.s3|97-98|in|O
DDI-MedLine.d128.s3|100-111|cecectomized|O
DDI-MedLine.d128.s3|113-116|rats|O
DDI-MedLine.d128.s3|117-117|.|O
DDI-MedLine.d128.s4|0-1|At|O
DDI-MedLine.d128.s4|3-5|0.3|O
DDI-MedLine.d128.s4|7-11|mg/kg|O
DDI-MedLine.d128.s4|12-12|,|O
DDI-MedLine.d128.s4|14-16|the|O
DDI-MedLine.d128.s4|18-34|diarrhea-inducing|O
DDI-MedLine.d128.s4|36-42|effects|O
DDI-MedLine.d128.s4|44-45|of|O
DDI-MedLine.d128.s4|54-57|were|O
DDI-MedLine.d128.s4|59-62|more|O
DDI-MedLine.d128.s4|64-73|pronounced|O
DDI-MedLine.d128.s4|75-76|in|O
DDI-MedLine.d128.s4|78-89|cecectomized|O
DDI-MedLine.d128.s4|91-94|than|O
DDI-MedLine.d128.s4|96-97|in|O
DDI-MedLine.d128.s4|99-105|control|O
DDI-MedLine.d128.s4|107-110|rats|O
DDI-MedLine.d128.s4|111-111|.|O
DDI-MedLine.d128.s5|0-3|When|O
DDI-MedLine.d128.s5|5-9|given|O
DDI-MedLine.d128.s5|11-14|i.p.|O
DDI-MedLine.d128.s5|15-15|,|O
DDI-MedLine.d128.s5|24-24|(|O
DDI-MedLine.d128.s5|25-27|0.3|O
DDI-MedLine.d128.s5|29-33|mg/kg|O
DDI-MedLine.d128.s5|34-34|)|O
DDI-MedLine.d128.s5|36-42|induced|O
DDI-MedLine.d128.s5|44-44|a|O
DDI-MedLine.d128.s5|46-51|watery|O
DDI-MedLine.d128.s5|53-57|stool|O
DDI-MedLine.d128.s5|59-60|in|O
DDI-MedLine.d128.s5|62-73|cecectomized|O
DDI-MedLine.d128.s5|75-77|and|O
DDI-MedLine.d128.s5|79-85|control|O
DDI-MedLine.d128.s5|87-90|rats|O
DDI-MedLine.d128.s5|92-95|with|O
DDI-MedLine.d128.s5|97-99|the|O
DDI-MedLine.d128.s5|101-104|same|O
DDI-MedLine.d128.s5|106-113|efficacy|O
DDI-MedLine.d128.s5|114-114|,|O
DDI-MedLine.d128.s5|116-123|although|O
DDI-MedLine.d128.s5|125-129|these|O
DDI-MedLine.d128.s5|131-137|effects|O
DDI-MedLine.d128.s5|139-142|were|O
DDI-MedLine.d128.s5|144-156|short-lasting|O
DDI-MedLine.d128.s5|158-159|as|O
DDI-MedLine.d128.s5|161-168|compared|O
DDI-MedLine.d128.s5|170-171|to|O
DDI-MedLine.d128.s5|173-176|oral|O
DDI-MedLine.d128.s5|178-191|administration|O
DDI-MedLine.d128.s5|192-192|.|O
DDI-MedLine.d128.s6|0-9|Castor oil|drug
DDI-MedLine.d128.s6|11-11|(|O
DDI-MedLine.d128.s6|12-12|4|O
DDI-MedLine.d128.s6|14-18|ml/kg|O
DDI-MedLine.d128.s6|19-19|,|O
DDI-MedLine.d128.s6|21-23|p.o|O
DDI-MedLine.d128.s6|24-24|.|O
DDI-MedLine.d128.s6|25-25|)|O
DDI-MedLine.d128.s7|0-3|also|O
DDI-MedLine.d128.s7|5-11|induced|O
DDI-MedLine.d128.s7|13-20|diarrhea|O
DDI-MedLine.d128.s7|21-21|,|O
DDI-MedLine.d128.s7|23-25|but|O
DDI-MedLine.d128.s7|27-29|did|O
DDI-MedLine.d128.s7|31-33|not|O
DDI-MedLine.d128.s7|35-41|produce|O
DDI-MedLine.d128.s7|43-43|a|O
DDI-MedLine.d128.s7|45-50|watery|O
DDI-MedLine.d128.s7|52-56|stool|O
DDI-MedLine.d128.s7|58-59|in|O
DDI-MedLine.d128.s7|61-72|cecectomized|O
DDI-MedLine.d128.s7|74-77|rats|O
DDI-MedLine.d128.s7|78-78|.|O
DDI-MedLine.d128.s8|0-4|There|O
DDI-MedLine.d128.s8|6-9|were|O
DDI-MedLine.d128.s8|11-12|no|O
DDI-MedLine.d128.s8|14-24|differences|O
DDI-MedLine.d128.s8|26-32|between|O
DDI-MedLine.d128.s8|34-45|cecectomized|O
DDI-MedLine.d128.s8|47-49|and|O
DDI-MedLine.d128.s8|51-57|control|O
DDI-MedLine.d128.s8|59-62|rats|O
DDI-MedLine.d128.s8|64-65|in|O
DDI-MedLine.d128.s8|67-71|basal|O
DDI-MedLine.d128.s8|73-77|small|O
DDI-MedLine.d128.s8|79-88|intestinal|O
DDI-MedLine.d128.s8|90-97|transits|O
DDI-MedLine.d128.s8|99-100|or|O
DDI-MedLine.d128.s8|102-103|in|O
DDI-MedLine.d128.s8|112-112|(|O
DDI-MedLine.d128.s8|113-115|0.3|O
DDI-MedLine.d128.s8|117-121|mg/kg|O
DDI-MedLine.d128.s8|122-122|,|O
DDI-MedLine.d128.s8|124-127|p.o.|O
DDI-MedLine.d128.s8|128-128|)|O
DDI-MedLine.d128.s8|129-136|-induced|O
DDI-MedLine.d128.s8|138-149|enhancements|O
DDI-MedLine.d128.s8|150-150|.|O
DDI-MedLine.d128.s9|0-7|Moreover|O
DDI-MedLine.d128.s9|8-8|,|O
DDI-MedLine.d128.s9|10-12|the|O
DDI-MedLine.d128.s9|14-18|basal|O
DDI-MedLine.d128.s9|20-22|and|O
DDI-MedLine.d128.s9|39-45|jejunal|O
DDI-MedLine.d128.s9|47-49|net|O
DDI-MedLine.d128.s9|51-55|fluid|O
DDI-MedLine.d128.s9|57-65|transfers|O
DDI-MedLine.d128.s9|67-70|were|O
DDI-MedLine.d128.s9|72-74|the|O
DDI-MedLine.d128.s9|76-79|same|O
DDI-MedLine.d128.s9|81-82|in|O
DDI-MedLine.d128.s9|84-95|cecectomized|O
DDI-MedLine.d128.s9|97-99|and|O
DDI-MedLine.d128.s9|101-102|in|O
DDI-MedLine.d128.s9|104-110|control|O
DDI-MedLine.d128.s9|112-115|rats|O
DDI-MedLine.d128.s9|116-116|.|O
DDI-MedLine.d128.s10|0-1|On|O
DDI-MedLine.d128.s10|3-5|the|O
DDI-MedLine.d128.s10|7-11|other|O
DDI-MedLine.d128.s10|13-16|hand|O
DDI-MedLine.d128.s10|17-17|,|O
DDI-MedLine.d128.s10|19-21|the|O
DDI-MedLine.d128.s10|23-30|enhanced|O
DDI-MedLine.d128.s10|32-40|secretion|O
DDI-MedLine.d128.s10|42-43|of|O
DDI-MedLine.d128.s10|45-51|colonic|O
DDI-MedLine.d128.s10|53-57|fluid|O
DDI-MedLine.d128.s10|59-60|by|O
DDI-MedLine.d128.s10|68-68|,|O
DDI-MedLine.d128.s10|70-74|given|O
DDI-MedLine.d128.s10|76-89|intraluminally|O
DDI-MedLine.d128.s10|90-90|,|O
DDI-MedLine.d128.s10|92-94|was|O
DDI-MedLine.d128.s10|96-99|only|O
DDI-MedLine.d128.s10|101-104|half|O
DDI-MedLine.d128.s10|106-107|of|O
DDI-MedLine.d128.s10|109-112|that|O
DDI-MedLine.d128.s10|114-115|in|O
DDI-MedLine.d128.s10|117-123|control|O
DDI-MedLine.d128.s10|125-128|rats|O
DDI-MedLine.d128.s10|129-129|,|O
DDI-MedLine.d128.s10|131-137|whereas|O
DDI-MedLine.d128.s10|139-141|the|O
DDI-MedLine.d128.s10|143-149|colonic|O
DDI-MedLine.d128.s10|151-167|transit-enhancing|O
DDI-MedLine.d128.s10|169-174|effect|O
DDI-MedLine.d128.s10|176-177|of|O
DDI-MedLine.d128.s10|186-187|in|O
DDI-MedLine.d128.s10|189-200|cecectomized|O
DDI-MedLine.d128.s10|202-205|rats|O
DDI-MedLine.d128.s10|207-209|was|O
DDI-MedLine.d128.s10|211-214|more|O
DDI-MedLine.d128.s10|216-225|pronounced|O
DDI-MedLine.d128.s10|227-230|than|O
DDI-MedLine.d128.s10|232-233|in|O
DDI-MedLine.d128.s10|235-241|control|O
DDI-MedLine.d128.s10|243-246|rats|O
DDI-MedLine.d128.s10|248-249|at|O
DDI-MedLine.d128.s10|251-252|15|O
DDI-MedLine.d128.s10|254-256|but|O
DDI-MedLine.d128.s10|258-260|not|O
DDI-MedLine.d128.s10|262-263|at|O
DDI-MedLine.d128.s10|265-266|30|O
DDI-MedLine.d128.s10|268-270|min|O
DDI-MedLine.d128.s10|272-276|after|O
DDI-MedLine.d128.s10|278-280|its|O
DDI-MedLine.d128.s10|282-295|administration|O
DDI-MedLine.d128.s10|296-296|.|O
DDI-MedLine.d128.s11|0-2|The|O
DDI-MedLine.d128.s11|4-8|basal|O
DDI-MedLine.d128.s11|10-16|colonic|O
DDI-MedLine.d128.s11|18-22|fluid|O
DDI-MedLine.d128.s11|24-31|contents|O
DDI-MedLine.d128.s11|33-35|and|O
DDI-MedLine.d128.s11|37-44|transits|O
DDI-MedLine.d128.s11|46-49|were|O
DDI-MedLine.d128.s11|51-53|the|O
DDI-MedLine.d128.s11|55-58|same|O
DDI-MedLine.d128.s11|60-61|in|O
DDI-MedLine.d128.s11|63-74|cecectomized|O
DDI-MedLine.d128.s11|76-78|and|O
DDI-MedLine.d128.s11|80-81|in|O
DDI-MedLine.d128.s11|83-89|control|O
DDI-MedLine.d128.s11|91-94|rats|O
DDI-MedLine.d128.s11|95-95|.|O
DDI-MedLine.d128.s12|0-9|Loperamide|drug
DDI-MedLine.d128.s12|11-13|and|O
DDI-MedLine.d128.s12|15-22|morphine|drug
DDI-MedLine.d128.s12|24-24|(|O
DDI-MedLine.d128.s12|25-27|0.1|O
DDI-MedLine.d128.s12|29-31|and|O
DDI-MedLine.d128.s12|33-35|1.0|O
DDI-MedLine.d128.s12|37-41|mg/kg|O
DDI-MedLine.d128.s12|42-42|,|O
DDI-MedLine.d128.s12|44-46|s.c|O
DDI-MedLine.d128.s12|47-47|.|O
DDI-MedLine.d128.s12|48-48|)|O
DDI-MedLine.d128.s13|0-9|Loperamide|drug
DDI-MedLine.d128.s13|11-13|and|O
DDI-MedLine.d128.s13|15-22|morphine|drug
DDI-MedLine.d128.s13|24-24|(|O
DDI-MedLine.d128.s13|25-27|0.1|O
DDI-MedLine.d128.s13|29-31|and|O
DDI-MedLine.d128.s13|33-35|1.0|O
DDI-MedLine.d128.s13|37-41|mg/kg|O
DDI-MedLine.d128.s13|42-42|,|O
DDI-MedLine.d128.s13|44-47|s.c.|O
DDI-MedLine.d128.s13|48-48|)|O
DDI-MedLine.d128.s13|50-58|inhibited|O
DDI-MedLine.d128.s13|60-62|the|O
DDI-MedLine.d128.s13|71-71|(|O
DDI-MedLine.d128.s13|72-74|0.3|O
DDI-MedLine.d128.s13|76-80|mg/kg|O
DDI-MedLine.d128.s13|81-81|,|O
DDI-MedLine.d128.s13|83-86|p.o.|O
DDI-MedLine.d128.s13|87-87|)|O
DDI-MedLine.d128.s13|88-95|-induced|O
DDI-MedLine.d128.s13|97-104|diarrhea|O
DDI-MedLine.d128.s13|106-107|in|O
DDI-MedLine.d128.s13|109-120|cecectomized|O
DDI-MedLine.d128.s13|122-125|rats|O
DDI-MedLine.d128.s13|126-126|.|O
DDI-MedLine.d128.s14|21-21|(|O
DDI-MedLine.d128.s14|22-22|5|O
DDI-MedLine.d128.s14|24-28|mg/kg|O
DDI-MedLine.d128.s14|29-29|,|O
DDI-MedLine.d128.s14|31-33|s.c|O
DDI-MedLine.d128.s14|34-34|.|O
DDI-MedLine.d128.s14|35-35|)|O
DDI-MedLine.d128.s15|21-21|(|O
DDI-MedLine.d128.s15|22-22|5|O
DDI-MedLine.d128.s15|24-28|mg/kg|O
DDI-MedLine.d128.s15|29-29|,|O
DDI-MedLine.d128.s15|31-34|s.c.|O
DDI-MedLine.d128.s15|35-35|)|O
DDI-MedLine.d128.s15|37-46|completely|O
DDI-MedLine.d128.s15|48-58|antagonized|O
DDI-MedLine.d128.s15|60-62|the|O
DDI-MedLine.d128.s15|64-73|inhibitory|O
DDI-MedLine.d128.s15|75-80|effect|O
DDI-MedLine.d128.s15|82-83|of|O
DDI-MedLine.d128.s15|85-94|loperamide|drug
DDI-MedLine.d128.s15|96-98|and|O
DDI-MedLine.d128.s15|100-105|partly|O
DDI-MedLine.d128.s15|107-117|antagonized|O
DDI-MedLine.d128.s15|119-121|the|O
DDI-MedLine.d128.s15|123-128|effect|O
DDI-MedLine.d128.s15|130-131|of|O
DDI-MedLine.d128.s15|133-140|morphine|drug
DDI-MedLine.d128.s15|141-141|.|O
DDI-MedLine.d128.s16|0-4|These|O
DDI-MedLine.d128.s16|6-12|results|O
DDI-MedLine.d128.s16|14-20|suggest|O
DDI-MedLine.d128.s16|22-25|that|O
DDI-MedLine.d128.s16|27-30|oral|O
DDI-MedLine.d128.s16|32-45|administration|O
DDI-MedLine.d128.s16|47-48|of|O
DDI-MedLine.d128.s16|57-63|induces|O
DDI-MedLine.d128.s16|65-65|a|O
DDI-MedLine.d128.s16|67-70|more|O
DDI-MedLine.d128.s16|72-81|pronounced|O
DDI-MedLine.d128.s16|83-91|secretory|O
DDI-MedLine.d128.s16|93-100|diarrhea|O
DDI-MedLine.d128.s16|102-103|in|O
DDI-MedLine.d128.s16|105-116|cecectomized|O
DDI-MedLine.d128.s16|118-121|than|O
DDI-MedLine.d128.s16|123-124|in|O
DDI-MedLine.d128.s16|126-132|control|O
DDI-MedLine.d128.s16|134-137|rats|O
DDI-MedLine.d128.s16|138-138|,|O
DDI-MedLine.d128.s16|140-147|probably|O
DDI-MedLine.d128.s16|149-151|due|O
DDI-MedLine.d128.s16|153-154|to|O
DDI-MedLine.d128.s16|156-158|the|O
DDI-MedLine.d128.s16|160-163|lack|O
DDI-MedLine.d128.s16|165-166|of|O
DDI-MedLine.d128.s16|168-170|the|O
DDI-MedLine.d128.s16|172-180|reservoir|O
DDI-MedLine.d128.s16|182-189|function|O
DDI-MedLine.d128.s16|191-192|of|O
DDI-MedLine.d128.s16|194-196|the|O
DDI-MedLine.d128.s16|198-202|cecum|O
DDI-MedLine.d128.s16|204-205|in|O
DDI-MedLine.d128.s16|207-209|the|O
DDI-MedLine.d128.s16|211-218|operated|O
DDI-MedLine.d128.s16|220-226|animals|O
DDI-MedLine.d128.s16|227-227|.|O
DDI-MedLine.d128.s17|0-3|This|O
DDI-MedLine.d128.s17|5-13|secretory|O
DDI-MedLine.d128.s17|15-22|diarrhea|O
DDI-MedLine.d128.s17|24-28|model|O
DDI-MedLine.d128.s17|30-31|is|O
DDI-MedLine.d128.s17|33-40|suitable|O
DDI-MedLine.d128.s17|42-44|for|O
DDI-MedLine.d128.s17|46-55|evaluating|O
DDI-MedLine.d128.s17|57-59|the|O
DDI-MedLine.d128.s17|61-73|antidiarrheal|O
DDI-MedLine.d128.s17|75-82|activity|O
DDI-MedLine.d128.s17|84-85|of|O
DDI-MedLine.d128.s17|87-91|drugs|O
DDI-MedLine.d128.s17|92-92|.|O
DDI-MedLine.d13.s0|0-4|Death|O
DDI-MedLine.d13.s0|6-7|in|O
DDI-MedLine.d13.s0|9-19|amphetamine|drug
DDI-MedLine.d13.s0|21-25|users|O
DDI-MedLine.d13.s0|26-26|:|O
DDI-MedLine.d13.s0|28-33|causes|O
DDI-MedLine.d13.s0|35-37|and|O
DDI-MedLine.d13.s0|39-43|rates|O
DDI-MedLine.d13.s0|44-44|.|O
DDI-MedLine.d13.s1|0-2|The|O
DDI-MedLine.d13.s1|4-8|world|O
DDI-MedLine.d13.s1|10-16|medical|O
DDI-MedLine.d13.s1|18-27|literature|O
DDI-MedLine.d13.s1|29-36|contains|O
DDI-MedLine.d13.s1|38-39|43|O
DDI-MedLine.d13.s1|41-47|reports|O
DDI-MedLine.d13.s1|49-50|of|O
DDI-MedLine.d13.s1|52-57|deaths|O
DDI-MedLine.d13.s1|59-68|associated|O
DDI-MedLine.d13.s1|70-73|with|O
DDI-MedLine.d13.s1|75-86|amphetamines|drug
DDI-MedLine.d13.s1|88-89|in|O
DDI-MedLine.d13.s1|91-91|a|O
DDI-MedLine.d13.s1|93-99|35-year|O
DDI-MedLine.d13.s1|101-106|period|O
DDI-MedLine.d13.s1|107-107|.|O
DDI-MedLine.d13.s2|0-4|These|O
DDI-MedLine.d13.s2|6-13|included|O
DDI-MedLine.d13.s2|15-19|seven|O
DDI-MedLine.d13.s2|21-35|cerebrovascular|O
DDI-MedLine.d13.s2|37-45|accidents|O
DDI-MedLine.d13.s2|46-46|,|O
DDI-MedLine.d13.s2|48-50|six|O
DDI-MedLine.d13.s2|52-57|sudden|O
DDI-MedLine.d13.s2|59-65|cardiac|O
DDI-MedLine.d13.s2|67-72|deaths|O
DDI-MedLine.d13.s2|73-73|,|O
DDI-MedLine.d13.s2|75-79|three|O
DDI-MedLine.d13.s2|81-85|cases|O
DDI-MedLine.d13.s2|87-88|of|O
DDI-MedLine.d13.s2|90-101|hyperpyrexia|O
DDI-MedLine.d13.s2|102-102|,|O
DDI-MedLine.d13.s2|104-108|eight|O
DDI-MedLine.d13.s2|110-119|poisonings|O
DDI-MedLine.d13.s2|121-122|of|O
DDI-MedLine.d13.s2|124-132|uncertain|O
DDI-MedLine.d13.s2|134-142|mechanism|O
DDI-MedLine.d13.s2|144-146|and|O
DDI-MedLine.d13.s2|148-152|seven|O
DDI-MedLine.d13.s2|154-158|cases|O
DDI-MedLine.d13.s2|160-161|of|O
DDI-MedLine.d13.s2|163-169|medical|O
DDI-MedLine.d13.s2|171-183|complications|O
DDI-MedLine.d13.s2|185-186|of|O
DDI-MedLine.d13.s2|188-198|intravenous|O
DDI-MedLine.d13.s2|200-208|injection|O
DDI-MedLine.d13.s2|209-209|;|O
DDI-MedLine.d13.s3|0-2|the|O
DDI-MedLine.d13.s3|4-12|remainder|O
DDI-MedLine.d13.s3|14-17|were|O
DDI-MedLine.d13.s3|19-20|of|O
DDI-MedLine.d13.s3|22-30|uncertain|O
DDI-MedLine.d13.s3|32-36|cause|O
DDI-MedLine.d13.s3|37-37|.|O
DDI-MedLine.d13.s4|0-1|In|O
DDI-MedLine.d13.s4|3-10|contrast|O
DDI-MedLine.d13.s4|11-11|,|O
DDI-MedLine.d13.s4|13-14|in|O
DDI-MedLine.d13.s4|16-22|Ontario|O
DDI-MedLine.d13.s4|24-28|alone|O
DDI-MedLine.d13.s4|29-29|,|O
DDI-MedLine.d13.s4|31-32|in|O
DDI-MedLine.d13.s4|34-37|1972|O
DDI-MedLine.d13.s4|39-41|and|O
DDI-MedLine.d13.s4|43-46|1973|O
DDI-MedLine.d13.s4|48-52|there|O
DDI-MedLine.d13.s4|54-57|were|O
DDI-MedLine.d13.s4|59-60|26|O
DDI-MedLine.d13.s4|62-67|deaths|O
DDI-MedLine.d13.s4|69-70|in|O
DDI-MedLine.d13.s4|72-82|amphetamine|drug
DDI-MedLine.d13.s4|84-88|users|O
DDI-MedLine.d13.s4|89-89|,|O
DDI-MedLine.d13.s4|91-92|of|O
DDI-MedLine.d13.s4|94-98|which|O
DDI-MedLine.d13.s4|100-101|16|O
DDI-MedLine.d13.s4|103-106|were|O
DDI-MedLine.d13.s4|108-110|due|O
DDI-MedLine.d13.s4|112-113|to|O
DDI-MedLine.d13.s4|115-122|accident|O
DDI-MedLine.d13.s4|124-130|suicide|O
DDI-MedLine.d13.s4|132-133|or|O
DDI-MedLine.d13.s4|135-142|homicide|O
DDI-MedLine.d13.s4|143-143|.|O
DDI-MedLine.d13.s5|0-1|Of|O
DDI-MedLine.d13.s5|3-5|the|O
DDI-MedLine.d13.s5|7-15|remaining|O
DDI-MedLine.d13.s5|17-21|cases|O
DDI-MedLine.d13.s5|22-22|,|O
DDI-MedLine.d13.s5|24-26|two|O
DDI-MedLine.d13.s5|28-31|were|O
DDI-MedLine.d13.s5|33-39|cardiac|O
DDI-MedLine.d13.s5|40-40|,|O
DDI-MedLine.d13.s5|42-44|two|O
DDI-MedLine.d13.s5|46-52|hepatic|O
DDI-MedLine.d13.s5|54-56|and|O
DDI-MedLine.d13.s5|58-60|the|O
DDI-MedLine.d13.s5|62-65|rest|O
DDI-MedLine.d13.s5|67-70|were|O
DDI-MedLine.d13.s5|72-76|mixed|O
DDI-MedLine.d13.s5|78-81|drug|O
DDI-MedLine.d13.s5|83-90|overdose|O
DDI-MedLine.d13.s5|91-91|.|O
DDI-MedLine.d13.s6|0-8|Pulmonary|O
DDI-MedLine.d13.s6|10-20|granulomata|O
DDI-MedLine.d13.s6|21-21|,|O
DDI-MedLine.d13.s6|23-30|subacute|O
DDI-MedLine.d13.s6|32-40|hepatitis|O
DDI-MedLine.d13.s6|42-44|and|O
DDI-MedLine.d13.s6|46-50|other|O
DDI-MedLine.d13.s6|52-58|lesions|O
DDI-MedLine.d13.s6|60-68|resulting|O
DDI-MedLine.d13.s6|70-73|from|O
DDI-MedLine.d13.s6|75-85|intravenous|O
DDI-MedLine.d13.s6|87-90|drug|O
DDI-MedLine.d13.s6|92-94|use|O
DDI-MedLine.d13.s6|96-99|were|O
DDI-MedLine.d13.s6|101-106|common|O
DDI-MedLine.d13.s6|108-115|findings|O
DDI-MedLine.d13.s6|117-118|at|O
DDI-MedLine.d13.s6|120-126|autopsy|O
DDI-MedLine.d13.s6|127-127|.|O
DDI-MedLine.d13.s7|0-1|On|O
DDI-MedLine.d13.s7|3-5|the|O
DDI-MedLine.d13.s7|7-11|basis|O
DDI-MedLine.d13.s7|13-14|of|O
DDI-MedLine.d13.s7|16-18|the|O
DDI-MedLine.d13.s7|20-28|estimated|O
DDI-MedLine.d13.s7|30-35|number|O
DDI-MedLine.d13.s7|37-38|of|O
DDI-MedLine.d13.s7|40-46|regular|O
DDI-MedLine.d13.s7|48-52|users|O
DDI-MedLine.d13.s7|54-55|of|O
DDI-MedLine.d13.s7|57-67|intravenous|O
DDI-MedLine.d13.s7|69-79|amphetamine|drug
DDI-MedLine.d13.s7|81-82|in|O
DDI-MedLine.d13.s7|84-90|Ontario|O
DDI-MedLine.d13.s7|91-91|,|O
DDI-MedLine.d13.s7|93-95|the|O
DDI-MedLine.d13.s7|97-105|mortality|O
DDI-MedLine.d13.s7|107-110|rate|O
DDI-MedLine.d13.s7|112-113|in|O
DDI-MedLine.d13.s7|115-118|such|O
DDI-MedLine.d13.s7|120-124|users|O
DDI-MedLine.d13.s7|126-127|is|O
DDI-MedLine.d13.s7|129-130|at|O
DDI-MedLine.d13.s7|132-136|least|O
DDI-MedLine.d13.s7|138-141|four|O
DDI-MedLine.d13.s7|143-147|times|O
DDI-MedLine.d13.s7|149-150|as|O
DDI-MedLine.d13.s7|152-155|high|O
DDI-MedLine.d13.s7|157-158|as|O
DDI-MedLine.d13.s7|160-161|in|O
DDI-MedLine.d13.s7|163-165|the|O
DDI-MedLine.d13.s7|167-173|general|O
DDI-MedLine.d13.s7|175-184|population|O
DDI-MedLine.d13.s7|186-187|of|O
DDI-MedLine.d13.s7|189-191|the|O
DDI-MedLine.d13.s7|193-196|same|O
DDI-MedLine.d13.s7|198-200|age|O
DDI-MedLine.d13.s7|201-201|,|O
DDI-MedLine.d13.s7|203-205|and|O
DDI-MedLine.d13.s7|207-208|is|O
DDI-MedLine.d13.s7|210-219|comparable|O
DDI-MedLine.d13.s7|221-222|to|O
DDI-MedLine.d13.s7|224-227|that|O
DDI-MedLine.d13.s7|229-230|in|O
DDI-MedLine.d13.s7|232-241|alcoholics|O
DDI-MedLine.d13.s7|243-245|and|O
DDI-MedLine.d13.s7|254-260|addicts|O
DDI-MedLine.d13.s7|261-261|.|O
DDI-MedLine.d13.s8|0-6|However|O
DDI-MedLine.d13.s8|7-7|,|O
DDI-MedLine.d13.s8|9-11|the|O
DDI-MedLine.d13.s8|13-20|absolute|O
DDI-MedLine.d13.s8|22-27|number|O
DDI-MedLine.d13.s8|29-30|of|O
DDI-MedLine.d13.s8|32-46|alcohol-related|drug
DDI-MedLine.d13.s8|48-53|deaths|O
DDI-MedLine.d13.s8|55-56|is|O
DDI-MedLine.d13.s8|58-60|far|O
DDI-MedLine.d13.s8|62-68|greater|O
DDI-MedLine.d13.s8|70-73|than|O
DDI-MedLine.d13.s8|75-77|the|O
DDI-MedLine.d13.s8|79-84|number|O
DDI-MedLine.d13.s8|86-87|of|O
DDI-MedLine.d13.s8|89-94|deaths|O
DDI-MedLine.d13.s8|96-97|in|O
DDI-MedLine.d13.s8|99-109|amphetamine|drug
DDI-MedLine.d13.s8|111-112|or|O
DDI-MedLine.d13.s8|121-125|users|O
DDI-MedLine.d13.s8|126-126|.|O
DDI-DrugBank.d483.s0|0-8|Increases|O
DDI-DrugBank.d483.s0|10-11|in|O
DDI-DrugBank.d483.s0|13-17|serum|O
DDI-DrugBank.d483.s0|19-28|creatinine|O
DDI-DrugBank.d483.s0|30-33|have|O
DDI-DrugBank.d483.s0|35-42|occurred|O
DDI-DrugBank.d483.s0|44-47|when|O
DDI-DrugBank.d483.s0|49-55|CEFOTAN|brand
DDI-DrugBank.d483.s0|57-59|was|O
DDI-DrugBank.d483.s0|61-65|given|O
DDI-DrugBank.d483.s0|67-71|alone|O
DDI-DrugBank.d483.s0|72-72|.|O
DDI-DrugBank.d483.s1|0-1|If|O
DDI-DrugBank.d483.s1|3-9|CEFOTAN|brand
DDI-DrugBank.d483.s1|11-13|and|O
DDI-DrugBank.d483.s1|15-16|an|O
DDI-DrugBank.d483.s1|18-31|aminoglycoside|group
DDI-DrugBank.d483.s1|33-35|are|O
DDI-DrugBank.d483.s1|37-40|used|O
DDI-DrugBank.d483.s1|42-54|concomitantly|O
DDI-DrugBank.d483.s1|55-55|,|O
DDI-DrugBank.d483.s1|57-61|renal|O
DDI-DrugBank.d483.s1|63-70|function|O
DDI-DrugBank.d483.s1|72-77|should|O
DDI-DrugBank.d483.s1|79-80|be|O
DDI-DrugBank.d483.s1|82-90|carefully|O
DDI-DrugBank.d483.s1|92-100|monitored|O
DDI-DrugBank.d483.s1|101-101|,|O
DDI-DrugBank.d483.s1|103-109|because|O
DDI-DrugBank.d483.s1|111-124|nephrotoxicity|O
DDI-DrugBank.d483.s1|126-128|may|O
DDI-DrugBank.d483.s1|130-131|be|O
DDI-DrugBank.d483.s1|133-143|potentiated|O
DDI-DrugBank.d483.s1|144-144|.|O
DDI-DrugBank.d483.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d483.s2|16-19|Test|O
DDI-DrugBank.d483.s2|21-32|Interactions|O
DDI-DrugBank.d483.s2|33-33|:|O
DDI-DrugBank.d483.s2|35-37|The|O
DDI-DrugBank.d483.s2|39-52|administration|O
DDI-DrugBank.d483.s2|54-55|of|O
DDI-DrugBank.d483.s2|57-63|CEFOTAN|brand
DDI-DrugBank.d483.s2|65-67|may|O
DDI-DrugBank.d483.s2|69-74|result|O
DDI-DrugBank.d483.s2|76-77|in|O
DDI-DrugBank.d483.s2|79-79|a|O
DDI-DrugBank.d483.s2|81-85|false|O
DDI-DrugBank.d483.s2|87-94|positive|O
DDI-DrugBank.d483.s2|96-103|reaction|O
DDI-DrugBank.d483.s2|105-107|for|O
DDI-DrugBank.d483.s2|109-115|glucose|O
DDI-DrugBank.d483.s2|117-118|in|O
DDI-DrugBank.d483.s2|120-122|the|O
DDI-DrugBank.d483.s2|124-128|urine|O
DDI-DrugBank.d483.s2|130-134|using|O
DDI-DrugBank.d483.s2|136-144|Clinitest|O
DDI-DrugBank.d483.s2|147-147|,|O
DDI-DrugBank.d483.s2|149-157|Benedicts|O
DDI-DrugBank.d483.s2|159-166|solution|O
DDI-DrugBank.d483.s2|167-167|,|O
DDI-DrugBank.d483.s2|169-170|or|O
DDI-DrugBank.d483.s2|172-179|Fehlings|O
DDI-DrugBank.d483.s2|181-188|solution|O
DDI-DrugBank.d483.s2|189-189|.|O
DDI-DrugBank.d483.s3|0-1|It|O
DDI-DrugBank.d483.s3|3-4|is|O
DDI-DrugBank.d483.s3|6-16|recommended|O
DDI-DrugBank.d483.s3|18-21|that|O
DDI-DrugBank.d483.s3|23-29|glucose|O
DDI-DrugBank.d483.s3|31-35|tests|O
DDI-DrugBank.d483.s3|37-41|based|O
DDI-DrugBank.d483.s3|43-44|on|O
DDI-DrugBank.d483.s3|46-54|enzymatic|O
DDI-DrugBank.d483.s3|56-62|glucose|O
DDI-DrugBank.d483.s3|64-70|oxidase|O
DDI-DrugBank.d483.s3|72-73|be|O
DDI-DrugBank.d483.s3|75-78|used|O
DDI-DrugBank.d483.s3|79-79|.|O
DDI-DrugBank.d483.s4|0-1|As|O
DDI-DrugBank.d483.s4|3-6|with|O
DDI-DrugBank.d483.s4|8-12|other|O
DDI-DrugBank.d483.s4|14-27|cephalosporins|group
DDI-DrugBank.d483.s4|28-28|,|O
DDI-DrugBank.d483.s4|30-33|high|O
DDI-DrugBank.d483.s4|35-48|concentrations|O
DDI-DrugBank.d483.s4|50-51|of|O
DDI-DrugBank.d483.s4|53-61|cefotetan|drug
DDI-DrugBank.d483.s4|63-65|may|O
DDI-DrugBank.d483.s4|67-75|interfere|O
DDI-DrugBank.d483.s4|77-80|with|O
DDI-DrugBank.d483.s4|82-92|measurement|O
DDI-DrugBank.d483.s4|94-95|of|O
DDI-DrugBank.d483.s4|97-101|serum|O
DDI-DrugBank.d483.s4|103-105|and|O
DDI-DrugBank.d483.s4|107-111|urine|O
DDI-DrugBank.d483.s4|113-122|creatinine|O
DDI-DrugBank.d483.s4|124-129|levels|O
DDI-DrugBank.d483.s4|131-132|by|O
DDI-DrugBank.d483.s4|134-138|Jaffe|O
DDI-DrugBank.d483.s4|141-148|reaction|O
DDI-DrugBank.d483.s4|150-152|and|O
DDI-DrugBank.d483.s4|154-160|produce|O
DDI-DrugBank.d483.s4|162-166|false|O
DDI-DrugBank.d483.s4|168-176|increases|O
DDI-DrugBank.d483.s4|178-179|in|O
DDI-DrugBank.d483.s4|181-183|the|O
DDI-DrugBank.d483.s4|185-190|levels|O
DDI-DrugBank.d483.s4|192-193|of|O
DDI-DrugBank.d483.s4|195-204|creatinine|O
DDI-DrugBank.d483.s4|206-213|reported|O
DDI-DrugBank.d483.s4|214-214|.|O
DDI-DrugBank.d295.s0|0-4|Since|O
DDI-DrugBank.d295.s0|6-14|entecavir|drug
DDI-DrugBank.d295.s0|16-17|is|O
DDI-DrugBank.d295.s0|19-27|primarily|O
DDI-DrugBank.d295.s0|29-38|eliminated|O
DDI-DrugBank.d295.s0|40-41|by|O
DDI-DrugBank.d295.s0|43-45|the|O
DDI-DrugBank.d295.s0|47-53|kidneys|O
DDI-DrugBank.d295.s0|54-54|,|O
DDI-DrugBank.d295.s0|56-71|coadministration|O
DDI-DrugBank.d295.s0|73-74|of|O
DDI-DrugBank.d295.s0|76-84|BARACLUDE|brand
DDI-DrugBank.d295.s0|86-89|with|O
DDI-DrugBank.d295.s0|91-95|drugs|O
DDI-DrugBank.d295.s0|97-100|that|O
DDI-DrugBank.d295.s0|102-107|reduce|O
DDI-DrugBank.d295.s0|109-113|renal|O
DDI-DrugBank.d295.s0|115-122|function|O
DDI-DrugBank.d295.s0|124-125|or|O
DDI-DrugBank.d295.s0|127-133|compete|O
DDI-DrugBank.d295.s0|135-137|for|O
DDI-DrugBank.d295.s0|139-144|active|O
DDI-DrugBank.d295.s0|146-152|tubular|O
DDI-DrugBank.d295.s0|154-162|secretion|O
DDI-DrugBank.d295.s0|164-166|may|O
DDI-DrugBank.d295.s0|168-175|increase|O
DDI-DrugBank.d295.s0|177-181|serum|O
DDI-DrugBank.d295.s0|183-196|concentrations|O
DDI-DrugBank.d295.s0|198-199|of|O
DDI-DrugBank.d295.s0|201-206|either|O
DDI-DrugBank.d295.s0|208-216|entecavir|drug
DDI-DrugBank.d295.s0|218-219|or|O
DDI-DrugBank.d295.s0|221-223|the|O
DDI-DrugBank.d295.s0|225-238|coadministered|O
DDI-DrugBank.d295.s0|240-243|drug|O
DDI-DrugBank.d295.s0|244-244|.|O
DDI-DrugBank.d295.s1|0-15|Coadministration|O
DDI-DrugBank.d295.s1|17-18|of|O
DDI-DrugBank.d295.s1|20-28|entecavir|drug
DDI-DrugBank.d295.s1|30-33|with|O
DDI-DrugBank.d295.s1|35-44|lamivudine|drug
DDI-DrugBank.d295.s1|45-45|,|O
DDI-DrugBank.d295.s1|47-64|adefovir dipivoxil|drug
DDI-DrugBank.d295.s1|65-65|,|O
DDI-DrugBank.d295.s1|66-67|or|O
DDI-DrugBank.d295.s1|69-97|tenofovir disoproxil fumarate|drug
DDI-DrugBank.d295.s1|99-101|did|O
DDI-DrugBank.d295.s1|103-105|not|O
DDI-DrugBank.d295.s1|107-112|result|O
DDI-DrugBank.d295.s1|114-115|in|O
DDI-DrugBank.d295.s1|117-127|significant|O
DDI-DrugBank.d295.s1|129-132|drug|O
DDI-DrugBank.d295.s1|134-145|interactions|O
DDI-DrugBank.d295.s1|146-146|.|O
DDI-DrugBank.d295.s2|0-2|The|O
DDI-DrugBank.d295.s2|4-10|effects|O
DDI-DrugBank.d295.s2|12-13|of|O
DDI-DrugBank.d295.s2|15-30|coadministration|O
DDI-DrugBank.d295.s2|32-33|of|O
DDI-DrugBank.d295.s2|35-43|BARACLUDE|brand
DDI-DrugBank.d295.s2|45-48|with|O
DDI-DrugBank.d295.s2|50-54|other|O
DDI-DrugBank.d295.s2|56-60|drugs|O
DDI-DrugBank.d295.s2|62-65|that|O
DDI-DrugBank.d295.s2|67-69|are|O
DDI-DrugBank.d295.s2|71-77|renally|O
DDI-DrugBank.d295.s2|79-88|eliminated|O
DDI-DrugBank.d295.s2|90-91|or|O
DDI-DrugBank.d295.s2|93-95|are|O
DDI-DrugBank.d295.s2|97-101|known|O
DDI-DrugBank.d295.s2|103-104|to|O
DDI-DrugBank.d295.s2|106-111|affect|O
DDI-DrugBank.d295.s2|113-117|renal|O
DDI-DrugBank.d295.s2|119-126|function|O
DDI-DrugBank.d295.s2|128-131|have|O
DDI-DrugBank.d295.s2|133-135|not|O
DDI-DrugBank.d295.s2|137-140|been|O
DDI-DrugBank.d295.s2|142-150|evaluated|O
DDI-DrugBank.d295.s2|151-151|,|O
DDI-DrugBank.d295.s2|153-155|and|O
DDI-DrugBank.d295.s2|157-164|patients|O
DDI-DrugBank.d295.s2|166-171|should|O
DDI-DrugBank.d295.s2|173-174|be|O
DDI-DrugBank.d295.s2|176-184|monitored|O
DDI-DrugBank.d295.s2|186-192|closely|O
DDI-DrugBank.d295.s2|194-196|for|O
DDI-DrugBank.d295.s2|198-204|adverse|O
DDI-DrugBank.d295.s2|206-211|events|O
DDI-DrugBank.d295.s2|213-216|when|O
DDI-DrugBank.d295.s2|218-226|BARACLUDE|brand
DDI-DrugBank.d295.s2|228-229|is|O
DDI-DrugBank.d295.s2|231-244|coadministered|O
DDI-DrugBank.d295.s2|246-249|with|O
DDI-DrugBank.d295.s2|251-254|such|O
DDI-DrugBank.d295.s2|256-260|drugs|O
DDI-DrugBank.d295.s2|261-261|.|O
DDI-DrugBank.d458.s0|0-11|Ketoconazole|drug
DDI-DrugBank.d458.s0|13-14|is|O
DDI-DrugBank.d458.s0|16-16|a|O
DDI-DrugBank.d458.s0|18-23|potent|O
DDI-DrugBank.d458.s0|25-33|inhibitor|O
DDI-DrugBank.d458.s0|35-36|of|O
DDI-DrugBank.d458.s0|38-40|the|O
DDI-DrugBank.d458.s0|42-51|cytochrome|O
DDI-DrugBank.d458.s0|53-56|P450|O
DDI-DrugBank.d458.s0|58-60|3A4|O
DDI-DrugBank.d458.s0|62-67|enzyme|O
DDI-DrugBank.d458.s0|69-74|system|O
DDI-DrugBank.d458.s0|75-75|.|O
DDI-DrugBank.d458.s1|0-15|Coadministration|O
DDI-DrugBank.d458.s1|17-18|of|O
DDI-DrugBank.d458.s1|20-26|NIZORAL|brand
DDI-DrugBank.d458.s1|29-35|Tablets|O
DDI-DrugBank.d458.s1|37-39|and|O
DDI-DrugBank.d458.s1|41-45|drugs|O
DDI-DrugBank.d458.s1|47-55|primarily|O
DDI-DrugBank.d458.s1|57-67|metabolized|O
DDI-DrugBank.d458.s1|69-70|by|O
DDI-DrugBank.d458.s1|72-74|the|O
DDI-DrugBank.d458.s1|76-85|cytochrome|O
DDI-DrugBank.d458.s1|87-90|P450|O
DDI-DrugBank.d458.s1|92-94|3A4|O
DDI-DrugBank.d458.s1|96-101|enzyme|O
DDI-DrugBank.d458.s1|103-108|system|O
DDI-DrugBank.d458.s1|110-112|may|O
DDI-DrugBank.d458.s1|114-119|result|O
DDI-DrugBank.d458.s1|121-122|in|O
DDI-DrugBank.d458.s1|124-132|increased|O
DDI-DrugBank.d458.s1|134-139|plasma|O
DDI-DrugBank.d458.s1|141-154|concentrations|O
DDI-DrugBank.d458.s1|156-157|of|O
DDI-DrugBank.d458.s1|159-161|the|O
DDI-DrugBank.d458.s1|163-167|drugs|O
DDI-DrugBank.d458.s1|169-172|that|O
DDI-DrugBank.d458.s1|174-178|could|O
DDI-DrugBank.d458.s1|180-187|increase|O
DDI-DrugBank.d458.s1|189-190|or|O
DDI-DrugBank.d458.s1|192-198|prolong|O
DDI-DrugBank.d458.s1|200-203|both|O
DDI-DrugBank.d458.s1|205-215|therapeutic|O
DDI-DrugBank.d458.s1|217-219|and|O
DDI-DrugBank.d458.s1|221-227|adverse|O
DDI-DrugBank.d458.s1|229-235|effects|O
DDI-DrugBank.d458.s1|236-236|.|O
DDI-DrugBank.d458.s2|0-8|Therefore|O
DDI-DrugBank.d458.s2|9-9|,|O
DDI-DrugBank.d458.s2|11-16|unless|O
DDI-DrugBank.d458.s2|18-26|otherwise|O
DDI-DrugBank.d458.s2|28-36|specified|O
DDI-DrugBank.d458.s2|37-37|,|O
DDI-DrugBank.d458.s2|39-49|appropriate|O
DDI-DrugBank.d458.s2|51-56|dosage|O
DDI-DrugBank.d458.s2|58-68|adjustments|O
DDI-DrugBank.d458.s2|70-72|may|O
DDI-DrugBank.d458.s2|74-75|be|O
DDI-DrugBank.d458.s2|77-85|necessary|O
DDI-DrugBank.d458.s2|86-86|.|O
DDI-DrugBank.d458.s3|0-2|The|O
DDI-DrugBank.d458.s3|4-12|following|O
DDI-DrugBank.d458.s3|14-17|drug|O
DDI-DrugBank.d458.s3|19-30|interactions|O
DDI-DrugBank.d458.s3|32-35|have|O
DDI-DrugBank.d458.s3|37-40|been|O
DDI-DrugBank.d458.s3|42-51|identified|O
DDI-DrugBank.d458.s3|53-61|involving|O
DDI-DrugBank.d458.s3|63-69|NIZORAL|brand
DDI-DrugBank.d458.s3|71-77|Tablets|O
DDI-DrugBank.d458.s3|79-81|and|O
DDI-DrugBank.d458.s3|83-87|other|O
DDI-DrugBank.d458.s3|89-93|drugs|O
DDI-DrugBank.d458.s3|95-105|metabolized|O
DDI-DrugBank.d458.s3|107-108|by|O
DDI-DrugBank.d458.s3|110-112|the|O
DDI-DrugBank.d458.s3|114-123|cytochrome|O
DDI-DrugBank.d458.s3|125-128|P450|O
DDI-DrugBank.d458.s3|130-132|3A4|O
DDI-DrugBank.d458.s3|134-139|enzyme|O
DDI-DrugBank.d458.s3|141-146|system|O
DDI-DrugBank.d458.s3|147-147|:|O
DDI-DrugBank.d458.s3|149-160|Ketoconazole|drug
DDI-DrugBank.d458.s3|162-168|tablets|O
DDI-DrugBank.d458.s3|170-176|inhibit|O
DDI-DrugBank.d458.s3|178-180|the|O
DDI-DrugBank.d458.s3|182-191|metabolism|O
DDI-DrugBank.d458.s3|193-194|of|O
DDI-DrugBank.d458.s3|196-206|terfenadine|drug
DDI-DrugBank.d458.s3|207-207|,|O
DDI-DrugBank.d458.s3|209-217|resulting|O
DDI-DrugBank.d458.s3|219-220|in|O
DDI-DrugBank.d458.s3|222-223|an|O
DDI-DrugBank.d458.s3|225-233|increased|O
DDI-DrugBank.d458.s3|235-240|plasma|O
DDI-DrugBank.d458.s3|242-254|concentration|O
DDI-DrugBank.d458.s3|256-257|of|O
DDI-DrugBank.d458.s3|259-269|terfenadine|drug
DDI-DrugBank.d458.s3|271-273|and|O
DDI-DrugBank.d458.s3|275-275|a|O
DDI-DrugBank.d458.s3|277-281|delay|O
DDI-DrugBank.d458.s3|283-284|in|O
DDI-DrugBank.d458.s3|286-288|the|O
DDI-DrugBank.d458.s3|290-300|elimination|O
DDI-DrugBank.d458.s3|302-303|of|O
DDI-DrugBank.d458.s3|305-307|its|O
DDI-DrugBank.d458.s3|309-312|acid|O
DDI-DrugBank.d458.s3|314-323|metabolite|O
DDI-DrugBank.d458.s3|324-324|.|O
DDI-DrugBank.d458.s4|0-2|The|O
DDI-DrugBank.d458.s4|4-12|increased|O
DDI-DrugBank.d458.s4|14-19|plasma|O
DDI-DrugBank.d458.s4|21-33|concentration|O
DDI-DrugBank.d458.s4|35-36|of|O
DDI-DrugBank.d458.s4|38-48|terfenadine|drug
DDI-DrugBank.d458.s4|50-51|or|O
DDI-DrugBank.d458.s4|53-55|its|O
DDI-DrugBank.d458.s4|57-66|metabolite|O
DDI-DrugBank.d458.s4|68-70|may|O
DDI-DrugBank.d458.s4|72-77|result|O
DDI-DrugBank.d458.s4|79-80|in|O
DDI-DrugBank.d458.s4|82-90|prolonged|O
DDI-DrugBank.d458.s4|92-93|QT|O
DDI-DrugBank.d458.s4|95-103|intervals|O
DDI-DrugBank.d458.s4|104-104|.|O
DDI-DrugBank.d458.s5|0-14|Pharmacokinetic|O
DDI-DrugBank.d458.s5|16-19|data|O
DDI-DrugBank.d458.s5|21-28|indicate|O
DDI-DrugBank.d458.s5|30-33|that|O
DDI-DrugBank.d458.s5|35-38|oral|O
DDI-DrugBank.d458.s5|40-51|ketoconazole|drug
DDI-DrugBank.d458.s5|53-60|inhibits|O
DDI-DrugBank.d458.s5|62-64|the|O
DDI-DrugBank.d458.s5|66-75|metabolism|O
DDI-DrugBank.d458.s5|77-78|of|O
DDI-DrugBank.d458.s5|80-89|astemizole|drug
DDI-DrugBank.d458.s5|90-90|,|O
DDI-DrugBank.d458.s5|92-100|resulting|O
DDI-DrugBank.d458.s5|102-103|in|O
DDI-DrugBank.d458.s5|105-112|elevated|O
DDI-DrugBank.d458.s5|114-119|plasma|O
DDI-DrugBank.d458.s5|121-126|levels|O
DDI-DrugBank.d458.s5|128-129|of|O
DDI-DrugBank.d458.s5|131-140|astemizole|drug
DDI-DrugBank.d458.s5|142-144|and|O
DDI-DrugBank.d458.s5|146-148|its|O
DDI-DrugBank.d458.s5|150-155|active|O
DDI-DrugBank.d458.s5|157-166|metabolite|O
DDI-DrugBank.d458.s5|188-192|which|O
DDI-DrugBank.d458.s5|194-196|may|O
DDI-DrugBank.d458.s5|198-204|prolong|O
DDI-DrugBank.d458.s5|206-207|QT|O
DDI-DrugBank.d458.s5|209-217|intervals|O
DDI-DrugBank.d458.s5|218-218|.|O
DDI-DrugBank.d458.s6|0-15|Coadministration|O
DDI-DrugBank.d458.s6|17-18|of|O
DDI-DrugBank.d458.s6|20-29|astemizole|drug
DDI-DrugBank.d458.s6|31-34|with|O
DDI-DrugBank.d458.s6|36-47|ketoconazole|drug
DDI-DrugBank.d458.s6|49-55|tablets|O
DDI-DrugBank.d458.s6|57-58|is|O
DDI-DrugBank.d458.s6|60-68|therefore|O
DDI-DrugBank.d458.s6|70-84|contraindicated|O
DDI-DrugBank.d458.s6|85-85|.|O
DDI-DrugBank.d458.s7|0-4|Human|O
DDI-DrugBank.d458.s7|6-21|pharmacokinetics|O
DDI-DrugBank.d458.s7|23-26|data|O
DDI-DrugBank.d458.s7|28-35|indicate|O
DDI-DrugBank.d458.s7|37-40|that|O
DDI-DrugBank.d458.s7|42-45|oral|O
DDI-DrugBank.d458.s7|47-58|ketoconazole|drug
DDI-DrugBank.d458.s7|60-67|potently|O
DDI-DrugBank.d458.s7|69-76|inhibits|O
DDI-DrugBank.d458.s7|78-80|the|O
DDI-DrugBank.d458.s7|82-91|metabolism|O
DDI-DrugBank.d458.s7|93-94|of|O
DDI-DrugBank.d458.s7|96-104|cisapride|drug
DDI-DrugBank.d458.s7|106-114|resulting|O
DDI-DrugBank.d458.s7|116-117|in|O
DDI-DrugBank.d458.s7|119-119|a|O
DDI-DrugBank.d458.s7|121-124|mean|O
DDI-DrugBank.d458.s7|126-135|eight-fold|O
DDI-DrugBank.d458.s7|137-144|increase|O
DDI-DrugBank.d458.s7|146-147|in|O
DDI-DrugBank.d458.s7|149-151|AUC|O
DDI-DrugBank.d458.s7|153-154|of|O
DDI-DrugBank.d458.s7|156-164|cisapride|drug
DDI-DrugBank.d458.s7|165-165|.|O
DDI-DrugBank.d458.s8|0-3|Data|O
DDI-DrugBank.d458.s8|5-11|suggest|O
DDI-DrugBank.d458.s8|13-16|that|O
DDI-DrugBank.d458.s8|18-33|coadministration|O
DDI-DrugBank.d458.s8|35-36|of|O
DDI-DrugBank.d458.s8|38-41|oral|O
DDI-DrugBank.d458.s8|43-54|ketoconazole|drug
DDI-DrugBank.d458.s8|56-58|and|O
DDI-DrugBank.d458.s8|60-68|cisapride|drug
DDI-DrugBank.d458.s8|70-72|can|O
DDI-DrugBank.d458.s8|74-79|result|O
DDI-DrugBank.d458.s8|81-82|in|O
DDI-DrugBank.d458.s8|84-95|prolongation|O
DDI-DrugBank.d458.s8|97-98|of|O
DDI-DrugBank.d458.s8|100-102|the|O
DDI-DrugBank.d458.s8|104-105|QT|O
DDI-DrugBank.d458.s8|107-114|interval|O
DDI-DrugBank.d458.s8|116-117|on|O
DDI-DrugBank.d458.s8|119-121|the|O
DDI-DrugBank.d458.s8|123-125|ECG|O
DDI-DrugBank.d458.s8|126-126|.|O
DDI-DrugBank.d458.s9|0-8|Therefore|O
DDI-DrugBank.d458.s9|10-20|concomitant|O
DDI-DrugBank.d458.s9|22-35|administration|O
DDI-DrugBank.d458.s9|37-38|of|O
DDI-DrugBank.d458.s9|40-51|ketoconazole|drug
DDI-DrugBank.d458.s9|53-59|tablets|O
DDI-DrugBank.d458.s9|61-64|with|O
DDI-DrugBank.d458.s9|66-74|cisapride|drug
DDI-DrugBank.d458.s9|76-77|is|O
DDI-DrugBank.d458.s9|79-93|contraindicated|O
DDI-DrugBank.d458.s9|94-94|.|O
DDI-DrugBank.d458.s10|0-11|Ketoconazole|drug
DDI-DrugBank.d458.s10|13-19|tablets|O
DDI-DrugBank.d458.s10|21-23|may|O
DDI-DrugBank.d458.s10|25-29|alter|O
DDI-DrugBank.d458.s10|31-33|the|O
DDI-DrugBank.d458.s10|35-44|metabolism|O
DDI-DrugBank.d458.s10|46-47|of|O
DDI-DrugBank.d458.s10|49-60|cyclosporine|drug
DDI-DrugBank.d458.s10|61-61|,|O
DDI-DrugBank.d458.s10|63-72|tacrolimus|drug
DDI-DrugBank.d458.s10|73-73|,|O
DDI-DrugBank.d458.s10|75-77|and|O
DDI-DrugBank.d458.s10|79-96|methylprednisolone|drug
DDI-DrugBank.d458.s10|97-97|,|O
DDI-DrugBank.d458.s10|99-107|resulting|O
DDI-DrugBank.d458.s10|109-110|in|O
DDI-DrugBank.d458.s10|112-119|elevated|O
DDI-DrugBank.d458.s10|121-126|plasma|O
DDI-DrugBank.d458.s10|128-141|concentrations|O
DDI-DrugBank.d458.s10|143-144|of|O
DDI-DrugBank.d458.s10|146-148|the|O
DDI-DrugBank.d458.s10|150-155|latter|O
DDI-DrugBank.d458.s10|157-161|drugs|O
DDI-DrugBank.d458.s10|162-162|.|O
DDI-DrugBank.d458.s11|0-5|Dosage|O
DDI-DrugBank.d458.s11|7-16|adjustment|O
DDI-DrugBank.d458.s11|18-20|may|O
DDI-DrugBank.d458.s11|22-23|be|O
DDI-DrugBank.d458.s11|25-32|required|O
DDI-DrugBank.d458.s11|34-35|if|O
DDI-DrugBank.d458.s11|37-48|cyclosporine|drug
DDI-DrugBank.d458.s11|49-49|,|O
DDI-DrugBank.d458.s11|51-60|tacrolimus|drug
DDI-DrugBank.d458.s11|61-61|,|O
DDI-DrugBank.d458.s11|63-64|or|O
DDI-DrugBank.d458.s11|66-83|methylprednisolone|drug
DDI-DrugBank.d458.s11|85-87|are|O
DDI-DrugBank.d458.s11|89-93|given|O
DDI-DrugBank.d458.s11|95-107|concomitantly|O
DDI-DrugBank.d458.s11|109-112|with|O
DDI-DrugBank.d458.s11|114-120|NIZORAL|brand
DDI-DrugBank.d458.s11|123-129|Tablets|O
DDI-DrugBank.d458.s11|130-130|.|O
DDI-DrugBank.d458.s12|0-15|Coadministration|O
DDI-DrugBank.d458.s12|17-18|of|O
DDI-DrugBank.d458.s12|20-26|NIZORAL|brand
DDI-DrugBank.d458.s12|29-35|Tablets|O
DDI-DrugBank.d458.s12|37-40|with|O
DDI-DrugBank.d458.s12|42-50|midazolam|drug
DDI-DrugBank.d458.s12|52-53|or|O
DDI-DrugBank.d458.s12|55-63|triazolam|drug
DDI-DrugBank.d458.s12|65-67|has|O
DDI-DrugBank.d458.s12|69-76|resulted|O
DDI-DrugBank.d458.s12|78-79|in|O
DDI-DrugBank.d458.s12|81-88|elevated|O
DDI-DrugBank.d458.s12|90-95|plasma|O
DDI-DrugBank.d458.s12|97-110|concentrations|O
DDI-DrugBank.d458.s12|112-113|of|O
DDI-DrugBank.d458.s12|115-117|the|O
DDI-DrugBank.d458.s12|119-124|latter|O
DDI-DrugBank.d458.s12|126-128|two|O
DDI-DrugBank.d458.s12|130-134|drugs|O
DDI-DrugBank.d458.s12|135-135|.|O
DDI-DrugBank.d458.s13|0-3|This|O
DDI-DrugBank.d458.s13|5-7|may|O
DDI-DrugBank.d458.s13|9-18|potentiate|O
DDI-DrugBank.d458.s13|20-22|and|O
DDI-DrugBank.d458.s13|24-30|prolong|O
DDI-DrugBank.d458.s13|32-39|hypnotic|O
DDI-DrugBank.d458.s13|41-43|and|O
DDI-DrugBank.d458.s13|45-52|sedative|O
DDI-DrugBank.d458.s13|54-60|effects|O
DDI-DrugBank.d458.s13|61-61|,|O
DDI-DrugBank.d458.s13|63-72|especially|O
DDI-DrugBank.d458.s13|74-77|with|O
DDI-DrugBank.d458.s13|79-86|repeated|O
DDI-DrugBank.d458.s13|88-93|dosing|O
DDI-DrugBank.d458.s13|95-96|or|O
DDI-DrugBank.d458.s13|98-104|chronic|O
DDI-DrugBank.d458.s13|106-119|administration|O
DDI-DrugBank.d458.s13|121-122|of|O
DDI-DrugBank.d458.s13|124-128|these|O
DDI-DrugBank.d458.s13|130-135|agents|O
DDI-DrugBank.d458.s13|136-136|.|O
DDI-DrugBank.d458.s14|0-4|These|O
DDI-DrugBank.d458.s14|6-11|agents|O
DDI-DrugBank.d458.s14|13-18|should|O
DDI-DrugBank.d458.s14|20-22|not|O
DDI-DrugBank.d458.s14|24-25|be|O
DDI-DrugBank.d458.s14|27-30|used|O
DDI-DrugBank.d458.s14|32-33|in|O
DDI-DrugBank.d458.s14|35-42|patients|O
DDI-DrugBank.d458.s14|44-50|treated|O
DDI-DrugBank.d458.s14|52-55|with|O
DDI-DrugBank.d458.s14|57-63|NIZORAL|brand
DDI-DrugBank.d458.s14|66-72|Tablets|O
DDI-DrugBank.d458.s14|73-73|.|O
DDI-DrugBank.d458.s15|0-1|If|O
DDI-DrugBank.d458.s15|3-11|midazolam|drug
DDI-DrugBank.d458.s15|13-14|is|O
DDI-DrugBank.d458.s15|16-27|administered|O
DDI-DrugBank.d458.s15|29-40|parenterally|O
DDI-DrugBank.d458.s15|41-41|,|O
DDI-DrugBank.d458.s15|43-49|special|O
DDI-DrugBank.d458.s15|51-60|precaution|O
DDI-DrugBank.d458.s15|62-63|is|O
DDI-DrugBank.d458.s15|65-72|required|O
DDI-DrugBank.d458.s15|74-78|since|O
DDI-DrugBank.d458.s15|80-82|the|O
DDI-DrugBank.d458.s15|84-91|sedative|O
DDI-DrugBank.d458.s15|93-98|effect|O
DDI-DrugBank.d458.s15|100-102|may|O
DDI-DrugBank.d458.s15|104-105|be|O
DDI-DrugBank.d458.s15|107-115|prolonged|O
DDI-DrugBank.d458.s15|116-116|.|O
DDI-DrugBank.d458.s16|0-3|Rare|O
DDI-DrugBank.d458.s16|5-9|cases|O
DDI-DrugBank.d458.s16|11-12|of|O
DDI-DrugBank.d458.s16|14-21|elevated|O
DDI-DrugBank.d458.s16|23-28|plasma|O
DDI-DrugBank.d458.s16|30-43|concentrations|O
DDI-DrugBank.d458.s16|45-46|of|O
DDI-DrugBank.d458.s16|48-54|digoxin|drug
DDI-DrugBank.d458.s16|56-59|have|O
DDI-DrugBank.d458.s16|61-64|been|O
DDI-DrugBank.d458.s16|66-73|reported|O
DDI-DrugBank.d458.s16|74-74|.|O
DDI-DrugBank.d458.s17|0-1|It|O
DDI-DrugBank.d458.s17|3-4|is|O
DDI-DrugBank.d458.s17|6-8|not|O
DDI-DrugBank.d458.s17|10-14|clear|O
DDI-DrugBank.d458.s17|16-22|whether|O
DDI-DrugBank.d458.s17|24-27|this|O
DDI-DrugBank.d458.s17|29-31|was|O
DDI-DrugBank.d458.s17|33-35|due|O
DDI-DrugBank.d458.s17|37-38|to|O
DDI-DrugBank.d458.s17|40-42|the|O
DDI-DrugBank.d458.s17|44-54|combination|O
DDI-DrugBank.d458.s17|56-57|of|O
DDI-DrugBank.d458.s17|59-65|therapy|O
DDI-DrugBank.d458.s17|66-66|.|O
DDI-DrugBank.d458.s18|0-1|It|O
DDI-DrugBank.d458.s18|3-4|is|O
DDI-DrugBank.d458.s18|5-5|,|O
DDI-DrugBank.d458.s18|7-15|therefore|O
DDI-DrugBank.d458.s18|16-16|,|O
DDI-DrugBank.d458.s18|18-26|advisable|O
DDI-DrugBank.d458.s18|28-29|to|O
DDI-DrugBank.d458.s18|31-37|monitor|O
DDI-DrugBank.d458.s18|39-45|digoxin|drug
DDI-DrugBank.d458.s18|47-60|concentrations|O
DDI-DrugBank.d458.s18|62-63|in|O
DDI-DrugBank.d458.s18|65-72|patients|O
DDI-DrugBank.d458.s18|74-82|receiving|O
DDI-DrugBank.d458.s18|84-95|ketoconazole|drug
DDI-DrugBank.d458.s18|96-96|.|O
DDI-DrugBank.d458.s19|0-3|When|O
DDI-DrugBank.d458.s19|5-9|taken|O
DDI-DrugBank.d458.s19|11-16|orally|O
DDI-DrugBank.d458.s19|18-18|,|O
DDI-DrugBank.d458.s19|20-38|imidazole compounds|group
DDI-DrugBank.d458.s19|40-43|like|O
DDI-DrugBank.d458.s19|45-56|ketoconazole|drug
DDI-DrugBank.d458.s19|58-60|may|O
DDI-DrugBank.d458.s19|62-68|enhance|O
DDI-DrugBank.d458.s19|70-72|the|O
DDI-DrugBank.d458.s19|74-86|anticoagulant|O
DDI-DrugBank.d458.s19|88-93|effect|O
DDI-DrugBank.d458.s19|95-96|of|O
DDI-DrugBank.d458.s19|98-110|coumarin-like|group
DDI-DrugBank.d458.s19|112-116|drugs|O
DDI-DrugBank.d458.s19|117-117|.|O
DDI-DrugBank.d458.s20|0-1|In|O
DDI-DrugBank.d458.s20|3-14|simultaneous|O
DDI-DrugBank.d458.s20|16-24|treatment|O
DDI-DrugBank.d458.s20|26-29|with|O
DDI-DrugBank.d458.s20|31-45|imidazole drugs|group
DDI-DrugBank.d458.s20|47-49|and|O
DDI-DrugBank.d458.s20|51-64|coumarin drugs|group
DDI-DrugBank.d458.s20|65-65|,|O
DDI-DrugBank.d458.s20|67-69|the|O
DDI-DrugBank.d458.s20|71-83|anticoagulant|O
DDI-DrugBank.d458.s20|85-90|effect|O
DDI-DrugBank.d458.s20|92-97|should|O
DDI-DrugBank.d458.s20|99-100|be|O
DDI-DrugBank.d458.s20|102-110|carefully|O
DDI-DrugBank.d458.s20|112-119|titrated|O
DDI-DrugBank.d458.s20|121-123|and|O
DDI-DrugBank.d458.s20|125-133|monitored|O
DDI-DrugBank.d458.s20|134-134|.|O
DDI-DrugBank.d458.s21|0-6|Because|O
DDI-DrugBank.d458.s21|8-13|severe|O
DDI-DrugBank.d458.s21|15-26|hypoglycemia|O
DDI-DrugBank.d458.s21|28-30|has|O
DDI-DrugBank.d458.s21|32-35|been|O
DDI-DrugBank.d458.s21|37-44|reported|O
DDI-DrugBank.d458.s21|46-47|in|O
DDI-DrugBank.d458.s21|49-56|patients|O
DDI-DrugBank.d458.s21|58-70|concomitantly|O
DDI-DrugBank.d458.s21|72-80|receiving|O
DDI-DrugBank.d458.s21|82-85|oral|O
DDI-DrugBank.d458.s21|87-96|miconazole|drug
DDI-DrugBank.d458.s21|98-98|(|O
DDI-DrugBank.d458.s21|99-100|an|O
DDI-DrugBank.d458.s21|102-110|imidazole|group
DDI-DrugBank.d458.s21|111-111|)|O
DDI-DrugBank.d458.s21|113-115|and|O
DDI-DrugBank.d458.s21|117-120|oral|O
DDI-DrugBank.d458.s21|122-140|hypoglycemic agents|group
DDI-DrugBank.d458.s21|141-141|,|O
DDI-DrugBank.d458.s21|143-146|such|O
DDI-DrugBank.d458.s21|148-148|a|O
DDI-DrugBank.d458.s21|150-158|potential|O
DDI-DrugBank.d458.s21|160-170|interaction|O
DDI-DrugBank.d458.s21|172-180|involving|O
DDI-DrugBank.d458.s21|182-184|the|O
DDI-DrugBank.d458.s21|186-191|latter|O
DDI-DrugBank.d458.s21|193-198|agents|O
DDI-DrugBank.d458.s21|200-203|when|O
DDI-DrugBank.d458.s21|205-208|used|O
DDI-DrugBank.d458.s21|210-222|concomitantly|O
DDI-DrugBank.d458.s21|224-227|with|O
DDI-DrugBank.d458.s21|229-240|ketoconazole|drug
DDI-DrugBank.d458.s21|242-248|tablets|O
DDI-DrugBank.d458.s21|250-250|(|O
DDI-DrugBank.d458.s21|251-252|an|O
DDI-DrugBank.d458.s21|254-262|imidazole|group
DDI-DrugBank.d458.s21|263-263|)|O
DDI-DrugBank.d458.s21|265-267|can|O
DDI-DrugBank.d458.s21|269-271|not|O
DDI-DrugBank.d458.s21|273-274|be|O
DDI-DrugBank.d458.s21|276-280|ruled|O
DDI-DrugBank.d458.s21|282-284|out|O
DDI-DrugBank.d458.s21|285-285|.|O
DDI-DrugBank.d458.s22|0-10|Concomitant|O
DDI-DrugBank.d458.s22|12-25|administration|O
DDI-DrugBank.d458.s22|27-28|of|O
DDI-DrugBank.d458.s22|30-41|ketoconazole|drug
DDI-DrugBank.d458.s22|43-49|tablets|O
DDI-DrugBank.d458.s22|51-54|with|O
DDI-DrugBank.d458.s22|56-64|phenytoin|drug
DDI-DrugBank.d458.s22|66-68|may|O
DDI-DrugBank.d458.s22|70-74|alter|O
DDI-DrugBank.d458.s22|76-78|the|O
DDI-DrugBank.d458.s22|80-89|metabolism|O
DDI-DrugBank.d458.s22|91-92|of|O
DDI-DrugBank.d458.s22|94-96|one|O
DDI-DrugBank.d458.s22|98-99|or|O
DDI-DrugBank.d458.s22|101-104|both|O
DDI-DrugBank.d458.s22|106-107|of|O
DDI-DrugBank.d458.s22|109-111|the|O
DDI-DrugBank.d458.s22|113-117|drugs|O
DDI-DrugBank.d458.s22|118-118|.|O
DDI-DrugBank.d458.s23|0-1|It|O
DDI-DrugBank.d458.s23|3-4|is|O
DDI-DrugBank.d458.s23|6-14|suggested|O
DDI-DrugBank.d458.s23|16-17|to|O
DDI-DrugBank.d458.s23|19-25|monitor|O
DDI-DrugBank.d458.s23|27-30|both|O
DDI-DrugBank.d458.s23|32-43|ketoconazole|drug
DDI-DrugBank.d458.s23|45-47|and|O
DDI-DrugBank.d458.s23|49-57|phenytoin|drug
DDI-DrugBank.d458.s23|58-58|.|O
DDI-DrugBank.d458.s24|0-10|Concomitant|O
DDI-DrugBank.d458.s24|12-25|administration|O
DDI-DrugBank.d458.s24|27-28|of|O
DDI-DrugBank.d458.s24|30-37|rifampin|drug
DDI-DrugBank.d458.s24|39-42|with|O
DDI-DrugBank.d458.s24|44-55|ketoconazole|drug
DDI-DrugBank.d458.s24|57-63|tablets|O
DDI-DrugBank.d458.s24|65-71|reduces|O
DDI-DrugBank.d458.s24|73-75|the|O
DDI-DrugBank.d458.s24|77-81|blood|O
DDI-DrugBank.d458.s24|83-88|levels|O
DDI-DrugBank.d458.s24|90-91|of|O
DDI-DrugBank.d458.s24|93-95|the|O
DDI-DrugBank.d458.s24|97-102|latter|O
DDI-DrugBank.d458.s24|103-103|.|O
DDI-DrugBank.d458.s25|0-2|INH|drug
DDI-DrugBank.d458.s25|4-4|(|O
DDI-DrugBank.d458.s25|5-13|Isoniazid|drug
DDI-DrugBank.d458.s25|14-14|)|O
DDI-DrugBank.d458.s25|16-17|is|O
DDI-DrugBank.d458.s25|19-22|also|O
DDI-DrugBank.d458.s25|24-31|reported|O
DDI-DrugBank.d458.s25|33-34|to|O
DDI-DrugBank.d458.s25|36-41|affect|O
DDI-DrugBank.d458.s25|43-54|ketoconazole|drug
DDI-DrugBank.d458.s25|56-69|concentrations|O
DDI-DrugBank.d458.s25|71-79|adversely|O
DDI-DrugBank.d458.s25|80-80|.|O
DDI-DrugBank.d458.s26|0-4|These|O
DDI-DrugBank.d458.s26|6-10|drugs|O
DDI-DrugBank.d458.s26|12-17|should|O
DDI-DrugBank.d458.s26|19-21|not|O
DDI-DrugBank.d458.s26|23-24|be|O
DDI-DrugBank.d458.s26|26-30|given|O
DDI-DrugBank.d458.s26|32-44|concomitantly|O
DDI-DrugBank.d458.s26|45-45|.|O
DDI-DrugBank.d458.s27|0-4|After|O
DDI-DrugBank.d458.s27|6-8|the|O
DDI-DrugBank.d458.s27|10-25|coadministration|O
DDI-DrugBank.d458.s27|27-28|of|O
DDI-DrugBank.d458.s27|30-32|200|O
DDI-DrugBank.d458.s27|34-35|mg|O
DDI-DrugBank.d458.s27|37-40|oral|O
DDI-DrugBank.d458.s27|42-53|ketoconazole|drug
DDI-DrugBank.d458.s27|55-59|twice|O
DDI-DrugBank.d458.s27|61-65|daily|O
DDI-DrugBank.d458.s27|67-69|and|O
DDI-DrugBank.d458.s27|71-73|one|O
DDI-DrugBank.d458.s27|75-76|20|O
DDI-DrugBank.d458.s27|78-79|mg|O
DDI-DrugBank.d458.s27|81-84|dose|O
DDI-DrugBank.d458.s27|86-87|of|O
DDI-DrugBank.d458.s27|89-98|loratadine|drug
DDI-DrugBank.d458.s27|100-101|to|O
DDI-DrugBank.d458.s27|103-104|11|O
DDI-DrugBank.d458.s27|106-113|subjects|O
DDI-DrugBank.d458.s27|114-114|,|O
DDI-DrugBank.d458.s27|116-118|the|O
DDI-DrugBank.d458.s27|120-122|AUC|O
DDI-DrugBank.d458.s27|124-126|and|O
DDI-DrugBank.d458.s27|128-131|Cmax|O
DDI-DrugBank.d458.s27|133-134|of|O
DDI-DrugBank.d458.s27|136-145|loratadine|drug
DDI-DrugBank.d458.s27|147-154|averaged|O
DDI-DrugBank.d458.s27|156-158|302|O
DDI-DrugBank.d458.s27|159-159|%|O
DDI-DrugBank.d458.s27|161-161|(|O
DDI-DrugBank.d458.s27|164-166|142|O
DDI-DrugBank.d458.s27|168-171|S.D.|O
DDI-DrugBank.d458.s27|172-172|)|O
DDI-DrugBank.d458.s27|174-176|and|O
DDI-DrugBank.d458.s27|178-180|251|O
DDI-DrugBank.d458.s27|181-181|%|O
DDI-DrugBank.d458.s27|183-183|(|O
DDI-DrugBank.d458.s27|186-187|68|O
DDI-DrugBank.d458.s27|189-192|S.D.|O
DDI-DrugBank.d458.s27|193-193|)|O
DDI-DrugBank.d458.s27|194-194|,|O
DDI-DrugBank.d458.s27|196-207|respectively|O
DDI-DrugBank.d458.s27|208-208|,|O
DDI-DrugBank.d458.s27|210-211|of|O
DDI-DrugBank.d458.s27|213-217|those|O
DDI-DrugBank.d458.s27|219-226|obtained|O
DDI-DrugBank.d458.s27|228-232|after|O
DDI-DrugBank.d458.s27|234-245|co-treatment|O
DDI-DrugBank.d458.s27|247-250|with|O
DDI-DrugBank.d458.s27|252-258|placebo|O
DDI-DrugBank.d458.s27|259-259|.|O
DDI-DrugBank.d458.s28|0-2|The|O
DDI-DrugBank.d458.s28|4-6|AUC|O
DDI-DrugBank.d458.s28|8-10|and|O
DDI-DrugBank.d458.s28|12-15|Cmax|O
DDI-DrugBank.d458.s28|17-18|of|O
DDI-DrugBank.d458.s28|44-44|,|O
DDI-DrugBank.d458.s28|46-47|an|O
DDI-DrugBank.d458.s28|49-54|active|O
DDI-DrugBank.d458.s28|56-65|metabolite|O
DDI-DrugBank.d458.s28|66-66|,|O
DDI-DrugBank.d458.s28|68-75|averaged|O
DDI-DrugBank.d458.s28|77-79|155|O
DDI-DrugBank.d458.s28|80-80|%|O
DDI-DrugBank.d458.s28|82-82|(|O
DDI-DrugBank.d458.s28|85-86|27|O
DDI-DrugBank.d458.s28|88-91|S.D.|O
DDI-DrugBank.d458.s28|92-92|)|O
DDI-DrugBank.d458.s28|94-96|and|O
DDI-DrugBank.d458.s28|98-100|141|O
DDI-DrugBank.d458.s28|101-101|%|O
DDI-DrugBank.d458.s28|103-103|(|O
DDI-DrugBank.d458.s28|106-107|35|O
DDI-DrugBank.d458.s28|109-112|S.D.|O
DDI-DrugBank.d458.s28|113-113|)|O
DDI-DrugBank.d458.s28|114-114|,|O
DDI-DrugBank.d458.s28|116-127|respectively|O
DDI-DrugBank.d458.s28|128-128|.|O
DDI-DrugBank.d458.s29|0-6|However|O
DDI-DrugBank.d458.s29|7-7|,|O
DDI-DrugBank.d458.s29|9-10|no|O
DDI-DrugBank.d458.s29|12-18|related|O
DDI-DrugBank.d458.s29|20-26|changes|O
DDI-DrugBank.d458.s29|28-31|were|O
DDI-DrugBank.d458.s29|33-37|noted|O
DDI-DrugBank.d458.s29|39-40|in|O
DDI-DrugBank.d458.s29|42-44|the|O
DDI-DrugBank.d458.s29|46-48|QT0|O
DDI-DrugBank.d458.s29|50-51|on|O
DDI-DrugBank.d458.s29|53-55|ECG|O
DDI-DrugBank.d458.s29|57-61|taken|O
DDI-DrugBank.d458.s29|63-64|at|O
DDI-DrugBank.d458.s29|66-66|2|O
DDI-DrugBank.d458.s29|67-67|,|O
DDI-DrugBank.d458.s29|69-69|6|O
DDI-DrugBank.d458.s29|70-70|,|O
DDI-DrugBank.d458.s29|72-74|and|O
DDI-DrugBank.d458.s29|76-77|24|O
DDI-DrugBank.d458.s29|79-83|hours|O
DDI-DrugBank.d458.s29|85-89|after|O
DDI-DrugBank.d458.s29|91-93|the|O
DDI-DrugBank.d458.s29|95-110|coadministration|O
DDI-DrugBank.d458.s29|111-111|.|O
DDI-DrugBank.d458.s30|0-3|Also|O
DDI-DrugBank.d458.s30|4-4|,|O
DDI-DrugBank.d458.s30|6-10|there|O
DDI-DrugBank.d458.s30|12-15|were|O
DDI-DrugBank.d458.s30|17-18|no|O
DDI-DrugBank.d458.s30|20-29|clinically|O
DDI-DrugBank.d458.s30|31-41|significant|O
DDI-DrugBank.d458.s30|43-53|differences|O
DDI-DrugBank.d458.s30|55-56|in|O
DDI-DrugBank.d458.s30|58-64|adverse|O
DDI-DrugBank.d458.s30|66-71|events|O
DDI-DrugBank.d458.s30|73-76|when|O
DDI-DrugBank.d458.s30|78-87|loratadine|drug
DDI-DrugBank.d458.s30|89-91|was|O
DDI-DrugBank.d458.s30|93-104|administered|O
DDI-DrugBank.d458.s30|106-109|with|O
DDI-DrugBank.d458.s30|111-112|or|O
DDI-DrugBank.d458.s30|114-120|without|O
DDI-DrugBank.d458.s30|122-133|ketoconazole|drug
DDI-DrugBank.d458.s30|134-134|.|O
DDI-DrugBank.d458.s31|0-3|Rare|O
DDI-DrugBank.d458.s31|5-9|cases|O
DDI-DrugBank.d458.s31|11-12|of|O
DDI-DrugBank.d458.s31|14-14|a|O
DDI-DrugBank.d458.s31|16-30|disulfiram-like|O
DDI-DrugBank.d458.s31|32-39|reaction|O
DDI-DrugBank.d458.s31|41-42|to|O
DDI-DrugBank.d458.s31|44-50|alcohol|drug
DDI-DrugBank.d458.s31|52-55|have|O
DDI-DrugBank.d458.s31|57-60|been|O
DDI-DrugBank.d458.s31|62-69|reported|O
DDI-DrugBank.d458.s31|70-70|.|O
DDI-DrugBank.d458.s32|0-4|These|O
DDI-DrugBank.d458.s32|6-16|experiences|O
DDI-DrugBank.d458.s32|18-21|have|O
DDI-DrugBank.d458.s32|23-26|been|O
DDI-DrugBank.d458.s32|28-40|characterized|O
DDI-DrugBank.d458.s32|42-43|by|O
DDI-DrugBank.d458.s32|45-52|flushing|O
DDI-DrugBank.d458.s32|53-53|,|O
DDI-DrugBank.d458.s32|55-58|rash|O
DDI-DrugBank.d458.s32|59-59|,|O
DDI-DrugBank.d458.s32|61-70|peripheral|O
DDI-DrugBank.d458.s32|72-76|edema|O
DDI-DrugBank.d458.s32|77-77|,|O
DDI-DrugBank.d458.s32|79-84|nausea|O
DDI-DrugBank.d458.s32|85-85|,|O
DDI-DrugBank.d458.s32|87-89|and|O
DDI-DrugBank.d458.s32|91-98|headache|O
DDI-DrugBank.d458.s32|99-99|.|O
DDI-DrugBank.d458.s33|0-7|Symptoms|O
DDI-DrugBank.d458.s33|9-16|resolved|O
DDI-DrugBank.d458.s33|18-23|within|O
DDI-DrugBank.d458.s33|25-25|a|O
DDI-DrugBank.d458.s33|27-29|few|O
DDI-DrugBank.d458.s33|31-35|hours|O
DDI-DrugBank.d458.s33|36-36|.|O
DDI-DrugBank.d543.s0|0-2|The|O
DDI-DrugBank.d543.s0|4-12|following|O
DDI-DrugBank.d543.s0|14-19|agents|O
DDI-DrugBank.d543.s0|21-23|may|O
DDI-DrugBank.d543.s0|25-32|increase|O
DDI-DrugBank.d543.s0|34-40|certain|O
DDI-DrugBank.d543.s0|42-48|actions|O
DDI-DrugBank.d543.s0|50-51|or|O
DDI-DrugBank.d543.s0|53-56|side|O
DDI-DrugBank.d543.s0|58-64|effects|O
DDI-DrugBank.d543.s0|66-67|of|O
DDI-DrugBank.d543.s0|69-83|anticholinergic|group
DDI-DrugBank.d543.s0|85-90|drugs.|O
DDI-DrugBank.d543.s0|92-101|amantadine|drug
DDI-DrugBank.d543.s0|92-101|amantadine|drug
DDI-DrugBank.d543.s0|118-123|agents|group
DDI-DrugBank.d543.s0|125-126|of|O
DDI-DrugBank.d543.s0|128-132|class|O
DDI-DrugBank.d543.s0|134-134|(|O
DDI-DrugBank.d543.s0|135-138|e.g.|O
DDI-DrugBank.d543.s0|140-148|quinidine|drug
DDI-DrugBank.d543.s0|149-149|)|O
DDI-DrugBank.d543.s0|150-150|,|O
DDI-DrugBank.d543.s0|152-165|antihistamines|group
DDI-DrugBank.d543.s0|152-186|antihistamines agents|group
DDI-DrugBank.d543.s0|188-188|(|O
DDI-DrugBank.d543.s0|189-192|e.g.|O
DDI-DrugBank.d543.s0|194-207|phenothiazines|group
DDI-DrugBank.d543.s0|208-208|)|O
DDI-DrugBank.d543.s0|209-209|,|O
DDI-DrugBank.d543.s0|211-225|benzodiazepines|group
DDI-DrugBank.d543.s0|226-226|.|O
DDI-DrugBank.d543.s1|0-13|MAO inhibitors|group
DDI-DrugBank.d543.s1|14-14|,|O
DDI-DrugBank.d543.s1|16-34|narcotic analgesics|group
DDI-DrugBank.d543.s1|36-36|(|O
DDI-DrugBank.d543.s1|37-40|e.g.|O
DDI-DrugBank.d543.s1|41-41|,|O
DDI-DrugBank.d543.s1|43-52|meperidine|drug
DDI-DrugBank.d543.s1|53-53|)|O
DDI-DrugBank.d543.s1|54-54|,|O
DDI-DrugBank.d543.s1|56-63|nitrates|group
DDI-DrugBank.d543.s1|65-67|and|O
DDI-DrugBank.d543.s1|69-76|nitrites|group
DDI-DrugBank.d543.s1|77-77|,|O
DDI-DrugBank.d543.s1|79-100|sympathomimetic agents|group
DDI-DrugBank.d543.s1|101-101|,|O
DDI-DrugBank.d543.s1|103-127|tricyclic antidepressants|group
DDI-DrugBank.d543.s1|128-128|,|O
DDI-DrugBank.d543.s1|130-132|and|O
DDI-DrugBank.d543.s1|134-138|other|O
DDI-DrugBank.d543.s1|140-144|drugs|O
DDI-DrugBank.d543.s1|146-151|having|O
DDI-DrugBank.d543.s1|153-167|anticholinergic|O
DDI-DrugBank.d543.s1|169-176|activity|O
DDI-DrugBank.d543.s1|177-177|.|O
DDI-DrugBank.d543.s2|0-15|Anticholinergics|group
DDI-DrugBank.d543.s2|17-26|antagonize|O
DDI-DrugBank.d543.s2|28-30|the|O
DDI-DrugBank.d543.s2|32-38|effects|O
DDI-DrugBank.d543.s2|40-41|of|O
DDI-DrugBank.d543.s2|43-61|antiglaucoma agents|group
DDI-DrugBank.d543.s2|62-62|.|O
DDI-DrugBank.d543.s3|0-20|Anticholinergic drugs|group
DDI-DrugBank.d543.s3|22-23|in|O
DDI-DrugBank.d543.s3|25-27|the|O
DDI-DrugBank.d543.s3|29-36|presence|O
DDI-DrugBank.d543.s3|38-39|of|O
DDI-DrugBank.d543.s3|41-49|increased|O
DDI-DrugBank.d543.s3|51-61|intraocular|O
DDI-DrugBank.d543.s3|63-70|pressure|O
DDI-DrugBank.d543.s3|72-74|may|O
DDI-DrugBank.d543.s3|76-77|be|O
DDI-DrugBank.d543.s3|79-87|hazardous|O
DDI-DrugBank.d543.s3|89-92|when|O
DDI-DrugBank.d543.s3|94-98|taken|O
DDI-DrugBank.d543.s3|100-111|concurrently|O
DDI-DrugBank.d543.s3|113-116|with|O
DDI-DrugBank.d543.s3|118-123|agents|O
DDI-DrugBank.d543.s3|125-128|such|O
DDI-DrugBank.d543.s3|130-131|as|O
DDI-DrugBank.d543.s3|133-137|corti|O
DDI-DrugBank.d543.s3|139-150|costeroids..|O
DDI-DrugBank.d543.s4|0-21|Anticholinergic agents|group
DDI-DrugBank.d543.s4|23-25|may|O
DDI-DrugBank.d543.s4|27-32|affect|O
DDI-DrugBank.d543.s4|34-49|gastrointestinal|O
DDI-DrugBank.d543.s4|51-60|absorption|O
DDI-DrugBank.d543.s4|62-63|of|O
DDI-DrugBank.d543.s4|65-71|various|O
DDI-DrugBank.d543.s4|73-77|drugs|O
DDI-DrugBank.d543.s4|78-78|,|O
DDI-DrugBank.d543.s4|80-83|such|O
DDI-DrugBank.d543.s4|85-86|as|O
DDI-DrugBank.d543.s4|88-93|slowly|O
DDI-DrugBank.d543.s4|95-104|dissolving|O
DDI-DrugBank.d543.s4|106-111|dosage|O
DDI-DrugBank.d543.s4|113-117|forms|O
DDI-DrugBank.d543.s4|119-120|of|O
DDI-DrugBank.d543.s4|122-128|digoxin|drug
DDI-DrugBank.d543.s4|129-129|;|O
DDI-DrugBank.d543.s5|0-8|increased|O
DDI-DrugBank.d543.s5|10-14|serum|O
DDI-DrugBank.d543.s5|16-22|digoxin|drug
DDI-DrugBank.d543.s5|24-37|concentrations|O
DDI-DrugBank.d543.s5|39-41|may|O
DDI-DrugBank.d543.s5|43-48|result|O
DDI-DrugBank.d543.s5|49-49|.|O
DDI-DrugBank.d543.s6|0-20|Anticholinergic drugs|group
DDI-DrugBank.d543.s6|22-24|may|O
DDI-DrugBank.d543.s6|26-35|antagonize|O
DDI-DrugBank.d543.s6|37-39|the|O
DDI-DrugBank.d543.s6|41-47|effects|O
DDI-DrugBank.d543.s6|49-50|of|O
DDI-DrugBank.d543.s6|52-54|the|O
DDI-DrugBank.d543.s6|56-60|drugs|O
DDI-DrugBank.d543.s6|62-65|that|O
DDI-DrugBank.d543.s6|67-71|alter|O
DDI-DrugBank.d543.s6|73-88|gastrointestinal|O
DDI-DrugBank.d543.s6|90-97|motility|O
DDI-DrugBank.d543.s6|98-98|,|O
DDI-DrugBank.d543.s6|100-103|such|O
DDI-DrugBank.d543.s6|105-106|as|O
DDI-DrugBank.d543.s6|108-121|metoclopramide|drug
DDI-DrugBank.d543.s6|122-122|.|O
DDI-DrugBank.d543.s7|0-6|Because|O
DDI-DrugBank.d543.s7|8-15|antacids|group
DDI-DrugBank.d543.s7|17-19|may|O
DDI-DrugBank.d543.s7|21-29|interfere|O
DDI-DrugBank.d543.s7|31-34|with|O
DDI-DrugBank.d543.s7|36-38|the|O
DDI-DrugBank.d543.s7|40-49|absorption|O
DDI-DrugBank.d543.s7|51-52|of|O
DDI-DrugBank.d543.s7|54-75|anticholinergic agents|group
DDI-DrugBank.d543.s7|76-76|,|O
DDI-DrugBank.d543.s7|78-89|simultaneous|O
DDI-DrugBank.d543.s7|91-93|use|O
DDI-DrugBank.d543.s7|95-96|of|O
DDI-DrugBank.d543.s7|98-102|these|O
DDI-DrugBank.d543.s7|104-108|drugs|O
DDI-DrugBank.d543.s7|110-115|should|O
DDI-DrugBank.d543.s7|117-118|be|O
DDI-DrugBank.d543.s7|120-126|avoided|O
DDI-DrugBank.d543.s7|127-127|.|O
DDI-DrugBank.d543.s8|0-2|The|O
DDI-DrugBank.d543.s8|4-13|inhibiting|O
DDI-DrugBank.d543.s8|15-21|effects|O
DDI-DrugBank.d543.s8|23-24|of|O
DDI-DrugBank.d543.s8|26-46|anticholinergic drugs|group
DDI-DrugBank.d543.s8|48-49|on|O
DDI-DrugBank.d543.s8|51-57|gastric|O
DDI-DrugBank.d543.s8|59-70|hydrochloric|O
DDI-DrugBank.d543.s8|72-75|acid|O
DDI-DrugBank.d543.s8|77-85|secretion|O
DDI-DrugBank.d543.s8|87-89|are|O
DDI-DrugBank.d543.s8|91-101|antagonized|O
DDI-DrugBank.d543.s8|103-104|by|O
DDI-DrugBank.d543.s8|106-111|agents|O
DDI-DrugBank.d543.s8|113-116|used|O
DDI-DrugBank.d543.s8|118-119|to|O
DDI-DrugBank.d543.s8|121-125|treat|O
DDI-DrugBank.d543.s8|127-138|achlorhydria|O
DDI-DrugBank.d543.s8|140-142|and|O
DDI-DrugBank.d543.s8|144-148|those|O
DDI-DrugBank.d543.s8|150-153|used|O
DDI-DrugBank.d543.s8|155-156|to|O
DDI-DrugBank.d543.s8|158-161|test|O
DDI-DrugBank.d543.s8|163-169|gastric|O
DDI-DrugBank.d543.s8|171-179|secretion|O
DDI-DrugBank.d543.s8|180-180|.|O
DDI-DrugBank.d349.s0|0-3|None|O
DDI-DrugBank.d349.s0|5-9|known|O
DDI-DrugBank.d349.s0|10-10|.|O
DDI-DrugBank.d564.s0|0-2|The|O
DDI-DrugBank.d564.s0|4-17|administration|O
DDI-DrugBank.d564.s0|19-20|of|O
DDI-DrugBank.d564.s0|22-26|local|O
DDI-DrugBank.d564.s0|28-47|anesthetic solutions|group
DDI-DrugBank.d564.s0|49-58|containing|O
DDI-DrugBank.d564.s0|60-70|epinephrine|drug
DDI-DrugBank.d564.s0|72-73|or|O
DDI-DrugBank.d564.s0|75-88|norepinephrine|drug
DDI-DrugBank.d564.s0|90-91|to|O
DDI-DrugBank.d564.s0|93-100|patients|O
DDI-DrugBank.d564.s0|102-110|receiving|O
DDI-DrugBank.d564.s0|112-139|monoamine oxidase inhibitors|group
DDI-DrugBank.d564.s0|141-142|or|O
DDI-DrugBank.d564.s0|144-168|tricyclic antidepressants|group
DDI-DrugBank.d564.s0|170-172|may|O
DDI-DrugBank.d564.s0|174-180|produce|O
DDI-DrugBank.d564.s0|182-187|severe|O
DDI-DrugBank.d564.s0|188-188|,|O
DDI-DrugBank.d564.s0|190-198|prolonged|O
DDI-DrugBank.d564.s0|200-211|hypertension|O
DDI-DrugBank.d564.s0|212-212|.|O
DDI-DrugBank.d564.s1|0-13|Phenothiazines|group
DDI-DrugBank.d564.s1|15-17|and|O
DDI-DrugBank.d564.s1|19-32|butyrophenones|group
DDI-DrugBank.d564.s1|34-36|may|O
DDI-DrugBank.d564.s1|38-43|reduce|O
DDI-DrugBank.d564.s1|45-46|or|O
DDI-DrugBank.d564.s1|48-54|reverse|O
DDI-DrugBank.d564.s1|56-58|the|O
DDI-DrugBank.d564.s1|60-66|pressor|O
DDI-DrugBank.d564.s1|68-73|effect|O
DDI-DrugBank.d564.s1|75-76|of|O
DDI-DrugBank.d564.s1|78-88|epinephrine|drug
DDI-DrugBank.d564.s1|89-89|.|O
DDI-DrugBank.d564.s2|0-9|Concurrent|O
DDI-DrugBank.d564.s2|11-13|use|O
DDI-DrugBank.d564.s2|15-16|of|O
DDI-DrugBank.d564.s2|18-22|these|O
DDI-DrugBank.d564.s2|24-29|agents|O
DDI-DrugBank.d564.s2|31-36|should|O
DDI-DrugBank.d564.s2|38-46|generally|O
DDI-DrugBank.d564.s2|48-49|be|O
DDI-DrugBank.d564.s2|51-57|avoided|O
DDI-DrugBank.d564.s2|58-58|.|O
DDI-DrugBank.d564.s3|0-1|In|O
DDI-DrugBank.d564.s3|3-12|situations|O
DDI-DrugBank.d564.s3|14-17|when|O
DDI-DrugBank.d564.s3|19-28|concurrent|O
DDI-DrugBank.d564.s3|30-36|therapy|O
DDI-DrugBank.d564.s3|38-39|is|O
DDI-DrugBank.d564.s3|41-49|necessary|O
DDI-DrugBank.d564.s3|50-50|,|O
DDI-DrugBank.d564.s3|52-58|careful|O
DDI-DrugBank.d564.s3|60-66|patient|O
DDI-DrugBank.d564.s3|68-77|monitoring|O
DDI-DrugBank.d564.s3|79-80|is|O
DDI-DrugBank.d564.s3|82-90|essential|O
DDI-DrugBank.d564.s3|91-91|.|O
DDI-DrugBank.d564.s4|0-9|Concurrent|O
DDI-DrugBank.d564.s4|11-24|administration|O
DDI-DrugBank.d564.s4|26-27|of|O
DDI-DrugBank.d564.s4|29-45|vasopressor drugs|group
DDI-DrugBank.d564.s4|47-47|(|O
DDI-DrugBank.d564.s4|48-50|for|O
DDI-DrugBank.d564.s4|52-54|the|O
DDI-DrugBank.d564.s4|56-64|treatment|O
DDI-DrugBank.d564.s4|66-67|of|O
DDI-DrugBank.d564.s4|69-79|hypotension|O
DDI-DrugBank.d564.s4|81-87|related|O
DDI-DrugBank.d564.s4|89-90|to|O
DDI-DrugBank.d564.s4|92-100|obstetric|O
DDI-DrugBank.d564.s4|102-107|blocks|O
DDI-DrugBank.d564.s4|108-108|)|O
DDI-DrugBank.d564.s4|110-112|and|O
DDI-DrugBank.d564.s4|114-138|ergot-type oxytocic drugs|group
DDI-DrugBank.d564.s4|140-142|may|O
DDI-DrugBank.d564.s4|144-148|cause|O
DDI-DrugBank.d564.s4|150-155|severe|O
DDI-DrugBank.d564.s4|156-156|,|O
DDI-DrugBank.d564.s4|158-167|persistent|O
DDI-DrugBank.d564.s4|169-180|hypertension|O
DDI-DrugBank.d564.s4|182-183|or|O
DDI-DrugBank.d564.s4|185-199|cerebrovascular|O
DDI-DrugBank.d564.s4|201-209|accidents|O
DDI-DrugBank.d564.s4|210-210|.|O
DDI-MedLine.d116.s0|0-7|Rifampin|drug
DDI-MedLine.d116.s0|9-11|and|O
DDI-MedLine.d116.s0|13-20|warfarin|drug
DDI-MedLine.d116.s0|21-21|:|O
DDI-MedLine.d116.s0|23-23|a|O
DDI-MedLine.d116.s0|25-28|drug|O
DDI-MedLine.d116.s0|30-40|interaction|O
DDI-MedLine.d116.s0|41-41|.|O
DDI-MedLine.d116.s1|0-2|The|O
DDI-MedLine.d116.s1|4-7|drug|O
DDI-MedLine.d116.s1|9-19|interaction|O
DDI-MedLine.d116.s1|21-27|between|O
DDI-MedLine.d116.s1|29-36|warfarin|drug
DDI-MedLine.d116.s1|38-40|and|O
DDI-MedLine.d116.s1|42-49|rifampin|drug
DDI-MedLine.d116.s1|51-52|is|O
DDI-MedLine.d116.s1|54-56|not|O
DDI-MedLine.d116.s1|58-61|well|O
DDI-MedLine.d116.s1|63-67|known|O
DDI-MedLine.d116.s1|68-68|.|O
DDI-MedLine.d116.s2|0-7|Rifampin|drug
DDI-MedLine.d116.s2|9-11|has|O
DDI-MedLine.d116.s2|13-16|been|O
DDI-MedLine.d116.s2|18-25|reported|O
DDI-MedLine.d116.s2|27-28|to|O
DDI-MedLine.d116.s2|30-37|increase|O
DDI-MedLine.d116.s2|39-41|the|O
DDI-MedLine.d116.s2|43-50|warfarin|drug
DDI-MedLine.d116.s2|52-63|requirements|O
DDI-MedLine.d116.s2|65-66|in|O
DDI-MedLine.d116.s2|68-72|human|O
DDI-MedLine.d116.s2|74-81|subjects|O
DDI-MedLine.d116.s2|83-91|ingesting|O
DDI-MedLine.d116.s2|93-97|these|O
DDI-MedLine.d116.s2|99-104|agents|O
DDI-MedLine.d116.s2|106-119|simultaneously|O
DDI-MedLine.d116.s2|120-120|.|O
DDI-MedLine.d116.s3|0-2|The|O
DDI-MedLine.d116.s3|4-14|concomitant|O
DDI-MedLine.d116.s3|16-29|administration|O
DDI-MedLine.d116.s3|31-32|of|O
DDI-MedLine.d116.s3|34-41|rifampin|drug
DDI-MedLine.d116.s3|43-45|and|O
DDI-MedLine.d116.s3|47-54|warfarin|drug
DDI-MedLine.d116.s3|56-63|resulted|O
DDI-MedLine.d116.s3|65-66|in|O
DDI-MedLine.d116.s3|68-70|the|O
DDI-MedLine.d116.s3|72-75|need|O
DDI-MedLine.d116.s3|77-79|for|O
DDI-MedLine.d116.s3|81-82|an|O
DDI-MedLine.d116.s3|84-92|unusually|O
DDI-MedLine.d116.s3|94-97|high|O
DDI-MedLine.d116.s3|99-109|maintenance|O
DDI-MedLine.d116.s3|111-114|dose|O
DDI-MedLine.d116.s3|116-117|of|O
DDI-MedLine.d116.s3|119-126|warfarin|drug
DDI-MedLine.d116.s3|128-128|(|O
DDI-MedLine.d116.s3|129-130|20|O
DDI-MedLine.d116.s3|132-133|mg|O
DDI-MedLine.d116.s3|135-137|per|O
DDI-MedLine.d116.s3|139-141|day|O
DDI-MedLine.d116.s3|142-142|)|O
DDI-MedLine.d116.s3|144-145|in|O
DDI-MedLine.d116.s3|147-151|order|O
DDI-MedLine.d116.s3|153-154|to|O
DDI-MedLine.d116.s3|156-162|produce|O
DDI-MedLine.d116.s3|164-164|a|O
DDI-MedLine.d116.s3|166-176|therapeutic|O
DDI-MedLine.d116.s3|178-183|effect|O
DDI-MedLine.d116.s3|184-184|.|O
DDI-MedLine.d116.s4|0-9|Withdrawal|O
DDI-MedLine.d116.s4|11-12|of|O
DDI-MedLine.d116.s4|14-21|rifampin|drug
DDI-MedLine.d116.s4|23-31|decreased|O
DDI-MedLine.d116.s4|33-35|the|O
DDI-MedLine.d116.s4|37-44|warfarin|drug
DDI-MedLine.d116.s4|46-56|requirement|O
DDI-MedLine.d116.s4|58-59|by|O
DDI-MedLine.d116.s4|61-62|50|O
DDI-MedLine.d116.s4|63-63|%|O
DDI-MedLine.d116.s4|64-64|.|O
DDI-MedLine.d116.s5|0-3|This|O
DDI-MedLine.d116.s5|5-10|effect|O
DDI-MedLine.d116.s5|12-14|may|O
DDI-MedLine.d116.s5|16-17|be|O
DDI-MedLine.d116.s5|19-26|mediated|O
DDI-MedLine.d116.s5|28-29|by|O
DDI-MedLine.d116.s5|31-33|the|O
DDI-MedLine.d116.s5|35-41|ability|O
DDI-MedLine.d116.s5|43-44|of|O
DDI-MedLine.d116.s5|46-53|rifampin|drug
DDI-MedLine.d116.s5|55-56|to|O
DDI-MedLine.d116.s5|58-63|induce|O
DDI-MedLine.d116.s5|65-74|microsomal|O
DDI-MedLine.d116.s5|76-82|enzymes|O
DDI-MedLine.d116.s5|84-86|and|O
DDI-MedLine.d116.s5|87-87|,|O
DDI-MedLine.d116.s5|89-92|thus|O
DDI-MedLine.d116.s5|93-93|,|O
DDI-MedLine.d116.s5|95-97|the|O
DDI-MedLine.d116.s5|99-108|catabolism|O
DDI-MedLine.d116.s5|110-111|of|O
DDI-MedLine.d116.s5|113-120|warfarin|drug
DDI-MedLine.d116.s5|121-121|.|O
DDI-MedLine.d116.s6|0-2|The|O
DDI-MedLine.d116.s6|4-9|effect|O
DDI-MedLine.d116.s6|11-12|of|O
DDI-MedLine.d116.s6|14-21|rifampin|drug
DDI-MedLine.d116.s6|23-24|on|O
DDI-MedLine.d116.s6|26-28|the|O
DDI-MedLine.d116.s6|30-37|warfarin|drug
DDI-MedLine.d116.s6|39-49|requirement|O
DDI-MedLine.d116.s6|51-52|of|O
DDI-MedLine.d116.s6|54-56|our|O
DDI-MedLine.d116.s6|58-64|patient|O
DDI-MedLine.d116.s6|66-73|appeared|O
DDI-MedLine.d116.s6|75-76|to|O
DDI-MedLine.d116.s6|78-79|be|O
DDI-MedLine.d116.s6|81-87|maximal|O
DDI-MedLine.d116.s6|89-89|5|O
DDI-MedLine.d116.s6|91-92|to|O
DDI-MedLine.d116.s6|94-94|7|O
DDI-MedLine.d116.s6|96-99|days|O
DDI-MedLine.d116.s6|101-105|after|O
DDI-MedLine.d116.s6|107-109|the|O
DDI-MedLine.d116.s6|111-120|initiation|O
DDI-MedLine.d116.s6|122-123|of|O
DDI-MedLine.d116.s6|125-132|rifampin|drug
DDI-MedLine.d116.s6|134-136|and|O
DDI-MedLine.d116.s6|138-145|extended|O
DDI-MedLine.d116.s6|147-147|a|O
DDI-MedLine.d116.s6|149-155|similar|O
DDI-MedLine.d116.s6|157-162|length|O
DDI-MedLine.d116.s6|164-165|of|O
DDI-MedLine.d116.s6|167-170|time|O
DDI-MedLine.d116.s6|172-176|after|O
DDI-MedLine.d116.s6|178-185|rifampin|drug
DDI-MedLine.d116.s6|187-196|withdrawal|O
DDI-MedLine.d116.s6|197-197|.|O
DDI-MedLine.d116.s7|0-3|This|O
DDI-MedLine.d116.s7|5-15|interaction|O
DDI-MedLine.d116.s7|17-23|appears|O
DDI-MedLine.d116.s7|25-26|to|O
DDI-MedLine.d116.s7|28-29|be|O
DDI-MedLine.d116.s7|31-40|clinically|O
DDI-MedLine.d116.s7|42-52|significant|O
DDI-MedLine.d116.s7|53-53|.|O
DDI-DrugBank.d120.s0|0-2|CNS|O
DDI-DrugBank.d120.s0|4-13|depression|O
DDI-DrugBank.d120.s0|15-23|producing|O
DDI-DrugBank.d120.s0|25-35|medications|O
DDI-DrugBank.d120.s0|37-37|-|O
DDI-DrugBank.d120.s0|39-48|concurrent|O
DDI-DrugBank.d120.s0|50-52|use|O
DDI-DrugBank.d120.s0|54-56|may|O
DDI-DrugBank.d120.s0|58-67|potentiate|O
DDI-DrugBank.d120.s0|69-71|the|O
DDI-DrugBank.d120.s0|73-79|effects|O
DDI-DrugBank.d120.s0|81-82|of|O
DDI-DrugBank.d120.s0|84-89|either|O
DDI-DrugBank.d120.s0|91-95|these|O
DDI-DrugBank.d120.s0|97-107|medications|O
DDI-DrugBank.d120.s0|109-110|or|O
DDI-DrugBank.d120.s0|112-121|diphenidol|drug
DDI-DrugBank.d120.s0|122-122|;|O
DDI-DrugBank.d120.s1|0-15|anticholinergics|group
DDI-DrugBank.d120.s1|17-18|or|O
DDI-DrugBank.d120.s1|20-24|other|O
DDI-DrugBank.d120.s1|26-36|medications|O
DDI-DrugBank.d120.s1|38-41|with|O
DDI-DrugBank.d120.s1|43-57|anticholinergic|O
DDI-DrugBank.d120.s1|59-66|activity|O
DDI-DrugBank.d120.s1|68-68|-|O
DDI-DrugBank.d120.s1|70-84|anticholinergic|O
DDI-DrugBank.d120.s1|86-92|effects|O
DDI-DrugBank.d120.s1|94-96|may|O
DDI-DrugBank.d120.s1|98-99|be|O
DDI-DrugBank.d120.s1|101-111|potentiated|O
DDI-DrugBank.d120.s1|113-116|when|O
DDI-DrugBank.d120.s1|118-122|these|O
DDI-DrugBank.d120.s1|124-134|medications|O
DDI-DrugBank.d120.s1|136-138|are|O
DDI-DrugBank.d120.s1|140-143|used|O
DDI-DrugBank.d120.s1|145-156|concurrently|O
DDI-DrugBank.d120.s1|158-161|with|O
DDI-DrugBank.d120.s1|163-172|diphenidol|drug
DDI-DrugBank.d120.s1|173-173|;|O
DDI-DrugBank.d120.s2|0-10|apomorphine|drug
DDI-DrugBank.d120.s2|12-12|-|O
DDI-DrugBank.d120.s2|14-18|prior|O
DDI-DrugBank.d120.s2|20-28|ingestion|O
DDI-DrugBank.d120.s2|30-31|of|O
DDI-DrugBank.d120.s2|33-42|diphenidol|drug
DDI-DrugBank.d120.s2|44-46|may|O
DDI-DrugBank.d120.s2|48-55|decrease|O
DDI-DrugBank.d120.s2|57-59|the|O
DDI-DrugBank.d120.s2|61-66|emetic|group
DDI-DrugBank.d120.s2|68-75|response|O
DDI-DrugBank.d120.s2|77-78|to|O
DDI-DrugBank.d120.s2|80-90|apomorphine|drug
DDI-DrugBank.d120.s2|92-93|in|O
DDI-DrugBank.d120.s2|95-97|the|O
DDI-DrugBank.d120.s2|99-107|treatment|O
DDI-DrugBank.d120.s2|109-110|of|O
DDI-DrugBank.d120.s2|112-120|poisoning|O
DDI-DrugBank.d120.s2|121-121|.|O
DDI-DrugBank.d132.s0|0-3|Oral|O
DDI-DrugBank.d132.s0|5-18|Anticoagulants|group
DDI-DrugBank.d132.s0|19-19|:|O
DDI-DrugBank.d132.s0|21-22|In|O
DDI-DrugBank.d132.s0|24-27|some|O
DDI-DrugBank.d132.s0|29-34|normal|O
DDI-DrugBank.d132.s0|36-45|volunteers|O
DDI-DrugBank.d132.s0|46-46|,|O
DDI-DrugBank.d132.s0|48-50|the|O
DDI-DrugBank.d132.s0|52-62|concomitant|O
DDI-DrugBank.d132.s0|64-77|administration|O
DDI-DrugBank.d132.s0|79-80|of|O
DDI-DrugBank.d132.s0|82-91|diflunisal|drug
DDI-DrugBank.d132.s0|93-95|and|O
DDI-DrugBank.d132.s0|97-104|warfarin|drug
DDI-DrugBank.d132.s0|105-105|,|O
DDI-DrugBank.d132.s0|107-119|acenocoumarol|drug
DDI-DrugBank.d132.s0|120-120|,|O
DDI-DrugBank.d132.s0|122-123|or|O
DDI-DrugBank.d132.s0|125-137|phenprocoumon|drug
DDI-DrugBank.d132.s0|139-146|resulted|O
DDI-DrugBank.d132.s0|148-149|in|O
DDI-DrugBank.d132.s0|151-162|prolongation|O
DDI-DrugBank.d132.s0|164-165|of|O
DDI-DrugBank.d132.s0|167-177|prothrombin|O
DDI-DrugBank.d132.s0|179-182|time|O
DDI-DrugBank.d132.s0|183-183|.|O
DDI-DrugBank.d132.s1|0-3|This|O
DDI-DrugBank.d132.s1|5-7|may|O
DDI-DrugBank.d132.s1|9-13|occur|O
DDI-DrugBank.d132.s1|15-21|because|O
DDI-DrugBank.d132.s1|23-32|diflunisal|drug
DDI-DrugBank.d132.s1|34-46|competitively|O
DDI-DrugBank.d132.s1|48-56|displaces|O
DDI-DrugBank.d132.s1|58-66|coumarins|group
DDI-DrugBank.d132.s1|68-71|from|O
DDI-DrugBank.d132.s1|73-79|protein|O
DDI-DrugBank.d132.s1|81-87|binding|O
DDI-DrugBank.d132.s1|89-93|sites|O
DDI-DrugBank.d132.s1|94-94|.|O
DDI-DrugBank.d132.s2|0-10|Accordingly|O
DDI-DrugBank.d132.s2|11-11|,|O
DDI-DrugBank.d132.s2|13-16|when|O
DDI-DrugBank.d132.s2|18-27|diflunisal|drug
DDI-DrugBank.d132.s2|29-30|is|O
DDI-DrugBank.d132.s2|32-43|administered|O
DDI-DrugBank.d132.s2|45-48|with|O
DDI-DrugBank.d132.s2|50-53|oral|O
DDI-DrugBank.d132.s2|55-68|anticoagulants|group
DDI-DrugBank.d132.s2|69-69|,|O
DDI-DrugBank.d132.s2|71-73|the|O
DDI-DrugBank.d132.s2|75-85|prothrombin|O
DDI-DrugBank.d132.s2|87-90|time|O
DDI-DrugBank.d132.s2|92-97|should|O
DDI-DrugBank.d132.s2|99-100|be|O
DDI-DrugBank.d132.s2|102-108|closely|O
DDI-DrugBank.d132.s2|110-118|monitored|O
DDI-DrugBank.d132.s2|120-125|during|O
DDI-DrugBank.d132.s2|127-129|and|O
DDI-DrugBank.d132.s2|131-133|for|O
DDI-DrugBank.d132.s2|135-141|several|O
DDI-DrugBank.d132.s2|143-146|days|O
DDI-DrugBank.d132.s2|148-152|after|O
DDI-DrugBank.d132.s2|154-164|concomitant|O
DDI-DrugBank.d132.s2|166-169|drug|O
DDI-DrugBank.d132.s2|171-184|administration|O
DDI-DrugBank.d132.s2|185-185|.|O
DDI-DrugBank.d132.s3|0-9|Adjustment|O
DDI-DrugBank.d132.s3|11-12|of|O
DDI-DrugBank.d132.s3|14-19|dosage|O
DDI-DrugBank.d132.s3|21-22|of|O
DDI-DrugBank.d132.s3|24-27|oral|O
DDI-DrugBank.d132.s3|29-42|anticoagulants|group
DDI-DrugBank.d132.s3|44-46|may|O
DDI-DrugBank.d132.s3|48-49|be|O
DDI-DrugBank.d132.s3|51-58|required|O
DDI-DrugBank.d132.s3|59-59|.|O
DDI-DrugBank.d132.s4|0-10|Tolbutamide|drug
DDI-DrugBank.d132.s4|11-11|:|O
DDI-DrugBank.d132.s4|13-14|In|O
DDI-DrugBank.d132.s4|16-23|diabetic|O
DDI-DrugBank.d132.s4|25-32|patients|O
DDI-DrugBank.d132.s4|34-42|receiving|O
DDI-DrugBank.d132.s4|44-53|diflunisal|drug
DDI-DrugBank.d132.s4|55-57|and|O
DDI-DrugBank.d132.s4|59-69|tolbutamide|drug
DDI-DrugBank.d132.s4|70-70|,|O
DDI-DrugBank.d132.s4|72-73|no|O
DDI-DrugBank.d132.s4|75-85|significant|O
DDI-DrugBank.d132.s4|87-93|effects|O
DDI-DrugBank.d132.s4|95-98|were|O
DDI-DrugBank.d132.s4|100-103|seen|O
DDI-DrugBank.d132.s4|105-106|on|O
DDI-DrugBank.d132.s4|108-118|tolbutamide|drug
DDI-DrugBank.d132.s4|120-125|plasma|O
DDI-DrugBank.d132.s4|127-132|levels|O
DDI-DrugBank.d132.s4|134-135|or|O
DDI-DrugBank.d132.s4|137-143|fasting|O
DDI-DrugBank.d132.s4|145-149|blood|O
DDI-DrugBank.d132.s4|151-157|glucose|O
DDI-DrugBank.d132.s4|158-158|.|O
DDI-DrugBank.d132.s5|0-18|Hydrochlorothiazide|drug
DDI-DrugBank.d132.s5|19-19|:|O
DDI-DrugBank.d132.s5|21-22|In|O
DDI-DrugBank.d132.s5|24-29|normal|O
DDI-DrugBank.d132.s5|31-40|volunteers|O
DDI-DrugBank.d132.s5|41-41|,|O
DDI-DrugBank.d132.s5|43-53|concomitant|O
DDI-DrugBank.d132.s5|55-68|administration|O
DDI-DrugBank.d132.s5|70-71|of|O
DDI-DrugBank.d132.s5|73-82|diflunisal|drug
DDI-DrugBank.d132.s5|84-86|and|O
DDI-DrugBank.d132.s5|88-106|hydrochlorothiazide|drug
DDI-DrugBank.d132.s5|108-115|resulted|O
DDI-DrugBank.d132.s5|117-118|in|O
DDI-DrugBank.d132.s5|120-132|significantly|O
DDI-DrugBank.d132.s5|134-142|increased|O
DDI-DrugBank.d132.s5|144-149|plasma|O
DDI-DrugBank.d132.s5|151-156|levels|O
DDI-DrugBank.d132.s5|158-159|of|O
DDI-DrugBank.d132.s5|161-179|hydrochlorothiazide|drug
DDI-DrugBank.d132.s5|180-180|.|O
DDI-DrugBank.d132.s6|0-9|Diflunisal|drug
DDI-DrugBank.d132.s6|11-19|decreased|O
DDI-DrugBank.d132.s6|21-23|the|O
DDI-DrugBank.d132.s6|25-37|hyperuricemic|O
DDI-DrugBank.d132.s6|39-44|effect|O
DDI-DrugBank.d132.s6|46-47|of|O
DDI-DrugBank.d132.s6|49-67|hydrochlorothiazide|drug
DDI-DrugBank.d132.s6|68-68|.|O
DDI-DrugBank.d132.s7|0-9|Furosemide|drug
DDI-DrugBank.d132.s7|10-10|:|O
DDI-DrugBank.d132.s7|12-13|In|O
DDI-DrugBank.d132.s7|15-20|normal|O
DDI-DrugBank.d132.s7|22-31|volunteers|O
DDI-DrugBank.d132.s7|32-32|,|O
DDI-DrugBank.d132.s7|34-36|the|O
DDI-DrugBank.d132.s7|38-48|concomitant|O
DDI-DrugBank.d132.s7|50-63|administration|O
DDI-DrugBank.d132.s7|65-66|of|O
DDI-DrugBank.d132.s7|68-77|diflunisal|drug
DDI-DrugBank.d132.s7|79-81|and|O
DDI-DrugBank.d132.s7|83-92|furosemide|drug
DDI-DrugBank.d132.s7|94-96|had|O
DDI-DrugBank.d132.s7|98-99|no|O
DDI-DrugBank.d132.s7|101-106|effect|O
DDI-DrugBank.d132.s7|108-109|on|O
DDI-DrugBank.d132.s7|111-113|the|O
DDI-DrugBank.d132.s7|115-122|diuretic|O
DDI-DrugBank.d132.s7|124-131|activity|O
DDI-DrugBank.d132.s7|133-134|of|O
DDI-DrugBank.d132.s7|136-145|furosemide|drug
DDI-DrugBank.d132.s7|146-146|.|O
DDI-DrugBank.d132.s8|0-9|Diflunisal|drug
DDI-DrugBank.d132.s8|11-19|decreased|O
DDI-DrugBank.d132.s8|21-23|the|O
DDI-DrugBank.d132.s8|25-37|hyperuricemic|O
DDI-DrugBank.d132.s8|39-44|effect|O
DDI-DrugBank.d132.s8|46-47|of|O
DDI-DrugBank.d132.s8|49-58|furosemide|drug
DDI-DrugBank.d132.s8|59-59|.|O
DDI-DrugBank.d132.s9|0-7|Antacids|group
DDI-DrugBank.d132.s9|8-8|:|O
DDI-DrugBank.d132.s9|10-20|Concomitant|O
DDI-DrugBank.d132.s9|22-35|administration|O
DDI-DrugBank.d132.s9|37-38|of|O
DDI-DrugBank.d132.s9|40-47|antacids|group
DDI-DrugBank.d132.s9|49-51|may|O
DDI-DrugBank.d132.s9|53-58|reduce|O
DDI-DrugBank.d132.s9|60-65|plasma|O
DDI-DrugBank.d132.s9|67-72|levels|O
DDI-DrugBank.d132.s9|74-75|of|O
DDI-DrugBank.d132.s9|77-86|diflunisal|drug
DDI-DrugBank.d132.s9|87-87|.|O
DDI-DrugBank.d132.s10|0-3|This|O
DDI-DrugBank.d132.s10|5-10|effect|O
DDI-DrugBank.d132.s10|12-13|is|O
DDI-DrugBank.d132.s10|15-19|small|O
DDI-DrugBank.d132.s10|21-24|with|O
DDI-DrugBank.d132.s10|26-35|occasional|O
DDI-DrugBank.d132.s10|37-41|doses|O
DDI-DrugBank.d132.s10|43-44|of|O
DDI-DrugBank.d132.s10|46-53|antacids|group
DDI-DrugBank.d132.s10|54-54|,|O
DDI-DrugBank.d132.s10|56-58|but|O
DDI-DrugBank.d132.s10|60-62|may|O
DDI-DrugBank.d132.s10|64-65|be|O
DDI-DrugBank.d132.s10|67-76|clinically|O
DDI-DrugBank.d132.s10|78-88|significant|O
DDI-DrugBank.d132.s10|90-93|when|O
DDI-DrugBank.d132.s10|95-102|antacids|group
DDI-DrugBank.d132.s10|104-106|are|O
DDI-DrugBank.d132.s10|108-111|used|O
DDI-DrugBank.d132.s10|113-114|on|O
DDI-DrugBank.d132.s10|116-116|a|O
DDI-DrugBank.d132.s10|118-127|continuous|O
DDI-DrugBank.d132.s10|129-136|schedule|O
DDI-DrugBank.d132.s10|137-137|.|O
DDI-DrugBank.d132.s11|0-12|Acetaminophen|drug
DDI-DrugBank.d132.s11|13-13|:|O
DDI-DrugBank.d132.s11|15-16|In|O
DDI-DrugBank.d132.s11|18-23|normal|O
DDI-DrugBank.d132.s11|25-34|volunteers|O
DDI-DrugBank.d132.s11|35-35|,|O
DDI-DrugBank.d132.s11|37-47|concomitant|O
DDI-DrugBank.d132.s11|49-62|administration|O
DDI-DrugBank.d132.s11|64-65|of|O
DDI-DrugBank.d132.s11|67-76|diflunisal|drug
DDI-DrugBank.d132.s11|78-80|and|O
DDI-DrugBank.d132.s11|82-94|acetaminophen|drug
DDI-DrugBank.d132.s11|96-103|resulted|O
DDI-DrugBank.d132.s11|105-106|in|O
DDI-DrugBank.d132.s11|108-109|an|O
DDI-DrugBank.d132.s11|111-121|approximate|O
DDI-DrugBank.d132.s11|123-124|50|O
DDI-DrugBank.d132.s11|125-125|%|O
DDI-DrugBank.d132.s11|127-134|increase|O
DDI-DrugBank.d132.s11|136-137|in|O
DDI-DrugBank.d132.s11|139-144|plasma|O
DDI-DrugBank.d132.s11|146-151|levels|O
DDI-DrugBank.d132.s11|153-154|of|O
DDI-DrugBank.d132.s11|156-168|acetaminophen|drug
DDI-DrugBank.d132.s11|169-169|.|O
DDI-DrugBank.d132.s12|0-12|Acetaminophen|drug
DDI-DrugBank.d132.s12|14-16|had|O
DDI-DrugBank.d132.s12|18-19|no|O
DDI-DrugBank.d132.s12|21-26|effect|O
DDI-DrugBank.d132.s12|28-29|on|O
DDI-DrugBank.d132.s12|31-36|plasma|O
DDI-DrugBank.d132.s12|38-43|levels|O
DDI-DrugBank.d132.s12|45-46|of|O
DDI-DrugBank.d132.s12|48-57|diflunisal|drug
DDI-DrugBank.d132.s12|58-58|.|O
DDI-DrugBank.d132.s13|0-4|Since|O
DDI-DrugBank.d132.s13|6-18|acetaminophen|drug
DDI-DrugBank.d132.s13|20-21|in|O
DDI-DrugBank.d132.s13|23-26|high|O
DDI-DrugBank.d132.s13|28-32|doses|O
DDI-DrugBank.d132.s13|34-36|has|O
DDI-DrugBank.d132.s13|38-41|been|O
DDI-DrugBank.d132.s13|43-52|associated|O
DDI-DrugBank.d132.s13|54-57|with|O
DDI-DrugBank.d132.s13|59-72|hepatotoxicity|O
DDI-DrugBank.d132.s13|73-73|,|O
DDI-DrugBank.d132.s13|75-85|concomitant|O
DDI-DrugBank.d132.s13|87-100|administration|O
DDI-DrugBank.d132.s13|102-103|of|O
DDI-DrugBank.d132.s13|105-114|diflunisal|drug
DDI-DrugBank.d132.s13|116-118|and|O
DDI-DrugBank.d132.s13|120-132|acetaminophen|drug
DDI-DrugBank.d132.s13|134-139|should|O
DDI-DrugBank.d132.s13|141-142|be|O
DDI-DrugBank.d132.s13|144-147|used|O
DDI-DrugBank.d132.s13|149-158|cautiously|O
DDI-DrugBank.d132.s13|159-159|,|O
DDI-DrugBank.d132.s13|161-164|with|O
DDI-DrugBank.d132.s13|166-172|careful|O
DDI-DrugBank.d132.s13|174-183|monitoring|O
DDI-DrugBank.d132.s13|185-186|of|O
DDI-DrugBank.d132.s13|188-195|patients|O
DDI-DrugBank.d132.s13|196-196|.|O
DDI-DrugBank.d132.s14|0-10|Concomitant|O
DDI-DrugBank.d132.s14|12-25|administration|O
DDI-DrugBank.d132.s14|27-28|of|O
DDI-DrugBank.d132.s14|30-39|diflunisal|drug
DDI-DrugBank.d132.s14|41-43|and|O
DDI-DrugBank.d132.s14|45-57|acetaminophen|drug
DDI-DrugBank.d132.s14|59-60|in|O
DDI-DrugBank.d132.s14|62-65|dogs|O
DDI-DrugBank.d132.s14|66-66|,|O
DDI-DrugBank.d132.s14|68-70|but|O
DDI-DrugBank.d132.s14|72-74|not|O
DDI-DrugBank.d132.s14|76-77|in|O
DDI-DrugBank.d132.s14|79-82|rats|O
DDI-DrugBank.d132.s14|83-83|,|O
DDI-DrugBank.d132.s14|85-86|at|O
DDI-DrugBank.d132.s14|88-100|approximately|O
DDI-DrugBank.d132.s14|102-102|2|O
DDI-DrugBank.d132.s14|104-108|times|O
DDI-DrugBank.d132.s14|110-112|the|O
DDI-DrugBank.d132.s14|114-124|recommended|O
DDI-DrugBank.d132.s14|126-132|maximum|O
DDI-DrugBank.d132.s14|134-138|human|O
DDI-DrugBank.d132.s14|140-150|therapeutic|O
DDI-DrugBank.d132.s14|152-155|dose|O
DDI-DrugBank.d132.s14|157-158|of|O
DDI-DrugBank.d132.s14|160-163|each|O
DDI-DrugBank.d132.s14|165-165|(|O
DDI-DrugBank.d132.s14|166-167|40|O
DDI-DrugBank.d132.s14|169-170|to|O
DDI-DrugBank.d132.s14|172-173|52|O
DDI-DrugBank.d132.s14|175-183|mg/kg/day|O
DDI-DrugBank.d132.s14|185-186|of|O
DDI-DrugBank.d132.s14|188-211|diflunisal/acetaminophen|drug
DDI-DrugBank.d132.s14|212-212|)|O
DDI-DrugBank.d132.s14|214-221|resulted|O
DDI-DrugBank.d132.s14|223-224|in|O
DDI-DrugBank.d132.s14|226-232|greater|O
DDI-DrugBank.d132.s14|234-249|gastrointestinal|O
DDI-DrugBank.d132.s14|251-258|toxicity|O
DDI-DrugBank.d132.s14|260-263|than|O
DDI-DrugBank.d132.s14|265-268|when|O
DDI-DrugBank.d132.s14|270-275|either|O
DDI-DrugBank.d132.s14|277-280|drug|O
DDI-DrugBank.d132.s14|282-284|was|O
DDI-DrugBank.d132.s14|286-297|administered|O
DDI-DrugBank.d132.s14|299-303|alone|O
DDI-DrugBank.d132.s14|304-304|.|O
DDI-DrugBank.d132.s15|0-2|The|O
DDI-DrugBank.d132.s15|4-11|clinical|O
DDI-DrugBank.d132.s15|13-24|significance|O
DDI-DrugBank.d132.s15|26-27|of|O
DDI-DrugBank.d132.s15|29-33|these|O
DDI-DrugBank.d132.s15|35-42|findings|O
DDI-DrugBank.d132.s15|44-46|has|O
DDI-DrugBank.d132.s15|48-50|not|O
DDI-DrugBank.d132.s15|52-55|been|O
DDI-DrugBank.d132.s15|57-67|established|O
DDI-DrugBank.d132.s15|68-68|.|O
DDI-DrugBank.d132.s16|0-11|Methotrexate|drug
DDI-DrugBank.d132.s16|12-12|:|O
DDI-DrugBank.d132.s16|14-20|Caution|O
DDI-DrugBank.d132.s16|22-27|should|O
DDI-DrugBank.d132.s16|29-30|be|O
DDI-DrugBank.d132.s16|32-35|used|O
DDI-DrugBank.d132.s16|37-38|if|O
DDI-DrugBank.d132.s16|40-49|diflunisal|drug
DDI-DrugBank.d132.s16|51-52|is|O
DDI-DrugBank.d132.s16|54-65|administered|O
DDI-DrugBank.d132.s16|67-79|concomitantly|O
DDI-DrugBank.d132.s16|81-84|with|O
DDI-DrugBank.d132.s16|86-97|methotrexate|drug
DDI-DrugBank.d132.s16|98-98|.|O
DDI-DrugBank.d132.s17|0-35|Nonsteroidal anti-inflammatory drugs|group
DDI-DrugBank.d132.s17|37-40|have|O
DDI-DrugBank.d132.s17|42-45|been|O
DDI-DrugBank.d132.s17|47-54|reported|O
DDI-DrugBank.d132.s17|56-57|to|O
DDI-DrugBank.d132.s17|59-66|decrease|O
DDI-DrugBank.d132.s17|68-70|the|O
DDI-DrugBank.d132.s17|72-78|tubular|O
DDI-DrugBank.d132.s17|80-88|secretion|O
DDI-DrugBank.d132.s17|90-91|of|O
DDI-DrugBank.d132.s17|93-104|methotrexate|drug
DDI-DrugBank.d132.s17|106-108|and|O
DDI-DrugBank.d132.s17|110-111|to|O
DDI-DrugBank.d132.s17|113-122|potentiate|O
DDI-DrugBank.d132.s17|124-126|its|O
DDI-DrugBank.d132.s17|128-135|toxicity|O
DDI-DrugBank.d132.s17|136-136|.|O
DDI-DrugBank.d132.s18|0-11|Cyclosporine|drug
DDI-DrugBank.d132.s18|12-12|:|O
DDI-DrugBank.d132.s18|14-27|Administration|O
DDI-DrugBank.d132.s18|29-30|of|O
DDI-DrugBank.d132.s18|32-66|nonsteroial anti-inflammatory drugs|group
DDI-DrugBank.d132.s18|68-80|concomitantly|O
DDI-DrugBank.d132.s18|82-85|with|O
DDI-DrugBank.d132.s18|87-98|cyclosporine|drug
DDI-DrugBank.d132.s18|100-102|has|O
DDI-DrugBank.d132.s18|104-107|been|O
DDI-DrugBank.d132.s18|109-118|associated|O
DDI-DrugBank.d132.s18|120-123|with|O
DDI-DrugBank.d132.s18|125-126|an|O
DDI-DrugBank.d132.s18|128-135|increase|O
DDI-DrugBank.d132.s18|137-138|in|O
DDI-DrugBank.d132.s18|140-159|cyclosporine-induced|drug
DDI-DrugBank.d132.s18|161-168|toxicity|O
DDI-DrugBank.d132.s18|169-169|,|O
DDI-DrugBank.d132.s18|171-178|possibly|O
DDI-DrugBank.d132.s18|180-182|due|O
DDI-DrugBank.d132.s18|184-185|to|O
DDI-DrugBank.d132.s18|187-195|decreased|O
DDI-DrugBank.d132.s18|197-205|synthesis|O
DDI-DrugBank.d132.s18|207-208|of|O
DDI-DrugBank.d132.s18|210-214|renal|O
DDI-DrugBank.d132.s18|216-227|prostacyclin|O
DDI-DrugBank.d132.s18|228-228|.|O
DDI-DrugBank.d132.s19|0-5|NSAIDs|group
DDI-DrugBank.d132.s19|7-12|should|O
DDI-DrugBank.d132.s19|14-15|be|O
DDI-DrugBank.d132.s19|17-20|used|O
DDI-DrugBank.d132.s19|22-25|with|O
DDI-DrugBank.d132.s19|27-33|caution|O
DDI-DrugBank.d132.s19|35-36|in|O
DDI-DrugBank.d132.s19|38-45|patients|O
DDI-DrugBank.d132.s19|47-52|taking|O
DDI-DrugBank.d132.s19|54-65|cyclosporine|drug
DDI-DrugBank.d132.s19|66-66|,|O
DDI-DrugBank.d132.s19|68-70|and|O
DDI-DrugBank.d132.s19|72-76|renal|O
DDI-DrugBank.d132.s19|78-85|function|O
DDI-DrugBank.d132.s19|87-92|should|O
DDI-DrugBank.d132.s19|94-95|be|O
DDI-DrugBank.d132.s19|97-105|carefully|O
DDI-DrugBank.d132.s19|107-115|monitored|O
DDI-DrugBank.d132.s19|116-116|.|O
DDI-DrugBank.d132.s20|0-35|Nonsteroidal Anti-Inflammatory Drugs|group
DDI-DrugBank.d132.s20|36-36|:|O
DDI-DrugBank.d132.s20|38-40|The|O
DDI-DrugBank.d132.s20|42-55|administration|O
DDI-DrugBank.d132.s20|57-58|of|O
DDI-DrugBank.d132.s20|60-69|diflunisal|drug
DDI-DrugBank.d132.s20|71-72|to|O
DDI-DrugBank.d132.s20|74-79|normal|O
DDI-DrugBank.d132.s20|81-90|volunteers|O
DDI-DrugBank.d132.s20|92-100|receiving|O
DDI-DrugBank.d132.s20|102-113|indomethacin|drug
DDI-DrugBank.d132.s20|115-123|decreased|O
DDI-DrugBank.d132.s20|125-127|the|O
DDI-DrugBank.d132.s20|129-133|renal|O
DDI-DrugBank.d132.s20|135-143|clearance|O
DDI-DrugBank.d132.s20|145-147|and|O
DDI-DrugBank.d132.s20|149-161|significantly|O
DDI-DrugBank.d132.s20|163-171|increased|O
DDI-DrugBank.d132.s20|173-175|the|O
DDI-DrugBank.d132.s20|177-182|plasma|O
DDI-DrugBank.d132.s20|184-189|levels|O
DDI-DrugBank.d132.s20|191-192|of|O
DDI-DrugBank.d132.s20|194-205|indomethacin|drug
DDI-DrugBank.d132.s20|206-206|.|O
DDI-DrugBank.d132.s21|0-1|In|O
DDI-DrugBank.d132.s21|3-6|some|O
DDI-DrugBank.d132.s21|8-15|patients|O
DDI-DrugBank.d132.s21|17-19|the|O
DDI-DrugBank.d132.s21|21-28|combined|O
DDI-DrugBank.d132.s21|30-32|use|O
DDI-DrugBank.d132.s21|34-35|of|O
DDI-DrugBank.d132.s21|37-48|indomethacin|drug
DDI-DrugBank.d132.s21|50-52|and|O
DDI-DrugBank.d132.s21|54-63|diflunisal|drug
DDI-DrugBank.d132.s21|65-67|has|O
DDI-DrugBank.d132.s21|69-72|been|O
DDI-DrugBank.d132.s21|74-83|associated|O
DDI-DrugBank.d132.s21|85-88|with|O
DDI-DrugBank.d132.s21|90-94|fatal|O
DDI-DrugBank.d132.s21|96-111|gastrointestinal|O
DDI-DrugBank.d132.s21|113-122|hemorrhage|O
DDI-DrugBank.d132.s21|123-123|.|O
DDI-DrugBank.d132.s22|0-8|Therefore|O
DDI-DrugBank.d132.s22|9-9|,|O
DDI-DrugBank.d132.s22|11-22|indomethacin|drug
DDI-DrugBank.d132.s22|24-26|and|O
DDI-DrugBank.d132.s22|28-37|diflunisal|drug
DDI-DrugBank.d132.s22|39-44|should|O
DDI-DrugBank.d132.s22|46-48|not|O
DDI-DrugBank.d132.s22|50-51|be|O
DDI-DrugBank.d132.s22|53-56|used|O
DDI-DrugBank.d132.s22|58-70|concomitantly|O
DDI-DrugBank.d132.s22|71-71|.|O
DDI-DrugBank.d132.s23|0-2|The|O
DDI-DrugBank.d132.s23|4-14|concomitant|O
DDI-DrugBank.d132.s23|16-18|use|O
DDI-DrugBank.d132.s23|20-21|of|O
DDI-DrugBank.d132.s23|23-32|diflunisal|drug
DDI-DrugBank.d132.s23|34-40|tablets|O
DDI-DrugBank.d132.s23|42-44|and|O
DDI-DrugBank.d132.s23|46-50|other|O
DDI-DrugBank.d132.s23|52-57|NSAIDs|group
DDI-DrugBank.d132.s23|59-60|is|O
DDI-DrugBank.d132.s23|62-64|not|O
DDI-DrugBank.d132.s23|66-76|recommended|O
DDI-DrugBank.d132.s23|78-80|due|O
DDI-DrugBank.d132.s23|82-83|to|O
DDI-DrugBank.d132.s23|85-87|the|O
DDI-DrugBank.d132.s23|89-97|increased|O
DDI-DrugBank.d132.s23|99-109|possibility|O
DDI-DrugBank.d132.s23|111-112|of|O
DDI-DrugBank.d132.s23|114-129|gastrointestinal|O
DDI-DrugBank.d132.s23|131-138|toxicity|O
DDI-DrugBank.d132.s23|139-139|,|O
DDI-DrugBank.d132.s23|141-144|with|O
DDI-DrugBank.d132.s23|146-151|little|O
DDI-DrugBank.d132.s23|153-154|or|O
DDI-DrugBank.d132.s23|156-157|no|O
DDI-DrugBank.d132.s23|159-166|increase|O
DDI-DrugBank.d132.s23|168-169|in|O
DDI-DrugBank.d132.s23|171-178|efficacy|O
DDI-DrugBank.d132.s23|179-179|.|O
DDI-DrugBank.d132.s24|0-2|The|O
DDI-DrugBank.d132.s24|4-12|following|O
DDI-DrugBank.d132.s24|14-24|information|O
DDI-DrugBank.d132.s24|26-28|was|O
DDI-DrugBank.d132.s24|30-37|obtained|O
DDI-DrugBank.d132.s24|39-42|from|O
DDI-DrugBank.d132.s24|44-50|studies|O
DDI-DrugBank.d132.s24|52-53|in|O
DDI-DrugBank.d132.s24|55-60|normal|O
DDI-DrugBank.d132.s24|62-71|volunteers|O
DDI-DrugBank.d132.s24|72-72|.|O
DDI-DrugBank.d132.s25|0-6|Aspirin|brand
DDI-DrugBank.d132.s25|7-7|:|O
DDI-DrugBank.d132.s25|9-10|In|O
DDI-DrugBank.d132.s25|12-17|normal|O
DDI-DrugBank.d132.s25|19-28|volunteers|O
DDI-DrugBank.d132.s25|29-29|,|O
DDI-DrugBank.d132.s25|31-31|a|O
DDI-DrugBank.d132.s25|33-37|small|O
DDI-DrugBank.d132.s25|39-46|decrease|O
DDI-DrugBank.d132.s25|48-49|in|O
DDI-DrugBank.d132.s25|51-60|diflunisal|drug
DDI-DrugBank.d132.s25|62-67|levels|O
DDI-DrugBank.d132.s25|69-71|was|O
DDI-DrugBank.d132.s25|73-80|observed|O
DDI-DrugBank.d132.s25|82-85|when|O
DDI-DrugBank.d132.s25|87-94|multiple|O
DDI-DrugBank.d132.s25|96-100|doses|O
DDI-DrugBank.d132.s25|102-103|of|O
DDI-DrugBank.d132.s25|105-114|diflunisal|drug
DDI-DrugBank.d132.s25|116-118|and|O
DDI-DrugBank.d132.s25|120-126|aspirin|brand
DDI-DrugBank.d132.s25|128-131|were|O
DDI-DrugBank.d132.s25|133-144|administered|O
DDI-DrugBank.d132.s25|146-158|concomitantly|O
DDI-DrugBank.d132.s25|159-159|.|O
DDI-DrugBank.d132.s26|0-7|Sulindac|drug
DDI-DrugBank.d132.s26|8-8|:|O
DDI-DrugBank.d132.s26|10-12|The|O
DDI-DrugBank.d132.s26|14-24|concomitant|O
DDI-DrugBank.d132.s26|26-39|administration|O
DDI-DrugBank.d132.s26|41-42|of|O
DDI-DrugBank.d132.s26|44-53|diflunisal|drug
DDI-DrugBank.d132.s26|55-57|and|O
DDI-DrugBank.d132.s26|59-66|sulindac|drug
DDI-DrugBank.d132.s26|68-69|in|O
DDI-DrugBank.d132.s26|71-76|normal|O
DDI-DrugBank.d132.s26|78-87|volunteers|O
DDI-DrugBank.d132.s26|89-96|resulted|O
DDI-DrugBank.d132.s26|98-99|in|O
DDI-DrugBank.d132.s26|101-108|lowering|O
DDI-DrugBank.d132.s26|110-111|of|O
DDI-DrugBank.d132.s26|113-115|the|O
DDI-DrugBank.d132.s26|117-122|plasma|O
DDI-DrugBank.d132.s26|124-129|levels|O
DDI-DrugBank.d132.s26|131-132|of|O
DDI-DrugBank.d132.s26|134-136|the|O
DDI-DrugBank.d132.s26|138-143|active|O
DDI-DrugBank.d132.s26|145-152|sulindac|O
DDI-DrugBank.d132.s26|154-160|sulfide|O
DDI-DrugBank.d132.s26|162-171|metabolite|O
DDI-DrugBank.d132.s26|173-174|by|O
DDI-DrugBank.d132.s26|176-188|approximately|O
DDI-DrugBank.d132.s26|190-198|one-third|O
DDI-DrugBank.d132.s26|199-199|.|O
DDI-DrugBank.d132.s27|0-7|Naproxen|drug
DDI-DrugBank.d132.s27|8-8|:|O
DDI-DrugBank.d132.s27|10-12|The|O
DDI-DrugBank.d132.s27|14-24|concomitant|O
DDI-DrugBank.d132.s27|26-39|administration|O
DDI-DrugBank.d132.s27|41-42|of|O
DDI-DrugBank.d132.s27|44-53|diflunisal|drug
DDI-DrugBank.d132.s27|55-57|and|O
DDI-DrugBank.d132.s27|59-66|naproxen|drug
DDI-DrugBank.d132.s27|68-69|in|O
DDI-DrugBank.d132.s27|71-76|normal|O
DDI-DrugBank.d132.s27|78-87|volunteers|O
DDI-DrugBank.d132.s27|89-91|had|O
DDI-DrugBank.d132.s27|93-94|no|O
DDI-DrugBank.d132.s27|96-101|effect|O
DDI-DrugBank.d132.s27|103-104|on|O
DDI-DrugBank.d132.s27|106-108|the|O
DDI-DrugBank.d132.s27|110-115|plasma|O
DDI-DrugBank.d132.s27|117-122|levels|O
DDI-DrugBank.d132.s27|124-125|of|O
DDI-DrugBank.d132.s27|127-134|naproxen|drug
DDI-DrugBank.d132.s27|135-135|,|O
DDI-DrugBank.d132.s27|137-139|but|O
DDI-DrugBank.d132.s27|141-153|significantly|O
DDI-DrugBank.d132.s27|155-163|decreased|O
DDI-DrugBank.d132.s27|165-167|the|O
DDI-DrugBank.d132.s27|169-175|urinary|O
DDI-DrugBank.d132.s27|177-185|excretion|O
DDI-DrugBank.d132.s27|187-188|of|O
DDI-DrugBank.d132.s27|190-197|naproxen|drug
DDI-DrugBank.d132.s27|199-201|and|O
DDI-DrugBank.d132.s27|203-205|its|O
DDI-DrugBank.d132.s27|207-217|glucuronide|O
DDI-DrugBank.d132.s27|219-228|metabolite|O
DDI-DrugBank.d132.s27|229-229|.|O
DDI-DrugBank.d132.s28|0-7|Naproxen|drug
DDI-DrugBank.d132.s28|9-11|had|O
DDI-DrugBank.d132.s28|13-14|no|O
DDI-DrugBank.d132.s28|16-21|effect|O
DDI-DrugBank.d132.s28|23-24|on|O
DDI-DrugBank.d132.s28|26-31|plasma|O
DDI-DrugBank.d132.s28|33-38|levels|O
DDI-DrugBank.d132.s28|40-41|of|O
DDI-DrugBank.d132.s28|43-52|diflunisal|drug
DDI-DrugBank.d132.s28|53-53|.|O
DDI-DrugBank.d132.s29|0-3|Drug|O
DDI-DrugBank.d132.s29|5-14|laboratory|O
DDI-DrugBank.d132.s29|16-19|Test|O
DDI-DrugBank.d132.s29|21-32|Interactions|O
DDI-DrugBank.d132.s29|34-38|Serum|O
DDI-DrugBank.d132.s29|40-49|Salicylate|O
DDI-DrugBank.d132.s29|51-56|Assays|O
DDI-DrugBank.d132.s29|57-57|:|O
DDI-DrugBank.d132.s29|59-65|Caution|O
DDI-DrugBank.d132.s29|67-72|should|O
DDI-DrugBank.d132.s29|74-75|be|O
DDI-DrugBank.d132.s29|77-80|used|O
DDI-DrugBank.d132.s29|82-83|in|O
DDI-DrugBank.d132.s29|85-96|interpreting|O
DDI-DrugBank.d132.s29|98-100|the|O
DDI-DrugBank.d132.s29|102-108|results|O
DDI-DrugBank.d132.s29|110-111|of|O
DDI-DrugBank.d132.s29|113-117|serum|O
DDI-DrugBank.d132.s29|119-128|salicylate|O
DDI-DrugBank.d132.s29|130-135|assays|O
DDI-DrugBank.d132.s29|137-140|when|O
DDI-DrugBank.d132.s29|142-151|diflunisal|drug
DDI-DrugBank.d132.s29|153-154|is|O
DDI-DrugBank.d132.s29|156-162|present|O
DDI-DrugBank.d132.s29|163-163|.|O
DDI-DrugBank.d132.s30|0-9|Salicylate|group
DDI-DrugBank.d132.s30|11-16|levels|O
DDI-DrugBank.d132.s30|18-21|have|O
DDI-DrugBank.d132.s30|23-26|been|O
DDI-DrugBank.d132.s30|28-32|found|O
DDI-DrugBank.d132.s30|34-35|to|O
DDI-DrugBank.d132.s30|37-38|be|O
DDI-DrugBank.d132.s30|40-46|falsely|O
DDI-DrugBank.d132.s30|48-55|elevated|O
DDI-DrugBank.d132.s30|57-60|with|O
DDI-DrugBank.d132.s30|62-65|some|O
DDI-DrugBank.d132.s30|67-71|assay|O
DDI-DrugBank.d132.s30|73-79|methods|O
DDI-DrugBank.d132.s30|80-80|.|O
DDI-DrugBank.d148.s0|0-6|Heparin|drug
DDI-DrugBank.d148.s0|7-7|:|O
DDI-DrugBank.d148.s0|9-13|Since|O
DDI-DrugBank.d148.s0|15-21|heparin|drug
DDI-DrugBank.d148.s0|23-24|is|O
DDI-DrugBank.d148.s0|26-40|contraindicated|O
DDI-DrugBank.d148.s0|42-43|in|O
DDI-DrugBank.d148.s0|45-52|patients|O
DDI-DrugBank.d148.s0|54-57|with|O
DDI-DrugBank.d148.s0|59-73|heparin-induced|drug
DDI-DrugBank.d148.s0|75-90|thrombocytopenia|O
DDI-DrugBank.d148.s0|91-91|,|O
DDI-DrugBank.d148.s0|93-95|the|O
DDI-DrugBank.d148.s0|97-113|co-administration|O
DDI-DrugBank.d148.s0|115-116|of|O
DDI-DrugBank.d148.s0|118-127|Argatroban|drug
DDI-DrugBank.d148.s0|129-131|and|O
DDI-DrugBank.d148.s0|133-139|heparin|drug
DDI-DrugBank.d148.s0|141-142|is|O
DDI-DrugBank.d148.s0|144-151|unlikely|O
DDI-DrugBank.d148.s0|153-155|for|O
DDI-DrugBank.d148.s0|157-160|this|O
DDI-DrugBank.d148.s0|162-171|indication|O
DDI-DrugBank.d148.s0|172-172|.|O
DDI-DrugBank.d148.s1|0-6|However|O
DDI-DrugBank.d148.s1|7-7|,|O
DDI-DrugBank.d148.s1|9-10|if|O
DDI-DrugBank.d148.s1|12-21|Argatroban|drug
DDI-DrugBank.d148.s1|23-24|is|O
DDI-DrugBank.d148.s1|26-27|to|O
DDI-DrugBank.d148.s1|29-30|be|O
DDI-DrugBank.d148.s1|32-40|initiated|O
DDI-DrugBank.d148.s1|42-46|after|O
DDI-DrugBank.d148.s1|48-56|cessation|O
DDI-DrugBank.d148.s1|58-59|of|O
DDI-DrugBank.d148.s1|61-67|heparin|drug
DDI-DrugBank.d148.s1|69-75|therapy|O
DDI-DrugBank.d148.s1|76-76|,|O
DDI-DrugBank.d148.s1|78-82|allow|O
DDI-DrugBank.d148.s1|84-93|sufficient|O
DDI-DrugBank.d148.s1|95-98|time|O
DDI-DrugBank.d148.s1|100-102|for|O
DDI-DrugBank.d148.s1|104-111|heparins|O
DDI-DrugBank.d148.s1|113-118|effect|O
DDI-DrugBank.d148.s1|120-121|on|O
DDI-DrugBank.d148.s1|123-125|the|O
DDI-DrugBank.d148.s1|127-130|aPTT|O
DDI-DrugBank.d148.s1|132-133|to|O
DDI-DrugBank.d148.s1|135-142|decrease|O
DDI-DrugBank.d148.s1|144-148|prior|O
DDI-DrugBank.d148.s1|150-151|to|O
DDI-DrugBank.d148.s1|153-162|initiation|O
DDI-DrugBank.d148.s1|164-165|of|O
DDI-DrugBank.d148.s1|167-176|Argatroban|drug
DDI-DrugBank.d148.s1|178-184|therapy|O
DDI-DrugBank.d148.s1|185-185|.|O
DDI-DrugBank.d148.s2|0-20|Aspirin/Acetaminophen|brand
DDI-DrugBank.d148.s2|21-21|:|O
DDI-DrugBank.d148.s2|23-37|Pharmacokinetic|O
DDI-DrugBank.d148.s2|39-40|or|O
DDI-DrugBank.d148.s2|42-56|pharmacodynamic|O
DDI-DrugBank.d148.s2|58-66|drug-drug|O
DDI-DrugBank.d148.s2|68-79|interactions|O
DDI-DrugBank.d148.s2|81-84|have|O
DDI-DrugBank.d148.s2|86-88|not|O
DDI-DrugBank.d148.s2|90-93|been|O
DDI-DrugBank.d148.s2|95-106|demonstrated|O
DDI-DrugBank.d148.s2|108-114|between|O
DDI-DrugBank.d148.s2|116-125|Argatroban|drug
DDI-DrugBank.d148.s2|127-129|and|O
DDI-DrugBank.d148.s2|131-143|concomitantly|O
DDI-DrugBank.d148.s2|145-156|administered|O
DDI-DrugBank.d148.s2|158-164|aspirin|brand
DDI-DrugBank.d148.s2|166-166|(|O
DDI-DrugBank.d148.s2|167-171|162.5|O
DDI-DrugBank.d148.s2|173-174|mg|O
DDI-DrugBank.d148.s2|176-181|orally|O
DDI-DrugBank.d148.s2|183-187|given|O
DDI-DrugBank.d148.s2|189-190|26|O
DDI-DrugBank.d148.s2|192-194|and|O
DDI-DrugBank.d148.s2|196-196|2|O
DDI-DrugBank.d148.s2|198-202|hours|O
DDI-DrugBank.d148.s2|204-208|prior|O
DDI-DrugBank.d148.s2|210-211|to|O
DDI-DrugBank.d148.s2|213-222|initiation|O
DDI-DrugBank.d148.s2|224-225|of|O
DDI-DrugBank.d148.s2|227-236|Argatroban|drug
DDI-DrugBank.d148.s2|238-238|1|O
DDI-DrugBank.d148.s2|241-249|g/kg/min.|O
DDI-DrugBank.d148.s2|251-254|over|O
DDI-DrugBank.d148.s2|256-256|4|O
DDI-DrugBank.d148.s2|258-262|hours|O
DDI-DrugBank.d148.s2|263-263|)|O
DDI-DrugBank.d148.s2|265-266|or|O
DDI-DrugBank.d148.s2|268-280|acetaminophen|drug
DDI-DrugBank.d148.s2|282-282|(|O
DDI-DrugBank.d148.s2|283-286|1000|O
DDI-DrugBank.d148.s2|288-289|mg|O
DDI-DrugBank.d148.s2|291-296|orally|O
DDI-DrugBank.d148.s2|298-302|given|O
DDI-DrugBank.d148.s2|304-305|12|O
DDI-DrugBank.d148.s2|306-306|,|O
DDI-DrugBank.d148.s2|308-308|6|O
DDI-DrugBank.d148.s2|310-312|and|O
DDI-DrugBank.d148.s2|314-314|0|O
DDI-DrugBank.d148.s2|316-320|hours|O
DDI-DrugBank.d148.s2|322-326|prior|O
DDI-DrugBank.d148.s2|328-329|to|O
DDI-DrugBank.d148.s2|330-330|,|O
DDI-DrugBank.d148.s2|332-334|and|O
DDI-DrugBank.d148.s2|336-336|6|O
DDI-DrugBank.d148.s2|338-340|and|O
DDI-DrugBank.d148.s2|342-343|12|O
DDI-DrugBank.d148.s2|345-349|hours|O
DDI-DrugBank.d148.s2|351-360|subsequent|O
DDI-DrugBank.d148.s2|362-363|to|O
DDI-DrugBank.d148.s2|364-364|,|O
DDI-DrugBank.d148.s2|366-375|initiation|O
DDI-DrugBank.d148.s2|377-378|of|O
DDI-DrugBank.d148.s2|380-389|Argatroban|drug
DDI-DrugBank.d148.s2|391-393|1.5|O
DDI-DrugBank.d148.s2|396-404|g/kg/min.|O
DDI-DrugBank.d148.s2|406-409|over|O
DDI-DrugBank.d148.s2|411-412|18|O
DDI-DrugBank.d148.s2|414-418|hours|O
DDI-DrugBank.d148.s2|419-419|)|O
DDI-DrugBank.d148.s2|420-420|.|O
DDI-DrugBank.d148.s3|0-3|Oral|O
DDI-DrugBank.d148.s3|5-24|anticoagulant agents|group
DDI-DrugBank.d148.s3|25-25|:|O
DDI-DrugBank.d148.s3|27-41|Pharmacokinetic|O
DDI-DrugBank.d148.s3|43-51|drug-drug|O
DDI-DrugBank.d148.s3|53-64|interactions|O
DDI-DrugBank.d148.s3|66-72|between|O
DDI-DrugBank.d148.s3|74-83|Argatroban|drug
DDI-DrugBank.d148.s3|85-87|and|O
DDI-DrugBank.d148.s3|89-96|warfarin|drug
DDI-DrugBank.d148.s3|98-98|(|O
DDI-DrugBank.d148.s3|99-101|7.5|O
DDI-DrugBank.d148.s3|103-104|mg|O
DDI-DrugBank.d148.s3|106-111|single|O
DDI-DrugBank.d148.s3|113-116|oral|O
DDI-DrugBank.d148.s3|118-121|dose|O
DDI-DrugBank.d148.s3|122-122|)|O
DDI-DrugBank.d148.s3|124-127|have|O
DDI-DrugBank.d148.s3|129-131|not|O
DDI-DrugBank.d148.s3|133-136|been|O
DDI-DrugBank.d148.s3|138-149|demonstrated|O
DDI-DrugBank.d148.s3|150-150|.|O
DDI-DrugBank.d148.s4|0-6|However|O
DDI-DrugBank.d148.s4|7-7|,|O
DDI-DrugBank.d148.s4|9-11|the|O
DDI-DrugBank.d148.s4|13-23|concomitant|O
DDI-DrugBank.d148.s4|25-27|use|O
DDI-DrugBank.d148.s4|29-30|of|O
DDI-DrugBank.d148.s4|32-41|Argatroban|drug
DDI-DrugBank.d148.s4|43-45|and|O
DDI-DrugBank.d148.s4|47-54|warfarin|drug
DDI-DrugBank.d148.s4|56-56|(|O
DDI-DrugBank.d148.s4|57-61|5-7.5|O
DDI-DrugBank.d148.s4|63-64|mg|O
DDI-DrugBank.d148.s4|66-72|initial|O
DDI-DrugBank.d148.s4|74-77|oral|O
DDI-DrugBank.d148.s4|79-82|dose|O
DDI-DrugBank.d148.s4|84-91|followed|O
DDI-DrugBank.d148.s4|93-94|by|O
DDI-DrugBank.d148.s4|96-100|2.5-6|O
DDI-DrugBank.d148.s4|102-107|mg/day|O
DDI-DrugBank.d148.s4|109-114|orally|O
DDI-DrugBank.d148.s4|116-118|for|O
DDI-DrugBank.d148.s4|120-123|6-10|O
DDI-DrugBank.d148.s4|125-128|days|O
DDI-DrugBank.d148.s4|129-129|)|O
DDI-DrugBank.d148.s4|131-137|results|O
DDI-DrugBank.d148.s4|139-140|in|O
DDI-DrugBank.d148.s4|142-153|prolongation|O
DDI-DrugBank.d148.s4|155-156|of|O
DDI-DrugBank.d148.s4|158-160|the|O
DDI-DrugBank.d148.s4|162-172|prothrombin|O
DDI-DrugBank.d148.s4|174-177|time|O
DDI-DrugBank.d148.s4|179-179|(|O
DDI-DrugBank.d148.s4|180-181|PT|O
DDI-DrugBank.d148.s4|182-182|)|O
DDI-DrugBank.d148.s4|184-186|and|O
DDI-DrugBank.d148.s4|188-200|International|O
DDI-DrugBank.d148.s4|202-211|Normalized|O
DDI-DrugBank.d148.s4|213-217|Ratio|O
DDI-DrugBank.d148.s4|219-219|(|O
DDI-DrugBank.d148.s4|220-222|INR|O
DDI-DrugBank.d148.s4|223-223|)|O
DDI-DrugBank.d148.s4|224-224|.|O
DDI-DrugBank.d148.s5|0-18|Thrombolytic agents|group
DDI-DrugBank.d148.s5|19-19|:|O
DDI-DrugBank.d148.s5|21-23|The|O
DDI-DrugBank.d148.s5|25-30|safety|O
DDI-DrugBank.d148.s5|32-34|and|O
DDI-DrugBank.d148.s5|36-48|effectiveness|O
DDI-DrugBank.d148.s5|50-51|of|O
DDI-DrugBank.d148.s5|53-62|Argatroban|drug
DDI-DrugBank.d148.s5|64-67|with|O
DDI-DrugBank.d148.s5|69-87|thrombolytic agents|group
DDI-DrugBank.d148.s5|89-92|have|O
DDI-DrugBank.d148.s5|94-96|not|O
DDI-DrugBank.d148.s5|98-101|been|O
DDI-DrugBank.d148.s5|103-113|established|O
DDI-DrugBank.d148.s5|114-114|.|O
DDI-DrugBank.d148.s6|0-16|Co-administration|O
DDI-DrugBank.d148.s6|17-17|:|O
DDI-DrugBank.d148.s6|19-29|Concomitant|O
DDI-DrugBank.d148.s6|31-33|use|O
DDI-DrugBank.d148.s6|35-36|of|O
DDI-DrugBank.d148.s6|38-47|Argatroban|drug
DDI-DrugBank.d148.s6|49-52|with|O
DDI-DrugBank.d148.s6|54-72|antiplatelet agents|group
DDI-DrugBank.d148.s6|73-73|,|O
DDI-DrugBank.d148.s6|75-87|thrombolytics|group
DDI-DrugBank.d148.s6|88-88|,|O
DDI-DrugBank.d148.s6|90-92|and|O
DDI-DrugBank.d148.s6|94-98|other|O
DDI-DrugBank.d148.s6|100-113|anticoagulants|group
DDI-DrugBank.d148.s6|115-117|may|O
DDI-DrugBank.d148.s6|119-126|increase|O
DDI-DrugBank.d148.s6|128-130|the|O
DDI-DrugBank.d148.s6|132-135|risk|O
DDI-DrugBank.d148.s6|137-138|of|O
DDI-DrugBank.d148.s6|140-147|bleeding|O
DDI-DrugBank.d148.s6|148-148|.|O
DDI-DrugBank.d148.s7|0-8|Drug-drug|O
DDI-DrugBank.d148.s7|10-21|interactions|O
DDI-DrugBank.d148.s7|23-26|have|O
DDI-DrugBank.d148.s7|28-30|not|O
DDI-DrugBank.d148.s7|32-35|been|O
DDI-DrugBank.d148.s7|37-44|observed|O
DDI-DrugBank.d148.s7|46-52|between|O
DDI-DrugBank.d148.s7|54-63|Argatroban|drug
DDI-DrugBank.d148.s7|65-67|and|O
DDI-DrugBank.d148.s7|69-75|digoxin|drug
DDI-DrugBank.d148.s7|77-78|or|O
DDI-DrugBank.d148.s7|80-91|erythromycin|drug
DDI-DrugBank.d148.s7|92-92|.|O
DDI-DrugBank.d39.s0|0-6|Persons|O
DDI-DrugBank.d39.s0|8-13|taking|O
DDI-DrugBank.d39.s0|15-18|most|O
DDI-DrugBank.d39.s0|20-30|antibiotics|group
DDI-DrugBank.d39.s0|31-31|,|O
DDI-DrugBank.d39.s0|33-44|methotrexate|drug
DDI-DrugBank.d39.s0|46-48|and|O
DDI-DrugBank.d39.s0|50-62|pyrimethamine|drug
DDI-DrugBank.d39.s0|64-73|invalidate|O
DDI-DrugBank.d39.s0|75-84|folic acid|drug
DDI-DrugBank.d39.s0|86-88|and|O
DDI-DrugBank.d39.s0|90-100|vitamin B12|drug
DDI-DrugBank.d39.s0|102-111|diagnostic|O
DDI-DrugBank.d39.s0|113-117|blood|O
DDI-DrugBank.d39.s0|119-124|assays|O
DDI-DrugBank.d39.s0|125-125|.|O
DDI-DrugBank.d39.s1|0-9|Colchicine|drug
DDI-DrugBank.d39.s1|0-34|Colchicine acid|drug
DDI-DrugBank.d39.s1|36-38|and|O
DDI-DrugBank.d39.s1|40-44|heavy|O
DDI-DrugBank.d39.s1|46-52|alcohol|drug
DDI-DrugBank.d39.s1|54-59|intake|O
DDI-DrugBank.d39.s1|61-63|for|O
DDI-DrugBank.d39.s1|65-70|longer|O
DDI-DrugBank.d39.s1|72-75|than|O
DDI-DrugBank.d39.s1|77-77|2|O
DDI-DrugBank.d39.s1|79-83|weeks|O
DDI-DrugBank.d39.s1|85-87|may|O
DDI-DrugBank.d39.s1|89-95|produce|O
DDI-DrugBank.d39.s1|97-109|malabsorption|O
DDI-DrugBank.d39.s1|111-112|of|O
DDI-DrugBank.d39.s1|114-124|vitamin B12|drug
DDI-DrugBank.d39.s1|125-125|.|O
DDI-DrugBank.d236.s0|0-16|Acidifying agents|group
DDI-DrugBank.d236.s0|17-17|:|O
DDI-DrugBank.d236.s0|19-52|Gastrointestinal acidifying agents|group
DDI-DrugBank.d236.s0|54-54|(|O
DDI-DrugBank.d236.s0|55-66|guanethidine|drug
DDI-DrugBank.d236.s0|67-67|,|O
DDI-DrugBank.d236.s0|69-77|reserpine|drug
DDI-DrugBank.d236.s0|78-78|,|O
DDI-DrugBank.d236.s0|80-96|glutamic acid HCl|drug
DDI-DrugBank.d236.s0|97-97|,|O
DDI-DrugBank.d236.s0|99-111|ascorbic acid|drug
DDI-DrugBank.d236.s0|112-112|,|O
DDI-DrugBank.d236.s0|114-118|fruit|O
DDI-DrugBank.d236.s0|120-125|juices|O
DDI-DrugBank.d236.s0|126-126|,|O
DDI-DrugBank.d236.s0|128-131|etc.|O
DDI-DrugBank.d236.s0|132-132|)|O
DDI-DrugBank.d236.s0|134-138|lower|O
DDI-DrugBank.d236.s0|140-149|absorption|O
DDI-DrugBank.d236.s0|151-152|of|O
DDI-DrugBank.d236.s0|154-165|amphetamines|group
DDI-DrugBank.d236.s0|166-166|.|O
DDI-DrugBank.d236.s1|0-24|Urinary acidifying agents|group
DDI-DrugBank.d236.s1|26-26|(|O
DDI-DrugBank.d236.s1|27-43|ammonium chloride|drug
DDI-DrugBank.d236.s1|44-44|,|O
DDI-DrugBank.d236.s1|46-66|sodium acid phosphate|drug
DDI-DrugBank.d236.s1|67-67|,|O
DDI-DrugBank.d236.s1|69-72|etc.|O
DDI-DrugBank.d236.s1|73-73|)|O
DDI-DrugBank.d236.s1|75-82|increase|O
DDI-DrugBank.d236.s1|84-86|the|O
DDI-DrugBank.d236.s1|88-100|concentration|O
DDI-DrugBank.d236.s1|102-103|of|O
DDI-DrugBank.d236.s1|105-107|the|O
DDI-DrugBank.d236.s1|109-115|ionized|O
DDI-DrugBank.d236.s1|117-123|species|O
DDI-DrugBank.d236.s1|125-126|of|O
DDI-DrugBank.d236.s1|128-130|the|O
DDI-DrugBank.d236.s1|132-142|amphetamine|drug
DDI-DrugBank.d236.s1|144-151|molecule|O
DDI-DrugBank.d236.s1|152-152|,|O
DDI-DrugBank.d236.s1|154-160|thereby|O
DDI-DrugBank.d236.s1|162-171|increasing|O
DDI-DrugBank.d236.s1|173-179|urinary|O
DDI-DrugBank.d236.s1|181-189|excretion|O
DDI-DrugBank.d236.s1|190-190|.|O
DDI-DrugBank.d236.s2|0-3|Both|O
DDI-DrugBank.d236.s2|5-10|groups|O
DDI-DrugBank.d236.s2|12-13|of|O
DDI-DrugBank.d236.s2|15-20|agents|O
DDI-DrugBank.d236.s2|22-26|lower|O
DDI-DrugBank.d236.s2|28-32|blood|O
DDI-DrugBank.d236.s2|34-39|levels|O
DDI-DrugBank.d236.s2|41-43|and|O
DDI-DrugBank.d236.s2|45-52|efficacy|O
DDI-DrugBank.d236.s2|54-55|of|O
DDI-DrugBank.d236.s2|57-68|amphetamines|group
DDI-DrugBank.d236.s2|69-69|.|O
DDI-DrugBank.d236.s3|0-18|Adrenergic blockers|group
DDI-DrugBank.d236.s3|19-19|:|O
DDI-DrugBank.d236.s3|21-39|Adrenergic blockers|group
DDI-DrugBank.d236.s3|41-43|are|O
DDI-DrugBank.d236.s3|45-53|inhibited|O
DDI-DrugBank.d236.s3|55-56|by|O
DDI-DrugBank.d236.s3|58-69|amphetamines|group
DDI-DrugBank.d236.s3|70-70|.|O
DDI-DrugBank.d236.s4|0-11|Alkalinizing|O
DDI-DrugBank.d236.s4|13-18|agents|O
DDI-DrugBank.d236.s4|19-19|:|O
DDI-DrugBank.d236.s4|21-36|Gastrointestinal|O
DDI-DrugBank.d236.s4|38-49|alkalinizing|O
DDI-DrugBank.d236.s4|51-56|agents|O
DDI-DrugBank.d236.s4|58-58|(|O
DDI-DrugBank.d236.s4|59-76|sodium bicarbonate|drug
DDI-DrugBank.d236.s4|77-77|,|O
DDI-DrugBank.d236.s4|79-82|etc.|O
DDI-DrugBank.d236.s4|83-83|)|O
DDI-DrugBank.d236.s4|85-92|increase|O
DDI-DrugBank.d236.s4|94-103|absorption|O
DDI-DrugBank.d236.s4|105-106|of|O
DDI-DrugBank.d236.s4|108-119|amphetamines|drug
DDI-DrugBank.d236.s4|120-120|.|O
DDI-DrugBank.d236.s5|0-6|Urinary|O
DDI-DrugBank.d236.s5|8-19|alkalinizing|O
DDI-DrugBank.d236.s5|21-26|agents|O
DDI-DrugBank.d236.s5|28-28|(|O
DDI-DrugBank.d236.s5|29-41|acetazolamide|drug
DDI-DrugBank.d236.s5|42-42|,|O
DDI-DrugBank.d236.s5|44-47|some|O
DDI-DrugBank.d236.s5|49-57|thiazides|group
DDI-DrugBank.d236.s5|58-58|)|O
DDI-DrugBank.d236.s5|60-67|increase|O
DDI-DrugBank.d236.s5|69-71|the|O
DDI-DrugBank.d236.s5|73-85|concentration|O
DDI-DrugBank.d236.s5|87-88|of|O
DDI-DrugBank.d236.s5|90-92|the|O
DDI-DrugBank.d236.s5|94-104|non-ionized|O
DDI-DrugBank.d236.s5|106-112|species|O
DDI-DrugBank.d236.s5|114-115|of|O
DDI-DrugBank.d236.s5|117-119|the|O
DDI-DrugBank.d236.s5|121-131|amphetamine|drug
DDI-DrugBank.d236.s5|133-140|molecule|O
DDI-DrugBank.d236.s5|141-141|,|O
DDI-DrugBank.d236.s5|143-149|thereby|O
DDI-DrugBank.d236.s5|151-160|decreasing|O
DDI-DrugBank.d236.s5|162-168|urinary|O
DDI-DrugBank.d236.s5|170-178|excretion|O
DDI-DrugBank.d236.s5|179-179|.|O
DDI-DrugBank.d236.s6|0-3|Both|O
DDI-DrugBank.d236.s6|5-10|groups|O
DDI-DrugBank.d236.s6|12-13|of|O
DDI-DrugBank.d236.s6|15-20|agents|O
DDI-DrugBank.d236.s6|22-29|increase|O
DDI-DrugBank.d236.s6|31-35|blood|O
DDI-DrugBank.d236.s6|37-42|levels|O
DDI-DrugBank.d236.s6|44-46|and|O
DDI-DrugBank.d236.s6|48-56|therefore|O
DDI-DrugBank.d236.s6|58-67|potentiate|O
DDI-DrugBank.d236.s6|69-71|the|O
DDI-DrugBank.d236.s6|73-79|actions|O
DDI-DrugBank.d236.s6|81-82|of|O
DDI-DrugBank.d236.s6|84-95|amphetamines|group
DDI-DrugBank.d236.s6|96-96|.|O
DDI-DrugBank.d236.s7|0-14|Antidepressants|group
DDI-DrugBank.d236.s7|15-15|,|O
DDI-DrugBank.d236.s7|17-25|tricyclic|group
DDI-DrugBank.d236.s7|26-26|:|O
DDI-DrugBank.d236.s7|28-39|Amphetamines|group
DDI-DrugBank.d236.s7|41-43|may|O
DDI-DrugBank.d236.s7|45-51|enhance|O
DDI-DrugBank.d236.s7|53-55|the|O
DDI-DrugBank.d236.s7|57-64|activity|O
DDI-DrugBank.d236.s7|66-67|of|O
DDI-DrugBank.d236.s7|69-77|tricyclic|group
DDI-DrugBank.d236.s7|79-80|or|O
DDI-DrugBank.d236.s7|82-103|sympathomimetic agents|group
DDI-DrugBank.d236.s7|104-104|;|O
DDI-DrugBank.d236.s8|0-12|d-amphetamine|drug
DDI-DrugBank.d236.s8|14-17|with|O
DDI-DrugBank.d236.s8|19-29|desipramine|drug
DDI-DrugBank.d236.s8|31-32|or|O
DDI-DrugBank.d236.s8|34-46|protriptyline|drug
DDI-DrugBank.d236.s8|48-50|and|O
DDI-DrugBank.d236.s8|52-59|possibly|O
DDI-DrugBank.d236.s8|61-65|other|O
DDI-DrugBank.d236.s8|67-76|tricyclics|group
DDI-DrugBank.d236.s8|78-82|cause|O
DDI-DrugBank.d236.s8|84-91|striking|O
DDI-DrugBank.d236.s8|93-95|and|O
DDI-DrugBank.d236.s8|97-105|sustained|O
DDI-DrugBank.d236.s8|107-115|increases|O
DDI-DrugBank.d236.s8|117-118|in|O
DDI-DrugBank.d236.s8|120-122|the|O
DDI-DrugBank.d236.s8|124-136|concentration|O
DDI-DrugBank.d236.s8|138-139|of|O
DDI-DrugBank.d236.s8|141-153|d-amphetamine|drug
DDI-DrugBank.d236.s8|155-156|in|O
DDI-DrugBank.d236.s8|158-160|the|O
DDI-DrugBank.d236.s8|162-166|brain|O
DDI-DrugBank.d236.s8|167-167|;|O
DDI-DrugBank.d236.s9|0-13|cardiovascular|O
DDI-DrugBank.d236.s9|15-21|effects|O
DDI-DrugBank.d236.s9|23-25|can|O
DDI-DrugBank.d236.s9|27-28|be|O
DDI-DrugBank.d236.s9|30-40|potentiated|O
DDI-DrugBank.d236.s9|41-41|.|O
DDI-DrugBank.d236.s10|0-13|MAO inhibitors|group
DDI-DrugBank.d236.s10|14-14|:|O
DDI-DrugBank.d236.s10|16-35|MAOI antidepressants|group
DDI-DrugBank.d236.s10|36-36|,|O
DDI-DrugBank.d236.s10|38-39|as|O
DDI-DrugBank.d236.s10|41-44|well|O
DDI-DrugBank.d236.s10|46-47|as|O
DDI-DrugBank.d236.s10|49-49|a|O
DDI-DrugBank.d236.s10|51-60|metabolite|O
DDI-DrugBank.d236.s10|62-63|of|O
DDI-DrugBank.d236.s10|65-76|furazolidone|drug
DDI-DrugBank.d236.s10|77-77|,|O
DDI-DrugBank.d236.s10|79-82|slow|O
DDI-DrugBank.d236.s10|84-94|amphetamine|group
DDI-DrugBank.d236.s10|96-105|metabolism|O
DDI-DrugBank.d236.s10|106-106|.|O
DDI-DrugBank.d236.s11|0-3|This|O
DDI-DrugBank.d236.s11|5-11|slowing|O
DDI-DrugBank.d236.s11|13-23|potentiates|O
DDI-DrugBank.d236.s11|25-36|amphetamines|group
DDI-DrugBank.d236.s11|37-37|,|O
DDI-DrugBank.d236.s11|39-48|increasing|O
DDI-DrugBank.d236.s11|50-54|their|O
DDI-DrugBank.d236.s11|56-61|effect|O
DDI-DrugBank.d236.s11|63-64|on|O
DDI-DrugBank.d236.s11|66-68|the|O
DDI-DrugBank.d236.s11|70-76|release|O
DDI-DrugBank.d236.s11|78-79|of|O
DDI-DrugBank.d236.s11|81-94|norepinephrine|O
DDI-DrugBank.d236.s11|96-98|and|O
DDI-DrugBank.d236.s11|100-104|other|O
DDI-DrugBank.d236.s11|106-115|monoamines|O
DDI-DrugBank.d236.s11|117-120|from|O
DDI-DrugBank.d236.s11|122-131|adrenergic|O
DDI-DrugBank.d236.s11|133-137|nerve|O
DDI-DrugBank.d236.s11|139-145|endings|O
DDI-DrugBank.d236.s11|146-146|;|O
DDI-DrugBank.d236.s12|0-3|this|O
DDI-DrugBank.d236.s12|5-7|can|O
DDI-DrugBank.d236.s12|9-13|cause|O
DDI-DrugBank.d236.s12|15-23|headaches|O
DDI-DrugBank.d236.s12|25-27|and|O
DDI-DrugBank.d236.s12|29-33|other|O
DDI-DrugBank.d236.s12|35-39|signs|O
DDI-DrugBank.d236.s12|41-42|of|O
DDI-DrugBank.d236.s12|44-55|hypertensive|O
DDI-DrugBank.d236.s12|57-62|crisis|O
DDI-DrugBank.d236.s12|63-63|.|O
DDI-DrugBank.d236.s13|0-0|A|O
DDI-DrugBank.d236.s13|2-8|variety|O
DDI-DrugBank.d236.s13|10-11|of|O
DDI-DrugBank.d236.s13|13-24|neurological|O
DDI-DrugBank.d236.s13|26-30|toxic|O
DDI-DrugBank.d236.s13|32-38|effects|O
DDI-DrugBank.d236.s13|40-42|and|O
DDI-DrugBank.d236.s13|44-52|malignant|O
DDI-DrugBank.d236.s13|54-65|hyperpyrexia|O
DDI-DrugBank.d236.s13|67-69|can|O
DDI-DrugBank.d236.s13|71-75|occur|O
DDI-DrugBank.d236.s13|76-76|,|O
DDI-DrugBank.d236.s13|78-86|sometimes|O
DDI-DrugBank.d236.s13|88-91|with|O
DDI-DrugBank.d236.s13|93-97|fatal|O
DDI-DrugBank.d236.s13|99-105|results|O
DDI-DrugBank.d236.s13|106-106|.|O
DDI-DrugBank.d236.s14|0-13|Antihistamines|group
DDI-DrugBank.d236.s14|14-14|:|O
DDI-DrugBank.d236.s14|16-27|Amphetamines|group
DDI-DrugBank.d236.s14|29-31|may|O
DDI-DrugBank.d236.s14|33-42|counteract|O
DDI-DrugBank.d236.s14|44-46|the|O
DDI-DrugBank.d236.s14|48-55|sedative|O
DDI-DrugBank.d236.s14|57-62|effect|O
DDI-DrugBank.d236.s14|64-65|of|O
DDI-DrugBank.d236.s14|67-80|antihistamines|group
DDI-DrugBank.d236.s14|81-81|.|O
DDI-DrugBank.d236.s15|0-16|Antihypertensives|group
DDI-DrugBank.d236.s15|17-17|:|O
DDI-DrugBank.d236.s15|19-30|Amphetamines|group
DDI-DrugBank.d236.s15|32-34|may|O
DDI-DrugBank.d236.s15|36-45|antagonize|O
DDI-DrugBank.d236.s15|47-49|the|O
DDI-DrugBank.d236.s15|51-61|hypotensive|O
DDI-DrugBank.d236.s15|63-69|effects|O
DDI-DrugBank.d236.s15|71-72|of|O
DDI-DrugBank.d236.s15|74-90|antihypertensives|group
DDI-DrugBank.d236.s15|91-91|.|O
DDI-DrugBank.d236.s16|0-13|Chlorpromazine|drug
DDI-DrugBank.d236.s16|14-14|:|O
DDI-DrugBank.d236.s16|16-29|Chlorpromazine|drug
DDI-DrugBank.d236.s16|31-36|blocks|O
DDI-DrugBank.d236.s16|38-45|dopamine|O
DDI-DrugBank.d236.s16|47-49|and|O
DDI-DrugBank.d236.s16|51-64|norepinephrine|O
DDI-DrugBank.d236.s16|66-73|reuptake|O
DDI-DrugBank.d236.s16|74-74|,|O
DDI-DrugBank.d236.s16|76-79|thus|O
DDI-DrugBank.d236.s16|81-90|inhibiting|O
DDI-DrugBank.d236.s16|92-94|the|O
DDI-DrugBank.d236.s16|96-102|central|O
DDI-DrugBank.d236.s16|104-112|stimulant|O
DDI-DrugBank.d236.s16|114-120|effects|O
DDI-DrugBank.d236.s16|122-123|of|O
DDI-DrugBank.d236.s16|125-136|amphetamines|group
DDI-DrugBank.d236.s16|137-137|,|O
DDI-DrugBank.d236.s16|139-141|and|O
DDI-DrugBank.d236.s16|143-145|can|O
DDI-DrugBank.d236.s16|147-148|be|O
DDI-DrugBank.d236.s16|150-153|used|O
DDI-DrugBank.d236.s16|155-156|to|O
DDI-DrugBank.d236.s16|158-162|treat|O
DDI-DrugBank.d236.s16|164-174|amphetamine|group
DDI-DrugBank.d236.s16|176-184|poisoning|O
DDI-DrugBank.d236.s16|185-185|.|O
DDI-DrugBank.d236.s17|0-11|Ethosuximide|drug
DDI-DrugBank.d236.s17|12-12|:|O
DDI-DrugBank.d236.s17|14-25|Amphetamines|group
DDI-DrugBank.d236.s17|27-29|may|O
DDI-DrugBank.d236.s17|31-35|delay|O
DDI-DrugBank.d236.s17|37-46|intestinal|O
DDI-DrugBank.d236.s17|48-57|absorption|O
DDI-DrugBank.d236.s17|59-60|of|O
DDI-DrugBank.d236.s17|62-73|ethosuximide|drug
DDI-DrugBank.d236.s17|74-74|.|O
DDI-DrugBank.d236.s18|0-10|Haloperidol|drug
DDI-DrugBank.d236.s18|11-11|:|O
DDI-DrugBank.d236.s18|13-23|Haloperidol|drug
DDI-DrugBank.d236.s18|25-30|blocks|O
DDI-DrugBank.d236.s18|32-39|dopamine|O
DDI-DrugBank.d236.s18|41-43|and|O
DDI-DrugBank.d236.s18|45-58|norepinephrine|O
DDI-DrugBank.d236.s18|60-67|reuptake|O
DDI-DrugBank.d236.s18|68-68|,|O
DDI-DrugBank.d236.s18|70-73|thus|O
DDI-DrugBank.d236.s18|75-84|inhibiting|O
DDI-DrugBank.d236.s18|86-88|the|O
DDI-DrugBank.d236.s18|90-96|central|O
DDI-DrugBank.d236.s18|98-106|stimulant|O
DDI-DrugBank.d236.s18|108-114|effects|O
DDI-DrugBank.d236.s18|116-117|of|O
DDI-DrugBank.d236.s18|119-130|amphetamines|group
DDI-DrugBank.d236.s18|131-131|.|O
DDI-DrugBank.d236.s19|0-16|Lithium carbonate|drug
DDI-DrugBank.d236.s19|17-17|:|O
DDI-DrugBank.d236.s19|19-21|The|O
DDI-DrugBank.d236.s19|23-33|stimulatory|O
DDI-DrugBank.d236.s19|35-41|effects|O
DDI-DrugBank.d236.s19|43-44|of|O
DDI-DrugBank.d236.s19|46-57|amphetamines|group
DDI-DrugBank.d236.s19|59-61|may|O
DDI-DrugBank.d236.s19|63-64|be|O
DDI-DrugBank.d236.s19|66-74|inhibited|O
DDI-DrugBank.d236.s19|76-77|by|O
DDI-DrugBank.d236.s19|79-95|lithium carbonate|drug
DDI-DrugBank.d236.s19|96-96|.|O
DDI-DrugBank.d236.s20|0-9|Meperidine|drug
DDI-DrugBank.d236.s20|10-10|:|O
DDI-DrugBank.d236.s20|12-23|Amphetamines|group
DDI-DrugBank.d236.s20|25-34|potentiate|O
DDI-DrugBank.d236.s20|36-38|the|O
DDI-DrugBank.d236.s20|40-48|analgesic|O
DDI-DrugBank.d236.s20|50-55|effect|O
DDI-DrugBank.d236.s20|57-58|of|O
DDI-DrugBank.d236.s20|60-69|meperidine|drug
DDI-DrugBank.d236.s20|70-70|.|O
DDI-DrugBank.d236.s21|0-10|Methenamine|drug
DDI-DrugBank.d236.s21|12-18|therapy|O
DDI-DrugBank.d236.s21|19-19|:|O
DDI-DrugBank.d236.s21|21-27|Urinary|O
DDI-DrugBank.d236.s21|29-37|excretion|O
DDI-DrugBank.d236.s21|39-40|of|O
DDI-DrugBank.d236.s21|42-53|amphetamines|group
DDI-DrugBank.d236.s21|55-56|is|O
DDI-DrugBank.d236.s21|58-66|increased|O
DDI-DrugBank.d236.s21|67-67|,|O
DDI-DrugBank.d236.s21|69-71|and|O
DDI-DrugBank.d236.s21|73-80|efficacy|O
DDI-DrugBank.d236.s21|82-83|is|O
DDI-DrugBank.d236.s21|85-91|reduced|O
DDI-DrugBank.d236.s21|92-92|,|O
DDI-DrugBank.d236.s21|94-95|by|O
DDI-DrugBank.d236.s21|97-113|acidifying agents|group
DDI-DrugBank.d236.s21|115-118|used|O
DDI-DrugBank.d236.s21|120-121|in|O
DDI-DrugBank.d236.s21|123-133|methenamine|drug
DDI-DrugBank.d236.s21|135-141|therapy|O
DDI-DrugBank.d236.s21|142-142|.|O
DDI-DrugBank.d236.s22|0-13|Norepinephrine|drug
DDI-DrugBank.d236.s22|14-14|:|O
DDI-DrugBank.d236.s22|16-27|Amphetamines|group
DDI-DrugBank.d236.s22|29-35|enhance|O
DDI-DrugBank.d236.s22|37-39|the|O
DDI-DrugBank.d236.s22|41-50|adrenergic|O
DDI-DrugBank.d236.s22|52-57|effect|O
DDI-DrugBank.d236.s22|59-60|of|O
DDI-DrugBank.d236.s22|62-75|norepinephrine|drug
DDI-DrugBank.d236.s22|76-76|.|O
DDI-DrugBank.d236.s23|0-12|Phenobarbital|drug
DDI-DrugBank.d236.s23|13-13|:|O
DDI-DrugBank.d236.s23|15-26|Amphetamines|group
DDI-DrugBank.d236.s23|28-30|may|O
DDI-DrugBank.d236.s23|32-36|delay|O
DDI-DrugBank.d236.s23|38-47|intestinal|O
DDI-DrugBank.d236.s23|49-58|absorption|O
DDI-DrugBank.d236.s23|60-61|of|O
DDI-DrugBank.d236.s23|63-75|phenobarbital|drug
DDI-DrugBank.d236.s23|76-76|;|O
DDI-DrugBank.d236.s24|0-16|co-administration|O
DDI-DrugBank.d236.s24|18-19|of|O
DDI-DrugBank.d236.s24|21-33|phenobarbital|drug
DDI-DrugBank.d236.s24|35-37|may|O
DDI-DrugBank.d236.s24|39-45|produce|O
DDI-DrugBank.d236.s24|47-47|a|O
DDI-DrugBank.d236.s24|49-59|synergistic|O
DDI-DrugBank.d236.s24|61-74|anticonvulsant|O
DDI-DrugBank.d236.s24|76-81|action|O
DDI-DrugBank.d236.s24|82-82|.|O
DDI-DrugBank.d236.s25|0-8|Phenytoin|drug
DDI-DrugBank.d236.s25|9-9|:|O
DDI-DrugBank.d236.s25|11-22|Amphetamines|group
DDI-DrugBank.d236.s25|24-26|may|O
DDI-DrugBank.d236.s25|28-32|delay|O
DDI-DrugBank.d236.s25|34-43|intestinal|O
DDI-DrugBank.d236.s25|45-54|absorption|O
DDI-DrugBank.d236.s25|56-57|of|O
DDI-DrugBank.d236.s25|59-67|phenytoin|drug
DDI-DrugBank.d236.s25|68-68|;|O
DDI-DrugBank.d236.s26|0-16|co-administration|O
DDI-DrugBank.d236.s26|18-19|of|O
DDI-DrugBank.d236.s26|21-29|phenytoin|drug
DDI-DrugBank.d236.s26|31-33|may|O
DDI-DrugBank.d236.s26|35-41|produce|O
DDI-DrugBank.d236.s26|43-43|a|O
DDI-DrugBank.d236.s26|45-55|synergistic|O
DDI-DrugBank.d236.s26|57-70|anticonvulsant|O
DDI-DrugBank.d236.s26|72-77|action|O
DDI-DrugBank.d236.s26|78-78|.|O
DDI-DrugBank.d236.s27|0-11|Propoxyphene|drug
DDI-DrugBank.d236.s27|12-12|:|O
DDI-DrugBank.d236.s27|14-15|In|O
DDI-DrugBank.d236.s27|17-21|cases|O
DDI-DrugBank.d236.s27|23-24|of|O
DDI-DrugBank.d236.s27|26-37|propoxyphene|drug
DDI-DrugBank.d236.s27|39-48|overdosage|O
DDI-DrugBank.d236.s27|49-49|,|O
DDI-DrugBank.d236.s27|51-61|amphetamine|group
DDI-DrugBank.d236.s27|63-65|CNS|O
DDI-DrugBank.d236.s27|67-77|stimulation|O
DDI-DrugBank.d236.s27|79-80|is|O
DDI-DrugBank.d236.s27|82-92|potentiated|O
DDI-DrugBank.d236.s27|94-96|and|O
DDI-DrugBank.d236.s27|98-102|fatal|O
DDI-DrugBank.d236.s27|104-114|convulsions|O
DDI-DrugBank.d236.s27|116-118|can|O
DDI-DrugBank.d236.s27|120-124|occur|O
DDI-DrugBank.d236.s27|125-125|.|O
DDI-DrugBank.d236.s28|0-17|Veratrum alkaloids|group
DDI-DrugBank.d236.s28|18-18|:|O
DDI-DrugBank.d236.s28|20-31|Amphetamines|group
DDI-DrugBank.d236.s28|33-39|inhibit|O
DDI-DrugBank.d236.s28|41-43|the|O
DDI-DrugBank.d236.s28|45-55|hypotensive|O
DDI-DrugBank.d236.s28|57-62|effect|O
DDI-DrugBank.d236.s28|64-65|of|O
DDI-DrugBank.d236.s28|67-84|veratrum alkaloids|group
DDI-DrugBank.d236.s28|85-85|.|O
DDI-DrugBank.d236.s29|0-14|Drug/Laboratory|O
DDI-DrugBank.d236.s29|16-19|Test|O
DDI-DrugBank.d236.s29|21-32|Interactions|O
DDI-DrugBank.d236.s29|33-33|:|O
DDI-DrugBank.d236.s29|35-46|Amphetamines|group
DDI-DrugBank.d236.s29|48-50|can|O
DDI-DrugBank.d236.s29|52-56|cause|O
DDI-DrugBank.d236.s29|58-58|a|O
DDI-DrugBank.d236.s29|60-70|significant|O
DDI-DrugBank.d236.s29|72-80|elevation|O
DDI-DrugBank.d236.s29|82-83|in|O
DDI-DrugBank.d236.s29|85-90|plasma|O
DDI-DrugBank.d236.s29|92-105|corticosteroid|group
DDI-DrugBank.d236.s29|107-112|levels|O
DDI-DrugBank.d236.s29|113-113|.|O
DDI-DrugBank.d236.s30|0-3|This|O
DDI-DrugBank.d236.s30|5-12|increase|O
DDI-DrugBank.d236.s30|14-15|is|O
DDI-DrugBank.d236.s30|17-24|greatest|O
DDI-DrugBank.d236.s30|26-27|in|O
DDI-DrugBank.d236.s30|29-31|the|O
DDI-DrugBank.d236.s30|33-39|evening|O
DDI-DrugBank.d236.s30|40-40|.|O
DDI-DrugBank.d236.s31|0-11|Amphetamines|group
DDI-DrugBank.d236.s31|13-15|may|O
DDI-DrugBank.d236.s31|17-25|interfere|O
DDI-DrugBank.d236.s31|27-30|with|O
DDI-DrugBank.d236.s31|32-38|urinary|O
DDI-DrugBank.d236.s31|40-46|steroid|O
DDI-DrugBank.d236.s31|48-61|determinations|O
DDI-DrugBank.d236.s31|62-62|.|O
DDI-DrugBank.d618.s0|0-2|The|O
DDI-DrugBank.d618.s0|4-14|interaction|O
DDI-DrugBank.d618.s0|16-17|of|O
DDI-DrugBank.d618.s0|19-26|Retavase|brand
DDI-DrugBank.d618.s0|31-34|with|O
DDI-DrugBank.d618.s0|36-40|other|O
DDI-DrugBank.d618.s0|42-53|cardioactive|O
DDI-DrugBank.d618.s0|55-59|drugs|O
DDI-DrugBank.d618.s0|61-63|has|O
DDI-DrugBank.d618.s0|65-67|not|O
DDI-DrugBank.d618.s0|69-72|been|O
DDI-DrugBank.d618.s0|74-80|studied|O
DDI-DrugBank.d618.s0|81-81|.|O
DDI-DrugBank.d618.s1|0-1|In|O
DDI-DrugBank.d618.s1|3-10|addition|O
DDI-DrugBank.d618.s1|12-13|to|O
DDI-DrugBank.d618.s1|15-22|bleeding|O
DDI-DrugBank.d618.s1|24-33|associated|O
DDI-DrugBank.d618.s1|35-38|with|O
DDI-DrugBank.d618.s1|40-46|heparin|drug
DDI-DrugBank.d618.s1|48-50|and|O
DDI-DrugBank.d618.s1|52-72|vitamin K antagonists|group
DDI-DrugBank.d618.s1|73-73|,|O
DDI-DrugBank.d618.s1|75-79|drugs|O
DDI-DrugBank.d618.s1|81-84|that|O
DDI-DrugBank.d618.s1|86-90|alter|O
DDI-DrugBank.d618.s1|92-99|platelet|O
DDI-DrugBank.d618.s1|101-108|function|O
DDI-DrugBank.d618.s1|110-110|(|O
DDI-DrugBank.d618.s1|111-114|such|O
DDI-DrugBank.d618.s1|116-117|as|O
DDI-DrugBank.d618.s1|119-125|aspirin|brand
DDI-DrugBank.d618.s1|126-126|,|O
DDI-DrugBank.d618.s1|128-139|dipyridamole|drug
DDI-DrugBank.d618.s1|140-140|,|O
DDI-DrugBank.d618.s1|142-144|and|O
DDI-DrugBank.d618.s1|146-154|abciximab|drug
DDI-DrugBank.d618.s1|155-155|)|O
DDI-DrugBank.d618.s1|157-159|may|O
DDI-DrugBank.d618.s1|161-168|increase|O
DDI-DrugBank.d618.s1|170-172|the|O
DDI-DrugBank.d618.s1|174-177|risk|O
DDI-DrugBank.d618.s1|179-180|of|O
DDI-DrugBank.d618.s1|182-189|bleeding|O
DDI-DrugBank.d618.s1|191-192|if|O
DDI-DrugBank.d618.s1|194-205|administered|O
DDI-DrugBank.d618.s1|207-211|prior|O
DDI-DrugBank.d618.s1|213-214|to|O
DDI-DrugBank.d618.s1|216-217|or|O
DDI-DrugBank.d618.s1|219-223|after|O
DDI-DrugBank.d618.s1|225-232|Retavase|brand
DDI-DrugBank.d618.s1|237-243|therapy|O
DDI-DrugBank.d618.s1|244-244|.|O
DDI-DrugBank.d468.s0|0-12|Beta-Blockers|group
DDI-DrugBank.d468.s0|13-13|:|O
DDI-DrugBank.d468.s0|15-16|In|O
DDI-DrugBank.d468.s0|18-27|controlled|O
DDI-DrugBank.d468.s0|29-36|clinical|O
DDI-DrugBank.d468.s0|38-44|studies|O
DDI-DrugBank.d468.s0|45-45|,|O
DDI-DrugBank.d468.s0|47-79|adrenergic beta-receptor blockers|group
DDI-DrugBank.d468.s0|81-84|have|O
DDI-DrugBank.d468.s0|86-89|been|O
DDI-DrugBank.d468.s0|91-100|frequently|O
DDI-DrugBank.d468.s0|102-113|administered|O
DDI-DrugBank.d468.s0|115-127|concomitantly|O
DDI-DrugBank.d468.s0|129-132|with|O
DDI-DrugBank.d468.s0|134-148|nicardipine HCl|drug
DDI-DrugBank.d468.s0|149-149|.|O
DDI-DrugBank.d468.s1|0-2|The|O
DDI-DrugBank.d468.s1|4-14|combination|O
DDI-DrugBank.d468.s1|16-17|is|O
DDI-DrugBank.d468.s1|19-22|well|O
DDI-DrugBank.d468.s1|24-32|tolerated|O
DDI-DrugBank.d468.s1|33-33|.|O
DDI-DrugBank.d468.s2|0-9|Cimetidine|drug
DDI-DrugBank.d468.s2|10-10|:|O
DDI-DrugBank.d468.s2|12-21|Cimetidine|drug
DDI-DrugBank.d468.s2|23-31|increases|O
DDI-DrugBank.d468.s2|33-47|nicardipine HCl|drug
DDI-DrugBank.d468.s2|49-54|plasma|O
DDI-DrugBank.d468.s2|56-61|levels|O
DDI-DrugBank.d468.s2|62-62|.|O
DDI-DrugBank.d468.s3|0-7|Patients|O
DDI-DrugBank.d468.s3|9-17|receiving|O
DDI-DrugBank.d468.s3|19-21|the|O
DDI-DrugBank.d468.s3|23-25|two|O
DDI-DrugBank.d468.s3|27-31|drugs|O
DDI-DrugBank.d468.s3|33-45|concomitantly|O
DDI-DrugBank.d468.s3|47-52|should|O
DDI-DrugBank.d468.s3|54-55|be|O
DDI-DrugBank.d468.s3|57-65|carefully|O
DDI-DrugBank.d468.s3|67-75|monitored|O
DDI-DrugBank.d468.s3|76-76|.|O
DDI-DrugBank.d468.s4|0-6|Digoxin|drug
DDI-DrugBank.d468.s4|7-7|:|O
DDI-DrugBank.d468.s4|9-12|Some|O
DDI-DrugBank.d468.s4|14-29|calcium blockers|group
DDI-DrugBank.d468.s4|31-33|may|O
DDI-DrugBank.d468.s4|35-42|increase|O
DDI-DrugBank.d468.s4|44-46|the|O
DDI-DrugBank.d468.s4|48-60|concentration|O
DDI-DrugBank.d468.s4|62-63|of|O
DDI-DrugBank.d468.s4|65-86|digitalis preparations|group
DDI-DrugBank.d468.s4|88-89|in|O
DDI-DrugBank.d468.s4|91-93|the|O
DDI-DrugBank.d468.s4|95-99|blood|O
DDI-DrugBank.d468.s4|100-100|.|O
DDI-DrugBank.d468.s5|0-14|Nicardipine HCl|drug
DDI-DrugBank.d468.s5|16-22|usually|O
DDI-DrugBank.d468.s5|24-27|does|O
DDI-DrugBank.d468.s5|29-31|not|O
DDI-DrugBank.d468.s5|33-37|alter|O
DDI-DrugBank.d468.s5|39-41|the|O
DDI-DrugBank.d468.s5|43-48|plasma|O
DDI-DrugBank.d468.s5|50-55|levels|O
DDI-DrugBank.d468.s5|57-58|of|O
DDI-DrugBank.d468.s5|60-66|digoxin|drug
DDI-DrugBank.d468.s5|67-67|,|O
DDI-DrugBank.d468.s5|69-75|however|O
DDI-DrugBank.d468.s5|76-76|,|O
DDI-DrugBank.d468.s5|78-82|serum|O
DDI-DrugBank.d468.s5|84-90|digoxin|drug
DDI-DrugBank.d468.s5|92-97|levels|O
DDI-DrugBank.d468.s5|99-104|should|O
DDI-DrugBank.d468.s5|106-107|be|O
DDI-DrugBank.d468.s5|109-117|evaluated|O
DDI-DrugBank.d468.s5|119-123|after|O
DDI-DrugBank.d468.s5|125-135|concomitant|O
DDI-DrugBank.d468.s5|137-143|therapy|O
DDI-DrugBank.d468.s5|145-148|with|O
DDI-DrugBank.d468.s5|150-164|nicardipine HCl|drug
DDI-DrugBank.d468.s5|166-167|is|O
DDI-DrugBank.d468.s5|169-177|initiated|O
DDI-DrugBank.d468.s5|178-178|.|O
DDI-DrugBank.d468.s6|0-5|Maalox|brand
DDI-DrugBank.d468.s6|7-7|*|O
DDI-DrugBank.d468.s6|9-24|Coadministration|O
DDI-DrugBank.d468.s6|26-27|of|O
DDI-DrugBank.d468.s6|29-37|Maalox TC|brand
DDI-DrugBank.d468.s6|39-41|had|O
DDI-DrugBank.d468.s6|43-44|no|O
DDI-DrugBank.d468.s6|46-51|effect|O
DDI-DrugBank.d468.s6|53-54|on|O
DDI-DrugBank.d468.s6|56-70|nicardipine HCl|drug
DDI-DrugBank.d468.s6|72-81|absorption|O
DDI-DrugBank.d468.s6|82-82|.|O
DDI-DrugBank.d468.s7|0-3|Even|O
DDI-DrugBank.d468.s7|5-10|though|O
DDI-DrugBank.d468.s7|12-15|such|O
DDI-DrugBank.d468.s7|17-28|interactions|O
DDI-DrugBank.d468.s7|30-33|were|O
DDI-DrugBank.d468.s7|35-37|not|O
DDI-DrugBank.d468.s7|39-42|seen|O
DDI-DrugBank.d468.s7|44-49|during|O
DDI-DrugBank.d468.s7|51-58|clinical|O
DDI-DrugBank.d468.s7|60-66|studies|O
DDI-DrugBank.d468.s7|68-71|with|O
DDI-DrugBank.d468.s7|73-87|nicardipine HCl|drug
DDI-DrugBank.d468.s7|88-88|,|O
DDI-DrugBank.d468.s7|90-91|an|O
DDI-DrugBank.d468.s7|93-101|increased|O
DDI-DrugBank.d468.s7|103-108|volume|O
DDI-DrugBank.d468.s7|110-111|of|O
DDI-DrugBank.d468.s7|113-123|circulating|O
DDI-DrugBank.d468.s7|125-130|fluids|O
DDI-DrugBank.d468.s7|132-136|might|O
DDI-DrugBank.d468.s7|138-139|be|O
DDI-DrugBank.d468.s7|141-148|required|O
DDI-DrugBank.d468.s7|150-151|if|O
DDI-DrugBank.d468.s7|153-156|such|O
DDI-DrugBank.d468.s7|158-159|an|O
DDI-DrugBank.d468.s7|161-171|interaction|O
DDI-DrugBank.d468.s7|173-176|were|O
DDI-DrugBank.d468.s7|178-179|to|O
DDI-DrugBank.d468.s7|181-185|occur|O
DDI-DrugBank.d468.s7|186-186|.|O
DDI-DrugBank.d468.s8|0-11|Cyclosporine|drug
DDI-DrugBank.d468.s8|12-12|:|O
DDI-DrugBank.d468.s8|14-24|Concomitant|O
DDI-DrugBank.d468.s8|26-39|administration|O
DDI-DrugBank.d468.s8|41-42|of|O
DDI-DrugBank.d468.s8|44-54|nicardipine|drug
DDI-DrugBank.d468.s8|56-58|and|O
DDI-DrugBank.d468.s8|60-71|cyclosporine|drug
DDI-DrugBank.d468.s8|73-78|levels|O
DDI-DrugBank.d468.s8|79-79|.|O
DDI-DrugBank.d468.s9|0-5|Plasma|O
DDI-DrugBank.d468.s9|7-20|concentrations|O
DDI-DrugBank.d468.s9|22-23|of|O
DDI-DrugBank.d468.s9|25-36|cyclosporine|drug
DDI-DrugBank.d468.s9|38-43|should|O
DDI-DrugBank.d468.s9|45-53|therefore|O
DDI-DrugBank.d468.s9|55-56|be|O
DDI-DrugBank.d468.s9|58-64|closely|O
DDI-DrugBank.d468.s9|66-74|monitored|O
DDI-DrugBank.d468.s9|75-75|,|O
DDI-DrugBank.d468.s9|77-79|and|O
DDI-DrugBank.d468.s9|81-83|its|O
DDI-DrugBank.d468.s9|85-90|dosage|O
DDI-DrugBank.d468.s9|92-98|reduced|O
DDI-DrugBank.d468.s9|100-110|accordingly|O
DDI-DrugBank.d468.s9|111-111|,|O
DDI-DrugBank.d468.s9|113-114|in|O
DDI-DrugBank.d468.s9|116-123|patients|O
DDI-DrugBank.d468.s9|125-131|treated|O
DDI-DrugBank.d468.s9|133-136|with|O
DDI-DrugBank.d468.s9|138-148|nicardipine|drug
DDI-DrugBank.d468.s9|149-149|.|O
DDI-DrugBank.d468.s10|0-3|When|O
DDI-DrugBank.d468.s10|5-15|therapeutic|O
DDI-DrugBank.d468.s10|17-30|concentrations|O
DDI-DrugBank.d468.s10|32-33|of|O
DDI-DrugBank.d468.s10|35-44|furosemide|drug
DDI-DrugBank.d468.s10|45-45|,|O
DDI-DrugBank.d468.s10|47-57|propranolol|drug
DDI-DrugBank.d468.s10|58-58|,|O
DDI-DrugBank.d468.s10|60-71|dipyridamole|drug
DDI-DrugBank.d468.s10|72-72|,|O
DDI-DrugBank.d468.s10|74-81|warfarin|drug
DDI-DrugBank.d468.s10|82-82|,|O
DDI-DrugBank.d468.s10|84-92|quinidine|drug
DDI-DrugBank.d468.s10|93-93|,|O
DDI-DrugBank.d468.s10|95-96|or|O
DDI-DrugBank.d468.s10|98-105|naproxen|drug
DDI-DrugBank.d468.s10|107-110|were|O
DDI-DrugBank.d468.s10|112-116|added|O
DDI-DrugBank.d468.s10|118-119|to|O
DDI-DrugBank.d468.s10|121-125|human|O
DDI-DrugBank.d468.s10|127-132|plasma|O
DDI-DrugBank.d468.s10|134-134|(|O
DDI-DrugBank.d468.s10|135-136|in|O
DDI-DrugBank.d468.s10|138-142|vitro|O
DDI-DrugBank.d468.s10|143-143|)|O
DDI-DrugBank.d468.s10|144-144|,|O
DDI-DrugBank.d468.s10|146-148|the|O
DDI-DrugBank.d468.s10|150-155|plasma|O
DDI-DrugBank.d468.s10|157-163|protein|O
DDI-DrugBank.d468.s10|165-171|binding|O
DDI-DrugBank.d468.s10|173-174|of|O
DDI-DrugBank.d468.s10|176-190|nicardipine HCl|drug
DDI-DrugBank.d468.s10|192-194|was|O
DDI-DrugBank.d468.s10|196-198|not|O
DDI-DrugBank.d468.s10|200-206|altered|O
DDI-DrugBank.d468.s10|207-207|.|O
DDI-DrugBank.d486.s0|0-1|No|O
DDI-DrugBank.d486.s0|3-6|drug|O
DDI-DrugBank.d486.s0|8-18|interaction|O
DDI-DrugBank.d486.s0|20-26|studies|O
DDI-DrugBank.d486.s0|28-31|have|O
DDI-DrugBank.d486.s0|33-36|been|O
DDI-DrugBank.d486.s0|38-46|conducted|O
DDI-DrugBank.d486.s0|48-50|for|O
DDI-DrugBank.d486.s0|52-58|COLAZAL|brand
DDI-DrugBank.d486.s0|59-59|,|O
DDI-DrugBank.d486.s0|61-67|however|O
DDI-DrugBank.d486.s0|69-71|the|O
DDI-DrugBank.d486.s0|73-75|use|O
DDI-DrugBank.d486.s0|77-78|of|O
DDI-DrugBank.d486.s0|80-85|orally|O
DDI-DrugBank.d486.s0|87-98|administered|O
DDI-DrugBank.d486.s0|100-110|antibiotics|group
DDI-DrugBank.d486.s0|112-116|could|O
DDI-DrugBank.d486.s0|117-117|,|O
DDI-DrugBank.d486.s0|119-131|theoretically|O
DDI-DrugBank.d486.s0|132-132|,|O
DDI-DrugBank.d486.s0|134-142|interfere|O
DDI-DrugBank.d486.s0|144-147|with|O
DDI-DrugBank.d486.s0|149-151|the|O
DDI-DrugBank.d486.s0|153-159|release|O
DDI-DrugBank.d486.s0|161-162|of|O
DDI-DrugBank.d486.s0|164-173|mesalamine|drug
DDI-DrugBank.d486.s0|175-176|in|O
DDI-DrugBank.d486.s0|178-180|the|O
DDI-DrugBank.d486.s0|182-186|colon|O
DDI-DrugBank.d486.s0|187-187|.|O
DDI-DrugBank.d410.s0|0-15|Vasoconstrictors|group
DDI-DrugBank.d410.s0|16-16|:|O
DDI-DrugBank.d410.s0|18-26|D.H.E. 45|brand
DDI-DrugBank.d410.s0|29-29|(|O
DDI-DrugBank.d410.s0|30-55|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s0|56-56|)|O
DDI-DrugBank.d410.s0|58-66|Injection|O
DDI-DrugBank.d410.s0|67-67|,|O
DDI-DrugBank.d410.s0|69-71|USP|O
DDI-DrugBank.d410.s0|73-78|should|O
DDI-DrugBank.d410.s0|80-82|not|O
DDI-DrugBank.d410.s0|84-85|be|O
DDI-DrugBank.d410.s0|87-90|used|O
DDI-DrugBank.d410.s0|92-95|with|O
DDI-DrugBank.d410.s0|97-123|peripheral vasoconstrictors|group
DDI-DrugBank.d410.s0|125-131|because|O
DDI-DrugBank.d410.s0|133-135|the|O
DDI-DrugBank.d410.s0|137-147|combination|O
DDI-DrugBank.d410.s0|149-151|may|O
DDI-DrugBank.d410.s0|153-157|cause|O
DDI-DrugBank.d410.s0|159-169|synergistic|O
DDI-DrugBank.d410.s0|171-179|elevation|O
DDI-DrugBank.d410.s0|181-182|of|O
DDI-DrugBank.d410.s0|184-188|blood|O
DDI-DrugBank.d410.s0|190-197|pressure|O
DDI-DrugBank.d410.s0|198-198|.|O
DDI-DrugBank.d410.s1|0-10|Sumatriptan|drug
DDI-DrugBank.d410.s1|11-11|:|O
DDI-DrugBank.d410.s1|13-23|Sumatriptan|drug
DDI-DrugBank.d410.s1|25-27|has|O
DDI-DrugBank.d410.s1|29-32|been|O
DDI-DrugBank.d410.s1|34-41|reported|O
DDI-DrugBank.d410.s1|43-44|to|O
DDI-DrugBank.d410.s1|46-50|cause|O
DDI-DrugBank.d410.s1|52-59|coronary|O
DDI-DrugBank.d410.s1|61-66|artery|O
DDI-DrugBank.d410.s1|68-76|vasospasm|O
DDI-DrugBank.d410.s1|77-77|,|O
DDI-DrugBank.d410.s1|79-81|and|O
DDI-DrugBank.d410.s1|83-85|its|O
DDI-DrugBank.d410.s1|87-92|effect|O
DDI-DrugBank.d410.s1|94-98|could|O
DDI-DrugBank.d410.s1|100-101|be|O
DDI-DrugBank.d410.s1|103-110|additive|O
DDI-DrugBank.d410.s1|112-115|with|O
DDI-DrugBank.d410.s1|117-125|D.H.E. 45|brand
DDI-DrugBank.d410.s1|128-128|(|O
DDI-DrugBank.d410.s1|129-154|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s1|155-155|)|O
DDI-DrugBank.d410.s1|157-165|Injection|O
DDI-DrugBank.d410.s1|166-166|,|O
DDI-DrugBank.d410.s1|168-170|USP|O
DDI-DrugBank.d410.s1|171-171|.|O
DDI-DrugBank.d410.s2|0-10|Sumatriptan|drug
DDI-DrugBank.d410.s2|12-14|and|O
DDI-DrugBank.d410.s2|16-24|D.H.E. 45|brand
DDI-DrugBank.d410.s2|27-27|(|O
DDI-DrugBank.d410.s2|28-53|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s2|54-54|)|O
DDI-DrugBank.d410.s2|56-64|Injection|O
DDI-DrugBank.d410.s2|65-65|,|O
DDI-DrugBank.d410.s2|67-69|USP|O
DDI-DrugBank.d410.s2|71-76|should|O
DDI-DrugBank.d410.s2|78-80|not|O
DDI-DrugBank.d410.s2|82-83|be|O
DDI-DrugBank.d410.s2|85-89|taken|O
DDI-DrugBank.d410.s2|91-96|within|O
DDI-DrugBank.d410.s2|98-99|24|O
DDI-DrugBank.d410.s2|101-105|hours|O
DDI-DrugBank.d410.s2|107-108|of|O
DDI-DrugBank.d410.s2|110-113|each|O
DDI-DrugBank.d410.s2|115-121|other..|O
DDI-DrugBank.d410.s3|0-12|Beta Blockers|group
DDI-DrugBank.d410.s3|13-13|:|O
DDI-DrugBank.d410.s3|15-22|Although|O
DDI-DrugBank.d410.s3|24-26|the|O
DDI-DrugBank.d410.s3|28-34|results|O
DDI-DrugBank.d410.s3|36-37|of|O
DDI-DrugBank.d410.s3|39-39|a|O
DDI-DrugBank.d410.s3|41-48|clinical|O
DDI-DrugBank.d410.s3|50-54|study|O
DDI-DrugBank.d410.s3|56-58|did|O
DDI-DrugBank.d410.s3|60-62|not|O
DDI-DrugBank.d410.s3|64-71|indicate|O
DDI-DrugBank.d410.s3|73-73|a|O
DDI-DrugBank.d410.s3|75-78|safe|O
DDI-DrugBank.d410.s3|80-86|problem|O
DDI-DrugBank.d410.s3|88-97|associated|O
DDI-DrugBank.d410.s3|99-102|with|O
DDI-DrugBank.d410.s3|104-106|the|O
DDI-DrugBank.d410.s3|108-121|administration|O
DDI-DrugBank.d410.s3|123-124|of|O
DDI-DrugBank.d410.s3|126-134|D.H.E. 45|brand
DDI-DrugBank.d410.s3|137-137|(|O
DDI-DrugBank.d410.s3|138-163|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s3|164-164|)|O
DDI-DrugBank.d410.s3|166-174|Injection|O
DDI-DrugBank.d410.s3|175-175|,|O
DDI-DrugBank.d410.s3|177-179|USP|O
DDI-DrugBank.d410.s3|181-182|to|O
DDI-DrugBank.d410.s3|184-191|subjects|O
DDI-DrugBank.d410.s3|193-199|already|O
DDI-DrugBank.d410.s3|201-209|receiving|O
DDI-DrugBank.d410.s3|211-221|propranolol|drug
DDI-DrugBank.d410.s3|222-222|,|O
DDI-DrugBank.d410.s3|224-228|there|O
DDI-DrugBank.d410.s3|230-233|have|O
DDI-DrugBank.d410.s3|235-238|been|O
DDI-DrugBank.d410.s3|240-246|reports|O
DDI-DrugBank.d410.s3|248-251|that|O
DDI-DrugBank.d410.s3|253-263|propranolol|drug
DDI-DrugBank.d410.s3|265-267|may|O
DDI-DrugBank.d410.s3|269-278|potentiate|O
DDI-DrugBank.d410.s3|280-282|the|O
DDI-DrugBank.d410.s3|284-299|vasoconstrictive|O
DDI-DrugBank.d410.s3|301-306|action|O
DDI-DrugBank.d410.s3|308-309|of|O
DDI-DrugBank.d410.s3|311-320|ergotamine|drug
DDI-DrugBank.d410.s3|322-323|by|O
DDI-DrugBank.d410.s3|325-332|blocking|O
DDI-DrugBank.d410.s3|334-336|the|O
DDI-DrugBank.d410.s3|338-349|vasodilating|O
DDI-DrugBank.d410.s3|351-358|property|O
DDI-DrugBank.d410.s3|360-361|of|O
DDI-DrugBank.d410.s3|363-373|epinephrine|O
DDI-DrugBank.d410.s3|374-374|.|O
DDI-DrugBank.d410.s4|0-7|Nicotine|drug
DDI-DrugBank.d410.s4|8-8|:|O
DDI-DrugBank.d410.s4|10-17|Nicotine|drug
DDI-DrugBank.d410.s4|19-21|may|O
DDI-DrugBank.d410.s4|23-29|provoke|O
DDI-DrugBank.d410.s4|31-46|vasoconstriction|O
DDI-DrugBank.d410.s4|48-49|in|O
DDI-DrugBank.d410.s4|51-54|some|O
DDI-DrugBank.d410.s4|56-63|patients|O
DDI-DrugBank.d410.s4|64-64|,|O
DDI-DrugBank.d410.s4|66-77|predisposing|O
DDI-DrugBank.d410.s4|79-80|to|O
DDI-DrugBank.d410.s4|82-82|a|O
DDI-DrugBank.d410.s4|84-90|greater|O
DDI-DrugBank.d410.s4|92-99|ischemic|O
DDI-DrugBank.d410.s4|101-108|response|O
DDI-DrugBank.d410.s4|110-111|to|O
DDI-DrugBank.d410.s4|113-117|ergot|drug
DDI-DrugBank.d410.s4|119-125|therapy|O
DDI-DrugBank.d410.s4|126-126|.|O
DDI-DrugBank.d410.s5|0-20|Macrolide Antibiotics|group
DDI-DrugBank.d410.s5|22-22|(|O
DDI-DrugBank.d410.s5|23-24|e.|O
DDI-DrugBank.d410.s5|26-27|g.|O
DDI-DrugBank.d410.s5|29-40|erythromycin|drug
DDI-DrugBank.d410.s5|42-44|and|O
DDI-DrugBank.d410.s5|46-59|troleandomycin|drug
DDI-DrugBank.d410.s5|60-60|)|O
DDI-DrugBank.d410.s5|61-61|:|O
DDI-DrugBank.d410.s5|63-68|Agents|O
DDI-DrugBank.d410.s5|70-71|of|O
DDI-DrugBank.d410.s5|73-75|the|O
DDI-DrugBank.d410.s5|77-96|ergot alkaloid class|group
DDI-DrugBank.d410.s5|97-97|,|O
DDI-DrugBank.d410.s5|99-100|of|O
DDI-DrugBank.d410.s5|102-106|which|O
DDI-DrugBank.d410.s5|108-116|D.H.E. 45|brand
DDI-DrugBank.d410.s5|119-119|(|O
DDI-DrugBank.d410.s5|120-145|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s5|146-146|)|O
DDI-DrugBank.d410.s5|148-156|Injection|O
DDI-DrugBank.d410.s5|157-157|,|O
DDI-DrugBank.d410.s5|159-161|USP|O
DDI-DrugBank.d410.s5|163-164|is|O
DDI-DrugBank.d410.s5|166-166|a|O
DDI-DrugBank.d410.s5|168-173|member|O
DDI-DrugBank.d410.s5|174-174|,|O
DDI-DrugBank.d410.s5|176-179|have|O
DDI-DrugBank.d410.s5|181-184|been|O
DDI-DrugBank.d410.s5|186-190|shown|O
DDI-DrugBank.d410.s5|192-193|to|O
DDI-DrugBank.d410.s5|195-202|interact|O
DDI-DrugBank.d410.s5|204-207|with|O
DDI-DrugBank.d410.s5|209-219|antibiotics|group
DDI-DrugBank.d410.s5|221-222|of|O
DDI-DrugBank.d410.s5|224-226|the|O
DDI-DrugBank.d410.s5|228-242|macrolide class|group
DDI-DrugBank.d410.s5|243-243|,|O
DDI-DrugBank.d410.s5|245-253|resulting|O
DDI-DrugBank.d410.s5|255-256|in|O
DDI-DrugBank.d410.s5|258-266|increased|O
DDI-DrugBank.d410.s5|268-273|plasma|O
DDI-DrugBank.d410.s5|275-280|levels|O
DDI-DrugBank.d410.s5|282-283|of|O
DDI-DrugBank.d410.s5|285-293|unchanged|O
DDI-DrugBank.d410.s5|295-303|alkaloids|O
DDI-DrugBank.d410.s5|305-307|and|O
DDI-DrugBank.d410.s5|309-318|peripheral|O
DDI-DrugBank.d410.s5|320-335|vasoconstriction|O
DDI-DrugBank.d410.s5|336-336|.|O
DDI-DrugBank.d410.s6|0-10|Vasospastic|O
DDI-DrugBank.d410.s6|12-20|reactions|O
DDI-DrugBank.d410.s6|22-25|have|O
DDI-DrugBank.d410.s6|27-30|been|O
DDI-DrugBank.d410.s6|32-39|reported|O
DDI-DrugBank.d410.s6|41-44|with|O
DDI-DrugBank.d410.s6|46-56|therapeutic|O
DDI-DrugBank.d410.s6|58-62|doses|O
DDI-DrugBank.d410.s6|64-65|of|O
DDI-DrugBank.d410.s6|67-87|ergotamine-containing|drug
DDI-DrugBank.d410.s6|89-93|drugs|O
DDI-DrugBank.d410.s6|95-98|when|O
DDI-DrugBank.d410.s6|100-114|co-administered|O
DDI-DrugBank.d410.s6|116-119|with|O
DDI-DrugBank.d410.s6|121-125|these|O
DDI-DrugBank.d410.s6|127-137|antibiotics|group
DDI-DrugBank.d410.s6|138-138|.|O
DDI-DrugBank.d410.s7|0-4|SSRIs|group
DDI-DrugBank.d410.s7|5-5|:|O
DDI-DrugBank.d410.s7|7-14|Weakness|O
DDI-DrugBank.d410.s7|16-28|hyperreflexia|O
DDI-DrugBank.d410.s7|29-29|,|O
DDI-DrugBank.d410.s7|31-33|and|O
DDI-DrugBank.d410.s7|35-48|incoordination|O
DDI-DrugBank.d410.s7|50-53|have|O
DDI-DrugBank.d410.s7|55-58|been|O
DDI-DrugBank.d410.s7|60-67|reported|O
DDI-DrugBank.d410.s7|69-74|rarely|O
DDI-DrugBank.d410.s7|76-79|when|O
DDI-DrugBank.d410.s7|81-94|5-HT1 agonists|group
DDI-DrugBank.d410.s7|96-99|have|O
DDI-DrugBank.d410.s7|101-104|been|O
DDI-DrugBank.d410.s7|106-120|co-administered|O
DDI-DrugBank.d410.s7|122-125|with|O
DDI-DrugBank.d410.s7|127-131|SSRIs|group
DDI-DrugBank.d410.s7|133-133|(|O
DDI-DrugBank.d410.s7|134-135|e.|O
DDI-DrugBank.d410.s7|137-137|g|O
DDI-DrugBank.d410.s7|138-138|.|O
DDI-DrugBank.d410.s8|0-9|fluoxetine|drug
DDI-DrugBank.d410.s8|10-10|,|O
DDI-DrugBank.d410.s8|12-22|fluvoxamine|drug
DDI-DrugBank.d410.s8|23-23|,|O
DDI-DrugBank.d410.s8|25-34|paroxetine|drug
DDI-DrugBank.d410.s8|35-35|,|O
DDI-DrugBank.d410.s8|37-46|sertraline|drug
DDI-DrugBank.d410.s8|47-47|)|O
DDI-DrugBank.d410.s8|48-48|.|O
DDI-DrugBank.d410.s9|0-4|There|O
DDI-DrugBank.d410.s9|6-9|have|O
DDI-DrugBank.d410.s9|11-14|been|O
DDI-DrugBank.d410.s9|16-17|no|O
DDI-DrugBank.d410.s9|19-26|reported|O
DDI-DrugBank.d410.s9|28-32|cases|O
DDI-DrugBank.d410.s9|34-37|from|O
DDI-DrugBank.d410.s9|39-49|spontaneous|O
DDI-DrugBank.d410.s9|51-57|reports|O
DDI-DrugBank.d410.s9|59-60|of|O
DDI-DrugBank.d410.s9|62-65|drug|O
DDI-DrugBank.d410.s9|67-77|interaction|O
DDI-DrugBank.d410.s9|79-85|between|O
DDI-DrugBank.d410.s9|87-91|SSRIs|group
DDI-DrugBank.d410.s9|93-95|and|O
DDI-DrugBank.d410.s9|97-105|D.H.E. 45|brand
DDI-DrugBank.d410.s9|108-108|(|O
DDI-DrugBank.d410.s9|109-134|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s9|135-135|)|O
DDI-DrugBank.d410.s9|137-145|Injection|O
DDI-DrugBank.d410.s9|146-146|,|O
DDI-DrugBank.d410.s9|148-150|USP|O
DDI-DrugBank.d410.s9|151-151|.|O
DDI-DrugBank.d410.s10|0-3|Oral|O
DDI-DrugBank.d410.s10|5-18|Contraceptives|group
DDI-DrugBank.d410.s10|19-19|:|O
DDI-DrugBank.d410.s10|21-23|The|O
DDI-DrugBank.d410.s10|25-30|effect|O
DDI-DrugBank.d410.s10|32-33|of|O
DDI-DrugBank.d410.s10|35-38|oral|O
DDI-DrugBank.d410.s10|40-53|contraceptives|group
DDI-DrugBank.d410.s10|55-56|on|O
DDI-DrugBank.d410.s10|58-60|the|O
DDI-DrugBank.d410.s10|62-77|pharmacokinetics|O
DDI-DrugBank.d410.s10|79-80|of|O
DDI-DrugBank.d410.s10|82-90|D.H.E. 45|brand
DDI-DrugBank.d410.s10|93-93|(|O
DDI-DrugBank.d410.s10|94-119|dihydroergotamine mesylate|drug
DDI-DrugBank.d410.s10|120-120|)|O
DDI-DrugBank.d410.s10|122-130|Injection|O
DDI-DrugBank.d410.s10|131-131|,|O
DDI-DrugBank.d410.s10|133-135|USP|O
DDI-DrugBank.d410.s10|137-139|has|O
DDI-DrugBank.d410.s10|141-143|not|O
DDI-DrugBank.d410.s10|145-148|been|O
DDI-DrugBank.d410.s10|150-156|studied|O
DDI-DrugBank.d410.s10|157-157|.|O
DDI-DrugBank.d467.s0|0-1|No|O
DDI-DrugBank.d467.s0|3-8|formal|O
DDI-DrugBank.d467.s0|10-16|studies|O
DDI-DrugBank.d467.s0|18-19|to|O
DDI-DrugBank.d467.s0|21-28|evaluate|O
DDI-DrugBank.d467.s0|30-33|drug|O
DDI-DrugBank.d467.s0|35-46|interactions|O
DDI-DrugBank.d467.s0|48-51|with|O
DDI-DrugBank.d467.s0|53-62|bexarotene|drug
DDI-DrugBank.d467.s0|64-67|have|O
DDI-DrugBank.d467.s0|69-72|been|O
DDI-DrugBank.d467.s0|74-82|conducted|O
DDI-DrugBank.d467.s0|83-83|.|O
DDI-DrugBank.d467.s1|0-9|Bexarotene|drug
DDI-DrugBank.d467.s1|11-19|oxidative|O
DDI-DrugBank.d467.s1|21-31|metabolites|O
DDI-DrugBank.d467.s1|33-38|appear|O
DDI-DrugBank.d467.s1|40-41|to|O
DDI-DrugBank.d467.s1|43-44|be|O
DDI-DrugBank.d467.s1|46-51|formed|O
DDI-DrugBank.d467.s1|53-54|by|O
DDI-DrugBank.d467.s1|56-65|cytochrome|O
DDI-DrugBank.d467.s1|67-70|P450|O
DDI-DrugBank.d467.s1|72-74|3A4|O
DDI-DrugBank.d467.s1|75-75|.|O
DDI-DrugBank.d467.s2|0-1|On|O
DDI-DrugBank.d467.s2|3-5|the|O
DDI-DrugBank.d467.s2|7-11|basis|O
DDI-DrugBank.d467.s2|13-14|of|O
DDI-DrugBank.d467.s2|16-18|the|O
DDI-DrugBank.d467.s2|20-29|metabolism|O
DDI-DrugBank.d467.s2|31-32|of|O
DDI-DrugBank.d467.s2|34-43|bexarotene|drug
DDI-DrugBank.d467.s2|45-46|by|O
DDI-DrugBank.d467.s2|48-57|cytochrome|O
DDI-DrugBank.d467.s2|59-62|P450|O
DDI-DrugBank.d467.s2|64-66|3A4|O
DDI-DrugBank.d467.s2|67-67|,|O
DDI-DrugBank.d467.s2|69-80|ketoconazole|drug
DDI-DrugBank.d467.s2|81-81|,|O
DDI-DrugBank.d467.s2|83-94|itraconazole|drug
DDI-DrugBank.d467.s2|95-95|,|O
DDI-DrugBank.d467.s2|97-108|erythromycin|drug
DDI-DrugBank.d467.s2|109-109|,|O
DDI-DrugBank.d467.s2|111-121|gemfibrozil|drug
DDI-DrugBank.d467.s2|122-122|,|O
DDI-DrugBank.d467.s2|124-133|grapefruit|O
DDI-DrugBank.d467.s2|135-139|juice|O
DDI-DrugBank.d467.s2|140-140|,|O
DDI-DrugBank.d467.s2|142-144|and|O
DDI-DrugBank.d467.s2|146-150|other|O
DDI-DrugBank.d467.s2|152-161|inhibitors|O
DDI-DrugBank.d467.s2|163-164|of|O
DDI-DrugBank.d467.s2|166-175|cytochrome|O
DDI-DrugBank.d467.s2|177-180|P450|O
DDI-DrugBank.d467.s2|182-184|3A4|O
DDI-DrugBank.d467.s2|186-190|would|O
DDI-DrugBank.d467.s2|192-193|be|O
DDI-DrugBank.d467.s2|195-202|expected|O
DDI-DrugBank.d467.s2|204-205|to|O
DDI-DrugBank.d467.s2|207-210|lead|O
DDI-DrugBank.d467.s2|212-213|to|O
DDI-DrugBank.d467.s2|215-216|an|O
DDI-DrugBank.d467.s2|218-225|increase|O
DDI-DrugBank.d467.s2|227-228|in|O
DDI-DrugBank.d467.s2|230-235|plasma|O
DDI-DrugBank.d467.s2|237-246|bexarotene|drug
DDI-DrugBank.d467.s2|248-261|concentrations|O
DDI-DrugBank.d467.s2|262-262|.|O
DDI-DrugBank.d467.s3|0-10|Furthermore|O
DDI-DrugBank.d467.s3|11-11|,|O
DDI-DrugBank.d467.s3|13-20|rifampin|drug
DDI-DrugBank.d467.s3|21-21|,|O
DDI-DrugBank.d467.s3|23-31|phenytoin|drug
DDI-DrugBank.d467.s3|32-32|,|O
DDI-DrugBank.d467.s3|34-46|phenobarbital|drug
DDI-DrugBank.d467.s3|47-47|,|O
DDI-DrugBank.d467.s3|49-51|and|O
DDI-DrugBank.d467.s3|53-57|other|O
DDI-DrugBank.d467.s3|59-66|inducers|O
DDI-DrugBank.d467.s3|68-69|of|O
DDI-DrugBank.d467.s3|71-80|cytochrome|O
DDI-DrugBank.d467.s3|82-85|P450|O
DDI-DrugBank.d467.s3|87-89|3A4|O
DDI-DrugBank.d467.s3|91-93|may|O
DDI-DrugBank.d467.s3|95-99|cause|O
DDI-DrugBank.d467.s3|101-101|a|O
DDI-DrugBank.d467.s3|103-111|reduction|O
DDI-DrugBank.d467.s3|113-114|in|O
DDI-DrugBank.d467.s3|116-121|plasma|O
DDI-DrugBank.d467.s3|123-132|bexarotene|drug
DDI-DrugBank.d467.s3|134-147|concentrations|O
DDI-DrugBank.d467.s3|148-148|.|O
DDI-DrugBank.d467.s4|0-10|Concomitant|O
DDI-DrugBank.d467.s4|12-25|administration|O
DDI-DrugBank.d467.s4|27-28|of|O
DDI-DrugBank.d467.s4|30-38|Targretin|brand
DDI-DrugBank.d467.s4|40-47|capsules|O
DDI-DrugBank.d467.s4|49-51|and|O
DDI-DrugBank.d467.s4|53-63|gemfibrozil|drug
DDI-DrugBank.d467.s4|65-72|resulted|O
DDI-DrugBank.d467.s4|74-75|in|O
DDI-DrugBank.d467.s4|77-87|substantial|O
DDI-DrugBank.d467.s4|89-97|increases|O
DDI-DrugBank.d467.s4|99-100|in|O
DDI-DrugBank.d467.s4|102-107|plasma|O
DDI-DrugBank.d467.s4|109-122|concentrations|O
DDI-DrugBank.d467.s4|124-125|of|O
DDI-DrugBank.d467.s4|127-136|bexarotene|drug
DDI-DrugBank.d467.s4|137-137|,|O
DDI-DrugBank.d467.s4|139-146|probably|O
DDI-DrugBank.d467.s4|148-149|at|O
DDI-DrugBank.d467.s4|151-155|least|O
DDI-DrugBank.d467.s4|157-165|partially|O
DDI-DrugBank.d467.s4|167-173|related|O
DDI-DrugBank.d467.s4|175-176|to|O
DDI-DrugBank.d467.s4|178-187|cytochrome|O
DDI-DrugBank.d467.s4|189-192|P450|O
DDI-DrugBank.d467.s4|194-196|3A4|O
DDI-DrugBank.d467.s4|198-207|inhibition|O
DDI-DrugBank.d467.s4|209-210|by|O
DDI-DrugBank.d467.s4|212-222|gemfibrozil|drug
DDI-DrugBank.d467.s4|223-223|.|O
DDI-DrugBank.d467.s5|0-4|Under|O
DDI-DrugBank.d467.s5|6-12|similar|O
DDI-DrugBank.d467.s5|14-23|conditions|O
DDI-DrugBank.d467.s5|24-24|,|O
DDI-DrugBank.d467.s5|26-35|bexarotene|drug
DDI-DrugBank.d467.s5|37-50|concentrations|O
DDI-DrugBank.d467.s5|52-55|were|O
DDI-DrugBank.d467.s5|57-59|not|O
DDI-DrugBank.d467.s5|61-68|affected|O
DDI-DrugBank.d467.s5|70-71|by|O
DDI-DrugBank.d467.s5|73-83|concomitant|O
DDI-DrugBank.d467.s5|85-96|atorvastatin|drug
DDI-DrugBank.d467.s5|98-111|administration|O
DDI-DrugBank.d467.s5|112-112|.|O
DDI-DrugBank.d467.s6|0-10|Concomitant|O
DDI-DrugBank.d467.s6|12-25|administration|O
DDI-DrugBank.d467.s6|27-28|of|O
DDI-DrugBank.d467.s6|30-40|gemfibrozil|drug
DDI-DrugBank.d467.s6|42-45|with|O
DDI-DrugBank.d467.s6|47-55|Targretin|brand
DDI-DrugBank.d467.s6|57-64|capsules|O
DDI-DrugBank.d467.s6|66-67|is|O
DDI-DrugBank.d467.s6|69-71|not|O
DDI-DrugBank.d467.s6|73-83|recommended|O
DDI-DrugBank.d467.s6|84-84|.|O
DDI-DrugBank.d757.s0|0-4|Usage|O
DDI-DrugBank.d757.s0|6-9|with|O
DDI-DrugBank.d757.s0|11-17|Alcohol|drug
DDI-DrugBank.d757.s0|18-18|:|O
DDI-DrugBank.d757.s0|20-22|Due|O
DDI-DrugBank.d757.s0|24-25|to|O
DDI-DrugBank.d757.s0|27-29|the|O
DDI-DrugBank.d757.s0|31-39|potential|O
DDI-DrugBank.d757.s0|41-43|for|O
DDI-DrugBank.d757.s0|45-53|increased|O
DDI-DrugBank.d757.s0|55-57|CNS|O
DDI-DrugBank.d757.s0|59-69|depressants|O
DDI-DrugBank.d757.s0|71-77|effects|O
DDI-DrugBank.d757.s0|78-78|,|O
DDI-DrugBank.d757.s0|80-86|alcohol|drug
DDI-DrugBank.d757.s0|88-93|should|O
DDI-DrugBank.d757.s0|95-96|be|O
DDI-DrugBank.d757.s0|98-101|used|O
DDI-DrugBank.d757.s0|103-106|with|O
DDI-DrugBank.d757.s0|108-114|caution|O
DDI-DrugBank.d757.s0|116-117|in|O
DDI-DrugBank.d757.s0|119-126|patients|O
DDI-DrugBank.d757.s0|128-130|who|O
DDI-DrugBank.d757.s0|132-134|are|O
DDI-DrugBank.d757.s0|136-144|currently|O
DDI-DrugBank.d757.s0|146-154|receiving|O
DDI-DrugBank.d757.s0|156-166|pentazocine|drug
DDI-DrugBank.d757.s0|167-167|.|O
DDI-DrugBank.d270.s0|0-9|Nevirapine|drug
DDI-DrugBank.d270.s0|11-12|is|O
DDI-DrugBank.d270.s0|14-24|principally|O
DDI-DrugBank.d270.s0|26-36|metabolized|O
DDI-DrugBank.d270.s0|38-39|by|O
DDI-DrugBank.d270.s0|41-43|the|O
DDI-DrugBank.d270.s0|45-49|liver|O
DDI-DrugBank.d270.s0|51-53|via|O
DDI-DrugBank.d270.s0|55-57|the|O
DDI-DrugBank.d270.s0|59-68|cytochrome|O
DDI-DrugBank.d270.s0|70-73|P450|O
DDI-DrugBank.d270.s0|75-84|isoenzymes|O
DDI-DrugBank.d270.s0|85-85|,|O
DDI-DrugBank.d270.s0|87-89|3A4|O
DDI-DrugBank.d270.s0|91-93|and|O
DDI-DrugBank.d270.s0|95-97|2B6|O
DDI-DrugBank.d270.s0|98-98|.|O
DDI-DrugBank.d270.s1|0-9|Nevirapine|drug
DDI-DrugBank.d270.s1|11-12|is|O
DDI-DrugBank.d270.s1|14-18|known|O
DDI-DrugBank.d270.s1|20-21|to|O
DDI-DrugBank.d270.s1|23-24|be|O
DDI-DrugBank.d270.s1|26-27|an|O
DDI-DrugBank.d270.s1|29-35|inducer|O
DDI-DrugBank.d270.s1|37-38|of|O
DDI-DrugBank.d270.s1|40-44|these|O
DDI-DrugBank.d270.s1|46-52|enzymes|O
DDI-DrugBank.d270.s1|53-53|.|O
DDI-DrugBank.d270.s2|0-1|As|O
DDI-DrugBank.d270.s2|3-3|a|O
DDI-DrugBank.d270.s2|5-10|result|O
DDI-DrugBank.d270.s2|11-11|,|O
DDI-DrugBank.d270.s2|13-17|drugs|O
DDI-DrugBank.d270.s2|19-22|that|O
DDI-DrugBank.d270.s2|24-26|are|O
DDI-DrugBank.d270.s2|28-38|metabolized|O
DDI-DrugBank.d270.s2|40-41|by|O
DDI-DrugBank.d270.s2|43-47|these|O
DDI-DrugBank.d270.s2|49-54|enzyme|O
DDI-DrugBank.d270.s2|56-62|systems|O
DDI-DrugBank.d270.s2|64-66|may|O
DDI-DrugBank.d270.s2|68-71|have|O
DDI-DrugBank.d270.s2|73-77|lower|O
DDI-DrugBank.d270.s2|79-82|than|O
DDI-DrugBank.d270.s2|84-91|expected|O
DDI-DrugBank.d270.s2|93-98|plasma|O
DDI-DrugBank.d270.s2|100-105|levels|O
DDI-DrugBank.d270.s2|107-110|when|O
DDI-DrugBank.d270.s2|112-125|coadministered|O
DDI-DrugBank.d270.s2|127-130|with|O
DDI-DrugBank.d270.s2|132-141|nevirapine|drug
DDI-DrugBank.d270.s2|142-142|.|O
DDI-DrugBank.d270.s3|0-2|The|O
DDI-DrugBank.d270.s3|4-11|specific|O
DDI-DrugBank.d270.s3|13-27|pharmacokinetic|O
DDI-DrugBank.d270.s3|29-35|changes|O
DDI-DrugBank.d270.s3|37-40|that|O
DDI-DrugBank.d270.s3|42-46|occur|O
DDI-DrugBank.d270.s3|48-51|with|O
DDI-DrugBank.d270.s3|53-69|co-administration|O
DDI-DrugBank.d270.s3|71-72|of|O
DDI-DrugBank.d270.s3|74-83|nevirapine|drug
DDI-DrugBank.d270.s3|85-87|and|O
DDI-DrugBank.d270.s3|89-93|other|O
DDI-DrugBank.d270.s3|95-99|drugs|O
DDI-DrugBank.d270.s3|101-103|are|O
DDI-DrugBank.d270.s3|105-110|listed|O
DDI-DrugBank.d270.s3|112-113|in|O
DDI-DrugBank.d270.s3|115-122|CLINICAL|O
DDI-DrugBank.d270.s3|124-135|PHARMACOLOGY|O
DDI-DrugBank.d270.s3|136-136|,|O
DDI-DrugBank.d270.s3|138-142|Table|O
DDI-DrugBank.d270.s3|144-144|1|O
DDI-DrugBank.d270.s3|145-145|.|O
DDI-DrugBank.d270.s4|0-7|Clinical|O
DDI-DrugBank.d270.s4|9-16|comments|O
DDI-DrugBank.d270.s4|18-22|about|O
DDI-DrugBank.d270.s4|24-31|possible|O
DDI-DrugBank.d270.s4|33-38|dosage|O
DDI-DrugBank.d270.s4|40-52|modifications|O
DDI-DrugBank.d270.s4|54-58|based|O
DDI-DrugBank.d270.s4|60-61|on|O
DDI-DrugBank.d270.s4|63-67|these|O
DDI-DrugBank.d270.s4|69-83|pharmacokinetic|O
DDI-DrugBank.d270.s4|85-91|changes|O
DDI-DrugBank.d270.s4|93-95|are|O
DDI-DrugBank.d270.s4|97-102|listed|O
DDI-DrugBank.d270.s4|104-105|in|O
DDI-DrugBank.d270.s4|107-111|Table|O
DDI-DrugBank.d270.s4|113-113|3|O
DDI-DrugBank.d270.s4|114-114|.|O
DDI-DrugBank.d270.s5|0-2|The|O
DDI-DrugBank.d270.s5|4-7|data|O
DDI-DrugBank.d270.s5|9-16|inTables|O
DDI-DrugBank.d270.s5|18-18|1|O
DDI-DrugBank.d270.s5|20-22|and|O
DDI-DrugBank.d270.s5|24-24|3|O
DDI-DrugBank.d270.s5|26-28|are|O
DDI-DrugBank.d270.s5|30-34|based|O
DDI-DrugBank.d270.s5|36-37|on|O
DDI-DrugBank.d270.s5|39-41|the|O
DDI-DrugBank.d270.s5|43-49|results|O
DDI-DrugBank.d270.s5|51-52|of|O
DDI-DrugBank.d270.s5|54-57|drug|O
DDI-DrugBank.d270.s5|59-69|interaction|O
DDI-DrugBank.d270.s5|71-77|studies|O
DDI-DrugBank.d270.s5|79-87|conducted|O
DDI-DrugBank.d270.s5|89-90|in|O
DDI-DrugBank.d270.s5|92-96|HIV-1|O
DDI-DrugBank.d270.s5|98-109|seropositive|O
DDI-DrugBank.d270.s5|111-118|subjects|O
DDI-DrugBank.d270.s5|120-125|unless|O
DDI-DrugBank.d270.s5|127-135|otherwise|O
DDI-DrugBank.d270.s5|137-145|indicated|O
DDI-DrugBank.d270.s5|146-146|.|O
DDI-DrugBank.d270.s6|0-1|In|O
DDI-DrugBank.d270.s6|3-10|addition|O
DDI-DrugBank.d270.s6|12-13|to|O
DDI-DrugBank.d270.s6|15-25|established|O
DDI-DrugBank.d270.s6|27-30|drug|O
DDI-DrugBank.d270.s6|32-43|interactions|O
DDI-DrugBank.d270.s6|44-44|,|O
DDI-DrugBank.d270.s6|46-50|there|O
DDI-DrugBank.d270.s6|52-54|may|O
DDI-DrugBank.d270.s6|56-57|be|O
DDI-DrugBank.d270.s6|59-67|potential|O
DDI-DrugBank.d270.s6|69-83|pharmacokinetic|O
DDI-DrugBank.d270.s6|85-96|interactions|O
DDI-DrugBank.d270.s6|98-104|between|O
DDI-DrugBank.d270.s6|106-115|nevirapine|drug
DDI-DrugBank.d270.s6|117-119|and|O
DDI-DrugBank.d270.s6|121-125|other|O
DDI-DrugBank.d270.s6|127-130|drug|O
DDI-DrugBank.d270.s6|132-138|classes|O
DDI-DrugBank.d270.s6|140-143|that|O
DDI-DrugBank.d270.s6|145-147|are|O
DDI-DrugBank.d270.s6|149-159|metabolized|O
DDI-DrugBank.d270.s6|161-162|by|O
DDI-DrugBank.d270.s6|164-166|the|O
DDI-DrugBank.d270.s6|168-177|cytochrome|O
DDI-DrugBank.d270.s6|179-182|P450|O
DDI-DrugBank.d270.s6|184-189|system|O
DDI-DrugBank.d270.s6|190-190|.|O
DDI-DrugBank.d270.s7|0-4|These|O
DDI-DrugBank.d270.s7|6-14|potential|O
DDI-DrugBank.d270.s7|16-19|drug|O
DDI-DrugBank.d270.s7|21-32|interactions|O
DDI-DrugBank.d270.s7|34-36|are|O
DDI-DrugBank.d270.s7|38-43|listed|O
DDI-DrugBank.d270.s7|45-46|in|O
DDI-DrugBank.d270.s7|48-52|Table|O
DDI-DrugBank.d270.s7|54-54|4|O
DDI-DrugBank.d270.s7|55-55|.|O
DDI-DrugBank.d270.s8|0-7|Although|O
DDI-DrugBank.d270.s8|9-16|specific|O
DDI-DrugBank.d270.s8|18-21|drug|O
DDI-DrugBank.d270.s8|23-33|interaction|O
DDI-DrugBank.d270.s8|35-41|studies|O
DDI-DrugBank.d270.s8|43-44|in|O
DDI-DrugBank.d270.s8|46-50|HIV-1|O
DDI-DrugBank.d270.s8|52-63|seropositive|O
DDI-DrugBank.d270.s8|65-72|subjects|O
DDI-DrugBank.d270.s8|74-77|have|O
DDI-DrugBank.d270.s8|79-81|not|O
DDI-DrugBank.d270.s8|83-86|been|O
DDI-DrugBank.d270.s8|88-96|conducted|O
DDI-DrugBank.d270.s8|98-100|for|O
DDI-DrugBank.d270.s8|102-104|the|O
DDI-DrugBank.d270.s8|106-112|classes|O
DDI-DrugBank.d270.s8|114-115|of|O
DDI-DrugBank.d270.s8|117-121|drugs|O
DDI-DrugBank.d270.s8|123-128|listed|O
DDI-DrugBank.d270.s8|130-131|in|O
DDI-DrugBank.d270.s8|133-137|Table|O
DDI-DrugBank.d270.s8|139-139|4|O
DDI-DrugBank.d270.s8|140-140|,|O
DDI-DrugBank.d270.s8|142-151|additional|O
DDI-DrugBank.d270.s8|153-160|clinical|O
DDI-DrugBank.d270.s8|162-171|monitoring|O
DDI-DrugBank.d270.s8|173-175|may|O
DDI-DrugBank.d270.s8|177-178|be|O
DDI-DrugBank.d270.s8|180-188|warranted|O
DDI-DrugBank.d270.s8|190-193|when|O
DDI-DrugBank.d270.s8|195-210|co-administering|O
DDI-DrugBank.d270.s8|212-216|these|O
DDI-DrugBank.d270.s8|218-222|drugs|O
DDI-DrugBank.d270.s8|223-223|.|O
DDI-DrugBank.d270.s9|0-2|The|O
DDI-DrugBank.d270.s9|4-5|in|O
DDI-DrugBank.d270.s9|7-11|vitro|O
DDI-DrugBank.d270.s9|13-23|interaction|O
DDI-DrugBank.d270.s9|25-31|between|O
DDI-DrugBank.d270.s9|33-42|nevirapine|drug
DDI-DrugBank.d270.s9|44-46|and|O
DDI-DrugBank.d270.s9|48-50|the|O
DDI-DrugBank.d270.s9|52-71|antithrombotic agent|group
DDI-DrugBank.d270.s9|52-71|antithrombotic agent|group
DDI-DrugBank.d270.s9|82-83|is|O
DDI-DrugBank.d270.s9|85-91|complex|O
DDI-DrugBank.d270.s9|92-92|.|O
DDI-DrugBank.d270.s10|0-1|As|O
DDI-DrugBank.d270.s10|3-3|a|O
DDI-DrugBank.d270.s10|5-10|result|O
DDI-DrugBank.d270.s10|11-11|,|O
DDI-DrugBank.d270.s10|13-16|when|O
DDI-DrugBank.d270.s10|18-23|giving|O
DDI-DrugBank.d270.s10|25-29|these|O
DDI-DrugBank.d270.s10|31-35|drugs|O
DDI-DrugBank.d270.s10|37-49|concomitantly|O
DDI-DrugBank.d270.s10|50-50|,|O
DDI-DrugBank.d270.s10|52-57|plasma|O
DDI-DrugBank.d270.s10|59-66|warfarin|drug
DDI-DrugBank.d270.s10|68-73|levels|O
DDI-DrugBank.d270.s10|75-77|may|O
DDI-DrugBank.d270.s10|79-84|change|O
DDI-DrugBank.d270.s10|86-89|with|O
DDI-DrugBank.d270.s10|91-93|the|O
DDI-DrugBank.d270.s10|95-103|potential|O
DDI-DrugBank.d270.s10|105-107|for|O
DDI-DrugBank.d270.s10|109-117|increases|O
DDI-DrugBank.d270.s10|119-120|in|O
DDI-DrugBank.d270.s10|122-132|coagulation|O
DDI-DrugBank.d270.s10|134-137|time|O
DDI-DrugBank.d270.s10|138-138|.|O
DDI-DrugBank.d270.s11|0-3|When|O
DDI-DrugBank.d270.s11|5-12|warfarin|drug
DDI-DrugBank.d270.s11|14-15|is|O
DDI-DrugBank.d270.s11|17-31|co-administered|O
DDI-DrugBank.d270.s11|33-36|with|O
DDI-DrugBank.d270.s11|38-47|nevirapine|drug
DDI-DrugBank.d270.s11|48-48|,|O
DDI-DrugBank.d270.s11|50-64|anticoagulation|O
DDI-DrugBank.d270.s11|66-71|levels|O
DDI-DrugBank.d270.s11|73-78|should|O
DDI-DrugBank.d270.s11|80-81|be|O
DDI-DrugBank.d270.s11|83-91|monitored|O
DDI-DrugBank.d270.s11|93-102|frequently|O
DDI-DrugBank.d270.s11|103-103|.|O
DDI-DrugBank.d270.s12|0-4|Table|O
DDI-DrugBank.d270.s12|6-6|3|O
DDI-DrugBank.d270.s12|8-18|Established|O
DDI-DrugBank.d270.s12|20-23|Drug|O
DDI-DrugBank.d270.s12|25-36|Interactions|O
DDI-DrugBank.d270.s12|37-37|:|O
DDI-DrugBank.d270.s12|39-48|Alteration|O
DDI-DrugBank.d270.s12|50-51|in|O
DDI-DrugBank.d270.s12|53-56|Dose|O
DDI-DrugBank.d270.s12|58-59|or|O
DDI-DrugBank.d270.s12|61-67|Regimen|O
DDI-DrugBank.d270.s12|69-71|May|O
DDI-DrugBank.d270.s12|73-74|Be|O
DDI-DrugBank.d270.s12|76-86|Recommended|O
DDI-DrugBank.d270.s12|88-92|Based|O
DDI-DrugBank.d270.s12|94-95|on|O
DDI-DrugBank.d270.s12|97-100|Drug|O
DDI-DrugBank.d270.s12|102-112|Interaction|O
DDI-DrugBank.d270.s12|114-120|Studies|O
DDI-DrugBank.d270.s13|0-3|Drug|O
DDI-DrugBank.d270.s13|5-8|Name|O
DDI-DrugBank.d270.s14|0-5|Effect|O
DDI-DrugBank.d270.s14|7-8|on|O
DDI-DrugBank.d270.s14|10-22|Concentration|O
DDI-DrugBank.d270.s14|24-25|of|O
DDI-DrugBank.d270.s14|27-36|Nevirapine|drug
DDI-DrugBank.d270.s14|38-39|or|O
DDI-DrugBank.d270.s14|41-51|Concomitant|O
DDI-DrugBank.d270.s14|53-56|Drug|O
DDI-DrugBank.d270.s15|0-7|Clinical|O
DDI-DrugBank.d270.s15|9-15|Comment|O
DDI-DrugBank.d270.s17|0-13|Clarithromycin|drug
DDI-DrugBank.d270.s17|16-20|14OH-|O
DDI-DrugBank.d270.s17|22-35|clarithromycin|O
DDI-DrugBank.d270.s18|0-13|Clarithromycin|drug
DDI-DrugBank.d270.s18|15-22|exposure|O
DDI-DrugBank.d270.s18|24-26|was|O
DDI-DrugBank.d270.s18|28-40|significantly|O
DDI-DrugBank.d270.s18|42-50|decreased|O
DDI-DrugBank.d270.s18|52-53|by|O
DDI-DrugBank.d270.s18|55-64|nevirapine|drug
DDI-DrugBank.d270.s18|65-65|;|O
DDI-DrugBank.d270.s19|0-6|however|O
DDI-DrugBank.d270.s19|7-7|,|O
DDI-DrugBank.d270.s19|9-13|14-OH|O
DDI-DrugBank.d270.s19|15-24|metabolite|O
DDI-DrugBank.d270.s19|26-39|concentrations|O
DDI-DrugBank.d270.s19|41-44|were|O
DDI-DrugBank.d270.s19|46-62|increased.Because|O
DDI-DrugBank.d270.s19|64-77|clarithromycin|drug
DDI-DrugBank.d270.s19|79-84|active|O
DDI-DrugBank.d270.s19|86-95|metabolite|O
DDI-DrugBank.d270.s19|97-99|has|O
DDI-DrugBank.d270.s19|101-107|reduced|O
DDI-DrugBank.d270.s19|109-116|activity|O
DDI-DrugBank.d270.s19|118-124|against|O
DDI-DrugBank.d270.s19|126-158|Mycobacteriumavium-intracellulare|O
DDI-DrugBank.d270.s19|160-166|complex|O
DDI-DrugBank.d270.s19|167-167|,|O
DDI-DrugBank.d270.s19|169-183|overallactivity|O
DDI-DrugBank.d270.s19|185-191|against|O
DDI-DrugBank.d270.s19|193-196|this|O
DDI-DrugBank.d270.s19|198-205|pathogen|O
DDI-DrugBank.d270.s19|207-209|may|O
DDI-DrugBank.d270.s19|211-219|bealtered|O
DDI-DrugBank.d270.s19|220-220|.|O
DDI-DrugBank.d270.s20|0-11|Alternatives|O
DDI-DrugBank.d270.s20|13-14|to|O
DDI-DrugBank.d270.s20|16-29|clarithromycin|drug
DDI-DrugBank.d270.s20|30-30|,|O
DDI-DrugBank.d270.s20|31-34|such|O
DDI-DrugBank.d270.s20|36-37|as|O
DDI-DrugBank.d270.s20|39-50|azithromycin|drug
DDI-DrugBank.d270.s20|51-51|,|O
DDI-DrugBank.d270.s20|53-58|should|O
DDI-DrugBank.d270.s20|60-61|be|O
DDI-DrugBank.d270.s20|63-72|considered|O
DDI-DrugBank.d270.s20|73-73|.|O
DDI-DrugBank.d270.s23|0-10|Appropriate|O
DDI-DrugBank.d270.s23|12-16|doses|O
DDI-DrugBank.d270.s23|18-20|for|O
DDI-DrugBank.d270.s23|22-25|this|O
DDI-DrugBank.d270.s23|27-37|combination|O
DDI-DrugBank.d270.s23|39-41|are|O
DDI-DrugBank.d270.s23|43-45|not|O
DDI-DrugBank.d270.s23|47-57|established|O
DDI-DrugBank.d270.s23|58-58|.|O
DDI-DrugBank.d270.s24|0-16|Ethinyl estradiol|drug
DDI-DrugBank.d270.s24|18-20|and|O
DDI-DrugBank.d270.s25|0-16|Ethinyl estradiol|drug
DDI-DrugBank.d270.s26|0-3|Oral|O
DDI-DrugBank.d270.s26|5-18|contraceptives|group
DDI-DrugBank.d270.s26|20-22|and|O
DDI-DrugBank.d270.s26|24-28|other|O
DDI-DrugBank.d270.s26|30-44|hormonalmethods|O
DDI-DrugBank.d270.s26|46-47|of|O
DDI-DrugBank.d270.s26|49-53|birth|O
DDI-DrugBank.d270.s26|55-61|control|O
DDI-DrugBank.d270.s26|63-68|should|O
DDI-DrugBank.d270.s26|70-72|not|O
DDI-DrugBank.d270.s26|74-75|be|O
DDI-DrugBank.d270.s26|77-82|usedas|O
DDI-DrugBank.d270.s26|84-86|the|O
DDI-DrugBank.d270.s26|88-91|sole|O
DDI-DrugBank.d270.s26|93-98|method|O
DDI-DrugBank.d270.s26|100-101|of|O
DDI-DrugBank.d270.s26|103-115|contraception|O
DDI-DrugBank.d270.s26|117-123|inwomen|O
DDI-DrugBank.d270.s26|125-130|taking|O
DDI-DrugBank.d270.s26|132-141|nevirapine|drug
DDI-DrugBank.d270.s26|142-142|,|O
DDI-DrugBank.d270.s26|144-148|since|O
DDI-DrugBank.d270.s26|150-162|nevirapinemay|O
DDI-DrugBank.d270.s26|164-168|lower|O
DDI-DrugBank.d270.s26|170-172|the|O
DDI-DrugBank.d270.s26|174-179|plasma|O
DDI-DrugBank.d270.s26|181-186|levels|O
DDI-DrugBank.d270.s26|188-189|of|O
DDI-DrugBank.d270.s26|191-206|thesemedications|O
DDI-DrugBank.d270.s26|207-207|.|O
DDI-DrugBank.d270.s27|0-1|An|O
DDI-DrugBank.d270.s27|3-13|alternative|O
DDI-DrugBank.d270.s27|15-16|or|O
DDI-DrugBank.d270.s27|18-27|additional|O
DDI-DrugBank.d270.s27|29-34|method|O
DDI-DrugBank.d270.s27|36-37|of|O
DDI-DrugBank.d270.s27|39-51|contraception|O
DDI-DrugBank.d270.s27|53-54|is|O
DDI-DrugBank.d270.s27|56-66|recommended|O
DDI-DrugBank.d270.s27|67-67|.|O
DDI-DrugBank.d270.s30|0-6|Because|O
DDI-DrugBank.d270.s30|8-9|of|O
DDI-DrugBank.d270.s30|11-13|the|O
DDI-DrugBank.d270.s30|15-18|risk|O
DDI-DrugBank.d270.s30|20-21|of|O
DDI-DrugBank.d270.s30|23-31|increased|O
DDI-DrugBank.d270.s30|33-40|exposure|O
DDI-DrugBank.d270.s30|42-53|tonevirapine|drug
DDI-DrugBank.d270.s30|54-54|,|O
DDI-DrugBank.d270.s30|56-62|caution|O
DDI-DrugBank.d270.s30|64-69|should|O
DDI-DrugBank.d270.s30|71-72|be|O
DDI-DrugBank.d270.s30|74-77|used|O
DDI-DrugBank.d270.s30|79-91|inconcomitant|O
DDI-DrugBank.d270.s30|93-106|administration|O
DDI-DrugBank.d270.s30|107-107|,|O
DDI-DrugBank.d270.s30|109-111|and|O
DDI-DrugBank.d270.s30|113-120|patients|O
DDI-DrugBank.d270.s30|122-127|should|O
DDI-DrugBank.d270.s30|129-130|be|O
DDI-DrugBank.d270.s30|132-140|monitored|O
DDI-DrugBank.d270.s30|142-148|closely|O
DDI-DrugBank.d270.s30|150-152|for|O
DDI-DrugBank.d270.s30|154-174|nevirapine-associated|O
DDI-DrugBank.d270.s30|176-182|adverse|O
DDI-DrugBank.d270.s30|184-189|events|O
DDI-DrugBank.d270.s30|190-190|.|O
DDI-DrugBank.d270.s33|0-10|Appropriate|O
DDI-DrugBank.d270.s33|12-16|doses|O
DDI-DrugBank.d270.s33|18-20|for|O
DDI-DrugBank.d270.s33|22-25|this|O
DDI-DrugBank.d270.s33|27-37|combination|O
DDI-DrugBank.d270.s33|39-44|arenot|O
DDI-DrugBank.d270.s33|46-56|established|O
DDI-DrugBank.d270.s33|57-57|,|O
DDI-DrugBank.d270.s33|59-61|but|O
DDI-DrugBank.d270.s33|63-64|an|O
DDI-DrugBank.d270.s33|66-73|increase|O
DDI-DrugBank.d270.s33|75-76|in|O
DDI-DrugBank.d270.s33|78-86|thedosage|O
DDI-DrugBank.d270.s33|88-89|of|O
DDI-DrugBank.d270.s33|91-99|indinavir|drug
DDI-DrugBank.d270.s33|101-103|may|O
DDI-DrugBank.d270.s33|105-106|be|O
DDI-DrugBank.d270.s33|108-115|required|O
DDI-DrugBank.d270.s33|116-116|.|O
DDI-DrugBank.d270.s36|0-9|Nevirapine|drug
DDI-DrugBank.d270.s36|11-13|and|O
DDI-DrugBank.d270.s36|15-26|ketoconazole|drug
DDI-DrugBank.d270.s36|28-33|should|O
DDI-DrugBank.d270.s36|35-37|not|O
DDI-DrugBank.d270.s36|39-52|beadministered|O
DDI-DrugBank.d270.s36|54-66|concomitantly|O
DDI-DrugBank.d270.s36|68-83|becausedecreases|O
DDI-DrugBank.d270.s36|85-86|in|O
DDI-DrugBank.d270.s36|88-99|ketoconazole|drug
DDI-DrugBank.d270.s36|101-120|plasmaconcentrations|O
DDI-DrugBank.d270.s36|122-124|may|O
DDI-DrugBank.d270.s36|126-131|reduce|O
DDI-DrugBank.d270.s36|133-135|the|O
DDI-DrugBank.d270.s36|137-144|efficacy|O
DDI-DrugBank.d270.s36|146-147|of|O
DDI-DrugBank.d270.s36|149-151|the|O
DDI-DrugBank.d270.s36|153-156|drug|O
DDI-DrugBank.d270.s36|157-157|.|O
DDI-DrugBank.d270.s39|0-0|A|O
DDI-DrugBank.d270.s39|2-5|dose|O
DDI-DrugBank.d270.s39|7-14|increase|O
DDI-DrugBank.d270.s39|16-17|of|O
DDI-DrugBank.d270.s39|19-37|lopinavir/ritonavir|drug
DDI-DrugBank.d270.s39|39-40|to|O
DDI-DrugBank.d270.s39|42-48|533/133|O
DDI-DrugBank.d270.s39|50-51|mg|O
DDI-DrugBank.d270.s39|53-57|twice|O
DDI-DrugBank.d270.s39|59-63|daily|O
DDI-DrugBank.d270.s39|65-68|with|O
DDI-DrugBank.d270.s39|70-73|food|O
DDI-DrugBank.d270.s39|75-87|isrecommended|O
DDI-DrugBank.d270.s39|89-90|in|O
DDI-DrugBank.d270.s39|92-102|combination|O
DDI-DrugBank.d270.s39|104-107|with|O
DDI-DrugBank.d270.s39|109-118|nevirapine|drug
DDI-DrugBank.d270.s39|119-119|.|O
DDI-DrugBank.d270.s41|0-9|Methadonea|O
DDI-DrugBank.d270.s42|0-8|Methadone|drug
DDI-DrugBank.d270.s42|10-15|levels|O
DDI-DrugBank.d270.s42|17-19|may|O
DDI-DrugBank.d270.s42|21-22|be|O
DDI-DrugBank.d270.s42|24-32|decreased|O
DDI-DrugBank.d270.s42|33-33|;|O
DDI-DrugBank.d270.s42|35-43|increased|O
DDI-DrugBank.d270.s42|45-51|dosages|O
DDI-DrugBank.d270.s42|53-55|may|O
DDI-DrugBank.d270.s42|57-58|be|O
DDI-DrugBank.d270.s42|60-67|required|O
DDI-DrugBank.d270.s42|69-70|to|O
DDI-DrugBank.d270.s42|72-78|prevent|O
DDI-DrugBank.d270.s42|80-87|symptoms|O
DDI-DrugBank.d270.s42|89-90|of|O
DDI-DrugBank.d270.s42|92-97|opiate|group
DDI-DrugBank.d270.s42|99-109|withdrawal.|O
DDI-DrugBank.d270.s42|111-119|Methadone|drug
DDI-DrugBank.d270.s42|121-130|maintained|O
DDI-DrugBank.d270.s42|132-139|patients|O
DDI-DrugBank.d270.s42|141-149|beginning|O
DDI-DrugBank.d270.s42|151-160|nevirapine|drug
DDI-DrugBank.d270.s42|162-168|therapy|O
DDI-DrugBank.d270.s42|170-175|should|O
DDI-DrugBank.d270.s42|177-178|be|O
DDI-DrugBank.d270.s42|180-188|monitored|O
DDI-DrugBank.d270.s42|190-200|forevidence|O
DDI-DrugBank.d270.s42|202-203|of|O
DDI-DrugBank.d270.s42|205-214|withdrawal|O
DDI-DrugBank.d270.s42|216-218|and|O
DDI-DrugBank.d270.s42|220-228|methadone|drug
DDI-DrugBank.d270.s42|230-233|dose|O
DDI-DrugBank.d270.s42|235-240|should|O
DDI-DrugBank.d270.s42|242-243|be|O
DDI-DrugBank.d270.s42|245-252|adjusted|O
DDI-DrugBank.d270.s42|254-264|accordingly|O
DDI-DrugBank.d270.s42|265-265|.|O
DDI-DrugBank.d270.s44|0-9|Nelfinavir|drug
DDI-DrugBank.d270.s44|11-12|M8|O
DDI-DrugBank.d270.s45|0-2|The|O
DDI-DrugBank.d270.s45|4-14|appropriate|O
DDI-DrugBank.d270.s45|16-19|dose|O
DDI-DrugBank.d270.s45|21-23|for|O
DDI-DrugBank.d270.s45|25-34|nelfinavir|drug
DDI-DrugBank.d270.s45|36-48|incombination|O
DDI-DrugBank.d270.s45|50-53|with|O
DDI-DrugBank.d270.s45|55-64|nevirapine|drug
DDI-DrugBank.d270.s45|65-65|,|O
DDI-DrugBank.d270.s45|67-70|with|O
DDI-DrugBank.d270.s45|72-80|respectto|O
DDI-DrugBank.d270.s45|82-87|safety|O
DDI-DrugBank.d270.s45|89-91|and|O
DDI-DrugBank.d270.s45|93-100|efficacy|O
DDI-DrugBank.d270.s45|101-101|,|O
DDI-DrugBank.d270.s45|103-105|has|O
DDI-DrugBank.d270.s45|107-109|not|O
DDI-DrugBank.d270.s45|111-114|been|O
DDI-DrugBank.d270.s45|116-126|established|O
DDI-DrugBank.d270.s45|127-127|.|O
DDI-DrugBank.d270.s48|0-8|Rifabutin|drug
DDI-DrugBank.d270.s48|10-12|and|O
DDI-DrugBank.d270.s48|14-16|its|O
DDI-DrugBank.d270.s48|18-27|metabolite|O
DDI-DrugBank.d270.s48|29-46|concentrationswere|O
DDI-DrugBank.d270.s48|48-57|moderately|O
DDI-DrugBank.d270.s48|59-67|increased|O
DDI-DrugBank.d270.s48|68-68|.|O
DDI-DrugBank.d270.s49|0-2|Due|O
DDI-DrugBank.d270.s49|4-5|to|O
DDI-DrugBank.d270.s49|7-22|highintersubject|O
DDI-DrugBank.d270.s49|24-34|variability|O
DDI-DrugBank.d270.s49|35-35|,|O
DDI-DrugBank.d270.s49|37-43|however|O
DDI-DrugBank.d270.s49|44-44|,|O
DDI-DrugBank.d270.s49|46-57|somepatients|O
DDI-DrugBank.d270.s49|59-61|may|O
DDI-DrugBank.d270.s49|63-72|experience|O
DDI-DrugBank.d270.s49|74-78|large|O
DDI-DrugBank.d270.s49|80-88|increases|O
DDI-DrugBank.d270.s49|90-100|inrifabutin|drug
DDI-DrugBank.d270.s49|102-109|exposure|O
DDI-DrugBank.d270.s49|111-113|and|O
DDI-DrugBank.d270.s49|115-117|may|O
DDI-DrugBank.d270.s49|119-120|be|O
DDI-DrugBank.d270.s49|122-123|at|O
DDI-DrugBank.d270.s49|125-130|higher|O
DDI-DrugBank.d270.s49|132-138|riskfor|O
DDI-DrugBank.d270.s49|140-148|rifabutin|O
DDI-DrugBank.d270.s49|150-157|toxicity|O
DDI-DrugBank.d270.s49|158-158|.|O
DDI-DrugBank.d270.s50|0-8|Therefore|O
DDI-DrugBank.d270.s50|9-9|,|O
DDI-DrugBank.d270.s50|11-17|caution|O
DDI-DrugBank.d270.s50|19-24|should|O
DDI-DrugBank.d270.s50|26-27|be|O
DDI-DrugBank.d270.s50|29-32|used|O
DDI-DrugBank.d270.s50|34-35|in|O
DDI-DrugBank.d270.s50|37-47|concomitant|O
DDI-DrugBank.d270.s50|49-62|administration|O
DDI-DrugBank.d270.s50|63-63|.|O
DDI-DrugBank.d270.s53|0-9|Nevirapine|drug
DDI-DrugBank.d270.s53|11-13|and|O
DDI-DrugBank.d270.s53|15-22|rifampin|drug
DDI-DrugBank.d270.s53|24-29|should|O
DDI-DrugBank.d270.s53|31-33|not|O
DDI-DrugBank.d270.s53|35-48|beadministered|O
DDI-DrugBank.d270.s53|50-62|concomitantly|O
DDI-DrugBank.d270.s53|64-79|becausedecreases|O
DDI-DrugBank.d270.s53|81-82|in|O
DDI-DrugBank.d270.s53|84-93|nevirapine|drug
DDI-DrugBank.d270.s53|95-114|plasmaconcentrations|O
DDI-DrugBank.d270.s53|116-118|may|O
DDI-DrugBank.d270.s53|120-125|reduce|O
DDI-DrugBank.d270.s53|127-129|the|O
DDI-DrugBank.d270.s53|131-138|efficacy|O
DDI-DrugBank.d270.s53|140-144|ofthe|O
DDI-DrugBank.d270.s53|146-149|drug|O
DDI-DrugBank.d270.s53|150-150|.|O
DDI-DrugBank.d270.s54|0-9|Physicians|O
DDI-DrugBank.d270.s54|11-17|needing|O
DDI-DrugBank.d270.s54|19-20|to|O
DDI-DrugBank.d270.s54|22-34|treatpatients|O
DDI-DrugBank.d270.s54|36-46|co-infected|O
DDI-DrugBank.d270.s54|48-51|with|O
DDI-DrugBank.d270.s54|53-64|tuberculosis|O
DDI-DrugBank.d270.s54|66-73|andusing|O
DDI-DrugBank.d270.s54|75-75|a|O
DDI-DrugBank.d270.s54|77-86|nevirapine|drug
DDI-DrugBank.d270.s54|88-97|containing|O
DDI-DrugBank.d270.s54|99-105|regimen|O
DDI-DrugBank.d270.s54|107-112|mayuse|O
DDI-DrugBank.d270.s54|114-122|rifabutin|drug
DDI-DrugBank.d270.s54|124-130|instead|O
DDI-DrugBank.d270.s54|131-131|.|O
DDI-DrugBank.d270.s57|0-10|Appropriate|O
DDI-DrugBank.d270.s57|12-16|doses|O
DDI-DrugBank.d270.s57|18-20|for|O
DDI-DrugBank.d270.s57|22-25|this|O
DDI-DrugBank.d270.s57|27-37|combination|O
DDI-DrugBank.d270.s57|39-44|arenot|O
DDI-DrugBank.d270.s57|46-56|established|O
DDI-DrugBank.d270.s57|57-57|,|O
DDI-DrugBank.d270.s57|59-61|but|O
DDI-DrugBank.d270.s57|63-64|an|O
DDI-DrugBank.d270.s57|66-73|increase|O
DDI-DrugBank.d270.s57|75-76|in|O
DDI-DrugBank.d270.s57|78-86|thedosage|O
DDI-DrugBank.d270.s57|88-89|of|O
DDI-DrugBank.d270.s57|91-100|saquinavir|drug
DDI-DrugBank.d270.s57|102-104|may|O
DDI-DrugBank.d270.s57|106-107|be|O
DDI-DrugBank.d270.s57|109-116|required|O
DDI-DrugBank.d270.s57|117-117|.|O
DDI-DrugBank.d270.s58|0-5|aBased|O
DDI-DrugBank.d270.s58|7-8|on|O
DDI-DrugBank.d270.s58|10-16|reports|O
DDI-DrugBank.d270.s58|18-19|of|O
DDI-DrugBank.d270.s58|21-28|narcotic|O
DDI-DrugBank.d270.s58|30-39|withdrawal|O
DDI-DrugBank.d270.s58|41-48|syndrome|O
DDI-DrugBank.d270.s58|50-51|in|O
DDI-DrugBank.d270.s58|53-60|patients|O
DDI-DrugBank.d270.s58|62-68|treated|O
DDI-DrugBank.d270.s58|70-73|with|O
DDI-DrugBank.d270.s58|75-84|nevirapine|drug
DDI-DrugBank.d270.s58|86-88|and|O
DDI-DrugBank.d270.s58|90-98|methadone|drug
DDI-DrugBank.d270.s58|100-111|concurrently|O
DDI-DrugBank.d270.s58|112-112|,|O
DDI-DrugBank.d270.s58|114-116|and|O
DDI-DrugBank.d270.s58|118-125|evidence|O
DDI-DrugBank.d270.s58|127-128|of|O
DDI-DrugBank.d270.s58|130-138|decreased|O
DDI-DrugBank.d270.s58|140-145|plasma|O
DDI-DrugBank.d270.s58|147-160|concentrations|O
DDI-DrugBank.d270.s58|162-163|of|O
DDI-DrugBank.d270.s58|165-173|methadone|drug
DDI-DrugBank.d270.s58|174-174|.|O
DDI-DrugBank.d270.s59|0-4|Table|O
DDI-DrugBank.d270.s59|6-6|4|O
DDI-DrugBank.d270.s59|15-23|Potential|O
DDI-DrugBank.d270.s59|25-28|Drug|O
DDI-DrugBank.d270.s59|30-41|Interactions|O
DDI-DrugBank.d270.s59|42-42|:|O
DDI-DrugBank.d270.s59|43-45|Use|O
DDI-DrugBank.d270.s59|47-50|With|O
DDI-DrugBank.d270.s59|52-58|Caution|O
DDI-DrugBank.d270.s59|59-59|,|O
DDI-DrugBank.d270.s59|61-64|Dose|O
DDI-DrugBank.d270.s59|66-75|Adjustment|O
DDI-DrugBank.d270.s59|77-78|of|O
DDI-DrugBank.d270.s59|80-94|Co-administered|O
DDI-DrugBank.d270.s59|96-99|Drug|O
DDI-DrugBank.d270.s59|101-103|May|O
DDI-DrugBank.d270.s59|105-106|Be|O
DDI-DrugBank.d270.s59|108-113|Needed|O
DDI-DrugBank.d270.s59|115-117|due|O
DDI-DrugBank.d270.s59|119-120|to|O
DDI-DrugBank.d270.s59|122-129|Possible|O
DDI-DrugBank.d270.s59|131-138|Decrease|O
DDI-DrugBank.d270.s59|140-141|in|O
DDI-DrugBank.d270.s59|143-150|Clinical|O
DDI-DrugBank.d270.s59|152-157|Effect|O
DDI-DrugBank.d270.s60|0-7|Examples|O
DDI-DrugBank.d270.s60|9-10|of|O
DDI-DrugBank.d270.s60|12-16|Drugs|O
DDI-DrugBank.d270.s60|18-19|in|O
DDI-DrugBank.d270.s60|21-25|Which|O
DDI-DrugBank.d270.s60|27-32|Plasma|O
DDI-DrugBank.d270.s60|34-47|Concentrations|O
DDI-DrugBank.d270.s60|49-51|May|O
DDI-DrugBank.d270.s60|53-54|Be|O
DDI-DrugBank.d270.s60|56-64|Decreased|O
DDI-DrugBank.d270.s60|66-67|By|O
DDI-DrugBank.d270.s60|69-85|Co-administration|O
DDI-DrugBank.d270.s60|87-90|With|O
DDI-DrugBank.d270.s61|0-3|Drug|O
DDI-DrugBank.d270.s61|5-9|Class|O
DDI-DrugBank.d270.s61|11-18|Examples|O
DDI-DrugBank.d270.s61|20-21|of|O
DDI-DrugBank.d270.s61|23-27|Drugs|O
DDI-DrugBank.d270.s63|0-9|Amiodarone|drug
DDI-DrugBank.d270.s63|10-10|,|O
DDI-DrugBank.d270.s63|12-23|disopyramide|drug
DDI-DrugBank.d270.s63|24-24|,|O
DDI-DrugBank.d270.s65|0-12|Carbamazepine|drug
DDI-DrugBank.d270.s65|13-13|,|O
DDI-DrugBank.d270.s65|15-24|clonazepam|drug
DDI-DrugBank.d270.s65|25-25|,|O
DDI-DrugBank.d270.s69|0-8|Diltiazem|drug
DDI-DrugBank.d270.s69|9-9|,|O
DDI-DrugBank.d270.s69|11-20|nifedipine|drug
DDI-DrugBank.d270.s69|21-21|,|O
DDI-DrugBank.d270.s70|0-5|Cancer|O
DDI-DrugBank.d270.s70|7-18|chemotherapy|O
DDI-DrugBank.d270.s75|0-10|Cyclosporin|drug
DDI-DrugBank.d270.s75|11-11|,|O
DDI-DrugBank.d270.s75|13-22|tacrolimus|drug
DDI-DrugBank.d270.s75|23-23|,|O
DDI-DrugBank.d270.s76|0-7|Motility|O
DDI-DrugBank.d270.s76|9-14|agents|O
DDI-DrugBank.d270.s80|0-7|Examples|O
DDI-DrugBank.d270.s80|9-10|of|O
DDI-DrugBank.d270.s80|12-16|Drugs|O
DDI-DrugBank.d270.s80|18-19|in|O
DDI-DrugBank.d270.s80|21-25|Which|O
DDI-DrugBank.d270.s80|27-32|Plasma|O
DDI-DrugBank.d270.s80|34-47|Concentrations|O
DDI-DrugBank.d270.s80|49-51|May|O
DDI-DrugBank.d270.s80|53-54|Be|O
DDI-DrugBank.d270.s80|56-64|Increased|O
DDI-DrugBank.d270.s80|66-67|By|O
DDI-DrugBank.d270.s80|69-85|Co-administration|O
DDI-DrugBank.d270.s80|87-90|With|O
DDI-DrugBank.d270.s83|0-8|Potential|O
DDI-DrugBank.d270.s83|10-15|effect|O
DDI-DrugBank.d270.s83|17-18|on|O
DDI-DrugBank.d270.s83|20-34|anticoagulation|O
DDI-DrugBank.d270.s83|35-35|.|O
DDI-DrugBank.d270.s84|0-9|Monitoring|O
DDI-DrugBank.d270.s84|11-12|of|O
DDI-DrugBank.d270.s84|14-28|anticoagulation|O
DDI-DrugBank.d270.s84|30-35|levels|O
DDI-DrugBank.d270.s84|37-38|is|O
DDI-DrugBank.d270.s84|40-50|recommended|O
DDI-DrugBank.d270.s84|51-51|.|O
DDI-DrugBank.d270.s85|0-2|Fat|O
DDI-DrugBank.d270.s85|4-17|redistribution|O
DDI-DrugBank.d270.s85|18-18|:|O
DDI-DrugBank.d270.s85|20-46|Redistribution/accumulation|O
DDI-DrugBank.d270.s85|48-49|of|O
DDI-DrugBank.d270.s85|51-54|body|O
DDI-DrugBank.d270.s85|56-58|fat|O
DDI-DrugBank.d270.s85|60-68|including|O
DDI-DrugBank.d270.s85|70-76|central|O
DDI-DrugBank.d270.s85|78-84|obesity|O
DDI-DrugBank.d270.s85|85-85|,|O
DDI-DrugBank.d270.s85|87-99|dorsocervical|O
DDI-DrugBank.d270.s85|101-103|fat|O
DDI-DrugBank.d270.s85|105-115|enlargement|O
DDI-DrugBank.d270.s85|117-117|(|O
DDI-DrugBank.d270.s85|118-124|buffalo|O
DDI-DrugBank.d270.s85|126-129|hump|O
DDI-DrugBank.d270.s85|130-130|)|O
DDI-DrugBank.d270.s85|131-131|,|O
DDI-DrugBank.d270.s85|133-142|peripheral|O
DDI-DrugBank.d270.s85|144-150|wasting|O
DDI-DrugBank.d270.s85|151-151|,|O
DDI-DrugBank.d270.s85|153-158|facial|O
DDI-DrugBank.d270.s85|160-166|wasting|O
DDI-DrugBank.d270.s85|167-167|,|O
DDI-DrugBank.d270.s85|169-174|breast|O
DDI-DrugBank.d270.s85|176-186|enlargement|O
DDI-DrugBank.d270.s85|187-187|,|O
DDI-DrugBank.d270.s85|189-191|and|O
DDI-DrugBank.d270.s85|193-202|cushingoid|O
DDI-DrugBank.d270.s85|204-213|appearance|O
DDI-DrugBank.d270.s85|215-218|have|O
DDI-DrugBank.d270.s85|220-223|been|O
DDI-DrugBank.d270.s85|225-232|observed|O
DDI-DrugBank.d270.s85|234-235|in|O
DDI-DrugBank.d270.s85|237-244|patients|O
DDI-DrugBank.d270.s85|246-254|receiving|O
DDI-DrugBank.d270.s85|256-269|antiretroviral|group
DDI-DrugBank.d270.s85|271-277|therapy|O
DDI-DrugBank.d270.s85|278-278|.|O
DDI-DrugBank.d270.s86|0-2|The|O
DDI-DrugBank.d270.s86|4-12|mechanism|O
DDI-DrugBank.d270.s86|14-16|and|O
DDI-DrugBank.d270.s86|18-26|long-term|O
DDI-DrugBank.d270.s86|28-39|consequences|O
DDI-DrugBank.d270.s86|41-42|of|O
DDI-DrugBank.d270.s86|44-48|these|O
DDI-DrugBank.d270.s86|50-55|events|O
DDI-DrugBank.d270.s86|57-59|are|O
DDI-DrugBank.d270.s86|61-69|currently|O
DDI-DrugBank.d270.s86|71-77|unknown|O
DDI-DrugBank.d270.s86|78-78|.|O
DDI-DrugBank.d270.s87|0-0|A|O
DDI-DrugBank.d270.s87|2-7|causal|O
DDI-DrugBank.d270.s87|9-20|relationship|O
DDI-DrugBank.d270.s87|22-24|has|O
DDI-DrugBank.d270.s87|26-28|not|O
DDI-DrugBank.d270.s87|30-33|been|O
DDI-DrugBank.d270.s87|35-45|established|O
DDI-DrugBank.d270.s88|0-0|.|O
DDI-DrugBank.d159.s0|0-1|No|O
DDI-DrugBank.d159.s0|3-6|drug|O
DDI-DrugBank.d159.s0|8-19|interactions|O
DDI-DrugBank.d159.s0|21-24|have|O
DDI-DrugBank.d159.s0|26-29|been|O
DDI-DrugBank.d159.s0|31-38|observed|O
DDI-DrugBank.d159.s0|40-43|with|O
DDI-DrugBank.d159.s0|45-47|the|O
DDI-DrugBank.d159.s0|49-57|Vitrasert|brand
DDI-DrugBank.d159.s0|59-65|Implant|O
DDI-DrugBank.d159.s0|66-66|.|O
DDI-DrugBank.d159.s1|0-4|There|O
DDI-DrugBank.d159.s1|6-7|is|O
DDI-DrugBank.d159.s1|9-15|limited|O
DDI-DrugBank.d159.s1|17-26|experience|O
DDI-DrugBank.d159.s1|28-31|with|O
DDI-DrugBank.d159.s1|33-35|use|O
DDI-DrugBank.d159.s1|37-38|of|O
DDI-DrugBank.d159.s1|40-46|retinal|O
DDI-DrugBank.d159.s1|48-57|tamponades|O
DDI-DrugBank.d159.s1|59-60|in|O
DDI-DrugBank.d159.s1|62-72|conjunction|O
DDI-DrugBank.d159.s1|74-77|with|O
DDI-DrugBank.d159.s1|79-81|the|O
DDI-DrugBank.d159.s1|83-91|Vitrasert|brand
DDI-DrugBank.d159.s1|93-99|Implant|O
DDI-DrugBank.d159.s1|100-100|.|O
DDI-DrugBank.d769.s0|0-33|Coumarin-Derivative Anticoagulants|group
DDI-DrugBank.d769.s0|34-34|:|O
DDI-DrugBank.d769.s0|36-47|Prolongation|O
DDI-DrugBank.d769.s0|49-50|of|O
DDI-DrugBank.d769.s0|52-62|prothrombin|O
DDI-DrugBank.d769.s0|64-67|time|O
DDI-DrugBank.d769.s0|69-69|(|O
DDI-DrugBank.d769.s0|70-71|PT|O
DDI-DrugBank.d769.s0|72-72|)|O
DDI-DrugBank.d769.s0|74-76|and|O
DDI-DrugBank.d769.s0|78-90|International|O
DDI-DrugBank.d769.s0|92-101|Normalized|O
DDI-DrugBank.d769.s0|103-107|Ratio|O
DDI-DrugBank.d769.s0|109-109|(|O
DDI-DrugBank.d769.s0|110-112|INR|O
DDI-DrugBank.d769.s0|113-113|)|O
DDI-DrugBank.d769.s0|115-118|were|O
DDI-DrugBank.d769.s0|120-127|observed|O
DDI-DrugBank.d769.s0|129-130|in|O
DDI-DrugBank.d769.s0|132-139|patients|O
DDI-DrugBank.d769.s0|141-149|receiving|O
DDI-DrugBank.d769.s0|151-157|ZOLINZA|brand
DDI-DrugBank.d769.s0|159-171|concomitantly|O
DDI-DrugBank.d769.s0|173-176|with|O
DDI-DrugBank.d769.s0|178-211|coumarin-derivative anticoagulants|group
DDI-DrugBank.d769.s0|212-212|.|O
DDI-DrugBank.d769.s1|0-9|Physicians|O
DDI-DrugBank.d769.s1|11-16|should|O
DDI-DrugBank.d769.s1|18-26|carefully|O
DDI-DrugBank.d769.s1|28-34|monitor|O
DDI-DrugBank.d769.s1|36-37|PT|O
DDI-DrugBank.d769.s1|39-41|and|O
DDI-DrugBank.d769.s1|43-45|INR|O
DDI-DrugBank.d769.s1|47-48|in|O
DDI-DrugBank.d769.s1|50-57|patients|O
DDI-DrugBank.d769.s1|59-70|concurrently|O
DDI-DrugBank.d769.s1|72-83|administered|O
DDI-DrugBank.d769.s1|85-91|ZOLINZA|brand
DDI-DrugBank.d769.s1|93-95|and|O
DDI-DrugBank.d769.s1|97-116|coumarin derivatives|group
DDI-DrugBank.d769.s1|117-117|.|O
DDI-DrugBank.d769.s2|0-4|Other|O
DDI-DrugBank.d769.s2|6-20|HDAC Inhibitors|group
DDI-DrugBank.d769.s2|22-27|Severe|O
DDI-DrugBank.d769.s2|29-44|thrombocytopenia|O
DDI-DrugBank.d769.s2|46-48|and|O
DDI-DrugBank.d769.s2|50-65|gastrointestinal|O
DDI-DrugBank.d769.s2|67-74|bleeding|O
DDI-DrugBank.d769.s2|76-79|have|O
DDI-DrugBank.d769.s2|81-84|been|O
DDI-DrugBank.d769.s2|86-93|reported|O
DDI-DrugBank.d769.s2|95-98|with|O
DDI-DrugBank.d769.s2|100-110|concomitant|O
DDI-DrugBank.d769.s2|112-114|use|O
DDI-DrugBank.d769.s2|116-117|of|O
DDI-DrugBank.d769.s2|119-125|ZOLINZA|brand
DDI-DrugBank.d769.s2|127-129|and|O
DDI-DrugBank.d769.s2|131-135|other|O
DDI-DrugBank.d769.s2|137-151|HDAC inhibitors|group
DDI-DrugBank.d769.s2|153-153|(|O
DDI-DrugBank.d769.s2|154-157|e.g.|O
DDI-DrugBank.d769.s2|158-158|,|O
DDI-DrugBank.d769.s2|160-172|valproic acid|drug
DDI-DrugBank.d769.s2|173-173|)|O
DDI-DrugBank.d769.s2|174-174|.|O
DDI-DrugBank.d769.s3|0-6|Monitor|O
DDI-DrugBank.d769.s3|8-15|platelet|O
DDI-DrugBank.d769.s3|17-21|count|O
DDI-DrugBank.d769.s3|23-27|every|O
DDI-DrugBank.d769.s3|29-29|2|O
DDI-DrugBank.d769.s3|31-35|weeks|O
DDI-DrugBank.d769.s3|37-39|for|O
DDI-DrugBank.d769.s3|41-43|the|O
DDI-DrugBank.d769.s3|45-49|first|O
DDI-DrugBank.d769.s3|51-51|2|O
DDI-DrugBank.d769.s3|53-58|months|O
DDI-DrugBank.d769.s3|59-59|.|O
DDI-DrugBank.d679.s0|0-10|Preliminary|O
DDI-DrugBank.d679.s0|12-19|evidence|O
DDI-DrugBank.d679.s0|21-28|suggests|O
DDI-DrugBank.d679.s0|30-33|that|O
DDI-DrugBank.d679.s0|35-44|cimetidine|drug
DDI-DrugBank.d679.s0|46-53|inhibits|O
DDI-DrugBank.d679.s0|55-65|mebendazole|drug
DDI-DrugBank.d679.s0|67-76|metabolism|O
DDI-DrugBank.d679.s0|78-80|and|O
DDI-DrugBank.d679.s0|82-84|may|O
DDI-DrugBank.d679.s0|86-91|result|O
DDI-DrugBank.d679.s0|93-94|in|O
DDI-DrugBank.d679.s0|96-97|an|O
DDI-DrugBank.d679.s0|99-106|increase|O
DDI-DrugBank.d679.s0|108-109|in|O
DDI-DrugBank.d679.s0|111-116|plasma|O
DDI-DrugBank.d679.s0|118-131|concentrations|O
DDI-DrugBank.d679.s0|133-134|of|O
DDI-DrugBank.d679.s0|136-146|mebendazole|drug
DDI-DrugBank.d679.s0|147-147|.|O
DDI-MedLine.d190.s0|0-9|Glycosidic|O
DDI-MedLine.d190.s0|11-17|enzymes|O
DDI-MedLine.d190.s0|19-25|enhance|O
DDI-MedLine.d190.s0|27-33|retinal|O
DDI-MedLine.d190.s0|35-46|transduction|O
DDI-MedLine.d190.s0|48-56|following|O
DDI-MedLine.d190.s0|58-69|intravitreal|O
DDI-MedLine.d190.s0|71-78|delivery|O
DDI-MedLine.d190.s0|80-81|of|O
DDI-MedLine.d190.s0|87-87|.|O
DDI-MedLine.d190.s1|0-1|To|O
DDI-MedLine.d190.s1|3-11|determine|O
DDI-MedLine.d190.s1|13-19|whether|O
DDI-MedLine.d190.s1|21-23|the|O
DDI-MedLine.d190.s1|25-36|co-injection|O
DDI-MedLine.d190.s1|38-39|of|O
DDI-MedLine.d190.s1|41-53|extracellular|O
DDI-MedLine.d190.s1|55-60|matrix|O
DDI-MedLine.d190.s1|62-70|degrading|O
DDI-MedLine.d190.s1|72-78|enzymes|O
DDI-MedLine.d190.s1|80-87|improves|O
DDI-MedLine.d190.s1|89-95|retinal|O
DDI-MedLine.d190.s1|97-108|transduction|O
DDI-MedLine.d190.s1|110-118|following|O
DDI-MedLine.d190.s1|120-131|intravitreal|O
DDI-MedLine.d190.s1|133-140|delivery|O
DDI-MedLine.d190.s1|142-143|of|O
DDI-MedLine.d190.s1|170-170|(|O
DDI-MedLine.d190.s1|175-175|)|O
DDI-MedLine.d190.s1|176-176|.|O
DDI-MedLine.d190.s2|5-14|containing|O
DDI-MedLine.d190.s2|16-19|cDNA|O
DDI-MedLine.d190.s2|21-28|encoding|O
DDI-MedLine.d190.s2|30-37|enhanced|O
DDI-MedLine.d190.s2|39-43|green|O
DDI-MedLine.d190.s2|45-55|fluorescent|O
DDI-MedLine.d190.s2|57-63|protein|O
DDI-MedLine.d190.s2|65-65|(|O
DDI-MedLine.d190.s2|66-68|GFP|O
DDI-MedLine.d190.s2|69-69|)|O
DDI-MedLine.d190.s2|70-70|,|O
DDI-MedLine.d190.s2|72-76|under|O
DDI-MedLine.d190.s2|78-80|the|O
DDI-MedLine.d190.s2|82-88|control|O
DDI-MedLine.d190.s2|90-91|of|O
DDI-MedLine.d190.s2|93-93|a|O
DDI-MedLine.d190.s2|95-101|chicken|O
DDI-MedLine.d190.s2|105-110|-actin|O
DDI-MedLine.d190.s2|112-119|promoter|O
DDI-MedLine.d190.s2|120-120|,|O
DDI-MedLine.d190.s2|122-124|was|O
DDI-MedLine.d190.s2|126-134|delivered|O
DDI-MedLine.d190.s2|136-137|by|O
DDI-MedLine.d190.s2|139-150|intravitreal|O
DDI-MedLine.d190.s2|152-160|injection|O
DDI-MedLine.d190.s2|162-163|to|O
DDI-MedLine.d190.s2|165-169|adult|O
DDI-MedLine.d190.s2|171-174|mice|O
DDI-MedLine.d190.s2|176-177|in|O
DDI-MedLine.d190.s2|179-189|conjunction|O
DDI-MedLine.d190.s2|191-194|with|O
DDI-MedLine.d190.s2|196-202|enzymes|O
DDI-MedLine.d190.s2|204-212|including|O
DDI-MedLine.d190.s2|225-225|,|O
DDI-MedLine.d190.s2|243-243|,|O
DDI-MedLine.d190.s2|259-259|,|O
DDI-MedLine.d190.s2|261-262|or|O
DDI-MedLine.d190.s2|285-285|.|O
DDI-MedLine.d190.s3|0-2|Two|O
DDI-MedLine.d190.s3|4-8|weeks|O
DDI-MedLine.d190.s3|10-14|later|O
DDI-MedLine.d190.s3|15-15|,|O
DDI-MedLine.d190.s3|17-23|retinal|O
DDI-MedLine.d190.s3|25-34|flatmounts|O
DDI-MedLine.d190.s3|36-39|were|O
DDI-MedLine.d190.s3|41-48|examined|O
DDI-MedLine.d190.s3|50-52|for|O
DDI-MedLine.d190.s3|54-56|GFP|O
DDI-MedLine.d190.s3|58-67|expression|O
DDI-MedLine.d190.s3|69-73|using|O
DDI-MedLine.d190.s3|75-82|confocal|O
DDI-MedLine.d190.s3|84-93|microscopy|O
DDI-MedLine.d190.s3|94-94|.|O
DDI-MedLine.d190.s4|0-6|Without|O
DDI-MedLine.d190.s4|8-10|the|O
DDI-MedLine.d190.s4|12-19|addition|O
DDI-MedLine.d190.s4|21-22|of|O
DDI-MedLine.d190.s4|24-30|enzymes|O
DDI-MedLine.d190.s4|31-31|,|O
DDI-MedLine.d190.s4|33-44|transduction|O
DDI-MedLine.d190.s4|46-48|was|O
DDI-MedLine.d190.s4|50-56|limited|O
DDI-MedLine.d190.s4|58-59|to|O
DDI-MedLine.d190.s4|61-70|occasional|O
DDI-MedLine.d190.s4|72-76|cells|O
DDI-MedLine.d190.s4|78-79|in|O
DDI-MedLine.d190.s4|81-83|the|O
DDI-MedLine.d190.s4|85-91|retinal|O
DDI-MedLine.d190.s4|93-100|ganglion|O
DDI-MedLine.d190.s4|102-105|cell|O
DDI-MedLine.d190.s4|107-111|layer|O
DDI-MedLine.d190.s4|112-112|.|O
DDI-MedLine.d190.s5|0-2|The|O
DDI-MedLine.d190.s5|4-11|addition|O
DDI-MedLine.d190.s5|13-14|of|O
DDI-MedLine.d190.s5|31-32|or|O
DDI-MedLine.d190.s5|56-62|greatly|O
DDI-MedLine.d190.s5|64-71|enhanced|O
DDI-MedLine.d190.s5|73-84|transduction|O
DDI-MedLine.d190.s5|86-87|of|O
DDI-MedLine.d190.s5|89-91|the|O
DDI-MedLine.d190.s5|93-99|retinal|O
DDI-MedLine.d190.s5|101-108|ganglion|O
DDI-MedLine.d190.s5|110-113|cell|O
DDI-MedLine.d190.s5|115-119|layer|O
DDI-MedLine.d190.s5|121-123|and|O
DDI-MedLine.d190.s5|125-133|increased|O
DDI-MedLine.d190.s5|135-137|the|O
DDI-MedLine.d190.s5|139-143|depth|O
DDI-MedLine.d190.s5|145-146|of|O
DDI-MedLine.d190.s5|148-159|transduction|O
DDI-MedLine.d190.s5|161-164|into|O
DDI-MedLine.d190.s5|166-168|the|O
DDI-MedLine.d190.s5|170-174|outer|O
DDI-MedLine.d190.s5|176-181|retina|O
DDI-MedLine.d190.s5|182-182|.|O
DDI-MedLine.d190.s6|17-19|had|O
DDI-MedLine.d190.s6|21-21|a|O
DDI-MedLine.d190.s6|23-29|limited|O
DDI-MedLine.d190.s6|31-36|effect|O
DDI-MedLine.d190.s6|38-40|and|O
DDI-MedLine.d190.s6|54-56|was|O
DDI-MedLine.d190.s6|58-68|ineffective|O
DDI-MedLine.d190.s6|69-69|.|O
DDI-MedLine.d190.s7|0-17|Electroretinograms|O
DDI-MedLine.d190.s7|19-26|survived|O
DDI-MedLine.d190.s7|28-31|with|O
DDI-MedLine.d190.s7|33-38|higher|O
DDI-MedLine.d190.s7|40-53|concentrations|O
DDI-MedLine.d190.s7|55-56|of|O
DDI-MedLine.d190.s7|73-75|and|O
DDI-MedLine.d190.s7|99-102|than|O
DDI-MedLine.d190.s7|104-107|were|O
DDI-MedLine.d190.s7|109-116|required|O
DDI-MedLine.d190.s7|118-120|for|O
DDI-MedLine.d190.s7|122-128|optimal|O
DDI-MedLine.d190.s7|130-136|retinal|O
DDI-MedLine.d190.s7|138-149|transduction|O
DDI-MedLine.d190.s7|150-150|.|O
DDI-MedLine.d190.s8|14-20|retinal|O
DDI-MedLine.d190.s8|22-33|transduction|O
DDI-MedLine.d190.s8|35-36|is|O
DDI-MedLine.d190.s8|38-45|improved|O
DDI-MedLine.d190.s8|47-48|by|O
DDI-MedLine.d190.s8|50-61|co-injection|O
DDI-MedLine.d190.s8|63-64|of|O
DDI-MedLine.d190.s8|81-82|or|O
DDI-MedLine.d190.s8|105-105|.|O
DDI-MedLine.d190.s9|0-7|Improved|O
DDI-MedLine.d190.s9|9-20|transduction|O
DDI-MedLine.d190.s9|22-31|efficiency|O
DDI-MedLine.d190.s9|33-35|may|O
DDI-MedLine.d190.s9|37-41|allow|O
DDI-MedLine.d190.s9|43-54|intravitreal|O
DDI-MedLine.d190.s9|56-64|injection|O
DDI-MedLine.d190.s9|66-67|to|O
DDI-MedLine.d190.s9|69-74|become|O
DDI-MedLine.d190.s9|76-78|the|O
DDI-MedLine.d190.s9|80-88|preferred|O
DDI-MedLine.d190.s9|90-94|route|O
DDI-MedLine.d190.s9|96-98|for|O
DDI-MedLine.d190.s9|100-109|delivering|O
DDI-MedLine.d190.s9|111-114|gene|O
DDI-MedLine.d190.s9|116-122|therapy|O
DDI-MedLine.d190.s9|124-125|to|O
DDI-MedLine.d190.s9|127-130|both|O
DDI-MedLine.d190.s9|132-134|the|O
DDI-MedLine.d190.s9|136-140|inner|O
DDI-MedLine.d190.s9|142-144|and|O
DDI-MedLine.d190.s9|146-150|outer|O
DDI-MedLine.d190.s9|152-157|retina|O
DDI-MedLine.d190.s9|158-158|.|O
DDI-DrugBank.d421.s0|0-1|No|O
DDI-DrugBank.d421.s0|3-13|information|O
DDI-DrugBank.d421.s0|15-23|available|O
DDI-DrugBank.d421.s0|24-24|.|O
DDI-DrugBank.d240.s0|0-12|Ethopropazine|drug
DDI-DrugBank.d240.s0|14-16|may|O
DDI-DrugBank.d240.s0|18-25|interact|O
DDI-DrugBank.d240.s0|27-30|with|O
DDI-DrugBank.d240.s0|32-38|alcohol|drug
DDI-DrugBank.d240.s0|40-41|or|O
DDI-DrugBank.d240.s0|43-47|other|O
DDI-DrugBank.d240.s0|49-63|CNS depressants|group
DDI-DrugBank.d240.s0|64-64|,|O
DDI-DrugBank.d240.s0|66-72|causing|O
DDI-DrugBank.d240.s0|74-82|increased|O
DDI-DrugBank.d240.s0|84-91|sedative|O
DDI-DrugBank.d240.s0|93-99|effects|O
DDI-DrugBank.d240.s0|100-100|.|O
DDI-DrugBank.d240.s1|0-1|It|O
DDI-DrugBank.d240.s1|3-5|may|O
DDI-DrugBank.d240.s1|7-10|also|O
DDI-DrugBank.d240.s1|12-19|interact|O
DDI-DrugBank.d240.s1|21-24|with|O
DDI-DrugBank.d240.s1|26-35|amantadine|drug
DDI-DrugBank.d240.s1|37-38|or|O
DDI-DrugBank.d240.s1|40-44|other|O
DDI-DrugBank.d240.s1|46-66|anticholinergic drugs|group
DDI-DrugBank.d240.s1|68-69|or|O
DDI-DrugBank.d240.s1|71-75|MAOIs|group
DDI-DrugBank.d240.s1|76-76|,|O
DDI-DrugBank.d240.s1|78-82|which|O
DDI-DrugBank.d240.s1|84-86|may|O
DDI-DrugBank.d240.s1|88-96|intensify|O
DDI-DrugBank.d240.s1|98-100|the|O
DDI-DrugBank.d240.s1|102-116|anticholinergic|O
DDI-DrugBank.d240.s1|118-123|action|O
DDI-DrugBank.d240.s1|124-124|.|O
DDI-DrugBank.d240.s2|0-12|Ethopropazine|drug
DDI-DrugBank.d240.s2|14-16|can|O
DDI-DrugBank.d240.s2|18-25|interact|O
DDI-DrugBank.d240.s2|27-30|with|O
DDI-DrugBank.d240.s2|32-45|chlorpromazine|drug
DDI-DrugBank.d240.s2|46-46|,|O
DDI-DrugBank.d240.s2|48-57|increasing|O
DDI-DrugBank.d240.s2|59-61|the|O
DDI-DrugBank.d240.s2|63-72|metabolism|O
DDI-DrugBank.d240.s2|74-75|of|O
DDI-DrugBank.d240.s2|77-90|chlorpromazine|drug
DDI-DrugBank.d240.s2|91-91|.|O
DDI-DrugBank.d61.s0|0-1|In|O
DDI-DrugBank.d61.s0|3-10|clinical|O
DDI-DrugBank.d61.s0|12-18|studies|O
DDI-DrugBank.d61.s0|19-19|,|O
DDI-DrugBank.d61.s0|21-26|Tilade|brand
DDI-DrugBank.d61.s0|28-30|has|O
DDI-DrugBank.d61.s0|32-35|been|O
DDI-DrugBank.d61.s0|37-51|co-administered|O
DDI-DrugBank.d61.s0|53-56|with|O
DDI-DrugBank.d61.s0|58-62|other|O
DDI-DrugBank.d61.s0|64-74|anti-asthma|O
DDI-DrugBank.d61.s0|76-86|medications|O
DDI-DrugBank.d61.s0|87-87|,|O
DDI-DrugBank.d61.s0|89-97|including|O
DDI-DrugBank.d61.s0|99-105|inhaled|O
DDI-DrugBank.d61.s0|107-109|and|O
DDI-DrugBank.d61.s0|111-114|oral|O
DDI-DrugBank.d61.s0|116-130|bronchodilators|group
DDI-DrugBank.d61.s0|131-131|,|O
DDI-DrugBank.d61.s0|133-135|and|O
DDI-DrugBank.d61.s0|137-143|inhaled|O
DDI-DrugBank.d61.s0|145-159|corticosteroids|group
DDI-DrugBank.d61.s0|160-160|,|O
DDI-DrugBank.d61.s0|162-165|with|O
DDI-DrugBank.d61.s0|167-168|no|O
DDI-DrugBank.d61.s0|170-177|evidence|O
DDI-DrugBank.d61.s0|179-180|of|O
DDI-DrugBank.d61.s0|182-190|increased|O
DDI-DrugBank.d61.s0|192-200|frequency|O
DDI-DrugBank.d61.s0|202-203|of|O
DDI-DrugBank.d61.s0|205-211|adverse|O
DDI-DrugBank.d61.s0|213-218|events|O
DDI-DrugBank.d61.s0|220-221|or|O
DDI-DrugBank.d61.s0|223-232|laboratory|O
DDI-DrugBank.d61.s0|234-246|abnormalities|O
DDI-DrugBank.d61.s0|247-247|.|O
DDI-DrugBank.d61.s1|0-1|No|O
DDI-DrugBank.d61.s1|3-8|formal|O
DDI-DrugBank.d61.s1|10-18|drug-drug|O
DDI-DrugBank.d61.s1|20-30|interaction|O
DDI-DrugBank.d61.s1|32-38|studies|O
DDI-DrugBank.d61.s1|39-39|,|O
DDI-DrugBank.d61.s1|41-47|however|O
DDI-DrugBank.d61.s1|48-48|,|O
DDI-DrugBank.d61.s1|50-53|have|O
DDI-DrugBank.d61.s1|55-58|been|O
DDI-DrugBank.d61.s1|60-68|conducted|O
DDI-DrugBank.d61.s1|69-69|.|O
DDI-DrugBank.d312.s0|0-1|No|O
DDI-DrugBank.d312.s0|3-8|formal|O
DDI-DrugBank.d312.s0|10-13|drug|O
DDI-DrugBank.d312.s0|15-25|interaction|O
DDI-DrugBank.d312.s0|27-33|studies|O
DDI-DrugBank.d312.s0|35-38|with|O
DDI-DrugBank.d312.s0|40-61|anti-neoplastic agents|group
DDI-DrugBank.d312.s0|63-66|have|O
DDI-DrugBank.d312.s0|68-71|been|O
DDI-DrugBank.d312.s0|73-81|conducted|O
DDI-DrugBank.d312.s0|82-82|.|O
DDI-DrugBank.d312.s1|0-1|In|O
DDI-DrugBank.d312.s1|3-7|Study|O
DDI-DrugBank.d312.s1|9-9|1|O
DDI-DrugBank.d312.s1|10-10|,|O
DDI-DrugBank.d312.s1|12-19|patients|O
DDI-DrugBank.d312.s1|21-24|with|O
DDI-DrugBank.d312.s1|26-35|colorectal|O
DDI-DrugBank.d312.s1|37-42|cancer|O
DDI-DrugBank.d312.s1|44-47|were|O
DDI-DrugBank.d312.s1|49-53|given|O
DDI-DrugBank.d312.s1|55-80|irinotecan/5-FU/leucovorin|drug
DDI-DrugBank.d312.s1|82-82|(|O
DDI-DrugBank.d312.s1|83-91|bolus-IFL|O
DDI-DrugBank.d312.s1|92-92|)|O
DDI-DrugBank.d312.s1|94-97|with|O
DDI-DrugBank.d312.s1|99-100|or|O
DDI-DrugBank.d312.s1|102-108|without|O
DDI-DrugBank.d312.s1|110-116|AVASTIN|brand
DDI-DrugBank.d312.s1|117-117|.|O
DDI-DrugBank.d312.s2|0-9|Irinotecan|drug
DDI-DrugBank.d312.s2|11-24|concentrations|O
DDI-DrugBank.d312.s2|26-29|were|O
DDI-DrugBank.d312.s2|31-37|similar|O
DDI-DrugBank.d312.s2|39-40|in|O
DDI-DrugBank.d312.s2|42-49|patients|O
DDI-DrugBank.d312.s2|51-59|receiving|O
DDI-DrugBank.d312.s2|61-69|bolus-IFL|O
DDI-DrugBank.d312.s2|71-75|alone|O
DDI-DrugBank.d312.s2|77-79|and|O
DDI-DrugBank.d312.s2|81-82|in|O
DDI-DrugBank.d312.s2|84-94|combination|O
DDI-DrugBank.d312.s2|96-99|with|O
DDI-DrugBank.d312.s2|101-107|AVASTIN|brand
DDI-DrugBank.d312.s2|108-108|.|O
DDI-DrugBank.d312.s3|0-2|The|O
DDI-DrugBank.d312.s3|4-17|concentrations|O
DDI-DrugBank.d312.s3|19-20|of|O
DDI-DrugBank.d312.s3|26-26|,|O
DDI-DrugBank.d312.s3|28-30|the|O
DDI-DrugBank.d312.s3|32-37|active|O
DDI-DrugBank.d312.s3|39-48|metabolite|O
DDI-DrugBank.d312.s3|50-51|of|O
DDI-DrugBank.d312.s3|53-62|irinotecan|drug
DDI-DrugBank.d312.s3|63-63|,|O
DDI-DrugBank.d312.s3|65-68|were|O
DDI-DrugBank.d312.s3|70-71|on|O
DDI-DrugBank.d312.s3|73-79|average|O
DDI-DrugBank.d312.s3|81-82|33|O
DDI-DrugBank.d312.s3|83-83|%|O
DDI-DrugBank.d312.s3|85-90|higher|O
DDI-DrugBank.d312.s3|92-93|in|O
DDI-DrugBank.d312.s3|95-102|patients|O
DDI-DrugBank.d312.s3|104-112|receiving|O
DDI-DrugBank.d312.s3|114-122|bolus-IFL|O
DDI-DrugBank.d312.s3|124-125|in|O
DDI-DrugBank.d312.s3|127-137|combination|O
DDI-DrugBank.d312.s3|139-142|with|O
DDI-DrugBank.d312.s3|144-150|AVASTIN|brand
DDI-DrugBank.d312.s3|152-155|when|O
DDI-DrugBank.d312.s3|157-164|compared|O
DDI-DrugBank.d312.s3|166-169|with|O
DDI-DrugBank.d312.s3|171-179|bolus-IFL|O
DDI-DrugBank.d312.s3|181-185|alone|O
DDI-DrugBank.d312.s3|186-186|.|O
DDI-DrugBank.d312.s4|0-1|In|O
DDI-DrugBank.d312.s4|3-7|Study|O
DDI-DrugBank.d312.s4|9-9|1|O
DDI-DrugBank.d312.s4|10-10|,|O
DDI-DrugBank.d312.s4|12-19|patients|O
DDI-DrugBank.d312.s4|21-29|receiving|O
DDI-DrugBank.d312.s4|31-39|bolus-IFL|O
DDI-DrugBank.d312.s4|41-44|plus|O
DDI-DrugBank.d312.s4|46-52|AVASTIN|brand
DDI-DrugBank.d312.s4|54-56|had|O
DDI-DrugBank.d312.s4|58-58|a|O
DDI-DrugBank.d312.s4|60-65|higher|O
DDI-DrugBank.d312.s4|67-75|incidence|O
DDI-DrugBank.d312.s4|77-78|of|O
DDI-DrugBank.d312.s4|80-84|Grade|O
DDI-DrugBank.d312.s4|86-88|3-4|O
DDI-DrugBank.d312.s4|90-97|diarrhea|O
DDI-DrugBank.d312.s4|99-101|and|O
DDI-DrugBank.d312.s4|103-113|neutropenia|O
DDI-DrugBank.d312.s4|114-114|.|O
DDI-DrugBank.d312.s5|0-2|Due|O
DDI-DrugBank.d312.s5|4-5|to|O
DDI-DrugBank.d312.s5|7-10|high|O
DDI-DrugBank.d312.s5|12-24|inter-patient|O
DDI-DrugBank.d312.s5|26-36|variability|O
DDI-DrugBank.d312.s5|38-40|and|O
DDI-DrugBank.d312.s5|42-48|limited|O
DDI-DrugBank.d312.s5|50-57|sampling|O
DDI-DrugBank.d312.s5|58-58|,|O
DDI-DrugBank.d312.s5|60-62|the|O
DDI-DrugBank.d312.s5|64-69|extent|O
DDI-DrugBank.d312.s5|71-72|of|O
DDI-DrugBank.d312.s5|74-76|the|O
DDI-DrugBank.d312.s5|78-85|increase|O
DDI-DrugBank.d312.s5|87-88|in|O
DDI-DrugBank.d312.s5|95-100|levels|O
DDI-DrugBank.d312.s5|102-103|in|O
DDI-DrugBank.d312.s5|105-112|patients|O
DDI-DrugBank.d312.s5|114-122|receiving|O
DDI-DrugBank.d312.s5|124-133|concurrent|O
DDI-DrugBank.d312.s5|135-144|irinotecan|drug
DDI-DrugBank.d312.s5|146-148|and|O
DDI-DrugBank.d312.s5|150-156|AVASTIN|brand
DDI-DrugBank.d312.s5|158-159|is|O
DDI-DrugBank.d312.s5|161-169|uncertain|O
DDI-DrugBank.d312.s5|170-170|.|O
DDI-DrugBank.d523.s0|0-8|Injection|O
DDI-DrugBank.d523.s0|10-14|There|O
DDI-DrugBank.d523.s0|16-17|is|O
DDI-DrugBank.d523.s0|19-28|inadequate|O
DDI-DrugBank.d523.s0|30-39|systematic|O
DDI-DrugBank.d523.s0|41-50|experience|O
DDI-DrugBank.d523.s0|52-55|with|O
DDI-DrugBank.d523.s0|57-59|the|O
DDI-DrugBank.d523.s0|61-63|use|O
DDI-DrugBank.d523.s0|65-66|of|O
DDI-DrugBank.d523.s0|68-75|baclofen|drug
DDI-DrugBank.d523.s0|77-85|injection|O
DDI-DrugBank.d523.s0|87-88|in|O
DDI-DrugBank.d523.s0|90-100|combination|O
DDI-DrugBank.d523.s0|102-105|with|O
DDI-DrugBank.d523.s0|107-111|other|O
DDI-DrugBank.d523.s0|113-123|medications|O
DDI-DrugBank.d523.s0|125-126|to|O
DDI-DrugBank.d523.s0|128-134|predict|O
DDI-DrugBank.d523.s0|136-143|specific|O
DDI-DrugBank.d523.s0|145-153|drug-drug|O
DDI-DrugBank.d523.s0|155-166|interactions|O
DDI-DrugBank.d523.s0|167-167|.|O
DDI-DrugBank.d523.s1|0-11|Interactions|O
DDI-DrugBank.d523.s1|13-22|attributed|O
DDI-DrugBank.d523.s1|24-25|to|O
DDI-DrugBank.d523.s1|27-29|the|O
DDI-DrugBank.d523.s1|31-38|combined|O
DDI-DrugBank.d523.s1|40-42|use|O
DDI-DrugBank.d523.s1|44-45|of|O
DDI-DrugBank.d523.s1|47-54|baclofen|drug
DDI-DrugBank.d523.s1|56-64|injection|O
DDI-DrugBank.d523.s1|66-68|and|O
DDI-DrugBank.d523.s1|70-77|epidural|O
DDI-DrugBank.d523.s1|79-86|morphine|drug
DDI-DrugBank.d523.s1|88-94|include|O
DDI-DrugBank.d523.s1|96-106|hypotension|O
DDI-DrugBank.d523.s1|108-110|and|O
DDI-DrugBank.d523.s1|112-118|dyspnea|O
DDI-DrugBank.d523.s1|119-119|.|O
DDI-DrugBank.d523.s2|0-3|SIDE|O
DDI-DrugBank.d523.s2|5-11|EFFECTS|O
DDI-DrugBank.d523.s2|13-13|(|O
DDI-DrugBank.d523.s2|14-20|KEMSTRO|brand
DDI-DrugBank.d523.s2|21-21|)|O
DDI-DrugBank.d523.s2|23-25|The|O
DDI-DrugBank.d523.s2|27-30|most|O
DDI-DrugBank.d523.s2|32-37|common|O
DDI-DrugBank.d523.s2|39-45|adverse|O
DDI-DrugBank.d523.s2|47-54|reaction|O
DDI-DrugBank.d523.s2|56-61|during|O
DDI-DrugBank.d523.s2|63-71|treatment|O
DDI-DrugBank.d523.s2|73-76|with|O
DDI-DrugBank.d523.s2|78-85|baclofen|drug
DDI-DrugBank.d523.s2|87-88|is|O
DDI-DrugBank.d523.s2|90-98|transient|O
DDI-DrugBank.d523.s2|100-109|drowsiness|O
DDI-DrugBank.d523.s2|111-111|(|O
DDI-DrugBank.d523.s2|112-116|10-63|O
DDI-DrugBank.d523.s2|117-117|%|O
DDI-DrugBank.d523.s2|118-118|)|O
DDI-DrugBank.d523.s2|119-119|.|O
DDI-DrugBank.d523.s3|0-1|In|O
DDI-DrugBank.d523.s3|3-5|one|O
DDI-DrugBank.d523.s3|7-16|controlled|O
DDI-DrugBank.d523.s3|18-22|study|O
DDI-DrugBank.d523.s3|24-25|of|O
DDI-DrugBank.d523.s3|27-29|175|O
DDI-DrugBank.d523.s3|31-38|patients|O
DDI-DrugBank.d523.s3|39-39|,|O
DDI-DrugBank.d523.s3|41-49|transient|O
DDI-DrugBank.d523.s3|51-60|drowsiness|O
DDI-DrugBank.d523.s3|62-64|was|O
DDI-DrugBank.d523.s3|66-73|observed|O
DDI-DrugBank.d523.s3|75-76|in|O
DDI-DrugBank.d523.s3|78-79|63|O
DDI-DrugBank.d523.s3|80-80|%|O
DDI-DrugBank.d523.s3|82-83|of|O
DDI-DrugBank.d523.s3|85-89|those|O
DDI-DrugBank.d523.s3|91-99|receiving|O
DDI-DrugBank.d523.s3|101-108|baclofen|drug
DDI-DrugBank.d523.s3|110-116|tablets|O
DDI-DrugBank.d523.s3|118-125|compared|O
DDI-DrugBank.d523.s3|127-128|to|O
DDI-DrugBank.d523.s3|130-131|36|O
DDI-DrugBank.d523.s3|132-132|%|O
DDI-DrugBank.d523.s3|134-135|of|O
DDI-DrugBank.d523.s3|137-141|those|O
DDI-DrugBank.d523.s3|143-144|in|O
DDI-DrugBank.d523.s3|146-148|the|O
DDI-DrugBank.d523.s3|150-156|placebo|O
DDI-DrugBank.d523.s3|158-162|group|O
DDI-DrugBank.d523.s3|163-163|.|O
DDI-DrugBank.d523.s4|0-4|Other|O
DDI-DrugBank.d523.s4|6-11|common|O
DDI-DrugBank.d523.s4|13-19|adverse|O
DDI-DrugBank.d523.s4|21-29|reactions|O
DDI-DrugBank.d523.s4|31-33|are|O
DDI-DrugBank.d523.s4|35-43|dizziness|O
DDI-DrugBank.d523.s4|45-45|(|O
DDI-DrugBank.d523.s4|46-49|5-15|O
DDI-DrugBank.d523.s4|50-50|%|O
DDI-DrugBank.d523.s4|51-51|)|O
DDI-DrugBank.d523.s4|52-52|,|O
DDI-DrugBank.d523.s4|54-61|weakness|O
DDI-DrugBank.d523.s4|63-63|(|O
DDI-DrugBank.d523.s4|64-67|5-15|O
DDI-DrugBank.d523.s4|68-68|%|O
DDI-DrugBank.d523.s4|69-69|)|O
DDI-DrugBank.d523.s4|71-73|and|O
DDI-DrugBank.d523.s4|75-81|fatigue|O
DDI-DrugBank.d523.s4|83-83|(|O
DDI-DrugBank.d523.s4|84-86|2-4|O
DDI-DrugBank.d523.s4|87-87|%|O
DDI-DrugBank.d523.s4|88-88|)|O
DDI-DrugBank.d523.s4|89-89|.|O
DDI-DrugBank.d523.s5|0-5|Others|O
DDI-DrugBank.d523.s5|7-14|reported|O
DDI-DrugBank.d523.s5|15-15|:|O
DDI-DrugBank.d523.s5|17-32|Neuropsychiatric|O
DDI-DrugBank.d523.s5|33-33|:|O
DDI-DrugBank.d523.s5|35-43|Confusion|O
DDI-DrugBank.d523.s5|45-45|(|O
DDI-DrugBank.d523.s5|46-49|1-11|O
DDI-DrugBank.d523.s5|50-50|%|O
DDI-DrugBank.d523.s5|51-51|)|O
DDI-DrugBank.d523.s5|52-52|,|O
DDI-DrugBank.d523.s5|54-61|headache|O
DDI-DrugBank.d523.s5|63-63|(|O
DDI-DrugBank.d523.s5|64-66|4-8|O
DDI-DrugBank.d523.s5|67-67|%|O
DDI-DrugBank.d523.s5|68-68|)|O
DDI-DrugBank.d523.s5|69-69|,|O
DDI-DrugBank.d523.s5|71-78|insomnia|O
DDI-DrugBank.d523.s5|80-80|(|O
DDI-DrugBank.d523.s5|81-83|2-7|O
DDI-DrugBank.d523.s5|84-84|%|O
DDI-DrugBank.d523.s5|85-85|)|O
DDI-DrugBank.d523.s5|86-86|;|O
DDI-DrugBank.d523.s6|0-2|and|O
DDI-DrugBank.d523.s6|3-3|,|O
DDI-DrugBank.d523.s6|5-10|rarely|O
DDI-DrugBank.d523.s6|11-11|,|O
DDI-DrugBank.d523.s6|13-20|euphoria|O
DDI-DrugBank.d523.s6|21-21|,|O
DDI-DrugBank.d523.s6|23-32|excitement|O
DDI-DrugBank.d523.s6|33-33|,|O
DDI-DrugBank.d523.s6|35-44|depression|O
DDI-DrugBank.d523.s6|45-45|,|O
DDI-DrugBank.d523.s6|47-60|hallucinations|O
DDI-DrugBank.d523.s6|61-61|,|O
DDI-DrugBank.d523.s6|63-73|paresthesia|O
DDI-DrugBank.d523.s6|74-74|,|O
DDI-DrugBank.d523.s6|76-81|muscle|O
DDI-DrugBank.d523.s6|83-86|pain|O
DDI-DrugBank.d523.s6|87-87|,|O
DDI-DrugBank.d523.s6|89-96|tinnitus|O
DDI-DrugBank.d523.s6|97-97|,|O
DDI-DrugBank.d523.s6|99-105|slurred|O
DDI-DrugBank.d523.s6|107-112|speech|O
DDI-DrugBank.d523.s6|113-113|,|O
DDI-DrugBank.d523.s6|115-126|coordination|O
DDI-DrugBank.d523.s6|128-135|disorder|O
DDI-DrugBank.d523.s6|136-136|,|O
DDI-DrugBank.d523.s6|138-143|tremor|O
DDI-DrugBank.d523.s6|144-144|,|O
DDI-DrugBank.d523.s6|146-153|rigidity|O
DDI-DrugBank.d523.s6|154-154|,|O
DDI-DrugBank.d523.s6|156-163|dystonia|O
DDI-DrugBank.d523.s6|164-164|,|O
DDI-DrugBank.d523.s6|166-171|ataxia|O
DDI-DrugBank.d523.s6|172-172|,|O
DDI-DrugBank.d523.s6|174-180|blurred|O
DDI-DrugBank.d523.s6|182-187|vision|O
DDI-DrugBank.d523.s6|188-188|,|O
DDI-DrugBank.d523.s6|190-198|nystagmus|O
DDI-DrugBank.d523.s6|199-199|,|O
DDI-DrugBank.d523.s6|201-210|strabismus|O
DDI-DrugBank.d523.s6|211-211|,|O
DDI-DrugBank.d523.s6|213-218|miosis|O
DDI-DrugBank.d523.s6|219-219|,|O
DDI-DrugBank.d523.s6|221-229|mydriasis|O
DDI-DrugBank.d523.s6|230-230|,|O
DDI-DrugBank.d523.s6|232-239|diplopia|O
DDI-DrugBank.d523.s6|240-240|,|O
DDI-DrugBank.d523.s6|242-251|dysarthria|O
DDI-DrugBank.d523.s6|252-252|,|O
DDI-DrugBank.d523.s6|254-262|epileptic|O
DDI-DrugBank.d523.s6|264-270|seizure|O
DDI-DrugBank.d523.s6|271-271|.|O
DDI-DrugBank.d523.s7|0-13|Cardiovascular|O
DDI-DrugBank.d523.s7|14-14|:|O
DDI-DrugBank.d523.s7|16-26|Hypotension|O
DDI-DrugBank.d523.s7|28-28|(|O
DDI-DrugBank.d523.s7|29-31|0-9|O
DDI-DrugBank.d523.s7|32-32|%|O
DDI-DrugBank.d523.s7|33-33|)|O
DDI-DrugBank.d523.s7|34-34|.|O
DDI-DrugBank.d523.s8|0-3|Rare|O
DDI-DrugBank.d523.s8|5-13|instances|O
DDI-DrugBank.d523.s8|15-16|of|O
DDI-DrugBank.d523.s8|18-24|dyspnea|O
DDI-DrugBank.d523.s8|25-25|,|O
DDI-DrugBank.d523.s8|27-37|palpitation|O
DDI-DrugBank.d523.s8|38-38|,|O
DDI-DrugBank.d523.s8|40-44|chest|O
DDI-DrugBank.d523.s8|46-49|pain|O
DDI-DrugBank.d523.s8|50-50|,|O
DDI-DrugBank.d523.s8|52-58|syncope|O
DDI-DrugBank.d523.s8|59-59|.|O
DDI-DrugBank.d523.s9|0-15|Gastrointestinal|O
DDI-DrugBank.d523.s9|16-16|:|O
DDI-DrugBank.d523.s9|18-23|Nausea|O
DDI-DrugBank.d523.s9|25-25|(|O
DDI-DrugBank.d523.s9|26-29|4-12|O
DDI-DrugBank.d523.s9|30-30|%|O
DDI-DrugBank.d523.s9|31-31|)|O
DDI-DrugBank.d523.s9|32-32|,|O
DDI-DrugBank.d523.s9|34-45|constipation|O
DDI-DrugBank.d523.s9|47-47|(|O
DDI-DrugBank.d523.s9|48-50|2-6|O
DDI-DrugBank.d523.s9|51-51|%|O
DDI-DrugBank.d523.s9|52-52|)|O
DDI-DrugBank.d523.s9|53-53|;|O
DDI-DrugBank.d523.s10|0-2|and|O
DDI-DrugBank.d523.s10|3-3|,|O
DDI-DrugBank.d523.s10|5-10|rarely|O
DDI-DrugBank.d523.s10|11-11|,|O
DDI-DrugBank.d523.s10|13-15|dry|O
DDI-DrugBank.d523.s10|17-21|mouth|O
DDI-DrugBank.d523.s10|22-22|,|O
DDI-DrugBank.d523.s10|24-31|anorexia|O
DDI-DrugBank.d523.s10|32-32|,|O
DDI-DrugBank.d523.s10|34-38|taste|O
DDI-DrugBank.d523.s10|40-47|disorder|O
DDI-DrugBank.d523.s10|48-48|,|O
DDI-DrugBank.d523.s10|50-58|abdominal|O
DDI-DrugBank.d523.s10|60-63|pain|O
DDI-DrugBank.d523.s10|64-64|,|O
DDI-DrugBank.d523.s10|66-73|vomiting|O
DDI-DrugBank.d523.s10|74-74|,|O
DDI-DrugBank.d523.s10|76-83|diarrhea|O
DDI-DrugBank.d523.s10|84-84|,|O
DDI-DrugBank.d523.s10|86-88|and|O
DDI-DrugBank.d523.s10|90-97|positive|O
DDI-DrugBank.d523.s10|99-102|test|O
DDI-DrugBank.d523.s10|104-106|for|O
DDI-DrugBank.d523.s10|108-113|occult|O
DDI-DrugBank.d523.s10|115-119|blood|O
DDI-DrugBank.d523.s10|121-122|in|O
DDI-DrugBank.d523.s10|124-128|stool|O
DDI-DrugBank.d523.s10|129-129|.|O
DDI-DrugBank.d523.s11|0-12|Genitourinary|O
DDI-DrugBank.d523.s11|13-13|:|O
DDI-DrugBank.d523.s11|15-21|Urinary|O
DDI-DrugBank.d523.s11|23-31|frequency|O
DDI-DrugBank.d523.s11|33-33|(|O
DDI-DrugBank.d523.s11|34-36|2-6|O
DDI-DrugBank.d523.s11|37-37|%|O
DDI-DrugBank.d523.s11|38-38|)|O
DDI-DrugBank.d523.s11|39-39|;|O
DDI-DrugBank.d523.s12|0-2|and|O
DDI-DrugBank.d523.s12|3-3|,|O
DDI-DrugBank.d523.s12|5-10|rarely|O
DDI-DrugBank.d523.s12|11-11|,|O
DDI-DrugBank.d523.s12|13-20|enuresis|O
DDI-DrugBank.d523.s12|21-21|,|O
DDI-DrugBank.d523.s12|23-29|urinary|O
DDI-DrugBank.d523.s12|31-39|retention|O
DDI-DrugBank.d523.s12|40-40|,|O
DDI-DrugBank.d523.s12|42-48|dysuria|O
DDI-DrugBank.d523.s12|49-49|,|O
DDI-DrugBank.d523.s12|51-59|impotence|O
DDI-DrugBank.d523.s12|60-60|,|O
DDI-DrugBank.d523.s12|62-70|inability|O
DDI-DrugBank.d523.s12|72-73|to|O
DDI-DrugBank.d523.s12|75-83|ejaculate|O
DDI-DrugBank.d523.s12|84-84|,|O
DDI-DrugBank.d523.s12|86-93|nocturia|O
DDI-DrugBank.d523.s12|94-94|,|O
DDI-DrugBank.d523.s12|96-104|hematuria|O
DDI-DrugBank.d523.s12|105-105|.|O
DDI-DrugBank.d523.s13|0-4|Other|O
DDI-DrugBank.d523.s13|5-5|:|O
DDI-DrugBank.d523.s13|7-15|Instances|O
DDI-DrugBank.d523.s13|17-18|of|O
DDI-DrugBank.d523.s13|20-23|rash|O
DDI-DrugBank.d523.s13|24-24|,|O
DDI-DrugBank.d523.s13|26-33|pruritus|O
DDI-DrugBank.d523.s13|34-34|,|O
DDI-DrugBank.d523.s13|36-40|ankle|O
DDI-DrugBank.d523.s13|42-46|edema|O
DDI-DrugBank.d523.s13|47-47|,|O
DDI-DrugBank.d523.s13|49-57|excessive|O
DDI-DrugBank.d523.s13|59-70|perspiration|O
DDI-DrugBank.d523.s13|71-71|,|O
DDI-DrugBank.d523.s13|73-78|weight|O
DDI-DrugBank.d523.s13|80-83|gain|O
DDI-DrugBank.d523.s13|84-84|,|O
DDI-DrugBank.d523.s13|86-90|nasal|O
DDI-DrugBank.d523.s13|92-101|congestion|O
DDI-DrugBank.d523.s13|102-102|.|O
DDI-DrugBank.d523.s14|0-3|Some|O
DDI-DrugBank.d523.s14|5-6|of|O
DDI-DrugBank.d523.s14|8-10|the|O
DDI-DrugBank.d523.s14|12-14|CNS|O
DDI-DrugBank.d523.s14|16-18|and|O
DDI-DrugBank.d523.s14|20-32|genitourinary|O
DDI-DrugBank.d523.s14|34-41|symptoms|O
DDI-DrugBank.d523.s14|43-45|may|O
DDI-DrugBank.d523.s14|47-48|be|O
DDI-DrugBank.d523.s14|50-56|related|O
DDI-DrugBank.d523.s14|58-59|to|O
DDI-DrugBank.d523.s14|61-63|the|O
DDI-DrugBank.d523.s14|65-74|underlying|O
DDI-DrugBank.d523.s14|76-82|disease|O
DDI-DrugBank.d523.s14|84-89|rather|O
DDI-DrugBank.d523.s14|91-94|than|O
DDI-DrugBank.d523.s14|96-97|to|O
DDI-DrugBank.d523.s14|99-102|drug|O
DDI-DrugBank.d523.s14|104-110|therapy|O
DDI-DrugBank.d523.s14|111-111|.|O
DDI-DrugBank.d523.s15|0-2|The|O
DDI-DrugBank.d523.s15|4-12|following|O
DDI-DrugBank.d523.s15|14-23|laboratory|O
DDI-DrugBank.d523.s15|25-29|tests|O
DDI-DrugBank.d523.s15|31-34|have|O
DDI-DrugBank.d523.s15|36-39|been|O
DDI-DrugBank.d523.s15|41-45|found|O
DDI-DrugBank.d523.s15|47-48|to|O
DDI-DrugBank.d523.s15|50-51|be|O
DDI-DrugBank.d523.s15|53-60|abnormal|O
DDI-DrugBank.d523.s15|62-63|in|O
DDI-DrugBank.d523.s15|65-65|a|O
DDI-DrugBank.d523.s15|67-69|few|O
DDI-DrugBank.d523.s15|71-78|patients|O
DDI-DrugBank.d523.s15|80-88|receiving|O
DDI-DrugBank.d523.s15|90-97|baclofen|drug
DDI-DrugBank.d523.s15|98-98|:|O
DDI-DrugBank.d523.s15|100-108|increased|O
DDI-DrugBank.d523.s15|110-113|SGOT|O
DDI-DrugBank.d523.s15|114-114|,|O
DDI-DrugBank.d523.s15|116-123|elevated|O
DDI-DrugBank.d523.s15|125-132|alkaline|O
DDI-DrugBank.d523.s15|134-144|phosphatase|O
DDI-DrugBank.d523.s15|145-145|,|O
DDI-DrugBank.d523.s15|147-149|and|O
DDI-DrugBank.d523.s15|151-159|elevation|O
DDI-DrugBank.d523.s15|161-162|of|O
DDI-DrugBank.d523.s15|164-168|blood|O
DDI-DrugBank.d523.s15|170-174|sugar|O
DDI-DrugBank.d523.s15|175-175|.|O
DDI-DrugBank.d523.s16|0-2|The|O
DDI-DrugBank.d523.s16|4-10|adverse|O
DDI-DrugBank.d523.s16|12-21|experience|O
DDI-DrugBank.d523.s16|23-29|profile|O
DDI-DrugBank.d523.s16|31-34|seen|O
DDI-DrugBank.d523.s16|36-39|with|O
DDI-DrugBank.d523.s16|41-49|KEMSTROTM|brand
DDI-DrugBank.d523.s16|51-53|was|O
DDI-DrugBank.d523.s16|55-61|similar|O
DDI-DrugBank.d523.s16|63-64|to|O
DDI-DrugBank.d523.s16|66-69|that|O
DDI-DrugBank.d523.s16|71-74|seen|O
DDI-DrugBank.d523.s16|76-79|with|O
DDI-DrugBank.d523.s16|81-88|baclofen|drug
DDI-DrugBank.d523.s16|90-96|tablets|O
DDI-DrugBank.d523.s16|97-97|.|O
DDI-DrugBank.d396.s0|0-7|Patients|O
DDI-DrugBank.d396.s0|9-17|receiving|O
DDI-DrugBank.d396.s0|19-23|other|O
DDI-DrugBank.d396.s0|25-43|narcotic analgesics|group
DDI-DrugBank.d396.s0|44-44|,|O
DDI-DrugBank.d396.s0|46-59|antipsychotics|group
DDI-DrugBank.d396.s0|60-60|,|O
DDI-DrugBank.d396.s0|62-79|antianxiety agents|group
DDI-DrugBank.d396.s0|80-80|,|O
DDI-DrugBank.d396.s0|82-83|or|O
DDI-DrugBank.d396.s0|85-89|other|O
DDI-DrugBank.d396.s0|91-105|CNS depressants|group
DDI-DrugBank.d396.s0|107-107|(|O
DDI-DrugBank.d396.s0|108-116|including|O
DDI-DrugBank.d396.s0|118-124|alcohol|drug
DDI-DrugBank.d396.s0|125-125|)|O
DDI-DrugBank.d396.s0|127-139|concomitantly|O
DDI-DrugBank.d396.s0|141-144|with|O
DDI-DrugBank.d396.s0|146-156|hydrocodone|drug
DDI-DrugBank.d396.s0|158-160|and|O
DDI-DrugBank.d396.s0|162-174|acetaminophen|drug
DDI-DrugBank.d396.s0|176-182|tablets|O
DDI-DrugBank.d396.s0|184-186|may|O
DDI-DrugBank.d396.s0|188-194|exhibit|O
DDI-DrugBank.d396.s0|196-197|an|O
DDI-DrugBank.d396.s0|199-206|additive|O
DDI-DrugBank.d396.s0|208-210|CNS|O
DDI-DrugBank.d396.s0|212-221|depression|O
DDI-DrugBank.d396.s0|222-222|.|O
DDI-DrugBank.d396.s1|0-3|When|O
DDI-DrugBank.d396.s1|5-12|combined|O
DDI-DrugBank.d396.s1|14-20|therapy|O
DDI-DrugBank.d396.s1|22-23|is|O
DDI-DrugBank.d396.s1|25-36|contemplated|O
DDI-DrugBank.d396.s1|37-37|,|O
DDI-DrugBank.d396.s1|39-41|the|O
DDI-DrugBank.d396.s1|43-46|dose|O
DDI-DrugBank.d396.s1|48-49|of|O
DDI-DrugBank.d396.s1|51-53|one|O
DDI-DrugBank.d396.s1|55-56|or|O
DDI-DrugBank.d396.s1|58-61|both|O
DDI-DrugBank.d396.s1|63-68|agents|O
DDI-DrugBank.d396.s1|70-75|should|O
DDI-DrugBank.d396.s1|77-78|be|O
DDI-DrugBank.d396.s1|80-86|reduced|O
DDI-DrugBank.d396.s1|87-87|.|O
DDI-DrugBank.d396.s2|0-2|The|O
DDI-DrugBank.d396.s2|4-6|use|O
DDI-DrugBank.d396.s2|8-9|of|O
DDI-DrugBank.d396.s2|11-24|MAO inhibitors|group
DDI-DrugBank.d396.s2|26-27|or|O
DDI-DrugBank.d396.s2|29-53|tricyclic antidepressants|group
DDI-DrugBank.d396.s2|55-58|with|O
DDI-DrugBank.d396.s2|60-70|hydrocodone|drug
DDI-DrugBank.d396.s2|72-83|preparations|O
DDI-DrugBank.d396.s2|85-87|may|O
DDI-DrugBank.d396.s2|89-96|increase|O
DDI-DrugBank.d396.s2|98-100|the|O
DDI-DrugBank.d396.s2|102-107|effect|O
DDI-DrugBank.d396.s2|109-110|of|O
DDI-DrugBank.d396.s2|112-117|either|O
DDI-DrugBank.d396.s2|119-121|the|O
DDI-DrugBank.d396.s2|123-136|antidepressant|group
DDI-DrugBank.d396.s2|138-139|or|O
DDI-DrugBank.d396.s2|141-151|hydrocodone|drug
DDI-DrugBank.d396.s2|152-152|.|O
DDI-DrugBank.d396.s3|0-2|The|O
DDI-DrugBank.d396.s3|4-13|concurrent|O
DDI-DrugBank.d396.s3|15-17|use|O
DDI-DrugBank.d396.s3|19-20|of|O
DDI-DrugBank.d396.s3|22-37|anticholinergics|group
DDI-DrugBank.d396.s3|39-42|with|O
DDI-DrugBank.d396.s3|44-54|hydrocodone|drug
DDI-DrugBank.d396.s3|56-58|may|O
DDI-DrugBank.d396.s3|60-66|produce|O
DDI-DrugBank.d396.s3|68-76|paralytic|O
DDI-DrugBank.d396.s3|78-82|ileus|O
DDI-DrugBank.d396.s3|83-83|.|O
DDI-DrugBank.d274.s0|0-5|Animal|O
DDI-DrugBank.d274.s0|7-13|studies|O
DDI-DrugBank.d274.s0|15-22|indicate|O
DDI-DrugBank.d274.s0|24-27|that|O
DDI-DrugBank.d274.s0|29-38|dobutamine|drug
DDI-DrugBank.d274.s0|40-42|may|O
DDI-DrugBank.d274.s0|44-45|be|O
DDI-DrugBank.d274.s0|47-57|ineffective|O
DDI-DrugBank.d274.s0|59-60|if|O
DDI-DrugBank.d274.s0|62-64|the|O
DDI-DrugBank.d274.s0|66-72|patient|O
DDI-DrugBank.d274.s0|74-76|has|O
DDI-DrugBank.d274.s0|78-85|recently|O
DDI-DrugBank.d274.s0|87-94|received|O
DDI-DrugBank.d274.s0|96-96|a|O
DDI-DrugBank.d274.s0|98-112|b-blocking drug|group
DDI-DrugBank.d274.s0|113-113|.|O
DDI-DrugBank.d274.s1|0-1|In|O
DDI-DrugBank.d274.s1|3-6|such|O
DDI-DrugBank.d274.s1|8-8|a|O
DDI-DrugBank.d274.s1|10-13|case|O
DDI-DrugBank.d274.s1|14-14|,|O
DDI-DrugBank.d274.s1|16-18|the|O
DDI-DrugBank.d274.s1|20-29|peripheral|O
DDI-DrugBank.d274.s1|31-38|vascular|O
DDI-DrugBank.d274.s1|40-49|resistance|O
DDI-DrugBank.d274.s1|51-53|may|O
DDI-DrugBank.d274.s1|55-62|increase|O
DDI-DrugBank.d274.s1|63-63|.|O
DDI-DrugBank.d274.s2|0-10|Preliminary|O
DDI-DrugBank.d274.s2|12-18|studies|O
DDI-DrugBank.d274.s2|20-27|indicate|O
DDI-DrugBank.d274.s2|29-32|that|O
DDI-DrugBank.d274.s2|34-36|the|O
DDI-DrugBank.d274.s2|38-48|concomitant|O
DDI-DrugBank.d274.s2|50-52|use|O
DDI-DrugBank.d274.s2|54-55|of|O
DDI-DrugBank.d274.s2|57-66|dobutamine|drug
DDI-DrugBank.d274.s2|68-70|and|O
DDI-DrugBank.d274.s2|72-84|nitroprusside|drug
DDI-DrugBank.d274.s2|86-92|results|O
DDI-DrugBank.d274.s2|94-95|in|O
DDI-DrugBank.d274.s2|97-97|a|O
DDI-DrugBank.d274.s2|99-104|higher|O
DDI-DrugBank.d274.s2|106-112|cardiac|O
DDI-DrugBank.d274.s2|114-119|output|O
DDI-DrugBank.d274.s2|121-123|and|O
DDI-DrugBank.d274.s2|124-124|,|O
DDI-DrugBank.d274.s2|126-132|usually|O
DDI-DrugBank.d274.s2|133-133|,|O
DDI-DrugBank.d274.s2|135-135|a|O
DDI-DrugBank.d274.s2|137-141|lower|O
DDI-DrugBank.d274.s2|143-151|pulmonary|O
DDI-DrugBank.d274.s2|153-157|wedge|O
DDI-DrugBank.d274.s2|159-166|pressure|O
DDI-DrugBank.d274.s2|168-171|than|O
DDI-DrugBank.d274.s2|173-176|when|O
DDI-DrugBank.d274.s2|178-183|either|O
DDI-DrugBank.d274.s2|185-188|drug|O
DDI-DrugBank.d274.s2|190-191|is|O
DDI-DrugBank.d274.s2|193-196|used|O
DDI-DrugBank.d274.s2|198-202|alone|O
DDI-DrugBank.d274.s2|203-203|.|O
DDI-DrugBank.d274.s3|0-4|There|O
DDI-DrugBank.d274.s3|6-8|was|O
DDI-DrugBank.d274.s3|10-11|no|O
DDI-DrugBank.d274.s3|13-20|evidence|O
DDI-DrugBank.d274.s3|22-23|of|O
DDI-DrugBank.d274.s3|25-28|drug|O
DDI-DrugBank.d274.s3|30-41|interactions|O
DDI-DrugBank.d274.s3|43-44|in|O
DDI-DrugBank.d274.s3|46-53|clinical|O
DDI-DrugBank.d274.s3|55-61|studies|O
DDI-DrugBank.d274.s3|63-64|in|O
DDI-DrugBank.d274.s3|66-70|which|O
DDI-DrugBank.d274.s3|72-81|dobutamine|drug
DDI-DrugBank.d274.s3|83-85|was|O
DDI-DrugBank.d274.s3|87-98|administered|O
DDI-DrugBank.d274.s3|100-111|concurrently|O
DDI-DrugBank.d274.s3|113-116|with|O
DDI-DrugBank.d274.s3|118-122|other|O
DDI-DrugBank.d274.s3|124-128|drugs|O
DDI-DrugBank.d274.s3|129-129|,|O
DDI-DrugBank.d274.s3|131-139|including|O
DDI-DrugBank.d274.s3|141-162|digitalis preparations|group
DDI-DrugBank.d274.s3|163-163|,|O
DDI-DrugBank.d274.s3|165-174|furosemide|drug
DDI-DrugBank.d274.s3|175-175|,|O
DDI-DrugBank.d274.s3|177-190|spironolactone|drug
DDI-DrugBank.d274.s3|191-191|,|O
DDI-DrugBank.d274.s3|193-201|lidocaine|drug
DDI-DrugBank.d274.s3|202-202|,|O
DDI-DrugBank.d274.s3|204-222|glyceryl trinitrate|drug
DDI-DrugBank.d274.s3|223-223|,|O
DDI-DrugBank.d274.s3|225-244|isosorbide dinitrate|drug
DDI-DrugBank.d274.s3|245-245|,|O
DDI-DrugBank.d274.s3|247-254|morphine|drug
DDI-DrugBank.d274.s3|255-255|,|O
DDI-DrugBank.d274.s3|257-264|atropine|drug
DDI-DrugBank.d274.s3|265-265|,|O
DDI-DrugBank.d274.s3|267-273|heparin|drug
DDI-DrugBank.d274.s3|274-274|,|O
DDI-DrugBank.d274.s3|276-284|protamine|drug
DDI-DrugBank.d274.s3|285-285|,|O
DDI-DrugBank.d274.s3|287-304|potassium chloride|drug
DDI-DrugBank.d274.s3|305-305|,|O
DDI-DrugBank.d274.s3|307-316|folic acid|drug
DDI-DrugBank.d274.s3|317-317|,|O
DDI-DrugBank.d274.s3|319-321|and|O
DDI-DrugBank.d274.s3|323-335|acetaminophen|drug
DDI-DrugBank.d274.s3|336-336|.|O
DDI-DrugBank.d192.s0|0-17|Dexbrompheniramine|drug
DDI-DrugBank.d192.s0|19-21|can|O
DDI-DrugBank.d192.s0|23-30|interact|O
DDI-DrugBank.d192.s0|32-35|with|O
DDI-DrugBank.d192.s0|37-43|alcohol|drug
DDI-DrugBank.d192.s0|45-46|or|O
DDI-DrugBank.d192.s0|48-52|other|O
DDI-DrugBank.d192.s0|54-68|CNS depressants|group
DDI-DrugBank.d192.s0|70-70|(|O
DDI-DrugBank.d192.s0|71-73|may|O
DDI-DrugBank.d192.s0|75-84|potentiate|O
DDI-DrugBank.d192.s0|86-88|the|O
DDI-DrugBank.d192.s0|90-92|CNS|O
DDI-DrugBank.d192.s0|94-103|depressant|O
DDI-DrugBank.d192.s0|105-111|effects|O
DDI-DrugBank.d192.s0|113-114|of|O
DDI-DrugBank.d192.s0|116-121|either|O
DDI-DrugBank.d192.s0|123-127|these|O
DDI-DrugBank.d192.s0|129-139|medications|O
DDI-DrugBank.d192.s0|141-142|or|O
DDI-DrugBank.d192.s0|144-157|antihistamines|group
DDI-DrugBank.d192.s0|158-158|)|O
DDI-DrugBank.d192.s0|159-159|,|O
DDI-DrugBank.d192.s0|161-176|anticholinergics|group
DDI-DrugBank.d192.s0|178-179|or|O
DDI-DrugBank.d192.s0|181-185|other|O
DDI-DrugBank.d192.s0|187-197|medications|O
DDI-DrugBank.d192.s0|199-202|with|O
DDI-DrugBank.d192.s0|204-218|anticholinergic|O
DDI-DrugBank.d192.s0|220-227|activity|O
DDI-DrugBank.d192.s0|229-229|(|O
DDI-DrugBank.d192.s0|230-244|anticholinergic|O
DDI-DrugBank.d192.s0|246-252|effects|O
DDI-DrugBank.d192.s0|254-256|may|O
DDI-DrugBank.d192.s0|258-259|be|O
DDI-DrugBank.d192.s0|261-271|potentiated|O
DDI-DrugBank.d192.s0|273-276|when|O
DDI-DrugBank.d192.s0|278-282|these|O
DDI-DrugBank.d192.s0|284-294|medications|O
DDI-DrugBank.d192.s0|296-298|are|O
DDI-DrugBank.d192.s0|300-303|used|O
DDI-DrugBank.d192.s0|305-316|concurrently|O
DDI-DrugBank.d192.s0|318-321|with|O
DDI-DrugBank.d192.s0|323-336|antihistamines|group
DDI-DrugBank.d192.s0|337-337|)|O
DDI-DrugBank.d192.s0|338-338|,|O
DDI-DrugBank.d192.s0|340-342|and|O
DDI-DrugBank.d192.s0|344-377|monoamine oxidase ( MAO ) inhibitors|group
DDI-DrugBank.d192.s0|379-379|(|O
DDI-DrugBank.d192.s0|380-389|concurrent|O
DDI-DrugBank.d192.s0|391-393|use|O
DDI-DrugBank.d192.s0|395-398|with|O
DDI-DrugBank.d192.s0|400-413|antihistamines|group
DDI-DrugBank.d192.s0|415-417|may|O
DDI-DrugBank.d192.s0|419-425|prolong|O
DDI-DrugBank.d192.s0|427-429|and|O
DDI-DrugBank.d192.s0|431-439|intensify|O
DDI-DrugBank.d192.s0|441-443|the|O
DDI-DrugBank.d192.s0|445-459|anticholinergic|O
DDI-DrugBank.d192.s0|461-463|and|O
DDI-DrugBank.d192.s0|465-467|CNS|O
DDI-DrugBank.d192.s0|469-478|depressant|O
DDI-DrugBank.d192.s0|480-486|effects|O
DDI-DrugBank.d192.s0|488-489|of|O
DDI-DrugBank.d192.s0|491-504|antihistamines|group
DDI-DrugBank.d192.s0|505-505|)|O
DDI-DrugBank.d192.s0|506-506|.|O
DDI-DrugBank.d661.s0|0-3|Drug|O
DDI-DrugBank.d661.s0|5-16|Interactions|O
DDI-DrugBank.d661.s0|17-17|:|O
DDI-DrugBank.d661.s0|19-21|The|O
DDI-DrugBank.d661.s0|23-25|use|O
DDI-DrugBank.d661.s0|27-28|of|O
DDI-DrugBank.d661.s0|30-36|ZEMURON|brand
DDI-DrugBank.d661.s0|41-41|(|O
DDI-DrugBank.d661.s0|42-59|rocuronium bromide|drug
DDI-DrugBank.d661.s0|60-60|)|O
DDI-DrugBank.d661.s0|62-70|Injection|O
DDI-DrugBank.d661.s0|72-77|before|O
DDI-DrugBank.d661.s0|79-93|succinylcholine|drug
DDI-DrugBank.d661.s0|94-94|,|O
DDI-DrugBank.d661.s0|96-98|for|O
DDI-DrugBank.d661.s0|100-102|the|O
DDI-DrugBank.d661.s0|104-110|purpose|O
DDI-DrugBank.d661.s0|112-113|of|O
DDI-DrugBank.d661.s0|115-125|attenuating|O
DDI-DrugBank.d661.s0|127-130|some|O
DDI-DrugBank.d661.s0|132-133|of|O
DDI-DrugBank.d661.s0|135-137|the|O
DDI-DrugBank.d661.s0|139-142|side|O
DDI-DrugBank.d661.s0|144-150|effects|O
DDI-DrugBank.d661.s0|152-153|of|O
DDI-DrugBank.d661.s0|155-169|succinylcholine|drug
DDI-DrugBank.d661.s0|170-170|,|O
DDI-DrugBank.d661.s0|172-174|has|O
DDI-DrugBank.d661.s0|176-178|not|O
DDI-DrugBank.d661.s0|180-183|been|O
DDI-DrugBank.d661.s0|185-191|studied|O
DDI-DrugBank.d661.s0|192-192|.|O
DDI-DrugBank.d661.s1|0-1|If|O
DDI-DrugBank.d661.s1|3-9|ZEMURON|brand
DDI-DrugBank.d661.s1|14-15|is|O
DDI-DrugBank.d661.s1|17-28|administered|O
DDI-DrugBank.d661.s1|30-38|following|O
DDI-DrugBank.d661.s1|40-53|administration|O
DDI-DrugBank.d661.s1|55-56|of|O
DDI-DrugBank.d661.s1|58-72|succinylcholine|drug
DDI-DrugBank.d661.s1|73-73|,|O
DDI-DrugBank.d661.s1|75-76|it|O
DDI-DrugBank.d661.s1|78-83|should|O
DDI-DrugBank.d661.s1|85-87|not|O
DDI-DrugBank.d661.s1|89-90|be|O
DDI-DrugBank.d661.s1|92-96|given|O
DDI-DrugBank.d661.s1|98-102|until|O
DDI-DrugBank.d661.s1|104-111|recovery|O
DDI-DrugBank.d661.s1|113-116|from|O
DDI-DrugBank.d661.s1|118-132|succinylcholine|drug
DDI-DrugBank.d661.s1|134-136|has|O
DDI-DrugBank.d661.s1|138-141|been|O
DDI-DrugBank.d661.s1|143-150|observed|O
DDI-DrugBank.d661.s1|151-151|.|O
DDI-DrugBank.d661.s2|0-2|The|O
DDI-DrugBank.d661.s2|4-9|median|O
DDI-DrugBank.d661.s2|11-18|duration|O
DDI-DrugBank.d661.s2|20-21|of|O
DDI-DrugBank.d661.s2|23-28|action|O
DDI-DrugBank.d661.s2|30-31|of|O
DDI-DrugBank.d661.s2|33-39|ZEMURON|brand
DDI-DrugBank.d661.s2|44-46|0.6|O
DDI-DrugBank.d661.s2|48-52|mg/kg|O
DDI-DrugBank.d661.s2|54-65|administered|O
DDI-DrugBank.d661.s2|67-71|after|O
DDI-DrugBank.d661.s2|73-73|a|O
DDI-DrugBank.d661.s2|75-75|1|O
DDI-DrugBank.d661.s2|77-81|mg/kg|O
DDI-DrugBank.d661.s2|83-86|dose|O
DDI-DrugBank.d661.s2|88-89|of|O
DDI-DrugBank.d661.s2|91-105|succinylcholine|drug
DDI-DrugBank.d661.s2|107-110|when|O
DDI-DrugBank.d661.s2|112-112|T|O
DDI-DrugBank.d661.s2|114-114|1|O
DDI-DrugBank.d661.s2|116-123|returned|O
DDI-DrugBank.d661.s2|125-126|to|O
DDI-DrugBank.d661.s2|128-129|75|O
DDI-DrugBank.d661.s2|130-130|%|O
DDI-DrugBank.d661.s2|132-133|of|O
DDI-DrugBank.d661.s2|135-141|control|O
DDI-DrugBank.d661.s2|143-145|was|O
DDI-DrugBank.d661.s2|147-148|36|O
DDI-DrugBank.d661.s2|150-156|minutes|O
DDI-DrugBank.d661.s2|158-158|(|O
DDI-DrugBank.d661.s2|159-163|range|O
DDI-DrugBank.d661.s2|165-169|14-57|O
DDI-DrugBank.d661.s2|170-170|,|O
DDI-DrugBank.d661.s2|172-175|n=12|O
DDI-DrugBank.d661.s2|176-176|)|O
DDI-DrugBank.d661.s2|178-179|vs|O
DDI-DrugBank.d661.s2|180-180|.|O
DDI-DrugBank.d661.s3|0-1|28|O
DDI-DrugBank.d661.s3|3-9|minutes|O
DDI-DrugBank.d661.s3|11-11|(|O
DDI-DrugBank.d661.s3|12-16|17-51|O
DDI-DrugBank.d661.s3|17-17|,|O
DDI-DrugBank.d661.s3|19-22|n=12|O
DDI-DrugBank.d661.s3|23-23|)|O
DDI-DrugBank.d661.s3|25-31|without|O
DDI-DrugBank.d661.s3|33-47|succinylcholine|drug
DDI-DrugBank.d661.s3|48-48|.|O
DDI-DrugBank.d661.s4|0-4|There|O
DDI-DrugBank.d661.s4|6-8|are|O
DDI-DrugBank.d661.s4|10-11|no|O
DDI-DrugBank.d661.s4|13-22|controlled|O
DDI-DrugBank.d661.s4|24-30|studies|O
DDI-DrugBank.d661.s4|32-42|documenting|O
DDI-DrugBank.d661.s4|44-46|the|O
DDI-DrugBank.d661.s4|48-50|use|O
DDI-DrugBank.d661.s4|52-53|of|O
DDI-DrugBank.d661.s4|55-61|ZEMURON|brand
DDI-DrugBank.d661.s4|66-71|before|O
DDI-DrugBank.d661.s4|73-74|or|O
DDI-DrugBank.d661.s4|76-80|after|O
DDI-DrugBank.d661.s4|82-86|other|O
DDI-DrugBank.d661.s4|88-119|nondepolarizing muscle relaxants|group
DDI-DrugBank.d661.s4|120-120|.|O
DDI-DrugBank.d661.s5|0-11|Interactions|O
DDI-DrugBank.d661.s5|13-16|have|O
DDI-DrugBank.d661.s5|18-21|been|O
DDI-DrugBank.d661.s5|23-30|observed|O
DDI-DrugBank.d661.s5|32-35|when|O
DDI-DrugBank.d661.s5|37-41|other|O
DDI-DrugBank.d661.s5|43-74|nondepolarizing muscle relaxants|group
DDI-DrugBank.d661.s5|76-79|have|O
DDI-DrugBank.d661.s5|81-84|been|O
DDI-DrugBank.d661.s5|86-97|administered|O
DDI-DrugBank.d661.s5|99-100|in|O
DDI-DrugBank.d661.s5|102-111|succession|O
DDI-DrugBank.d661.s5|112-112|.|O
DDI-DrugBank.d661.s6|0-14|Drug/Laboratory|O
DDI-DrugBank.d661.s6|16-19|Test|O
DDI-DrugBank.d661.s6|21-32|Interactions|O
DDI-DrugBank.d661.s6|33-33|:|O
DDI-DrugBank.d661.s6|41-44|None|O
DDI-DrugBank.d661.s6|46-50|known|O
DDI-DrugBank.d661.s6|51-51|.|O
DDI-DrugBank.d351.s0|0-9|Probenecid|drug
DDI-DrugBank.d351.s0|10-10|:|O
DDI-DrugBank.d351.s0|12-13|As|O
DDI-DrugBank.d351.s0|15-18|with|O
DDI-DrugBank.d351.s0|20-24|other|O
DDI-DrugBank.d351.s0|26-45|b-lactam antibiotics|group
DDI-DrugBank.d351.s0|46-46|,|O
DDI-DrugBank.d351.s0|48-52|renal|O
DDI-DrugBank.d351.s0|54-62|excretion|O
DDI-DrugBank.d351.s0|64-65|of|O
DDI-DrugBank.d351.s0|67-76|loracarbef|drug
DDI-DrugBank.d351.s0|78-79|is|O
DDI-DrugBank.d351.s0|81-89|inhibited|O
DDI-DrugBank.d351.s0|91-92|by|O
DDI-DrugBank.d351.s0|94-103|probenecid|drug
DDI-DrugBank.d351.s0|105-107|and|O
DDI-DrugBank.d351.s0|109-116|resulted|O
DDI-DrugBank.d351.s0|118-119|in|O
DDI-DrugBank.d351.s0|121-122|an|O
DDI-DrugBank.d351.s0|124-134|approximate|O
DDI-DrugBank.d351.s0|136-137|80|O
DDI-DrugBank.d351.s0|138-138|%|O
DDI-DrugBank.d351.s0|140-147|increase|O
DDI-DrugBank.d351.s0|149-150|in|O
DDI-DrugBank.d351.s0|152-154|the|O
DDI-DrugBank.d351.s0|156-158|AUC|O
DDI-DrugBank.d351.s0|160-162|for|O
DDI-DrugBank.d351.s0|164-173|loracarbef|drug
DDI-DrugBank.d351.s0|174-174|.|O
DDI-DrugBank.d87.s0|0-3|Drug|O
DDI-DrugBank.d87.s0|5-16|Interactions|O
DDI-DrugBank.d87.s0|17-17|.|O
DDI-DrugBank.d87.s1|0-7|TAMBOCOR|brand
DDI-DrugBank.d87.s1|9-11|has|O
DDI-DrugBank.d87.s1|13-16|been|O
DDI-DrugBank.d87.s1|18-29|administered|O
DDI-DrugBank.d87.s1|31-32|to|O
DDI-DrugBank.d87.s1|34-41|patients|O
DDI-DrugBank.d87.s1|43-51|receiving|O
DDI-DrugBank.d87.s1|53-74|digitalis preparations|group
DDI-DrugBank.d87.s1|76-77|or|O
DDI-DrugBank.d87.s1|79-109|beta-adrenergic blocking agents|group
DDI-DrugBank.d87.s1|111-117|without|O
DDI-DrugBank.d87.s1|119-125|adverse|O
DDI-DrugBank.d87.s1|127-133|effects|O
DDI-DrugBank.d87.s1|134-134|.|O
DDI-DrugBank.d87.s2|0-5|During|O
DDI-DrugBank.d87.s2|7-20|administration|O
DDI-DrugBank.d87.s2|22-23|of|O
DDI-DrugBank.d87.s2|25-32|multiple|O
DDI-DrugBank.d87.s2|34-37|oral|O
DDI-DrugBank.d87.s2|39-43|doses|O
DDI-DrugBank.d87.s2|45-46|of|O
DDI-DrugBank.d87.s2|48-55|TAMBOCOR|brand
DDI-DrugBank.d87.s2|57-58|to|O
DDI-DrugBank.d87.s2|60-66|healthy|O
DDI-DrugBank.d87.s2|68-75|subjects|O
DDI-DrugBank.d87.s2|77-86|stabilized|O
DDI-DrugBank.d87.s2|88-89|on|O
DDI-DrugBank.d87.s2|91-91|a|O
DDI-DrugBank.d87.s2|93-103|maintenance|O
DDI-DrugBank.d87.s2|105-108|dose|O
DDI-DrugBank.d87.s2|110-111|of|O
DDI-DrugBank.d87.s2|113-119|digoxin|drug
DDI-DrugBank.d87.s2|120-120|,|O
DDI-DrugBank.d87.s2|122-122|a|O
DDI-DrugBank.d87.s2|124-125|13|O
DDI-DrugBank.d87.s2|126-126|%|O
DDI-DrugBank.d87.s2|127-129|-19|O
DDI-DrugBank.d87.s2|130-130|%|O
DDI-DrugBank.d87.s2|132-139|increase|O
DDI-DrugBank.d87.s2|141-142|in|O
DDI-DrugBank.d87.s2|144-149|plasma|O
DDI-DrugBank.d87.s2|151-157|digoxin|drug
DDI-DrugBank.d87.s2|159-164|levels|O
DDI-DrugBank.d87.s2|166-173|occurred|O
DDI-DrugBank.d87.s2|175-176|at|O
DDI-DrugBank.d87.s2|178-180|six|O
DDI-DrugBank.d87.s2|182-186|hours|O
DDI-DrugBank.d87.s2|188-195|postdose|O
DDI-DrugBank.d87.s2|196-196|.|O
DDI-DrugBank.d87.s3|0-1|In|O
DDI-DrugBank.d87.s3|3-3|a|O
DDI-DrugBank.d87.s3|5-9|study|O
DDI-DrugBank.d87.s3|11-19|involving|O
DDI-DrugBank.d87.s3|21-27|healthy|O
DDI-DrugBank.d87.s3|29-36|subjects|O
DDI-DrugBank.d87.s3|38-46|receiving|O
DDI-DrugBank.d87.s3|48-55|TAMBOCOR|brand
DDI-DrugBank.d87.s3|57-59|and|O
DDI-DrugBank.d87.s3|61-71|propranolol|drug
DDI-DrugBank.d87.s3|73-84|concurrently|O
DDI-DrugBank.d87.s3|85-85|,|O
DDI-DrugBank.d87.s3|87-92|plasma|O
DDI-DrugBank.d87.s3|94-103|flecainide|drug
DDI-DrugBank.d87.s3|105-110|levels|O
DDI-DrugBank.d87.s3|112-115|were|O
DDI-DrugBank.d87.s3|117-125|increased|O
DDI-DrugBank.d87.s3|127-131|about|O
DDI-DrugBank.d87.s3|133-134|20|O
DDI-DrugBank.d87.s3|135-135|%|O
DDI-DrugBank.d87.s3|137-139|and|O
DDI-DrugBank.d87.s3|141-151|propranolol|drug
DDI-DrugBank.d87.s3|153-158|levels|O
DDI-DrugBank.d87.s3|160-163|were|O
DDI-DrugBank.d87.s3|165-173|increased|O
DDI-DrugBank.d87.s3|175-179|about|O
DDI-DrugBank.d87.s3|181-182|30|O
DDI-DrugBank.d87.s3|183-183|%|O
DDI-DrugBank.d87.s3|185-192|compared|O
DDI-DrugBank.d87.s3|194-195|to|O
DDI-DrugBank.d87.s3|197-203|control|O
DDI-DrugBank.d87.s3|205-210|values|O
DDI-DrugBank.d87.s3|211-211|.|O
DDI-DrugBank.d87.s4|0-1|In|O
DDI-DrugBank.d87.s4|3-6|this|O
DDI-DrugBank.d87.s4|8-13|formal|O
DDI-DrugBank.d87.s4|15-25|interaction|O
DDI-DrugBank.d87.s4|27-31|study|O
DDI-DrugBank.d87.s4|32-32|,|O
DDI-DrugBank.d87.s4|34-41|TAMBOCOR|brand
DDI-DrugBank.d87.s4|43-45|and|O
DDI-DrugBank.d87.s4|47-57|propranolol|drug
DDI-DrugBank.d87.s4|59-62|were|O
DDI-DrugBank.d87.s4|64-67|each|O
DDI-DrugBank.d87.s4|69-73|found|O
DDI-DrugBank.d87.s4|75-76|to|O
DDI-DrugBank.d87.s4|78-81|have|O
DDI-DrugBank.d87.s4|83-90|negative|O
DDI-DrugBank.d87.s4|92-100|inotropic|O
DDI-DrugBank.d87.s4|102-108|effects|O
DDI-DrugBank.d87.s4|109-109|;|O
DDI-DrugBank.d87.s5|0-3|when|O
DDI-DrugBank.d87.s5|5-7|the|O
DDI-DrugBank.d87.s5|9-13|drugs|O
DDI-DrugBank.d87.s5|15-18|were|O
DDI-DrugBank.d87.s5|20-31|administered|O
DDI-DrugBank.d87.s5|33-40|together|O
DDI-DrugBank.d87.s5|41-41|,|O
DDI-DrugBank.d87.s5|43-45|the|O
DDI-DrugBank.d87.s5|47-53|effects|O
DDI-DrugBank.d87.s5|55-58|were|O
DDI-DrugBank.d87.s5|60-67|additive|O
DDI-DrugBank.d87.s5|68-68|.|O
DDI-DrugBank.d87.s6|0-2|The|O
DDI-DrugBank.d87.s6|4-10|effects|O
DDI-DrugBank.d87.s6|12-13|of|O
DDI-DrugBank.d87.s6|15-25|concomitant|O
DDI-DrugBank.d87.s6|27-40|administration|O
DDI-DrugBank.d87.s6|42-43|of|O
DDI-DrugBank.d87.s6|45-52|TAMBOCOR|brand
DDI-DrugBank.d87.s6|54-56|and|O
DDI-DrugBank.d87.s6|58-68|propranolol|drug
DDI-DrugBank.d87.s6|70-71|on|O
DDI-DrugBank.d87.s6|73-75|the|O
DDI-DrugBank.d87.s6|77-78|PR|O
DDI-DrugBank.d87.s6|80-87|interval|O
DDI-DrugBank.d87.s6|89-92|were|O
DDI-DrugBank.d87.s6|94-97|less|O
DDI-DrugBank.d87.s6|99-102|than|O
DDI-DrugBank.d87.s6|104-111|additive|O
DDI-DrugBank.d87.s6|112-112|.|O
DDI-DrugBank.d87.s7|0-1|In|O
DDI-DrugBank.d87.s7|3-10|TAMBOCOR|brand
DDI-DrugBank.d87.s7|12-19|clinical|O
DDI-DrugBank.d87.s7|21-26|trials|O
DDI-DrugBank.d87.s7|27-27|,|O
DDI-DrugBank.d87.s7|29-36|patients|O
DDI-DrugBank.d87.s7|38-40|who|O
DDI-DrugBank.d87.s7|42-45|were|O
DDI-DrugBank.d87.s7|47-55|receiving|O
DDI-DrugBank.d87.s7|57-69|beta blockers|group
DDI-DrugBank.d87.s7|71-82|concurrently|O
DDI-DrugBank.d87.s7|84-86|did|O
DDI-DrugBank.d87.s7|88-90|not|O
DDI-DrugBank.d87.s7|92-101|experience|O
DDI-DrugBank.d87.s7|103-104|an|O
DDI-DrugBank.d87.s7|106-114|increased|O
DDI-DrugBank.d87.s7|116-124|incidence|O
DDI-DrugBank.d87.s7|126-127|of|O
DDI-DrugBank.d87.s7|129-132|side|O
DDI-DrugBank.d87.s7|134-140|effects|O
DDI-DrugBank.d87.s7|141-141|.|O
DDI-DrugBank.d87.s8|0-11|Nevertheless|O
DDI-DrugBank.d87.s8|12-12|,|O
DDI-DrugBank.d87.s8|14-16|the|O
DDI-DrugBank.d87.s8|18-28|possibility|O
DDI-DrugBank.d87.s8|30-31|of|O
DDI-DrugBank.d87.s8|33-40|additive|O
DDI-DrugBank.d87.s8|42-49|negative|O
DDI-DrugBank.d87.s8|51-59|inotropic|O
DDI-DrugBank.d87.s8|61-67|effects|O
DDI-DrugBank.d87.s8|69-70|of|O
DDI-DrugBank.d87.s8|72-84|beta blockers|group
DDI-DrugBank.d87.s8|86-88|and|O
DDI-DrugBank.d87.s8|90-99|flecainide|drug
DDI-DrugBank.d87.s8|101-106|should|O
DDI-DrugBank.d87.s8|108-109|be|O
DDI-DrugBank.d87.s8|111-120|recognized|O
DDI-DrugBank.d87.s8|121-121|.|O
DDI-DrugBank.d87.s9|0-9|Flecainide|drug
DDI-DrugBank.d87.s9|11-12|is|O
DDI-DrugBank.d87.s9|14-16|not|O
DDI-DrugBank.d87.s9|18-28|extensively|O
DDI-DrugBank.d87.s9|30-34|bound|O
DDI-DrugBank.d87.s9|36-37|to|O
DDI-DrugBank.d87.s9|39-44|plasma|O
DDI-DrugBank.d87.s9|46-53|proteins|O
DDI-DrugBank.d87.s9|54-54|.|O
DDI-DrugBank.d87.s10|0-1|In|O
DDI-DrugBank.d87.s10|3-7|vitro|O
DDI-DrugBank.d87.s10|9-15|studies|O
DDI-DrugBank.d87.s10|17-20|with|O
DDI-DrugBank.d87.s10|22-28|several|O
DDI-DrugBank.d87.s10|30-34|drugs|O
DDI-DrugBank.d87.s10|36-40|which|O
DDI-DrugBank.d87.s10|42-44|may|O
DDI-DrugBank.d87.s10|46-47|be|O
DDI-DrugBank.d87.s10|49-60|administered|O
DDI-DrugBank.d87.s10|62-74|concomitantly|O
DDI-DrugBank.d87.s10|76-81|showed|O
DDI-DrugBank.d87.s10|83-86|that|O
DDI-DrugBank.d87.s10|88-90|the|O
DDI-DrugBank.d87.s10|92-97|extent|O
DDI-DrugBank.d87.s10|99-100|of|O
DDI-DrugBank.d87.s10|102-111|flecainide|drug
DDI-DrugBank.d87.s10|113-119|binding|O
DDI-DrugBank.d87.s10|121-122|to|O
DDI-DrugBank.d87.s10|124-128|human|O
DDI-DrugBank.d87.s10|130-135|plasma|O
DDI-DrugBank.d87.s10|137-144|proteins|O
DDI-DrugBank.d87.s10|146-147|is|O
DDI-DrugBank.d87.s10|149-154|either|O
DDI-DrugBank.d87.s10|156-164|unchanged|O
DDI-DrugBank.d87.s10|166-167|or|O
DDI-DrugBank.d87.s10|169-172|only|O
DDI-DrugBank.d87.s10|174-181|slightly|O
DDI-DrugBank.d87.s10|183-186|less|O
DDI-DrugBank.d87.s10|187-187|.|O
DDI-DrugBank.d87.s11|0-11|Consequently|O
DDI-DrugBank.d87.s11|12-12|,|O
DDI-DrugBank.d87.s11|14-25|interactions|O
DDI-DrugBank.d87.s11|27-30|with|O
DDI-DrugBank.d87.s11|32-36|other|O
DDI-DrugBank.d87.s11|38-42|drugs|O
DDI-DrugBank.d87.s11|44-48|which|O
DDI-DrugBank.d87.s11|50-52|are|O
DDI-DrugBank.d87.s11|54-59|highly|O
DDI-DrugBank.d87.s11|61-67|protein|O
DDI-DrugBank.d87.s11|69-73|bound|O
DDI-DrugBank.d87.s11|75-75|(|O
DDI-DrugBank.d87.s11|76-79|e.g.|O
DDI-DrugBank.d87.s11|80-80|,|O
DDI-DrugBank.d87.s11|82-95|anticoagulants|group
DDI-DrugBank.d87.s11|97-97|)|O
DDI-DrugBank.d87.s11|99-103|would|O
DDI-DrugBank.d87.s11|105-107|not|O
DDI-DrugBank.d87.s11|109-110|be|O
DDI-DrugBank.d87.s11|112-119|expected|O
DDI-DrugBank.d87.s11|120-120|.|O
DDI-DrugBank.d87.s12|0-7|TAMBOCOR|brand
DDI-DrugBank.d87.s12|9-11|has|O
DDI-DrugBank.d87.s12|13-16|been|O
DDI-DrugBank.d87.s12|18-21|used|O
DDI-DrugBank.d87.s12|23-24|in|O
DDI-DrugBank.d87.s12|26-26|a|O
DDI-DrugBank.d87.s12|28-32|large|O
DDI-DrugBank.d87.s12|34-39|number|O
DDI-DrugBank.d87.s12|41-42|of|O
DDI-DrugBank.d87.s12|44-51|patients|O
DDI-DrugBank.d87.s12|53-61|receiving|O
DDI-DrugBank.d87.s12|63-71|diuretics|group
DDI-DrugBank.d87.s12|73-79|without|O
DDI-DrugBank.d87.s12|81-88|apparent|O
DDI-DrugBank.d87.s12|90-100|interaction|O
DDI-DrugBank.d87.s12|101-101|.|O
DDI-DrugBank.d87.s13|0-6|Limited|O
DDI-DrugBank.d87.s13|8-11|data|O
DDI-DrugBank.d87.s13|13-14|in|O
DDI-DrugBank.d87.s13|16-23|patients|O
DDI-DrugBank.d87.s13|25-33|receiving|O
DDI-DrugBank.d87.s13|35-39|known|O
DDI-DrugBank.d87.s13|41-46|enzyme|O
DDI-DrugBank.d87.s13|48-55|inducers|O
DDI-DrugBank.d87.s13|57-57|(|O
DDI-DrugBank.d87.s13|59-67|phenytoin|drug
DDI-DrugBank.d87.s13|68-68|,|O
DDI-DrugBank.d87.s13|70-82|phenobarbital|drug
DDI-DrugBank.d87.s13|83-83|,|O
DDI-DrugBank.d87.s13|85-97|carbamazepine|drug
DDI-DrugBank.d87.s13|99-99|)|O
DDI-DrugBank.d87.s13|101-108|indicate|O
DDI-DrugBank.d87.s13|110-113|only|O
DDI-DrugBank.d87.s13|115-115|a|O
DDI-DrugBank.d87.s13|117-118|30|O
DDI-DrugBank.d87.s13|119-119|%|O
DDI-DrugBank.d87.s13|121-128|increase|O
DDI-DrugBank.d87.s13|130-131|in|O
DDI-DrugBank.d87.s13|133-135|the|O
DDI-DrugBank.d87.s13|137-140|rate|O
DDI-DrugBank.d87.s13|142-143|of|O
DDI-DrugBank.d87.s13|145-154|flecainide|drug
DDI-DrugBank.d87.s13|156-166|elimination|O
DDI-DrugBank.d87.s13|167-167|.|O
DDI-DrugBank.d87.s14|0-1|In|O
DDI-DrugBank.d87.s14|3-9|healthy|O
DDI-DrugBank.d87.s14|11-18|subjects|O
DDI-DrugBank.d87.s14|20-28|receiving|O
DDI-DrugBank.d87.s14|30-39|cimetidine|drug
DDI-DrugBank.d87.s14|41-41|(|O
DDI-DrugBank.d87.s14|42-42|1|O
DDI-DrugBank.d87.s14|44-45|gm|O
DDI-DrugBank.d87.s14|47-51|daily|O
DDI-DrugBank.d87.s14|52-52|)|O
DDI-DrugBank.d87.s14|54-56|for|O
DDI-DrugBank.d87.s14|58-60|one|O
DDI-DrugBank.d87.s14|62-65|week|O
DDI-DrugBank.d87.s14|66-66|,|O
DDI-DrugBank.d87.s14|68-73|plasma|O
DDI-DrugBank.d87.s14|75-84|flecainide|drug
DDI-DrugBank.d87.s14|86-91|levels|O
DDI-DrugBank.d87.s14|93-101|increased|O
DDI-DrugBank.d87.s14|103-104|by|O
DDI-DrugBank.d87.s14|106-110|about|O
DDI-DrugBank.d87.s14|112-113|30|O
DDI-DrugBank.d87.s14|114-114|%|O
DDI-DrugBank.d87.s14|116-118|and|O
DDI-DrugBank.d87.s14|120-128|half-life|O
DDI-DrugBank.d87.s14|130-138|increased|O
DDI-DrugBank.d87.s14|140-141|by|O
DDI-DrugBank.d87.s14|143-147|about|O
DDI-DrugBank.d87.s14|149-150|10|O
DDI-DrugBank.d87.s14|151-151|%|O
DDI-DrugBank.d87.s14|152-152|.|O
DDI-DrugBank.d87.s15|0-3|When|O
DDI-DrugBank.d87.s15|5-14|amiodarone|drug
DDI-DrugBank.d87.s15|16-17|is|O
DDI-DrugBank.d87.s15|19-23|added|O
DDI-DrugBank.d87.s15|25-26|to|O
DDI-DrugBank.d87.s15|28-37|flecainide|drug
DDI-DrugBank.d87.s15|39-45|therapy|O
DDI-DrugBank.d87.s15|46-46|,|O
DDI-DrugBank.d87.s15|48-53|plasma|O
DDI-DrugBank.d87.s15|55-64|flecainide|drug
DDI-DrugBank.d87.s15|66-71|levels|O
DDI-DrugBank.d87.s15|73-75|may|O
DDI-DrugBank.d87.s15|77-84|increase|O
DDI-DrugBank.d87.s15|86-93|two-fold|O
DDI-DrugBank.d87.s15|95-96|or|O
DDI-DrugBank.d87.s15|98-101|more|O
DDI-DrugBank.d87.s15|103-104|in|O
DDI-DrugBank.d87.s15|106-109|some|O
DDI-DrugBank.d87.s15|111-118|patients|O
DDI-DrugBank.d87.s15|119-119|,|O
DDI-DrugBank.d87.s15|121-122|if|O
DDI-DrugBank.d87.s15|124-133|flecainide|drug
DDI-DrugBank.d87.s15|135-140|dosage|O
DDI-DrugBank.d87.s15|142-143|is|O
DDI-DrugBank.d87.s15|145-147|not|O
DDI-DrugBank.d87.s15|149-155|reduced|O
DDI-DrugBank.d87.s15|156-156|.|O
DDI-DrugBank.d87.s16|0-4|Drugs|O
DDI-DrugBank.d87.s16|6-9|that|O
DDI-DrugBank.d87.s16|11-17|inhibit|O
DDI-DrugBank.d87.s16|19-28|cytochrome|O
DDI-DrugBank.d87.s16|30-37|P450IID6|O
DDI-DrugBank.d87.s16|38-38|,|O
DDI-DrugBank.d87.s16|40-43|such|O
DDI-DrugBank.d87.s16|45-46|as|O
DDI-DrugBank.d87.s16|48-56|quinidine|drug
DDI-DrugBank.d87.s16|58-58|,|O
DDI-DrugBank.d87.s16|60-64|might|O
DDI-DrugBank.d87.s16|66-73|increase|O
DDI-DrugBank.d87.s16|75-77|the|O
DDI-DrugBank.d87.s16|79-84|plasma|O
DDI-DrugBank.d87.s16|86-99|concentrations|O
DDI-DrugBank.d87.s16|101-102|of|O
DDI-DrugBank.d87.s16|104-113|flecainide|drug
DDI-DrugBank.d87.s16|115-116|in|O
DDI-DrugBank.d87.s16|118-125|patients|O
DDI-DrugBank.d87.s16|127-130|that|O
DDI-DrugBank.d87.s16|132-134|are|O
DDI-DrugBank.d87.s16|136-137|on|O
DDI-DrugBank.d87.s16|139-145|chronic|O
DDI-DrugBank.d87.s16|147-156|flecainide|drug
DDI-DrugBank.d87.s16|158-164|therapy|O
DDI-DrugBank.d87.s16|165-165|;|O
DDI-DrugBank.d87.s17|0-9|especially|O
DDI-DrugBank.d87.s17|11-12|if|O
DDI-DrugBank.d87.s17|14-18|these|O
DDI-DrugBank.d87.s17|20-27|patients|O
DDI-DrugBank.d87.s17|29-31|are|O
DDI-DrugBank.d87.s17|33-41|extensive|O
DDI-DrugBank.d87.s17|43-54|metabolizers|O
DDI-DrugBank.d87.s17|55-55|.|O
DDI-DrugBank.d87.s18|0-4|There|O
DDI-DrugBank.d87.s18|6-8|has|O
DDI-DrugBank.d87.s18|10-13|been|O
DDI-DrugBank.d87.s18|15-20|little|O
DDI-DrugBank.d87.s18|22-31|experience|O
DDI-DrugBank.d87.s18|33-36|with|O
DDI-DrugBank.d87.s18|38-40|the|O
DDI-DrugBank.d87.s18|42-57|coadministration|O
DDI-DrugBank.d87.s18|59-60|of|O
DDI-DrugBank.d87.s18|62-69|TAMBOCOR|brand
DDI-DrugBank.d87.s18|71-73|and|O
DDI-DrugBank.d87.s18|75-80|either|O
DDI-DrugBank.d87.s18|82-93|disopyramide|drug
DDI-DrugBank.d87.s18|95-96|or|O
DDI-DrugBank.d87.s18|98-106|verapamil|drug
DDI-DrugBank.d87.s18|107-107|.|O
DDI-DrugBank.d87.s19|0-6|Because|O
DDI-DrugBank.d87.s19|8-11|both|O
DDI-DrugBank.d87.s19|13-14|of|O
DDI-DrugBank.d87.s19|16-20|these|O
DDI-DrugBank.d87.s19|22-26|drugs|O
DDI-DrugBank.d87.s19|28-31|have|O
DDI-DrugBank.d87.s19|33-40|negative|O
DDI-DrugBank.d87.s19|42-50|inotropic|O
DDI-DrugBank.d87.s19|52-61|properties|O
DDI-DrugBank.d87.s19|63-65|and|O
DDI-DrugBank.d87.s19|67-69|the|O
DDI-DrugBank.d87.s19|71-77|effects|O
DDI-DrugBank.d87.s19|79-80|of|O
DDI-DrugBank.d87.s19|82-97|coadministration|O
DDI-DrugBank.d87.s19|99-102|with|O
DDI-DrugBank.d87.s19|104-111|TAMBOCOR|brand
DDI-DrugBank.d87.s19|113-115|are|O
DDI-DrugBank.d87.s19|117-123|unknown|O
DDI-DrugBank.d87.s19|124-124|,|O
DDI-DrugBank.d87.s19|126-132|neither|O
DDI-DrugBank.d87.s19|134-145|disopyramide|drug
DDI-DrugBank.d87.s19|147-149|nor|O
DDI-DrugBank.d87.s19|151-159|verapamil|drug
DDI-DrugBank.d87.s19|161-166|should|O
DDI-DrugBank.d87.s19|168-169|be|O
DDI-DrugBank.d87.s19|171-182|administered|O
DDI-DrugBank.d87.s19|184-195|concurrently|O
DDI-DrugBank.d87.s19|197-200|with|O
DDI-DrugBank.d87.s19|202-209|TAMBOCOR|brand
DDI-DrugBank.d87.s19|211-216|unless|O
DDI-DrugBank.d87.s19|217-217|,|O
DDI-DrugBank.d87.s19|219-220|in|O
DDI-DrugBank.d87.s19|222-224|the|O
DDI-DrugBank.d87.s19|226-233|judgment|O
DDI-DrugBank.d87.s19|235-236|of|O
DDI-DrugBank.d87.s19|238-240|the|O
DDI-DrugBank.d87.s19|242-250|physician|O
DDI-DrugBank.d87.s19|251-251|,|O
DDI-DrugBank.d87.s19|253-255|the|O
DDI-DrugBank.d87.s19|257-264|benefits|O
DDI-DrugBank.d87.s19|266-267|of|O
DDI-DrugBank.d87.s19|269-272|this|O
DDI-DrugBank.d87.s19|274-284|combination|O
DDI-DrugBank.d87.s19|286-293|outweigh|O
DDI-DrugBank.d87.s19|295-297|the|O
DDI-DrugBank.d87.s19|299-303|risks|O
DDI-DrugBank.d87.s19|304-304|.|O
DDI-DrugBank.d87.s20|0-4|There|O
DDI-DrugBank.d87.s20|6-8|has|O
DDI-DrugBank.d87.s20|10-13|been|O
DDI-DrugBank.d87.s20|15-17|too|O
DDI-DrugBank.d87.s20|19-24|little|O
DDI-DrugBank.d87.s20|26-35|experience|O
DDI-DrugBank.d87.s20|37-40|with|O
DDI-DrugBank.d87.s20|42-44|the|O
DDI-DrugBank.d87.s20|46-61|coadministration|O
DDI-DrugBank.d87.s20|63-64|of|O
DDI-DrugBank.d87.s20|66-73|TAMBOCOR|brand
DDI-DrugBank.d87.s20|75-78|with|O
DDI-DrugBank.d87.s20|80-89|nifedipine|drug
DDI-DrugBank.d87.s20|91-92|or|O
DDI-DrugBank.d87.s20|94-102|diltiazem|drug
DDI-DrugBank.d87.s20|104-105|to|O
DDI-DrugBank.d87.s20|107-115|recommend|O
DDI-DrugBank.d87.s20|117-127|concomitant|O
DDI-DrugBank.d87.s20|129-131|use|O
DDI-DrugBank.d87.s20|132-132|.|O
DDI-DrugBank.d176.s0|0-8|Diuretics|group
DDI-DrugBank.d176.s0|9-9|:|O
DDI-DrugBank.d176.s0|11-18|Patients|O
DDI-DrugBank.d176.s0|20-21|on|O
DDI-DrugBank.d176.s0|23-31|diuretics|group
DDI-DrugBank.d176.s0|32-32|,|O
DDI-DrugBank.d176.s0|34-43|especially|O
DDI-DrugBank.d176.s0|45-49|those|O
DDI-DrugBank.d176.s0|51-54|with|O
DDI-DrugBank.d176.s0|56-68|intravascular|O
DDI-DrugBank.d176.s0|70-75|volume|O
DDI-DrugBank.d176.s0|77-85|depletion|O
DDI-DrugBank.d176.s0|86-86|,|O
DDI-DrugBank.d176.s0|88-90|may|O
DDI-DrugBank.d176.s0|92-103|occasionally|O
DDI-DrugBank.d176.s0|105-114|experience|O
DDI-DrugBank.d176.s0|116-117|an|O
DDI-DrugBank.d176.s0|119-127|excessive|O
DDI-DrugBank.d176.s0|129-137|reduction|O
DDI-DrugBank.d176.s0|139-140|of|O
DDI-DrugBank.d176.s0|142-146|blood|O
DDI-DrugBank.d176.s0|148-155|pressure|O
DDI-DrugBank.d176.s0|157-161|after|O
DDI-DrugBank.d176.s0|163-172|initiation|O
DDI-DrugBank.d176.s0|174-175|of|O
DDI-DrugBank.d176.s0|177-183|therapy|O
DDI-DrugBank.d176.s0|185-188|with|O
DDI-DrugBank.d176.s0|190-206|fosinopril sodium|drug
DDI-DrugBank.d176.s0|207-207|.|O
DDI-DrugBank.d176.s1|0-2|The|O
DDI-DrugBank.d176.s1|4-14|possibility|O
DDI-DrugBank.d176.s1|16-17|of|O
DDI-DrugBank.d176.s1|19-29|hypotensive|O
DDI-DrugBank.d176.s1|31-37|effects|O
DDI-DrugBank.d176.s1|39-41|can|O
DDI-DrugBank.d176.s1|43-44|be|O
DDI-DrugBank.d176.s1|46-54|minimized|O
DDI-DrugBank.d176.s1|56-57|by|O
DDI-DrugBank.d176.s1|59-64|either|O
DDI-DrugBank.d176.s1|66-78|discontinuing|O
DDI-DrugBank.d176.s1|80-82|the|O
DDI-DrugBank.d176.s1|84-91|diuretic|group
DDI-DrugBank.d176.s1|93-94|or|O
DDI-DrugBank.d176.s1|96-105|increasing|O
DDI-DrugBank.d176.s1|107-110|salt|O
DDI-DrugBank.d176.s1|112-117|intake|O
DDI-DrugBank.d176.s1|119-123|prior|O
DDI-DrugBank.d176.s1|125-126|to|O
DDI-DrugBank.d176.s1|128-137|initiation|O
DDI-DrugBank.d176.s1|139-140|of|O
DDI-DrugBank.d176.s1|142-150|treatment|O
DDI-DrugBank.d176.s1|152-155|with|O
DDI-DrugBank.d176.s1|157-173|fosinopril sodium|drug
DDI-DrugBank.d176.s1|174-174|.|O
DDI-DrugBank.d176.s2|0-1|If|O
DDI-DrugBank.d176.s2|3-6|this|O
DDI-DrugBank.d176.s2|8-9|is|O
DDI-DrugBank.d176.s2|11-13|not|O
DDI-DrugBank.d176.s2|15-22|possible|O
DDI-DrugBank.d176.s2|23-23|,|O
DDI-DrugBank.d176.s2|25-27|the|O
DDI-DrugBank.d176.s2|29-36|starting|O
DDI-DrugBank.d176.s2|38-41|dose|O
DDI-DrugBank.d176.s2|43-48|should|O
DDI-DrugBank.d176.s2|50-51|be|O
DDI-DrugBank.d176.s2|53-59|reduced|O
DDI-DrugBank.d176.s2|61-63|and|O
DDI-DrugBank.d176.s2|65-67|the|O
DDI-DrugBank.d176.s2|69-75|patient|O
DDI-DrugBank.d176.s2|77-82|should|O
DDI-DrugBank.d176.s2|84-85|be|O
DDI-DrugBank.d176.s2|87-94|observed|O
DDI-DrugBank.d176.s2|96-102|closely|O
DDI-DrugBank.d176.s2|104-106|for|O
DDI-DrugBank.d176.s2|108-114|several|O
DDI-DrugBank.d176.s2|116-120|hours|O
DDI-DrugBank.d176.s2|122-130|following|O
DDI-DrugBank.d176.s2|132-133|an|O
DDI-DrugBank.d176.s2|135-141|initial|O
DDI-DrugBank.d176.s2|143-146|dose|O
DDI-DrugBank.d176.s2|148-150|and|O
DDI-DrugBank.d176.s2|152-156|until|O
DDI-DrugBank.d176.s2|158-162|blood|O
DDI-DrugBank.d176.s2|164-171|pressure|O
DDI-DrugBank.d176.s2|173-175|has|O
DDI-DrugBank.d176.s2|177-186|stabilized|O
DDI-DrugBank.d176.s2|188-188|(|O
DDI-DrugBank.d176.s2|189-191|see|O
DDI-DrugBank.d176.s2|193-198|DOSAGE|O
DDI-DrugBank.d176.s2|200-202|AND|O
DDI-DrugBank.d176.s2|204-217|ADMINISTRATION|O
DDI-DrugBank.d176.s2|218-218|.|O
DDI-DrugBank.d176.s2|219-219|)|O
DDI-DrugBank.d176.s3|0-8|Potassium|drug
DDI-DrugBank.d176.s3|10-20|Supplements|O
DDI-DrugBank.d176.s3|22-24|and|O
DDI-DrugBank.d176.s3|26-52|Potassium-Sparing Diuretics|group
DDI-DrugBank.d176.s3|53-53|:|O
DDI-DrugBank.d176.s3|55-71|Fosinopril sodium|drug
DDI-DrugBank.d176.s3|73-75|can|O
DDI-DrugBank.d176.s3|77-85|attenuate|O
DDI-DrugBank.d176.s3|87-95|potassium|O
DDI-DrugBank.d176.s3|97-100|loss|O
DDI-DrugBank.d176.s3|102-107|caused|O
DDI-DrugBank.d176.s3|109-110|by|O
DDI-DrugBank.d176.s3|112-129|thiazide diuretics|group
DDI-DrugBank.d176.s3|130-130|.|O
DDI-DrugBank.d176.s4|0-26|Potassium-sparing diuretics|group
DDI-DrugBank.d176.s4|28-28|(|O
DDI-DrugBank.d176.s4|29-42|spironolactone|drug
DDI-DrugBank.d176.s4|43-43|,|O
DDI-DrugBank.d176.s4|45-53|amiloride|drug
DDI-DrugBank.d176.s4|54-54|,|O
DDI-DrugBank.d176.s4|55-65|triamterene|drug
DDI-DrugBank.d176.s4|66-66|,|O
DDI-DrugBank.d176.s4|68-70|and|O
DDI-DrugBank.d176.s4|72-77|others|O
DDI-DrugBank.d176.s4|78-78|)|O
DDI-DrugBank.d176.s4|80-81|or|O
DDI-DrugBank.d176.s4|83-91|potassium|drug
DDI-DrugBank.d176.s4|93-103|supplements|O
DDI-DrugBank.d176.s4|105-107|can|O
DDI-DrugBank.d176.s4|109-116|increase|O
DDI-DrugBank.d176.s4|118-120|the|O
DDI-DrugBank.d176.s4|122-125|risk|O
DDI-DrugBank.d176.s4|127-128|of|O
DDI-DrugBank.d176.s4|130-141|hyperkalemia|O
DDI-DrugBank.d176.s4|142-142|.|O
DDI-DrugBank.d176.s5|0-8|Therefore|O
DDI-DrugBank.d176.s5|9-9|,|O
DDI-DrugBank.d176.s5|11-12|if|O
DDI-DrugBank.d176.s5|14-24|concomitant|O
DDI-DrugBank.d176.s5|26-28|use|O
DDI-DrugBank.d176.s5|30-31|of|O
DDI-DrugBank.d176.s5|33-36|such|O
DDI-DrugBank.d176.s5|38-43|agents|O
DDI-DrugBank.d176.s5|45-46|is|O
DDI-DrugBank.d176.s5|48-56|indicated|O
DDI-DrugBank.d176.s5|57-57|,|O
DDI-DrugBank.d176.s5|59-62|they|O
DDI-DrugBank.d176.s5|64-69|should|O
DDI-DrugBank.d176.s5|71-72|be|O
DDI-DrugBank.d176.s5|74-78|given|O
DDI-DrugBank.d176.s5|80-83|with|O
DDI-DrugBank.d176.s5|85-91|caution|O
DDI-DrugBank.d176.s5|92-92|,|O
DDI-DrugBank.d176.s5|94-96|and|O
DDI-DrugBank.d176.s5|98-100|the|O
DDI-DrugBank.d176.s5|102-109|patients|O
DDI-DrugBank.d176.s5|111-115|serum|O
DDI-DrugBank.d176.s5|117-125|potassium|O
DDI-DrugBank.d176.s5|127-132|should|O
DDI-DrugBank.d176.s5|134-135|be|O
DDI-DrugBank.d176.s5|137-145|monitored|O
DDI-DrugBank.d176.s5|147-156|frequently|O
DDI-DrugBank.d176.s5|157-157|.|O
DDI-DrugBank.d176.s6|0-6|Lithium|drug
DDI-DrugBank.d176.s6|7-7|:|O
DDI-DrugBank.d176.s6|9-17|Increased|O
DDI-DrugBank.d176.s6|19-23|serum|O
DDI-DrugBank.d176.s6|25-31|lithium|drug
DDI-DrugBank.d176.s6|33-38|levels|O
DDI-DrugBank.d176.s6|40-42|and|O
DDI-DrugBank.d176.s6|44-51|symptoms|O
DDI-DrugBank.d176.s6|53-54|of|O
DDI-DrugBank.d176.s6|56-62|lithium|drug
DDI-DrugBank.d176.s6|64-71|toxicity|O
DDI-DrugBank.d176.s6|73-76|have|O
DDI-DrugBank.d176.s6|78-81|been|O
DDI-DrugBank.d176.s6|83-90|reported|O
DDI-DrugBank.d176.s6|92-93|in|O
DDI-DrugBank.d176.s6|95-102|patients|O
DDI-DrugBank.d176.s6|104-112|receiving|O
DDI-DrugBank.d176.s6|114-127|ACE inhibitors|group
DDI-DrugBank.d176.s6|129-134|during|O
DDI-DrugBank.d176.s6|136-142|therapy|O
DDI-DrugBank.d176.s6|144-147|with|O
DDI-DrugBank.d176.s6|149-155|lithium|drug
DDI-DrugBank.d176.s6|156-156|.|O
DDI-DrugBank.d176.s7|0-4|These|O
DDI-DrugBank.d176.s7|6-10|drugs|O
DDI-DrugBank.d176.s7|12-17|should|O
DDI-DrugBank.d176.s7|19-20|be|O
DDI-DrugBank.d176.s7|22-35|coadministered|O
DDI-DrugBank.d176.s7|37-40|with|O
DDI-DrugBank.d176.s7|42-48|caution|O
DDI-DrugBank.d176.s7|49-49|,|O
DDI-DrugBank.d176.s7|51-53|and|O
DDI-DrugBank.d176.s7|55-62|frequent|O
DDI-DrugBank.d176.s7|64-73|monitoring|O
DDI-DrugBank.d176.s7|75-76|of|O
DDI-DrugBank.d176.s7|78-82|serum|O
DDI-DrugBank.d176.s7|84-90|lithium|drug
DDI-DrugBank.d176.s7|92-97|levels|O
DDI-DrugBank.d176.s7|99-100|is|O
DDI-DrugBank.d176.s7|102-112|recommended|O
DDI-DrugBank.d176.s7|113-113|.|O
DDI-DrugBank.d176.s8|0-1|If|O
DDI-DrugBank.d176.s8|3-3|a|O
DDI-DrugBank.d176.s8|5-12|diuretic|group
DDI-DrugBank.d176.s8|14-15|is|O
DDI-DrugBank.d176.s8|17-20|also|O
DDI-DrugBank.d176.s8|22-25|used|O
DDI-DrugBank.d176.s8|26-26|,|O
DDI-DrugBank.d176.s8|28-30|the|O
DDI-DrugBank.d176.s8|32-35|risk|O
DDI-DrugBank.d176.s8|37-38|of|O
DDI-DrugBank.d176.s8|40-46|lithium|O
DDI-DrugBank.d176.s8|48-55|toxicity|O
DDI-DrugBank.d176.s8|57-59|may|O
DDI-DrugBank.d176.s8|61-62|be|O
DDI-DrugBank.d176.s8|64-72|increased|O
DDI-DrugBank.d176.s8|73-73|.|O
DDI-DrugBank.d176.s9|0-7|Antacids|group
DDI-DrugBank.d176.s9|8-8|:|O
DDI-DrugBank.d176.s9|10-11|In|O
DDI-DrugBank.d176.s9|13-13|a|O
DDI-DrugBank.d176.s9|15-22|clinical|O
DDI-DrugBank.d176.s9|24-35|pharmacology|O
DDI-DrugBank.d176.s9|37-41|study|O
DDI-DrugBank.d176.s9|42-42|,|O
DDI-DrugBank.d176.s9|44-59|coadministration|O
DDI-DrugBank.d176.s9|61-62|of|O
DDI-DrugBank.d176.s9|64-65|an|O
DDI-DrugBank.d176.s9|67-73|antacid|group
DDI-DrugBank.d176.s9|75-75|(|O
DDI-DrugBank.d176.s9|76-93|aluminum hydroxide|drug
DDI-DrugBank.d176.s9|94-94|,|O
DDI-DrugBank.d176.s9|96-114|magnesium hydroxide|drug
DDI-DrugBank.d176.s9|115-115|,|O
DDI-DrugBank.d176.s9|117-119|and|O
DDI-DrugBank.d176.s9|121-131|simethicone|drug
DDI-DrugBank.d176.s9|132-132|)|O
DDI-DrugBank.d176.s9|134-137|with|O
DDI-DrugBank.d176.s9|139-148|fosinopril|drug
DDI-DrugBank.d176.s9|150-156|reduced|O
DDI-DrugBank.d176.s9|158-162|serum|O
DDI-DrugBank.d176.s9|164-169|levels|O
DDI-DrugBank.d176.s9|171-173|and|O
DDI-DrugBank.d176.s9|175-181|urinary|O
DDI-DrugBank.d176.s9|183-191|excretion|O
DDI-DrugBank.d176.s9|193-194|of|O
DDI-DrugBank.d176.s9|209-210|as|O
DDI-DrugBank.d176.s9|212-219|compared|O
DDI-DrugBank.d176.s9|221-224|with|O
DDI-DrugBank.d176.s9|226-235|fosinopril|drug
DDI-DrugBank.d176.s9|237-248|administered|O
DDI-DrugBank.d176.s9|250-254|alone|O
DDI-DrugBank.d176.s9|255-255|,|O
DDI-DrugBank.d176.s9|257-266|suggesting|O
DDI-DrugBank.d176.s9|268-271|that|O
DDI-DrugBank.d176.s9|273-280|antacids|group
DDI-DrugBank.d176.s9|282-284|may|O
DDI-DrugBank.d176.s9|286-291|impair|O
DDI-DrugBank.d176.s9|293-302|absorption|O
DDI-DrugBank.d176.s9|304-305|of|O
DDI-DrugBank.d176.s9|307-316|fosinopril|drug
DDI-DrugBank.d176.s9|317-317|.|O
DDI-DrugBank.d176.s10|0-8|Therefore|O
DDI-DrugBank.d176.s10|9-9|,|O
DDI-DrugBank.d176.s10|11-12|if|O
DDI-DrugBank.d176.s10|14-24|concomitant|O
DDI-DrugBank.d176.s10|26-39|administration|O
DDI-DrugBank.d176.s10|41-42|of|O
DDI-DrugBank.d176.s10|44-48|these|O
DDI-DrugBank.d176.s10|50-55|agents|O
DDI-DrugBank.d176.s10|57-58|is|O
DDI-DrugBank.d176.s10|60-68|indicated|O
DDI-DrugBank.d176.s10|69-69|,|O
DDI-DrugBank.d176.s10|71-76|dosing|O
DDI-DrugBank.d176.s10|78-83|should|O
DDI-DrugBank.d176.s10|85-86|be|O
DDI-DrugBank.d176.s10|88-96|separated|O
DDI-DrugBank.d176.s10|98-99|by|O
DDI-DrugBank.d176.s10|101-101|2|O
DDI-DrugBank.d176.s10|103-107|hours|O
DDI-DrugBank.d176.s10|108-108|.|O
DDI-DrugBank.d176.s11|0-4|Other|O
DDI-DrugBank.d176.s11|5-5|:|O
DDI-DrugBank.d176.s11|7-13|Neither|O
DDI-DrugBank.d176.s11|15-31|fosinopril sodium|drug
DDI-DrugBank.d176.s11|33-35|nor|O
DDI-DrugBank.d176.s11|37-39|its|O
DDI-DrugBank.d176.s11|41-51|metabolites|O
DDI-DrugBank.d176.s11|53-56|have|O
DDI-DrugBank.d176.s11|58-61|been|O
DDI-DrugBank.d176.s11|63-67|found|O
DDI-DrugBank.d176.s11|69-70|to|O
DDI-DrugBank.d176.s11|72-79|interact|O
DDI-DrugBank.d176.s11|81-84|with|O
DDI-DrugBank.d176.s11|86-89|food|O
DDI-DrugBank.d176.s11|90-90|.|O
DDI-DrugBank.d176.s12|0-1|In|O
DDI-DrugBank.d176.s12|3-10|separate|O
DDI-DrugBank.d176.s12|12-17|single|O
DDI-DrugBank.d176.s12|19-20|or|O
DDI-DrugBank.d176.s12|22-29|multiple|O
DDI-DrugBank.d176.s12|31-34|dose|O
DDI-DrugBank.d176.s12|36-50|pharmacokinetic|O
DDI-DrugBank.d176.s12|52-62|interaction|O
DDI-DrugBank.d176.s12|64-70|studies|O
DDI-DrugBank.d176.s12|72-75|with|O
DDI-DrugBank.d176.s12|77-90|chlorthalidone|drug
DDI-DrugBank.d176.s12|91-91|,|O
DDI-DrugBank.d176.s12|93-102|nifedipine|drug
DDI-DrugBank.d176.s12|103-103|,|O
DDI-DrugBank.d176.s12|105-114|propanolol|drug
DDI-DrugBank.d176.s12|115-115|,|O
DDI-DrugBank.d176.s12|117-135|hydrochlorothiazide|drug
DDI-DrugBank.d176.s12|136-136|,|O
DDI-DrugBank.d176.s12|138-147|cimetidine|drug
DDI-DrugBank.d176.s12|148-148|,|O
DDI-DrugBank.d176.s12|150-163|metoclopramide|drug
DDI-DrugBank.d176.s12|164-164|,|O
DDI-DrugBank.d176.s12|166-178|propantheline|drug
DDI-DrugBank.d176.s12|179-179|,|O
DDI-DrugBank.d176.s12|181-187|digoxin|drug
DDI-DrugBank.d176.s12|188-188|,|O
DDI-DrugBank.d176.s12|190-192|and|O
DDI-DrugBank.d176.s12|194-201|warfarin|drug
DDI-DrugBank.d176.s12|202-202|,|O
DDI-DrugBank.d176.s12|204-206|the|O
DDI-DrugBank.d176.s12|208-222|bioavailability|O
DDI-DrugBank.d176.s12|224-225|of|O
DDI-DrugBank.d176.s12|240-242|was|O
DDI-DrugBank.d176.s12|244-246|not|O
DDI-DrugBank.d176.s12|248-254|altered|O
DDI-DrugBank.d176.s12|256-257|by|O
DDI-DrugBank.d176.s12|259-274|coadministration|O
DDI-DrugBank.d176.s12|276-277|of|O
DDI-DrugBank.d176.s12|279-288|fosinopril|drug
DDI-DrugBank.d176.s12|290-293|with|O
DDI-DrugBank.d176.s12|295-297|any|O
DDI-DrugBank.d176.s12|299-301|one|O
DDI-DrugBank.d176.s12|303-304|of|O
DDI-DrugBank.d176.s12|306-310|these|O
DDI-DrugBank.d176.s12|312-316|drugs|O
DDI-DrugBank.d176.s12|317-317|.|O
DDI-DrugBank.d176.s13|0-1|In|O
DDI-DrugBank.d176.s13|3-3|a|O
DDI-DrugBank.d176.s13|5-9|study|O
DDI-DrugBank.d176.s13|11-14|with|O
DDI-DrugBank.d176.s13|16-26|concomitant|O
DDI-DrugBank.d176.s13|28-41|administration|O
DDI-DrugBank.d176.s13|43-44|of|O
DDI-DrugBank.d176.s13|46-52|aspirin|brand
DDI-DrugBank.d176.s13|54-56|and|O
DDI-DrugBank.d176.s13|58-74|fosinopril sodium|drug
DDI-DrugBank.d176.s13|75-75|,|O
DDI-DrugBank.d176.s13|77-79|the|O
DDI-DrugBank.d176.s13|81-95|bioavailability|O
DDI-DrugBank.d176.s13|97-98|of|O
DDI-DrugBank.d176.s13|100-106|unbound|O
DDI-DrugBank.d176.s13|121-123|was|O
DDI-DrugBank.d176.s13|125-127|not|O
DDI-DrugBank.d176.s13|129-135|altered|O
DDI-DrugBank.d176.s13|136-136|.|O
DDI-DrugBank.d176.s14|0-1|In|O
DDI-DrugBank.d176.s14|3-3|a|O
DDI-DrugBank.d176.s14|5-19|pharmacokinetic|O
DDI-DrugBank.d176.s14|21-31|interaction|O
DDI-DrugBank.d176.s14|33-37|study|O
DDI-DrugBank.d176.s14|39-42|with|O
DDI-DrugBank.d176.s14|44-51|warfarin|drug
DDI-DrugBank.d176.s14|52-52|,|O
DDI-DrugBank.d176.s14|54-68|bioavailability|O
DDI-DrugBank.d176.s14|70-79|parameters|O
DDI-DrugBank.d176.s14|80-80|,|O
DDI-DrugBank.d176.s14|82-84|the|O
DDI-DrugBank.d176.s14|86-91|degree|O
DDI-DrugBank.d176.s14|93-94|of|O
DDI-DrugBank.d176.s14|96-102|protein|O
DDI-DrugBank.d176.s14|104-110|binding|O
DDI-DrugBank.d176.s14|111-111|,|O
DDI-DrugBank.d176.s14|113-115|and|O
DDI-DrugBank.d176.s14|117-119|the|O
DDI-DrugBank.d176.s14|121-133|anticoagulant|O
DDI-DrugBank.d176.s14|135-140|effect|O
DDI-DrugBank.d176.s14|142-142|(|O
DDI-DrugBank.d176.s14|143-150|measured|O
DDI-DrugBank.d176.s14|152-153|by|O
DDI-DrugBank.d176.s14|155-165|prothrombin|O
DDI-DrugBank.d176.s14|167-170|time|O
DDI-DrugBank.d176.s14|171-171|)|O
DDI-DrugBank.d176.s14|173-174|of|O
DDI-DrugBank.d176.s14|176-183|warfarin|drug
DDI-DrugBank.d176.s14|185-188|were|O
DDI-DrugBank.d176.s14|190-192|not|O
DDI-DrugBank.d176.s14|194-206|significantly|O
DDI-DrugBank.d176.s14|208-214|changed|O
DDI-DrugBank.d176.s14|215-215|.|O
DDI-DrugBank.d176.s15|0-14|Drug/Laboratory|O
DDI-DrugBank.d176.s15|16-19|Test|O
DDI-DrugBank.d176.s15|21-31|Interaction|O
DDI-DrugBank.d176.s15|33-42|Fosinopril|drug
DDI-DrugBank.d176.s15|44-46|may|O
DDI-DrugBank.d176.s15|48-52|cause|O
DDI-DrugBank.d176.s15|54-54|a|O
DDI-DrugBank.d176.s15|56-60|false|O
DDI-DrugBank.d176.s15|62-64|low|O
DDI-DrugBank.d176.s15|66-76|measurement|O
DDI-DrugBank.d176.s15|78-79|of|O
DDI-DrugBank.d176.s15|81-85|serum|O
DDI-DrugBank.d176.s15|87-93|digoxin|drug
DDI-DrugBank.d176.s15|95-100|levels|O
DDI-DrugBank.d176.s15|102-105|with|O
DDI-DrugBank.d176.s15|107-109|the|O
DDI-DrugBank.d176.s15|111-115|Digi-|O
DDI-DrugBank.d176.s15|117-119|Tab|O
DDI-DrugBank.d176.s15|122-124|RIA|O
DDI-DrugBank.d176.s15|126-128|Kit|O
DDI-DrugBank.d176.s15|130-132|for|O
DDI-DrugBank.d176.s15|134-140|Digoxin|drug
DDI-DrugBank.d176.s15|141-141|.|O
DDI-DrugBank.d176.s16|0-4|Other|O
DDI-DrugBank.d176.s16|6-9|kits|O
DDI-DrugBank.d176.s16|10-10|,|O
DDI-DrugBank.d176.s16|12-15|such|O
DDI-DrugBank.d176.s16|17-18|as|O
DDI-DrugBank.d176.s16|20-22|the|O
DDI-DrugBank.d176.s16|24-35|Coat-A-Count|O
DDI-DrugBank.d176.s16|38-40|RIA|O
DDI-DrugBank.d176.s16|42-44|Kit|O
DDI-DrugBank.d176.s16|45-45|,|O
DDI-DrugBank.d176.s16|47-49|may|O
DDI-DrugBank.d176.s16|51-52|be|O
DDI-DrugBank.d176.s16|54-57|used|O
DDI-DrugBank.d176.s16|58-58|.|O
DDI-DrugBank.d435.s0|0-9|Exemestane|drug
DDI-DrugBank.d435.s0|11-12|is|O
DDI-DrugBank.d435.s0|14-24|extensively|O
DDI-DrugBank.d435.s0|26-36|metabolized|O
DDI-DrugBank.d435.s0|38-39|by|O
DDI-DrugBank.d435.s0|41-43|CYP|O
DDI-DrugBank.d435.s0|45-47|3A4|O
DDI-DrugBank.d435.s0|48-48|,|O
DDI-DrugBank.d435.s0|50-52|but|O
DDI-DrugBank.d435.s0|54-69|coadministration|O
DDI-DrugBank.d435.s0|71-72|of|O
DDI-DrugBank.d435.s0|74-85|ketoconazole|drug
DDI-DrugBank.d435.s0|86-86|,|O
DDI-DrugBank.d435.s0|88-88|a|O
DDI-DrugBank.d435.s0|90-95|potent|O
DDI-DrugBank.d435.s0|97-105|inhibitor|O
DDI-DrugBank.d435.s0|107-108|of|O
DDI-DrugBank.d435.s0|110-112|CYP|O
DDI-DrugBank.d435.s0|114-116|3A4|O
DDI-DrugBank.d435.s0|117-117|,|O
DDI-DrugBank.d435.s0|119-121|has|O
DDI-DrugBank.d435.s0|123-124|no|O
DDI-DrugBank.d435.s0|126-136|significant|O
DDI-DrugBank.d435.s0|138-143|effect|O
DDI-DrugBank.d435.s0|145-146|on|O
DDI-DrugBank.d435.s0|148-157|exemestane|drug
DDI-DrugBank.d435.s0|159-174|pharmacokinetics|O
DDI-DrugBank.d435.s0|175-175|.|O
DDI-DrugBank.d435.s1|0-10|Significant|O
DDI-DrugBank.d435.s1|12-26|pharmacokinetic|O
DDI-DrugBank.d435.s1|28-39|interactions|O
DDI-DrugBank.d435.s1|41-48|mediated|O
DDI-DrugBank.d435.s1|50-51|by|O
DDI-DrugBank.d435.s1|53-62|inhibition|O
DDI-DrugBank.d435.s1|64-65|of|O
DDI-DrugBank.d435.s1|67-69|CYP|O
DDI-DrugBank.d435.s1|71-80|isoenzymes|O
DDI-DrugBank.d435.s1|82-90|therefore|O
DDI-DrugBank.d435.s1|92-97|appear|O
DDI-DrugBank.d435.s1|99-106|unlikely|O
DDI-DrugBank.d435.s1|107-107|.|O
DDI-DrugBank.d435.s2|0-13|Co-medications|O
DDI-DrugBank.d435.s2|15-18|that|O
DDI-DrugBank.d435.s2|20-25|induce|O
DDI-DrugBank.d435.s2|27-29|CYP|O
DDI-DrugBank.d435.s2|31-33|3A4|O
DDI-DrugBank.d435.s2|35-35|(|O
DDI-DrugBank.d435.s2|36-39|e.g.|O
DDI-DrugBank.d435.s2|40-40|,|O
DDI-DrugBank.d435.s2|42-51|rifampicin|drug
DDI-DrugBank.d435.s2|52-52|,|O
DDI-DrugBank.d435.s2|54-62|phenytoin|drug
DDI-DrugBank.d435.s2|63-63|,|O
DDI-DrugBank.d435.s2|65-77|carbamazepine|drug
DDI-DrugBank.d435.s2|78-78|,|O
DDI-DrugBank.d435.s2|80-92|phenobarbital|drug
DDI-DrugBank.d435.s2|93-93|,|O
DDI-DrugBank.d435.s2|95-96|or|O
DDI-DrugBank.d435.s2|98-100|St.|O
DDI-DrugBank.d435.s2|102-105|John|O
DDI-DrugBank.d435.s2|107-107|s|O
DDI-DrugBank.d435.s2|109-112|wort|O
DDI-DrugBank.d435.s2|113-113|)|O
DDI-DrugBank.d435.s2|115-117|may|O
DDI-DrugBank.d435.s2|119-131|significantly|O
DDI-DrugBank.d435.s2|133-140|decrease|O
DDI-DrugBank.d435.s2|142-149|exposure|O
DDI-DrugBank.d435.s2|151-152|to|O
DDI-DrugBank.d435.s2|154-163|exemestane|drug
DDI-DrugBank.d435.s2|164-164|.|O
DDI-DrugBank.d435.s3|0-3|Dose|O
DDI-DrugBank.d435.s3|5-16|modification|O
DDI-DrugBank.d435.s3|18-19|is|O
DDI-DrugBank.d435.s3|21-31|recommended|O
DDI-DrugBank.d435.s3|33-35|for|O
DDI-DrugBank.d435.s3|37-44|patients|O
DDI-DrugBank.d435.s3|46-48|who|O
DDI-DrugBank.d435.s3|50-52|are|O
DDI-DrugBank.d435.s3|54-57|also|O
DDI-DrugBank.d435.s3|59-67|receiving|O
DDI-DrugBank.d435.s3|69-69|a|O
DDI-DrugBank.d435.s3|71-76|potent|O
DDI-DrugBank.d435.s3|78-80|CYP|O
DDI-DrugBank.d435.s3|82-84|3A4|O
DDI-DrugBank.d435.s3|86-92|inducer|O
DDI-DrugBank.d435.s3|93-93|.|O
DDI-DrugBank.d435.s4|0-14|Drug/Laboratory|O
DDI-DrugBank.d435.s4|16-20|Tests|O
DDI-DrugBank.d435.s4|22-33|Interactions|O
DDI-DrugBank.d435.s4|35-36|No|O
DDI-DrugBank.d435.s4|38-47|clinically|O
DDI-DrugBank.d435.s4|49-56|relevant|O
DDI-DrugBank.d435.s4|58-64|changes|O
DDI-DrugBank.d435.s4|66-67|in|O
DDI-DrugBank.d435.s4|69-71|the|O
DDI-DrugBank.d435.s4|73-79|results|O
DDI-DrugBank.d435.s4|81-82|of|O
DDI-DrugBank.d435.s4|84-91|clinical|O
DDI-DrugBank.d435.s4|93-102|laboratory|O
DDI-DrugBank.d435.s4|104-108|tests|O
DDI-DrugBank.d435.s4|110-113|have|O
DDI-DrugBank.d435.s4|115-118|been|O
DDI-DrugBank.d435.s4|120-127|observed|O
DDI-DrugBank.d435.s4|128-128|.|O
DDI-DrugBank.d32.s0|0-11|Theophylline|drug
DDI-DrugBank.d32.s0|12-12|:|O
DDI-DrugBank.d32.s0|14-19|Twelve|O
DDI-DrugBank.d32.s0|21-27|healthy|O
DDI-DrugBank.d32.s0|29-32|male|O
DDI-DrugBank.d32.s0|34-43|volunteers|O
DDI-DrugBank.d32.s0|45-48|were|O
DDI-DrugBank.d32.s0|50-61|administered|O
DDI-DrugBank.d32.s0|63-65|one|O
DDI-DrugBank.d32.s0|67-72|200-mg|O
DDI-DrugBank.d32.s0|74-83|ceftibuten|drug
DDI-DrugBank.d32.s0|85-91|capsule|O
DDI-DrugBank.d32.s0|93-97|twice|O
DDI-DrugBank.d32.s0|99-103|daily|O
DDI-DrugBank.d32.s0|105-107|for|O
DDI-DrugBank.d32.s0|109-109|6|O
DDI-DrugBank.d32.s0|111-114|days|O
DDI-DrugBank.d32.s0|115-115|.|O
DDI-DrugBank.d32.s1|0-3|With|O
DDI-DrugBank.d32.s1|5-7|the|O
DDI-DrugBank.d32.s1|9-15|morning|O
DDI-DrugBank.d32.s1|17-20|dose|O
DDI-DrugBank.d32.s1|22-23|of|O
DDI-DrugBank.d32.s1|25-34|ceftibuten|drug
DDI-DrugBank.d32.s1|36-37|on|O
DDI-DrugBank.d32.s1|39-41|day|O
DDI-DrugBank.d32.s1|43-43|6|O
DDI-DrugBank.d32.s1|44-44|,|O
DDI-DrugBank.d32.s1|46-49|each|O
DDI-DrugBank.d32.s1|51-59|volunteer|O
DDI-DrugBank.d32.s1|61-68|received|O
DDI-DrugBank.d32.s1|70-70|a|O
DDI-DrugBank.d32.s1|72-77|single|O
DDI-DrugBank.d32.s1|79-89|intravenous|O
DDI-DrugBank.d32.s1|91-98|infusion|O
DDI-DrugBank.d32.s1|100-101|of|O
DDI-DrugBank.d32.s1|103-114|theophylline|drug
DDI-DrugBank.d32.s1|116-116|(|O
DDI-DrugBank.d32.s1|117-117|4|O
DDI-DrugBank.d32.s1|119-123|mg/kg|O
DDI-DrugBank.d32.s1|124-124|)|O
DDI-DrugBank.d32.s1|125-125|.|O
DDI-DrugBank.d32.s2|0-2|The|O
DDI-DrugBank.d32.s2|4-19|pharmacokinetics|O
DDI-DrugBank.d32.s2|21-22|of|O
DDI-DrugBank.d32.s2|24-35|theophylline|drug
DDI-DrugBank.d32.s2|37-40|were|O
DDI-DrugBank.d32.s2|42-44|not|O
DDI-DrugBank.d32.s2|46-52|altered|O
DDI-DrugBank.d32.s2|53-53|.|O
DDI-DrugBank.d32.s3|0-2|The|O
DDI-DrugBank.d32.s3|4-9|effect|O
DDI-DrugBank.d32.s3|11-12|of|O
DDI-DrugBank.d32.s3|14-23|ceftibuten|drug
DDI-DrugBank.d32.s3|25-26|on|O
DDI-DrugBank.d32.s3|28-30|the|O
DDI-DrugBank.d32.s3|32-47|pharmacokinetics|O
DDI-DrugBank.d32.s3|49-50|of|O
DDI-DrugBank.d32.s3|52-63|theophylline|drug
DDI-DrugBank.d32.s3|65-76|administered|O
DDI-DrugBank.d32.s3|78-83|orally|O
DDI-DrugBank.d32.s3|85-87|has|O
DDI-DrugBank.d32.s3|89-91|not|O
DDI-DrugBank.d32.s3|93-96|been|O
DDI-DrugBank.d32.s3|98-109|investigated|O
DDI-DrugBank.d32.s3|110-110|.|O
DDI-DrugBank.d32.s4|0-7|Antacids|group
DDI-DrugBank.d32.s4|9-10|or|O
DDI-DrugBank.d32.s4|12-36|H 2 -receptor antagonists|group
DDI-DrugBank.d32.s4|37-37|:|O
DDI-DrugBank.d32.s4|39-41|The|O
DDI-DrugBank.d32.s4|43-48|effect|O
DDI-DrugBank.d32.s4|50-51|of|O
DDI-DrugBank.d32.s4|53-61|increased|O
DDI-DrugBank.d32.s4|63-69|gastric|O
DDI-DrugBank.d32.s4|71-72|pH|O
DDI-DrugBank.d32.s4|74-75|on|O
DDI-DrugBank.d32.s4|77-79|the|O
DDI-DrugBank.d32.s4|81-95|bioavailability|O
DDI-DrugBank.d32.s4|97-98|of|O
DDI-DrugBank.d32.s4|100-109|ceftibuten|drug
DDI-DrugBank.d32.s4|111-113|was|O
DDI-DrugBank.d32.s4|115-123|evaluated|O
DDI-DrugBank.d32.s4|125-126|in|O
DDI-DrugBank.d32.s4|128-129|18|O
DDI-DrugBank.d32.s4|131-137|healthy|O
DDI-DrugBank.d32.s4|139-143|adult|O
DDI-DrugBank.d32.s4|145-154|volunteers|O
DDI-DrugBank.d32.s4|155-155|.|O
DDI-DrugBank.d32.s5|0-3|Each|O
DDI-DrugBank.d32.s5|5-13|volunteer|O
DDI-DrugBank.d32.s5|15-17|was|O
DDI-DrugBank.d32.s5|19-30|administered|O
DDI-DrugBank.d32.s5|32-34|one|O
DDI-DrugBank.d32.s5|36-41|400-mg|O
DDI-DrugBank.d32.s5|43-52|ceftibuten|drug
DDI-DrugBank.d32.s5|54-60|capsule|O
DDI-DrugBank.d32.s5|61-61|.|O
DDI-DrugBank.d32.s6|0-0|A|O
DDI-DrugBank.d32.s6|2-7|single|O
DDI-DrugBank.d32.s6|9-12|dose|O
DDI-DrugBank.d32.s6|14-15|of|O
DDI-DrugBank.d32.s6|17-22|liquid|O
DDI-DrugBank.d32.s6|24-30|antacid|group
DDI-DrugBank.d32.s6|32-34|did|O
DDI-DrugBank.d32.s6|36-38|not|O
DDI-DrugBank.d32.s6|40-45|affect|O
DDI-DrugBank.d32.s6|47-49|the|O
DDI-DrugBank.d32.s6|51-51|C|O
DDI-DrugBank.d32.s6|53-55|max|O
DDI-DrugBank.d32.s6|57-58|or|O
DDI-DrugBank.d32.s6|60-62|AUC|O
DDI-DrugBank.d32.s6|64-65|of|O
DDI-DrugBank.d32.s6|67-76|ceftibuten|drug
DDI-DrugBank.d32.s6|77-77|;|O
DDI-DrugBank.d32.s7|0-6|however|O
DDI-DrugBank.d32.s7|7-7|,|O
DDI-DrugBank.d32.s7|9-11|150|O
DDI-DrugBank.d32.s7|13-14|mg|O
DDI-DrugBank.d32.s7|16-17|of|O
DDI-DrugBank.d32.s7|19-28|ranitidine|drug
DDI-DrugBank.d32.s7|30-33|q12h|O
DDI-DrugBank.d32.s7|35-37|for|O
DDI-DrugBank.d32.s7|39-39|3|O
DDI-DrugBank.d32.s7|41-44|days|O
DDI-DrugBank.d32.s7|46-54|increased|O
DDI-DrugBank.d32.s7|56-58|the|O
DDI-DrugBank.d32.s7|60-69|ceftibuten|drug
DDI-DrugBank.d32.s7|71-71|C|O
DDI-DrugBank.d32.s7|73-75|max|O
DDI-DrugBank.d32.s7|77-78|by|O
DDI-DrugBank.d32.s7|80-81|23|O
DDI-DrugBank.d32.s7|82-82|%|O
DDI-DrugBank.d32.s7|84-86|and|O
DDI-DrugBank.d32.s7|88-97|ceftibuten|drug
DDI-DrugBank.d32.s7|99-101|AUC|O
DDI-DrugBank.d32.s7|103-104|by|O
DDI-DrugBank.d32.s7|106-107|16|O
DDI-DrugBank.d32.s7|108-108|%|O
DDI-DrugBank.d32.s7|109-109|.|O
DDI-DrugBank.d32.s8|0-2|The|O
DDI-DrugBank.d32.s8|4-11|clinical|O
DDI-DrugBank.d32.s8|13-21|relevance|O
DDI-DrugBank.d32.s8|23-24|of|O
DDI-DrugBank.d32.s8|26-30|these|O
DDI-DrugBank.d32.s8|32-40|increases|O
DDI-DrugBank.d32.s8|42-43|is|O
DDI-DrugBank.d32.s8|45-47|not|O
DDI-DrugBank.d32.s8|49-53|known|O
DDI-DrugBank.d32.s8|54-54|.|O
DDI-DrugBank.d32.s9|0-14|Drug/Laboratory|O
DDI-DrugBank.d32.s9|16-19|Test|O
DDI-DrugBank.d32.s9|21-32|Interactions|O
DDI-DrugBank.d32.s9|33-33|:|O
DDI-DrugBank.d32.s9|35-39|There|O
DDI-DrugBank.d32.s9|41-44|have|O
DDI-DrugBank.d32.s9|46-49|been|O
DDI-DrugBank.d32.s9|51-52|no|O
DDI-DrugBank.d32.s9|54-61|chemical|O
DDI-DrugBank.d32.s9|63-64|or|O
DDI-DrugBank.d32.s9|66-75|laboratory|O
DDI-DrugBank.d32.s9|77-80|test|O
DDI-DrugBank.d32.s9|82-93|interactions|O
DDI-DrugBank.d32.s9|95-98|with|O
DDI-DrugBank.d32.s9|100-109|ceftibuten|drug
DDI-DrugBank.d32.s9|111-115|noted|O
DDI-DrugBank.d32.s9|117-118|to|O
DDI-DrugBank.d32.s9|120-123|date|O
DDI-DrugBank.d32.s9|124-124|.|O
DDI-DrugBank.d32.s10|0-13|False-positive|O
DDI-DrugBank.d32.s10|15-20|direct|O
DDI-DrugBank.d32.s10|22-27|Coombs|O
DDI-DrugBank.d32.s10|29-33|tests|O
DDI-DrugBank.d32.s10|35-38|have|O
DDI-DrugBank.d32.s10|40-43|been|O
DDI-DrugBank.d32.s10|45-52|reported|O
DDI-DrugBank.d32.s10|54-59|during|O
DDI-DrugBank.d32.s10|61-69|treatment|O
DDI-DrugBank.d32.s10|71-74|with|O
DDI-DrugBank.d32.s10|76-80|other|O
DDI-DrugBank.d32.s10|82-95|cephalosporins|group
DDI-DrugBank.d32.s10|96-96|.|O
DDI-DrugBank.d32.s11|0-8|Therefore|O
DDI-DrugBank.d32.s11|9-9|,|O
DDI-DrugBank.d32.s11|11-12|it|O
DDI-DrugBank.d32.s11|14-19|should|O
DDI-DrugBank.d32.s11|21-22|be|O
DDI-DrugBank.d32.s11|24-33|recognized|O
DDI-DrugBank.d32.s11|35-38|that|O
DDI-DrugBank.d32.s11|40-40|a|O
DDI-DrugBank.d32.s11|42-49|positive|O
DDI-DrugBank.d32.s11|51-56|Coombs|O
DDI-DrugBank.d32.s11|58-61|test|O
DDI-DrugBank.d32.s11|63-67|could|O
DDI-DrugBank.d32.s11|69-70|be|O
DDI-DrugBank.d32.s11|72-74|due|O
DDI-DrugBank.d32.s11|76-77|to|O
DDI-DrugBank.d32.s11|79-81|the|O
DDI-DrugBank.d32.s11|83-86|drug|O
DDI-DrugBank.d32.s11|87-87|.|O
DDI-DrugBank.d32.s12|0-2|The|O
DDI-DrugBank.d32.s12|4-10|results|O
DDI-DrugBank.d32.s12|12-13|of|O
DDI-DrugBank.d32.s12|15-20|assays|O
DDI-DrugBank.d32.s12|22-26|using|O
DDI-DrugBank.d32.s12|28-30|red|O
DDI-DrugBank.d32.s12|32-36|cells|O
DDI-DrugBank.d32.s12|38-41|from|O
DDI-DrugBank.d32.s12|43-49|healthy|O
DDI-DrugBank.d32.s12|51-58|subjects|O
DDI-DrugBank.d32.s12|60-61|to|O
DDI-DrugBank.d32.s12|63-71|determine|O
DDI-DrugBank.d32.s12|73-79|whether|O
DDI-DrugBank.d32.s12|81-90|ceftibuten|drug
DDI-DrugBank.d32.s12|92-96|would|O
DDI-DrugBank.d32.s12|98-102|cause|O
DDI-DrugBank.d32.s12|104-109|direct|O
DDI-DrugBank.d32.s12|111-116|Coombs|O
DDI-DrugBank.d32.s12|118-126|reactions|O
DDI-DrugBank.d32.s12|128-129|in|O
DDI-DrugBank.d32.s12|131-135|vitro|O
DDI-DrugBank.d32.s12|137-142|showed|O
DDI-DrugBank.d32.s12|144-145|no|O
DDI-DrugBank.d32.s12|147-154|positive|O
DDI-DrugBank.d32.s12|156-163|reaction|O
DDI-DrugBank.d32.s12|165-166|at|O
DDI-DrugBank.d32.s12|168-177|ceftibuten|drug
DDI-DrugBank.d32.s12|179-192|concentrations|O
DDI-DrugBank.d32.s12|194-195|as|O
DDI-DrugBank.d32.s12|197-200|high|O
DDI-DrugBank.d32.s12|202-203|as|O
DDI-DrugBank.d32.s12|205-206|40|O
DDI-DrugBank.d32.s12|209-212|g/mL|O
DDI-DrugBank.d32.s12|213-213|.|O
DDI-DrugBank.d457.s0|0-11|Barbiturates|group
DDI-DrugBank.d457.s0|13-15|may|O
DDI-DrugBank.d457.s0|17-24|decrease|O
DDI-DrugBank.d457.s0|26-28|the|O
DDI-DrugBank.d457.s0|30-42|effectiveness|O
DDI-DrugBank.d457.s0|44-45|of|O
DDI-DrugBank.d457.s0|47-50|oral|O
DDI-DrugBank.d457.s0|52-65|contraceptives|group
DDI-DrugBank.d457.s0|66-66|,|O
DDI-DrugBank.d457.s0|68-74|certain|O
DDI-DrugBank.d457.s0|76-86|antibiotics|group
DDI-DrugBank.d457.s0|87-87|,|O
DDI-DrugBank.d457.s0|89-97|quinidine|drug
DDI-DrugBank.d457.s0|98-98|,|O
DDI-DrugBank.d457.s0|100-111|theophylline|drug
DDI-DrugBank.d457.s0|112-112|,|O
DDI-DrugBank.d457.s0|114-128|corticosteroids|group
DDI-DrugBank.d457.s0|129-129|,|O
DDI-DrugBank.d457.s0|131-144|anticoagulants|group
DDI-DrugBank.d457.s0|145-145|,|O
DDI-DrugBank.d457.s0|147-149|and|O
DDI-DrugBank.d457.s0|151-163|beta blockers|group
DDI-DrugBank.d457.s0|164-164|.|O
DDI-DrugBank.d379.s0|0-4|There|O
DDI-DrugBank.d379.s0|6-9|have|O
DDI-DrugBank.d379.s0|11-14|been|O
DDI-DrugBank.d379.s0|16-17|no|O
DDI-DrugBank.d379.s0|19-24|formal|O
DDI-DrugBank.d379.s0|26-32|studies|O
DDI-DrugBank.d379.s0|34-35|of|O
DDI-DrugBank.d379.s0|37-39|the|O
DDI-DrugBank.d379.s0|41-51|interaction|O
DDI-DrugBank.d379.s0|53-54|of|O
DDI-DrugBank.d379.s0|56-72|LEVULAN KERASTICK|brand
DDI-DrugBank.d379.s0|74-76|for|O
DDI-DrugBank.d379.s0|78-84|Topical|O
DDI-DrugBank.d379.s0|86-93|Solution|O
DDI-DrugBank.d379.s0|95-98|with|O
DDI-DrugBank.d379.s0|100-102|any|O
DDI-DrugBank.d379.s0|104-108|other|O
DDI-DrugBank.d379.s0|110-114|drugs|O
DDI-DrugBank.d379.s0|115-115|,|O
DDI-DrugBank.d379.s0|117-119|and|O
DDI-DrugBank.d379.s0|121-122|no|O
DDI-DrugBank.d379.s0|124-136|drug-specific|O
DDI-DrugBank.d379.s0|138-149|interactions|O
DDI-DrugBank.d379.s0|151-154|were|O
DDI-DrugBank.d379.s0|156-160|noted|O
DDI-DrugBank.d379.s0|162-167|during|O
DDI-DrugBank.d379.s0|169-171|any|O
DDI-DrugBank.d379.s0|173-174|of|O
DDI-DrugBank.d379.s0|176-178|the|O
DDI-DrugBank.d379.s0|180-189|controlled|O
DDI-DrugBank.d379.s0|191-198|clinical|O
DDI-DrugBank.d379.s0|200-205|trials|O
DDI-DrugBank.d379.s0|206-206|.|O
DDI-DrugBank.d379.s1|0-1|It|O
DDI-DrugBank.d379.s1|3-4|is|O
DDI-DrugBank.d379.s1|5-5|,|O
DDI-DrugBank.d379.s1|7-13|however|O
DDI-DrugBank.d379.s1|14-14|,|O
DDI-DrugBank.d379.s1|16-23|possible|O
DDI-DrugBank.d379.s1|25-28|that|O
DDI-DrugBank.d379.s1|30-40|concomitant|O
DDI-DrugBank.d379.s1|42-44|use|O
DDI-DrugBank.d379.s1|46-47|of|O
DDI-DrugBank.d379.s1|49-53|other|O
DDI-DrugBank.d379.s1|55-59|known|O
DDI-DrugBank.d379.s1|61-83|photosensitizing agents|group
DDI-DrugBank.d379.s1|85-88|such|O
DDI-DrugBank.d379.s1|90-91|as|O
DDI-DrugBank.d379.s1|93-104|griseofulvin|drug
DDI-DrugBank.d379.s1|105-105|,|O
DDI-DrugBank.d379.s1|107-124|thiazide diuretics|group
DDI-DrugBank.d379.s1|125-125|,|O
DDI-DrugBank.d379.s1|127-139|sulfonylureas|group
DDI-DrugBank.d379.s1|140-140|,|O
DDI-DrugBank.d379.s1|142-155|phenothiazines|group
DDI-DrugBank.d379.s1|156-156|,|O
DDI-DrugBank.d379.s1|158-169|sulfonamides|group
DDI-DrugBank.d379.s1|171-173|and|O
DDI-DrugBank.d379.s1|175-187|tetracyclines|group
DDI-DrugBank.d379.s1|189-193|might|O
DDI-DrugBank.d379.s1|195-202|increase|O
DDI-DrugBank.d379.s1|204-206|the|O
DDI-DrugBank.d379.s1|208-223|photosensitivity|O
DDI-DrugBank.d379.s1|225-232|reaction|O
DDI-DrugBank.d379.s1|234-235|of|O
DDI-DrugBank.d379.s1|237-243|actinic|O
DDI-DrugBank.d379.s1|245-253|keratoses|O
DDI-DrugBank.d379.s1|255-261|treated|O
DDI-DrugBank.d379.s1|263-266|with|O
DDI-DrugBank.d379.s1|268-270|the|O
DDI-DrugBank.d379.s1|272-288|LEVULAN KERASTICK|brand
DDI-DrugBank.d379.s1|290-292|for|O
DDI-DrugBank.d379.s1|294-300|Topical|O
DDI-DrugBank.d379.s1|302-309|Solution|O
DDI-DrugBank.d379.s1|310-310|.|O
DDI-DrugBank.d605.s0|0-7|SKELAXIN|brand
DDI-DrugBank.d605.s0|9-11|may|O
DDI-DrugBank.d605.s0|13-19|enhance|O
DDI-DrugBank.d605.s0|21-23|the|O
DDI-DrugBank.d605.s0|25-31|effects|O
DDI-DrugBank.d605.s0|33-34|of|O
DDI-DrugBank.d605.s0|36-42|alcohol|drug
DDI-DrugBank.d605.s0|43-43|,|O
DDI-DrugBank.d605.s0|45-56|barbiturates|group
DDI-DrugBank.d605.s0|58-60|and|O
DDI-DrugBank.d605.s0|62-66|other|O
DDI-DrugBank.d605.s0|68-82|CNS depressants|group
DDI-DrugBank.d605.s0|83-83|.|O
DDI-DrugBank.d482.s0|0-1|Do|O
DDI-DrugBank.d482.s0|3-5|not|O
DDI-DrugBank.d482.s0|7-10|take|O
DDI-DrugBank.d482.s0|12-15|this|O
DDI-DrugBank.d482.s0|17-24|medicine|O
DDI-DrugBank.d482.s0|26-29|with|O
DDI-DrugBank.d482.s0|31-42|thioridizine|O
DDI-DrugBank.d482.s0|43-43|,|O
DDI-DrugBank.d482.s0|45-46|or|O
DDI-DrugBank.d482.s0|48-53|within|O
DDI-DrugBank.d482.s0|55-55|5|O
DDI-DrugBank.d482.s0|57-61|weeks|O
DDI-DrugBank.d482.s0|63-64|of|O
DDI-DrugBank.d482.s0|66-71|taking|O
DDI-DrugBank.d482.s0|73-82|fluoxetine|drug
DDI-DrugBank.d482.s0|83-83|.|O
DDI-DrugBank.d482.s1|0-3|Talk|O
DDI-DrugBank.d482.s1|5-6|to|O
DDI-DrugBank.d482.s1|8-11|your|O
DDI-DrugBank.d482.s1|13-18|doctor|O
DDI-DrugBank.d482.s1|20-21|if|O
DDI-DrugBank.d482.s1|23-25|you|O
DDI-DrugBank.d482.s1|27-29|are|O
DDI-DrugBank.d482.s1|31-36|taking|O
DDI-DrugBank.d482.s1|38-44|certain|O
DDI-DrugBank.d482.s1|46-56|antibiotics|group
DDI-DrugBank.d482.s1|58-61|such|O
DDI-DrugBank.d482.s1|63-64|as|O
DDI-DrugBank.d482.s1|66-77|erythromycin|drug
DDI-DrugBank.d482.s1|78-78|,|O
DDI-DrugBank.d482.s1|80-93|clarithromycin|drug
DDI-DrugBank.d482.s1|95-96|or|O
DDI-DrugBank.d482.s1|98-109|azithromycin|drug
DDI-DrugBank.d482.s1|110-110|.|O
DDI-DrugBank.d482.s2|0-3|This|O
DDI-DrugBank.d482.s2|5-12|medicine|O
DDI-DrugBank.d482.s2|14-19|should|O
DDI-DrugBank.d482.s2|21-23|not|O
DDI-DrugBank.d482.s2|25-26|be|O
DDI-DrugBank.d482.s2|28-32|taken|O
DDI-DrugBank.d482.s2|34-37|with|O
DDI-DrugBank.d482.s2|39-52|MAO inhibitors|group
DDI-DrugBank.d482.s2|53-53|.|O
DDI-DrugBank.d482.s3|0-6|Caution|O
DDI-DrugBank.d482.s3|8-13|should|O
DDI-DrugBank.d482.s3|15-16|be|O
DDI-DrugBank.d482.s3|18-26|exercised|O
DDI-DrugBank.d482.s3|28-31|when|O
DDI-DrugBank.d482.s3|33-38|taking|O
DDI-DrugBank.d482.s3|40-43|this|O
DDI-DrugBank.d482.s3|45-52|medicine|O
DDI-DrugBank.d482.s3|54-60|certain|O
DDI-DrugBank.d482.s3|62-72|antibiotics|group
DDI-DrugBank.d482.s3|73-73|,|O
DDI-DrugBank.d482.s3|75-78|such|O
DDI-DrugBank.d482.s3|80-81|as|O
DDI-DrugBank.d482.s3|83-94|erythromycin|drug
DDI-DrugBank.d482.s3|95-95|,|O
DDI-DrugBank.d482.s3|97-110|clarithromycin|drug
DDI-DrugBank.d482.s3|111-111|,|O
DDI-DrugBank.d482.s3|113-114|or|O
DDI-DrugBank.d482.s3|116-127|azithromycin|drug
DDI-DrugBank.d482.s3|128-128|.|O
DDI-DrugBank.d482.s4|0-3|This|O
DDI-DrugBank.d482.s4|5-12|medicine|O
DDI-DrugBank.d482.s4|14-19|should|O
DDI-DrugBank.d482.s4|21-23|not|O
DDI-DrugBank.d482.s4|25-26|be|O
DDI-DrugBank.d482.s4|28-32|taken|O
DDI-DrugBank.d482.s4|34-37|with|O
DDI-DrugBank.d482.s4|39-52|MAO inhibitors|group
DDI-DrugBank.d482.s4|53-53|.|O
DDI-DrugBank.d482.s5|0-1|If|O
DDI-DrugBank.d482.s5|3-5|you|O
DDI-DrugBank.d482.s5|7-11|think|O
DDI-DrugBank.d482.s5|13-15|you|O
DDI-DrugBank.d482.s5|17-19|are|O
DDI-DrugBank.d482.s5|21-26|taking|O
DDI-DrugBank.d482.s5|28-29|an|O
DDI-DrugBank.d482.s5|31-43|MAO inhibitor|group
DDI-DrugBank.d482.s5|45-48|talk|O
DDI-DrugBank.d482.s5|50-51|to|O
DDI-DrugBank.d482.s5|53-56|your|O
DDI-DrugBank.d482.s5|58-63|doctor|O
DDI-DrugBank.d482.s5|65-66|or|O
DDI-DrugBank.d482.s5|68-77|pharmacist|O
DDI-DrugBank.d482.s5|78-78|.|O
DDI-DrugBank.d482.s6|0-1|Do|O
DDI-DrugBank.d482.s6|3-5|not|O
DDI-DrugBank.d482.s6|7-10|take|O
DDI-DrugBank.d482.s6|12-15|this|O
DDI-DrugBank.d482.s6|17-24|medicine|O
DDI-DrugBank.d482.s6|26-29|with|O
DDI-DrugBank.d482.s6|31-33|St.|O
DDI-DrugBank.d482.s6|35-39|Johns|O
DDI-DrugBank.d482.s6|41-44|Wort|O
DDI-DrugBank.d482.s6|46-52|because|O
DDI-DrugBank.d482.s6|54-55|of|O
DDI-DrugBank.d482.s6|57-59|the|O
DDI-DrugBank.d482.s6|61-68|additive|O
DDI-DrugBank.d482.s6|70-76|effects|O
DDI-DrugBank.d482.s6|78-79|of|O
DDI-DrugBank.d482.s6|81-88|sertonin|O
DDI-DrugBank.d482.s6|89-89|.|O
DDI-DrugBank.d482.s7|0-3|This|O
DDI-DrugBank.d482.s7|5-14|medication|O
DDI-DrugBank.d482.s7|16-21|should|O
DDI-DrugBank.d482.s7|23-25|not|O
DDI-DrugBank.d482.s7|27-28|be|O
DDI-DrugBank.d482.s7|30-34|taken|O
DDI-DrugBank.d482.s7|36-39|with|O
DDI-DrugBank.d482.s7|41-54|MAO inhibitors|group
DDI-DrugBank.d482.s7|55-55|.|O
DDI-DrugBank.d482.s8|0-3|Your|O
DDI-DrugBank.d482.s8|5-10|doctor|O
DDI-DrugBank.d482.s8|12-13|or|O
DDI-DrugBank.d482.s8|15-24|pharmacist|O
DDI-DrugBank.d482.s8|26-28|can|O
DDI-DrugBank.d482.s8|30-33|give|O
DDI-DrugBank.d482.s8|35-37|you|O
DDI-DrugBank.d482.s8|39-42|more|O
DDI-DrugBank.d482.s8|44-54|information|O
DDI-DrugBank.d482.s8|56-57|on|O
DDI-DrugBank.d482.s8|59-72|MAO inhibitors|group
DDI-DrugBank.d482.s8|73-73|.|O
DDI-DrugBank.d482.s9|0-3|Wait|O
DDI-DrugBank.d482.s9|5-5|5|O
DDI-DrugBank.d482.s9|7-11|weeks|O
DDI-DrugBank.d482.s9|13-17|after|O
DDI-DrugBank.d482.s9|19-26|stopping|O
DDI-DrugBank.d482.s9|28-39|escitalopram|drug
DDI-DrugBank.d482.s9|41-46|before|O
DDI-DrugBank.d482.s9|48-55|starting|O
DDI-DrugBank.d482.s9|57-57|a|O
DDI-DrugBank.d482.s9|59-85|non-selective MAO inhibitor|group
DDI-DrugBank.d482.s9|86-86|.|O
DDI-DrugBank.d482.s10|0-3|Wait|O
DDI-DrugBank.d482.s10|5-5|2|O
DDI-DrugBank.d482.s10|7-11|weeks|O
DDI-DrugBank.d482.s10|13-17|after|O
DDI-DrugBank.d482.s10|19-26|stopping|O
DDI-DrugBank.d482.s10|28-29|an|O
DDI-DrugBank.d482.s10|31-43|MAO inhibitor|group
DDI-DrugBank.d482.s10|45-50|before|O
DDI-DrugBank.d482.s10|52-59|starting|O
DDI-DrugBank.d482.s10|61-72|escitalopram|drug
DDI-DrugBank.d482.s10|73-73|.|O
DDI-DrugBank.d482.s11|0-1|If|O
DDI-DrugBank.d482.s11|3-5|you|O
DDI-DrugBank.d482.s11|7-9|are|O
DDI-DrugBank.d482.s11|11-16|taking|O
DDI-DrugBank.d482.s11|18-28|medications|O
DDI-DrugBank.d482.s11|30-32|for|O
DDI-DrugBank.d482.s11|34-42|migraines|O
DDI-DrugBank.d482.s11|44-47|such|O
DDI-DrugBank.d482.s11|49-50|as|O
DDI-DrugBank.d482.s11|52-58|Imitrex|brand
DDI-DrugBank.d482.s11|59-59|,|O
DDI-DrugBank.d482.s11|61-64|talk|O
DDI-DrugBank.d482.s11|66-67|to|O
DDI-DrugBank.d482.s11|69-72|your|O
DDI-DrugBank.d482.s11|74-79|doctor|O
DDI-DrugBank.d482.s11|81-86|before|O
DDI-DrugBank.d482.s11|88-95|starting|O
DDI-DrugBank.d482.s11|97-100|this|O
DDI-DrugBank.d482.s11|102-109|medicine|O
DDI-DrugBank.d482.s11|110-110|.|O
DDI-DrugBank.d482.s12|0-1|If|O
DDI-DrugBank.d482.s12|3-5|you|O
DDI-DrugBank.d482.s12|7-9|are|O
DDI-DrugBank.d482.s12|11-16|taking|O
DDI-DrugBank.d482.s12|18-18|a|O
DDI-DrugBank.d482.s12|20-43|tricyclic antidepressant|group
DDI-DrugBank.d482.s12|44-44|,|O
DDI-DrugBank.d482.s12|46-49|talk|O
DDI-DrugBank.d482.s12|51-52|to|O
DDI-DrugBank.d482.s12|54-57|your|O
DDI-DrugBank.d482.s12|59-64|doctor|O
DDI-DrugBank.d482.s12|66-71|before|O
DDI-DrugBank.d482.s12|73-78|taking|O
DDI-DrugBank.d482.s12|80-83|this|O
DDI-DrugBank.d482.s12|85-92|medicine|O
DDI-DrugBank.d482.s12|93-93|.|O
DDI-DrugBank.d482.s13|0-2|St.|O
DDI-DrugBank.d482.s13|4-7|John|O
DDI-DrugBank.d482.s13|10-10|s|O
DDI-DrugBank.d482.s13|12-15|Wort|O
DDI-DrugBank.d482.s13|17-22|should|O
DDI-DrugBank.d482.s13|24-25|be|O
DDI-DrugBank.d482.s13|27-33|avoided|O
DDI-DrugBank.d482.s13|35-39|while|O
DDI-DrugBank.d482.s13|41-46|taking|O
DDI-DrugBank.d482.s13|48-51|this|O
DDI-DrugBank.d482.s13|53-60|medicine|O
DDI-DrugBank.d482.s13|62-64|due|O
DDI-DrugBank.d482.s13|66-67|to|O
DDI-DrugBank.d482.s13|69-71|the|O
DDI-DrugBank.d482.s13|73-80|additive|O
DDI-DrugBank.d482.s13|82-88|effects|O
DDI-DrugBank.d482.s13|90-91|of|O
DDI-DrugBank.d482.s13|93-101|serotonin|O
DDI-DrugBank.d482.s13|102-102|.|O
DDI-DrugBank.d482.s14|0-3|Tell|O
DDI-DrugBank.d482.s14|5-8|your|O
DDI-DrugBank.d482.s14|10-15|doctor|O
DDI-DrugBank.d482.s14|17-18|if|O
DDI-DrugBank.d482.s14|20-22|you|O
DDI-DrugBank.d482.s14|24-26|are|O
DDI-DrugBank.d482.s14|28-33|taking|O
DDI-DrugBank.d482.s14|35-37|any|O
DDI-DrugBank.d482.s14|39-40|of|O
DDI-DrugBank.d482.s14|42-44|the|O
DDI-DrugBank.d482.s14|46-54|following|O
DDI-DrugBank.d482.s14|56-60|drugs|O
DDI-DrugBank.d482.s14|61-61|:|O
DDI-DrugBank.d482.s14|63-67|blood|group
DDI-DrugBank.d482.s14|69-76|thinners|O
DDI-DrugBank.d482.s14|78-78|(|O
DDI-DrugBank.d482.s14|79-86|Coumadin|brand
DDI-DrugBank.d482.s14|87-87|)|O
DDI-DrugBank.d482.s14|89-93|other|O
DDI-DrugBank.d482.s14|95-109|antidepressants|group
DDI-DrugBank.d482.s14|95-109|antidepressants|group
DDI-DrugBank.d482.s14|95-109|antidepressants|group
DDI-DrugBank.d482.s14|95-109|antidepressants|group
DDI-DrugBank.d482.s14|151-151|(|O
DDI-DrugBank.d482.s14|152-159|Tegretol|brand
DDI-DrugBank.d482.s14|160-160|)|O
DDI-DrugBank.d482.s14|162-171|cimetidine|drug
DDI-DrugBank.d482.s14|173-173|(|O
DDI-DrugBank.d482.s14|174-180|Tagamet|brand
DDI-DrugBank.d482.s14|181-181|)|O
DDI-DrugBank.d482.s14|183-191|estrogens|group
DDI-DrugBank.d482.s14|183-191|estrogens|group
DDI-DrugBank.d482.s14|204-204|(|O
DDI-DrugBank.d482.s14|205-210|Prozac|brand
DDI-DrugBank.d482.s14|211-211|)|O
DDI-DrugBank.d482.s14|213-225|intraconazole|O
DDI-DrugBank.d482.s14|227-227|(|O
DDI-DrugBank.d482.s14|228-235|Sporanox|brand
DDI-DrugBank.d482.s14|236-236|)|O
DDI-DrugBank.d482.s14|238-249|ketoconazole|drug
DDI-DrugBank.d482.s14|251-251|(|O
DDI-DrugBank.d482.s14|252-258|Nizoral|brand
DDI-DrugBank.d482.s14|259-259|)|O
DDI-DrugBank.d482.s14|261-268|levodopa|drug
DDI-DrugBank.d482.s14|261-268|levodopa|drug
DDI-DrugBank.d482.s14|261-268|levodopa|drug
DDI-DrugBank.d482.s14|285-293|relaxants|group
DDI-DrugBank.d482.s14|295-299|birth|O
DDI-DrugBank.d482.s14|301-307|control|O
DDI-DrugBank.d482.s14|309-313|pills|O
DDI-DrugBank.d482.s14|315-322|sleeping|O
DDI-DrugBank.d482.s14|324-328|pills|O
DDI-DrugBank.d482.s14|330-336|thyroid|O
DDI-DrugBank.d482.s14|338-348|medications|O
DDI-DrugBank.d735.s0|0-0|A|O
DDI-DrugBank.d735.s0|2-6|total|O
DDI-DrugBank.d735.s0|8-9|of|O
DDI-DrugBank.d735.s0|11-12|11|O
DDI-DrugBank.d735.s0|14-21|clinical|O
DDI-DrugBank.d735.s0|23-31|drug-drug|O
DDI-DrugBank.d735.s0|33-43|interaction|O
DDI-DrugBank.d735.s0|45-51|studies|O
DDI-DrugBank.d735.s0|53-56|were|O
DDI-DrugBank.d735.s0|58-66|conducted|O
DDI-DrugBank.d735.s0|68-69|in|O
DDI-DrugBank.d735.s0|71-77|healthy|O
DDI-DrugBank.d735.s0|79-88|volunteers|O
DDI-DrugBank.d735.s0|90-91|to|O
DDI-DrugBank.d735.s0|93-100|evaluate|O
DDI-DrugBank.d735.s0|102-104|the|O
DDI-DrugBank.d735.s0|106-114|potential|O
DDI-DrugBank.d735.s0|116-118|for|O
DDI-DrugBank.d735.s0|120-130|interaction|O
DDI-DrugBank.d735.s0|132-138|between|O
DDI-DrugBank.d735.s0|140-147|MYCAMINE|brand
DDI-DrugBank.d735.s0|149-151|and|O
DDI-DrugBank.d735.s0|153-173|mycophenolate mofetil|drug
DDI-DrugBank.d735.s0|174-174|,|O
DDI-DrugBank.d735.s0|176-187|cyclosporine|drug
DDI-DrugBank.d735.s0|188-188|,|O
DDI-DrugBank.d735.s0|190-199|tacrolimus|drug
DDI-DrugBank.d735.s0|200-200|,|O
DDI-DrugBank.d735.s0|202-213|prednisolone|drug
DDI-DrugBank.d735.s0|214-214|,|O
DDI-DrugBank.d735.s0|216-224|sirolimus|drug
DDI-DrugBank.d735.s0|225-225|,|O
DDI-DrugBank.d735.s0|227-236|nifedipine|drug
DDI-DrugBank.d735.s0|237-237|,|O
DDI-DrugBank.d735.s0|239-249|fluconazole|drug
DDI-DrugBank.d735.s0|250-250|,|O
DDI-DrugBank.d735.s0|252-260|ritonavir|drug
DDI-DrugBank.d735.s0|261-261|,|O
DDI-DrugBank.d735.s0|263-265|and|O
DDI-DrugBank.d735.s0|267-274|rifampin|drug
DDI-DrugBank.d735.s0|275-275|.|O
DDI-DrugBank.d735.s1|0-1|In|O
DDI-DrugBank.d735.s1|3-7|these|O
DDI-DrugBank.d735.s1|9-15|studies|O
DDI-DrugBank.d735.s1|16-16|,|O
DDI-DrugBank.d735.s1|18-19|no|O
DDI-DrugBank.d735.s1|21-31|interaction|O
DDI-DrugBank.d735.s1|33-36|that|O
DDI-DrugBank.d735.s1|38-44|altered|O
DDI-DrugBank.d735.s1|46-48|the|O
DDI-DrugBank.d735.s1|50-65|pharmacokinetics|O
DDI-DrugBank.d735.s1|67-68|of|O
DDI-DrugBank.d735.s1|70-79|micafungin|drug
DDI-DrugBank.d735.s1|81-83|was|O
DDI-DrugBank.d735.s1|85-92|observed|O
DDI-DrugBank.d735.s1|93-93|.|O
DDI-DrugBank.d735.s2|0-4|There|O
DDI-DrugBank.d735.s2|6-8|was|O
DDI-DrugBank.d735.s2|10-11|no|O
DDI-DrugBank.d735.s2|13-18|effect|O
DDI-DrugBank.d735.s2|20-21|of|O
DDI-DrugBank.d735.s2|23-23|a|O
DDI-DrugBank.d735.s2|25-30|single|O
DDI-DrugBank.d735.s2|32-35|dose|O
DDI-DrugBank.d735.s2|37-38|or|O
DDI-DrugBank.d735.s2|40-47|multiple|O
DDI-DrugBank.d735.s2|49-53|doses|O
DDI-DrugBank.d735.s2|55-56|of|O
DDI-DrugBank.d735.s2|58-65|MYCAMINE|brand
DDI-DrugBank.d735.s2|67-68|on|O
DDI-DrugBank.d735.s2|70-90|mycophenolate mofetil|drug
DDI-DrugBank.d735.s2|91-91|,|O
DDI-DrugBank.d735.s2|93-104|cyclosporine|drug
DDI-DrugBank.d735.s2|105-105|,|O
DDI-DrugBank.d735.s2|107-116|tacrolimus|drug
DDI-DrugBank.d735.s2|117-117|,|O
DDI-DrugBank.d735.s2|119-130|prednisolone|drug
DDI-DrugBank.d735.s2|131-131|,|O
DDI-DrugBank.d735.s2|133-135|and|O
DDI-DrugBank.d735.s2|137-147|fluconazole|drug
DDI-DrugBank.d735.s2|149-164|pharmacokinetics|O
DDI-DrugBank.d735.s2|165-165|.|O
DDI-DrugBank.d735.s3|0-8|Sirolimus|drug
DDI-DrugBank.d735.s3|10-12|AUC|O
DDI-DrugBank.d735.s3|14-16|was|O
DDI-DrugBank.d735.s3|18-26|increased|O
DDI-DrugBank.d735.s3|28-29|by|O
DDI-DrugBank.d735.s3|31-32|21|O
DDI-DrugBank.d735.s3|33-33|%|O
DDI-DrugBank.d735.s3|35-38|with|O
DDI-DrugBank.d735.s3|40-41|no|O
DDI-DrugBank.d735.s3|43-48|effect|O
DDI-DrugBank.d735.s3|50-51|on|O
DDI-DrugBank.d735.s3|53-56|Cmax|O
DDI-DrugBank.d735.s3|58-59|in|O
DDI-DrugBank.d735.s3|61-63|the|O
DDI-DrugBank.d735.s3|65-72|presence|O
DDI-DrugBank.d735.s3|74-75|of|O
DDI-DrugBank.d735.s3|77-88|steady-state|O
DDI-DrugBank.d735.s3|90-97|MYCAMINE|brand
DDI-DrugBank.d735.s3|99-106|compared|O
DDI-DrugBank.d735.s3|108-111|with|O
DDI-DrugBank.d735.s3|113-121|sirolimus|drug
DDI-DrugBank.d735.s3|123-127|alone|O
DDI-DrugBank.d735.s3|128-128|.|O
DDI-DrugBank.d735.s4|0-9|Nifedipine|drug
DDI-DrugBank.d735.s4|11-13|AUC|O
DDI-DrugBank.d735.s4|15-17|and|O
DDI-DrugBank.d735.s4|19-22|Cmax|O
DDI-DrugBank.d735.s4|24-27|were|O
DDI-DrugBank.d735.s4|29-37|increased|O
DDI-DrugBank.d735.s4|39-40|by|O
DDI-DrugBank.d735.s4|42-43|18|O
DDI-DrugBank.d735.s4|44-44|%|O
DDI-DrugBank.d735.s4|46-48|and|O
DDI-DrugBank.d735.s4|50-51|42|O
DDI-DrugBank.d735.s4|52-52|%|O
DDI-DrugBank.d735.s4|53-53|,|O
DDI-DrugBank.d735.s4|55-66|respectively|O
DDI-DrugBank.d735.s4|67-67|,|O
DDI-DrugBank.d735.s4|69-70|in|O
DDI-DrugBank.d735.s4|72-74|the|O
DDI-DrugBank.d735.s4|76-83|presence|O
DDI-DrugBank.d735.s4|85-86|of|O
DDI-DrugBank.d735.s4|88-99|steady-state|O
DDI-DrugBank.d735.s4|101-108|MYCAMINE|brand
DDI-DrugBank.d735.s4|110-117|compared|O
DDI-DrugBank.d735.s4|119-122|with|O
DDI-DrugBank.d735.s4|124-133|nifedipine|drug
DDI-DrugBank.d735.s4|135-139|alone|O
DDI-DrugBank.d735.s4|140-140|.|O
DDI-DrugBank.d735.s5|0-7|Patients|O
DDI-DrugBank.d735.s5|9-17|receiving|O
DDI-DrugBank.d735.s5|19-27|sirolimus|drug
DDI-DrugBank.d735.s5|29-30|or|O
DDI-DrugBank.d735.s5|32-41|nifedipine|drug
DDI-DrugBank.d735.s5|43-44|in|O
DDI-DrugBank.d735.s5|46-56|combination|O
DDI-DrugBank.d735.s5|58-61|with|O
DDI-DrugBank.d735.s5|63-70|MYCAMINE|brand
DDI-DrugBank.d735.s5|72-77|should|O
DDI-DrugBank.d735.s5|79-80|be|O
DDI-DrugBank.d735.s5|82-90|monitored|O
DDI-DrugBank.d735.s5|92-94|for|O
DDI-DrugBank.d735.s5|96-104|sirolimus|drug
DDI-DrugBank.d735.s5|106-107|or|O
DDI-DrugBank.d735.s5|109-118|nifedipine|drug
DDI-DrugBank.d735.s5|120-127|toxicity|O
DDI-DrugBank.d735.s5|129-131|and|O
DDI-DrugBank.d735.s5|133-141|sirolimus|drug
DDI-DrugBank.d735.s5|143-144|or|O
DDI-DrugBank.d735.s5|146-155|nifedipine|drug
DDI-DrugBank.d735.s5|157-162|dosage|O
DDI-DrugBank.d735.s5|164-169|should|O
DDI-DrugBank.d735.s5|171-172|be|O
DDI-DrugBank.d735.s5|174-180|reduced|O
DDI-DrugBank.d735.s5|182-183|if|O
DDI-DrugBank.d735.s5|185-193|necessary|O
DDI-DrugBank.d735.s5|194-194|.|O
DDI-DrugBank.d735.s6|0-9|Micafungin|drug
DDI-DrugBank.d735.s6|11-12|is|O
DDI-DrugBank.d735.s6|14-16|not|O
DDI-DrugBank.d735.s6|18-19|an|O
DDI-DrugBank.d735.s6|21-29|inhibitor|O
DDI-DrugBank.d735.s6|31-32|of|O
DDI-DrugBank.d735.s6|34-47|P-glycoprotein|O
DDI-DrugBank.d735.s6|49-51|and|O
DDI-DrugBank.d735.s6|52-52|,|O
DDI-DrugBank.d735.s6|54-62|therefore|O
DDI-DrugBank.d735.s6|63-63|,|O
DDI-DrugBank.d735.s6|65-69|would|O
DDI-DrugBank.d735.s6|71-73|not|O
DDI-DrugBank.d735.s6|75-76|be|O
DDI-DrugBank.d735.s6|78-85|expected|O
DDI-DrugBank.d735.s6|87-88|to|O
DDI-DrugBank.d735.s6|90-94|alter|O
DDI-DrugBank.d735.s6|96-118|P-glycoprotein-mediated|O
DDI-DrugBank.d735.s6|120-123|drug|O
DDI-DrugBank.d735.s6|125-133|transport|O
DDI-DrugBank.d735.s6|135-142|activity|O
DDI-DrugBank.d735.s6|143-143|.|O
DDI-DrugBank.d20.s0|0-9|Inhibitors|O
DDI-DrugBank.d20.s0|11-12|of|O
DDI-DrugBank.d20.s0|14-30|CYP3A4-Eplerenone|drug
DDI-DrugBank.d20.s0|32-41|metabolism|O
DDI-DrugBank.d20.s0|43-44|is|O
DDI-DrugBank.d20.s0|46-58|predominantly|O
DDI-DrugBank.d20.s0|60-67|mediated|O
DDI-DrugBank.d20.s0|69-71|via|O
DDI-DrugBank.d20.s0|73-78|CYP3A4|O
DDI-DrugBank.d20.s0|79-79|.|O
DDI-DrugBank.d20.s1|0-0|A|O
DDI-DrugBank.d20.s1|2-16|pharmacokinetic|O
DDI-DrugBank.d20.s1|18-22|study|O
DDI-DrugBank.d20.s1|24-33|evaluating|O
DDI-DrugBank.d20.s1|35-37|the|O
DDI-DrugBank.d20.s1|39-52|administration|O
DDI-DrugBank.d20.s1|54-55|of|O
DDI-DrugBank.d20.s1|57-57|a|O
DDI-DrugBank.d20.s1|59-64|single|O
DDI-DrugBank.d20.s1|66-69|dose|O
DDI-DrugBank.d20.s1|71-72|of|O
DDI-DrugBank.d20.s1|74-79|INSPRA|brand
DDI-DrugBank.d20.s1|81-83|100|O
DDI-DrugBank.d20.s1|85-86|mg|O
DDI-DrugBank.d20.s1|88-91|with|O
DDI-DrugBank.d20.s1|93-104|ketoconazole|drug
DDI-DrugBank.d20.s1|106-108|200|O
DDI-DrugBank.d20.s1|110-111|mg|O
DDI-DrugBank.d20.s1|113-115|BID|O
DDI-DrugBank.d20.s1|116-116|,|O
DDI-DrugBank.d20.s1|118-118|a|O
DDI-DrugBank.d20.s1|120-125|potent|O
DDI-DrugBank.d20.s1|127-135|inhibitor|O
DDI-DrugBank.d20.s1|137-138|of|O
DDI-DrugBank.d20.s1|140-142|the|O
DDI-DrugBank.d20.s1|144-149|CYP3A4|O
DDI-DrugBank.d20.s1|151-157|pathway|O
DDI-DrugBank.d20.s1|158-158|,|O
DDI-DrugBank.d20.s1|160-165|showed|O
DDI-DrugBank.d20.s1|167-167|a|O
DDI-DrugBank.d20.s1|169-176|1.7-fold|O
DDI-DrugBank.d20.s1|178-185|increase|O
DDI-DrugBank.d20.s1|187-188|in|O
DDI-DrugBank.d20.s1|190-193|Cmax|O
DDI-DrugBank.d20.s1|195-196|of|O
DDI-DrugBank.d20.s1|198-207|eplerenone|drug
DDI-DrugBank.d20.s1|209-211|and|O
DDI-DrugBank.d20.s1|213-213|a|O
DDI-DrugBank.d20.s1|215-222|5.4-fold|O
DDI-DrugBank.d20.s1|224-231|increase|O
DDI-DrugBank.d20.s1|233-234|in|O
DDI-DrugBank.d20.s1|236-238|AUC|O
DDI-DrugBank.d20.s1|240-241|of|O
DDI-DrugBank.d20.s1|243-252|eplerenone|drug
DDI-DrugBank.d20.s1|253-253|.|O
DDI-DrugBank.d20.s2|0-5|INSPRA|brand
DDI-DrugBank.d20.s2|7-12|should|O
DDI-DrugBank.d20.s2|14-16|not|O
DDI-DrugBank.d20.s2|18-19|be|O
DDI-DrugBank.d20.s2|21-24|used|O
DDI-DrugBank.d20.s2|26-29|with|O
DDI-DrugBank.d20.s2|31-35|drugs|O
DDI-DrugBank.d20.s2|37-45|described|O
DDI-DrugBank.d20.s2|47-48|as|O
DDI-DrugBank.d20.s2|50-55|strong|O
DDI-DrugBank.d20.s2|57-66|inhibitors|O
DDI-DrugBank.d20.s2|68-69|of|O
DDI-DrugBank.d20.s2|71-76|CYP3A4|O
DDI-DrugBank.d20.s2|78-79|in|O
DDI-DrugBank.d20.s2|81-85|their|O
DDI-DrugBank.d20.s2|87-94|labeling|O
DDI-DrugBank.d20.s2|95-95|.|O
DDI-DrugBank.d20.s3|0-13|Administration|O
DDI-DrugBank.d20.s3|15-16|of|O
DDI-DrugBank.d20.s3|18-27|eplerenone|drug
DDI-DrugBank.d20.s3|29-32|with|O
DDI-DrugBank.d20.s3|34-38|other|O
DDI-DrugBank.d20.s3|40-45|CYP3A4|O
DDI-DrugBank.d20.s3|47-56|inhibitors|O
DDI-DrugBank.d20.s3|58-58|(|O
DDI-DrugBank.d20.s3|59-62|e.g.|O
DDI-DrugBank.d20.s3|63-63|,|O
DDI-DrugBank.d20.s3|65-76|erythromycin|drug
DDI-DrugBank.d20.s3|78-80|500|O
DDI-DrugBank.d20.s3|82-83|mg|O
DDI-DrugBank.d20.s3|85-87|BID|O
DDI-DrugBank.d20.s3|88-88|,|O
DDI-DrugBank.d20.s3|90-98|verapamil|drug
DDI-DrugBank.d20.s3|100-102|240|O
DDI-DrugBank.d20.s3|104-105|mg|O
DDI-DrugBank.d20.s3|107-108|QD|O
DDI-DrugBank.d20.s3|109-109|,|O
DDI-DrugBank.d20.s3|111-120|saquinavir|drug
DDI-DrugBank.d20.s3|122-125|1200|O
DDI-DrugBank.d20.s3|127-128|mg|O
DDI-DrugBank.d20.s3|130-132|TID|O
DDI-DrugBank.d20.s3|133-133|,|O
DDI-DrugBank.d20.s3|135-145|fluconazole|drug
DDI-DrugBank.d20.s3|147-149|200|O
DDI-DrugBank.d20.s3|151-152|mg|O
DDI-DrugBank.d20.s3|154-155|QD|O
DDI-DrugBank.d20.s3|156-156|)|O
DDI-DrugBank.d20.s3|158-165|resulted|O
DDI-DrugBank.d20.s3|167-168|in|O
DDI-DrugBank.d20.s3|170-178|increases|O
DDI-DrugBank.d20.s3|180-181|in|O
DDI-DrugBank.d20.s3|183-186|Cmax|O
DDI-DrugBank.d20.s3|188-189|of|O
DDI-DrugBank.d20.s3|191-200|eplerenone|drug
DDI-DrugBank.d20.s3|202-208|ranging|O
DDI-DrugBank.d20.s3|210-213|from|O
DDI-DrugBank.d20.s3|215-218|1.4-|O
DDI-DrugBank.d20.s3|220-221|to|O
DDI-DrugBank.d20.s3|223-226|1.6-|O
DDI-DrugBank.d20.s3|228-231|fold|O
DDI-DrugBank.d20.s3|233-235|and|O
DDI-DrugBank.d20.s3|237-239|AUC|O
DDI-DrugBank.d20.s3|241-244|from|O
DDI-DrugBank.d20.s3|246-249|2.0-|O
DDI-DrugBank.d20.s3|251-252|to|O
DDI-DrugBank.d20.s3|254-257|2.9-|O
DDI-DrugBank.d20.s3|259-262|fold|O
DDI-DrugBank.d20.s3|263-263|.|O
DDI-DrugBank.d20.s4|0-13|ACE Inhibitors|group
DDI-DrugBank.d20.s4|15-17|and|O
DDI-DrugBank.d20.s4|19-53|Angiotensin II Receptor Antagonists|group
DDI-DrugBank.d20.s4|55-55|(|O
DDI-DrugBank.d20.s4|56-65|Congestive|O
DDI-DrugBank.d20.s4|67-71|Heart|O
DDI-DrugBank.d20.s4|73-79|Failure|O
DDI-DrugBank.d20.s4|81-95|Post-Myocardial|O
DDI-DrugBank.d20.s4|97-106|Infarction|O
DDI-DrugBank.d20.s4|107-107|)|O
DDI-DrugBank.d20.s4|108-108|-|O
DDI-DrugBank.d20.s4|110-111|In|O
DDI-DrugBank.d20.s4|113-119|EPHESUS|O
DDI-DrugBank.d20.s4|120-120|,|O
DDI-DrugBank.d20.s4|122-125|3020|O
DDI-DrugBank.d20.s4|127-127|(|O
DDI-DrugBank.d20.s4|128-129|91|O
DDI-DrugBank.d20.s4|130-130|%|O
DDI-DrugBank.d20.s4|131-131|)|O
DDI-DrugBank.d20.s4|133-140|patients|O
DDI-DrugBank.d20.s4|142-150|receiving|O
DDI-DrugBank.d20.s4|152-157|INSPRA|brand
DDI-DrugBank.d20.s4|159-160|25|O
DDI-DrugBank.d20.s4|162-163|to|O
DDI-DrugBank.d20.s4|165-166|50|O
DDI-DrugBank.d20.s4|168-169|mg|O
DDI-DrugBank.d20.s4|171-174|also|O
DDI-DrugBank.d20.s4|176-183|received|O
DDI-DrugBank.d20.s4|185-198|ACE inhibitors|group
DDI-DrugBank.d20.s4|200-201|or|O
DDI-DrugBank.d20.s4|203-237|angiotensin II receptor antagonists|group
DDI-DrugBank.d20.s4|239-239|(|O
DDI-DrugBank.d20.s4|240-247|ACEI/ARB|group
DDI-DrugBank.d20.s4|248-248|)|O
DDI-DrugBank.d20.s4|249-249|.|O
DDI-DrugBank.d20.s5|0-4|Rates|O
DDI-DrugBank.d20.s5|6-7|of|O
DDI-DrugBank.d20.s5|9-16|patients|O
DDI-DrugBank.d20.s5|18-21|with|O
DDI-DrugBank.d20.s5|23-29|maximum|O
DDI-DrugBank.d20.s5|31-39|potassium|O
DDI-DrugBank.d20.s5|41-46|levels|O
DDI-DrugBank.d20.s5|49-51|5.5|O
DDI-DrugBank.d20.s5|53-57|mEq/L|O
DDI-DrugBank.d20.s5|59-62|were|O
DDI-DrugBank.d20.s5|64-70|similar|O
DDI-DrugBank.d20.s5|72-81|regardless|O
DDI-DrugBank.d20.s5|83-84|of|O
DDI-DrugBank.d20.s5|86-88|the|O
DDI-DrugBank.d20.s5|90-92|use|O
DDI-DrugBank.d20.s5|94-95|of|O
DDI-DrugBank.d20.s5|97-104|ACEI/ARB|group
DDI-DrugBank.d20.s5|105-105|.|O
DDI-DrugBank.d20.s6|0-13|ACE Inhibitors|group
DDI-DrugBank.d20.s6|15-17|and|O
DDI-DrugBank.d20.s6|19-53|Angiotensin II Receptor Antagonists|group
DDI-DrugBank.d20.s6|55-55|(|O
DDI-DrugBank.d20.s6|56-67|Hypertension|O
DDI-DrugBank.d20.s6|68-68|)|O
DDI-DrugBank.d20.s6|69-69|-|O
DDI-DrugBank.d20.s6|71-72|In|O
DDI-DrugBank.d20.s6|74-81|clinical|O
DDI-DrugBank.d20.s6|83-89|studies|O
DDI-DrugBank.d20.s6|91-92|of|O
DDI-DrugBank.d20.s6|94-101|patients|O
DDI-DrugBank.d20.s6|103-106|with|O
DDI-DrugBank.d20.s6|108-119|hypertension|O
DDI-DrugBank.d20.s6|120-120|,|O
DDI-DrugBank.d20.s6|122-124|the|O
DDI-DrugBank.d20.s6|126-133|addition|O
DDI-DrugBank.d20.s6|135-136|of|O
DDI-DrugBank.d20.s6|138-143|INSPRA|brand
DDI-DrugBank.d20.s6|145-146|50|O
DDI-DrugBank.d20.s6|148-149|to|O
DDI-DrugBank.d20.s6|151-153|100|O
DDI-DrugBank.d20.s6|155-156|mg|O
DDI-DrugBank.d20.s6|158-159|to|O
DDI-DrugBank.d20.s6|161-174|ACE inhibitors|group
DDI-DrugBank.d20.s6|176-178|and|O
DDI-DrugBank.d20.s6|180-214|angiotensin II receptor antagonists|group
DDI-DrugBank.d20.s6|216-224|increased|O
DDI-DrugBank.d20.s6|226-229|mean|O
DDI-DrugBank.d20.s6|231-235|serum|O
DDI-DrugBank.d20.s6|237-245|potassium|O
DDI-DrugBank.d20.s6|247-254|slightly|O
DDI-DrugBank.d20.s6|256-256|(|O
DDI-DrugBank.d20.s6|257-261|about|O
DDI-DrugBank.d20.s6|263-271|0.09-0.13|O
DDI-DrugBank.d20.s6|273-277|mEq/L|O
DDI-DrugBank.d20.s6|278-278|)|O
DDI-DrugBank.d20.s6|279-279|.|O
DDI-DrugBank.d20.s7|0-1|In|O
DDI-DrugBank.d20.s7|3-3|a|O
DDI-DrugBank.d20.s7|5-9|study|O
DDI-DrugBank.d20.s7|11-12|in|O
DDI-DrugBank.d20.s7|14-22|diabetics|O
DDI-DrugBank.d20.s7|24-27|with|O
DDI-DrugBank.d20.s7|29-44|microalbuminuria|O
DDI-DrugBank.d20.s7|46-51|INSPRA|brand
DDI-DrugBank.d20.s7|53-55|200|O
DDI-DrugBank.d20.s7|57-58|mg|O
DDI-DrugBank.d20.s7|60-67|combined|O
DDI-DrugBank.d20.s7|69-72|with|O
DDI-DrugBank.d20.s7|74-76|the|O
DDI-DrugBank.d20.s7|78-90|ACE inhibitor|group
DDI-DrugBank.d20.s7|78-90|ACE inhibitor|group
DDI-DrugBank.d20.s7|102-103|10|O
DDI-DrugBank.d20.s7|105-106|mg|O
DDI-DrugBank.d20.s7|108-116|increased|O
DDI-DrugBank.d20.s7|118-120|the|O
DDI-DrugBank.d20.s7|122-130|frequency|O
DDI-DrugBank.d20.s7|132-133|of|O
DDI-DrugBank.d20.s7|135-146|hyperkalemia|O
DDI-DrugBank.d20.s7|148-148|(|O
DDI-DrugBank.d20.s7|149-153|serum|O
DDI-DrugBank.d20.s7|155-163|potassium|O
DDI-DrugBank.d20.s7|166-168|5.5|O
DDI-DrugBank.d20.s7|170-174|mEq/L|O
DDI-DrugBank.d20.s7|175-175|)|O
DDI-DrugBank.d20.s7|177-180|from|O
DDI-DrugBank.d20.s7|182-183|17|O
DDI-DrugBank.d20.s7|184-184|%|O
DDI-DrugBank.d20.s7|186-187|on|O
DDI-DrugBank.d20.s7|189-197|enalapril|drug
DDI-DrugBank.d20.s7|199-203|alone|O
DDI-DrugBank.d20.s7|205-206|to|O
DDI-DrugBank.d20.s7|208-209|38|O
DDI-DrugBank.d20.s7|210-210|%|O
DDI-DrugBank.d20.s7|211-211|.|O
DDI-DrugBank.d20.s8|0-8|Lithium-A|drug
DDI-DrugBank.d20.s8|10-13|drug|O
DDI-DrugBank.d20.s8|15-25|interaction|O
DDI-DrugBank.d20.s8|27-31|study|O
DDI-DrugBank.d20.s8|33-34|of|O
DDI-DrugBank.d20.s8|36-45|eplerenone|drug
DDI-DrugBank.d20.s8|47-50|with|O
DDI-DrugBank.d20.s8|52-58|lithium|drug
DDI-DrugBank.d20.s8|60-62|has|O
DDI-DrugBank.d20.s8|64-66|not|O
DDI-DrugBank.d20.s8|68-71|been|O
DDI-DrugBank.d20.s8|73-81|conducted|O
DDI-DrugBank.d20.s8|82-82|.|O
DDI-DrugBank.d20.s9|0-4|Serum|O
DDI-DrugBank.d20.s9|6-12|lithium|drug
DDI-DrugBank.d20.s9|14-19|levels|O
DDI-DrugBank.d20.s9|21-26|should|O
DDI-DrugBank.d20.s9|28-29|be|O
DDI-DrugBank.d20.s9|31-39|monitored|O
DDI-DrugBank.d20.s9|41-50|frequently|O
DDI-DrugBank.d20.s9|52-53|if|O
DDI-DrugBank.d20.s9|55-60|INSPRA|brand
DDI-DrugBank.d20.s9|62-63|is|O
DDI-DrugBank.d20.s9|65-76|administered|O
DDI-DrugBank.d20.s9|78-90|concomitantly|O
DDI-DrugBank.d20.s9|92-95|with|O
DDI-DrugBank.d20.s9|97-103|lithium|drug
DDI-DrugBank.d20.s9|104-104|.|O
DDI-DrugBank.d20.s10|0-35|Nonsteroidal Anti-Inflammatory Drugs|group
DDI-DrugBank.d20.s10|37-37|(|O
DDI-DrugBank.d20.s10|38-43|NSAIDs|group
DDI-DrugBank.d20.s10|44-44|)|O
DDI-DrugBank.d20.s10|45-46|-A|O
DDI-DrugBank.d20.s10|48-51|drug|O
DDI-DrugBank.d20.s10|53-63|interaction|O
DDI-DrugBank.d20.s10|65-69|study|O
DDI-DrugBank.d20.s10|71-72|of|O
DDI-DrugBank.d20.s10|74-83|eplerenone|drug
DDI-DrugBank.d20.s10|85-88|with|O
DDI-DrugBank.d20.s10|90-91|an|O
DDI-DrugBank.d20.s10|93-97|NSAID|group
DDI-DrugBank.d20.s10|99-101|has|O
DDI-DrugBank.d20.s10|103-105|not|O
DDI-DrugBank.d20.s10|107-110|been|O
DDI-DrugBank.d20.s10|112-120|conducted|O
DDI-DrugBank.d20.s10|121-121|.|O
DDI-DrugBank.d20.s11|0-2|The|O
DDI-DrugBank.d20.s11|4-17|administration|O
DDI-DrugBank.d20.s11|19-20|of|O
DDI-DrugBank.d20.s11|22-26|other|O
DDI-DrugBank.d20.s11|28-62|potassium-sparing antihypertensives|group
DDI-DrugBank.d20.s11|64-67|with|O
DDI-DrugBank.d20.s11|69-74|NSAIDs|group
DDI-DrugBank.d20.s11|76-78|has|O
DDI-DrugBank.d20.s11|80-83|been|O
DDI-DrugBank.d20.s11|85-89|shown|O
DDI-DrugBank.d20.s11|91-92|to|O
DDI-DrugBank.d20.s11|94-99|reduce|O
DDI-DrugBank.d20.s11|101-103|the|O
DDI-DrugBank.d20.s11|105-120|antihypertensive|O
DDI-DrugBank.d20.s11|122-127|effect|O
DDI-DrugBank.d20.s11|129-130|in|O
DDI-DrugBank.d20.s11|132-135|some|O
DDI-DrugBank.d20.s11|137-144|patients|O
DDI-DrugBank.d20.s11|146-148|and|O
DDI-DrugBank.d20.s11|150-155|result|O
DDI-DrugBank.d20.s11|157-158|in|O
DDI-DrugBank.d20.s11|160-165|severe|O
DDI-DrugBank.d20.s11|167-178|hyperkalemia|O
DDI-DrugBank.d20.s11|180-181|in|O
DDI-DrugBank.d20.s11|183-190|patients|O
DDI-DrugBank.d20.s11|192-195|with|O
DDI-DrugBank.d20.s11|197-204|impaired|O
DDI-DrugBank.d20.s11|206-210|renal|O
DDI-DrugBank.d20.s11|212-219|function|O
DDI-DrugBank.d20.s11|220-220|.|O
DDI-DrugBank.d20.s12|0-8|Therefore|O
DDI-DrugBank.d20.s12|9-9|,|O
DDI-DrugBank.d20.s12|11-14|when|O
DDI-DrugBank.d20.s12|16-21|INSPRA|brand
DDI-DrugBank.d20.s12|23-25|and|O
DDI-DrugBank.d20.s12|27-32|NSAIDs|group
DDI-DrugBank.d20.s12|34-36|are|O
DDI-DrugBank.d20.s12|38-41|used|O
DDI-DrugBank.d20.s12|43-55|concomitantly|O
DDI-DrugBank.d20.s12|56-56|,|O
DDI-DrugBank.d20.s12|58-65|patients|O
DDI-DrugBank.d20.s12|67-72|should|O
DDI-DrugBank.d20.s12|74-75|be|O
DDI-DrugBank.d20.s12|77-84|observed|O
DDI-DrugBank.d20.s12|86-87|to|O
DDI-DrugBank.d20.s12|89-97|determine|O
DDI-DrugBank.d20.s12|99-105|whether|O
DDI-DrugBank.d20.s12|107-109|the|O
DDI-DrugBank.d20.s12|111-117|desired|O
DDI-DrugBank.d20.s12|119-124|effect|O
DDI-DrugBank.d20.s12|126-127|on|O
DDI-DrugBank.d20.s12|129-133|blood|O
DDI-DrugBank.d20.s12|135-142|pressure|O
DDI-DrugBank.d20.s12|144-145|is|O
DDI-DrugBank.d20.s12|147-154|obtained|O
DDI-DrugBank.d20.s12|155-155|.|O
DDI-DrugBank.d86.s0|0-2|The|O
DDI-DrugBank.d86.s0|4-13|concurrent|O
DDI-DrugBank.d86.s0|15-17|use|O
DDI-DrugBank.d86.s0|19-20|of|O
DDI-DrugBank.d86.s0|22-24|two|O
DDI-DrugBank.d86.s0|26-27|or|O
DDI-DrugBank.d86.s0|29-32|more|O
DDI-DrugBank.d86.s0|34-38|drugs|O
DDI-DrugBank.d86.s0|40-43|with|O
DDI-DrugBank.d86.s0|45-59|anticholinergic|O
DDI-DrugBank.d86.s0|61-68|activity|O
DDI-DrugBank.d86.s0|69-70|--|O
DDI-DrugBank.d86.s0|71-74|such|O
DDI-DrugBank.d86.s0|76-77|as|O
DDI-DrugBank.d86.s0|79-80|an|O
DDI-DrugBank.d86.s0|82-99|antipsychotic drug|group
DDI-DrugBank.d86.s0|101-101|(|O
DDI-DrugBank.d86.s0|102-103|eg|O
DDI-DrugBank.d86.s0|104-104|,|O
DDI-DrugBank.d86.s0|106-119|chlorpromazine|drug
DDI-DrugBank.d86.s0|120-120|)|O
DDI-DrugBank.d86.s0|121-121|,|O
DDI-DrugBank.d86.s0|123-124|an|O
DDI-DrugBank.d86.s0|126-146|antiparkinsonian drug|group
DDI-DrugBank.d86.s0|148-148|(|O
DDI-DrugBank.d86.s0|149-150|eg|O
DDI-DrugBank.d86.s0|151-151|,|O
DDI-DrugBank.d86.s0|153-167|trihexyphenidyl|drug
DDI-DrugBank.d86.s0|168-168|)|O
DDI-DrugBank.d86.s0|169-169|,|O
DDI-DrugBank.d86.s0|171-176|and/or|O
DDI-DrugBank.d86.s0|178-178|a|O
DDI-DrugBank.d86.s0|180-203|tricyclic antidepressant|group
DDI-DrugBank.d86.s0|205-205|(|O
DDI-DrugBank.d86.s0|206-207|eg|O
DDI-DrugBank.d86.s0|208-208|,|O
DDI-DrugBank.d86.s0|210-222|amitriptyline|drug
DDI-DrugBank.d86.s0|223-223|)|O
DDI-DrugBank.d86.s0|224-225|--|O
DDI-DrugBank.d86.s0|226-233|commonly|O
DDI-DrugBank.d86.s0|235-241|results|O
DDI-DrugBank.d86.s0|243-244|in|O
DDI-DrugBank.d86.s0|246-254|excessive|O
DDI-DrugBank.d86.s0|256-270|anticholinergic|O
DDI-DrugBank.d86.s0|272-278|effects|O
DDI-DrugBank.d86.s0|279-279|,|O
DDI-DrugBank.d86.s0|281-289|including|O
DDI-DrugBank.d86.s0|291-293|dry|O
DDI-DrugBank.d86.s0|295-299|mouth|O
DDI-DrugBank.d86.s0|301-303|and|O
DDI-DrugBank.d86.s0|305-314|associated|O
DDI-DrugBank.d86.s0|316-321|dental|O
DDI-DrugBank.d86.s0|323-335|complications|O
DDI-DrugBank.d86.s0|336-336|,|O
DDI-DrugBank.d86.s0|338-344|blurred|O
DDI-DrugBank.d86.s0|346-351|vision|O
DDI-DrugBank.d86.s0|352-352|,|O
DDI-DrugBank.d86.s0|354-356|and|O
DDI-DrugBank.d86.s0|357-357|,|O
DDI-DrugBank.d86.s0|359-360|in|O
DDI-DrugBank.d86.s0|362-369|patients|O
DDI-DrugBank.d86.s0|371-377|exposed|O
DDI-DrugBank.d86.s0|379-380|to|O
DDI-DrugBank.d86.s0|382-385|high|O
DDI-DrugBank.d86.s0|387-397|temperature|O
DDI-DrugBank.d86.s0|399-401|and|O
DDI-DrugBank.d86.s0|403-410|humidity|O
DDI-DrugBank.d86.s0|411-411|,|O
DDI-DrugBank.d86.s0|413-424|hyperpyrexia|O
DDI-DrugBank.d86.s0|425-425|.|O
DDI-DrugBank.d86.s1|0-11|Interactions|O
DDI-DrugBank.d86.s1|13-15|may|O
DDI-DrugBank.d86.s1|17-20|also|O
DDI-DrugBank.d86.s1|22-26|occur|O
DDI-DrugBank.d86.s1|28-31|with|O
DDI-DrugBank.d86.s1|33-35|the|O
DDI-DrugBank.d86.s1|37-45|following|O
DDI-DrugBank.d86.s1|46-46|:|O
DDI-DrugBank.d86.s1|48-82|anti-depressants/anti-anxiety drugs|group
DDI-DrugBank.d86.s1|83-83|,|O
DDI-DrugBank.d86.s1|85-89|drugs|O
DDI-DrugBank.d86.s1|91-94|used|O
DDI-DrugBank.d86.s1|96-97|to|O
DDI-DrugBank.d86.s1|99-103|treat|O
DDI-DrugBank.d86.s1|105-106|an|O
DDI-DrugBank.d86.s1|108-117|overactive|O
DDI-DrugBank.d86.s1|119-125|thyroid|O
DDI-DrugBank.d86.s1|126-126|,|O
DDI-DrugBank.d86.s1|128-140|beta-blockers|group
DDI-DrugBank.d86.s1|142-142|(|O
DDI-DrugBank.d86.s1|143-146|e.g.|O
DDI-DrugBank.d86.s1|147-147|,|O
DDI-DrugBank.d86.s1|149-159|propranolol|drug
DDI-DrugBank.d86.s1|160-160|)|O
DDI-DrugBank.d86.s1|161-161|,|O
DDI-DrugBank.d86.s1|163-174|sparfloxacin|drug
DDI-DrugBank.d86.s1|175-175|,|O
DDI-DrugBank.d86.s1|177-189|grepafloxacin|drug
DDI-DrugBank.d86.s1|190-190|,|O
DDI-DrugBank.d86.s1|192-203|guanethidine|drug
DDI-DrugBank.d86.s1|204-204|,|O
DDI-DrugBank.d86.s1|206-214|guanadrel|drug
DDI-DrugBank.d86.s1|215-215|,|O
DDI-DrugBank.d86.s1|217-227|metrizamide|drug
DDI-DrugBank.d86.s1|228-228|,|O
DDI-DrugBank.d86.s1|230-240|cabergoline|drug
DDI-DrugBank.d86.s1|241-241|,|O
DDI-DrugBank.d86.s1|243-249|lithium|drug
DDI-DrugBank.d86.s1|250-250|,|O
DDI-DrugBank.d86.s1|252-259|narcotic|group
DDI-DrugBank.d86.s1|261-264|pain|O
DDI-DrugBank.d86.s1|266-275|medication|O
DDI-DrugBank.d86.s1|277-277|(|O
DDI-DrugBank.d86.s1|278-281|e.g.|O
DDI-DrugBank.d86.s1|282-282|,|O
DDI-DrugBank.d86.s1|284-290|codeine|drug
DDI-DrugBank.d86.s1|291-291|)|O
DDI-DrugBank.d86.s1|292-292|,|O
DDI-DrugBank.d86.s1|294-298|drugs|O
DDI-DrugBank.d86.s1|300-303|used|O
DDI-DrugBank.d86.s1|305-306|to|O
DDI-DrugBank.d86.s1|308-310|aid|O
DDI-DrugBank.d86.s1|312-316|sleep|O
DDI-DrugBank.d86.s1|317-317|,|O
DDI-DrugBank.d86.s1|319-336|drowsiness-causing|O
DDI-DrugBank.d86.s1|338-351|antihistamines|group
DDI-DrugBank.d86.s1|353-353|(|O
DDI-DrugBank.d86.s1|354-357|e.g.|O
DDI-DrugBank.d86.s1|358-358|,|O
DDI-DrugBank.d86.s1|360-374|diphenhydramine|drug
DDI-DrugBank.d86.s1|375-375|)|O
DDI-DrugBank.d86.s1|376-376|,|O
DDI-DrugBank.d86.s1|378-380|any|O
DDI-DrugBank.d86.s1|382-386|other|O
DDI-DrugBank.d86.s1|388-392|drugs|O
DDI-DrugBank.d86.s1|394-397|that|O
DDI-DrugBank.d86.s1|399-401|may|O
DDI-DrugBank.d86.s1|403-406|make|O
DDI-DrugBank.d86.s1|408-410|you|O
DDI-DrugBank.d86.s1|412-417|drowsy|O
DDI-DrugBank.d86.s1|418-418|.|O
DDI-DrugBank.d424.s0|0-9|Atovaquone|drug
DDI-DrugBank.d424.s0|11-12|is|O
DDI-DrugBank.d424.s0|14-19|highly|O
DDI-DrugBank.d424.s0|21-25|bound|O
DDI-DrugBank.d424.s0|27-28|to|O
DDI-DrugBank.d424.s0|30-35|plasma|O
DDI-DrugBank.d424.s0|37-43|protein|O
DDI-DrugBank.d424.s0|45-45|(|O
DDI-DrugBank.d424.s0|46-49|99.9|O
DDI-DrugBank.d424.s0|50-50|%|O
DDI-DrugBank.d424.s0|51-51|)|O
DDI-DrugBank.d424.s0|52-52|.|O
DDI-DrugBank.d424.s1|0-8|Therefore|O
DDI-DrugBank.d424.s1|9-9|,|O
DDI-DrugBank.d424.s1|11-17|caution|O
DDI-DrugBank.d424.s1|19-24|should|O
DDI-DrugBank.d424.s1|26-27|be|O
DDI-DrugBank.d424.s1|29-32|used|O
DDI-DrugBank.d424.s1|34-37|when|O
DDI-DrugBank.d424.s1|39-51|administering|O
DDI-DrugBank.d424.s1|53-58|MEPRON|brand
DDI-DrugBank.d424.s1|60-71|concurrently|O
DDI-DrugBank.d424.s1|73-76|with|O
DDI-DrugBank.d424.s1|78-82|other|O
DDI-DrugBank.d424.s1|84-89|highly|O
DDI-DrugBank.d424.s1|91-96|plasma|O
DDI-DrugBank.d424.s1|98-105|protein-|O
DDI-DrugBank.d424.s1|107-111|bound|O
DDI-DrugBank.d424.s1|113-117|drugs|O
DDI-DrugBank.d424.s1|119-122|with|O
DDI-DrugBank.d424.s1|124-129|narrow|O
DDI-DrugBank.d424.s1|131-141|therapeutic|O
DDI-DrugBank.d424.s1|143-149|indices|O
DDI-DrugBank.d424.s1|150-150|,|O
DDI-DrugBank.d424.s1|152-153|as|O
DDI-DrugBank.d424.s1|155-165|competition|O
DDI-DrugBank.d424.s1|167-169|for|O
DDI-DrugBank.d424.s1|171-177|binding|O
DDI-DrugBank.d424.s1|179-183|sites|O
DDI-DrugBank.d424.s1|185-187|may|O
DDI-DrugBank.d424.s1|189-193|occur|O
DDI-DrugBank.d424.s1|194-194|.|O
DDI-DrugBank.d424.s2|0-2|The|O
DDI-DrugBank.d424.s2|4-9|extent|O
DDI-DrugBank.d424.s2|11-12|of|O
DDI-DrugBank.d424.s2|14-19|plasma|O
DDI-DrugBank.d424.s2|21-27|protein|O
DDI-DrugBank.d424.s2|29-35|binding|O
DDI-DrugBank.d424.s2|37-38|of|O
DDI-DrugBank.d424.s2|40-49|atovaquone|drug
DDI-DrugBank.d424.s2|51-52|in|O
DDI-DrugBank.d424.s2|54-58|human|O
DDI-DrugBank.d424.s2|60-65|plasma|O
DDI-DrugBank.d424.s2|67-68|is|O
DDI-DrugBank.d424.s2|70-72|not|O
DDI-DrugBank.d424.s2|74-81|affected|O
DDI-DrugBank.d424.s2|83-84|by|O
DDI-DrugBank.d424.s2|86-88|the|O
DDI-DrugBank.d424.s2|90-97|presence|O
DDI-DrugBank.d424.s2|99-100|of|O
DDI-DrugBank.d424.s2|102-112|therapeutic|O
DDI-DrugBank.d424.s2|114-127|concentrations|O
DDI-DrugBank.d424.s2|129-130|of|O
DDI-DrugBank.d424.s2|132-140|phenytoin|drug
DDI-DrugBank.d424.s2|142-142|(|O
DDI-DrugBank.d424.s2|143-144|15|O
DDI-DrugBank.d424.s2|146-149|mcg/|O
DDI-DrugBank.d424.s2|151-152|mL|O
DDI-DrugBank.d424.s2|153-153|)|O
DDI-DrugBank.d424.s2|154-154|,|O
DDI-DrugBank.d424.s2|156-158|nor|O
DDI-DrugBank.d424.s2|160-161|is|O
DDI-DrugBank.d424.s2|163-165|the|O
DDI-DrugBank.d424.s2|167-173|binding|O
DDI-DrugBank.d424.s2|175-176|of|O
DDI-DrugBank.d424.s2|178-186|phenytoin|drug
DDI-DrugBank.d424.s2|188-195|affected|O
DDI-DrugBank.d424.s2|197-198|by|O
DDI-DrugBank.d424.s2|200-202|the|O
DDI-DrugBank.d424.s2|204-211|presence|O
DDI-DrugBank.d424.s2|213-214|of|O
DDI-DrugBank.d424.s2|216-225|atovaquone|drug
DDI-DrugBank.d424.s2|226-226|.|O
DDI-DrugBank.d424.s3|0-7|Rifampin|drug
DDI-DrugBank.d424.s3|8-8|:|O
DDI-DrugBank.d424.s3|10-25|Coadministration|O
DDI-DrugBank.d424.s3|27-28|of|O
DDI-DrugBank.d424.s3|30-37|rifampin|drug
DDI-DrugBank.d424.s3|39-41|and|O
DDI-DrugBank.d424.s3|43-48|MEPRON|brand
DDI-DrugBank.d424.s3|50-59|Suspension|O
DDI-DrugBank.d424.s3|61-67|results|O
DDI-DrugBank.d424.s3|69-70|in|O
DDI-DrugBank.d424.s3|72-72|a|O
DDI-DrugBank.d424.s3|74-84|significant|O
DDI-DrugBank.d424.s3|86-93|decrease|O
DDI-DrugBank.d424.s3|95-96|in|O
DDI-DrugBank.d424.s3|98-104|average|O
DDI-DrugBank.d424.s3|106-112|steady-|O
DDI-DrugBank.d424.s3|114-118|state|O
DDI-DrugBank.d424.s3|120-125|plasma|O
DDI-DrugBank.d424.s3|127-136|atovaquone|drug
DDI-DrugBank.d424.s3|138-151|concentrations|O
DDI-DrugBank.d424.s3|152-152|.|O
DDI-DrugBank.d424.s4|0-11|Alternatives|O
DDI-DrugBank.d424.s4|13-14|to|O
DDI-DrugBank.d424.s4|16-23|rifampin|drug
DDI-DrugBank.d424.s4|25-30|should|O
DDI-DrugBank.d424.s4|32-33|be|O
DDI-DrugBank.d424.s4|35-44|considered|O
DDI-DrugBank.d424.s4|46-51|during|O
DDI-DrugBank.d424.s4|53-55|the|O
DDI-DrugBank.d424.s4|57-62|course|O
DDI-DrugBank.d424.s4|64-65|of|O
DDI-DrugBank.d424.s4|67-69|PCP|O
DDI-DrugBank.d424.s4|71-79|treatment|O
DDI-DrugBank.d424.s4|81-84|with|O
DDI-DrugBank.d424.s4|86-91|MEPRON|brand
DDI-DrugBank.d424.s4|92-92|.|O
DDI-DrugBank.d424.s5|0-8|Rifabutin|drug
DDI-DrugBank.d424.s5|9-9|,|O
DDI-DrugBank.d424.s5|11-17|another|O
DDI-DrugBank.d424.s5|19-27|rifamycin|drug
DDI-DrugBank.d424.s5|28-28|,|O
DDI-DrugBank.d424.s5|30-31|is|O
DDI-DrugBank.d424.s5|33-44|structurally|O
DDI-DrugBank.d424.s5|46-52|similar|O
DDI-DrugBank.d424.s5|54-55|to|O
DDI-DrugBank.d424.s5|57-64|rifampin|drug
DDI-DrugBank.d424.s5|66-68|and|O
DDI-DrugBank.d424.s5|70-72|may|O
DDI-DrugBank.d424.s5|74-81|possibly|O
DDI-DrugBank.d424.s5|83-86|have|O
DDI-DrugBank.d424.s5|88-91|some|O
DDI-DrugBank.d424.s5|93-94|of|O
DDI-DrugBank.d424.s5|96-98|the|O
DDI-DrugBank.d424.s5|100-103|same|O
DDI-DrugBank.d424.s5|105-108|drug|O
DDI-DrugBank.d424.s5|110-121|interactions|O
DDI-DrugBank.d424.s5|123-124|as|O
DDI-DrugBank.d424.s5|126-133|rifampin|drug
DDI-DrugBank.d424.s5|134-134|.|O
DDI-DrugBank.d424.s6|0-1|No|O
DDI-DrugBank.d424.s6|3-13|interaction|O
DDI-DrugBank.d424.s6|15-20|trials|O
DDI-DrugBank.d424.s6|22-25|have|O
DDI-DrugBank.d424.s6|27-30|been|O
DDI-DrugBank.d424.s6|32-40|conducted|O
DDI-DrugBank.d424.s6|42-45|with|O
DDI-DrugBank.d424.s6|47-52|MEPRON|brand
DDI-DrugBank.d424.s6|54-56|and|O
DDI-DrugBank.d424.s6|58-66|rifabutin|drug
DDI-DrugBank.d424.s6|67-67|.|O
DDI-DrugBank.d424.s7|0-4|Drug/|O
DDI-DrugBank.d424.s7|6-15|Laboratory|O
DDI-DrugBank.d424.s7|17-20|Test|O
DDI-DrugBank.d424.s7|22-33|Interactions|O
DDI-DrugBank.d424.s7|34-34|:|O
DDI-DrugBank.d424.s7|36-37|It|O
DDI-DrugBank.d424.s7|39-40|is|O
DDI-DrugBank.d424.s7|42-44|not|O
DDI-DrugBank.d424.s7|46-50|known|O
DDI-DrugBank.d424.s7|52-53|if|O
DDI-DrugBank.d424.s7|55-60|MEPRON|brand
DDI-DrugBank.d424.s7|62-71|interferes|O
DDI-DrugBank.d424.s7|73-76|with|O
DDI-DrugBank.d424.s7|78-85|clinical|O
DDI-DrugBank.d424.s7|87-96|laboratory|O
DDI-DrugBank.d424.s7|98-101|test|O
DDI-DrugBank.d424.s7|103-104|or|O
DDI-DrugBank.d424.s7|106-110|assay|O
DDI-DrugBank.d424.s7|112-118|results|O
DDI-DrugBank.d424.s7|119-119|.|O
DDI-DrugBank.d303.s0|0-8|Metformin|drug
DDI-DrugBank.d303.s0|9-9|:|O
DDI-DrugBank.d303.s0|11-12|In|O
DDI-DrugBank.d303.s0|14-20|healthy|O
DDI-DrugBank.d303.s0|22-29|subjects|O
DDI-DrugBank.d303.s0|31-35|given|O
DDI-DrugBank.d303.s0|37-42|single|O
DDI-DrugBank.d303.s0|44-46|500|O
DDI-DrugBank.d303.s0|48-49|mg|O
DDI-DrugBank.d303.s0|51-55|doses|O
DDI-DrugBank.d303.s0|57-58|of|O
DDI-DrugBank.d303.s0|60-69|cephalexin|drug
DDI-DrugBank.d303.s0|71-73|and|O
DDI-DrugBank.d303.s0|75-83|metformin|drug
DDI-DrugBank.d303.s0|84-84|,|O
DDI-DrugBank.d303.s0|86-91|plasma|O
DDI-DrugBank.d303.s0|93-101|metformin|drug
DDI-DrugBank.d303.s0|103-106|mean|O
DDI-DrugBank.d303.s0|108-111|cmax|O
DDI-DrugBank.d303.s0|113-115|and|O
DDI-DrugBank.d303.s0|117-119|AUC|O
DDI-DrugBank.d303.s0|121-129|increased|O
DDI-DrugBank.d303.s0|131-132|by|O
DDI-DrugBank.d303.s0|134-135|an|O
DDI-DrugBank.d303.s0|137-143|average|O
DDI-DrugBank.d303.s0|145-146|of|O
DDI-DrugBank.d303.s0|148-149|34|O
DDI-DrugBank.d303.s0|150-150|%|O
DDI-DrugBank.d303.s0|152-154|and|O
DDI-DrugBank.d303.s0|156-157|24|O
DDI-DrugBank.d303.s0|158-158|%|O
DDI-DrugBank.d303.s0|159-159|,|O
DDI-DrugBank.d303.s0|161-172|respectively|O
DDI-DrugBank.d303.s0|173-173|,|O
DDI-DrugBank.d303.s0|175-177|and|O
DDI-DrugBank.d303.s0|179-187|metformin|drug
DDI-DrugBank.d303.s0|189-192|mean|O
DDI-DrugBank.d303.s0|194-198|renal|O
DDI-DrugBank.d303.s0|200-208|clearance|O
DDI-DrugBank.d303.s0|210-218|decreased|O
DDI-DrugBank.d303.s0|220-221|by|O
DDI-DrugBank.d303.s0|223-224|14|O
DDI-DrugBank.d303.s0|225-225|%|O
DDI-DrugBank.d303.s0|226-226|.|O
DDI-DrugBank.d303.s1|0-1|No|O
DDI-DrugBank.d303.s1|3-13|information|O
DDI-DrugBank.d303.s1|15-16|is|O
DDI-DrugBank.d303.s1|18-26|available|O
DDI-DrugBank.d303.s1|28-32|about|O
DDI-DrugBank.d303.s1|34-36|the|O
DDI-DrugBank.d303.s1|38-48|interaction|O
DDI-DrugBank.d303.s1|50-51|of|O
DDI-DrugBank.d303.s1|53-62|cephalexin|drug
DDI-DrugBank.d303.s1|64-66|and|O
DDI-DrugBank.d303.s1|68-76|metformin|drug
DDI-DrugBank.d303.s1|78-86|following|O
DDI-DrugBank.d303.s1|88-95|multiple|O
DDI-DrugBank.d303.s1|97-101|doses|O
DDI-DrugBank.d303.s1|103-104|of|O
DDI-DrugBank.d303.s1|106-111|either|O
DDI-DrugBank.d303.s1|113-116|drug|O
DDI-DrugBank.d303.s1|117-117|.|O
DDI-DrugBank.d303.s2|0-7|Although|O
DDI-DrugBank.d303.s2|9-11|not|O
DDI-DrugBank.d303.s2|13-20|observed|O
DDI-DrugBank.d303.s2|22-23|in|O
DDI-DrugBank.d303.s2|25-28|this|O
DDI-DrugBank.d303.s2|30-34|study|O
DDI-DrugBank.d303.s2|35-35|,|O
DDI-DrugBank.d303.s2|37-43|adverse|O
DDI-DrugBank.d303.s2|45-51|effects|O
DDI-DrugBank.d303.s2|53-57|could|O
DDI-DrugBank.d303.s2|59-69|potentially|O
DDI-DrugBank.d303.s2|71-75|arise|O
DDI-DrugBank.d303.s2|77-80|from|O
DDI-DrugBank.d303.s2|82-98|co-administration|O
DDI-DrugBank.d303.s2|100-101|of|O
DDI-DrugBank.d303.s2|103-112|cephalexin|drug
DDI-DrugBank.d303.s2|114-116|and|O
DDI-DrugBank.d303.s2|118-126|metformin|drug
DDI-DrugBank.d303.s2|128-129|by|O
DDI-DrugBank.d303.s2|131-140|inhibition|O
DDI-DrugBank.d303.s2|142-143|of|O
DDI-DrugBank.d303.s2|145-151|tubular|O
DDI-DrugBank.d303.s2|153-161|secretion|O
DDI-DrugBank.d303.s2|163-165|via|O
DDI-DrugBank.d303.s2|167-173|organic|O
DDI-DrugBank.d303.s2|175-182|cationic|O
DDI-DrugBank.d303.s2|184-194|transporter|O
DDI-DrugBank.d303.s2|196-202|systems|O
DDI-DrugBank.d303.s2|203-203|.|O
DDI-DrugBank.d303.s3|0-10|Accordingly|O
DDI-DrugBank.d303.s3|11-11|,|O
DDI-DrugBank.d303.s3|13-19|careful|O
DDI-DrugBank.d303.s3|21-27|patient|O
DDI-DrugBank.d303.s3|29-38|monitoring|O
DDI-DrugBank.d303.s3|40-42|and|O
DDI-DrugBank.d303.s3|44-47|dose|O
DDI-DrugBank.d303.s3|49-58|adjustment|O
DDI-DrugBank.d303.s3|60-61|of|O
DDI-DrugBank.d303.s3|63-71|metformin|drug
DDI-DrugBank.d303.s3|73-74|is|O
DDI-DrugBank.d303.s3|76-86|recommended|O
DDI-DrugBank.d303.s3|88-89|in|O
DDI-DrugBank.d303.s3|91-98|patients|O
DDI-DrugBank.d303.s3|100-112|concomitantly|O
DDI-DrugBank.d303.s3|114-119|taking|O
DDI-DrugBank.d303.s3|121-130|cephalexin|drug
DDI-DrugBank.d303.s3|132-134|and|O
DDI-DrugBank.d303.s3|136-144|metformin|drug
DDI-DrugBank.d303.s3|145-145|.|O
DDI-DrugBank.d303.s4|0-9|Probenecid|drug
DDI-DrugBank.d303.s4|10-10|:|O
DDI-DrugBank.d303.s4|12-13|As|O
DDI-DrugBank.d303.s4|15-18|with|O
DDI-DrugBank.d303.s4|20-24|other|O
DDI-DrugBank.d303.s4|26-34|b-lactams|group
DDI-DrugBank.d303.s4|35-35|,|O
DDI-DrugBank.d303.s4|37-39|the|O
DDI-DrugBank.d303.s4|41-45|renal|O
DDI-DrugBank.d303.s4|47-55|excretion|O
DDI-DrugBank.d303.s4|57-58|of|O
DDI-DrugBank.d303.s4|60-69|cephalexin|drug
DDI-DrugBank.d303.s4|71-72|is|O
DDI-DrugBank.d303.s4|74-82|inhibited|O
DDI-DrugBank.d303.s4|84-85|by|O
DDI-DrugBank.d303.s4|87-96|probenecid|drug
DDI-DrugBank.d303.s4|97-97|.|O
DDI-DrugBank.d303.s5|0-3|Drug|O
DDI-DrugBank.d303.s5|5-5|/|O
DDI-DrugBank.d303.s5|7-16|Laboratory|O
DDI-DrugBank.d303.s5|18-21|Test|O
DDI-DrugBank.d303.s5|23-34|Interactions|O
DDI-DrugBank.d303.s5|36-37|As|O
DDI-DrugBank.d303.s5|39-39|a|O
DDI-DrugBank.d303.s5|41-46|result|O
DDI-DrugBank.d303.s5|48-49|of|O
DDI-DrugBank.d303.s5|51-64|administration|O
DDI-DrugBank.d303.s5|66-67|of|O
DDI-DrugBank.d303.s5|69-74|Keflex|brand
DDI-DrugBank.d303.s5|75-75|,|O
DDI-DrugBank.d303.s5|77-77|a|O
DDI-DrugBank.d303.s5|79-92|false-positive|O
DDI-DrugBank.d303.s5|94-101|reaction|O
DDI-DrugBank.d303.s5|103-105|for|O
DDI-DrugBank.d303.s5|107-113|glucose|O
DDI-DrugBank.d303.s5|115-116|in|O
DDI-DrugBank.d303.s5|118-120|the|O
DDI-DrugBank.d303.s5|122-126|urine|O
DDI-DrugBank.d303.s5|128-130|may|O
DDI-DrugBank.d303.s5|132-136|occur|O
DDI-DrugBank.d303.s5|137-137|.|O
DDI-DrugBank.d303.s6|0-3|This|O
DDI-DrugBank.d303.s6|5-7|has|O
DDI-DrugBank.d303.s6|9-12|been|O
DDI-DrugBank.d303.s6|14-21|observed|O
DDI-DrugBank.d303.s6|23-26|with|O
DDI-DrugBank.d303.s6|28-35|Benedict|O
DDI-DrugBank.d303.s6|37-37|s|O
DDI-DrugBank.d303.s6|39-41|and|O
DDI-DrugBank.d303.s6|43-49|Fehling|O
DDI-DrugBank.d303.s6|51-51|s|O
DDI-DrugBank.d303.s6|53-61|solutions|O
DDI-DrugBank.d303.s6|63-65|and|O
DDI-DrugBank.d303.s6|67-70|also|O
DDI-DrugBank.d303.s6|72-75|with|O
DDI-DrugBank.d303.s6|77-85|Clinitest|O
DDI-DrugBank.d303.s6|88-94|tablets|O
DDI-DrugBank.d303.s6|95-95|.|O
DDI-DrugBank.d205.s0|0-4|Since|O
DDI-DrugBank.d205.s0|6-13|Zarontin|brand
DDI-DrugBank.d205.s0|15-15|(|O
DDI-DrugBank.d205.s0|16-27|ethosuximide|drug
DDI-DrugBank.d205.s0|28-28|)|O
DDI-DrugBank.d205.s0|30-32|may|O
DDI-DrugBank.d205.s0|34-41|interact|O
DDI-DrugBank.d205.s0|43-46|with|O
DDI-DrugBank.d205.s0|48-59|concurrently|O
DDI-DrugBank.d205.s0|61-72|administered|O
DDI-DrugBank.d205.s0|74-92|antiepileptic drugs|group
DDI-DrugBank.d205.s0|93-93|,|O
DDI-DrugBank.d205.s0|95-102|periodic|O
DDI-DrugBank.d205.s0|104-108|serum|O
DDI-DrugBank.d205.s0|110-114|level|O
DDI-DrugBank.d205.s0|116-129|determinations|O
DDI-DrugBank.d205.s0|131-132|of|O
DDI-DrugBank.d205.s0|134-138|these|O
DDI-DrugBank.d205.s0|140-144|drugs|O
DDI-DrugBank.d205.s0|146-148|may|O
DDI-DrugBank.d205.s0|150-151|be|O
DDI-DrugBank.d205.s0|153-161|necessary|O
DDI-DrugBank.d205.s0|163-163|(|O
DDI-DrugBank.d205.s0|164-165|eg|O
DDI-DrugBank.d205.s0|166-166|,|O
DDI-DrugBank.d205.s0|168-179|ethosuximide|drug
DDI-DrugBank.d205.s0|181-183|may|O
DDI-DrugBank.d205.s0|185-191|elevate|O
DDI-DrugBank.d205.s0|193-201|phenytoin|drug
DDI-DrugBank.d205.s0|203-207|serum|O
DDI-DrugBank.d205.s0|209-214|levels|O
DDI-DrugBank.d205.s0|216-218|and|O
DDI-DrugBank.d205.s0|220-232|valproic acid|drug
DDI-DrugBank.d205.s0|234-236|has|O
DDI-DrugBank.d205.s0|238-241|been|O
DDI-DrugBank.d205.s0|243-250|reported|O
DDI-DrugBank.d205.s0|252-253|to|O
DDI-DrugBank.d205.s0|255-258|both|O
DDI-DrugBank.d205.s0|260-267|increase|O
DDI-DrugBank.d205.s0|269-271|and|O
DDI-DrugBank.d205.s0|273-280|decrease|O
DDI-DrugBank.d205.s0|282-293|ethosuximide|drug
DDI-DrugBank.d205.s0|295-300|levels|O
DDI-DrugBank.d205.s0|301-301|)|O
DDI-DrugBank.d205.s0|302-302|.|O
DDI-DrugBank.d742.s0|0-1|As|O
DDI-DrugBank.d742.s0|3-6|with|O
DDI-DrugBank.d742.s0|8-12|other|O
DDI-DrugBank.d742.s0|14-18|drugs|O
DDI-DrugBank.d742.s0|19-19|,|O
DDI-DrugBank.d742.s0|21-23|the|O
DDI-DrugBank.d742.s0|25-33|potential|O
DDI-DrugBank.d742.s0|35-37|for|O
DDI-DrugBank.d742.s0|39-49|interaction|O
DDI-DrugBank.d742.s0|51-52|by|O
DDI-DrugBank.d742.s0|54-54|a|O
DDI-DrugBank.d742.s0|56-62|variety|O
DDI-DrugBank.d742.s0|64-65|of|O
DDI-DrugBank.d742.s0|67-76|mechanisms|O
DDI-DrugBank.d742.s0|78-78|(|O
DDI-DrugBank.d742.s0|79-82|e.g.|O
DDI-DrugBank.d742.s0|83-83|,|O
DDI-DrugBank.d742.s0|85-99|pharmacodynamic|O
DDI-DrugBank.d742.s0|100-100|,|O
DDI-DrugBank.d742.s0|102-116|pharmacokinetic|O
DDI-DrugBank.d742.s0|118-127|inhibition|O
DDI-DrugBank.d742.s0|129-130|or|O
DDI-DrugBank.d742.s0|132-142|enhancement|O
DDI-DrugBank.d742.s0|143-143|,|O
DDI-DrugBank.d742.s0|145-147|etc|O
DDI-DrugBank.d742.s0|148-148|.|O
DDI-DrugBank.d742.s0|149-149|)|O
DDI-DrugBank.d742.s1|0-1|is|O
DDI-DrugBank.d742.s1|3-3|a|O
DDI-DrugBank.d742.s1|5-15|possibility|O
DDI-DrugBank.d742.s1|16-16|.|O
DDI-DrugBank.d742.s2|0-4|Drugs|O
DDI-DrugBank.d742.s2|6-14|Affecting|O
DDI-DrugBank.d742.s2|16-22|Hepatic|O
DDI-DrugBank.d742.s2|24-33|Metabolism|O
DDI-DrugBank.d742.s2|35-37|The|O
DDI-DrugBank.d742.s2|39-48|metabolism|O
DDI-DrugBank.d742.s2|50-52|and|O
DDI-DrugBank.d742.s2|54-69|pharmacokinetics|O
DDI-DrugBank.d742.s2|71-72|of|O
DDI-DrugBank.d742.s2|74-87|REMERON SolTab|brand
DDI-DrugBank.d742.s2|92-92|(|O
DDI-DrugBank.d742.s2|93-103|mirtazapine|drug
DDI-DrugBank.d742.s2|104-104|)|O
DDI-DrugBank.d742.s2|106-111|Orally|O
DDI-DrugBank.d742.s2|113-126|Disintegrating|O
DDI-DrugBank.d742.s2|128-134|Tablets|O
DDI-DrugBank.d742.s2|136-138|may|O
DDI-DrugBank.d742.s2|140-141|be|O
DDI-DrugBank.d742.s2|143-150|affected|O
DDI-DrugBank.d742.s2|152-153|by|O
DDI-DrugBank.d742.s2|155-157|the|O
DDI-DrugBank.d742.s2|159-167|induction|O
DDI-DrugBank.d742.s2|169-170|or|O
DDI-DrugBank.d742.s2|172-181|inhibition|O
DDI-DrugBank.d742.s2|183-184|of|O
DDI-DrugBank.d742.s2|186-203|drug-metab-olizing|O
DDI-DrugBank.d742.s2|205-211|enzymes|O
DDI-DrugBank.d742.s2|212-212|.|O
DDI-DrugBank.d742.s3|0-4|Drugs|O
DDI-DrugBank.d742.s3|6-9|that|O
DDI-DrugBank.d742.s3|11-13|are|O
DDI-DrugBank.d742.s3|15-25|Metabolized|O
DDI-DrugBank.d742.s3|27-28|by|O
DDI-DrugBank.d742.s3|30-35|and/or|O
DDI-DrugBank.d742.s3|37-43|Inhibit|O
DDI-DrugBank.d742.s3|45-54|Cytochrome|O
DDI-DrugBank.d742.s3|56-59|P450|O
DDI-DrugBank.d742.s3|61-67|Enzymes|O
DDI-DrugBank.d742.s3|69-72|Many|O
DDI-DrugBank.d742.s3|74-78|drugs|O
DDI-DrugBank.d742.s3|80-82|are|O
DDI-DrugBank.d742.s3|84-94|metabolized|O
DDI-DrugBank.d742.s3|96-97|by|O
DDI-DrugBank.d742.s3|99-104|and/or|O
DDI-DrugBank.d742.s3|106-112|inhibit|O
DDI-DrugBank.d742.s3|114-120|various|O
DDI-DrugBank.d742.s3|122-131|cytochrome|O
DDI-DrugBank.d742.s3|133-136|P450|O
DDI-DrugBank.d742.s3|138-144|enzymes|O
DDI-DrugBank.d742.s3|145-145|,|O
DDI-DrugBank.d742.s3|147-150|e.g.|O
DDI-DrugBank.d742.s3|151-151|,|O
DDI-DrugBank.d742.s3|153-155|2D6|O
DDI-DrugBank.d742.s3|156-156|,|O
DDI-DrugBank.d742.s3|158-160|1A2|O
DDI-DrugBank.d742.s3|161-161|,|O
DDI-DrugBank.d742.s3|163-165|3A4|O
DDI-DrugBank.d742.s3|166-166|,|O
DDI-DrugBank.d742.s3|168-170|etc|O
DDI-DrugBank.d742.s3|171-171|.|O
DDI-DrugBank.d742.s4|0-1|In|O
DDI-DrugBank.d742.s4|3-7|vitro|O
DDI-DrugBank.d742.s4|9-15|studies|O
DDI-DrugBank.d742.s4|17-20|have|O
DDI-DrugBank.d742.s4|22-26|shown|O
DDI-DrugBank.d742.s4|28-31|that|O
DDI-DrugBank.d742.s4|33-43|mirtazapine|drug
DDI-DrugBank.d742.s4|45-46|is|O
DDI-DrugBank.d742.s4|48-48|a|O
DDI-DrugBank.d742.s4|50-58|substrate|O
DDI-DrugBank.d742.s4|60-62|for|O
DDI-DrugBank.d742.s4|64-70|several|O
DDI-DrugBank.d742.s4|72-73|of|O
DDI-DrugBank.d742.s4|75-79|these|O
DDI-DrugBank.d742.s4|81-87|enzymes|O
DDI-DrugBank.d742.s4|88-88|,|O
DDI-DrugBank.d742.s4|90-98|including|O
DDI-DrugBank.d742.s4|100-102|2D6|O
DDI-DrugBank.d742.s4|103-103|,|O
DDI-DrugBank.d742.s4|105-107|1A2|O
DDI-DrugBank.d742.s4|108-108|,|O
DDI-DrugBank.d742.s4|110-112|and|O
DDI-DrugBank.d742.s4|114-116|3A4|O
DDI-DrugBank.d742.s4|117-117|.|O
DDI-DrugBank.d742.s5|0-4|While|O
DDI-DrugBank.d742.s5|6-7|in|O
DDI-DrugBank.d742.s5|9-13|vitro|O
DDI-DrugBank.d742.s5|15-21|studies|O
DDI-DrugBank.d742.s5|23-26|have|O
DDI-DrugBank.d742.s5|28-32|shown|O
DDI-DrugBank.d742.s5|34-37|that|O
DDI-DrugBank.d742.s5|39-49|mirtazapine|drug
DDI-DrugBank.d742.s5|51-52|is|O
DDI-DrugBank.d742.s5|54-56|not|O
DDI-DrugBank.d742.s5|58-58|a|O
DDI-DrugBank.d742.s5|60-65|potent|O
DDI-DrugBank.d742.s5|67-75|inhibitor|O
DDI-DrugBank.d742.s5|77-78|of|O
DDI-DrugBank.d742.s5|80-82|any|O
DDI-DrugBank.d742.s5|84-85|of|O
DDI-DrugBank.d742.s5|87-91|these|O
DDI-DrugBank.d742.s5|93-99|enzymes|O
DDI-DrugBank.d742.s5|100-100|,|O
DDI-DrugBank.d742.s5|102-103|an|O
DDI-DrugBank.d742.s5|105-114|indication|O
DDI-DrugBank.d742.s5|116-119|that|O
DDI-DrugBank.d742.s5|121-131|mirtazapine|drug
DDI-DrugBank.d742.s5|133-134|is|O
DDI-DrugBank.d742.s5|136-138|not|O
DDI-DrugBank.d742.s5|140-145|likely|O
DDI-DrugBank.d742.s5|147-148|to|O
DDI-DrugBank.d742.s5|150-153|have|O
DDI-DrugBank.d742.s5|155-155|a|O
DDI-DrugBank.d742.s5|157-166|clinically|O
DDI-DrugBank.d742.s5|168-178|significant|O
DDI-DrugBank.d742.s5|180-189|inhibitory|O
DDI-DrugBank.d742.s5|191-196|effect|O
DDI-DrugBank.d742.s5|198-199|on|O
DDI-DrugBank.d742.s5|201-203|the|O
DDI-DrugBank.d742.s5|205-214|metabolism|O
DDI-DrugBank.d742.s5|216-217|of|O
DDI-DrugBank.d742.s5|219-223|other|O
DDI-DrugBank.d742.s5|225-229|drugs|O
DDI-DrugBank.d742.s5|231-234|that|O
DDI-DrugBank.d742.s5|236-238|are|O
DDI-DrugBank.d742.s5|240-249|substrates|O
DDI-DrugBank.d742.s5|251-253|for|O
DDI-DrugBank.d742.s5|255-259|these|O
DDI-DrugBank.d742.s5|261-270|cytochrome|O
DDI-DrugBank.d742.s5|272-275|P450|O
DDI-DrugBank.d742.s5|277-283|enzymes|O
DDI-DrugBank.d742.s5|284-284|,|O
DDI-DrugBank.d742.s5|286-288|the|O
DDI-DrugBank.d742.s5|290-300|concomitant|O
DDI-DrugBank.d742.s5|302-304|use|O
DDI-DrugBank.d742.s5|306-307|of|O
DDI-DrugBank.d742.s5|309-322|REMERON SolTab|brand
DDI-DrugBank.d742.s5|324-327|with|O
DDI-DrugBank.d742.s5|329-332|most|O
DDI-DrugBank.d742.s5|334-338|other|O
DDI-DrugBank.d742.s5|340-344|drugs|O
DDI-DrugBank.d742.s5|346-356|metabolized|O
DDI-DrugBank.d742.s5|358-359|by|O
DDI-DrugBank.d742.s5|361-365|these|O
DDI-DrugBank.d742.s5|367-373|enzymes|O
DDI-DrugBank.d742.s5|375-377|has|O
DDI-DrugBank.d742.s5|379-381|not|O
DDI-DrugBank.d742.s5|383-386|been|O
DDI-DrugBank.d742.s5|388-395|formally|O
DDI-DrugBank.d742.s5|397-403|studied|O
DDI-DrugBank.d742.s5|404-404|.|O
DDI-DrugBank.d742.s6|0-11|Consequently|O
DDI-DrugBank.d742.s6|12-12|,|O
DDI-DrugBank.d742.s6|14-15|it|O
DDI-DrugBank.d742.s6|17-18|is|O
DDI-DrugBank.d742.s6|20-22|not|O
DDI-DrugBank.d742.s6|24-31|possible|O
DDI-DrugBank.d742.s6|33-34|to|O
DDI-DrugBank.d742.s6|36-39|make|O
DDI-DrugBank.d742.s6|41-43|any|O
DDI-DrugBank.d742.s6|45-54|definitive|O
DDI-DrugBank.d742.s6|56-65|statements|O
DDI-DrugBank.d742.s6|67-71|about|O
DDI-DrugBank.d742.s6|73-75|the|O
DDI-DrugBank.d742.s6|77-81|risks|O
DDI-DrugBank.d742.s6|83-84|of|O
DDI-DrugBank.d742.s6|86-101|coadministration|O
DDI-DrugBank.d742.s6|103-104|of|O
DDI-DrugBank.d742.s6|106-119|REMERON SolTab|brand
DDI-DrugBank.d742.s6|124-127|with|O
DDI-DrugBank.d742.s6|129-132|such|O
DDI-DrugBank.d742.s6|134-138|drugs|O
DDI-DrugBank.d742.s6|139-139|.|O
DDI-DrugBank.d742.s7|0-6|Alcohol|drug
DDI-DrugBank.d742.s7|7-7|:|O
DDI-DrugBank.d742.s7|9-19|Concomitant|O
DDI-DrugBank.d742.s7|21-34|administration|O
DDI-DrugBank.d742.s7|36-37|of|O
DDI-DrugBank.d742.s7|39-45|alcohol|drug
DDI-DrugBank.d742.s7|47-47|(|O
DDI-DrugBank.d742.s7|48-57|equivalent|O
DDI-DrugBank.d742.s7|59-60|to|O
DDI-DrugBank.d742.s7|62-63|60|O
DDI-DrugBank.d742.s7|65-65|g|O
DDI-DrugBank.d742.s7|66-66|)|O
DDI-DrugBank.d742.s7|68-70|had|O
DDI-DrugBank.d742.s7|72-72|a|O
DDI-DrugBank.d742.s7|74-80|minimal|O
DDI-DrugBank.d742.s7|82-87|effect|O
DDI-DrugBank.d742.s7|89-90|on|O
DDI-DrugBank.d742.s7|92-97|plasma|O
DDI-DrugBank.d742.s7|99-104|levels|O
DDI-DrugBank.d742.s7|106-107|of|O
DDI-DrugBank.d742.s7|109-119|mirtazapine|drug
DDI-DrugBank.d742.s7|121-121|(|O
DDI-DrugBank.d742.s7|122-123|15|O
DDI-DrugBank.d742.s7|125-126|mg|O
DDI-DrugBank.d742.s7|127-127|)|O
DDI-DrugBank.d742.s7|129-130|in|O
DDI-DrugBank.d742.s7|132-132|6|O
DDI-DrugBank.d742.s7|134-140|healthy|O
DDI-DrugBank.d742.s7|142-145|male|O
DDI-DrugBank.d742.s7|147-154|subjects|O
DDI-DrugBank.d742.s7|155-155|.|O
DDI-DrugBank.d742.s8|0-6|However|O
DDI-DrugBank.d742.s8|7-7|,|O
DDI-DrugBank.d742.s8|9-11|the|O
DDI-DrugBank.d742.s8|13-22|impairment|O
DDI-DrugBank.d742.s8|24-25|of|O
DDI-DrugBank.d742.s8|27-35|cognitive|O
DDI-DrugBank.d742.s8|37-39|and|O
DDI-DrugBank.d742.s8|41-45|motor|O
DDI-DrugBank.d742.s8|47-52|skills|O
DDI-DrugBank.d742.s8|54-61|produced|O
DDI-DrugBank.d742.s8|63-64|by|O
DDI-DrugBank.d742.s8|66-72|REMERON|brand
DDI-DrugBank.d742.s8|77-80|were|O
DDI-DrugBank.d742.s8|82-86|shown|O
DDI-DrugBank.d742.s8|88-89|to|O
DDI-DrugBank.d742.s8|91-92|be|O
DDI-DrugBank.d742.s8|94-101|additive|O
DDI-DrugBank.d742.s8|103-106|with|O
DDI-DrugBank.d742.s8|108-112|those|O
DDI-DrugBank.d742.s8|114-121|produced|O
DDI-DrugBank.d742.s8|123-124|by|O
DDI-DrugBank.d742.s8|126-132|alcohol|drug
DDI-DrugBank.d742.s8|133-133|.|O
DDI-DrugBank.d742.s9|0-10|Accordingly|O
DDI-DrugBank.d742.s9|11-11|,|O
DDI-DrugBank.d742.s9|13-20|patients|O
DDI-DrugBank.d742.s9|22-27|should|O
DDI-DrugBank.d742.s9|29-30|be|O
DDI-DrugBank.d742.s9|32-38|advised|O
DDI-DrugBank.d742.s9|40-41|to|O
DDI-DrugBank.d742.s9|43-47|avoid|O
DDI-DrugBank.d742.s9|49-55|alcohol|drug
DDI-DrugBank.d742.s9|57-61|while|O
DDI-DrugBank.d742.s9|63-68|taking|O
DDI-DrugBank.d742.s9|70-76|REMERON|brand
DDI-DrugBank.d742.s9|78-84|SolTab.|O
DDI-DrugBank.d742.s9|86-93|Diazepam|drug
DDI-DrugBank.d742.s9|94-94|:|O
DDI-DrugBank.d742.s9|96-106|Concomitant|O
DDI-DrugBank.d742.s9|108-121|administration|O
DDI-DrugBank.d742.s9|123-124|of|O
DDI-DrugBank.d742.s9|126-133|diazepam|drug
DDI-DrugBank.d742.s9|135-135|(|O
DDI-DrugBank.d742.s9|136-137|15|O
DDI-DrugBank.d742.s9|139-140|mg|O
DDI-DrugBank.d742.s9|141-141|)|O
DDI-DrugBank.d742.s9|143-145|had|O
DDI-DrugBank.d742.s9|147-147|a|O
DDI-DrugBank.d742.s9|149-155|minimal|O
DDI-DrugBank.d742.s9|157-162|effect|O
DDI-DrugBank.d742.s9|164-165|on|O
DDI-DrugBank.d742.s9|167-172|plasma|O
DDI-DrugBank.d742.s9|174-179|levels|O
DDI-DrugBank.d742.s9|181-182|of|O
DDI-DrugBank.d742.s9|184-194|mirtazapine|drug
DDI-DrugBank.d742.s9|196-196|(|O
DDI-DrugBank.d742.s9|197-198|15|O
DDI-DrugBank.d742.s9|200-201|mg|O
DDI-DrugBank.d742.s9|202-202|)|O
DDI-DrugBank.d742.s9|204-205|in|O
DDI-DrugBank.d742.s9|207-208|12|O
DDI-DrugBank.d742.s9|210-216|healthy|O
DDI-DrugBank.d742.s9|218-225|subjects|O
DDI-DrugBank.d742.s9|226-226|.|O
DDI-DrugBank.d742.s10|0-6|However|O
DDI-DrugBank.d742.s10|7-7|,|O
DDI-DrugBank.d742.s10|9-11|the|O
DDI-DrugBank.d742.s10|13-22|impairment|O
DDI-DrugBank.d742.s10|24-25|of|O
DDI-DrugBank.d742.s10|27-31|motor|O
DDI-DrugBank.d742.s10|33-38|skills|O
DDI-DrugBank.d742.s10|40-47|produced|O
DDI-DrugBank.d742.s10|49-50|by|O
DDI-DrugBank.d742.s10|52-58|REMERON|brand
DDI-DrugBank.d742.s10|60-62|has|O
DDI-DrugBank.d742.s10|64-67|been|O
DDI-DrugBank.d742.s10|69-73|shown|O
DDI-DrugBank.d742.s10|75-76|to|O
DDI-DrugBank.d742.s10|78-79|be|O
DDI-DrugBank.d742.s10|81-88|additive|O
DDI-DrugBank.d742.s10|90-93|with|O
DDI-DrugBank.d742.s10|95-99|those|O
DDI-DrugBank.d742.s10|101-106|caused|O
DDI-DrugBank.d742.s10|108-109|by|O
DDI-DrugBank.d742.s10|111-118|diazepam|drug
DDI-DrugBank.d742.s10|119-119|.|O
DDI-DrugBank.d742.s11|0-10|Accordingly|O
DDI-DrugBank.d742.s11|11-11|,|O
DDI-DrugBank.d742.s11|13-20|patients|O
DDI-DrugBank.d742.s11|22-27|should|O
DDI-DrugBank.d742.s11|29-30|be|O
DDI-DrugBank.d742.s11|32-38|advised|O
DDI-DrugBank.d742.s11|40-41|to|O
DDI-DrugBank.d742.s11|43-47|avoid|O
DDI-DrugBank.d742.s11|49-56|diazepam|drug
DDI-DrugBank.d742.s11|58-60|and|O
DDI-DrugBank.d742.s11|62-66|other|O
DDI-DrugBank.d742.s11|68-74|similar|O
DDI-DrugBank.d742.s11|76-80|drugs|O
DDI-DrugBank.d742.s11|82-86|while|O
DDI-DrugBank.d742.s11|88-93|taking|O
DDI-DrugBank.d742.s11|95-108|REMERON SolTab|brand
DDI-DrugBank.d742.s11|109-109|.|O
DDI-DrugBank.d324.s0|0-1|As|O
DDI-DrugBank.d324.s0|3-6|with|O
DDI-DrugBank.d324.s0|8-10|all|O
DDI-DrugBank.d324.s0|12-16|drugs|O
DDI-DrugBank.d324.s0|17-17|,|O
DDI-DrugBank.d324.s0|19-21|the|O
DDI-DrugBank.d324.s0|23-31|potential|O
DDI-DrugBank.d324.s0|33-38|exists|O
DDI-DrugBank.d324.s0|40-42|for|O
DDI-DrugBank.d324.s0|44-54|interaction|O
DDI-DrugBank.d324.s0|56-59|with|O
DDI-DrugBank.d324.s0|61-65|other|O
DDI-DrugBank.d324.s0|67-71|drugs|O
DDI-DrugBank.d324.s0|73-74|by|O
DDI-DrugBank.d324.s0|76-76|a|O
DDI-DrugBank.d324.s0|78-84|variety|O
DDI-DrugBank.d324.s0|86-87|of|O
DDI-DrugBank.d324.s0|89-98|mechanisms|O
DDI-DrugBank.d324.s0|99-99|.|O
DDI-DrugBank.d324.s1|0-9|CNS-Active|O
DDI-DrugBank.d324.s1|11-15|Drugs|O
DDI-DrugBank.d324.s1|17-23|Ethanol|drug
DDI-DrugBank.d324.s1|24-24|:|O
DDI-DrugBank.d324.s1|26-31|Sonata|brand
DDI-DrugBank.d324.s1|33-34|10|O
DDI-DrugBank.d324.s1|36-37|mg|O
DDI-DrugBank.d324.s1|39-49|potentiated|O
DDI-DrugBank.d324.s1|51-53|the|O
DDI-DrugBank.d324.s1|55-67|CNS-impairing|O
DDI-DrugBank.d324.s1|69-75|effects|O
DDI-DrugBank.d324.s1|77-78|of|O
DDI-DrugBank.d324.s1|80-86|ethanol|drug
DDI-DrugBank.d324.s1|88-91|0.75|O
DDI-DrugBank.d324.s1|93-96|g/kg|O
DDI-DrugBank.d324.s1|98-99|on|O
DDI-DrugBank.d324.s1|101-107|balance|O
DDI-DrugBank.d324.s1|109-115|testing|O
DDI-DrugBank.d324.s1|117-119|and|O
DDI-DrugBank.d324.s1|121-128|reaction|O
DDI-DrugBank.d324.s1|130-133|time|O
DDI-DrugBank.d324.s1|135-137|for|O
DDI-DrugBank.d324.s1|139-139|1|O
DDI-DrugBank.d324.s1|141-144|hour|O
DDI-DrugBank.d324.s1|146-150|after|O
DDI-DrugBank.d324.s1|152-158|ethanol|drug
DDI-DrugBank.d324.s1|160-173|administration|O
DDI-DrugBank.d324.s1|175-177|and|O
DDI-DrugBank.d324.s1|179-180|on|O
DDI-DrugBank.d324.s1|182-184|the|O
DDI-DrugBank.d324.s1|186-190|digit|O
DDI-DrugBank.d324.s1|192-197|symbol|O
DDI-DrugBank.d324.s1|199-210|substitution|O
DDI-DrugBank.d324.s1|212-215|test|O
DDI-DrugBank.d324.s1|217-217|(|O
DDI-DrugBank.d324.s1|218-221|DSST|O
DDI-DrugBank.d324.s1|222-222|)|O
DDI-DrugBank.d324.s1|223-223|,|O
DDI-DrugBank.d324.s1|225-230|symbol|O
DDI-DrugBank.d324.s1|232-238|copying|O
DDI-DrugBank.d324.s1|240-243|test|O
DDI-DrugBank.d324.s1|244-244|,|O
DDI-DrugBank.d324.s1|246-248|and|O
DDI-DrugBank.d324.s1|250-252|the|O
DDI-DrugBank.d324.s1|254-264|variability|O
DDI-DrugBank.d324.s1|266-274|component|O
DDI-DrugBank.d324.s1|276-277|of|O
DDI-DrugBank.d324.s1|279-281|the|O
DDI-DrugBank.d324.s1|283-289|divided|O
DDI-DrugBank.d324.s1|291-299|attention|O
DDI-DrugBank.d324.s1|301-304|test|O
DDI-DrugBank.d324.s1|306-308|for|O
DDI-DrugBank.d324.s1|310-312|2.5|O
DDI-DrugBank.d324.s1|314-318|hours|O
DDI-DrugBank.d324.s1|320-324|after|O
DDI-DrugBank.d324.s1|326-332|ethanol|drug
DDI-DrugBank.d324.s1|334-347|administration|O
DDI-DrugBank.d324.s1|348-348|.|O
DDI-DrugBank.d324.s2|0-2|The|O
DDI-DrugBank.d324.s2|4-15|potentiation|O
DDI-DrugBank.d324.s2|17-24|resulted|O
DDI-DrugBank.d324.s2|26-29|from|O
DDI-DrugBank.d324.s2|31-31|a|O
DDI-DrugBank.d324.s2|33-35|CNS|O
DDI-DrugBank.d324.s2|37-51|pharmacodynamic|O
DDI-DrugBank.d324.s2|53-63|interaction|O
DDI-DrugBank.d324.s2|64-64|;|O
DDI-DrugBank.d324.s3|0-7|zaleplon|drug
DDI-DrugBank.d324.s3|9-11|did|O
DDI-DrugBank.d324.s3|13-15|not|O
DDI-DrugBank.d324.s3|17-22|affect|O
DDI-DrugBank.d324.s3|24-26|the|O
DDI-DrugBank.d324.s3|28-43|pharmacokinetics|O
DDI-DrugBank.d324.s3|45-46|of|O
DDI-DrugBank.d324.s3|48-54|ethanol|drug
DDI-DrugBank.d324.s3|55-55|.|O
DDI-DrugBank.d324.s4|0-9|Imipramine|drug
DDI-DrugBank.d324.s4|10-10|:|O
DDI-DrugBank.d324.s4|12-27|Coadministration|O
DDI-DrugBank.d324.s4|29-30|of|O
DDI-DrugBank.d324.s4|32-37|single|O
DDI-DrugBank.d324.s4|39-43|doses|O
DDI-DrugBank.d324.s4|45-46|of|O
DDI-DrugBank.d324.s4|48-53|Sonata|brand
DDI-DrugBank.d324.s4|55-56|20|O
DDI-DrugBank.d324.s4|58-59|mg|O
DDI-DrugBank.d324.s4|61-63|and|O
DDI-DrugBank.d324.s4|65-74|imipramine|drug
DDI-DrugBank.d324.s4|76-77|75|O
DDI-DrugBank.d324.s4|79-80|mg|O
DDI-DrugBank.d324.s4|82-89|produced|O
DDI-DrugBank.d324.s4|91-98|additive|O
DDI-DrugBank.d324.s4|100-106|effects|O
DDI-DrugBank.d324.s4|108-109|on|O
DDI-DrugBank.d324.s4|111-119|decreased|O
DDI-DrugBank.d324.s4|121-129|alertness|O
DDI-DrugBank.d324.s4|131-133|and|O
DDI-DrugBank.d324.s4|135-142|impaired|O
DDI-DrugBank.d324.s4|144-154|psychomotor|O
DDI-DrugBank.d324.s4|156-166|performance|O
DDI-DrugBank.d324.s4|168-170|for|O
DDI-DrugBank.d324.s4|172-172|2|O
DDI-DrugBank.d324.s4|174-175|to|O
DDI-DrugBank.d324.s4|177-177|4|O
DDI-DrugBank.d324.s4|179-183|hours|O
DDI-DrugBank.d324.s4|185-189|after|O
DDI-DrugBank.d324.s4|191-204|administration|O
DDI-DrugBank.d324.s4|205-205|.|O
DDI-DrugBank.d324.s5|0-2|The|O
DDI-DrugBank.d324.s5|4-14|interaction|O
DDI-DrugBank.d324.s5|16-18|was|O
DDI-DrugBank.d324.s5|20-34|pharmacodynamic|O
DDI-DrugBank.d324.s5|36-39|with|O
DDI-DrugBank.d324.s5|41-42|no|O
DDI-DrugBank.d324.s5|44-53|alteration|O
DDI-DrugBank.d324.s5|55-56|of|O
DDI-DrugBank.d324.s5|58-60|the|O
DDI-DrugBank.d324.s5|62-77|pharmacokinetics|O
DDI-DrugBank.d324.s5|79-80|of|O
DDI-DrugBank.d324.s5|82-87|either|O
DDI-DrugBank.d324.s5|89-92|drug|O
DDI-DrugBank.d324.s5|93-93|.|O
DDI-DrugBank.d324.s6|0-9|Paroxetine|drug
DDI-DrugBank.d324.s6|10-10|:|O
DDI-DrugBank.d324.s6|12-27|Coadministration|O
DDI-DrugBank.d324.s6|29-30|of|O
DDI-DrugBank.d324.s6|32-32|a|O
DDI-DrugBank.d324.s6|34-39|single|O
DDI-DrugBank.d324.s6|41-44|dose|O
DDI-DrugBank.d324.s6|46-47|of|O
DDI-DrugBank.d324.s6|49-54|Sonata|brand
DDI-DrugBank.d324.s6|56-57|20|O
DDI-DrugBank.d324.s6|59-60|mg|O
DDI-DrugBank.d324.s6|62-64|and|O
DDI-DrugBank.d324.s6|66-75|paroxetine|drug
DDI-DrugBank.d324.s6|77-78|20|O
DDI-DrugBank.d324.s6|80-81|mg|O
DDI-DrugBank.d324.s6|83-87|daily|O
DDI-DrugBank.d324.s6|89-91|for|O
DDI-DrugBank.d324.s6|93-93|7|O
DDI-DrugBank.d324.s6|95-98|days|O
DDI-DrugBank.d324.s6|100-102|did|O
DDI-DrugBank.d324.s6|104-106|not|O
DDI-DrugBank.d324.s6|108-114|produce|O
DDI-DrugBank.d324.s6|116-118|any|O
DDI-DrugBank.d324.s6|120-130|interaction|O
DDI-DrugBank.d324.s6|132-133|on|O
DDI-DrugBank.d324.s6|135-145|psychomotor|O
DDI-DrugBank.d324.s6|147-157|performance|O
DDI-DrugBank.d324.s6|158-158|.|O
DDI-DrugBank.d324.s7|0-11|Additionally|O
DDI-DrugBank.d324.s7|12-12|,|O
DDI-DrugBank.d324.s7|14-23|paroxetine|drug
DDI-DrugBank.d324.s7|25-27|did|O
DDI-DrugBank.d324.s7|29-31|not|O
DDI-DrugBank.d324.s7|33-37|alter|O
DDI-DrugBank.d324.s7|39-41|the|O
DDI-DrugBank.d324.s7|43-58|pharmacokinetics|O
DDI-DrugBank.d324.s7|60-61|of|O
DDI-DrugBank.d324.s7|63-68|Sonata|brand
DDI-DrugBank.d324.s7|69-69|,|O
DDI-DrugBank.d324.s7|71-80|reflecting|O
DDI-DrugBank.d324.s7|82-84|the|O
DDI-DrugBank.d324.s7|86-92|absence|O
DDI-DrugBank.d324.s7|94-95|of|O
DDI-DrugBank.d324.s7|97-97|a|O
DDI-DrugBank.d324.s7|99-102|role|O
DDI-DrugBank.d324.s7|104-105|of|O
DDI-DrugBank.d324.s7|107-112|CYP2D6|O
DDI-DrugBank.d324.s7|114-115|in|O
DDI-DrugBank.d324.s7|117-124|zaleplon|drug
DDI-DrugBank.d324.s7|126-126|s|O
DDI-DrugBank.d324.s7|128-137|metabolism|O
DDI-DrugBank.d324.s7|138-138|.|O
DDI-DrugBank.d324.s8|0-11|Thioridazine|drug
DDI-DrugBank.d324.s8|12-12|:|O
DDI-DrugBank.d324.s8|14-29|Coadministration|O
DDI-DrugBank.d324.s8|31-32|of|O
DDI-DrugBank.d324.s8|34-39|single|O
DDI-DrugBank.d324.s8|41-45|doses|O
DDI-DrugBank.d324.s8|47-48|of|O
DDI-DrugBank.d324.s8|50-55|Sonata|brand
DDI-DrugBank.d324.s8|57-58|20|O
DDI-DrugBank.d324.s8|60-61|mg|O
DDI-DrugBank.d324.s8|63-65|and|O
DDI-DrugBank.d324.s8|67-78|thioridazine|drug
DDI-DrugBank.d324.s8|80-81|50|O
DDI-DrugBank.d324.s8|83-84|mg|O
DDI-DrugBank.d324.s8|86-93|produced|O
DDI-DrugBank.d324.s8|95-102|additive|O
DDI-DrugBank.d324.s8|104-110|effects|O
DDI-DrugBank.d324.s8|112-113|on|O
DDI-DrugBank.d324.s8|115-123|decreased|O
DDI-DrugBank.d324.s8|125-133|alertness|O
DDI-DrugBank.d324.s8|135-137|and|O
DDI-DrugBank.d324.s8|139-146|impaired|O
DDI-DrugBank.d324.s8|148-158|psychomotor|O
DDI-DrugBank.d324.s8|160-170|performance|O
DDI-DrugBank.d324.s8|172-174|for|O
DDI-DrugBank.d324.s8|176-176|2|O
DDI-DrugBank.d324.s8|178-179|to|O
DDI-DrugBank.d324.s8|181-181|4|O
DDI-DrugBank.d324.s8|183-187|hours|O
DDI-DrugBank.d324.s8|189-193|after|O
DDI-DrugBank.d324.s8|195-208|administration|O
DDI-DrugBank.d324.s8|209-209|.|O
DDI-DrugBank.d324.s9|0-2|The|O
DDI-DrugBank.d324.s9|4-14|interaction|O
DDI-DrugBank.d324.s9|16-18|was|O
DDI-DrugBank.d324.s9|20-34|pharmacodynamic|O
DDI-DrugBank.d324.s9|36-39|with|O
DDI-DrugBank.d324.s9|41-42|no|O
DDI-DrugBank.d324.s9|44-53|alteration|O
DDI-DrugBank.d324.s9|55-56|of|O
DDI-DrugBank.d324.s9|58-60|the|O
DDI-DrugBank.d324.s9|62-77|pharmacokinetics|O
DDI-DrugBank.d324.s9|79-80|of|O
DDI-DrugBank.d324.s9|82-87|either|O
DDI-DrugBank.d324.s9|89-92|drug|O
DDI-DrugBank.d324.s9|93-93|.|O
DDI-DrugBank.d324.s10|0-10|Venlafaxine|drug
DDI-DrugBank.d324.s10|11-11|:|O
DDI-DrugBank.d324.s10|13-28|Coadministration|O
DDI-DrugBank.d324.s10|30-31|of|O
DDI-DrugBank.d324.s10|33-33|a|O
DDI-DrugBank.d324.s10|35-40|single|O
DDI-DrugBank.d324.s10|42-45|dose|O
DDI-DrugBank.d324.s10|47-48|of|O
DDI-DrugBank.d324.s10|50-57|zaleplon|drug
DDI-DrugBank.d324.s10|59-60|10|O
DDI-DrugBank.d324.s10|62-63|mg|O
DDI-DrugBank.d324.s10|65-67|and|O
DDI-DrugBank.d324.s10|69-76|multiple|O
DDI-DrugBank.d324.s10|78-82|doses|O
DDI-DrugBank.d324.s10|84-85|of|O
DDI-DrugBank.d324.s10|87-97|venlafaxine|drug
DDI-DrugBank.d324.s10|99-100|ER|O
DDI-DrugBank.d324.s10|102-102|(|O
DDI-DrugBank.d324.s10|103-110|extended|O
DDI-DrugBank.d324.s10|112-118|release|O
DDI-DrugBank.d324.s10|119-119|)|O
DDI-DrugBank.d324.s10|121-123|150|O
DDI-DrugBank.d324.s10|125-126|mg|O
DDI-DrugBank.d324.s10|128-130|did|O
DDI-DrugBank.d324.s10|132-134|not|O
DDI-DrugBank.d324.s10|136-141|result|O
DDI-DrugBank.d324.s10|143-144|in|O
DDI-DrugBank.d324.s10|146-148|any|O
DDI-DrugBank.d324.s10|150-160|significant|O
DDI-DrugBank.d324.s10|162-168|changes|O
DDI-DrugBank.d324.s10|170-171|in|O
DDI-DrugBank.d324.s10|173-175|the|O
DDI-DrugBank.d324.s10|177-192|pharmacokinetics|O
DDI-DrugBank.d324.s10|194-195|of|O
DDI-DrugBank.d324.s10|197-202|either|O
DDI-DrugBank.d324.s10|204-211|zaleplon|drug
DDI-DrugBank.d324.s10|213-214|or|O
DDI-DrugBank.d324.s10|216-226|venlafaxine|drug
DDI-DrugBank.d324.s10|227-227|.|O
DDI-DrugBank.d324.s11|0-1|In|O
DDI-DrugBank.d324.s11|3-10|addition|O
DDI-DrugBank.d324.s11|11-11|,|O
DDI-DrugBank.d324.s11|13-17|there|O
DDI-DrugBank.d324.s11|19-21|was|O
DDI-DrugBank.d324.s11|23-24|no|O
DDI-DrugBank.d324.s11|26-40|pharmacodynamic|O
DDI-DrugBank.d324.s11|42-52|interaction|O
DDI-DrugBank.d324.s11|54-55|as|O
DDI-DrugBank.d324.s11|57-57|a|O
DDI-DrugBank.d324.s11|59-64|result|O
DDI-DrugBank.d324.s11|66-67|of|O
DDI-DrugBank.d324.s11|69-84|coadministration|O
DDI-DrugBank.d324.s11|86-87|of|O
DDI-DrugBank.d324.s11|89-96|zaleplon|drug
DDI-DrugBank.d324.s11|98-100|and|O
DDI-DrugBank.d324.s11|102-112|venlafaxine|drug
DDI-DrugBank.d324.s11|114-115|ER|O
DDI-DrugBank.d324.s11|116-116|.|O
DDI-DrugBank.d324.s12|0-11|Promethazine|drug
DDI-DrugBank.d324.s12|12-12|:|O
DDI-DrugBank.d324.s12|14-29|Coadministration|O
DDI-DrugBank.d324.s12|31-32|of|O
DDI-DrugBank.d324.s12|34-34|a|O
DDI-DrugBank.d324.s12|36-41|single|O
DDI-DrugBank.d324.s12|43-46|dose|O
DDI-DrugBank.d324.s12|48-49|of|O
DDI-DrugBank.d324.s12|51-58|zaleplon|drug
DDI-DrugBank.d324.s12|60-62|and|O
DDI-DrugBank.d324.s12|64-75|promethazine|drug
DDI-DrugBank.d324.s12|77-77|(|O
DDI-DrugBank.d324.s12|78-79|10|O
DDI-DrugBank.d324.s12|81-83|and|O
DDI-DrugBank.d324.s12|85-86|25|O
DDI-DrugBank.d324.s12|88-89|mg|O
DDI-DrugBank.d324.s12|90-90|,|O
DDI-DrugBank.d324.s12|92-103|respectively|O
DDI-DrugBank.d324.s12|104-104|)|O
DDI-DrugBank.d324.s12|106-113|resulted|O
DDI-DrugBank.d324.s12|115-116|in|O
DDI-DrugBank.d324.s12|118-118|a|O
DDI-DrugBank.d324.s12|120-121|15|O
DDI-DrugBank.d324.s12|122-122|%|O
DDI-DrugBank.d324.s12|124-131|decrease|O
DDI-DrugBank.d324.s12|133-134|in|O
DDI-DrugBank.d324.s12|136-142|maximal|O
DDI-DrugBank.d324.s12|144-149|plasma|O
DDI-DrugBank.d324.s12|151-164|concentrations|O
DDI-DrugBank.d324.s12|166-167|of|O
DDI-DrugBank.d324.s12|169-176|zaleplon|drug
DDI-DrugBank.d324.s12|177-177|,|O
DDI-DrugBank.d324.s12|179-181|but|O
DDI-DrugBank.d324.s12|183-184|no|O
DDI-DrugBank.d324.s12|186-191|change|O
DDI-DrugBank.d324.s12|193-194|in|O
DDI-DrugBank.d324.s12|196-198|the|O
DDI-DrugBank.d324.s12|200-203|area|O
DDI-DrugBank.d324.s12|205-209|under|O
DDI-DrugBank.d324.s12|211-213|the|O
DDI-DrugBank.d324.s12|215-220|plasma|O
DDI-DrugBank.d324.s12|222-239|concentration-time|O
DDI-DrugBank.d324.s12|241-245|curve|O
DDI-DrugBank.d324.s12|246-246|.|O
DDI-DrugBank.d324.s13|0-6|However|O
DDI-DrugBank.d324.s13|7-7|,|O
DDI-DrugBank.d324.s13|9-11|the|O
DDI-DrugBank.d324.s13|13-28|pharmacodynamics|O
DDI-DrugBank.d324.s13|30-31|of|O
DDI-DrugBank.d324.s13|33-48|coadministration|O
DDI-DrugBank.d324.s13|50-51|of|O
DDI-DrugBank.d324.s13|53-60|zaleplon|drug
DDI-DrugBank.d324.s13|62-64|and|O
DDI-DrugBank.d324.s13|66-77|promethazine|drug
DDI-DrugBank.d324.s13|79-82|have|O
DDI-DrugBank.d324.s13|84-86|not|O
DDI-DrugBank.d324.s13|88-91|been|O
DDI-DrugBank.d324.s13|93-101|evaluated|O
DDI-DrugBank.d324.s13|102-102|.|O
DDI-DrugBank.d324.s14|0-6|Caution|O
DDI-DrugBank.d324.s14|8-13|should|O
DDI-DrugBank.d324.s14|15-16|be|O
DDI-DrugBank.d324.s14|18-26|exercised|O
DDI-DrugBank.d324.s14|28-31|when|O
DDI-DrugBank.d324.s14|33-37|these|O
DDI-DrugBank.d324.s14|39-39|2|O
DDI-DrugBank.d324.s14|41-46|agents|O
DDI-DrugBank.d324.s14|48-50|are|O
DDI-DrugBank.d324.s14|52-65|coadministered|O
DDI-DrugBank.d324.s14|66-66|.|O
DDI-DrugBank.d324.s15|0-4|Drugs|O
DDI-DrugBank.d324.s15|6-9|That|O
DDI-DrugBank.d324.s15|11-16|Induce|O
DDI-DrugBank.d324.s15|18-23|CYP3A4|O
DDI-DrugBank.d324.s15|25-32|Rifampin|drug
DDI-DrugBank.d324.s15|33-33|:|O
DDI-DrugBank.d324.s15|35-40|CYP3A4|O
DDI-DrugBank.d324.s15|42-43|is|O
DDI-DrugBank.d324.s15|45-54|ordinarily|O
DDI-DrugBank.d324.s15|56-56|a|O
DDI-DrugBank.d324.s15|58-62|minor|O
DDI-DrugBank.d324.s15|64-75|metabolizing|O
DDI-DrugBank.d324.s15|77-82|enzyme|O
DDI-DrugBank.d324.s15|84-85|of|O
DDI-DrugBank.d324.s15|87-94|zaleplon|drug
DDI-DrugBank.d324.s15|95-95|.|O
DDI-DrugBank.d324.s16|0-12|Multiple-dose|O
DDI-DrugBank.d324.s16|14-27|administration|O
DDI-DrugBank.d324.s16|29-30|of|O
DDI-DrugBank.d324.s16|32-34|the|O
DDI-DrugBank.d324.s16|36-41|potent|O
DDI-DrugBank.d324.s16|43-48|CYP3A4|O
DDI-DrugBank.d324.s16|50-56|inducer|O
DDI-DrugBank.d324.s16|58-65|rifampin|drug
DDI-DrugBank.d324.s16|67-67|(|O
DDI-DrugBank.d324.s16|68-70|600|O
DDI-DrugBank.d324.s16|72-73|mg|O
DDI-DrugBank.d324.s16|75-79|every|O
DDI-DrugBank.d324.s16|81-82|24|O
DDI-DrugBank.d324.s16|84-88|hours|O
DDI-DrugBank.d324.s16|89-89|,|O
DDI-DrugBank.d324.s16|91-94|q24h|O
DDI-DrugBank.d324.s16|95-95|,|O
DDI-DrugBank.d324.s16|97-99|for|O
DDI-DrugBank.d324.s16|101-102|14|O
DDI-DrugBank.d324.s16|104-107|days|O
DDI-DrugBank.d324.s16|108-108|)|O
DDI-DrugBank.d324.s16|109-109|,|O
DDI-DrugBank.d324.s16|111-117|however|O
DDI-DrugBank.d324.s16|118-118|,|O
DDI-DrugBank.d324.s16|120-126|reduced|O
DDI-DrugBank.d324.s16|128-135|zaleplon|drug
DDI-DrugBank.d324.s16|137-140|Cmax|O
DDI-DrugBank.d324.s16|142-144|and|O
DDI-DrugBank.d324.s16|146-148|AUC|O
DDI-DrugBank.d324.s16|150-151|by|O
DDI-DrugBank.d324.s16|153-165|approximately|O
DDI-DrugBank.d324.s16|167-168|80|O
DDI-DrugBank.d324.s16|169-169|%|O
DDI-DrugBank.d324.s16|170-170|.|O
DDI-DrugBank.d324.s17|0-2|The|O
DDI-DrugBank.d324.s17|4-19|coadministration|O
DDI-DrugBank.d324.s17|21-22|of|O
DDI-DrugBank.d324.s17|24-24|a|O
DDI-DrugBank.d324.s17|26-31|potent|O
DDI-DrugBank.d324.s17|33-38|CYP3A4|O
DDI-DrugBank.d324.s17|40-45|enzyme|O
DDI-DrugBank.d324.s17|47-53|inducer|O
DDI-DrugBank.d324.s17|54-54|,|O
DDI-DrugBank.d324.s17|56-63|although|O
DDI-DrugBank.d324.s17|65-67|not|O
DDI-DrugBank.d324.s17|69-74|posing|O
DDI-DrugBank.d324.s17|76-76|a|O
DDI-DrugBank.d324.s17|78-83|safety|O
DDI-DrugBank.d324.s17|85-91|concern|O
DDI-DrugBank.d324.s17|92-92|,|O
DDI-DrugBank.d324.s17|94-97|thus|O
DDI-DrugBank.d324.s17|99-103|could|O
DDI-DrugBank.d324.s17|105-108|lead|O
DDI-DrugBank.d324.s17|110-111|to|O
DDI-DrugBank.d324.s17|113-127|ineffectiveness|O
DDI-DrugBank.d324.s17|129-130|of|O
DDI-DrugBank.d324.s17|132-139|zaleplon|drug
DDI-DrugBank.d324.s17|140-140|.|O
DDI-DrugBank.d324.s18|0-1|An|O
DDI-DrugBank.d324.s18|3-13|alternative|O
DDI-DrugBank.d324.s18|15-24|non-CYP3A4|O
DDI-DrugBank.d324.s18|26-34|substrate|O
DDI-DrugBank.d324.s18|36-49|hypnotic agent|group
DDI-DrugBank.d324.s18|51-53|may|O
DDI-DrugBank.d324.s18|55-56|be|O
DDI-DrugBank.d324.s18|58-67|considered|O
DDI-DrugBank.d324.s18|69-70|in|O
DDI-DrugBank.d324.s18|72-79|patients|O
DDI-DrugBank.d324.s18|81-86|taking|O
DDI-DrugBank.d324.s18|88-93|CYP3A4|O
DDI-DrugBank.d324.s18|95-102|inducers|O
DDI-DrugBank.d324.s18|104-107|such|O
DDI-DrugBank.d324.s18|109-110|as|O
DDI-DrugBank.d324.s18|112-119|rifampin|drug
DDI-DrugBank.d324.s18|120-120|,|O
DDI-DrugBank.d324.s18|122-130|phenytoin|drug
DDI-DrugBank.d324.s18|131-131|,|O
DDI-DrugBank.d324.s18|133-145|carbamazepine|drug
DDI-DrugBank.d324.s18|146-146|,|O
DDI-DrugBank.d324.s18|148-150|and|O
DDI-DrugBank.d324.s18|152-164|phenobarbital|drug
DDI-DrugBank.d324.s18|165-165|.|O
DDI-DrugBank.d324.s19|0-4|Drugs|O
DDI-DrugBank.d324.s19|6-9|That|O
DDI-DrugBank.d324.s19|11-17|Inhibit|O
DDI-DrugBank.d324.s19|19-24|CYP3A4|O
DDI-DrugBank.d324.s19|26-31|CYP3A4|O
DDI-DrugBank.d324.s19|33-34|is|O
DDI-DrugBank.d324.s19|36-36|a|O
DDI-DrugBank.d324.s19|38-42|minor|O
DDI-DrugBank.d324.s19|44-52|metabolic|O
DDI-DrugBank.d324.s19|54-60|pathway|O
DDI-DrugBank.d324.s19|62-64|for|O
DDI-DrugBank.d324.s19|66-68|the|O
DDI-DrugBank.d324.s19|70-80|elimination|O
DDI-DrugBank.d324.s19|82-83|of|O
DDI-DrugBank.d324.s19|85-92|zaleplon|drug
DDI-DrugBank.d324.s19|94-100|because|O
DDI-DrugBank.d324.s19|102-104|the|O
DDI-DrugBank.d324.s19|106-108|sum|O
DDI-DrugBank.d324.s19|110-111|of|O
DDI-DrugBank.d324.s19|113-128|desethylzaleplon|O
DDI-DrugBank.d324.s19|130-130|(|O
DDI-DrugBank.d324.s19|131-136|formed|O
DDI-DrugBank.d324.s19|138-140|via|O
DDI-DrugBank.d324.s19|142-147|CYP3A4|O
DDI-DrugBank.d324.s19|149-150|in|O
DDI-DrugBank.d324.s19|152-156|vitro|O
DDI-DrugBank.d324.s19|157-157|)|O
DDI-DrugBank.d324.s19|159-161|and|O
DDI-DrugBank.d324.s19|163-165|its|O
DDI-DrugBank.d324.s19|167-177|metabolites|O
DDI-DrugBank.d324.s19|178-178|,|O
DDI-DrugBank.d324.s19|203-205|and|O
DDI-DrugBank.d324.s19|241-241|,|O
DDI-DrugBank.d324.s19|243-249|account|O
DDI-DrugBank.d324.s19|251-253|for|O
DDI-DrugBank.d324.s19|255-258|only|O
DDI-DrugBank.d324.s19|260-260|9|O
DDI-DrugBank.d324.s19|261-261|%|O
DDI-DrugBank.d324.s19|263-264|of|O
DDI-DrugBank.d324.s19|266-268|the|O
DDI-DrugBank.d324.s19|270-276|urinary|O
DDI-DrugBank.d324.s19|278-285|recovery|O
DDI-DrugBank.d324.s19|287-288|of|O
DDI-DrugBank.d324.s19|290-290|a|O
DDI-DrugBank.d324.s19|292-299|zaleplon|drug
DDI-DrugBank.d324.s19|301-304|dose|O
DDI-DrugBank.d324.s19|305-305|.|O
DDI-DrugBank.d324.s20|0-15|Coadministration|O
DDI-DrugBank.d324.s20|17-18|of|O
DDI-DrugBank.d324.s20|20-25|single|O
DDI-DrugBank.d324.s20|26-26|,|O
DDI-DrugBank.d324.s20|28-31|oral|O
DDI-DrugBank.d324.s20|33-37|doses|O
DDI-DrugBank.d324.s20|39-40|of|O
DDI-DrugBank.d324.s20|42-49|zaleplon|drug
DDI-DrugBank.d324.s20|51-54|with|O
DDI-DrugBank.d324.s20|56-67|erythromycin|drug
DDI-DrugBank.d324.s20|69-69|(|O
DDI-DrugBank.d324.s20|70-71|10|O
DDI-DrugBank.d324.s20|73-74|mg|O
DDI-DrugBank.d324.s20|76-78|and|O
DDI-DrugBank.d324.s20|80-82|800|O
DDI-DrugBank.d324.s20|84-85|mg|O
DDI-DrugBank.d324.s20|86-86|,|O
DDI-DrugBank.d324.s20|88-99|respectively|O
DDI-DrugBank.d324.s20|100-100|)|O
DDI-DrugBank.d324.s20|101-101|,|O
DDI-DrugBank.d324.s20|103-103|a|O
DDI-DrugBank.d324.s20|105-110|strong|O
DDI-DrugBank.d324.s20|111-111|,|O
DDI-DrugBank.d324.s20|113-121|selective|O
DDI-DrugBank.d324.s20|123-128|CYP3A4|O
DDI-DrugBank.d324.s20|130-138|inhibitor|O
DDI-DrugBank.d324.s20|140-147|produced|O
DDI-DrugBank.d324.s20|149-149|a|O
DDI-DrugBank.d324.s20|151-152|34|O
DDI-DrugBank.d324.s20|153-153|%|O
DDI-DrugBank.d324.s20|155-162|increase|O
DDI-DrugBank.d324.s20|164-165|in|O
DDI-DrugBank.d324.s20|167-175|zaleplons|drug
DDI-DrugBank.d324.s20|177-183|maximal|O
DDI-DrugBank.d324.s20|185-190|plasma|O
DDI-DrugBank.d324.s20|192-205|concentrations|O
DDI-DrugBank.d324.s20|207-209|and|O
DDI-DrugBank.d324.s20|211-211|a|O
DDI-DrugBank.d324.s20|213-214|20|O
DDI-DrugBank.d324.s20|215-215|%|O
DDI-DrugBank.d324.s20|217-224|increase|O
DDI-DrugBank.d324.s20|226-227|in|O
DDI-DrugBank.d324.s20|229-231|the|O
DDI-DrugBank.d324.s20|233-236|area|O
DDI-DrugBank.d324.s20|238-242|under|O
DDI-DrugBank.d324.s20|244-246|the|O
DDI-DrugBank.d324.s20|248-253|plasma|O
DDI-DrugBank.d324.s20|255-272|concentration-time|O
DDI-DrugBank.d324.s20|274-278|curve|O
DDI-DrugBank.d324.s20|279-279|.|O
DDI-DrugBank.d324.s21|0-2|The|O
DDI-DrugBank.d324.s21|4-12|magnitude|O
DDI-DrugBank.d324.s21|14-15|of|O
DDI-DrugBank.d324.s21|17-27|interaction|O
DDI-DrugBank.d324.s21|29-32|with|O
DDI-DrugBank.d324.s21|34-41|multiple|O
DDI-DrugBank.d324.s21|43-47|doses|O
DDI-DrugBank.d324.s21|49-50|of|O
DDI-DrugBank.d324.s21|52-63|erythromycin|drug
DDI-DrugBank.d324.s21|65-66|is|O
DDI-DrugBank.d324.s21|68-74|unknown|O
DDI-DrugBank.d324.s21|75-75|.|O
DDI-DrugBank.d324.s22|0-4|Other|O
DDI-DrugBank.d324.s22|6-11|strong|O
DDI-DrugBank.d324.s22|13-21|selective|O
DDI-DrugBank.d324.s22|23-28|CYP3A4|O
DDI-DrugBank.d324.s22|30-39|inhibitors|O
DDI-DrugBank.d324.s22|41-44|such|O
DDI-DrugBank.d324.s22|46-47|as|O
DDI-DrugBank.d324.s22|49-60|ketoconazole|drug
DDI-DrugBank.d324.s22|62-64|can|O
DDI-DrugBank.d324.s22|66-69|also|O
DDI-DrugBank.d324.s22|71-72|be|O
DDI-DrugBank.d324.s22|74-81|expected|O
DDI-DrugBank.d324.s22|83-84|to|O
DDI-DrugBank.d324.s22|86-93|increase|O
DDI-DrugBank.d324.s22|95-97|the|O
DDI-DrugBank.d324.s22|99-106|exposure|O
DDI-DrugBank.d324.s22|108-109|of|O
DDI-DrugBank.d324.s22|111-118|zaleplon|drug
DDI-DrugBank.d324.s22|119-119|.|O
DDI-DrugBank.d324.s23|0-0|A|O
DDI-DrugBank.d324.s23|2-8|routine|O
DDI-DrugBank.d324.s23|10-15|dosage|O
DDI-DrugBank.d324.s23|17-26|adjustment|O
DDI-DrugBank.d324.s23|28-29|of|O
DDI-DrugBank.d324.s23|31-38|zaleplon|drug
DDI-DrugBank.d324.s23|40-41|is|O
DDI-DrugBank.d324.s23|43-45|not|O
DDI-DrugBank.d324.s23|47-56|considered|O
DDI-DrugBank.d324.s23|58-66|necessary|O
DDI-DrugBank.d324.s23|67-67|.|O
DDI-DrugBank.d324.s24|0-4|Drugs|O
DDI-DrugBank.d324.s24|6-9|That|O
DDI-DrugBank.d324.s24|11-17|Inhibit|O
DDI-DrugBank.d324.s24|19-26|Aldehyde|O
DDI-DrugBank.d324.s24|28-34|Oxidase|O
DDI-DrugBank.d324.s24|36-38|The|O
DDI-DrugBank.d324.s24|40-47|aldehyde|O
DDI-DrugBank.d324.s24|49-55|oxidase|O
DDI-DrugBank.d324.s24|57-62|enzyme|O
DDI-DrugBank.d324.s24|64-69|system|O
DDI-DrugBank.d324.s24|71-72|is|O
DDI-DrugBank.d324.s24|74-77|less|O
DDI-DrugBank.d324.s24|79-82|well|O
DDI-DrugBank.d324.s24|84-90|studied|O
DDI-DrugBank.d324.s24|92-95|than|O
DDI-DrugBank.d324.s24|97-99|the|O
DDI-DrugBank.d324.s24|101-110|cytochrome|O
DDI-DrugBank.d324.s24|112-115|P450|O
DDI-DrugBank.d324.s24|117-122|enzyme|O
DDI-DrugBank.d324.s24|124-129|system|O
DDI-DrugBank.d324.s24|130-130|.|O
DDI-DrugBank.d324.s25|0-14|Diphenhydramine|drug
DDI-DrugBank.d324.s25|15-15|:|O
DDI-DrugBank.d324.s25|17-31|Diphenhydramine|drug
DDI-DrugBank.d324.s25|33-34|is|O
DDI-DrugBank.d324.s25|36-43|reported|O
DDI-DrugBank.d324.s25|45-46|to|O
DDI-DrugBank.d324.s25|48-49|be|O
DDI-DrugBank.d324.s25|51-51|a|O
DDI-DrugBank.d324.s25|53-56|weak|O
DDI-DrugBank.d324.s25|58-66|inhibitor|O
DDI-DrugBank.d324.s25|68-69|of|O
DDI-DrugBank.d324.s25|71-78|aldehyde|O
DDI-DrugBank.d324.s25|80-86|oxidase|O
DDI-DrugBank.d324.s25|88-89|in|O
DDI-DrugBank.d324.s25|91-93|rat|O
DDI-DrugBank.d324.s25|95-99|liver|O
DDI-DrugBank.d324.s25|100-100|,|O
DDI-DrugBank.d324.s25|102-104|but|O
DDI-DrugBank.d324.s25|106-108|its|O
DDI-DrugBank.d324.s25|110-119|inhibitory|O
DDI-DrugBank.d324.s25|121-127|effects|O
DDI-DrugBank.d324.s25|129-130|in|O
DDI-DrugBank.d324.s25|132-136|human|O
DDI-DrugBank.d324.s25|138-142|liver|O
DDI-DrugBank.d324.s25|144-146|are|O
DDI-DrugBank.d324.s25|148-150|not|O
DDI-DrugBank.d324.s25|152-156|known|O
DDI-DrugBank.d324.s25|157-157|.|O
DDI-DrugBank.d324.s26|0-4|There|O
DDI-DrugBank.d324.s26|6-7|is|O
DDI-DrugBank.d324.s26|9-10|no|O
DDI-DrugBank.d324.s26|12-26|pharmacokinetic|O
DDI-DrugBank.d324.s26|28-38|interaction|O
DDI-DrugBank.d324.s26|40-46|between|O
DDI-DrugBank.d324.s26|48-55|zaleplon|drug
DDI-DrugBank.d324.s26|57-59|and|O
DDI-DrugBank.d324.s26|61-75|diphenhydramine|drug
DDI-DrugBank.d324.s26|77-85|following|O
DDI-DrugBank.d324.s26|87-89|the|O
DDI-DrugBank.d324.s26|91-104|administration|O
DDI-DrugBank.d324.s26|106-107|of|O
DDI-DrugBank.d324.s26|109-109|a|O
DDI-DrugBank.d324.s26|111-116|single|O
DDI-DrugBank.d324.s26|118-121|dose|O
DDI-DrugBank.d324.s26|123-123|(|O
DDI-DrugBank.d324.s26|124-125|10|O
DDI-DrugBank.d324.s26|127-128|mg|O
DDI-DrugBank.d324.s26|130-132|and|O
DDI-DrugBank.d324.s26|134-135|50|O
DDI-DrugBank.d324.s26|137-138|mg|O
DDI-DrugBank.d324.s26|139-139|,|O
DDI-DrugBank.d324.s26|141-152|respectively|O
DDI-DrugBank.d324.s26|153-153|)|O
DDI-DrugBank.d324.s26|155-156|of|O
DDI-DrugBank.d324.s26|158-161|each|O
DDI-DrugBank.d324.s26|163-166|drug|O
DDI-DrugBank.d324.s26|167-167|.|O
DDI-DrugBank.d324.s27|0-6|However|O
DDI-DrugBank.d324.s27|7-7|,|O
DDI-DrugBank.d324.s27|9-15|because|O
DDI-DrugBank.d324.s27|17-20|both|O
DDI-DrugBank.d324.s27|22-23|of|O
DDI-DrugBank.d324.s27|25-29|these|O
DDI-DrugBank.d324.s27|31-39|compounds|O
DDI-DrugBank.d324.s27|41-44|have|O
DDI-DrugBank.d324.s27|46-48|CNS|O
DDI-DrugBank.d324.s27|50-56|effects|O
DDI-DrugBank.d324.s27|57-57|,|O
DDI-DrugBank.d324.s27|59-60|an|O
DDI-DrugBank.d324.s27|62-69|additive|O
DDI-DrugBank.d324.s27|71-85|pharmacodynamic|O
DDI-DrugBank.d324.s27|87-92|effect|O
DDI-DrugBank.d324.s27|94-95|is|O
DDI-DrugBank.d324.s27|97-104|possible|O
DDI-DrugBank.d324.s27|105-105|.|O
DDI-DrugBank.d324.s28|0-4|Drugs|O
DDI-DrugBank.d324.s28|6-9|That|O
DDI-DrugBank.d324.s28|11-17|Inhibit|O
DDI-DrugBank.d324.s28|19-22|Both|O
DDI-DrugBank.d324.s28|24-31|Aldehyde|O
DDI-DrugBank.d324.s28|33-39|Oxidase|O
DDI-DrugBank.d324.s28|41-43|and|O
DDI-DrugBank.d324.s28|45-50|CYP3A4|O
DDI-DrugBank.d324.s28|52-61|Cimetidine|drug
DDI-DrugBank.d324.s28|62-62|:|O
DDI-DrugBank.d324.s28|64-73|Cimetidine|drug
DDI-DrugBank.d324.s28|75-82|inhibits|O
DDI-DrugBank.d324.s28|84-87|both|O
DDI-DrugBank.d324.s28|89-96|aldehyde|O
DDI-DrugBank.d324.s28|98-104|oxidase|O
DDI-DrugBank.d324.s28|106-106|(|O
DDI-DrugBank.d324.s28|107-108|in|O
DDI-DrugBank.d324.s28|110-114|vitro|O
DDI-DrugBank.d324.s28|115-115|)|O
DDI-DrugBank.d324.s28|117-119|and|O
DDI-DrugBank.d324.s28|121-126|CYP3A4|O
DDI-DrugBank.d324.s28|128-128|(|O
DDI-DrugBank.d324.s28|129-130|in|O
DDI-DrugBank.d324.s28|132-136|vitro|O
DDI-DrugBank.d324.s28|138-140|and|O
DDI-DrugBank.d324.s28|142-143|in|O
DDI-DrugBank.d324.s28|145-148|vivo|O
DDI-DrugBank.d324.s28|149-149|)|O
DDI-DrugBank.d324.s28|150-150|,|O
DDI-DrugBank.d324.s28|152-154|the|O
DDI-DrugBank.d324.s28|156-162|primary|O
DDI-DrugBank.d324.s28|164-166|and|O
DDI-DrugBank.d324.s28|168-176|secondary|O
DDI-DrugBank.d324.s28|178-184|enzymes|O
DDI-DrugBank.d324.s28|185-185|,|O
DDI-DrugBank.d324.s28|187-198|respectively|O
DDI-DrugBank.d324.s28|199-199|,|O
DDI-DrugBank.d324.s28|201-211|responsible|O
DDI-DrugBank.d324.s28|213-215|for|O
DDI-DrugBank.d324.s28|217-224|zaleplon|drug
DDI-DrugBank.d324.s28|226-235|metabolism|O
DDI-DrugBank.d324.s28|236-236|.|O
DDI-DrugBank.d324.s29|0-10|Concomitant|O
DDI-DrugBank.d324.s29|12-25|administration|O
DDI-DrugBank.d324.s29|27-28|of|O
DDI-DrugBank.d324.s29|30-35|Sonata|brand
DDI-DrugBank.d324.s29|37-37|(|O
DDI-DrugBank.d324.s29|38-39|10|O
DDI-DrugBank.d324.s29|41-42|mg|O
DDI-DrugBank.d324.s29|43-43|)|O
DDI-DrugBank.d324.s29|45-47|and|O
DDI-DrugBank.d324.s29|49-58|cimetidine|drug
DDI-DrugBank.d324.s29|60-60|(|O
DDI-DrugBank.d324.s29|61-63|800|O
DDI-DrugBank.d324.s29|65-66|mg|O
DDI-DrugBank.d324.s29|67-67|)|O
DDI-DrugBank.d324.s29|69-76|produced|O
DDI-DrugBank.d324.s29|78-79|an|O
DDI-DrugBank.d324.s29|81-82|85|O
DDI-DrugBank.d324.s29|83-83|%|O
DDI-DrugBank.d324.s29|85-92|increase|O
DDI-DrugBank.d324.s29|94-95|in|O
DDI-DrugBank.d324.s29|97-99|the|O
DDI-DrugBank.d324.s29|101-104|mean|O
DDI-DrugBank.d324.s29|106-109|Cmax|O
DDI-DrugBank.d324.s29|111-113|and|O
DDI-DrugBank.d324.s29|115-117|AUC|O
DDI-DrugBank.d324.s29|119-120|of|O
DDI-DrugBank.d324.s29|122-129|zaleplon|drug
DDI-DrugBank.d324.s29|130-130|.|O
DDI-DrugBank.d324.s30|0-1|An|O
DDI-DrugBank.d324.s30|3-9|initial|O
DDI-DrugBank.d324.s30|11-14|dose|O
DDI-DrugBank.d324.s30|16-17|of|O
DDI-DrugBank.d324.s30|19-19|5|O
DDI-DrugBank.d324.s30|21-22|mg|O
DDI-DrugBank.d324.s30|24-29|should|O
DDI-DrugBank.d324.s30|31-32|be|O
DDI-DrugBank.d324.s30|34-38|given|O
DDI-DrugBank.d324.s30|40-41|to|O
DDI-DrugBank.d324.s30|43-50|patients|O
DDI-DrugBank.d324.s30|52-54|who|O
DDI-DrugBank.d324.s30|56-58|are|O
DDI-DrugBank.d324.s30|60-72|concomitantly|O
DDI-DrugBank.d324.s30|74-78|being|O
DDI-DrugBank.d324.s30|80-86|treated|O
DDI-DrugBank.d324.s30|88-91|with|O
DDI-DrugBank.d324.s30|93-102|cimetidine|drug
DDI-DrugBank.d324.s30|103-103|.|O
DDI-DrugBank.d324.s31|0-4|Drugs|O
DDI-DrugBank.d324.s31|6-11|Highly|O
DDI-DrugBank.d324.s31|13-17|Bound|O
DDI-DrugBank.d324.s31|19-20|to|O
DDI-DrugBank.d324.s31|22-27|Plasma|O
DDI-DrugBank.d324.s31|29-35|Protein|O
DDI-DrugBank.d324.s31|37-44|Zaleplon|drug
DDI-DrugBank.d324.s31|46-47|is|O
DDI-DrugBank.d324.s31|49-51|not|O
DDI-DrugBank.d324.s31|53-58|highly|O
DDI-DrugBank.d324.s31|60-64|bound|O
DDI-DrugBank.d324.s31|66-67|to|O
DDI-DrugBank.d324.s31|69-74|plasma|O
DDI-DrugBank.d324.s31|76-83|proteins|O
DDI-DrugBank.d324.s31|85-85|(|O
DDI-DrugBank.d324.s31|86-93|fraction|O
DDI-DrugBank.d324.s31|95-99|bound|O
DDI-DrugBank.d324.s31|101-102|60|O
DDI-DrugBank.d324.s31|103-103|%|O
DDI-DrugBank.d324.s31|105-106|15|O
DDI-DrugBank.d324.s31|107-107|%|O
DDI-DrugBank.d324.s31|108-108|)|O
DDI-DrugBank.d324.s31|109-109|;|O
DDI-DrugBank.d324.s32|0-8|therefore|O
DDI-DrugBank.d324.s32|9-9|,|O
DDI-DrugBank.d324.s32|11-13|the|O
DDI-DrugBank.d324.s32|15-25|disposition|O
DDI-DrugBank.d324.s32|27-28|of|O
DDI-DrugBank.d324.s32|30-37|zaleplon|drug
DDI-DrugBank.d324.s32|39-40|is|O
DDI-DrugBank.d324.s32|42-44|not|O
DDI-DrugBank.d324.s32|46-53|expected|O
DDI-DrugBank.d324.s32|55-56|to|O
DDI-DrugBank.d324.s32|58-59|be|O
DDI-DrugBank.d324.s32|61-69|sensitive|O
DDI-DrugBank.d324.s32|71-72|to|O
DDI-DrugBank.d324.s32|74-84|alterations|O
DDI-DrugBank.d324.s32|86-87|in|O
DDI-DrugBank.d324.s32|89-95|protein|O
DDI-DrugBank.d324.s32|97-103|binding|O
DDI-DrugBank.d324.s32|104-104|.|O
DDI-DrugBank.d324.s33|0-1|In|O
DDI-DrugBank.d324.s33|3-10|addition|O
DDI-DrugBank.d324.s33|11-11|,|O
DDI-DrugBank.d324.s33|13-26|administration|O
DDI-DrugBank.d324.s33|28-29|of|O
DDI-DrugBank.d324.s33|31-36|Sonata|brand
DDI-DrugBank.d324.s33|38-39|to|O
DDI-DrugBank.d324.s33|41-41|a|O
DDI-DrugBank.d324.s33|43-49|patient|O
DDI-DrugBank.d324.s33|51-56|taking|O
DDI-DrugBank.d324.s33|58-64|another|O
DDI-DrugBank.d324.s33|66-69|drug|O
DDI-DrugBank.d324.s33|71-74|that|O
DDI-DrugBank.d324.s33|76-77|is|O
DDI-DrugBank.d324.s33|79-84|highly|O
DDI-DrugBank.d324.s33|86-92|protein|O
DDI-DrugBank.d324.s33|94-98|bound|O
DDI-DrugBank.d324.s33|100-105|should|O
DDI-DrugBank.d324.s33|107-109|not|O
DDI-DrugBank.d324.s33|111-115|cause|O
DDI-DrugBank.d324.s33|117-125|transient|O
DDI-DrugBank.d324.s33|127-134|increase|O
DDI-DrugBank.d324.s33|136-137|in|O
DDI-DrugBank.d324.s33|139-142|free|O
DDI-DrugBank.d324.s33|144-157|concentrations|O
DDI-DrugBank.d324.s33|159-160|of|O
DDI-DrugBank.d324.s33|162-164|the|O
DDI-DrugBank.d324.s33|166-170|other|O
DDI-DrugBank.d324.s33|172-175|drug|O
DDI-DrugBank.d324.s33|176-176|.|O
DDI-DrugBank.d324.s34|0-4|Drugs|O
DDI-DrugBank.d324.s34|6-9|with|O
DDI-DrugBank.d324.s34|11-11|a|O
DDI-DrugBank.d324.s34|13-18|Narrow|O
DDI-DrugBank.d324.s34|20-30|Therapeutic|O
DDI-DrugBank.d324.s34|32-36|Index|O
DDI-DrugBank.d324.s34|38-44|Digoxin|drug
DDI-DrugBank.d324.s34|45-45|:|O
DDI-DrugBank.d324.s34|47-52|Sonata|brand
DDI-DrugBank.d324.s34|54-54|(|O
DDI-DrugBank.d324.s34|55-56|10|O
DDI-DrugBank.d324.s34|58-59|mg|O
DDI-DrugBank.d324.s34|60-60|)|O
DDI-DrugBank.d324.s34|62-64|did|O
DDI-DrugBank.d324.s34|66-68|not|O
DDI-DrugBank.d324.s34|70-75|affect|O
DDI-DrugBank.d324.s34|77-79|the|O
DDI-DrugBank.d324.s34|81-95|pharmacokinetic|O
DDI-DrugBank.d324.s34|97-98|or|O
DDI-DrugBank.d324.s34|100-114|pharmacodynamic|O
DDI-DrugBank.d324.s34|116-122|profile|O
DDI-DrugBank.d324.s34|124-125|of|O
DDI-DrugBank.d324.s34|127-133|digoxin|drug
DDI-DrugBank.d324.s34|135-135|(|O
DDI-DrugBank.d324.s34|136-140|0.375|O
DDI-DrugBank.d324.s34|142-143|mg|O
DDI-DrugBank.d324.s34|145-148|q24h|O
DDI-DrugBank.d324.s34|150-152|for|O
DDI-DrugBank.d324.s34|154-154|8|O
DDI-DrugBank.d324.s34|156-159|days|O
DDI-DrugBank.d324.s34|160-160|)|O
DDI-DrugBank.d324.s34|161-161|.|O
DDI-DrugBank.d324.s35|0-7|Warfarin|drug
DDI-DrugBank.d324.s35|8-8|:|O
DDI-DrugBank.d324.s35|10-17|Multiple|O
DDI-DrugBank.d324.s35|19-22|oral|O
DDI-DrugBank.d324.s35|24-28|doses|O
DDI-DrugBank.d324.s35|30-31|of|O
DDI-DrugBank.d324.s35|33-38|Sonata|brand
DDI-DrugBank.d324.s35|40-40|(|O
DDI-DrugBank.d324.s35|41-42|20|O
DDI-DrugBank.d324.s35|44-45|mg|O
DDI-DrugBank.d324.s35|47-50|q24h|O
DDI-DrugBank.d324.s35|52-54|for|O
DDI-DrugBank.d324.s35|56-57|13|O
DDI-DrugBank.d324.s35|59-62|days|O
DDI-DrugBank.d324.s35|63-63|)|O
DDI-DrugBank.d324.s35|65-67|did|O
DDI-DrugBank.d324.s35|69-71|not|O
DDI-DrugBank.d324.s35|73-78|affect|O
DDI-DrugBank.d324.s35|80-82|the|O
DDI-DrugBank.d324.s35|84-99|pharmacokinetics|O
DDI-DrugBank.d324.s35|101-102|of|O
DDI-DrugBank.d324.s35|104-111|warfarin|drug
DDI-DrugBank.d324.s35|113-113|(|O
DDI-DrugBank.d324.s35|114-115|R+|O
DDI-DrugBank.d324.s35|116-116|)|O
DDI-DrugBank.d324.s35|117-117|-|O
DDI-DrugBank.d324.s35|119-120|or|O
DDI-DrugBank.d324.s35|122-122|(|O
DDI-DrugBank.d324.s35|123-124|S-|O
DDI-DrugBank.d324.s35|125-125|)|O
DDI-DrugBank.d324.s35|126-137|-enantiomers|O
DDI-DrugBank.d324.s35|139-140|or|O
DDI-DrugBank.d324.s35|142-144|the|O
DDI-DrugBank.d324.s35|146-161|pharmacodynamics|O
DDI-DrugBank.d324.s35|163-163|(|O
DDI-DrugBank.d324.s35|164-174|prothrombin|O
DDI-DrugBank.d324.s35|176-179|time|O
DDI-DrugBank.d324.s35|180-180|)|O
DDI-DrugBank.d324.s35|182-190|following|O
DDI-DrugBank.d324.s35|192-192|a|O
DDI-DrugBank.d324.s35|194-199|single|O
DDI-DrugBank.d324.s35|201-205|25-mg|O
DDI-DrugBank.d324.s35|207-210|oral|O
DDI-DrugBank.d324.s35|212-215|dose|O
DDI-DrugBank.d324.s35|217-218|of|O
DDI-DrugBank.d324.s35|220-227|warfarin|drug
DDI-DrugBank.d324.s35|228-228|.|O
DDI-DrugBank.d324.s36|0-4|Drugs|O
DDI-DrugBank.d324.s36|6-9|That|O
DDI-DrugBank.d324.s36|11-15|Alter|O
DDI-DrugBank.d324.s36|17-21|Renal|O
DDI-DrugBank.d324.s36|23-31|Excretion|O
DDI-DrugBank.d324.s36|33-41|Ibuprofen|drug
DDI-DrugBank.d324.s36|42-42|:|O
DDI-DrugBank.d324.s36|44-52|Ibuprofen|drug
DDI-DrugBank.d324.s36|54-55|is|O
DDI-DrugBank.d324.s36|57-61|known|O
DDI-DrugBank.d324.s36|63-64|to|O
DDI-DrugBank.d324.s36|66-71|affect|O
DDI-DrugBank.d324.s36|73-77|renal|O
DDI-DrugBank.d324.s36|79-86|function|O
DDI-DrugBank.d324.s36|88-90|and|O
DDI-DrugBank.d324.s36|91-91|,|O
DDI-DrugBank.d324.s36|93-104|consequently|O
DDI-DrugBank.d324.s36|105-105|,|O
DDI-DrugBank.d324.s36|107-111|alter|O
DDI-DrugBank.d324.s36|113-115|the|O
DDI-DrugBank.d324.s36|117-121|renal|O
DDI-DrugBank.d324.s36|123-131|excretion|O
DDI-DrugBank.d324.s36|133-134|of|O
DDI-DrugBank.d324.s36|136-140|other|O
DDI-DrugBank.d324.s36|142-146|drugs|O
DDI-DrugBank.d324.s36|147-147|.|O
DDI-DrugBank.d324.s37|0-4|There|O
DDI-DrugBank.d324.s37|6-8|was|O
DDI-DrugBank.d324.s37|10-11|no|O
DDI-DrugBank.d324.s37|13-20|apparent|O
DDI-DrugBank.d324.s37|22-36|pharmacokinetic|O
DDI-DrugBank.d324.s37|38-48|interaction|O
DDI-DrugBank.d324.s37|50-56|between|O
DDI-DrugBank.d324.s37|58-65|zaleplon|drug
DDI-DrugBank.d324.s37|67-69|and|O
DDI-DrugBank.d324.s37|71-79|ibuprofen|drug
DDI-DrugBank.d324.s37|81-89|following|O
DDI-DrugBank.d324.s37|91-96|single|O
DDI-DrugBank.d324.s37|98-101|dose|O
DDI-DrugBank.d324.s37|103-116|administration|O
DDI-DrugBank.d324.s37|118-118|(|O
DDI-DrugBank.d324.s37|119-120|10|O
DDI-DrugBank.d324.s37|122-123|mg|O
DDI-DrugBank.d324.s37|125-127|and|O
DDI-DrugBank.d324.s37|129-131|600|O
DDI-DrugBank.d324.s37|133-134|mg|O
DDI-DrugBank.d324.s37|135-135|,|O
DDI-DrugBank.d324.s37|137-148|respectively|O
DDI-DrugBank.d324.s37|149-149|)|O
DDI-DrugBank.d324.s37|151-152|of|O
DDI-DrugBank.d324.s37|154-157|each|O
DDI-DrugBank.d324.s37|159-162|drug|O
DDI-DrugBank.d324.s37|163-163|.|O
DDI-DrugBank.d324.s38|0-3|This|O
DDI-DrugBank.d324.s38|5-7|was|O
DDI-DrugBank.d324.s38|9-16|expected|O
DDI-DrugBank.d324.s38|18-24|because|O
DDI-DrugBank.d324.s38|26-33|zaleplon|drug
DDI-DrugBank.d324.s38|35-36|is|O
DDI-DrugBank.d324.s38|38-46|primarily|O
DDI-DrugBank.d324.s38|48-58|metabolized|O
DDI-DrugBank.d324.s38|60-62|and|O
DDI-DrugBank.d324.s38|64-68|renal|O
DDI-DrugBank.d324.s38|70-78|excretion|O
DDI-DrugBank.d324.s38|80-81|of|O
DDI-DrugBank.d324.s38|83-91|unchanged|O
DDI-DrugBank.d324.s38|93-100|zaleplon|drug
DDI-DrugBank.d324.s38|102-109|accounts|O
DDI-DrugBank.d324.s38|111-113|for|O
DDI-DrugBank.d324.s38|115-118|less|O
DDI-DrugBank.d324.s38|120-123|than|O
DDI-DrugBank.d324.s38|125-125|1|O
DDI-DrugBank.d324.s38|126-126|%|O
DDI-DrugBank.d324.s38|128-129|of|O
DDI-DrugBank.d324.s38|131-133|the|O
DDI-DrugBank.d324.s38|135-146|administered|O
DDI-DrugBank.d324.s38|148-151|dose|O
DDI-DrugBank.d324.s38|152-152|.|O
DDI-MedLine.d63.s0|0-11|Differential|O
DDI-MedLine.d63.s0|13-19|actions|O
DDI-MedLine.d63.s0|21-22|of|O
DDI-MedLine.d63.s0|24-34|intrathecal|O
DDI-MedLine.d63.s0|36-43|naloxone|drug
DDI-MedLine.d63.s0|45-46|on|O
DDI-MedLine.d63.s0|48-55|blocking|O
DDI-MedLine.d63.s0|57-59|the|O
DDI-MedLine.d63.s0|61-70|tail-flick|O
DDI-MedLine.d63.s0|72-81|inhibition|O
DDI-MedLine.d63.s0|83-89|induced|O
DDI-MedLine.d63.s0|91-92|by|O
DDI-MedLine.d63.s0|94-109|intraventricular|O
DDI-MedLine.d63.s0|126-128|and|O
DDI-MedLine.d63.s0|130-137|morphine|drug
DDI-MedLine.d63.s0|139-140|in|O
DDI-MedLine.d63.s0|142-145|rats|O
DDI-MedLine.d63.s0|146-146|.|O
DDI-MedLine.d63.s1|0-1|In|O
DDI-MedLine.d63.s1|3-5|the|O
DDI-MedLine.d63.s1|7-13|present|O
DDI-MedLine.d63.s1|15-19|study|O
DDI-MedLine.d63.s1|20-20|,|O
DDI-MedLine.d63.s1|22-23|it|O
DDI-MedLine.d63.s1|25-26|is|O
DDI-MedLine.d63.s1|28-35|proposed|O
DDI-MedLine.d63.s1|37-40|that|O
DDI-MedLine.d63.s1|42-44|the|O
DDI-MedLine.d63.s1|46-52|opioids|group
DDI-MedLine.d63.s1|54-60|applied|O
DDI-MedLine.d63.s1|62-63|to|O
DDI-MedLine.d63.s1|65-75|supraspinal|O
DDI-MedLine.d63.s1|77-81|brain|O
DDI-MedLine.d63.s1|83-87|sites|O
DDI-MedLine.d63.s1|89-96|produced|O
DDI-MedLine.d63.s1|98-102|their|O
DDI-MedLine.d63.s1|104-112|analgesic|O
DDI-MedLine.d63.s1|114-120|effects|O
DDI-MedLine.d63.s1|122-123|by|O
DDI-MedLine.d63.s1|125-127|the|O
DDI-MedLine.d63.s1|129-138|activation|O
DDI-MedLine.d63.s1|140-141|of|O
DDI-MedLine.d63.s1|143-151|different|O
DDI-MedLine.d63.s1|153-162|descending|O
DDI-MedLine.d63.s1|164-167|pain|O
DDI-MedLine.d63.s1|169-178|inhibitory|O
DDI-MedLine.d63.s1|180-186|systems|O
DDI-MedLine.d63.s1|187-187|.|O
DDI-MedLine.d63.s2|0-2|The|O
DDI-MedLine.d63.s2|4-11|blockade|O
DDI-MedLine.d63.s2|13-14|of|O
DDI-MedLine.d63.s2|16-18|the|O
DDI-MedLine.d63.s2|20-25|spinal|O
DDI-MedLine.d63.s2|27-40|endorphinergic|O
DDI-MedLine.d63.s2|42-47|system|O
DDI-MedLine.d63.s2|49-50|by|O
DDI-MedLine.d63.s2|52-62|intrathecal|O
DDI-MedLine.d63.s2|64-71|naloxone|drug
DDI-MedLine.d63.s2|73-74|on|O
DDI-MedLine.d63.s2|76-78|the|O
DDI-MedLine.d63.s2|80-89|production|O
DDI-MedLine.d63.s2|91-92|of|O
DDI-MedLine.d63.s2|94-103|tail-flick|O
DDI-MedLine.d63.s2|105-114|inhibition|O
DDI-MedLine.d63.s2|116-122|induced|O
DDI-MedLine.d63.s2|124-125|by|O
DDI-MedLine.d63.s2|127-142|intraventricular|O
DDI-MedLine.d63.s2|159-161|and|O
DDI-MedLine.d63.s2|163-170|morphine|drug
DDI-MedLine.d63.s2|172-174|was|O
DDI-MedLine.d63.s2|176-179|then|O
DDI-MedLine.d63.s2|181-187|studied|O
DDI-MedLine.d63.s2|188-188|.|O
DDI-MedLine.d63.s3|0-15|Intraventricular|O
DDI-MedLine.d63.s3|17-25|injection|O
DDI-MedLine.d63.s3|27-28|of|O
DDI-MedLine.d63.s3|45-47|and|O
DDI-MedLine.d63.s3|49-56|morphine|drug
DDI-MedLine.d63.s3|58-65|produced|O
DDI-MedLine.d63.s3|67-68|an|O
DDI-MedLine.d63.s3|70-79|inhibition|O
DDI-MedLine.d63.s3|81-82|of|O
DDI-MedLine.d63.s3|84-86|the|O
DDI-MedLine.d63.s3|88-97|tail-flick|O
DDI-MedLine.d63.s3|99-106|response|O
DDI-MedLine.d63.s3|108-109|to|O
DDI-MedLine.d63.s3|111-113|the|O
DDI-MedLine.d63.s3|115-118|heat|O
DDI-MedLine.d63.s3|120-127|stimulus|O
DDI-MedLine.d63.s3|129-130|in|O
DDI-MedLine.d63.s3|132-135|rats|O
DDI-MedLine.d63.s3|136-136|.|O
DDI-MedLine.d63.s4|0-10|Intrathecal|O
DDI-MedLine.d63.s4|12-20|injection|O
DDI-MedLine.d63.s4|22-23|of|O
DDI-MedLine.d63.s4|25-32|naloxone|drug
DDI-MedLine.d63.s4|34-35|at|O
DDI-MedLine.d63.s4|37-41|doses|O
DDI-MedLine.d63.s4|43-44|of|O
DDI-MedLine.d63.s4|46-48|0.4|O
DDI-MedLine.d63.s4|50-51|to|O
DDI-MedLine.d63.s4|53-54|40|O
DDI-MedLine.d63.s4|56-65|micrograms|O
DDI-MedLine.d63.s4|67-72|caused|O
DDI-MedLine.d63.s4|74-74|a|O
DDI-MedLine.d63.s4|76-87|dose-related|O
DDI-MedLine.d63.s4|89-96|blockade|O
DDI-MedLine.d63.s4|98-99|of|O
DDI-MedLine.d63.s4|101-103|the|O
DDI-MedLine.d63.s4|105-114|inhibition|O
DDI-MedLine.d63.s4|116-117|of|O
DDI-MedLine.d63.s4|119-121|the|O
DDI-MedLine.d63.s4|123-132|tail-flick|O
DDI-MedLine.d63.s4|134-141|response|O
DDI-MedLine.d63.s4|143-149|induced|O
DDI-MedLine.d63.s4|151-152|by|O
DDI-MedLine.d63.s4|154-169|intraventricular|O
DDI-MedLine.d63.s4|171-179|injection|O
DDI-MedLine.d63.s4|181-182|of|O
DDI-MedLine.d63.s4|198-198|,|O
DDI-MedLine.d63.s4|200-202|and|O
DDI-MedLine.d63.s4|204-204|a|O
DDI-MedLine.d63.s4|206-209|high|O
DDI-MedLine.d63.s4|211-214|dose|O
DDI-MedLine.d63.s4|216-217|of|O
DDI-MedLine.d63.s4|219-226|naloxone|drug
DDI-MedLine.d63.s4|228-228|(|O
DDI-MedLine.d63.s4|229-230|40|O
DDI-MedLine.d63.s4|232-241|micrograms|O
DDI-MedLine.d63.s4|242-242|)|O
DDI-MedLine.d63.s4|244-253|completely|O
DDI-MedLine.d63.s4|255-261|blocked|O
DDI-MedLine.d63.s4|263-265|the|O
DDI-MedLine.d63.s4|267-276|tail-flick|O
DDI-MedLine.d63.s4|278-287|inhibition|O
DDI-MedLine.d63.s4|289-295|induced|O
DDI-MedLine.d63.s4|297-298|by|O
DDI-MedLine.d63.s4|300-315|intraventricular|O
DDI-MedLine.d63.s4|332-332|(|O
DDI-MedLine.d63.s4|333-334|16|O
DDI-MedLine.d63.s4|336-345|micrograms|O
DDI-MedLine.d63.s4|346-346|)|O
DDI-MedLine.d63.s4|347-347|.|O
DDI-MedLine.d63.s5|0-1|On|O
DDI-MedLine.d63.s5|3-5|the|O
DDI-MedLine.d63.s5|7-11|other|O
DDI-MedLine.d63.s5|13-16|hand|O
DDI-MedLine.d63.s5|17-17|,|O
DDI-MedLine.d63.s5|19-29|intrathecal|O
DDI-MedLine.d63.s5|31-38|naloxone|drug
DDI-MedLine.d63.s5|40-40|(|O
DDI-MedLine.d63.s5|41-46|12-120|O
DDI-MedLine.d63.s5|48-57|micrograms|O
DDI-MedLine.d63.s5|58-58|)|O
DDI-MedLine.d63.s5|60-62|had|O
DDI-MedLine.d63.s5|64-67|only|O
DDI-MedLine.d63.s5|69-69|a|O
DDI-MedLine.d63.s5|71-74|very|O
DDI-MedLine.d63.s5|76-79|weak|O
DDI-MedLine.d63.s5|81-86|effect|O
DDI-MedLine.d63.s5|88-89|on|O
DDI-MedLine.d63.s5|91-93|the|O
DDI-MedLine.d63.s5|95-104|tail-flick|O
DDI-MedLine.d63.s5|106-115|inhibition|O
DDI-MedLine.d63.s5|117-123|induced|O
DDI-MedLine.d63.s5|125-126|by|O
DDI-MedLine.d63.s5|128-143|intraventricular|O
DDI-MedLine.d63.s5|145-152|morphine|drug
DDI-MedLine.d63.s5|154-154|(|O
DDI-MedLine.d63.s5|155-156|40|O
DDI-MedLine.d63.s5|158-167|micrograms|O
DDI-MedLine.d63.s5|168-168|)|O
DDI-MedLine.d63.s5|169-169|.|O
DDI-MedLine.d63.s6|0-15|Intraventricular|O
DDI-MedLine.d63.s6|17-25|injection|O
DDI-MedLine.d63.s6|27-28|of|O
DDI-MedLine.d63.s6|30-37|naloxone|drug
DDI-MedLine.d63.s6|39-40|at|O
DDI-MedLine.d63.s6|42-46|doses|O
DDI-MedLine.d63.s6|48-49|of|O
DDI-MedLine.d63.s6|51-53|1.2|O
DDI-MedLine.d63.s6|55-56|to|O
DDI-MedLine.d63.s6|58-59|12|O
DDI-MedLine.d63.s6|61-70|micrograms|O
DDI-MedLine.d63.s6|72-78|equally|O
DDI-MedLine.d63.s6|80-90|antagonized|O
DDI-MedLine.d63.s6|92-93|in|O
DDI-MedLine.d63.s6|95-95|a|O
DDI-MedLine.d63.s6|97-110|dose-dependent|O
DDI-MedLine.d63.s6|112-117|manner|O
DDI-MedLine.d63.s6|119-121|the|O
DDI-MedLine.d63.s6|123-132|tail-flick|O
DDI-MedLine.d63.s6|134-143|inhibition|O
DDI-MedLine.d63.s6|145-151|induced|O
DDI-MedLine.d63.s6|153-154|by|O
DDI-MedLine.d63.s6|156-171|intraventricular|O
DDI-MedLine.d63.s6|188-190|and|O
DDI-MedLine.d63.s6|192-199|morphine|drug
DDI-MedLine.d63.s6|200-200|.|O
DDI-MedLine.d63.s7|0-2|The|O
DDI-MedLine.d63.s7|4-10|results|O
DDI-MedLine.d63.s7|12-19|indicate|O
DDI-MedLine.d63.s7|21-24|that|O
DDI-MedLine.d63.s7|26-26|a|O
DDI-MedLine.d63.s7|28-33|spinal|O
DDI-MedLine.d63.s7|35-52|naloxone-sensitive|drug
DDI-MedLine.d63.s7|54-67|endorphinergic|O
DDI-MedLine.d63.s7|69-74|system|O
DDI-MedLine.d63.s7|76-77|is|O
DDI-MedLine.d63.s7|79-86|involved|O
DDI-MedLine.d63.s7|88-89|in|O
DDI-MedLine.d63.s7|91-93|the|O
DDI-MedLine.d63.s7|95-104|production|O
DDI-MedLine.d63.s7|106-107|of|O
DDI-MedLine.d63.s7|124-126|but|O
DDI-MedLine.d63.s7|128-130|not|O
DDI-MedLine.d63.s7|132-147|morphine-induced|drug
DDI-MedLine.d63.s7|149-158|tail-flick|O
DDI-MedLine.d63.s7|160-169|inhibition|O
DDI-MedLine.d63.s7|170-170|,|O
DDI-MedLine.d63.s7|172-174|and|O
DDI-MedLine.d63.s7|176-182|suggest|O
DDI-MedLine.d63.s7|184-187|that|O
DDI-MedLine.d63.s7|189-204|intraventricular|O
DDI-MedLine.d63.s7|221-223|and|O
DDI-MedLine.d63.s7|225-232|morphine|drug
DDI-MedLine.d63.s7|234-239|elicit|O
DDI-MedLine.d63.s7|241-245|their|O
DDI-MedLine.d63.s7|247-261|pharmacological|O
DDI-MedLine.d63.s7|263-269|actions|O
DDI-MedLine.d63.s7|271-273|via|O
DDI-MedLine.d63.s7|275-277|the|O
DDI-MedLine.d63.s7|279-288|activation|O
DDI-MedLine.d63.s7|290-291|of|O
DDI-MedLine.d63.s7|293-301|different|O
DDI-MedLine.d63.s7|303-312|descending|O
DDI-MedLine.d63.s7|314-317|pain|O
DDI-MedLine.d63.s7|319-328|inhibitory|O
DDI-MedLine.d63.s7|330-336|systems|O
DDI-MedLine.d63.s7|337-337|;|O
DDI-MedLine.d63.s8|0-9|descending|O
DDI-MedLine.d63.s8|11-17|epsilon|O
DDI-MedLine.d63.s8|19-21|and|O
DDI-MedLine.d63.s8|23-24|mu|O
DDI-MedLine.d63.s8|26-32|systems|O
DDI-MedLine.d63.s8|34-36|for|O
DDI-MedLine.d63.s8|53-55|and|O
DDI-MedLine.d63.s8|57-64|morphine|drug
DDI-MedLine.d63.s8|65-65|,|O
DDI-MedLine.d63.s8|67-78|respectively|O
DDI-MedLine.d63.s8|79-79|,|O
DDI-MedLine.d63.s8|81-83|are|O
DDI-MedLine.d63.s8|85-92|proposed|O
DDI-MedLine.d63.s8|93-93|.|O
DDI-DrugBank.d26.s0|0-7|Patients|O
DDI-DrugBank.d26.s0|9-17|receiving|O
DDI-DrugBank.d26.s0|19-23|other|O
DDI-DrugBank.d26.s0|25-32|narcotic|group
DDI-DrugBank.d26.s0|34-43|analgesics|O
DDI-DrugBank.d26.s0|44-44|,|O
DDI-DrugBank.d26.s0|46-52|general|O
DDI-DrugBank.d26.s0|54-64|anesthetics|group
DDI-DrugBank.d26.s0|65-65|,|O
DDI-DrugBank.d26.s0|67-80|phenothiazines|group
DDI-DrugBank.d26.s0|81-81|,|O
DDI-DrugBank.d26.s0|83-95|tranquilizers|group
DDI-DrugBank.d26.s0|96-96|,|O
DDI-DrugBank.d26.s0|98-115|sedative-hypnotics|group
DDI-DrugBank.d26.s0|116-116|,|O
DDI-DrugBank.d26.s0|118-142|tricyclic antidepressants|group
DDI-DrugBank.d26.s0|144-145|or|O
DDI-DrugBank.d26.s0|147-151|other|O
DDI-DrugBank.d26.s0|153-167|CNS depressants|group
DDI-DrugBank.d26.s0|169-169|(|O
DDI-DrugBank.d26.s0|170-178|including|O
DDI-DrugBank.d26.s0|180-186|alcohol|drug
DDI-DrugBank.d26.s0|187-187|)|O
DDI-DrugBank.d26.s0|189-201|concomitantly|O
DDI-DrugBank.d26.s0|203-206|with|O
DDI-DrugBank.d26.s0|208-215|DILAUDID|brand
DDI-DrugBank.d26.s0|217-219|may|O
DDI-DrugBank.d26.s0|221-227|exhibit|O
DDI-DrugBank.d26.s0|229-230|an|O
DDI-DrugBank.d26.s0|232-239|additive|O
DDI-DrugBank.d26.s0|241-243|CNS|O
DDI-DrugBank.d26.s0|245-254|depression|O
DDI-DrugBank.d26.s0|255-255|.|O
DDI-DrugBank.d26.s1|0-3|When|O
DDI-DrugBank.d26.s1|5-8|such|O
DDI-DrugBank.d26.s1|10-17|combined|O
DDI-DrugBank.d26.s1|19-25|therapy|O
DDI-DrugBank.d26.s1|27-28|is|O
DDI-DrugBank.d26.s1|30-41|contemplated|O
DDI-DrugBank.d26.s1|42-42|,|O
DDI-DrugBank.d26.s1|44-46|the|O
DDI-DrugBank.d26.s1|48-51|dose|O
DDI-DrugBank.d26.s1|53-54|of|O
DDI-DrugBank.d26.s1|56-58|one|O
DDI-DrugBank.d26.s1|60-61|or|O
DDI-DrugBank.d26.s1|63-66|both|O
DDI-DrugBank.d26.s1|68-73|agents|O
DDI-DrugBank.d26.s1|75-80|should|O
DDI-DrugBank.d26.s1|82-83|be|O
DDI-DrugBank.d26.s1|85-91|reduced|O
DDI-DrugBank.d26.s1|92-92|.|O
DDI-MedLine.d60.s0|0-8|Phenytoin|O
DDI-MedLine.d60.s0|10-21|intoxication|O
DDI-MedLine.d60.s0|23-29|induced|O
DDI-MedLine.d60.s0|31-32|by|O
DDI-MedLine.d60.s0|34-44|fluvoxamine|drug
DDI-MedLine.d60.s0|45-45|.|O
DDI-MedLine.d60.s1|0-0|A|O
DDI-MedLine.d60.s1|2-8|patient|O
DDI-MedLine.d60.s1|10-12|had|O
DDI-MedLine.d60.s1|14-22|phenytoin|O
DDI-MedLine.d60.s1|24-35|intoxication|O
DDI-MedLine.d60.s1|37-41|after|O
DDI-MedLine.d60.s1|43-56|administration|O
DDI-MedLine.d60.s1|58-59|of|O
DDI-MedLine.d60.s1|61-71|fluvoxamine|drug
DDI-MedLine.d60.s1|72-72|,|O
DDI-MedLine.d60.s1|74-74|a|O
DDI-MedLine.d60.s1|76-84|selective|O
DDI-MedLine.d60.s1|86-94|serotonin|O
DDI-MedLine.d60.s1|96-103|reuptake|O
DDI-MedLine.d60.s1|105-113|inhibitor|O
DDI-MedLine.d60.s1|114-114|.|O
DDI-MedLine.d60.s2|0-2|The|O
DDI-MedLine.d60.s2|4-8|serum|O
DDI-MedLine.d60.s2|10-22|concentration|O
DDI-MedLine.d60.s2|24-25|of|O
DDI-MedLine.d60.s2|27-35|phenytoin|drug
DDI-MedLine.d60.s2|37-45|increased|O
DDI-MedLine.d60.s2|47-58|dramatically|O
DDI-MedLine.d60.s2|60-63|from|O
DDI-MedLine.d60.s2|65-68|16.6|O
DDI-MedLine.d60.s2|70-71|to|O
DDI-MedLine.d60.s2|73-76|49.1|O
DDI-MedLine.d60.s2|78-86|microg/mL|O
DDI-MedLine.d60.s2|88-91|when|O
DDI-MedLine.d60.s2|93-103|fluvoxamine|drug
DDI-MedLine.d60.s2|105-107|was|O
DDI-MedLine.d60.s2|109-122|coadministered|O
DDI-MedLine.d60.s2|123-123|,|O
DDI-MedLine.d60.s2|125-132|although|O
DDI-MedLine.d60.s2|134-136|the|O
DDI-MedLine.d60.s2|138-142|daily|O
DDI-MedLine.d60.s2|144-149|dosage|O
DDI-MedLine.d60.s2|151-152|of|O
DDI-MedLine.d60.s2|154-162|phenytoin|drug
DDI-MedLine.d60.s2|164-166|and|O
DDI-MedLine.d60.s2|168-172|other|O
DDI-MedLine.d60.s2|174-178|drugs|drug
DDI-MedLine.d60.s2|180-182|had|O
DDI-MedLine.d60.s2|184-186|not|O
DDI-MedLine.d60.s2|188-194|changed|O
DDI-MedLine.d60.s2|195-195|.|O
DDI-MedLine.d60.s3|0-5|During|O
DDI-MedLine.d60.s3|7-15|phenytoin|drug
DDI-MedLine.d60.s3|17-19|and|O
DDI-MedLine.d60.s3|21-31|fluvoxamine|O
DDI-MedLine.d60.s3|33-41|treatment|O
DDI-MedLine.d60.s3|42-42|,|O
DDI-MedLine.d60.s3|44-49|ataxia|O
DDI-MedLine.d60.s3|50-50|,|O
DDI-MedLine.d60.s3|52-52|a|O
DDI-MedLine.d60.s3|54-60|typical|O
DDI-MedLine.d60.s3|62-65|side|O
DDI-MedLine.d60.s3|67-72|effect|O
DDI-MedLine.d60.s3|74-75|of|O
DDI-MedLine.d60.s3|77-85|phenytoin|drug
DDI-MedLine.d60.s3|86-86|,|O
DDI-MedLine.d60.s3|88-90|was|O
DDI-MedLine.d60.s3|92-99|observed|O
DDI-MedLine.d60.s3|100-100|.|O
DDI-MedLine.d60.s4|0-2|The|O
DDI-MedLine.d60.s4|4-12|genotypes|O
DDI-MedLine.d60.s4|14-15|of|O
DDI-MedLine.d60.s4|17-22|CYP2C9|drug
DDI-MedLine.d60.s4|24-26|and|O
DDI-MedLine.d60.s4|28-31|2C19|O
DDI-MedLine.d60.s4|32-32|,|O
DDI-MedLine.d60.s4|34-36|the|O
DDI-MedLine.d60.s4|38-44|enzymes|O
DDI-MedLine.d60.s4|46-56|responsible|O
DDI-MedLine.d60.s4|58-60|for|O
DDI-MedLine.d60.s4|62-70|phenytoin|O
DDI-MedLine.d60.s4|72-81|metabolism|O
DDI-MedLine.d60.s4|82-82|,|O
DDI-MedLine.d60.s4|84-87|were|O
DDI-MedLine.d60.s4|89-98|homozygous|O
DDI-MedLine.d60.s4|100-102|for|O
DDI-MedLine.d60.s4|104-106|the|O
DDI-MedLine.d60.s4|108-116|wild-type|O
DDI-MedLine.d60.s4|118-124|alleles|O
DDI-MedLine.d60.s4|126-126|(|O
DDI-MedLine.d60.s4|127-137|CYP2C9*1/*1|drug
DDI-MedLine.d60.s4|139-141|and|O
DDI-MedLine.d60.s4|143-149|2C19*1/|O
DDI-MedLine.d60.s4|151-152|*1|O
DDI-MedLine.d60.s4|153-153|)|O
DDI-MedLine.d60.s4|154-154|.|O
DDI-MedLine.d60.s5|0-2|The|O
DDI-MedLine.d60.s5|4-14|interaction|O
DDI-MedLine.d60.s5|16-18|may|O
DDI-MedLine.d60.s5|20-21|be|O
DDI-MedLine.d60.s5|23-23|a|O
DDI-MedLine.d60.s5|25-30|result|O
DDI-MedLine.d60.s5|32-33|of|O
DDI-MedLine.d60.s5|35-44|inhibition|O
DDI-MedLine.d60.s5|46-47|of|O
DDI-MedLine.d60.s5|49-52|both|O
DDI-MedLine.d60.s5|54-59|CYP2C9|drug
DDI-MedLine.d60.s5|61-63|and|O
DDI-MedLine.d60.s5|65-68|2C19|O
DDI-MedLine.d60.s5|70-71|by|O
DDI-MedLine.d60.s5|73-83|fluvoxamine|drug
DDI-MedLine.d60.s5|84-84|.|O
DDI-DrugBank.d763.s0|0-10|Ondansetron|drug
DDI-DrugBank.d763.s0|12-15|does|O
DDI-DrugBank.d763.s0|17-19|not|O
DDI-DrugBank.d763.s0|21-26|itself|O
DDI-DrugBank.d763.s0|28-33|appear|O
DDI-DrugBank.d763.s0|35-36|to|O
DDI-DrugBank.d763.s0|38-43|induce|O
DDI-DrugBank.d763.s0|45-46|or|O
DDI-DrugBank.d763.s0|48-54|inhibit|O
DDI-DrugBank.d763.s0|56-58|the|O
DDI-DrugBank.d763.s0|60-69|cytochrome|O
DDI-DrugBank.d763.s0|71-75|P-450|O
DDI-DrugBank.d763.s0|77-93|drug-metabolizing|O
DDI-DrugBank.d763.s0|95-100|enzyme|O
DDI-DrugBank.d763.s0|102-107|system|O
DDI-DrugBank.d763.s0|109-110|of|O
DDI-DrugBank.d763.s0|112-114|the|O
DDI-DrugBank.d763.s0|116-120|liver|O
DDI-DrugBank.d763.s0|121-121|.|O
DDI-DrugBank.d763.s1|0-6|Because|O
DDI-DrugBank.d763.s1|8-18|ondansetron|drug
DDI-DrugBank.d763.s1|20-21|is|O
DDI-DrugBank.d763.s1|23-33|metabolized|O
DDI-DrugBank.d763.s1|35-36|by|O
DDI-DrugBank.d763.s1|38-44|hepatic|O
DDI-DrugBank.d763.s1|46-55|cytochrome|O
DDI-DrugBank.d763.s1|57-61|P-450|O
DDI-DrugBank.d763.s1|63-79|drug-metabolizing|O
DDI-DrugBank.d763.s1|81-87|enzymes|O
DDI-DrugBank.d763.s1|89-89|(|O
DDI-DrugBank.d763.s1|90-95|CYP3A4|O
DDI-DrugBank.d763.s1|96-96|,|O
DDI-DrugBank.d763.s1|98-103|CYP2D6|O
DDI-DrugBank.d763.s1|104-104|,|O
DDI-DrugBank.d763.s1|106-111|CYP1A2|O
DDI-DrugBank.d763.s1|112-112|)|O
DDI-DrugBank.d763.s1|113-113|,|O
DDI-DrugBank.d763.s1|115-122|inducers|O
DDI-DrugBank.d763.s1|124-125|or|O
DDI-DrugBank.d763.s1|127-136|inhibitors|O
DDI-DrugBank.d763.s1|138-139|of|O
DDI-DrugBank.d763.s1|141-145|these|O
DDI-DrugBank.d763.s1|147-153|enzymes|O
DDI-DrugBank.d763.s1|155-157|may|O
DDI-DrugBank.d763.s1|159-164|change|O
DDI-DrugBank.d763.s1|166-168|the|O
DDI-DrugBank.d763.s1|170-178|clearance|O
DDI-DrugBank.d763.s1|180-182|and|O
DDI-DrugBank.d763.s1|183-183|,|O
DDI-DrugBank.d763.s1|185-189|hence|O
DDI-DrugBank.d763.s1|190-190|,|O
DDI-DrugBank.d763.s1|192-194|the|O
DDI-DrugBank.d763.s1|196-204|half-life|O
DDI-DrugBank.d763.s1|206-207|of|O
DDI-DrugBank.d763.s1|209-219|ondansetron|drug
DDI-DrugBank.d763.s1|220-220|.|O
DDI-DrugBank.d763.s2|0-1|On|O
DDI-DrugBank.d763.s2|3-5|the|O
DDI-DrugBank.d763.s2|7-11|basis|O
DDI-DrugBank.d763.s2|13-14|of|O
DDI-DrugBank.d763.s2|16-22|limited|O
DDI-DrugBank.d763.s2|24-32|available|O
DDI-DrugBank.d763.s2|34-37|data|O
DDI-DrugBank.d763.s2|38-38|,|O
DDI-DrugBank.d763.s2|40-41|no|O
DDI-DrugBank.d763.s2|43-48|dosage|O
DDI-DrugBank.d763.s2|50-59|adjustment|O
DDI-DrugBank.d763.s2|61-62|is|O
DDI-DrugBank.d763.s2|64-74|recommended|O
DDI-DrugBank.d763.s2|76-78|for|O
DDI-DrugBank.d763.s2|80-87|patients|O
DDI-DrugBank.d763.s2|89-90|on|O
DDI-DrugBank.d763.s2|92-96|these|O
DDI-DrugBank.d763.s2|98-102|drugs|O
DDI-DrugBank.d763.s2|103-103|.|O
DDI-DrugBank.d763.s3|0-8|Phenytoin|drug
DDI-DrugBank.d763.s3|9-9|,|O
DDI-DrugBank.d763.s3|11-23|Carbamazepine|drug
DDI-DrugBank.d763.s3|24-24|,|O
DDI-DrugBank.d763.s3|26-28|and|O
DDI-DrugBank.d763.s3|30-39|Rifampicin|drug
DDI-DrugBank.d763.s3|40-40|:|O
DDI-DrugBank.d763.s3|42-43|In|O
DDI-DrugBank.d763.s3|45-52|patients|O
DDI-DrugBank.d763.s3|54-60|treated|O
DDI-DrugBank.d763.s3|62-65|with|O
DDI-DrugBank.d763.s3|67-72|potent|O
DDI-DrugBank.d763.s3|74-81|inducers|O
DDI-DrugBank.d763.s3|83-84|of|O
DDI-DrugBank.d763.s3|86-91|CYP3A4|O
DDI-DrugBank.d763.s3|93-93|(|O
DDI-DrugBank.d763.s3|94-97|i.e.|O
DDI-DrugBank.d763.s3|98-98|,|O
DDI-DrugBank.d763.s3|100-108|phenytoin|drug
DDI-DrugBank.d763.s3|109-109|,|O
DDI-DrugBank.d763.s3|111-123|carbamazepine|drug
DDI-DrugBank.d763.s3|124-124|,|O
DDI-DrugBank.d763.s3|126-128|and|O
DDI-DrugBank.d763.s3|130-139|rifampicin|drug
DDI-DrugBank.d763.s3|140-140|)|O
DDI-DrugBank.d763.s3|141-141|,|O
DDI-DrugBank.d763.s3|143-145|the|O
DDI-DrugBank.d763.s3|147-155|clearance|O
DDI-DrugBank.d763.s3|157-158|of|O
DDI-DrugBank.d763.s3|160-170|ondansetron|drug
DDI-DrugBank.d763.s3|172-174|was|O
DDI-DrugBank.d763.s3|176-188|significantly|O
DDI-DrugBank.d763.s3|190-198|increased|O
DDI-DrugBank.d763.s3|200-202|and|O
DDI-DrugBank.d763.s3|204-214|ondansetron|drug
DDI-DrugBank.d763.s3|216-220|blood|O
DDI-DrugBank.d763.s3|222-235|concentrations|O
DDI-DrugBank.d763.s3|237-240|were|O
DDI-DrugBank.d763.s3|242-250|decreased|O
DDI-DrugBank.d763.s3|251-251|.|O
DDI-DrugBank.d763.s4|0-6|However|O
DDI-DrugBank.d763.s4|7-7|,|O
DDI-DrugBank.d763.s4|9-10|on|O
DDI-DrugBank.d763.s4|12-14|the|O
DDI-DrugBank.d763.s4|16-20|basis|O
DDI-DrugBank.d763.s4|22-23|of|O
DDI-DrugBank.d763.s4|25-33|available|O
DDI-DrugBank.d763.s4|35-38|data|O
DDI-DrugBank.d763.s4|39-39|,|O
DDI-DrugBank.d763.s4|41-42|no|O
DDI-DrugBank.d763.s4|44-49|dosage|O
DDI-DrugBank.d763.s4|51-60|adjustment|O
DDI-DrugBank.d763.s4|62-64|for|O
DDI-DrugBank.d763.s4|66-76|ondansetron|drug
DDI-DrugBank.d763.s4|78-79|is|O
DDI-DrugBank.d763.s4|81-91|recommended|O
DDI-DrugBank.d763.s4|93-95|for|O
DDI-DrugBank.d763.s4|97-104|patients|O
DDI-DrugBank.d763.s4|106-107|on|O
DDI-DrugBank.d763.s4|109-113|these|O
DDI-DrugBank.d763.s4|115-123|drugs.1,3|O
DDI-DrugBank.d763.s4|126-133|Tramadol|drug
DDI-DrugBank.d763.s4|134-134|:|O
DDI-DrugBank.d763.s4|136-143|Although|O
DDI-DrugBank.d763.s4|145-146|no|O
DDI-DrugBank.d763.s4|148-162|pharmacokinetic|O
DDI-DrugBank.d763.s4|164-167|drug|O
DDI-DrugBank.d763.s4|169-179|interaction|O
DDI-DrugBank.d763.s4|181-187|between|O
DDI-DrugBank.d763.s4|189-199|ondansetron|drug
DDI-DrugBank.d763.s4|201-203|and|O
DDI-DrugBank.d763.s4|205-212|tramadol|drug
DDI-DrugBank.d763.s4|214-216|has|O
DDI-DrugBank.d763.s4|218-221|been|O
DDI-DrugBank.d763.s4|223-230|observed|O
DDI-DrugBank.d763.s4|231-231|,|O
DDI-DrugBank.d763.s4|233-236|data|O
DDI-DrugBank.d763.s4|238-241|from|O
DDI-DrugBank.d763.s4|243-243|2|O
DDI-DrugBank.d763.s4|245-249|small|O
DDI-DrugBank.d763.s4|251-257|studies|O
DDI-DrugBank.d763.s4|259-266|indicate|O
DDI-DrugBank.d763.s4|268-271|that|O
DDI-DrugBank.d763.s4|273-283|ondansetron|drug
DDI-DrugBank.d763.s4|285-287|may|O
DDI-DrugBank.d763.s4|289-290|be|O
DDI-DrugBank.d763.s4|292-301|associated|O
DDI-DrugBank.d763.s4|303-306|with|O
DDI-DrugBank.d763.s4|308-309|an|O
DDI-DrugBank.d763.s4|311-318|increase|O
DDI-DrugBank.d763.s4|320-321|in|O
DDI-DrugBank.d763.s4|323-329|patient|O
DDI-DrugBank.d763.s4|331-340|controlled|O
DDI-DrugBank.d763.s4|342-355|administration|O
DDI-DrugBank.d763.s4|357-358|of|O
DDI-DrugBank.d763.s4|360-371|tramadol.4,5|drug
DDI-DrugBank.d763.s4|374-385|Chemotherapy|O
DDI-DrugBank.d763.s4|386-386|:|O
DDI-DrugBank.d763.s4|388-392|Tumor|O
DDI-DrugBank.d763.s4|394-401|response|O
DDI-DrugBank.d763.s4|403-404|to|O
DDI-DrugBank.d763.s4|406-417|chemotherapy|O
DDI-DrugBank.d763.s4|419-420|in|O
DDI-DrugBank.d763.s4|422-424|the|O
DDI-DrugBank.d763.s4|426-426|P|O
DDI-DrugBank.d763.s4|428-430|388|O
DDI-DrugBank.d763.s4|432-436|mouse|O
DDI-DrugBank.d763.s4|438-445|leukemia|O
DDI-DrugBank.d763.s4|447-451|model|O
DDI-DrugBank.d763.s4|453-454|is|O
DDI-DrugBank.d763.s4|456-458|not|O
DDI-DrugBank.d763.s4|460-467|affected|O
DDI-DrugBank.d763.s4|469-470|by|O
DDI-DrugBank.d763.s4|472-482|ondansetron|drug
DDI-DrugBank.d763.s4|483-483|.|O
DDI-DrugBank.d763.s5|0-1|In|O
DDI-DrugBank.d763.s5|3-8|humans|O
DDI-DrugBank.d763.s5|9-9|,|O
DDI-DrugBank.d763.s5|11-20|carmustine|drug
DDI-DrugBank.d763.s5|21-21|,|O
DDI-DrugBank.d763.s5|23-31|etoposide|drug
DDI-DrugBank.d763.s5|32-32|,|O
DDI-DrugBank.d763.s5|34-36|and|O
DDI-DrugBank.d763.s5|38-46|cisplatin|drug
DDI-DrugBank.d763.s5|48-49|do|O
DDI-DrugBank.d763.s5|51-53|not|O
DDI-DrugBank.d763.s5|55-60|affect|O
DDI-DrugBank.d763.s5|62-64|the|O
DDI-DrugBank.d763.s5|66-81|pharmacokinetics|O
DDI-DrugBank.d763.s5|83-84|of|O
DDI-DrugBank.d763.s5|86-96|ondansetron|drug
DDI-DrugBank.d763.s5|97-97|.|O
DDI-DrugBank.d763.s6|0-1|In|O
DDI-DrugBank.d763.s6|3-3|a|O
DDI-DrugBank.d763.s6|5-13|crossover|O
DDI-DrugBank.d763.s6|15-19|study|O
DDI-DrugBank.d763.s6|21-22|in|O
DDI-DrugBank.d763.s6|24-25|76|O
DDI-DrugBank.d763.s6|27-35|pediatric|O
DDI-DrugBank.d763.s6|37-44|patients|O
DDI-DrugBank.d763.s6|45-45|,|O
DDI-DrugBank.d763.s6|47-49|I.V|O
DDI-DrugBank.d763.s6|50-50|.|O
DDI-DrugBank.d763.s7|0-10|ondansetron|drug
DDI-DrugBank.d763.s7|12-14|did|O
DDI-DrugBank.d763.s7|16-18|not|O
DDI-DrugBank.d763.s7|20-27|increase|O
DDI-DrugBank.d763.s7|29-33|blood|O
DDI-DrugBank.d763.s7|35-40|levels|O
DDI-DrugBank.d763.s7|42-43|of|O
DDI-DrugBank.d763.s7|45-53|high-dose|O
DDI-DrugBank.d763.s7|55-66|methotrexate|drug
DDI-DrugBank.d763.s7|67-67|.|O
DDI-DrugBank.d268.s0|0-3|Oils|O
DDI-DrugBank.d268.s0|5-7|may|O
DDI-DrugBank.d268.s0|9-15|enhance|O
DDI-DrugBank.d268.s0|17-26|absorption|O
DDI-DrugBank.d268.s0|27-27|.|O
DDI-DrugBank.d268.s1|0-8|Therefore|O
DDI-DrugBank.d268.s1|9-9|,|O
DDI-DrugBank.d268.s1|11-22|simultaneous|O
DDI-DrugBank.d268.s1|24-26|use|O
DDI-DrugBank.d268.s1|28-29|of|O
DDI-DrugBank.d268.s1|31-36|creams|O
DDI-DrugBank.d268.s1|37-37|,|O
DDI-DrugBank.d268.s1|39-47|ointments|O
DDI-DrugBank.d268.s1|49-50|or|O
DDI-DrugBank.d268.s1|52-55|oils|O
DDI-DrugBank.d268.s1|57-62|should|O
DDI-DrugBank.d268.s1|64-65|be|O
DDI-DrugBank.d268.s1|67-73|avoided|O
DDI-DrugBank.d268.s1|74-74|.|O
DDI-DrugBank.d570.s0|0-4|Drug/|O
DDI-DrugBank.d570.s0|6-15|Laboratory|O
DDI-DrugBank.d570.s0|17-20|Test|O
DDI-DrugBank.d570.s0|22-33|Interactions|O
DDI-DrugBank.d570.s0|35-41|Certain|O
DDI-DrugBank.d570.s0|43-51|endocrine|O
DDI-DrugBank.d570.s0|53-55|and|O
DDI-DrugBank.d570.s0|57-61|liver|O
DDI-DrugBank.d570.s0|63-70|function|O
DDI-DrugBank.d570.s0|72-76|tests|O
DDI-DrugBank.d570.s0|78-80|may|O
DDI-DrugBank.d570.s0|82-83|be|O
DDI-DrugBank.d570.s0|85-92|affected|O
DDI-DrugBank.d570.s0|94-95|by|O
DDI-DrugBank.d570.s0|97-115|estrogen-containing|group
DDI-DrugBank.d570.s0|117-120|oral|O
DDI-DrugBank.d570.s0|122-135|contraceptives|group
DDI-DrugBank.d570.s0|136-136|.|O
DDI-DrugBank.d570.s1|0-2|The|O
DDI-DrugBank.d570.s1|4-12|following|O
DDI-DrugBank.d570.s1|14-20|similar|O
DDI-DrugBank.d570.s1|22-28|changes|O
DDI-DrugBank.d570.s1|30-32|may|O
DDI-DrugBank.d570.s1|34-35|be|O
DDI-DrugBank.d570.s1|37-44|expected|O
DDI-DrugBank.d570.s1|46-49|with|O
DDI-DrugBank.d570.s1|51-56|larger|O
DDI-DrugBank.d570.s1|58-62|doses|O
DDI-DrugBank.d570.s1|64-65|of|O
DDI-DrugBank.d570.s1|67-74|estrogen|group
DDI-DrugBank.d570.s1|75-75|:|O
DDI-DrugBank.d570.s1|77-77|-|O
DDI-DrugBank.d570.s1|79-87|Increased|O
DDI-DrugBank.d570.s1|89-107|sulfobromophthalein|O
DDI-DrugBank.d570.s1|109-117|retention|O
DDI-DrugBank.d570.s2|0-0|.|O
DDI-DrugBank.d570.s3|0-0|-|O
DDI-DrugBank.d570.s3|2-10|Increased|O
DDI-DrugBank.d570.s3|12-22|prothrombin|O
DDI-DrugBank.d570.s3|24-26|and|O
DDI-DrugBank.d570.s3|28-34|factors|O
DDI-DrugBank.d570.s3|36-38|VII|O
DDI-DrugBank.d570.s3|39-39|,|O
DDI-DrugBank.d570.s3|41-44|VIII|O
DDI-DrugBank.d570.s3|45-45|,|O
DDI-DrugBank.d570.s3|47-48|IX|O
DDI-DrugBank.d570.s3|49-49|,|O
DDI-DrugBank.d570.s3|51-53|and|O
DDI-DrugBank.d570.s3|55-55|X|O
DDI-DrugBank.d570.s3|56-56|;|O
DDI-DrugBank.d570.s4|0-8|decreased|O
DDI-DrugBank.d570.s4|10-23|antithrombin 3|drug
DDI-DrugBank.d570.s4|24-24|;|O
DDI-DrugBank.d570.s5|0-8|increased|O
DDI-DrugBank.d570.s5|10-31|norepinephrine-induced|O
DDI-DrugBank.d570.s5|33-40|platelet|O
DDI-DrugBank.d570.s5|42-54|aggregability|O
DDI-DrugBank.d570.s6|0-0|.|O
DDI-DrugBank.d570.s7|0-0|-|O
DDI-DrugBank.d570.s7|2-10|Increased|O
DDI-DrugBank.d570.s7|12-26|thyroid-binding|O
DDI-DrugBank.d570.s7|28-35|globulin|O
DDI-DrugBank.d570.s7|37-37|(|O
DDI-DrugBank.d570.s7|38-40|TBG|O
DDI-DrugBank.d570.s7|41-41|)|O
DDI-DrugBank.d570.s7|43-49|leading|O
DDI-DrugBank.d570.s7|51-52|to|O
DDI-DrugBank.d570.s7|54-63|in-creased|O
DDI-DrugBank.d570.s7|65-75|circulating|O
DDI-DrugBank.d570.s7|77-81|total|O
DDI-DrugBank.d570.s7|83-89|thyroid|O
DDI-DrugBank.d570.s7|91-97|hormone|O
DDI-DrugBank.d570.s7|98-98|;|O
DDI-DrugBank.d570.s8|0-1|as|O
DDI-DrugBank.d570.s8|3-10|measured|O
DDI-DrugBank.d570.s8|12-13|by|O
DDI-DrugBank.d570.s8|15-17|PBI|O
DDI-DrugBank.d570.s8|18-18|,|O
DDI-DrugBank.d570.s8|20-21|T4|O
DDI-DrugBank.d570.s8|23-24|by|O
DDI-DrugBank.d570.s8|26-31|column|O
DDI-DrugBank.d570.s8|32-32|,|O
DDI-DrugBank.d570.s8|34-35|or|O
DDI-DrugBank.d570.s8|37-38|T4|O
DDI-DrugBank.d570.s8|40-41|by|O
DDI-DrugBank.d570.s8|43-58|radioimmunoassay|O
DDI-DrugBank.d570.s8|59-59|.|O
DDI-DrugBank.d570.s9|0-3|Free|O
DDI-DrugBank.d570.s9|5-6|T3|O
DDI-DrugBank.d570.s9|8-12|resin|O
DDI-DrugBank.d570.s9|14-19|uptake|O
DDI-DrugBank.d570.s9|21-22|is|O
DDI-DrugBank.d570.s9|24-32|decreased|O
DDI-DrugBank.d570.s9|33-33|,|O
DDI-DrugBank.d570.s9|35-44|reflecting|O
DDI-DrugBank.d570.s9|46-48|the|O
DDI-DrugBank.d570.s9|50-57|elevated|O
DDI-DrugBank.d570.s9|59-61|TBG|O
DDI-DrugBank.d570.s9|62-62|;|O
DDI-DrugBank.d570.s10|0-3|free|O
DDI-DrugBank.d570.s10|5-6|T4|O
DDI-DrugBank.d570.s10|8-20|concentration|O
DDI-DrugBank.d570.s10|22-23|is|O
DDI-DrugBank.d570.s10|25-33|unaltered|O
DDI-DrugBank.d570.s11|0-0|.|O
DDI-DrugBank.d570.s12|0-0|-|O
DDI-DrugBank.d570.s12|2-9|Impaired|O
DDI-DrugBank.d570.s12|11-17|glucose|O
DDI-DrugBank.d570.s12|19-27|tolerance|O
DDI-DrugBank.d570.s13|0-0|.|O
DDI-DrugBank.d570.s14|0-0|-|O
DDI-DrugBank.d570.s14|2-10|Decreased|O
DDI-DrugBank.d570.s14|12-23|pregnanediol|O
DDI-DrugBank.d570.s14|25-33|excretion|O
DDI-DrugBank.d570.s15|0-0|.|O
DDI-DrugBank.d570.s16|0-0|-|O
DDI-DrugBank.d570.s16|2-8|Reduced|O
DDI-DrugBank.d570.s16|10-17|response|O
DDI-DrugBank.d570.s16|19-20|to|O
DDI-DrugBank.d570.s16|22-31|metyrapone|O
DDI-DrugBank.d570.s16|33-36|test|O
DDI-DrugBank.d570.s17|0-0|.|O
DDI-DrugBank.d570.s18|0-0|-|O
DDI-DrugBank.d570.s18|2-8|Reduced|O
DDI-DrugBank.d570.s18|10-14|serum|O
DDI-DrugBank.d570.s18|16-21|folate|O
DDI-DrugBank.d570.s18|23-35|concentration|O
DDI-DrugBank.d570.s19|0-0|.|O
DDI-DrugBank.d570.s20|0-0|-|O
DDI-DrugBank.d570.s20|2-10|Increased|O
DDI-DrugBank.d570.s20|12-16|serum|O
DDI-DrugBank.d570.s20|18-29|triglyceride|O
DDI-DrugBank.d570.s20|31-33|and|O
DDI-DrugBank.d570.s20|35-46|phospholipid|O
DDI-DrugBank.d570.s20|48-60|concentration|O
DDI-DrugBank.d570.s20|61-61|.|O
DDI-DrugBank.d561.s0|0-8|Diuretics|group
DDI-DrugBank.d561.s0|9-9|:|O
DDI-DrugBank.d561.s0|11-18|Patients|O
DDI-DrugBank.d561.s0|20-21|on|O
DDI-DrugBank.d561.s0|23-31|diuretics|group
DDI-DrugBank.d561.s0|32-32|,|O
DDI-DrugBank.d561.s0|34-43|especially|O
DDI-DrugBank.d561.s0|45-49|those|O
DDI-DrugBank.d561.s0|51-52|in|O
DDI-DrugBank.d561.s0|54-57|whom|O
DDI-DrugBank.d561.s0|59-66|diuretic|O
DDI-DrugBank.d561.s0|68-74|therapy|O
DDI-DrugBank.d561.s0|76-78|was|O
DDI-DrugBank.d561.s0|80-87|recently|O
DDI-DrugBank.d561.s0|89-98|instituted|O
DDI-DrugBank.d561.s0|99-99|,|O
DDI-DrugBank.d561.s0|101-103|may|O
DDI-DrugBank.d561.s0|105-116|occasionally|O
DDI-DrugBank.d561.s0|118-127|experience|O
DDI-DrugBank.d561.s0|129-130|an|O
DDI-DrugBank.d561.s0|132-140|excessive|O
DDI-DrugBank.d561.s0|142-150|reduction|O
DDI-DrugBank.d561.s0|152-153|of|O
DDI-DrugBank.d561.s0|155-159|blood|O
DDI-DrugBank.d561.s0|161-168|pressure|O
DDI-DrugBank.d561.s0|170-174|after|O
DDI-DrugBank.d561.s0|176-185|initiation|O
DDI-DrugBank.d561.s0|187-188|of|O
DDI-DrugBank.d561.s0|190-196|therapy|O
DDI-DrugBank.d561.s0|198-201|with|O
DDI-DrugBank.d561.s0|203-210|Lotensin|brand
DDI-DrugBank.d561.s0|211-211|.|O
DDI-DrugBank.d561.s1|0-2|The|O
DDI-DrugBank.d561.s1|4-14|possibility|O
DDI-DrugBank.d561.s1|16-17|of|O
DDI-DrugBank.d561.s1|19-29|hypotensive|O
DDI-DrugBank.d561.s1|31-37|effects|O
DDI-DrugBank.d561.s1|39-42|with|O
DDI-DrugBank.d561.s1|44-51|Lotensin|brand
DDI-DrugBank.d561.s1|53-55|can|O
DDI-DrugBank.d561.s1|57-58|be|O
DDI-DrugBank.d561.s1|60-68|minimized|O
DDI-DrugBank.d561.s1|70-71|by|O
DDI-DrugBank.d561.s1|73-78|either|O
DDI-DrugBank.d561.s1|80-92|discontinuing|O
DDI-DrugBank.d561.s1|94-96|the|O
DDI-DrugBank.d561.s1|98-105|diuretic|group
DDI-DrugBank.d561.s1|107-108|or|O
DDI-DrugBank.d561.s1|110-119|increasing|O
DDI-DrugBank.d561.s1|121-123|the|O
DDI-DrugBank.d561.s1|125-128|salt|O
DDI-DrugBank.d561.s1|130-135|intake|O
DDI-DrugBank.d561.s1|137-141|prior|O
DDI-DrugBank.d561.s1|143-144|to|O
DDI-DrugBank.d561.s1|146-155|initiation|O
DDI-DrugBank.d561.s1|157-158|of|O
DDI-DrugBank.d561.s1|160-168|treatment|O
DDI-DrugBank.d561.s1|170-173|with|O
DDI-DrugBank.d561.s1|175-182|Lotensin|brand
DDI-DrugBank.d561.s1|183-183|.|O
DDI-DrugBank.d561.s2|0-1|If|O
DDI-DrugBank.d561.s2|3-6|this|O
DDI-DrugBank.d561.s2|8-9|is|O
DDI-DrugBank.d561.s2|11-13|not|O
DDI-DrugBank.d561.s2|15-22|possible|O
DDI-DrugBank.d561.s2|23-23|,|O
DDI-DrugBank.d561.s2|25-27|the|O
DDI-DrugBank.d561.s2|29-36|starting|O
DDI-DrugBank.d561.s2|38-41|dose|O
DDI-DrugBank.d561.s2|43-48|should|O
DDI-DrugBank.d561.s2|50-51|be|O
DDI-DrugBank.d561.s2|53-59|reduced|O
DDI-DrugBank.d561.s2|60-60|.|O
DDI-DrugBank.d561.s3|0-8|Potassium|drug
DDI-DrugBank.d561.s3|10-20|Supplements|O
DDI-DrugBank.d561.s3|22-24|and|O
DDI-DrugBank.d561.s3|26-52|Potassium-Sparing Diuretics|group
DDI-DrugBank.d561.s3|54-61|Lotensin|O
DDI-DrugBank.d561.s3|63-65|can|O
DDI-DrugBank.d561.s3|67-75|attenuate|O
DDI-DrugBank.d561.s3|77-85|potassium|O
DDI-DrugBank.d561.s3|87-90|loss|O
DDI-DrugBank.d561.s3|92-97|caused|O
DDI-DrugBank.d561.s3|99-100|by|O
DDI-DrugBank.d561.s3|102-119|thiazide diuretics|group
DDI-DrugBank.d561.s3|120-120|.|O
DDI-DrugBank.d561.s4|0-26|Potassium-sparing diuretics|group
DDI-DrugBank.d561.s4|28-28|(|O
DDI-DrugBank.d561.s4|29-42|spironolactone|drug
DDI-DrugBank.d561.s4|43-43|,|O
DDI-DrugBank.d561.s4|45-53|amiloride|drug
DDI-DrugBank.d561.s4|54-54|,|O
DDI-DrugBank.d561.s4|56-66|triamterene|drug
DDI-DrugBank.d561.s4|67-67|,|O
DDI-DrugBank.d561.s4|69-71|and|O
DDI-DrugBank.d561.s4|73-78|others|O
DDI-DrugBank.d561.s4|79-79|)|O
DDI-DrugBank.d561.s4|81-82|or|O
DDI-DrugBank.d561.s4|84-92|potassium|drug
DDI-DrugBank.d561.s4|94-104|supplements|O
DDI-DrugBank.d561.s4|106-108|can|O
DDI-DrugBank.d561.s4|110-117|increase|O
DDI-DrugBank.d561.s4|119-121|the|O
DDI-DrugBank.d561.s4|123-126|risk|O
DDI-DrugBank.d561.s4|128-129|of|O
DDI-DrugBank.d561.s4|131-142|hyperkalemia|O
DDI-DrugBank.d561.s4|143-143|.|O
DDI-DrugBank.d561.s5|0-8|Therefore|O
DDI-DrugBank.d561.s5|9-9|,|O
DDI-DrugBank.d561.s5|11-12|if|O
DDI-DrugBank.d561.s5|14-24|concomitant|O
DDI-DrugBank.d561.s5|26-28|use|O
DDI-DrugBank.d561.s5|30-31|of|O
DDI-DrugBank.d561.s5|33-36|such|O
DDI-DrugBank.d561.s5|38-43|agents|O
DDI-DrugBank.d561.s5|45-46|is|O
DDI-DrugBank.d561.s5|48-56|indicated|O
DDI-DrugBank.d561.s5|57-57|,|O
DDI-DrugBank.d561.s5|59-62|they|O
DDI-DrugBank.d561.s5|64-69|should|O
DDI-DrugBank.d561.s5|71-72|be|O
DDI-DrugBank.d561.s5|74-78|given|O
DDI-DrugBank.d561.s5|80-83|with|O
DDI-DrugBank.d561.s5|85-91|caution|O
DDI-DrugBank.d561.s5|92-92|,|O
DDI-DrugBank.d561.s5|94-96|and|O
DDI-DrugBank.d561.s5|98-100|the|O
DDI-DrugBank.d561.s5|102-108|patient|O
DDI-DrugBank.d561.s5|109-110|'s|O
DDI-DrugBank.d561.s5|112-116|serum|O
DDI-DrugBank.d561.s5|118-126|potassium|O
DDI-DrugBank.d561.s5|128-133|should|O
DDI-DrugBank.d561.s5|135-136|be|O
DDI-DrugBank.d561.s5|138-146|monitored|O
DDI-DrugBank.d561.s5|148-157|frequently|O
DDI-DrugBank.d561.s5|158-158|.|O
DDI-DrugBank.d561.s6|0-3|Oral|O
DDI-DrugBank.d561.s6|5-18|Anticoagulants|group
DDI-DrugBank.d561.s6|20-30|Interaction|O
DDI-DrugBank.d561.s6|32-38|studies|O
DDI-DrugBank.d561.s6|40-43|with|O
DDI-DrugBank.d561.s6|45-52|warfarin|drug
DDI-DrugBank.d561.s6|54-56|and|O
DDI-DrugBank.d561.s6|58-70|acenocoumarol|drug
DDI-DrugBank.d561.s6|72-77|failed|O
DDI-DrugBank.d561.s6|79-80|to|O
DDI-DrugBank.d561.s6|82-89|identify|O
DDI-DrugBank.d561.s6|91-93|any|O
DDI-DrugBank.d561.s6|95-104|clinically|O
DDI-DrugBank.d561.s6|106-114|important|O
DDI-DrugBank.d561.s6|116-122|effects|O
DDI-DrugBank.d561.s6|124-125|on|O
DDI-DrugBank.d561.s6|127-129|the|O
DDI-DrugBank.d561.s6|131-135|serum|O
DDI-DrugBank.d561.s6|137-150|concentrations|O
DDI-DrugBank.d561.s6|152-153|or|O
DDI-DrugBank.d561.s6|155-162|clinical|O
DDI-DrugBank.d561.s6|164-170|effects|O
DDI-DrugBank.d561.s6|172-173|of|O
DDI-DrugBank.d561.s6|175-179|these|O
DDI-DrugBank.d561.s6|181-194|anticoagulants|group
DDI-DrugBank.d561.s6|195-195|.|O
DDI-DrugBank.d561.s7|0-6|Lithium|drug
DDI-DrugBank.d561.s7|7-7|:|O
DDI-DrugBank.d561.s7|9-17|Increased|O
DDI-DrugBank.d561.s7|19-23|serum|O
DDI-DrugBank.d561.s7|25-31|lithium|drug
DDI-DrugBank.d561.s7|33-38|levels|O
DDI-DrugBank.d561.s7|40-42|and|O
DDI-DrugBank.d561.s7|44-51|symptoms|O
DDI-DrugBank.d561.s7|53-54|of|O
DDI-DrugBank.d561.s7|56-62|lithium|drug
DDI-DrugBank.d561.s7|64-71|toxicity|O
DDI-DrugBank.d561.s7|73-76|have|O
DDI-DrugBank.d561.s7|78-81|been|O
DDI-DrugBank.d561.s7|83-90|reported|O
DDI-DrugBank.d561.s7|92-93|in|O
DDI-DrugBank.d561.s7|95-102|patients|O
DDI-DrugBank.d561.s7|104-112|receiving|O
DDI-DrugBank.d561.s7|114-127|ACE inhibitors|group
DDI-DrugBank.d561.s7|129-134|during|O
DDI-DrugBank.d561.s7|136-142|therapy|O
DDI-DrugBank.d561.s7|144-147|with|O
DDI-DrugBank.d561.s7|149-155|lithium|drug
DDI-DrugBank.d561.s7|156-156|.|O
DDI-DrugBank.d561.s8|0-4|These|O
DDI-DrugBank.d561.s8|6-10|drugs|O
DDI-DrugBank.d561.s8|12-17|should|O
DDI-DrugBank.d561.s8|19-20|be|O
DDI-DrugBank.d561.s8|22-35|coadministered|O
DDI-DrugBank.d561.s8|37-40|with|O
DDI-DrugBank.d561.s8|42-48|caution|O
DDI-DrugBank.d561.s8|49-49|,|O
DDI-DrugBank.d561.s8|51-53|and|O
DDI-DrugBank.d561.s8|55-62|frequent|O
DDI-DrugBank.d561.s8|64-73|monitoring|O
DDI-DrugBank.d561.s8|75-76|of|O
DDI-DrugBank.d561.s8|78-82|serum|O
DDI-DrugBank.d561.s8|84-90|lithium|drug
DDI-DrugBank.d561.s8|92-97|levels|O
DDI-DrugBank.d561.s8|99-100|is|O
DDI-DrugBank.d561.s8|102-112|recommended|O
DDI-DrugBank.d561.s8|113-113|.|O
DDI-DrugBank.d561.s9|0-1|If|O
DDI-DrugBank.d561.s9|3-3|a|O
DDI-DrugBank.d561.s9|5-12|diuretic|group
DDI-DrugBank.d561.s9|14-15|is|O
DDI-DrugBank.d561.s9|17-20|also|O
DDI-DrugBank.d561.s9|22-25|used|O
DDI-DrugBank.d561.s9|26-26|,|O
DDI-DrugBank.d561.s9|28-30|the|O
DDI-DrugBank.d561.s9|32-35|risk|O
DDI-DrugBank.d561.s9|37-38|of|O
DDI-DrugBank.d561.s9|40-46|lithium|drug
DDI-DrugBank.d561.s9|48-55|toxicity|O
DDI-DrugBank.d561.s9|57-59|may|O
DDI-DrugBank.d561.s9|61-62|be|O
DDI-DrugBank.d561.s9|64-72|increased|O
DDI-DrugBank.d561.s9|73-73|.|O
DDI-DrugBank.d561.s10|0-4|Other|O
DDI-DrugBank.d561.s10|6-7|No|O
DDI-DrugBank.d561.s10|9-18|clinically|O
DDI-DrugBank.d561.s10|20-28|important|O
DDI-DrugBank.d561.s10|30-44|pharmacokinetic|O
DDI-DrugBank.d561.s10|46-57|interactions|O
DDI-DrugBank.d561.s10|59-66|occurred|O
DDI-DrugBank.d561.s10|68-71|when|O
DDI-DrugBank.d561.s10|73-80|Lotensin|brand
DDI-DrugBank.d561.s10|82-84|was|O
DDI-DrugBank.d561.s10|86-97|administered|O
DDI-DrugBank.d561.s10|99-111|concomitantly|O
DDI-DrugBank.d561.s10|113-116|with|O
DDI-DrugBank.d561.s10|118-136|hydrochlorothiazide|drug
DDI-DrugBank.d561.s10|137-137|,|O
DDI-DrugBank.d561.s10|139-152|chlorthalidone|drug
DDI-DrugBank.d561.s10|153-153|,|O
DDI-DrugBank.d561.s10|155-164|furosemide|drug
DDI-DrugBank.d561.s10|165-165|,|O
DDI-DrugBank.d561.s10|167-173|digoxin|drug
DDI-DrugBank.d561.s10|174-174|,|O
DDI-DrugBank.d561.s10|176-186|propranolol|drug
DDI-DrugBank.d561.s10|187-187|,|O
DDI-DrugBank.d561.s10|189-196|atenolol|drug
DDI-DrugBank.d561.s10|197-197|,|O
DDI-DrugBank.d561.s10|199-206|naproxen|drug
DDI-DrugBank.d561.s10|207-207|,|O
DDI-DrugBank.d561.s10|209-210|or|O
DDI-DrugBank.d561.s10|212-221|cimetidine|drug
DDI-DrugBank.d561.s10|222-222|.|O
DDI-DrugBank.d561.s11|0-7|Lotensin|brand
DDI-DrugBank.d561.s11|9-11|has|O
DDI-DrugBank.d561.s11|13-16|been|O
DDI-DrugBank.d561.s11|18-21|used|O
DDI-DrugBank.d561.s11|23-35|concomitantly|O
DDI-DrugBank.d561.s11|37-40|with|O
DDI-DrugBank.d561.s11|42-72|beta-adrenergic-blocking agents|group
DDI-DrugBank.d561.s11|73-73|,|O
DDI-DrugBank.d561.s11|75-105|calcium-channel-blocking agents|group
DDI-DrugBank.d561.s11|106-106|,|O
DDI-DrugBank.d561.s11|108-116|diuretics|group
DDI-DrugBank.d561.s11|117-117|,|O
DDI-DrugBank.d561.s11|119-125|digoxin|drug
DDI-DrugBank.d561.s11|126-126|,|O
DDI-DrugBank.d561.s11|128-130|and|O
DDI-DrugBank.d561.s11|132-142|hydralazine|drug
DDI-DrugBank.d561.s11|143-143|,|O
DDI-DrugBank.d561.s11|145-151|without|O
DDI-DrugBank.d561.s11|153-160|evidence|O
DDI-DrugBank.d561.s11|162-163|of|O
DDI-DrugBank.d561.s11|165-174|clinically|O
DDI-DrugBank.d561.s11|176-184|important|O
DDI-DrugBank.d561.s11|186-192|adverse|O
DDI-DrugBank.d561.s11|194-205|interactions|O
DDI-DrugBank.d561.s11|206-206|.|O
DDI-DrugBank.d561.s12|0-9|Benazepril|drug
DDI-DrugBank.d561.s12|10-10|,|O
DDI-DrugBank.d561.s12|12-15|like|O
DDI-DrugBank.d561.s12|17-21|other|O
DDI-DrugBank.d561.s12|23-36|ACE inhibitors|group
DDI-DrugBank.d561.s12|37-37|,|O
DDI-DrugBank.d561.s12|39-41|has|O
DDI-DrugBank.d561.s12|43-45|had|O
DDI-DrugBank.d561.s12|47-50|less|O
DDI-DrugBank.d561.s12|52-55|than|O
DDI-DrugBank.d561.s12|57-64|additive|O
DDI-DrugBank.d561.s12|66-72|effects|O
DDI-DrugBank.d561.s12|74-77|with|O
DDI-DrugBank.d561.s12|79-102|beta-adrenergic blockers|group
DDI-DrugBank.d561.s12|103-103|,|O
DDI-DrugBank.d561.s12|105-114|presumably|O
DDI-DrugBank.d561.s12|116-122|because|O
DDI-DrugBank.d561.s12|124-127|both|O
DDI-DrugBank.d561.s12|129-133|drugs|O
DDI-DrugBank.d561.s12|135-139|lower|O
DDI-DrugBank.d561.s12|141-145|blood|O
DDI-DrugBank.d561.s12|147-154|pressure|O
DDI-DrugBank.d561.s12|156-157|by|O
DDI-DrugBank.d561.s12|159-168|inhibiting|O
DDI-DrugBank.d561.s12|170-174|parts|O
DDI-DrugBank.d561.s12|176-177|of|O
DDI-DrugBank.d561.s12|179-181|the|O
DDI-DrugBank.d561.s12|183-199|renin-angiotensin|O
DDI-DrugBank.d561.s12|201-206|system|O
DDI-DrugBank.d561.s13|0-0|.|O
DDI-DrugBank.d210.s0|0-13|ACE inhibitors|group
DDI-DrugBank.d210.s0|14-14|:|O
DDI-DrugBank.d210.s0|16-22|Reports|O
DDI-DrugBank.d210.s0|24-30|suggest|O
DDI-DrugBank.d210.s0|32-35|that|O
DDI-DrugBank.d210.s0|37-42|NSAIDs|group
DDI-DrugBank.d210.s0|44-46|may|O
DDI-DrugBank.d210.s0|48-55|diminish|O
DDI-DrugBank.d210.s0|57-59|the|O
DDI-DrugBank.d210.s0|61-76|antihypertensive|O
DDI-DrugBank.d210.s0|78-83|effect|O
DDI-DrugBank.d210.s0|85-86|of|O
DDI-DrugBank.d210.s0|88-133|Angiotensin Converting Enzyme ( ACE ) inhibitors|group
DDI-DrugBank.d210.s0|134-134|.|O
DDI-DrugBank.d210.s1|0-1|In|O
DDI-DrugBank.d210.s1|3-10|patients|O
DDI-DrugBank.d210.s1|12-15|with|O
DDI-DrugBank.d210.s1|17-20|mild|O
DDI-DrugBank.d210.s1|22-23|to|O
DDI-DrugBank.d210.s1|25-32|moderate|O
DDI-DrugBank.d210.s1|34-45|hypertension|O
DDI-DrugBank.d210.s1|46-46|,|O
DDI-DrugBank.d210.s1|48-61|administration|O
DDI-DrugBank.d210.s1|63-64|of|O
DDI-DrugBank.d210.s1|66-67|25|O
DDI-DrugBank.d210.s1|69-70|mg|O
DDI-DrugBank.d210.s1|72-76|daily|O
DDI-DrugBank.d210.s1|78-79|of|O
DDI-DrugBank.d210.s1|81-85|VIOXX|brand
DDI-DrugBank.d210.s1|87-90|with|O
DDI-DrugBank.d210.s1|92-94|the|O
DDI-DrugBank.d210.s1|96-108|ACE inhibitor|group
DDI-DrugBank.d210.s1|96-108|ACE inhibitor|group
DDI-DrugBank.d210.s1|120-120|,|O
DDI-DrugBank.d210.s1|122-123|10|O
DDI-DrugBank.d210.s1|125-126|to|O
DDI-DrugBank.d210.s1|128-129|40|O
DDI-DrugBank.d210.s1|131-132|mg|O
DDI-DrugBank.d210.s1|134-136|for|O
DDI-DrugBank.d210.s1|138-138|4|O
DDI-DrugBank.d210.s1|140-144|weeks|O
DDI-DrugBank.d210.s1|145-145|,|O
DDI-DrugBank.d210.s1|147-149|was|O
DDI-DrugBank.d210.s1|151-160|associated|O
DDI-DrugBank.d210.s1|162-165|with|O
DDI-DrugBank.d210.s1|167-168|an|O
DDI-DrugBank.d210.s1|170-176|average|O
DDI-DrugBank.d210.s1|178-185|increase|O
DDI-DrugBank.d210.s1|187-188|in|O
DDI-DrugBank.d210.s1|190-193|mean|O
DDI-DrugBank.d210.s1|195-202|arterial|O
DDI-DrugBank.d210.s1|204-211|pressure|O
DDI-DrugBank.d210.s1|213-214|of|O
DDI-DrugBank.d210.s1|216-220|about|O
DDI-DrugBank.d210.s1|222-222|3|O
DDI-DrugBank.d210.s1|224-225|mm|O
DDI-DrugBank.d210.s1|227-228|Hg|O
DDI-DrugBank.d210.s1|230-237|compared|O
DDI-DrugBank.d210.s1|239-240|to|O
DDI-DrugBank.d210.s1|242-254|ACE inhibitor|group
DDI-DrugBank.d210.s1|256-260|alone|O
DDI-DrugBank.d210.s1|261-261|.|O
DDI-DrugBank.d210.s2|0-3|This|O
DDI-DrugBank.d210.s2|5-15|interaction|O
DDI-DrugBank.d210.s2|17-22|should|O
DDI-DrugBank.d210.s2|24-25|be|O
DDI-DrugBank.d210.s2|27-31|given|O
DDI-DrugBank.d210.s2|33-45|consideration|O
DDI-DrugBank.d210.s2|47-48|in|O
DDI-DrugBank.d210.s2|50-57|patients|O
DDI-DrugBank.d210.s2|59-64|taking|O
DDI-DrugBank.d210.s2|66-70|VIOXX|brand
DDI-DrugBank.d210.s2|72-84|concomitantly|O
DDI-DrugBank.d210.s2|86-89|with|O
DDI-DrugBank.d210.s2|91-104|ACE inhibitors|group
DDI-DrugBank.d210.s2|105-105|.|O
DDI-DrugBank.d210.s3|0-6|Aspirin|brand
DDI-DrugBank.d210.s3|7-7|:|O
DDI-DrugBank.d210.s3|9-19|Concomitant|O
DDI-DrugBank.d210.s3|21-34|administration|O
DDI-DrugBank.d210.s3|36-37|of|O
DDI-DrugBank.d210.s3|39-46|low-dose|O
DDI-DrugBank.d210.s3|48-54|aspirin|brand
DDI-DrugBank.d210.s3|56-59|with|O
DDI-DrugBank.d210.s3|61-65|VIOXX|brand
DDI-DrugBank.d210.s3|67-69|may|O
DDI-DrugBank.d210.s3|71-76|result|O
DDI-DrugBank.d210.s3|78-79|in|O
DDI-DrugBank.d210.s3|81-82|an|O
DDI-DrugBank.d210.s3|84-92|increased|O
DDI-DrugBank.d210.s3|94-97|rate|O
DDI-DrugBank.d210.s3|99-100|of|O
DDI-DrugBank.d210.s3|102-103|GI|O
DDI-DrugBank.d210.s3|105-114|ulceration|O
DDI-DrugBank.d210.s3|116-117|or|O
DDI-DrugBank.d210.s3|119-123|other|O
DDI-DrugBank.d210.s3|125-137|complications|O
DDI-DrugBank.d210.s3|138-138|,|O
DDI-DrugBank.d210.s3|140-147|compared|O
DDI-DrugBank.d210.s3|149-150|to|O
DDI-DrugBank.d210.s3|152-154|use|O
DDI-DrugBank.d210.s3|156-157|of|O
DDI-DrugBank.d210.s3|159-163|VIOXX|brand
DDI-DrugBank.d210.s3|165-169|alone|O
DDI-DrugBank.d210.s3|170-170|.|O
DDI-DrugBank.d210.s4|0-1|In|O
DDI-DrugBank.d210.s4|3-3|a|O
DDI-DrugBank.d210.s4|5-11|12-week|O
DDI-DrugBank.d210.s4|13-21|endoscopy|O
DDI-DrugBank.d210.s4|23-27|study|O
DDI-DrugBank.d210.s4|29-37|conducted|O
DDI-DrugBank.d210.s4|39-40|in|O
DDI-DrugBank.d210.s4|42-43|OA|O
DDI-DrugBank.d210.s4|45-52|patients|O
DDI-DrugBank.d210.s4|54-58|there|O
DDI-DrugBank.d210.s4|60-62|was|O
DDI-DrugBank.d210.s4|64-65|no|O
DDI-DrugBank.d210.s4|67-76|difference|O
DDI-DrugBank.d210.s4|78-79|in|O
DDI-DrugBank.d210.s4|81-83|the|O
DDI-DrugBank.d210.s4|85-94|cumulative|O
DDI-DrugBank.d210.s4|96-104|incidence|O
DDI-DrugBank.d210.s4|106-107|of|O
DDI-DrugBank.d210.s4|109-118|endoscopic|O
DDI-DrugBank.d210.s4|120-133|gastroduodenal|O
DDI-DrugBank.d210.s4|135-140|ulcers|O
DDI-DrugBank.d210.s4|142-143|in|O
DDI-DrugBank.d210.s4|145-152|patients|O
DDI-DrugBank.d210.s4|154-159|taking|O
DDI-DrugBank.d210.s4|161-168|low-dose|O
DDI-DrugBank.d210.s4|170-170|(|O
DDI-DrugBank.d210.s4|171-172|81|O
DDI-DrugBank.d210.s4|174-175|mg|O
DDI-DrugBank.d210.s4|176-176|)|O
DDI-DrugBank.d210.s4|178-184|enteric|O
DDI-DrugBank.d210.s4|186-191|coated|O
DDI-DrugBank.d210.s4|193-199|aspirin|brand
DDI-DrugBank.d210.s4|201-204|plus|O
DDI-DrugBank.d210.s4|206-210|VIOXX|brand
DDI-DrugBank.d210.s4|212-213|25|O
DDI-DrugBank.d210.s4|215-216|mg|O
DDI-DrugBank.d210.s4|218-222|daily|O
DDI-DrugBank.d210.s4|223-223|,|O
DDI-DrugBank.d210.s4|225-226|as|O
DDI-DrugBank.d210.s4|228-235|compared|O
DDI-DrugBank.d210.s4|237-238|to|O
DDI-DrugBank.d210.s4|240-244|those|O
DDI-DrugBank.d210.s4|246-251|taking|O
DDI-DrugBank.d210.s4|253-261|ibuprofen|drug
DDI-DrugBank.d210.s4|263-266|2400|O
DDI-DrugBank.d210.s4|268-269|mg|O
DDI-DrugBank.d210.s4|271-275|daily|O
DDI-DrugBank.d210.s4|277-281|alone|O
DDI-DrugBank.d210.s4|282-282|.|O
DDI-DrugBank.d210.s5|0-7|Patients|O
DDI-DrugBank.d210.s5|9-14|taking|O
DDI-DrugBank.d210.s5|16-23|low-dose|O
DDI-DrugBank.d210.s5|25-31|aspirin|brand
DDI-DrugBank.d210.s5|33-36|plus|O
DDI-DrugBank.d210.s5|38-46|ibuprofen|drug
DDI-DrugBank.d210.s5|48-51|were|O
DDI-DrugBank.d210.s5|53-55|not|O
DDI-DrugBank.d210.s5|57-63|studied|O
DDI-DrugBank.d210.s5|64-64|.|O
DDI-DrugBank.d210.s6|0-1|At|O
DDI-DrugBank.d210.s6|3-8|steady|O
DDI-DrugBank.d210.s6|10-14|state|O
DDI-DrugBank.d210.s6|15-15|,|O
DDI-DrugBank.d210.s6|17-21|VIOXX|brand
DDI-DrugBank.d210.s6|23-24|50|O
DDI-DrugBank.d210.s6|26-27|mg|O
DDI-DrugBank.d210.s6|29-32|once|O
DDI-DrugBank.d210.s6|34-38|daily|O
DDI-DrugBank.d210.s6|40-42|had|O
DDI-DrugBank.d210.s6|44-45|no|O
DDI-DrugBank.d210.s6|47-52|effect|O
DDI-DrugBank.d210.s6|54-55|on|O
DDI-DrugBank.d210.s6|57-59|the|O
DDI-DrugBank.d210.s6|61-73|anti-platelet|O
DDI-DrugBank.d210.s6|75-82|activity|O
DDI-DrugBank.d210.s6|84-85|of|O
DDI-DrugBank.d210.s6|87-94|low-dose|O
DDI-DrugBank.d210.s6|96-96|(|O
DDI-DrugBank.d210.s6|97-98|81|O
DDI-DrugBank.d210.s6|100-101|mg|O
DDI-DrugBank.d210.s6|103-106|once|O
DDI-DrugBank.d210.s6|108-112|daily|O
DDI-DrugBank.d210.s6|113-113|)|O
DDI-DrugBank.d210.s6|115-121|aspirin|brand
DDI-DrugBank.d210.s6|122-122|,|O
DDI-DrugBank.d210.s6|124-125|as|O
DDI-DrugBank.d210.s6|127-134|assessed|O
DDI-DrugBank.d210.s6|136-137|by|O
DDI-DrugBank.d210.s6|139-140|ex|O
DDI-DrugBank.d210.s6|142-145|vivo|O
DDI-DrugBank.d210.s6|147-154|platelet|O
DDI-DrugBank.d210.s6|156-166|aggregation|O
DDI-DrugBank.d210.s6|168-170|and|O
DDI-DrugBank.d210.s6|172-176|serum|O
DDI-DrugBank.d210.s6|178-181|TXB2|O
DDI-DrugBank.d210.s6|183-192|generation|O
DDI-DrugBank.d210.s6|194-195|in|O
DDI-DrugBank.d210.s6|197-204|clotting|O
DDI-DrugBank.d210.s6|206-210|blood|O
DDI-DrugBank.d210.s6|211-211|.|O
DDI-DrugBank.d210.s7|0-6|Because|O
DDI-DrugBank.d210.s7|8-9|of|O
DDI-DrugBank.d210.s7|11-13|its|O
DDI-DrugBank.d210.s7|15-18|lack|O
DDI-DrugBank.d210.s7|20-21|of|O
DDI-DrugBank.d210.s7|23-30|platelet|O
DDI-DrugBank.d210.s7|32-38|effects|O
DDI-DrugBank.d210.s7|39-39|,|O
DDI-DrugBank.d210.s7|41-45|VIOXX|brand
DDI-DrugBank.d210.s7|47-48|is|O
DDI-DrugBank.d210.s7|50-52|not|O
DDI-DrugBank.d210.s7|54-54|a|O
DDI-DrugBank.d210.s7|56-65|substitute|O
DDI-DrugBank.d210.s7|67-69|for|O
DDI-DrugBank.d210.s7|71-77|aspirin|brand
DDI-DrugBank.d210.s7|79-81|for|O
DDI-DrugBank.d210.s7|83-96|cardiovascular|O
DDI-DrugBank.d210.s7|98-108|prophylaxis|O
DDI-DrugBank.d210.s7|109-109|.|O
DDI-DrugBank.d210.s8|0-8|Therefore|O
DDI-DrugBank.d210.s8|9-9|,|O
DDI-DrugBank.d210.s8|11-12|in|O
DDI-DrugBank.d210.s8|14-21|patients|O
DDI-DrugBank.d210.s8|23-28|taking|O
DDI-DrugBank.d210.s8|30-34|VIOXX|brand
DDI-DrugBank.d210.s8|35-35|,|O
DDI-DrugBank.d210.s8|37-48|antiplatelet|O
DDI-DrugBank.d210.s8|50-58|therapies|O
DDI-DrugBank.d210.s8|60-65|should|O
DDI-DrugBank.d210.s8|67-69|not|O
DDI-DrugBank.d210.s8|71-72|be|O
DDI-DrugBank.d210.s8|74-85|discontinued|O
DDI-DrugBank.d210.s8|87-89|and|O
DDI-DrugBank.d210.s8|91-96|should|O
DDI-DrugBank.d210.s8|98-99|be|O
DDI-DrugBank.d210.s8|101-110|considered|O
DDI-DrugBank.d210.s8|112-113|in|O
DDI-DrugBank.d210.s8|115-122|patients|O
DDI-DrugBank.d210.s8|124-127|with|O
DDI-DrugBank.d210.s8|129-130|an|O
DDI-DrugBank.d210.s8|132-141|indication|O
DDI-DrugBank.d210.s8|143-145|for|O
DDI-DrugBank.d210.s8|147-160|cardiovascular|O
DDI-DrugBank.d210.s8|162-172|prophylaxis|O
DDI-DrugBank.d210.s8|173-173|.|O
DDI-DrugBank.d210.s9|0-10|Prospective|O
DDI-DrugBank.d210.s9|11-11|,|O
DDI-DrugBank.d210.s9|13-21|long-term|O
DDI-DrugBank.d210.s9|23-29|studies|O
DDI-DrugBank.d210.s9|31-32|on|O
DDI-DrugBank.d210.s9|34-44|concomitant|O
DDI-DrugBank.d210.s9|46-59|administration|O
DDI-DrugBank.d210.s9|61-62|of|O
DDI-DrugBank.d210.s9|64-68|VIOXX|brand
DDI-DrugBank.d210.s9|70-72|and|O
DDI-DrugBank.d210.s9|74-80|aspirin|brand
DDI-DrugBank.d210.s9|82-85|have|O
DDI-DrugBank.d210.s9|87-89|not|O
DDI-DrugBank.d210.s9|91-94|been|O
DDI-DrugBank.d210.s9|96-104|conducted|O
DDI-DrugBank.d210.s9|105-105|.|O
DDI-DrugBank.d210.s10|0-9|Cimetidine|drug
DDI-DrugBank.d210.s10|10-10|:|O
DDI-DrugBank.d210.s10|12-28|Co-administration|O
DDI-DrugBank.d210.s10|30-33|with|O
DDI-DrugBank.d210.s10|35-38|high|O
DDI-DrugBank.d210.s10|40-44|doses|O
DDI-DrugBank.d210.s10|46-47|of|O
DDI-DrugBank.d210.s10|49-58|cimetidine|drug
DDI-DrugBank.d210.s10|60-60|[|O
DDI-DrugBank.d210.s10|61-63|800|O
DDI-DrugBank.d210.s10|65-66|mg|O
DDI-DrugBank.d210.s10|68-72|twice|O
DDI-DrugBank.d210.s10|74-78|daily|O
DDI-DrugBank.d210.s10|79-79|]|O
DDI-DrugBank.d210.s10|81-89|increased|O
DDI-DrugBank.d210.s10|91-93|the|O
DDI-DrugBank.d210.s10|95-98|Cmax|O
DDI-DrugBank.d210.s10|100-101|of|O
DDI-DrugBank.d210.s10|103-111|rofecoxib|drug
DDI-DrugBank.d210.s10|113-114|by|O
DDI-DrugBank.d210.s10|116-117|21|O
DDI-DrugBank.d210.s10|118-118|%|O
DDI-DrugBank.d210.s10|119-119|,|O
DDI-DrugBank.d210.s10|121-123|the|O
DDI-DrugBank.d210.s10|125-134|AUC0-120hr|O
DDI-DrugBank.d210.s10|136-137|by|O
DDI-DrugBank.d210.s10|139-140|23|O
DDI-DrugBank.d210.s10|141-141|%|O
DDI-DrugBank.d210.s10|143-145|and|O
DDI-DrugBank.d210.s10|147-149|the|O
DDI-DrugBank.d210.s10|151-154|t1/2|O
DDI-DrugBank.d210.s10|156-157|by|O
DDI-DrugBank.d210.s10|159-160|15|O
DDI-DrugBank.d210.s10|161-161|%|O
DDI-DrugBank.d210.s10|162-162|.|O
DDI-DrugBank.d210.s11|0-4|These|O
DDI-DrugBank.d210.s11|6-10|small|O
DDI-DrugBank.d210.s11|12-18|changes|O
DDI-DrugBank.d210.s11|20-22|are|O
DDI-DrugBank.d210.s11|24-26|not|O
DDI-DrugBank.d210.s11|28-37|clinically|O
DDI-DrugBank.d210.s11|39-49|significant|O
DDI-DrugBank.d210.s11|51-53|and|O
DDI-DrugBank.d210.s11|55-56|no|O
DDI-DrugBank.d210.s11|58-61|dose|O
DDI-DrugBank.d210.s11|63-72|adjustment|O
DDI-DrugBank.d210.s11|74-75|is|O
DDI-DrugBank.d210.s11|77-85|necessary|O
DDI-DrugBank.d210.s11|86-86|.|O
DDI-DrugBank.d210.s12|0-6|Digoxin|drug
DDI-DrugBank.d210.s12|7-7|:|O
DDI-DrugBank.d210.s12|9-17|Rofecoxib|drug
DDI-DrugBank.d210.s12|19-20|75|O
DDI-DrugBank.d210.s12|22-23|mg|O
DDI-DrugBank.d210.s12|25-28|once|O
DDI-DrugBank.d210.s12|30-34|daily|O
DDI-DrugBank.d210.s12|36-38|for|O
DDI-DrugBank.d210.s12|40-41|11|O
DDI-DrugBank.d210.s12|43-46|days|O
DDI-DrugBank.d210.s12|48-51|does|O
DDI-DrugBank.d210.s12|53-55|not|O
DDI-DrugBank.d210.s12|57-61|alter|O
DDI-DrugBank.d210.s12|63-65|the|O
DDI-DrugBank.d210.s12|67-72|plasma|O
DDI-DrugBank.d210.s12|74-86|concentration|O
DDI-DrugBank.d210.s12|88-94|profile|O
DDI-DrugBank.d210.s12|96-97|or|O
DDI-DrugBank.d210.s12|99-103|renal|O
DDI-DrugBank.d210.s12|105-115|elimination|O
DDI-DrugBank.d210.s12|117-118|of|O
DDI-DrugBank.d210.s12|120-126|digoxin|drug
DDI-DrugBank.d210.s12|128-132|after|O
DDI-DrugBank.d210.s12|134-134|a|O
DDI-DrugBank.d210.s12|136-141|single|O
DDI-DrugBank.d210.s12|143-145|0.5|O
DDI-DrugBank.d210.s12|147-148|mg|O
DDI-DrugBank.d210.s12|150-153|oral|O
DDI-DrugBank.d210.s12|155-158|dose|O
DDI-DrugBank.d210.s12|159-159|.|O
DDI-DrugBank.d210.s13|0-9|Furosemide|drug
DDI-DrugBank.d210.s13|10-10|:|O
DDI-DrugBank.d210.s13|12-19|Clinical|O
DDI-DrugBank.d210.s13|21-27|studies|O
DDI-DrugBank.d210.s13|28-28|,|O
DDI-DrugBank.d210.s13|30-31|as|O
DDI-DrugBank.d210.s13|33-36|well|O
DDI-DrugBank.d210.s13|38-39|as|O
DDI-DrugBank.d210.s13|41-54|post-marketing|O
DDI-DrugBank.d210.s13|56-67|observations|O
DDI-DrugBank.d210.s13|68-68|,|O
DDI-DrugBank.d210.s13|70-73|have|O
DDI-DrugBank.d210.s13|75-79|shown|O
DDI-DrugBank.d210.s13|81-84|that|O
DDI-DrugBank.d210.s13|86-91|NSAIDs|group
DDI-DrugBank.d210.s13|93-95|can|O
DDI-DrugBank.d210.s13|97-102|reduce|O
DDI-DrugBank.d210.s13|104-106|the|O
DDI-DrugBank.d210.s13|108-118|natriuretic|O
DDI-DrugBank.d210.s13|120-125|effect|O
DDI-DrugBank.d210.s13|127-128|of|O
DDI-DrugBank.d210.s13|130-139|furosemide|drug
DDI-DrugBank.d210.s13|141-143|and|O
DDI-DrugBank.d210.s13|145-153|thiazides|group
DDI-DrugBank.d210.s13|155-156|in|O
DDI-DrugBank.d210.s13|158-161|some|O
DDI-DrugBank.d210.s13|163-170|patients|O
DDI-DrugBank.d210.s13|171-171|.|O
DDI-DrugBank.d210.s14|0-3|This|O
DDI-DrugBank.d210.s14|5-12|response|O
DDI-DrugBank.d210.s14|14-16|has|O
DDI-DrugBank.d210.s14|18-21|been|O
DDI-DrugBank.d210.s14|23-32|attributed|O
DDI-DrugBank.d210.s14|34-35|to|O
DDI-DrugBank.d210.s14|37-46|inhibition|O
DDI-DrugBank.d210.s14|48-49|of|O
DDI-DrugBank.d210.s14|51-55|renal|O
DDI-DrugBank.d210.s14|57-69|prostaglandin|O
DDI-DrugBank.d210.s14|71-79|synthesis|O
DDI-DrugBank.d210.s14|80-80|.|O
DDI-DrugBank.d210.s15|0-11|Ketoconazole|drug
DDI-DrugBank.d210.s15|12-12|:|O
DDI-DrugBank.d210.s15|14-25|Ketoconazole|drug
DDI-DrugBank.d210.s15|27-29|400|O
DDI-DrugBank.d210.s15|31-32|mg|O
DDI-DrugBank.d210.s15|34-38|daily|O
DDI-DrugBank.d210.s15|40-42|did|O
DDI-DrugBank.d210.s15|44-46|not|O
DDI-DrugBank.d210.s15|48-51|have|O
DDI-DrugBank.d210.s15|53-55|any|O
DDI-DrugBank.d210.s15|57-66|clinically|O
DDI-DrugBank.d210.s15|68-76|important|O
DDI-DrugBank.d210.s15|78-83|effect|O
DDI-DrugBank.d210.s15|85-86|on|O
DDI-DrugBank.d210.s15|88-90|the|O
DDI-DrugBank.d210.s15|92-107|pharmacokinetics|O
DDI-DrugBank.d210.s15|109-110|of|O
DDI-DrugBank.d210.s15|112-120|rofecoxib|drug
DDI-DrugBank.d210.s15|121-121|.|O
DDI-DrugBank.d210.s16|0-6|Lithium|drug
DDI-DrugBank.d210.s16|7-7|:|O
DDI-DrugBank.d210.s16|9-14|NSAIDs|group
DDI-DrugBank.d210.s16|16-19|have|O
DDI-DrugBank.d210.s16|21-28|produced|O
DDI-DrugBank.d210.s16|30-31|an|O
DDI-DrugBank.d210.s16|33-41|elevation|O
DDI-DrugBank.d210.s16|43-44|of|O
DDI-DrugBank.d210.s16|46-51|plasma|O
DDI-DrugBank.d210.s16|53-59|lithium|drug
DDI-DrugBank.d210.s16|61-66|levels|O
DDI-DrugBank.d210.s16|68-70|and|O
DDI-DrugBank.d210.s16|72-72|a|O
DDI-DrugBank.d210.s16|74-82|reduction|O
DDI-DrugBank.d210.s16|84-85|in|O
DDI-DrugBank.d210.s16|87-91|renal|O
DDI-DrugBank.d210.s16|93-99|lithium|drug
DDI-DrugBank.d210.s16|101-109|clearance|O
DDI-DrugBank.d210.s16|110-110|.|O
DDI-DrugBank.d210.s17|0-1|In|O
DDI-DrugBank.d210.s17|3-16|post-marketing|O
DDI-DrugBank.d210.s17|18-27|experience|O
DDI-DrugBank.d210.s17|29-33|there|O
DDI-DrugBank.d210.s17|35-38|have|O
DDI-DrugBank.d210.s17|40-43|been|O
DDI-DrugBank.d210.s17|45-51|reports|O
DDI-DrugBank.d210.s17|53-54|of|O
DDI-DrugBank.d210.s17|56-64|increases|O
DDI-DrugBank.d210.s17|66-67|in|O
DDI-DrugBank.d210.s17|69-74|plasma|O
DDI-DrugBank.d210.s17|76-82|lithium|drug
DDI-DrugBank.d210.s17|84-89|levels|O
DDI-DrugBank.d210.s17|90-90|.|O
DDI-DrugBank.d210.s18|0-3|Thus|O
DDI-DrugBank.d210.s18|4-4|,|O
DDI-DrugBank.d210.s18|6-9|when|O
DDI-DrugBank.d210.s18|11-15|VIOXX|brand
DDI-DrugBank.d210.s18|17-19|and|O
DDI-DrugBank.d210.s18|21-27|lithium|drug
DDI-DrugBank.d210.s18|29-31|are|O
DDI-DrugBank.d210.s18|33-44|administered|O
DDI-DrugBank.d210.s18|46-57|concurrently|O
DDI-DrugBank.d210.s18|58-58|,|O
DDI-DrugBank.d210.s18|60-67|subjects|O
DDI-DrugBank.d210.s18|69-74|should|O
DDI-DrugBank.d210.s18|76-77|be|O
DDI-DrugBank.d210.s18|79-86|observed|O
DDI-DrugBank.d210.s18|88-96|carefully|O
DDI-DrugBank.d210.s18|98-100|for|O
DDI-DrugBank.d210.s18|102-106|signs|O
DDI-DrugBank.d210.s18|108-109|of|O
DDI-DrugBank.d210.s18|111-117|lithium|drug
DDI-DrugBank.d210.s18|119-126|toxicity|O
DDI-DrugBank.d210.s18|127-127|.|O
DDI-DrugBank.d210.s19|0-11|Methotrexate|drug
DDI-DrugBank.d210.s19|0-11|Methotrexate|drug
DDI-DrugBank.d210.s19|19-22|12.5|O
DDI-DrugBank.d210.s19|23-23|,|O
DDI-DrugBank.d210.s19|25-26|25|O
DDI-DrugBank.d210.s19|27-27|,|O
DDI-DrugBank.d210.s19|29-31|and|O
DDI-DrugBank.d210.s19|33-34|50|O
DDI-DrugBank.d210.s19|36-37|mg|O
DDI-DrugBank.d210.s19|38-38|,|O
DDI-DrugBank.d210.s19|40-43|each|O
DDI-DrugBank.d210.s19|45-48|dose|O
DDI-DrugBank.d210.s19|50-61|administered|O
DDI-DrugBank.d210.s19|63-66|once|O
DDI-DrugBank.d210.s19|68-72|daily|O
DDI-DrugBank.d210.s19|74-76|for|O
DDI-DrugBank.d210.s19|78-78|7|O
DDI-DrugBank.d210.s19|80-83|days|O
DDI-DrugBank.d210.s19|84-84|,|O
DDI-DrugBank.d210.s19|86-88|had|O
DDI-DrugBank.d210.s19|90-91|no|O
DDI-DrugBank.d210.s19|93-98|effect|O
DDI-DrugBank.d210.s19|100-101|on|O
DDI-DrugBank.d210.s19|103-105|the|O
DDI-DrugBank.d210.s19|107-112|plasma|O
DDI-DrugBank.d210.s19|114-126|concentration|O
DDI-DrugBank.d210.s19|128-129|of|O
DDI-DrugBank.d210.s19|131-142|methotrexate|drug
DDI-DrugBank.d210.s19|144-145|as|O
DDI-DrugBank.d210.s19|147-154|measured|O
DDI-DrugBank.d210.s19|156-157|by|O
DDI-DrugBank.d210.s19|159-167|AUC0-24hr|O
DDI-DrugBank.d210.s19|169-170|in|O
DDI-DrugBank.d210.s19|172-179|patients|O
DDI-DrugBank.d210.s19|181-189|receiving|O
DDI-DrugBank.d210.s19|191-196|single|O
DDI-DrugBank.d210.s19|198-203|weekly|O
DDI-DrugBank.d210.s19|205-216|methotrexate|drug
DDI-DrugBank.d210.s19|218-222|doses|O
DDI-DrugBank.d210.s19|224-225|of|O
DDI-DrugBank.d210.s19|227-229|7.5|O
DDI-DrugBank.d210.s19|231-232|to|O
DDI-DrugBank.d210.s19|234-235|20|O
DDI-DrugBank.d210.s19|237-238|mg|O
DDI-DrugBank.d210.s19|240-242|for|O
DDI-DrugBank.d210.s19|244-253|rheumatoid|O
DDI-DrugBank.d210.s19|255-263|arthritis|O
DDI-DrugBank.d210.s19|264-264|.|O
DDI-DrugBank.d210.s20|0-1|At|O
DDI-DrugBank.d210.s20|3-8|higher|O
DDI-DrugBank.d210.s20|10-13|than|O
DDI-DrugBank.d210.s20|15-25|recommended|O
DDI-DrugBank.d210.s20|27-31|doses|O
DDI-DrugBank.d210.s20|32-32|,|O
DDI-DrugBank.d210.s20|34-38|VIOXX|brand
DDI-DrugBank.d210.s20|40-41|75|O
DDI-DrugBank.d210.s20|43-44|mg|O
DDI-DrugBank.d210.s20|46-57|administered|O
DDI-DrugBank.d210.s20|59-62|once|O
DDI-DrugBank.d210.s20|64-68|daily|O
DDI-DrugBank.d210.s20|70-72|for|O
DDI-DrugBank.d210.s20|74-75|10|O
DDI-DrugBank.d210.s20|77-80|days|O
DDI-DrugBank.d210.s20|82-90|increased|O
DDI-DrugBank.d210.s20|92-97|plasma|O
DDI-DrugBank.d210.s20|99-112|concentrations|O
DDI-DrugBank.d210.s20|114-115|by|O
DDI-DrugBank.d210.s20|117-118|23|O
DDI-DrugBank.d210.s20|119-119|%|O
DDI-DrugBank.d210.s20|121-122|as|O
DDI-DrugBank.d210.s20|124-131|measured|O
DDI-DrugBank.d210.s20|133-134|by|O
DDI-DrugBank.d210.s20|136-144|AUC0-24hr|O
DDI-DrugBank.d210.s20|146-147|in|O
DDI-DrugBank.d210.s20|149-156|patients|O
DDI-DrugBank.d210.s20|158-166|receiving|O
DDI-DrugBank.d210.s20|168-179|methotrexate|drug
DDI-DrugBank.d210.s20|181-183|7.5|O
DDI-DrugBank.d210.s20|185-186|to|O
DDI-DrugBank.d210.s20|188-189|15|O
DDI-DrugBank.d210.s20|191-197|mg/week|O
DDI-DrugBank.d210.s20|199-201|for|O
DDI-DrugBank.d210.s20|203-212|rheumatoid|O
DDI-DrugBank.d210.s20|214-222|arthritis|O
DDI-DrugBank.d210.s20|223-223|.|O
DDI-DrugBank.d210.s21|0-1|At|O
DDI-DrugBank.d210.s21|3-4|24|O
DDI-DrugBank.d210.s21|6-10|hours|O
DDI-DrugBank.d210.s21|12-19|postdose|O
DDI-DrugBank.d210.s21|20-20|,|O
DDI-DrugBank.d210.s21|22-22|a|O
DDI-DrugBank.d210.s21|24-30|similar|O
DDI-DrugBank.d210.s21|32-41|proportion|O
DDI-DrugBank.d210.s21|43-44|of|O
DDI-DrugBank.d210.s21|46-53|patients|O
DDI-DrugBank.d210.s21|55-61|treated|O
DDI-DrugBank.d210.s21|63-66|with|O
DDI-DrugBank.d210.s21|68-79|methotrexate|drug
DDI-DrugBank.d210.s21|81-85|alone|O
DDI-DrugBank.d210.s21|87-87|(|O
DDI-DrugBank.d210.s21|88-89|94|O
DDI-DrugBank.d210.s21|90-90|%|O
DDI-DrugBank.d210.s21|91-91|)|O
DDI-DrugBank.d210.s21|93-95|and|O
DDI-DrugBank.d210.s21|97-108|subsequently|O
DDI-DrugBank.d210.s21|110-116|treated|O
DDI-DrugBank.d210.s21|118-121|with|O
DDI-DrugBank.d210.s21|123-134|methotrexate|drug
DDI-DrugBank.d210.s21|136-150|co-administered|O
DDI-DrugBank.d210.s21|152-155|with|O
DDI-DrugBank.d210.s21|157-158|75|O
DDI-DrugBank.d210.s21|160-161|mg|O
DDI-DrugBank.d210.s21|163-164|of|O
DDI-DrugBank.d210.s21|166-174|rofecoxib|drug
DDI-DrugBank.d210.s21|176-176|(|O
DDI-DrugBank.d210.s21|177-178|88|O
DDI-DrugBank.d210.s21|179-179|%|O
DDI-DrugBank.d210.s21|180-180|)|O
DDI-DrugBank.d210.s21|182-184|had|O
DDI-DrugBank.d210.s21|186-197|methotrexate|drug
DDI-DrugBank.d210.s21|199-204|plasma|O
DDI-DrugBank.d210.s21|206-219|concentrations|O
DDI-DrugBank.d210.s21|221-225|below|O
DDI-DrugBank.d210.s21|227-229|the|O
DDI-DrugBank.d210.s21|231-240|measurable|O
DDI-DrugBank.d210.s21|242-246|limit|O
DDI-DrugBank.d210.s21|248-248|(|O
DDI-DrugBank.d210.s21|249-249|5|O
DDI-DrugBank.d210.s21|251-255|ng/mL|O
DDI-DrugBank.d210.s21|256-256|)|O
DDI-DrugBank.d210.s21|257-257|.|O
DDI-DrugBank.d210.s22|0-7|Standard|O
DDI-DrugBank.d210.s22|9-18|monitoring|O
DDI-DrugBank.d210.s22|20-21|of|O
DDI-DrugBank.d210.s22|23-42|methotrexate-related|drug
DDI-DrugBank.d210.s22|44-51|toxicity|O
DDI-DrugBank.d210.s22|53-58|should|O
DDI-DrugBank.d210.s22|60-61|be|O
DDI-DrugBank.d210.s22|63-71|continued|O
DDI-DrugBank.d210.s22|73-74|if|O
DDI-DrugBank.d210.s22|76-80|VIOXX|brand
DDI-DrugBank.d210.s22|82-84|and|O
DDI-DrugBank.d210.s22|86-97|methotrexate|drug
DDI-DrugBank.d210.s22|99-101|are|O
DDI-DrugBank.d210.s22|103-114|administered|O
DDI-DrugBank.d210.s22|116-128|concomitantly|O
DDI-DrugBank.d210.s22|129-129|.|O
DDI-DrugBank.d210.s23|0-3|Oral|O
DDI-DrugBank.d210.s23|5-18|Contraceptives|group
DDI-DrugBank.d210.s23|5-18|Contraceptives|group
DDI-DrugBank.d210.s23|30-32|did|O
DDI-DrugBank.d210.s23|34-36|not|O
DDI-DrugBank.d210.s23|38-41|have|O
DDI-DrugBank.d210.s23|43-45|any|O
DDI-DrugBank.d210.s23|47-56|clinically|O
DDI-DrugBank.d210.s23|58-66|important|O
DDI-DrugBank.d210.s23|68-73|effect|O
DDI-DrugBank.d210.s23|75-76|on|O
DDI-DrugBank.d210.s23|78-80|the|O
DDI-DrugBank.d210.s23|82-97|pharmacokinetics|O
DDI-DrugBank.d210.s23|99-100|of|O
DDI-DrugBank.d210.s23|102-118|ethinyl estradiol|drug
DDI-DrugBank.d210.s23|120-122|and|O
DDI-DrugBank.d210.s23|124-136|norethindrone|drug
DDI-DrugBank.d210.s23|137-137|.|O
DDI-DrugBank.d210.s24|0-22|Prednisone/prednisolone|drug
DDI-DrugBank.d210.s24|23-23|:|O
DDI-DrugBank.d210.s24|25-33|Rofecoxib|drug
DDI-DrugBank.d210.s24|35-37|did|O
DDI-DrugBank.d210.s24|39-41|not|O
DDI-DrugBank.d210.s24|43-46|have|O
DDI-DrugBank.d210.s24|48-50|any|O
DDI-DrugBank.d210.s24|52-61|clinically|O
DDI-DrugBank.d210.s24|63-71|important|O
DDI-DrugBank.d210.s24|73-78|effect|O
DDI-DrugBank.d210.s24|80-81|on|O
DDI-DrugBank.d210.s24|83-85|the|O
DDI-DrugBank.d210.s24|87-102|pharmacokinetics|O
DDI-DrugBank.d210.s24|104-105|of|O
DDI-DrugBank.d210.s24|107-118|prednisolone|drug
DDI-DrugBank.d210.s24|120-121|or|O
DDI-DrugBank.d210.s24|123-132|prednisone|drug
DDI-DrugBank.d210.s24|133-133|.|O
DDI-DrugBank.d210.s25|0-7|Rifampin|drug
DDI-DrugBank.d210.s25|8-8|:|O
DDI-DrugBank.d210.s25|10-26|Co-administration|O
DDI-DrugBank.d210.s25|28-29|of|O
DDI-DrugBank.d210.s25|31-35|VIOXX|brand
DDI-DrugBank.d210.s25|37-40|with|O
DDI-DrugBank.d210.s25|42-49|rifampin|drug
DDI-DrugBank.d210.s25|51-53|600|O
DDI-DrugBank.d210.s25|55-56|mg|O
DDI-DrugBank.d210.s25|58-62|daily|O
DDI-DrugBank.d210.s25|63-63|,|O
DDI-DrugBank.d210.s25|65-65|a|O
DDI-DrugBank.d210.s25|67-72|potent|O
DDI-DrugBank.d210.s25|74-80|inducer|O
DDI-DrugBank.d210.s25|82-83|of|O
DDI-DrugBank.d210.s25|85-91|hepatic|O
DDI-DrugBank.d210.s25|93-102|metabolism|O
DDI-DrugBank.d210.s25|103-103|,|O
DDI-DrugBank.d210.s25|105-112|produced|O
DDI-DrugBank.d210.s25|114-115|an|O
DDI-DrugBank.d210.s25|117-127|approximate|O
DDI-DrugBank.d210.s25|129-130|50|O
DDI-DrugBank.d210.s25|131-131|%|O
DDI-DrugBank.d210.s25|133-140|decrease|O
DDI-DrugBank.d210.s25|142-143|in|O
DDI-DrugBank.d210.s25|145-153|rofecoxib|drug
DDI-DrugBank.d210.s25|155-160|plasma|O
DDI-DrugBank.d210.s25|162-175|concentrations|O
DDI-DrugBank.d210.s25|176-176|.|O
DDI-DrugBank.d210.s26|0-8|Therefore|O
DDI-DrugBank.d210.s26|9-9|,|O
DDI-DrugBank.d210.s26|11-11|a|O
DDI-DrugBank.d210.s26|13-20|starting|O
DDI-DrugBank.d210.s26|22-26|daily|O
DDI-DrugBank.d210.s26|28-31|dose|O
DDI-DrugBank.d210.s26|33-34|of|O
DDI-DrugBank.d210.s26|36-37|25|O
DDI-DrugBank.d210.s26|39-40|mg|O
DDI-DrugBank.d210.s26|42-43|of|O
DDI-DrugBank.d210.s26|45-49|VIOXX|brand
DDI-DrugBank.d210.s26|51-56|should|O
DDI-DrugBank.d210.s26|58-59|be|O
DDI-DrugBank.d210.s26|61-70|considered|O
DDI-DrugBank.d210.s26|72-74|for|O
DDI-DrugBank.d210.s26|76-78|the|O
DDI-DrugBank.d210.s26|80-88|treatment|O
DDI-DrugBank.d210.s26|90-91|of|O
DDI-DrugBank.d210.s26|93-106|osteoarthritis|O
DDI-DrugBank.d210.s26|108-111|when|O
DDI-DrugBank.d210.s26|113-117|VIOXX|brand
DDI-DrugBank.d210.s26|119-120|is|O
DDI-DrugBank.d210.s26|122-136|co-administered|O
DDI-DrugBank.d210.s26|138-141|with|O
DDI-DrugBank.d210.s26|143-148|potent|O
DDI-DrugBank.d210.s26|150-157|inducers|O
DDI-DrugBank.d210.s26|159-160|of|O
DDI-DrugBank.d210.s26|162-168|hepatic|O
DDI-DrugBank.d210.s26|170-179|metabolism|O
DDI-DrugBank.d210.s26|180-180|.|O
DDI-DrugBank.d210.s27|0-11|Theophylline|drug
DDI-DrugBank.d210.s27|0-11|Theophylline|drug
DDI-DrugBank.d210.s27|19-22|12.5|O
DDI-DrugBank.d210.s27|23-23|,|O
DDI-DrugBank.d210.s27|25-26|25|O
DDI-DrugBank.d210.s27|27-27|,|O
DDI-DrugBank.d210.s27|29-31|and|O
DDI-DrugBank.d210.s27|33-34|50|O
DDI-DrugBank.d210.s27|36-37|mg|O
DDI-DrugBank.d210.s27|39-50|administered|O
DDI-DrugBank.d210.s27|52-55|once|O
DDI-DrugBank.d210.s27|57-61|daily|O
DDI-DrugBank.d210.s27|63-65|for|O
DDI-DrugBank.d210.s27|67-67|7|O
DDI-DrugBank.d210.s27|69-72|days|O
DDI-DrugBank.d210.s27|74-82|increased|O
DDI-DrugBank.d210.s27|84-89|plasma|O
DDI-DrugBank.d210.s27|91-102|theophylline|drug
DDI-DrugBank.d210.s27|104-117|concentrations|O
DDI-DrugBank.d210.s27|119-119|(|O
DDI-DrugBank.d210.s27|120-122|AUC|O
DDI-DrugBank.d210.s27|123-123|(|O
DDI-DrugBank.d210.s27|124-125|0-|O
DDI-DrugBank.d210.s27|127-127|)|O
DDI-DrugBank.d210.s27|128-128|)|O
DDI-DrugBank.d210.s27|130-131|by|O
DDI-DrugBank.d210.s27|133-134|38|O
DDI-DrugBank.d210.s27|136-137|to|O
DDI-DrugBank.d210.s27|139-140|60|O
DDI-DrugBank.d210.s27|141-141|%|O
DDI-DrugBank.d210.s27|143-144|in|O
DDI-DrugBank.d210.s27|146-152|healthy|O
DDI-DrugBank.d210.s27|154-161|subjects|O
DDI-DrugBank.d210.s27|163-174|administered|O
DDI-DrugBank.d210.s27|176-176|a|O
DDI-DrugBank.d210.s27|178-183|single|O
DDI-DrugBank.d210.s27|185-190|300-mg|O
DDI-DrugBank.d210.s27|192-195|dose|O
DDI-DrugBank.d210.s27|197-198|of|O
DDI-DrugBank.d210.s27|200-211|theophylline|drug
DDI-DrugBank.d210.s27|212-212|.|O
DDI-DrugBank.d210.s28|0-7|Adequate|O
DDI-DrugBank.d210.s28|9-18|monitoring|O
DDI-DrugBank.d210.s28|20-21|of|O
DDI-DrugBank.d210.s28|23-34|theophylline|drug
DDI-DrugBank.d210.s28|36-41|plasma|O
DDI-DrugBank.d210.s28|43-56|concentrations|O
DDI-DrugBank.d210.s28|58-63|should|O
DDI-DrugBank.d210.s28|65-66|be|O
DDI-DrugBank.d210.s28|68-77|considered|O
DDI-DrugBank.d210.s28|79-82|when|O
DDI-DrugBank.d210.s28|84-90|therapy|O
DDI-DrugBank.d210.s28|92-95|with|O
DDI-DrugBank.d210.s28|97-101|VIOXX|brand
DDI-DrugBank.d210.s28|103-104|is|O
DDI-DrugBank.d210.s28|106-114|initiated|O
DDI-DrugBank.d210.s28|116-117|or|O
DDI-DrugBank.d210.s28|119-125|changed|O
DDI-DrugBank.d210.s28|127-128|in|O
DDI-DrugBank.d210.s28|130-137|patients|O
DDI-DrugBank.d210.s28|139-147|receiving|O
DDI-DrugBank.d210.s28|149-160|theophylline|drug
DDI-DrugBank.d210.s28|161-161|.|O
DDI-DrugBank.d210.s29|0-4|These|O
DDI-DrugBank.d210.s29|6-9|data|O
DDI-DrugBank.d210.s29|11-17|suggest|O
DDI-DrugBank.d210.s29|19-22|that|O
DDI-DrugBank.d210.s29|24-32|rofecoxib|drug
DDI-DrugBank.d210.s29|34-36|may|O
DDI-DrugBank.d210.s29|38-44|produce|O
DDI-DrugBank.d210.s29|46-46|a|O
DDI-DrugBank.d210.s29|48-53|modest|O
DDI-DrugBank.d210.s29|55-64|inhibition|O
DDI-DrugBank.d210.s29|66-67|of|O
DDI-DrugBank.d210.s29|69-78|cytochrome|O
DDI-DrugBank.d210.s29|80-83|P450|O
DDI-DrugBank.d210.s29|85-85|(|O
DDI-DrugBank.d210.s29|86-88|CYP|O
DDI-DrugBank.d210.s29|89-89|)|O
DDI-DrugBank.d210.s29|91-93|1A2|O
DDI-DrugBank.d210.s29|94-94|.|O
DDI-DrugBank.d210.s30|0-8|Therefore|O
DDI-DrugBank.d210.s30|9-9|,|O
DDI-DrugBank.d210.s30|11-15|there|O
DDI-DrugBank.d210.s30|17-18|is|O
DDI-DrugBank.d210.s30|20-20|a|O
DDI-DrugBank.d210.s30|22-30|potential|O
DDI-DrugBank.d210.s30|32-34|for|O
DDI-DrugBank.d210.s30|36-37|an|O
DDI-DrugBank.d210.s30|39-49|interaction|O
DDI-DrugBank.d210.s30|51-54|with|O
DDI-DrugBank.d210.s30|56-60|other|O
DDI-DrugBank.d210.s30|62-66|drugs|O
DDI-DrugBank.d210.s30|68-71|that|O
DDI-DrugBank.d210.s30|73-75|are|O
DDI-DrugBank.d210.s30|77-87|metabolized|O
DDI-DrugBank.d210.s30|89-90|by|O
DDI-DrugBank.d210.s30|92-94|CYP|O
DDI-DrugBank.d210.s30|96-98|1A2|O
DDI-DrugBank.d210.s30|100-100|(|O
DDI-DrugBank.d210.s30|101-104|e.g.|O
DDI-DrugBank.d210.s30|105-105|,|O
DDI-DrugBank.d210.s30|107-119|amitriptyline|drug
DDI-DrugBank.d210.s30|120-120|,|O
DDI-DrugBank.d210.s30|122-128|tacrine|drug
DDI-DrugBank.d210.s30|129-129|,|O
DDI-DrugBank.d210.s30|131-133|and|O
DDI-DrugBank.d210.s30|135-142|zileuton|drug
DDI-DrugBank.d210.s30|143-143|)|O
DDI-DrugBank.d210.s30|144-144|.|O
DDI-DrugBank.d210.s31|0-7|Warfarin|drug
DDI-DrugBank.d210.s31|8-8|:|O
DDI-DrugBank.d210.s31|10-22|Anticoagulant|O
DDI-DrugBank.d210.s31|24-31|activity|O
DDI-DrugBank.d210.s31|33-38|should|O
DDI-DrugBank.d210.s31|40-41|be|O
DDI-DrugBank.d210.s31|43-51|monitored|O
DDI-DrugBank.d210.s31|52-52|,|O
DDI-DrugBank.d210.s31|54-65|particularly|O
DDI-DrugBank.d210.s31|67-68|in|O
DDI-DrugBank.d210.s31|70-72|the|O
DDI-DrugBank.d210.s31|74-78|first|O
DDI-DrugBank.d210.s31|80-82|few|O
DDI-DrugBank.d210.s31|84-87|days|O
DDI-DrugBank.d210.s31|89-93|after|O
DDI-DrugBank.d210.s31|95-104|initiating|O
DDI-DrugBank.d210.s31|106-107|or|O
DDI-DrugBank.d210.s31|109-116|changing|O
DDI-DrugBank.d210.s31|118-122|VIOXX|brand
DDI-DrugBank.d210.s31|124-130|therapy|O
DDI-DrugBank.d210.s31|132-133|in|O
DDI-DrugBank.d210.s31|135-142|patients|O
DDI-DrugBank.d210.s31|144-152|receiving|O
DDI-DrugBank.d210.s31|154-161|warfarin|drug
DDI-DrugBank.d210.s31|163-164|or|O
DDI-DrugBank.d210.s31|166-172|similar|O
DDI-DrugBank.d210.s31|174-179|agents|O
DDI-DrugBank.d210.s31|180-180|,|O
DDI-DrugBank.d210.s31|182-186|since|O
DDI-DrugBank.d210.s31|188-192|these|O
DDI-DrugBank.d210.s31|194-201|patients|O
DDI-DrugBank.d210.s31|203-205|are|O
DDI-DrugBank.d210.s31|207-208|at|O
DDI-DrugBank.d210.s31|210-211|an|O
DDI-DrugBank.d210.s31|213-221|increased|O
DDI-DrugBank.d210.s31|223-226|risk|O
DDI-DrugBank.d210.s31|228-229|of|O
DDI-DrugBank.d210.s31|231-238|bleeding|O
DDI-DrugBank.d210.s31|240-252|complications|O
DDI-DrugBank.d210.s31|253-253|.|O
DDI-DrugBank.d210.s32|0-1|In|O
DDI-DrugBank.d210.s32|3-8|single|O
DDI-DrugBank.d210.s32|10-12|and|O
DDI-DrugBank.d210.s32|14-21|multiple|O
DDI-DrugBank.d210.s32|23-26|dose|O
DDI-DrugBank.d210.s32|28-34|studies|O
DDI-DrugBank.d210.s32|36-37|in|O
DDI-DrugBank.d210.s32|39-45|healthy|O
DDI-DrugBank.d210.s32|47-54|subjects|O
DDI-DrugBank.d210.s32|56-64|receiving|O
DDI-DrugBank.d210.s32|66-69|both|O
DDI-DrugBank.d210.s32|71-78|warfarin|drug
DDI-DrugBank.d210.s32|80-82|and|O
DDI-DrugBank.d210.s32|84-92|rofecoxib|drug
DDI-DrugBank.d210.s32|93-93|,|O
DDI-DrugBank.d210.s32|95-105|prothrombin|O
DDI-DrugBank.d210.s32|107-110|time|O
DDI-DrugBank.d210.s32|112-112|(|O
DDI-DrugBank.d210.s32|113-120|measured|O
DDI-DrugBank.d210.s32|122-123|as|O
DDI-DrugBank.d210.s32|125-127|INR|O
DDI-DrugBank.d210.s32|128-128|)|O
DDI-DrugBank.d210.s32|130-132|was|O
DDI-DrugBank.d210.s32|134-142|increased|O
DDI-DrugBank.d210.s32|144-145|by|O
DDI-DrugBank.d210.s32|147-159|approximately|O
DDI-DrugBank.d210.s32|161-161|8|O
DDI-DrugBank.d210.s32|162-162|%|O
DDI-DrugBank.d210.s32|164-165|to|O
DDI-DrugBank.d210.s32|167-168|11|O
DDI-DrugBank.d210.s32|169-169|%|O
DDI-DrugBank.d210.s32|170-170|.|O
DDI-DrugBank.d210.s33|0-1|In|O
DDI-DrugBank.d210.s33|3-16|post-marketing|O
DDI-DrugBank.d210.s33|18-27|experience|O
DDI-DrugBank.d210.s33|28-28|,|O
DDI-DrugBank.d210.s33|30-37|bleeding|O
DDI-DrugBank.d210.s33|39-44|events|O
DDI-DrugBank.d210.s33|46-49|have|O
DDI-DrugBank.d210.s33|51-54|been|O
DDI-DrugBank.d210.s33|56-63|reported|O
DDI-DrugBank.d210.s33|64-64|,|O
DDI-DrugBank.d210.s33|66-78|predominantly|O
DDI-DrugBank.d210.s33|80-81|in|O
DDI-DrugBank.d210.s33|83-85|the|O
DDI-DrugBank.d210.s33|87-93|elderly|O
DDI-DrugBank.d210.s33|94-94|,|O
DDI-DrugBank.d210.s33|96-97|in|O
DDI-DrugBank.d210.s33|99-109|association|O
DDI-DrugBank.d210.s33|111-114|with|O
DDI-DrugBank.d210.s33|116-124|increases|O
DDI-DrugBank.d210.s33|126-127|in|O
DDI-DrugBank.d210.s33|129-139|prothrombin|O
DDI-DrugBank.d210.s33|141-144|time|O
DDI-DrugBank.d210.s33|146-147|in|O
DDI-DrugBank.d210.s33|149-156|patients|O
DDI-DrugBank.d210.s33|158-166|receiving|O
DDI-DrugBank.d210.s33|168-172|VIOXX|brand
DDI-DrugBank.d210.s33|174-185|concurrently|O
DDI-DrugBank.d210.s33|187-190|with|O
DDI-DrugBank.d210.s33|192-199|warfarin|drug
DDI-DrugBank.d210.s33|200-200|.|O
DDI-MedLine.d161.s0|0-11|Metabotropic|O
DDI-MedLine.d161.s0|13-21|glutamate|O
DDI-MedLine.d161.s0|23-30|receptor|O
DDI-MedLine.d161.s0|32-32|5|O
DDI-MedLine.d161.s0|34-43|antagonist|O
DDI-MedLine.d161.s0|45-52|protects|O
DDI-MedLine.d161.s0|54-65|dopaminergic|O
DDI-MedLine.d161.s0|67-69|and|O
DDI-MedLine.d161.s0|71-83|noradrenergic|O
DDI-MedLine.d161.s0|85-91|neurons|O
DDI-MedLine.d161.s0|93-96|from|O
DDI-MedLine.d161.s0|98-109|degeneration|O
DDI-MedLine.d161.s0|111-112|in|O
DDI-MedLine.d161.s0|127-133|monkeys|O
DDI-MedLine.d161.s0|134-134|.|O
DDI-MedLine.d161.s1|0-11|Degeneration|O
DDI-MedLine.d161.s1|13-14|of|O
DDI-MedLine.d161.s1|16-18|the|O
DDI-MedLine.d161.s1|20-31|dopaminergic|O
DDI-MedLine.d161.s1|33-45|nigrostriatal|O
DDI-MedLine.d161.s1|47-52|system|O
DDI-MedLine.d161.s1|54-56|and|O
DDI-MedLine.d161.s1|58-59|of|O
DDI-MedLine.d161.s1|61-73|noradrenergic|O
DDI-MedLine.d161.s1|75-81|neurons|O
DDI-MedLine.d161.s1|83-84|in|O
DDI-MedLine.d161.s1|86-88|the|O
DDI-MedLine.d161.s1|90-94|locus|O
DDI-MedLine.d161.s1|96-104|coeruleus|O
DDI-MedLine.d161.s1|106-108|are|O
DDI-MedLine.d161.s1|110-118|important|O
DDI-MedLine.d161.s1|120-131|pathological|O
DDI-MedLine.d161.s1|133-140|features|O
DDI-MedLine.d161.s1|142-143|of|O
DDI-MedLine.d161.s1|145-153|Parkinson|O
DDI-MedLine.d161.s1|154-155|'s|O
DDI-MedLine.d161.s1|157-163|disease|O
DDI-MedLine.d161.s1|164-164|.|O
DDI-MedLine.d161.s2|0-4|There|O
DDI-MedLine.d161.s2|6-7|is|O
DDI-MedLine.d161.s2|9-10|an|O
DDI-MedLine.d161.s2|12-17|urgent|O
DDI-MedLine.d161.s2|19-22|need|O
DDI-MedLine.d161.s2|24-25|to|O
DDI-MedLine.d161.s2|27-33|develop|O
DDI-MedLine.d161.s2|35-43|therapies|O
DDI-MedLine.d161.s2|45-48|that|O
DDI-MedLine.d161.s2|50-53|slow|O
DDI-MedLine.d161.s2|55-58|down|O
DDI-MedLine.d161.s2|60-62|the|O
DDI-MedLine.d161.s2|64-74|progression|O
DDI-MedLine.d161.s2|76-77|of|O
DDI-MedLine.d161.s2|79-95|neurodegeneration|O
DDI-MedLine.d161.s2|97-98|in|O
DDI-MedLine.d161.s2|100-108|Parkinson|O
DDI-MedLine.d161.s2|109-110|'s|O
DDI-MedLine.d161.s2|112-118|disease|O
DDI-MedLine.d161.s2|119-119|.|O
DDI-MedLine.d161.s3|0-1|In|O
DDI-MedLine.d161.s3|3-5|the|O
DDI-MedLine.d161.s3|7-13|present|O
DDI-MedLine.d161.s3|15-19|study|O
DDI-MedLine.d161.s3|20-20|,|O
DDI-MedLine.d161.s3|22-23|we|O
DDI-MedLine.d161.s3|25-30|tested|O
DDI-MedLine.d161.s3|32-38|whether|O
DDI-MedLine.d161.s3|40-42|the|O
DDI-MedLine.d161.s3|44-49|highly|O
DDI-MedLine.d161.s3|51-58|specific|O
DDI-MedLine.d161.s3|60-71|metabotropic|O
DDI-MedLine.d161.s3|73-81|glutamate|O
DDI-MedLine.d161.s3|83-90|receptor|O
DDI-MedLine.d161.s3|92-92|5|O
DDI-MedLine.d161.s3|94-103|antagonist|O
DDI-MedLine.d161.s3|104-104|,|O
DDI-MedLine.d161.s3|154-154|,|O
DDI-MedLine.d161.s3|156-162|reduces|O
DDI-MedLine.d161.s3|164-175|dopaminergic|O
DDI-MedLine.d161.s3|177-179|and|O
DDI-MedLine.d161.s3|181-193|noradrenergic|O
DDI-MedLine.d161.s3|195-202|neuronal|O
DDI-MedLine.d161.s3|204-207|loss|O
DDI-MedLine.d161.s3|209-210|in|O
DDI-MedLine.d161.s3|212-218|monkeys|O
DDI-MedLine.d161.s3|220-227|rendered|O
DDI-MedLine.d161.s3|229-240|parkinsonian|O
DDI-MedLine.d161.s3|242-243|by|O
DDI-MedLine.d161.s3|245-251|chronic|O
DDI-MedLine.d161.s3|253-261|treatment|O
DDI-MedLine.d161.s3|263-266|with|O
DDI-MedLine.d161.s3|268-270|low|O
DDI-MedLine.d161.s3|272-276|doses|O
DDI-MedLine.d161.s3|278-279|of|O
DDI-MedLine.d161.s3|325-325|.|O
DDI-MedLine.d161.s4|0-5|Weekly|O
DDI-MedLine.d161.s4|7-19|intramuscular|O
DDI-MedLine.d161.s4|66-75|injections|O
DDI-MedLine.d161.s4|77-77|(|O
DDI-MedLine.d161.s4|78-84|0.2-0.5|O
DDI-MedLine.d161.s4|86-90|mg/kg|O
DDI-MedLine.d161.s4|92-95|body|O
DDI-MedLine.d161.s4|97-102|weight|O
DDI-MedLine.d161.s4|103-103|)|O
DDI-MedLine.d161.s4|104-104|,|O
DDI-MedLine.d161.s4|106-107|in|O
DDI-MedLine.d161.s4|109-119|combination|O
DDI-MedLine.d161.s4|121-124|with|O
DDI-MedLine.d161.s4|126-130|daily|O
DDI-MedLine.d161.s4|132-145|administration|O
DDI-MedLine.d161.s4|147-148|of|O
DDI-MedLine.d161.s4|199-200|or|O
DDI-MedLine.d161.s4|202-208|vehicle|O
DDI-MedLine.d161.s4|209-209|,|O
DDI-MedLine.d161.s4|211-214|were|O
DDI-MedLine.d161.s4|216-224|performed|O
DDI-MedLine.d161.s4|226-230|until|O
DDI-MedLine.d161.s4|232-234|the|O
DDI-MedLine.d161.s4|236-246|development|O
DDI-MedLine.d161.s4|248-249|of|O
DDI-MedLine.d161.s4|251-262|parkinsonian|O
DDI-MedLine.d161.s4|264-268|motor|O
DDI-MedLine.d161.s4|270-277|symptoms|O
DDI-MedLine.d161.s4|279-280|in|O
DDI-MedLine.d161.s4|282-287|either|O
DDI-MedLine.d161.s4|289-290|of|O
DDI-MedLine.d161.s4|292-294|the|O
DDI-MedLine.d161.s4|296-298|two|O
DDI-MedLine.d161.s4|300-311|experimental|O
DDI-MedLine.d161.s4|313-318|groups|O
DDI-MedLine.d161.s4|320-320|(|O
DDI-MedLine.d161.s4|415-420|versus|O
DDI-MedLine.d161.s4|474-474|)|O
DDI-MedLine.d161.s4|475-475|.|O
DDI-MedLine.d161.s5|0-4|After|O
DDI-MedLine.d161.s5|6-7|21|O
DDI-MedLine.d161.s5|9-13|weeks|O
DDI-MedLine.d161.s5|15-16|of|O
DDI-MedLine.d161.s5|63-71|treatment|O
DDI-MedLine.d161.s5|72-72|,|O
DDI-MedLine.d161.s5|74-76|all|O
DDI-MedLine.d161.s5|139-145|animals|O
DDI-MedLine.d161.s5|147-155|displayed|O
DDI-MedLine.d161.s5|157-168|parkinsonian|O
DDI-MedLine.d161.s5|170-177|symptoms|O
DDI-MedLine.d161.s5|178-178|,|O
DDI-MedLine.d161.s5|180-186|whereas|O
DDI-MedLine.d161.s5|188-191|none|O
DDI-MedLine.d161.s5|193-194|of|O
DDI-MedLine.d161.s5|196-198|the|O
DDI-MedLine.d161.s5|285-300|pyridine-treated|O
DDI-MedLine.d161.s5|302-308|monkeys|O
DDI-MedLine.d161.s5|310-313|were|O
DDI-MedLine.d161.s5|315-327|significantly|O
DDI-MedLine.d161.s5|329-336|affected|O
DDI-MedLine.d161.s5|337-337|.|O
DDI-MedLine.d161.s6|0-4|These|O
DDI-MedLine.d161.s6|6-16|behavioural|O
DDI-MedLine.d161.s6|18-29|observations|O
DDI-MedLine.d161.s6|31-34|were|O
DDI-MedLine.d161.s6|36-45|consistent|O
DDI-MedLine.d161.s6|47-50|with|O
DDI-MedLine.d161.s6|52-53|in|O
DDI-MedLine.d161.s6|55-58|vivo|O
DDI-MedLine.d161.s6|60-67|positron|O
DDI-MedLine.d161.s6|69-76|emission|O
DDI-MedLine.d161.s6|78-87|tomography|O
DDI-MedLine.d161.s6|89-96|dopamine|O
DDI-MedLine.d161.s6|98-108|transporter|O
DDI-MedLine.d161.s6|110-116|imaging|O
DDI-MedLine.d161.s6|118-121|data|O
DDI-MedLine.d161.s6|122-122|,|O
DDI-MedLine.d161.s6|124-126|and|O
DDI-MedLine.d161.s6|128-131|with|O
DDI-MedLine.d161.s6|133-143|post-mortem|O
DDI-MedLine.d161.s6|145-157|stereological|O
DDI-MedLine.d161.s6|159-164|counts|O
DDI-MedLine.d161.s6|166-167|of|O
DDI-MedLine.d161.s6|169-176|midbrain|O
DDI-MedLine.d161.s6|178-189|dopaminergic|O
DDI-MedLine.d161.s6|191-197|neurons|O
DDI-MedLine.d161.s6|198-198|,|O
DDI-MedLine.d161.s6|200-201|as|O
DDI-MedLine.d161.s6|203-206|well|O
DDI-MedLine.d161.s6|208-209|as|O
DDI-MedLine.d161.s6|211-218|striatal|O
DDI-MedLine.d161.s6|220-228|intensity|O
DDI-MedLine.d161.s6|230-241|measurements|O
DDI-MedLine.d161.s6|243-244|of|O
DDI-MedLine.d161.s6|246-253|dopamine|O
DDI-MedLine.d161.s6|255-265|transporter|O
DDI-MedLine.d161.s6|267-269|and|O
DDI-MedLine.d161.s6|271-278|tyrosine|O
DDI-MedLine.d161.s6|280-290|hydroxylase|O
DDI-MedLine.d161.s6|292-307|immunoreactivity|O
DDI-MedLine.d161.s6|308-308|,|O
DDI-MedLine.d161.s6|310-314|which|O
DDI-MedLine.d161.s6|316-319|were|O
DDI-MedLine.d161.s6|321-323|all|O
DDI-MedLine.d161.s6|325-337|significantly|O
DDI-MedLine.d161.s6|339-344|higher|O
DDI-MedLine.d161.s6|346-347|in|O
DDI-MedLine.d161.s6|434-449|pyridine-treated|O
DDI-MedLine.d161.s6|451-457|animals|O
DDI-MedLine.d161.s6|459-462|than|O
DDI-MedLine.d161.s6|464-465|in|O
DDI-MedLine.d161.s6|528-534|monkeys|O
DDI-MedLine.d161.s6|535-535|.|O
DDI-MedLine.d161.s7|0-2|The|O
DDI-MedLine.d161.s7|53-61|treatment|O
DDI-MedLine.d161.s7|63-66|also|O
DDI-MedLine.d161.s7|68-70|had|O
DDI-MedLine.d161.s7|72-72|a|O
DDI-MedLine.d161.s7|74-84|significant|O
DDI-MedLine.d161.s7|86-91|effect|O
DDI-MedLine.d161.s7|93-94|on|O
DDI-MedLine.d161.s7|96-98|the|O
DDI-MedLine.d161.s7|153-156|loss|O
DDI-MedLine.d161.s7|158-159|of|O
DDI-MedLine.d161.s7|161-174|norepinephrine|O
DDI-MedLine.d161.s7|176-182|neurons|O
DDI-MedLine.d161.s7|184-185|in|O
DDI-MedLine.d161.s7|187-189|the|O
DDI-MedLine.d161.s7|191-195|locus|O
DDI-MedLine.d161.s7|197-205|coeruleus|O
DDI-MedLine.d161.s7|207-209|and|O
DDI-MedLine.d161.s7|211-219|adjoining|O
DDI-MedLine.d161.s7|221-222|A5|O
DDI-MedLine.d161.s7|224-226|and|O
DDI-MedLine.d161.s7|228-229|A7|O
DDI-MedLine.d161.s7|231-243|noradrenaline|O
DDI-MedLine.d161.s7|245-248|cell|O
DDI-MedLine.d161.s7|250-255|groups|O
DDI-MedLine.d161.s7|256-256|.|O
DDI-MedLine.d161.s8|0-1|In|O
DDI-MedLine.d161.s8|64-70|animals|O
DDI-MedLine.d161.s8|71-71|,|O
DDI-MedLine.d161.s8|73-78|almost|O
DDI-MedLine.d161.s8|80-81|40|O
DDI-MedLine.d161.s8|82-82|%|O
DDI-MedLine.d161.s8|84-87|loss|O
DDI-MedLine.d161.s8|89-90|of|O
DDI-MedLine.d161.s8|92-99|tyrosine|O
DDI-MedLine.d161.s8|101-120|hydroxylase-positive|O
DDI-MedLine.d161.s8|122-135|norepinephrine|O
DDI-MedLine.d161.s8|137-143|neurons|O
DDI-MedLine.d161.s8|145-147|was|O
DDI-MedLine.d161.s8|149-153|found|O
DDI-MedLine.d161.s8|155-156|in|O
DDI-MedLine.d161.s8|158-162|locus|O
DDI-MedLine.d161.s8|164-178|coeruleus/A5/A7|O
DDI-MedLine.d161.s8|180-192|noradrenaline|O
DDI-MedLine.d161.s8|194-197|cell|O
DDI-MedLine.d161.s8|199-204|groups|O
DDI-MedLine.d161.s8|205-205|,|O
DDI-MedLine.d161.s8|207-213|whereas|O
DDI-MedLine.d161.s8|215-217|the|O
DDI-MedLine.d161.s8|219-224|extent|O
DDI-MedLine.d161.s8|226-227|of|O
DDI-MedLine.d161.s8|229-236|neuronal|O
DDI-MedLine.d161.s8|238-241|loss|O
DDI-MedLine.d161.s8|243-245|was|O
DDI-MedLine.d161.s8|247-251|lower|O
DDI-MedLine.d161.s8|253-256|than|O
DDI-MedLine.d161.s8|258-259|15|O
DDI-MedLine.d161.s8|260-260|%|O
DDI-MedLine.d161.s8|262-263|of|O
DDI-MedLine.d161.s8|265-271|control|O
DDI-MedLine.d161.s8|273-278|values|O
DDI-MedLine.d161.s8|280-281|in|O
DDI-MedLine.d161.s8|368-383|pyridine-treated|O
DDI-MedLine.d161.s8|385-391|monkeys|O
DDI-MedLine.d161.s8|392-392|.|O
DDI-MedLine.d161.s9|0-2|Our|O
DDI-MedLine.d161.s9|4-7|data|O
DDI-MedLine.d161.s9|9-19|demonstrate|O
DDI-MedLine.d161.s9|21-24|that|O
DDI-MedLine.d161.s9|26-32|chronic|O
DDI-MedLine.d161.s9|34-42|treatment|O
DDI-MedLine.d161.s9|44-47|with|O
DDI-MedLine.d161.s9|49-51|the|O
DDI-MedLine.d161.s9|53-64|metabotropic|O
DDI-MedLine.d161.s9|66-74|glutamate|O
DDI-MedLine.d161.s9|76-83|receptor|O
DDI-MedLine.d161.s9|85-85|5|O
DDI-MedLine.d161.s9|87-96|antagonist|O
DDI-MedLine.d161.s9|97-97|,|O
DDI-MedLine.d161.s9|147-147|,|O
DDI-MedLine.d161.s9|149-161|significantly|O
DDI-MedLine.d161.s9|163-169|reduces|O
DDI-MedLine.d161.s9|216-223|toxicity|O
DDI-MedLine.d161.s9|225-231|towards|O
DDI-MedLine.d161.s9|233-244|dopaminergic|O
DDI-MedLine.d161.s9|246-248|and|O
DDI-MedLine.d161.s9|250-262|noradrenergic|O
DDI-MedLine.d161.s9|264-267|cell|O
DDI-MedLine.d161.s9|269-274|groups|O
DDI-MedLine.d161.s9|276-277|in|O
DDI-MedLine.d161.s9|279-287|non-human|O
DDI-MedLine.d161.s9|289-296|primates|O
DDI-MedLine.d161.s9|297-297|.|O
DDI-MedLine.d161.s10|0-3|This|O
DDI-MedLine.d161.s10|5-12|suggests|O
DDI-MedLine.d161.s10|14-17|that|O
DDI-MedLine.d161.s10|19-21|the|O
DDI-MedLine.d161.s10|23-25|use|O
DDI-MedLine.d161.s10|27-28|of|O
DDI-MedLine.d161.s10|30-41|metabotropic|O
DDI-MedLine.d161.s10|43-51|glutamate|O
DDI-MedLine.d161.s10|53-60|receptor|O
DDI-MedLine.d161.s10|62-62|5|O
DDI-MedLine.d161.s10|64-74|antagonists|O
DDI-MedLine.d161.s10|76-78|may|O
DDI-MedLine.d161.s10|80-81|be|O
DDI-MedLine.d161.s10|83-83|a|O
DDI-MedLine.d161.s10|85-90|useful|O
DDI-MedLine.d161.s10|92-99|strategy|O
DDI-MedLine.d161.s10|101-102|to|O
DDI-MedLine.d161.s10|104-109|reduce|O
DDI-MedLine.d161.s10|111-122|degeneration|O
DDI-MedLine.d161.s10|124-125|of|O
DDI-MedLine.d161.s10|127-143|catecholaminergic|O
DDI-MedLine.d161.s10|145-151|neurons|O
DDI-MedLine.d161.s10|153-154|in|O
DDI-MedLine.d161.s10|156-164|Parkinson|O
DDI-MedLine.d161.s10|165-166|'s|O
DDI-MedLine.d161.s10|168-174|disease|O
DDI-MedLine.d161.s10|175-175|.|O
DDI-DrugBank.d419.s0|0-2|The|O
DDI-DrugBank.d419.s0|4-13|concurrent|O
DDI-DrugBank.d419.s0|15-28|administration|O
DDI-DrugBank.d419.s0|30-31|of|O
DDI-DrugBank.d419.s0|33-43|allopurinol|drug
DDI-DrugBank.d419.s0|45-47|and|O
DDI-DrugBank.d419.s0|49-58|ampicillin|drug
DDI-DrugBank.d419.s0|60-68|increases|O
DDI-DrugBank.d419.s0|70-82|substantially|O
DDI-DrugBank.d419.s0|84-86|the|O
DDI-DrugBank.d419.s0|88-96|incidence|O
DDI-DrugBank.d419.s0|98-99|of|O
DDI-DrugBank.d419.s0|101-106|rashes|O
DDI-DrugBank.d419.s0|108-109|in|O
DDI-DrugBank.d419.s0|111-118|patients|O
DDI-DrugBank.d419.s0|120-128|receiving|O
DDI-DrugBank.d419.s0|130-133|both|O
DDI-DrugBank.d419.s0|135-139|drugs|O
DDI-DrugBank.d419.s0|141-142|as|O
DDI-DrugBank.d419.s0|144-151|compared|O
DDI-DrugBank.d419.s0|153-154|to|O
DDI-DrugBank.d419.s0|156-163|patients|O
DDI-DrugBank.d419.s0|165-173|receiving|O
DDI-DrugBank.d419.s0|175-184|ampicillin|drug
DDI-DrugBank.d419.s0|186-190|alone|O
DDI-DrugBank.d419.s0|191-191|.|O
DDI-DrugBank.d419.s1|0-1|It|O
DDI-DrugBank.d419.s1|3-4|is|O
DDI-DrugBank.d419.s1|6-8|not|O
DDI-DrugBank.d419.s1|10-14|known|O
DDI-DrugBank.d419.s1|16-22|whether|O
DDI-DrugBank.d419.s1|24-27|this|O
DDI-DrugBank.d419.s1|29-40|potentiation|O
DDI-DrugBank.d419.s1|42-43|of|O
DDI-DrugBank.d419.s1|45-54|ampicillin|drug
DDI-DrugBank.d419.s1|56-61|rashes|O
DDI-DrugBank.d419.s1|63-64|is|O
DDI-DrugBank.d419.s1|66-68|due|O
DDI-DrugBank.d419.s1|70-71|to|O
DDI-DrugBank.d419.s1|73-83|allopurinol|drug
DDI-DrugBank.d419.s1|85-86|or|O
DDI-DrugBank.d419.s1|88-90|the|O
DDI-DrugBank.d419.s1|92-104|hyperuricemia|O
DDI-DrugBank.d419.s1|106-112|present|O
DDI-DrugBank.d419.s1|114-115|in|O
DDI-DrugBank.d419.s1|117-121|these|O
DDI-DrugBank.d419.s1|123-130|patients|O
DDI-DrugBank.d419.s1|131-131|.|O
DDI-DrugBank.d419.s2|0-1|In|O
DDI-DrugBank.d419.s2|3-12|controlled|O
DDI-DrugBank.d419.s2|14-21|clinical|O
DDI-DrugBank.d419.s2|23-28|trials|O
DDI-DrugBank.d419.s2|30-31|of|O
DDI-DrugBank.d419.s2|33-44|AUGMENTIN XR|brand
DDI-DrugBank.d419.s2|45-45|,|O
DDI-DrugBank.d419.s2|47-48|22|O
DDI-DrugBank.d419.s2|50-57|patients|O
DDI-DrugBank.d419.s2|59-66|received|O
DDI-DrugBank.d419.s2|68-78|concomitant|O
DDI-DrugBank.d419.s2|80-90|allopurinol|drug
DDI-DrugBank.d419.s2|92-94|and|O
DDI-DrugBank.d419.s2|96-107|AUGMENTIN XR|brand
DDI-DrugBank.d419.s2|108-108|.|O
DDI-DrugBank.d419.s3|0-1|No|O
DDI-DrugBank.d419.s3|3-8|rashes|O
DDI-DrugBank.d419.s3|10-13|were|O
DDI-DrugBank.d419.s3|15-22|reported|O
DDI-DrugBank.d419.s3|24-25|in|O
DDI-DrugBank.d419.s3|27-31|these|O
DDI-DrugBank.d419.s3|33-40|patients|O
DDI-DrugBank.d419.s3|41-41|.|O
DDI-DrugBank.d419.s4|0-6|However|O
DDI-DrugBank.d419.s4|7-7|,|O
DDI-DrugBank.d419.s4|9-12|this|O
DDI-DrugBank.d419.s4|14-19|sample|O
DDI-DrugBank.d419.s4|21-24|size|O
DDI-DrugBank.d419.s4|26-27|is|O
DDI-DrugBank.d419.s4|29-31|too|O
DDI-DrugBank.d419.s4|33-37|small|O
DDI-DrugBank.d419.s4|39-40|to|O
DDI-DrugBank.d419.s4|42-46|allow|O
DDI-DrugBank.d419.s4|48-50|for|O
DDI-DrugBank.d419.s4|52-54|any|O
DDI-DrugBank.d419.s4|56-66|conclusions|O
DDI-DrugBank.d419.s4|68-69|to|O
DDI-DrugBank.d419.s4|71-72|be|O
DDI-DrugBank.d419.s4|74-78|drawn|O
DDI-DrugBank.d419.s4|80-88|regarding|O
DDI-DrugBank.d419.s4|90-92|the|O
DDI-DrugBank.d419.s4|94-97|risk|O
DDI-DrugBank.d419.s4|99-100|of|O
DDI-DrugBank.d419.s4|102-107|rashes|O
DDI-DrugBank.d419.s4|109-112|with|O
DDI-DrugBank.d419.s4|114-124|concomitant|O
DDI-DrugBank.d419.s4|126-137|AUGMENTIN XR|brand
DDI-DrugBank.d419.s4|139-141|and|O
DDI-DrugBank.d419.s4|143-153|allopurinol|drug
DDI-DrugBank.d419.s4|155-157|use|O
DDI-DrugBank.d419.s4|158-158|.|O
DDI-DrugBank.d419.s5|0-1|In|O
DDI-DrugBank.d419.s5|3-8|common|O
DDI-DrugBank.d419.s5|10-13|with|O
DDI-DrugBank.d419.s5|15-19|other|O
DDI-DrugBank.d419.s5|21-46|broad-spectrum antibiotics|group
DDI-DrugBank.d419.s5|47-47|,|O
DDI-DrugBank.d419.s5|49-60|AUGMENTIN XR|brand
DDI-DrugBank.d419.s5|62-64|may|O
DDI-DrugBank.d419.s5|66-71|reduce|O
DDI-DrugBank.d419.s5|73-75|the|O
DDI-DrugBank.d419.s5|77-84|efficacy|O
DDI-DrugBank.d419.s5|86-87|of|O
DDI-DrugBank.d419.s5|89-92|oral|O
DDI-DrugBank.d170.s0|0-5|Agents|O
DDI-DrugBank.d170.s0|7-15|Affecting|O
DDI-DrugBank.d170.s0|17-26|Cytochrome|O
DDI-DrugBank.d170.s0|28-31|P450|O
DDI-DrugBank.d170.s0|33-35|3A4|O
DDI-DrugBank.d170.s0|37-45|Isoenzyme|O
DDI-DrugBank.d170.s0|47-52|System|O
DDI-DrugBank.d170.s0|54-61|Fentanyl|drug
DDI-DrugBank.d170.s0|63-64|is|O
DDI-DrugBank.d170.s0|66-76|metabolized|O
DDI-DrugBank.d170.s0|78-83|mainly|O
DDI-DrugBank.d170.s0|85-87|via|O
DDI-DrugBank.d170.s0|89-91|the|O
DDI-DrugBank.d170.s0|93-97|human|O
DDI-DrugBank.d170.s0|99-108|cytochrome|O
DDI-DrugBank.d170.s0|110-113|P450|O
DDI-DrugBank.d170.s0|115-117|3A4|O
DDI-DrugBank.d170.s0|119-127|isoenzyme|O
DDI-DrugBank.d170.s0|129-134|system|O
DDI-DrugBank.d170.s0|136-136|(|O
DDI-DrugBank.d170.s0|137-142|CYP3A4|O
DDI-DrugBank.d170.s0|143-143|)|O
DDI-DrugBank.d170.s0|144-144|,|O
DDI-DrugBank.d170.s0|146-154|therefore|O
DDI-DrugBank.d170.s0|156-164|potential|O
DDI-DrugBank.d170.s0|166-177|interactions|O
DDI-DrugBank.d170.s0|179-181|may|O
DDI-DrugBank.d170.s0|183-187|occur|O
DDI-DrugBank.d170.s0|189-192|when|O
DDI-DrugBank.d170.s0|194-202|DURAGESIC|brand
DDI-DrugBank.d170.s0|205-206|is|O
DDI-DrugBank.d170.s0|208-212|given|O
DDI-DrugBank.d170.s0|214-225|concurrently|O
DDI-DrugBank.d170.s0|227-230|with|O
DDI-DrugBank.d170.s0|232-237|agents|O
DDI-DrugBank.d170.s0|239-242|that|O
DDI-DrugBank.d170.s0|244-249|affect|O
DDI-DrugBank.d170.s0|251-256|CYP3A4|O
DDI-DrugBank.d170.s0|258-265|activity|O
DDI-DrugBank.d170.s0|266-266|.|O
DDI-DrugBank.d170.s1|0-14|Coadminstration|O
DDI-DrugBank.d170.s1|16-19|with|O
DDI-DrugBank.d170.s1|21-26|agents|O
DDI-DrugBank.d170.s1|28-31|that|O
DDI-DrugBank.d170.s1|33-38|induce|O
DDI-DrugBank.d170.s1|40-42|3A4|O
DDI-DrugBank.d170.s1|44-51|activity|O
DDI-DrugBank.d170.s1|53-55|may|O
DDI-DrugBank.d170.s1|57-62|reduce|O
DDI-DrugBank.d170.s1|64-66|the|O
DDI-DrugBank.d170.s1|68-75|efficacy|O
DDI-DrugBank.d170.s1|77-78|of|O
DDI-DrugBank.d170.s1|80-88|DURAGESIC|brand
DDI-DrugBank.d170.s1|90-90|.|O
DDI-DrugBank.d170.s2|0-2|The|O
DDI-DrugBank.d170.s2|4-14|concomitant|O
DDI-DrugBank.d170.s2|16-18|use|O
DDI-DrugBank.d170.s2|20-21|of|O
DDI-DrugBank.d170.s2|23-33|transdermal|O
DDI-DrugBank.d170.s2|35-42|fentanyl|drug
DDI-DrugBank.d170.s2|44-47|with|O
DDI-DrugBank.d170.s2|49-57|ritonavir|drug
DDI-DrugBank.d170.s2|59-60|or|O
DDI-DrugBank.d170.s2|62-66|other|O
DDI-DrugBank.d170.s2|68-73|potent|O
DDI-DrugBank.d170.s2|75-77|3A4|O
DDI-DrugBank.d170.s2|79-88|inhibitors|O
DDI-DrugBank.d170.s2|90-93|such|O
DDI-DrugBank.d170.s2|95-96|as|O
DDI-DrugBank.d170.s2|98-109|ketoconazole|drug
DDI-DrugBank.d170.s2|110-110|,|O
DDI-DrugBank.d170.s2|112-123|itraconazole|drug
DDI-DrugBank.d170.s2|124-124|,|O
DDI-DrugBank.d170.s2|126-139|troleandomycin|drug
DDI-DrugBank.d170.s2|140-140|,|O
DDI-DrugBank.d170.s2|142-155|clarithromycin|drug
DDI-DrugBank.d170.s2|156-156|,|O
DDI-DrugBank.d170.s2|158-167|nelfinavir|drug
DDI-DrugBank.d170.s2|168-168|,|O
DDI-DrugBank.d170.s2|170-172|and|O
DDI-DrugBank.d170.s2|174-183|nefazadone|O
DDI-DrugBank.d170.s2|185-187|may|O
DDI-DrugBank.d170.s2|189-194|result|O
DDI-DrugBank.d170.s2|196-197|in|O
DDI-DrugBank.d170.s2|199-200|an|O
DDI-DrugBank.d170.s2|202-209|increase|O
DDI-DrugBank.d170.s2|211-212|in|O
DDI-DrugBank.d170.s2|214-221|fentanyl|drug
DDI-DrugBank.d170.s2|223-228|plasma|O
DDI-DrugBank.d170.s2|230-243|concentrations|O
DDI-DrugBank.d170.s2|244-244|.|O
DDI-DrugBank.d170.s3|0-2|The|O
DDI-DrugBank.d170.s3|4-14|concomitant|O
DDI-DrugBank.d170.s3|16-18|use|O
DDI-DrugBank.d170.s3|20-21|of|O
DDI-DrugBank.d170.s3|23-27|other|O
DDI-DrugBank.d170.s3|29-34|CYP3A4|O
DDI-DrugBank.d170.s3|36-45|inhibitors|O
DDI-DrugBank.d170.s3|47-50|such|O
DDI-DrugBank.d170.s3|52-53|as|O
DDI-DrugBank.d170.s3|55-63|diltiazem|drug
DDI-DrugBank.d170.s3|65-67|and|O
DDI-DrugBank.d170.s3|69-80|erythromycin|drug
DDI-DrugBank.d170.s3|82-85|with|O
DDI-DrugBank.d170.s3|87-97|transdermal|O
DDI-DrugBank.d170.s3|99-106|fentanyl|drug
DDI-DrugBank.d170.s3|108-110|may|O
DDI-DrugBank.d170.s3|112-115|also|O
DDI-DrugBank.d170.s3|117-122|result|O
DDI-DrugBank.d170.s3|124-125|in|O
DDI-DrugBank.d170.s3|127-128|an|O
DDI-DrugBank.d170.s3|130-137|increase|O
DDI-DrugBank.d170.s3|139-140|in|O
DDI-DrugBank.d170.s3|142-149|fentanyl|drug
DDI-DrugBank.d170.s3|151-156|plasma|O
DDI-DrugBank.d170.s3|158-171|concentrations|O
DDI-DrugBank.d170.s3|172-172|,|O
DDI-DrugBank.d170.s3|174-178|which|O
DDI-DrugBank.d170.s3|180-184|could|O
DDI-DrugBank.d170.s3|186-193|increase|O
DDI-DrugBank.d170.s3|195-196|or|O
DDI-DrugBank.d170.s3|198-204|prolong|O
DDI-DrugBank.d170.s3|206-212|adverse|O
DDI-DrugBank.d170.s3|214-217|drug|O
DDI-DrugBank.d170.s3|219-225|effects|O
DDI-DrugBank.d170.s3|227-229|and|O
DDI-DrugBank.d170.s3|231-233|may|O
DDI-DrugBank.d170.s3|235-239|cause|O
DDI-DrugBank.d170.s3|241-247|serious|O
DDI-DrugBank.d170.s3|249-259|respiratory|O
DDI-DrugBank.d170.s3|261-270|depression|O
DDI-DrugBank.d170.s3|271-271|.|O
DDI-DrugBank.d170.s4|0-1|In|O
DDI-DrugBank.d170.s4|3-6|this|O
DDI-DrugBank.d170.s4|8-16|situation|O
DDI-DrugBank.d170.s4|17-17|,|O
DDI-DrugBank.d170.s4|19-25|special|O
DDI-DrugBank.d170.s4|27-33|patient|O
DDI-DrugBank.d170.s4|35-38|care|O
DDI-DrugBank.d170.s4|40-42|and|O
DDI-DrugBank.d170.s4|44-54|observation|O
DDI-DrugBank.d170.s4|56-58|are|O
DDI-DrugBank.d170.s4|60-70|appropriate|O
DDI-DrugBank.d170.s4|71-71|.|O
DDI-DrugBank.d170.s5|0-33|Central Nervous System Depressants|group
DDI-DrugBank.d170.s5|34-34|:|O
DDI-DrugBank.d170.s5|36-38|The|O
DDI-DrugBank.d170.s5|40-50|concomitant|O
DDI-DrugBank.d170.s5|52-54|use|O
DDI-DrugBank.d170.s5|56-57|of|O
DDI-DrugBank.d170.s5|59-67|DURAGESIC|brand
DDI-DrugBank.d170.s5|70-70|(|O
DDI-DrugBank.d170.s5|71-78|fentanyl|drug
DDI-DrugBank.d170.s5|80-90|transdermal|O
DDI-DrugBank.d170.s5|92-97|system|O
DDI-DrugBank.d170.s5|98-98|)|O
DDI-DrugBank.d170.s5|100-103|with|O
DDI-DrugBank.d170.s5|105-109|other|O
DDI-DrugBank.d170.s5|111-144|central nervous system depressants|group
DDI-DrugBank.d170.s5|145-145|,|O
DDI-DrugBank.d170.s5|147-155|including|O
DDI-DrugBank.d170.s5|157-159|but|O
DDI-DrugBank.d170.s5|161-163|not|O
DDI-DrugBank.d170.s5|165-171|limited|O
DDI-DrugBank.d170.s5|173-174|to|O
DDI-DrugBank.d170.s5|176-180|other|O
DDI-DrugBank.d170.s5|182-188|opioids|group
DDI-DrugBank.d170.s5|189-189|,|O
DDI-DrugBank.d170.s5|191-199|sedatives|group
DDI-DrugBank.d170.s5|200-200|,|O
DDI-DrugBank.d170.s5|202-210|hypnotics|group
DDI-DrugBank.d170.s5|211-211|,|O
DDI-DrugBank.d170.s5|213-225|tranquilizers|group
DDI-DrugBank.d170.s5|227-227|(|O
DDI-DrugBank.d170.s5|228-231|e.g.|O
DDI-DrugBank.d170.s5|232-232|,|O
DDI-DrugBank.d170.s5|234-248|benzodiazepines|group
DDI-DrugBank.d170.s5|249-249|)|O
DDI-DrugBank.d170.s5|250-250|,|O
DDI-DrugBank.d170.s5|252-258|general|O
DDI-DrugBank.d170.s5|260-270|anesthetics|group
DDI-DrugBank.d170.s5|271-271|,|O
DDI-DrugBank.d170.s5|273-286|phenothiazines|group
DDI-DrugBank.d170.s5|287-287|,|O
DDI-DrugBank.d170.s5|289-313|skeletal muscle relaxants|group
DDI-DrugBank.d170.s5|314-314|,|O
DDI-DrugBank.d170.s5|316-318|and|O
DDI-DrugBank.d170.s5|320-326|alcohol|drug
DDI-DrugBank.d170.s5|327-327|,|O
DDI-DrugBank.d170.s5|329-331|may|O
DDI-DrugBank.d170.s5|333-337|cause|O
DDI-DrugBank.d170.s5|339-349|respiratory|O
DDI-DrugBank.d170.s5|351-360|depression|O
DDI-DrugBank.d170.s5|361-361|,|O
DDI-DrugBank.d170.s5|363-373|hypotension|O
DDI-DrugBank.d170.s5|374-374|,|O
DDI-DrugBank.d170.s5|376-378|and|O
DDI-DrugBank.d170.s5|380-387|profound|O
DDI-DrugBank.d170.s5|389-396|sedation|O
DDI-DrugBank.d170.s5|397-397|,|O
DDI-DrugBank.d170.s5|399-400|or|O
DDI-DrugBank.d170.s5|402-412|potentially|O
DDI-DrugBank.d170.s5|414-419|result|O
DDI-DrugBank.d170.s5|421-422|in|O
DDI-DrugBank.d170.s5|424-427|coma|O
DDI-DrugBank.d170.s5|429-430|or|O
DDI-DrugBank.d170.s5|432-436|death|O
DDI-DrugBank.d170.s5|437-437|.|O
DDI-DrugBank.d170.s6|0-3|When|O
DDI-DrugBank.d170.s6|5-8|such|O
DDI-DrugBank.d170.s6|10-17|combined|O
DDI-DrugBank.d170.s6|19-25|therapy|O
DDI-DrugBank.d170.s6|27-28|is|O
DDI-DrugBank.d170.s6|30-41|contemplated|O
DDI-DrugBank.d170.s6|42-42|,|O
DDI-DrugBank.d170.s6|44-46|the|O
DDI-DrugBank.d170.s6|48-51|dose|O
DDI-DrugBank.d170.s6|53-54|of|O
DDI-DrugBank.d170.s6|56-58|one|O
DDI-DrugBank.d170.s6|60-61|or|O
DDI-DrugBank.d170.s6|63-66|both|O
DDI-DrugBank.d170.s6|68-73|agents|O
DDI-DrugBank.d170.s6|75-80|should|O
DDI-DrugBank.d170.s6|82-83|be|O
DDI-DrugBank.d170.s6|85-97|significantly|O
DDI-DrugBank.d170.s6|99-105|reduced|O
DDI-DrugBank.d170.s6|106-106|.|O
DDI-DrugBank.d170.s7|0-13|MAO Inhibitors|group
DDI-DrugBank.d170.s7|14-14|:|O
DDI-DrugBank.d170.s7|16-24|DURAGESIC|brand
DDI-DrugBank.d170.s7|27-28|is|O
DDI-DrugBank.d170.s7|30-32|not|O
DDI-DrugBank.d170.s7|34-44|recommended|O
DDI-DrugBank.d170.s7|46-48|for|O
DDI-DrugBank.d170.s7|50-52|use|O
DDI-DrugBank.d170.s7|54-55|in|O
DDI-DrugBank.d170.s7|57-64|patients|O
DDI-DrugBank.d170.s7|66-68|who|O
DDI-DrugBank.d170.s7|70-73|have|O
DDI-DrugBank.d170.s7|75-82|received|O
DDI-DrugBank.d170.s7|84-87|MAOI|group
DDI-DrugBank.d170.s7|89-94|within|O
DDI-DrugBank.d170.s7|96-97|14|O
DDI-DrugBank.d170.s7|99-102|days|O
DDI-DrugBank.d170.s7|104-110|because|O
DDI-DrugBank.d170.s7|112-117|severe|O
DDI-DrugBank.d170.s7|119-121|and|O
DDI-DrugBank.d170.s7|123-135|unpredictable|O
DDI-DrugBank.d170.s7|137-148|potentiation|O
DDI-DrugBank.d170.s7|150-151|by|O
DDI-DrugBank.d170.s7|153-166|MAO inhibitors|group
DDI-DrugBank.d170.s7|168-170|has|O
DDI-DrugBank.d170.s7|172-175|been|O
DDI-DrugBank.d170.s7|177-184|reported|O
DDI-DrugBank.d170.s7|186-189|with|O
DDI-DrugBank.d170.s8|0-0|.|O
DDI-MedLine.d75.s0|0-11|Interference|O
DDI-MedLine.d75.s0|13-14|of|O
DDI-MedLine.d75.s0|16-23|biocytin|O
DDI-MedLine.d75.s0|25-28|with|O
DDI-MedLine.d75.s0|30-42|opioid-evoked|group
DDI-MedLine.d75.s0|44-60|hyperpolarization|O
DDI-MedLine.d75.s0|62-64|and|O
DDI-MedLine.d75.s0|66-73|membrane|O
DDI-MedLine.d75.s0|75-84|properties|O
DDI-MedLine.d75.s0|86-87|of|O
DDI-MedLine.d75.s0|89-91|rat|O
DDI-MedLine.d75.s0|93-98|spinal|O
DDI-MedLine.d75.s0|100-109|substantia|O
DDI-MedLine.d75.s0|111-120|gelatinosa|O
DDI-MedLine.d75.s0|122-128|neurons|O
DDI-MedLine.d75.s0|129-129|.|O
DDI-MedLine.d75.s1|0-1|In|O
DDI-MedLine.d75.s1|3-5|our|O
DDI-MedLine.d75.s1|7-16|laboratory|O
DDI-MedLine.d75.s1|17-17|,|O
DDI-MedLine.d75.s1|19-29|preliminary|O
DDI-MedLine.d75.s1|31-40|whole-cell|O
DDI-MedLine.d75.s1|41-41|,|O
DDI-MedLine.d75.s1|43-47|tight|O
DDI-MedLine.d75.s1|49-52|seal|O
DDI-MedLine.d75.s1|54-63|recordings|O
DDI-MedLine.d75.s1|65-66|of|O
DDI-MedLine.d75.s1|68-70|rat|O
DDI-MedLine.d75.s1|72-77|spinal|O
DDI-MedLine.d75.s1|79-88|substantia|O
DDI-MedLine.d75.s1|90-99|gelatinosa|O
DDI-MedLine.d75.s1|101-107|neurons|O
DDI-MedLine.d75.s1|109-117|including|O
DDI-MedLine.d75.s1|119-126|biocytin|O
DDI-MedLine.d75.s1|128-129|in|O
DDI-MedLine.d75.s1|131-133|the|O
DDI-MedLine.d75.s1|135-139|patch|O
DDI-MedLine.d75.s1|141-147|pipette|O
DDI-MedLine.d75.s1|149-155|yielded|O
DDI-MedLine.d75.s1|157-157|a|O
DDI-MedLine.d75.s1|159-171|significantly|O
DDI-MedLine.d75.s1|173-179|smaller|O
DDI-MedLine.d75.s1|181-190|proportion|O
DDI-MedLine.d75.s1|192-193|of|O
DDI-MedLine.d75.s1|195-201|neurons|O
DDI-MedLine.d75.s1|203-216|hyperpolarized|O
DDI-MedLine.d75.s1|218-219|by|O
DDI-MedLine.d75.s1|221-245|selective opioid agonists|group
DDI-MedLine.d75.s1|247-254|compared|O
DDI-MedLine.d75.s1|256-259|with|O
DDI-MedLine.d75.s1|261-270|recordings|O
DDI-MedLine.d75.s1|272-278|without|O
DDI-MedLine.d75.s1|280-287|biocytin|O
DDI-MedLine.d75.s1|288-288|.|O
DDI-MedLine.d75.s2|0-8|Therefore|O
DDI-MedLine.d75.s2|9-9|,|O
DDI-MedLine.d75.s2|11-12|we|O
DDI-MedLine.d75.s2|14-25|investigated|O
DDI-MedLine.d75.s2|27-29|the|O
DDI-MedLine.d75.s2|31-37|effects|O
DDI-MedLine.d75.s2|39-40|of|O
DDI-MedLine.d75.s2|42-49|biocytin|O
DDI-MedLine.d75.s2|51-59|inclusion|O
DDI-MedLine.d75.s2|61-62|on|O
DDI-MedLine.d75.s2|64-69|opioid|group
DDI-MedLine.d75.s2|71-79|responses|O
DDI-MedLine.d75.s2|81-83|and|O
DDI-MedLine.d75.s2|85-89|other|O
DDI-MedLine.d75.s2|91-98|membrane|O
DDI-MedLine.d75.s2|100-109|properties|O
DDI-MedLine.d75.s2|111-116|during|O
DDI-MedLine.d75.s2|118-127|whole-cell|O
DDI-MedLine.d75.s2|128-128|,|O
DDI-MedLine.d75.s2|130-134|tight|O
DDI-MedLine.d75.s2|136-139|seal|O
DDI-MedLine.d75.s2|141-150|recordings|O
DDI-MedLine.d75.s2|152-153|of|O
DDI-MedLine.d75.s2|155-159|these|O
DDI-MedLine.d75.s2|161-167|neurons|O
DDI-MedLine.d75.s2|168-168|.|O
DDI-MedLine.d75.s3|0-2|The|O
DDI-MedLine.d75.s3|4-13|percentage|O
DDI-MedLine.d75.s3|15-16|of|O
DDI-MedLine.d75.s3|18-24|neurons|O
DDI-MedLine.d75.s3|26-39|hyperpolarized|O
DDI-MedLine.d75.s3|41-42|by|O
DDI-MedLine.d75.s3|44-46|mu-|group
DDI-MedLine.d75.s3|47-47|,|O
DDI-MedLine.d75.s3|49-57|delta ( 1 ) -|group
DDI-MedLine.d75.s3|58-58|,|O
DDI-MedLine.d75.s3|60-62|and|O
DDI-MedLine.d75.s3|64-86|kappa-selective opioids|group
DDI-MedLine.d75.s3|88-90|was|O
DDI-MedLine.d75.s3|92-104|significantly|O
DDI-MedLine.d75.s3|106-112|reduced|O
DDI-MedLine.d75.s3|114-117|when|O
DDI-MedLine.d75.s3|119-119|1|O
DDI-MedLine.d75.s3|120-120|%|O
DDI-MedLine.d75.s3|122-124|but|O
DDI-MedLine.d75.s3|126-128|not|O
DDI-MedLine.d75.s3|130-130|<|O
DDI-MedLine.d75.s4|0-1|or|O
DDI-MedLine.d75.s4|3-6|=0.2|O
DDI-MedLine.d75.s4|7-7|%|O
DDI-MedLine.d75.s4|9-16|biocytin|O
DDI-MedLine.d75.s4|18-20|was|O
DDI-MedLine.d75.s4|22-29|included|O
DDI-MedLine.d75.s4|31-32|in|O
DDI-MedLine.d75.s4|34-36|the|O
DDI-MedLine.d75.s4|38-46|recording|O
DDI-MedLine.d75.s4|48-54|pipette|O
DDI-MedLine.d75.s4|55-55|,|O
DDI-MedLine.d75.s4|57-64|compared|O
DDI-MedLine.d75.s4|66-69|with|O
DDI-MedLine.d75.s4|71-77|neurons|O
DDI-MedLine.d75.s4|79-86|recorded|O
DDI-MedLine.d75.s4|88-94|without|O
DDI-MedLine.d75.s4|96-103|biocytin|O
DDI-MedLine.d75.s4|104-104|.|O
DDI-MedLine.d75.s5|0-6|However|O
DDI-MedLine.d75.s5|7-7|,|O
DDI-MedLine.d75.s5|9-9|a|O
DDI-MedLine.d75.s5|11-23|significantly|O
DDI-MedLine.d75.s5|25-30|higher|O
DDI-MedLine.d75.s5|32-41|proportion|O
DDI-MedLine.d75.s5|43-44|of|O
DDI-MedLine.d75.s5|46-52|neurons|O
DDI-MedLine.d75.s5|54-58|fired|O
DDI-MedLine.d75.s5|60-70|spontaneous|O
DDI-MedLine.d75.s5|72-77|action|O
DDI-MedLine.d75.s5|79-88|potentials|O
DDI-MedLine.d75.s5|90-93|with|O
DDI-MedLine.d75.s5|95-100|either|O
DDI-MedLine.d75.s5|102-109|0.05-0.2|O
DDI-MedLine.d75.s5|111-112|or|O
DDI-MedLine.d75.s5|114-114|1|O
DDI-MedLine.d75.s5|115-115|%|O
DDI-MedLine.d75.s5|117-124|biocytin|O
DDI-MedLine.d75.s5|126-133|compared|O
DDI-MedLine.d75.s5|135-136|to|O
DDI-MedLine.d75.s5|138-139|no|O
DDI-MedLine.d75.s5|141-148|biocytin|O
DDI-MedLine.d75.s5|149-149|.|O
DDI-MedLine.d75.s6|0-6|Resting|O
DDI-MedLine.d75.s6|8-15|membrane|O
DDI-MedLine.d75.s6|17-25|potential|O
DDI-MedLine.d75.s6|26-26|,|O
DDI-MedLine.d75.s6|28-32|input|O
DDI-MedLine.d75.s6|34-42|impedance|O
DDI-MedLine.d75.s6|44-46|and|O
DDI-MedLine.d75.s6|48-50|the|O
DDI-MedLine.d75.s6|52-61|proportion|O
DDI-MedLine.d75.s6|63-64|of|O
DDI-MedLine.d75.s6|66-72|neurons|O
DDI-MedLine.d75.s6|74-83|displaying|O
DDI-MedLine.d75.s6|85-93|transient|O
DDI-MedLine.d75.s6|95-101|outward|O
DDI-MedLine.d75.s6|103-115|rectification|O
DDI-MedLine.d75.s6|117-120|were|O
DDI-MedLine.d75.s6|122-125|each|O
DDI-MedLine.d75.s6|127-139|significantly|O
DDI-MedLine.d75.s6|141-147|altered|O
DDI-MedLine.d75.s6|149-151|for|O
DDI-MedLine.d75.s6|153-159|neurons|O
DDI-MedLine.d75.s6|161-168|recorded|O
DDI-MedLine.d75.s6|170-173|with|O
DDI-MedLine.d75.s6|175-175|1|O
DDI-MedLine.d75.s6|176-176|%|O
DDI-MedLine.d75.s6|178-180|but|O
DDI-MedLine.d75.s6|182-184|not|O
DDI-MedLine.d75.s6|186-193|0.05-0.2|O
DDI-MedLine.d75.s6|194-194|%|O
DDI-MedLine.d75.s6|196-203|biocytin|O
DDI-MedLine.d75.s6|204-204|.|O
DDI-MedLine.d75.s7|0-4|These|O
DDI-MedLine.d75.s7|6-12|effects|O
DDI-MedLine.d75.s7|14-16|may|O
DDI-MedLine.d75.s7|18-19|be|O
DDI-MedLine.d75.s7|21-23|due|O
DDI-MedLine.d75.s7|25-26|to|O
DDI-MedLine.d75.s7|28-28|a|O
DDI-MedLine.d75.s7|30-39|relatively|O
DDI-MedLine.d75.s7|41-48|specific|O
DDI-MedLine.d75.s7|50-57|blockade|O
DDI-MedLine.d75.s7|59-60|of|O
DDI-MedLine.d75.s7|62-68|diverse|O
DDI-MedLine.d75.s7|70-78|potassium|O
DDI-MedLine.d75.s7|80-86|channel|O
DDI-MedLine.d75.s7|88-92|types|O
DDI-MedLine.d75.s7|93-93|.|O
DDI-MedLine.d75.s8|0-6|Because|O
DDI-MedLine.d75.s8|8-16|efficient|O
DDI-MedLine.d75.s8|18-25|labeling|O
DDI-MedLine.d75.s8|27-29|can|O
DDI-MedLine.d75.s8|31-32|be|O
DDI-MedLine.d75.s8|34-41|achieved|O
DDI-MedLine.d75.s8|43-46|with|O
DDI-MedLine.d75.s8|48-50|0.1|O
DDI-MedLine.d75.s8|51-51|%|O
DDI-MedLine.d75.s8|53-60|biocytin|O
DDI-MedLine.d75.s8|62-65|with|O
DDI-MedLine.d75.s8|67-76|whole-cell|O
DDI-MedLine.d75.s8|78-86|recording|O
DDI-MedLine.d75.s8|87-87|,|O
DDI-MedLine.d75.s8|89-94|higher|O
DDI-MedLine.d75.s8|96-109|concentrations|O
DDI-MedLine.d75.s8|111-113|are|O
DDI-MedLine.d75.s8|115-129|contraindicated|O
DDI-MedLine.d75.s8|130-130|.|O
DDI-DrugBank.d675.s0|0-2|CYP|O
DDI-DrugBank.d675.s0|4-6|3A4|O
DDI-DrugBank.d675.s0|8-17|Inhibitors|O
DDI-DrugBank.d675.s0|19-19|(|O
DDI-DrugBank.d675.s0|20-23|e.g.|O
DDI-DrugBank.d675.s0|25-45|Macrolide Antibiotics|group
DDI-DrugBank.d675.s0|47-49|and|O
DDI-DrugBank.d675.s0|51-69|Protease Inhibitors|group
DDI-DrugBank.d675.s0|70-70|)|O
DDI-DrugBank.d675.s0|72-76|There|O
DDI-DrugBank.d675.s0|78-81|have|O
DDI-DrugBank.d675.s0|83-86|been|O
DDI-DrugBank.d675.s0|88-91|rare|O
DDI-DrugBank.d675.s0|93-99|reports|O
DDI-DrugBank.d675.s0|101-102|of|O
DDI-DrugBank.d675.s0|104-110|serious|O
DDI-DrugBank.d675.s0|112-118|adverse|O
DDI-DrugBank.d675.s0|120-125|events|O
DDI-DrugBank.d675.s0|127-128|in|O
DDI-DrugBank.d675.s0|130-139|connection|O
DDI-DrugBank.d675.s0|141-144|with|O
DDI-DrugBank.d675.s0|146-148|the|O
DDI-DrugBank.d675.s0|150-165|coadministration|O
DDI-DrugBank.d675.s0|167-168|of|O
DDI-DrugBank.d675.s0|170-176|certain|O
DDI-DrugBank.d675.s0|178-197|ergot alkaloid drugs|group
DDI-DrugBank.d675.s0|199-199|(|O
DDI-DrugBank.d675.s0|200-203|e.g.|O
DDI-DrugBank.d675.s0|205-221|dihydroergotamine|drug
DDI-DrugBank.d675.s0|223-225|and|O
DDI-DrugBank.d675.s0|227-236|ergotamine|drug
DDI-DrugBank.d675.s0|237-237|)|O
DDI-DrugBank.d675.s0|239-241|and|O
DDI-DrugBank.d675.s0|243-248|potent|O
DDI-DrugBank.d675.s0|250-252|CYP|O
DDI-DrugBank.d675.s0|254-256|3A4|O
DDI-DrugBank.d675.s0|258-267|inhibitors|O
DDI-DrugBank.d675.s0|268-268|,|O
DDI-DrugBank.d675.s0|270-278|resulting|O
DDI-DrugBank.d675.s0|280-281|in|O
DDI-DrugBank.d675.s0|283-291|vasospasm|O
DDI-DrugBank.d675.s0|293-299|leading|O
DDI-DrugBank.d675.s0|301-302|to|O
DDI-DrugBank.d675.s0|304-311|cerebral|O
DDI-DrugBank.d675.s0|313-320|ischemia|O
DDI-DrugBank.d675.s0|322-327|and/or|O
DDI-DrugBank.d675.s0|329-336|ischemia|O
DDI-DrugBank.d675.s0|338-339|of|O
DDI-DrugBank.d675.s0|341-343|the|O
DDI-DrugBank.d675.s0|345-355|extremities|O
DDI-DrugBank.d675.s0|356-356|.|O
DDI-DrugBank.d675.s1|0-7|Although|O
DDI-DrugBank.d675.s1|9-13|there|O
DDI-DrugBank.d675.s1|15-18|have|O
DDI-DrugBank.d675.s1|20-23|been|O
DDI-DrugBank.d675.s1|25-26|no|O
DDI-DrugBank.d675.s1|28-34|reports|O
DDI-DrugBank.d675.s1|36-37|of|O
DDI-DrugBank.d675.s1|39-42|such|O
DDI-DrugBank.d675.s1|44-55|interactions|O
DDI-DrugBank.d675.s1|57-60|with|O
DDI-DrugBank.d675.s1|62-77|methylergonovine|drug
DDI-DrugBank.d675.s1|79-83|alone|O
DDI-DrugBank.d675.s1|84-84|,|O
DDI-DrugBank.d675.s1|86-91|potent|O
DDI-DrugBank.d675.s1|93-95|CYP|O
DDI-DrugBank.d675.s1|97-99|3A4|O
DDI-DrugBank.d675.s1|101-110|inhibitors|O
DDI-DrugBank.d675.s1|112-117|should|O
DDI-DrugBank.d675.s1|119-121|not|O
DDI-DrugBank.d675.s1|123-124|be|O
DDI-DrugBank.d675.s1|126-139|coadministered|O
DDI-DrugBank.d675.s1|141-144|with|O
DDI-DrugBank.d675.s1|146-161|methylergonovine|O
DDI-DrugBank.d675.s1|162-162|.|O
DDI-DrugBank.d675.s2|0-7|Examples|O
DDI-DrugBank.d675.s2|9-10|of|O
DDI-DrugBank.d675.s2|12-15|some|O
DDI-DrugBank.d675.s2|17-18|of|O
DDI-DrugBank.d675.s2|20-22|the|O
DDI-DrugBank.d675.s2|24-27|more|O
DDI-DrugBank.d675.s2|29-34|potent|O
DDI-DrugBank.d675.s2|36-38|CYP|O
DDI-DrugBank.d675.s2|40-42|3A4|O
DDI-DrugBank.d675.s2|44-53|inhibitors|O
DDI-DrugBank.d675.s2|55-61|include|O
DDI-DrugBank.d675.s2|63-83|macrolide antibiotics|group
DDI-DrugBank.d675.s2|85-85|(|O
DDI-DrugBank.d675.s2|86-89|e.g.|O
DDI-DrugBank.d675.s2|90-90|,|O
DDI-DrugBank.d675.s2|92-103|erythromycin|drug
DDI-DrugBank.d675.s2|104-104|,|O
DDI-DrugBank.d675.s2|106-119|troleandomycin|drug
DDI-DrugBank.d675.s2|120-120|,|O
DDI-DrugBank.d675.s2|122-135|clarithromycin|drug
DDI-DrugBank.d675.s2|136-136|)|O
DDI-DrugBank.d675.s2|137-137|,|O
DDI-DrugBank.d675.s2|139-150|HIV protease|group
DDI-DrugBank.d675.s2|152-153|or|O
DDI-DrugBank.d675.s2|155-186|reverse transcriptase inhibitors|group
DDI-DrugBank.d675.s2|188-188|(|O
DDI-DrugBank.d675.s2|189-192|e.g.|O
DDI-DrugBank.d675.s2|193-193|,|O
DDI-DrugBank.d675.s2|195-203|ritonavir|drug
DDI-DrugBank.d675.s2|204-204|,|O
DDI-DrugBank.d675.s2|206-214|indinavir|drug
DDI-DrugBank.d675.s2|215-215|,|O
DDI-DrugBank.d675.s2|217-226|nelfinavir|drug
DDI-DrugBank.d675.s2|227-227|,|O
DDI-DrugBank.d675.s2|229-239|delavirdine|drug
DDI-DrugBank.d675.s2|240-240|)|O
DDI-DrugBank.d675.s2|242-243|or|O
DDI-DrugBank.d675.s2|245-261|azole antifungals|group
DDI-DrugBank.d675.s2|263-263|(|O
DDI-DrugBank.d675.s2|264-267|e.g.|O
DDI-DrugBank.d675.s2|268-268|,|O
DDI-DrugBank.d675.s2|270-281|ketoconazole|drug
DDI-DrugBank.d675.s2|282-282|,|O
DDI-DrugBank.d675.s2|284-295|itraconazole|drug
DDI-DrugBank.d675.s2|296-296|,|O
DDI-DrugBank.d675.s2|298-309|voriconazole|drug
DDI-DrugBank.d675.s2|310-310|)|O
DDI-DrugBank.d675.s2|311-311|.|O
DDI-DrugBank.d675.s3|0-3|Less|O
DDI-DrugBank.d675.s3|5-10|potent|O
DDI-DrugBank.d675.s3|12-14|CYP|O
DDI-DrugBank.d675.s3|16-18|3A4|O
DDI-DrugBank.d675.s3|20-29|inhibitors|O
DDI-DrugBank.d675.s3|31-36|should|O
DDI-DrugBank.d675.s3|38-39|be|O
DDI-DrugBank.d675.s3|41-52|administered|O
DDI-DrugBank.d675.s3|54-57|with|O
DDI-DrugBank.d675.s3|59-65|caution|O
DDI-DrugBank.d675.s3|66-66|.|O
DDI-DrugBank.d675.s4|0-3|Less|O
DDI-DrugBank.d675.s4|5-10|potent|O
DDI-DrugBank.d675.s4|12-21|inhibitors|O
DDI-DrugBank.d675.s4|23-29|include|O
DDI-DrugBank.d675.s4|31-40|saquinavir|drug
DDI-DrugBank.d675.s4|41-41|,|O
DDI-DrugBank.d675.s4|43-52|nefazodone|drug
DDI-DrugBank.d675.s4|53-53|,|O
DDI-DrugBank.d675.s4|55-65|fluconazole|drug
DDI-DrugBank.d675.s4|66-66|,|O
DDI-DrugBank.d675.s4|68-77|grapefruit|O
DDI-DrugBank.d675.s4|79-83|juice|O
DDI-DrugBank.d675.s4|84-84|,|O
DDI-DrugBank.d675.s4|86-95|fluoxetine|drug
DDI-DrugBank.d675.s4|96-96|,|O
DDI-DrugBank.d675.s4|98-108|fluvoxamine|drug
DDI-DrugBank.d675.s4|109-109|,|O
DDI-DrugBank.d675.s4|111-118|zileuton|drug
DDI-DrugBank.d675.s4|119-119|,|O
DDI-DrugBank.d675.s4|121-123|and|O
DDI-DrugBank.d675.s4|125-136|clotrimazole|drug
DDI-DrugBank.d675.s4|137-137|.|O
DDI-DrugBank.d675.s5|0-4|These|O
DDI-DrugBank.d675.s5|6-10|lists|O
DDI-DrugBank.d675.s5|12-14|are|O
DDI-DrugBank.d675.s5|16-18|not|O
DDI-DrugBank.d675.s5|20-29|exhaustive|O
DDI-DrugBank.d675.s5|30-30|,|O
DDI-DrugBank.d675.s5|32-34|and|O
DDI-DrugBank.d675.s5|36-38|the|O
DDI-DrugBank.d675.s5|40-49|prescriber|O
DDI-DrugBank.d675.s5|51-56|should|O
DDI-DrugBank.d675.s5|58-65|consider|O
DDI-DrugBank.d675.s5|67-69|the|O
DDI-DrugBank.d675.s5|71-77|effects|O
DDI-DrugBank.d675.s5|79-80|on|O
DDI-DrugBank.d675.s5|82-84|CYP|O
DDI-DrugBank.d675.s5|86-88|3A4|O
DDI-DrugBank.d675.s5|90-91|of|O
DDI-DrugBank.d675.s5|93-97|other|O
DDI-DrugBank.d675.s5|99-104|agents|O
DDI-DrugBank.d675.s5|106-110|being|O
DDI-DrugBank.d675.s5|112-121|considered|O
DDI-DrugBank.d675.s5|123-125|for|O
DDI-DrugBank.d675.s5|127-137|concomitant|O
DDI-DrugBank.d675.s5|139-141|use|O
DDI-DrugBank.d675.s5|143-146|with|O
DDI-DrugBank.d675.s5|148-163|methylergonovine|drug
DDI-DrugBank.d675.s5|164-164|.|O
DDI-DrugBank.d675.s6|0-1|No|O
DDI-DrugBank.d675.s6|3-17|pharmacokinetic|O
DDI-DrugBank.d675.s6|19-30|interactions|O
DDI-DrugBank.d675.s6|32-40|involving|O
DDI-DrugBank.d675.s6|42-46|other|O
DDI-DrugBank.d675.s6|48-57|cytochrome|O
DDI-DrugBank.d675.s6|59-62|P450|O
DDI-DrugBank.d675.s6|64-73|isoenzymes|O
DDI-DrugBank.d675.s6|75-77|are|O
DDI-DrugBank.d675.s6|79-83|known|O
DDI-DrugBank.d675.s6|84-84|.|O
DDI-DrugBank.d675.s7|0-6|Caution|O
DDI-DrugBank.d675.s7|8-13|should|O
DDI-DrugBank.d675.s7|15-16|be|O
DDI-DrugBank.d675.s7|18-26|exercised|O
DDI-DrugBank.d675.s7|28-31|when|O
DDI-DrugBank.d675.s7|33-42|Methergine|brand
DDI-DrugBank.d675.s7|47-47|(|O
DDI-DrugBank.d675.s7|48-71|methylergonovine maleate|drug
DDI-DrugBank.d675.s7|72-72|)|O
DDI-DrugBank.d675.s7|74-75|is|O
DDI-DrugBank.d675.s7|77-80|used|O
DDI-DrugBank.d675.s7|82-93|concurrently|O
DDI-DrugBank.d675.s7|95-98|with|O
DDI-DrugBank.d675.s7|100-104|other|O
DDI-DrugBank.d675.s7|106-121|vasoconstrictors|group
DDI-DrugBank.d675.s7|123-124|or|O
DDI-DrugBank.d675.s7|126-140|ergot alkaloids|group
DDI-DrugBank.d675.s7|141-141|.|O
DDI-DrugBank.d58.s0|0-1|No|O
DDI-DrugBank.d58.s0|3-8|formal|O
DDI-DrugBank.d58.s0|10-13|drug|O
DDI-DrugBank.d58.s0|15-25|interaction|O
DDI-DrugBank.d58.s0|27-33|studies|O
DDI-DrugBank.d58.s0|35-38|have|O
DDI-DrugBank.d58.s0|40-43|been|O
DDI-DrugBank.d58.s0|45-53|conducted|O
DDI-DrugBank.d58.s0|54-54|.|O
DDI-DrugBank.d326.s0|0-13|Phenothiazines|group
DDI-DrugBank.d326.s0|15-15|-|O
DDI-DrugBank.d326.s0|17-22|Taking|O
DDI-DrugBank.d326.s0|24-33|piperazine|drug
DDI-DrugBank.d326.s0|35-37|and|O
DDI-DrugBank.d326.s0|39-39|a|O
DDI-DrugBank.d326.s0|41-53|phenothiazine|group
DDI-DrugBank.d326.s0|55-62|together|O
DDI-DrugBank.d326.s0|64-66|may|O
DDI-DrugBank.d326.s0|68-75|increase|O
DDI-DrugBank.d326.s0|77-79|the|O
DDI-DrugBank.d326.s0|81-84|risk|O
DDI-DrugBank.d326.s0|86-87|of|O
DDI-DrugBank.d326.s0|89-99|convulsions|O
DDI-DrugBank.d326.s0|101-101|(|O
DDI-DrugBank.d326.s0|102-109|seizures|O
DDI-DrugBank.d326.s0|110-110|)|O
DDI-DrugBank.d326.s0|111-111|.|O
DDI-DrugBank.d326.s1|0-7|Pyrantel|drug
DDI-DrugBank.d326.s1|9-9|(|O
DDI-DrugBank.d326.s1|10-13|e.g.|O
DDI-DrugBank.d326.s1|14-14|,|O
DDI-DrugBank.d326.s1|16-24|Antiminth|drug
DDI-DrugBank.d326.s1|25-25|)|O
DDI-DrugBank.d326.s1|27-27|-|O
DDI-DrugBank.d326.s1|29-34|Taking|O
DDI-DrugBank.d326.s1|36-45|piperazine|drug
DDI-DrugBank.d326.s1|47-49|and|O
DDI-DrugBank.d326.s1|51-58|pyrantel|drug
DDI-DrugBank.d326.s1|60-67|together|O
DDI-DrugBank.d326.s1|69-71|may|O
DDI-DrugBank.d326.s1|73-80|decrease|O
DDI-DrugBank.d326.s1|82-84|the|O
DDI-DrugBank.d326.s1|86-92|effects|O
DDI-DrugBank.d326.s1|94-95|of|O
DDI-DrugBank.d326.s1|97-106|piperazine|drug
DDI-DrugBank.d326.s1|107-107|.|O
DDI-DrugBank.d575.s0|0-1|In|O
DDI-DrugBank.d575.s0|3-3|a|O
DDI-DrugBank.d575.s0|5-9|study|O
DDI-DrugBank.d575.s0|11-12|in|O
DDI-DrugBank.d575.s0|14-18|which|O
DDI-DrugBank.d575.s0|20-21|34|O
DDI-DrugBank.d575.s0|23-31|different|O
DDI-DrugBank.d575.s0|33-37|drugs|O
DDI-DrugBank.d575.s0|39-42|were|O
DDI-DrugBank.d575.s0|44-49|tested|O
DDI-DrugBank.d575.s0|50-50|,|O
DDI-DrugBank.d575.s0|52-66|therapeutically|O
DDI-DrugBank.d575.s0|68-75|relevant|O
DDI-DrugBank.d575.s0|77-90|concentrations|O
DDI-DrugBank.d575.s0|92-93|of|O
DDI-DrugBank.d575.s0|95-105|tolbutamide|drug
DDI-DrugBank.d575.s0|106-106|,|O
DDI-DrugBank.d575.s0|108-124|sodium salicylate|drug
DDI-DrugBank.d575.s0|126-128|and|O
DDI-DrugBank.d575.s0|130-143|sulfamethizole|drug
DDI-DrugBank.d575.s0|145-153|displaced|O
DDI-DrugBank.d575.s0|155-167|protein-bound|O
DDI-DrugBank.d575.s0|169-178|teniposide|drug
DDI-DrugBank.d575.s0|180-181|in|O
DDI-DrugBank.d575.s0|183-187|fresh|O
DDI-DrugBank.d575.s0|189-193|human|O
DDI-DrugBank.d575.s0|195-199|serum|O
DDI-DrugBank.d575.s0|201-202|to|O
DDI-DrugBank.d575.s0|204-204|a|O
DDI-DrugBank.d575.s0|206-210|small|O
DDI-DrugBank.d575.s0|212-214|but|O
DDI-DrugBank.d575.s0|216-226|significant|O
DDI-DrugBank.d575.s0|228-233|extent|O
DDI-DrugBank.d575.s0|234-234|.|O
DDI-DrugBank.d575.s1|0-6|Because|O
DDI-DrugBank.d575.s1|8-9|of|O
DDI-DrugBank.d575.s1|11-13|the|O
DDI-DrugBank.d575.s1|15-23|extremely|O
DDI-DrugBank.d575.s1|25-28|high|O
DDI-DrugBank.d575.s1|30-36|binding|O
DDI-DrugBank.d575.s1|38-39|of|O
DDI-DrugBank.d575.s1|41-50|teniposide|drug
DDI-DrugBank.d575.s1|52-53|to|O
DDI-DrugBank.d575.s1|55-60|plasma|O
DDI-DrugBank.d575.s1|62-69|proteins|O
DDI-DrugBank.d575.s1|70-70|,|O
DDI-DrugBank.d575.s1|72-76|these|O
DDI-DrugBank.d575.s1|78-82|small|O
DDI-DrugBank.d575.s1|84-92|decreases|O
DDI-DrugBank.d575.s1|94-95|in|O
DDI-DrugBank.d575.s1|97-103|binding|O
DDI-DrugBank.d575.s1|105-109|could|O
DDI-DrugBank.d575.s1|111-115|cause|O
DDI-DrugBank.d575.s1|117-127|substantial|O
DDI-DrugBank.d575.s1|129-137|increases|O
DDI-DrugBank.d575.s1|139-140|in|O
DDI-DrugBank.d575.s1|142-145|free|O
DDI-DrugBank.d575.s1|147-150|drug|O
DDI-DrugBank.d575.s1|152-157|levels|O
DDI-DrugBank.d575.s1|159-160|in|O
DDI-DrugBank.d575.s1|162-167|plasma|O
DDI-DrugBank.d575.s1|169-173|which|O
DDI-DrugBank.d575.s1|175-179|could|O
DDI-DrugBank.d575.s1|181-186|result|O
DDI-DrugBank.d575.s1|188-189|in|O
DDI-DrugBank.d575.s1|191-202|potentiation|O
DDI-DrugBank.d575.s1|204-205|of|O
DDI-DrugBank.d575.s1|207-210|drug|O
DDI-DrugBank.d575.s1|212-219|toxicity|O
DDI-DrugBank.d575.s1|220-220|.|O
DDI-DrugBank.d575.s2|0-8|Therefore|O
DDI-DrugBank.d575.s2|9-9|,|O
DDI-DrugBank.d575.s2|11-17|caution|O
DDI-DrugBank.d575.s2|19-24|should|O
DDI-DrugBank.d575.s2|26-27|be|O
DDI-DrugBank.d575.s2|29-32|used|O
DDI-DrugBank.d575.s2|34-35|in|O
DDI-DrugBank.d575.s2|37-49|administering|O
DDI-DrugBank.d575.s2|51-55|VUMON|brand
DDI-DrugBank.d575.s2|57-57|(|O
DDI-DrugBank.d575.s2|58-67|teniposide|drug
DDI-DrugBank.d575.s2|69-77|injection|O
DDI-DrugBank.d575.s2|78-78|)|O
DDI-DrugBank.d575.s2|80-81|to|O
DDI-DrugBank.d575.s2|83-90|patients|O
DDI-DrugBank.d575.s2|92-100|receiving|O
DDI-DrugBank.d575.s2|102-106|these|O
DDI-DrugBank.d575.s2|108-112|other|O
DDI-DrugBank.d575.s2|114-119|agents|O
DDI-DrugBank.d575.s2|120-120|.|O
DDI-DrugBank.d575.s3|0-4|There|O
DDI-DrugBank.d575.s3|6-8|was|O
DDI-DrugBank.d575.s3|10-11|no|O
DDI-DrugBank.d575.s3|13-18|change|O
DDI-DrugBank.d575.s3|20-21|in|O
DDI-DrugBank.d575.s3|23-25|the|O
DDI-DrugBank.d575.s3|27-32|plasma|O
DDI-DrugBank.d575.s3|34-41|kinetics|O
DDI-DrugBank.d575.s3|43-44|of|O
DDI-DrugBank.d575.s3|46-55|teniposide|drug
DDI-DrugBank.d575.s3|57-60|when|O
DDI-DrugBank.d575.s3|62-75|coadministered|O
DDI-DrugBank.d575.s3|77-80|with|O
DDI-DrugBank.d575.s3|82-93|methotrexate|drug
DDI-DrugBank.d575.s3|94-94|.|O
DDI-DrugBank.d575.s4|0-6|However|O
DDI-DrugBank.d575.s4|7-7|,|O
DDI-DrugBank.d575.s4|9-11|the|O
DDI-DrugBank.d575.s4|13-18|plasma|O
DDI-DrugBank.d575.s4|20-28|clearance|O
DDI-DrugBank.d575.s4|30-31|of|O
DDI-DrugBank.d575.s4|33-44|methotrexate|drug
DDI-DrugBank.d575.s4|46-48|was|O
DDI-DrugBank.d575.s4|50-57|slightly|O
DDI-DrugBank.d575.s4|59-67|increased|O
DDI-DrugBank.d575.s4|68-68|.|O
DDI-DrugBank.d575.s5|0-1|An|O
DDI-DrugBank.d575.s5|3-10|increase|O
DDI-DrugBank.d575.s5|12-13|in|O
DDI-DrugBank.d575.s5|15-27|intracellular|O
DDI-DrugBank.d575.s5|29-34|levels|O
DDI-DrugBank.d575.s5|36-37|of|O
DDI-DrugBank.d575.s5|39-50|methotrexate|drug
DDI-DrugBank.d575.s5|52-54|was|O
DDI-DrugBank.d575.s5|56-63|observed|O
DDI-DrugBank.d575.s5|65-66|in|O
DDI-DrugBank.d575.s5|68-72|vitro|O
DDI-DrugBank.d575.s5|74-75|in|O
DDI-DrugBank.d575.s5|77-79|the|O
DDI-DrugBank.d575.s5|81-88|presence|O
DDI-DrugBank.d575.s5|90-91|of|O
DDI-DrugBank.d575.s5|93-102|teniposide|drug
DDI-DrugBank.d575.s5|103-103|.|O
DDI-DrugBank.d177.s0|0-1|In|O
DDI-DrugBank.d177.s0|3-7|vitro|O
DDI-DrugBank.d177.s0|8-8|,|O
DDI-DrugBank.d177.s0|10-19|nilutamide|drug
DDI-DrugBank.d177.s0|21-23|has|O
DDI-DrugBank.d177.s0|25-28|been|O
DDI-DrugBank.d177.s0|30-34|shown|O
DDI-DrugBank.d177.s0|36-37|to|O
DDI-DrugBank.d177.s0|39-45|inhibit|O
DDI-DrugBank.d177.s0|47-49|the|O
DDI-DrugBank.d177.s0|51-58|activity|O
DDI-DrugBank.d177.s0|60-61|of|O
DDI-DrugBank.d177.s0|63-67|liver|O
DDI-DrugBank.d177.s0|69-78|cytochrome|O
DDI-DrugBank.d177.s0|80-84|P-450|O
DDI-DrugBank.d177.s0|86-95|isoenzymes|O
DDI-DrugBank.d177.s0|97-99|and|O
DDI-DrugBank.d177.s0|101-109|therefore|O
DDI-DrugBank.d177.s0|110-110|,|O
DDI-DrugBank.d177.s0|112-114|may|O
DDI-DrugBank.d177.s0|116-121|reduce|O
DDI-DrugBank.d177.s0|123-125|the|O
DDI-DrugBank.d177.s0|127-136|metabolism|O
DDI-DrugBank.d177.s0|138-139|of|O
DDI-DrugBank.d177.s0|141-149|compounds|O
DDI-DrugBank.d177.s0|151-159|requiring|O
DDI-DrugBank.d177.s0|161-165|these|O
DDI-DrugBank.d177.s0|167-173|systems|O
DDI-DrugBank.d177.s0|174-174|.|O
DDI-DrugBank.d177.s1|0-11|Consequently|O
DDI-DrugBank.d177.s1|12-12|,|O
DDI-DrugBank.d177.s1|14-18|drugs|O
DDI-DrugBank.d177.s1|20-23|with|O
DDI-DrugBank.d177.s1|25-25|a|O
DDI-DrugBank.d177.s1|27-29|low|O
DDI-DrugBank.d177.s1|31-41|therapeutic|O
DDI-DrugBank.d177.s1|43-48|margin|O
DDI-DrugBank.d177.s1|49-49|,|O
DDI-DrugBank.d177.s1|51-54|such|O
DDI-DrugBank.d177.s1|56-57|as|O
DDI-DrugBank.d177.s1|59-79|vitamin K antagonists|group
DDI-DrugBank.d177.s1|80-80|,|O
DDI-DrugBank.d177.s1|82-90|phenytoin|drug
DDI-DrugBank.d177.s1|91-91|,|O
DDI-DrugBank.d177.s1|93-95|and|O
DDI-DrugBank.d177.s1|97-108|theophylline|drug
DDI-DrugBank.d177.s1|109-109|,|O
DDI-DrugBank.d177.s1|111-115|could|O
DDI-DrugBank.d177.s1|117-120|have|O
DDI-DrugBank.d177.s1|122-122|a|O
DDI-DrugBank.d177.s1|124-130|delayed|O
DDI-DrugBank.d177.s1|132-142|elimination|O
DDI-DrugBank.d177.s1|144-146|and|O
DDI-DrugBank.d177.s1|148-156|increases|O
DDI-DrugBank.d177.s1|158-159|in|O
DDI-DrugBank.d177.s1|161-165|their|O
DDI-DrugBank.d177.s1|167-171|serum|O
DDI-DrugBank.d177.s1|173-181|half-life|O
DDI-DrugBank.d177.s1|183-189|leading|O
DDI-DrugBank.d177.s1|191-192|to|O
DDI-DrugBank.d177.s1|194-194|a|O
DDI-DrugBank.d177.s1|196-200|toxic|O
DDI-DrugBank.d177.s1|202-206|level|O
DDI-DrugBank.d177.s1|207-207|.|O
DDI-DrugBank.d177.s2|0-2|The|O
DDI-DrugBank.d177.s2|4-9|dosage|O
DDI-DrugBank.d177.s2|11-12|of|O
DDI-DrugBank.d177.s2|14-18|these|O
DDI-DrugBank.d177.s2|20-24|drugs|O
DDI-DrugBank.d177.s2|26-27|or|O
DDI-DrugBank.d177.s2|29-34|others|O
DDI-DrugBank.d177.s2|36-39|with|O
DDI-DrugBank.d177.s2|41-41|a|O
DDI-DrugBank.d177.s2|43-49|similar|O
DDI-DrugBank.d177.s2|51-60|metabolism|O
DDI-DrugBank.d177.s2|62-64|may|O
DDI-DrugBank.d177.s2|66-69|need|O
DDI-DrugBank.d177.s2|71-72|to|O
DDI-DrugBank.d177.s2|74-75|be|O
DDI-DrugBank.d177.s2|77-84|modified|O
DDI-DrugBank.d177.s2|86-87|if|O
DDI-DrugBank.d177.s2|89-92|they|O
DDI-DrugBank.d177.s2|94-96|are|O
DDI-DrugBank.d177.s2|98-109|administered|O
DDI-DrugBank.d177.s2|111-123|concomitantly|O
DDI-DrugBank.d177.s2|125-128|with|O
DDI-DrugBank.d177.s2|130-139|nilutamide|drug
DDI-DrugBank.d177.s2|140-140|.|O
DDI-DrugBank.d177.s3|0-2|For|O
DDI-DrugBank.d177.s3|4-10|example|O
DDI-DrugBank.d177.s3|11-11|,|O
DDI-DrugBank.d177.s3|13-16|when|O
DDI-DrugBank.d177.s3|18-38|vitamin K antagonists|group
DDI-DrugBank.d177.s3|40-42|are|O
DDI-DrugBank.d177.s3|44-55|administered|O
DDI-DrugBank.d177.s3|57-69|concomitantly|O
DDI-DrugBank.d177.s3|71-74|with|O
DDI-DrugBank.d177.s3|76-85|nilutamide|drug
DDI-DrugBank.d177.s3|86-86|,|O
DDI-DrugBank.d177.s3|88-98|prothrombin|O
DDI-DrugBank.d177.s3|100-103|time|O
DDI-DrugBank.d177.s3|105-110|should|O
DDI-DrugBank.d177.s3|112-113|be|O
DDI-DrugBank.d177.s3|115-123|carefully|O
DDI-DrugBank.d177.s3|125-133|monitored|O
DDI-DrugBank.d177.s3|135-137|and|O
DDI-DrugBank.d177.s3|139-140|if|O
DDI-DrugBank.d177.s3|142-150|necessary|O
DDI-DrugBank.d177.s3|151-151|,|O
DDI-DrugBank.d177.s3|153-155|the|O
DDI-DrugBank.d177.s3|157-162|dosage|O
DDI-DrugBank.d177.s3|164-165|of|O
DDI-DrugBank.d177.s3|167-187|vitamin K antagonists|group
DDI-DrugBank.d177.s3|189-194|should|O
DDI-DrugBank.d177.s3|196-197|be|O
DDI-DrugBank.d177.s3|199-205|reduced|O
DDI-DrugBank.d177.s3|206-206|.|O
DDI-MedLine.d139.s0|0-0|[|O
DDI-MedLine.d139.s0|1-12|Quantitative|O
DDI-MedLine.d139.s0|14-21|approach|O
DDI-MedLine.d139.s0|23-24|to|O
DDI-MedLine.d139.s0|26-34|treatment|O
DDI-MedLine.d139.s0|36-39|with|O
DDI-MedLine.d139.s0|41-48|incisive|O
DDI-MedLine.d139.s0|50-61|neuroleptics|group
DDI-MedLine.d139.s0|63-64|by|O
DDI-MedLine.d139.s0|66-76|therapeutic|O
DDI-MedLine.d139.s0|78-87|monitoring|O
DDI-MedLine.d139.s0|88-88|]|O
DDI-MedLine.d139.s0|89-89|;|O
DDI-MedLine.d139.s0|91-93|The|O
DDI-MedLine.d139.s0|95-102|problems|O
DDI-MedLine.d139.s0|104-114|encountered|O
DDI-MedLine.d139.s0|116-121|during|O
DDI-MedLine.d139.s0|123-125|the|O
DDI-MedLine.d139.s0|127-134|longterm|O
DDI-MedLine.d139.s0|136-144|treatment|O
DDI-MedLine.d139.s0|146-147|of|O
DDI-MedLine.d139.s0|149-157|psychotic|O
DDI-MedLine.d139.s0|159-166|patients|O
DDI-MedLine.d139.s0|168-171|with|O
DDI-MedLine.d139.s0|173-184|neuroleptics|group
DDI-MedLine.d139.s0|186-188|are|O
DDI-MedLine.d139.s0|190-200|illustrated|O
DDI-MedLine.d139.s0|202-203|by|O
DDI-MedLine.d139.s0|205-207|six|O
DDI-MedLine.d139.s0|209-215|typical|O
DDI-MedLine.d139.s0|217-220|case|O
DDI-MedLine.d139.s0|222-228|reports|O
DDI-MedLine.d139.s0|229-229|.|O
DDI-MedLine.d139.s1|0-0|A|O
DDI-MedLine.d139.s1|2-6|group|O
DDI-MedLine.d139.s1|8-9|of|O
DDI-MedLine.d139.s1|11-18|patients|O
DDI-MedLine.d139.s1|20-22|who|O
DDI-MedLine.d139.s1|24-26|had|O
DDI-MedLine.d139.s1|28-30|had|O
DDI-MedLine.d139.s1|32-32|a|O
DDI-MedLine.d139.s1|34-36|new|O
DDI-MedLine.d139.s1|38-42|acute|O
DDI-MedLine.d139.s1|44-50|episode|O
DDI-MedLine.d139.s1|52-58|despite|O
DDI-MedLine.d139.s1|60-68|seemingly|O
DDI-MedLine.d139.s1|70-77|adequate|O
DDI-MedLine.d139.s1|79-87|treatment|O
DDI-MedLine.d139.s1|89-92|were|O
DDI-MedLine.d139.s1|94-101|selected|O
DDI-MedLine.d139.s1|102-102|.|O
DDI-MedLine.d139.s2|0-1|In|O
DDI-MedLine.d139.s2|3-7|these|O
DDI-MedLine.d139.s2|9-11|six|O
DDI-MedLine.d139.s2|13-17|cases|O
DDI-MedLine.d139.s2|19-20|it|O
DDI-MedLine.d139.s2|22-24|was|O
DDI-MedLine.d139.s2|26-37|demonstrated|O
DDI-MedLine.d139.s2|39-42|that|O
DDI-MedLine.d139.s2|44-46|the|O
DDI-MedLine.d139.s2|48-59|neuroleptics|group
DDI-MedLine.d139.s2|61-66|dosage|O
DDI-MedLine.d139.s2|68-70|was|O
DDI-MedLine.d139.s2|72-84|inappropriate|O
DDI-MedLine.d139.s2|85-85|,|O
DDI-MedLine.d139.s2|87-91|being|O
DDI-MedLine.d139.s2|93-98|either|O
DDI-MedLine.d139.s2|100-102|too|O
DDI-MedLine.d139.s2|104-107|high|O
DDI-MedLine.d139.s2|109-110|or|O
DDI-MedLine.d139.s2|112-114|too|O
DDI-MedLine.d139.s2|116-118|low|O
DDI-MedLine.d139.s2|120-121|as|O
DDI-MedLine.d139.s2|123-128|judged|O
DDI-MedLine.d139.s2|130-133|from|O
DDI-MedLine.d139.s2|135-137|the|O
DDI-MedLine.d139.s2|139-144|plasma|O
DDI-MedLine.d139.s2|146-159|concentrations|O
DDI-MedLine.d139.s2|160-160|.|O
DDI-MedLine.d139.s3|0-3|Ways|O
DDI-MedLine.d139.s3|5-6|of|O
DDI-MedLine.d139.s3|8-16|improving|O
DDI-MedLine.d139.s3|18-20|the|O
DDI-MedLine.d139.s3|22-29|adequacy|O
DDI-MedLine.d139.s3|31-32|of|O
DDI-MedLine.d139.s3|34-36|the|O
DDI-MedLine.d139.s3|38-46|treatment|O
DDI-MedLine.d139.s3|48-49|of|O
DDI-MedLine.d139.s3|51-59|psychotic|O
DDI-MedLine.d139.s3|61-68|patients|O
DDI-MedLine.d139.s3|70-73|with|O
DDI-MedLine.d139.s3|75-86|neuroleptics|group
DDI-MedLine.d139.s3|88-90|are|O
DDI-MedLine.d139.s3|92-100|discussed|O
DDI-MedLine.d139.s3|101-101|.|O
DDI-DrugBank.d690.s0|0-2|The|O
DDI-DrugBank.d690.s0|4-17|CNS-depressant|O
DDI-DrugBank.d690.s0|19-24|effect|O
DDI-DrugBank.d690.s0|26-27|of|O
DDI-DrugBank.d690.s0|29-40|propoxyphene|drug
DDI-DrugBank.d690.s0|42-43|is|O
DDI-DrugBank.d690.s0|45-52|additive|O
DDI-DrugBank.d690.s0|54-57|with|O
DDI-DrugBank.d690.s0|59-62|that|O
DDI-DrugBank.d690.s0|64-65|of|O
DDI-DrugBank.d690.s0|67-71|other|O
DDI-DrugBank.d690.s0|73-87|CNS depressants|group
DDI-DrugBank.d690.s0|88-88|,|O
DDI-DrugBank.d690.s0|90-98|including|O
DDI-DrugBank.d690.s0|100-106|alcohol|drug
DDI-DrugBank.d690.s0|107-107|.|O
DDI-DrugBank.d690.s1|0-1|As|O
DDI-DrugBank.d690.s1|3-4|is|O
DDI-DrugBank.d690.s1|6-8|the|O
DDI-DrugBank.d690.s1|10-13|case|O
DDI-DrugBank.d690.s1|15-18|with|O
DDI-DrugBank.d690.s1|20-23|many|O
DDI-DrugBank.d690.s1|25-33|medicinal|O
DDI-DrugBank.d690.s1|35-40|agents|O
DDI-DrugBank.d690.s1|41-41|,|O
DDI-DrugBank.d690.s1|43-54|propoxyphene|drug
DDI-DrugBank.d690.s1|56-58|may|O
DDI-DrugBank.d690.s1|60-63|slow|O
DDI-DrugBank.d690.s1|65-67|the|O
DDI-DrugBank.d690.s1|69-78|metabolism|O
DDI-DrugBank.d690.s1|80-81|of|O
DDI-DrugBank.d690.s1|83-83|a|O
DDI-DrugBank.d690.s1|85-97|concomitantly|O
DDI-DrugBank.d690.s1|99-110|administered|O
DDI-DrugBank.d690.s1|112-115|drug|O
DDI-DrugBank.d690.s1|116-116|.|O
DDI-DrugBank.d690.s2|0-5|Should|O
DDI-DrugBank.d690.s2|7-10|this|O
DDI-DrugBank.d690.s2|12-16|occur|O
DDI-DrugBank.d690.s2|17-17|,|O
DDI-DrugBank.d690.s2|19-21|the|O
DDI-DrugBank.d690.s2|23-28|higher|O
DDI-DrugBank.d690.s2|30-34|serum|O
DDI-DrugBank.d690.s2|36-49|concentrations|O
DDI-DrugBank.d690.s2|51-52|of|O
DDI-DrugBank.d690.s2|54-57|that|O
DDI-DrugBank.d690.s2|59-62|drug|O
DDI-DrugBank.d690.s2|64-66|may|O
DDI-DrugBank.d690.s2|68-73|result|O
DDI-DrugBank.d690.s2|75-76|in|O
DDI-DrugBank.d690.s2|78-86|increased|O
DDI-DrugBank.d690.s2|88-100|pharmacologic|O
DDI-DrugBank.d690.s2|102-103|or|O
DDI-DrugBank.d690.s2|105-111|adverse|O
DDI-DrugBank.d690.s2|113-119|effects|O
DDI-DrugBank.d690.s2|121-122|of|O
DDI-DrugBank.d690.s2|124-127|that|O
DDI-DrugBank.d690.s2|129-132|drug|O
DDI-DrugBank.d690.s2|133-133|.|O
DDI-DrugBank.d690.s3|0-3|Such|O
DDI-DrugBank.d690.s3|5-15|occurrences|O
DDI-DrugBank.d690.s3|17-20|have|O
DDI-DrugBank.d690.s3|22-25|been|O
DDI-DrugBank.d690.s3|27-34|reported|O
DDI-DrugBank.d690.s3|36-39|when|O
DDI-DrugBank.d690.s3|41-52|propoxyphene|drug
DDI-DrugBank.d690.s3|54-56|was|O
DDI-DrugBank.d690.s3|58-69|administered|O
DDI-DrugBank.d690.s3|71-72|to|O
DDI-DrugBank.d690.s3|74-81|patients|O
DDI-DrugBank.d690.s3|83-84|on|O
DDI-DrugBank.d690.s3|86-100|antidepressants|group
DDI-DrugBank.d690.s3|101-101|,|O
DDI-DrugBank.d690.s3|103-117|anticonvulsants|group
DDI-DrugBank.d690.s3|118-118|,|O
DDI-DrugBank.d690.s3|120-121|or|O
DDI-DrugBank.d690.s3|123-135|warfarin-like|drug
DDI-DrugBank.d690.s3|137-141|drugs|O
DDI-DrugBank.d690.s3|142-142|.|O
DDI-DrugBank.d690.s4|0-4|Sever|O
DDI-DrugBank.d690.s4|6-15|neurologic|O
DDI-DrugBank.d690.s4|17-21|signs|O
DDI-DrugBank.d690.s4|22-22|,|O
DDI-DrugBank.d690.s4|24-32|including|O
DDI-DrugBank.d690.s4|34-37|coma|O
DDI-DrugBank.d690.s4|38-38|,|O
DDI-DrugBank.d690.s4|40-43|have|O
DDI-DrugBank.d690.s4|45-52|occurred|O
DDI-DrugBank.d690.s4|54-57|with|O
DDI-DrugBank.d690.s4|59-68|concurrent|O
DDI-DrugBank.d690.s4|70-72|use|O
DDI-DrugBank.d690.s4|74-75|of|O
DDI-DrugBank.d690.s4|77-89|carbamazepine|drug
DDI-DrugBank.d690.s4|90-90|.|O
DDI-DrugBank.d400.s0|0-6|Aspirin|brand
DDI-DrugBank.d400.s0|7-7|:|O
DDI-DrugBank.d400.s0|9-10|As|O
DDI-DrugBank.d400.s0|12-15|with|O
DDI-DrugBank.d400.s0|17-21|other|O
DDI-DrugBank.d400.s0|23-28|NSAIDs|group
DDI-DrugBank.d400.s0|29-29|,|O
DDI-DrugBank.d400.s0|31-41|concomitant|O
DDI-DrugBank.d400.s0|43-56|administration|O
DDI-DrugBank.d400.s0|58-59|of|O
DDI-DrugBank.d400.s0|61-67|Ponstel|brand
DDI-DrugBank.d400.s0|69-71|and|O
DDI-DrugBank.d400.s0|73-79|aspirin|brand
DDI-DrugBank.d400.s0|81-82|is|O
DDI-DrugBank.d400.s0|84-86|not|O
DDI-DrugBank.d400.s0|88-96|generally|O
DDI-DrugBank.d400.s0|98-108|recommended|O
DDI-DrugBank.d400.s0|110-116|because|O
DDI-DrugBank.d400.s0|118-119|of|O
DDI-DrugBank.d400.s0|121-123|the|O
DDI-DrugBank.d400.s0|125-133|potential|O
DDI-DrugBank.d400.s0|135-136|of|O
DDI-DrugBank.d400.s0|138-146|increased|O
DDI-DrugBank.d400.s0|148-154|adverse|O
DDI-DrugBank.d400.s0|156-162|effects|O
DDI-DrugBank.d400.s0|163-163|.|O
DDI-DrugBank.d400.s1|0-11|Methotrexate|drug
DDI-DrugBank.d400.s1|12-12|:|O
DDI-DrugBank.d400.s1|14-19|NSAIDs|group
DDI-DrugBank.d400.s1|21-24|have|O
DDI-DrugBank.d400.s1|26-29|been|O
DDI-DrugBank.d400.s1|31-38|reported|O
DDI-DrugBank.d400.s1|40-41|to|O
DDI-DrugBank.d400.s1|43-55|competitively|O
DDI-DrugBank.d400.s1|57-63|inhibit|O
DDI-DrugBank.d400.s1|65-76|methotrexate|drug
DDI-DrugBank.d400.s1|78-89|accumulation|O
DDI-DrugBank.d400.s1|91-92|in|O
DDI-DrugBank.d400.s1|94-99|rabbit|O
DDI-DrugBank.d400.s1|101-106|kidney|O
DDI-DrugBank.d400.s1|108-113|slices|O
DDI-DrugBank.d400.s1|114-114|.|O
DDI-DrugBank.d400.s2|0-3|This|O
DDI-DrugBank.d400.s2|5-7|may|O
DDI-DrugBank.d400.s2|9-16|indicate|O
DDI-DrugBank.d400.s2|18-21|that|O
DDI-DrugBank.d400.s2|23-26|they|O
DDI-DrugBank.d400.s2|28-32|could|O
DDI-DrugBank.d400.s2|34-40|enhance|O
DDI-DrugBank.d400.s2|42-44|the|O
DDI-DrugBank.d400.s2|46-53|toxicity|O
DDI-DrugBank.d400.s2|55-56|of|O
DDI-DrugBank.d400.s2|58-69|methotrexate|drug
DDI-DrugBank.d400.s2|70-70|.|O
DDI-DrugBank.d400.s3|0-6|Caution|O
DDI-DrugBank.d400.s3|8-13|should|O
DDI-DrugBank.d400.s3|15-16|be|O
DDI-DrugBank.d400.s3|18-21|used|O
DDI-DrugBank.d400.s3|23-26|when|O
DDI-DrugBank.d400.s3|28-33|NSAIDs|group
DDI-DrugBank.d400.s3|35-37|are|O
DDI-DrugBank.d400.s3|39-50|administered|O
DDI-DrugBank.d400.s3|52-64|concomitantly|O
DDI-DrugBank.d400.s3|66-69|with|O
DDI-DrugBank.d400.s3|71-82|methotrexate|drug
DDI-DrugBank.d400.s3|83-83|.|O
DDI-DrugBank.d400.s4|0-13|ACE inhibitors|group
DDI-DrugBank.d400.s4|14-14|:|O
DDI-DrugBank.d400.s4|16-22|Reports|O
DDI-DrugBank.d400.s4|24-30|suggest|O
DDI-DrugBank.d400.s4|32-35|that|O
DDI-DrugBank.d400.s4|37-42|NSAIDs|group
DDI-DrugBank.d400.s4|44-46|may|O
DDI-DrugBank.d400.s4|48-55|diminish|O
DDI-DrugBank.d400.s4|57-59|the|O
DDI-DrugBank.d400.s4|61-76|antihypertensive|O
DDI-DrugBank.d400.s4|78-83|effect|O
DDI-DrugBank.d400.s4|85-86|of|O
DDI-DrugBank.d400.s4|88-101|ACE inhibitors|group
DDI-DrugBank.d400.s4|102-102|.|O
DDI-DrugBank.d400.s5|0-3|This|O
DDI-DrugBank.d400.s5|5-15|interaction|O
DDI-DrugBank.d400.s5|17-22|should|O
DDI-DrugBank.d400.s5|24-25|be|O
DDI-DrugBank.d400.s5|27-31|given|O
DDI-DrugBank.d400.s5|33-45|consideration|O
DDI-DrugBank.d400.s5|47-48|in|O
DDI-DrugBank.d400.s5|50-57|patients|O
DDI-DrugBank.d400.s5|59-64|taking|O
DDI-DrugBank.d400.s5|66-71|NSAIDs|group
DDI-DrugBank.d400.s5|73-85|concomitantly|O
DDI-DrugBank.d400.s5|87-90|with|O
DDI-DrugBank.d400.s5|92-105|ACE inhibitors|group
DDI-DrugBank.d400.s5|106-106|.|O
DDI-DrugBank.d400.s6|0-9|Furosemide|drug
DDI-DrugBank.d400.s6|10-10|:|O
DDI-DrugBank.d400.s6|12-19|Clinical|O
DDI-DrugBank.d400.s6|21-27|studies|O
DDI-DrugBank.d400.s6|28-28|,|O
DDI-DrugBank.d400.s6|30-31|as|O
DDI-DrugBank.d400.s6|33-36|well|O
DDI-DrugBank.d400.s6|38-39|as|O
DDI-DrugBank.d400.s6|41-54|post-marketing|O
DDI-DrugBank.d400.s6|56-67|observations|O
DDI-DrugBank.d400.s6|68-68|,|O
DDI-DrugBank.d400.s6|70-73|have|O
DDI-DrugBank.d400.s6|75-79|shown|O
DDI-DrugBank.d400.s6|81-84|that|O
DDI-DrugBank.d400.s6|86-91|NSAIDs|group
DDI-DrugBank.d400.s6|93-95|can|O
DDI-DrugBank.d400.s6|97-102|reduce|O
DDI-DrugBank.d400.s6|104-106|the|O
DDI-DrugBank.d400.s6|108-118|natriuretic|O
DDI-DrugBank.d400.s6|120-125|effect|O
DDI-DrugBank.d400.s6|127-128|of|O
DDI-DrugBank.d400.s6|130-139|furosemide|drug
DDI-DrugBank.d400.s6|141-143|and|O
DDI-DrugBank.d400.s6|145-153|thiazides|group
DDI-DrugBank.d400.s6|155-156|in|O
DDI-DrugBank.d400.s6|158-161|some|O
DDI-DrugBank.d400.s6|163-170|patients|O
DDI-DrugBank.d400.s6|171-171|.|O
DDI-DrugBank.d400.s7|0-3|This|O
DDI-DrugBank.d400.s7|5-12|response|O
DDI-DrugBank.d400.s7|14-16|has|O
DDI-DrugBank.d400.s7|18-21|been|O
DDI-DrugBank.d400.s7|23-32|attributed|O
DDI-DrugBank.d400.s7|34-35|to|O
DDI-DrugBank.d400.s7|37-46|inhibition|O
DDI-DrugBank.d400.s7|48-49|of|O
DDI-DrugBank.d400.s7|51-55|renal|O
DDI-DrugBank.d400.s7|57-69|prostaglandin|O
DDI-DrugBank.d400.s7|71-79|synthesis|O
DDI-DrugBank.d400.s7|80-80|.|O
DDI-DrugBank.d400.s8|0-5|During|O
DDI-DrugBank.d400.s8|7-17|concomitant|O
DDI-DrugBank.d400.s8|19-25|therapy|O
DDI-DrugBank.d400.s8|27-28|of|O
DDI-DrugBank.d400.s8|30-36|Ponstel|brand
DDI-DrugBank.d400.s8|38-41|with|O
DDI-DrugBank.d400.s8|43-52|furosemide|drug
DDI-DrugBank.d400.s8|53-53|,|O
DDI-DrugBank.d400.s8|55-57|the|O
DDI-DrugBank.d400.s8|59-65|patient|O
DDI-DrugBank.d400.s8|67-72|should|O
DDI-DrugBank.d400.s8|74-75|be|O
DDI-DrugBank.d400.s8|77-84|observed|O
DDI-DrugBank.d400.s8|86-92|closely|O
DDI-DrugBank.d400.s8|94-96|for|O
DDI-DrugBank.d400.s8|98-102|signs|O
DDI-DrugBank.d400.s8|104-105|of|O
DDI-DrugBank.d400.s8|107-111|renal|O
DDI-DrugBank.d400.s8|113-119|failure|O
DDI-DrugBank.d400.s8|120-120|,|O
DDI-DrugBank.d400.s8|122-123|as|O
DDI-DrugBank.d400.s8|125-128|well|O
DDI-DrugBank.d400.s8|130-131|as|O
DDI-DrugBank.d400.s8|133-134|to|O
DDI-DrugBank.d400.s8|136-141|assure|O
DDI-DrugBank.d400.s8|143-150|diuretic|O
DDI-DrugBank.d400.s8|152-159|efficacy|O
DDI-DrugBank.d400.s8|160-160|.|O
DDI-DrugBank.d400.s9|0-6|Lithium|drug
DDI-DrugBank.d400.s9|7-7|:|O
DDI-DrugBank.d400.s9|9-14|NSAIDs|group
DDI-DrugBank.d400.s9|16-19|have|O
DDI-DrugBank.d400.s9|21-28|produced|O
DDI-DrugBank.d400.s9|30-31|an|O
DDI-DrugBank.d400.s9|33-41|elevation|O
DDI-DrugBank.d400.s9|43-44|of|O
DDI-DrugBank.d400.s9|46-51|plasma|O
DDI-DrugBank.d400.s9|53-59|lithium|drug
DDI-DrugBank.d400.s9|61-66|levels|O
DDI-DrugBank.d400.s9|68-70|and|O
DDI-DrugBank.d400.s9|72-72|a|O
DDI-DrugBank.d400.s9|74-82|reduction|O
DDI-DrugBank.d400.s9|84-85|in|O
DDI-DrugBank.d400.s9|87-91|renal|O
DDI-DrugBank.d400.s9|93-99|lithium|drug
DDI-DrugBank.d400.s9|101-109|clearance|O
DDI-DrugBank.d400.s9|110-110|.|O
DDI-DrugBank.d400.s10|0-2|The|O
DDI-DrugBank.d400.s10|4-7|mean|O
DDI-DrugBank.d400.s10|9-15|minimum|O
DDI-DrugBank.d400.s10|17-23|lithium|drug
DDI-DrugBank.d400.s10|25-37|concentration|O
DDI-DrugBank.d400.s10|39-47|increased|O
DDI-DrugBank.d400.s10|49-50|15|O
DDI-DrugBank.d400.s10|51-51|%|O
DDI-DrugBank.d400.s10|53-55|and|O
DDI-DrugBank.d400.s10|57-59|the|O
DDI-DrugBank.d400.s10|61-65|renal|O
DDI-DrugBank.d400.s10|67-75|clearance|O
DDI-DrugBank.d400.s10|77-79|was|O
DDI-DrugBank.d400.s10|81-89|decreased|O
DDI-DrugBank.d400.s10|91-92|by|O
DDI-DrugBank.d400.s10|94-106|approximately|O
DDI-DrugBank.d400.s10|108-109|20|O
DDI-DrugBank.d400.s10|110-110|%|O
DDI-DrugBank.d400.s10|111-111|.|O
DDI-DrugBank.d400.s11|0-4|These|O
DDI-DrugBank.d400.s11|6-12|effects|O
DDI-DrugBank.d400.s11|14-17|have|O
DDI-DrugBank.d400.s11|19-22|been|O
DDI-DrugBank.d400.s11|24-33|attributed|O
DDI-DrugBank.d400.s11|35-36|to|O
DDI-DrugBank.d400.s11|38-47|inhibition|O
DDI-DrugBank.d400.s11|49-50|of|O
DDI-DrugBank.d400.s11|52-56|renal|O
DDI-DrugBank.d400.s11|58-70|prostaglandin|O
DDI-DrugBank.d400.s11|72-80|synthesis|O
DDI-DrugBank.d400.s11|82-83|by|O
DDI-DrugBank.d400.s11|85-87|the|O
DDI-DrugBank.d400.s11|89-93|NSAID|group
DDI-DrugBank.d400.s11|94-94|.|O
DDI-DrugBank.d400.s12|0-3|Thus|O
DDI-DrugBank.d400.s12|4-4|,|O
DDI-DrugBank.d400.s12|6-9|when|O
DDI-DrugBank.d400.s12|11-16|NSAIDs|group
DDI-DrugBank.d400.s12|18-20|and|O
DDI-DrugBank.d400.s12|22-28|lithium|drug
DDI-DrugBank.d400.s12|30-32|are|O
DDI-DrugBank.d400.s12|34-45|administered|O
DDI-DrugBank.d400.s12|47-58|concurrently|O
DDI-DrugBank.d400.s12|59-59|,|O
DDI-DrugBank.d400.s12|61-68|subjects|O
DDI-DrugBank.d400.s12|70-75|should|O
DDI-DrugBank.d400.s12|77-78|be|O
DDI-DrugBank.d400.s12|80-87|observed|O
DDI-DrugBank.d400.s12|89-97|carefully|O
DDI-DrugBank.d400.s12|99-101|for|O
DDI-DrugBank.d400.s12|103-107|signs|O
DDI-DrugBank.d400.s12|109-110|of|O
DDI-DrugBank.d400.s12|112-118|lithium|drug
DDI-DrugBank.d400.s12|120-127|toxicity|O
DDI-DrugBank.d400.s12|128-128|.|O
DDI-DrugBank.d400.s13|0-7|Warfarin|drug
DDI-DrugBank.d400.s13|8-8|:|O
DDI-DrugBank.d400.s13|10-12|The|O
DDI-DrugBank.d400.s13|14-20|effects|O
DDI-DrugBank.d400.s13|22-23|of|O
DDI-DrugBank.d400.s13|25-32|warfarin|drug
DDI-DrugBank.d400.s13|34-36|and|O
DDI-DrugBank.d400.s13|38-43|NSAIDs|group
DDI-DrugBank.d400.s13|45-46|on|O
DDI-DrugBank.d400.s13|48-49|GI|O
DDI-DrugBank.d400.s13|51-58|bleeding|O
DDI-DrugBank.d400.s13|60-62|are|O
DDI-DrugBank.d400.s13|64-74|synergistic|O
DDI-DrugBank.d400.s13|75-75|,|O
DDI-DrugBank.d400.s13|77-80|such|O
DDI-DrugBank.d400.s13|82-85|that|O
DDI-DrugBank.d400.s13|87-91|users|O
DDI-DrugBank.d400.s13|93-94|of|O
DDI-DrugBank.d400.s13|96-99|both|O
DDI-DrugBank.d400.s13|101-105|drugs|O
DDI-DrugBank.d400.s13|107-114|together|O
DDI-DrugBank.d400.s13|116-119|have|O
DDI-DrugBank.d400.s13|121-121|a|O
DDI-DrugBank.d400.s13|123-126|risk|O
DDI-DrugBank.d400.s13|128-129|of|O
DDI-DrugBank.d400.s13|131-137|serious|O
DDI-DrugBank.d400.s13|139-140|GI|O
DDI-DrugBank.d400.s13|142-149|bleeding|O
DDI-DrugBank.d400.s13|151-156|higher|O
DDI-DrugBank.d400.s13|158-161|than|O
DDI-DrugBank.d400.s13|163-167|users|O
DDI-DrugBank.d400.s13|169-170|of|O
DDI-DrugBank.d400.s13|172-177|either|O
DDI-DrugBank.d400.s13|179-182|drug|O
DDI-DrugBank.d400.s13|184-188|alone|O
DDI-DrugBank.d400.s13|189-189|.|O
DDI-DrugBank.d400.s14|0-7|Antacids|group
DDI-DrugBank.d400.s14|8-8|:|O
DDI-DrugBank.d400.s14|10-11|In|O
DDI-DrugBank.d400.s14|13-13|a|O
DDI-DrugBank.d400.s14|15-20|single|O
DDI-DrugBank.d400.s14|22-25|dose|O
DDI-DrugBank.d400.s14|27-31|study|O
DDI-DrugBank.d400.s14|33-33|(|O
DDI-DrugBank.d400.s14|34-36|n=6|O
DDI-DrugBank.d400.s14|37-37|)|O
DDI-DrugBank.d400.s14|38-38|,|O
DDI-DrugBank.d400.s14|40-48|ingestion|O
DDI-DrugBank.d400.s14|50-51|of|O
DDI-DrugBank.d400.s14|53-54|an|O
DDI-DrugBank.d400.s14|56-62|antacid|group
DDI-DrugBank.d400.s14|64-73|containing|O
DDI-DrugBank.d400.s14|75-82|1.7-gram|O
DDI-DrugBank.d400.s14|84-85|of|O
DDI-DrugBank.d400.s14|87-105|magnesium hydroxide|drug
DDI-DrugBank.d400.s14|107-110|with|O
DDI-DrugBank.d400.s14|112-117|500-mg|O
DDI-DrugBank.d400.s14|119-120|of|O
DDI-DrugBank.d400.s14|122-135|mefenamic acid|drug
DDI-DrugBank.d400.s14|137-145|increased|O
DDI-DrugBank.d400.s14|147-149|the|O
DDI-DrugBank.d400.s14|151-154|Cmax|O
DDI-DrugBank.d400.s14|156-158|and|O
DDI-DrugBank.d400.s14|160-162|AUC|O
DDI-DrugBank.d400.s14|164-165|of|O
DDI-DrugBank.d400.s14|167-180|mefenamic acid|drug
DDI-DrugBank.d400.s14|182-183|by|O
DDI-DrugBank.d400.s14|185-187|125|O
DDI-DrugBank.d400.s14|188-188|%|O
DDI-DrugBank.d400.s14|190-192|and|O
DDI-DrugBank.d400.s14|194-195|36|O
DDI-DrugBank.d400.s14|196-196|%|O
DDI-DrugBank.d400.s14|197-197|,|O
DDI-DrugBank.d400.s14|199-211|respectively.|O
DDI-DrugBank.d400.s14|214-214|A|O
DDI-DrugBank.d400.s14|216-221|number|O
DDI-DrugBank.d400.s14|223-224|of|O
DDI-DrugBank.d400.s14|226-234|compounds|O
DDI-DrugBank.d400.s14|236-238|are|O
DDI-DrugBank.d400.s14|240-249|inhibitors|O
DDI-DrugBank.d400.s14|251-252|of|O
DDI-DrugBank.d400.s14|254-259|CYP2C9|O
DDI-DrugBank.d400.s14|261-269|including|O
DDI-DrugBank.d400.s14|271-281|fluconazole|drug
DDI-DrugBank.d400.s14|282-282|,|O
DDI-DrugBank.d400.s14|284-293|lovastatin|drug
DDI-DrugBank.d400.s14|295-297|and|O
DDI-DrugBank.d400.s14|299-310|trimethoprim|drug
DDI-DrugBank.d400.s14|311-311|.|O
DDI-DrugBank.d400.s15|0-3|Drug|O
DDI-DrugBank.d400.s15|5-15|interaction|O
DDI-DrugBank.d400.s15|17-23|studies|O
DDI-DrugBank.d400.s15|25-26|of|O
DDI-DrugBank.d400.s15|28-41|mefenamic acid|drug
DDI-DrugBank.d400.s15|43-45|and|O
DDI-DrugBank.d400.s15|47-51|these|O
DDI-DrugBank.d400.s15|53-61|compounds|O
DDI-DrugBank.d400.s15|63-66|have|O
DDI-DrugBank.d400.s15|68-70|not|O
DDI-DrugBank.d400.s15|72-75|been|O
DDI-DrugBank.d400.s15|77-85|conducted|O
DDI-DrugBank.d400.s15|86-86|.|O
DDI-DrugBank.d400.s16|0-2|The|O
DDI-DrugBank.d400.s16|4-14|possibility|O
DDI-DrugBank.d400.s16|16-17|of|O
DDI-DrugBank.d400.s16|19-25|altered|O
DDI-DrugBank.d400.s16|27-32|safety|O
DDI-DrugBank.d400.s16|34-36|and|O
DDI-DrugBank.d400.s16|38-45|efficacy|O
DDI-DrugBank.d400.s16|47-52|should|O
DDI-DrugBank.d400.s16|54-55|be|O
DDI-DrugBank.d400.s16|57-66|considered|O
DDI-DrugBank.d400.s16|68-71|when|O
DDI-DrugBank.d400.s16|73-79|Ponstel|brand
DDI-DrugBank.d400.s16|81-82|is|O
DDI-DrugBank.d400.s16|84-87|used|O
DDI-DrugBank.d400.s16|89-101|concomitantly|O
DDI-DrugBank.d400.s16|103-106|with|O
DDI-DrugBank.d400.s16|108-112|these|O
DDI-DrugBank.d400.s16|114-118|drugs|O
DDI-DrugBank.d400.s16|119-119|.|O
DDI-MedLine.d38.s0|0-4|Acute|O
DDI-MedLine.d38.s0|6-19|hydrocortisone|drug
DDI-MedLine.d38.s0|21-34|administration|O
DDI-MedLine.d38.s0|36-39|does|O
DDI-MedLine.d38.s0|41-43|not|O
DDI-MedLine.d38.s0|45-50|affect|O
DDI-MedLine.d38.s0|52-61|subjective|O
DDI-MedLine.d38.s0|63-71|responses|O
DDI-MedLine.d38.s0|73-74|to|O
DDI-MedLine.d38.s0|76-88|d-amphetamine|drug
DDI-MedLine.d38.s0|90-91|in|O
DDI-MedLine.d38.s0|93-98|humans|O
DDI-MedLine.d38.s0|99-99|.|O
DDI-MedLine.d38.s1|0-8|RATIONALE|O
DDI-MedLine.d38.s1|9-9|:|O
DDI-MedLine.d38.s1|11-16|Stress|O
DDI-MedLine.d38.s1|18-20|and|O
DDI-MedLine.d38.s1|22-36|glucocorticoids|group
DDI-MedLine.d38.s1|38-47|facilitate|O
DDI-MedLine.d38.s1|49-51|and|O
DDI-MedLine.d38.s1|53-61|reinstate|O
DDI-MedLine.d38.s1|63-77|psychostimulant|O
DDI-MedLine.d38.s1|79-97|self-administration|O
DDI-MedLine.d38.s1|99-100|in|O
DDI-MedLine.d38.s1|102-108|rodents|O
DDI-MedLine.d38.s1|109-109|.|O
DDI-MedLine.d38.s2|0-6|However|O
DDI-MedLine.d38.s2|7-7|,|O
DDI-MedLine.d38.s2|9-11|the|O
DDI-MedLine.d38.s2|13-19|effects|O
DDI-MedLine.d38.s2|21-22|of|O
DDI-MedLine.d38.s2|24-29|stress|O
DDI-MedLine.d38.s2|31-33|and|O
DDI-MedLine.d38.s2|35-49|glucocorticoids|group
DDI-MedLine.d38.s2|51-52|on|O
DDI-MedLine.d38.s2|54-56|the|O
DDI-MedLine.d38.s2|58-67|subjective|O
DDI-MedLine.d38.s2|69-71|and|O
DDI-MedLine.d38.s2|73-82|behavioral|O
DDI-MedLine.d38.s2|84-90|effects|O
DDI-MedLine.d38.s2|92-93|of|O
DDI-MedLine.d38.s2|95-110|psychostimulants|group
DDI-MedLine.d38.s2|112-115|have|O
DDI-MedLine.d38.s2|117-119|not|O
DDI-MedLine.d38.s2|121-124|been|O
DDI-MedLine.d38.s2|126-129|well|O
DDI-MedLine.d38.s2|131-137|studied|O
DDI-MedLine.d38.s2|139-140|in|O
DDI-MedLine.d38.s2|142-147|humans|O
DDI-MedLine.d38.s2|148-148|.|O
DDI-MedLine.d38.s3|0-9|OBJECTIVES|O
DDI-MedLine.d38.s3|10-10|:|O
DDI-MedLine.d38.s3|12-13|To|O
DDI-MedLine.d38.s3|15-21|examine|O
DDI-MedLine.d38.s3|23-25|the|O
DDI-MedLine.d38.s3|27-33|effects|O
DDI-MedLine.d38.s3|35-36|of|O
DDI-MedLine.d38.s3|38-42|acute|O
DDI-MedLine.d38.s3|44-57|hydrocortisone|drug
DDI-MedLine.d38.s3|59-70|pretreatment|O
DDI-MedLine.d38.s3|72-73|on|O
DDI-MedLine.d38.s3|75-77|the|O
DDI-MedLine.d38.s3|79-88|subjective|O
DDI-MedLine.d38.s3|90-92|and|O
DDI-MedLine.d38.s3|94-103|behavioral|O
DDI-MedLine.d38.s3|105-111|effects|O
DDI-MedLine.d38.s3|113-114|of|O
DDI-MedLine.d38.s3|116-128|d-amphetamine|drug
DDI-MedLine.d38.s3|129-129|.|O
DDI-MedLine.d38.s4|0-6|METHODS|O
DDI-MedLine.d38.s4|7-7|:|O
DDI-MedLine.d38.s4|9-22|Hydrocortisone|drug
DDI-MedLine.d38.s4|24-24|(|O
DDI-MedLine.d38.s4|25-27|100|O
DDI-MedLine.d38.s4|29-30|mg|O
DDI-MedLine.d38.s4|31-31|)|O
DDI-MedLine.d38.s4|33-35|and|O
DDI-MedLine.d38.s4|37-49|d-amphetamine|drug
DDI-MedLine.d38.s4|51-51|(|O
DDI-MedLine.d38.s4|52-53|20|O
DDI-MedLine.d38.s4|55-56|mg|O
DDI-MedLine.d38.s4|57-57|)|O
DDI-MedLine.d38.s4|59-62|were|O
DDI-MedLine.d38.s4|64-75|administered|O
DDI-MedLine.d38.s4|77-82|orally|O
DDI-MedLine.d38.s4|84-85|to|O
DDI-MedLine.d38.s4|87-88|16|O
DDI-MedLine.d38.s4|90-96|healthy|O
DDI-MedLine.d38.s4|98-101|male|O
DDI-MedLine.d38.s4|103-105|and|O
DDI-MedLine.d38.s4|107-112|female|O
DDI-MedLine.d38.s4|114-123|volunteers|O
DDI-MedLine.d38.s4|125-126|in|O
DDI-MedLine.d38.s4|128-128|a|O
DDI-MedLine.d38.s4|130-141|four-session|O
DDI-MedLine.d38.s4|142-142|,|O
DDI-MedLine.d38.s4|144-161|placebo-controlled|O
DDI-MedLine.d38.s4|162-162|,|O
DDI-MedLine.d38.s4|164-177|within-subject|O
DDI-MedLine.d38.s4|178-178|,|O
DDI-MedLine.d38.s4|180-188|crossover|O
DDI-MedLine.d38.s4|190-195|design|O
DDI-MedLine.d38.s4|196-196|.|O
DDI-MedLine.d38.s5|0-1|To|O
DDI-MedLine.d38.s5|3-9|prevent|O
DDI-MedLine.d38.s5|11-17|stomach|O
DDI-MedLine.d38.s5|19-28|irritation|O
DDI-MedLine.d38.s5|29-29|,|O
DDI-MedLine.d38.s5|31-38|subjects|O
DDI-MedLine.d38.s5|40-47|received|O
DDI-MedLine.d38.s5|49-71|rantidine hydrochloride|drug
DDI-MedLine.d38.s5|73-78|before|O
DDI-MedLine.d38.s5|80-83|each|O
DDI-MedLine.d38.s5|85-96|experimental|O
DDI-MedLine.d38.s5|98-104|session|O
DDI-MedLine.d38.s5|105-105|.|O
DDI-MedLine.d38.s6|0-8|Dependent|O
DDI-MedLine.d38.s6|10-17|measures|O
DDI-MedLine.d38.s6|19-26|included|O
DDI-MedLine.d38.s6|28-40|self-reported|O
DDI-MedLine.d38.s6|42-45|mood|O
DDI-MedLine.d38.s6|47-49|and|O
DDI-MedLine.d38.s6|51-60|subjective|O
DDI-MedLine.d38.s6|62-68|effects|O
DDI-MedLine.d38.s6|70-70|(|O
DDI-MedLine.d38.s6|71-79|Addiction|O
DDI-MedLine.d38.s6|81-88|Research|O
DDI-MedLine.d38.s6|90-95|Center|O
DDI-MedLine.d38.s6|97-105|inventory|O
DDI-MedLine.d38.s6|106-106|,|O
DDI-MedLine.d38.s6|108-110|the|O
DDI-MedLine.d38.s6|112-118|profile|O
DDI-MedLine.d38.s6|120-121|of|O
DDI-MedLine.d38.s6|123-126|mood|O
DDI-MedLine.d38.s6|128-133|states|O
DDI-MedLine.d38.s6|134-134|,|O
DDI-MedLine.d38.s6|136-138|and|O
DDI-MedLine.d38.s6|140-140|a|O
DDI-MedLine.d38.s6|142-147|series|O
DDI-MedLine.d38.s6|149-150|of|O
DDI-MedLine.d38.s6|152-157|visual|O
DDI-MedLine.d38.s6|159-166|analogue|O
DDI-MedLine.d38.s6|168-173|scales|O
DDI-MedLine.d38.s6|174-174|)|O
DDI-MedLine.d38.s6|175-175|,|O
DDI-MedLine.d38.s6|177-181|vital|O
DDI-MedLine.d38.s6|183-187|signs|O
DDI-MedLine.d38.s6|188-188|,|O
DDI-MedLine.d38.s6|190-197|salivary|O
DDI-MedLine.d38.s6|199-206|cortisol|O
DDI-MedLine.d38.s6|207-207|,|O
DDI-MedLine.d38.s6|209-211|and|O
DDI-MedLine.d38.s6|213-223|psychomotor|O
DDI-MedLine.d38.s6|225-235|performance|O
DDI-MedLine.d38.s6|236-236|.|O
DDI-MedLine.d38.s7|0-6|RESULTS|O
DDI-MedLine.d38.s7|7-7|:|O
DDI-MedLine.d38.s7|9-22|Hydrocortisone|drug
DDI-MedLine.d38.s7|24-31|elevated|O
DDI-MedLine.d38.s7|33-40|salivary|O
DDI-MedLine.d38.s7|42-49|cortisol|O
DDI-MedLine.d38.s7|51-56|levels|O
DDI-MedLine.d38.s7|57-57|,|O
DDI-MedLine.d38.s7|59-66|produced|O
DDI-MedLine.d38.s7|68-73|modest|O
DDI-MedLine.d38.s7|75-83|dysphoria|O
DDI-MedLine.d38.s7|84-84|,|O
DDI-MedLine.d38.s7|86-88|and|O
DDI-MedLine.d38.s7|90-96|reduced|O
DDI-MedLine.d38.s7|98-105|subjects|O
DDI-MedLine.d38.s7|106-106|'|O
DDI-MedLine.d38.s7|108-114|reports|O
DDI-MedLine.d38.s7|116-117|of|O
DDI-MedLine.d38.s7|119-125|wanting|O
DDI-MedLine.d38.s7|127-130|more|O
DDI-MedLine.d38.s7|132-135|drug|O
DDI-MedLine.d38.s7|136-136|.|O
DDI-MedLine.d38.s8|0-6|However|O
DDI-MedLine.d38.s8|7-7|,|O
DDI-MedLine.d38.s8|9-22|hydrocortisone|drug
DDI-MedLine.d38.s8|24-35|pretreatment|O
DDI-MedLine.d38.s8|37-39|did|O
DDI-MedLine.d38.s8|41-43|not|O
DDI-MedLine.d38.s8|45-50|affect|O
DDI-MedLine.d38.s8|52-54|any|O
DDI-MedLine.d38.s8|56-57|of|O
DDI-MedLine.d38.s8|59-61|the|O
DDI-MedLine.d38.s8|63-75|physiological|O
DDI-MedLine.d38.s8|76-76|,|O
DDI-MedLine.d38.s8|78-87|behavioral|O
DDI-MedLine.d38.s8|88-88|,|O
DDI-MedLine.d38.s8|90-91|or|O
DDI-MedLine.d38.s8|93-102|subjective|O
DDI-MedLine.d38.s8|104-110|effects|O
DDI-MedLine.d38.s8|112-113|of|O
DDI-MedLine.d38.s8|115-127|d-amphetamine|drug
DDI-MedLine.d38.s8|128-128|.|O
DDI-MedLine.d38.s9|0-10|CONCLUSIONS|O
DDI-MedLine.d38.s9|11-11|:|O
DDI-MedLine.d38.s9|13-14|In|O
DDI-MedLine.d38.s9|16-23|contrast|O
DDI-MedLine.d38.s9|25-26|to|O
DDI-MedLine.d38.s9|28-30|the|O
DDI-MedLine.d38.s9|32-38|effects|O
DDI-MedLine.d38.s9|40-41|of|O
DDI-MedLine.d38.s9|43-57|glucocorticoids|group
DDI-MedLine.d38.s9|59-60|in|O
DDI-MedLine.d38.s9|62-67|rodent|O
DDI-MedLine.d38.s9|69-75|studies|O
DDI-MedLine.d38.s9|76-76|,|O
DDI-MedLine.d38.s9|78-82|these|O
DDI-MedLine.d38.s9|84-90|results|O
DDI-MedLine.d38.s9|92-99|indicate|O
DDI-MedLine.d38.s9|101-104|that|O
DDI-MedLine.d38.s9|106-107|an|O
DDI-MedLine.d38.s9|109-113|acute|O
DDI-MedLine.d38.s9|115-122|increase|O
DDI-MedLine.d38.s9|124-125|in|O
DDI-MedLine.d38.s9|127-134|cortisol|O
DDI-MedLine.d38.s9|136-139|does|O
DDI-MedLine.d38.s9|141-143|not|O
DDI-MedLine.d38.s9|145-151|enhance|O
DDI-MedLine.d38.s9|153-155|the|O
DDI-MedLine.d38.s9|157-171|psychostimulant|O
DDI-MedLine.d38.s9|173-179|effects|O
DDI-MedLine.d38.s9|181-182|of|O
DDI-MedLine.d38.s9|184-196|d-amphetamine|drug
DDI-MedLine.d38.s9|198-199|in|O
DDI-MedLine.d38.s9|201-206|humans|O
DDI-MedLine.d38.s9|207-207|.|O
DDI-DrugBank.d539.s0|0-8|Interacts|O
DDI-DrugBank.d539.s0|10-13|with|O
DDI-DrugBank.d256.s0|0-10|Clindamycin|drug
DDI-DrugBank.d256.s0|12-14|has|O
DDI-DrugBank.d256.s0|16-19|been|O
DDI-DrugBank.d256.s0|21-25|shown|O
DDI-DrugBank.d256.s0|27-28|to|O
DDI-DrugBank.d256.s0|30-33|have|O
DDI-DrugBank.d256.s0|35-47|neuromuscular|O
DDI-DrugBank.d256.s0|49-56|blocking|O
DDI-DrugBank.d256.s0|58-67|properties|O
DDI-DrugBank.d256.s0|69-72|that|O
DDI-DrugBank.d256.s0|74-76|may|O
DDI-DrugBank.d256.s0|78-84|enhance|O
DDI-DrugBank.d256.s0|86-88|the|O
DDI-DrugBank.d256.s0|90-95|action|O
DDI-DrugBank.d256.s0|97-98|of|O
DDI-DrugBank.d256.s0|100-104|other|O
DDI-DrugBank.d256.s0|106-134|neuromuscular blocking agents|group
DDI-DrugBank.d256.s0|135-135|.|O
DDI-DrugBank.d256.s1|0-8|Therefore|O
DDI-DrugBank.d256.s1|9-9|,|O
DDI-DrugBank.d256.s1|11-12|it|O
DDI-DrugBank.d256.s1|14-19|should|O
DDI-DrugBank.d256.s1|21-22|be|O
DDI-DrugBank.d256.s1|24-27|used|O
DDI-DrugBank.d256.s1|29-32|with|O
DDI-DrugBank.d256.s1|34-40|caution|O
DDI-DrugBank.d256.s1|42-43|in|O
DDI-DrugBank.d256.s1|45-52|patients|O
DDI-DrugBank.d256.s1|54-62|receiving|O
DDI-DrugBank.d256.s1|64-67|such|O
DDI-DrugBank.d256.s1|69-74|agents|O
DDI-DrugBank.d256.s1|75-75|.|O
DDI-DrugBank.d256.s2|0-9|Antagonism|O
DDI-DrugBank.d256.s2|11-13|has|O
DDI-DrugBank.d256.s2|15-18|been|O
DDI-DrugBank.d256.s2|20-31|demonstrated|O
DDI-DrugBank.d256.s2|33-39|between|O
DDI-DrugBank.d256.s2|41-51|clindamycin|drug
DDI-DrugBank.d256.s2|53-55|and|O
DDI-DrugBank.d256.s2|57-68|erythromycin|drug
DDI-DrugBank.d256.s2|70-71|in|O
DDI-DrugBank.d256.s2|73-77|vitro|O
DDI-DrugBank.d256.s2|78-78|.|O
DDI-DrugBank.d256.s3|0-6|Because|O
DDI-DrugBank.d256.s3|8-9|of|O
DDI-DrugBank.d256.s3|11-18|possible|O
DDI-DrugBank.d256.s3|20-27|clinical|O
DDI-DrugBank.d256.s3|29-40|significance|O
DDI-DrugBank.d256.s3|41-41|,|O
DDI-DrugBank.d256.s3|43-47|these|O
DDI-DrugBank.d256.s3|49-51|two|O
DDI-DrugBank.d256.s3|53-57|drugs|O
DDI-DrugBank.d256.s3|59-64|should|O
DDI-DrugBank.d256.s3|66-68|not|O
DDI-DrugBank.d256.s3|70-71|be|O
DDI-DrugBank.d256.s3|73-84|administered|O
DDI-DrugBank.d256.s3|86-97|concurrently|O
DDI-DrugBank.d256.s3|98-98|.|O
DDI-DrugBank.d365.s0|0-26|Medroxyprogesterone Acetate|drug
DDI-DrugBank.d365.s0|28-28|-|O
DDI-DrugBank.d365.s0|30-40|L-histidine|drug
DDI-DrugBank.d365.s0|42-44|was|O
DDI-DrugBank.d365.s0|46-53|observed|O
DDI-DrugBank.d365.s0|55-56|to|O
DDI-DrugBank.d365.s0|58-64|enhance|O
DDI-DrugBank.d365.s0|66-66|(|O
DDI-DrugBank.d365.s0|67-68|in|O
DDI-DrugBank.d365.s0|70-75|tissue|O
DDI-DrugBank.d365.s0|77-83|culture|O
DDI-DrugBank.d365.s0|84-84|)|O
DDI-DrugBank.d365.s0|86-88|the|O
DDI-DrugBank.d365.s0|90-95|effect|O
DDI-DrugBank.d365.s0|97-98|of|O
DDI-DrugBank.d365.s0|100-126|medroxyprogesterone acetate|drug
DDI-DrugBank.d365.s0|128-129|in|O
DDI-DrugBank.d365.s0|131-138|reducing|O
DDI-DrugBank.d365.s0|140-142|the|O
DDI-DrugBank.d365.s0|144-149|number|O
DDI-DrugBank.d365.s0|151-152|of|O
DDI-DrugBank.d365.s0|154-158|human|O
DDI-DrugBank.d365.s0|160-165|breast|O
DDI-DrugBank.d365.s0|167-172|cancer|O
DDI-DrugBank.d365.s0|174-178|cells|O
DDI-DrugBank.d365.s0|180-183|that|O
DDI-DrugBank.d365.s0|185-188|were|O
DDI-DrugBank.d365.s0|190-191|in|O
DDI-DrugBank.d365.s0|193-195|the|O
DDI-DrugBank.d365.s0|197-197|S|O
DDI-DrugBank.d365.s0|199-203|phase|O
DDI-DrugBank.d365.s0|204-204|.|O
DDI-DrugBank.d365.s1|0-1|H1|group
DDI-DrugBank.d365.s1|3-5|and|O
DDI-DrugBank.d365.s1|7-17|H2 Blockers|group
DDI-DrugBank.d365.s1|19-19|-|O
DDI-DrugBank.d365.s1|21-28|Although|O
DDI-DrugBank.d365.s1|30-32|not|O
DDI-DrugBank.d365.s1|34-41|reported|O
DDI-DrugBank.d365.s1|42-42|,|O
DDI-DrugBank.d365.s1|44-54|L-histidine|drug
DDI-DrugBank.d365.s1|55-55|,|O
DDI-DrugBank.d365.s1|57-59|via|O
DDI-DrugBank.d365.s1|61-63|its|O
DDI-DrugBank.d365.s1|65-74|metabolism|O
DDI-DrugBank.d365.s1|76-77|to|O
DDI-DrugBank.d365.s1|79-87|histamine|O
DDI-DrugBank.d365.s1|88-88|,|O
DDI-DrugBank.d365.s1|90-94|might|O
DDI-DrugBank.d365.s1|96-103|decrease|O
DDI-DrugBank.d365.s1|105-107|the|O
DDI-DrugBank.d365.s1|109-116|efficacy|O
DDI-DrugBank.d365.s1|118-119|of|O
DDI-DrugBank.d365.s1|121-122|H1|group
DDI-DrugBank.d365.s1|124-126|and|O
DDI-DrugBank.d365.s1|128-138|H2 blockers|group
DDI-DrugBank.d365.s1|139-139|.|O
DDI-DrugBank.d519.s0|0-1|No|O
DDI-DrugBank.d519.s0|3-8|formal|O
DDI-DrugBank.d519.s0|10-18|drug/drug|O
DDI-DrugBank.d519.s0|20-30|interaction|O
DDI-DrugBank.d519.s0|32-38|studies|O
DDI-DrugBank.d519.s0|40-43|with|O
DDI-DrugBank.d519.s0|45-52|Plenaxis|brand
DDI-DrugBank.d519.s0|54-57|were|O
DDI-DrugBank.d519.s0|59-67|performed|O
DDI-DrugBank.d519.s0|68-68|.|O
DDI-DrugBank.d519.s1|0-9|Cytochrome|O
DDI-DrugBank.d519.s1|11-15|P-450|O
DDI-DrugBank.d519.s1|17-18|is|O
DDI-DrugBank.d519.s1|20-22|not|O
DDI-DrugBank.d519.s1|24-28|known|O
DDI-DrugBank.d519.s1|30-31|to|O
DDI-DrugBank.d519.s1|33-34|be|O
DDI-DrugBank.d519.s1|36-43|involved|O
DDI-DrugBank.d519.s1|45-46|in|O
DDI-DrugBank.d519.s1|48-50|the|O
DDI-DrugBank.d519.s1|52-61|metabolism|O
DDI-DrugBank.d519.s1|63-64|of|O
DDI-DrugBank.d519.s1|66-73|Plenaxis|brand
DDI-DrugBank.d519.s1|74-74|.|O
DDI-DrugBank.d519.s2|0-7|Plenaxis|brand
DDI-DrugBank.d519.s2|9-10|is|O
DDI-DrugBank.d519.s2|12-17|highly|O
DDI-DrugBank.d519.s2|19-23|bound|O
DDI-DrugBank.d519.s2|25-26|to|O
DDI-DrugBank.d519.s2|28-33|plasma|O
DDI-DrugBank.d519.s2|35-42|proteins|O
DDI-DrugBank.d519.s2|44-44|(|O
DDI-DrugBank.d519.s2|45-46|96|O
DDI-DrugBank.d519.s2|48-49|to|O
DDI-DrugBank.d519.s2|51-52|99|O
DDI-DrugBank.d519.s2|53-53|%|O
DDI-DrugBank.d519.s2|54-54|)|O
DDI-DrugBank.d519.s2|55-55|.|O
DDI-DrugBank.d519.s3|0-9|Laboratory|O
DDI-DrugBank.d519.s3|11-15|Tests|O
DDI-DrugBank.d519.s3|17-24|Response|O
DDI-DrugBank.d519.s3|26-27|to|O
DDI-DrugBank.d519.s3|29-36|Plenaxis|brand
DDI-DrugBank.d519.s3|38-43|should|O
DDI-DrugBank.d519.s3|45-46|be|O
DDI-DrugBank.d519.s3|48-56|monitored|O
DDI-DrugBank.d519.s3|58-59|by|O
DDI-DrugBank.d519.s3|61-69|measuring|O
DDI-DrugBank.d519.s3|71-75|serum|O
DDI-DrugBank.d519.s3|77-81|total|O
DDI-DrugBank.d519.s3|83-94|testosterone|drug
DDI-DrugBank.d519.s3|96-109|concentrations|O
DDI-DrugBank.d519.s3|111-114|just|O
DDI-DrugBank.d519.s3|116-120|prior|O
DDI-DrugBank.d519.s3|122-123|to|O
DDI-DrugBank.d519.s3|125-138|administration|O
DDI-DrugBank.d519.s3|140-141|on|O
DDI-DrugBank.d519.s3|143-145|Day|O
DDI-DrugBank.d519.s3|147-148|29|O
DDI-DrugBank.d519.s3|150-152|and|O
DDI-DrugBank.d519.s3|154-158|every|O
DDI-DrugBank.d519.s3|160-160|8|O
DDI-DrugBank.d519.s3|162-166|weeks|O
DDI-DrugBank.d519.s3|168-177|thereafter|O
DDI-DrugBank.d519.s3|178-178|.|O
DDI-DrugBank.d519.s4|0-4|Serum|O
DDI-DrugBank.d519.s4|6-17|transaminase|O
DDI-DrugBank.d519.s4|19-24|levels|O
DDI-DrugBank.d519.s4|26-31|should|O
DDI-DrugBank.d519.s4|33-34|be|O
DDI-DrugBank.d519.s4|36-43|obtained|O
DDI-DrugBank.d519.s4|45-50|before|O
DDI-DrugBank.d519.s4|52-59|starting|O
DDI-DrugBank.d519.s4|61-69|treatment|O
DDI-DrugBank.d519.s4|71-74|with|O
DDI-DrugBank.d519.s4|76-83|Plenaxis|brand
DDI-DrugBank.d519.s4|85-87|and|O
DDI-DrugBank.d519.s4|89-100|periodically|O
DDI-DrugBank.d519.s4|102-107|during|O
DDI-DrugBank.d519.s4|109-117|treatment|O
DDI-DrugBank.d519.s4|118-118|.|O
DDI-DrugBank.d519.s5|0-7|Periodic|O
DDI-DrugBank.d519.s5|9-19|measurement|O
DDI-DrugBank.d519.s5|21-22|of|O
DDI-DrugBank.d519.s5|24-28|serum|O
DDI-DrugBank.d519.s5|30-32|PSA|O
DDI-DrugBank.d519.s5|34-39|levels|O
DDI-DrugBank.d519.s5|41-43|may|O
DDI-DrugBank.d519.s5|45-48|also|O
DDI-DrugBank.d519.s5|50-51|be|O
DDI-DrugBank.d519.s5|53-62|considered|O
DDI-DrugBank.d519.s5|63-63|.|O
DDI-DrugBank.d369.s0|0-2|The|O
DDI-DrugBank.d369.s0|4-10|Factrel|brand
DDI-DrugBank.d369.s0|12-15|test|O
DDI-DrugBank.d369.s0|17-22|should|O
DDI-DrugBank.d369.s0|24-25|be|O
DDI-DrugBank.d369.s0|27-35|conducted|O
DDI-DrugBank.d369.s0|37-38|in|O
DDI-DrugBank.d369.s0|40-42|the|O
DDI-DrugBank.d369.s0|44-50|absence|O
DDI-DrugBank.d369.s0|52-53|of|O
DDI-DrugBank.d369.s0|55-59|other|O
DDI-DrugBank.d369.s0|61-65|drugs|O
DDI-DrugBank.d369.s0|67-71|which|O
DDI-DrugBank.d369.s0|73-80|directly|O
DDI-DrugBank.d369.s0|82-87|affect|O
DDI-DrugBank.d369.s0|89-91|the|O
DDI-DrugBank.d369.s0|93-101|pituitary|O
DDI-DrugBank.d369.s0|103-111|secretion|O
DDI-DrugBank.d369.s0|113-114|of|O
DDI-DrugBank.d369.s0|116-118|the|O
DDI-DrugBank.d369.s0|120-132|gonadotropins|O
DDI-DrugBank.d369.s0|133-133|.|O
DDI-DrugBank.d369.s1|0-4|These|O
DDI-DrugBank.d369.s1|6-10|would|O
DDI-DrugBank.d369.s1|12-18|include|O
DDI-DrugBank.d369.s1|20-20|a|O
DDI-DrugBank.d369.s1|22-28|variety|O
DDI-DrugBank.d369.s1|30-31|of|O
DDI-DrugBank.d369.s1|33-44|preparations|O
DDI-DrugBank.d369.s1|46-50|which|O
DDI-DrugBank.d369.s1|52-58|contain|O
DDI-DrugBank.d369.s1|60-68|androgens|group
DDI-DrugBank.d369.s1|69-69|,|O
DDI-DrugBank.d369.s1|71-79|estrogens|group
DDI-DrugBank.d369.s1|80-80|,|O
DDI-DrugBank.d369.s1|82-91|progestins|group
DDI-DrugBank.d369.s1|92-92|,|O
DDI-DrugBank.d369.s1|94-95|or|O
DDI-DrugBank.d369.s1|97-111|glucocorticoids|group
DDI-DrugBank.d369.s1|112-112|.|O
DDI-DrugBank.d369.s2|0-2|The|O
DDI-DrugBank.d369.s2|4-15|gonadotropin|O
DDI-DrugBank.d369.s2|17-22|levels|O
DDI-DrugBank.d369.s2|24-26|may|O
DDI-DrugBank.d369.s2|28-29|be|O
DDI-DrugBank.d369.s2|31-41|transiently|O
DDI-DrugBank.d369.s2|43-50|elevated|O
DDI-DrugBank.d369.s2|52-53|by|O
DDI-DrugBank.d369.s2|55-68|spironolactone|drug
DDI-DrugBank.d369.s2|69-69|,|O
DDI-DrugBank.d369.s2|71-79|minimally|O
DDI-DrugBank.d369.s2|81-88|elevated|O
DDI-DrugBank.d369.s2|90-91|by|O
DDI-DrugBank.d369.s2|93-100|levodopa|drug
DDI-DrugBank.d369.s2|101-101|,|O
DDI-DrugBank.d369.s2|103-105|and|O
DDI-DrugBank.d369.s2|107-116|suppressed|O
DDI-DrugBank.d369.s2|118-119|by|O
DDI-DrugBank.d369.s2|121-124|oral|O
DDI-DrugBank.d369.s2|126-139|contraceptives|group
DDI-DrugBank.d369.s2|141-143|and|O
DDI-DrugBank.d369.s2|145-151|digoxin|drug
DDI-DrugBank.d369.s2|152-152|.|O
DDI-DrugBank.d369.s3|0-2|The|O
DDI-DrugBank.d369.s3|4-11|response|O
DDI-DrugBank.d369.s3|13-14|to|O
DDI-DrugBank.d369.s3|16-22|Factrel|brand
DDI-DrugBank.d369.s3|24-26|may|O
DDI-DrugBank.d369.s3|28-29|be|O
DDI-DrugBank.d369.s3|31-37|blunted|O
DDI-DrugBank.d369.s3|39-40|by|O
DDI-DrugBank.d369.s3|42-55|phenothiazines|group
DDI-DrugBank.d369.s3|57-59|and|O
DDI-DrugBank.d369.s3|61-80|dopamine antagonists|group
DDI-DrugBank.d369.s3|82-86|which|O
DDI-DrugBank.d369.s3|88-92|cause|O
DDI-DrugBank.d369.s3|94-94|a|O
DDI-DrugBank.d369.s3|96-99|rise|O
DDI-DrugBank.d369.s3|101-102|in|O
DDI-DrugBank.d369.s3|104-112|prolactin|O
DDI-DrugBank.d369.s3|113-113|.|O
DDI-DrugBank.d332.s0|0-13|Administration|O
DDI-DrugBank.d332.s0|15-16|of|O
DDI-DrugBank.d332.s0|18-25|doxapram|drug
DDI-DrugBank.d332.s0|27-28|to|O
DDI-DrugBank.d332.s0|30-37|patients|O
DDI-DrugBank.d332.s0|39-41|who|O
DDI-DrugBank.d332.s0|43-45|are|O
DDI-DrugBank.d332.s0|47-55|receiving|O
DDI-DrugBank.d332.s0|57-71|sympathomimetic|group
DDI-DrugBank.d332.s0|73-74|or|O
DDI-DrugBank.d332.s0|76-109|monoamine oxidase inhibiting drugs|group
DDI-DrugBank.d332.s0|111-113|may|O
DDI-DrugBank.d332.s0|115-120|result|O
DDI-DrugBank.d332.s0|122-123|in|O
DDI-DrugBank.d332.s0|125-126|an|O
DDI-DrugBank.d332.s0|128-135|additive|O
DDI-DrugBank.d332.s0|137-143|pressor|O
DDI-DrugBank.d332.s0|145-150|effect|O
DDI-DrugBank.d332.s0|152-152|.|O
DDI-DrugBank.d332.s1|0-1|In|O
DDI-DrugBank.d332.s1|3-10|patients|O
DDI-DrugBank.d332.s1|12-14|who|O
DDI-DrugBank.d332.s1|16-19|have|O
DDI-DrugBank.d332.s1|21-28|received|O
DDI-DrugBank.d332.s1|30-45|muscle relaxants|group
DDI-DrugBank.d332.s1|46-46|,|O
DDI-DrugBank.d332.s1|48-55|doxapram|drug
DDI-DrugBank.d332.s1|57-59|may|O
DDI-DrugBank.d332.s1|61-71|temporarily|O
DDI-DrugBank.d332.s1|73-76|mask|O
DDI-DrugBank.d332.s1|78-80|the|O
DDI-DrugBank.d332.s1|82-89|residual|O
DDI-DrugBank.d332.s1|91-97|effects|O
DDI-DrugBank.d332.s1|99-100|of|O
DDI-DrugBank.d332.s1|102-122|muscle relaxant drugs|group
DDI-DrugBank.d332.s1|123-123|.|O
DDI-DrugBank.d332.s2|0-1|In|O
DDI-DrugBank.d332.s2|3-10|patients|O
DDI-DrugBank.d332.s2|12-14|who|O
DDI-DrugBank.d332.s2|16-19|have|O
DDI-DrugBank.d332.s2|21-28|received|O
DDI-DrugBank.d332.s2|30-36|general|O
DDI-DrugBank.d332.s2|38-47|anesthesia|O
DDI-DrugBank.d332.s2|49-57|utilizing|O
DDI-DrugBank.d332.s2|59-59|a|O
DDI-DrugBank.d332.s2|61-68|volatile|O
DDI-DrugBank.d332.s2|70-74|agent|O
DDI-DrugBank.d332.s2|76-80|known|O
DDI-DrugBank.d332.s2|82-83|to|O
DDI-DrugBank.d332.s2|85-93|sensitize|O
DDI-DrugBank.d332.s2|95-97|the|O
DDI-DrugBank.d332.s2|99-108|myocardium|O
DDI-DrugBank.d332.s2|110-111|to|O
DDI-DrugBank.d332.s2|113-126|catecholamines|O
DDI-DrugBank.d332.s2|127-127|,|O
DDI-DrugBank.d332.s2|129-142|administration|O
DDI-DrugBank.d332.s2|144-145|of|O
DDI-DrugBank.d332.s2|147-154|doxapram|drug
DDI-DrugBank.d332.s2|156-161|should|O
DDI-DrugBank.d332.s2|163-164|be|O
DDI-DrugBank.d332.s2|166-172|delayed|O
DDI-DrugBank.d332.s2|174-178|until|O
DDI-DrugBank.d332.s2|180-182|the|O
DDI-DrugBank.d332.s2|184-191|volatile|O
DDI-DrugBank.d332.s2|193-197|agent|O
DDI-DrugBank.d332.s2|199-201|has|O
DDI-DrugBank.d332.s2|203-206|been|O
DDI-DrugBank.d332.s2|208-215|excreted|O
DDI-DrugBank.d332.s2|217-218|in|O
DDI-DrugBank.d332.s2|220-224|order|O
DDI-DrugBank.d332.s2|226-227|to|O
DDI-DrugBank.d332.s2|229-234|lessen|O
DDI-DrugBank.d332.s2|236-238|the|O
DDI-DrugBank.d332.s2|240-248|potential|O
DDI-DrugBank.d332.s2|250-252|for|O
DDI-DrugBank.d332.s2|254-264|arrhythmias|O
DDI-DrugBank.d332.s2|265-265|,|O
DDI-DrugBank.d332.s2|267-275|including|O
DDI-DrugBank.d332.s2|277-287|ventricular|O
DDI-DrugBank.d332.s2|289-299|tachycardia|O
DDI-DrugBank.d332.s2|301-303|and|O
DDI-DrugBank.d332.s2|305-315|ventricular|O
DDI-DrugBank.d332.s2|317-328|fibrillation|O
DDI-DrugBank.d332.s2|329-329|.|O
DDI-DrugBank.d154.s0|0-2|The|O
DDI-DrugBank.d154.s0|4-19|coadministration|O
DDI-DrugBank.d154.s0|21-22|of|O
DDI-DrugBank.d154.s0|24-30|aspirin|brand
DDI-DrugBank.d154.s0|32-40|decreases|O
DDI-DrugBank.d154.s0|42-44|the|O
DDI-DrugBank.d154.s0|46-53|biologic|O
DDI-DrugBank.d154.s0|55-63|half-life|O
DDI-DrugBank.d154.s0|65-66|of|O
DDI-DrugBank.d154.s0|68-77|fenoprofen|drug
DDI-DrugBank.d154.s0|79-85|because|O
DDI-DrugBank.d154.s0|87-88|of|O
DDI-DrugBank.d154.s0|90-91|an|O
DDI-DrugBank.d154.s0|93-100|increase|O
DDI-DrugBank.d154.s0|102-103|in|O
DDI-DrugBank.d154.s0|105-113|metabolic|O
DDI-DrugBank.d154.s0|115-123|clearance|O
DDI-DrugBank.d154.s0|125-128|that|O
DDI-DrugBank.d154.s0|130-136|results|O
DDI-DrugBank.d154.s0|138-139|in|O
DDI-DrugBank.d154.s0|141-141|a|O
DDI-DrugBank.d154.s0|143-149|greater|O
DDI-DrugBank.d154.s0|151-156|amount|O
DDI-DrugBank.d154.s0|158-159|of|O
DDI-DrugBank.d154.s0|185-186|in|O
DDI-DrugBank.d154.s0|188-190|the|O
DDI-DrugBank.d154.s0|192-196|urine|O
DDI-DrugBank.d154.s0|197-197|.|O
DDI-DrugBank.d154.s1|0-7|Although|O
DDI-DrugBank.d154.s1|9-11|the|O
DDI-DrugBank.d154.s1|13-21|mechanism|O
DDI-DrugBank.d154.s1|23-24|of|O
DDI-DrugBank.d154.s1|26-36|interaction|O
DDI-DrugBank.d154.s1|38-44|between|O
DDI-DrugBank.d154.s1|46-55|fenoprofen|drug
DDI-DrugBank.d154.s1|57-59|and|O
DDI-DrugBank.d154.s1|61-67|aspirin|brand
DDI-DrugBank.d154.s1|69-70|is|O
DDI-DrugBank.d154.s1|72-74|not|O
DDI-DrugBank.d154.s1|76-82|totally|O
DDI-DrugBank.d154.s1|84-88|known|O
DDI-DrugBank.d154.s1|89-89|,|O
DDI-DrugBank.d154.s1|91-96|enzyme|O
DDI-DrugBank.d154.s1|98-106|induction|O
DDI-DrugBank.d154.s1|108-110|and|O
DDI-DrugBank.d154.s1|112-123|displacement|O
DDI-DrugBank.d154.s1|125-126|of|O
DDI-DrugBank.d154.s1|128-137|fenoprofen|drug
DDI-DrugBank.d154.s1|139-142|from|O
DDI-DrugBank.d154.s1|144-149|plasma|O
DDI-DrugBank.d154.s1|151-157|albumin|O
DDI-DrugBank.d154.s1|159-165|binding|O
DDI-DrugBank.d154.s1|167-171|sites|O
DDI-DrugBank.d154.s1|173-175|are|O
DDI-DrugBank.d154.s1|177-189|possibilities|O
DDI-DrugBank.d154.s1|190-190|.|O
DDI-DrugBank.d154.s2|0-6|Because|O
DDI-DrugBank.d154.s2|8-13|Nalfon|brand
DDI-DrugBank.d154.s2|15-17|has|O
DDI-DrugBank.d154.s2|19-21|not|O
DDI-DrugBank.d154.s2|23-26|been|O
DDI-DrugBank.d154.s2|28-32|shown|O
DDI-DrugBank.d154.s2|34-35|to|O
DDI-DrugBank.d154.s2|37-43|produce|O
DDI-DrugBank.d154.s2|45-47|any|O
DDI-DrugBank.d154.s2|49-58|additional|O
DDI-DrugBank.d154.s2|60-65|effect|O
DDI-DrugBank.d154.s2|67-72|beyond|O
DDI-DrugBank.d154.s2|74-77|that|O
DDI-DrugBank.d154.s2|79-86|obtained|O
DDI-DrugBank.d154.s2|88-91|with|O
DDI-DrugBank.d154.s2|93-99|aspirin|brand
DDI-DrugBank.d154.s2|101-105|alone|O
DDI-DrugBank.d154.s2|107-109|and|O
DDI-DrugBank.d154.s2|111-117|because|O
DDI-DrugBank.d154.s2|119-125|aspirin|brand
DDI-DrugBank.d154.s2|127-135|increases|O
DDI-DrugBank.d154.s2|137-139|the|O
DDI-DrugBank.d154.s2|141-144|rate|O
DDI-DrugBank.d154.s2|146-147|of|O
DDI-DrugBank.d154.s2|149-157|excretion|O
DDI-DrugBank.d154.s2|159-160|of|O
DDI-DrugBank.d154.s2|162-167|Nalfon|brand
DDI-DrugBank.d154.s2|168-168|,|O
DDI-DrugBank.d154.s2|170-172|the|O
DDI-DrugBank.d154.s2|174-184|concomitant|O
DDI-DrugBank.d154.s2|186-188|use|O
DDI-DrugBank.d154.s2|190-191|of|O
DDI-DrugBank.d154.s2|193-198|Nalfon|brand
DDI-DrugBank.d154.s2|200-202|and|O
DDI-DrugBank.d154.s2|204-214|salicylates|group
DDI-DrugBank.d154.s2|216-217|is|O
DDI-DrugBank.d154.s2|219-221|not|O
DDI-DrugBank.d154.s2|223-233|recommended|O
DDI-DrugBank.d154.s2|234-234|.|O
DDI-DrugBank.d154.s3|0-6|Chronic|O
DDI-DrugBank.d154.s3|8-21|administration|O
DDI-DrugBank.d154.s3|23-24|of|O
DDI-DrugBank.d154.s3|26-38|phenobarbital|drug
DDI-DrugBank.d154.s3|39-39|,|O
DDI-DrugBank.d154.s3|41-41|a|O
DDI-DrugBank.d154.s3|43-47|known|O
DDI-DrugBank.d154.s3|49-54|enzyme|O
DDI-DrugBank.d154.s3|56-62|inducer|O
DDI-DrugBank.d154.s3|63-63|,|O
DDI-DrugBank.d154.s3|65-67|may|O
DDI-DrugBank.d154.s3|69-70|be|O
DDI-DrugBank.d154.s3|72-81|associated|O
DDI-DrugBank.d154.s3|83-86|with|O
DDI-DrugBank.d154.s3|88-88|a|O
DDI-DrugBank.d154.s3|90-97|decrease|O
DDI-DrugBank.d154.s3|99-100|in|O
DDI-DrugBank.d154.s3|102-104|the|O
DDI-DrugBank.d154.s3|106-111|plasma|O
DDI-DrugBank.d154.s3|113-121|half-life|O
DDI-DrugBank.d154.s3|123-124|of|O
DDI-DrugBank.d154.s3|126-135|fenoprofen|drug
DDI-DrugBank.d154.s3|136-136|.|O
DDI-DrugBank.d154.s4|0-3|When|O
DDI-DrugBank.d154.s4|5-17|phenobarbital|drug
DDI-DrugBank.d154.s4|19-20|is|O
DDI-DrugBank.d154.s4|22-26|added|O
DDI-DrugBank.d154.s4|28-29|to|O
DDI-DrugBank.d154.s4|31-32|or|O
DDI-DrugBank.d154.s4|34-42|withdrawn|O
DDI-DrugBank.d154.s4|44-47|from|O
DDI-DrugBank.d154.s4|49-57|treatment|O
DDI-DrugBank.d154.s4|58-58|,|O
DDI-DrugBank.d154.s4|60-65|dosage|O
DDI-DrugBank.d154.s4|67-76|adjustment|O
DDI-DrugBank.d154.s4|78-79|of|O
DDI-DrugBank.d154.s4|81-86|Nalfon|brand
DDI-DrugBank.d154.s4|88-90|may|O
DDI-DrugBank.d154.s4|92-93|be|O
DDI-DrugBank.d154.s4|95-102|required|O
DDI-DrugBank.d154.s4|103-103|.|O
DDI-DrugBank.d154.s5|0-1|In|O
DDI-DrugBank.d154.s5|3-7|vitro|O
DDI-DrugBank.d154.s5|9-15|studies|O
DDI-DrugBank.d154.s5|17-20|have|O
DDI-DrugBank.d154.s5|22-26|shown|O
DDI-DrugBank.d154.s5|28-31|that|O
DDI-DrugBank.d154.s5|33-42|fenoprofen|drug
DDI-DrugBank.d154.s5|43-43|,|O
DDI-DrugBank.d154.s5|45-51|because|O
DDI-DrugBank.d154.s5|53-54|of|O
DDI-DrugBank.d154.s5|56-58|its|O
DDI-DrugBank.d154.s5|60-67|affinity|O
DDI-DrugBank.d154.s5|69-71|for|O
DDI-DrugBank.d154.s5|73-79|albumin|O
DDI-DrugBank.d154.s5|80-80|,|O
DDI-DrugBank.d154.s5|82-84|may|O
DDI-DrugBank.d154.s5|86-93|displace|O
DDI-DrugBank.d154.s5|95-98|from|O
DDI-DrugBank.d154.s5|100-104|their|O
DDI-DrugBank.d154.s5|106-112|binding|O
DDI-DrugBank.d154.s5|114-118|sites|O
DDI-DrugBank.d154.s5|120-124|other|O
DDI-DrugBank.d154.s5|126-130|drugs|O
DDI-DrugBank.d154.s5|132-135|that|O
DDI-DrugBank.d154.s5|137-139|are|O
DDI-DrugBank.d154.s5|141-144|also|O
DDI-DrugBank.d154.s5|146-152|albumin|O
DDI-DrugBank.d154.s5|154-158|bound|O
DDI-DrugBank.d154.s5|159-159|,|O
DDI-DrugBank.d154.s5|161-163|and|O
DDI-DrugBank.d154.s5|165-168|this|O
DDI-DrugBank.d154.s5|170-172|may|O
DDI-DrugBank.d154.s5|174-177|lead|O
DDI-DrugBank.d154.s5|179-180|to|O
DDI-DrugBank.d154.s5|182-185|drug|O
DDI-DrugBank.d154.s5|187-197|interaction|O
DDI-DrugBank.d154.s5|198-198|.|O
DDI-DrugBank.d154.s6|0-12|Theoretically|O
DDI-DrugBank.d154.s6|13-13|,|O
DDI-DrugBank.d154.s6|15-24|fenoprofen|drug
DDI-DrugBank.d154.s6|26-30|could|O
DDI-DrugBank.d154.s6|32-39|likewise|O
DDI-DrugBank.d154.s6|41-42|be|O
DDI-DrugBank.d154.s6|44-52|displaced|O
DDI-DrugBank.d154.s6|53-53|.|O
DDI-DrugBank.d154.s7|0-7|Patients|O
DDI-DrugBank.d154.s7|9-17|receiving|O
DDI-DrugBank.d154.s7|19-28|hydantoins|group
DDI-DrugBank.d154.s7|29-29|,|O
DDI-DrugBank.d154.s7|31-42|sulfonamides|group
DDI-DrugBank.d154.s7|43-43|,|O
DDI-DrugBank.d154.s7|45-46|or|O
DDI-DrugBank.d154.s7|48-60|sulfonylureas|group
DDI-DrugBank.d154.s7|62-67|should|O
DDI-DrugBank.d154.s7|69-70|be|O
DDI-DrugBank.d154.s7|72-79|observed|O
DDI-DrugBank.d154.s7|81-83|for|O
DDI-DrugBank.d154.s7|85-93|increased|O
DDI-DrugBank.d154.s7|95-102|activity|O
DDI-DrugBank.d154.s7|104-105|of|O
DDI-DrugBank.d154.s7|107-111|these|O
DDI-DrugBank.d154.s7|113-117|drugs|O
DDI-DrugBank.d154.s7|119-121|and|O
DDI-DrugBank.d154.s7|122-122|,|O
DDI-DrugBank.d154.s7|124-132|therefore|O
DDI-DrugBank.d154.s7|133-133|,|O
DDI-DrugBank.d154.s7|135-139|signs|O
DDI-DrugBank.d154.s7|141-142|of|O
DDI-DrugBank.d154.s7|144-151|toxicity|O
DDI-DrugBank.d154.s7|153-156|from|O
DDI-DrugBank.d154.s7|158-162|these|O
DDI-DrugBank.d154.s7|164-168|drugs|O
DDI-DrugBank.d154.s7|169-169|.|O
DDI-DrugBank.d154.s8|0-1|In|O
DDI-DrugBank.d154.s8|3-10|patients|O
DDI-DrugBank.d154.s8|12-20|receiving|O
DDI-DrugBank.d154.s8|22-49|coumarin-type anticoagulants|group
DDI-DrugBank.d154.s8|50-50|,|O
DDI-DrugBank.d154.s8|52-54|the|O
DDI-DrugBank.d154.s8|56-63|addition|O
DDI-DrugBank.d154.s8|65-66|of|O
DDI-DrugBank.d154.s8|68-73|Nalfon|brand
DDI-DrugBank.d154.s8|75-76|to|O
DDI-DrugBank.d154.s8|78-84|therapy|O
DDI-DrugBank.d154.s8|86-90|could|O
DDI-DrugBank.d154.s8|92-98|prolong|O
DDI-DrugBank.d154.s8|100-102|the|O
DDI-DrugBank.d154.s8|104-114|prothrombin|O
DDI-DrugBank.d154.s8|116-119|time|O
DDI-DrugBank.d154.s8|120-120|.|O
DDI-DrugBank.d154.s9|0-7|Patients|O
DDI-DrugBank.d154.s9|9-17|receiving|O
DDI-DrugBank.d154.s9|19-22|both|O
DDI-DrugBank.d154.s9|24-28|drugs|O
DDI-DrugBank.d154.s9|30-35|should|O
DDI-DrugBank.d154.s9|37-38|be|O
DDI-DrugBank.d154.s9|40-44|under|O
DDI-DrugBank.d154.s9|46-52|careful|O
DDI-DrugBank.d154.s9|54-64|observation|O
DDI-DrugBank.d154.s9|65-65|.|O
DDI-DrugBank.d154.s10|0-7|Patients|O
DDI-DrugBank.d154.s10|9-15|treated|O
DDI-DrugBank.d154.s10|17-20|with|O
DDI-DrugBank.d154.s10|22-27|Nalfon|brand
DDI-DrugBank.d154.s10|29-31|may|O
DDI-DrugBank.d154.s10|33-34|be|O
DDI-DrugBank.d154.s10|36-44|resistant|O
DDI-DrugBank.d154.s10|46-47|to|O
DDI-DrugBank.d154.s10|49-51|the|O
DDI-DrugBank.d154.s10|53-59|effects|O
DDI-DrugBank.d154.s10|61-62|of|O
DDI-DrugBank.d154.s10|64-77|loop diuretics|group
DDI-DrugBank.d154.s10|78-78|.|O
DDI-DrugBank.d154.s11|0-1|In|O
DDI-DrugBank.d154.s11|3-10|patients|O
DDI-DrugBank.d154.s11|12-20|receiving|O
DDI-DrugBank.d154.s11|22-27|Nalfon|brand
DDI-DrugBank.d154.s11|29-31|and|O
DDI-DrugBank.d154.s11|33-33|a|O
DDI-DrugBank.d154.s11|35-41|steroid|group
DDI-DrugBank.d154.s11|43-55|concomitantly|O
DDI-DrugBank.d154.s11|56-56|,|O
DDI-DrugBank.d154.s11|58-60|any|O
DDI-DrugBank.d154.s11|62-70|reduction|O
DDI-DrugBank.d154.s11|72-73|in|O
DDI-DrugBank.d154.s11|75-81|steroid|group
DDI-DrugBank.d154.s11|83-88|dosage|O
DDI-DrugBank.d154.s11|90-95|should|O
DDI-DrugBank.d154.s11|97-98|be|O
DDI-DrugBank.d154.s11|100-106|gradual|O
DDI-DrugBank.d154.s11|108-109|in|O
DDI-DrugBank.d154.s11|111-115|order|O
DDI-DrugBank.d154.s11|117-118|to|O
DDI-DrugBank.d154.s11|120-124|avoid|O
DDI-DrugBank.d154.s11|126-128|the|O
DDI-DrugBank.d154.s11|130-137|possible|O
DDI-DrugBank.d154.s11|139-151|complications|O
DDI-DrugBank.d154.s11|153-154|of|O
DDI-DrugBank.d154.s11|156-161|sudden|O
DDI-DrugBank.d154.s11|163-169|steroid|group
DDI-DrugBank.d154.s11|171-180|withdrawal|O
DDI-DrugBank.d154.s11|181-181|.|O
DDI-DrugBank.d25.s0|0-12|Corticotropin|drug
DDI-DrugBank.d25.s0|14-16|may|O
DDI-DrugBank.d25.s0|18-27|accentuate|O
DDI-DrugBank.d25.s0|29-31|the|O
DDI-DrugBank.d25.s0|33-43|electrolyte|O
DDI-DrugBank.d25.s0|45-48|loss|O
DDI-DrugBank.d25.s0|50-59|associated|O
DDI-DrugBank.d25.s0|61-64|with|O
DDI-DrugBank.d25.s0|66-73|diuretic|drug
DDI-DrugBank.d25.s0|75-81|therapy|O
DDI-DrugBank.d25.s0|82-82|.|O
DDI-DrugBank.d775.s0|0-7|Although|O
DDI-DrugBank.d775.s0|9-16|MIVACRON|brand
DDI-DrugBank.d775.s0|18-18|(|O
DDI-DrugBank.d775.s0|19-19|a|O
DDI-DrugBank.d775.s0|21-27|mixture|O
DDI-DrugBank.d775.s0|29-30|of|O
DDI-DrugBank.d775.s0|32-36|three|O
DDI-DrugBank.d775.s0|38-50|stereoisomers|O
DDI-DrugBank.d775.s0|51-51|)|O
DDI-DrugBank.d775.s0|53-55|has|O
DDI-DrugBank.d775.s0|57-60|been|O
DDI-DrugBank.d775.s0|62-73|administered|O
DDI-DrugBank.d775.s0|75-80|safely|O
DDI-DrugBank.d775.s0|82-90|following|O
DDI-DrugBank.d775.s0|92-118|succinylcholine-facilitated|O
DDI-DrugBank.d775.s0|120-127|tracheal|O
DDI-DrugBank.d775.s0|129-138|intubation|O
DDI-DrugBank.d775.s0|139-139|,|O
DDI-DrugBank.d775.s0|141-143|the|O
DDI-DrugBank.d775.s0|145-155|interaction|O
DDI-DrugBank.d775.s0|157-163|between|O
DDI-DrugBank.d775.s0|165-172|MIVACRON|brand
DDI-DrugBank.d775.s0|174-176|and|O
DDI-DrugBank.d775.s0|178-192|succinylcholine|drug
DDI-DrugBank.d775.s0|194-196|has|O
DDI-DrugBank.d775.s0|198-200|not|O
DDI-DrugBank.d775.s0|202-205|been|O
DDI-DrugBank.d775.s0|207-220|systematically|O
DDI-DrugBank.d775.s0|222-228|studied|O
DDI-DrugBank.d775.s0|229-229|.|O
DDI-DrugBank.d775.s1|0-4|Prior|O
DDI-DrugBank.d775.s1|6-19|administration|O
DDI-DrugBank.d775.s1|21-22|of|O
DDI-DrugBank.d775.s1|24-38|succinylcholine|drug
DDI-DrugBank.d775.s1|40-42|can|O
DDI-DrugBank.d775.s1|44-53|potentiate|O
DDI-DrugBank.d775.s1|55-57|the|O
DDI-DrugBank.d775.s1|59-71|neuromuscular|O
DDI-DrugBank.d775.s1|73-80|blocking|O
DDI-DrugBank.d775.s1|82-88|effects|O
DDI-DrugBank.d775.s1|90-91|of|O
DDI-DrugBank.d775.s1|93-114|nondepolarizing agents|group
DDI-DrugBank.d775.s1|115-115|.|O
DDI-DrugBank.d775.s2|0-7|Evidence|O
DDI-DrugBank.d775.s2|9-10|of|O
DDI-DrugBank.d775.s2|12-22|spontaneous|O
DDI-DrugBank.d775.s2|24-31|recovery|O
DDI-DrugBank.d775.s2|33-36|from|O
DDI-DrugBank.d775.s2|38-52|succinylcholine|drug
DDI-DrugBank.d775.s2|54-59|should|O
DDI-DrugBank.d775.s2|61-62|be|O
DDI-DrugBank.d775.s2|64-71|observed|O
DDI-DrugBank.d775.s2|73-78|before|O
DDI-DrugBank.d775.s2|80-82|the|O
DDI-DrugBank.d775.s2|84-97|administration|O
DDI-DrugBank.d775.s2|99-100|of|O
DDI-DrugBank.d775.s2|102-109|MIVACRON|brand
DDI-DrugBank.d775.s2|110-110|.|O
DDI-DrugBank.d775.s3|0-2|The|O
DDI-DrugBank.d775.s3|4-6|use|O
DDI-DrugBank.d775.s3|8-9|of|O
DDI-DrugBank.d775.s3|11-18|MIVACRON|brand
DDI-DrugBank.d775.s3|20-25|before|O
DDI-DrugBank.d775.s3|27-41|succinylcholine|drug
DDI-DrugBank.d775.s3|43-44|to|O
DDI-DrugBank.d775.s3|46-54|attenuate|O
DDI-DrugBank.d775.s3|56-59|some|O
DDI-DrugBank.d775.s3|61-62|of|O
DDI-DrugBank.d775.s3|64-66|the|O
DDI-DrugBank.d775.s3|68-71|side|O
DDI-DrugBank.d775.s3|73-79|effects|O
DDI-DrugBank.d775.s3|81-82|of|O
DDI-DrugBank.d775.s3|84-98|succinylcholine|drug
DDI-DrugBank.d775.s3|100-102|has|O
DDI-DrugBank.d775.s3|104-106|not|O
DDI-DrugBank.d775.s3|108-111|been|O
DDI-DrugBank.d775.s3|113-119|studied|O
DDI-DrugBank.d775.s3|120-120|.|O
DDI-DrugBank.d775.s4|0-4|There|O
DDI-DrugBank.d775.s4|6-8|are|O
DDI-DrugBank.d775.s4|10-11|no|O
DDI-DrugBank.d775.s4|13-20|clinical|O
DDI-DrugBank.d775.s4|22-25|data|O
DDI-DrugBank.d775.s4|27-28|on|O
DDI-DrugBank.d775.s4|30-32|the|O
DDI-DrugBank.d775.s4|34-36|use|O
DDI-DrugBank.d775.s4|38-39|of|O
DDI-DrugBank.d775.s4|41-48|MIVACRON|brand
DDI-DrugBank.d775.s4|50-53|with|O
DDI-DrugBank.d775.s4|55-59|other|O
DDI-DrugBank.d775.s4|61-105|nondepolarizing neuromuscular blocking agents|group
DDI-DrugBank.d775.s4|106-106|.|O
DDI-DrugBank.d775.s5|0-9|Isoflurane|drug
DDI-DrugBank.d775.s5|11-13|and|O
DDI-DrugBank.d775.s5|15-23|enflurane|drug
DDI-DrugBank.d775.s5|25-25|(|O
DDI-DrugBank.d775.s5|26-37|administered|O
DDI-DrugBank.d775.s5|39-42|with|O
DDI-DrugBank.d775.s5|44-63|nitrous oxide/oxygen|drug
DDI-DrugBank.d775.s5|65-66|to|O
DDI-DrugBank.d775.s5|68-74|achieve|O
DDI-DrugBank.d775.s5|76-79|1.25|O
DDI-DrugBank.d775.s5|81-83|M.C|O
DDI-DrugBank.d775.s5|84-84|.|O
DDI-DrugBank.d775.s6|0-7|decrease|O
DDI-DrugBank.d775.s6|9-11|the|O
DDI-DrugBank.d775.s6|13-16|ED50|O
DDI-DrugBank.d775.s6|18-19|of|O
DDI-DrugBank.d775.s6|21-28|MIVACRON|brand
DDI-DrugBank.d775.s6|30-31|by|O
DDI-DrugBank.d775.s6|33-34|as|O
DDI-DrugBank.d775.s6|36-39|much|O
DDI-DrugBank.d775.s6|41-42|as|O
DDI-DrugBank.d775.s6|44-45|25|O
DDI-DrugBank.d775.s6|46-46|%|O
DDI-DrugBank.d775.s6|48-48|(|O
DDI-DrugBank.d775.s6|49-51|see|O
DDI-DrugBank.d775.s6|53-60|CLINICAL|O
DDI-DrugBank.d775.s6|62-73|PHARMACOLOGY|O
DDI-DrugBank.d775.s6|74-74|:|O
DDI-DrugBank.d775.s6|76-91|Pharmacodynamics|O
DDI-DrugBank.d775.s6|93-95|and|O
DDI-DrugBank.d775.s6|97-113|Individualization|O
DDI-DrugBank.d775.s6|115-116|of|O
DDI-DrugBank.d775.s6|118-124|Dosages|O
DDI-DrugBank.d775.s6|125-125|)|O
DDI-DrugBank.d775.s6|126-126|.|O
DDI-DrugBank.d775.s7|0-4|These|O
DDI-DrugBank.d775.s7|6-11|agents|O
DDI-DrugBank.d775.s7|13-15|may|O
DDI-DrugBank.d775.s7|17-20|also|O
DDI-DrugBank.d775.s7|22-28|prolong|O
DDI-DrugBank.d775.s7|30-32|the|O
DDI-DrugBank.d775.s7|34-43|clinically|O
DDI-DrugBank.d775.s7|45-53|effective|O
DDI-DrugBank.d775.s7|55-62|duration|O
DDI-DrugBank.d775.s7|64-65|of|O
DDI-DrugBank.d775.s7|67-72|action|O
DDI-DrugBank.d775.s7|74-76|and|O
DDI-DrugBank.d775.s7|78-85|decrease|O
DDI-DrugBank.d775.s7|87-89|the|O
DDI-DrugBank.d775.s7|91-97|average|O
DDI-DrugBank.d775.s7|99-106|infusion|O
DDI-DrugBank.d775.s7|108-118|requirement|O
DDI-DrugBank.d775.s7|120-121|of|O
DDI-DrugBank.d775.s7|123-130|MIVACRON|brand
DDI-DrugBank.d775.s7|132-133|by|O
DDI-DrugBank.d775.s7|135-136|as|O
DDI-DrugBank.d775.s7|138-141|much|O
DDI-DrugBank.d775.s7|143-144|as|O
DDI-DrugBank.d775.s7|146-147|35|O
DDI-DrugBank.d775.s7|148-148|%|O
DDI-DrugBank.d775.s7|150-151|to|O
DDI-DrugBank.d775.s7|153-154|40|O
DDI-DrugBank.d775.s7|155-155|%|O
DDI-DrugBank.d775.s7|156-156|.|O
DDI-DrugBank.d775.s8|0-0|A|O
DDI-DrugBank.d775.s8|2-8|greater|O
DDI-DrugBank.d775.s8|10-21|potentiation|O
DDI-DrugBank.d775.s8|23-24|of|O
DDI-DrugBank.d775.s8|26-28|the|O
DDI-DrugBank.d775.s8|30-42|neuromuscular|O
DDI-DrugBank.d775.s8|44-51|blocking|O
DDI-DrugBank.d775.s8|53-59|effects|O
DDI-DrugBank.d775.s8|61-62|of|O
DDI-DrugBank.d775.s8|64-71|MIVACRON|brand
DDI-DrugBank.d775.s8|73-75|may|O
DDI-DrugBank.d775.s8|77-78|be|O
DDI-DrugBank.d775.s8|80-87|expected|O
DDI-DrugBank.d775.s8|89-92|with|O
DDI-DrugBank.d775.s8|94-99|higher|O
DDI-DrugBank.d775.s8|101-114|concentrations|O
DDI-DrugBank.d775.s8|116-117|of|O
DDI-DrugBank.d775.s8|119-127|enflurane|drug
DDI-DrugBank.d775.s8|129-130|or|O
DDI-DrugBank.d775.s8|132-141|isoflurane|drug
DDI-DrugBank.d775.s8|142-142|.|O
DDI-DrugBank.d775.s9|0-8|Halothane|drug
DDI-DrugBank.d775.s9|10-12|has|O
DDI-DrugBank.d775.s9|14-19|little|O
DDI-DrugBank.d775.s9|21-22|or|O
DDI-DrugBank.d775.s9|24-25|no|O
DDI-DrugBank.d775.s9|27-32|effect|O
DDI-DrugBank.d775.s9|34-35|on|O
DDI-DrugBank.d775.s9|37-39|the|O
DDI-DrugBank.d775.s9|41-44|ED50|O
DDI-DrugBank.d775.s9|46-46|,|O
DDI-DrugBank.d775.s9|48-50|but|O
DDI-DrugBank.d775.s9|52-54|may|O
DDI-DrugBank.d775.s9|56-62|prolong|O
DDI-DrugBank.d775.s9|64-66|the|O
DDI-DrugBank.d775.s9|68-75|duration|O
DDI-DrugBank.d775.s9|77-78|of|O
DDI-DrugBank.d775.s9|80-85|action|O
DDI-DrugBank.d775.s9|87-89|and|O
DDI-DrugBank.d775.s9|91-98|decrease|O
DDI-DrugBank.d775.s9|100-102|the|O
DDI-DrugBank.d775.s9|104-110|average|O
DDI-DrugBank.d775.s9|112-119|infusion|O
DDI-DrugBank.d775.s9|121-131|requirement|O
DDI-DrugBank.d775.s9|133-134|by|O
DDI-DrugBank.d775.s9|136-137|as|O
DDI-DrugBank.d775.s9|139-142|much|O
DDI-DrugBank.d775.s9|144-145|as|O
DDI-DrugBank.d775.s9|147-148|20|O
DDI-DrugBank.d775.s9|149-149|%|O
DDI-DrugBank.d775.s9|150-150|.|O
DDI-DrugBank.d775.s10|0-4|Other|O
DDI-DrugBank.d775.s10|6-10|drugs|O
DDI-DrugBank.d775.s10|12-16|which|O
DDI-DrugBank.d775.s10|18-20|may|O
DDI-DrugBank.d775.s10|22-28|enhance|O
DDI-DrugBank.d775.s10|30-32|the|O
DDI-DrugBank.d775.s10|34-46|neuromuscular|O
DDI-DrugBank.d775.s10|48-55|blocking|O
DDI-DrugBank.d775.s10|57-62|action|O
DDI-DrugBank.d775.s10|64-65|of|O
DDI-DrugBank.d775.s10|67-88|nondepolarizing agents|drug
DDI-DrugBank.d775.s10|90-93|such|O
DDI-DrugBank.d775.s10|95-96|as|O
DDI-DrugBank.d775.s10|98-105|MIVACRON|brand
DDI-DrugBank.d775.s10|107-113|include|O
DDI-DrugBank.d775.s10|115-121|certain|O
DDI-DrugBank.d775.s10|123-133|antibiotics|group
DDI-DrugBank.d775.s10|135-135|(|O
DDI-DrugBank.d775.s10|136-139|e.g.|O
DDI-DrugBank.d775.s10|140-140|,|O
DDI-DrugBank.d775.s10|142-156|aminoglycosides|group
DDI-DrugBank.d775.s10|157-157|,|O
DDI-DrugBank.d775.s10|159-171|tetracyclines|group
DDI-DrugBank.d775.s10|172-172|,|O
DDI-DrugBank.d775.s10|174-183|bacitracin|drug
DDI-DrugBank.d775.s10|184-184|,|O
DDI-DrugBank.d775.s10|186-195|polymyxins|group
DDI-DrugBank.d775.s10|196-196|,|O
DDI-DrugBank.d775.s10|198-207|lincomycin|drug
DDI-DrugBank.d775.s10|208-208|,|O
DDI-DrugBank.d775.s10|210-220|clindamycin|drug
DDI-DrugBank.d775.s10|221-221|,|O
DDI-DrugBank.d775.s10|223-230|colistin|drug
DDI-DrugBank.d775.s10|231-231|,|O
DDI-DrugBank.d775.s10|233-235|and|O
DDI-DrugBank.d775.s10|237-257|sodium colistimethate|drug
DDI-DrugBank.d775.s10|258-258|)|O
DDI-DrugBank.d775.s10|259-259|,|O
DDI-DrugBank.d775.s10|261-269|magnesium|group
DDI-DrugBank.d775.s10|271-275|salts|O
DDI-DrugBank.d775.s10|276-276|,|O
DDI-DrugBank.d775.s10|278-284|lithium|drug
DDI-DrugBank.d775.s10|285-285|,|O
DDI-DrugBank.d775.s10|287-291|local|O
DDI-DrugBank.d775.s10|293-303|anesthetics|group
DDI-DrugBank.d775.s10|304-304|,|O
DDI-DrugBank.d775.s10|306-317|procainamide|drug
DDI-DrugBank.d775.s10|318-318|,|O
DDI-DrugBank.d775.s10|320-322|and|O
DDI-DrugBank.d775.s10|324-332|quinidine|drug
DDI-DrugBank.d775.s10|333-333|.|O
DDI-DrugBank.d775.s11|0-2|The|O
DDI-DrugBank.d775.s11|4-16|neuromuscular|O
DDI-DrugBank.d775.s11|18-25|blocking|O
DDI-DrugBank.d775.s11|27-32|effect|O
DDI-DrugBank.d775.s11|34-35|of|O
DDI-DrugBank.d775.s11|37-44|MIVACRON|brand
DDI-DrugBank.d775.s11|46-48|may|O
DDI-DrugBank.d775.s11|50-51|be|O
DDI-DrugBank.d775.s11|53-60|enhanced|O
DDI-DrugBank.d775.s11|62-63|by|O
DDI-DrugBank.d775.s11|65-69|drugs|O
DDI-DrugBank.d775.s11|71-74|that|O
DDI-DrugBank.d775.s11|76-81|reduce|O
DDI-DrugBank.d775.s11|83-88|plasma|O
DDI-DrugBank.d775.s11|90-103|cholinesterase|O
DDI-DrugBank.d775.s11|105-112|activity|O
DDI-DrugBank.d775.s11|114-114|(|O
DDI-DrugBank.d775.s11|115-118|e.g.|O
DDI-DrugBank.d775.s11|119-119|,|O
DDI-DrugBank.d775.s11|121-131|chronically|O
DDI-DrugBank.d775.s11|133-144|administered|O
DDI-DrugBank.d775.s11|146-149|oral|O
DDI-DrugBank.d775.s11|151-164|contraceptives|group
DDI-DrugBank.d775.s11|165-165|,|O
DDI-DrugBank.d775.s11|167-181|glucocorticoids|group
DDI-DrugBank.d775.s11|182-182|,|O
DDI-DrugBank.d775.s11|184-185|or|O
DDI-DrugBank.d775.s11|187-193|certain|O
DDI-DrugBank.d775.s11|195-222|monoamine oxidase inhibitors|group
DDI-DrugBank.d775.s11|223-223|)|O
DDI-DrugBank.d775.s11|225-226|or|O
DDI-DrugBank.d775.s11|228-229|by|O
DDI-DrugBank.d775.s11|231-235|drugs|O
DDI-DrugBank.d775.s11|237-240|that|O
DDI-DrugBank.d775.s11|242-253|irreversibly|O
DDI-DrugBank.d775.s11|255-261|inhibit|O
DDI-DrugBank.d775.s11|263-268|plasma|O
DDI-DrugBank.d775.s11|270-283|cholinesterase|O
DDI-DrugBank.d775.s11|285-285|.|O
DDI-DrugBank.d775.s11|287-296|Resistance|O
DDI-DrugBank.d775.s11|298-299|to|O
DDI-DrugBank.d775.s11|301-303|the|O
DDI-DrugBank.d775.s11|305-317|neuromuscular|O
DDI-DrugBank.d775.s11|319-326|blocking|O
DDI-DrugBank.d775.s11|328-333|action|O
DDI-DrugBank.d775.s11|335-336|of|O
DDI-DrugBank.d775.s11|338-352|nondepolarizing|O
DDI-DrugBank.d775.s11|354-382|neuromuscular blocking agents|group
DDI-DrugBank.d775.s11|384-386|has|O
DDI-DrugBank.d775.s11|388-391|been|O
DDI-DrugBank.d775.s11|393-404|demonstrated|O
DDI-DrugBank.d775.s11|406-407|in|O
DDI-DrugBank.d775.s11|409-416|patients|O
DDI-DrugBank.d775.s11|418-428|chronically|O
DDI-DrugBank.d775.s11|430-441|administered|O
DDI-DrugBank.d775.s11|443-451|phenytoin|drug
DDI-DrugBank.d775.s11|453-454|or|O
DDI-DrugBank.d775.s11|456-468|carbamazepine|drug
DDI-DrugBank.d775.s11|469-469|.|O
DDI-DrugBank.d775.s12|0-4|While|O
DDI-DrugBank.d775.s12|6-8|the|O
DDI-DrugBank.d775.s12|10-16|effects|O
DDI-DrugBank.d775.s12|18-19|of|O
DDI-DrugBank.d775.s12|21-27|chronic|O
DDI-DrugBank.d775.s12|29-37|phenytoin|drug
DDI-DrugBank.d775.s12|39-40|or|O
DDI-DrugBank.d775.s12|42-54|carbamazepine|drug
DDI-DrugBank.d775.s12|56-62|therapy|O
DDI-DrugBank.d775.s12|64-65|on|O
DDI-DrugBank.d775.s12|67-69|the|O
DDI-DrugBank.d775.s12|71-76|action|O
DDI-DrugBank.d775.s12|78-79|of|O
DDI-DrugBank.d775.s12|81-88|MIVACRON|brand
DDI-DrugBank.d775.s12|90-92|are|O
DDI-DrugBank.d775.s12|94-100|unknown|O
DDI-DrugBank.d775.s12|101-101|,|O
DDI-DrugBank.d775.s12|103-110|slightly|O
DDI-DrugBank.d775.s12|112-118|shorter|O
DDI-DrugBank.d775.s12|120-128|durations|O
DDI-DrugBank.d775.s12|130-131|of|O
DDI-DrugBank.d775.s12|133-145|neuromuscular|O
DDI-DrugBank.d775.s12|147-151|block|O
DDI-DrugBank.d775.s12|153-155|may|O
DDI-DrugBank.d775.s12|157-158|be|O
DDI-DrugBank.d775.s12|160-170|anticipated|O
DDI-DrugBank.d775.s12|172-174|and|O
DDI-DrugBank.d775.s12|176-183|infusion|O
DDI-DrugBank.d775.s12|185-188|rate|O
DDI-DrugBank.d775.s12|190-201|requirements|O
DDI-DrugBank.d775.s12|203-205|may|O
DDI-DrugBank.d775.s12|207-208|be|O
DDI-DrugBank.d775.s12|210-215|higher|O
DDI-DrugBank.d775.s12|216-216|.|O
DDI-DrugBank.d775.s13|0-3|Some|O
DDI-DrugBank.d775.s13|5-8|drug|O
DDI-DrugBank.d775.s13|10-21|interactions|O
DDI-DrugBank.d775.s13|23-25|are|O
DDI-DrugBank.d775.s13|26-26|:|O
DDI-DrugBank.d775.s13|29-29|-|O
DDI-DrugBank.d775.s13|31-35|birth|O
DDI-DrugBank.d775.s13|37-43|control|O
DDI-DrugBank.d775.s13|45-49|pills|O
DDI-DrugBank.d775.s13|51-51|-|O
DDI-DrugBank.d775.s13|53-67|corticosteroids|group
DDI-DrugBank.d775.s13|69-69|-|O
DDI-DrugBank.d775.s13|71-79|medicines|O
DDI-DrugBank.d775.s13|81-83|for|O
DDI-DrugBank.d775.s13|85-90|angina|O
DDI-DrugBank.d775.s13|92-93|or|O
DDI-DrugBank.d775.s13|95-98|high|O
DDI-DrugBank.d775.s13|100-104|blood|O
DDI-DrugBank.d775.s13|106-113|pressure|O
DDI-DrugBank.d775.s13|115-115|-|O
DDI-DrugBank.d775.s13|117-125|medicines|O
DDI-DrugBank.d775.s13|127-129|for|O
DDI-DrugBank.d775.s13|131-134|pain|O
DDI-DrugBank.d775.s13|136-136|-|O
DDI-DrugBank.d775.s13|138-146|medicines|O
DDI-DrugBank.d775.s13|148-149|to|O
DDI-DrugBank.d775.s13|151-157|control|O
DDI-DrugBank.d775.s13|159-166|seizures|O
DDI-DrugBank.d775.s13|168-171|such|O
DDI-DrugBank.d775.s13|173-174|as|O
DDI-DrugBank.d775.s13|176-184|phenytoin|drug
DDI-DrugBank.d775.s13|186-187|or|O
DDI-DrugBank.d775.s13|189-201|carbamazepine|drug
DDI-DrugBank.d775.s13|203-203|-|O
DDI-DrugBank.d775.s13|205-211|certain|O
DDI-DrugBank.d775.s13|213-223|antibiotics|group
DDI-DrugBank.d775.s13|225-229|given|O
DDI-DrugBank.d775.s13|231-232|by|O
DDI-DrugBank.d775.s13|234-242|injection|O
DDI-DrugBank.d775.s13|244-244|-|O
DDI-DrugBank.d775.s13|246-254|cisplatin|drug
DDI-DrugBank.d775.s13|256-256|-|O
DDI-DrugBank.d775.s13|258-268|edrophonium|drug
DDI-DrugBank.d775.s13|270-270|-|O
DDI-DrugBank.d775.s13|272-282|neostigmine|drug
DDI-DrugBank.d775.s13|284-284|-|O
DDI-DrugBank.d775.s13|286-296|polymyxin B|drug
DDI-DrugBank.d775.s13|298-299|or|O
DDI-DrugBank.d775.s13|301-310|bacitracin|drug
DDI-DrugBank.d775.s13|312-312|-|O
DDI-DrugBank.d775.s13|314-318|local|O
DDI-DrugBank.d775.s13|320-330|anesthetics|group
DDI-DrugBank.d775.s13|332-335|such|O
DDI-DrugBank.d775.s13|337-338|as|O
DDI-DrugBank.d775.s13|340-347|procaine|drug
DDI-DrugBank.d775.s13|349-349|-|O
DDI-DrugBank.d775.s13|351-357|general|O
DDI-DrugBank.d775.s13|359-369|anesthetics|group
DDI-DrugBank.d775.s13|371-371|-|O
DDI-DrugBank.d775.s13|373-387|succinylcholine|drug
DDI-DrugBank.d775.s13|389-390|or|O
DDI-DrugBank.d775.s13|392-396|other|O
DDI-DrugBank.d145.s0|0-5|Plasma|O
DDI-DrugBank.d145.s0|7-12|levels|O
DDI-DrugBank.d145.s0|14-15|of|O
DDI-DrugBank.d145.s0|17-37|anticonvulsant agents|group
DDI-DrugBank.d145.s0|39-41|may|O
DDI-DrugBank.d145.s0|43-48|become|O
DDI-DrugBank.d145.s0|50-63|subtherapeutic|O
DDI-DrugBank.d145.s0|65-70|during|O
DDI-DrugBank.d145.s0|72-80|cisplatin|drug
DDI-DrugBank.d145.s0|82-88|therapy|O
DDI-DrugBank.d145.s0|89-89|.|O
DDI-DrugBank.d773.s0|0-5|Formal|O
DDI-DrugBank.d773.s0|7-17|interaction|O
DDI-DrugBank.d773.s0|19-25|studies|O
DDI-DrugBank.d773.s0|27-28|of|O
DDI-DrugBank.d773.s0|30-35|TNKase|brand
DDI-DrugBank.d773.s0|37-40|with|O
DDI-DrugBank.d773.s0|42-46|other|O
DDI-DrugBank.d773.s0|48-52|drugs|O
DDI-DrugBank.d773.s0|54-57|have|O
DDI-DrugBank.d773.s0|59-61|not|O
DDI-DrugBank.d773.s0|63-66|been|O
DDI-DrugBank.d773.s0|68-76|performed|O
DDI-DrugBank.d773.s0|77-77|.|O
DDI-DrugBank.d773.s1|0-7|Patients|O
DDI-DrugBank.d773.s1|9-15|studied|O
DDI-DrugBank.d773.s1|17-18|in|O
DDI-DrugBank.d773.s1|20-27|clinical|O
DDI-DrugBank.d773.s1|29-34|trials|O
DDI-DrugBank.d773.s1|36-37|of|O
DDI-DrugBank.d773.s1|39-44|TNKase|brand
DDI-DrugBank.d773.s1|46-49|were|O
DDI-DrugBank.d773.s1|51-59|routinely|O
DDI-DrugBank.d773.s1|61-67|treated|O
DDI-DrugBank.d773.s1|69-72|with|O
DDI-DrugBank.d773.s1|74-80|heparin|drug
DDI-DrugBank.d773.s1|82-84|and|O
DDI-DrugBank.d773.s1|86-92|aspirin|brand
DDI-DrugBank.d773.s1|93-93|.|O
DDI-DrugBank.d773.s2|0-13|Anticoagulants|group
DDI-DrugBank.d773.s2|15-15|(|O
DDI-DrugBank.d773.s2|16-19|such|O
DDI-DrugBank.d773.s2|21-22|as|O
DDI-DrugBank.d773.s2|24-30|heparin|drug
DDI-DrugBank.d773.s2|32-34|and|O
DDI-DrugBank.d773.s2|36-56|vitamin K antagonists|group
DDI-DrugBank.d773.s2|57-57|)|O
DDI-DrugBank.d773.s2|59-61|and|O
DDI-DrugBank.d773.s2|63-67|drugs|O
DDI-DrugBank.d773.s2|69-72|that|O
DDI-DrugBank.d773.s2|74-78|alter|O
DDI-DrugBank.d773.s2|80-87|platelet|O
DDI-DrugBank.d773.s2|89-96|function|O
DDI-DrugBank.d773.s2|98-98|(|O
DDI-DrugBank.d773.s2|99-102|such|O
DDI-DrugBank.d773.s2|104-105|as|O
DDI-DrugBank.d773.s2|107-126|acetylsalicylic acid|drug
DDI-DrugBank.d773.s2|127-127|,|O
DDI-DrugBank.d773.s2|129-140|dipyridamole|drug
DDI-DrugBank.d773.s2|141-141|,|O
DDI-DrugBank.d773.s2|143-145|and|O
DDI-DrugBank.d773.s2|147-148|GP|O
DDI-DrugBank.d773.s2|150-157|IIb/IIIa|O
DDI-DrugBank.d773.s2|159-168|inhibitors|O
DDI-DrugBank.d773.s2|169-169|)|O
DDI-DrugBank.d773.s2|171-173|may|O
DDI-DrugBank.d773.s2|175-182|increase|O
DDI-DrugBank.d773.s2|184-186|the|O
DDI-DrugBank.d773.s2|188-191|risk|O
DDI-DrugBank.d773.s2|193-194|of|O
DDI-DrugBank.d773.s2|196-203|bleeding|O
DDI-DrugBank.d773.s2|205-206|if|O
DDI-DrugBank.d773.s2|208-219|administered|O
DDI-DrugBank.d773.s2|221-225|prior|O
DDI-DrugBank.d773.s2|227-228|to|O
DDI-DrugBank.d773.s2|229-229|,|O
DDI-DrugBank.d773.s2|231-236|during|O
DDI-DrugBank.d773.s2|237-237|,|O
DDI-DrugBank.d773.s2|239-240|or|O
DDI-DrugBank.d773.s2|242-246|after|O
DDI-DrugBank.d773.s2|248-253|TNKase|brand
DDI-DrugBank.d773.s2|255-261|therapy|O
DDI-DrugBank.d773.s2|262-262|.|O
DDI-DrugBank.d773.s3|0-14|Drug/Laboratory|O
DDI-DrugBank.d773.s3|16-19|Test|O
DDI-DrugBank.d773.s3|21-32|Interactions|O
DDI-DrugBank.d773.s3|34-39|During|O
DDI-DrugBank.d773.s3|41-46|TNKase|brand
DDI-DrugBank.d773.s3|48-54|therapy|O
DDI-DrugBank.d773.s3|55-55|,|O
DDI-DrugBank.d773.s3|57-63|results|O
DDI-DrugBank.d773.s3|65-66|of|O
DDI-DrugBank.d773.s3|68-78|coagulation|O
DDI-DrugBank.d773.s3|80-84|tests|O
DDI-DrugBank.d773.s3|86-91|and/or|O
DDI-DrugBank.d773.s3|93-100|measures|O
DDI-DrugBank.d773.s3|102-103|of|O
DDI-DrugBank.d773.s3|105-116|fibrinolytic|O
DDI-DrugBank.d773.s3|118-125|activity|O
DDI-DrugBank.d773.s3|127-129|may|O
DDI-DrugBank.d773.s3|131-132|be|O
DDI-DrugBank.d773.s3|134-143|unreliable|O
DDI-DrugBank.d773.s3|145-150|unless|O
DDI-DrugBank.d773.s3|152-159|specific|O
DDI-DrugBank.d773.s3|161-171|precautions|O
DDI-DrugBank.d773.s3|173-175|are|O
DDI-DrugBank.d773.s3|177-181|taken|O
DDI-DrugBank.d773.s3|183-184|to|O
DDI-DrugBank.d773.s3|186-192|prevent|O
DDI-DrugBank.d773.s3|194-195|in|O
DDI-DrugBank.d773.s3|197-201|vitro|O
DDI-DrugBank.d773.s3|203-211|artifacts|O
DDI-DrugBank.d773.s3|212-212|.|O
DDI-DrugBank.d773.s4|0-11|Tenecteplase|drug
DDI-DrugBank.d773.s4|13-14|is|O
DDI-DrugBank.d773.s4|16-17|an|O
DDI-DrugBank.d773.s4|19-24|enzyme|O
DDI-DrugBank.d773.s4|26-29|that|O
DDI-DrugBank.d773.s4|30-30|,|O
DDI-DrugBank.d773.s4|32-35|when|O
DDI-DrugBank.d773.s4|37-43|present|O
DDI-DrugBank.d773.s4|45-46|in|O
DDI-DrugBank.d773.s4|48-52|blood|O
DDI-DrugBank.d773.s4|54-55|in|O
DDI-DrugBank.d773.s4|57-69|pharmacologic|O
DDI-DrugBank.d773.s4|71-84|concentrations|O
DDI-DrugBank.d773.s4|85-85|,|O
DDI-DrugBank.d773.s4|87-93|remains|O
DDI-DrugBank.d773.s4|95-100|active|O
DDI-DrugBank.d773.s4|102-106|under|O
DDI-DrugBank.d773.s4|108-109|in|O
DDI-DrugBank.d773.s4|111-115|vitro|O
DDI-DrugBank.d773.s4|117-126|conditions|O
DDI-DrugBank.d773.s4|127-127|.|O
DDI-DrugBank.d773.s5|0-3|This|O
DDI-DrugBank.d773.s5|5-7|can|O
DDI-DrugBank.d773.s5|9-12|lead|O
DDI-DrugBank.d773.s5|14-15|to|O
DDI-DrugBank.d773.s5|17-27|degradation|O
DDI-DrugBank.d773.s5|29-30|of|O
DDI-DrugBank.d773.s5|32-41|fibrinogen|O
DDI-DrugBank.d773.s5|43-44|in|O
DDI-DrugBank.d773.s5|46-50|blood|O
DDI-DrugBank.d773.s5|52-58|samples|O
DDI-DrugBank.d773.s5|60-66|removed|O
DDI-DrugBank.d773.s5|68-70|for|O
DDI-DrugBank.d773.s5|72-79|analysis|O
DDI-DrugBank.d773.s5|80-80|.|O
DDI-DrugBank.d115.s0|0-4|Drugs|O
DDI-DrugBank.d115.s0|6-9|that|O
DDI-DrugBank.d115.s0|11-13|may|O
DDI-DrugBank.d115.s0|15-19|alter|O
DDI-DrugBank.d115.s0|21-28|imatinib|drug
DDI-DrugBank.d115.s0|30-35|plasma|O
DDI-DrugBank.d115.s0|37-50|concentrations|O
DDI-DrugBank.d115.s0|52-56|Drugs|O
DDI-DrugBank.d115.s0|58-61|that|O
DDI-DrugBank.d115.s0|63-65|may|O
DDI-DrugBank.d115.s0|67-74|increase|O
DDI-DrugBank.d115.s0|76-83|imatinib|drug
DDI-DrugBank.d115.s0|85-90|plasma|O
DDI-DrugBank.d115.s0|92-105|concentrations|O
DDI-DrugBank.d115.s0|106-106|:|O
DDI-DrugBank.d115.s0|108-114|Caution|O
DDI-DrugBank.d115.s0|116-117|is|O
DDI-DrugBank.d115.s0|119-129|recommended|O
DDI-DrugBank.d115.s0|131-134|when|O
DDI-DrugBank.d115.s0|136-148|administering|O
DDI-DrugBank.d115.s0|150-156|Gleevec|brand
DDI-DrugBank.d115.s0|158-161|with|O
DDI-DrugBank.d115.s0|163-172|inhibitors|O
DDI-DrugBank.d115.s0|174-175|of|O
DDI-DrugBank.d115.s0|177-179|the|O
DDI-DrugBank.d115.s0|181-186|CYP3A4|O
DDI-DrugBank.d115.s0|188-193|family|O
DDI-DrugBank.d115.s0|195-195|(|O
DDI-DrugBank.d115.s0|196-199|e.g.|O
DDI-DrugBank.d115.s0|200-200|,|O
DDI-DrugBank.d115.s0|202-213|ketoconazole|drug
DDI-DrugBank.d115.s0|214-214|,|O
DDI-DrugBank.d115.s0|216-227|itraconazole|drug
DDI-DrugBank.d115.s0|228-228|,|O
DDI-DrugBank.d115.s0|230-241|erythromycin|drug
DDI-DrugBank.d115.s0|242-242|,|O
DDI-DrugBank.d115.s0|244-257|clarithromycin|drug
DDI-DrugBank.d115.s0|258-258|)|O
DDI-DrugBank.d115.s0|259-259|.|O
DDI-DrugBank.d115.s1|0-9|Substances|O
DDI-DrugBank.d115.s1|11-14|that|O
DDI-DrugBank.d115.s1|16-22|inhibit|O
DDI-DrugBank.d115.s1|24-26|the|O
DDI-DrugBank.d115.s1|28-37|cytochrome|O
DDI-DrugBank.d115.s1|39-42|P450|O
DDI-DrugBank.d115.s1|44-52|isoenzyme|O
DDI-DrugBank.d115.s1|54-54|(|O
DDI-DrugBank.d115.s1|55-60|CYP3A4|O
DDI-DrugBank.d115.s1|61-61|)|O
DDI-DrugBank.d115.s1|63-70|activity|O
DDI-DrugBank.d115.s1|72-74|may|O
DDI-DrugBank.d115.s1|76-83|decrease|O
DDI-DrugBank.d115.s1|85-94|metabolism|O
DDI-DrugBank.d115.s1|96-98|and|O
DDI-DrugBank.d115.s1|100-107|increase|O
DDI-DrugBank.d115.s1|109-116|imatinib|drug
DDI-DrugBank.d115.s1|118-131|concentrations|O
DDI-DrugBank.d115.s1|132-132|.|O
DDI-DrugBank.d115.s2|0-4|There|O
DDI-DrugBank.d115.s2|6-7|is|O
DDI-DrugBank.d115.s2|9-9|a|O
DDI-DrugBank.d115.s2|11-21|significant|O
DDI-DrugBank.d115.s2|23-30|increase|O
DDI-DrugBank.d115.s2|32-33|in|O
DDI-DrugBank.d115.s2|35-42|exposure|O
DDI-DrugBank.d115.s2|44-45|to|O
DDI-DrugBank.d115.s2|47-54|imatinib|drug
DDI-DrugBank.d115.s2|56-59|when|O
DDI-DrugBank.d115.s2|61-67|Gleevec|brand
DDI-DrugBank.d115.s2|69-70|is|O
DDI-DrugBank.d115.s2|72-85|coadministered|O
DDI-DrugBank.d115.s2|87-90|with|O
DDI-DrugBank.d115.s2|92-103|ketoconazole|drug
DDI-DrugBank.d115.s2|105-105|(|O
DDI-DrugBank.d115.s2|106-111|CYP3A4|O
DDI-DrugBank.d115.s2|113-121|inhibitor|O
DDI-DrugBank.d115.s2|122-122|)|O
DDI-DrugBank.d115.s2|123-123|.|O
DDI-DrugBank.d115.s3|0-4|Drugs|O
DDI-DrugBank.d115.s3|6-9|that|O
DDI-DrugBank.d115.s3|11-13|may|O
DDI-DrugBank.d115.s3|15-22|decrease|O
DDI-DrugBank.d115.s3|24-31|imatinib|drug
DDI-DrugBank.d115.s3|33-38|plasma|O
DDI-DrugBank.d115.s3|40-53|concentrations|O
DDI-DrugBank.d115.s3|54-54|:|O
DDI-DrugBank.d115.s3|56-65|Substances|O
DDI-DrugBank.d115.s3|67-70|that|O
DDI-DrugBank.d115.s3|72-74|are|O
DDI-DrugBank.d115.s3|76-83|inducers|O
DDI-DrugBank.d115.s3|85-86|of|O
DDI-DrugBank.d115.s3|88-93|CYP3A4|O
DDI-DrugBank.d115.s3|95-102|activity|O
DDI-DrugBank.d115.s3|104-106|may|O
DDI-DrugBank.d115.s3|108-115|increase|O
DDI-DrugBank.d115.s3|117-126|metabolism|O
DDI-DrugBank.d115.s3|128-130|and|O
DDI-DrugBank.d115.s3|132-139|decrease|O
DDI-DrugBank.d115.s3|141-148|imatinib|drug
DDI-DrugBank.d115.s3|150-155|plasma|O
DDI-DrugBank.d115.s3|157-170|concentrations|O
DDI-DrugBank.d115.s3|171-171|.|O
DDI-DrugBank.d115.s4|0-13|Co-medications|O
DDI-DrugBank.d115.s4|15-18|that|O
DDI-DrugBank.d115.s4|20-25|induce|O
DDI-DrugBank.d115.s4|27-32|CYP3A4|O
DDI-DrugBank.d115.s4|34-34|(|O
DDI-DrugBank.d115.s4|35-38|e.g.|O
DDI-DrugBank.d115.s4|39-39|,|O
DDI-DrugBank.d115.s4|41-53|dexamethasone|drug
DDI-DrugBank.d115.s4|54-54|,|O
DDI-DrugBank.d115.s4|56-64|phenytoin|drug
DDI-DrugBank.d115.s4|65-65|,|O
DDI-DrugBank.d115.s4|67-79|carbamazepine|drug
DDI-DrugBank.d115.s4|80-80|,|O
DDI-DrugBank.d115.s4|82-89|rifampin|drug
DDI-DrugBank.d115.s4|90-90|,|O
DDI-DrugBank.d115.s4|92-104|phenobarbital|drug
DDI-DrugBank.d115.s4|106-107|or|O
DDI-DrugBank.d115.s4|109-110|St|O
DDI-DrugBank.d115.s4|111-111|.|O
DDI-DrugBank.d115.s5|0-4|Johns|O
DDI-DrugBank.d115.s5|6-9|Wort|O
DDI-DrugBank.d115.s5|10-10|)|O
DDI-DrugBank.d115.s5|12-14|may|O
DDI-DrugBank.d115.s5|16-28|significantly|O
DDI-DrugBank.d115.s5|30-35|reduce|O
DDI-DrugBank.d115.s5|37-44|exposure|O
DDI-DrugBank.d115.s5|46-47|to|O
DDI-DrugBank.d115.s5|49-55|Gleevec|brand
DDI-DrugBank.d115.s5|56-56|.|O
DDI-DrugBank.d115.s6|0-11|Pretreatment|O
DDI-DrugBank.d115.s6|13-14|of|O
DDI-DrugBank.d115.s6|16-22|healthy|O
DDI-DrugBank.d115.s6|24-33|volunteers|O
DDI-DrugBank.d115.s6|35-38|with|O
DDI-DrugBank.d115.s6|40-47|multiple|O
DDI-DrugBank.d115.s6|49-53|doses|O
DDI-DrugBank.d115.s6|55-56|of|O
DDI-DrugBank.d115.s6|58-65|rifampin|drug
DDI-DrugBank.d115.s6|67-74|followed|O
DDI-DrugBank.d115.s6|76-77|by|O
DDI-DrugBank.d115.s6|79-79|a|O
DDI-DrugBank.d115.s6|81-86|single|O
DDI-DrugBank.d115.s6|88-91|dose|O
DDI-DrugBank.d115.s6|93-94|of|O
DDI-DrugBank.d115.s6|96-102|Gleevec|brand
DDI-DrugBank.d115.s6|103-103|,|O
DDI-DrugBank.d115.s6|105-113|increased|O
DDI-DrugBank.d115.s6|115-121|Gleevec|brand
DDI-DrugBank.d115.s6|123-131|oral-dose|O
DDI-DrugBank.d115.s6|133-141|clearance|O
DDI-DrugBank.d115.s6|143-144|by|O
DDI-DrugBank.d115.s6|146-153|3.8-fold|O
DDI-DrugBank.d115.s6|154-154|,|O
DDI-DrugBank.d115.s6|156-160|which|O
DDI-DrugBank.d115.s6|162-174|significantly|O
DDI-DrugBank.d115.s6|176-176|(|O
DDI-DrugBank.d115.s6|177-177|p|O
DDI-DrugBank.d115.s6|179-182|0.05|O
DDI-DrugBank.d115.s6|183-183|)|O
DDI-DrugBank.d115.s6|185-193|decreased|O
DDI-DrugBank.d115.s6|195-198|mean|O
DDI-DrugBank.d115.s6|200-203|cmax|O
DDI-DrugBank.d115.s6|205-207|and|O
DDI-DrugBank.d115.s6|209-211|AUC|O
DDI-DrugBank.d115.s6|212-212|(|O
DDI-DrugBank.d115.s6|213-215|0-8|O
DDI-DrugBank.d115.s6|216-216|)|O
DDI-DrugBank.d115.s6|217-217|.|O
DDI-DrugBank.d115.s7|0-1|In|O
DDI-DrugBank.d115.s7|3-10|patients|O
DDI-DrugBank.d115.s7|12-16|where|O
DDI-DrugBank.d115.s7|18-25|rifampin|drug
DDI-DrugBank.d115.s7|27-28|or|O
DDI-DrugBank.d115.s7|30-34|other|O
DDI-DrugBank.d115.s7|36-41|CYP3A4|O
DDI-DrugBank.d115.s7|43-50|inducers|O
DDI-DrugBank.d115.s7|52-54|are|O
DDI-DrugBank.d115.s7|56-64|indicated|O
DDI-DrugBank.d115.s7|65-65|,|O
DDI-DrugBank.d115.s7|67-77|alternative|O
DDI-DrugBank.d115.s7|79-89|therapeutic|O
DDI-DrugBank.d115.s7|91-96|agents|O
DDI-DrugBank.d115.s7|98-101|with|O
DDI-DrugBank.d115.s7|103-106|less|O
DDI-DrugBank.d115.s7|108-113|enzyme|O
DDI-DrugBank.d115.s7|115-123|induction|O
DDI-DrugBank.d115.s7|125-133|potential|O
DDI-DrugBank.d115.s7|135-140|should|O
DDI-DrugBank.d115.s7|142-143|be|O
DDI-DrugBank.d115.s7|145-154|considered|O
DDI-DrugBank.d115.s7|155-155|.|O
DDI-DrugBank.d115.s8|0-4|Drugs|O
DDI-DrugBank.d115.s8|6-9|that|O
DDI-DrugBank.d115.s8|11-13|may|O
DDI-DrugBank.d115.s8|15-18|have|O
DDI-DrugBank.d115.s8|20-24|their|O
DDI-DrugBank.d115.s8|26-31|plasma|O
DDI-DrugBank.d115.s8|33-45|concentration|O
DDI-DrugBank.d115.s8|47-53|altered|O
DDI-DrugBank.d115.s8|55-56|by|O
DDI-DrugBank.d115.s8|58-64|Gleevec|brand
DDI-DrugBank.d115.s8|58-64|Gleevec|brand
DDI-DrugBank.d115.s8|74-82|increases|O
DDI-DrugBank.d115.s8|84-86|the|O
DDI-DrugBank.d115.s8|88-91|mean|O
DDI-DrugBank.d115.s8|93-96|cmax|O
DDI-DrugBank.d115.s8|98-100|and|O
DDI-DrugBank.d115.s8|102-104|AUC|O
DDI-DrugBank.d115.s8|106-107|of|O
DDI-DrugBank.d115.s8|109-119|simvastatin|drug
DDI-DrugBank.d115.s8|121-121|(|O
DDI-DrugBank.d115.s8|122-127|CYP3A4|O
DDI-DrugBank.d115.s8|129-137|substrate|O
DDI-DrugBank.d115.s8|138-138|)|O
DDI-DrugBank.d115.s8|140-141|2-|O
DDI-DrugBank.d115.s8|143-145|and|O
DDI-DrugBank.d115.s8|147-154|3.5-fold|O
DDI-DrugBank.d115.s8|155-155|,|O
DDI-DrugBank.d115.s8|157-168|respectively|O
DDI-DrugBank.d115.s8|169-169|,|O
DDI-DrugBank.d115.s8|171-180|suggesting|O
DDI-DrugBank.d115.s8|182-183|an|O
DDI-DrugBank.d115.s8|185-194|inhibition|O
DDI-DrugBank.d115.s8|196-197|of|O
DDI-DrugBank.d115.s8|199-201|the|O
DDI-DrugBank.d115.s8|203-208|CYP3A4|O
DDI-DrugBank.d115.s8|210-211|by|O
DDI-DrugBank.d115.s8|213-219|Gleevec|brand
DDI-DrugBank.d115.s8|220-220|.|O
DDI-DrugBank.d115.s9|0-9|Particular|O
DDI-DrugBank.d115.s9|11-17|caution|O
DDI-DrugBank.d115.s9|19-20|is|O
DDI-DrugBank.d115.s9|22-32|recommended|O
DDI-DrugBank.d115.s9|34-37|when|O
DDI-DrugBank.d115.s9|39-51|administering|O
DDI-DrugBank.d115.s9|53-59|Gleevec|brand
DDI-DrugBank.d115.s9|61-64|with|O
DDI-DrugBank.d115.s9|66-71|CYP3A4|O
DDI-DrugBank.d115.s9|73-82|substrates|O
DDI-DrugBank.d115.s9|84-87|that|O
DDI-DrugBank.d115.s9|89-92|have|O
DDI-DrugBank.d115.s9|94-94|a|O
DDI-DrugBank.d115.s9|96-101|narrow|O
DDI-DrugBank.d115.s9|103-113|therapeutic|O
DDI-DrugBank.d115.s9|115-120|window|O
DDI-DrugBank.d115.s9|122-122|(|O
DDI-DrugBank.d115.s9|123-126|e.g.|O
DDI-DrugBank.d115.s9|127-127|,|O
DDI-DrugBank.d115.s9|129-140|cyclosporine|drug
DDI-DrugBank.d115.s9|142-143|or|O
DDI-DrugBank.d115.s9|145-152|pimozide|drug
DDI-DrugBank.d115.s9|153-153|)|O
DDI-DrugBank.d115.s9|154-154|.|O
DDI-DrugBank.d115.s10|0-6|Gleevec|brand
DDI-DrugBank.d115.s10|8-11|will|O
DDI-DrugBank.d115.s10|13-20|increase|O
DDI-DrugBank.d115.s10|22-40|plasmaconcentration|O
DDI-DrugBank.d115.s10|42-43|of|O
DDI-DrugBank.d115.s10|45-49|other|O
DDI-DrugBank.d115.s10|51-56|CYP3A4|O
DDI-DrugBank.d115.s10|58-68|metabolized|O
DDI-DrugBank.d115.s10|70-74|drugs|O
DDI-DrugBank.d115.s10|76-76|(|O
DDI-DrugBank.d115.s10|77-80|e.g.|O
DDI-DrugBank.d115.s10|81-81|,|O
DDI-DrugBank.d115.s10|83-106|triazolo-benzodiazepines|group
DDI-DrugBank.d115.s10|107-107|,|O
DDI-DrugBank.d115.s10|109-148|dihydropyridine calcium channel blockers|group
DDI-DrugBank.d115.s10|149-149|,|O
DDI-DrugBank.d115.s10|151-157|certain|O
DDI-DrugBank.d115.s10|159-186|HMG-CoA reductase inhibitors|group
DDI-DrugBank.d115.s10|187-187|,|O
DDI-DrugBank.d115.s10|189-192|etc.|O
DDI-DrugBank.d115.s10|193-193|)|O
DDI-DrugBank.d115.s10|194-194|.|O
DDI-DrugBank.d115.s11|0-6|Because|O
DDI-DrugBank.d115.s11|8-15|warfarin|drug
DDI-DrugBank.d115.s11|17-18|is|O
DDI-DrugBank.d115.s11|20-30|metabolized|O
DDI-DrugBank.d115.s11|32-33|by|O
DDI-DrugBank.d115.s11|35-40|CYP2C9|O
DDI-DrugBank.d115.s11|42-44|and|O
DDI-DrugBank.d115.s11|46-51|CYP3A4|O
DDI-DrugBank.d115.s11|52-52|,|O
DDI-DrugBank.d115.s11|54-61|patients|O
DDI-DrugBank.d115.s11|63-65|who|O
DDI-DrugBank.d115.s11|67-73|require|O
DDI-DrugBank.d115.s11|75-89|anticoagulation|O
DDI-DrugBank.d115.s11|91-96|should|O
DDI-DrugBank.d115.s11|98-104|receive|O
DDI-DrugBank.d115.s11|106-118|low-molecular|O
DDI-DrugBank.d115.s11|120-125|weight|O
DDI-DrugBank.d115.s11|127-128|or|O
DDI-DrugBank.d115.s11|130-137|standard|O
DDI-DrugBank.d115.s11|139-145|heparin|drug
DDI-DrugBank.d115.s11|146-146|.|O
DDI-DrugBank.d115.s12|0-1|in|O
DDI-DrugBank.d115.s12|3-7|vitro|O
DDI-DrugBank.d115.s12|8-8|,|O
DDI-DrugBank.d115.s12|10-16|Gleevec|brand
DDI-DrugBank.d115.s12|18-25|inhibits|O
DDI-DrugBank.d115.s12|27-29|the|O
DDI-DrugBank.d115.s12|31-40|cytochrome|O
DDI-DrugBank.d115.s12|42-45|P450|O
DDI-DrugBank.d115.s12|47-55|isoenzyme|O
DDI-DrugBank.d115.s12|57-62|CYP2D6|O
DDI-DrugBank.d115.s12|64-71|activity|O
DDI-DrugBank.d115.s12|73-74|at|O
DDI-DrugBank.d115.s12|76-82|similar|O
DDI-DrugBank.d115.s12|84-97|concentrations|O
DDI-DrugBank.d115.s12|99-102|that|O
DDI-DrugBank.d115.s12|104-109|affect|O
DDI-DrugBank.d115.s12|111-116|CYP3A4|O
DDI-DrugBank.d115.s12|118-125|activity|O
DDI-DrugBank.d115.s12|126-126|.|O
DDI-DrugBank.d115.s13|0-7|Systemic|O
DDI-DrugBank.d115.s13|9-16|exposure|O
DDI-DrugBank.d115.s13|18-19|to|O
DDI-DrugBank.d115.s13|21-30|substrates|O
DDI-DrugBank.d115.s13|32-33|of|O
DDI-DrugBank.d115.s13|35-40|CYP2D6|O
DDI-DrugBank.d115.s13|42-43|is|O
DDI-DrugBank.d115.s13|45-52|expected|O
DDI-DrugBank.d115.s13|54-55|to|O
DDI-DrugBank.d115.s13|57-58|be|O
DDI-DrugBank.d115.s13|60-68|increased|O
DDI-DrugBank.d115.s13|70-73|when|O
DDI-DrugBank.d115.s13|75-88|coadministered|O
DDI-DrugBank.d115.s13|90-93|with|O
DDI-DrugBank.d115.s13|95-101|Gleevec|O
DDI-DrugBank.d115.s13|102-102|.|O
DDI-DrugBank.d115.s14|0-1|No|O
DDI-DrugBank.d115.s14|3-10|specific|O
DDI-DrugBank.d115.s14|12-18|studies|O
DDI-DrugBank.d115.s14|20-23|have|O
DDI-DrugBank.d115.s14|25-28|been|O
DDI-DrugBank.d115.s14|30-38|performed|O
DDI-DrugBank.d115.s14|40-42|and|O
DDI-DrugBank.d115.s14|44-50|caution|O
DDI-DrugBank.d115.s14|52-53|is|O
DDI-DrugBank.d115.s14|55-65|recommended|O
DDI-DrugBank.d115.s14|66-66|.|O
DDI-DrugBank.d115.s15|0-1|in|O
DDI-DrugBank.d115.s15|3-7|vitro|O
DDI-DrugBank.d115.s15|8-8|,|O
DDI-DrugBank.d115.s15|10-16|Gleevec|brand
DDI-DrugBank.d115.s15|18-25|inhibits|O
DDI-DrugBank.d115.s15|27-39|acetaminophen|O
DDI-DrugBank.d115.s15|41-57|O-glucuronidation|O
DDI-DrugBank.d115.s15|59-59|(|O
DDI-DrugBank.d115.s15|60-61|Ki|O
DDI-DrugBank.d115.s15|63-67|value|O
DDI-DrugBank.d115.s15|69-70|of|O
DDI-DrugBank.d115.s15|72-75|58.5|O
DDI-DrugBank.d115.s15|78-78|M|O
DDI-DrugBank.d115.s15|79-79|)|O
DDI-DrugBank.d115.s15|81-82|at|O
DDI-DrugBank.d115.s15|84-94|therapeutic|O
DDI-DrugBank.d115.s15|96-101|levels|O
DDI-DrugBank.d115.s15|102-102|.|O
DDI-DrugBank.d115.s16|0-7|Systemic|O
DDI-DrugBank.d115.s16|9-16|exposure|O
DDI-DrugBank.d115.s16|18-19|to|O
DDI-DrugBank.d115.s16|21-33|acetaminophen|drug
DDI-DrugBank.d115.s16|35-36|is|O
DDI-DrugBank.d115.s16|38-45|expected|O
DDI-DrugBank.d115.s16|47-48|to|O
DDI-DrugBank.d115.s16|50-51|be|O
DDI-DrugBank.d115.s16|53-61|increased|O
DDI-DrugBank.d115.s16|63-66|when|O
DDI-DrugBank.d115.s16|68-81|coadministered|O
DDI-DrugBank.d115.s16|83-86|with|O
DDI-DrugBank.d115.s16|88-94|Gleevec|brand
DDI-DrugBank.d115.s16|95-95|.|O
DDI-DrugBank.d115.s17|0-1|No|O
DDI-DrugBank.d115.s17|3-10|specific|O
DDI-DrugBank.d115.s17|12-18|studies|O
DDI-DrugBank.d115.s17|20-21|in|O
DDI-DrugBank.d115.s17|23-28|humans|O
DDI-DrugBank.d115.s17|30-33|have|O
DDI-DrugBank.d115.s17|35-38|been|O
DDI-DrugBank.d115.s17|40-48|performed|O
DDI-DrugBank.d115.s17|50-52|and|O
DDI-DrugBank.d115.s17|54-60|caution|O
DDI-DrugBank.d115.s17|62-63|is|O
DDI-DrugBank.d115.s17|65-75|recommended|O
DDI-DrugBank.d115.s17|76-76|.|O
DDI-MedLine.d123.s0|0-9|Vancomycin|O
DDI-MedLine.d123.s0|11-20|resistance|O
DDI-MedLine.d123.s0|22-29|reversal|O
DDI-MedLine.d123.s0|31-32|in|O
DDI-MedLine.d123.s0|34-44|enterococci|O
DDI-MedLine.d123.s0|46-47|by|O
DDI-MedLine.d123.s0|49-58|flavonoids|O
DDI-MedLine.d123.s0|59-59|.|O
DDI-MedLine.d123.s1|0-2|The|O
DDI-MedLine.d123.s1|4-14|development|O
DDI-MedLine.d123.s1|16-17|of|O
DDI-MedLine.d123.s1|19-26|clinical|O
DDI-MedLine.d123.s1|28-47|vancomycin-resistant|O
DDI-MedLine.d123.s1|49-55|strains|O
DDI-MedLine.d123.s1|57-58|of|O
DDI-MedLine.d123.s1|60-70|enterococci|O
DDI-MedLine.d123.s1|72-72|(|O
DDI-MedLine.d123.s1|73-75|VRE|O
DDI-MedLine.d123.s1|76-76|)|O
DDI-MedLine.d123.s1|78-79|is|O
DDI-MedLine.d123.s1|81-81|a|O
DDI-MedLine.d123.s1|83-87|major|O
DDI-MedLine.d123.s1|89-93|cause|O
DDI-MedLine.d123.s1|95-97|for|O
DDI-MedLine.d123.s1|99-105|concern|O
DDI-MedLine.d123.s1|106-106|.|O
DDI-MedLine.d123.s2|0-3|Here|O
DDI-MedLine.d123.s2|5-6|we|O
DDI-MedLine.d123.s2|8-11|show|O
DDI-MedLine.d123.s2|13-16|that|O
DDI-MedLine.d123.s2|18-18|a|O
DDI-MedLine.d123.s2|20-30|combination|O
DDI-MedLine.d123.s2|32-33|of|O
DDI-MedLine.d123.s2|35-42|galangin|drug
DDI-MedLine.d123.s2|44-45|or|O
DDI-MedLine.d123.s2|47-66|3,7-dihydroxyflavone|O
DDI-MedLine.d123.s2|68-71|with|O
DDI-MedLine.d123.s2|73-82|vancomycin|drug
DDI-MedLine.d123.s2|84-86|may|O
DDI-MedLine.d123.s2|88-89|be|O
DDI-MedLine.d123.s2|91-94|used|O
DDI-MedLine.d123.s2|96-97|to|O
DDI-MedLine.d123.s2|99-107|sensitize|O
DDI-MedLine.d123.s2|109-117|resistant|O
DDI-MedLine.d123.s2|119-125|strains|O
DDI-MedLine.d123.s2|127-128|of|O
DDI-MedLine.d123.s2|130-141|Enterococcus|O
DDI-MedLine.d123.s2|143-150|faecalis|O
DDI-MedLine.d123.s2|152-154|and|O
DDI-MedLine.d123.s2|156-167|Enterococcus|O
DDI-MedLine.d123.s2|169-175|faecium|O
DDI-MedLine.d123.s2|177-178|to|O
DDI-MedLine.d123.s2|180-182|the|O
DDI-MedLine.d123.s2|184-188|level|O
DDI-MedLine.d123.s2|190-191|of|O
DDI-MedLine.d123.s2|193-212|vancomycin-sensitive|O
DDI-MedLine.d123.s2|214-220|strains|O
DDI-MedLine.d123.s2|221-221|.|O
DDI-MedLine.d123.s3|0-6|Minimum|O
DDI-MedLine.d123.s3|8-17|inhibitory|O
DDI-MedLine.d123.s3|19-32|concentrations|O
DDI-MedLine.d123.s3|34-34|(|O
DDI-MedLine.d123.s3|35-38|MICs|O
DDI-MedLine.d123.s3|39-39|)|O
DDI-MedLine.d123.s3|41-43|and|O
DDI-MedLine.d123.s3|45-50|viable|O
DDI-MedLine.d123.s3|52-57|counts|O
DDI-MedLine.d123.s3|59-62|were|O
DDI-MedLine.d123.s3|64-73|determined|O
DDI-MedLine.d123.s3|75-76|in|O
DDI-MedLine.d123.s3|78-90|Iso-sensitest|O
DDI-MedLine.d123.s3|92-96|broth|O
DDI-MedLine.d123.s3|98-102|using|O
DDI-MedLine.d123.s3|104-104|a|O
DDI-MedLine.d123.s3|106-115|microtitre|O
DDI-MedLine.d123.s3|117-122|method|O
DDI-MedLine.d123.s3|123-123|.|O
DDI-MedLine.d123.s4|0-3|MICs|O
DDI-MedLine.d123.s4|5-6|of|O
DDI-MedLine.d123.s4|8-17|vancomycin|drug
DDI-MedLine.d123.s4|19-25|against|O
DDI-MedLine.d123.s4|27-28|67|O
DDI-MedLine.d123.s4|29-29|%|O
DDI-MedLine.d123.s4|31-32|of|O
DDI-MedLine.d123.s4|34-42|resistant|O
DDI-MedLine.d123.s4|44-51|clinical|O
DDI-MedLine.d123.s4|53-60|isolates|O
DDI-MedLine.d123.s4|62-64|and|O
DDI-MedLine.d123.s4|66-66|a|O
DDI-MedLine.d123.s4|68-71|type|O
DDI-MedLine.d123.s4|73-78|strain|O
DDI-MedLine.d123.s4|80-81|of|O
DDI-MedLine.d123.s4|83-93|enterococci|O
DDI-MedLine.d123.s4|95-98|were|O
DDI-MedLine.d123.s4|100-106|lowered|O
DDI-MedLine.d123.s4|108-111|from|O
DDI-MedLine.d123.s4|113-113|>|O
DDI-MedLine.d123.s4|115-117|250|O
DDI-MedLine.d123.s4|119-124|microg|O
DDI-MedLine.d123.s4|126-127|mL|O
DDI-MedLine.d123.s4|128-128|(|O
DDI-MedLine.d123.s4|129-130|-1|O
DDI-MedLine.d123.s4|131-131|)|O
DDI-MedLine.d123.s4|133-134|to|O
DDI-MedLine.d123.s4|136-136|1|O
DDI-MedLine.d123.s5|0-0|4|O
DDI-MedLine.d123.s5|2-7|microg|O
DDI-MedLine.d123.s5|9-10|mL|O
DDI-MedLine.d123.s5|11-11|(|O
DDI-MedLine.d123.s5|12-13|-1|O
DDI-MedLine.d123.s5|14-14|)|O
DDI-MedLine.d123.s5|16-17|in|O
DDI-MedLine.d123.s5|19-21|the|O
DDI-MedLine.d123.s5|23-30|presence|O
DDI-MedLine.d123.s5|32-33|of|O
DDI-MedLine.d123.s5|35-42|galangin|drug
DDI-MedLine.d123.s5|44-44|(|O
DDI-MedLine.d123.s5|45-48|12.5|O
DDI-MedLine.d123.s5|50-55|microg|O
DDI-MedLine.d123.s5|57-58|mL|O
DDI-MedLine.d123.s5|59-59|(|O
DDI-MedLine.d123.s5|60-61|-1|O
DDI-MedLine.d123.s5|62-62|)|O
DDI-MedLine.d123.s5|63-63|)|O
DDI-MedLine.d123.s5|65-66|or|O
DDI-MedLine.d123.s5|68-87|3,7-dihydroxyflavone|O
DDI-MedLine.d123.s5|89-89|(|O
DDI-MedLine.d123.s5|90-93|6.25|O
DDI-MedLine.d123.s5|95-100|microg|O
DDI-MedLine.d123.s5|102-103|mL|O
DDI-MedLine.d123.s5|104-104|(|O
DDI-MedLine.d123.s5|105-106|-1|O
DDI-MedLine.d123.s5|107-107|)|O
DDI-MedLine.d123.s5|108-108|)|O
DDI-MedLine.d123.s5|109-109|.|O
DDI-MedLine.d123.s6|0-5|Viable|O
DDI-MedLine.d123.s6|7-12|counts|O
DDI-MedLine.d123.s6|14-16|for|O
DDI-MedLine.d123.s6|18-21|type|O
DDI-MedLine.d123.s6|23-29|culture|O
DDI-MedLine.d123.s6|31-31|E|O
DDI-MedLine.d123.s6|32-32|.|O
DDI-MedLine.d123.s7|0-7|faecalis|O
DDI-MedLine.d123.s7|9-12|ATCC|O
DDI-MedLine.d123.s7|14-18|51299|O
DDI-MedLine.d123.s7|20-25|showed|O
DDI-MedLine.d123.s7|27-29|the|O
DDI-MedLine.d123.s7|31-40|flavonoids|O
DDI-MedLine.d123.s7|42-46|alone|O
DDI-MedLine.d123.s7|48-60|significantly|O
DDI-MedLine.d123.s7|62-68|lowered|O
DDI-MedLine.d123.s7|70-76|numbers|O
DDI-MedLine.d123.s7|78-79|of|O
DDI-MedLine.d123.s7|81-86|colony|O
DDI-MedLine.d123.s7|88-94|forming|O
DDI-MedLine.d123.s7|96-100|units|O
DDI-MedLine.d123.s7|102-102|(|O
DDI-MedLine.d123.s7|103-106|CFUs|O
DDI-MedLine.d123.s7|107-107|)|O
DDI-MedLine.d123.s7|108-108|.|O
DDI-MedLine.d123.s8|0-3|CFUs|O
DDI-MedLine.d123.s8|5-8|were|O
DDI-MedLine.d123.s8|10-19|maintained|O
DDI-MedLine.d123.s8|21-22|at|O
DDI-MedLine.d123.s8|24-26|low|O
DDI-MedLine.d123.s8|28-33|levels|O
DDI-MedLine.d123.s8|35-35|(|O
DDI-MedLine.d123.s8|36-37|10|O
DDI-MedLine.d123.s8|38-38|(|O
DDI-MedLine.d123.s8|39-39|3|O
DDI-MedLine.d123.s8|40-40|)|O
DDI-MedLine.d123.s8|42-44|CFU|O
DDI-MedLine.d123.s8|46-47|mL|O
DDI-MedLine.d123.s8|48-48|(|O
DDI-MedLine.d123.s8|49-50|-1|O
DDI-MedLine.d123.s8|51-51|)|O
DDI-MedLine.d123.s8|52-52|)|O
DDI-MedLine.d123.s8|54-56|for|O
DDI-MedLine.d123.s8|58-59|24|O
DDI-MedLine.d123.s8|61-61|h|O
DDI-MedLine.d123.s8|63-64|by|O
DDI-MedLine.d123.s8|66-83|vancomycin/flavone|drug
DDI-MedLine.d123.s8|85-96|combinations|O
DDI-MedLine.d123.s8|97-97|.|O
DDI-MedLine.d123.s9|0-3|This|O
DDI-MedLine.d123.s9|5-17|combinational|O
DDI-MedLine.d123.s9|19-24|action|O
DDI-MedLine.d123.s9|26-27|in|O
DDI-MedLine.d123.s9|29-37|reversing|O
DDI-MedLine.d123.s9|39-48|vancomycin|O
DDI-MedLine.d123.s9|50-59|resistance|O
DDI-MedLine.d123.s9|61-62|of|O
DDI-MedLine.d123.s9|64-74|enterococci|O
DDI-MedLine.d123.s9|76-85|highlights|O
DDI-MedLine.d123.s9|87-91|novel|O
DDI-MedLine.d123.s9|93-96|drug|O
DDI-MedLine.d123.s9|98-104|targets|O
DDI-MedLine.d123.s9|106-108|and|O
DDI-MedLine.d123.s9|110-112|has|O
DDI-MedLine.d123.s9|114-123|importance|O
DDI-MedLine.d123.s9|125-126|in|O
DDI-MedLine.d123.s9|128-130|the|O
DDI-MedLine.d123.s9|132-137|design|O
DDI-MedLine.d123.s9|139-140|of|O
DDI-MedLine.d123.s9|142-144|new|O
DDI-MedLine.d123.s9|146-156|therapeutic|O
DDI-MedLine.d123.s9|158-164|regimes|O
DDI-MedLine.d123.s9|166-172|against|O
DDI-MedLine.d123.s9|174-182|resistant|O
DDI-MedLine.d123.s9|184-192|pathogens|O
DDI-MedLine.d123.s9|193-193|.|O
DDI-DrugBank.d338.s0|0-1|If|O
DDI-DrugBank.d338.s0|3-8|ProSom|brand
DDI-DrugBank.d338.s0|10-11|is|O
DDI-DrugBank.d338.s0|13-17|given|O
DDI-DrugBank.d338.s0|19-31|concomitantly|O
DDI-DrugBank.d338.s0|33-36|with|O
DDI-DrugBank.d338.s0|38-42|other|O
DDI-DrugBank.d338.s0|44-48|drugs|O
DDI-DrugBank.d338.s0|50-55|acting|O
DDI-DrugBank.d338.s0|57-58|on|O
DDI-DrugBank.d338.s0|60-62|the|O
DDI-DrugBank.d338.s0|64-70|central|O
DDI-DrugBank.d338.s0|72-78|nervous|O
DDI-DrugBank.d338.s0|80-85|system|O
DDI-DrugBank.d338.s0|86-86|,|O
DDI-DrugBank.d338.s0|88-94|careful|O
DDI-DrugBank.d338.s0|96-108|consideration|O
DDI-DrugBank.d338.s0|110-115|should|O
DDI-DrugBank.d338.s0|117-118|be|O
DDI-DrugBank.d338.s0|120-124|given|O
DDI-DrugBank.d338.s0|126-127|to|O
DDI-DrugBank.d338.s0|129-131|the|O
DDI-DrugBank.d338.s0|133-144|pharmacology|O
DDI-DrugBank.d338.s0|146-147|of|O
DDI-DrugBank.d338.s0|149-151|all|O
DDI-DrugBank.d338.s0|153-158|agents|O
DDI-DrugBank.d338.s0|159-159|.|O
DDI-DrugBank.d338.s1|0-2|The|O
DDI-DrugBank.d338.s1|4-9|action|O
DDI-DrugBank.d338.s1|11-12|of|O
DDI-DrugBank.d338.s1|14-16|the|O
DDI-DrugBank.d338.s1|18-32|benzodiazepines|group
DDI-DrugBank.d338.s1|34-36|may|O
DDI-DrugBank.d338.s1|38-39|be|O
DDI-DrugBank.d338.s1|41-51|potentiated|O
DDI-DrugBank.d338.s1|53-54|by|O
DDI-DrugBank.d338.s1|56-70|anticonvulsants|group
DDI-DrugBank.d338.s1|71-71|,|O
DDI-DrugBank.d338.s1|73-86|antihistamines|group
DDI-DrugBank.d338.s1|87-87|,|O
DDI-DrugBank.d338.s1|89-95|alcohol|drug
DDI-DrugBank.d338.s1|96-96|,|O
DDI-DrugBank.d338.s1|98-109|barbiturates|group
DDI-DrugBank.d338.s1|110-110|,|O
DDI-DrugBank.d338.s1|112-139|monoamine oxidase inhibitors|group
DDI-DrugBank.d338.s1|140-140|,|O
DDI-DrugBank.d338.s1|142-150|narcotics|group
DDI-DrugBank.d338.s1|151-151|,|O
DDI-DrugBank.d338.s1|153-166|phenothiazines|group
DDI-DrugBank.d338.s1|167-167|,|O
DDI-DrugBank.d338.s1|169-192|psychotropic medications|group
DDI-DrugBank.d338.s1|193-193|,|O
DDI-DrugBank.d338.s1|195-196|or|O
DDI-DrugBank.d338.s1|198-202|other|O
DDI-DrugBank.d338.s1|204-208|drugs|O
DDI-DrugBank.d338.s1|210-213|that|O
DDI-DrugBank.d338.s1|215-221|produce|O
DDI-DrugBank.d338.s1|223-225|CNS|O
DDI-DrugBank.d338.s1|227-236|depression|O
DDI-DrugBank.d338.s1|237-237|.|O
DDI-DrugBank.d338.s2|0-6|Smokers|O
DDI-DrugBank.d338.s2|8-11|have|O
DDI-DrugBank.d338.s2|13-14|an|O
DDI-DrugBank.d338.s2|16-24|increased|O
DDI-DrugBank.d338.s2|26-34|clearance|O
DDI-DrugBank.d338.s2|36-37|of|O
DDI-DrugBank.d338.s2|39-53|benzodiazepines|group
DDI-DrugBank.d338.s2|55-56|as|O
DDI-DrugBank.d338.s2|58-65|compared|O
DDI-DrugBank.d338.s2|67-68|to|O
DDI-DrugBank.d338.s2|70-79|nonsmokers|O
DDI-DrugBank.d338.s2|80-80|;|O
DDI-DrugBank.d338.s3|0-3|this|O
DDI-DrugBank.d338.s3|5-7|was|O
DDI-DrugBank.d338.s3|9-12|seen|O
DDI-DrugBank.d338.s3|14-15|in|O
DDI-DrugBank.d338.s3|17-23|studies|O
DDI-DrugBank.d338.s3|25-28|with|O
DDI-DrugBank.d338.s3|30-38|estazolam|drug
DDI-DrugBank.d338.s3|39-39|.|O
DDI-DrugBank.d338.s4|0-4|While|O
DDI-DrugBank.d338.s4|6-7|no|O
DDI-DrugBank.d338.s4|9-10|in|O
DDI-DrugBank.d338.s4|12-15|vivo|O
DDI-DrugBank.d338.s4|17-25|drug-drug|O
DDI-DrugBank.d338.s4|27-37|interaction|O
DDI-DrugBank.d338.s4|39-45|studies|O
DDI-DrugBank.d338.s4|47-50|were|O
DDI-DrugBank.d338.s4|52-60|conducted|O
DDI-DrugBank.d338.s4|62-68|between|O
DDI-DrugBank.d338.s4|70-78|estazolam|drug
DDI-DrugBank.d338.s4|80-82|and|O
DDI-DrugBank.d338.s4|84-91|inducers|O
DDI-DrugBank.d338.s4|93-94|of|O
DDI-DrugBank.d338.s4|96-100|CYP3A|O
DDI-DrugBank.d338.s4|101-101|,|O
DDI-DrugBank.d338.s4|103-111|compounds|O
DDI-DrugBank.d338.s4|113-116|that|O
DDI-DrugBank.d338.s4|118-120|are|O
DDI-DrugBank.d338.s4|122-127|potent|O
DDI-DrugBank.d338.s4|129-133|CYP3A|O
DDI-DrugBank.d338.s4|135-142|inducers|O
DDI-DrugBank.d338.s4|144-144|(|O
DDI-DrugBank.d338.s4|145-148|such|O
DDI-DrugBank.d338.s4|150-151|as|O
DDI-DrugBank.d338.s4|153-165|carbamazepine|drug
DDI-DrugBank.d338.s4|166-166|,|O
DDI-DrugBank.d338.s4|168-176|phenytoin|drug
DDI-DrugBank.d338.s4|177-177|,|O
DDI-DrugBank.d338.s4|179-186|rifampin|drug
DDI-DrugBank.d338.s4|187-187|,|O
DDI-DrugBank.d338.s4|189-191|and|O
DDI-DrugBank.d338.s4|193-204|barbiturates|group
DDI-DrugBank.d338.s4|205-205|)|O
DDI-DrugBank.d338.s4|207-211|would|O
DDI-DrugBank.d338.s4|213-214|be|O
DDI-DrugBank.d338.s4|216-223|expected|O
DDI-DrugBank.d338.s4|225-226|to|O
DDI-DrugBank.d338.s4|228-235|decrease|O
DDI-DrugBank.d338.s4|237-245|estazolam|drug
DDI-DrugBank.d338.s4|247-260|concentrations|O
DDI-DrugBank.d338.s4|261-261|.|O
DDI-DrugBank.d338.s5|0-8|Estazolam|drug
DDI-DrugBank.d338.s5|9-9|:|O
DDI-DrugBank.d338.s5|11-21|Interaction|O
DDI-DrugBank.d338.s5|23-26|with|O
DDI-DrugBank.d338.s5|28-32|Drugs|O
DDI-DrugBank.d338.s5|34-37|that|O
DDI-DrugBank.d338.s5|39-45|Inhibit|O
DDI-DrugBank.d338.s5|47-56|Metabolism|O
DDI-DrugBank.d338.s5|58-60|via|O
DDI-DrugBank.d338.s5|62-71|Cytochrome|O
DDI-DrugBank.d338.s5|73-76|P450|O
DDI-DrugBank.d338.s5|78-79|3A|O
DDI-DrugBank.d338.s5|81-81|(|O
DDI-DrugBank.d338.s5|82-86|CYP3A|O
DDI-DrugBank.d338.s5|87-87|)|O
DDI-DrugBank.d338.s5|88-88|:|O
DDI-DrugBank.d338.s5|90-92|The|O
DDI-DrugBank.d338.s5|94-103|metabolism|O
DDI-DrugBank.d338.s5|105-106|of|O
DDI-DrugBank.d338.s5|108-116|estazolam|drug
DDI-DrugBank.d338.s5|118-119|to|O
DDI-DrugBank.d338.s5|121-123|the|O
DDI-DrugBank.d338.s5|125-129|major|O
DDI-DrugBank.d338.s5|131-141|circulating|O
DDI-DrugBank.d338.s5|143-152|metabolite|O
DDI-DrugBank.d338.s5|174-176|and|O
DDI-DrugBank.d338.s5|178-180|the|O
DDI-DrugBank.d338.s5|182-191|metabolism|O
DDI-DrugBank.d338.s5|193-194|of|O
DDI-DrugBank.d338.s5|196-200|other|O
DDI-DrugBank.d338.s5|202-224|triazolobenzodiazepines|group
DDI-DrugBank.d338.s5|226-227|is|O
DDI-DrugBank.d338.s5|229-237|catalyzed|O
DDI-DrugBank.d338.s5|239-240|by|O
DDI-DrugBank.d338.s5|242-246|CYP3A|O
DDI-DrugBank.d338.s5|247-247|.|O
DDI-DrugBank.d338.s6|0-11|Consequently|O
DDI-DrugBank.d338.s6|12-12|,|O
DDI-DrugBank.d338.s6|14-22|estazolam|drug
DDI-DrugBank.d338.s6|24-29|should|O
DDI-DrugBank.d338.s6|31-32|be|O
DDI-DrugBank.d338.s6|34-40|avoided|O
DDI-DrugBank.d338.s6|42-43|in|O
DDI-DrugBank.d338.s6|45-52|patients|O
DDI-DrugBank.d338.s6|54-62|receiving|O
DDI-DrugBank.d338.s6|64-75|ketoconazole|drug
DDI-DrugBank.d338.s6|77-79|and|O
DDI-DrugBank.d338.s6|81-92|itraconazole|drug
DDI-DrugBank.d338.s6|93-93|,|O
DDI-DrugBank.d338.s6|95-99|which|O
DDI-DrugBank.d338.s6|101-103|are|O
DDI-DrugBank.d338.s6|105-108|very|O
DDI-DrugBank.d338.s6|110-115|potent|O
DDI-DrugBank.d338.s6|117-126|inhibitors|O
DDI-DrugBank.d338.s6|128-129|of|O
DDI-DrugBank.d338.s6|131-135|CYP3A|O
DDI-DrugBank.d338.s6|136-136|.|O
DDI-DrugBank.d338.s7|0-3|With|O
DDI-DrugBank.d338.s7|5-9|drugs|O
DDI-DrugBank.d338.s7|11-20|inhibiting|O
DDI-DrugBank.d338.s7|22-26|CYP3A|O
DDI-DrugBank.d338.s7|28-29|to|O
DDI-DrugBank.d338.s7|31-31|a|O
DDI-DrugBank.d338.s7|33-38|lesser|O
DDI-DrugBank.d338.s7|39-39|,|O
DDI-DrugBank.d338.s7|41-43|but|O
DDI-DrugBank.d338.s7|45-49|still|O
DDI-DrugBank.d338.s7|51-61|significant|O
DDI-DrugBank.d338.s7|63-68|degree|O
DDI-DrugBank.d338.s7|69-69|,|O
DDI-DrugBank.d338.s7|71-79|estazolam|drug
DDI-DrugBank.d338.s7|81-86|should|O
DDI-DrugBank.d338.s7|88-89|be|O
DDI-DrugBank.d338.s7|91-94|used|O
DDI-DrugBank.d338.s7|96-99|only|O
DDI-DrugBank.d338.s7|101-104|with|O
DDI-DrugBank.d338.s7|106-112|caution|O
DDI-DrugBank.d338.s7|114-116|and|O
DDI-DrugBank.d338.s7|118-130|consideration|O
DDI-DrugBank.d338.s7|132-133|of|O
DDI-DrugBank.d338.s7|135-145|appropriate|O
DDI-DrugBank.d338.s7|147-152|dosage|O
DDI-DrugBank.d338.s7|154-162|reduction|O
DDI-DrugBank.d338.s7|163-163|.|O
DDI-DrugBank.d338.s8|0-2|The|O
DDI-DrugBank.d338.s8|4-12|following|O
DDI-DrugBank.d338.s8|14-16|are|O
DDI-DrugBank.d338.s8|18-25|examples|O
DDI-DrugBank.d338.s8|27-28|of|O
DDI-DrugBank.d338.s8|30-34|drugs|O
DDI-DrugBank.d338.s8|36-40|known|O
DDI-DrugBank.d338.s8|42-43|to|O
DDI-DrugBank.d338.s8|45-51|inhibit|O
DDI-DrugBank.d338.s8|53-55|the|O
DDI-DrugBank.d338.s8|57-66|metabolism|O
DDI-DrugBank.d338.s8|68-69|of|O
DDI-DrugBank.d338.s8|71-75|other|O
DDI-DrugBank.d338.s8|77-83|related|O
DDI-DrugBank.d338.s8|85-99|benzodiazepines|group
DDI-DrugBank.d338.s8|100-100|,|O
DDI-DrugBank.d338.s8|102-111|presumably|O
DDI-DrugBank.d338.s8|113-119|through|O
DDI-DrugBank.d338.s8|121-130|inhibition|O
DDI-DrugBank.d338.s8|132-133|of|O
DDI-DrugBank.d338.s8|135-139|CYP3A|O
DDI-DrugBank.d338.s8|140-140|:|O
DDI-DrugBank.d338.s8|142-151|nefazodone|drug
DDI-DrugBank.d338.s8|152-152|,|O
DDI-DrugBank.d338.s8|154-164|fluvoxamine|drug
DDI-DrugBank.d338.s8|165-165|,|O
DDI-DrugBank.d338.s8|167-176|cimetidine|drug
DDI-DrugBank.d338.s8|177-177|,|O
DDI-DrugBank.d338.s8|179-187|diltiazem|drug
DDI-DrugBank.d338.s8|188-188|,|O
DDI-DrugBank.d338.s8|190-199|isoniazide|drug
DDI-DrugBank.d338.s8|200-200|,|O
DDI-DrugBank.d338.s8|202-204|and|O
DDI-DrugBank.d338.s8|206-209|some|O
DDI-DrugBank.d338.s8|211-231|macrolide antibiotics|group
DDI-DrugBank.d338.s8|232-232|.|O
DDI-DrugBank.d338.s9|0-3|Drug|O
DDI-DrugBank.d338.s9|5-15|Interaction|O
DDI-DrugBank.d338.s9|17-20|with|O
DDI-DrugBank.d338.s9|22-31|Fluoxetine|drug
DDI-DrugBank.d338.s9|32-32|:|O
DDI-DrugBank.d338.s9|34-34|A|O
DDI-DrugBank.d338.s9|36-48|multiple-dose|O
DDI-DrugBank.d338.s9|50-54|study|O
DDI-DrugBank.d338.s9|56-58|was|O
DDI-DrugBank.d338.s9|60-68|conducted|O
DDI-DrugBank.d338.s9|70-71|to|O
DDI-DrugBank.d338.s9|73-78|assess|O
DDI-DrugBank.d338.s9|80-82|the|O
DDI-DrugBank.d338.s9|84-89|effect|O
DDI-DrugBank.d338.s9|91-92|of|O
DDI-DrugBank.d338.s9|94-103|fluoxetine|drug
DDI-DrugBank.d338.s9|105-106|20|O
DDI-DrugBank.d338.s9|108-109|mg|O
DDI-DrugBank.d338.s9|111-113|BID|O
DDI-DrugBank.d338.s9|115-116|on|O
DDI-DrugBank.d338.s9|118-120|the|O
DDI-DrugBank.d338.s9|122-137|pharmacokinetics|O
DDI-DrugBank.d338.s9|139-140|of|O
DDI-DrugBank.d338.s9|142-150|estazolam|drug
DDI-DrugBank.d338.s9|152-152|2|O
DDI-DrugBank.d338.s9|154-155|mg|O
DDI-DrugBank.d338.s9|157-159|QHS|O
DDI-DrugBank.d338.s9|161-165|after|O
DDI-DrugBank.d338.s9|167-171|seven|O
DDI-DrugBank.d338.s9|173-176|days|O
DDI-DrugBank.d338.s9|177-177|.|O
DDI-DrugBank.d338.s10|0-2|The|O
DDI-DrugBank.d338.s10|4-19|pharmacokinetics|O
DDI-DrugBank.d338.s10|21-22|of|O
DDI-DrugBank.d338.s10|24-32|estazolam|drug
DDI-DrugBank.d338.s10|34-34|(|O
DDI-DrugBank.d338.s10|35-38|Cmax|O
DDI-DrugBank.d338.s10|40-42|and|O
DDI-DrugBank.d338.s10|44-46|AUC|O
DDI-DrugBank.d338.s10|47-47|)|O
DDI-DrugBank.d338.s10|49-52|were|O
DDI-DrugBank.d338.s10|54-56|not|O
DDI-DrugBank.d338.s10|58-65|affected|O
DDI-DrugBank.d338.s10|67-72|during|O
DDI-DrugBank.d338.s10|74-86|multiple-dose|O
DDI-DrugBank.d338.s10|88-97|fluoxetine|drug
DDI-DrugBank.d338.s10|98-98|,|O
DDI-DrugBank.d338.s10|100-109|suggesting|O
DDI-DrugBank.d338.s10|111-112|no|O
DDI-DrugBank.d338.s10|114-123|clinically|O
DDI-DrugBank.d338.s10|125-135|significant|O
DDI-DrugBank.d338.s10|137-151|pharmacokinetic|O
DDI-DrugBank.d338.s10|153-163|interaction|O
DDI-DrugBank.d338.s10|164-164|.|O
DDI-DrugBank.d338.s11|0-8|Estazolam|drug
DDI-DrugBank.d338.s11|9-9|:|O
DDI-DrugBank.d338.s11|11-21|Interaction|O
DDI-DrugBank.d338.s11|23-26|with|O
DDI-DrugBank.d338.s11|28-32|Other|O
DDI-DrugBank.d338.s11|34-38|Drugs|O
DDI-DrugBank.d338.s11|40-43|that|O
DDI-DrugBank.d338.s11|45-47|are|O
DDI-DrugBank.d338.s11|49-59|Metabolized|O
DDI-DrugBank.d338.s11|61-62|by|O
DDI-DrugBank.d338.s11|64-73|Cytochrome|O
DDI-DrugBank.d338.s11|75-78|P450|O
DDI-DrugBank.d338.s11|80-80|(|O
DDI-DrugBank.d338.s11|81-83|CYP|O
DDI-DrugBank.d338.s11|84-84|)|O
DDI-DrugBank.d338.s11|85-85|:|O
DDI-DrugBank.d338.s11|87-88|At|O
DDI-DrugBank.d338.s11|90-99|clinically|O
DDI-DrugBank.d338.s11|101-108|relevant|O
DDI-DrugBank.d338.s11|110-123|concentrations|O
DDI-DrugBank.d338.s11|124-124|,|O
DDI-DrugBank.d338.s11|126-127|in|O
DDI-DrugBank.d338.s11|129-133|vitro|O
DDI-DrugBank.d338.s11|135-141|studies|O
DDI-DrugBank.d338.s11|143-150|indicate|O
DDI-DrugBank.d338.s11|152-155|that|O
DDI-DrugBank.d338.s11|157-165|estazolam|drug
DDI-DrugBank.d338.s11|167-167|(|O
DDI-DrugBank.d338.s11|168-170|0.6|O
DDI-DrugBank.d338.s11|172-172|M|O
DDI-DrugBank.d338.s11|173-173|)|O
DDI-DrugBank.d338.s11|175-177|was|O
DDI-DrugBank.d338.s11|179-181|not|O
DDI-DrugBank.d338.s11|183-192|inhibitory|O
DDI-DrugBank.d338.s11|194-200|towards|O
DDI-DrugBank.d338.s11|202-204|the|O
DDI-DrugBank.d338.s11|206-210|major|O
DDI-DrugBank.d338.s11|212-221|cytochrome|O
DDI-DrugBank.d338.s11|223-226|P450|O
DDI-DrugBank.d338.s11|228-235|isoforms|O
DDI-DrugBank.d338.s11|237-242|CYP1A2|O
DDI-DrugBank.d338.s11|243-243|,|O
DDI-DrugBank.d338.s11|245-250|CYP2A6|O
DDI-DrugBank.d338.s11|251-251|,|O
DDI-DrugBank.d338.s11|253-258|CYP2C9|O
DDI-DrugBank.d338.s11|259-259|,|O
DDI-DrugBank.d338.s11|261-267|CYP2C19|O
DDI-DrugBank.d338.s11|268-268|,|O
DDI-DrugBank.d338.s11|270-275|CYP2D6|O
DDI-DrugBank.d338.s11|276-276|,|O
DDI-DrugBank.d338.s11|278-283|CYP2E1|O
DDI-DrugBank.d338.s11|284-284|,|O
DDI-DrugBank.d338.s11|286-288|and|O
DDI-DrugBank.d338.s11|290-294|CYP3A|O
DDI-DrugBank.d338.s11|295-295|.|O
DDI-DrugBank.d338.s12|0-8|Therefore|O
DDI-DrugBank.d338.s12|9-9|,|O
DDI-DrugBank.d338.s12|11-15|based|O
DDI-DrugBank.d338.s12|17-18|on|O
DDI-DrugBank.d338.s12|20-24|these|O
DDI-DrugBank.d338.s12|26-27|in|O
DDI-DrugBank.d338.s12|29-33|vitro|O
DDI-DrugBank.d338.s12|35-38|data|O
DDI-DrugBank.d338.s12|39-39|,|O
DDI-DrugBank.d338.s12|41-49|estazolam|drug
DDI-DrugBank.d338.s12|51-52|is|O
DDI-DrugBank.d338.s12|54-57|very|O
DDI-DrugBank.d338.s12|59-66|unlikely|O
DDI-DrugBank.d338.s12|68-69|to|O
DDI-DrugBank.d338.s12|71-77|inhibit|O
DDI-DrugBank.d338.s12|79-81|the|O
DDI-DrugBank.d338.s12|83-99|biotransformation|O
DDI-DrugBank.d338.s12|101-102|of|O
DDI-DrugBank.d338.s12|104-108|other|O
DDI-DrugBank.d338.s12|110-114|drugs|O
DDI-DrugBank.d338.s12|116-126|metabolized|O
DDI-DrugBank.d338.s12|128-129|by|O
DDI-DrugBank.d338.s12|131-135|these|O
DDI-DrugBank.d338.s12|137-139|CYP|O
DDI-DrugBank.d338.s12|141-148|isoforms|O
DDI-DrugBank.d338.s13|0-0|.|O
DDI-DrugBank.d456.s0|0-11|Co-treatment|O
DDI-DrugBank.d456.s0|13-16|with|O
DDI-DrugBank.d456.s0|18-20|the|O
DDI-DrugBank.d456.s0|22-27|potent|O
DDI-DrugBank.d456.s0|29-34|CYP3A4|O
DDI-DrugBank.d456.s0|36-44|inhibitor|O
DDI-DrugBank.d456.s0|46-57|ketoconazole|drug
DDI-DrugBank.d456.s0|59-67|increases|O
DDI-DrugBank.d456.s0|69-77|erlotinib|drug
DDI-DrugBank.d456.s0|79-81|AUC|O
DDI-DrugBank.d456.s0|83-84|by|O
DDI-DrugBank.d456.s0|86-88|2/3|O
DDI-DrugBank.d456.s0|89-89|.|O
DDI-DrugBank.d456.s1|0-6|Caution|O
DDI-DrugBank.d456.s1|8-13|should|O
DDI-DrugBank.d456.s1|15-16|be|O
DDI-DrugBank.d456.s1|18-21|used|O
DDI-DrugBank.d456.s1|23-26|when|O
DDI-DrugBank.d456.s1|28-40|administering|O
DDI-DrugBank.d456.s1|42-43|or|O
DDI-DrugBank.d456.s1|45-50|taking|O
DDI-DrugBank.d456.s1|52-58|TARCEVA|brand
DDI-DrugBank.d456.s1|60-63|with|O
DDI-DrugBank.d456.s1|65-76|ketoconazole|drug
DDI-DrugBank.d456.s1|78-80|and|O
DDI-DrugBank.d456.s1|82-86|other|O
DDI-DrugBank.d456.s1|88-93|strong|O
DDI-DrugBank.d456.s1|95-100|CYP3A4|O
DDI-DrugBank.d456.s1|102-111|inhibitors|O
DDI-DrugBank.d456.s1|113-116|such|O
DDI-DrugBank.d456.s1|118-119|as|O
DDI-DrugBank.d456.s1|120-120|,|O
DDI-DrugBank.d456.s1|122-124|but|O
DDI-DrugBank.d456.s1|126-128|not|O
DDI-DrugBank.d456.s1|130-136|limited|O
DDI-DrugBank.d456.s1|138-139|to|O
DDI-DrugBank.d456.s1|140-140|,|O
DDI-DrugBank.d456.s1|142-151|atazanavir|drug
DDI-DrugBank.d456.s1|152-152|,|O
DDI-DrugBank.d456.s1|154-167|clarithromycin|drug
DDI-DrugBank.d456.s1|168-168|,|O
DDI-DrugBank.d456.s1|170-178|indinavir|drug
DDI-DrugBank.d456.s1|179-179|,|O
DDI-DrugBank.d456.s1|181-192|itraconazole|drug
DDI-DrugBank.d456.s1|193-193|,|O
DDI-DrugBank.d456.s1|195-204|nefazodone|drug
DDI-DrugBank.d456.s1|205-205|,|O
DDI-DrugBank.d456.s1|207-216|nelfinavir|drug
DDI-DrugBank.d456.s1|217-217|,|O
DDI-DrugBank.d456.s1|219-227|ritonavir|drug
DDI-DrugBank.d456.s1|228-228|,|O
DDI-DrugBank.d456.s1|230-239|saquinavir|drug
DDI-DrugBank.d456.s1|240-240|,|O
DDI-DrugBank.d456.s1|242-254|telithromycin|drug
DDI-DrugBank.d456.s1|255-255|,|O
DDI-DrugBank.d456.s1|257-270|troleandomycin|drug
DDI-DrugBank.d456.s1|272-272|(|O
DDI-DrugBank.d456.s1|273-275|TAO|drug
DDI-DrugBank.d456.s1|276-276|)|O
DDI-DrugBank.d456.s1|277-277|,|O
DDI-DrugBank.d456.s1|279-281|and|O
DDI-DrugBank.d456.s1|283-294|voriconazole|drug
DDI-DrugBank.d456.s1|296-296|.|O
DDI-DrugBank.d456.s2|0-12|Pre-treatment|O
DDI-DrugBank.d456.s2|14-17|with|O
DDI-DrugBank.d456.s2|19-21|the|O
DDI-DrugBank.d456.s2|23-28|CYP3A4|O
DDI-DrugBank.d456.s2|30-36|inducer|O
DDI-DrugBank.d456.s2|38-47|rifampicin|drug
DDI-DrugBank.d456.s2|49-57|decreased|O
DDI-DrugBank.d456.s2|59-67|erlotinib|drug
DDI-DrugBank.d456.s2|69-71|AUC|O
DDI-DrugBank.d456.s2|73-74|by|O
DDI-DrugBank.d456.s2|76-80|about|O
DDI-DrugBank.d456.s2|82-84|2/3|O
DDI-DrugBank.d456.s2|85-85|.|O
DDI-DrugBank.d456.s3|0-8|Alternate|O
DDI-DrugBank.d456.s3|10-19|treatments|O
DDI-DrugBank.d456.s3|21-27|lacking|O
DDI-DrugBank.d456.s3|29-34|CYP3A4|O
DDI-DrugBank.d456.s3|36-43|inducing|O
DDI-DrugBank.d456.s3|45-52|activity|O
DDI-DrugBank.d456.s3|54-59|should|O
DDI-DrugBank.d456.s3|61-62|be|O
DDI-DrugBank.d456.s3|64-73|considered|O
DDI-DrugBank.d456.s3|74-74|.|O
DDI-DrugBank.d456.s4|0-1|If|O
DDI-DrugBank.d456.s4|3-4|an|O
DDI-DrugBank.d456.s4|6-16|alternative|O
DDI-DrugBank.d456.s4|18-26|treatment|O
DDI-DrugBank.d456.s4|28-29|is|O
DDI-DrugBank.d456.s4|31-41|unavailable|O
DDI-DrugBank.d456.s4|42-42|,|O
DDI-DrugBank.d456.s4|44-44|a|O
DDI-DrugBank.d456.s4|46-52|TARCEVA|brand
DDI-DrugBank.d456.s4|54-57|dose|O
DDI-DrugBank.d456.s4|59-65|greater|O
DDI-DrugBank.d456.s4|67-70|than|O
DDI-DrugBank.d456.s4|72-74|150|O
DDI-DrugBank.d456.s4|76-77|mg|O
DDI-DrugBank.d456.s4|79-84|should|O
DDI-DrugBank.d456.s4|86-87|be|O
DDI-DrugBank.d456.s4|89-98|considered|O
DDI-DrugBank.d456.s4|100-102|for|O
DDI-DrugBank.d456.s4|104-108|NSCLC|O
DDI-DrugBank.d456.s4|110-117|patients|O
DDI-DrugBank.d456.s4|118-118|,|O
DDI-DrugBank.d456.s4|120-122|and|O
DDI-DrugBank.d456.s4|124-130|greater|O
DDI-DrugBank.d456.s4|132-135|than|O
DDI-DrugBank.d456.s4|137-139|100|O
DDI-DrugBank.d456.s4|141-142|mg|O
DDI-DrugBank.d456.s4|144-153|considered|O
DDI-DrugBank.d456.s4|155-157|for|O
DDI-DrugBank.d456.s4|159-168|pancreatic|O
DDI-DrugBank.d456.s4|170-175|cancer|O
DDI-DrugBank.d456.s4|177-184|patients|O
DDI-DrugBank.d456.s4|185-185|.|O
DDI-DrugBank.d456.s5|0-1|If|O
DDI-DrugBank.d456.s5|3-5|the|O
DDI-DrugBank.d456.s5|7-13|TARCEVA|brand
DDI-DrugBank.d456.s5|15-18|dose|O
DDI-DrugBank.d456.s5|20-21|is|O
DDI-DrugBank.d456.s5|23-30|adjusted|O
DDI-DrugBank.d456.s5|32-37|upward|O
DDI-DrugBank.d456.s5|38-38|,|O
DDI-DrugBank.d456.s5|40-42|the|O
DDI-DrugBank.d456.s5|44-47|dose|O
DDI-DrugBank.d456.s5|49-52|will|O
DDI-DrugBank.d456.s5|54-57|need|O
DDI-DrugBank.d456.s5|59-60|to|O
DDI-DrugBank.d456.s5|62-63|be|O
DDI-DrugBank.d456.s5|65-71|reduced|O
DDI-DrugBank.d456.s5|73-76|upon|O
DDI-DrugBank.d456.s5|78-92|discontinuation|O
DDI-DrugBank.d456.s5|94-95|of|O
DDI-DrugBank.d456.s5|97-106|rifampicin|drug
DDI-DrugBank.d456.s5|108-109|or|O
DDI-DrugBank.d456.s5|111-115|other|O
DDI-DrugBank.d456.s5|117-124|inducers|O
DDI-DrugBank.d456.s5|125-125|.|O
DDI-DrugBank.d456.s6|0-4|Other|O
DDI-DrugBank.d456.s6|6-11|CYP3A4|O
DDI-DrugBank.d456.s6|13-20|inducers|O
DDI-DrugBank.d456.s6|22-28|include|O
DDI-DrugBank.d456.s6|29-29|,|O
DDI-DrugBank.d456.s6|31-33|but|O
DDI-DrugBank.d456.s6|35-37|are|O
DDI-DrugBank.d456.s6|39-41|not|O
DDI-DrugBank.d456.s6|43-49|limited|O
DDI-DrugBank.d456.s6|51-52|to|O
DDI-DrugBank.d456.s6|53-53|,|O
DDI-DrugBank.d456.s6|55-63|rifabutin|drug
DDI-DrugBank.d456.s6|64-64|,|O
DDI-DrugBank.d456.s6|66-76|rifapentine|drug
DDI-DrugBank.d456.s6|77-77|,|O
DDI-DrugBank.d456.s6|79-87|phenytoin|drug
DDI-DrugBank.d456.s6|88-88|,|O
DDI-DrugBank.d456.s6|90-102|carbamazepine|drug
DDI-DrugBank.d456.s6|103-103|,|O
DDI-DrugBank.d456.s6|105-117|phenobarbital|drug
DDI-DrugBank.d456.s6|119-121|and|O
DDI-DrugBank.d456.s6|123-125|St.|O
DDI-DrugBank.d456.s6|127-131|Johns|O
DDI-DrugBank.d456.s6|133-136|Wort|O
DDI-DrugBank.d456.s6|137-137|.|O
DDI-DrugBank.d456.s7|0-13|Hepatotoxicity|O
DDI-DrugBank.d456.s7|15-26|Asymptomatic|O
DDI-DrugBank.d456.s7|28-36|increases|O
DDI-DrugBank.d456.s7|38-39|in|O
DDI-DrugBank.d456.s7|41-45|liver|O
DDI-DrugBank.d456.s7|47-59|transaminases|O
DDI-DrugBank.d456.s7|61-64|have|O
DDI-DrugBank.d456.s7|66-69|been|O
DDI-DrugBank.d456.s7|71-78|observed|O
DDI-DrugBank.d456.s7|80-81|in|O
DDI-DrugBank.d456.s7|83-89|TARCEVA|brand
DDI-DrugBank.d456.s7|91-97|treated|O
DDI-DrugBank.d456.s7|99-106|patients|O
DDI-DrugBank.d456.s7|107-107|;|O
DDI-DrugBank.d456.s8|0-8|therefore|O
DDI-DrugBank.d456.s8|9-9|,|O
DDI-DrugBank.d456.s8|11-18|periodic|O
DDI-DrugBank.d456.s8|20-24|liver|O
DDI-DrugBank.d456.s8|26-33|function|O
DDI-DrugBank.d456.s8|35-41|testing|O
DDI-DrugBank.d456.s8|43-43|(|O
DDI-DrugBank.d456.s8|44-56|transaminases|O
DDI-DrugBank.d456.s8|57-57|,|O
DDI-DrugBank.d456.s8|59-67|bilirubin|O
DDI-DrugBank.d456.s8|68-68|,|O
DDI-DrugBank.d456.s8|70-72|and|O
DDI-DrugBank.d456.s8|74-81|alkaline|O
DDI-DrugBank.d456.s8|83-93|phosphatase|O
DDI-DrugBank.d456.s8|94-94|)|O
DDI-DrugBank.d456.s8|96-101|should|O
DDI-DrugBank.d456.s8|103-104|be|O
DDI-DrugBank.d456.s8|106-115|considered|O
DDI-DrugBank.d456.s8|116-116|.|O
DDI-DrugBank.d456.s9|0-3|Dose|O
DDI-DrugBank.d456.s9|5-13|reduction|O
DDI-DrugBank.d456.s9|15-16|or|O
DDI-DrugBank.d456.s9|18-29|interruption|O
DDI-DrugBank.d456.s9|31-32|of|O
DDI-DrugBank.d456.s9|34-40|TARCEVA|brand
DDI-DrugBank.d456.s9|42-47|should|O
DDI-DrugBank.d456.s9|49-50|be|O
DDI-DrugBank.d456.s9|52-61|considered|O
DDI-DrugBank.d456.s9|63-64|if|O
DDI-DrugBank.d456.s9|66-72|changes|O
DDI-DrugBank.d456.s9|74-75|in|O
DDI-DrugBank.d456.s9|77-81|liver|O
DDI-DrugBank.d456.s9|83-90|function|O
DDI-DrugBank.d456.s9|92-94|are|O
DDI-DrugBank.d456.s9|96-101|severe|O
DDI-DrugBank.d456.s9|102-102|.|O
DDI-DrugBank.d456.s10|0-7|Patients|O
DDI-DrugBank.d456.s10|9-12|with|O
DDI-DrugBank.d456.s10|14-20|Hepatic|O
DDI-DrugBank.d456.s10|22-31|Impairment|O
DDI-DrugBank.d456.s10|33-34|In|O
DDI-DrugBank.d456.s10|36-40|vitro|O
DDI-DrugBank.d456.s10|42-44|and|O
DDI-DrugBank.d456.s10|46-47|in|O
DDI-DrugBank.d456.s10|49-52|vivo|O
DDI-DrugBank.d456.s10|54-61|evidence|O
DDI-DrugBank.d456.s10|63-69|suggest|O
DDI-DrugBank.d456.s10|71-74|that|O
DDI-DrugBank.d456.s10|76-84|erlotinib|drug
DDI-DrugBank.d456.s10|86-87|is|O
DDI-DrugBank.d456.s10|89-95|cleared|O
DDI-DrugBank.d456.s10|97-105|primarily|O
DDI-DrugBank.d456.s10|107-108|by|O
DDI-DrugBank.d456.s10|110-112|the|O
DDI-DrugBank.d456.s10|114-118|liver|O
DDI-DrugBank.d456.s10|119-119|.|O
DDI-DrugBank.d456.s11|0-8|Therefore|O
DDI-DrugBank.d456.s11|9-9|,|O
DDI-DrugBank.d456.s11|11-19|erlotinib|drug
DDI-DrugBank.d456.s11|21-28|exposure|O
DDI-DrugBank.d456.s11|30-32|may|O
DDI-DrugBank.d456.s11|34-35|be|O
DDI-DrugBank.d456.s11|37-45|increased|O
DDI-DrugBank.d456.s11|47-48|in|O
DDI-DrugBank.d456.s11|50-57|patients|O
DDI-DrugBank.d456.s11|59-62|with|O
DDI-DrugBank.d456.s11|64-70|hepatic|O
DDI-DrugBank.d456.s11|72-82|dysfunction|O
DDI-DrugBank.d456.s11|83-83|.|O
DDI-DrugBank.d456.s12|0-7|Elevated|O
DDI-DrugBank.d456.s12|9-21|International|O
DDI-DrugBank.d456.s12|23-32|Normalized|O
DDI-DrugBank.d456.s12|34-38|Ratio|O
DDI-DrugBank.d456.s12|40-42|and|O
DDI-DrugBank.d456.s12|44-52|Potential|O
DDI-DrugBank.d456.s12|54-61|Bleeding|O
DDI-DrugBank.d456.s12|63-75|International|O
DDI-DrugBank.d456.s12|77-86|Normalized|O
DDI-DrugBank.d456.s12|88-92|Ratio|O
DDI-DrugBank.d456.s12|94-94|(|O
DDI-DrugBank.d456.s12|95-97|INR|O
DDI-DrugBank.d456.s12|98-98|)|O
DDI-DrugBank.d456.s12|100-109|elevations|O
DDI-DrugBank.d456.s12|111-113|and|O
DDI-DrugBank.d456.s12|115-124|infrequent|O
DDI-DrugBank.d456.s12|126-132|reports|O
DDI-DrugBank.d456.s12|134-135|of|O
DDI-DrugBank.d456.s12|137-144|bleeding|O
DDI-DrugBank.d456.s12|146-151|events|O
DDI-DrugBank.d456.s12|153-161|including|O
DDI-DrugBank.d456.s12|163-178|gastrointestinal|O
DDI-DrugBank.d456.s12|180-182|and|O
DDI-DrugBank.d456.s12|184-203|non-gastrointestinal|O
DDI-DrugBank.d456.s12|205-213|bleedings|O
DDI-DrugBank.d456.s12|215-218|have|O
DDI-DrugBank.d456.s12|220-223|been|O
DDI-DrugBank.d456.s12|225-232|reported|O
DDI-DrugBank.d456.s12|234-235|in|O
DDI-DrugBank.d456.s12|237-244|clinical|O
DDI-DrugBank.d456.s12|246-252|studies|O
DDI-DrugBank.d456.s12|253-253|,|O
DDI-DrugBank.d456.s12|255-258|some|O
DDI-DrugBank.d456.s12|260-269|associated|O
DDI-DrugBank.d456.s12|271-274|with|O
DDI-DrugBank.d456.s12|276-286|concomitant|O
DDI-DrugBank.d456.s12|288-295|warfarin|drug
DDI-DrugBank.d456.s12|297-310|administration|O
DDI-DrugBank.d456.s12|311-311|.|O
DDI-DrugBank.d456.s13|0-7|Patients|O
DDI-DrugBank.d456.s13|9-14|taking|O
DDI-DrugBank.d456.s13|16-23|warfarin|drug
DDI-DrugBank.d456.s13|25-26|or|O
DDI-DrugBank.d456.s13|28-32|other|O
DDI-DrugBank.d456.s13|34-67|coumarin-derivative anticoagulants|group
DDI-DrugBank.d456.s13|69-74|should|O
DDI-DrugBank.d456.s13|76-77|be|O
DDI-DrugBank.d456.s13|79-87|monitored|O
DDI-DrugBank.d456.s13|89-97|regularly|O
DDI-DrugBank.d456.s13|99-101|for|O
DDI-DrugBank.d456.s13|103-109|changes|O
DDI-DrugBank.d456.s13|111-112|in|O
DDI-DrugBank.d456.s13|114-124|prothrombin|O
DDI-DrugBank.d456.s13|126-129|time|O
DDI-DrugBank.d456.s13|131-132|or|O
DDI-DrugBank.d456.s13|134-136|INR|O
DDI-DrugBank.d456.s14|0-0|.|O
DDI-DrugBank.d98.s0|0-11|Interactions|O
DDI-DrugBank.d98.s0|13-15|for|O
DDI-DrugBank.d98.s0|17-35|vitamin D analogues|group
DDI-DrugBank.d98.s0|37-37|(|O
DDI-DrugBank.d98.s0|38-47|Vitamin D2|drug
DDI-DrugBank.d98.s0|48-48|,|O
DDI-DrugBank.d98.s0|50-59|Vitamin D3|drug
DDI-DrugBank.d98.s0|60-60|,|O
DDI-DrugBank.d98.s0|62-71|Calcitriol|drug
DDI-DrugBank.d98.s0|72-72|,|O
DDI-DrugBank.d98.s0|74-76|and|O
DDI-DrugBank.d98.s0|78-86|Calcidiol|drug
DDI-DrugBank.d98.s0|87-87|)|O
DDI-DrugBank.d98.s0|88-88|:|O
DDI-DrugBank.d98.s0|90-103|Cholestyramine|drug
DDI-DrugBank.d98.s0|104-104|:|O
DDI-DrugBank.d98.s0|106-119|Cholestyramine|drug
DDI-DrugBank.d98.s0|121-123|has|O
DDI-DrugBank.d98.s0|125-128|been|O
DDI-DrugBank.d98.s0|130-137|reported|O
DDI-DrugBank.d98.s0|139-140|to|O
DDI-DrugBank.d98.s0|142-147|reduce|O
DDI-DrugBank.d98.s0|149-158|intestinal|O
DDI-DrugBank.d98.s0|160-169|absorption|O
DDI-DrugBank.d98.s0|171-172|of|O
DDI-DrugBank.d98.s0|174-193|fat soluble vitamins|group
DDI-DrugBank.d98.s0|194-194|;|O
DDI-DrugBank.d98.s1|0-1|as|O
DDI-DrugBank.d98.s1|3-6|such|O
DDI-DrugBank.d98.s1|8-9|it|O
DDI-DrugBank.d98.s1|11-13|may|O
DDI-DrugBank.d98.s1|15-20|impair|O
DDI-DrugBank.d98.s1|22-31|intestinal|O
DDI-DrugBank.d98.s1|33-42|absorption|O
DDI-DrugBank.d98.s1|44-45|of|O
DDI-DrugBank.d98.s1|47-49|any|O
DDI-DrugBank.d98.s1|51-52|of|O
DDI-DrugBank.d98.s1|54-62|vitamin D|group
DDI-DrugBank.d98.s1|63-63|.|O
DDI-DrugBank.d98.s2|0-22|Phenytoin/Phenobarbital|drug
DDI-DrugBank.d98.s2|23-23|:|O
DDI-DrugBank.d98.s2|25-27|The|O
DDI-DrugBank.d98.s2|29-44|coadministration|O
DDI-DrugBank.d98.s2|46-47|of|O
DDI-DrugBank.d98.s2|49-57|phenytoin|drug
DDI-DrugBank.d98.s2|59-60|or|O
DDI-DrugBank.d98.s2|62-74|phenobarbital|drug
DDI-DrugBank.d98.s2|76-79|will|O
DDI-DrugBank.d98.s2|81-83|not|O
DDI-DrugBank.d98.s2|85-90|affect|O
DDI-DrugBank.d98.s2|92-97|plasma|O
DDI-DrugBank.d98.s2|99-112|concentrations|O
DDI-DrugBank.d98.s2|114-115|of|O
DDI-DrugBank.d98.s2|117-125|vitamin D|group
DDI-DrugBank.d98.s2|126-126|,|O
DDI-DrugBank.d98.s2|128-130|but|O
DDI-DrugBank.d98.s2|132-134|may|O
DDI-DrugBank.d98.s2|136-141|reduce|O
DDI-DrugBank.d98.s2|143-152|endogenous|O
DDI-DrugBank.d98.s2|154-159|plasma|O
DDI-DrugBank.d98.s2|161-166|levels|O
DDI-DrugBank.d98.s2|168-169|of|O
DDI-DrugBank.d98.s2|171-195|calcitriol/ergocalcitriol|drug
DDI-DrugBank.d98.s2|197-198|by|O
DDI-DrugBank.d98.s2|200-211|accelerating|O
DDI-DrugBank.d98.s2|213-222|metabolism|O
DDI-DrugBank.d98.s2|223-223|.|O
DDI-DrugBank.d98.s3|0-4|Since|O
DDI-DrugBank.d98.s3|6-10|blood|O
DDI-DrugBank.d98.s3|12-16|level|O
DDI-DrugBank.d98.s3|18-19|of|O
DDI-DrugBank.d98.s3|21-45|calcitriol/ergocalcitriol|drug
DDI-DrugBank.d98.s3|47-50|will|O
DDI-DrugBank.d98.s3|52-53|be|O
DDI-DrugBank.d98.s3|55-61|reduced|O
DDI-DrugBank.d98.s3|62-62|,|O
DDI-DrugBank.d98.s3|64-69|higher|O
DDI-DrugBank.d98.s3|71-75|doses|O
DDI-DrugBank.d98.s3|77-78|of|O
DDI-DrugBank.d98.s3|80-88|Rocaltrol|brand
DDI-DrugBank.d98.s3|90-92|may|O
DDI-DrugBank.d98.s3|94-95|be|O
DDI-DrugBank.d98.s3|97-105|necessary|O
DDI-DrugBank.d98.s3|107-108|if|O
DDI-DrugBank.d98.s3|110-114|these|O
DDI-DrugBank.d98.s3|116-120|drugs|O
DDI-DrugBank.d98.s3|122-124|are|O
DDI-DrugBank.d98.s3|126-137|administered|O
DDI-DrugBank.d98.s3|139-152|simultaneously|O
DDI-DrugBank.d98.s3|153-153|.|O
DDI-DrugBank.d98.s4|0-8|Thiazides|group
DDI-DrugBank.d98.s4|9-9|:|O
DDI-DrugBank.d98.s4|11-19|Thiazides|group
DDI-DrugBank.d98.s4|21-23|are|O
DDI-DrugBank.d98.s4|25-29|known|O
DDI-DrugBank.d98.s4|31-32|to|O
DDI-DrugBank.d98.s4|34-39|induce|O
DDI-DrugBank.d98.s4|41-53|hypercalcemia|O
DDI-DrugBank.d98.s4|55-56|by|O
DDI-DrugBank.d98.s4|58-60|the|O
DDI-DrugBank.d98.s4|62-70|reduction|O
DDI-DrugBank.d98.s4|72-73|of|O
DDI-DrugBank.d98.s4|75-81|calcium|O
DDI-DrugBank.d98.s4|83-91|excretion|O
DDI-DrugBank.d98.s4|93-94|in|O
DDI-DrugBank.d98.s4|96-100|urine|O
DDI-DrugBank.d98.s4|101-101|.|O
DDI-DrugBank.d98.s5|0-3|Some|O
DDI-DrugBank.d98.s5|5-11|reports|O
DDI-DrugBank.d98.s5|13-16|have|O
DDI-DrugBank.d98.s5|18-22|shown|O
DDI-DrugBank.d98.s5|24-27|that|O
DDI-DrugBank.d98.s5|29-31|the|O
DDI-DrugBank.d98.s5|33-43|concomitant|O
DDI-DrugBank.d98.s5|45-58|administration|O
DDI-DrugBank.d98.s5|60-61|of|O
DDI-DrugBank.d98.s5|63-71|thiazides|group
DDI-DrugBank.d98.s5|73-76|with|O
DDI-DrugBank.d98.s5|78-86|vitamin D|group
DDI-DrugBank.d98.s5|88-93|causes|O
DDI-DrugBank.d98.s5|95-107|hypercalcemia|O
DDI-DrugBank.d98.s5|108-108|.|O
DDI-DrugBank.d98.s6|0-8|Therefore|O
DDI-DrugBank.d98.s6|9-9|,|O
DDI-DrugBank.d98.s6|11-20|precaution|O
DDI-DrugBank.d98.s6|22-27|should|O
DDI-DrugBank.d98.s6|29-30|be|O
DDI-DrugBank.d98.s6|32-36|taken|O
DDI-DrugBank.d98.s6|38-41|when|O
DDI-DrugBank.d98.s6|43-58|coadministration|O
DDI-DrugBank.d98.s6|60-61|is|O
DDI-DrugBank.d98.s6|63-71|necessary|O
DDI-DrugBank.d98.s6|72-72|.|O
DDI-DrugBank.d98.s7|0-8|Digitalis|group
DDI-DrugBank.d98.s7|9-9|:|O
DDI-DrugBank.d98.s7|11-19|Vitamin D|group
DDI-DrugBank.d98.s7|21-26|dosage|O
DDI-DrugBank.d98.s7|28-31|must|O
DDI-DrugBank.d98.s7|33-34|be|O
DDI-DrugBank.d98.s7|36-45|determined|O
DDI-DrugBank.d98.s7|47-50|with|O
DDI-DrugBank.d98.s7|52-55|care|O
DDI-DrugBank.d98.s7|57-58|in|O
DDI-DrugBank.d98.s7|60-67|patients|O
DDI-DrugBank.d98.s7|69-78|undergoing|O
DDI-DrugBank.d98.s7|80-88|treatment|O
DDI-DrugBank.d98.s7|90-93|with|O
DDI-DrugBank.d98.s7|95-103|digitalis|group
DDI-DrugBank.d98.s7|104-104|,|O
DDI-DrugBank.d98.s7|106-107|as|O
DDI-DrugBank.d98.s7|109-121|hypercalcemia|O
DDI-DrugBank.d98.s7|123-124|in|O
DDI-DrugBank.d98.s7|126-129|such|O
DDI-DrugBank.d98.s7|131-138|patients|O
DDI-DrugBank.d98.s7|140-142|may|O
DDI-DrugBank.d98.s7|144-154|precipitate|O
DDI-DrugBank.d98.s7|156-162|cardiac|O
DDI-DrugBank.d98.s7|164-174|arrhythmias|O
DDI-DrugBank.d98.s7|175-175|.|O
DDI-DrugBank.d98.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d98.s8|12-12|:|O
DDI-DrugBank.d98.s8|14-25|Ketoconazole|drug
DDI-DrugBank.d98.s8|27-29|may|O
DDI-DrugBank.d98.s8|31-37|inhibit|O
DDI-DrugBank.d98.s8|39-42|both|O
DDI-DrugBank.d98.s8|44-52|synthetic|O
DDI-DrugBank.d98.s8|54-56|and|O
DDI-DrugBank.d98.s8|58-66|catabolic|O
DDI-DrugBank.d98.s8|68-74|enzymes|O
DDI-DrugBank.d98.s8|76-77|of|O
DDI-DrugBank.d98.s8|79-87|vitamin D|group
DDI-DrugBank.d98.s8|88-88|.|O
DDI-DrugBank.d98.s9|0-9|Reductions|O
DDI-DrugBank.d98.s9|11-12|in|O
DDI-DrugBank.d98.s9|14-18|serum|O
DDI-DrugBank.d98.s9|20-29|endogenous|O
DDI-DrugBank.d98.s9|31-37|vitamin|O
DDI-DrugBank.d98.s9|39-39|D|O
DDI-DrugBank.d98.s9|41-54|concentrations|O
DDI-DrugBank.d98.s9|56-59|have|O
DDI-DrugBank.d98.s9|61-64|been|O
DDI-DrugBank.d98.s9|66-73|observed|O
DDI-DrugBank.d98.s9|75-83|following|O
DDI-DrugBank.d98.s9|85-87|the|O
DDI-DrugBank.d98.s9|89-102|administration|O
DDI-DrugBank.d98.s9|104-105|of|O
DDI-DrugBank.d98.s9|107-109|300|O
DDI-DrugBank.d98.s9|111-116|mg/day|O
DDI-DrugBank.d98.s9|118-119|to|O
DDI-DrugBank.d98.s9|121-124|1200|O
DDI-DrugBank.d98.s9|126-131|mg/day|O
DDI-DrugBank.d98.s9|133-144|ketoconazole|drug
DDI-DrugBank.d98.s9|146-148|for|O
DDI-DrugBank.d98.s9|150-150|a|O
DDI-DrugBank.d98.s9|152-155|week|O
DDI-DrugBank.d98.s9|157-158|to|O
DDI-DrugBank.d98.s9|160-166|healthy|O
DDI-DrugBank.d98.s9|168-170|men|O
DDI-DrugBank.d98.s9|171-171|.|O
DDI-DrugBank.d98.s10|0-6|However|O
DDI-DrugBank.d98.s10|7-7|,|O
DDI-DrugBank.d98.s10|9-10|in|O
DDI-DrugBank.d98.s10|12-15|vivo|O
DDI-DrugBank.d98.s10|17-20|drug|O
DDI-DrugBank.d98.s10|22-32|interaction|O
DDI-DrugBank.d98.s10|34-40|studies|O
DDI-DrugBank.d98.s10|42-43|of|O
DDI-DrugBank.d98.s10|45-56|ketoconazole|drug
DDI-DrugBank.d98.s10|58-61|with|O
DDI-DrugBank.d98.s10|63-71|vitamin D|group
DDI-DrugBank.d98.s10|73-76|have|O
DDI-DrugBank.d98.s10|78-80|not|O
DDI-DrugBank.d98.s10|82-85|been|O
DDI-DrugBank.d98.s10|87-98|investigated|O
DDI-DrugBank.d98.s10|99-99|.|O
DDI-DrugBank.d98.s11|0-14|Corticosteroids|group
DDI-DrugBank.d98.s11|15-15|:|O
DDI-DrugBank.d98.s11|17-17|A|O
DDI-DrugBank.d98.s11|19-30|relationship|O
DDI-DrugBank.d98.s11|32-33|of|O
DDI-DrugBank.d98.s11|35-44|functional|O
DDI-DrugBank.d98.s11|46-55|antagonism|O
DDI-DrugBank.d98.s11|57-62|exists|O
DDI-DrugBank.d98.s11|64-70|between|O
DDI-DrugBank.d98.s11|72-90|vitamin D analogues|group
DDI-DrugBank.d98.s11|91-91|,|O
DDI-DrugBank.d98.s11|93-97|which|O
DDI-DrugBank.d98.s11|99-105|promote|O
DDI-DrugBank.d98.s11|107-113|calcium|O
DDI-DrugBank.d98.s11|115-124|absorption|O
DDI-DrugBank.d98.s11|125-125|,|O
DDI-DrugBank.d98.s11|127-129|and|O
DDI-DrugBank.d98.s11|131-145|corticosteroids|group
DDI-DrugBank.d98.s11|146-146|,|O
DDI-DrugBank.d98.s11|148-152|which|O
DDI-DrugBank.d98.s11|154-160|inhibit|O
DDI-DrugBank.d98.s11|162-168|calcium|O
DDI-DrugBank.d98.s11|170-179|absorption|O
DDI-DrugBank.d98.s11|180-180|.|O
DDI-DrugBank.d98.s12|0-16|Phosphate-Binding|O
DDI-DrugBank.d98.s12|18-23|Agents|O
DDI-DrugBank.d98.s12|24-24|:|O
DDI-DrugBank.d98.s12|26-30|Since|O
DDI-DrugBank.d98.s12|32-40|vitamin D|group
DDI-DrugBank.d98.s12|42-45|also|O
DDI-DrugBank.d98.s12|47-49|has|O
DDI-DrugBank.d98.s12|51-52|an|O
DDI-DrugBank.d98.s12|54-59|effect|O
DDI-DrugBank.d98.s12|61-62|on|O
DDI-DrugBank.d98.s12|64-72|phosphate|O
DDI-DrugBank.d98.s12|74-82|transport|O
DDI-DrugBank.d98.s12|84-85|in|O
DDI-DrugBank.d98.s12|87-89|the|O
DDI-DrugBank.d98.s12|91-99|intestine|O
DDI-DrugBank.d98.s12|100-100|,|O
DDI-DrugBank.d98.s12|102-108|kidneys|O
DDI-DrugBank.d98.s12|110-112|and|O
DDI-DrugBank.d98.s12|114-118|bones|O
DDI-DrugBank.d98.s12|119-119|,|O
DDI-DrugBank.d98.s12|121-123|the|O
DDI-DrugBank.d98.s12|125-130|dosage|O
DDI-DrugBank.d98.s12|132-133|of|O
DDI-DrugBank.d98.s12|135-151|phosphate-binding|O
DDI-DrugBank.d98.s12|153-158|agents|O
DDI-DrugBank.d98.s12|160-163|must|O
DDI-DrugBank.d98.s12|165-166|be|O
DDI-DrugBank.d98.s12|168-175|adjusted|O
DDI-DrugBank.d98.s12|177-178|in|O
DDI-DrugBank.d98.s12|180-189|accordance|O
DDI-DrugBank.d98.s12|191-194|with|O
DDI-DrugBank.d98.s12|196-198|the|O
DDI-DrugBank.d98.s12|200-204|serum|O
DDI-DrugBank.d98.s12|206-214|phosphate|O
DDI-DrugBank.d98.s12|216-228|concentration|O
DDI-DrugBank.d98.s12|229-229|.|O
DDI-DrugBank.d98.s13|0-8|Vitamin D|group
DDI-DrugBank.d98.s13|9-9|:|O
DDI-DrugBank.d98.s13|11-13|The|O
DDI-DrugBank.d98.s13|15-30|coadministration|O
DDI-DrugBank.d98.s13|32-33|of|O
DDI-DrugBank.d98.s13|35-37|any|O
DDI-DrugBank.d98.s13|39-40|of|O
DDI-DrugBank.d98.s13|42-44|the|O
DDI-DrugBank.d98.s13|46-64|vitamin D analogues|group
DDI-DrugBank.d98.s13|66-71|should|O
DDI-DrugBank.d98.s13|73-74|be|O
DDI-DrugBank.d98.s13|76-82|avoided|O
DDI-DrugBank.d98.s13|84-85|as|O
DDI-DrugBank.d98.s13|87-90|this|O
DDI-DrugBank.d98.s13|92-96|could|O
DDI-DrugBank.d98.s13|98-103|create|O
DDI-DrugBank.d98.s13|105-112|possible|O
DDI-DrugBank.d98.s13|114-121|additive|O
DDI-DrugBank.d98.s13|123-129|effects|O
DDI-DrugBank.d98.s13|131-133|and|O
DDI-DrugBank.d98.s13|135-147|hypercalcemia|O
DDI-DrugBank.d98.s13|148-148|.|O
DDI-DrugBank.d98.s14|0-6|Calcium|drug
DDI-DrugBank.d98.s14|8-18|Supplements|O
DDI-DrugBank.d98.s14|19-19|:|O
DDI-DrugBank.d98.s14|21-32|Uncontrolled|O
DDI-DrugBank.d98.s14|34-39|intake|O
DDI-DrugBank.d98.s14|41-42|of|O
DDI-DrugBank.d98.s14|44-53|additional|O
DDI-DrugBank.d98.s14|55-72|calcium-containing|drug
DDI-DrugBank.d98.s14|74-85|preparations|O
DDI-DrugBank.d98.s14|87-92|should|O
DDI-DrugBank.d98.s14|94-95|be|O
DDI-DrugBank.d98.s14|97-103|avoided|O
DDI-DrugBank.d98.s14|104-104|.|O
DDI-DrugBank.d98.s15|0-8|Magnesium|drug
DDI-DrugBank.d98.s15|9-9|:|O
DDI-DrugBank.d98.s15|11-30|Magnesium-containing|drug
DDI-DrugBank.d98.s15|32-43|preparations|O
DDI-DrugBank.d98.s15|45-45|(|O
DDI-DrugBank.d98.s15|46-47|eg|O
DDI-DrugBank.d98.s15|48-48|,|O
DDI-DrugBank.d98.s15|50-57|antacids|group
DDI-DrugBank.d98.s15|58-58|)|O
DDI-DrugBank.d98.s15|60-62|may|O
DDI-DrugBank.d98.s15|64-68|cause|O
DDI-DrugBank.d98.s15|70-84|hypermagnesemia|O
DDI-DrugBank.d98.s15|86-88|and|O
DDI-DrugBank.d98.s15|90-95|should|O
DDI-DrugBank.d98.s15|97-105|therefore|O
DDI-DrugBank.d98.s15|107-109|not|O
DDI-DrugBank.d98.s15|111-112|be|O
DDI-DrugBank.d98.s15|114-118|taken|O
DDI-DrugBank.d98.s15|120-125|during|O
DDI-DrugBank.d98.s15|127-133|therapy|O
DDI-DrugBank.d98.s15|135-138|with|O
DDI-DrugBank.d98.s15|140-148|vitamin D|group
DDI-DrugBank.d98.s15|150-151|by|O
DDI-DrugBank.d98.s15|153-160|patients|O
DDI-DrugBank.d98.s15|162-163|on|O
DDI-DrugBank.d98.s15|165-171|chronic|O
DDI-DrugBank.d98.s15|173-177|renal|O
DDI-DrugBank.d98.s15|179-186|dialysis|O
DDI-DrugBank.d98.s15|187-187|.|O
DDI-DrugBank.d147.s0|0-1|No|O
DDI-DrugBank.d147.s0|3-8|formal|O
DDI-DrugBank.d147.s0|10-20|assessments|O
DDI-DrugBank.d147.s0|22-23|of|O
DDI-DrugBank.d147.s0|25-33|drug-drug|O
DDI-DrugBank.d147.s0|35-46|interactions|O
DDI-DrugBank.d147.s0|48-54|between|O
DDI-DrugBank.d147.s0|56-61|Vidaza|brand
DDI-DrugBank.d147.s0|63-65|and|O
DDI-DrugBank.d147.s0|67-71|other|O
DDI-DrugBank.d147.s0|73-78|agents|O
DDI-DrugBank.d147.s0|80-83|have|O
DDI-DrugBank.d147.s0|85-88|been|O
DDI-DrugBank.d147.s0|90-98|conducted|O
DDI-DrugBank.d147.s1|0-0|.|O
DDI-DrugBank.d108.s0|0-12|Isocarboxazid|drug
DDI-DrugBank.d108.s0|14-19|should|O
DDI-DrugBank.d108.s0|21-22|be|O
DDI-DrugBank.d108.s0|24-35|administered|O
DDI-DrugBank.d108.s0|37-40|with|O
DDI-DrugBank.d108.s0|42-48|caution|O
DDI-DrugBank.d108.s0|50-51|to|O
DDI-DrugBank.d108.s0|53-60|patients|O
DDI-DrugBank.d108.s0|62-70|receiving|O
DDI-DrugBank.d108.s0|72-79|Antabuse|brand
DDI-DrugBank.d108.s0|81-81|(|O
DDI-DrugBank.d108.s0|82-91|disulfiram|drug
DDI-DrugBank.d108.s0|92-92|,|O
DDI-DrugBank.d108.s0|94-105|Wyeth-Ayerst|O
DDI-DrugBank.d108.s0|107-118|Laboratories|O
DDI-DrugBank.d108.s0|119-119|)|O
DDI-DrugBank.d108.s0|120-120|.|O
DDI-DrugBank.d108.s1|0-1|In|O
DDI-DrugBank.d108.s1|3-3|a|O
DDI-DrugBank.d108.s1|5-10|single|O
DDI-DrugBank.d108.s1|12-16|study|O
DDI-DrugBank.d108.s1|17-17|,|O
DDI-DrugBank.d108.s1|19-22|rats|O
DDI-DrugBank.d108.s1|24-28|given|O
DDI-DrugBank.d108.s1|30-33|high|O
DDI-DrugBank.d108.s1|35-49|intraperitoneal|O
DDI-DrugBank.d108.s1|51-55|doses|O
DDI-DrugBank.d108.s1|57-58|of|O
DDI-DrugBank.d108.s1|60-61|an|O
DDI-DrugBank.d108.s1|63-75|MAO inhibitor|group
DDI-DrugBank.d108.s1|77-80|plus|O
DDI-DrugBank.d108.s1|82-91|disulfiram|drug
DDI-DrugBank.d108.s1|93-103|experienced|O
DDI-DrugBank.d108.s1|105-110|severe|O
DDI-DrugBank.d108.s1|112-119|toxicity|O
DDI-DrugBank.d108.s1|120-120|,|O
DDI-DrugBank.d108.s1|122-130|including|O
DDI-DrugBank.d108.s1|132-142|convulsions|O
DDI-DrugBank.d108.s1|144-146|and|O
DDI-DrugBank.d108.s1|148-152|death|O
DDI-DrugBank.d108.s1|153-153|.|O
DDI-DrugBank.d108.s2|0-10|Concomitant|O
DDI-DrugBank.d108.s2|12-14|use|O
DDI-DrugBank.d108.s2|16-17|of|O
DDI-DrugBank.d108.s2|19-31|Isocarboxazid|drug
DDI-DrugBank.d108.s2|33-35|and|O
DDI-DrugBank.d108.s2|37-41|other|O
DDI-DrugBank.d108.s2|43-61|psychotropic agents|group
DDI-DrugBank.d108.s2|63-64|is|O
DDI-DrugBank.d108.s2|66-74|generally|O
DDI-DrugBank.d108.s2|76-78|not|O
DDI-DrugBank.d108.s2|80-90|recommended|O
DDI-DrugBank.d108.s2|92-98|because|O
DDI-DrugBank.d108.s2|100-101|of|O
DDI-DrugBank.d108.s2|103-110|possible|O
DDI-DrugBank.d108.s2|112-123|potentiating|O
DDI-DrugBank.d108.s2|125-131|effects|O
DDI-DrugBank.d108.s2|132-132|.|O
DDI-DrugBank.d108.s3|0-3|This|O
DDI-DrugBank.d108.s3|5-6|is|O
DDI-DrugBank.d108.s3|8-17|especially|O
DDI-DrugBank.d108.s3|19-22|true|O
DDI-DrugBank.d108.s3|24-25|in|O
DDI-DrugBank.d108.s3|27-34|patients|O
DDI-DrugBank.d108.s3|36-38|who|O
DDI-DrugBank.d108.s3|40-42|may|O
DDI-DrugBank.d108.s3|44-50|subject|O
DDI-DrugBank.d108.s3|52-61|themselves|O
DDI-DrugBank.d108.s3|63-64|to|O
DDI-DrugBank.d108.s3|66-67|an|O
DDI-DrugBank.d108.s3|69-78|overdosage|O
DDI-DrugBank.d108.s3|80-81|of|O
DDI-DrugBank.d108.s3|83-87|drugs|O
DDI-DrugBank.d108.s3|88-88|.|O
DDI-DrugBank.d108.s4|0-1|If|O
DDI-DrugBank.d108.s4|3-13|combination|O
DDI-DrugBank.d108.s4|15-21|therapy|O
DDI-DrugBank.d108.s4|23-24|is|O
DDI-DrugBank.d108.s4|26-31|needed|O
DDI-DrugBank.d108.s4|32-32|,|O
DDI-DrugBank.d108.s4|34-40|careful|O
DDI-DrugBank.d108.s4|42-54|consideration|O
DDI-DrugBank.d108.s4|56-61|should|O
DDI-DrugBank.d108.s4|63-64|be|O
DDI-DrugBank.d108.s4|66-70|given|O
DDI-DrugBank.d108.s4|72-73|to|O
DDI-DrugBank.d108.s4|75-77|the|O
DDI-DrugBank.d108.s4|79-90|pharmacology|O
DDI-DrugBank.d108.s4|92-93|of|O
DDI-DrugBank.d108.s4|95-97|all|O
DDI-DrugBank.d108.s4|99-104|agents|O
DDI-DrugBank.d108.s4|106-107|to|O
DDI-DrugBank.d108.s4|109-110|be|O
DDI-DrugBank.d108.s4|112-115|used|O
DDI-DrugBank.d108.s4|116-116|.|O
DDI-DrugBank.d108.s5|0-2|The|O
DDI-DrugBank.d108.s5|4-12|monoamine|O
DDI-DrugBank.d108.s5|14-20|oxidase|O
DDI-DrugBank.d108.s5|22-31|inhibitory|O
DDI-DrugBank.d108.s5|33-39|effects|O
DDI-DrugBank.d108.s5|41-42|of|O
DDI-DrugBank.d108.s5|44-56|Isocarboxazid|drug
DDI-DrugBank.d108.s5|58-60|may|O
DDI-DrugBank.d108.s5|62-68|persist|O
DDI-DrugBank.d108.s5|70-72|for|O
DDI-DrugBank.d108.s5|74-74|a|O
DDI-DrugBank.d108.s5|76-86|substantial|O
DDI-DrugBank.d108.s5|88-93|period|O
DDI-DrugBank.d108.s5|95-99|after|O
DDI-DrugBank.d108.s5|101-115|discontinuation|O
DDI-DrugBank.d108.s5|117-118|of|O
DDI-DrugBank.d108.s5|120-122|the|O
DDI-DrugBank.d108.s5|124-127|drug|O
DDI-DrugBank.d108.s5|128-128|,|O
DDI-DrugBank.d108.s5|130-132|and|O
DDI-DrugBank.d108.s5|134-137|this|O
DDI-DrugBank.d108.s5|139-144|should|O
DDI-DrugBank.d108.s5|146-147|be|O
DDI-DrugBank.d108.s5|149-153|borne|O
DDI-DrugBank.d108.s5|155-156|in|O
DDI-DrugBank.d108.s5|158-161|mind|O
DDI-DrugBank.d108.s5|163-166|when|O
DDI-DrugBank.d108.s5|168-174|another|O
DDI-DrugBank.d108.s5|176-179|drug|O
DDI-DrugBank.d108.s5|181-182|is|O
DDI-DrugBank.d108.s5|184-193|prescribed|O
DDI-DrugBank.d108.s5|195-203|following|O
DDI-DrugBank.d108.s5|205-217|Isocarboxazid|drug
DDI-DrugBank.d108.s5|218-218|.|O
DDI-DrugBank.d108.s6|0-1|To|O
DDI-DrugBank.d108.s6|3-7|avoid|O
DDI-DrugBank.d108.s6|9-20|potentiation|O
DDI-DrugBank.d108.s6|21-21|,|O
DDI-DrugBank.d108.s6|23-25|the|O
DDI-DrugBank.d108.s6|27-35|physician|O
DDI-DrugBank.d108.s6|37-43|wishing|O
DDI-DrugBank.d108.s6|45-46|to|O
DDI-DrugBank.d108.s6|48-56|terminate|O
DDI-DrugBank.d108.s6|58-66|treatment|O
DDI-DrugBank.d108.s6|68-71|with|O
DDI-DrugBank.d108.s6|73-85|Isocarboxazid|drug
DDI-DrugBank.d108.s6|87-89|and|O
DDI-DrugBank.d108.s6|91-95|begin|O
DDI-DrugBank.d108.s6|97-103|therapy|O
DDI-DrugBank.d108.s6|105-108|with|O
DDI-DrugBank.d108.s6|110-116|another|O
DDI-DrugBank.d108.s6|118-122|agent|O
DDI-DrugBank.d108.s6|124-129|should|O
DDI-DrugBank.d108.s6|131-135|allow|O
DDI-DrugBank.d108.s6|137-139|for|O
DDI-DrugBank.d108.s6|141-142|an|O
DDI-DrugBank.d108.s6|144-151|interval|O
DDI-DrugBank.d108.s6|153-154|of|O
DDI-DrugBank.d108.s6|156-157|10|O
DDI-DrugBank.d108.s6|159-162|days|O
DDI-DrugBank.d108.s6|163-163|.|O
DDI-MedLine.d78.s0|0-2|The|O
DDI-MedLine.d78.s0|4-19|fluoroquinolones|group
DDI-MedLine.d78.s0|21-23|for|O
DDI-MedLine.d78.s0|25-31|urinary|O
DDI-MedLine.d78.s0|33-37|tract|O
DDI-MedLine.d78.s0|39-48|infections|O
DDI-MedLine.d78.s0|49-49|:|O
DDI-MedLine.d78.s0|51-51|a|O
DDI-MedLine.d78.s0|53-58|review|O
DDI-MedLine.d78.s0|59-59|.|O
DDI-MedLine.d78.s1|0-2|The|O
DDI-MedLine.d78.s1|4-19|fluoroquinolones|group
DDI-MedLine.d78.s1|21-23|are|O
DDI-MedLine.d78.s1|25-25|a|O
DDI-MedLine.d78.s1|27-33|rapidly|O
DDI-MedLine.d78.s1|35-41|growing|O
DDI-MedLine.d78.s1|43-47|class|O
DDI-MedLine.d78.s1|49-50|of|O
DDI-MedLine.d78.s1|52-62|antibiotics|group
DDI-MedLine.d78.s1|64-67|with|O
DDI-MedLine.d78.s1|69-69|a|O
DDI-MedLine.d78.s1|71-75|broad|O
DDI-MedLine.d78.s1|77-84|spectrum|O
DDI-MedLine.d78.s1|86-87|of|O
DDI-MedLine.d78.s1|89-96|activity|O
DDI-MedLine.d78.s1|98-104|against|O
DDI-MedLine.d78.s1|106-118|gram-negative|O
DDI-MedLine.d78.s1|120-122|and|O
DDI-MedLine.d78.s1|124-127|some|O
DDI-MedLine.d78.s1|129-141|gram-positive|O
DDI-MedLine.d78.s1|143-149|aerobic|O
DDI-MedLine.d78.s1|151-158|bacteria|O
DDI-MedLine.d78.s1|159-159|.|O
DDI-MedLine.d78.s2|0-4|These|O
DDI-MedLine.d78.s2|6-11|agents|O
DDI-MedLine.d78.s2|12-12|,|O
DDI-MedLine.d78.s2|14-22|including|O
DDI-MedLine.d78.s2|24-34|norfloxacin|drug
DDI-MedLine.d78.s2|35-35|,|O
DDI-MedLine.d78.s2|37-49|ciprofloxacin|drug
DDI-MedLine.d78.s2|50-50|,|O
DDI-MedLine.d78.s2|52-60|ofloxacin|drug
DDI-MedLine.d78.s2|61-61|,|O
DDI-MedLine.d78.s2|63-70|enoxacin|drug
DDI-MedLine.d78.s2|71-71|,|O
DDI-MedLine.d78.s2|73-75|and|O
DDI-MedLine.d78.s2|77-88|lomefloxacin|drug
DDI-MedLine.d78.s2|89-89|,|O
DDI-MedLine.d78.s2|91-94|have|O
DDI-MedLine.d78.s2|96-99|been|O
DDI-MedLine.d78.s2|101-111|extensively|O
DDI-MedLine.d78.s2|113-119|studied|O
DDI-MedLine.d78.s2|121-123|and|O
DDI-MedLine.d78.s2|125-128|have|O
DDI-MedLine.d78.s2|130-141|demonstrated|O
DDI-MedLine.d78.s2|143-150|efficacy|O
DDI-MedLine.d78.s2|152-154|and|O
DDI-MedLine.d78.s2|156-161|safety|O
DDI-MedLine.d78.s2|163-170|profiles|O
DDI-MedLine.d78.s2|172-181|comparable|O
DDI-MedLine.d78.s2|183-184|to|O
DDI-MedLine.d78.s2|186-190|those|O
DDI-MedLine.d78.s2|192-193|of|O
DDI-MedLine.d78.s2|195-199|other|O
DDI-MedLine.d78.s2|201-211|traditional|O
DDI-MedLine.d78.s2|213-218|agents|O
DDI-MedLine.d78.s2|220-222|for|O
DDI-MedLine.d78.s2|224-226|the|O
DDI-MedLine.d78.s2|228-236|treatment|O
DDI-MedLine.d78.s2|238-239|of|O
DDI-MedLine.d78.s2|241-251|complicated|O
DDI-MedLine.d78.s2|253-254|or|O
DDI-MedLine.d78.s2|256-268|uncomplicated|O
DDI-MedLine.d78.s2|270-276|urinary|O
DDI-MedLine.d78.s2|278-282|tract|O
DDI-MedLine.d78.s2|284-293|infections|O
DDI-MedLine.d78.s2|295-297|and|O
DDI-MedLine.d78.s2|299-309|prostatitis|O
DDI-MedLine.d78.s2|310-310|.|O
DDI-MedLine.d78.s3|0-9|Advantages|O
DDI-MedLine.d78.s3|11-17|offered|O
DDI-MedLine.d78.s3|19-20|by|O
DDI-MedLine.d78.s3|22-25|this|O
DDI-MedLine.d78.s3|27-31|class|O
DDI-MedLine.d78.s3|33-34|of|O
DDI-MedLine.d78.s3|36-46|antibiotics|group
DDI-MedLine.d78.s3|48-54|include|O
DDI-MedLine.d78.s3|56-62|optimal|O
DDI-MedLine.d78.s3|64-79|pharmacokinetics|O
DDI-MedLine.d78.s3|80-80|,|O
DDI-MedLine.d78.s3|82-94|effectiveness|O
DDI-MedLine.d78.s3|96-102|against|O
DDI-MedLine.d78.s3|104-122|multidrug-resistant|O
DDI-MedLine.d78.s3|124-132|organisms|O
DDI-MedLine.d78.s3|133-133|,|O
DDI-MedLine.d78.s3|135-137|and|O
DDI-MedLine.d78.s3|139-142|oral|O
DDI-MedLine.d78.s3|144-157|administration|O
DDI-MedLine.d78.s3|159-162|even|O
DDI-MedLine.d78.s3|164-167|when|O
DDI-MedLine.d78.s3|169-178|parenteral|O
DDI-MedLine.d78.s3|180-190|antibiotics|drug
DDI-MedLine.d78.s3|192-194|are|O
DDI-MedLine.d78.s3|196-204|generally|O
DDI-MedLine.d78.s3|206-209|used|O
DDI-MedLine.d78.s3|210-210|.|O
DDI-MedLine.d78.s4|0-2|The|O
DDI-MedLine.d78.s4|4-19|fluoroquinolones|group
DDI-MedLine.d78.s4|21-23|are|O
DDI-MedLine.d78.s4|25-28|also|O
DDI-MedLine.d78.s4|30-40|extensively|O
DDI-MedLine.d78.s4|42-45|used|O
DDI-MedLine.d78.s4|47-48|in|O
DDI-MedLine.d78.s4|50-57|urologic|O
DDI-MedLine.d78.s4|59-65|surgery|O
DDI-MedLine.d78.s4|66-66|.|O
DDI-DrugBank.d160.s0|0-2|The|O
DDI-DrugBank.d160.s0|4-10|results|O
DDI-DrugBank.d160.s0|12-13|of|O
DDI-DrugBank.d160.s0|15-15|a|O
DDI-DrugBank.d160.s0|17-21|study|O
DDI-DrugBank.d160.s0|23-24|of|O
DDI-DrugBank.d160.s0|26-41|coadministration|O
DDI-DrugBank.d160.s0|43-44|of|O
DDI-DrugBank.d160.s0|46-55|ethambutol|drug
DDI-DrugBank.d160.s0|57-57|(|O
DDI-DrugBank.d160.s0|58-59|50|O
DDI-DrugBank.d160.s0|61-65|mg/kg|O
DDI-DrugBank.d160.s0|66-66|)|O
DDI-DrugBank.d160.s0|68-71|with|O
DDI-DrugBank.d160.s0|73-74|an|O
DDI-DrugBank.d160.s0|76-93|aluminum hydroxide|drug
DDI-DrugBank.d160.s0|95-104|containing|O
DDI-DrugBank.d160.s0|106-112|antacid|group
DDI-DrugBank.d160.s0|114-115|to|O
DDI-DrugBank.d160.s0|117-118|13|O
DDI-DrugBank.d160.s0|120-127|patients|O
DDI-DrugBank.d160.s0|129-132|with|O
DDI-DrugBank.d160.s0|134-145|tuberculosis|O
DDI-DrugBank.d160.s0|147-152|showed|O
DDI-DrugBank.d160.s0|154-154|a|O
DDI-DrugBank.d160.s0|156-164|reduction|O
DDI-DrugBank.d160.s0|166-167|of|O
DDI-DrugBank.d160.s0|169-172|mean|O
DDI-DrugBank.d160.s0|174-178|serum|O
DDI-DrugBank.d160.s0|180-193|concentrations|O
DDI-DrugBank.d160.s0|195-197|and|O
DDI-DrugBank.d160.s0|199-205|urinary|O
DDI-DrugBank.d160.s0|207-215|excretion|O
DDI-DrugBank.d160.s0|217-218|of|O
DDI-DrugBank.d160.s0|220-229|ethambutol|drug
DDI-DrugBank.d160.s0|231-232|of|O
DDI-DrugBank.d160.s0|234-246|approximately|O
DDI-DrugBank.d160.s0|248-249|20|O
DDI-DrugBank.d160.s0|250-250|%|O
DDI-DrugBank.d160.s0|252-254|and|O
DDI-DrugBank.d160.s0|256-257|13|O
DDI-DrugBank.d160.s0|258-258|%|O
DDI-DrugBank.d160.s0|259-259|,|O
DDI-DrugBank.d160.s0|261-272|respectively|O
DDI-DrugBank.d160.s0|273-273|,|O
DDI-DrugBank.d160.s0|275-284|suggesting|O
DDI-DrugBank.d160.s0|286-289|that|O
DDI-DrugBank.d160.s0|291-293|the|O
DDI-DrugBank.d160.s0|295-298|oral|O
DDI-DrugBank.d160.s0|300-309|absorption|O
DDI-DrugBank.d160.s0|311-312|of|O
DDI-DrugBank.d160.s0|314-323|ethambutol|drug
DDI-DrugBank.d160.s0|325-327|may|O
DDI-DrugBank.d160.s0|329-330|be|O
DDI-DrugBank.d160.s0|332-338|reduced|O
DDI-DrugBank.d160.s0|340-341|by|O
DDI-DrugBank.d160.s0|343-347|these|O
DDI-DrugBank.d160.s0|349-364|antacid products|group
DDI-DrugBank.d160.s0|365-365|.|O
DDI-DrugBank.d160.s1|0-1|It|O
DDI-DrugBank.d160.s1|3-4|is|O
DDI-DrugBank.d160.s1|6-16|recommended|O
DDI-DrugBank.d160.s1|18-19|to|O
DDI-DrugBank.d160.s1|21-25|avoid|O
DDI-DrugBank.d160.s1|27-36|concurrent|O
DDI-DrugBank.d160.s1|38-51|administration|O
DDI-DrugBank.d160.s1|53-54|of|O
DDI-DrugBank.d160.s1|56-65|ethambutol|drug
DDI-DrugBank.d160.s1|67-70|with|O
DDI-DrugBank.d160.s1|72-89|aluminum hydroxide|drug
DDI-DrugBank.d160.s1|91-100|containing|O
DDI-DrugBank.d160.s1|102-109|antacids|group
DDI-DrugBank.d160.s1|111-113|for|O
DDI-DrugBank.d160.s1|115-116|at|O
DDI-DrugBank.d160.s1|118-122|least|O
DDI-DrugBank.d160.s1|124-124|4|O
DDI-DrugBank.d160.s1|126-130|hours|O
DDI-DrugBank.d160.s1|132-140|following|O
DDI-DrugBank.d160.s1|142-151|ethambutol|drug
DDI-DrugBank.d160.s1|153-166|administration|O
DDI-DrugBank.d160.s1|167-167|.|O
DDI-DrugBank.d341.s0|0-7|Specific|O
DDI-DrugBank.d341.s0|9-12|drug|O
DDI-DrugBank.d341.s0|14-24|interaction|O
DDI-DrugBank.d341.s0|26-32|studies|O
DDI-DrugBank.d341.s0|34-37|have|O
DDI-DrugBank.d341.s0|39-41|not|O
DDI-DrugBank.d341.s0|43-46|been|O
DDI-DrugBank.d341.s0|48-56|conducted|O
DDI-DrugBank.d341.s0|58-61|with|O
DDI-DrugBank.d341.s0|63-68|ENBREL|brand
DDI-DrugBank.d341.s0|70-70|.|O
DDI-DrugBank.d341.s1|0-6|However|O
DDI-DrugBank.d341.s1|7-7|,|O
DDI-DrugBank.d341.s1|9-10|it|O
DDI-DrugBank.d341.s1|12-14|was|O
DDI-DrugBank.d341.s1|16-23|observed|O
DDI-DrugBank.d341.s1|25-28|that|O
DDI-DrugBank.d341.s1|30-32|the|O
DDI-DrugBank.d341.s1|34-49|pharmacokinetics|O
DDI-DrugBank.d341.s1|51-52|of|O
DDI-DrugBank.d341.s1|54-59|ENBREL|brand
DDI-DrugBank.d341.s1|62-64|was|O
DDI-DrugBank.d341.s1|66-74|unaltered|O
DDI-DrugBank.d341.s1|76-77|by|O
DDI-DrugBank.d341.s1|79-89|concomitant|O
DDI-DrugBank.d341.s1|91-102|methotrexate|drug
DDI-DrugBank.d341.s1|104-105|in|O
DDI-DrugBank.d341.s1|107-116|rheumatoid|O
DDI-DrugBank.d341.s1|118-126|arthritis|O
DDI-DrugBank.d341.s1|128-135|patients|O
DDI-DrugBank.d341.s1|136-136|.|O
DDI-DrugBank.d341.s2|0-1|In|O
DDI-DrugBank.d341.s2|3-3|a|O
DDI-DrugBank.d341.s2|5-9|study|O
DDI-DrugBank.d341.s2|11-12|in|O
DDI-DrugBank.d341.s2|14-18|which|O
DDI-DrugBank.d341.s2|20-27|patients|O
DDI-DrugBank.d341.s2|29-32|with|O
DDI-DrugBank.d341.s2|34-39|active|O
DDI-DrugBank.d341.s2|41-42|RA|O
DDI-DrugBank.d341.s2|44-47|were|O
DDI-DrugBank.d341.s2|49-55|treated|O
DDI-DrugBank.d341.s2|57-59|for|O
DDI-DrugBank.d341.s2|61-62|up|O
DDI-DrugBank.d341.s2|64-65|to|O
DDI-DrugBank.d341.s2|67-68|24|O
DDI-DrugBank.d341.s2|70-74|weeks|O
DDI-DrugBank.d341.s2|76-79|with|O
DDI-DrugBank.d341.s2|81-90|concurrent|O
DDI-DrugBank.d341.s2|92-97|ENBREL|brand
DDI-DrugBank.d341.s2|100-102|and|O
DDI-DrugBank.d341.s2|104-111|anakinra|drug
DDI-DrugBank.d341.s2|113-119|therapy|O
DDI-DrugBank.d341.s2|120-120|,|O
DDI-DrugBank.d341.s2|122-122|a|O
DDI-DrugBank.d341.s2|124-124|7|O
DDI-DrugBank.d341.s2|125-125|%|O
DDI-DrugBank.d341.s2|127-130|rate|O
DDI-DrugBank.d341.s2|132-133|of|O
DDI-DrugBank.d341.s2|135-141|serious|O
DDI-DrugBank.d341.s2|143-152|infections|O
DDI-DrugBank.d341.s2|154-156|was|O
DDI-DrugBank.d341.s2|158-165|observed|O
DDI-DrugBank.d341.s2|166-166|,|O
DDI-DrugBank.d341.s2|168-172|which|O
DDI-DrugBank.d341.s2|174-176|was|O
DDI-DrugBank.d341.s2|178-183|higher|O
DDI-DrugBank.d341.s2|185-188|than|O
DDI-DrugBank.d341.s2|190-193|that|O
DDI-DrugBank.d341.s2|195-202|observed|O
DDI-DrugBank.d341.s2|204-207|with|O
DDI-DrugBank.d341.s2|209-214|ENBREL|brand
DDI-DrugBank.d341.s2|217-221|alone|O
DDI-DrugBank.d341.s2|223-223|(|O
DDI-DrugBank.d341.s2|224-224|0|O
DDI-DrugBank.d341.s2|225-225|%|O
DDI-DrugBank.d341.s2|226-226|)|O
DDI-DrugBank.d341.s2|227-227|.|O
DDI-DrugBank.d341.s3|0-2|Two|O
DDI-DrugBank.d341.s3|4-10|percent|O
DDI-DrugBank.d341.s3|12-13|of|O
DDI-DrugBank.d341.s3|15-22|patients|O
DDI-DrugBank.d341.s3|24-30|treated|O
DDI-DrugBank.d341.s3|32-43|concurrently|O
DDI-DrugBank.d341.s3|45-48|with|O
DDI-DrugBank.d341.s3|50-55|ENBREL|brand
DDI-DrugBank.d341.s3|58-60|and|O
DDI-DrugBank.d341.s3|62-69|anakinra|drug
DDI-DrugBank.d341.s3|71-79|developed|O
DDI-DrugBank.d341.s3|81-91|neutropenia|O
DDI-DrugBank.d341.s3|93-93|(|O
DDI-DrugBank.d341.s3|94-96|ANC|O
DDI-DrugBank.d341.s3|100-100|1|O
DDI-DrugBank.d341.s3|102-102|x|O
DDI-DrugBank.d341.s3|104-108|109/L|O
DDI-DrugBank.d341.s3|109-109|)|O
DDI-DrugBank.d341.s3|110-110|.|O
DDI-DrugBank.d341.s4|0-7|Patients|O
DDI-DrugBank.d341.s4|9-10|in|O
DDI-DrugBank.d341.s4|12-12|a|O
DDI-DrugBank.d341.s4|14-21|clinical|O
DDI-DrugBank.d341.s4|23-27|study|O
DDI-DrugBank.d341.s4|29-31|who|O
DDI-DrugBank.d341.s4|33-36|were|O
DDI-DrugBank.d341.s4|38-39|on|O
DDI-DrugBank.d341.s4|41-51|established|O
DDI-DrugBank.d341.s4|53-59|therapy|O
DDI-DrugBank.d341.s4|61-64|with|O
DDI-DrugBank.d341.s4|66-78|sulfasalazine|drug
DDI-DrugBank.d341.s4|79-79|,|O
DDI-DrugBank.d341.s4|81-82|to|O
DDI-DrugBank.d341.s4|84-88|which|O
DDI-DrugBank.d341.s4|90-95|ENBREL|brand
DDI-DrugBank.d341.s4|97-99|was|O
DDI-DrugBank.d341.s4|101-105|added|O
DDI-DrugBank.d341.s4|106-106|,|O
DDI-DrugBank.d341.s4|108-111|were|O
DDI-DrugBank.d341.s4|113-117|noted|O
DDI-DrugBank.d341.s4|119-120|to|O
DDI-DrugBank.d341.s4|122-128|develop|O
DDI-DrugBank.d341.s4|130-130|a|O
DDI-DrugBank.d341.s4|132-135|mild|O
DDI-DrugBank.d341.s4|137-144|decrease|O
DDI-DrugBank.d341.s4|146-147|in|O
DDI-DrugBank.d341.s4|149-152|mean|O
DDI-DrugBank.d341.s4|154-163|neutrophil|O
DDI-DrugBank.d341.s4|165-170|counts|O
DDI-DrugBank.d341.s4|172-173|in|O
DDI-DrugBank.d341.s4|175-184|comparison|O
DDI-DrugBank.d341.s4|186-187|to|O
DDI-DrugBank.d341.s4|189-194|groups|O
DDI-DrugBank.d341.s4|196-202|treated|O
DDI-DrugBank.d341.s4|204-207|with|O
DDI-DrugBank.d341.s4|209-214|either|O
DDI-DrugBank.d341.s4|216-221|ENBREL|brand
DDI-DrugBank.d341.s4|223-224|CI|O
DDI-DrugBank.d341.s4|226-227|or|O
DDI-DrugBank.d341.s4|229-241|sulfasalazine|drug
DDI-DrugBank.d341.s4|243-247|alone|O
DDI-DrugBank.d341.s4|248-248|.|O
DDI-DrugBank.d341.s5|0-2|The|O
DDI-DrugBank.d341.s5|4-11|clinical|O
DDI-DrugBank.d341.s5|13-24|significance|O
DDI-DrugBank.d341.s5|26-27|of|O
DDI-DrugBank.d341.s5|29-32|this|O
DDI-DrugBank.d341.s5|34-44|observation|O
DDI-DrugBank.d341.s5|46-47|is|O
DDI-DrugBank.d341.s5|49-55|unknown|O
DDI-DrugBank.d341.s5|56-56|.|O
DDI-DrugBank.d535.s0|0-5|CYP450|O
DDI-DrugBank.d535.s0|7-17|Metabolized|O
DDI-DrugBank.d535.s0|19-23|Drugs|O
DDI-DrugBank.d535.s0|25-31|Results|O
DDI-DrugBank.d535.s0|33-36|from|O
DDI-DrugBank.d535.s0|38-39|in|O
DDI-DrugBank.d535.s0|41-45|vitro|O
DDI-DrugBank.d535.s0|47-49|and|O
DDI-DrugBank.d535.s0|51-52|in|O
DDI-DrugBank.d535.s0|54-57|vivo|O
DDI-DrugBank.d535.s0|59-65|studies|O
DDI-DrugBank.d535.s0|67-73|suggest|O
DDI-DrugBank.d535.s0|75-78|that|O
DDI-DrugBank.d535.s0|80-90|enfuvirtide|drug
DDI-DrugBank.d535.s0|92-93|is|O
DDI-DrugBank.d535.s0|95-102|unlikely|O
DDI-DrugBank.d535.s0|104-105|to|O
DDI-DrugBank.d535.s0|107-110|have|O
DDI-DrugBank.d535.s0|112-122|significant|O
DDI-DrugBank.d535.s0|124-127|drug|O
DDI-DrugBank.d535.s0|129-140|interactions|O
DDI-DrugBank.d535.s0|142-145|with|O
DDI-DrugBank.d535.s0|147-159|concomitantly|O
DDI-DrugBank.d535.s0|161-172|administered|O
DDI-DrugBank.d535.s0|174-178|drugs|O
DDI-DrugBank.d535.s0|180-190|metabolized|O
DDI-DrugBank.d535.s0|192-193|by|O
DDI-DrugBank.d535.s0|195-200|CYP450|O
DDI-DrugBank.d535.s0|202-208|enzymes|O
DDI-DrugBank.d535.s0|209-209|.|O
DDI-DrugBank.d535.s1|0-20|Antiretroviral Agents|group
DDI-DrugBank.d535.s1|21-21|:|O
DDI-DrugBank.d535.s1|23-24|No|O
DDI-DrugBank.d535.s1|26-29|drug|O
DDI-DrugBank.d535.s1|31-42|interactions|O
DDI-DrugBank.d535.s1|44-47|with|O
DDI-DrugBank.d535.s1|49-53|other|O
DDI-DrugBank.d535.s1|55-80|antiretroviral medications|group
DDI-DrugBank.d535.s1|82-85|have|O
DDI-DrugBank.d535.s1|87-90|been|O
DDI-DrugBank.d535.s1|92-101|identified|O
DDI-DrugBank.d535.s1|103-106|that|O
DDI-DrugBank.d535.s1|108-112|would|O
DDI-DrugBank.d535.s1|114-120|warrant|O
DDI-DrugBank.d535.s1|122-131|alteration|O
DDI-DrugBank.d535.s1|133-134|of|O
DDI-DrugBank.d535.s1|136-141|either|O
DDI-DrugBank.d535.s1|143-145|the|O
DDI-DrugBank.d535.s1|147-157|enfuvirtide|drug
DDI-DrugBank.d535.s1|159-162|dose|O
DDI-DrugBank.d535.s1|164-165|or|O
DDI-DrugBank.d535.s1|167-169|the|O
DDI-DrugBank.d535.s1|171-174|dose|O
DDI-DrugBank.d535.s1|176-177|of|O
DDI-DrugBank.d535.s1|179-181|the|O
DDI-DrugBank.d535.s1|183-187|other|O
DDI-DrugBank.d535.s1|189-213|antiretroviral medication|group
DDI-DrugBank.d535.s1|214-214|.|O
DDI-DrugBank.d90.s0|0-1|No|O
DDI-DrugBank.d90.s0|3-6|drug|O
DDI-DrugBank.d90.s0|8-18|interaction|O
DDI-DrugBank.d90.s0|20-26|studies|O
DDI-DrugBank.d90.s0|28-31|have|O
DDI-DrugBank.d90.s0|33-36|been|O
DDI-DrugBank.d90.s0|38-46|performed|O
DDI-DrugBank.d90.s0|47-47|.|O
DDI-DrugBank.d393.s0|0-14|Pharmacokinetic|O
DDI-DrugBank.d393.s0|16-26|interaction|O
DDI-DrugBank.d393.s0|28-34|studies|O
DDI-DrugBank.d393.s0|36-39|with|O
DDI-DrugBank.d393.s0|41-50|cetirizine|drug
DDI-DrugBank.d393.s0|52-53|in|O
DDI-DrugBank.d393.s0|55-60|adults|O
DDI-DrugBank.d393.s0|62-65|were|O
DDI-DrugBank.d393.s0|67-75|conducted|O
DDI-DrugBank.d393.s0|77-80|with|O
DDI-DrugBank.d393.s0|82-96|pseudoephedrine|drug
DDI-DrugBank.d393.s0|97-97|,|O
DDI-DrugBank.d393.s0|99-108|antipyrine|drug
DDI-DrugBank.d393.s0|109-109|,|O
DDI-DrugBank.d393.s0|111-122|ketoconazole|drug
DDI-DrugBank.d393.s0|123-123|,|O
DDI-DrugBank.d393.s0|125-136|erythromycin|drug
DDI-DrugBank.d393.s0|138-140|and|O
DDI-DrugBank.d393.s0|142-153|azithromycin|drug
DDI-DrugBank.d393.s0|154-154|.|O
DDI-DrugBank.d393.s1|0-1|No|O
DDI-DrugBank.d393.s1|3-14|interactions|O
DDI-DrugBank.d393.s1|16-19|were|O
DDI-DrugBank.d393.s1|21-28|observed|O
DDI-DrugBank.d393.s1|29-29|.|O
DDI-DrugBank.d393.s2|0-1|In|O
DDI-DrugBank.d393.s2|3-3|a|O
DDI-DrugBank.d393.s2|5-12|multiple|O
DDI-DrugBank.d393.s2|14-17|dose|O
DDI-DrugBank.d393.s2|19-23|study|O
DDI-DrugBank.d393.s2|25-26|of|O
DDI-DrugBank.d393.s2|28-39|theophylline|drug
DDI-DrugBank.d393.s2|41-41|(|O
DDI-DrugBank.d393.s2|42-44|400|O
DDI-DrugBank.d393.s2|46-47|mg|O
DDI-DrugBank.d393.s2|49-52|once|O
DDI-DrugBank.d393.s2|54-58|daily|O
DDI-DrugBank.d393.s2|60-62|for|O
DDI-DrugBank.d393.s2|64-64|3|O
DDI-DrugBank.d393.s2|66-69|days|O
DDI-DrugBank.d393.s2|70-70|)|O
DDI-DrugBank.d393.s2|72-74|and|O
DDI-DrugBank.d393.s2|76-85|cetirizine|drug
DDI-DrugBank.d393.s2|87-87|(|O
DDI-DrugBank.d393.s2|88-89|20|O
DDI-DrugBank.d393.s2|91-92|mg|O
DDI-DrugBank.d393.s2|94-97|once|O
DDI-DrugBank.d393.s2|99-103|daily|O
DDI-DrugBank.d393.s2|105-107|for|O
DDI-DrugBank.d393.s2|109-109|3|O
DDI-DrugBank.d393.s2|111-114|days|O
DDI-DrugBank.d393.s2|115-115|)|O
DDI-DrugBank.d393.s2|116-116|,|O
DDI-DrugBank.d393.s2|118-118|a|O
DDI-DrugBank.d393.s2|120-121|16|O
DDI-DrugBank.d393.s2|122-122|%|O
DDI-DrugBank.d393.s2|124-131|decrease|O
DDI-DrugBank.d393.s2|133-134|in|O
DDI-DrugBank.d393.s2|136-138|the|O
DDI-DrugBank.d393.s2|140-148|clearance|O
DDI-DrugBank.d393.s2|150-151|of|O
DDI-DrugBank.d393.s2|153-162|cetirizine|drug
DDI-DrugBank.d393.s2|164-166|was|O
DDI-DrugBank.d393.s2|168-175|observed|O
DDI-DrugBank.d393.s2|176-176|.|O
DDI-DrugBank.d393.s3|0-2|The|O
DDI-DrugBank.d393.s3|4-14|disposition|O
DDI-DrugBank.d393.s3|16-17|of|O
DDI-DrugBank.d393.s3|19-30|theophylline|drug
DDI-DrugBank.d393.s3|32-34|was|O
DDI-DrugBank.d393.s3|36-38|not|O
DDI-DrugBank.d393.s3|40-46|altered|O
DDI-DrugBank.d393.s3|48-49|by|O
DDI-DrugBank.d393.s3|51-61|concomitant|O
DDI-DrugBank.d393.s3|63-72|cetirizine|drug
DDI-DrugBank.d393.s3|74-87|administration|O
DDI-DrugBank.d393.s3|88-88|.|O
DDI-DrugBank.d393.s4|0-8|Drug-Drug|O
DDI-DrugBank.d393.s4|10-21|Interactions|O
DDI-DrugBank.d393.s4|22-22|:|O
DDI-DrugBank.d393.s4|24-25|No|O
DDI-DrugBank.d393.s4|27-36|clinically|O
DDI-DrugBank.d393.s4|38-48|significant|O
DDI-DrugBank.d393.s4|50-53|drug|O
DDI-DrugBank.d393.s4|55-66|interactions|O
DDI-DrugBank.d393.s4|68-71|have|O
DDI-DrugBank.d393.s4|73-76|been|O
DDI-DrugBank.d393.s4|78-82|found|O
DDI-DrugBank.d393.s4|84-87|with|O
DDI-DrugBank.d393.s4|89-100|theophylline|drug
DDI-DrugBank.d393.s4|102-103|at|O
DDI-DrugBank.d393.s4|105-105|a|O
DDI-DrugBank.d393.s4|107-109|low|O
DDI-DrugBank.d393.s4|111-114|dose|O
DDI-DrugBank.d393.s4|115-115|,|O
DDI-DrugBank.d393.s4|117-128|azithromycin|drug
DDI-DrugBank.d393.s4|129-129|,|O
DDI-DrugBank.d393.s4|131-145|pseudoephedrine|drug
DDI-DrugBank.d393.s4|146-146|,|O
DDI-DrugBank.d393.s4|148-159|ketoconazole|drug
DDI-DrugBank.d393.s4|160-160|,|O
DDI-DrugBank.d393.s4|162-163|or|O
DDI-DrugBank.d393.s4|165-176|erythromycin|drug
DDI-DrugBank.d393.s4|177-177|.|O
DDI-DrugBank.d393.s5|0-4|There|O
DDI-DrugBank.d393.s5|6-8|was|O
DDI-DrugBank.d393.s5|10-10|a|O
DDI-DrugBank.d393.s5|12-16|small|O
DDI-DrugBank.d393.s5|18-25|decrease|O
DDI-DrugBank.d393.s5|27-28|in|O
DDI-DrugBank.d393.s5|30-32|the|O
DDI-DrugBank.d393.s5|34-42|clearance|O
DDI-DrugBank.d393.s5|44-45|of|O
DDI-DrugBank.d393.s5|47-56|cetirizine|drug
DDI-DrugBank.d393.s5|58-63|caused|O
DDI-DrugBank.d393.s5|65-66|by|O
DDI-DrugBank.d393.s5|68-68|a|O
DDI-DrugBank.d393.s5|70-75|400-mg|O
DDI-DrugBank.d393.s5|77-80|dose|O
DDI-DrugBank.d393.s5|82-83|of|O
DDI-DrugBank.d393.s5|85-96|theophylline|drug
DDI-DrugBank.d393.s5|97-97|;|O
DDI-DrugBank.d393.s6|0-1|it|O
DDI-DrugBank.d393.s6|3-4|is|O
DDI-DrugBank.d393.s6|6-13|possible|O
DDI-DrugBank.d393.s6|15-18|that|O
DDI-DrugBank.d393.s6|20-25|larger|O
DDI-DrugBank.d393.s6|27-38|theophylline|drug
DDI-DrugBank.d393.s6|40-44|doses|O
DDI-DrugBank.d393.s6|46-50|could|O
DDI-DrugBank.d393.s6|52-55|have|O
DDI-DrugBank.d393.s6|57-57|a|O
DDI-DrugBank.d393.s6|59-65|greater|O
DDI-DrugBank.d393.s6|67-72|effect|O
DDI-DrugBank.d393.s6|73-73|.|O
DDI-DrugBank.d566.s0|0-13|Cholestyramine|drug
DDI-DrugBank.d566.s0|0-13|Cholestyramine|drug
DDI-DrugBank.d566.s0|21-23|may|O
DDI-DrugBank.d566.s0|25-29|delay|O
DDI-DrugBank.d566.s0|31-32|or|O
DDI-DrugBank.d566.s0|34-39|reduce|O
DDI-DrugBank.d566.s0|41-43|the|O
DDI-DrugBank.d566.s0|45-54|absorption|O
DDI-DrugBank.d566.s0|56-57|of|O
DDI-DrugBank.d566.s0|59-69|concomitant|O
DDI-DrugBank.d566.s0|71-74|oral|O
DDI-DrugBank.d566.s0|76-85|medication|O
DDI-DrugBank.d566.s0|87-90|such|O
DDI-DrugBank.d566.s0|92-93|as|O
DDI-DrugBank.d566.s0|95-108|phenylbutazone|group
DDI-DrugBank.d566.s0|109-109|,|O
DDI-DrugBank.d566.s0|111-118|warfarin|drug
DDI-DrugBank.d566.s0|119-119|,|O
DDI-DrugBank.d566.s0|121-138|thiazide diuretics|group
DDI-DrugBank.d566.s0|140-140|(|O
DDI-DrugBank.d566.s0|141-146|acidic|O
DDI-DrugBank.d566.s0|147-147|)|O
DDI-DrugBank.d566.s0|149-150|or|O
DDI-DrugBank.d566.s0|152-162|propranolol|drug
DDI-DrugBank.d566.s0|164-164|(|O
DDI-DrugBank.d566.s0|165-169|basic|O
DDI-DrugBank.d566.s0|170-170|)|O
DDI-DrugBank.d566.s0|171-171|,|O
DDI-DrugBank.d566.s0|173-174|as|O
DDI-DrugBank.d566.s0|176-179|well|O
DDI-DrugBank.d566.s0|181-182|as|O
DDI-DrugBank.d566.s0|184-195|tetracycline|drug
DDI-DrugBank.d566.s0|184-208|tetracycline G|drug
DDI-DrugBank.d566.s0|209-209|,|O
DDI-DrugBank.d566.s0|211-223|phenobarbital|drug
DDI-DrugBank.d566.s0|224-224|,|O
DDI-DrugBank.d566.s0|226-232|thyroid|O
DDI-DrugBank.d566.s0|234-236|and|O
DDI-DrugBank.d566.s0|238-246|thyroxine|drug
DDI-DrugBank.d566.s0|248-259|preparations|O
DDI-DrugBank.d566.s0|260-260|,|O
DDI-DrugBank.d566.s0|262-270|estrogens|group
DDI-DrugBank.d566.s0|272-274|and|O
DDI-DrugBank.d566.s0|276-285|progestins|group
DDI-DrugBank.d566.s0|286-286|,|O
DDI-DrugBank.d566.s0|288-290|and|O
DDI-DrugBank.d566.s0|292-300|digitalis|group
DDI-DrugBank.d566.s0|301-301|.|O
DDI-DrugBank.d566.s1|0-11|Interference|O
DDI-DrugBank.d566.s1|13-16|with|O
DDI-DrugBank.d566.s1|18-20|the|O
DDI-DrugBank.d566.s1|22-31|absorption|O
DDI-DrugBank.d566.s1|33-34|of|O
DDI-DrugBank.d566.s1|36-39|oral|O
DDI-DrugBank.d566.s1|51-61|supplements|O
DDI-DrugBank.d566.s1|63-65|has|O
DDI-DrugBank.d566.s1|67-70|been|O
DDI-DrugBank.d566.s1|72-79|observed|O
DDI-DrugBank.d566.s1|81-84|with|O
DDI-DrugBank.d566.s1|86-92|another|O
DDI-DrugBank.d566.s1|94-111|positively-charged|O
DDI-DrugBank.d566.s1|113-116|bile|O
DDI-DrugBank.d566.s1|118-121|acid|O
DDI-DrugBank.d566.s1|123-133|sequestrant|O
DDI-DrugBank.d566.s1|134-134|.|O
DDI-DrugBank.d566.s2|0-13|Cholestyramine|drug
DDI-DrugBank.d566.s2|0-13|Cholestyramine|drug
DDI-DrugBank.d566.s2|21-23|may|O
DDI-DrugBank.d566.s2|25-33|interfere|O
DDI-DrugBank.d566.s2|35-38|with|O
DDI-DrugBank.d566.s2|40-42|the|O
DDI-DrugBank.d566.s2|44-59|pharmacokinetics|O
DDI-DrugBank.d566.s2|61-62|of|O
DDI-DrugBank.d566.s2|64-68|drugs|O
DDI-DrugBank.d566.s2|70-73|that|O
DDI-DrugBank.d566.s2|75-81|undergo|O
DDI-DrugBank.d566.s2|83-95|enterohepatic|O
DDI-DrugBank.d566.s2|97-107|circulation|O
DDI-DrugBank.d566.s2|108-108|,|O
DDI-DrugBank.d566.s2|110-112|The|O
DDI-DrugBank.d566.s2|114-127|discontinuance|O
DDI-DrugBank.d566.s2|129-130|of|O
DDI-DrugBank.d566.s2|132-145|cholestyramine|drug
DDI-DrugBank.d566.s2|132-145|cholestyramine|drug
DDI-DrugBank.d566.s2|153-157|could|O
DDI-DrugBank.d566.s2|159-162|pose|O
DDI-DrugBank.d566.s2|164-164|a|O
DDI-DrugBank.d566.s2|166-171|hazard|O
DDI-DrugBank.d566.s2|173-174|to|O
DDI-DrugBank.d566.s2|176-181|health|O
DDI-DrugBank.d566.s2|183-184|if|O
DDI-DrugBank.d566.s2|186-186|a|O
DDI-DrugBank.d566.s2|188-198|potentially|O
DDI-DrugBank.d566.s2|200-204|toxic|O
DDI-DrugBank.d566.s2|206-209|drug|O
DDI-DrugBank.d566.s2|211-214|such|O
DDI-DrugBank.d566.s2|216-217|as|O
DDI-DrugBank.d566.s2|219-227|digitalis|group
DDI-DrugBank.d566.s2|229-231|has|O
DDI-DrugBank.d566.s2|233-236|been|O
DDI-DrugBank.d566.s2|238-246|filtrated|O
DDI-DrugBank.d566.s2|248-249|to|O
DDI-DrugBank.d566.s2|251-251|a|O
DDI-DrugBank.d566.s2|253-263|maintenance|O
DDI-DrugBank.d566.s2|265-269|level|O
DDI-DrugBank.d566.s2|271-275|while|O
DDI-DrugBank.d566.s2|277-279|the|O
DDI-DrugBank.d566.s2|281-287|patient|O
DDI-DrugBank.d566.s2|289-291|was|O
DDI-DrugBank.d566.s2|293-298|taking|O
DDI-DrugBank.d566.s2|300-313|cholestyramine|drug
DDI-DrugBank.d566.s2|300-313|cholestyramine|drug
DDI-DrugBank.d566.s2|320-320|.|O
DDI-DrugBank.d566.s3|0-6|Because|O
DDI-DrugBank.d566.s3|8-21|cholestyramine|drug
DDI-DrugBank.d566.s3|23-27|binds|O
DDI-DrugBank.d566.s3|29-32|bile|O
DDI-DrugBank.d566.s3|34-38|acids|O
DDI-DrugBank.d566.s3|39-39|,|O
DDI-DrugBank.d566.s3|41-54|cholestyramine|drug
DDI-DrugBank.d566.s3|41-54|cholestyramine|drug
DDI-DrugBank.d566.s3|62-64|may|O
DDI-DrugBank.d566.s3|66-74|interfere|O
DDI-DrugBank.d566.s3|76-79|with|O
DDI-DrugBank.d566.s3|81-86|normal|O
DDI-DrugBank.d566.s3|88-90|fat|O
DDI-DrugBank.d566.s3|92-100|digestion|O
DDI-DrugBank.d566.s3|102-104|and|O
DDI-DrugBank.d566.s3|106-115|absorption|O
DDI-DrugBank.d566.s3|117-119|and|O
DDI-DrugBank.d566.s3|121-124|thus|O
DDI-DrugBank.d566.s3|126-128|may|O
DDI-DrugBank.d566.s3|130-136|prevent|O
DDI-DrugBank.d566.s3|138-147|absorption|O
DDI-DrugBank.d566.s3|149-150|of|O
DDI-DrugBank.d566.s3|152-171|fat soluble vitamins|group
DDI-DrugBank.d566.s3|173-176|such|O
DDI-DrugBank.d566.s3|178-179|as|O
DDI-DrugBank.d566.s3|181-181|A|O
DDI-DrugBank.d566.s3|182-182|,|O
DDI-DrugBank.d566.s3|184-184|D|O
DDI-DrugBank.d566.s3|185-185|,|O
DDI-DrugBank.d566.s3|187-187|E|O
DDI-DrugBank.d566.s3|188-188|,|O
DDI-DrugBank.d566.s3|190-192|and|O
DDI-DrugBank.d566.s3|194-194|K|O
DDI-DrugBank.d566.s3|195-195|.|O
DDI-DrugBank.d566.s4|0-3|When|O
DDI-DrugBank.d566.s4|5-18|cholestyramine|drug
DDI-DrugBank.d566.s4|5-18|cholestyramine|drug
DDI-DrugBank.d566.s4|26-27|is|O
DDI-DrugBank.d566.s4|29-33|given|O
DDI-DrugBank.d566.s4|35-37|for|O
DDI-DrugBank.d566.s4|39-42|long|O
DDI-DrugBank.d566.s4|44-50|periods|O
DDI-DrugBank.d566.s4|52-53|of|O
DDI-DrugBank.d566.s4|55-58|time|O
DDI-DrugBank.d566.s4|59-59|,|O
DDI-DrugBank.d566.s4|61-71|concomitant|O
DDI-DrugBank.d566.s4|73-87|supplementation|O
DDI-DrugBank.d566.s4|89-92|with|O
DDI-DrugBank.d566.s4|94-107|water-miscible|O
DDI-DrugBank.d566.s4|109-109|(|O
DDI-DrugBank.d566.s4|110-111|or|O
DDI-DrugBank.d566.s4|113-122|parenteral|O
DDI-DrugBank.d566.s4|123-123|)|O
DDI-DrugBank.d566.s4|125-129|forms|O
DDI-DrugBank.d566.s4|131-132|of|O
DDI-DrugBank.d566.s4|134-153|fat-soluble vitamins|group
DDI-DrugBank.d566.s4|155-160|should|O
DDI-DrugBank.d566.s4|162-163|be|O
DDI-DrugBank.d566.s4|165-174|considered|O
DDI-DrugBank.d566.s4|175-175|.|O
DDI-DrugBank.d566.s5|0-4|SINCE|O
DDI-DrugBank.d566.s5|6-19|CHOLESTYRAMINE|drug
DDI-DrugBank.d566.s5|6-19|CHOLESTYRAMINE|drug
DDI-DrugBank.d566.s5|27-29|MAY|O
DDI-DrugBank.d566.s5|31-34|BIND|O
DDI-DrugBank.d566.s5|36-40|OTHER|O
DDI-DrugBank.d566.s5|42-46|DRUGS|O
DDI-DrugBank.d566.s5|48-52|GIVEN|O
DDI-DrugBank.d566.s5|54-65|CONCURRENTLY|O
DDI-DrugBank.d566.s5|66-66|,|O
DDI-DrugBank.d566.s5|68-69|IT|O
DDI-DrugBank.d566.s5|71-72|IS|O
DDI-DrugBank.d566.s5|74-84|RECOMMENDED|O
DDI-DrugBank.d566.s5|86-89|THAT|O
DDI-DrugBank.d566.s5|91-98|PATIENTS|O
DDI-DrugBank.d566.s5|100-103|TAKE|O
DDI-DrugBank.d566.s5|105-109|OTHER|O
DDI-DrugBank.d566.s5|111-115|DRUGS|O
DDI-DrugBank.d566.s5|117-118|AT|O
DDI-DrugBank.d566.s5|120-124|LEAST|O
DDI-DrugBank.d566.s5|126-126|1|O
DDI-DrugBank.d566.s5|128-131|HOUR|O
DDI-DrugBank.d566.s5|133-138|BEFORE|O
DDI-DrugBank.d566.s5|140-141|OR|O
DDI-DrugBank.d566.s5|143-143|4|O
DDI-DrugBank.d566.s5|145-146|TO|O
DDI-DrugBank.d566.s5|148-148|6|O
DDI-DrugBank.d566.s5|150-154|HOURS|O
DDI-DrugBank.d566.s5|156-160|AFTER|O
DDI-DrugBank.d566.s5|162-175|CHOLESTYRAMINE|drug
DDI-DrugBank.d566.s5|162-175|CHOLESTYRAMINE|drug
DDI-DrugBank.d566.s5|183-183|(|O
DDI-DrugBank.d566.s5|184-185|OR|O
DDI-DrugBank.d566.s5|187-188|AT|O
DDI-DrugBank.d566.s5|190-191|AS|O
DDI-DrugBank.d566.s5|193-197|GREAT|O
DDI-DrugBank.d566.s5|199-200|AN|O
DDI-DrugBank.d566.s5|202-209|INTERVAL|O
DDI-DrugBank.d566.s5|211-212|AS|O
DDI-DrugBank.d566.s5|214-221|POSSIBLE|O
DDI-DrugBank.d566.s5|222-222|)|O
DDI-DrugBank.d566.s5|224-225|TO|O
DDI-DrugBank.d566.s5|227-231|AVOID|O
DDI-DrugBank.d566.s5|233-240|IMPEDING|O
DDI-DrugBank.d566.s5|242-246|THEIR|O
DDI-DrugBank.d566.s5|248-257|ABSORPTION|O
DDI-DrugBank.d566.s5|258-258|.|O
DDI-DrugBank.d215.s0|0-6|Caution|O
DDI-DrugBank.d215.s0|8-13|should|O
DDI-DrugBank.d215.s0|15-16|be|O
DDI-DrugBank.d215.s0|18-25|observed|O
DDI-DrugBank.d215.s0|27-30|when|O
DDI-DrugBank.d215.s0|32-42|anileridine|drug
DDI-DrugBank.d215.s0|44-45|is|O
DDI-DrugBank.d215.s0|47-60|coadministered|O
DDI-DrugBank.d215.s0|62-65|with|O
DDI-DrugBank.d215.s0|67-71|other|O
DDI-DrugBank.d215.s0|73-79|opioids|group
DDI-DrugBank.d215.s0|80-80|,|O
DDI-DrugBank.d215.s0|82-90|sedatives|group
DDI-DrugBank.d215.s0|91-91|,|O
DDI-DrugBank.d215.s0|93-106|phenothiazines|group
DDI-DrugBank.d215.s0|107-107|,|O
DDI-DrugBank.d215.s0|109-110|or|O
DDI-DrugBank.d215.s0|112-122|anesthetics|group
DDI-DrugBank.d215.s0|123-123|,|O
DDI-DrugBank.d215.s0|125-126|as|O
DDI-DrugBank.d215.s0|128-132|these|O
DDI-DrugBank.d215.s0|134-139|agents|O
DDI-DrugBank.d215.s0|141-143|may|O
DDI-DrugBank.d215.s0|145-152|increase|O
DDI-DrugBank.d215.s0|154-164|respiratory|O
DDI-DrugBank.d215.s0|166-168|and|O
DDI-DrugBank.d215.s0|170-180|circulatory|O
DDI-DrugBank.d215.s0|182-191|depression|O
DDI-DrugBank.d215.s0|192-192|.|O
DDI-DrugBank.d409.s0|0-6|Because|O
DDI-DrugBank.d409.s0|8-10|the|O
DDI-DrugBank.d409.s0|12-24|tetracyclines|group
DDI-DrugBank.d409.s0|26-29|have|O
DDI-DrugBank.d409.s0|31-34|been|O
DDI-DrugBank.d409.s0|36-40|shown|O
DDI-DrugBank.d409.s0|42-43|to|O
DDI-DrugBank.d409.s0|45-51|depress|O
DDI-DrugBank.d409.s0|53-58|plasma|O
DDI-DrugBank.d409.s0|60-70|prothrombin|O
DDI-DrugBank.d409.s0|72-79|activity|O
DDI-DrugBank.d409.s0|80-80|,|O
DDI-DrugBank.d409.s0|82-89|patients|O
DDI-DrugBank.d409.s0|91-93|who|O
DDI-DrugBank.d409.s0|95-97|are|O
DDI-DrugBank.d409.s0|99-100|on|O
DDI-DrugBank.d409.s0|102-114|anticoagulant|group
DDI-DrugBank.d409.s0|116-122|therapy|O
DDI-DrugBank.d409.s0|124-126|may|O
DDI-DrugBank.d409.s0|128-134|require|O
DDI-DrugBank.d409.s0|136-143|downward|O
DDI-DrugBank.d409.s0|145-154|adjustment|O
DDI-DrugBank.d409.s0|156-157|of|O
DDI-DrugBank.d409.s0|159-163|their|O
DDI-DrugBank.d409.s0|165-177|anticoagulant|group
DDI-DrugBank.d409.s0|179-184|dosage|O
DDI-DrugBank.d409.s0|185-185|.|O
DDI-DrugBank.d409.s1|0-4|Since|O
DDI-DrugBank.d409.s1|6-19|bacteriostatic|O
DDI-DrugBank.d409.s1|21-25|drugs|O
DDI-DrugBank.d409.s1|26-26|,|O
DDI-DrugBank.d409.s1|28-31|such|O
DDI-DrugBank.d409.s1|33-34|as|O
DDI-DrugBank.d409.s1|36-38|the|O
DDI-DrugBank.d409.s1|40-57|tetracycline class|group
DDI-DrugBank.d409.s1|59-60|of|O
DDI-DrugBank.d409.s1|62-72|antibiotics|group
DDI-DrugBank.d409.s1|73-73|,|O
DDI-DrugBank.d409.s1|75-77|may|O
DDI-DrugBank.d409.s1|79-87|interfere|O
DDI-DrugBank.d409.s1|89-92|with|O
DDI-DrugBank.d409.s1|94-96|the|O
DDI-DrugBank.d409.s1|98-109|bactericidal|O
DDI-DrugBank.d409.s1|111-116|action|O
DDI-DrugBank.d409.s1|118-119|of|O
DDI-DrugBank.d409.s1|121-131|penicillins|group
DDI-DrugBank.d409.s1|132-132|,|O
DDI-DrugBank.d409.s1|134-135|it|O
DDI-DrugBank.d409.s1|137-138|is|O
DDI-DrugBank.d409.s1|140-142|not|O
DDI-DrugBank.d409.s1|144-152|advisable|O
DDI-DrugBank.d409.s1|154-155|to|O
DDI-DrugBank.d409.s1|157-166|administer|O
DDI-DrugBank.d409.s1|168-172|these|O
DDI-DrugBank.d409.s1|174-178|drugs|O
DDI-DrugBank.d409.s1|180-192|concomitantly|O
DDI-DrugBank.d409.s1|193-193|.|O
DDI-DrugBank.d409.s2|0-9|Concurrent|O
DDI-DrugBank.d409.s2|11-13|use|O
DDI-DrugBank.d409.s2|15-16|of|O
DDI-DrugBank.d409.s2|18-30|tetracyclines|group
DDI-DrugBank.d409.s2|32-35|with|O
DDI-DrugBank.d409.s2|37-40|oral|O
DDI-DrugBank.d409.s2|42-55|contraceptives|group
DDI-DrugBank.d409.s2|57-59|may|O
DDI-DrugBank.d409.s2|61-66|render|O
DDI-DrugBank.d409.s2|68-71|oral|O
DDI-DrugBank.d409.s2|73-86|contraceptives|group
DDI-DrugBank.d409.s2|88-91|less|O
DDI-DrugBank.d409.s2|93-101|effective|O
DDI-DrugBank.d409.s2|102-102|.|O
DDI-DrugBank.d409.s3|0-11|Breakthrough|O
DDI-DrugBank.d409.s3|13-20|bleeding|O
DDI-DrugBank.d409.s3|22-24|has|O
DDI-DrugBank.d409.s3|26-29|been|O
DDI-DrugBank.d409.s3|31-38|reported|O
DDI-DrugBank.d201.s0|0-1|No|O
DDI-DrugBank.d201.s0|3-10|reported|O
DDI-DrugBank.d201.s0|12-23|interactions|O
DDI-DrugBank.d201.s0|24-24|.|O
DDI-DrugBank.d266.s0|0-1|In|O
DDI-DrugBank.d266.s0|3-7|vitro|O
DDI-DrugBank.d266.s0|9-15|studies|O
DDI-DrugBank.d266.s0|17-20|have|O
DDI-DrugBank.d266.s0|22-26|shown|O
DDI-DrugBank.d266.s0|28-34|CASODEX|brand
DDI-DrugBank.d266.s0|36-38|can|O
DDI-DrugBank.d266.s0|40-47|displace|O
DDI-DrugBank.d266.s0|49-56|coumarin|group
DDI-DrugBank.d266.s0|58-71|anticoagulants|O
DDI-DrugBank.d266.s0|72-72|,|O
DDI-DrugBank.d266.s0|74-77|such|O
DDI-DrugBank.d266.s0|79-80|as|O
DDI-DrugBank.d266.s0|82-89|warfarin|drug
DDI-DrugBank.d266.s0|90-90|,|O
DDI-DrugBank.d266.s0|92-95|from|O
DDI-DrugBank.d266.s0|97-101|their|O
DDI-DrugBank.d266.s0|103-117|protein-binding|O
DDI-DrugBank.d266.s0|119-123|sites|O
DDI-DrugBank.d266.s0|124-124|.|O
DDI-DrugBank.d266.s1|0-1|It|O
DDI-DrugBank.d266.s1|3-4|is|O
DDI-DrugBank.d266.s1|6-16|recommended|O
DDI-DrugBank.d266.s1|18-21|that|O
DDI-DrugBank.d266.s1|23-24|if|O
DDI-DrugBank.d266.s1|26-32|CASODEX|brand
DDI-DrugBank.d266.s1|34-35|is|O
DDI-DrugBank.d266.s1|37-43|started|O
DDI-DrugBank.d266.s1|45-46|in|O
DDI-DrugBank.d266.s1|48-55|patients|O
DDI-DrugBank.d266.s1|57-63|already|O
DDI-DrugBank.d266.s1|65-73|receiving|O
DDI-DrugBank.d266.s1|75-97|coumarin anticoagulants|group
DDI-DrugBank.d266.s1|98-98|,|O
DDI-DrugBank.d266.s1|100-110|prothrombin|O
DDI-DrugBank.d266.s1|112-116|times|O
DDI-DrugBank.d266.s1|118-123|should|O
DDI-DrugBank.d266.s1|125-126|be|O
DDI-DrugBank.d266.s1|128-134|closely|O
DDI-DrugBank.d266.s1|136-144|monitored|O
DDI-DrugBank.d266.s1|146-148|and|O
DDI-DrugBank.d266.s1|150-159|adjustment|O
DDI-DrugBank.d266.s1|161-162|of|O
DDI-DrugBank.d266.s1|164-166|the|O
DDI-DrugBank.d266.s1|168-180|anticoagulant|group
DDI-DrugBank.d266.s1|182-185|dose|O
DDI-DrugBank.d266.s1|187-189|may|O
DDI-DrugBank.d266.s1|191-192|be|O
DDI-DrugBank.d266.s1|194-202|necessary|O
DDI-DrugBank.d266.s1|203-203|.|O
DDI-MedLine.d46.s0|0-8|Influence|O
DDI-MedLine.d46.s0|10-11|of|O
DDI-MedLine.d46.s0|13-28|coadministration|O
DDI-MedLine.d46.s0|30-31|of|O
DDI-MedLine.d46.s0|33-42|fluoxetine|drug
DDI-MedLine.d46.s0|44-45|on|O
DDI-MedLine.d46.s0|47-55|cisapride|drug
DDI-MedLine.d46.s0|57-72|pharmacokinetics|O
DDI-MedLine.d46.s0|74-76|and|O
DDI-MedLine.d46.s0|78-80|QTc|O
DDI-MedLine.d46.s0|82-90|intervals|O
DDI-MedLine.d46.s0|92-93|in|O
DDI-MedLine.d46.s0|95-101|healthy|O
DDI-MedLine.d46.s0|103-112|volunteers|O
DDI-MedLine.d46.s0|113-113|.|O
DDI-MedLine.d46.s1|0-4|STUDY|O
DDI-MedLine.d46.s1|6-14|OBJECTIVE|O
DDI-MedLine.d46.s1|15-15|:|O
DDI-MedLine.d46.s1|17-18|To|O
DDI-MedLine.d46.s1|20-27|evaluate|O
DDI-MedLine.d46.s1|29-31|the|O
DDI-MedLine.d46.s1|33-38|effect|O
DDI-MedLine.d46.s1|40-41|of|O
DDI-MedLine.d46.s1|43-52|fluoxetine|drug
DDI-MedLine.d46.s1|54-55|on|O
DDI-MedLine.d46.s1|57-59|the|O
DDI-MedLine.d46.s1|61-76|pharmacokinetics|O
DDI-MedLine.d46.s1|78-80|and|O
DDI-MedLine.d46.s1|82-95|cardiovascular|O
DDI-MedLine.d46.s1|97-102|safety|O
DDI-MedLine.d46.s1|104-105|of|O
DDI-MedLine.d46.s1|107-115|cisapride|drug
DDI-MedLine.d46.s1|117-118|at|O
DDI-MedLine.d46.s1|120-125|steady|O
DDI-MedLine.d46.s1|127-131|state|O
DDI-MedLine.d46.s1|133-134|in|O
DDI-MedLine.d46.s1|136-142|healthy|O
DDI-MedLine.d46.s1|144-146|men|O
DDI-MedLine.d46.s1|147-147|.|O
DDI-MedLine.d46.s2|0-5|DESIGN|O
DDI-MedLine.d46.s2|6-6|:|O
DDI-MedLine.d46.s2|8-17|Open-label|O
DDI-MedLine.d46.s2|18-18|,|O
DDI-MedLine.d46.s2|20-30|three-phase|O
DDI-MedLine.d46.s2|31-31|,|O
DDI-MedLine.d46.s2|33-42|sequential|O
DDI-MedLine.d46.s2|44-48|study|O
DDI-MedLine.d46.s2|49-49|.|O
DDI-MedLine.d46.s3|0-6|SETTING|O
DDI-MedLine.d46.s3|7-7|:|O
DDI-MedLine.d46.s3|9-16|Clinical|O
DDI-MedLine.d46.s3|18-25|research|O
DDI-MedLine.d46.s3|27-32|center|O
DDI-MedLine.d46.s3|33-33|.|O
DDI-MedLine.d46.s4|0-7|SUBJECTS|O
DDI-MedLine.d46.s4|8-8|:|O
DDI-MedLine.d46.s4|9-14|Twelve|O
DDI-MedLine.d46.s4|16-22|healthy|O
DDI-MedLine.d46.s4|24-27|male|O
DDI-MedLine.d46.s4|29-38|volunteers|O
DDI-MedLine.d46.s4|39-39|.|O
DDI-MedLine.d46.s5|0-12|INTERVENTIONS|O
DDI-MedLine.d46.s5|13-13|:|O
DDI-MedLine.d46.s5|15-18|Each|O
DDI-MedLine.d46.s5|20-26|subject|O
DDI-MedLine.d46.s5|28-30|was|O
DDI-MedLine.d46.s5|32-38|treated|O
DDI-MedLine.d46.s5|40-48|according|O
DDI-MedLine.d46.s5|50-51|to|O
DDI-MedLine.d46.s5|53-55|the|O
DDI-MedLine.d46.s5|57-65|following|O
DDI-MedLine.d46.s5|67-74|sequence|O
DDI-MedLine.d46.s5|75-75|:|O
DDI-MedLine.d46.s5|77-84|baseline|O
DDI-MedLine.d46.s5|85-85|;|O
DDI-MedLine.d46.s6|0-4|phase|O
DDI-MedLine.d46.s6|6-6|1|O
DDI-MedLine.d46.s6|8-8|(|O
DDI-MedLine.d46.s6|9-12|days|O
DDI-MedLine.d46.s6|14-16|1-6|O
DDI-MedLine.d46.s6|17-17|)|O
DDI-MedLine.d46.s6|18-18|:|O
DDI-MedLine.d46.s6|20-28|cisapride|drug
DDI-MedLine.d46.s6|30-31|10|O
DDI-MedLine.d46.s6|33-34|mg|O
DDI-MedLine.d46.s6|36-36|4|O
DDI-MedLine.d46.s6|38-46|times/day|O
DDI-MedLine.d46.s6|47-47|;|O
DDI-MedLine.d46.s7|0-6|washout|O
DDI-MedLine.d46.s7|8-8|(|O
DDI-MedLine.d46.s7|9-12|days|O
DDI-MedLine.d46.s7|14-17|7-13|O
DDI-MedLine.d46.s7|18-18|)|O
DDI-MedLine.d46.s7|19-19|;|O
DDI-MedLine.d46.s8|0-4|phase|O
DDI-MedLine.d46.s8|6-6|2|O
DDI-MedLine.d46.s8|8-8|(|O
DDI-MedLine.d46.s8|9-12|days|O
DDI-MedLine.d46.s8|14-18|14-44|O
DDI-MedLine.d46.s8|19-19|)|O
DDI-MedLine.d46.s8|20-20|:|O
DDI-MedLine.d46.s8|22-31|fluoxetine|drug
DDI-MedLine.d46.s8|33-34|20|O
DDI-MedLine.d46.s8|36-41|mg/day|O
DDI-MedLine.d46.s8|42-42|;|O
DDI-MedLine.d46.s9|0-2|and|O
DDI-MedLine.d46.s9|4-8|phase|O
DDI-MedLine.d46.s9|10-10|3|O
DDI-MedLine.d46.s9|12-12|(|O
DDI-MedLine.d46.s9|13-16|days|O
DDI-MedLine.d46.s9|18-22|45-52|O
DDI-MedLine.d46.s9|23-23|)|O
DDI-MedLine.d46.s9|24-24|:|O
DDI-MedLine.d46.s9|26-34|cisapride|drug
DDI-MedLine.d46.s9|36-37|10|O
DDI-MedLine.d46.s9|39-40|mg|O
DDI-MedLine.d46.s9|42-42|4|O
DDI-MedLine.d46.s9|44-52|times/day|O
DDI-MedLine.d46.s9|54-54|(|O
DDI-MedLine.d46.s9|55-58|days|O
DDI-MedLine.d46.s9|60-64|45-51|O
DDI-MedLine.d46.s9|65-65|)|O
DDI-MedLine.d46.s9|67-70|plus|O
DDI-MedLine.d46.s9|72-81|fluoxetine|drug
DDI-MedLine.d46.s9|83-84|20|O
DDI-MedLine.d46.s9|86-91|mg/day|O
DDI-MedLine.d46.s9|93-93|(|O
DDI-MedLine.d46.s9|94-97|days|O
DDI-MedLine.d46.s9|99-103|45-52|O
DDI-MedLine.d46.s9|104-104|)|O
DDI-MedLine.d46.s9|105-105|.|O
DDI-MedLine.d46.s10|0-11|MEASUREMENTS|O
DDI-MedLine.d46.s10|13-15|and|O
DDI-MedLine.d46.s10|17-20|MAIN|O
DDI-MedLine.d46.s10|22-28|RESULTS|O
DDI-MedLine.d46.s10|29-29|:|O
DDI-MedLine.d46.s10|31-35|Blood|O
DDI-MedLine.d46.s10|37-43|samples|O
DDI-MedLine.d46.s10|45-48|were|O
DDI-MedLine.d46.s10|50-54|drawn|O
DDI-MedLine.d46.s10|56-58|and|O
DDI-MedLine.d46.s10|60-66|12-lead|O
DDI-MedLine.d46.s10|68-85|electrocardiograms|O
DDI-MedLine.d46.s10|87-95|performed|O
DDI-MedLine.d46.s10|97-98|at|O
DDI-MedLine.d46.s10|100-108|specified|O
DDI-MedLine.d46.s10|110-113|time|O
DDI-MedLine.d46.s10|115-120|points|O
DDI-MedLine.d46.s10|122-126|after|O
DDI-MedLine.d46.s10|128-130|the|O
DDI-MedLine.d46.s10|132-135|last|O
DDI-MedLine.d46.s10|137-143|morning|O
DDI-MedLine.d46.s10|145-148|dose|O
DDI-MedLine.d46.s10|150-151|of|O
DDI-MedLine.d46.s10|153-161|cisapride|drug
DDI-MedLine.d46.s10|163-164|in|O
DDI-MedLine.d46.s10|166-171|phases|O
DDI-MedLine.d46.s10|173-173|1|O
DDI-MedLine.d46.s10|175-177|and|O
DDI-MedLine.d46.s10|179-179|3|O
DDI-MedLine.d46.s10|180-180|.|O
DDI-MedLine.d46.s11|0-4|Blood|O
DDI-MedLine.d46.s11|6-12|samples|O
DDI-MedLine.d46.s11|14-17|also|O
DDI-MedLine.d46.s11|19-22|were|O
DDI-MedLine.d46.s11|24-28|taken|O
DDI-MedLine.d46.s11|30-35|before|O
DDI-MedLine.d46.s11|37-43|morning|O
DDI-MedLine.d46.s11|45-49|doses|O
DDI-MedLine.d46.s11|51-52|on|O
DDI-MedLine.d46.s11|54-56|the|O
DDI-MedLine.d46.s11|58-60|3rd|O
DDI-MedLine.d46.s11|61-61|,|O
DDI-MedLine.d46.s11|63-65|4th|O
DDI-MedLine.d46.s11|66-66|,|O
DDI-MedLine.d46.s11|68-70|and|O
DDI-MedLine.d46.s11|72-74|5th|O
DDI-MedLine.d46.s11|76-79|days|O
DDI-MedLine.d46.s11|81-82|of|O
DDI-MedLine.d46.s11|84-89|phases|O
DDI-MedLine.d46.s11|91-91|1|O
DDI-MedLine.d46.s11|93-95|and|O
DDI-MedLine.d46.s11|97-97|3|O
DDI-MedLine.d46.s11|98-98|.|O
DDI-MedLine.d46.s12|0-17|Electrocardiograms|O
DDI-MedLine.d46.s12|19-22|were|O
DDI-MedLine.d46.s12|24-27|done|O
DDI-MedLine.d46.s12|29-30|at|O
DDI-MedLine.d46.s12|32-39|baseline|O
DDI-MedLine.d46.s12|41-43|and|O
DDI-MedLine.d46.s12|45-46|on|O
DDI-MedLine.d46.s12|48-50|the|O
DDI-MedLine.d46.s12|52-55|last|O
DDI-MedLine.d46.s12|57-59|day|O
DDI-MedLine.d46.s12|61-62|of|O
DDI-MedLine.d46.s12|64-66|the|O
DDI-MedLine.d46.s12|68-74|washout|O
DDI-MedLine.d46.s12|76-81|period|O
DDI-MedLine.d46.s12|83-85|and|O
DDI-MedLine.d46.s12|87-91|phase|O
DDI-MedLine.d46.s12|93-93|2|O
DDI-MedLine.d46.s12|94-94|.|O
DDI-MedLine.d46.s13|0-15|Coadministration|O
DDI-MedLine.d46.s13|17-18|of|O
DDI-MedLine.d46.s13|20-29|fluoxetine|drug
DDI-MedLine.d46.s13|31-43|significantly|O
DDI-MedLine.d46.s13|45-53|decreased|O
DDI-MedLine.d46.s13|55-63|cisapride|drug
DDI-MedLine.d46.s13|65-70|plasma|O
DDI-MedLine.d46.s13|72-85|concentrations|O
DDI-MedLine.d46.s13|86-86|.|O
DDI-MedLine.d46.s14|0-4|There|O
DDI-MedLine.d46.s14|6-9|were|O
DDI-MedLine.d46.s14|11-12|no|O
DDI-MedLine.d46.s14|14-23|clinically|O
DDI-MedLine.d46.s14|25-35|significant|O
DDI-MedLine.d46.s14|37-43|changes|O
DDI-MedLine.d46.s14|45-46|in|O
DDI-MedLine.d46.s14|48-56|corrected|O
DDI-MedLine.d46.s14|58-59|QT|O
DDI-MedLine.d46.s14|61-69|intervals|O
DDI-MedLine.d46.s14|71-76|during|O
DDI-MedLine.d46.s14|78-91|administration|O
DDI-MedLine.d46.s14|93-94|of|O
DDI-MedLine.d46.s14|96-104|cisapride|drug
DDI-MedLine.d46.s14|106-110|alone|O
DDI-MedLine.d46.s14|112-113|or|O
DDI-MedLine.d46.s14|115-118|with|O
DDI-MedLine.d46.s14|120-129|fluoxetine|drug
DDI-MedLine.d46.s14|130-130|.|O
DDI-MedLine.d46.s15|0-8|Cisapride|drug
DDI-MedLine.d46.s15|10-12|was|O
DDI-MedLine.d46.s15|14-17|well|O
DDI-MedLine.d46.s15|19-27|tolerated|O
DDI-MedLine.d46.s15|29-32|when|O
DDI-MedLine.d46.s15|34-45|administered|O
DDI-MedLine.d46.s15|47-51|alone|O
DDI-MedLine.d46.s15|53-54|or|O
DDI-MedLine.d46.s15|56-59|with|O
DDI-MedLine.d46.s15|61-70|fluoxetine|drug
DDI-MedLine.d46.s15|71-71|.|O
DDI-MedLine.d46.s16|0-9|CONCLUSION|O
DDI-MedLine.d46.s16|10-10|:|O
DDI-MedLine.d46.s16|12-20|Cisapride|drug
DDI-MedLine.d46.s16|22-24|can|O
DDI-MedLine.d46.s16|26-27|be|O
DDI-MedLine.d46.s16|29-40|administered|O
DDI-MedLine.d46.s16|42-47|safely|O
DDI-MedLine.d46.s16|49-50|to|O
DDI-MedLine.d46.s16|52-59|patients|O
DDI-MedLine.d46.s16|61-69|receiving|O
DDI-MedLine.d46.s16|71-73|low|O
DDI-MedLine.d46.s16|75-85|therapeutic|O
DDI-MedLine.d46.s16|87-93|dosages|O
DDI-MedLine.d46.s16|95-96|of|O
DDI-MedLine.d46.s16|98-107|fluoxetine|drug
DDI-MedLine.d46.s16|108-108|.|O
DDI-MedLine.d97.s0|0-0|[|O
DDI-MedLine.d97.s0|1-1|2|O
DDI-MedLine.d97.s0|3-11|epidemics|O
DDI-MedLine.d97.s0|13-14|of|O
DDI-MedLine.d97.s0|16-24|arsenical|O
DDI-MedLine.d97.s0|26-39|encephalopathy|O
DDI-MedLine.d97.s0|41-42|in|O
DDI-MedLine.d97.s0|44-46|the|O
DDI-MedLine.d97.s0|48-56|treatment|O
DDI-MedLine.d97.s0|58-59|of|O
DDI-MedLine.d97.s0|61-75|trypanosomiasis|O
DDI-MedLine.d97.s0|76-76|,|O
DDI-MedLine.d97.s0|78-83|Uganda|O
DDI-MedLine.d97.s0|84-84|,|O
DDI-MedLine.d97.s0|86-94|1992-1993|O
DDI-MedLine.d97.s0|95-95|]|O
DDI-MedLine.d97.s0|98-102|Since|O
DDI-MedLine.d97.s0|104-107|1988|O
DDI-MedLine.d97.s0|108-108|,|O
DDI-MedLine.d97.s0|110-112|the|O
DDI-MedLine.d97.s0|114-119|french|O
DDI-MedLine.d97.s0|121-136|non-governmental|O
DDI-MedLine.d97.s0|138-149|organisation|O
DDI-MedLine.d97.s0|151-151|M|O
DDI-MedLine.d97.s0|154-159|decins|O
DDI-MedLine.d97.s0|161-164|Sans|O
DDI-MedLine.d97.s0|166-171|Fronti|O
DDI-MedLine.d97.s0|174-176|res|O
DDI-MedLine.d97.s0|178-179|is|O
DDI-MedLine.d97.s0|181-187|running|O
DDI-MedLine.d97.s0|189-189|a|O
DDI-MedLine.d97.s0|191-197|control|O
DDI-MedLine.d97.s0|199-205|program|O
DDI-MedLine.d97.s0|207-208|of|O
DDI-MedLine.d97.s0|210-214|human|O
DDI-MedLine.d97.s0|216-222|african|O
DDI-MedLine.d97.s0|224-238|trypanosomiasis|O
DDI-MedLine.d97.s0|240-241|in|O
DDI-MedLine.d97.s0|243-245|the|O
DDI-MedLine.d97.s0|247-254|district|O
DDI-MedLine.d97.s0|256-257|of|O
DDI-MedLine.d97.s0|259-262|Moyo|O
DDI-MedLine.d97.s0|263-263|,|O
DDI-MedLine.d97.s0|265-276|North-Uganda|O
DDI-MedLine.d97.s0|277-277|.|O
DDI-MedLine.d97.s1|0-6|Between|O
DDI-MedLine.d97.s1|8-11|1988|O
DDI-MedLine.d97.s1|13-15|and|O
DDI-MedLine.d97.s1|17-20|1993|O
DDI-MedLine.d97.s1|21-21|,|O
DDI-MedLine.d97.s1|23-26|more|O
DDI-MedLine.d97.s1|28-31|than|O
DDI-MedLine.d97.s1|33-37|7,000|O
DDI-MedLine.d97.s1|39-46|patients|O
DDI-MedLine.d97.s1|48-51|were|O
DDI-MedLine.d97.s1|53-61|diagnosed|O
DDI-MedLine.d97.s1|63-65|and|O
DDI-MedLine.d97.s1|67-73|treated|O
DDI-MedLine.d97.s1|74-74|.|O
DDI-MedLine.d97.s2|0-4|Since|O
DDI-MedLine.d97.s2|6-9|1988|O
DDI-MedLine.d97.s2|10-10|,|O
DDI-MedLine.d97.s2|12-13|it|O
DDI-MedLine.d97.s2|15-17|has|O
DDI-MedLine.d97.s2|19-22|been|O
DDI-MedLine.d97.s2|24-28|noted|O
DDI-MedLine.d97.s2|30-33|that|O
DDI-MedLine.d97.s2|35-43|incidence|O
DDI-MedLine.d97.s2|45-46|of|O
DDI-MedLine.d97.s2|48-58|melarsoprol|drug
DDI-MedLine.d97.s2|60-67|reaction|O
DDI-MedLine.d97.s2|69-71|had|O
DDI-MedLine.d97.s2|73-81|increased|O
DDI-MedLine.d97.s2|83-96|systematically|O
DDI-MedLine.d97.s2|98-104|between|O
DDI-MedLine.d97.s2|106-109|June|O
DDI-MedLine.d97.s2|111-113|and|O
DDI-MedLine.d97.s2|115-121|October|O
DDI-MedLine.d97.s2|123-124|of|O
DDI-MedLine.d97.s2|126-129|each|O
DDI-MedLine.d97.s2|131-134|year|O
DDI-MedLine.d97.s2|135-135|,|O
DDI-MedLine.d97.s2|137-146|indicating|O
DDI-MedLine.d97.s2|148-153|strong|O
DDI-MedLine.d97.s2|155-162|seasonal|O
DDI-MedLine.d97.s2|164-172|variation|O
DDI-MedLine.d97.s2|173-173|.|O
DDI-MedLine.d97.s3|0-1|In|O
DDI-MedLine.d97.s3|3-6|1992|O
DDI-MedLine.d97.s3|8-10|and|O
DDI-MedLine.d97.s3|12-15|1993|O
DDI-MedLine.d97.s3|16-16|,|O
DDI-MedLine.d97.s3|18-20|two|O
DDI-MedLine.d97.s3|22-30|outbreaks|O
DDI-MedLine.d97.s3|32-33|of|O
DDI-MedLine.d97.s3|35-43|arsenical|O
DDI-MedLine.d97.s3|45-52|reactive|O
DDI-MedLine.d97.s3|54-67|encephalopathy|O
DDI-MedLine.d97.s3|69-69|(|O
DDI-MedLine.d97.s3|70-72|ARE|O
DDI-MedLine.d97.s3|73-73|)|O
DDI-MedLine.d97.s3|75-82|occurred|O
DDI-MedLine.d97.s3|84-85|in|O
DDI-MedLine.d97.s3|87-89|the|O
DDI-MedLine.d97.s3|91-98|sleeping|O
DDI-MedLine.d97.s3|100-107|sickness|O
DDI-MedLine.d97.s3|109-114|center|O
DDI-MedLine.d97.s3|116-117|of|O
DDI-MedLine.d97.s3|119-126|Adjumani|O
DDI-MedLine.d97.s3|127-127|.|O
DDI-MedLine.d97.s4|0-2|The|O
DDI-MedLine.d97.s4|4-12|incidence|O
DDI-MedLine.d97.s4|14-15|of|O
DDI-MedLine.d97.s4|17-19|ARE|O
DDI-MedLine.d97.s4|21-28|suddenly|O
DDI-MedLine.d97.s4|30-37|exceeded|O
DDI-MedLine.d97.s4|39-40|10|O
DDI-MedLine.d97.s4|41-41|%|O
DDI-MedLine.d97.s4|43-44|of|O
DDI-MedLine.d97.s4|46-48|the|O
DDI-MedLine.d97.s4|50-57|patients|O
DDI-MedLine.d97.s4|59-65|treated|O
DDI-MedLine.d97.s4|67-68|by|O
DDI-MedLine.d97.s4|70-80|melarsoprol|drug
DDI-MedLine.d97.s4|82-87|during|O
DDI-MedLine.d97.s4|89-94|August|O
DDI-MedLine.d97.s4|96-99|1992|O
DDI-MedLine.d97.s4|101-103|and|O
DDI-MedLine.d97.s4|105-113|September|O
DDI-MedLine.d97.s4|115-118|1993|O
DDI-MedLine.d97.s4|119-119|.|O
DDI-MedLine.d97.s5|0-2|The|O
DDI-MedLine.d97.s5|4-8|onset|O
DDI-MedLine.d97.s5|10-11|of|O
DDI-MedLine.d97.s5|13-14|80|O
DDI-MedLine.d97.s5|15-15|%|O
DDI-MedLine.d97.s5|17-18|of|O
DDI-MedLine.d97.s5|20-24|those|O
DDI-MedLine.d97.s5|26-26|"|O
DDI-MedLine.d97.s5|27-34|epidemic|O
DDI-MedLine.d97.s5|35-35|"|O
DDI-MedLine.d97.s6|0-4|cases|O
DDI-MedLine.d97.s6|5-5|,|O
DDI-MedLine.d97.s6|7-14|occurred|O
DDI-MedLine.d97.s6|16-22|between|O
DDI-MedLine.d97.s6|24-26|the|O
DDI-MedLine.d97.s6|28-30|5th|O
DDI-MedLine.d97.s6|32-34|and|O
DDI-MedLine.d97.s6|36-38|the|O
DDI-MedLine.d97.s6|40-43|11th|O
DDI-MedLine.d97.s6|45-47|day|O
DDI-MedLine.d97.s6|49-50|of|O
DDI-MedLine.d97.s6|52-60|treatment|O
DDI-MedLine.d97.s6|61-61|.|O
DDI-MedLine.d97.s7|0-2|Two|O
DDI-MedLine.d97.s7|4-16|retrospective|O
DDI-MedLine.d97.s7|18-24|studies|O
DDI-MedLine.d97.s7|26-29|were|O
DDI-MedLine.d97.s7|31-39|conducted|O
DDI-MedLine.d97.s7|41-42|in|O
DDI-MedLine.d97.s7|44-47|1992|O
DDI-MedLine.d97.s7|49-49|(|O
DDI-MedLine.d97.s7|50-51|75|O
DDI-MedLine.d97.s7|53-57|cases|O
DDI-MedLine.d97.s7|58-58|)|O
DDI-MedLine.d97.s7|60-62|and|O
DDI-MedLine.d97.s7|64-65|in|O
DDI-MedLine.d97.s7|67-70|1993|O
DDI-MedLine.d97.s7|72-72|(|O
DDI-MedLine.d97.s7|73-74|51|O
DDI-MedLine.d97.s7|76-80|cases|O
DDI-MedLine.d97.s7|81-81|)|O
DDI-MedLine.d97.s7|82-82|.|O
DDI-MedLine.d97.s8|0-4|Among|O
DDI-MedLine.d97.s8|6-8|the|O
DDI-MedLine.d97.s8|10-13|risk|O
DDI-MedLine.d97.s8|15-21|factors|O
DDI-MedLine.d97.s8|23-29|studied|O
DDI-MedLine.d97.s8|30-30|,|O
DDI-MedLine.d97.s8|32-34|two|O
DDI-MedLine.d97.s8|36-41|appear|O
DDI-MedLine.d97.s8|43-44|to|O
DDI-MedLine.d97.s8|46-53|increase|O
DDI-MedLine.d97.s8|55-57|the|O
DDI-MedLine.d97.s8|59-62|risk|O
DDI-MedLine.d97.s8|64-65|of|O
DDI-MedLine.d97.s8|67-69|ARE|O
DDI-MedLine.d97.s8|70-70|:|O
DDI-MedLine.d97.s8|72-74|the|O
DDI-MedLine.d97.s8|76-87|prescription|O
DDI-MedLine.d97.s8|89-90|of|O
DDI-MedLine.d97.s8|92-104|thiabendazole|drug
DDI-MedLine.d97.s8|106-107|to|O
DDI-MedLine.d97.s8|109-113|treat|O
DDI-MedLine.d97.s8|115-130|strongyloidiasis|O
DDI-MedLine.d97.s8|132-137|during|O
DDI-MedLine.d97.s8|139-141|the|O
DDI-MedLine.d97.s8|143-153|melarsoprol|drug
DDI-MedLine.d97.s8|155-158|cure|O
DDI-MedLine.d97.s8|160-162|and|O
DDI-MedLine.d97.s8|164-166|the|O
DDI-MedLine.d97.s8|168-170|bad|O
DDI-MedLine.d97.s8|172-178|general|O
DDI-MedLine.d97.s8|180-187|clinical|O
DDI-MedLine.d97.s8|189-198|conditions|O
DDI-MedLine.d97.s8|200-201|of|O
DDI-MedLine.d97.s8|203-210|patients|O
DDI-MedLine.d97.s8|211-211|.|O
DDI-MedLine.d97.s9|0-4|These|O
DDI-MedLine.d97.s9|6-17|observations|O
DDI-MedLine.d97.s9|19-25|suggest|O
DDI-MedLine.d97.s9|27-30|that|O
DDI-MedLine.d97.s9|32-40|exogenous|O
DDI-MedLine.d97.s9|42-51|co-factors|O
DDI-MedLine.d97.s9|53-57|could|O
DDI-MedLine.d97.s9|59-60|be|O
DDI-MedLine.d97.s9|62-69|involved|O
DDI-MedLine.d97.s9|71-72|in|O
DDI-MedLine.d97.s9|74-76|the|O
DDI-MedLine.d97.s9|78-87|occurrence|O
DDI-MedLine.d97.s9|89-90|of|O
DDI-MedLine.d97.s9|92-94|ARE|O
DDI-MedLine.d97.s9|95-95|.|O
DDI-MedLine.d97.s10|0-14|Recommendations|O
DDI-MedLine.d97.s10|16-19|were|O
DDI-MedLine.d97.s10|21-22|to|O
DDI-MedLine.d97.s10|24-28|avoid|O
DDI-MedLine.d97.s10|30-43|administration|O
DDI-MedLine.d97.s10|45-46|of|O
DDI-MedLine.d97.s10|48-57|diffusible|O
DDI-MedLine.d97.s10|59-73|anti-helminthic|group
DDI-MedLine.d97.s10|75-83|treatment|O
DDI-MedLine.d97.s10|85-90|during|O
DDI-MedLine.d97.s10|92-94|the|O
DDI-MedLine.d97.s10|96-99|cure|O
DDI-MedLine.d97.s10|100-100|,|O
DDI-MedLine.d97.s10|102-104|and|O
DDI-MedLine.d97.s10|106-107|to|O
DDI-MedLine.d97.s10|109-115|improve|O
DDI-MedLine.d97.s10|117-119|the|O
DDI-MedLine.d97.s10|121-127|general|O
DDI-MedLine.d97.s10|129-138|conditions|O
DDI-MedLine.d97.s10|140-141|of|O
DDI-MedLine.d97.s10|143-150|patients|O
DDI-MedLine.d97.s10|152-157|before|O
DDI-MedLine.d97.s10|159-161|the|O
DDI-MedLine.d97.s10|163-166|cure|O
DDI-MedLine.d97.s10|168-169|of|O
DDI-MedLine.d97.s10|171-181|melarsoprol|drug
DDI-MedLine.d97.s10|182-182|.|O
DDI-DrugBank.d53.s0|0-16|Co-administration|O
DDI-DrugBank.d53.s0|18-19|of|O
DDI-DrugBank.d53.s0|21-30|nelfinavir|drug
DDI-DrugBank.d53.s0|32-33|at|O
DDI-DrugBank.d53.s0|35-46|steady-state|O
DDI-DrugBank.d53.s0|48-51|with|O
DDI-DrugBank.d53.s0|53-53|a|O
DDI-DrugBank.d53.s0|55-60|single|O
DDI-DrugBank.d53.s0|62-65|dose|O
DDI-DrugBank.d53.s0|67-68|of|O
DDI-DrugBank.d53.s0|70-81|azithromycin|drug
DDI-DrugBank.d53.s0|82-82|.|O
DDI-DrugBank.d53.s1|0-16|Co-administration|O
DDI-DrugBank.d53.s1|18-19|of|O
DDI-DrugBank.d53.s1|21-30|nelfinavir|drug
DDI-DrugBank.d53.s1|32-33|at|O
DDI-DrugBank.d53.s1|35-46|steady-state|O
DDI-DrugBank.d53.s1|48-51|with|O
DDI-DrugBank.d53.s1|53-53|a|O
DDI-DrugBank.d53.s1|55-60|single|O
DDI-DrugBank.d53.s1|62-65|dose|O
DDI-DrugBank.d53.s1|67-68|of|O
DDI-DrugBank.d53.s1|70-81|azithromycin|drug
DDI-DrugBank.d53.s1|83-83|(|O
DDI-DrugBank.d53.s1|84-84|2|O
DDI-DrugBank.d53.s1|86-86|x|O
DDI-DrugBank.d53.s1|88-90|600|O
DDI-DrugBank.d53.s1|92-93|mg|O
DDI-DrugBank.d53.s1|95-101|tablets|O
DDI-DrugBank.d53.s1|102-102|)|O
DDI-DrugBank.d53.s1|104-110|results|O
DDI-DrugBank.d53.s1|112-113|in|O
DDI-DrugBank.d53.s1|115-123|increased|O
DDI-DrugBank.d53.s1|125-136|azithromycin|drug
DDI-DrugBank.d53.s1|138-142|serum|O
DDI-DrugBank.d53.s1|144-157|concentrations|O
DDI-DrugBank.d53.s1|158-158|.|O
DDI-DrugBank.d53.s2|0-7|Although|O
DDI-DrugBank.d53.s2|9-9|a|O
DDI-DrugBank.d53.s2|11-14|dose|O
DDI-DrugBank.d53.s2|16-25|adjustment|O
DDI-DrugBank.d53.s2|27-28|of|O
DDI-DrugBank.d53.s2|30-41|azithromycin|drug
DDI-DrugBank.d53.s2|43-44|is|O
DDI-DrugBank.d53.s2|46-48|not|O
DDI-DrugBank.d53.s2|50-60|recommended|O
DDI-DrugBank.d53.s2|62-65|when|O
DDI-DrugBank.d53.s2|67-78|administered|O
DDI-DrugBank.d53.s2|80-81|in|O
DDI-DrugBank.d53.s2|83-93|combination|O
DDI-DrugBank.d53.s2|95-98|with|O
DDI-DrugBank.d53.s2|100-109|nelfinavir|drug
DDI-DrugBank.d53.s2|110-110|,|O
DDI-DrugBank.d53.s2|112-116|close|O
DDI-DrugBank.d53.s2|118-127|monitoring|O
DDI-DrugBank.d53.s2|129-131|for|O
DDI-DrugBank.d53.s2|133-137|known|O
DDI-DrugBank.d53.s2|139-142|side|O
DDI-DrugBank.d53.s2|144-150|effects|O
DDI-DrugBank.d53.s2|152-153|of|O
DDI-DrugBank.d53.s2|155-166|azithromycin|drug
DDI-DrugBank.d53.s2|167-167|,|O
DDI-DrugBank.d53.s2|169-172|such|O
DDI-DrugBank.d53.s2|174-175|as|O
DDI-DrugBank.d53.s2|177-181|liver|O
DDI-DrugBank.d53.s2|183-188|enzyme|O
DDI-DrugBank.d53.s2|190-202|abnormalities|O
DDI-DrugBank.d53.s2|204-206|and|O
DDI-DrugBank.d53.s2|208-214|hearing|O
DDI-DrugBank.d53.s2|216-225|impairment|O
DDI-DrugBank.d53.s2|226-226|,|O
DDI-DrugBank.d53.s2|228-229|is|O
DDI-DrugBank.d53.s2|231-239|warranted|O
DDI-DrugBank.d53.s2|240-240|.|O
DDI-DrugBank.d53.s3|0-11|Azithromycin|drug
DDI-DrugBank.d53.s3|13-15|did|O
DDI-DrugBank.d53.s3|17-19|not|O
DDI-DrugBank.d53.s3|21-26|affect|O
DDI-DrugBank.d53.s3|28-30|the|O
DDI-DrugBank.d53.s3|32-42|prothrombin|O
DDI-DrugBank.d53.s3|44-47|time|O
DDI-DrugBank.d53.s3|49-56|response|O
DDI-DrugBank.d53.s3|58-59|to|O
DDI-DrugBank.d53.s3|61-61|a|O
DDI-DrugBank.d53.s3|63-68|single|O
DDI-DrugBank.d53.s3|70-73|dose|O
DDI-DrugBank.d53.s3|75-76|of|O
DDI-DrugBank.d53.s3|78-85|warfarin|drug
DDI-DrugBank.d53.s3|86-86|.|O
DDI-DrugBank.d53.s4|0-6|However|O
DDI-DrugBank.d53.s4|7-7|,|O
DDI-DrugBank.d53.s4|9-15|prudent|O
DDI-DrugBank.d53.s4|17-23|medical|O
DDI-DrugBank.d53.s4|25-32|practice|O
DDI-DrugBank.d53.s4|34-41|dictates|O
DDI-DrugBank.d53.s4|43-49|careful|O
DDI-DrugBank.d53.s4|51-60|monitoring|O
DDI-DrugBank.d53.s4|62-63|of|O
DDI-DrugBank.d53.s4|65-75|prothrombin|O
DDI-DrugBank.d53.s4|77-80|time|O
DDI-DrugBank.d53.s4|82-83|in|O
DDI-DrugBank.d53.s4|85-87|all|O
DDI-DrugBank.d53.s4|89-96|patients|O
DDI-DrugBank.d53.s4|98-104|treated|O
DDI-DrugBank.d53.s4|106-109|with|O
DDI-DrugBank.d53.s4|111-122|azithromycin|drug
DDI-DrugBank.d53.s4|124-126|and|O
DDI-DrugBank.d53.s4|128-135|warfarin|drug
DDI-DrugBank.d53.s4|137-149|concomitantly|O
DDI-DrugBank.d53.s4|150-150|.|O
DDI-DrugBank.d53.s5|0-9|Concurrent|O
DDI-DrugBank.d53.s5|11-13|use|O
DDI-DrugBank.d53.s5|15-16|of|O
DDI-DrugBank.d53.s5|18-27|macrolides|group
DDI-DrugBank.d53.s5|29-31|and|O
DDI-DrugBank.d53.s5|33-40|warfarin|drug
DDI-DrugBank.d53.s5|42-43|in|O
DDI-DrugBank.d53.s5|45-52|clinical|O
DDI-DrugBank.d53.s5|54-61|practice|O
DDI-DrugBank.d53.s5|63-65|has|O
DDI-DrugBank.d53.s5|67-70|been|O
DDI-DrugBank.d53.s5|72-81|associated|O
DDI-DrugBank.d53.s5|83-86|with|O
DDI-DrugBank.d53.s5|88-96|increased|O
DDI-DrugBank.d53.s5|98-110|anticoagulant|O
DDI-DrugBank.d53.s5|112-118|effects|O
DDI-DrugBank.d53.s5|119-119|.|O
DDI-DrugBank.d53.s6|0-3|Drug|O
DDI-DrugBank.d53.s6|5-15|interaction|O
DDI-DrugBank.d53.s6|17-23|studies|O
DDI-DrugBank.d53.s6|25-28|were|O
DDI-DrugBank.d53.s6|30-38|performed|O
DDI-DrugBank.d53.s6|40-43|with|O
DDI-DrugBank.d53.s6|45-56|azithromycin|drug
DDI-DrugBank.d53.s6|58-60|and|O
DDI-DrugBank.d53.s6|62-66|other|O
DDI-DrugBank.d53.s6|68-72|drugs|O
DDI-DrugBank.d53.s6|74-79|likely|O
DDI-DrugBank.d53.s6|81-82|to|O
DDI-DrugBank.d53.s6|84-85|be|O
DDI-DrugBank.d53.s6|87-101|co-administered|O
DDI-DrugBank.d53.s6|102-102|.|O
DDI-DrugBank.d53.s7|0-3|When|O
DDI-DrugBank.d53.s7|5-8|used|O
DDI-DrugBank.d53.s7|10-11|in|O
DDI-DrugBank.d53.s7|13-23|therapeutic|O
DDI-DrugBank.d53.s7|25-29|doses|O
DDI-DrugBank.d53.s7|30-30|,|O
DDI-DrugBank.d53.s7|32-43|azithromycin|drug
DDI-DrugBank.d53.s7|45-47|had|O
DDI-DrugBank.d53.s7|49-49|a|O
DDI-DrugBank.d53.s7|51-56|modest|O
DDI-DrugBank.d53.s7|58-63|effect|O
DDI-DrugBank.d53.s7|65-66|on|O
DDI-DrugBank.d53.s7|68-70|the|O
DDI-DrugBank.d53.s7|72-87|pharmacokinetics|O
DDI-DrugBank.d53.s7|89-90|of|O
DDI-DrugBank.d53.s7|92-103|atorvastatin|drug
DDI-DrugBank.d53.s7|104-104|,|O
DDI-DrugBank.d53.s7|106-118|carbamazepine|drug
DDI-DrugBank.d53.s7|119-119|,|O
DDI-DrugBank.d53.s7|121-130|cetirizine|drug
DDI-DrugBank.d53.s7|131-131|,|O
DDI-DrugBank.d53.s7|133-142|didanosine|drug
DDI-DrugBank.d53.s7|143-143|,|O
DDI-DrugBank.d53.s7|145-153|efavirenz|drug
DDI-DrugBank.d53.s7|154-154|,|O
DDI-DrugBank.d53.s7|156-166|fluconazole|drug
DDI-DrugBank.d53.s7|167-167|,|O
DDI-DrugBank.d53.s7|169-177|indinavir|drug
DDI-DrugBank.d53.s7|178-178|,|O
DDI-DrugBank.d53.s7|180-188|midazolam|drug
DDI-DrugBank.d53.s7|189-189|,|O
DDI-DrugBank.d53.s7|191-199|rifabutin|drug
DDI-DrugBank.d53.s7|200-200|,|O
DDI-DrugBank.d53.s7|202-211|sildenafil|drug
DDI-DrugBank.d53.s7|212-212|,|O
DDI-DrugBank.d53.s7|214-225|theophylline|drug
DDI-DrugBank.d53.s7|227-227|(|O
DDI-DrugBank.d53.s7|228-238|intravenous|O
DDI-DrugBank.d53.s7|240-242|and|O
DDI-DrugBank.d53.s7|244-247|oral|O
DDI-DrugBank.d53.s7|248-248|)|O
DDI-DrugBank.d53.s7|249-249|,|O
DDI-DrugBank.d53.s7|251-259|triazolam|drug
DDI-DrugBank.d53.s7|260-260|,|O
DDI-DrugBank.d53.s7|262-290|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d53.s7|292-293|or|O
DDI-DrugBank.d53.s7|295-304|zidovudine|drug
DDI-DrugBank.d53.s7|305-305|.|O
DDI-DrugBank.d53.s8|0-16|Co-administration|O
DDI-DrugBank.d53.s8|18-21|with|O
DDI-DrugBank.d53.s8|23-31|efavirenz|drug
DDI-DrugBank.d53.s8|33-34|or|O
DDI-DrugBank.d53.s8|36-46|fluconazole|drug
DDI-DrugBank.d53.s8|48-50|had|O
DDI-DrugBank.d53.s8|52-52|a|O
DDI-DrugBank.d53.s8|54-59|modest|O
DDI-DrugBank.d53.s8|61-66|effect|O
DDI-DrugBank.d53.s8|68-69|on|O
DDI-DrugBank.d53.s8|71-73|the|O
DDI-DrugBank.d53.s8|75-90|pharmacokinetics|O
DDI-DrugBank.d53.s8|92-93|of|O
DDI-DrugBank.d53.s8|95-106|azithromycin|drug
DDI-DrugBank.d53.s8|107-107|.|O
DDI-DrugBank.d53.s9|0-1|No|O
DDI-DrugBank.d53.s9|3-8|dosage|O
DDI-DrugBank.d53.s9|10-19|adjustment|O
DDI-DrugBank.d53.s9|21-22|of|O
DDI-DrugBank.d53.s9|24-29|either|O
DDI-DrugBank.d53.s9|31-34|drug|O
DDI-DrugBank.d53.s9|36-37|is|O
DDI-DrugBank.d53.s9|39-49|recommended|O
DDI-DrugBank.d53.s9|51-54|when|O
DDI-DrugBank.d53.s9|56-67|azithromycin|drug
DDI-DrugBank.d53.s9|69-70|is|O
DDI-DrugBank.d53.s9|72-73|co|O
DDI-DrugBank.d53.s9|75-86|administered|O
DDI-DrugBank.d53.s9|88-91|with|O
DDI-DrugBank.d53.s9|93-95|any|O
DDI-DrugBank.d53.s9|97-98|of|O
DDI-DrugBank.d53.s9|100-102|the|O
DDI-DrugBank.d53.s9|104-108|above|O
DDI-DrugBank.d53.s9|110-115|agents|O
DDI-DrugBank.d53.s9|116-116|.|O
DDI-DrugBank.d53.s10|0-11|Interactions|O
DDI-DrugBank.d53.s10|13-16|with|O
DDI-DrugBank.d53.s10|18-20|the|O
DDI-DrugBank.d53.s10|22-26|drugs|O
DDI-DrugBank.d53.s10|28-33|listed|O
DDI-DrugBank.d53.s10|35-39|below|O
DDI-DrugBank.d53.s10|41-44|have|O
DDI-DrugBank.d53.s10|46-48|not|O
DDI-DrugBank.d53.s10|50-53|been|O
DDI-DrugBank.d53.s10|55-62|reported|O
DDI-DrugBank.d53.s10|64-65|in|O
DDI-DrugBank.d53.s10|67-74|clinical|O
DDI-DrugBank.d53.s10|76-81|trials|O
DDI-DrugBank.d53.s10|83-86|with|O
DDI-DrugBank.d53.s10|88-99|azithromycin|drug
DDI-DrugBank.d53.s10|100-100|;|O
DDI-DrugBank.d53.s11|0-6|however|O
DDI-DrugBank.d53.s11|7-7|,|O
DDI-DrugBank.d53.s11|9-10|no|O
DDI-DrugBank.d53.s11|12-19|specific|O
DDI-DrugBank.d53.s11|21-24|drug|O
DDI-DrugBank.d53.s11|26-36|interaction|O
DDI-DrugBank.d53.s11|38-44|studies|O
DDI-DrugBank.d53.s11|46-49|have|O
DDI-DrugBank.d53.s11|51-54|been|O
DDI-DrugBank.d53.s11|56-64|performed|O
DDI-DrugBank.d53.s11|66-67|to|O
DDI-DrugBank.d53.s11|69-76|evaluate|O
DDI-DrugBank.d53.s11|78-86|potential|O
DDI-DrugBank.d53.s11|88-96|drug-drug|O
DDI-DrugBank.d53.s11|98-108|interaction|O
DDI-DrugBank.d53.s11|109-109|.|O
DDI-DrugBank.d53.s12|0-10|Nonetheless|O
DDI-DrugBank.d53.s12|11-11|,|O
DDI-DrugBank.d53.s12|13-16|they|O
DDI-DrugBank.d53.s12|18-21|have|O
DDI-DrugBank.d53.s12|23-26|been|O
DDI-DrugBank.d53.s12|28-35|observed|O
DDI-DrugBank.d53.s12|37-40|with|O
DDI-DrugBank.d53.s12|42-59|macrolide products|group
DDI-DrugBank.d53.s12|60-60|.|O
DDI-DrugBank.d53.s13|0-4|Until|O
DDI-DrugBank.d53.s13|6-12|further|O
DDI-DrugBank.d53.s13|14-17|data|O
DDI-DrugBank.d53.s13|19-21|are|O
DDI-DrugBank.d53.s13|23-31|developed|O
DDI-DrugBank.d53.s13|33-41|regarding|O
DDI-DrugBank.d53.s13|43-46|drug|O
DDI-DrugBank.d53.s13|48-59|interactions|O
DDI-DrugBank.d53.s13|61-64|when|O
DDI-DrugBank.d53.s13|66-77|azithromycin|drug
DDI-DrugBank.d53.s13|79-81|and|O
DDI-DrugBank.d53.s13|83-87|these|O
DDI-DrugBank.d53.s13|89-93|drugs|O
DDI-DrugBank.d53.s13|95-97|are|O
DDI-DrugBank.d53.s13|99-102|used|O
DDI-DrugBank.d53.s13|104-116|concomitantly|O
DDI-DrugBank.d53.s13|117-117|,|O
DDI-DrugBank.d53.s13|119-125|careful|O
DDI-DrugBank.d53.s13|127-136|monitoring|O
DDI-DrugBank.d53.s13|138-139|of|O
DDI-DrugBank.d53.s13|141-148|patients|O
DDI-DrugBank.d53.s13|150-151|is|O
DDI-DrugBank.d53.s13|153-159|advised|O
DDI-DrugBank.d53.s13|160-160|:|O
DDI-DrugBank.d53.s13|162-168|Digoxin|drug
DDI-DrugBank.d53.s13|170-177|elevated|O
DDI-DrugBank.d53.s13|179-185|digoxin|drug
DDI-DrugBank.d53.s13|187-200|concentrations|O
DDI-DrugBank.d53.s13|201-201|.|O
DDI-DrugBank.d53.s14|0-9|Ergotamine|drug
DDI-DrugBank.d53.s14|11-12|or|O
DDI-DrugBank.d53.s14|14-30|dihydroergotamine|drug
DDI-DrugBank.d53.s14|32-36|acute|O
DDI-DrugBank.d53.s14|38-42|ergot|O
DDI-DrugBank.d53.s14|44-51|toxicity|O
DDI-DrugBank.d53.s14|53-65|characterized|O
DDI-DrugBank.d53.s14|67-68|by|O
DDI-DrugBank.d53.s14|70-75|severe|O
DDI-DrugBank.d53.s14|77-86|peripheral|O
DDI-DrugBank.d53.s14|88-96|vasospasm|O
DDI-DrugBank.d53.s14|98-100|and|O
DDI-DrugBank.d53.s14|102-112|dysesthesia|O
DDI-DrugBank.d53.s14|113-113|.|O
DDI-DrugBank.d53.s15|0-11|Cyclosporine|drug
DDI-DrugBank.d53.s15|12-12|,|O
DDI-DrugBank.d53.s15|14-25|hexobarbital|drug
DDI-DrugBank.d53.s15|27-29|and|O
DDI-DrugBank.d53.s15|31-39|phenytoin|drug
DDI-DrugBank.d53.s15|41-54|concentrations|O
DDI-DrugBank.d53.s15|55-55|.|O
DDI-DrugBank.d53.s16|0-9|Laboratory|O
DDI-DrugBank.d53.s16|11-14|Test|O
DDI-DrugBank.d53.s16|16-27|Interactions|O
DDI-DrugBank.d53.s16|29-33|There|O
DDI-DrugBank.d53.s16|35-37|are|O
DDI-DrugBank.d53.s16|39-40|no|O
DDI-DrugBank.d53.s16|42-49|reported|O
DDI-DrugBank.d53.s16|51-60|laboratory|O
DDI-DrugBank.d53.s16|62-65|test|O
DDI-DrugBank.d53.s16|67-78|interactions|O
DDI-DrugBank.d53.s16|79-79|.|O
DDI-DrugBank.d53.s17|0-5|Repeat|O
DDI-DrugBank.d53.s17|7-15|Treatment|O
DDI-DrugBank.d53.s17|17-23|Studies|O
DDI-DrugBank.d53.s17|25-34|evaluating|O
DDI-DrugBank.d53.s17|36-38|the|O
DDI-DrugBank.d53.s17|40-42|use|O
DDI-DrugBank.d53.s17|44-45|of|O
DDI-DrugBank.d53.s17|47-54|repeated|O
DDI-DrugBank.d53.s17|56-62|courses|O
DDI-DrugBank.d53.s17|64-65|of|O
DDI-DrugBank.d53.s17|67-70|Zmax|brand
DDI-DrugBank.d53.s17|72-75|have|O
DDI-DrugBank.d53.s17|77-79|not|O
DDI-DrugBank.d53.s17|81-84|been|O
DDI-DrugBank.d53.s17|86-94|conducted|O
DDI-DrugBank.d53.s17|95-95|.|O
DDI-DrugBank.d653.s0|0-2|The|O
DDI-DrugBank.d653.s0|4-18|pharmacokinetic|O
DDI-DrugBank.d653.s0|20-31|interactions|O
DDI-DrugBank.d653.s0|33-38|listed|O
DDI-DrugBank.d653.s0|40-44|below|O
DDI-DrugBank.d653.s0|46-48|are|O
DDI-DrugBank.d653.s0|50-60|potentially|O
DDI-DrugBank.d653.s0|62-71|clinically|O
DDI-DrugBank.d653.s0|73-81|important|O
DDI-DrugBank.d653.s0|82-82|.|O
DDI-DrugBank.d653.s1|0-4|Drugs|O
DDI-DrugBank.d653.s1|6-9|that|O
DDI-DrugBank.d653.s1|11-16|induce|O
DDI-DrugBank.d653.s1|18-24|hepatic|O
DDI-DrugBank.d653.s1|26-32|enzymes|O
DDI-DrugBank.d653.s1|34-37|such|O
DDI-DrugBank.d653.s1|39-40|as|O
DDI-DrugBank.d653.s1|42-54|phenobarbital|drug
DDI-DrugBank.d653.s1|55-55|,|O
DDI-DrugBank.d653.s1|57-65|phenytoin|drug
DDI-DrugBank.d653.s1|67-69|and|O
DDI-DrugBank.d653.s1|71-78|rifampin|drug
DDI-DrugBank.d653.s1|80-82|may|O
DDI-DrugBank.d653.s1|84-91|increase|O
DDI-DrugBank.d653.s1|93-95|the|O
DDI-DrugBank.d653.s1|97-105|clearance|O
DDI-DrugBank.d653.s1|107-108|of|O
DDI-DrugBank.d653.s1|110-124|corticosteroids|group
DDI-DrugBank.d653.s1|126-128|and|O
DDI-DrugBank.d653.s1|130-132|may|O
DDI-DrugBank.d653.s1|134-140|require|O
DDI-DrugBank.d653.s1|142-150|increases|O
DDI-DrugBank.d653.s1|152-153|in|O
DDI-DrugBank.d653.s1|155-168|corticosteroid|group
DDI-DrugBank.d653.s1|170-173|dose|O
DDI-DrugBank.d653.s1|175-176|to|O
DDI-DrugBank.d653.s1|178-184|achieve|O
DDI-DrugBank.d653.s1|186-188|the|O
DDI-DrugBank.d653.s1|190-196|desired|O
DDI-DrugBank.d653.s1|198-205|response|O
DDI-DrugBank.d653.s1|206-206|.|O
DDI-DrugBank.d653.s2|0-4|Drugs|O
DDI-DrugBank.d653.s2|6-9|such|O
DDI-DrugBank.d653.s2|11-12|as|O
DDI-DrugBank.d653.s2|14-27|troleandomycin|drug
DDI-DrugBank.d653.s2|29-31|and|O
DDI-DrugBank.d653.s2|33-44|ketoconazole|drug
DDI-DrugBank.d653.s2|46-48|may|O
DDI-DrugBank.d653.s2|50-56|inhibit|O
DDI-DrugBank.d653.s2|58-60|the|O
DDI-DrugBank.d653.s2|62-71|metabolism|O
DDI-DrugBank.d653.s2|73-74|of|O
DDI-DrugBank.d653.s2|76-90|corticosteroids|group
DDI-DrugBank.d653.s2|92-94|and|O
DDI-DrugBank.d653.s2|96-99|thus|O
DDI-DrugBank.d653.s2|101-108|decrease|O
DDI-DrugBank.d653.s2|110-114|their|O
DDI-DrugBank.d653.s2|116-124|clearance|O
DDI-DrugBank.d653.s2|125-125|.|O
DDI-DrugBank.d653.s3|0-8|Therefore|O
DDI-DrugBank.d653.s3|9-9|,|O
DDI-DrugBank.d653.s3|11-13|the|O
DDI-DrugBank.d653.s3|15-18|dose|O
DDI-DrugBank.d653.s3|20-21|of|O
DDI-DrugBank.d653.s3|23-36|corticosteroid|group
DDI-DrugBank.d653.s3|38-43|should|O
DDI-DrugBank.d653.s3|45-46|be|O
DDI-DrugBank.d653.s3|48-55|titrated|O
DDI-DrugBank.d653.s3|57-58|to|O
DDI-DrugBank.d653.s3|60-64|avoid|O
DDI-DrugBank.d653.s3|66-72|steroid|O
DDI-DrugBank.d653.s3|74-81|toxicity|O
DDI-DrugBank.d653.s3|82-82|.|O
DDI-DrugBank.d653.s4|0-14|Corticosteroids|group
DDI-DrugBank.d653.s4|16-18|may|O
DDI-DrugBank.d653.s4|20-27|increase|O
DDI-DrugBank.d653.s4|29-31|the|O
DDI-DrugBank.d653.s4|33-41|clearance|O
DDI-DrugBank.d653.s4|43-44|of|O
DDI-DrugBank.d653.s4|46-52|chronic|O
DDI-DrugBank.d653.s4|54-57|high|O
DDI-DrugBank.d653.s4|59-62|dose|O
DDI-DrugBank.d653.s4|64-70|aspirin|brand
DDI-DrugBank.d653.s4|71-71|.|O
DDI-DrugBank.d653.s5|0-3|This|O
DDI-DrugBank.d653.s5|5-9|could|O
DDI-DrugBank.d653.s5|11-14|lead|O
DDI-DrugBank.d653.s5|16-17|to|O
DDI-DrugBank.d653.s5|19-27|decreased|O
DDI-DrugBank.d653.s5|29-38|salicylate|group
DDI-DrugBank.d653.s5|40-44|serum|O
DDI-DrugBank.d653.s5|46-51|levels|O
DDI-DrugBank.d653.s5|53-54|or|O
DDI-DrugBank.d653.s5|56-63|increase|O
DDI-DrugBank.d653.s5|65-67|the|O
DDI-DrugBank.d653.s5|69-72|risk|O
DDI-DrugBank.d653.s5|74-75|of|O
DDI-DrugBank.d653.s5|77-86|salicylate|group
DDI-DrugBank.d653.s5|88-95|toxicity|O
DDI-DrugBank.d653.s5|97-100|when|O
DDI-DrugBank.d653.s5|102-115|corticosteroid|group
DDI-DrugBank.d653.s5|117-118|is|O
DDI-DrugBank.d653.s5|120-128|withdrawn|O
DDI-DrugBank.d653.s5|129-129|.|O
DDI-DrugBank.d653.s6|0-6|Aspirin|brand
DDI-DrugBank.d653.s6|8-13|should|O
DDI-DrugBank.d653.s6|15-16|be|O
DDI-DrugBank.d653.s6|18-21|used|O
DDI-DrugBank.d653.s6|23-32|cautiously|O
DDI-DrugBank.d653.s6|34-35|in|O
DDI-DrugBank.d653.s6|37-47|conjunction|O
DDI-DrugBank.d653.s6|49-52|with|O
DDI-DrugBank.d653.s6|54-68|corticosteroids|group
DDI-DrugBank.d653.s6|70-71|in|O
DDI-DrugBank.d653.s6|73-80|patients|O
DDI-DrugBank.d653.s6|82-90|suffering|O
DDI-DrugBank.d653.s6|92-95|from|O
DDI-DrugBank.d653.s6|97-115|hypoprothrombinemia|O
DDI-DrugBank.d653.s6|116-116|.|O
DDI-DrugBank.d653.s7|0-2|The|O
DDI-DrugBank.d653.s7|4-9|effect|O
DDI-DrugBank.d653.s7|11-12|of|O
DDI-DrugBank.d653.s7|14-28|corticosteroids|group
DDI-DrugBank.d653.s7|30-31|on|O
DDI-DrugBank.d653.s7|33-36|oral|O
DDI-DrugBank.d653.s7|38-51|anticoagulants|group
DDI-DrugBank.d653.s7|53-54|is|O
DDI-DrugBank.d653.s7|56-63|variable|O
DDI-DrugBank.d653.s7|64-64|.|O
DDI-DrugBank.d653.s8|0-4|There|O
DDI-DrugBank.d653.s8|6-8|are|O
DDI-DrugBank.d653.s8|10-16|reports|O
DDI-DrugBank.d653.s8|18-19|of|O
DDI-DrugBank.d653.s8|21-28|enhanced|O
DDI-DrugBank.d653.s8|30-31|as|O
DDI-DrugBank.d653.s8|33-36|well|O
DDI-DrugBank.d653.s8|38-39|as|O
DDI-DrugBank.d653.s8|41-50|diminished|O
DDI-DrugBank.d653.s8|52-58|effects|O
DDI-DrugBank.d653.s8|60-61|of|O
DDI-DrugBank.d653.s8|63-76|anticoagulants|group
DDI-DrugBank.d653.s8|78-81|when|O
DDI-DrugBank.d653.s8|83-87|given|O
DDI-DrugBank.d653.s8|89-100|concurrently|O
DDI-DrugBank.d653.s8|102-105|with|O
DDI-DrugBank.d653.s8|107-121|corticosteroids|group
DDI-DrugBank.d653.s8|122-122|.|O
DDI-DrugBank.d653.s9|0-8|Therefore|O
DDI-DrugBank.d653.s9|9-9|,|O
DDI-DrugBank.d653.s9|11-21|coagulation|O
DDI-DrugBank.d653.s9|23-29|indices|O
DDI-DrugBank.d653.s9|31-36|should|O
DDI-DrugBank.d653.s9|38-39|be|O
DDI-DrugBank.d653.s9|41-49|monitored|O
DDI-DrugBank.d653.s9|51-52|to|O
DDI-DrugBank.d653.s9|54-61|maintain|O
DDI-DrugBank.d653.s9|63-65|the|O
DDI-DrugBank.d653.s9|67-73|desired|O
DDI-DrugBank.d653.s9|75-87|anticoagulant|O
DDI-DrugBank.d653.s9|89-94|effect|O
DDI-DrugBank.d653.s9|95-95|.|O
DDI-MedLine.d218.s0|0-22|Antidepressant-warfarin|group
DDI-MedLine.d218.s0|24-34|interaction|O
DDI-MedLine.d218.s0|36-38|and|O
DDI-MedLine.d218.s0|40-49|associated|O
DDI-MedLine.d218.s0|51-66|gastrointestinal|O
DDI-MedLine.d218.s0|68-75|bleeding|O
DDI-MedLine.d218.s0|77-80|risk|O
DDI-MedLine.d218.s0|82-83|in|O
DDI-MedLine.d218.s0|85-85|a|O
DDI-MedLine.d218.s0|87-98|case-control|O
DDI-MedLine.d218.s0|100-104|study|O
DDI-MedLine.d218.s0|105-105|.|O
DDI-MedLine.d218.s1|0-7|Bleeding|O
DDI-MedLine.d218.s1|9-10|is|O
DDI-MedLine.d218.s1|12-14|the|O
DDI-MedLine.d218.s1|16-19|most|O
DDI-MedLine.d218.s1|21-26|common|O
DDI-MedLine.d218.s1|28-30|and|O
DDI-MedLine.d218.s1|32-40|worrisome|O
DDI-MedLine.d218.s1|42-48|adverse|O
DDI-MedLine.d218.s1|50-55|effect|O
DDI-MedLine.d218.s1|57-58|of|O
DDI-MedLine.d218.s1|60-67|warfarin|drug
DDI-MedLine.d218.s1|69-75|therapy|O
DDI-MedLine.d218.s1|76-76|.|O
DDI-MedLine.d218.s2|0-2|One|O
DDI-MedLine.d218.s2|4-5|of|O
DDI-MedLine.d218.s2|7-9|the|O
DDI-MedLine.d218.s2|11-17|factors|O
DDI-MedLine.d218.s2|19-22|that|O
DDI-MedLine.d218.s2|24-28|might|O
DDI-MedLine.d218.s2|30-37|increase|O
DDI-MedLine.d218.s2|39-46|bleeding|O
DDI-MedLine.d218.s2|48-51|risk|O
DDI-MedLine.d218.s2|53-54|is|O
DDI-MedLine.d218.s2|56-65|initiation|O
DDI-MedLine.d218.s2|67-68|of|O
DDI-MedLine.d218.s2|70-80|interacting|O
DDI-MedLine.d218.s2|82-86|drugs|O
DDI-MedLine.d218.s2|88-91|that|O
DDI-MedLine.d218.s2|93-102|potentiate|O
DDI-MedLine.d218.s2|104-111|warfarin|drug
DDI-MedLine.d218.s2|112-112|.|O
DDI-MedLine.d218.s3|0-1|We|O
DDI-MedLine.d218.s3|3-8|sought|O
DDI-MedLine.d218.s3|10-11|to|O
DDI-MedLine.d218.s3|13-20|evaluate|O
DDI-MedLine.d218.s3|22-28|whether|O
DDI-MedLine.d218.s3|30-39|initiation|O
DDI-MedLine.d218.s3|41-42|of|O
DDI-MedLine.d218.s3|44-45|an|O
DDI-MedLine.d218.s3|47-60|antidepressant|group
DDI-MedLine.d218.s3|62-70|increases|O
DDI-MedLine.d218.s3|72-74|the|O
DDI-MedLine.d218.s3|76-79|risk|O
DDI-MedLine.d218.s3|81-82|of|O
DDI-MedLine.d218.s3|84-98|hospitalization|O
DDI-MedLine.d218.s3|100-102|for|O
DDI-MedLine.d218.s3|104-119|gastrointestinal|O
DDI-MedLine.d218.s3|121-128|bleeding|O
DDI-MedLine.d218.s3|130-131|in|O
DDI-MedLine.d218.s3|133-140|warfarin|drug
DDI-MedLine.d218.s3|142-146|users|O
DDI-MedLine.d218.s3|147-147|.|O
DDI-MedLine.d218.s4|0-7|Medicaid|O
DDI-MedLine.d218.s4|9-14|claims|O
DDI-MedLine.d218.s4|16-19|data|O
DDI-MedLine.d218.s4|21-21|(|O
DDI-MedLine.d218.s4|22-30|1999-2005|O
DDI-MedLine.d218.s4|31-31|)|O
DDI-MedLine.d218.s4|33-36|were|O
DDI-MedLine.d218.s4|38-41|used|O
DDI-MedLine.d218.s4|43-44|to|O
DDI-MedLine.d218.s4|46-52|perform|O
DDI-MedLine.d218.s4|54-55|an|O
DDI-MedLine.d218.s4|57-69|observational|O
DDI-MedLine.d218.s4|71-82|case-control|O
DDI-MedLine.d218.s4|84-88|study|O
DDI-MedLine.d218.s4|90-95|nested|O
DDI-MedLine.d218.s4|97-102|within|O
DDI-MedLine.d218.s4|104-114|person-time|O
DDI-MedLine.d218.s4|116-122|exposed|O
DDI-MedLine.d218.s4|124-125|to|O
DDI-MedLine.d218.s4|127-134|warfarin|drug
DDI-MedLine.d218.s4|136-137|in|O
DDI-MedLine.d218.s4|139-143|those|O
DDI-MedLine.d218.s4|147-148|18|O
DDI-MedLine.d218.s4|150-154|years|O
DDI-MedLine.d218.s4|155-155|.|O
DDI-MedLine.d218.s5|0-1|In|O
DDI-MedLine.d218.s5|3-7|total|O
DDI-MedLine.d218.s5|8-8|,|O
DDI-MedLine.d218.s5|10-16|430,455|O
DDI-MedLine.d218.s5|18-25|warfarin|drug
DDI-MedLine.d218.s5|27-31|users|O
DDI-MedLine.d218.s5|33-43|contributed|O
DDI-MedLine.d218.s5|45-51|407,370|O
DDI-MedLine.d218.s5|53-64|person-years|O
DDI-MedLine.d218.s5|66-67|of|O
DDI-MedLine.d218.s5|69-76|warfarin|drug
DDI-MedLine.d218.s5|78-80|use|O
DDI-MedLine.d218.s5|81-81|.|O
DDI-MedLine.d218.s6|0-2|The|O
DDI-MedLine.d218.s6|4-12|incidence|O
DDI-MedLine.d218.s6|14-17|rate|O
DDI-MedLine.d218.s6|19-20|of|O
DDI-MedLine.d218.s6|22-36|hospitalization|O
DDI-MedLine.d218.s6|38-40|for|O
DDI-MedLine.d218.s6|42-43|GI|O
DDI-MedLine.d218.s6|45-52|bleeding|O
DDI-MedLine.d218.s6|54-58|among|O
DDI-MedLine.d218.s6|60-67|warfarin|drug
DDI-MedLine.d218.s6|69-73|users|O
DDI-MedLine.d218.s6|75-77|was|O
DDI-MedLine.d218.s6|79-82|4.48|O
DDI-MedLine.d218.s6|84-86|per|O
DDI-MedLine.d218.s6|88-90|100|O
DDI-MedLine.d218.s6|92-103|person-years|O
DDI-MedLine.d218.s6|105-105|(|O
DDI-MedLine.d218.s6|106-107|95|O
DDI-MedLine.d218.s6|108-108|%|O
DDI-MedLine.d218.s6|110-111|CI|O
DDI-MedLine.d218.s6|112-112|,|O
DDI-MedLine.d218.s6|114-122|4.42-4.55|O
DDI-MedLine.d218.s6|123-123|)|O
DDI-MedLine.d218.s6|124-124|.|O
DDI-MedLine.d218.s7|0-3|Each|O
DDI-MedLine.d218.s7|5-20|gastrointestinal|O
DDI-MedLine.d218.s7|22-29|bleeding|O
DDI-MedLine.d218.s7|31-35|cases|O
DDI-MedLine.d218.s7|37-39|was|O
DDI-MedLine.d218.s7|41-47|matched|O
DDI-MedLine.d218.s7|49-50|to|O
DDI-MedLine.d218.s7|52-53|50|O
DDI-MedLine.d218.s7|55-62|controls|O
DDI-MedLine.d218.s7|64-68|based|O
DDI-MedLine.d218.s7|70-71|on|O
DDI-MedLine.d218.s7|73-77|index|O
DDI-MedLine.d218.s7|79-82|date|O
DDI-MedLine.d218.s7|84-86|and|O
DDI-MedLine.d218.s7|88-92|state|O
DDI-MedLine.d218.s7|93-93|.|O
DDI-MedLine.d218.s8|0-7|Warfarin|drug
DDI-MedLine.d218.s8|9-13|users|O
DDI-MedLine.d218.s8|15-17|had|O
DDI-MedLine.d218.s8|19-20|an|O
DDI-MedLine.d218.s8|22-30|increased|O
DDI-MedLine.d218.s8|32-35|odds|O
DDI-MedLine.d218.s8|37-41|ratio|O
DDI-MedLine.d218.s8|43-44|of|O
DDI-MedLine.d218.s8|46-61|gastrointestinal|O
DDI-MedLine.d218.s8|63-70|bleeding|O
DDI-MedLine.d218.s8|72-75|upon|O
DDI-MedLine.d218.s8|77-86|initiation|O
DDI-MedLine.d218.s8|88-89|of|O
DDI-MedLine.d218.s8|91-100|citalopram|drug
DDI-MedLine.d218.s8|102-102|(|O
DDI-MedLine.d218.s8|103-104|OR|O
DDI-MedLine.d218.s8|108-108|=|O
DDI-MedLine.d218.s8|112-115|1.73|O
DDI-MedLine.d218.s8|117-117|[|O
DDI-MedLine.d218.s8|118-119|95|O
DDI-MedLine.d218.s8|120-120|%|O
DDI-MedLine.d218.s8|122-123|CI|O
DDI-MedLine.d218.s8|124-124|,|O
DDI-MedLine.d218.s8|126-134|1.25-2.38|O
DDI-MedLine.d218.s8|135-135|]|O
DDI-MedLine.d218.s8|136-136|)|O
DDI-MedLine.d218.s8|137-137|,|O
DDI-MedLine.d218.s8|139-148|fluoxetine|drug
DDI-MedLine.d218.s8|150-150|(|O
DDI-MedLine.d218.s8|151-152|OR|O
DDI-MedLine.d218.s8|156-156|=|O
DDI-MedLine.d218.s8|160-163|1.63|O
DDI-MedLine.d218.s8|165-165|[|O
DDI-MedLine.d218.s8|166-167|95|O
DDI-MedLine.d218.s8|168-168|%|O
DDI-MedLine.d218.s8|170-171|CI|O
DDI-MedLine.d218.s8|172-172|,|O
DDI-MedLine.d218.s8|174-182|1.11-2.38|O
DDI-MedLine.d218.s8|183-183|]|O
DDI-MedLine.d218.s8|184-184|)|O
DDI-MedLine.d218.s8|185-185|,|O
DDI-MedLine.d218.s8|187-196|paroxetine|drug
DDI-MedLine.d218.s8|198-198|(|O
DDI-MedLine.d218.s8|199-200|OR|O
DDI-MedLine.d218.s8|204-204|=|O
DDI-MedLine.d218.s8|208-211|1.64|O
DDI-MedLine.d218.s8|213-213|[|O
DDI-MedLine.d218.s8|214-215|95|O
DDI-MedLine.d218.s8|216-216|%|O
DDI-MedLine.d218.s8|218-219|CI|O
DDI-MedLine.d218.s8|220-220|,|O
DDI-MedLine.d218.s8|222-230|1.27-2.12|O
DDI-MedLine.d218.s8|231-231|]|O
DDI-MedLine.d218.s8|232-232|)|O
DDI-MedLine.d218.s8|233-233|,|O
DDI-MedLine.d218.s8|235-247|amitriptyline|drug
DDI-MedLine.d218.s8|249-249|(|O
DDI-MedLine.d218.s8|250-251|OR|O
DDI-MedLine.d218.s8|255-255|=|O
DDI-MedLine.d218.s8|259-262|1.47|O
DDI-MedLine.d218.s8|264-264|[|O
DDI-MedLine.d218.s8|265-266|95|O
DDI-MedLine.d218.s8|267-267|%|O
DDI-MedLine.d218.s8|269-270|CI|O
DDI-MedLine.d218.s8|271-271|,|O
DDI-MedLine.d218.s8|273-281|1.02-2.11|O
DDI-MedLine.d218.s8|282-282|]|O
DDI-MedLine.d218.s8|283-283|)|O
DDI-MedLine.d218.s8|284-284|.|O
DDI-MedLine.d218.s9|0-3|Also|O
DDI-MedLine.d218.s9|5-15|mirtazapine|drug
DDI-MedLine.d218.s9|16-16|,|O
DDI-MedLine.d218.s9|18-22|which|O
DDI-MedLine.d218.s9|24-25|is|O
DDI-MedLine.d218.s9|27-29|not|O
DDI-MedLine.d218.s9|31-38|believed|O
DDI-MedLine.d218.s9|40-41|to|O
DDI-MedLine.d218.s9|43-50|interact|O
DDI-MedLine.d218.s9|52-55|with|O
DDI-MedLine.d218.s9|57-64|warfarin|drug
DDI-MedLine.d218.s9|65-65|,|O
DDI-MedLine.d218.s9|67-75|increased|O
DDI-MedLine.d218.s9|77-79|the|O
DDI-MedLine.d218.s9|81-84|risk|O
DDI-MedLine.d218.s9|86-87|of|O
DDI-MedLine.d218.s9|89-90|GI|O
DDI-MedLine.d218.s9|92-99|bleeding|O
DDI-MedLine.d218.s9|101-101|(|O
DDI-MedLine.d218.s9|102-103|OR|O
DDI-MedLine.d218.s9|107-107|=|O
DDI-MedLine.d218.s9|111-114|1.75|O
DDI-MedLine.d218.s9|116-116|[|O
DDI-MedLine.d218.s9|117-118|95|O
DDI-MedLine.d218.s9|119-119|%|O
DDI-MedLine.d218.s9|121-122|CI|O
DDI-MedLine.d218.s9|123-123|,|O
DDI-MedLine.d218.s9|125-133|1.30-2.35|O
DDI-MedLine.d218.s9|134-134|]|O
DDI-MedLine.d218.s9|135-135|)|O
DDI-MedLine.d218.s9|136-136|.|O
DDI-MedLine.d218.s10|0-7|Warfarin|drug
DDI-MedLine.d218.s10|9-13|users|O
DDI-MedLine.d218.s10|15-17|who|O
DDI-MedLine.d218.s10|19-27|initiated|O
DDI-MedLine.d218.s10|29-38|citalopram|drug
DDI-MedLine.d218.s10|39-39|,|O
DDI-MedLine.d218.s10|41-50|fluoxetine|drug
DDI-MedLine.d218.s10|51-51|,|O
DDI-MedLine.d218.s10|53-62|paroxetine|drug
DDI-MedLine.d218.s10|63-63|,|O
DDI-MedLine.d218.s10|65-77|amitriptyline|drug
DDI-MedLine.d218.s10|78-78|,|O
DDI-MedLine.d218.s10|80-81|or|O
DDI-MedLine.d218.s10|83-93|mirtazapine|drug
DDI-MedLine.d218.s10|95-97|had|O
DDI-MedLine.d218.s10|99-100|an|O
DDI-MedLine.d218.s10|102-110|increased|O
DDI-MedLine.d218.s10|112-115|risk|O
DDI-MedLine.d218.s10|117-118|of|O
DDI-MedLine.d218.s10|120-134|hospitalization|O
DDI-MedLine.d218.s10|136-138|for|O
DDI-MedLine.d218.s10|140-155|gastrointestinal|O
DDI-MedLine.d218.s10|157-164|bleeding|O
DDI-MedLine.d218.s10|165-165|.|O
DDI-MedLine.d218.s11|0-6|However|O
DDI-MedLine.d218.s11|7-7|,|O
DDI-MedLine.d218.s11|9-11|the|O
DDI-MedLine.d218.s11|13-20|elevated|O
DDI-MedLine.d218.s11|22-25|risk|O
DDI-MedLine.d218.s11|27-30|with|O
DDI-MedLine.d218.s11|32-42|mirtazapine|drug
DDI-MedLine.d218.s11|44-51|suggests|O
DDI-MedLine.d218.s11|53-56|that|O
DDI-MedLine.d218.s11|58-58|a|O
DDI-MedLine.d218.s11|60-68|drug-drug|O
DDI-MedLine.d218.s11|70-80|interaction|O
DDI-MedLine.d218.s11|82-84|may|O
DDI-MedLine.d218.s11|86-88|not|O
DDI-MedLine.d218.s11|90-93|have|O
DDI-MedLine.d218.s11|95-98|been|O
DDI-MedLine.d218.s11|100-110|responsible|O
DDI-MedLine.d218.s11|112-114|for|O
DDI-MedLine.d218.s11|116-118|all|O
DDI-MedLine.d218.s11|120-121|of|O
DDI-MedLine.d218.s11|123-125|the|O
DDI-MedLine.d218.s11|127-134|observed|O
DDI-MedLine.d218.s11|136-144|increased|O
DDI-MedLine.d218.s11|146-149|risk|O
DDI-MedLine.d218.s11|150-150|.|O
DDI-DrugBank.d386.s0|0-0|1|O
DDI-DrugBank.d386.s0|1-1|.|O
DDI-DrugBank.d386.s1|0-4|Drugs|O
DDI-DrugBank.d386.s1|6-16|Metabolized|O
DDI-DrugBank.d386.s1|18-19|by|O
DDI-DrugBank.d386.s1|21-24|P450|O
DDI-DrugBank.d386.s1|26-28|2D6|O
DDI-DrugBank.d386.s1|29-29|:|O
DDI-DrugBank.d386.s1|31-33|The|O
DDI-DrugBank.d386.s1|35-45|biochemical|O
DDI-DrugBank.d386.s1|47-54|activity|O
DDI-DrugBank.d386.s1|56-57|of|O
DDI-DrugBank.d386.s1|59-61|the|O
DDI-DrugBank.d386.s1|63-66|drug|O
DDI-DrugBank.d386.s1|68-79|metabolizing|O
DDI-DrugBank.d386.s1|81-87|isozyme|O
DDI-DrugBank.d386.s1|89-98|cytochrome|O
DDI-DrugBank.d386.s1|100-103|P450|O
DDI-DrugBank.d386.s1|105-107|2D6|O
DDI-DrugBank.d386.s1|109-109|(|O
DDI-DrugBank.d386.s1|110-120|debrisoquin|O
DDI-DrugBank.d386.s1|122-132|hydroxylase|O
DDI-DrugBank.d386.s1|133-133|)|O
DDI-DrugBank.d386.s1|135-136|is|O
DDI-DrugBank.d386.s1|138-144|reduced|O
DDI-DrugBank.d386.s1|146-147|in|O
DDI-DrugBank.d386.s1|149-149|a|O
DDI-DrugBank.d386.s1|151-156|subset|O
DDI-DrugBank.d386.s1|158-159|of|O
DDI-DrugBank.d386.s1|161-163|the|O
DDI-DrugBank.d386.s1|165-173|caucasian|O
DDI-DrugBank.d386.s1|175-184|population|O
DDI-DrugBank.d386.s1|186-186|(|O
DDI-DrugBank.d386.s1|187-191|about|O
DDI-DrugBank.d386.s1|193-193|7|O
DDI-DrugBank.d386.s1|195-196|to|O
DDI-DrugBank.d386.s1|198-199|10|O
DDI-DrugBank.d386.s1|200-200|%|O
DDI-DrugBank.d386.s1|202-203|of|O
DDI-DrugBank.d386.s1|205-214|caucasians|O
DDI-DrugBank.d386.s1|216-218|are|O
DDI-DrugBank.d386.s1|220-221|so|O
DDI-DrugBank.d386.s1|223-228|called|O
DDI-DrugBank.d386.s1|230-233|poor|O
DDI-DrugBank.d386.s1|235-246|metabolizers|O
DDI-DrugBank.d386.s1|247-247|)|O
DDI-DrugBank.d386.s1|248-248|;|O
DDI-DrugBank.d386.s2|0-7|reliable|O
DDI-DrugBank.d386.s2|9-17|estimates|O
DDI-DrugBank.d386.s2|19-20|of|O
DDI-DrugBank.d386.s2|22-24|the|O
DDI-DrugBank.d386.s2|26-35|prevalence|O
DDI-DrugBank.d386.s2|37-38|of|O
DDI-DrugBank.d386.s2|40-46|reduced|O
DDI-DrugBank.d386.s2|48-51|P450|O
DDI-DrugBank.d386.s2|53-55|2D6|O
DDI-DrugBank.d386.s2|57-63|isozyme|O
DDI-DrugBank.d386.s2|65-72|activity|O
DDI-DrugBank.d386.s2|74-78|among|O
DDI-DrugBank.d386.s2|80-84|Asian|O
DDI-DrugBank.d386.s2|85-85|,|O
DDI-DrugBank.d386.s2|87-93|African|O
DDI-DrugBank.d386.s2|95-97|and|O
DDI-DrugBank.d386.s2|99-103|other|O
DDI-DrugBank.d386.s2|105-115|populations|O
DDI-DrugBank.d386.s2|117-119|are|O
DDI-DrugBank.d386.s2|121-123|not|O
DDI-DrugBank.d386.s2|125-127|yet|O
DDI-DrugBank.d386.s2|129-137|available|O
DDI-DrugBank.d386.s2|138-138|.|O
DDI-DrugBank.d386.s3|0-3|Poor|O
DDI-DrugBank.d386.s3|5-16|metabolizers|O
DDI-DrugBank.d386.s3|18-21|have|O
DDI-DrugBank.d386.s3|23-28|higher|O
DDI-DrugBank.d386.s3|30-33|than|O
DDI-DrugBank.d386.s3|35-42|expected|O
DDI-DrugBank.d386.s3|44-49|plasma|O
DDI-DrugBank.d386.s3|51-64|concentrations|O
DDI-DrugBank.d386.s3|66-67|of|O
DDI-DrugBank.d386.s3|69-93|tricyclic antidepressants|group
DDI-DrugBank.d386.s3|95-95|(|O
DDI-DrugBank.d386.s3|96-99|TCAs|group
DDI-DrugBank.d386.s3|100-100|)|O
DDI-DrugBank.d386.s3|102-105|when|O
DDI-DrugBank.d386.s3|107-111|given|O
DDI-DrugBank.d386.s3|113-117|usual|O
DDI-DrugBank.d386.s3|119-123|doses|O
DDI-DrugBank.d386.s3|124-124|.|O
DDI-DrugBank.d386.s4|0-8|Depending|O
DDI-DrugBank.d386.s4|10-11|on|O
DDI-DrugBank.d386.s4|13-15|the|O
DDI-DrugBank.d386.s4|17-24|traction|O
DDI-DrugBank.d386.s4|26-27|of|O
DDI-DrugBank.d386.s4|29-32|drug|O
DDI-DrugBank.d386.s4|34-44|metabolized|O
DDI-DrugBank.d386.s4|46-47|by|O
DDI-DrugBank.d386.s4|49-52|P450|O
DDI-DrugBank.d386.s4|54-56|2D6|O
DDI-DrugBank.d386.s4|57-57|,|O
DDI-DrugBank.d386.s4|59-61|the|O
DDI-DrugBank.d386.s4|63-70|increase|O
DDI-DrugBank.d386.s4|72-73|in|O
DDI-DrugBank.d386.s4|75-80|plasma|O
DDI-DrugBank.d386.s4|82-94|concentration|O
DDI-DrugBank.d386.s4|96-98|may|O
DDI-DrugBank.d386.s4|100-101|be|O
DDI-DrugBank.d386.s4|103-107|small|O
DDI-DrugBank.d386.s4|108-108|,|O
DDI-DrugBank.d386.s4|110-111|or|O
DDI-DrugBank.d386.s4|113-117|quite|O
DDI-DrugBank.d386.s4|119-123|large|O
DDI-DrugBank.d386.s4|125-125|(|O
DDI-DrugBank.d386.s4|126-126|8|O
DDI-DrugBank.d386.s4|128-131|fold|O
DDI-DrugBank.d386.s4|133-140|increase|O
DDI-DrugBank.d386.s4|142-143|in|O
DDI-DrugBank.d386.s4|145-150|plasma|O
DDI-DrugBank.d386.s4|152-154|AUC|O
DDI-DrugBank.d386.s4|156-157|of|O
DDI-DrugBank.d386.s4|159-161|the|O
DDI-DrugBank.d386.s4|163-165|TCA|group
DDI-DrugBank.d386.s4|166-166|)|O
DDI-DrugBank.d386.s4|167-167|.|O
DDI-DrugBank.d386.s5|0-1|In|O
DDI-DrugBank.d386.s5|3-10|addition|O
DDI-DrugBank.d386.s5|11-11|,|O
DDI-DrugBank.d386.s5|13-19|certain|O
DDI-DrugBank.d386.s5|21-25|drugs|O
DDI-DrugBank.d386.s5|27-33|inhibit|O
DDI-DrugBank.d386.s5|35-37|the|O
DDI-DrugBank.d386.s5|39-46|activity|O
DDI-DrugBank.d386.s5|48-49|of|O
DDI-DrugBank.d386.s5|51-54|this|O
DDI-DrugBank.d386.s5|56-62|isozyme|O
DDI-DrugBank.d386.s5|64-66|and|O
DDI-DrugBank.d386.s5|68-71|make|O
DDI-DrugBank.d386.s5|73-78|normal|O
DDI-DrugBank.d386.s5|80-91|metabolizers|O
DDI-DrugBank.d386.s5|93-100|resemble|O
DDI-DrugBank.d386.s5|102-104|p.o|O
DDI-DrugBank.d386.s5|105-105|.|O
DDI-DrugBank.d386.s6|0-11|metabolizers|O
DDI-DrugBank.d386.s6|12-12|.|O
DDI-DrugBank.d386.s7|0-1|An|O
DDI-DrugBank.d386.s7|3-12|individual|O
DDI-DrugBank.d386.s7|14-16|who|O
DDI-DrugBank.d386.s7|18-19|is|O
DDI-DrugBank.d386.s7|21-26|stable|O
DDI-DrugBank.d386.s7|28-29|on|O
DDI-DrugBank.d386.s7|31-31|a|O
DDI-DrugBank.d386.s7|33-37|given|O
DDI-DrugBank.d386.s7|39-42|dose|O
DDI-DrugBank.d386.s7|44-45|of|O
DDI-DrugBank.d386.s7|47-49|TCA|group
DDI-DrugBank.d386.s7|51-53|may|O
DDI-DrugBank.d386.s7|55-60|become|O
DDI-DrugBank.d386.s7|62-69|abruptly|O
DDI-DrugBank.d386.s7|71-75|toxic|O
DDI-DrugBank.d386.s7|77-80|when|O
DDI-DrugBank.d386.s7|82-86|given|O
DDI-DrugBank.d386.s7|88-90|one|O
DDI-DrugBank.d386.s7|92-93|of|O
DDI-DrugBank.d386.s7|95-99|these|O
DDI-DrugBank.d386.s7|101-110|inhibiting|O
DDI-DrugBank.d386.s7|112-116|drugs|O
DDI-DrugBank.d386.s7|118-119|as|O
DDI-DrugBank.d386.s7|121-131|concomitant|O
DDI-DrugBank.d386.s7|133-139|therapy|O
DDI-DrugBank.d386.s7|140-140|.|O
DDI-DrugBank.d386.s8|0-2|The|O
DDI-DrugBank.d386.s8|4-8|drugs|O
DDI-DrugBank.d386.s8|10-13|that|O
DDI-DrugBank.d386.s8|15-21|inhibit|O
DDI-DrugBank.d386.s8|23-32|cytochrome|O
DDI-DrugBank.d386.s8|34-37|P450|O
DDI-DrugBank.d386.s8|39-41|2D6|O
DDI-DrugBank.d386.s8|43-49|include|O
DDI-DrugBank.d386.s8|51-54|some|O
DDI-DrugBank.d386.s8|56-59|that|O
DDI-DrugBank.d386.s8|61-63|are|O
DDI-DrugBank.d386.s8|65-67|not|O
DDI-DrugBank.d386.s8|69-79|metabolized|O
DDI-DrugBank.d386.s8|81-82|by|O
DDI-DrugBank.d386.s8|84-86|the|O
DDI-DrugBank.d386.s8|88-93|enzyme|O
DDI-DrugBank.d386.s8|95-95|(|O
DDI-DrugBank.d386.s8|96-104|quinidine|drug
DDI-DrugBank.d386.s8|105-105|;|O
DDI-DrugBank.d386.s9|0-9|cimetidine|drug
DDI-DrugBank.d386.s9|10-10|)|O
DDI-DrugBank.d386.s9|12-14|and|O
DDI-DrugBank.d386.s9|16-19|many|O
DDI-DrugBank.d386.s9|21-24|that|O
DDI-DrugBank.d386.s9|26-28|are|O
DDI-DrugBank.d386.s9|30-39|substrates|O
DDI-DrugBank.d386.s9|41-43|for|O
DDI-DrugBank.d386.s9|45-48|P450|O
DDI-DrugBank.d386.s9|50-52|2D6|O
DDI-DrugBank.d386.s9|54-54|(|O
DDI-DrugBank.d386.s9|55-58|many|O
DDI-DrugBank.d386.s9|60-64|other|O
DDI-DrugBank.d386.s9|66-80|antidepressants|group
DDI-DrugBank.d386.s9|81-81|,|O
DDI-DrugBank.d386.s9|83-96|phenothiazines|group
DDI-DrugBank.d386.s9|97-97|,|O
DDI-DrugBank.d386.s9|99-101|and|O
DDI-DrugBank.d386.s9|103-105|the|O
DDI-DrugBank.d386.s9|107-110|Type|O
DDI-DrugBank.d386.s9|112-113|1C|O
DDI-DrugBank.d386.s9|115-130|antiarrhythrnics|O
DDI-DrugBank.d386.s9|132-142|propatenone|O
DDI-DrugBank.d386.s9|144-146|and|O
DDI-DrugBank.d386.s9|148-157|flecainide|drug
DDI-DrugBank.d386.s9|158-158|)|O
DDI-DrugBank.d386.s9|159-159|.|O
DDI-DrugBank.d386.s10|0-4|While|O
DDI-DrugBank.d386.s10|6-8|all|O
DDI-DrugBank.d386.s10|10-12|the|O
DDI-DrugBank.d386.s10|14-52|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d386.s10|54-54|(|O
DDI-DrugBank.d386.s10|55-59|SSRIs|group
DDI-DrugBank.d386.s10|60-60|)|O
DDI-DrugBank.d386.s10|61-61|,|O
DDI-DrugBank.d386.s10|63-66|e.g.|O
DDI-DrugBank.d386.s10|67-67|,|O
DDI-DrugBank.d386.s10|69-78|fluoxetine|drug
DDI-DrugBank.d386.s10|79-79|,|O
DDI-DrugBank.d386.s10|81-90|seriraline|O
DDI-DrugBank.d386.s10|91-91|,|O
DDI-DrugBank.d386.s10|93-95|and|O
DDI-DrugBank.d386.s10|97-106|paroxetine|drug
DDI-DrugBank.d386.s10|107-107|,|O
DDI-DrugBank.d386.s10|109-115|inhibit|O
DDI-DrugBank.d386.s10|117-120|P450|O
DDI-DrugBank.d386.s10|122-124|2D6|O
DDI-DrugBank.d386.s10|125-125|,|O
DDI-DrugBank.d386.s10|127-130|they|O
DDI-DrugBank.d386.s10|132-134|may|O
DDI-DrugBank.d386.s10|136-139|vary|O
DDI-DrugBank.d386.s10|141-142|in|O
DDI-DrugBank.d386.s10|144-146|the|O
DDI-DrugBank.d386.s10|148-153|extent|O
DDI-DrugBank.d386.s10|155-156|of|O
DDI-DrugBank.d386.s10|158-167|inhibition|O
DDI-DrugBank.d386.s10|168-168|.|O
DDI-DrugBank.d386.s11|0-2|The|O
DDI-DrugBank.d386.s11|4-9|extent|O
DDI-DrugBank.d386.s11|11-12|to|O
DDI-DrugBank.d386.s11|14-18|which|O
DDI-DrugBank.d386.s11|20-27|SSRI-TCA|group
DDI-DrugBank.d386.s11|29-40|interactions|O
DDI-DrugBank.d386.s11|42-44|may|O
DDI-DrugBank.d386.s11|46-49|pose|O
DDI-DrugBank.d386.s11|51-58|clinical|O
DDI-DrugBank.d386.s11|60-67|problems|O
DDI-DrugBank.d386.s11|69-72|will|O
DDI-DrugBank.d386.s11|74-79|depend|O
DDI-DrugBank.d386.s11|81-82|on|O
DDI-DrugBank.d386.s11|84-86|the|O
DDI-DrugBank.d386.s11|88-93|degree|O
DDI-DrugBank.d386.s11|95-96|of|O
DDI-DrugBank.d386.s11|98-107|inhibition|O
DDI-DrugBank.d386.s11|109-111|and|O
DDI-DrugBank.d386.s11|113-115|the|O
DDI-DrugBank.d386.s11|117-132|pharmacokinetics|O
DDI-DrugBank.d386.s11|134-135|of|O
DDI-DrugBank.d386.s11|137-139|the|O
DDI-DrugBank.d386.s11|141-144|SSRI|group
DDI-DrugBank.d386.s11|146-153|involved|O
DDI-DrugBank.d386.s11|154-154|.|O
DDI-DrugBank.d386.s12|0-11|Nevertheless|O
DDI-DrugBank.d386.s12|12-12|,|O
DDI-DrugBank.d386.s12|14-20|caution|O
DDI-DrugBank.d386.s12|22-23|is|O
DDI-DrugBank.d386.s12|25-33|indicated|O
DDI-DrugBank.d386.s12|35-36|in|O
DDI-DrugBank.d386.s12|38-40|the|O
DDI-DrugBank.d386.s12|42-58|co-administration|O
DDI-DrugBank.d386.s12|60-61|of|O
DDI-DrugBank.d386.s12|63-66|T.A.|group
DDI-DrugBank.d386.s12|68-71|with|O
DDI-DrugBank.d386.s12|73-75|any|O
DDI-DrugBank.d386.s12|77-78|of|O
DDI-DrugBank.d386.s12|80-82|the|O
DDI-DrugBank.d386.s12|84-88|SSRIs|group
DDI-DrugBank.d386.s12|90-92|and|O
DDI-DrugBank.d386.s12|94-97|also|O
DDI-DrugBank.d386.s12|99-100|in|O
DDI-DrugBank.d386.s12|102-110|switching|O
DDI-DrugBank.d386.s12|112-115|from|O
DDI-DrugBank.d386.s12|117-119|one|O
DDI-DrugBank.d386.s12|121-125|class|O
DDI-DrugBank.d386.s12|127-128|to|O
DDI-DrugBank.d386.s12|130-132|the|O
DDI-DrugBank.d386.s12|134-138|other|O
DDI-DrugBank.d386.s12|139-139|.|O
DDI-DrugBank.d386.s13|0-1|Of|O
DDI-DrugBank.d386.s13|3-12|particular|O
DDI-DrugBank.d386.s13|14-23|importance|O
DDI-DrugBank.d386.s13|24-24|,|O
DDI-DrugBank.d386.s13|26-35|sufficient|O
DDI-DrugBank.d386.s13|37-40|time|O
DDI-DrugBank.d386.s13|42-45|must|O
DDI-DrugBank.d386.s13|47-52|elapse|O
DDI-DrugBank.d386.s13|54-59|before|O
DDI-DrugBank.d386.s13|61-70|initiating|O
DDI-DrugBank.d386.s13|72-74|TCA|O
DDI-DrugBank.d386.s13|76-84|treatment|O
DDI-DrugBank.d386.s13|86-87|in|O
DDI-DrugBank.d386.s13|89-89|a|O
DDI-DrugBank.d386.s13|91-97|patient|O
DDI-DrugBank.d386.s13|99-103|being|O
DDI-DrugBank.d386.s13|105-113|withdrawn|O
DDI-DrugBank.d386.s13|115-118|from|O
DDI-DrugBank.d386.s13|120-129|fluoxetine|drug
DDI-DrugBank.d386.s13|130-130|,|O
DDI-DrugBank.d386.s13|132-136|given|O
DDI-DrugBank.d386.s13|138-140|the|O
DDI-DrugBank.d386.s13|142-145|long|O
DDI-DrugBank.d386.s13|147-155|half-life|O
DDI-DrugBank.d386.s13|157-158|of|O
DDI-DrugBank.d386.s13|160-162|the|O
DDI-DrugBank.d386.s13|164-169|parent|O
DDI-DrugBank.d386.s13|171-173|and|O
DDI-DrugBank.d386.s13|175-180|active|O
DDI-DrugBank.d386.s13|182-191|metabolite|O
DDI-DrugBank.d386.s13|193-193|(|O
DDI-DrugBank.d386.s13|194-195|at|O
DDI-DrugBank.d386.s13|197-201|least|O
DDI-DrugBank.d386.s13|203-203|5|O
DDI-DrugBank.d386.s13|205-209|weeks|O
DDI-DrugBank.d386.s13|211-213|may|O
DDI-DrugBank.d386.s13|215-216|be|O
DDI-DrugBank.d386.s13|218-226|necessary|O
DDI-DrugBank.d386.s13|227-227|)|O
DDI-DrugBank.d386.s13|228-228|.|O
DDI-DrugBank.d386.s14|0-10|Concomitant|O
DDI-DrugBank.d386.s14|12-14|use|O
DDI-DrugBank.d386.s14|16-17|of|O
DDI-DrugBank.d386.s14|19-43|tricyclic antidepressants|group
DDI-DrugBank.d386.s14|45-48|with|O
DDI-DrugBank.d386.s14|50-54|drugs|O
DDI-DrugBank.d386.s14|56-59|that|O
DDI-DrugBank.d386.s14|61-63|can|O
DDI-DrugBank.d386.s14|65-71|inhibit|O
DDI-DrugBank.d386.s14|73-82|cytochrome|O
DDI-DrugBank.d386.s14|84-87|P450|O
DDI-DrugBank.d386.s14|89-91|2D6|O
DDI-DrugBank.d386.s14|93-95|may|O
DDI-DrugBank.d386.s14|97-103|require|O
DDI-DrugBank.d386.s14|105-109|lower|O
DDI-DrugBank.d386.s14|111-115|doses|O
DDI-DrugBank.d386.s14|117-120|than|O
DDI-DrugBank.d386.s14|122-128|usually|O
DDI-DrugBank.d386.s14|130-139|prescribed|O
DDI-DrugBank.d386.s14|141-143|for|O
DDI-DrugBank.d386.s14|145-150|either|O
DDI-DrugBank.d386.s14|152-154|the|O
DDI-DrugBank.d386.s14|156-179|tricyclic antidepressant|group
DDI-DrugBank.d386.s14|181-182|or|O
DDI-DrugBank.d386.s14|184-186|the|O
DDI-DrugBank.d386.s14|188-192|other|O
DDI-DrugBank.d386.s14|194-197|drug|O
DDI-DrugBank.d386.s14|198-198|.|O
DDI-DrugBank.d386.s15|0-10|Furthermore|O
DDI-DrugBank.d386.s15|11-11|,|O
DDI-DrugBank.d386.s15|13-20|whenever|O
DDI-DrugBank.d386.s15|22-24|one|O
DDI-DrugBank.d386.s15|26-27|of|O
DDI-DrugBank.d386.s15|29-33|these|O
DDI-DrugBank.d386.s15|35-39|other|O
DDI-DrugBank.d386.s15|41-45|drugs|O
DDI-DrugBank.d386.s15|47-48|is|O
DDI-DrugBank.d386.s15|50-58|withdrawn|O
DDI-DrugBank.d386.s15|60-63|from|O
DDI-DrugBank.d386.s15|65-74|co-therapy|O
DDI-DrugBank.d386.s15|75-75|,|O
DDI-DrugBank.d386.s15|77-78|an|O
DDI-DrugBank.d386.s15|80-88|increased|O
DDI-DrugBank.d386.s15|90-93|dose|O
DDI-DrugBank.d386.s15|95-96|of|O
DDI-DrugBank.d386.s15|98-121|tricyclic antidepressant|group
DDI-DrugBank.d386.s15|123-125|may|O
DDI-DrugBank.d386.s15|127-128|be|O
DDI-DrugBank.d386.s15|130-137|required|O
DDI-DrugBank.d386.s15|138-138|.|O
DDI-DrugBank.d386.s16|0-1|It|O
DDI-DrugBank.d386.s16|3-4|is|O
DDI-DrugBank.d386.s16|6-14|desirable|O
DDI-DrugBank.d386.s16|16-17|to|O
DDI-DrugBank.d386.s16|19-25|monitor|O
DDI-DrugBank.d386.s16|27-29|TCA|group
DDI-DrugBank.d386.s16|31-36|plasma|O
DDI-DrugBank.d386.s16|38-43|levels|O
DDI-DrugBank.d386.s16|45-52|whenever|O
DDI-DrugBank.d386.s16|54-54|a|O
DDI-DrugBank.d386.s16|56-58|TCA|group
DDI-DrugBank.d386.s16|60-61|is|O
DDI-DrugBank.d386.s16|63-67|going|O
DDI-DrugBank.d386.s16|69-70|to|O
DDI-DrugBank.d386.s16|72-73|be|O
DDI-DrugBank.d386.s16|75-89|co-administered|O
DDI-DrugBank.d386.s16|91-94|with|O
DDI-DrugBank.d386.s16|96-102|another|O
DDI-DrugBank.d386.s16|104-107|drug|O
DDI-DrugBank.d386.s16|109-113|known|O
DDI-DrugBank.d386.s16|115-116|to|O
DDI-DrugBank.d386.s16|118-119|be|O
DDI-DrugBank.d386.s16|121-122|an|O
DDI-DrugBank.d386.s16|124-132|inhibitor|O
DDI-DrugBank.d386.s16|134-135|of|O
DDI-DrugBank.d386.s16|137-140|P450|O
DDI-DrugBank.d386.s16|142-144|2D6|O
DDI-DrugBank.d386.s16|145-145|.|O
DDI-DrugBank.d386.s17|0-0|2|O
DDI-DrugBank.d386.s17|1-1|.|O
DDI-DrugBank.d386.s18|0-4|Close|O
DDI-DrugBank.d386.s18|6-16|supervision|O
DDI-DrugBank.d386.s18|18-20|and|O
DDI-DrugBank.d386.s18|22-28|careful|O
DDI-DrugBank.d386.s18|30-39|adjustment|O
DDI-DrugBank.d386.s18|41-42|of|O
DDI-DrugBank.d386.s18|44-49|dosage|O
DDI-DrugBank.d386.s18|51-53|are|O
DDI-DrugBank.d386.s18|55-62|required|O
DDI-DrugBank.d386.s18|64-67|when|O
DDI-DrugBank.d386.s18|69-72|this|O
DDI-DrugBank.d386.s18|74-77|drug|O
DDI-DrugBank.d386.s18|79-80|is|O
DDI-DrugBank.d386.s18|82-86|given|O
DDI-DrugBank.d386.s18|88-100|concomitantly|O
DDI-DrugBank.d386.s18|102-105|with|O
DDI-DrugBank.d386.s18|107-121|anticholinergic|group
DDI-DrugBank.d386.s18|123-124|or|O
DDI-DrugBank.d386.s18|126-146|sympathomimetic drugs|group
DDI-DrugBank.d386.s18|147-147|.|O
DDI-DrugBank.d386.s19|0-0|3|O
DDI-DrugBank.d386.s19|1-1|.|O
DDI-DrugBank.d386.s20|0-7|Clinical|O
DDI-DrugBank.d386.s20|9-18|experience|O
DDI-DrugBank.d386.s20|20-21|in|O
DDI-DrugBank.d386.s20|23-25|the|O
DDI-DrugBank.d386.s20|27-36|concurrent|O
DDI-DrugBank.d386.s20|38-51|administration|O
DDI-DrugBank.d386.s20|53-54|of|O
DDI-DrugBank.d386.s20|56-58|ECT|O
DDI-DrugBank.d386.s20|60-62|and|O
DDI-DrugBank.d386.s20|64-83|antidepressant drugs|group
DDI-DrugBank.d386.s20|85-86|is|O
DDI-DrugBank.d386.s20|88-94|limited|O
DDI-DrugBank.d386.s20|95-95|.|O
DDI-DrugBank.d386.s21|0-3|Thus|O
DDI-DrugBank.d386.s21|4-4|,|O
DDI-DrugBank.d386.s21|6-7|if|O
DDI-DrugBank.d386.s21|9-12|such|O
DDI-DrugBank.d386.s21|14-22|treatment|O
DDI-DrugBank.d386.s21|24-25|is|O
DDI-DrugBank.d386.s21|27-35|essential|O
DDI-DrugBank.d386.s21|36-36|,|O
DDI-DrugBank.d386.s21|38-40|the|O
DDI-DrugBank.d386.s21|42-52|possibility|O
DDI-DrugBank.d386.s21|54-55|of|O
DDI-DrugBank.d386.s21|57-65|increased|O
DDI-DrugBank.d386.s21|67-70|risk|O
DDI-DrugBank.d386.s21|72-79|relative|O
DDI-DrugBank.d386.s21|81-82|to|O
DDI-DrugBank.d386.s21|84-91|benefits|O
DDI-DrugBank.d386.s21|93-98|should|O
DDI-DrugBank.d386.s21|100-101|be|O
DDI-DrugBank.d386.s21|103-112|considered|O
DDI-DrugBank.d386.s21|113-113|.|O
DDI-DrugBank.d386.s22|0-0|4|O
DDI-DrugBank.d386.s22|1-1|.|O
DDI-DrugBank.d386.s23|0-1|If|O
DDI-DrugBank.d386.s23|3-27|desipramine hydrochloride|drug
DDI-DrugBank.d386.s23|29-30|is|O
DDI-DrugBank.d386.s23|32-33|to|O
DDI-DrugBank.d386.s23|35-36|be|O
DDI-DrugBank.d386.s23|38-45|combined|O
DDI-DrugBank.d386.s23|47-50|with|O
DDI-DrugBank.d386.s23|52-56|other|O
DDI-DrugBank.d386.s23|58-76|psychotropic agents|group
DDI-DrugBank.d386.s23|78-81|such|O
DDI-DrugBank.d386.s23|83-84|as|O
DDI-DrugBank.d386.s23|86-98|tranquilizers|group
DDI-DrugBank.d386.s23|100-101|or|O
DDI-DrugBank.d386.s23|103-120|sedative/hypnotics|group
DDI-DrugBank.d386.s23|121-121|,|O
DDI-DrugBank.d386.s23|123-129|careful|O
DDI-DrugBank.d386.s23|131-143|consideration|O
DDI-DrugBank.d386.s23|145-150|should|O
DDI-DrugBank.d386.s23|152-153|be|O
DDI-DrugBank.d386.s23|155-159|given|O
DDI-DrugBank.d386.s23|161-162|to|O
DDI-DrugBank.d386.s23|164-166|the|O
DDI-DrugBank.d386.s23|168-179|pharmacology|O
DDI-DrugBank.d386.s23|181-182|of|O
DDI-DrugBank.d386.s23|184-186|the|O
DDI-DrugBank.d386.s23|188-193|agents|O
DDI-DrugBank.d386.s23|195-202|employed|O
DDI-DrugBank.d386.s23|204-208|since|O
DDI-DrugBank.d386.s23|210-212|the|O
DDI-DrugBank.d386.s23|214-221|sedative|O
DDI-DrugBank.d386.s23|223-229|effects|O
DDI-DrugBank.d386.s23|231-232|of|O
DDI-DrugBank.d386.s23|234-244|desipramine|drug
DDI-DrugBank.d386.s23|246-248|and|O
DDI-DrugBank.d386.s23|250-264|benzodiazepines|group
DDI-DrugBank.d386.s23|266-266|(|O
DDI-DrugBank.d386.s23|267-270|e.g.|O
DDI-DrugBank.d386.s23|271-271|,|O
DDI-DrugBank.d386.s23|273-288|chlordiazepoxide|drug
DDI-DrugBank.d386.s23|290-291|or|O
DDI-DrugBank.d386.s23|293-300|diazepam|drug
DDI-DrugBank.d386.s23|301-301|)|O
DDI-DrugBank.d386.s23|303-305|are|O
DDI-DrugBank.d386.s23|307-314|additive|O
DDI-DrugBank.d386.s23|315-315|.|O
DDI-DrugBank.d386.s24|0-3|Both|O
DDI-DrugBank.d386.s24|5-7|the|O
DDI-DrugBank.d386.s24|9-16|sedative|O
DDI-DrugBank.d386.s24|18-20|and|O
DDI-DrugBank.d386.s24|22-36|anticholinergic|O
DDI-DrugBank.d386.s24|38-44|effects|O
DDI-DrugBank.d386.s24|46-47|of|O
DDI-DrugBank.d386.s24|49-51|the|O
DDI-DrugBank.d386.s24|53-71|major tranquilizers|group
DDI-DrugBank.d386.s24|73-75|are|O
DDI-DrugBank.d386.s24|77-80|also|O
DDI-DrugBank.d386.s24|82-89|additive|O
DDI-DrugBank.d386.s24|91-92|to|O
DDI-DrugBank.d386.s24|94-98|those|O
DDI-DrugBank.d386.s24|100-101|of|O
DDI-DrugBank.d386.s24|103-113|desipramine|drug
DDI-DrugBank.d386.s24|114-114|.|O
DDI-DrugBank.d386.s25|0-0|5|O
DDI-DrugBank.d386.s25|1-1|.|O
DDI-DrugBank.d386.s26|0-9|Concurrent|O
DDI-DrugBank.d386.s26|11-24|administration|O
DDI-DrugBank.d386.s26|26-27|of|O
DDI-DrugBank.d386.s26|29-38|cimetidine|drug
DDI-DrugBank.d386.s26|40-42|and|O
DDI-DrugBank.d386.s26|44-68|tricyclic antidepressants|group
DDI-DrugBank.d386.s26|70-72|can|O
DDI-DrugBank.d386.s26|74-80|produce|O
DDI-DrugBank.d386.s26|82-91|clinically|O
DDI-DrugBank.d386.s26|93-103|significant|O
DDI-DrugBank.d386.s26|105-113|increases|O
DDI-DrugBank.d386.s26|115-116|in|O
DDI-DrugBank.d386.s26|118-120|the|O
DDI-DrugBank.d386.s26|122-127|plasma|O
DDI-DrugBank.d386.s26|129-134|levels|O
DDI-DrugBank.d386.s26|136-137|of|O
DDI-DrugBank.d386.s26|139-141|the|O
DDI-DrugBank.d386.s26|143-167|tricyclic antidepressants|group
DDI-DrugBank.d386.s26|168-168|.|O
DDI-DrugBank.d386.s27|0-9|Conversely|O
DDI-DrugBank.d386.s27|10-10|,|O
DDI-DrugBank.d386.s27|12-20|decreases|O
DDI-DrugBank.d386.s27|22-23|in|O
DDI-DrugBank.d386.s27|25-30|plasma|O
DDI-DrugBank.d386.s27|32-37|levels|O
DDI-DrugBank.d386.s27|39-40|of|O
DDI-DrugBank.d386.s27|42-44|the|O
DDI-DrugBank.d386.s27|46-70|tricyclic antidepressants|group
DDI-DrugBank.d386.s27|72-75|have|O
DDI-DrugBank.d386.s27|77-80|been|O
DDI-DrugBank.d386.s27|82-89|reported|O
DDI-DrugBank.d386.s27|91-94|upon|O
DDI-DrugBank.d386.s27|96-110|discontinuation|O
DDI-DrugBank.d386.s27|112-113|of|O
DDI-DrugBank.d386.s27|115-124|cimetidine|drug
DDI-DrugBank.d386.s27|126-130|which|O
DDI-DrugBank.d386.s27|132-134|may|O
DDI-DrugBank.d386.s27|136-141|result|O
DDI-DrugBank.d386.s27|143-144|in|O
DDI-DrugBank.d386.s27|146-148|the|O
DDI-DrugBank.d386.s27|150-153|loss|O
DDI-DrugBank.d386.s27|155-156|of|O
DDI-DrugBank.d386.s27|158-160|the|O
DDI-DrugBank.d386.s27|162-172|therapeutic|O
DDI-DrugBank.d386.s27|174-181|efficacy|O
DDI-DrugBank.d386.s27|183-184|of|O
DDI-DrugBank.d386.s27|186-188|the|O
DDI-DrugBank.d386.s27|190-213|tricyclic antidepressant|group
DDI-DrugBank.d386.s27|215-215|6|O
DDI-DrugBank.d386.s27|216-216|.|O
DDI-DrugBank.d386.s28|0-4|There|O
DDI-DrugBank.d386.s28|6-9|have|O
DDI-DrugBank.d386.s28|11-14|been|O
DDI-DrugBank.d386.s28|16-22|greater|O
DDI-DrugBank.d386.s28|24-27|than|O
DDI-DrugBank.d386.s28|29-36|two-fold|O
DDI-DrugBank.d386.s28|38-46|increases|O
DDI-DrugBank.d386.s28|48-49|of|O
DDI-DrugBank.d386.s28|51-60|previously|O
DDI-DrugBank.d386.s28|62-67|stable|O
DDI-DrugBank.d386.s28|69-74|plasma|O
DDI-DrugBank.d386.s28|76-81|levels|O
DDI-DrugBank.d386.s28|83-84|of|O
DDI-DrugBank.d386.s28|86-110|tricyclic antidepressants|group
DDI-DrugBank.d386.s28|112-115|when|O
DDI-DrugBank.d386.s28|117-126|fluoxetine|drug
DDI-DrugBank.d386.s28|128-130|has|O
DDI-DrugBank.d386.s28|132-135|been|O
DDI-DrugBank.d386.s28|137-148|administered|O
DDI-DrugBank.d386.s28|150-151|in|O
DDI-DrugBank.d386.s28|153-163|combination|O
DDI-DrugBank.d386.s28|165-168|with|O
DDI-DrugBank.d386.s28|170-174|these|O
DDI-DrugBank.d386.s28|176-181|agents|O
DDI-DrugBank.d386.s28|182-182|.|O
DDI-DrugBank.d436.s0|0-1|No|O
DDI-DrugBank.d436.s0|3-6|drug|O
DDI-DrugBank.d436.s0|7-7|,|O
DDI-DrugBank.d436.s0|9-19|nutritional|O
DDI-DrugBank.d436.s0|21-30|supplement|O
DDI-DrugBank.d436.s0|31-31|,|O
DDI-DrugBank.d436.s0|33-36|food|O
DDI-DrugBank.d436.s0|38-39|or|O
DDI-DrugBank.d436.s0|41-44|herb|O
DDI-DrugBank.d436.s0|46-57|interactions|O
DDI-DrugBank.d436.s0|59-62|have|O
DDI-DrugBank.d436.s0|64-66|yet|O
DDI-DrugBank.d436.s0|68-71|been|O
DDI-DrugBank.d436.s0|73-80|reported|O
DDI-DrugBank.d436.s0|81-81|.|O
DDI-MedLine.d200.s0|0-0|[|O
DDI-MedLine.d200.s0|1-8|Efficacy|O
DDI-MedLine.d200.s0|10-11|of|O
DDI-MedLine.d200.s0|13-17|fixed|O
DDI-MedLine.d200.s0|19-29|combination|O
DDI-MedLine.d200.s0|31-50|amlodipine/valsartan|drug
DDI-MedLine.d200.s0|52-53|in|O
DDI-MedLine.d200.s0|55-66|hospitalized|O
DDI-MedLine.d200.s0|68-75|patients|O
DDI-MedLine.d200.s0|77-80|with|O
DDI-MedLine.d200.s0|82-93|hypertensive|O
DDI-MedLine.d200.s0|95-101|disease|O
DDI-MedLine.d200.s0|102-102|]|O
DDI-MedLine.d200.s1|0-7|Efficacy|O
DDI-MedLine.d200.s1|9-11|and|O
DDI-MedLine.d200.s1|13-24|tolerability|O
DDI-MedLine.d200.s1|26-27|of|O
DDI-MedLine.d200.s1|29-33|fixed|O
DDI-MedLine.d200.s1|35-54|amlodipine/valsartan|drug
DDI-MedLine.d200.s1|56-66|combination|O
DDI-MedLine.d200.s1|68-70|was|O
DDI-MedLine.d200.s1|72-78|studied|O
DDI-MedLine.d200.s1|80-81|in|O
DDI-MedLine.d200.s1|83-84|86|O
DDI-MedLine.d200.s1|86-93|patients|O
DDI-MedLine.d200.s1|95-98|with|O
DDI-MedLine.d200.s1|100-111|hypertensive|O
DDI-MedLine.d200.s1|113-119|disease|O
DDI-MedLine.d200.s1|121-132|hospitalized|O
DDI-MedLine.d200.s1|134-135|in|O
DDI-MedLine.d200.s1|137-147|departments|O
DDI-MedLine.d200.s1|149-150|of|O
DDI-MedLine.d200.s1|152-158|general|O
DDI-MedLine.d200.s1|160-167|internal|O
DDI-MedLine.d200.s1|169-176|medicine|O
DDI-MedLine.d200.s1|178-179|or|O
DDI-MedLine.d200.s1|181-190|cardiology|O
DDI-MedLine.d200.s1|191-191|.|O
DDI-MedLine.d200.s2|0-2|All|O
DDI-MedLine.d200.s2|4-11|patients|O
DDI-MedLine.d200.s2|13-15|had|O
DDI-MedLine.d200.s2|17-27|indications|O
DDI-MedLine.d200.s2|29-31|for|O
DDI-MedLine.d200.s2|33-48|antihypertensive|O
DDI-MedLine.d200.s2|50-56|therapy|O
DDI-MedLine.d200.s2|58-60|and|O
DDI-MedLine.d200.s2|62-65|were|O
DDI-MedLine.d200.s2|67-76|randomized|O
DDI-MedLine.d200.s2|78-83|either|O
DDI-MedLine.d200.s2|85-86|to|O
DDI-MedLine.d200.s2|88-92|fixed|O
DDI-MedLine.d200.s2|94-104|combination|O
DDI-MedLine.d200.s2|106-125|amlodipine/valsartan|drug
DDI-MedLine.d200.s2|127-127|(|O
DDI-MedLine.d200.s2|128-131|n=43|O
DDI-MedLine.d200.s2|132-132|)|O
DDI-MedLine.d200.s2|134-135|or|O
DDI-MedLine.d200.s2|137-138|to|O
DDI-MedLine.d200.s2|140-146|therapy|O
DDI-MedLine.d200.s2|148-152|which|O
DDI-MedLine.d200.s2|154-165|corresponded|O
DDI-MedLine.d200.s2|167-168|to|O
DDI-MedLine.d200.s2|170-172|the|O
DDI-MedLine.d200.s2|174-181|hospital|O
DDI-MedLine.d200.s2|183-191|formulary|O
DDI-MedLine.d200.s2|193-193|(|O
DDI-MedLine.d200.s2|194-197|n=43|O
DDI-MedLine.d200.s2|198-198|)|O
DDI-MedLine.d200.s2|199-199|.|O
DDI-MedLine.d200.s3|0-9|Correction|O
DDI-MedLine.d200.s3|11-12|of|O
DDI-MedLine.d200.s3|14-29|antihypertensive|group
DDI-MedLine.d200.s3|31-37|therapy|O
DDI-MedLine.d200.s3|39-41|was|O
DDI-MedLine.d200.s3|43-51|performed|O
DDI-MedLine.d200.s3|53-54|by|O
DDI-MedLine.d200.s3|56-63|treating|O
DDI-MedLine.d200.s3|65-73|physician|O
DDI-MedLine.d200.s3|75-76|at|O
DDI-MedLine.d200.s3|78-82|daily|O
DDI-MedLine.d200.s3|84-89|rounds|O
DDI-MedLine.d200.s3|90-90|.|O
DDI-MedLine.d200.s4|0-11|Self-control|O
DDI-MedLine.d200.s4|13-14|of|O
DDI-MedLine.d200.s4|16-20|blood|O
DDI-MedLine.d200.s4|22-29|pressure|O
DDI-MedLine.d200.s4|31-31|(|O
DDI-MedLine.d200.s4|32-33|BP|O
DDI-MedLine.d200.s4|34-34|)|O
DDI-MedLine.d200.s4|36-38|was|O
DDI-MedLine.d200.s4|40-48|performed|O
DDI-MedLine.d200.s4|50-51|by|O
DDI-MedLine.d200.s4|53-60|patients|O
DDI-MedLine.d200.s4|62-65|with|O
DDI-MedLine.d200.s4|67-69|the|O
DDI-MedLine.d200.s4|71-73|use|O
DDI-MedLine.d200.s4|75-76|of|O
DDI-MedLine.d200.s4|78-84|UA767PC|O
DDI-MedLine.d200.s4|86-94|apparatus|O
DDI-MedLine.d200.s4|95-95|.|O
DDI-MedLine.d200.s5|0-6|Results|O
DDI-MedLine.d200.s5|8-9|of|O
DDI-MedLine.d200.s5|11-12|BP|O
DDI-MedLine.d200.s5|14-25|self-control|O
DDI-MedLine.d200.s5|27-30|were|O
DDI-MedLine.d200.s5|32-39|compared|O
DDI-MedLine.d200.s5|41-44|with|O
DDI-MedLine.d200.s5|46-53|clinical|O
DDI-MedLine.d200.s5|55-66|measurements|O
DDI-MedLine.d200.s5|68-69|in|O
DDI-MedLine.d200.s5|71-75|order|O
DDI-MedLine.d200.s5|77-78|to|O
DDI-MedLine.d200.s5|80-85|detect|O
DDI-MedLine.d200.s5|87-95|concealed|O
DDI-MedLine.d200.s5|97-106|inefficacy|O
DDI-MedLine.d200.s5|108-109|of|O
DDI-MedLine.d200.s5|111-119|treatment|O
DDI-MedLine.d200.s5|120-120|.|O
DDI-MedLine.d200.s6|0-6|Results|O
DDI-MedLine.d200.s6|7-7|.|O
DDI-MedLine.d200.s7|0-3|Rate|O
DDI-MedLine.d200.s7|5-6|of|O
DDI-MedLine.d200.s7|8-18|achievement|O
DDI-MedLine.d200.s7|20-21|of|O
DDI-MedLine.d200.s7|23-28|target|O
DDI-MedLine.d200.s7|30-31|BP|O
DDI-MedLine.d200.s7|33-36|with|O
DDI-MedLine.d200.s7|38-42|fixed|O
DDI-MedLine.d200.s7|44-54|combination|O
DDI-MedLine.d200.s7|56-75|amlodipine/valsartan|drug
DDI-MedLine.d200.s7|77-77|(|O
DDI-MedLine.d200.s7|78-79|93|O
DDI-MedLine.d200.s7|80-80|%|O
DDI-MedLine.d200.s7|81-81|)|O
DDI-MedLine.d200.s7|83-85|was|O
DDI-MedLine.d200.s7|87-96|comparable|O
DDI-MedLine.d200.s7|98-101|with|O
DDI-MedLine.d200.s7|103-106|that|O
DDI-MedLine.d200.s7|108-109|on|O
DDI-MedLine.d200.s7|111-121|traditional|O
DDI-MedLine.d200.s7|123-129|therapy|O
DDI-MedLine.d200.s7|131-131|(|O
DDI-MedLine.d200.s7|132-133|90|O
DDI-MedLine.d200.s7|134-134|%|O
DDI-MedLine.d200.s7|135-135|)|O
DDI-MedLine.d200.s7|136-136|.|O
DDI-MedLine.d200.s8|0-2|But|O
DDI-MedLine.d200.s8|4-6|the|O
DDI-MedLine.d200.s8|8-10|use|O
DDI-MedLine.d200.s8|12-13|of|O
DDI-MedLine.d200.s8|15-19|fixed|O
DDI-MedLine.d200.s8|21-31|combination|O
DDI-MedLine.d200.s8|33-52|amlodipine/valsartan|drug
DDI-MedLine.d200.s8|54-61|compared|O
DDI-MedLine.d200.s8|63-66|with|O
DDI-MedLine.d200.s8|68-78|traditional|O
DDI-MedLine.d200.s8|80-86|therapy|O
DDI-MedLine.d200.s8|88-90|was|O
DDI-MedLine.d200.s8|92-101|associated|O
DDI-MedLine.d200.s8|103-106|with|O
DDI-MedLine.d200.s8|108-112|lower|O
DDI-MedLine.d200.s8|114-121|clinical|O
DDI-MedLine.d200.s8|123-125|and|O
DDI-MedLine.d200.s8|127-130|self|O
DDI-MedLine.d200.s8|132-139|measured|O
DDI-MedLine.d200.s8|141-142|BP|O
DDI-MedLine.d200.s8|143-143|,|O
DDI-MedLine.d200.s8|145-151|quicker|O
DDI-MedLine.d200.s8|153-163|achievement|O
DDI-MedLine.d200.s8|165-166|of|O
DDI-MedLine.d200.s8|168-173|target|O
DDI-MedLine.d200.s8|175-176|BP|O
DDI-MedLine.d200.s8|178-178|(|O
DDI-MedLine.d200.s8|179-187|5.8+/-2.3|O
DDI-MedLine.d200.s8|189-191|and|O
DDI-MedLine.d200.s8|193-201|9.2+/-1.8|O
DDI-MedLine.d200.s8|203-206|days|O
DDI-MedLine.d200.s8|207-207|,|O
DDI-MedLine.d200.s8|209-220|respectively|O
DDI-MedLine.d200.s8|221-221|,|O
DDI-MedLine.d200.s8|223-226|0.05|O
DDI-MedLine.d200.s8|227-227|)|O
DDI-MedLine.d200.s8|228-228|,|O
DDI-MedLine.d200.s8|230-235|lesser|O
DDI-MedLine.d200.s8|237-242|number|O
DDI-MedLine.d200.s8|244-245|of|O
DDI-MedLine.d200.s8|247-268|antihypertensive drugs|group
DDI-MedLine.d200.s8|270-270|(|O
DDI-MedLine.d200.s8|271-279|2.5+/-0.6|O
DDI-MedLine.d200.s8|281-283|and|O
DDI-MedLine.d200.s8|285-293|3.0+/-0.9|O
DDI-MedLine.d200.s8|295-298|days|O
DDI-MedLine.d200.s8|299-299|,|O
DDI-MedLine.d200.s8|301-312|respectively|O
DDI-MedLine.d200.s8|313-313|)|O
DDI-MedLine.d200.s8|314-314|,|O
DDI-MedLine.d200.s8|316-320|lower|O
DDI-MedLine.d200.s8|322-325|rate|O
DDI-MedLine.d200.s8|327-328|of|O
DDI-MedLine.d200.s8|330-338|concealed|O
DDI-MedLine.d200.s8|340-349|inefficacy|O
DDI-MedLine.d200.s8|351-352|of|O
DDI-MedLine.d200.s8|354-362|treatment|O
DDI-MedLine.d200.s8|364-364|(|O
DDI-MedLine.d200.s8|365-366|12|O
DDI-MedLine.d200.s8|368-370|and|O
DDI-MedLine.d200.s8|372-373|31|O
DDI-MedLine.d200.s8|374-374|%|O
DDI-MedLine.d200.s8|375-375|,|O
DDI-MedLine.d200.s8|377-388|respectively|O
DDI-MedLine.d200.s8|389-389|,|O
DDI-MedLine.d200.s8|391-394|0.05|O
DDI-MedLine.d200.s8|395-395|)|O
DDI-MedLine.d200.s8|396-396|.|O
DDI-MedLine.d200.s9|0-10|Conclusions|O
DDI-MedLine.d200.s9|11-11|.|O
DDI-MedLine.d200.s10|0-1|We|O
DDI-MedLine.d200.s10|3-6|have|O
DDI-MedLine.d200.s10|8-19|demonstrated|O
DDI-MedLine.d200.s10|21-35|appropriateness|O
DDI-MedLine.d200.s10|37-38|of|O
DDI-MedLine.d200.s10|40-49|inhospital|O
DDI-MedLine.d200.s10|51-64|administration|O
DDI-MedLine.d200.s10|66-67|of|O
DDI-MedLine.d200.s10|69-73|fixed|O
DDI-MedLine.d200.s10|75-94|amlodipine/valsartan|drug
DDI-MedLine.d200.s10|96-106|combination|O
DDI-MedLine.d200.s10|108-109|as|O
DDI-MedLine.d200.s10|111-112|an|O
DDI-MedLine.d200.s10|114-121|approach|O
DDI-MedLine.d200.s10|123-130|allowing|O
DDI-MedLine.d200.s10|132-133|to|O
DDI-MedLine.d200.s10|135-141|achieve|O
DDI-MedLine.d200.s10|143-148|target|O
DDI-MedLine.d200.s10|150-151|BP|O
DDI-MedLine.d200.s10|153-154|in|O
DDI-MedLine.d200.s10|156-162|shorter|O
DDI-MedLine.d200.s10|164-167|time|O
DDI-MedLine.d200.s10|168-168|,|O
DDI-MedLine.d200.s10|170-173|with|O
DDI-MedLine.d200.s10|175-177|the|O
DDI-MedLine.d200.s10|179-181|use|O
DDI-MedLine.d200.s10|183-184|of|O
DDI-MedLine.d200.s10|186-190|fewer|O
DDI-MedLine.d200.s10|192-213|antihypertensive drugs|group
DDI-MedLine.d200.s10|214-214|,|O
DDI-MedLine.d200.s10|216-218|and|O
DDI-MedLine.d200.s10|220-230|diminishing|O
DDI-MedLine.d200.s10|232-240|concealed|O
DDI-MedLine.d200.s10|242-251|inefficacy|O
DDI-MedLine.d200.s10|253-254|of|O
DDI-MedLine.d200.s10|256-264|treatment|O
DDI-MedLine.d200.s10|265-265|.|O
DDI-DrugBank.d335.s0|0-1|If|O
DDI-DrugBank.d335.s0|3-10|TRANXENE|brand
DDI-DrugBank.d335.s0|12-13|is|O
DDI-DrugBank.d335.s0|15-16|to|O
DDI-DrugBank.d335.s0|18-19|be|O
DDI-DrugBank.d335.s0|21-28|combined|O
DDI-DrugBank.d335.s0|30-33|with|O
DDI-DrugBank.d335.s0|35-39|other|O
DDI-DrugBank.d335.s0|41-45|drugs|O
DDI-DrugBank.d335.s0|47-52|acting|O
DDI-DrugBank.d335.s0|54-55|on|O
DDI-DrugBank.d335.s0|57-59|the|O
DDI-DrugBank.d335.s0|61-67|central|O
DDI-DrugBank.d335.s0|69-75|nervous|O
DDI-DrugBank.d335.s0|77-82|system|O
DDI-DrugBank.d335.s0|83-83|,|O
DDI-DrugBank.d335.s0|85-91|careful|O
DDI-DrugBank.d335.s0|93-105|consideration|O
DDI-DrugBank.d335.s0|107-112|should|O
DDI-DrugBank.d335.s0|114-115|be|O
DDI-DrugBank.d335.s0|117-121|given|O
DDI-DrugBank.d335.s0|123-124|to|O
DDI-DrugBank.d335.s0|126-128|the|O
DDI-DrugBank.d335.s0|130-141|pharmacology|O
DDI-DrugBank.d335.s0|143-144|of|O
DDI-DrugBank.d335.s0|146-148|the|O
DDI-DrugBank.d335.s0|150-155|agents|O
DDI-DrugBank.d335.s0|157-158|to|O
DDI-DrugBank.d335.s0|160-161|be|O
DDI-DrugBank.d335.s0|163-170|employed|O
DDI-DrugBank.d335.s0|171-171|.|O
DDI-DrugBank.d335.s1|0-5|Animal|O
DDI-DrugBank.d335.s1|7-16|experience|O
DDI-DrugBank.d335.s1|18-26|indicates|O
DDI-DrugBank.d335.s1|28-31|that|O
DDI-DrugBank.d335.s1|33-55|clorazepate dipotassium|drug
DDI-DrugBank.d335.s1|57-64|prolongs|O
DDI-DrugBank.d335.s1|66-68|the|O
DDI-DrugBank.d335.s1|70-77|sleeping|O
DDI-DrugBank.d335.s1|79-82|time|O
DDI-DrugBank.d335.s1|84-88|after|O
DDI-DrugBank.d335.s1|90-101|hexobarbital|drug
DDI-DrugBank.d335.s1|103-104|or|O
DDI-DrugBank.d335.s1|106-110|after|O
DDI-DrugBank.d335.s1|112-124|ethyl alcohol|drug
DDI-DrugBank.d335.s1|125-125|,|O
DDI-DrugBank.d335.s1|127-135|increases|O
DDI-DrugBank.d335.s1|137-139|the|O
DDI-DrugBank.d335.s1|141-150|inhibitory|O
DDI-DrugBank.d335.s1|152-158|effects|O
DDI-DrugBank.d335.s1|160-161|of|O
DDI-DrugBank.d335.s1|163-176|chlorpromazine|drug
DDI-DrugBank.d335.s1|177-177|,|O
DDI-DrugBank.d335.s1|179-181|but|O
DDI-DrugBank.d335.s1|183-186|does|O
DDI-DrugBank.d335.s1|188-190|not|O
DDI-DrugBank.d335.s1|192-198|exhibit|O
DDI-DrugBank.d335.s1|200-208|monoamine|O
DDI-DrugBank.d335.s1|210-216|oxidase|O
DDI-DrugBank.d335.s1|218-227|inhibition|O
DDI-DrugBank.d335.s1|228-228|.|O
DDI-DrugBank.d335.s2|0-7|Clinical|O
DDI-DrugBank.d335.s2|9-15|studies|O
DDI-DrugBank.d335.s2|17-20|have|O
DDI-DrugBank.d335.s2|22-26|shown|O
DDI-DrugBank.d335.s2|28-36|increased|O
DDI-DrugBank.d335.s2|38-45|sedation|O
DDI-DrugBank.d335.s2|47-50|with|O
DDI-DrugBank.d335.s2|52-61|concurrent|O
DDI-DrugBank.d335.s2|63-82|hypnotic medications|group
DDI-DrugBank.d335.s2|83-83|.|O
DDI-DrugBank.d335.s3|0-2|The|O
DDI-DrugBank.d335.s3|4-10|actions|O
DDI-DrugBank.d335.s3|12-13|of|O
DDI-DrugBank.d335.s3|15-17|the|O
DDI-DrugBank.d335.s3|19-33|benzodiazepines|group
DDI-DrugBank.d335.s3|35-37|may|O
DDI-DrugBank.d335.s3|39-40|be|O
DDI-DrugBank.d335.s3|42-52|potentiated|O
DDI-DrugBank.d335.s3|54-55|by|O
DDI-DrugBank.d335.s3|57-68|barbiturates|group
DDI-DrugBank.d335.s3|69-69|,|O
DDI-DrugBank.d335.s3|71-79|narcotics|group
DDI-DrugBank.d335.s3|80-80|,|O
DDI-DrugBank.d335.s3|82-95|phenothiazines|group
DDI-DrugBank.d335.s3|96-96|,|O
DDI-DrugBank.d335.s3|98-125|monoamine oxidase inhibitors|group
DDI-DrugBank.d335.s3|127-128|or|O
DDI-DrugBank.d335.s3|130-134|other|O
DDI-DrugBank.d335.s3|136-150|antidepressants|group
DDI-DrugBank.d335.s3|151-151|.|O
DDI-DrugBank.d335.s4|0-1|If|O
DDI-DrugBank.d335.s4|3-10|TRANXENE|brand
DDI-DrugBank.d335.s4|12-18|tablets|O
DDI-DrugBank.d335.s4|20-22|are|O
DDI-DrugBank.d335.s4|24-27|used|O
DDI-DrugBank.d335.s4|29-30|to|O
DDI-DrugBank.d335.s4|32-36|treat|O
DDI-DrugBank.d335.s4|38-44|anxiety|O
DDI-DrugBank.d335.s4|46-55|associated|O
DDI-DrugBank.d335.s4|57-60|with|O
DDI-DrugBank.d335.s4|62-68|somatic|O
DDI-DrugBank.d335.s4|70-76|disease|O
DDI-DrugBank.d335.s4|78-83|states|O
DDI-DrugBank.d335.s4|84-84|,|O
DDI-DrugBank.d335.s4|86-92|careful|O
DDI-DrugBank.d335.s4|94-102|attention|O
DDI-DrugBank.d335.s4|104-107|must|O
DDI-DrugBank.d335.s4|109-110|be|O
DDI-DrugBank.d335.s4|112-115|paid|O
DDI-DrugBank.d335.s4|117-118|to|O
DDI-DrugBank.d335.s4|120-127|possible|O
DDI-DrugBank.d335.s4|129-132|drug|O
DDI-DrugBank.d335.s4|134-144|interaction|O
DDI-DrugBank.d335.s4|146-149|with|O
DDI-DrugBank.d335.s4|151-161|concomitant|O
DDI-DrugBank.d335.s4|163-172|medication|O
DDI-DrugBank.d335.s4|173-173|.|O
DDI-DrugBank.d335.s5|0-1|In|O
DDI-DrugBank.d335.s5|3-17|bioavailability|O
DDI-DrugBank.d335.s5|19-25|studies|O
DDI-DrugBank.d335.s5|27-30|with|O
DDI-DrugBank.d335.s5|32-37|normal|O
DDI-DrugBank.d335.s5|39-46|subjects|O
DDI-DrugBank.d335.s5|47-47|,|O
DDI-DrugBank.d335.s5|49-51|the|O
DDI-DrugBank.d335.s5|53-62|concurrent|O
DDI-DrugBank.d335.s5|64-77|administration|O
DDI-DrugBank.d335.s5|79-80|of|O
DDI-DrugBank.d335.s5|82-89|antacids|group
DDI-DrugBank.d335.s5|91-92|at|O
DDI-DrugBank.d335.s5|94-104|therapeutic|O
DDI-DrugBank.d335.s5|106-111|levels|O
DDI-DrugBank.d335.s5|113-115|did|O
DDI-DrugBank.d335.s5|117-119|not|O
DDI-DrugBank.d335.s5|121-133|significantly|O
DDI-DrugBank.d335.s5|135-143|influence|O
DDI-DrugBank.d335.s5|145-147|the|O
DDI-DrugBank.d335.s5|149-163|bioavailability|O
DDI-DrugBank.d335.s5|165-166|of|O
DDI-DrugBank.d335.s5|168-175|TRANXENE|brand
DDI-DrugBank.d335.s5|177-183|tablets|O
DDI-DrugBank.d335.s5|184-184|.|O
DDI-DrugBank.d762.s0|0-9|Probenecid|drug
DDI-DrugBank.d762.s0|11-18|competes|O
DDI-DrugBank.d762.s0|20-23|with|O
DDI-DrugBank.d762.s0|25-33|meropenem|drug
DDI-DrugBank.d762.s0|35-37|for|O
DDI-DrugBank.d762.s0|39-44|active|O
DDI-DrugBank.d762.s0|46-52|tubular|O
DDI-DrugBank.d762.s0|54-62|secretion|O
DDI-DrugBank.d762.s0|64-66|and|O
DDI-DrugBank.d762.s0|68-71|thus|O
DDI-DrugBank.d762.s0|73-80|inhibits|O
DDI-DrugBank.d762.s0|82-84|the|O
DDI-DrugBank.d762.s0|86-90|renal|O
DDI-DrugBank.d762.s0|92-100|excretion|O
DDI-DrugBank.d762.s0|102-103|of|O
DDI-DrugBank.d762.s0|105-113|meropenem|drug
DDI-DrugBank.d762.s0|114-114|.|O
DDI-DrugBank.d762.s1|0-3|This|O
DDI-DrugBank.d762.s1|5-7|led|O
DDI-DrugBank.d762.s1|9-10|to|O
DDI-DrugBank.d762.s1|12-24|statistically|O
DDI-DrugBank.d762.s1|26-36|significant|O
DDI-DrugBank.d762.s1|38-46|increases|O
DDI-DrugBank.d762.s1|48-49|in|O
DDI-DrugBank.d762.s1|51-53|the|O
DDI-DrugBank.d762.s1|55-65|elimination|O
DDI-DrugBank.d762.s1|67-75|half-life|O
DDI-DrugBank.d762.s1|77-77|(|O
DDI-DrugBank.d762.s1|78-79|38|O
DDI-DrugBank.d762.s1|80-80|%|O
DDI-DrugBank.d762.s1|81-81|)|O
DDI-DrugBank.d762.s1|83-85|and|O
DDI-DrugBank.d762.s1|87-88|in|O
DDI-DrugBank.d762.s1|90-92|the|O
DDI-DrugBank.d762.s1|94-99|extent|O
DDI-DrugBank.d762.s1|101-102|of|O
DDI-DrugBank.d762.s1|104-111|systemic|O
DDI-DrugBank.d762.s1|113-120|exposure|O
DDI-DrugBank.d762.s1|122-122|(|O
DDI-DrugBank.d762.s1|123-124|56|O
DDI-DrugBank.d762.s1|125-125|%|O
DDI-DrugBank.d762.s1|126-126|)|O
DDI-DrugBank.d762.s1|127-127|.|O
DDI-DrugBank.d762.s2|0-8|Therefore|O
DDI-DrugBank.d762.s2|9-9|,|O
DDI-DrugBank.d762.s2|11-13|the|O
DDI-DrugBank.d762.s2|15-30|coadministration|O
DDI-DrugBank.d762.s2|32-33|of|O
DDI-DrugBank.d762.s2|35-44|probenecid|drug
DDI-DrugBank.d762.s2|46-49|with|O
DDI-DrugBank.d762.s2|51-59|meropenem|drug
DDI-DrugBank.d762.s2|61-62|is|O
DDI-DrugBank.d762.s2|64-66|not|O
DDI-DrugBank.d762.s2|68-78|recommended|O
DDI-DrugBank.d762.s2|79-79|.|O
DDI-DrugBank.d762.s3|0-4|There|O
DDI-DrugBank.d762.s3|6-7|is|O
DDI-DrugBank.d762.s3|9-16|evidence|O
DDI-DrugBank.d762.s3|18-21|that|O
DDI-DrugBank.d762.s3|23-31|meropenem|drug
DDI-DrugBank.d762.s3|33-35|may|O
DDI-DrugBank.d762.s3|37-42|reduce|O
DDI-DrugBank.d762.s3|44-48|serum|O
DDI-DrugBank.d762.s3|50-55|levels|O
DDI-DrugBank.d762.s3|57-58|of|O
DDI-DrugBank.d762.s3|60-72|valproic acid|drug
DDI-DrugBank.d762.s3|74-75|to|O
DDI-DrugBank.d762.s3|77-90|subtherapeutic|O
DDI-DrugBank.d762.s3|92-97|levels|O
DDI-DrugBank.d762.s3|99-99|(|O
DDI-DrugBank.d762.s3|100-110|therapeutic|O
DDI-DrugBank.d762.s3|112-116|range|O
DDI-DrugBank.d762.s3|118-127|considered|O
DDI-DrugBank.d762.s3|129-130|to|O
DDI-DrugBank.d762.s3|132-133|be|O
DDI-DrugBank.d762.s3|135-136|50|O
DDI-DrugBank.d762.s3|138-139|to|O
DDI-DrugBank.d762.s3|141-143|100|O
DDI-DrugBank.d762.s3|148-151|g/mL|O
DDI-DrugBank.d762.s3|153-157|total|O
DDI-DrugBank.d762.s3|159-167|valproate|drug
DDI-DrugBank.d762.s3|168-168|)|O
DDI-DrugBank.d762.s3|169-169|.|O
DDI-DrugBank.d76.s0|0-8|Potential|O
DDI-DrugBank.d76.s0|10-12|for|O
DDI-DrugBank.d76.s0|14-24|Interaction|O
DDI-DrugBank.d76.s0|26-29|with|O
DDI-DrugBank.d76.s1|0-1|In|O
DDI-DrugBank.d76.s1|3-10|patients|O
DDI-DrugBank.d76.s1|12-20|receiving|O
DDI-DrugBank.d76.s1|22-28|another|O
DDI-DrugBank.d76.s1|30-62|serotonin reuptake inhibitor drug|group
DDI-DrugBank.d76.s1|64-65|in|O
DDI-DrugBank.d76.s1|67-77|combination|O
DDI-DrugBank.d76.s1|79-82|with|O
DDI-DrugBank.d76.s1|84-111|monoamine oxidase inhibitors|group
DDI-DrugBank.d76.s1|113-113|(|O
DDI-DrugBank.d76.s1|114-117|MAOI|group
DDI-DrugBank.d76.s1|118-118|)|O
DDI-DrugBank.d76.s1|119-119|,|O
DDI-DrugBank.d76.s1|121-125|there|O
DDI-DrugBank.d76.s1|127-130|have|O
DDI-DrugBank.d76.s1|132-135|been|O
DDI-DrugBank.d76.s1|137-143|reports|O
DDI-DrugBank.d76.s1|145-146|of|O
DDI-DrugBank.d76.s1|148-154|serious|O
DDI-DrugBank.d76.s1|155-155|,|O
DDI-DrugBank.d76.s1|157-165|sometimes|O
DDI-DrugBank.d76.s1|167-171|fatal|O
DDI-DrugBank.d76.s1|172-172|,|O
DDI-DrugBank.d76.s1|174-182|reactions|O
DDI-DrugBank.d76.s1|184-192|including|O
DDI-DrugBank.d76.s1|194-205|hyperthermia|O
DDI-DrugBank.d76.s1|206-206|,|O
DDI-DrugBank.d76.s1|208-215|rigidity|O
DDI-DrugBank.d76.s1|216-216|,|O
DDI-DrugBank.d76.s1|218-226|myoclonus|O
DDI-DrugBank.d76.s1|227-227|,|O
DDI-DrugBank.d76.s1|229-237|autonomic|O
DDI-DrugBank.d76.s1|239-249|instability|O
DDI-DrugBank.d76.s1|251-254|with|O
DDI-DrugBank.d76.s1|256-263|possible|O
DDI-DrugBank.d76.s1|265-269|rapid|O
DDI-DrugBank.d76.s1|271-282|fluctuations|O
DDI-DrugBank.d76.s1|284-285|of|O
DDI-DrugBank.d76.s1|287-291|vital|O
DDI-DrugBank.d76.s1|293-297|signs|O
DDI-DrugBank.d76.s1|298-298|,|O
DDI-DrugBank.d76.s1|300-302|and|O
DDI-DrugBank.d76.s1|304-309|mental|O
DDI-DrugBank.d76.s1|311-316|status|O
DDI-DrugBank.d76.s1|318-324|changes|O
DDI-DrugBank.d76.s1|326-329|that|O
DDI-DrugBank.d76.s1|331-337|include|O
DDI-DrugBank.d76.s1|339-345|extreme|O
DDI-DrugBank.d76.s1|347-355|agitation|O
DDI-DrugBank.d76.s1|357-367|progressing|O
DDI-DrugBank.d76.s1|369-370|to|O
DDI-DrugBank.d76.s1|372-379|delirium|O
DDI-DrugBank.d76.s1|381-383|and|O
DDI-DrugBank.d76.s1|385-388|coma|O
DDI-DrugBank.d76.s1|389-389|.|O
DDI-DrugBank.d76.s2|0-4|These|O
DDI-DrugBank.d76.s2|6-14|reactions|O
DDI-DrugBank.d76.s2|16-19|have|O
DDI-DrugBank.d76.s2|21-24|also|O
DDI-DrugBank.d76.s2|26-29|been|O
DDI-DrugBank.d76.s2|31-38|reported|O
DDI-DrugBank.d76.s2|40-41|in|O
DDI-DrugBank.d76.s2|43-50|patients|O
DDI-DrugBank.d76.s2|52-54|who|O
DDI-DrugBank.d76.s2|56-59|have|O
DDI-DrugBank.d76.s2|61-72|discontinued|O
DDI-DrugBank.d76.s2|74-77|that|O
DDI-DrugBank.d76.s2|79-82|drug|O
DDI-DrugBank.d76.s2|84-86|and|O
DDI-DrugBank.d76.s2|88-91|have|O
DDI-DrugBank.d76.s2|93-96|been|O
DDI-DrugBank.d76.s2|98-104|started|O
DDI-DrugBank.d76.s2|106-107|on|O
DDI-DrugBank.d76.s2|109-109|a|O
DDI-DrugBank.d76.s2|111-114|MAOI|group
DDI-DrugBank.d76.s2|115-115|.|O
DDI-DrugBank.d76.s3|0-3|Some|O
DDI-DrugBank.d76.s3|5-9|cases|O
DDI-DrugBank.d76.s3|11-19|presented|O
DDI-DrugBank.d76.s3|21-24|with|O
DDI-DrugBank.d76.s3|26-33|features|O
DDI-DrugBank.d76.s3|35-44|resembling|O
DDI-DrugBank.d76.s3|46-56|neuroleptic|O
DDI-DrugBank.d76.s3|58-66|malignant|O
DDI-DrugBank.d76.s3|68-75|syndrome|O
DDI-DrugBank.d76.s3|76-76|.|O
DDI-DrugBank.d76.s4|0-8|Therefore|O
DDI-DrugBank.d76.s4|9-9|,|O
DDI-DrugBank.d76.s4|11-12|it|O
DDI-DrugBank.d76.s4|14-15|is|O
DDI-DrugBank.d76.s4|17-27|recommended|O
DDI-DrugBank.d76.s4|29-32|that|O
DDI-DrugBank.d76.s4|34-44|Fluvoxamine|drug
DDI-DrugBank.d76.s4|46-52|Tablets|O
DDI-DrugBank.d76.s4|54-56|not|O
DDI-DrugBank.d76.s4|58-59|be|O
DDI-DrugBank.d76.s4|61-64|used|O
DDI-DrugBank.d76.s4|66-67|in|O
DDI-DrugBank.d76.s4|69-79|combination|O
DDI-DrugBank.d76.s4|81-84|with|O
DDI-DrugBank.d76.s4|86-90|MAOIs|group
DDI-DrugBank.d76.s4|91-91|,|O
DDI-DrugBank.d76.s4|93-94|or|O
DDI-DrugBank.d76.s4|96-101|within|O
DDI-DrugBank.d76.s4|103-104|14|O
DDI-DrugBank.d76.s4|106-109|days|O
DDI-DrugBank.d76.s4|111-112|of|O
DDI-DrugBank.d76.s4|114-126|discontinuing|O
DDI-DrugBank.d76.s4|128-136|treatment|O
DDI-DrugBank.d76.s4|138-141|with|O
DDI-DrugBank.d76.s4|143-143|a|O
DDI-DrugBank.d76.s4|145-148|MAOI|group
DDI-DrugBank.d76.s4|149-149|.|O
DDI-DrugBank.d76.s5|0-4|After|O
DDI-DrugBank.d76.s5|6-13|stopping|O
DDI-DrugBank.d76.s5|15-25|Fluvoxamine|drug
DDI-DrugBank.d76.s5|27-33|Tablets|O
DDI-DrugBank.d76.s5|34-34|,|O
DDI-DrugBank.d76.s5|36-37|at|O
DDI-DrugBank.d76.s5|39-43|least|O
DDI-DrugBank.d76.s5|45-45|2|O
DDI-DrugBank.d76.s5|47-51|weeks|O
DDI-DrugBank.d76.s5|53-58|should|O
DDI-DrugBank.d76.s5|60-61|be|O
DDI-DrugBank.d76.s5|63-69|allowed|O
DDI-DrugBank.d76.s5|71-76|before|O
DDI-DrugBank.d76.s5|78-85|starting|O
DDI-DrugBank.d76.s5|87-87|a|O
DDI-DrugBank.d76.s5|89-92|MAOI|group
DDI-DrugBank.d76.s5|93-93|.|O
DDI-DrugBank.d76.s6|0-8|Potential|O
DDI-DrugBank.d76.s6|10-20|Terfenadine|drug
DDI-DrugBank.d76.s6|21-21|,|O
DDI-DrugBank.d76.s6|23-32|Astemizole|drug
DDI-DrugBank.d76.s6|33-33|,|O
DDI-DrugBank.d76.s6|35-37|and|O
DDI-DrugBank.d76.s6|39-47|Cisapride|drug
DDI-DrugBank.d76.s6|49-60|Interactions|O
DDI-DrugBank.d76.s7|0-10|Terfenadine|drug
DDI-DrugBank.d76.s7|11-11|,|O
DDI-DrugBank.d76.s7|13-22|astemizole|drug
DDI-DrugBank.d76.s7|24-26|and|O
DDI-DrugBank.d76.s7|28-36|cisapride|drug
DDI-DrugBank.d76.s7|38-40|are|O
DDI-DrugBank.d76.s7|42-44|all|O
DDI-DrugBank.d76.s7|46-56|metabolized|O
DDI-DrugBank.d76.s7|58-59|by|O
DDI-DrugBank.d76.s7|61-63|the|O
DDI-DrugBank.d76.s7|65-74|cytochrome|O
DDI-DrugBank.d76.s7|76-84|P450IIIA4|O
DDI-DrugBank.d76.s7|86-92|isozyme|O
DDI-DrugBank.d76.s7|93-93|,|O
DDI-DrugBank.d76.s7|95-97|and|O
DDI-DrugBank.d76.s7|99-100|it|O
DDI-DrugBank.d76.s7|102-104|has|O
DDI-DrugBank.d76.s7|106-109|been|O
DDI-DrugBank.d76.s7|111-122|demonstrated|O
DDI-DrugBank.d76.s7|124-127|that|O
DDI-DrugBank.d76.s7|129-140|ketoconazole|drug
DDI-DrugBank.d76.s7|141-141|,|O
DDI-DrugBank.d76.s7|143-143|a|O
DDI-DrugBank.d76.s7|145-150|potent|O
DDI-DrugBank.d76.s7|152-160|inhibitor|O
DDI-DrugBank.d76.s7|162-163|of|O
DDI-DrugBank.d76.s7|165-169|IIIA4|O
DDI-DrugBank.d76.s7|170-170|,|O
DDI-DrugBank.d76.s7|172-177|blocks|O
DDI-DrugBank.d76.s7|179-181|the|O
DDI-DrugBank.d76.s7|183-192|metabolism|O
DDI-DrugBank.d76.s7|194-195|of|O
DDI-DrugBank.d76.s7|197-201|these|O
DDI-DrugBank.d76.s7|203-207|drugs|O
DDI-DrugBank.d76.s7|208-208|,|O
DDI-DrugBank.d76.s7|210-218|resulting|O
DDI-DrugBank.d76.s7|220-221|in|O
DDI-DrugBank.d76.s7|223-231|increased|O
DDI-DrugBank.d76.s7|233-238|plasma|O
DDI-DrugBank.d76.s7|240-253|concentrations|O
DDI-DrugBank.d76.s7|255-256|of|O
DDI-DrugBank.d76.s7|258-263|parent|O
DDI-DrugBank.d76.s7|265-268|drug|O
DDI-DrugBank.d76.s7|269-269|.|O
DDI-DrugBank.d76.s8|0-8|Increased|O
DDI-DrugBank.d76.s8|10-15|plasma|O
DDI-DrugBank.d76.s8|17-30|concentrations|O
DDI-DrugBank.d76.s8|32-33|of|O
DDI-DrugBank.d76.s8|35-45|terfenadine|drug
DDI-DrugBank.d76.s8|46-46|,|O
DDI-DrugBank.d76.s8|48-57|astemizole|drug
DDI-DrugBank.d76.s8|58-58|,|O
DDI-DrugBank.d76.s8|60-62|and|O
DDI-DrugBank.d76.s8|64-72|cisapride|drug
DDI-DrugBank.d76.s8|74-78|cause|O
DDI-DrugBank.d76.s8|80-81|QT|O
DDI-DrugBank.d76.s8|83-94|prolongation|O
DDI-DrugBank.d76.s8|96-98|and|O
DDI-DrugBank.d76.s8|100-103|have|O
DDI-DrugBank.d76.s8|105-108|been|O
DDI-DrugBank.d76.s8|110-119|associated|O
DDI-DrugBank.d76.s8|121-124|with|O
DDI-DrugBank.d76.s8|126-133|torsades|O
DDI-DrugBank.d76.s8|135-136|de|O
DDI-DrugBank.d76.s8|138-149|pointes-type|O
DDI-DrugBank.d76.s8|151-161|ventricular|O
DDI-DrugBank.d76.s8|163-173|tachycardia|O
DDI-DrugBank.d76.s8|174-174|,|O
DDI-DrugBank.d76.s8|176-184|sometimes|O
DDI-DrugBank.d76.s8|186-190|fatal|O
DDI-DrugBank.d76.s8|191-191|.|O
DDI-DrugBank.d76.s9|0-1|As|O
DDI-DrugBank.d76.s9|3-7|noted|O
DDI-DrugBank.d76.s9|9-13|below|O
DDI-DrugBank.d76.s9|14-14|,|O
DDI-DrugBank.d76.s9|16-16|a|O
DDI-DrugBank.d76.s9|18-21|sub-|O
DDI-DrugBank.d76.s9|23-25|for|O
DDI-DrugBank.d76.s9|27-37|fluvoxamine|drug
DDI-DrugBank.d76.s9|39-40|in|O
DDI-DrugBank.d76.s9|42-52|combination|O
DDI-DrugBank.d76.s9|54-57|with|O
DDI-DrugBank.d76.s9|59-68|alprazolam|drug
DDI-DrugBank.d76.s9|69-69|,|O
DDI-DrugBank.d76.s9|71-71|a|O
DDI-DrugBank.d76.s9|73-76|drug|O
DDI-DrugBank.d76.s9|78-81|that|O
DDI-DrugBank.d76.s9|83-84|is|O
DDI-DrugBank.d76.s9|86-90|known|O
DDI-DrugBank.d76.s9|92-93|to|O
DDI-DrugBank.d76.s9|95-96|be|O
DDI-DrugBank.d76.s9|98-108|metabolized|O
DDI-DrugBank.d76.s9|110-111|by|O
DDI-DrugBank.d76.s9|113-115|the|O
DDI-DrugBank.d76.s9|117-121|IIIA4|O
DDI-DrugBank.d76.s9|123-129|isozyme|O
DDI-DrugBank.d76.s9|130-130|.|O
DDI-DrugBank.d76.s10|0-7|Although|O
DDI-DrugBank.d76.s10|9-10|it|O
DDI-DrugBank.d76.s10|12-14|has|O
DDI-DrugBank.d76.s10|16-18|not|O
DDI-DrugBank.d76.s10|20-23|been|O
DDI-DrugBank.d76.s10|25-36|definitively|O
DDI-DrugBank.d76.s10|38-49|demonstrated|O
DDI-DrugBank.d76.s10|51-54|that|O
DDI-DrugBank.d76.s10|56-66|fluvoxamine|drug
DDI-DrugBank.d76.s10|68-69|is|O
DDI-DrugBank.d76.s10|71-71|a|O
DDI-DrugBank.d76.s10|73-78|potent|O
DDI-DrugBank.d76.s10|80-84|IIIA4|O
DDI-DrugBank.d76.s10|86-94|inhibitor|O
DDI-DrugBank.d76.s10|95-95|,|O
DDI-DrugBank.d76.s10|97-98|it|O
DDI-DrugBank.d76.s10|100-101|is|O
DDI-DrugBank.d76.s10|103-108|likely|O
DDI-DrugBank.d76.s10|110-111|to|O
DDI-DrugBank.d76.s10|113-114|be|O
DDI-DrugBank.d76.s10|115-115|,|O
DDI-DrugBank.d76.s10|117-121|given|O
DDI-DrugBank.d76.s10|123-125|the|O
DDI-DrugBank.d76.s10|127-137|substantial|O
DDI-DrugBank.d76.s10|139-149|interaction|O
DDI-DrugBank.d76.s10|151-152|of|O
DDI-DrugBank.d76.s10|154-164|fluvoxamine|drug
DDI-DrugBank.d76.s10|166-169|with|O
DDI-DrugBank.d76.s10|171-180|alprazolam|drug
DDI-DrugBank.d76.s10|181-181|.|O
DDI-DrugBank.d76.s11|0-11|Consequently|O
DDI-DrugBank.d76.s11|12-12|,|O
DDI-DrugBank.d76.s11|14-15|it|O
DDI-DrugBank.d76.s11|17-18|is|O
DDI-DrugBank.d76.s11|20-30|recommended|O
DDI-DrugBank.d76.s11|32-35|that|O
DDI-DrugBank.d76.s11|37-47|fluvoxamine|drug
DDI-DrugBank.d76.s11|49-51|not|O
DDI-DrugBank.d76.s11|53-54|be|O
DDI-DrugBank.d76.s11|56-59|used|O
DDI-DrugBank.d76.s11|61-62|in|O
DDI-DrugBank.d76.s11|64-74|combination|O
DDI-DrugBank.d76.s11|76-79|with|O
DDI-DrugBank.d76.s11|81-86|either|O
DDI-DrugBank.d76.s11|88-98|terbinafine|drug
DDI-DrugBank.d76.s11|99-99|,|O
DDI-DrugBank.d76.s11|101-110|astemizole|drug
DDI-DrugBank.d76.s11|111-111|,|O
DDI-DrugBank.d76.s11|113-114|or|O
DDI-DrugBank.d76.s11|116-124|cisapride|drug
DDI-DrugBank.d76.s11|125-125|.|O
DDI-DrugBank.d76.s12|0-4|Other|O
DDI-DrugBank.d76.s12|6-16|Potentially|O
DDI-DrugBank.d76.s12|18-26|Important|O
DDI-DrugBank.d76.s12|28-31|Drug|O
DDI-DrugBank.d76.s12|33-44|Interactions|O
DDI-DrugBank.d76.s12|45-45|:|O
DDI-DrugBank.d76.s12|47-61|Benzodiazepines|group
DDI-DrugBank.d76.s12|62-62|:|O
DDI-DrugBank.d76.s12|64-78|Benzodiazepines|group
DDI-DrugBank.d76.s12|80-90|metabolized|O
DDI-DrugBank.d76.s12|92-93|by|O
DDI-DrugBank.d76.s12|95-101|hepatic|O
DDI-DrugBank.d76.s12|103-111|oxidation|O
DDI-DrugBank.d76.s12|113-113|(|O
DDI-DrugBank.d76.s12|114-117|e.g.|O
DDI-DrugBank.d76.s12|118-118|,|O
DDI-DrugBank.d76.s12|120-129|alprazolam|drug
DDI-DrugBank.d76.s12|130-130|,|O
DDI-DrugBank.d76.s12|132-140|midazolam|drug
DDI-DrugBank.d76.s12|141-141|,|O
DDI-DrugBank.d76.s12|143-151|triazolam|drug
DDI-DrugBank.d76.s12|153-156|elc.|O
DDI-DrugBank.d76.s12|157-157|)|O
DDI-DrugBank.d76.s12|159-164|should|O
DDI-DrugBank.d76.s12|166-167|be|O
DDI-DrugBank.d76.s12|169-172|used|O
DDI-DrugBank.d76.s12|174-177|with|O
DDI-DrugBank.d76.s12|179-185|caution|O
DDI-DrugBank.d76.s12|187-193|because|O
DDI-DrugBank.d76.s12|195-197|the|O
DDI-DrugBank.d76.s12|199-207|clearance|O
DDI-DrugBank.d76.s12|209-210|of|O
DDI-DrugBank.d76.s12|212-216|these|O
DDI-DrugBank.d76.s12|218-222|drugs|O
DDI-DrugBank.d76.s12|224-225|is|O
DDI-DrugBank.d76.s12|227-232|likely|O
DDI-DrugBank.d76.s12|234-235|to|O
DDI-DrugBank.d76.s12|237-238|be|O
DDI-DrugBank.d76.s12|240-246|reduced|O
DDI-DrugBank.d76.s12|248-249|by|O
DDI-DrugBank.d76.s12|251-261|fluvoxamine|drug
DDI-DrugBank.d76.s12|262-262|.|O
DDI-DrugBank.d76.s13|0-2|The|O
DDI-DrugBank.d76.s13|4-12|clearance|O
DDI-DrugBank.d76.s13|14-15|of|O
DDI-DrugBank.d76.s13|17-31|benzodiazepines|group
DDI-DrugBank.d76.s13|33-43|metabolized|O
DDI-DrugBank.d76.s13|45-46|by|O
DDI-DrugBank.d76.s13|48-62|glucuronidation|O
DDI-DrugBank.d76.s13|64-64|(|O
DDI-DrugBank.d76.s13|65-66|e.|O
DDI-DrugBank.d76.s13|68-69|g.|O
DDI-DrugBank.d76.s13|70-70|,|O
DDI-DrugBank.d76.s13|72-80|lorazepam|drug
DDI-DrugBank.d76.s13|81-81|,|O
DDI-DrugBank.d76.s13|83-90|oxazepam|drug
DDI-DrugBank.d76.s13|91-91|,|O
DDI-DrugBank.d76.s13|93-101|temazepam|drug
DDI-DrugBank.d76.s13|102-102|)|O
DDI-DrugBank.d76.s13|104-105|is|O
DDI-DrugBank.d76.s13|107-114|unlikely|O
DDI-DrugBank.d76.s13|116-117|to|O
DDI-DrugBank.d76.s13|119-120|be|O
DDI-DrugBank.d76.s13|122-129|affected|O
DDI-DrugBank.d76.s13|131-132|by|O
DDI-DrugBank.d76.s13|134-144|fluvoxamine|drug
DDI-DrugBank.d76.s13|145-145|.|O
DDI-DrugBank.d76.s14|0-9|Alprazolam|drug
DDI-DrugBank.d76.s14|10-10|:|O
DDI-DrugBank.d76.s14|12-15|When|O
DDI-DrugBank.d76.s14|17-35|fluvoxamine maleate|drug
DDI-DrugBank.d76.s14|37-37|(|O
DDI-DrugBank.d76.s14|38-40|100|O
DDI-DrugBank.d76.s14|42-43|mg|O
DDI-DrugBank.d76.s14|45-46|qd|O
DDI-DrugBank.d76.s14|47-47|)|O
DDI-DrugBank.d76.s14|49-51|and|O
DDI-DrugBank.d76.s14|53-62|alprazolam|drug
DDI-DrugBank.d76.s14|64-64|(|O
DDI-DrugBank.d76.s14|65-65|1|O
DDI-DrugBank.d76.s14|67-68|mg|O
DDI-DrugBank.d76.s14|70-73|q.d.|O
DDI-DrugBank.d76.s14|75-78|were|O
DDI-DrugBank.d76.s14|80-94|co-administered|O
DDI-DrugBank.d76.s14|96-97|to|O
DDI-DrugBank.d76.s14|99-104|steady|O
DDI-DrugBank.d76.s14|106-110|state|O
DDI-DrugBank.d76.s14|111-111|,|O
DDI-DrugBank.d76.s14|113-118|plasma|O
DDI-DrugBank.d76.s14|120-132|concentration|O
DDI-DrugBank.d76.s14|134-136|and|O
DDI-DrugBank.d76.s14|138-142|other|O
DDI-DrugBank.d76.s14|144-159|pharmacokinetics|O
DDI-DrugBank.d76.s14|161-170|parameters|O
DDI-DrugBank.d76.s14|172-172|(|O
DDI-DrugBank.d76.s14|173-175|AUC|O
DDI-DrugBank.d76.s14|176-176|,|O
DDI-DrugBank.d76.s14|178-181|Cmax|O
DDI-DrugBank.d76.s14|182-182|,|O
DDI-DrugBank.d76.s14|184-187|T1/2|O
DDI-DrugBank.d76.s14|188-188|,|O
DDI-DrugBank.d76.s14|189-189|)|O
DDI-DrugBank.d76.s14|191-192|of|O
DDI-DrugBank.d76.s14|194-203|alprazolam|drug
DDI-DrugBank.d76.s14|205-208|were|O
DDI-DrugBank.d76.s14|210-222|approximately|O
DDI-DrugBank.d76.s14|224-228|twice|O
DDI-DrugBank.d76.s14|230-234|those|O
DDI-DrugBank.d76.s14|236-243|observed|O
DDI-DrugBank.d76.s14|245-248|when|O
DDI-DrugBank.d76.s14|250-259|alprazolam|drug
DDI-DrugBank.d76.s14|261-263|was|O
DDI-DrugBank.d76.s14|265-276|administered|O
DDI-DrugBank.d76.s14|278-282|alone|O
DDI-DrugBank.d76.s14|283-283|;|O
DDI-DrugBank.d76.s15|0-3|oral|O
DDI-DrugBank.d76.s15|5-13|clearance|O
DDI-DrugBank.d76.s15|15-17|was|O
DDI-DrugBank.d76.s15|19-25|reduced|O
DDI-DrugBank.d76.s15|27-28|by|O
DDI-DrugBank.d76.s15|30-34|about|O
DDI-DrugBank.d76.s15|36-37|50|O
DDI-DrugBank.d76.s15|38-38|%|O
DDI-DrugBank.d76.s15|39-39|.|O
DDI-DrugBank.d76.s16|0-2|The|O
DDI-DrugBank.d76.s16|4-11|elevated|O
DDI-DrugBank.d76.s16|13-18|plasma|O
DDI-DrugBank.d76.s16|20-29|alprazolam|drug
DDI-DrugBank.d76.s16|31-44|concentrations|O
DDI-DrugBank.d76.s16|46-53|resulted|O
DDI-DrugBank.d76.s16|55-56|in|O
DDI-DrugBank.d76.s16|58-66|decreased|O
DDI-DrugBank.d76.s16|68-78|psychomotor|O
DDI-DrugBank.d76.s16|80-90|performance|O
DDI-DrugBank.d76.s16|92-94|and|O
DDI-DrugBank.d76.s16|96-101|memory|O
DDI-DrugBank.d76.s16|102-102|.|O
DDI-DrugBank.d76.s17|0-3|This|O
DDI-DrugBank.d76.s17|5-15|interaction|O
DDI-DrugBank.d76.s17|16-16|,|O
DDI-DrugBank.d76.s17|18-22|which|O
DDI-DrugBank.d76.s17|24-26|has|O
DDI-DrugBank.d76.s17|28-30|not|O
DDI-DrugBank.d76.s17|32-35|been|O
DDI-DrugBank.d76.s17|37-48|investigated|O
DDI-DrugBank.d76.s17|50-54|using|O
DDI-DrugBank.d76.s17|56-61|higher|O
DDI-DrugBank.d76.s17|63-67|doses|O
DDI-DrugBank.d76.s17|69-70|of|O
DDI-DrugBank.d76.s17|72-82|fluvoxamine|drug
DDI-DrugBank.d76.s17|83-83|,|O
DDI-DrugBank.d76.s17|85-87|may|O
DDI-DrugBank.d76.s17|89-90|be|O
DDI-DrugBank.d76.s17|92-95|more|O
DDI-DrugBank.d76.s17|97-106|pronounced|O
DDI-DrugBank.d76.s17|108-109|if|O
DDI-DrugBank.d76.s17|111-111|a|O
DDI-DrugBank.d76.s17|113-115|300|O
DDI-DrugBank.d76.s17|117-118|mg|O
DDI-DrugBank.d76.s17|120-124|daily|O
DDI-DrugBank.d76.s17|126-129|dose|O
DDI-DrugBank.d76.s17|131-132|is|O
DDI-DrugBank.d76.s17|134-148|co-administered|O
DDI-DrugBank.d76.s17|149-149|,|O
DDI-DrugBank.d76.s17|151-162|particularly|O
DDI-DrugBank.d76.s17|164-168|since|O
DDI-DrugBank.d76.s17|170-180|fluvoxamine|drug
DDI-DrugBank.d76.s17|182-189|exhibits|O
DDI-DrugBank.d76.s17|191-200|non-linear|O
DDI-DrugBank.d76.s17|202-217|pharmacokinetics|O
DDI-DrugBank.d76.s17|219-222|over|O
DDI-DrugBank.d76.s17|224-226|the|O
DDI-DrugBank.d76.s17|228-233|dosage|O
DDI-DrugBank.d76.s17|235-239|range|O
DDI-DrugBank.d76.s17|241-247|100-300|O
DDI-DrugBank.d76.s17|249-251|mg.|O
DDI-DrugBank.d76.s17|253-254|If|O
DDI-DrugBank.d76.s17|256-265|alprazolam|drug
DDI-DrugBank.d76.s17|267-268|is|O
DDI-DrugBank.d76.s17|270-284|co-administered|O
DDI-DrugBank.d76.s17|286-289|with|O
DDI-DrugBank.d76.s17|291-301|Fluvoxamine|drug
DDI-DrugBank.d76.s17|303-309|Tablets|O
DDI-DrugBank.d76.s17|310-310|,|O
DDI-DrugBank.d76.s17|312-314|the|O
DDI-DrugBank.d76.s17|316-322|initial|O
DDI-DrugBank.d76.s17|324-333|alprazolam|drug
DDI-DrugBank.d76.s17|335-340|dosage|O
DDI-DrugBank.d76.s17|342-347|should|O
DDI-DrugBank.d76.s17|349-350|be|O
DDI-DrugBank.d76.s17|352-353|at|O
DDI-DrugBank.d76.s17|355-359|least|O
DDI-DrugBank.d76.s17|361-366|halved|O
DDI-DrugBank.d76.s17|368-370|and|O
DDI-DrugBank.d76.s17|372-380|titration|O
DDI-DrugBank.d76.s17|382-383|to|O
DDI-DrugBank.d76.s17|385-387|the|O
DDI-DrugBank.d76.s17|389-394|lowest|O
DDI-DrugBank.d76.s17|396-404|effective|O
DDI-DrugBank.d76.s17|406-409|dose|O
DDI-DrugBank.d76.s17|411-412|is|O
DDI-DrugBank.d76.s17|414-424|recommended|O
DDI-DrugBank.d76.s17|425-425|.|O
DDI-DrugBank.d76.s18|0-1|No|O
DDI-DrugBank.d76.s18|3-8|dosage|O
DDI-DrugBank.d76.s18|10-19|adjustment|O
DDI-DrugBank.d76.s18|21-22|is|O
DDI-DrugBank.d76.s18|24-31|required|O
DDI-DrugBank.d76.s18|33-35|for|O
DDI-DrugBank.d76.s18|37-47|Fluvoxamine|drug
DDI-DrugBank.d76.s18|49-55|Tablets|O
DDI-DrugBank.d76.s18|56-56|.|O
DDI-DrugBank.d76.s19|0-7|Diazepam|drug
DDI-DrugBank.d76.s19|8-8|:|O
DDI-DrugBank.d76.s19|10-12|The|O
DDI-DrugBank.d76.s19|14-30|co-administration|O
DDI-DrugBank.d76.s19|32-33|of|O
DDI-DrugBank.d76.s19|35-45|Fluvoxamine|drug
DDI-DrugBank.d76.s19|47-53|Tablets|O
DDI-DrugBank.d76.s19|55-57|and|O
DDI-DrugBank.d76.s19|59-66|diazepam|drug
DDI-DrugBank.d76.s19|68-69|is|O
DDI-DrugBank.d76.s19|71-79|generally|O
DDI-DrugBank.d76.s19|81-83|not|O
DDI-DrugBank.d76.s19|85-93|advisable|O
DDI-DrugBank.d76.s19|94-94|.|O
DDI-DrugBank.d76.s20|0-6|Because|O
DDI-DrugBank.d76.s20|8-18|fluvoxamine|drug
DDI-DrugBank.d76.s20|20-26|reduces|O
DDI-DrugBank.d76.s20|28-30|the|O
DDI-DrugBank.d76.s20|32-40|clearance|O
DDI-DrugBank.d76.s20|42-43|of|O
DDI-DrugBank.d76.s20|45-48|both|O
DDI-DrugBank.d76.s20|50-57|diazepam|drug
DDI-DrugBank.d76.s20|59-61|and|O
DDI-DrugBank.d76.s20|63-65|its|O
DDI-DrugBank.d76.s20|67-72|active|O
DDI-DrugBank.d76.s20|74-83|metabolite|O
DDI-DrugBank.d76.s20|84-84|,|O
DDI-DrugBank.d76.s20|105-105|,|O
DDI-DrugBank.d76.s20|107-111|there|O
DDI-DrugBank.d76.s20|113-114|is|O
DDI-DrugBank.d76.s20|116-116|a|O
DDI-DrugBank.d76.s20|118-123|strong|O
DDI-DrugBank.d76.s20|125-134|likelihood|O
DDI-DrugBank.d76.s20|136-137|of|O
DDI-DrugBank.d76.s20|139-149|substantial|O
DDI-DrugBank.d76.s20|151-162|accumulation|O
DDI-DrugBank.d76.s20|164-165|of|O
DDI-DrugBank.d76.s20|167-170|both|O
DDI-DrugBank.d76.s20|172-178|species|O
DDI-DrugBank.d76.s20|180-185|during|O
DDI-DrugBank.d76.s20|187-193|chronic|O
DDI-DrugBank.d76.s20|195-211|co-administration|O
DDI-DrugBank.d76.s20|212-212|.|O
DDI-DrugBank.d76.s21|0-7|Evidence|O
DDI-DrugBank.d76.s21|9-18|supporting|O
DDI-DrugBank.d76.s21|20-22|the|O
DDI-DrugBank.d76.s21|24-33|conclusion|O
DDI-DrugBank.d76.s21|35-38|that|O
DDI-DrugBank.d76.s21|40-41|it|O
DDI-DrugBank.d76.s21|43-44|is|O
DDI-DrugBank.d76.s21|46-56|inadvisable|O
DDI-DrugBank.d76.s21|58-59|to|O
DDI-DrugBank.d76.s21|61-73|co-administer|O
DDI-DrugBank.d76.s21|75-85|fluvoxamine|drug
DDI-DrugBank.d76.s21|87-89|and|O
DDI-DrugBank.d76.s21|91-98|diazepam|drug
DDI-DrugBank.d76.s21|100-101|is|O
DDI-DrugBank.d76.s21|103-109|derived|O
DDI-DrugBank.d76.s21|111-114|from|O
DDI-DrugBank.d76.s21|116-116|a|O
DDI-DrugBank.d76.s21|118-122|study|O
DDI-DrugBank.d76.s21|124-125|in|O
DDI-DrugBank.d76.s21|127-131|which|O
DDI-DrugBank.d76.s21|133-139|healthy|O
DDI-DrugBank.d76.s21|141-150|volunteers|O
DDI-DrugBank.d76.s21|152-157|taking|O
DDI-DrugBank.d76.s21|159-161|150|O
DDI-DrugBank.d76.s21|163-168|mg/day|O
DDI-DrugBank.d76.s21|170-171|of|O
DDI-DrugBank.d76.s21|173-183|fluvoxamine|drug
DDI-DrugBank.d76.s21|185-188|were|O
DDI-DrugBank.d76.s21|190-201|administered|O
DDI-DrugBank.d76.s21|203-203|a|O
DDI-DrugBank.d76.s21|205-210|single|O
DDI-DrugBank.d76.s21|212-215|oral|O
DDI-DrugBank.d76.s21|217-220|dose|O
DDI-DrugBank.d76.s21|222-223|of|O
DDI-DrugBank.d76.s21|225-226|10|O
DDI-DrugBank.d76.s21|228-229|mg|O
DDI-DrugBank.d76.s21|231-232|of|O
DDI-DrugBank.d76.s21|234-241|diazepam|drug
DDI-DrugBank.d76.s21|242-242|.|O
DDI-DrugBank.d76.s22|0-1|In|O
DDI-DrugBank.d76.s22|3-7|these|O
DDI-DrugBank.d76.s22|9-16|subjects|O
DDI-DrugBank.d76.s22|18-18|(|O
DDI-DrugBank.d76.s22|19-20|R=|O
DDI-DrugBank.d76.s22|22-22|B|O
DDI-DrugBank.d76.s22|23-23|)|O
DDI-DrugBank.d76.s22|24-24|,|O
DDI-DrugBank.d76.s22|26-28|the|O
DDI-DrugBank.d76.s22|30-38|clearance|O
DDI-DrugBank.d76.s22|40-41|of|O
DDI-DrugBank.d76.s22|43-50|diazepam|drug
DDI-DrugBank.d76.s22|52-54|was|O
DDI-DrugBank.d76.s22|56-62|reduced|O
DDI-DrugBank.d76.s22|64-65|by|O
DDI-DrugBank.d76.s22|67-68|65|O
DDI-DrugBank.d76.s22|69-69|%|O
DDI-DrugBank.d76.s22|71-73|and|O
DDI-DrugBank.d76.s22|75-78|that|O
DDI-DrugBank.d76.s22|80-81|of|O
DDI-DrugBank.d76.s22|103-104|to|O
DDI-DrugBank.d76.s22|106-106|a|O
DDI-DrugBank.d76.s22|108-112|level|O
DDI-DrugBank.d76.s22|114-117|that|O
DDI-DrugBank.d76.s22|119-121|was|O
DDI-DrugBank.d76.s22|123-125|too|O
DDI-DrugBank.d76.s22|127-129|low|O
DDI-DrugBank.d76.s22|131-132|to|O
DDI-DrugBank.d76.s22|134-140|measure|O
DDI-DrugBank.d76.s22|142-145|over|O
DDI-DrugBank.d76.s22|147-149|the|O
DDI-DrugBank.d76.s22|151-156|course|O
DDI-DrugBank.d76.s22|158-159|of|O
DDI-DrugBank.d76.s22|161-163|the|O
DDI-DrugBank.d76.s22|165-165|2|O
DDI-DrugBank.d76.s22|167-170|week|O
DDI-DrugBank.d76.s22|172-175|long|O
DDI-DrugBank.d76.s22|177-181|study|O
DDI-DrugBank.d76.s22|182-182|.|O
DDI-DrugBank.d76.s23|0-1|It|O
DDI-DrugBank.d76.s23|3-4|is|O
DDI-DrugBank.d76.s23|6-11|likely|O
DDI-DrugBank.d76.s23|13-16|that|O
DDI-DrugBank.d76.s23|18-27|experience|O
DDI-DrugBank.d76.s23|29-41|significantly|O
DDI-DrugBank.d76.s23|43-56|underestimates|O
DDI-DrugBank.d76.s23|58-60|the|O
DDI-DrugBank.d76.s23|62-67|degree|O
DDI-DrugBank.d76.s23|69-70|of|O
DDI-DrugBank.d76.s23|72-83|accumulation|O
DDI-DrugBank.d76.s23|85-88|that|O
DDI-DrugBank.d76.s23|90-94|might|O
DDI-DrugBank.d76.s23|96-100|occur|O
DDI-DrugBank.d76.s23|102-105|with|O
DDI-DrugBank.d76.s23|107-114|repealed|O
DDI-DrugBank.d76.s23|116-123|diazepam|drug
DDI-DrugBank.d76.s23|125-138|administration|O
DDI-DrugBank.d76.s23|139-139|.|O
DDI-DrugBank.d76.s24|0-7|Moreover|O
DDI-DrugBank.d76.s24|8-8|,|O
DDI-DrugBank.d76.s24|10-11|as|O
DDI-DrugBank.d76.s24|13-17|noted|O
DDI-DrugBank.d76.s24|19-22|with|O
DDI-DrugBank.d76.s24|24-33|alprazolam|drug
DDI-DrugBank.d76.s24|34-34|,|O
DDI-DrugBank.d76.s24|36-38|the|O
DDI-DrugBank.d76.s24|40-45|effect|O
DDI-DrugBank.d76.s24|47-48|of|O
DDI-DrugBank.d76.s24|50-60|fluvoxamine|drug
DDI-DrugBank.d76.s24|62-64|may|O
DDI-DrugBank.d76.s24|66-69|even|O
DDI-DrugBank.d76.s24|71-72|be|O
DDI-DrugBank.d76.s24|74-77|more|O
DDI-DrugBank.d76.s24|79-88|pronounced|O
DDI-DrugBank.d76.s24|90-93|when|O
DDI-DrugBank.d76.s24|95-96|it|O
DDI-DrugBank.d76.s24|98-99|is|O
DDI-DrugBank.d76.s24|101-112|administered|O
DDI-DrugBank.d76.s24|114-115|at|O
DDI-DrugBank.d76.s24|117-122|higher|O
DDI-DrugBank.d76.s24|124-128|doses|O
DDI-DrugBank.d76.s24|129-129|.|O
DDI-DrugBank.d76.s25|0-10|Accordingly|O
DDI-DrugBank.d76.s25|11-11|,|O
DDI-DrugBank.d76.s25|13-20|diazepam|drug
DDI-DrugBank.d76.s25|22-24|and|O
DDI-DrugBank.d76.s25|26-36|fluvoxamine|drug
DDI-DrugBank.d76.s25|38-43|should|O
DDI-DrugBank.d76.s25|45-47|not|O
DDI-DrugBank.d76.s25|49-58|ordinarily|O
DDI-DrugBank.d76.s25|60-61|be|O
DDI-DrugBank.d76.s25|63-77|co-administered|O
DDI-DrugBank.d76.s25|78-78|.|O
DDI-DrugBank.d76.s26|0-11|Theophylline|drug
DDI-DrugBank.d76.s26|12-12|:|O
DDI-DrugBank.d76.s26|14-16|The|O
DDI-DrugBank.d76.s26|18-23|effect|O
DDI-DrugBank.d76.s26|25-26|of|O
DDI-DrugBank.d76.s26|28-39|steady-state|O
DDI-DrugBank.d76.s26|41-51|fluvoxamine|drug
DDI-DrugBank.d76.s26|53-55|l50|O
DDI-DrugBank.d76.s26|57-58|mg|O
DDI-DrugBank.d76.s26|60-62|bid|O
DDI-DrugBank.d76.s26|64-65|on|O
DDI-DrugBank.d76.s26|67-69|the|O
DDI-DrugBank.d76.s26|71-86|pharmacokinetics|O
DDI-DrugBank.d76.s26|88-89|of|O
DDI-DrugBank.d76.s26|91-91|a|O
DDI-DrugBank.d76.s26|93-98|single|O
DDI-DrugBank.d76.s26|100-103|dose|O
DDI-DrugBank.d76.s26|105-106|of|O
DDI-DrugBank.d76.s26|108-119|Theophylline|drug
DDI-DrugBank.d76.s26|121-121|(|O
DDI-DrugBank.d76.s26|122-124|375|O
DDI-DrugBank.d76.s26|126-127|mg|O
DDI-DrugBank.d76.s26|128-128|)|O
DDI-DrugBank.d76.s26|130-131|as|O
DDI-DrugBank.d76.s26|133-135|442|O
DDI-DrugBank.d76.s26|137-138|mg|O
DDI-DrugBank.d76.s26|140-152|aminophylline|drug
DDI-DrugBank.d76.s26|154-156|was|O
DDI-DrugBank.d76.s26|158-166|evaluated|O
DDI-DrugBank.d76.s26|168-169|in|O
DDI-DrugBank.d76.s26|171-172|12|O
DDI-DrugBank.d76.s26|174-180|healthy|O
DDI-DrugBank.d76.s26|182-192|non-smoking|O
DDI-DrugBank.d76.s26|193-193|,|O
DDI-DrugBank.d76.s26|195-198|male|O
DDI-DrugBank.d76.s26|200-209|volunteers|O
DDI-DrugBank.d76.s26|210-210|.|O
DDI-DrugBank.d76.s27|0-2|The|O
DDI-DrugBank.d76.s27|4-12|clearance|O
DDI-DrugBank.d76.s27|14-15|of|O
DDI-DrugBank.d76.s27|17-28|theophylline|drug
DDI-DrugBank.d76.s27|30-32|was|O
DDI-DrugBank.d76.s27|34-42|decreased|O
DDI-DrugBank.d76.s27|44-56|approximately|O
DDI-DrugBank.d76.s27|58-63|3-fold|O
DDI-DrugBank.d76.s27|64-64|.|O
DDI-DrugBank.d76.s28|0-8|Therefore|O
DDI-DrugBank.d76.s28|9-9|,|O
DDI-DrugBank.d76.s28|11-12|if|O
DDI-DrugBank.d76.s28|14-25|theophylline|drug
DDI-DrugBank.d76.s28|27-28|is|O
DDI-DrugBank.d76.s28|30-44|co-administered|O
DDI-DrugBank.d76.s28|46-49|with|O
DDI-DrugBank.d76.s28|51-69|fluvoxamine maleate|drug
DDI-DrugBank.d76.s28|70-70|,|O
DDI-DrugBank.d76.s28|72-74|its|O
DDI-DrugBank.d76.s28|76-79|dose|O
DDI-DrugBank.d76.s28|81-86|should|O
DDI-DrugBank.d76.s28|88-89|be|O
DDI-DrugBank.d76.s28|91-97|reduced|O
DDI-DrugBank.d76.s28|99-100|to|O
DDI-DrugBank.d76.s28|102-104|one|O
DDI-DrugBank.d76.s28|106-110|third|O
DDI-DrugBank.d76.s28|112-113|of|O
DDI-DrugBank.d76.s28|115-117|the|O
DDI-DrugBank.d76.s28|119-123|usual|O
DDI-DrugBank.d76.s28|125-129|daily|O
DDI-DrugBank.d76.s28|131-141|maintenance|O
DDI-DrugBank.d76.s28|143-146|dose|O
DDI-DrugBank.d76.s28|148-150|and|O
DDI-DrugBank.d76.s28|152-157|plasma|O
DDI-DrugBank.d76.s28|159-172|concentrations|O
DDI-DrugBank.d76.s28|174-175|of|O
DDI-DrugBank.d76.s28|177-188|theophylline|drug
DDI-DrugBank.d76.s28|190-195|should|O
DDI-DrugBank.d76.s28|197-198|to|O
DDI-DrugBank.d76.s28|200-208|monitored|O
DDI-DrugBank.d76.s28|209-209|.|O
DDI-DrugBank.d76.s29|0-1|No|O
DDI-DrugBank.d76.s29|3-8|dosage|O
DDI-DrugBank.d76.s29|10-19|adjustment|O
DDI-DrugBank.d76.s29|21-22|is|O
DDI-DrugBank.d76.s29|24-31|required|O
DDI-DrugBank.d76.s29|33-35|for|O
DDI-DrugBank.d76.s29|37-47|Fluvoxamine|drug
DDI-DrugBank.d76.s29|49-55|Tablets|O
DDI-DrugBank.d76.s29|56-56|.|O
DDI-DrugBank.d76.s30|0-7|Warfarin|drug
DDI-DrugBank.d76.s30|8-8|:|O
DDI-DrugBank.d76.s30|10-13|When|O
DDI-DrugBank.d76.s30|15-33|fluvoxamine maleate|drug
DDI-DrugBank.d76.s30|35-35|(|O
DDI-DrugBank.d76.s30|36-37|50|O
DDI-DrugBank.d76.s30|39-40|mg|O
DDI-DrugBank.d76.s30|42-44|tid|O
DDI-DrugBank.d76.s30|45-45|)|O
DDI-DrugBank.d76.s30|47-49|was|O
DDI-DrugBank.d76.s30|51-62|administered|O
DDI-DrugBank.d76.s30|64-76|concomitantly|O
DDI-DrugBank.d76.s30|78-81|with|O
DDI-DrugBank.d76.s30|83-90|warfarin|drug
DDI-DrugBank.d76.s30|92-94|for|O
DDI-DrugBank.d76.s30|96-98|two|O
DDI-DrugBank.d76.s30|100-104|weeks|O
DDI-DrugBank.d76.s30|105-105|,|O
DDI-DrugBank.d76.s30|107-114|warfarin|drug
DDI-DrugBank.d76.s30|116-121|plasma|O
DDI-DrugBank.d76.s30|123-136|concentrations|O
DDI-DrugBank.d76.s30|138-146|increased|O
DDI-DrugBank.d76.s30|148-149|by|O
DDI-DrugBank.d76.s30|151-152|98|O
DDI-DrugBank.d76.s30|153-153|%|O
DDI-DrugBank.d76.s30|155-157|and|O
DDI-DrugBank.d76.s30|159-169|prothrombin|O
DDI-DrugBank.d76.s30|171-175|times|O
DDI-DrugBank.d76.s30|177-180|were|O
DDI-DrugBank.d76.s30|182-190|prolonged|O
DDI-DrugBank.d76.s30|191-191|.|O
DDI-DrugBank.d76.s31|0-3|Thus|O
DDI-DrugBank.d76.s31|5-12|patients|O
DDI-DrugBank.d76.s31|14-22|receiving|O
DDI-DrugBank.d76.s31|24-27|oral|O
DDI-DrugBank.d76.s31|29-42|anticoagulants|group
DDI-DrugBank.d76.s31|44-46|and|O
DDI-DrugBank.d76.s31|48-58|Fluvoxamine|drug
DDI-DrugBank.d76.s31|60-66|Tablets|O
DDI-DrugBank.d76.s31|68-73|should|O
DDI-DrugBank.d76.s31|75-78|have|O
DDI-DrugBank.d76.s31|80-84|their|O
DDI-DrugBank.d76.s31|86-96|prothrombin|O
DDI-DrugBank.d76.s31|98-101|time|O
DDI-DrugBank.d76.s31|103-111|monitored|O
DDI-DrugBank.d76.s31|113-115|and|O
DDI-DrugBank.d76.s31|117-121|their|O
DDI-DrugBank.d76.s31|123-135|anticoagulant|group
DDI-DrugBank.d76.s31|137-140|dose|O
DDI-DrugBank.d76.s31|142-149|adjusted|O
DDI-DrugBank.d76.s31|151-161|accordingly|O
DDI-DrugBank.d76.s31|162-162|.|O
DDI-DrugBank.d76.s32|0-1|No|O
DDI-DrugBank.d76.s32|3-8|dosage|O
DDI-DrugBank.d76.s32|10-19|adjustment|O
DDI-DrugBank.d76.s32|21-22|is|O
DDI-DrugBank.d76.s32|24-31|required|O
DDI-DrugBank.d76.s32|33-35|for|O
DDI-DrugBank.d76.s32|37-47|Fluvoxamine|drug
DDI-DrugBank.d76.s32|49-55|Tablets|O
DDI-DrugBank.d76.s32|56-56|.|O
DDI-DrugBank.d448.s0|0-13|MAO inhibitors|group
DDI-DrugBank.d448.s0|15-21|prolong|O
DDI-DrugBank.d448.s0|23-25|and|O
DDI-DrugBank.d448.s0|27-35|intensify|O
DDI-DrugBank.d448.s0|37-39|the|O
DDI-DrugBank.d448.s0|41-47|effects|O
DDI-DrugBank.d448.s0|49-50|of|O
DDI-DrugBank.d448.s0|52-65|antihistamines|group
DDI-DrugBank.d448.s0|66-66|.|O
DDI-DrugBank.d448.s1|0-10|Concomitant|O
DDI-DrugBank.d448.s1|12-14|use|O
DDI-DrugBank.d448.s1|16-17|of|O
DDI-DrugBank.d448.s1|19-32|antihistamines|group
DDI-DrugBank.d448.s1|34-37|with|O
DDI-DrugBank.d448.s1|39-45|alcohol|drug
DDI-DrugBank.d448.s1|46-46|,|O
DDI-DrugBank.d448.s1|48-72|tricyclic antidepressants|group
DDI-DrugBank.d448.s1|73-73|,|O
DDI-DrugBank.d448.s1|75-86|barbiturates|group
DDI-DrugBank.d448.s1|87-87|,|O
DDI-DrugBank.d448.s1|89-90|or|O
DDI-DrugBank.d448.s1|92-96|other|O
DDI-DrugBank.d448.s1|98-131|central nervous system depressants|group
DDI-DrugBank.d448.s1|133-135|may|O
DDI-DrugBank.d448.s1|137-140|have|O
DDI-DrugBank.d448.s1|142-143|an|O
DDI-DrugBank.d448.s1|145-152|additive|O
DDI-DrugBank.d448.s1|154-159|effect|O
DDI-DrugBank.d448.s1|160-160|.|O
DDI-DrugBank.d448.s2|0-3|When|O
DDI-DrugBank.d448.s2|5-25|sympathomimetic drugs|group
DDI-DrugBank.d448.s2|27-29|are|O
DDI-DrugBank.d448.s2|31-35|given|O
DDI-DrugBank.d448.s2|37-38|to|O
DDI-DrugBank.d448.s2|40-47|patients|O
DDI-DrugBank.d448.s2|49-57|receiving|O
DDI-DrugBank.d448.s2|59-86|monoamine oxidase inhibitors|group
DDI-DrugBank.d448.s2|87-87|,|O
DDI-DrugBank.d448.s2|89-100|hypertensive|O
DDI-DrugBank.d448.s2|102-110|reactions|O
DDI-DrugBank.d448.s2|111-111|,|O
DDI-DrugBank.d448.s2|113-121|including|O
DDI-DrugBank.d448.s2|123-134|hypertensive|O
DDI-DrugBank.d448.s2|136-141|crises|O
DDI-DrugBank.d448.s2|142-142|,|O
DDI-DrugBank.d448.s2|144-146|may|O
DDI-DrugBank.d448.s2|148-152|occur|O
DDI-DrugBank.d448.s2|153-153|.|O
DDI-DrugBank.d448.s3|0-2|The|O
DDI-DrugBank.d448.s3|4-19|antihypertensive|O
DDI-DrugBank.d448.s3|21-27|effects|O
DDI-DrugBank.d448.s3|29-30|of|O
DDI-DrugBank.d448.s3|32-41|methyldopa|drug
DDI-DrugBank.d448.s3|42-42|,|O
DDI-DrugBank.d448.s3|44-55|mecamylamine|drug
DDI-DrugBank.d448.s3|56-56|,|O
DDI-DrugBank.d448.s3|58-66|reserpine|drug
DDI-DrugBank.d448.s3|67-67|,|O
DDI-DrugBank.d448.s3|69-71|and|O
DDI-DrugBank.d448.s3|73-90|veratrum alkaloids|drug
DDI-DrugBank.d448.s3|92-94|may|O
DDI-DrugBank.d448.s3|96-97|be|O
DDI-DrugBank.d448.s3|99-105|reduced|O
DDI-DrugBank.d448.s3|107-108|by|O
DDI-DrugBank.d448.s3|110-125|sympathomimetics|group
DDI-DrugBank.d448.s3|126-126|.|O
DDI-DrugBank.d448.s4|0-30|Beta-adrenergic blocking agents|group
DDI-DrugBank.d448.s4|32-34|may|O
DDI-DrugBank.d448.s4|36-39|also|O
DDI-DrugBank.d448.s4|41-48|interact|O
DDI-DrugBank.d448.s4|50-53|with|O
DDI-DrugBank.d448.s4|55-70|sympathomimetics|group
DDI-DrugBank.d448.s4|71-71|.|O
DDI-DrugBank.d448.s5|0-8|Increased|O
DDI-DrugBank.d448.s5|10-16|ectopic|O
DDI-DrugBank.d448.s5|18-26|pacemaker|O
DDI-DrugBank.d448.s5|28-35|activity|O
DDI-DrugBank.d448.s5|37-39|can|O
DDI-DrugBank.d448.s5|41-45|occur|O
DDI-DrugBank.d448.s5|47-50|when|O
DDI-DrugBank.d448.s5|52-66|pseudoephedrine|drug
DDI-DrugBank.d448.s5|68-69|is|O
DDI-DrugBank.d448.s5|71-74|used|O
DDI-DrugBank.d448.s5|76-88|concomitantly|O
DDI-DrugBank.d448.s5|90-93|with|O
DDI-DrugBank.d448.s5|95-103|digitalis|group
DDI-DrugBank.d448.s5|104-104|.|O
DDI-DrugBank.d448.s6|0-7|Antacids|group
DDI-DrugBank.d448.s6|9-16|increase|O
DDI-DrugBank.d448.s6|18-20|the|O
DDI-DrugBank.d448.s6|22-25|rate|O
DDI-DrugBank.d448.s6|27-28|of|O
DDI-DrugBank.d448.s6|30-39|absorption|O
DDI-DrugBank.d448.s6|41-42|of|O
DDI-DrugBank.d448.s6|44-58|pseudoephedrine|drug
DDI-DrugBank.d448.s6|59-59|,|O
DDI-DrugBank.d448.s6|61-65|while|O
DDI-DrugBank.d448.s6|67-72|kaolin|drug
DDI-DrugBank.d448.s6|74-82|decreases|O
DDI-DrugBank.d448.s6|84-85|it|O
DDI-DrugBank.d448.s6|86-86|.|O
DDI-DrugBank.d182.s0|0-1|No|O
DDI-DrugBank.d182.s0|3-10|clinical|O
DDI-DrugBank.d182.s0|12-15|drug|O
DDI-DrugBank.d182.s0|17-27|interaction|O
DDI-DrugBank.d182.s0|29-35|studies|O
DDI-DrugBank.d182.s0|37-40|have|O
DDI-DrugBank.d182.s0|42-45|been|O
DDI-DrugBank.d182.s0|47-55|conducted|O
DDI-DrugBank.d182.s0|56-56|.|O
DDI-DrugBank.d182.s1|0-6|However|O
DDI-DrugBank.d182.s1|7-7|,|O
DDI-DrugBank.d182.s1|9-10|in|O
DDI-DrugBank.d182.s1|12-12|a|O
DDI-DrugBank.d182.s1|14-19|single|O
DDI-DrugBank.d182.s1|21-22|in|O
DDI-DrugBank.d182.s1|24-27|vivo|O
DDI-DrugBank.d182.s1|29-34|rodent|O
DDI-DrugBank.d182.s1|36-40|study|O
DDI-DrugBank.d182.s1|42-60|denileukin diftitox|drug
DDI-DrugBank.d182.s1|62-64|had|O
DDI-DrugBank.d182.s1|66-67|no|O
DDI-DrugBank.d182.s1|69-74|effect|O
DDI-DrugBank.d182.s1|76-77|on|O
DDI-DrugBank.d182.s1|79-82|P450|O
DDI-DrugBank.d182.s1|84-89|levels|O
DDI-DrugBank.d182.s1|90-90|.|O
DDI-DrugBank.d695.s0|0-4|While|O
DDI-DrugBank.d695.s0|6-22|co-administration|O
DDI-DrugBank.d695.s0|24-25|of|O
DDI-DrugBank.d695.s0|27-33|ZAVESCA|brand
DDI-DrugBank.d695.s0|38-45|appeared|O
DDI-DrugBank.d695.s0|47-48|to|O
DDI-DrugBank.d695.s0|50-57|increase|O
DDI-DrugBank.d695.s0|59-61|the|O
DDI-DrugBank.d695.s0|63-71|clearance|O
DDI-DrugBank.d695.s0|73-74|of|O
DDI-DrugBank.d695.s0|76-83|Cerezyme|brand
DDI-DrugBank.d695.s0|85-86|by|O
DDI-DrugBank.d695.s0|88-89|70|O
DDI-DrugBank.d695.s0|90-90|%|O
DDI-DrugBank.d695.s0|91-91|,|O
DDI-DrugBank.d695.s0|93-97|these|O
DDI-DrugBank.d695.s0|99-105|results|O
DDI-DrugBank.d695.s0|107-109|are|O
DDI-DrugBank.d695.s0|111-113|not|O
DDI-DrugBank.d695.s0|115-124|conclusive|O
DDI-DrugBank.d695.s0|126-132|because|O
DDI-DrugBank.d695.s0|134-135|of|O
DDI-DrugBank.d695.s0|137-139|the|O
DDI-DrugBank.d695.s0|141-145|small|O
DDI-DrugBank.d695.s0|147-152|number|O
DDI-DrugBank.d695.s0|154-155|of|O
DDI-DrugBank.d695.s0|157-164|subjects|O
DDI-DrugBank.d695.s0|166-172|studied|O
DDI-DrugBank.d695.s0|174-176|and|O
DDI-DrugBank.d695.s0|178-184|because|O
DDI-DrugBank.d695.s0|186-193|patients|O
DDI-DrugBank.d695.s0|195-198|took|O
DDI-DrugBank.d695.s0|200-207|variable|O
DDI-DrugBank.d695.s0|209-213|doses|O
DDI-DrugBank.d695.s0|215-216|of|O
DDI-DrugBank.d695.s0|218-225|Cerezyme|brand
DDI-DrugBank.d695.s0|226-226|.|O
DDI-DrugBank.d695.s1|0-10|Combination|O
DDI-DrugBank.d695.s1|12-18|therapy|O
DDI-DrugBank.d695.s1|20-23|with|O
DDI-DrugBank.d695.s1|25-32|Cerezyme|brand
DDI-DrugBank.d695.s1|37-37|(|O
DDI-DrugBank.d695.s1|38-49|imiglucerase|drug
DDI-DrugBank.d695.s1|50-50|)|O
DDI-DrugBank.d695.s1|52-54|and|O
DDI-DrugBank.d695.s1|56-62|ZAVESCA|brand
DDI-DrugBank.d695.s1|67-68|is|O
DDI-DrugBank.d695.s1|70-72|not|O
DDI-DrugBank.d695.s1|74-82|indicated|O
DDI-DrugBank.d695.s1|83-83|.|O
DDI-DrugBank.d100.s0|0-8|Increased|O
DDI-DrugBank.d100.s0|10-23|nephrotoxicity|O
DDI-DrugBank.d100.s0|25-27|has|O
DDI-DrugBank.d100.s0|29-32|been|O
DDI-DrugBank.d100.s0|34-41|reported|O
DDI-DrugBank.d100.s0|43-51|following|O
DDI-DrugBank.d100.s0|53-63|concomitant|O
DDI-DrugBank.d100.s0|65-78|administration|O
DDI-DrugBank.d100.s0|80-81|of|O
DDI-DrugBank.d100.s0|83-96|cephalosporins|group
DDI-DrugBank.d100.s0|98-100|and|O
DDI-DrugBank.d100.s0|102-127|aminoglycoside antibiotics|group
DDI-DrugBank.d100.s0|128-128|.|O
DDI-DrugBank.d100.s1|0-14|Drug/Laboratory|O
DDI-DrugBank.d100.s1|16-19|Test|O
DDI-DrugBank.d100.s1|21-32|Interactions|O
DDI-DrugBank.d100.s1|34-47|Cephalosporins|group
DDI-DrugBank.d100.s1|48-48|,|O
DDI-DrugBank.d100.s1|50-58|including|O
DDI-DrugBank.d100.s1|60-76|cefotaxime sodium|drug
DDI-DrugBank.d100.s1|77-77|,|O
DDI-DrugBank.d100.s1|79-81|are|O
DDI-DrugBank.d100.s1|83-87|known|O
DDI-DrugBank.d100.s1|89-90|to|O
DDI-DrugBank.d100.s1|92-103|occasionally|O
DDI-DrugBank.d100.s1|105-110|induce|O
DDI-DrugBank.d100.s1|112-112|a|O
DDI-DrugBank.d100.s1|114-121|positive|O
DDI-DrugBank.d100.s1|123-128|direct|O
DDI-DrugBank.d100.s1|130-135|Coombs|O
DDI-DrugBank.d100.s1|137-140|test|O
DDI-DrugBank.d100.s1|141-141|.|O
DDI-DrugBank.d427.s0|0-7|Elevated|O
DDI-DrugBank.d427.s0|9-14|plasma|O
DDI-DrugBank.d427.s0|16-21|levels|O
DDI-DrugBank.d427.s0|23-24|of|O
DDI-DrugBank.d427.s0|26-37|theophylline|drug
DDI-DrugBank.d427.s0|39-42|have|O
DDI-DrugBank.d427.s0|44-47|been|O
DDI-DrugBank.d427.s0|49-56|reported|O
DDI-DrugBank.d427.s0|58-61|with|O
DDI-DrugBank.d427.s0|63-73|concomitant|O
DDI-DrugBank.d427.s0|75-83|quinolone|group
DDI-DrugBank.d427.s0|85-87|use|O
DDI-DrugBank.d427.s0|88-88|.|O
DDI-DrugBank.d427.s1|0-4|There|O
DDI-DrugBank.d427.s1|6-9|have|O
DDI-DrugBank.d427.s1|11-14|been|O
DDI-DrugBank.d427.s1|16-22|reports|O
DDI-DrugBank.d427.s1|24-25|of|O
DDI-DrugBank.d427.s1|27-46|theophylline-related|drug
DDI-DrugBank.d427.s1|48-51|side|O
DDI-DrugBank.d427.s1|53-59|effects|O
DDI-DrugBank.d427.s1|61-62|in|O
DDI-DrugBank.d427.s1|64-71|patients|O
DDI-DrugBank.d427.s1|73-74|on|O
DDI-DrugBank.d427.s1|76-86|concomitant|O
DDI-DrugBank.d427.s1|88-94|therapy|O
DDI-DrugBank.d427.s1|96-99|with|O
DDI-DrugBank.d427.s1|101-110|quinolones|group
DDI-DrugBank.d427.s1|112-114|and|O
DDI-DrugBank.d427.s1|116-127|theophylline|drug
DDI-DrugBank.d427.s1|128-128|.|O
DDI-DrugBank.d427.s2|0-8|Therefore|O
DDI-DrugBank.d427.s2|9-9|,|O
DDI-DrugBank.d427.s2|11-20|monitoring|O
DDI-DrugBank.d427.s2|22-23|of|O
DDI-DrugBank.d427.s2|25-36|theophylline|drug
DDI-DrugBank.d427.s2|38-43|plasma|O
DDI-DrugBank.d427.s2|45-50|levels|O
DDI-DrugBank.d427.s2|52-57|should|O
DDI-DrugBank.d427.s2|59-60|be|O
DDI-DrugBank.d427.s2|62-71|considered|O
DDI-DrugBank.d427.s2|73-75|and|O
DDI-DrugBank.d427.s2|77-82|dosage|O
DDI-DrugBank.d427.s2|84-85|of|O
DDI-DrugBank.d427.s2|87-98|theophylline|drug
DDI-DrugBank.d427.s2|100-107|adjusted|O
DDI-DrugBank.d427.s2|108-108|,|O
DDI-DrugBank.d427.s2|110-111|as|O
DDI-DrugBank.d427.s2|113-120|required|O
DDI-DrugBank.d427.s2|121-121|.|O
DDI-DrugBank.d427.s3|0-9|Quinolones|group
DDI-DrugBank.d427.s3|11-14|have|O
DDI-DrugBank.d427.s3|16-19|been|O
DDI-DrugBank.d427.s3|21-25|shown|O
DDI-DrugBank.d427.s3|27-28|to|O
DDI-DrugBank.d427.s3|30-38|interfere|O
DDI-DrugBank.d427.s3|40-43|with|O
DDI-DrugBank.d427.s3|45-47|the|O
DDI-DrugBank.d427.s3|49-58|metabolism|O
DDI-DrugBank.d427.s3|60-61|of|O
DDI-DrugBank.d427.s3|63-70|caffeine|drug
DDI-DrugBank.d427.s3|71-71|.|O
DDI-DrugBank.d427.s4|0-3|This|O
DDI-DrugBank.d427.s4|5-7|may|O
DDI-DrugBank.d427.s4|9-12|lead|O
DDI-DrugBank.d427.s4|14-15|to|O
DDI-DrugBank.d427.s4|17-23|reduced|O
DDI-DrugBank.d427.s4|25-33|clearance|O
DDI-DrugBank.d427.s4|35-36|of|O
DDI-DrugBank.d427.s4|38-45|caffeine|drug
DDI-DrugBank.d427.s4|47-49|and|O
DDI-DrugBank.d427.s4|51-53|the|O
DDI-DrugBank.d427.s4|55-66|prolongation|O
DDI-DrugBank.d427.s4|68-69|of|O
DDI-DrugBank.d427.s4|71-73|its|O
DDI-DrugBank.d427.s4|75-80|plasma|O
DDI-DrugBank.d427.s4|82-90|half-life|O
DDI-DrugBank.d427.s4|91-91|.|O
DDI-DrugBank.d427.s5|0-9|Quinolones|group
DDI-DrugBank.d427.s5|10-10|,|O
DDI-DrugBank.d427.s5|12-20|including|O
DDI-DrugBank.d427.s5|22-35|nalidixic acid|drug
DDI-DrugBank.d427.s5|36-36|,|O
DDI-DrugBank.d427.s5|38-40|may|O
DDI-DrugBank.d427.s5|42-48|enhance|O
DDI-DrugBank.d427.s5|50-52|the|O
DDI-DrugBank.d427.s5|54-60|effects|O
DDI-DrugBank.d427.s5|62-63|of|O
DDI-DrugBank.d427.s5|65-67|the|O
DDI-DrugBank.d427.s5|69-72|oral|O
DDI-DrugBank.d427.s5|74-86|anticoagulant|group
DDI-DrugBank.d427.s5|74-86|anticoagulant|group
DDI-DrugBank.d427.s5|97-98|or|O
DDI-DrugBank.d427.s5|100-102|its|O
DDI-DrugBank.d427.s5|104-114|derivatives|O
DDI-DrugBank.d427.s5|115-115|.|O
DDI-DrugBank.d427.s6|0-3|When|O
DDI-DrugBank.d427.s6|5-9|these|O
DDI-DrugBank.d427.s6|11-18|products|O
DDI-DrugBank.d427.s6|20-22|are|O
DDI-DrugBank.d427.s6|24-35|administered|O
DDI-DrugBank.d427.s6|37-49|concomitantly|O
DDI-DrugBank.d427.s6|50-50|,|O
DDI-DrugBank.d427.s6|52-62|prothrombin|O
DDI-DrugBank.d427.s6|64-67|time|O
DDI-DrugBank.d427.s6|69-70|or|O
DDI-DrugBank.d427.s6|72-76|other|O
DDI-DrugBank.d427.s6|78-85|suitable|O
DDI-DrugBank.d427.s6|87-97|coagulation|O
DDI-DrugBank.d427.s6|99-102|test|O
DDI-DrugBank.d427.s6|104-109|should|O
DDI-DrugBank.d427.s6|111-112|be|O
DDI-DrugBank.d427.s6|114-120|closely|O
DDI-DrugBank.d427.s6|122-130|monitored|O
DDI-DrugBank.d427.s6|131-131|.|O
DDI-DrugBank.d427.s7|0-13|Nitrofurantoin|drug
DDI-DrugBank.d427.s7|15-24|interferes|O
DDI-DrugBank.d427.s7|26-29|with|O
DDI-DrugBank.d427.s7|31-33|the|O
DDI-DrugBank.d427.s7|35-45|therapeutic|O
DDI-DrugBank.d427.s7|47-52|action|O
DDI-DrugBank.d427.s7|54-55|of|O
DDI-DrugBank.d427.s7|57-70|nalidixic acid|drug
DDI-DrugBank.d427.s7|71-71|.|O
DDI-DrugBank.d427.s8|0-7|Antacids|group
DDI-DrugBank.d427.s8|9-18|containing|O
DDI-DrugBank.d427.s8|20-28|magnesium|drug
DDI-DrugBank.d427.s8|29-29|,|O
DDI-DrugBank.d427.s8|31-38|aluminum|drug
DDI-DrugBank.d427.s8|39-39|,|O
DDI-DrugBank.d427.s8|41-42|or|O
DDI-DrugBank.d427.s8|44-50|calcium|drug
DDI-DrugBank.d427.s8|51-51|;|O
DDI-DrugBank.d427.s9|0-9|sucralfate|drug
DDI-DrugBank.d427.s9|11-12|or|O
DDI-DrugBank.d427.s9|14-21|divalent|O
DDI-DrugBank.d427.s9|23-24|or|O
DDI-DrugBank.d427.s9|26-34|trivalent|O
DDI-DrugBank.d427.s9|36-42|cations|O
DDI-DrugBank.d427.s9|44-47|such|O
DDI-DrugBank.d427.s9|49-50|as|O
DDI-DrugBank.d427.s9|52-55|iron|drug
DDI-DrugBank.d427.s9|56-56|;|O
DDI-DrugBank.d427.s10|0-12|multivitamins|group
DDI-DrugBank.d427.s10|14-23|containing|O
DDI-DrugBank.d427.s10|25-28|zinc|drug
DDI-DrugBank.d427.s10|29-29|;|O
DDI-DrugBank.d427.s11|0-2|and|O
DDI-DrugBank.d427.s11|4-8|Videx|brand
DDI-DrugBank.d427.s11|10-10|,|O
DDI-DrugBank.d427.s11|12-12|(|O
DDI-DrugBank.d427.s11|13-22|Didanosine|drug
DDI-DrugBank.d427.s11|23-23|)|O
DDI-DrugBank.d427.s11|24-24|,|O
DDI-DrugBank.d427.s11|26-42|chewable/buffered|O
DDI-DrugBank.d427.s11|44-50|tablets|O
DDI-DrugBank.d427.s11|52-53|or|O
DDI-DrugBank.d427.s11|55-57|the|O
DDI-DrugBank.d427.s11|59-67|pediatric|O
DDI-DrugBank.d427.s11|69-74|powder|O
DDI-DrugBank.d427.s11|76-78|for|O
DDI-DrugBank.d427.s11|80-83|oral|O
DDI-DrugBank.d427.s11|85-92|solution|O
DDI-DrugBank.d427.s11|94-96|may|O
DDI-DrugBank.d427.s11|98-110|substantially|O
DDI-DrugBank.d427.s11|112-120|interfere|O
DDI-DrugBank.d427.s11|122-125|with|O
DDI-DrugBank.d427.s11|127-129|the|O
DDI-DrugBank.d427.s11|131-140|absorption|O
DDI-DrugBank.d427.s11|142-143|of|O
DDI-DrugBank.d427.s11|145-154|quinolones|group
DDI-DrugBank.d427.s11|155-155|,|O
DDI-DrugBank.d427.s11|157-165|resulting|O
DDI-DrugBank.d427.s11|167-168|in|O
DDI-DrugBank.d427.s11|170-177|systemic|O
DDI-DrugBank.d427.s11|179-184|levels|O
DDI-DrugBank.d427.s11|186-197|considerably|O
DDI-DrugBank.d427.s11|199-203|lower|O
DDI-DrugBank.d427.s11|205-208|than|O
DDI-DrugBank.d427.s11|210-216|desired|O
DDI-DrugBank.d427.s11|217-217|.|O
DDI-DrugBank.d427.s12|0-4|These|O
DDI-DrugBank.d427.s12|6-11|agents|O
DDI-DrugBank.d427.s12|13-18|should|O
DDI-DrugBank.d427.s12|20-22|not|O
DDI-DrugBank.d427.s12|24-25|be|O
DDI-DrugBank.d427.s12|27-31|taken|O
DDI-DrugBank.d427.s12|33-38|within|O
DDI-DrugBank.d427.s12|40-42|the|O
DDI-DrugBank.d427.s12|44-46|two|O
DDI-DrugBank.d427.s12|48-51|hour|O
DDI-DrugBank.d427.s12|53-58|period|O
DDI-DrugBank.d427.s12|60-65|before|O
DDI-DrugBank.d427.s12|67-68|or|O
DDI-DrugBank.d427.s12|70-75|within|O
DDI-DrugBank.d427.s12|77-79|the|O
DDI-DrugBank.d427.s12|81-88|two-hour|O
DDI-DrugBank.d427.s12|90-95|period|O
DDI-DrugBank.d427.s12|97-101|after|O
DDI-DrugBank.d427.s12|103-116|nalidixic acid|drug
DDI-DrugBank.d427.s12|118-131|administration|O
DDI-DrugBank.d427.s12|132-132|.|O
DDI-DrugBank.d427.s13|0-7|Elevated|O
DDI-DrugBank.d427.s13|9-13|serum|O
DDI-DrugBank.d427.s13|15-20|levels|O
DDI-DrugBank.d427.s13|22-23|of|O
DDI-DrugBank.d427.s13|25-36|cyclosporine|drug
DDI-DrugBank.d427.s13|38-41|have|O
DDI-DrugBank.d427.s13|43-46|been|O
DDI-DrugBank.d427.s13|48-55|reported|O
DDI-DrugBank.d427.s13|57-60|with|O
DDI-DrugBank.d427.s13|62-64|the|O
DDI-DrugBank.d427.s13|66-76|concomitant|O
DDI-DrugBank.d427.s13|78-80|use|O
DDI-DrugBank.d427.s13|82-83|of|O
DDI-DrugBank.d427.s13|85-88|some|O
DDI-DrugBank.d427.s13|90-99|quinolones|group
DDI-DrugBank.d427.s13|101-103|and|O
DDI-DrugBank.d427.s13|105-116|cyclosporine|drug
DDI-DrugBank.d427.s13|117-117|.|O
DDI-DrugBank.d427.s14|0-8|Therefore|O
DDI-DrugBank.d427.s14|9-9|,|O
DDI-DrugBank.d427.s14|11-22|cyclosporine|drug
DDI-DrugBank.d427.s14|24-28|serum|O
DDI-DrugBank.d427.s14|30-35|levels|O
DDI-DrugBank.d427.s14|37-42|should|O
DDI-DrugBank.d427.s14|44-45|be|O
DDI-DrugBank.d427.s14|47-55|monitored|O
DDI-DrugBank.d427.s14|57-59|and|O
DDI-DrugBank.d427.s14|61-71|appropriate|O
DDI-DrugBank.d427.s14|73-84|cyclosporine|drug
DDI-DrugBank.d427.s14|86-91|dosage|O
DDI-DrugBank.d427.s14|93-103|adjustments|O
DDI-DrugBank.d427.s14|105-108|made|O
DDI-DrugBank.d427.s14|110-113|when|O
DDI-DrugBank.d427.s14|115-119|these|O
DDI-DrugBank.d427.s14|121-125|drugs|O
DDI-DrugBank.d427.s14|127-129|are|O
DDI-DrugBank.d427.s14|131-134|used|O
DDI-DrugBank.d427.s14|136-148|concomitantly|O
DDI-DrugBank.d427.s14|149-149|.|O
DDI-DrugBank.d48.s0|0-4|Drugs|O
DDI-DrugBank.d48.s0|6-9|that|O
DDI-DrugBank.d48.s0|11-13|may|O
DDI-DrugBank.d48.s0|15-22|increase|O
DDI-DrugBank.d48.s0|24-32|dasatinib|drug
DDI-DrugBank.d48.s0|34-39|plasma|O
DDI-DrugBank.d48.s0|41-54|concentrations|O
DDI-DrugBank.d48.s0|56-61|CYP3A4|O
DDI-DrugBank.d48.s0|63-72|Inhibitors|O
DDI-DrugBank.d48.s0|73-73|:|O
DDI-DrugBank.d48.s0|75-83|Dasatinib|drug
DDI-DrugBank.d48.s0|85-86|is|O
DDI-DrugBank.d48.s0|88-88|a|O
DDI-DrugBank.d48.s0|90-95|CYP3A4|O
DDI-DrugBank.d48.s0|97-105|substrate|O
DDI-DrugBank.d48.s0|106-106|.|O
DDI-DrugBank.d48.s1|0-10|Concomitant|O
DDI-DrugBank.d48.s1|12-14|use|O
DDI-DrugBank.d48.s1|16-17|of|O
DDI-DrugBank.d48.s1|19-25|SPRYCEL|brand
DDI-DrugBank.d48.s1|27-29|and|O
DDI-DrugBank.d48.s1|31-35|drugs|O
DDI-DrugBank.d48.s1|37-40|that|O
DDI-DrugBank.d48.s1|42-48|inhibit|O
DDI-DrugBank.d48.s1|50-55|CYP3A4|O
DDI-DrugBank.d48.s1|57-57|(|O
DDI-DrugBank.d48.s1|58-59|eg|O
DDI-DrugBank.d48.s1|60-60|,|O
DDI-DrugBank.d48.s1|62-73|ketoconazole|drug
DDI-DrugBank.d48.s1|74-74|,|O
DDI-DrugBank.d48.s1|76-87|itraconazole|drug
DDI-DrugBank.d48.s1|88-88|,|O
DDI-DrugBank.d48.s1|90-101|erythromycin|drug
DDI-DrugBank.d48.s1|102-102|,|O
DDI-DrugBank.d48.s1|104-117|clarithromycin|drug
DDI-DrugBank.d48.s1|118-118|,|O
DDI-DrugBank.d48.s1|120-128|ritonavir|drug
DDI-DrugBank.d48.s1|129-129|,|O
DDI-DrugBank.d48.s1|131-140|atazanavir|drug
DDI-DrugBank.d48.s1|141-141|,|O
DDI-DrugBank.d48.s1|143-151|indinavir|drug
DDI-DrugBank.d48.s1|152-152|,|O
DDI-DrugBank.d48.s1|154-163|nefazodone|drug
DDI-DrugBank.d48.s1|164-164|,|O
DDI-DrugBank.d48.s1|166-175|nelfinavir|drug
DDI-DrugBank.d48.s1|176-176|,|O
DDI-DrugBank.d48.s1|178-187|saquinavir|drug
DDI-DrugBank.d48.s1|188-188|,|O
DDI-DrugBank.d48.s1|190-202|telithromycin|drug
DDI-DrugBank.d48.s1|203-203|)|O
DDI-DrugBank.d48.s1|205-207|may|O
DDI-DrugBank.d48.s1|209-216|increase|O
DDI-DrugBank.d48.s1|218-225|exposure|O
DDI-DrugBank.d48.s1|227-228|to|O
DDI-DrugBank.d48.s1|230-238|dasatinib|drug
DDI-DrugBank.d48.s1|240-242|and|O
DDI-DrugBank.d48.s1|244-249|should|O
DDI-DrugBank.d48.s1|251-252|be|O
DDI-DrugBank.d48.s1|254-260|avoided|O
DDI-DrugBank.d48.s1|261-261|.|O
DDI-DrugBank.d48.s2|0-1|In|O
DDI-DrugBank.d48.s2|3-10|patients|O
DDI-DrugBank.d48.s2|12-20|receiving|O
DDI-DrugBank.d48.s2|22-30|treatment|O
DDI-DrugBank.d48.s2|32-35|with|O
DDI-DrugBank.d48.s2|37-43|SPRYCEL|brand
DDI-DrugBank.d48.s2|44-44|,|O
DDI-DrugBank.d48.s2|46-50|close|O
DDI-DrugBank.d48.s2|52-61|monitoring|O
DDI-DrugBank.d48.s2|63-65|for|O
DDI-DrugBank.d48.s2|67-74|toxicity|O
DDI-DrugBank.d48.s2|76-78|and|O
DDI-DrugBank.d48.s2|80-80|a|O
DDI-DrugBank.d48.s2|82-88|SPRYCEL|brand
DDI-DrugBank.d48.s2|90-93|dose|O
DDI-DrugBank.d48.s2|95-103|reduction|O
DDI-DrugBank.d48.s2|105-110|should|O
DDI-DrugBank.d48.s2|112-113|be|O
DDI-DrugBank.d48.s2|115-124|considered|O
DDI-DrugBank.d48.s2|126-127|if|O
DDI-DrugBank.d48.s2|129-136|systemic|O
DDI-DrugBank.d48.s2|138-151|administration|O
DDI-DrugBank.d48.s2|153-154|of|O
DDI-DrugBank.d48.s2|156-156|a|O
DDI-DrugBank.d48.s2|158-163|potent|O
DDI-DrugBank.d48.s2|165-170|CYP3A4|O
DDI-DrugBank.d48.s2|172-180|inhibitor|O
DDI-DrugBank.d48.s2|182-184|can|O
DDI-DrugBank.d48.s2|185-187|not|O
DDI-DrugBank.d48.s2|189-190|be|O
DDI-DrugBank.d48.s2|192-198|avoided|O
DDI-DrugBank.d48.s2|199-199|.|O
DDI-DrugBank.d48.s3|0-4|Drugs|O
DDI-DrugBank.d48.s3|6-9|that|O
DDI-DrugBank.d48.s3|11-13|may|O
DDI-DrugBank.d48.s3|15-22|decrease|O
DDI-DrugBank.d48.s3|24-32|dasatinib|drug
DDI-DrugBank.d48.s3|34-39|plasma|O
DDI-DrugBank.d48.s3|41-54|concentrations|O
DDI-DrugBank.d48.s3|56-61|CYP3A4|O
DDI-DrugBank.d48.s3|63-70|Inducers|O
DDI-DrugBank.d48.s3|71-71|:|O
DDI-DrugBank.d48.s3|73-77|Drugs|O
DDI-DrugBank.d48.s3|79-82|that|O
DDI-DrugBank.d48.s3|84-89|induce|O
DDI-DrugBank.d48.s3|91-96|CYP3A4|O
DDI-DrugBank.d48.s3|98-105|activity|O
DDI-DrugBank.d48.s3|107-109|may|O
DDI-DrugBank.d48.s3|111-118|decrease|O
DDI-DrugBank.d48.s3|120-128|dasatinib|drug
DDI-DrugBank.d48.s3|130-135|plasma|O
DDI-DrugBank.d48.s3|137-150|concentrations|O
DDI-DrugBank.d48.s3|151-151|.|O
DDI-DrugBank.d48.s4|0-1|In|O
DDI-DrugBank.d48.s4|3-10|patients|O
DDI-DrugBank.d48.s4|12-13|in|O
DDI-DrugBank.d48.s4|15-18|whom|O
DDI-DrugBank.d48.s4|20-25|CYP3A4|O
DDI-DrugBank.d48.s4|27-34|inducers|O
DDI-DrugBank.d48.s4|36-36|(|O
DDI-DrugBank.d48.s4|37-38|eg|O
DDI-DrugBank.d48.s4|39-39|,|O
DDI-DrugBank.d48.s4|41-53|dexamethasone|drug
DDI-DrugBank.d48.s4|54-54|,|O
DDI-DrugBank.d48.s4|56-64|phenytoin|drug
DDI-DrugBank.d48.s4|65-65|,|O
DDI-DrugBank.d48.s4|67-79|carbamazepine|drug
DDI-DrugBank.d48.s4|80-80|,|O
DDI-DrugBank.d48.s4|82-91|rifampicin|drug
DDI-DrugBank.d48.s4|92-92|,|O
DDI-DrugBank.d48.s4|94-106|phenobarbital|drug
DDI-DrugBank.d48.s4|107-107|)|O
DDI-DrugBank.d48.s4|109-111|are|O
DDI-DrugBank.d48.s4|113-121|indicated|O
DDI-DrugBank.d48.s4|122-122|,|O
DDI-DrugBank.d48.s4|124-134|alternative|O
DDI-DrugBank.d48.s4|136-141|agents|O
DDI-DrugBank.d48.s4|143-146|with|O
DDI-DrugBank.d48.s4|148-151|less|O
DDI-DrugBank.d48.s4|153-158|enzyme|O
DDI-DrugBank.d48.s4|160-168|induction|O
DDI-DrugBank.d48.s4|170-178|potential|O
DDI-DrugBank.d48.s4|180-185|should|O
DDI-DrugBank.d48.s4|187-188|be|O
DDI-DrugBank.d48.s4|190-193|used|O
DDI-DrugBank.d48.s4|194-194|.|O
DDI-DrugBank.d48.s5|0-1|If|O
DDI-DrugBank.d48.s5|3-9|SPRYCEL|brand
DDI-DrugBank.d48.s5|11-14|must|O
DDI-DrugBank.d48.s5|16-17|be|O
DDI-DrugBank.d48.s5|19-30|administered|O
DDI-DrugBank.d48.s5|32-35|with|O
DDI-DrugBank.d48.s5|37-37|a|O
DDI-DrugBank.d48.s5|39-44|CYP3A4|O
DDI-DrugBank.d48.s5|46-52|inducer|O
DDI-DrugBank.d48.s5|53-53|,|O
DDI-DrugBank.d48.s5|55-55|a|O
DDI-DrugBank.d48.s5|57-60|dose|O
DDI-DrugBank.d48.s5|62-69|increase|O
DDI-DrugBank.d48.s5|71-72|in|O
DDI-DrugBank.d48.s5|74-80|SPRYCEL|brand
DDI-DrugBank.d48.s5|82-87|should|O
DDI-DrugBank.d48.s5|89-90|be|O
DDI-DrugBank.d48.s5|92-101|considered|O
DDI-DrugBank.d48.s5|102-102|.|O
DDI-DrugBank.d48.s6|0-2|St.|O
DDI-DrugBank.d48.s6|4-8|Johns|O
DDI-DrugBank.d48.s6|10-13|wort|O
DDI-DrugBank.d48.s6|15-15|(|O
DDI-DrugBank.d48.s6|16-24|Hypericum|O
DDI-DrugBank.d48.s6|26-35|perforatum|O
DDI-DrugBank.d48.s6|36-36|)|O
DDI-DrugBank.d48.s6|38-40|may|O
DDI-DrugBank.d48.s6|42-49|decrease|O
DDI-DrugBank.d48.s6|51-57|SPRYCEL|brand
DDI-DrugBank.d48.s6|59-64|plasma|O
DDI-DrugBank.d48.s6|66-79|concentrations|O
DDI-DrugBank.d48.s6|81-93|unpredictably|O
DDI-DrugBank.d48.s6|94-94|.|O
DDI-DrugBank.d48.s7|0-7|Patients|O
DDI-DrugBank.d48.s7|9-17|receiving|O
DDI-DrugBank.d48.s7|19-25|SPRYCEL|brand
DDI-DrugBank.d48.s7|27-32|should|O
DDI-DrugBank.d48.s7|34-36|not|O
DDI-DrugBank.d48.s7|38-41|take|O
DDI-DrugBank.d48.s7|43-45|St.|O
DDI-DrugBank.d48.s7|47-51|Johns|O
DDI-DrugBank.d48.s7|53-56|wort|O
DDI-DrugBank.d48.s7|57-57|.|O
DDI-DrugBank.d48.s8|0-7|Antacids|group
DDI-DrugBank.d48.s8|8-8|:|O
DDI-DrugBank.d48.s8|10-20|Nonclinical|O
DDI-DrugBank.d48.s8|22-25|data|O
DDI-DrugBank.d48.s8|27-37|demonstrate|O
DDI-DrugBank.d48.s8|39-42|that|O
DDI-DrugBank.d48.s8|44-46|the|O
DDI-DrugBank.d48.s8|48-57|solubility|O
DDI-DrugBank.d48.s8|59-60|of|O
DDI-DrugBank.d48.s8|62-70|dasatinib|drug
DDI-DrugBank.d48.s8|72-73|is|O
DDI-DrugBank.d48.s8|75-76|pH|O
DDI-DrugBank.d48.s8|78-86|dependent|O
DDI-DrugBank.d48.s8|87-87|.|O
DDI-DrugBank.d48.s9|0-11|Simultaneous|O
DDI-DrugBank.d48.s9|13-26|administration|O
DDI-DrugBank.d48.s9|28-29|of|O
DDI-DrugBank.d48.s9|31-37|SPRYCEL|brand
DDI-DrugBank.d48.s9|39-42|with|O
DDI-DrugBank.d48.s9|44-51|antacids|group
DDI-DrugBank.d48.s9|53-58|should|O
DDI-DrugBank.d48.s9|60-61|be|O
DDI-DrugBank.d48.s9|63-69|avoided|O
DDI-DrugBank.d48.s9|70-70|.|O
DDI-DrugBank.d48.s10|0-1|If|O
DDI-DrugBank.d48.s10|3-9|antacid|group
DDI-DrugBank.d48.s10|11-17|therapy|O
DDI-DrugBank.d48.s10|19-20|is|O
DDI-DrugBank.d48.s10|22-27|needed|O
DDI-DrugBank.d48.s10|28-28|,|O
DDI-DrugBank.d48.s10|30-32|the|O
DDI-DrugBank.d48.s10|34-40|antacid|O
DDI-DrugBank.d48.s10|42-45|dose|O
DDI-DrugBank.d48.s10|47-52|should|O
DDI-DrugBank.d48.s10|54-55|be|O
DDI-DrugBank.d48.s10|57-68|administered|O
DDI-DrugBank.d48.s10|70-71|at|O
DDI-DrugBank.d48.s10|73-77|least|O
DDI-DrugBank.d48.s10|79-79|2|O
DDI-DrugBank.d48.s10|81-85|hours|O
DDI-DrugBank.d48.s10|87-91|prior|O
DDI-DrugBank.d48.s10|93-94|to|O
DDI-DrugBank.d48.s10|96-97|or|O
DDI-DrugBank.d48.s10|99-99|2|O
DDI-DrugBank.d48.s10|101-105|hours|O
DDI-DrugBank.d48.s10|107-111|after|O
DDI-DrugBank.d48.s10|113-115|the|O
DDI-DrugBank.d48.s10|117-120|dose|O
DDI-DrugBank.d48.s10|122-123|of|O
DDI-DrugBank.d48.s10|125-131|SPRYCEL|brand
DDI-DrugBank.d48.s10|132-132|.|O
DDI-DrugBank.d48.s11|0-1|H2|group
DDI-DrugBank.d48.s11|3-17|Blockers/Proton|O
DDI-DrugBank.d48.s11|19-33|Pump Inhibitors|group
DDI-DrugBank.d48.s11|34-34|:|O
DDI-DrugBank.d48.s11|36-44|Long-term|O
DDI-DrugBank.d48.s11|46-56|suppression|O
DDI-DrugBank.d48.s11|58-59|of|O
DDI-DrugBank.d48.s11|61-67|gastric|O
DDI-DrugBank.d48.s11|69-72|acid|O
DDI-DrugBank.d48.s11|74-82|secretion|O
DDI-DrugBank.d48.s11|84-85|by|O
DDI-DrugBank.d48.s11|87-97|H2 blockers|group
DDI-DrugBank.d48.s11|99-100|or|O
DDI-DrugBank.d48.s11|102-123|proton pump inhibitors|group
DDI-DrugBank.d48.s11|125-125|(|O
DDI-DrugBank.d48.s11|126-127|eg|O
DDI-DrugBank.d48.s11|128-128|,|O
DDI-DrugBank.d48.s11|130-139|famotidine|drug
DDI-DrugBank.d48.s11|141-143|and|O
DDI-DrugBank.d48.s11|145-154|omeprazole|drug
DDI-DrugBank.d48.s11|155-155|)|O
DDI-DrugBank.d48.s11|157-158|is|O
DDI-DrugBank.d48.s11|160-165|likely|O
DDI-DrugBank.d48.s11|167-168|to|O
DDI-DrugBank.d48.s11|170-175|reduce|O
DDI-DrugBank.d48.s11|177-185|dasatinib|drug
DDI-DrugBank.d48.s11|187-194|exposure|O
DDI-DrugBank.d48.s11|195-195|.|O
DDI-DrugBank.d48.s12|0-2|The|O
DDI-DrugBank.d48.s12|4-14|concomitant|O
DDI-DrugBank.d48.s12|16-18|use|O
DDI-DrugBank.d48.s12|20-21|of|O
DDI-DrugBank.d48.s12|23-33|H2 blockers|group
DDI-DrugBank.d48.s12|35-36|or|O
DDI-DrugBank.d48.s12|38-59|proton pump inhibitors|group
DDI-DrugBank.d48.s12|61-64|with|O
DDI-DrugBank.d48.s12|66-72|SPRYCEL|brand
DDI-DrugBank.d48.s12|74-75|is|O
DDI-DrugBank.d48.s12|77-79|not|O
DDI-DrugBank.d48.s12|81-91|recommended|O
DDI-DrugBank.d48.s12|92-92|.|O
DDI-DrugBank.d48.s13|0-2|The|O
DDI-DrugBank.d48.s13|4-6|use|O
DDI-DrugBank.d48.s13|8-9|of|O
DDI-DrugBank.d48.s13|11-18|antacids|group
DDI-DrugBank.d48.s13|20-25|should|O
DDI-DrugBank.d48.s13|27-28|be|O
DDI-DrugBank.d48.s13|30-39|considered|O
DDI-DrugBank.d48.s13|41-42|in|O
DDI-DrugBank.d48.s13|44-48|place|O
DDI-DrugBank.d48.s13|50-51|of|O
DDI-DrugBank.d48.s13|53-63|H2 blockers|group
DDI-DrugBank.d48.s13|65-66|or|O
DDI-DrugBank.d48.s13|68-89|proton pump inhibitors|group
DDI-DrugBank.d48.s13|91-92|in|O
DDI-DrugBank.d48.s13|94-101|patients|O
DDI-DrugBank.d48.s13|103-111|receiving|O
DDI-DrugBank.d48.s13|113-119|SPRYCEL|brand
DDI-DrugBank.d48.s13|121-127|therapy|O
DDI-DrugBank.d48.s13|128-128|.|O
DDI-DrugBank.d48.s14|0-4|Drugs|O
DDI-DrugBank.d48.s14|6-9|that|O
DDI-DrugBank.d48.s14|11-13|may|O
DDI-DrugBank.d48.s14|15-18|have|O
DDI-DrugBank.d48.s14|20-24|their|O
DDI-DrugBank.d48.s14|26-31|plasma|O
DDI-DrugBank.d48.s14|33-45|concentration|O
DDI-DrugBank.d48.s14|47-53|altered|O
DDI-DrugBank.d48.s14|55-56|by|O
DDI-DrugBank.d48.s14|58-66|dasatinib|drug
DDI-DrugBank.d48.s14|68-73|CYP3A4|O
DDI-DrugBank.d48.s14|75-84|Substrates|O
DDI-DrugBank.d48.s14|85-85|:|O
DDI-DrugBank.d48.s14|87-95|Dasatinib|drug
DDI-DrugBank.d48.s14|97-98|is|O
DDI-DrugBank.d48.s14|100-100|a|O
DDI-DrugBank.d48.s14|102-115|time-dependent|O
DDI-DrugBank.d48.s14|117-125|inhibitor|O
DDI-DrugBank.d48.s14|127-128|of|O
DDI-DrugBank.d48.s14|130-135|CYP3A4|O
DDI-DrugBank.d48.s14|136-136|.|O
DDI-DrugBank.d48.s15|0-8|Therefore|O
DDI-DrugBank.d48.s15|9-9|,|O
DDI-DrugBank.d48.s15|11-16|CYP3A4|O
DDI-DrugBank.d48.s15|18-27|substrates|O
DDI-DrugBank.d48.s15|29-33|known|O
DDI-DrugBank.d48.s15|35-36|to|O
DDI-DrugBank.d48.s15|38-41|have|O
DDI-DrugBank.d48.s15|43-43|a|O
DDI-DrugBank.d48.s15|45-50|narrow|O
DDI-DrugBank.d48.s15|52-62|therapeutic|O
DDI-DrugBank.d48.s15|64-68|index|O
DDI-DrugBank.d48.s15|70-73|such|O
DDI-DrugBank.d48.s15|75-76|as|O
DDI-DrugBank.d48.s15|78-87|alfentanil|drug
DDI-DrugBank.d48.s15|88-88|,|O
DDI-DrugBank.d48.s15|90-99|astemizole|drug
DDI-DrugBank.d48.s15|100-100|,|O
DDI-DrugBank.d48.s15|102-112|terfenadine|drug
DDI-DrugBank.d48.s15|113-113|,|O
DDI-DrugBank.d48.s15|115-123|cisapride|drug
DDI-DrugBank.d48.s15|124-124|,|O
DDI-DrugBank.d48.s15|126-137|cyclosporine|drug
DDI-DrugBank.d48.s15|138-138|,|O
DDI-DrugBank.d48.s15|140-147|fentanyl|drug
DDI-DrugBank.d48.s15|148-148|,|O
DDI-DrugBank.d48.s15|150-157|pimozide|drug
DDI-DrugBank.d48.s15|158-158|,|O
DDI-DrugBank.d48.s15|160-168|quinidine|drug
DDI-DrugBank.d48.s15|169-169|,|O
DDI-DrugBank.d48.s15|171-179|sirolimus|drug
DDI-DrugBank.d48.s15|180-180|,|O
DDI-DrugBank.d48.s15|182-191|tacrolimus|drug
DDI-DrugBank.d48.s15|192-192|,|O
DDI-DrugBank.d48.s15|194-195|or|O
DDI-DrugBank.d48.s15|197-211|ergot alkaloids|group
DDI-DrugBank.d48.s15|213-213|(|O
DDI-DrugBank.d48.s15|214-223|ergotamine|drug
DDI-DrugBank.d48.s15|224-224|,|O
DDI-DrugBank.d48.s15|226-242|dihydroergotamine|drug
DDI-DrugBank.d48.s15|243-243|)|O
DDI-DrugBank.d48.s15|245-250|should|O
DDI-DrugBank.d48.s15|252-253|be|O
DDI-DrugBank.d48.s15|255-266|administered|O
DDI-DrugBank.d48.s15|268-271|with|O
DDI-DrugBank.d48.s15|273-279|caution|O
DDI-DrugBank.d48.s15|281-282|in|O
DDI-DrugBank.d48.s15|284-291|patients|O
DDI-DrugBank.d48.s15|293-301|receiving|O
DDI-DrugBank.d48.s15|303-309|SPRYCEL|brand
DDI-DrugBank.d48.s15|310-310|.|O
DDI-DrugBank.d48.s16|0-6|Hepatic|O
DDI-DrugBank.d48.s16|8-17|Impairment|O
DDI-DrugBank.d48.s16|19-23|There|O
DDI-DrugBank.d48.s16|25-27|are|O
DDI-DrugBank.d48.s16|29-37|currently|O
DDI-DrugBank.d48.s16|39-40|no|O
DDI-DrugBank.d48.s16|42-49|clinical|O
DDI-DrugBank.d48.s16|51-57|studies|O
DDI-DrugBank.d48.s16|59-62|with|O
DDI-DrugBank.d48.s16|64-70|SPRYCEL|brand
DDI-DrugBank.d48.s16|72-73|in|O
DDI-DrugBank.d48.s16|75-82|patients|O
DDI-DrugBank.d48.s16|84-87|with|O
DDI-DrugBank.d48.s16|89-96|impaired|O
DDI-DrugBank.d48.s16|98-102|liver|O
DDI-DrugBank.d48.s16|104-111|function|O
DDI-DrugBank.d48.s16|113-113|(|O
DDI-DrugBank.d48.s16|114-121|clinical|O
DDI-DrugBank.d48.s16|123-129|studies|O
DDI-DrugBank.d48.s16|131-134|have|O
DDI-DrugBank.d48.s16|136-143|excluded|O
DDI-DrugBank.d48.s16|145-152|patients|O
DDI-DrugBank.d48.s16|154-157|with|O
DDI-DrugBank.d48.s16|159-161|ALT|O
DDI-DrugBank.d48.s16|163-168|and/or|O
DDI-DrugBank.d48.s16|170-172|AST|O
DDI-DrugBank.d48.s16|175-177|2.5|O
DDI-DrugBank.d48.s16|179-183|times|O
DDI-DrugBank.d48.s16|185-187|the|O
DDI-DrugBank.d48.s16|189-193|upper|O
DDI-DrugBank.d48.s16|195-199|limit|O
DDI-DrugBank.d48.s16|201-202|of|O
DDI-DrugBank.d48.s16|204-206|the|O
DDI-DrugBank.d48.s16|208-213|normal|O
DDI-DrugBank.d48.s16|215-219|range|O
DDI-DrugBank.d48.s16|221-226|and/or|O
DDI-DrugBank.d48.s16|228-232|total|O
DDI-DrugBank.d48.s16|234-242|bilirubin|O
DDI-DrugBank.d48.s16|245-245|2|O
DDI-DrugBank.d48.s16|247-251|times|O
DDI-DrugBank.d48.s16|253-255|the|O
DDI-DrugBank.d48.s16|257-261|upper|O
DDI-DrugBank.d48.s16|263-267|limit|O
DDI-DrugBank.d48.s16|269-270|of|O
DDI-DrugBank.d48.s16|272-274|the|O
DDI-DrugBank.d48.s16|276-281|normal|O
DDI-DrugBank.d48.s16|283-287|range|O
DDI-DrugBank.d48.s16|288-288|)|O
DDI-DrugBank.d48.s16|289-289|.|O
DDI-DrugBank.d48.s17|0-9|Metabolism|O
DDI-DrugBank.d48.s17|11-12|of|O
DDI-DrugBank.d48.s17|14-22|dasatinib|drug
DDI-DrugBank.d48.s17|24-25|is|O
DDI-DrugBank.d48.s17|27-32|mainly|O
DDI-DrugBank.d48.s17|34-40|hepatic|O
DDI-DrugBank.d48.s17|41-41|.|O
DDI-DrugBank.d48.s18|0-6|Caution|O
DDI-DrugBank.d48.s18|8-9|is|O
DDI-DrugBank.d48.s18|11-21|recommended|O
DDI-DrugBank.d48.s18|23-24|in|O
DDI-DrugBank.d48.s18|26-33|patients|O
DDI-DrugBank.d48.s18|35-38|with|O
DDI-DrugBank.d48.s18|40-46|hepatic|O
DDI-DrugBank.d48.s18|48-57|impairment|O
DDI-DrugBank.d48.s18|58-58|.|O
DDI-DrugBank.d48.s19|0-4|Renal|O
DDI-DrugBank.d48.s19|6-15|Impairment|O
DDI-DrugBank.d48.s19|17-21|There|O
DDI-DrugBank.d48.s19|23-25|are|O
DDI-DrugBank.d48.s19|27-35|currently|O
DDI-DrugBank.d48.s19|37-38|no|O
DDI-DrugBank.d48.s19|40-47|clinical|O
DDI-DrugBank.d48.s19|49-55|studies|O
DDI-DrugBank.d48.s19|57-60|with|O
DDI-DrugBank.d48.s19|62-68|SPRYCEL|brand
DDI-DrugBank.d48.s19|70-71|in|O
DDI-DrugBank.d48.s19|73-80|patients|O
DDI-DrugBank.d48.s19|82-85|with|O
DDI-DrugBank.d48.s19|87-94|impaired|O
DDI-DrugBank.d48.s19|96-100|renal|O
DDI-DrugBank.d48.s19|102-109|function|O
DDI-DrugBank.d48.s19|111-111|(|O
DDI-DrugBank.d48.s19|112-119|clinical|O
DDI-DrugBank.d48.s19|121-127|studies|O
DDI-DrugBank.d48.s19|129-132|have|O
DDI-DrugBank.d48.s19|134-141|excluded|O
DDI-DrugBank.d48.s19|143-150|patients|O
DDI-DrugBank.d48.s19|152-155|with|O
DDI-DrugBank.d48.s19|157-161|serum|O
DDI-DrugBank.d48.s19|163-172|creatinine|O
DDI-DrugBank.d48.s19|174-186|concentration|O
DDI-DrugBank.d48.s19|189-191|1.5|O
DDI-DrugBank.d48.s19|193-197|times|O
DDI-DrugBank.d48.s19|199-201|the|O
DDI-DrugBank.d48.s19|203-207|upper|O
DDI-DrugBank.d48.s19|209-213|limit|O
DDI-DrugBank.d48.s19|215-216|of|O
DDI-DrugBank.d48.s19|218-220|the|O
DDI-DrugBank.d48.s19|222-227|normal|O
DDI-DrugBank.d48.s19|229-233|range|O
DDI-DrugBank.d48.s19|234-234|)|O
DDI-DrugBank.d48.s19|235-235|.|O
DDI-DrugBank.d48.s20|0-8|Dasatinib|drug
DDI-DrugBank.d48.s20|10-12|and|O
DDI-DrugBank.d48.s20|14-16|its|O
DDI-DrugBank.d48.s20|18-28|metabolites|O
DDI-DrugBank.d48.s20|30-32|are|O
DDI-DrugBank.d48.s20|34-42|minimally|O
DDI-DrugBank.d48.s20|44-51|excreted|O
DDI-DrugBank.d48.s20|53-55|via|O
DDI-DrugBank.d48.s20|57-59|the|O
DDI-DrugBank.d48.s20|61-66|kidney|O
DDI-DrugBank.d48.s20|67-67|.|O
DDI-DrugBank.d48.s21|0-4|Since|O
DDI-DrugBank.d48.s21|6-8|the|O
DDI-DrugBank.d48.s21|10-14|renal|O
DDI-DrugBank.d48.s21|16-24|excretion|O
DDI-DrugBank.d48.s21|26-27|of|O
DDI-DrugBank.d48.s21|29-37|unchanged|O
DDI-DrugBank.d48.s21|39-47|dasatinib|drug
DDI-DrugBank.d48.s21|49-51|and|O
DDI-DrugBank.d48.s21|53-55|its|O
DDI-DrugBank.d48.s21|57-67|metabolites|O
DDI-DrugBank.d48.s21|69-70|is|O
DDI-DrugBank.d48.s21|73-73|4|O
DDI-DrugBank.d48.s21|74-74|%|O
DDI-DrugBank.d48.s21|75-75|,|O
DDI-DrugBank.d48.s21|77-77|a|O
DDI-DrugBank.d48.s21|79-86|decrease|O
DDI-DrugBank.d48.s21|88-89|in|O
DDI-DrugBank.d48.s21|91-95|total|O
DDI-DrugBank.d48.s21|97-100|body|O
DDI-DrugBank.d48.s21|102-110|clearance|O
DDI-DrugBank.d48.s21|112-113|is|O
DDI-DrugBank.d48.s21|115-117|not|O
DDI-DrugBank.d48.s21|119-126|expected|O
DDI-DrugBank.d48.s21|128-129|in|O
DDI-DrugBank.d48.s21|131-138|patients|O
DDI-DrugBank.d48.s21|140-143|with|O
DDI-DrugBank.d48.s21|145-149|renal|O
DDI-DrugBank.d48.s21|151-163|insufficiency|O
DDI-DrugBank.d48.s21|164-164|.|O
DDI-DrugBank.d533.s0|0-6|Effects|O
DDI-DrugBank.d533.s0|8-9|of|O
DDI-DrugBank.d533.s0|11-15|Other|O
DDI-DrugBank.d533.s0|17-21|Drugs|O
DDI-DrugBank.d533.s0|23-24|on|O
DDI-DrugBank.d533.s0|26-34|Aliskiren|drug
DDI-DrugBank.d533.s0|36-40|Based|O
DDI-DrugBank.d533.s0|42-43|on|O
DDI-DrugBank.d533.s0|45-52|in-vitro|O
DDI-DrugBank.d533.s0|54-60|studies|O
DDI-DrugBank.d533.s0|61-61|,|O
DDI-DrugBank.d533.s0|63-71|aliskiren|drug
DDI-DrugBank.d533.s0|73-74|is|O
DDI-DrugBank.d533.s0|76-86|metabolized|O
DDI-DrugBank.d533.s0|88-89|by|O
DDI-DrugBank.d533.s0|91-93|CYP|O
DDI-DrugBank.d533.s0|95-97|3A4|O
DDI-DrugBank.d533.s0|98-98|.|O
DDI-DrugBank.d533.s1|0-16|Co-administration|O
DDI-DrugBank.d533.s1|18-19|of|O
DDI-DrugBank.d533.s1|21-30|lovastatin|drug
DDI-DrugBank.d533.s1|31-31|,|O
DDI-DrugBank.d533.s1|33-40|atenolol|drug
DDI-DrugBank.d533.s1|41-41|,|O
DDI-DrugBank.d533.s1|43-50|warfarin|drug
DDI-DrugBank.d533.s1|51-51|,|O
DDI-DrugBank.d533.s1|53-62|furosemide|drug
DDI-DrugBank.d533.s1|63-63|,|O
DDI-DrugBank.d533.s1|65-71|digoxin|drug
DDI-DrugBank.d533.s1|72-72|,|O
DDI-DrugBank.d533.s1|74-82|celecoxib|drug
DDI-DrugBank.d533.s1|83-83|,|O
DDI-DrugBank.d533.s1|85-103|hydrochlorothiazide|drug
DDI-DrugBank.d533.s1|104-104|,|O
DDI-DrugBank.d533.s1|106-113|ramipril|drug
DDI-DrugBank.d533.s1|114-114|,|O
DDI-DrugBank.d533.s1|116-124|valsartan|drug
DDI-DrugBank.d533.s1|125-125|,|O
DDI-DrugBank.d533.s1|127-135|metformin|drug
DDI-DrugBank.d533.s1|137-139|and|O
DDI-DrugBank.d533.s1|141-150|amlodipine|drug
DDI-DrugBank.d533.s1|152-154|did|O
DDI-DrugBank.d533.s1|156-158|not|O
DDI-DrugBank.d533.s1|160-165|result|O
DDI-DrugBank.d533.s1|167-168|in|O
DDI-DrugBank.d533.s1|170-179|clinically|O
DDI-DrugBank.d533.s1|181-191|significant|O
DDI-DrugBank.d533.s1|193-201|increases|O
DDI-DrugBank.d533.s1|203-204|in|O
DDI-DrugBank.d533.s1|206-214|aliskiren|drug
DDI-DrugBank.d533.s1|216-223|exposure|O
DDI-DrugBank.d533.s1|224-224|.|O
DDI-DrugBank.d533.s2|0-16|Co-administration|O
DDI-DrugBank.d533.s2|18-19|of|O
DDI-DrugBank.d533.s2|21-30|irbesartan|drug
DDI-DrugBank.d533.s2|32-38|reduced|O
DDI-DrugBank.d533.s2|40-48|aliskiren|drug
DDI-DrugBank.d533.s2|50-53|Cmax|O
DDI-DrugBank.d533.s2|55-56|up|O
DDI-DrugBank.d533.s2|58-59|to|O
DDI-DrugBank.d533.s2|61-62|50|O
DDI-DrugBank.d533.s2|63-63|%|O
DDI-DrugBank.d533.s2|65-69|after|O
DDI-DrugBank.d533.s2|71-78|multiple|O
DDI-DrugBank.d533.s2|80-85|dosing|O
DDI-DrugBank.d533.s2|86-86|.|O
DDI-DrugBank.d533.s3|0-16|Co-administration|O
DDI-DrugBank.d533.s3|18-19|of|O
DDI-DrugBank.d533.s3|21-32|atorvastatin|drug
DDI-DrugBank.d533.s3|34-41|resulted|O
DDI-DrugBank.d533.s3|43-44|in|O
DDI-DrugBank.d533.s3|46-50|about|O
DDI-DrugBank.d533.s3|52-52|a|O
DDI-DrugBank.d533.s3|54-55|50|O
DDI-DrugBank.d533.s3|56-56|%|O
DDI-DrugBank.d533.s3|58-65|increase|O
DDI-DrugBank.d533.s3|67-68|in|O
DDI-DrugBank.d533.s3|70-78|aliskiren|drug
DDI-DrugBank.d533.s3|80-83|Cmax|O
DDI-DrugBank.d533.s3|85-87|and|O
DDI-DrugBank.d533.s3|89-91|AUC|O
DDI-DrugBank.d533.s3|93-97|after|O
DDI-DrugBank.d533.s3|99-106|multiple|O
DDI-DrugBank.d533.s3|108-113|dosing|O
DDI-DrugBank.d533.s3|114-114|.|O
DDI-DrugBank.d533.s4|0-11|Ketoconazole|drug
DDI-DrugBank.d533.s4|12-12|:|O
DDI-DrugBank.d533.s4|14-30|Co-administration|O
DDI-DrugBank.d533.s4|32-33|of|O
DDI-DrugBank.d533.s4|35-37|200|O
DDI-DrugBank.d533.s4|39-40|mg|O
DDI-DrugBank.d533.s4|42-52|twice-daily|O
DDI-DrugBank.d533.s4|54-65|ketoconazole|drug
DDI-DrugBank.d533.s4|67-70|with|O
DDI-DrugBank.d533.s4|72-80|aliskiren|drug
DDI-DrugBank.d533.s4|82-89|resulted|O
DDI-DrugBank.d533.s4|91-92|in|O
DDI-DrugBank.d533.s4|94-95|an|O
DDI-DrugBank.d533.s4|97-107|approximate|O
DDI-DrugBank.d533.s4|109-110|80|O
DDI-DrugBank.d533.s4|111-111|%|O
DDI-DrugBank.d533.s4|113-120|increase|O
DDI-DrugBank.d533.s4|122-123|in|O
DDI-DrugBank.d533.s4|125-130|plasma|O
DDI-DrugBank.d533.s4|132-137|levels|O
DDI-DrugBank.d533.s4|139-140|of|O
DDI-DrugBank.d533.s4|142-150|aliskiren|drug
DDI-DrugBank.d533.s4|151-151|.|O
DDI-DrugBank.d533.s5|0-0|A|O
DDI-DrugBank.d533.s5|2-4|400|O
DDI-DrugBank.d533.s5|6-7|mg|O
DDI-DrugBank.d533.s5|9-18|once-daily|O
DDI-DrugBank.d533.s5|20-23|dose|O
DDI-DrugBank.d533.s5|25-27|was|O
DDI-DrugBank.d533.s5|29-31|not|O
DDI-DrugBank.d533.s5|33-39|studied|O
DDI-DrugBank.d533.s5|41-43|but|O
DDI-DrugBank.d533.s5|45-49|would|O
DDI-DrugBank.d533.s5|51-52|be|O
DDI-DrugBank.d533.s5|54-61|expected|O
DDI-DrugBank.d533.s5|63-64|to|O
DDI-DrugBank.d533.s5|66-73|increase|O
DDI-DrugBank.d533.s5|75-83|aliskiren|drug
DDI-DrugBank.d533.s5|85-89|blood|O
DDI-DrugBank.d533.s5|91-96|levels|O
DDI-DrugBank.d533.s5|98-104|further|O
DDI-DrugBank.d533.s5|105-105|.|O
DDI-DrugBank.d533.s6|0-6|Effects|O
DDI-DrugBank.d533.s6|8-9|of|O
DDI-DrugBank.d533.s6|11-19|Aliskiren|drug
DDI-DrugBank.d533.s6|21-22|on|O
DDI-DrugBank.d533.s6|24-28|Other|O
DDI-DrugBank.d533.s6|30-34|Drugs|O
DDI-DrugBank.d533.s6|36-44|Aliskiren|drug
DDI-DrugBank.d533.s6|46-49|does|O
DDI-DrugBank.d533.s6|51-53|not|O
DDI-DrugBank.d533.s6|55-61|inhibit|O
DDI-DrugBank.d533.s6|63-65|the|O
DDI-DrugBank.d533.s6|67-72|CYP450|O
DDI-DrugBank.d533.s6|74-83|isoenzymes|O
DDI-DrugBank.d533.s6|85-85|(|O
DDI-DrugBank.d533.s6|86-91|CYP1A2|O
DDI-DrugBank.d533.s6|92-92|,|O
DDI-DrugBank.d533.s6|94-96|2C8|O
DDI-DrugBank.d533.s6|97-97|,|O
DDI-DrugBank.d533.s6|99-101|2C9|O
DDI-DrugBank.d533.s6|102-102|,|O
DDI-DrugBank.d533.s6|104-107|2C19|O
DDI-DrugBank.d533.s6|108-108|,|O
DDI-DrugBank.d533.s6|110-112|2D6|O
DDI-DrugBank.d533.s6|113-113|,|O
DDI-DrugBank.d533.s6|115-117|2E1|O
DDI-DrugBank.d533.s6|118-118|,|O
DDI-DrugBank.d533.s6|120-122|and|O
DDI-DrugBank.d533.s6|124-126|CYP|O
DDI-DrugBank.d533.s6|128-129|3A|O
DDI-DrugBank.d533.s6|130-130|)|O
DDI-DrugBank.d533.s6|132-133|or|O
DDI-DrugBank.d533.s6|135-140|induce|O
DDI-DrugBank.d533.s6|142-144|CYP|O
DDI-DrugBank.d533.s6|146-148|3A4|O
DDI-DrugBank.d533.s6|149-149|.|O
DDI-DrugBank.d533.s7|0-16|Co-administration|O
DDI-DrugBank.d533.s7|18-19|of|O
DDI-DrugBank.d533.s7|21-29|aliskiren|drug
DDI-DrugBank.d533.s7|31-33|did|O
DDI-DrugBank.d533.s7|35-37|not|O
DDI-DrugBank.d533.s7|39-51|significantly|O
DDI-DrugBank.d533.s7|53-58|affect|O
DDI-DrugBank.d533.s7|60-62|the|O
DDI-DrugBank.d533.s7|64-79|pharmacokinetics|O
DDI-DrugBank.d533.s7|81-82|of|O
DDI-DrugBank.d533.s7|84-93|lovastatin|drug
DDI-DrugBank.d533.s7|94-94|,|O
DDI-DrugBank.d533.s7|96-102|digoxin|drug
DDI-DrugBank.d533.s7|103-103|,|O
DDI-DrugBank.d533.s7|105-113|valsartan|drug
DDI-DrugBank.d533.s7|114-114|,|O
DDI-DrugBank.d533.s7|116-125|amlodipine|drug
DDI-DrugBank.d533.s7|126-126|,|O
DDI-DrugBank.d533.s7|128-136|metformin|drug
DDI-DrugBank.d533.s7|137-137|,|O
DDI-DrugBank.d533.s7|139-147|celecoxib|drug
DDI-DrugBank.d533.s7|148-148|,|O
DDI-DrugBank.d533.s7|150-157|atenolol|drug
DDI-DrugBank.d533.s7|158-158|,|O
DDI-DrugBank.d533.s7|160-171|atorvastatin|drug
DDI-DrugBank.d533.s7|172-172|,|O
DDI-DrugBank.d533.s7|174-181|ramipril|drug
DDI-DrugBank.d533.s7|183-184|or|O
DDI-DrugBank.d533.s7|186-204|hydrochlorothiazide|drug
DDI-DrugBank.d533.s7|205-205|.|O
DDI-DrugBank.d533.s8|0-7|Warfarin|drug
DDI-DrugBank.d533.s8|8-8|:|O
DDI-DrugBank.d533.s8|10-12|The|O
DDI-DrugBank.d533.s8|14-20|effects|O
DDI-DrugBank.d533.s8|22-23|of|O
DDI-DrugBank.d533.s8|25-33|aliskiren|drug
DDI-DrugBank.d533.s8|35-36|on|O
DDI-DrugBank.d533.s8|38-45|warfarin|drug
DDI-DrugBank.d533.s8|47-62|pharmacokinetics|O
DDI-DrugBank.d533.s8|64-67|have|O
DDI-DrugBank.d533.s8|69-71|not|O
DDI-DrugBank.d533.s8|73-76|been|O
DDI-DrugBank.d533.s8|78-86|evaluated|O
DDI-DrugBank.d533.s8|88-89|in|O
DDI-DrugBank.d533.s8|91-91|a|O
DDI-DrugBank.d533.s8|93-107|well-controlled|O
DDI-DrugBank.d533.s8|109-116|clinical|O
DDI-DrugBank.d533.s8|118-122|trial|O
DDI-DrugBank.d533.s8|123-123|.|O
DDI-DrugBank.d533.s9|0-9|Furosemide|drug
DDI-DrugBank.d533.s9|10-10|:|O
DDI-DrugBank.d533.s9|12-15|When|O
DDI-DrugBank.d533.s9|17-25|aliskiren|drug
DDI-DrugBank.d533.s9|27-29|was|O
DDI-DrugBank.d533.s9|31-45|co-administered|O
DDI-DrugBank.d533.s9|47-50|with|O
DDI-DrugBank.d533.s9|52-61|furosemide|drug
DDI-DrugBank.d533.s9|62-62|,|O
DDI-DrugBank.d533.s9|64-66|the|O
DDI-DrugBank.d533.s9|68-70|AUC|O
DDI-DrugBank.d533.s9|72-74|and|O
DDI-DrugBank.d533.s9|76-79|Cmax|O
DDI-DrugBank.d533.s9|81-82|of|O
DDI-DrugBank.d533.s9|84-93|furosemide|drug
DDI-DrugBank.d533.s9|95-98|were|O
DDI-DrugBank.d533.s9|100-106|reduced|O
DDI-DrugBank.d533.s9|108-109|by|O
DDI-DrugBank.d533.s9|111-115|about|O
DDI-DrugBank.d533.s9|117-118|30|O
DDI-DrugBank.d533.s9|119-119|%|O
DDI-DrugBank.d533.s9|121-123|and|O
DDI-DrugBank.d533.s9|125-126|50|O
DDI-DrugBank.d533.s9|127-127|%|O
DDI-DrugBank.d533.s9|128-128|,|O
DDI-DrugBank.d533.s9|130-141|respectively|O
DDI-DrugBank.d533.s9|142-142|.|O
DDI-DrugBank.d372.s0|0-7|Cytadren|brand
DDI-DrugBank.d372.s0|9-19|accelerates|O
DDI-DrugBank.d372.s0|21-23|the|O
DDI-DrugBank.d372.s0|25-34|metabolism|O
DDI-DrugBank.d372.s0|36-37|of|O
DDI-DrugBank.d372.s0|39-51|dexamethasone|drug
DDI-DrugBank.d372.s0|52-52|;|O
DDI-DrugBank.d372.s1|0-8|therefore|O
DDI-DrugBank.d372.s1|9-9|,|O
DDI-DrugBank.d372.s1|11-12|if|O
DDI-DrugBank.d372.s1|14-27|glucocorticoid|group
DDI-DrugBank.d372.s1|29-39|replacement|O
DDI-DrugBank.d372.s1|41-42|is|O
DDI-DrugBank.d372.s1|44-49|needed|O
DDI-DrugBank.d372.s1|50-50|,|O
DDI-DrugBank.d372.s1|52-65|hydrocortisone|drug
DDI-DrugBank.d372.s1|67-72|should|O
DDI-DrugBank.d372.s1|74-75|be|O
DDI-DrugBank.d372.s1|77-86|prescribed|O
DDI-DrugBank.d372.s1|87-87|.|O
DDI-DrugBank.d372.s2|0-16|Aminoglutethimide|drug
DDI-DrugBank.d372.s2|18-27|diminishes|O
DDI-DrugBank.d372.s2|29-31|the|O
DDI-DrugBank.d372.s2|33-38|effect|O
DDI-DrugBank.d372.s2|40-41|of|O
DDI-DrugBank.d372.s2|43-50|coumarin|group
DDI-DrugBank.d372.s2|52-54|and|O
DDI-DrugBank.d372.s2|56-63|warfarin|drug
DDI-DrugBank.d372.s2|64-64|.|O
DDI-DrugBank.d781.s0|0-8|Diuretics|group
DDI-DrugBank.d781.s0|9-9|:|O
DDI-DrugBank.d781.s0|11-18|Patients|O
DDI-DrugBank.d781.s0|20-21|on|O
DDI-DrugBank.d781.s0|23-31|diuretics|group
DDI-DrugBank.d781.s0|32-32|,|O
DDI-DrugBank.d781.s0|34-36|and|O
DDI-DrugBank.d781.s0|38-47|especially|O
DDI-DrugBank.d781.s0|49-53|those|O
DDI-DrugBank.d781.s0|55-61|started|O
DDI-DrugBank.d781.s0|63-70|recently|O
DDI-DrugBank.d781.s0|71-71|,|O
DDI-DrugBank.d781.s0|73-75|may|O
DDI-DrugBank.d781.s0|77-88|occasionally|O
DDI-DrugBank.d781.s0|90-99|experience|O
DDI-DrugBank.d781.s0|101-102|an|O
DDI-DrugBank.d781.s0|104-112|excessive|O
DDI-DrugBank.d781.s0|114-122|reduction|O
DDI-DrugBank.d781.s0|124-125|of|O
DDI-DrugBank.d781.s0|127-131|blood|O
DDI-DrugBank.d781.s0|133-140|pressure|O
DDI-DrugBank.d781.s0|142-146|after|O
DDI-DrugBank.d781.s0|148-157|initiation|O
DDI-DrugBank.d781.s0|159-160|of|O
DDI-DrugBank.d781.s0|162-166|ACEON|brand
DDI-DrugBank.d781.s0|171-177|Tablets|O
DDI-DrugBank.d781.s0|179-185|therapy|O
DDI-DrugBank.d781.s0|186-186|.|O
DDI-DrugBank.d781.s1|0-2|The|O
DDI-DrugBank.d781.s1|4-14|possibility|O
DDI-DrugBank.d781.s1|16-17|of|O
DDI-DrugBank.d781.s1|19-29|hypotensive|O
DDI-DrugBank.d781.s1|31-37|effects|O
DDI-DrugBank.d781.s1|39-41|can|O
DDI-DrugBank.d781.s1|43-44|be|O
DDI-DrugBank.d781.s1|46-54|minimized|O
DDI-DrugBank.d781.s1|56-57|by|O
DDI-DrugBank.d781.s1|59-64|either|O
DDI-DrugBank.d781.s1|66-78|discontinuing|O
DDI-DrugBank.d781.s1|80-82|the|O
DDI-DrugBank.d781.s1|84-91|diuretic|group
DDI-DrugBank.d781.s1|93-94|or|O
DDI-DrugBank.d781.s1|96-105|increasing|O
DDI-DrugBank.d781.s1|107-109|the|O
DDI-DrugBank.d781.s1|111-114|salt|O
DDI-DrugBank.d781.s1|116-121|intake|O
DDI-DrugBank.d781.s1|123-127|prior|O
DDI-DrugBank.d781.s1|129-130|to|O
DDI-DrugBank.d781.s1|132-141|initiation|O
DDI-DrugBank.d781.s1|143-144|of|O
DDI-DrugBank.d781.s1|146-154|treatment|O
DDI-DrugBank.d781.s1|156-159|with|O
DDI-DrugBank.d781.s1|161-171|perindopril|drug
DDI-DrugBank.d781.s1|172-172|.|O
DDI-DrugBank.d781.s2|0-1|If|O
DDI-DrugBank.d781.s2|3-11|diuretics|group
DDI-DrugBank.d781.s2|13-15|can|O
DDI-DrugBank.d781.s2|16-18|not|O
DDI-DrugBank.d781.s2|20-21|be|O
DDI-DrugBank.d781.s2|23-33|interrupted|O
DDI-DrugBank.d781.s2|34-34|,|O
DDI-DrugBank.d781.s2|36-40|close|O
DDI-DrugBank.d781.s2|42-48|medical|O
DDI-DrugBank.d781.s2|50-60|supervision|O
DDI-DrugBank.d781.s2|62-67|should|O
DDI-DrugBank.d781.s2|69-70|be|O
DDI-DrugBank.d781.s2|72-79|provided|O
DDI-DrugBank.d781.s2|81-84|with|O
DDI-DrugBank.d781.s2|86-88|the|O
DDI-DrugBank.d781.s2|90-94|first|O
DDI-DrugBank.d781.s2|96-99|dose|O
DDI-DrugBank.d781.s2|101-102|of|O
DDI-DrugBank.d781.s2|104-108|ACEON|brand
DDI-DrugBank.d781.s2|113-119|Tablets|O
DDI-DrugBank.d781.s2|120-120|,|O
DDI-DrugBank.d781.s2|122-124|for|O
DDI-DrugBank.d781.s2|126-127|at|O
DDI-DrugBank.d781.s2|129-133|least|O
DDI-DrugBank.d781.s2|135-137|two|O
DDI-DrugBank.d781.s2|139-143|hours|O
DDI-DrugBank.d781.s2|145-147|and|O
DDI-DrugBank.d781.s2|149-153|until|O
DDI-DrugBank.d781.s2|155-159|blood|O
DDI-DrugBank.d781.s2|161-168|pressure|O
DDI-DrugBank.d781.s2|170-172|has|O
DDI-DrugBank.d781.s2|174-183|stabilized|O
DDI-DrugBank.d781.s2|185-187|for|O
DDI-DrugBank.d781.s2|189-195|another|O
DDI-DrugBank.d781.s2|197-200|hour|O
DDI-DrugBank.d781.s2|201-201|.|O
DDI-DrugBank.d781.s3|0-2|The|O
DDI-DrugBank.d781.s3|4-7|rate|O
DDI-DrugBank.d781.s3|9-11|and|O
DDI-DrugBank.d781.s3|13-18|extent|O
DDI-DrugBank.d781.s3|20-21|of|O
DDI-DrugBank.d781.s3|23-33|perindopril|drug
DDI-DrugBank.d781.s3|35-44|absorption|O
DDI-DrugBank.d781.s3|46-48|and|O
DDI-DrugBank.d781.s3|50-60|elimination|O
DDI-DrugBank.d781.s3|62-64|are|O
DDI-DrugBank.d781.s3|66-68|not|O
DDI-DrugBank.d781.s3|70-77|affected|O
DDI-DrugBank.d781.s3|79-80|by|O
DDI-DrugBank.d781.s3|82-92|concomitant|O
DDI-DrugBank.d781.s3|94-102|diuretics|group
DDI-DrugBank.d781.s3|103-103|.|O
DDI-DrugBank.d781.s4|0-2|The|O
DDI-DrugBank.d781.s4|4-18|bioavailability|O
DDI-DrugBank.d781.s4|20-21|of|O
DDI-DrugBank.d781.s4|37-39|was|O
DDI-DrugBank.d781.s4|41-47|reduced|O
DDI-DrugBank.d781.s4|49-50|by|O
DDI-DrugBank.d781.s4|52-60|diuretics|group
DDI-DrugBank.d781.s4|61-61|,|O
DDI-DrugBank.d781.s4|63-69|however|O
DDI-DrugBank.d781.s4|70-70|,|O
DDI-DrugBank.d781.s4|72-74|and|O
DDI-DrugBank.d781.s4|76-79|this|O
DDI-DrugBank.d781.s4|81-83|was|O
DDI-DrugBank.d781.s4|85-94|associated|O
DDI-DrugBank.d781.s4|96-99|with|O
DDI-DrugBank.d781.s4|101-101|a|O
DDI-DrugBank.d781.s4|103-110|decrease|O
DDI-DrugBank.d781.s4|112-113|in|O
DDI-DrugBank.d781.s4|115-120|plasma|O
DDI-DrugBank.d781.s4|122-124|ACE|O
DDI-DrugBank.d781.s4|126-135|inhibition|O
DDI-DrugBank.d781.s4|136-136|.|O
DDI-DrugBank.d781.s5|0-8|Potassium|drug
DDI-DrugBank.d781.s5|10-20|Supplements|O
DDI-DrugBank.d781.s5|22-24|and|O
DDI-DrugBank.d781.s5|26-52|Potassium-Sparing Diuretics|group
DDI-DrugBank.d781.s5|53-53|:|O
DDI-DrugBank.d781.s5|55-59|ACEON|brand
DDI-DrugBank.d781.s5|64-70|Tablets|O
DDI-DrugBank.d781.s5|72-74|may|O
DDI-DrugBank.d781.s5|76-83|increase|O
DDI-DrugBank.d781.s5|85-89|serum|O
DDI-DrugBank.d781.s5|91-99|potassium|O
DDI-DrugBank.d781.s5|101-107|because|O
DDI-DrugBank.d781.s5|109-110|of|O
DDI-DrugBank.d781.s5|112-114|its|O
DDI-DrugBank.d781.s5|116-124|potential|O
DDI-DrugBank.d781.s5|126-127|to|O
DDI-DrugBank.d781.s5|129-136|decrease|O
DDI-DrugBank.d781.s5|138-148|aldosterone|O
DDI-DrugBank.d781.s5|150-159|production|O
DDI-DrugBank.d781.s5|160-160|.|O
DDI-DrugBank.d781.s6|0-2|Use|O
DDI-DrugBank.d781.s6|4-5|of|O
DDI-DrugBank.d781.s6|7-33|potassium-sparing diuretics|group
DDI-DrugBank.d781.s6|35-35|(|O
DDI-DrugBank.d781.s6|36-49|spironolactone|drug
DDI-DrugBank.d781.s6|50-50|,|O
DDI-DrugBank.d781.s6|52-60|amiloride|drug
DDI-DrugBank.d781.s6|61-61|,|O
DDI-DrugBank.d781.s6|63-73|triamterene|drug
DDI-DrugBank.d781.s6|75-77|and|O
DDI-DrugBank.d781.s6|79-84|others|O
DDI-DrugBank.d781.s6|85-85|)|O
DDI-DrugBank.d781.s6|86-86|,|O
DDI-DrugBank.d781.s6|88-96|potassium|drug
DDI-DrugBank.d781.s6|98-108|supplements|O
DDI-DrugBank.d781.s6|110-111|or|O
DDI-DrugBank.d781.s6|113-117|other|O
DDI-DrugBank.d781.s6|119-123|drugs|O
DDI-DrugBank.d781.s6|125-131|capable|O
DDI-DrugBank.d781.s6|133-134|of|O
DDI-DrugBank.d781.s6|136-145|increasing|O
DDI-DrugBank.d781.s6|147-151|serum|O
DDI-DrugBank.d781.s6|153-161|potassium|O
DDI-DrugBank.d781.s6|163-163|(|O
DDI-DrugBank.d781.s6|164-175|indomethacin|drug
DDI-DrugBank.d781.s6|176-176|,|O
DDI-DrugBank.d781.s6|178-184|heparin|drug
DDI-DrugBank.d781.s6|185-185|,|O
DDI-DrugBank.d781.s6|187-198|cyclosporine|drug
DDI-DrugBank.d781.s6|200-202|and|O
DDI-DrugBank.d781.s6|204-209|others|O
DDI-DrugBank.d781.s6|210-210|)|O
DDI-DrugBank.d781.s6|212-214|can|O
DDI-DrugBank.d781.s6|216-223|increase|O
DDI-DrugBank.d781.s6|225-227|the|O
DDI-DrugBank.d781.s6|229-232|risk|O
DDI-DrugBank.d781.s6|234-235|of|O
DDI-DrugBank.d781.s6|237-248|hyperkalemia|O
DDI-DrugBank.d781.s6|249-249|.|O
DDI-DrugBank.d781.s7|0-8|Therefore|O
DDI-DrugBank.d781.s7|9-9|,|O
DDI-DrugBank.d781.s7|11-12|if|O
DDI-DrugBank.d781.s7|14-24|concomitant|O
DDI-DrugBank.d781.s7|26-28|use|O
DDI-DrugBank.d781.s7|30-31|of|O
DDI-DrugBank.d781.s7|33-36|such|O
DDI-DrugBank.d781.s7|38-43|agents|O
DDI-DrugBank.d781.s7|45-46|is|O
DDI-DrugBank.d781.s7|48-56|indicated|O
DDI-DrugBank.d781.s7|57-57|,|O
DDI-DrugBank.d781.s7|59-62|they|O
DDI-DrugBank.d781.s7|64-69|should|O
DDI-DrugBank.d781.s7|71-72|be|O
DDI-DrugBank.d781.s7|74-78|given|O
DDI-DrugBank.d781.s7|80-83|with|O
DDI-DrugBank.d781.s7|85-91|caution|O
DDI-DrugBank.d781.s7|93-95|and|O
DDI-DrugBank.d781.s7|97-99|the|O
DDI-DrugBank.d781.s7|101-107|patient|O
DDI-DrugBank.d781.s7|108-109|'s|O
DDI-DrugBank.d781.s7|111-115|serum|O
DDI-DrugBank.d781.s7|117-125|potassium|O
DDI-DrugBank.d781.s7|127-132|should|O
DDI-DrugBank.d781.s7|134-135|be|O
DDI-DrugBank.d781.s7|137-145|monitored|O
DDI-DrugBank.d781.s7|147-156|frequently|O
DDI-DrugBank.d781.s7|157-157|.|O
DDI-DrugBank.d781.s8|0-6|Lithium|drug
DDI-DrugBank.d781.s8|7-7|:|O
DDI-DrugBank.d781.s8|9-17|Increased|O
DDI-DrugBank.d781.s8|19-23|serum|O
DDI-DrugBank.d781.s8|25-31|lithium|drug
DDI-DrugBank.d781.s8|33-35|and|O
DDI-DrugBank.d781.s8|37-44|symptoms|O
DDI-DrugBank.d781.s8|46-47|of|O
DDI-DrugBank.d781.s8|49-55|lithium|drug
DDI-DrugBank.d781.s8|57-64|toxicity|O
DDI-DrugBank.d781.s8|66-69|have|O
DDI-DrugBank.d781.s8|71-74|been|O
DDI-DrugBank.d781.s8|76-83|reported|O
DDI-DrugBank.d781.s8|85-86|in|O
DDI-DrugBank.d781.s8|88-95|patients|O
DDI-DrugBank.d781.s8|97-105|receiving|O
DDI-DrugBank.d781.s8|107-117|concomitant|O
DDI-DrugBank.d781.s8|119-125|lithium|drug
DDI-DrugBank.d781.s8|127-129|and|O
DDI-DrugBank.d781.s8|131-133|ACE|O
DDI-DrugBank.d781.s8|135-143|inhibitor|O
DDI-DrugBank.d781.s8|145-151|therapy|O
DDI-DrugBank.d781.s8|152-152|.|O
DDI-DrugBank.d781.s9|0-4|These|O
DDI-DrugBank.d781.s9|6-10|drugs|O
DDI-DrugBank.d781.s9|12-17|should|O
DDI-DrugBank.d781.s9|19-20|be|O
DDI-DrugBank.d781.s9|22-35|coadministered|O
DDI-DrugBank.d781.s9|37-40|with|O
DDI-DrugBank.d781.s9|42-48|caution|O
DDI-DrugBank.d781.s9|50-52|and|O
DDI-DrugBank.d781.s9|54-61|frequent|O
DDI-DrugBank.d781.s9|63-72|monitoring|O
DDI-DrugBank.d781.s9|74-75|of|O
DDI-DrugBank.d781.s9|77-81|serum|O
DDI-DrugBank.d781.s9|83-89|lithium|drug
DDI-DrugBank.d781.s9|91-103|concentration|O
DDI-DrugBank.d781.s9|105-106|is|O
DDI-DrugBank.d781.s9|108-118|recommended|O
DDI-DrugBank.d781.s9|119-119|.|O
DDI-DrugBank.d781.s10|0-2|Use|O
DDI-DrugBank.d781.s10|4-5|of|O
DDI-DrugBank.d781.s10|7-7|a|O
DDI-DrugBank.d781.s10|9-16|diuretic|group
DDI-DrugBank.d781.s10|18-20|may|O
DDI-DrugBank.d781.s10|22-28|further|O
DDI-DrugBank.d781.s10|30-37|increase|O
DDI-DrugBank.d781.s10|39-41|the|O
DDI-DrugBank.d781.s10|43-46|risk|O
DDI-DrugBank.d781.s10|48-49|of|O
DDI-DrugBank.d781.s10|51-57|lithium|drug
DDI-DrugBank.d781.s10|59-66|toxicity|O
DDI-DrugBank.d781.s10|67-67|.|O
DDI-DrugBank.d781.s11|0-6|Digoxin|drug
DDI-DrugBank.d781.s11|7-7|:|O
DDI-DrugBank.d781.s11|9-9|A|O
DDI-DrugBank.d781.s11|11-20|controlled|O
DDI-DrugBank.d781.s11|22-36|pharmacokinetic|O
DDI-DrugBank.d781.s11|38-42|study|O
DDI-DrugBank.d781.s11|44-46|has|O
DDI-DrugBank.d781.s11|48-52|shown|O
DDI-DrugBank.d781.s11|54-55|no|O
DDI-DrugBank.d781.s11|57-62|effect|O
DDI-DrugBank.d781.s11|64-65|on|O
DDI-DrugBank.d781.s11|67-72|plasma|O
DDI-DrugBank.d781.s11|74-80|digoxin|drug
DDI-DrugBank.d781.s11|82-95|concentrations|O
DDI-DrugBank.d781.s11|97-100|when|O
DDI-DrugBank.d781.s11|102-115|coadministered|O
DDI-DrugBank.d781.s11|117-120|with|O
DDI-DrugBank.d781.s11|122-126|ACEON|brand
DDI-DrugBank.d781.s11|131-137|Tablets|O
DDI-DrugBank.d781.s11|138-138|,|O
DDI-DrugBank.d781.s11|140-142|but|O
DDI-DrugBank.d781.s11|144-145|an|O
DDI-DrugBank.d781.s11|147-152|effect|O
DDI-DrugBank.d781.s11|154-155|of|O
DDI-DrugBank.d781.s11|157-163|digoxin|drug
DDI-DrugBank.d781.s11|165-166|on|O
DDI-DrugBank.d781.s11|168-170|the|O
DDI-DrugBank.d781.s11|172-177|plasma|O
DDI-DrugBank.d781.s11|179-191|concentration|O
DDI-DrugBank.d781.s11|193-194|of|O
DDI-DrugBank.d781.s11|196-220|perindopril/perindoprilat|drug
DDI-DrugBank.d781.s11|222-224|has|O
DDI-DrugBank.d781.s11|226-228|not|O
DDI-DrugBank.d781.s11|230-233|been|O
DDI-DrugBank.d781.s11|235-242|excluded|O
DDI-DrugBank.d781.s11|243-243|.|O
DDI-DrugBank.d781.s12|0-9|Gentamicin|drug
DDI-DrugBank.d781.s12|10-10|:|O
DDI-DrugBank.d781.s12|12-17|Animal|O
DDI-DrugBank.d781.s12|19-22|data|O
DDI-DrugBank.d781.s12|24-27|have|O
DDI-DrugBank.d781.s12|29-37|suggested|O
DDI-DrugBank.d781.s12|39-41|the|O
DDI-DrugBank.d781.s12|43-53|possibility|O
DDI-DrugBank.d781.s12|55-56|of|O
DDI-DrugBank.d781.s12|58-68|interaction|O
DDI-DrugBank.d781.s12|70-76|between|O
DDI-DrugBank.d781.s12|78-88|perindopril|drug
DDI-DrugBank.d781.s12|90-92|and|O
DDI-DrugBank.d781.s12|94-103|gentamicin|drug
DDI-DrugBank.d781.s12|104-104|.|O
DDI-DrugBank.d781.s13|0-6|However|O
DDI-DrugBank.d781.s13|7-7|,|O
DDI-DrugBank.d781.s13|9-12|this|O
DDI-DrugBank.d781.s13|14-16|has|O
DDI-DrugBank.d781.s13|18-20|not|O
DDI-DrugBank.d781.s13|22-25|been|O
DDI-DrugBank.d781.s13|27-38|investigated|O
DDI-DrugBank.d781.s13|40-41|in|O
DDI-DrugBank.d781.s13|43-47|human|O
DDI-DrugBank.d781.s13|49-55|studies|O
DDI-DrugBank.d781.s13|56-56|.|O
DDI-DrugBank.d781.s14|0-15|Coadministration|O
DDI-DrugBank.d781.s14|17-18|of|O
DDI-DrugBank.d781.s14|20-23|both|O
DDI-DrugBank.d781.s14|25-29|drugs|O
DDI-DrugBank.d781.s14|31-36|should|O
DDI-DrugBank.d781.s14|38-44|proceed|O
DDI-DrugBank.d781.s14|46-49|with|O
DDI-DrugBank.d781.s14|51-57|caution|O
DDI-DrugBank.d781.s14|58-58|.|O
DDI-DrugBank.d781.s15|0-3|Food|O
DDI-DrugBank.d781.s15|5-15|Interaction|O
DDI-DrugBank.d781.s15|16-16|:|O
DDI-DrugBank.d781.s15|18-21|Oral|O
DDI-DrugBank.d781.s15|23-36|administration|O
DDI-DrugBank.d781.s15|38-39|of|O
DDI-DrugBank.d781.s15|41-45|ACEON|brand
DDI-DrugBank.d781.s15|50-56|Tablets|O
DDI-DrugBank.d781.s15|58-61|with|O
DDI-DrugBank.d781.s15|63-66|food|O
DDI-DrugBank.d781.s15|68-71|does|O
DDI-DrugBank.d781.s15|73-75|not|O
DDI-DrugBank.d781.s15|77-89|significantly|O
DDI-DrugBank.d781.s15|91-95|lower|O
DDI-DrugBank.d781.s15|97-99|the|O
DDI-DrugBank.d781.s15|101-104|rate|O
DDI-DrugBank.d781.s15|106-107|or|O
DDI-DrugBank.d781.s15|109-114|extent|O
DDI-DrugBank.d781.s15|116-117|of|O
DDI-DrugBank.d781.s15|119-129|perindopril|drug
DDI-DrugBank.d781.s15|131-140|absorption|O
DDI-DrugBank.d781.s15|142-149|relative|O
DDI-DrugBank.d781.s15|151-152|to|O
DDI-DrugBank.d781.s15|154-156|the|O
DDI-DrugBank.d781.s15|158-163|fasted|O
DDI-DrugBank.d781.s15|165-169|state|O
DDI-DrugBank.d781.s15|170-170|.|O
DDI-DrugBank.d781.s16|0-6|However|O
DDI-DrugBank.d781.s16|7-7|,|O
DDI-DrugBank.d781.s16|9-11|the|O
DDI-DrugBank.d781.s16|13-18|extent|O
DDI-DrugBank.d781.s16|20-21|of|O
DDI-DrugBank.d781.s16|23-39|biotransformation|O
DDI-DrugBank.d781.s16|41-42|of|O
DDI-DrugBank.d781.s16|44-54|perindopril|drug
DDI-DrugBank.d781.s16|56-57|to|O
DDI-DrugBank.d781.s16|59-61|the|O
DDI-DrugBank.d781.s16|63-68|active|O
DDI-DrugBank.d781.s16|70-79|metabolite|O
DDI-DrugBank.d781.s16|80-80|,|O
DDI-DrugBank.d781.s16|95-95|,|O
DDI-DrugBank.d781.s16|97-98|is|O
DDI-DrugBank.d781.s16|100-106|reduced|O
DDI-DrugBank.d781.s16|108-120|approximately|O
DDI-DrugBank.d781.s16|122-123|43|O
DDI-DrugBank.d781.s16|124-124|%|O
DDI-DrugBank.d781.s16|125-125|,|O
DDI-DrugBank.d781.s16|127-135|resulting|O
DDI-DrugBank.d781.s16|137-138|in|O
DDI-DrugBank.d781.s16|140-140|a|O
DDI-DrugBank.d781.s16|142-150|reduction|O
DDI-DrugBank.d781.s16|152-153|in|O
DDI-DrugBank.d781.s16|155-157|the|O
DDI-DrugBank.d781.s16|159-164|plasma|O
DDI-DrugBank.d781.s16|166-168|ACE|O
DDI-DrugBank.d781.s16|170-179|inhibition|O
DDI-DrugBank.d781.s16|181-185|curve|O
DDI-DrugBank.d781.s16|187-188|of|O
DDI-DrugBank.d781.s16|190-202|approximately|O
DDI-DrugBank.d781.s16|204-205|20|O
DDI-DrugBank.d781.s16|206-206|%|O
DDI-DrugBank.d781.s16|207-207|,|O
DDI-DrugBank.d781.s16|209-216|probably|O
DDI-DrugBank.d781.s16|218-227|clinically|O
DDI-DrugBank.d781.s16|229-241|insignificant|O
DDI-DrugBank.d781.s16|242-242|.|O
DDI-DrugBank.d781.s17|0-1|In|O
DDI-DrugBank.d781.s17|3-10|clinical|O
DDI-DrugBank.d781.s17|12-17|trials|O
DDI-DrugBank.d781.s17|18-18|,|O
DDI-DrugBank.d781.s17|20-30|perindopril|drug
DDI-DrugBank.d781.s17|32-34|was|O
DDI-DrugBank.d781.s17|36-44|generally|O
DDI-DrugBank.d781.s17|46-57|administered|O
DDI-DrugBank.d781.s17|59-60|in|O
DDI-DrugBank.d781.s17|62-62|a|O
DDI-DrugBank.d781.s17|64-74|non-fasting|O
DDI-DrugBank.d781.s17|76-80|state|O
DDI-DrugBank.d781.s17|81-81|.|O
DDI-MedLine.d194.s0|0-2|The|O
DDI-MedLine.d194.s0|4-7|role|O
DDI-MedLine.d194.s0|9-10|of|O
DDI-MedLine.d194.s0|12-14|p27|O
DDI-MedLine.d194.s0|15-15|(|O
DDI-MedLine.d194.s0|16-19|Kip1|O
DDI-MedLine.d194.s0|20-20|)|O
DDI-MedLine.d194.s0|22-23|in|O
DDI-MedLine.d194.s0|25-42|dasatinib-enhanced|drug
DDI-MedLine.d194.s0|25-42|dasatinib-enhanced|drug
DDI-MedLine.d194.s0|55-66|cytotoxicity|O
DDI-MedLine.d194.s0|68-69|in|O
DDI-MedLine.d194.s0|71-75|human|O
DDI-MedLine.d194.s0|77-83|ovarian|O
DDI-MedLine.d194.s0|85-90|cancer|O
DDI-MedLine.d194.s0|92-96|cells|O
DDI-MedLine.d194.s0|97-97|.|O
DDI-MedLine.d194.s1|0-3|Less|O
DDI-MedLine.d194.s1|5-8|than|O
DDI-MedLine.d194.s1|10-11|50|O
DDI-MedLine.d194.s1|12-12|%|O
DDI-MedLine.d194.s1|14-15|of|O
DDI-MedLine.d194.s1|17-23|ovarian|O
DDI-MedLine.d194.s1|25-31|cancers|O
DDI-MedLine.d194.s1|33-39|respond|O
DDI-MedLine.d194.s1|41-42|to|O
DDI-MedLine.d194.s1|44-53|paclitaxel|drug
DDI-MedLine.d194.s1|54-54|.|O
DDI-MedLine.d194.s2|0-8|Effective|O
DDI-MedLine.d194.s2|10-19|strategies|O
DDI-MedLine.d194.s2|21-23|are|O
DDI-MedLine.d194.s2|25-30|needed|O
DDI-MedLine.d194.s2|32-33|to|O
DDI-MedLine.d194.s2|35-41|enhance|O
DDI-MedLine.d194.s2|43-52|paclitaxel|drug
DDI-MedLine.d194.s2|54-64|sensitivity|O
DDI-MedLine.d194.s2|65-65|.|O
DDI-MedLine.d194.s3|0-0|A|O
DDI-MedLine.d194.s3|2-8|library|O
DDI-MedLine.d194.s3|10-11|of|O
DDI-MedLine.d194.s3|13-21|silencing|O
DDI-MedLine.d194.s3|23-26|RNAs|O
DDI-MedLine.d194.s3|28-28|(|O
DDI-MedLine.d194.s3|29-34|siRNAs|O
DDI-MedLine.d194.s3|35-35|)|O
DDI-MedLine.d194.s3|37-39|was|O
DDI-MedLine.d194.s3|41-44|used|O
DDI-MedLine.d194.s3|46-47|to|O
DDI-MedLine.d194.s3|49-56|identify|O
DDI-MedLine.d194.s3|58-64|kinases|O
DDI-MedLine.d194.s3|66-69|that|O
DDI-MedLine.d194.s3|71-78|regulate|O
DDI-MedLine.d194.s3|80-89|paclitaxel|drug
DDI-MedLine.d194.s3|91-101|sensitivity|O
DDI-MedLine.d194.s3|103-104|in|O
DDI-MedLine.d194.s3|106-110|human|O
DDI-MedLine.d194.s3|112-118|ovarian|O
DDI-MedLine.d194.s3|120-125|cancer|O
DDI-MedLine.d194.s3|127-131|SKOv3|O
DDI-MedLine.d194.s3|133-137|cells|O
DDI-MedLine.d194.s3|138-138|.|O
DDI-MedLine.d194.s4|0-2|The|O
DDI-MedLine.d194.s4|4-9|effect|O
DDI-MedLine.d194.s4|11-12|of|O
DDI-MedLine.d194.s4|14-22|dasatinib|drug
DDI-MedLine.d194.s4|23-23|,|O
DDI-MedLine.d194.s4|25-26|an|O
DDI-MedLine.d194.s4|28-36|inhibitor|O
DDI-MedLine.d194.s4|38-39|of|O
DDI-MedLine.d194.s4|41-43|Src|O
DDI-MedLine.d194.s4|45-47|and|O
DDI-MedLine.d194.s4|49-51|Abl|O
DDI-MedLine.d194.s4|53-59|kinases|O
DDI-MedLine.d194.s4|60-60|,|O
DDI-MedLine.d194.s4|62-63|on|O
DDI-MedLine.d194.s4|65-74|paclitaxel|drug
DDI-MedLine.d194.s4|76-86|sensitivity|O
DDI-MedLine.d194.s4|88-90|was|O
DDI-MedLine.d194.s4|92-99|measured|O
DDI-MedLine.d194.s4|101-102|in|O
DDI-MedLine.d194.s4|104-110|ovarian|O
DDI-MedLine.d194.s4|112-117|cancer|O
DDI-MedLine.d194.s4|119-123|cells|O
DDI-MedLine.d194.s4|125-127|and|O
DDI-MedLine.d194.s4|129-131|HEY|O
DDI-MedLine.d194.s4|133-142|xenografts|O
DDI-MedLine.d194.s4|143-143|.|O
DDI-MedLine.d194.s5|0-2|The|O
DDI-MedLine.d194.s5|4-8|roles|O
DDI-MedLine.d194.s5|10-11|of|O
DDI-MedLine.d194.s5|13-15|p27|O
DDI-MedLine.d194.s5|16-16|(|O
DDI-MedLine.d194.s5|17-20|Kip1|O
DDI-MedLine.d194.s5|21-21|)|O
DDI-MedLine.d194.s5|22-22|,|O
DDI-MedLine.d194.s5|24-28|Bcl-2|O
DDI-MedLine.d194.s5|29-29|,|O
DDI-MedLine.d194.s5|31-33|and|O
DDI-MedLine.d194.s5|35-38|Cdk1|O
DDI-MedLine.d194.s5|40-41|in|O
DDI-MedLine.d194.s5|43-51|apoptosis|O
DDI-MedLine.d194.s5|53-59|induced|O
DDI-MedLine.d194.s5|61-62|by|O
DDI-MedLine.d194.s5|64-72|dasatinib|drug
DDI-MedLine.d194.s5|74-76|and|O
DDI-MedLine.d194.s5|78-87|paclitaxel|drug
DDI-MedLine.d194.s5|89-92|were|O
DDI-MedLine.d194.s5|94-101|assessed|O
DDI-MedLine.d194.s5|103-107|using|O
DDI-MedLine.d194.s5|109-109|a|O
DDI-MedLine.d194.s5|111-118|terminal|O
DDI-MedLine.d194.s5|120-135|deoxynucleotidyl|O
DDI-MedLine.d194.s5|137-156|transferase-mediated|O
DDI-MedLine.d194.s5|158-161|dUTP|O
DDI-MedLine.d194.s5|163-170|nick-end|O
DDI-MedLine.d194.s5|172-179|labeling|O
DDI-MedLine.d194.s5|181-181|(|O
DDI-MedLine.d194.s5|182-186|TUNEL|O
DDI-MedLine.d194.s5|187-187|)|O
DDI-MedLine.d194.s5|189-193|assay|O
DDI-MedLine.d194.s5|194-194|,|O
DDI-MedLine.d194.s5|196-200|siRNA|O
DDI-MedLine.d194.s5|202-210|knockdown|O
DDI-MedLine.d194.s5|212-213|of|O
DDI-MedLine.d194.s5|215-218|gene|O
DDI-MedLine.d194.s5|220-229|expression|O
DDI-MedLine.d194.s5|230-230|,|O
DDI-MedLine.d194.s5|232-243|transfection|O
DDI-MedLine.d194.s5|245-248|with|O
DDI-MedLine.d194.s5|250-254|Bcl-2|O
DDI-MedLine.d194.s5|256-258|and|O
DDI-MedLine.d194.s5|260-263|Cdk1|O
DDI-MedLine.d194.s5|265-274|expression|O
DDI-MedLine.d194.s5|276-282|vectors|O
DDI-MedLine.d194.s5|283-283|,|O
DDI-MedLine.d194.s5|285-287|and|O
DDI-MedLine.d194.s5|289-292|flow|O
DDI-MedLine.d194.s5|294-302|cytometry|O
DDI-MedLine.d194.s5|303-303|.|O
DDI-MedLine.d194.s6|0-2|All|O
DDI-MedLine.d194.s6|4-14|statistical|O
DDI-MedLine.d194.s6|16-20|tests|O
DDI-MedLine.d194.s6|22-25|were|O
DDI-MedLine.d194.s6|27-35|two-sided|O
DDI-MedLine.d194.s6|36-36|.|O
DDI-MedLine.d194.s7|0-2|Src|O
DDI-MedLine.d194.s7|4-9|family|O
DDI-MedLine.d194.s7|11-13|and|O
DDI-MedLine.d194.s7|15-17|Abl|O
DDI-MedLine.d194.s7|19-25|kinases|O
DDI-MedLine.d194.s7|27-30|were|O
DDI-MedLine.d194.s7|32-41|identified|O
DDI-MedLine.d194.s7|43-44|as|O
DDI-MedLine.d194.s7|46-55|modulators|O
DDI-MedLine.d194.s7|57-58|of|O
DDI-MedLine.d194.s7|60-69|paclitaxel|drug
DDI-MedLine.d194.s7|71-81|sensitivity|O
DDI-MedLine.d194.s7|83-84|in|O
DDI-MedLine.d194.s7|86-90|SKOv3|O
DDI-MedLine.d194.s7|92-96|cells|O
DDI-MedLine.d194.s7|97-97|.|O
DDI-MedLine.d194.s8|0-2|The|O
DDI-MedLine.d194.s8|4-8|siRNA|O
DDI-MedLine.d194.s8|10-18|knockdown|O
DDI-MedLine.d194.s8|20-21|of|O
DDI-MedLine.d194.s8|23-25|Src|O
DDI-MedLine.d194.s8|26-26|,|O
DDI-MedLine.d194.s8|28-30|Fyn|O
DDI-MedLine.d194.s8|31-31|,|O
DDI-MedLine.d194.s8|33-34|or|O
DDI-MedLine.d194.s8|36-39|Abl1|O
DDI-MedLine.d194.s8|41-48|enhanced|O
DDI-MedLine.d194.s8|50-68|paclitaxel-mediated|drug
DDI-MedLine.d194.s8|70-75|growth|O
DDI-MedLine.d194.s8|77-86|inhibition|O
DDI-MedLine.d194.s8|88-89|in|O
DDI-MedLine.d194.s8|91-97|ovarian|O
DDI-MedLine.d194.s8|99-104|cancer|O
DDI-MedLine.d194.s8|106-110|cells|O
DDI-MedLine.d194.s8|112-119|compared|O
DDI-MedLine.d194.s8|121-124|with|O
DDI-MedLine.d194.s8|126-126|a|O
DDI-MedLine.d194.s8|128-134|control|O
DDI-MedLine.d194.s8|136-140|siRNA|O
DDI-MedLine.d194.s8|141-141|.|O
DDI-MedLine.d194.s9|0-2|HEY|O
DDI-MedLine.d194.s9|4-8|cells|O
DDI-MedLine.d194.s9|10-16|treated|O
DDI-MedLine.d194.s9|18-21|with|O
DDI-MedLine.d194.s9|23-31|dasatinib|drug
DDI-MedLine.d194.s9|33-36|plus|O
DDI-MedLine.d194.s9|38-47|paclitaxel|drug
DDI-MedLine.d194.s9|49-54|formed|O
DDI-MedLine.d194.s9|56-60|fewer|O
DDI-MedLine.d194.s9|62-69|colonies|O
DDI-MedLine.d194.s9|71-74|than|O
DDI-MedLine.d194.s9|76-78|did|O
DDI-MedLine.d194.s9|80-84|cells|O
DDI-MedLine.d194.s9|86-92|treated|O
DDI-MedLine.d194.s9|94-97|with|O
DDI-MedLine.d194.s9|99-104|either|O
DDI-MedLine.d194.s9|106-110|agent|O
DDI-MedLine.d194.s9|112-116|alone|O
DDI-MedLine.d194.s9|117-117|.|O
DDI-MedLine.d194.s10|0-8|Treatment|O
DDI-MedLine.d194.s10|10-11|of|O
DDI-MedLine.d194.s10|13-15|HEY|O
DDI-MedLine.d194.s10|17-33|xenograft-bearing|O
DDI-MedLine.d194.s10|35-38|mice|O
DDI-MedLine.d194.s10|40-43|with|O
DDI-MedLine.d194.s10|45-53|dasatinib|drug
DDI-MedLine.d194.s10|55-58|plus|O
DDI-MedLine.d194.s10|60-69|paclitaxel|drug
DDI-MedLine.d194.s10|71-79|inhibited|O
DDI-MedLine.d194.s10|81-85|tumor|O
DDI-MedLine.d194.s10|87-92|growth|O
DDI-MedLine.d194.s10|94-97|more|O
DDI-MedLine.d194.s10|99-102|than|O
DDI-MedLine.d194.s10|104-112|treatment|O
DDI-MedLine.d194.s10|114-117|with|O
DDI-MedLine.d194.s10|119-124|either|O
DDI-MedLine.d194.s10|126-130|agent|O
DDI-MedLine.d194.s10|132-136|alone|O
DDI-MedLine.d194.s10|138-138|(|O
DDI-MedLine.d194.s10|139-145|average|O
DDI-MedLine.d194.s10|147-151|tumor|O
DDI-MedLine.d194.s10|153-158|volume|O
DDI-MedLine.d194.s10|160-162|per|O
DDI-MedLine.d194.s10|164-168|mouse|O
DDI-MedLine.d194.s10|169-169|,|O
DDI-MedLine.d194.s10|171-179|dasatinib|drug
DDI-MedLine.d194.s10|181-181|+|O
DDI-MedLine.d194.s10|183-192|paclitaxel|drug
DDI-MedLine.d194.s10|194-195|vs|O
DDI-MedLine.d194.s10|197-206|paclitaxel|drug
DDI-MedLine.d194.s10|207-207|:|O
DDI-MedLine.d194.s10|209-212|0.28|O
DDI-MedLine.d194.s10|214-216|vs.|O
DDI-MedLine.d194.s10|218-221|0.81|O
DDI-MedLine.d194.s10|223-225|cm3|O
DDI-MedLine.d194.s10|226-226|,|O
DDI-MedLine.d194.s10|228-237|difference|O
DDI-MedLine.d194.s10|239-239|=|O
DDI-MedLine.d194.s10|241-244|0.53|O
DDI-MedLine.d194.s10|246-248|cm3|O
DDI-MedLine.d194.s10|249-249|,|O
DDI-MedLine.d194.s10|251-252|95|O
DDI-MedLine.d194.s10|253-253|%|O
DDI-MedLine.d194.s10|255-264|confidence|O
DDI-MedLine.d194.s10|266-273|interval|O
DDI-MedLine.d194.s10|275-275|[|O
DDI-MedLine.d194.s10|276-277|CI|O
DDI-MedLine.d194.s10|278-278|]|O
DDI-MedLine.d194.s10|280-280|=|O
DDI-MedLine.d194.s10|282-285|0.44|O
DDI-MedLine.d194.s10|287-288|to|O
DDI-MedLine.d194.s10|290-293|0.62|O
DDI-MedLine.d194.s10|295-297|cm3|O
DDI-MedLine.d194.s10|298-298|,|O
DDI-MedLine.d194.s10|300-300|P|O
DDI-MedLine.d194.s10|302-302|=|O
DDI-MedLine.d194.s10|304-307|.014|O
DDI-MedLine.d194.s10|308-308|)|O
DDI-MedLine.d194.s10|309-309|;|O
DDI-MedLine.d194.s11|0-8|dasatinib|drug
DDI-MedLine.d194.s11|10-10|+|O
DDI-MedLine.d194.s11|12-21|paclitaxel|drug
DDI-MedLine.d194.s11|23-24|vs|O
DDI-MedLine.d194.s11|25-25|.|O
DDI-MedLine.d194.s12|0-8|dasatinib|drug
DDI-MedLine.d194.s12|9-9|:|O
DDI-MedLine.d194.s12|11-14|0.28|O
DDI-MedLine.d194.s12|16-17|vs|O
DDI-MedLine.d194.s12|18-18|.|O
DDI-MedLine.d194.s13|0-3|0.55|O
DDI-MedLine.d194.s13|5-7|cm3|O
DDI-MedLine.d194.s13|8-8|,|O
DDI-MedLine.d194.s13|10-19|difference|O
DDI-MedLine.d194.s13|21-21|=|O
DDI-MedLine.d194.s13|23-26|0.27|O
DDI-MedLine.d194.s13|28-30|cm3|O
DDI-MedLine.d194.s13|31-31|,|O
DDI-MedLine.d194.s13|33-34|95|O
DDI-MedLine.d194.s13|35-35|%|O
DDI-MedLine.d194.s13|37-38|CI|O
DDI-MedLine.d194.s13|40-40|=|O
DDI-MedLine.d194.s13|42-45|0.21|O
DDI-MedLine.d194.s13|47-48|to|O
DDI-MedLine.d194.s13|50-53|0.33|O
DDI-MedLine.d194.s13|55-57|cm3|O
DDI-MedLine.d194.s13|58-58|,|O
DDI-MedLine.d194.s13|60-60|P|O
DDI-MedLine.d194.s13|62-62|=|O
DDI-MedLine.d194.s13|64-67|.035|O
DDI-MedLine.d194.s13|68-68|)|O
DDI-MedLine.d194.s13|69-69|.|O
DDI-MedLine.d194.s14|0-7|Combined|O
DDI-MedLine.d194.s14|9-17|treatment|O
DDI-MedLine.d194.s14|19-25|induced|O
DDI-MedLine.d194.s14|27-30|more|O
DDI-MedLine.d194.s14|32-45|TUNEL-positive|O
DDI-MedLine.d194.s14|47-55|apoptotic|O
DDI-MedLine.d194.s14|57-61|cells|O
DDI-MedLine.d194.s14|63-66|than|O
DDI-MedLine.d194.s14|68-70|did|O
DDI-MedLine.d194.s14|72-77|either|O
DDI-MedLine.d194.s14|79-83|agent|O
DDI-MedLine.d194.s14|85-89|alone|O
DDI-MedLine.d194.s14|90-90|.|O
DDI-MedLine.d194.s15|0-2|The|O
DDI-MedLine.d194.s15|4-8|siRNA|O
DDI-MedLine.d194.s15|10-18|knockdown|O
DDI-MedLine.d194.s15|20-21|of|O
DDI-MedLine.d194.s15|23-25|p27|O
DDI-MedLine.d194.s15|26-26|(|O
DDI-MedLine.d194.s15|27-30|Kip1|O
DDI-MedLine.d194.s15|31-31|)|O
DDI-MedLine.d194.s15|33-41|decreased|O
DDI-MedLine.d194.s15|43-52|dasatinib-|drug
DDI-MedLine.d194.s15|54-56|and|O
DDI-MedLine.d194.s15|58-75|paclitaxel-induced|drug
DDI-MedLine.d194.s15|77-85|apoptosis|O
DDI-MedLine.d194.s15|87-94|compared|O
DDI-MedLine.d194.s15|96-99|with|O
DDI-MedLine.d194.s15|101-101|a|O
DDI-MedLine.d194.s15|103-110|negative|O
DDI-MedLine.d194.s15|112-118|control|O
DDI-MedLine.d194.s15|120-124|siRNA|O
DDI-MedLine.d194.s15|126-126|(|O
DDI-MedLine.d194.s15|127-132|sub-G1|O
DDI-MedLine.d194.s15|134-141|fraction|O
DDI-MedLine.d194.s15|142-142|,|O
DDI-MedLine.d194.s15|144-150|control|O
DDI-MedLine.d194.s15|152-156|siRNA|O
DDI-MedLine.d194.s15|158-160|vs.|O
DDI-MedLine.d194.s15|162-164|p27|O
DDI-MedLine.d194.s15|165-165|(|O
DDI-MedLine.d194.s15|166-169|Kip1|O
DDI-MedLine.d194.s15|170-170|)|O
DDI-MedLine.d194.s15|172-176|siRNA|O
DDI-MedLine.d194.s15|177-177|:|O
DDI-MedLine.d194.s15|179-182|42.5|O
DDI-MedLine.d194.s15|183-183|%|O
DDI-MedLine.d194.s15|185-187|vs.|O
DDI-MedLine.d194.s15|189-192|20.1|O
DDI-MedLine.d194.s15|193-193|%|O
DDI-MedLine.d194.s15|194-194|,|O
DDI-MedLine.d194.s15|196-205|difference|O
DDI-MedLine.d194.s15|207-207|=|O
DDI-MedLine.d194.s15|209-212|22.4|O
DDI-MedLine.d194.s15|213-213|%|O
DDI-MedLine.d194.s15|214-214|,|O
DDI-MedLine.d194.s15|216-217|95|O
DDI-MedLine.d194.s15|218-218|%|O
DDI-MedLine.d194.s15|220-221|CI|O
DDI-MedLine.d194.s15|223-223|=|O
DDI-MedLine.d194.s15|225-228|20.1|O
DDI-MedLine.d194.s15|229-229|%|O
DDI-MedLine.d194.s15|231-232|to|O
DDI-MedLine.d194.s15|234-237|24.7|O
DDI-MedLine.d194.s15|238-238|%|O
DDI-MedLine.d194.s15|239-239|,|O
DDI-MedLine.d194.s15|241-241|P|O
DDI-MedLine.d194.s15|243-243|=|O
DDI-MedLine.d194.s15|245-248|.017|O
DDI-MedLine.d194.s15|249-249|)|O
DDI-MedLine.d194.s15|250-250|.|O
DDI-MedLine.d194.s16|0-6|Studies|O
DDI-MedLine.d194.s16|8-11|with|O
DDI-MedLine.d194.s16|13-18|forced|O
DDI-MedLine.d194.s16|20-29|expression|O
DDI-MedLine.d194.s16|31-33|and|O
DDI-MedLine.d194.s16|35-39|siRNA|O
DDI-MedLine.d194.s16|41-49|knockdown|O
DDI-MedLine.d194.s16|51-52|of|O
DDI-MedLine.d194.s16|54-58|Bcl-2|O
DDI-MedLine.d194.s16|60-62|and|O
DDI-MedLine.d194.s16|64-67|Cdk1|O
DDI-MedLine.d194.s16|69-75|suggest|O
DDI-MedLine.d194.s16|77-80|that|O
DDI-MedLine.d194.s16|82-99|dasatinib-mediated|drug
DDI-MedLine.d194.s16|101-109|induction|O
DDI-MedLine.d194.s16|111-112|of|O
DDI-MedLine.d194.s16|114-116|p27|O
DDI-MedLine.d194.s16|117-117|(|O
DDI-MedLine.d194.s16|118-121|Kip1|O
DDI-MedLine.d194.s16|122-122|)|O
DDI-MedLine.d194.s16|124-131|enhanced|O
DDI-MedLine.d194.s16|133-150|paclitaxel-induced|drug
DDI-MedLine.d194.s16|152-160|apoptosis|O
DDI-MedLine.d194.s16|162-163|by|O
DDI-MedLine.d194.s16|165-174|negatively|O
DDI-MedLine.d194.s16|176-185|regulating|O
DDI-MedLine.d194.s16|187-191|Bcl-2|O
DDI-MedLine.d194.s16|193-195|and|O
DDI-MedLine.d194.s16|197-200|Cdk1|O
DDI-MedLine.d194.s16|202-211|expression|O
DDI-MedLine.d194.s16|212-212|.|O
DDI-MedLine.d194.s17|0-9|Inhibition|O
DDI-MedLine.d194.s17|11-12|of|O
DDI-MedLine.d194.s17|14-16|Src|O
DDI-MedLine.d194.s17|18-23|family|O
DDI-MedLine.d194.s17|25-27|and|O
DDI-MedLine.d194.s17|29-31|Abl|O
DDI-MedLine.d194.s17|33-39|kinases|O
DDI-MedLine.d194.s17|41-44|with|O
DDI-MedLine.d194.s17|46-51|either|O
DDI-MedLine.d194.s17|53-58|siRNAs|O
DDI-MedLine.d194.s17|60-61|or|O
DDI-MedLine.d194.s17|63-71|dasatinib|drug
DDI-MedLine.d194.s17|73-80|enhances|O
DDI-MedLine.d194.s17|82-91|paclitaxel|drug
DDI-MedLine.d194.s17|93-103|sensitivity|O
DDI-MedLine.d194.s17|105-106|of|O
DDI-MedLine.d194.s17|108-114|ovarian|O
DDI-MedLine.d194.s17|116-121|cancer|O
DDI-MedLine.d194.s17|123-127|cells|O
DDI-MedLine.d194.s17|129-135|through|O
DDI-MedLine.d194.s17|137-139|p27|O
DDI-MedLine.d194.s17|140-140|(|O
DDI-MedLine.d194.s17|141-144|Kip1|O
DDI-MedLine.d194.s17|145-145|)|O
DDI-MedLine.d194.s17|146-154|-mediated|O
DDI-MedLine.d194.s17|156-166|suppression|O
DDI-MedLine.d194.s17|168-169|of|O
DDI-MedLine.d194.s17|171-175|Bcl-2|O
DDI-MedLine.d194.s17|177-179|and|O
DDI-MedLine.d194.s17|181-184|Cdk1|O
DDI-MedLine.d194.s17|186-195|expression|O
DDI-MedLine.d194.s17|196-196|.|O
DDI-DrugBank.d343.s0|0-6|Aspirin|brand
DDI-DrugBank.d343.s0|7-7|,|O
DDI-DrugBank.d343.s0|9-16|warfarin|drug
DDI-DrugBank.d343.s0|17-17|,|O
DDI-DrugBank.d343.s0|19-25|heparin|drug
DDI-DrugBank.d343.s0|26-26|,|O
DDI-DrugBank.d83.s0|0-7|Patients|O
DDI-DrugBank.d83.s0|9-10|on|O
DDI-DrugBank.d83.s0|12-38|warfarin-type anticoagulant|group
DDI-DrugBank.d83.s0|40-46|therapy|O
DDI-DrugBank.d83.s0|48-50|may|O
DDI-DrugBank.d83.s0|52-58|require|O
DDI-DrugBank.d83.s0|60-65|dosage|O
DDI-DrugBank.d83.s0|67-76|adjustment|O
DDI-DrugBank.d83.s0|78-79|of|O
DDI-DrugBank.d83.s0|81-83|the|O
DDI-DrugBank.d83.s0|85-97|anticoagulant|O
DDI-DrugBank.d83.s0|99-104|during|O
DDI-DrugBank.d83.s0|106-108|and|O
DDI-DrugBank.d83.s0|110-114|after|O
DDI-DrugBank.d83.s0|116-127|griseofulvin|drug
DDI-DrugBank.d83.s0|129-135|therapy|O
DDI-DrugBank.d83.s0|136-136|.|O
DDI-DrugBank.d83.s1|0-10|Concomitant|O
DDI-DrugBank.d83.s1|12-14|use|O
DDI-DrugBank.d83.s1|16-17|of|O
DDI-DrugBank.d83.s1|19-30|barbiturates|group
DDI-DrugBank.d83.s1|32-38|usually|O
DDI-DrugBank.d83.s1|40-48|depresses|O
DDI-DrugBank.d83.s1|50-61|griseofulvin|drug
DDI-DrugBank.d83.s1|63-70|activity|O
DDI-DrugBank.d83.s1|72-74|and|O
DDI-DrugBank.d83.s1|76-78|may|O
DDI-DrugBank.d83.s1|80-90|necessitate|O
DDI-DrugBank.d83.s1|92-98|raising|O
DDI-DrugBank.d83.s1|100-102|the|O
DDI-DrugBank.d83.s1|104-109|dosage|O
DDI-DrugBank.d83.s1|110-110|.|O
DDI-DrugBank.d83.s2|0-2|The|O
DDI-DrugBank.d83.s2|4-14|concomitant|O
DDI-DrugBank.d83.s2|16-29|administration|O
DDI-DrugBank.d83.s2|31-32|of|O
DDI-DrugBank.d83.s2|34-45|griseofulvin|drug
DDI-DrugBank.d83.s2|47-49|has|O
DDI-DrugBank.d83.s2|51-54|been|O
DDI-DrugBank.d83.s2|56-63|reported|O
DDI-DrugBank.d83.s2|65-66|to|O
DDI-DrugBank.d83.s2|68-73|reduce|O
DDI-DrugBank.d83.s2|75-77|the|O
DDI-DrugBank.d83.s2|79-86|efficacy|O
DDI-DrugBank.d83.s2|88-89|of|O
DDI-DrugBank.d83.s2|91-94|oral|O
DDI-DrugBank.d83.s2|96-109|contraceptives|group
DDI-DrugBank.d83.s2|111-113|and|O
DDI-DrugBank.d83.s2|115-116|to|O
DDI-DrugBank.d83.s2|118-125|increase|O
DDI-DrugBank.d83.s2|127-129|the|O
DDI-DrugBank.d83.s2|131-139|incidence|O
DDI-DrugBank.d83.s2|141-142|of|O
DDI-DrugBank.d83.s2|144-155|breakthrough|O
DDI-DrugBank.d83.s2|157-164|bleeding|O
DDI-DrugBank.d83.s2|165-165|.|O
DDI-DrugBank.d0.s0|0-2|The|O
DDI-DrugBank.d0.s0|4-14|concomitant|O
DDI-DrugBank.d0.s0|16-21|intake|O
DDI-DrugBank.d0.s0|23-24|of|O
DDI-DrugBank.d0.s0|26-32|alcohol|drug
DDI-DrugBank.d0.s0|34-36|and|O
DDI-DrugBank.d0.s0|38-48|Acamprosate|drug
DDI-DrugBank.d0.s0|50-53|does|O
DDI-DrugBank.d0.s0|55-57|not|O
DDI-DrugBank.d0.s0|59-64|affect|O
DDI-DrugBank.d0.s0|66-68|the|O
DDI-DrugBank.d0.s0|70-85|pharmacokinetics|O
DDI-DrugBank.d0.s0|87-88|of|O
DDI-DrugBank.d0.s0|90-95|either|O
DDI-DrugBank.d0.s0|97-103|alcohol|drug
DDI-DrugBank.d0.s0|105-106|or|O
DDI-DrugBank.d0.s0|108-118|acamprosate|drug
DDI-DrugBank.d0.s0|119-119|.|O
DDI-DrugBank.d0.s1|0-14|Pharmacokinetic|O
DDI-DrugBank.d0.s1|16-22|studies|O
DDI-DrugBank.d0.s1|24-31|indicate|O
DDI-DrugBank.d0.s1|33-36|that|O
DDI-DrugBank.d0.s1|38-51|administration|O
DDI-DrugBank.d0.s1|53-54|of|O
DDI-DrugBank.d0.s1|56-65|disulfiram|drug
DDI-DrugBank.d0.s1|67-68|or|O
DDI-DrugBank.d0.s1|70-77|diazepam|drug
DDI-DrugBank.d0.s1|79-82|does|O
DDI-DrugBank.d0.s1|84-86|not|O
DDI-DrugBank.d0.s1|88-93|affect|O
DDI-DrugBank.d0.s1|95-97|the|O
DDI-DrugBank.d0.s1|99-114|pharmacokinetics|O
DDI-DrugBank.d0.s1|116-117|of|O
DDI-DrugBank.d0.s1|119-129|acamprosate|drug
DDI-DrugBank.d0.s1|130-130|.|O
DDI-DrugBank.d0.s2|0-16|Co-administration|O
DDI-DrugBank.d0.s2|18-19|of|O
DDI-DrugBank.d0.s2|21-30|naltrexone|drug
DDI-DrugBank.d0.s2|32-35|with|O
DDI-DrugBank.d0.s2|37-47|Acamprosate|drug
DDI-DrugBank.d0.s2|49-56|produced|O
DDI-DrugBank.d0.s2|58-58|a|O
DDI-DrugBank.d0.s2|60-61|25|O
DDI-DrugBank.d0.s2|62-62|%|O
DDI-DrugBank.d0.s2|64-71|increase|O
DDI-DrugBank.d0.s2|73-74|in|O
DDI-DrugBank.d0.s2|76-78|AUC|O
DDI-DrugBank.d0.s2|80-82|and|O
DDI-DrugBank.d0.s2|84-84|a|O
DDI-DrugBank.d0.s2|86-87|33|O
DDI-DrugBank.d0.s2|88-88|%|O
DDI-DrugBank.d0.s2|90-97|increase|O
DDI-DrugBank.d0.s2|99-100|in|O
DDI-DrugBank.d0.s2|102-104|the|O
DDI-DrugBank.d0.s2|106-109|Cmax|O
DDI-DrugBank.d0.s2|111-112|of|O
DDI-DrugBank.d0.s2|114-124|acamprosate|drug
DDI-DrugBank.d0.s2|125-125|.|O
DDI-DrugBank.d0.s3|0-1|No|O
DDI-DrugBank.d0.s3|3-12|adjustment|O
DDI-DrugBank.d0.s3|14-15|of|O
DDI-DrugBank.d0.s3|17-22|dosage|O
DDI-DrugBank.d0.s3|24-25|is|O
DDI-DrugBank.d0.s3|27-37|recommended|O
DDI-DrugBank.d0.s3|39-40|in|O
DDI-DrugBank.d0.s3|42-45|such|O
DDI-DrugBank.d0.s3|47-54|patients|O
DDI-DrugBank.d0.s3|55-55|.|O
DDI-DrugBank.d0.s4|0-2|The|O
DDI-DrugBank.d0.s4|4-19|pharmacokinetics|O
DDI-DrugBank.d0.s4|21-22|of|O
DDI-DrugBank.d0.s4|24-33|naltrexone|drug
DDI-DrugBank.d0.s4|35-37|and|O
DDI-DrugBank.d0.s4|39-41|its|O
DDI-DrugBank.d0.s4|43-47|major|O
DDI-DrugBank.d0.s4|49-58|metabolite|O
DDI-DrugBank.d0.s4|77-80|were|O
DDI-DrugBank.d0.s4|82-91|unaffected|O
DDI-DrugBank.d0.s4|93-101|following|O
DDI-DrugBank.d0.s4|103-119|co-administration|O
DDI-DrugBank.d0.s4|121-124|with|O
DDI-DrugBank.d0.s4|126-136|Acamprosate|drug
DDI-DrugBank.d0.s4|137-137|.|O
DDI-DrugBank.d0.s5|0-4|Other|O
DDI-DrugBank.d0.s5|6-16|concomitant|O
DDI-DrugBank.d0.s5|18-26|therapies|O
DDI-DrugBank.d0.s5|27-27|:|O
DDI-DrugBank.d0.s5|29-30|In|O
DDI-DrugBank.d0.s5|32-39|clinical|O
DDI-DrugBank.d0.s5|41-46|trials|O
DDI-DrugBank.d0.s5|47-47|,|O
DDI-DrugBank.d0.s5|49-51|the|O
DDI-DrugBank.d0.s5|53-58|safety|O
DDI-DrugBank.d0.s5|60-66|profile|O
DDI-DrugBank.d0.s5|68-69|in|O
DDI-DrugBank.d0.s5|71-78|subjects|O
DDI-DrugBank.d0.s5|80-86|treated|O
DDI-DrugBank.d0.s5|88-91|with|O
DDI-DrugBank.d0.s5|93-103|Acamprosate|drug
DDI-DrugBank.d0.s5|105-117|concomitantly|O
DDI-DrugBank.d0.s5|119-122|with|O
DDI-DrugBank.d0.s5|124-134|anxiolytics|group
DDI-DrugBank.d0.s5|135-135|,|O
DDI-DrugBank.d0.s5|137-145|hypnotics|group
DDI-DrugBank.d0.s5|147-149|and|O
DDI-DrugBank.d0.s5|151-159|sedatives|group
DDI-DrugBank.d0.s5|161-161|(|O
DDI-DrugBank.d0.s5|162-170|including|O
DDI-DrugBank.d0.s5|172-186|benzodiazepines|group
DDI-DrugBank.d0.s5|187-187|)|O
DDI-DrugBank.d0.s5|188-188|,|O
DDI-DrugBank.d0.s5|190-191|or|O
DDI-DrugBank.d0.s5|193-213|non-opioid analgesics|group
DDI-DrugBank.d0.s5|215-217|was|O
DDI-DrugBank.d0.s5|219-225|similar|O
DDI-DrugBank.d0.s5|227-228|to|O
DDI-DrugBank.d0.s5|230-233|that|O
DDI-DrugBank.d0.s5|235-236|of|O
DDI-DrugBank.d0.s5|238-245|subjects|O
DDI-DrugBank.d0.s5|247-252|taking|O
DDI-DrugBank.d0.s5|254-260|placebo|O
DDI-DrugBank.d0.s5|262-265|with|O
DDI-DrugBank.d0.s5|267-271|these|O
DDI-DrugBank.d0.s5|273-283|concomitant|O
DDI-DrugBank.d0.s5|285-295|medications|O
DDI-DrugBank.d0.s5|296-296|.|O
DDI-DrugBank.d0.s6|0-7|Patients|O
DDI-DrugBank.d0.s6|9-14|taking|O
DDI-DrugBank.d0.s6|16-26|Acamprosate|drug
DDI-DrugBank.d0.s6|28-40|concomitantly|O
DDI-DrugBank.d0.s6|42-45|with|O
DDI-DrugBank.d0.s6|47-61|antidepressants|group
DDI-DrugBank.d0.s6|63-66|more|O
DDI-DrugBank.d0.s6|68-75|commonly|O
DDI-DrugBank.d0.s6|77-84|reported|O
DDI-DrugBank.d0.s6|86-89|both|O
DDI-DrugBank.d0.s6|91-96|weight|O
DDI-DrugBank.d0.s6|98-101|gain|O
DDI-DrugBank.d0.s6|103-105|and|O
DDI-DrugBank.d0.s6|107-112|weight|O
DDI-DrugBank.d0.s6|114-117|loss|O
DDI-DrugBank.d0.s6|118-118|,|O
DDI-DrugBank.d0.s6|120-127|compared|O
DDI-DrugBank.d0.s6|129-132|with|O
DDI-DrugBank.d0.s6|134-141|patients|O
DDI-DrugBank.d0.s6|143-148|taking|O
DDI-DrugBank.d0.s6|150-155|either|O
DDI-DrugBank.d0.s6|157-166|medication|O
DDI-DrugBank.d0.s6|168-172|alone|O
DDI-DrugBank.d0.s6|173-173|.|O
DDI-DrugBank.d402.s0|0-1|No|O
DDI-DrugBank.d402.s0|3-11|drug/drug|O
DDI-DrugBank.d402.s0|13-23|interaction|O
DDI-DrugBank.d402.s0|25-31|studies|O
DDI-DrugBank.d402.s0|33-36|have|O
DDI-DrugBank.d402.s0|38-41|been|O
DDI-DrugBank.d402.s0|43-51|performed|O
DDI-DrugBank.d402.s0|52-52|.|O
DDI-DrugBank.d281.s0|0-9|Probenecid|drug
DDI-DrugBank.d281.s0|11-13|may|O
DDI-DrugBank.d281.s0|15-22|decrease|O
DDI-DrugBank.d281.s0|24-28|renal|O
DDI-DrugBank.d281.s0|30-36|tubular|O
DDI-DrugBank.d281.s0|38-46|secretion|O
DDI-DrugBank.d281.s0|48-49|of|O
DDI-DrugBank.d281.s0|51-64|cephalosporins|group
DDI-DrugBank.d281.s0|66-69|when|O
DDI-DrugBank.d281.s0|71-74|used|O
DDI-DrugBank.d281.s0|76-87|concurrently|O
DDI-DrugBank.d281.s0|88-88|,|O
DDI-DrugBank.d281.s0|90-98|resulting|O
DDI-DrugBank.d281.s0|100-101|in|O
DDI-DrugBank.d281.s0|103-111|increased|O
DDI-DrugBank.d281.s0|113-115|and|O
DDI-DrugBank.d281.s0|117-120|more|O
DDI-DrugBank.d281.s0|122-130|prolonged|O
DDI-DrugBank.d281.s0|132-144|cephalosporin|group
DDI-DrugBank.d281.s0|146-150|blood|O
DDI-DrugBank.d281.s0|152-157|levels|O
DDI-DrugBank.d281.s0|158-158|.|O
DDI-DrugBank.d281.s1|0-14|Drug/Laboratory|O
DDI-DrugBank.d281.s1|16-19|Test|O
DDI-DrugBank.d281.s1|21-32|Interactions|O
DDI-DrugBank.d281.s1|34-34|A|O
DDI-DrugBank.d281.s1|36-40|false|O
DDI-DrugBank.d281.s1|42-49|positive|O
DDI-DrugBank.d281.s1|51-58|reaction|O
DDI-DrugBank.d281.s1|60-62|for|O
DDI-DrugBank.d281.s1|64-70|glucose|O
DDI-DrugBank.d281.s1|72-73|in|O
DDI-DrugBank.d281.s1|75-77|the|O
DDI-DrugBank.d281.s1|79-83|urine|O
DDI-DrugBank.d281.s1|85-87|may|O
DDI-DrugBank.d281.s1|89-93|occur|O
DDI-DrugBank.d281.s1|95-98|with|O
DDI-DrugBank.d281.s1|100-108|Benedicts|O
DDI-DrugBank.d281.s1|110-117|solution|O
DDI-DrugBank.d281.s1|118-118|,|O
DDI-DrugBank.d281.s1|120-127|Fehlings|O
DDI-DrugBank.d281.s1|129-136|solution|O
DDI-DrugBank.d281.s1|138-139|or|O
DDI-DrugBank.d281.s1|141-144|with|O
DDI-DrugBank.d281.s1|146-154|CLINITEST|O
DDI-DrugBank.d281.s1|157-163|tablets|O
DDI-DrugBank.d281.s1|164-164|,|O
DDI-DrugBank.d281.s1|166-168|but|O
DDI-DrugBank.d281.s1|170-172|not|O
DDI-DrugBank.d281.s1|174-177|with|O
DDI-DrugBank.d281.s1|179-190|enzyme-based|O
DDI-DrugBank.d281.s1|192-196|tests|O
DDI-DrugBank.d281.s1|198-201|such|O
DDI-DrugBank.d281.s1|203-204|as|O
DDI-DrugBank.d281.s1|206-214|CLINISTIX|O
DDI-DrugBank.d281.s1|216-216|.|O
DDI-DrugBank.d281.s2|0-7|Positive|O
DDI-DrugBank.d281.s2|9-14|direct|O
DDI-DrugBank.d281.s2|16-18|and|O
DDI-DrugBank.d281.s2|20-27|indirect|O
DDI-DrugBank.d281.s2|29-40|antiglobulin|O
DDI-DrugBank.d281.s2|42-42|(|O
DDI-DrugBank.d281.s2|43-48|Coombs|O
DDI-DrugBank.d281.s2|49-49|)|O
DDI-DrugBank.d281.s2|51-55|tests|O
DDI-DrugBank.d281.s2|57-60|have|O
DDI-DrugBank.d281.s2|62-69|occurred|O
DDI-DrugBank.d281.s2|70-70|;|O
DDI-DrugBank.d281.s3|0-4|these|O
DDI-DrugBank.d281.s3|6-8|may|O
DDI-DrugBank.d281.s3|10-13|also|O
DDI-DrugBank.d281.s3|15-19|occur|O
DDI-DrugBank.d281.s3|21-22|in|O
DDI-DrugBank.d281.s3|24-31|neonates|O
DDI-DrugBank.d281.s3|33-37|whose|O
DDI-DrugBank.d281.s3|39-45|mothers|O
DDI-DrugBank.d281.s3|47-54|received|O
DDI-DrugBank.d281.s3|56-69|cephalosporins|group
DDI-DrugBank.d281.s3|71-76|before|O
DDI-DrugBank.d281.s3|78-85|delivery|O
DDI-DrugBank.d281.s3|86-86|.|O
DDI-DrugBank.d38.s0|0-7|ZINECARD|brand
DDI-DrugBank.d38.s0|9-12|does|O
DDI-DrugBank.d38.s0|14-16|not|O
DDI-DrugBank.d38.s0|18-26|influence|O
DDI-DrugBank.d38.s0|28-30|the|O
DDI-DrugBank.d38.s0|32-47|pharmacokinetics|O
DDI-DrugBank.d38.s0|49-50|of|O
DDI-DrugBank.d38.s0|52-62|doxorubicin|drug
DDI-DrugBank.d38.s0|63-63|.|O
DDI-DrugBank.d38.s1|0-13|Carcinogenesis|O
DDI-DrugBank.d38.s1|14-14|,|O
DDI-DrugBank.d38.s1|16-26|Mutagenesis|O
DDI-DrugBank.d38.s1|27-27|,|O
DDI-DrugBank.d38.s1|29-38|Impairment|O
DDI-DrugBank.d38.s1|40-41|of|O
DDI-DrugBank.d38.s1|43-51|Fertility|O
DDI-DrugBank.d38.s1|53-54|No|O
DDI-DrugBank.d38.s1|56-64|long-term|O
DDI-DrugBank.d38.s1|66-80|carcinogenicity|O
DDI-DrugBank.d38.s1|82-88|studies|O
DDI-DrugBank.d38.s1|90-93|have|O
DDI-DrugBank.d38.s1|95-98|been|O
DDI-DrugBank.d38.s1|100-106|carried|O
DDI-DrugBank.d38.s1|108-110|out|O
DDI-DrugBank.d38.s1|112-115|with|O
DDI-DrugBank.d38.s1|117-127|dexrazoxane|drug
DDI-DrugBank.d38.s1|129-130|in|O
DDI-DrugBank.d38.s1|132-138|animals|O
DDI-DrugBank.d38.s1|139-139|.|O
DDI-DrugBank.d38.s2|0-10|Dexrazoxane|drug
DDI-DrugBank.d38.s2|12-14|was|O
DDI-DrugBank.d38.s2|16-18|not|O
DDI-DrugBank.d38.s2|20-28|mutagenic|O
DDI-DrugBank.d38.s2|30-31|in|O
DDI-DrugBank.d38.s2|33-35|the|O
DDI-DrugBank.d38.s2|37-40|Ames|O
DDI-DrugBank.d38.s2|42-45|test|O
DDI-DrugBank.d38.s2|47-49|but|O
DDI-DrugBank.d38.s2|51-53|was|O
DDI-DrugBank.d38.s2|55-59|found|O
DDI-DrugBank.d38.s2|61-62|to|O
DDI-DrugBank.d38.s2|64-65|be|O
DDI-DrugBank.d38.s2|67-77|clastogenic|O
DDI-DrugBank.d38.s2|79-80|to|O
DDI-DrugBank.d38.s2|82-86|human|O
DDI-DrugBank.d38.s2|88-98|lymphocytes|O
DDI-DrugBank.d38.s2|100-101|in|O
DDI-DrugBank.d38.s2|103-107|vitro|O
DDI-DrugBank.d38.s2|109-111|and|O
DDI-DrugBank.d38.s2|113-114|to|O
DDI-DrugBank.d38.s2|116-120|mouse|O
DDI-DrugBank.d38.s2|122-125|bone|O
DDI-DrugBank.d38.s2|127-132|marrow|O
DDI-DrugBank.d38.s2|134-145|erythrocytes|O
DDI-DrugBank.d38.s2|147-148|in|O
DDI-DrugBank.d38.s2|150-153|vivo|O
DDI-DrugBank.d38.s2|155-155|(|O
DDI-DrugBank.d38.s2|156-167|micronucleus|O
DDI-DrugBank.d38.s2|169-172|test|O
DDI-DrugBank.d38.s2|173-173|)|O
DDI-DrugBank.d38.s2|174-174|.|O
DDI-DrugBank.d38.s3|0-2|The|O
DDI-DrugBank.d38.s3|4-11|possible|O
DDI-DrugBank.d38.s3|13-19|adverse|O
DDI-DrugBank.d38.s3|21-27|effects|O
DDI-DrugBank.d38.s3|29-30|of|O
DDI-DrugBank.d38.s3|32-39|ZINECARD|brand
DDI-DrugBank.d38.s3|41-42|on|O
DDI-DrugBank.d38.s3|44-46|the|O
DDI-DrugBank.d38.s3|48-56|fertility|O
DDI-DrugBank.d38.s3|58-59|of|O
DDI-DrugBank.d38.s3|61-66|humans|O
DDI-DrugBank.d38.s3|68-70|and|O
DDI-DrugBank.d38.s3|72-83|experimental|O
DDI-DrugBank.d38.s3|85-91|animals|O
DDI-DrugBank.d38.s3|92-92|,|O
DDI-DrugBank.d38.s3|94-97|male|O
DDI-DrugBank.d38.s3|99-100|or|O
DDI-DrugBank.d38.s3|102-107|female|O
DDI-DrugBank.d38.s3|108-108|,|O
DDI-DrugBank.d38.s3|110-113|have|O
DDI-DrugBank.d38.s3|115-117|not|O
DDI-DrugBank.d38.s3|119-122|been|O
DDI-DrugBank.d38.s3|124-133|adequately|O
DDI-DrugBank.d38.s3|135-141|studied|O
DDI-DrugBank.d38.s3|142-142|.|O
DDI-DrugBank.d38.s4|0-9|Testicular|O
DDI-DrugBank.d38.s4|11-17|atrophy|O
DDI-DrugBank.d38.s4|19-21|was|O
DDI-DrugBank.d38.s4|23-26|seen|O
DDI-DrugBank.d38.s4|28-31|with|O
DDI-DrugBank.d38.s4|33-43|dexrazoxane|drug
DDI-DrugBank.d38.s4|45-58|administration|O
DDI-DrugBank.d38.s4|60-61|at|O
DDI-DrugBank.d38.s4|63-67|doses|O
DDI-DrugBank.d38.s4|69-70|as|O
DDI-DrugBank.d38.s4|72-74|low|O
DDI-DrugBank.d38.s4|76-77|as|O
DDI-DrugBank.d38.s4|79-80|30|O
DDI-DrugBank.d38.s4|82-86|mg/kg|O
DDI-DrugBank.d38.s4|88-93|weekly|O
DDI-DrugBank.d38.s4|95-97|for|O
DDI-DrugBank.d38.s4|99-99|6|O
DDI-DrugBank.d38.s4|101-105|weeks|O
DDI-DrugBank.d38.s4|107-108|in|O
DDI-DrugBank.d38.s4|110-113|rats|O
DDI-DrugBank.d38.s4|115-115|(|O
DDI-DrugBank.d38.s4|116-118|1/3|O
DDI-DrugBank.d38.s4|120-122|the|O
DDI-DrugBank.d38.s4|124-128|human|O
DDI-DrugBank.d38.s4|130-133|dose|O
DDI-DrugBank.d38.s4|135-136|on|O
DDI-DrugBank.d38.s4|138-138|a|O
DDI-DrugBank.d38.s4|140-143|mg/m|O
DDI-DrugBank.d38.s4|145-145|2|O
DDI-DrugBank.d38.s4|147-151|basis|O
DDI-DrugBank.d38.s4|152-152|)|O
DDI-DrugBank.d38.s4|154-156|and|O
DDI-DrugBank.d38.s4|158-159|as|O
DDI-DrugBank.d38.s4|161-163|low|O
DDI-DrugBank.d38.s4|165-166|as|O
DDI-DrugBank.d38.s4|168-169|20|O
DDI-DrugBank.d38.s4|171-175|mg/kg|O
DDI-DrugBank.d38.s4|177-182|weekly|O
DDI-DrugBank.d38.s4|184-186|for|O
DDI-DrugBank.d38.s4|188-189|13|O
DDI-DrugBank.d38.s4|191-195|weeks|O
DDI-DrugBank.d38.s4|197-198|in|O
DDI-DrugBank.d38.s4|200-203|dogs|O
DDI-DrugBank.d38.s4|205-205|(|O
DDI-DrugBank.d38.s4|206-218|approximately|O
DDI-DrugBank.d38.s4|220-224|equal|O
DDI-DrugBank.d38.s4|226-227|to|O
DDI-DrugBank.d38.s4|229-231|the|O
DDI-DrugBank.d38.s4|233-237|human|O
DDI-DrugBank.d38.s4|239-242|dose|O
DDI-DrugBank.d38.s4|244-245|on|O
DDI-DrugBank.d38.s4|247-247|a|O
DDI-DrugBank.d38.s4|249-252|mg/m|O
DDI-DrugBank.d38.s4|254-254|2|O
DDI-DrugBank.d38.s4|256-260|basis|O
DDI-DrugBank.d38.s4|261-261|)|O
DDI-DrugBank.d38.s4|262-262|.|O
DDI-DrugBank.d513.s0|0-6|Special|O
DDI-DrugBank.d513.s0|8-11|care|O
DDI-DrugBank.d513.s0|13-14|is|O
DDI-DrugBank.d513.s0|16-23|required|O
DDI-DrugBank.d513.s0|25-26|if|O
DDI-DrugBank.d513.s0|28-31|this|O
DDI-DrugBank.d513.s0|33-36|drug|O
DDI-DrugBank.d513.s0|38-39|is|O
DDI-DrugBank.d513.s0|41-45|given|O
DDI-DrugBank.d513.s0|47-48|to|O
DDI-DrugBank.d513.s0|50-57|patients|O
DDI-DrugBank.d513.s0|59-67|receiving|O
DDI-DrugBank.d513.s0|69-95|ganglion blocking compounds|group
DDI-DrugBank.d513.s0|97-103|because|O
DDI-DrugBank.d513.s0|105-105|a|O
DDI-DrugBank.d513.s0|107-114|critical|O
DDI-DrugBank.d513.s0|116-119|fall|O
DDI-DrugBank.d513.s0|121-122|in|O
DDI-DrugBank.d513.s0|124-128|blood|O
DDI-DrugBank.d513.s0|130-137|pressure|O
DDI-DrugBank.d513.s0|139-141|may|O
DDI-DrugBank.d513.s0|143-147|occur|O
DDI-DrugBank.d513.s0|148-148|.|O
DDI-DrugBank.d513.s1|0-6|Usually|O
DDI-DrugBank.d513.s1|7-7|,|O
DDI-DrugBank.d513.s1|9-14|severe|O
DDI-DrugBank.d513.s1|16-24|abdominal|O
DDI-DrugBank.d513.s1|26-33|symptoms|O
DDI-DrugBank.d513.s1|35-40|appear|O
DDI-DrugBank.d513.s1|42-47|before|O
DDI-DrugBank.d513.s1|49-53|there|O
DDI-DrugBank.d513.s1|55-56|is|O
DDI-DrugBank.d513.s1|58-61|such|O
DDI-DrugBank.d513.s1|63-63|a|O
DDI-DrugBank.d513.s1|65-68|fall|O
DDI-DrugBank.d513.s1|70-71|in|O
DDI-DrugBank.d513.s1|73-75|the|O
DDI-DrugBank.d513.s1|77-81|blood|O
DDI-DrugBank.d513.s1|83-90|pressure|O
DDI-DrugBank.d513.s1|91-91|.|O
DDI-DrugBank.d49.s0|0-3|Drug|O
DDI-DrugBank.d49.s0|5-15|interaction|O
DDI-DrugBank.d49.s0|17-23|studies|O
DDI-DrugBank.d49.s0|25-28|have|O
DDI-DrugBank.d49.s0|30-32|not|O
DDI-DrugBank.d49.s0|34-37|been|O
DDI-DrugBank.d49.s0|39-47|performed|O
DDI-DrugBank.d49.s0|49-52|with|O
DDI-DrugBank.d49.s0|54-60|Soliris|brand
DDI-DrugBank.d49.s0|61-61|.|O
DDI-DrugBank.d93.s0|0-7|Clinical|O
DDI-DrugBank.d93.s0|9-14|trials|O
DDI-DrugBank.d93.s0|16-19|have|O
DDI-DrugBank.d93.s0|21-29|indicated|O
DDI-DrugBank.d93.s0|31-34|that|O
DDI-DrugBank.d93.s0|36-44|Pulmozyme|brand
DDI-DrugBank.d93.s0|46-48|can|O
DDI-DrugBank.d93.s0|50-51|be|O
DDI-DrugBank.d93.s0|53-63|effectively|O
DDI-DrugBank.d93.s0|65-67|and|O
DDI-DrugBank.d93.s0|69-74|safely|O
DDI-DrugBank.d93.s0|76-79|used|O
DDI-DrugBank.d93.s0|81-82|in|O
DDI-DrugBank.d93.s0|84-94|conjunction|O
DDI-DrugBank.d93.s0|96-99|with|O
DDI-DrugBank.d93.s0|101-108|standard|O
DDI-DrugBank.d93.s0|110-115|cystic|O
DDI-DrugBank.d93.s0|117-124|fibrosis|O
DDI-DrugBank.d93.s0|126-134|therapies|O
DDI-DrugBank.d93.s0|136-144|including|O
DDI-DrugBank.d93.s0|146-149|oral|O
DDI-DrugBank.d93.s0|150-150|,|O
DDI-DrugBank.d93.s0|152-158|inhaled|O
DDI-DrugBank.d93.s0|160-165|and/or|O
DDI-DrugBank.d93.s0|167-176|parenteral|O
DDI-DrugBank.d93.s0|178-188|antibiotics|group
DDI-DrugBank.d93.s0|189-189|,|O
DDI-DrugBank.d93.s0|191-205|bronchodilators|group
DDI-DrugBank.d93.s0|206-206|,|O
DDI-DrugBank.d93.s0|208-213|enzyme|O
DDI-DrugBank.d93.s0|215-225|supplements|O
DDI-DrugBank.d93.s0|226-226|,|O
DDI-DrugBank.d93.s0|228-235|vitamins|group
DDI-DrugBank.d93.s0|236-236|,|O
DDI-DrugBank.d93.s0|238-241|oral|O
DDI-DrugBank.d93.s0|243-244|or|O
DDI-DrugBank.d93.s0|246-252|inhaled|O
DDI-DrugBank.d93.s0|254-268|corticosteroids|group
DDI-DrugBank.d93.s0|269-269|,|O
DDI-DrugBank.d93.s0|271-273|and|O
DDI-DrugBank.d93.s0|275-284|analgesics|group
DDI-DrugBank.d93.s0|285-285|.|O
DDI-DrugBank.d93.s1|0-1|No|O
DDI-DrugBank.d93.s1|3-8|formal|O
DDI-DrugBank.d93.s1|10-13|drug|O
DDI-DrugBank.d93.s1|15-25|interaction|O
DDI-DrugBank.d93.s1|27-33|studies|O
DDI-DrugBank.d93.s1|35-38|have|O
DDI-DrugBank.d93.s1|40-43|been|O
DDI-DrugBank.d93.s1|45-53|performed|O
DDI-DrugBank.d93.s1|54-54|.|O
DDI-MedLine.d90.s0|0-10|Interaction|O
DDI-MedLine.d90.s0|12-13|of|O
DDI-MedLine.d90.s0|15-24|gentamycin|drug
DDI-MedLine.d90.s0|26-28|and|O
DDI-MedLine.d90.s0|30-39|atracurium|drug
DDI-MedLine.d90.s0|41-42|in|O
DDI-MedLine.d90.s0|44-56|anaesthetised|O
DDI-MedLine.d90.s0|58-63|horses|O
DDI-MedLine.d90.s0|64-64|.|O
DDI-MedLine.d90.s1|0-5|Evoked|O
DDI-MedLine.d90.s1|7-10|hind|O
DDI-MedLine.d90.s1|12-15|limb|O
DDI-MedLine.d90.s1|17-23|digital|O
DDI-MedLine.d90.s1|25-32|extensor|O
DDI-MedLine.d90.s1|34-40|tension|O
DDI-MedLine.d90.s1|42-42|(|O
DDI-MedLine.d90.s1|43-46|hoof|O
DDI-MedLine.d90.s1|48-53|twitch|O
DDI-MedLine.d90.s1|54-54|)|O
DDI-MedLine.d90.s1|56-58|was|O
DDI-MedLine.d90.s1|60-69|maintained|O
DDI-MedLine.d90.s1|71-72|at|O
DDI-MedLine.d90.s1|74-75|40|O
DDI-MedLine.d90.s1|76-76|%|O
DDI-MedLine.d90.s1|78-79|of|O
DDI-MedLine.d90.s1|81-88|baseline|O
DDI-MedLine.d90.s1|90-92|for|O
DDI-MedLine.d90.s1|94-94|1|O
DDI-MedLine.d90.s1|96-96|h|O
DDI-MedLine.d90.s1|98-99|by|O
DDI-MedLine.d90.s1|101-110|atracurium|drug
DDI-MedLine.d90.s1|112-119|infusion|O
DDI-MedLine.d90.s1|121-122|in|O
DDI-MedLine.d90.s1|124-124|7|O
DDI-MedLine.d90.s1|126-131|horses|O
DDI-MedLine.d90.s1|133-145|anaesthetised|O
DDI-MedLine.d90.s1|147-150|with|O
DDI-MedLine.d90.s1|152-160|halothane|drug
DDI-MedLine.d90.s1|161-161|.|O
DDI-MedLine.d90.s2|0-4|After|O
DDI-MedLine.d90.s2|6-6|1|O
DDI-MedLine.d90.s2|8-8|h|O
DDI-MedLine.d90.s2|9-9|,|O
DDI-MedLine.d90.s2|11-20|atracurium|drug
DDI-MedLine.d90.s2|22-24|was|O
DDI-MedLine.d90.s2|26-37|discontinued|O
DDI-MedLine.d90.s2|39-41|and|O
DDI-MedLine.d90.s2|43-46|hoof|O
DDI-MedLine.d90.s2|48-53|twitch|O
DDI-MedLine.d90.s2|55-61|allowed|O
DDI-MedLine.d90.s2|63-64|to|O
DDI-MedLine.d90.s2|66-72|recover|O
DDI-MedLine.d90.s2|74-75|to|O
DDI-MedLine.d90.s2|77-78|75|O
DDI-MedLine.d90.s2|79-79|%|O
DDI-MedLine.d90.s2|80-80|.|O
DDI-MedLine.d90.s3|0-9|Atracurium|drug
DDI-MedLine.d90.s3|11-13|was|O
DDI-MedLine.d90.s3|15-19|again|O
DDI-MedLine.d90.s3|21-25|given|O
DDI-MedLine.d90.s3|27-28|by|O
DDI-MedLine.d90.s3|30-37|infusion|O
DDI-MedLine.d90.s3|39-40|to|O
DDI-MedLine.d90.s3|42-49|maintain|O
DDI-MedLine.d90.s3|51-52|40|O
DDI-MedLine.d90.s3|53-53|%|O
DDI-MedLine.d90.s3|55-60|twitch|O
DDI-MedLine.d90.s3|62-64|for|O
DDI-MedLine.d90.s3|66-66|a|O
DDI-MedLine.d90.s3|68-73|second|O
DDI-MedLine.d90.s3|75-78|hour|O
DDI-MedLine.d90.s3|79-79|,|O
DDI-MedLine.d90.s3|81-84|then|O
DDI-MedLine.d90.s3|86-86|2|O
DDI-MedLine.d90.s3|88-89|mg|O
DDI-MedLine.d90.s3|91-103|gentamycin/kg|drug
DDI-MedLine.d90.s3|105-107|bwt|O
DDI-MedLine.d90.s3|109-112|were|O
DDI-MedLine.d90.s3|114-118|given|O
DDI-MedLine.d90.s3|120-122|i.v|O
DDI-MedLine.d90.s3|123-123|.|O
DDI-MedLine.d90.s4|0-9|Atracurium|drug
DDI-MedLine.d90.s4|11-18|infusion|O
DDI-MedLine.d90.s4|20-22|was|O
DDI-MedLine.d90.s4|24-32|continued|O
DDI-MedLine.d90.s4|34-36|for|O
DDI-MedLine.d90.s4|38-38|a|O
DDI-MedLine.d90.s4|40-44|third|O
DDI-MedLine.d90.s4|46-49|hour|O
DDI-MedLine.d90.s4|50-50|,|O
DDI-MedLine.d90.s4|52-54|and|O
DDI-MedLine.d90.s4|56-59|then|O
DDI-MedLine.d90.s4|61-64|hoof|O
DDI-MedLine.d90.s4|66-71|twitch|O
DDI-MedLine.d90.s4|73-75|was|O
DDI-MedLine.d90.s4|77-81|again|O
DDI-MedLine.d90.s4|83-89|allowed|O
DDI-MedLine.d90.s4|91-92|to|O
DDI-MedLine.d90.s4|94-100|recover|O
DDI-MedLine.d90.s4|102-114|spontaneously|O
DDI-MedLine.d90.s4|116-117|to|O
DDI-MedLine.d90.s4|119-120|75|O
DDI-MedLine.d90.s4|121-121|%|O
DDI-MedLine.d90.s4|122-122|.|O
DDI-MedLine.d90.s5|0-9|Gentamycin|drug
DDI-MedLine.d90.s5|11-17|reduced|O
DDI-MedLine.d90.s5|19-24|twitch|O
DDI-MedLine.d90.s5|26-33|strength|O
DDI-MedLine.d90.s5|35-38|from|O
DDI-MedLine.d90.s5|40-41|40|O
DDI-MedLine.d90.s5|43-45|+/-|O
DDI-MedLine.d90.s5|47-47|1|O
DDI-MedLine.d90.s5|48-48|%|O
DDI-MedLine.d90.s5|50-50|(|O
DDI-MedLine.d90.s5|51-54|mean|O
DDI-MedLine.d90.s5|56-58|+/-|O
DDI-MedLine.d90.s5|60-62|sem|O
DDI-MedLine.d90.s5|63-63|)|O
DDI-MedLine.d90.s5|65-66|to|O
DDI-MedLine.d90.s5|68-69|29|O
DDI-MedLine.d90.s5|71-73|+/-|O
DDI-MedLine.d90.s5|75-75|4|O
DDI-MedLine.d90.s5|76-76|%|O
DDI-MedLine.d90.s5|78-83|within|O
DDI-MedLine.d90.s5|85-87|7.0|O
DDI-MedLine.d90.s5|89-91|+/-|O
DDI-MedLine.d90.s5|93-95|1.5|O
DDI-MedLine.d90.s5|97-99|min|O
DDI-MedLine.d90.s5|101-101|(|O
DDI-MedLine.d90.s5|102-102|P|O
DDI-MedLine.d90.s5|104-104|=|O
DDI-MedLine.d90.s5|106-109|0.02|O
DDI-MedLine.d90.s5|110-110|)|O
DDI-MedLine.d90.s5|111-111|.|O
DDI-MedLine.d90.s6|0-5|Twitch|O
DDI-MedLine.d90.s6|7-15|gradually|O
DDI-MedLine.d90.s6|17-24|returned|O
DDI-MedLine.d90.s6|26-27|to|O
DDI-MedLine.d90.s6|29-42|pre-gentamycin|drug
DDI-MedLine.d90.s6|44-51|strength|O
DDI-MedLine.d90.s6|53-56|over|O
DDI-MedLine.d90.s6|58-60|the|O
DDI-MedLine.d90.s6|62-67|course|O
DDI-MedLine.d90.s6|69-70|of|O
DDI-MedLine.d90.s6|72-74|the|O
DDI-MedLine.d90.s6|76-79|next|O
DDI-MedLine.d90.s6|81-84|hour|O
DDI-MedLine.d90.s6|85-85|.|O
DDI-MedLine.d90.s7|0-7|Recovery|O
DDI-MedLine.d90.s7|9-10|of|O
DDI-MedLine.d90.s7|12-15|hoof|O
DDI-MedLine.d90.s7|17-22|twitch|O
DDI-MedLine.d90.s7|24-27|from|O
DDI-MedLine.d90.s7|29-30|50|O
DDI-MedLine.d90.s7|31-31|%|O
DDI-MedLine.d90.s7|33-34|to|O
DDI-MedLine.d90.s7|36-37|75|O
DDI-MedLine.d90.s7|38-38|%|O
DDI-MedLine.d90.s7|40-43|took|O
DDI-MedLine.d90.s7|45-47|7.7|O
DDI-MedLine.d90.s7|49-51|+/-|O
DDI-MedLine.d90.s7|53-55|0.7|O
DDI-MedLine.d90.s7|57-59|min|O
DDI-MedLine.d90.s7|61-63|for|O
DDI-MedLine.d90.s7|65-74|atracurium|drug
DDI-MedLine.d90.s7|76-80|alone|O
DDI-MedLine.d90.s7|82-84|and|O
DDI-MedLine.d90.s7|86-89|11.5|O
DDI-MedLine.d90.s7|91-93|+/-|O
DDI-MedLine.d90.s7|95-97|2.7|O
DDI-MedLine.d90.s7|99-101|min|O
DDI-MedLine.d90.s7|103-105|for|O
DDI-MedLine.d90.s7|107-116|atracurium|drug
DDI-MedLine.d90.s7|118-121|plus|O
DDI-MedLine.d90.s7|123-132|gentamycin|drug
DDI-MedLine.d90.s7|134-134|(|O
DDI-MedLine.d90.s7|135-135|P|O
DDI-MedLine.d90.s7|137-137|=|O
DDI-MedLine.d90.s7|139-142|0.03|O
DDI-MedLine.d90.s7|143-143|)|O
DDI-MedLine.d90.s7|144-144|.|O
DDI-MedLine.d90.s8|0-7|Recovery|O
DDI-MedLine.d90.s8|9-12|from|O
DDI-MedLine.d90.s8|14-15|50|O
DDI-MedLine.d90.s8|16-16|%|O
DDI-MedLine.d90.s8|18-23|twitch|O
DDI-MedLine.d90.s8|25-26|to|O
DDI-MedLine.d90.s8|28-29|75|O
DDI-MedLine.d90.s8|30-30|%|O
DDI-MedLine.d90.s8|32-35|fade|O
DDI-MedLine.d90.s8|37-44|recovery|O
DDI-MedLine.d90.s8|46-49|took|O
DDI-MedLine.d90.s8|51-54|13.8|O
DDI-MedLine.d90.s8|56-58|+/-|O
DDI-MedLine.d90.s8|60-62|0.8|O
DDI-MedLine.d90.s8|64-66|min|O
DDI-MedLine.d90.s8|68-70|for|O
DDI-MedLine.d90.s8|72-81|atracurium|drug
DDI-MedLine.d90.s8|83-87|alone|O
DDI-MedLine.d90.s8|89-91|and|O
DDI-MedLine.d90.s8|93-96|13.7|O
DDI-MedLine.d90.s8|98-100|+/-|O
DDI-MedLine.d90.s8|102-104|1.2|O
DDI-MedLine.d90.s8|106-108|min|O
DDI-MedLine.d90.s8|110-112|for|O
DDI-MedLine.d90.s8|114-123|atracurium|drug
DDI-MedLine.d90.s8|125-128|plus|O
DDI-MedLine.d90.s8|130-139|gentamycin|drug
DDI-MedLine.d90.s8|140-140|.|O
DDI-MedLine.d90.s9|0-1|At|O
DDI-MedLine.d90.s9|3-4|75|O
DDI-MedLine.d90.s9|5-5|%|O
DDI-MedLine.d90.s9|7-14|recovery|O
DDI-MedLine.d90.s9|16-17|of|O
DDI-MedLine.d90.s9|19-22|fade|O
DDI-MedLine.d90.s9|23-23|,|O
DDI-MedLine.d90.s9|25-28|hoof|O
DDI-MedLine.d90.s9|30-35|twitch|O
DDI-MedLine.d90.s9|37-39|was|O
DDI-MedLine.d90.s9|41-42|87|O
DDI-MedLine.d90.s9|44-46|+/-|O
DDI-MedLine.d90.s9|48-48|3|O
DDI-MedLine.d90.s9|49-49|%|O
DDI-MedLine.d90.s9|51-53|for|O
DDI-MedLine.d90.s9|55-64|atracurium|drug
DDI-MedLine.d90.s9|66-70|alone|O
DDI-MedLine.d90.s9|72-74|and|O
DDI-MedLine.d90.s9|76-77|82|O
DDI-MedLine.d90.s9|79-81|+/-|O
DDI-MedLine.d90.s9|83-83|4|O
DDI-MedLine.d90.s9|84-84|%|O
DDI-MedLine.d90.s9|86-88|for|O
DDI-MedLine.d90.s9|90-99|atracurium|drug
DDI-MedLine.d90.s9|101-104|plus|O
DDI-MedLine.d90.s9|106-115|gentamycin|drug
DDI-MedLine.d90.s9|116-116|.|O
DDI-MedLine.d90.s10|0-7|Reversal|O
DDI-MedLine.d90.s10|9-10|of|O
DDI-MedLine.d90.s10|12-14|the|O
DDI-MedLine.d90.s10|16-20|block|O
DDI-MedLine.d90.s10|22-25|with|O
DDI-MedLine.d90.s10|27-37|edrophonium|drug
DDI-MedLine.d90.s10|39-41|and|O
DDI-MedLine.d90.s10|43-52|subsequent|O
DDI-MedLine.d90.s10|54-61|recovery|O
DDI-MedLine.d90.s10|63-64|of|O
DDI-MedLine.d90.s10|66-68|the|O
DDI-MedLine.d90.s10|70-75|horses|O
DDI-MedLine.d90.s10|77-80|from|O
DDI-MedLine.d90.s10|82-92|anaesthesia|O
DDI-MedLine.d90.s10|94-97|were|O
DDI-MedLine.d90.s10|99-108|uneventful|O
DDI-MedLine.d90.s10|109-109|.|O
DDI-MedLine.d90.s11|0-1|It|O
DDI-MedLine.d90.s11|3-5|was|O
DDI-MedLine.d90.s11|7-15|concluded|O
DDI-MedLine.d90.s11|17-20|that|O
DDI-MedLine.d90.s11|21-21|,|O
DDI-MedLine.d90.s11|23-30|although|O
DDI-MedLine.d90.s11|32-41|gentamycin|drug
DDI-MedLine.d90.s11|43-45|did|O
DDI-MedLine.d90.s11|47-53|augment|O
DDI-MedLine.d90.s11|55-57|the|O
DDI-MedLine.d90.s11|59-71|neuromuscular|O
DDI-MedLine.d90.s11|73-80|blockade|O
DDI-MedLine.d90.s11|82-83|of|O
DDI-MedLine.d90.s11|85-94|atracurium|drug
DDI-MedLine.d90.s11|95-95|,|O
DDI-MedLine.d90.s11|97-99|the|O
DDI-MedLine.d90.s11|101-106|effect|O
DDI-MedLine.d90.s11|108-110|was|O
DDI-MedLine.d90.s11|112-118|minimal|O
DDI-MedLine.d90.s11|119-119|.|O
DDI-DrugBank.d122.s0|0-13|Nephrotoxicity|O
DDI-DrugBank.d122.s0|15-17|has|O
DDI-DrugBank.d122.s0|19-22|been|O
DDI-DrugBank.d122.s0|24-31|reported|O
DDI-DrugBank.d122.s0|33-41|following|O
DDI-DrugBank.d122.s0|43-53|concomitant|O
DDI-DrugBank.d122.s0|55-68|administration|O
DDI-DrugBank.d122.s0|70-71|of|O
DDI-DrugBank.d122.s0|73-86|cephalosporins|group
DDI-DrugBank.d122.s0|88-91|with|O
DDI-DrugBank.d122.s0|93-118|aminoglycoside antibiotics|group
DDI-DrugBank.d122.s0|120-121|or|O
DDI-DrugBank.d122.s0|123-128|potent|O
DDI-DrugBank.d122.s0|130-138|diuretics|group
DDI-DrugBank.d122.s0|140-143|such|O
DDI-DrugBank.d122.s0|145-146|as|O
DDI-DrugBank.d122.s0|148-157|furosemide|drug
DDI-DrugBank.d122.s0|158-158|.|O
DDI-DrugBank.d122.s1|0-4|Renal|O
DDI-DrugBank.d122.s1|6-13|function|O
DDI-DrugBank.d122.s1|15-20|should|O
DDI-DrugBank.d122.s1|22-23|be|O
DDI-DrugBank.d122.s1|25-33|carefully|O
DDI-DrugBank.d122.s1|35-43|monitored|O
DDI-DrugBank.d122.s1|44-44|,|O
DDI-DrugBank.d122.s1|46-55|especially|O
DDI-DrugBank.d122.s1|57-58|if|O
DDI-DrugBank.d122.s1|60-65|higher|O
DDI-DrugBank.d122.s1|67-73|dosages|O
DDI-DrugBank.d122.s1|75-76|of|O
DDI-DrugBank.d122.s1|78-80|the|O
DDI-DrugBank.d122.s1|82-96|aminoglycosides|group
DDI-DrugBank.d122.s1|98-100|are|O
DDI-DrugBank.d122.s1|102-103|to|O
DDI-DrugBank.d122.s1|105-106|be|O
DDI-DrugBank.d122.s1|108-119|administered|O
DDI-DrugBank.d122.s1|121-122|or|O
DDI-DrugBank.d122.s1|124-125|if|O
DDI-DrugBank.d122.s1|127-133|therapy|O
DDI-DrugBank.d122.s1|135-136|is|O
DDI-DrugBank.d122.s1|138-146|prolonged|O
DDI-DrugBank.d122.s1|147-147|,|O
DDI-DrugBank.d122.s1|149-155|because|O
DDI-DrugBank.d122.s1|157-158|of|O
DDI-DrugBank.d122.s1|160-162|the|O
DDI-DrugBank.d122.s1|164-172|potential|O
DDI-DrugBank.d122.s1|174-187|nephrotoxicity|O
DDI-DrugBank.d122.s1|189-191|and|O
DDI-DrugBank.d122.s1|193-203|ototoxicity|O
DDI-DrugBank.d122.s1|205-206|of|O
DDI-DrugBank.d122.s1|208-234|aminoglycosidic antibiotics|group
DDI-DrugBank.d122.s1|235-235|.|O
DDI-DrugBank.d122.s2|0-13|Nephrotoxicity|O
DDI-DrugBank.d122.s2|15-17|and|O
DDI-DrugBank.d122.s2|19-29|ototoxicity|O
DDI-DrugBank.d122.s2|31-34|were|O
DDI-DrugBank.d122.s2|36-38|not|O
DDI-DrugBank.d122.s2|40-44|noted|O
DDI-DrugBank.d122.s2|46-49|when|O
DDI-DrugBank.d122.s2|51-61|ceftazidime|drug
DDI-DrugBank.d122.s2|63-65|was|O
DDI-DrugBank.d122.s2|67-71|given|O
DDI-DrugBank.d122.s2|73-77|alone|O
DDI-DrugBank.d122.s2|79-80|in|O
DDI-DrugBank.d122.s2|82-89|clinical|O
DDI-DrugBank.d122.s2|91-96|trials|O
DDI-DrugBank.d122.s2|97-97|.|O
DDI-DrugBank.d122.s3|0-14|Chloramphenicol|drug
DDI-DrugBank.d122.s3|16-18|has|O
DDI-DrugBank.d122.s3|20-23|been|O
DDI-DrugBank.d122.s3|25-29|shown|O
DDI-DrugBank.d122.s3|31-32|to|O
DDI-DrugBank.d122.s3|34-35|be|O
DDI-DrugBank.d122.s3|37-48|antagonistic|O
DDI-DrugBank.d122.s3|50-51|to|O
DDI-DrugBank.d122.s3|53-75|beta-lactam antibiotics|group
DDI-DrugBank.d122.s3|76-76|,|O
DDI-DrugBank.d122.s3|78-86|including|O
DDI-DrugBank.d122.s3|88-98|ceftazidime|drug
DDI-DrugBank.d122.s3|99-99|,|O
DDI-DrugBank.d122.s3|101-105|based|O
DDI-DrugBank.d122.s3|107-108|on|O
DDI-DrugBank.d122.s3|110-111|in|O
DDI-DrugBank.d122.s3|113-117|vitro|O
DDI-DrugBank.d122.s3|119-125|studies|O
DDI-DrugBank.d122.s3|127-129|and|O
DDI-DrugBank.d122.s3|131-134|time|O
DDI-DrugBank.d122.s3|136-139|kill|O
DDI-DrugBank.d122.s3|141-146|curves|O
DDI-DrugBank.d122.s3|148-151|with|O
DDI-DrugBank.d122.s3|153-159|enteric|O
DDI-DrugBank.d122.s3|161-173|gram-negative|O
DDI-DrugBank.d122.s3|175-181|bacilli|O
DDI-DrugBank.d122.s3|182-182|.|O
DDI-DrugBank.d122.s4|0-2|Due|O
DDI-DrugBank.d122.s4|4-5|to|O
DDI-DrugBank.d122.s4|7-9|the|O
DDI-DrugBank.d122.s4|11-21|possibility|O
DDI-DrugBank.d122.s4|23-24|of|O
DDI-DrugBank.d122.s4|26-35|antagonism|O
DDI-DrugBank.d122.s4|37-38|in|O
DDI-DrugBank.d122.s4|40-43|vivo|O
DDI-DrugBank.d122.s4|44-44|,|O
DDI-DrugBank.d122.s4|46-57|particularly|O
DDI-DrugBank.d122.s4|59-62|when|O
DDI-DrugBank.d122.s4|64-75|bactericidal|O
DDI-DrugBank.d122.s4|77-84|activity|O
DDI-DrugBank.d122.s4|86-87|is|O
DDI-DrugBank.d122.s4|89-95|desired|O
DDI-DrugBank.d122.s4|96-96|,|O
DDI-DrugBank.d122.s4|98-101|this|O
DDI-DrugBank.d122.s4|103-106|drug|O
DDI-DrugBank.d122.s4|108-118|combination|O
DDI-DrugBank.d122.s4|120-125|should|O
DDI-DrugBank.d122.s4|127-128|be|O
DDI-DrugBank.d122.s4|130-136|avoided|O
DDI-DrugBank.d122.s4|137-137|.|O
DDI-DrugBank.d122.s5|0-14|Drug/Laboratory|O
DDI-DrugBank.d122.s5|16-19|Test|O
DDI-DrugBank.d122.s5|21-32|Interactions|O
DDI-DrugBank.d122.s5|34-36|The|O
DDI-DrugBank.d122.s5|38-51|administration|O
DDI-DrugBank.d122.s5|53-54|of|O
DDI-DrugBank.d122.s5|56-66|ceftazidime|drug
DDI-DrugBank.d122.s5|68-70|may|O
DDI-DrugBank.d122.s5|72-77|result|O
DDI-DrugBank.d122.s5|79-80|in|O
DDI-DrugBank.d122.s5|82-82|a|O
DDI-DrugBank.d122.s5|84-97|false-positive|O
DDI-DrugBank.d122.s5|99-106|reaction|O
DDI-DrugBank.d122.s5|108-110|for|O
DDI-DrugBank.d122.s5|112-118|glucose|O
DDI-DrugBank.d122.s5|120-121|in|O
DDI-DrugBank.d122.s5|123-125|the|O
DDI-DrugBank.d122.s5|127-131|urine|O
DDI-DrugBank.d122.s5|133-136|when|O
DDI-DrugBank.d122.s5|138-142|using|O
DDI-DrugBank.d122.s5|144-152|CLINITEST|O
DDI-DrugBank.d122.s5|155-161|tablets|O
DDI-DrugBank.d122.s5|162-162|,|O
DDI-DrugBank.d122.s5|164-172|Benedicts|O
DDI-DrugBank.d122.s5|174-181|solution|O
DDI-DrugBank.d122.s5|182-182|,|O
DDI-DrugBank.d122.s5|184-185|or|O
DDI-DrugBank.d122.s5|187-194|Fehlings|O
DDI-DrugBank.d122.s5|196-203|solution|O
DDI-DrugBank.d122.s5|204-204|.|O
DDI-DrugBank.d122.s6|0-1|It|O
DDI-DrugBank.d122.s6|3-4|is|O
DDI-DrugBank.d122.s6|6-16|recommended|O
DDI-DrugBank.d122.s6|18-21|that|O
DDI-DrugBank.d122.s6|23-29|glucose|O
DDI-DrugBank.d122.s6|31-35|tests|O
DDI-DrugBank.d122.s6|37-41|based|O
DDI-DrugBank.d122.s6|43-44|on|O
DDI-DrugBank.d122.s6|46-54|enzymatic|O
DDI-DrugBank.d122.s6|56-62|glucose|O
DDI-DrugBank.d122.s6|64-70|oxidase|O
DDI-DrugBank.d122.s6|72-80|reactions|O
DDI-DrugBank.d122.s6|82-82|(|O
DDI-DrugBank.d122.s6|83-86|such|O
DDI-DrugBank.d122.s6|88-89|as|O
DDI-DrugBank.d122.s6|91-99|CLINISTIX|O
DDI-DrugBank.d122.s6|102-103|or|O
DDI-DrugBank.d122.s6|105-112|TES-TAPE|O
DDI-DrugBank.d122.s6|114-114|)|O
DDI-DrugBank.d122.s6|116-117|be|O
DDI-DrugBank.d122.s6|119-122|used|O
DDI-DrugBank.d122.s6|123-123|.|O
DDI-DrugBank.d625.s0|0-3|DRUG|O
DDI-DrugBank.d625.s0|5-16|INTERACTIONS|O
DDI-DrugBank.d625.s0|19-23|There|O
DDI-DrugBank.d625.s0|25-27|are|O
DDI-DrugBank.d625.s0|29-30|no|O
DDI-DrugBank.d625.s0|32-36|known|O
DDI-DrugBank.d625.s0|38-46|drug/drug|O
DDI-DrugBank.d625.s0|48-59|interactions|O
DDI-DrugBank.d625.s0|61-64|with|O
DDI-DrugBank.d625.s0|66-69|oral|O
DDI-DrugBank.d625.s0|71-77|ALKERAN|brand
DDI-DrugBank.d625.s0|80-91|Vaccinations|O
DDI-DrugBank.d625.s0|93-96|with|O
DDI-DrugBank.d625.s0|98-119|live organism vaccines|group
DDI-DrugBank.d625.s0|121-123|are|O
DDI-DrugBank.d625.s0|125-127|not|O
DDI-DrugBank.d625.s0|129-139|recommended|O
DDI-DrugBank.d625.s0|141-142|in|O
DDI-DrugBank.d625.s0|144-160|immunocompromised|O
DDI-DrugBank.d625.s0|162-172|individuals|O
DDI-DrugBank.d625.s0|175-188|Nalidixic acid|drug
DDI-DrugBank.d625.s0|190-197|together|O
DDI-DrugBank.d625.s0|199-202|with|O
DDI-DrugBank.d625.s0|204-212|high-dose|O
DDI-DrugBank.d625.s0|214-224|intravenous|O
DDI-DrugBank.d625.s0|226-234|melphalan|drug
DDI-DrugBank.d625.s0|236-238|has|O
DDI-DrugBank.d625.s0|240-245|caused|O
DDI-DrugBank.d625.s0|247-252|deaths|O
DDI-DrugBank.d625.s0|254-255|in|O
DDI-DrugBank.d625.s0|257-264|children|O
DDI-DrugBank.d625.s0|266-268|due|O
DDI-DrugBank.d625.s0|270-271|to|O
DDI-DrugBank.d625.s0|273-284|haemorrhagic|O
DDI-DrugBank.d625.s0|286-298|enterocolitis|O
DDI-DrugBank.d625.s0|299-299|.|O
DDI-DrugBank.d625.s1|0-7|Impaired|O
DDI-DrugBank.d625.s1|9-13|renal|O
DDI-DrugBank.d625.s1|15-22|function|O
DDI-DrugBank.d625.s1|24-26|has|O
DDI-DrugBank.d625.s1|28-31|been|O
DDI-DrugBank.d625.s1|33-41|described|O
DDI-DrugBank.d625.s1|43-44|in|O
DDI-DrugBank.d625.s1|46-49|bone|O
DDI-DrugBank.d625.s1|51-56|marrow|O
DDI-DrugBank.d625.s1|58-67|transplant|O
DDI-DrugBank.d625.s1|69-76|patients|O
DDI-DrugBank.d625.s1|78-80|who|O
DDI-DrugBank.d625.s1|82-85|were|O
DDI-DrugBank.d625.s1|87-97|conditioned|O
DDI-DrugBank.d625.s1|99-102|with|O
DDI-DrugBank.d625.s1|104-112|high-dose|O
DDI-DrugBank.d625.s1|114-124|intravenous|O
DDI-DrugBank.d625.s1|126-134|melphalan|drug
DDI-DrugBank.d625.s1|136-138|and|O
DDI-DrugBank.d625.s1|140-142|who|O
DDI-DrugBank.d625.s1|144-155|subsequently|O
DDI-DrugBank.d625.s1|157-164|received|O
DDI-DrugBank.d625.s1|166-176|cyclosporin|drug
DDI-DrugBank.d625.s1|178-179|to|O
DDI-DrugBank.d625.s1|181-187|prevent|O
DDI-DrugBank.d625.s1|189-205|graft-versus-host|O
DDI-DrugBank.d625.s1|207-213|disease|O
DDI-DrugBank.d647.s0|0-6|ZANOSAR|brand
DDI-DrugBank.d647.s0|8-10|may|O
DDI-DrugBank.d647.s0|12-22|demonstrate|O
DDI-DrugBank.d647.s0|24-31|additive|O
DDI-DrugBank.d647.s0|33-40|toxicity|O
DDI-DrugBank.d647.s0|42-45|when|O
DDI-DrugBank.d647.s0|47-50|used|O
DDI-DrugBank.d647.s0|52-53|in|O
DDI-DrugBank.d647.s0|55-65|combination|O
DDI-DrugBank.d647.s0|67-70|with|O
DDI-DrugBank.d647.s0|72-76|other|O
DDI-DrugBank.d647.s0|78-86|cytotoxic|O
DDI-DrugBank.d647.s0|88-92|drugs|O
DDI-DrugBank.d647.s0|93-93|.|O
DDI-DrugBank.d647.s1|0-11|Streptozocin|drug
DDI-DrugBank.d647.s1|13-15|has|O
DDI-DrugBank.d647.s1|17-20|been|O
DDI-DrugBank.d647.s1|22-29|reported|O
DDI-DrugBank.d647.s1|31-32|to|O
DDI-DrugBank.d647.s1|34-40|prolong|O
DDI-DrugBank.d647.s1|42-44|the|O
DDI-DrugBank.d647.s1|46-56|elimination|O
DDI-DrugBank.d647.s1|58-66|half-life|O
DDI-DrugBank.d647.s1|68-69|of|O
DDI-DrugBank.d647.s1|71-81|doxorubicin|drug
DDI-DrugBank.d647.s1|83-85|and|O
DDI-DrugBank.d647.s1|87-89|may|O
DDI-DrugBank.d647.s1|91-94|lead|O
DDI-DrugBank.d647.s1|96-97|to|O
DDI-DrugBank.d647.s1|99-104|severe|O
DDI-DrugBank.d647.s1|106-109|bone|O
DDI-DrugBank.d647.s1|111-116|marrow|O
DDI-DrugBank.d647.s1|118-128|suppression|O
DDI-DrugBank.d647.s1|129-129|;|O
DDI-DrugBank.d647.s2|0-0|a|O
DDI-DrugBank.d647.s2|2-10|reduction|O
DDI-DrugBank.d647.s2|12-13|of|O
DDI-DrugBank.d647.s2|15-17|the|O
DDI-DrugBank.d647.s2|19-29|doxorubicin|drug
DDI-DrugBank.d647.s2|31-36|dosage|O
DDI-DrugBank.d647.s2|38-43|should|O
DDI-DrugBank.d647.s2|45-46|be|O
DDI-DrugBank.d647.s2|48-57|considered|O
DDI-DrugBank.d647.s2|59-60|in|O
DDI-DrugBank.d647.s2|62-69|patients|O
DDI-DrugBank.d647.s2|71-79|receiving|O
DDI-DrugBank.d647.s2|81-87|ZANOSAR|brand
DDI-DrugBank.d647.s2|89-100|concurrently|O
DDI-DrugBank.d647.s2|101-101|.|O
DDI-DrugBank.d647.s3|0-2|The|O
DDI-DrugBank.d647.s3|4-13|concurrent|O
DDI-DrugBank.d647.s3|15-17|use|O
DDI-DrugBank.d647.s3|19-20|of|O
DDI-DrugBank.d647.s3|22-33|streptozocin|drug
DDI-DrugBank.d647.s3|35-37|and|O
DDI-DrugBank.d647.s3|39-47|phenytoin|drug
DDI-DrugBank.d647.s3|49-51|has|O
DDI-DrugBank.d647.s3|53-56|been|O
DDI-DrugBank.d647.s3|58-65|reported|O
DDI-DrugBank.d647.s3|67-68|in|O
DDI-DrugBank.d647.s3|70-72|one|O
DDI-DrugBank.d647.s3|74-77|case|O
DDI-DrugBank.d647.s3|79-80|to|O
DDI-DrugBank.d647.s3|82-87|result|O
DDI-DrugBank.d647.s3|89-90|in|O
DDI-DrugBank.d647.s3|92-98|reduced|O
DDI-DrugBank.d647.s3|100-111|streptozocin|drug
DDI-DrugBank.d647.s3|113-124|cytotoxicity|O
DDI-DrugBank.d647.s3|125-125|.|O
DDI-DrugBank.d655.s0|0-14|Methscopolamine|drug
DDI-DrugBank.d655.s0|16-18|may|O
DDI-DrugBank.d655.s0|20-27|interact|O
DDI-DrugBank.d655.s0|29-32|with|O
DDI-DrugBank.d655.s0|34-48|antidepressants|group
DDI-DrugBank.d655.s0|50-50|(|O
DDI-DrugBank.d655.s0|51-59|tricyclic|group
DDI-DrugBank.d655.s0|61-64|type|O
DDI-DrugBank.d655.s0|65-65|)|O
DDI-DrugBank.d655.s0|66-66|,|O
DDI-DrugBank.d655.s0|68-81|MAO inhibitors|group
DDI-DrugBank.d655.s0|83-83|(|O
DDI-DrugBank.d655.s0|84-87|e.g.|O
DDI-DrugBank.d655.s0|88-88|,|O
DDI-DrugBank.d655.s0|90-99|phenelzine|drug
DDI-DrugBank.d655.s0|100-100|,|O
DDI-DrugBank.d655.s0|102-110|linezolid|drug
DDI-DrugBank.d655.s0|111-111|,|O
DDI-DrugBank.d655.s0|113-127|tranylcypromine|drug
DDI-DrugBank.d655.s0|128-128|,|O
DDI-DrugBank.d655.s0|130-142|isocarboxazid|drug
DDI-DrugBank.d655.s0|143-143|,|O
DDI-DrugBank.d655.s0|145-154|selegiline|drug
DDI-DrugBank.d655.s0|155-155|,|O
DDI-DrugBank.d655.s0|157-168|furazolidone|drug
DDI-DrugBank.d655.s0|169-169|)|O
DDI-DrugBank.d655.s0|170-170|,|O
DDI-DrugBank.d655.s0|172-180|quinidine|drug
DDI-DrugBank.d655.s0|181-181|,|O
DDI-DrugBank.d655.s0|183-192|amantadine|drug
DDI-DrugBank.d655.s0|193-193|,|O
DDI-DrugBank.d655.s0|195-208|antihistamines|group
DDI-DrugBank.d655.s0|210-210|(|O
DDI-DrugBank.d655.s0|211-214|e.g.|O
DDI-DrugBank.d655.s0|215-215|,|O
DDI-DrugBank.d655.s0|217-231|diphenhydramine|drug
DDI-DrugBank.d655.s0|232-232|)|O
DDI-DrugBank.d655.s0|233-233|,|O
DDI-DrugBank.d655.s0|235-239|other|O
DDI-DrugBank.d655.s0|241-256|anticholinergics|group
DDI-DrugBank.d655.s0|257-257|,|O
DDI-DrugBank.d655.s0|259-276|potassium chloride|drug
DDI-DrugBank.d655.s0|278-288|supplements|O
DDI-DrugBank.d655.s0|289-289|,|O
DDI-DrugBank.d655.s0|291-298|antacids|group
DDI-DrugBank.d655.s0|299-299|,|O
DDI-DrugBank.d655.s0|301-338|absorbent-type anti-diarrhea medicines|group
DDI-DrugBank.d655.s0|340-340|(|O
DDI-DrugBank.d655.s0|341-344|e.g.|O
DDI-DrugBank.d655.s0|345-345|,|O
DDI-DrugBank.d655.s0|347-359|kaolin-pectin|drug
DDI-DrugBank.d655.s0|360-360|)|O
DDI-DrugBank.d655.s0|361-361|,|O
DDI-DrugBank.d655.s0|363-376|phenothiazines|group
DDI-DrugBank.d655.s0|378-378|(|O
DDI-DrugBank.d655.s0|379-382|e.g.|O
DDI-DrugBank.d655.s0|383-383|,|O
DDI-DrugBank.d655.s0|385-398|chlorpromazine|drug
DDI-DrugBank.d655.s0|399-399|,|O
DDI-DrugBank.d655.s0|401-412|promethazine|drug
DDI-DrugBank.d655.s0|413-413|)|O
DDI-DrugBank.d655.s0|414-414|.|O
DDI-DrugBank.d362.s0|0-4|Based|O
DDI-DrugBank.d362.s0|6-7|on|O
DDI-DrugBank.d362.s0|9-10|in|O
DDI-DrugBank.d362.s0|12-16|vitro|O
DDI-DrugBank.d362.s0|18-24|studies|O
DDI-DrugBank.d362.s0|26-27|in|O
DDI-DrugBank.d362.s0|29-33|human|O
DDI-DrugBank.d362.s0|35-39|liver|O
DDI-DrugBank.d362.s0|41-50|microsomes|O
DDI-DrugBank.d362.s0|51-51|,|O
DDI-DrugBank.d362.s0|53-67|des-ciclesonide|drug
DDI-DrugBank.d362.s0|69-75|appears|O
DDI-DrugBank.d362.s0|77-78|to|O
DDI-DrugBank.d362.s0|80-83|have|O
DDI-DrugBank.d362.s0|85-86|no|O
DDI-DrugBank.d362.s0|88-97|inhibitory|O
DDI-DrugBank.d362.s0|99-100|or|O
DDI-DrugBank.d362.s0|102-110|induction|O
DDI-DrugBank.d362.s0|112-120|potential|O
DDI-DrugBank.d362.s0|122-123|on|O
DDI-DrugBank.d362.s0|125-127|the|O
DDI-DrugBank.d362.s0|129-138|metabolism|O
DDI-DrugBank.d362.s0|140-141|of|O
DDI-DrugBank.d362.s0|143-147|other|O
DDI-DrugBank.d362.s0|149-153|drugs|O
DDI-DrugBank.d362.s0|155-165|metabolized|O
DDI-DrugBank.d362.s0|167-168|by|O
DDI-DrugBank.d362.s0|170-172|CYP|O
DDI-DrugBank.d362.s0|174-176|450|O
DDI-DrugBank.d362.s0|178-184|enzymes|O
DDI-DrugBank.d362.s0|185-185|.|O
DDI-DrugBank.d362.s1|0-2|The|O
DDI-DrugBank.d362.s1|4-13|inhibitory|O
DDI-DrugBank.d362.s1|15-23|potential|O
DDI-DrugBank.d362.s1|25-26|of|O
DDI-DrugBank.d362.s1|28-38|ciclesonide|drug
DDI-DrugBank.d362.s1|40-41|on|O
DDI-DrugBank.d362.s1|43-48|CYP450|O
DDI-DrugBank.d362.s1|50-59|isoenzymes|O
DDI-DrugBank.d362.s1|61-63|has|O
DDI-DrugBank.d362.s1|65-67|not|O
DDI-DrugBank.d362.s1|69-72|been|O
DDI-DrugBank.d362.s1|74-80|studied|O
DDI-DrugBank.d362.s1|81-81|.|O
DDI-DrugBank.d362.s2|0-1|In|O
DDI-DrugBank.d362.s2|3-7|vitro|O
DDI-DrugBank.d362.s2|9-15|studies|O
DDI-DrugBank.d362.s2|17-28|demonstrated|O
DDI-DrugBank.d362.s2|30-33|that|O
DDI-DrugBank.d362.s2|35-37|the|O
DDI-DrugBank.d362.s2|39-44|plasma|O
DDI-DrugBank.d362.s2|46-52|protein|O
DDI-DrugBank.d362.s2|54-60|binding|O
DDI-DrugBank.d362.s2|62-63|of|O
DDI-DrugBank.d362.s2|65-79|des-ciclesonide|drug
DDI-DrugBank.d362.s2|81-83|was|O
DDI-DrugBank.d362.s2|85-87|not|O
DDI-DrugBank.d362.s2|89-96|affected|O
DDI-DrugBank.d362.s2|98-99|by|O
DDI-DrugBank.d362.s2|101-108|warfarin|drug
DDI-DrugBank.d362.s2|110-111|or|O
DDI-DrugBank.d362.s2|113-126|salicylic acid|drug
DDI-DrugBank.d362.s2|127-127|,|O
DDI-DrugBank.d362.s2|129-138|indicating|O
DDI-DrugBank.d362.s2|140-141|no|O
DDI-DrugBank.d362.s2|143-151|potential|O
DDI-DrugBank.d362.s2|153-155|for|O
DDI-DrugBank.d362.s2|157-163|protein|O
DDI-DrugBank.d362.s2|165-177|binding-based|O
DDI-DrugBank.d362.s2|179-182|drug|O
DDI-DrugBank.d362.s2|184-195|interactions|O
DDI-DrugBank.d362.s2|196-196|.|O
DDI-DrugBank.d362.s3|0-1|In|O
DDI-DrugBank.d362.s3|3-3|a|O
DDI-DrugBank.d362.s3|5-8|drug|O
DDI-DrugBank.d362.s3|10-20|interaction|O
DDI-DrugBank.d362.s3|22-26|study|O
DDI-DrugBank.d362.s3|27-27|,|O
DDI-DrugBank.d362.s3|29-45|co-administration|O
DDI-DrugBank.d362.s3|47-48|of|O
DDI-DrugBank.d362.s3|50-55|orally|O
DDI-DrugBank.d362.s3|57-63|inhaled|O
DDI-DrugBank.d362.s3|65-75|ciclesonide|drug
DDI-DrugBank.d362.s3|77-79|and|O
DDI-DrugBank.d362.s3|81-84|oral|O
DDI-DrugBank.d362.s3|86-97|erythromycin|drug
DDI-DrugBank.d362.s3|98-98|,|O
DDI-DrugBank.d362.s3|100-101|an|O
DDI-DrugBank.d362.s3|103-111|inhibitor|O
DDI-DrugBank.d362.s3|113-114|of|O
DDI-DrugBank.d362.s3|116-125|cytochrome|O
DDI-DrugBank.d362.s3|127-130|P450|O
DDI-DrugBank.d362.s3|132-134|3A4|O
DDI-DrugBank.d362.s3|135-135|,|O
DDI-DrugBank.d362.s3|137-139|had|O
DDI-DrugBank.d362.s3|141-142|no|O
DDI-DrugBank.d362.s3|144-149|effect|O
DDI-DrugBank.d362.s3|151-152|on|O
DDI-DrugBank.d362.s3|154-156|the|O
DDI-DrugBank.d362.s3|158-173|pharmacokinetics|O
DDI-DrugBank.d362.s3|175-176|of|O
DDI-DrugBank.d362.s3|178-183|either|O
DDI-DrugBank.d362.s3|185-199|des-ciclesonide|drug
DDI-DrugBank.d362.s3|201-202|or|O
DDI-DrugBank.d362.s3|204-215|erythromycin|drug
DDI-DrugBank.d362.s3|216-216|.|O
DDI-DrugBank.d362.s4|0-1|In|O
DDI-DrugBank.d362.s4|3-9|another|O
DDI-DrugBank.d362.s4|11-14|drug|O
DDI-DrugBank.d362.s4|16-26|interaction|O
DDI-DrugBank.d362.s4|28-32|study|O
DDI-DrugBank.d362.s4|33-33|,|O
DDI-DrugBank.d362.s4|35-51|co-administration|O
DDI-DrugBank.d362.s4|53-54|of|O
DDI-DrugBank.d362.s4|56-61|orally|O
DDI-DrugBank.d362.s4|63-69|inhaled|O
DDI-DrugBank.d362.s4|71-81|ciclesonide|drug
DDI-DrugBank.d362.s4|83-85|and|O
DDI-DrugBank.d362.s4|87-90|oral|O
DDI-DrugBank.d362.s4|92-103|ketoconazole|drug
DDI-DrugBank.d362.s4|104-104|,|O
DDI-DrugBank.d362.s4|106-106|a|O
DDI-DrugBank.d362.s4|108-113|potent|O
DDI-DrugBank.d362.s4|115-123|inhibitor|O
DDI-DrugBank.d362.s4|125-126|of|O
DDI-DrugBank.d362.s4|128-137|cytochrome|O
DDI-DrugBank.d362.s4|139-142|P450|O
DDI-DrugBank.d362.s4|144-146|3A4|O
DDI-DrugBank.d362.s4|147-147|,|O
DDI-DrugBank.d362.s4|149-157|increased|O
DDI-DrugBank.d362.s4|159-161|the|O
DDI-DrugBank.d362.s4|163-170|exposure|O
DDI-DrugBank.d362.s4|172-172|(|O
DDI-DrugBank.d362.s4|173-175|AUC|O
DDI-DrugBank.d362.s4|176-176|)|O
DDI-DrugBank.d362.s4|178-179|of|O
DDI-DrugBank.d362.s4|181-195|des-ciclesonide|drug
DDI-DrugBank.d362.s4|197-198|by|O
DDI-DrugBank.d362.s4|200-212|approximately|O
DDI-DrugBank.d362.s4|214-221|3.6-fold|O
DDI-DrugBank.d362.s4|223-224|at|O
DDI-DrugBank.d362.s4|226-231|steady|O
DDI-DrugBank.d362.s4|233-237|state|O
DDI-DrugBank.d362.s4|238-238|,|O
DDI-DrugBank.d362.s4|240-244|while|O
DDI-DrugBank.d362.s4|246-251|levels|O
DDI-DrugBank.d362.s4|253-254|of|O
DDI-DrugBank.d362.s4|256-266|ciclesonide|drug
DDI-DrugBank.d362.s4|268-275|remained|O
DDI-DrugBank.d362.s4|277-285|unchanged|O
DDI-DrugBank.d362.s4|286-286|.|O
DDI-DrugBank.d362.s5|0-8|Therefore|O
DDI-DrugBank.d362.s5|9-9|,|O
DDI-DrugBank.d362.s5|11-22|ketoconazole|drug
DDI-DrugBank.d362.s5|24-29|should|O
DDI-DrugBank.d362.s5|31-32|be|O
DDI-DrugBank.d362.s5|34-45|administered|O
DDI-DrugBank.d362.s5|47-50|with|O
DDI-DrugBank.d362.s5|52-58|caution|O
DDI-DrugBank.d362.s5|60-63|with|O
DDI-DrugBank.d362.s5|65-74|intranasal|O
DDI-DrugBank.d362.s5|76-86|ciclesonide|drug
DDI-DrugBank.d362.s5|87-87|.|O
DDI-DrugBank.d187.s0|0-3|Food|O
DDI-DrugBank.d187.s0|4-4|:|O
DDI-DrugBank.d187.s0|6-14|Isoniazid|drug
DDI-DrugBank.d187.s0|16-21|should|O
DDI-DrugBank.d187.s0|23-25|not|O
DDI-DrugBank.d187.s0|27-28|be|O
DDI-DrugBank.d187.s0|30-41|administered|O
DDI-DrugBank.d187.s0|43-46|with|O
DDI-DrugBank.d187.s0|48-51|food|O
DDI-DrugBank.d187.s0|52-52|.|O
DDI-DrugBank.d187.s1|0-6|Studies|O
DDI-DrugBank.d187.s1|8-11|have|O
DDI-DrugBank.d187.s1|13-17|shown|O
DDI-DrugBank.d187.s1|19-22|that|O
DDI-DrugBank.d187.s1|24-26|the|O
DDI-DrugBank.d187.s1|28-42|bioavailability|O
DDI-DrugBank.d187.s1|44-45|of|O
DDI-DrugBank.d187.s1|47-55|isoniazid|drug
DDI-DrugBank.d187.s1|57-58|is|O
DDI-DrugBank.d187.s1|60-66|reduced|O
DDI-DrugBank.d187.s1|68-80|significantly|O
DDI-DrugBank.d187.s1|82-85|when|O
DDI-DrugBank.d187.s1|87-98|administered|O
DDI-DrugBank.d187.s1|100-103|with|O
DDI-DrugBank.d187.s1|105-108|food|O
DDI-DrugBank.d187.s1|109-109|.|O
DDI-DrugBank.d187.s2|0-12|Acetaminophen|drug
DDI-DrugBank.d187.s2|13-13|:|O
DDI-DrugBank.d187.s2|15-15|A|O
DDI-DrugBank.d187.s2|17-22|report|O
DDI-DrugBank.d187.s2|24-25|of|O
DDI-DrugBank.d187.s2|27-32|severe|O
DDI-DrugBank.d187.s2|34-46|acetaminophen|drug
DDI-DrugBank.d187.s2|48-55|toxicity|O
DDI-DrugBank.d187.s2|57-59|was|O
DDI-DrugBank.d187.s2|61-68|reported|O
DDI-DrugBank.d187.s2|70-71|in|O
DDI-DrugBank.d187.s2|73-73|a|O
DDI-DrugBank.d187.s2|75-81|patient|O
DDI-DrugBank.d187.s2|83-91|receiving|O
DDI-DrugBank.d187.s2|93-101|Isoniazid|drug
DDI-DrugBank.d187.s2|102-102|.|O
DDI-DrugBank.d187.s3|0-1|It|O
DDI-DrugBank.d187.s3|3-4|is|O
DDI-DrugBank.d187.s3|6-13|believed|O
DDI-DrugBank.d187.s3|15-18|that|O
DDI-DrugBank.d187.s3|20-22|the|O
DDI-DrugBank.d187.s3|24-31|toxicity|O
DDI-DrugBank.d187.s3|33-35|may|O
DDI-DrugBank.d187.s3|37-40|have|O
DDI-DrugBank.d187.s3|42-49|resulted|O
DDI-DrugBank.d187.s3|51-54|from|O
DDI-DrugBank.d187.s3|56-56|a|O
DDI-DrugBank.d187.s3|58-67|previously|O
DDI-DrugBank.d187.s3|69-80|unrecognized|O
DDI-DrugBank.d187.s3|82-92|interaction|O
DDI-DrugBank.d187.s3|94-100|between|O
DDI-DrugBank.d187.s3|102-110|isoniazid|drug
DDI-DrugBank.d187.s3|112-114|and|O
DDI-DrugBank.d187.s3|116-128|acetaminophen|drug
DDI-DrugBank.d187.s3|130-132|and|O
DDI-DrugBank.d187.s3|134-134|a|O
DDI-DrugBank.d187.s3|136-144|molecular|O
DDI-DrugBank.d187.s3|146-150|basis|O
DDI-DrugBank.d187.s3|152-154|for|O
DDI-DrugBank.d187.s3|156-159|this|O
DDI-DrugBank.d187.s3|161-171|interaction|O
DDI-DrugBank.d187.s3|173-175|has|O
DDI-DrugBank.d187.s3|177-180|been|O
DDI-DrugBank.d187.s3|182-189|proposed|O
DDI-DrugBank.d187.s3|190-190|.|O
DDI-DrugBank.d187.s4|0-6|However|O
DDI-DrugBank.d187.s4|7-7|,|O
DDI-DrugBank.d187.s4|9-15|current|O
DDI-DrugBank.d187.s4|17-24|evidence|O
DDI-DrugBank.d187.s4|26-33|suggests|O
DDI-DrugBank.d187.s4|35-38|that|O
DDI-DrugBank.d187.s4|40-48|isoniazid|drug
DDI-DrugBank.d187.s4|50-53|does|O
DDI-DrugBank.d187.s4|55-60|induce|O
DDI-DrugBank.d187.s4|62-70|P-450IIE1|O
DDI-DrugBank.d187.s4|71-71|,|O
DDI-DrugBank.d187.s4|73-73|a|O
DDI-DrugBank.d187.s4|75-88|mixed-function|O
DDI-DrugBank.d187.s4|90-96|oxidase|O
DDI-DrugBank.d187.s4|98-103|enzyme|O
DDI-DrugBank.d187.s4|105-108|that|O
DDI-DrugBank.d187.s4|110-116|appears|O
DDI-DrugBank.d187.s4|118-119|to|O
DDI-DrugBank.d187.s4|121-128|generate|O
DDI-DrugBank.d187.s4|130-132|the|O
DDI-DrugBank.d187.s4|134-138|toxic|O
DDI-DrugBank.d187.s4|140-150|metabolites|O
DDI-DrugBank.d187.s4|151-151|,|O
DDI-DrugBank.d187.s4|153-154|in|O
DDI-DrugBank.d187.s4|156-158|the|O
DDI-DrugBank.d187.s4|160-164|liver|O
DDI-DrugBank.d187.s4|165-165|.|O
DDI-DrugBank.d187.s5|0-10|Furthermore|O
DDI-DrugBank.d187.s5|12-13|it|O
DDI-DrugBank.d187.s5|15-17|has|O
DDI-DrugBank.d187.s5|19-22|been|O
DDI-DrugBank.d187.s5|24-31|proposed|O
DDI-DrugBank.d187.s5|33-36|that|O
DDI-DrugBank.d187.s5|38-46|isoniazid|drug
DDI-DrugBank.d187.s5|48-55|resulted|O
DDI-DrugBank.d187.s5|57-58|In|O
DDI-DrugBank.d187.s5|60-68|induction|O
DDI-DrugBank.d187.s5|70-71|of|O
DDI-DrugBank.d187.s5|73-81|P-450IIE1|O
DDI-DrugBank.d187.s5|83-84|in|O
DDI-DrugBank.d187.s5|86-88|the|O
DDI-DrugBank.d187.s5|90-97|patients|O
DDI-DrugBank.d187.s5|99-103|liver|O
DDI-DrugBank.d187.s5|105-109|which|O
DDI-DrugBank.d187.s5|110-110|,|O
DDI-DrugBank.d187.s5|112-113|in|O
DDI-DrugBank.d187.s5|115-118|turn|O
DDI-DrugBank.d187.s5|119-119|,|O
DDI-DrugBank.d187.s5|121-128|resulted|O
DDI-DrugBank.d187.s5|130-131|in|O
DDI-DrugBank.d187.s5|133-133|a|O
DDI-DrugBank.d187.s5|135-141|greater|O
DDI-DrugBank.d187.s5|143-152|proportion|O
DDI-DrugBank.d187.s5|154-155|of|O
DDI-DrugBank.d187.s5|157-159|the|O
DDI-DrugBank.d187.s5|161-168|ingested|O
DDI-DrugBank.d187.s5|170-182|acetaminophen|drug
DDI-DrugBank.d187.s5|184-188|being|O
DDI-DrugBank.d187.s5|190-198|converted|O
DDI-DrugBank.d187.s5|200-201|to|O
DDI-DrugBank.d187.s5|203-205|the|O
DDI-DrugBank.d187.s5|207-211|toxic|O
DDI-DrugBank.d187.s5|213-223|metabolites|O
DDI-DrugBank.d187.s5|224-224|.|O
DDI-DrugBank.d187.s6|0-6|Studies|O
DDI-DrugBank.d187.s6|8-11|have|O
DDI-DrugBank.d187.s6|13-24|demonstrated|O
DDI-DrugBank.d187.s6|26-29|that|O
DDI-DrugBank.d187.s6|31-42|pretreatment|O
DDI-DrugBank.d187.s6|44-47|with|O
DDI-DrugBank.d187.s6|49-57|isoniazid|drug
DDI-DrugBank.d187.s6|59-69|potentiates|O
DDI-DrugBank.d187.s6|71-71|a|O
DDI-DrugBank.d187.s6|73-84|cetaminophen|O
DDI-DrugBank.d187.s6|86-97|hepatoxicity|O
DDI-DrugBank.d187.s6|99-100|in|O
DDI-DrugBank.d187.s6|102-105|rats|O
DDI-DrugBank.d187.s6|106-106|.|O
DDI-DrugBank.d187.s7|0-12|Carbamazepine|drug
DDI-DrugBank.d187.s7|13-13|:|O
DDI-DrugBank.d187.s7|15-23|Isoniazid|drug
DDI-DrugBank.d187.s7|25-26|is|O
DDI-DrugBank.d187.s7|28-32|known|O
DDI-DrugBank.d187.s7|34-35|to|O
DDI-DrugBank.d187.s7|37-40|slow|O
DDI-DrugBank.d187.s7|42-44|the|O
DDI-DrugBank.d187.s7|46-55|metabolism|O
DDI-DrugBank.d187.s7|57-58|of|O
DDI-DrugBank.d187.s7|60-72|carbamazepine|drug
DDI-DrugBank.d187.s7|74-76|and|O
DDI-DrugBank.d187.s7|78-85|increase|O
DDI-DrugBank.d187.s7|87-89|its|O
DDI-DrugBank.d187.s7|91-95|serum|O
DDI-DrugBank.d187.s7|97-102|levels|O
DDI-DrugBank.d187.s7|104-116|Carbamazepine|drug
DDI-DrugBank.d187.s7|118-123|levels|O
DDI-DrugBank.d187.s7|125-130|should|O
DDI-DrugBank.d187.s7|132-133|be|O
DDI-DrugBank.d187.s7|135-144|determined|O
DDI-DrugBank.d187.s7|146-150|prior|O
DDI-DrugBank.d187.s7|152-153|to|O
DDI-DrugBank.d187.s7|155-164|concurrent|O
DDI-DrugBank.d187.s7|166-179|administration|O
DDI-DrugBank.d187.s7|181-184|with|O
DDI-DrugBank.d187.s7|186-194|isoniazid|drug
DDI-DrugBank.d187.s7|195-195|,|O
DDI-DrugBank.d187.s7|197-201|signs|O
DDI-DrugBank.d187.s7|203-205|and|O
DDI-DrugBank.d187.s7|207-214|symptoms|O
DDI-DrugBank.d187.s7|216-217|of|O
DDI-DrugBank.d187.s7|219-231|carbamazepine|drug
DDI-DrugBank.d187.s7|233-240|toxicity|O
DDI-DrugBank.d187.s7|242-247|should|O
DDI-DrugBank.d187.s7|249-250|be|O
DDI-DrugBank.d187.s7|252-260|monitored|O
DDI-DrugBank.d187.s7|262-268|closely|O
DDI-DrugBank.d187.s7|269-269|,|O
DDI-DrugBank.d187.s7|271-273|and|O
DDI-DrugBank.d187.s7|275-285|appropriate|O
DDI-DrugBank.d187.s7|287-292|dosage|O
DDI-DrugBank.d187.s7|294-303|adjustment|O
DDI-DrugBank.d187.s7|305-306|of|O
DDI-DrugBank.d187.s7|308-310|the|O
DDI-DrugBank.d187.s7|312-325|anticonvulsant|group
DDI-DrugBank.d187.s7|327-332|should|O
DDI-DrugBank.d187.s7|334-335|be|O
DDI-DrugBank.d187.s7|337-340|made|O
DDI-DrugBank.d187.s7|341-341|.|O
DDI-DrugBank.d187.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d187.s8|12-12|:|O
DDI-DrugBank.d187.s8|14-22|Potential|O
DDI-DrugBank.d187.s8|24-34|interaction|O
DDI-DrugBank.d187.s8|36-37|of|O
DDI-DrugBank.d187.s8|39-50|Ketoconazole|drug
DDI-DrugBank.d187.s8|52-54|and|O
DDI-DrugBank.d187.s8|56-64|Isoniazid|drug
DDI-DrugBank.d187.s8|66-68|may|O
DDI-DrugBank.d187.s8|70-74|exist|O
DDI-DrugBank.d187.s8|75-75|.|O
DDI-DrugBank.d187.s9|0-8|Phenytoin|drug
DDI-DrugBank.d187.s9|9-9|:|O
DDI-DrugBank.d187.s9|11-19|Isoniazid|drug
DDI-DrugBank.d187.s9|21-23|may|O
DDI-DrugBank.d187.s9|25-32|increase|O
DDI-DrugBank.d187.s9|34-38|serum|O
DDI-DrugBank.d187.s9|40-45|levels|O
DDI-DrugBank.d187.s9|47-48|of|O
DDI-DrugBank.d187.s9|50-58|phenytoin|drug
DDI-DrugBank.d187.s9|59-59|.|O
DDI-DrugBank.d187.s10|0-1|To|O
DDI-DrugBank.d187.s10|3-7|avoid|O
DDI-DrugBank.d187.s10|9-17|phenytoin|drug
DDI-DrugBank.d187.s10|19-30|intoxication|O
DDI-DrugBank.d187.s10|31-31|,|O
DDI-DrugBank.d187.s10|33-43|appropriate|O
DDI-DrugBank.d187.s10|45-54|adjustment|O
DDI-DrugBank.d187.s10|56-57|of|O
DDI-DrugBank.d187.s10|59-61|the|O
DDI-DrugBank.d187.s10|63-76|anticonvulsant|group
DDI-DrugBank.d187.s10|78-83|should|O
DDI-DrugBank.d187.s10|85-86|be|O
DDI-DrugBank.d187.s10|88-91|made|O
DDI-DrugBank.d187.s10|92-92|.|O
DDI-DrugBank.d187.s11|0-12|Therophylline|O
DDI-DrugBank.d187.s11|13-13|:|O
DDI-DrugBank.d187.s11|15-15|A|O
DDI-DrugBank.d187.s11|17-22|recent|O
DDI-DrugBank.d187.s11|24-28|study|O
DDI-DrugBank.d187.s11|30-32|has|O
DDI-DrugBank.d187.s11|34-38|shown|O
DDI-DrugBank.d187.s11|40-43|that|O
DDI-DrugBank.d187.s11|45-54|concomitan|O
DDI-DrugBank.d187.s11|56-69|administration|O
DDI-DrugBank.d187.s11|71-72|of|O
DDI-DrugBank.d187.s11|74-82|isoniazid|drug
DDI-DrugBank.d187.s11|84-86|and|O
DDI-DrugBank.d187.s11|88-99|theophylline|drug
DDI-DrugBank.d187.s11|101-103|may|O
DDI-DrugBank.d187.s11|105-109|cause|O
DDI-DrugBank.d187.s11|111-118|elevated|O
DDI-DrugBank.d187.s11|120-125|plasma|O
DDI-DrugBank.d187.s11|127-132|levels|O
DDI-DrugBank.d187.s11|134-135|of|O
DDI-DrugBank.d187.s11|137-148|theophylline|drug
DDI-DrugBank.d187.s11|149-149|,|O
DDI-DrugBank.d187.s11|151-153|and|O
DDI-DrugBank.d187.s11|155-156|in|O
DDI-DrugBank.d187.s11|158-161|some|O
DDI-DrugBank.d187.s11|163-171|instances|O
DDI-DrugBank.d187.s11|173-173|a|O
DDI-DrugBank.d187.s11|175-180|slight|O
DDI-DrugBank.d187.s11|182-189|decrease|O
DDI-DrugBank.d187.s11|191-192|in|O
DDI-DrugBank.d187.s11|194-196|the|O
DDI-DrugBank.d187.s11|198-208|elimination|O
DDI-DrugBank.d187.s11|210-211|of|O
DDI-DrugBank.d187.s11|213-221|isoniazid|drug
DDI-DrugBank.d187.s11|222-222|.|O
DDI-DrugBank.d187.s12|0-4|Since|O
DDI-DrugBank.d187.s12|6-8|the|O
DDI-DrugBank.d187.s12|10-20|therapeutic|O
DDI-DrugBank.d187.s12|22-26|range|O
DDI-DrugBank.d187.s12|28-29|of|O
DDI-DrugBank.d187.s12|31-42|theophylline|drug
DDI-DrugBank.d187.s12|44-45|is|O
DDI-DrugBank.d187.s12|47-52|narrow|O
DDI-DrugBank.d187.s12|54-65|theophylline|drug
DDI-DrugBank.d187.s12|67-71|serum|O
DDI-DrugBank.d187.s12|73-78|levels|O
DDI-DrugBank.d187.s12|80-85|should|O
DDI-DrugBank.d187.s12|87-88|be|O
DDI-DrugBank.d187.s12|90-98|monitored|O
DDI-DrugBank.d187.s12|100-106|closely|O
DDI-DrugBank.d187.s12|107-107|,|O
DDI-DrugBank.d187.s12|109-111|and|O
DDI-DrugBank.d187.s12|113-123|appropriate|O
DDI-DrugBank.d187.s12|125-130|dosage|O
DDI-DrugBank.d187.s12|132-142|adjustments|O
DDI-DrugBank.d187.s12|144-145|of|O
DDI-DrugBank.d187.s12|147-158|theophylline|drug
DDI-DrugBank.d187.s12|160-165|should|O
DDI-DrugBank.d187.s12|167-168|be|O
DDI-DrugBank.d187.s12|170-173|made|O
DDI-DrugBank.d187.s12|174-174|.|O
DDI-DrugBank.d187.s13|0-8|Valproate|drug
DDI-DrugBank.d187.s13|9-9|:|O
DDI-DrugBank.d187.s13|11-11|A|O
DDI-DrugBank.d187.s13|13-18|recent|O
DDI-DrugBank.d187.s13|20-23|case|O
DDI-DrugBank.d187.s13|25-29|study|O
DDI-DrugBank.d187.s13|31-33|has|O
DDI-DrugBank.d187.s13|35-39|shown|O
DDI-DrugBank.d187.s13|41-41|a|O
DDI-DrugBank.d187.s13|43-50|possible|O
DDI-DrugBank.d187.s13|52-59|increase|O
DDI-DrugBank.d187.s13|61-62|in|O
DDI-DrugBank.d187.s13|64-66|the|O
DDI-DrugBank.d187.s13|68-73|plasma|O
DDI-DrugBank.d187.s13|75-79|level|O
DDI-DrugBank.d187.s13|81-82|of|O
DDI-DrugBank.d187.s13|84-92|valproate|drug
DDI-DrugBank.d187.s13|94-97|when|O
DDI-DrugBank.d187.s13|99-100|co|O
DDI-DrugBank.d187.s13|102-113|administered|O
DDI-DrugBank.d187.s13|115-118|with|O
DDI-DrugBank.d187.s13|120-128|isoniazid|drug
DDI-DrugBank.d187.s13|129-129|.|O
DDI-DrugBank.d187.s14|0-5|Plasma|O
DDI-DrugBank.d187.s14|7-15|valproate|drug
DDI-DrugBank.d187.s14|17-29|concentration|O
DDI-DrugBank.d187.s14|31-36|should|O
DDI-DrugBank.d187.s14|38-39|be|O
DDI-DrugBank.d187.s14|41-49|monitored|O
DDI-DrugBank.d187.s14|51-54|when|O
DDI-DrugBank.d187.s14|56-64|isoniazid|drug
DDI-DrugBank.d187.s14|66-68|and|O
DDI-DrugBank.d187.s14|70-78|valproate|drug
DDI-DrugBank.d187.s14|80-82|are|O
DDI-DrugBank.d187.s14|84-85|co|O
DDI-DrugBank.d187.s14|87-98|administered|O
DDI-DrugBank.d187.s14|99-99|,|O
DDI-DrugBank.d187.s14|101-103|and|O
DDI-DrugBank.d187.s14|105-115|appropriate|O
DDI-DrugBank.d187.s14|117-122|dosage|O
DDI-DrugBank.d187.s14|124-134|adjustments|O
DDI-DrugBank.d187.s14|136-137|of|O
DDI-DrugBank.d187.s14|139-147|valproate|drug
DDI-DrugBank.d187.s14|149-154|should|O
DDI-DrugBank.d187.s14|156-157|be|O
DDI-DrugBank.d187.s14|159-162|made|O
DDI-DrugBank.d187.s14|163-163|.|O
DDI-MedLine.d82.s0|0-9|Intestinal|O
DDI-MedLine.d82.s0|11-20|absorption|O
DDI-MedLine.d82.s0|22-23|of|O
DDI-MedLine.d82.s0|34-35|in|O
DDI-MedLine.d82.s0|37-39|the|O
DDI-MedLine.d82.s0|41-45|chick|O
DDI-MedLine.d82.s0|46-46|.|O
DDI-MedLine.d82.s1|0-2|The|O
DDI-MedLine.d82.s1|4-13|intestinal|O
DDI-MedLine.d82.s1|15-24|absorption|O
DDI-MedLine.d82.s1|26-27|of|O
DDI-MedLine.d82.s1|37-37|(|O
DDI-MedLine.d82.s1|43-43|)|O
DDI-MedLine.d82.s1|45-47|has|O
DDI-MedLine.d82.s1|49-52|been|O
DDI-MedLine.d82.s1|54-65|investigated|O
DDI-MedLine.d82.s1|67-68|in|O
DDI-MedLine.d82.s1|70-72|the|O
DDI-MedLine.d82.s1|74-78|chick|O
DDI-MedLine.d82.s1|80-81|by|O
DDI-MedLine.d82.s1|83-87|means|O
DDI-MedLine.d82.s1|89-90|of|O
DDI-MedLine.d82.s1|92-94|the|O
DDI-MedLine.d82.s1|96-97|in|O
DDI-MedLine.d82.s1|99-102|situ|O
DDI-MedLine.d82.s1|104-110|ligated|O
DDI-MedLine.d82.s1|112-119|duodenal|O
DDI-MedLine.d82.s1|121-124|loop|O
DDI-MedLine.d82.s1|126-134|technique|O
DDI-MedLine.d82.s1|135-135|.|O
DDI-MedLine.d82.s2|0-1|By|O
DDI-MedLine.d82.s2|3-6|this|O
DDI-MedLine.d82.s2|8-16|procedure|O
DDI-MedLine.d82.s2|17-17|,|O
DDI-MedLine.d82.s2|19-20|it|O
DDI-MedLine.d82.s2|22-24|was|O
DDI-MedLine.d82.s2|26-33|observed|O
DDI-MedLine.d82.s2|35-38|that|O
DDI-MedLine.d82.s2|49-50|is|O
DDI-MedLine.d82.s2|52-58|rapidly|O
DDI-MedLine.d82.s2|60-62|and|O
DDI-MedLine.d82.s2|64-74|essentially|O
DDI-MedLine.d82.s2|76-85|completely|O
DDI-MedLine.d82.s2|87-94|absorbed|O
DDI-MedLine.d82.s2|96-96|(|O
DDI-MedLine.d82.s2|97-101|80-95|O
DDI-MedLine.d82.s2|102-102|%|O
DDI-MedLine.d82.s2|103-103|)|O
DDI-MedLine.d82.s2|105-108|from|O
DDI-MedLine.d82.s2|110-112|the|O
DDI-MedLine.d82.s2|114-118|lumen|O
DDI-MedLine.d82.s2|120-121|at|O
DDI-MedLine.d82.s2|129-142|concentrations|O
DDI-MedLine.d82.s2|144-145|up|O
DDI-MedLine.d82.s2|147-148|to|O
DDI-MedLine.d82.s2|150-150|5|O
DDI-MedLine.d82.s2|152-153|mM|O
DDI-MedLine.d82.s2|154-154|,|O
DDI-MedLine.d82.s2|156-164|declining|O
DDI-MedLine.d82.s2|166-167|to|O
DDI-MedLine.d82.s2|169-173|about|O
DDI-MedLine.d82.s2|175-176|50|O
DDI-MedLine.d82.s2|177-177|%|O
DDI-MedLine.d82.s2|179-188|absorption|O
DDI-MedLine.d82.s2|190-191|at|O
DDI-MedLine.d82.s2|193-194|50|O
DDI-MedLine.d82.s2|196-197|mM|O
DDI-MedLine.d82.s2|198-198|.|O
DDI-MedLine.d82.s3|0-7|Transfer|O
DDI-MedLine.d82.s3|9-12|from|O
DDI-MedLine.d82.s3|14-16|the|O
DDI-MedLine.d82.s3|18-27|intestinal|O
DDI-MedLine.d82.s3|29-33|lumen|O
DDI-MedLine.d82.s3|35-36|to|O
DDI-MedLine.d82.s3|38-40|the|O
DDI-MedLine.d82.s3|42-48|mucosal|O
DDI-MedLine.d82.s3|50-54|cells|O
DDI-MedLine.d82.s3|56-57|at|O
DDI-MedLine.d82.s3|59-61|low|O
DDI-MedLine.d82.s3|69-81|concentration|O
DDI-MedLine.d82.s3|83-83|(|O
DDI-MedLine.d82.s3|84-86|0.1|O
DDI-MedLine.d82.s3|88-89|mM|O
DDI-MedLine.d82.s3|90-90|)|O
DDI-MedLine.d82.s3|92-93|is|O
DDI-MedLine.d82.s3|95-99|rapid|O
DDI-MedLine.d82.s3|100-100|,|O
DDI-MedLine.d82.s3|102-106|while|O
DDI-MedLine.d82.s3|108-115|transfer|O
DDI-MedLine.d82.s3|117-120|from|O
DDI-MedLine.d82.s3|122-124|the|O
DDI-MedLine.d82.s3|126-132|mucosal|O
DDI-MedLine.d82.s3|134-138|cells|O
DDI-MedLine.d82.s3|140-141|to|O
DDI-MedLine.d82.s3|143-145|the|O
DDI-MedLine.d82.s3|147-150|body|O
DDI-MedLine.d82.s3|152-157|occurs|O
DDI-MedLine.d82.s3|159-162|more|O
DDI-MedLine.d82.s3|164-169|slowly|O
DDI-MedLine.d82.s3|170-170|.|O
DDI-MedLine.d82.s4|0-1|At|O
DDI-MedLine.d82.s4|3-8|stable|O
DDI-MedLine.d82.s4|16-29|concentrations|O
DDI-MedLine.d82.s4|31-37|greater|O
DDI-MedLine.d82.s4|39-42|than|O
DDI-MedLine.d82.s4|44-44|1|O
DDI-MedLine.d82.s4|46-47|mM|O
DDI-MedLine.d82.s4|48-48|,|O
DDI-MedLine.d82.s4|50-59|fractional|O
DDI-MedLine.d82.s4|61-67|mucosal|O
DDI-MedLine.d82.s4|69-72|cell|O
DDI-MedLine.d82.s4|74-85|accumulation|O
DDI-MedLine.d82.s4|87-88|of|O
DDI-MedLine.d82.s4|96-102|remains|O
DDI-MedLine.d82.s4|104-111|constant|O
DDI-MedLine.d82.s4|112-112|,|O
DDI-MedLine.d82.s4|114-118|while|O
DDI-MedLine.d82.s4|120-129|fractional|O
DDI-MedLine.d82.s4|131-138|transfer|O
DDI-MedLine.d82.s4|140-141|to|O
DDI-MedLine.d82.s4|143-145|the|O
DDI-MedLine.d82.s4|147-150|body|O
DDI-MedLine.d82.s4|152-159|declines|O
DDI-MedLine.d82.s4|160-160|.|O
DDI-MedLine.d82.s5|0-6|However|O
DDI-MedLine.d82.s5|7-7|,|O
DDI-MedLine.d82.s5|9-13|total|O
DDI-MedLine.d82.s5|15-21|mucosal|O
DDI-MedLine.d82.s5|23-34|accumulation|O
DDI-MedLine.d82.s5|36-37|of|O
DDI-MedLine.d82.s5|45-47|and|O
DDI-MedLine.d82.s5|49-52|that|O
DDI-MedLine.d82.s5|54-64|transferred|O
DDI-MedLine.d82.s5|66-67|to|O
DDI-MedLine.d82.s5|69-71|the|O
DDI-MedLine.d82.s5|73-76|body|O
DDI-MedLine.d82.s5|78-85|increase|O
DDI-MedLine.d82.s5|87-88|in|O
DDI-MedLine.d82.s5|90-90|a|O
DDI-MedLine.d82.s5|92-97|linear|O
DDI-MedLine.d82.s5|99-109|logarithmic|O
DDI-MedLine.d82.s5|111-117|fashion|O
DDI-MedLine.d82.s5|119-122|from|O
DDI-MedLine.d82.s5|124-127|0.05|O
DDI-MedLine.d82.s5|129-130|to|O
DDI-MedLine.d82.s5|132-132|5|O
DDI-MedLine.d82.s5|134-135|mm|O
DDI-MedLine.d82.s5|142-142|.|O
DDI-MedLine.d82.s6|0-2|The|O
DDI-MedLine.d82.s6|4-10|results|O
DDI-MedLine.d82.s6|12-19|indicate|O
DDI-MedLine.d82.s6|21-24|that|O
DDI-MedLine.d82.s6|32-38|readily|O
DDI-MedLine.d82.s6|40-49|penetrates|O
DDI-MedLine.d82.s6|51-54|both|O
DDI-MedLine.d82.s6|56-58|the|O
DDI-MedLine.d82.s6|60-66|mucosal|O
DDI-MedLine.d82.s6|68-70|and|O
DDI-MedLine.d82.s6|72-78|serosal|O
DDI-MedLine.d82.s6|80-87|surfaces|O
DDI-MedLine.d82.s6|89-90|of|O
DDI-MedLine.d82.s6|92-94|the|O
DDI-MedLine.d82.s6|96-105|epithelial|O
DDI-MedLine.d82.s6|107-114|membrane|O
DDI-MedLine.d82.s6|115-115|.|O
DDI-MedLine.d82.s7|0-10|Furthermore|O
DDI-MedLine.d82.s7|11-11|,|O
DDI-MedLine.d82.s7|22-24|and|O
DDI-MedLine.d82.s7|26-34|phosphate|drug
DDI-MedLine.d82.s7|36-37|do|O
DDI-MedLine.d82.s7|39-41|not|O
DDI-MedLine.d82.s7|43-48|appear|O
DDI-MedLine.d82.s7|50-51|to|O
DDI-MedLine.d82.s7|53-57|share|O
DDI-MedLine.d82.s7|59-59|a|O
DDI-MedLine.d82.s7|61-66|common|O
DDI-MedLine.d82.s7|68-76|transport|O
DDI-MedLine.d82.s7|78-84|pathway|O
DDI-MedLine.d82.s7|86-87|in|O
DDI-MedLine.d82.s7|89-91|the|O
DDI-MedLine.d82.s7|93-100|duodenum|O
DDI-MedLine.d82.s7|102-104|and|O
DDI-MedLine.d82.s7|106-107|no|O
DDI-MedLine.d82.s7|109-116|evidence|O
DDI-MedLine.d82.s7|118-120|was|O
DDI-MedLine.d82.s7|122-129|obtained|O
DDI-MedLine.d82.s7|131-133|for|O
DDI-MedLine.d82.s7|135-137|any|O
DDI-MedLine.d82.s7|139-149|interaction|O
DDI-MedLine.d82.s7|151-157|between|O
DDI-MedLine.d82.s7|159-161|the|O
DDI-MedLine.d82.s7|163-165|two|O
DDI-MedLine.d82.s7|167-168|at|O
DDI-MedLine.d82.s7|170-173|this|O
DDI-MedLine.d82.s7|175-179|level|O
DDI-MedLine.d82.s7|180-180|.|O
DDI-MedLine.d82.s8|0-9|Vitamin D3|drug
DDI-MedLine.d82.s8|11-24|administration|O
DDI-MedLine.d82.s8|26-27|to|O
DDI-MedLine.d82.s8|29-36|rachitic|O
DDI-MedLine.d82.s8|38-43|chicks|O
DDI-MedLine.d82.s8|45-47|was|O
DDI-MedLine.d82.s8|49-57|effective|O
DDI-MedLine.d82.s8|59-60|in|O
DDI-MedLine.d82.s8|62-74|significantly|O
DDI-MedLine.d82.s8|76-84|elevating|O
DDI-MedLine.d82.s8|86-93|duodenal|O
DDI-MedLine.d82.s8|104-113|absorption|O
DDI-MedLine.d82.s8|114-114|,|O
DDI-MedLine.d82.s8|116-121|acting|O
DDI-MedLine.d82.s8|123-131|primarily|O
DDI-MedLine.d82.s8|133-134|to|O
DDI-MedLine.d82.s8|136-142|enhance|O
DDI-MedLine.d82.s8|144-150|serosal|O
DDI-MedLine.d82.s8|152-160|transport|O
DDI-MedLine.d82.s8|161-161|.|O
DDI-MedLine.d68.s0|0-0|[|O
DDI-MedLine.d68.s0|1-3|The|O
DDI-MedLine.d68.s0|5-10|effect|O
DDI-MedLine.d68.s0|12-13|of|O
DDI-MedLine.d68.s0|15-24|cimetidine|drug
DDI-MedLine.d68.s0|26-27|on|O
DDI-MedLine.d68.s0|29-31|the|O
DDI-MedLine.d68.s0|33-37|renal|O
DDI-MedLine.d68.s0|39-47|excretion|O
DDI-MedLine.d68.s0|49-50|of|O
DDI-MedLine.d68.s0|52-61|verografin|drug
DDI-MedLine.d68.s0|63-65|and|O
DDI-MedLine.d68.s0|67-74|iodamide|drug
DDI-MedLine.d68.s0|76-77|in|O
DDI-MedLine.d68.s0|79-82|dogs|O
DDI-MedLine.d68.s0|83-83|]|O
DDI-MedLine.d68.s0|86-88|The|O
DDI-MedLine.d68.s0|90-100|intravenous|O
DDI-MedLine.d68.s0|102-110|injection|O
DDI-MedLine.d68.s0|112-113|of|O
DDI-MedLine.d68.s0|115-124|cimetidine|drug
DDI-MedLine.d68.s0|126-127|in|O
DDI-MedLine.d68.s0|129-129|a|O
DDI-MedLine.d68.s0|131-134|dose|O
DDI-MedLine.d68.s0|136-137|of|O
DDI-MedLine.d68.s0|139-140|20|O
DDI-MedLine.d68.s0|142-146|mg/kg|O
DDI-MedLine.d68.s0|148-155|enhanced|O
DDI-MedLine.d68.s0|157-167|verografine|drug
DDI-MedLine.d68.s0|169-171|and|O
DDI-MedLine.d68.s0|173-180|iodamide|drug
DDI-MedLine.d68.s0|182-190|excretion|O
DDI-MedLine.d68.s0|192-193|in|O
DDI-MedLine.d68.s0|195-201|chronic|O
DDI-MedLine.d68.s0|203-208|canine|O
DDI-MedLine.d68.s0|210-220|experiments|O
DDI-MedLine.d68.s0|221-221|.|O
DDI-MedLine.d68.s1|0-2|The|O
DDI-MedLine.d68.s1|4-9|higher|O
DDI-MedLine.d68.s1|11-21|verografine|drug
DDI-MedLine.d68.s1|23-25|and|O
DDI-MedLine.d68.s1|27-34|iodamide|drug
DDI-MedLine.d68.s1|36-44|excretion|O
DDI-MedLine.d68.s1|46-48|was|O
DDI-MedLine.d68.s1|50-52|due|O
DDI-MedLine.d68.s1|54-55|to|O
DDI-MedLine.d68.s1|57-61|their|O
DDI-MedLine.d68.s1|63-71|increased|O
DDI-MedLine.d68.s1|73-77|renal|O
DDI-MedLine.d68.s1|79-85|tubular|O
DDI-MedLine.d68.s1|87-95|secretion|O
DDI-MedLine.d68.s1|96-96|.|O
DDI-MedLine.d68.s2|0-1|In|O
DDI-MedLine.d68.s2|3-6|dogs|O
DDI-MedLine.d68.s2|7-7|,|O
DDI-MedLine.d68.s2|9-18|cimetidine|drug
DDI-MedLine.d68.s2|20-28|unchanged|O
DDI-MedLine.d68.s2|30-32|the|O
DDI-MedLine.d68.s2|34-42|secretion|O
DDI-MedLine.d68.s2|44-45|of|O
DDI-MedLine.d68.s2|47-57|cardiotrast|drug
DDI-MedLine.d68.s2|58-58|,|O
DDI-MedLine.d68.s2|60-60|a|O
DDI-MedLine.d68.s2|62-65|test|O
DDI-MedLine.d68.s2|67-71|agent|O
DDI-MedLine.d68.s2|73-75|for|O
DDI-MedLine.d68.s2|77-83|anionic|O
DDI-MedLine.d68.s2|85-93|transport|O
DDI-MedLine.d68.s2|94-94|.|O
DDI-MedLine.d68.s3|0-7|Possible|O
DDI-MedLine.d68.s3|9-18|extrarenal|O
DDI-MedLine.d68.s3|20-29|mechanisms|O
DDI-MedLine.d68.s3|31-32|of|O
DDI-MedLine.d68.s3|34-39|action|O
DDI-MedLine.d68.s3|41-42|of|O
DDI-MedLine.d68.s3|44-53|cimetidine|drug
DDI-MedLine.d68.s3|55-56|on|O
DDI-MedLine.d68.s3|58-68|verografine|drug
DDI-MedLine.d68.s3|70-72|and|O
DDI-MedLine.d68.s3|74-81|iodamide|drug
DDI-MedLine.d68.s3|83-91|transport|O
DDI-MedLine.d68.s3|93-96|were|O
DDI-MedLine.d68.s3|98-101|also|O
DDI-MedLine.d68.s3|103-110|examined|O
DDI-MedLine.d68.s3|111-111|.|O
DDI-DrugBank.d780.s0|0-18|Anticholinesterases|group
DDI-DrugBank.d780.s0|19-19|:|O
DDI-DrugBank.d780.s0|21-30|Concurrent|O
DDI-DrugBank.d780.s0|32-34|use|O
DDI-DrugBank.d780.s0|36-37|of|O
DDI-DrugBank.d780.s0|39-60|procaine hydrochloride|drug
DDI-DrugBank.d780.s0|62-64|and|O
DDI-DrugBank.d780.s0|66-90|anticholinesterase agents|group
DDI-DrugBank.d780.s0|92-94|may|O
DDI-DrugBank.d780.s0|96-101|result|O
DDI-DrugBank.d780.s0|103-104|in|O
DDI-DrugBank.d780.s0|106-114|increased|O
DDI-DrugBank.d780.s0|116-123|systemic|O
DDI-DrugBank.d780.s0|125-132|toxicity|O
DDI-DrugBank.d780.s0|134-138|since|O
DDI-DrugBank.d780.s0|140-158|anticholinesterases|group
DDI-DrugBank.d780.s0|160-166|inhibit|O
DDI-DrugBank.d780.s0|168-170|the|O
DDI-DrugBank.d780.s0|172-180|breakdown|O
DDI-DrugBank.d780.s0|182-183|of|O
DDI-DrugBank.d780.s0|185-206|procaine hydrochloride|drug
DDI-DrugBank.d780.s0|207-207|.|O
DDI-DrugBank.d780.s1|0-14|Antimyasthenics|O
DDI-DrugBank.d780.s1|16-25|Concurrent|O
DDI-DrugBank.d780.s1|27-29|use|O
DDI-DrugBank.d780.s1|31-32|of|O
DDI-DrugBank.d780.s1|34-55|procaine hydrochloride|drug
DDI-DrugBank.d780.s1|57-59|and|O
DDI-DrugBank.d780.s1|61-75|antimyasthenics|O
DDI-DrugBank.d780.s1|77-79|may|O
DDI-DrugBank.d780.s1|81-86|result|O
DDI-DrugBank.d780.s1|88-89|in|O
DDI-DrugBank.d780.s1|91-94|loss|O
DDI-DrugBank.d780.s1|96-97|of|O
DDI-DrugBank.d780.s1|99-105|control|O
DDI-DrugBank.d780.s1|107-108|of|O
DDI-DrugBank.d780.s1|110-117|symptoms|O
DDI-DrugBank.d780.s1|119-120|of|O
DDI-DrugBank.d780.s1|122-131|myasthenia|O
DDI-DrugBank.d780.s1|133-138|gravis|O
DDI-DrugBank.d780.s1|140-142|due|O
DDI-DrugBank.d780.s1|144-145|to|O
DDI-DrugBank.d780.s1|147-156|antagonism|O
DDI-DrugBank.d780.s1|158-159|of|O
DDI-DrugBank.d780.s1|161-163|the|O
DDI-DrugBank.d780.s1|165-171|effects|O
DDI-DrugBank.d780.s1|173-174|of|O
DDI-DrugBank.d780.s1|176-190|antimyasthenics|O
DDI-DrugBank.d780.s1|192-193|on|O
DDI-DrugBank.d780.s1|195-202|skeletal|O
DDI-DrugBank.d780.s1|204-209|muscle|O
DDI-DrugBank.d780.s1|210-210|.|O
DDI-DrugBank.d780.s2|0-8|Temporary|O
DDI-DrugBank.d780.s2|10-15|dosage|O
DDI-DrugBank.d780.s2|17-26|adjustment|O
DDI-DrugBank.d780.s2|28-29|of|O
DDI-DrugBank.d780.s2|31-45|antimyasthenics|O
DDI-DrugBank.d780.s2|47-49|may|O
DDI-DrugBank.d780.s2|51-52|be|O
DDI-DrugBank.d780.s2|54-61|required|O
DDI-DrugBank.d780.s2|62-62|.|O
DDI-DrugBank.d780.s3|0-3|Also|O
DDI-DrugBank.d780.s3|5-19|antimyasthenics|O
DDI-DrugBank.d780.s3|21-23|may|O
DDI-DrugBank.d780.s3|25-28|have|O
DDI-DrugBank.d780.s3|30-47|anticholinesterase|O
DDI-DrugBank.d780.s3|49-56|activity|O
DDI-DrugBank.d780.s3|57-57|.|O
DDI-DrugBank.d780.s4|0-13|CNS depressant|group
DDI-DrugBank.d780.s4|15-25|medications|O
DDI-DrugBank.d780.s4|26-26|:|O
DDI-DrugBank.d780.s4|28-37|Concurrent|O
DDI-DrugBank.d780.s4|39-41|use|O
DDI-DrugBank.d780.s4|43-44|of|O
DDI-DrugBank.d780.s4|46-67|procaine hydrochloride|drug
DDI-DrugBank.d780.s4|69-71|and|O
DDI-DrugBank.d780.s4|73-98|CNS depressant medications|group
DDI-DrugBank.d780.s4|100-102|may|O
DDI-DrugBank.d780.s4|104-109|result|O
DDI-DrugBank.d780.s4|111-112|in|O
DDI-DrugBank.d780.s4|114-121|additive|O
DDI-DrugBank.d780.s4|123-132|depressant|O
DDI-DrugBank.d780.s4|134-140|effects|O
DDI-DrugBank.d780.s4|141-141|.|O
DDI-DrugBank.d780.s5|0-12|Hyaluronidase|drug
DDI-DrugBank.d780.s5|13-13|:|O
DDI-DrugBank.d780.s5|15-27|Hyaluronidase|drug
DDI-DrugBank.d780.s5|29-31|may|O
DDI-DrugBank.d780.s5|33-40|increase|O
DDI-DrugBank.d780.s5|42-44|the|O
DDI-DrugBank.d780.s5|46-54|diffusion|O
DDI-DrugBank.d780.s5|56-59|rate|O
DDI-DrugBank.d780.s5|61-62|of|O
DDI-DrugBank.d780.s5|64-85|procaine hydrochloride|drug
DDI-DrugBank.d780.s5|86-86|,|O
DDI-DrugBank.d780.s5|88-96|resulting|O
DDI-DrugBank.d780.s5|98-99|in|O
DDI-DrugBank.d780.s5|101-101|a|O
DDI-DrugBank.d780.s5|103-111|decreased|O
DDI-DrugBank.d780.s5|113-116|time|O
DDI-DrugBank.d780.s5|118-119|of|O
DDI-DrugBank.d780.s5|121-125|onset|O
DDI-DrugBank.d780.s5|126-126|,|O
DDI-DrugBank.d780.s5|128-130|but|O
DDI-DrugBank.d780.s5|132-133|an|O
DDI-DrugBank.d780.s5|135-142|increase|O
DDI-DrugBank.d780.s5|144-145|in|O
DDI-DrugBank.d780.s5|147-154|systemic|O
DDI-DrugBank.d780.s5|156-163|toxicity|O
DDI-DrugBank.d780.s5|164-164|.|O
DDI-DrugBank.d780.s6|0-28|Neuromuscular blocking agents|group
DDI-DrugBank.d780.s6|30-30|(|O
DDI-DrugBank.d780.s6|31-34|such|O
DDI-DrugBank.d780.s6|36-37|as|O
DDI-DrugBank.d780.s6|39-60|suxamethonium chloride|drug
DDI-DrugBank.d780.s6|61-61|)|O
DDI-DrugBank.d780.s6|62-62|:|O
DDI-DrugBank.d780.s6|64-73|Concurrent|O
DDI-DrugBank.d780.s6|75-77|use|O
DDI-DrugBank.d780.s6|79-80|of|O
DDI-DrugBank.d780.s6|82-103|procaine hydrochloride|drug
DDI-DrugBank.d780.s6|105-107|and|O
DDI-DrugBank.d780.s6|109-137|neuromuscular blocking agents|group
DDI-DrugBank.d780.s6|139-141|may|O
DDI-DrugBank.d780.s6|143-148|result|O
DDI-DrugBank.d780.s6|150-151|in|O
DDI-DrugBank.d780.s6|153-164|prolongation|O
DDI-DrugBank.d780.s6|166-167|or|O
DDI-DrugBank.d780.s6|169-179|enhancement|O
DDI-DrugBank.d780.s6|181-182|of|O
DDI-DrugBank.d780.s6|184-186|the|O
DDI-DrugBank.d780.s6|188-200|neuromuscular|O
DDI-DrugBank.d780.s6|202-209|blockade|O
DDI-DrugBank.d780.s6|210-210|.|O
DDI-DrugBank.d780.s7|0-11|Sulfonamides|group
DDI-DrugBank.d780.s7|12-12|:|O
DDI-DrugBank.d780.s7|14-23|Concurrent|O
DDI-DrugBank.d780.s7|25-27|use|O
DDI-DrugBank.d780.s7|29-30|of|O
DDI-DrugBank.d780.s7|32-53|procaine hydrochloride|drug
DDI-DrugBank.d780.s7|55-57|and|O
DDI-DrugBank.d780.s7|59-70|sulfonamides|group
DDI-DrugBank.d780.s7|72-74|may|O
DDI-DrugBank.d780.s7|76-81|result|O
DDI-DrugBank.d780.s7|83-84|in|O
DDI-DrugBank.d780.s7|86-86|a|O
DDI-DrugBank.d780.s7|88-96|reduction|O
DDI-DrugBank.d780.s7|98-99|of|O
DDI-DrugBank.d780.s7|101-103|the|O
DDI-DrugBank.d780.s7|105-117|antibacterial|O
DDI-DrugBank.d780.s7|119-124|action|O
DDI-DrugBank.d780.s7|126-127|of|O
DDI-DrugBank.d780.s7|129-131|the|O
DDI-DrugBank.d780.s7|133-143|sulfonamide|group
DDI-DrugBank.d780.s7|144-144|.|O
DDI-DrugBank.d780.s8|0-12|Acetazolamide|drug
DDI-DrugBank.d780.s8|13-13|:|O
DDI-DrugBank.d780.s8|15-24|Concurrent|O
DDI-DrugBank.d780.s8|26-28|use|O
DDI-DrugBank.d780.s8|30-31|of|O
DDI-DrugBank.d780.s8|33-45|acetazolamide|drug
DDI-DrugBank.d780.s8|47-49|and|O
DDI-DrugBank.d780.s8|51-72|procaine hydrochloride|drug
DDI-DrugBank.d780.s8|74-76|may|O
DDI-DrugBank.d780.s8|78-83|extend|O
DDI-DrugBank.d780.s8|85-87|the|O
DDI-DrugBank.d780.s8|89-94|plasma|O
DDI-DrugBank.d780.s8|96-104|half-life|O
DDI-DrugBank.d780.s8|106-107|of|O
DDI-DrugBank.d780.s8|109-116|procaine|drug
DDI-DrugBank.d780.s8|117-117|.|O
DDI-MedLine.d91.s0|0-9|Diagnostic|O
DDI-MedLine.d91.s0|10-10|,|O
DDI-MedLine.d91.s0|12-20|treatment|O
DDI-MedLine.d91.s0|22-24|and|O
DDI-MedLine.d91.s0|26-34|aftercare|O
DDI-MedLine.d91.s0|36-45|approaches|O
DDI-MedLine.d91.s0|47-48|to|O
DDI-MedLine.d91.s0|50-56|cocaine|drug
DDI-MedLine.d91.s0|58-62|abuse|O
DDI-MedLine.d91.s0|63-63|.|O
DDI-MedLine.d91.s1|0-2|The|O
DDI-MedLine.d91.s1|4-10|general|O
DDI-MedLine.d91.s1|12-17|public|O
DDI-MedLine.d91.s1|19-23|feels|O
DDI-MedLine.d91.s1|25-28|that|O
DDI-MedLine.d91.s1|30-36|cocaine|drug
DDI-MedLine.d91.s1|38-39|is|O
DDI-MedLine.d91.s1|41-43|not|O
DDI-MedLine.d91.s1|45-56|particularly|O
DDI-MedLine.d91.s1|58-66|dangerous|O
DDI-MedLine.d91.s1|68-74|because|O
DDI-MedLine.d91.s1|76-77|it|O
DDI-MedLine.d91.s1|79-82|does|O
DDI-MedLine.d91.s1|84-86|not|O
DDI-MedLine.d91.s1|88-94|produce|O
DDI-MedLine.d91.s1|96-96|a|O
DDI-MedLine.d91.s1|98-101|well|O
DDI-MedLine.d91.s1|103-109|defined|O
DDI-MedLine.d91.s1|111-118|physical|O
DDI-MedLine.d91.s1|120-129|dependency|O
DDI-MedLine.d91.s1|131-133|and|O
DDI-MedLine.d91.s1|135-144|abstinence|O
DDI-MedLine.d91.s1|146-153|syndrome|O
DDI-MedLine.d91.s1|154-154|.|O
DDI-MedLine.d91.s2|0-6|However|O
DDI-MedLine.d91.s2|7-7|,|O
DDI-MedLine.d91.s2|9-12|when|O
DDI-MedLine.d91.s2|14-22|addiction|O
DDI-MedLine.d91.s2|24-25|is|O
DDI-MedLine.d91.s2|27-33|defined|O
DDI-MedLine.d91.s2|35-36|as|O
DDI-MedLine.d91.s2|38-47|compulsion|O
DDI-MedLine.d91.s2|48-48|,|O
DDI-MedLine.d91.s2|50-53|loss|O
DDI-MedLine.d91.s2|55-56|of|O
DDI-MedLine.d91.s2|58-64|control|O
DDI-MedLine.d91.s2|66-68|and|O
DDI-MedLine.d91.s2|70-78|continued|O
DDI-MedLine.d91.s2|80-82|use|O
DDI-MedLine.d91.s2|84-85|in|O
DDI-MedLine.d91.s2|87-91|spite|O
DDI-MedLine.d91.s2|93-94|of|O
DDI-MedLine.d91.s2|96-102|adverse|O
DDI-MedLine.d91.s2|104-115|consequences|O
DDI-MedLine.d91.s2|116-116|,|O
DDI-MedLine.d91.s2|118-124|cocaine|drug
DDI-MedLine.d91.s2|126-129|drug|O
DDI-MedLine.d91.s2|131-136|hunger|O
DDI-MedLine.d91.s2|138-140|can|O
DDI-MedLine.d91.s2|142-143|be|O
DDI-MedLine.d91.s2|145-148|seen|O
DDI-MedLine.d91.s2|150-151|as|O
DDI-MedLine.d91.s2|153-154|an|O
DDI-MedLine.d91.s2|156-160|agent|O
DDI-MedLine.d91.s2|162-163|of|O
DDI-MedLine.d91.s2|165-173|addictive|O
DDI-MedLine.d91.s2|175-181|disease|O
DDI-MedLine.d91.s2|182-182|.|O
DDI-MedLine.d91.s3|0-9|Withdrawal|O
DDI-MedLine.d91.s3|11-14|from|O
DDI-MedLine.d91.s3|16-22|cocaine|drug
DDI-MedLine.d91.s3|24-33|dependence|O
DDI-MedLine.d91.s3|35-41|usually|O
DDI-MedLine.d91.s3|43-50|involves|O
DDI-MedLine.d91.s3|52-61|depression|O
DDI-MedLine.d91.s3|62-62|,|O
DDI-MedLine.d91.s3|64-70|anxiety|O
DDI-MedLine.d91.s3|72-74|and|O
DDI-MedLine.d91.s3|76-83|lethargy|O
DDI-MedLine.d91.s3|84-84|.|O
DDI-MedLine.d91.s4|0-4|These|O
DDI-MedLine.d91.s4|6-12|usually|O
DDI-MedLine.d91.s4|14-18|clear|O
DDI-MedLine.d91.s4|20-25|within|O
DDI-MedLine.d91.s4|27-27|a|O
DDI-MedLine.d91.s4|29-32|week|O
DDI-MedLine.d91.s4|33-33|,|O
DDI-MedLine.d91.s4|35-41|leaving|O
DDI-MedLine.d91.s4|43-46|only|O
DDI-MedLine.d91.s4|48-50|the|O
DDI-MedLine.d91.s4|52-52|"|O
DDI-MedLine.d91.s4|53-56|drug|O
DDI-MedLine.d91.s4|58-63|hunger|O
DDI-MedLine.d91.s4|64-64|"|O
DDI-MedLine.d91.s5|0-1|to|O
DDI-MedLine.d91.s5|3-9|contend|O
DDI-MedLine.d91.s5|11-14|with|O
DDI-MedLine.d91.s5|15-15|.|O
DDI-MedLine.d91.s6|0-9|Medication|O
DDI-MedLine.d91.s6|11-12|is|O
DDI-MedLine.d91.s6|14-19|rarely|O
DDI-MedLine.d91.s6|21-26|needed|O
DDI-MedLine.d91.s6|27-27|.|O
DDI-MedLine.d91.s7|0-3|When|O
DDI-MedLine.d91.s7|5-11|cocaine|drug
DDI-MedLine.d91.s7|13-14|is|O
DDI-MedLine.d91.s7|16-18|the|O
DDI-MedLine.d91.s7|20-26|primary|O
DDI-MedLine.d91.s7|28-36|addiction|O
DDI-MedLine.d91.s7|37-37|,|O
DDI-MedLine.d91.s7|39-43|after|O
DDI-MedLine.d91.s7|45-54|withdrawal|O
DDI-MedLine.d91.s7|56-58|the|O
DDI-MedLine.d91.s7|60-63|most|O
DDI-MedLine.d91.s7|65-73|effective|O
DDI-MedLine.d91.s7|75-83|treatment|O
DDI-MedLine.d91.s7|85-86|is|O
DDI-MedLine.d91.s7|88-92|group|O
DDI-MedLine.d91.s7|94-100|therapy|O
DDI-MedLine.d91.s7|102-105|with|O
DDI-MedLine.d91.s7|107-111|other|O
DDI-MedLine.d91.s7|113-122|recovering|O
DDI-MedLine.d91.s7|124-130|cocaine|O
DDI-MedLine.d91.s7|132-138|abusers|O
DDI-MedLine.d91.s7|139-139|.|O
DDI-MedLine.d91.s8|0-1|We|O
DDI-MedLine.d91.s8|3-13|incorporate|O
DDI-MedLine.d91.s8|15-17|the|O
DDI-MedLine.d91.s8|19-28|principles|O
DDI-MedLine.d91.s8|30-31|of|O
DDI-MedLine.d91.s8|33-40|recovery|O
DDI-MedLine.d91.s8|42-44|and|O
DDI-MedLine.d91.s8|46-51|define|O
DDI-MedLine.d91.s8|53-60|positive|O
DDI-MedLine.d91.s8|62-64|and|O
DDI-MedLine.d91.s8|66-77|constructive|O
DDI-MedLine.d91.s8|79-90|alternatives|O
DDI-MedLine.d91.s8|92-93|in|O
DDI-MedLine.d91.s8|95-101|dealing|O
DDI-MedLine.d91.s8|103-106|with|O
DDI-MedLine.d91.s8|108-114|cocaine|O
DDI-MedLine.d91.s8|116-121|hunger|O
DDI-MedLine.d91.s8|122-122|.|O
DDI-MedLine.d91.s9|0-7|Recovery|O
DDI-MedLine.d91.s9|9-16|programs|O
DDI-MedLine.d91.s9|18-23|should|O
DDI-MedLine.d91.s9|25-26|be|O
DDI-MedLine.d91.s9|28-35|flexible|O
DDI-MedLine.d91.s9|37-39|and|O
DDI-MedLine.d91.s9|41-47|involve|O
DDI-MedLine.d91.s9|49-58|individual|O
DDI-MedLine.d91.s9|60-62|and|O
DDI-MedLine.d91.s9|64-69|family|O
DDI-MedLine.d91.s9|71-79|education|O
DDI-MedLine.d91.s9|81-82|on|O
DDI-MedLine.d91.s9|84-91|recovery|O
DDI-MedLine.d91.s9|93-95|and|O
DDI-MedLine.d91.s9|97-99|the|O
DDI-MedLine.d91.s9|101-106|nature|O
DDI-MedLine.d91.s9|108-109|of|O
DDI-MedLine.d91.s9|111-119|addictive|O
DDI-MedLine.d91.s9|121-127|disease|O
DDI-MedLine.d91.s9|128-128|.|O
DDI-MedLine.d91.s10|0-7|Exercise|O
DDI-MedLine.d91.s10|9-12|that|O
DDI-MedLine.d91.s10|14-21|produces|O
DDI-MedLine.d91.s10|23-37|cardiopulmonary|O
DDI-MedLine.d91.s10|39-49|stimulation|O
DDI-MedLine.d91.s10|51-52|is|O
DDI-MedLine.d91.s10|54-54|a|O
DDI-MedLine.d91.s10|56-62|helpful|O
DDI-MedLine.d91.s10|64-68|means|O
DDI-MedLine.d91.s10|70-71|of|O
DDI-MedLine.d91.s10|73-80|reducing|O
DDI-MedLine.d91.s10|82-85|drug|O
DDI-MedLine.d91.s10|87-92|hunger|O
DDI-MedLine.d91.s10|94-96|and|O
DDI-MedLine.d91.s10|98-104|anxiety|O
DDI-MedLine.d91.s10|106-111|during|O
DDI-MedLine.d91.s10|113-120|recovery|O
DDI-MedLine.d91.s10|122-128|therapy|O
DDI-MedLine.d91.s10|129-129|.|O
DDI-DrugBank.d325.s0|0-6|Because|O
DDI-DrugBank.d325.s0|8-15|dopamine|drug
DDI-DrugBank.d325.s0|17-18|is|O
DDI-DrugBank.d325.s0|20-30|metabolized|O
DDI-DrugBank.d325.s0|32-33|by|O
DDI-DrugBank.d325.s0|35-43|monoamine|O
DDI-DrugBank.d325.s0|45-51|oxidase|O
DDI-DrugBank.d325.s0|53-53|(|O
DDI-DrugBank.d325.s0|54-56|MAO|O
DDI-DrugBank.d325.s0|57-57|)|O
DDI-DrugBank.d325.s0|58-58|,|O
DDI-DrugBank.d325.s0|60-69|inhibition|O
DDI-DrugBank.d325.s0|71-72|of|O
DDI-DrugBank.d325.s0|74-77|this|O
DDI-DrugBank.d325.s0|79-84|enzyme|O
DDI-DrugBank.d325.s0|86-93|prolongs|O
DDI-DrugBank.d325.s0|95-97|and|O
DDI-DrugBank.d325.s0|99-109|potentiates|O
DDI-DrugBank.d325.s0|111-113|the|O
DDI-DrugBank.d325.s0|115-120|effect|O
DDI-DrugBank.d325.s0|122-123|of|O
DDI-DrugBank.d325.s0|125-132|dopamine|drug
DDI-DrugBank.d325.s0|133-133|.|O
DDI-DrugBank.d325.s1|0-7|Patients|O
DDI-DrugBank.d325.s1|9-11|who|O
DDI-DrugBank.d325.s1|13-16|have|O
DDI-DrugBank.d325.s1|18-21|been|O
DDI-DrugBank.d325.s1|23-29|treated|O
DDI-DrugBank.d325.s1|31-34|with|O
DDI-DrugBank.d325.s1|36-49|MAO inhibitors|group
DDI-DrugBank.d325.s1|51-56|within|O
DDI-DrugBank.d325.s1|58-60|two|O
DDI-DrugBank.d325.s1|62-63|to|O
DDI-DrugBank.d325.s1|65-69|three|O
DDI-DrugBank.d325.s1|71-75|weeks|O
DDI-DrugBank.d325.s1|77-81|prior|O
DDI-DrugBank.d325.s1|83-84|to|O
DDI-DrugBank.d325.s1|86-88|the|O
DDI-DrugBank.d325.s1|90-103|administration|O
DDI-DrugBank.d325.s1|105-106|of|O
DDI-DrugBank.d325.s1|108-119|dopamine HCl|drug
DDI-DrugBank.d325.s1|121-126|should|O
DDI-DrugBank.d325.s1|128-134|receive|O
DDI-DrugBank.d325.s1|136-142|initial|O
DDI-DrugBank.d325.s1|144-148|doses|O
DDI-DrugBank.d325.s1|150-151|of|O
DDI-DrugBank.d325.s1|153-164|dopamine HCl|drug
DDI-DrugBank.d325.s1|166-167|no|O
DDI-DrugBank.d325.s1|169-175|greater|O
DDI-DrugBank.d325.s1|177-180|than|O
DDI-DrugBank.d325.s1|182-190|one-tenth|O
DDI-DrugBank.d325.s1|192-192|(|O
DDI-DrugBank.d325.s1|193-196|1/10|O
DDI-DrugBank.d325.s1|197-197|)|O
DDI-DrugBank.d325.s1|199-200|of|O
DDI-DrugBank.d325.s1|202-204|the|O
DDI-DrugBank.d325.s1|206-210|usual|O
DDI-DrugBank.d325.s1|212-215|dose|O
DDI-DrugBank.d325.s1|216-216|.|O
DDI-DrugBank.d325.s2|0-9|Concurrent|O
DDI-DrugBank.d325.s2|11-24|administration|O
DDI-DrugBank.d325.s2|26-27|of|O
DDI-DrugBank.d325.s2|29-36|low-dose|O
DDI-DrugBank.d325.s2|38-49|dopamine HCl|drug
DDI-DrugBank.d325.s2|51-53|and|O
DDI-DrugBank.d325.s2|55-69|diuretic agents|group
DDI-DrugBank.d325.s2|71-73|may|O
DDI-DrugBank.d325.s2|75-81|produce|O
DDI-DrugBank.d325.s2|83-84|an|O
DDI-DrugBank.d325.s2|86-93|additive|O
DDI-DrugBank.d325.s2|95-96|or|O
DDI-DrugBank.d325.s2|98-109|potentiating|O
DDI-DrugBank.d325.s2|111-116|effect|O
DDI-DrugBank.d325.s2|118-119|on|O
DDI-DrugBank.d325.s2|121-125|urine|O
DDI-DrugBank.d325.s2|127-130|flow|O
DDI-DrugBank.d325.s2|131-131|.|O
DDI-DrugBank.d325.s3|0-24|Tricyclic antidepressants|group
DDI-DrugBank.d325.s3|26-28|may|O
DDI-DrugBank.d325.s3|30-39|potentiate|O
DDI-DrugBank.d325.s3|41-43|the|O
DDI-DrugBank.d325.s3|45-58|cardiovascular|O
DDI-DrugBank.d325.s3|60-66|effects|O
DDI-DrugBank.d325.s3|68-69|of|O
DDI-DrugBank.d325.s3|71-79|adreneric|O
DDI-DrugBank.d325.s3|81-86|agents|O
DDI-DrugBank.d325.s3|87-87|.|O
DDI-DrugBank.d325.s4|0-6|Cardiac|O
DDI-DrugBank.d325.s4|8-14|effects|O
DDI-DrugBank.d325.s4|16-17|of|O
DDI-DrugBank.d325.s4|19-26|dopamine|drug
DDI-DrugBank.d325.s4|28-30|are|O
DDI-DrugBank.d325.s4|32-42|antagonized|O
DDI-DrugBank.d325.s4|44-45|by|O
DDI-DrugBank.d325.s4|47-77|beta-adrenergic blocking agents|group
DDI-DrugBank.d325.s4|78-78|,|O
DDI-DrugBank.d325.s4|80-83|such|O
DDI-DrugBank.d325.s4|85-86|as|O
DDI-DrugBank.d325.s4|88-98|propranolol|drug
DDI-DrugBank.d325.s4|100-102|and|O
DDI-DrugBank.d325.s4|104-113|metoprolol|drug
DDI-DrugBank.d325.s4|114-114|.|O
DDI-DrugBank.d325.s5|0-2|The|O
DDI-DrugBank.d325.s5|4-13|peripheral|O
DDI-DrugBank.d325.s5|15-30|vasoconstriction|O
DDI-DrugBank.d325.s5|32-37|caused|O
DDI-DrugBank.d325.s5|39-40|by|O
DDI-DrugBank.d325.s5|42-45|high|O
DDI-DrugBank.d325.s5|47-51|doses|O
DDI-DrugBank.d325.s5|53-54|of|O
DDI-DrugBank.d325.s5|56-67|dopamine HCl|drug
DDI-DrugBank.d325.s5|69-70|is|O
DDI-DrugBank.d325.s5|72-82|antagonized|O
DDI-DrugBank.d325.s5|84-85|by|O
DDI-DrugBank.d325.s5|87-118|alpha-adrenergic blocking agents|group
DDI-DrugBank.d325.s5|119-119|.|O
DDI-DrugBank.d325.s6|0-15|Dopamine-induced|drug
DDI-DrugBank.d325.s6|17-21|renal|O
DDI-DrugBank.d325.s6|23-25|and|O
DDI-DrugBank.d325.s6|27-36|mesenteric|O
DDI-DrugBank.d325.s6|38-49|vasodilation|O
DDI-DrugBank.d325.s6|51-52|is|O
DDI-DrugBank.d325.s6|54-56|not|O
DDI-DrugBank.d325.s6|58-68|antagonized|O
DDI-DrugBank.d325.s6|70-71|by|O
DDI-DrugBank.d325.s6|73-78|either|O
DDI-DrugBank.d325.s6|80-85|alpha-|group
DDI-DrugBank.d325.s6|87-88|or|O
DDI-DrugBank.d325.s6|90-120|beta-adrenergic blocking agents|drug
DDI-DrugBank.d325.s6|121-121|.|O
DDI-DrugBank.d325.s7|0-13|Butyrophenones|group
DDI-DrugBank.d325.s7|15-15|(|O
DDI-DrugBank.d325.s7|16-19|such|O
DDI-DrugBank.d325.s7|21-22|as|O
DDI-DrugBank.d325.s7|24-34|haloperidol|drug
DDI-DrugBank.d325.s7|35-35|)|O
DDI-DrugBank.d325.s7|37-39|and|O
DDI-DrugBank.d325.s7|41-54|phenothiazines|group
DDI-DrugBank.d325.s7|56-58|can|O
DDI-DrugBank.d325.s7|60-67|suppress|O
DDI-DrugBank.d325.s7|69-71|the|O
DDI-DrugBank.d325.s7|73-84|dopaminergic|drug
DDI-DrugBank.d325.s7|86-90|renal|O
DDI-DrugBank.d325.s7|92-94|and|O
DDI-DrugBank.d325.s7|96-105|mesenteric|O
DDI-DrugBank.d325.s7|107-118|vasodilation|O
DDI-DrugBank.d325.s7|120-126|induced|O
DDI-DrugBank.d325.s7|128-131|with|O
DDI-DrugBank.d325.s7|133-135|low|O
DDI-DrugBank.d325.s7|137-140|dose|O
DDI-DrugBank.d325.s7|142-149|dopamine|O
DDI-DrugBank.d325.s7|151-158|infusion|O
DDI-DrugBank.d325.s7|159-159|.|O
DDI-DrugBank.d325.s8|0-11|Cyclopropane|drug
DDI-DrugBank.d325.s8|13-14|or|O
DDI-DrugBank.d325.s8|16-50|halogenated hydrocarbon anesthetics|group
DDI-DrugBank.d325.s8|52-59|increase|O
DDI-DrugBank.d325.s8|61-67|cardiac|O
DDI-DrugBank.d325.s8|69-77|autonomic|O
DDI-DrugBank.d325.s8|79-90|irritability|O
DDI-DrugBank.d325.s8|92-94|and|O
DDI-DrugBank.d325.s8|96-98|may|O
DDI-DrugBank.d325.s8|100-108|sensitize|O
DDI-DrugBank.d325.s8|110-112|the|O
DDI-DrugBank.d325.s8|114-123|myocardium|O
DDI-DrugBank.d325.s8|125-126|to|O
DDI-DrugBank.d325.s8|128-130|the|O
DDI-DrugBank.d325.s8|132-137|action|O
DDI-DrugBank.d325.s8|139-140|of|O
DDI-DrugBank.d325.s8|142-148|certain|O
DDI-DrugBank.d325.s8|150-162|intravenously|O
DDI-DrugBank.d325.s8|164-175|administered|O
DDI-DrugBank.d325.s8|177-190|catecholamines|group
DDI-DrugBank.d325.s8|191-191|,|O
DDI-DrugBank.d325.s8|193-196|such|O
DDI-DrugBank.d325.s8|198-199|as|O
DDI-DrugBank.d325.s8|201-208|dopamine|drug
DDI-DrugBank.d325.s8|209-209|.|O
DDI-DrugBank.d325.s9|0-3|This|O
DDI-DrugBank.d325.s9|5-15|interaction|O
DDI-DrugBank.d325.s9|17-23|appears|O
DDI-DrugBank.d325.s9|25-26|to|O
DDI-DrugBank.d325.s9|28-29|be|O
DDI-DrugBank.d325.s9|31-37|related|O
DDI-DrugBank.d325.s9|39-42|both|O
DDI-DrugBank.d325.s9|44-45|to|O
DDI-DrugBank.d325.s9|47-53|pressor|O
DDI-DrugBank.d325.s9|55-62|activity|O
DDI-DrugBank.d325.s9|64-66|and|O
DDI-DrugBank.d325.s9|68-69|to|O
DDI-DrugBank.d325.s9|71-85|beta-adrenergic|O
DDI-DrugBank.d325.s9|87-97|stimulating|O
DDI-DrugBank.d325.s9|99-108|properties|O
DDI-DrugBank.d325.s9|110-111|of|O
DDI-DrugBank.d325.s9|113-117|these|O
DDI-DrugBank.d325.s9|119-132|catecholamines|group
DDI-DrugBank.d325.s9|134-136|and|O
DDI-DrugBank.d325.s9|138-140|may|O
DDI-DrugBank.d325.s9|142-148|produce|O
DDI-DrugBank.d325.s9|150-160|ventricular|O
DDI-DrugBank.d325.s9|162-172|arrhythmias|O
DDI-DrugBank.d325.s9|174-176|and|O
DDI-DrugBank.d325.s9|178-189|hypertension|O
DDI-DrugBank.d325.s9|190-190|.|O
DDI-DrugBank.d325.s10|0-8|Therefore|O
DDI-DrugBank.d325.s10|9-9|,|O
DDI-DrugBank.d325.s10|11-17|EXTREME|O
DDI-DrugBank.d325.s10|19-25|CAUTION|O
DDI-DrugBank.d325.s10|27-32|should|O
DDI-DrugBank.d325.s10|34-35|be|O
DDI-DrugBank.d325.s10|37-45|exercised|O
DDI-DrugBank.d325.s10|47-50|when|O
DDI-DrugBank.d325.s10|52-64|administering|O
DDI-DrugBank.d325.s10|66-77|dopamine HCl|drug
DDI-DrugBank.d325.s10|79-80|to|O
DDI-DrugBank.d325.s10|82-89|patients|O
DDI-DrugBank.d325.s10|91-99|receiving|O
DDI-DrugBank.d325.s10|101-112|cyclopropane|drug
DDI-DrugBank.d325.s10|114-115|or|O
DDI-DrugBank.d325.s10|117-151|halogenated hydrocarbon anesthetics|group
DDI-DrugBank.d325.s10|152-152|.|O
DDI-DrugBank.d325.s11|0-1|It|O
DDI-DrugBank.d325.s11|3-5|has|O
DDI-DrugBank.d325.s11|7-10|been|O
DDI-DrugBank.d325.s11|12-19|reported|O
DDI-DrugBank.d325.s11|21-24|that|O
DDI-DrugBank.d325.s11|26-32|results|O
DDI-DrugBank.d325.s11|34-35|of|O
DDI-DrugBank.d325.s11|37-43|studies|O
DDI-DrugBank.d325.s11|45-46|in|O
DDI-DrugBank.d325.s11|48-54|animals|O
DDI-DrugBank.d325.s11|56-63|indicate|O
DDI-DrugBank.d325.s11|65-68|that|O
DDI-DrugBank.d325.s11|70-85|dopamine-induced|drug
DDI-DrugBank.d325.s11|87-97|ventricular|O
DDI-DrugBank.d325.s11|99-109|arrhythmias|O
DDI-DrugBank.d325.s11|111-116|during|O
DDI-DrugBank.d325.s11|118-127|anesthesia|O
DDI-DrugBank.d325.s11|129-131|can|O
DDI-DrugBank.d325.s11|133-134|be|O
DDI-DrugBank.d325.s11|136-143|reversed|O
DDI-DrugBank.d325.s11|145-146|by|O
DDI-DrugBank.d325.s11|148-158|propranolol|drug
DDI-DrugBank.d325.s11|159-159|.|O
DDI-DrugBank.d325.s12|0-2|The|O
DDI-DrugBank.d325.s12|4-14|concomitant|O
DDI-DrugBank.d325.s12|16-18|use|O
DDI-DrugBank.d325.s12|20-21|of|O
DDI-DrugBank.d325.s12|23-34|vasopressors|group
DDI-DrugBank.d325.s12|35-35|,|O
DDI-DrugBank.d325.s12|37-52|vasoconstricting|O
DDI-DrugBank.d325.s12|54-59|agents|O
DDI-DrugBank.d325.s12|61-61|(|O
DDI-DrugBank.d325.s12|62-65|such|O
DDI-DrugBank.d325.s12|67-68|as|O
DDI-DrugBank.d325.s12|70-79|ergonovine|drug
DDI-DrugBank.d325.s12|80-80|)|O
DDI-DrugBank.d325.s12|82-84|and|O
DDI-DrugBank.d325.s12|86-89|some|O
DDI-DrugBank.d325.s12|91-104|oxytocic drugs|group
DDI-DrugBank.d325.s12|106-108|may|O
DDI-DrugBank.d325.s12|110-115|result|O
DDI-DrugBank.d325.s12|117-118|in|O
DDI-DrugBank.d325.s12|120-125|severe|O
DDI-DrugBank.d325.s12|127-138|hypertension|O
DDI-DrugBank.d325.s12|139-139|.|O
DDI-DrugBank.d325.s13|0-13|Administration|O
DDI-DrugBank.d325.s13|15-16|of|O
DDI-DrugBank.d325.s13|18-26|phenytoin|drug
DDI-DrugBank.d325.s13|28-29|to|O
DDI-DrugBank.d325.s13|31-38|patients|O
DDI-DrugBank.d325.s13|40-48|receiving|O
DDI-DrugBank.d325.s13|50-61|dopamine HCl|drug
DDI-DrugBank.d325.s13|63-65|has|O
DDI-DrugBank.d325.s13|67-70|been|O
DDI-DrugBank.d325.s13|72-79|reported|O
DDI-DrugBank.d325.s13|81-82|to|O
DDI-DrugBank.d325.s13|84-87|lead|O
DDI-DrugBank.d325.s13|89-90|to|O
DDI-DrugBank.d325.s13|92-102|hypotension|O
DDI-DrugBank.d325.s13|104-106|and|O
DDI-DrugBank.d325.s13|108-118|bradycardia|O
DDI-DrugBank.d325.s13|119-119|.|O
DDI-DrugBank.d325.s14|0-1|It|O
DDI-DrugBank.d325.s14|3-4|is|O
DDI-DrugBank.d325.s14|6-14|suggested|O
DDI-DrugBank.d325.s14|16-19|that|O
DDI-DrugBank.d325.s14|21-22|in|O
DDI-DrugBank.d325.s14|24-31|patients|O
DDI-DrugBank.d325.s14|33-41|receiving|O
DDI-DrugBank.d325.s14|43-54|dopamine HCl|drug
DDI-DrugBank.d325.s14|55-55|,|O
DDI-DrugBank.d325.s14|57-68|alternatives|O
DDI-DrugBank.d325.s14|70-71|to|O
DDI-DrugBank.d325.s14|73-81|phenytoin|drug
DDI-DrugBank.d325.s14|83-88|should|O
DDI-DrugBank.d325.s14|90-91|be|O
DDI-DrugBank.d325.s14|93-96|used|O
DDI-DrugBank.d325.s14|98-99|if|O
DDI-DrugBank.d325.s14|101-114|anticonvulsant|group
DDI-DrugBank.d325.s14|116-122|therapy|O
DDI-DrugBank.d325.s14|124-125|is|O
DDI-DrugBank.d325.s14|127-132|needed|O
DDI-DrugBank.d325.s14|133-133|.|O
DDI-DrugBank.d373.s0|0-30|Beta-adrenergic Blocking Agents|group
DDI-DrugBank.d373.s0|31-31|:|O
DDI-DrugBank.d373.s0|33-42|Experience|O
DDI-DrugBank.d373.s0|44-45|in|O
DDI-DrugBank.d373.s0|47-50|over|O
DDI-DrugBank.d373.s0|52-55|1400|O
DDI-DrugBank.d373.s0|57-64|patients|O
DDI-DrugBank.d373.s0|66-67|in|O
DDI-DrugBank.d373.s0|69-69|a|O
DDI-DrugBank.d373.s0|71-85|non-comparative|O
DDI-DrugBank.d373.s0|87-94|clinical|O
DDI-DrugBank.d373.s0|96-100|trial|O
DDI-DrugBank.d373.s0|102-104|has|O
DDI-DrugBank.d373.s0|106-110|shown|O
DDI-DrugBank.d373.s0|112-115|that|O
DDI-DrugBank.d373.s0|117-127|concomitant|O
DDI-DrugBank.d373.s0|129-142|administration|O
DDI-DrugBank.d373.s0|144-145|of|O
DDI-DrugBank.d373.s0|147-156|nifedipine|drug
DDI-DrugBank.d373.s0|158-160|and|O
DDI-DrugBank.d373.s0|162-181|beta-blocking agents|group
DDI-DrugBank.d373.s0|183-184|is|O
DDI-DrugBank.d373.s0|186-192|usually|O
DDI-DrugBank.d373.s0|194-197|well|O
DDI-DrugBank.d373.s0|199-207|tolerated|O
DDI-DrugBank.d373.s0|208-208|,|O
DDI-DrugBank.d373.s0|210-212|but|O
DDI-DrugBank.d373.s0|214-218|there|O
DDI-DrugBank.d373.s0|220-223|have|O
DDI-DrugBank.d373.s0|225-228|been|O
DDI-DrugBank.d373.s0|230-239|occasional|O
DDI-DrugBank.d373.s0|241-250|literature|O
DDI-DrugBank.d373.s0|252-258|reports|O
DDI-DrugBank.d373.s0|260-269|suggesting|O
DDI-DrugBank.d373.s0|271-274|that|O
DDI-DrugBank.d373.s0|276-278|the|O
DDI-DrugBank.d373.s0|280-290|combination|O
DDI-DrugBank.d373.s0|292-294|may|O
DDI-DrugBank.d373.s0|296-303|increase|O
DDI-DrugBank.d373.s0|305-307|the|O
DDI-DrugBank.d373.s0|309-318|likelihood|O
DDI-DrugBank.d373.s0|320-321|of|O
DDI-DrugBank.d373.s0|323-332|congestive|O
DDI-DrugBank.d373.s0|334-338|heart|O
DDI-DrugBank.d373.s0|340-346|failure|O
DDI-DrugBank.d373.s0|347-347|,|O
DDI-DrugBank.d373.s0|349-354|severe|O
DDI-DrugBank.d373.s0|356-366|hypotension|O
DDI-DrugBank.d373.s0|368-369|or|O
DDI-DrugBank.d373.s0|371-382|exacerbation|O
DDI-DrugBank.d373.s0|384-385|of|O
DDI-DrugBank.d373.s0|387-392|angina|O
DDI-DrugBank.d373.s0|393-393|.|O
DDI-DrugBank.d373.s1|0-3|Long|O
DDI-DrugBank.d373.s1|5-10|Acting|O
DDI-DrugBank.d373.s1|12-19|Nitrates|group
DDI-DrugBank.d373.s1|20-20|:|O
DDI-DrugBank.d373.s1|22-31|Nifedipine|drug
DDI-DrugBank.d373.s1|33-35|may|O
DDI-DrugBank.d373.s1|37-38|be|O
DDI-DrugBank.d373.s1|40-45|safely|O
DDI-DrugBank.d373.s1|47-61|co-administered|O
DDI-DrugBank.d373.s1|63-66|with|O
DDI-DrugBank.d373.s1|68-75|nitrates|group
DDI-DrugBank.d373.s1|76-76|,|O
DDI-DrugBank.d373.s1|78-80|but|O
DDI-DrugBank.d373.s1|82-86|there|O
DDI-DrugBank.d373.s1|88-91|have|O
DDI-DrugBank.d373.s1|93-96|been|O
DDI-DrugBank.d373.s1|98-99|no|O
DDI-DrugBank.d373.s1|101-110|controlled|O
DDI-DrugBank.d373.s1|112-118|studies|O
DDI-DrugBank.d373.s1|120-121|to|O
DDI-DrugBank.d373.s1|123-130|evaluate|O
DDI-DrugBank.d373.s1|132-134|the|O
DDI-DrugBank.d373.s1|136-146|antianginal|O
DDI-DrugBank.d373.s1|148-160|effectiveness|O
DDI-DrugBank.d373.s1|162-163|of|O
DDI-DrugBank.d373.s1|165-168|this|O
DDI-DrugBank.d373.s1|170-180|combination|O
DDI-DrugBank.d373.s1|181-181|.|O
DDI-DrugBank.d373.s2|0-8|Digitalis|group
DDI-DrugBank.d373.s2|9-9|:|O
DDI-DrugBank.d373.s2|11-19|Immediate|O
DDI-DrugBank.d373.s2|21-27|Release|O
DDI-DrugBank.d373.s2|29-36|Capsules|O
DDI-DrugBank.d373.s2|37-37|:|O
DDI-DrugBank.d373.s2|39-43|Since|O
DDI-DrugBank.d373.s2|45-49|there|O
DDI-DrugBank.d373.s2|51-54|have|O
DDI-DrugBank.d373.s2|56-59|been|O
DDI-DrugBank.d373.s2|61-68|isolated|O
DDI-DrugBank.d373.s2|70-76|reports|O
DDI-DrugBank.d373.s2|78-79|of|O
DDI-DrugBank.d373.s2|81-88|patients|O
DDI-DrugBank.d373.s2|90-93|with|O
DDI-DrugBank.d373.s2|95-102|elevated|O
DDI-DrugBank.d373.s2|104-110|digoxin|drug
DDI-DrugBank.d373.s2|112-117|levels|O
DDI-DrugBank.d373.s2|118-118|,|O
DDI-DrugBank.d373.s2|120-122|and|O
DDI-DrugBank.d373.s2|124-128|there|O
DDI-DrugBank.d373.s2|130-131|is|O
DDI-DrugBank.d373.s2|133-133|a|O
DDI-DrugBank.d373.s2|135-142|possible|O
DDI-DrugBank.d373.s2|144-154|interaction|O
DDI-DrugBank.d373.s2|156-162|between|O
DDI-DrugBank.d373.s2|164-170|digoxin|drug
DDI-DrugBank.d373.s2|172-174|and|O
DDI-DrugBank.d373.s2|176-185|nifedipine|drug
DDI-DrugBank.d373.s2|186-186|,|O
DDI-DrugBank.d373.s2|188-189|it|O
DDI-DrugBank.d373.s2|191-192|is|O
DDI-DrugBank.d373.s2|194-204|recommended|O
DDI-DrugBank.d373.s2|206-209|that|O
DDI-DrugBank.d373.s2|211-217|digoxin|drug
DDI-DrugBank.d373.s2|219-224|levels|O
DDI-DrugBank.d373.s2|226-227|be|O
DDI-DrugBank.d373.s2|229-237|monitored|O
DDI-DrugBank.d373.s2|239-242|when|O
DDI-DrugBank.d373.s2|244-253|initiating|O
DDI-DrugBank.d373.s2|254-254|,|O
DDI-DrugBank.d373.s2|256-264|adjusting|O
DDI-DrugBank.d373.s2|265-265|,|O
DDI-DrugBank.d373.s2|267-269|and|O
DDI-DrugBank.d373.s2|271-283|discontinuing|O
DDI-DrugBank.d373.s2|285-294|nifedipine|drug
DDI-DrugBank.d373.s2|296-297|to|O
DDI-DrugBank.d373.s2|299-303|avoid|O
DDI-DrugBank.d373.s2|305-312|possible|O
DDI-DrugBank.d373.s2|314-318|over-|O
DDI-DrugBank.d373.s2|320-321|or|O
DDI-DrugBank.d373.s2|323-342|under-digitalization|O
DDI-DrugBank.d373.s2|343-343|.|O
DDI-DrugBank.d373.s3|0-7|Extended|O
DDI-DrugBank.d373.s3|9-15|Release|O
DDI-DrugBank.d373.s3|17-23|Tablets|O
DDI-DrugBank.d373.s3|24-24|:|O
DDI-DrugBank.d373.s3|26-39|Administration|O
DDI-DrugBank.d373.s3|41-42|of|O
DDI-DrugBank.d373.s3|44-53|nifedipine|drug
DDI-DrugBank.d373.s3|55-58|with|O
DDI-DrugBank.d373.s3|60-66|digoxin|drug
DDI-DrugBank.d373.s3|68-76|increased|O
DDI-DrugBank.d373.s3|78-84|digoxin|drug
DDI-DrugBank.d373.s3|86-91|levels|O
DDI-DrugBank.d373.s3|93-94|in|O
DDI-DrugBank.d373.s3|96-96|9|O
DDI-DrugBank.d373.s3|98-99|of|O
DDI-DrugBank.d373.s3|101-102|12|O
DDI-DrugBank.d373.s3|104-109|normal|O
DDI-DrugBank.d373.s3|111-120|volunteers|O
DDI-DrugBank.d373.s3|121-121|.|O
DDI-DrugBank.d373.s4|0-2|The|O
DDI-DrugBank.d373.s4|4-10|average|O
DDI-DrugBank.d373.s4|12-19|increase|O
DDI-DrugBank.d373.s4|21-23|was|O
DDI-DrugBank.d373.s4|25-26|45|O
DDI-DrugBank.d373.s4|27-27|%|O
DDI-DrugBank.d373.s4|28-28|.|O
DDI-DrugBank.d373.s5|0-6|Another|O
DDI-DrugBank.d373.s5|8-19|investigator|O
DDI-DrugBank.d373.s5|21-25|found|O
DDI-DrugBank.d373.s5|27-28|no|O
DDI-DrugBank.d373.s5|30-37|increase|O
DDI-DrugBank.d373.s5|39-40|in|O
DDI-DrugBank.d373.s5|42-48|digoxin|drug
DDI-DrugBank.d373.s5|50-55|levels|O
DDI-DrugBank.d373.s5|57-58|in|O
DDI-DrugBank.d373.s5|60-61|13|O
DDI-DrugBank.d373.s5|63-70|patients|O
DDI-DrugBank.d373.s5|72-75|with|O
DDI-DrugBank.d373.s5|77-84|coronary|O
DDI-DrugBank.d373.s5|86-91|artery|O
DDI-DrugBank.d373.s5|93-99|disease|O
DDI-DrugBank.d373.s5|100-100|.|O
DDI-DrugBank.d373.s6|0-1|In|O
DDI-DrugBank.d373.s6|3-4|an|O
DDI-DrugBank.d373.s6|6-17|uncontrolled|O
DDI-DrugBank.d373.s6|19-23|study|O
DDI-DrugBank.d373.s6|25-26|of|O
DDI-DrugBank.d373.s6|28-31|over|O
DDI-DrugBank.d373.s6|33-35|200|O
DDI-DrugBank.d373.s6|37-44|patients|O
DDI-DrugBank.d373.s6|46-49|with|O
DDI-DrugBank.d373.s6|51-60|congestive|O
DDI-DrugBank.d373.s6|62-66|heart|O
DDI-DrugBank.d373.s6|68-74|failure|O
DDI-DrugBank.d373.s6|76-81|during|O
DDI-DrugBank.d373.s6|83-87|which|O
DDI-DrugBank.d373.s6|89-95|digoxin|drug
DDI-DrugBank.d373.s6|97-101|blood|O
DDI-DrugBank.d373.s6|103-108|levels|O
DDI-DrugBank.d373.s6|110-113|were|O
DDI-DrugBank.d373.s6|115-117|not|O
DDI-DrugBank.d373.s6|119-126|measured|O
DDI-DrugBank.d373.s6|127-127|,|O
DDI-DrugBank.d373.s6|129-137|digitalis|O
DDI-DrugBank.d373.s6|139-146|toxicity|O
DDI-DrugBank.d373.s6|148-150|was|O
DDI-DrugBank.d373.s6|152-154|not|O
DDI-DrugBank.d373.s6|156-163|observed|O
DDI-DrugBank.d373.s6|164-164|.|O
DDI-DrugBank.d373.s7|0-4|Since|O
DDI-DrugBank.d373.s7|6-10|there|O
DDI-DrugBank.d373.s7|12-15|have|O
DDI-DrugBank.d373.s7|17-20|been|O
DDI-DrugBank.d373.s7|22-29|isolated|O
DDI-DrugBank.d373.s7|31-37|reports|O
DDI-DrugBank.d373.s7|39-40|of|O
DDI-DrugBank.d373.s7|42-49|patients|O
DDI-DrugBank.d373.s7|51-54|with|O
DDI-DrugBank.d373.s7|56-63|elevated|O
DDI-DrugBank.d373.s7|65-71|digoxin|drug
DDI-DrugBank.d373.s7|73-78|levels|O
DDI-DrugBank.d373.s7|79-79|,|O
DDI-DrugBank.d373.s7|81-82|it|O
DDI-DrugBank.d373.s7|84-85|is|O
DDI-DrugBank.d373.s7|87-97|recommended|O
DDI-DrugBank.d373.s7|99-102|that|O
DDI-DrugBank.d373.s7|104-110|digoxin|drug
DDI-DrugBank.d373.s7|112-117|levels|O
DDI-DrugBank.d373.s7|119-120|be|O
DDI-DrugBank.d373.s7|122-130|monitored|O
DDI-DrugBank.d373.s7|132-135|when|O
DDI-DrugBank.d373.s7|137-146|initiating|O
DDI-DrugBank.d373.s7|147-147|,|O
DDI-DrugBank.d373.s7|149-157|adjusting|O
DDI-DrugBank.d373.s7|158-158|,|O
DDI-DrugBank.d373.s7|160-162|and|O
DDI-DrugBank.d373.s7|164-176|discontinuing|O
DDI-DrugBank.d373.s7|178-187|nifedipine|drug
DDI-DrugBank.d373.s7|189-190|to|O
DDI-DrugBank.d373.s7|192-196|avoid|O
DDI-DrugBank.d373.s7|198-205|possible|O
DDI-DrugBank.d373.s7|207-211|over-|O
DDI-DrugBank.d373.s7|213-214|or|O
DDI-DrugBank.d373.s7|216-235|under-digitalization|O
DDI-DrugBank.d373.s7|236-236|.|O
DDI-DrugBank.d373.s8|0-8|Quinidine|drug
DDI-DrugBank.d373.s8|9-9|:|O
DDI-DrugBank.d373.s8|11-19|Immediate|O
DDI-DrugBank.d373.s8|21-27|Release|O
DDI-DrugBank.d373.s8|29-36|Capsules|O
DDI-DrugBank.d373.s8|37-37|:|O
DDI-DrugBank.d373.s8|39-43|There|O
DDI-DrugBank.d373.s8|45-48|have|O
DDI-DrugBank.d373.s8|50-53|been|O
DDI-DrugBank.d373.s8|55-58|rare|O
DDI-DrugBank.d373.s8|60-66|reports|O
DDI-DrugBank.d373.s8|68-69|of|O
DDI-DrugBank.d373.s8|71-72|an|O
DDI-DrugBank.d373.s8|74-84|interaction|O
DDI-DrugBank.d373.s8|86-92|between|O
DDI-DrugBank.d373.s8|94-102|quinidine|drug
DDI-DrugBank.d373.s8|104-106|and|O
DDI-DrugBank.d373.s8|108-117|nifedipine|drug
DDI-DrugBank.d373.s8|119-119|(|O
DDI-DrugBank.d373.s8|120-123|with|O
DDI-DrugBank.d373.s8|125-125|a|O
DDI-DrugBank.d373.s8|127-135|decreased|O
DDI-DrugBank.d373.s8|137-142|plasma|O
DDI-DrugBank.d373.s8|144-148|level|O
DDI-DrugBank.d373.s8|150-151|of|O
DDI-DrugBank.d373.s8|153-161|quinidine|drug
DDI-DrugBank.d373.s8|162-162|)|O
DDI-DrugBank.d373.s8|163-163|.|O
DDI-DrugBank.d373.s9|0-22|Coumarin Anticoagulants|group
DDI-DrugBank.d373.s9|23-23|:|O
DDI-DrugBank.d373.s9|25-29|There|O
DDI-DrugBank.d373.s9|31-34|have|O
DDI-DrugBank.d373.s9|36-39|been|O
DDI-DrugBank.d373.s9|41-44|rare|O
DDI-DrugBank.d373.s9|46-52|reports|O
DDI-DrugBank.d373.s9|54-55|of|O
DDI-DrugBank.d373.s9|57-65|increased|O
DDI-DrugBank.d373.s9|67-77|prothrombin|O
DDI-DrugBank.d373.s9|79-82|time|O
DDI-DrugBank.d373.s9|84-85|in|O
DDI-DrugBank.d373.s9|87-94|patients|O
DDI-DrugBank.d373.s9|96-101|taking|O
DDI-DrugBank.d373.s9|103-125|coumarin anticoagulants|group
DDI-DrugBank.d373.s9|127-128|to|O
DDI-DrugBank.d373.s9|130-133|whom|O
DDI-DrugBank.d373.s9|135-144|nifedipine|drug
DDI-DrugBank.d373.s9|146-148|was|O
DDI-DrugBank.d373.s9|150-161|administered|O
DDI-DrugBank.d373.s9|162-162|.|O
DDI-DrugBank.d373.s10|0-6|However|O
DDI-DrugBank.d373.s10|7-7|,|O
DDI-DrugBank.d373.s10|9-11|the|O
DDI-DrugBank.d373.s10|13-24|relationship|O
DDI-DrugBank.d373.s10|26-27|to|O
DDI-DrugBank.d373.s10|29-38|nifedipine|drug
DDI-DrugBank.d373.s10|40-46|therapy|O
DDI-DrugBank.d373.s10|48-49|is|O
DDI-DrugBank.d373.s10|51-59|uncertain|O
DDI-DrugBank.d373.s10|60-60|.|O
DDI-DrugBank.d373.s11|0-9|Cimetidine|drug
DDI-DrugBank.d373.s11|10-10|:|O
DDI-DrugBank.d373.s11|12-12|A|O
DDI-DrugBank.d373.s11|14-18|study|O
DDI-DrugBank.d373.s11|20-21|in|O
DDI-DrugBank.d373.s11|23-23|6|O
DDI-DrugBank.d373.s11|25-31|healthy|O
DDI-DrugBank.d373.s11|33-42|volunteers|O
DDI-DrugBank.d373.s11|44-46|has|O
DDI-DrugBank.d373.s11|48-52|shown|O
DDI-DrugBank.d373.s11|54-54|a|O
DDI-DrugBank.d373.s11|56-66|significant|O
DDI-DrugBank.d373.s11|68-75|increase|O
DDI-DrugBank.d373.s11|77-78|in|O
DDI-DrugBank.d373.s11|80-83|peak|O
DDI-DrugBank.d373.s11|85-94|nifedipine|drug
DDI-DrugBank.d373.s11|96-101|plasma|O
DDI-DrugBank.d373.s11|103-108|levels|O
DDI-DrugBank.d373.s11|110-110|(|O
DDI-DrugBank.d373.s11|111-112|80|O
DDI-DrugBank.d373.s11|113-113|%|O
DDI-DrugBank.d373.s11|114-114|)|O
DDI-DrugBank.d373.s11|116-118|and|O
DDI-DrugBank.d373.s11|120-139|area-under-the-curve|O
DDI-DrugBank.d373.s11|141-141|(|O
DDI-DrugBank.d373.s11|142-143|74|O
DDI-DrugBank.d373.s11|144-144|%|O
DDI-DrugBank.d373.s11|145-145|)|O
DDI-DrugBank.d373.s11|147-151|after|O
DDI-DrugBank.d373.s11|153-153|a|O
DDI-DrugBank.d373.s11|155-155|1|O
DDI-DrugBank.d373.s11|157-160|week|O
DDI-DrugBank.d373.s11|162-167|course|O
DDI-DrugBank.d373.s11|169-170|of|O
DDI-DrugBank.d373.s11|172-181|cimetidine|drug
DDI-DrugBank.d373.s11|183-184|at|O
DDI-DrugBank.d373.s11|186-189|1000|O
DDI-DrugBank.d373.s11|191-192|mg|O
DDI-DrugBank.d373.s11|194-196|per|O
DDI-DrugBank.d373.s11|198-200|day|O
DDI-DrugBank.d373.s11|202-204|and|O
DDI-DrugBank.d373.s11|206-215|nifedipine|drug
DDI-DrugBank.d373.s11|217-218|at|O
DDI-DrugBank.d373.s11|220-221|40|O
DDI-DrugBank.d373.s11|223-224|mg|O
DDI-DrugBank.d373.s11|226-228|per|O
DDI-DrugBank.d373.s11|230-232|day|O
DDI-DrugBank.d373.s11|233-233|.|O
DDI-DrugBank.d373.s12|0-9|Ranitidine|drug
DDI-DrugBank.d373.s12|11-18|produced|O
DDI-DrugBank.d373.s12|20-26|smaller|O
DDI-DrugBank.d373.s12|27-27|,|O
DDI-DrugBank.d373.s12|29-43|non-significant|O
DDI-DrugBank.d373.s12|45-53|increases|O
DDI-DrugBank.d373.s12|54-54|.|O
DDI-DrugBank.d373.s13|0-2|The|O
DDI-DrugBank.d373.s13|4-9|effect|O
DDI-DrugBank.d373.s13|11-13|may|O
DDI-DrugBank.d373.s13|15-16|be|O
DDI-DrugBank.d373.s13|18-25|mediated|O
DDI-DrugBank.d373.s13|27-28|by|O
DDI-DrugBank.d373.s13|30-32|the|O
DDI-DrugBank.d373.s13|34-38|known|O
DDI-DrugBank.d373.s13|40-49|inhibition|O
DDI-DrugBank.d373.s13|51-52|of|O
DDI-DrugBank.d373.s13|54-63|cimetidine|drug
DDI-DrugBank.d373.s13|65-66|on|O
DDI-DrugBank.d373.s13|68-74|hepatic|O
DDI-DrugBank.d373.s13|76-85|cytochrome|O
DDI-DrugBank.d373.s13|87-91|P-450|O
DDI-DrugBank.d373.s13|92-92|,|O
DDI-DrugBank.d373.s13|94-96|the|O
DDI-DrugBank.d373.s13|98-103|enzyme|O
DDI-DrugBank.d373.s13|105-110|system|O
DDI-DrugBank.d373.s13|112-119|probably|O
DDI-DrugBank.d373.s13|121-131|responsible|O
DDI-DrugBank.d373.s13|133-135|for|O
DDI-DrugBank.d373.s13|137-139|the|O
DDI-DrugBank.d373.s13|141-150|first-pass|O
DDI-DrugBank.d373.s13|152-161|metabolism|O
DDI-DrugBank.d373.s13|163-164|of|O
DDI-DrugBank.d373.s13|166-175|nifedipine|drug
DDI-DrugBank.d373.s13|176-176|.|O
DDI-DrugBank.d373.s14|0-1|If|O
DDI-DrugBank.d373.s14|3-12|nifedipine|drug
DDI-DrugBank.d373.s14|14-20|therapy|O
DDI-DrugBank.d373.s14|22-23|is|O
DDI-DrugBank.d373.s14|25-33|initiated|O
DDI-DrugBank.d373.s14|35-36|in|O
DDI-DrugBank.d373.s14|38-38|a|O
DDI-DrugBank.d373.s14|40-46|patient|O
DDI-DrugBank.d373.s14|48-56|currently|O
DDI-DrugBank.d373.s14|58-66|receiving|O
DDI-DrugBank.d373.s14|68-77|cimetidine|drug
DDI-DrugBank.d373.s14|78-78|,|O
DDI-DrugBank.d373.s14|80-87|cautious|O
DDI-DrugBank.d373.s14|89-97|titration|O
DDI-DrugBank.d373.s14|99-100|is|O
DDI-DrugBank.d373.s14|102-108|advised|O
DDI-DrugBank.d373.s14|109-109|.|O
DDI-MedLine.d99.s0|0-10|Fluvoxamine|drug
DDI-MedLine.d99.s0|12-19|inhibits|O
DDI-MedLine.d99.s0|21-23|the|O
DDI-MedLine.d99.s0|25-30|CYP2C9|O
DDI-MedLine.d99.s0|32-40|catalyzed|O
DDI-MedLine.d99.s0|42-58|biotransformation|O
DDI-MedLine.d99.s0|60-61|of|O
DDI-MedLine.d99.s0|63-73|tolbutamide|drug
DDI-MedLine.d99.s0|74-74|.|O
DDI-MedLine.d99.s1|0-8|OBJECTIVE|O
DDI-MedLine.d99.s1|9-9|:|O
DDI-MedLine.d99.s1|11-13|Our|O
DDI-MedLine.d99.s1|15-23|objective|O
DDI-MedLine.d99.s1|25-27|was|O
DDI-MedLine.d99.s1|29-30|to|O
DDI-MedLine.d99.s1|32-38|examine|O
DDI-MedLine.d99.s1|40-42|the|O
DDI-MedLine.d99.s1|44-54|interaction|O
DDI-MedLine.d99.s1|56-62|between|O
DDI-MedLine.d99.s1|64-74|fluvoxamine|drug
DDI-MedLine.d99.s1|76-78|and|O
DDI-MedLine.d99.s1|80-90|tolbutamide|drug
DDI-MedLine.d99.s1|92-93|to|O
DDI-MedLine.d99.s1|95-101|confirm|O
DDI-MedLine.d99.s1|103-106|that|O
DDI-MedLine.d99.s1|108-118|fluvoxamine|drug
DDI-MedLine.d99.s1|120-127|inhibits|O
DDI-MedLine.d99.s1|129-134|CYP2C9|O
DDI-MedLine.d99.s1|135-135|.|O
DDI-MedLine.d99.s2|0-6|METHODS|O
DDI-MedLine.d99.s2|7-7|:|O
DDI-MedLine.d99.s2|9-11|The|O
DDI-MedLine.d99.s2|13-17|study|O
DDI-MedLine.d99.s2|19-21|was|O
DDI-MedLine.d99.s2|23-29|carried|O
DDI-MedLine.d99.s2|31-33|out|O
DDI-MedLine.d99.s2|35-36|as|O
DDI-MedLine.d99.s2|38-39|an|O
DDI-MedLine.d99.s2|41-44|open|O
DDI-MedLine.d99.s2|45-45|,|O
DDI-MedLine.d99.s2|47-56|randomized|O
DDI-MedLine.d99.s2|57-57|,|O
DDI-MedLine.d99.s2|59-67|crossover|O
DDI-MedLine.d99.s2|69-74|design|O
DDI-MedLine.d99.s2|76-79|with|O
DDI-MedLine.d99.s2|81-82|14|O
DDI-MedLine.d99.s2|84-90|healthy|O
DDI-MedLine.d99.s2|92-103|participants|O
DDI-MedLine.d99.s2|104-104|.|O
DDI-MedLine.d99.s3|0-1|In|O
DDI-MedLine.d99.s3|3-8|period|O
DDI-MedLine.d99.s3|10-10|A|O
DDI-MedLine.d99.s3|11-11|,|O
DDI-MedLine.d99.s3|13-15|all|O
DDI-MedLine.d99.s3|17-26|volunteers|O
DDI-MedLine.d99.s3|28-31|took|O
DDI-MedLine.d99.s3|33-35|500|O
DDI-MedLine.d99.s3|37-38|mg|O
DDI-MedLine.d99.s3|40-41|of|O
DDI-MedLine.d99.s3|43-53|tolbutamide|drug
DDI-MedLine.d99.s3|55-60|orally|O
DDI-MedLine.d99.s3|61-61|.|O
DDI-MedLine.d99.s4|0-1|In|O
DDI-MedLine.d99.s4|3-8|period|O
DDI-MedLine.d99.s4|10-10|B|O
DDI-MedLine.d99.s4|11-11|,|O
DDI-MedLine.d99.s4|13-15|the|O
DDI-MedLine.d99.s4|17-26|volunteers|O
DDI-MedLine.d99.s4|28-31|were|O
DDI-MedLine.d99.s4|33-40|randomly|O
DDI-MedLine.d99.s4|42-49|assigned|O
DDI-MedLine.d99.s4|51-52|to|O
DDI-MedLine.d99.s4|54-56|one|O
DDI-MedLine.d99.s4|58-59|of|O
DDI-MedLine.d99.s4|61-63|two|O
DDI-MedLine.d99.s4|65-70|groups|O
DDI-MedLine.d99.s4|71-71|.|O
DDI-MedLine.d99.s5|0-3|Each|O
DDI-MedLine.d99.s5|5-9|group|O
DDI-MedLine.d99.s5|11-14|took|O
DDI-MedLine.d99.s5|16-21|either|O
DDI-MedLine.d99.s5|23-25|150|O
DDI-MedLine.d99.s5|27-28|mg|O
DDI-MedLine.d99.s5|30-31|or|O
DDI-MedLine.d99.s5|33-34|75|O
DDI-MedLine.d99.s5|36-37|mg|O
DDI-MedLine.d99.s5|39-40|of|O
DDI-MedLine.d99.s5|42-52|fluvoxamine|drug
DDI-MedLine.d99.s5|54-54|a|O
DDI-MedLine.d99.s5|56-58|day|O
DDI-MedLine.d99.s5|60-62|for|O
DDI-MedLine.d99.s5|64-64|5|O
DDI-MedLine.d99.s5|66-69|days|O
DDI-MedLine.d99.s5|71-71|(|O
DDI-MedLine.d99.s5|72-74|day|O
DDI-MedLine.d99.s5|76-77|-3|O
DDI-MedLine.d99.s5|79-80|to|O
DDI-MedLine.d99.s5|82-84|day|O
DDI-MedLine.d99.s5|86-86|2|O
DDI-MedLine.d99.s5|87-87|)|O
DDI-MedLine.d99.s5|88-88|.|O
DDI-MedLine.d99.s6|0-2|The|O
DDI-MedLine.d99.s6|4-9|groups|O
DDI-MedLine.d99.s6|11-14|then|O
DDI-MedLine.d99.s6|16-19|took|O
DDI-MedLine.d99.s6|21-23|500|O
DDI-MedLine.d99.s6|25-26|mg|O
DDI-MedLine.d99.s6|28-29|of|O
DDI-MedLine.d99.s6|31-41|tolbutamide|drug
DDI-MedLine.d99.s6|43-44|as|O
DDI-MedLine.d99.s6|46-46|a|O
DDI-MedLine.d99.s6|48-53|single|O
DDI-MedLine.d99.s6|55-58|dose|O
DDI-MedLine.d99.s6|60-60|(|O
DDI-MedLine.d99.s6|61-63|day|O
DDI-MedLine.d99.s6|65-65|0|O
DDI-MedLine.d99.s6|66-66|)|O
DDI-MedLine.d99.s6|67-67|.|O
DDI-MedLine.d99.s7|0-1|In|O
DDI-MedLine.d99.s7|3-6|both|O
DDI-MedLine.d99.s7|8-14|periods|O
DDI-MedLine.d99.s7|15-15|,|O
DDI-MedLine.d99.s7|17-21|blood|O
DDI-MedLine.d99.s7|23-25|and|O
DDI-MedLine.d99.s7|27-31|urine|O
DDI-MedLine.d99.s7|33-36|were|O
DDI-MedLine.d99.s7|38-44|sampled|O
DDI-MedLine.d99.s7|46-47|at|O
DDI-MedLine.d99.s7|49-55|regular|O
DDI-MedLine.d99.s7|57-65|intervals|O
DDI-MedLine.d99.s7|66-66|.|O
DDI-MedLine.d99.s8|0-5|Plasma|O
DDI-MedLine.d99.s8|7-9|was|O
DDI-MedLine.d99.s8|11-18|analyzed|O
DDI-MedLine.d99.s8|20-22|for|O
DDI-MedLine.d99.s8|24-34|tolbutamide|drug
DDI-MedLine.d99.s8|35-35|,|O
DDI-MedLine.d99.s8|37-39|and|O
DDI-MedLine.d99.s8|41-45|urine|O
DDI-MedLine.d99.s8|47-49|was|O
DDI-MedLine.d99.s8|51-58|analyzed|O
DDI-MedLine.d99.s8|60-62|for|O
DDI-MedLine.d99.s8|64-74|tolbutamide|drug
DDI-MedLine.d99.s8|76-78|and|O
DDI-MedLine.d99.s8|80-82|its|O
DDI-MedLine.d99.s8|84-86|two|O
DDI-MedLine.d99.s8|88-98|metabolites|O
DDI-MedLine.d99.s8|99-99|,|O
DDI-MedLine.d99.s8|122-124|and|O
DDI-MedLine.d99.s8|145-146|by|O
DDI-MedLine.d99.s8|148-152|means|O
DDI-MedLine.d99.s8|154-155|of|O
DDI-MedLine.d99.s8|157-160|HPLC|O
DDI-MedLine.d99.s8|161-161|.|O
DDI-MedLine.d99.s9|0-6|RESULTS|O
DDI-MedLine.d99.s9|7-7|:|O
DDI-MedLine.d99.s9|9-14|During|O
DDI-MedLine.d99.s9|16-24|treatment|O
DDI-MedLine.d99.s9|26-29|with|O
DDI-MedLine.d99.s9|31-41|fluvoxamine|drug
DDI-MedLine.d99.s9|42-42|,|O
DDI-MedLine.d99.s9|44-48|there|O
DDI-MedLine.d99.s9|50-52|was|O
DDI-MedLine.d99.s9|54-54|a|O
DDI-MedLine.d99.s9|56-68|statistically|O
DDI-MedLine.d99.s9|70-80|significant|O
DDI-MedLine.d99.s9|82-89|decrease|O
DDI-MedLine.d99.s9|91-92|in|O
DDI-MedLine.d99.s9|94-96|the|O
DDI-MedLine.d99.s9|98-103|median|O
DDI-MedLine.d99.s9|105-106|of|O
DDI-MedLine.d99.s9|108-110|the|O
DDI-MedLine.d99.s9|112-116|total|O
DDI-MedLine.d99.s9|118-126|clearance|O
DDI-MedLine.d99.s9|128-129|of|O
DDI-MedLine.d99.s9|131-141|tolbutamide|drug
DDI-MedLine.d99.s9|142-142|,|O
DDI-MedLine.d99.s9|144-147|from|O
DDI-MedLine.d99.s9|149-151|845|O
DDI-MedLine.d99.s9|153-156|mL/h|O
DDI-MedLine.d99.s9|158-159|to|O
DDI-MedLine.d99.s9|161-163|688|O
DDI-MedLine.d99.s9|165-168|mL/h|O
DDI-MedLine.d99.s9|169-169|,|O
DDI-MedLine.d99.s9|171-175|among|O
DDI-MedLine.d99.s9|177-179|the|O
DDI-MedLine.d99.s9|181-190|volunteers|O
DDI-MedLine.d99.s9|192-194|who|O
DDI-MedLine.d99.s9|196-203|received|O
DDI-MedLine.d99.s9|205-206|75|O
DDI-MedLine.d99.s9|208-211|mg/d|O
DDI-MedLine.d99.s9|212-212|.|O
DDI-MedLine.d99.s10|0-4|There|O
DDI-MedLine.d99.s10|6-8|was|O
DDI-MedLine.d99.s10|10-10|a|O
DDI-MedLine.d99.s10|12-20|reduction|O
DDI-MedLine.d99.s10|22-25|that|O
DDI-MedLine.d99.s10|27-33|reached|O
DDI-MedLine.d99.s10|35-44|borderline|O
DDI-MedLine.d99.s10|46-56|statistical|O
DDI-MedLine.d99.s10|58-69|significance|O
DDI-MedLine.d99.s10|71-72|in|O
DDI-MedLine.d99.s10|74-76|the|O
DDI-MedLine.d99.s10|78-82|group|O
DDI-MedLine.d99.s10|84-87|that|O
DDI-MedLine.d99.s10|89-96|received|O
DDI-MedLine.d99.s10|98-100|150|O
DDI-MedLine.d99.s10|102-105|mg/d|O
DDI-MedLine.d99.s10|107-108|of|O
DDI-MedLine.d99.s10|110-120|tolbutamide|drug
DDI-MedLine.d99.s10|121-121|.|O
DDI-MedLine.d99.s11|0-2|The|O
DDI-MedLine.d99.s11|4-12|clearance|O
DDI-MedLine.d99.s11|14-15|by|O
DDI-MedLine.d99.s11|17-21|means|O
DDI-MedLine.d99.s11|23-24|of|O
DDI-MedLine.d99.s11|47-49|and|O
DDI-MedLine.d99.s11|70-72|was|O
DDI-MedLine.d99.s11|74-86|significantly|O
DDI-MedLine.d99.s11|88-94|reduced|O
DDI-MedLine.d99.s11|96-97|in|O
DDI-MedLine.d99.s11|99-102|both|O
DDI-MedLine.d99.s11|104-109|groups|O
DDI-MedLine.d99.s11|111-111|(|O
DDI-MedLine.d99.s11|112-113|ie|O
DDI-MedLine.d99.s11|114-114|,|O
DDI-MedLine.d99.s11|116-119|from|O
DDI-MedLine.d99.s11|121-123|901|O
DDI-MedLine.d99.s11|125-128|mL/h|O
DDI-MedLine.d99.s11|130-131|to|O
DDI-MedLine.d99.s11|133-135|318|O
DDI-MedLine.d99.s11|137-140|mL/h|O
DDI-MedLine.d99.s11|142-143|in|O
DDI-MedLine.d99.s11|145-147|the|O
DDI-MedLine.d99.s11|149-153|group|O
DDI-MedLine.d99.s11|155-158|that|O
DDI-MedLine.d99.s11|160-167|received|O
DDI-MedLine.d99.s11|169-171|150|O
DDI-MedLine.d99.s11|173-174|mg|O
DDI-MedLine.d99.s11|176-177|of|O
DDI-MedLine.d99.s11|179-189|tolbutamide|drug
DDI-MedLine.d99.s11|191-193|per|O
DDI-MedLine.d99.s11|195-197|day|O
DDI-MedLine.d99.s11|199-201|and|O
DDI-MedLine.d99.s11|203-206|from|O
DDI-MedLine.d99.s11|208-210|723|O
DDI-MedLine.d99.s11|212-215|mL/h|O
DDI-MedLine.d99.s11|217-218|to|O
DDI-MedLine.d99.s11|220-222|457|O
DDI-MedLine.d99.s11|224-227|mL/h|O
DDI-MedLine.d99.s11|229-230|in|O
DDI-MedLine.d99.s11|232-234|the|O
DDI-MedLine.d99.s11|236-240|group|O
DDI-MedLine.d99.s11|242-245|that|O
DDI-MedLine.d99.s11|247-254|received|O
DDI-MedLine.d99.s11|256-257|75|O
DDI-MedLine.d99.s11|259-260|mg|O
DDI-MedLine.d99.s11|262-263|of|O
DDI-MedLine.d99.s11|265-275|tolbutamide|drug
DDI-MedLine.d99.s11|277-279|per|O
DDI-MedLine.d99.s11|281-283|day|O
DDI-MedLine.d99.s11|284-284|)|O
DDI-MedLine.d99.s11|285-285|.|O
DDI-MedLine.d99.s12|0-3|Thus|O
DDI-MedLine.d99.s12|5-9|there|O
DDI-MedLine.d99.s12|11-13|was|O
DDI-MedLine.d99.s12|15-15|a|O
DDI-MedLine.d99.s12|17-24|tendency|O
DDI-MedLine.d99.s12|26-31|toward|O
DDI-MedLine.d99.s12|33-33|a|O
DDI-MedLine.d99.s12|35-38|more|O
DDI-MedLine.d99.s12|40-49|pronounced|O
DDI-MedLine.d99.s12|51-60|inhibition|O
DDI-MedLine.d99.s12|62-63|of|O
DDI-MedLine.d99.s12|65-67|the|O
DDI-MedLine.d99.s12|69-83|4-hydroxylation|O
DDI-MedLine.d99.s12|85-90|during|O
DDI-MedLine.d99.s12|92-100|treatment|O
DDI-MedLine.d99.s12|102-105|with|O
DDI-MedLine.d99.s12|107-109|150|O
DDI-MedLine.d99.s12|111-114|mg/d|O
DDI-MedLine.d99.s12|116-117|of|O
DDI-MedLine.d99.s12|119-129|fluvoxamine|drug
DDI-MedLine.d99.s12|131-138|compared|O
DDI-MedLine.d99.s12|140-143|with|O
DDI-MedLine.d99.s12|145-146|75|O
DDI-MedLine.d99.s12|148-151|mg/d|O
DDI-MedLine.d99.s12|152-152|,|O
DDI-MedLine.d99.s12|154-156|but|O
DDI-MedLine.d99.s12|158-160|the|O
DDI-MedLine.d99.s12|162-171|difference|O
DDI-MedLine.d99.s12|173-175|was|O
DDI-MedLine.d99.s12|177-179|not|O
DDI-MedLine.d99.s12|181-193|statistically|O
DDI-MedLine.d99.s12|195-205|significant|O
DDI-MedLine.d99.s12|206-206|.|O
DDI-MedLine.d99.s13|0-9|CONCLUSION|O
DDI-MedLine.d99.s13|10-10|:|O
DDI-MedLine.d99.s13|12-22|Fluvoxamine|drug
DDI-MedLine.d99.s13|24-25|is|O
DDI-MedLine.d99.s13|27-27|a|O
DDI-MedLine.d99.s13|29-36|moderate|O
DDI-MedLine.d99.s13|38-46|inhibitor|O
DDI-MedLine.d99.s13|48-49|of|O
DDI-MedLine.d99.s13|51-56|CYP2C9|O
DDI-MedLine.d99.s13|58-59|in|O
DDI-MedLine.d99.s13|61-64|vivo|O
DDI-MedLine.d99.s13|65-65|.|O
DDI-MedLine.d214.s0|0-0|[|O
DDI-MedLine.d214.s0|1-9|Influence|O
DDI-MedLine.d214.s0|11-12|of|O
DDI-MedLine.d214.s0|24-26|and|O
DDI-MedLine.d214.s0|28-38|doxycycline|drug
DDI-MedLine.d214.s0|40-41|on|O
DDI-MedLine.d214.s0|43-53|MPTP-evoked|O
DDI-MedLine.d214.s0|55-62|behavior|O
DDI-MedLine.d214.s0|64-73|violations|O
DDI-MedLine.d214.s0|75-76|in|O
DDI-MedLine.d214.s0|78-84|C57BL/6|O
DDI-MedLine.d214.s0|86-89|mice|O
DDI-MedLine.d214.s0|90-90|]|O
DDI-MedLine.d214.s0|91-91|.|O
DDI-MedLine.d214.s1|0-2|The|O
DDI-MedLine.d214.s1|4-10|effects|O
DDI-MedLine.d214.s1|12-13|of|O
DDI-MedLine.d214.s1|15-36|anti-parkinsonian drug|group
DDI-MedLine.d214.s1|48-48|[|O
DDI-MedLine.d214.s1|79-79|]|O
DDI-MedLine.d214.s1|81-81|(|O
DDI-MedLine.d214.s1|82-83|10|O
DDI-MedLine.d214.s1|85-89|mg/kg|O
DDI-MedLine.d214.s1|90-90|,|O
DDI-MedLine.d214.s1|92-93|p.|O
DDI-MedLine.d214.s1|95-95|o|O
DDI-MedLine.d214.s1|96-96|.|O
DDI-MedLine.d214.s1|97-97|)|O
DDI-MedLine.d214.s2|0-5|and/or|O
DDI-MedLine.d214.s2|7-21|antibiotic drug|group
DDI-MedLine.d214.s2|7-21|antibiotic drug|group
DDI-MedLine.d214.s2|35-35|(|O
DDI-MedLine.d214.s2|36-38|100|O
DDI-MedLine.d214.s2|40-44|mg/kg|O
DDI-MedLine.d214.s2|45-45|,|O
DDI-MedLine.d214.s2|47-48|p.|O
DDI-MedLine.d214.s2|50-51|o.|O
DDI-MedLine.d214.s2|52-52|)|O
DDI-MedLine.d214.s2|53-53|,|O
DDI-MedLine.d214.s2|55-56|as|O
DDI-MedLine.d214.s2|58-61|well|O
DDI-MedLine.d214.s2|63-64|as|O
DDI-MedLine.d214.s2|66-69|that|O
DDI-MedLine.d214.s2|71-72|of|O
DDI-MedLine.d214.s2|74-83|neurotoxin|O
DDI-MedLine.d214.s2|130-130|(|O
DDI-MedLine.d214.s2|135-135|)|O
DDI-MedLine.d214.s2|137-137|(|O
DDI-MedLine.d214.s2|138-138|4|O
DDI-MedLine.d214.s2|140-140|x|O
DDI-MedLine.d214.s2|142-143|20|O
DDI-MedLine.d214.s2|145-149|mg/kg|O
DDI-MedLine.d214.s2|150-150|,|O
DDI-MedLine.d214.s2|152-153|i.|O
DDI-MedLine.d214.s2|155-155|p|O
DDI-MedLine.d214.s2|156-156|.|O
DDI-MedLine.d214.s2|157-157|)|O
DDI-MedLine.d214.s3|0-3|were|O
DDI-MedLine.d214.s3|5-11|studied|O
DDI-MedLine.d214.s3|13-14|in|O
DDI-MedLine.d214.s3|16-23|elevated|O
DDI-MedLine.d214.s3|25-28|plus|O
DDI-MedLine.d214.s3|30-33|maze|O
DDI-MedLine.d214.s3|35-38|test|O
DDI-MedLine.d214.s3|40-41|on|O
DDI-MedLine.d214.s3|43-49|C57BL/6|O
DDI-MedLine.d214.s3|51-54|mice|O
DDI-MedLine.d214.s3|55-55|.|O
DDI-MedLine.d214.s4|0-1|On|O
DDI-MedLine.d214.s4|3-8|second|O
DDI-MedLine.d214.s4|10-12|day|O
DDI-MedLine.d214.s4|14-18|after|O
DDI-MedLine.d214.s4|20-28|injection|O
DDI-MedLine.d214.s4|29-29|,|O
DDI-MedLine.d214.s4|36-44|decreased|O
DDI-MedLine.d214.s4|46-48|the|O
DDI-MedLine.d214.s4|50-56|locomot|O
DDI-MedLine.d214.s4|58-59|or|O
DDI-MedLine.d214.s4|61-68|activity|O
DDI-MedLine.d214.s4|70-71|in|O
DDI-MedLine.d214.s4|73-82|comparison|O
DDI-MedLine.d214.s4|84-85|to|O
DDI-MedLine.d214.s4|87-92|saline|O
DDI-MedLine.d214.s4|93-93|.|O
DDI-MedLine.d214.s5|0-4|Acute|O
DDI-MedLine.d214.s5|6-19|administration|O
DDI-MedLine.d214.s5|21-22|of|O
DDI-MedLine.d214.s5|34-35|or|O
DDI-MedLine.d214.s5|37-47|doxycycline|drug
DDI-MedLine.d214.s5|49-54|failed|O
DDI-MedLine.d214.s5|56-57|to|O
DDI-MedLine.d214.s5|59-67|influence|O
DDI-MedLine.d214.s5|69-78|locomotion|O
DDI-MedLine.d214.s5|80-81|in|O
DDI-MedLine.d214.s5|83-86|mice|O
DDI-MedLine.d214.s5|87-87|,|O
DDI-MedLine.d214.s5|89-93|while|O
DDI-MedLine.d214.s5|95-99|their|O
DDI-MedLine.d214.s5|101-111|combination|O
DDI-MedLine.d214.s5|113-122|normalized|O
DDI-MedLine.d214.s5|124-128|motor|O
DDI-MedLine.d214.s5|130-137|activity|O
DDI-MedLine.d214.s5|138-138|.|O
DDI-MedLine.d214.s6|0-2|The|O
DDI-MedLine.d214.s6|4-10|results|O
DDI-MedLine.d214.s6|12-19|obtained|O
DDI-MedLine.d214.s6|21-27|confirm|O
DDI-MedLine.d214.s6|29-31|the|O
DDI-MedLine.d214.s6|33-36|role|O
DDI-MedLine.d214.s6|38-39|of|O
DDI-MedLine.d214.s6|41-52|inflammatory|O
DDI-MedLine.d214.s6|54-62|processes|O
DDI-MedLine.d214.s6|64-65|in|O
DDI-MedLine.d214.s6|67-78|parkinsonism|O
DDI-MedLine.d214.s6|80-82|and|O
DDI-MedLine.d214.s6|84-90|suggest|O
DDI-MedLine.d214.s6|92-101|expediency|O
DDI-MedLine.d214.s6|103-104|of|O
DDI-MedLine.d214.s6|106-113|combined|O
DDI-MedLine.d214.s6|115-129|pharmacotherapy|O
DDI-MedLine.d214.s6|131-132|of|O
DDI-MedLine.d214.s6|134-150|neurodegenerative|O
DDI-MedLine.d214.s6|152-159|diseases|O
DDI-MedLine.d214.s6|160-160|.|O
DDI-DrugBank.d441.s0|0-8|Monoamine|O
DDI-DrugBank.d441.s0|10-16|Oxidase|O
DDI-DrugBank.d441.s0|18-27|Inhibition|O
DDI-DrugBank.d441.s0|28-28|:|O
DDI-DrugBank.d441.s0|30-38|Linezolid|drug
DDI-DrugBank.d441.s0|40-41|is|O
DDI-DrugBank.d441.s0|43-43|a|O
DDI-DrugBank.d441.s0|45-54|reversible|O
DDI-DrugBank.d441.s0|55-55|,|O
DDI-DrugBank.d441.s0|57-68|nonselective|O
DDI-DrugBank.d441.s0|70-78|inhibitor|O
DDI-DrugBank.d441.s0|80-81|of|O
DDI-DrugBank.d441.s0|83-91|monoamine|O
DDI-DrugBank.d441.s0|93-99|oxidase|O
DDI-DrugBank.d441.s0|100-100|.|O
DDI-DrugBank.d441.s1|0-8|Therefore|O
DDI-DrugBank.d441.s1|9-9|,|O
DDI-DrugBank.d441.s1|11-19|linezolid|drug
DDI-DrugBank.d441.s1|21-23|has|O
DDI-DrugBank.d441.s1|25-27|the|O
DDI-DrugBank.d441.s1|29-37|potential|O
DDI-DrugBank.d441.s1|39-41|for|O
DDI-DrugBank.d441.s1|43-53|interaction|O
DDI-DrugBank.d441.s1|55-58|with|O
DDI-DrugBank.d441.s1|60-69|adrenergic|group
DDI-DrugBank.d441.s1|71-73|and|O
DDI-DrugBank.d441.s1|75-93|serotonergic agents|group
DDI-DrugBank.d441.s1|94-94|.|O
DDI-DrugBank.d441.s2|0-16|Adrenergic Agents|group
DDI-DrugBank.d441.s2|17-17|:|O
DDI-DrugBank.d441.s2|18-21|Some|O
DDI-DrugBank.d441.s2|23-33|individuals|O
DDI-DrugBank.d441.s2|35-43|receiving|O
DDI-DrugBank.d441.s2|45-49|ZYVOX|brand
DDI-DrugBank.d441.s2|51-53|may|O
DDI-DrugBank.d441.s2|55-64|experience|O
DDI-DrugBank.d441.s2|66-66|a|O
DDI-DrugBank.d441.s2|68-77|reversible|O
DDI-DrugBank.d441.s2|79-89|enhancement|O
DDI-DrugBank.d441.s2|91-92|of|O
DDI-DrugBank.d441.s2|94-96|the|O
DDI-DrugBank.d441.s2|98-104|pressor|O
DDI-DrugBank.d441.s2|106-113|response|O
DDI-DrugBank.d441.s2|115-116|to|O
DDI-DrugBank.d441.s2|118-132|indirect-acting|O
DDI-DrugBank.d441.s2|134-155|sympathomimetic agents|group
DDI-DrugBank.d441.s2|156-156|,|O
DDI-DrugBank.d441.s2|158-168|vasopressor|group
DDI-DrugBank.d441.s2|170-171|or|O
DDI-DrugBank.d441.s2|173-191|dopaminergic agents|group
DDI-DrugBank.d441.s2|192-192|.|O
DDI-DrugBank.d441.s3|0-7|Commonly|O
DDI-DrugBank.d441.s3|9-12|used|O
DDI-DrugBank.d441.s3|14-18|drugs|O
DDI-DrugBank.d441.s3|20-23|such|O
DDI-DrugBank.d441.s3|25-26|as|O
DDI-DrugBank.d441.s3|28-46|phenylpropanolamine|drug
DDI-DrugBank.d441.s3|48-50|and|O
DDI-DrugBank.d441.s3|52-66|pseudoephedrine|drug
DDI-DrugBank.d441.s3|68-71|have|O
DDI-DrugBank.d441.s3|73-76|been|O
DDI-DrugBank.d441.s3|78-89|specifically|O
DDI-DrugBank.d441.s3|91-97|studied|O
DDI-DrugBank.d441.s3|98-98|.|O
DDI-DrugBank.d441.s4|0-6|Initial|O
DDI-DrugBank.d441.s4|8-12|doses|O
DDI-DrugBank.d441.s4|14-15|of|O
DDI-DrugBank.d441.s4|17-33|adrenergic agents|group
DDI-DrugBank.d441.s4|34-34|,|O
DDI-DrugBank.d441.s4|36-39|such|O
DDI-DrugBank.d441.s4|41-42|as|O
DDI-DrugBank.d441.s4|44-51|dopamine|drug
DDI-DrugBank.d441.s4|53-54|or|O
DDI-DrugBank.d441.s4|56-66|epinephrine|drug
DDI-DrugBank.d441.s4|67-67|,|O
DDI-DrugBank.d441.s4|69-74|should|O
DDI-DrugBank.d441.s4|76-77|be|O
DDI-DrugBank.d441.s4|79-85|reduced|O
DDI-DrugBank.d441.s4|87-89|and|O
DDI-DrugBank.d441.s4|91-98|titrated|O
DDI-DrugBank.d441.s4|100-101|to|O
DDI-DrugBank.d441.s4|103-109|achieve|O
DDI-DrugBank.d441.s4|111-113|the|O
DDI-DrugBank.d441.s4|115-121|desired|O
DDI-DrugBank.d441.s4|123-130|response|O
DDI-DrugBank.d441.s4|131-131|.|O
DDI-DrugBank.d441.s5|0-18|Serotonergic Agents|group
DDI-DrugBank.d441.s5|19-19|:|O
DDI-DrugBank.d441.s5|21-37|Co-administration|O
DDI-DrugBank.d441.s5|39-40|of|O
DDI-DrugBank.d441.s5|42-50|linezolid|drug
DDI-DrugBank.d441.s5|52-54|and|O
DDI-DrugBank.d441.s5|56-74|serotonergic agents|group
DDI-DrugBank.d441.s5|76-78|was|O
DDI-DrugBank.d441.s5|80-82|not|O
DDI-DrugBank.d441.s5|84-93|associated|O
DDI-DrugBank.d441.s5|95-98|with|O
DDI-DrugBank.d441.s5|100-108|serotonin|O
DDI-DrugBank.d441.s5|110-117|syndrome|O
DDI-DrugBank.d441.s5|119-120|in|O
DDI-DrugBank.d441.s5|122-126|Phase|O
DDI-DrugBank.d441.s5|128-128|1|O
DDI-DrugBank.d441.s5|129-129|,|O
DDI-DrugBank.d441.s5|131-131|2|O
DDI-DrugBank.d441.s5|133-134|or|O
DDI-DrugBank.d441.s5|136-136|3|O
DDI-DrugBank.d441.s5|138-144|studies|O
DDI-DrugBank.d441.s5|145-145|.|O
DDI-DrugBank.d441.s6|0-10|Spontaneous|O
DDI-DrugBank.d441.s6|12-18|reports|O
DDI-DrugBank.d441.s6|20-21|of|O
DDI-DrugBank.d441.s6|23-31|serotonin|O
DDI-DrugBank.d441.s6|33-40|syndrome|O
DDI-DrugBank.d441.s6|42-51|associated|O
DDI-DrugBank.d441.s6|53-56|with|O
DDI-DrugBank.d441.s6|58-74|co-administration|O
DDI-DrugBank.d441.s6|76-77|of|O
DDI-DrugBank.d441.s6|79-83|ZYVOX|brand
DDI-DrugBank.d441.s6|85-87|and|O
DDI-DrugBank.d441.s6|89-107|serotonergic agents|group
DDI-DrugBank.d441.s6|108-108|,|O
DDI-DrugBank.d441.s6|110-118|including|O
DDI-DrugBank.d441.s6|120-134|antidepressants|group
DDI-DrugBank.d441.s6|136-139|such|O
DDI-DrugBank.d441.s6|141-142|as|O
DDI-DrugBank.d441.s6|144-182|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d441.s6|184-184|(|O
DDI-DrugBank.d441.s6|185-189|SSRIs|group
DDI-DrugBank.d441.s6|190-190|)|O
DDI-DrugBank.d441.s6|191-191|,|O
DDI-DrugBank.d441.s6|193-196|have|O
DDI-DrugBank.d441.s6|198-201|been|O
DDI-DrugBank.d441.s6|203-210|reported|O
DDI-DrugBank.d441.s6|211-211|.|O
DDI-DrugBank.d441.s7|0-7|Patients|O
DDI-DrugBank.d441.s7|9-11|who|O
DDI-DrugBank.d441.s7|13-15|are|O
DDI-DrugBank.d441.s7|17-23|treated|O
DDI-DrugBank.d441.s7|25-28|with|O
DDI-DrugBank.d441.s7|30-34|ZYVOX|brand
DDI-DrugBank.d441.s7|36-38|and|O
DDI-DrugBank.d441.s7|40-50|concomitant|O
DDI-DrugBank.d441.s7|52-70|serotonergic agents|group
DDI-DrugBank.d441.s7|72-77|should|O
DDI-DrugBank.d441.s7|79-80|be|O
DDI-DrugBank.d441.s7|82-88|closely|O
DDI-DrugBank.d441.s7|90-97|observed|O
DDI-DrugBank.d441.s7|99-101|for|O
DDI-DrugBank.d441.s7|103-107|signs|O
DDI-DrugBank.d441.s7|109-111|and|O
DDI-DrugBank.d441.s7|113-120|symptoms|O
DDI-DrugBank.d441.s7|122-123|of|O
DDI-DrugBank.d441.s7|125-133|serotonin|O
DDI-DrugBank.d441.s7|135-142|syndrome|O
DDI-DrugBank.d441.s7|144-144|(|O
DDI-DrugBank.d441.s7|145-148|e.g.|O
DDI-DrugBank.d441.s7|149-149|,|O
DDI-DrugBank.d441.s7|151-159|cognitive|O
DDI-DrugBank.d441.s7|161-171|dysfunction|O
DDI-DrugBank.d441.s7|172-172|,|O
DDI-DrugBank.d441.s7|174-185|hyperpyrexia|O
DDI-DrugBank.d441.s7|186-186|,|O
DDI-DrugBank.d441.s7|188-200|hyperreflexia|O
DDI-DrugBank.d441.s7|201-201|,|O
DDI-DrugBank.d441.s7|203-216|incoordination|O
DDI-DrugBank.d441.s7|217-217|)|O
DDI-DrugBank.d441.s7|218-218|.|O
DDI-DrugBank.d441.s8|0-1|If|O
DDI-DrugBank.d441.s8|3-5|any|O
DDI-DrugBank.d441.s8|7-11|signs|O
DDI-DrugBank.d441.s8|13-14|or|O
DDI-DrugBank.d441.s8|16-23|symptoms|O
DDI-DrugBank.d441.s8|25-29|occur|O
DDI-DrugBank.d441.s8|31-40|physicians|O
DDI-DrugBank.d441.s8|42-47|should|O
DDI-DrugBank.d441.s8|49-56|consider|O
DDI-DrugBank.d441.s8|58-72|discontinuation|O
DDI-DrugBank.d441.s8|74-75|of|O
DDI-DrugBank.d441.s8|77-82|either|O
DDI-DrugBank.d441.s8|84-86|one|O
DDI-DrugBank.d441.s8|88-89|or|O
DDI-DrugBank.d441.s8|91-94|both|O
DDI-DrugBank.d441.s8|96-101|agents|O
DDI-DrugBank.d441.s8|103-103|(|O
DDI-DrugBank.d441.s8|104-108|ZYVOX|brand
DDI-DrugBank.d441.s8|110-111|or|O
DDI-DrugBank.d441.s8|113-123|concomitant|O
DDI-DrugBank.d441.s8|125-143|serotonergic agents|group
DDI-DrugBank.d441.s8|144-144|)|O
DDI-DrugBank.d441.s8|145-145|.|O
DDI-DrugBank.d441.s9|0-14|Drug-Laboratory|O
DDI-DrugBank.d441.s9|16-19|Test|O
DDI-DrugBank.d441.s9|21-32|Interactions|O
DDI-DrugBank.d441.s9|34-38|There|O
DDI-DrugBank.d441.s9|40-42|are|O
DDI-DrugBank.d441.s9|44-45|no|O
DDI-DrugBank.d441.s9|47-54|reported|O
DDI-DrugBank.d441.s9|56-70|drug-laboratory|O
DDI-DrugBank.d441.s9|72-75|test|O
DDI-DrugBank.d441.s9|77-88|interactions|O
DDI-DrugBank.d441.s9|89-89|.|O
DDI-DrugBank.d783.s0|0-6|Posicor|brand
DDI-DrugBank.d783.s0|8-15|inhibits|O
DDI-DrugBank.d783.s0|17-20|some|O
DDI-DrugBank.d783.s0|22-23|of|O
DDI-DrugBank.d783.s0|25-27|the|O
DDI-DrugBank.d783.s0|29-33|liver|O
DDI-DrugBank.d783.s0|34-35|'s|O
DDI-DrugBank.d783.s0|37-43|ability|O
DDI-DrugBank.d783.s0|45-46|to|O
DDI-DrugBank.d783.s0|48-57|metabolize|O
DDI-DrugBank.d783.s0|59-62|some|O
DDI-DrugBank.d783.s0|64-68|other|O
DDI-DrugBank.d783.s0|70-74|drugs|O
DDI-DrugBank.d783.s0|76-76|-|O
DDI-DrugBank.d783.s0|78-88|terfenadine|drug
DDI-DrugBank.d783.s0|89-89|,|O
DDI-DrugBank.d783.s0|91-100|astemizole|drug
DDI-DrugBank.d783.s0|101-101|,|O
DDI-DrugBank.d783.s0|103-111|cisapride|drug
DDI-DrugBank.d783.s0|112-112|,|O
DDI-DrugBank.d783.s0|114-125|cyclosporine|drug
DDI-DrugBank.d783.s0|126-126|,|O
DDI-DrugBank.d783.s0|128-130|and|O
DDI-DrugBank.d783.s0|132-156|tricyclic antidepressants|group
DDI-DrugBank.d783.s0|157-157|.|O
DDI-DrugBank.d783.s1|0-3|Thus|O
DDI-DrugBank.d783.s1|5-7|the|O
DDI-DrugBank.d783.s1|9-22|concentrations|O
DDI-DrugBank.d783.s1|24-25|of|O
DDI-DrugBank.d783.s1|27-31|these|O
DDI-DrugBank.d783.s1|33-37|drugs|O
DDI-DrugBank.d783.s1|39-43|would|O
DDI-DrugBank.d783.s1|45-52|increase|O
DDI-DrugBank.d783.s1|54-60|meaning|O
DDI-DrugBank.d783.s1|62-65|side|O
DDI-DrugBank.d783.s1|67-73|effects|O
DDI-DrugBank.d783.s1|75-77|may|O
DDI-DrugBank.d783.s1|79-80|be|O
DDI-DrugBank.d783.s1|82-85|seen|O
DDI-DrugBank.d783.s1|86-86|.|O
DDI-DrugBank.d783.s2|0-0|A|O
DDI-DrugBank.d783.s2|2-5|dose|O
DDI-DrugBank.d783.s2|7-16|adjustment|O
DDI-DrugBank.d783.s2|18-20|may|O
DDI-DrugBank.d783.s2|22-23|be|O
DDI-DrugBank.d783.s2|25-32|required|O
DDI-DrugBank.d783.s2|33-33|.|O
DDI-DrugBank.d442.s0|0-8|Increases|O
DDI-DrugBank.d442.s0|10-11|in|O
DDI-DrugBank.d442.s0|13-23|prothrombin|O
DDI-DrugBank.d442.s0|25-28|time|O
DDI-DrugBank.d442.s0|30-33|have|O
DDI-DrugBank.d442.s0|35-38|been|O
DDI-DrugBank.d442.s0|40-44|noted|O
DDI-DrugBank.d442.s0|46-47|in|O
DDI-DrugBank.d442.s0|49-56|patients|O
DDI-DrugBank.d442.s0|58-66|receiving|O
DDI-DrugBank.d442.s0|68-72|long-|O
DDI-DrugBank.d442.s0|74-77|term|O
DDI-DrugBank.d442.s0|79-86|warfarin|drug
DDI-DrugBank.d442.s0|88-94|therapy|O
DDI-DrugBank.d442.s0|96-100|after|O
DDI-DrugBank.d442.s0|102-110|flutamide|drug
DDI-DrugBank.d442.s0|112-114|was|O
DDI-DrugBank.d442.s0|116-124|initiated|O
DDI-DrugBank.d442.s0|125-125|.|O
DDI-DrugBank.d442.s1|0-8|Therefore|O
DDI-DrugBank.d442.s1|9-9|,|O
DDI-DrugBank.d442.s1|11-15|close|O
DDI-DrugBank.d442.s1|17-26|monitoring|O
DDI-DrugBank.d442.s1|28-29|of|O
DDI-DrugBank.d442.s1|31-41|prothrombin|O
DDI-DrugBank.d442.s1|43-46|time|O
DDI-DrugBank.d442.s1|48-49|is|O
DDI-DrugBank.d442.s1|51-61|recommended|O
DDI-DrugBank.d442.s1|63-65|and|O
DDI-DrugBank.d442.s1|67-76|adjustment|O
DDI-DrugBank.d442.s1|78-79|of|O
DDI-DrugBank.d442.s1|81-83|the|O
DDI-DrugBank.d442.s1|85-97|anticoagulant|group
DDI-DrugBank.d442.s1|99-102|dose|O
DDI-DrugBank.d442.s1|104-106|may|O
DDI-DrugBank.d442.s1|108-109|be|O
DDI-DrugBank.d442.s1|111-119|necessary|O
DDI-DrugBank.d442.s1|121-124|when|O
DDI-DrugBank.d442.s1|126-132|EULEXIN|brand
DDI-DrugBank.d442.s1|134-141|Capsules|O
DDI-DrugBank.d442.s1|143-145|are|O
DDI-DrugBank.d442.s1|147-158|administered|O
DDI-DrugBank.d442.s1|160-172|concomitantly|O
DDI-DrugBank.d442.s1|174-177|with|O
DDI-DrugBank.d442.s1|179-186|warfarin|drug
DDI-DrugBank.d442.s1|187-187|.|O
DDI-DrugBank.d244.s0|0-5|Before|O
DDI-DrugBank.d244.s0|7-11|using|O
DDI-DrugBank.d244.s0|13-16|this|O
DDI-DrugBank.d244.s0|18-27|medication|O
DDI-DrugBank.d244.s0|28-28|,|O
DDI-DrugBank.d244.s0|30-33|tell|O
DDI-DrugBank.d244.s0|35-38|your|O
DDI-DrugBank.d244.s0|40-45|doctor|O
DDI-DrugBank.d244.s0|47-48|or|O
DDI-DrugBank.d244.s0|50-59|pharmacist|O
DDI-DrugBank.d244.s0|61-62|of|O
DDI-DrugBank.d244.s0|64-66|all|O
DDI-DrugBank.d244.s0|68-79|prescription|O
DDI-DrugBank.d244.s0|81-83|and|O
DDI-DrugBank.d244.s0|85-99|nonprescription|O
DDI-DrugBank.d244.s0|101-108|products|O
DDI-DrugBank.d244.s0|110-112|you|O
DDI-DrugBank.d244.s0|114-116|may|O
DDI-DrugBank.d244.s0|118-120|use|O
DDI-DrugBank.d244.s0|121-121|,|O
DDI-DrugBank.d244.s0|123-132|especially|O
DDI-DrugBank.d244.s0|134-135|of|O
DDI-DrugBank.d244.s0|136-136|:|O
DDI-DrugBank.d244.s0|138-152|aminoglycosides|group
DDI-DrugBank.d244.s0|154-154|(|O
DDI-DrugBank.d244.s0|155-158|e.g.|O
DDI-DrugBank.d244.s0|159-159|,|O
DDI-DrugBank.d244.s0|161-170|gentamicin|drug
DDI-DrugBank.d244.s0|171-171|,|O
DDI-DrugBank.d244.s0|173-180|amikacin|drug
DDI-DrugBank.d244.s0|181-181|)|O
DDI-DrugBank.d244.s0|182-182|,|O
DDI-DrugBank.d244.s0|184-197|amphotericin B|drug
DDI-DrugBank.d244.s0|198-198|,|O
DDI-DrugBank.d244.s0|200-211|cyclosporine|drug
DDI-DrugBank.d244.s0|212-212|,|O
DDI-DrugBank.d244.s0|214-244|non-steroidal anti-inflammatory|group
DDI-DrugBank.d244.s0|246-250|drugs|O
DDI-DrugBank.d244.s0|252-252|(|O
DDI-DrugBank.d244.s0|253-256|e.g.|O
DDI-DrugBank.d244.s0|257-257|,|O
DDI-DrugBank.d244.s0|259-267|ibuprofen|drug
DDI-DrugBank.d244.s0|268-268|)|O
DDI-DrugBank.d244.s0|269-269|,|O
DDI-DrugBank.d244.s0|271-280|tacrolimus|drug
DDI-DrugBank.d244.s0|281-281|,|O
DDI-DrugBank.d244.s0|283-292|vancomycin|drug
DDI-DrugBank.d244.s0|293-293|.|O
DDI-DrugBank.d244.s1|0-1|Do|O
DDI-DrugBank.d244.s1|3-5|not|O
DDI-DrugBank.d244.s1|7-11|start|O
DDI-DrugBank.d244.s1|13-14|or|O
DDI-DrugBank.d244.s1|16-19|stop|O
DDI-DrugBank.d244.s1|21-23|any|O
DDI-DrugBank.d244.s1|25-32|medicine|O
DDI-DrugBank.d244.s1|34-40|without|O
DDI-DrugBank.d244.s1|42-47|doctor|O
DDI-DrugBank.d244.s1|49-50|or|O
DDI-DrugBank.d244.s1|52-61|pharmacist|O
DDI-DrugBank.d244.s1|63-70|approval|O
DDI-DrugBank.d244.s1|71-71|.|O
DDI-DrugBank.d267.s0|0-4|Prior|O
DDI-DrugBank.d267.s0|6-19|administration|O
DDI-DrugBank.d267.s0|21-22|of|O
DDI-DrugBank.d267.s0|24-38|succinylcholine|drug
DDI-DrugBank.d267.s0|40-42|has|O
DDI-DrugBank.d267.s0|44-45|no|O
DDI-DrugBank.d267.s0|47-56|clinically|O
DDI-DrugBank.d267.s0|58-66|important|O
DDI-DrugBank.d267.s0|68-73|effect|O
DDI-DrugBank.d267.s0|75-76|on|O
DDI-DrugBank.d267.s0|78-80|the|O
DDI-DrugBank.d267.s0|82-94|neuromuscular|O
DDI-DrugBank.d267.s0|96-103|blocking|O
DDI-DrugBank.d267.s0|105-110|action|O
DDI-DrugBank.d267.s0|112-113|of|O
DDI-DrugBank.d267.s0|115-121|NUROMAX|brand
DDI-DrugBank.d267.s0|122-122|.|O
DDI-DrugBank.d267.s1|0-2|The|O
DDI-DrugBank.d267.s1|4-6|use|O
DDI-DrugBank.d267.s1|8-9|of|O
DDI-DrugBank.d267.s1|11-17|NUROMAX|brand
DDI-DrugBank.d267.s1|19-24|before|O
DDI-DrugBank.d267.s1|26-40|succinylcholine|drug
DDI-DrugBank.d267.s1|42-43|to|O
DDI-DrugBank.d267.s1|45-53|attenuate|O
DDI-DrugBank.d267.s1|55-58|some|O
DDI-DrugBank.d267.s1|60-61|of|O
DDI-DrugBank.d267.s1|63-65|the|O
DDI-DrugBank.d267.s1|67-70|side|O
DDI-DrugBank.d267.s1|72-78|effects|O
DDI-DrugBank.d267.s1|80-81|of|O
DDI-DrugBank.d267.s1|83-97|succinylcholine|drug
DDI-DrugBank.d267.s1|99-101|has|O
DDI-DrugBank.d267.s1|103-105|not|O
DDI-DrugBank.d267.s1|107-110|been|O
DDI-DrugBank.d267.s1|112-118|studied|O
DDI-DrugBank.d267.s1|119-119|.|O
DDI-DrugBank.d267.s2|0-4|There|O
DDI-DrugBank.d267.s2|6-8|are|O
DDI-DrugBank.d267.s2|10-11|no|O
DDI-DrugBank.d267.s2|13-20|clinical|O
DDI-DrugBank.d267.s2|22-25|data|O
DDI-DrugBank.d267.s2|27-28|on|O
DDI-DrugBank.d267.s2|30-40|concomitant|O
DDI-DrugBank.d267.s2|42-44|use|O
DDI-DrugBank.d267.s2|46-47|of|O
DDI-DrugBank.d267.s2|49-55|NUROMAX|brand
DDI-DrugBank.d267.s2|57-59|and|O
DDI-DrugBank.d267.s2|61-65|other|O
DDI-DrugBank.d267.s2|67-81|nondepolarizing|O
DDI-DrugBank.d267.s2|83-111|neuromuscular blocking agents|group
DDI-DrugBank.d267.s2|112-112|.|O
DDI-DrugBank.d267.s3|0-9|Isoflurane|drug
DDI-DrugBank.d267.s3|10-10|,|O
DDI-DrugBank.d267.s3|12-20|enflurane|drug
DDI-DrugBank.d267.s3|21-21|,|O
DDI-DrugBank.d267.s3|23-25|and|O
DDI-DrugBank.d267.s3|27-35|halothane|drug
DDI-DrugBank.d267.s3|37-44|decrease|O
DDI-DrugBank.d267.s3|46-48|the|O
DDI-DrugBank.d267.s3|50-53|ED50|O
DDI-DrugBank.d267.s3|55-56|of|O
DDI-DrugBank.d267.s3|58-64|NUROMAX|brand
DDI-DrugBank.d267.s3|66-67|by|O
DDI-DrugBank.d267.s3|69-70|30|O
DDI-DrugBank.d267.s3|71-71|%|O
DDI-DrugBank.d267.s3|73-74|to|O
DDI-DrugBank.d267.s3|76-77|45|O
DDI-DrugBank.d267.s3|78-78|%|O
DDI-DrugBank.d267.s3|79-79|.|O
DDI-DrugBank.d267.s4|0-4|These|O
DDI-DrugBank.d267.s4|6-11|agents|O
DDI-DrugBank.d267.s4|13-15|may|O
DDI-DrugBank.d267.s4|17-20|also|O
DDI-DrugBank.d267.s4|22-28|prolong|O
DDI-DrugBank.d267.s4|30-32|the|O
DDI-DrugBank.d267.s4|34-43|clinically|O
DDI-DrugBank.d267.s4|45-53|effective|O
DDI-DrugBank.d267.s4|55-62|duration|O
DDI-DrugBank.d267.s4|64-65|of|O
DDI-DrugBank.d267.s4|67-72|action|O
DDI-DrugBank.d267.s4|74-75|by|O
DDI-DrugBank.d267.s4|77-78|up|O
DDI-DrugBank.d267.s4|80-81|to|O
DDI-DrugBank.d267.s4|83-84|25|O
DDI-DrugBank.d267.s4|85-85|%|O
DDI-DrugBank.d267.s4|86-86|.|O
DDI-DrugBank.d267.s5|0-4|Other|O
DDI-DrugBank.d267.s5|6-10|drugs|O
DDI-DrugBank.d267.s5|12-16|which|O
DDI-DrugBank.d267.s5|18-20|may|O
DDI-DrugBank.d267.s5|22-28|enhance|O
DDI-DrugBank.d267.s5|30-32|the|O
DDI-DrugBank.d267.s5|34-46|neuromuscular|O
DDI-DrugBank.d267.s5|48-55|blocking|O
DDI-DrugBank.d267.s5|57-62|action|O
DDI-DrugBank.d267.s5|64-65|of|O
DDI-DrugBank.d267.s5|67-81|nondepolarizing|O
DDI-DrugBank.d267.s5|83-88|agents|O
DDI-DrugBank.d267.s5|90-93|such|O
DDI-DrugBank.d267.s5|95-96|as|O
DDI-DrugBank.d267.s5|98-104|NUROMAX|brand
DDI-DrugBank.d267.s5|106-112|include|O
DDI-DrugBank.d267.s5|114-120|certain|O
DDI-DrugBank.d267.s5|122-132|antibiotics|group
DDI-DrugBank.d267.s5|134-134|(|O
DDI-DrugBank.d267.s5|135-136|e.|O
DDI-DrugBank.d267.s5|138-139|g.|O
DDI-DrugBank.d267.s5|140-140|,|O
DDI-DrugBank.d267.s5|142-156|aminoglycosides|group
DDI-DrugBank.d267.s5|157-157|,|O
DDI-DrugBank.d267.s5|159-171|tetracyclines|group
DDI-DrugBank.d267.s5|172-172|,|O
DDI-DrugBank.d267.s5|174-183|bacitracin|group
DDI-DrugBank.d267.s5|184-184|,|O
DDI-DrugBank.d267.s5|186-195|polymyxins|group
DDI-DrugBank.d267.s5|196-196|,|O
DDI-DrugBank.d267.s5|198-207|lincomycin|drug
DDI-DrugBank.d267.s5|208-208|,|O
DDI-DrugBank.d267.s5|210-220|clindamycin|drug
DDI-DrugBank.d267.s5|221-221|,|O
DDI-DrugBank.d267.s5|223-230|colistin|drug
DDI-DrugBank.d267.s5|231-231|,|O
DDI-DrugBank.d267.s5|233-235|and|O
DDI-DrugBank.d267.s5|237-257|sodium colistimethate|drug
DDI-DrugBank.d267.s5|258-258|)|O
DDI-DrugBank.d267.s5|259-259|,|O
DDI-DrugBank.d267.s5|261-269|magnesium|drug
DDI-DrugBank.d267.s5|271-275|salts|O
DDI-DrugBank.d267.s5|276-276|,|O
DDI-DrugBank.d267.s5|278-284|lithium|drug
DDI-DrugBank.d267.s5|285-285|,|O
DDI-DrugBank.d267.s5|287-291|local|O
DDI-DrugBank.d267.s5|293-303|anesthetics|group
DDI-DrugBank.d267.s5|304-304|,|O
DDI-DrugBank.d267.s5|306-317|procainamide|drug
DDI-DrugBank.d267.s5|318-318|,|O
DDI-DrugBank.d267.s5|320-322|and|O
DDI-DrugBank.d267.s5|324-332|quinidine|drug
DDI-DrugBank.d267.s5|333-333|.|O
DDI-DrugBank.d267.s6|0-1|As|O
DDI-DrugBank.d267.s6|3-6|with|O
DDI-DrugBank.d267.s6|8-11|some|O
DDI-DrugBank.d267.s6|13-17|other|O
DDI-DrugBank.d267.s6|19-63|nondepolarizing neuromuscular blocking agents|group
DDI-DrugBank.d267.s6|64-64|,|O
DDI-DrugBank.d267.s6|66-68|the|O
DDI-DrugBank.d267.s6|70-73|time|O
DDI-DrugBank.d267.s6|75-76|of|O
DDI-DrugBank.d267.s6|78-82|onset|O
DDI-DrugBank.d267.s6|84-85|of|O
DDI-DrugBank.d267.s6|87-99|neuromuscular|O
DDI-DrugBank.d267.s6|101-105|block|O
DDI-DrugBank.d267.s6|107-113|induced|O
DDI-DrugBank.d267.s6|115-116|by|O
DDI-DrugBank.d267.s6|118-124|NUROMAX|brand
DDI-DrugBank.d267.s6|126-127|is|O
DDI-DrugBank.d267.s6|129-138|lengthened|O
DDI-DrugBank.d267.s6|140-142|and|O
DDI-DrugBank.d267.s6|144-146|the|O
DDI-DrugBank.d267.s6|148-155|duration|O
DDI-DrugBank.d267.s6|157-158|of|O
DDI-DrugBank.d267.s6|160-164|block|O
DDI-DrugBank.d267.s6|166-167|is|O
DDI-DrugBank.d267.s6|169-177|shortened|O
DDI-DrugBank.d267.s6|179-180|in|O
DDI-DrugBank.d267.s6|182-189|patients|O
DDI-DrugBank.d267.s6|191-199|receiving|O
DDI-DrugBank.d267.s6|201-209|phenytoin|drug
DDI-DrugBank.d267.s6|211-212|or|O
DDI-DrugBank.d267.s6|214-226|carbamazepine|drug
DDI-DrugBank.d267.s6|227-227|.|O
DDI-DrugBank.d198.s0|0-5|Effect|O
DDI-DrugBank.d198.s0|7-8|of|O
DDI-DrugBank.d198.s0|10-14|other|O
DDI-DrugBank.d198.s0|16-20|drugs|O
DDI-DrugBank.d198.s0|22-23|on|O
DDI-DrugBank.d198.s1|0-1|In|O
DDI-DrugBank.d198.s1|3-7|vitro|O
DDI-DrugBank.d198.s1|9-15|studies|O
DDI-DrugBank.d198.s1|16-16|:|O
DDI-DrugBank.d198.s1|18-24|Studies|O
DDI-DrugBank.d198.s1|26-27|in|O
DDI-DrugBank.d198.s1|29-33|human|O
DDI-DrugBank.d198.s1|35-39|liver|O
DDI-DrugBank.d198.s1|41-50|microsomes|O
DDI-DrugBank.d198.s1|52-57|showed|O
DDI-DrugBank.d198.s1|59-62|that|O
DDI-DrugBank.d198.s1|64-73|vardenafil|drug
DDI-DrugBank.d198.s1|75-76|is|O
DDI-DrugBank.d198.s1|78-88|metabolized|O
DDI-DrugBank.d198.s1|90-98|primarily|O
DDI-DrugBank.d198.s1|100-101|by|O
DDI-DrugBank.d198.s1|103-112|cytochrome|O
DDI-DrugBank.d198.s1|114-117|P450|O
DDI-DrugBank.d198.s1|119-119|(|O
DDI-DrugBank.d198.s1|120-122|CYP|O
DDI-DrugBank.d198.s1|123-123|)|O
DDI-DrugBank.d198.s1|125-132|isoforms|O
DDI-DrugBank.d198.s1|134-138|3A4/5|O
DDI-DrugBank.d198.s1|139-139|,|O
DDI-DrugBank.d198.s1|141-143|and|O
DDI-DrugBank.d198.s1|145-146|to|O
DDI-DrugBank.d198.s1|148-148|a|O
DDI-DrugBank.d198.s1|150-155|lesser|O
DDI-DrugBank.d198.s1|157-162|degree|O
DDI-DrugBank.d198.s1|164-165|by|O
DDI-DrugBank.d198.s1|167-172|CYP2C9|O
DDI-DrugBank.d198.s1|173-173|.|O
DDI-DrugBank.d198.s2|0-8|Therefore|O
DDI-DrugBank.d198.s2|9-9|,|O
DDI-DrugBank.d198.s2|11-20|inhibitors|O
DDI-DrugBank.d198.s2|22-23|of|O
DDI-DrugBank.d198.s2|25-29|these|O
DDI-DrugBank.d198.s2|31-37|enzymes|O
DDI-DrugBank.d198.s2|39-41|are|O
DDI-DrugBank.d198.s2|43-50|expected|O
DDI-DrugBank.d198.s2|52-53|to|O
DDI-DrugBank.d198.s2|55-60|reduce|O
DDI-DrugBank.d198.s2|62-71|vardenafil|drug
DDI-DrugBank.d198.s2|73-81|clearance|O
DDI-DrugBank.d198.s2|82-82|.|O
DDI-DrugBank.d198.s3|0-1|In|O
DDI-DrugBank.d198.s3|3-6|vivo|O
DDI-DrugBank.d198.s3|8-14|studies|O
DDI-DrugBank.d198.s3|15-15|:|O
DDI-DrugBank.d198.s3|17-26|Cytochrome|O
DDI-DrugBank.d198.s3|28-31|P450|O
DDI-DrugBank.d198.s3|33-42|Inhibitors|O
DDI-DrugBank.d198.s4|0-9|Cimetidine|drug
DDI-DrugBank.d198.s4|11-11|(|O
DDI-DrugBank.d198.s4|12-14|400|O
DDI-DrugBank.d198.s4|16-17|mg|O
DDI-DrugBank.d198.s4|19-24|b.i.d.|O
DDI-DrugBank.d198.s4|25-25|)|O
DDI-DrugBank.d198.s4|27-29|had|O
DDI-DrugBank.d198.s4|31-32|no|O
DDI-DrugBank.d198.s4|34-39|effect|O
DDI-DrugBank.d198.s4|41-42|on|O
DDI-DrugBank.d198.s4|44-53|vardenafil|drug
DDI-DrugBank.d198.s4|55-69|bioavailability|O
DDI-DrugBank.d198.s4|71-71|(|O
DDI-DrugBank.d198.s4|72-74|AUC|O
DDI-DrugBank.d198.s4|75-75|)|O
DDI-DrugBank.d198.s4|77-79|and|O
DDI-DrugBank.d198.s4|81-87|maximum|O
DDI-DrugBank.d198.s4|89-101|concentration|O
DDI-DrugBank.d198.s4|103-103|(|O
DDI-DrugBank.d198.s4|104-107|Cmax|O
DDI-DrugBank.d198.s4|108-108|)|O
DDI-DrugBank.d198.s4|110-111|of|O
DDI-DrugBank.d198.s4|113-122|vardenafil|drug
DDI-DrugBank.d198.s4|124-127|when|O
DDI-DrugBank.d198.s4|129-143|co-administered|O
DDI-DrugBank.d198.s4|145-148|with|O
DDI-DrugBank.d198.s4|150-151|20|O
DDI-DrugBank.d198.s4|153-154|mg|O
DDI-DrugBank.d198.s4|156-165|Vardenafil|drug
DDI-DrugBank.d198.s4|167-168|in|O
DDI-DrugBank.d198.s4|170-176|healthy|O
DDI-DrugBank.d198.s4|178-187|volunteers|O
DDI-DrugBank.d198.s4|188-188|.|O
DDI-DrugBank.d198.s5|0-11|Erythromycin|drug
DDI-DrugBank.d198.s5|13-13|(|O
DDI-DrugBank.d198.s5|14-16|500|O
DDI-DrugBank.d198.s5|18-19|mg|O
DDI-DrugBank.d198.s5|21-25|t.i.d|O
DDI-DrugBank.d198.s5|26-26|)|O
DDI-DrugBank.d198.s5|28-35|produced|O
DDI-DrugBank.d198.s5|37-37|a|O
DDI-DrugBank.d198.s5|39-44|4-fold|O
DDI-DrugBank.d198.s5|46-53|increase|O
DDI-DrugBank.d198.s5|55-56|in|O
DDI-DrugBank.d198.s5|58-67|vardenafil|drug
DDI-DrugBank.d198.s5|69-71|AUC|O
DDI-DrugBank.d198.s5|73-75|and|O
DDI-DrugBank.d198.s5|77-77|a|O
DDI-DrugBank.d198.s5|79-84|3-fold|O
DDI-DrugBank.d198.s5|86-93|increase|O
DDI-DrugBank.d198.s5|95-96|in|O
DDI-DrugBank.d198.s5|98-101|Cmax|O
DDI-DrugBank.d198.s5|103-106|when|O
DDI-DrugBank.d198.s5|108-122|co-administered|O
DDI-DrugBank.d198.s5|124-127|with|O
DDI-DrugBank.d198.s5|129-138|Vardenafil|drug
DDI-DrugBank.d198.s5|140-140|5|O
DDI-DrugBank.d198.s5|142-143|mg|O
DDI-DrugBank.d198.s5|145-146|in|O
DDI-DrugBank.d198.s5|148-154|healthy|O
DDI-DrugBank.d198.s5|156-165|volunteers|O
DDI-DrugBank.d198.s5|166-166|.|O
DDI-DrugBank.d198.s6|0-1|It|O
DDI-DrugBank.d198.s6|3-4|is|O
DDI-DrugBank.d198.s6|6-16|recommended|O
DDI-DrugBank.d198.s6|18-20|not|O
DDI-DrugBank.d198.s6|22-23|to|O
DDI-DrugBank.d198.s6|25-30|exceed|O
DDI-DrugBank.d198.s6|32-32|a|O
DDI-DrugBank.d198.s6|34-39|single|O
DDI-DrugBank.d198.s6|41-41|5|O
DDI-DrugBank.d198.s6|43-44|mg|O
DDI-DrugBank.d198.s6|46-49|dose|O
DDI-DrugBank.d198.s6|51-52|of|O
DDI-DrugBank.d198.s6|54-63|Vardenafil|drug
DDI-DrugBank.d198.s6|65-66|in|O
DDI-DrugBank.d198.s6|68-68|a|O
DDI-DrugBank.d198.s6|70-76|24-hour|O
DDI-DrugBank.d198.s6|78-83|period|O
DDI-DrugBank.d198.s6|85-88|when|O
DDI-DrugBank.d198.s6|90-93|used|O
DDI-DrugBank.d198.s6|95-96|in|O
DDI-DrugBank.d198.s6|98-108|combination|O
DDI-DrugBank.d198.s6|110-113|with|O
DDI-DrugBank.d198.s6|115-126|erythromycin|drug
DDI-DrugBank.d198.s6|127-127|.|O
DDI-DrugBank.d198.s7|0-11|Ketoconazole|drug
DDI-DrugBank.d198.s7|13-13|(|O
DDI-DrugBank.d198.s7|14-16|200|O
DDI-DrugBank.d198.s7|18-19|mg|O
DDI-DrugBank.d198.s7|21-24|once|O
DDI-DrugBank.d198.s7|26-30|daily|O
DDI-DrugBank.d198.s7|31-31|)|O
DDI-DrugBank.d198.s7|33-40|produced|O
DDI-DrugBank.d198.s7|42-42|a|O
DDI-DrugBank.d198.s7|44-50|10-fold|O
DDI-DrugBank.d198.s7|52-59|increase|O
DDI-DrugBank.d198.s7|61-62|in|O
DDI-DrugBank.d198.s7|64-73|vardenafil|drug
DDI-DrugBank.d198.s7|75-77|AUC|O
DDI-DrugBank.d198.s7|79-81|and|O
DDI-DrugBank.d198.s7|83-83|a|O
DDI-DrugBank.d198.s7|85-90|4-fold|O
DDI-DrugBank.d198.s7|92-99|increase|O
DDI-DrugBank.d198.s7|101-102|in|O
DDI-DrugBank.d198.s7|104-107|Cmax|O
DDI-DrugBank.d198.s7|109-112|when|O
DDI-DrugBank.d198.s7|114-128|co-administered|O
DDI-DrugBank.d198.s7|130-133|with|O
DDI-DrugBank.d198.s7|135-144|Vardenafil|drug
DDI-DrugBank.d198.s7|146-146|(|O
DDI-DrugBank.d198.s7|147-147|5|O
DDI-DrugBank.d198.s7|149-150|mg|O
DDI-DrugBank.d198.s7|151-151|)|O
DDI-DrugBank.d198.s7|153-154|in|O
DDI-DrugBank.d198.s7|156-162|healthy|O
DDI-DrugBank.d198.s7|164-173|volunteers|O
DDI-DrugBank.d198.s7|174-174|.|O
DDI-DrugBank.d198.s8|0-0|A|O
DDI-DrugBank.d198.s8|2-5|5-mg|O
DDI-DrugBank.d198.s8|7-16|Vardenafil|drug
DDI-DrugBank.d198.s8|18-21|dose|O
DDI-DrugBank.d198.s8|23-28|should|O
DDI-DrugBank.d198.s8|30-32|not|O
DDI-DrugBank.d198.s8|34-35|be|O
DDI-DrugBank.d198.s8|37-44|exceeded|O
DDI-DrugBank.d198.s8|46-49|when|O
DDI-DrugBank.d198.s8|51-54|used|O
DDI-DrugBank.d198.s8|56-57|in|O
DDI-DrugBank.d198.s8|59-69|combination|O
DDI-DrugBank.d198.s8|71-74|with|O
DDI-DrugBank.d198.s8|76-78|200|O
DDI-DrugBank.d198.s8|80-81|mg|O
DDI-DrugBank.d198.s8|83-86|once|O
DDI-DrugBank.d198.s8|88-92|daily|O
DDI-DrugBank.d198.s8|94-105|ketoconazole|drug
DDI-DrugBank.d198.s8|106-106|.|O
DDI-DrugBank.d198.s9|0-4|Since|O
DDI-DrugBank.d198.s9|6-11|higher|O
DDI-DrugBank.d198.s9|13-17|doses|O
DDI-DrugBank.d198.s9|19-20|of|O
DDI-DrugBank.d198.s9|22-33|ketoconazole|drug
DDI-DrugBank.d198.s9|35-35|(|O
DDI-DrugBank.d198.s9|36-38|400|O
DDI-DrugBank.d198.s9|40-41|mg|O
DDI-DrugBank.d198.s9|43-47|daily|O
DDI-DrugBank.d198.s9|48-48|)|O
DDI-DrugBank.d198.s9|50-52|may|O
DDI-DrugBank.d198.s9|54-59|result|O
DDI-DrugBank.d198.s9|61-62|in|O
DDI-DrugBank.d198.s9|64-69|higher|O
DDI-DrugBank.d198.s9|71-79|increases|O
DDI-DrugBank.d198.s9|81-82|in|O
DDI-DrugBank.d198.s9|84-87|Cmax|O
DDI-DrugBank.d198.s9|89-91|and|O
DDI-DrugBank.d198.s9|93-95|AUC|O
DDI-DrugBank.d198.s9|96-96|,|O
DDI-DrugBank.d198.s9|98-98|a|O
DDI-DrugBank.d198.s9|100-105|single|O
DDI-DrugBank.d198.s9|107-109|2.5|O
DDI-DrugBank.d198.s9|111-112|mg|O
DDI-DrugBank.d198.s9|114-117|dose|O
DDI-DrugBank.d198.s9|119-120|of|O
DDI-DrugBank.d198.s9|122-131|Vardenafil|drug
DDI-DrugBank.d198.s9|133-138|should|O
DDI-DrugBank.d198.s9|140-142|not|O
DDI-DrugBank.d198.s9|144-145|be|O
DDI-DrugBank.d198.s9|147-154|exceeded|O
DDI-DrugBank.d198.s9|156-157|in|O
DDI-DrugBank.d198.s9|159-159|a|O
DDI-DrugBank.d198.s9|161-167|24-hour|O
DDI-DrugBank.d198.s9|169-174|period|O
DDI-DrugBank.d198.s9|176-179|when|O
DDI-DrugBank.d198.s9|181-184|used|O
DDI-DrugBank.d198.s9|186-187|in|O
DDI-DrugBank.d198.s9|189-199|combination|O
DDI-DrugBank.d198.s9|201-204|with|O
DDI-DrugBank.d198.s9|206-217|ketoconazole|drug
DDI-DrugBank.d198.s9|219-221|400|O
DDI-DrugBank.d198.s9|223-224|mg|O
DDI-DrugBank.d198.s9|226-230|daily|O
DDI-DrugBank.d198.s9|231-231|.|O
DDI-DrugBank.d198.s10|0-22|HIV Protease Inhibitors|group
DDI-DrugBank.d198.s10|23-23|:|O
DDI-DrugBank.d198.s10|25-33|Indinavir|drug
DDI-DrugBank.d198.s10|35-35|(|O
DDI-DrugBank.d198.s10|36-38|800|O
DDI-DrugBank.d198.s10|40-41|mg|O
DDI-DrugBank.d198.s10|43-48|t.i.d.|O
DDI-DrugBank.d198.s10|49-49|)|O
DDI-DrugBank.d198.s10|51-65|co-administered|O
DDI-DrugBank.d198.s10|67-70|with|O
DDI-DrugBank.d198.s10|72-81|Vardenafil|drug
DDI-DrugBank.d198.s10|83-84|10|O
DDI-DrugBank.d198.s10|86-87|mg|O
DDI-DrugBank.d198.s10|89-96|resulted|O
DDI-DrugBank.d198.s10|98-99|in|O
DDI-DrugBank.d198.s10|101-101|a|O
DDI-DrugBank.d198.s10|103-109|16-fold|O
DDI-DrugBank.d198.s10|111-118|increase|O
DDI-DrugBank.d198.s10|120-121|in|O
DDI-DrugBank.d198.s10|123-132|vardenafil|drug
DDI-DrugBank.d198.s10|134-136|AUC|O
DDI-DrugBank.d198.s10|137-137|,|O
DDI-DrugBank.d198.s10|139-139|a|O
DDI-DrugBank.d198.s10|141-146|7-fold|O
DDI-DrugBank.d198.s10|148-155|increase|O
DDI-DrugBank.d198.s10|157-158|in|O
DDI-DrugBank.d198.s10|160-169|vardenafil|drug
DDI-DrugBank.d198.s10|171-174|Cmax|O
DDI-DrugBank.d198.s10|176-178|and|O
DDI-DrugBank.d198.s10|180-180|a|O
DDI-DrugBank.d198.s10|182-187|2-fold|O
DDI-DrugBank.d198.s10|189-196|increase|O
DDI-DrugBank.d198.s10|198-199|in|O
DDI-DrugBank.d198.s10|201-210|vardenafil|drug
DDI-DrugBank.d198.s10|212-220|half-life|O
DDI-DrugBank.d198.s10|221-221|.|O
DDI-DrugBank.d198.s11|0-1|It|O
DDI-DrugBank.d198.s11|3-4|is|O
DDI-DrugBank.d198.s11|6-16|recommended|O
DDI-DrugBank.d198.s11|18-20|not|O
DDI-DrugBank.d198.s11|22-23|to|O
DDI-DrugBank.d198.s11|25-30|exceed|O
DDI-DrugBank.d198.s11|32-32|a|O
DDI-DrugBank.d198.s11|34-39|single|O
DDI-DrugBank.d198.s11|41-43|2.5|O
DDI-DrugBank.d198.s11|45-46|mg|O
DDI-DrugBank.d198.s11|48-57|Vardenafil|drug
DDI-DrugBank.d198.s11|59-62|dose|O
DDI-DrugBank.d198.s11|64-65|in|O
DDI-DrugBank.d198.s11|67-67|a|O
DDI-DrugBank.d198.s11|69-75|24-hour|O
DDI-DrugBank.d198.s11|77-82|period|O
DDI-DrugBank.d198.s11|84-87|when|O
DDI-DrugBank.d198.s11|89-92|used|O
DDI-DrugBank.d198.s11|94-95|in|O
DDI-DrugBank.d198.s11|97-107|combination|O
DDI-DrugBank.d198.s11|109-112|with|O
DDI-DrugBank.d198.s11|114-122|indinavir|drug
DDI-DrugBank.d198.s11|123-123|.|O
DDI-DrugBank.d198.s12|0-8|Ritonavir|drug
DDI-DrugBank.d198.s12|10-10|(|O
DDI-DrugBank.d198.s12|11-13|600|O
DDI-DrugBank.d198.s12|15-16|mg|O
DDI-DrugBank.d198.s12|18-23|b.i.d.|O
DDI-DrugBank.d198.s12|24-24|)|O
DDI-DrugBank.d198.s12|26-40|co-administered|O
DDI-DrugBank.d198.s12|42-45|with|O
DDI-DrugBank.d198.s12|47-56|Vardenafil|drug
DDI-DrugBank.d198.s12|58-58|5|O
DDI-DrugBank.d198.s12|60-61|mg|O
DDI-DrugBank.d198.s12|63-70|resulted|O
DDI-DrugBank.d198.s12|72-73|in|O
DDI-DrugBank.d198.s12|75-75|a|O
DDI-DrugBank.d198.s12|77-83|49-fold|O
DDI-DrugBank.d198.s12|85-92|increase|O
DDI-DrugBank.d198.s12|94-95|in|O
DDI-DrugBank.d198.s12|97-106|vardenafil|drug
DDI-DrugBank.d198.s12|108-110|AUC|O
DDI-DrugBank.d198.s12|112-114|and|O
DDI-DrugBank.d198.s12|116-116|a|O
DDI-DrugBank.d198.s12|118-124|13-fold|O
DDI-DrugBank.d198.s12|126-133|increase|O
DDI-DrugBank.d198.s12|135-136|in|O
DDI-DrugBank.d198.s12|138-147|vardenafil|drug
DDI-DrugBank.d198.s12|149-152|Cmax|O
DDI-DrugBank.d198.s12|153-153|.|O
DDI-DrugBank.d198.s13|0-2|The|O
DDI-DrugBank.d198.s13|4-14|interaction|O
DDI-DrugBank.d198.s13|16-17|is|O
DDI-DrugBank.d198.s13|19-19|a|O
DDI-DrugBank.d198.s13|21-31|consequence|O
DDI-DrugBank.d198.s13|33-34|of|O
DDI-DrugBank.d198.s13|36-43|blocking|O
DDI-DrugBank.d198.s13|45-51|hepatic|O
DDI-DrugBank.d198.s13|53-62|metabolism|O
DDI-DrugBank.d198.s13|64-65|of|O
DDI-DrugBank.d198.s13|67-76|vardenafil|drug
DDI-DrugBank.d198.s13|78-79|by|O
DDI-DrugBank.d198.s13|81-89|ritonavir|drug
DDI-DrugBank.d198.s13|90-90|,|O
DDI-DrugBank.d198.s13|92-92|a|O
DDI-DrugBank.d198.s13|94-99|highly|O
DDI-DrugBank.d198.s13|101-106|potent|O
DDI-DrugBank.d198.s13|108-113|CYP3A4|O
DDI-DrugBank.d198.s13|115-123|inhibitor|O
DDI-DrugBank.d198.s13|124-124|,|O
DDI-DrugBank.d198.s13|126-130|which|O
DDI-DrugBank.d198.s13|132-135|also|O
DDI-DrugBank.d198.s13|137-144|inhibits|O
DDI-DrugBank.d198.s13|146-151|CYP2C9|O
DDI-DrugBank.d198.s13|152-152|.|O
DDI-DrugBank.d198.s14|0-8|Ritonavir|drug
DDI-DrugBank.d198.s14|10-22|significantly|O
DDI-DrugBank.d198.s14|24-32|prolonged|O
DDI-DrugBank.d198.s14|34-36|the|O
DDI-DrugBank.d198.s14|38-46|half-life|O
DDI-DrugBank.d198.s14|48-49|of|O
DDI-DrugBank.d198.s14|51-60|vardenafil|drug
DDI-DrugBank.d198.s14|62-63|to|O
DDI-DrugBank.d198.s14|65-66|26|O
DDI-DrugBank.d198.s14|68-72|hours|O
DDI-DrugBank.d198.s14|73-73|.|O
DDI-DrugBank.d198.s15|0-11|Consequently|O
DDI-DrugBank.d198.s15|12-12|,|O
DDI-DrugBank.d198.s15|14-15|it|O
DDI-DrugBank.d198.s15|17-18|is|O
DDI-DrugBank.d198.s15|20-30|recommended|O
DDI-DrugBank.d198.s15|32-34|not|O
DDI-DrugBank.d198.s15|36-37|to|O
DDI-DrugBank.d198.s15|39-44|exceed|O
DDI-DrugBank.d198.s15|46-46|a|O
DDI-DrugBank.d198.s15|48-53|single|O
DDI-DrugBank.d198.s15|55-57|2.5|O
DDI-DrugBank.d198.s15|59-60|mg|O
DDI-DrugBank.d198.s15|62-71|Vardenafil|drug
DDI-DrugBank.d198.s15|73-76|dose|O
DDI-DrugBank.d198.s15|78-79|in|O
DDI-DrugBank.d198.s15|81-81|a|O
DDI-DrugBank.d198.s15|83-89|72-hour|O
DDI-DrugBank.d198.s15|91-96|period|O
DDI-DrugBank.d198.s15|98-101|when|O
DDI-DrugBank.d198.s15|103-106|used|O
DDI-DrugBank.d198.s15|108-109|in|O
DDI-DrugBank.d198.s15|111-121|combination|O
DDI-DrugBank.d198.s15|123-126|with|O
DDI-DrugBank.d198.s15|128-136|ritonavir|drug
DDI-DrugBank.d198.s15|137-137|.|O
DDI-DrugBank.d198.s16|0-4|Other|O
DDI-DrugBank.d198.s16|6-9|Drug|O
DDI-DrugBank.d198.s16|11-22|Interactions|O
DDI-DrugBank.d198.s16|23-23|:|O
DDI-DrugBank.d198.s16|25-26|No|O
DDI-DrugBank.d198.s16|28-42|pharmacokinetic|O
DDI-DrugBank.d198.s16|44-55|interactions|O
DDI-DrugBank.d198.s16|57-60|were|O
DDI-DrugBank.d198.s16|62-69|observed|O
DDI-DrugBank.d198.s16|71-77|between|O
DDI-DrugBank.d198.s16|79-88|vardenafil|drug
DDI-DrugBank.d198.s16|90-92|and|O
DDI-DrugBank.d198.s16|94-96|the|O
DDI-DrugBank.d198.s16|98-106|following|O
DDI-DrugBank.d198.s16|108-112|drugs|O
DDI-DrugBank.d198.s16|113-113|:|O
DDI-DrugBank.d198.s16|115-123|glyburide|drug
DDI-DrugBank.d198.s16|124-124|,|O
DDI-DrugBank.d198.s16|126-133|warfarin|drug
DDI-DrugBank.d198.s16|134-134|,|O
DDI-DrugBank.d198.s16|136-142|digoxin|drug
DDI-DrugBank.d198.s16|143-143|,|O
DDI-DrugBank.d198.s16|145-150|Maalox|brand
DDI-DrugBank.d198.s16|151-151|,|O
DDI-DrugBank.d198.s16|153-155|and|O
DDI-DrugBank.d198.s16|157-166|ranitidine|drug
DDI-DrugBank.d198.s16|167-167|.|O
DDI-DrugBank.d198.s17|0-1|In|O
DDI-DrugBank.d198.s17|3-5|the|O
DDI-DrugBank.d198.s17|7-14|warfarin|drug
DDI-DrugBank.d198.s17|16-20|study|O
DDI-DrugBank.d198.s17|21-21|,|O
DDI-DrugBank.d198.s17|23-32|vardenafil|drug
DDI-DrugBank.d198.s17|34-36|had|O
DDI-DrugBank.d198.s17|38-39|no|O
DDI-DrugBank.d198.s17|41-46|effect|O
DDI-DrugBank.d198.s17|48-49|on|O
DDI-DrugBank.d198.s17|51-53|the|O
DDI-DrugBank.d198.s17|55-65|prothrombin|O
DDI-DrugBank.d198.s17|67-70|time|O
DDI-DrugBank.d198.s17|72-73|or|O
DDI-DrugBank.d198.s17|75-79|other|O
DDI-DrugBank.d198.s17|81-95|pharmacodynamic|O
DDI-DrugBank.d198.s17|97-106|parameters|O
DDI-DrugBank.d198.s17|107-107|.|O
DDI-DrugBank.d198.s18|0-6|Effects|O
DDI-DrugBank.d198.s18|8-9|of|O
DDI-DrugBank.d198.s18|11-20|Vardenafil|drug
DDI-DrugBank.d198.s18|22-23|on|O
DDI-DrugBank.d198.s18|25-29|other|O
DDI-DrugBank.d198.s18|31-35|drugs|O
DDI-DrugBank.d198.s19|0-1|In|O
DDI-DrugBank.d198.s19|3-7|vitro|O
DDI-DrugBank.d198.s19|9-15|studies|O
DDI-DrugBank.d198.s19|16-16|:|O
DDI-DrugBank.d198.s19|18-27|Vardenafil|drug
DDI-DrugBank.d198.s19|29-31|and|O
DDI-DrugBank.d198.s19|33-35|its|O
DDI-DrugBank.d198.s19|37-47|metabolites|O
DDI-DrugBank.d198.s19|49-51|had|O
DDI-DrugBank.d198.s19|53-54|no|O
DDI-DrugBank.d198.s19|56-61|effect|O
DDI-DrugBank.d198.s19|63-64|on|O
DDI-DrugBank.d198.s19|66-71|CYP1A2|O
DDI-DrugBank.d198.s19|72-72|,|O
DDI-DrugBank.d198.s19|74-76|2A6|O
DDI-DrugBank.d198.s19|77-77|,|O
DDI-DrugBank.d198.s19|79-81|and|O
DDI-DrugBank.d198.s19|83-85|2E1|O
DDI-DrugBank.d198.s19|87-87|(|O
DDI-DrugBank.d198.s19|88-89|Ki|O
DDI-DrugBank.d198.s19|93-97|100uM|O
DDI-DrugBank.d198.s19|98-98|)|O
DDI-DrugBank.d198.s19|99-99|.|O
DDI-DrugBank.d198.s20|0-3|Weak|O
DDI-DrugBank.d198.s20|5-14|inhibitory|O
DDI-DrugBank.d198.s20|16-22|effects|O
DDI-DrugBank.d198.s20|24-29|toward|O
DDI-DrugBank.d198.s20|31-35|other|O
DDI-DrugBank.d198.s20|37-44|isoforms|O
DDI-DrugBank.d198.s20|46-46|(|O
DDI-DrugBank.d198.s20|47-52|CYP2C8|O
DDI-DrugBank.d198.s20|53-53|,|O
DDI-DrugBank.d198.s20|55-57|2C9|O
DDI-DrugBank.d198.s20|58-58|,|O
DDI-DrugBank.d198.s20|60-63|2C19|O
DDI-DrugBank.d198.s20|64-64|,|O
DDI-DrugBank.d198.s20|66-68|2D6|O
DDI-DrugBank.d198.s20|69-69|,|O
DDI-DrugBank.d198.s20|71-73|3A4|O
DDI-DrugBank.d198.s20|74-74|)|O
DDI-DrugBank.d198.s20|76-79|were|O
DDI-DrugBank.d198.s20|81-85|found|O
DDI-DrugBank.d198.s20|86-86|,|O
DDI-DrugBank.d198.s20|88-90|but|O
DDI-DrugBank.d198.s20|92-93|Ki|O
DDI-DrugBank.d198.s20|95-100|values|O
DDI-DrugBank.d198.s20|102-105|were|O
DDI-DrugBank.d198.s20|107-108|in|O
DDI-DrugBank.d198.s20|110-115|excess|O
DDI-DrugBank.d198.s20|117-118|of|O
DDI-DrugBank.d198.s20|120-125|plasma|O
DDI-DrugBank.d198.s20|127-140|concentrations|O
DDI-DrugBank.d198.s20|142-149|achieved|O
DDI-DrugBank.d198.s20|151-159|following|O
DDI-DrugBank.d198.s20|161-166|dosing|O
DDI-DrugBank.d198.s20|167-167|.|O
DDI-DrugBank.d198.s21|0-2|The|O
DDI-DrugBank.d198.s21|4-7|most|O
DDI-DrugBank.d198.s21|9-14|potent|O
DDI-DrugBank.d198.s21|16-25|inhibitory|O
DDI-DrugBank.d198.s21|27-34|activity|O
DDI-DrugBank.d198.s21|36-38|was|O
DDI-DrugBank.d198.s21|40-47|observed|O
DDI-DrugBank.d198.s21|49-51|for|O
DDI-DrugBank.d198.s21|53-62|vardenafil|O
DDI-DrugBank.d198.s21|64-73|metabolite|O
DDI-DrugBank.d198.s21|75-76|M1|O
DDI-DrugBank.d198.s21|77-77|,|O
DDI-DrugBank.d198.s21|79-83|which|O
DDI-DrugBank.d198.s21|85-87|had|O
DDI-DrugBank.d198.s21|89-89|a|O
DDI-DrugBank.d198.s21|91-92|Ki|O
DDI-DrugBank.d198.s21|94-95|of|O
DDI-DrugBank.d198.s21|97-99|1.4|O
DDI-DrugBank.d198.s21|101-102|uM|O
DDI-DrugBank.d198.s21|104-109|toward|O
DDI-DrugBank.d198.s21|111-116|CYP3A4|O
DDI-DrugBank.d198.s21|117-117|,|O
DDI-DrugBank.d198.s21|119-123|which|O
DDI-DrugBank.d198.s21|125-126|is|O
DDI-DrugBank.d198.s21|128-132|about|O
DDI-DrugBank.d198.s21|134-135|20|O
DDI-DrugBank.d198.s21|137-141|times|O
DDI-DrugBank.d198.s21|143-148|higher|O
DDI-DrugBank.d198.s21|150-153|than|O
DDI-DrugBank.d198.s21|155-157|the|O
DDI-DrugBank.d198.s21|159-160|M1|O
DDI-DrugBank.d198.s21|162-165|Cmax|O
DDI-DrugBank.d198.s21|167-172|values|O
DDI-DrugBank.d198.s21|174-178|after|O
DDI-DrugBank.d198.s21|180-181|an|O
DDI-DrugBank.d198.s21|183-184|80|O
DDI-DrugBank.d198.s21|186-187|mg|O
DDI-DrugBank.d198.s21|189-198|Vardenafil|drug
DDI-DrugBank.d198.s21|200-203|dose|O
DDI-DrugBank.d198.s21|204-204|.|O
DDI-DrugBank.d198.s22|0-1|In|O
DDI-DrugBank.d198.s22|3-6|vivo|O
DDI-DrugBank.d198.s22|8-14|studies|O
DDI-DrugBank.d198.s22|15-15|:|O
DDI-DrugBank.d198.s22|17-24|Nitrates|group
DDI-DrugBank.d198.s22|25-25|:|O
DDI-DrugBank.d198.s22|27-29|The|O
DDI-DrugBank.d198.s22|31-35|blood|O
DDI-DrugBank.d198.s22|37-44|pressure|O
DDI-DrugBank.d198.s22|46-53|lowering|O
DDI-DrugBank.d198.s22|55-61|effects|O
DDI-DrugBank.d198.s22|63-64|of|O
DDI-DrugBank.d198.s22|66-75|sublingual|O
DDI-DrugBank.d198.s22|77-84|nitrates|group
DDI-DrugBank.d198.s22|86-86|(|O
DDI-DrugBank.d198.s22|87-89|0.4|O
DDI-DrugBank.d198.s22|91-92|mg|O
DDI-DrugBank.d198.s22|93-93|)|O
DDI-DrugBank.d198.s22|95-99|taken|O
DDI-DrugBank.d198.s22|101-101|1|O
DDI-DrugBank.d198.s22|103-105|and|O
DDI-DrugBank.d198.s22|107-107|4|O
DDI-DrugBank.d198.s22|109-113|hours|O
DDI-DrugBank.d198.s22|115-119|after|O
DDI-DrugBank.d198.s22|121-130|vardenafil|drug
DDI-DrugBank.d198.s22|132-134|and|O
DDI-DrugBank.d198.s22|136-144|increases|O
DDI-DrugBank.d198.s22|146-147|in|O
DDI-DrugBank.d198.s22|149-153|heart|O
DDI-DrugBank.d198.s22|155-158|rate|O
DDI-DrugBank.d198.s22|160-163|when|O
DDI-DrugBank.d198.s22|165-169|taken|O
DDI-DrugBank.d198.s22|171-172|at|O
DDI-DrugBank.d198.s22|174-174|1|O
DDI-DrugBank.d198.s22|175-175|,|O
DDI-DrugBank.d198.s22|177-177|4|O
DDI-DrugBank.d198.s22|179-181|and|O
DDI-DrugBank.d198.s22|183-183|8|O
DDI-DrugBank.d198.s22|185-189|hours|O
DDI-DrugBank.d198.s22|191-194|were|O
DDI-DrugBank.d198.s22|196-206|potentiated|O
DDI-DrugBank.d198.s22|208-209|by|O
DDI-DrugBank.d198.s22|211-211|a|O
DDI-DrugBank.d198.s22|213-214|20|O
DDI-DrugBank.d198.s22|216-217|mg|O
DDI-DrugBank.d198.s22|219-222|dose|O
DDI-DrugBank.d198.s22|224-225|of|O
DDI-DrugBank.d198.s22|227-236|Vardenafil|drug
DDI-DrugBank.d198.s22|238-239|in|O
DDI-DrugBank.d198.s22|241-247|healthy|O
DDI-DrugBank.d198.s22|249-259|middle-aged|O
DDI-DrugBank.d198.s22|261-268|subjects|O
DDI-DrugBank.d198.s22|269-269|.|O
DDI-DrugBank.d198.s23|0-4|These|O
DDI-DrugBank.d198.s23|6-12|effects|O
DDI-DrugBank.d198.s23|14-17|were|O
DDI-DrugBank.d198.s23|19-21|not|O
DDI-DrugBank.d198.s23|23-30|observed|O
DDI-DrugBank.d198.s23|32-35|when|O
DDI-DrugBank.d198.s23|37-46|Vardenafil|drug
DDI-DrugBank.d198.s23|48-49|20|O
DDI-DrugBank.d198.s23|51-52|mg|O
DDI-DrugBank.d198.s23|54-56|was|O
DDI-DrugBank.d198.s23|58-62|taken|O
DDI-DrugBank.d198.s23|64-65|24|O
DDI-DrugBank.d198.s23|67-71|hours|O
DDI-DrugBank.d198.s23|73-78|before|O
DDI-DrugBank.d198.s23|80-82|the|O
DDI-DrugBank.d198.s23|84-86|NTG|drug
DDI-DrugBank.d198.s23|87-87|.|O
DDI-DrugBank.d198.s24|0-11|Potentiation|O
DDI-DrugBank.d198.s24|13-14|of|O
DDI-DrugBank.d198.s24|16-18|the|O
DDI-DrugBank.d198.s24|20-30|hypotensive|O
DDI-DrugBank.d198.s24|32-38|effects|O
DDI-DrugBank.d198.s24|40-41|of|O
DDI-DrugBank.d198.s24|43-50|nitrates|group
DDI-DrugBank.d198.s24|52-54|for|O
DDI-DrugBank.d198.s24|56-63|patients|O
DDI-DrugBank.d198.s24|65-68|with|O
DDI-DrugBank.d198.s24|70-77|ischemic|O
DDI-DrugBank.d198.s24|79-83|heart|O
DDI-DrugBank.d198.s24|85-91|disease|O
DDI-DrugBank.d198.s24|93-95|has|O
DDI-DrugBank.d198.s24|97-99|not|O
DDI-DrugBank.d198.s24|101-104|been|O
DDI-DrugBank.d198.s24|106-114|evaluated|O
DDI-DrugBank.d198.s24|115-115|,|O
DDI-DrugBank.d198.s24|117-119|and|O
DDI-DrugBank.d198.s24|121-131|concomitant|O
DDI-DrugBank.d198.s24|133-135|use|O
DDI-DrugBank.d198.s24|137-138|of|O
DDI-DrugBank.d198.s24|140-149|Vardenafil|drug
DDI-DrugBank.d198.s24|151-153|and|O
DDI-DrugBank.d198.s24|155-162|nitrates|group
DDI-DrugBank.d198.s24|164-165|is|O
DDI-DrugBank.d198.s24|167-181|contraindicated|O
DDI-DrugBank.d198.s24|182-182|.|O
DDI-DrugBank.d198.s25|0-9|Nifedipine|drug
DDI-DrugBank.d198.s25|10-10|:|O
DDI-DrugBank.d198.s25|12-21|Vardenafil|drug
DDI-DrugBank.d198.s25|23-24|20|O
DDI-DrugBank.d198.s25|26-27|mg|O
DDI-DrugBank.d198.s25|28-28|,|O
DDI-DrugBank.d198.s25|30-33|when|O
DDI-DrugBank.d198.s25|35-49|co-administered|O
DDI-DrugBank.d198.s25|51-54|with|O
DDI-DrugBank.d198.s25|56-67|slow-release|O
DDI-DrugBank.d198.s25|69-78|nifedipine|drug
DDI-DrugBank.d198.s25|80-81|30|O
DDI-DrugBank.d198.s25|83-84|mg|O
DDI-DrugBank.d198.s25|86-87|or|O
DDI-DrugBank.d198.s25|89-90|60|O
DDI-DrugBank.d198.s25|92-93|mg|O
DDI-DrugBank.d198.s25|95-98|once|O
DDI-DrugBank.d198.s25|100-104|daily|O
DDI-DrugBank.d198.s25|105-105|,|O
DDI-DrugBank.d198.s25|107-109|did|O
DDI-DrugBank.d198.s25|111-113|not|O
DDI-DrugBank.d198.s25|115-120|affect|O
DDI-DrugBank.d198.s25|122-124|the|O
DDI-DrugBank.d198.s25|126-133|relative|O
DDI-DrugBank.d198.s25|135-149|bioavailability|O
DDI-DrugBank.d198.s25|151-151|(|O
DDI-DrugBank.d198.s25|152-154|AUC|O
DDI-DrugBank.d198.s25|155-155|)|O
DDI-DrugBank.d198.s25|157-158|or|O
DDI-DrugBank.d198.s25|160-166|maximum|O
DDI-DrugBank.d198.s25|168-180|concentration|O
DDI-DrugBank.d198.s25|182-182|(|O
DDI-DrugBank.d198.s25|183-186|Cmax|O
DDI-DrugBank.d198.s25|187-187|)|O
DDI-DrugBank.d198.s25|189-190|of|O
DDI-DrugBank.d198.s25|192-201|nifedipine|drug
DDI-DrugBank.d198.s25|202-202|,|O
DDI-DrugBank.d198.s25|204-204|a|O
DDI-DrugBank.d198.s25|206-209|drug|O
DDI-DrugBank.d198.s25|211-214|that|O
DDI-DrugBank.d198.s25|216-217|is|O
DDI-DrugBank.d198.s25|219-229|metabolized|O
DDI-DrugBank.d198.s25|231-233|via|O
DDI-DrugBank.d198.s25|235-240|CYP3A4|O
DDI-DrugBank.d198.s25|241-241|.|O
DDI-DrugBank.d198.s26|0-9|Nifedipine|drug
DDI-DrugBank.d198.s26|11-13|did|O
DDI-DrugBank.d198.s26|15-17|not|O
DDI-DrugBank.d198.s26|19-23|alter|O
DDI-DrugBank.d198.s26|25-27|the|O
DDI-DrugBank.d198.s26|29-34|plasma|O
DDI-DrugBank.d198.s26|36-41|levels|O
DDI-DrugBank.d198.s26|43-44|of|O
DDI-DrugBank.d198.s26|46-55|Vardenafil|drug
DDI-DrugBank.d198.s26|57-60|when|O
DDI-DrugBank.d198.s26|62-66|taken|O
DDI-DrugBank.d198.s26|68-69|in|O
DDI-DrugBank.d198.s26|71-81|combination|O
DDI-DrugBank.d198.s26|82-82|.|O
DDI-DrugBank.d198.s27|0-1|In|O
DDI-DrugBank.d198.s27|3-7|these|O
DDI-DrugBank.d198.s27|9-16|patients|O
DDI-DrugBank.d198.s27|18-22|whose|O
DDI-DrugBank.d198.s27|24-35|hypertension|O
DDI-DrugBank.d198.s27|37-39|was|O
DDI-DrugBank.d198.s27|41-50|controlled|O
DDI-DrugBank.d198.s27|52-55|with|O
DDI-DrugBank.d198.s27|57-66|nifedipine|drug
DDI-DrugBank.d198.s27|67-67|,|O
DDI-DrugBank.d198.s27|69-78|Vardenafil|drug
DDI-DrugBank.d198.s27|80-81|20|O
DDI-DrugBank.d198.s27|83-84|mg|O
DDI-DrugBank.d198.s27|86-93|produced|O
DDI-DrugBank.d198.s27|95-98|mean|O
DDI-DrugBank.d198.s27|100-109|additional|O
DDI-DrugBank.d198.s27|111-116|supine|O
DDI-DrugBank.d198.s27|118-135|systolic/diastolic|O
DDI-DrugBank.d198.s27|137-141|blood|O
DDI-DrugBank.d198.s27|143-150|pressure|O
DDI-DrugBank.d198.s27|152-161|reductions|O
DDI-DrugBank.d198.s27|163-164|of|O
DDI-DrugBank.d198.s27|166-168|6/5|O
DDI-DrugBank.d198.s27|170-171|mm|O
DDI-DrugBank.d198.s27|173-174|Hg|O
DDI-DrugBank.d198.s27|176-183|compared|O
DDI-DrugBank.d198.s27|185-186|to|O
DDI-DrugBank.d198.s27|188-194|placebo|O
DDI-DrugBank.d198.s27|195-195|.|O
DDI-DrugBank.d198.s28|0-13|Alpha-blockers|group
DDI-DrugBank.d198.s28|14-14|:|O
DDI-DrugBank.d198.s28|16-19|When|O
DDI-DrugBank.d198.s28|21-30|Vardenafil|drug
DDI-DrugBank.d198.s28|32-33|10|O
DDI-DrugBank.d198.s28|35-36|or|O
DDI-DrugBank.d198.s28|38-39|20|O
DDI-DrugBank.d198.s28|41-42|mg|O
DDI-DrugBank.d198.s28|44-46|was|O
DDI-DrugBank.d198.s28|48-52|given|O
DDI-DrugBank.d198.s28|54-55|to|O
DDI-DrugBank.d198.s28|57-63|healthy|O
DDI-DrugBank.d198.s28|65-74|volunteers|O
DDI-DrugBank.d198.s28|76-81|either|O
DDI-DrugBank.d198.s28|83-96|simultaneously|O
DDI-DrugBank.d198.s28|98-99|or|O
DDI-DrugBank.d198.s28|101-101|6|O
DDI-DrugBank.d198.s28|103-107|hours|O
DDI-DrugBank.d198.s28|109-113|after|O
DDI-DrugBank.d198.s28|115-115|a|O
DDI-DrugBank.d198.s28|117-118|10|O
DDI-DrugBank.d198.s28|120-121|mg|O
DDI-DrugBank.d198.s28|123-126|dose|O
DDI-DrugBank.d198.s28|128-129|of|O
DDI-DrugBank.d198.s28|131-139|terazosin|drug
DDI-DrugBank.d198.s28|140-140|,|O
DDI-DrugBank.d198.s28|142-152|significant|O
DDI-DrugBank.d198.s28|154-164|hypotension|O
DDI-DrugBank.d198.s28|166-174|developed|O
DDI-DrugBank.d198.s28|176-177|in|O
DDI-DrugBank.d198.s28|179-179|a|O
DDI-DrugBank.d198.s28|181-191|substantial|O
DDI-DrugBank.d198.s28|193-198|number|O
DDI-DrugBank.d198.s28|200-201|of|O
DDI-DrugBank.d198.s28|203-210|subjects|O
DDI-DrugBank.d198.s28|211-211|.|O
DDI-DrugBank.d198.s29|0-3|With|O
DDI-DrugBank.d198.s29|5-16|simultaneous|O
DDI-DrugBank.d198.s29|18-23|dosing|O
DDI-DrugBank.d198.s29|25-26|of|O
DDI-DrugBank.d198.s29|28-37|Vardenafil|drug
DDI-DrugBank.d198.s29|39-40|10|O
DDI-DrugBank.d198.s29|42-43|mg|O
DDI-DrugBank.d198.s29|45-47|and|O
DDI-DrugBank.d198.s29|49-57|terazosin|drug
DDI-DrugBank.d198.s29|59-60|10|O
DDI-DrugBank.d198.s29|62-63|mg|O
DDI-DrugBank.d198.s29|64-64|,|O
DDI-DrugBank.d198.s29|66-66|6|O
DDI-DrugBank.d198.s29|68-69|of|O
DDI-DrugBank.d198.s29|71-71|8|O
DDI-DrugBank.d198.s29|73-80|subjects|O
DDI-DrugBank.d198.s29|82-92|experienced|O
DDI-DrugBank.d198.s29|94-94|a|O
DDI-DrugBank.d198.s29|96-103|standing|O
DDI-DrugBank.d198.s29|105-112|systolic|O
DDI-DrugBank.d198.s29|114-118|blood|O
DDI-DrugBank.d198.s29|120-127|pressure|O
DDI-DrugBank.d198.s29|129-130|of|O
DDI-DrugBank.d198.s29|132-135|less|O
DDI-DrugBank.d198.s29|137-140|than|O
DDI-DrugBank.d198.s29|142-143|85|O
DDI-DrugBank.d198.s29|145-146|mm|O
DDI-DrugBank.d198.s29|148-149|Hg|O
DDI-DrugBank.d198.s29|150-150|.|O
DDI-DrugBank.d198.s30|0-3|With|O
DDI-DrugBank.d198.s30|5-16|simultaneous|O
DDI-DrugBank.d198.s30|18-23|dosing|O
DDI-DrugBank.d198.s30|25-26|of|O
DDI-DrugBank.d198.s30|28-37|Vardenafil|drug
DDI-DrugBank.d198.s30|39-40|20|O
DDI-DrugBank.d198.s30|42-43|mg|O
DDI-DrugBank.d198.s30|45-47|and|O
DDI-DrugBank.d198.s30|49-57|terazosin|drug
DDI-DrugBank.d198.s30|59-60|10|O
DDI-DrugBank.d198.s30|62-63|mg|O
DDI-DrugBank.d198.s30|64-64|,|O
DDI-DrugBank.d198.s30|66-66|2|O
DDI-DrugBank.d198.s30|68-69|of|O
DDI-DrugBank.d198.s30|71-71|9|O
DDI-DrugBank.d198.s30|73-80|subjects|O
DDI-DrugBank.d198.s30|82-92|experienced|O
DDI-DrugBank.d198.s30|94-94|a|O
DDI-DrugBank.d198.s30|96-103|standing|O
DDI-DrugBank.d198.s30|105-112|systolic|O
DDI-DrugBank.d198.s30|114-118|blood|O
DDI-DrugBank.d198.s30|120-127|pressure|O
DDI-DrugBank.d198.s30|129-130|of|O
DDI-DrugBank.d198.s30|132-135|less|O
DDI-DrugBank.d198.s30|137-140|than|O
DDI-DrugBank.d198.s30|142-143|85|O
DDI-DrugBank.d198.s30|145-146|mm|O
DDI-DrugBank.d198.s30|148-149|Hg|O
DDI-DrugBank.d198.s30|150-150|.|O
DDI-DrugBank.d198.s31|0-3|When|O
DDI-DrugBank.d198.s31|5-14|Vardenafil|drug
DDI-DrugBank.d198.s31|16-21|dosing|O
DDI-DrugBank.d198.s31|23-25|was|O
DDI-DrugBank.d198.s31|27-35|separated|O
DDI-DrugBank.d198.s31|37-40|from|O
DDI-DrugBank.d198.s31|42-50|terazosin|drug
DDI-DrugBank.d198.s31|52-53|10|O
DDI-DrugBank.d198.s31|55-56|mg|O
DDI-DrugBank.d198.s31|58-59|by|O
DDI-DrugBank.d198.s31|61-61|6|O
DDI-DrugBank.d198.s31|63-67|hours|O
DDI-DrugBank.d198.s31|68-68|,|O
DDI-DrugBank.d198.s31|70-70|7|O
DDI-DrugBank.d198.s31|72-73|of|O
DDI-DrugBank.d198.s31|75-76|28|O
DDI-DrugBank.d198.s31|78-85|subjects|O
DDI-DrugBank.d198.s31|87-89|who|O
DDI-DrugBank.d198.s31|91-98|received|O
DDI-DrugBank.d198.s31|100-101|20|O
DDI-DrugBank.d198.s31|103-104|mg|O
DDI-DrugBank.d198.s31|106-107|of|O
DDI-DrugBank.d198.s31|109-118|Vardenafil|drug
DDI-DrugBank.d198.s31|120-130|experienced|O
DDI-DrugBank.d198.s31|132-132|a|O
DDI-DrugBank.d198.s31|134-141|decrease|O
DDI-DrugBank.d198.s31|143-144|in|O
DDI-DrugBank.d198.s31|146-153|standing|O
DDI-DrugBank.d198.s31|155-162|systolic|O
DDI-DrugBank.d198.s31|164-168|blood|O
DDI-DrugBank.d198.s31|170-177|pressure|O
DDI-DrugBank.d198.s31|179-183|below|O
DDI-DrugBank.d198.s31|185-186|85|O
DDI-DrugBank.d198.s31|188-189|mm|O
DDI-DrugBank.d198.s31|191-192|Hg|O
DDI-DrugBank.d198.s31|193-193|.|O
DDI-DrugBank.d198.s32|0-1|In|O
DDI-DrugBank.d198.s32|3-3|a|O
DDI-DrugBank.d198.s32|5-11|similar|O
DDI-DrugBank.d198.s32|13-17|study|O
DDI-DrugBank.d198.s32|19-22|with|O
DDI-DrugBank.d198.s32|24-33|tamsulosin|drug
DDI-DrugBank.d198.s32|35-36|in|O
DDI-DrugBank.d198.s32|38-44|healthy|O
DDI-DrugBank.d198.s32|46-55|volunteers|O
DDI-DrugBank.d198.s32|56-56|,|O
DDI-DrugBank.d198.s32|58-58|1|O
DDI-DrugBank.d198.s32|60-61|of|O
DDI-DrugBank.d198.s32|63-64|24|O
DDI-DrugBank.d198.s32|66-73|subjects|O
DDI-DrugBank.d198.s32|75-79|dosed|O
DDI-DrugBank.d198.s32|81-84|with|O
DDI-DrugBank.d198.s32|86-95|Vardenafil|drug
DDI-DrugBank.d198.s32|97-98|20|O
DDI-DrugBank.d198.s32|100-101|mg|O
DDI-DrugBank.d198.s32|103-105|and|O
DDI-DrugBank.d198.s32|107-116|tamsulosin|drug
DDI-DrugBank.d198.s32|118-120|0.4|O
DDI-DrugBank.d198.s32|122-123|mg|O
DDI-DrugBank.d198.s32|125-133|separated|O
DDI-DrugBank.d198.s32|135-136|by|O
DDI-DrugBank.d198.s32|138-138|6|O
DDI-DrugBank.d198.s32|140-144|hours|O
DDI-DrugBank.d198.s32|146-156|experienced|O
DDI-DrugBank.d198.s32|158-158|a|O
DDI-DrugBank.d198.s32|160-167|standing|O
DDI-DrugBank.d198.s32|169-176|systolic|O
DDI-DrugBank.d198.s32|178-182|blood|O
DDI-DrugBank.d198.s32|184-191|pressure|O
DDI-DrugBank.d198.s32|193-197|below|O
DDI-DrugBank.d198.s32|199-200|85|O
DDI-DrugBank.d198.s32|202-203|mm|O
DDI-DrugBank.d198.s32|205-206|Hg|O
DDI-DrugBank.d198.s32|207-207|.|O
DDI-DrugBank.d198.s33|0-2|Two|O
DDI-DrugBank.d198.s33|4-5|of|O
DDI-DrugBank.d198.s33|7-8|16|O
DDI-DrugBank.d198.s33|10-17|subjects|O
DDI-DrugBank.d198.s33|19-23|dosed|O
DDI-DrugBank.d198.s33|25-38|simultaneously|O
DDI-DrugBank.d198.s33|40-43|with|O
DDI-DrugBank.d198.s33|45-54|Vardenafil|drug
DDI-DrugBank.d198.s33|56-57|10|O
DDI-DrugBank.d198.s33|59-60|mg|O
DDI-DrugBank.d198.s33|62-64|and|O
DDI-DrugBank.d198.s33|66-75|tamsulosin|drug
DDI-DrugBank.d198.s33|77-79|0.4|O
DDI-DrugBank.d198.s33|81-82|mg|O
DDI-DrugBank.d198.s33|84-94|experienced|O
DDI-DrugBank.d198.s33|96-96|a|O
DDI-DrugBank.d198.s33|98-105|standing|O
DDI-DrugBank.d198.s33|107-114|systolic|O
DDI-DrugBank.d198.s33|116-120|blood|O
DDI-DrugBank.d198.s33|122-129|pressure|O
DDI-DrugBank.d198.s33|131-135|below|O
DDI-DrugBank.d198.s33|137-138|85|O
DDI-DrugBank.d198.s33|140-141|mm|O
DDI-DrugBank.d198.s33|143-144|Hg|O
DDI-DrugBank.d198.s33|145-145|.|O
DDI-DrugBank.d198.s34|0-2|The|O
DDI-DrugBank.d198.s34|4-17|administration|O
DDI-DrugBank.d198.s34|19-20|of|O
DDI-DrugBank.d198.s34|22-26|lower|O
DDI-DrugBank.d198.s34|28-32|doses|O
DDI-DrugBank.d198.s34|34-35|of|O
DDI-DrugBank.d198.s34|37-46|Vardenafil|drug
DDI-DrugBank.d198.s34|48-51|with|O
DDI-DrugBank.d198.s34|53-66|alpha-blockers|group
DDI-DrugBank.d198.s34|68-70|has|O
DDI-DrugBank.d198.s34|72-74|not|O
DDI-DrugBank.d198.s34|76-79|been|O
DDI-DrugBank.d198.s34|81-90|completely|O
DDI-DrugBank.d198.s34|92-100|evaluated|O
DDI-DrugBank.d198.s34|102-103|to|O
DDI-DrugBank.d198.s34|105-113|determine|O
DDI-DrugBank.d198.s34|115-116|if|O
DDI-DrugBank.d198.s34|118-121|they|O
DDI-DrugBank.d198.s34|123-125|can|O
DDI-DrugBank.d198.s34|127-128|be|O
DDI-DrugBank.d198.s34|130-135|safely|O
DDI-DrugBank.d198.s34|137-148|administered|O
DDI-DrugBank.d198.s34|150-157|together|O
DDI-DrugBank.d198.s34|158-158|.|O
DDI-DrugBank.d198.s35|0-4|Based|O
DDI-DrugBank.d198.s35|6-7|on|O
DDI-DrugBank.d198.s35|9-13|these|O
DDI-DrugBank.d198.s35|15-18|data|O
DDI-DrugBank.d198.s35|19-19|,|O
DDI-DrugBank.d198.s35|21-30|Vardenafil|drug
DDI-DrugBank.d198.s35|32-37|should|O
DDI-DrugBank.d198.s35|39-41|not|O
DDI-DrugBank.d198.s35|43-44|be|O
DDI-DrugBank.d198.s35|46-49|used|O
DDI-DrugBank.d198.s35|51-52|in|O
DDI-DrugBank.d198.s35|54-61|patients|O
DDI-DrugBank.d198.s35|63-64|on|O
DDI-DrugBank.d198.s35|66-78|alpha-blocker|group
DDI-DrugBank.d198.s35|80-86|therapy|O
DDI-DrugBank.d198.s35|87-87|.|O
DDI-DrugBank.d198.s36|0-8|Ritonavir|drug
DDI-DrugBank.d198.s36|10-12|and|O
DDI-DrugBank.d198.s36|14-22|indinavir|drug
DDI-DrugBank.d198.s36|23-23|:|O
DDI-DrugBank.d198.s36|25-28|Upon|O
DDI-DrugBank.d198.s36|30-40|concomitant|O
DDI-DrugBank.d198.s36|42-55|administration|O
DDI-DrugBank.d198.s36|57-58|of|O
DDI-DrugBank.d198.s36|60-60|5|O
DDI-DrugBank.d198.s36|62-63|mg|O
DDI-DrugBank.d198.s36|65-66|of|O
DDI-DrugBank.d198.s36|68-77|Vardenafil|drug
DDI-DrugBank.d198.s36|79-82|with|O
DDI-DrugBank.d198.s36|84-86|600|O
DDI-DrugBank.d198.s36|88-89|mg|O
DDI-DrugBank.d198.s36|91-93|BID|O
DDI-DrugBank.d198.s36|95-103|ritonavir|drug
DDI-DrugBank.d198.s36|104-104|,|O
DDI-DrugBank.d198.s36|106-108|the|O
DDI-DrugBank.d198.s36|110-113|Cmax|O
DDI-DrugBank.d198.s36|115-117|and|O
DDI-DrugBank.d198.s36|119-121|AUC|O
DDI-DrugBank.d198.s36|123-124|of|O
DDI-DrugBank.d198.s36|126-134|ritonavir|drug
DDI-DrugBank.d198.s36|136-139|were|O
DDI-DrugBank.d198.s36|141-147|reduced|O
DDI-DrugBank.d198.s36|149-150|by|O
DDI-DrugBank.d198.s36|152-164|approximately|O
DDI-DrugBank.d198.s36|166-167|20|O
DDI-DrugBank.d198.s36|168-168|%|O
DDI-DrugBank.d198.s36|169-169|.|O
DDI-DrugBank.d198.s37|0-3|Upon|O
DDI-DrugBank.d198.s37|5-18|administration|O
DDI-DrugBank.d198.s37|20-21|of|O
DDI-DrugBank.d198.s37|23-24|10|O
DDI-DrugBank.d198.s37|26-27|mg|O
DDI-DrugBank.d198.s37|29-30|of|O
DDI-DrugBank.d198.s37|32-41|Vardenafil|drug
DDI-DrugBank.d198.s37|43-46|with|O
DDI-DrugBank.d198.s37|48-50|800|O
DDI-DrugBank.d198.s37|52-53|mg|O
DDI-DrugBank.d198.s37|55-57|TID|O
DDI-DrugBank.d198.s37|59-67|indinavir|drug
DDI-DrugBank.d198.s37|68-68|,|O
DDI-DrugBank.d198.s37|70-72|the|O
DDI-DrugBank.d198.s37|74-77|Cmax|O
DDI-DrugBank.d198.s37|79-81|and|O
DDI-DrugBank.d198.s37|83-85|AUC|O
DDI-DrugBank.d198.s37|87-88|of|O
DDI-DrugBank.d198.s37|90-98|indinavir|drug
DDI-DrugBank.d198.s37|100-103|were|O
DDI-DrugBank.d198.s37|105-111|reduced|O
DDI-DrugBank.d198.s37|113-114|by|O
DDI-DrugBank.d198.s37|116-117|40|O
DDI-DrugBank.d198.s37|118-118|%|O
DDI-DrugBank.d198.s37|120-122|and|O
DDI-DrugBank.d198.s37|124-125|30|O
DDI-DrugBank.d198.s37|126-126|%|O
DDI-DrugBank.d198.s37|127-127|,|O
DDI-DrugBank.d198.s37|129-140|respectively|O
DDI-DrugBank.d198.s37|141-141|.|O
DDI-DrugBank.d198.s38|0-6|Alcohol|drug
DDI-DrugBank.d198.s38|7-7|:|O
DDI-DrugBank.d198.s38|9-15|Alcohol|drug
DDI-DrugBank.d198.s38|17-17|(|O
DDI-DrugBank.d198.s38|18-20|0.5|O
DDI-DrugBank.d198.s38|22-25|g/kg|O
DDI-DrugBank.d198.s38|27-30|body|O
DDI-DrugBank.d198.s38|32-37|weight|O
DDI-DrugBank.d198.s38|38-38|:|O
DDI-DrugBank.d198.s38|40-52|approximately|O
DDI-DrugBank.d198.s38|54-55|40|O
DDI-DrugBank.d198.s38|57-58|mL|O
DDI-DrugBank.d198.s38|60-61|of|O
DDI-DrugBank.d198.s38|63-70|absolute|O
DDI-DrugBank.d198.s38|72-78|alcohol|O
DDI-DrugBank.d198.s38|80-81|in|O
DDI-DrugBank.d198.s38|83-83|a|O
DDI-DrugBank.d198.s38|85-86|70|O
DDI-DrugBank.d198.s38|88-89|kg|O
DDI-DrugBank.d198.s38|91-96|person|O
DDI-DrugBank.d198.s38|97-97|)|O
DDI-DrugBank.d198.s38|99-101|and|O
DDI-DrugBank.d198.s38|103-112|vardenafil|drug
DDI-DrugBank.d198.s38|114-119|plasma|O
DDI-DrugBank.d198.s38|121-126|levels|O
DDI-DrugBank.d198.s38|128-131|were|O
DDI-DrugBank.d198.s38|133-135|not|O
DDI-DrugBank.d198.s38|137-143|altered|O
DDI-DrugBank.d198.s38|145-148|when|O
DDI-DrugBank.d198.s38|150-154|dosed|O
DDI-DrugBank.d198.s38|156-169|simultaneously|O
DDI-DrugBank.d198.s38|170-170|.|O
DDI-DrugBank.d198.s39|0-9|Vardenafil|drug
DDI-DrugBank.d198.s39|11-11|(|O
DDI-DrugBank.d198.s39|12-13|20|O
DDI-DrugBank.d198.s39|15-16|mg|O
DDI-DrugBank.d198.s39|17-17|)|O
DDI-DrugBank.d198.s39|19-21|did|O
DDI-DrugBank.d198.s39|23-25|not|O
DDI-DrugBank.d198.s39|27-36|potentiate|O
DDI-DrugBank.d198.s39|38-40|the|O
DDI-DrugBank.d198.s39|42-52|hypotensive|O
DDI-DrugBank.d198.s39|54-60|effects|O
DDI-DrugBank.d198.s39|62-63|of|O
DDI-DrugBank.d198.s39|65-71|alcohol|drug
DDI-DrugBank.d198.s39|73-78|during|O
DDI-DrugBank.d198.s39|80-82|the|O
DDI-DrugBank.d198.s39|84-89|4-hour|O
DDI-DrugBank.d198.s39|91-101|observation|O
DDI-DrugBank.d198.s39|103-108|period|O
DDI-DrugBank.d198.s39|110-111|in|O
DDI-DrugBank.d198.s39|113-119|healthy|O
DDI-DrugBank.d198.s39|121-130|volunteers|O
DDI-DrugBank.d198.s39|132-135|when|O
DDI-DrugBank.d198.s39|137-148|administered|O
DDI-DrugBank.d198.s39|150-153|with|O
DDI-DrugBank.d198.s39|155-161|alcohol|drug
DDI-DrugBank.d198.s39|163-163|(|O
DDI-DrugBank.d198.s39|164-166|0.5|O
DDI-DrugBank.d198.s39|168-171|g/kg|O
DDI-DrugBank.d198.s39|173-176|body|O
DDI-DrugBank.d198.s39|178-183|weight|O
DDI-DrugBank.d198.s39|184-184|)|O
DDI-DrugBank.d198.s39|185-185|.|O
DDI-DrugBank.d198.s40|0-6|Aspirin|brand
DDI-DrugBank.d198.s40|7-7|:|O
DDI-DrugBank.d198.s40|9-18|Vardenafil|drug
DDI-DrugBank.d198.s40|20-20|(|O
DDI-DrugBank.d198.s40|21-22|10|O
DDI-DrugBank.d198.s40|24-25|mg|O
DDI-DrugBank.d198.s40|27-29|and|O
DDI-DrugBank.d198.s40|31-32|20|O
DDI-DrugBank.d198.s40|34-35|mg|O
DDI-DrugBank.d198.s40|36-36|)|O
DDI-DrugBank.d198.s40|38-40|did|O
DDI-DrugBank.d198.s40|42-44|not|O
DDI-DrugBank.d198.s40|46-55|potentiate|O
DDI-DrugBank.d198.s40|57-59|the|O
DDI-DrugBank.d198.s40|61-68|increase|O
DDI-DrugBank.d198.s40|70-71|in|O
DDI-DrugBank.d198.s40|73-80|bleeding|O
DDI-DrugBank.d198.s40|82-85|time|O
DDI-DrugBank.d198.s40|87-92|caused|O
DDI-DrugBank.d198.s40|94-95|by|O
DDI-DrugBank.d198.s40|97-103|aspirin|brand
DDI-DrugBank.d198.s40|105-105|(|O
DDI-DrugBank.d198.s40|106-108|two|O
DDI-DrugBank.d198.s40|110-111|81|O
DDI-DrugBank.d198.s40|113-114|mg|O
DDI-DrugBank.d198.s40|116-122|tablets|O
DDI-DrugBank.d198.s40|123-123|)|O
DDI-DrugBank.d198.s40|124-124|.|O
DDI-DrugBank.d198.s41|0-4|Other|O
DDI-DrugBank.d198.s41|6-17|interactions|O
DDI-DrugBank.d198.s41|18-18|:|O
DDI-DrugBank.d198.s41|20-29|Vardenafil|drug
DDI-DrugBank.d198.s41|31-33|had|O
DDI-DrugBank.d198.s41|35-36|no|O
DDI-DrugBank.d198.s41|38-43|effect|O
DDI-DrugBank.d198.s41|45-46|on|O
DDI-DrugBank.d198.s41|48-50|the|O
DDI-DrugBank.d198.s41|52-67|pharmacodynamics|O
DDI-DrugBank.d198.s41|69-70|of|O
DDI-DrugBank.d198.s41|72-80|glyburide|drug
DDI-DrugBank.d198.s41|82-82|(|O
DDI-DrugBank.d198.s41|83-89|glucose|O
DDI-DrugBank.d198.s41|91-93|and|O
DDI-DrugBank.d198.s41|95-101|insulin|O
DDI-DrugBank.d198.s41|103-116|concentrations|O
DDI-DrugBank.d198.s41|117-117|)|O
DDI-DrugBank.d198.s41|119-121|and|O
DDI-DrugBank.d198.s41|123-130|warfarin|drug
DDI-DrugBank.d198.s41|132-132|(|O
DDI-DrugBank.d198.s41|133-143|prothrombin|O
DDI-DrugBank.d198.s41|145-148|time|O
DDI-DrugBank.d198.s41|150-151|or|O
DDI-DrugBank.d198.s41|153-157|other|O
DDI-DrugBank.d198.s41|159-173|pharmacodynamic|O
DDI-DrugBank.d198.s41|175-184|parameters|O
DDI-DrugBank.d198.s41|185-185|)|O
DDI-DrugBank.d198.s41|186-186|.|O
DDI-MedLine.d109.s0|0-5|Effect|O
DDI-MedLine.d109.s0|7-8|of|O
DDI-MedLine.d109.s0|10-18|rofecoxib|drug
DDI-MedLine.d109.s0|20-21|on|O
DDI-MedLine.d109.s0|23-25|the|O
DDI-MedLine.d109.s0|27-42|pharmacokinetics|O
DDI-MedLine.d109.s0|44-45|of|O
DDI-MedLine.d109.s0|47-53|digoxin|drug
DDI-MedLine.d109.s0|55-56|in|O
DDI-MedLine.d109.s0|58-64|healthy|O
DDI-MedLine.d109.s0|66-75|volunteers|O
DDI-MedLine.d109.s0|76-76|.|O
DDI-MedLine.d109.s1|0-2|The|O
DDI-MedLine.d109.s1|4-10|authors|O
DDI-MedLine.d109.s1|12-19|examined|O
DDI-MedLine.d109.s1|21-23|the|O
DDI-MedLine.d109.s1|25-30|effect|O
DDI-MedLine.d109.s1|32-33|of|O
DDI-MedLine.d109.s1|35-37|the|O
DDI-MedLine.d109.s1|39-54|cyclooxygenase-2|O
DDI-MedLine.d109.s1|56-56|(|O
DDI-MedLine.d109.s1|57-61|COX-2|O
DDI-MedLine.d109.s1|62-62|)|O
DDI-MedLine.d109.s1|64-72|inhibitor|O
DDI-MedLine.d109.s1|73-73|,|O
DDI-MedLine.d109.s1|75-83|rofecoxib|drug
DDI-MedLine.d109.s1|84-84|,|O
DDI-MedLine.d109.s1|86-87|at|O
DDI-MedLine.d109.s1|89-94|steady|O
DDI-MedLine.d109.s1|96-100|state|O
DDI-MedLine.d109.s1|102-103|on|O
DDI-MedLine.d109.s1|105-107|the|O
DDI-MedLine.d109.s1|109-124|pharmacokinetics|O
DDI-MedLine.d109.s1|126-127|of|O
DDI-MedLine.d109.s1|129-135|digoxin|drug
DDI-MedLine.d109.s1|137-145|following|O
DDI-MedLine.d109.s1|147-147|a|O
DDI-MedLine.d109.s1|149-154|single|O
DDI-MedLine.d109.s1|156-159|dose|O
DDI-MedLine.d109.s1|161-162|in|O
DDI-MedLine.d109.s1|164-170|healthy|O
DDI-MedLine.d109.s1|172-179|subjects|O
DDI-MedLine.d109.s1|180-180|.|O
DDI-MedLine.d109.s2|0-3|Each|O
DDI-MedLine.d109.s2|5-11|healthy|O
DDI-MedLine.d109.s2|13-19|subject|O
DDI-MedLine.d109.s2|21-21|(|O
DDI-MedLine.d109.s2|22-22|N|O
DDI-MedLine.d109.s2|24-24|=|O
DDI-MedLine.d109.s2|26-27|10|O
DDI-MedLine.d109.s2|28-28|)|O
DDI-MedLine.d109.s2|30-37|received|O
DDI-MedLine.d109.s2|39-47|rofecoxib|drug
DDI-MedLine.d109.s2|49-49|(|O
DDI-MedLine.d109.s2|50-51|75|O
DDI-MedLine.d109.s2|53-54|mg|O
DDI-MedLine.d109.s2|56-59|once|O
DDI-MedLine.d109.s2|61-65|daily|O
DDI-MedLine.d109.s2|66-66|)|O
DDI-MedLine.d109.s2|68-69|or|O
DDI-MedLine.d109.s2|71-77|placebo|O
DDI-MedLine.d109.s2|79-81|for|O
DDI-MedLine.d109.s2|83-84|11|O
DDI-MedLine.d109.s2|86-89|days|O
DDI-MedLine.d109.s2|91-92|in|O
DDI-MedLine.d109.s2|94-94|a|O
DDI-MedLine.d109.s2|96-107|double-blind|O
DDI-MedLine.d109.s2|108-108|,|O
DDI-MedLine.d109.s2|110-119|randomized|O
DDI-MedLine.d109.s2|120-120|,|O
DDI-MedLine.d109.s2|122-129|balanced|O
DDI-MedLine.d109.s2|130-130|,|O
DDI-MedLine.d109.s2|132-141|two-period|O
DDI-MedLine.d109.s2|143-151|crossover|O
DDI-MedLine.d109.s2|153-157|study|O
DDI-MedLine.d109.s2|158-158|.|O
DDI-MedLine.d109.s3|0-0|A|O
DDI-MedLine.d109.s3|2-7|single|O
DDI-MedLine.d109.s3|9-11|0.5|O
DDI-MedLine.d109.s3|13-14|mg|O
DDI-MedLine.d109.s3|16-19|oral|O
DDI-MedLine.d109.s3|21-24|dose|O
DDI-MedLine.d109.s3|26-27|of|O
DDI-MedLine.d109.s3|29-35|digoxin|drug
DDI-MedLine.d109.s3|37-42|elixir|O
DDI-MedLine.d109.s3|44-46|was|O
DDI-MedLine.d109.s3|48-59|administered|O
DDI-MedLine.d109.s3|61-62|on|O
DDI-MedLine.d109.s3|64-66|the|O
DDI-MedLine.d109.s3|68-70|7th|O
DDI-MedLine.d109.s3|72-74|day|O
DDI-MedLine.d109.s3|76-77|of|O
DDI-MedLine.d109.s3|79-82|each|O
DDI-MedLine.d109.s3|84-89|11-day|O
DDI-MedLine.d109.s3|91-96|period|O
DDI-MedLine.d109.s3|97-97|.|O
DDI-MedLine.d109.s4|0-3|Each|O
DDI-MedLine.d109.s4|5-13|treatment|O
DDI-MedLine.d109.s4|15-20|period|O
DDI-MedLine.d109.s4|22-24|was|O
DDI-MedLine.d109.s4|26-34|separated|O
DDI-MedLine.d109.s4|36-37|by|O
DDI-MedLine.d109.s4|39-40|14|O
DDI-MedLine.d109.s4|42-43|to|O
DDI-MedLine.d109.s4|45-46|21|O
DDI-MedLine.d109.s4|48-51|days|O
DDI-MedLine.d109.s4|52-52|.|O
DDI-MedLine.d109.s5|0-6|Samples|O
DDI-MedLine.d109.s5|8-10|for|O
DDI-MedLine.d109.s5|12-17|plasma|O
DDI-MedLine.d109.s5|19-21|and|O
DDI-MedLine.d109.s5|23-27|urine|O
DDI-MedLine.d109.s5|29-42|immunoreactive|O
DDI-MedLine.d109.s5|44-50|digoxin|drug
DDI-MedLine.d109.s5|52-65|concentrations|O
DDI-MedLine.d109.s5|67-70|were|O
DDI-MedLine.d109.s5|72-80|collected|O
DDI-MedLine.d109.s5|82-88|through|O
DDI-MedLine.d109.s5|90-92|120|O
DDI-MedLine.d109.s5|94-98|hours|O
DDI-MedLine.d109.s5|100-108|following|O
DDI-MedLine.d109.s5|110-112|the|O
DDI-MedLine.d109.s5|114-120|digoxin|drug
DDI-MedLine.d109.s5|122-125|dose|O
DDI-MedLine.d109.s5|126-126|.|O
DDI-MedLine.d109.s6|0-1|No|O
DDI-MedLine.d109.s6|3-15|statistically|O
DDI-MedLine.d109.s6|17-27|significant|O
DDI-MedLine.d109.s6|29-39|differences|O
DDI-MedLine.d109.s6|41-47|between|O
DDI-MedLine.d109.s6|49-57|treatment|O
DDI-MedLine.d109.s6|59-64|groups|O
DDI-MedLine.d109.s6|66-69|were|O
DDI-MedLine.d109.s6|71-78|observed|O
DDI-MedLine.d109.s6|80-82|for|O
DDI-MedLine.d109.s6|84-86|any|O
DDI-MedLine.d109.s6|88-89|of|O
DDI-MedLine.d109.s6|91-93|the|O
DDI-MedLine.d109.s6|95-104|calculated|O
DDI-MedLine.d109.s6|106-112|digoxin|drug
DDI-MedLine.d109.s6|114-128|pharmacokinetic|O
DDI-MedLine.d109.s6|130-139|parameters|O
DDI-MedLine.d109.s6|140-140|.|O
DDI-MedLine.d109.s7|0-2|For|O
DDI-MedLine.d109.s7|4-10|digoxin|drug
DDI-MedLine.d109.s7|12-14|AUC|O
DDI-MedLine.d109.s7|15-15|(|O
DDI-MedLine.d109.s7|16-25|0-infinity|O
DDI-MedLine.d109.s7|26-26|)|O
DDI-MedLine.d109.s7|27-27|,|O
DDI-MedLine.d109.s7|29-31|AUC|O
DDI-MedLine.d109.s7|32-32|(|O
DDI-MedLine.d109.s7|33-36|0-24|O
DDI-MedLine.d109.s7|37-37|)|O
DDI-MedLine.d109.s7|38-38|,|O
DDI-MedLine.d109.s7|40-42|and|O
DDI-MedLine.d109.s7|44-47|Cmax|O
DDI-MedLine.d109.s7|48-48|,|O
DDI-MedLine.d109.s7|50-52|the|O
DDI-MedLine.d109.s7|54-62|geometric|O
DDI-MedLine.d109.s7|64-67|mean|O
DDI-MedLine.d109.s7|69-74|ratios|O
DDI-MedLine.d109.s7|76-76|(|O
DDI-MedLine.d109.s7|77-78|90|O
DDI-MedLine.d109.s7|79-79|%|O
DDI-MedLine.d109.s7|81-90|confidence|O
DDI-MedLine.d109.s7|92-99|interval|O
DDI-MedLine.d109.s7|100-100|)|O
DDI-MedLine.d109.s7|102-104|for|O
DDI-MedLine.d109.s7|106-106|(|O
DDI-MedLine.d109.s7|107-115|rofecoxib|drug
DDI-MedLine.d109.s7|117-117|+|O
DDI-MedLine.d109.s7|119-133|digoxin/placebo|drug
DDI-MedLine.d109.s7|135-135|+|O
DDI-MedLine.d109.s7|137-143|digoxin|drug
DDI-MedLine.d109.s7|144-144|)|O
DDI-MedLine.d109.s7|146-149|were|O
DDI-MedLine.d109.s7|151-154|1.04|O
DDI-MedLine.d109.s7|156-156|(|O
DDI-MedLine.d109.s7|157-160|0.94|O
DDI-MedLine.d109.s7|161-161|,|O
DDI-MedLine.d109.s7|163-166|1.14|O
DDI-MedLine.d109.s7|167-167|)|O
DDI-MedLine.d109.s7|168-168|,|O
DDI-MedLine.d109.s7|170-173|1.02|O
DDI-MedLine.d109.s7|175-175|(|O
DDI-MedLine.d109.s7|176-179|0.94|O
DDI-MedLine.d109.s7|180-180|,|O
DDI-MedLine.d109.s7|182-185|1.09|O
DDI-MedLine.d109.s7|186-186|)|O
DDI-MedLine.d109.s7|187-187|,|O
DDI-MedLine.d109.s7|189-191|and|O
DDI-MedLine.d109.s7|193-196|1.00|O
DDI-MedLine.d109.s7|198-198|(|O
DDI-MedLine.d109.s7|199-202|0.91|O
DDI-MedLine.d109.s7|203-203|,|O
DDI-MedLine.d109.s7|205-208|1.10|O
DDI-MedLine.d109.s7|209-209|)|O
DDI-MedLine.d109.s7|210-210|,|O
DDI-MedLine.d109.s7|212-223|respectively|O
DDI-MedLine.d109.s7|224-224|.|O
DDI-MedLine.d109.s8|0-2|The|O
DDI-MedLine.d109.s8|4-10|digoxin|drug
DDI-MedLine.d109.s8|12-17|median|O
DDI-MedLine.d109.s8|19-22|tmax|O
DDI-MedLine.d109.s8|24-26|was|O
DDI-MedLine.d109.s8|28-30|0.5|O
DDI-MedLine.d109.s8|32-36|hours|O
DDI-MedLine.d109.s8|38-40|for|O
DDI-MedLine.d109.s8|42-45|both|O
DDI-MedLine.d109.s8|47-56|treatments|O
DDI-MedLine.d109.s8|57-57|.|O
DDI-MedLine.d109.s9|0-2|The|O
DDI-MedLine.d109.s9|4-11|harmonic|O
DDI-MedLine.d109.s9|13-16|mean|O
DDI-MedLine.d109.s9|18-28|elimination|O
DDI-MedLine.d109.s9|30-38|half-life|O
DDI-MedLine.d109.s9|40-42|was|O
DDI-MedLine.d109.s9|44-47|45.7|O
DDI-MedLine.d109.s9|49-51|and|O
DDI-MedLine.d109.s9|53-56|43.4|O
DDI-MedLine.d109.s9|58-62|hours|O
DDI-MedLine.d109.s9|64-66|for|O
DDI-MedLine.d109.s9|68-76|rofecoxib|drug
DDI-MedLine.d109.s9|78-78|+|O
DDI-MedLine.d109.s9|80-86|digoxin|drug
DDI-MedLine.d109.s9|88-90|and|O
DDI-MedLine.d109.s9|92-98|placebo|O
DDI-MedLine.d109.s9|100-100|+|O
DDI-MedLine.d109.s9|102-108|digoxin|drug
DDI-MedLine.d109.s9|110-119|treatments|O
DDI-MedLine.d109.s9|120-120|,|O
DDI-MedLine.d109.s9|122-133|respectively|O
DDI-MedLine.d109.s9|134-134|.|O
DDI-MedLine.d109.s10|0-6|Digoxin|drug
DDI-MedLine.d109.s10|8-9|is|O
DDI-MedLine.d109.s10|11-20|eliminated|O
DDI-MedLine.d109.s10|22-28|renally|O
DDI-MedLine.d109.s10|29-29|.|O
DDI-MedLine.d109.s11|0-2|The|O
DDI-MedLine.d109.s11|4-7|mean|O
DDI-MedLine.d109.s11|9-9|(|O
DDI-MedLine.d109.s11|10-11|SD|O
DDI-MedLine.d109.s11|12-12|)|O
DDI-MedLine.d109.s11|14-23|cumulative|O
DDI-MedLine.d109.s11|25-31|urinary|O
DDI-MedLine.d109.s11|33-41|excretion|O
DDI-MedLine.d109.s11|43-44|of|O
DDI-MedLine.d109.s11|46-59|immunoreactive|O
DDI-MedLine.d109.s11|61-67|digoxin|drug
DDI-MedLine.d109.s11|69-73|after|O
DDI-MedLine.d109.s11|75-84|concurrent|O
DDI-MedLine.d109.s11|86-94|treatment|O
DDI-MedLine.d109.s11|96-99|with|O
DDI-MedLine.d109.s11|101-109|rofecoxib|drug
DDI-MedLine.d109.s11|111-112|or|O
DDI-MedLine.d109.s11|114-120|placebo|O
DDI-MedLine.d109.s11|122-124|was|O
DDI-MedLine.d109.s11|126-130|228.2|O
DDI-MedLine.d109.s11|132-132|(|O
DDI-MedLine.d109.s11|133-135|+/-|O
DDI-MedLine.d109.s11|137-140|30.8|O
DDI-MedLine.d109.s11|141-141|)|O
DDI-MedLine.d109.s11|143-145|and|O
DDI-MedLine.d109.s11|147-151|235.1|O
DDI-MedLine.d109.s11|153-153|(|O
DDI-MedLine.d109.s11|154-156|+/-|O
DDI-MedLine.d109.s11|158-161|39.1|O
DDI-MedLine.d109.s11|162-162|)|O
DDI-MedLine.d109.s11|164-177|micrograms/120|O
DDI-MedLine.d109.s11|179-183|hours|O
DDI-MedLine.d109.s11|184-184|,|O
DDI-MedLine.d109.s11|186-197|respectively|O
DDI-MedLine.d109.s11|198-198|.|O
DDI-MedLine.d109.s12|0-8|Transient|O
DDI-MedLine.d109.s12|10-12|and|O
DDI-MedLine.d109.s12|14-18|minor|O
DDI-MedLine.d109.s12|20-26|adverse|O
DDI-MedLine.d109.s12|28-33|events|O
DDI-MedLine.d109.s12|35-42|occurred|O
DDI-MedLine.d109.s12|44-47|with|O
DDI-MedLine.d109.s12|49-55|similar|O
DDI-MedLine.d109.s12|57-65|frequency|O
DDI-MedLine.d109.s12|67-68|on|O
DDI-MedLine.d109.s12|70-76|placebo|O
DDI-MedLine.d109.s12|78-80|and|O
DDI-MedLine.d109.s12|82-90|rofecoxib|drug
DDI-MedLine.d109.s12|92-101|treatments|O
DDI-MedLine.d109.s12|102-102|,|O
DDI-MedLine.d109.s12|104-106|and|O
DDI-MedLine.d109.s12|108-109|no|O
DDI-MedLine.d109.s12|111-127|treatment-related|O
DDI-MedLine.d109.s12|129-135|pattern|O
DDI-MedLine.d109.s12|137-139|was|O
DDI-MedLine.d109.s12|141-148|apparent|O
DDI-MedLine.d109.s12|149-149|.|O
DDI-MedLine.d109.s13|0-8|Rofecoxib|drug
DDI-MedLine.d109.s13|10-12|did|O
DDI-MedLine.d109.s13|14-16|not|O
DDI-MedLine.d109.s13|18-26|influence|O
DDI-MedLine.d109.s13|28-30|the|O
DDI-MedLine.d109.s13|32-37|plasma|O
DDI-MedLine.d109.s13|39-54|pharmacokinetics|O
DDI-MedLine.d109.s13|56-57|or|O
DDI-MedLine.d109.s13|59-63|renal|O
DDI-MedLine.d109.s13|65-75|elimination|O
DDI-MedLine.d109.s13|77-78|of|O
DDI-MedLine.d109.s13|80-80|a|O
DDI-MedLine.d109.s13|82-87|single|O
DDI-MedLine.d109.s13|89-92|oral|O
DDI-MedLine.d109.s13|94-97|dose|O
DDI-MedLine.d109.s13|99-100|of|O
DDI-MedLine.d109.s13|102-108|digoxin|drug
DDI-MedLine.d109.s13|109-109|.|O
DDI-DrugBank.d251.s0|0-7|Antiacid|O
DDI-DrugBank.d251.s0|8-8|,|O
DDI-DrugBank.d251.s0|10-23|clarithromycin|drug
DDI-DrugBank.d251.s0|24-24|,|O
DDI-DrugBank.d251.s0|26-35|Didanosine|drug
DDI-DrugBank.d251.s0|36-36|,|O
DDI-DrugBank.d251.s0|38-48|Fluconazole|drug
DDI-DrugBank.d251.s0|49-49|,|O
DDI-DrugBank.d251.s0|51-60|Fluoxetine|drug
DDI-DrugBank.d251.s0|61-61|,|O
DDI-DrugBank.d251.s0|63-71|Indanavir|O
DDI-DrugBank.d251.s0|72-72|,|O
DDI-DrugBank.d251.s0|74-85|Ketoconazole|drug
DDI-DrugBank.d251.s0|86-86|,|O
DDI-DrugBank.d251.s0|88-96|Phenytoin|drug
DDI-DrugBank.d251.s0|97-97|,|O
DDI-DrugBank.d251.s0|99-111|Phenobarbitol|O
DDI-DrugBank.d251.s0|112-112|,|O
DDI-DrugBank.d251.s0|114-126|carbamazepine|drug
DDI-DrugBank.d251.s0|127-127|,|O
DDI-DrugBank.d251.s0|129-137|Rifabutin|drug
DDI-DrugBank.d251.s0|138-138|,|O
DDI-DrugBank.d251.s0|140-147|Rifampin|drug
DDI-DrugBank.d251.s0|148-148|,|O
DDI-DrugBank.d251.s0|150-158|Ritanovir|O
DDI-DrugBank.d251.s0|159-159|,|O
DDI-DrugBank.d251.s0|161-170|Saquinavir|drug
DDI-DrugBank.d251.s0|171-171|.|O
DDI-DrugBank.d206.s0|0-6|Results|O
DDI-DrugBank.d206.s0|8-9|of|O
DDI-DrugBank.d206.s0|11-21|preliminary|O
DDI-DrugBank.d206.s0|23-29|studies|O
DDI-DrugBank.d206.s0|31-32|in|O
DDI-DrugBank.d206.s0|34-39|humans|O
DDI-DrugBank.d206.s0|41-43|and|O
DDI-DrugBank.d206.s0|45-48|rats|O
DDI-DrugBank.d206.s0|50-56|suggest|O
DDI-DrugBank.d206.s0|58-61|that|O
DDI-DrugBank.d206.s0|63-75|nonabsorbable|O
DDI-DrugBank.d206.s0|77-84|antacids|group
DDI-DrugBank.d206.s0|86-90|given|O
DDI-DrugBank.d206.s0|92-103|concurrently|O
DDI-DrugBank.d206.s0|105-108|with|O
DDI-DrugBank.d206.s0|110-118|lactulose|drug
DDI-DrugBank.d206.s0|120-122|may|O
DDI-DrugBank.d206.s0|124-130|inhibit|O
DDI-DrugBank.d206.s0|132-134|the|O
DDI-DrugBank.d206.s0|136-142|desired|O
DDI-DrugBank.d206.s0|144-160|lactulose-induced|drug
DDI-DrugBank.d206.s0|162-165|drop|O
DDI-DrugBank.d206.s0|167-168|in|O
DDI-DrugBank.d206.s0|170-176|colonic|O
DDI-DrugBank.d206.s0|178-179|pH|O
DDI-DrugBank.d206.s0|180-180|.|O
DDI-DrugBank.d206.s1|0-8|Therefore|O
DDI-DrugBank.d206.s1|9-9|,|O
DDI-DrugBank.d206.s1|11-11|a|O
DDI-DrugBank.d206.s1|13-20|possible|O
DDI-DrugBank.d206.s1|22-25|lack|O
DDI-DrugBank.d206.s1|27-28|of|O
DDI-DrugBank.d206.s1|30-36|desired|O
DDI-DrugBank.d206.s1|38-43|effect|O
DDI-DrugBank.d206.s1|45-46|of|O
DDI-DrugBank.d206.s1|48-56|treatment|O
DDI-DrugBank.d206.s1|58-63|should|O
DDI-DrugBank.d206.s1|65-66|be|O
DDI-DrugBank.d206.s1|68-72|taken|O
DDI-DrugBank.d206.s1|74-77|into|O
DDI-DrugBank.d206.s1|79-91|consideration|O
DDI-DrugBank.d206.s1|93-98|before|O
DDI-DrugBank.d206.s1|100-103|such|O
DDI-DrugBank.d206.s1|105-109|drugs|O
DDI-DrugBank.d206.s1|111-113|are|O
DDI-DrugBank.d206.s1|115-119|given|O
DDI-DrugBank.d206.s1|121-133|concomitantly|O
DDI-DrugBank.d206.s1|135-138|with|O
DDI-DrugBank.d206.s1|140-148|lactulose|drug
DDI-DrugBank.d206.s1|149-149|.|O
DDI-MedLine.d83.s0|0-9|Olanzapine|drug
DDI-MedLine.d83.s0|10-10|:|O
DDI-MedLine.d83.s0|12-13|an|O
DDI-MedLine.d83.s0|15-21|updated|O
DDI-MedLine.d83.s0|23-28|review|O
DDI-MedLine.d83.s0|30-31|of|O
DDI-MedLine.d83.s0|33-35|its|O
DDI-MedLine.d83.s0|37-39|use|O
DDI-MedLine.d83.s0|41-42|in|O
DDI-MedLine.d83.s0|44-46|the|O
DDI-MedLine.d83.s0|48-57|management|O
DDI-MedLine.d83.s0|59-60|of|O
DDI-MedLine.d83.s0|62-74|schizophrenia|O
DDI-MedLine.d83.s0|75-75|.|O
DDI-MedLine.d83.s1|0-9|Olanzapine|drug
DDI-MedLine.d83.s1|10-10|,|O
DDI-MedLine.d83.s1|12-12|a|O
DDI-MedLine.d83.s1|14-44|thienobenzodiazepine derivative|group
DDI-MedLine.d83.s1|45-45|,|O
DDI-MedLine.d83.s1|47-48|is|O
DDI-MedLine.d83.s1|50-50|a|O
DDI-MedLine.d83.s1|52-99|second generation ( atypical ) antipsychotic agent|group
DDI-MedLine.d83.s1|101-105|which|O
DDI-MedLine.d83.s1|107-109|has|O
DDI-MedLine.d83.s1|111-116|proven|O
DDI-MedLine.d83.s1|118-125|efficacy|O
DDI-MedLine.d83.s1|127-133|against|O
DDI-MedLine.d83.s1|135-137|the|O
DDI-MedLine.d83.s1|139-146|positive|O
DDI-MedLine.d83.s1|148-150|and|O
DDI-MedLine.d83.s1|152-159|negative|O
DDI-MedLine.d83.s1|161-168|symptoms|O
DDI-MedLine.d83.s1|170-171|of|O
DDI-MedLine.d83.s1|173-185|schizophrenia|O
DDI-MedLine.d83.s1|186-186|.|O
DDI-MedLine.d83.s2|0-7|Compared|O
DDI-MedLine.d83.s2|9-12|with|O
DDI-MedLine.d83.s2|14-40|conventional antipsychotics|group
DDI-MedLine.d83.s2|41-41|,|O
DDI-MedLine.d83.s2|43-44|it|O
DDI-MedLine.d83.s2|46-48|has|O
DDI-MedLine.d83.s2|50-56|greater|O
DDI-MedLine.d83.s2|58-65|affinity|O
DDI-MedLine.d83.s2|67-69|for|O
DDI-MedLine.d83.s2|71-79|serotonin|O
DDI-MedLine.d83.s2|81-86|5-HT2A|O
DDI-MedLine.d83.s2|88-91|than|O
DDI-MedLine.d83.s2|93-95|for|O
DDI-MedLine.d83.s2|97-104|dopamine|O
DDI-MedLine.d83.s2|106-107|D2|O
DDI-MedLine.d83.s2|109-117|receptors|O
DDI-MedLine.d83.s2|118-118|.|O
DDI-MedLine.d83.s3|0-1|In|O
DDI-MedLine.d83.s3|3-7|large|O
DDI-MedLine.d83.s3|8-8|,|O
DDI-MedLine.d83.s3|10-13|well|O
DDI-MedLine.d83.s3|15-24|controlled|O
DDI-MedLine.d83.s3|26-31|trials|O
DDI-MedLine.d83.s3|33-34|in|O
DDI-MedLine.d83.s3|36-43|patients|O
DDI-MedLine.d83.s3|45-48|with|O
DDI-MedLine.d83.s3|50-62|schizophrenia|O
DDI-MedLine.d83.s3|64-65|or|O
DDI-MedLine.d83.s3|67-73|related|O
DDI-MedLine.d83.s3|75-83|psychoses|O
DDI-MedLine.d83.s3|84-84|,|O
DDI-MedLine.d83.s3|86-95|olanzapine|drug
DDI-MedLine.d83.s3|97-97|5|O
DDI-MedLine.d83.s3|99-100|to|O
DDI-MedLine.d83.s3|102-103|20|O
DDI-MedLine.d83.s3|105-110|mg/day|O
DDI-MedLine.d83.s3|112-114|was|O
DDI-MedLine.d83.s3|116-128|significantly|O
DDI-MedLine.d83.s3|130-137|superior|O
DDI-MedLine.d83.s3|139-140|to|O
DDI-MedLine.d83.s3|142-152|haloperidol|drug
DDI-MedLine.d83.s3|154-154|5|O
DDI-MedLine.d83.s3|156-157|to|O
DDI-MedLine.d83.s3|159-160|20|O
DDI-MedLine.d83.s3|162-167|mg/day|O
DDI-MedLine.d83.s3|169-170|in|O
DDI-MedLine.d83.s3|172-178|overall|O
DDI-MedLine.d83.s3|180-191|improvements|O
DDI-MedLine.d83.s3|193-194|in|O
DDI-MedLine.d83.s3|196-210|psychopathology|O
DDI-MedLine.d83.s3|212-217|rating|O
DDI-MedLine.d83.s3|219-224|scales|O
DDI-MedLine.d83.s3|226-228|and|O
DDI-MedLine.d83.s3|230-231|in|O
DDI-MedLine.d83.s3|233-235|the|O
DDI-MedLine.d83.s3|237-245|treatment|O
DDI-MedLine.d83.s3|247-248|of|O
DDI-MedLine.d83.s3|250-259|depressive|O
DDI-MedLine.d83.s3|261-263|and|O
DDI-MedLine.d83.s3|265-272|negative|O
DDI-MedLine.d83.s3|274-281|symptoms|O
DDI-MedLine.d83.s3|282-282|,|O
DDI-MedLine.d83.s3|284-286|and|O
DDI-MedLine.d83.s3|288-290|was|O
DDI-MedLine.d83.s3|292-301|comparable|O
DDI-MedLine.d83.s3|303-304|in|O
DDI-MedLine.d83.s3|306-312|effects|O
DDI-MedLine.d83.s3|314-315|on|O
DDI-MedLine.d83.s3|317-324|positive|O
DDI-MedLine.d83.s3|326-334|psychotic|O
DDI-MedLine.d83.s3|336-343|symptoms|O
DDI-MedLine.d83.s3|344-344|.|O
DDI-MedLine.d83.s4|0-2|The|O
DDI-MedLine.d83.s4|4-9|1-year|O
DDI-MedLine.d83.s4|11-14|risk|O
DDI-MedLine.d83.s4|16-17|of|O
DDI-MedLine.d83.s4|19-25|relapse|O
DDI-MedLine.d83.s4|27-27|(|O
DDI-MedLine.d83.s4|28-44|rehospitalisation|O
DDI-MedLine.d83.s4|45-45|)|O
DDI-MedLine.d83.s4|47-49|was|O
DDI-MedLine.d83.s4|51-63|significantly|O
DDI-MedLine.d83.s4|65-69|lower|O
DDI-MedLine.d83.s4|71-74|with|O
DDI-MedLine.d83.s4|76-85|olanzapine|drug
DDI-MedLine.d83.s4|87-90|than|O
DDI-MedLine.d83.s4|92-95|with|O
DDI-MedLine.d83.s4|97-107|haloperidol|drug
DDI-MedLine.d83.s4|109-117|treatment|O
DDI-MedLine.d83.s4|118-118|.|O
DDI-MedLine.d83.s5|0-1|In|O
DDI-MedLine.d83.s5|3-5|the|O
DDI-MedLine.d83.s5|7-11|first|O
DDI-MedLine.d83.s5|13-24|double-blind|O
DDI-MedLine.d83.s5|26-36|comparative|O
DDI-MedLine.d83.s5|38-42|study|O
DDI-MedLine.d83.s5|44-44|(|O
DDI-MedLine.d83.s5|45-51|28-week|O
DDI-MedLine.d83.s5|52-52|)|O
DDI-MedLine.d83.s5|54-55|of|O
DDI-MedLine.d83.s5|57-66|olanzapine|drug
DDI-MedLine.d83.s5|68-70|and|O
DDI-MedLine.d83.s5|72-82|risperidone|drug
DDI-MedLine.d83.s5|83-83|,|O
DDI-MedLine.d83.s5|85-94|olanzapine|drug
DDI-MedLine.d83.s5|96-97|10|O
DDI-MedLine.d83.s5|99-100|to|O
DDI-MedLine.d83.s5|102-103|20|O
DDI-MedLine.d83.s5|105-110|mg/day|O
DDI-MedLine.d83.s5|112-117|proved|O
DDI-MedLine.d83.s5|119-120|to|O
DDI-MedLine.d83.s5|122-123|be|O
DDI-MedLine.d83.s5|125-137|significantly|O
DDI-MedLine.d83.s5|139-142|more|O
DDI-MedLine.d83.s5|144-152|effective|O
DDI-MedLine.d83.s5|154-157|than|O
DDI-MedLine.d83.s5|159-169|risperidone|drug
DDI-MedLine.d83.s5|171-171|4|O
DDI-MedLine.d83.s5|173-174|to|O
DDI-MedLine.d83.s5|176-177|12|O
DDI-MedLine.d83.s5|179-184|mg/day|O
DDI-MedLine.d83.s5|186-187|in|O
DDI-MedLine.d83.s5|189-191|the|O
DDI-MedLine.d83.s5|193-201|treatment|O
DDI-MedLine.d83.s5|203-204|of|O
DDI-MedLine.d83.s5|206-213|negative|O
DDI-MedLine.d83.s5|215-217|and|O
DDI-MedLine.d83.s5|219-228|depressive|O
DDI-MedLine.d83.s5|230-237|symptoms|O
DDI-MedLine.d83.s5|239-241|but|O
DDI-MedLine.d83.s5|243-245|not|O
DDI-MedLine.d83.s5|247-248|on|O
DDI-MedLine.d83.s5|250-256|overall|O
DDI-MedLine.d83.s5|258-272|psychopathology|O
DDI-MedLine.d83.s5|274-281|symptoms|O
DDI-MedLine.d83.s5|282-282|.|O
DDI-MedLine.d83.s6|0-1|In|O
DDI-MedLine.d83.s6|3-10|contrast|O
DDI-MedLine.d83.s6|11-11|,|O
DDI-MedLine.d83.s6|13-23|preliminary|O
DDI-MedLine.d83.s6|25-31|results|O
DDI-MedLine.d83.s6|33-36|from|O
DDI-MedLine.d83.s6|38-39|an|O
DDI-MedLine.d83.s6|41-46|8-week|O
DDI-MedLine.d83.s6|48-57|controlled|O
DDI-MedLine.d83.s6|59-63|study|O
DDI-MedLine.d83.s6|65-73|suggested|O
DDI-MedLine.d83.s6|75-85|risperidone|drug
DDI-MedLine.d83.s6|87-87|2|O
DDI-MedLine.d83.s6|89-90|to|O
DDI-MedLine.d83.s6|92-92|6|O
DDI-MedLine.d83.s6|94-99|mg/day|O
DDI-MedLine.d83.s6|101-103|was|O
DDI-MedLine.d83.s6|105-112|superior|O
DDI-MedLine.d83.s6|114-115|to|O
DDI-MedLine.d83.s6|117-126|olanzapine|drug
DDI-MedLine.d83.s6|128-128|5|O
DDI-MedLine.d83.s6|130-131|to|O
DDI-MedLine.d83.s6|133-134|20|O
DDI-MedLine.d83.s6|136-141|mg/day|O
DDI-MedLine.d83.s6|143-149|against|O
DDI-MedLine.d83.s6|151-158|positive|O
DDI-MedLine.d83.s6|160-162|and|O
DDI-MedLine.d83.s6|164-181|anxiety/depressive|O
DDI-MedLine.d83.s6|183-190|symptoms|O
DDI-MedLine.d83.s6|192-192|(|O
DDI-MedLine.d83.s6|193-193|p|O
DDI-MedLine.d83.s6|195-195|<|O
DDI-MedLine.d83.s6|197-200|0.05|O
DDI-MedLine.d83.s6|201-201|)|O
DDI-MedLine.d83.s6|202-202|,|O
DDI-MedLine.d83.s6|204-211|although|O
DDI-MedLine.d83.s6|213-222|consistent|O
DDI-MedLine.d83.s6|224-227|with|O
DDI-MedLine.d83.s6|229-231|the|O
DDI-MedLine.d83.s6|233-237|first|O
DDI-MedLine.d83.s6|239-243|study|O
DDI-MedLine.d83.s6|244-244|,|O
DDI-MedLine.d83.s6|246-249|both|O
DDI-MedLine.d83.s6|251-256|agents|O
DDI-MedLine.d83.s6|258-269|demonstrated|O
DDI-MedLine.d83.s6|271-277|similar|O
DDI-MedLine.d83.s6|279-286|efficacy|O
DDI-MedLine.d83.s6|288-289|on|O
DDI-MedLine.d83.s6|291-298|measures|O
DDI-MedLine.d83.s6|300-301|of|O
DDI-MedLine.d83.s6|303-309|overall|O
DDI-MedLine.d83.s6|311-325|psychopathology|O
DDI-MedLine.d83.s6|326-326|.|O
DDI-MedLine.d83.s7|0-11|Improvements|O
DDI-MedLine.d83.s7|13-14|in|O
DDI-MedLine.d83.s7|16-22|general|O
DDI-MedLine.d83.s7|24-32|cognitive|O
DDI-MedLine.d83.s7|34-41|function|O
DDI-MedLine.d83.s7|43-46|seen|O
DDI-MedLine.d83.s7|48-51|with|O
DDI-MedLine.d83.s7|53-62|olanzapine|drug
DDI-MedLine.d83.s7|64-72|treatment|O
DDI-MedLine.d83.s7|74-75|in|O
DDI-MedLine.d83.s7|77-77|a|O
DDI-MedLine.d83.s7|79-84|1-year|O
DDI-MedLine.d83.s7|86-95|controlled|O
DDI-MedLine.d83.s7|97-101|study|O
DDI-MedLine.d83.s7|103-104|of|O
DDI-MedLine.d83.s7|106-113|patients|O
DDI-MedLine.d83.s7|115-118|with|O
DDI-MedLine.d83.s7|120-130|early-phase|O
DDI-MedLine.d83.s7|132-144|schizophrenia|O
DDI-MedLine.d83.s7|145-145|,|O
DDI-MedLine.d83.s7|147-150|were|O
DDI-MedLine.d83.s7|152-164|significantly|O
DDI-MedLine.d83.s7|166-172|greater|O
DDI-MedLine.d83.s7|174-177|than|O
DDI-MedLine.d83.s7|179-185|changes|O
DDI-MedLine.d83.s7|187-190|seen|O
DDI-MedLine.d83.s7|192-195|with|O
DDI-MedLine.d83.s7|197-202|either|O
DDI-MedLine.d83.s7|204-214|risperidone|drug
DDI-MedLine.d83.s7|216-217|or|O
DDI-MedLine.d83.s7|219-229|haloperidol|drug
DDI-MedLine.d83.s7|230-230|.|O
DDI-MedLine.d83.s8|0-6|However|O
DDI-MedLine.d83.s8|7-7|,|O
DDI-MedLine.d83.s8|9-19|preliminary|O
DDI-MedLine.d83.s8|21-27|results|O
DDI-MedLine.d83.s8|29-32|from|O
DDI-MedLine.d83.s8|34-35|an|O
DDI-MedLine.d83.s8|37-42|8-week|O
DDI-MedLine.d83.s8|44-48|trial|O
DDI-MedLine.d83.s8|50-55|showed|O
DDI-MedLine.d83.s8|57-66|comparable|O
DDI-MedLine.d83.s8|68-76|cognitive|O
DDI-MedLine.d83.s8|78-86|enhancing|O
DDI-MedLine.d83.s8|88-94|effects|O
DDI-MedLine.d83.s8|96-97|of|O
DDI-MedLine.d83.s8|99-108|olanzapine|drug
DDI-MedLine.d83.s8|110-112|and|O
DDI-MedLine.d83.s8|114-124|risperidone|drug
DDI-MedLine.d83.s8|126-134|treatment|O
DDI-MedLine.d83.s8|136-137|in|O
DDI-MedLine.d83.s8|139-146|patients|O
DDI-MedLine.d83.s8|148-151|with|O
DDI-MedLine.d83.s8|153-165|schizophrenia|O
DDI-MedLine.d83.s8|167-168|or|O
DDI-MedLine.d83.s8|170-184|schizoaffective|O
DDI-MedLine.d83.s8|186-193|disorder|O
DDI-MedLine.d83.s8|194-194|.|O
DDI-MedLine.d83.s9|0-6|Several|O
DDI-MedLine.d83.s9|8-14|studies|O
DDI-MedLine.d83.s9|16-23|indicate|O
DDI-MedLine.d83.s9|25-28|that|O
DDI-MedLine.d83.s9|30-39|olanzapine|drug
DDI-MedLine.d83.s9|41-43|has|O
DDI-MedLine.d83.s9|45-52|benefits|O
DDI-MedLine.d83.s9|54-60|against|O
DDI-MedLine.d83.s9|62-69|symptoms|O
DDI-MedLine.d83.s9|71-72|of|O
DDI-MedLine.d83.s9|74-83|aggression|O
DDI-MedLine.d83.s9|85-87|and|O
DDI-MedLine.d83.s9|89-97|agitation|O
DDI-MedLine.d83.s9|98-98|,|O
DDI-MedLine.d83.s9|100-104|while|O
DDI-MedLine.d83.s9|106-110|other|O
DDI-MedLine.d83.s9|112-118|studies|O
DDI-MedLine.d83.s9|120-127|strongly|O
DDI-MedLine.d83.s9|129-135|support|O
DDI-MedLine.d83.s9|137-139|the|O
DDI-MedLine.d83.s9|141-153|effectiveness|O
DDI-MedLine.d83.s9|155-156|of|O
DDI-MedLine.d83.s9|158-167|olanzapine|drug
DDI-MedLine.d83.s9|169-170|in|O
DDI-MedLine.d83.s9|172-174|the|O
DDI-MedLine.d83.s9|176-184|treatment|O
DDI-MedLine.d83.s9|186-187|of|O
DDI-MedLine.d83.s9|189-198|depressive|O
DDI-MedLine.d83.s9|200-213|symptomatology|O
DDI-MedLine.d83.s9|214-214|.|O
DDI-MedLine.d83.s10|0-9|Olanzapine|drug
DDI-MedLine.d83.s10|11-12|is|O
DDI-MedLine.d83.s10|14-23|associated|O
DDI-MedLine.d83.s10|25-28|with|O
DDI-MedLine.d83.s10|30-42|significantly|O
DDI-MedLine.d83.s10|44-48|fewer|O
DDI-MedLine.d83.s10|50-63|extrapyramidal|O
DDI-MedLine.d83.s10|65-72|symptoms|O
DDI-MedLine.d83.s10|74-77|than|O
DDI-MedLine.d83.s10|79-89|haloperidol|drug
DDI-MedLine.d83.s10|91-93|and|O
DDI-MedLine.d83.s10|95-105|risperidone|drug
DDI-MedLine.d83.s10|106-106|.|O
DDI-MedLine.d83.s11|0-1|In|O
DDI-MedLine.d83.s11|3-10|addition|O
DDI-MedLine.d83.s11|11-11|,|O
DDI-MedLine.d83.s11|13-22|olanzapine|drug
DDI-MedLine.d83.s11|24-25|is|O
DDI-MedLine.d83.s11|27-29|not|O
DDI-MedLine.d83.s11|31-40|associated|O
DDI-MedLine.d83.s11|42-45|with|O
DDI-MedLine.d83.s11|47-47|a|O
DDI-MedLine.d83.s11|49-52|risk|O
DDI-MedLine.d83.s11|54-55|of|O
DDI-MedLine.d83.s11|57-71|agranulocytosis|O
DDI-MedLine.d83.s11|73-74|as|O
DDI-MedLine.d83.s11|76-79|seen|O
DDI-MedLine.d83.s11|81-84|with|O
DDI-MedLine.d83.s11|86-94|clozapine|drug
DDI-MedLine.d83.s11|96-97|or|O
DDI-MedLine.d83.s11|99-108|clinically|O
DDI-MedLine.d83.s11|110-120|significant|O
DDI-MedLine.d83.s11|122-140|hyperprolactinaemia|O
DDI-MedLine.d83.s11|142-143|as|O
DDI-MedLine.d83.s11|145-148|seen|O
DDI-MedLine.d83.s11|150-153|with|O
DDI-MedLine.d83.s11|155-165|risperidone|drug
DDI-MedLine.d83.s11|167-168|or|O
DDI-MedLine.d83.s11|170-181|prolongation|O
DDI-MedLine.d83.s11|183-184|of|O
DDI-MedLine.d83.s11|186-188|the|O
DDI-MedLine.d83.s11|190-191|QT|O
DDI-MedLine.d83.s11|193-200|interval|O
DDI-MedLine.d83.s11|201-201|.|O
DDI-MedLine.d83.s12|0-2|The|O
DDI-MedLine.d83.s12|4-7|most|O
DDI-MedLine.d83.s12|9-14|common|O
DDI-MedLine.d83.s12|16-22|adverse|O
DDI-MedLine.d83.s12|24-30|effects|O
DDI-MedLine.d83.s12|32-39|reported|O
DDI-MedLine.d83.s12|41-44|with|O
DDI-MedLine.d83.s12|46-55|olanzapine|drug
DDI-MedLine.d83.s12|57-59|are|O
DDI-MedLine.d83.s12|61-70|bodyweight|O
DDI-MedLine.d83.s12|72-75|gain|O
DDI-MedLine.d83.s12|76-76|,|O
DDI-MedLine.d83.s12|78-87|somnolence|O
DDI-MedLine.d83.s12|88-88|,|O
DDI-MedLine.d83.s12|90-98|dizziness|O
DDI-MedLine.d83.s12|99-99|,|O
DDI-MedLine.d83.s12|101-115|anticholinergic|O
DDI-MedLine.d83.s12|117-123|effects|O
DDI-MedLine.d83.s12|125-125|(|O
DDI-MedLine.d83.s12|126-137|constipation|O
DDI-MedLine.d83.s12|139-141|and|O
DDI-MedLine.d83.s12|143-145|dry|O
DDI-MedLine.d83.s12|147-151|mouth|O
DDI-MedLine.d83.s12|152-152|)|O
DDI-MedLine.d83.s12|154-156|and|O
DDI-MedLine.d83.s12|158-166|transient|O
DDI-MedLine.d83.s12|168-179|asymptomatic|O
DDI-MedLine.d83.s12|181-185|liver|O
DDI-MedLine.d83.s12|187-192|enzyme|O
DDI-MedLine.d83.s12|194-203|elevations|O
DDI-MedLine.d83.s12|204-204|.|O
DDI-MedLine.d83.s13|0-1|In|O
DDI-MedLine.d83.s13|3-12|comparison|O
DDI-MedLine.d83.s13|14-17|with|O
DDI-MedLine.d83.s13|19-29|haloperidol|drug
DDI-MedLine.d83.s13|30-30|,|O
DDI-MedLine.d83.s13|32-34|the|O
DDI-MedLine.d83.s13|36-42|adverse|O
DDI-MedLine.d83.s13|44-49|events|O
DDI-MedLine.d83.s13|51-58|reported|O
DDI-MedLine.d83.s13|60-72|significantly|O
DDI-MedLine.d83.s13|74-77|more|O
DDI-MedLine.d83.s13|79-88|frequently|O
DDI-MedLine.d83.s13|90-93|with|O
DDI-MedLine.d83.s13|95-104|olanzapine|drug
DDI-MedLine.d83.s13|106-107|in|O
DDI-MedLine.d83.s13|109-109|>|O
DDI-MedLine.d83.s13|111-112|or|O
DDI-MedLine.d83.s13|114-114|=|O
DDI-MedLine.d83.s13|116-118|3.5|O
DDI-MedLine.d83.s13|119-119|%|O
DDI-MedLine.d83.s13|121-122|of|O
DDI-MedLine.d83.s13|124-131|patients|O
DDI-MedLine.d83.s13|133-136|were|O
DDI-MedLine.d83.s13|138-140|dry|O
DDI-MedLine.d83.s13|142-146|mouth|O
DDI-MedLine.d83.s13|147-147|,|O
DDI-MedLine.d83.s13|149-158|bodyweight|O
DDI-MedLine.d83.s13|160-163|gain|O
DDI-MedLine.d83.s13|165-167|and|O
DDI-MedLine.d83.s13|169-177|increased|O
DDI-MedLine.d83.s13|179-186|appetite|O
DDI-MedLine.d83.s13|188-190|and|O
DDI-MedLine.d83.s13|192-199|compared|O
DDI-MedLine.d83.s13|201-204|with|O
DDI-MedLine.d83.s13|206-216|risperidone|drug
DDI-MedLine.d83.s13|217-217|,|O
DDI-MedLine.d83.s13|219-222|only|O
DDI-MedLine.d83.s13|224-233|bodyweight|O
DDI-MedLine.d83.s13|235-238|gain|O
DDI-MedLine.d83.s13|240-247|occurred|O
DDI-MedLine.d83.s13|249-261|significantly|O
DDI-MedLine.d83.s13|263-266|more|O
DDI-MedLine.d83.s13|268-277|frequently|O
DDI-MedLine.d83.s13|279-282|with|O
DDI-MedLine.d83.s13|284-293|olanzapine|drug
DDI-MedLine.d83.s13|294-294|.|O
DDI-MedLine.d83.s14|0-2|The|O
DDI-MedLine.d83.s14|4-7|high|O
DDI-MedLine.d83.s14|9-19|acquisition|O
DDI-MedLine.d83.s14|21-24|cost|O
DDI-MedLine.d83.s14|26-27|of|O
DDI-MedLine.d83.s14|29-38|olanzapine|drug
DDI-MedLine.d83.s14|40-41|is|O
DDI-MedLine.d83.s14|43-48|offset|O
DDI-MedLine.d83.s14|50-51|by|O
DDI-MedLine.d83.s14|53-62|reductions|O
DDI-MedLine.d83.s14|64-65|in|O
DDI-MedLine.d83.s14|67-71|other|O
DDI-MedLine.d83.s14|73-81|treatment|O
DDI-MedLine.d83.s14|83-87|costs|O
DDI-MedLine.d83.s14|89-89|(|O
DDI-MedLine.d83.s14|90-98|inpatient|O
DDI-MedLine.d83.s14|100-105|and/or|O
DDI-MedLine.d83.s14|107-116|outpatient|O
DDI-MedLine.d83.s14|118-125|services|O
DDI-MedLine.d83.s14|126-126|)|O
DDI-MedLine.d83.s14|128-129|of|O
DDI-MedLine.d83.s14|131-143|schizophrenia|O
DDI-MedLine.d83.s14|144-144|.|O
DDI-MedLine.d83.s15|0-15|Pharmacoeconomic|O
DDI-MedLine.d83.s15|17-24|analyses|O
DDI-MedLine.d83.s15|26-33|indicate|O
DDI-MedLine.d83.s15|35-38|that|O
DDI-MedLine.d83.s15|40-49|olanzapine|drug
DDI-MedLine.d83.s15|51-54|does|O
DDI-MedLine.d83.s15|56-58|not|O
DDI-MedLine.d83.s15|60-72|significantly|O
DDI-MedLine.d83.s15|74-81|increase|O
DDI-MedLine.d83.s15|82-82|,|O
DDI-MedLine.d83.s15|84-86|and|O
DDI-MedLine.d83.s15|88-90|may|O
DDI-MedLine.d83.s15|92-95|even|O
DDI-MedLine.d83.s15|97-104|decrease|O
DDI-MedLine.d83.s15|105-105|,|O
DDI-MedLine.d83.s15|107-109|the|O
DDI-MedLine.d83.s15|111-117|overall|O
DDI-MedLine.d83.s15|119-124|direct|O
DDI-MedLine.d83.s15|126-134|treatment|O
DDI-MedLine.d83.s15|136-140|costs|O
DDI-MedLine.d83.s15|142-143|of|O
DDI-MedLine.d83.s15|145-157|schizophrenia|O
DDI-MedLine.d83.s15|158-158|,|O
DDI-MedLine.d83.s15|160-167|compared|O
DDI-MedLine.d83.s15|169-172|with|O
DDI-MedLine.d83.s15|174-184|haloperidol|drug
DDI-MedLine.d83.s15|185-185|.|O
DDI-MedLine.d83.s16|0-7|Compared|O
DDI-MedLine.d83.s16|9-12|with|O
DDI-MedLine.d83.s16|14-24|risperidone|drug
DDI-MedLine.d83.s16|25-25|,|O
DDI-MedLine.d83.s16|27-36|olanzapine|drug
DDI-MedLine.d83.s16|38-40|has|O
DDI-MedLine.d83.s16|42-45|also|O
DDI-MedLine.d83.s16|47-50|been|O
DDI-MedLine.d83.s16|52-59|reported|O
DDI-MedLine.d83.s16|61-62|to|O
DDI-MedLine.d83.s16|64-71|decrease|O
DDI-MedLine.d83.s16|73-79|overall|O
DDI-MedLine.d83.s16|81-89|treatment|O
DDI-MedLine.d83.s16|91-95|costs|O
DDI-MedLine.d83.s16|96-96|,|O
DDI-MedLine.d83.s16|98-104|despite|O
DDI-MedLine.d83.s16|106-108|the|O
DDI-MedLine.d83.s16|110-121|several-fold|O
DDI-MedLine.d83.s16|123-128|higher|O
DDI-MedLine.d83.s16|130-134|daily|O
DDI-MedLine.d83.s16|136-146|acquisition|O
DDI-MedLine.d83.s16|148-151|cost|O
DDI-MedLine.d83.s16|153-154|of|O
DDI-MedLine.d83.s16|156-158|the|O
DDI-MedLine.d83.s16|160-163|drug|O
DDI-MedLine.d83.s16|164-164|.|O
DDI-MedLine.d83.s17|0-9|Olanzapine|drug
DDI-MedLine.d83.s17|11-19|treatment|O
DDI-MedLine.d83.s17|21-28|improves|O
DDI-MedLine.d83.s17|30-36|quality|O
DDI-MedLine.d83.s17|38-39|of|O
DDI-MedLine.d83.s17|41-44|life|O
DDI-MedLine.d83.s17|46-47|in|O
DDI-MedLine.d83.s17|49-56|patients|O
DDI-MedLine.d83.s17|58-61|with|O
DDI-MedLine.d83.s17|63-75|schizophrenia|O
DDI-MedLine.d83.s17|77-79|and|O
DDI-MedLine.d83.s17|81-87|related|O
DDI-MedLine.d83.s17|89-97|psychoses|O
DDI-MedLine.d83.s17|99-100|to|O
DDI-MedLine.d83.s17|102-102|a|O
DDI-MedLine.d83.s17|104-110|greater|O
DDI-MedLine.d83.s17|112-117|extent|O
DDI-MedLine.d83.s17|119-122|than|O
DDI-MedLine.d83.s17|124-134|haloperidol|drug
DDI-MedLine.d83.s17|135-135|,|O
DDI-MedLine.d83.s17|137-139|and|O
DDI-MedLine.d83.s17|141-142|to|O
DDI-MedLine.d83.s17|144-150|broadly|O
DDI-MedLine.d83.s17|152-154|the|O
DDI-MedLine.d83.s17|156-159|same|O
DDI-MedLine.d83.s17|161-166|extent|O
DDI-MedLine.d83.s17|168-169|as|O
DDI-MedLine.d83.s17|171-181|risperidone|drug
DDI-MedLine.d83.s17|182-182|.|O
DDI-MedLine.d83.s18|0-10|CONCLUSIONS|O
DDI-MedLine.d83.s18|11-11|:|O
DDI-MedLine.d83.s18|13-22|Olanzapine|drug
DDI-MedLine.d83.s18|24-35|demonstrated|O
DDI-MedLine.d83.s18|37-44|superior|O
DDI-MedLine.d83.s18|46-58|antipsychotic|O
DDI-MedLine.d83.s18|60-67|efficacy|O
DDI-MedLine.d83.s18|69-76|compared|O
DDI-MedLine.d83.s18|78-81|with|O
DDI-MedLine.d83.s18|83-93|haloperidol|drug
DDI-MedLine.d83.s18|95-96|in|O
DDI-MedLine.d83.s18|98-100|the|O
DDI-MedLine.d83.s18|102-110|treatment|O
DDI-MedLine.d83.s18|112-113|of|O
DDI-MedLine.d83.s18|115-119|acute|O
DDI-MedLine.d83.s18|121-125|phase|O
DDI-MedLine.d83.s18|127-139|schizophrenia|O
DDI-MedLine.d83.s18|140-140|,|O
DDI-MedLine.d83.s18|142-144|and|O
DDI-MedLine.d83.s18|146-147|in|O
DDI-MedLine.d83.s18|149-151|the|O
DDI-MedLine.d83.s18|153-161|treatment|O
DDI-MedLine.d83.s18|163-164|of|O
DDI-MedLine.d83.s18|166-169|some|O
DDI-MedLine.d83.s18|171-178|patients|O
DDI-MedLine.d83.s18|180-183|with|O
DDI-MedLine.d83.s18|185-197|first-episode|O
DDI-MedLine.d83.s18|199-200|or|O
DDI-MedLine.d83.s18|202-220|treatment-resistant|O
DDI-MedLine.d83.s18|222-234|schizophrenia|O
DDI-MedLine.d83.s18|235-235|.|O
DDI-MedLine.d83.s19|0-2|The|O
DDI-MedLine.d83.s19|4-10|reduced|O
DDI-MedLine.d83.s19|12-15|risk|O
DDI-MedLine.d83.s19|17-18|of|O
DDI-MedLine.d83.s19|20-26|adverse|O
DDI-MedLine.d83.s19|28-33|events|O
DDI-MedLine.d83.s19|35-37|and|O
DDI-MedLine.d83.s19|39-49|therapeutic|O
DDI-MedLine.d83.s19|51-61|superiority|O
DDI-MedLine.d83.s19|63-70|compared|O
DDI-MedLine.d83.s19|72-75|with|O
DDI-MedLine.d83.s19|77-87|haloperidol|drug
DDI-MedLine.d83.s19|89-91|and|O
DDI-MedLine.d83.s19|93-103|risperidone|drug
DDI-MedLine.d83.s19|105-106|in|O
DDI-MedLine.d83.s19|108-110|the|O
DDI-MedLine.d83.s19|112-120|treatment|O
DDI-MedLine.d83.s19|122-123|of|O
DDI-MedLine.d83.s19|125-132|negative|O
DDI-MedLine.d83.s19|134-136|and|O
DDI-MedLine.d83.s19|138-147|depressive|O
DDI-MedLine.d83.s19|149-156|symptoms|O
DDI-MedLine.d83.s19|158-164|support|O
DDI-MedLine.d83.s19|166-168|the|O
DDI-MedLine.d83.s19|170-175|choice|O
DDI-MedLine.d83.s19|177-178|of|O
DDI-MedLine.d83.s19|180-189|olanzapine|drug
DDI-MedLine.d83.s19|191-192|as|O
DDI-MedLine.d83.s19|194-194|a|O
DDI-MedLine.d83.s19|196-205|first-line|O
DDI-MedLine.d83.s19|207-212|option|O
DDI-MedLine.d83.s19|214-215|in|O
DDI-MedLine.d83.s19|217-219|the|O
DDI-MedLine.d83.s19|221-230|management|O
DDI-MedLine.d83.s19|232-233|of|O
DDI-MedLine.d83.s19|235-247|schizophrenia|O
DDI-MedLine.d83.s19|249-250|in|O
DDI-MedLine.d83.s19|252-254|the|O
DDI-MedLine.d83.s19|256-260|acute|O
DDI-MedLine.d83.s19|262-266|phase|O
DDI-MedLine.d83.s19|268-270|and|O
DDI-MedLine.d83.s19|272-274|for|O
DDI-MedLine.d83.s19|276-278|the|O
DDI-MedLine.d83.s19|280-290|maintenance|O
DDI-MedLine.d83.s19|292-293|of|O
DDI-MedLine.d83.s19|295-303|treatment|O
DDI-MedLine.d83.s19|305-312|response|O
DDI-MedLine.d83.s19|313-313|.|O
DDI-DrugBank.d697.s0|0-11|Interactions|O
DDI-DrugBank.d697.s0|13-15|for|O
DDI-DrugBank.d697.s0|17-26|Vitamin B1|drug
DDI-DrugBank.d697.s0|28-28|(|O
DDI-DrugBank.d697.s0|29-36|Thiamine|drug
DDI-DrugBank.d697.s0|37-37|)|O
DDI-DrugBank.d697.s0|38-38|:|O
DDI-DrugBank.d697.s0|41-54|Loop Diuretics|group
DDI-DrugBank.d697.s0|55-55|,|O
DDI-DrugBank.d697.s0|57-60|Oral|O
DDI-DrugBank.d697.s0|62-75|Contraceptives|group
DDI-DrugBank.d697.s0|76-76|,|O
DDI-DrugBank.d697.s0|78-86|Stavudine|drug
DDI-DrugBank.d697.s0|87-87|,|O
DDI-DrugBank.d222.s0|0-3|When|O
DDI-DrugBank.d222.s0|5-12|atropine|drug
DDI-DrugBank.d222.s0|14-16|and|O
DDI-DrugBank.d222.s0|18-28|pralidoxime|drug
DDI-DrugBank.d222.s0|30-32|are|O
DDI-DrugBank.d222.s0|34-37|used|O
DDI-DrugBank.d222.s0|39-46|together|O
DDI-DrugBank.d222.s0|47-47|,|O
DDI-DrugBank.d222.s0|49-51|the|O
DDI-DrugBank.d222.s0|53-57|signs|O
DDI-DrugBank.d222.s0|59-60|of|O
DDI-DrugBank.d222.s0|62-75|atropinization|O
DDI-DrugBank.d222.s0|77-77|(|O
DDI-DrugBank.d222.s0|78-85|flushing|O
DDI-DrugBank.d222.s0|86-86|,|O
DDI-DrugBank.d222.s0|88-96|mydriasis|O
DDI-DrugBank.d222.s0|97-97|,|O
DDI-DrugBank.d222.s0|99-109|tachycardia|O
DDI-DrugBank.d222.s0|110-110|,|O
DDI-DrugBank.d222.s0|112-118|dryness|O
DDI-DrugBank.d222.s0|120-121|of|O
DDI-DrugBank.d222.s0|123-125|the|O
DDI-DrugBank.d222.s0|127-131|mouth|O
DDI-DrugBank.d222.s0|133-135|and|O
DDI-DrugBank.d222.s0|137-140|nose|O
DDI-DrugBank.d222.s0|141-141|)|O
DDI-DrugBank.d222.s0|143-145|may|O
DDI-DrugBank.d222.s0|147-151|occur|O
DDI-DrugBank.d222.s0|153-159|earlier|O
DDI-DrugBank.d222.s0|161-164|than|O
DDI-DrugBank.d222.s0|166-170|might|O
DDI-DrugBank.d222.s0|172-173|be|O
DDI-DrugBank.d222.s0|175-182|expected|O
DDI-DrugBank.d222.s0|184-187|than|O
DDI-DrugBank.d222.s0|189-192|when|O
DDI-DrugBank.d222.s0|194-201|atropine|drug
DDI-DrugBank.d222.s0|203-204|is|O
DDI-DrugBank.d222.s0|206-209|used|O
DDI-DrugBank.d222.s0|211-215|alone|O
DDI-DrugBank.d222.s0|217-223|because|O
DDI-DrugBank.d222.s0|225-235|pralidoxime|drug
DDI-DrugBank.d222.s0|237-239|may|O
DDI-DrugBank.d222.s0|241-250|potentiate|O
DDI-DrugBank.d222.s0|252-254|the|O
DDI-DrugBank.d222.s0|256-261|effect|O
DDI-DrugBank.d222.s0|263-264|of|O
DDI-DrugBank.d222.s0|266-273|atropine|drug
DDI-DrugBank.d222.s0|274-274|.|O
DDI-DrugBank.d222.s1|0-2|The|O
DDI-DrugBank.d222.s1|4-12|following|O
DDI-DrugBank.d222.s1|14-24|precautions|O
DDI-DrugBank.d222.s1|26-31|should|O
DDI-DrugBank.d222.s1|33-34|be|O
DDI-DrugBank.d222.s1|36-39|kept|O
DDI-DrugBank.d222.s1|41-42|in|O
DDI-DrugBank.d222.s1|44-47|mind|O
DDI-DrugBank.d222.s1|49-50|in|O
DDI-DrugBank.d222.s1|52-54|the|O
DDI-DrugBank.d222.s1|56-64|treatment|O
DDI-DrugBank.d222.s1|66-67|of|O
DDI-DrugBank.d222.s1|69-86|anticholinesterase|O
DDI-DrugBank.d222.s1|88-96|poisoning|O
DDI-DrugBank.d222.s1|98-105|although|O
DDI-DrugBank.d222.s1|107-110|they|O
DDI-DrugBank.d222.s1|112-113|do|O
DDI-DrugBank.d222.s1|115-117|not|O
DDI-DrugBank.d222.s1|119-122|bear|O
DDI-DrugBank.d222.s1|124-131|directly|O
DDI-DrugBank.d222.s1|133-134|on|O
DDI-DrugBank.d222.s1|136-138|the|O
DDI-DrugBank.d222.s1|140-142|use|O
DDI-DrugBank.d222.s1|144-145|of|O
DDI-DrugBank.d222.s1|147-154|atropine|drug
DDI-DrugBank.d222.s1|156-158|and|O
DDI-DrugBank.d222.s1|160-170|pralidoxime|drug
DDI-DrugBank.d222.s1|171-171|.|O
DDI-DrugBank.d222.s2|0-4|Since|O
DDI-DrugBank.d222.s2|6-17|barbiturates|group
DDI-DrugBank.d222.s2|19-21|are|O
DDI-DrugBank.d222.s2|23-33|potentiated|O
DDI-DrugBank.d222.s2|35-36|by|O
DDI-DrugBank.d222.s2|38-40|the|O
DDI-DrugBank.d222.s2|42-60|anticholinesterases|group
DDI-DrugBank.d222.s2|61-61|,|O
DDI-DrugBank.d222.s2|63-66|they|O
DDI-DrugBank.d222.s2|68-73|should|O
DDI-DrugBank.d222.s2|75-76|be|O
DDI-DrugBank.d222.s2|78-81|used|O
DDI-DrugBank.d222.s2|83-92|cautiously|O
DDI-DrugBank.d222.s2|94-95|in|O
DDI-DrugBank.d222.s2|97-99|the|O
DDI-DrugBank.d222.s2|101-109|treatment|O
DDI-DrugBank.d222.s2|111-112|of|O
DDI-DrugBank.d222.s2|114-124|convulsions|O
DDI-DrugBank.d222.s2|125-125|.|O
DDI-MedLine.d20.s0|0-10|Interaction|O
DDI-MedLine.d20.s0|12-18|between|O
DDI-MedLine.d20.s0|20-26|glycine|drug
DDI-MedLine.d20.s0|28-30|and|O
DDI-MedLine.d20.s0|32-40|glutamate|drug
DDI-MedLine.d20.s0|42-43|in|O
DDI-MedLine.d20.s0|45-47|the|O
DDI-MedLine.d20.s0|49-59|development|O
DDI-MedLine.d20.s0|61-62|of|O
DDI-MedLine.d20.s0|64-74|spontaneous|O
DDI-MedLine.d20.s0|76-83|motility|O
DDI-MedLine.d20.s0|85-86|in|O
DDI-MedLine.d20.s0|88-92|chick|O
DDI-MedLine.d20.s0|94-100|embryos|O
DDI-MedLine.d20.s0|101-101|.|O
DDI-MedLine.d20.s1|0-1|In|O
DDI-MedLine.d20.s1|3-6|this|O
DDI-MedLine.d20.s1|8-12|study|O
DDI-MedLine.d20.s1|14-15|we|O
DDI-MedLine.d20.s1|17-28|investigated|O
DDI-MedLine.d20.s1|30-36|whether|O
DDI-MedLine.d20.s1|38-41|also|O
DDI-MedLine.d20.s1|43-49|glycine|drug
DDI-MedLine.d20.s1|51-57|fulfils|O
DDI-MedLine.d20.s1|59-61|the|O
DDI-MedLine.d20.s1|63-70|function|O
DDI-MedLine.d20.s1|72-73|as|O
DDI-MedLine.d20.s1|75-86|co-activator|O
DDI-MedLine.d20.s1|88-89|in|O
DDI-MedLine.d20.s1|91-103|glutamatergic|O
DDI-MedLine.d20.s1|105-114|activation|O
DDI-MedLine.d20.s1|116-117|of|O
DDI-MedLine.d20.s1|119-122|NMDA|O
DDI-MedLine.d20.s1|124-132|receptors|O
DDI-MedLine.d20.s1|134-135|in|O
DDI-MedLine.d20.s1|137-139|the|O
DDI-MedLine.d20.s1|141-148|neuronal|O
DDI-MedLine.d20.s1|150-158|apparatus|O
DDI-MedLine.d20.s1|160-161|of|O
DDI-MedLine.d20.s1|163-173|spontaneous|O
DDI-MedLine.d20.s1|175-182|motility|O
DDI-MedLine.d20.s1|184-185|in|O
DDI-MedLine.d20.s1|187-191|chick|O
DDI-MedLine.d20.s1|193-199|embryos|O
DDI-MedLine.d20.s1|200-200|.|O
DDI-MedLine.d20.s2|0-2|The|O
DDI-MedLine.d20.s2|4-13|successive|O
DDI-MedLine.d20.s2|15-25|application|O
DDI-MedLine.d20.s2|27-28|of|O
DDI-MedLine.d20.s2|30-36|glycine|drug
DDI-MedLine.d20.s2|38-38|(|O
DDI-MedLine.d20.s2|39-39|5|O
DDI-MedLine.d20.s2|41-42|or|O
DDI-MedLine.d20.s2|44-45|10|O
DDI-MedLine.d20.s2|47-51|mg/kg|O
DDI-MedLine.d20.s2|53-55|egg|O
DDI-MedLine.d20.s2|57-62|weight|O
DDI-MedLine.d20.s2|64-64|(|O
DDI-MedLine.d20.s2|65-67|e.w|O
DDI-MedLine.d20.s2|68-68|.|O
DDI-MedLine.d20.s2|69-69|)|O
DDI-MedLine.d20.s3|0-2|and|O
DDI-MedLine.d20.s3|4-12|glutamate|drug
DDI-MedLine.d20.s3|14-14|(|O
DDI-MedLine.d20.s3|15-16|15|O
DDI-MedLine.d20.s3|18-22|mg/kg|O
DDI-MedLine.d20.s3|24-26|e.w|O
DDI-MedLine.d20.s3|27-27|.|O
DDI-MedLine.d20.s3|28-28|)|O
DDI-MedLine.d20.s4|0-2|The|O
DDI-MedLine.d20.s4|4-13|successive|O
DDI-MedLine.d20.s4|15-25|application|O
DDI-MedLine.d20.s4|27-28|of|O
DDI-MedLine.d20.s4|30-36|glycine|drug
DDI-MedLine.d20.s4|38-38|(|O
DDI-MedLine.d20.s4|39-39|5|O
DDI-MedLine.d20.s4|41-42|or|O
DDI-MedLine.d20.s4|44-45|10|O
DDI-MedLine.d20.s4|47-51|mg/kg|O
DDI-MedLine.d20.s4|53-55|egg|O
DDI-MedLine.d20.s4|57-62|weight|O
DDI-MedLine.d20.s4|64-64|(|O
DDI-MedLine.d20.s4|65-68|e.w.|O
DDI-MedLine.d20.s4|69-69|)|O
DDI-MedLine.d20.s4|71-73|and|O
DDI-MedLine.d20.s4|75-83|glutamate|drug
DDI-MedLine.d20.s4|85-85|(|O
DDI-MedLine.d20.s4|86-87|15|O
DDI-MedLine.d20.s4|89-93|mg/kg|O
DDI-MedLine.d20.s4|95-98|e.w.|O
DDI-MedLine.d20.s4|99-99|)|O
DDI-MedLine.d20.s4|101-102|in|O
DDI-MedLine.d20.s4|104-104|a|O
DDI-MedLine.d20.s4|106-107|10|O
DDI-MedLine.d20.s4|109-111|min|O
DDI-MedLine.d20.s4|113-120|interval|O
DDI-MedLine.d20.s4|122-134|significantly|O
DDI-MedLine.d20.s4|136-144|increased|O
DDI-MedLine.d20.s4|146-148|the|O
DDI-MedLine.d20.s4|150-159|activation|O
DDI-MedLine.d20.s4|161-162|of|O
DDI-MedLine.d20.s4|164-174|spontaneous|O
DDI-MedLine.d20.s4|176-183|motility|O
DDI-MedLine.d20.s4|185-186|of|O
DDI-MedLine.d20.s4|188-197|17-day-old|O
DDI-MedLine.d20.s4|199-203|chick|O
DDI-MedLine.d20.s4|205-211|embryos|O
DDI-MedLine.d20.s4|213-214|in|O
DDI-MedLine.d20.s4|216-225|comparison|O
DDI-MedLine.d20.s4|227-230|with|O
DDI-MedLine.d20.s4|232-234|the|O
DDI-MedLine.d20.s4|236-241|effect|O
DDI-MedLine.d20.s4|243-244|of|O
DDI-MedLine.d20.s4|246-254|glutamate|drug
DDI-MedLine.d20.s4|256-260|alone|O
DDI-MedLine.d20.s4|261-261|.|O
DDI-MedLine.d20.s5|0-3|This|O
DDI-MedLine.d20.s5|5-10|effect|O
DDI-MedLine.d20.s5|12-14|did|O
DDI-MedLine.d20.s5|16-18|not|O
DDI-MedLine.d20.s5|20-25|depend|O
DDI-MedLine.d20.s5|27-28|on|O
DDI-MedLine.d20.s5|30-32|the|O
DDI-MedLine.d20.s5|34-38|order|O
DDI-MedLine.d20.s5|40-41|of|O
DDI-MedLine.d20.s5|43-53|application|O
DDI-MedLine.d20.s5|55-56|of|O
DDI-MedLine.d20.s5|58-60|the|O
DDI-MedLine.d20.s5|62-66|drugs|O
DDI-MedLine.d20.s5|67-67|.|O
DDI-MedLine.d20.s6|0-1|In|O
DDI-MedLine.d20.s6|3-12|13-day-old|O
DDI-MedLine.d20.s6|14-20|embryos|O
DDI-MedLine.d20.s6|21-21|,|O
DDI-MedLine.d20.s6|23-29|glycine|drug
DDI-MedLine.d20.s6|31-33|was|O
DDI-MedLine.d20.s6|35-45|ineffective|O
DDI-MedLine.d20.s6|47-48|in|O
DDI-MedLine.d20.s6|50-53|both|O
DDI-MedLine.d20.s6|55-59|doses|O
DDI-MedLine.d20.s6|60-60|.|O
DDI-MedLine.d20.s7|0-1|It|O
DDI-MedLine.d20.s7|3-4|is|O
DDI-MedLine.d20.s7|6-14|concluded|O
DDI-MedLine.d20.s7|16-19|from|O
DDI-MedLine.d20.s7|21-25|these|O
DDI-MedLine.d20.s7|27-33|results|O
DDI-MedLine.d20.s7|35-38|that|O
DDI-MedLine.d20.s7|40-42|the|O
DDI-MedLine.d20.s7|44-53|modulatory|O
DDI-MedLine.d20.s7|55-60|effect|O
DDI-MedLine.d20.s7|62-63|of|O
DDI-MedLine.d20.s7|65-71|glycine|drug
DDI-MedLine.d20.s7|73-74|is|O
DDI-MedLine.d20.s7|76-84|evidently|O
DDI-MedLine.d20.s7|86-86|a|O
DDI-MedLine.d20.s7|88-92|later|O
DDI-MedLine.d20.s7|94-106|developmental|O
DDI-MedLine.d20.s7|108-118|acquisition|O
DDI-MedLine.d20.s7|120-120|(|O
DDI-MedLine.d20.s7|121-125|after|O
DDI-MedLine.d20.s7|127-129|day|O
DDI-MedLine.d20.s7|131-132|15|O
DDI-MedLine.d20.s7|134-135|of|O
DDI-MedLine.d20.s7|137-146|incubation|O
DDI-MedLine.d20.s7|147-147|)|O
DDI-MedLine.d20.s7|149-150|in|O
DDI-MedLine.d20.s7|152-154|the|O
DDI-MedLine.d20.s7|156-168|embryogenesis|O
DDI-MedLine.d20.s7|170-171|of|O
DDI-MedLine.d20.s7|173-182|NMDA-ergic|O
DDI-MedLine.d20.s7|184-193|activation|O
DDI-MedLine.d20.s7|195-196|of|O
DDI-MedLine.d20.s7|198-208|spontaneous|O
DDI-MedLine.d20.s7|210-217|motility|O
DDI-MedLine.d20.s7|219-220|in|O
DDI-MedLine.d20.s7|222-226|chick|O
DDI-MedLine.d20.s7|228-234|embryos|O
DDI-MedLine.d20.s7|236-244|similarly|O
DDI-MedLine.d20.s7|246-247|as|O
DDI-MedLine.d20.s7|249-259|glycinergic|O
DDI-MedLine.d20.s7|261-270|inhibition|O
DDI-MedLine.d20.s7|271-271|.|O
DDI-DrugBank.d54.s0|0-3|Oral|O
DDI-DrugBank.d54.s0|5-18|Anticoagulants|group
DDI-DrugBank.d54.s0|19-19|:|O
DDI-DrugBank.d54.s0|21-36|Thyroid hormones|group
DDI-DrugBank.d54.s0|38-43|appear|O
DDI-DrugBank.d54.s0|45-46|to|O
DDI-DrugBank.d54.s0|48-55|increase|O
DDI-DrugBank.d54.s0|57-66|catabolism|O
DDI-DrugBank.d54.s0|68-69|of|O
DDI-DrugBank.d54.s0|71-77|vitamin|O
DDI-DrugBank.d54.s0|79-89|K-dependent|O
DDI-DrugBank.d54.s0|91-98|clotting|O
DDI-DrugBank.d54.s0|100-106|factors|O
DDI-DrugBank.d54.s0|107-107|.|O
DDI-DrugBank.d54.s1|0-1|If|O
DDI-DrugBank.d54.s1|3-6|oral|O
DDI-DrugBank.d54.s1|8-21|anticoagulants|group
DDI-DrugBank.d54.s1|23-25|are|O
DDI-DrugBank.d54.s1|27-30|also|O
DDI-DrugBank.d54.s1|32-36|being|O
DDI-DrugBank.d54.s1|38-42|given|O
DDI-DrugBank.d54.s1|43-43|,|O
DDI-DrugBank.d54.s1|45-56|compensatory|O
DDI-DrugBank.d54.s1|58-66|increases|O
DDI-DrugBank.d54.s1|68-69|in|O
DDI-DrugBank.d54.s1|71-78|clotting|O
DDI-DrugBank.d54.s1|80-85|factor|O
DDI-DrugBank.d54.s1|87-95|synthesis|O
DDI-DrugBank.d54.s1|97-99|are|O
DDI-DrugBank.d54.s1|101-108|impaired|O
DDI-DrugBank.d54.s1|109-109|.|O
DDI-DrugBank.d54.s2|0-7|Patients|O
DDI-DrugBank.d54.s2|9-18|stabilized|O
DDI-DrugBank.d54.s2|20-21|on|O
DDI-DrugBank.d54.s2|23-26|oral|O
DDI-DrugBank.d54.s2|28-41|anticoagulants|group
DDI-DrugBank.d54.s2|43-45|who|O
DDI-DrugBank.d54.s2|47-49|are|O
DDI-DrugBank.d54.s2|51-55|found|O
DDI-DrugBank.d54.s2|57-58|to|O
DDI-DrugBank.d54.s2|60-66|require|O
DDI-DrugBank.d54.s2|68-74|thyroid|group
DDI-DrugBank.d54.s2|76-86|replacement|O
DDI-DrugBank.d54.s2|88-94|therapy|O
DDI-DrugBank.d54.s2|96-101|should|O
DDI-DrugBank.d54.s2|103-104|be|O
DDI-DrugBank.d54.s2|106-112|watched|O
DDI-DrugBank.d54.s2|114-117|very|O
DDI-DrugBank.d54.s2|119-125|closely|O
DDI-DrugBank.d54.s2|127-130|when|O
DDI-DrugBank.d54.s2|132-138|thyroid|O
DDI-DrugBank.d54.s2|140-141|is|O
DDI-DrugBank.d54.s2|143-149|started|O
DDI-DrugBank.d54.s2|150-150|.|O
DDI-DrugBank.d54.s3|0-1|If|O
DDI-DrugBank.d54.s3|3-3|a|O
DDI-DrugBank.d54.s3|5-11|patient|O
DDI-DrugBank.d54.s3|13-14|is|O
DDI-DrugBank.d54.s3|16-20|truly|O
DDI-DrugBank.d54.s3|22-32|hypothyroid|O
DDI-DrugBank.d54.s3|33-33|,|O
DDI-DrugBank.d54.s3|35-36|it|O
DDI-DrugBank.d54.s3|38-39|is|O
DDI-DrugBank.d54.s3|41-46|likely|O
DDI-DrugBank.d54.s3|48-51|that|O
DDI-DrugBank.d54.s3|53-53|a|O
DDI-DrugBank.d54.s3|55-63|reduction|O
DDI-DrugBank.d54.s3|65-66|in|O
DDI-DrugBank.d54.s3|68-80|anticoagulant|group
DDI-DrugBank.d54.s3|82-87|dosage|O
DDI-DrugBank.d54.s3|89-92|will|O
DDI-DrugBank.d54.s3|94-95|be|O
DDI-DrugBank.d54.s3|97-104|required|O
DDI-DrugBank.d54.s3|105-105|.|O
DDI-DrugBank.d54.s4|0-1|No|O
DDI-DrugBank.d54.s4|3-9|special|O
DDI-DrugBank.d54.s4|11-21|precautions|O
DDI-DrugBank.d54.s4|23-28|appear|O
DDI-DrugBank.d54.s4|30-31|to|O
DDI-DrugBank.d54.s4|33-34|be|O
DDI-DrugBank.d54.s4|36-44|necessary|O
DDI-DrugBank.d54.s4|46-49|when|O
DDI-DrugBank.d54.s4|51-54|oral|O
DDI-DrugBank.d54.s4|56-68|anticoagulant|O
DDI-DrugBank.d54.s4|70-76|therapy|O
DDI-DrugBank.d54.s4|78-79|is|O
DDI-DrugBank.d54.s4|81-85|begun|O
DDI-DrugBank.d54.s4|87-88|in|O
DDI-DrugBank.d54.s4|90-90|a|O
DDI-DrugBank.d54.s4|92-98|patient|O
DDI-DrugBank.d54.s4|100-106|already|O
DDI-DrugBank.d54.s4|108-117|stabilized|O
DDI-DrugBank.d54.s4|119-120|on|O
DDI-DrugBank.d54.s4|122-132|maintenance|O
DDI-DrugBank.d54.s4|134-140|thyroid|O
DDI-DrugBank.d54.s4|142-152|replacement|O
DDI-DrugBank.d54.s4|154-160|therapy|O
DDI-DrugBank.d54.s4|161-161|.|O
DDI-DrugBank.d54.s5|0-6|Insulin|drug
DDI-DrugBank.d54.s5|8-9|or|O
DDI-DrugBank.d54.s5|11-14|Oral|O
DDI-DrugBank.d54.s5|16-28|Hypoglycemics|group
DDI-DrugBank.d54.s5|29-29|:|O
DDI-DrugBank.d54.s5|31-40|Initiating|O
DDI-DrugBank.d54.s5|42-48|thyroid|O
DDI-DrugBank.d54.s5|50-60|replacement|O
DDI-DrugBank.d54.s5|62-68|therapy|O
DDI-DrugBank.d54.s5|70-72|may|O
DDI-DrugBank.d54.s5|74-78|cause|O
DDI-DrugBank.d54.s5|80-88|increases|O
DDI-DrugBank.d54.s5|90-91|in|O
DDI-DrugBank.d54.s5|93-99|insulin|drug
DDI-DrugBank.d54.s5|101-102|or|O
DDI-DrugBank.d54.s5|104-107|oral|O
DDI-DrugBank.d54.s5|109-120|hypoglycemic|group
DDI-DrugBank.d54.s5|122-133|requirements|O
DDI-DrugBank.d54.s5|134-134|.|O
DDI-DrugBank.d54.s6|0-2|The|O
DDI-DrugBank.d54.s6|4-10|effects|O
DDI-DrugBank.d54.s6|12-15|seen|O
DDI-DrugBank.d54.s6|17-19|are|O
DDI-DrugBank.d54.s6|21-26|poorly|O
DDI-DrugBank.d54.s6|28-37|understood|O
DDI-DrugBank.d54.s6|39-41|and|O
DDI-DrugBank.d54.s6|43-48|depend|O
DDI-DrugBank.d54.s6|50-53|upon|O
DDI-DrugBank.d54.s6|55-55|a|O
DDI-DrugBank.d54.s6|57-63|variety|O
DDI-DrugBank.d54.s6|65-66|of|O
DDI-DrugBank.d54.s6|68-74|factors|O
DDI-DrugBank.d54.s6|76-79|such|O
DDI-DrugBank.d54.s6|81-82|as|O
DDI-DrugBank.d54.s6|84-87|dose|O
DDI-DrugBank.d54.s6|89-91|and|O
DDI-DrugBank.d54.s6|93-96|type|O
DDI-DrugBank.d54.s6|98-99|of|O
DDI-DrugBank.d54.s6|101-120|thyroid preparations|group
DDI-DrugBank.d54.s6|122-124|and|O
DDI-DrugBank.d54.s6|126-134|endocrine|O
DDI-DrugBank.d54.s6|136-141|status|O
DDI-DrugBank.d54.s6|143-144|of|O
DDI-DrugBank.d54.s6|146-148|the|O
DDI-DrugBank.d54.s6|150-156|patient|O
DDI-DrugBank.d54.s6|157-157|.|O
DDI-DrugBank.d54.s7|0-7|Patients|O
DDI-DrugBank.d54.s7|9-17|receiving|O
DDI-DrugBank.d54.s7|19-25|insulin|drug
DDI-DrugBank.d54.s7|27-28|or|O
DDI-DrugBank.d54.s7|30-33|oral|O
DDI-DrugBank.d54.s7|35-47|hypoglycemics|group
DDI-DrugBank.d54.s7|49-54|should|O
DDI-DrugBank.d54.s7|56-57|be|O
DDI-DrugBank.d54.s7|59-65|closely|O
DDI-DrugBank.d54.s7|67-73|watched|O
DDI-DrugBank.d54.s7|75-80|during|O
DDI-DrugBank.d54.s7|82-91|initiation|O
DDI-DrugBank.d54.s7|93-94|of|O
DDI-DrugBank.d54.s7|96-102|thyroid|O
DDI-DrugBank.d54.s7|104-114|replacement|O
DDI-DrugBank.d54.s7|116-122|therapy|O
DDI-DrugBank.d54.s7|123-123|.|O
DDI-DrugBank.d54.s8|0-13|Cholestyramine|drug
DDI-DrugBank.d54.s8|14-14|:|O
DDI-DrugBank.d54.s8|16-29|Cholestyramine|drug
DDI-DrugBank.d54.s8|31-35|binds|O
DDI-DrugBank.d54.s8|37-40|both|O
DDI-DrugBank.d54.s8|42-43|T4|drug
DDI-DrugBank.d54.s8|45-47|and|O
DDI-DrugBank.d54.s8|49-50|T3|drug
DDI-DrugBank.d54.s8|52-53|in|O
DDI-DrugBank.d54.s8|55-57|the|O
DDI-DrugBank.d54.s8|59-67|intestine|O
DDI-DrugBank.d54.s8|68-68|,|O
DDI-DrugBank.d54.s8|70-73|thus|O
DDI-DrugBank.d54.s8|75-83|impairing|O
DDI-DrugBank.d54.s8|85-94|absorption|O
DDI-DrugBank.d54.s8|96-97|of|O
DDI-DrugBank.d54.s8|99-103|these|O
DDI-DrugBank.d54.s8|105-120|thyroid hormones|group
DDI-DrugBank.d54.s8|121-121|.|O
DDI-DrugBank.d54.s9|0-1|In|O
DDI-DrugBank.d54.s9|3-7|vitro|O
DDI-DrugBank.d54.s9|9-15|studies|O
DDI-DrugBank.d54.s9|17-24|indicate|O
DDI-DrugBank.d54.s9|26-29|that|O
DDI-DrugBank.d54.s9|31-33|the|O
DDI-DrugBank.d54.s9|35-41|binding|O
DDI-DrugBank.d54.s9|43-44|is|O
DDI-DrugBank.d54.s9|46-48|not|O
DDI-DrugBank.d54.s9|50-55|easily|O
DDI-DrugBank.d54.s9|57-63|removed|O
DDI-DrugBank.d54.s9|64-64|.|O
DDI-DrugBank.d54.s10|0-8|Therefore|O
DDI-DrugBank.d54.s10|9-9|,|O
DDI-DrugBank.d54.s10|11-11|4|O
DDI-DrugBank.d54.s10|13-14|to|O
DDI-DrugBank.d54.s10|16-16|5|O
DDI-DrugBank.d54.s10|18-22|hours|O
DDI-DrugBank.d54.s10|24-29|should|O
DDI-DrugBank.d54.s10|31-36|elapse|O
DDI-DrugBank.d54.s10|38-44|between|O
DDI-DrugBank.d54.s10|46-59|administration|O
DDI-DrugBank.d54.s10|61-62|of|O
DDI-DrugBank.d54.s10|64-77|cholestyramine|drug
DDI-DrugBank.d54.s10|79-81|and|O
DDI-DrugBank.d54.s10|83-98|thyroid hormones|group
DDI-DrugBank.d54.s10|99-99|.|O
DDI-DrugBank.d54.s11|0-7|Estrogen|group
DDI-DrugBank.d54.s11|8-8|,|O
DDI-DrugBank.d54.s11|10-13|Oral|O
DDI-DrugBank.d54.s11|15-28|Contraceptives|group
DDI-DrugBank.d54.s11|29-29|:|O
DDI-DrugBank.d54.s11|31-39|Estrogens|group
DDI-DrugBank.d54.s11|41-44|tend|O
DDI-DrugBank.d54.s11|46-47|to|O
DDI-DrugBank.d54.s11|49-56|increase|O
DDI-DrugBank.d54.s11|58-62|serum|O
DDI-DrugBank.d54.s11|64-80|thyroxine-binding|O
DDI-DrugBank.d54.s11|82-89|globulin|O
DDI-DrugBank.d54.s11|91-91|(|O
DDI-DrugBank.d54.s11|92-94|TBg|O
DDI-DrugBank.d54.s11|95-95|)|O
DDI-DrugBank.d54.s11|96-96|.|O
DDI-DrugBank.d54.s12|0-1|In|O
DDI-DrugBank.d54.s12|3-3|a|O
DDI-DrugBank.d54.s12|5-11|patient|O
DDI-DrugBank.d54.s12|13-16|with|O
DDI-DrugBank.d54.s12|18-18|a|O
DDI-DrugBank.d54.s12|20-33|nonfunctioning|O
DDI-DrugBank.d54.s12|35-41|thyroid|O
DDI-DrugBank.d54.s12|43-47|gland|O
DDI-DrugBank.d54.s12|49-51|who|O
DDI-DrugBank.d54.s12|53-54|is|O
DDI-DrugBank.d54.s12|56-64|receiving|O
DDI-DrugBank.d54.s12|66-72|thyroid|O
DDI-DrugBank.d54.s12|74-84|replacement|O
DDI-DrugBank.d54.s12|86-92|therapy|O
DDI-DrugBank.d54.s12|93-93|,|O
DDI-DrugBank.d54.s12|95-98|free|O
DDI-DrugBank.d54.s12|100-112|levothyroxine|drug
DDI-DrugBank.d54.s12|114-116|may|O
DDI-DrugBank.d54.s12|118-119|be|O
DDI-DrugBank.d54.s12|121-129|decreased|O
DDI-DrugBank.d54.s12|131-134|when|O
DDI-DrugBank.d54.s12|136-144|estrogens|group
DDI-DrugBank.d54.s12|146-148|are|O
DDI-DrugBank.d54.s12|150-156|started|O
DDI-DrugBank.d54.s12|158-161|thus|O
DDI-DrugBank.d54.s12|163-172|increasing|O
DDI-DrugBank.d54.s12|174-180|thyroid|group
DDI-DrugBank.d54.s12|182-193|requirements|O
DDI-DrugBank.d54.s12|194-194|.|O
DDI-DrugBank.d54.s13|0-6|However|O
DDI-DrugBank.d54.s13|7-7|,|O
DDI-DrugBank.d54.s13|9-10|if|O
DDI-DrugBank.d54.s13|12-14|the|O
DDI-DrugBank.d54.s13|16-23|patients|O
DDI-DrugBank.d54.s13|25-31|thyroid|O
DDI-DrugBank.d54.s13|33-37|gland|O
DDI-DrugBank.d54.s13|39-41|has|O
DDI-DrugBank.d54.s13|43-52|sufficient|O
DDI-DrugBank.d54.s13|54-61|function|O
DDI-DrugBank.d54.s13|62-62|,|O
DDI-DrugBank.d54.s13|64-66|the|O
DDI-DrugBank.d54.s13|68-76|decreased|O
DDI-DrugBank.d54.s13|78-81|free|O
DDI-DrugBank.d54.s13|83-91|thyroxine|drug
DDI-DrugBank.d54.s13|93-96|will|O
DDI-DrugBank.d54.s13|98-103|result|O
DDI-DrugBank.d54.s13|105-106|in|O
DDI-DrugBank.d54.s13|108-108|a|O
DDI-DrugBank.d54.s13|110-121|compensatory|O
DDI-DrugBank.d54.s13|123-130|increase|O
DDI-DrugBank.d54.s13|132-133|in|O
DDI-DrugBank.d54.s13|135-143|thyroxine|O
DDI-DrugBank.d54.s13|145-150|output|O
DDI-DrugBank.d54.s13|152-153|by|O
DDI-DrugBank.d54.s13|155-157|the|O
DDI-DrugBank.d54.s13|159-165|thyroid|O
DDI-DrugBank.d54.s13|166-166|.|O
DDI-DrugBank.d54.s14|0-8|Therefore|O
DDI-DrugBank.d54.s14|9-9|,|O
DDI-DrugBank.d54.s14|11-18|patients|O
DDI-DrugBank.d54.s14|20-26|without|O
DDI-DrugBank.d54.s14|28-28|a|O
DDI-DrugBank.d54.s14|30-40|functioning|O
DDI-DrugBank.d54.s14|42-48|thyroid|group
DDI-DrugBank.d54.s14|50-54|gland|O
DDI-DrugBank.d54.s14|56-58|who|O
DDI-DrugBank.d54.s14|60-62|are|O
DDI-DrugBank.d54.s14|64-65|on|O
DDI-DrugBank.d54.s14|67-73|thyroid|O
DDI-DrugBank.d54.s14|75-85|replacement|O
DDI-DrugBank.d54.s14|87-93|therapy|O
DDI-DrugBank.d54.s14|95-97|may|O
DDI-DrugBank.d54.s14|99-102|need|O
DDI-DrugBank.d54.s14|104-105|to|O
DDI-DrugBank.d54.s14|107-114|increase|O
DDI-DrugBank.d54.s14|116-120|their|O
DDI-DrugBank.d54.s14|122-128|thyroid|O
DDI-DrugBank.d54.s14|130-133|dose|O
DDI-DrugBank.d54.s14|135-136|if|O
DDI-DrugBank.d54.s14|138-146|estrogens|group
DDI-DrugBank.d54.s14|148-149|or|O
DDI-DrugBank.d54.s14|151-169|estrogen-containing|group
DDI-DrugBank.d54.s14|171-174|oral|O
DDI-DrugBank.d54.s14|176-189|contraceptives|group
DDI-DrugBank.d54.s14|191-193|are|O
DDI-DrugBank.d54.s14|195-199|given|O
DDI-DrugBank.d54.s14|200-200|.|O
DDI-DrugBank.d54.s15|0-24|Tricyclic Antidepressants|group
DDI-DrugBank.d54.s15|25-25|:|O
DDI-DrugBank.d54.s15|27-29|Use|O
DDI-DrugBank.d54.s15|31-32|of|O
DDI-DrugBank.d54.s15|34-49|thyroid products|group
DDI-DrugBank.d54.s15|51-54|with|O
DDI-DrugBank.d54.s15|56-65|imipramine|drug
DDI-DrugBank.d54.s15|67-69|and|O
DDI-DrugBank.d54.s15|71-75|other|O
DDI-DrugBank.d54.s15|77-101|tricyclic antidepressants|group
DDI-DrugBank.d54.s15|103-105|may|O
DDI-DrugBank.d54.s15|107-114|increase|O
DDI-DrugBank.d54.s15|116-123|receptor|O
DDI-DrugBank.d54.s15|125-135|sensitivity|O
DDI-DrugBank.d54.s15|137-139|and|O
DDI-DrugBank.d54.s15|141-147|enhance|O
DDI-DrugBank.d54.s15|149-162|antidepressant|O
DDI-DrugBank.d54.s15|164-171|activity|O
DDI-DrugBank.d54.s15|173-181|transient|O
DDI-DrugBank.d54.s15|183-189|cardiac|O
DDI-DrugBank.d54.s15|191-201|arrhythmias|O
DDI-DrugBank.d54.s15|203-206|have|O
DDI-DrugBank.d54.s15|208-211|been|O
DDI-DrugBank.d54.s15|213-220|observed|O
DDI-DrugBank.d54.s15|221-221|.|O
DDI-DrugBank.d54.s16|0-14|Thyroid hormone|group
DDI-DrugBank.d54.s16|16-23|activity|O
DDI-DrugBank.d54.s16|25-27|may|O
DDI-DrugBank.d54.s16|29-32|also|O
DDI-DrugBank.d54.s16|34-35|be|O
DDI-DrugBank.d54.s16|37-44|enhanced|O
DDI-DrugBank.d54.s16|45-45|.|O
DDI-DrugBank.d54.s17|0-8|Digitalis|group
DDI-DrugBank.d54.s17|9-9|:|O
DDI-DrugBank.d54.s17|11-30|Thyroid preparations|group
DDI-DrugBank.d54.s17|32-34|may|O
DDI-DrugBank.d54.s17|36-45|potentiate|O
DDI-DrugBank.d54.s17|47-49|the|O
DDI-DrugBank.d54.s17|51-55|toxic|O
DDI-DrugBank.d54.s17|57-63|effects|O
DDI-DrugBank.d54.s17|65-66|of|O
DDI-DrugBank.d54.s17|68-76|digitalis|group
DDI-DrugBank.d54.s17|77-77|.|O
DDI-DrugBank.d54.s18|0-6|Thyroid|O
DDI-DrugBank.d54.s18|8-15|hormonal|O
DDI-DrugBank.d54.s18|17-27|replacement|O
DDI-DrugBank.d54.s18|29-37|increases|O
DDI-DrugBank.d54.s18|39-47|metabolic|O
DDI-DrugBank.d54.s18|49-52|rate|O
DDI-DrugBank.d54.s18|53-53|,|O
DDI-DrugBank.d54.s18|55-59|which|O
DDI-DrugBank.d54.s18|61-68|requires|O
DDI-DrugBank.d54.s18|70-71|an|O
DDI-DrugBank.d54.s18|73-80|increase|O
DDI-DrugBank.d54.s18|82-83|in|O
DDI-DrugBank.d54.s18|85-93|digitalis|group
DDI-DrugBank.d54.s18|95-100|dosage|O
DDI-DrugBank.d54.s18|101-101|.|O
DDI-DrugBank.d54.s19|0-7|Ketamine|drug
DDI-DrugBank.d54.s19|8-8|:|O
DDI-DrugBank.d54.s19|10-13|When|O
DDI-DrugBank.d54.s19|15-26|administered|O
DDI-DrugBank.d54.s19|28-29|to|O
DDI-DrugBank.d54.s19|31-38|patients|O
DDI-DrugBank.d54.s19|40-41|on|O
DDI-DrugBank.d54.s19|43-43|a|O
DDI-DrugBank.d54.s19|45-63|thyroid preparation|group
DDI-DrugBank.d54.s19|64-64|,|O
DDI-DrugBank.d54.s19|66-69|this|O
DDI-DrugBank.d54.s19|71-80|parenteral|O
DDI-DrugBank.d54.s19|82-91|anesthetic|group
DDI-DrugBank.d54.s19|93-95|may|O
DDI-DrugBank.d54.s19|97-101|cause|O
DDI-DrugBank.d54.s19|103-114|hypertension|O
DDI-DrugBank.d54.s19|116-118|and|O
DDI-DrugBank.d54.s19|120-130|tachycardia|O
DDI-DrugBank.d54.s19|131-131|.|O
DDI-DrugBank.d54.s20|0-2|Use|O
DDI-DrugBank.d54.s20|4-7|with|O
DDI-DrugBank.d54.s20|9-15|caution|O
DDI-DrugBank.d54.s20|17-19|and|O
DDI-DrugBank.d54.s20|21-22|be|O
DDI-DrugBank.d54.s20|24-31|prepared|O
DDI-DrugBank.d54.s20|33-34|to|O
DDI-DrugBank.d54.s20|36-40|treat|O
DDI-DrugBank.d54.s20|42-53|hypertension|O
DDI-DrugBank.d54.s20|54-54|,|O
DDI-DrugBank.d54.s20|56-57|if|O
DDI-DrugBank.d54.s20|59-67|necessary|O
DDI-DrugBank.d54.s20|68-68|.|O
DDI-DrugBank.d54.s21|0-11|Vasopressors|group
DDI-DrugBank.d54.s21|12-12|:|O
DDI-DrugBank.d54.s21|14-22|Thyroxine|drug
DDI-DrugBank.d54.s21|24-32|increases|O
DDI-DrugBank.d54.s21|34-36|the|O
DDI-DrugBank.d54.s21|38-47|adrenergic|O
DDI-DrugBank.d54.s21|49-54|effect|O
DDI-DrugBank.d54.s21|56-57|of|O
DDI-DrugBank.d54.s21|59-72|catecholamines|O
DDI-DrugBank.d54.s21|74-77|such|O
DDI-DrugBank.d54.s21|79-80|as|O
DDI-DrugBank.d54.s21|82-92|epinephrine|drug
DDI-DrugBank.d54.s21|94-96|and|O
DDI-DrugBank.d54.s21|98-111|norepinephrine|drug
DDI-DrugBank.d54.s21|112-112|.|O
DDI-DrugBank.d54.s22|0-8|Therefore|O
DDI-DrugBank.d54.s22|9-9|,|O
DDI-DrugBank.d54.s22|11-19|injection|O
DDI-DrugBank.d54.s22|21-22|of|O
DDI-DrugBank.d54.s22|24-28|these|O
DDI-DrugBank.d54.s22|30-35|agents|O
DDI-DrugBank.d54.s22|37-40|into|O
DDI-DrugBank.d54.s22|42-49|patients|O
DDI-DrugBank.d54.s22|51-59|receiving|O
DDI-DrugBank.d54.s22|61-80|thyroid preparations|group
DDI-DrugBank.d54.s22|82-90|increases|O
DDI-DrugBank.d54.s22|92-94|the|O
DDI-DrugBank.d54.s22|96-99|risk|O
DDI-DrugBank.d54.s22|101-102|of|O
DDI-DrugBank.d54.s22|104-116|precipitating|O
DDI-DrugBank.d54.s22|118-125|coronary|O
DDI-DrugBank.d54.s22|127-139|insufficiency|O
DDI-DrugBank.d54.s22|141-150|especially|O
DDI-DrugBank.d54.s22|152-153|in|O
DDI-DrugBank.d54.s22|155-162|patients|O
DDI-DrugBank.d54.s22|164-167|with|O
DDI-DrugBank.d54.s22|169-176|coronary|O
DDI-DrugBank.d54.s22|178-183|artery|O
DDI-DrugBank.d54.s22|185-191|disease|O
DDI-DrugBank.d54.s22|192-192|.|O
DDI-DrugBank.d54.s23|0-6|Careful|O
DDI-DrugBank.d54.s23|8-18|observation|O
DDI-DrugBank.d54.s23|20-21|is|O
DDI-DrugBank.d54.s23|23-30|required|O
DDI-DrugBank.d54.s23|31-31|.|O
DDI-DrugBank.d54.s24|0-14|Drug/Laboratory|O
DDI-DrugBank.d54.s24|16-19|Test|O
DDI-DrugBank.d54.s24|21-32|Interactions|O
DDI-DrugBank.d54.s24|34-36|The|O
DDI-DrugBank.d54.s24|38-46|following|O
DDI-DrugBank.d54.s24|48-52|drugs|O
DDI-DrugBank.d54.s24|54-55|or|O
DDI-DrugBank.d54.s24|57-64|moieties|O
DDI-DrugBank.d54.s24|66-68|are|O
DDI-DrugBank.d54.s24|70-74|known|O
DDI-DrugBank.d54.s24|76-77|to|O
DDI-DrugBank.d54.s24|79-87|interfere|O
DDI-DrugBank.d54.s24|89-92|with|O
DDI-DrugBank.d54.s24|94-103|laboratory|O
DDI-DrugBank.d54.s24|105-109|tests|O
DDI-DrugBank.d54.s24|111-119|performed|O
DDI-DrugBank.d54.s24|121-122|in|O
DDI-DrugBank.d54.s24|124-131|patients|O
DDI-DrugBank.d54.s24|133-134|on|O
DDI-DrugBank.d54.s24|136-150|thyroid hormone|group
DDI-DrugBank.d54.s24|152-158|therapy|O
DDI-DrugBank.d54.s24|159-159|:|O
DDI-DrugBank.d54.s24|161-169|androgens|group
DDI-DrugBank.d54.s24|170-170|,|O
DDI-DrugBank.d54.s24|172-186|corticosteroids|group
DDI-DrugBank.d54.s24|187-187|,|O
DDI-DrugBank.d54.s24|189-197|estrogens|group
DDI-DrugBank.d54.s24|198-198|,|O
DDI-DrugBank.d54.s24|200-203|oral|O
DDI-DrugBank.d54.s24|205-218|contraceptives|group
DDI-DrugBank.d54.s24|220-229|containing|O
DDI-DrugBank.d54.s24|231-239|estrogens|group
DDI-DrugBank.d54.s24|240-240|,|O
DDI-DrugBank.d54.s24|242-258|iodine-containing|group
DDI-DrugBank.d54.s24|260-271|preparations|O
DDI-DrugBank.d54.s24|273-275|and|O
DDI-DrugBank.d54.s24|277-279|the|O
DDI-DrugBank.d54.s24|281-288|numerous|O
DDI-DrugBank.d54.s24|290-301|preparations|O
DDI-DrugBank.d54.s24|303-312|containing|O
DDI-DrugBank.d54.s24|314-324|salicylates|group
DDI-DrugBank.d54.s24|325-325|.|O
DDI-DrugBank.d54.s25|0-0|-|O
DDI-DrugBank.d54.s25|2-8|Changes|O
DDI-DrugBank.d54.s25|10-11|in|O
DDI-DrugBank.d54.s25|13-15|TBg|O
DDI-DrugBank.d54.s25|17-29|concentration|O
DDI-DrugBank.d54.s25|31-36|should|O
DDI-DrugBank.d54.s25|38-39|be|O
DDI-DrugBank.d54.s25|41-45|taken|O
DDI-DrugBank.d54.s25|47-50|into|O
DDI-DrugBank.d54.s25|52-64|consideration|O
DDI-DrugBank.d54.s25|66-67|in|O
DDI-DrugBank.d54.s25|69-71|the|O
DDI-DrugBank.d54.s25|73-86|interpretation|O
DDI-DrugBank.d54.s25|88-89|of|O
DDI-DrugBank.d54.s25|91-92|T4|O
DDI-DrugBank.d54.s25|94-96|and|O
DDI-DrugBank.d54.s25|98-99|T3|O
DDI-DrugBank.d54.s25|101-106|values|O
DDI-DrugBank.d54.s25|107-107|.|O
DDI-DrugBank.d54.s26|0-1|In|O
DDI-DrugBank.d54.s26|3-6|such|O
DDI-DrugBank.d54.s26|8-12|cases|O
DDI-DrugBank.d54.s26|13-13|,|O
DDI-DrugBank.d54.s26|15-17|the|O
DDI-DrugBank.d54.s26|19-25|unbound|O
DDI-DrugBank.d54.s26|27-27|(|O
DDI-DrugBank.d54.s26|28-31|free|O
DDI-DrugBank.d54.s26|32-32|)|O
DDI-DrugBank.d54.s26|34-40|hormone|O
DDI-DrugBank.d54.s26|42-47|should|O
DDI-DrugBank.d54.s26|49-50|be|O
DDI-DrugBank.d54.s26|52-59|measured|O
DDI-DrugBank.d54.s26|60-60|.|O
DDI-DrugBank.d54.s27|0-8|Pregnancy|O
DDI-DrugBank.d54.s27|10-18|estrogens|group
DDI-DrugBank.d54.s27|20-22|and|O
DDI-DrugBank.d54.s27|24-42|estrogen-containing|group
DDI-DrugBank.d54.s27|44-47|oral|O
DDI-DrugBank.d54.s27|49-62|contraceptives|group
DDI-DrugBank.d54.s27|64-71|increase|O
DDI-DrugBank.d54.s27|73-75|TBg|O
DDI-DrugBank.d54.s27|77-90|concentrations|O
DDI-DrugBank.d54.s27|91-91|.|O
DDI-DrugBank.d54.s28|0-2|TBg|O
DDI-DrugBank.d54.s28|4-6|may|O
DDI-DrugBank.d54.s28|8-11|also|O
DDI-DrugBank.d54.s28|13-14|be|O
DDI-DrugBank.d54.s28|16-24|increased|O
DDI-DrugBank.d54.s28|26-31|during|O
DDI-DrugBank.d54.s28|33-42|infectious|O
DDI-DrugBank.d54.s28|44-52|hepatitis|O
DDI-DrugBank.d54.s28|53-53|.|O
DDI-DrugBank.d54.s29|0-8|Decreases|O
DDI-DrugBank.d54.s29|10-11|in|O
DDI-DrugBank.d54.s29|13-15|TBg|O
DDI-DrugBank.d54.s29|17-30|concentrations|O
DDI-DrugBank.d54.s29|32-34|are|O
DDI-DrugBank.d54.s29|36-43|observed|O
DDI-DrugBank.d54.s29|45-46|in|O
DDI-DrugBank.d54.s29|48-56|nephrosis|O
DDI-DrugBank.d54.s29|57-57|,|O
DDI-DrugBank.d54.s29|59-68|acromegaly|O
DDI-DrugBank.d54.s29|70-72|and|O
DDI-DrugBank.d54.s29|74-78|after|O
DDI-DrugBank.d54.s29|80-87|androgen|group
DDI-DrugBank.d54.s29|89-90|or|O
DDI-DrugBank.d54.s29|92-105|corticosteroid|group
DDI-DrugBank.d54.s29|107-113|therapy|O
DDI-DrugBank.d54.s29|114-114|.|O
DDI-DrugBank.d54.s30|0-7|Familial|O
DDI-DrugBank.d54.s30|9-14|hyper-|O
DDI-DrugBank.d54.s30|16-17|or|O
DDI-DrugBank.d54.s30|19-54|hypo-thyroxine-binding-globulinemias|O
DDI-DrugBank.d54.s30|56-59|have|O
DDI-DrugBank.d54.s30|61-64|been|O
DDI-DrugBank.d54.s30|66-74|described|O
DDI-DrugBank.d54.s30|75-75|.|O
DDI-DrugBank.d54.s31|0-2|The|O
DDI-DrugBank.d54.s31|4-12|incidence|O
DDI-DrugBank.d54.s31|14-15|of|O
DDI-DrugBank.d54.s31|17-19|TBg|O
DDI-DrugBank.d54.s31|21-30|deficiency|O
DDI-DrugBank.d54.s31|32-43|approximates|O
DDI-DrugBank.d54.s31|45-45|1|O
DDI-DrugBank.d54.s31|47-48|in|O
DDI-DrugBank.d54.s31|50-53|9000|O
DDI-DrugBank.d54.s31|54-54|.|O
DDI-DrugBank.d54.s32|0-2|The|O
DDI-DrugBank.d54.s32|4-10|binding|O
DDI-DrugBank.d54.s32|12-13|of|O
DDI-DrugBank.d54.s32|15-23|thyroxine|O
DDI-DrugBank.d54.s32|25-26|by|O
DDI-DrugBank.d54.s32|28-44|thyroxine-binding|O
DDI-DrugBank.d54.s32|46-55|prealbumin|O
DDI-DrugBank.d54.s32|57-57|(|O
DDI-DrugBank.d54.s32|58-61|TBPA|O
DDI-DrugBank.d54.s32|62-62|)|O
DDI-DrugBank.d54.s32|64-65|is|O
DDI-DrugBank.d54.s32|67-75|inhibited|O
DDI-DrugBank.d54.s32|77-78|by|O
DDI-DrugBank.d54.s33|0-0|.|O
DDI-DrugBank.d54.s34|0-0|-|O
DDI-DrugBank.d54.s34|2-10|Medicinal|O
DDI-DrugBank.d54.s34|12-13|or|O
DDI-DrugBank.d54.s34|15-21|dietary|O
DDI-DrugBank.d54.s34|23-28|iodine|group
DDI-DrugBank.d54.s34|30-39|interferes|O
DDI-DrugBank.d54.s34|41-44|with|O
DDI-DrugBank.d54.s34|46-48|all|O
DDI-DrugBank.d54.s34|50-51|in|O
DDI-DrugBank.d54.s34|53-56|vivo|O
DDI-DrugBank.d54.s34|58-62|tests|O
DDI-DrugBank.d54.s34|64-65|of|O
DDI-DrugBank.d54.s34|67-78|radio-iodine|O
DDI-DrugBank.d54.s34|80-85|uptake|O
DDI-DrugBank.d54.s34|87-95|producing|O
DDI-DrugBank.d54.s34|97-99|low|O
DDI-DrugBank.d54.s34|101-107|uptakes|O
DDI-DrugBank.d54.s34|109-113|which|O
DDI-DrugBank.d54.s34|115-117|may|O
DDI-DrugBank.d54.s34|119-121|not|O
DDI-DrugBank.d54.s34|123-124|be|O
DDI-DrugBank.d54.s34|126-135|reflective|O
DDI-DrugBank.d54.s34|137-138|of|O
DDI-DrugBank.d54.s34|140-140|a|O
DDI-DrugBank.d54.s34|142-145|true|O
DDI-DrugBank.d54.s34|147-154|decrease|O
DDI-DrugBank.d54.s34|156-157|in|O
DDI-DrugBank.d54.s34|159-165|hormone|O
DDI-DrugBank.d54.s34|167-175|synthesis|O
DDI-DrugBank.d54.s35|0-0|.|O
DDI-DrugBank.d54.s36|0-0|-|O
DDI-DrugBank.d54.s36|2-4|The|O
DDI-DrugBank.d54.s36|6-16|persistence|O
DDI-DrugBank.d54.s36|18-19|of|O
DDI-DrugBank.d54.s36|21-28|clinical|O
DDI-DrugBank.d54.s36|30-32|and|O
DDI-DrugBank.d54.s36|34-43|laboratory|O
DDI-DrugBank.d54.s36|45-52|evidence|O
DDI-DrugBank.d54.s36|54-55|of|O
DDI-DrugBank.d54.s36|57-70|hypothyroidism|O
DDI-DrugBank.d54.s36|72-73|in|O
DDI-DrugBank.d54.s36|75-79|spite|O
DDI-DrugBank.d54.s36|81-82|of|O
DDI-DrugBank.d54.s36|84-91|adequate|O
DDI-DrugBank.d54.s36|93-98|dosage|O
DDI-DrugBank.d54.s36|100-110|replacement|O
DDI-DrugBank.d54.s36|112-120|indicates|O
DDI-DrugBank.d54.s36|122-127|either|O
DDI-DrugBank.d54.s36|129-132|poor|O
DDI-DrugBank.d54.s36|134-140|patient|O
DDI-DrugBank.d54.s36|142-151|compliance|O
DDI-DrugBank.d54.s36|152-152|,|O
DDI-DrugBank.d54.s36|154-157|poor|O
DDI-DrugBank.d54.s36|159-168|absorption|O
DDI-DrugBank.d54.s36|169-169|,|O
DDI-DrugBank.d54.s36|171-179|excessive|O
DDI-DrugBank.d54.s36|181-185|fecal|O
DDI-DrugBank.d54.s36|187-190|loss|O
DDI-DrugBank.d54.s36|191-191|,|O
DDI-DrugBank.d54.s36|193-194|or|O
DDI-DrugBank.d54.s36|196-205|inactivity|O
DDI-DrugBank.d54.s36|207-208|of|O
DDI-DrugBank.d54.s36|210-212|the|O
DDI-DrugBank.d54.s36|214-224|preparation|O
DDI-DrugBank.d54.s36|225-225|.|O
DDI-DrugBank.d54.s37|0-12|Intracellular|O
DDI-DrugBank.d54.s37|14-23|resistance|O
DDI-DrugBank.d54.s37|25-26|to|O
DDI-DrugBank.d54.s37|28-42|thyroid hormone|group
DDI-DrugBank.d54.s37|44-45|is|O
DDI-DrugBank.d54.s37|47-51|quite|O
DDI-DrugBank.d54.s37|53-56|rare|O
DDI-DrugBank.d54.s37|57-57|.|O
DDI-MedLine.d12.s0|0-12|Dexamethasone|drug
DDI-MedLine.d12.s0|14-16|and|O
DDI-MedLine.d12.s0|18-32|retinyl acetate|drug
DDI-MedLine.d12.s0|34-42|similarly|O
DDI-MedLine.d12.s0|44-50|inhibit|O
DDI-MedLine.d12.s0|52-54|and|O
DDI-MedLine.d12.s0|56-64|stimulate|O
DDI-MedLine.d12.s0|71-72|or|O
DDI-MedLine.d12.s0|74-88|insulin-induced|drug
DDI-MedLine.d12.s0|90-102|proliferation|O
DDI-MedLine.d12.s0|104-105|of|O
DDI-MedLine.d12.s0|107-115|prostatic|O
DDI-MedLine.d12.s0|117-126|epithelium|O
DDI-MedLine.d12.s0|127-127|.|O
DDI-MedLine.d12.s1|0-8|Prostatic|O
DDI-MedLine.d12.s1|10-19|epithelium|O
DDI-MedLine.d12.s1|21-32|proliferates|O
DDI-MedLine.d12.s1|34-35|in|O
DDI-MedLine.d12.s1|37-37|a|O
DDI-MedLine.d12.s1|39-45|defined|O
DDI-MedLine.d12.s1|47-52|medium|O
DDI-MedLine.d12.s1|54-63|consisting|O
DDI-MedLine.d12.s1|65-66|of|O
DDI-MedLine.d12.s1|68-72|basal|O
DDI-MedLine.d12.s1|74-79|medium|O
DDI-MedLine.d12.s1|81-88|RPMI1640|O
DDI-MedLine.d12.s1|90-99|containing|O
DDI-MedLine.d12.s1|113-113|(|O
DDI-MedLine.d12.s1|114-114|1|O
DDI-MedLine.d12.s1|116-127|microgram/ml|O
DDI-MedLine.d12.s1|128-128|)|O
DDI-MedLine.d12.s1|129-129|,|O
DDI-MedLine.d12.s1|135-135|(|O
DDI-MedLine.d12.s1|136-137|10|O
DDI-MedLine.d12.s1|139-143|ng/ml|O
DDI-MedLine.d12.s1|144-144|)|O
DDI-MedLine.d12.s1|145-145|,|O
DDI-MedLine.d12.s1|147-149|and|O
DDI-MedLine.d12.s1|151-157|insulin|drug
DDI-MedLine.d12.s1|159-159|(|O
DDI-MedLine.d12.s1|160-162|3.7|O
DDI-MedLine.d12.s1|164-176|micrograms/ml|O
DDI-MedLine.d12.s1|178-179|or|O
DDI-MedLine.d12.s1|181-183|0.1|O
DDI-MedLine.d12.s1|185-189|IU/ml|O
DDI-MedLine.d12.s1|190-190|)|O
DDI-MedLine.d12.s1|191-191|.|O
DDI-MedLine.d12.s2|0-7|Although|O
DDI-MedLine.d12.s2|9-15|neither|O
DDI-MedLine.d12.s2|17-29|dexamethasone|drug
DDI-MedLine.d12.s2|31-33|nor|O
DDI-MedLine.d12.s2|35-49|retinyl acetate|drug
DDI-MedLine.d12.s2|51-58|affected|O
DDI-MedLine.d12.s2|60-62|the|O
DDI-MedLine.d12.s2|64-76|proliferation|O
DDI-MedLine.d12.s2|78-79|of|O
DDI-MedLine.d12.s2|81-89|prostatic|O
DDI-MedLine.d12.s2|91-100|epithelium|O
DDI-MedLine.d12.s2|102-103|in|O
DDI-MedLine.d12.s2|105-112|RPMI1640|O
DDI-MedLine.d12.s2|114-123|containing|O
DDI-MedLine.d12.s2|137-141|alone|O
DDI-MedLine.d12.s2|142-142|,|O
DDI-MedLine.d12.s2|144-147|they|O
DDI-MedLine.d12.s2|149-154|modify|O
DDI-MedLine.d12.s2|156-158|the|O
DDI-MedLine.d12.s2|160-168|mitogenic|O
DDI-MedLine.d12.s2|170-175|effect|O
DDI-MedLine.d12.s2|177-178|of|O
DDI-MedLine.d12.s2|184-186|and|O
DDI-MedLine.d12.s2|188-194|insulin|drug
DDI-MedLine.d12.s2|195-195|.|O
DDI-MedLine.d12.s3|0-12|Dexamethasone|drug
DDI-MedLine.d12.s3|14-15|at|O
DDI-MedLine.d12.s3|17-18|10|O
DDI-MedLine.d12.s3|19-19|(|O
DDI-MedLine.d12.s3|20-22|-10|O
DDI-MedLine.d12.s3|23-23|)|O
DDI-MedLine.d12.s3|25-25|M|O
DDI-MedLine.d12.s3|27-28|or|O
DDI-MedLine.d12.s3|30-44|retinyl acetate|drug
DDI-MedLine.d12.s3|46-47|at|O
DDI-MedLine.d12.s3|49-53|about|O
DDI-MedLine.d12.s3|55-55|3|O
DDI-MedLine.d12.s3|57-57|X|O
DDI-MedLine.d12.s3|59-60|10|O
DDI-MedLine.d12.s3|61-61|(|O
DDI-MedLine.d12.s3|62-63|-9|O
DDI-MedLine.d12.s3|64-64|)|O
DDI-MedLine.d12.s3|66-66|M|O
DDI-MedLine.d12.s3|68-75|inhibits|O
DDI-MedLine.d12.s3|77-89|proliferation|O
DDI-MedLine.d12.s3|91-100|stimulated|O
DDI-MedLine.d12.s3|102-103|by|O
DDI-MedLine.d12.s3|108-108|.|O
DDI-MedLine.d12.s4|0-5|Higher|O
DDI-MedLine.d12.s4|7-20|concentrations|O
DDI-MedLine.d12.s4|22-23|of|O
DDI-MedLine.d12.s4|25-37|dexamethasone|drug
DDI-MedLine.d12.s4|39-39|(|O
DDI-MedLine.d12.s4|40-41|10|O
DDI-MedLine.d12.s4|42-42|(|O
DDI-MedLine.d12.s4|43-44|-8|O
DDI-MedLine.d12.s4|45-45|)|O
DDI-MedLine.d12.s4|47-47|-|O
DDI-MedLine.d12.s4|49-50|10|O
DDI-MedLine.d12.s4|51-51|(|O
DDI-MedLine.d12.s4|52-53|-6|O
DDI-MedLine.d12.s4|54-54|)|O
DDI-MedLine.d12.s4|56-56|M|O
DDI-MedLine.d12.s4|57-57|)|O
DDI-MedLine.d12.s4|59-60|or|O
DDI-MedLine.d12.s4|62-76|retinyl acetate|drug
DDI-MedLine.d12.s4|78-78|(|O
DDI-MedLine.d12.s4|79-79|3|O
DDI-MedLine.d12.s4|81-81|X|O
DDI-MedLine.d12.s4|83-84|10|O
DDI-MedLine.d12.s4|85-85|(|O
DDI-MedLine.d12.s4|86-87|-8|O
DDI-MedLine.d12.s4|88-88|)|O
DDI-MedLine.d12.s4|90-90|-|O
DDI-MedLine.d12.s4|92-93|10|O
DDI-MedLine.d12.s4|94-94|(|O
DDI-MedLine.d12.s4|95-96|-7|O
DDI-MedLine.d12.s4|97-97|)|O
DDI-MedLine.d12.s4|99-99|M|O
DDI-MedLine.d12.s4|100-100|)|O
DDI-MedLine.d12.s4|102-108|enhance|O
DDI-MedLine.d12.s4|110-112|the|O
DDI-MedLine.d12.s4|114-122|mitogenic|O
DDI-MedLine.d12.s4|124-131|activity|O
DDI-MedLine.d12.s4|133-134|of|O
DDI-MedLine.d12.s4|139-139|.|O
DDI-MedLine.d12.s5|0-12|Dexamethasone|drug
DDI-MedLine.d12.s5|14-16|had|O
DDI-MedLine.d12.s5|18-18|a|O
DDI-MedLine.d12.s5|20-26|similar|O
DDI-MedLine.d12.s5|28-33|effect|O
DDI-MedLine.d12.s5|35-36|in|O
DDI-MedLine.d12.s5|38-40|the|O
DDI-MedLine.d12.s5|42-49|presence|O
DDI-MedLine.d12.s5|51-52|of|O
DDI-MedLine.d12.s5|54-60|insulin|drug
DDI-MedLine.d12.s5|61-61|.|O
DDI-MedLine.d12.s6|0-6|However|O
DDI-MedLine.d12.s6|7-7|,|O
DDI-MedLine.d12.s6|9-23|retinyl acetate|drug
DDI-MedLine.d12.s6|25-34|stimulated|O
DDI-MedLine.d12.s6|35-35|,|O
DDI-MedLine.d12.s6|37-39|but|O
DDI-MedLine.d12.s6|41-43|did|O
DDI-MedLine.d12.s6|45-47|not|O
DDI-MedLine.d12.s6|49-61|significantly|O
DDI-MedLine.d12.s6|63-69|inhibit|O
DDI-MedLine.d12.s6|70-70|,|O
DDI-MedLine.d12.s6|72-84|proliferation|O
DDI-MedLine.d12.s6|86-87|in|O
DDI-MedLine.d12.s6|89-91|the|O
DDI-MedLine.d12.s6|93-100|presence|O
DDI-MedLine.d12.s6|102-103|of|O
DDI-MedLine.d12.s6|105-111|insulin|drug
DDI-MedLine.d12.s6|112-112|.|O
DDI-MedLine.d12.s7|0-4|These|O
DDI-MedLine.d12.s7|6-12|results|O
DDI-MedLine.d12.s7|14-20|suggest|O
DDI-MedLine.d12.s7|22-25|that|O
DDI-MedLine.d12.s7|27-30|both|O
DDI-MedLine.d12.s7|32-44|dexamethasone|drug
DDI-MedLine.d12.s7|46-48|and|O
DDI-MedLine.d12.s7|50-64|retinyl acetate|drug
DDI-MedLine.d12.s7|65-65|,|O
DDI-MedLine.d12.s7|67-69|and|O
DDI-MedLine.d12.s7|71-78|possibly|O
DDI-MedLine.d12.s7|80-84|other|O
DDI-MedLine.d12.s7|86-100|glucocorticoids|group
DDI-MedLine.d12.s7|102-104|and|O
DDI-MedLine.d12.s7|106-114|retinoids|group
DDI-MedLine.d12.s7|115-115|,|O
DDI-MedLine.d12.s7|117-119|may|O
DDI-MedLine.d12.s7|121-128|regulate|O
DDI-MedLine.d12.s7|130-132|the|O
DDI-MedLine.d12.s7|134-146|proliferation|O
DDI-MedLine.d12.s7|148-149|of|O
DDI-MedLine.d12.s7|151-158|prostate|O
DDI-MedLine.d12.s7|160-169|epithelium|O
DDI-MedLine.d12.s7|171-172|by|O
DDI-MedLine.d12.s7|174-174|a|O
DDI-MedLine.d12.s7|176-189|dose-dependent|O
DDI-MedLine.d12.s7|191-202|modification|O
DDI-MedLine.d12.s7|204-205|of|O
DDI-MedLine.d12.s7|207-209|the|O
DDI-MedLine.d12.s7|211-218|activity|O
DDI-MedLine.d12.s7|220-221|of|O
DDI-MedLine.d12.s7|223-229|insulin|drug
DDI-MedLine.d12.s7|231-233|and|O
DDI-MedLine.d12.s7|238-238|.|O
DDI-DrugBank.d648.s0|0-13|Cholestyramine|drug
DDI-DrugBank.d648.s0|14-14|:|O
DDI-DrugBank.d648.s0|16-29|Cholestyramine|drug
DDI-DrugBank.d648.s0|31-36|causes|O
DDI-DrugBank.d648.s0|38-38|a|O
DDI-DrugBank.d648.s0|40-41|60|O
DDI-DrugBank.d648.s0|42-42|%|O
DDI-DrugBank.d648.s0|44-52|reduction|O
DDI-DrugBank.d648.s0|54-55|in|O
DDI-DrugBank.d648.s0|57-59|the|O
DDI-DrugBank.d648.s0|61-70|absorption|O
DDI-DrugBank.d648.s0|72-74|and|O
DDI-DrugBank.d648.s0|76-88|enterohepatic|O
DDI-DrugBank.d648.s0|90-96|cycling|O
DDI-DrugBank.d648.s0|98-99|of|O
DDI-DrugBank.d648.s0|101-110|raloxifene|drug
DDI-DrugBank.d648.s0|112-114|and|O
DDI-DrugBank.d648.s0|116-121|should|O
DDI-DrugBank.d648.s0|123-125|not|O
DDI-DrugBank.d648.s0|127-128|be|O
DDI-DrugBank.d648.s0|130-143|coadministered|O
DDI-DrugBank.d648.s0|145-148|with|O
DDI-DrugBank.d648.s0|150-155|EVISTA|brand
DDI-DrugBank.d648.s0|156-156|.|O
DDI-DrugBank.d648.s1|0-7|Warfarin|drug
DDI-DrugBank.d648.s1|8-8|:|O
DDI-DrugBank.d648.s1|10-12|The|O
DDI-DrugBank.d648.s1|14-29|coadministration|O
DDI-DrugBank.d648.s1|31-32|of|O
DDI-DrugBank.d648.s1|34-39|EVISTA|brand
DDI-DrugBank.d648.s1|41-43|and|O
DDI-DrugBank.d648.s1|45-52|warfarin|drug
DDI-DrugBank.d648.s1|54-56|has|O
DDI-DrugBank.d648.s1|58-60|not|O
DDI-DrugBank.d648.s1|62-65|been|O
DDI-DrugBank.d648.s1|67-74|assessed|O
DDI-DrugBank.d648.s1|76-80|under|O
DDI-DrugBank.d648.s1|82-88|chronic|O
DDI-DrugBank.d648.s1|90-99|conditions|O
DDI-DrugBank.d648.s1|100-100|.|O
DDI-DrugBank.d648.s2|0-6|However|O
DDI-DrugBank.d648.s2|7-7|,|O
DDI-DrugBank.d648.s2|9-10|10|O
DDI-DrugBank.d648.s2|11-11|%|O
DDI-DrugBank.d648.s2|13-21|decreases|O
DDI-DrugBank.d648.s2|23-24|in|O
DDI-DrugBank.d648.s2|26-36|prothrombin|O
DDI-DrugBank.d648.s2|38-41|time|O
DDI-DrugBank.d648.s2|43-46|have|O
DDI-DrugBank.d648.s2|48-51|been|O
DDI-DrugBank.d648.s2|53-60|observed|O
DDI-DrugBank.d648.s2|62-63|in|O
DDI-DrugBank.d648.s2|65-75|single-dose|O
DDI-DrugBank.d648.s2|77-83|studies|O
DDI-DrugBank.d648.s2|84-84|.|O
DDI-DrugBank.d648.s3|0-1|If|O
DDI-DrugBank.d648.s3|3-8|EVISTA|brand
DDI-DrugBank.d648.s3|10-11|is|O
DDI-DrugBank.d648.s3|13-17|given|O
DDI-DrugBank.d648.s3|19-30|concurrently|O
DDI-DrugBank.d648.s3|32-35|with|O
DDI-DrugBank.d648.s3|37-44|warfarin|drug
DDI-DrugBank.d648.s3|45-45|,|O
DDI-DrugBank.d648.s3|47-57|prothrombin|O
DDI-DrugBank.d648.s3|59-62|time|O
DDI-DrugBank.d648.s3|64-69|should|O
DDI-DrugBank.d648.s3|71-72|be|O
DDI-DrugBank.d648.s3|74-82|monitored|O
DDI-DrugBank.d648.s3|83-83|.|O
DDI-DrugBank.d648.s4|0-4|Other|O
DDI-DrugBank.d648.s4|6-11|Highly|O
DDI-DrugBank.d648.s4|13-25|Protein-Bound|O
DDI-DrugBank.d648.s4|27-31|Drugs|O
DDI-DrugBank.d648.s4|32-32|:|O
DDI-DrugBank.d648.s4|34-43|Raloxifene|drug
DDI-DrugBank.d648.s4|45-46|is|O
DDI-DrugBank.d648.s4|48-51|more|O
DDI-DrugBank.d648.s4|53-56|than|O
DDI-DrugBank.d648.s4|58-59|95|O
DDI-DrugBank.d648.s4|60-60|%|O
DDI-DrugBank.d648.s4|62-66|bound|O
DDI-DrugBank.d648.s4|68-69|to|O
DDI-DrugBank.d648.s4|71-76|plasma|O
DDI-DrugBank.d648.s4|78-85|proteins|O
DDI-DrugBank.d648.s4|86-86|.|O
DDI-DrugBank.d648.s5|0-1|In|O
DDI-DrugBank.d648.s5|3-7|vitro|O
DDI-DrugBank.d648.s5|8-8|,|O
DDI-DrugBank.d648.s5|10-19|raloxifene|drug
DDI-DrugBank.d648.s5|21-23|did|O
DDI-DrugBank.d648.s5|25-27|not|O
DDI-DrugBank.d648.s5|29-34|affect|O
DDI-DrugBank.d648.s5|36-38|the|O
DDI-DrugBank.d648.s5|40-46|binding|O
DDI-DrugBank.d648.s5|48-49|of|O
DDI-DrugBank.d648.s5|51-58|warfarin|drug
DDI-DrugBank.d648.s5|59-59|,|O
DDI-DrugBank.d648.s5|61-69|phenytoin|drug
DDI-DrugBank.d648.s5|70-70|,|O
DDI-DrugBank.d648.s5|72-73|or|O
DDI-DrugBank.d648.s5|75-83|tamoxifen|drug
DDI-DrugBank.d648.s5|84-84|.|O
DDI-DrugBank.d648.s6|0-6|Caution|O
DDI-DrugBank.d648.s6|8-13|should|O
DDI-DrugBank.d648.s6|15-16|be|O
DDI-DrugBank.d648.s6|18-21|used|O
DDI-DrugBank.d648.s6|23-26|when|O
DDI-DrugBank.d648.s6|28-33|EVISTA|brand
DDI-DrugBank.d648.s6|35-36|is|O
DDI-DrugBank.d648.s6|38-51|coadministered|O
DDI-DrugBank.d648.s6|53-56|with|O
DDI-DrugBank.d648.s6|58-62|other|O
DDI-DrugBank.d648.s6|64-69|highly|O
DDI-DrugBank.d648.s6|71-83|protein-bound|O
DDI-DrugBank.d648.s6|85-89|drugs|O
DDI-DrugBank.d648.s6|90-90|,|O
DDI-DrugBank.d648.s6|92-95|such|O
DDI-DrugBank.d648.s6|97-98|as|O
DDI-DrugBank.d648.s6|100-109|clofibrate|drug
DDI-DrugBank.d648.s6|110-110|,|O
DDI-DrugBank.d648.s6|112-123|indomethacin|drug
DDI-DrugBank.d648.s6|124-124|,|O
DDI-DrugBank.d648.s6|126-133|naproxen|drug
DDI-DrugBank.d648.s6|134-134|,|O
DDI-DrugBank.d648.s6|136-144|ibuprofen|drug
DDI-DrugBank.d648.s6|145-145|,|O
DDI-DrugBank.d648.s6|147-154|diazepam|drug
DDI-DrugBank.d648.s6|155-155|,|O
DDI-DrugBank.d648.s6|157-159|and|O
DDI-DrugBank.d648.s6|161-169|diazoxide|drug
DDI-DrugBank.d648.s6|170-170|.|O
DDI-DrugBank.d648.s7|0-2|See|O
DDI-DrugBank.d648.s7|4-7|also|O
DDI-DrugBank.d648.s7|9-16|CLINICAL|O
DDI-DrugBank.d648.s7|18-29|PHARMACOLOGY|O
DDI-DrugBank.d648.s7|30-30|,|O
DDI-DrugBank.d648.s7|32-40|Drug-Drug|O
DDI-DrugBank.d648.s7|42-53|Interactions|O
DDI-DrugBank.d96.s0|0-13|Dimenhydrinate|drug
DDI-DrugBank.d96.s0|15-17|may|O
DDI-DrugBank.d96.s0|19-26|decrease|O
DDI-DrugBank.d96.s0|28-33|emetic|group
DDI-DrugBank.d96.s0|35-42|response|O
DDI-DrugBank.d96.s0|44-45|to|O
DDI-DrugBank.d96.s0|47-57|apomorphine|drug
DDI-DrugBank.d96.s0|58-58|.|O
DDI-DrugBank.d702.s0|0-6|SPIRIVA|brand
DDI-DrugBank.d702.s0|8-10|has|O
DDI-DrugBank.d702.s0|12-15|been|O
DDI-DrugBank.d702.s0|17-20|used|O
DDI-DrugBank.d702.s0|22-34|concomitantly|O
DDI-DrugBank.d702.s0|36-39|with|O
DDI-DrugBank.d702.s0|41-45|other|O
DDI-DrugBank.d702.s0|47-51|drugs|O
DDI-DrugBank.d702.s0|53-60|commonly|O
DDI-DrugBank.d702.s0|62-65|used|O
DDI-DrugBank.d702.s0|67-68|in|O
DDI-DrugBank.d702.s0|70-73|COPD|O
DDI-DrugBank.d702.s0|75-81|without|O
DDI-DrugBank.d702.s0|83-91|increases|O
DDI-DrugBank.d702.s0|93-94|in|O
DDI-DrugBank.d702.s0|96-102|adverse|O
DDI-DrugBank.d702.s0|104-107|drug|O
DDI-DrugBank.d702.s0|109-117|reactions|O
DDI-DrugBank.d702.s0|118-118|.|O
DDI-DrugBank.d702.s1|0-4|These|O
DDI-DrugBank.d702.s1|6-12|include|O
DDI-DrugBank.d702.s1|14-44|sympathomimetic bronchodilators|group
DDI-DrugBank.d702.s1|45-45|,|O
DDI-DrugBank.d702.s1|47-61|methylxanthines|group
DDI-DrugBank.d702.s1|62-62|,|O
DDI-DrugBank.d702.s1|64-66|and|O
DDI-DrugBank.d702.s1|68-71|oral|O
DDI-DrugBank.d702.s1|73-75|and|O
DDI-DrugBank.d702.s1|77-83|inhaled|O
DDI-DrugBank.d702.s1|85-92|steroids|group
DDI-DrugBank.d702.s1|93-93|.|O
DDI-DrugBank.d702.s2|0-6|However|O
DDI-DrugBank.d702.s2|7-7|,|O
DDI-DrugBank.d702.s2|9-11|the|O
DDI-DrugBank.d702.s2|13-14|co|O
DDI-DrugBank.d702.s2|18-31|administration|O
DDI-DrugBank.d702.s2|33-34|of|O
DDI-DrugBank.d702.s2|36-42|SPIRIVA|brand
DDI-DrugBank.d702.s2|44-47|with|O
DDI-DrugBank.d702.s2|49-53|other|O
DDI-DrugBank.d702.s2|55-69|anticholinergic|group
DDI-DrugBank.d702.s2|73-82|containing|O
DDI-DrugBank.d702.s2|84-88|drugs|O
DDI-DrugBank.d702.s2|90-90|(|O
DDI-DrugBank.d702.s2|91-94|e.g.|O
DDI-DrugBank.d702.s2|95-95|,|O
DDI-DrugBank.d702.s2|97-107|ipratropium|drug
DDI-DrugBank.d702.s2|108-108|)|O
DDI-DrugBank.d702.s2|110-112|has|O
DDI-DrugBank.d702.s2|114-116|not|O
DDI-DrugBank.d702.s2|118-121|been|O
DDI-DrugBank.d702.s2|123-129|studied|O
DDI-DrugBank.d702.s2|131-133|and|O
DDI-DrugBank.d702.s2|135-136|is|O
DDI-DrugBank.d702.s2|138-146|therefore|O
DDI-DrugBank.d702.s2|148-150|not|O
DDI-DrugBank.d702.s2|152-162|recommended|O
DDI-DrugBank.d702.s2|163-163|.|O
DDI-DrugBank.d462.s0|0-14|Aminoglycosides|group
DDI-DrugBank.d462.s0|15-15|:|O
DDI-DrugBank.d462.s0|17-19|The|O
DDI-DrugBank.d462.s0|21-26|mixing|O
DDI-DrugBank.d462.s0|28-29|of|O
DDI-DrugBank.d462.s0|31-42|piperacillin|drug
DDI-DrugBank.d462.s0|44-47|with|O
DDI-DrugBank.d462.s0|49-50|an|O
DDI-DrugBank.d462.s0|52-65|aminoglycoside|group
DDI-DrugBank.d462.s0|67-68|in|O
DDI-DrugBank.d462.s0|70-74|vitro|O
DDI-DrugBank.d462.s0|76-78|can|O
DDI-DrugBank.d462.s0|80-85|result|O
DDI-DrugBank.d462.s0|87-88|in|O
DDI-DrugBank.d462.s0|90-100|substantial|O
DDI-DrugBank.d462.s0|102-113|inactivation|O
DDI-DrugBank.d462.s0|115-116|of|O
DDI-DrugBank.d462.s0|118-120|the|O
DDI-DrugBank.d462.s0|122-135|aminoglycoside|group
DDI-DrugBank.d462.s0|136-136|.|O
DDI-DrugBank.d462.s1|0-9|Vecuronium|drug
DDI-DrugBank.d462.s1|10-10|:|O
DDI-DrugBank.d462.s1|12-15|When|O
DDI-DrugBank.d462.s1|17-20|used|O
DDI-DrugBank.d462.s1|22-23|in|O
DDI-DrugBank.d462.s1|25-27|the|O
DDI-DrugBank.d462.s1|29-41|perioperative|O
DDI-DrugBank.d462.s1|43-48|period|O
DDI-DrugBank.d462.s1|49-49|,|O
DDI-DrugBank.d462.s1|51-62|piperacillin|drug
DDI-DrugBank.d462.s1|64-66|has|O
DDI-DrugBank.d462.s1|68-71|been|O
DDI-DrugBank.d462.s1|73-82|implicated|O
DDI-DrugBank.d462.s1|84-85|in|O
DDI-DrugBank.d462.s1|87-89|the|O
DDI-DrugBank.d462.s1|91-102|prolongation|O
DDI-DrugBank.d462.s1|104-105|of|O
DDI-DrugBank.d462.s1|107-109|the|O
DDI-DrugBank.d462.s1|111-123|neuromuscular|O
DDI-DrugBank.d462.s1|125-132|blockade|O
DDI-DrugBank.d462.s1|134-135|of|O
DDI-DrugBank.d462.s1|137-146|vecuronium|drug
DDI-DrugBank.d462.s1|147-147|.|O
DDI-DrugBank.d462.s2|0-6|Caution|O
DDI-DrugBank.d462.s2|8-9|is|O
DDI-DrugBank.d462.s2|11-19|indicated|O
DDI-DrugBank.d462.s2|21-24|when|O
DDI-DrugBank.d462.s2|26-37|piperacillin|drug
DDI-DrugBank.d462.s2|39-40|is|O
DDI-DrugBank.d462.s2|42-45|used|O
DDI-DrugBank.d462.s2|47-61|perioperatively|O
DDI-DrugBank.d462.s2|62-62|.|O
DDI-DrugBank.d462.s3|0-1|In|O
DDI-DrugBank.d462.s3|3-5|one|O
DDI-DrugBank.d462.s3|7-16|controlled|O
DDI-DrugBank.d462.s3|18-25|clinical|O
DDI-DrugBank.d462.s3|27-31|study|O
DDI-DrugBank.d462.s3|32-32|,|O
DDI-DrugBank.d462.s3|34-36|the|O
DDI-DrugBank.d462.s3|38-54|ureidopenicillins|O
DDI-DrugBank.d462.s3|55-55|,|O
DDI-DrugBank.d462.s3|57-65|including|O
DDI-DrugBank.d462.s3|67-78|piperacillin|drug
DDI-DrugBank.d462.s3|79-79|,|O
DDI-DrugBank.d462.s3|81-84|were|O
DDI-DrugBank.d462.s3|86-93|reported|O
DDI-DrugBank.d462.s3|95-96|to|O
DDI-DrugBank.d462.s3|98-104|prolong|O
DDI-DrugBank.d462.s3|106-108|the|O
DDI-DrugBank.d462.s3|110-115|action|O
DDI-DrugBank.d462.s3|117-118|of|O
DDI-DrugBank.d462.s3|120-129|vecuronium|drug
DDI-DrugBank.d462.s3|130-130|.|O
DDI-DrugBank.d462.s4|0-2|Due|O
DDI-DrugBank.d462.s4|4-5|to|O
DDI-DrugBank.d462.s4|7-11|their|O
DDI-DrugBank.d462.s4|13-19|similar|O
DDI-DrugBank.d462.s4|21-29|mechanism|O
DDI-DrugBank.d462.s4|31-32|of|O
DDI-DrugBank.d462.s4|34-39|action|O
DDI-DrugBank.d462.s4|40-40|,|O
DDI-DrugBank.d462.s4|42-43|it|O
DDI-DrugBank.d462.s4|45-46|is|O
DDI-DrugBank.d462.s4|48-55|expected|O
DDI-DrugBank.d462.s4|57-60|that|O
DDI-DrugBank.d462.s4|62-64|the|O
DDI-DrugBank.d462.s4|66-78|neuromuscular|O
DDI-DrugBank.d462.s4|80-87|blockade|O
DDI-DrugBank.d462.s4|89-96|produced|O
DDI-DrugBank.d462.s4|98-99|by|O
DDI-DrugBank.d462.s4|101-103|any|O
DDI-DrugBank.d462.s4|105-106|of|O
DDI-DrugBank.d462.s4|108-110|the|O
DDI-DrugBank.d462.s4|112-144|non-depolarizing muscle relaxants|group
DDI-DrugBank.d462.s4|146-150|could|O
DDI-DrugBank.d462.s4|152-153|be|O
DDI-DrugBank.d462.s4|155-163|prolonged|O
DDI-DrugBank.d462.s4|165-166|in|O
DDI-DrugBank.d462.s4|168-170|the|O
DDI-DrugBank.d462.s4|172-179|presence|O
DDI-DrugBank.d462.s4|181-182|of|O
DDI-DrugBank.d462.s4|184-195|piperacillin|drug
DDI-DrugBank.d462.s4|196-196|.|O
DDI-DrugBank.d462.s5|0-9|Probenecid|drug
DDI-DrugBank.d462.s5|10-10|:|O
DDI-DrugBank.d462.s5|12-14|The|O
DDI-DrugBank.d462.s5|16-19|oral|O
DDI-DrugBank.d462.s5|21-31|combination|O
DDI-DrugBank.d462.s5|33-34|of|O
DDI-DrugBank.d462.s5|36-45|probenecid|drug
DDI-DrugBank.d462.s5|47-52|before|O
DDI-DrugBank.d462.s5|54-66|intramuscular|O
DDI-DrugBank.d462.s5|68-76|injection|O
DDI-DrugBank.d462.s5|78-79|of|O
DDI-DrugBank.d462.s5|81-88|PIPRACIL|brand
DDI-DrugBank.d462.s5|90-97|produces|O
DDI-DrugBank.d462.s5|99-100|an|O
DDI-DrugBank.d462.s5|102-109|increase|O
DDI-DrugBank.d462.s5|111-112|in|O
DDI-DrugBank.d462.s5|114-125|piperacillin|drug
DDI-DrugBank.d462.s5|127-130|peak|O
DDI-DrugBank.d462.s5|132-136|serum|O
DDI-DrugBank.d462.s5|138-142|level|O
DDI-DrugBank.d462.s5|144-145|of|O
DDI-DrugBank.d462.s5|147-151|about|O
DDI-DrugBank.d462.s5|153-154|30|O
DDI-DrugBank.d462.s5|155-155|%|O
DDI-DrugBank.d462.s5|156-156|.|O
DDI-DrugBank.d462.s6|0-13|Anticoagulants|group
DDI-DrugBank.d462.s6|14-14|:|O
DDI-DrugBank.d462.s6|16-26|Coagulation|O
DDI-DrugBank.d462.s6|28-37|parameters|O
DDI-DrugBank.d462.s6|39-44|should|O
DDI-DrugBank.d462.s6|46-47|be|O
DDI-DrugBank.d462.s6|49-54|tested|O
DDI-DrugBank.d462.s6|56-59|more|O
DDI-DrugBank.d462.s6|61-70|frequently|O
DDI-DrugBank.d462.s6|72-74|and|O
DDI-DrugBank.d462.s6|76-84|monitored|O
DDI-DrugBank.d462.s6|86-94|regularly|O
DDI-DrugBank.d462.s6|96-101|during|O
DDI-DrugBank.d462.s6|103-114|simultaneous|O
DDI-DrugBank.d462.s6|116-129|administration|O
DDI-DrugBank.d462.s6|131-132|of|O
DDI-DrugBank.d462.s6|134-137|high|O
DDI-DrugBank.d462.s6|139-143|doses|O
DDI-DrugBank.d462.s6|145-146|of|O
DDI-DrugBank.d462.s6|148-154|heparin|drug
DDI-DrugBank.d462.s6|155-155|,|O
DDI-DrugBank.d462.s6|157-160|oral|O
DDI-DrugBank.d462.s6|162-175|anticoagulants|group
DDI-DrugBank.d462.s6|176-176|,|O
DDI-DrugBank.d462.s6|178-179|or|O
DDI-DrugBank.d462.s6|181-185|other|O
DDI-DrugBank.d462.s6|187-191|drugs|O
DDI-DrugBank.d462.s6|193-196|that|O
DDI-DrugBank.d462.s6|198-200|may|O
DDI-DrugBank.d462.s6|202-207|affect|O
DDI-DrugBank.d462.s6|209-211|the|O
DDI-DrugBank.d462.s6|213-217|blood|O
DDI-DrugBank.d462.s6|219-229|coagulation|O
DDI-DrugBank.d462.s6|231-236|system|O
DDI-DrugBank.d462.s6|238-239|or|O
DDI-DrugBank.d462.s6|241-243|the|O
DDI-DrugBank.d462.s6|245-255|thrombocyte|O
DDI-DrugBank.d462.s6|257-264|function|O
DDI-DrugBank.d462.s6|265-265|.|O
DDI-DrugBank.d462.s7|0-11|Methotrexate|drug
DDI-DrugBank.d462.s7|12-12|:|O
DDI-DrugBank.d462.s7|14-32|Piperacillin sodium|drug
DDI-DrugBank.d462.s7|34-36|may|O
DDI-DrugBank.d462.s7|38-43|reduce|O
DDI-DrugBank.d462.s7|45-47|the|O
DDI-DrugBank.d462.s7|49-57|excretion|O
DDI-DrugBank.d462.s7|59-60|of|O
DDI-DrugBank.d462.s7|62-73|methotrexate|drug
DDI-DrugBank.d462.s7|74-74|.|O
DDI-DrugBank.d462.s8|0-8|Therefore|O
DDI-DrugBank.d462.s8|9-9|,|O
DDI-DrugBank.d462.s8|11-15|serum|O
DDI-DrugBank.d462.s8|17-22|levels|O
DDI-DrugBank.d462.s8|24-25|of|O
DDI-DrugBank.d462.s8|27-38|methotrexate|drug
DDI-DrugBank.d462.s8|40-45|should|O
DDI-DrugBank.d462.s8|47-48|be|O
DDI-DrugBank.d462.s8|50-58|monitored|O
DDI-DrugBank.d462.s8|60-61|in|O
DDI-DrugBank.d462.s8|63-70|patients|O
DDI-DrugBank.d462.s8|72-73|to|O
DDI-DrugBank.d462.s8|75-79|avoid|O
DDI-DrugBank.d462.s8|81-84|drug|O
DDI-DrugBank.d462.s8|86-93|toxicity|O
DDI-DrugBank.d462.s8|94-94|.|O
DDI-DrugBank.d462.s9|0-14|Drug/Laboratory|O
DDI-DrugBank.d462.s9|16-19|Test|O
DDI-DrugBank.d462.s9|21-32|Interactions|O
DDI-DrugBank.d462.s9|34-35|As|O
DDI-DrugBank.d462.s9|37-40|with|O
DDI-DrugBank.d462.s9|42-46|other|O
DDI-DrugBank.d462.s9|48-58|penicillins|drug
DDI-DrugBank.d462.s9|59-59|,|O
DDI-DrugBank.d462.s9|61-63|the|O
DDI-DrugBank.d462.s9|65-78|administration|O
DDI-DrugBank.d462.s9|80-81|of|O
DDI-DrugBank.d462.s9|83-90|PIPRACIL|brand
DDI-DrugBank.d462.s9|92-94|may|O
DDI-DrugBank.d462.s9|96-101|result|O
DDI-DrugBank.d462.s9|103-104|in|O
DDI-DrugBank.d462.s9|106-106|a|O
DDI-DrugBank.d462.s9|108-121|false-positive|O
DDI-DrugBank.d462.s9|123-130|reaction|O
DDI-DrugBank.d462.s9|132-134|for|O
DDI-DrugBank.d462.s9|136-142|glucose|O
DDI-DrugBank.d462.s9|144-145|in|O
DDI-DrugBank.d462.s9|147-149|the|O
DDI-DrugBank.d462.s9|151-155|urine|O
DDI-DrugBank.d462.s9|157-161|using|O
DDI-DrugBank.d462.s9|163-163|a|O
DDI-DrugBank.d462.s9|165-180|copper-reduction|O
DDI-DrugBank.d462.s9|182-187|method|O
DDI-DrugBank.d462.s9|188-188|.|O
DDI-DrugBank.d462.s10|0-1|It|O
DDI-DrugBank.d462.s10|3-4|is|O
DDI-DrugBank.d462.s10|6-16|recommended|O
DDI-DrugBank.d462.s10|18-21|that|O
DDI-DrugBank.d462.s10|23-29|glucose|O
DDI-DrugBank.d462.s10|31-35|tests|O
DDI-DrugBank.d462.s10|37-41|based|O
DDI-DrugBank.d462.s10|43-44|on|O
DDI-DrugBank.d462.s10|46-54|enzymatic|O
DDI-DrugBank.d462.s10|56-62|glucose|O
DDI-DrugBank.d462.s10|64-70|oxidase|O
DDI-DrugBank.d462.s10|72-80|reactions|O
DDI-DrugBank.d462.s10|82-83|be|O
DDI-DrugBank.d462.s10|85-88|used|O
DDI-DrugBank.d462.s10|89-89|.|O
DDI-DrugBank.d462.s11|0-4|There|O
DDI-DrugBank.d462.s11|6-9|have|O
DDI-DrugBank.d462.s11|11-14|been|O
DDI-DrugBank.d462.s11|16-22|reports|O
DDI-DrugBank.d462.s11|24-25|of|O
DDI-DrugBank.d462.s11|27-34|positive|O
DDI-DrugBank.d462.s11|36-39|test|O
DDI-DrugBank.d462.s11|41-47|results|O
DDI-DrugBank.d462.s11|49-53|using|O
DDI-DrugBank.d462.s11|55-57|the|O
DDI-DrugBank.d462.s11|59-65|Bio-Rad|O
DDI-DrugBank.d462.s11|67-78|Laboratories|O
DDI-DrugBank.d462.s11|80-87|Platelia|O
DDI-DrugBank.d462.s11|89-99|Aspergillus|O
DDI-DrugBank.d462.s11|101-103|EIA|O
DDI-DrugBank.d462.s11|105-108|test|O
DDI-DrugBank.d462.s11|110-111|in|O
DDI-DrugBank.d462.s11|113-120|patients|O
DDI-DrugBank.d462.s11|122-130|receiving|O
DDI-DrugBank.d462.s11|132-154|piperacillin/tazobactam|drug
DDI-DrugBank.d462.s11|156-164|injection|O
DDI-DrugBank.d462.s11|166-168|who|O
DDI-DrugBank.d462.s11|170-173|were|O
DDI-DrugBank.d462.s11|175-186|subsequently|O
DDI-DrugBank.d462.s11|188-192|found|O
DDI-DrugBank.d462.s11|194-195|to|O
DDI-DrugBank.d462.s11|197-198|be|O
DDI-DrugBank.d462.s11|200-203|free|O
DDI-DrugBank.d462.s11|205-206|of|O
DDI-DrugBank.d462.s11|208-218|Aspergillus|O
DDI-DrugBank.d462.s11|220-228|infection|O
DDI-DrugBank.d462.s11|229-229|.|O
DDI-DrugBank.d462.s12|0-14|Cross-reactions|O
DDI-DrugBank.d462.s12|16-19|with|O
DDI-DrugBank.d462.s12|21-35|non-Aspergillus|O
DDI-DrugBank.d462.s12|37-51|polysaccharides|O
DDI-DrugBank.d462.s12|53-55|and|O
DDI-DrugBank.d462.s12|57-69|polyfuranoses|O
DDI-DrugBank.d462.s12|71-74|with|O
DDI-DrugBank.d462.s12|76-78|the|O
DDI-DrugBank.d462.s12|80-86|Bio-Rad|O
DDI-DrugBank.d462.s12|88-99|Laboratories|O
DDI-DrugBank.d462.s12|101-108|Platelia|O
DDI-DrugBank.d462.s12|110-120|Aspergillus|O
DDI-DrugBank.d462.s12|122-124|EIA|O
DDI-DrugBank.d462.s12|126-129|test|O
DDI-DrugBank.d462.s12|131-134|have|O
DDI-DrugBank.d462.s12|136-139|been|O
DDI-DrugBank.d462.s12|141-148|reported|O
DDI-DrugBank.d462.s12|149-149|.|O
DDI-DrugBank.d462.s13|0-8|Therefore|O
DDI-DrugBank.d462.s13|9-9|,|O
DDI-DrugBank.d462.s13|11-18|positive|O
DDI-DrugBank.d462.s13|20-23|test|O
DDI-DrugBank.d462.s13|25-31|results|O
DDI-DrugBank.d462.s13|33-34|in|O
DDI-DrugBank.d462.s13|36-43|patients|O
DDI-DrugBank.d462.s13|45-53|receiving|O
DDI-DrugBank.d462.s13|55-66|piperacillin|drug
DDI-DrugBank.d462.s13|68-73|should|O
DDI-DrugBank.d462.s13|75-76|be|O
DDI-DrugBank.d462.s13|78-88|interpreted|O
DDI-DrugBank.d462.s13|90-99|cautiously|O
DDI-DrugBank.d462.s13|101-103|and|O
DDI-DrugBank.d462.s13|105-113|confirmed|O
DDI-DrugBank.d462.s13|115-116|by|O
DDI-DrugBank.d462.s13|118-122|other|O
DDI-DrugBank.d462.s13|124-133|diagnostic|O
DDI-DrugBank.d462.s13|135-141|methods|O
DDI-DrugBank.d462.s13|142-142|.|O
DDI-DrugBank.d238.s0|0-2|The|O
DDI-DrugBank.d238.s0|4-8|risks|O
DDI-DrugBank.d238.s0|10-11|of|O
DDI-DrugBank.d238.s0|13-17|using|O
DDI-DrugBank.d238.s0|19-27|Anafranil|brand
DDI-DrugBank.d238.s0|29-30|in|O
DDI-DrugBank.d238.s0|32-42|combination|O
DDI-DrugBank.d238.s0|44-47|with|O
DDI-DrugBank.d238.s0|49-53|other|O
DDI-DrugBank.d238.s0|55-59|drugs|O
DDI-DrugBank.d238.s0|61-64|have|O
DDI-DrugBank.d238.s0|66-68|not|O
DDI-DrugBank.d238.s0|70-73|been|O
DDI-DrugBank.d238.s0|75-88|systematically|O
DDI-DrugBank.d238.s0|90-98|evaluated|O
DDI-DrugBank.d238.s0|99-99|.|O
DDI-DrugBank.d238.s1|0-4|Given|O
DDI-DrugBank.d238.s1|6-8|the|O
DDI-DrugBank.d238.s1|10-16|primary|O
DDI-DrugBank.d238.s1|18-20|CNS|O
DDI-DrugBank.d238.s1|22-28|effects|O
DDI-DrugBank.d238.s1|30-31|of|O
DDI-DrugBank.d238.s1|33-41|Anafranil|brand
DDI-DrugBank.d238.s1|42-42|,|O
DDI-DrugBank.d238.s1|44-50|caution|O
DDI-DrugBank.d238.s1|52-53|is|O
DDI-DrugBank.d238.s1|55-61|advised|O
DDI-DrugBank.d238.s1|63-64|in|O
DDI-DrugBank.d238.s1|66-70|using|O
DDI-DrugBank.d238.s1|72-73|it|O
DDI-DrugBank.d238.s1|75-87|concomitantly|O
DDI-DrugBank.d238.s1|89-92|with|O
DDI-DrugBank.d238.s1|94-98|other|O
DDI-DrugBank.d238.s1|100-109|CNS-active|O
DDI-DrugBank.d238.s1|111-115|drugs|O
DDI-DrugBank.d238.s1|116-116|.|O
DDI-DrugBank.d238.s2|0-8|Anafranil|brand
DDI-DrugBank.d238.s2|10-15|should|O
DDI-DrugBank.d238.s2|17-19|not|O
DDI-DrugBank.d238.s2|21-22|be|O
DDI-DrugBank.d238.s2|24-27|used|O
DDI-DrugBank.d238.s2|29-32|with|O
DDI-DrugBank.d238.s2|34-47|MAO inhibitors|group
DDI-DrugBank.d238.s2|48-48|.|O
DDI-DrugBank.d238.s3|0-4|Close|O
DDI-DrugBank.d238.s3|6-16|supervision|O
DDI-DrugBank.d238.s3|18-20|and|O
DDI-DrugBank.d238.s3|22-28|careful|O
DDI-DrugBank.d238.s3|30-39|adjustment|O
DDI-DrugBank.d238.s3|41-42|of|O
DDI-DrugBank.d238.s3|44-49|dosage|O
DDI-DrugBank.d238.s3|51-53|are|O
DDI-DrugBank.d238.s3|55-62|required|O
DDI-DrugBank.d238.s3|64-67|when|O
DDI-DrugBank.d238.s3|69-77|Anafranil|brand
DDI-DrugBank.d238.s3|79-80|is|O
DDI-DrugBank.d238.s3|82-93|administered|O
DDI-DrugBank.d238.s3|95-98|with|O
DDI-DrugBank.d238.s3|100-114|anticholinergic|group
DDI-DrugBank.d238.s3|116-117|or|O
DDI-DrugBank.d238.s3|119-139|sympathomimetic drugs|group
DDI-DrugBank.d238.s3|140-140|.|O
DDI-DrugBank.d238.s4|0-6|Several|O
DDI-DrugBank.d238.s4|8-32|tricyclic antidepressants|group
DDI-DrugBank.d238.s4|34-37|have|O
DDI-DrugBank.d238.s4|39-42|been|O
DDI-DrugBank.d238.s4|44-51|reported|O
DDI-DrugBank.d238.s4|53-54|to|O
DDI-DrugBank.d238.s4|56-60|block|O
DDI-DrugBank.d238.s4|62-64|the|O
DDI-DrugBank.d238.s4|66-78|pharmacologic|O
DDI-DrugBank.d238.s4|80-86|effects|O
DDI-DrugBank.d238.s4|88-89|of|O
DDI-DrugBank.d238.s4|91-102|guanethidine|drug
DDI-DrugBank.d238.s4|103-103|,|O
DDI-DrugBank.d238.s4|105-113|clonidine|drug
DDI-DrugBank.d238.s4|114-114|,|O
DDI-DrugBank.d238.s4|116-117|or|O
DDI-DrugBank.d238.s4|119-125|similar|O
DDI-DrugBank.d238.s4|127-132|agents|O
DDI-DrugBank.d238.s4|133-133|,|O
DDI-DrugBank.d238.s4|135-137|and|O
DDI-DrugBank.d238.s4|139-142|such|O
DDI-DrugBank.d238.s4|144-145|an|O
DDI-DrugBank.d238.s4|147-152|effect|O
DDI-DrugBank.d238.s4|154-156|may|O
DDI-DrugBank.d238.s4|158-159|be|O
DDI-DrugBank.d238.s4|161-171|anticipated|O
DDI-DrugBank.d238.s4|173-176|with|O
DDI-DrugBank.d238.s4|178-180|CMI|drug
DDI-DrugBank.d238.s4|182-188|because|O
DDI-DrugBank.d238.s4|190-191|of|O
DDI-DrugBank.d238.s4|193-195|its|O
DDI-DrugBank.d238.s4|197-206|structural|O
DDI-DrugBank.d238.s4|208-217|similarity|O
DDI-DrugBank.d238.s4|219-220|to|O
DDI-DrugBank.d238.s4|222-226|other|O
DDI-DrugBank.d238.s4|228-252|tricyclic antidepressants|group
DDI-DrugBank.d238.s4|253-253|.|O
DDI-DrugBank.d238.s5|0-2|The|O
DDI-DrugBank.d238.s5|4-9|plasma|O
DDI-DrugBank.d238.s5|11-23|concentration|O
DDI-DrugBank.d238.s5|25-26|of|O
DDI-DrugBank.d238.s5|28-30|CMI|drug
DDI-DrugBank.d238.s5|32-34|has|O
DDI-DrugBank.d238.s5|36-39|been|O
DDI-DrugBank.d238.s5|41-48|reported|O
DDI-DrugBank.d238.s5|50-51|to|O
DDI-DrugBank.d238.s5|53-54|be|O
DDI-DrugBank.d238.s5|56-64|increased|O
DDI-DrugBank.d238.s5|66-67|by|O
DDI-DrugBank.d238.s5|69-71|the|O
DDI-DrugBank.d238.s5|73-83|concomitant|O
DDI-DrugBank.d238.s5|85-98|administration|O
DDI-DrugBank.d238.s5|100-101|of|O
DDI-DrugBank.d238.s5|103-113|haloperidol|drug
DDI-DrugBank.d238.s5|114-114|;|O
DDI-DrugBank.d238.s6|0-5|plasma|O
DDI-DrugBank.d238.s6|7-12|levels|O
DDI-DrugBank.d238.s6|14-15|of|O
DDI-DrugBank.d238.s6|17-23|several|O
DDI-DrugBank.d238.s6|25-31|closely|O
DDI-DrugBank.d238.s6|33-39|related|O
DDI-DrugBank.d238.s6|41-65|tricyclic antidepressants|group
DDI-DrugBank.d238.s6|67-70|have|O
DDI-DrugBank.d238.s6|72-75|been|O
DDI-DrugBank.d238.s6|77-84|reported|O
DDI-DrugBank.d238.s6|86-87|to|O
DDI-DrugBank.d238.s6|89-90|be|O
DDI-DrugBank.d238.s6|92-100|increased|O
DDI-DrugBank.d238.s6|102-103|by|O
DDI-DrugBank.d238.s6|105-107|the|O
DDI-DrugBank.d238.s6|109-119|concomitant|O
DDI-DrugBank.d238.s6|121-134|administration|O
DDI-DrugBank.d238.s6|136-137|of|O
DDI-DrugBank.d238.s6|139-153|methylphenidate|drug
DDI-DrugBank.d238.s6|155-156|or|O
DDI-DrugBank.d238.s6|158-164|hepatic|O
DDI-DrugBank.d238.s6|166-171|enzyme|O
DDI-DrugBank.d238.s6|173-182|inhibitors|O
DDI-DrugBank.d238.s6|184-184|(|O
DDI-DrugBank.d238.s6|185-188|e.g.|O
DDI-DrugBank.d238.s6|189-189|,|O
DDI-DrugBank.d238.s6|191-200|cimetidine|drug
DDI-DrugBank.d238.s6|201-201|,|O
DDI-DrugBank.d238.s6|203-212|fluoxetine|drug
DDI-DrugBank.d238.s6|213-213|)|O
DDI-DrugBank.d238.s6|215-217|and|O
DDI-DrugBank.d238.s6|219-227|decreased|O
DDI-DrugBank.d238.s6|229-230|by|O
DDI-DrugBank.d238.s6|232-234|the|O
DDI-DrugBank.d238.s6|236-246|concomitant|O
DDI-DrugBank.d238.s6|248-261|administration|O
DDI-DrugBank.d238.s6|263-264|of|O
DDI-DrugBank.d238.s6|266-272|hepatic|O
DDI-DrugBank.d238.s6|274-279|enzyme|O
DDI-DrugBank.d238.s6|281-288|inducers|O
DDI-DrugBank.d238.s6|290-290|(|O
DDI-DrugBank.d238.s6|291-294|e.g.|O
DDI-DrugBank.d238.s6|295-295|,|O
DDI-DrugBank.d238.s6|297-308|barbiturates|group
DDI-DrugBank.d238.s6|309-309|,|O
DDI-DrugBank.d238.s6|311-319|phenytoin|drug
DDI-DrugBank.d238.s6|320-320|)|O
DDI-DrugBank.d238.s6|321-321|,|O
DDI-DrugBank.d238.s6|323-325|and|O
DDI-DrugBank.d238.s6|327-330|such|O
DDI-DrugBank.d238.s6|332-333|an|O
DDI-DrugBank.d238.s6|335-340|effect|O
DDI-DrugBank.d238.s6|342-344|may|O
DDI-DrugBank.d238.s6|346-347|be|O
DDI-DrugBank.d238.s6|349-359|anticipated|O
DDI-DrugBank.d238.s6|361-364|with|O
DDI-DrugBank.d238.s6|366-368|CMI|drug
DDI-DrugBank.d238.s6|370-371|as|O
DDI-DrugBank.d238.s6|373-376|well|O
DDI-DrugBank.d238.s6|377-377|.|O
DDI-DrugBank.d238.s7|0-13|Administration|O
DDI-DrugBank.d238.s7|15-16|of|O
DDI-DrugBank.d238.s7|18-20|CMI|drug
DDI-DrugBank.d238.s7|22-24|has|O
DDI-DrugBank.d238.s7|26-29|been|O
DDI-DrugBank.d238.s7|31-38|reported|O
DDI-DrugBank.d238.s7|40-41|to|O
DDI-DrugBank.d238.s7|43-50|increase|O
DDI-DrugBank.d238.s7|52-54|the|O
DDI-DrugBank.d238.s7|56-61|plasma|O
DDI-DrugBank.d238.s7|63-68|levels|O
DDI-DrugBank.d238.s7|70-71|of|O
DDI-DrugBank.d238.s7|73-85|phenobarbital|drug
DDI-DrugBank.d238.s7|86-86|,|O
DDI-DrugBank.d238.s7|88-89|if|O
DDI-DrugBank.d238.s7|91-95|given|O
DDI-DrugBank.d238.s7|97-109|concomitantly|O
DDI-DrugBank.d238.s7|110-110|.|O
DDI-DrugBank.d238.s8|0-4|Drugs|O
DDI-DrugBank.d238.s8|6-16|Metabolized|O
DDI-DrugBank.d238.s8|18-19|by|O
DDI-DrugBank.d238.s8|21-24|P450|O
DDI-DrugBank.d238.s8|26-28|2D6|O
DDI-DrugBank.d238.s8|29-29|:|O
DDI-DrugBank.d238.s8|31-33|The|O
DDI-DrugBank.d238.s8|35-45|biochemical|O
DDI-DrugBank.d238.s8|47-54|activity|O
DDI-DrugBank.d238.s8|56-57|of|O
DDI-DrugBank.d238.s8|59-61|the|O
DDI-DrugBank.d238.s8|63-66|drug|O
DDI-DrugBank.d238.s8|68-79|metabolizing|O
DDI-DrugBank.d238.s8|81-87|isozyme|O
DDI-DrugBank.d238.s8|89-98|cytochrome|O
DDI-DrugBank.d238.s8|100-103|P450|O
DDI-DrugBank.d238.s8|105-107|2D6|O
DDI-DrugBank.d238.s8|109-109|(|O
DDI-DrugBank.d238.s8|110-120|debrisoquin|O
DDI-DrugBank.d238.s8|122-132|hydroxylase|O
DDI-DrugBank.d238.s8|133-133|)|O
DDI-DrugBank.d238.s8|135-136|is|O
DDI-DrugBank.d238.s8|138-144|reduced|O
DDI-DrugBank.d238.s8|146-147|in|O
DDI-DrugBank.d238.s8|149-149|a|O
DDI-DrugBank.d238.s8|151-156|subset|O
DDI-DrugBank.d238.s8|158-159|of|O
DDI-DrugBank.d238.s8|161-163|the|O
DDI-DrugBank.d238.s8|165-172|aucasian|O
DDI-DrugBank.d238.s8|174-183|population|O
DDI-DrugBank.d238.s8|185-185|(|O
DDI-DrugBank.d238.s8|186-190|about|O
DDI-DrugBank.d238.s8|192-192|7|O
DDI-DrugBank.d238.s8|193-193|%|O
DDI-DrugBank.d238.s8|194-196|-10|O
DDI-DrugBank.d238.s8|197-197|%|O
DDI-DrugBank.d238.s8|199-200|of|O
DDI-DrugBank.d238.s8|202-211|Caucasians|O
DDI-DrugBank.d238.s8|213-215|are|O
DDI-DrugBank.d238.s8|217-225|so-called|O
DDI-DrugBank.d238.s8|227-230|poor|O
DDI-DrugBank.d238.s8|232-243|metabolizers|O
DDI-DrugBank.d238.s8|244-244|)|O
DDI-DrugBank.d238.s8|245-245|;|O
DDI-DrugBank.d238.s9|0-7|reliable|O
DDI-DrugBank.d238.s9|9-17|estimates|O
DDI-DrugBank.d238.s9|19-20|of|O
DDI-DrugBank.d238.s9|22-24|the|O
DDI-DrugBank.d238.s9|26-35|prevalence|O
DDI-DrugBank.d238.s9|37-38|of|O
DDI-DrugBank.d238.s9|40-46|reduced|O
DDI-DrugBank.d238.s9|48-51|P450|O
DDI-DrugBank.d238.s9|53-55|2D6|O
DDI-DrugBank.d238.s9|57-63|isozyme|O
DDI-DrugBank.d238.s9|65-72|activity|O
DDI-DrugBank.d238.s9|74-78|among|O
DDI-DrugBank.d238.s9|80-84|Asian|O
DDI-DrugBank.d238.s9|85-85|,|O
DDI-DrugBank.d238.s9|87-93|African|O
DDI-DrugBank.d238.s9|95-97|and|O
DDI-DrugBank.d238.s9|99-103|other|O
DDI-DrugBank.d238.s9|105-115|populations|O
DDI-DrugBank.d238.s9|117-119|are|O
DDI-DrugBank.d238.s9|121-123|not|O
DDI-DrugBank.d238.s9|125-127|yet|O
DDI-DrugBank.d238.s9|129-137|available|O
DDI-DrugBank.d238.s9|138-138|.|O
DDI-DrugBank.d238.s10|0-3|Poor|O
DDI-DrugBank.d238.s10|5-16|metabolizers|O
DDI-DrugBank.d238.s10|18-21|have|O
DDI-DrugBank.d238.s10|23-28|higher|O
DDI-DrugBank.d238.s10|30-33|than|O
DDI-DrugBank.d238.s10|35-42|expected|O
DDI-DrugBank.d238.s10|44-48|lasma|O
DDI-DrugBank.d238.s10|50-63|concentrations|O
DDI-DrugBank.d238.s10|65-66|of|O
DDI-DrugBank.d238.s10|68-92|tricyclic antidepressants|group
DDI-DrugBank.d238.s10|94-94|(|O
DDI-DrugBank.d238.s10|95-98|TCAs|group
DDI-DrugBank.d238.s10|99-99|)|O
DDI-DrugBank.d238.s10|101-104|when|O
DDI-DrugBank.d238.s10|106-110|given|O
DDI-DrugBank.d238.s10|112-116|usual|O
DDI-DrugBank.d238.s10|118-122|doses|O
DDI-DrugBank.d238.s10|123-123|.|O
DDI-DrugBank.d238.s11|0-8|Depending|O
DDI-DrugBank.d238.s11|10-11|on|O
DDI-DrugBank.d238.s11|13-15|the|O
DDI-DrugBank.d238.s11|17-24|fraction|O
DDI-DrugBank.d238.s11|26-27|of|O
DDI-DrugBank.d238.s11|29-32|drug|O
DDI-DrugBank.d238.s11|34-44|metabolized|O
DDI-DrugBank.d238.s11|46-47|by|O
DDI-DrugBank.d238.s11|49-52|P450|O
DDI-DrugBank.d238.s11|54-56|2D6|O
DDI-DrugBank.d238.s11|57-57|,|O
DDI-DrugBank.d238.s11|59-61|the|O
DDI-DrugBank.d238.s11|63-70|increase|O
DDI-DrugBank.d238.s11|72-73|in|O
DDI-DrugBank.d238.s11|75-80|plasma|O
DDI-DrugBank.d238.s11|82-94|concentration|O
DDI-DrugBank.d238.s11|96-98|may|O
DDI-DrugBank.d238.s11|100-101|be|O
DDI-DrugBank.d238.s11|103-107|small|O
DDI-DrugBank.d238.s11|108-108|,|O
DDI-DrugBank.d238.s11|110-111|or|O
DDI-DrugBank.d238.s11|113-117|quite|O
DDI-DrugBank.d238.s11|119-123|large|O
DDI-DrugBank.d238.s11|125-125|(|O
DDI-DrugBank.d238.s11|126-126|8|O
DDI-DrugBank.d238.s11|128-131|fold|O
DDI-DrugBank.d238.s11|133-140|increase|O
DDI-DrugBank.d238.s11|142-143|in|O
DDI-DrugBank.d238.s11|145-150|plasma|O
DDI-DrugBank.d238.s11|152-154|AUC|O
DDI-DrugBank.d238.s11|156-157|of|O
DDI-DrugBank.d238.s11|159-161|the|O
DDI-DrugBank.d238.s11|163-165|TCA|group
DDI-DrugBank.d238.s11|166-166|)|O
DDI-DrugBank.d238.s11|167-167|.|O
DDI-DrugBank.d238.s12|0-1|In|O
DDI-DrugBank.d238.s12|3-10|addition|O
DDI-DrugBank.d238.s12|11-11|,|O
DDI-DrugBank.d238.s12|13-19|certain|O
DDI-DrugBank.d238.s12|21-25|drugs|O
DDI-DrugBank.d238.s12|27-33|inhibit|O
DDI-DrugBank.d238.s12|35-37|the|O
DDI-DrugBank.d238.s12|39-46|activity|O
DDI-DrugBank.d238.s12|48-49|of|O
DDI-DrugBank.d238.s12|51-54|this|O
DDI-DrugBank.d238.s12|56-62|isozyme|O
DDI-DrugBank.d238.s12|64-66|and|O
DDI-DrugBank.d238.s12|68-71|make|O
DDI-DrugBank.d238.s12|73-78|normal|O
DDI-DrugBank.d238.s12|80-91|metabolizers|O
DDI-DrugBank.d238.s12|93-100|resemble|O
DDI-DrugBank.d238.s12|102-105|poor|O
DDI-DrugBank.d238.s12|107-118|metabolizers|O
DDI-DrugBank.d238.s12|119-119|.|O
DDI-DrugBank.d238.s13|0-1|An|O
DDI-DrugBank.d238.s13|3-12|individual|O
DDI-DrugBank.d238.s13|14-16|who|O
DDI-DrugBank.d238.s13|18-19|is|O
DDI-DrugBank.d238.s13|21-26|stable|O
DDI-DrugBank.d238.s13|28-29|on|O
DDI-DrugBank.d238.s13|31-31|a|O
DDI-DrugBank.d238.s13|33-37|given|O
DDI-DrugBank.d238.s13|39-42|dose|O
DDI-DrugBank.d238.s13|44-45|of|O
DDI-DrugBank.d238.s13|47-52|TCAmay|group
DDI-DrugBank.d238.s13|54-59|become|O
DDI-DrugBank.d238.s13|61-68|abruptly|O
DDI-DrugBank.d238.s13|70-74|toxic|O
DDI-DrugBank.d238.s13|76-79|when|O
DDI-DrugBank.d238.s13|81-85|given|O
DDI-DrugBank.d238.s13|87-89|one|O
DDI-DrugBank.d238.s13|91-92|of|O
DDI-DrugBank.d238.s13|94-98|these|O
DDI-DrugBank.d238.s13|100-109|inhibiting|O
DDI-DrugBank.d238.s13|111-115|drugs|O
DDI-DrugBank.d238.s13|117-118|as|O
DDI-DrugBank.d238.s13|120-130|concomitant|O
DDI-DrugBank.d238.s13|132-138|therapy|O
DDI-DrugBank.d238.s13|139-139|.|O
DDI-DrugBank.d238.s14|0-2|The|O
DDI-DrugBank.d238.s14|4-8|drugs|O
DDI-DrugBank.d238.s14|10-13|that|O
DDI-DrugBank.d238.s14|15-21|inhibit|O
DDI-DrugBank.d238.s14|23-32|cytochrome|O
DDI-DrugBank.d238.s14|34-37|P450|O
DDI-DrugBank.d238.s14|39-41|2D6|O
DDI-DrugBank.d238.s14|43-49|include|O
DDI-DrugBank.d238.s14|51-54|some|O
DDI-DrugBank.d238.s14|56-59|that|O
DDI-DrugBank.d238.s14|61-63|are|O
DDI-DrugBank.d238.s14|65-67|not|O
DDI-DrugBank.d238.s14|69-79|metabolized|O
DDI-DrugBank.d238.s14|81-82|by|O
DDI-DrugBank.d238.s14|84-86|the|O
DDI-DrugBank.d238.s14|88-93|enzyme|O
DDI-DrugBank.d238.s14|95-95|(|O
DDI-DrugBank.d238.s14|96-104|quinidine|drug
DDI-DrugBank.d238.s14|105-105|;|O
DDI-DrugBank.d238.s15|0-9|cimetidine|drug
DDI-DrugBank.d238.s15|10-10|)|O
DDI-DrugBank.d238.s15|12-14|and|O
DDI-DrugBank.d238.s15|16-19|many|O
DDI-DrugBank.d238.s15|21-24|that|O
DDI-DrugBank.d238.s15|26-28|are|O
DDI-DrugBank.d238.s15|30-39|substrates|O
DDI-DrugBank.d238.s15|41-43|for|O
DDI-DrugBank.d238.s15|45-48|P450|O
DDI-DrugBank.d238.s15|50-52|2D6|O
DDI-DrugBank.d238.s15|54-54|(|O
DDI-DrugBank.d238.s15|55-58|many|O
DDI-DrugBank.d238.s15|60-64|other|O
DDI-DrugBank.d238.s15|66-80|antidepressants|group
DDI-DrugBank.d238.s15|81-81|,|O
DDI-DrugBank.d238.s15|83-96|phenothiazines|group
DDI-DrugBank.d238.s15|97-97|,|O
DDI-DrugBank.d238.s15|99-101|and|O
DDI-DrugBank.d238.s15|103-105|the|O
DDI-DrugBank.d238.s15|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d238.s15|107-129|Type 1C antiarrhythmics|group
DDI-DrugBank.d238.s15|143-145|and|O
DDI-DrugBank.d238.s15|147-156|flecainide|drug
DDI-DrugBank.d238.s15|157-157|)|O
DDI-DrugBank.d238.s15|158-158|.|O
DDI-DrugBank.d238.s16|0-4|While|O
DDI-DrugBank.d238.s16|6-8|all|O
DDI-DrugBank.d238.s16|10-12|the|O
DDI-DrugBank.d238.s16|14-52|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d238.s16|54-54|(|O
DDI-DrugBank.d238.s16|55-59|SSRIs|group
DDI-DrugBank.d238.s16|60-60|)|O
DDI-DrugBank.d238.s16|61-61|,|O
DDI-DrugBank.d238.s16|63-66|e.g.|O
DDI-DrugBank.d238.s16|67-67|,|O
DDI-DrugBank.d238.s16|69-78|fluoxetine|drug
DDI-DrugBank.d238.s16|79-79|,|O
DDI-DrugBank.d238.s16|81-90|sertraline|drug
DDI-DrugBank.d238.s16|91-91|,|O
DDI-DrugBank.d238.s16|93-102|paroxetine|drug
DDI-DrugBank.d238.s16|103-103|,|O
DDI-DrugBank.d238.s16|105-107|and|O
DDI-DrugBank.d238.s16|109-119|fluvoxamine|drug
DDI-DrugBank.d238.s16|120-120|,|O
DDI-DrugBank.d238.s16|122-128|inhibit|O
DDI-DrugBank.d238.s16|130-133|P450|O
DDI-DrugBank.d238.s16|135-137|2D6|O
DDI-DrugBank.d238.s16|138-138|,|O
DDI-DrugBank.d238.s16|140-143|they|O
DDI-DrugBank.d238.s16|145-147|may|O
DDI-DrugBank.d238.s16|149-152|vary|O
DDI-DrugBank.d238.s16|154-155|in|O
DDI-DrugBank.d238.s16|157-159|the|O
DDI-DrugBank.d238.s16|161-166|extent|O
DDI-DrugBank.d238.s16|168-169|of|O
DDI-DrugBank.d238.s16|171-180|inhibition|O
DDI-DrugBank.d238.s16|181-181|.|O
DDI-DrugBank.d238.s17|0-10|Fluvoxamine|drug
DDI-DrugBank.d238.s17|12-14|has|O
DDI-DrugBank.d238.s17|16-19|also|O
DDI-DrugBank.d238.s17|21-24|been|O
DDI-DrugBank.d238.s17|26-30|shown|O
DDI-DrugBank.d238.s17|32-33|to|O
DDI-DrugBank.d238.s17|35-41|inhibit|O
DDI-DrugBank.d238.s17|43-46|P450|O
DDI-DrugBank.d238.s17|48-50|1A2|O
DDI-DrugBank.d238.s17|51-51|,|O
DDI-DrugBank.d238.s17|53-54|an|O
DDI-DrugBank.d238.s17|56-62|isoform|O
DDI-DrugBank.d238.s17|64-67|also|O
DDI-DrugBank.d238.s17|69-76|involved|O
DDI-DrugBank.d238.s17|78-79|in|O
DDI-DrugBank.d238.s17|81-93|TCAmetabolism|group
DDI-DrugBank.d238.s17|94-94|.|O
DDI-DrugBank.d238.s18|0-2|The|O
DDI-DrugBank.d238.s18|4-9|extent|O
DDI-DrugBank.d238.s18|11-12|to|O
DDI-DrugBank.d238.s18|14-18|which|O
DDI-DrugBank.d238.s18|20-39|SSRI-TCAinteractions|group
DDI-DrugBank.d238.s18|41-43|may|O
DDI-DrugBank.d238.s18|45-48|pose|O
DDI-DrugBank.d238.s18|50-57|clinical|O
DDI-DrugBank.d238.s18|59-66|problems|O
DDI-DrugBank.d238.s18|68-71|will|O
DDI-DrugBank.d238.s18|73-78|depend|O
DDI-DrugBank.d238.s18|80-81|on|O
DDI-DrugBank.d238.s18|83-85|the|O
DDI-DrugBank.d238.s18|87-92|degree|O
DDI-DrugBank.d238.s18|94-95|of|O
DDI-DrugBank.d238.s18|97-106|inhibition|O
DDI-DrugBank.d238.s18|108-110|and|O
DDI-DrugBank.d238.s18|112-114|the|O
DDI-DrugBank.d238.s18|116-131|pharmacokinetics|O
DDI-DrugBank.d238.s18|133-134|of|O
DDI-DrugBank.d238.s18|136-138|the|O
DDI-DrugBank.d238.s18|140-143|SSRI|group
DDI-DrugBank.d238.s18|145-152|involved|O
DDI-DrugBank.d238.s18|153-153|.|O
DDI-DrugBank.d238.s19|0-11|Nevertheless|O
DDI-DrugBank.d238.s19|12-12|,|O
DDI-DrugBank.d238.s19|14-20|caution|O
DDI-DrugBank.d238.s19|22-23|is|O
DDI-DrugBank.d238.s19|25-33|indicated|O
DDI-DrugBank.d238.s19|35-36|in|O
DDI-DrugBank.d238.s19|38-40|the|O
DDI-DrugBank.d238.s19|42-58|co-administration|O
DDI-DrugBank.d238.s19|60-61|of|O
DDI-DrugBank.d238.s19|63-66|TCAs|group
DDI-DrugBank.d238.s19|68-71|with|O
DDI-DrugBank.d238.s19|73-75|any|O
DDI-DrugBank.d238.s19|77-78|of|O
DDI-DrugBank.d238.s19|80-82|the|O
DDI-DrugBank.d238.s19|84-88|SSRIs|group
DDI-DrugBank.d238.s19|90-92|and|O
DDI-DrugBank.d238.s19|94-97|also|O
DDI-DrugBank.d238.s19|99-100|in|O
DDI-DrugBank.d238.s19|102-110|switching|O
DDI-DrugBank.d238.s19|112-115|from|O
DDI-DrugBank.d238.s19|117-119|one|O
DDI-DrugBank.d238.s19|121-125|class|O
DDI-DrugBank.d238.s19|127-128|to|O
DDI-DrugBank.d238.s19|130-132|the|O
DDI-DrugBank.d238.s19|134-138|other|O
DDI-DrugBank.d238.s19|139-139|.|O
DDI-DrugBank.d238.s20|0-1|Of|O
DDI-DrugBank.d238.s20|3-12|particular|O
DDI-DrugBank.d238.s20|14-23|importance|O
DDI-DrugBank.d238.s20|24-24|,|O
DDI-DrugBank.d238.s20|26-35|sufficient|O
DDI-DrugBank.d238.s20|37-40|time|O
DDI-DrugBank.d238.s20|42-45|must|O
DDI-DrugBank.d238.s20|47-52|elapse|O
DDI-DrugBank.d238.s20|54-59|before|O
DDI-DrugBank.d238.s20|61-70|initiating|O
DDI-DrugBank.d238.s20|72-83|TCAtreatment|group
DDI-DrugBank.d238.s20|85-86|in|O
DDI-DrugBank.d238.s20|88-88|a|O
DDI-DrugBank.d238.s20|90-96|patient|O
DDI-DrugBank.d238.s20|98-102|being|O
DDI-DrugBank.d238.s20|104-112|withdrawn|O
DDI-DrugBank.d238.s20|114-117|from|O
DDI-DrugBank.d238.s20|119-128|fluoxetine|drug
DDI-DrugBank.d238.s20|129-129|,|O
DDI-DrugBank.d238.s20|131-135|given|O
DDI-DrugBank.d238.s20|137-139|the|O
DDI-DrugBank.d238.s20|141-144|long|O
DDI-DrugBank.d238.s20|146-154|half-life|O
DDI-DrugBank.d238.s20|156-157|of|O
DDI-DrugBank.d238.s20|159-161|the|O
DDI-DrugBank.d238.s20|163-168|parent|O
DDI-DrugBank.d238.s20|170-172|and|O
DDI-DrugBank.d238.s20|174-179|active|O
DDI-DrugBank.d238.s20|181-190|metabolite|O
DDI-DrugBank.d238.s20|192-192|(|O
DDI-DrugBank.d238.s20|193-194|at|O
DDI-DrugBank.d238.s20|196-200|least|O
DDI-DrugBank.d238.s20|202-202|5|O
DDI-DrugBank.d238.s20|204-208|weeks|O
DDI-DrugBank.d238.s20|210-212|may|O
DDI-DrugBank.d238.s20|214-215|be|O
DDI-DrugBank.d238.s20|217-225|necessary|O
DDI-DrugBank.d238.s20|226-226|)|O
DDI-DrugBank.d238.s20|227-227|.|O
DDI-DrugBank.d238.s21|0-10|Concomitant|O
DDI-DrugBank.d238.s21|12-14|use|O
DDI-DrugBank.d238.s21|16-17|of|O
DDI-DrugBank.d238.s21|19-24|agents|O
DDI-DrugBank.d238.s21|26-27|in|O
DDI-DrugBank.d238.s21|29-31|the|O
DDI-DrugBank.d238.s21|33-62|tricyclic antidepressant class|group
DDI-DrugBank.d238.s21|64-64|(|O
DDI-DrugBank.d238.s21|65-69|which|O
DDI-DrugBank.d238.s21|71-78|includes|O
DDI-DrugBank.d238.s21|80-88|Anafranil|brand
DDI-DrugBank.d238.s21|89-89|)|O
DDI-DrugBank.d238.s21|91-94|with|O
DDI-DrugBank.d238.s21|96-100|drugs|O
DDI-DrugBank.d238.s21|102-105|that|O
DDI-DrugBank.d238.s21|107-109|can|O
DDI-DrugBank.d238.s21|111-117|inhibit|O
DDI-DrugBank.d238.s21|119-128|cytochrome|O
DDI-DrugBank.d238.s21|130-133|P450|O
DDI-DrugBank.d238.s21|135-137|2D6|O
DDI-DrugBank.d238.s21|139-141|may|O
DDI-DrugBank.d238.s21|143-149|require|O
DDI-DrugBank.d238.s21|151-155|lower|O
DDI-DrugBank.d238.s21|157-161|doses|O
DDI-DrugBank.d238.s21|163-166|than|O
DDI-DrugBank.d238.s21|168-174|usually|O
DDI-DrugBank.d238.s21|176-185|prescribed|O
DDI-DrugBank.d238.s21|187-189|for|O
DDI-DrugBank.d238.s21|191-196|either|O
DDI-DrugBank.d238.s21|198-200|the|O
DDI-DrugBank.d238.s21|202-231|tricyclic antidepressant agent|group
DDI-DrugBank.d238.s21|233-234|or|O
DDI-DrugBank.d238.s21|236-238|the|O
DDI-DrugBank.d238.s21|240-244|other|O
DDI-DrugBank.d238.s21|246-249|drug|O
DDI-DrugBank.d238.s21|250-250|.|O
DDI-DrugBank.d238.s22|0-10|Furthermore|O
DDI-DrugBank.d238.s22|11-11|,|O
DDI-DrugBank.d238.s22|13-20|whenever|O
DDI-DrugBank.d238.s22|22-24|one|O
DDI-DrugBank.d238.s22|26-27|of|O
DDI-DrugBank.d238.s22|29-33|these|O
DDI-DrugBank.d238.s22|35-39|drugs|O
DDI-DrugBank.d238.s22|41-42|is|O
DDI-DrugBank.d238.s22|44-52|withdrawn|O
DDI-DrugBank.d238.s22|54-57|from|O
DDI-DrugBank.d238.s22|59-68|co-therapy|O
DDI-DrugBank.d238.s22|69-69|,|O
DDI-DrugBank.d238.s22|71-72|an|O
DDI-DrugBank.d238.s22|74-82|increased|O
DDI-DrugBank.d238.s22|84-87|dose|O
DDI-DrugBank.d238.s22|89-90|of|O
DDI-DrugBank.d238.s22|92-121|tricyclic antidepressant agent|group
DDI-DrugBank.d238.s22|123-125|may|O
DDI-DrugBank.d238.s22|127-128|be|O
DDI-DrugBank.d238.s22|130-137|required|O
DDI-DrugBank.d238.s22|138-138|.|O
DDI-DrugBank.d238.s23|0-1|It|O
DDI-DrugBank.d238.s23|3-4|is|O
DDI-DrugBank.d238.s23|6-14|desirable|O
DDI-DrugBank.d238.s23|16-17|to|O
DDI-DrugBank.d238.s23|19-25|monitor|O
DDI-DrugBank.d238.s23|27-35|TCAplasma|group
DDI-DrugBank.d238.s23|37-42|levels|O
DDI-DrugBank.d238.s23|44-51|whenever|O
DDI-DrugBank.d238.s23|53-54|an|O
DDI-DrugBank.d238.s23|56-60|agent|O
DDI-DrugBank.d238.s23|62-63|of|O
DDI-DrugBank.d238.s23|65-67|the|O
DDI-DrugBank.d238.s23|69-98|tricyclic antidepressant class|group
DDI-DrugBank.d238.s23|100-108|including|O
DDI-DrugBank.d238.s23|110-118|Anafranil|brand
DDI-DrugBank.d238.s23|120-121|is|O
DDI-DrugBank.d238.s23|123-127|going|O
DDI-DrugBank.d238.s23|129-130|to|O
DDI-DrugBank.d238.s23|132-133|be|O
DDI-DrugBank.d238.s23|135-149|co-administered|O
DDI-DrugBank.d238.s23|151-154|with|O
DDI-DrugBank.d238.s23|156-162|another|O
DDI-DrugBank.d238.s23|164-167|drug|O
DDI-DrugBank.d238.s23|169-173|known|O
DDI-DrugBank.d238.s23|175-176|to|O
DDI-DrugBank.d238.s23|178-179|be|O
DDI-DrugBank.d238.s23|181-182|an|O
DDI-DrugBank.d238.s23|184-192|inhibitor|O
DDI-DrugBank.d238.s23|194-195|of|O
DDI-DrugBank.d238.s23|197-200|P450|O
DDI-DrugBank.d238.s23|202-204|2D6|O
DDI-DrugBank.d238.s23|206-206|(|O
DDI-DrugBank.d238.s23|207-212|and/or|O
DDI-DrugBank.d238.s23|214-217|P450|O
DDI-DrugBank.d238.s23|219-221|1A2|O
DDI-DrugBank.d238.s23|222-222|)|O
DDI-DrugBank.d238.s23|223-223|.|O
DDI-DrugBank.d238.s24|0-6|Because|O
DDI-DrugBank.d238.s24|8-16|Anafranil|brand
DDI-DrugBank.d238.s24|18-19|is|O
DDI-DrugBank.d238.s24|21-26|highly|O
DDI-DrugBank.d238.s24|28-32|bound|O
DDI-DrugBank.d238.s24|34-35|to|O
DDI-DrugBank.d238.s24|37-41|serum|O
DDI-DrugBank.d238.s24|43-49|protein|O
DDI-DrugBank.d238.s24|50-50|,|O
DDI-DrugBank.d238.s24|52-54|the|O
DDI-DrugBank.d238.s24|56-69|administration|O
DDI-DrugBank.d238.s24|71-72|of|O
DDI-DrugBank.d238.s24|74-82|Anafranil|brand
DDI-DrugBank.d238.s24|84-85|to|O
DDI-DrugBank.d238.s24|87-94|patients|O
DDI-DrugBank.d238.s24|96-101|taking|O
DDI-DrugBank.d238.s24|103-107|other|O
DDI-DrugBank.d238.s24|109-113|drugs|O
DDI-DrugBank.d238.s24|115-118|that|O
DDI-DrugBank.d238.s24|120-122|are|O
DDI-DrugBank.d238.s24|124-129|highly|O
DDI-DrugBank.d238.s24|131-135|bound|O
DDI-DrugBank.d238.s24|137-138|to|O
DDI-DrugBank.d238.s24|140-146|protein|O
DDI-DrugBank.d238.s24|148-148|(|O
DDI-DrugBank.d238.s24|149-152|e.g.|O
DDI-DrugBank.d238.s24|153-153|,|O
DDI-DrugBank.d238.s24|155-162|warfarin|drug
DDI-DrugBank.d238.s24|163-163|,|O
DDI-DrugBank.d238.s24|165-171|digoxin|drug
DDI-DrugBank.d238.s24|172-172|)|O
DDI-DrugBank.d238.s24|174-176|may|O
DDI-DrugBank.d238.s24|178-182|cause|O
DDI-DrugBank.d238.s24|184-185|an|O
DDI-DrugBank.d238.s24|187-194|increase|O
DDI-DrugBank.d238.s24|196-197|in|O
DDI-DrugBank.d238.s24|199-204|plasma|O
DDI-DrugBank.d238.s24|206-219|concentrations|O
DDI-DrugBank.d238.s24|221-222|of|O
DDI-DrugBank.d238.s24|224-228|these|O
DDI-DrugBank.d238.s24|230-234|drugs|O
DDI-DrugBank.d238.s24|235-235|,|O
DDI-DrugBank.d238.s24|237-247|potentially|O
DDI-DrugBank.d238.s24|249-257|resulting|O
DDI-DrugBank.d238.s24|259-260|in|O
DDI-DrugBank.d238.s24|262-268|adverse|O
DDI-DrugBank.d238.s24|270-276|effects|O
DDI-DrugBank.d238.s24|277-277|.|O
DDI-DrugBank.d238.s25|0-9|Conversely|O
DDI-DrugBank.d238.s25|10-10|,|O
DDI-DrugBank.d238.s25|12-18|adverse|O
DDI-DrugBank.d238.s25|20-26|effects|O
DDI-DrugBank.d238.s25|28-30|may|O
DDI-DrugBank.d238.s25|32-37|result|O
DDI-DrugBank.d238.s25|39-42|from|O
DDI-DrugBank.d238.s25|44-55|displacement|O
DDI-DrugBank.d238.s25|57-58|of|O
DDI-DrugBank.d238.s25|60-72|protein-bound|O
DDI-DrugBank.d238.s25|74-82|Anafranil|brand
DDI-DrugBank.d238.s25|84-85|by|O
DDI-DrugBank.d238.s25|87-91|other|O
DDI-DrugBank.d238.s25|93-98|highly|O
DDI-DrugBank.d238.s25|100-104|bound|O
DDI-DrugBank.d238.s25|106-110|drugs|O
DDI-DrugBank.d238.s25|111-111|.|O
DDI-DrugBank.d548.s0|0-8|Potential|O
DDI-DrugBank.d548.s0|10-12|for|O
DDI-DrugBank.d548.s0|14-18|Other|O
DDI-DrugBank.d548.s0|20-24|Drugs|O
DDI-DrugBank.d548.s0|26-27|to|O
DDI-DrugBank.d548.s0|29-34|Affect|O
DDI-DrugBank.d548.s0|36-45|Duloxetine|drug
DDI-DrugBank.d548.s0|46-46|:|O
DDI-DrugBank.d548.s0|48-51|Both|O
DDI-DrugBank.d548.s0|53-58|CYP1A2|O
DDI-DrugBank.d548.s0|60-62|and|O
DDI-DrugBank.d548.s0|64-69|CYP2D6|O
DDI-DrugBank.d548.s0|71-73|are|O
DDI-DrugBank.d548.s0|75-85|responsible|O
DDI-DrugBank.d548.s0|87-89|for|O
DDI-DrugBank.d548.s0|91-100|duloxetine|drug
DDI-DrugBank.d548.s0|102-111|metabolism|O
DDI-DrugBank.d548.s0|112-112|.|O
DDI-DrugBank.d548.s1|0-9|Inhibitors|O
DDI-DrugBank.d548.s1|11-12|of|O
DDI-DrugBank.d548.s1|14-19|CYP1A2|O
DDI-DrugBank.d548.s1|20-20|:|O
DDI-DrugBank.d548.s1|22-32|Concomitant|O
DDI-DrugBank.d548.s1|34-36|use|O
DDI-DrugBank.d548.s1|38-39|of|O
DDI-DrugBank.d548.s1|41-50|duloxetine|drug
DDI-DrugBank.d548.s1|52-55|with|O
DDI-DrugBank.d548.s1|57-67|fluvoxamine|drug
DDI-DrugBank.d548.s1|68-68|,|O
DDI-DrugBank.d548.s1|70-71|an|O
DDI-DrugBank.d548.s1|73-81|inhibitor|O
DDI-DrugBank.d548.s1|83-84|of|O
DDI-DrugBank.d548.s1|86-91|CYP1A2|O
DDI-DrugBank.d548.s1|92-92|,|O
DDI-DrugBank.d548.s1|94-100|results|O
DDI-DrugBank.d548.s1|102-103|in|O
DDI-DrugBank.d548.s1|105-117|approximately|O
DDI-DrugBank.d548.s1|119-119|a|O
DDI-DrugBank.d548.s1|121-126|6-fold|O
DDI-DrugBank.d548.s1|128-135|increase|O
DDI-DrugBank.d548.s1|137-138|in|O
DDI-DrugBank.d548.s1|140-142|AUC|O
DDI-DrugBank.d548.s1|144-146|and|O
DDI-DrugBank.d548.s1|148-152|about|O
DDI-DrugBank.d548.s1|154-154|a|O
DDI-DrugBank.d548.s1|156-163|2.5-fold|O
DDI-DrugBank.d548.s1|165-172|increase|O
DDI-DrugBank.d548.s1|174-175|in|O
DDI-DrugBank.d548.s1|177-180|Cmax|O
DDI-DrugBank.d548.s1|182-183|of|O
DDI-DrugBank.d548.s1|185-194|duloxetine|drug
DDI-DrugBank.d548.s1|195-195|.|O
DDI-DrugBank.d548.s2|0-3|Some|O
DDI-DrugBank.d548.s2|5-25|quinolone antibiotics|group
DDI-DrugBank.d548.s2|27-31|would|O
DDI-DrugBank.d548.s2|33-34|be|O
DDI-DrugBank.d548.s2|36-43|expected|O
DDI-DrugBank.d548.s2|45-46|to|O
DDI-DrugBank.d548.s2|48-51|have|O
DDI-DrugBank.d548.s2|53-59|similar|O
DDI-DrugBank.d548.s2|61-67|effects|O
DDI-DrugBank.d548.s2|69-71|and|O
DDI-DrugBank.d548.s2|73-77|these|O
DDI-DrugBank.d548.s2|79-90|combinations|O
DDI-DrugBank.d548.s2|92-97|should|O
DDI-DrugBank.d548.s2|99-100|be|O
DDI-DrugBank.d548.s2|102-108|avoided|O
DDI-DrugBank.d548.s2|109-109|.|O
DDI-DrugBank.d548.s3|0-9|Inhibitors|O
DDI-DrugBank.d548.s3|11-12|of|O
DDI-DrugBank.d548.s3|14-19|CYP2D6|O
DDI-DrugBank.d548.s3|20-20|:|O
DDI-DrugBank.d548.s3|22-28|Because|O
DDI-DrugBank.d548.s3|30-35|CYP2D6|O
DDI-DrugBank.d548.s3|37-38|is|O
DDI-DrugBank.d548.s3|40-47|involved|O
DDI-DrugBank.d548.s3|49-50|in|O
DDI-DrugBank.d548.s3|52-61|duloxetine|drug
DDI-DrugBank.d548.s3|63-72|metabolism|O
DDI-DrugBank.d548.s3|73-73|,|O
DDI-DrugBank.d548.s3|75-85|concomitant|O
DDI-DrugBank.d548.s3|87-89|use|O
DDI-DrugBank.d548.s3|91-92|of|O
DDI-DrugBank.d548.s3|94-103|duloxetine|drug
DDI-DrugBank.d548.s3|105-108|with|O
DDI-DrugBank.d548.s3|110-115|potent|O
DDI-DrugBank.d548.s3|117-126|inhibitors|O
DDI-DrugBank.d548.s3|128-129|of|O
DDI-DrugBank.d548.s3|131-136|CYP2D6|O
DDI-DrugBank.d548.s3|138-140|may|O
DDI-DrugBank.d548.s3|142-147|result|O
DDI-DrugBank.d548.s3|149-150|in|O
DDI-DrugBank.d548.s3|152-157|higher|O
DDI-DrugBank.d548.s3|159-172|concentrations|O
DDI-DrugBank.d548.s3|174-175|of|O
DDI-DrugBank.d548.s3|177-186|duloxetine|drug
DDI-DrugBank.d548.s3|187-187|.|O
DDI-DrugBank.d548.s4|0-9|Paroxetine|drug
DDI-DrugBank.d548.s4|11-11|(|O
DDI-DrugBank.d548.s4|12-13|20|O
DDI-DrugBank.d548.s4|15-16|mg|O
DDI-DrugBank.d548.s4|18-19|QD|O
DDI-DrugBank.d548.s4|20-20|)|O
DDI-DrugBank.d548.s4|22-30|increased|O
DDI-DrugBank.d548.s4|32-34|the|O
DDI-DrugBank.d548.s4|36-48|concentration|O
DDI-DrugBank.d548.s4|50-51|of|O
DDI-DrugBank.d548.s4|53-62|duloxetine|drug
DDI-DrugBank.d548.s4|64-64|(|O
DDI-DrugBank.d548.s4|65-66|40|O
DDI-DrugBank.d548.s4|68-69|mg|O
DDI-DrugBank.d548.s4|71-72|QD|O
DDI-DrugBank.d548.s4|73-73|)|O
DDI-DrugBank.d548.s4|75-76|by|O
DDI-DrugBank.d548.s4|78-82|about|O
DDI-DrugBank.d548.s4|84-85|60|O
DDI-DrugBank.d548.s4|86-86|%|O
DDI-DrugBank.d548.s4|87-87|,|O
DDI-DrugBank.d548.s4|89-91|and|O
DDI-DrugBank.d548.s4|93-99|greater|O
DDI-DrugBank.d548.s4|101-107|degrees|O
DDI-DrugBank.d548.s4|109-110|of|O
DDI-DrugBank.d548.s4|112-121|inhibition|O
DDI-DrugBank.d548.s4|123-125|are|O
DDI-DrugBank.d548.s4|127-134|expected|O
DDI-DrugBank.d548.s4|136-139|with|O
DDI-DrugBank.d548.s4|141-146|higher|O
DDI-DrugBank.d548.s4|148-152|doses|O
DDI-DrugBank.d548.s4|154-155|of|O
DDI-DrugBank.d548.s4|157-166|paroxetine|drug
DDI-DrugBank.d548.s4|167-167|.|O
DDI-DrugBank.d548.s5|0-6|Similar|O
DDI-DrugBank.d548.s5|8-14|effects|O
DDI-DrugBank.d548.s5|16-20|would|O
DDI-DrugBank.d548.s5|22-23|be|O
DDI-DrugBank.d548.s5|25-32|expected|O
DDI-DrugBank.d548.s5|34-37|with|O
DDI-DrugBank.d548.s5|39-43|other|O
DDI-DrugBank.d548.s5|45-50|potent|O
DDI-DrugBank.d548.s5|52-57|CYP2D6|O
DDI-DrugBank.d548.s5|59-68|inhibitors|O
DDI-DrugBank.d548.s5|70-70|(|O
DDI-DrugBank.d548.s5|71-74|e.g.|O
DDI-DrugBank.d548.s5|75-75|,|O
DDI-DrugBank.d548.s5|77-86|fluoxetine|drug
DDI-DrugBank.d548.s5|87-87|,|O
DDI-DrugBank.d548.s5|89-97|quinidine|drug
DDI-DrugBank.d548.s5|98-98|)|O
DDI-DrugBank.d548.s5|99-99|.|O
DDI-DrugBank.d548.s6|0-8|Potential|O
DDI-DrugBank.d548.s6|10-12|for|O
DDI-DrugBank.d548.s6|14-23|Duloxetine|drug
DDI-DrugBank.d548.s6|25-26|to|O
DDI-DrugBank.d548.s6|28-33|Affect|O
DDI-DrugBank.d548.s6|35-39|Other|O
DDI-DrugBank.d548.s6|41-45|Drugs|O
DDI-DrugBank.d548.s6|46-46|:|O
DDI-DrugBank.d548.s6|48-52|Drugs|O
DDI-DrugBank.d548.s6|54-64|Metabolized|O
DDI-DrugBank.d548.s6|66-67|by|O
DDI-DrugBank.d548.s6|69-74|CYP1A2|O
DDI-DrugBank.d548.s6|75-75|:|O
DDI-DrugBank.d548.s6|77-78|In|O
DDI-DrugBank.d548.s6|80-84|vitro|O
DDI-DrugBank.d548.s6|86-89|drug|O
DDI-DrugBank.d548.s6|91-101|interaction|O
DDI-DrugBank.d548.s6|103-109|studies|O
DDI-DrugBank.d548.s6|111-121|demonstrate|O
DDI-DrugBank.d548.s6|123-126|that|O
DDI-DrugBank.d548.s6|128-137|duloxetine|drug
DDI-DrugBank.d548.s6|139-142|does|O
DDI-DrugBank.d548.s6|144-146|not|O
DDI-DrugBank.d548.s6|148-153|induce|O
DDI-DrugBank.d548.s6|155-160|CYP1A2|O
DDI-DrugBank.d548.s6|162-169|activity|O
DDI-DrugBank.d548.s6|170-170|,|O
DDI-DrugBank.d548.s6|172-174|and|O
DDI-DrugBank.d548.s6|176-177|it|O
DDI-DrugBank.d548.s6|179-180|is|O
DDI-DrugBank.d548.s6|182-189|unlikely|O
DDI-DrugBank.d548.s6|191-192|to|O
DDI-DrugBank.d548.s6|194-197|have|O
DDI-DrugBank.d548.s6|199-199|a|O
DDI-DrugBank.d548.s6|201-210|clinically|O
DDI-DrugBank.d548.s6|212-222|significant|O
DDI-DrugBank.d548.s6|224-229|effect|O
DDI-DrugBank.d548.s6|231-232|on|O
DDI-DrugBank.d548.s6|234-236|the|O
DDI-DrugBank.d548.s6|238-247|metabolism|O
DDI-DrugBank.d548.s6|249-250|of|O
DDI-DrugBank.d548.s6|252-257|CYP1A2|O
DDI-DrugBank.d548.s6|259-268|substrates|O
DDI-DrugBank.d548.s6|269-269|.|O
DDI-DrugBank.d548.s7|0-4|Drugs|O
DDI-DrugBank.d548.s7|6-16|Metabolized|O
DDI-DrugBank.d548.s7|18-19|by|O
DDI-DrugBank.d548.s7|21-26|CYP2D6|O
DDI-DrugBank.d548.s7|27-27|:|O
DDI-DrugBank.d548.s7|29-38|Duloxetine|drug
DDI-DrugBank.d548.s7|40-41|is|O
DDI-DrugBank.d548.s7|43-43|a|O
DDI-DrugBank.d548.s7|45-52|moderate|O
DDI-DrugBank.d548.s7|54-62|inhibitor|O
DDI-DrugBank.d548.s7|64-65|of|O
DDI-DrugBank.d548.s7|67-72|CYP2D6|O
DDI-DrugBank.d548.s7|73-73|.|O
DDI-DrugBank.d548.s8|0-3|When|O
DDI-DrugBank.d548.s8|5-14|duloxetine|drug
DDI-DrugBank.d548.s8|16-18|was|O
DDI-DrugBank.d548.s8|20-31|administered|O
DDI-DrugBank.d548.s8|33-33|(|O
DDI-DrugBank.d548.s8|34-35|at|O
DDI-DrugBank.d548.s8|37-37|a|O
DDI-DrugBank.d548.s8|39-42|dose|O
DDI-DrugBank.d548.s8|44-45|of|O
DDI-DrugBank.d548.s8|47-48|60|O
DDI-DrugBank.d548.s8|50-51|mg|O
DDI-DrugBank.d548.s8|53-55|BID|O
DDI-DrugBank.d548.s8|56-56|)|O
DDI-DrugBank.d548.s8|58-59|in|O
DDI-DrugBank.d548.s8|61-71|conjunction|O
DDI-DrugBank.d548.s8|73-76|with|O
DDI-DrugBank.d548.s8|78-78|a|O
DDI-DrugBank.d548.s8|80-85|single|O
DDI-DrugBank.d548.s8|87-91|50-mg|O
DDI-DrugBank.d548.s8|93-96|dose|O
DDI-DrugBank.d548.s8|98-99|of|O
DDI-DrugBank.d548.s8|101-111|desipramine|drug
DDI-DrugBank.d548.s8|112-112|,|O
DDI-DrugBank.d548.s8|114-114|a|O
DDI-DrugBank.d548.s8|116-121|CYP2D6|O
DDI-DrugBank.d548.s8|123-131|substrate|O
DDI-DrugBank.d548.s8|132-132|,|O
DDI-DrugBank.d548.s8|134-136|the|O
DDI-DrugBank.d548.s8|138-140|AUC|O
DDI-DrugBank.d548.s8|142-143|of|O
DDI-DrugBank.d548.s8|145-155|desipramine|drug
DDI-DrugBank.d548.s8|157-165|increased|O
DDI-DrugBank.d548.s8|167-172|3-fold|O
DDI-DrugBank.d548.s8|173-173|.|O
DDI-DrugBank.d548.s9|0-8|Therefore|O
DDI-DrugBank.d548.s9|9-9|,|O
DDI-DrugBank.d548.s9|11-27|co-administration|O
DDI-DrugBank.d548.s9|29-30|of|O
DDI-DrugBank.d548.s9|32-41|Duloxetine|drug
DDI-DrugBank.d548.s9|43-46|with|O
DDI-DrugBank.d548.s9|48-52|other|O
DDI-DrugBank.d548.s9|54-58|drugs|O
DDI-DrugBank.d548.s9|60-63|that|O
DDI-DrugBank.d548.s9|65-67|are|O
DDI-DrugBank.d548.s9|69-79|extensively|O
DDI-DrugBank.d548.s9|81-91|metabolized|O
DDI-DrugBank.d548.s9|93-94|by|O
DDI-DrugBank.d548.s9|96-99|this|O
DDI-DrugBank.d548.s9|101-107|isozyme|O
DDI-DrugBank.d548.s9|109-111|and|O
DDI-DrugBank.d548.s9|113-117|which|O
DDI-DrugBank.d548.s9|119-122|have|O
DDI-DrugBank.d548.s9|124-124|a|O
DDI-DrugBank.d548.s9|126-131|narrow|O
DDI-DrugBank.d548.s9|133-143|therapeutic|O
DDI-DrugBank.d548.s9|145-149|index|O
DDI-DrugBank.d548.s9|150-150|,|O
DDI-DrugBank.d548.s9|152-160|including|O
DDI-DrugBank.d548.s9|162-168|certain|O
DDI-DrugBank.d548.s9|170-184|antidepressants|group
DDI-DrugBank.d548.s9|186-186|(|O
DDI-DrugBank.d548.s9|187-211|tricyclic antidepressants|group
DDI-DrugBank.d548.s9|213-213|[|O
DDI-DrugBank.d548.s9|214-217|TCAs|group
DDI-DrugBank.d548.s9|218-218|]|O
DDI-DrugBank.d548.s9|219-219|,|O
DDI-DrugBank.d548.s9|221-224|such|O
DDI-DrugBank.d548.s9|226-227|as|O
DDI-DrugBank.d548.s9|229-241|nortriptyline|drug
DDI-DrugBank.d548.s9|242-242|,|O
DDI-DrugBank.d548.s9|244-256|amitriptyline|drug
DDI-DrugBank.d548.s9|257-257|,|O
DDI-DrugBank.d548.s9|259-261|and|O
DDI-DrugBank.d548.s9|263-272|imipramine|drug
DDI-DrugBank.d548.s9|273-273|)|O
DDI-DrugBank.d548.s9|274-274|,|O
DDI-DrugBank.d548.s9|276-289|phenothiazines|group
DDI-DrugBank.d548.s9|291-293|and|O
DDI-DrugBank.d548.s9|295-317|Type 1C antiarrhythmics|group
DDI-DrugBank.d548.s9|319-319|(|O
DDI-DrugBank.d548.s9|320-323|e.g.|O
DDI-DrugBank.d548.s9|324-324|,|O
DDI-DrugBank.d548.s9|326-336|propafenone|drug
DDI-DrugBank.d548.s9|337-337|,|O
DDI-DrugBank.d548.s9|339-348|flecainide|drug
DDI-DrugBank.d548.s9|349-349|)|O
DDI-DrugBank.d548.s9|350-350|,|O
DDI-DrugBank.d548.s9|352-357|should|O
DDI-DrugBank.d548.s9|359-360|be|O
DDI-DrugBank.d548.s9|362-371|approached|O
DDI-DrugBank.d548.s9|373-376|with|O
DDI-DrugBank.d548.s9|378-384|caution|O
DDI-DrugBank.d548.s9|385-385|.|O
DDI-DrugBank.d548.s10|0-5|Plasma|O
DDI-DrugBank.d548.s10|7-9|TCA|group
DDI-DrugBank.d548.s10|11-24|concentrations|O
DDI-DrugBank.d548.s10|26-28|may|O
DDI-DrugBank.d548.s10|30-33|need|O
DDI-DrugBank.d548.s10|35-36|to|O
DDI-DrugBank.d548.s10|38-39|be|O
DDI-DrugBank.d548.s10|41-49|monitored|O
DDI-DrugBank.d548.s10|51-53|and|O
DDI-DrugBank.d548.s10|55-57|the|O
DDI-DrugBank.d548.s10|59-62|dose|O
DDI-DrugBank.d548.s10|64-65|of|O
DDI-DrugBank.d548.s10|67-69|the|O
DDI-DrugBank.d548.s10|71-73|TCA|group
DDI-DrugBank.d548.s10|75-77|may|O
DDI-DrugBank.d548.s10|79-82|need|O
DDI-DrugBank.d548.s10|84-85|to|O
DDI-DrugBank.d548.s10|87-88|be|O
DDI-DrugBank.d548.s10|90-96|reduced|O
DDI-DrugBank.d548.s10|98-99|if|O
DDI-DrugBank.d548.s10|101-101|a|O
DDI-DrugBank.d548.s10|103-105|TCA|group
DDI-DrugBank.d548.s10|107-108|is|O
DDI-DrugBank.d548.s10|110-124|co-administered|O
DDI-DrugBank.d548.s10|126-129|with|O
DDI-DrugBank.d548.s10|131-140|Duloxetine|drug
DDI-DrugBank.d548.s10|141-141|.|O
DDI-DrugBank.d548.s11|0-6|Because|O
DDI-DrugBank.d548.s11|8-9|of|O
DDI-DrugBank.d548.s11|11-13|the|O
DDI-DrugBank.d548.s11|15-18|risk|O
DDI-DrugBank.d548.s11|20-21|of|O
DDI-DrugBank.d548.s11|23-29|serious|O
DDI-DrugBank.d548.s11|31-41|ventricular|O
DDI-DrugBank.d548.s11|43-53|arrhythmias|O
DDI-DrugBank.d548.s11|55-57|and|O
DDI-DrugBank.d548.s11|59-64|sudden|O
DDI-DrugBank.d548.s11|66-70|death|O
DDI-DrugBank.d548.s11|72-82|potentially|O
DDI-DrugBank.d548.s11|84-93|associated|O
DDI-DrugBank.d548.s11|95-98|with|O
DDI-DrugBank.d548.s11|100-107|elevated|O
DDI-DrugBank.d548.s11|109-114|plasma|O
DDI-DrugBank.d548.s11|116-121|levels|O
DDI-DrugBank.d548.s11|123-124|of|O
DDI-DrugBank.d548.s11|126-137|thioridazine|drug
DDI-DrugBank.d548.s11|138-138|,|O
DDI-DrugBank.d548.s11|140-149|Duloxetine|drug
DDI-DrugBank.d548.s11|151-153|and|O
DDI-DrugBank.d548.s11|155-166|thioridazine|drug
DDI-DrugBank.d548.s11|168-173|should|O
DDI-DrugBank.d548.s11|175-177|not|O
DDI-DrugBank.d548.s11|179-180|be|O
DDI-DrugBank.d548.s11|182-196|co-administered|O
DDI-DrugBank.d548.s11|197-197|.|O
DDI-DrugBank.d548.s12|0-4|Drugs|O
DDI-DrugBank.d548.s12|6-16|Metabolized|O
DDI-DrugBank.d548.s12|18-19|by|O
DDI-DrugBank.d548.s12|21-25|CYP3A|O
DDI-DrugBank.d548.s12|26-26|:|O
DDI-DrugBank.d548.s12|28-34|Results|O
DDI-DrugBank.d548.s12|36-37|of|O
DDI-DrugBank.d548.s12|39-40|in|O
DDI-DrugBank.d548.s12|42-46|vitro|O
DDI-DrugBank.d548.s12|48-54|studies|O
DDI-DrugBank.d548.s12|56-66|demonstrate|O
DDI-DrugBank.d548.s12|68-71|that|O
DDI-DrugBank.d548.s12|73-82|duloxetine|drug
DDI-DrugBank.d548.s12|84-87|does|O
DDI-DrugBank.d548.s12|89-91|not|O
DDI-DrugBank.d548.s12|93-99|inhibit|O
DDI-DrugBank.d548.s12|101-102|or|O
DDI-DrugBank.d548.s12|104-109|induce|O
DDI-DrugBank.d548.s12|111-115|CYP3A|O
DDI-DrugBank.d548.s12|117-124|activity|O
DDI-DrugBank.d548.s12|125-125|.|O
DDI-DrugBank.d548.s13|0-9|Duloxetine|drug
DDI-DrugBank.d548.s13|11-13|May|O
DDI-DrugBank.d548.s13|15-18|Have|O
DDI-DrugBank.d548.s13|20-20|a|O
DDI-DrugBank.d548.s13|22-31|Clinically|O
DDI-DrugBank.d548.s13|33-41|Important|O
DDI-DrugBank.d548.s13|43-53|Interaction|O
DDI-DrugBank.d548.s13|55-58|with|O
DDI-DrugBank.d548.s13|60-62|the|O
DDI-DrugBank.d548.s13|64-72|Following|O
DDI-DrugBank.d548.s13|74-78|Other|O
DDI-DrugBank.d548.s13|80-84|Drugs|O
DDI-DrugBank.d548.s13|85-85|:|O
DDI-DrugBank.d548.s13|87-93|Alcohol|drug
DDI-DrugBank.d548.s13|94-94|:|O
DDI-DrugBank.d548.s13|96-99|When|O
DDI-DrugBank.d548.s13|101-110|Duloxetine|drug
DDI-DrugBank.d548.s13|112-114|and|O
DDI-DrugBank.d548.s13|116-122|ethanol|drug
DDI-DrugBank.d548.s13|124-127|were|O
DDI-DrugBank.d548.s13|129-140|administered|O
DDI-DrugBank.d548.s13|142-148|several|O
DDI-DrugBank.d548.s13|150-154|hours|O
DDI-DrugBank.d548.s13|156-160|apart|O
DDI-DrugBank.d548.s13|162-163|so|O
DDI-DrugBank.d548.s13|165-168|that|O
DDI-DrugBank.d548.s13|170-173|peak|O
DDI-DrugBank.d548.s13|175-188|concentrations|O
DDI-DrugBank.d548.s13|190-191|of|O
DDI-DrugBank.d548.s13|193-196|each|O
DDI-DrugBank.d548.s13|198-202|would|O
DDI-DrugBank.d548.s13|204-211|coincide|O
DDI-DrugBank.d548.s13|212-212|,|O
DDI-DrugBank.d548.s13|214-223|Duloxetine|drug
DDI-DrugBank.d548.s13|225-227|did|O
DDI-DrugBank.d548.s13|229-231|not|O
DDI-DrugBank.d548.s13|233-240|increase|O
DDI-DrugBank.d548.s13|242-244|the|O
DDI-DrugBank.d548.s13|246-255|impairment|O
DDI-DrugBank.d548.s13|257-258|of|O
DDI-DrugBank.d548.s13|260-265|mental|O
DDI-DrugBank.d548.s13|267-269|and|O
DDI-DrugBank.d548.s13|271-275|motor|O
DDI-DrugBank.d548.s13|277-282|skills|O
DDI-DrugBank.d548.s13|284-289|caused|O
DDI-DrugBank.d548.s13|291-292|by|O
DDI-DrugBank.d548.s13|294-300|alcohol|drug
DDI-DrugBank.d548.s13|301-301|.|O
DDI-DrugBank.d548.s14|0-1|In|O
DDI-DrugBank.d548.s14|3-5|the|O
DDI-DrugBank.d548.s14|7-16|Duloxetine|drug
DDI-DrugBank.d548.s14|18-25|clinical|O
DDI-DrugBank.d548.s14|27-32|trials|O
DDI-DrugBank.d548.s14|34-41|database|O
DDI-DrugBank.d548.s14|42-42|,|O
DDI-DrugBank.d548.s14|44-48|three|O
DDI-DrugBank.d548.s14|50-67|Duloxetine-treated|drug
DDI-DrugBank.d548.s14|69-76|patients|O
DDI-DrugBank.d548.s14|78-80|had|O
DDI-DrugBank.d548.s14|82-86|liver|O
DDI-DrugBank.d548.s14|88-93|injury|O
DDI-DrugBank.d548.s14|95-96|as|O
DDI-DrugBank.d548.s14|98-107|manifested|O
DDI-DrugBank.d548.s14|109-110|by|O
DDI-DrugBank.d548.s14|112-114|ALT|O
DDI-DrugBank.d548.s14|116-118|and|O
DDI-DrugBank.d548.s14|120-124|total|O
DDI-DrugBank.d548.s14|126-134|bilirubin|O
DDI-DrugBank.d548.s14|136-145|elevations|O
DDI-DrugBank.d548.s14|146-146|,|O
DDI-DrugBank.d548.s14|148-151|with|O
DDI-DrugBank.d548.s14|153-160|evidence|O
DDI-DrugBank.d548.s14|162-163|of|O
DDI-DrugBank.d548.s14|165-175|obstruction|O
DDI-DrugBank.d548.s14|176-176|.|O
DDI-DrugBank.d548.s15|0-10|Substantial|O
DDI-DrugBank.d548.s15|12-23|intercurrent|O
DDI-DrugBank.d548.s15|25-31|ethanol|drug
DDI-DrugBank.d548.s15|33-35|use|O
DDI-DrugBank.d548.s15|37-39|was|O
DDI-DrugBank.d548.s15|41-47|present|O
DDI-DrugBank.d548.s15|49-50|in|O
DDI-DrugBank.d548.s15|52-55|each|O
DDI-DrugBank.d548.s15|57-58|of|O
DDI-DrugBank.d548.s15|60-64|these|O
DDI-DrugBank.d548.s15|66-70|cases|O
DDI-DrugBank.d548.s15|71-71|,|O
DDI-DrugBank.d548.s15|73-75|and|O
DDI-DrugBank.d548.s15|77-80|this|O
DDI-DrugBank.d548.s15|82-84|may|O
DDI-DrugBank.d548.s15|86-89|have|O
DDI-DrugBank.d548.s15|91-101|contributed|O
DDI-DrugBank.d548.s15|103-104|to|O
DDI-DrugBank.d548.s15|106-108|the|O
DDI-DrugBank.d548.s15|110-122|abnormalities|O
DDI-DrugBank.d548.s15|124-127|seen|O
DDI-DrugBank.d548.s15|128-128|.|O
DDI-DrugBank.d548.s16|0-2|CNS|O
DDI-DrugBank.d548.s16|4-9|Acting|O
DDI-DrugBank.d548.s16|11-15|Drugs|O
DDI-DrugBank.d548.s16|16-16|:|O
DDI-DrugBank.d548.s16|18-22|Given|O
DDI-DrugBank.d548.s16|24-26|the|O
DDI-DrugBank.d548.s16|28-34|primary|O
DDI-DrugBank.d548.s16|36-38|CNS|O
DDI-DrugBank.d548.s16|40-46|effects|O
DDI-DrugBank.d548.s16|48-49|of|O
DDI-DrugBank.d548.s16|51-60|Duloxetine|drug
DDI-DrugBank.d548.s16|61-61|,|O
DDI-DrugBank.d548.s16|63-64|it|O
DDI-DrugBank.d548.s16|66-71|should|O
DDI-DrugBank.d548.s16|73-74|be|O
DDI-DrugBank.d548.s16|76-79|used|O
DDI-DrugBank.d548.s16|81-84|with|O
DDI-DrugBank.d548.s16|86-92|caution|O
DDI-DrugBank.d548.s16|94-97|when|O
DDI-DrugBank.d548.s16|99-100|it|O
DDI-DrugBank.d548.s16|102-103|is|O
DDI-DrugBank.d548.s16|105-109|taken|O
DDI-DrugBank.d548.s16|111-112|in|O
DDI-DrugBank.d548.s16|114-124|combination|O
DDI-DrugBank.d548.s16|126-129|with|O
DDI-DrugBank.d548.s16|131-132|or|O
DDI-DrugBank.d548.s16|134-144|substituted|O
DDI-DrugBank.d548.s16|146-148|for|O
DDI-DrugBank.d548.s16|150-154|other|O
DDI-DrugBank.d548.s16|156-164|centrally|O
DDI-DrugBank.d548.s16|166-171|acting|O
DDI-DrugBank.d548.s16|173-177|drugs|O
DDI-DrugBank.d548.s16|178-178|,|O
DDI-DrugBank.d548.s16|180-188|including|O
DDI-DrugBank.d548.s16|190-194|those|O
DDI-DrugBank.d548.s16|196-199|with|O
DDI-DrugBank.d548.s16|201-201|a|O
DDI-DrugBank.d548.s16|203-209|similar|O
DDI-DrugBank.d548.s16|211-219|mechanism|O
DDI-DrugBank.d548.s16|221-222|of|O
DDI-DrugBank.d548.s16|224-229|action|O
DDI-DrugBank.d548.s16|230-230|.|O
DDI-DrugBank.d548.s17|0-8|Potential|O
DDI-DrugBank.d548.s17|10-12|for|O
DDI-DrugBank.d548.s17|14-24|Interaction|O
DDI-DrugBank.d548.s17|26-29|with|O
DDI-DrugBank.d548.s17|31-35|Drugs|O
DDI-DrugBank.d548.s17|37-40|that|O
DDI-DrugBank.d548.s17|42-47|Affect|O
DDI-DrugBank.d548.s17|49-55|Gastric|O
DDI-DrugBank.d548.s17|57-63|Acidity|O
DDI-DrugBank.d548.s17|64-64|:|O
DDI-DrugBank.d548.s17|66-75|Duloxetine|drug
DDI-DrugBank.d548.s17|77-79|has|O
DDI-DrugBank.d548.s17|81-82|an|O
DDI-DrugBank.d548.s17|84-90|enteric|O
DDI-DrugBank.d548.s17|92-98|coating|O
DDI-DrugBank.d548.s17|100-103|that|O
DDI-DrugBank.d548.s17|105-111|resists|O
DDI-DrugBank.d548.s17|113-123|dissolution|O
DDI-DrugBank.d548.s17|125-129|until|O
DDI-DrugBank.d548.s17|131-138|reaching|O
DDI-DrugBank.d548.s17|140-140|a|O
DDI-DrugBank.d548.s17|142-148|segment|O
DDI-DrugBank.d548.s17|150-151|of|O
DDI-DrugBank.d548.s17|153-155|the|O
DDI-DrugBank.d548.s17|157-172|gastrointestinal|O
DDI-DrugBank.d548.s17|174-178|tract|O
DDI-DrugBank.d548.s17|180-184|where|O
DDI-DrugBank.d548.s17|186-188|the|O
DDI-DrugBank.d548.s17|190-191|pH|O
DDI-DrugBank.d548.s17|193-199|exceeds|O
DDI-DrugBank.d548.s17|201-203|5.5|O
DDI-DrugBank.d548.s17|204-204|.|O
DDI-DrugBank.d548.s18|0-1|In|O
DDI-DrugBank.d548.s18|3-11|extremely|O
DDI-DrugBank.d548.s18|13-18|acidic|O
DDI-DrugBank.d548.s18|20-29|conditions|O
DDI-DrugBank.d548.s18|30-30|,|O
DDI-DrugBank.d548.s18|32-41|Duloxetine|drug
DDI-DrugBank.d548.s18|42-42|,|O
DDI-DrugBank.d548.s18|44-54|unprotected|O
DDI-DrugBank.d548.s18|56-57|by|O
DDI-DrugBank.d548.s18|59-61|the|O
DDI-DrugBank.d548.s18|63-69|enteric|O
DDI-DrugBank.d548.s18|71-77|coating|O
DDI-DrugBank.d548.s18|78-78|,|O
DDI-DrugBank.d548.s18|80-82|may|O
DDI-DrugBank.d548.s18|84-90|undergo|O
DDI-DrugBank.d548.s18|92-101|hydrolysis|O
DDI-DrugBank.d548.s18|103-104|to|O
DDI-DrugBank.d548.s18|106-109|form|O
DDI-DrugBank.d548.s18|111-118|naphthol|O
DDI-DrugBank.d548.s18|119-119|.|O
DDI-DrugBank.d548.s19|0-6|Caution|O
DDI-DrugBank.d548.s19|8-9|is|O
DDI-DrugBank.d548.s19|11-17|advised|O
DDI-DrugBank.d548.s19|19-20|in|O
DDI-DrugBank.d548.s19|22-26|using|O
DDI-DrugBank.d548.s19|28-37|Duloxetine|drug
DDI-DrugBank.d548.s19|39-40|in|O
DDI-DrugBank.d548.s19|42-49|patients|O
DDI-DrugBank.d548.s19|51-54|with|O
DDI-DrugBank.d548.s19|56-65|conditions|O
DDI-DrugBank.d548.s19|67-70|that|O
DDI-DrugBank.d548.s19|72-74|may|O
DDI-DrugBank.d548.s19|76-79|slow|O
DDI-DrugBank.d548.s19|81-87|gastric|O
DDI-DrugBank.d548.s19|89-96|emptying|O
DDI-DrugBank.d548.s19|98-98|(|O
DDI-DrugBank.d548.s19|99-102|e.g.|O
DDI-DrugBank.d548.s19|103-103|,|O
DDI-DrugBank.d548.s19|105-108|some|O
DDI-DrugBank.d548.s19|110-118|diabetics|O
DDI-DrugBank.d548.s19|119-119|)|O
DDI-DrugBank.d548.s19|120-120|.|O
DDI-DrugBank.d548.s20|0-4|Drugs|O
DDI-DrugBank.d548.s20|6-9|that|O
DDI-DrugBank.d548.s20|11-15|raise|O
DDI-DrugBank.d548.s20|17-19|the|O
DDI-DrugBank.d548.s20|21-36|gastrointestinal|O
DDI-DrugBank.d548.s20|38-39|pH|O
DDI-DrugBank.d548.s20|41-43|may|O
DDI-DrugBank.d548.s20|45-48|lead|O
DDI-DrugBank.d548.s20|50-51|to|O
DDI-DrugBank.d548.s20|53-54|an|O
DDI-DrugBank.d548.s20|56-62|earlier|O
DDI-DrugBank.d548.s20|64-70|release|O
DDI-DrugBank.d548.s20|72-73|of|O
DDI-DrugBank.d548.s20|75-84|duloxetine|drug
DDI-DrugBank.d548.s20|85-85|.|O
DDI-DrugBank.d548.s21|0-6|However|O
DDI-DrugBank.d548.s21|7-7|,|O
DDI-DrugBank.d548.s21|9-25|co-administration|O
DDI-DrugBank.d548.s21|27-28|of|O
DDI-DrugBank.d548.s21|30-39|Duloxetine|drug
DDI-DrugBank.d548.s21|41-44|with|O
DDI-DrugBank.d548.s21|46-54|aluminum-|drug
DDI-DrugBank.d548.s21|56-58|and|O
DDI-DrugBank.d548.s21|60-79|magnesium-containing|drug
DDI-DrugBank.d548.s21|60-79|magnesium-containing|drug
DDI-DrugBank.d548.s21|90-90|(|O
DDI-DrugBank.d548.s21|91-92|51|O
DDI-DrugBank.d548.s21|94-96|mEq|O
DDI-DrugBank.d548.s21|97-97|)|O
DDI-DrugBank.d548.s21|99-100|or|O
DDI-DrugBank.d548.s21|102-111|Duloxetine|drug
DDI-DrugBank.d548.s21|113-116|with|O
DDI-DrugBank.d548.s21|118-127|famotidine|drug
DDI-DrugBank.d548.s21|128-128|,|O
DDI-DrugBank.d548.s21|130-132|had|O
DDI-DrugBank.d548.s21|134-135|no|O
DDI-DrugBank.d548.s21|137-147|significant|O
DDI-DrugBank.d548.s21|149-154|effect|O
DDI-DrugBank.d548.s21|156-157|on|O
DDI-DrugBank.d548.s21|159-161|the|O
DDI-DrugBank.d548.s21|163-166|rate|O
DDI-DrugBank.d548.s21|168-169|or|O
DDI-DrugBank.d548.s21|171-176|extent|O
DDI-DrugBank.d548.s21|178-179|of|O
DDI-DrugBank.d548.s21|181-190|duloxetine|drug
DDI-DrugBank.d548.s21|192-201|absorption|O
DDI-DrugBank.d548.s21|203-207|after|O
DDI-DrugBank.d548.s21|209-222|administration|O
DDI-DrugBank.d548.s21|224-225|of|O
DDI-DrugBank.d548.s21|227-227|a|O
DDI-DrugBank.d548.s21|229-233|40-mg|O
DDI-DrugBank.d548.s21|235-238|oral|O
DDI-DrugBank.d548.s21|240-243|dose|O
DDI-DrugBank.d548.s21|244-244|.|O
DDI-DrugBank.d548.s22|0-1|It|O
DDI-DrugBank.d548.s22|3-4|is|O
DDI-DrugBank.d548.s22|6-12|unknown|O
DDI-DrugBank.d548.s22|14-20|whether|O
DDI-DrugBank.d548.s22|22-24|the|O
DDI-DrugBank.d548.s22|26-36|concomitant|O
DDI-DrugBank.d548.s22|38-51|administration|O
DDI-DrugBank.d548.s22|53-54|of|O
DDI-DrugBank.d548.s22|56-77|proton pump inhibitors|group
DDI-DrugBank.d548.s22|79-85|affects|O
DDI-DrugBank.d548.s22|87-96|duloxetine|drug
DDI-DrugBank.d548.s22|98-107|absorption|O
DDI-DrugBank.d548.s22|108-108|.|O
DDI-DrugBank.d541.s0|0-2|May|O
DDI-DrugBank.d541.s0|4-11|interact|O
DDI-DrugBank.d541.s0|13-16|with|O
DDI-DrugBank.d541.s0|18-20|the|O
DDI-DrugBank.d541.s0|22-30|following|O
DDI-DrugBank.d541.s0|31-31|:|O
DDI-DrugBank.d541.s0|33-63|beta-adrenergic blocking agents|group
DDI-DrugBank.d541.s0|65-65|(|O
DDI-DrugBank.d541.s0|66-70|these|O
DDI-DrugBank.d541.s0|72-80|medicines|O
DDI-DrugBank.d541.s0|82-84|may|O
DDI-DrugBank.d541.s0|86-89|make|O
DDI-DrugBank.d541.s0|91-94|your|O
DDI-DrugBank.d541.s0|96-104|condition|O
DDI-DrugBank.d541.s0|106-110|worse|O
DDI-DrugBank.d541.s0|112-114|and|O
DDI-DrugBank.d541.s0|116-122|prevent|O
DDI-DrugBank.d541.s0|124-126|the|O
DDI-DrugBank.d541.s0|128-153|adrenergic bronchodilators|group
DDI-DrugBank.d541.s0|155-158|from|O
DDI-DrugBank.d541.s0|160-166|working|O
DDI-DrugBank.d541.s0|168-175|properly|O
DDI-DrugBank.d541.s0|176-176|)|O
DDI-DrugBank.d541.s0|178-180|and|O
DDI-DrugBank.d541.s0|182-193|disopyramide|drug
DDI-DrugBank.d541.s0|194-194|,|O
DDI-DrugBank.d541.s0|196-204|quinidine|drug
DDI-DrugBank.d541.s0|205-205|,|O
DDI-DrugBank.d541.s0|207-220|phenothiazines|group
DDI-DrugBank.d541.s0|221-221|,|O
DDI-DrugBank.d541.s0|223-225|and|O
DDI-DrugBank.d541.s0|227-238|procainamide|drug
DDI-DrugBank.d541.s0|240-240|(|O
DDI-DrugBank.d541.s0|241-245|these|O
DDI-DrugBank.d541.s0|247-255|medicines|O
DDI-DrugBank.d541.s0|257-259|may|O
DDI-DrugBank.d541.s0|261-268|increase|O
DDI-DrugBank.d541.s0|270-272|the|O
DDI-DrugBank.d541.s0|274-277|risk|O
DDI-DrugBank.d541.s0|279-280|of|O
DDI-DrugBank.d541.s0|282-286|heart|O
DDI-DrugBank.d541.s0|288-295|problems|O
DDI-DrugBank.d541.s0|296-296|)|O
DDI-DrugBank.d541.s0|297-297|.|O
DDI-DrugBank.d390.s0|0-18|Antipsychotic drugs|group
DDI-DrugBank.d390.s0|20-23|such|O
DDI-DrugBank.d390.s0|25-26|as|O
DDI-DrugBank.d390.s0|28-41|phenothiazines|group
DDI-DrugBank.d390.s0|43-44|or|O
DDI-DrugBank.d390.s0|46-56|haloperidol|drug
DDI-DrugBank.d390.s0|57-57|;|O
DDI-DrugBank.d390.s1|0-24|tricyclic antidepressants|group
DDI-DrugBank.d390.s1|25-25|.|O
DDI-MedLine.d107.s0|0-10|Interaction|O
DDI-MedLine.d107.s0|12-13|of|O
DDI-MedLine.d107.s0|15-17|the|O
DDI-MedLine.d107.s0|19-30|constituents|O
DDI-MedLine.d107.s0|32-33|of|O
DDI-MedLine.d107.s0|35-43|alcoholic|O
DDI-MedLine.d107.s0|45-53|beverages|O
DDI-MedLine.d107.s0|55-56|in|O
DDI-MedLine.d107.s0|58-60|the|O
DDI-MedLine.d107.s0|62-70|promotion|O
DDI-MedLine.d107.s0|72-73|of|O
DDI-MedLine.d107.s0|75-79|liver|O
DDI-MedLine.d107.s0|81-86|damage|O
DDI-MedLine.d107.s0|87-87|.|O
DDI-MedLine.d107.s1|0-5|Little|O
DDI-MedLine.d107.s1|7-9|has|O
DDI-MedLine.d107.s1|11-14|been|O
DDI-MedLine.d107.s1|16-22|studied|O
DDI-MedLine.d107.s1|24-25|of|O
DDI-MedLine.d107.s1|27-29|the|O
DDI-MedLine.d107.s1|31-37|adverse|O
DDI-MedLine.d107.s1|39-45|effects|O
DDI-MedLine.d107.s1|47-48|of|O
DDI-MedLine.d107.s1|50-52|the|O
DDI-MedLine.d107.s1|54-61|exposure|O
DDI-MedLine.d107.s1|63-64|of|O
DDI-MedLine.d107.s1|66-68|the|O
DDI-MedLine.d107.s1|70-74|liver|O
DDI-MedLine.d107.s1|76-77|to|O
DDI-MedLine.d107.s1|79-81|the|O
DDI-MedLine.d107.s1|83-93|interaction|O
DDI-MedLine.d107.s1|95-96|of|O
DDI-MedLine.d107.s1|98-104|ethanol|drug
DDI-MedLine.d107.s1|106-109|with|O
DDI-MedLine.d107.s1|111-113|its|O
DDI-MedLine.d107.s1|115-123|congeners|O
DDI-MedLine.d107.s1|125-127|and|O
DDI-MedLine.d107.s1|141-141|,|O
DDI-MedLine.d107.s1|143-152|coexisting|O
DDI-MedLine.d107.s1|154-155|in|O
DDI-MedLine.d107.s1|157-159|the|O
DDI-MedLine.d107.s1|161-168|contents|O
DDI-MedLine.d107.s1|170-171|of|O
DDI-MedLine.d107.s1|173-181|alcoholic|O
DDI-MedLine.d107.s1|183-191|beverages|O
DDI-MedLine.d107.s1|192-192|.|O
DDI-MedLine.d107.s2|0-5|Twenty|O
DDI-MedLine.d107.s2|7-10|four|O
DDI-MedLine.d107.s2|12-15|male|O
DDI-MedLine.d107.s2|17-22|Wistar|O
DDI-MedLine.d107.s2|24-27|rats|O
DDI-MedLine.d107.s2|29-32|were|O
DDI-MedLine.d107.s2|34-40|divided|O
DDI-MedLine.d107.s2|42-45|into|O
DDI-MedLine.d107.s2|47-50|four|O
DDI-MedLine.d107.s2|52-57|groups|O
DDI-MedLine.d107.s2|58-58|.|O
DDI-MedLine.d107.s3|0-2|Two|O
DDI-MedLine.d107.s3|4-9|groups|O
DDI-MedLine.d107.s3|11-11|(|O
DDI-MedLine.d107.s3|12-16|SH/DA|O
DDI-MedLine.d107.s3|17-17|;|O
DDI-MedLine.d107.s3|19-23|SH/FA|O
DDI-MedLine.d107.s3|24-24|)|O
DDI-MedLine.d107.s3|26-29|were|O
DDI-MedLine.d107.s3|31-39|submitted|O
DDI-MedLine.d107.s3|41-42|to|O
DDI-MedLine.d107.s3|44-48|daily|O
DDI-MedLine.d107.s3|50-58|treatment|O
DDI-MedLine.d107.s3|60-63|with|O
DDI-MedLine.d107.s3|65-73|synthetic|O
DDI-MedLine.d107.s3|75-88|hydroalcoholic|O
DDI-MedLine.d107.s3|90-98|solutions|O
DDI-MedLine.d107.s3|100-109|containing|O
DDI-MedLine.d107.s3|111-117|ethanol|drug
DDI-MedLine.d107.s3|118-118|,|O
DDI-MedLine.d107.s3|128-128|,|O
DDI-MedLine.d107.s3|130-135|higher|O
DDI-MedLine.d107.s3|146-148|and|O
DDI-MedLine.d107.s3|163-164|in|O
DDI-MedLine.d107.s3|166-168|the|O
DDI-MedLine.d107.s3|170-173|same|O
DDI-MedLine.d107.s3|175-185|proportions|O
DDI-MedLine.d107.s3|187-188|as|O
DDI-MedLine.d107.s3|190-194|those|O
DDI-MedLine.d107.s3|196-200|found|O
DDI-MedLine.d107.s3|202-203|in|O
DDI-MedLine.d107.s3|205-208|most|O
DDI-MedLine.d107.s3|210-215|common|O
DDI-MedLine.d107.s3|217-225|distilled|O
DDI-MedLine.d107.s3|227-229|and|O
DDI-MedLine.d107.s3|231-239|fermented|O
DDI-MedLine.d107.s3|241-249|alcoholic|O
DDI-MedLine.d107.s3|251-259|beverages|O
DDI-MedLine.d107.s3|260-260|;|O
DDI-MedLine.d107.s4|0-2|the|O
DDI-MedLine.d107.s4|4-8|third|O
DDI-MedLine.d107.s4|10-14|group|O
DDI-MedLine.d107.s4|16-16|(|O
DDI-MedLine.d107.s4|17-21|SH/EA|O
DDI-MedLine.d107.s4|22-22|)|O
DDI-MedLine.d107.s4|24-26|was|O
DDI-MedLine.d107.s4|28-34|treated|O
DDI-MedLine.d107.s4|36-39|with|O
DDI-MedLine.d107.s4|41-41|a|O
DDI-MedLine.d107.s4|43-56|hydroalcoholic|O
DDI-MedLine.d107.s4|58-65|solution|O
DDI-MedLine.d107.s4|67-68|of|O
DDI-MedLine.d107.s4|70-76|ethanol|drug
DDI-MedLine.d107.s4|77-77|;|O
DDI-MedLine.d107.s5|0-2|the|O
DDI-MedLine.d107.s5|4-9|fourth|O
DDI-MedLine.d107.s5|11-15|group|O
DDI-MedLine.d107.s5|17-22|served|O
DDI-MedLine.d107.s5|24-25|as|O
DDI-MedLine.d107.s5|27-33|control|O
DDI-MedLine.d107.s5|35-37|and|O
DDI-MedLine.d107.s5|39-46|received|O
DDI-MedLine.d107.s5|48-49|an|O
DDI-MedLine.d107.s5|51-60|equivalent|O
DDI-MedLine.d107.s5|62-67|volume|O
DDI-MedLine.d107.s5|69-70|of|O
DDI-MedLine.d107.s5|72-73|an|O
DDI-MedLine.d107.s5|75-84|isocaloric|O
DDI-MedLine.d107.s5|86-93|solution|O
DDI-MedLine.d107.s5|95-96|of|O
DDI-MedLine.d107.s5|98-105|dextrose|drug
DDI-MedLine.d107.s5|106-106|.|O
DDI-MedLine.d107.s6|0-2|All|O
DDI-MedLine.d107.s6|4-6|the|O
DDI-MedLine.d107.s6|8-14|animals|O
DDI-MedLine.d107.s6|16-19|were|O
DDI-MedLine.d107.s6|21-26|killed|O
DDI-MedLine.d107.s6|28-29|at|O
DDI-MedLine.d107.s6|31-33|the|O
DDI-MedLine.d107.s6|35-37|end|O
DDI-MedLine.d107.s6|39-40|of|O
DDI-MedLine.d107.s6|42-44|the|O
DDI-MedLine.d107.s6|46-48|9th|O
DDI-MedLine.d107.s6|50-53|week|O
DDI-MedLine.d107.s6|55-56|of|O
DDI-MedLine.d107.s6|58-60|the|O
DDI-MedLine.d107.s6|62-71|experiment|O
DDI-MedLine.d107.s6|72-72|.|O
DDI-MedLine.d107.s7|0-2|The|O
DDI-MedLine.d107.s7|4-8|ratio|O
DDI-MedLine.d107.s7|10-16|between|O
DDI-MedLine.d107.s7|18-20|the|O
DDI-MedLine.d107.s7|22-26|liver|O
DDI-MedLine.d107.s7|28-33|weight|O
DDI-MedLine.d107.s7|35-37|and|O
DDI-MedLine.d107.s7|39-42|body|O
DDI-MedLine.d107.s7|44-49|weight|O
DDI-MedLine.d107.s7|51-53|was|O
DDI-MedLine.d107.s7|55-59|found|O
DDI-MedLine.d107.s7|61-62|to|O
DDI-MedLine.d107.s7|64-65|be|O
DDI-MedLine.d107.s7|67-71|lower|O
DDI-MedLine.d107.s7|73-74|in|O
DDI-MedLine.d107.s7|76-78|the|O
DDI-MedLine.d107.s7|80-86|treated|O
DDI-MedLine.d107.s7|88-94|animals|O
DDI-MedLine.d107.s7|96-99|than|O
DDI-MedLine.d107.s7|101-102|in|O
DDI-MedLine.d107.s7|104-106|the|O
DDI-MedLine.d107.s7|108-114|control|O
DDI-MedLine.d107.s7|116-120|group|O
DDI-MedLine.d107.s7|121-121|.|O
DDI-MedLine.d107.s8|0-2|The|O
DDI-MedLine.d107.s8|4-12|histology|O
DDI-MedLine.d107.s8|14-15|of|O
DDI-MedLine.d107.s8|17-19|the|O
DDI-MedLine.d107.s8|21-25|liver|O
DDI-MedLine.d107.s8|27-29|was|O
DDI-MedLine.d107.s8|31-37|altered|O
DDI-MedLine.d107.s8|39-40|in|O
DDI-MedLine.d107.s8|42-44|the|O
DDI-MedLine.d107.s8|46-50|three|O
DDI-MedLine.d107.s8|52-57|groups|O
DDI-MedLine.d107.s8|59-63|which|O
DDI-MedLine.d107.s8|65-68|were|O
DDI-MedLine.d107.s8|70-78|submitted|O
DDI-MedLine.d107.s8|80-81|to|O
DDI-MedLine.d107.s8|83-91|treatment|O
DDI-MedLine.d107.s8|93-96|with|O
DDI-MedLine.d107.s8|98-100|the|O
DDI-MedLine.d107.s8|102-115|hydroalcoholic|O
DDI-MedLine.d107.s8|117-125|solutions|O
DDI-MedLine.d107.s8|126-126|,|O
DDI-MedLine.d107.s8|128-131|with|O
DDI-MedLine.d107.s8|133-144|quantitative|O
DDI-MedLine.d107.s8|146-148|and|O
DDI-MedLine.d107.s8|150-160|qualitative|O
DDI-MedLine.d107.s8|162-172|differences|O
DDI-MedLine.d107.s8|174-180|between|O
DDI-MedLine.d107.s8|182-184|the|O
DDI-MedLine.d107.s8|186-191|groups|O
DDI-MedLine.d107.s8|192-192|.|O
DDI-MedLine.d107.s9|0-4|These|O
DDI-MedLine.d107.s9|6-12|results|O
DDI-MedLine.d107.s9|14-20|suggest|O
DDI-MedLine.d107.s9|22-25|that|O
DDI-MedLine.d107.s9|27-29|the|O
DDI-MedLine.d107.s9|31-42|hepatoxicity|O
DDI-MedLine.d107.s9|44-45|of|O
DDI-MedLine.d107.s9|47-53|ethanol|drug
DDI-MedLine.d107.s9|55-56|in|O
DDI-MedLine.d107.s9|58-66|alcoholic|O
DDI-MedLine.d107.s9|68-76|beverages|O
DDI-MedLine.d107.s9|78-79|is|O
DDI-MedLine.d107.s9|81-88|enhanced|O
DDI-MedLine.d107.s9|90-91|by|O
DDI-MedLine.d107.s9|93-103|interaction|O
DDI-MedLine.d107.s9|105-108|with|O
DDI-MedLine.d107.s9|110-112|its|O
DDI-MedLine.d107.s9|114-122|congeners|O
DDI-MedLine.d107.s9|124-126|and|O
DDI-MedLine.d107.s9|140-140|;|O
DDI-MedLine.d107.s10|0-3|they|O
DDI-MedLine.d107.s10|5-8|also|O
DDI-MedLine.d107.s10|10-16|suggest|O
DDI-MedLine.d107.s10|18-21|that|O
DDI-MedLine.d107.s10|23-31|alcoholic|O
DDI-MedLine.d107.s10|33-41|beverages|O
DDI-MedLine.d107.s10|43-45|are|O
DDI-MedLine.d107.s10|47-49|not|O
DDI-MedLine.d107.s10|51-60|equivalent|O
DDI-MedLine.d107.s10|62-63|in|O
DDI-MedLine.d107.s10|65-69|their|O
DDI-MedLine.d107.s10|71-79|potential|O
DDI-MedLine.d107.s10|81-82|to|O
DDI-MedLine.d107.s10|84-88|cause|O
DDI-MedLine.d107.s10|90-94|liver|O
DDI-MedLine.d107.s10|96-101|damage|O
DDI-MedLine.d107.s10|102-102|.|O
DDI-MedLine.d53.s0|0-8|Induction|O
DDI-MedLine.d53.s0|10-11|of|O
DDI-MedLine.d53.s0|13-21|apoptosis|O
DDI-MedLine.d53.s0|23-24|in|O
DDI-MedLine.d53.s0|26-31|breast|O
DDI-MedLine.d53.s0|33-38|cancer|O
DDI-MedLine.d53.s0|40-44|cells|O
DDI-MedLine.d53.s0|46-47|in|O
DDI-MedLine.d53.s0|49-56|response|O
DDI-MedLine.d53.s0|58-59|to|O
DDI-MedLine.d53.s0|61-69|vitamin D|group
DDI-MedLine.d53.s0|71-73|and|O
DDI-MedLine.d53.s0|75-87|antiestrogens|group
DDI-MedLine.d53.s0|88-88|.|O
DDI-MedLine.d53.s1|0-28|1,25-Dihydroxycholecalciferol|O
DDI-MedLine.d53.s1|30-31|D3|drug
DDI-MedLine.d53.s1|33-33|(|O
DDI-MedLine.d53.s1|34-44|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s1|45-45|)|O
DDI-MedLine.d53.s1|46-46|,|O
DDI-MedLine.d53.s1|48-50|the|O
DDI-MedLine.d53.s1|52-57|active|O
DDI-MedLine.d53.s1|59-68|metabolite|O
DDI-MedLine.d53.s1|70-71|of|O
DDI-MedLine.d53.s1|73-81|vitamin D|group
DDI-MedLine.d53.s1|82-82|,|O
DDI-MedLine.d53.s1|84-85|is|O
DDI-MedLine.d53.s1|87-87|a|O
DDI-MedLine.d53.s1|89-94|potent|O
DDI-MedLine.d53.s1|96-104|inhibitor|O
DDI-MedLine.d53.s1|106-107|of|O
DDI-MedLine.d53.s1|109-114|breast|O
DDI-MedLine.d53.s1|116-121|cancer|O
DDI-MedLine.d53.s1|123-126|cell|O
DDI-MedLine.d53.s1|128-133|growth|O
DDI-MedLine.d53.s1|135-138|both|O
DDI-MedLine.d53.s1|140-141|in|O
DDI-MedLine.d53.s1|143-146|vivo|O
DDI-MedLine.d53.s1|148-150|and|O
DDI-MedLine.d53.s1|152-153|in|O
DDI-MedLine.d53.s1|155-159|vitro|O
DDI-MedLine.d53.s1|160-160|.|O
DDI-MedLine.d53.s2|0-1|We|O
DDI-MedLine.d53.s2|3-6|have|O
DDI-MedLine.d53.s2|8-12|shown|O
DDI-MedLine.d53.s2|14-17|that|O
DDI-MedLine.d53.s2|19-23|MCF-7|O
DDI-MedLine.d53.s2|25-29|cells|O
DDI-MedLine.d53.s2|31-37|treated|O
DDI-MedLine.d53.s2|39-42|with|O
DDI-MedLine.d53.s2|44-46|100|O
DDI-MedLine.d53.s2|48-49|nM|O
DDI-MedLine.d53.s2|51-61|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s2|63-69|exhibit|O
DDI-MedLine.d53.s2|71-84|characteristic|O
DDI-MedLine.d53.s2|86-94|apoptotic|O
DDI-MedLine.d53.s2|96-105|morphology|O
DDI-MedLine.d53.s2|107-107|(|O
DDI-MedLine.d53.s2|108-115|pyknotic|O
DDI-MedLine.d53.s2|117-122|nuclei|O
DDI-MedLine.d53.s2|123-123|,|O
DDI-MedLine.d53.s2|125-133|chromatin|O
DDI-MedLine.d53.s2|135-137|and|O
DDI-MedLine.d53.s2|139-149|cytoplasmic|O
DDI-MedLine.d53.s2|151-162|condensation|O
DDI-MedLine.d53.s2|163-163|,|O
DDI-MedLine.d53.s2|165-171|nuclear|O
DDI-MedLine.d53.s2|173-178|matrix|O
DDI-MedLine.d53.s2|180-186|protein|O
DDI-MedLine.d53.s2|188-201|reorganization|O
DDI-MedLine.d53.s2|202-202|)|O
DDI-MedLine.d53.s2|204-209|within|O
DDI-MedLine.d53.s2|211-212|48|O
DDI-MedLine.d53.s2|214-214|h|O
DDI-MedLine.d53.s2|215-215|.|O
DDI-MedLine.d53.s3|0-1|In|O
DDI-MedLine.d53.s3|3-5|the|O
DDI-MedLine.d53.s3|7-17|experiments|O
DDI-MedLine.d53.s3|19-26|reported|O
DDI-MedLine.d53.s3|28-31|here|O
DDI-MedLine.d53.s3|32-32|,|O
DDI-MedLine.d53.s3|34-35|we|O
DDI-MedLine.d53.s3|37-44|examined|O
DDI-MedLine.d53.s3|46-48|the|O
DDI-MedLine.d53.s3|50-61|interactions|O
DDI-MedLine.d53.s3|63-69|between|O
DDI-MedLine.d53.s3|71-81|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s3|83-85|and|O
DDI-MedLine.d53.s3|87-89|the|O
DDI-MedLine.d53.s3|91-102|antiestrogen|group
DDI-MedLine.d53.s3|123-123|(|O
DDI-MedLine.d53.s3|127-127|)|O
DDI-MedLine.d53.s3|128-128|,|O
DDI-MedLine.d53.s3|130-134|which|O
DDI-MedLine.d53.s3|136-139|also|O
DDI-MedLine.d53.s3|141-147|induces|O
DDI-MedLine.d53.s3|149-157|apoptosis|O
DDI-MedLine.d53.s3|159-160|in|O
DDI-MedLine.d53.s3|162-166|MCF-7|O
DDI-MedLine.d53.s3|168-172|cells|O
DDI-MedLine.d53.s3|173-173|.|O
DDI-MedLine.d53.s4|0-2|Our|O
DDI-MedLine.d53.s4|4-7|data|O
DDI-MedLine.d53.s4|9-15|suggest|O
DDI-MedLine.d53.s4|17-20|that|O
DDI-MedLine.d53.s4|26-38|significantly|O
DDI-MedLine.d53.s4|40-50|potentiates|O
DDI-MedLine.d53.s4|52-54|the|O
DDI-MedLine.d53.s4|56-64|reduction|O
DDI-MedLine.d53.s4|66-67|in|O
DDI-MedLine.d53.s4|69-72|cell|O
DDI-MedLine.d53.s4|74-79|number|O
DDI-MedLine.d53.s4|81-87|induced|O
DDI-MedLine.d53.s4|89-90|by|O
DDI-MedLine.d53.s4|92-102|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s4|104-108|alone|O
DDI-MedLine.d53.s4|109-109|.|O
DDI-MedLine.d53.s5|0-7|Combined|O
DDI-MedLine.d53.s5|9-17|treatment|O
DDI-MedLine.d53.s5|19-22|with|O
DDI-MedLine.d53.s5|24-34|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s5|36-38|and|O
DDI-MedLine.d53.s5|44-51|enhances|O
DDI-MedLine.d53.s5|53-55|the|O
DDI-MedLine.d53.s5|57-62|degree|O
DDI-MedLine.d53.s5|64-65|of|O
DDI-MedLine.d53.s5|67-75|apoptosis|O
DDI-MedLine.d53.s5|77-84|assessed|O
DDI-MedLine.d53.s5|86-90|using|O
DDI-MedLine.d53.s5|92-104|morphological|O
DDI-MedLine.d53.s5|106-112|markers|O
DDI-MedLine.d53.s5|114-117|that|O
DDI-MedLine.d53.s5|119-126|identify|O
DDI-MedLine.d53.s5|128-136|chromatin|O
DDI-MedLine.d53.s5|138-140|and|O
DDI-MedLine.d53.s5|142-148|nuclear|O
DDI-MedLine.d53.s5|150-155|matrix|O
DDI-MedLine.d53.s5|157-163|protein|O
DDI-MedLine.d53.s5|165-176|condensation|O
DDI-MedLine.d53.s5|177-177|.|O
DDI-MedLine.d53.s6|0-1|We|O
DDI-MedLine.d53.s6|3-6|have|O
DDI-MedLine.d53.s6|8-15|selected|O
DDI-MedLine.d53.s6|17-17|a|O
DDI-MedLine.d53.s6|19-26|subclone|O
DDI-MedLine.d53.s6|28-29|of|O
DDI-MedLine.d53.s6|31-35|MCF-7|O
DDI-MedLine.d53.s6|37-41|cells|O
DDI-MedLine.d53.s6|43-51|resistant|O
DDI-MedLine.d53.s6|53-54|to|O
DDI-MedLine.d53.s6|56-66|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s6|68-68|(|O
DDI-MedLine.d53.s6|69-78|MCF-7D3Res|O
DDI-MedLine.d53.s6|79-79|)|O
DDI-MedLine.d53.s6|80-80|.|O
DDI-MedLine.d53.s7|0-4|These|O
DDI-MedLine.d53.s7|6-10|cells|O
DDI-MedLine.d53.s7|12-18|express|O
DDI-MedLine.d53.s7|20-22|the|O
DDI-MedLine.d53.s7|24-30|vitamin|O
DDI-MedLine.d53.s7|32-32|D|O
DDI-MedLine.d53.s7|34-41|receptor|O
DDI-MedLine.d53.s7|43-45|and|O
DDI-MedLine.d53.s7|47-53|exhibit|O
DDI-MedLine.d53.s7|55-62|doubling|O
DDI-MedLine.d53.s7|64-68|times|O
DDI-MedLine.d53.s7|70-79|comparable|O
DDI-MedLine.d53.s7|81-82|to|O
DDI-MedLine.d53.s7|84-86|the|O
DDI-MedLine.d53.s7|88-95|parental|O
DDI-MedLine.d53.s7|97-101|MCF-7|O
DDI-MedLine.d53.s7|103-107|cells|O
DDI-MedLine.d53.s7|108-108|,|O
DDI-MedLine.d53.s7|110-113|even|O
DDI-MedLine.d53.s7|115-118|when|O
DDI-MedLine.d53.s7|120-124|grown|O
DDI-MedLine.d53.s7|126-127|in|O
DDI-MedLine.d53.s7|129-131|100|O
DDI-MedLine.d53.s7|133-134|mM|O
DDI-MedLine.d53.s7|136-146|1,25 ( OH ) 2D3|drug
DDI-MedLine.d53.s7|147-147|.|O
DDI-MedLine.d53.s8|0-8|Treatment|O
DDI-MedLine.d53.s8|10-11|of|O
DDI-MedLine.d53.s8|13-16|both|O
DDI-MedLine.d53.s8|18-25|parental|O
DDI-MedLine.d53.s8|27-29|and|O
DDI-MedLine.d53.s8|31-39|resistant|O
DDI-MedLine.d53.s8|41-45|MCF-7|O
DDI-MedLine.d53.s8|47-51|cells|O
DDI-MedLine.d53.s8|53-56|with|O
DDI-MedLine.d53.s8|62-68|induces|O
DDI-MedLine.d53.s8|70-78|apoptosis|O
DDI-MedLine.d53.s8|80-82|and|O
DDI-MedLine.d53.s8|84-92|clusterin|O
DDI-MedLine.d53.s8|93-93|.|O
DDI-MedLine.d53.s9|0-4|These|O
DDI-MedLine.d53.s9|6-9|data|O
DDI-MedLine.d53.s9|11-19|emphasize|O
DDI-MedLine.d53.s9|21-24|that|O
DDI-MedLine.d53.s9|26-34|apoptosis|O
DDI-MedLine.d53.s9|36-38|can|O
DDI-MedLine.d53.s9|40-41|be|O
DDI-MedLine.d53.s9|43-49|induced|O
DDI-MedLine.d53.s9|51-52|in|O
DDI-MedLine.d53.s9|54-58|MCF-7|O
DDI-MedLine.d53.s9|60-64|cells|O
DDI-MedLine.d53.s9|66-71|either|O
DDI-MedLine.d53.s9|73-74|by|O
DDI-MedLine.d53.s9|76-85|activation|O
DDI-MedLine.d53.s9|87-88|of|O
DDI-MedLine.d53.s9|90-107|vitamin-D-mediated|group
DDI-MedLine.d53.s9|109-118|signalling|O
DDI-MedLine.d53.s9|120-121|or|O
DDI-MedLine.d53.s9|123-132|disruption|O
DDI-MedLine.d53.s9|134-135|of|O
DDI-MedLine.d53.s9|137-154|estrogen-dependent|group
DDI-MedLine.d53.s9|156-165|signalling|O
DDI-MedLine.d53.s9|166-166|.|O
DDI-DrugBank.d477.s0|0-11|Hypertensive|O
DDI-DrugBank.d477.s0|13-18|crises|O
DDI-DrugBank.d477.s0|20-23|have|O
DDI-DrugBank.d477.s0|25-32|resulted|O
DDI-DrugBank.d477.s0|34-37|when|O
DDI-DrugBank.d477.s0|39-60|sympathomimetic amines|group
DDI-DrugBank.d477.s0|62-65|have|O
DDI-DrugBank.d477.s0|67-70|been|O
DDI-DrugBank.d477.s0|72-75|used|O
DDI-DrugBank.d477.s0|77-89|concomitantly|O
DDI-DrugBank.d477.s0|91-98|within14|O
DDI-DrugBank.d477.s0|100-103|days|O
DDI-DrugBank.d477.s0|105-113|following|O
DDI-DrugBank.d477.s0|115-117|use|O
DDI-DrugBank.d477.s0|119-120|of|O
DDI-DrugBank.d477.s0|122-149|monoamine oxidase inhibitors|group
DDI-DrugBank.d477.s0|150-150|.|O
DDI-DrugBank.d477.s1|0-5|DIDREX|brand
DDI-DrugBank.d477.s1|7-12|should|O
DDI-DrugBank.d477.s1|14-16|not|O
DDI-DrugBank.d477.s1|18-19|be|O
DDI-DrugBank.d477.s1|21-24|used|O
DDI-DrugBank.d477.s1|26-38|concomitantly|O
DDI-DrugBank.d477.s1|40-43|with|O
DDI-DrugBank.d477.s1|45-49|other|O
DDI-DrugBank.d477.s1|51-64|CNS stimulants|group
DDI-DrugBank.d477.s1|65-65|.|O
DDI-DrugBank.d477.s2|0-11|Amphetamines|group
DDI-DrugBank.d477.s2|13-15|may|O
DDI-DrugBank.d477.s2|17-24|decrease|O
DDI-DrugBank.d477.s2|26-28|the|O
DDI-DrugBank.d477.s2|30-40|hypotensive|O
DDI-DrugBank.d477.s2|42-47|effect|O
DDI-DrugBank.d477.s2|49-50|of|O
DDI-DrugBank.d477.s2|52-68|antihypertensives|group
DDI-DrugBank.d477.s2|69-69|.|O
DDI-DrugBank.d477.s3|0-11|Amphetamines|group
DDI-DrugBank.d477.s3|13-15|may|O
DDI-DrugBank.d477.s3|17-23|enhance|O
DDI-DrugBank.d477.s3|25-27|the|O
DDI-DrugBank.d477.s3|29-35|effects|O
DDI-DrugBank.d477.s3|37-38|of|O
DDI-DrugBank.d477.s3|40-64|tricyclic antidepressants|group
DDI-DrugBank.d477.s3|65-65|.|O
DDI-DrugBank.d477.s4|0-6|Urinary|O
DDI-DrugBank.d477.s4|8-19|alkalinizing|O
DDI-DrugBank.d477.s4|21-26|agents|O
DDI-DrugBank.d477.s4|28-35|increase|O
DDI-DrugBank.d477.s4|37-41|blood|O
DDI-DrugBank.d477.s4|43-48|levels|O
DDI-DrugBank.d477.s4|50-52|and|O
DDI-DrugBank.d477.s4|54-61|decrease|O
DDI-DrugBank.d477.s4|63-71|excretion|O
DDI-DrugBank.d477.s4|73-74|of|O
DDI-DrugBank.d477.s4|76-87|amphetamines|group
DDI-DrugBank.d477.s4|88-88|.|O
DDI-DrugBank.d477.s5|0-17|Urinary acidifying|drug
DDI-DrugBank.d477.s5|19-24|agents|O
DDI-DrugBank.d477.s5|26-33|decrease|O
DDI-DrugBank.d477.s5|35-39|blood|O
DDI-DrugBank.d477.s5|41-46|levels|O
DDI-DrugBank.d477.s5|48-50|and|O
DDI-DrugBank.d477.s5|52-59|increase|O
DDI-DrugBank.d477.s5|61-69|excretion|O
DDI-DrugBank.d477.s5|71-72|of|O
DDI-DrugBank.d477.s5|74-85|amphetamines|group
DDI-DrugBank.d477.s5|86-86|.|O
DDI-DrugBank.d173.s0|0-2|May|O
DDI-DrugBank.d173.s0|4-11|interact|O
DDI-DrugBank.d173.s0|13-16|with|O
DDI-DrugBank.d173.s0|18-22|other|O
DDI-DrugBank.d173.s0|24-29|creams|O
DDI-DrugBank.d173.s0|30-30|,|O
DDI-DrugBank.d173.s0|32-38|lotions|O
DDI-DrugBank.d173.s0|39-39|,|O
DDI-DrugBank.d173.s0|41-42|or|O
DDI-DrugBank.d173.s0|44-47|skin|O
DDI-DrugBank.d173.s0|49-57|medicines|O
DDI-DrugBank.d173.s0|59-62|when|O
DDI-DrugBank.d173.s0|64-69|placed|O
DDI-DrugBank.d173.s0|71-72|on|O
DDI-DrugBank.d173.s0|74-76|the|O
DDI-DrugBank.d173.s0|78-81|same|O
DDI-DrugBank.d173.s0|83-87|areas|O
DDI-DrugBank.d173.s0|89-90|of|O
DDI-DrugBank.d173.s0|92-95|your|O
DDI-DrugBank.d173.s0|97-100|skin|O
DDI-DrugBank.d173.s0|102-105|that|O
DDI-DrugBank.d173.s0|107-109|you|O
DDI-DrugBank.d173.s0|111-113|are|O
DDI-DrugBank.d173.s0|115-119|using|O
DDI-DrugBank.d173.s0|132-132|.|O
DDI-MedLine.d40.s0|0-6|Studies|O
DDI-MedLine.d40.s0|8-9|on|O
DDI-MedLine.d40.s0|11-13|the|O
DDI-MedLine.d40.s0|15-23|mechanism|O
DDI-MedLine.d40.s0|25-26|of|O
DDI-MedLine.d40.s0|28-33|action|O
DDI-MedLine.d40.s0|35-36|of|O
DDI-MedLine.d40.s0|38-47|miconazole|drug
DDI-MedLine.d40.s0|48-48|:|O
DDI-MedLine.d40.s0|50-55|effect|O
DDI-MedLine.d40.s0|57-58|of|O
DDI-MedLine.d40.s0|60-69|miconazole|drug
DDI-MedLine.d40.s0|71-72|on|O
DDI-MedLine.d40.s0|74-84|respiration|O
DDI-MedLine.d40.s0|86-88|and|O
DDI-MedLine.d40.s0|90-93|cell|O
DDI-MedLine.d40.s0|95-106|permeability|O
DDI-MedLine.d40.s0|108-109|of|O
DDI-MedLine.d40.s0|111-117|Candida|O
DDI-MedLine.d40.s0|119-126|albicans|O
DDI-MedLine.d40.s0|127-127|.|O
DDI-MedLine.d40.s1|0-2|The|O
DDI-MedLine.d40.s1|4-18|antifungal drug|group
DDI-MedLine.d40.s1|19-19|,|O
DDI-MedLine.d40.s1|21-38|miconazole nitrate|drug
DDI-MedLine.d40.s1|39-39|,|O
DDI-MedLine.d40.s1|41-48|inhibits|O
DDI-MedLine.d40.s1|50-52|the|O
DDI-MedLine.d40.s1|54-59|growth|O
DDI-MedLine.d40.s1|61-62|of|O
DDI-MedLine.d40.s1|64-70|several|O
DDI-MedLine.d40.s1|72-78|species|O
DDI-MedLine.d40.s1|80-81|of|O
DDI-MedLine.d40.s1|83-89|Candida|O
DDI-MedLine.d40.s1|90-90|.|O
DDI-MedLine.d40.s2|0-6|Candida|O
DDI-MedLine.d40.s2|8-15|albicans|O
DDI-MedLine.d40.s2|16-16|,|O
DDI-MedLine.d40.s2|18-20|one|O
DDI-MedLine.d40.s2|22-23|of|O
DDI-MedLine.d40.s2|25-27|the|O
DDI-MedLine.d40.s2|29-38|pathogenic|O
DDI-MedLine.d40.s2|40-46|species|O
DDI-MedLine.d40.s2|47-47|,|O
DDI-MedLine.d40.s2|49-51|was|O
DDI-MedLine.d40.s2|53-59|totally|O
DDI-MedLine.d40.s2|61-69|inhibited|O
DDI-MedLine.d40.s2|71-72|at|O
DDI-MedLine.d40.s2|74-74|a|O
DDI-MedLine.d40.s2|76-88|concentration|O
DDI-MedLine.d40.s2|90-91|of|O
DDI-MedLine.d40.s2|93-105|approximately|O
DDI-MedLine.d40.s2|107-108|10|O
DDI-MedLine.d40.s2|110-115|mug/ml|O
DDI-MedLine.d40.s2|116-116|.|O
DDI-MedLine.d40.s3|0-9|Endogenous|O
DDI-MedLine.d40.s3|11-21|respiration|O
DDI-MedLine.d40.s3|23-25|was|O
DDI-MedLine.d40.s3|27-36|unaffected|O
DDI-MedLine.d40.s3|38-39|by|O
DDI-MedLine.d40.s3|41-43|the|O
DDI-MedLine.d40.s3|45-48|drug|O
DDI-MedLine.d40.s3|50-51|at|O
DDI-MedLine.d40.s3|53-53|a|O
DDI-MedLine.d40.s3|55-67|concentration|O
DDI-MedLine.d40.s3|69-70|as|O
DDI-MedLine.d40.s3|72-75|high|O
DDI-MedLine.d40.s3|77-78|as|O
DDI-MedLine.d40.s3|80-82|100|O
DDI-MedLine.d40.s3|84-89|mug/ml|O
DDI-MedLine.d40.s3|90-90|,|O
DDI-MedLine.d40.s3|92-98|whereas|O
DDI-MedLine.d40.s3|100-108|exogenous|O
DDI-MedLine.d40.s3|110-120|respiration|O
DDI-MedLine.d40.s3|122-124|was|O
DDI-MedLine.d40.s3|126-133|markedly|O
DDI-MedLine.d40.s3|135-143|sensitive|O
DDI-MedLine.d40.s3|145-147|and|O
DDI-MedLine.d40.s3|149-157|inhibited|O
DDI-MedLine.d40.s3|159-160|to|O
DDI-MedLine.d40.s3|162-163|an|O
DDI-MedLine.d40.s3|165-170|extent|O
DDI-MedLine.d40.s3|172-173|of|O
DDI-MedLine.d40.s3|175-176|85|O
DDI-MedLine.d40.s3|177-177|%|O
DDI-MedLine.d40.s3|178-178|.|O
DDI-MedLine.d40.s4|0-2|The|O
DDI-MedLine.d40.s4|4-15|permeability|O
DDI-MedLine.d40.s4|17-18|of|O
DDI-MedLine.d40.s4|20-22|the|O
DDI-MedLine.d40.s4|24-27|cell|O
DDI-MedLine.d40.s4|29-36|membrane|O
DDI-MedLine.d40.s4|38-40|was|O
DDI-MedLine.d40.s4|42-48|changed|O
DDI-MedLine.d40.s4|50-51|as|O
DDI-MedLine.d40.s4|53-61|evidenced|O
DDI-MedLine.d40.s4|63-64|by|O
DDI-MedLine.d40.s4|66-68|the|O
DDI-MedLine.d40.s4|70-76|leakage|O
DDI-MedLine.d40.s4|78-79|of|O
DDI-MedLine.d40.s4|81-86|260-nm|O
DDI-MedLine.d40.s4|88-96|absorbing|O
DDI-MedLine.d40.s4|98-106|materials|O
DDI-MedLine.d40.s4|107-107|,|O
DDI-MedLine.d40.s4|109-113|amino|O
DDI-MedLine.d40.s4|115-119|acids|O
DDI-MedLine.d40.s4|120-120|,|O
DDI-MedLine.d40.s4|122-129|proteins|O
DDI-MedLine.d40.s4|130-130|,|O
DDI-MedLine.d40.s4|132-134|and|O
DDI-MedLine.d40.s4|136-144|inorganic|O
DDI-MedLine.d40.s4|146-152|cations|O
DDI-MedLine.d40.s4|153-153|.|O
DDI-MedLine.d40.s5|0-2|The|O
DDI-MedLine.d40.s5|4-10|results|O
DDI-MedLine.d40.s5|12-13|we|O
DDI-MedLine.d40.s5|15-21|present|O
DDI-MedLine.d40.s5|23-29|clearly|O
DDI-MedLine.d40.s5|31-34|show|O
DDI-MedLine.d40.s5|36-39|that|O
DDI-MedLine.d40.s5|41-43|the|O
DDI-MedLine.d40.s5|45-48|drug|O
DDI-MedLine.d40.s5|50-55|alters|O
DDI-MedLine.d40.s5|57-59|the|O
DDI-MedLine.d40.s5|61-68|cellular|O
DDI-MedLine.d40.s5|70-81|permeability|O
DDI-MedLine.d40.s5|82-82|,|O
DDI-MedLine.d40.s5|84-86|and|O
DDI-MedLine.d40.s5|88-91|thus|O
DDI-MedLine.d40.s5|93-95|the|O
DDI-MedLine.d40.s5|97-105|exogenous|O
DDI-MedLine.d40.s5|107-117|respiration|O
DDI-MedLine.d40.s5|119-125|becomes|O
DDI-MedLine.d40.s5|127-135|sensitive|O
DDI-MedLine.d40.s5|137-138|to|O
DDI-MedLine.d40.s5|140-142|the|O
DDI-MedLine.d40.s5|144-147|drug|O
DDI-MedLine.d40.s5|148-148|.|O
DDI-MedLine.d41.s0|0-9|Interferon|O
DDI-MedLine.d41.s0|11-19|induction|O
DDI-MedLine.d41.s0|20-20|:|O
DDI-MedLine.d41.s0|22-25|tool|O
DDI-MedLine.d41.s0|27-29|for|O
DDI-MedLine.d41.s0|31-42|establishing|O
DDI-MedLine.d41.s0|44-55|interactions|O
DDI-MedLine.d41.s0|57-61|among|O
DDI-MedLine.d41.s0|63-85|homopolyribonucleotides|O
DDI-MedLine.d41.s0|86-86|.|O
DDI-MedLine.d41.s1|0-7|Hitherto|O
DDI-MedLine.d41.s1|9-20|unrecognized|O
DDI-MedLine.d41.s1|22-33|interactions|O
DDI-MedLine.d41.s1|35-41|between|O
DDI-MedLine.d41.s1|43-65|homopolyribonucleotides|O
DDI-MedLine.d41.s1|67-69|and|O
DDI-MedLine.d41.s1|71-79|complexes|O
DDI-MedLine.d41.s1|81-87|thereof|O
DDI-MedLine.d41.s1|89-91|are|O
DDI-MedLine.d41.s1|93-101|suggested|O
DDI-MedLine.d41.s1|103-104|by|O
DDI-MedLine.d41.s1|106-115|interferon|O
DDI-MedLine.d41.s1|117-125|induction|O
DDI-MedLine.d41.s1|127-130|data|O
DDI-MedLine.d41.s1|132-139|obtained|O
DDI-MedLine.d41.s1|141-142|in|O
DDI-MedLine.d41.s1|144-144|a|O
DDI-MedLine.d41.s1|146-151|highly|O
DDI-MedLine.d41.s1|153-161|sensitive|O
DDI-MedLine.d41.s1|163-167|assay|O
DDI-MedLine.d41.s1|169-174|system|O
DDI-MedLine.d41.s1|176-177|of|O
DDI-MedLine.d41.s1|179-185|primary|O
DDI-MedLine.d41.s1|187-192|rabbit|O
DDI-MedLine.d41.s1|194-199|kidney|O
DDI-MedLine.d41.s1|201-204|cell|O
DDI-MedLine.d41.s1|206-213|cultures|O
DDI-MedLine.d41.s1|215-226|superinduced|O
DDI-MedLine.d41.s1|228-229|by|O
DDI-MedLine.d41.s1|231-239|metabolic|O
DDI-MedLine.d41.s1|241-250|inhibitors|O
DDI-MedLine.d41.s1|251-251|.|O
DDI-MedLine.d45.s0|0-8|Selective|O
DDI-MedLine.d45.s0|10-17|survival|O
DDI-MedLine.d45.s0|19-20|in|O
DDI-MedLine.d45.s0|22-32|pentazocine|drug
DDI-MedLine.d45.s0|34-36|and|O
DDI-MedLine.d45.s0|38-51|tripelennamine|drug
DDI-MedLine.d45.s0|53-54|of|O
DDI-MedLine.d45.s0|56-66|Pseudomonas|O
DDI-MedLine.d45.s0|68-77|aeruginosa|O
DDI-MedLine.d45.s0|79-86|serotype|O
DDI-MedLine.d45.s0|88-90|O11|O
DDI-MedLine.d45.s0|92-95|from|O
DDI-MedLine.d45.s0|97-100|drug|O
DDI-MedLine.d45.s0|102-108|addicts|O
DDI-MedLine.d45.s0|109-109|.|O
DDI-MedLine.d45.s1|0-2|The|O
DDI-MedLine.d45.s1|4-9|growth|O
DDI-MedLine.d45.s1|11-12|of|O
DDI-MedLine.d45.s1|14-24|Pseudomonas|O
DDI-MedLine.d45.s1|26-35|aeruginosa|O
DDI-MedLine.d45.s1|36-36|,|O
DDI-MedLine.d45.s1|38-49|particularly|O
DDI-MedLine.d45.s1|51-58|serotype|O
DDI-MedLine.d45.s1|60-62|O11|O
DDI-MedLine.d45.s1|63-63|,|O
DDI-MedLine.d45.s1|65-66|in|O
DDI-MedLine.d45.s1|68-78|pentazocine|drug
DDI-MedLine.d45.s1|80-82|and|O
DDI-MedLine.d45.s2|0-2|was|O
DDI-MedLine.d45.s2|4-12|evaluated|O
DDI-MedLine.d45.s2|14-15|as|O
DDI-MedLine.d45.s2|17-17|a|O
DDI-MedLine.d45.s2|19-26|possible|O
DDI-MedLine.d45.s2|28-38|explanation|O
DDI-MedLine.d45.s2|40-42|for|O
DDI-MedLine.d45.s2|44-46|the|O
DDI-MedLine.d45.s2|48-58|association|O
DDI-MedLine.d45.s2|60-61|of|O
DDI-MedLine.d45.s2|63-73|deep-seated|O
DDI-MedLine.d45.s2|75-83|infection|O
DDI-MedLine.d45.s2|85-88|with|O
DDI-MedLine.d45.s2|90-93|this|O
DDI-MedLine.d45.s2|95-102|organism|O
DDI-MedLine.d45.s2|104-106|and|O
DDI-MedLine.d45.s2|108-112|abuse|O
DDI-MedLine.d45.s2|114-115|of|O
DDI-MedLine.d45.s2|117-121|these|O
DDI-MedLine.d45.s2|123-127|drugs|O
DDI-MedLine.d45.s2|128-128|.|O
DDI-MedLine.d45.s3|0-2|The|O
DDI-MedLine.d45.s3|4-7|mean|O
DDI-MedLine.d45.s3|9-17|reduction|O
DDI-MedLine.d45.s3|19-20|of|O
DDI-MedLine.d45.s3|22-27|growth|O
DDI-MedLine.d45.s3|29-34|caused|O
DDI-MedLine.d45.s3|36-37|by|O
DDI-MedLine.d45.s3|39-41|the|O
DDI-MedLine.d45.s3|43-47|drugs|O
DDI-MedLine.d45.s3|49-51|was|O
DDI-MedLine.d45.s3|53-62|1,000-fold|O
DDI-MedLine.d45.s3|64-70|greater|O
DDI-MedLine.d45.s3|72-74|for|O
DDI-MedLine.d45.s3|76-77|49|O
DDI-MedLine.d45.s3|79-89|Pseudomonas|O
DDI-MedLine.d45.s3|91-97|strains|O
DDI-MedLine.d45.s3|99-102|from|O
DDI-MedLine.d45.s3|104-109|normal|O
DDI-MedLine.d45.s3|111-118|subjects|O
DDI-MedLine.d45.s3|120-123|than|O
DDI-MedLine.d45.s3|125-127|for|O
DDI-MedLine.d45.s3|129-130|32|O
DDI-MedLine.d45.s3|132-138|strains|O
DDI-MedLine.d45.s3|140-143|from|O
DDI-MedLine.d45.s3|145-148|drug|O
DDI-MedLine.d45.s3|150-156|addicts|O
DDI-MedLine.d45.s3|158-158|(|O
DDI-MedLine.d45.s3|159-161|4.2|O
DDI-MedLine.d45.s3|163-165|vs.|O
DDI-MedLine.d45.s3|167-169|1.3|O
DDI-MedLine.d45.s3|171-174|logs|O
DDI-MedLine.d45.s3|176-177|of|O
DDI-MedLine.d45.s3|179-187|reduction|O
DDI-MedLine.d45.s3|189-190|at|O
DDI-MedLine.d45.s3|192-192|2|O
DDI-MedLine.d45.s3|194-195|hr|O
DDI-MedLine.d45.s3|196-196|,|O
DDI-MedLine.d45.s3|198-198|P|O
DDI-MedLine.d45.s3|200-203|less|O
DDI-MedLine.d45.s3|205-208|than|O
DDI-MedLine.d45.s3|210-214|.0005|O
DDI-MedLine.d45.s3|215-215|)|O
DDI-MedLine.d45.s3|216-216|.|O
DDI-MedLine.d45.s4|0-0|A|O
DDI-MedLine.d45.s4|2-7|common|O
DDI-MedLine.d45.s4|9-18|phenotypic|O
DDI-MedLine.d45.s4|20-25|subset|O
DDI-MedLine.d45.s4|27-28|of|O
DDI-MedLine.d45.s4|30-32|the|O
DDI-MedLine.d45.s4|34-41|serotype|O
DDI-MedLine.d45.s4|43-45|O11|O
DDI-MedLine.d45.s4|47-53|strains|O
DDI-MedLine.d45.s4|55-58|from|O
DDI-MedLine.d45.s4|60-63|drug|O
DDI-MedLine.d45.s4|65-71|addicts|O
DDI-MedLine.d45.s4|73-75|was|O
DDI-MedLine.d45.s4|77-86|especially|O
DDI-MedLine.d45.s4|88-96|resistant|O
DDI-MedLine.d45.s4|98-99|to|O
DDI-MedLine.d45.s4|101-103|the|O
DDI-MedLine.d45.s4|105-114|inhibitory|O
DDI-MedLine.d45.s4|116-122|effects|O
DDI-MedLine.d45.s4|123-123|.|O
DDI-MedLine.d45.s5|0-5|Twelve|O
DDI-MedLine.d45.s5|7-13|strains|O
DDI-MedLine.d45.s5|15-16|of|O
DDI-MedLine.d45.s5|18-31|Staphylococcus|O
DDI-MedLine.d45.s5|33-38|aureus|O
DDI-MedLine.d45.s5|40-40|(|O
DDI-MedLine.d45.s5|41-41|a|O
DDI-MedLine.d45.s5|43-50|frequent|O
DDI-MedLine.d45.s5|52-56|cause|O
DDI-MedLine.d45.s5|58-59|of|O
DDI-MedLine.d45.s5|61-69|infection|O
DDI-MedLine.d45.s5|71-72|in|O
DDI-MedLine.d45.s5|80-80|,|O
DDI-MedLine.d45.s5|82-84|but|O
DDI-MedLine.d45.s5|86-88|not|O
DDI-MedLine.d45.s5|90-91|in|O
DDI-MedLine.d45.s5|93-103|pentazocine|drug
DDI-MedLine.d45.s5|105-107|and|O
DDI-MedLine.d45.s5|109-122|tripelennamine|drug
DDI-MedLine.d45.s5|123-123|,|O
DDI-MedLine.d45.s5|125-131|addicts|O
DDI-MedLine.d45.s5|132-132|)|O
DDI-MedLine.d45.s5|134-137|were|O
DDI-MedLine.d45.s5|139-148|completely|O
DDI-MedLine.d45.s5|150-158|inhibited|O
DDI-MedLine.d45.s5|160-161|by|O
DDI-MedLine.d45.s5|163-165|the|O
DDI-MedLine.d45.s5|167-170|drug|O
DDI-MedLine.d45.s5|172-182|combination|O
DDI-MedLine.d45.s5|183-183|.|O
DDI-MedLine.d45.s6|0-12|Dose-response|O
DDI-MedLine.d45.s6|14-19|curves|O
DDI-MedLine.d45.s6|21-21|(|O
DDI-MedLine.d45.s6|22-28|derived|O
DDI-MedLine.d45.s6|30-33|from|O
DDI-MedLine.d45.s6|35-37|the|O
DDI-MedLine.d45.s6|39-45|results|O
DDI-MedLine.d45.s6|47-48|of|O
DDI-MedLine.d45.s6|50-54|using|O
DDI-MedLine.d45.s6|56-58|the|O
DDI-MedLine.d45.s6|60-66|tablets|O
DDI-MedLine.d45.s6|68-69|as|O
DDI-MedLine.d45.s6|71-74|well|O
DDI-MedLine.d45.s6|76-77|as|O
DDI-MedLine.d45.s6|79-82|pure|O
DDI-MedLine.d45.s6|84-90|powders|O
DDI-MedLine.d45.s6|91-91|)|O
DDI-MedLine.d45.s6|93-98|showed|O
DDI-MedLine.d45.s6|100-103|that|O
DDI-MedLine.d45.s6|105-118|tripelennamine|drug
DDI-MedLine.d45.s6|120-122|was|O
DDI-MedLine.d45.s6|124-134|responsible|O
DDI-MedLine.d45.s6|136-138|for|O
DDI-MedLine.d45.s6|140-142|the|O
DDI-MedLine.d45.s6|144-153|inhibitory|O
DDI-MedLine.d45.s6|155-162|activity|O
DDI-MedLine.d45.s6|163-163|,|O
DDI-MedLine.d45.s6|165-169|which|O
DDI-MedLine.d45.s6|171-173|was|O
DDI-MedLine.d45.s6|175-183|partially|O
DDI-MedLine.d45.s6|185-195|antagonized|O
DDI-MedLine.d45.s6|197-198|by|O
DDI-MedLine.d45.s6|200-210|pentazocine|drug
DDI-MedLine.d45.s6|211-211|.|O
DDI-MedLine.d45.s7|0-1|We|O
DDI-MedLine.d45.s7|3-10|conclude|O
DDI-MedLine.d45.s7|12-15|that|O
DDI-MedLine.d45.s7|17-18|an|O
DDI-MedLine.d45.s7|20-26|ability|O
DDI-MedLine.d45.s7|28-29|of|O
DDI-MedLine.d45.s7|31-34|some|O
DDI-MedLine.d45.s7|36-36|P|O
DDI-MedLine.d45.s7|37-37|.|O
DDI-MedLine.d45.s8|0-9|aeruginosa|O
DDI-MedLine.d45.s8|11-18|serotype|O
DDI-MedLine.d45.s8|20-22|O11|O
DDI-MedLine.d45.s8|24-30|strains|O
DDI-MedLine.d45.s8|31-31|,|O
DDI-MedLine.d45.s8|33-35|but|O
DDI-MedLine.d45.s8|37-39|not|O
DDI-MedLine.d45.s8|41-41|S|O
DDI-MedLine.d45.s8|42-42|.|O
DDI-MedLine.d45.s9|0-5|aureus|O
DDI-MedLine.d45.s9|6-6|,|O
DDI-MedLine.d45.s9|8-9|to|O
DDI-MedLine.d45.s9|11-17|survive|O
DDI-MedLine.d45.s9|19-20|in|O
DDI-MedLine.d45.s9|22-32|pentazocine|drug
DDI-MedLine.d45.s9|34-36|and|O
DDI-MedLine.d45.s9|38-51|tripelennamine|drug
DDI-MedLine.d45.s9|53-55|may|O
DDI-MedLine.d45.s9|57-63|explain|O
DDI-MedLine.d45.s9|65-66|in|O
DDI-MedLine.d45.s9|68-71|part|O
DDI-MedLine.d45.s9|73-73|a|O
DDI-MedLine.d45.s9|75-79|shift|O
DDI-MedLine.d45.s9|81-84|from|O
DDI-MedLine.d45.s9|86-86|S|O
DDI-MedLine.d45.s9|87-87|.|O
DDI-MedLine.d45.s10|0-5|aureus|O
DDI-MedLine.d45.s10|7-8|to|O
DDI-MedLine.d45.s10|10-10|P|O
DDI-MedLine.d45.s10|11-11|.|O
DDI-MedLine.d45.s11|0-9|aeruginosa|O
DDI-MedLine.d45.s11|11-12|as|O
DDI-MedLine.d45.s11|14-19|common|O
DDI-MedLine.d45.s11|21-29|pathogens|O
DDI-MedLine.d45.s11|31-32|of|O
DDI-MedLine.d45.s11|34-37|drug|O
DDI-MedLine.d45.s11|39-45|addicts|O
DDI-MedLine.d45.s11|47-48|in|O
DDI-MedLine.d45.s11|50-54|areas|O
DDI-MedLine.d45.s11|56-60|where|O
DDI-MedLine.d45.s11|62-66|abuse|O
DDI-MedLine.d45.s11|68-69|of|O
DDI-MedLine.d45.s11|71-74|this|O
DDI-MedLine.d45.s11|76-86|combination|O
DDI-MedLine.d45.s11|88-89|of|O
DDI-MedLine.d45.s11|91-95|drugs|O
DDI-MedLine.d45.s11|97-99|has|O
DDI-MedLine.d45.s11|101-109|increased|O
DDI-MedLine.d45.s11|110-110|.|O
DDI-DrugBank.d112.s0|0-9|Concurrent|O
DDI-DrugBank.d112.s0|11-13|use|O
DDI-DrugBank.d112.s0|15-18|with|O
DDI-DrugBank.d112.s0|20-29|probenecid|drug
DDI-DrugBank.d112.s0|31-32|or|O
DDI-DrugBank.d112.s0|34-38|other|O
DDI-DrugBank.d112.s0|40-44|drugs|O
DDI-DrugBank.d112.s0|46-58|significantly|O
DDI-DrugBank.d112.s0|60-69|eliminated|O
DDI-DrugBank.d112.s0|71-72|by|O
DDI-DrugBank.d112.s0|74-79|active|O
DDI-DrugBank.d112.s0|81-85|renal|O
DDI-DrugBank.d112.s0|87-93|tubular|O
DDI-DrugBank.d112.s0|95-103|secretion|O
DDI-DrugBank.d112.s0|105-107|may|O
DDI-DrugBank.d112.s0|109-114|result|O
DDI-DrugBank.d112.s0|116-117|in|O
DDI-DrugBank.d112.s0|119-127|increased|O
DDI-DrugBank.d112.s0|129-134|plasma|O
DDI-DrugBank.d112.s0|136-149|concentrations|O
DDI-DrugBank.d112.s0|151-152|of|O
DDI-DrugBank.d112.s0|154-164|penciclovir|drug
DDI-DrugBank.d112.s0|165-165|.|O
DDI-DrugBank.d112.s1|0-2|The|O
DDI-DrugBank.d112.s1|4-13|conversion|O
DDI-DrugBank.d112.s1|15-16|of|O
DDI-DrugBank.d112.s1|38-39|to|O
DDI-DrugBank.d112.s1|41-51|penciclovir|drug
DDI-DrugBank.d112.s1|53-54|is|O
DDI-DrugBank.d112.s1|56-64|catalyzed|O
DDI-DrugBank.d112.s1|66-67|by|O
DDI-DrugBank.d112.s1|69-76|aldehyde|O
DDI-DrugBank.d112.s1|78-84|oxidase|O
DDI-DrugBank.d112.s1|85-85|.|O
DDI-DrugBank.d112.s2|0-11|Interactions|O
DDI-DrugBank.d112.s2|13-16|with|O
DDI-DrugBank.d112.s2|18-22|other|O
DDI-DrugBank.d112.s2|24-28|drugs|O
DDI-DrugBank.d112.s2|30-40|metabolized|O
DDI-DrugBank.d112.s2|42-43|by|O
DDI-DrugBank.d112.s2|45-48|this|O
DDI-DrugBank.d112.s2|50-55|enzyme|O
DDI-DrugBank.d112.s2|57-61|could|O
DDI-DrugBank.d112.s2|63-73|potentially|O
DDI-DrugBank.d112.s2|75-79|occur|O
DDI-DrugBank.d112.s2|80-80|.|O
DDI-DrugBank.d651.s0|0-3|Drug|O
DDI-DrugBank.d651.s0|5-16|Interactions|O
DDI-DrugBank.d651.s0|17-17|:|O
DDI-DrugBank.d651.s0|19-23|Women|O
DDI-DrugBank.d651.s0|25-26|on|O
DDI-DrugBank.d651.s0|28-31|oral|O
DDI-DrugBank.d651.s0|33-46|contraceptives|group
DDI-DrugBank.d651.s0|48-51|have|O
DDI-DrugBank.d651.s0|53-57|shown|O
DDI-DrugBank.d651.s0|59-59|a|O
DDI-DrugBank.d651.s0|61-71|significant|O
DDI-DrugBank.d651.s0|73-80|increase|O
DDI-DrugBank.d651.s0|82-83|in|O
DDI-DrugBank.d651.s0|85-90|plasma|O
DDI-DrugBank.d651.s0|92-100|vitamin A|group
DDI-DrugBank.d651.s0|102-107|levels|O
DDI-DrugBank.d651.s0|108-108|.|O
DDI-DrugBank.d156.s0|0-3|None|O
DDI-DrugBank.d156.s0|5-12|Reported|O
DDI-MedLine.d137.s0|0-6|Glucose|drug
DDI-MedLine.d137.s0|8-10|and|O
DDI-MedLine.d137.s0|12-18|insulin|drug
DDI-MedLine.d137.s0|20-24|exert|O
DDI-MedLine.d137.s0|26-33|additive|O
DDI-MedLine.d137.s0|35-40|ocular|O
DDI-MedLine.d137.s0|42-44|and|O
DDI-MedLine.d137.s0|46-50|renal|O
DDI-MedLine.d137.s0|52-62|vasodilator|O
DDI-MedLine.d137.s0|64-70|effects|O
DDI-MedLine.d137.s0|72-73|on|O
DDI-MedLine.d137.s0|75-81|healthy|O
DDI-MedLine.d137.s0|83-88|humans|O
DDI-MedLine.d137.s0|89-89|.|O
DDI-MedLine.d137.s1|0-14|AIMS/HYPOTHESIS|O
DDI-MedLine.d137.s1|15-15|:|O
DDI-MedLine.d137.s1|17-21|There|O
DDI-MedLine.d137.s1|23-24|is|O
DDI-MedLine.d137.s1|26-33|evidence|O
DDI-MedLine.d137.s1|35-38|that|O
DDI-MedLine.d137.s1|40-46|insulin|drug
DDI-MedLine.d137.s1|48-50|and|O
DDI-MedLine.d137.s1|52-58|glucose|drug
DDI-MedLine.d137.s1|60-64|cause|O
DDI-MedLine.d137.s1|66-70|renal|O
DDI-MedLine.d137.s1|72-74|and|O
DDI-MedLine.d137.s1|76-81|ocular|O
DDI-MedLine.d137.s1|83-94|vasodilation|O
DDI-MedLine.d137.s1|95-95|.|O
DDI-MedLine.d137.s2|0-4|There|O
DDI-MedLine.d137.s2|6-7|is|O
DDI-MedLine.d137.s2|8-8|,|O
DDI-MedLine.d137.s2|10-16|however|O
DDI-MedLine.d137.s2|17-17|,|O
DDI-MedLine.d137.s2|19-27|currently|O
DDI-MedLine.d137.s2|29-30|no|O
DDI-MedLine.d137.s2|32-35|data|O
DDI-MedLine.d137.s2|37-38|on|O
DDI-MedLine.d137.s2|40-42|the|O
DDI-MedLine.d137.s2|44-49|effect|O
DDI-MedLine.d137.s2|51-52|of|O
DDI-MedLine.d137.s2|54-61|combined|O
DDI-MedLine.d137.s2|63-76|hyperglycaemia|O
DDI-MedLine.d137.s2|78-80|and|O
DDI-MedLine.d137.s2|82-98|hyperinsulinaemia|O
DDI-MedLine.d137.s2|100-101|on|O
DDI-MedLine.d137.s2|103-105|the|O
DDI-MedLine.d137.s2|107-111|renal|O
DDI-MedLine.d137.s2|113-115|and|O
DDI-MedLine.d137.s2|117-122|ocular|O
DDI-MedLine.d137.s2|124-128|blood|O
DDI-MedLine.d137.s2|130-133|flow|O
DDI-MedLine.d137.s2|135-138|seen|O
DDI-MedLine.d137.s2|140-141|in|O
DDI-MedLine.d137.s2|143-150|diabetic|O
DDI-MedLine.d137.s2|152-159|patients|O
DDI-MedLine.d137.s2|161-162|on|O
DDI-MedLine.d137.s2|164-170|insulin|O
DDI-MedLine.d137.s2|172-178|therapy|O
DDI-MedLine.d137.s2|179-179|.|O
DDI-MedLine.d137.s3|0-6|METHODS|O
DDI-MedLine.d137.s3|7-7|:|O
DDI-MedLine.d137.s3|9-10|We|O
DDI-MedLine.d137.s3|12-18|carried|O
DDI-MedLine.d137.s3|20-22|out|O
DDI-MedLine.d137.s3|24-26|two|O
DDI-MedLine.d137.s3|28-36|different|O
DDI-MedLine.d137.s3|38-42|3-way|O
DDI-MedLine.d137.s3|44-52|crossover|O
DDI-MedLine.d137.s3|54-60|studies|O
DDI-MedLine.d137.s3|62-63|in|O
DDI-MedLine.d137.s3|65-71|healthy|O
DDI-MedLine.d137.s3|73-80|subjects|O
DDI-MedLine.d137.s3|82-82|(|O
DDI-MedLine.d137.s3|83-86|each|O
DDI-MedLine.d137.s3|87-87|,|O
DDI-MedLine.d137.s3|89-89|n|O
DDI-MedLine.d137.s3|91-91|=|O
DDI-MedLine.d137.s3|93-93|9|O
DDI-MedLine.d137.s3|94-94|)|O
DDI-MedLine.d137.s3|95-95|.|O
DDI-MedLine.d137.s4|0-1|In|O
DDI-MedLine.d137.s4|3-7|study|O
DDI-MedLine.d137.s4|9-11|one|O
DDI-MedLine.d137.s4|12-12|,|O
DDI-MedLine.d137.s4|14-27|hyperglycaemic|O
DDI-MedLine.d137.s4|29-34|clamps|O
DDI-MedLine.d137.s4|36-36|(|O
DDI-MedLine.d137.s4|37-39|5.6|O
DDI-MedLine.d137.s4|41-46|mmol/l|O
DDI-MedLine.d137.s4|47-47|,|O
DDI-MedLine.d137.s4|49-52|11.1|O
DDI-MedLine.d137.s4|54-58|mmol/|O
DDI-MedLine.d137.s4|60-60|1|O
DDI-MedLine.d137.s4|61-61|,|O
DDI-MedLine.d137.s4|63-66|16.7|O
DDI-MedLine.d137.s4|68-73|mmol/l|O
DDI-MedLine.d137.s4|74-74|)|O
DDI-MedLine.d137.s4|76-79|were|O
DDI-MedLine.d137.s4|81-87|carried|O
DDI-MedLine.d137.s4|89-91|out|O
DDI-MedLine.d137.s4|93-98|during|O
DDI-MedLine.d137.s4|100-106|placebo|O
DDI-MedLine.d137.s4|108-109|or|O
DDI-MedLine.d137.s4|111-117|insulin|drug
DDI-MedLine.d137.s4|119-119|(|O
DDI-MedLine.d137.s4|120-123|dose|O
DDI-MedLine.d137.s4|125-125|1|O
DDI-MedLine.d137.s4|126-126|:|O
DDI-MedLine.d137.s4|128-128|1|O
DDI-MedLine.d137.s4|130-138|mU/kg/min|O
DDI-MedLine.d137.s4|139-139|;|O
DDI-MedLine.d137.s4|141-144|dose|O
DDI-MedLine.d137.s4|146-146|2|O
DDI-MedLine.d137.s4|147-147|:|O
DDI-MedLine.d137.s4|149-149|2|O
DDI-MedLine.d137.s4|151-159|mU/kg/min|O
DDI-MedLine.d137.s4|160-160|)|O
DDI-MedLine.d137.s4|162-169|infusion|O
DDI-MedLine.d137.s4|170-170|.|O
DDI-MedLine.d137.s5|0-2|The|O
DDI-MedLine.d137.s5|4-9|second|O
DDI-MedLine.d137.s5|11-15|study|O
DDI-MedLine.d137.s5|17-19|was|O
DDI-MedLine.d137.s5|21-29|identical|O
DDI-MedLine.d137.s5|31-33|but|O
DDI-MedLine.d137.s5|35-44|endogenous|O
DDI-MedLine.d137.s5|46-52|insulin|O
DDI-MedLine.d137.s5|54-62|secretion|O
DDI-MedLine.d137.s5|64-66|was|O
DDI-MedLine.d137.s5|68-74|blocked|O
DDI-MedLine.d137.s5|76-79|with|O
DDI-MedLine.d137.s5|81-92|somatostatin|drug
DDI-MedLine.d137.s5|93-93|.|O
DDI-MedLine.d137.s6|0-2|The|O
DDI-MedLine.d137.s6|4-8|renal|O
DDI-MedLine.d137.s6|10-15|plasma|O
DDI-MedLine.d137.s6|17-20|flow|O
DDI-MedLine.d137.s6|21-21|,|O
DDI-MedLine.d137.s6|23-32|glomerular|O
DDI-MedLine.d137.s6|34-43|filtration|O
DDI-MedLine.d137.s6|45-48|rate|O
DDI-MedLine.d137.s6|50-52|and|O
DDI-MedLine.d137.s6|54-62|pulsatile|O
DDI-MedLine.d137.s6|64-72|choroidal|O
DDI-MedLine.d137.s6|74-78|blood|O
DDI-MedLine.d137.s6|80-83|flow|O
DDI-MedLine.d137.s6|85-88|were|O
DDI-MedLine.d137.s6|90-97|measured|O
DDI-MedLine.d137.s6|99-103|using|O
DDI-MedLine.d137.s6|105-107|the|O
DDI-MedLine.d137.s6|109-126|paraaminohippurate|O
DDI-MedLine.d137.s6|128-133|method|O
DDI-MedLine.d137.s6|134-134|,|O
DDI-MedLine.d137.s6|136-138|the|O
DDI-MedLine.d137.s6|140-145|inulin|O
DDI-MedLine.d137.s6|147-152|method|O
DDI-MedLine.d137.s6|154-156|and|O
DDI-MedLine.d137.s6|158-158|a|O
DDI-MedLine.d137.s6|160-164|laser|O
DDI-MedLine.d137.s6|166-180|interferometric|O
DDI-MedLine.d137.s6|182-192|measurement|O
DDI-MedLine.d137.s6|194-195|of|O
DDI-MedLine.d137.s6|197-202|fundus|O
DDI-MedLine.d137.s6|204-212|pulsation|O
DDI-MedLine.d137.s6|214-222|amplitude|O
DDI-MedLine.d137.s6|223-223|,|O
DDI-MedLine.d137.s6|225-236|respectively|O
DDI-MedLine.d137.s6|237-237|.|O
DDI-MedLine.d137.s7|0-6|RESULTS|O
DDI-MedLine.d137.s7|7-7|:|O
DDI-MedLine.d137.s7|9-15|Insulin|drug
DDI-MedLine.d137.s7|17-25|increased|O
DDI-MedLine.d137.s7|27-31|renal|O
DDI-MedLine.d137.s7|33-38|plasma|O
DDI-MedLine.d137.s7|40-43|flow|O
DDI-MedLine.d137.s7|45-47|and|O
DDI-MedLine.d137.s7|49-54|fundus|O
DDI-MedLine.d137.s7|56-64|pulsation|O
DDI-MedLine.d137.s7|66-74|amplitude|O
DDI-MedLine.d137.s7|76-78|but|O
DDI-MedLine.d137.s7|80-82|not|O
DDI-MedLine.d137.s7|84-86|the|O
DDI-MedLine.d137.s7|88-97|glomerular|O
DDI-MedLine.d137.s7|99-108|filtration|O
DDI-MedLine.d137.s7|110-113|rate|O
DDI-MedLine.d137.s7|114-114|.|O
DDI-MedLine.d137.s8|0-13|Hyperglycaemia|O
DDI-MedLine.d137.s8|15-23|increased|O
DDI-MedLine.d137.s8|25-27|all|O
DDI-MedLine.d137.s8|29-31|the|O
DDI-MedLine.d137.s8|33-37|renal|O
DDI-MedLine.d137.s8|39-41|and|O
DDI-MedLine.d137.s8|43-48|ocular|O
DDI-MedLine.d137.s8|50-59|parameters|O
DDI-MedLine.d137.s8|61-67|studied|O
DDI-MedLine.d137.s8|68-68|.|O
DDI-MedLine.d137.s9|0-11|Haemodynamic|O
DDI-MedLine.d137.s9|13-19|effects|O
DDI-MedLine.d137.s9|21-22|of|O
DDI-MedLine.d137.s9|24-30|glucose|drug
DDI-MedLine.d137.s9|32-34|and|O
DDI-MedLine.d137.s9|36-42|insulin|drug
DDI-MedLine.d137.s9|44-47|were|O
DDI-MedLine.d137.s9|49-56|additive|O
DDI-MedLine.d137.s9|58-61|when|O
DDI-MedLine.d137.s9|63-74|somatostatin|drug
DDI-MedLine.d137.s9|76-78|was|O
DDI-MedLine.d137.s9|80-94|co-administered|O
DDI-MedLine.d137.s9|96-98|but|O
DDI-MedLine.d137.s9|100-102|not|O
DDI-MedLine.d137.s9|104-108|under|O
DDI-MedLine.d137.s9|110-114|basal|O
DDI-MedLine.d137.s9|116-125|conditions|O
DDI-MedLine.d137.s9|126-126|.|O
DDI-MedLine.d137.s10|0-25|CONCLUSIONS/INTERPRETATION|O
DDI-MedLine.d137.s10|26-26|:|O
DDI-MedLine.d137.s10|28-34|Glucose|drug
DDI-MedLine.d137.s10|36-38|and|O
DDI-MedLine.d137.s10|40-46|insulin|drug
DDI-MedLine.d137.s10|48-50|can|O
DDI-MedLine.d137.s10|52-56|exert|O
DDI-MedLine.d137.s10|58-65|additive|O
DDI-MedLine.d137.s10|67-77|vasodilator|O
DDI-MedLine.d137.s10|79-88|properties|O
DDI-MedLine.d137.s10|90-91|on|O
DDI-MedLine.d137.s10|93-97|renal|O
DDI-MedLine.d137.s10|99-101|and|O
DDI-MedLine.d137.s10|103-108|ocular|O
DDI-MedLine.d137.s10|110-120|circulation|O
DDI-MedLine.d137.s10|121-121|.|O
DDI-MedLine.d137.s11|0-1|To|O
DDI-MedLine.d137.s11|3-6|find|O
DDI-MedLine.d137.s11|8-10|out|O
DDI-MedLine.d137.s11|12-18|whether|O
DDI-MedLine.d137.s11|20-23|this|O
DDI-MedLine.d137.s11|25-35|observation|O
DDI-MedLine.d137.s11|37-38|is|O
DDI-MedLine.d137.s11|40-46|related|O
DDI-MedLine.d137.s11|48-49|to|O
DDI-MedLine.d137.s11|51-53|the|O
DDI-MedLine.d137.s11|55-63|increased|O
DDI-MedLine.d137.s11|65-72|regional|O
DDI-MedLine.d137.s11|74-82|perfusion|O
DDI-MedLine.d137.s11|84-85|in|O
DDI-MedLine.d137.s11|87-94|diabetes|O
DDI-MedLine.d137.s11|96-107|longitudinal|O
DDI-MedLine.d137.s11|109-115|studies|O
DDI-MedLine.d137.s11|117-118|on|O
DDI-MedLine.d137.s11|120-127|patients|O
DDI-MedLine.d137.s11|129-132|with|O
DDI-MedLine.d137.s11|134-137|Type|O
DDI-MedLine.d137.s11|139-139|I|O
DDI-MedLine.d137.s11|141-141|(|O
DDI-MedLine.d137.s11|142-158|insulin-dependent|O
DDI-MedLine.d137.s11|159-159|)|O
DDI-MedLine.d137.s11|161-168|diabetes|O
DDI-MedLine.d137.s11|170-177|mellitus|O
DDI-MedLine.d137.s11|179-181|are|O
DDI-MedLine.d137.s11|183-188|needed|O
DDI-MedLine.d137.s11|189-189|.|O
DDI-DrugBank.d74.s0|0-8|FLUOTHANE|brand
DDI-DrugBank.d74.s0|10-17|augments|O
DDI-DrugBank.d74.s0|19-21|the|O
DDI-DrugBank.d74.s0|23-28|action|O
DDI-DrugBank.d74.s0|30-31|of|O
DDI-DrugBank.d74.s0|33-55|non-depolarising muscle|group
DDI-DrugBank.d74.s0|57-65|relaxants|O
DDI-DrugBank.d74.s0|67-69|and|O
DDI-DrugBank.d74.s0|71-73|the|O
DDI-DrugBank.d74.s0|75-80|muscle|O
DDI-DrugBank.d74.s0|82-89|relaxant|O
DDI-DrugBank.d74.s0|91-97|effects|O
DDI-DrugBank.d74.s0|99-100|of|O
DDI-DrugBank.d74.s0|102-116|aminoglycosides|group
DDI-DrugBank.d74.s0|117-117|.|O
DDI-DrugBank.d74.s1|0-8|FLUOTHANE|brand
DDI-DrugBank.d74.s1|10-12|may|O
DDI-DrugBank.d74.s1|14-20|augment|O
DDI-DrugBank.d74.s1|22-24|the|O
DDI-DrugBank.d74.s1|26-36|hypotension|O
DDI-DrugBank.d74.s1|38-43|caused|O
DDI-DrugBank.d74.s1|45-46|by|O
DDI-DrugBank.d74.s1|48-50|the|O
DDI-DrugBank.d74.s1|52-70|ganglionic-blocking|O
DDI-DrugBank.d74.s1|72-77|effect|O
DDI-DrugBank.d74.s1|79-80|of|O
DDI-DrugBank.d74.s1|82-93|tubocurarine|drug
DDI-DrugBank.d74.s1|94-94|.|O
DDI-DrugBank.d74.s2|0-6|Caution|O
DDI-DrugBank.d74.s2|8-13|should|O
DDI-DrugBank.d74.s2|15-16|be|O
DDI-DrugBank.d74.s2|18-26|exercised|O
DDI-DrugBank.d74.s2|28-33|during|O
DDI-DrugBank.d74.s2|35-37|the|O
DDI-DrugBank.d74.s2|39-52|administration|O
DDI-DrugBank.d74.s2|54-55|of|O
DDI-DrugBank.d74.s2|57-66|adrenaline|drug
DDI-DrugBank.d74.s2|68-69|to|O
DDI-DrugBank.d74.s2|71-78|patients|O
DDI-DrugBank.d74.s2|80-92|anaesthetised|O
DDI-DrugBank.d74.s2|94-97|with|O
DDI-DrugBank.d74.s2|99-107|FLUOTHANE|brand
DDI-DrugBank.d74.s2|109-110|as|O
DDI-DrugBank.d74.s2|112-122|arrhythmias|O
DDI-DrugBank.d74.s2|124-126|may|O
DDI-DrugBank.d74.s2|128-129|be|O
DDI-DrugBank.d74.s2|131-142|precipitated|O
DDI-DrugBank.d74.s2|143-143|.|O
DDI-DrugBank.d74.s3|0-2|For|O
DDI-DrugBank.d74.s3|4-7|this|O
DDI-DrugBank.d74.s3|9-14|reason|O
DDI-DrugBank.d74.s3|16-18|the|O
DDI-DrugBank.d74.s3|20-23|dose|O
DDI-DrugBank.d74.s3|25-26|of|O
DDI-DrugBank.d74.s3|28-37|adrenaline|drug
DDI-DrugBank.d74.s3|39-44|should|O
DDI-DrugBank.d74.s3|46-47|be|O
DDI-DrugBank.d74.s3|49-58|restricted|O
DDI-DrugBank.d74.s3|60-62|and|O
DDI-DrugBank.d74.s3|64-65|an|O
DDI-DrugBank.d74.s3|67-86|antiarrhythmic agent|group
DDI-DrugBank.d74.s3|88-99|administered|O
DDI-DrugBank.d74.s3|101-102|as|O
DDI-DrugBank.d74.s3|104-114|appropriate|O
DDI-DrugBank.d74.s3|115-115|.|O
DDI-DrugBank.d74.s4|0-6|Caution|O
DDI-DrugBank.d74.s4|8-13|should|O
DDI-DrugBank.d74.s4|15-18|also|O
DDI-DrugBank.d74.s4|20-21|be|O
DDI-DrugBank.d74.s4|23-29|applied|O
DDI-DrugBank.d74.s4|31-33|for|O
DDI-DrugBank.d74.s4|35-39|other|O
DDI-DrugBank.d74.s4|41-56|sympathomimetics|group
DDI-DrugBank.d74.s4|57-57|,|O
DDI-DrugBank.d74.s4|59-61|and|O
DDI-DrugBank.d74.s4|63-65|for|O
DDI-DrugBank.d74.s4|67-79|aminophylline|drug
DDI-DrugBank.d74.s4|81-83|and|O
DDI-DrugBank.d74.s4|85-96|theophylline|drug
DDI-DrugBank.d74.s4|98-100|and|O
DDI-DrugBank.d74.s4|102-126|tricyclic antidepressants|group
DDI-DrugBank.d74.s4|127-127|,|O
DDI-DrugBank.d74.s4|129-133|which|O
DDI-DrugBank.d74.s4|135-137|may|O
DDI-DrugBank.d74.s4|139-142|also|O
DDI-DrugBank.d74.s4|144-154|precipitate|O
DDI-DrugBank.d74.s4|156-166|arrhythmias|O
DDI-DrugBank.d74.s4|167-167|.|O
DDI-DrugBank.d567.s0|0-5|CYP3A4|O
DDI-DrugBank.d567.s0|7-18|Interactions|O
DDI-DrugBank.d567.s1|0-9|Lovastatin|drug
DDI-DrugBank.d567.s1|11-12|is|O
DDI-DrugBank.d567.s1|14-24|metabolized|O
DDI-DrugBank.d567.s1|26-27|by|O
DDI-DrugBank.d567.s1|29-34|CYP3A4|O
DDI-DrugBank.d567.s1|36-38|but|O
DDI-DrugBank.d567.s1|40-42|has|O
DDI-DrugBank.d567.s1|44-45|no|O
DDI-DrugBank.d567.s1|47-52|CYP3A4|O
DDI-DrugBank.d567.s1|54-63|inhibitory|O
DDI-DrugBank.d567.s1|65-72|activity|O
DDI-DrugBank.d567.s1|73-73|;|O
DDI-DrugBank.d567.s2|0-8|therefore|O
DDI-DrugBank.d567.s2|10-11|it|O
DDI-DrugBank.d567.s2|13-14|is|O
DDI-DrugBank.d567.s2|16-18|not|O
DDI-DrugBank.d567.s2|20-27|expected|O
DDI-DrugBank.d567.s2|29-30|to|O
DDI-DrugBank.d567.s2|32-37|affect|O
DDI-DrugBank.d567.s2|39-41|the|O
DDI-DrugBank.d567.s2|43-48|plasma|O
DDI-DrugBank.d567.s2|50-63|concentrations|O
DDI-DrugBank.d567.s2|65-66|of|O
DDI-DrugBank.d567.s2|68-72|other|O
DDI-DrugBank.d567.s2|74-78|drugs|O
DDI-DrugBank.d567.s2|80-90|metabolized|O
DDI-DrugBank.d567.s2|92-93|by|O
DDI-DrugBank.d567.s2|95-100|CYP3A4|O
DDI-DrugBank.d567.s2|101-101|.|O
DDI-DrugBank.d567.s3|0-5|Potent|O
DDI-DrugBank.d567.s3|7-16|inhibitors|O
DDI-DrugBank.d567.s3|18-19|of|O
DDI-DrugBank.d567.s3|21-26|CYP3A4|O
DDI-DrugBank.d567.s3|28-28|(|O
DDI-DrugBank.d567.s3|29-33|below|O
DDI-DrugBank.d567.s3|34-34|)|O
DDI-DrugBank.d567.s3|36-43|increase|O
DDI-DrugBank.d567.s3|45-47|the|O
DDI-DrugBank.d567.s3|49-52|risk|O
DDI-DrugBank.d567.s3|54-55|of|O
DDI-DrugBank.d567.s3|57-64|myopathy|O
DDI-DrugBank.d567.s3|66-67|by|O
DDI-DrugBank.d567.s3|69-76|reducing|O
DDI-DrugBank.d567.s3|78-80|the|O
DDI-DrugBank.d567.s3|82-92|elimination|O
DDI-DrugBank.d567.s3|94-95|of|O
DDI-DrugBank.d567.s3|97-106|lovastatin|drug
DDI-DrugBank.d567.s3|107-107|.|O
DDI-DrugBank.d567.s4|0-15|Pharmacokinetics|O
DDI-DrugBank.d567.s4|16-16|.|O
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|0-11|Itraconazole|drug
DDI-DrugBank.d567.s5|72-90|protease inhibitors|group
DDI-DrugBank.d567.s5|72-90|protease inhibitors|group
DDI-DrugBank.d567.s5|72-90|protease inhibitors|group
DDI-DrugBank.d567.s5|116-120|Large|O
DDI-DrugBank.d567.s5|122-131|quantities|O
DDI-DrugBank.d567.s5|133-134|of|O
DDI-DrugBank.d567.s5|136-145|grapefruit|O
DDI-DrugBank.d567.s5|147-151|juice|O
DDI-DrugBank.d567.s5|153-153|(|O
DDI-DrugBank.d567.s5|155-155|1|O
DDI-DrugBank.d567.s5|157-161|quart|O
DDI-DrugBank.d567.s5|163-167|daily|O
DDI-DrugBank.d567.s5|168-168|)|O
DDI-DrugBank.d567.s6|0-11|Interactions|O
DDI-DrugBank.d567.s6|13-16|with|O
DDI-DrugBank.d567.s6|18-31|lipid-lowering|O
DDI-DrugBank.d567.s6|33-37|drugs|O
DDI-DrugBank.d567.s6|39-42|that|O
DDI-DrugBank.d567.s6|44-46|can|O
DDI-DrugBank.d567.s6|48-52|cause|O
DDI-DrugBank.d567.s6|54-61|myopathy|O
DDI-DrugBank.d567.s6|63-66|when|O
DDI-DrugBank.d567.s6|68-72|given|O
DDI-DrugBank.d567.s6|74-78|alone|O
DDI-DrugBank.d567.s6|79-79|.|O
DDI-DrugBank.d567.s7|0-2|The|O
DDI-DrugBank.d567.s7|4-7|risk|O
DDI-DrugBank.d567.s7|9-10|of|O
DDI-DrugBank.d567.s7|12-19|myopathy|O
DDI-DrugBank.d567.s7|21-22|is|O
DDI-DrugBank.d567.s7|24-27|also|O
DDI-DrugBank.d567.s7|29-37|increased|O
DDI-DrugBank.d567.s7|39-40|by|O
DDI-DrugBank.d567.s7|42-44|the|O
DDI-DrugBank.d567.s7|46-54|following|O
DDI-DrugBank.d567.s7|56-69|lipid-lowering|O
DDI-DrugBank.d567.s7|71-75|drugs|O
DDI-DrugBank.d567.s7|77-80|that|O
DDI-DrugBank.d567.s7|82-84|are|O
DDI-DrugBank.d567.s7|86-88|not|O
DDI-DrugBank.d567.s7|90-95|potent|O
DDI-DrugBank.d567.s7|97-102|CYP3A4|O
DDI-DrugBank.d567.s7|104-113|inhibitors|O
DDI-DrugBank.d567.s7|114-114|,|O
DDI-DrugBank.d567.s7|116-118|but|O
DDI-DrugBank.d567.s7|120-124|which|O
DDI-DrugBank.d567.s7|126-128|can|O
DDI-DrugBank.d567.s7|130-134|cause|O
DDI-DrugBank.d567.s7|136-143|myopathy|O
DDI-DrugBank.d567.s7|145-148|when|O
DDI-DrugBank.d567.s7|150-154|given|O
DDI-DrugBank.d567.s7|156-160|alone|O
DDI-DrugBank.d567.s7|161-161|.|O
DDI-DrugBank.d567.s8|0-2|See|O
DDI-DrugBank.d567.s8|4-11|WARNINGS|O
DDI-DrugBank.d567.s8|12-12|,|O
DDI-DrugBank.d567.s8|14-36|Myopathy/Rhabdomyolysis|O
DDI-DrugBank.d567.s8|37-37|.|O
DDI-DrugBank.d567.s9|0-10|Gemfibrozil|drug
DDI-DrugBank.d567.s9|12-16|Other|O
DDI-DrugBank.d567.s9|18-25|fibrates|group
DDI-DrugBank.d567.s9|18-25|fibrates|group
DDI-DrugBank.d567.s9|34-34|(|O
DDI-DrugBank.d567.s9|35-48|nicotinic acid|drug
DDI-DrugBank.d567.s9|49-49|)|O
DDI-DrugBank.d567.s9|51-51|(|O
DDI-DrugBank.d567.s9|52-53|=1|O
DDI-DrugBank.d567.s9|55-59|g/day|O
DDI-DrugBank.d567.s9|60-60|)|O
DDI-DrugBank.d567.s10|0-4|Other|O
DDI-DrugBank.d567.s10|6-9|drug|O
DDI-DrugBank.d567.s10|11-22|interactions|O
DDI-DrugBank.d567.s11|0-6|Danazol|drug
DDI-DrugBank.d567.s11|7-7|:|O
DDI-DrugBank.d567.s11|9-11|The|O
DDI-DrugBank.d567.s11|13-16|risk|O
DDI-DrugBank.d567.s11|18-19|of|O
DDI-DrugBank.d567.s11|21-43|myopathy/rhabdomyolysis|O
DDI-DrugBank.d567.s11|45-46|is|O
DDI-DrugBank.d567.s11|48-56|increased|O
DDI-DrugBank.d567.s11|58-59|by|O
DDI-DrugBank.d567.s11|61-71|concomitant|O
DDI-DrugBank.d567.s11|73-86|administration|O
DDI-DrugBank.d567.s11|88-89|of|O
DDI-DrugBank.d567.s11|91-97|danazol|drug
DDI-DrugBank.d567.s11|99-110|particularly|O
DDI-DrugBank.d567.s11|112-115|with|O
DDI-DrugBank.d567.s11|117-122|higher|O
DDI-DrugBank.d567.s11|124-128|doses|O
DDI-DrugBank.d567.s11|130-131|of|O
DDI-DrugBank.d567.s11|133-142|lovastatin|drug
DDI-DrugBank.d567.s11|144-144|(|O
DDI-DrugBank.d567.s11|145-147|see|O
DDI-DrugBank.d567.s11|149-156|WARNINGS|O
DDI-DrugBank.d567.s11|157-157|,|O
DDI-DrugBank.d567.s11|159-181|Myopathy/Rhabdomyolysis|O
DDI-DrugBank.d567.s11|182-182|)|O
DDI-DrugBank.d567.s11|183-183|.|O
DDI-DrugBank.d567.s12|0-9|Amiodarone|drug
DDI-DrugBank.d567.s12|11-12|or|O
DDI-DrugBank.d567.s12|14-22|Verapamil|drug
DDI-DrugBank.d567.s12|23-23|:|O
DDI-DrugBank.d567.s12|25-27|The|O
DDI-DrugBank.d567.s12|29-32|risk|O
DDI-DrugBank.d567.s12|34-35|of|O
DDI-DrugBank.d567.s12|37-59|myopathy/rhabdomyolysis|O
DDI-DrugBank.d567.s12|61-62|is|O
DDI-DrugBank.d567.s12|64-72|increased|O
DDI-DrugBank.d567.s12|74-77|when|O
DDI-DrugBank.d567.s12|79-84|either|O
DDI-DrugBank.d567.s12|86-95|amiodarone|drug
DDI-DrugBank.d567.s12|97-98|or|O
DDI-DrugBank.d567.s12|100-108|verapamil|drug
DDI-DrugBank.d567.s12|110-111|is|O
DDI-DrugBank.d567.s12|113-116|used|O
DDI-DrugBank.d567.s12|118-130|concomitantly|O
DDI-DrugBank.d567.s12|132-135|with|O
DDI-DrugBank.d567.s12|137-137|a|O
DDI-DrugBank.d567.s12|139-145|closely|O
DDI-DrugBank.d567.s12|147-153|related|O
DDI-DrugBank.d567.s12|155-160|member|O
DDI-DrugBank.d567.s12|162-163|of|O
DDI-DrugBank.d567.s12|165-167|the|O
DDI-DrugBank.d567.s12|169-201|HMG-CoA reductase inhibitor class|group
DDI-DrugBank.d567.s12|203-203|(|O
DDI-DrugBank.d567.s12|204-206|see|O
DDI-DrugBank.d567.s12|208-215|WARNINGS|O
DDI-DrugBank.d567.s12|216-216|,|O
DDI-DrugBank.d567.s12|218-240|Myopathy/Rhabdomyolysis|O
DDI-DrugBank.d567.s12|241-241|)|O
DDI-DrugBank.d567.s12|242-242|.|O
DDI-DrugBank.d567.s13|0-7|Coumarin|group
DDI-DrugBank.d567.s13|9-22|Anticoagulants|O
DDI-DrugBank.d567.s13|23-23|:|O
DDI-DrugBank.d567.s13|25-26|In|O
DDI-DrugBank.d567.s13|28-28|a|O
DDI-DrugBank.d567.s13|30-34|small|O
DDI-DrugBank.d567.s13|36-43|clinical|O
DDI-DrugBank.d567.s13|45-49|trial|O
DDI-DrugBank.d567.s13|51-52|in|O
DDI-DrugBank.d567.s13|54-58|which|O
DDI-DrugBank.d567.s13|60-69|lovastatin|drug
DDI-DrugBank.d567.s13|71-73|was|O
DDI-DrugBank.d567.s13|75-86|administered|O
DDI-DrugBank.d567.s13|88-89|to|O
DDI-DrugBank.d567.s13|91-98|warfarin|drug
DDI-DrugBank.d567.s13|100-106|treated|O
DDI-DrugBank.d567.s13|108-115|patients|O
DDI-DrugBank.d567.s13|116-116|,|O
DDI-DrugBank.d567.s13|118-119|no|O
DDI-DrugBank.d567.s13|121-126|effect|O
DDI-DrugBank.d567.s13|128-129|on|O
DDI-DrugBank.d567.s13|131-141|prothrombin|O
DDI-DrugBank.d567.s13|143-146|time|O
DDI-DrugBank.d567.s13|148-150|was|O
DDI-DrugBank.d567.s13|152-159|detected|O
DDI-DrugBank.d567.s13|160-160|.|O
DDI-DrugBank.d567.s14|0-6|However|O
DDI-DrugBank.d567.s14|7-7|,|O
DDI-DrugBank.d567.s14|9-15|another|O
DDI-DrugBank.d567.s14|17-43|HMG-CoA reductase inhibitor|group
DDI-DrugBank.d567.s14|45-47|has|O
DDI-DrugBank.d567.s14|49-52|been|O
DDI-DrugBank.d567.s14|54-58|found|O
DDI-DrugBank.d567.s14|60-61|to|O
DDI-DrugBank.d567.s14|63-69|produce|O
DDI-DrugBank.d567.s14|71-71|a|O
DDI-DrugBank.d567.s14|73-76|less|O
DDI-DrugBank.d567.s14|78-81|than|O
DDI-DrugBank.d567.s14|83-92|two-second|O
DDI-DrugBank.d567.s14|94-101|increase|O
DDI-DrugBank.d567.s14|103-104|in|O
DDI-DrugBank.d567.s14|106-116|prothrombin|O
DDI-DrugBank.d567.s14|118-121|time|O
DDI-DrugBank.d567.s14|123-124|in|O
DDI-DrugBank.d567.s14|126-132|healthy|O
DDI-DrugBank.d567.s14|134-143|volunteers|O
DDI-DrugBank.d567.s14|145-153|receiving|O
DDI-DrugBank.d567.s14|155-157|low|O
DDI-DrugBank.d567.s14|159-163|doses|O
DDI-DrugBank.d567.s14|165-166|of|O
DDI-DrugBank.d567.s14|168-175|warfarin|drug
DDI-DrugBank.d567.s14|176-176|.|O
DDI-DrugBank.d567.s15|0-3|Also|O
DDI-DrugBank.d567.s15|4-4|,|O
DDI-DrugBank.d567.s15|6-13|bleeding|O
DDI-DrugBank.d567.s15|15-20|and/or|O
DDI-DrugBank.d567.s15|22-30|increased|O
DDI-DrugBank.d567.s15|32-42|prothrombin|O
DDI-DrugBank.d567.s15|44-47|time|O
DDI-DrugBank.d567.s15|49-52|have|O
DDI-DrugBank.d567.s15|54-57|been|O
DDI-DrugBank.d567.s15|59-66|reported|O
DDI-DrugBank.d567.s15|68-69|in|O
DDI-DrugBank.d567.s15|71-71|a|O
DDI-DrugBank.d567.s15|73-75|few|O
DDI-DrugBank.d567.s15|77-84|patients|O
DDI-DrugBank.d567.s15|86-91|taking|O
DDI-DrugBank.d567.s15|93-100|coumarin|group
DDI-DrugBank.d567.s15|102-115|anticoagulants|O
DDI-DrugBank.d567.s15|117-129|concomitantly|O
DDI-DrugBank.d567.s15|131-134|with|O
DDI-DrugBank.d567.s15|136-145|lovastatin|drug
DDI-DrugBank.d567.s15|146-146|.|O
DDI-DrugBank.d567.s16|0-1|It|O
DDI-DrugBank.d567.s16|3-4|is|O
DDI-DrugBank.d567.s16|6-16|recommended|O
DDI-DrugBank.d567.s16|18-21|that|O
DDI-DrugBank.d567.s16|23-24|in|O
DDI-DrugBank.d567.s16|26-33|patients|O
DDI-DrugBank.d567.s16|35-40|taking|O
DDI-DrugBank.d567.s16|42-55|anticoagulants|group
DDI-DrugBank.d567.s16|56-56|,|O
DDI-DrugBank.d567.s16|58-68|prothrombin|O
DDI-DrugBank.d567.s16|70-73|time|O
DDI-DrugBank.d567.s16|75-76|be|O
DDI-DrugBank.d567.s16|78-87|determined|O
DDI-DrugBank.d567.s16|89-94|before|O
DDI-DrugBank.d567.s16|96-103|starting|O
DDI-DrugBank.d567.s16|105-114|lovastatin|drug
DDI-DrugBank.d567.s16|116-118|and|O
DDI-DrugBank.d567.s16|120-129|frequently|O
DDI-DrugBank.d567.s16|131-136|enough|O
DDI-DrugBank.d567.s16|138-143|during|O
DDI-DrugBank.d567.s16|145-149|early|O
DDI-DrugBank.d567.s16|151-157|therapy|O
DDI-DrugBank.d567.s16|159-160|to|O
DDI-DrugBank.d567.s16|162-167|insure|O
DDI-DrugBank.d567.s16|169-172|that|O
DDI-DrugBank.d567.s16|174-175|no|O
DDI-DrugBank.d567.s16|177-187|significant|O
DDI-DrugBank.d567.s16|189-198|alteration|O
DDI-DrugBank.d567.s16|200-201|of|O
DDI-DrugBank.d567.s16|203-213|prothrombin|O
DDI-DrugBank.d567.s16|215-218|time|O
DDI-DrugBank.d567.s16|220-225|occurs|O
DDI-DrugBank.d567.s16|226-226|.|O
DDI-DrugBank.d567.s17|0-3|Once|O
DDI-DrugBank.d567.s17|5-5|a|O
DDI-DrugBank.d567.s17|7-12|stable|O
DDI-DrugBank.d567.s17|14-24|prothrombin|O
DDI-DrugBank.d567.s17|26-29|time|O
DDI-DrugBank.d567.s17|31-33|has|O
DDI-DrugBank.d567.s17|35-38|been|O
DDI-DrugBank.d567.s17|40-49|documented|O
DDI-DrugBank.d567.s17|50-50|,|O
DDI-DrugBank.d567.s17|52-62|prothrombin|O
DDI-DrugBank.d567.s17|64-68|times|O
DDI-DrugBank.d567.s17|70-72|can|O
DDI-DrugBank.d567.s17|74-75|be|O
DDI-DrugBank.d567.s17|77-85|monitored|O
DDI-DrugBank.d567.s17|87-88|at|O
DDI-DrugBank.d567.s17|90-92|the|O
DDI-DrugBank.d567.s17|94-102|intervals|O
DDI-DrugBank.d567.s17|104-110|usually|O
DDI-DrugBank.d567.s17|112-122|recommended|O
DDI-DrugBank.d567.s17|124-126|for|O
DDI-DrugBank.d567.s17|128-135|patients|O
DDI-DrugBank.d567.s17|137-138|on|O
DDI-DrugBank.d567.s17|140-162|coumarin anticoagulants|group
DDI-DrugBank.d567.s17|163-163|.|O
DDI-DrugBank.d567.s18|0-1|If|O
DDI-DrugBank.d567.s18|3-5|the|O
DDI-DrugBank.d567.s18|7-10|dose|O
DDI-DrugBank.d567.s18|12-13|of|O
DDI-DrugBank.d567.s18|15-24|lovastatin|drug
DDI-DrugBank.d567.s18|26-27|is|O
DDI-DrugBank.d567.s18|29-35|changed|O
DDI-DrugBank.d567.s18|36-36|,|O
DDI-DrugBank.d567.s18|38-40|the|O
DDI-DrugBank.d567.s18|42-45|same|O
DDI-DrugBank.d567.s18|47-55|procedure|O
DDI-DrugBank.d567.s18|57-62|should|O
DDI-DrugBank.d567.s18|64-65|be|O
DDI-DrugBank.d567.s18|67-74|repeated|O
DDI-DrugBank.d567.s18|75-75|.|O
DDI-DrugBank.d567.s19|0-9|Lovastatin|drug
DDI-DrugBank.d567.s19|11-17|therapy|O
DDI-DrugBank.d567.s19|19-21|has|O
DDI-DrugBank.d567.s19|23-25|not|O
DDI-DrugBank.d567.s19|27-30|been|O
DDI-DrugBank.d567.s19|32-41|associated|O
DDI-DrugBank.d567.s19|43-46|with|O
DDI-DrugBank.d567.s19|48-55|bleeding|O
DDI-DrugBank.d567.s19|57-58|or|O
DDI-DrugBank.d567.s19|60-63|with|O
DDI-DrugBank.d567.s19|65-71|changes|O
DDI-DrugBank.d567.s19|73-74|in|O
DDI-DrugBank.d567.s19|76-86|prothrombin|O
DDI-DrugBank.d567.s19|88-91|time|O
DDI-DrugBank.d567.s19|93-94|in|O
DDI-DrugBank.d567.s19|96-103|patients|O
DDI-DrugBank.d567.s19|105-107|not|O
DDI-DrugBank.d567.s19|109-114|taking|O
DDI-DrugBank.d567.s19|116-129|anticoagulants|group
DDI-DrugBank.d567.s19|130-130|.|O
DDI-DrugBank.d567.s20|0-10|Propranolol|drug
DDI-DrugBank.d567.s20|11-11|:|O
DDI-DrugBank.d567.s20|13-14|In|O
DDI-DrugBank.d567.s20|16-21|normal|O
DDI-DrugBank.d567.s20|23-32|volunteers|O
DDI-DrugBank.d567.s20|33-33|,|O
DDI-DrugBank.d567.s20|35-39|there|O
DDI-DrugBank.d567.s20|41-43|was|O
DDI-DrugBank.d567.s20|45-46|no|O
DDI-DrugBank.d567.s20|48-57|clinically|O
DDI-DrugBank.d567.s20|59-69|significant|O
DDI-DrugBank.d567.s20|71-85|pharmacokinetic|O
DDI-DrugBank.d567.s20|87-88|or|O
DDI-DrugBank.d567.s20|90-104|pharmacodynamic|O
DDI-DrugBank.d567.s20|106-116|interaction|O
DDI-DrugBank.d567.s20|118-121|with|O
DDI-DrugBank.d567.s20|123-133|concomitant|O
DDI-DrugBank.d567.s20|135-148|administration|O
DDI-DrugBank.d567.s20|150-151|of|O
DDI-DrugBank.d567.s20|153-158|single|O
DDI-DrugBank.d567.s20|160-164|doses|O
DDI-DrugBank.d567.s20|166-167|of|O
DDI-DrugBank.d567.s20|169-178|lovastatin|drug
DDI-DrugBank.d567.s20|180-182|and|O
DDI-DrugBank.d567.s20|184-194|propranolol|drug
DDI-DrugBank.d567.s20|195-195|.|O
DDI-DrugBank.d567.s21|0-6|Digoxin|drug
DDI-DrugBank.d567.s21|7-7|:|O
DDI-DrugBank.d567.s21|9-10|In|O
DDI-DrugBank.d567.s21|12-19|patients|O
DDI-DrugBank.d567.s21|21-24|with|O
DDI-DrugBank.d567.s21|26-45|hypercholesterolemia|O
DDI-DrugBank.d567.s21|46-46|,|O
DDI-DrugBank.d567.s21|48-58|concomitant|O
DDI-DrugBank.d567.s21|60-73|administration|O
DDI-DrugBank.d567.s21|75-76|of|O
DDI-DrugBank.d567.s21|78-87|lovastatin|drug
DDI-DrugBank.d567.s21|89-91|and|O
DDI-DrugBank.d567.s21|93-99|digoxin|drug
DDI-DrugBank.d567.s21|101-108|resulted|O
DDI-DrugBank.d567.s21|110-111|in|O
DDI-DrugBank.d567.s21|113-114|no|O
DDI-DrugBank.d567.s21|116-121|effect|O
DDI-DrugBank.d567.s21|123-124|on|O
DDI-DrugBank.d567.s21|126-132|digoxin|drug
DDI-DrugBank.d567.s21|134-139|plasma|O
DDI-DrugBank.d567.s21|141-154|concentrations|O
DDI-DrugBank.d567.s21|155-155|.|O
DDI-DrugBank.d567.s22|0-3|Oral|O
DDI-DrugBank.d567.s22|5-23|Hypoglycemic Agents|group
DDI-DrugBank.d567.s22|24-24|:|O
DDI-DrugBank.d567.s22|26-27|In|O
DDI-DrugBank.d567.s22|29-43|pharmacokinetic|O
DDI-DrugBank.d567.s22|45-51|studies|O
DDI-DrugBank.d567.s22|53-54|of|O
DDI-DrugBank.d567.s22|56-62|MEVACOR|brand
DDI-DrugBank.d567.s22|64-65|in|O
DDI-DrugBank.d567.s22|67-86|hypercholesterolemic|O
DDI-DrugBank.d567.s22|88-97|noninsulin|O
DDI-DrugBank.d567.s22|99-107|dependent|O
DDI-DrugBank.d567.s22|109-116|diabetic|O
DDI-DrugBank.d567.s22|118-125|patients|O
DDI-DrugBank.d567.s22|126-126|,|O
DDI-DrugBank.d567.s22|128-132|there|O
DDI-DrugBank.d567.s22|134-136|was|O
DDI-DrugBank.d567.s22|138-139|no|O
DDI-DrugBank.d567.s22|141-144|drug|O
DDI-DrugBank.d567.s22|146-156|interaction|O
DDI-DrugBank.d567.s22|158-161|with|O
DDI-DrugBank.d567.s22|163-171|glipizide|drug
DDI-DrugBank.d567.s22|173-174|or|O
DDI-DrugBank.d567.s22|176-179|with|O
DDI-DrugBank.d116.s0|0-6|Careful|O
DDI-DrugBank.d116.s0|8-18|observation|O
DDI-DrugBank.d116.s0|20-21|is|O
DDI-DrugBank.d116.s0|23-30|required|O
DDI-DrugBank.d116.s0|32-35|when|O
DDI-DrugBank.d116.s0|37-46|amantadine|drug
DDI-DrugBank.d116.s0|48-49|is|O
DDI-DrugBank.d116.s0|51-62|administered|O
DDI-DrugBank.d116.s0|64-75|concurrently|O
DDI-DrugBank.d116.s0|77-80|with|O
DDI-DrugBank.d116.s0|82-114|central nervous system stimulants|group
DDI-DrugBank.d116.s0|115-115|.|O
DDI-DrugBank.d116.s1|0-15|Coadministration|O
DDI-DrugBank.d116.s1|17-18|of|O
DDI-DrugBank.d116.s1|20-31|thioridazine|drug
DDI-DrugBank.d116.s1|33-35|has|O
DDI-DrugBank.d116.s1|37-40|been|O
DDI-DrugBank.d116.s1|42-49|reported|O
DDI-DrugBank.d116.s1|51-52|to|O
DDI-DrugBank.d116.s1|54-59|worsen|O
DDI-DrugBank.d116.s1|61-63|the|O
DDI-DrugBank.d116.s1|65-70|tremor|O
DDI-DrugBank.d116.s1|72-73|in|O
DDI-DrugBank.d116.s1|75-81|elderly|O
DDI-DrugBank.d116.s1|83-90|patients|O
DDI-DrugBank.d116.s1|92-95|with|O
DDI-DrugBank.d116.s1|97-106|Parkinsons|O
DDI-DrugBank.d116.s1|108-114|disease|O
DDI-DrugBank.d116.s1|115-115|;|O
DDI-DrugBank.d116.s2|0-6|however|O
DDI-DrugBank.d116.s2|7-7|,|O
DDI-DrugBank.d116.s2|9-10|it|O
DDI-DrugBank.d116.s2|12-13|is|O
DDI-DrugBank.d116.s2|15-17|not|O
DDI-DrugBank.d116.s2|19-23|known|O
DDI-DrugBank.d116.s2|25-26|if|O
DDI-DrugBank.d116.s2|28-32|other|O
DDI-DrugBank.d116.s2|34-47|phenothiazines|group
DDI-DrugBank.d116.s2|49-55|produce|O
DDI-DrugBank.d116.s2|57-57|a|O
DDI-DrugBank.d116.s2|59-65|similar|O
DDI-DrugBank.d116.s2|67-74|response|O
DDI-DrugBank.d116.s2|75-75|.|O
DDI-DrugBank.d354.s0|0-9|Tizoxanide|drug
DDI-DrugBank.d354.s0|11-12|is|O
DDI-DrugBank.d354.s0|14-19|highly|O
DDI-DrugBank.d354.s0|21-25|bound|O
DDI-DrugBank.d354.s0|27-28|to|O
DDI-DrugBank.d354.s0|30-35|plasma|O
DDI-DrugBank.d354.s0|37-43|protein|O
DDI-DrugBank.d354.s0|45-45|(|O
DDI-DrugBank.d354.s0|47-50|99.9|O
DDI-DrugBank.d354.s0|51-51|%|O
DDI-DrugBank.d354.s0|52-52|)|O
DDI-DrugBank.d354.s0|53-53|.|O
DDI-DrugBank.d354.s1|0-8|Therefore|O
DDI-DrugBank.d354.s1|9-9|,|O
DDI-DrugBank.d354.s1|11-17|caution|O
DDI-DrugBank.d354.s1|19-24|should|O
DDI-DrugBank.d354.s1|26-27|be|O
DDI-DrugBank.d354.s1|29-32|used|O
DDI-DrugBank.d354.s1|34-37|when|O
DDI-DrugBank.d354.s1|39-51|administering|O
DDI-DrugBank.d354.s1|53-64|nitazoxanide|drug
DDI-DrugBank.d354.s1|66-77|concurrently|O
DDI-DrugBank.d354.s1|79-82|with|O
DDI-DrugBank.d354.s1|84-88|other|O
DDI-DrugBank.d354.s1|90-95|highly|O
DDI-DrugBank.d354.s1|97-102|plasma|O
DDI-DrugBank.d354.s1|104-116|protein-bound|O
DDI-DrugBank.d354.s1|118-122|drugs|O
DDI-DrugBank.d354.s1|124-127|with|O
DDI-DrugBank.d354.s1|129-134|narrow|O
DDI-DrugBank.d354.s1|136-146|therapeutic|O
DDI-DrugBank.d354.s1|148-154|indices|O
DDI-DrugBank.d354.s1|155-155|,|O
DDI-DrugBank.d354.s1|157-158|as|O
DDI-DrugBank.d354.s1|160-170|competition|O
DDI-DrugBank.d354.s1|172-174|for|O
DDI-DrugBank.d354.s1|176-182|binding|O
DDI-DrugBank.d354.s1|184-188|sites|O
DDI-DrugBank.d354.s1|190-192|may|O
DDI-DrugBank.d354.s1|194-198|occur|O
DDI-DrugBank.d354.s1|200-200|(|O
DDI-DrugBank.d354.s1|201-204|e.g.|O
DDI-DrugBank.d354.s1|205-205|,|O
DDI-DrugBank.d354.s1|207-214|warfarin|drug
DDI-DrugBank.d354.s1|215-215|)|O
DDI-DrugBank.d354.s1|216-216|.|O
DDI-DrugBank.d354.s2|0-1|In|O
DDI-DrugBank.d354.s2|3-7|vitro|O
DDI-DrugBank.d354.s2|9-18|metabolism|O
DDI-DrugBank.d354.s2|20-26|studies|O
DDI-DrugBank.d354.s2|28-31|have|O
DDI-DrugBank.d354.s2|33-44|demonstrated|O
DDI-DrugBank.d354.s2|46-49|that|O
DDI-DrugBank.d354.s2|51-60|tizoxanide|drug
DDI-DrugBank.d354.s2|62-64|has|O
DDI-DrugBank.d354.s2|66-67|no|O
DDI-DrugBank.d354.s2|69-79|significant|O
DDI-DrugBank.d354.s2|81-90|inhibitory|O
DDI-DrugBank.d354.s2|92-97|effect|O
DDI-DrugBank.d354.s2|99-100|on|O
DDI-DrugBank.d354.s2|102-111|cytochrome|O
DDI-DrugBank.d354.s2|113-116|P450|O
DDI-DrugBank.d354.s2|118-124|enzymes|O
DDI-DrugBank.d354.s2|125-125|.|O
DDI-DrugBank.d354.s3|0-7|Although|O
DDI-DrugBank.d354.s3|9-10|no|O
DDI-DrugBank.d354.s3|12-20|drug-drug|O
DDI-DrugBank.d354.s3|22-32|interaction|O
DDI-DrugBank.d354.s3|34-40|studies|O
DDI-DrugBank.d354.s3|42-45|have|O
DDI-DrugBank.d354.s3|47-50|been|O
DDI-DrugBank.d354.s3|52-60|conducted|O
DDI-DrugBank.d354.s3|62-63|in|O
DDI-DrugBank.d354.s3|65-68|vivo|O
DDI-DrugBank.d354.s3|69-69|,|O
DDI-DrugBank.d354.s3|71-72|it|O
DDI-DrugBank.d354.s3|74-75|is|O
DDI-DrugBank.d354.s3|77-84|expected|O
DDI-DrugBank.d354.s3|86-89|that|O
DDI-DrugBank.d354.s3|91-92|no|O
DDI-DrugBank.d354.s3|94-104|significant|O
DDI-DrugBank.d354.s3|106-116|interaction|O
DDI-DrugBank.d354.s3|118-122|would|O
DDI-DrugBank.d354.s3|124-128|occur|O
DDI-DrugBank.d354.s3|130-133|when|O
DDI-DrugBank.d354.s3|135-146|nitazoxanide|drug
DDI-DrugBank.d354.s3|148-149|is|O
DDI-DrugBank.d354.s3|151-165|co-administered|O
DDI-DrugBank.d354.s3|167-170|with|O
DDI-DrugBank.d354.s3|172-176|drugs|O
DDI-DrugBank.d354.s3|178-181|that|O
DDI-DrugBank.d354.s3|183-188|either|O
DDI-DrugBank.d354.s3|190-192|are|O
DDI-DrugBank.d354.s3|194-204|metabolized|O
DDI-DrugBank.d354.s3|206-207|by|O
DDI-DrugBank.d354.s3|209-210|or|O
DDI-DrugBank.d354.s3|212-218|inhibit|O
DDI-DrugBank.d354.s3|220-229|cytochrome|O
DDI-DrugBank.d354.s3|231-234|P450|O
DDI-DrugBank.d354.s3|236-242|enzymes|O
DDI-DrugBank.d354.s3|243-243|.|O
DDI-DrugBank.d607.s0|0-11|Interactions|O
DDI-DrugBank.d607.s0|13-19|between|O
DDI-DrugBank.d607.s0|21-27|Leukine|brand
DDI-DrugBank.d607.s0|29-31|and|O
DDI-DrugBank.d607.s0|33-37|other|O
DDI-DrugBank.d607.s0|39-43|drugs|O
DDI-DrugBank.d607.s0|45-48|have|O
DDI-DrugBank.d607.s0|50-52|not|O
DDI-DrugBank.d607.s0|54-57|been|O
DDI-DrugBank.d607.s0|59-63|fully|O
DDI-DrugBank.d607.s0|65-73|evaluated|O
DDI-DrugBank.d607.s0|74-74|.|O
DDI-DrugBank.d607.s1|0-4|Drugs|O
DDI-DrugBank.d607.s1|6-10|which|O
DDI-DrugBank.d607.s1|12-14|may|O
DDI-DrugBank.d607.s1|16-25|potentiate|O
DDI-DrugBank.d607.s1|27-29|the|O
DDI-DrugBank.d607.s1|31-48|myeloproliferative|O
DDI-DrugBank.d607.s1|50-56|effects|O
DDI-DrugBank.d607.s1|58-59|of|O
DDI-DrugBank.d607.s1|61-67|Leukine|brand
DDI-DrugBank.d607.s1|68-68|,|O
DDI-DrugBank.d607.s1|70-73|such|O
DDI-DrugBank.d607.s1|75-76|as|O
DDI-DrugBank.d607.s1|78-84|lithium|drug
DDI-DrugBank.d607.s1|86-88|and|O
DDI-DrugBank.d607.s1|90-104|corticosteroids|group
DDI-DrugBank.d607.s1|105-105|,|O
DDI-DrugBank.d607.s1|107-112|should|O
DDI-DrugBank.d607.s1|114-115|be|O
DDI-DrugBank.d607.s1|117-120|used|O
DDI-DrugBank.d607.s1|122-125|with|O
DDI-DrugBank.d607.s1|127-133|caution|O
DDI-DrugBank.d607.s1|134-134|.|O
DDI-DrugBank.d23.s0|0-7|HEMABATE|brand
DDI-DrugBank.d23.s0|9-11|may|O
DDI-DrugBank.d23.s0|13-19|augment|O
DDI-DrugBank.d23.s0|21-23|the|O
DDI-DrugBank.d23.s0|25-32|activity|O
DDI-DrugBank.d23.s0|34-35|of|O
DDI-DrugBank.d23.s0|37-41|other|O
DDI-DrugBank.d23.s0|43-57|oxytocic agents|group
DDI-DrugBank.d23.s0|58-58|.|O
DDI-DrugBank.d23.s1|0-10|Concomitant|O
DDI-DrugBank.d23.s1|12-14|use|O
DDI-DrugBank.d23.s1|16-19|with|O
DDI-DrugBank.d23.s1|21-25|other|O
DDI-DrugBank.d23.s1|27-41|oxytocic agents|group
DDI-DrugBank.d23.s1|43-44|is|O
DDI-DrugBank.d23.s1|46-48|not|O
DDI-DrugBank.d23.s1|50-60|recommended|O
DDI-DrugBank.d23.s2|0-0|.|O
DDI-DrugBank.d403.s0|0-4|There|O
DDI-DrugBank.d403.s0|6-9|have|O
DDI-DrugBank.d403.s0|11-14|been|O
DDI-DrugBank.d403.s0|16-17|no|O
DDI-DrugBank.d403.s0|19-24|formal|O
DDI-DrugBank.d403.s0|26-41|drug-interaction|O
DDI-DrugBank.d403.s0|43-49|studies|O
DDI-DrugBank.d403.s0|51-59|performed|O
DDI-DrugBank.d403.s0|61-64|with|O
DDI-DrugBank.d403.s0|66-73|Mylotarg|brand
DDI-DrugBank.d403.s0|74-74|.|O
DDI-DrugBank.d403.s1|0-2|The|O
DDI-DrugBank.d403.s1|4-12|potential|O
DDI-DrugBank.d403.s1|14-16|for|O
DDI-DrugBank.d403.s1|18-26|drug-drug|O
DDI-DrugBank.d403.s1|28-38|interaction|O
DDI-DrugBank.d403.s1|40-43|with|O
DDI-DrugBank.d403.s1|45-49|drugs|O
DDI-DrugBank.d403.s1|51-58|affected|O
DDI-DrugBank.d403.s1|60-61|by|O
DDI-DrugBank.d403.s1|63-72|cytochrome|O
DDI-DrugBank.d403.s1|74-77|P450|O
DDI-DrugBank.d403.s1|79-85|enzymes|O
DDI-DrugBank.d403.s1|87-89|may|O
DDI-DrugBank.d403.s1|91-93|not|O
DDI-DrugBank.d403.s1|95-96|be|O
DDI-DrugBank.d403.s1|98-102|ruled|O
DDI-DrugBank.d403.s1|104-106|out|O
DDI-DrugBank.d403.s1|107-107|.|O
DDI-DrugBank.d403.s2|0-9|Laboratory|O
DDI-DrugBank.d403.s2|11-14|Test|O
DDI-DrugBank.d403.s2|16-27|Interactions|O
DDI-DrugBank.d403.s3|0-7|Mylotarg|brand
DDI-DrugBank.d403.s3|9-10|is|O
DDI-DrugBank.d403.s3|12-14|not|O
DDI-DrugBank.d403.s3|16-20|known|O
DDI-DrugBank.d403.s3|22-23|to|O
DDI-DrugBank.d403.s3|25-33|interfere|O
DDI-DrugBank.d403.s3|35-38|with|O
DDI-DrugBank.d403.s3|40-42|any|O
DDI-DrugBank.d403.s3|44-50|routine|O
DDI-DrugBank.d403.s3|52-61|diagnostic|O
DDI-DrugBank.d403.s3|63-67|tests|O
DDI-DrugBank.d403.s3|68-68|.|O
DDI-DrugBank.d423.s0|0-1|In|O
DDI-DrugBank.d423.s0|3-10|patients|O
DDI-DrugBank.d423.s0|12-20|receiving|O
DDI-DrugBank.d423.s0|22-33|nonselective|O
DDI-DrugBank.d423.s0|35-62|monoamine oxidase inhibitors|group
DDI-DrugBank.d423.s0|64-64|(|O
DDI-DrugBank.d423.s0|65-69|MAOIs|group
DDI-DrugBank.d423.s0|70-70|)|O
DDI-DrugBank.d423.s0|72-72|(|O
DDI-DrugBank.d423.s0|73-76|e.g.|O
DDI-DrugBank.d423.s0|77-77|,|O
DDI-DrugBank.d423.s0|79-102|selegiline hydrochloride|drug
DDI-DrugBank.d423.s0|103-103|)|O
DDI-DrugBank.d423.s0|105-106|in|O
DDI-DrugBank.d423.s0|108-118|combination|O
DDI-DrugBank.d423.s0|120-123|with|O
DDI-DrugBank.d423.s0|125-145|serotoninergic agents|group
DDI-DrugBank.d423.s0|147-147|(|O
DDI-DrugBank.d423.s0|148-151|e.g.|O
DDI-DrugBank.d423.s0|152-152|,|O
DDI-DrugBank.d423.s0|154-163|fluoxetine|drug
DDI-DrugBank.d423.s0|164-164|,|O
DDI-DrugBank.d423.s0|166-176|fluvoxamine|drug
DDI-DrugBank.d423.s0|177-177|,|O
DDI-DrugBank.d423.s0|179-188|paroxetine|drug
DDI-DrugBank.d423.s0|189-189|,|O
DDI-DrugBank.d423.s0|191-200|sertraline|drug
DDI-DrugBank.d423.s0|201-201|,|O
DDI-DrugBank.d423.s0|203-213|venlafaxine|drug
DDI-DrugBank.d423.s0|214-214|)|O
DDI-DrugBank.d423.s0|215-215|,|O
DDI-DrugBank.d423.s0|217-221|there|O
DDI-DrugBank.d423.s0|223-226|have|O
DDI-DrugBank.d423.s0|228-231|been|O
DDI-DrugBank.d423.s0|233-239|reports|O
DDI-DrugBank.d423.s0|241-242|of|O
DDI-DrugBank.d423.s0|244-250|serious|O
DDI-DrugBank.d423.s0|251-251|,|O
DDI-DrugBank.d423.s0|253-261|sometimes|O
DDI-DrugBank.d423.s0|263-267|fatal|O
DDI-DrugBank.d423.s0|268-268|,|O
DDI-DrugBank.d423.s0|270-278|reactions|O
DDI-DrugBank.d423.s0|279-279|.|O
DDI-DrugBank.d423.s1|0-6|Because|O
DDI-DrugBank.d423.s1|8-22|dexfenfluramine|drug
DDI-DrugBank.d423.s1|24-25|is|O
DDI-DrugBank.d423.s1|27-27|a|O
DDI-DrugBank.d423.s1|29-37|serotonin|O
DDI-DrugBank.d423.s1|39-46|releaser|O
DDI-DrugBank.d423.s1|48-50|and|O
DDI-DrugBank.d423.s1|52-59|reuptake|O
DDI-DrugBank.d423.s1|61-69|inhibitor|O
DDI-DrugBank.d423.s1|70-70|,|O
DDI-DrugBank.d423.s1|72-86|dexfenfluramine|drug
DDI-DrugBank.d423.s1|88-93|should|O
DDI-DrugBank.d423.s1|95-97|not|O
DDI-DrugBank.d423.s1|99-100|be|O
DDI-DrugBank.d423.s1|102-105|used|O
DDI-DrugBank.d423.s1|107-119|concomitantly|O
DDI-DrugBank.d423.s1|121-124|with|O
DDI-DrugBank.d423.s1|126-126|a|O
DDI-DrugBank.d423.s1|128-140|MAO inhibitor|group
DDI-DrugBank.d423.s1|141-141|.|O
DDI-DrugBank.d423.s2|0-1|At|O
DDI-DrugBank.d423.s2|3-7|least|O
DDI-DrugBank.d423.s2|9-10|14|O
DDI-DrugBank.d423.s2|12-15|days|O
DDI-DrugBank.d423.s2|17-22|should|O
DDI-DrugBank.d423.s2|24-29|elapse|O
DDI-DrugBank.d423.s2|31-37|between|O
DDI-DrugBank.d423.s2|39-53|discontinuation|O
DDI-DrugBank.d423.s2|55-56|of|O
DDI-DrugBank.d423.s2|58-58|a|O
DDI-DrugBank.d423.s2|60-72|MAO inhibitor|group
DDI-DrugBank.d423.s2|74-76|and|O
DDI-DrugBank.d423.s2|78-87|initiation|O
DDI-DrugBank.d423.s2|89-90|of|O
DDI-DrugBank.d423.s2|92-100|treatment|O
DDI-DrugBank.d423.s2|102-105|with|O
DDI-DrugBank.d423.s2|107-121|dexfenfluramine|drug
DDI-DrugBank.d423.s2|122-122|.|O
DDI-DrugBank.d423.s3|0-1|At|O
DDI-DrugBank.d423.s3|3-7|least|O
DDI-DrugBank.d423.s3|9-9|3|O
DDI-DrugBank.d423.s3|11-15|weeks|O
DDI-DrugBank.d423.s3|17-22|should|O
DDI-DrugBank.d423.s3|24-29|elapse|O
DDI-DrugBank.d423.s3|31-37|between|O
DDI-DrugBank.d423.s3|39-53|discontinuation|O
DDI-DrugBank.d423.s3|55-56|of|O
DDI-DrugBank.d423.s3|58-72|dexfenfluramine|drug
DDI-DrugBank.d423.s3|74-76|and|O
DDI-DrugBank.d423.s3|78-87|initiation|O
DDI-DrugBank.d423.s3|89-90|of|O
DDI-DrugBank.d423.s3|92-100|treatment|O
DDI-DrugBank.d423.s3|102-105|with|O
DDI-DrugBank.d423.s3|107-107|a|O
DDI-DrugBank.d423.s3|109-121|MAO inhibitor|group
DDI-DrugBank.d423.s3|122-122|.|O
DDI-DrugBank.d423.s4|0-0|A|O
DDI-DrugBank.d423.s4|2-5|rare|O
DDI-DrugBank.d423.s4|6-6|,|O
DDI-DrugBank.d423.s4|8-10|but|O
DDI-DrugBank.d423.s4|12-18|serious|O
DDI-DrugBank.d423.s4|19-19|,|O
DDI-DrugBank.d423.s4|21-33|constellation|O
DDI-DrugBank.d423.s4|35-36|of|O
DDI-DrugBank.d423.s4|38-45|symptoms|O
DDI-DrugBank.d423.s4|46-46|,|O
DDI-DrugBank.d423.s4|48-53|termed|O
DDI-DrugBank.d423.s4|55-63|serotonin|O
DDI-DrugBank.d423.s4|65-72|syndrome|O
DDI-DrugBank.d423.s4|73-73|,|O
DDI-DrugBank.d423.s4|75-77|has|O
DDI-DrugBank.d423.s4|79-82|been|O
DDI-DrugBank.d423.s4|84-91|reported|O
DDI-DrugBank.d423.s4|93-96|with|O
DDI-DrugBank.d423.s4|98-100|the|O
DDI-DrugBank.d423.s4|102-112|concomitant|O
DDI-DrugBank.d423.s4|114-116|use|O
DDI-DrugBank.d423.s4|118-119|of|O
DDI-DrugBank.d423.s4|121-159|selective serotonin reuptake inhibitors|group
DDI-DrugBank.d423.s4|161-161|(|O
DDI-DrugBank.d423.s4|162-166|SSRIs|group
DDI-DrugBank.d423.s4|167-167|)|O
DDI-DrugBank.d423.s4|169-171|and|O
DDI-DrugBank.d423.s4|173-178|agents|O
DDI-DrugBank.d423.s4|180-182|for|O
DDI-DrugBank.d423.s4|184-191|migraine|O
DDI-DrugBank.d423.s4|193-199|therapy|O
DDI-DrugBank.d423.s4|200-200|,|O
DDI-DrugBank.d423.s4|202-205|such|O
DDI-DrugBank.d423.s4|207-208|as|O
DDI-DrugBank.d423.s4|210-216|Imitrex|brand
DDI-DrugBank.d423.s4|218-218|(|O
DDI-DrugBank.d423.s4|219-239|sumatriptan succinate|drug
DDI-DrugBank.d423.s4|240-240|)|O
DDI-DrugBank.d423.s4|242-244|and|O
DDI-DrugBank.d423.s4|246-262|dihydroergotamine|drug
DDI-DrugBank.d423.s4|263-263|.|O
DDI-DrugBank.d423.s5|0-2|The|O
DDI-DrugBank.d423.s5|4-11|syndrome|O
DDI-DrugBank.d423.s5|13-20|requires|O
DDI-DrugBank.d423.s5|22-30|immediate|O
DDI-DrugBank.d423.s5|32-38|medical|O
DDI-DrugBank.d423.s5|40-48|attention|O
DDI-DrugBank.d423.s5|50-52|and|O
DDI-DrugBank.d423.s5|54-56|may|O
DDI-DrugBank.d423.s5|58-64|include|O
DDI-DrugBank.d423.s5|66-68|one|O
DDI-DrugBank.d423.s5|70-71|or|O
DDI-DrugBank.d423.s5|73-76|more|O
DDI-DrugBank.d423.s5|78-79|of|O
DDI-DrugBank.d423.s5|81-83|the|O
DDI-DrugBank.d423.s5|85-93|following|O
DDI-DrugBank.d423.s5|95-102|symptoms|O
DDI-DrugBank.d423.s5|103-103|:|O
DDI-DrugBank.d423.s5|105-114|excitement|O
DDI-DrugBank.d423.s5|115-115|,|O
DDI-DrugBank.d423.s5|117-125|hypomania|O
DDI-DrugBank.d423.s5|126-126|,|O
DDI-DrugBank.d423.s5|128-139|restlessness|O
DDI-DrugBank.d423.s5|140-140|,|O
DDI-DrugBank.d423.s5|142-145|loss|O
DDI-DrugBank.d423.s5|147-148|of|O
DDI-DrugBank.d423.s5|150-162|consciousness|O
DDI-DrugBank.d423.s5|163-163|,|O
DDI-DrugBank.d423.s5|165-173|confusion|O
DDI-DrugBank.d423.s5|174-174|,|O
DDI-DrugBank.d423.s5|176-189|disorientation|O
DDI-DrugBank.d423.s5|190-190|,|O
DDI-DrugBank.d423.s5|192-198|anxiety|O
DDI-DrugBank.d423.s5|199-199|,|O
DDI-DrugBank.d423.s5|201-209|agitation|O
DDI-DrugBank.d423.s5|210-210|,|O
DDI-DrugBank.d423.s5|212-216|motor|O
DDI-DrugBank.d423.s5|218-225|weakness|O
DDI-DrugBank.d423.s5|226-226|,|O
DDI-DrugBank.d423.s5|228-236|myoclonus|O
DDI-DrugBank.d423.s5|237-237|,|O
DDI-DrugBank.d423.s5|239-244|tremor|O
DDI-DrugBank.d423.s5|245-245|,|O
DDI-DrugBank.d423.s5|247-259|hemiballismus|O
DDI-DrugBank.d423.s5|260-260|,|O
DDI-DrugBank.d423.s5|262-274|hyperreflexia|O
DDI-DrugBank.d423.s5|275-275|,|O
DDI-DrugBank.d423.s5|277-282|ataxia|O
DDI-DrugBank.d423.s5|283-283|,|O
DDI-DrugBank.d423.s5|285-294|dysarthria|O
DDI-DrugBank.d423.s5|295-295|,|O
DDI-DrugBank.d423.s5|297-310|incoordination|O
DDI-DrugBank.d423.s5|311-311|,|O
DDI-DrugBank.d423.s5|313-324|hyperthermia|O
DDI-DrugBank.d423.s5|325-325|,|O
DDI-DrugBank.d423.s5|327-335|shivering|O
DDI-DrugBank.d423.s5|336-336|,|O
DDI-DrugBank.d423.s5|338-346|pupillary|O
DDI-DrugBank.d423.s5|348-355|dilation|O
DDI-DrugBank.d423.s5|356-356|,|O
DDI-DrugBank.d423.s5|358-368|diaphoresis|O
DDI-DrugBank.d423.s5|369-369|,|O
DDI-DrugBank.d423.s5|371-376|emesis|O
DDI-DrugBank.d423.s5|377-377|,|O
DDI-DrugBank.d423.s5|379-381|and|O
DDI-DrugBank.d423.s5|383-393|tachycardia|O
DDI-DrugBank.d423.s5|394-394|.|O
DDI-DrugBank.d423.s6|0-14|Dexfenfluramine|drug
DDI-DrugBank.d423.s6|16-21|should|O
DDI-DrugBank.d423.s6|23-25|not|O
DDI-DrugBank.d423.s6|27-28|be|O
DDI-DrugBank.d423.s6|30-41|administered|O
DDI-DrugBank.d423.s6|43-46|with|O
DDI-DrugBank.d423.s6|48-52|other|O
DDI-DrugBank.d423.s6|54-74|serotoninergic agents|group
DDI-DrugBank.d423.s6|75-75|.|O
DDI-DrugBank.d423.s7|0-2|The|O
DDI-DrugBank.d423.s7|4-14|appropriate|O
DDI-DrugBank.d423.s7|16-23|interval|O
DDI-DrugBank.d423.s7|25-31|between|O
DDI-DrugBank.d423.s7|33-46|administration|O
DDI-DrugBank.d423.s7|48-49|of|O
DDI-DrugBank.d423.s7|51-55|these|O
DDI-DrugBank.d423.s7|57-62|agents|O
DDI-DrugBank.d423.s7|64-66|and|O
DDI-DrugBank.d423.s7|68-82|dexfenfluramine|drug
DDI-DrugBank.d423.s7|84-86|has|O
DDI-DrugBank.d423.s7|88-90|not|O
DDI-DrugBank.d423.s7|92-95|been|O
DDI-DrugBank.d423.s7|97-107|established|O
DDI-DrugBank.d423.s7|108-108|.|O
DDI-DrugBank.d423.s8|0-2|The|O
DDI-DrugBank.d423.s8|4-6|use|O
DDI-DrugBank.d423.s8|8-9|of|O
DDI-DrugBank.d423.s8|11-25|dexfenfluramine|drug
DDI-DrugBank.d423.s8|27-30|with|O
DDI-DrugBank.d423.s8|32-36|other|O
DDI-DrugBank.d423.s8|38-47|CNS-active|O
DDI-DrugBank.d423.s8|49-53|drugs|O
DDI-DrugBank.d423.s8|55-57|has|O
DDI-DrugBank.d423.s8|59-61|not|O
DDI-DrugBank.d423.s8|63-66|been|O
DDI-DrugBank.d423.s8|68-81|systematically|O
DDI-DrugBank.d423.s8|83-91|evaluated|O
DDI-DrugBank.d423.s8|92-92|;|O
DDI-DrugBank.d423.s9|0-11|consequently|O
DDI-DrugBank.d423.s9|12-12|,|O
DDI-DrugBank.d423.s9|14-20|caution|O
DDI-DrugBank.d423.s9|22-23|is|O
DDI-DrugBank.d423.s9|25-31|advised|O
DDI-DrugBank.d423.s9|33-34|if|O
DDI-DrugBank.d423.s9|36-50|dexfenfluramine|drug
DDI-DrugBank.d423.s9|52-54|and|O
DDI-DrugBank.d423.s9|56-59|such|O
DDI-DrugBank.d423.s9|61-65|drugs|O
DDI-DrugBank.d423.s9|67-69|are|O
DDI-DrugBank.d423.s9|71-80|prescribed|O
DDI-DrugBank.d423.s9|82-93|concurrently|O
DDI-DrugBank.d423.s9|94-94|.|O
DDI-DrugBank.d641.s0|0-5|ALIMTA|brand
DDI-DrugBank.d641.s0|7-8|is|O
DDI-DrugBank.d641.s0|10-18|primarily|O
DDI-DrugBank.d641.s0|20-29|eliminated|O
DDI-DrugBank.d641.s0|31-39|unchanged|O
DDI-DrugBank.d641.s0|41-47|renally|O
DDI-DrugBank.d641.s0|49-50|as|O
DDI-DrugBank.d641.s0|52-52|a|O
DDI-DrugBank.d641.s0|54-59|result|O
DDI-DrugBank.d641.s0|61-62|of|O
DDI-DrugBank.d641.s0|64-73|glomerular|O
DDI-DrugBank.d641.s0|75-84|filtration|O
DDI-DrugBank.d641.s0|86-88|and|O
DDI-DrugBank.d641.s0|90-96|tubular|O
DDI-DrugBank.d641.s0|98-106|secretion|O
DDI-DrugBank.d641.s0|107-107|.|O
DDI-DrugBank.d641.s1|0-10|Concomitant|O
DDI-DrugBank.d641.s1|12-25|administration|O
DDI-DrugBank.d641.s1|27-28|of|O
DDI-DrugBank.d641.s1|30-40|nephrotoxic|O
DDI-DrugBank.d641.s1|42-46|drugs|O
DDI-DrugBank.d641.s1|48-52|could|O
DDI-DrugBank.d641.s1|54-59|result|O
DDI-DrugBank.d641.s1|61-62|in|O
DDI-DrugBank.d641.s1|64-70|delayed|O
DDI-DrugBank.d641.s1|72-80|clearance|O
DDI-DrugBank.d641.s1|82-83|of|O
DDI-DrugBank.d641.s1|85-90|ALIMTA|brand
DDI-DrugBank.d641.s1|91-91|.|O
DDI-DrugBank.d641.s2|0-10|Concomitant|O
DDI-DrugBank.d641.s2|12-25|administration|O
DDI-DrugBank.d641.s2|27-28|of|O
DDI-DrugBank.d641.s2|30-39|substances|O
DDI-DrugBank.d641.s2|41-44|that|O
DDI-DrugBank.d641.s2|46-48|are|O
DDI-DrugBank.d641.s2|50-53|also|O
DDI-DrugBank.d641.s2|55-63|tubularly|O
DDI-DrugBank.d641.s2|65-72|secreted|O
DDI-DrugBank.d641.s2|74-74|(|O
DDI-DrugBank.d641.s2|75-78|e.g.|O
DDI-DrugBank.d641.s2|79-79|,|O
DDI-DrugBank.d641.s2|81-90|probenecid|drug
DDI-DrugBank.d641.s2|91-91|)|O
DDI-DrugBank.d641.s2|93-97|could|O
DDI-DrugBank.d641.s2|99-109|potentially|O
DDI-DrugBank.d641.s2|111-116|result|O
DDI-DrugBank.d641.s2|118-119|in|O
DDI-DrugBank.d641.s2|121-127|delayed|O
DDI-DrugBank.d641.s2|129-137|clearance|O
DDI-DrugBank.d641.s2|139-140|of|O
DDI-DrugBank.d641.s2|142-147|ALIMTA|brand
DDI-DrugBank.d641.s2|148-148|.|O
DDI-DrugBank.d641.s3|0-7|Although|O
DDI-DrugBank.d641.s3|9-17|ibuprofen|drug
DDI-DrugBank.d641.s3|19-19|(|O
DDI-DrugBank.d641.s3|20-22|400|O
DDI-DrugBank.d641.s3|24-25|mg|O
DDI-DrugBank.d641.s3|27-29|qid|O
DDI-DrugBank.d641.s3|30-30|)|O
DDI-DrugBank.d641.s3|32-34|can|O
DDI-DrugBank.d641.s3|36-37|be|O
DDI-DrugBank.d641.s3|39-50|administered|O
DDI-DrugBank.d641.s3|52-55|with|O
DDI-DrugBank.d641.s3|57-62|ALIMTA|brand
DDI-DrugBank.d641.s3|64-65|in|O
DDI-DrugBank.d641.s3|67-74|patients|O
DDI-DrugBank.d641.s3|76-79|with|O
DDI-DrugBank.d641.s3|81-86|normal|O
DDI-DrugBank.d641.s3|88-92|renal|O
DDI-DrugBank.d641.s3|94-101|function|O
DDI-DrugBank.d641.s3|103-103|(|O
DDI-DrugBank.d641.s3|104-113|creatinine|O
DDI-DrugBank.d641.s3|115-123|clearance|O
DDI-DrugBank.d641.s3|128-129|80|O
DDI-DrugBank.d641.s3|131-136|mL/min|O
DDI-DrugBank.d641.s3|137-137|)|O
DDI-DrugBank.d641.s3|138-138|,|O
DDI-DrugBank.d641.s3|140-146|caution|O
DDI-DrugBank.d641.s3|148-153|should|O
DDI-DrugBank.d641.s3|155-156|be|O
DDI-DrugBank.d641.s3|158-161|used|O
DDI-DrugBank.d641.s3|163-166|when|O
DDI-DrugBank.d641.s3|168-180|administering|O
DDI-DrugBank.d641.s3|182-190|ibuprofen|drug
DDI-DrugBank.d641.s3|192-203|concurrently|O
DDI-DrugBank.d641.s3|205-208|with|O
DDI-DrugBank.d641.s3|210-215|ALIMTA|brand
DDI-DrugBank.d641.s3|217-218|to|O
DDI-DrugBank.d641.s3|220-227|patients|O
DDI-DrugBank.d641.s3|229-232|with|O
DDI-DrugBank.d641.s3|234-237|mild|O
DDI-DrugBank.d641.s3|239-240|to|O
DDI-DrugBank.d641.s3|242-249|moderate|O
DDI-DrugBank.d641.s3|251-255|renal|O
DDI-DrugBank.d641.s3|257-269|insufficiency|O
DDI-DrugBank.d641.s3|271-271|(|O
DDI-DrugBank.d641.s3|272-281|creatinine|O
DDI-DrugBank.d641.s3|283-291|clearance|O
DDI-DrugBank.d641.s3|293-296|from|O
DDI-DrugBank.d641.s3|298-299|45|O
DDI-DrugBank.d641.s3|301-302|to|O
DDI-DrugBank.d641.s3|304-305|79|O
DDI-DrugBank.d641.s3|307-312|mL/min|O
DDI-DrugBank.d641.s3|313-313|)|O
DDI-DrugBank.d641.s3|314-314|.|O
DDI-DrugBank.d641.s4|0-7|Patients|O
DDI-DrugBank.d641.s4|9-12|with|O
DDI-DrugBank.d641.s4|14-17|mild|O
DDI-DrugBank.d641.s4|19-20|to|O
DDI-DrugBank.d641.s4|22-29|moderate|O
DDI-DrugBank.d641.s4|31-35|renal|O
DDI-DrugBank.d641.s4|37-49|insufficiency|O
DDI-DrugBank.d641.s4|51-56|should|O
DDI-DrugBank.d641.s4|58-62|avoid|O
DDI-DrugBank.d641.s4|64-69|taking|O
DDI-DrugBank.d641.s4|71-76|NSAIDs|group
DDI-DrugBank.d641.s4|78-81|with|O
DDI-DrugBank.d641.s4|83-87|short|O
DDI-DrugBank.d641.s4|89-99|elimination|O
DDI-DrugBank.d641.s4|101-110|half-lives|O
DDI-DrugBank.d641.s4|112-114|for|O
DDI-DrugBank.d641.s4|116-116|a|O
DDI-DrugBank.d641.s4|118-123|period|O
DDI-DrugBank.d641.s4|125-126|of|O
DDI-DrugBank.d641.s4|128-128|2|O
DDI-DrugBank.d641.s4|130-133|days|O
DDI-DrugBank.d641.s4|135-140|before|O
DDI-DrugBank.d641.s4|141-141|,|O
DDI-DrugBank.d641.s4|143-145|the|O
DDI-DrugBank.d641.s4|147-149|day|O
DDI-DrugBank.d641.s4|151-152|of|O
DDI-DrugBank.d641.s4|153-153|,|O
DDI-DrugBank.d641.s4|155-157|and|O
DDI-DrugBank.d641.s4|159-159|2|O
DDI-DrugBank.d641.s4|161-164|days|O
DDI-DrugBank.d641.s4|166-174|following|O
DDI-DrugBank.d641.s4|176-189|administration|O
DDI-DrugBank.d641.s4|191-192|of|O
DDI-DrugBank.d641.s4|194-199|ALIMTA|brand
DDI-DrugBank.d641.s4|200-200|.|O
DDI-DrugBank.d641.s5|0-1|In|O
DDI-DrugBank.d641.s5|3-5|the|O
DDI-DrugBank.d641.s5|7-13|absence|O
DDI-DrugBank.d641.s5|15-16|of|O
DDI-DrugBank.d641.s5|18-21|data|O
DDI-DrugBank.d641.s5|23-31|regarding|O
DDI-DrugBank.d641.s5|33-41|potential|O
DDI-DrugBank.d641.s5|43-53|interaction|O
DDI-DrugBank.d641.s5|55-61|between|O
DDI-DrugBank.d641.s5|63-68|ALIMTA|brand
DDI-DrugBank.d641.s5|70-72|and|O
DDI-DrugBank.d641.s5|74-79|NSAIDs|group
DDI-DrugBank.d641.s5|81-84|with|O
DDI-DrugBank.d641.s5|86-91|longer|O
DDI-DrugBank.d641.s5|93-102|half-lives|O
DDI-DrugBank.d641.s5|103-103|,|O
DDI-DrugBank.d641.s5|105-107|all|O
DDI-DrugBank.d641.s5|109-116|patients|O
DDI-DrugBank.d641.s5|118-123|taking|O
DDI-DrugBank.d641.s5|125-129|these|O
DDI-DrugBank.d641.s5|131-136|NSAIDs|group
DDI-DrugBank.d641.s5|138-143|should|O
DDI-DrugBank.d641.s5|145-153|interrupt|O
DDI-DrugBank.d641.s5|155-160|dosing|O
DDI-DrugBank.d641.s5|162-164|for|O
DDI-DrugBank.d641.s5|166-167|at|O
DDI-DrugBank.d641.s5|169-173|least|O
DDI-DrugBank.d641.s5|175-175|5|O
DDI-DrugBank.d641.s5|177-180|days|O
DDI-DrugBank.d641.s5|182-187|before|O
DDI-DrugBank.d641.s5|188-188|,|O
DDI-DrugBank.d641.s5|190-192|the|O
DDI-DrugBank.d641.s5|194-196|day|O
DDI-DrugBank.d641.s5|198-199|of|O
DDI-DrugBank.d641.s5|200-200|,|O
DDI-DrugBank.d641.s5|202-204|and|O
DDI-DrugBank.d641.s5|206-206|2|O
DDI-DrugBank.d641.s5|208-211|days|O
DDI-DrugBank.d641.s5|213-221|following|O
DDI-DrugBank.d641.s5|223-228|ALIMTA|brand
DDI-DrugBank.d641.s5|230-243|administration|O
DDI-DrugBank.d641.s5|244-244|.|O
DDI-DrugBank.d641.s6|0-1|If|O
DDI-DrugBank.d641.s6|3-13|concomitant|O
DDI-DrugBank.d641.s6|15-28|administration|O
DDI-DrugBank.d641.s6|30-31|of|O
DDI-DrugBank.d641.s6|33-34|an|O
DDI-DrugBank.d641.s6|36-40|NSAID|group
DDI-DrugBank.d641.s6|42-43|is|O
DDI-DrugBank.d641.s6|45-53|necessary|O
DDI-DrugBank.d641.s6|54-54|,|O
DDI-DrugBank.d641.s6|56-63|patients|O
DDI-DrugBank.d641.s6|65-70|should|O
DDI-DrugBank.d641.s6|72-73|be|O
DDI-DrugBank.d641.s6|75-83|monitored|O
DDI-DrugBank.d641.s6|85-91|closely|O
DDI-DrugBank.d641.s6|93-95|for|O
DDI-DrugBank.d641.s6|97-104|toxicity|O
DDI-DrugBank.d641.s6|105-105|,|O
DDI-DrugBank.d641.s6|107-116|especially|O
DDI-DrugBank.d641.s6|118-133|myelosuppression|O
DDI-DrugBank.d641.s6|134-134|,|O
DDI-DrugBank.d641.s6|136-140|renal|O
DDI-DrugBank.d641.s6|141-141|,|O
DDI-DrugBank.d641.s6|143-145|and|O
DDI-DrugBank.d641.s6|147-162|gastrointestinal|O
DDI-DrugBank.d641.s6|164-171|toxicity|O
DDI-DrugBank.d641.s6|172-172|.|O
DDI-DrugBank.d641.s7|0-14|Drug/Laboratory|O
DDI-DrugBank.d641.s7|16-19|Test|O
DDI-DrugBank.d641.s7|21-32|Interactions|O
DDI-DrugBank.d641.s7|34-37|None|O
DDI-DrugBank.d641.s7|39-43|known|O
DDI-DrugBank.d641.s7|44-44|.|O
DDI-MedLine.d39.s0|0-5|Effect|O
DDI-MedLine.d39.s0|7-8|of|O
DDI-MedLine.d39.s0|10-18|estradiol|drug
DDI-MedLine.d39.s0|20-21|on|O
DDI-MedLine.d39.s0|41-47|changes|O
DDI-MedLine.d39.s0|49-50|in|O
DDI-MedLine.d39.s0|52-58|steroid|O
DDI-MedLine.d39.s0|60-66|hormone|O
DDI-MedLine.d39.s0|68-73|levels|O
DDI-MedLine.d39.s0|75-77|and|O
DDI-MedLine.d39.s0|79-87|lethality|O
DDI-MedLine.d39.s0|89-90|in|O
DDI-MedLine.d39.s0|92-95|male|O
DDI-MedLine.d39.s0|97-100|rats|O
DDI-MedLine.d39.s0|101-101|.|O
DDI-MedLine.d39.s1|0-1|We|O
DDI-MedLine.d39.s1|3-10|examined|O
DDI-MedLine.d39.s1|12-14|the|O
DDI-MedLine.d39.s1|16-21|effect|O
DDI-MedLine.d39.s1|23-24|of|O
DDI-MedLine.d39.s1|26-34|exogenous|O
DDI-MedLine.d39.s1|36-44|estradiol|drug
DDI-MedLine.d39.s1|46-47|on|O
DDI-MedLine.d39.s1|49-51|the|O
DDI-MedLine.d39.s1|53-59|changes|O
DDI-MedLine.d39.s1|61-62|in|O
DDI-MedLine.d39.s1|64-68|serum|O
DDI-MedLine.d39.s1|70-76|steroid|O
DDI-MedLine.d39.s1|78-84|hormone|O
DDI-MedLine.d39.s1|86-91|levels|O
DDI-MedLine.d39.s1|93-99|induced|O
DDI-MedLine.d39.s1|101-102|by|O
DDI-MedLine.d39.s1|104-104|a|O
DDI-MedLine.d39.s1|106-114|nonlethal|O
DDI-MedLine.d39.s1|116-119|dose|O
DDI-MedLine.d39.s1|121-122|of|O
DDI-MedLine.d39.s1|124-134|Escherichia|O
DDI-MedLine.d39.s1|136-139|coli|O
DDI-MedLine.d39.s1|151-152|in|O
DDI-MedLine.d39.s1|154-157|male|O
DDI-MedLine.d39.s1|159-162|rats|O
DDI-MedLine.d39.s1|164-166|and|O
DDI-MedLine.d39.s1|168-170|the|O
DDI-MedLine.d39.s1|172-177|deaths|O
DDI-MedLine.d39.s1|179-181|due|O
DDI-MedLine.d39.s1|183-184|to|O
DDI-MedLine.d39.s1|186-194|nonlethal|O
DDI-MedLine.d39.s1|196-198|and|O
DDI-MedLine.d39.s1|200-205|lethal|O
DDI-MedLine.d39.s1|207-211|doses|O
DDI-MedLine.d39.s1|213-214|of|O
DDI-MedLine.d39.s1|225-225|.|O
DDI-MedLine.d39.s2|0-8|Injection|O
DDI-MedLine.d39.s2|10-11|of|O
DDI-MedLine.d39.s2|13-21|estradiol|drug
DDI-MedLine.d39.s2|23-23|5|O
DDI-MedLine.d39.s2|25-27|min|O
DDI-MedLine.d39.s2|29-34|before|O
DDI-MedLine.d39.s2|36-36|a|O
DDI-MedLine.d39.s2|38-46|nonlethal|O
DDI-MedLine.d39.s2|48-51|dose|O
DDI-MedLine.d39.s2|53-54|of|O
DDI-MedLine.d39.s2|66-72|changed|O
DDI-MedLine.d39.s2|74-76|the|O
DDI-MedLine.d39.s2|78-82|serum|O
DDI-MedLine.d39.s2|84-86|sex|O
DDI-MedLine.d39.s2|88-94|steroid|O
DDI-MedLine.d39.s2|96-102|hormone|O
DDI-MedLine.d39.s2|104-111|response|O
DDI-MedLine.d39.s2|113-114|of|O
DDI-MedLine.d39.s2|116-119|male|O
DDI-MedLine.d39.s2|121-124|rats|O
DDI-MedLine.d39.s2|126-127|to|O
DDI-MedLine.d39.s2|138-138|.|O
DDI-MedLine.d39.s3|0-2|The|O
DDI-MedLine.d39.s3|4-8|serum|O
DDI-MedLine.d39.s3|10-17|estrogen|O
DDI-MedLine.d39.s3|19-32|concentrations|O
DDI-MedLine.d39.s3|34-35|of|O
DDI-MedLine.d39.s3|37-45|estradiol|drug
DDI-MedLine.d39.s3|47-47|+|O
DDI-MedLine.d39.s3|67-70|rats|O
DDI-MedLine.d39.s3|72-80|decreased|O
DDI-MedLine.d39.s3|82-83|by|O
DDI-MedLine.d39.s3|85-86|50|O
DDI-MedLine.d39.s3|87-87|%|O
DDI-MedLine.d39.s3|88-88|,|O
DDI-MedLine.d39.s3|90-94|while|O
DDI-MedLine.d39.s3|96-100|those|O
DDI-MedLine.d39.s3|102-103|of|O
DDI-MedLine.d39.s3|105-107|the|O
DDI-MedLine.d39.s3|127-130|rats|O
DDI-MedLine.d39.s3|132-140|increased|O
DDI-MedLine.d39.s3|142-142|(|O
DDI-MedLine.d39.s3|143-144|2-|O
DDI-MedLine.d39.s3|146-147|to|O
DDI-MedLine.d39.s3|149-154|5-fold|O
DDI-MedLine.d39.s3|155-155|)|O
DDI-MedLine.d39.s3|156-156|.|O
DDI-MedLine.d39.s4|0-2|The|O
DDI-MedLine.d39.s4|4-8|serum|O
DDI-MedLine.d39.s4|10-17|androgen|O
DDI-MedLine.d39.s4|19-32|concentrations|O
DDI-MedLine.d39.s4|34-35|of|O
DDI-MedLine.d39.s4|37-45|estradiol|drug
DDI-MedLine.d39.s4|47-47|+|O
DDI-MedLine.d39.s4|67-70|rats|O
DDI-MedLine.d39.s4|72-74|did|O
DDI-MedLine.d39.s4|76-78|not|O
DDI-MedLine.d39.s4|80-85|change|O
DDI-MedLine.d39.s4|87-99|significantly|O
DDI-MedLine.d39.s4|100-100|,|O
DDI-MedLine.d39.s4|102-106|while|O
DDI-MedLine.d39.s4|108-112|those|O
DDI-MedLine.d39.s4|114-115|of|O
DDI-MedLine.d39.s4|135-138|rats|O
DDI-MedLine.d39.s4|140-146|dropped|O
DDI-MedLine.d39.s4|148-149|to|O
DDI-MedLine.d39.s4|151-155|30-40|O
DDI-MedLine.d39.s4|156-156|%|O
DDI-MedLine.d39.s5|0-4|0.001|O
DDI-MedLine.d39.s5|5-5|.|O
DDI-MedLine.d39.s6|0-8|Exogenous|O
DDI-MedLine.d39.s6|10-18|estradiol|drug
DDI-MedLine.d39.s6|20-23|also|O
DDI-MedLine.d39.s6|25-32|appeared|O
DDI-MedLine.d39.s6|34-35|to|O
DDI-MedLine.d39.s6|37-45|influence|O
DDI-MedLine.d39.s6|47-49|the|O
DDI-MedLine.d39.s6|51-60|percentage|O
DDI-MedLine.d39.s6|62-63|of|O
DDI-MedLine.d39.s6|83-88|deaths|O
DDI-MedLine.d39.s6|90-91|in|O
DDI-MedLine.d39.s6|93-93|a|O
DDI-MedLine.d39.s6|95-108|dose-dependent|O
DDI-MedLine.d39.s6|110-115|manner|O
DDI-MedLine.d39.s6|116-116|.|O
DDI-MedLine.d39.s7|0-1|It|O
DDI-MedLine.d39.s7|3-9|reduced|O
DDI-MedLine.d39.s7|11-13|the|O
DDI-MedLine.d39.s7|15-20|number|O
DDI-MedLine.d39.s7|22-23|of|O
DDI-MedLine.d39.s7|25-30|deaths|O
DDI-MedLine.d39.s7|32-38|induced|O
DDI-MedLine.d39.s7|40-41|by|O
DDI-MedLine.d39.s7|43-51|nonlethal|O
DDI-MedLine.d39.s7|53-53|(|O
DDI-MedLine.d39.s7|54-54|2|O
DDI-MedLine.d39.s7|56-60|mg/kg|O
DDI-MedLine.d39.s7|61-61|)|O
DDI-MedLine.d39.s7|63-66|dose|O
DDI-MedLine.d39.s7|68-69|of|O
DDI-MedLine.d39.s7|81-83|but|O
DDI-MedLine.d39.s7|85-93|increased|O
DDI-MedLine.d39.s7|95-97|the|O
DDI-MedLine.d39.s7|99-104|number|O
DDI-MedLine.d39.s7|106-107|of|O
DDI-MedLine.d39.s7|109-114|deaths|O
DDI-MedLine.d39.s7|116-122|induced|O
DDI-MedLine.d39.s7|124-125|by|O
DDI-MedLine.d39.s7|127-127|a|O
DDI-MedLine.d39.s7|129-134|highly|O
DDI-MedLine.d39.s7|136-141|lethal|O
DDI-MedLine.d39.s7|143-146|dose|O
DDI-MedLine.d39.s7|148-148|(|O
DDI-MedLine.d39.s7|149-149|8|O
DDI-MedLine.d39.s7|151-155|mg/kg|O
DDI-MedLine.d39.s7|156-156|)|O
DDI-MedLine.d39.s7|157-157|.|O
DDI-MedLine.d39.s8|0-4|These|O
DDI-MedLine.d39.s8|6-12|results|O
DDI-MedLine.d39.s8|13-13|,|O
DDI-MedLine.d39.s8|15-22|together|O
DDI-MedLine.d39.s8|24-27|with|O
DDI-MedLine.d39.s8|29-31|the|O
DDI-MedLine.d39.s8|33-37|known|O
DDI-MedLine.d39.s8|39-51|relationships|O
DDI-MedLine.d39.s8|53-59|between|O
DDI-MedLine.d39.s8|61-68|estrogen|group
DDI-MedLine.d39.s8|70-72|and|O
DDI-MedLine.d39.s8|74-76|the|O
DDI-MedLine.d39.s8|78-83|immune|O
DDI-MedLine.d39.s8|85-92|response|O
DDI-MedLine.d39.s8|93-93|,|O
DDI-MedLine.d39.s8|95-101|suggest|O
DDI-MedLine.d39.s8|103-106|that|O
DDI-MedLine.d39.s8|108-116|estrogens|group
DDI-MedLine.d39.s8|118-123|affect|O
DDI-MedLine.d39.s8|125-127|the|O
DDI-MedLine.d39.s8|129-134|course|O
DDI-MedLine.d39.s8|136-137|of|O
DDI-MedLine.d39.s8|139-144|septic|O
DDI-MedLine.d39.s8|146-150|shock|O
DDI-MedLine.d39.s8|152-153|in|O
DDI-MedLine.d39.s8|155-155|a|O
DDI-MedLine.d39.s8|157-163|complex|O
DDI-MedLine.d39.s8|165-171|fashion|O
DDI-MedLine.d39.s8|173-175|and|O
DDI-MedLine.d39.s8|177-179|may|O
DDI-MedLine.d39.s8|181-184|have|O
DDI-MedLine.d39.s8|186-191|either|O
DDI-MedLine.d39.s8|193-202|protective|O
DDI-MedLine.d39.s8|204-205|or|O
DDI-MedLine.d39.s8|207-217|deleterious|O
DDI-MedLine.d39.s8|219-224|effect|O
DDI-MedLine.d39.s8|225-225|.|O
DDI-MedLine.d67.s0|0-5|Effect|O
DDI-MedLine.d67.s0|7-8|of|O
DDI-MedLine.d67.s0|10-17|diazepam|drug
DDI-MedLine.d67.s0|19-21|and|O
DDI-MedLine.d67.s0|23-31|midazolam|drug
DDI-MedLine.d67.s0|33-34|on|O
DDI-MedLine.d67.s0|36-38|the|O
DDI-MedLine.d67.s0|40-54|antinociceptive|O
DDI-MedLine.d67.s0|56-61|effect|O
DDI-MedLine.d67.s0|63-64|of|O
DDI-MedLine.d67.s0|66-73|morphine|drug
DDI-MedLine.d67.s0|74-74|,|O
DDI-MedLine.d67.s0|76-84|metamizol|drug
DDI-MedLine.d67.s0|86-88|and|O
DDI-MedLine.d67.s0|90-101|indomethacin|drug
DDI-MedLine.d67.s0|103-104|in|O
DDI-MedLine.d67.s0|106-109|mice|O
DDI-MedLine.d67.s0|110-110|.|O
DDI-MedLine.d67.s1|0-2|The|O
DDI-MedLine.d67.s1|4-12|influence|O
DDI-MedLine.d67.s1|14-15|of|O
DDI-MedLine.d67.s1|17-25|midazolam|drug
DDI-MedLine.d67.s1|27-29|and|O
DDI-MedLine.d67.s1|31-38|diazepam|drug
DDI-MedLine.d67.s1|40-41|on|O
DDI-MedLine.d67.s1|43-57|antinociceptive|O
DDI-MedLine.d67.s1|59-64|effect|O
DDI-MedLine.d67.s1|66-67|of|O
DDI-MedLine.d67.s1|69-76|morphine|drug
DDI-MedLine.d67.s1|78-78|(|O
DDI-MedLine.d67.s1|79-80|10|O
DDI-MedLine.d67.s1|82-86|mg/kg|O
DDI-MedLine.d67.s1|87-87|)|O
DDI-MedLine.d67.s1|88-88|,|O
DDI-MedLine.d67.s1|90-98|metamizol|drug
DDI-MedLine.d67.s1|100-100|(|O
DDI-MedLine.d67.s1|101-103|500|O
DDI-MedLine.d67.s1|105-109|mg/kg|O
DDI-MedLine.d67.s1|110-110|)|O
DDI-MedLine.d67.s1|112-114|and|O
DDI-MedLine.d67.s1|116-127|indomethacin|drug
DDI-MedLine.d67.s1|129-129|(|O
DDI-MedLine.d67.s1|130-131|10|O
DDI-MedLine.d67.s1|133-137|mg/kg|O
DDI-MedLine.d67.s1|138-138|)|O
DDI-MedLine.d67.s1|140-142|was|O
DDI-MedLine.d67.s1|144-155|investigated|O
DDI-MedLine.d67.s1|157-158|in|O
DDI-MedLine.d67.s1|160-160|a|O
DDI-MedLine.d67.s1|162-166|mouse|O
DDI-MedLine.d67.s1|168-172|model|O
DDI-MedLine.d67.s1|174-178|using|O
DDI-MedLine.d67.s1|180-182|the|O
DDI-MedLine.d67.s1|184-193|tail-flick|O
DDI-MedLine.d67.s1|195-197|and|O
DDI-MedLine.d67.s1|199-207|hot-plate|O
DDI-MedLine.d67.s1|209-213|tests|O
DDI-MedLine.d67.s1|214-214|.|O
DDI-MedLine.d67.s2|0-2|All|O
DDI-MedLine.d67.s2|4-8|drugs|O
DDI-MedLine.d67.s2|10-13|were|O
DDI-MedLine.d67.s2|15-22|injected|O
DDI-MedLine.d67.s2|24-40|intraperitoneally|O
DDI-MedLine.d67.s2|41-41|.|O
DDI-MedLine.d67.s3|0-14|Benzodiazepines|group
DDI-MedLine.d67.s3|16-19|were|O
DDI-MedLine.d67.s3|21-32|administered|O
DDI-MedLine.d67.s3|34-35|to|O
DDI-MedLine.d67.s3|37-40|mice|O
DDI-MedLine.d67.s3|42-43|30|O
DDI-MedLine.d67.s3|45-47|min|O
DDI-MedLine.d67.s3|49-54|before|O
DDI-MedLine.d67.s3|56-63|applying|O
DDI-MedLine.d67.s3|65-67|the|O
DDI-MedLine.d67.s3|69-83|analgesic drugs|group
DDI-MedLine.d67.s3|84-84|.|O
DDI-MedLine.d67.s4|0-10|Measurement|O
DDI-MedLine.d67.s4|12-13|of|O
DDI-MedLine.d67.s4|15-25|nociception|O
DDI-MedLine.d67.s4|27-29|was|O
DDI-MedLine.d67.s4|31-39|performed|O
DDI-MedLine.d67.s4|41-46|within|O
DDI-MedLine.d67.s4|48-48|2|O
DDI-MedLine.d67.s4|50-50|h|O
DDI-MedLine.d67.s4|52-56|after|O
DDI-MedLine.d67.s4|58-71|benzodiazepine|group
DDI-MedLine.d67.s4|73-86|administration|O
DDI-MedLine.d67.s4|87-87|.|O
DDI-MedLine.d67.s5|0-7|Diazepam|drug
DDI-MedLine.d67.s5|9-10|at|O
DDI-MedLine.d67.s5|12-16|doses|O
DDI-MedLine.d67.s5|18-19|of|O
DDI-MedLine.d67.s5|21-24|0.25|O
DDI-MedLine.d67.s5|26-30|mg/kg|O
DDI-MedLine.d67.s5|32-34|and|O
DDI-MedLine.d67.s5|36-38|2.5|O
DDI-MedLine.d67.s5|40-44|mg/kg|O
DDI-MedLine.d67.s5|46-53|injected|O
DDI-MedLine.d67.s5|55-58|with|O
DDI-MedLine.d67.s5|60-67|morphine|drug
DDI-MedLine.d67.s5|69-71|was|O
DDI-MedLine.d67.s5|73-77|found|O
DDI-MedLine.d67.s5|79-80|to|O
DDI-MedLine.d67.s5|82-89|decrease|O
DDI-MedLine.d67.s5|91-93|the|O
DDI-MedLine.d67.s5|95-109|antinociceptive|O
DDI-MedLine.d67.s5|111-116|effect|O
DDI-MedLine.d67.s5|118-119|of|O
DDI-MedLine.d67.s5|121-128|morphine|drug
DDI-MedLine.d67.s5|129-129|.|O
DDI-MedLine.d67.s6|0-8|Similarly|O
DDI-MedLine.d67.s6|9-9|,|O
DDI-MedLine.d67.s6|11-18|diazepam|drug
DDI-MedLine.d67.s6|20-28|decreased|O
DDI-MedLine.d67.s6|30-32|the|O
DDI-MedLine.d67.s6|34-48|antinociceptive|O
DDI-MedLine.d67.s6|50-55|effect|O
DDI-MedLine.d67.s6|57-58|of|O
DDI-MedLine.d67.s6|60-68|metamizol|drug
DDI-MedLine.d67.s6|70-70|(|O
DDI-MedLine.d67.s6|71-74|only|O
DDI-MedLine.d67.s6|76-77|in|O
DDI-MedLine.d67.s6|79-81|the|O
DDI-MedLine.d67.s6|83-92|tail-flick|O
DDI-MedLine.d67.s6|94-97|test|O
DDI-MedLine.d67.s6|98-98|)|O
DDI-MedLine.d67.s6|100-102|and|O
DDI-MedLine.d67.s6|104-115|indomethacin|drug
DDI-MedLine.d67.s6|116-116|.|O
DDI-MedLine.d67.s7|0-8|Midazolam|drug
DDI-MedLine.d67.s7|10-13|used|O
DDI-MedLine.d67.s7|15-16|at|O
DDI-MedLine.d67.s7|18-22|doses|O
DDI-MedLine.d67.s7|24-25|of|O
DDI-MedLine.d67.s7|27-30|1.25|O
DDI-MedLine.d67.s7|32-36|mg/kg|O
DDI-MedLine.d67.s7|38-40|and|O
DDI-MedLine.d67.s7|42-44|2.5|O
DDI-MedLine.d67.s7|46-50|mg/kg|O
DDI-MedLine.d67.s7|52-60|decreased|O
DDI-MedLine.d67.s7|62-64|the|O
DDI-MedLine.d67.s7|66-80|antinociceptive|O
DDI-MedLine.d67.s7|82-87|effect|O
DDI-MedLine.d67.s7|89-90|of|O
DDI-MedLine.d67.s7|92-99|morphine|drug
DDI-MedLine.d67.s7|100-100|,|O
DDI-MedLine.d67.s7|102-110|metamizol|drug
DDI-MedLine.d67.s7|112-112|(|O
DDI-MedLine.d67.s7|113-116|only|O
DDI-MedLine.d67.s7|118-119|in|O
DDI-MedLine.d67.s7|121-123|the|O
DDI-MedLine.d67.s7|125-134|tail-flick|O
DDI-MedLine.d67.s7|136-139|test|O
DDI-MedLine.d67.s7|140-140|)|O
DDI-MedLine.d67.s7|142-144|and|O
DDI-MedLine.d67.s7|146-157|indomethacin|drug
DDI-MedLine.d67.s7|158-158|.|O
DDI-DrugBank.d212.s0|0-1|in|O
DDI-DrugBank.d212.s0|3-7|vitro|O
DDI-DrugBank.d212.s0|9-12|data|O
DDI-DrugBank.d212.s0|14-15|on|O
DDI-DrugBank.d212.s0|17-25|metabolic|O
DDI-DrugBank.d212.s0|27-38|interactions|O
DDI-DrugBank.d212.s0|40-47|indicate|O
DDI-DrugBank.d212.s0|49-52|that|O
DDI-DrugBank.d212.s0|54-59|Keppra|brand
DDI-DrugBank.d212.s0|62-63|is|O
DDI-DrugBank.d212.s0|65-72|unlikely|O
DDI-DrugBank.d212.s0|74-75|to|O
DDI-DrugBank.d212.s0|77-83|produce|O
DDI-DrugBank.d212.s0|84-84|,|O
DDI-DrugBank.d212.s0|86-87|or|O
DDI-DrugBank.d212.s0|89-90|be|O
DDI-DrugBank.d212.s0|92-98|subject|O
DDI-DrugBank.d212.s0|100-101|to|O
DDI-DrugBank.d212.s0|102-102|,|O
DDI-DrugBank.d212.s0|104-118|pharmacokinetic|O
DDI-DrugBank.d212.s0|120-131|interactions|O
DDI-DrugBank.d212.s0|132-132|.|O
DDI-DrugBank.d212.s1|0-12|Levetiracetam|drug
DDI-DrugBank.d212.s1|14-16|and|O
DDI-DrugBank.d212.s1|18-20|its|O
DDI-DrugBank.d212.s1|22-26|major|O
DDI-DrugBank.d212.s1|28-37|metabolite|O
DDI-DrugBank.d212.s1|38-38|,|O
DDI-DrugBank.d212.s1|40-41|at|O
DDI-DrugBank.d212.s1|43-56|concentrations|O
DDI-DrugBank.d212.s1|58-61|well|O
DDI-DrugBank.d212.s1|63-67|above|O
DDI-DrugBank.d212.s1|69-72|cmax|O
DDI-DrugBank.d212.s1|74-79|levels|O
DDI-DrugBank.d212.s1|81-88|achieved|O
DDI-DrugBank.d212.s1|90-95|within|O
DDI-DrugBank.d212.s1|97-99|the|O
DDI-DrugBank.d212.s1|101-111|therapeutic|O
DDI-DrugBank.d212.s1|113-116|dose|O
DDI-DrugBank.d212.s1|118-122|range|O
DDI-DrugBank.d212.s1|123-123|,|O
DDI-DrugBank.d212.s1|125-127|are|O
DDI-DrugBank.d212.s1|129-135|neither|O
DDI-DrugBank.d212.s1|137-146|inhibitors|O
DDI-DrugBank.d212.s1|148-149|of|O
DDI-DrugBank.d212.s1|151-153|nor|O
DDI-DrugBank.d212.s1|155-158|high|O
DDI-DrugBank.d212.s1|160-167|affinity|O
DDI-DrugBank.d212.s1|169-178|substrates|O
DDI-DrugBank.d212.s1|180-182|for|O
DDI-DrugBank.d212.s1|184-188|human|O
DDI-DrugBank.d212.s1|190-194|liver|O
DDI-DrugBank.d212.s1|196-205|cytochrome|O
DDI-DrugBank.d212.s1|207-210|P450|O
DDI-DrugBank.d212.s1|212-219|isoforms|O
DDI-DrugBank.d212.s1|220-220|,|O
DDI-DrugBank.d212.s1|222-228|epoxide|O
DDI-DrugBank.d212.s1|230-238|hydrolase|O
DDI-DrugBank.d212.s1|240-241|or|O
DDI-DrugBank.d212.s1|243-261|UDP-glucuronidation|O
DDI-DrugBank.d212.s1|263-269|enzymes|O
DDI-DrugBank.d212.s1|270-270|.|O
DDI-DrugBank.d212.s2|0-1|In|O
DDI-DrugBank.d212.s2|3-10|addition|O
DDI-DrugBank.d212.s2|11-11|,|O
DDI-DrugBank.d212.s2|13-25|levetiracetam|drug
DDI-DrugBank.d212.s2|27-30|does|O
DDI-DrugBank.d212.s2|32-34|not|O
DDI-DrugBank.d212.s2|36-41|affect|O
DDI-DrugBank.d212.s2|43-45|the|O
DDI-DrugBank.d212.s2|47-48|in|O
DDI-DrugBank.d212.s2|50-54|vitro|O
DDI-DrugBank.d212.s2|56-70|glucuronidation|O
DDI-DrugBank.d212.s2|72-73|of|O
DDI-DrugBank.d212.s2|75-87|valproic acid|drug
DDI-DrugBank.d212.s2|88-88|.|O
DDI-DrugBank.d212.s3|0-12|Levetiracetam|drug
DDI-DrugBank.d212.s3|14-23|circulates|O
DDI-DrugBank.d212.s3|25-31|largely|O
DDI-DrugBank.d212.s3|33-39|unbound|O
DDI-DrugBank.d212.s3|41-41|(|O
DDI-DrugBank.d212.s3|43-44|10|O
DDI-DrugBank.d212.s3|45-45|%|O
DDI-DrugBank.d212.s3|47-51|bound|O
DDI-DrugBank.d212.s3|52-52|)|O
DDI-DrugBank.d212.s3|54-55|to|O
DDI-DrugBank.d212.s3|57-62|plasma|O
DDI-DrugBank.d212.s3|64-71|proteins|O
DDI-DrugBank.d212.s3|72-72|;|O
DDI-DrugBank.d212.s4|0-9|clinically|O
DDI-DrugBank.d212.s4|11-21|significant|O
DDI-DrugBank.d212.s4|23-34|interactions|O
DDI-DrugBank.d212.s4|36-39|with|O
DDI-DrugBank.d212.s4|41-45|other|O
DDI-DrugBank.d212.s4|47-51|drugs|O
DDI-DrugBank.d212.s4|53-59|through|O
DDI-DrugBank.d212.s4|61-71|competition|O
DDI-DrugBank.d212.s4|73-75|for|O
DDI-DrugBank.d212.s4|77-83|protein|O
DDI-DrugBank.d212.s4|85-91|binding|O
DDI-DrugBank.d212.s4|93-97|sites|O
DDI-DrugBank.d212.s4|99-101|are|O
DDI-DrugBank.d212.s4|103-111|therefore|O
DDI-DrugBank.d212.s4|113-120|unlikely|O
DDI-DrugBank.d212.s4|121-121|.|O
DDI-DrugBank.d212.s5|0-8|Potential|O
DDI-DrugBank.d212.s5|10-24|pharmacokinetic|O
DDI-DrugBank.d212.s5|26-37|interactions|O
DDI-DrugBank.d212.s5|39-42|were|O
DDI-DrugBank.d212.s5|44-51|assessed|O
DDI-DrugBank.d212.s5|53-54|in|O
DDI-DrugBank.d212.s5|56-63|clinical|O
DDI-DrugBank.d212.s5|65-79|pharmacokinetic|O
DDI-DrugBank.d212.s5|81-87|studies|O
DDI-DrugBank.d212.s5|89-89|(|O
DDI-DrugBank.d212.s5|90-98|phenytoin|drug
DDI-DrugBank.d212.s5|99-99|,|O
DDI-DrugBank.d212.s5|101-109|valproate|drug
DDI-DrugBank.d212.s5|110-110|,|O
DDI-DrugBank.d212.s5|112-115|oral|O
DDI-DrugBank.d212.s5|117-129|contraceptive|group
DDI-DrugBank.d212.s5|130-130|,|O
DDI-DrugBank.d212.s5|132-138|digoxin|drug
DDI-DrugBank.d212.s5|139-139|,|O
DDI-DrugBank.d212.s5|141-148|warfarin|drug
DDI-DrugBank.d212.s5|149-149|,|O
DDI-DrugBank.d212.s5|151-160|probenecid|drug
DDI-DrugBank.d212.s5|161-161|)|O
DDI-DrugBank.d212.s5|163-165|and|O
DDI-DrugBank.d212.s5|167-173|through|O
DDI-DrugBank.d212.s5|175-189|pharmacokinetic|O
DDI-DrugBank.d212.s5|191-199|screening|O
DDI-DrugBank.d212.s5|201-202|in|O
DDI-DrugBank.d212.s5|204-206|the|O
DDI-DrugBank.d212.s5|208-225|placebo-controlled|O
DDI-DrugBank.d212.s5|227-234|clinical|O
DDI-DrugBank.d212.s5|236-242|studies|O
DDI-DrugBank.d212.s5|244-245|in|O
DDI-DrugBank.d212.s5|247-254|epilepsy|O
DDI-DrugBank.d212.s5|256-263|patients|O
DDI-DrugBank.d212.s5|264-264|.|O
DDI-DrugBank.d212.s6|0-8|Drug-Drug|O
DDI-DrugBank.d212.s6|10-21|Interactions|O
DDI-DrugBank.d212.s6|23-29|Between|O
DDI-DrugBank.d212.s6|31-36|Keppra|brand
DDI-DrugBank.d212.s6|39-41|And|O
DDI-DrugBank.d212.s6|43-47|Other|O
DDI-DrugBank.d212.s6|49-67|Antiepileptic Drugs|group
DDI-DrugBank.d212.s6|69-69|(|O
DDI-DrugBank.d212.s6|70-73|AEDs|group
DDI-DrugBank.d212.s6|74-74|)|O
DDI-DrugBank.d212.s6|76-84|Phenytoin|drug
DDI-DrugBank.d212.s6|76-84|Phenytoin|drug
DDI-DrugBank.d212.s6|94-94|(|O
DDI-DrugBank.d212.s6|95-98|3000|O
DDI-DrugBank.d212.s6|100-101|mg|O
DDI-DrugBank.d212.s6|103-107|daily|O
DDI-DrugBank.d212.s6|108-108|)|O
DDI-DrugBank.d212.s6|110-112|had|O
DDI-DrugBank.d212.s6|114-115|no|O
DDI-DrugBank.d212.s6|117-122|effect|O
DDI-DrugBank.d212.s6|124-125|on|O
DDI-DrugBank.d212.s6|127-129|the|O
DDI-DrugBank.d212.s6|131-145|pharmacokinetic|O
DDI-DrugBank.d212.s6|147-157|disposition|O
DDI-DrugBank.d212.s6|159-160|of|O
DDI-DrugBank.d212.s6|162-170|phenytoin|drug
DDI-DrugBank.d212.s6|172-173|in|O
DDI-DrugBank.d212.s6|175-182|patients|O
DDI-DrugBank.d212.s6|184-187|with|O
DDI-DrugBank.d212.s6|189-198|refractory|O
DDI-DrugBank.d212.s6|200-207|epilepsy|O
DDI-DrugBank.d212.s6|208-208|.|O
DDI-DrugBank.d212.s7|0-15|Pharmacokinetics|O
DDI-DrugBank.d212.s7|17-18|of|O
DDI-DrugBank.d212.s7|20-32|levetiracetam|drug
DDI-DrugBank.d212.s7|34-37|were|O
DDI-DrugBank.d212.s7|39-42|also|O
DDI-DrugBank.d212.s7|44-46|not|O
DDI-DrugBank.d212.s7|48-55|affected|O
DDI-DrugBank.d212.s7|57-58|by|O
DDI-DrugBank.d212.s7|60-68|phenytoin|drug
DDI-DrugBank.d212.s7|69-69|.|O
DDI-DrugBank.d212.s8|0-8|Valproate|drug
DDI-DrugBank.d212.s8|0-8|Valproate|drug
DDI-DrugBank.d212.s8|18-18|(|O
DDI-DrugBank.d212.s8|19-22|1500|O
DDI-DrugBank.d212.s8|24-25|mg|O
DDI-DrugBank.d212.s8|27-31|twice|O
DDI-DrugBank.d212.s8|33-37|daily|O
DDI-DrugBank.d212.s8|38-38|)|O
DDI-DrugBank.d212.s8|40-42|did|O
DDI-DrugBank.d212.s8|44-46|not|O
DDI-DrugBank.d212.s8|48-52|alter|O
DDI-DrugBank.d212.s8|54-56|the|O
DDI-DrugBank.d212.s8|58-73|pharmacokinetics|O
DDI-DrugBank.d212.s8|75-76|of|O
DDI-DrugBank.d212.s8|78-86|valproate|drug
DDI-DrugBank.d212.s8|88-89|in|O
DDI-DrugBank.d212.s8|91-97|healthy|O
DDI-DrugBank.d212.s8|99-108|volunteers|O
DDI-DrugBank.d212.s8|109-109|.|O
DDI-DrugBank.d212.s9|0-8|Valproate|drug
DDI-DrugBank.d212.s9|10-12|500|O
DDI-DrugBank.d212.s9|14-15|mg|O
DDI-DrugBank.d212.s9|17-21|twice|O
DDI-DrugBank.d212.s9|23-27|daily|O
DDI-DrugBank.d212.s9|29-31|did|O
DDI-DrugBank.d212.s9|33-35|not|O
DDI-DrugBank.d212.s9|37-42|modify|O
DDI-DrugBank.d212.s9|44-46|the|O
DDI-DrugBank.d212.s9|48-51|rate|O
DDI-DrugBank.d212.s9|53-54|or|O
DDI-DrugBank.d212.s9|56-61|extent|O
DDI-DrugBank.d212.s9|63-64|of|O
DDI-DrugBank.d212.s9|66-78|levetiracetam|drug
DDI-DrugBank.d212.s9|80-89|absorption|O
DDI-DrugBank.d212.s9|91-92|or|O
DDI-DrugBank.d212.s9|94-96|its|O
DDI-DrugBank.d212.s9|98-103|plasma|O
DDI-DrugBank.d212.s9|105-113|clearance|O
DDI-DrugBank.d212.s9|115-116|or|O
DDI-DrugBank.d212.s9|118-124|urinary|O
DDI-DrugBank.d212.s9|126-134|excretion|O
DDI-DrugBank.d212.s9|135-135|.|O
DDI-DrugBank.d212.s10|0-4|There|O
DDI-DrugBank.d212.s10|6-9|also|O
DDI-DrugBank.d212.s10|11-13|was|O
DDI-DrugBank.d212.s10|15-16|no|O
DDI-DrugBank.d212.s10|18-23|effect|O
DDI-DrugBank.d212.s10|25-26|on|O
DDI-DrugBank.d212.s10|28-35|exposure|O
DDI-DrugBank.d212.s10|37-38|to|O
DDI-DrugBank.d212.s10|40-42|and|O
DDI-DrugBank.d212.s10|44-46|the|O
DDI-DrugBank.d212.s10|48-56|excretion|O
DDI-DrugBank.d212.s10|58-59|of|O
DDI-DrugBank.d212.s10|61-63|the|O
DDI-DrugBank.d212.s10|65-71|primary|O
DDI-DrugBank.d212.s10|73-82|metabolite|O
DDI-DrugBank.d212.s10|83-83|,|O
DDI-DrugBank.d212.s10|85-87|ucb|O
DDI-DrugBank.d212.s10|89-92|L057|O
DDI-DrugBank.d212.s10|93-93|.|O
DDI-DrugBank.d212.s11|0-8|Potential|O
DDI-DrugBank.d212.s11|10-13|drug|O
DDI-DrugBank.d212.s11|15-26|interactions|O
DDI-DrugBank.d212.s11|28-34|between|O
DDI-DrugBank.d212.s11|36-41|Keppra|brand
DDI-DrugBank.d212.s11|44-46|and|O
DDI-DrugBank.d212.s11|48-52|other|O
DDI-DrugBank.d212.s11|54-57|AEDs|group
DDI-DrugBank.d212.s11|59-59|(|O
DDI-DrugBank.d212.s11|60-72|carbamazepine|drug
DDI-DrugBank.d212.s11|73-73|,|O
DDI-DrugBank.d212.s11|75-84|gabapentin|drug
DDI-DrugBank.d212.s11|85-85|,|O
DDI-DrugBank.d212.s11|87-97|lamotrigine|drug
DDI-DrugBank.d212.s11|98-98|,|O
DDI-DrugBank.d212.s11|100-112|phenobarbital|drug
DDI-DrugBank.d212.s11|113-113|,|O
DDI-DrugBank.d212.s11|115-123|phenytoin|drug
DDI-DrugBank.d212.s11|124-124|,|O
DDI-DrugBank.d212.s11|126-134|primidone|drug
DDI-DrugBank.d212.s11|136-138|and|O
DDI-DrugBank.d212.s11|140-148|valproate|drug
DDI-DrugBank.d212.s11|149-149|)|O
DDI-DrugBank.d212.s11|151-154|were|O
DDI-DrugBank.d212.s11|156-159|also|O
DDI-DrugBank.d212.s11|161-168|assessed|O
DDI-DrugBank.d212.s11|170-171|by|O
DDI-DrugBank.d212.s11|173-182|evaluating|O
DDI-DrugBank.d212.s11|184-186|the|O
DDI-DrugBank.d212.s11|188-192|serum|O
DDI-DrugBank.d212.s11|194-207|concentrations|O
DDI-DrugBank.d212.s11|209-210|of|O
DDI-DrugBank.d212.s11|212-224|levetiracetam|drug
DDI-DrugBank.d212.s11|226-228|and|O
DDI-DrugBank.d212.s11|230-234|these|O
DDI-DrugBank.d212.s11|236-239|AEDs|group
DDI-DrugBank.d212.s11|241-246|during|O
DDI-DrugBank.d212.s11|248-265|placebo-controlled|O
DDI-DrugBank.d212.s11|267-274|clinical|O
DDI-DrugBank.d212.s11|276-282|studies|O
DDI-DrugBank.d212.s11|283-283|.|O
DDI-DrugBank.d212.s12|0-4|These|O
DDI-DrugBank.d212.s12|6-9|data|O
DDI-DrugBank.d212.s12|11-18|indicate|O
DDI-DrugBank.d212.s12|20-23|that|O
DDI-DrugBank.d212.s12|25-37|levetiracetam|drug
DDI-DrugBank.d212.s12|39-42|does|O
DDI-DrugBank.d212.s12|44-46|not|O
DDI-DrugBank.d212.s12|48-56|influence|O
DDI-DrugBank.d212.s12|58-60|the|O
DDI-DrugBank.d212.s12|62-67|plasma|O
DDI-DrugBank.d212.s12|69-81|concentration|O
DDI-DrugBank.d212.s12|83-84|of|O
DDI-DrugBank.d212.s12|86-90|other|O
DDI-DrugBank.d212.s12|92-95|AEDs|group
DDI-DrugBank.d212.s12|97-99|and|O
DDI-DrugBank.d212.s12|101-104|that|O
DDI-DrugBank.d212.s12|106-110|these|O
DDI-DrugBank.d212.s12|112-115|AEDs|group
DDI-DrugBank.d212.s12|117-118|do|O
DDI-DrugBank.d212.s12|120-122|not|O
DDI-DrugBank.d212.s12|124-132|influence|O
DDI-DrugBank.d212.s12|134-136|the|O
DDI-DrugBank.d212.s12|138-153|pharmacokinetics|O
DDI-DrugBank.d212.s12|155-156|of|O
DDI-DrugBank.d212.s12|158-170|levetiracetam|drug
DDI-DrugBank.d212.s12|171-171|.|O
DDI-DrugBank.d212.s13|0-5|Effect|O
DDI-DrugBank.d212.s13|7-8|of|O
DDI-DrugBank.d212.s13|10-13|AEDs|group
DDI-DrugBank.d212.s13|15-16|in|O
DDI-DrugBank.d212.s13|18-26|Pediatric|O
DDI-DrugBank.d212.s13|28-35|Patients|O
DDI-DrugBank.d212.s13|37-41|There|O
DDI-DrugBank.d212.s13|43-45|was|O
DDI-DrugBank.d212.s13|47-51|about|O
DDI-DrugBank.d212.s13|53-53|a|O
DDI-DrugBank.d212.s13|55-56|22|O
DDI-DrugBank.d212.s13|57-57|%|O
DDI-DrugBank.d212.s13|59-66|increase|O
DDI-DrugBank.d212.s13|68-69|of|O
DDI-DrugBank.d212.s13|71-78|apparent|O
DDI-DrugBank.d212.s13|80-84|total|O
DDI-DrugBank.d212.s13|86-89|body|O
DDI-DrugBank.d212.s13|91-99|clearance|O
DDI-DrugBank.d212.s13|101-102|of|O
DDI-DrugBank.d212.s13|104-116|levetiracetam|drug
DDI-DrugBank.d212.s13|118-121|when|O
DDI-DrugBank.d212.s13|123-124|it|O
DDI-DrugBank.d212.s13|126-128|was|O
DDI-DrugBank.d212.s13|130-144|co-administered|O
DDI-DrugBank.d212.s13|146-149|with|O
DDI-DrugBank.d212.s13|151-165|enzyme-inducing|O
DDI-DrugBank.d212.s13|167-170|AEDs|group
DDI-DrugBank.d212.s13|171-171|.|O
DDI-DrugBank.d212.s14|0-3|Dose|O
DDI-DrugBank.d212.s14|5-14|adjustment|O
DDI-DrugBank.d212.s14|16-17|is|O
DDI-DrugBank.d212.s14|19-21|not|O
DDI-DrugBank.d212.s14|23-47|recommended.Levetiracetam|drug
DDI-DrugBank.d212.s14|49-51|had|O
DDI-DrugBank.d212.s14|53-54|no|O
DDI-DrugBank.d212.s14|56-61|effect|O
DDI-DrugBank.d212.s14|63-64|on|O
DDI-DrugBank.d212.s14|66-71|plasma|O
DDI-DrugBank.d212.s14|73-86|concentrations|O
DDI-DrugBank.d212.s14|88-89|of|O
DDI-DrugBank.d212.s14|91-103|carbamazepine|drug
DDI-DrugBank.d212.s14|104-104|,|O
DDI-DrugBank.d212.s14|106-114|valproate|drug
DDI-DrugBank.d212.s14|115-115|,|O
DDI-DrugBank.d212.s14|117-126|topiramate|drug
DDI-DrugBank.d212.s14|127-127|,|O
DDI-DrugBank.d212.s14|129-130|or|O
DDI-DrugBank.d212.s14|132-142|lamotrigine|drug
DDI-DrugBank.d212.s14|143-143|.|O
DDI-DrugBank.d212.s15|0-4|Other|O
DDI-DrugBank.d212.s15|6-9|Drug|O
DDI-DrugBank.d212.s15|11-22|Interactions|O
DDI-DrugBank.d212.s15|24-27|Oral|O
DDI-DrugBank.d212.s15|29-42|Contraceptives|group
DDI-DrugBank.d212.s15|29-42|Contraceptives|group
DDI-DrugBank.d212.s15|52-52|(|O
DDI-DrugBank.d212.s15|53-55|500|O
DDI-DrugBank.d212.s15|57-58|mg|O
DDI-DrugBank.d212.s15|60-64|twice|O
DDI-DrugBank.d212.s15|66-70|daily|O
DDI-DrugBank.d212.s15|71-71|)|O
DDI-DrugBank.d212.s15|73-75|did|O
DDI-DrugBank.d212.s15|77-79|not|O
DDI-DrugBank.d212.s15|81-89|influence|O
DDI-DrugBank.d212.s15|91-93|the|O
DDI-DrugBank.d212.s15|95-110|pharmacokinetics|O
DDI-DrugBank.d212.s15|112-113|of|O
DDI-DrugBank.d212.s15|115-116|an|O
DDI-DrugBank.d212.s15|118-121|oral|O
DDI-DrugBank.d212.s15|123-135|contraceptive|group
DDI-DrugBank.d212.s15|137-146|containing|O
DDI-DrugBank.d212.s15|148-151|0.03|O
DDI-DrugBank.d212.s15|153-154|mg|O
DDI-DrugBank.d212.s15|156-172|ethinyl estradiol|drug
DDI-DrugBank.d212.s15|174-176|and|O
DDI-DrugBank.d212.s15|178-181|0.15|O
DDI-DrugBank.d212.s15|183-184|mg|O
DDI-DrugBank.d212.s15|186-199|levonorgestrel|drug
DDI-DrugBank.d212.s15|200-200|,|O
DDI-DrugBank.d212.s15|202-203|or|O
DDI-DrugBank.d212.s15|205-206|of|O
DDI-DrugBank.d212.s15|208-210|the|O
DDI-DrugBank.d212.s15|212-222|luteinizing|O
DDI-DrugBank.d212.s15|224-230|hormone|O
DDI-DrugBank.d212.s15|232-234|and|O
DDI-DrugBank.d212.s15|236-247|progesterone|O
DDI-DrugBank.d212.s15|249-254|levels|O
DDI-DrugBank.d212.s15|255-255|,|O
DDI-DrugBank.d212.s15|257-266|indicating|O
DDI-DrugBank.d212.s15|268-271|that|O
DDI-DrugBank.d212.s15|273-282|impairment|O
DDI-DrugBank.d212.s15|284-285|of|O
DDI-DrugBank.d212.s15|287-299|contraceptive|O
DDI-DrugBank.d212.s15|301-308|efficacy|O
DDI-DrugBank.d212.s15|310-311|is|O
DDI-DrugBank.d212.s15|313-320|unlikely|O
DDI-DrugBank.d212.s15|321-321|.|O
DDI-DrugBank.d212.s16|0-15|Coadministration|O
DDI-DrugBank.d212.s16|17-18|of|O
DDI-DrugBank.d212.s16|20-23|this|O
DDI-DrugBank.d212.s16|25-28|oral|O
DDI-DrugBank.d212.s16|30-42|contraceptive|group
DDI-DrugBank.d212.s16|44-46|did|O
DDI-DrugBank.d212.s16|48-50|not|O
DDI-DrugBank.d212.s16|52-60|influence|O
DDI-DrugBank.d212.s16|62-64|the|O
DDI-DrugBank.d212.s16|66-81|pharmacokinetics|O
DDI-DrugBank.d212.s16|83-84|of|O
DDI-DrugBank.d212.s16|86-98|levetiracetam|drug
DDI-DrugBank.d212.s16|99-99|.|O
DDI-DrugBank.d212.s17|0-6|Digoxin|drug
DDI-DrugBank.d212.s17|0-6|Digoxin|drug
DDI-DrugBank.d212.s17|16-16|(|O
DDI-DrugBank.d212.s17|17-20|1000|O
DDI-DrugBank.d212.s17|22-23|mg|O
DDI-DrugBank.d212.s17|25-29|twice|O
DDI-DrugBank.d212.s17|31-35|daily|O
DDI-DrugBank.d212.s17|36-36|)|O
DDI-DrugBank.d212.s17|38-40|did|O
DDI-DrugBank.d212.s17|42-44|not|O
DDI-DrugBank.d212.s17|46-54|influence|O
DDI-DrugBank.d212.s17|56-58|the|O
DDI-DrugBank.d212.s17|60-75|pharmacokinetics|O
DDI-DrugBank.d212.s17|77-79|and|O
DDI-DrugBank.d212.s17|81-96|pharmacodynamics|O
DDI-DrugBank.d212.s17|98-98|(|O
DDI-DrugBank.d212.s17|99-101|ECG|O
DDI-DrugBank.d212.s17|102-102|)|O
DDI-DrugBank.d212.s17|104-105|of|O
DDI-DrugBank.d212.s17|107-113|digoxin|drug
DDI-DrugBank.d212.s17|115-119|given|O
DDI-DrugBank.d212.s17|121-122|as|O
DDI-DrugBank.d212.s17|124-124|a|O
DDI-DrugBank.d212.s17|126-129|0.25|O
DDI-DrugBank.d212.s17|131-132|mg|O
DDI-DrugBank.d212.s17|134-137|dose|O
DDI-DrugBank.d212.s17|139-143|every|O
DDI-DrugBank.d212.s17|145-147|day|O
DDI-DrugBank.d212.s17|148-148|.|O
DDI-DrugBank.d212.s18|0-15|Coadministration|O
DDI-DrugBank.d212.s18|17-18|of|O
DDI-DrugBank.d212.s18|20-26|digoxin|drug
DDI-DrugBank.d212.s18|28-30|did|O
DDI-DrugBank.d212.s18|32-34|not|O
DDI-DrugBank.d212.s18|36-44|influence|O
DDI-DrugBank.d212.s18|46-48|the|O
DDI-DrugBank.d212.s18|50-65|pharmacokinetics|O
DDI-DrugBank.d212.s18|67-68|of|O
DDI-DrugBank.d212.s18|70-82|levetiracetam|drug
DDI-DrugBank.d212.s18|83-83|.|O
DDI-DrugBank.d212.s19|0-7|Warfarin|drug
DDI-DrugBank.d212.s19|0-7|Warfarin|drug
DDI-DrugBank.d212.s19|17-17|(|O
DDI-DrugBank.d212.s19|18-21|1000|O
DDI-DrugBank.d212.s19|23-24|mg|O
DDI-DrugBank.d212.s19|26-30|twice|O
DDI-DrugBank.d212.s19|32-36|daily|O
DDI-DrugBank.d212.s19|37-37|)|O
DDI-DrugBank.d212.s19|39-41|did|O
DDI-DrugBank.d212.s19|43-45|not|O
DDI-DrugBank.d212.s19|47-55|influence|O
DDI-DrugBank.d212.s19|57-59|the|O
DDI-DrugBank.d212.s19|61-76|pharmacokinetics|O
DDI-DrugBank.d212.s19|78-79|of|O
DDI-DrugBank.d212.s19|81-81|R|drug
DDI-DrugBank.d212.s19|83-85|and|O
DDI-DrugBank.d212.s19|87-96|S warfarin|drug
DDI-DrugBank.d212.s19|97-97|.|O
DDI-DrugBank.d212.s20|0-10|Prothrombin|O
DDI-DrugBank.d212.s20|12-15|time|O
DDI-DrugBank.d212.s20|17-19|was|O
DDI-DrugBank.d212.s20|21-23|not|O
DDI-DrugBank.d212.s20|25-32|affected|O
DDI-DrugBank.d212.s20|34-35|by|O
DDI-DrugBank.d212.s20|37-49|levetiracetam|drug
DDI-DrugBank.d212.s20|50-50|.|O
DDI-DrugBank.d212.s21|0-15|Coadministration|O
DDI-DrugBank.d212.s21|17-18|of|O
DDI-DrugBank.d212.s21|20-27|warfarin|drug
DDI-DrugBank.d212.s21|29-31|did|O
DDI-DrugBank.d212.s21|33-35|not|O
DDI-DrugBank.d212.s21|37-42|affect|O
DDI-DrugBank.d212.s21|44-46|the|O
DDI-DrugBank.d212.s21|48-63|pharmacokinetics|O
DDI-DrugBank.d212.s21|65-66|of|O
DDI-DrugBank.d212.s21|68-80|levetiracetam|drug
DDI-DrugBank.d212.s21|81-81|.|O
DDI-DrugBank.d212.s22|0-9|Probenecid|drug
DDI-DrugBank.d212.s22|10-10|:|O
DDI-DrugBank.d212.s22|12-21|Probenecid|drug
DDI-DrugBank.d212.s22|22-22|,|O
DDI-DrugBank.d212.s22|24-24|a|O
DDI-DrugBank.d212.s22|26-30|renal|O
DDI-DrugBank.d212.s22|32-38|tubular|O
DDI-DrugBank.d212.s22|40-48|secretion|O
DDI-DrugBank.d212.s22|50-57|blocking|O
DDI-DrugBank.d212.s22|59-63|agent|O
DDI-DrugBank.d212.s22|64-64|,|O
DDI-DrugBank.d212.s22|66-77|administered|O
DDI-DrugBank.d212.s22|79-80|at|O
DDI-DrugBank.d212.s22|82-82|a|O
DDI-DrugBank.d212.s22|84-87|dose|O
DDI-DrugBank.d212.s22|89-90|of|O
DDI-DrugBank.d212.s22|92-94|500|O
DDI-DrugBank.d212.s22|96-97|mg|O
DDI-DrugBank.d212.s22|99-102|four|O
DDI-DrugBank.d212.s22|104-108|times|O
DDI-DrugBank.d212.s22|110-110|a|O
DDI-DrugBank.d212.s22|112-114|day|O
DDI-DrugBank.d212.s22|115-115|,|O
DDI-DrugBank.d212.s22|117-119|did|O
DDI-DrugBank.d212.s22|121-123|not|O
DDI-DrugBank.d212.s22|125-130|change|O
DDI-DrugBank.d212.s22|132-134|the|O
DDI-DrugBank.d212.s22|136-151|pharmacokinetics|O
DDI-DrugBank.d212.s22|153-154|of|O
DDI-DrugBank.d212.s22|156-168|levetiracetam|drug
DDI-DrugBank.d212.s22|170-173|1000|O
DDI-DrugBank.d212.s22|175-176|mg|O
DDI-DrugBank.d212.s22|178-182|twice|O
DDI-DrugBank.d212.s22|184-188|daily|O
DDI-DrugBank.d212.s22|189-189|.|O
DDI-DrugBank.d212.s23|0-5|Cssmax|O
DDI-DrugBank.d212.s23|7-8|of|O
DDI-DrugBank.d212.s23|10-12|the|O
DDI-DrugBank.d212.s23|14-23|metabolite|O
DDI-DrugBank.d212.s23|24-24|,|O
DDI-DrugBank.d212.s23|26-28|ucb|O
DDI-DrugBank.d212.s23|30-33|L057|O
DDI-DrugBank.d212.s23|34-34|,|O
DDI-DrugBank.d212.s23|36-38|was|O
DDI-DrugBank.d212.s23|40-52|approximately|O
DDI-DrugBank.d212.s23|54-60|doubled|O
DDI-DrugBank.d212.s23|62-63|in|O
DDI-DrugBank.d212.s23|65-67|the|O
DDI-DrugBank.d212.s23|69-76|presence|O
DDI-DrugBank.d212.s23|78-79|of|O
DDI-DrugBank.d212.s23|81-90|probenecid|drug
DDI-DrugBank.d212.s23|92-96|while|O
DDI-DrugBank.d212.s23|98-100|the|O
DDI-DrugBank.d212.s23|102-109|fraction|O
DDI-DrugBank.d212.s23|111-112|of|O
DDI-DrugBank.d212.s23|114-117|drug|O
DDI-DrugBank.d212.s23|119-126|excreted|O
DDI-DrugBank.d212.s23|128-136|unchanged|O
DDI-DrugBank.d212.s23|138-139|in|O
DDI-DrugBank.d212.s23|141-143|the|O
DDI-DrugBank.d212.s23|145-149|urine|O
DDI-DrugBank.d212.s23|151-158|remained|O
DDI-DrugBank.d212.s23|160-162|the|O
DDI-DrugBank.d212.s23|164-167|same|O
DDI-DrugBank.d212.s23|168-168|.|O
DDI-DrugBank.d212.s24|0-4|Renal|O
DDI-DrugBank.d212.s24|6-14|clearance|O
DDI-DrugBank.d212.s24|16-17|of|O
DDI-DrugBank.d212.s24|19-21|ucb|O
DDI-DrugBank.d212.s24|23-26|L057|O
DDI-DrugBank.d212.s24|28-29|in|O
DDI-DrugBank.d212.s24|31-33|the|O
DDI-DrugBank.d212.s24|35-42|presence|O
DDI-DrugBank.d212.s24|44-45|of|O
DDI-DrugBank.d212.s24|47-56|probenecid|drug
DDI-DrugBank.d212.s24|58-66|decreased|O
DDI-DrugBank.d212.s24|68-69|60|O
DDI-DrugBank.d212.s24|70-70|%|O
DDI-DrugBank.d212.s24|71-71|,|O
DDI-DrugBank.d212.s24|73-80|probably|O
DDI-DrugBank.d212.s24|82-88|related|O
DDI-DrugBank.d212.s24|90-91|to|O
DDI-DrugBank.d212.s24|93-103|competitive|O
DDI-DrugBank.d212.s24|105-114|inhibition|O
DDI-DrugBank.d212.s24|116-117|of|O
DDI-DrugBank.d212.s24|119-125|tubular|O
DDI-DrugBank.d212.s24|127-135|secretion|O
DDI-DrugBank.d212.s24|137-138|of|O
DDI-DrugBank.d212.s24|140-142|ucb|O
DDI-DrugBank.d212.s24|144-147|L057|O
DDI-DrugBank.d212.s24|148-148|.|O
DDI-DrugBank.d212.s25|0-2|The|O
DDI-DrugBank.d212.s25|4-9|effect|O
DDI-DrugBank.d212.s25|11-12|of|O
DDI-DrugBank.d212.s25|14-19|Keppra|brand
DDI-DrugBank.d212.s25|22-23|on|O
DDI-DrugBank.d212.s25|25-34|probenecid|drug
DDI-DrugBank.d212.s25|36-38|was|O
DDI-DrugBank.d212.s25|40-42|not|O
DDI-DrugBank.d212.s25|44-50|studied|O
DDI-DrugBank.d212.s25|51-51|.|O
